id|nct_id|group_type|title|description
33069925|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
33069926|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.~A single treatment will be provided."
33069927|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.~A single treatment will be provided"
33069928|NCT00523393|No Intervention|1|
33069929|NCT00523393|Experimental|2|
33069930|NCT00523393|Active Comparator|3|
33069931|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
33069932|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
33069933|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
33231937|NCT00840190|Experimental|P1446A-05|
33231938|NCT04101708|Experimental|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
33231939|NCT04101708|Active Comparator|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
32747399|NCT05696223||Early fetal growth restriction|Fetal growth restriction diagnosed before 32 SA
32747400|NCT05696223||Late fetal growth restriction|Fetal growth restriction diagnosed after 32 SA
33231940|NCT00825760|Other|1|Single treatment
33231941|NCT00825760|Other|2|12 treatments, once weekly
33231942|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
33231943|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
33231944|NCT04105140|Experimental|male oxytocin group|male subjects with oxytocin treatment
33231945|NCT04105140|Placebo Comparator|male placebo group|male subjects with placebo treatment
32747407|NCT04629339|Experimental|INCB086550|INCB086550 will be administered orally twice a day.
32761916|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
33231946|NCT00622180|Active Comparator|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
33231947|NCT00622180|Active Comparator|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
33231948|NCT02601768||ASD II|Transcatheter closure of ASD II
33231949|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
33231950|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
33231951|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
33231952|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
33231953|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
33231954|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
33231955|NCT04101084|Experimental|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
33231956|NCT00843544|Experimental|Integrative Medicine|
33231957|NCT00843544|No Intervention|Control|
33231958|NCT05546346|Experimental|wearable magnet tracking system|
33231959|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
33231960|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
33241407|NCT04394858|Experimental|Arm I (temozolomide, olaparib)|Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32747408|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32747409|NCT04626297|Experimental|Lebrikizumab|Lebrikizumab given by subcutaneous (SC) injection.
32747410|NCT04626297|Placebo Comparator|Placebo|Placebo given by SC injection.
32747411|NCT05544279|Experimental|Intervention group that given education|"7 interviews are held. 3 meaurements are explored. In the first measurement (first interview) Personal information form, Zarit Burden Interview (ZBI), STAI-S and STAI-T are filled in preoperatively within 24-48 hours, and the planned training and booklet are given. Second measurement (4th interview) is done on the phone within the 1st week after discharge. Third measurement (7th interview) is explored within the 4th week after discharge. In the interim interviews, the training is repeated and the questions about the places that were not understood are answered."
32747412|NCT05544279|No Intervention|Control group|"1. Interview (pre-test): 1st interview: Personal information form, ZBI, STAI were filled in preoperatively within 24-48 hours. They receive routine care at the hospital 2nd interview (on the phone within the 1st week after discharge): ZBYÖ, STAI-S and Education follow-up form are filled.~3rd interview (post-test): ZBYÖ, STAI-S and Education follow-up forms were filled on the phone within the 4th week after discharge. A pdf format of the training material was sent to the mothers in the control group via whatsapp application."
32747413|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
32747414|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
32747415|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
32747416|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
32747417|NCT05699109||Aranesp group|Aranesp group: patients received darbepoetin alpha prefilled syringe subcutaneously once weekly or biweekly
32747418|NCT05699109||Eprex group|Eprex group: patients received epoetin alpha prefilled syringe subcutaneously one to three times per week
32747419|NCT05696067|Experimental|Group 0a|Single dose of 7.2 lg EID50 of H3N2 vaccine component
33398689|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
32747420|NCT05696067|Experimental|Group 0b|Single dose of 7.5 lg EID50 of H1N1pdm09 vaccine component
32747421|NCT05696067|Experimental|Group 0c|Single dose of 8.0 lg EID50 of H3N2 vaccine component
32747422|NCT05696067|Experimental|Group 0d|Single dose of 8.3 lg EID50 of H1N1pdm09 vaccine component
32747423|NCT05696067|Experimental|Group 1a|Low dose vaccine, two components received three weeks apart
32747424|NCT05696067|Experimental|Group 1b|High dose vaccine, two components received three weeks apart
32747425|NCT05696067|Placebo Comparator|Group 1c|Placebo, two doses received three weeks apart
32747426|NCT05696067|Experimental|Group 2a|High dose vaccine, two components received three weeks apart
32747427|NCT05696067|Placebo Comparator|Group 2b|Placebo, two doses received three weeks apart
32747428|NCT04448535|Experimental|Gingko Biloba|oral intake of gingko biloba for 4 weeks
32747429|NCT05695989|Experimental|Dual Robotic Arm Accessory (DRAA)|
32747430|NCT05696613|Experimental|Phase 3a Cohort 1|3 mg SNP-ACTH Gel sc injection 3 times per week
32747431|NCT05696613|Experimental|Phase 3a Cohort 2|5 mg SNP-ACTH Gel sc injection 3 times per week
32747432|NCT05696613|Experimental|Phase 3b Cohort 1|Dose level to be confirmed once Phase 3a part is completed
32747433|NCT05696613|Active Comparator|Phase 3b Cohort 2|Rituximab arm: Patients randomized to the rituximab arm will receive 1 g IV infusion on T0 (after baseline measures are collected) and day 15. A second course of rituximab 1g IV infusion will be administered 6 months after the first rituximab infusion and an additional 1 g IV infusion 14 days following the first 6-month infusion.
32747434|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
32747435|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
32747436|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
32747437|NCT05543889||Patients|100 patient participants will be recruited for limbal anterior chamber depth image capture. These images will be used to develop the clinical vignette database
32747438|NCT05543889||Optometrists|50 optometrists will be recruited to undertake the clinical vignette assessment
32747439|NCT05695833|Experimental|Radiofrequency|Device
32747440|NCT05695833|Active Comparator|Nd Yag Laser|Device
32747441|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
32747442|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
32747443|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
32747444|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
33398690|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
33398691|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.~Intervention: Prescription of spectacles"
32747445|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
33069934|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
33069935|NCT04725890|Experimental|Intervention|All eligible participants will receive the DyaMX procedure.
33069936|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
32747446|NCT05543655|Experimental|simulated|The 'Simulation training', using high fidelity simulation with a simulated patient, is composed of 2 training sessions of 3 hours each. The training will include a high-fidelity scenario whose events will be adapted to medication administration in conventional care services. This scenario is developed by a multidisciplinary team of healthcare professionals, experts in simulation and risk management
32747447|NCT05543421|Active Comparator|rTMS active|
32747448|NCT05543421|Sham Comparator|rTMS sham|
32747449|NCT05543421|Experimental|iTBS active|
32747450|NCT05543421|Sham Comparator|iTBS sham|
33069937|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
33069938|NCT00523666|Active Comparator|1|
32747451|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
32747452|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
32908677|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
32747453|NCT04254783|Experimental|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
32747454|NCT04090203|Experimental|Boiled Peanut Powder|Boiled Peanut Powder
32747455|NCT04088097|Experimental|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
32747456|NCT04088097|Other|Control Condition|Educational materials related to adolescent health and nutrition.
32747457|NCT04062201|Experimental|Study Strategy|
32747458|NCT04062201|Active Comparator|Control Strategy|
33069939|NCT00523666|Placebo Comparator|2|
32747459|NCT04316715|Experimental|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
32747460|NCT04316715|No Intervention|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
32747461|NCT05696457|Experimental|AML-E|Acute myeloblastic leukemia - experimental
32747462|NCT05696457|No Intervention|AML-C|Acute myeloblastic leukemia - control
32747463|NCT05696457|Experimental|AlloSCT-E|Allogeneic stem cell transplantation - experimental
32747464|NCT05696457|No Intervention|AlloSCT-C|Allogeneic stem cell transplantation - control
32747465|NCT05696457|Experimental|AutoSCT-E(I)|Autologous stem cell transplantation - experimental (inpatient)
32747466|NCT05696457|No Intervention|AutoSCT-C(I)|Autologous stem cell transplantation - control (inpatient)
32747467|NCT05696457|Experimental|AutoSCT-E(O)|Autologous stem cell transplantation - experimental (outpatient)
33069940|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
33069941|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
33069942|NCT00512200||Case|Patients aged 65 or older
32747468|NCT05696457|No Intervention|AutoSCT-C(O)|Autologous stem cell transplantation - control (outpatient)
32747469|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
32747470|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
32747471|NCT05696379||STEMI with high Angio-IMR|Patients with ST segment elevation myocardial infarction and high Angio-IMR
32747472|NCT05696379||STEMI with low Angio-IMR|Patients with ST segment elevation myocardial infarction and low Angio-IMR
32747473|NCT05696379||NSTEMI with high Angio-IMR|Patients with non-ST segment elevation myocardial infarction and high Angio-IMR
32747474|NCT05696379||NSTEMI with low Angio-IMR|Patients with non-ST segment elevation myocardial infarction and low Angio-IMR
32747475|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
33398692|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
33398693|NCT03170986|No Intervention|Control Arm|
33398694|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
33398695|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
33398696|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
32908678|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
32908679|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
32908680|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
32908681|NCT00972530|No Intervention|Activity|Normal activity without restrictions
32908682|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
33069943|NCT00512200||Control|Patients aged 20 to 40
33069944|NCT00512200||Control 2|Healthy volunteers aged 65 or older
33069945|NCT03943511|Active Comparator|Group 1|Oral Antibiotics
33069946|NCT03943511|Active Comparator|Group 2|Standard of Care
33069947|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
33069948|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
33069949|NCT03922802|Experimental|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
33069950|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
33069951|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
33069952|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
33069953|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
33069954|NCT04696120|Experimental|Study group: apixaban|apixaban 2.5mg or 5mg bid
33069955|NCT04696120|Placebo Comparator|Control group: placebo|placebo bid
32747476|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
33069956|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
33069957|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
32747477|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
33069958|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
33069959|NCT03890120|Experimental|Blinded Phase: Cilofexor|Cilofexor for 96 weeks
33069960|NCT03890120|Placebo Comparator|Blinded Phase: Placebo|Placebo for 96 weeks
33069961|NCT03890120|Experimental|Open-Label Phase: Cilofexor|Cilofexor for 96 weeks
33069962|NCT04694014||Emotional Intelligence Skills study among frontline HCW managing Covid19 in Busia Kenya|Researchers from Alupe University College will select study participants as follows 6 Clinical officers, 2 nurses, 1 nutritionist, 1 lab technician, 2 lab technologists, 7 members on the sub county surveillance Matayos, Teso north and Bunyala 2 from UHC office
33393640|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
33231961|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
33069963|NCT04693741|Other|"Autogenous iliac bone graft group A"|The autogenous iliac bone graft will be used to fill the alveolar defect.
33069964|NCT04693741|Other|"Xenograft with PRF group B"|Xenograft with PRF will be used to fill the alveolar defect.
33069965|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069966|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069967|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069968|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069969|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069970|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069971|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069972|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069973|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
32747480|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
32747481|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
32747482|NCT05535153||Experime|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
32747483|NCT05468463|Active Comparator|Living Donor Navigator Program In-person|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN in-person will receive the program locally at the transplant center.
32747484|NCT05468463|Active Comparator|Living Donor Navigator Program Tele-health|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN tele-health will receive the program virtually at a local health department within the Alabama Department of Public Health's tele-health network.
32747485|NCT05679297||Patients with thalamic CPSP (central post-stroke pain)|Patients with CPSP of thalamic origin due to stroke.
32747486|NCT05679297||Patients with thalamic stroke without CPSP|Patients with thalamic stroke at least 2 years ago, but without CPSP or other chronic pain disorders
32747487|NCT05679297||Patients with migraine|Patients with migraine (other central pain disorder)
32747488|NCT05679297||Healthy controls|Age- and gender-matched healthy control subjects
32747489|NCT05679219|Active Comparator|Structured Pes Planus Exercise Group|23 individuals will be included in this group. Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. The purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
32747490|NCT05679219|Active Comparator|Wii Based Exergame Group|23 individuals will be included in this group. Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
32761917|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
33069974|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069975|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
33069976|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
32747491|NCT05679219|Active Comparator|Wii Based Serious Game Group|23 individuals will be included in this group. The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
32747492|NCT05454657|Experimental|Heart rate variability biofeedback + treatment as usual|The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.
32747493|NCT05454657|Active Comparator|Treatment as usual only|The control group will participate in 8 weeks of treatment as usual only.
32747494|NCT05454189|Active Comparator|4-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 4 weeks.
32908683|NCT05394272|Experimental|Efficacy of Energy Therapy - Pranic Healing with chronic pain|Energy therapy - Pranic Healing to be applied for 8 weeks weekly and 3 times 4 weeks apart for relief of chronic pain
33069977|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
33069978|NCT00167622|Experimental|2|Mechanical ventilation
33393641|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
33393642|NCT01350297|Experimental|Patients|Patients
33393643|NCT01350375|Placebo Comparator|Saline|
32908684|NCT05394272|Experimental|Efficacy of Energy Therapy - Pranic Healing - with linked medical condition|Energy Therapy - Pranic Healing protocol for linked medical condition applied for 8 weeks weekly and 3 times 4 weeks apart , relevant BT/Urine sample /stool sample 4 weeks apart to evaluate changes.
32908685|NCT01689701|Experimental|Hizikia Fusiformis extract|
32908686|NCT01689701|Placebo Comparator|Placebo|
32908687|NCT05394194||3DCRT group|In this plan, we will create plans using three dimensional conformal radiotherapy, evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
32908688|NCT05394194||IMRT group|In this plan, we will create plans using intensity modulated radiotherapy (IMRT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
32908689|NCT05394194||VMAT plan|In this plan, we will create plans using volumetric modulated radiotherapy (VMAT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
32908690|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
32911038|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
32911039|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
33069979|NCT00512395|Active Comparator|1|epidural analgesia
33069980|NCT00512395|No Intervention|2|traditional analgesia with opioids
33393644|NCT01350375|Active Comparator|Botox|
33393645|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
33393646|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
33393647|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
32747495|NCT05454189|Experimental|12-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 12 weeks.
32747496|NCT05678985|Experimental|Choose to Move|"CTM (Phase 4) is a 3-month, flexible, choice-based program for low active older adults that can be delivered in-person or online.~CTM includes~One-on-One Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Over the 3-months, participants will attend eight, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic (health-related) and provide time and space for social connection between participants. Group meetings are held in person or online as public health restrictions and community preference dictate."
32747497|NCT02580591|Experimental|Empagliflozin low dose|
32747498|NCT02580591|Experimental|Empagliflozin high dose|
32747499|NCT02580591|Experimental|Empagliflozin medium dose|
32747500|NCT02580591|Placebo Comparator|Placebo|
33241408|NCT04394858|Active Comparator|Arm II (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
33241409|NCT00767013|Experimental|AVS, CAD|DSCT
33241410|NCT00759837|Experimental|1|
33393648|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
32911040|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
32747501|NCT05695677|Other|Tecar treatment sucess|
32747502|NCT05561439||Cardiology: Coronary/Valvular|
32747503|NCT05561439||Cardiology: Rhythmology|
32747504|NCT05561439||Cardiology: Mixed|
32747505|NCT05561439||Radiology: Simple Vascular|
32747506|NCT05561439||Radiology: Complex Vascular|
32747507|NCT05561439||Radiology: Mixed Vascular|
32747508|NCT05561439||Radiology: Simple Osteoarticular|
32747509|NCT05561439||Radiology: Complex Osteoarticular|
32747510|NCT05561439||Radiology: Mixed Osteoarticular|
32747511|NCT05561439||Radiology: Simple Neuroradiology|
32747512|NCT05561439||Radiology: Complex Neuroradiology|
32747513|NCT05561439||Radiology: Mixed Neuroradiology|
32747514|NCT05561439||Radiology: Mixed|
32747515|NCT05561439||Radiology: Simple Oncology|
32747516|NCT05561439||Radiology: Complex Oncology|
32747517|NCT05561439||Radiology: Mixed Oncology|
32747518|NCT05557461||Group-1|"group with fluid responsiveness in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
32747519|NCT05557461||Group-2|"group with no fluid response in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
32911041|NCT01312766|Active Comparator|Menopur|
32911042|NCT01749215|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
32747521|NCT05556057|Experimental|mindfulness meditation(MM)|
32747522|NCT05556057|Active Comparator|Health Education|
32747523|NCT05555043|Active Comparator|Control group|Participants receive passive ultrasonic irrigation for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
32911043|NCT01749215|Placebo Comparator|Placebo|Placebo capsules daily - up to 300 mg
32911044|NCT04577859|Active Comparator|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees covering ablation of the left atrial posterior wall.
32911045|NCT04577859|Active Comparator|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anaesthetic. The esophageal temperature probe is sited close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
32911046|NCT04522167|Experimental|FYB203 (Proposed aflibercept biosimilar)|Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
32911047|NCT04522167|Active Comparator|Eylea® (Aflibercept)|Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
32911048|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
32911049|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
32911050|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
32911051|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
32911052|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
32911053|NCT01749293|Experimental|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
32747524|NCT05555043|Experimental|GentleWave group|Participants receive GentleWave System for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
32747525|NCT05555043|Experimental|Waterlase group|Participants receive Waterlase iPlus for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
32747526|NCT05552001|Experimental|Single arm receiving sacituzumab govitecan|
33231962|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
32747527|NCT05695599|Experimental|Whole body vibration|Participants will undergo a whole body vibration training
32747528|NCT05695599|No Intervention|Control Group|Participants will not perform an intervention
32747529|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
33231963|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
33231964|NCT00840736|Active Comparator|2|vertical banded gastroplasty
33231965|NCT05546268|Experimental|Phase 1 Dose Escalation|Patients with NSCLC, SCLC, high-grade neuroendocrine cancer of any primary site, any solid tumors with L-MYC or N-MYC amplification, or DLBCL
32747530|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
32747531|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
32761918|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
32761919|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
32761920|NCT02326753|Experimental|No. 7 oral airway|
33069981|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
33069982|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
33069983|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
33069984|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
33069985|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
33393649|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
33069986|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
33069987|NCT00524095|No Intervention|1|standard of care
33069988|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
32761921|NCT02326753|Experimental|No. 8 oral airway|
32761922|NCT02326753|Active Comparator|No. 9 oral airway|
33069989|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
33069990|NCT00167700|Experimental|Probiotics|
33069991|NCT00167700|Experimental|Probiotics + Dietary counseling|
33069992|NCT00167700|Experimental|Dietary counseling + placebo|
33069993|NCT00167700|Experimental|Prebiotics|
33069994|NCT00167700|Placebo Comparator|Placebo|
33069995|NCT00167700|No Intervention|Control|
33069996|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
33069997|NCT00512590|Experimental|Experimental|
33069998|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
33069999|NCT00512629|Active Comparator|Intralipid|
33393650|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
33070000|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
33070001|NCT00524212||IE confirmed IE rejected|
33070002|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
33070003|NCT00512746|Other|Surveillance|Screened arm
33070004|NCT00512746|Active Comparator|Control|Control arm
33070005|NCT00512785|Experimental|E1|
33070006|NCT00512785|Experimental|E2|
33070007|NCT00512824|Placebo Comparator|1|
33070008|NCT00512824|Active Comparator|2|
33070009|NCT00512824|Active Comparator|3|
33070010|NCT00512824|Active Comparator|4|
33070011|NCT00512941||1|HBV: Carrier
33070012|NCT00512941||2|HBV: cure
33070013|NCT00512941||3|HBV: isolate anti-HBc
33070014|NCT00512941||4|HBV: vaccinated
33070015|NCT00512941||5|HCV: anti-HCV positive test
32747532|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
32747533|NCT05684523|Experimental|Redormin® 500|fixed combination of valerian and hops dry extract, 500 mg, once daily for 21 days
32747534|NCT05684523|Placebo Comparator|Placebo|matching placebo, once daily for 21 days
32747535|NCT05680311|Active Comparator|Breast Cancer Patients|Group of patients with verified breast cancer diagnosis
32747536|NCT05680311|Sham Comparator|Non-Cancer patients|Group of healthy patients with no verified any type of cancer.
32747537|NCT04159155|Experimental|Early Stage Cohort - Arm A|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
32747538|NCT04159155|Experimental|Early Stage Cohort - Arm B1|"External beam radiotherapy, 5 days per week, for 4-5 weeks~Cisplatin intravenously, on the first and fourth week of radiotherapy.~Brachytherapy will be given if needed Then~Carboplatin, intravenously, once every 3 weeks for 4 cycles~Paclitaxel, intravenously, once every 3 weeks for 4 cycles"
32747539|NCT04159155|Experimental|Advanced Stage Cohort Arm C|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
33070016|NCT00512941||6|HBV/HCV co-infection
32747540|NCT04159155|Experimental|Advanced Stage Cohort Arm D1|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles Then Niraparib daily continuous dosing for 28 day cycles
32747541|NCT04159155|No Intervention|Exploratory Cohort|Observation on Standard of care
32747542|NCT05678751||case group|patients with infertility
32747543|NCT05678751||control group|women that are capable of spontaneous intrauterine pregnanc
32747544|NCT05404191|Experimental|burn wound receiving low level laser therapy|
33070017|NCT00512941||7|Susceptible individuals
33070018|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
33070019|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
33070020|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
33070021|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
33070022|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
33070023|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
33070024|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
33070025|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
33070026|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
33070027|NCT03868982|Experimental|NAVA group|Participent in this group will received NAVA for two days
33393651|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
33070028|NCT03868982|No Intervention|Control group|Participent in this group will received standard care
33070029|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
32747545|NCT05390307|Experimental|GLP1RA alone|Participants in the GLP1RA will be prescribed either Liraglutide 3.0mg or Semaglutide 1.0mg, whichever is licensed and available locally. The dose and titration will follow the usual clinical practice. The treatment will continue for 6 months.
32747546|NCT05390307|Experimental|SGLT2i alone|Participants in the SGLT2i group will be prescribed dapagliflozin 5-10mg once daily for 6 months.
32747547|NCT05390307|Experimental|GLP1RA/SGLT2i combination|Participants in the combination GLP1RA and SGLT2i group will be prescribed liraglutide 3mg once daily or semaglutide1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg for 6 months.
32747548|NCT05390307|Experimental|GLP1RA/SGLT2i combination with intensive lifestyle changes|Participants in the combination GLP1RA and SGLT2i and intensive weight loss groupwill be prescribed liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg together with an intensive dietary and lifestyle approach for 6 months. This typically involves dietary advice to reduce energy intake (and may includea period of partial or total meal replacement), accompanied -if available -by a physical activity programme, both supported by behavioural change techniqueswith regular professional contacts.
32747549|NCT05390307|Experimental|Usual Care|Participants in the usual care arm will follow the best medical care by following the international guidelines for 6 months. This usually involves diet and exercise advice.
32747550|NCT05678517||Patients|Patients with AMD
33070030|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
32747551|NCT04079439|Other|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
32747552|NCT04079439|No Intervention|Control group|Standard care
33070031|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
32747553|NCT04425369|No Intervention|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
32747554|NCT04425369|Experimental|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
32747555|NCT05542563|Experimental|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
32747556|NCT05542563|No Intervention|Standard of Care|Control group receives standard of care only
32747557|NCT05695443|Experimental|Motivational Interviewing|Prisoners in this group are subjected to a MI-based conversation lasting up to 30 minutes aiming at improving oral health and oral health related behavior
32747558|NCT05695443|No Intervention|Control group|Prisoners in this group do not receive the MI-based intervention
32747559|NCT04012749|Active Comparator|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
32747560|NCT04012749|Active Comparator|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
33070032|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
33070033|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
32747561|NCT04012749|Active Comparator|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
32747562|NCT04000035|Experimental|Health in work|The interdisciplinary Health in work intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
32761923|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
33070034|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
33070035|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
33070036|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
33070037|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
33070038|NCT02947906||Control Group|Healthy participants
33070039|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
33393652|NCT03894501|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
33398697|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
33398698|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
33070040|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
33070041|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
33070042|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
33070043|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
33070044|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
33070045|NCT04723563|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: Four times per day Duration: until hospital discharge
33070046|NCT04723563|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: Four times per day Duration: until hospital discharge
33070047|NCT00525967|Active Comparator|1|Methadone plus Placebo
33070048|NCT00525967|Experimental|2|Methadone plus Acetaminophen
33070049|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
33070050|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
33070051|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
33070052|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
33070053|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
33070054|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
33070055|NCT00167856|Active Comparator|2|Benztropine Mesylate
33070056|NCT04693273||Carpal Tunnel Release surgical patients|This is the group the investigators survey who are candidates for carpal tunnel release (CTR) surgery: patients should be 18 years or older, comprehend and read English, and patients who consent to do the survey.
33070057|NCT03737357|Experimental|SLActive® implant|
33070058|NCT03737357|Active Comparator|SLA® implant|
32747563|NCT04000035|Active Comparator|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
33070059|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
33070060|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
33070061|NCT04693117|Experimental|Study Group|Participants were voluntarily participated by non-probability consecutive sampling. It was a one group study with a limitation of non-randomization. The interventional group had performed interval training for 12 weeks, 3 days/week (figure 1). They sedentary conferring to activity level (≥ 30-minute, 3 days/weeks, moderate-intensity physical activity). They were not participated in any interval training program before participating in the study from six months. Written consent was taken after demonstration of the purpose, procedure, and related pros and cons. They were instructed to participate regularly in interval training.
33070062|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
33070063|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
33070064|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
33070065|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
33070066|NCT02946346|Experimental|Vaginal and blood sampling|
33070067|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
33393653|NCT03894501|Other|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
33393654|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
33070068|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
33070069|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
33070070|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
33070071|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
33070072|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
33070073|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
33393655|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
32747564|NCT03988569|Experimental|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
32747565|NCT03988569|No Intervention|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
32747566|NCT05357313|Experimental|Bright light therapy group|10,000lux bright light
32747567|NCT05357313|Placebo Comparator|Placebo group|inactive negative ion generator
32747568|NCT04716777|Experimental|Brief Transdiagnostic GCBT|Participants receive Brief Transdiagnostic group cognitive-behavioral treatment. Eight weekly sessions.
32747569|NCT04716777|No Intervention|Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
33070074|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
33070075|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
33070076|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
32747570|NCT05319249|Experimental|NK cells combined with PARP inhibition|Combination of NK cell therapy and PARP inhibition by Talazoparib after immunosuppression with cyclophosphamide and fludarabine
32747571|NCT05318469|Experimental|Treatment (ivermectin, balstilimab)|Patients receive ivermectin PO QD on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive balstilimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
32747572|NCT05539131|Active Comparator|active transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 6 weeks
33070077|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
33070078|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
33070079|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
33070080|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
33070081|NCT00524914|Experimental|1|Apomorphine
33070082|NCT00524914|Placebo Comparator|2|Placebo
33070083|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
33070084|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
33231966|NCT05546268|Experimental|Phase 2 Expansion - NSCLC|Patients with NSCLC with high or low L-MYC or N-MYC mRNA expression
33231967|NCT05546268|Experimental|Phase 2 Expansion - SCLC|Patients with SCLC with high or low L-MYC or N-MYC mRNA expression
33231968|NCT05546268|Experimental|Phase 2 Expansion - L-MYC or N-MYC amplified solid tumors|Patients with L-MYC or N-MYC amplified solid tumors
33231969|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
33231970|NCT05514834|Experimental|combined HA with PRP|Hyaluronic acid and PRP combination treatment
33231971|NCT05514834|Placebo Comparator|Placebo|saline solution
33231972|NCT05514834|Active Comparator|PRP|Platelet rich plasma without hyaluronic acid
33231973|NCT00701831|Experimental|1|Insulin glargine
33231974|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
33231975|NCT00840892|No Intervention|Usual Care|
33231976|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
33231977|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
33231978|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
33231979|NCT00841048|Placebo Comparator|2|Placebo
32747573|NCT05539131|Sham Comparator|sham transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 3 weeks + daily sham transcranial direct current stimulation (tDCS) use for 3 weeks
33231980|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
33231981|NCT00778830|Experimental|Cetuximab plus FOLFOX|
32747576|NCT05678361|Experimental|Sleep after exposure|Participants take a nap during 90 min following three exposure (WET) sessions.
32747577|NCT05678361|No Intervention|Wake after exposure|Participants watch a 90 min documentary following three exposure (WET) sessions.
32747578|NCT03849885|No Intervention|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
33231982|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
33231983|NCT04102332||After arm|Safe Infusion Device
33231984|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~Rituximab~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
33231985|NCT05544708|Experimental|Intervention|House Chat Leaders will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the intervention group will deliver the intervention immediately following baseline visits and randomization.
33231986|NCT05544708|No Intervention|Delayed Intervention|House Chat Leaders will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the delayed intervention group will deliver the intervention after 24 week data collection visits are complete.
33231987|NCT04101318|Experimental|New Stoma Baseplate with Protective Layer|New Stoma baseplate with Protective layer
33231988|NCT04101318|Active Comparator|Standard of Care|1-piece and 2-piece stoma devices already on the market.
33231989|NCT00786474|Placebo Comparator|Placebo|
33231990|NCT00786474|Experimental|Dalteparin|
33231991|NCT05543616|Experimental|3 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
33231992|NCT05543616|Experimental|6 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
32761924|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
32761925|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
33231993|NCT05543616|Experimental|10 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
33231994|NCT05543616|Experimental|Selected dose, 6 Months to <4 Years 3 Months (Substudy A, Phase 2/3) - 0/3/11 week primary series|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
33231995|NCT05543616|Experimental|Selected dose, 6 Months to <4 Years 3 Months (Substudy A, Phase 2/3) - 0/8/16 week primary series|Injection in the muscle at 0-, 8-, and 16-weeks and 6-months post-Dose 3
33231996|NCT05543616|Experimental|3 microgram dose, 6 Months to <4 Years 6 Months (Substudy B, Group 1)|Injection in the muscle, 2 doses 2 months apart
33231997|NCT05543616|Experimental|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 2)|Injection in the muscle, 1 dose
33231998|NCT05543616|Experimental|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 3)|Injection in the muscle, 1 dose
33231999|NCT05543616|Experimental|6 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
33393656|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
33393657|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
32747579|NCT03849885|Experimental|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
32747580|NCT04668885|Experimental|Primary refractory/relapsed AML|Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351
32747581|NCT04668885|Experimental|MDS after HMA failure|Lower dose CPX-351 in participants with MDS after HMA failure. Participants will receive an induction and maintenance phase of CPX-351
32747582|NCT05271747|Active Comparator|Lactoflora colicare|Probiotic multi-strain formulation comprising Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 in sunflower oil and medium-chain triglyceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
32747583|NCT05271747|Active Comparator|Reuteri gotas|Probiotic single-strain formulation comprising Lactobacillus reuteri DSM17938 in sunflower oil and medium-chain triglyceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
32747584|NCT05678283|Experimental|Part 1: CC-90010 followed by [14C]CC-90010|
32747585|NCT05678283|Experimental|Part 2: CC-90010|
32747586|NCT01664091|Experimental|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
33232000|NCT05543616|Experimental|10 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
32747588|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
32747589|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
32747590|NCT05535777|Active Comparator|Enhanced Text Reminders with Callback by Person|"Participants in this arm will receive up to 3 R/R messages by text. R/R message will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
32747591|NCT05535777|Active Comparator|Enhanced Bidirectional Text Reminders|"Participants in this arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient. Bidirectional texts will be exchanged on a HIPAA compliant bidirectional text messaging platform. The patient will use the regular SMS function on their cellphone and the agent will receive and respond to the bidirectional text on the HIPAA compliant platform."
32761926|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
33232001|NCT05543616|Experimental|Selected dose, 6 Months to <5 Years (Substudy C, Phase 2/3)|Injection in the muscle, 1 dose
33232002|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 1)|Injection in the muscle, 1 dose
33232003|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 2)|Injection in the muscle, 1 dose
33232004|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 3)|Injection in the muscle, 1 dose
33232005|NCT05543616|Experimental|3 microgram dose, >2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
33232006|NCT05543616|Experimental|6 microgram dose, >2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
33232007|NCT05543616|Experimental|10 microgram dose, >2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and 6-months post-Dose 3
32747592|NCT05535777|No Intervention|Standard Text Reminders|Participants in this arm will receive up to 3 text messages, reminding them about the importance of influenza vaccination. The standard texts will include a clinic call back number and patient portal self-scheduling for patients to schedule their influenza vaccines. The direct scheduling texts includes a direct number to an agent that can help schedule and answer questions on the phone in real time. The texts with a direct number to schedule will link a specified phone number to call and schedule. This number would be answered by a central agent quickly and a patient could schedule their flu shot at any clinic site. This specific phone number would not go through the multiple option menus a patient would normally experience when calling their clinic.
32747593|NCT05529069|Experimental|Pirtobrutinib (LOXO-305) and Venetoclax (combination)|Participants will have study visits every week during Cycle 1, and then on Day 1 of every cycle for the first year. After that, they will have study visits on Day 1 of every 2 cycles.
32747594|NCT04713345|Experimental|Experimental group|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
33232008|NCT05543616|Experimental|6 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
33232009|NCT05543616|Experimental|10 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
32747595|NCT04713345|Sham Comparator|Control group|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
32747596|NCT05524545|Experimental|Evorpacept (ALX148) + Enfortumab Vedotin|"Phase 1a Dose Escalation: Evorpacept (ALX148) infusions will be administered every two weeks.~Enfortumab vedotin will be administered at 1.25 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle."
32747597|NCT03827031|No Intervention|Control group|
32747598|NCT03827031|Experimental|B1 interventional group|
32747599|NCT03827031|Experimental|B2 interventional group|
32747600|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay~The results of Prosigna assay will be provided to the study team in a standardized report.~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
32747601|NCT05675631|Experimental|Experimental Group|This group will perform training using suspension elements.
32747602|NCT05675631|Active Comparator|Control Group|This group will perform training using weights and elastic bands.
32747603|NCT05220657||Low active subjects|No intervention
32747604|NCT05220657||Moderately active subjects|No intervention
32747605|NCT05220657||Elite soccer players|No intervention
32747606|NCT05220657||Elite cyclists|No intervention
32747607|NCT05219175|Experimental|Co-occurring PTSD and OUD prior and after treatment with MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (~80 mg MDMA) to 140 mg MDMA HCL (~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (~100 mg MDMA) to 180 mg MDMA HCL (~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (~280 mg MDMA) to 500 mg MDMA HCL (~435 mg MDMA)"
32747608|NCT05215119||Immediate|NC endometrial preparation will start immediately after blastocyst cryopreservation confirmation.
32747609|NCT05215119||Delayed|NC endometrial preparation will start on day 1 of the patient's 2nd menstruation after the oocyte retrieval cycle menstruation or in a subsequent cycle.
32747610|NCT05211297||Exposed cohort:|Children whose mothers suffered a suspected preterm labour during pregnancy.
32747611|NCT05211297||Unexposed cohort|Children born at term (> 37 weeks) whose mothers did not suffer a suspected preterm labour during pregnancy.
32747612|NCT05210283||Stage ll or lll|Patients with stage ll or lll colorectal cancer
32747613|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
32747614|NCT03688503|Placebo Comparator|placebo|placebo supplement
32747615|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
32911060|NCT04944147|Experimental|Anodal tDCS + cognitive training|"device: anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
33232010|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
33232011|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
33232012|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
33232013|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
33241411|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
32747616|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
33070085|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
33070086|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
32908691|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
32908692|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
32908693|NCT05631977||POCUS acquisition|"Prospective noninterventional single arm study collection of cardiac POCUS examination according to prespecified acquisition protocol.~Alongside POCUS images the study will also collect demographic and clinical information from the study participants and some information from the healthcare personal performing the POCUS exam (experience in US image acquisition, physician specialty or sonographer).~Patient management will not be impacted, and usual care will follow the regular practices at the study site."
32908694|NCT05394038||CPC Cohort|A patient with chest tightness and pain during the Covid-19 outbreak.
32908695|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
33070087|NCT02946541|Placebo Comparator|placebo|Placebo QD
33070088|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
33070089|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
33070090|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
33070091|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
33070092|NCT00525109||1|Single family cohort
32908696|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
32908697|NCT05390450|Experimental|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block.
32908698|NCT05390450|Experimental|Ultrasound-Guided Fascia Iliaca block|Patients in this group will receive Fascia Iliaca block.
32908699|NCT05388500|Active Comparator|Group A (Paclitaxel + Trastuzumab)|
32908700|NCT05388500|Experimental|Group B (Trastuzumab)|
32908701|NCT05626673|Experimental|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
33070093|NCT03585452|Active Comparator|Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
33070094|NCT03585452|Experimental|Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
33070095|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
33070096|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
33070097|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
33070098|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
33070099|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
33070100|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
33070101|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
33070102|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
33070103|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
33070104|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
33070105|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
33070106|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
33070107|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
33070108|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
33070109|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
33070110|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
32747617|NCT05187117|Experimental|Open Label Pilot|"The Open Label Pilot (Phase 4) will include testing the CAPABLE Family intervention with 6 individuals with MCI or early-stage dementia. At least 5 of the 6 older adults will be required to have a family member involved. Assuming all have a family member involved (though one may not), 12 participants will be enrolled in the open label pilot.~Open label pilot participants will be asked to provide feedback halfway through the intervention and at the end via phone conversations with the research study team, allowing the study team to make changes accordingly."
32747618|NCT05187117|Experimental|Randomized Control Pilot - Intervention Arm|After the open label pilot, 17 older adults (and if available, care partners) will be randomized to the CAPABLE Family intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
33070111|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
33070112|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
33070113|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
33070114|NCT03490565|Active Comparator|EX group|Exercise training
33070115|NCT03490565|No Intervention|CON-group|Usual Care
32747619|NCT05187117|Active Comparator|Randomized Control Pilot - Waitlist Control Arm|The waitlist control group, 17 older adults and if available, care partners, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
33070116|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
33070117|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
33070118|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with long acting beta agonists (LABA) + high doses inhaled corticosteroids (ICS) with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
32908702|NCT05387174|Experimental|Experimental group nursing intervention with technological support|Experimental group composed of 40 with the same characteristics as above and attending the San Antonio de Pichincha Health Center, this group will additionally receive a nursing intervention of 3 months, to reduce the risk factors of MS and improve the quality of life related to health. The nursing intervention with web application support will consist of three elements: Individual face-to-face individual Nursing Counseling, Group Education and Physical Activity sessions through virtual platform.
33070119|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
33070120|NCT04693312|Experimental|Group I|scalene muscle level injection of depomedrol
33070121|NCT04693312|Experimental|Group II|Rheumboid muscle level injection of depomedrol
33070122|NCT04710381|Experimental|IMUNOR|Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.
33070123|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
33070124|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
33070125|NCT04692571|Experimental|Study B: Limb-Absent Subject|"Ten unilateral transradial limb-absent subjects will each participate in one, half-day experimental session. Subjects will be seated and prepared in test apparatus seat (16 electrodes on the affected side, hand-wrist on the able side secured to load cells). Subjects will complete the 1-DoF and 2-DoF dynamic (force-varying) contractions (40-s duration, 0.75 Hz bandlimited, uniform random target). With 2 DoF contraction trials, hand Opn-Cls will always be one of the dimensions. The subject will then be released from the cuff and their able side not further involved in the experiment. The force feedback triangle cursor on the computer screen will be deleted such that only the target remains. Subjects will then repeat 1-DoF and 2-DoF trials in which the affected side attempts to produce hand-wrist effort that mimic movement of the target (with no feedback provided)."
33232014|NCT04104711|Experimental|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
32747620|NCT05695365|Experimental|Resistance Exercise Training|Participants will complete a 16-week, twice/week program to increase strength.
33232015|NCT04104711|No Intervention|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
33232016|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
33232017|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
33232018|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
33232019|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
33232020|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
33232021|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
33241412|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
33241413|NCT00767169|Experimental|coated implant and control|
33241414|NCT00767247||1|Male or female with arterial hypertension
32747621|NCT05172609|Experimental|Exposure Based Implementation Strategy (EBIS)|EBIS is informed by the latest science in exposure theory, borrowing heavily from brief exposure-based treatments that can be delivered in a single session. We anticipate that EBIS will occur in four phases that map on to standard exposure therapy practice for patients with anxiety disorders: psychoeducation, assessment, practice, and relapse prevention; however, the final version will depend on the outcomes of the preparatory phases of this study. Clinicians assigned to the EBIS arm will also receive all elements of IAU.
32747622|NCT05172609|Active Comparator|Implementation as Usual (IAU)|Gold-standard IAU for SSAIs typically comprises pre-implementation preparation, didactic training, knowledge tests, experiential role plays, ongoing expert consultation, and providing certification status to clinicians who attain established benchmarks. Pre-implementation preparation will include provision of materials. Didactic training will occur in two parts: (1) suicide screening and assessment, and (2) Safety Planning Intervention (SPI) use. Part one will consist of materials we previously developed based on community clinician feedback. Part two will follow established SPI guidelines, including didactic training about SPI rationale and evidence base and experiential practice. IAU also will include supports for electronic health record integration (e.g., previously developed templates). After training, clinicians will receive 8 weeks of expert consultation to discuss implementation barriers and receive more role play practice.
32747623|NCT05509413|No Intervention|Control Arm|Wait-and-see approach.
32747624|NCT05509413|Experimental|DEFLAGYN Arm|Application of DEFLAGYN vaginal gel for 3x 28days (as per instructions provided by the manufacturer)
32747625|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
32747626|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
32747627|NCT03569085|Experimental|Sevoflurane then isoflurane|
32747628|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
32747629|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
32747630|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
32747631|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
32747632|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
32747633|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
32747634|NCT05657379|Experimental|Product X moisturizer|Participants will used Product X moisturizer twice daily for 8 weeks
32747635|NCT02711345|Experimental|Escalation|
33393658|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
32747636|NCT02711345|Experimental|Expansion Group 1|
32747637|NCT02711345|Experimental|Expansion Group 2|
32747638|NCT02711345|Experimental|Expansion Group 3|
32747639|NCT02711345|Experimental|Expansion Group 4|
32747640|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
32747641|NCT03398655|Active Comparator|Arm 2|Placebo + Paclitaxel
32747642|NCT03391479|Experimental|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks~Best supportive care will be provided as required."
32747643|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
32747644|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
32747645|NCT03873623||Kidney Transplant Recipients|
32747646|NCT05695287|Other|Propofol|Anesthesia
32747647|NCT05695287|Other|Isofluran|Anesthesia
32747648|NCT05695287|Other|Sevofluran|Anesthesia
32747649|NCT03808025|Experimental|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
32747650|NCT03808025|No Intervention|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
32747651|NCT03081429||Perioperative covert stroke|
32747652|NCT03081429||Postoperative cognitive dysfunction|
33072231|NCT05350449|Experimental|Loving kindness meditation|Loving-kindness meditation is a contemplative practice that focuses on developing compassion for oneself and others through mindfulness. Participants will be shown the recorded loving-kindness training video during the first week of the intervention. Participants will be encouraged to use the mp3 device with guided meditation recording to practice mindfulness meditation for 10 minutes every day for two weeks. We will also provide participants with a diary to record their daily meditation experiences. For the remaining two weeks, participants are encouraged to meditate 20 minutes a day.
32747653|NCT03772691|Experimental|lateral suspension|All operations will be performed with patient in loyd davies position, sterilization of the perineum then sterilization of the vagina
32747654|NCT03772691|Active Comparator|sacropexy|Our ﬁrst passage is the peritoneum incision overlying the sacral promontory (L5-S1) to expose the anterior longitudinal ligament, which is the anchorage point of the mesh on the sacrum. We create a tunnel under the peritoneum on the right side through the cul-de-sac of Douglas till reach the cervix or vaginal cuff (after hysterectomy).
32747655|NCT05501067|Active Comparator|tai chi group|patients will receive tai chi exercise program
33393659|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
33393660|NCT01350531|Experimental|Skills training|
33393661|NCT01350531|Experimental|Contingency Management|
32747656|NCT05501067|Active Comparator|control group|no intervention
32747657|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
32747658|NCT05097495|Experimental|Control group (Only NNS)|NNS will be started 5 minutes before diaper change. The use of NNS will continue during diaper change and up to 5 minutes after the application.
33072232|NCT05350449|No Intervention|Waitlist control|The arm will eventually get the intervention.
33072233|NCT05350397|Experimental|Acupressure group|The patients in the intervention group were informed about what acupressure was and why it was applied. An acupressure wristband was correctly worn on both wrists to provide patients with adequate pressure on the HT7 point for 5 minutes
33072234|NCT05350397|Placebo Comparator|Placebo Group|Patients in the placebo group were informed about what acupressure was and why it was applied. In order not to apply pressure to the Shenmen (HT7) pressure point in the patients in this group, the acupressure wristband was placed on both wrists in an inverted and loose manner and the wristband was worn for 5 minutes, the procedure was completed.
33072235|NCT05350397|No Intervention|Control group|No procedure was applied to the patients in the control group. The patients received routine treatment and care.
33072236|NCT05345847|Experimental|1- Active Surveillance|Active surveillance with rescue corticosteroids
33072237|NCT05345847|Active Comparator|2- Early initiation of steroid (Standard)|Early intervention with high-dose steroids
33072238|NCT05337982|Experimental|SCI Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate low levels of inflammation will start immediately.
33072239|NCT05337982|Experimental|SCI No Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate high levels of inflammation will have a delayed start of 3 months.
33072240|NCT05337982|No Intervention|SCI SOC|Participants with SCI randomized to the standard of care (SOC) group will continue with regular therapy.
33072241|NCT05337982|No Intervention|Healthy Control|Healthy controls will provide biomarker and/or myelin (MRI) data
33072242|NCT05334017|Active Comparator|Xylometazoline|Xylometazoline 0,1% as nasal solution given immediately prior to nasal intubation
33072243|NCT05334017|Active Comparator|Cocaine|Cocaine 4% as nasal solution given immediately prior to nasal intubation
33072244|NCT05330104|Experimental|mEMA Arm|In this arm, participants will be using a mobile survey system to track the emergence of Chemotherapy-Induced Peripheral Neuropathy symptoms and fall risk over the course of the participant's chemotherapy.
33072247|NCT05327595|Experimental|LY3549492 (Part A)|LY3549492 administered orally as multiple ascending doses.
33072248|NCT05327595|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
33072249|NCT05327595|Experimental|LY3549492 + Midazolam + Atorvastatin (Part B)|LY3549492 coadministered orally with midazolam and atorvastatin.
33072250|NCT05327595|Placebo Comparator|Placebo + Midazolam + Atorvastatin (Part B)|Placebo coadministered orally with midazolam and atorvastatin.
33072251|NCT05326971|Experimental|Tenofovir disoproxil TDF|Participants who have used TDF as part of their stable antiretroviral regimen for at least past six months.
33072252|NCT05326971|Active Comparator|Tenofovir alafenamide (TAF)|Participants who have used TAF as part of their stable antiretroviral regimen for at least past six months.
33072253|NCT05319639|Experimental|POFI and Tislelizumab|"This study will include a sequential evaluation of 3 subjects per cohort. Irinotecan 135 → 150 and paclitaxel 45 → 67.5 → 90 → 112.5 mg/m2 on day 1.~The rest of regimen is that oxaliplatin (85 mg/m2) and Lev-leucovolin (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. Tislelizumab 200mg，repeating the cycle every 21 days.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days); Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
33072254|NCT05316623|Sham Comparator|Control group|Simulated TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
33072255|NCT05316623|Experimental|Intervention group|Real TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
33072256|NCT05308446|Experimental|Arm I (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33393662|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
32747659|NCT05097495|Experimental|Experimental Group (NNS Combined with Breast Milk)|NNS combined with breast milk will be started 5 minutes before diaper change. The use of NNS combined with breast milk will continue during diaper change and up to 5 minutes after the application.
33070126|NCT04692571|Experimental|Study B: Able-bodied Subjects|Ten able-bodied subjects, the electrodes will be mounted on the dominant arm for the EMG-force and EMG-target tracking trials. In addition, the non-dominant arm will also be constrained and measured in a second load cell. This load cell will not be used for feedback during the experiment, but will compare (RMS error, off-line) the dominant vs. non-dominant forces. For EMG-target tracking, the dominant hand will remain in the wrist cuff (to prevent flailing during contractions), with the screen feedback disabled. These subjects will repeat the trials with the electrodes moved to the non-dominant side. EMG-force tracking will be repeated using mirrored contractions. The three training methods (EMG-force ipsilateral, EMG-force contralateral mirrored, EMG-target on the dominant side) will be contrasted to help understand the source of errors when training with limb-absent subjects.
32747660|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
32747661|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
33070127|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.~Test time points:~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
33070128|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
33393663|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
32747662|NCT05677347|Experimental|Part 1: GSK3923868 or placebo|Participants allocation to GSK3923868 and placebo will be in 3:1 ratio. In treatment period 1, participants will receive GSK3923868 (Dose 1) or Placebo; in treatment period 2, GSK3923868 (Dose 2) or Placebo. There will be a washout period of at least 5 days after each treatment periods.
32747663|NCT05677347|Experimental|Part 2: GSK3923868 or placebo|Participants from Part 1 will be allocated to GSK3923868 and placebo in 3:1 ratio to receive single repeat dose of GSK3923868 (Dose 3) or placebo for 14 days in treatment period 3 with up to 14 days of follow up.
32747664|NCT05497869|Experimental|Experimental interventional group|Active Release Technique (ART)
32747665|NCT05497869|Active Comparator|active control group|conventional group
32747666|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33393664|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
33070129|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
32747667|NCT00591227|Active Comparator|aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
32747668|NCT00591227|No Intervention|usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
32747669|NCT05494437|Experimental|PP-01 High Dose|Oral PP-01 High Dose tapered/titrated over 34 days
32747670|NCT05494437|Experimental|PP-01 Low Dose|Oral PP-01 Low Dose tapered/titrated over 34 days
32747671|NCT05494437|Placebo Comparator|Placebo|Oral placebo, given daily for 34 days
32747672|NCT05494437|Active Comparator|Nabilone|oral nabilone, tapered/titrated over 28 days
32747673|NCT05494437|Active Comparator|Gabapentin|oral gabapentin, tapered/titrated over 34 days
33070130|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
33070131|NCT04692805|Experimental|EUS-guided treatment of varices|"Procedure: EUS-guided injection of coils with cyanoacrylate glue (CYA) and sclerosing agent.~First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with Coils plus CYA and sclerosing agent (Group A)."
32747674|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
32747675|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
32747676|NCT00189293|Experimental|1|Imiquimod 5% cream
33072257|NCT05308446|Active Comparator|Arm II (encorafenib, cetuximab)|Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32747677|NCT00189293|Other|2|vehicle cream
32747678|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
32747679|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
32747680|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
32747681|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
32747682|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
32747683|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
33070132|NCT04692805|Experimental|EUS-guided partial splenic embolization + EUS-guided treatment of varices|"Procedure: EUS-guided partial splenic embolization + EUS-guided treatment of varices First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with coils plus CYA and sclerosing agent.~At the same procedure, a branch of splenic artery will be identified by EUS and implanted with coils plus CYA (Group B)."
33070133|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
33070134|NCT02946112||Shoulder pain|volleyball players with shoulder pain
33070135|NCT02946112||No shoulder pain|volleyball players without shoulder pain
33070136|NCT02946151|Experimental|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
33070137|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
32747684|NCT03193385||Closed reduction|
32747685|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
33070138|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
33070139|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
33070140|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
33070141|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
32747686|NCT03192605|Placebo Comparator|Placebo|Placebo control
32747687|NCT03192683|Active Comparator|Regular sling|
32747688|NCT03192683|Experimental|Cast-sling|
32747689|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
33070142|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
32747690|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~External beam Radiotherapy~Surgery"
32747691|NCT03192527|Experimental|Arm A|KN015, Triptorelin
32747692|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
32747693|NCT05655195|Active Comparator|Alzheimer's Active Arm|Exposure to active sensory stimulation (40Hz) for 60 minutes daily for the length of the trial (6 months).
32747694|NCT05655195|Sham Comparator|Alzheimer's Control Arm|Exposure to control stimulation (sham) for 60 minutes daily for the length of the trial (6 months).
32747695|NCT02444351|Active Comparator|control group|
32747696|NCT02444351|Experimental|botox group|
32747697|NCT05677269||Colorectal endometriosis patients|Subfertile women between 18 and 43 years with colorectal endometriosis facing the choice between IVF or laparoscopic resection of (colorectal) endometriosis.
32747698|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
32747699|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
32747700|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
32747701|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
32747702|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
32747703|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
32747704|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
32747705|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
32747706|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
32747707|NCT05487417|Experimental|Minocycline treatment group|Patients were given minocycline 200mg/d orally from the day of admission for 5 days. At the same time, the patient received mechanical thrombectomy and other standard treatments for acute ischemic stroke.
32747708|NCT05487417|No Intervention|Routine treatment group|Patients were given mechanical thrombectomy and other standard treatment for acute ischemic stroke, without minocycline treatment.
32747709|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
32747710|NCT03281057|Experimental|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
32747711|NCT03281057|Experimental|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
32747712|NCT03281057|Experimental|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
32747713|NCT05694819|Experimental|Darolutamide monotherapy|Targeted patients: 24
32747714|NCT05694819|Experimental|Darolutamide plus Goserelin|Targeted patients: 32
32747715|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
32747716|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
32747717|NCT05677113|Experimental|QBECO|QBECO is an SSI formulated from inactivated E. coli bacteria that is specifically designed to target pathologies of the gastrointestinal (GI) tract and related organs, such as the liver. This trial will test the hypothesis that in patients undergoing resection of colorectal liver metastases (CRLMs), perioperative treatment with QBECO will attenuate the postoperative immune suppression and will improve progression-free survival (PFS).
32747718|NCT05677113|Placebo Comparator|Placebo|A placebo is a liquid that looks like the study drug, but contains no medication.
33241415|NCT05256381|Experimental|SOT101 and Pembrolizumab|Participants will be treated with 12 μg/kg of SOT101 on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
32747720|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
32747721|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
32747722|NCT05676411|Active Comparator|Electrocautery-incision alone group|The skin inicsion will be made using electrocautery during shoulder replacement in patients assigned this group with no other preoperative treatment.
32747723|NCT05676411|Experimental|Electrocautery-incision and BPO group|Patients assigned in this group will undergo an application of topical benzoyl peroxide to the shoulder skin prior to shoulder replacement surgery in addition to their skin incision being made using electrocautery.
32747724|NCT03200327|Active Comparator|laparoscopic promontofixation|
32747725|NCT03200327|Experimental|Anterior vaginal sacrospinofixation|
32747726|NCT03192839|Experimental|Low dose PUFA|
32747727|NCT03192839|Experimental|High dose PUFA|
32747728|NCT03192839|Placebo Comparator|Placebo|
32747729|NCT05174741|Active Comparator|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
32747730|NCT05174741|Experimental|Aerobic Training group|"Supervised Conventional chest physiotherapy+ Aerobic training Conventional chest physiotherapy supervised (1st week) Then non supervised for 2nd to 6th week Warm-up (5 minutes) Breathing exercise and stepping Diaphragmatic Breathing exercise *15 Reps* TD~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day Cool down (5 minutes) AROM +Body stretch"
32747731|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
32747732|NCT04484129||Close contacts of MDR-TB patients|"Close contacts of MDR-TB who met the inclusion and exclusion criteria were enrolled. Routine follow-up is scheduled at week 8, 20, 32, and 80. During the visit, participants with suspected tuberculosis symptoms will have detailed clincial assessent, weight measurement, sputum smear, sputum culture and drug sensitivity examination, imaging examinations, etc. For patients diagnosed with TB, the trial ends. Proper treatment will be started. For all paricipants who are not diagnosed with tuebrculosis in previous follow-up, the last follow-up of this study is all face-to-face visits. Sputum smear, sputum culture and chest imaging screening will be performed when necessary to exclude the possibility of tuberculosis infection. In addition, If the participants has suspected TB symptoms or is diagnosed with TB in another hospital, the researchers can be contacted for follow-up at any time."
32747733|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
32747734|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
32747735|NCT02600897|Experimental|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
32747736|NCT02600897|Experimental|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
32747737|NCT02600897|Experimental|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
32747738|NCT02600897|Experimental|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
32747739|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
32747740|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
33241416|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
32747743|NCT02232191|Active Comparator|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
32747744|NCT02232191|Active Comparator|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
32908703|NCT05387174|No Intervention|Group compared regular care at the MSP Health Center|Comparison group composed of 40 women in the climacteric stage between 40 and 59 years old who have two risk factors of MS (abdominal obesity and arterial hypertension), who go to the Health Center of the People's Committee, to the group of the Hypertensive Program that receive the usual attention of the Institution on group talks, health fairs based on general topics of the disease.
32908704|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
32908705|NCT05616533||focused group|Advanced gastric patients that will be treated with neoadjuvant therapy are enrolled. Every clinical decision such as regimen or dosage will be decided by their own doctors without any interventions. Tumor samples will be obtained before the first cycle of the treatment and will be transplanted to the zebrafish model. Compared results will be analyzed in future.
32908706|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
32908707|NCT03212885|Experimental|1|STN Monopolar Stimulation
32908708|NCT03212885|Experimental|2|rZI + STN stimulation
32908709|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
33241417|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
33241418|NCT00767403|Experimental|1|
32908712|NCT05581199|Experimental|Treatment Period 1: Cohort A, Dose 1|
32908713|NCT05581199|Experimental|Treatment Period 1: Cohort A, Dose 2|
32908714|NCT05581199|Experimental|Treatment Period 1: Cohort B, Dose 1|
32908715|NCT05581199|Experimental|Treatment Period 1: Cohort B, Dose 2|
32908716|NCT05581199|Experimental|Treatment Period 1: Cohort C, Dose 1|
32908717|NCT05581199|Experimental|Treatment Period 1: Cohort C, Dose 2|
32908718|NCT05581199|Experimental|Withdrawal Period 2: Cohort A, Dose 1|
32908719|NCT05581199|Experimental|Withdrawal Period 2: Cohort A, Dose 2|
32908720|NCT05581199|Experimental|Withdrawal Period 2: Cohort B, Dose 1|
32908721|NCT05581199|Experimental|Withdrawal Period 2: Cohort B, Dose 2|
32908722|NCT05581199|Experimental|Withdrawal Period 2: Cohort C, Dose 1|
32908723|NCT05581199|Experimental|Withdrawal Period 2: Cohort C, Dose 2|
32908724|NCT05581199|Experimental|LTE Phase: With Relapse in Period 2: Dose 1 and Dose 2|
32908725|NCT05581199|Experimental|LTE Phase: Without Relapse in Period 2: Dose 2|
32908726|NCT05572073||Retrospective|
32908727|NCT05572073||Prospective|
32908728|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
32911061|NCT04944147|Placebo Comparator|Sham tDCS + cognitive training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
33241419|NCT00767403|Active Comparator|2|
33072258|NCT05307822|Experimental|Cohort 1: Menthol with HTP device (20020064)|Subjects will self-assign to one of three menthol flavor variants of non-combusted cigarette products based on their self-reported flavor usage history.
32747745|NCT02232191|Active Comparator|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
32747746|NCT05470335|No Intervention|physician insertion|radial sheath insertion is performed by physicians
32747747|NCT05470335|Experimental|nurse insertion|radial sheath insertion is performed by nurses
32747748|NCT01774019|Active Comparator|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
32747749|NCT01774019|No Intervention|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
32747750|NCT05674305|Experimental|Radiotherapy alone|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region.
32747751|NCT05674305|Active Comparator|Concurrent chemoradiotherapy|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region plus two cycles of concurent chemotherapy （cisplatin 80mg/m2）
32911062|NCT04944147|Active Comparator|Sham tDCS + Progressive Muscle Relaxation training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: progressive muscle relaxation (PMR) standardized instructed PMR (20 minutes), 9 sessions"
32747752|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
32747753|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
32747754|NCT04958889||HIV+ adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
32747755|NCT04958889||HIV- adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
33241420|NCT00767403|Active Comparator|3|
32747756|NCT04958889||HIV+ adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Height, weight, vital signs, and blood sampling at enrollment.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
32747757|NCT04958889||HIV- adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
32747758|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
32747759|NCT05666973|Active Comparator|Group 1: Scalpel|"Skin Incision for inguinal hernia repair will be given by Stainless steel blade no.10.~Open Mesh Hernioplasty"
32747760|NCT05666973|Experimental|Group 2 : Electrocautery|"Open Mesh Hernioplasty~Skin Incision for inguinal hernia repair will be given by following:~Cautery machine: Erbe VIO 300 S~Cut setting: Cut:30 Coagulate:30~Cautery tip (tip pointed)~Mode: Monopolar"
32747761|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
32747762|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
32747763|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
32908729|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
32747764|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
32747765|NCT02443415||Healthy Controls|Non-diabetic subjects
32747766|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
32747767|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
32747768|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
32747769|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
32747770|NCT02443259||late preterms|late preterm neonates
32747771|NCT05691933|Active Comparator|Block group|Patients will be subjected to bilateral external oblique intercostal plane block
32747772|NCT05691933|Active Comparator|Opioid group|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
32747773|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
32747774|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
32747775|NCT00977483|Experimental|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
32747776|NCT00977483|Placebo Comparator|Drug: Placebo|1 tablet once daily throughout the trial
32747777|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
32747778|NCT02439905|Experimental|Dexmedetomidine group|
32747779|NCT02439905|Placebo Comparator|Normal saline group|
32747780|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
32747781|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
32747782|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
32747783|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
32747784|NCT02439983|Placebo Comparator|Placebo|
32747785|NCT02439983|Experimental|Proprietary Nutritional Supplement|
32747786|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
33241421|NCT04383314|Experimental|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
33241422|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
33241423|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
33241424|NCT00767481|Active Comparator|Cosopt|Cosopt BID
33241425|NCT04306874|Experimental|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
32908730|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
32908731|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes greater than 13F.
33241426|NCT04306874|No Intervention|Control|No intervention on diet; routine dietary practice
33241427|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
32747787|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
33070143|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
33393665|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
33393666|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
33393667|NCT02454010|Experimental|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
33393668|NCT02454010|Experimental|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
33393669|NCT03249688|Other|Control|Regular health advice
33393670|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
33393671|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
33393672|NCT01346865|Experimental|cilostazol|cilostazol 100mg
32747788|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
32747789|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
32747790|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
33070144|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
33070145|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
33070146|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
33070147|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
33070148|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
33070149|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
33070150|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
33070151|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
33070152|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
33070153|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
33070154|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
33070155|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
33070156|NCT00525577|Experimental|1:A|Placebo
33070157|NCT00525577|Experimental|2:B|AGI-1067 75 mg
33070158|NCT00525577|Experimental|3:C|AGI-1067 150 mg
33070159|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
33070160|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
33070161|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
33070162|NCT00525655|Experimental|Multimedia Intervention|
33070163|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
33070164|NCT00526864||Elderly patients|
33070165|NCT00526864||HIV infected patients|
33070166|NCT00526864||Immunosuppressed patients|
33070167|NCT00525694|Other|1|glucose tolerance test solution
33070168|NCT00525694|Other|2|Diet Coke
33070169|NCT00525694|Other|3.|Coke Zero
33070170|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
33070171|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
33070172|NCT00405470|Active Comparator|Medial Pivot|
33070173|NCT00405470|Active Comparator|Posterior Stabilized|
33070174|NCT00526942|No Intervention|I|No contact control (NCC)
33070175|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
32747791|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
32747792|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
32747793|NCT05663073|Experimental|Irbesartan/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan/Amlodipine FDC in a crossover design
32747794|NCT05663073|Experimental|Co-administration of Irbesartan and Amlodipine|participants will receive one table each of Irbesartan and Amlodipine in a crossover design
32747795|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
32747796|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
32747797|NCT05654259||obese women with normal gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain 5-9 kg
32747798|NCT05654259||obese women excessive gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain >9 kg
32747799|NCT05654259||non-obese women with normal gestational weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain 11.5-16 kg
32747800|NCT05654259||non-obese women with excessive weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain >16 kg
32747801|NCT05654259||obese women with OSA|obese women (body mass index ≥30 kg/m2) with Obstructive Sleep Apnea (OSA) (Apnea and Hypopnea Index (AHI) ≥5 events/hr
32747802|NCT05654259||obese women without OSA|obese women (body mass index ≥30 kg/m2) without Obstructive Sleep Apnea (OSA) (AHI <5 events/ hr)
32747803|NCT05654259||non-obese women without OSA|non-obese women without OSA (AHI <5 events/ hr)
32747804|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:~NBC protective garment (charcoal base).~combat garment.~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
32747805|NCT05653323|Experimental|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
32747806|NCT05653323|Experimental|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
33070176|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
33393673|NCT01346865|Placebo Comparator|dual therapy group|Placebo
33393674|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845~single oral dose of BAY1834845 + i.v. BAY1834845~single oral dose of BAY1834845 under fed conditions"
33393675|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845+ i.v. BAY1834845~single oral dose of BAY1834845~single oral dose of BAY1834845 under fed conditions"
33393676|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX)~single oral dose of MTX + single oral dose of BAY1834845"
33393677|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~single oral dose of MTX"
32747807|NCT05653323|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-993.
32747808|NCT05653323|Placebo Comparator|Placebo Part B|Participants will be randomized to receive multiple doses of placebo matched to VX-993.
32747809|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
32747810|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
32747811|NCT05632341|Experimental|GCWB1176|1 capsule once a day
32747812|NCT05632341|Active Comparator|Placebo|1 capsule once a day
32747813|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
32747814|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
33070177|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
33070178|NCT02947282|Active Comparator|Intervention|Educational Workshop
33070179|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
33070180|NCT04693000|Experimental|Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|"An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.~Keratotic nodular size observation after 12 weeks"
32747815|NCT04852653||Patients with adenocarcinoma of rectum histologically proven|
32747816|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
32747817|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
32747818|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
32747819|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
32747820|NCT04771221|Experimental|Main group|Patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
32747821|NCT04771221|Experimental|Control group 1|Patients with an early diagnosis of Gastroesophageal reflux disease
32747822|NCT04771221|Experimental|Control group 2|Patients without complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
32747823|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
32747824|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
32747825|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
32747826|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
32747827|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
32747828|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
32747829|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
33070181|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
33070182|NCT02946970|Placebo Comparator|Control|Intragastric infusion
33070183|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
33393678|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
33393679|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
32747830|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
32747831|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
32747832|NCT04756557|Experimental|Tooth Brushing HAP Toothpaste|"Experimental: Tooth Brushing HAP HAP-Toothpaste Tooth Brushing HAP Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite two x daily over the duration of the study (18 months).~Procedure: Tooth Brushing HAP"
32747833|NCT04756557|Active Comparator|Tooth Brushing F Toothpaste|Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (1450 ppm F-), (two x daily over the duration of the study (18 months).
32747834|NCT02442635|Experimental|Condition 1|Yoga Breathing
32747835|NCT02442635|Experimental|Condition 2|Static Yoga
32747836|NCT02442635|Experimental|Condition 3|Flowing Yoga
32747837|NCT04742673|Placebo Comparator|Placebo|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
32747838|NCT04742673|Experimental|IV Guanfacine|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
32747839|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
32747840|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
33070184|NCT04692727|Active Comparator|Exercise grup|An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 6 weeks, 2 times a week (12 sessions). Each session will take approximately 40 minutes and patients will be asked to repeat the exercises at least 2 sets a day at home when they are not in the clinic (other 5 days a week). The home program will be followed by the exercise daily form.
33070185|NCT04692727|Experimental|McConnell patellar taping grup|McConnell patellar taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group. The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
33070186|NCT04692727|Experimental|Femoral rotational taping grup|Femoral lateral rotation taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group.The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
33070187|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
33070188|NCT00526981|No Intervention|Control|Conventional treatment
33393680|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
33393681|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
32747841|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
32747842|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
32747843|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
32747844|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
32747845|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
32747846|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
32908732|NCT04632641|Active Comparator|Figure 8 Suture - LARGE-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes greater than 13F.
32747847|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
32747848|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
32747849|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
32908733|NCT04538261|Sham Comparator|Control|Non-inflation of the balloon device
32908734|NCT04538261|Experimental|Intervention|Inflation of the balloon device
32908735|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
32908736|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
33393682|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
32747850|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:~Drug and Radiation~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
32747851|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:~Drug, Radiation and Hyperthermia~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
32747852|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
32747853|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
32747854|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
32747855|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
33070189|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
33232022|NCT05539365|Experimental|Treatment (ST-alpha-DC1, pembrolizumab)|Patients undergo leukapheresis over 90 minutes. Patients then receive ST-alpha-DC1 IT on days 1, 8, and 50 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on days 8, 29, 50, and 71 in the absence of disease progression or unacceptable toxicity. Patients who are receiving clinical benefit from treatment at the end of day 85, may continue to receive pembrolizumab IV every 3 weeks beyond the 4 study doses. Patients also undergo tumor biopsies on days 1, 8, and 50 and CT scans at baseline and days 50 and 85.
32747856|NCT02439359|Placebo Comparator|Placebo|Placebo
32747857|NCT02439359|Experimental|CF-301|CF-301
32747858|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
32747859|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
32908737|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
33070190|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
33070191|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
33232023|NCT00592553|Experimental|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
33232024|NCT00592553|Experimental|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
33232025|NCT00592553|Placebo Comparator|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
33232026|NCT00701909|Experimental|1|During the first wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK) before the WCP according to randomization. During the second wound care procedure, they will receive the drugs and doses that they had not received the first time.
32747860|NCT04314843|Experimental|Lenzilumab and Axicabtagene Ciloleucel|Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab. Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0.
32747861|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
32747862|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
32747863|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~Metformin: 850mg (one tablet) twice a day~Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
33232027|NCT00701909|Active Comparator|2|During the second wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK), whichever drugs and doses that they had not received the first time.
33232028|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
33232029|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
33232030|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
33232031|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
33232032|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
33232033|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
33232034|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
33232035|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
33232036|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
33232037|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
33232038|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
33232039|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
33232040|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
33232041|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
32747864|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
32747865|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
32747866|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
32747867|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
32747868|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
32747869|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
32747870|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
32747871|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
32747872|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
32747873|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
32747874|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
32908738|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
32747875|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
32747876|NCT02439203|Experimental|JM-010|JM-010
32747877|NCT02439203|Placebo Comparator|Placebo|Placebo
32747878|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
32747879|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
33232042|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
33232043|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
33232044|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
33232045|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
33232046|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
33232047|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
33232048|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
33232049|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
33232050|NCT04115891|Experimental|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
33232051|NCT04115891|Sham Comparator|Control group|"No application prior to interventions. No lavender oil inhalation.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
33232052|NCT04115657|Experimental|Starch 1|Tapioca starch
32747880|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
32747881|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
32747882|NCT02441933|Active Comparator|control group|
32747883|NCT02441933|Experimental|carboplatin group|
32747884|NCT01604265|Placebo Comparator|Placebo|Placebo control.
32747885|NCT01604265|Experimental|Sativex|Active treatment.
32747886|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
32747887|NCT02441855||pneumonia|patients with community-acquired pneumonia
32747888|NCT02441855||control|patients admitted to emergency department with shortness of breath
32747889|NCT04313751|Experimental|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
32747890|NCT04313751|Active Comparator|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
32747891|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
32747892|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
32747893|NCT04705233|Experimental|Sputum chart|Use of the 5 point sputum colour chart, adapted from Bronkotest® a self-management (SM) plan and rescue pack (RP) containing 5 days supply of antibiotic and steroid treatment
32747894|NCT04705233|No Intervention|Control|Use of the plan and rescue pack alone (best usual care)
32747895|NCT04483427|Experimental|OSA patients after multilevel surgery|
32747896|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
32747897|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
32747898|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
32747899|NCT01664247|Experimental|IDeg + Lira|
32747900|NCT01664247|Experimental|Placebo + Lira|
32747901|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
32747902|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
32747903|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
32747904|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:~increase of the volume (0.5 mL) in case of failure,~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
32747905|NCT02441621|Other|Passive leg raising|
32747906|NCT02441621|Other|premedication|
32747907|NCT02441621|Other|intubation and mechanical ventilation|
32747908|NCT02441621|Other|central venous catheter|
32747909|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
32747910|NCT02441621|Other|transesophageal echocardiography|
32747911|NCT02441621|Other|transpulmonary thermodilution catheter|
32747912|NCT05441085|Active Comparator|Nulliparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age > 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain > 5
32747913|NCT05441085|Active Comparator|Multiparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age > 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain > 5
32747914|NCT05690373|Experimental|Probiotic|2B Colony Forming Unit/ day
32747915|NCT05690373|Placebo Comparator|Placebo|Equivalent placebo
32747916|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
32747917|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
32747918|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
32747919|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
32747920|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
32747921|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
32747922|NCT00587067|Experimental|1|
32747923|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
32747924|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
32747925|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
32747926|NCT04687683|Experimental|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
32747927|NCT04687683|Experimental|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
32747928|NCT04687683|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
32747929|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
32747930|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
33393683|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
32747931|NCT04664751||Patients scheduled for general surgery with anesthesia|Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order.
32747932|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
32747933|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
32747934|NCT05562999|Experimental|Deep neuromuscular blockade|Participant will receive deep neuromuscular blockade (PTC 1-2)
32747935|NCT05562999|Active Comparator|Moderate neuromuscular blockade|Participant will receive moderate neuromuscular blockade (TOF 1-2)
32747936|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
32747937|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
32747938|NCT05247489|Experimental|Group A: Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB)|Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have < 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
32747939|NCT05247489|Experimental|Group B: Ruxolitinib Monotherapy|Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.
32747940|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
32747941|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
32747942|NCT05641077|Experimental|Virtual Visit|Patients randomized to the experimental arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
33232053|NCT04115657|Experimental|Starch 2|High amylose
33232054|NCT04115657|Experimental|Starch 3|Kithul flour
33393684|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
32747943|NCT05641077|Active Comparator|Office Visit|Patients randomized to the active comparator arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
32747944|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
32747945|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
32747946|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
32747947|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
32747948|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
32747949|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
32747950|NCT05245851|Experimental|Opportunistic screening for low BMD|Outpatients aged over 50 years undergoing x-ray of the thoracic spine, lumbar spine, chest, pelvis, hand or knee will have their x-rays screened for low BMD by the software-as-a-medical device. If low BMD is identified by the software, a radiologist reviewing the x-ray may choose to incorporate this as an incidental finding in their report to the referring physician.
32747951|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
32747952|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
32747953|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
33072259|NCT05307822|Experimental|Cohort 2: Non-Menthol with HTP device (20020064)|Subjects will self-assign to a non-menthol flavor variant of a non-combusted cigarette product based on their self-reported flavor usage history.
32747954|NCT05225415|Active Comparator|CT1812 300 mg|CT1812 300 mg
32747955|NCT05225415|Active Comparator|CT1812 100 mg|CT1812 100 mg
32747956|NCT05225415|Placebo Comparator|Placebo|Placebo
32747957|NCT05535075|Active Comparator|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring (TDM), according to institutional guidelines during 20 day study period
32747958|NCT05535075|Experimental|Vancomycin model-informed precision dosing|Area Under the Concentration-time curve ((AUC)/Minimal Inhibitory Concentration (MIC)-based model-informed precision dosing of vancomycin using a dosing calculator during 20 day study period
32747959|NCT05534997|Experimental|Group A|will receive the post covid protocol conventional treatment in form of medication and 24 sessions of combined rehabilitation exercise program in the form of Graded exercise therapy (GET) and cognitive behavioral therapy (CBT). Patients will attend two sessions per week for 12 weeks. Sessions will be taken at Modern university for technology and information physical therapy rehabilitation center . A home exercise program will be prescribed on at least five days a week. Patients will be contacted by phone daily for the 12 weeks treatment sessions, for following up the home exercise program.
32908739|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
33072260|NCT05306418|Experimental|Mim8|52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis
33232055|NCT04115657|Experimental|Starch 4|Sago flour
32747960|NCT05534997|No Intervention|Group B|will receive the post covid protocol conventional treatment in form of medication and specialist medical care provided by doctors with specialist experience in CFS. All patients will be given a leaflet explaining the illness and the nature of this treatment. Treatment will consist of an explanation of chronic fatigue syndrome, generic advice such as to avoid extremes of activity and rest, specific advice on self-help and symptomatic pharmacotherapy (especially for insomnia, pain and mood) .
33232056|NCT04115657|Experimental|Sugar 1|Pure palatinose
33232057|NCT04115657|Experimental|Sugar 2|Blend of sucrose and palatinose
33232058|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
33232059|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
33232060|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
33232061|NCT04120337|Experimental|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
33232062|NCT04120337|Experimental|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
33232063|NCT04120337|Active Comparator|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
32747961|NCT05534919|Experimental|Nefecon active treatment|Nefecon 16mg once daily for 9 months.
32908740|NCT03168347|Active Comparator|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
32908741|NCT03168347|Active Comparator|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
33070192|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
33070193|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
33070194|NCT00407277|Experimental|1A|
33070195|NCT00407277|Placebo Comparator|1B|
33070196|NCT00407277|Experimental|2A|
33070197|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
33070198|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
33070199|NCT00527059|Experimental|1|patients with acute heart failure
33070200|NCT00527059|Active Comparator|2|standard therapy for heart failure
33070201|NCT04693078|Experimental|Intervention Arm|Consecutive patients undergoing screening or surveillance colonoscopy in whom a new polyp detection system based on deep learning will be used during the procedure.
33070202|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
33070203|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
33070204|NCT04692844||Patients with essential tremor treated with Propranolol|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Propranolol in the course of routine medical practice, will be included.
33070205|NCT04692844||Patients with essential tremor treated with Primidone|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Primidone in the course of routine medical practice, will be included.
33070206|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
33070207|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
33070208|NCT00525811|Experimental|A|Interactive decision aid
33070209|NCT00525811|Active Comparator|B|Regular patient information
33070210|NCT00525850|Other|1|high saturated fat diet
33070211|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
33072261|NCT05306288||Individuals with elevated-risk lung cancer (screening population)|
33232064|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
33232065|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
33232066|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
33232067|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
33232068|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
33232069|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
33232070|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
33232071|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
33232072|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
33232073|NCT04117061|No Intervention|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
33232074|NCT04117061|Active Comparator|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
33232075|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
33232076|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
33232077|NCT04115813|Experimental|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
33232078|NCT04115813|Other|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
33232079|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
33232080|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
33232081|NCT00784719|Experimental|Treatment 1|
33232082|NCT00784719|Experimental|Treatment 2|
33232083|NCT00784719|Experimental|Treatment 3|
32908742|NCT03168347|Active Comparator|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
33393685|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
33232084|NCT00784719|Experimental|Treatment 4|
32908743|NCT03168347|Placebo Comparator|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
32908744|NCT02249429|Experimental|bimiralisib (PQR309)|
32908745|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
33232085|NCT00784719|Active Comparator|Active comparator|
33232086|NCT00784719|Placebo Comparator|Placebo|
33232087|NCT04120103|Experimental|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
33232088|NCT04120103|Active Comparator|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
33232089|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
32747962|NCT04609683|Experimental|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
32747963|NCT05530941|Experimental|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire and then received access to the online prevention campaign during three days, after which they were asked to complete another questionnaire.
32747964|NCT05534841||Pathological complete response|Patients with a complete response to the neoadjuvant therapy on the definitive anatomopathology study.
32747965|NCT05534841||Non pathological complete response|Patients without complete response to the neoadjuvant therapy on the definitive anatomopathology study.
33232090|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
33232091|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
33393686|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
33393687|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
33393688|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
32747966|NCT05534763|Experimental|IERGD|I-ER GD is a 10-week intervention directed to the person with GD, provided via the internet with therapist-support. During treatment, participants have an assigned psychologist to interact with and be offered support by, either through feedback on assignments, asynchronous chats or, if needed, by telephone. I-ER GD will focus on increasing adaptive emotion regulation skills, healthy identity development, interpersonal effectiveness skills, coping and building a resilient lifestyle through psychoeducation on gender minority stress, practicing adaptive emotion regulation skills, and reducing emotional and behavioral avoidance.
32901611|NCT03839472|Experimental|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
33393689|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
33393690|NCT03243916|Experimental|combination|TACE plus cyber knife
33393691|NCT03893799|Experimental|Cohort 1, Healthy Volunteers|Dose A, single dose
33393692|NCT03893799|Experimental|Cohort 2, Healthy Volunteers|Dose B, single dose
33393693|NCT03893799|Experimental|Cohort 3, Healthy Volunteers|Dose C, single dose
33393694|NCT03893799|Experimental|Cohort 4, Subjects with CKD Stage 3|Dose D, single dose
33393695|NCT03893799|Experimental|Cohort 5, Subjects with CKD Stage 3|Dose E, single dose
33393696|NCT03893799|Experimental|Cohort 6, Subjects with CKD Stage 4|Dose F, single dose
33393697|NCT03893799|Experimental|Cohort 7, Subjects with CKD Stage 4|Dose G, single dose
33232092|NCT00852917|Placebo Comparator|4: Placebo|
33232093|NCT00700583|Experimental|1|
33232094|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
33232095|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
33232096|NCT04117139|Other|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
33393698|NCT03893799|Experimental|Cohort 8, Subjects with CKD Stage 3 or 4|Dose H, single dose
33393699|NCT03893799|Experimental|Cohort 9, Subjects with CKD Stage 3 or 4|Dose I, single dose
33393700|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
33393701|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
33393702|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
33232097|NCT02612597|Experimental|Bedrest|4 days of bedrest
33232098|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
33232099|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
33232100|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
33393703|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
33393704|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
33393705|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
33393706|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
33393707|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
33393708|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
33070214|NCT02945956|Placebo Comparator|Entecavir|Tablet with Entrcavir
33070215|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
33070216|NCT04692610|Placebo Comparator|Group A|Postoperative Education Group received stoma education and stoma care after surgery beginning from the postoperative day-1. In the preoperative period they were informed about stoma and stoma sites were marked.
33070217|NCT04692610|Active Comparator|Group B|Pre- and Postoperative Education Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual. In the preoperative period they were also informed about stoma and stoma sites were marked.
33070218|NCT04692610|Experimental|Group C|Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
33070219|NCT04692454|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
33070220|NCT04692259|Experimental|experimental arm|Single arm study. All patient who had an MRI performed before liver resection is included
33070221|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
32901612|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
32901613|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
32901614|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
32901615|NCT02207803|No Intervention|Control|Control
32901616|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
32901617|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
32901618|NCT05081466||United Kingdom Women's Cohort|United Kingdom Women's Cohort Study. No interventions are to be administered in this observational prospective cohort study.
32901619|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
32901620|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
32901621|NCT05030688|Active Comparator|Group FICB = Fascia iliaca compartment block|FICB will be performed with a suprainguinal approach under US guidance. The probe will be placed sagittally to view the ilium and iliacus muscle. The probe will be moved medially and inferiorly along the inguinal ligament to view the femoral artery. The probe will then be moved superiorly and laterally along the inguinal ligament towards the anterior superior iliac crest to reach the lateral aspect of the femoral nerve. The deep circumflex artery will be visualized 1-2 cm cephalad to the inguinal ligament and superficial to the iliac fascia. The needle will be inserted with in-plane method 2-4 cm caudal to the inguinal ligament to reach below the fascia ilica. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
32901622|NCT05030688|Active Comparator|Group PENG|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
32901623|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
32901624|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
32901625|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
33070222|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
33070223|NCT00527137|Active Comparator|rHuEPO|
33070224|NCT00527137|Experimental|darbepoetin alfa|
33072262|NCT05306015|Experimental|test group|Patients undergoing brain-computer interface-based mindfulness meditation training during the perioperative period of radiofrequency ablation.
33072263|NCT05306015|Active Comparator|control group|Patients receiving routine care for radiofrequency ablation.
33070225|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
33070226|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
33070227|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
32908746|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
32908747|NCT02249507|No Intervention|Control|sited rest for 45 minutes
33070228|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
33070229|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
33070230|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
33070231|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
33070232|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
33070233|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
33070234|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
33070235|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
33070236|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33070237|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33070238|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
33070239|NCT00516451|Experimental|1|
33070240|NCT00516490|Experimental|1|GnRH agonist administration
32908748|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
32908749|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
32908750|NCT03032627|Other|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
33070241|NCT00516490|Placebo Comparator|2|Sterile saline injection
33070242|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
33070243|NCT04695145|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer with special training in medical issues. The exercise will be monitored with continuous heart rate registration.~The group training session will begin with a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied."
33232101|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
33232102|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
33232103|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
33232104|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
33232105|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
33232106|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
33232107|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
33232108|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
33232109|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
33232110|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
33232111|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
33232112|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
33232113|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
33232114|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
33232115|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
33232116|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
33393709|NCT03249298|Active Comparator|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
33232117|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
33232118|NCT04100031|Experimental|BCL group|
33232119|NCT04100031|Active Comparator|control group|
33232120|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
33232121|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
33232122|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
33232123|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
33232124|NCT05486793|Experimental|Written Exposure Therapy (WET)|Participants randomized into this arm will receive the WET intervention administered by mental health clinicians.
33232125|NCT05486793|Experimental|Community Health Workers- Written Exposure Therapy (CHW-WET)|Participants randomized into this arm will receive the WET intervention administered by community health workers.
33232126|NCT05486793|Active Comparator|Emotion Focused Supportive Therapy (EFST)|Participants randomized into this arm will receive the EFST intervention.
33393710|NCT04541979|Active Comparator|Aerosolized DNase I|
33232127|NCT00702065||1|
33232128|NCT00702065||2|
32898183|NCT03932240|Active Comparator|Cryoprecipitate|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
33232129|NCT04099563|Experimental|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
33393711|NCT04541979|Placebo Comparator|NaCl|
33232130|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
33232131|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
33232132|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
33232133|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
33232134|NCT00767325|Experimental|Abatacept, 10 mg/kg|
33232135|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
33232136|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
33232137|NCT04119947|Experimental|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
33232138|NCT04119947|Experimental|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
33232139|NCT04119947|Experimental|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
33232140|NCT04119947|Experimental|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
33232141|NCT04119947|Experimental|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
33393712|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
33232142|NCT04119947|Experimental|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
33232143|NCT04119947|Placebo Comparator|SY-009 matching placebo|from 2-40mg
33393713|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
33393714|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
33232144|NCT04115579|Experimental|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
33232145|NCT04115579|Experimental|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
33232146|NCT00702455|Active Comparator|Self-Directed|
33232147|NCT00702455|Active Comparator|Guided|
33398699|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
33398700|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
32898184|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
33232148|NCT04116905|Experimental|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
32901626|NCT05030610|Experimental|Intervention Group|Participants, along with a support person, will complete 12 weekly sessions of the BeatIt-ASD intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
32901627|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
33232149|NCT04116905|Active Comparator|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
33232150|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group~Analgesia~Dexmedetomidine start at 0.7ug/kg/hour~Dose range: 0.2- 0.7 u/kg/hour~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
33232151|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group~Analgesia~Control drug~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
33232152|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
33398701|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
33398702|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
33398703|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
33398704|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
33398705|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
33398706|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
33398707|NCT04482010|No Intervention|Classic HIV care|Participants diangosed HIV positive at the time of the community-based activities conducted by ARCAD Santé PLUS. They will be referred to the referral centers (CSRéf) for the classic HIV care in the Malian public health system.
33398708|NCT04482010|Other|Community-based HIV care|Participants diagnosed HIV positive at the time of the community-based activities by ARCAD Santé PLUS. They will receive community-based HIV care by the NGO at the gold-mining site.
33398709|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
33398710|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
33398711|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
33398712|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
33398713|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
33398714|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
33398715|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
33398716|NCT02404246|No Intervention|Usual Care|Usual Care
33398717|NCT05236218||Pilot study (n = 10)|10 participants will be recruited to complete the questionnaire (version 1). A research assistant will be present to help support them /answer any questions around the format. Readability and comprehension will be noted. Any changes (if needed) can be implemented to its format before the main data collection.
33398718|NCT05236218||Discrete Choice Experiment Questionnaire (n = 50)|Discrete Choice Experiment (DCE) Patients
33398719|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
33398720|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
33398721|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
32747967|NCT05534763|Other|IER SUPPORT|I-ER Support is a 5-week intervention directed to a support person, provided as an optional addition to I-ER GD. I-ER Support is administered in the same manner and in parallel to the I-ER GD intervention. Treatment content is based on the same principles as I-ER GD, but from the perspective of increasing emotional support and understanding of GD. The support person could benefit from increased coping and emotion regulation skills, as they may also be exposed to discrimination or stigma due to having a transgender child, sibling or loved one. In better understanding the processes of being stigmatized and with improved emotion regulation skills, the support person may offer better support and help alleviate burdening effects for the individual with GD. For this reason, I-ER support is primarily aimed at people without trans-experience.
32747968|NCT05530863|Active Comparator|Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other advice. Additional details cannot be provided since that will compromise the participant blinding
33070244|NCT04695145|Active Comparator|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
32747969|NCT05530863|Experimental|ART and Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other training. Additional details cannot be provided since that will compromise the participant blinding
32747970|NCT05428761|Experimental|TP1|Participants will receive TP1 during one experimental trial.
32747971|NCT05428761|Experimental|TP2|Participants will receive TP2 during one experimental trial.
32747972|NCT05428761|Placebo Comparator|Placebo|Participants will receive placebo during one experimental trial.
32747973|NCT05530785|Experimental|treatment group|radiotherapy combined with sintilimab and bevacizumab biosimilar
32747974|NCT05425173|Active Comparator|Conventional treatment|Chest Physical Therapy
32747975|NCT05425173|Experimental|Limb Range of Motion Exercises + Chest Physical Therapy|Limb Range of Motion Exercises + Chest Physical Therapy
32901628|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
32901629|NCT05080998||Single arm - Patients undergoing surveillance for UC recurrence|Subjects previously diagnosed with UC and are undergoing a schedule of surveillance cystoscopies and treatment for the possible recurrence of UC will be recruited. Only intermediate and high-risk group, according to AUA /SUO risk categorisation for non-muscle invasive UC, will be eligible for this study. All subjects will undergo CxBladder urine diagnostic testing.
32901630|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
33070245|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
33070246|NCT00516646|Placebo Comparator|2|
33070247|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
33070248|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
33072264|NCT05302700|Experimental|Early Parental Sensitivity Intervention Program|The protocol will last five to seven days for preterm infant mothers.
33398722|NCT04853004||Study cohort|Personnel in health and care in Stockholm County, who have previously participated in a study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels were collected and documented form the study cohort.
33072265|NCT05302700|No Intervention|Control group|The control group received general routine nursing guidance.
33072266|NCT05296473|Experimental|ADHD Therapy|
33072267|NCT05296473|Active Comparator|Control Therapy|
33072268|NCT05295940|Experimental|LY3841136 (Part A)|Single ascending doses of LY3841136 administered subcutaneously (SC).
33398723|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
33398724|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
33398725|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
33398726|NCT05417802||Stroke with acute stroke|"Inclusion criteria~Episode of single stroke within the past twelve weeks~Individuals' age over 18 years old.~Exclusion criteria~Pregnant women , neurological disorders other than stroke (i.e. Parkinson's), non-ischemic stroke~Individuals with severe cognitive impairments (demonstrating difficulty to understand, read, and answer the questions in writing)~Individuals with difficulties to listen the instruction and video of the robotic device"
33398727|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
33398728|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
32747976|NCT05530629|Experimental|High intensity of resistance training|"The intensity of 75-80% 1RM is used for high intensity resistance training group. The number of repetitions of each set is relatively few, only 6-8 times. The rest time between sets is relatively long, 2-3 minutes, so that the participants can better adapt to this intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
32747977|NCT05530629|Experimental|Moderate intensity of resistance training|"The intensity of 60-65% 1RM is used for moderate intensity resistance training group. The repetition times of each set are relatively moderate, 10-12 times. The rest time between sets is relatively moderate, 1-2 minutes. The relative exercise volume of this group was consistent with that of other experimental groups chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
33072269|NCT05295940|Experimental|LY3841136 (Part B)|Multiple ascending doses of LY3841136 administered SC.
33072270|NCT05295940|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
33072271|NCT05295940|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
33072272|NCT05294991|Experimental|Calm Meditation|"Participants assigned to the Calm group will be asked to complete a minimum of 10 minutes per day of meditation, at any time of day they choose for eight weeks. During weeks 1-4 participants in the Calm group will be asked to complete the introductory 30-day program How to Meditate. Weeks 5-8, participants will be asked to complete one daily meditation that may include the Daily Calm, a different 10-minute mindfulness meditation each day, or a meditation from a various series of meditations (e.g., loving-kindness, seven days of managing stress). Participants will have complete autonomy to choose the meditation. After the participant has completed their daily meditation, participants will also be able to use the app content more broadly based on their preference."
33072273|NCT05294991|Active Comparator|Health Education Podcast|Similar to the Calm group, participants in the POD group will listen to a minimum of 10 minutes per day of a health education podcast delivered via a mobile app for eight weeks. Content was carefully chosen to exclude any recommendations for sleep, meditation, or for mindfulness-like principles or practice. A library of podcasts is available on the app. Participants are able to select the podcast based on title, time or both in an effort to mirror the delivery of the meditations in the Calm group.
33072274|NCT05292339|Active Comparator|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
33072275|NCT05292339|Active Comparator|Ketorolac injection to the shoulder, elbow, wrist, or hand|Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
33072276|NCT05291676|Active Comparator|21-30 standard dose Fluad|Participants age 21-30 years will receive the standard dose Fluad
33072277|NCT05291676|Active Comparator|21-30 high dose Fluzone|Participants age 21-30 years will receive the high dose Fluzone
33232153|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
33232154|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
33232155|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
33232156|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
33232157|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
33232158|NCT04119869|Experimental|iaya Smart Phone Application|"Pre-study evaluation~Access to the smartphone intervention over the course of 12 weeks~Post-study evaluation and interview"
33232159|NCT00912899|Experimental|One|Noscapine HCl
33232160|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
33241428|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
32747978|NCT05530629|Experimental|Low intensity of resistance training|"The intensity of 40-45% 1RM is used for low intensity resistance training group. The repetition times of each set are relatively more, 16-18 times. The rest time between groups is short, only about 1 minute, so that the participants can still maintain sufficient total exercise load under low intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
32747979|NCT05530629|Other|Normal P.E. course|Carry out general teaching content according to the college syllabus.
32747980|NCT04655703|Experimental|DJO X4 Brace with Motion Intelligence Platform: Home discharge|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
32747981|NCT04655703|No Intervention|Control group: Home discharge|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
32747982|NCT04655703|Experimental|DJO X4 Brace with Motion Intelligence Platform: Discharge to rehabilitation center|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
32747983|NCT04655703|No Intervention|Control group: Discharge to rehabilitation center|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
32747984|NCT05638581|Active Comparator|LTOWB|Participants randomized to receive (Low Titer O Whole Blood [LTOWB])
32747985|NCT05638581|Active Comparator|Components|Participants randomized to receive the component blood products.
32747986|NCT05637255|Experimental|SYL1801 ophthalmic solution Low Dose once daily|42 treatment days
33241429|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
33241430|NCT04305236|Experimental|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
33241431|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
32747987|NCT05637255|Experimental|SYL1801 ophthalmic solution Middle Dose once daily|42 treatment days
32747988|NCT05637255|Experimental|SYL1801 ophthalmic solution High Dose once daily|42 treatment days
33241432|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
32747989|NCT05633745|Experimental|NEU-723|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
32747990|NCT05633745|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
32747991|NCT04692441|Other|Intervention|All participants undergo the same intervention: Drinking heavy cream and undergoing MRI.
33072278|NCT05291676|Experimental|≥65 years standard dose Fluad|Participants age ≥65 years will receive standard dose Fluad
33072279|NCT05291676|Experimental|≥65 years high dose Fluzone|Participants age ≥65 years will receive high dose Fluzone
33072280|NCT05291650|Active Comparator|glucocorticoid injection into infrapatellar fat pad|
33072281|NCT05291650|Placebo Comparator|placebo injection into infrapatellar fat pad|
33072282|NCT05288855|Experimental|Voclosporin treatment group 1|2 capsules (15.8 mg) BID of voclosporin
33072283|NCT05288855|Placebo Comparator|Placebo treatment group|2 capsules BID of placebo
33072284|NCT05288855|Experimental|Voclosporin treatment group 3|3 capsules (23.7 mg) BID of voclosporin
33072285|NCT05288855|Experimental|Voclosporin treatment group 4|Maximum dose of 4 capsules (31.6 mg) BID of voclosporin.
33072286|NCT05288166|Experimental|Abemaciclib + Abiraterone + Prednisone/Prednisolone|Abemaciclib plus (+) abiraterone + prednisone/prednisolone administered orally.
33072287|NCT05288166|Active Comparator|Placebo + Abiraterone + Prednisone/Prednisolone|Placebo + abiraterone + prednisone/prednisolone administered orally.
33072289|NCT05285644|Experimental|AR 15512 Ophthalmic Solution (0.003%)|0.003% AR 15512 to be administered BID for 90 days. Both eyes will be treated.
33072290|NCT05285644|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
33072291|NCT05285059||Patients|8- to 14-years-old children with epilepsy
33072292|NCT05285059||Control|8- to 14-years-old children without neurological, psychiatric, or developmental impairments
33072293|NCT05283486|Experimental|Cohort 1: MYMD1 600mg|Subjects randomly assigned to the MYMD1 600mg cohort
33072294|NCT05283486|Placebo Comparator|Cohort 1: Placebo 600mg|Subjects assigned to the 600mg placebo group
33072295|NCT05283486|Experimental|Cohort 2: MYMD1 750mg|Subjects randomly assigned to the MYMD1 750 cohort
33398729|NCT05417724|Other|Battlefield Acupuncture|All subjects will receive BFA treatment weekly for 12 weeks.
32747992|NCT04545957|Experimental|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
32747993|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
32747994|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
33398730|NCT04847934|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the intramuscular injection
33398731|NCT04847934|Experimental|Manual Pressure Vibration Technique Group|Application of manual pressure vibration technique to the area where the intervention will be made
32747995|NCT05407701|Experimental|Cranberry|100% juice active: water, cranberry juice concentrate.
32747996|NCT05407701|Placebo Comparator|Placebo|100% juice placebo: water, fructose, dextrose, citric acid, malic acid, natural flavors, pectin, cherry colorant, sucralose.
32747997|NCT05400057||group 1|Oral Lichen Planus patients. Patients will be diagnosed clinically and histologically.
32747998|NCT05400057||Group 2|Healthy patients. Patients without any systemic or oral lesions, not taking drugs for at least the the last 6 months
32747999|NCT05400057||Group 3|Oral Squamous Cell Carcinoma
32748003|NCT05389995|Active Comparator|Potassium citrate|
32748004|NCT05389995|Active Comparator|Crystal light|
32748005|NCT05389995|Active Comparator|Crystal light + potassium citrate|
32748006|NCT04529265|Experimental|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 1mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
32748007|NCT04529265|Placebo Comparator|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
32748008|NCT03191903|Experimental|Cingal|Cingal is a combination product consisting of 88 milligrams of cross-linked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
32748009|NCT03191903|Active Comparator|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
32748010|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
32748011|NCT05530239||Healthy subjects|Subjects with no documented hematological pathology (neither constitutional nor acquired). From the recruitment of living kidney donors, transplantation unit of Grenoble Alpes University Hospital
32748012|NCT05530239||SCD patients|Patients with SCD
32748013|NCT05530239||Control patients|With a constitutional non-sickle cell disease of the red blood cell, or an acquired red blood cell disease.
32748014|NCT05530161||trauma induced coagulopathy|patients with INR>1.2
32748015|NCT05530161||non-trauma induced coagulopathy|patients with INR≤1.2
32748016|NCT05534685|Experimental|intratracheal administration of surfactant/budesonide on the incidence of bronchopulmonary dysplasia|Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg.
33072296|NCT05283486|Placebo Comparator|Cohort 2: Placebo 750mg|Subjects assigned to the 750mg placebo group
33072297|NCT05283486|Experimental|Cohort 3: MYMD1 900mg|Subjects randomly assigned to the MYMD1 900mg cohort
33072298|NCT05283486|Placebo Comparator|Cohort 3: Placebo 900mg|Subjects assigned to the 900mg placebo group
33072299|NCT05283486|Active Comparator|Cohort 4: MYMD1 1050mg|Subjects randomly assigned to the MYMD1 1050mg cohort
33072300|NCT05283486|Placebo Comparator|Cohort 4: Placebo group 1050mg|Subjects assigned to the 1050mg placebo group
33072301|NCT05283330|Experimental|²¹²Pb-DOTAM-GRPR1|In the dose escalation portion, a classic 3+3 design will be utilized. Doses will be increased by approximately 30% in subsequent cohorts as per Table 1. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%. The maximum total dose that may be administered to a subject in the MAD regimen is 24 mCi over 4 cycles.
33072302|NCT05281393|No Intervention|Control|Access to mobile health platform for resources and information about PrEP
33072303|NCT05281393|Experimental|Experimental|Access to mobile health platform for resources and information about PrEP plus sessions with peer health support navigator, social app interactions, goal setting capabilities
33072304|NCT05275400|Experimental|Insulin Efsitora Alfa|Participants will be given insulin efsitora alfa subcutaneously (SC).
33072305|NCT05275400|Active Comparator|Insulin Degludec|Participants with be given insulin degludec SC.
33072306|NCT05273190|Experimental|Vibrotactile Stimulation|
33072307|NCT05272046|Active Comparator|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their POEM procedure.
33072308|NCT05272046|Experimental|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their POEM procedure.
33072309|NCT05266950|Experimental|CI-135 CAR-T|chimeric antigen receptor T cell treatment
33072310|NCT05266469||Ofatumumab|Patients prescribed with Ofatumumab
33072311|NCT05266469||Ocrelizumab|Patients prescribed with Ocrelizumab
33072312|NCT05266027|Experimental|Experimental Group|Nalbuphine Sebacate (Naldebain) intramuscular injection
33072313|NCT05266027|Placebo Comparator|Placebo Group|Placebo medication intramuscular injection
33072314|NCT05258669|Active Comparator|BBV152|BBV152
33072315|NCT05258669|Placebo Comparator|Placebo|0.9% normal saline
32748017|NCT05534685|Experimental|intratracheal administration of surfactant on the incidence of bronchopulmonary dysplasia|Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
32748018|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
32748019|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
32748020|NCT05530083|Experimental|group education|The investigators will provide experimental groups with group education of smoking cessation, including lectures in groups of 50 to 100 people and panel discussion in groups of 5 to 10 people.
32908751|NCT04474379|Experimental|Strategy Training|Consists of 8-90 minute sessions over 4 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
33070249|NCT03016871|Experimental|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
33070250|NCT03016871|Experimental|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
33241433|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
32748021|NCT05530083|Other|conventional smoking cessation management|The investigators will provide control groups with conventional smoking cessation management, including regular follow-up of smoking status and giving advice of smoking cessation.
32748022|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
33070251|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
32748023|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
32748024|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
32748025|NCT04524195|Experimental|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
33070252|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
33070253|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
33070254|NCT00527215|Experimental|darbepoetin alfa|
33070255|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
33070256|NCT00527254|No Intervention|Control group|
33070257|NCT00527254|Active Comparator|Telemedicine group|
33070258|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
33070259|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
33070260|NCT04692142|Active Comparator|Passive online|Before L1, all students will be asked to complete a set of multiple-choice questions (MCQs), formative exam (i.e. pre-test). Following the test , the lecture will be delivered to the participants of PG using a passive online teaching format for 60 minutes (i.e., live-video streaming). After the lecture is completed, students will be asked to re-take the same pre-test exam and complete questionnaire regarding their experience with the teaching methods.
32748026|NCT04303689|Experimental|Colchicine|3 weeks of treatment with colchicine
32748027|NCT04303689|Placebo Comparator|Placebo|3 weeks of placebo-treatment
32748028|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
33232161|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
33232162|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
32748029|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
33232163|NCT00766467|Experimental|Group 1|Armodafinil
33232164|NCT00766467|Placebo Comparator|Group 2|Placebo
33232165|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
33232166|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
33232167|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
33232168|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
33232169|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm of a previously completed two level cervical disc trial.
32911063|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
33232170|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
33232171|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
33241434|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
32748030|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
32748031|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
32748032|NCT05530005|Active Comparator|Hands on|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
32748033|NCT05530005|No Intervention|Hands off|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
32748034|NCT05534529|Experimental|Rezafungin|It is IMP.
32748035|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
32748036|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
32911064|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
32911065|NCT04893213|Active Comparator|Baseline availability|Baseline availability of lower energy meal options
32911066|NCT04893213|Experimental|Increased availability|Increased availability of lower energy meal options
32911067|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
32911068|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
32911069|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
32911070|NCT01749605|Active Comparator|nitrofurantoin 100 mg|
32911071|NCT01749605|Active Comparator|Ciprofloxacin 250 mg|
32911072|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
32911073|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
32911074|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
32911075|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
32911076|NCT04510389|Placebo Comparator|Placebo|volunteers will receive 28 sachets containing 30g of maltodextrin to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
32911077|NCT04510389|Experimental|Whey|volunteers will receive 28 sachets containing 30g of whey protein to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
32911078|NCT04351568||medical personel|
32911079|NCT04351568||non medical personel|
32748037|NCT05529927|Experimental|Sustained-release Dexamphetamine|Tablets of 30 mg sustained-release dexamphetamine sulphate. Target dose: 90 mg/day, if tolerated. Tablets have to be taken daily, in the morning, per os for 24 weeks.
32748038|NCT05529927|Placebo Comparator|Placebo|Identical matched placebo, dispensed under the same conditions and with similar frequency as the investigational product (see above).
33393715|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
33393716|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
33232172|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
33232173|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
33232174|NCT04022265|Active Comparator|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
33232175|NCT04022265|Experimental|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
33232176|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
33232177|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
33232178|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
33232179|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
33232180|NCT00765999|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
32748039|NCT03191591|Experimental|First 1,000 Days Program|
32748040|NCT05534451|Experimental|video rigid laryngoscope group|Similarly during intubation, the patient should be placed in the supine position with the neutral head. The endoscopic body of video rigid laryngoscope covered by a lubricated endotracheal tube enters the airway through the nasal cavity, then proceeds under visual conditions. When the epiglottis is exposed, if necessary, gently lift the patient's lower jaw so that the glottis is fully visible. The tube is pushed to approach and pass the glottis. Withdraw the endoscopic body while adjusting the depth of tube in the trachea. The intubation ends with tube fixation.
33232181|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
33232182|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
33232183|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
33232184|NCT04099407|Experimental|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
33232185|NCT00765063|Experimental|Active|Active study treatment
33232186|NCT04098939||Healthy participants|Participants without any known cardiac or pulmonary disease.
33232187|NCT04098939||Heart disease participants|Participants with heart disease.
33232188|NCT04098939||Lung disease participants|Participants with lung disease.
33232189|NCT00764751|Experimental|1|
32748041|NCT05534451|Experimental|video laryngoscope group|First of all, participants will be asked to take supine position with neutral head. The operator will insert a lubricated endotracheal tube through the nasal cavity into the oropharynx, while he/she holds the handle of video laryngoscope in his/her left hand. Laryngoscope blade can be placed into oral cavity along the right corner of the patient's mouth, and the tongue is pushed to the left by moving the handle. Blade should arrive at a suitable depth to fully expose the epiglottis and glottis. After that, the operator can push the catheter with the right hand to approach and pass the glottis, sometimes Magill forceps are necessary. Finally, the tube is inserted into the trachea to the appropriate depth and fixed firmly.
32748042|NCT05534451|Experimental|video fiberoptic scope group|It is suggested to apply paraffin oil to the surface of the insertion tube of video fiberoptic scope, where the friction with the inner wall of the endotracheal catheter will be reduced. The insertion tube together with a lubricated endotracheal tube will be placed into the nasopharynx through the nasal cavity of patient who takes supine position with neutral head. Push the insertion tube slowly and continuously along the airway until cuff passes through the glottis. Next carefully, the endotracheal tube can be delivered into the trachea, and the insertion tube can be withdrawn from the trachea. At last, the tracheal catheter can be fixed after the depth is adjusted to an appropriate level.
32748043|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
32748044|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
32748045|NCT05534217|Experimental|debridement+traditional treatment|The experimental group receives debridement of the abrasion wound before receiving traditional treatment including evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
32748046|NCT05534217|Active Comparator|traditional treatment|The traditional group receives evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
32748047|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
32748048|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
32748049|NCT05534139||Healthy controls|Partner/spouse of a patient not at risk of HD OR sibling with genetic test results available that show a normal CAG repeat length for both HTT alleles (<36); No other known cognitive, neurological or psychiatric disorders.
32748050|NCT05534139||Premanifest HD expanded gene carrier|HDGEC before clinical onset: TMS <5, DCL <4, TFC = 13. No other major comorbidity.
32748051|NCT05534139||Early Manifest HD patient|HDGEC after clincial onset: TMS >5, DCL = 4. Early stage of disease: TFC 11-13. No other major comorbidity.
32748052|NCT05534139||Moderate Manifest HD patient|HDGEC after clincial onset: TMS >5, DCL = 4. Moderate stage of disease: TFC 7-10. No other major comorbidity.
32748053|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
32748054|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
32748055|NCT02437721|No Intervention|Breast milk|non randomized reference group
32748056|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
32748057|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
32748058|NCT05378373|Active Comparator|SHEETS Arm 1|Participants will receive sleep education-related content on factors that impact sleep, like getting enough exercise.
32748059|NCT05378373|Experimental|SHEETS Arm 2|Participants will receive sleep education-related content to support good sleep, like setting schedules.
32748060|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
32748061|NCT05533983|Experimental|Preparation of Frozen Stool Suspensions for FMT|The study will enroll patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
32748062|NCT05370183|Experimental|Hyperambulatory tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head by mini-optics in consultation
32748063|NCT05370183|Active Comparator|Operating room tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head upon arthroscopy under normal operating condition
32748064|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
33232190|NCT00764751|Active Comparator|2|
33232191|NCT00764751|Placebo Comparator|3|
33241435|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
33241436|NCT04303364||Subjects without T2DM and without HF|
33241437|NCT04303364||Patients without T2DM and with HFpEF|
33232192|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
33072316|NCT05257408|Experimental|Nab-paclitaxel 80 mg/m^2 with Relacorilant 150 mg|Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.
33072317|NCT05257408|Active Comparator|Nab-paclitaxel 100 mg/m^2|Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
33072318|NCT05255250|Experimental|PLAYshop Intervention|Participants will receive a 60 minute virtual physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
33072319|NCT05255250|No Intervention|Control|Participants will receive the 60 minute virtual physical literacy workshop, equipment goody-bag, and access to the digital app after completing 2-month follow-up measures.
33072320|NCT05248867|Experimental|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
33072321|NCT05248867|Placebo Comparator|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
33072322|NCT05245266|Other|Analysis of blood samples from healthy pregnant women|Analysis of blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
33072327|NCT05236465|Experimental|A 3-day course|The course consists of teaching in basic psychology, stress physiology and practice of a specific technique with self-instructions and visualization in a group setting by non-health personnel
33072328|NCT05236465|Active Comparator|Waiting list|Treatment as usual (TAU)
33072329|NCT05228886|Active Comparator|Call + Resources|Participants receive standard care typically provided to 211 callers, including ad hoc follow-up.
33072330|NCT05228886|Experimental|Call + Resources + Scheduled Follow-Up|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the Scheduled Follow-Up intervention description.
33072331|NCT05228886|Experimental|Call + Resources + SINCERE|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the SINCERE intervention description (scheduled follow up with active collaborative goal setting).
33072332|NCT05224869|Experimental|Patients with prostate cancer|Patients undergo hydrogel rectal spacer placement on day 1. Within 2 weeks (+/-1 week) after Rectal Spacer placement, patients will be scheduled for CT simulation for external beam treatment planning. Patients will begin the SBRT of 24Gy in 5 fractions within 2 weeks (+/-1 week) from the simulation date. Within 4 weeks (+/-1 week) of last day of SBRT, patients undergo brachytherapy. Patient will return for post-implant CT-based dosimetry analysis 4 weeks (+/- 1 week) post brachytherapy,
33393717|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393718|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393719|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
32748065|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
33070261|NCT04692142|Experimental|Flipped classroom|"Participants of FG will have an access to a recorded lecture. and they will be taught using an active teaching model known as flipped classroom model. In this model, participants will have 7 -day monitored remote access to the recorded L1. Similar to PG, completing the online pre-test formative exam will be preliminary requirement to access the published recorded L1.~At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately. After the lecture is completed, students will be asked to re-take the same pre-test of L1 and complete questionnaire regarding their experience with the teaching methods."
33070262|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
32911080|NCT04498767|Active Comparator|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
33393720|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
32748066|NCT05533827|Experimental|Kaleidoscope|Kaleidoscope
32748067|NCT05533827|Experimental|Music|Music listening
33393721|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393722|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
32748068|NCT05533827|Experimental|Virtual reality glasses|Virtual reality glasses
32748069|NCT05533827|No Intervention|Control|Control
32748070|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
32748071|NCT05533749|Experimental|GILL eHealth module|Patients will perform the GILL eHealth. This eHealth contains two modules focusing on systematic somatic screening and lifestyle behaviors.
32748072|NCT05533749|No Intervention|Care as usual|Patients will receive usual care and have unrestricted access to mental care and treatment.
32748073|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
32748074|NCT05627271||ocrelizumab|patients prescribed with ocrelizumab
33070263|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
33070264|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
33070265|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
33070266|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
33070267|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
33070268|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
33070269|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
33070270|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
33070271|NCT02945644|Active Comparator|Trazodone 50mg|
32748075|NCT05627271||natalizumab|Patients prescribed with natalizumab
32748076|NCT05627271||ofatumumab|Patients prescribed with ofatumumab
32748077|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
32748078|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
32748079|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
32748080|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
33232193|NCT00764673|Other|Primary|Post market study
33070272|NCT02945644|Active Comparator|Trazodone 100mg|
33241438|NCT04303364||Patients with T2DM and without HFpEF|
33232194|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33232195|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33232196|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
33232197|NCT00764361|Placebo Comparator|Placebo|placebo gel
33232198|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
33232199|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
33232200|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
33232201|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
33232202|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
33232203|NCT00763269|Experimental|A|sensitive toothpaste
33232204|NCT00763269|Active Comparator|B|Triclosan control toothpaste
33232205|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
32748082|NCT02436551||Pregnant women in Tajikistan|
33232206|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
33232207|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
33232208|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
33232209|NCT04098861|Experimental|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
33232210|NCT04098861|Experimental|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
33232211|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
32748083|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
32748084|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
33232212|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
33232213|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
33232214|NCT04098705|No Intervention|Pre-intervention|Pre-intervention period
33232215|NCT04098705|Experimental|Post-intervention|Post-intervention period
33232216|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
33232217|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
33232218|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
33232219|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
33232220|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
33241439|NCT04303364||Patients with T2DM and HFpEF|
33241440|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
32748085|NCT04496739|Active Comparator|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
33232221|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
33232222|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
33232223|NCT00699179||A|
33232224|NCT04119557|Experimental|LY3471851|LY3471851 administered subcutaneously (SC)
33232225|NCT04119557|Placebo Comparator|Placebo|Placebo administered SC
33232226|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
33232227|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
33232228|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
33232229|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
33232230|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
33232231|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
33232232|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
32761927|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
33070273|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
33070274|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
33070275|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
33070276|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
33232233|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
33070277|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
33070278|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
33070279|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
33232234|NCT00785928|Experimental|Placebo|
33232235|NCT00785928|Experimental|1 mg LY2127399|
33070280|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
33070281|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
33070282|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
33070283|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
33072333|NCT05219500|Experimental|Ac225-PSMA I&T|All patients will receive 225Ac-PSMA-I&T, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%), then de-escalation to 87 kBq/kg (±10%), 75 kBq/kg (±10%) or 50 kBq/kg (±10%) in cases of good response (PSA decline >50%), at the discretion of the principal investigator.
33072334|NCT05201508|Active Comparator|Sutures only|Traditional suture closure of hiatal defect
33072335|NCT05201508|Experimental|Polyglactin mesh|In addition to traditional sutures, key hole polyglactin mesh for hiatal defect closure.
33072336|NCT05200624|Active Comparator|Active laser|Application of the active 2RT sub threshold laser
33072337|NCT05200624|Sham Comparator|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
33072338|NCT05186974|Experimental|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)|Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
33072339|NCT05186974|Experimental|SG + Pembrolizumab (Cohort B)|Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
33072340|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin Safety Run-in|Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.
33393723|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393724|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393725|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
33393726|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
33393727|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
33393728|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
33232236|NCT00785928|Experimental|3 mg LY2127399|
33232237|NCT00785928|Experimental|10 mg LY2127399|
33232238|NCT00785928|Experimental|30 mg LY2127399|
33232239|NCT00785928|Experimental|60 mg LY2127399|
33232240|NCT00785928|Experimental|120 mg LY2127399|
33232241|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
33232242|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
33232243|NCT00699257||Oxford® Partial Knee System|
33232244|NCT04119401|Active Comparator|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
33393729|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
33232245|NCT04119401|Experimental|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
32748086|NCT04496739|Experimental|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
32748087|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
33232246|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
33232247|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
33232248|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
33232249|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
33232250|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
33232251|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
33232252|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
33232253|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
33232254|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine (TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1).
33232255|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV).
33232256|NCT00838331|Experimental|Fresh blood, then aged blood|
33232257|NCT05603429||CABG with cold blood cardioplegia|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of cold blood cardioplegia solution for myocardial protection
33232258|NCT05603429||CABG with Del Nido|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of Del Nido cardioplegia solution as myocardial protection
33232259|NCT05603429||AVR with cold blood cardioplegia|Subjects undergo Aortic Valve Replacement with the use of cold blood cardioplegia solution as myocardial protection
33232260|NCT05603429||AVR with Del Nido|Subjects undergo Aortic Valve Replacement with the use of Del Nido cardioplegia solution as myocardial protection
33232261|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
33232262|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
33232263|NCT00785538|Experimental|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
33232264|NCT04102488|Experimental|6-step hygiene technique, application time of 30 seconds|
33232265|NCT04102488|Experimental|6-step hygiene technique, application time of 15 seconds|
33232266|NCT04102488|Experimental|3-step hygiene technique, application time of 30 seconds|
33232267|NCT04102488|Experimental|3-step hygiene technique, application time of 15 seconds|
33232268|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
33232269|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test > 15 seconds
33232270|NCT04101162|Other|liver biopsy|
32748088|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
32748089|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
32748090|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
32748091|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
32748092|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
32748093|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
32748094|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
32748095|NCT04480047|Experimental|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
32748096|NCT05233553||post-COVID-patients|
32748097|NCT05529849|Experimental|TCMCB07|once daily subcutaneous injection
32748098|NCT05529849|Placebo Comparator|TCMCB07 Matching Placebo|once daily subcutaneous injection
32748099|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.~We declare that we have no conflicts of interest."
33232271|NCT04101162|Other|ATI|
33232272|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57~Drug: Bazedoxifene 20 mg/day (Viviant)~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
33232273|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
33232274|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
33232275|NCT04100850|Experimental|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
33232276|NCT04100850|Active Comparator|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
33232277|NCT04100850|No Intervention|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
33072341|NCT05186974|Experimental|SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)|Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m^2 on Day 1 of a 21-day cycle.
33232278|NCT04105296|Experimental|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
33232279|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
33232280|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
33232281|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
33232282|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
33232283|NCT04104906|Experimental|motor control training|8-week exercise program, twice a week, with motor control training
33232284|NCT04104906|Active Comparator|exercises|8-week exercise program, twice a week.
33232285|NCT05542290|Experimental|With capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation with capsular tension ring implantation combined with goniosynechialysis.
32748100|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.~We declare that we have no conflicts of interest."
33232286|NCT05542290|Other|Without capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation without capsular tension ring implantation combined with goniosynechialysis.
33232287|NCT04099758|Experimental|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
33232288|NCT04099758|Placebo Comparator|Audio-recording control|10 minute non-fiction audio-recording delivered online
33232289|NCT05491434|No Intervention|Control|The usual pre-surgical preparation and conditioning will be carried out, without providing nutritional supplements or increased physical activity
33232290|NCT05491434|Experimental|Experimental|In addition to the usual pre-surgical preparation and conditioning, a nutritional supplement and increased physical activity will be provided in a controlled manner for 3 weeks.
33232291|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
33232292|NCT05603351|Experimental|Preventive prostate examination by bpMRI|"The cohort consists of patients:~with age 50-69 years~without any contraindications to MRI or biopsy~without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)~without known BRCA mutation~without PSA test or prostate MRI in the past 2 years~without any signs of prostatitis or urinary tract infection in the past 6 months."
33232293|NCT00703313|Active Comparator|2|described in intervention
33232294|NCT00703313|Active Comparator|3|described in intervention
33232295|NCT00703313|Active Comparator|1|described in intervention
33232296|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
33232297|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
33232298|NCT00703079||Group C|>15 patients cured after surgery only
33232299|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
33232300|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
33241441|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
33241442|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
33241443|NCT00767559|Active Comparator|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
33241444|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
33241445|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
33241446|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
33241447|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
32748101|NCT05368311|Experimental|Group receiving dietary recommendations including protein enriched bars .|Experimental group will consume two protein enriched bars per day during 12 weeks. First bar will be consumed 45 minutes before lunch and second bar will be consumed 45 minutes before dinner.
32748102|NCT05368311|Placebo Comparator|Group receiving dietary recommendations without protein enriched bars.|Placebo group will follow just dietary recommendations during 12 weeks.
33072342|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)|Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
33241448|NCT00767637|Experimental|Arm 1|
33232301|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
33232302|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
33232303|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
33232304|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
33232305|NCT00840749|Active Comparator|Surgery|
32911081|NCT04498767|Experimental|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
33232306|NCT00703469|Experimental|1|
33232307|NCT00703469|Placebo Comparator|2|
33232308|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33232309|NCT04030715|Other|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
33232310|NCT04030715|Other|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
33232311|NCT00592007|Experimental|A|Single-arm study
33232312|NCT00591851|No Intervention|1|single arm study
33232313|NCT00913289|Other|adipose tissue derived stromal cells|
33232314|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
33232315|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
33232316|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
33232317|NCT04030793|Experimental|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
33232318|NCT04030793|Active Comparator|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
33232319|NCT00839423|Placebo Comparator|Placebo|
33232320|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
33232321|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
32748103|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
32748104|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
32748105|NCT02436083|No Intervention|control|no antibiotics
32748106|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
32748107|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
32748108|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
32911082|NCT01750931|Other|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
32911083|NCT01750931|Other|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
33232322|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
33232323|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
33232324|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
33232325|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
32911084|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
32911085|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
33232326|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
33232327|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
33232328|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
32748109|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
32748110|NCT05599815|Experimental|ADX-629|
32748111|NCT03189095|Experimental|Intervention|
32748112|NCT03189095|No Intervention|Wait-List Control|
32748113|NCT05207631|No Intervention|Control cohort|Participants in the control cohort received standard care.
32908752|NCT04474379|No Intervention|Process Training|Consists of 8, 90 minute sessions over 4 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
32908753|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
32908754|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
32908755|NCT03018782|Other|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
32908756|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
32908757|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
32748114|NCT05207631|Active Comparator|Cohort with intervention|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhaler on admission to our department. Their inhalers are adapted in accordance with a prescribing guide.
33232329|NCT00703703|Experimental|1|Darifenacin
32908758|NCT05362448|Active Comparator|80 Hz|Stimulation with a frequency of 80 Hz
32908759|NCT05362448|Active Comparator|130 Hz|Stimulation with a frequency of 130 Hz
32908760|NCT05362448|Active Comparator|180 Hz|Stimulation with a frequency of 180 Hz
33232330|NCT00703703|Active Comparator|2|Tolterodine
33232331|NCT00703703|Placebo Comparator|3|Placebo
33232332|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
33232333|NCT02611973|Experimental|HU without aspirin|
33232334|NCT02611973|Active Comparator|HU + aspirin maintenance|
33232335|NCT02611973|Other|HU + AAG|Observational arm
33232336|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
33232337|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
33232338|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
33232339|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
33232340|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
33232341|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
32748115|NCT05533593||AKI Group|
33232342|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
33232343|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
32748116|NCT05533593||Non-AKI Group|
32748117|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
32748118|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
32908761|NCT05362448|Sham Comparator|DBS off|Absence of stimulation
32908762|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
32748119|NCT05533515||RP Treatment cohort|We will use participants who have been deemed eligible for radical prostatectomy based on the current European Urology Association classification system, and who have been scheduled for surgery to completely remove the cancer in the prostate gland.
32748120|NCT05533437|Experimental|Dry needling|During dry needling, a practitioner inserts several filiform needles into your skin. Filiform needles are fine, short, stainless steel needles that don't inject fluid into the body.
32748121|NCT05533437|Active Comparator|kinesio taping|The Kinesio Taping Method is a therapeutic taping technique which alleviates pain and facilitates lymphatic drainage by microscopically lifting the skin. This lifting affect forms convolutions in the skin increasing interstitial space and allowing for decreased inflammation in affected areas. Based upon research and years of clinical use, The Kinesio Taping Method specifically applies Kinesio tape based on evaluation and assessment to dictate a specific application.
32748122|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
33232344|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
33241449|NCT04078022|Experimental|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
32748123|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
32748124|NCT02435771|Experimental|BMI <25|Normal BMI
32748125|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
32748126|NCT02435771|Experimental|BMI >35|Obese by BMI
32748127|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
32748128|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
32748129|NCT02435693|Other|control|without pharmaceutical care programe (control)
32748130|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
32748131|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
32748132|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
32748133|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
32748134|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
32748135|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
32748136|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
33232345|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
32748137|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
33232346|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
33393730|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
33393731|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
32748138|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
33232347|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
33232348|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
33232349|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
33232350|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
33232351|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
33232352|NCT00771030|Placebo Comparator|Placebo SC (Cohorts 1-3)|Participants received placebo to brodalumab by subcutaneous (SC) injection once every 2 weeks for a total of six doses.
32748139|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
32748140|NCT02440685|Experimental|ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
32748141|NCT02440685|Experimental|ASN002 Recommended dose (RD) - DLBCL|ASN002 administered at the recommended dose in subjects with DLBCL. Arm Closed
32748142|NCT02440685|Experimental|ASN002 RD - Mantle Cell Lymphoma|ASN002 administered at the recommended dose in subjects with MCL. Arm Closed
32748143|NCT02440685|Experimental|ASN002 RD - Follicular Lymphoma|ASN002 administered at the recommended dose in subjects with FL.
32748144|NCT02440685|Experimental|ASN002 RD - Peripheral T-cell Lymphoma|ASN002 administered at the recommended dose in subjects with PTCL.
32748145|NCT02440685|Experimental|ASN002 RD - Myelofibrosis|ASN002 administered at the recommended dose in subjects with MF.
32748146|NCT02440685|Experimental|ASN002 RD - Chronic Lymphocytic Leukemia|ASN002 administered at the recommended dose in subjects with CLL.
32748147|NCT05207085|Experimental|Valbenazine|Participants randomized1:1 to receive valbenazine
32748148|NCT05207085|Placebo Comparator|Placebo|Participants randomized 1:1 to receive placebo
32748149|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
33393732|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
33393733|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
33393734|NCT03249064||Vitiligo untreated patients|
33393735|NCT03249064||Control. Patients without vitiligo|
33393736|NCT00832455|Experimental|Montelukast|
33393737|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
33393738|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
33398732|NCT04847934|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be injected
33398733|NCT04847934|No Intervention|Control Group|Standart care
33232353|NCT00771030|Placebo Comparator|Placebo IV (Cohorts 5-6)|Participants received placebo to brodalumab by intravenous (IV) infusion every 4 weeks for a total of two doses.
33232354|NCT00771030|Experimental|Brodalumab 50 mg SC (Cohort 1)|Participants received 50 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
32748150|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
32748151|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
32748152|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
32908763|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
32748153|NCT02576067|Placebo Comparator|Placebo|matching placebo
33232355|NCT00771030|Experimental|Brodalumab 140 mg SC (Cohort 2)|Participants received 140 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
32748154|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
32748155|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
32748156|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
32748157|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
33232356|NCT00771030|Experimental|Brodalumab 210 mg SC (Cohort 3)|Participants received 210 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
32748158|NCT05199909|Experimental|Intervention ( zanubrutinib)|10 enrolled patients are picked up to take zanubrutinib at the indicated dose.
32748159|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
32748160|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
32748161|NCT05529615|Other|stage II with high risk and stage III with low risk（T1-3N1）|ctDNA will be detected at 7 days after surgical treatment. If，ctDNA(-)-> observation； ctDNA(+)-> 1:1 randomized as Capeox chemotherapy 3 months and observation. CtDNA will be detected at 4 months after surgical treatment.
32748162|NCT05529615|Other|stage III with high risk（T4 or N2 or both）|"ctDNA will be detected at 7 days after surgical treatment. All the stage III with high risk will receive Capeox chemotherapy 3 months. ctDNA will be detected after the completion of Capeox chemotherapy 3 months. If，ctDNA(-) -> observation； ctDNA(+) -> 1:2 randomized as Capeox chemotherapy 3 monthsand second line treatment（decided by physician）.~CtDNA will be detected at 7 months after surgical treatment."
32748163|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
32748164|NCT05533047|Active Comparator|Bipolar TURP|Patients thats will undergo bipolar TURP
32748165|NCT05533047|Active Comparator|Monopolar TURP|Patients thats will undergo monopolar TURP
32748166|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
32748167|NCT05363787|Experimental|The effect of therapeutic touch on sleep patterns of elderly patients|The important effects of the therapeutic approach made by the researcher to the elderly patients hospitalized in the intensive care unit will be evaluated.
32748168|NCT05363787|No Intervention|Determining the sleep pattern of the Control Group|It will be evaluated whether there is a change in sleep patterns without intervention in the control group.
32748169|NCT02434835|Experimental|[14C]KWA-0711|
32748170|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
32748171|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
32748172|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
32748173|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
32748174|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
32748175|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
32748176|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
32748177|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
32748178|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
32748179|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
32908764|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
33232357|NCT00771030|Experimental|Brodalumab 420 mg IV (Cohort 5)|Participants received 420 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
32742605|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
32742606|NCT04974411||Infection|Patients diagnosed with infection but did not reach the sepsis marker.
32742607|NCT04974411||sepsis|The patient was diagnosed with sepsis but did not develop septic shock
32742608|NCT04974411||sepsis shock|The patient was diagnosed with sepsis shock
32742609|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
32742610|NCT03261401|Experimental|Part A: M5717|
32742611|NCT03261401|Placebo Comparator|Part A: Placebo|
32742612|NCT03261401|Experimental|Part B: M5717|
32742613|NCT03261401|Placebo Comparator|Part B: Placebo|
32742614|NCT03261401|Experimental|Part C: M5717|
32742615|NCT04831203|Experimental|Protein-hydrolysate|Dietary supplement: an egg-protein hydrolysate (NWT-03) Study volunteers will receive a daily powder of 5 g of protein hydrolysate to mix with 200 mL of water for 36 weeks.
32742616|NCT04831203|Placebo Comparator|Control|Control: 5 g of maltodextrin powder mixed with 250 mL of water for 36 weeks.
32742617|NCT03260777||children with Alopecia Areata|
32742618|NCT03260777||children with tinea capitis|
32742619|NCT03260777||children with trichotillomania|
32742620|NCT03260777||children with tractional alopecia|
32742621|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
32742622|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
32742623|NCT04967547|Experimental|Intervention group|be evaluated by using the self-care PD feasibility assessment in addition to education on renal replacement therapy and dialysis
32742624|NCT04967547|Active Comparator|Control group|education on renal replacement therapy and dialysis
32742625|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
32742626|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
32742627|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
32742628|NCT04964037||Treatment success group|No intervention
32742629|NCT04964037||Treatment failure group|No intervention
32742630|NCT04853433|Experimental|Radiation therapy group|Single-institution pilot study to evaluate the safety and efficacy of radiation therapy (RT) for the treatment of unresected keloids. The primary endpoint will be toxicity within 10 weeks of follow-up. Secondary endpoints will include cessation of growth or shrinkage of keloids, symptomatic response, and impact on quality of life.
32742631|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
32742632|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
32742633|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
32742634|NCT04842591||kidney transplant candidates|Patients listed for first kidney transplantation
32742635|NCT03255161|Experimental|Immediate communication education and support group|
32742636|NCT03255161|No Intervention|Waitlist|
32742637|NCT04967469|Experimental|take calcitriol|End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol
32742638|NCT04967469|Experimental|take alphacalcidol|End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)
32742639|NCT04967469|No Intervention|control|End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment
32742640|NCT03261011|Experimental|AK-104|Single-arm
32742641|NCT04954755||RFS|
32742642|NCT04954755||non-RFS|
32742643|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
32742644|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
32908765|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
32908766|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
32908767|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
32908768|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
32908769|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
32908770|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
33232358|NCT00771030|Experimental|Brodalumab 700 mg IV (Cohort 6)|Participants received 700 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
32742645|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
32742646|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
32742647|NCT04954209||Hospital program of resumption|Program of resumption with physical activities in the hospital
32742648|NCT04954209||Non hospital program of resumption|Program of resumption outside hospital with discovery sessions
32742649|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
32742650|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
32742651|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
32742652|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
32742653|NCT04963335|Experimental|Intervention|Participants perform 16 exergame training (video game-based physical exercise) sessions over a period of 4 to 8 weeks (depending on in-patient or out-patient). Each training lasts between 15 to 25 minutes. Exergames automatically adjust the game difficulty to the abilities of the respective participant.
32742654|NCT04963335|No Intervention|Control|Participants of the control group are instructed to continue their normal daily routine for eight weeks and to record their physical activities.
32742655|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
32742656|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
32742657|NCT04432155|Experimental|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
32742658|NCT04432155|Placebo Comparator|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
32742659|NCT04487951||Moderate|Moderate: moderate COVID -19 pneumonia
32742660|NCT04487951||Severe|_severe COVID-19 pneumonia
32742661|NCT03260621|Other|echocardiographic increase in left atrial pressure|
32742662|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
32742663|NCT04487639|Experimental|Cohort : patients needing oncofertility preservation|
32742664|NCT04963257|Experimental|sertraline combined with fluvoxamine|Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
32742665|NCT04963257|Active Comparator|sertraline combined with aripiprazole|sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
32742666|NCT04953819||Revascularization group|This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease.
32742667|NCT04953819||Medical treatment group|This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting.
32742668|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
32742669|NCT03260309|Experimental|control group|Routine infusion therapy tactic
32742670|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
32742671|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
32742672|NCT04966845||Smokers|Exclusive smokers of convnetional cigarettes
32742673|NCT04966845||HNBC|Exclusive smokers of Heat-Not-Burn Cigarettes (HNBC)
32742674|NCT04966845||Nonsmokers|Subjects that abstain from smoking for at least one year
32742675|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
32742676|NCT04953741|Active Comparator|Stop Fluticasone propionate Inhaled Aerosol Firstly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day
32748180|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
32748181|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
33232359|NCT00768300|Experimental|Ambrisentan|
32748182|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
33232360|NCT00768300|Placebo Comparator|Placebo|
33232361|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
33232362|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
33232363|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
33232364|NCT05540574|Experimental|Zolpidem, then Placebo|"Participants will first receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
33232365|NCT05540574|Experimental|Placebo, then Zolpidem|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
33232366|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
33232367|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:~Without macrovascular invasion Tumor burden <=8 cm Preoperative AFP level <=400 ng/mL Histopathologic grades I, II"
33232368|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
33232369|NCT04104984|Experimental|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
33232370|NCT04104984|Experimental|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
33232371|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
32748183|NCT05532969||Observation group of newly diffuse astrocytoma patients with high-level psychological stress|The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
32748184|NCT05532969||Observation group of newly diffuse astrocytoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
32748185|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
32908771|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
32908772|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
32911086|NCT05516277|Experimental|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
33232372|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
33232373|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
33232374|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
33232375|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
33232376|NCT00767676|Other|1|
33232377|NCT00767520|Active Comparator|A|
33232378|NCT00767520|Placebo Comparator|B|
33232379|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
33232380|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
33232381|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
33232382|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
33232383|NCT00838565|Placebo Comparator|Placebo|
33232384|NCT00838565|Experimental|PF-04236921|
32911087|NCT05516277|Experimental|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
33232385|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
33232386|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
33232387|NCT05591339|Experimental|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (e.g. BCG-Denmark or BCG-Japan) in the skin covering the left upper deltoid muscle. Two doses will be given, 4 weeks apart.~Intervention: Biological BCG-vaccine."
33232388|NCT05591339|Placebo Comparator|Placebo|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine. Two placebo doses will be given, 4 weeks apart.
33232389|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
33232390|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
33232391|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
33232392|NCT05565287|Experimental|Brazelton and Prechtl Assessment Group|Parental advise and intervention based on the combination of neonatal neurobehaviourism (Brazelton) and motor behaviour (Prechtl)
33232393|NCT05565287|No Intervention|No intervention group|Basic hospital guidelines
33232394|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
33232395|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
33232396|NCT00836693|Experimental|Tadalafil|
33232397|NCT00836693|Placebo Comparator|Placebo|
33232398|NCT00770484|Experimental|Propranolol then placebo|Active treatment
33232399|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
33232400|NCT04099602|Experimental|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
33232401|NCT04099602|No Intervention|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
33232402|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
33232403|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
33232404|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
33232405|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
33232406|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
33232407|NCT04100070|Other|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
33232408|NCT04100070|Other|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
33232409|NCT04119245|Experimental|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.~The patient will be returned to supine position."
33232410|NCT05502588|Active Comparator|Self-Guided Forest Bathing|Forest Bathing intervention without a guide and basic navigational instructions, explanation of forest bathing, and time to return.
33232411|NCT05502588|Experimental|Guided Forest Bathing|Forest Bathing intervention led by a certified Forest Therapy guide.
33232412|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
33232413|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
33232414|NCT04097886|Experimental|Morning Exercise Group|Participants perform moderate exercise in the morning.
33232415|NCT04097886|Experimental|Evening Exercise Group|Participants perform moderate exercise in the evening.
33232416|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
33232417|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
33232418|NCT05500092|Active Comparator|Nivolumab + Platinum Doublet Chemotherapy|All participants will receive platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. Carboplatinum (AUC=5) can be used instead of Cisplatin (75 mg/m2) from cycle 2 for Cisplatin induced neuro/oto/nephrotoxicity as long as the subject remains eligible for doublet chemotherapy. Participants with nonsquamous tumors will receive pemetrexed (500 mg/m2). Participants with squamous tumors will receive either docetaxel (75 mg/m2 on day 1) or gemcitabine (1000 mg/m2 on days 1, 8). Cycles will be every 3 weeks and a maximum of a 2 week delay will be permitted for resolution of toxicities.
33232419|NCT05500092|Experimental|Nivolumab + Platinum Doublet Chemotherapy + SBRT (8gy x 3)|SBRT will be delivered near the conclusion of cycle 1 with platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. The intent is to deliver SBRT on three consecutive days when the concentration of radiosensitizing chemotherapy agents in the subject's system is at a minimum, to minimize toxicity risks. It is expected that some subjects may not receive SBRT on three consecutive days due to machine breakdown, inclement weather, or other logistic issues. Subjects must not receive SBRT within 72 hours after a cisplatin or carboplatin infusion
33232420|NCT04097496|Experimental|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
33232421|NCT04097496|No Intervention|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
33232422|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
33232423|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
32748186|NCT05357469|Experimental|Immediate St (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment right away.
32748187|NCT05357469|Experimental|Waitlist ST (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment about 4 weeks after your Baseline Visit.
32748188|NCT04436289|No Intervention|Care-as-usual (CAU) study arm|Participants will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
32748189|NCT04436289|Experimental|Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
32748190|NCT04434729|Experimental|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
32748191|NCT05528991||mesangial hypercellularity, M|the histopathology was graded based on the revised Oxford Classification system as follows: M absent (M0) or M present (M1)
33232424|NCT03110094|Other|Healthy volunteer|
33232425|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
33232426|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
33393739|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
32748192|NCT05528991||endocapillary hypercellularity, E|E absent (E0) or E present (E1)
32748193|NCT05528991||segmental glomerulosclerosis, S|S absent (S0) or S present (S1)
32748194|NCT05528991||tubular atrophy/interstitial fibrosis, T|T ≤ 25% (T0) or T 26%-50% (T1), or T > 50% (T2)
32748195|NCT05528991||crescents, C|C absent (C0) or C present ≥ 1 glomerulus (C1) or C > 25% glomeruli (C2)
32748196|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
32748197|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
32748198|NCT05532891||Pre-pandemic|Patients that underwent elective bariatric surgery in a control period prior to the pandemic (one year from 1st September 2018).
32748199|NCT05532891||Pandemic|Patients that underwent elective bariatric surgery during the pandemic (one year from 1st April 2020)
32748200|NCT05353335|Experimental|nighttime dosing of one anti-hypertensive medication|13 participants will be randomized to nighttime dosing of one anti-hypertensive medication. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
32748201|NCT05353335|Active Comparator|remain on their current regimen|13 participants will be randomized to remain on their current regimen. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
32748202|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
32748203|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
32748204|NCT05346627|Other|mitochondrial myopathy|Patient affected by mitochondrial myopathy, with genetic confirmation of mitochondrial DNA mutation
32748205|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
32748206|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
32748207|NCT05528835||Group A|Women with history of previous one Caesarean section
32748208|NCT05528835||Group B|Women with history of previous normal vaginal delivery.
32748209|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
32908773|NCT04353518|Experimental|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
33232427|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
32748210|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
32748211|NCT05528757||LGMDs Patients|Patients with a genetically confirmed diagnosis of a LGMD subtype 2A, 2B, or 2I
33232428|NCT05499078|Experimental|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day).
33232429|NCT04097574|Active Comparator|NPO-13 0.8%|Low dose
33232430|NCT04097574|Active Comparator|NPO-13 1.6%|High dose
33232431|NCT04097574|Placebo Comparator|NPO-13 0%|Placebo
32748212|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
32748213|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
32748214|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
32748215|NCT05528679|Experimental|Treatment group A|610 100 mg administered subcutaneously every 4 weeks
32748216|NCT05528679|Experimental|Treatment group B|610 300 mg administered subcutaneously every 4 weeks
32748217|NCT05528679|Placebo Comparator|placebo Arm Type：no inter|placebo administered subcutaneously every 4 weeks
33232432|NCT04099680|Active Comparator|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
33232433|NCT04099680|Experimental|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
33232434|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
33232435|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
33232436|NCT04100304|Other|patient under going liver resection|
33232437|NCT00765882|Experimental|1|Linaclotide 290 micrograms
33232438|NCT00765882|Experimental|2|Linaclotide 145 micrograms
33232439|NCT00765882|Placebo Comparator|3|Matching placebo
33241450|NCT04078022|Experimental|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
33241451|NCT04078022|Experimental|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
33241452|NCT04078022|Experimental|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
33241453|NCT00767715|Experimental|A|Patients will be given olanzapine
32748218|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
32748219|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
32748220|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
32748221|NCT04650087|Active Comparator|Apixaban|Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
32761928|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
32761929|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
33241454|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
33241455|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
33241456|NCT02584946|Experimental|High-AVA oat flour cookies|
33241457|NCT04048941|Experimental|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
33241458|NCT04048941|Active Comparator|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
33241459|NCT04048941|Sham Comparator|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
33241460|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
33393740|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
33232440|NCT04097418|Experimental|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
33232441|NCT04097418|Active Comparator|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
33232442|NCT04097418|Experimental|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
33232443|NCT04097418|Active Comparator|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
33232444|NCT05297136|Experimental|Pre-op Stenting|Pre-operative pancreatic stent inserted by Endoscopic Retrograde Cholangiography, followed by distal pancreatectomy
33232445|NCT05297136|Active Comparator|Surgery alone|Distal pancreatectomy alone
33232446|NCT00769860|Active Comparator|1|Arimoclomol
33232447|NCT00769860|Placebo Comparator|2|
33232448|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
33232449|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
33232450|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
33232451|NCT00858143||1|
33232452|NCT04118933|Experimental|MSI-H advanced colorectal cancer|
33232453|NCT00913367|Active Comparator|Amaryl group|
32742677|NCT04953741|Active Comparator|Stop Montelukast Secondly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day
32911088|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
33232454|NCT00913367|Experimental|Amaryl M group|
33232455|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
33232456|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
33393741|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
33393742|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
33393743|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
32742678|NCT04953741|Active Comparator|Stop Montelukast Firstly|stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day
32742679|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
32742680|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
32742681|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
32742682|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
32742683|NCT04966143|Experimental|Treatment group|
32742684|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
32742685|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
33232457|NCT00704015|Experimental|A|Smoking cessation
33232458|NCT00704015|No Intervention|B|
33232459|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
33232460|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
33232461|NCT00707135|Experimental|1|
33072343|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)|Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
33072344|NCT05186974|Experimental|SG + Pembrolizumab + Cisplatin (Cohort E)|Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m^2 on Day 1 of a 21-day cycle.
33072345|NCT05182749|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
32911089|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
32911090|NCT04831671|Active Comparator|Infra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an infra-patella approach.
32911091|NCT04831671|Experimental|Supra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an supra-patella approach.
32911092|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
33072346|NCT05182749|Experimental|Bacteriophage|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
32742686|NCT04953663|Experimental|Low dose group|0.5 × 10 ^ 6 / kg (body weight) of it-hMSC per person
33072347|NCT05176483|Experimental|XL092 + Nivolumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
33072348|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
32742687|NCT04953663|Experimental|Middle dose group|1 × 10 ^ 6 / kg (body weight) of it-hMSC per person
32742688|NCT04953663|Experimental|High dose group|2 × 10 ^ 6 / kg (body weight) of it-hMSC per person
32742689|NCT04953663|Experimental|Highest dose cell group|Highest dose of it-hMSC
32742690|NCT04953663|Experimental|Sub high dose cell group|Sub high dose of it-hMSC
32742691|NCT04953663|Placebo Comparator|placebo group|placebo
32742692|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
32742693|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
32742694|NCT04953585||Normal D-dimer group|preoperative plasma D-dimer levels less than or equal to 1mg/L
32742695|NCT04953585||Elevated D-dimer group|preoperative plasma D-dimer levels greater than 1mg/L
32742696|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
32742697|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
32742698|NCT04953429||nurses|nurses in a third-grade hospital in Beijing
32742699|NCT03254537|Experimental|Mediterranean Organic|
32742700|NCT03254537|Experimental|Mediterranean conventional|
32742701|NCT04953351|Experimental|cognitive registration targeted biopsy|
32742702|NCT04953351|Active Comparator|MRI-ultrasound fusion targeted biopsy|
32742703|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
32742704|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
32742705|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
32742706|NCT04963491|Experimental|3D printed personalized TKA prosthesis|Design：Personalized TKA prosthesis Manufacture：3D
32742707|NCT04963491|Active Comparator|Zimmer NexGen TKA prostheses|Prosthesis has been widely used in clinic
32742708|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
32742709|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
32742710|NCT04965987|Active Comparator|Oxaloacetate|"Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase.~Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to."
32742711|NCT04965987|Placebo Comparator|Placebo|Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to.
32742712|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
32742713|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
32742714|NCT04962945|Active Comparator|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
32742715|NCT04962945|Active Comparator|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
32742716|NCT04953507|Experimental|Thermal Radiofrequency|T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds
32742717|NCT04953507|Active Comparator|Chemical Neurolysis|T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%
32742718|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
32742719|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
33393744|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
33393745|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
33393746|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
33393747|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
32761930|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
33072349|NCT05176483|Experimental|XL092 + Nivolumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
33072350|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
33393748|NCT04487392|Active Comparator|Estrogen vaginal cream group (group A)|22 participants will be included in this group. The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home.
33393749|NCT04487392|Experimental|Photobiomodutation group (group B)|22 participants will be included in this group. The participants selected for group B will be undergo photobiomodulation with red LED.
32761931|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
32761932|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
33072351|NCT05176483|Experimental|XL092 Single-Agent Expansion Cohorts|
33072352|NCT05176483|Experimental|XL092 + Nivolumab + Relatlimab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
33072353|NCT05176483|Experimental|XL092 + Nivolumab + Relatlimab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
33072354|NCT05172726|Experimental|Open Label|
33072355|NCT05172544|Experimental|Low Dose Sentinel|3 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
33072356|NCT05172544|Experimental|Low Dose Expanded|7 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 2 subject will receive placebo IM on Days 1 and 29.
33072357|NCT05172544|Experimental|High Dose Sentinel|3 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
33072358|NCT05172544|Experimental|High Dose Expanded|7 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
33072359|NCT05172089||Diabetic Foot Ulcer parent study|405 clinically diagnosed Diabetic Foot Ulcer (DFU) patients who are suspected to be infected will be recruited . Wound swab for culture obtained. Baseline digital imaging of target wound(s). SF-12 Health survey, Visual Analogue Pain scale, Cardiff wound impact questionnaires. Wound site evaluation including TcOM/TBI/ankle brachial index (ABI) will be completed for subjects with wounds below the knee, if not already completed per standard of care within the previous 12 months. Hemoglobin A1c point of care testing will be drawn for diabetic subjects who do not have an A1c available within 90 days prior to enrollment; 3mm biopsy tissue or debrided tissue will be collected. Ideally, two tissue samples will be obtained; the subject's medical records will be reviewed and followed for up to 16 weeks or until their wound has closed, whichever comes first. The research staff will also call the patient or care facility as needed to check for wound closure.
33072360|NCT05172089||Imaging sub study- 30 subjects|"All of the above items will be performed in this arm in addition to the below:~Wound perfusion will also be measured by laser speckle imaging (LSI) using the Pericam PSI-NR instrument (Perimed Inc.). PeriCam PSI is a non-invasive non-contact device providing two-dimensional imaging of peripheral tissue blood perfusion. Reduced blood flow may lead to insufficient tissue oxygenation and, thus, assessment of peripheral vascular function has several clinical applications. The PeriCam PSI System is FDA 510(k) (#K063586) approved instrument imaging of peripheral tissue blood perfusion. The additional Pericam imaging for perfusion will be performed only in a small pilot cohort of n=40 patients at an IU site to compare this imaging modality with established modalities such as TcOM/TBI/ABI measurements performed within this study."
33072361|NCT05172089||Alzheimer and/or related dementia|"All items in the group: Diabetic Foot Ulcer Parent study will be performed plus:~15 patients that currently have an open chronic wound and are clinically diagnosed with Alzheimer's Disease or Related Dementias (AD/ADRD) will be recruited for this additional cohort."
33072362|NCT05170074||SRS implant|Surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant
33072363|NCT05169567|Experimental|Arm A: Abemaciclib plus Fulvestrant|Abemaciclib administered orally in combination with fulvestrant administered intramuscularly (IM).
33072364|NCT05169567|Active Comparator|Arm B: Placebo plus Fulvestrant|Placebo administered orally in combination with fulvestrant administered IM.
33072365|NCT05168046|Experimental|Parkinson Mindfullness Based Stress Reduction|Patients who have an assessment before and after a mindfulness based stress reduction intervention for 6 months
33072366|NCT05168046|No Intervention|Parkinson controls|Patients who have an assessment before and after 6 monthswithout intervention
33072367|NCT05160922|Other|crizotinib|crizotinib oral treatment
33072368|NCT05159466||Kidney transplant recipients|Up to 25 HIV-positive participants requiring kidney organ transplantation
33232462|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
33232463|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
33232464|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
33232465|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
33232466|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
32742720|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
32742721|NCT04965831|Experimental|Furmonertinib|Furmonertinib as perioperation therapy
32742722|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
32742723|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
32742724|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
32742725|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
32742726|NCT03259997|Active Comparator|Probiotic supplement|
32742727|NCT03259997|Placebo Comparator|Placebo|
32742728|NCT04953117|Experimental|small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort
32742729|NCT04953117|Active Comparator|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB in small vessel cohort
32742730|NCT04953117|Other|very small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter<2.00 mm) in very small vessel cohort
32742731|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
32742732|NCT02455661|Active Comparator|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
32742733|NCT02455661|Active Comparator|Femoral PCI with StarClose device|
32742734|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
32742735|NCT04965441||Computer-assisted surgery (CAS) group|
32742736|NCT04965441||Non-CAS group|
32742737|NCT03260075||ward cat|Patients and staff at wards that have a cat present
32742738|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
32742739|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
32742740|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
32742741|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
32748222|NCT04650087|Placebo Comparator|Placebo|Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
33232467|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
32748223|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
32748224|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
33393750|NCT01347411|No Intervention|Control|Usual treatment
33393751|NCT01347411|Experimental|CPAP|Treatment with CPAP
33393752|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
32748225|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
32748226|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
32748227|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
32748228|NCT05528601|Experimental|users|app users
33070284|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
33393753|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
32748229|NCT05528601|No Intervention|non-users|app non-users
32748230|NCT05532579|Experimental|Invasive Physiotherapy|
32748231|NCT05532579|Placebo Comparator|Sham Group|
33393754|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
32748232|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
33393755|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
32748233|NCT05532501|Active Comparator|Oral Oxytocin|Administer oxytocin (24 IU) orally
32748234|NCT05532501|Active Comparator|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally
32748235|NCT05532501|Placebo Comparator|Oral placebo|Administer placebo orally (identical ingredients, except the active agent)
32748236|NCT05532501|Placebo Comparator|Intranasal placebo|Administer placebo intranasally (identical ingredients, except the active agent)
32748237|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
32748238|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
32748239|NCT05524857|Experimental|Fedratinib 300 mg|Cohort 1: 300 mg of Fedratinib by mouth, once daily during each 28-day cycle
32748240|NCT05524857|Experimental|Fedratinib 400 mg|Cohort 2: 400 mg of Fedratinib by mouth, once daily during each 28-day cycle
32748241|NCT05524779|Experimental|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
33072369|NCT05159466||Kidney living donors|Up to 5 HIV-positive living donors will be enrolled.
33072370|NCT05159427|Experimental|G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
32748242|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
33072371|NCT05159427|Experimental|SmartPill®|Single dose of Glipizide (5 mg modified-release tablet), Rifaximin (200 mg tablet) and SmartPill® administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water.
33072372|NCT05157867|Experimental|Amylase trypsin inhibitors (ATIs), then placebo|Test day 1: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline. After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of placebo (physiological saline).
33072373|NCT05157867|Experimental|Placebo, then Amylase trypsin inhibitors|Test day 1: intraduodenal administration of placebo (physiological saline). After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline.
33232468|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
33232469|NCT00765726|Other|Moroctocog alfa(AF-CC)|
33232470|NCT04100226|Experimental|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
33241461|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
32748243|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
32761933|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
32761934|NCT02331277|Experimental|Multiple dose|Weekly dosing for four weeks
33072374|NCT05153759|Active Comparator|High protein|Consuming a meal composed of 2:1 grams of protein to carbohydrate during the night shift between 7pm-7am
33072375|NCT05153759|Placebo Comparator|Moderate protein|Consuming a meal composed of 1:1 grams of protein to carbohydrate during the night shift between 7pm-7am
33072376|NCT05152628|Experimental|Tacrolimus granules (Modigraf)|Participants will receive the first dose of Modigraf in the morning within 24 hours after reperfusion. Total initial dose will be received in two divided doses post operatively. Subsequent oral Modigraf doses will be adjusted by the investigator and will be received in two doses (recommended interval 12 hours)
33072377|NCT05151744|Experimental|Arm A: RO7200220 + Ranibizumab|Participants will receive RO7200220, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
33072378|NCT05151744|Active Comparator|Arm B: Ranibizumab|Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
32761935|NCT02331277|Placebo Comparator|Placebo|Placebo
32761936|NCT02326441|Experimental|KX2-361|
32761937|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
32761938|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
32761939|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
32761940|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
32761941|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
32761942|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
32761943|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
32761944|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
33072379|NCT05151731|Experimental|Arm A: 0.25 mg RO7200220 Q8W|Participants will receive RO7200220 0.25 milligrams (mg), by Intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
33072380|NCT05151731|Experimental|Arm B: 1.0 mg RO7200220 Q8W|Participants will receive RO7200220 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
33072381|NCT05151731|Experimental|Arm C: 1.0 mg RO7200220 Q4W|Participants will receive RO7200220 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 44 for a total of 12 injections.
33072382|NCT05151731|Active Comparator|Arm D: 0.5 mg Ranibizumab Q4W|Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 44 for a total of 12 injections.
33072383|NCT05145023||Development of the CARD-SARC (n=20)|"Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy.~Field-testing: 20 participants using a convenience/consecutive sampling strategy."
33072384|NCT05145023||Validation of the CARD-SARC (n=100)|The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
33072385|NCT05144997|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
33072386|NCT05144984|Experimental|2.4 mg semaglutide + 2.4 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
33072387|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
33072388|NCT05144984|Experimental|2.4 mg semaglutide + 7.2 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
33072389|NCT05144984|Experimental|2.4 mg semaglutide + 12.0 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
33072390|NCT05144984|Experimental|2.4 mg semaglutide + 21.6 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
33072391|NCT05144984|Experimental|NNC0480-0389 + placebo (semaglutide)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
33072392|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
32748244|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
32748245|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
32748246|NCT05528523|Other|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
32748247|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
32748248|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
32748249|NCT05528445||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE) and Montreal-Cognitive-Assessment-Test(MoCA)
32748250|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
32748251|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
32748252|NCT05524701|Experimental|Sleep Restriction Condition|Participants will be asked to restrict their sleep duration to a maximum of four hours per night (3 am to 7 am) for the two nights prior to the measurement day.
33072393|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
32748253|NCT05524701|Experimental|Normal Sleep Condition|Participants will be asked to sleep for at least eight hours per night (11 pm to 7 am) for two nights prior to the measurement day.
32748254|NCT05192889|Experimental|Block 1|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, Leucovorin, Intrathecal (IT) MHA (methotrexate/hydrocortisone/cytarabine)"
32748255|NCT05192889|Experimental|Block 2|"Block 2a Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Cytarabine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, IT MHA, Radiation~Block 2b Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Blinatumomab, Dexamethasone, Dasatinib, IT MHA~Following Block 2 of therapy, late (≥36 months from diagnosis) first relapse B-ALL who are MRD negative after Block 1 will continue chemotherapy using adapted R3 intensification, interim, and continuation therapies.~Patients receive intervention according to the Detailed Description section with the following:~Methotrexate, Mercaptopurine, IT MHA, Leucovorin, Dexamethasone, Vincristine, Cyclophosphamide, Etoposide, Cytarabine, Dasatinib, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Radiation"
33232471|NCT04100226|No Intervention|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
32748256|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
32748257|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).~(Blood Draw)"
32748258|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
33232472|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
33393756|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
33393757|NCT04487002|Experimental|group A|underwent localized resection
33232473|NCT00765336|Placebo Comparator|Placebo|
33232474|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
33393758|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
33393759|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
33232475|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
33232476|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
33232477|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
33393760|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
32748259|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.~(Blood Draw)"
32748260|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
32908774|NCT04353518|Placebo Comparator|Placebo|"Placebo will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
32908775|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
32908776|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
32748261|NCT05327439|Experimental|Electronic Cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
32748262|NCT05327439|Experimental|Nicotine Pouch|Participants in this experimental condition will be provided with nicotine pouches.
33393761|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
32748263|NCT05327439|No Intervention|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
32908777|NCT04353908|Active Comparator|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
33232478|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
33232479|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
33232480|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
33232481|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
33232482|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
32761945|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
32748264|NCT05528367|Experimental|CRT with Tirelizumab|"Chemotherapy+Tirelizumab:PS regimen:S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w；adjuvant:100mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~Concurrent Chemoradiotherapy:~Radiation: 45-50Gy/25Fx;During radiation: Nab-PTX:100mg qw,Tirelizumab：200mg d1 q3w.~Chemotherapy+Tirelizumab:PS regimen:S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~We will evaluate whether the tumor could be resectable through CT scan and Endoscope after two cycles of Chemotherapy+Tirelizumab and CRT.If it could be resctable,three cycles of adjuvant chemotherapy+Tirelizumab will be arranged;If not,another three cycles of chemotherapy+Tirelizumab will be arranged，then evaluate again."
33070285|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
33070286|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
33070287|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
33070288|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
33070289|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
33070290|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
33070291|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
33232483|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
33232484|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
33232485|NCT04100460|Experimental|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
33232486|NCT04100460|Experimental|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
33070292|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
32748265|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
32748266|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
32748267|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
32748268|NCT05528289|Active Comparator|HFNC 30 L/min with conventional symmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 30 L/min with standard interface
32748269|NCT05528289|Active Comparator|HFNC 30 L/min with new asymmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 30 L/min with the new asymmetric nasal cannula
32748270|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
32748271|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
32748272|NCT05322213|Active Comparator|Active THC|Daily, inhaled, flexible dose of cannabis product with THC.
32748273|NCT05322213|Placebo Comparator|Placebo Cannabis|Daily, inhaled, flexible dose of cannabis product without THC.
32748274|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
32748275|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
32748276|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
33070293|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
33070294|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
33232487|NCT04100460|Placebo Comparator|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
32748277|NCT05524467||Haemodialysis Patients|Only one data collection timepoint per patient is planned. Eligible and consenting patients will be asked to complete several PROs and one questionnaire, and their respective medical charts will be assessed retrospectively
32761946|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
33070295|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
33232488|NCT05548907|Experimental|Sleep restriction treatment|In this condition participants receive a behavioral sleep restriction intervention for six weeks
32748278|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
32748279|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
33232489|NCT05548907|Placebo Comparator|Sleep monitoring|In this control condition people fill out a sleep diary for six weeks
33232490|NCT00764946|Experimental|1|raltegravir
32748280|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
32748281|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
32748282|NCT05184855|Experimental|Blueberry|26 g freeze-dried blueberry powder per day or approximately one cup fresh blueberries equivalent; two weeks intake.
32748283|NCT05184855|Placebo Comparator|Placebo|26 g placebo powder per day matched for color, taste, aroma; two weeks intake.
32748284|NCT05532267|Experimental|Test Product (T)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
32748285|NCT05532267|Active Comparator|Reference Product (R)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
32748286|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
32748287|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
32748288|NCT05528055|Experimental|Dose escalation|Participants will receive SCR-6920 capsule orally at escalating doses, till the maximum tolerated dose level is reached, and the recommended phase 2 dose(RP2D) will be determined.
32908778|NCT04353908|Experimental|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
32908779|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
32748289|NCT05528055|Experimental|Dose expansion: non small cell lung cancer(NSCLC)|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose
32748290|NCT05528055|Experimental|Dose expansion: NHL|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
32748291|NCT05528055|Experimental|Dose expansion: solid tumors|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
32748292|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
32748293|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
32748294|NCT05524155|Experimental|Sintilimab Combined With Regorafenib and HAIC|Sintilimab Combined With Regorafenib and HAIC
32748295|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
32748296|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
32908780|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
33232491|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
33232492|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
33232493|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
33241462|NCT00762957|Active Comparator|Metformin QD|
32748297|NCT05184075|Active Comparator|Reverse hybrid coronary revascularization (HCR)|Patients will undergo reverse hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
32748298|NCT05184075|Active Comparator|Standard hybrid coronary revascularization (HCR)|Patients will undergo standard hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
32748299|NCT03187145||diabetic patients|
32748300|NCT03187145||healthy control|
32748301|NCT05532111|Experimental|RT-R Group|Rituximab combined with tacrolimus induction + rituximab maintenance
32748302|NCT05532111|Experimental|RT-T Group|Rituximab combined with tacrolimus induction + tacrolimus maintenance
32908781|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
32908782|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
32748303|NCT05532111|Experimental|PC-C Group|Glucocorticoid combined with cyclophosphamide induction + maintenance
32748304|NCT03187067||Mozambique, cases|
32748305|NCT03187067||Mozambique, controls|
33232494|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
33232495|NCT04096950|Experimental|MT-3921|Intravenous, single dose
32748306|NCT03187067||Pakistan, cases|
32748307|NCT03187067||Pakistan, controls|
32748308|NCT05532033|Experimental|high flow nasal cannula|Two hours after extubation patients will received high flow nasal cannula oxygenation therapy for 24 hours
32748309|NCT05532033|Active Comparator|Standard oxygen therapy|Two hours after extubation patients will received standard oxygenation therapy for 24 hours
32748310|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
32748311|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
32748312|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.~Patient with monthly feedback call~Patients on continuous MEMS monitoring."
33232496|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
33232497|NCT03776162|Experimental|Bridge Enhanced ACL Restoration|Procedure/Surgery Bridge Enhanced ACL Restoration (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
33232498|NCT05752916|Experimental|Intravenous rhTNK-tPA|rhTNK-tPA(0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 5-10 seconds as per the standard manufacturers' instructions for use.
33232499|NCT05752916|Active Comparator|Antiplatelet agents|Patients will be treated with standard guideline-directed antiplatelet treatment-choice at the discretion of the clinician. Aspirin will be the choice of most physicians; some will choose to use the clopidogrel. Standard of care medication(s) should be given immediately upon randomization.
33232500|NCT03990896|Experimental|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
33232501|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
33232502|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
32748313|NCT05527899|Placebo Comparator|Placebo|½ RDA of micronutrients including 5 mg/d Zn
32748314|NCT05527899|Experimental|Zinc 30 mg|½ RDA of micronutrients including 30 mg/d Zn
32748315|NCT05527899|Experimental|Zinc 60 mg|½ RDA of micronutrients including 60 mg/d Zn
32748316|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
32748317|NCT03117959|Experimental|Stryker shape match|no longer RCT
32748318|NCT05524077|Experimental|Ablation|"Patients will be expected to have a catheter ablation procedure within 2 weeks post randomisation and no longer than 30 days post randomisation.~Medical therapy can be used as a temporising measure before catheter ablation, as is standard of care. If there is breakthrough VT during the period before the clinical procedure, standard practice will be followed in stabilising the ventricular tachycardia (VT) including intravenous short acting anti-arrhythmic drugs (AAD), admission to hospital, internal or external cardioversion. However, preference will be given to scheduling the procedure within 24-48 hours in this situation."
33070296|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
33070297|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
33070298|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
33070299|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
32748319|NCT05524077|Active Comparator|Anti-arrhythmic drugs (AAD)|Patients managed with medical therapy alone by their usual medical practitioners. A protocol aligned with standard clinical care/current clinical guidelines will be provided for guidance, the objective being that the control arm replicates what would constitute standard of care for patients with ventricular tachycardia managed with a non-interventional approach.
32748320|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
32748321|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
33070300|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
33070301|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
33070302|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
33070303|NCT00173862|Experimental|A|
33070304|NCT00529711|Experimental|Group 1|Hypertonic lactate
33070305|NCT00529711|Active Comparator|Group 2|Ringer's lactate
33070306|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
33232503|NCT04099368|Experimental|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
33232504|NCT04099368|Active Comparator|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
33232505|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
33232506|NCT05493072|Other|1 - Control (scenarios 1-5) then intervention (scenarios 6-10)|Observation of control arm practice for scenarios 1-5, followed by intervention arm for scenarios 6-10.
32748322|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
33232507|NCT05493072|Other|2- Intervention (scenarios 6-10) then control (scenarios 1-5)|Observation of intervention arm for scenarios 6-10, followed by control arm practice for scenarios 1-5
33232508|NCT05493072|Other|3- Intervention (scenarios 1-5) then control (scenarios 6-10)|Observation of intervention arm practice for scenarios 1-5, followed by control arm for scenarios 6-10.
33232509|NCT05493072|Other|4- Control (scenarios 6-10) then intervention (scenarios 1-5)|Observation of control arm practice for scenarios 6-10, followed by intervention arm for scenarios 1-5.
33232510|NCT00769002|Active Comparator|Natural Infection|previously naturally infected
33232511|NCT00769002|Active Comparator|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
33232512|NCT00769002|Active Comparator|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
32761947|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
33232513|NCT00769002|Active Comparator|FluMist|prior FluMist vaccinated.
33232514|NCT04100382|Experimental|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
33232515|NCT05480124|Sham Comparator|Sham stimulation treatment|Sham stimulation during a computerized task and electroencephalogram (EEG) recording.
33232516|NCT05480124|Experimental|tACS brain stimulation treatment|tACS brain stimulation during a computerized task and EEG recording. Participants will receive tACS using individualized peak Phase-amplitude coupling (PAC) frequency pairs determined in Session 1.
33232517|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
33232518|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
32748323|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
33070307|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
33070308|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
33070309|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
33070310|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
32908783|NCT05160038|Experimental|Bodily illusions|Participants in the experimental group see a bodily illusion applied to their embodied virtual avatar.
32908784|NCT05160038|No Intervention|No bodily illusions|Participants in the control group embody a virtual avatar, but without bodily illusions
33070311|NCT00529867|Active Comparator|A|
33070312|NCT00529867|Active Comparator|B|
33070313|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
33232519|NCT00806156|Experimental|NKTR-102 q14d|NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 4 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
33232520|NCT00806156|Experimental|NKTR-102 q21d|NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 6 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
33070314|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
33070315|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
32748324|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
33232521|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
32748325|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
33070316|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
33070317|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
33070318|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
32748326|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
33070319|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
33070320|NCT00168480|Experimental|1|Botulinum Toxin Type A
33070321|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
33070322|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
33070323|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
33070324|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
33232522|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
33232523|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
33232524|NCT05755022|Experimental|Maxillary segment repositioning by utilizing reverse engineering using the 3D photogrammetry.|"The printed stereolithographic model with the adapted miniplates will be scanned using 3D photogrammetry technique and a specific software dedicated for image acquisition will be used.~A guide will be designed on the reproduced virtual model. This guide will be used intraoperative as a locating and positioning guide for the maxilla and the plates."
33232525|NCT05755022|Active Comparator|Maxillary segment repositioning by utilizing reverse engineering using the commercial scanners.|• The printed stereolithographic model with the adapted miniplates will be scanned using the commercial scanners and imported for virtual designing of the positioning and locating guide that will be used intraoperative for positioning the maxilla.
33241463|NCT04295720|Experimental|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
33241464|NCT00763113|Experimental|1|Vanguard PS Knee
33070325|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
33070326|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
33070327|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
33070328|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
33070329|NCT00168519|Active Comparator|1|
33070330|NCT00144521|Experimental|1|
33070331|NCT00144521|Active Comparator|2|
33070332|NCT04692376|Experimental|MSCs group|MSCs group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.
33393762|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
33070333|NCT04692376|Active Comparator|Control group|Glucocorticoids and CsA will be used for treatment.
33070334|NCT00527527|Active Comparator|1|8 flexion distraction visits
33232526|NCT03968276|Experimental|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
33232527|NCT00805766|Experimental|TA-650|
33232528|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
33232529|NCT02608970|Other|Placebo|Placebo specified dose on specified days
33232530|NCT00805532|Experimental|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
33232531|NCT00805532|Active Comparator|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
33232532|NCT05752838||Diagnosed with LDH and had LDH-related radiating leg pain|
33232533|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
33232534|NCT04634084|Experimental|Experimental group|
33232535|NCT04634084|Active Comparator|Control Group|
33232536|NCT03947138|Experimental|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
33232537|NCT03947138|Experimental|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
33232538|NCT03947138|Active Comparator|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
33232539|NCT03947138|Active Comparator|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
33232540|NCT05752760|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 12 weeks.
33232541|NCT05752760|Placebo Comparator|Placebo Control|Subjects will consume potato starch (2 capsules) once daily for 12 weeks.
32748327|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
33232542|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
32748328|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
32748329|NCT05531877|Experimental|Patients undergoing Penile Implant Surgery|"All intraoperative measurements are documented in real time. Measurements recorded are as follows:~Preoperative Pre-ICI penile length and circumference, both in relaxed and stretched states. Preoperative post-ICI penile length and circumference, both in relaxed and stretched states. Postoperative penile length and circumference. Penile implant length and girth."
32748330|NCT05527821|Experimental|Surufatinib Combined With Sintilimab and SCRT|
32748331|NCT05527743|Experimental|Invasive Physiotherapy|
32748332|NCT05527743|Placebo Comparator|Sham Group|
32748333|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
32748334|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
32748335|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
33232543|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
33232544|NCT03908060|Experimental|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
32748336|NCT05531799|Other|Group 1 DARE/CYTOLOGY/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
32748337|NCT05531799|Other|Group 2 DARE/CYTOLOGY/HPV|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test for every 6 months within 12 months period
33232545|NCT03908060|Active Comparator|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
33232546|NCT00752856|Experimental|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
33232547|NCT00752856|Active Comparator|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
33232548|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
33232549|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
33232550|NCT05457816||family members|family members of those with rheumatoid arthritis
33232551|NCT05457816||rheumatoid arthritis|persons with rheumatoid arthritis
33232552|NCT05745740|Experimental|RC48-ADC + Pyrotinib|
33232553|NCT04096404|No Intervention|Control|no advice
33232554|NCT04096404|Active Comparator|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
33232555|NCT04096404|Experimental|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
33232556|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
33232557|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
33232558|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
33232559|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
33232560|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
33232561|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
33232562|NCT04020510|Active Comparator|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
33232563|NCT04020510|Experimental|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
33232564|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
33232565|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
33232566|NCT00761631|Experimental|Single|Open label
33232567|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
33232568|NCT04620668|Experimental|Treatment Group (Wysa)|
33232569|NCT04620668|No Intervention|Control Group|
33232570|NCT03684980|Experimental|Arm A - Rituximab + MTX + Glucarpidase|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
33232571|NCT03684980|Experimental|Arm B - Rituximab + MTX + Glucarpidase|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
33241465|NCT00763113|Active Comparator|2|Vanguard CR Knee
33241466|NCT05292014||Coronary Artery Disease (CAD)|
33241467|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
33070335|NCT00527527|Active Comparator|2|12 flexion distraction visits
33232572|NCT03684980|Experimental|Arm C - HD-MTX (Arm Outpatient MTX Therapy in times of COVID-19)|MTX ≤ 3.5 g/m2 will be administered on Day 1, along with pre- and post- hydration. Patients will return on Day 2 for continued hydration and glucarpidase 2000 units. Glucarpidase rapidly and sustainably reduces serum MTX levels >95% without crossing the blood brain barrier, effectively resulting in systemic MTX clearance. Patients will return for bloodwork on Day 3 to document MTX clearance. Arm Outpatient MTX Therapy in times of COVID-19 will only be a single-institution arm, only open at Memorial Sloan Kettering Cancer Center.
33232573|NCT03684980|Experimental|Arm D -Rituximab + MTX + Glucarpidase|Up to 12 patients will be included in Arm D of this study. Cycles will be 14 days long. All patients will receive MTX 3.5 g/m2 administered Day 1 of each cycle (+/- 7 days, a minimum of 14 days required between doses). Glucarpidase will be administered 24 hours (+/- 2 hr) after start of MTX infusion except in cycles 1-2 of Cohort B. Dose of glucarpidase will be 2000 units in Cohort A (first 4 patients) and 1000 units in Cohort B (remaining 8 patients). Patients in Arm D will receive 8 cycles of treatment. Cycles 1 and 2 will be administered in patient while Cycles 3-8 may be in the outpatient setting. Concurrent chemotherapy such as vincristine, procarbazine, and/or ibrutinib may be administered at the investigator's discretion and in accordance with standard of care. In Cohort B, all cycles will be administered with rituximab 500 mg/m2. Rituximab should be administered prior to glucarpidase (window -4 days).
33232574|NCT04098627|Experimental|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
33232575|NCT04098627|No Intervention|Usual Care|Usual care
33232576|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
33232577|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
33232578|NCT03901274|Active Comparator|Clinical Services Support Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework.
33232579|NCT03901274|Experimental|Patient-Centered Enhancements|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework. The clinicians in this condition will receive additional training on two Patient-Centered Enhancements (PCE).
33232580|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
33232581|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
32748338|NCT05531799|Other|Group 3 DARE/CYTOLOGY/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology and High resolution anoscopy for every 6 months within 12 months period
32748339|NCT05531799|Other|Group 4 DARE/CYTOLOGY|Participant request physician assessment for Digital anal rectal exam, Anal cytology for every 6 months within 12 months period
33232582|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
33232583|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
33232584|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
33232585|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
33232586|NCT04599296|Active Comparator|Hip Brace|This group will be assigned to wear a hip brace post surgery.
33232587|NCT04599296|No Intervention|No Intervention|This group will not be assigned a hip brace after surgery.
32748340|NCT05531799|Other|Group 5 DARE/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
33241468|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
32748341|NCT05531799|Other|Group 6 DARE/HPV|Participant request physician assessment for Digital anal rectal exam and Anal HPV test for every 6 months within 12 months period
32748342|NCT05531799|Other|Group 7 DARE/HRA|Participant request physician assessment for Digital anal rectal exam and High resolution anoscopy for every 6 months within 12 months period
32748343|NCT05531799|Other|Group 8 DARE|Participant request physician assessment for Digital anal rectal exam for every 6 months within 12 months period
32748344|NCT05531799|Other|Self-collection CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV test for every 6 months within 12 months period
32748345|NCT05531799|Other|Self-collection CYTOLOGY|Participant request Self-sampling collection for Anal cytology for every 6 months within 12 months period
32748346|NCT05531799|Other|Self-collection HPV|Participant request Self-sampling collection for Anal HPV test for every 6 months within 12 months period
32748347|NCT05531799|Other|Self-collection control group CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV only at month 12
32748348|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
32748349|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
32748350|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
32748351|NCT04299009|Experimental|Retimer bright light therapy glasses|active bright light therapy in the green/blue spectrum range
33070336|NCT00527527|Active Comparator|3|18 flexion distraction visits
33070337|NCT00527527|Placebo Comparator|4|8 placebo control visits
32748352|NCT04299009|Sham Comparator|sham-Retimer bright light therapy glasses|bright light therapy with light in the red spectrum (not active)
33232588|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
33241469|NCT04283552|Experimental|Main Cohort: Dynamic PET Imaging|-Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan
33241470|NCT04283552|Experimental|Repeatability Cohort: Dynamic PET Imaging|"Dynamic PET/CT imaging will begin at approximately the same time as the FDG or DOTATATE injection and will continue until approximately the start of the clinical scan~A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study."
33241471|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
33241472|NCT00759993|Placebo Comparator|A,2|matching placebo
32748353|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
32748354|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
32748355|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
32748356|NCT05110599|Active Comparator|Bryophyllum 50%|Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
32748357|NCT05110599|Placebo Comparator|Placebo|Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
33241473|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
33241474|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
33241475|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
32748358|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
32748359|NCT03190811|Active Comparator|Anti-PD-1 alone|
32748360|NCT05527665||Patient group|"Women over 90 years of age Women who have received a suburethral sling at CHUGA in the gynecology or urology departments between January 2015 and June 2020.~Women who agreed to complete the PPSSQ"
33241476|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
33241477|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
33232589|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
33232590|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
33232591|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
33232592|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
33232593|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
33232594|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
33232595|NCT05305235|Experimental|RISE Guide|"The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)~RISE Guide delivered by smartphone via Qualtrics and is completed in ~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault."
33232596|NCT05305235|Active Comparator|Relaxation Control|Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.
33232597|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
33232598|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
33232599|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
33232600|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
33232601|NCT04041557||controls|healthy peers
33070338|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
33232602|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
33232603|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
33070339|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
33232604|NCT05758571|Experimental|EGCG（Epigallocatechin-3-gallate ）|Epigallocatechin-3-gallate (EGCG) (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day. From the beginning of the diagnosis and 7 days after the signing of the informed consent form, the medication can be continued according to the wishes of the patients, but the total medication time is not more than 14 days.
33232605|NCT05758571|Placebo Comparator|0.9% saline solution|The placebo is 0.9% saline solution.
33232606|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~No further treatment just observation"
33232607|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
33241478|NCT05507450|Experimental|V181 High-Potency Level Group|Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.
33070340|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
33070341|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
33070342|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
33070343|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
33241479|NCT05507450|Experimental|V181 Mid-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.
33241480|NCT05507450|Experimental|V181 Low-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.
33241481|NCT05507450|Placebo Comparator|Placebo|Participants will receive a single SC 0.5 mL dose of placebo.
33241482|NCT00763347|Experimental|SYR-619 12.5 mg QD|
33241483|NCT00763347|Experimental|SYR-619 50 mg QD|
33241484|NCT00763347|Experimental|SYR-619 100 mg QD|
33241485|NCT00763347|Experimental|SYR-619 200 mg QD|
33241486|NCT00763347|Placebo Comparator|Placebo QD|
33241487|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
33241488|NCT04276142|Experimental|Migraine - ceprica|online program: ceprica in addition to treatment as usual
33241489|NCT04276142|Other|Migraine - Treatment as usual|Other: treatment as usual
33241490|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
33241491|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
33241492|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
33241493|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
32748361|NCT05527665||Healthy volunteers group|"-Adult women under 90 years of age, matched on age and menopausal status to the patient group Women who have never had surgery for stress urinary incontinence with a sub-urethral sling.~Women who agreed to complete the PPSSQ"
32748362|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
32748363|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
32748364|NCT05527587|Experimental|Nature Connections Group|Participants will be screened to confirm their eligibility to partake in the study. Participants who meet the study criteria will then be invited to participate in the nature connections intervention. At the start of the intervention, mid-intervention and post intervention, participants will be invited to participate in assessments of their behaviour and mood symptoms, cognition, quality of life, caregiver burden and stress levels using different measures and questionnaires at the University of Calgary. Participants will be provided with a visit passport to record a log of activities completed during the park visits.
32748365|NCT05307627||Long-term (>5 years) LDN users|Participants who have been using LDN for over 5 years
32748366|NCT05307627||intermediate-term (1-5 years) LDN users|Participants who have been using LDN for at least 1 year, but shorter than 5 years.
32748367|NCT05307627||short-term (<12 months) LDN users|Participants who have been using LDN for less than a year. This group will serve as the control group.
32748368|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
32748369|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
32748370|NCT04648605|Experimental|Questionary|Questionary for all parents
32748371|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
32748372|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
32748373|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
32748374|NCT05527509|Active Comparator|Standard Training Condition (STC)|"The STC has received the standard RCMP Depot Division (Depot) Cadet Training Program as has been provided to cadets prior to June 2022. The STC and the ATC will complete the same standardized self-report assessments, clinical interview assessments, and biometric assessments, and receive the same feedback and reporting based on those assessments."
33070344|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
33070345|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
33070346|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
32748375|NCT05527509|Experimental|Augmented Training Condition (ATC)|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based cognitive-behavioral intervention designed to cultivate constructive approach-oriented emotional engagement. The 13-week Emotional Resilience Training (ERST) is an adaptation of the UP designed for use as a proactive training course. The ERST frames emotional experiences as natural responses to threat, rather than pathological occurrences to avoid; as such, the ERST is well-suited for mitigating health challenges and the skills may also help PSP to support persons in distress, including other PSP and the community members they all serve. The ERST training materials include an instructor guide, didactic PowerPoints, and a trainee workbook. The ERST was designed for seamless integration with the Cadet Training Program, effective June 2022, which is what creates the augmented training arm (i.e., the ATC).
33070347|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
33070348|NCT00144599|Experimental|1|
33070349|NCT00144599|Placebo Comparator|2|
33070350|NCT02945293||Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
33070351|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
32748376|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
32748377|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
32748378|NCT05178459||Diabetic|Patient diagnosed with diabetes
32748379|NCT05178459||Neuropathic without diabetes|Patient diagnosed with neuropathy without diabetes
32748380|NCT04425135|Experimental|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
32748381|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
32748382|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
32748383|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
32748384|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
32748385|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
32748386|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
32748387|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
32748388|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
32748389|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
32748390|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
32748391|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
32748392|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
32748393|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
33070352|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
33070353|NCT04692415|Active Comparator|degludec arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
33070354|NCT04692415|Active Comparator|glargine arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
33070355|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
33070356|NCT00527917|Placebo Comparator|Placebo|placebo
33241494|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
32748394|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
32748395|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
32748396|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
32748397|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
32748398|NCT04298697|Experimental|TDF/FTC for one week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week and will have biologic specimens collected at 8 study time points.
32748399|NCT04298697|Experimental|TDF/FTC for four weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for four weeks and will have biologic specimens collected at 20 study time points.
32748400|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
32748401|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
32748402|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
32748403|NCT05527431|Active Comparator|high flow nasal cannula|
32748404|NCT05527431|Active Comparator|noninvasive mechanical ventilation|
32748405|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
32748406|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
32748407|NCT05527353||Women with PCOS|Women born in Northern Finland during 1985-1987 fulfilling ≥2 Rotterdam criteria.
32748408|NCT05527353||Controls|Women born in Northern Finland during 1985-1987 who are PCOM negative with no other diagnostic features of PCOS according to the Rotterdam criteria.
33070357|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation~Accessories: MESOGRAPH reading device, Implant Injector"
33070358|NCT02945215|Experimental|IBI301|
32748409|NCT05531721||pediatric patients affected by hemophagocytic lymphohistiocytoses|pediatric patients with HLH
32748410|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
32748411|NCT05170737|Experimental|PART I: SINGLE ASCENDING DOSE (FIH-SAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-group, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in single ascending doses.
32748412|NCT05170737|Experimental|PART II: MULTIPLE ASCENDING DOSES (FIH-MAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-groups, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in multiple ascending doses.
32748413|NCT05170737|Experimental|PART III: FOOD EFFECT (FIH-FE)|Prospective, open-label single dose, two-condition (fed versus fasting), two sequences, crossover phase I investigation to assess the effects of food on the bioavailability of AEF0217.
32748414|NCT05527275|Experimental|Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide|
32748415|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
32748416|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
32748417|NCT05527197|Other|Patient reported function of daily ADL's post combined first MTP/TMT joint arthrodesis|Patients that meet the inclusion criteria will be contacted for participation in the study. If the patient agrees to participate in the study, informed consent will be obtained. The retrospective study will consist of a chart review and baseline radiographic analysis. The prospective follow-up will consist of the patient completing the Post-Operative Function and Satisfaction Survey via phone call with study staff. Radiographic images will be analyzed by a single central radiologist.
32748418|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
32748419|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
32748420|NCT05164653|Experimental|Sacubitril Valsartan Sodium Hydrate|Entresto® Tablets
32748421|NCT05164653|Active Comparator|No Sacubitril Valsartan Sodium Hydrate|Standard treatment for HF (ARB, ACE inhibitor etc.)
32748422|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
32748423|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
32748424|NCT05531487||Medical students|Undergraduate medical students at one Medical University.
32748425|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
32748426|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
33070359|NCT02945215|Active Comparator|Rituximab|
33070360|NCT00531115|Experimental|1|
33232608|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
33232609|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
33232610|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
33232611|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
33232612|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
33232613|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
33232614|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
33232615|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
33232616|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
33232617|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
33232618|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
33232619|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
33232620|NCT00760929|Experimental|R1507 (16mg/kg iv)|
33232621|NCT00760929|Experimental|R1507 (9mg/kg iv)|
33232622|NCT05474417||Cystic Fibrosis Carrier Group|Participants who have been identified as Cystic Fibrosis Carriers via previous genetic testing.
33232623|NCT05474417||Control Group|Participants who have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
33232624|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
33232625|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
33393763|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
33393764|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
33232626|NCT00704795||1|Patients with type 1 diabetes mellitus
33232627|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
33232628|NCT00707525|No Intervention|1|Natural cycle oocyte donation
33393765|NCT04533945|Other|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
33393766|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
33232629|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
33232630|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
33232631|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
33232632|NCT00707603||Controls|Healthy males
33232633|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
33232634|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
33232635|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
32761948|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
33070361|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
33070362|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
33070363|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
33070364|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
33232636|NCT04098783|Experimental|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
32761949|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
33070365|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
33070366|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
32761950|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
32761951|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
32761952|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
32761953|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
32761954|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
33070367|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
33070368|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
33070369|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
33070370|NCT00528034|Experimental|Lymphoscintigraphy|
33241495|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
32748427|NCT05531409|Experimental|Intervention Arm|Students from 6th and 7th grades from two schools were randomized to receive the RBYC curriculum. The RBYC curriculum has eight core content sessions, each of which lasts approximately 45 minutes. These include sessions that address: 1) Developmental differences between children versus teenagers; 2) Perspective-taking of and empathic responding to younger children; 3) and 4) Healthy versus unhealthy teenage-younger child relationships; 5) Misconceptions versus facts about child sexual abuse and legal ramifications; 6) Why adolescents may engage in harmful sexual behaviors; 7) Peer sexual harassment, what it is and how to avoid or address it; and 8) Being a good bystander or upstander when you have concerns that another child or peer has been or may be harmed. The RBYC curriculum was integrated into each school's existing health education curriculum.
32748428|NCT05531409|No Intervention|Waitlist Control|Students from 6th and 7th grades from the two schools that were randomized to the waitlist control condition received the RBYC curriculum once the study was completed (i.e., baseline and post-assessment data were collected).
32748429|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
32748430|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
33070371|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33070372|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
33070373|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
32761955|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
33070374|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
33070375|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
33241496|NCT00760071||2 controls|age matched controls
33232637|NCT04098783|No Intervention|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
33232638|NCT04098549|Experimental|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
32748431|NCT05287581|Experimental|Experimental|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
32748432|NCT05287581|No Intervention|Waitlist Control|24-week waitlist control condition
32748433|NCT04483193||Critically ill patients|Critically ill patients hospitalised at the intensive care unit.
32748434|NCT05527041||Concussed|Subjects age 17-34 years within 72 hours of injury.
32748435|NCT05527041||Non-concussed|In Phase I, uninjured, matched controls. In Phase II, subjects completing baseline concussion testing as part of the standard of care or athletics pre-season.
32748436|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
32748437|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
32748438|NCT05273463|Experimental|Video-Based Education Group|Approximately 4 weeks before scheduled surgery, participants will receive the video-based intervention regarding pre-and postoperative care for ACL reconstruction.
32748439|NCT05273463|Experimental|Virtual Classroom Course Group|Approximately 4 weeks before scheduled surgery, participants will receive the classroom-based intervention regarding pre-and postoperative care for ACL reconstruction.
32748440|NCT05273463|No Intervention|Standard of Care Group|Participants will receive verbal and written pre-and postoperative instruction as typically received by all ACL reconstruction patients treated by the attending physicians before and after surgery.
32748441|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
32748442|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
33070376|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
33232639|NCT04098549|Experimental|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
33232640|NCT04098159|Experimental|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
33232641|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
33232642|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
33232643|NCT04098471|Experimental|single transanal loca excision|
33232644|NCT04098471|Experimental|transanal local excision following radiotherapy|
33232645|NCT04098471|Experimental|total mesorectal excision|
33232646|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
33232647|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
32748443|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
32748444|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
32748445|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
32748446|NCT05526963|Experimental|Intervention Group|Medication review (STOPP/START-criteria) + telephone-based adherence support measure (motivational interviewing)
32748447|NCT05526963|No Intervention|Control Group|Usual care
32748448|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
32748449|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
32748450|NCT05523375|Experimental|Intensive Lifestyle Intervention|"The intervention arm receives a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Obesity Guidelines, delivered remotely using eHealth technology, by trained health coaches embedded in the Digital Medicine Group in the Ochsner Health System. The intervention includes remote sessions with the health coach using evidence-based components such as the use of portion control and various behavioral strategies .Patients in the Intervention arm attend weekly sessions in the first six months, followed by monthly sessions for the remaining 18 months."
32748451|NCT05523375|No Intervention|Usual Care|Patients in the usual care arm will receive their normal, usual care from their primary care team.
33232648|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
33232649|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
32748452|NCT05526807|Experimental|Ursodeoxycholic acid|Only one arm - subjects receiving ursodeoxycholic acid
33232650|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
33232651|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
33232652|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
33232653|NCT00707681|Active Comparator|I|MS-20
33232654|NCT00707681|Placebo Comparator|2|Placebo
33232655|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
33232656|NCT05467371|Experimental|Parenting Action Plan|The parenting action plan is a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby. Maternal caregivers will receive the booklet via mail and a trained research staff member will virtually go over the booklet using motivational interviewing strategies
33232657|NCT05467371|Active Comparator|Safe Kids Home Safety Checklist|The Safe Kids Home Safety Checklist is a handout with information that focuses on home safety for parents of young children. Maternal caregivers will receive the handout via mail and a trained research staff member will virtually go over the handout with the parent using educational strategies.
33232658|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
33232659|NCT00758589|Placebo Comparator|Placebo|Placebo
33232660|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
33232661|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
33232662|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
33232663|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
33232664|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
33232665|NCT00762372|Experimental|desflurane|
33232666|NCT00762372|Experimental|desflurane/N2O|
33232667|NCT00762372|Active Comparator|sevoflurane/N2O|
33232668|NCT00833261|Experimental|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
32748453|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
33072394|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
33072395|NCT05144984|Experimental|Semaglutide 2.4 mg + placebo (NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
33072396|NCT05131581|No Intervention|Group 1|Standard care for cervical screening test (CST) at the midwifery clinic (control group)
33072397|NCT05131581|Experimental|Group 2|Standard care for CST at the youth clinic (intervention group 1)
32748454|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
32748455|NCT05531331|Experimental|Intervention Group|After discharge, the individuals in the experimental group were given training by the researcher through training booklets prepared by the Association of Wound Ostomy Incontinence Nurses and video conference in four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month.
32748456|NCT05531331|No Intervention|Control Group|Individuals with stoma in the control group received the training of the company representative that sells stoma materials routinely in the hospital.
33232669|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
33232670|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
33232671|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
33232672|NCT00833027|Experimental|1|Sitagliptin
33232673|NCT05758493|Experimental|Patients with ATTR-CM|Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.
33232674|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
33232675|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
33232676|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
33232677|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
33232678|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
33232679|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
33232680|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
33232681|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
33232682|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
33232683|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
33232684|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
33393767|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
33232685|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
33232686|NCT04093440|Other|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
33232687|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
33232688|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
32748457|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
32748458|NCT04644783|Experimental|Blood test with assays|Ten patients with FPIES exhibiting reactions to 2-3 foods, and up to 10 exhibiting FPIES reactions to 4 or more foods will be recruited.
32748459|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
32748460|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
32748461|NCT04639947|Experimental|EyeCheck|EyeCheck pressures will be measured with contact lens in place
33232689|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
33232690|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
33232691|NCT05469971||NCWS patients|"The researchers will enrol NCWS, presenting with IBS and/or dyspepsia-like symptoms, according to the Rome IV criteria (20). These patients were diagnosed by DBPC wheat challenge between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
33232692|NCT05469971||Celiac disease|"The researchers will enrol CD patients diagnosed between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
33393768|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
33232693|NCT05469971||Blood donors|The researchers will enroll blood donors from the Transfusion Centre of the University Hospital of Palermo, Italy.
33232694|NCT05454839||Participants|Adult patients within 6 months of ART initiation or re-initiation
33232695|NCT00754572|Experimental|1|
33393769|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
32908785|NCT05130944|Experimental|Entre Nosotras (group psychosocial intervention) + stress management intervention|Experimental condition: Women residing in the study community (displaced and host population) will receive both group psychosocial intervention and stress management intervention. Participants will be given the Spanish version of the Doing What Matters in Times of Stress illustrated guide, that is published and made publicly available by the World Health Organization.
32908786|NCT05130944|Active Comparator|Entre Nosostras (group psychosocial intervention)|Comparison condition: Women residing in the study community (displaced and host population) will receive group psychosocial intervention only.
32908787|NCT05129618|Active Comparator|Product Tolerability Arm|active product: MHS 1031 Panosyl-isomaltooligosaccharides liquid 1 g (1.4 ml) per day
32908788|NCT05129618|Placebo Comparator|Placebo Tolerability Arm|Placebo liquid 1 g (1.4 ml) per day
33072398|NCT05131581|Experimental|Group 3|Standard care for CST at the youth clinic with extra time allotted (intervention group 2)
33072399|NCT05131581|Experimental|Group 4|Standard care for CST at the youth clinic with extra time allotted and the RLP-information (intervention group 3)
32744549|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
32744816|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
32744817|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
32744818|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
32744819|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
32744820|NCT04484753|Other|Home Exercise Sheet|The participant took the sheet with the description of the exercises to his address.
32744821|NCT04484753|Other|Ipelvis mobile application|The participant received the app and performs home exercises guided by the app.
33072400|NCT05131386|Experimental|Multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas|"Premedication~4 mg oral dexamethasone 24h and 12h before trabectedin administration, 20 mg IV dexamethasone 30 minutes before treatment. Ondansetron or analogue will also be given prior to trabectedin.~Medication~Trabectedin at 1.5 mg/m2 24-h IV CI along with radiation therapy (30 Gy, 3 Gy/day for 10 days for non-extremity location and 45 Gy, 1.8 Gy/day for 25 days for extremity location of target lesion(s)), starting within 1 hour after the first trabectedin infusion withdrawal (day 2)) will be given every 3 weeks up to progression or intolerance."
33072401|NCT05129332|Experimental|Vaginal Dilator Intervention|Patients assigned to the vaginal dilator group will be provided the device, vaginal moisturizer, an adherence calendar, and standardized verbal and written instructions from a trained health professional to apply the moisturizer and use the dilator for 15 minutes daily. Standard medical grade vaginal dilators and pure Vitamin E oil will be provided for each study participant. They have the option of purchasing a dilator and/or moisturizer of a similar nature if they choose to.
33072402|NCT05129332|Other|Control (Vaginal Moisturizer Only)|Patients assigned to vaginal moisturizer alone will receive pure Vitamin E oil and similar standardized instructions on daily use and an adherence calendar. They will apply a dime-sized amount of Vitamin E oil every day. They have the option of purchasing their own moisturizer if they choose to.
33072405|NCT05119907|Experimental|Cohort A: Esophageal Squamous Cell Carcinoma (ESCC)|Participants will receive Sacituzumab Govitecan-hziy (SG) 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
32744822|NCT04484753|Active Comparator|Home exercise sheet + Pelvic Physiotherapy|The participant did group physical therapy and used the exercise sheet at home on other days.
32744823|NCT04484753|Active Comparator|Ipelvis mobile application + Pelvic Physiotherapy|The participant did group physical therapy and used the mobile application on other days.
32744824|NCT03221231|Experimental|N-acetylcysteine|
33072406|NCT05119907|Experimental|Cohort B: Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
33072407|NCT05119907|Experimental|Cohort C: Cervical Cancer (CC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
33072408|NCT05119907|Experimental|Cohort D: Biliary Tract Cancer (BTC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
33072409|NCT05119907|Experimental|Cohort E: Lung Adenocarcinoma (LAC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
33232696|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
33232697|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
33232698|NCT05758415|Experimental|Secukinumab|"Name and Strength: 2 X Secukinumab 150 mg / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
33232699|NCT05758415|Placebo Comparator|Placebo|"Name and Strength: 2 X Placebo / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
33232700|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
33232701|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
33232702|NCT04095312|Experimental|pancreaticobiliary disease|10 pancreaticobiliary disease cases
33232703|NCT04095312|Experimental|Urinary tract disease|13 urinary tract disease cases
33232704|NCT04095312|Experimental|Colon disease|10 colon disease cases
33232705|NCT04093674|Experimental|Clinical evaluation|Clinical periodontal parameters
32744825|NCT03221231|Placebo Comparator|Placebo|
33232706|NCT04093674|Experimental|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
33232707|NCT04093674|Experimental|Patient centered outcomes|Pain and discomfort/ Esthetics
33232708|NCT04095390|Experimental|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
33232709|NCT04095390|Experimental|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
33232710|NCT04095390|Experimental|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
33241497|NCT04049019|Experimental|Urine collection|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
33232711|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
33232712|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
33232713|NCT04095468||Resectable rectal cancer|
33232714|NCT04095468||Rectal cancer with threatened mesorectal fascia|
33232715|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
33232716|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
33232717|NCT00754338|Active Comparator|Phase1 - Arm 1|
33232718|NCT00754338|Active Comparator|Phase1 - Arm 2|
33393770|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
33393771|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
33232719|NCT00754338|Active Comparator|Phase 2 - Arm 1|
33232720|NCT00754338|Active Comparator|Phase 2 - Arm 2|
33232721|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
33232722|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
33232723|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
32744826|NCT03221231|Active Comparator|Healthy controls|
33232724|NCT00916734|Active Comparator|McKenzie MDT Group|
33232725|NCT04016051|Experimental|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:~125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).~187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).~250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
33232726|NCT04016051|Active Comparator|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:~2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).~3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).~5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
33232727|NCT00761514|Experimental|1|All subjects will receive Adalimumab
33232728|NCT00831779|Experimental|Dapagliflozin|
33232729|NCT00831779|Placebo Comparator|Placebo|
33232730|NCT04098510|Experimental|MitoQ|Subjects ingest 160 mg of MitoQ
33232731|NCT05441891|No Intervention|Control group|Participants assigned to the control group are cited to the Health centre, but they do not suffer any intervention. These subjects followed the same evaluation and data collection process.
33232732|NCT05441891|Active Comparator|Auditory intervention filter-modulated|Participants assigned to this group listened classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).
33232733|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
33232734|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
33232735|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
33232736|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
33232737|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
33232738|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
33232739|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
33232740|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
33232741|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
33232742|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
33393772|NCT04520685|Experimental|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
33393773|NCT04520685|Experimental|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
33393774|NCT04520685|Experimental|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
33393775|NCT04296123|Experimental|Intervention|
33070377|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
33070378|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
33070379|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
33070380|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
33070381|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
33070382|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
33070383|NCT00528151|Placebo Comparator|2|"curcumin~placebo"
33070384|NCT00144911|Experimental|Arm 1|
33070385|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
33070386|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
33232743|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
33232744|NCT05426837|Placebo Comparator|Health Education Training|Health Education Training (HET) control condition covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. The HET protocol has been used in prior studies as a control condition for CSI to account for intervention modality and time (e.g. Schmidt et al., 2014). HET is perceived positively, with high rates of acceptability. Importantly, HET is inert with respect to the proposed mechanism of action (PB/TB) (Schmidt et al., 2014; Schmidt et al., 2007; Short et al., 2015). Also, home practice will be prescribed to match the procedures used in CSI and practice forms are provided wherein participants will self-monitor some of the behaviors addressed in HET.
33070387|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
33070388|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
33070389|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
33070390|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
33070391|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
33232745|NCT05426837|Active Comparator|Combatting Social Isolation|"Combating Social Isolation (CSI). CSI and a similar version of this intervention called Building Stronger Allies, has gone through a rigorous treatment development phase, pilot RCT, and larger RCTs (Schmidt et al., 2014; Schmidt et al., 2017; Schmidt et al., 2007; Norr et al., 2017; Short et al., 2015; Short et al., 2017a; Schmidt et al., submitted for publication). CSI is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated perceived burdensomeness (PB) and thwarted belongingness (TB). The CSI intervention was designed in consultation with clinicians experienced in treating individuals dealing with issues related to PB/TB. CSI is a fully computerized, 1-hour intervention. The latest version of CSI uses Vyond software for video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques."
33232746|NCT05425355|Experimental|Intravenous (IV) acetaminophen plus oral placebo|In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
33232747|NCT05425355|Active Comparator|Intravenous (IV) placebo plus oral acetaminophen|In this group the IV study drug will be normal saline and the pill will be acetaminophen
33070392|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
33070393|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
33070394|NCT02944786|No Intervention|Control|Standard care
33070395|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
33070396|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
33070397|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
33070398|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
33070399|NCT04692025|Experimental|Group 1|ASC41 one tablet, on Day 1 before meal；ASC41 one tablet, on Day 15 after meal.
33070400|NCT04692025|Experimental|Group 2|ASC41 one tablet, on Day 1 after meal；ASC41 one tablet, on Day 15 before meal.
33070401|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
33070402|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
33070403|NCT00528619|Experimental|A|
33070404|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
33070405|NCT00528658|Experimental|1|
33070406|NCT00528658|Experimental|2|
33070407|NCT00528658|Experimental|3|
33070408|NCT04691674|Experimental|Study group|Endoscopic removal of pancreatic duct stent at 4 weeks following ERCP, unless spontaneously dislodged.
33070409|NCT04691674|Placebo Comparator|Control group|Endoscopic removal of pancreatic duct stent at 2 weeks following ERCP, unless spontaneously dislodged.
33070410|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
33070411|NCT00528814|No Intervention|Usual Care Hand Hygiene|
33070412|NCT04691752||COPD patients|"Adults (men or women) aged more than 40 years old~Diagnostic code in Andalusian clinical records (Diraya) in accordance with ICD-9 (Diagnostic codes 496, 492.8, 494.0, 491.20, 493.2)~Current of former smokers of at least 10 pack- years~Patient with a minimum follow up of 1 year, who have been assisted in a scheduled primary care appointment at inclusion date."
33070413|NCT01580527|Active Comparator|total parenteral nutrition|
33070414|NCT01580527|Experimental|Early enteral nutrition|
33070415|NCT05647603||"group Parents of adolescents"|Parents of adolescents aged 12 to 18
33070416|NCT00168753|Experimental|1|
33070417|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
33232748|NCT05758337|Experimental|A group with exposure of vibropneumostimulation|The first group is a group of subjects on whom, after implantation, a new technique was applied, including the effect of vibropneumostimulation on the pereimplant tissues.
33232749|NCT05758337|No Intervention|A group of standart therapy|The second is a group of subjects whose rehabilitation was carried out by the well-known classical method.
33232750|NCT00705497|Experimental|1|
33232751|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
33232752|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
33232753|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
33232754|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
33232755|NCT04093713|Other|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
33232756|NCT04093635||Group I|Those patients that will be treated by NPWT.
33232757|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
33232758|NCT00916851||Control group|Normally developing children and adolescents
33232759|NCT00916851||ADHD group|Children and adolescents with ADHD
32748462|NCT04639947|Active Comparator|Traditional Tonometer (Goldmann and Tonopen)|Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).
33232760|NCT00916851||ASD group|Children and adolescents with ASD
33232761|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
33232762|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
33232763|NCT04093557|Active Comparator|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
33232764|NCT04093557|Placebo Comparator|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
33232765|NCT04093557|Other|Retrospective Cohort (before Orton Score)|
33232766|NCT05438511||Participants of focus groups|Breast cancer survivor, patient advocate or key healthcare personnel including hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons
32748463|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
33232767|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
33232768|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
33232769|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
33232770|NCT05438277|Experimental|methylprednisolone acetate (MPA)|subacromial or glenohumeral shoulder injection
33232771|NCT05438277|Active Comparator|triamcinolone acetonide (TA)|subacromial or glenohumeral shoulder injection
33232772|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
33232773|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
33232774|NCT04093089|Experimental|Test Group|
33232775|NCT04093089|Placebo Comparator|Control Group|
33232776|NCT05255081|Experimental|Treatment Arm|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
32748464|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
32748465|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
32748466|NCT05155293|Experimental|AVT06 (proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of AVT06 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
33232777|NCT05255081|Placebo Comparator|Control Arm|Spray with saline would be applied to organs under incision
33232778|NCT05435859|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 25-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
33232779|NCT00916890|Active Comparator|Oral extended-release morphine|
33232780|NCT00916890|Active Comparator|Oral extended-release oxycodone|
33232781|NCT00916890|Active Comparator|Transdermal fentanyl|
33232782|NCT00916890|Active Comparator|Transdermal buprenorphine|
33232783|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
33232784|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
33232785|NCT04093401|No Intervention|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
33232786|NCT04093401|Experimental|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
33241498|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
33393776|NCT04296123|No Intervention|Control|
32748467|NCT05155293|Experimental|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
32748468|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
32748469|NCT05526651|Experimental|True electroacupuncture group|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
32748470|NCT05526651|Sham Comparator|sham electroacupuncture group|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
32748471|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
32748472|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
32748473|NCT05531175|Experimental|İntervention Group|A total of 10 sessions of reiki were applied to the patients in the intervention group twice a week for 5 weeks, lasting 40-45 minutes during dialysis. The scales were administered to the individuals in the intervention groups three times in total.
32748474|NCT05531175|No Intervention|Control Group|No treatment was applied to the control group. The scales were administered to the individuals in the control groups three times in total.
32748475|NCT05531097|Experimental|HSK31679|
32748476|NCT05531097|Placebo Comparator|Placebo|
32748477|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
32748478|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
32748479|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
32748480|NCT04628091|Experimental|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
32748481|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
32748482|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
32748483|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
32748484|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
32748485|NCT05522985|Experimental|Treprizumab combined with TP|"treprizumab injection: 240mg once, intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.~paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles; Treprizumab was infused before and at least 60 minutes apart from chemotherapy; The intravenous infusion time of treprizumab shall be at least 60 minutes. Intravenous bolus or single rapid intravenous injection is not allowed."
33241499|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
32748486|NCT05522985|Active Comparator|TP（paclitaxel +cisplatin）|paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles;
32748487|NCT05526495|Experimental|De-implementation|"A multi-behaviour technique will be used along with theoretical domains framework.~Clinicians will be provided with continuing multi-behaviour component intervention to increase accountability for preoperative test ordering in patients having low risk surgeries."
32748488|NCT05526495|No Intervention|Comparator|Standard of care
32748489|NCT05526339|Experimental|High-flow nasal oxygenation combined with nasopharyngeal airway|High-flow nasal oxygenation combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
32748490|NCT05526339|Active Comparator|Regular nasal cannula combined with nasopharyngeal airway|Regular nasal cannula combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
32748491|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
32748492|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
32748493|NCT05522907||Neoadjuvant|From the beginning of the project for the past five years to the next three years, underwent prostate cancer biopsies at the First Affiliated Hospital of Xi'an Jiaotong University before neoadjuvant therapy, and underwent radical prostatectomy after 3-6 months of neoadjuvant therapy.
32748494|NCT05522907||CRPC|Patients with CRPC-diagnosed prostate cancer after initial continuous ADT therapy, with serum testosterone reaching castration levels (<50ng/dl or <1.7nmol/L) but with progressive disease, and who were diagnosed with CRPC at Xi'an Jiaotong University The First Affiliated Hospital did a prostate cancer biopsy.
33232787|NCT04093245|No Intervention|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
33232788|NCT04093245|Experimental|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
33232789|NCT04093245|Experimental|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
33232790|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
33393777|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
33393778|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
33393779|NCT01352481|Experimental|Intervention group|
33393780|NCT01352481|No Intervention|Control group|
32748495|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
32748496|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
32748497|NCT05522829|Experimental|Cohort 1: Group SCTV01E-1|3 doses of SCTV01E-1
32748498|NCT05522829|Active Comparator|Cohort 1: Group SCTV01E|3 doses of SCTV01E
33070418|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
33393781|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
33393782|NCT03248050|No Intervention|Control pharmacy|
32748499|NCT05522829|Experimental|Cohort 2: Group SCTV01E-1|2 doses of SCTV01E-1
33393783|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
33393784|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
33393785|NCT03247972||Patients with PAD|
32748500|NCT05522829|Active Comparator|Cohort 2: Group SCTV01E|2 doses of SCTV01E
32748501|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
32748502|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
32748503|NCT05518539||The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
33393786|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
33070419|NCT04691401|No Intervention|Standard WL (white light) colonoscopy|all patients receive standard colonoscopy (with high definition- HD- endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
33070420|NCT04691401|Experimental|Standard colonoscopy with assistance of Artificial Intelligence (CAD-EYE (Fujifilm Co, Tokyo, Japan)|all patients receive colonoscopy examinations (with HD endoscopes) equipped with an Ai system (CAD-EYE, Fujifilm Co, Tokyo, Japan) in both insertion and withdrawal phase). This system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.All polyps identified are removed and sent for histopathology examination.
33070421|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
33070422|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
33232791|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
33232792|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
33232793|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
33232794|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
33232795|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
33232796|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
32748504|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
32748505|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
32748506|NCT05025345|Experimental|Study Lens|Tecnis Eyhance
32748507|NCT05025345|Active Comparator|Control Lens|Tecnis 1 piece IOL (Intraocular lens)
32748508|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
32748509|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
32748510|NCT05518383|Experimental|R1: stage I and II|R1: resection status: complete, stage I and II
32748511|NCT05518383|Experimental|R2: incomplete, stage I and II|R2: resection status: incomplete, stage I and II
32748512|NCT05518383|Experimental|R3: incomplete, stage III and LDH < 2 x ULN|R3: resection status: incomplete, stage III and LDH < 2 x ULN
32748513|NCT05518383|Experimental|R4: stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +|R4: resection status: incomplete, stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +
32748514|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
32748515|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
32748516|NCT02432027|Active Comparator|IMP 3|Daivonex cream
32748517|NCT02432027|Active Comparator|IMP 4|Diprosis gel
32748518|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
32748519|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
33070423|NCT00531466|Active Comparator|1|
33070424|NCT00531466|Placebo Comparator|2|
33070425|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
32748520|NCT05526183|Experimental|Low dose arm|Low dose (5x1010 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGA1320, CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 0.5 solution) Intramuscular injection, two injections 28 days apart
32748521|NCT05526183|Experimental|High dose arm|High dose (1x1011 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 1.0 solution) Intramuscular injections, two injections 28 days apart
32748522|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
32748523|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
32748524|NCT05526027|Other|ETI|pwCF which are CFTR-modulator naive and pwCF previously treated with a CFTR-modulator (i.e. tezacaftor-ivacaftor or lumacaftor-ivacaftor) will undergo standard-of-care examinations as well as examinations in the context of this trial (i.e. CFQ-R, PHQ-9, GAD-7 and SNOT-22 questionnaires, fecal elastase measurement)
32748525|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
32748526|NCT05517993|Experimental|Group A|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) 3g orally twice daily for 12 weeks.
33070426|NCT00405665|Experimental|1|
33070427|NCT00405665|Experimental|2|
33232797|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
33232798|NCT04094922|Experimental|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
33232799|NCT04094922|No Intervention|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
33232800|NCT04095000|Experimental|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
33232801|NCT04095000|Active Comparator|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
33232802|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
33232803|NCT00824291|Placebo Comparator|1|
33232804|NCT00824291|Experimental|2|
32748527|NCT05517993|No Intervention|Group B|No intervention.
32748528|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
32748529|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
32748530|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
32748531|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
33232805|NCT05297747|Experimental|Apical periodontitis|Radiography of the patients in the apical periodontitis group was evaluated and blood samples were collected from those patients
33232806|NCT05297747|Experimental|Chronic periodontitis|Radiography of the patients in the chronic periodontitis group was evaluated and blood samples were collected from those patients
32748532|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
32748533|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
32748534|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
32748535|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
32748536|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
32748537|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
33232807|NCT05297747|No Intervention|Control|Radiography of the participants in the healthy, control group was evaluated and blood samples were collected from those participants
33232808|NCT05239871||Women with surgical diagnosis of parametrial endometriosis|This cohort will include patients with surgical diagnosis of parametrial endometriosis
33070428|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
33232809|NCT05239871||Women without surgical diagnosis of parametrial endometriosis|This cohort will include patients without surgical diagnosis of parametrial endometriosis
32748538|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
32748539|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
32748540|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
32748541|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
32748542|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
32748543|NCT05517915|Experimental|IMT group|IMT training with 70% threshold was given.
32748544|NCT05517915|Sham Comparator|Sham group|unloaded IMT training was given.
32748545|NCT05105841|Experimental|Venetoclax + Obinutuzumab (V+G)|Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
32748546|NCT05105841|Experimental|Venetoclax + Ibrutinib (V+I)|Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
32748547|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
32748548|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
32748549|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
32748550|NCT03184415|Active Comparator|DWC20155 Monotherapy|
32748551|NCT03184415|Active Comparator|DWC20156 Monotherapy|
32748552|NCT05522595|Experimental|Standard of care arm|The patient is his own comparator. During the intervention, the eyes movements measurements will be performed using the standard of care and the medical device S360.
32748553|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
32748554|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
32748555|NCT05525871|Experimental|Nitrates and Citrulline Malate|Gel elaborated from fruit puree with high polyphenol content, with the addition of nitrates and citrulline malate as study supplements. addition of nitrates and citrulline malate as study supplements.
32748556|NCT05525871|Placebo Comparator|Control product|Consumption of placebo product (Fruit puree)
32748557|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
32748558|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
32748559|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
33070429|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
33232810|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
33232811|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
32748560|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
32748561|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
32748562|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
32748563|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
32748564|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
32748565|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
32748566|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
32748567|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
32748568|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
33070430|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
33070431|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
32748569|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
32748570|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
32748571|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
33070432|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
33070433|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
33232812|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
33232813|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
33393787|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
33393788|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
33393789|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
33393790|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
33393791|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
33393792|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
33393793|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
33393794|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
33393795|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
33393796|NCT01351311|Other|Control Group|Drug treatment
33393797|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
33232814|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
33232815|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
33232816|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
33232817|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
33232818|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
33232819|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
33070434|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
33232820|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
33232821|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
33232822|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
32748572|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
33232823|NCT02600442||main and unique cohort|
32748573|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
32748574|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
32748575|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
32748576|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
32748577|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
32748578|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
32748579|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
32748580|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
32748581|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
33232824|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
33232825|NCT00760266|Active Comparator|HCTZ 25 mg|
33393798|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
33393799|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
33393800|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
33393801|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
33393802|NCT01351389|Active Comparator|Brief Advice|
32748582|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
32748583|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
32748584|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
32748585|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
33232826|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
33232827|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
32748586|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
32748587|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
32748588|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
33232828|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
33232829|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
32748589|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
32748590|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
32748591|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
32748592|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
32748593|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
33232830|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
33232831|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
33232832|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
33232833|NCT05433948||Liver cirrhosis with normal cognition|Liver cirrhosis and performs normally in all psychometric tests. n=100
33232834|NCT05433948||Liver cirrhosis with minimal hepatic encephalopathy|Liver cirrhosis and performs abnormally en 2 or more psychometric test. n=100
33232835|NCT05433948||Liver cirrhosis and overt hepatic encephalopathy|West Haven grade 2 or more. n=50
33232836|NCT05433948||Healthy control persons|Completely healthy persons, age, and gender-matched to cirrhosis patients. n=100
33232837|NCT05433948||Sick control persons|Persons with other chronic diseases than liver disease. n=100
33232838|NCT05433948||Pre-cirrhotic liver disease|Not yet cirrhosis. Will primarily be NAFLD patients. n=100
33232839|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
33232840|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
33070435|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
33070436|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
33232841|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
33232842|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
33232843|NCT05751278|Experimental|Cryoprobe|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe
33232844|NCT05751278|Active Comparator|Forceps|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using forceps
33232845|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
33232846|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
33232847|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
33232848|NCT05754944||Cancer patients having surgery|This is a prospective cohort study where patients who are 65 years or older with either a history of diabetes (requiring medication or insulin) or smoking history (current smoker, smoker within the last 15 years, or ≥ 20 year pack history), facing major head and neck, thoracic, abdominal, or pelvic surgery will be screened for PAD with an ABI/TBI to establish prevalence and to compare prevalence among races to meet
32748594|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
32748595|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
33070437|NCT00145184|Placebo Comparator|Placebo|Placebo
33070438|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
33232849|NCT00759876|Experimental|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
33232850|NCT04569344||Patients with Covid-19|Patients with laboratory test positive for SARS-CoV-2 virus
33232851|NCT05750264|Active Comparator|ibuprofen group|intravenous ibuprofen 800mg in 200 ml normal saline+IV paracetamol 1000mg+Transversus abdominis plane block
33232852|NCT05750264|No Intervention|Control group|200 ml normal saline+IV paracetamol1000mg+Transversus abdominis plane block
33393803|NCT04343313|Experimental|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
33393804|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
33232853|NCT05716724||Participants with T2D|The study is non-interventional as there are no interventions involved and the decision to initiate oral semaglutide treatment is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study. Participants will be treated with oral semaglutide (at least 4 weeks on maintenance dose) once daily with or without other oral antidiabetics (OADs) as per local label at the discretion of the treating physician.
33232854|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
33232855|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
33232856|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
33232857|NCT05742854|Active Comparator|Oxytocin|(subjects administered oxytocin as a uterotonic agent) (5 IU oxytocin diluted with 10 ml saline followed by slow injection) (for 3 minutes)
33232858|NCT05742854|Active Comparator|Carbetocin|subjects administered carbetocin as a uterotonic agent) (100µg carbetocin diluted with 10 ml saline followed by slow injection (for 3 minutes))
32748596|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
33072410|NCT05118282|Experimental|Combined coping skills + asthma management arm|The combined coping skills + asthma management arm is a family-based coping skills + asthma management intervention that is bilingual and culturally relevant for Latino families. This program is manualized with video-guided and interactive content to improve coping with stress and asthma management behaviors for both children and their parents. Coping strategies taught include primary and secondary control coping. Asthma management content is interactive and culturally tailored.
33232859|NCT00823979|Experimental|UK- 453,061 Dose One|
33232860|NCT00823979|Experimental|UK- 453,061 Dose Two|
33232861|NCT00823979|Active Comparator|Comparator|
32748597|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
32748598|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
32748599|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
32748600|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
32748601|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
32748602|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
32748603|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
32748604|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
32748605|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
32748606|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
33232862|NCT04093284|Experimental|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
33232863|NCT04093284|Experimental|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
33232864|NCT05754866|Experimental|Transbronchial lung cryobiopsy|
32748607|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
32748608|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
33232865|NCT05754866|Active Comparator|Transbronchial lung biopsy|
33232866|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
33232867|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
33232868|NCT05741918|Experimental|Pediatric Intensive Care Units Patients|Patients under 18 admitted in pediatric intensive care unit
33232869|NCT04094766|Experimental|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.
33232870|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
33232871|NCT05428722|Experimental|deep breathing group|The intervention group is the group in which the investigators applied deep breathing exercises with incentive spirometer starting from the preoperative period.
33232872|NCT05428722|No Intervention|Control group|The control group is the group that receives standard clinical care.
33232873|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
32748609|NCT02430779|No Intervention|Control|The patients without treatment
32748610|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
32748611|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
32748612|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
32748613|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
32748614|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
32748615|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
33232874|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
33232875|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
32748616|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
32748617|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
32748618|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
32748619|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
32748620|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
33232876|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
33070439|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo cystectomy during course 8.~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
32748621|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
33070440|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
33070441|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
33232877|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
33232878|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
33232879|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
33232880|NCT05521607|Other|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.
33232881|NCT05741372|Experimental|Group 1: Healthy participants|Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.
33232882|NCT05741372|Experimental|Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) subjects (compensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Compensated=without any disease symptoms"
33232883|NCT05741372|Experimental|Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) subjects (decompensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome"
33232884|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
33232885|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
33232886|NCT05754788||Favorable-prognosis pancreatic adenocarcinoma|Patients experiencing favorable prognosis (defined as RFS≥60 months) following resection for pancreatic adenocarcinoma
33232887|NCT05754788||Unfavorable-prognosis pancreatic adenocarcinoma|Patients experiencing unfavorable prognosis (defined as RFS<12 months) following resection for pancreatic adenocarcinoma
33232888|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
32748622|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
33070442|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
33070443|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
33232889|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
33232890|NCT05741216|Experimental|OTF Test 1|One application of ocular lubricant to each eye at night for 5 consecutive nights
33232891|NCT05741216|Experimental|OTF Test 2|One application of ocular lubricant to each eye at night for 5 consecutive nights
33232892|NCT05741216|Experimental|OTF Test 3|One application of ocular lubricant to each eye at night for 5 consecutive nights
33232893|NCT05741216|Active Comparator|Ocular lubricant|1-2 drops of ocular lubricant applied to each eye at night for 5 consecutive nights
33241500|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
33070444|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
33241501|NCT00767949|Experimental|1|iSONEP
33241502|NCT00671853|Experimental|1|Quetiapine XR
33241503|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
33241504|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
33241505|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
33241506|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
33241507|NCT00768105|Experimental|1|
33241508|NCT00768105|Placebo Comparator|2|
33241509|NCT00768183|Experimental|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
33241510|NCT00768183|Experimental|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
33241511|NCT00768183|Experimental|Regimen C|KADIAN Capsule + water (under fasting conditions)
33241512|NCT00768183|Experimental|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
33241513|NCT00763425|Experimental|1|
33241514|NCT00763425|Active Comparator|2|
33241515|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
33241516|NCT00760305|No Intervention|2|Patients who received standard care
33232894|NCT05740592|Experimental|tooth-tooth borne RPE with MOPs|many approaches have been established to speed up orthodontic tooth movement and to decrease adverse effects. These methods are classified as, microinvasive methods include cortectomies and distraction osteogenesis and microinvasive methods include micro-osteoperforations (MOPs) and piezocision Microtrauma to the bone showed increase the synthesis of cytokines and chemokines, which are routinely released when orthodontic forces are applied . As a result, the affected area is undergoing a faster bone regeneration process
33232895|NCT05740592|Experimental|Tooth-Tooth borne RPE with Piezocision group|"Piezosurgery is an ultrasonic micro vibration-based bone cutting method. It used as a careful, promising, and soft tissue sparing method. In addition to its simplicity of use in the clinic, scientific evidence from animal models measuring wound healing and bone formation suggests that, piezosurgery has a better tissue response than traditional bone-cutting procedures~."
32748623|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
33232896|NCT05740592|Active Comparator|Tooth-Bone borne RPE group (MARPE)|The MARPE is a RPE device with a rigid element that attached to palate by the aid of miniscrew, exerting the expansion force directly to the maxilla's basal bone
33232897|NCT05714072|Experimental|Ruxolitinib plus Abemaciclib|"This will be a phase 1 study with a traditional 3+3 design of combination ruxolitinib (at fixed doses of 10mg BID or 15mg BID) and abemaciclib. There are 3 planned dose levels of abemaciclib: 50, 100 and 150 mg. Cycles will be 4 weeks (28 days) long and DLT window will consist of first cycle."
33232898|NCT04540094|Experimental|5% Human Albumin Solution|Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
33232899|NCT04540094|Active Comparator|Intravenous balanced crystalloid|Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
33232900|NCT04518098|Experimental|Intervention group|Participants in the IG will receive the STABLE intervention, which entails orientation, and undertaking a remotely delivered resistance and balance training regimen 3 times weekly for 3 months
33232901|NCT04518098|No Intervention|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities.
33393805|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
33393806|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
33232902|NCT02926898|Experimental|Cohort 2: ZX008 0.5 mg/kg/day|ZX008 0.5 mg/kg/day (maximum 20 mg/day) dose supplied as an oral solution administered twice a day (BID) in equally divided doses with food.
33232903|NCT02926898|Placebo Comparator|Cohort 2: Matching Placebo|Matching placebo administered twice a day (BID) in equally divided doses with food.
33232904|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
33393807|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
33393808|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
33232905|NCT03633032|Other|UTE MRI|
33232906|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
32748624|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
33232907|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
33232908|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
33232909|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
33232910|NCT00816023|Placebo Comparator|Placebo|placebo
32748625|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
32748626|NCT02430701|No Intervention|Control|The patients without treatment
33232911|NCT00759174||Case Group|
33232912|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
32748627|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
32748628|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
32748629|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
32748630|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~."
32748631|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
32748632|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
33232913|NCT03631784|Experimental|Cohort A|Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray [Gy] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
33232914|NCT03631784|Experimental|Cohort B|Participants received 3 cycles of cisplatin 75 mg/m^2 with pemetrexed 500 mg/m^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
33232915|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
33393809|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
33393810|NCT04487158|Active Comparator|Small Changes|
33393811|NCT04487158|Experimental|INSPIRE|
33393812|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
33393813|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~Estimation of cone dimensions/volume~Calculation of the proportion of volume/length excised"
33393814|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
33393815|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
33393816|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
33393817|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
32748633|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
33070445|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
33232916|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
33232917|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
33232918|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
33232919|NCT03610724|Experimental|Tisagenlecleucel|CAR-positive viable T cells infusion
33232920|NCT04093206|Experimental|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
33232921|NCT04093206|Active Comparator|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
33232922|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
33232923|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
33232924|NCT00830375|Experimental|Memantine|10-30mg, memantine
33232925|NCT04094454|Experimental|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
33232926|NCT04094454|Active Comparator|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
33232927|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
33232928|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~Behavioral therapy."
33232929|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
33232930|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
33232931|NCT05516537|Experimental|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Participants in this condition will receive a 4-month home-based, remotely supported aerobic and resistance exercise program based on the Guidelines for Exercise in Multiple Sclerosis (GEMS).
33232932|NCT05516537|Sham Comparator|FLEX Stretching and Toning Program|Participants in this condition will receive a 4-month home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
33232933|NCT00751998||Arm 1|Test of SpyGlass device
33070446|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
33070447|NCT00529984|Experimental|Cohort 1|
33232934|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on >= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
33232935|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
33232936|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE > 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
33232937|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
33232938|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
33232939|NCT04094532|Active Comparator|ultrasound guided transverse thoracic muscle plane block|
33232940|NCT04094532|Sham Comparator|ultrasound guided sham block|
33232941|NCT00708773|Experimental|Single Arm|
33232942|NCT05701826|Experimental|Treatment group A1|HRS3797 for injection
33232943|NCT05701826|Experimental|Treatment group A2|HRS3797 for injection
33232944|NCT05701826|Experimental|Treatment group B1|HRS3797 for injection
33232945|NCT05701826|Experimental|Treatment group B2|HRS3797 for injection
33232946|NCT05701826|Experimental|Treatment group C1|HRS3797 for injection
33232947|NCT05701826|Experimental|Treatment group C2|HRS3797 for injection
33232948|NCT05758259|Experimental|combination vitamin D oral and topical cholecalciferol|combination topical vitamin D and supplementation Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
33241517|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
33070448|NCT00529984|Experimental|Cohort 2|
33232949|NCT05758259|Active Comparator|oral placebo and topical vitamin D|oral placebo and topical vitamin D Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
33232950|NCT05758259|Placebo Comparator|oral placebo and basic ingredient placebo topical vitamin D|Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
33232951|NCT05455476|Experimental|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
33232952|NCT05455476|Active Comparator|CBT for Chronic Pain|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
32748634|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
32748635|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
32748636|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
32748637|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
32748638|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
32748639|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
32748640|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
32748641|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
32748642|NCT02430623|No Intervention|Control|The patients without treatment
33070449|NCT00529984|Experimental|Cohort 3|
33232953|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
33232954|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
33232955|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
33232956|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
33232957|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
33232958|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
33232959|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
33232960|NCT04097808|Experimental|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
33232961|NCT04097808|Experimental|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
33232962|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
32748643|NCT02707055|Experimental|PF-05190457, then placebo|Participants with alcohol use disorder received PF-05190457 100 mg twice a day for a maximum of 14 days followed by a minimum of 2-day washout period, then placebo twice a day for a maximum of 14 days.
32748644|NCT02707055|Placebo Comparator|Placebo, then PF-05190457|Participants with alcohol use disorder received placebo twice a day for a maximum of 14 days followed by a minimum of 2-day washout period then PF-05190457 100 mg twice a day for a maximum of 14 days.
32748645|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
33232963|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
33241518|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
32748646|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
32748647|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
32748648|NCT03183557|Active Comparator|ZA alone|
32748649|NCT03183557|Active Comparator|ZA plus VD|
32908789|NCT05128682|Other|Urodynamic testing with and without pudendal nerve stimulation|"The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject."
32908790|NCT05127512|No Intervention|Control Group|Control participants will only complete the knowledge questionnaire in addition to a non-validated survey created by the investigators to collect demographic information as well as attitudes towards treatments of pelvic floor disorders.
32908791|NCT05127512|Experimental|Video Group|These participants will be administered the study intervention, which entails viewing an education video on pelvic floor disorders.
32908792|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
32908793|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
32908794|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
33393818|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
32748650|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
32748651|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
32908795|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
32908796|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
33070450|NCT00529984|Experimental|Cohort 4|
33232964|NCT04097808|Experimental|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
33232965|NCT04097808|Experimental|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
33232966|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
32908797|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
32908798|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
33232967|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
32748652|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
32748653|NCT02425397||patients controls with no signs of ototoxicity|
32748654|NCT02425475||Mole|Patients with suspicious moles
32748655|NCT02425319||patients with CapFlex-PIP© implant|
32748656|NCT02425319||patients with silicone implant|
32748657|NCT02425319||patients with healthy PIP joints|
32748658|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
32748659|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
32908799|NCT05096546||Group I|"20 years old or older (regardless of sex)~Outpatients~Newly-diagnosed with dry eye disease (DED) within 6 months prior to signing the informed consent under hospital-based practice in Taiwan"
33070451|NCT00529984|Experimental|Cohort 5|
33070452|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
33070453|NCT02944279||Peking University Third Hospital|
32748660|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
32748661|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
33070454|NCT02944279||Beijing Friendship Hospital|
33070455|NCT02944279||Beijing Shijitan Hospital|
33070456|NCT02944279||Beijing Xiyuan Hospital|
33070457|NCT02944279||China-Japan Friendship Hospital|
33070458|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
33070459|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
33232968|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
33232969|NCT04094376|Other|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
32748662|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
33232970|NCT04094376|Other|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
33232971|NCT04093128|Experimental|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
33232972|NCT04093050|Experimental|TT Genotype|
33232973|NCT04093050|Experimental|AA/AT Genotype|
33232974|NCT04092972|Experimental|Atherectomy|Atherectomy and drug-coated balloon (DCB)
33232975|NCT04092972|Active Comparator|Standard care|Standard care with predilation (POBA) and DCB
33232976|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in community pharmacy|This group of patients have chosen the dispensing of Emicizumab (HEMLIBRA®) in community pharmacy. This choice involves the contribution of the community pharmacist in the dispensing circuit who does not replace the hospital pharmacist but interact together for prescriptions renewals, emergency treatment or sharing information if necessary.
33232977|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in hospital pharmacy|This group of patients have kept the dispensing of Emicizumab (HEMLIBRA®) in hospital pharmacy
33232978|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
32748663|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.~Intervention: inhaler sensor"
33232979|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
33232980|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
33232981|NCT02601144|No Intervention|DBS off|deep brain stimulation off
33232982|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
33232983|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
33232984|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
33232985|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
33232986|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
33232987|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
33232988|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
32748664|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).~Interventions: inhaler sensor and mobile application for asthma adherence"
33232989|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
33241519|NCT00768495||One Cohort|
33241520|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
33241521|NCT02557581|Placebo Comparator|Placebo|Placebo
33241522|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
33241523|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
33241524|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
33241525|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
33241526|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
33241527|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
33241528|NCT02807636|Experimental|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
33241529|NCT02807636|Placebo Comparator|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
32748665|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
32748666|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
32748667|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
32748668|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
33232990|NCT04092738|Experimental|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
33232991|NCT04092738|No Intervention|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
32748669|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
32748670|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
33232992|NCT04450394|Experimental|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 milligrams per deciliter (mg/dL).
33232993|NCT04450394|Experimental|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
33232994|NCT04450394|Active Comparator|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of <=100 mg/dL.
32748671|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
32748672|NCT00709865|Experimental|1|.03 mg/kg
33232995|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
33241530|NCT02807636|Experimental|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
33241531|NCT00768573||1. Taste test|
33241532|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
33241533|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
32748673|NCT00709865|Experimental|2|.15 mg/kg
32748674|NCT00709865|Experimental|3|.3 mg/kg
32748675|NCT00709865|Placebo Comparator|4|Placebo
32748676|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
32748677|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
32748678|NCT02425007|Experimental|Spiro|Incentive spirometry
33241534|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
33241535|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
33241536|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
33241537|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
32748679|NCT02425007|No Intervention|Control|Control group
32748680|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
32748681|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
32748682|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
33070460|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
32748683|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
32748684|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
32748685|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
32748686|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
33232996|NCT05699564|Experimental|Early biomarker-based cardiological assessment and structured feedback in the EHR|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
33232997|NCT05699564|No Intervention|Standard of care|Routine standard of care according to the treating physician
33232998|NCT02599740|Placebo Comparator|Placebo|Rice only
33232999|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
33233000|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
33233001|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
33233002|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
33233003|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
33233004|NCT04094220|Experimental|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
33233005|NCT04094220|Experimental|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
33233006|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 1)|Participants will receive 0.3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
33233007|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 2)|After the safety and tolerability for cohort 1 has been evaluated, participants will receive 1 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
33233008|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 3)|After the safety and tolerability for cohort 2 has been evaluated, participants will receive 3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
33233009|NCT05695898|Experimental|Phase 2: Dose Expansion (Cohort A)|Participants will no central nervous system disease (No CNS) will receive the RP2D of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
33241538|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
33241539|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
33241540|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
33241541|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
33241542|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
33241543|NCT04617314|Experimental|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
33241544|NCT04048629|Experimental|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
33233010|NCT05695898|Experimental|Phase 2: Dose Expansion (Cohort B)|Participants will stable or asymptomatic CNS disease will receive the RP2D of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first,
33233011|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
32748687|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
33233012|NCT00757848|Experimental|AZD9668|
32748688|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
32748689|NCT02424929|Other|Awake|"Original surgery intervention.~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
33233013|NCT00757848|Placebo Comparator|Placebo|
33233014|NCT05695742||Active smokers|Having smoked at least 1 cigarette per day for at least 2 years.
33233015|NCT05695742||Pasive smokers|Being exposed to secondhand smoke for more than 15 minutes at home, school, office or anywhere in the past year, once a week.
33233016|NCT05695742||Non-smokers|Not being an active or passive smoker.
33233017|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
33233018|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
33233019|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
33233020|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
33233021|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
33233022|NCT04015986|Experimental|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
33233023|NCT04015986|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
33233024|NCT05734898|Experimental|rrAML|
33233025|NCT05424510|Active Comparator|Fluid Bolus (FB+)|Patients in the FB+ group will receive a single bolus of 500 ml of Ringer's Lactate over 5-10 minutes.
33233026|NCT05424510|Placebo Comparator|Non fluid bolus (FB-)|Patients in the FB- group will not receive a fluid bolus.
32748690|NCT02424929|Other|Asleep|"Sedation intervention.~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
32748691|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
33233027|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
32748692|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
33233028|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
33233029|NCT04094142|Experimental|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
33233030|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
33233031|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
33233032|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
33233033|NCT05694260|Experimental|Cohort 1|Patients at 16 to <30 kg body weight at screening receiving once daily 60 mg bempedoic acid for 8 weeks followed by 90 mg bempedoic acid for 8 weeks.
33233034|NCT05694260|Experimental|Cohort 2|Patients at 30 to 60 kg body weight at screening receiving once daily120 mg bempedoic acid for 8 weeks followed by 150 mg bempedoic acid for 8 weeks.
33233035|NCT05694260|Experimental|Cohort 3|Patients at greater than 60 kg body weight at screening receiving once daily 180 mg bempedoic acid for 8 weeks.
33233036|NCT05423964|Active Comparator|Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a room with AI (intervention)
33233037|NCT05423964|Active Comparator|Non-Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a non-AI endoscopy room (standard of care).
33233038|NCT05693090|Experimental|Escalation Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
33233039|NCT05693090|Experimental|Expansion Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
33233040|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-~Full history and clinical evaluation.~collection of individual data ( residency , occupation , special habbit , chronic illness )~Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
32748693|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
32748694|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
32748695|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
32748696|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
32748697|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
32748698|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
32748699|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
32748700|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
32748701|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
32748702|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
32748703|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
32748704|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
32748705|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
32748706|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
32748707|NCT03182543|Experimental|AM1|Mango pulp beverage
32748708|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
32748709|NCT03182543|Placebo Comparator|Control|Control beverage
32748710|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
32748711|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
33233041|NCT05692466||Active|Newly diagnosed cancer patients.
33233042|NCT05692466||Control|Historically diagnosed cancer patients.
33233043|NCT05692388||Aim 1|Qualitative Aim
33233044|NCT05692388||Aim 2|Quantitative Aim
33233045|NCT05692388||Aim 3|Integrative Aim
32748712|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
32748713|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
32748714|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
32748715|NCT03183089|Experimental|Active|
32748716|NCT03183089|Active Comparator|Active Comparator|
32748717|NCT02073682|Experimental|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
32748718|NCT02073682|Active Comparator|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
32748719|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
32748720|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
32748721|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
32748722|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
32748723|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
32748724|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
32748725|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
32748726|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
32748727|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
32748728|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
32748729|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
32748730|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
32748731|NCT02425553||Faculty and Delegates of Ascona II Meeting|
32748732|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
33233046|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
32748733|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
32748734|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
32748735|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
32748736|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
32748737|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
32748738|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
32748739|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :~- Oral intake of 50 mg once daily for 6 months."
32748740|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
32748741|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
32748742|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
32748743|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
32748744|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
32748745|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
32748746|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
32748747|NCT02421107|Other|all patients|all patients
32748748|NCT02424461|Active Comparator|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days~Placebo of ofloxacine for 7 days"
32748749|NCT02424461|Active Comparator|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
32748750|NCT02072824|Experimental|Study Drug Level 1|
32748751|NCT02072824|Experimental|Study Drug Level 2|
32748752|NCT02072824|Placebo Comparator|Placebo|
32748753|NCT04440605||cI|clincal TNM stage I
32748754|NCT04440605||cII|clinical TNM stage II
32748755|NCT04440605||cIII|clinical TNM stage III
32748756|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
32748757|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
32748758|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
32748759|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
32748760|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
33393819|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
33233047|NCT02598804|Other|control group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
33233048|NCT00917202|Experimental|MB3|3 days
33233049|NCT00917202|Experimental|MB5|5 days
32748761|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
32748762|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
32748763|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
32748764|NCT03117179|Other|Patient with an interview|
32748765|NCT03117179|Other|Patient without an interview|
32748766|NCT04750876|Active Comparator|Conventional support|
32748767|NCT04750876|Experimental|Specific care, including the intervention of a psychologist and a physical therapist.|
32748768|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
32748769|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
32748770|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
32748771|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
32748772|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
32748773|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
32748774|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
32748775|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
32748776|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
32748777|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
32748778|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
32748779|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
32748780|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
32748781|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
33233050|NCT00917202|Experimental|MB7|
33233051|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
33233052|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
33233053|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
33393820|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
33233054|NCT05754476||Brain Diseases|This study does not limit the kinds of brain diseases. The cohort includes patients with suspected or known brain diseases including tumors, vascular disorder, inflammatory disease, neurodegenerative diseases and trauma, follow-up, routine brain, and others requiring MRI exams with GBCAs.
33233055|NCT05690516|Experimental|Face masks|Participants in the experimental arm are asked to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
33393821|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
33393822|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
33233056|NCT05690516|No Intervention|Not face masks|Participants in the no intervention arm arm are asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
33233057|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
33233058|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
33233059|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
33233060|NCT04339166|Experimental|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
33233061|NCT04339166|No Intervention|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
32748782|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
33233062|NCT04093830|Experimental|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
33233063|NCT05689658|Experimental|Brazilian Diabetes Prevention Program Group|The program will be based on the American Diabetes Prevention Program (DPP), whose published results are used as a reference for prediabetic care patients in the Brazilian Diabetes Guideline. In order to reach the weight loss goal estimated at 0.5 to 1 Kg per week and 150 minutes of moderate physical activity per week, the program will offer individual and group visits, qualitative guidelines for improving diet, lifestyle and self-care.
33233064|NCT05689658|Active Comparator|Diet Group|Diet prescription for weight loss
33233065|NCT04093518|Active Comparator|Active Comparator|Estradiol 200µg
33233066|NCT04093518|Placebo Comparator|Placebo Comparator|Placebo
33233067|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
33233068|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
32748783|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
32748784|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
33233069|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
33233070|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
33233071|NCT05733260|Experimental|Culturally Tailored|10 weeks of resistance training utilizing culturally tailored prompts, feedback and high autonomy approaches.
33233072|NCT05733260|Experimental|Control|10 weeks of resistance training
33233073|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
33393823|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
33393824|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
33233074|NCT05732168||Subjects with chronic ankle instability|Men and women with recurrent unilateral ankle instability problems
33233075|NCT05732168||Control group|Healthy men and women without ankle problems
33233076|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) <65 mmHg
33233077|NCT05754398|Other|Single group will receive the nurse-led intervention|A single group of community-dwelling older persons will receive a nurse-led intervention after an initial screening and eligibility checks.
33233078|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
33233079|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
33233080|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
33233081|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
33233082|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
33233083|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
33233084|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
33393825|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
33393826|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
33233085|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
33233086|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
33233087|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
33233088|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
32744827|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
33233089|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
33233090|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
33233091|NCT00914030||A1|Patients with schizophrenia
33233092|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
33233093|NCT00914030||B1|Adult subjects with autism
33233094|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
33233095|NCT00914030||C1|Children with autism
33233096|NCT00914030||C2|Control subjects matched individually with children with autism
33393827|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
33393828|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
33393829|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
33393830|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
33393831|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
33393832|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
33393833|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
33393834|NCT04486846|Experimental|eVisit|The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.
33393835|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
33393836|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
33393837|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
32748785|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
33233097|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
33393838|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
33393839|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
33233098|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
33233099|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
33233100|NCT05754320|Experimental|Tension Band Wire fixation|patients suffering simple olecranon fracture, randomized for treatment of tension band wire fixation
33233101|NCT05754320|Experimental|Plate fixation|patients suffering simple olecranon fracture, randomized for treatment of plate fixation
33233102|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
33233103|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
33233104|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
33233105|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
33233106|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
33233107|NCT04091802|Experimental|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
33233108|NCT04091802|Experimental|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
33393840|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
33393841|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
33233109|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
33233110|NCT04089462|Other|"1. Five sessions per period - Two sessions per period"|
33233111|NCT04089462|Other|"2. Two sessions per period - Five sessions per period"|
33233112|NCT05420064||Proband-mediated cascade testing arm|Control arm
33233113|NCT05420064||Provider-facilitated cascade testing arm|Intervention arm
33233114|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
33233115|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
33233116|NCT05407662||Survey on users of sMRA therapies|sMRA stands for steroidal mineralocorticoid receptor antagonist.
33233117|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
33233118|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
33233119|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
33233120|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
33233121|NCT04091958|Experimental|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
33393842|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
33393843|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
33393844|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
32748786|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
32748787|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
32748788|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
32748789|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
32748790|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
32748791|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
32748792|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
32748793|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
32748794|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
32748795|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
32748796|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
32748797|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
32748798|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Mesna administered on Day -8 immediately following completion of the Fludarabine.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD transplant on Day 0.~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
32901631|NCT05141526|Experimental|Non-restrictive satiating intervention|The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin).
33233122|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
33233123|NCT05406726|Experimental|palmitoylethanolamide (PEA)|Palmitoylethanolamide (PEA) is a lipid based endocannabinoid dietary supplement currently marketed.
33233124|NCT05406726|Placebo Comparator|Placebo|A similar size and shaped capsule containing maltodextrin will be used as a placebo comparator.
33233125|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
32748799|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
32748800|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
32748801|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
32748802|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
32748803|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
32748804|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
32748805|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
32748806|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
33393845|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
32748807|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
32748808|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
32748809|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
32748810|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
32748811|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
32748812|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
32748813|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
32748814|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
32748815|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
33233126|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
33393846|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
33393847|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
32748816|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
33233127|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording."
33233128|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording"
33233129|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.~Procedure: ULNT 1 and EMG recording."
33233130|NCT00916968|Active Comparator|Standard CR-Flex|
33233131|NCT00916968|Experimental|Gender specific CR-Flex|
33233132|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
33233133|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
33233134|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
33233135|NCT04019886|Experimental|Experimental Group|"It consists following techniques-~Peri-oral stimulation~Vertebral pressure~Anterior stretch -lifting posterior basal area~Co-contraction -abdomen~Intercoastal stretch~Moderate manual pressure"
33233136|NCT04019886|No Intervention|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
33233137|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
33233138|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
33233139|NCT00830063|Experimental|1|
33233140|NCT00830063|Experimental|2|
33233141|NCT00830063|Active Comparator|3|
33233142|NCT00830063|Placebo Comparator|4|
33393848|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
33393849|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
33393850|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
32901632|NCT05141526|Experimental|Conventional restrictive intervention + non-restrictive satiating intervention|Conventional restrictive intervention consisting of a -500 kcal/d calorie deficit (P1) followed by a non-restrictive satiating intervention (P2)
33393851|NCT02690584|Experimental|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
33393852|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
33233143|NCT02599350||1|Patients receiving mechanical ventilation
33233144|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.~Interventions:~In hospital pain evaluation~In hospital questionnaires~Telephone conctact at 3 months"
33233145|NCT04092621|Experimental|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
33233146|NCT04092621|Active Comparator|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
33233147|NCT00750438|Experimental|Propionate ester|
33233148|NCT00750438|Placebo Comparator|Fermentable control|
33233149|NCT00750438|Placebo Comparator|Non fermentable control|
33233150|NCT04092699|Other|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
33233151|NCT04092699|Other|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
33233152|NCT04092387|Experimental|RC 1 only|Research cigarettes #1
33233153|NCT04092387|Experimental|RC 2 only|Research Cigarettes #2
33233154|NCT04092387|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
33233155|NCT04092387|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
32748817|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
32748818|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
32748819|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
32748820|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
32748821|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
32748822|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
32748823|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
32748824|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
32748825|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
32748826|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
32748827|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
32748828|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
32748829|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
32748830|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
32748831|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
32748832|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
32748833|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
32748834|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
32748835|NCT03180983|No Intervention|CONTROL GROUP|No intervention
32748836|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
32748837|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
32748838|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
33233156|NCT00586326|Experimental|Women with DCIS|Women with DCIS
32748839|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
32748840|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
32748841|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
32748842|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
33233157|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
33233158|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
33393853|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
33393854|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
33233159|NCT00751101|Experimental|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
33233160|NCT00751101|Experimental|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
33393855|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
33393856|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
32901633|NCT05141526|Placebo Comparator|Minimal healthy guidelines|Considering recommendations from the latest Canadian Obesity Guidelines, the control group will receive a minimal intervention based on the Canada's Food Guide for Healthy Eating
33233161|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
33233162|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
33233163|NCT04092309|Other|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
33393857|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
33393858|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
33393859|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
33393860|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
33233164|NCT04092309|Other|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
33233165|NCT04092309|Other|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
33233166|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
33233167|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
33233168|NCT04020003|Other|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
33233169|NCT04091334|Experimental|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
32901634|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
33233170|NCT04091334|Active Comparator|Standard care group|Standard care and monitoring.
33233171|NCT00751023|Experimental|1|Modafinil 400 mg daily
33233172|NCT00751023|Placebo Comparator|2|Placebo
33393861|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
33393862|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
33393863|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
33393864|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
33233173|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
33233174|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
33233175|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
33233176|NCT04091412|Experimental|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
33233177|NCT04091412|No Intervention|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
33233178|NCT04092075|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
33233179|NCT04092075|Sham Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
33233180|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
33233181|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
33233182|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
33233183|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
33233184|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
33233185|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
33233186|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
33393865|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
33233187|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs > 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
33233188|NCT04091919||Controlled group|Age matched controlled subjects without ASD
33393866|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
32901635|NCT01468675|No Intervention|Control|Usual Care
32901636|NCT05080296||All patients underwent DaTSCAN SPECT scans|
33233189|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
33233190|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
33233191|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
33233192|NCT04091841|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
33233193|NCT04091841|Placebo Comparator|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
33233194|NCT00744042|Other|asfotase alfa|asfotase alfa
33233195|NCT04091763|Experimental|Polidocanol foam sclerotherapy|"Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);~Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;~Patients treated in a maximum of 3 sessions at 3 weeks intervals;~Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;~In each session more than one hemorrhoid cushion could be treated."
33233196|NCT04091763|Experimental|Rubber band ligation|"Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;~A maximum of 3 sessions of ligation at 3-week intervals were performed;~More than 1 band per session could be applied."
33233197|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
33233198|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
33233199|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
32901637|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
33233200|NCT05419089|Experimental|Robotic surgery only|"Complete resection to negative frozen section margins (pT1-2)~< 4 nodes, ≤ 2 mm extranodal extension (ENE), no supraclavicular nodes"
33233201|NCT05419089|Experimental|Robotic surgery with de-intensified adjuvant therapy|"The presence of any of the following: 4 positive nodes, gross ENE, final positive margins, or bilateral neck disease~High-risk PNI/LVI (defined as PNI and LVI in combination or either factor in the presence of 3 or more positive nodes)"
33233202|NCT04091529|Experimental|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
33233203|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
33233204|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
33233205|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
33233206|NCT04091373|Experimental|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
33393867|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
33393868|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
33233207|NCT04091373|Experimental|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
33233208|NCT04091373|Experimental|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
33233209|NCT04091373|Experimental|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
33233210|NCT04091373|Experimental|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
33233211|NCT04091373|Experimental|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
33233212|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
33233213|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
33233214|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
32901638|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
33233215|NCT05510297|Other|In-home feasibility test|In this single-arm trial, participants will use an active seating system for a 3- to 7-day period. The system provides a seating platform and treadles to pedal while in a seated or semi-reclined position. The system will also include a digital user interface to track performance.
33233216|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
33233217|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
33393869|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
33233218|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
33233219|NCT00917007||ABO compatible|
33233220|NCT00917007||ABO incompatible, antiglobulin positive|
33233221|NCT00917007||ABO incompatible, antiglobulin negative|
33233222|NCT05758103|Experimental|Mechanical debridement + probiotic supplement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains).
33233223|NCT05758103|No Intervention|Mechanical debridement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement alone
33233224|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
33233225|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
33393870|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
32744570|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
32744571|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
33233226|NCT00829283|Active Comparator|1|Standard Care
33233227|NCT00829283|Experimental|2|Stepped-care
33233228|NCT04091139|Experimental|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
33233229|NCT04091139|Active Comparator|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
33233230|NCT05758025|Experimental|"Resection based on thymus-vascular-inferior parathyroid complex"|
33233231|NCT05758025|No Intervention|Traditional thyroidectomy method|
33233232|NCT00706199||Group A|donors
33233233|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
32901639|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
33233234|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
33233235|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
33233236|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
33233237|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
33233238|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
32908800|NCT05096546||Group II|"20 years old or older (regardless of sex)~Outpatients~Patients who had undergone cataract surgery and~was suspected to have dry eye disease (dry eye evaluations conducted based on the routine practice) within 6 months prior to signing the informed consent or~was diagnosed with dry eye disease within 6 months prior to signing the informed consent"
33233239|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
33233240|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
33233241|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
33233242|NCT05413161|Experimental|ADL-018|150 mg/mL, Solution for injection in PFS
33233243|NCT05413161|Active Comparator|US-Licensed XOLAIR|150 mg/mL, Solution for injection in PFS
33233244|NCT05413161|Active Comparator|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
33233245|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
33233246|NCT05412459||The tested injected doses of 99mTc-DARPinG3 3000 μg (SPECT)|"Maximum (15) evaluable subjects with HER2-positive status in primary tumour before, after 2 and 4 courses of chemo+targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
33393871|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
33393872|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
33233247|NCT05412069|Experimental|Fecobionics study|Fecobionics
33233248|NCT04090671|Active Comparator|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
33233249|NCT04090671|Active Comparator|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
33233250|NCT04090671|Active Comparator|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
33233251|NCT04090671|Active Comparator|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
33233252|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
33233253|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
33233254|NCT00706667|Active Comparator|3|Ferinject ® + EPO
33233255|NCT04090437|Active Comparator|Group1 - PVI first step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~PVI as first step~Remap to assess any change in activation~Ablate all rotors (API) in LA until SR or DCCV~Deployment of RA CTI line and demonstration of bidirectional block"
33233256|NCT04090437|Active Comparator|Group2 - PVI last step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~Ablate all rotors (API) in LA until SR or DCCV~Remap to assess any change in activation~PVI as last step even when SR achieved earlier~Deployment of RA CTI line and demonstration of bidirectional block"
33233257|NCT04090593|Experimental|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
33233258|NCT04090593|No Intervention|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
33233259|NCT04015973|No Intervention|Group A: Control|Standard Care
33233260|NCT04015973|Experimental|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
33393873|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
33393874|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
33393875|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
33393876|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
33393877|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
33393878|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
33393879|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
33393880|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
33393881|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
32908801|NCT05084066|Experimental|Experimental group|20 patients with PAD and claudication
33233261|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
32908802|NCT05084066|Sham Comparator|Control group (sham)|20 patients with PAD and claudication
33233262|NCT00917085|Experimental|Skin-to-Skin group|
33233263|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
33233264|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
33233265|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33233266|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33233267|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
33233268|NCT00709085||1|HCC patients without liver cirrhosis
33233269|NCT00709085||2|HCC patients with liver cirrhosis
33233270|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
33233271|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
33233272|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
33233273|NCT05229809|Experimental|Yiqi Wenyang Jiedu prescription Group|
33233274|NCT05229809|Placebo Comparator|Simulation agent of Yiqi Wenyang Jiedu prescription Group|
33233275|NCT00709163|Active Comparator|1|
33233276|NCT00709163|Placebo Comparator|2|
33393882|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
33233277|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
33233278|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
33233279|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
33233280|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
33233281|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
33393883|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
33393884|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
33393885|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
33393886|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
33233282|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
33233283|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
33233284|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
33233285|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
33233286|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
33233287|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
33393887|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
33393888|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
33393889|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
33393890|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
33393891|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
33393892|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear sham-acupuncture needles bitten once (day 0-5)~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
33393893|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
33233288|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
33233289|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
33233290|NCT04089384|Active Comparator|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
33233291|NCT04089384|Placebo Comparator|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
33233292|NCT04089540|Experimental|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
33233293|NCT04089540|Other|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
33233294|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
33233295|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
33233296|NCT04089228|Experimental|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
33233297|NCT04089228|Active Comparator|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
33233298|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
33233299|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
33233300|NCT04090086|Experimental|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
33233301|NCT04090086|Experimental|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
33233302|NCT04090086|Experimental|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
33233303|NCT04090086|Experimental|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
33233304|NCT04090086|Experimental|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
33393894|NCT04481607|Experimental|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
32908803|NCT05067842||Locally advanced esophageal or gastroesophageal adenocarcinoma|Subjects with diagnosed locally advanced esophageal or gastroesophageal adenocarcinoma.
32908804|NCT05061602||Diabetic Group|The patients were included if they were of 18 years or older, with a diagnosis of diabetes mellitus for more than three years.
32748843|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
32748844|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
32748845|NCT02072434|Experimental|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
32748846|NCT02072434|Active Comparator|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
32748847|NCT04725994|Other|Group 1|
32748848|NCT04725994|Other|Group 2|
32748849|NCT04725916|Active Comparator|Study Arm 1|Subjects assigned to Arm 1 will be instructed to shower daily beginning on post-operative Day 2 and maintain this daily schedule until the subject's 3-month standard of care clinic follow-up visit. They will receive specific instructions on caring for the incision site and drains until they are removed.
32748850|NCT04725916|Active Comparator|Study Arm 2|Subjects assigned to Arm 2 will be instructed not to shower post-operatively until their surgical drains are removed. They will receive specific instructions on bathing and caring for the incision sites and drains.
32748851|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
32748852|NCT02101060|No Intervention|control|usual care controls
32748853|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
32748854|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
33233305|NCT04090086|Experimental|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
32908805|NCT05061602||NonDiabetic Group|The healthy age-matched control group was included.
33233306|NCT00917787||Healthy, Non-asthmatic|
33233307|NCT00917787||Asthma|
33233308|NCT00749892|Experimental|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
32748855|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
32748856|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
32748857|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
32748858|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32748859|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
33070461|NCT00530179|Active Comparator|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
33070462|NCT00530179|Active Comparator|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
33233309|NCT04088487|Experimental|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
33233310|NCT04088487|Other|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
32748860|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32748861|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32748862|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32748863|NCT04735354||sacubitril/valsartan|Patients administered sacubitril/valsartan by prescription
32748864|NCT04734262|Experimental|Cohort A|Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32748865|NCT04734262|Experimental|Cohort B|Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32748866|NCT04734262|Experimental|Cohort C|Subjects will receive sitravatinib in combination with 200mg tislelizumab and 100 mg/m2 nab-paclitaxel until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32748867|NCT02138890|Experimental|APS injection|Autologous Protein Solution
32748868|NCT02138890|Placebo Comparator|Control|Saline
32748869|NCT04725526|No Intervention|usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care on site
32748870|NCT04725526|Experimental|mHealth intervention plus usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care plus mHealth intervention on site
32748871|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
32748872|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
32748873|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
32748874|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
32748875|NCT02070484|Experimental|NuCel|Stemcell allograft
32748876|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
32748877|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
32748878|NCT02100514|Placebo Comparator|placebo|
32748879|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
32748880|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
33070463|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
33070464|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
33233311|NCT04091256|Experimental|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
33233312|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
33233313|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
33233314|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
32748881|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~If <PR, move directly to CRT if not surgical candidates.~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
32748882|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~If CR/PR, three more weeks of nab-paclitaxel followed by CRT~If <PR, move directly to CRT if not surgical candidates.~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
32748883|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
32748884|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
32748885|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
32748886|NCT02047318|Experimental|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) administered orally up to twice each day
32748887|NCT05517681|Placebo Comparator|non-ICG Group|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection
32748888|NCT05517681|Experimental|ICG Group|ICG was injected preoperatively via anoscope or anal dilator in the mucosal layer around the tumor, and surgical treatment was performed after visualization. The surgical approach was performed by laparoscopic radical rectal cancer with an intermediate approach step.The IMA root is treated with low ligation of the IMA, while lymph node dissection is performed while preserving the autonomic nerves around the IMA
32748889|NCT05525793|Experimental|Transitional care|This group is the actual intervention group.
32748890|NCT05525793|No Intervention|Usual care|This group is the routine treatment (control) valid in the clinical practice.
32748891|NCT05522361|Experimental|Open-label crossover|Participants crossover to 36 months of open-label risdiplam mono therapy following a comparable period of nusinersen treatment.
32748892|NCT05525715|Experimental|Phase Ib Cohort 1（2mg QY201 tablets or 2mg QY201 placebo）|8 subjects use 2mg QY201 tablets，2 subject uses 2mg QY201 placebo ，BID，29 days
32748893|NCT05525715|Experimental|Phase Ib Cohort 2（5mg QY201 tablets or 5mg QY201 placebo）|8 subjects use 5mg QY201 tablets，2 subject uses 5mg QY201 placebo ，BID，29 days
32748894|NCT05525715|Experimental|Phase Ib Cohort 3（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，QD，29 days
32748895|NCT05525715|Experimental|Phase Ib Cohort 4（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，BID，29 days
32748896|NCT05525715|Experimental|Phase Ib Cohort 5（15mg QY201 tablets or 15mg QY201 placebo）|8 subjects use 15mg QY201 tablets，2 subject uses 15mg QY201 placebo，BID，29 days
32748897|NCT05525715|Experimental|Phase Ib Cohort 6（20mg QY201 tablets or 20mg QY201 placebo）|8 subjects use 20mg QY201 tablets，2 subject uses 20mg QY201 placebo，BID，29 days
32748898|NCT05525715|Experimental|Phase II Cohort1 (5mg QY201 tablets)|50 subjects use 5mg QY201 tablets twice daily for 12 weeks
32748899|NCT05525715|Experimental|Phase II Cohort2 (10mg QY201 tablets)|50 subjects use 10mg QY201 tablets twice daily for 12 weeks
32748900|NCT05525715|Experimental|Phase II Cohort3 (20mg QY201 tablets)|50 subjects use 20mg QY201 tablets twice daily for 12 weeks
32748901|NCT05525715|Experimental|Phase II Cohort4 (QY201 placebo)|50 subjects use QY201 placebo twice daily for 12 weeks
32748902|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
32748903|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
32748904|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
32748905|NCT05522283||CMV colitis|Patients with the detection of either cytomegalic cells or IHC-CMV cells were diagnosed with CMV colitis.
32748906|NCT05522283||Non-CMV colitis|Symptomatic patients were not detected with either cytomegalic cells or IHC-CMV cells.
32748907|NCT05522283||Healthy volunteers|Asymptomatic patients underwent colonoscopy for screening.
32748908|NCT05522205|Experimental|Experimental group|Immediately regulated cannabis access in pharmacies.
32748909|NCT05522205|No Intervention|Control group|During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access.
33393895|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
33233315|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
33233316|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
33233317|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
33233318|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
33233319|NCT05377905|Experimental|Microneedle Array Doxorubicin (MNA-D)|Immunocompetent and immuno-incompetent subjects will receive the MNA-D patch on 4 subsequent visits for a 20 minute time period at each application and will include patients who have competent immune systems with cSCC meeting all other inclusion/exclusion criteria and patients considered immuno-incompetent post transplant with cSCC meeting all other inclusion/exclusion criteria.
33233320|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
33233321|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
33233322|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
33233323|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
33233324|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention"
33233325|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention"
33233326|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
33233327|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
33233328|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
33233329|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
33233330|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
33233331|NCT04091100|Active Comparator|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
33233332|NCT04091100|Active Comparator|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
33233333|NCT04091178|Experimental|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).~In parallel,a calcium supplementation is prescribed."
33233334|NCT04090008|Active Comparator|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
33233335|NCT04090008|Active Comparator|Saline dressing|daily dressing of the ulcer with normal saline was done
33233336|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
33233337|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
33233338|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
33233339|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
33233340|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
32748912|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
33233341|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
32748913|NCT05016921|Experimental|Transcutaneous magnetic stimulation|Transcutaneous magnetic stimulation targeting the stellate ganglion
33233342|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
33233343|NCT04090944|Active Comparator|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
33233344|NCT04090944|Active Comparator|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
33233345|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
33233346|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
33233347|NCT04090788|Experimental|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
33233348|NCT04090788|Active Comparator|dried cucumber supplements|2.4 gram per day for 4 weeks
33233349|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
33233350|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
33233351|NCT04090632|Experimental|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
33233352|NCT04090554|Other|Cytosponge™|Single intervention arm of feasibility study
33233353|NCT05403450|Experimental|Phases 1 and 2: Tolinapant + Oral Decitabine/Cedazuridine|"Tolinapant, orally, once daily (QD) on Days 1 to 7 and 15 to 21 of each 28-day cycle in combination with oral decitabine/cedazuridine fixed-dose combination (FDC) tablet, QD on days determined by the Lead-in Phase during each 28-day cycle. The starting dose of tolinapant will be escalated stepwise in successive cohorts until the RP2D is determined.~Based on RP2D and results determined from Phase 1 participants would receive tolinapant at the identified RP2D in combination with decitabine/cedazuridine, FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle in Phase 2."
33233354|NCT05403450|Experimental|Phase 1: Oral Decitabine/Cedazuridine|Decitabine/cedazuridine FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle.
32748914|NCT05015049||Neonatal population - hypertensive disorder of pregnancy|All babies born to a woman with a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
32748915|NCT05015049||Neonatal population - no hypertensive disorder of pregnancy|All babies born to a woman without a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
32898240|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
33233355|NCT02597322|Experimental|AXITINIB|
33233356|NCT04090320|Experimental|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
33233357|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
33233358|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
33233359|NCT02596932|Other|Tight control|"Intervention Standard Care:~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60 mg/dL"
33233360|NCT02596932|Experimental|Less tight control|"Intervention:~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60mg/dL"
33233361|NCT00814307|Experimental|Active 5mg|
33233362|NCT00814307|Experimental|Active 10 mg|
33233363|NCT00814307|Placebo Comparator|Placebo Sequence 1|
33233364|NCT00814307|Placebo Comparator|Placebo Sequence 2|
33233365|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
33233366|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
33233367|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
33233368|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
33233369|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
33233370|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
33233371|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
33233372|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
33233373|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
33233374|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
33233375|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
33233376|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
33233377|NCT05399550|Experimental|Balovaptan|Balovaptan will be administered as IV infusion once a day over 3 days
33233378|NCT05399550|Placebo Comparator|Placebo|Placebo will be administered as IV infusion once a day over 3 days
33233379|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
33233380|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
33233381|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
33233382|NCT00813995|Experimental|Sitagliptin|
33233383|NCT00813995|Placebo Comparator|Placebo|
33233384|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
33233385|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
33393896|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
33233386|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
33233387|NCT02596542|Experimental|Water temperature|
33233388|NCT00813917|Active Comparator|varenicline|
33233389|NCT00813917|Placebo Comparator|Placebo|
33233390|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
32748916|NCT05013099|Experimental|Subjects with melanoma, Merkel cell, renal cell, or NSCLC|Eligible subjects will receive up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
33233391|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
32908806|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33233392|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
33233393|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
32748917|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
33233394|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
33233395|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
33233396|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
33233397|NCT05757947|Active Comparator|"no-touch saphenous vein as I-graft"|Coronary bypass surgery according to the I-graft method. Proximal anastomosis to RIMA.
33233398|NCT05757947|Active Comparator|"no-touch saphenous vein as conventional free graft"|Coronary artery bypass grafting using the free conduit technique. Proximal anastomosis to aorta.
33233399|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
33233400|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
33233401|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
33233402|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.~Intervention: Tapping test"
33233403|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.~Intervention: Wrist anesthesia~Intervention: Tapping test"
33233404|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Tapping test"
33233405|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Anti-noise helmet~Intervention: Tapping test"
33233406|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Anti-noise helmet~Intervention: Tapping test"
33233407|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
33233408|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
33233409|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
33233410|NCT02595840|Experimental|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
33233411|NCT02595840|Experimental|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
32748918|NCT05525559|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0038 administered, once daily (QD).
32748919|NCT04425057|Experimental|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
32748920|NCT04425057|No Intervention|Control group|No physiotherapy
32748921|NCT05525481|Experimental|Intervention arm|This is a single-arm trial. We only have one experimental arm. The control arm will be provided by another study.
32748922|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
33233412|NCT05756855|Experimental|behavioral intervention|This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.
32748923|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
33233413|NCT04089774|Experimental|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
33393897|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
33233414|NCT04089774|No Intervention|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
33233415|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
33233416|NCT05756777|Experimental|gilteritinib + ivosidenib (Cohort 1)|Each patient will take the combination of gilteritinib/ ivosidenib (Cohort 1) , daily, in continuous 28-day cycles at the dose level that they are assigned.
32748924|NCT05525091||Premature|Feeding assessment of High-risk premature infants cared for in the Level IV NICU
33233417|NCT05756777|Experimental|gilteritinib + enasidenib (Cohort 2)|Each patient will take the combination of gilteritinib/enasidenib (Cohort 2) daily, in continuous 28-day cycles at the dose level that they are assigned.
32748925|NCT05525091||CHD|Feeding assessment of infants having cardiac surgery within the first month of life.
33233418|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
33233419|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
33233420|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
32748926|NCT04706026|Experimental|Local anesthesia|This arm will receive local anesthesia for their inguinal hernia repair.
33233421|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
33233422|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
33233423|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
32748927|NCT04706026|Active Comparator|General anesthesia|This arm will receive general anesthesia for their inguinal hernia repair.
32748928|NCT05517447|Other|Observational cohort|Proptosis responders in feeder studies will enter in a non-treatment observational study
33233424|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
33233425|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
32748929|NCT05517447|Experimental|Treatment Cohort|Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
32748930|NCT05517369|Experimental|Hybrid-ESD+|All participants receive resection of non-pedunculated colorectal polyp between 2 and 3 cm using the Hybrid-ESD+ method.
33233426|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
33233427|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
33233428|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
33233429|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
33233430|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
33233431|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
33233432|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
33233433|NCT05256927||All Participants|
33233434|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
33233435|NCT00585975|Experimental|Xibrom 0.09%|
32748931|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
33070465|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
33233436|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
33233437|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
33233438|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
32748932|NCT05517213|Experimental|Etoposide|Etoposide1.2g/m2(Pump continuously for 24h)+G-CSF10ug/kg.
33233439|NCT04088253|Experimental|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
33233440|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
33233441|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
33233442|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
33233443|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
33233444|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
33233445|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
33233446|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
33233447|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
33233448|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
33233449|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
33233450|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
33233451|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
33233452|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
33233453|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
33233454|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
32748933|NCT05517213|Experimental|Cyclophosphamide|Cyclophosphamide 3.0g/m2+Grh-CSF10ug/kg.
32748934|NCT05517135||Arm 1|Arm 1: EBV DNA <4000 copies/mL AND T3N0-2 or T4N0 (TNM AJCC/UICC 8th edition)
32748935|NCT05517135||Arm 2|Arm 2: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA undetectable after 2-3 cycles of induction chemotherapy (IC)
32748936|NCT05517135||Arm 3|Arm 3: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA detectable after 2-3 cycles of IC
32748937|NCT05517135||Group 1|Group 1: Recurrent/metastatic NPC, EBV DNA <4000 copies/mL
32748938|NCT05517135||Group 2|Group 2: Recurrent/metastatic NPC, EBV DNA ≥4000 copies/mL
32748939|NCT05517057||success of the medical management|Patients that recovered flatus and stools, and that tolerated solid food within the 3 days after the admission
33233455|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
33233456|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
33233457|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
33233458|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
33233459|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
33233460|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
33393898|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
33233461|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
33233462|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
33233463|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
33233464|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
33233465|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
33233466|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
33233467|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
33233468|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
32748940|NCT05517057||failure of the medical management|Patients that did not recover flatus and stools, and that did not tolerate solid food within the 3 days after the admission. These patients had an indication for surgery.
32748941|NCT05512455||virtual articulator mounting using an average facebow|indirect virtual mounting in MS VA by using an average facebow
33233469|NCT02593695|Active Comparator|Standard Control|Fluoxetine
33233470|NCT05758727|Experimental|Home-based exercise group|This group will be asked to practise the 'exercise snacking and Tai-chi snacking' exercises once each and record the exercise bouts in a log book.
32748942|NCT05512455||virtual articulator mounting by using average values|virtual mounting in MS VA by using average values;
32908807|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32908808|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
32908809|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
33233471|NCT05758727|No Intervention|Control group|Usual care control group
32908810|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
33233472|NCT00734097|Experimental|Nexium 40 mgs|
33393899|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
33393900|NCT01353027|Placebo Comparator|Placebo|
33070466|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
33070467|NCT00168909|Experimental|1|alfacalcidol 1µg/d
33070468|NCT00168909|Placebo Comparator|2|placebo
33233473|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
33241545|NCT04048629|Active Comparator|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
33241546|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
33241547|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
32748943|NCT05512455||virtual articulator mounting by using professional facial scanner|virtual mounting in MS VA by using professional facial scanner
32748944|NCT05512455||virtual articulator mounting by using smartphone facial scanner|virtual mounting in MS VA by using smartphone facial scanner
32748945|NCT05512455||virtual articulator mounting by using CBCT located in Bergstrom's point|virtual mounting in MS VA by using CBCT located in Bergstrom's point
32748946|NCT05512455||virtual articulator mounting by using CBCT located in the medial poles of the condyle|virtual mounting in MS VA by using CBCT located in the medial poles of the condyle
32748947|NCT05512455||virtual articulator mounting by using JMA|virtual mounting in CA VA by using JMA,as the group to compare with the other mounting procedures.
32908811|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
32908812|NCT04431323|Experimental|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).~[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.]"
33070469|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
32748948|NCT05516979|Experimental|100 mg AP1189|Treatment period of 12 weeks given as 1 tablet daily
32748949|NCT05516979|Placebo Comparator|Placebo|Treatment period of 12 weeks given as 1 tablet daily
33070470|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
33070471|NCT00531778||NYU OCEDP Population|
33070472|NCT00145379|Experimental|Metformin|
33070473|NCT00145379|Placebo Comparator|Placebo comparator|
33070474|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
33070475|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
33070476|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
33070477|NCT00530413|Placebo Comparator|2|Placebo group
33070478|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
33070479|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
33070480|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
33070481|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
33241548|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
33241549|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
33241550|NCT04266080|Experimental|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
33241551|NCT00760773|Experimental|1|
33241552|NCT00760773|Experimental|2|
33241553|NCT00760773|Placebo Comparator|3|
33241554|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
33241555|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
33241556|NCT04077554||Study group|women and men with excess body mass
33241557|NCT04077554||Control group|women and men with proper body mass
33241558|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
33241559|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
33241560|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
33241561|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
33393901|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
33393902|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~Pre gemcitabine urine sample~Blood sample 30 minutes post Gemcitabine infusion~Urine and blood sample 2 hours post Gemcitabine infusion"
33393903|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
33233474|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
33233475|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
33233476|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
33233477|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
33233478|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
33233479|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
33233480|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
33233481|NCT00922961|Experimental|cellular apoptosis|
33393904|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
33393905|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
33233482|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
33233483|NCT00918099|Active Comparator|Anterior repair|Anterior repair
33393906|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32748950|NCT05516901|Experimental|The erector spinae plane block group|The erector spinae plane block group: Patients will receive general anesthesia plus bilateral ultrasound guided ESP block.
32748951|NCT05516901|Placebo Comparator|Control group|Control group (group І): Patients will receive general anesthesia alone.
32748952|NCT05516823||Group: Psychedelics-only Group|"A group of participants who reported using in their past psychedelic substances only (both classical and non-classical psychedelics are included). Specifically, in the current study this group included reports on the following substances:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)"
32748953|NCT05516823||Group: Stimulants-only Group|"A group of participants who reported using in their past drugs identified as stimulating compounds only (both recreational and prescribed usages are included). Stimulating compounds are considered, in the context of the current study, substances that increase the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta)"
32748954|NCT05516823||Depressants-only Group|"A group of participants who reported using in their past drugs identified as depressing compounds only (both recreational and prescribed usages are included). Depressing compounds are considered, in the context of the current study, substances that decrease the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Benzodiazepines Opiates (recreational use of heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
32748955|NCT05516823||Cannabinoids Group|"A group of participants who reported using in their past cannabinoids compounds only (both recreational and prescribed usages are included). Specifically, in the current study this group included reports on the following substances:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD)"
32908813|NCT02659241|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
33233484|NCT05297357|Experimental|Mediterranean Diet group|
33233485|NCT05297357|No Intervention|Control group|
33233486|NCT04088175|Experimental|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
33233487|NCT04088175|Experimental|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
33233488|NCT00733005|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
33393907|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33393908|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33233489|NCT00733005|Placebo Comparator|Arm 2|Matching placebo nasal spray
33233490|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
33233491|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
33233492|NCT05756621||Dual anti-glutamate therapy (DUAL)|"Patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual dose reduction according to clinical evolution."
33233493|NCT05756621||Control (OTHERS)|Patients who received any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs ketamine and perampanel.
33233494|NCT05226689|Other|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert.
33233495|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
33233496|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
33233497|NCT05221229||Study Cohort|A total of 30 patients will be included in the study group after screening of inclusion and exclusion criteria. Patients will have upstream risk factors assessed at the clinic consultation and offered risk factor optimization advice. In addition, they will received daily Liraglutide injections for 13 weeks before and 52 weeks after ablation.
33233498|NCT00923039||Exposed/ Not exposed|
33233499|NCT00732381|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
32748956|NCT05516823||Psychedelic and Non-psychedelic Substances Group|"A group of participants who reported using in their past drugs identified as psychedelics and stimulants and/or depressants (both recreational and prescribed usages are included). In this group participants will be included who reported using at least one non-psychedelic drug additionally to a psychedelic one. Specifically, the following options were provided:~Psychedelic compounds:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)~Non-psychedelic compounds:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD) MDMA (ecstasy) Ketamine Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta) Benzodiazepines Opiates (e.g., heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
32748957|NCT05516823||Substance-naive Group|"A group of participants who reported no past experience with any of the substances listed in the current study nor reported using other substances (excluding alcohol and nicotine). Participants will be assigned to this group if and only if they choose the None of the above option from the Substance Use Survey (item 1)."
32748958|NCT05512299||PD with resting tremor|Parkinson's disease patient with pure resting tremor.
32748959|NCT05512299||PD with postural tremor|Parkinson's disease patient with postural tremor.
32748960|NCT05512299||Cerebellar degeneration with intention tremor|Cerebellar degeneration patient with intention tremor.
32748961|NCT05521971|Other|Before group|In the usual care cohort, there was no systematic clinical pharmacist involvement regarding deprescribing of hypnotics.
32748962|NCT05521971|Experimental|After group|In the intervention cohort a pharmacist-led intervention was implemented comprising the four following components: 1) education of health care personnel; 2) access to standardized discontinuation regimens; 3) patient education; 4) support of transitional care.
32748963|NCT05521893|Experimental|Telemedicine group|
32748964|NCT05521893|Active Comparator|Standard care group|
32748965|NCT05077761|Experimental|High-intensity laser therapy|77 participants will receive active high-intensity laser therapy interventions on hamstring muscle to improve the flexibility of muscle
32748966|NCT05077761|Sham Comparator|Sham High-intensity laser therapy|77 participants will receive sham high-intensity laser therapy on hamstring muscle
33233500|NCT00732381|Placebo Comparator|Arm 2|Matching placebo nasal spray
32748967|NCT05521815|Active Comparator|Study group|The group that are going to receive the coma arousal therapy program
32748968|NCT05521815|Placebo Comparator|Control group|This group will receive only traditional treatment program
32748969|NCT05516745|Experimental|arm with intervention (AioCare spirometry)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring
32748970|NCT05516745|Experimental|arm with intervention (AioCare spirometry with telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring with the AioCare device and pulmonary rehabilitation exercises
32748971|NCT05516745|Experimental|arm with intervention (telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to pulmonary rehabilitation exercises
32748972|NCT05516745|No Intervention|control arm (no intervention)|50 participants with DMD aged 7-17 years, subject to a standard of care
32748973|NCT04903977|Experimental|Impedance spectroscopy|ONIRY examination
33233501|NCT04871711|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
33233502|NCT04871711|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
33233503|NCT05756543||Cases|Individuals diagnosed with Parkinson's Disease consecutively recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor or psychiatric disorders were exclusion criteria.
33233504|NCT05756543||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
33233505|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
32748974|NCT05516589|Experimental|Treatment Cohort|"Participants will receive~TP chemotherapy every 3 weeks x 2 cycles (Nab-paclitaxel 260mg/m^2 IV on day1, Cisplatin 75mg/m^2 IV on days 1-3);~Tislelizumab 200mg IV every 3 weeks x 2 cycles;~Afatinib 30mg PO everyday x 6 weeks."
32761956|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
33393909|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
33233506|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
33070482|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
33070483|NCT00530491|Experimental|2|fast track management for lung surgery
33393910|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
33393911|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
33393912|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
33233507|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
33233508|NCT05756465|Experimental|SVR group|Participant in the intervention arm will receive immersive virtual reality intervention in the form of VR box (Shinecon 6.0 VR Box Virtual Reality Glasses with headphones). SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) which attached to the head of cancer patient during chemotherapy, by displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical audio instruments (non-copyright).
33233509|NCT05756465|No Intervention|Control group|In the control group, participants will be given standard care in the form of guided imagery leaflets. It is an information sheets in the form of leaflets about the meaning, benefits, and ways of doing guided imagery relaxation therapy for cancer patient during chemotherapy. RA will guide the participants to practice the guided imagery relaxation therapy listed on the leaflet for ± 10 minutes.
33233510|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
33233511|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
33233512|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
33233513|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
33233514|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
33233515|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
33233516|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
33233517|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
33233518|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
33233519|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
33233520|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
33233521|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
33393913|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
33233522|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
33233523|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
33233524|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
33233525|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
33233526|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
33233527|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
33233528|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
33070484|NCT00530530|Experimental|1|Dose 1
33233529|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
33233530|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
33233531|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
33393914|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
33393915|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
33393916|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
32748975|NCT05511987|Active Comparator|Madela THOPAZ Suction Pump|Digital chest tube drainage systems utilize sensors to objectively quantify the size of air leaks as well as adjust the amount of suction applied to the pleural cavity in order to maintain a constant negative pressure(4). Studies in the adult population have showed that using a digital system allows for objective criteria regarding when it is safe to remove the chest tube and thus decreased time of chest tube drainage. This has also translated into decreased length of stay and cost(2, 6-8). Early data suggests that these same benefits may apply to pediatric patients, however a prospective randomized trial comparing the two systems has not been performed(9, 10).
32748976|NCT05511987|Active Comparator|Atrium Dry Suction Control Water Seal Chest Drain|there are several limitations to this analog system. First, although the system can manually be set to a certain negative pressure, the actual pressure experienced by the patient varies dependent on the amount of fluid in the tube and the level of the device relative to the patient(2). This leads to inconsistency of pleural pressure which has been associated with an increased incidence of prolonged air leak(2). Second, the analog system relies on a water chamber where bubbles are visualized to indicate an air leak. Air leaks are a common cause of increased duration of chest tube drainage and subsequent length of stay(3). There is high interobserver variability in the subjective measurement of air leaks when using the analog system thus exacerbating the amount of time the chest tube remains in the patient as well as the length of stay(4, 5).
32748977|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
32748978|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
32748979|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
32748980|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
32748981|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
32748982|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
32748983|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
32748984|NCT01624090|Experimental|1/mithramycin|Single agent intravenous (IV) mithramycin
32748985|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
33233532|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
33393917|NCT01351935|Experimental|AVL-292|
32748986|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
32748987|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
33233533|NCT04856813|Experimental|active|this is the group that does a treatment with active movement, a program of pain education and a program of home exercise.
33233534|NCT04856813|Active Comparator|non active|this is the group that does a treatment without active movement, a program of pain education and a program of home exercise.
33233535|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
33393918|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
33233536|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
33233537|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
33233538|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
33393919|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
33393920|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
33393921|NCT01352013|Placebo Comparator|Colored olive oil|
33393922|NCT01352013|Active Comparator|Omega-3 (oil)|
32748988|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
32748989|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
32908814|NCT04337177|Experimental|90 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
33070485|NCT00530530|Experimental|2|Dose 2
33070486|NCT00530530|Experimental|3|Dose 3
33070487|NCT00530530|Placebo Comparator|4|
33233539|NCT05756387||COPD patients with Chronic Respiratory Failure|
33393923|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
33393924|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
33233540|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
33233541|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
32748990|NCT05516355|Experimental|Group 1 (MBSR + CCT)|Group 1 will begin the retreat with a 3-day MBSR intervention. On day 4 of the retreat, they will crossover and begin a 3-day CCT intervention.
32908815|NCT04337177|Experimental|110 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
33233542|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
33233543|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
33233544|NCT04812119||Patients with the CTNNB1 mutation|Patient with a diagnosed CTNNB1 mutation.
33233545|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
33233546|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
33233547|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
33233548|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
33233549|NCT05326451|Experimental|active tDCS|
33233550|NCT05756309|Experimental|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
33233551|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
33233552|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
33233553|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
33233554|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
33233555|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
33233556|NCT04793711|Experimental|EpiCeram|Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
33233557|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
33393925|NCT01353339|Placebo Comparator|sugar pill|
33393926|NCT01353339|Active Comparator|levofloxacin|
33393927|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
33393928|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
33393929|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
33393930|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
33393931|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
32748991|NCT05516355|Experimental|Group 2 (CCT + MBSR)|Group 2 will begin the retreat with a 3-day CCT intervention. On day 4 of the retreat, they will crossover and begin a 3-day MBSR intervention.
33233558|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
33393932|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
33393933|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
33393934|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
33393935|NCT03241264|Experimental|Module A|Lyophilized Formulation
33393936|NCT03241264|Experimental|Module B|Frozen Formulation
33393937|NCT01353417||Renal allograft|
33393938|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
33393939|NCT01317771||Proximal Biceps Tendon Tenodesis|
33393940|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
33233559|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
33233560|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
33233561|NCT05756231|Experimental|Turkish Adaptation Study of Free and Cued Selective Reminding Test (SIHT-16)|Outcomes of Turkish adaptation of Free and cued selective reminding test (SIHT-16) is compared with memory and non-memory test in three alternative lists: a,b, and c parallel lists. The participants are assessed in neurological diagnosis routine.
33233562|NCT04790825|Experimental|Intensive periodontal treatment|Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia.
33233563|NCT04790825|Active Comparator|Community-based periodontal care|Standard cycle of supragingival mechanical scaling and polishing.
33233564|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
33393941|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
33393942|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
33393943|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
33393944|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
33393945|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
32748992|NCT05521737|Sham Comparator|Sham group|Sham acupuncture will be administered in a total of 16 sessions, for two months.
32748993|NCT05521737|Experimental|Interventional group|Electroacupuncture will be administered in a total of 16 sessions, for two months.
32748994|NCT05521659|Experimental|Standardized oral care protocol|Intervention: Patients in experimental group were given oral care 3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate.
32748995|NCT05521659|No Intervention|Control Group|Routine oral care (usual oral care with the same appliances and solution but applied twice a day without following a protocol)
32748996|NCT05521581|Experimental|intervention|Hand massage will be applied to primiparous mothers who gave birth by cesarean section
32748997|NCT05521581|No Intervention|control|Routine care will be given to mothers who have given cesarean section and hand massage will not be applied.
32748998|NCT05521503||Biological specimens|Biological specimens taken from cardiovascular procedures
32748999|NCT05516199|Experimental|Antenatal breastmilk expression|Breastfeeding consultation with trained midwife in week 33 + antenatal breastmilk expression from week 34
32749000|NCT05516199|Other|Control|Breastfeeding consultation with trained midwife in week 33
32749001|NCT05511831|Experimental|ketotifen|Ketotifen was added to the standard treatment within 24 hours after the completion of primary PCI for 3 months, taking 1 mg each time, 1-2 times a day according to the patient's tolerance.
32749002|NCT05511831|Sham Comparator|Control group|Standard treatment according to guidelines
33393946|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
33393947|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
32749003|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
32749004|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
32749005|NCT04986423|Experimental|Cohort A - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
32761957|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
33070488|NCT04711070||Patients with sepsis|Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test
32908816|NCT04337177|Experimental|75 mg/m2/day VAL-413 (Orotecan®)|In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. Orotecan® at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
33233565|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
33393948|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
33233566|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
33393949|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
33233567|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
32908817|NCT05546333||Patients receiving CTA|Patients who will receive a CTA due to clinical need will be imaged with electrical impedance tomography in addition to the CTA.
32908818|NCT05532683|Experimental|Health Behavior Group|9- week health behavior promotion group intervention
33070489|NCT04711070||Patients with chronic renal failure|
33070490|NCT04711070||Healthy control|
33233568|NCT02610257|No Intervention|No Vibration|
33233569|NCT00729651|Experimental|1|Alendronate sodium/Cholecalciferol
33233570|NCT00729651|Active Comparator|2|Alendronate sodium
33233571|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.~Examinations:~Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.~Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
33233572|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
33233573|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
33233574|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
33233575|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
33233576|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
33233577|NCT04773353|Experimental|Follitropin Delta (FE 999049)|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
33233578|NCT04773353|Experimental|Follitropin Alfa (GONAL-F)|rFSH. Follitropin alfa for subcutaneous injection
33233579|NCT00918177|Experimental|Early patients|
33233580|NCT00918177|Experimental|Moderate Patients|
33233581|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
33233582|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
32749006|NCT04986423|Active Comparator|Cohort A - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
32749007|NCT04986423|Experimental|Cohort B - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
32749008|NCT04986423|Active Comparator|Cohort B - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
32749009|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
32749010|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab~Subjects will be separated further into cohorts by tumor type"
32749011|NCT05521425|Experimental|Intervention Group|"Training + Helping Hands provided for CAPD bag exchange procedures at home"
32749012|NCT05521425|No Intervention|Control Group|"Training alone (without Helping Hands provided to assist in bag exchange procedures)"
32749013|NCT05511753|Experimental|pure tone audiometry improving|Pure tone audiometry: observe changes in hearing ability Evaluation time: Before acupuncture treatment, 2 weeks, 4 weeks, 6 weeks after treatment, and 2 weeks after acupuncture treatment, pure-tone audiometry was performed. The pure tone audiometry measures the hearing thresholds of 2KHz, 4KHz and 8KHz respectively.
32749014|NCT05521347|Experimental|caffeine|capsules with 3 mg/kg of caffeine
32749015|NCT05521347|Placebo Comparator|placebo|The placebo capsule contained flour
32749016|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
32749017|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
32749018|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
32749019|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
32749020|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
32749021|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
32749022|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
32749023|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
32749024|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
32749025|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
32749026|NCT05511675|No Intervention|control group|Patients who are in the control group will receive standard clinical care and pain level and hematoma condition will be recorded. In addition usage time of the TR band will be in accordance with the manufacturer's guidelines and will be recorded with the help of a chronometer.
32749027|NCT05511675|Experimental|experimental group I|Study group I patients will have cold application twice for a twenty minute period each time. For study group I extremity pain and hematoma will be followed and the TR band will be removed after one and a half hours.
32761958|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
33233583|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
33233584|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
33233585|NCT04087941|Placebo Comparator|Placebo|
33233586|NCT04087941|Experimental|VM-202|
33233587|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
33233588|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
33233589|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
33233590|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
33233591|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
33233592|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
33233593|NCT04748861|Experimental|Indoor Cycling (IC)|Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
33233594|NCT04748861|No Intervention|Usual and Customary Care (UCC)|Participants engage in their habitual level of physical activity.
33233595|NCT04087863||Atopic Dermatitis|
33233596|NCT05755217|Active Comparator|Dark chocolate|Single dose of 1g/kg of dark chocolate (70% cocoa, Lindt Excellence Tablette Noir 70% cacao; Lindt & Sprüngli SAS, FR-64400 Oloron-Sainte-Marie, France).
33233597|NCT05755217|Placebo Comparator|White chocolate|Single dose of 1g/kg of white chocolate (4% cocoa, Nestle Galak).
33233598|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
33233599|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
33233600|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
33233601|NCT04087551|Experimental|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
33233602|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
33233603|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
33233604|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
33233605|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
33233606|NCT00726999|Active Comparator|1|Gabapentin
33233607|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
33233608|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
33233609|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
33233610|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
33233611|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
33233612|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
33233613|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
33070491|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
32749028|NCT05511675|Experimental|experimental group II|Study group II patients will have cold application twice for a twenty minute period each time and extremity pain and hematoma will be followed but the TR band will be removed in accordance with manufacturer's guidelines as in the control group.
32749029|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
32749030|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
32749031|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
32749032|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
32749033|NCT05093517|Experimental|Glucagon Receptor Agonist (GRA) REMD-477 group|Participants are assigned to a 12 week treatment of REMD-477
32749034|NCT05093517|Placebo Comparator|Placebo group|Participants are assigned to a 12 week course of placebo for REMD-477
32749035|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
32749036|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
32749037|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
32749038|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
32749039|NCT05516121|Experimental|patients|Each patient takes 100 mg single dose, after wash-out period 200 mg single dose, then, after wash-out period 200 mg single dose two following days
32749040|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
32749041|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
33393950|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
33393951|NCT03256942|No Intervention|No Treatment|
33233614|NCT00813293|Experimental|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
33393952|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
32749042|NCT05057169|Experimental|BNT162b2 third dose after two doses of BNT162b2|
33070492|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
33393953|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
32749043|NCT05057169|Experimental|CoronaVac third dose after two doses of BNT162b2|
32749044|NCT05057169|Experimental|BNT162b2 third dose after two doses of CoronaVac|
32749045|NCT05057169|Experimental|CoronaVac third dose after two doses of CoronaVac|
32749046|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
32749047|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
32749048|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
32749049|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
32749050|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
32749051|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
32749052|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
32749053|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
33233615|NCT00813293|Placebo Comparator|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
32908819|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
32908820|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
32908821|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
32908822|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
32908823|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
32908824|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
32908825|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
32908826|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5~Cycle 2-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
32908827|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)~Cycle 1:~Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5;~Cycle 2-6:~Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
32908828|NCT02435849|Experimental|Single dose of CTL019|Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
33393954|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
33398734|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~reporting all the falls occurring during the night~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
33233616|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
33233617|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
33233618|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
33233619|NCT04087629|Experimental|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.
33233620|NCT04087629|Experimental|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataCTX® gel.
33233621|NCT05755919||Patients with epilepsy|Patients with drug-resistant focal epilepsy who undergo resective epilepsy surgery.
33233622|NCT05757479|Experimental|Steroid-eluting stent implant|Subjects randomized to the experimental group will receive steroid-eluting stent implantation in the affected sinus and saline rinses.
33233623|NCT05757479|Active Comparator|Nasal steroid spray|Subjects randomized to the comparator group will receive nasal steroid spray and saline rinses.
33233624|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.~Prophylaxis of invasive fungal infection."
33233625|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
33393955|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive.~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
32749054|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
32749055|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
32749056|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
33233626|NCT00726063|Experimental|Nanotite implant|Nanotite dental implant
33233627|NCT00726063|Active Comparator|Osseotite implant|Osseotite dental implant
33233628|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
33233629|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
33233630|NCT04019457|Experimental|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
33233631|NCT04019457|Experimental|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
33233632|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
33233633|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
33233634|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
33233635|NCT00808028|Placebo Comparator|4|normal saline (placebo)
33233636|NCT03466346|Active Comparator|Interpersonal psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
33233637|NCT03466346|Active Comparator|fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
33233638|NCT03466346|Active Comparator|Fluoxetine after IPT|participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
33233639|NCT03466346|Active Comparator|IPT after fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
33233640|NCT03466346|Active Comparator|IPT + fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.
33233641|NCT05754242|Experimental|Ascorbic acid|1.5 gr of ascorbic acid diluted in 100 ml of 0.9% saline solution will be administered intravenously during the anhepatic phase of liver transplantation
33233642|NCT05754242|Placebo Comparator|Saline solution|100 ml of 0.9% saline solution will be administered during the anhepatic phase of liver transplantation
33233643|NCT05728736|Experimental|treatment|20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
33233644|NCT05728736|Placebo Comparator|placebo|10 participants will be randomized to take placebo at h.s. for two consecutive nights.
33233645|NCT04030364|Other|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
33233646|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
32908829|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
33233647|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
33233648|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
33233649|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
33233650|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
33233651|NCT05676944|Experimental|vestibular implant|Up to 15 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
33233652|NCT05675462|Experimental|H101 + Tislelizumab+ Lenvatinib|"(Dose escalation and cohort expansion) H101 administered by intratumoral injection in combination with Tislelizumab administered intravenously (IV), and Lenvatinib administered orally.~H101 intratumorally injection starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."
33233653|NCT05727800|Experimental|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-668.
33233654|NCT05727800|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-668.
33233655|NCT05727800|Experimental|Part B|Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A.
33233656|NCT05727800|Placebo Comparator|Placebo Part B|Participants will be randomized to receive placebo matched to VX-668.
33233657|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
33233658|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
33233659|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
33233660|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 & 5), and be aged 16 years or over.
33233661|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 & 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
33241562|NCT04612790|Experimental|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
33241563|NCT04612790|Experimental|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
33241564|NCT00769041|Placebo Comparator|placebo|
33241565|NCT00769041|Active Comparator|moxifloxacin|
33241566|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
33241567|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
33241568|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
33241569|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
33241570|NCT00763659|Placebo Comparator|3|Placebo
33241571|NCT04077476|Active Comparator|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
33241572|NCT04077476|Experimental|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
33241573|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
33241574|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
33241575|NCT04019678|Experimental|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
33241576|NCT04019678|Active Comparator|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
33241577|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
32908830|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
33241578|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
32908831|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
33241579|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
33070493|NCT04691479|Experimental|PIMAGroup|"Educational and training program using motivational interview technical.~Stratification labels: to determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables. For psychological variables the Perceived Competence Evaluation Questionnaire validated in Adherence to CPAP in OSA (CEPCA) is used. Drowsiness is obtained through the administration of the Epworth Somnolence Test, and the apnoea-hypopnea index is taken from the patient's clinical history.~Segmentation: With the psychological and clinical variables, in this first visit, predictive information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence.~Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used."
33070494|NCT04691479|Experimental|Control|The patients followed the standard of care, which consists of starting therapy in the hospital, where the nurse performed training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient was always referred to the Hospital, with a frequency established by the Spanish Society of Pulmonology and Thoracic Surgery (Day 30, Day 90 and Day 180). The follow-up procedure consisted of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, and explanation of specific aspects).
33233662|NCT05754164|Experimental|Attention Control Training|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 80 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
33233663|NCT05754164|No Intervention|Control|
33070495|NCT00174369|Experimental|PD0325901|15 mg BID
33233664|NCT04700111|Experimental|Treatment 1 - DOT Pattern|Spectacle lens or treatment 1
33233665|NCT04700111|Active Comparator|Treatment 2 - Control Spectacles|Comparator lens or control arm
33233666|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
33233667|NCT05755139|Experimental|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
33233668|NCT00809471|Placebo Comparator|placebo|
33070496|NCT00145535|Experimental|1|Titanium sapphire laser treatment
33233669|NCT00809471|Experimental|avanafil 100 mg|
33233670|NCT00809471|Experimental|avanafil 200 mg|
33233671|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
33233672|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
33233673|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
33233674|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
32908832|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
32908833|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
33070497|NCT00145535|Active Comparator|2|Argon laser treatment
33070498|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
33070499|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
33070500|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
33070501|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
33070502|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
33070503|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
33070504|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
33070505|NCT00145613|Other|1|
33393956|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
32749057|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
32749058|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
32749059|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
32749060|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
32749061|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
32749062|NCT02423603|Active Comparator|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
32749063|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
32749064|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
32749065|NCT03178409||HCC|Patients affected by classical HCC
32749066|NCT03178409||MFCCC|Patients affected by classical MFCCC
32749067|NCT03178253||3|
32749068|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
32749069|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
32749070|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
32749071|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
32749072|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
32749073|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
32749074|NCT05091437||Retrospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2019 to the study initiation date. [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm) for subject inclusion].
32749075|NCT05091437||Prospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm)) for subject inclusion]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered.
33070506|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
33070507|NCT00531973|Experimental|A|Liposomal doxorubicin
33070508|NCT00531973|Active Comparator|B|epirubicin
33070509|NCT02942992|No Intervention|Control|Usual Care Group
33070510|NCT02942992|Other|Intervention|Intervention Group
33070511|NCT05319769||Zero fluoroscopy|"Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography.~Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter."
32749076|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
32749077|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
32749078|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
32749079|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
32749080|NCT03117023|No Intervention|control group|sufentanil + saline
32749081|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
32749082|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
32749083|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
32749084|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
32749085|NCT03178019||Prediabetes group|Subjects with prediabetes
32749086|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
32749087|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
32749088|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
32749089|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32749090|NCT04703842|Experimental|SRD-001|3E13 vg; one-time intracoronary infusion
32749091|NCT04703842|Placebo Comparator|Placebo|One-time intracoronary infusion
32749092|NCT04703764|Experimental|HSG4112 480 mg|60 mg HSG4112 tablet, 8 tablets, once-daily, 14-day multiple oral administration
33393957|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
32749093|NCT04703764|Placebo Comparator|Placebo 480 mg|60 mg placebo tablet, 8 tablets, once-daily, 14-day multiple oral administration
32749094|NCT04703764|Experimental|HSG4112 720 mg|60 mg HSG4112 tablet, 12 tablets, once-daily, 14-day multiple oral administration
32749095|NCT04703764|Placebo Comparator|Placebo 720 mg|60 mg placebo tablet, 12 tablets, once-daily, 14-day multiple oral administration
32749096|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
32749097|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
32749098|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
32749099|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
32749100|NCT02419625|Other|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
32749101|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
32749102|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
32749103|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
32749104|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
32749105|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
32749106|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
32749107|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
32749108|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
32749109|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
32749110|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
32749111|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
32749112|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
33233675|NCT05755061|Experimental|GEMS Plus|Home-based aerobic walking exercise that exceeds published physical activity guidelines for adults with MS
33233676|NCT05755061|Active Comparator|GEMS|Home-based aerobic walking exercise that meets published physical activity guidelines for adults with MS
33398735|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
33233677|NCT05326295||Breast cancer patients|
32749113|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
32749114|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
32749115|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
32749116|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
32749117|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
32749118|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
32749119|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
32749120|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
32749121|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
32749122|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
32749123|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
32749124|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
32749125|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
33393958|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
33393959|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
33393960|NCT04486612||hypotension|
33393961|NCT04486612||non-hypotension|
33393962|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
33393963|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
33233678|NCT02610491|Placebo Comparator|Placebo|Cellulose
33233679|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
33233680|NCT05720936||patients with electric storm|patients with electric storm defined as the occurrence of at least three episodes of ventricular fibrillation/tachycardia in 24 hours
33233681|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
33393964|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
33393965|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
33393966|NCT01353651|Experimental|Endovascular treatment|
32749126|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
33233682|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
33233683|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
33233684|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
33233685|NCT05297669|Experimental|group1|Generic name: Felbinac Trometamol Injection; Dosage form: Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 132 subjects received the test drug .
33233686|NCT05297669|Placebo Comparator|group2|Placebo:Normal saline Dosage form:Injection Dosage:0mg Volume:0ml Frequency:Multi-dose Duration:1 day A total of 132 subjects received the placebo.
33233687|NCT05720624|Active Comparator|Cohort I, Arm A (standard of care therapy)|Patients in Cohort I, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
33233688|NCT05720624|Experimental|Cohort I, Arm B ( standard of care therapy, AEO)|Patients in Cohort I, Arm B receive standard of care therapy and receive AEO PO BID for 1 month on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
33233689|NCT05720624|Active Comparator|Cohort II, Arm A (standard of care therapy)|Patients in Cohort II, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
33233690|NCT05720624|Experimental|Cohort II, Arm B (standard of care therapy, AEO)|Patients in Cohort II, Arm B receive standard of care therapy and receive AEO PO BID for 3 months on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
33233691|NCT05180513|Other|Teleconference Mindfulness Intervention Group|MBSR training program that has been adapted for use via Zoom teleconferencing and for cultural relevancy
33233692|NCT05180513|Other|Smartphone App Mindfulness Intervention Group|MBSR training program that has been adapted for use via smartphone app and for cultural relevancy
33233693|NCT05180513|No Intervention|Waitlist Control Group|No intervention; control group
33393967|NCT01353651|Active Comparator|Open repair treatment|
33233694|NCT05757323|Experimental|test formula|hydrolysed protein-based infant formula
33233695|NCT05757323|Active Comparator|control formula|standard intact protein-based formula
33233696|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
33233697|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
33233698|NCT05720546||Outpatient treatment center|Subjects received an infusion in an outpatient infusion center.
33393968|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
33393969|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
33233699|NCT05720546||Inpatient Infusion Center|Subjects received an infusion in an inpatient infusion center.
33233700|NCT04660955||Patients|Patients who had ACL reconstruction
33233701|NCT04660955||Controls|Controls who have no previous knee injury or surgery, no diagnosis of osteoarthritis
33233702|NCT00914576|Active Comparator|1|
33233703|NCT00914576|Placebo Comparator|2|
33233704|NCT00914654|Other|Healthty|10 healthy men
33233705|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
33233706|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
33233707|NCT04115618|Experimental|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
33233708|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
33233709|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
33393970|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
33393971|NCT03240718|No Intervention|Control scar|Standard care
32749127|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
33233710|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
33233711|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
33233712|NCT04115462|Active Comparator|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
33233713|NCT04115462|Placebo Comparator|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
33233714|NCT05754008|Experimental|AURORA Care Strategy|Participants will receive the AURORA Care Strategy in addition to their usual diabetes care.
33233715|NCT05754008|No Intervention|Usual Care|No intervention will be employed. This arm will continue to receive their usual diabetes care.
33233716|NCT05662982|Experimental|Intervention Group|Participants will be assessed for 12 weeks in their usual ischial containment socket before receiving a subischial socket to be worn and assessed for 24 weeks.
33233717|NCT05662982|No Intervention|Reference Group|Participants will be assessed for 36 weeks in their usual ischial containment socket. No intervention will be provided.
33393972|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
33233718|NCT04026932|Placebo Comparator|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
33233719|NCT04026932|Experimental|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
33393973|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
32749128|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
32749129|NCT04440683||Antler plate group|Antler plate group
33070512|NCT05319769||Traditional approach|"Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach.~The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip."
33070513|NCT05319418|Experimental|Hypertensive Patients Monitored Daily|Physicians utilize DailyDoctor remote monitoring platform to virtually monitor daily BP of patients. Physicians use their independent medical judgement to recommend any clinical follow up or adjustment in medications/prescriptions for any patients whose daily reporting of BP triggers an alert based on physician-driven alert thresholds.
33070514|NCT05319340|Other|anticoagulants arm|The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines). The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
33070515|NCT05319301|Experimental|Patients with hypopituitarism|A single dose of melatonin administration
33070516|NCT05319301|Active Comparator|Healthy controls|A single dose of melatonin administration
33070517|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
33070518|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
33070519|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
33070520|NCT05319223||Patient management group|patient blood management group
33070521|NCT05319223||Control|control
33233720|NCT02605460|Other|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
33233721|NCT05667116||EVUSHELD arm|3,000 Individuals given EVUSHELD for pre-exposure prophylaxis
33070522|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
33070523|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
33070524|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
33070525|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
33070526|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
33070527|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
33233722|NCT05667116||Concurrent Control arm|3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
33233723|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
33070528|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
33233724|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
33233725|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
33233726|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
32749130|NCT03179501|Experimental|NP001|NP001
33070529|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
33233727|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
33233728|NCT04112420|Other|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
32749131|NCT03179501|Placebo Comparator|Placebo|Normal saline
32749132|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
32749133|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
32761959|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
33070530|NCT02942719||Shanghai First Maternity and Infant Hospital|
33070531|NCT02942719||Dalian Maternity and Child Health Hospital|
33070532|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
33233729|NCT04112264|Experimental|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
33233730|NCT04112264|Active Comparator|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
33233731|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~Shared Care include the following~Formal Care Coordination Plan~Patient Engagement and Education~Local Oncologist Engagement and Education~Patient/Local Oncologist/Transplant Oncologist Web Portal"
33233732|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~Majority of routine visits in first 180 days will be at DFCI."
33393974|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
33233733|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
33233734|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
33233735|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
33070533|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
33070534|NCT02942719||The Children and Women's Healthcare of Laiwu City|
33233736|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
33233737|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
33233738|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
33233739|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
33233740|NCT05720390|Active Comparator|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-leucine.
33233741|NCT05720390|Active Comparator|L-leucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
33233742|NCT05720390|Active Comparator|Quinine + L-leucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
33233743|NCT05720390|Placebo Comparator|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
33233744|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
33233745|NCT04112498|Experimental|nivolumab + relatlimab + rHuPH20|
32749134|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
32749135|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
33070535|NCT02942719||Suzhou Municipal Hospital|
33233746|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
33233747|NCT04111718|Experimental|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
33233748|NCT04111718|Sham Comparator|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
33233749|NCT04111640|Experimental|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
33233750|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
33233751|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
33233752|NCT00915044||Controls|Approximately 100 healthy controls
33233753|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
32749136|NCT02422589|Experimental|Ceritinib|
32749137|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
33070536|NCT02942719||Wenling Women's and Children's Hospital|
33070537|NCT02942719||First Affiliated Hospital of Kunming Medical University|
33233754|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
33233755|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
33233756|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
33393975|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
33393976|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
33233757|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
33233758|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
33233759|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
33233760|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
33393977|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
33393978|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
33233761|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
33233762|NCT05638802|Experimental|DS-7011a|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive DS-7011a 20 mg/kg every 4 weeks by intravenous infusion.
33233763|NCT05638802|Placebo Comparator|Placebo|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive placebo every 4 weeks by intravenous infusion.
33393979|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
33393980|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
33393981|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
33393982|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
33393983|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
33393984|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
33393985|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
33393986|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
32749138|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
33233764|NCT05637866||Soy Milk|Soy milk beverage
32749139|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
33233765|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
33233766|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
33233767|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
33233768|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
33233769|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33233770|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33070538|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
32749140|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
32749141|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
32749142|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
32749143|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
32749144|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
32749145|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
32749146|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
32749147|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
33070539|NCT02942719||Xinxiang Maternity and Child Health Hospital|
33070540|NCT02942719||Yanshi People's Hospital|
33070541|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
33070542|NCT02942719||Northwest Women and Children's Hospital|
33233771|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33233772|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
33070543|NCT02942719||Suining Central Hospital|
33393987|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
33393988|NCT03137121|Experimental|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
33233773|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
33233774|NCT04111796|Experimental|group in nature|they participate in nature based-program during work hours
33233775|NCT04111796|No Intervention|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
33393989|NCT03137121|Placebo Comparator|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
33393990|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
33070544|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
33070545|NCT02942719||Fujian Province Maternity and Child Health Hospital|
33070546|NCT02942719||Qinghai Red Cross Hospital|
33393991|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
32749148|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
32749149|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~placebo tablet - per oral, twice a day, until the event or censoring occurs"
32749150|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
33070547|NCT02942719||Xinjiang Maternity and Child Health Hospital|
33070548|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
33070549|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
33070550|NCT00529048||T2DM|T2DM patients (WHO-criteria)
33070551|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
33070552|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
33070553|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
33070554|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
33233776|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
33233777|NCT04111562|Other|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
33233778|NCT04025840|No Intervention|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
33393992|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~81 depressed patients admitted after a recent suicidal act (<8 days)~81 depressed subjects with a past history of suicidal act (>1month)~80 depressed subjects without any personal history of suicidal behaviour"
32908834|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
33070555|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
33233779|NCT04025840|Experimental|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
33233780|NCT04025840|Experimental|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
33233781|NCT04025840|Experimental|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
33233782|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
33233783|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
33233784|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
33233785|NCT02607020|Experimental|Physical exercise|
33393993|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
33393994|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
33233786|NCT02607020|Active Comparator|Relaxation|
33233787|NCT00914342||Upper-GI symptoms in primary-care patients|
33233788|NCT05757245|Experimental|GMCN-508A|GMCN-508A infusion
33233789|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
33233790|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
33393995|NCT01317849|Experimental|vitamin supplements|
33233791|NCT04619225|Experimental|TetraGraph monitoring|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on either hand at a discretion of the anesthesiologist
33233792|NCT04618289|Experimental|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
33233793|NCT04618289|Placebo Comparator|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
33233794|NCT00744978|Experimental|Varenicline|
33070556|NCT05318989||Premenopausal women (PREM)|Control group
33233795|NCT00744978|Placebo Comparator|Placebo|
33233796|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
33233797|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
33233798|NCT05326217|No Intervention|Control Group|non-dysmenorrhea population with original lifestyle
33233799|NCT05326217|No Intervention|Dysmenorrhea|dysmenorrhea population without exercise intervention
33233800|NCT05326217|Experimental|Dysmenorrhea+Aerobic Exercise|dysmenorrhea population with aerobic exercise intervention
33233801|NCT05326217|Experimental|Dysmenorrhea+Resistant Exercise|dysmenorrhea population with resistant exercise intervention
33233802|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
32749151|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
32749152|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
32749153|NCT02416427|No Intervention|Arm B|Observation
33070557|NCT05318989||Postmenopausal women (POSMA)|Test group A : postmenopausal women not treated with topical estrogens
33070558|NCT05318989||Postmenopausal women (POSMB)|Test group B: postmenopausal women treated with topical estrogens
33233803|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
33233804|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
33233805|NCT04089618|Experimental|Baseline 10 Days|10 days baseline before intervention starts.
33233806|NCT04089618|Experimental|Baseline 17 Days|17 days baseline before intervention starts.
33233807|NCT04089618|Experimental|Baseline 24 Days|24 days baseline before intervention starts.
33233808|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
33233809|NCT02595606|No Intervention|control group|without treatment
33233810|NCT05755685|Experimental|Group1|The preoperative clinical stage was M1c colon or peritoneal retroflex superior rectum adenocarcinoma
33393996|NCT01317849|Placebo Comparator|Placebo|
33393997|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
33233811|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
32749154|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
33233812|NCT05757167|Experimental|HS-RDT screening/AL treatment|Pregnant women will be screened with a malaria HS-RDT and, if positive, treated with artemether-lumefantrine
33233813|NCT05757167|No Intervention|Usual antenatal care|Pregnant women will receive usual antenatal care
33233814|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
33233815|NCT00739908|Experimental|CX157 (TriRima)|
33233816|NCT00739908|Placebo Comparator|Placebo|
33233817|NCT04578431|Experimental|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
33233818|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
33233819|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
33233820|NCT04570475|Experimental|vitamin D+multivitamin|
33233821|NCT04570475|Active Comparator|placebo+multivitamin|
33233822|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
33233823|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
33233824|NCT05052125|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94% Intervention: Drug: Oxygen gas
33233825|NCT05052125|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas
33233826|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
33233827|NCT00739596|Active Comparator|Amlodipine|
33233828|NCT05754905||Normal hip joint|The normal side of patients with hip joint disease
33233829|NCT05754905||Abnormal hip joint|The abnormal side of patients with hip joint disease
33233830|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
33233831|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
33233832|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
32749155|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
33233833|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
33233834|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
33233835|NCT05757089|Experimental|ALCOFILTRUM|"ALCOFILTRUM, 4 tablets in a single dose, 30 minutes prior to consumption of alcohol.~Ingredients per tablet:~Lignin hydrolyzed 800 mg; Glycine 150 mg; Dihydromyricetin 30 mg; Vitamin B1 30 mg."
33233836|NCT05757089|No Intervention|Control|
33233837|NCT04088760|Experimental|TCRαβ+/CD19+ depleted HSCT|
33393998|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
32908835|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
33233838|NCT05755607|Other|laparoscopic pancreaticoduodenectomy group|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
33233839|NCT05755607|Other|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
33233840|NCT04088604|Experimental|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
32908836|NCT05478863|Placebo Comparator|Oral placebo|Acute administration of oral placebo three times in study session (Time 0, 60, and 120).
32749156|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
33233841|NCT04088604|Experimental|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
33233842|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
33233843|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
33233844|NCT04088604|Active Comparator|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
33233845|NCT05124119||Focus Group One|Participants in Focus Group 1 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
32908837|NCT05478863|Experimental|Oral administration of 2.5 mg THC|Acute administration of oral THC (2.5 mg) three times in study session (Time 0, 60, and 120).
33070559|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
33233846|NCT05124119||Focus Group Two|Participants in Focus Group 2 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
33233847|NCT04234919||Consented adult lung transplant recipients|
33233848|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
33233849|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
33233850|NCT05754749|Experimental|Contrast-enhanced digital breast tomosynthesis (CE-DBT)|Participants with known breast lesions will be imaged using contrast-enhanced digital breast tomosynthesis (CE-DBT) with Iohexol 350 mg I/mL.
33233851|NCT02608853||Liraglutide-like Cohort|
33233852|NCT02608853||LEADER™-like Cohort|
33233853|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
33233854|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
33233855|NCT05754671|Experimental|laryngectomized patients|
33233856|NCT05754671|Experimental|health professionals|
33233857|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization~5 times a week~During 6 weeks~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
33233858|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
33233859|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
33233860|NCT00811187|Experimental|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
33233861|NCT00811187|Placebo Comparator|Saline placebo injection|5cc Normal Saline injection in each paracervical region
32749157|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
32749158|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
32749159|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
32749160|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
32749161|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
32749162|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
32749163|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
32749164|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
32749165|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
32749166|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
32749167|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
32749168|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
32749169|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
32749170|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
32749171|NCT02416037|Experimental|Prone Proseva|
32749172|NCT02416037|Active Comparator|Prone Talmor|
32749173|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
32749174|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
32749175|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
32749176|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
33070560|NCT00145847|Placebo Comparator|Lactose pill|
32749177|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
32749178|NCT04482881|Active Comparator|women receiving isosorbide mononitrates lower dose|women who will receive isosorbide mononitrates lower dose
33233862|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
33233863|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
33233864|NCT04421729|Active Comparator|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
33233865|NCT04421729|Active Comparator|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
33393999|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
33233866|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
33394000|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
33233867|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
33233868|NCT05754515||target controlled infusion (TCI) group|Propofol and remifentanil will be used in TCI anesthesia, and while the patient is under adequate sedation (BIS40-60), muscle relaxation will be provided with 0.6 mg/kg rocurium bromide. While applying TCI anesthesia, the device will use the Minto model for Remifentanil infusion and the Schnider model for Propofol infusion.
33233869|NCT05754515||inhalation anesthesia (IA) groups|During anesthesia induction of patients receiving inhalation anesthesia, 60 mg 2% lidocaine, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide and 1 mcg/kg fentanyl will be used. Desflurane will be used with a minimum alveolar concentration of 1 and for additional intraoperative sedation. remifentanil will be given between 0.05 and 0.2mcg/kg/min according to the patient's needs.
33233870|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
33233871|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
33233872|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
33233873|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
33233874|NCT02595138|Experimental|A|zoledronic acid received
33233875|NCT02595138|No Intervention|B|observation
33233876|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
33233877|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
32749179|NCT04482881|Active Comparator|women receiving isosorbide mononitrates higher dose|women who will receive isosorbide mononitrates higher dose
32749180|NCT04482881|Active Comparator|Women receiving misoprostol|Women who will receive misoprostol
33233878|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
33233879|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
33233880|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
32749181|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
33233881|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
33233882|NCT05753813|Experimental|Study group|This is a single-arm study. all participants are assigned to this arm. all study participants will receive Phexxi, the study drug. 8 pre-filled vaginal inserters with vaginal gel, Phexxi, will be provided to each of the participants with verbal and written instructions for application. Patients will be instructed to use Phexxi twice per week, on the same days every week.
33233883|NCT04181723|Experimental|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
33233884|NCT04181723|Placebo Comparator|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
33233885|NCT04173065|Placebo Comparator|Placebo|
33233886|NCT04173065|Experimental|1.0 mg|
32749182|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
33233887|NCT04173065|Experimental|2.5mg|
32749183|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
32908838|NCT05478863|Experimental|Oral administration of 2.5 mg THC + 60 mg caffeine|Acute administration of oral THC (2.5 mg) and oral caffeine (60 mg) three times in study session (Time 0, 60, and 120).
32908839|NCT05478863|Experimental|Oral administration of 2.5 mg THC + 60 mg caffeine + 35 mg CBD|Acute administration of oral THC (2.5 mg), oral caffeine (60 mg), and oral CBD (35 mg) three times in study session (Time 0, 60, and 120).
32908840|NCT03016520|Experimental|Test drug|DWJ1392
33233888|NCT04173065|Experimental|5.0 mg|
33233889|NCT04173065|Experimental|10 mg|
33233890|NCT00793598|Experimental|Brincidofovir|"Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:~20 mg BCV once weekly (QW) on Days 0, 7, and 14; or~10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28."
33233891|NCT00793598|Placebo Comparator|Placebo|"Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28."
33233892|NCT04115072|Active Comparator|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
33233893|NCT04115072|Experimental|B - Five doses of PZQ|"Five doses of Praziquantel~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment~1 x 40 mg/kg Praziquantel five weeks following the 1st dose~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
33394001|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
33233894|NCT04025294|Experimental|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
33233895|NCT04025294|Active Comparator|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
33233896|NCT05631548|Experimental|iTBS to dmPFC, Then Sham iTBS|
33233897|NCT05631548|Sham Comparator|Sham iTBS, Then iTBS to dmPFC|
33233898|NCT00796562|Experimental|Myeloablative haploidentical BMT|"All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.~Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
33233899|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
33233900|NCT04111484|Active Comparator|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
33233901|NCT04111484|Placebo Comparator|Saline|Saline
33233902|NCT05630690|Experimental|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
33233903|NCT04109300|Experimental|preemptive screening|prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
33233904|NCT04109300|Active Comparator|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
33233905|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
33233906|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
32749184|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
32749185|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
32749186|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
32749187|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
32749188|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
33394002|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
32749189|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
32749190|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
32749191|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
32908841|NCT03016520|Experimental|Reference drug|DWC20164
32908842|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
32908843|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
32908844|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
32908845|NCT04917224|Experimental|Cohort A: Central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
33233907|NCT04111328|Experimental|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
33394003|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
33394004|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
33233908|NCT04111328|Experimental|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
33233909|NCT04111328|Experimental|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
33233910|NCT04111328|Experimental|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
33233911|NCT04111328|Experimental|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
33233912|NCT04111328|Experimental|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
33233913|NCT04111328|Experimental|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
33233914|NCT04111328|Experimental|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
33233915|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
33233916|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
33233917|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
33233918|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
33233919|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
33233920|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
33233921|NCT04109534|Placebo Comparator|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
33233922|NCT04109534|Active Comparator|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
32908846|NCT04917224|Experimental|Cohort B: Ultra-central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
33233923|NCT05659940||Healthy people|Healthy participants whose age and gender are consistent with CNV patients
33233924|NCT05659940||CNV patients|Patients who are diagnosed ocular chemical injury coming to Zhongshan Eye Center, Sun Yat-sen University for medical care
33233925|NCT05753735|Active Comparator|Standard perioperative antibiotics|The control group will be treated according to current standard perioperative antibiotic practice, and perioperative antibiotics will not exceed 24 hours postoperatively.
32908847|NCT04352972|Active Comparator|Hospital-based rehabilitation program|
33233926|NCT05753735|Experimental|Extended antibiotic prophylaxis|The intervention group will receive an extended duration of current standard perioperative antibiotics, then converted to amoxicillin/clavulanic at discharge
33233927|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
33233928|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
33233929|NCT05754437|Experimental|Low Level Light Therapy Group|Patients enrolled in the treatment group will undergo Low Level Light therapy using Meibomask (Espansione Marketing S.p.A., Bologna, Italy) for 15 minutes one week (±2 days) before surgery (T0) and one week (±2 days) after surgery (T1).
33233930|NCT05754437|No Intervention|Control group|Patients enrolled in the control group will not receive Low Level Light therapy at any time.
33233931|NCT04377659|Experimental|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
33233932|NCT04377659|Experimental|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
33233933|NCT05630066|Experimental|Part 1 Adult Alogabat High Dose (aged 15-17)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat.
33233934|NCT05630066|Experimental|Part 1 Age adjusted high dose (age 10-14)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat.
33233935|NCT05630066|Experimental|Part 1 Age Adjusted Low Dose (age 5-9)|In Part 1 of the study, participants will receive age-adjusted dose 20 mg QD alogabat.
33233936|NCT05630066|Experimental|Part 2 Cohort 1|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
33233937|NCT05630066|Experimental|Part 2 Cohort 2|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
33233938|NCT05630066|Experimental|Part 2 Cohort 3|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
33394005|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
33233939|NCT05630066|Experimental|Part 1 Optional Cohort|If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, up to 8 additional participants may be recruited in any of the 3 age-groups in order to confirm the exposure equivalence prior to selecting doses and proceeding to Part 2.
33233940|NCT04111250|Experimental|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
33233941|NCT04111250|Active Comparator|Lateral sinus lift|"Conventional procedure.~Lateral approach to the sinus was made following the conventional procedure.~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants [Maxillent] are placed, and flap is sutured."
33233942|NCT05326139|Active Comparator|Tranexamic acid|Group TA (n=25): TA ( Tranexamic acid, 250mg/2.5 ml inj ) soaked pledgets were placed under the skin flap to cover the osteotomy line
33233943|NCT05326139|Placebo Comparator|Isotonic saline|Group Co (n=25): Isotonic saline ( NaCl, 0.9 %) soaked pledgets were placed under the skin flap to cover the osteotomy line
33394006|NCT04461483|Experimental|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
32749192|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
33233944|NCT04110782||Radium223|
33233945|NCT05754359|Experimental|I'm an Active Hero (IAAH) Intervention program (intervention group)|Preschool where the intervention implement will be run.
33233946|NCT05754359|No Intervention|Usual physical activities (control group)|No intervention will be delivered in the control group, and children were requested to continue their usual physical activities.
33233947|NCT05628350|Experimental|No UPF (Ultra-processed foods)|Participants will consume a diet containing 0% total energy from UPF for 6 weeks
32749193|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
33233948|NCT05628350|Active Comparator|Standard UPF|Participants will consume a diet containing 59% total energy from UPF for 6 weeks
33233949|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
33233950|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)~Prednisone (100 mg) will be administered."
33233951|NCT05621096|Experimental|Single arm|Subjects will receive 4 gray (Gy) radiation in 2 fractions in the bridging period following lymphocyte pheresis, prior to lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T-cell infusion. Post CAR T-cell infusion radiation therapy will be allowed as determined by study investigator but prespecified at time of radiation oncology consultation.
33233952|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
33233953|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
33233954|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
33233955|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
33233956|NCT00800384|Experimental|1|ICD implant without defibrillation testing
33233957|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
33233958|NCT04108832|Experimental|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
33233959|NCT04108832|Placebo Comparator|PLACEBO|PLACEBO
33233960|NCT00796328|Experimental|1|
33233961|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
33233962|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
33394007|NCT04461483|Experimental|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
33394008|NCT04461483|Experimental|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
32749194|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
32749195|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
32749196|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
32908848|NCT04352972|Experimental|Tele-monitored home exercise program|
33070561|NCT00169182|Experimental|TPF|Docetaxel, Cisplatine, 5-FU
32749197|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
32749198|NCT02414945|Experimental|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
33233963|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
32749199|NCT02414789|Experimental|SRM / MS-MS|
32749200|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
32749201|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
32749202|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
32749203|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
32749204|NCT02414087|Active Comparator|study group|ICB Medical Insoles
32749205|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
32749206|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
33233964|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
32749207|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
33233965|NCT04114916|Experimental|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
33233966|NCT04114916|Placebo Comparator|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
33233967|NCT04110860|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
32749208|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
33233968|NCT04110860|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
33233969|NCT04110860|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
32749209|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 400 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
32749210|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
32749211|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the morning (Observation Group)|routine bowel preparation before colonoscopy in the morning
32749212|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the afternoon (Random)|routine bowel preparation before colonoscopy in the afternoon
32749213|NCT04483037|Experimental|two dose in the same day, colonoscopy in the afternoon (Random)|experimental group
33233970|NCT04114760|Active Comparator|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
33233971|NCT04114760|Experimental|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using patchy-type wireless device.~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
33233972|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
33233973|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
33233974|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
33394009|NCT04461483|Placebo Comparator|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
33233975|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
32749214|NCT04992065|Experimental|Oral NNC0385-0434 15 mg once-daily (OD)|15 mg NNC0385-0434 co-formulated with 500 mg Salcaprozate sodium (SNAC) tablet once daily
32749215|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 15 mg)|15 MG placebo administered as tablets (without SNAC) once daily
32749216|NCT04992065|Experimental|Oral NNC0385-0434 40 mg OD|40 mg study drug co-formulated with 500 mg SNAC tablet once daily
32749217|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 40 mg)|placebo administered as tablets (without SNAC) once daily
33233976|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
33070562|NCT00169182|Active Comparator|PF|Cisplatine, 5-FU
33233977|NCT04114526|Experimental|Community Health Advisor 4-step Program|
33233978|NCT05618054|Other|Adolescents with POTS|
33233979|NCT05618054|Other|Adolescents without POTS|
33233980|NCT04110704|Active Comparator|Transvaginal cerclage|
33233981|NCT04110704|No Intervention|Active monitoring|
33233982|NCT04110548|Experimental|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
33233983|NCT04110548|Experimental|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
33233984|NCT04110548|Experimental|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
33233985|NCT05616104||FLEX Vessel Prep followed by angioplasty|Eligible subjects will be treated with the FLEX Vessel Prep system followed by balloon angioplasty.
33233986|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
32749218|NCT04992065|Experimental|Oral NNC0385-0434 100 mg|100 mg NNC0385-0434 co-formulated with 500 mg SNAC tablet once daily (51 participants)
33233987|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
32749219|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 100 mg)|placebo administered as tablets (without SNAC) once daily
33233988|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
33233989|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
33233990|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
33233991|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
33233992|NCT05600036|Experimental|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
32749220|NCT04992065|Active Comparator|Subcutaneous evolocumab 140 mg Q2W|140 mg evolocumab Subcutaneous (s.c.) injections every 2 weeks (51 participants). The s.c. evolocumab arm is open-label to limit unnecessary injections
32749221|NCT01663857|Experimental|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
32749222|NCT01663857|Experimental|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
33070563|NCT04691908|Active Comparator|Phase III Adult-vaccine (A Sample, blind study)|Group 1 (phase III): 2400 volunteers from 18 years old and elder who will be the QazCovid-in® twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
33070564|NCT04691908|Placebo Comparator|Phase III Adult-Placebo (A Sample, blind study)|Group 1 (phase III): 600 volunteers from 18 years old and elder who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
33233993|NCT05600036|Experimental|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
33233994|NCT05600036|Experimental|ESK-001 Dose Level 3|ESK-001 administered as an oral tablet
33233995|NCT05600036|Experimental|ESK-001 Dose Level 4|ESK-001 administered as an oral tablet
33233996|NCT05600036|Experimental|ESK-001 Dose Level 5|ESK-001 administered as an oral tablet
33233997|NCT05600036|Placebo Comparator|Placebo|Placebo administered as an oral tablet
33233998|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
33233999|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
33234000|NCT02604602||PPH|
33234001|NCT02604602||non-PPH|
33234002|NCT05653622|Experimental|SIB-DOPA|
33234003|NCT05613764|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
32749223|NCT01663857|Experimental|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
32749224|NCT01663857|Placebo Comparator|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
32749225|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
33234004|NCT05613764|Experimental|Message from local pharmacy team|This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
33234005|NCT04110470|Active Comparator|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
33234006|NCT04110470|Experimental|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
33234007|NCT04110002|Experimental|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
33234008|NCT04110002|No Intervention|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
33234009|NCT00795704|Placebo Comparator|Placebo|Control Group
33234010|NCT00795704|Active Comparator|Mulberry Leaf Extract|
32908849|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
32908850|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
33234011|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
33234012|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
33234013|NCT04110392|Experimental|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
33234014|NCT04108520|Experimental|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
33234015|NCT04108442|Active Comparator|Traditional|
33234016|NCT04108442|Experimental|Virtual|
33234017|NCT05597228|Experimental|Behavioral: Cognitive-Behavioral Stress Management and Health Education|Weekly video conference groups led by a trained facilitator
33234018|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
33234019|NCT05653544||Mitochondrial myopathy|Mitochondrial myopathy, confirmed genetically
33234020|NCT00444457|Experimental|1|
33234021|NCT00444457|Experimental|2|
33234022|NCT00444457|Experimental|3|
33234023|NCT00444457|Active Comparator|4|
33234024|NCT05612360|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
33234025|NCT05612360|Experimental|Message encouraging vaccination in preparation for the holidays|This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.
33234026|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
33234027|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
33394010|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
33394011|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
33394012|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
33394013|NCT04461483|Placebo Comparator|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
33394014|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
32749226|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:~at a dose of 50 mg/m2 PO once daily continuously, or~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
32749227|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
32749228|NCT04887831|Active Comparator|Platinum-based chemotherapy followed by avelumab maintenance therapy|Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Avelumab (800 mg)
32749229|NCT04887831|Experimental|Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy|Trilaciclib (240 mg/m2) + Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Trilaciclib (240 mg/m2) + Avelumab (800 mg)
32749230|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
32749231|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
32749232|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
32749233|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
32749234|NCT05521113||Home Rehabilitation Monitoring System|Subjects will complete a home pulmonary rehabilitation program while using a home rehabilitation monitoring system and completing health coaching calls.
32908851|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
33234028|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
33234029|NCT00725985|Experimental|Cladribine 5.25 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
33234030|NCT00725985|Experimental|Cladribine 3.5 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
33234031|NCT00725985|Placebo Comparator|Placebo (ITP)|Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
33234032|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (OLMP)|Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
33234033|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (OLMP)|Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
32749235|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32749236|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32749237|NCT04977297|Experimental|Move to Music Video Intervention|Participants in this arm will receive the Move to Music with Video (M2M-V) intervention. The participant will be asked to exercise twice daily for 5 consecutive days.
32749238|NCT04977297|Active Comparator|Move to Music Intervention|Participants in this arm will receive the Move to Music (M2M) only intervention without video. The participant will be asked to exercise twice daily for 5 consecutive days.
32749239|NCT05515965|Experimental|Kinesiotape|The patients in the Kinesiotape group were taped with the mechanical correction method.
32749240|NCT05515965|Sham Comparator|Control|In the patients in the Control group were taped with tensionless gluing of the I tape.
33234034|NCT00725985|Experimental|Placebo, Rebif (OLMP)|Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
33234035|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33234036|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33234037|NCT00725985|Experimental|Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33394015|NCT04251585|Experimental|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
32749241|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
32749242|NCT04598295|Experimental|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
32749243|NCT04598295|Placebo Comparator|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
32749244|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
32749245|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
32749246|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
32749247|NCT00704483|Experimental|1|1g tid
32749248|NCT00704483|Active Comparator|2|Sevelamer HCl
32749249|NCT00704483|Experimental|3|SBR759 1.5 g tid
32749250|NCT00704483|Active Comparator|4|Sevelamer HCl
33234038|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33241580|NCT04077398|Experimental|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
33394016|NCT04251585|Experimental|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
32749251|NCT04596189|Experimental|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
32749252|NCT04596189|Placebo Comparator|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
32749253|NCT04590885|Other|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
32749254|NCT04590885|Other|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
32749255|NCT03176537|Placebo Comparator|Placebo|Gel, daily
32749256|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
33234039|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33234040|NCT00725985|Experimental|Placebo, Rebif (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
33234041|NCT04107974|Experimental|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
33234042|NCT04107974|Experimental|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
33234043|NCT04113824|Experimental|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
33234044|NCT04113824|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
33234045|NCT04113980|Experimental|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
33234046|NCT04113980|Experimental|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
33234047|NCT04113980|Experimental|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
33234048|NCT04113980|No Intervention|control group|No intervention was made to children in the control group
33234049|NCT04109768|Experimental|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
33234050|NCT00793910|Active Comparator|Gabapentin|oral medication
33234051|NCT00793910|Placebo Comparator|placebo|
33234052|NCT04113902|Experimental|intervention group|Health education is given intervention group and 12 weeks follow up.
33234053|NCT04113902|No Intervention|control group|Control group takes standard health care and 12 weeks follow up.
33234054|NCT05609084|Other|Control|Patients will have speech therapy assessment in addition to standard care.
32749257|NCT05511441|Experimental|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
32749258|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
33234055|NCT05609084|Experimental|Experimental|Patients will have speech therapy assessment and intensive speech rehabilitation
33234056|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
32749259|NCT05515809|Experimental|interventional arm|the experimental arm will receive the parasternal block with injection of locoregional anesthesia
32749260|NCT05515809|Active Comparator|control arm not requiring loco-regional anesthesia.|the control arm will receive a standard treatment, without locoregional anesthesia
32749261|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
32749262|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
33234057|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
33234058|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
33234059|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
33234060|NCT05589818|Experimental|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab (200mg IV every 3 weeks) for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV.
33234061|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
33234062|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
33234063|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
33234064|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
33234065|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
33234066|NCT04113668|Experimental|Arm A: Single Dose (BMS-986165)|
33234067|NCT04113668|Experimental|Arm B:Diflunisal and Single Dose (BMS-986165)|
33234068|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
33234069|NCT04108286|Experimental|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
33234070|NCT04108286|Experimental|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
33234071|NCT04107896|Experimental|Silodosin|8 mg daily by mouth, 12 weeks
33394017|NCT04251585|Experimental|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
32749263|NCT05515731|Experimental|Autologous platelet-rich plasma eye drops|Autologous platelet-rich plasma eye drops are derived from treatment of patients plasma using special process.
33234072|NCT04107896|Active Comparator|Tamsulosin|0.4 mg daily by mouth, 12 weeks
33234073|NCT01024699||XLIF|This group will have the XLIF procedure done.
33394018|NCT04251585|Placebo Comparator|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
33234074|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
33234075|NCT05582720|Active Comparator|Conventional burger group|This arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
33234076|NCT05582720|Experimental|Vegan burger group|This arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
33234077|NCT04103983|Active Comparator|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A pad consisting of twelve equally spaced electrodes is placed over the residual limb. This pad is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
33234078|NCT04103983|Placebo Comparator|Placebo Sensory Retraining Interactive Device|The placebo device is visually identical to the active device
33234079|NCT04103983|Active Comparator|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. This device delivers the stimulation using microcurrents that the participants may or may not feel. There is no interaction required with this device i.e. there is no Q&A element, feedback nor response dependent progression.
33234080|NCT04103983|Placebo Comparator|Placebo Sensory Retraining Non-Interactive Device|The placebo device is visually identical to the active device
33234081|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
33234082|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
33394019|NCT04486300|No Intervention|Season of presentation|Comparison of number of presented cases in each season
33394020|NCT04486300|Active Comparator|Intervention|Surgical intervention of failed Pneumatic cases is done
33394021|NCT04418427|Experimental|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
33394022|NCT04418427|Experimental|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
33394023|NCT04418427|Active Comparator|3|Aflibercept 2mg IVT
33394024|NCT04486534||Case group|36 patients between the ages of 18-65, who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation and who have been using prostheses for at least 3 months
33394025|NCT04486534||Control group|36 age and body mass index (BMI)-matched healthy controls
33234083|NCT04113590|Experimental|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
33234084|NCT04106882|Experimental|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
33234085|NCT04106882|Experimental|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
33234086|NCT04106882|Experimental|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
33234087|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
33234088|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
32908852|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
33234089|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
33234090|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
33234091|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
33234092|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
33234093|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
33234094|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
33234095|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
33234096|NCT01323361|No Intervention|Non-immunosupressed|Normal population
33234097|NCT04071769|Experimental|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
33234098|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
33234099|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
33234100|NCT04107740|Experimental|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
33234101|NCT04107740|Placebo Comparator|Placebo (0mg Taltirelin Hydrate)|BID for 24 weeks
33234102|NCT00724971|Experimental|Inotuzumab Ozogamicin + Rituximab|
33234103|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
33234104|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
33234105|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
33234106|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
33234107|NCT04113512|Experimental|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
33234108|NCT04113512|No Intervention|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
33234109|NCT04107428|Active Comparator|Somatostatin|
33234110|NCT04107428|Placebo Comparator|Placebo|
33234111|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
33234112|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
32749264|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
32749265|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
33234113|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
33234114|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
33234115|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
33234116|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
33234117|NCT05559476|Experimental|Co-Ad Group|Participants randomized to Co-Ad Group receive 1 dose of RSVPreF3 OA investigational vaccine and 1 dose of FLU HD at Day 1 and are followed up until the study end.
32749266|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
32749267|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
33234118|NCT05559476|Active Comparator|Control Group|Participants randomized to Control Group receive 1 dose of FLU HD at Day 1, followed by 1 dose of RSVPreF3 OA investigational vaccine at Day 31 and are followed up until the study end.
33234119|NCT00454987|Experimental|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
33234120|NCT00454987|Active Comparator|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
33234121|NCT00454987|Active Comparator|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
33234122|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
33234123|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
33234124|NCT00789698|Experimental|Lurasidone HC1|
33234125|NCT00789698|Active Comparator|Quetiapine|
33234126|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
33234127|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
33234129|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
33234130|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
33234131|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
33234132|NCT00798590|Experimental|GLP-1|
32749268|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
33234133|NCT00798590|Placebo Comparator|Saline|
33234134|NCT05368155|Experimental|ACT and Education Group|The Acceptance and Commitment Training (ACT) and education group will receive the Brief ACT for Pelvic Pain treatment, which will include three weekly, 90-minute group sessions.
33234135|NCT05368155|No Intervention|Enhanced Treatment As Usual|The Enhanced treatment as usual (TAU) condition will receive a letter with treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.
33234136|NCT05366673|Experimental|Massage therapy|Patients will receive massage therapy for 10 minutes, once per day from the first day to the seventh day of admission to the intensive care unit.
33234137|NCT05366673|No Intervention|Control group|Patients will maintain usual care.
33234138|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
33234139|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
33234140|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
33234141|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
33234142|NCT00481195|Active Comparator|Armodafinil|
33234143|NCT00481195|Placebo Comparator|Placebo|
33234144|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
33234145|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
33234146|NCT04068649|Experimental|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
32749269|NCT04883463|Experimental|Epidural Stimulation for Respiratory Function|Self-controlled longitudinal safety and feasibility of stimulation and respiratory training.
32749270|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
32749271|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
32749272|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
33234147|NCT04068649|Experimental|Arm II (SBRT)|Patients undergo single fraction SBRT.
33234148|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
33234149|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
33234150|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
33234151|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
33234152|NCT01020253|Active Comparator|Alendronate medication|
33234153|NCT01020253|Active Comparator|Alfacalcidol medication|
33234154|NCT01020253|No Intervention|Non-medication|
33234155|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
33234156|NCT01020331|Experimental|ACTIVE|
33234157|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
33234158|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
33234159|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
32749273|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
32908853|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
33234160|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
33234161|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
32908854|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
32908855|NCT04443608|Active Comparator|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
33234162|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
33234163|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
33234164|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
33234165|NCT01027663|No Intervention|Iron Deficiency Anemia|
33234166|NCT01027663|No Intervention|Hereditary Hemochromatosis|
33234167|NCT01027663|Active Comparator|Iron Supplements|
33234168|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
33234169|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
33234170|NCT02593734|No Intervention|Control|No intervention
33234171|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
33234172|NCT04088526|Experimental|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
33234173|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
33234174|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
33234175|NCT00724503|Experimental|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
33234176|NCT00724503|Active Comparator|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
33234177|NCT00791648|Experimental|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
33234178|NCT00791648|Placebo Comparator|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
33234179|NCT05366595|Active Comparator|Treatment group|who received oral zinc sulfate supplementation on dose doses ranging from 10 mg (infants) to 20 mg (under-five children) of elemental zinc per day, a dosage that is safe in these children
33234180|NCT05366595|No Intervention|Control group|who didn't receive zinc sulfate supplementation.
33234181|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
33234182|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
33070565|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
32908856|NCT04443608|Placebo Comparator|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
33234183|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
33234184|NCT04017260|Experimental|open and closed technique|treatment of pilonidal sinus by open and closed approach
33234185|NCT04017260|Experimental|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
33234186|NCT04017260|Experimental|karydakis technique|treatment of pilonidal sinus by Karydakis
33070566|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
33070567|NCT02942797||NRS 2002 score ≥ 3|
33070568|NCT02942797||NRS 2002 score < 3|
33070569|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
33070570|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
33070571|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
32749274|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
33070572|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
33070573|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
33070574|NCT05318950|No Intervention|Control|No intervention
33070575|NCT05318950|Experimental|E-learning|E-learning: 8 lessons about nutrition and lifestyle
33070576|NCT05318950|Experimental|Diet A|MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids)
33234187|NCT04017260|Experimental|open technique|treatment of pilonidal sinus by open approach
33234188|NCT00791492|Experimental|Fx-1006A|
33234189|NCT04017338|Experimental|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
33234190|NCT04106726|Experimental|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
33234191|NCT04106726|Active Comparator|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
32749275|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
32761960|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
32908857|NCT04409600|Active Comparator|Home Based Gait Retraining + Saline Injection|
32908858|NCT04409600|Experimental|Home Based Gait Retraining + Botulinum Toxin Injection|
32908859|NCT04409600|Active Comparator|Supervised Gait Retraining + Saline Injection|
32908860|NCT04409600|Experimental|Supervised Gait Retraining + Botulinum Toxin Injection|
33234192|NCT04106726|Placebo Comparator|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
32908861|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
33070577|NCT05318950|Experimental|Diet B|MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
33070578|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
33070579|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
33070580|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
33070581|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
33070582|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
33070583|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
33072411|NCT05118282|Active Comparator|Standard asthma management arm|The standard asthma management (AM) arm is an asthma management intervention covering standard asthma self-management content (e.g., symptom recognition, self-monitoring). AM is manualized and is matched in length, time, and number of sessions to the experimental arm.
33234193|NCT05555732|Experimental|Dato-DXd + Pembrolizumab + Platinum Chemotherapy|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).
32749276|NCT05090865|Other|Liberalized dietary potassium and then restricted potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.
32749277|NCT05090865|Other|Restricted dietary potassium and then liberalized potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet
33234194|NCT05555732|Experimental|Dato-DXd + Pembrolizumab|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.
32749278|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
32749279|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
32749280|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
32749281|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
32749282|NCT05515653||Case - atherosclerotic cardiovascular disease|Patients with the first atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events)
32908862|NCT04358276|Experimental|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
32908863|NCT04358276|Experimental|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
33070584|NCT05318482|Experimental|Motivational group|The patients of this group will be equipped with an electronic wristwatch and will be monitored every day by the physiotherapist (PT) through an application on their mobiles. The PT will follow these patients with a daily motivational session (15 minutes, modality 1 patient: 1 PT) and with an educational program about the definition, importance and benefits of physical activity.
33234195|NCT05555732|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Chemotherapy|Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).
33234196|NCT04106336|No Intervention|non cannabis addict|30 non cannabis addict will be control group
33234197|NCT04106336|Active Comparator|cannabis addict|30 cannabis addict will undergo rTMS
33234198|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
32749283|NCT05515653||Control - without atherosclerotic cardiovascular disease ou healthy|Patients who sought medical care at the same site as cases without atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events) or healthy individuals
32749284|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
32749285|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
32749286|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
32749287|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
33234199|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
33234200|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
33234201|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
33234202|NCT04106180|Experimental|SBRT + sintilimab + GM-CSF|
33234203|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
32749288|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
32749289|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
32749290|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
32749291|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
32749292|NCT04880733|Experimental|Acupuncture|This arm will receive acupuncture for pain management, and any pain medications will be delayed until after receipt of acupuncture.
32749293|NCT04880733|Active Comparator|Usual Care|This arm will receive usual care for pain management.
32749294|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
32749295|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
32749296|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
33234204|NCT04087005|Experimental|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
33234205|NCT04087005|Active Comparator|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
32749297|NCT04588311|Active Comparator|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
32749298|NCT04588311|Placebo Comparator|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
32749299|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
32749300|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
32749301|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
32749302|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
33072412|NCT05111262|Active Comparator|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
33234206|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
33234207|NCT05362929|Experimental|Hybrid Fractional laser|23 participants with fitzpatrick skin type IV-V will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.
33234208|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
32749303|NCT04482101|Experimental|Ah-Plus sealer|"Root canal sealer which is a resin-based formula with excellent radiopacity , low shrinkage , low solubility and outstanding flow characteristics .~It features a 1:1 , paste-to-paste mixing system for fast , easy preparation and less waste . It is biocompatible and silver free ."
32749304|NCT04482101|Experimental|Endosequence BC sealer|"It is a root canal sealer which is premixed ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications.~It is insoluble , radiopaque and aluminum-free material based on calcium silicate composition , which requires the presence of water to set and hardens . It does not shrink during setting and demonstrate excellent physical properties ."
32749305|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
32749306|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
32749307|NCT02412449|Experimental|Treatment A|AKB-6548
32749308|NCT02412449|Experimental|Treatment B|AKB-6548
32749309|NCT02412449|Experimental|Treatment C|AKB-6548
33070585|NCT05318482|Sham Comparator|Control|The patients of this group will have an electronic wristwatch and will be advised by the PT only with generic recommendations of daily exercise during the hospitalization, besides the usual activities of the rehabilitation program.
33070586|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
33234209|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
33234210|NCT04087083|Experimental|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
33070587|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
33070588|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
33234211|NCT04087083|Active Comparator|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
33234212|NCT04086927|No Intervention|Control Group|Patients will not receive compression dressing
33234213|NCT04086927|Experimental|Experimental Group|Patients will receive compression dressing
33234214|NCT00797966|Experimental|1|OPC-34712 + ADT
33234215|NCT00797966|Placebo Comparator|2|Placebo + ADT
33241581|NCT04077398|Experimental|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
32749310|NCT05515497|Experimental|BMT4me 2.0 Intervention Group|The intervention group will be receiving the BMT4me 2.0 app at discharge as the primary intervention.
32749311|NCT05515497|No Intervention|BMT4me 2.0 Control Group|The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.
32749312|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
32749313|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
32749314|NCT05515263|Experimental|Intervention snack|The intervention group will receive a snack food believed to be beneficial for immune function (high content of immunoregulatory nutrients).
32749315|NCT05515263|Placebo Comparator|Control snack|The control group will receive an isocaloric, commercially available snack food (low content of immunoregulatory nutrients).
32749316|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
32749317|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
32749318|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
32749319|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
32749320|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
33234216|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
33234217|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
33234218|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
33234219|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
32749321|NCT05090475|Experimental|Hospital A-team led intervention in Koprivnica Križevci County|Hospital A-team will give educational outreach intervention to primary care physicians
32749322|NCT05090475|No Intervention|Control group|Primary care physicians in Bjelovar Bilogora county will not receive intervention
32749323|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
33070589|NCT05318248|Experimental|Clonidin|pill 0,15 mg clonidin
33234220|NCT05362695|Experimental|Cohort 1: Dose 1|Dose 1: active drug (IW-3300) once daily for 7 days
32749324|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
32749325|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
33070590|NCT05318248|Placebo Comparator|Placebo|placebo pill
33234221|NCT05362695|Placebo Comparator|Cohort 1: Placebo|Dose 1: matching placebo once daily for 7 days
33234222|NCT05362695|Experimental|Cohort 2: Dose 2|Dose 2: active drug (IW-3300) once daily for 7 days
33234223|NCT05362695|Placebo Comparator|Cohort 2: Placebo|Dose 2: matching placebo once daily for 7 days
33072413|NCT05111262|No Intervention|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
33234224|NCT05362695|Experimental|Cohort 3 (optional): Dose 3|Dose 3: active drug (IW-3300) once daily for 7 days
33234225|NCT05362695|Placebo Comparator|Cohort 3 (optional): Placebo|Dose 3: matching placebo once daily for 7 days
33234226|NCT05361837|Active Comparator|Single level serratus anterior plane block|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics only
33234227|NCT05361837|Experimental|Single level serratus anterior plane block with dexmedetomidine|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics and dexmedetomidine
33234228|NCT05361837|Experimental|Bilevel serratus anterior plane block|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics only
33234229|NCT05361837|Experimental|Bilevel serratus anterior plane block with dexmedetomidine|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics and dexmedetomidine
33234230|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
33234231|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
33072414|NCT05102019|Experimental|Arm 1 (treatment arm):Implantation of the Reducer device|
33234232|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
33234233|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
33234234|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
33234235|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
33234236|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
33234237|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
32749326|NCT05090085|Active Comparator|3M Scotchbond Universal Plus|O.I. will clean the labial surface of the tooth with polishing paste and brush Roughening of the surface may be needed by the diamond point The tooth will be isolated by a rubber dam. Apply etchant for 30 s for enamel and 5 s for dentin. Rinse thoroughly with water for 15 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist. Active application of consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 20 s. Light curing of all resin materials was performed using (3M Elipar Curing Light) delivering 1100 mW/cm2.
33234238|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
33234239|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
33234240|NCT00723021|Experimental|PF-04191834 30mg|
33234241|NCT00723021|Experimental|PF-04191834 100mg|
33234242|NCT00723021|Experimental|PF-04191834 2000mg|
33234243|NCT00723021|Active Comparator|zileuton|
33072415|NCT05102019|Sham Comparator|Arm 2 (sham-control arm): Control (no device implantation)|
33072416|NCT05102019|Other|Arm 3 (unblinded, non-randomized): Single Arm Registry|
33072417|NCT05098613|Experimental|CD19x22 CAR T Cell Infusion|Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells
33072418|NCT05098431|Experimental|Experimental Arm|Receive Quadriceps MEPs during procedure
33072419|NCT05094128||Participants Receiving Upadacitinib|
33234244|NCT00723021|Placebo Comparator|placebo|
33234245|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
33234246|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
33234247|NCT05359653|Experimental|Clemastine 8 mg, then Placebo|Group 1 will receive the treatment (clemastine 8mg/day) for the first 90 days and then switch to the placebo (a sugar pill) for the remaining 90 days
33234248|NCT05359653|Experimental|Placebo, then Clemastine 8 mg|Group 2 will receive the placebo (a sugar pill) for the first 90 days and then switch to the treatment (clemastine 8mg/day) for the remaining 90 days
33234249|NCT04087317|Experimental|Fixed time interval group.|Once the patient will arrive at the maternity ward the patient will receive paracetamol 1 gram and a tablet of ibuprofen 400 mg. Six hours after patient arrival and every 6 hours the patient will receive a tablet of paracetamol 500 mg and a tablet of ibuprofen 400 mg.
33234250|NCT04087317|Experimental|'On-demand' group.|Patients allocated to this group will receive the same medications in the same combinations and order as described in the 'fixed time interval' group protocol, patients in this group will receive pain treatment only following demand, and the time intervals described above will be considered as the minimal time for giving the next combination of drugs.
33234251|NCT05754281||Study Cohort|60 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the 2nd Gen LabPatch Continuous Glucose Sensing will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
33234252|NCT04309409|Experimental|Nivolumab (Arm A)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
33234253|NCT04309409|No Intervention|Observation, High Risk (Arm B)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
33234254|NCT04309409|No Intervention|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
33234255|NCT05358717|Experimental|PTC518 5 mg|Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.
32749327|NCT05090085|Experimental|DMSO application before 3M Scotchbond MultiPurpose, etch and rinse adhesive|The same steps of the comparator group with an additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 10% DMSO/H2O (OT Primer, OT Dent) solutions on etched-dentin for 1 minute followed by 20 seconds of air drying then apply adhesive.
33234256|NCT05358717|Experimental|PTC518 10 mg|Participants will receive PTC518 10 mg tablets once daily orally for 12 months.
33234257|NCT05358717|Experimental|PTC518 20 mg|Participants will receive PTC518 20 mg tablets once daily orally for 12 months.
33234258|NCT05358717|Placebo Comparator|Placebo|Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.
33070591|NCT05318053||2022 Cohort|"Successful completion of screening checklist to indicate one of the following conditions:~recurring, long-standing fantasies that focus on kink, in areas such as: power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities. By fetish, we mean a type of sexual desire in which gratification depends on or is significantly increased by particular objects, clothing items, parts of the body, or types of persons.~OR currently engaging, or have engaged in the past, in consensual kink activities such as power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities.~Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18)~English-language proficiency sufficient to understand the study instruments~Completion of an electronically signed and dated informed consent form"
33234259|NCT04980521|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
32749328|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
32749329|NCT05520645|Experimental|Eto 0.15mg/kg|Etomidate 0.15mg/kg for anesthesia induction
33070592|NCT05318014|Experimental|Intervention group|Regular nutrition education and supply one serving per day of 6% low protein formula.
33234260|NCT04980521|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
33234261|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
33234262|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
33234263|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
33234264|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
32749330|NCT05520645|Experimental|Eto 0.2mg/kg|Etomidate 0.2mg/kg for anesthesia induction
33234265|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
33241582|NCT00763737|Experimental|FETO|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
32749331|NCT05520645|Experimental|Eto 0.25mg/kg|Etomidate 0.25mg/kg for anesthesia induction
32749332|NCT05520645|Active Comparator|Propofol 2mg/kg|propofol 2mg/kg for anesthesia induction
32749333|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
33070593|NCT05318014|Placebo Comparator|Regular nutrition education|Regular nutrition education
33234266|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
33070594|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
33234267|NCT05754203|Experimental|Super-hyperfractionation Pulse Radiotherapy Combined With Immune Checkpoint Inhibitor|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy * 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
33234268|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
33234269|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
33234270|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
33234271|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
33241583|NCT00763737|No Intervention|Expectant management|expectant management during pregnancy followed by standardized neonatal care
32749334|NCT03175757|Placebo Comparator|Placebo|Placebo
32901640|NCT05029596|Active Comparator|Heparin Group|"Participants will receive the UTSW standard of of care for PICC line maintenance.~All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws."
32901641|NCT05029596|Experimental|Normal Saline Group|Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
33070595|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
33070596|NCT05317975|Experimental|Add-on telerehabilitation combined with usual home-based rehabilitation|Add-on telerehabilitation combined with usual home-based rehabilitation
33070597|NCT05317975|Experimental|Stand-alone usual home-based rehabilitation|Stand-alone usual home-based rehabilitation
33070598|NCT05317975|No Intervention|Usual care|Usual care
33070599|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
33070600|NCT00169260|Experimental|1|Intervention
33234272|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone~saving stem cell transplant for a later time."
33234273|NCT00721149|Experimental|NaviStar ThermoCool|
33234274|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
33234275|NCT04086459|Active Comparator|Active repetitive transcranial magnetic stimulation|
33234276|NCT04086459|Sham Comparator|Sham repetitive transcranial magnetic stimulation|
33234277|NCT04086459|No Intervention|No repetitive transcranial magnetic stimulation|
33234278|NCT05754125|Experimental|Di-Leucine supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
33234279|NCT05754125|Experimental|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
33234280|NCT05754125|Experimental|Collagen Supplement|Participants will consume a amino acid supplement containing collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
32761961|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
33070601|NCT00169260|Placebo Comparator|2|Control
33234281|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
33234282|NCT05754047||HER2-low|patients with HER2 IHC1+ and HER2 IHC2+/ISH-negative in their pathology
33234283|NCT05754047||HER2-negative|patients with HER2-zero in their pathology
33234284|NCT05754047||HER2-positive|patients with HER2 IHC2+/ISH-positive and HER2 IHC 3+ in their pathology
33234285|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
33234286|NCT04106102|Active Comparator|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
33234287|NCT04106102|Placebo Comparator|Placebo|
33234288|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
33234289|NCT05753657|Experimental|Treatment arm|treating hyperinsulinemia and hyperglycemia with pioglitazone in patients treated with Alpelisib for metastatic breast cancer
33234290|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
33234291|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
33234292|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
33234293|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
33234294|NCT04017494||Single ventricle|Patients with single ventricle lesions
33234295|NCT00918060|Experimental|gel a|
33234296|NCT00918060|Placebo Comparator|gel b|
33234297|NCT00918411|Experimental|Ramosetron group|oral
33234298|NCT00918411|Placebo Comparator|Placebo group|oral
33234300|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
33234301|NCT00720213|Active Comparator|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
33234302|NCT00720213|Experimental|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
33234303|NCT05573984||Vision Cohort 1|Score of ≥ 54 ETDRS letters read and a VF diameter ≥ 10 degrees in every meridian of the central field
32901642|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
33234304|NCT05573984||Vision Cohort 2|Score of ≥ 35 ETDRS letters read and a VF diameter < 10 degrees in any meridian of the central field
33234305|NCT05573984||Vision Cohort 3|Score of < 35 ETDRS letters read
33234306|NCT05353647|Experimental|Treatment Arm|Open-label, non-randomized, single arm study of a single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a.
33234307|NCT04086303|Experimental|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
33234308|NCT04086303|Active Comparator|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
33234309|NCT04112966|Experimental|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
33234310|NCT04112966|Other|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
33234311|NCT04086381|Active Comparator|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
33234312|NCT04086381|Placebo Comparator|Placebo|Oral injestion of 20 grams of cellulose daily
33234313|NCT04107350|Experimental|whole body vibration on|vibration machine on combined with conventional physical therapy
33234314|NCT04107350|Sham Comparator|whole body vibration off|vibration machine off combined with conventional physical therapy
33234315|NCT00810407||rifabutin|Patients administered Rifabutin.
33234316|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
33234317|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
33234318|NCT04134689|Active Comparator|DOT Selfie Intervention Arm|"The DOT Selfie Intervention will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders.~Patients in this arm will receive detailed training (in English or Luganda) on VDOT use prior to starting treatment. Each patient will be required to record and submit daily videos as they self-administer their medication. Patients who successfully submit their videos for seven consecutive days will receive a weekly incentive in the form of social bundles of airtime minutes. A prepaid internet bundle will also be uploaded to each mobile phone weekly to allow for daily video uploads. Additionally, patients will receive text message medication reminders to encourage treatment compliance."
33234319|NCT04134689|Active Comparator|In-person DOT Control Arm.|Patients in this arm will be managed according to the usual clinical practice in Uganda i.e. community- or home-based directly observed treatment .Patients in this arm will make prior arrangements with a study nurse to determine a convenient meeting place (e.g. at the patient's work, home etc.) The study nurse will then meet the patient at this location. At each daily meeting, the patient will self-administer the TB drugs as the study nurse directly observes and documents (date, time, drug dosing etc.) At the end of each meeting, the patient and nurse will agree on a convenient meeting place for the next day's dosing. These daily meetings will continue until treatment completion. The study nurse will record patient's medication intake, as well as the time taken to reach the patient, amount of money spent on round-trip transportation, and total amount of time spent during each patient encounter.
33234320|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
33234321|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
33234322|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
33234323|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
33234324|NCT04105556|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;~Standard maintenance interventions,~Emotional focused comfort care interventions,~Cognitive and functional comfort care interventions."
33234325|NCT04105556|No Intervention|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
33234326|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33070602|NCT05318911|Active Comparator|Supplement Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of novel yogurt drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any yoghurt drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
33070603|NCT05318911|Placebo Comparator|Placebo Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of placebo drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
33070604|NCT05318833|Experimental|HRS7415|
33234327|NCT04253717|Experimental|Motor control exercise program|Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
33234328|NCT04253717|No Intervention|Control|Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
33234329|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
32749335|NCT04974099|Experimental|RoadMAB dashboard system|The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
32749336|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
32749337|NCT05515185|Experimental|KT095 CAR-T|KT095 CAR-T injection Intravenous infusion
33234330|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
33234331|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
33234332|NCT03951675||Individuals Living with DMD|90 patients/parents
33234333|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
32749338|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
32749339|NCT05511051|Experimental|Fruquintinib + HAIC|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w); HAIC: oxaliplatin 100 mg/m2, leucovorin calcium 200 mg/m2, fluorouracil 2000 mg/m2 24-hour drip, q4w, 2 cycles; HAIC treatment was administered during fruquintinib rest; HAIC was discontinued 1 day before surgery, on the day of completion of surgery, and 5 days after surgery;
32749340|NCT05511051|Active Comparator|Fruquintinib|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w);
32749341|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
32901643|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
32901644|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
33234334|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
33234335|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
33234336|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
33234337|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
33234338|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
33234339|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
33234340|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
33234341|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
33234342|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
33234343|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
33234344|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
33234345|NCT02591355|Placebo Comparator|Saline|Saline solution injection
33234346|NCT05753969|Experimental|MPH / AMPH Treatment|
33234347|NCT05753969|Placebo Comparator|Placebo|
33234348|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
33234349|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
33234350|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
33234351|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
33234352|NCT05753579|Active Comparator|Control Group|In our study, stabilization exercises were applied to the patients in the control group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Stabilization exercises: It is an approach that is combined with diaphragmatic breathing and activates the passive. The stabilization exercise program was applied in three phases and was progressed in line with the developments in the patients.
33234353|NCT05753579|Experimental|Intervention Group|In our study, stabilization exercises and spinal mobilization practices were performed to the patients in the intervention group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Mobilization applications were applied at Maitland IV degree as standard.Three mobilization methods were applied Anterior-Posterior Lumbal Spinal Mobilization Lumbal Spinal Rotational Mobilization Joint Mobilization in Lumbal Flexion Position
33234354|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
33234355|NCT04973657|Experimental|VK0214 Active 20mg|20mg QD
33394026|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
32749342|NCT04871529|Experimental|Arm A (avelumab, gemcitabine, carboplatin, surgery)|Patients receive avelumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up 4 in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks after final systemic therapy, patients undergo standard of care surgery.
32749343|NCT04871529|Experimental|Arm B (surgery)|Patients undergo standard of care surgery.
32749344|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
32749345|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
32749346|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
32749347|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
32749348|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
32749349|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
32749350|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
32749351|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
32749352|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
32749353|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
33234356|NCT04973657|Experimental|VK0214 Active 40mg|40mg QD
33234357|NCT04973657|Placebo Comparator|Placebo|Placebo QD
33234358|NCT05753501|Experimental|Dose Escalation ABBV-101|Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101 in 28-day cycles, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined.
33234359|NCT05753501|Experimental|Dose Expansion ABBV-101 R/R Chronic Lymphocytic Lymphoma (CLL)|Participants with R/R CLL will receive ABBV-101 at the dose determined in the dose escalation arm in 28-day cycles.
33234360|NCT05753501|Experimental|Dose Expansion ABBV-101 R/R non-GCB DLBCL|Participants with R/R non-germinal center B cell (GCB) diffuse large B-cell lymphoma (DLBCL) will receive ABBV-101 at the dose determined in the dose escalation arm in 28-day cycles.
33234361|NCT05749601|Active Comparator|Patients without knee osteoarthritis (KOA) grade 0|Patient without knee affection
33070605|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
32749354|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
32749355|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
32749356|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
32749357|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
33070606|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
33070607|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
32749359|NCT04424901|No Intervention|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
32749360|NCT04424901|Experimental|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
32749361|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
32749362|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
32749363|NCT05520489|Active Comparator|treatment as usual, physiotherapy|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section
32749364|NCT05520489|Active Comparator|Transcranial magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
32749365|NCT05520489|Active Comparator|robot assisted training|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
32749366|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
32749367|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
32749368|NCT05510895|Experimental|neoadjuvant and adjuvant triplet combination of encorafenib, binimetinib and cetuximab|"Neoadjuvant treatment with encorafenib, binimetinib and cetuximab for up to 8 weeks (4 biweekly cycles). In Week 10-12 surgery of the tumor followed by central determination of tumor regression grade (TRG).~TRG0-1: insufficient response to neoadjuvant triplet. Standard chemotherapy with fluoropyrimidines and oxaliplatin should be applied. TRG2-4: 4-8 weeks after surgery adjuvant treatment with encorafenib, binimetinib and cetuximab continues for up to 16 Weeks (8 biweekly cycles)."
32749369|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
32749370|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
32749371|NCT05510817|Other|RRMS patients|RRMS patients initiating a new DMT
32749372|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
32908864|NCT04358276|Experimental|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
33234362|NCT05749601|Experimental|Patients with KOA grade I|Kellgren-Lawrence classification (KL) grade I- doubtful narrowing of the joint space and possible osteophytes
32908865|NCT04340492|Experimental|Adapted Physical Activity group|
32908866|NCT04340492|Sham Comparator|control group|
33070608|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
33234363|NCT05749601|Experimental|Patients with KOA grade II|KL grade II - definite osteophytes and possible narrowing of joint space.
33070609|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
33070610|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
33070611|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
33234364|NCT05749601|Experimental|Patients with KOA grade III|KL grade III- definite narrowing of the joint space, significant osteophytosis, and possible bone deformities.
33234365|NCT05749601|Experimental|Patients with KOA grade IV|KL grade IV- marked joint space narrowing accompanied by deformities, bone sclerosis, and large osteophytes
33234366|NCT05748821|Active Comparator|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
32749373|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
32749374|NCT05510739|Experimental|Motor-cognitive exercise using eHealth|10-week eHealth based motor-cognitive home training using digital tablets. Cognitive behavioural strategies to promote increase in physical activity levels (walking). Participants will be encouraged to perform 150 minutes of home exercise per week, occurring on three non-consecutive days.
32749375|NCT05510739|Active Comparator|Individualised home training program|Participants will receive an individualized home exercise program on paper and one instructional session. They will receive written instructions on performing the program 2-3 times weekly and instructions on exercise progression. They will receive no support during the 10-week period.
32749376|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
32749377|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
32749378|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
33070612|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
32749379|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
32749380|NCT05510583||Group 1|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
32749381|NCT05510583||Group 2|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
32749382|NCT03175211|Experimental|BI 456906|
32749383|NCT03175211|Placebo Comparator|Placebo|
32749384|NCT03175055|Experimental|Phoenix|Phoenix
32749385|NCT03174977|Experimental|18F-Raltegravir|
32749386|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
32749387|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
32749388|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
32749389|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
33072420|NCT05092958|Active Comparator|Arm A (avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
33234367|NCT05748821|Active Comparator|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
33234368|NCT05748821|Active Comparator|No blood flow restriction|This group serves as the control group for this study
33070613|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
32749390|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
32749391|NCT05514405|Experimental|Remimazolam group|Remimazolam is started during induction of anesthesia at the rate of 6 mg/kg/hr and continued at the rate of 1 mg/kg/hr (within 0.3-2 mg/kg/hr). Remimazolam is stopped 20 minutes before end of operation.
32908867|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
33234369|NCT05748665|Experimental|remimazolam|remimazolam induction
32908868|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
32908869|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
32908870|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
33070614|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
33070615|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
33234370|NCT05748665|Active Comparator|etomidate|etomidate induction
33234371|NCT04967807|Other|Cohort A - Symptomatic|Those with clinical findings suggestive of myocarditis/myocardial injury after COVID-19 vaccination
33234372|NCT04967807|Other|Cohort B - Asymptomatic|Those without signs or symptoms suggestive of myocarditis after COVID-19 vaccination
33234373|NCT04016207||Guanfacin regular treatment|
33234374|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
33234375|NCT05753423||Egyptian mothers-children pairs|Egyptian mothers-children pairs attending the Faculty of Dentistry, Ain Shams University will be recruited.
33234376|NCT04030091|Experimental|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
33234377|NCT04030091|Experimental|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
33234378|NCT05753345|Experimental|Intervention: aquatic occupational therapy (AquOTic-NM)|aquatic occupational therapy 30 minutes, self care training 15 minutes
33234379|NCT04030013|Active Comparator|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
33234380|NCT04030013|Active Comparator|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
33234381|NCT04030013|No Intervention|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
33234382|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
32749392|NCT05514405|Active Comparator|Propofol group|Propofol is continuously infused within 1-5 μg/mL.
32908871|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32908872|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
32908873|NCT00990236|Active Comparator|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
32908874|NCT00990236|Experimental|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
33070616|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
33234383|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
32749393|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
32749394|NCT05514327|Experimental|treatment group|ultra-fraction radiotherapy + CAR-T
33234384|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
33234385|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
32749395|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
32749396|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
32749397|NCT05520333|Experimental|Intervention arm|Families receive intervention from primary care provider and text messages for six months.
32749398|NCT05520333|No Intervention|Control arm|Families do not receive any intervention.
32749399|NCT05070351|Experimental|PPI deprescribing arm|Patients taking a PPI (at least 20 mg omeprazole equivalent daily) will be instructed to stop taking their PPI.
32749400|NCT05070351|No Intervention|PPI continuation arm|Patients will be instructed to continue taking their PPI (at least 20 mg omeprazole equivalent daily) as usual.
32749401|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
32749402|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
33234386|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
33234387|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
33234388|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
33234389|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
33234390|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
33234391|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
33234392|NCT04939415|Experimental|modified Qing Fei Pei Du Tang|encapsulated modified Qing Fei Pai Du Tang
33234393|NCT04939415|Placebo Comparator|Placebo|Organic brown rice
32749403|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
32749404|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
33234394|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.~Intervention: Behavioral: Quality improvement strategies and tools"
33234395|NCT05755373||Cardiologists|Cardiologists treating patients with ASCVD and CKD
33234396|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
33234397|NCT05745701|Active Comparator|Period 1: PF-07081532|Participants will receive PF-07081532 as a single dose on Day 1.
33234398|NCT05745701|Experimental|Period 2: Cyclosporine + PF-07081532|Participants will receive a single dose of PF-07081532 and a single dose of cyclosporine on Day 1.
33234399|NCT05745701|Experimental|Period 3: Itraconazole + PF-07081532|Participants will receive itraconazole daily for 9 days plus a single dose of PF-07081532 on Day 4.
33234400|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
33234401|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
33234402|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
32749405|NCT04859127||Patient Group|"The criteria for inclusion in the study were determined as voluntary patients between the ages of 18-65 with neck pain lasting more than 3 months who were clinically diagnosed with chronic neck pain by a specialist physician.~Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc."
33234403|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
33234404|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
33234405|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
32749406|NCT04859127||Control Group|Asymptomatic individuals between the ages of 18-65 who have not experienced neck pain during the last 1 year will be included in the control group. Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc.
32749407|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).~The procedure will be repeated twice a day for 10 days over 2 weeks."
32749408|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.~Coil and stimulator will remain the same between individualized and as usual proceedures."
32749409|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
32749410|NCT05514249|Experimental|Single patient|Single dose of CRD-TMH-001 administered by IV
32749411|NCT05510505|Active Comparator|ATG arm (control group)|"4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~4.2.2 Unrelated donor and haploidentical donor~1) ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）"
32749412|NCT05510505|Experimental|ATG + CD20 monoclonal antibody (test arm)|"4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
32749413|NCT05514171||Neoadyuvant therapy|Patients with borderline or resectable ADK subjected to neoadyuvant therapy
32749414|NCT05514171||Upfront surgery|Patients with borderline or resectable ADK who undergo upfront surgery
32749415|NCT04987775|Active Comparator|N-Acetyl Cysteine (NAC)|Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first dose of study drug.
32749416|NCT04987775|Placebo Comparator|Placebo|Participants who are randomized to the placebo arm will take matching placebo two times a day for 8 weeks after the initiation of the first dose of study drug.
32749417|NCT05514093||App users|As this is a single cohort study, there is only one group consisting of the Beyond Silence app users.
33234406|NCT00734214|Experimental|0.9% NaCl|
33234407|NCT00734214|Active Comparator|0.45% NaCl|
32749418|NCT04987385|Other|single arm: Phase 1: protein supplementation, Phase 2: Urea|
32749419|NCT05510349|Experimental|All the patients|Sonographic measure of placental elasticity and viscosity
32749420|NCT05514015|Experimental|Intervention arm|Rituximab combined with steroid treatment group
33234408|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
33234409|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
32749421|NCT05514015|Active Comparator|Control arm|Cyclophosphamide-steroid alternating cycle treatment
32749422|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
32749423|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
32749424|NCT05520021|Active Comparator|Magnesium sulfate treatment|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
32749425|NCT05520021|Active Comparator|Nifedipine treatment|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
32749426|NCT05520021|No Intervention|Healthy pregnant women|A total of 30 pregnancies without preterm labor threat will be included.
32749427|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
32749428|NCT05510271|Experimental|White Noise|
32749429|NCT05510271|Experimental|Yakson touch|
32749430|NCT05510271|No Intervention|Control|
32749431|NCT02410109|Experimental|SCRIPT intervention|
32749432|NCT02410109|No Intervention|Historical Control|
32749433|NCT04939701|Experimental|Phase 1 ASP0739 Monotherapy Dose Escalation|Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the Recommended Phase 2 Dose (RP2D).
32749434|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Safety Lead-in|Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with pembrolizumab on Cycle 1 Day 1, and then every 6 weeks up to 4 doses during the treatment period to determine the RP2D of ASP0739 with pembrolizumab. A total of 17 doses of pembrolizumab may be available for qualifying participants.
32749435|NCT04939701|Experimental|Phase 2 ASP0739 Monotherapy Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.
32749436|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of pembrolizumab administered on cycle 1 day 1, and then every 6 weeks during the treatment period. A total of 17 doses of pembrolizumab may be available for qualifying participants.
32749437|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
32749438|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
32749439|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
32749440|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
32749441|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
32749442|NCT05055453|Experimental|Experimental Study Group|"It is a prospective study to investigate whether the MyPhonak Junior app can improve speech understanding in children with hearing aids, by evaluating the use of the volume, noise reduction and directional microphone using the MyPhonak Junior App.. The study is linked to randomized patient and test allocation carried out.~Introduction to the MyPhonak Junior app. There are measurements of speech understanding of sentences Carried out in background noise with the Oldenburg sentence test (OLSA). The language test is hard of hearing children and adolescents known from routine clinical practice. Various everyday situations / noise scenarios are played out. Questionnaire (E-HAK, also known from routine) and interview of the children regarding the use of the app in everyday life."
32749443|NCT02409953|Experimental|Bath|
32749444|NCT02409953|Placebo Comparator|Bed|
32749445|NCT04842981|Experimental|Interleukin 6 receptor antibody|Tocilizumab, 162 mg subcutaneous, once every week OR Sarilumab, 200 mg subcutaneous, once every two weeks.
32749446|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
33234410|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
33234411|NCT05247372|Other|The effect of Iyengar yoga practice on patients with multiple sclerosis|
32749447|NCT05049837||Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
32749448|NCT05049837||Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
32749449|NCT05049837||Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
32749450|NCT05049837||Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
32749451|NCT05049837||Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
32749452|NCT05049837||Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
32749453|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
32749454|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
32749455|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
32908875|NCT01024010|Experimental|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32908876|NCT01024010|Experimental|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33070617|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
33070618|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
33070619|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
33070620|NCT02958176|No Intervention|Wait List|Wait list control
33234412|NCT02607995||low key intervention|for the whole group
32749456|NCT05513625|Experimental|100 mg pritelivir|Single dose 100 mg pritelivir (PTV) administered day 1
32749457|NCT05513625|Experimental|40 mg qd ESO and 100 mg pritelivir|40 mg qd ESO Day -3 to Day1. Single dose of 100 mg PTV on Day 1
32749458|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
33234413|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
32749459|NCT04839705|Other|WEB Aneurysm Embolization Device|WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
32749460|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
32749461|NCT05519943|Experimental|group cognitive behavioral therapy intervention|
32749462|NCT05519943|Experimental|Treatment as usual (TAU)|
33234414|NCT00787202|Experimental|15 mg BID|
33234415|NCT00787202|Experimental|10 mg BID|
33234416|NCT00787202|Experimental|3 mg BID|
33234417|NCT00787202|Experimental|0.5 mg BID|
33234418|NCT00787202|Placebo Comparator|Placebo|
33234419|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
33234420|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
33234421|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
32749463|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749464|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749465|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749466|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749467|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749468|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
32749469|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
32901645|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised adult patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and <80 years) HSCT recipients (Arm A)
33070621|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
33070622|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
33070623|NCT05318794|Experimental|Neoadjuvant systemic and peritoneal chemotherapy|Standard neoadjuvant systemic and pressurised intraperitoneal aerosol chemotherapy
33234422|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
33234423|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
33234424|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
33234425|NCT05744999||Patients treated with the reported technique|Two females and 1 male with a mean age of 50 years were diagnosed by CT scan with stage II acute cholecystitis according to the Tokyo guidelines and were operated on within three days of symptom onset
33234426|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
33234427|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
33234428|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
33234429|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
33234430|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
33234431|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
33234432|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
33234433|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
33234434|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
32749470|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
32749471|NCT05510115|Experimental|Experimental|Empagliflozin
32749472|NCT05510115|Placebo Comparator|Placebo comparator|Placebo
33234435|NCT04041791|Active Comparator|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
33234436|NCT04041791|Experimental|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
33234437|NCT04041791|Experimental|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
32749473|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
32749474|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
32749475|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
32749476|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
32749477|NCT05513547|Other|resting subgroup|Will be allowed to engage in activities that do not require self-luminous displays (e.g., study/read, play boardgames, listen to podcasts) during the three scheduled 7-hour light exposure (LE) conditions. For 'resting' participants, the time they spend under the open sky, in the shade or half-shade, will be matched to what the 'hikers' experience.
32749478|NCT05513547|Other|hiking subgroup|Will have 4 hours of scheduled moderate physical activity (average approx. 70-75% of maximum heart rate during each LE starting 3h after waking up to meet the circadian time when the most pronounced phase-advance is expected. The scheduled 4-hour activity will be a hike in the greater Basel area, which will cover about 12-14 km and a gain in elevation of less than 500 metres. Participants will be instructed to walk at their own speed. During protocol 1, which will take place in the lab, participants in the 'hiking' group will walk on a tiltable treadmill.
32749479|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
32749480|NCT03116243||MSHS children and families|"Cohort includes:~children (1272)~parents (1272)~teachers (159)~teaching assistants (159)~program and center directors (253)"
32749481|NCT05513469|Other|Peptide receptor radionuclide therapy|PRRT 4x7.4GBq
32749482|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
32749483|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
33234438|NCT04041791|Experimental|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
32749484|NCT04417816|Experimental|Exercise training + adipose tissue cavitation|
32908877|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
32908878|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
33234439|NCT04041791|Experimental|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
33234440|NCT04041791|Experimental|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
33234441|NCT05572502|Experimental|Vegan diet|All participants will follow a low-fat vegan diet. There are no other study arms or control group.
33234442|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
33234443|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
33234444|NCT05571878|Experimental|Crossover: Insulin and Placebo|"Twelve adolescents who have a confirmed depression diagnosis or experiencing depression will be used as the study population group against 12 healthy adolescents who will be used as the healthy study population group.~Both the health control group and medication-free adolescents with depression will receive the same drug conditions (intranasal insulin and intranasal placebo)."
33234445|NCT04033367|Experimental|Dupilumab/Dupilumab|Participants received dupilumab 600 milligrams (mg) (loading dose) injection subcutaneously (SC) on Day 1 followed by dupilumab 300 mg injection SC every 2 weeks (q2w) up to Week 10 in the double-blind (DB) period of 12 weeks. After completion of DB period, participants entered in the open-label extension (OLE) period (Week 12 to 24) and continued to receive dupilumab 300 mg injection SC q2w from Week 12 up to Week 22.
33234446|NCT04033367|Placebo Comparator|Placebo/Dupilumab|Participants received placebo matching to dupilumab injection SC on Day 1 then followed by placebo injection SC q2w up to Week 10 in the DB period of 12 weeks. After completion of DB period, participants entered in the OLE period (Week 12 to 24) and received dupilumab 600 mg (loading dose) at Week 12 followed by dupilumab 300 mg injection SC q2w up to Week 22.
33234447|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
33234448|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
33234449|NCT05753189|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|LNZ 101: Aceclidine/Brimonidine Ophthalmic Solution
33234450|NCT05753189|Placebo Comparator|Placebo (Vehicle) ophthalmic solution dosed bilaterally|Placebo: Proprietary Vehicle Ophthalmic Solution
32749485|NCT04417816|Sham Comparator|Exercise training + sham procedure|
32908879|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
33234451|NCT05753189|Experimental|Aceclidine ophthalmic solution dosed bilaterally|LNZ 100: Aceclidine ophthalmic solution
33234452|NCT05755295|Experimental|horse therapy|
33234453|NCT04088448|Placebo Comparator|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
33234454|NCT04088448|Experimental|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
33234455|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
33234456|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
32908880|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
33234457|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
33234458|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
33234459|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
33234460|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
33234461|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
33234462|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
33234463|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
33234464|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
33234465|NCT02607761|No Intervention|Control|No intervention
33234466|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
32749486|NCT04912713|Active Comparator|Arm 1|This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
32749487|NCT04912713|Active Comparator|Arm 2|This group will not be falsely recorded or evaluated. They will be randomly immersed in warm water (35-37°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the simple counting task, in which they will have to count consecutively from 1 to 25 at their own pace. If they reach 25 they must start again and will never be given negative feedback. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively
33234470|NCT05740553|Experimental|Training First|
33234471|NCT05740553|Experimental|Training Second|
32749488|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
33234472|NCT05753111|Placebo Comparator|Placebo|Participants receive placebo supplements on two separate occasions in a randomized order. The placebo supplements contain 350 mg of maltodextrine. Placebo supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
33234473|NCT05753111|Experimental|Palmitoylethanolamide (PEA) supplementation|Participants receive PEA supplements on two separate occasions in a randomized order. The PEA supplements contain 350 mg of Levagen+ (315 mg of PEA and 35 mg of excipients). Levagen+ consists for 90% of palmitoylethanolamide and for 10% of a mixture of coconut oil (fractionated), polyglycerol polyricinoleate, citrus oil, olive oil, lecithin, dl-alpha tocopheryl acetate, and silicon dioxide to improve the bioavailability of PEA. Both PEA supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
32749489|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
33234474|NCT00480025|Experimental|GSK1572932 Group|Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
32749490|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
32749491|NCT05510037||HER2-0|
32749492|NCT05510037||HER2-LOW|
33234475|NCT00480025|Placebo Comparator|Placebo Group|Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
33234476|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
33234477|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
32749493|NCT05510037||HER2-POSITIVE|
32749494|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
32749495|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
33234478|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
33234479|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
33234480|NCT03995251|Experimental|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
33234481|NCT03995251|Active Comparator|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
33234482|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
33234483|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
33234484|NCT01031017|Placebo Comparator|placebo|group taking placebo
33234485|NCT01031017|Active Comparator|study group|group taking progesterone
33234486|NCT03635177|Experimental|Remote ischemic conditioning|The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mmHg and occludes blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min occlusion period is interspersed by 5 min.
32749496|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
32749497|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
32749498|NCT05513313||Jynneos vaccine with out other vaccines|Allocated to Jynneos without any need for additional indicated/required vaccines intervention. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection. Administer two doses (0.5 mL each) 4 weeks apart. Each dose (0.5 mL) is supplied in a singledose vial.
32749499|NCT05513313||Jynneos vaccine with other vaccines at dose 1|Allocated to Jynneos with concomitant vaccines given at time of first dose of Jynneos intervention.
32749500|NCT05513313||Jynneos vaccine with other vaccines at dose 2|Allocated to Jynneos with concomitant vaccines given at time of second dose of Jynneos.
32749501|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
33234487|NCT03635177|Sham Comparator|Sham occlusion|The participant will conduct a sham procedure of remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates minimally and does not occlude blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min of sham occlusion is interspersed by 5 min.
32749502|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
32749503|NCT05513079|No Intervention|Control group|"Individuals in the control group agreed to participate in the study after being explained about the research.~Verbal and written consent will be obtained from individuals who do so. Initial interview with individuals who agreed to participate in the study Introductory Information Form, Trait Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. Patients in this group have routine chronic No application will be made other than the treatment of urticaria. 5 months after the pre-test Trait State Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. After the study is completed, individuals in the control group can also request it.~counseling will be provided."
32749504|NCT05513079|Experimental|Intervention Group|Positive psychotherapy counseling sessions, specialist psychiatry who completed positive psychotherapy training will be done by the nurse. The first one face-to-face with each individual in the intervention group. A total of 8 sessions will be held, theothers being online. Audio and video with attendees Other sessions will be completed through a program that allows sharing (WhatsAap, zoom etc.). Each session will be applied once a week, lasting 45-50 minutes. Interviews with individuals No audio or video recording will be taken during the recording.
33070624|NCT05318716|Experimental|Reconstructive group|This group of patients would be undergoing fat grafting following implant-based reconstruction. We will be excluding patients that have had autologous based reconstruction, including regional and free flaps. This group will be analyzed based on volume (<200cc or 50% and >200cc or 50%) as well as subgroup analysis based on adjuvant chemo or radiation therapy.
33234488|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
32901646|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised pediatric patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for pediatric (≥12 years of age and <18 years) HSCT recipients (Arm B).
32901647|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
32901648|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
32901649|NCT05080218|Experimental|Treatment Interruption - UPA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901650|NCT05080218|No Intervention|Treatment Continuation|Treatment Continuation of All Immunomodulatory Therapy at the time of COVID Vaccine Booster
32901651|NCT05080218|Experimental|Treatment Interruption - ABA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901652|NCT05080218|Experimental|Treatment Interruption - TOF|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901653|NCT05080218|Experimental|Treatment Interruption - SEC|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901654|NCT05080218|Experimental|Treatment Interruption - TNFi SQ|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901655|NCT05080218|Experimental|Treatment Interruption - CAN|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901656|NCT05080218|Experimental|Treatment Interruption - BAR|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901657|NCT05080218|Experimental|Treatment Interruption - IXE|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
32901658|NCT05079984|Experimental|Graded Exposure Intervention|For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.
32901659|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
32901660|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
32901661|NCT05079750|Experimental|Group 1: Low Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^9 vp
32749505|NCT05519709||Asymptomatic Adolescent Tennis Players|Adolescent tennis players aged 7-17 years who have been actively attending tennis club for at least 1 year will be form adolescent tennis players groups. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, training duration(min/day), frequency (times/week) and sport age will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist.
32749506|NCT04824105|Experimental|Neurostimulation Group|"On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day.~Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec."
32749507|NCT05519631||subacute stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
32749508|NCT05519631||chronic stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
33234489|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
33234490|NCT05738135|Experimental|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
32749509|NCT05519631||healthy|Only the EEG will be collected
32749510|NCT05519553|Experimental|Experimental group|30 MS (Multiple sclerosis, relapsing-remitting) patients
32749511|NCT05519553|No Intervention|Control group|30 MS (Multiple sclerosis, relapsing-remitting) patients
32749512|NCT05512845||Double factor group|"Patients treated with full arch implant supported prostheses based on the All-on-four® concept. All implants were placed using the double factor computer assisted surgery technique, which involves combination of the static and dynamic computer assisted surgery protocols."
32749514|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
32901662|NCT05079750|Experimental|Group 2: Mid Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10^10 vp Note: may be increased to n=9 following interim safety reviews
33234491|NCT05738135|Placebo Comparator|Control group|Patients will receive 50 ml normal saline over 30 minutes.
33234492|NCT00733902|Experimental|Tanezumab 10 mg|
33234493|NCT00733902|Experimental|Tanezumab 5 mg|
33234494|NCT00733902|Experimental|Tanezumab 2.5 mg|
33234495|NCT00733902|Placebo Comparator|Placebo|
33234496|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
33234497|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
32749515|NCT05509881|Experimental|Continuous glucose monitoring (CGM) arm|"During the intervention period, patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom G6 CGM devices."
32749516|NCT05509881|Active Comparator|Usual care arm|During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.
32749517|NCT05509725|Experimental|Intervention|Participants in this group will be randomized to receive probiotic formulation for the following 8 weeks.
32749518|NCT05509725|Placebo Comparator|Control|Participants in this group will be randomized to receive placebo for the following 8 weeks.
32749519|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
32749520|NCT05512689|No Intervention|Control group|In the control group, the healthcare professional ventilates the infants without any feedback about the ventilation. This represents the normal clinical setting. The RFM will be recording data on the ventilation quality.
32749521|NCT05512689|Active Comparator|Interventional group|In the interventional group, healthcare professionals will ventilate the infants using the RFM and are able to adapt their ventilations according to the RFM feedback.
32749522|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
32749523|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
33234498|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
33234499|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
32749524|NCT05512533|Experimental|BF-UC290F for diagnosing PPLs|Thin EBUS endoscope is inserted and used to visualize peripheral pulmonary lesions, and biopsies will be conducted by EBUS-TBNA.
32749525|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
32749526|NCT02409173|No Intervention|Control Group|
32749527|NCT02065570|Experimental|Induction: Standard Induction Dose|Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
32749528|NCT02065570|Experimental|Induction: Higher Induction Dose|Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
32749529|NCT02065570|Experimental|Maintenance: Clinically Adjusted (CA) Regimen|Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
32749530|NCT02065570|Experimental|Maintenance: Therapeutic Drug Monitoring (TDM) Regimen|At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
32749531|NCT04810611|Experimental|Arm 1: MBG453 single agent|Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.
32749532|NCT04810611|Experimental|Arm 2: NIS793 single agent|Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.
33070625|NCT05318716|Experimental|Cosmetic augmentation group|This group of patients will be undergoing a primary or secondary augmentation for cosmesis. They will be included if this is a primary augmentation using fat grafting or a secondary augmentation with no history of fat grafting to the breasts.
32908881|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
33394027|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
32749533|NCT04810611|Experimental|Arm 3: canakinumab single agent|Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.
32749534|NCT04810611|Experimental|Arm 4: MBG453 + NIS793 combination|Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.
32749535|NCT04810611|Experimental|Arm 5: MBG453 + canakinumab combination|Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.
32749536|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
32749537|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
32749538|NCT05509569||Icatibant|Participants will be recieved Icatibant 10 to 30 mg injection subcutaneously.
32749539|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
32749540|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
32749541|NCT04804449||Rheumatoid arthritis and psoriatic arthritis|Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection
32749542|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
32749543|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
32749544|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
32749545|NCT05507697|Experimental|Experimental|MSCs Participants will received i. m. HUC-MSCs both lower extremities
32749546|NCT05507697|Placebo Comparator|Comparator|The control group will receive i.v Lipoic Acid Injection
32749547|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
32749548|NCT04292223|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg administered orally
32749549|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
32749550|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
32749551|NCT05509491|Experimental|Postural Awareness Program with Exercises in people with neck pain|Postural education, bad posture, good posture, awareness, their effects in daily life
32749552|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
32749553|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
32749554|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
32749555|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
32749556|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
32749557|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
32749558|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
33394028|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
32749559|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
33394029|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
33394030|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
33394031|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
32749560|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
32749561|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
32749562|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
32749563|NCT05519163||Patients with type 2 diabetes|Patients with type 2 diabetes who were hospitalized in The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital between January 1, 2016 and December 31, 2021.
32749564|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
32749565|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
32749566|NCT05041335|Experimental|Heparin and microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
32749567|NCT05041335|Experimental|Heparin and no microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
32749568|NCT05041335|Experimental|No heparin and microsieve|The needle not be prepped. The provider will expel the tissue onto the microsieve
32749569|NCT05041335|Active Comparator|No heparina nd no microsieve|The needle not be prepped. The provider will expel the tissue into formalin
32749570|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
32749571|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
32749572|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
32901663|NCT05079750|Experimental|Group 3: High Dose|n=14 participants vaccinated with two doses of ChAdOx1 biEBOV 5x10^10 vp, twelve weeks apart Note: will be decreased to n=11 if Group 2 is increased to n=9
32901664|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
32749573|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
32749574|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
32749575|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline."
32749576|NCT05507619|Active Comparator|Control|
32749577|NCT05507619|Experimental|Intervention|
32749578|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
33070626|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
33394032|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
32749579|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
32749580|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
32749581|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
32749582|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
32749583|NCT05507463|Experimental|KBP-7072|Proposed dose levels for Part A: 25, 50, 100, 150 and 200mg KBP-7072. Proposed dose levels for Part B: 50 and 100mg. Administration route is intravenous infusion.
32749584|NCT05507463|Placebo Comparator|Placebo|Placebo for intravenous infusion.
32749585|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
32749586|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
32749587|NCT05507307|Experimental|MBSR group|mindfulness-based pregnancy education program group
32749588|NCT05507307|No Intervention|Control group|control group standard care group
32749589|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
32749590|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
32749591|NCT05507229|Experimental|Arm 1|Hillchol®(BBV131) vaccine - (Lot-I ) administered to 450 subjects on day 0 and 14.
32749592|NCT05507229|Experimental|Arm 2|Hillchol®(BBV131) vaccine - (Lot-II) administered to 450 subjects on day 0 and 14.
32749593|NCT05507229|Experimental|Arm 3|Hillchol®(BBV131) vaccine - (Lot-III ) administered to 450 subjects on day 0 and 14 .
32749594|NCT05507229|Active Comparator|Arm 4|Shanchol Vaccine administered to 450 subjects on day 0 and 14
32749595|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
32749596|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
32908882|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
33070627|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
32749597|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
32749598|NCT05507151||Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
32749599|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
32749600|NCT05509101|Active Comparator|Clinically Available Control Algorithm (MyoPro)|Binary control of the orthosis is based on a clinically available control algorithm. This condition serves as a control. Participants will use a commercially available device, the MyoPro.
32749601|NCT05509101|Experimental|High-Density EMG Control Algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using advanced predicted algorithms. This condition is a novel algorithm and serves as the experimental condition.
32749602|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
32749603|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
32749604|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
32749605|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
32749606|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
32749607|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
33394033|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
32908883|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
32908884|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
32908885|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
32908886|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
32908887|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
33394034|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
33394035|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
33398736|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
32749608|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
32749609|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
32749610|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
32749611|NCT05507073|Active Comparator|Manual Total Hip Replacement|Manual Total Hip Replacement
32749612|NCT05507073|Experimental|Robot-Assisted Total Hip Replacement|Robot-Assisted Total Hip Replacement
32749613|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
32749614|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
32749615|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
32749616|NCT05508945|Experimental|Surgical Incision|Abdominoplasty Surgical Incision, Breast Reduction Surgical Incision, Mastopexy Surgical Incision, or Belt Lipectomy Surgical Incision
32749617|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
33234500|NCT05737355|Experimental|ANKASCIN 568-P Red yeast rice capsules|ANKASCIN 568-P is a fermented product from the red yeast rice fungus <Monascus purpureus NTU 568>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
33234501|NCT05737355|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
33234502|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
33234503|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
33234504|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
33234505|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
33234506|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
33234507|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
33234508|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
33234509|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
33234510|NCT04008173||Male|Non-interventional patient registry
33234511|NCT04008173||Female|Non-interventional patient registry
33234512|NCT04008173||Kidney Disease|Non-interventional patient registry
33234513|NCT04008173||Diabetes|Non-interventional patient registry
33234514|NCT04008173||Elderly|Non-interventional patient registry
33234515|NCT04002167|Experimental|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
33234516|NCT04002167|Active Comparator|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
33234517|NCT04002167|No Intervention|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
33234518|NCT05736497|Experimental|Intervention: Digital Care Plans with Accompanying Text Messages|Investigators will recruit families and patients diagnosed with a Cancer Predisposition Syndrome within 3 years. Participants will be provided with a digital care plan and optional accompanying text message reminders.
33234519|NCT02607527|Other|Device Implantation|Transcatheter IRIS placement
33234520|NCT05714033|Experimental|Group 1|Group 1, Participants will receive VESAP during the bronchoscopy. Ventilatory Strategy To Prevent Atelectasis versus a Lateral Decubitus Strategy During Robotic Bronchoscopy
33234521|NCT05714033|Experimental|Group 2|Group 2, Participants will receive LADS Lateral Decubitus Strategy During Robotic Bronchoscopy during the bronchoscopy.
33234522|NCT05735171|Active Comparator|Conventional gross total resection surgery|Retrospective cohort of patients who underwent conventional surgery between 2018 and 2021. Confirmed gross total resection (removal of 100 % of contrast-enhancing tumor).
32744828|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
32744829|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
32744830|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
32744831|NCT03221075||Invasive Aspergillosis|
32744832|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
32744833|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
32744834|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
32749618|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
32901665|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
33234523|NCT05735171|Experimental|AI-guided resection|Tailored supramarginal surgery guided by AI-based recurrence probability maps. Aim of supramarginal resection, where the high-risk of recurrence areas identified by the AI-based model are subsidiary to be removed as safe locations for the patient.
33234524|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
33234525|NCT05753033|Experimental|SR750 tablet|Ascending single and multiple doses of SR750 orally
33234526|NCT05753033|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
33234527|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
33234528|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
33234529|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
33234530|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
33394036|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
33234531|NCT05733611|Experimental|RP2 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP2 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
33234532|NCT05733611|Experimental|RP3 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP3 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
33234533|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
33234534|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
33234535|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
33234536|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
33234537|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
33234538|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
33234539|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
33394037|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
32901666|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
32901667|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
32901668|NCT05622656|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline
33394038|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
33394039|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
33394040|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
33394041|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
33394042|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
33394043|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
33394044|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
32744835|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
32744836|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
32744837|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
32744838|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
33394045|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
32744839|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
32744840|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
32744841|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
32749619|NCT04759911|Experimental|Treatment (selpercatinib)|Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
32749620|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
32749621|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
32749622|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
32749623|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
33234540|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.~Progression of exercise is performance dependent and will be based on the previous 2 sessions.~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
33234541|NCT05752955|Experimental|SMARThealth Pregnancy|"SMART Health Pregnancy is a complex intervention designed to be delivered on top of usual care. It comprises three parts:~(i) A regular screening program focused on women's health during pregnancy and in the year following birth.~(ii) An electronic decision support system (EDSS) (iii) An short messaging service (SMS) appointment reminder system"
33234542|NCT05752955|No Intervention|Active Comparator: Usual Care|Usual antenatal and postnatal care. Women and health workers in the usual care clusters will not receive any additional support beyond that already offered under the local government programs
33234543|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
33234544|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
33234545|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
33234546|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
33234547|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
33234548|NCT00914888|Experimental|A|Tigecycline
33234549|NCT00914888|Active Comparator|B|Ceftriaxone regimen
32749624|NCT04757805|Experimental|Spinal anesthesia|Infants receiving spinal anesthesia for standard of care procedure
33234553|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
33394046|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
33234554|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
33234555|NCT04105790|Experimental|Participants|Participants in class-based mental health intervention.
33234556|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
33234557|NCT04105478|Experimental|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
33234558|NCT04105478|Active Comparator|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
32744842|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
32744843|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
32744844|NCT04866927||Adults|"Inclusion criteria: Healthy, non-pregnant women, adults aged 18-65 years, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range.~Exclusion criteria: Children and elderly (over 65), pregnant women, individuals diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study."
32744845|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
32744846|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
32744847|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
32744848|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
32744849|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
33070628|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
33070629|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
33234559|NCT04105322|Experimental|Kinesio Taping on Abdominal Muscles|
33234560|NCT04105322|Experimental|Kinesio Taping on Back Muscles|
32749625|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
32749626|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
32749627|NCT05506995||Vitiligo vulgaris|A serial of vitiligo patients under treatment with UVB-NB
32749628|NCT02065336|Experimental|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
32749629|NCT02065336|Placebo Comparator|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
32749630|NCT02065336|Experimental|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
33234561|NCT04105322|No Intervention|Control|
32749631|NCT02065336|Experimental|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
33234562|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
32749632|NCT02065336|Experimental|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
32749633|NCT02065336|Experimental|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
32749634|NCT02065336|Experimental|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
32749635|NCT02065336|Experimental|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
32749636|NCT02065336|Experimental|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
32749637|NCT02065336|Experimental|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
32749638|NCT02065336|Experimental|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
33070630|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
33234563|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
33241584|NCT04239716|Experimental|regional anesthesia|combination of erector spinae plane block (ESPB) and interscalene block(IB).the ESPB will be performed using linear ultrasound transducer (Philips® cx 50 extreme edition, USA) and we will inject 20 ml solution(10 ml 0.5% bupivacaine, 5 ml 2% lidocaine, and 5 ml normal saline). the IB will be performed using the same ultrasound machine and injecting the same solution
33241585|NCT04078256|Experimental|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
32749639|NCT02065336|Experimental|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
33070631|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
33070632|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
33070633|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
33070634|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
32749640|NCT02065336|Experimental|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
33234564|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
33234565|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
33234566|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
33234567|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
33234568|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
33234569|NCT04105166|Experimental|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
33234570|NCT05545280|Active Comparator|Neostigmine|Reversal of Neuromuscular Block by Neostigmine.
33234571|NCT05545280|Active Comparator|Sugammadex|Reversal of Neuromuscular Block by Sugammadex.
33234572|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
33234573|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
33234574|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
33234575|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
33234576|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
33234577|NCT00790556|Experimental|1|MK8245
33234578|NCT00790556|Placebo Comparator|2|Placebo Comparator
33234579|NCT04112732|Experimental|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
33234580|NCT04112732|Placebo Comparator|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
33234581|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
33234582|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
33234583|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
33234584|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
33234585|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
33234586|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33234587|NCT04086069|Experimental|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
33234588|NCT04086069|No Intervention|Standard Training|Standard training of standing-up with the help of a physiotherapist
33234589|NCT00585039|Experimental|A|levalbuterol nebulization
33234590|NCT04085913|Active Comparator|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
33241586|NCT04078256|Placebo Comparator|Control group|Control group will continue with their usual training routine
33241587|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
33234591|NCT04085913|Experimental|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
33070635|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
33070636|NCT02942251|Experimental|Treatment as usual|Control group.
33070637|NCT04691596|Active Comparator|Control Group|One fourth of participants were assigned to the Control Group, and received a basic training with the StepUp app and were asked to contact the study team with any problems or questions they encountered during the eight-week study period. No other intervention tools or app reminders were provided to the Control Group.
33070638|NCT04691596|Experimental|Treatment Group 1|Additionally eligible to receive weekly $5 Amazon gift cards over the first four weeks of the study for performing a ≥10-minute walk (i.e. non-cue-contingent incentives)
33234592|NCT04085913|Experimental|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
33241588|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
32744572|NCT04485299|Experimental|bifluorid 10 varnish|Bifluorid 10 (NaF and CaF) lead to reduce the dentin hypersensitivity, the sodium fluoride (NaF) dissociates and releases F ions, that diffuse through the tubules and then precipitates as calcium fluoride as a consequence of the high of calcium content in saliva and dentinal fluid ,The calcium fluoride (CaF) present in the varnish composition diffuses into the tubules and block the canal with a semi-permanent protective layer.The calcium fluoride is added to block the dentin tubules mechanically, by the combination with the calcium fluoride resulted from the sodium fluoride reaction to the calcium of dentin.
32744850|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
32744851|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
32744852|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
32744853|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
32744854|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
32744855|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
32744856|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
32744857|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
32744858|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
32744859|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
32744860|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
32744861|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
32744862|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
32744863|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
32744864|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
32744865|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
32744866|NCT04497545|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual therapy and 30 minutes of therapy on the Luna EMG device.
32744867|NCT04497545|Other|Control Group|A four-week rehabilitation program (Monday to Friday) involving one hour of individual therapy and 30 minutes on lower limb rotor
32744868|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
32744869|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
32744870|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
32744871|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
32744872|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
32744873|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
32744874|NCT04497389|Experimental|Intervention|10ml intravenous hAF QD for 5 consecutive days
33070639|NCT04691596|Experimental|Treatment Group 2|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were similarly eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any time of day (i.e. non-cue-contingent incentives)
33234593|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
33234594|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
33234595|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
33234596|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
33234597|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
33234598|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
33234599|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
33241589|NCT05179395|Experimental|Brasthesis|All five participants will wear Brasthesis for 4-weeks
33072421|NCT05092958|Experimental|Arm B (avelumab, cabozantinib)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
32744875|NCT04497389|No Intervention|Standard of Care|10 mL normal saline QD for 5 days
32744876|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
32744877|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
32744878|NCT04497311||SARS-CoV-2|Patients with a SARS-CoV-2 polymerase chain reaction positive test upon admission to the emergency department.
32744879|NCT04497311||H1N1 influenza|Patients with an influenza H1N1 polymerase chain reaction positive test upon admission to the emergency department.
32744880|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
32744881|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
32744882|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
32744883|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
32744884|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
32744885|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
32744886|NCT03343769||Patient|
32744887|NCT03343769||Control|
32744888|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
32744889|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
32744890|NCT04497077|Experimental|single dose tart cherry capsule|single dose tart cherry capsule
32744891|NCT04497077|Experimental|double dose tart cherry capsule|double dose tart cherry capsule
32744892|NCT04497077|Experimental|single dose tart cherry juice|single dose tart cherry juice
32744893|NCT04497077|Experimental|double dose tart cherry juice|double dose tart cherry juice
32744894|NCT04497077|Experimental|single placebo capsule|single placebo capsule
32744895|NCT04497077|Experimental|single placebo juice|single placebo juice
32744896|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
32744897|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
32744898|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
32744899|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
32744900|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
32744901|NCT03220061|No Intervention|control|usual care was given to participant in control group
32744902|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
32744903|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
32744904|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
32744905|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
32744906|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
32744907|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
32744908|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
32744909|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
32744910|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
32744911|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
32744912|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
32749641|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
32749642|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
32749643|NCT05518929|Active Comparator|Control group(Propofol group)|Anesthesia induction:Propofol 1.5mg/kg Anesthesia maintenance: Propofol 0.75mg/kg
32749644|NCT05518929|Experimental|Experimental group(ciprofol group)|Anesthesia induction:ciprofol 0.4mg/kg Anesthesia maintenance: ciprofol 0.2mg/kg
32749645|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
32749646|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
32749647|NCT04790409|Experimental|Sintilimab with anlotinib|Patients received sintilimab (anti-PD-1) combined with anlotinib (multi-target anti-angiogenesis).
32749648|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
32749649|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
32749650|NCT02407535|Experimental|Endometrial carcinoma patient|
32901669|NCT05622656|Active Comparator|Dexmedetomidines|Intraperitoneal instillation Dexmedetomidine 5ug/ml (10ml,50ug)
32901670|NCT05079282|Experimental|ONO-4685 monotherapy|Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy
32901671|NCT05079126|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.
32901672|NCT05079126|Placebo Comparator|Placebo|Subjects will receive a single IV bolus dose of 7 mL Normal Saline.
32901673|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
32901674|NCT05140278|Experimental|1-step Artesunate parenteral arm|Argesun (Artesunate 60 mg)
32749651|NCT05518617||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology.
32749652|NCT05518617||Parkin (Parkin gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
32749653|NCT05518617||PINK1 (Phosphatase and Tensin Homolog (PTEN)-Induced Kinase 1 gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
32749654|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
32749655|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
32749656|NCT04747431|Experimental|Cohort 1|"Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
32749657|NCT04747431|Experimental|Cohort 2|"Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
32749658|NCT04747431|Experimental|Optional Cohort 3|"Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
32749659|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
32749660|NCT05506917|Experimental|Periodontal treatment group|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
33234600|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
32749661|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
32749662|NCT05506839|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
32749663|NCT05506761|No Intervention|Group I|This group includes patients with rib fractures receiving patient-controlled analgesia.
32749664|NCT05506761|Experimental|Group II|This group includes patients with rib fractures receiving continuous ultrasound-guided erector spinae plane block.
33234601|NCT05752877|Experimental|Interventional Group|
32749665|NCT05506761|Experimental|Group III|This group includes patients with rib fractures receiving continuous ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block.
32749666|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
32749667|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
32749668|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
32749669|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
32749670|NCT05508711||Group 1|"st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~nd cardiac output measurement (Trendelenburg position): The operating table was then tilted in - 30 ° Trendelenburg (head-down) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~rd cardiac output measurement: The patients were positioned from Trendelenburg to reverse-Trendelenburg, the above-described data were recorded again."
32749671|NCT05508711||Group 2|"st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~nd cardiac output measurement (reverse Trendelenburg position): The operating table was then tilted in + 30 ° reverse Trendelenburg (head-up) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~rd cardiac output measurement: The patients were positioned from reverse Trendelenburg to Trendelenburg, the above-described data were recorded again."
32749672|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
32749673|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
32749674|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses~Post-Study Follow-up: until 1 year after administration"
32749675|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
32749676|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
32749677|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
32749678|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
32749679|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
32749680|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
32749681|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
32749682|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
32749683|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
32749684|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
32749685|NCT03116087|Placebo Comparator|Placebo|Placebo patches
32749686|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
32749687|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
32749688|NCT04968821|Experimental|Physical Activity|Participants randomized to the physical activity intervention will receive usual postoperative care and a tele-health physical activity intervention.
33234602|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
33234603|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
32749689|NCT04968821|Other|Usual Care|Participants randomized to usual care will receive postoperative care as determined by their treating surgeon.
32749690|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
32749691|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
32749692|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
32749693|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
32749694|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
32749695|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
32749696|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
32749697|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
32749698|NCT03172637||Group A|50 female end stage renal disease patients
32749699|NCT03172637||Group B|50 normal female patients
32749700|NCT04482023||Nurses COVID 19|Nurses from any unit of the Consortium Parc Taulí Corporation who have been in direct care of patients diagnosed with COVID 19 between March 9, 2020 and May 15, 2020
32749701|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
32901675|NCT05140278|Experimental|2-step Artesunate parenteral arm|Artesun (Artesunate 60 mg)
33241590|NCT04079972|Experimental|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
33241591|NCT04079972|Active Comparator|general lifestyle intervention|to provide general lifestyle guidance for weight loss
33241592|NCT04048707|Active Comparator|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
33241593|NCT04048707|Experimental|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
32749702|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
32749703|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
32749704|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
32749705|NCT03172169||Healthy control group|no intervention
32749706|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
33394047|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
32749707|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
32749708|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
32749709|NCT02064868|Other|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
33070640|NCT04691596|Experimental|Treatment Group 3|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any the pre-specified time of their chosen contextual cue (i.e. cue-contingent incentives)
33070641|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
33070642|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
33070643|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
33070644|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
33070645|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
33070646|NCT05318677||1|"Fifteen patients with spina bifida aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
33072422|NCT05091580|Experimental|Intervention: Interpersonal Counseling for Depression|New adult TB patients with depressive symptoms (PHQ-9 > 10) will be offered 4-8 sessions of Interpersonal Counseling delivered by a trained lay counsellor.
33394048|NCT04385433|Experimental|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
33394049|NCT04385433|Placebo Comparator|CONTROL GROUP|RADIOTHERAPY + PLACEBO
32744913|NCT02504567|Other|Laser ablation|Ablation with laser catheter
32744914|NCT02504567|Other|RF ablation|Ablation with RF catheter
32744915|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
32744916|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
32744917|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.~A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
33394050|NCT00700570|Experimental|1|
33394051|NCT02453698|Experimental|Methylphenidate|
32749710|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
32749711|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
32749712|NCT03171935|Active Comparator|Conventional Weaning|
32749713|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
32749714|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
32749715|NCT03172013||Healthy volunteers|Healthy individuals
32749716|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
32749717|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
32749718|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy~Pazopanib oral, daily and at predetermined dosage per cycle~Radium-223 predetermined dosage via IV, per cycle"
32749719|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:~Sorafenib at predetermined dosage, mouth twice daily~Radium-223 predetermined dosage via IV, per cycle"
33070647|NCT05318677||2|"20 healthy subjects as a control group aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
33234604|NCT05728151|Experimental|For group A|Group A will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Articaine 4 % with adrenaline 1/100000 mixed with 10IU of Hyaluronidase by a single injection technique: a 26/27 gauge needle will be inserted as far laterally as possible in the inferotemporal quadrant. Once the needle is under the globe, it will be directed along the orbital floor, passing the globe equator to a depth controlled by observing the needle/hub junction reaching the plane of the iris. After negative aspiration for blood, with the globe in primary gaze, and start injection and the injected volume will be guided by digital intraocular pressure.
33234605|NCT05728151|Experimental|Group L|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Lidocaine 2%mixed with 10IU of Hyaluronidase by a single injection technique.
32749720|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
33234606|NCT05728151|Experimental|Group M|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml (according to the volume of the eye) of Mepivacaine 3% mixed with 10IU of Hyaluronidase by a single injection technique.
33234607|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33241594|NCT04371536|Active Comparator|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
32749721|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
32749722|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
32749723|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
32901676|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
32901677|NCT05139654||Shoulder pain climbers group|Subjects with shoulder pain will be included to perform scaption and pull-up, and assess shoulder kinematics and muscle activation at the same time.
33394052|NCT02453698|Placebo Comparator|Control Group|
33394053|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
32749724|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
32749725|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
32749726|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
32749727|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
32749728|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
32749729|NCT02406053||OSAS|Obstructive sleep apnea syndrome
32749730|NCT02406053||COPD|Chronic obstructive pulmonary disease
32749731|NCT02406053||LC|Lung cancer
32749732|NCT02406053||HC|Healthy controls
32908888|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
32908889|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
32908890|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
32908891|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
33070648|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
32908892|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
32908893|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
32908894|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
32908895|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
32908896|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
32908897|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
32908898|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
32908899|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
32908900|NCT04084652|Experimental|Mycoprotein|Mycoprotein in its full food matrix
32908901|NCT04084652|Experimental|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
32908902|NCT04061876|Experimental|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
32908903|NCT04061876|Active Comparator|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
33394054|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
32749733|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
32749734|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
32749735|NCT04482335||Main Study|Participants complete questionnaires and agree to have their retrospective and prospective medical data used as part f this research project. All participants will take part in this arm.
32749736|NCT04482335||Biosample Sub-Study|A subset of the participants will take part of this. Participants will agree to have blood samples taken at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to provide urine samples.
32749737|NCT04482335||Synovial Biopsy and Synovial Fluid Sub-Study|A subset of the participants will take part of this. Participants will agree to synovial biopsies at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to donate waste synovial fluid.
32749738|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
32744573|NCT04485299|Active Comparator|sodium fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
32744574|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
32744575|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
32744576|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
32744577|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
32744578|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
32744579|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
32744580|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
32744581|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
32744582|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
32744583|NCT04863651||Securely Attached Parturients|Parturients who have a secure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
32744584|NCT04863651||Insecurely Attached Parturients|Parturients who have an insecure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
32744585|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
32744586|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
32744587|NCT04863183|Active Comparator|Group 1 (control-Triamcinolone acetonide)|Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).
32744588|NCT04863183|Experimental|Group 2 (experimental- CELLISTEM-OA)|CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).
32744589|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
32744590|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
32744591|NCT04874103||EUS guided gallbladder drainage and cholecystoscopy|"EUS-GBD will be performed using LAMS (such as Hot-AxiosTM device). A 10mm x 10mm stent system will be used if the largest gallstone is smaller than 10mm in size and a 15 x 10mm stent will be used if the largest gallstone is larger than 10mm.~Colecystoscopy will be subsequently performed after at least 2 weeks using standard or therapeutic gastroscope. Lithotripsy will be performed using mechanical lithotripsy or laser lithotripsy."
32744592|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
32744593|NCT04874181|Experimental|Silverfit 3D|The subject will use SIlverfit 3D for rehabilitation of his/her shoulder/knee strength post stroke.
32744594|NCT04868955|Experimental|Intervention group|Usual care and oral screen (IQoro®) training.
32744595|NCT04868955|No Intervention|Control group|Usual care.
32744596|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
32744597|NCT04873947||healthy adult volunteer|Subject is 18 to 50 years of age. Subject is a non-smoker or who has not smoked within 2 days prior to the study.
32744598|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
32744599|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
32749739|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
32749740|NCT03171701||maturation of arteriovenous fistula|
32749741|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
32749742|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
32749743|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
32749744|NCT03171779||Usual practice|
32749745|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
32749746|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
32749747|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
32749748|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
32749749|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
32749750|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
32749751|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
32749752|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
32749753|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
32749754|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
32749755|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
32749756|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
33394055|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
32749757|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
32749758|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
32749759|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
32749760|NCT02405273|Active Comparator|Control Group|Standard Care
32749761|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
32749762|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
32749763|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
32749764|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
32749765|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
32749766|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
32749767|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
33234608|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33241595|NCT04371536|Experimental|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
32749770|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
32749771|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
32749772|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
32749773|NCT05508633|Experimental|Low dose Alverine|Alverine 60mg (1 capsule), orally
32749774|NCT05508633|Experimental|High dose Alverine|Alverine 120mg (2 capsules), orally
32749775|NCT04482257|Experimental|T-R|Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV
32749776|NCT04482257|Experimental|R-T|Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV
32749777|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
32749778|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
32749779|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
32749780|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
32749781|NCT05506527|Experimental|study group 1|Study group A: will receive combined plyometric exercises and sensorimotor program
32749782|NCT05506527|Experimental|study group 2|Study group B: will receive sensorimotor program alone
32749783|NCT05506449|Active Comparator|Control Arm|Subjects randomized to the Control Arm will be treated based on recommendations for cardiogenic shock in the contemporary AHA/ACC/SCAI and ESC Practice Guidelines for STEMI and Heart Failure Management and local standard of care.
32749784|NCT05506449|Experimental|Treatment Arm|Subjects randomized to the Treatment Arm will receive hemodynamic support using an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI).
32749785|NCT04935671|Active Comparator|Allopathic + Herbal|"20mg of chamomile and 1 mg saffron in form of teabag for preparation of herbal decoction in dose of two teabags per day for a month as an ADJUVANT THERAPY with standard allopathic treatment for depression."
32749786|NCT04935671|No Intervention|Allopathic only|Only allopathic medication for depression.
32749787|NCT05506371|Experimental|Az group|"Periodontitis patients, who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure and additionally received oral azithromycin (Health Pharmaceutical Company, Kharkiv, Ukraine) in a dose of 500 mg q.d. for 7 days, then 500 mg q.w. for the next 3 weeks"
32749788|NCT05506371|Active Comparator|SRP group|Periodontitis patients who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure.
32749789|NCT05506371|Other|H group|Reference group. 25 healthy volunteers who underwent only diagnostics to confirm the clinical healthy state of the gingiva
32749790|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
32749791|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
32749792|NCT05508555|Active Comparator|HITHOC group|the group that will receive HITHOC after pleurectomy decortication
33398737|NCT05200650|Experimental|TumoCure Treatment|Subjects will be treated with a single intra-tumor injection of TumoCure, containing the polymeric delivery system and the Cisplatin hemotherapy agent at a dose of 100mg.
32749793|NCT05508555|No Intervention|pleurectomy decortication without HITOC|the group who received pleurectomy decortication without HITHOC
32749794|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
32749795|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
32749796|NCT05502705|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
32749797|NCT05502705|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
32749798|NCT05508477|Experimental|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given twice with 28 days interval.
32749799|NCT05508477|Active Comparator|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine is CoronaVac Bio Farma vaccine, supplied by Ministry of Health of Indonesia, in the form of two doses vial. The vaccine will be given twice with 28 days interval.
32908904|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
32908905|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
32908906|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
32908907|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
32908908|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
33398738|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
33398739|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
33398740|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
33398741|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
33398742|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
33398743|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
33398744|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
33398745|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
33398746|NCT04913142||control|patients not suffering from COVID-19 hospitalized in intensive care unit
33398747|NCT04913142||patients COVID-19|patients suffering from COVID-19 hospitalized in intensive care unit
33398748|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
33398749|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
33398750|NCT05492994|Experimental|Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
32749800|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
32749801|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
33234609|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
32908909|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
33234610|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33234611|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33394056|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
33398751|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
33234612|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33234613|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33234614|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
33072423|NCT05091580|Other|Control: Enhanced Treatment as Usual|"New adult TB patients will be screened for depression and those with significant symptoms (PHQ-9 > 15 and/or suicidal ideation) will be referred to the clinic nurse for evaluation and referral to specialized mental health care as needed. Routine screening for depression is not a standard practice for TB patients; therefore assessment and referral is considered enhanced treatment as usual. Individuals will be interviewed at baseline and treatment completion."
33072424|NCT05091242|Experimental|Clonidine|Participants receive Clonidine solution for injection, 3 microg/kg, administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Injection is administered from a dilated solution of Clonidine 15 microg/mL (ie., 0.2 mL/kg).
33234615|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
33234616|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
33234617|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
33234618|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
33234619|NCT05704361|Experimental|RO7121932: Dose Escalation Cohorts 1 to 6|Participants will receive a single IV dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 7 milligrams (mg) and will be escalated up to 2000 mg. The maximum dose will not exceed 4000 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.
33234620|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
33234621|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
33398752|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
33234622|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
33234623|NCT00718419|Experimental|A: Enzastaurin|
33398753|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
33398754|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
33234624|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
33234625|NCT03350243|No Intervention|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
33234626|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 during Part A [Single Ascending Dose (SAD)].
33234627|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 2|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
33234628|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 3|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
33234629|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 4|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
33234630|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 5|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
33398755|NCT05194176|No Intervention|Control|The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercises include using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with the exercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
33234631|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 6|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
33234632|NCT03976349|Experimental|Part B (MAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 on multiple days during Part B [Multiple Ascending Dose (MAD)].
33234633|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 2|Participants [Non leucine-rich repeat kinase 2 (Non LRRK2)] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
33234634|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 2|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
33234635|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 3|Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
33234636|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 3|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
33234637|NCT03976349|Placebo Comparator|Part A (SAD): Matching Placebo|Participants will receive matching placebo during Part A [Single Ascending Dose (SAD)].
33234638|NCT03976349|Placebo Comparator|Part B (MAD): Matching Placebo|Participants will receive matching placebo on multiple days during Part B (MAD).
33234639|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
33234640|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
33234641|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
33234642|NCT04085757|Experimental|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
33241596|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
33241597|NCT00769275||2|No screening
33241598|NCT05346458|Experimental|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients with coronary heart disease and undergoing coronary physiology investigations (pressure wire measurements) will have additional coronary pressure and flow measurements using the iKOs rapid-exchange microcatheter and iKOr console.
33241599|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
33241600|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
33241601|NCT00769431|No Intervention|Focus group|
32749802|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
32749803|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
32749804|NCT04591431|Experimental|Tailored Therapy|"Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by the FO (Foundation One) profiling. Patients will be treated with one or more drugs of the following list according to their genomic profile and independently from their type of cancer:~TARGETED THERAPY (MOLECULAR TARGET) ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1)~IMMUNOTHERAPY (BIOMARKERS) ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER ) Drugs will be administered according to their respective SmPCs (or IBs in case of drugs under development)."
32749805|NCT04591431|Active Comparator|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
32749806|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
32749807|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
32749808|NCT05506293||paravalvular leak|patients referred for percutaneous paravalvular leak closure
32749809|NCT05508321|Experimental|Patients with confirmed or suspected telomeropathy|Patients with idiopathic pulmonary fibrosis, adult or pediatric medullar dysplasia or myelodysplasia, unexplained liver cirrhosis or unexplained liver regenerative nodular hyperplasia.
33070649|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
32749810|NCT05508321|Other|Controls|Age and sex-matched control participants
32749811|NCT05502627||Experimental group|scaling was done along with intervention (0.25% lemongrass mouthwash was given)
32749812|NCT05502627||control group|only scaling was done
32749813|NCT05506137|Experimental|Treatment|
32749814|NCT05506137|Placebo Comparator|Placebo|
32908910|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
32908911|NCT04200066|Experimental|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
33241602|NCT04077632|Experimental|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
33241603|NCT04077632|Sham Comparator|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
32749815|NCT04742283|Experimental|DE-126 Opthalmic Solution 0.002% QD and Vehicle QD|DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)
32749816|NCT04742283|Active Comparator|Timolol Maleate Opthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)
32749817|NCT04289805|Active Comparator|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
32908912|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
33234643|NCT04085757|Active Comparator|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
33234644|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
33234645|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
32749818|NCT04289805|Experimental|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
33070650|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
33070651|NCT02941042|Experimental|NNC9204-1177|
33070652|NCT02941042|Placebo Comparator|Placebo|
33070653|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
33070654|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
33070655|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
33070656|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
33070657|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
33070658|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
33070659|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
33070660|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
33070661|NCT00174798|Placebo Comparator|Placebo|
33070662|NCT00174798|Experimental|SSR240600C|
33070663|NCT00174798|Active Comparator|Tolterodine|
33070664|NCT05200975|Other|Adequate renal function|Patients with adequate renal function (egfr>30ml/min) receiving a regular cefuroxime dose
33070665|NCT05200975|Other|Impaired renal function|Patients with impaired renal function (egfr<30ml/min) receiving a guideline recommended reduced dose
33070666|NCT05193955|Experimental|Intervention Group|undergraduate students who practice laughter yoga and simulation education together
33070667|NCT05193955|No Intervention|Control Group|undergraduate students who practice simulation education
33070668|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
33070669|NCT00146315|Experimental|Supervised exercise|
33070670|NCT05187520|Active Comparator|Patient-controlled epidural analgesia (PCEA)|Patients assigned to PCEA group will receive epidural analgesia as the standard postoperative pain control strategy. After completion of cesarean section, a PCEA device will be connected to the epidural catheter to deliver mixture of local anesthetic (0.8 mg/ml) and fentanyl (2 mcg/ml) with preset continuous dose of 3-5 ml/h and a bolus dose of 3-4 ml.
33070671|NCT05187520|Experimental|Naldebain®|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance after completion of cesarean section.
33070672|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
33070673|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
33234646|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).~The final beverage shall consist of:~Oily phase: refined sunflower oil 5% w/w of the emulsion~Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:~Solution A:~Hydrolyzed Lupine (1.17% w/w)~Sucrose (14.03% w/w)~Vanilla flavor (0.42% w/w)~Drinking water (84.38% w/v)~Solution B:~Xanthan gum (0.28% w/w)~Drinking water (99.72% w/v)~The samples will guard and kept by the investigator until the day of delivery to the volunteers.~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
33234647|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
33234648|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
33241604|NCT00763893|Placebo Comparator|A: Placebo|placebo
33241605|NCT00763893|Active Comparator|B: Losartan|Losartan
33234649|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
32749819|NCT04289805|No Intervention|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
32749820|NCT05502549|Experimental|CB03-154 SAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state.
33234650|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
33234651|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
32749821|NCT05502549|Placebo Comparator|Placebo SAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state.
32749822|NCT05502549|Experimental|CB03-154 SAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state.
33234652|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
33234653|NCT00727194|Experimental|1|eculizumab
33234654|NCT00727194|Placebo Comparator|2|Placebo
33234655|NCT00717093|Experimental|Active|
33234656|NCT00717093|Placebo Comparator|Placebo|
33234657|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
33234658|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
33234659|NCT02592642|Experimental|Group a|Para-spinal TENS
33072425|NCT05091242|Placebo Comparator|Placebo|Participants receive Sodium Chloride isotonic (9mg/mL) solution for injection administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Dosage is administered according to weight: 0.2 mL/kg.
33234660|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
33234661|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
33234662|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
33234663|NCT00716859|Active Comparator|Timolol|
33234664|NCT00716859|Experimental|latanoprost|
32749823|NCT05502549|Placebo Comparator|Placebo SAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state.
32749824|NCT05502549|Experimental|CB03-154 SAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state.
32749825|NCT05502549|Placebo Comparator|Placebo SAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state.
33072426|NCT05090891|Experimental|Group A: INCB000928|Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.
32749826|NCT05502549|Experimental|CB03-154 SAD 60mg|Participants will receive CB03-154 60mg orally once daily in a fasted state.
32749827|NCT05502549|Placebo Comparator|Placebo SAD 60mg|Participants will receive placebo 60mg orally once daily in a fasted state.
32749828|NCT05502549|Experimental|CB03-154 FE|Participants will receive CB03-154 orally once daily in a fed state.
32749829|NCT05502549|Experimental|CB03-154 MAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.
33234665|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
33234666|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
33234667|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
33234668|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
33234669|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
33234670|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
33234671|NCT03957161|Experimental|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
33234672|NCT03957161|No Intervention|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
33234673|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
33234674|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
33234675|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
33234676|NCT02607137|Experimental|Health Education|Health information related to physical activity
33234677|NCT05752799|Active Comparator|Opioid Based Anaesthesia|"This arm will receive:~2 mcg/kg fentanyl in 10 ml volume~0.2 mL/kg/h remifentanil infusion~0.1 mg/kg morphine"
33234678|NCT05752799|Active Comparator|Opioid Free Anaesthesia|"This arm will receive~40 mg/kg magnesium sulfate in 100 ml N/S infusion~0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~0.3 mg/kg ketamine in 10 ml volume~0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion"
33234679|NCT03945305|Experimental|RIC+ antihypertensive treatment|Baseline blood pressure and heart rate are measured 2 times a day for 3 days. And then the blood pressure and heart rate are measured before and after remote ischemic conditioning. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
33241606|NCT04019366|Experimental|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
33234680|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
32749830|NCT05502549|Placebo Comparator|Placebo MAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.
33234681|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
33234682|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
33072427|NCT05090891|Placebo Comparator|Group B: Placebo followed by INCB000928|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.
33234683|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
32749831|NCT05502549|Experimental|CB03-154 MAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.
32749832|NCT05502549|Placebo Comparator|Placebo MAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.
32749833|NCT05502549|Experimental|CB03-154 MAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state, for 14 consecutive days.
32749834|NCT05502549|Placebo Comparator|Placebo MAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state, for 14 consecutive days.
32749835|NCT05502549|Experimental|CB03-154 SAD 5mg|Participants will receive CB03-154 5mg orally once daily in a fasted state.
32749836|NCT05502549|Placebo Comparator|Placebo SAD 5mg|Participants will receive placebo 5mg orally once daily in a fasted state.
33234684|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
33234685|NCT03964428||periodontitis|
32749839|NCT05508165|No Intervention|Cohort 1a: in-person clinical assessment of LUTS/BPH|COHORT 1a: Subjects randomized to undergo in-person initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and in-person clinical follow-up after 3 months of clinical intervention. In-person clinical workup at both the initial and Month 3 follow-up timepoint includes International Prostate Symptom Score (IPSS), and standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA) assessments.
32749840|NCT05508165|Experimental|Cohort 1b: virtual (telehealth) clinical assessment of LUTS/BPH|COHORT 1b: Subjects randomized to undergo virtual initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and virtual clinical follow-up after 3 months of clinical intervention. Virtual clinical workup at both the initial and Month 3 follow-up timepoint includes at home completion of International Prostate Symptom Score (IPSS), at home uroflowmetry assessment through use of the Stream Dx device, at home assessment of post void residual (PVR) through use of the DFree device, and at home urinalysis (UA) through use of the TestCard device.
32749841|NCT05508165|Other|Cohort 2: Validation Cohort|COHORT 2: Non-randomized subjects who will attend a single, clinically scheduled, in-person follow-up appointment to directly compare the standard of care assessments/devices to the experimental assessments/devices. Prior to the in-person appointment, patients will complete at home uroflowmetry assessment through use of the Stream Dx device. At the in-person appointment, the clinic staff will perform standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA). At this visit, clinic staff will also obtain PVR measurements through use of the DFree device and urinalysis through the TestCard device.
32898241|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
32898242|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32898243|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
33072428|NCT05090150|No Intervention|Best clinic practices|Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)
33234686|NCT03964428||periodontitis with T2DM|
33234687|NCT03964428||control|
33234688|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.~Participants received no treatment in this follow-up study."
33234689|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
33234690|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
33234691|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
33234692|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
33234693|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
33234694|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
33234695|NCT00915512|Experimental|Paliperidone extended-release (ER)|
33070674|NCT04691284|Experimental|Observational arm|Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
33070675|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
32749842|NCT05505981|Experimental|Immediate Functional Progression Group|Athletes randomized to this group will start Physical Therapy immediately (with 7 days of diagnosis). Once in PT, Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
32749843|NCT05505981|Active Comparator|Rest until pain resolves Group|Athletes with an active spondylolysis randomized into the control group will rest from all activity until their pain has resolved. Physicians will assess pain resolution at each visit which occurs every four weeks. Once the pain has resolved, the patient will be referred to physical therapy (PT) two times per week. The time, frequency, and exercise progression will be the same as the IFPP group. Since the pain has resolved in these participants be-fore initiating PT, the criteria to progress through phases will be time-based, not pain and function-based.
33070676|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
33070677|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
33234696|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
33070678|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
33070679|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
33070680|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
33070681|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
33070682|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
33234697|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
32749844|NCT04286373|Experimental|Group A: active stimulation then placebo stimulation|"VNS active stimulation: Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks, then VNS placebo for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
33070683|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
33070684|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
33070685|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
33070686|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
33234698|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
33234699|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
33234700|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
33234701|NCT04088058|Experimental|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
33234702|NCT04088214|Experimental|ArtDSTP|Arthroscopic lateral soft tissue release
33234703|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
33234704|NCT04087668|Other|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
32749845|NCT04286373|Experimental|Group B: placebo stimulation then active stimulation|"VNS placebo for 8 weeks, then VNS active stimulation Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
33234705|NCT04087668|Other|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
33234706|NCT04087668|Other|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
33234707|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
33234708|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.~Treatment period 2:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
33234709|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.~Treatment period 2:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
33234710|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
33234711|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
33234712|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
33234713|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
33234714|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
33234715|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
33234716|NCT00716625||sunitinib malate|Patients taking sunitinib malate
33234717|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
33234718|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
33234719|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
33234720|NCT00917904|Placebo Comparator|vehicle placebo gel|
33234721|NCT00917904|Experimental|dapivirine gel|
33234722|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
33234723|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
33234724|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
33234725|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
33234726|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
33234727|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
33234728|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
33234729|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
33234730|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
33234731|NCT04085055|Active Comparator|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
33234732|NCT04085055|Active Comparator|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
32898244|NCT03527719|Experimental|Experimental Group|Village-doctor-led multifaceted intervention
33234733|NCT04085055|Active Comparator|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
33234734|NCT04085055|Active Comparator|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
33234735|NCT05543252|Experimental|UCB0599 High Dose Arm|Participants will receive a predefined high dosage of UCB0599 during the Treatment Period.
33234736|NCT05543252|Experimental|UCB0599 Low Dose Arm|Participants will receive a predefined low dosage of UCB0599 during the Treatment Period.
33234737|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
33234738|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
32749846|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
33234739|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
33234740|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
33234741|NCT05541614|Experimental|Subgingival debridement + Flapless Enamel Matrix Derivative|"Subgingival debridement following a minimally-invasive non-surgical treatment (MINST) approach with flapless application of EMD~Root instrumentation under local anesthesia using mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area of mandibular first or second molars with class II buccal furcation defects. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain® FL. Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets."
33234742|NCT05541614|Active Comparator|Periodontal surgery + Enamel Matrix Derivative|"Periodontal surgery following a minimally-invasive surgical treatment (MIST) protocol with application of EMD~Following local anesthesia, minimal flap elevation on the buccal aspect of first or second molars associated with a grade II furcation defect will be performed.Removal of granulation tissues and root instrumentation with mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area will then be carried out. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain®. Then, the surgical flaps will be positioned and sutured in order to completely cover the defects."
33234743|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
33234744|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
33234745|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
33234746|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
33234747|NCT02590575|Other|CO2 removal|
33234748|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
33234749|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
33234750|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
33234751|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
33234752|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
33234753|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
33241607|NCT04019366|Active Comparator|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
33241608|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
33241609|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
32749847|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
32749848|NCT04782921|Experimental|Gel 40|Application of Gel 40
32749849|NCT04782921|Active Comparator|Gen-Os|Application of Gen-Os
32749850|NCT05502471|Other|ADHD|Children with ADHD
32749851|NCT05502471|Other|Control|Children without any psychiatric disorder
32749852|NCT05508009|Experimental|Cohort 1b: Conditioning Regimen A|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen A (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
32749853|NCT05508009|Experimental|Cohort 2a: Conditioning Regimen A|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
32749854|NCT05508009|Experimental|Cohort 1b: Conditioning Regimen B|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen B (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
32749855|NCT05508009|Experimental|Cohort 2a: Conditioning Regimen B|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
32749856|NCT04715139||All Products listed in Descriptions|"ProStop~BioCompression Screw~TRIM-IT Drill Pin/TRIM-IT Spin Pin~Headless Compression Screw/Compression FT Screw~DynaNite Nitinol Staple~Beveled Headed FT Screw"
32749857|NCT05505669||Adults with type 1 diabetes|Adults with type 1 diabetes
32749858|NCT05505669||Adult healthy volunteers|Adult healthy volunteers
33070687|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
32749859|NCT05505669||Children with type 1 diabetes|Children with type 1 diabetes
33234754|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
32749860|NCT05505669||Adults with type 2 diabetes|Adults with type 2 diabetes
32749861|NCT05505669||Adults with high blood sugar|Adults with high blood sugar
33234755|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
33234756|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
33234757|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
32749862|NCT05505669||Those at risk of developing type 1 diabetes|Those at risk of developing type 1 diabetes
32749863|NCT05502393|Experimental|JS107|
32749864|NCT05502393|Experimental|JS107 combination with Toripalimab|
32749865|NCT05449431|Experimental|TLC1_TM6|Patient doing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6).
32749866|NCT05449431|Experimental|TM6_TLC1|Patient performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1)
32749867|NCT05505591||High bleeding risk|Patients treated with cangrelor who met the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
32749868|NCT05505591||Non-high bleeding risk|Patients treated with cangrelor who did not meet the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
33234758|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
33234759|NCT04084977||Sydenam Chorea (SC)|individuals with SC
33234760|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
32749869|NCT05448807|Experimental|participants receiving oraverse injection after local anaesthetic administration|participants receive phentolamine mesylate (Oraverse) injection after the completion of their dental procedures with ratio 1:1 to LA in children weighed 30 kg and more while in children less than 30 kg only half of the amount of the cartridge is administrated.
32749870|NCT05448807|No Intervention|participants with no drug after local anaesthetic administration|participants don't receive any reversal agent or placebo after the completion of their dental procedures.
32749871|NCT05402631||New patient with lower back pain|
32749872|NCT05402631||known patient with lower back pain|
32749873|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
32749874|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
33070688|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Well State|Subjects with confirmed PCD in Well State
33070689|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Sick State|Subjects with confirmed PCD in Sick State
33070690|NCT04691440|Experimental|HBOT|Hyperbaric oxygen breathing at 2.4 atm.abs for 90 minutes. The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
33070691|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
32749875|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
32749876|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
32749877|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
33070692|NCT00146471|Active Comparator|2|
33234761|NCT04084977||control|children wit no tonsilitis
33070693|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
33070694|NCT04691245|Experimental|Intervention|Femoral access using 3D US
33070695|NCT04691245|Active Comparator|Control|Femoral access using 2D US
32749878|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
32749879|NCT05366283|Experimental|Cohort 1 (Part 1)|Single dose of 250 microgram (mcg) sargramostim IV over 2 hours
32749880|NCT05366283|Experimental|Cohort 2 (Part 1)|Single dose of 25 mcg sargramostim SC
32749881|NCT05366283|Experimental|Cohort 3 (Part 1)|Single dose of 125 mcg sargramostim SC
32749882|NCT05366283|Experimental|Cohort 4 (Part 1)|Single dose of 250 mcg sargramostim SC
32749883|NCT05366283|Experimental|Cohort 5 (Part 1)|Single dose of 500 mcg sargramostim SC
32749884|NCT05366283|Experimental|Cohort 6 (Part 1)|Single dose of 250 mcg sargramostim IH
32749885|NCT05366283|Experimental|Cohort 7 (Part 2)|Two doses of 500 mg sargramostim SC, weekly
33070696|NCT04691713|Experimental|Targeting CD276 autologous chimeric antigen receptor T cells|
33070697|NCT04690933||Multicentric NAViRe cohort with biocollection|"The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, new or less recent, thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients."
33070698|NCT00174993|Experimental|Pioglitazone QD|
33234762|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
33234763|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
33241610|NCT04228016|Experimental|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
32749886|NCT05319951|Experimental|Oral Rehydration Salts Power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
32749887|NCT05319951|Experimental|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
32749888|NCT05319951|Placebo Comparator|recommended water intake|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
32749889|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling"
32749890|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Contingent financial rewards for smoking abstinence"
32749891|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Text messages to support smoking abstinence"
33070699|NCT00174993|Placebo Comparator|Placebo QD|
33070700|NCT04690894|Active Comparator|Erector spinae group|the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle
33070701|NCT04690894|Active Comparator|caudal group|child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%
33241611|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
33070702|NCT04690894|No Intervention|control|child didn't received any regional block
33070703|NCT04691830|Experimental|group IA|"Preschool cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
33070704|NCT04691830|Active Comparator|group IB|preschool control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the preschool age control group.
33070705|NCT04691830|Experimental|group IIA|"School age cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
33070706|NCT04691830|Active Comparator|group IIB|School age control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the school age control group.
33234764|NCT04107194|Experimental|Tailored therapy|"Clarithromycin-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)~Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)~Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
33241612|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
32908913|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
32749892|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32908914|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
32749893|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32749894|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32749895|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32749896|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32749897|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
32908915|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
32908916|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
32908917|NCT04005716|Experimental|tislelizumab plus etoposide and platinum|
32908918|NCT04005716|Active Comparator|Placebo plus etoposide and platinum|
32908919|NCT03941288|Active Comparator|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
32908920|NCT03941288|Placebo Comparator|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
32908921|NCT04420650|Active Comparator|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
32908922|NCT04420650|Active Comparator|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
32749898|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
33070707|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
32749899|NCT04411719|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
33234765|NCT04107194|Active Comparator|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
33234766|NCT03180827|Experimental|ovarian tissue cryopreservation|
33234767|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
33070708|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
33234768|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
33234769|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
33234770|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
33234771|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
33234772|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
33234773|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
33234774|NCT00914303|Experimental|Placebo|Placebo Tablets
33234775|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
33234776|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
33234777|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
33234778|NCT00736476|Experimental|1|
33234779|NCT00736476|Placebo Comparator|2|
33234780|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
33234781|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
33234782|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
33234783|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
33234784|NCT05642078|Experimental|Investigational Vaccine(Low dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.25mL/branch, each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
33234785|NCT05642078|Experimental|Investigational Vaccine(High dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.5mL/branch, each contains 15 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
33234786|NCT05642078|Active Comparator|Active compared Vaccine|Influenza Vaccine(Split Virion),Inactivated Quadrivalent,Produced by Hualan Biological Vaccine Co., Ltd.;0.25mL/branch,each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
33234787|NCT04019496||Episodic Migraine|
33234788|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
33234789|NCT04104386|Experimental|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
33234790|NCT04104386|No Intervention|Non-Disclosure|Telomere Length results were not provided.
33234791|NCT05717153|Experimental|Arm I (MRI, resection, DFMO, AMXT 1501)|Patients undergo magnetic resonance imaging (MRI) and surgical resection at baseline. Patients receive eflornithine PO in combination with AMXT 1501 PO on days 1-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
33234792|NCT05717153|Placebo Comparator|Arm II (MRI, resection, placebo, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive placebo PO on days 1 and 2 post-surgery, and then receive eflornithine PO and AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
33234793|NCT05717153|Active Comparator|Arm III (MRI, resection, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive eflornithine PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
33234794|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
33234795|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
33234796|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
33234797|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
33394057|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
32749900|NCT04411719|Experimental|Electric stimulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
32749901|NCT04411719|No Intervention|No treatment group|No electric stimulation is applied.
32749902|NCT04458051|Experimental|SAR442168|Dose 1 of oral SAR442168 daily
32749903|NCT04458051|Placebo Comparator|Placebo|Placebo to match the SAR442168 daily
32749904|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
33234798|NCT04112888|Experimental|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
33234799|NCT04112888|Active Comparator|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
33070709|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
33234800|NCT05690087|Experimental|Lidocaine group|Intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation.
33070710|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
33234801|NCT05690087|Placebo Comparator|Control group|Intravenous sodium chloride 0.9% solution volume matched in bolus and infusion.
33234802|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
33234803|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
33234804|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
33234805|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
33234806|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
33234807|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
33070711|NCT04690972||Hepato-bilio-pancreatic surgery|Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
33234808|NCT00730236|Experimental|AEGR-733|
33394058|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
33234809|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
33234810|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
33234811|NCT05665595|Experimental|Pembrolizumab/Vibostolimab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
33234812|NCT05665595|Active Comparator|Pembrolizumab|Adult participants receive 200 mg and adolescent participants ≥40 kg receive 2 mg/kg (up to a max of 200 mg) pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
33234813|NCT04084743|Experimental|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
33234814|NCT04084743|Active Comparator|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
33234815|NCT05663957||EVUSHELD arm|Individuals given EVUSHELD for prophylaxis
33234816|NCT05663957||Concurrent Control arm|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
33394059|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
33234817|NCT05752721||Food Pantry Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Food selections for participants in the this arm will be accessible through the online ordering platform.
33070712|NCT04690972||biopsy of the hepatic parenchyma|Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
33070713|NCT04690972||Viral chronic infection|Patients with a viral chronic liver disease
32749905|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
32749906|NCT04701333|Experimental|Cabergoline|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
32749907|NCT04701333|Placebo Comparator|Placebo|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
32749908|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
32749909|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
32749910|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
32749911|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
32749912|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
32749913|NCT04701112|Experimental|His-bundle pacing first|"AV sequential His-bundle pacing (or VVI pacing if in atrial fibrillation) via temporary right atrial and His-bundle electrodes.~Then AV sequential Biventricular pacing via the patient's already implanted CRT device.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
33234818|NCT05752721||Food Pantry NOT Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is NOT scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Participants in this arm will record their food selections and send them to the study team.
32749914|NCT04701112|Active Comparator|Biventricular pacing first|"AV sequential biventricular pacing (or VVI pacing if in atrial fibrillation) via the patient's already implanted CRT device. Then AV sequential or VVI His-bundle pacing via temporary right atrial and His-bundle electrodes.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
32749915|NCT04701034|Active Comparator|Active treatment group|"Intravenous immunoglobulin(IVIg) and prednisolone. IVIG is administered at the time of embryo/blastocyst transfer (ET) (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion (same dose) is repeated in gestational week 5, 6, and 7.~Participants with pre-pregnancy weight ≤70 kg will receive 25 g immunoglobulin (250 ml), participants with weight 70-85 kg will receive 30 g immunoglobulin (300 ml), and participants with weight ≥85 kg will receive 35 g immunoglobulin (350 ml) at each infusion, which will approximate 0.4 g IVIg per kg body weight.~Prednisolone, tablets, 5mg. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
32749916|NCT04701034|Placebo Comparator|Passive treatment group|"Human albumin infusion and placebo tablets.~Human albumin, 5%, (CLS Behring). Participants with pre-pregnancy weight ≤70 kg will receive 250 ml, participants with weight 70-85 kg will receive 300 ml, and participants with weight ≥85 kg will receive 350 ml at each infusion. Administration is planned at the time of ET (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion is repeated in the same volume in gestational week 5, 6, and 7.~Placebo tablets: contain 85 mg of lactose monohydrate, 86 mg potato starch, 8.1 mg talc, 3 mg gelatine, and 0.9 mg magnesium stearate. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
32749917|NCT04700956|Active Comparator|the primary suture group|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
32908923|NCT04420650|Sham Comparator|Sham Stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
32908924|NCT00994760||GENISIS|
33072429|NCT05090150|Experimental|Best clinic practices plus lottery incentives|Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)
33072430|NCT05090150|Experimental|Randomized from best clinic practices to smart lockers|Second randomization into community ART through the use of smart lockers
33072431|NCT05090150|Experimental|Randomized from best clinic practices to home delivery|Second randomization into home ART delivery
32749918|NCT04700956|Experimental|mesh group|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
32749919|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
32749920|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
32749921|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
32749922|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
32749923|NCT04582305|Active Comparator|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
32749924|NCT04582305|Placebo Comparator|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
33234819|NCT03899597|Experimental|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
33234820|NCT03899597|Placebo Comparator|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
33234821|NCT05752097||Renal inflammatory or fibrotic disease|[18F]AIF-NOTA-FAPI-04 (4.81MBq/Kg) will be injected intravenously according to the patient's body weight. PET/CT examination will be performed 50-60 minutes after the injection of radiotracer. The patients will undergo renal puncture biopsy one day after PET/CT examination.
33234822|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
33234823|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
33234824|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
33234825|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
33234826|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
33234827|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
33234828|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
33234829|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
33234830|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
33234831|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
33234832|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
33234833|NCT05751317||samples containing Enterococci|"Isolates of Enterococci will be identified by Gram staining, colony morphology, catalase test, and growth on Bile Esculin agar. All isolates will be identified to species level using Vitek2 automated system Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on MuellerHinton Agar.~The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique Detection of the effect of nanoparticles on the antibiotic susceptibility profile of Enterococci. Detection of the effect of nanoparticles on the biofilm producing Enterococci. Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR"
33234834|NCT05751317||samples with bacteria other than enterococci|
33234835|NCT04084665|Experimental|Intervention|Guselkumab 200mg q4 weekly
33234836|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
33234837|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
33234838|NCT05751239||Bisexual-Biromantic|People that self-identify as bisexual-biromantic
33234839|NCT05751239||Heterosexual-heteroromantic|People that self-identify as heterosexual-heteroromantic
33234840|NCT05751239||Homosexual-homoromantic|People that self-identify as homosexual-homoromantic
33234841|NCT05751239||Pansexual-panromantic|People that self-identify as pansexual-panromantic
33234842|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
33234843|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
33234844|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
33234845|NCT05685147|Experimental|Intervention group|the intervention group using morphology and niPGT-A
33234846|NCT05685147|No Intervention|Control group|the control group based on morphology alone.
33234847|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
32749925|NCT04551417|Active Comparator|Dorsal onlay graft urethroplasty|
33234848|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
33234849|NCT04026659|Experimental|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
33234850|NCT05685069||Standardized work-up|A standardized workup procedures including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, stroke laboratory, risk factor assessment and noninvasive angiography of the cervical and intracranial arteries will be performed.
33234851|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
33234852|NCT04015557|Experimental|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
32749926|NCT04551417|Experimental|Ventral onlay graft urethroplasty|
33234853|NCT04015557|Experimental|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
33234854|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
33234855|NCT05534282|Experimental|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists
32749927|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
32749928|NCT04700410|Experimental|Pure-Vu|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
32749929|NCT05504967|Active Comparator|dexamethasone|"12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total).~Single dosage pre-incisional."
33070714|NCT05157802|Experimental|Physical Activity Coaching|Participants will receive up to 5 individualized coaching sessions delivered via telehealth to facilitate and optimize exercise uptake. The therapist will facilitate discussion on specific and measurable goals, and will provide options for tracking their progress, such as written or web-based exercise logs or an activity monitor. The recommended exercises will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. Balance and strengthening exercises will also be recommended as appropriate.
33070715|NCT05146843|Experimental|Mitoquinone|MitoQ, 20 mg per day for three months
33070716|NCT05146843|Placebo Comparator|Placebo|Placebo, 20 mg per day for three months
32908925|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
32908926|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
33070717|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
33070718|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
32908927|NCT04927572|Experimental|FMX114|
32908928|NCT04927572|Placebo Comparator|Vehicle|
33070719|NCT05139355|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33070720|NCT05139355|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33234856|NCT05534282|Experimental|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
33234857|NCT05534282|Experimental|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
33070721|NCT05139355|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil C. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33070722|NCT05139355|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil.
33070723|NCT05108233||Observational (survey)|"COHORT 1-TP1: Patients complete surveys over 20 minutes on post-op day 3 and on day of discharge (or within 1 week).~COHORT 1-TP2: Patients complete surveys over 15 minutes at all regularly scheduled follow-up appointments (approximately 1 month, 3 months, 6 months, 12 months).~COHORT 2: Patients complete surveys over 15 minutes once."
33234858|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
33070724|NCT05106361|Experimental|MOSAIC Plus|"Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
33070725|NCT05106361|Active Comparator|MOSAIC|"Those in the active comparator will receive the Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV."
33234859|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
33234860|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
33234861|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
33234862|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
33234863|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
33234864|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
33234865|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
33234866|NCT05490368|Experimental|Bed mattress sensor system|The experimental group uses the new bed mattress sensor system for 6 months.
33234867|NCT05490368|No Intervention|Control Group|In the control group, participants do not use any of the following bedside fall-prevention tools: bed-exit alarm system, ultra low bed, and ripple bed during the same 6-month period.
33070726|NCT04691050|Other|OrthoMta (BioMTA)|OrthoMTA was applied in primary molars without successors
33070727|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
33070728|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
33070729|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
33070730|NCT02940457|Experimental|Verum tDCS|prefrontal anodal stimulation
33070731|NCT02940457|Experimental|Sham tDCS|sham stimulation, same electrode positions
33070732|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
32749930|NCT05504967|Active Comparator|ropivacain|"18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total).~Single dosage pre-incisional."
32749931|NCT05504967|Experimental|ropivacain + dexamethasone|"18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca).~Single dosage pre-incisional."
32749932|NCT05504967|Placebo Comparator|placebo|Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.
32749933|NCT05504889||OPTIMOM residual samples|"Residual plasma samples collected in one of our prior studies monthly across pregnancy (OPTIMOM, NICHD 1U54HD085601-01, Clinical Trials.gov ID NCT02519790; K. Wisner, PI) will be evaluated for cholesterol and 4β-hydroxycholesterol.~These samples were obtained from women who gave their consent for use of their blood samples for future studies. All OPTI-MOM participants have been genotyped for variants in CYP3A5 using commercial allelic discrimination assays (ThermoFisher Scientific, Waltham, MA, with Taqman probes.)"
32749934|NCT05504889||Newly recruited subjects|Plasma samples will be collected from newly recruited subjects.
32749935|NCT02041702|Experimental|Cardiac MRI Scan Group|
32749936|NCT02041702|No Intervention|Control Group|
32749937|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
32749938|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
32749939|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
32749940|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
32749941|NCT05501847|No Intervention|Patient with ventricular hypertrophy|Screening for cardiac amyloidosis in a patient with heart failure and ventricular hypertrophy is performed as part of routine care according to a standardised care protocol that follows the Gullimor algorithm.
32749942|NCT05501847|Experimental|Patient with no ventricular hypertrophy|"In the context of TEAM-HF research, the heart failure patient without ventricular hypertrophy will undergo a bone scan.~If the diagnosis of amyloidosis is most often suspected on the electrocardiogram and cardiac echography, only cardiac MRI or bone scan with diphosphonates (for transthyretin amyloidosis) can make the diagnosis."
32749943|NCT05150925|Experimental|Immediate mobilization after distal radius fracture treated with volar locking plate|
32749944|NCT05150925|Active Comparator|2 weeks cast immobilization after distal radius fracture treated with volar locking plate|
32908929|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
32749945|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
32749946|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
32908930|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
33070733|NCT05085808|Active Comparator|Quetiapine|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
33070734|NCT05085808|Experimental|Trazodone|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
33072432|NCT05090150|Experimental|Randomized from best clinic practices plus lottery incentives to smart lockers|Second randomization into community ART through the use of smart lockers
33072433|NCT05090150|Experimental|Randomized from best clinic practices plus lottery incentives to home delivery|Second randomization into home ART delivery
32749947|NCT05112172|Experimental|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
32749948|NCT04541433|Experimental|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
32908931|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
32908932|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
33072434|NCT05089734|Experimental|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met.
33234868|NCT04114799|Active Comparator|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
33234869|NCT04114799|Experimental|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
33234870|NCT05684991|Experimental|Treatment Group|One capsule of KSM-66 300 mg (contains Ashwagandha extract) two times a day, orally with water
33234871|NCT05684991|Placebo Comparator|Control Group|One capsule of Placebo two times a day, orally with water
33234872|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
33234873|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
33234874|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
33234875|NCT05324163|Experimental|X0002 spray group|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
33234876|NCT05324163|Active Comparator|Celecoxib capsule Group:|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
32749949|NCT04664361|Experimental|NMN 250|NMN tablet (250 mg)
32749950|NCT04664361|Experimental|NMN 500|NMN tablet (500 mg)
32749951|NCT04664361|Placebo Comparator|Placebo|NMN-free placebo tablet.
33234877|NCT05324163|Placebo Comparator|The placebo group|X0002 spray placebo 17.5 mg, twice a day; Celecoxib placebo 200mg, once a day
32908933|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
32749952|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal primary care.
32749953|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
32749954|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
32749955|NCT05504811|Experimental|Experimental: FitMi AD Exercise Program|Participants will perform exercises by interacting with FitMi pucks, as described and monitored on a tablet computer. Participants will be asked to exercise at least 30 minutes per day for 3 months.
32749956|NCT05504811|Active Comparator|Active Comparator: Conventional booklet of exercise program|Participants will perform exercises described in a booklet similar to what is typically provided to individuals. Participants will be asked to exercise at least 30 minutes per day for 3 months.
32749957|NCT05504733|Experimental|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|For participants in the experimental arm, the Layperson Audiovisual Assist Tourniquet (LAVA TQ) is the first tourniquet applied to their leg as the intervention.
32749958|NCT05504733|Active Comparator|Combat Application Tourniquet (CAT)|For participants in the control/active comparator arm, the Combat Application Tourniquet (CAT) is the first tourniquet applied to their leg as the intervention.
32749959|NCT04698850|Active Comparator|aflibercept|Patients with RAP who will be receiving aflibercept.
32908934|NCT01030406|Active Comparator|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
32908935|NCT01030406|Active Comparator|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
32908936|NCT01030406|Experimental|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
32908937|NCT01030406|Experimental|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
32908938|NCT01030406|Placebo Comparator|0/0mg taken first|Placebo
32908939|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
32749960|NCT04698850|Experimental|brolucizumab|Patients with RAP who will be receiving brolucizumab.
32749961|NCT05113953|Experimental|Low Dose: 200 mg Total Daily Dose (TDD) of Centanafadine|200 mg TTD of centanafadine will be administered as 1x 100 mg tablet and 1 placebo tablet twice daily (BID) 4-6 hours apart.
32908940|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
32908941|NCT03894098|Active Comparator|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
32908942|NCT03894098|Experimental|High ankle block|High ankle block for acute pain control after elective ankle surgery
33234878|NCT00730158|Experimental|Arm A|irinotecan+ KD018
33234879|NCT00730158|Experimental|Arm B|irinotecan + placebo
33234880|NCT05316051|Experimental|25° inverted angle foot orthoses|
33234881|NCT05316051|Experimental|15° inverted angle foot orthoses|
32749962|NCT05113953|Experimental|High Dose: 400 mg Total Daily Dose (TDD) of Centanafadine|400 mg TTD of centanafadine will be administered as 2x 100 mg tablets twice daily (BID) 4-6 hours apart.
33070735|NCT05085808|Placebo Comparator|Placebo|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
33070736|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
33070737|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
33234882|NCT05316051|No Intervention|Control|
33234883|NCT04104074|Experimental|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
33234884|NCT04114643|Active Comparator|Prothrombin Complex Concentrate|
33234885|NCT04114643|Active Comparator|Frozen Plasma|
33234886|NCT04114487|No Intervention|control 1|The control 1 group will not be subjected to any application except education.
33234887|NCT04114487|Active Comparator|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
33234888|NCT04114487|Experimental|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
33234889|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
33234890|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
33234891|NCT05750849||OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day over the threshold point calculated
33234892|NCT05750849||SUB-OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day below the threshold point calculated
33234893|NCT04084587|Experimental|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.~Exams performed before and after treatment:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~Microperimetry and analysis of fixation (OCT-SLO OPTOS)~QoL (VFQ-25)"
33234894|NCT04084587|No Intervention|Control Group|"Group B: 9 patients control group without rehabilitation.~Exams performed twice, at the same time interval elapsed for the treated group:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~QoL (VFQ-25)"
33234895|NCT05685173|Experimental|Odronextamab and REGN5837|Odronextamab and REGN5837 will be administered by IV infusion using a step-up dosing schedule.
33234896|NCT00918372||Extreme fitness|Female competitive long distance runners
33234897|NCT00918372||Control|Age and Risk matched controls
33234898|NCT05305443|Experimental|Navigation/tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will continue receiving NS.
33234899|NCT05305443|Experimental|Navigation/tested/brief counseling|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC)
33234900|NCT05305443|Experimental|Navigation/not tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who do not complete the COVID-19 testing will again be randomized and some will continue receiving NS.
33234901|NCT05305443|Experimental|Navigation/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD)
33234902|NCT05305443|Experimental|Referral/tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
33234903|NCT05305443|Experimental|Referral/tested/brief counseling|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC).
33234904|NCT05305443|Experimental|Referral/not tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
33234905|NCT05305443|Experimental|Referral/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD).
33234906|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
33234907|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
33234908|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
33241613|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
33241614|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
33394060|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
33394061|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
33394062|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
33394063|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
33394064|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
33394065|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
33394066|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
33394067|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
33394068|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
33394069|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
32749963|NCT05113953|Placebo Comparator|Placebo|Placebo will be administered as 2 placebo tablets twice daily (BID) 4-6 hours apart.
32749964|NCT04698226|Active Comparator|ILM peel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade.
32749965|NCT04698226|Experimental|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
32749966|NCT05504577|Experimental|QCG group|After the prosthesis are all implanted, apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the QCG from the knee joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
32749967|NCT05504577|Active Comparator|Surgical gauze group|After the prosthesis are all implanted, apply the surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the gauze from the joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
32749968|NCT05504577|Placebo Comparator|Control group|fter the prosthesis are all implanted, we close the joint capsule directly. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
32749969|NCT05504499|Experimental|Single Arm|A Prospective, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
32749970|NCT05501535||pseudophakic patients before and after having ND YAG laser|
32749971|NCT05043441|Experimental|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
32749972|NCT05043441|Sham Comparator|Psychoeducation control group|Care as usual with psychoeducation materials provided
32749973|NCT05026281|Experimental|Group 1|at H0 and H0+30min = blood sample taken
32749974|NCT05501457|Experimental|The gastrocnemius group|The patients in the first group (n=15) were given a pulmonary rehabilitation program and additionally 20 minutes of Neuromuscular electrical stimulation (Group 1) to the gastrocnemius muscle,
32749975|NCT05501457|Experimental|The quadriceps femoris group|The second group was given a pulmonary rehabilitation program and an additionally 20 minutes of neuromuscular electrical stimulation to the quadriceps femoris muscle (Group 2),
33394070|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
33394071|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
33394072|NCT01318161|Experimental|Epidural anesthesia and analgesia|
33394073|NCT01318161|Active Comparator|Patient controlled analgesia|
33394074|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
33394075|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
33394076|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
33394077|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
33394078|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
33394079|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
32749976|NCT05501457|Experimental|The control group|The third group, which was the control group, was given only a pulmonary rehabilitation program (Group 3).
32749977|NCT05016297|Experimental|baricitinib 4mg per day + HCQ 200mg twice a day|On the basis of the HCQ treatment before, patients in this group will be added on baricitinib 4mg once a day.
32749978|NCT05016297|Active Comparator|HCQ 200mg twice a day|Patients in this group will be given HCQ 200mg twice a day for 12 weeks. Patients who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and added on baricitinib 4mg per day until the end of the study (week 24).
32749979|NCT05504343|Other|Single Arm|This study is a prospective, single arm single center, open label study.
32749980|NCT05504265|Other|Postoperative NSAIDs|
32749981|NCT05504265|Experimental|Preemptive analgesia followed by Postoperative NSAIDs|
32749982|NCT05504265|Experimental|Postoperative patient-controlled analgesia pump|
32749983|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
32749984|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
32749985|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
32749986|NCT05504109|Active Comparator|Group A|patients who will undergo mitral valve replacement through full sternotomy approach
32749987|NCT05504109|Active Comparator|Group B|patients who will undergo mitral valve replacement through right mini thoracotomy approach
32749988|NCT05504031|Experimental|Hybrid Group|Revascularization in the form of a combined MIDCAB (LIMA-LAD graft trough a minimal invasive left anterior thoracotomy) and PCI (of all non-LAD stenoses)
32749989|NCT05504031|Active Comparator|CABG Group|Conventional CABG through a sternotomy
32749990|NCT05503953|Experimental|AGSAVI|
32749991|NCT05503953|Active Comparator|AGLS|
32749992|NCT05501301||Immune tolerance cohort|"Patients that are enrolled into this cohort will receive IS minimization if virus infection or side effects of IS was found. The strategy of IS minimization will follow the Clinical guidelines for pediatric liver transplantation in China(2015). Blood test and liver biopsy will be conducted to monitor liver function and intrahepatic pathological conditions. If IS is ceased for more than one year without liver dysfunction or signs of acute rejection in liver biopsy, immune tolerance was considered reached."
32749993|NCT04698148||CDI patients|Patients with Clostridium Difficile Infection
32749994|NCT04698148||MDRO patients|Patients with Multi Drug Resistant Organisms infection
32749995|NCT04698148||IBD patients|Patients with Chronic Inflammatory Bowel Disease
32749996|NCT04698148||IBS patients|Patients with Irritable Bowel Syndrome
32749997|NCT04698148||Hepatic Encephalopathy patients|Patients with Hepatic Encephalopathy
32908943|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
32908944|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
33241615|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
33241616|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
32749998|NCT04698148||healthy volunteers|healthy volunteers
32749999|NCT02560623|Experimental|Phase 1: Sponge on a String 25 mm 10 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
32750000|NCT02560623|Experimental|Phase 1: Sponge on a String 25 mm 20 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 20 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
32750001|NCT02560623|Experimental|Phase 2: Cases - Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
32750002|NCT02560623|Experimental|Phase 2: Controls - No Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
32750003|NCT05501223|Other|Intervention|Standard care + medication review
32750004|NCT05501223|Other|Control|Standard care
32750005|NCT04916613|Experimental|ADT + darolutamide|ADT + darolutamide 600 mg po bid
32750006|NCT04916613|Placebo Comparator|ADT + placebo|ADT + placebo po bid
32750008|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
32750009|NCT04740099|Experimental|SOONER Training (Intervention)|Arm receives video training and kit designed by SOONER team.
32908945|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
32908946|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
32908947|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
32908948|NCT03804554||Patients taking nivolumab|
32750010|NCT04740099|Other|Standard of care training (control)|Participant referred to standard of care (community based Naloxone training)
32750011|NCT05503563||tetra modal bladder preservation|
32750012|NCT05503485|Experimental|Existential group treatment|Participants who are randomized to the experimental condition will participate in an existential group treatment together with 3 to 6 other participants in seven group sessions of 90-120 minutes each for seven weeks.
32750013|NCT05503485|Active Comparator|Supportive telephone calls|Participants who are randomized to the control condition will receive brief supportive telephone calls once a week for 7 weeks.
32750014|NCT04537299|Experimental|Treatment Group|Subjects will receive treatment drug (Fisetin)
32750015|NCT04537299|Placebo Comparator|Placebo Group|Subjects will receive placebo
32750016|NCT04535115|Experimental|Group 1|Starting LRM (Lung Recruitment Maneuver)
32750017|NCT04535115|Experimental|Group 2|Starting VtC (Tidal Volume Challenge)
32750018|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
32750019|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
32750020|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
32750021|NCT04653051||Patients who received DVR Plating System|
32750022|NCT05500989||Short track controls|"Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies).~Follow up roughly 18 months postpartum."
33070738|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
33070739|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
33234909|NCT05298423|Experimental|pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy|For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray [Gy] in 2 Gy fractions for 30 days total) during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to ~14 months). Cycles 1-20 are 21-day cycles. Investigator's choice of chemotherapy: cisplatin 75 mg/m^2 and pemetrexed 500 mg/m^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m^2 on Day 1 of Cycle 1 and 45 mg/m^2 on Days 1, 8, 15 of Cycles 2-3.
33234910|NCT05298423|Active Comparator|chemotherapy+radiotherapy+durvalumab|"For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy in 2 Gy fractions for 30 days total) during Cycles 2 and 3. Following cCRT, participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.~Investigator's choice of chemotherapy: cisplatin 75 mg/m^2 and pemetrexed 500 mg/m^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m^2 on Day 1 of Cycle 1 and 45 mg/m^2 on Days 1, 8, 15 of Cycles 2-3."
33234911|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
33234912|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
32750023|NCT05500989||Short track early PE with IUGR|"These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
32750024|NCT05500989||Short track early PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
32750025|NCT05500989||Short track late PE with IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
32908949|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
32908950|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
33234913|NCT05659121|Experimental|EksoGT group|Participants in the intervention group will receive 12 sessions of robotic exoskeleton training incorporated into their conventional physiotherapy session.
33234914|NCT05659121|No Intervention|Control group|Participants in the control group will only undergo outcome measures assessment. They will continue with their conventional physiotherapy and the frequency and type of activity at physiotherapy will be recorded.
33234915|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
33234916|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
33234917|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
33234918|NCT04027829|Experimental|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
33234919|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
33234920|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
32750026|NCT05500989||Short track late PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
32908951|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
33234921|NCT00917982|Other|Vision therapy|
33234922|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
33234923|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
33234924|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32908952|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
33070740|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
33070741|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
33234925|NCT05684913|Experimental|Zinc granulate group|The patients in this group will receive a chair-side prepared surgical stent from Zn granulates on the palatal wound after FGG surgery.
33234926|NCT05684913|Active Comparator|Hemostatic agent group|The patients in this group will receive hemostatic agent sutured on the palatal wound after FGG surgery.
33234927|NCT04102202|Experimental|BOL-DP-o-05|
33234928|NCT04102202|Placebo Comparator|Placebo|
33070742|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
33070743|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
33234929|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.~50 µg CN54gp140, intradermally without electroporation, at Week 20."
33234930|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
33234931|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
33234932|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
33234933|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
33234934|NCT05325801|Experimental|BMCA and GPRC5D dual target CAR-T cells （OriC321）|
33234935|NCT05489510|Other|Pulsed lighting|
33234936|NCT05489510|Other|Continuous lighting|
33234937|NCT00585546|Experimental|LVAD and Clenbuterol|
33234938|NCT05288283|Experimental|GWP42003-P|Participants will be initiated on a dose of GWP42003-P 2.5 milligrams per kilogram (mg/kg) twice a day (BID) (5 mg/kg/day); after 1 week, the dose will be increased to 5 mg/kg BID (10 mg/kg/day). Dose escalation up to a maximum daily dosage of 20 mg/kg/day (in increments of 5 mg/kg/day [2.5 mg/kg BID] no more rapidly than every 7 days) may occur after Day 15 based on the investigator's assessment of efficacy, safety and tolerability.
33070744|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
33070745|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
33070746|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
33070747|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
33070748|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
33070749|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
32750027|NCT05500989||Long term follow up track controls|"Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies).~Follow up 10 to 20 years postpartum."
33070750|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
33070751|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
33070752|NCT00530881|Placebo Comparator|4|
33070753|NCT00530881|Placebo Comparator|3 active, 1 placebo|
33070754|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
33070755|NCT00175149|No Intervention|2|The untreated arm
33070756|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
33070757|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
33070758|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
32750028|NCT05500989||Long term follow up track cases|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
33070759|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
33070760|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
33070761|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
33234939|NCT05288283|Placebo Comparator|Placebo|Participants will receive the matching placebo.
33234940|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
33070762|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
33234941|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
33070763|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
33070764|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
33070765|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
33070766|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
33070767|NCT05085067|No Intervention|Group A: no auto-cross linked hyaluronic acid gel|no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
33070768|NCT05085067|Experimental|Group B: infusing auto-cross linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
33234942|NCT04099550|Active Comparator|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
33234943|NCT04099550|Experimental|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
33234944|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
33234945|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
33234946|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
33234947|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
33234948|NCT05684757|Active Comparator|Dietary Advice: Sweet Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in sweet taste, eg. fruit, low-calorie sweetened foods and drinks. The intervention will be provided to participants in written form, in an opaque sealed envelope.
33234949|NCT05684757|Active Comparator|Dietary Advice: Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in taste, eg. nuts, foods and drinks flavoured with herbs and spices. The intervention will be provided to participants in written form, in an opaque sealed envelope.
32750029|NCT05500911|Active Comparator|NINA- MultiNeO NH|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) treatment group will be treated with a bioactive surfaced implant (NINA MultiNeO NH)
32750030|NCT05500911|Active Comparator|MultiNeO CS|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) control group will be treated with a traditional implant surface (MultiNeO CS)
33234950|NCT05684757|Active Comparator|Dietary Advice: No taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that are low in taste, eg. foods and drinks that are plain-flavoured, wholegrains. The intervention will be provided to participants in written form, in an opaque sealed envelope.
33234951|NCT05486390|Experimental|Intervention|
32750031|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
32750032|NCT04639245|Experimental|Treatment (FH-MagIC TCR-T cells, atezolizumab)|"LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.~T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.~In the Phase 2 portion of the study, atezolizumab will be administered as standard of care beginning 24-72 hours after T-cell infusion. Atezolizumab will be given IV every 3 weeks for at least 1 year in the absence of disease progression or unacceptable toxicity. An alternative PD1 inhibitor may be substituted if atezolizumab (preferred) is not available."
32750033|NCT05503407|Experimental|Baseline V-RESOLVE score-guided PCI|"Lesions with baseline V-RESOLVE <14 scores would undergo either jailed wire technique (diameter of side branch [SB]<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of SB≥2.5mm);~Lesions with baseline V-RESOLVE ≥14 scores would undergo either jailed balloon technique (diameter of SB<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of SB≥2.5mm)."
32750034|NCT05503407|Placebo Comparator|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
32750035|NCT04596579||Participants age 18-34|Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
32750036|NCT04596579||Participants age 35-54|Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
33234952|NCT05486390|No Intervention|Control|
33234953|NCT04084431|Active Comparator|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
33234954|NCT04084431|Experimental|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
33234955|NCT04103684|Experimental|Patients will receive steroid pulse therapy|
33234956|NCT04103684|Active Comparator|Patients will receive low dose steroids|
33234957|NCT04084275|Experimental|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
33234958|NCT04084275|No Intervention|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
33234959|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
33234960|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
33394080|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
32750037|NCT04596579||Participants age 55-64|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
33234961|NCT00775268|Experimental|Group A - Participants Scanned at Baseline & After Chemotherapy|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fluorodeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
33234962|NCT00775268|Experimental|Group B - Participants Scanned in the Evaluation of Residual Masses After Therapy|Patients who have completed treatment in whom FDG-PET shows a remaining tumor mass undergo an FLT PET/CT scan . Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
33234963|NCT05257629|Active Comparator|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Patients in the combination therapy arm will be supplied funds and instructions for the purchase of e-cigarettes and cartridges/pods upon hospital discharge and at the week 4 and 12 clinic visits. As with standard NRTs such as the gum, inhaler, and lozenge, we expect smokers will self-regulate administration according to their withdrawal symptoms. Use will be monitored via self-report for telephone follow-ups. At clinic visits, patients will be asked to bring their e-cigarettes, used and unused cartridges/pods, and purchasing receipts. Patients will be advised regarding the signs and symptoms of nicotine toxicity and of an allergic reaction.
33394081|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
33394082|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
32750038|NCT04596579||Participants 65 and over|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
32750039|NCT04465461|Experimental|Treatment|Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
32750040|NCT04619901||Parents only|
32750041|NCT04619901||Children and Parents|
32750042|NCT04465383|Experimental|Digital Sedation|Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
32750043|NCT04465383|Active Comparator|Intravenous sedation|Control arm with conventional Intravenous sedation
32750044|NCT04388865|Experimental|Control|Usual Care
32750045|NCT04388865|Experimental|Clinical Hovering|Remote monitoring with feedback to social support
32750046|NCT05500755||Patients DS Prime Taper|Patients who receive al least one DS Prime Taper on his dental implant treatment.
32750047|NCT05500677|Active Comparator|Lidocaine|10% lidocaine spray was applied on the broken rib from a distance of 10 cm, 1-2 puffs. Each puff contains 10 mg of lidocaine.
32750048|NCT05500677|Active Comparator|Tramadol|100 mg of tramadol hydrochloride was placed in 150 cc isotonic saline and given as a 15-minute intravenous infusion.
32750049|NCT05500677|Active Comparator|Fentanyl|50 mcg of fentanyl citrate was given as a 15-minute intravenous infusion in 150 cc isotonic.
32750050|NCT04361955|Other|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
33070769|NCT05061706|Experimental|Lumateperone 42 mg|
32750051|NCT04361955|Other|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
32750052|NCT04361955|Other|ET with DBS on|intervention is EEG while performing tasks and at rest
32750053|NCT04361955|Other|ET with DBS off|intervention is EEG while performing tasks and at rest
32750054|NCT04331535|Experimental|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
32750055|NCT04331535|Active Comparator|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
32750056|NCT04331535|Experimental|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
32750057|NCT04331535|Active Comparator|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
32750058|NCT04511013|Experimental|Arm I (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32750059|NCT04511013|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
32750060|NCT04198779|Experimental|APPLI|Care support with implementation of the application
33070770|NCT05061706|Placebo Comparator|Placebo|
32750061|NCT04198779|No Intervention|CONTROL|Conventional care support
33070771|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
33070772|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
33070773|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
32750062|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
32750063|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count <800 / µl or serum CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml will be included in group II.
32750064|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (> 125 / min) or respiratory distress or tachypnea (> 22 / min) or hypotension <90/60 mmHg or SPO2 <93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
32750065|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
32750066|NCT04698070|Active Comparator|Standard|RUTF 130-200 kcal/kg/day for children with nutritional edema or MUAC < 115 mm or WHZ <-3 and RUSF 500 kcal/d for children 6-23 months with WHZ between -2 and -3 Z and MUAC 115-124 mm.
32750067|NCT04698070|Experimental|OptiMA|RUTF 170 kcal/kg/d for children with nutritional edema or MUAC < 115 mm; 125 kcal/kg/d for MUAC 115-119 mm and 75 kcal/kg/d for MUAC 120-124 mm.
32750068|NCT04698070|Experimental|ComPAS|RUTF 1000 kcal/d for children with nutritional edema or MUAC < 115 mm and 500 kcal/day for MUAC 115-124 mm.
32750069|NCT04697602|Experimental|Dose titration group|Stepwise dose titration of febuxostat and low-dose colchicine
32750070|NCT04697602|Active Comparator|Standard treatment group|Fixed dose febuxostat and low-dose colchicine
32750071|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
32750072|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
32908953|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
32908954|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
33394083|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
33394084|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
33394085|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
33394086|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
33394087|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
33394088|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
33394089|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
32750073|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
32750074|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
32750075|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
32908955|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
32908956|NCT05593874||Diabetic foot ulcer with osteoarticular infections|Diabetic patients suffering from ulcer that led to an osteoarticular infection (e.g. chronic osteomyelitis, septic arthritis)
32908957|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
32908958|NCT03425006|Experimental|Itacitinib and Pembrolizumab|
32908959|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
32908960|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
32908961|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
32908962|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
33394090|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
33394091|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
33394092|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
32750076|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
33394093|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
33234964|NCT05257629|Other|Varenicline Plus Counseling|All patients will begin varenicline in-hospital upon randomization. For the first 3 days, patients will take a 0.5 mg tablet once a day. They will then take a 0.5 mg tablet twice a day for the following 4 days, and one 1 mg tablet twice a day from day 8 onward for the remainder of the 12-week treatment. Use will be monitored via self-report for telephone follow-ups and return of all unused tablets at the end of the treatment period. Should a patient experience severe side effects (such as headache, nausea, vomiting, dizziness, dyspepsia, fatigue, insomnia, abnormal dreams, constipation, or flatulence) on day 8 onward, the varenicline dose should be reduced from 1 mg twice daily to 0.5 mg twice daily prior to study medication discontinuation.
33234965|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
33394094|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
33234966|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
33234967|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
33234968|NCT00479557|Active Comparator|2|arm 2: ACC-001
33234969|NCT00479557|Placebo Comparator|3|arm 3: QS-21
32750077|NCT04721158|Other|CGM Arm|Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.
33070774|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
33070775|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
33234970|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
33234971|NCT04099472|Placebo Comparator|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
33234972|NCT04099472|Experimental|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
33234973|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
33234974|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
33241617|NCT04223960|Experimental|Part A: SAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 of SAD part of the study. There will be a maximum of six dose levels (three planned and three optional cohorts) per formulation.
33241618|NCT04223960|Experimental|Part A: FE and Optional BA in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to eight- way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
33241619|NCT04223960|Experimental|Part A: FE and Optional BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to four-way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
32750078|NCT04417582||life syte modification only|obese patients followed with life style modification
32750079|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
32750080|NCT04417582||bariatric surgery|patients undergone bariatric surgery
33234975|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
33234976|NCT05254743|Experimental|Pirtobrutinib|Administered orally.
32750081|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
32750082|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
32750083|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
33234977|NCT05254743|Experimental|Ibrutinib|Administered orally.
33234978|NCT00479167|Experimental|Bortezomib and Tositumomab I-131|
33234979|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
33234980|NCT00725712|Experimental|daily dosing|dosed every day
33234981|NCT05253651|Experimental|Tucatinib Arm|Tucatinib + trastuzumab + mFOLFOX6
32750084|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
33234982|NCT05253651|Active Comparator|Standard of Care Arm|mFOLFOX6 + (bevacizumab OR cetuximab). Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab
33234983|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
33234984|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
33234985|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
33234986|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
33234987|NCT05246787|Experimental|Breastfeeding intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. If necessary, the researcher may verbally warn the mother in a calm tone to continue breastfeeding throughout the procedure. During the resting period (last 2 minutes) after the blood draw is completed, the baby stays on the mother's lap.
33234988|NCT05246787|Experimental|Shotblocker intervention|2 minutes before the procedure, the baby will be placed on the mother's lap. ShotBlocker is a small plastic tool that is blunt, short, has many points in contact with the skin, does not contain drugs, is in the shape of a horseshoe, invasive interventions can be applied through the space in the middle. It is positioned on the skin before the invasive procedure. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
33234989|NCT05246787|Experimental|Breastfeeding and Shotblocker intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
33234990|NCT05246787|No Intervention|Control group/ Standard Care|The baby is placed on the mother's lap 2 minutes before the procedure and the mother is provided to hold the baby effectively and graspingly. Standard heel lance procedure is applied. No additional interventions are applied to the baby. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
33234991|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
33234992|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
33234993|NCT04087824|Experimental|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
33234994|NCT05232825|Active Comparator|Ocrelizumab: Intravenous (IV) formulation|Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 48 weeks of study treatment.
33234995|NCT05232825|Experimental|Ocrelizumab: Subcutaneous (SC) formulation|Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 48 weeks of study treatment.
33234996|NCT00725322|Experimental|Placebo then Botox|
33234997|NCT00725322|Experimental|Botox then Placebo|
33234998|NCT04084197|Experimental|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
33234999|NCT04084197|Experimental|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
33235000|NCT04084197|Experimental|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
32750085|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
32750086|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
32750087|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
32750088|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
32750089|NCT04731688|Experimental|Weight Maintenance Group|Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.
32750090|NCT04731688|No Intervention|Provider Directed Group|Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.
32750091|NCT04695730|Active Comparator|Active physical therapy|Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
32908963|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
33235001|NCT04084197|Experimental|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
33235002|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
33235003|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
33235004|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
33235005|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
33235006|NCT05228457|Active Comparator|Active Transcranial Magnetic Stimulation|Active Intensive iTBS involves intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over the left dorsal lateral prefrontal cortex (L-DLPFC).
33235007|NCT05228457|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham Intensive iTBS involves using the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the TMS pulse, which mimics the scalp sensation from active stimulation.
33235008|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
33235009|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
33235010|NCT05684601|Placebo Comparator|rotating drills device|Third molar surgery performed with traditional rotating devices
33235011|NCT05684601|Active Comparator|Piezoelectric device|Third molar surgery performed with piezoelectric surgery device
33241620|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
33241621|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
33235012|NCT05216055|Experimental|Investigational Arm|"The study drug volume, concentration, and dose of treatment arm #1 selected is based on the Principal Investigator's prior experience recommendations by the Food Drug Administration (FDA), and evidence based on prior literature. The final concentration of ropivacaine is 0.375% and final volume of the mixture is 60mL.~Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg)~Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug)~Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg)~Normal saline 0.9%, 18.5mL"
32750092|NCT04695730|Experimental|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
32750093|NCT04417270|Other|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
33235013|NCT05216055|Active Comparator|Liposomal Bupivacaine (Exparel)|"The study drug for patients in the treatment arm #2 will be a mixture of liposomal bupivacaine and bupivacaine 0.25% as follows:~Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg)~Normal saline 0.9%, 40mL The total volume to be injected in each patient will be 60 mL (see below for different treatment arms)."
33235014|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
32750094|NCT04417270|Other|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
32750095|NCT04417348|Active Comparator|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
32750096|NCT04417348|Placebo Comparator|Sunscreen|patients with melasma treated with UV-Visible light filter alone
32750097|NCT04720300|Active Comparator|MaaS app|The Mobility-as-a-Service (MaaS) App will be provided to students in the Intervention Group and is intended to facilitate their use of alternative transportation modes such as public transit, ride-hailing, walking, biking, bike share, and e-scooter share to get to campus. The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app. This means, for instance, that a student can plan a trip that includes driving to a train station, taking the train, and then walking from the alighting train station to their final destination. The app will be white label, i.e. it will have a customized look and feel specific to the participating south Florida colleges, and it will have personalization features so that students can tailor the app to their travel patterns. Students in a cluster assigned to the MaaS group will also receive information concerning housing options. Students complete surveys
32750098|NCT04720300|Placebo Comparator|No app|Students receive no app, no housing information, students complete surveys.
32750099|NCT02058940|Experimental|Exenatide|
33235015|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
33235016|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
32750100|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
32750101|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
32750102|NCT04694638|Experimental|HFNC and NIPPV|Combined use of prone positioning and non-invasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC)
32750103|NCT04731610|Other|Post-operative radiotherapy|Tumour resection followed by radiotherapy.
32750104|NCT04731610|Other|Surveillance after tumour resection|Tumour resection
32750105|NCT04731298|Experimental|Emapalumab|"The first cohort of patients will receive a first infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days (treatment day 3 - TD3). Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment.~A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s). Efficacy and safety data will also be considered before adding additional cohorts."
32750106|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
32750107|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
32750108|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
32750109|NCT02090764|Placebo Comparator|Placebo|Placebo cream
32750110|NCT04718896|Experimental|Bimekizumab Dose A|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
33235017|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
33235018|NCT00767000|Experimental|MK-0941 10 mg|
33235019|NCT00767000|Experimental|MK-0941 20 mg|
33235020|NCT00767000|Experimental|MK-0941 30 mg|
33235021|NCT00767000|Experimental|MK-0941 40 mg|
33235022|NCT00767000|Placebo Comparator|Placebo|
33235023|NCT05194449|Experimental|Comfort Talk® App (Cft) Group|Mobile app with elements of relaxation, self-hypnosis, and reframing of distress
33235024|NCT05194449|Placebo Comparator|Placebo Group|Mobile app with white noise choices having the same looks and functionality as the active Comfort Talk® 1st app
33235025|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
33235026|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
33235027|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
33235028|NCT05684445|Experimental|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
32750111|NCT04718896|Experimental|Bimekizumab Dose B|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
32750112|NCT04718506|Experimental|Exercise|Supervised exercise training
32750113|NCT04718506|Experimental|Inspiratory muscle training|Non-supervised inspiratory muscle training protocol
32750114|NCT04718506|Active Comparator|Controls|Non-supervised WHO exercise guidelines
32750115|NCT04730830|Experimental|Only experimental arm|Only experimental arm. Patients filling out questionnaires.
32750116|NCT02057692|Experimental|LUM001|LUM001 for oral administration
32750117|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
32750118|NCT02038036|Experimental|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
32750119|NCT02038036|Active Comparator|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
32750120|NCT04693234|Other|Tislelizumab and Ociperlimab (BGB-A1217) Combination (Cohort 1)|Participants will receive tislelizumab 200 milligrams (mg) on Day 1 followed by the administration of ociperlimab (BGB-A1217) 900 mg of each 21-day cycle.
32750121|NCT04693234|Other|Tislelizumab Monotherapy (Cohort 2)|Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle
32750122|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
32750123|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
32750124|NCT02088034|Experimental|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
32750125|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
32750126|NCT02088034|Active Comparator|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
32750127|NCT02037256|Experimental|A Treatment (bortezomib and filgrastim)|GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
32750128|NCT02037256|Experimental|B Treatment (bortezomib and filgrastim)|GROUP B: Bortexomib administered on days 4 & day 7, before administration of filgrastim.
32750129|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
32750130|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
32750131|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
32750132|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
32750133|NCT02057458|Experimental|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
32750134|NCT02057458|Experimental|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
32750135|NCT02057458|Experimental|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
32750136|NCT04717804|Active Comparator|AIP (Average Intensity Projection) CT (Computed Tomagraphy)|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
32750137|NCT04717804|Placebo Comparator|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
32898245|NCT03527719|No Intervention|Control Group|Village doctors in usual care group will not receive hypertension management training or support. However, they will be trained in standardized BP measurement. Participants in control group will receive their usual care from village doctors or primary care physicians in township hospitals
32898246|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
32898247|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
33235029|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
33070776|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
32750138|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~. SLEEP-E Dyads book~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
32750139|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
33235030|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
33235031|NCT04083807|Experimental|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
33235032|NCT04083807|Active Comparator|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
33235033|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
33235034|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
33235035|NCT05188989|Experimental|TPN171H 2.5mg group|
33235036|NCT05188989|Experimental|TPN171H 5mg group|
33235037|NCT05188989|Experimental|TPN171H 10mg group|
33235038|NCT05188989|Placebo Comparator|Placebo group|
33235039|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
32908964|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
32908965|NCT00998660|Experimental|Patients receiving an Activa RC implant|
32908966|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
32908967|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
32908968|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
33070777|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
33235040|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
33235041|NCT02589249|Placebo Comparator|Placebo|placebo
33235042|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
33235043|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
33235044|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
33235045|NCT02589327|No Intervention|Control|No-exercise control group
33235046|NCT04103918|Other|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
33235047|NCT05183685|Experimental|Intervention group|The participants will receive alternative telecare consultation and face to face consultation every 14 weeks.
33235048|NCT05183685|Placebo Comparator|Control group|The participants will receive usual face to face consultation every 14 weeks.
33235049|NCT04022018|Experimental|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
33235050|NCT04022018|Active Comparator|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
33235051|NCT04084041|Experimental|Device|Device group
33235052|NCT04084041|Active Comparator|Conventional chest physiotherapy|Control group
33235053|NCT00916214|Experimental|Intervention|
33235054|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
33235055|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
33235056|NCT05167695|Experimental|Habit-based Sleep Health Intervention (HABITs)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x20-minute weekly sessions.~Participants in this group will not receive the texts discussed below."
33235057|NCT05167695|Experimental|Habit-based Sleep Health Intervention plus text messages (HABITs+texts)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x20-minute weekly sessions.~Additionally, participants in this group will receive the text messaging intervention."
33235058|NCT05163483|Experimental|Tucidinostat (chidamide), PD-1 inhibitor （Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
33235059|NCT05163093||Angle closure glaucoma patients with or without abnormal zonular.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
33235060|NCT05163093||Patients with age-related cataract.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
32750140|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
32750141|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
32750142|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
33070778|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
33070779|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
33070780|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
33070781|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
33235061|NCT05511038|Experimental|Aflibercept|Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration
33070782|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
33070783|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
33235062|NCT05161533|Experimental|Treatment (durvalumab, chemotherapy, radiation therapy)|"INDUCTION: Patients receive standard of care chemotherapy consisting of carboplatin or cisplatin and etoposide. Patients also receive durvalumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive durvalumab IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning cycle 5 or 6 of durvalumab, patients undergo hypofractionated radiation therapy."
33235063|NCT00587054|Experimental|Transplant Patients|
32750143|NCT02056288|Active Comparator|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
32750144|NCT02056288|Active Comparator|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
32750145|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
32750146|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
32750147|NCT02701283|Experimental|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
32750148|NCT02701283|Active Comparator|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
32750149|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
32750150|NCT03115697|Active Comparator|Lactulose with Rifaximin|
33070784|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
33070785|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
33070786|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
33070787|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
33070788|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
33070789|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
33070790|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
33070791|NCT02939443|Other|cross-sectional study|
33235064|NCT04083729|Active Comparator|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
33235065|NCT04083729|Active Comparator|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
33235066|NCT00766142|Experimental|Chemotherapy + Cetuximab|Surgery + Chemotherapy + Cetuximab
33235067|NCT05152563|Experimental|SC 150 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.
33235068|NCT05152563|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 300 mg of lirentelimab (AK002) administered subcutaneously.
33235069|NCT05152563|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.
33235070|NCT05152563|Other|Placebo|Placebo
33241622|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
33235071|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
33235072|NCT05147649|Active Comparator|non-OSAS patients|Patients without OSAS (Apnea-Hypopnea Index (AHI) < 15/h and absence of excessive daytime sleepiness with Epworth score <11)
33394095|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
33394096|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
33394097|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
33394098|NCT04488328|Experimental|Magnetic Therapy Group|patients received the routine medical treatment (Bisphosphonates, Calcium, and Vitamin D) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks
33394099|NCT04488328|Experimental|Exercise group|patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks
33235073|NCT05147649|Experimental|OSAS patients|Patients with severe OSAS with an Apnea-Hypopnea Index (AHI) > 30/h
33235074|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
33394100|NCT04488328|Experimental|Combined Magnetic Therapy and Exercise Therapy group|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
33235075|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
33235076|NCT04023734|Experimental|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
33235077|NCT04023734|Active Comparator|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
33235078|NCT05527964||Patients with severe refractory atopic dermatitis|Patients eligible for Dupixent therapy of AD
33235079|NCT04083651|Experimental|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
33235080|NCT04083651|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
33235081|NCT00728988|Experimental|Atorvastatin Group|
33235082|NCT00728988|Other|Usual Care Group|
33235083|NCT05133531|Experimental|Ravulizumab|Randomized 1:1
33235084|NCT05133531|Experimental|Pozelimab and Cemdisiran|Randomized 1:1
32898248|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
33235085|NCT05130957|Experimental|Experimental Group|The pregnant women in the experimental group are given a massage with clove oil.
33235086|NCT05130957|Other|Control Group|The pregnant women in the control group are given a massage without any oil as standard midwifery care
33235087|NCT05129241||Cohort 1|Patients for whom the treating physician has decided to initiate lipid-lowering treatment with the PRALUENT® 2 ml SYDNEY auto-injector, irrespective of participation in the study
33235088|NCT04087746|Active Comparator|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
33235089|NCT04087746|Active Comparator|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
33235090|NCT05128929|Experimental|Experimental Treatment Oral Hymecromone (H01)|Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.
33235091|NCT05128929|Placebo Comparator|Placebo|Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) two times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.
33235092|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
33235093|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
33235094|NCT05684133||Patients with Sepsis|Adult patients (18 years or older) meeting Sepsis-3 criteria within 6 hours of emergency department admission. Patients will be excluded with the following conditions: traumatic injury, cardiac arrest, stroke, comfort measures only.
33235095|NCT04083417|Active Comparator|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
32750151|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
32750152|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
32750153|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
32750154|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
32750155|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
32750156|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
32750157|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
32750158|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
32750159|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
32750160|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
32750161|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
32750162|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
32750163|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
32750164|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
32750165|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
32750166|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
32750167|NCT03170687|Experimental|foot cast|
32750168|NCT03170687|Active Comparator|short leg cast|
32750169|NCT03170531||Custom MR spine coil|
32750170|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
32750171|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
32750172|NCT04481633|Other|Patient treated with Hydroxy-chloroquine|patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
32750173|NCT04481633|Other|Patient without treatment with Hydroxy-chloroquine|patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
32750174|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
32750175|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
32750176|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
32750177|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
33394101|NCT04488172|Experimental|Epilepsy subjects|Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial
32750178|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
32750179|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
32908969|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
33072435|NCT05089734|Active Comparator|Docetaxel|Participants will receive docetaxel 75 mg/m^2 on Day 1 of a 21-day cycle (ie, once every 3 weeks) until PD, death, unacceptable toxicity, or another treatment discontinuation criterion is met.
32750180|NCT04481867|Active Comparator|intervention arm :densah bur group|at the maxillary molar area for implant placement ,,just after making initial drilling perforation close to the sinus floor, the direction of the drill is reversed and the cutting speed is raised to 1200 rpm, then 2 successive densah burs are used to elevate sinus membrane 2 mm and to prepare implant hole to the selected implant size .for both groups the selected implant size, 4.2 mm width and 10 mm. length
32750181|NCT04481867|Other|control group :osteotome group|at the maxillary molar area for implant placement .a set of concave osteotomes with different dimensions sequentially used to widen the osteotomy site by surgical mallet. Osteotome 2.5 mm is inserted into the osteotomy firstly to a depth of 1 mm away from the sinus floor with light malleting by the nylon cap mallet then 3 mm osteotome is used to fracture up the sinus floor and finally 3.5 mm osteotome is tapped gently to elevate the sinus floor to the desired depth of the implant in the maxillary sinus.
33394102|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
33394103|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
33394104|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
33235096|NCT04083417|Experimental|No antibiotic treatment group|Patients randomized to no antibiotic treatment
33235097|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
32750182|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
32750183|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
32750184|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
33235098|NCT05125809|Experimental|Low Dose Setrusumab -> Open-Label (OL) Setrusumab Selected Dose|"Single-blind setrusumab low dose during phase 2 followed by open-label setrusumab selected dose~During treatment and treatment extension periods, participants will receive daily supplementation with calcium and vitamin D as directed by the treating physician"
33235099|NCT05125809|Experimental|High Dose Setrusumab -> OL Setrusumab Selected Dose|"Single-blind setrusumab high dose during phase 2 followed by open-label setrusumab~During treatment and treatment extension periods, participants will receive daily supplementation with calcium and vitamin D as directed by the treating physician"
33235100|NCT05125809|Experimental|Setrusumab Selected Dose -> OL Setrusumab Selected Dose|"Double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants will receive daily supplementation with calcium and vitamin D as directed by the treating physician"
33235101|NCT05125809|Placebo Comparator|Placebo -> OL Setrusumab Selected Dose|"Double-blind placebo during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants will receive daily supplementation with calcium and vitamin D as directed by the treating physician"
33235102|NCT02588937|Experimental|EntecaBell ODT.|
33235103|NCT02588937|Active Comparator|Baraclude Tab.|
32750185|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
32750186|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
32750187|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
33235104|NCT04083105|Experimental|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
33235105|NCT04083105|Experimental|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
33235106|NCT05112003|Experimental|TLNS|Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
33235107|NCT05112003|No Intervention|Control|No TLNS
33235108|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
33235109|NCT05111613|Active Comparator|Randomized Controlled Trial Cohort - FlowTriever Arm|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
33394105|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
33394106|NCT03237442|Experimental|group 1|
33394107|NCT03237442|Active Comparator|group 2|
33394108|NCT04488016|Experimental|Cohort 1 -Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
33394109|NCT04488016|Experimental|Cohort 2- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
32750188|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
32750189|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
32750190|NCT02700815|Active Comparator|Diclofenac|
32750191|NCT02700815|Active Comparator|Capsaicin|
32750192|NCT02700815|Placebo Comparator|Placebo|
32750193|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
32750194|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
32750195|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
33235110|NCT05111613|Active Comparator|Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
33235111|NCT05111613|Other|Non-Randomized Absolute Contraindication to Thrombolytics Cohort|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
32750196|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
32750197|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
32750198|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
32750199|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
32750200|NCT02402855|Experimental|Group Intervention: Financial support|
32750201|NCT02402855|Active Comparator|Group Control: no financial support|
32750202|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
32750203|NCT02402621|Experimental|Model based analgesic group|fentanyl
32750204|NCT04481789|Experimental|Rosuvastatin, Sildenafil, and MT-1186|"Group 1 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively."
32750205|NCT04481789|Experimental|Furosemide and MT-1186|"Group 2 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6."
32750206|NCT04481789|Experimental|MT-1186|"Cohort 2:~A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule."
32750207|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
32750208|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
32750209|NCT02402387|Experimental|Extended|The patient's head will be extended.
32750210|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
33235112|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
33235113|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
33235114|NCT02591862|Other|Coversin|"This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given."
33235115|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
33235116|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
33235117|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
32750211|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
32750212|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
32750213|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
33235118|NCT00478231|Experimental|1|
33235119|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
33235120|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
33235121|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
33235122|NCT05095233|Experimental|Young Adults Culturally Adapted Therapy for Suicidal Prevention|Young Adults Adapted Manual Assisted Psychological Therapy for Suicide Prevention
33241623|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional).
33241624|NCT04223960|Experimental|Part A: MAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional) per formulation.
33241625|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
33241626|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
32750214|NCT04481711|Experimental|Study group|Twenty-nine patients (female/male: 24/5) with grade 4 osteoarthritis were included in the study group. These patients underwent total knee arthroplasty
32750215|NCT04481711|No Intervention|Control group|Twenty-two patients (female/male:13/9) with <grade 4 osteoarthritis were included in the control group.
32750216|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
32750217|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
32750218|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
32750219|NCT02402075||Brain tumor|patients with glioma
32750220|NCT02401841||Sugammadex|Patients treated with Sugammadex
32750221|NCT02401841||Neostigmine|Patients treated with Neostigmine
33235123|NCT05095233|Active Comparator|MINPLAN TOOL|Research has shown that user engagement, rather than the modality of therapy is the key to achieving successful outcomes and given that just 50% and 13% of patients currently have a choice of when and where they receive therapy, self-help tool apps Like MIN PLAN may not only be equally effective as some forms of traditional psychotherapy but also provide a flexible and pragmatic means of increasing patient access, through removing barriers to treatment that do not respond to financial impetus.
33235124|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
32750222|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
32750223|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
32750224|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
32750225|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
33235125|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
32750226|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
32750227|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
33235126|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
33235127|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
33235128|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
33235129|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
33235130|NCT00474175|Placebo Comparator|1|Placebo control
33235131|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
33235132|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
33235133|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
33235134|NCT05075577|Experimental|Phase 1 Cohort 1|600 mg QD EPI-7386 in combination of Enzalutamide120 mg
33235135|NCT05075577|Experimental|Phase 1 Cohort 2|800 mg QD EPI-7386 in combination of Enzalutamide120 mg
33235136|NCT05075577|Experimental|Phase 1 Cohort 3|600 mg BID EPI-7386 in combination of Enzalutamide120 mg
33235137|NCT05075577|Experimental|Phase 1 Cohort 4|RP2D mg EPI-7386 in combination of Enzalutamide160 mg
33235138|NCT05075577|Experimental|Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)|RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
33235139|NCT05075577|Active Comparator|Phase 2 Enzalutamide single agent|Enzalutamide 160 mg
33235140|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
33235141|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
33235142|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
33235143|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
33235144|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
33235145|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
33235146|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
33235147|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
33235148|NCT05064579||Patients with asthma|Children and adolescents aged 8 to 17 years old with a doctor's diagnosis of asthma and controller asthma treatment
33235149|NCT05064579||Holders of parental authority|Holders of parental authority of patients with asthma described in group A
33235150|NCT05064579||Doctors|Doctors caring for patients with asthma described in group A
33235151|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
33235152|NCT01020643|Experimental|controlled sedation using propofol|
33235153|NCT05062161|Experimental|Sleep Hygiene/Extension Intervention|Participants with short sleep duration will receive a 60-minute educational session on sleep hygiene/extension. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts and/or complete questionnaires about sleep. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
33235154|NCT05062161|Active Comparator|Control Condition|Participants with short sleep duration will receive a 60-minute educational session on sleep physiology. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
33235155|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~Whole-body contrast enhanced computer tomography~Planar bone scintigraphy~Novel imaging (investigational imaging);~SPECT/CT (investigational imaging)~18F-PSMA-PET/CT (investigational imaging)~Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
33235156|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
33235157|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
33235158|NCT05053191|Experimental|Nurses|MSKCC day-shift nurses (Clinical Nurse I to IV) assigned to the GI inpatient unit (MH16) at the time of study, all of whom provide initial and ongoing assessment of patients' physical, psychosocial, cultural and informational needs
33235159|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
33235160|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
33235161|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
33235162|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
33235163|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
33235164|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
33235165|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
33235166|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
33235167|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
33235168|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
33235169|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
33235170|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
33235171|NCT05045391||pulmonary tuberculosis (smear-positive) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-positive)
33235172|NCT05045391||pulmonary tuberculosis (smear-negative) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-negative)
33235173|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
33235174|NCT05036733|Experimental|Dupilumab|
33235175|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
33235176|NCT05034939|Active Comparator|FLEX Vessel Prep System followed with PTA (TEST arm)|FLEX Vessel Prep System is used to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion. Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
33235177|NCT05034939|Active Comparator|PTA only (CONTROL arm)|Standard Balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
33235178|NCT05030649|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
33235179|NCT05030649|Active Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
32750228|NCT04481477||Patients COVID-19|Patients over the age of 18 who were admitted with a diagnosis of COVID-19 to any CCSPT unit between March 13, 2020 and April 30, 2020 and were discharged with a recovery result
33235180|NCT04082715|Experimental|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
33235181|NCT04082715|Placebo Comparator|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
32750229|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
32898249|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
33394110|NCT04488016|Experimental|Cohort 3- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
32750230|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
32750231|NCT05232305|Experimental|People with type 2 diabetes who eat bread with pomegranate crust - Experimental Group|"Individuals with type 2 diabetes who met the inclusion criteria and participated in the study will divided into two groups by Specialist Akkız Zuhal ÖZTAŞ and Specialist Doctor Emel ŞENOL, and they will be asked to consume the breads produced (in the preliminary study) produced as a standard (n=15) and with the addition of pomegranate peel (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of bread during the study and will be contacted weekly by Zeynep ÇAMLIK, a specialist dietitian, to verify whether they consume bread regularly."
32750232|NCT05232305|No Intervention|No intervention - Control Group|Individuals with type 2 diabetes will not eat pomegranate crust bread
32750233|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
32750234|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
32750237|NCT04897763|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
32750238|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
32750239|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
32750240|NCT03169205||preexisting Diabetes mellitus type 1|
32750241|NCT03169205||preexisting Diabetes mellitus type 2|
32750242|NCT03169205||Gestational Diabetes mellitus|
32750243|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
32750244|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
32750245|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
32750246|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
32750247|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
32750248|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
32750249|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
32750250|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
32750251|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
32750252|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
32750253|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
32750254|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
33235182|NCT04082715|Placebo Comparator|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
33235183|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
33235184|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
33235185|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
33235186|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
32750255|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
32750256|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
32750257|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
32750258|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
32750259|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
32750260|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
32750261|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
32750262|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile~Overweight before 10 years of age~Informed consent from both obese children subject and legal representative e.g. parents"
32750263|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:~Must be parent or direct sibling of obese subject~Informed consent from both subject and parent is subject is below 21 years of age"
32750264|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
32750265|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
32750266|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
32750267|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
32750268|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
32750269|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
32750270|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
32898250|NCT03507452|Experimental|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
33235187|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
33235188|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
33235189|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
33235190|NCT05025267|Other|Enteral Tube-fed Adults|Adults being fed an enteral formula with a feeding tube
33235191|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
33235192|NCT05023551|Experimental|Single arm DSP-0390|Arm Description [*] DSP-0390 by oral administration
33235193|NCT05023317|Experimental|Strengths-based linkage to alcohol care (SLAC)|SLAC is a behavioral intervention designed to link persons with substance use/misuse to a care or help option
33235194|NCT05023317|Active Comparator|Usual care|Usual care consists of brief intervention in primary care and/or standard referral to more intensive alcohol care (e.g., outpatient/inpatient, pharmacotherapy)
33235195|NCT05015985|Active Comparator|MUSIC-CARE Group|"In the Music-Care group, a program of music therapy was administered through a hardware and software provided to the investigative team by the Music-Care Company. The standardized techniques include three sequences in which the relaxing, maintenance and simulating times differ.~Music-Care utilizes the U technique designed to gradually relax the listener. In the current study, music sequences during patients' sessions were based on the mount U, and instrumental musical works were selected for a varying numbers styles (classical, jazz, world music, etc.) and adapted to the patient's style via patient request."
33235196|NCT05015985|Sham Comparator|CONTROL group|In the control group, a music program from an established playlist with various instrumental music is chosen by the patient and delivered by the same tablet.
33235197|NCT04082793|Experimental|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
32744952|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
32744953|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
32744954|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:~Verum- Experimental Sham- Sham comparator"
33235198|NCT04082793|Experimental|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
32908970|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
33235199|NCT04996875|Experimental|CGT9486|
32744955|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
33235200|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
33235201|NCT01021189|Experimental|1|AZD1446
33235202|NCT01021189|Placebo Comparator|2|Placebo
33235203|NCT04993755|Experimental|TPN-101, 400 mg/day|
33235204|NCT04993755|Placebo Comparator|Placebo|
33235205|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
33235206|NCT01031485|Placebo Comparator|Standard spread|
33235207|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
33235208|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
32744956|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
32744957|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
32744958|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
33235209|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
33235210|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
33235211|NCT04992273|Experimental|≥20 kg to <40 kg|SC administration
32744959|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
32744960|NCT04496843||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings HWA09 Device and overnight PSG
32744961|NCT04496765||< 40 years|Patients with rectal cancer ageing 40 years or less
32744962|NCT04496765||> 40 years|Patients with rectal cancer ageing more than 40 years
33235212|NCT04992273|Experimental|≥10 kg to <20 kg|SC administration
32744963|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
32744964|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
32744965|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
32744966|NCT02610777|Active Comparator|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
32750271|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
32750272|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
32750273|NCT02400827||cryopreservation|
32908971|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
32908972|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
32908973|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
32908974|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
32908975|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
32908976|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
32750274|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
32750275|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
32908977|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
33235213|NCT04992273|Experimental|≥5 kg to <10 kg|SC administration
32908979|NCT04927104|Experimental|PEEK Knee Prosthesis|In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis.
32908980|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
32908981|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
32908982|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
32908983|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
32908984|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
32908985|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
32750276|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
32750277|NCT02418065|Other|control group|oral nutritional supplementation
32908986|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
32908987|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
32908988|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
32908989|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
32908990|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
33235214|NCT04992273|Experimental|≥3 kg to <5 kg|SC administration
33235215|NCT05683509|Active Comparator|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
33235216|NCT05683509|Active Comparator|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane alone
33235217|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
32750278|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:~10 mls 0.5% bupivacaine hydrochloride and~20 mg of Depomedrol (hydrocortisone)~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
32750279|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
32750280|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
32750281|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
32750282|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
32750283|NCT05058443|Experimental|Denosumab|Denosumab 60 mg were injected subcutaneously every 6 months (Q6M)
32750284|NCT05058443|Placebo Comparator|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously every 6 months (Q6M)
32750285|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
32750286|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
32750287|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
32750288|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
32750289|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
32750290|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
32750291|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
32750292|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
32750293|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
33235218|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
33235219|NCT04973163|Experimental|Monotherapy Arm|Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
33235220|NCT04973163|Experimental|Combination Therapy Arm|Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
33235221|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
32750294|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
32750295|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
33235222|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
33235223|NCT04082871|Active Comparator|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
32750296|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
32750297|NCT04717258|Experimental|Main FIREFLI trial: Intervention arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) offered by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer) once randomised.
32750298|NCT04717258|No Intervention|Main FIREFLI trial: Control arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer offered 12 months post-randomisation)
32750299|NCT04717258|Experimental|Recruitment SWAT: Self-Determination Theory informed invitation letter|The recruitment pack to take part in the FIREFLI study will include an invitation letter informed by Self-Determination Theory.
32750300|NCT04717258|No Intervention|Recruitment SWAT: Standard invitation letter|The recruitment pack to take part in the FIREFLI study will include the University of York, York Trials Unit's standard invitation letter
32750301|NCT04717258|Experimental|Retention SWAT: Pen arm|A pen (which has the University of York logo on it) will be included with the first four-month reminder questionnaire.
32750302|NCT04717258|No Intervention|Retention SWAT: No pen|No pen will be included with the four-month reminder questionnaire.
33235224|NCT04082871|Active Comparator|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
33235225|NCT04959903|Experimental|Adult patients affected by hematological malignancies|Adult patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) or myelodysplastic syndrome eligible for a T depleted allogeneic HSCT
33235226|NCT04959903|Experimental|Pediatric patients affected by hematological malignancies|Pediatric patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) eligible for a T depleted allogeneic HSCT
33235227|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
33235228|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
33235229|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
32750303|NCT02055898|Experimental|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
33072436|NCT05086172|Experimental|UBA Arm|All subjects in this arm will receive ultrabrief behavioral activation therapy via a single, 90-minute session.
33235230|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
33235231|NCT00919581||Healthy controls|
33235232|NCT00919581||Subjects with spinal cord injury|
33235233|NCT04102124|Experimental|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
33235234|NCT04102124|Experimental|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
33235235|NCT04102124|Placebo Comparator|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
33235236|NCT04015479|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
33235237|NCT04015479|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
33235238|NCT04082559|Other|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.~Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks~Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
33235239|NCT04082559|Other|Combination therapy (Antibiotics + diet)|"Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.~Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
33235240|NCT04082559|Other|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.~Mediterranean diet~Control- based on the American Dietetic Association recommendations for patients with IBD~Personalized nutrition group- based on prior results from study- NCT02858557"
33235241|NCT04082325|Experimental|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
33235242|NCT04082325|Experimental|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
33235243|NCT04082325|Experimental|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
33235244|NCT04082325|Experimental|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
33235245|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
33235246|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
33235247|NCT04103528|Other|morning group(from 8:00 to 12:00)|
33235248|NCT04103528|Other|afternoon group(from 14:00 to 18:00)|
33235249|NCT05683431|Experimental|Cognitive Control of Emotion (CCE) Training|"Mobile (iphone/ipad) App with game-like exercises designed to improve Cognitive Control of Emotion (CCE), i.e. the ability to control the influence of emotional information on behavior. Participants do 20 sessions (approximately 30min each), over 4 weeks."
33235250|NCT05526716|Experimental|Concomitant group (V116 + QIV followed by placebo)|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
33235251|NCT05526716|Experimental|Sequential group (placebo + QIV followed by V116)|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30
33235252|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
33235253|NCT04103840||Control|Apparently healthy Family controls
33235254|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
32750304|NCT02055898|Experimental|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
33235255|NCT04099394|Experimental|Behavioral Health|Ten behavioral health classes.
33235256|NCT04099394|Active Comparator|Health Education|Ten health education classes covering healthy aging.
33235257|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
33235258|NCT04937829|Experimental|BI 1569912 treatment group|
33235259|NCT04937829|Placebo Comparator|Placebo group|
33235260|NCT04934163|Experimental|60 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.
33235261|NCT04934163|Experimental|40 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.
32750305|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
33235262|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
33235263|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
33235264|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
33235265|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
32750306|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
33235266|NCT04933617|Experimental|1- Dose Escalation|Copanlisib (IV) per dose level (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R to determine RP2D and MTD of copanlisib. Up to 6 cycles total.
33235267|NCT04933617|Experimental|2 - Dose Expansion|Copanlisib (IV) at the RP2D or MTD on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R. Up to 6 cycles total.
33235268|NCT04932291|Experimental|vafidemstat 1.2mg|Vafidemstat is administered as capsules.
33235269|NCT04932291|Placebo Comparator|placebo|Placebo is administered as capsules.
33235270|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
33235271|NCT04231929|Experimental|BioPearl™ loaded with doxorubicin|Chemoembolization with doxorubicin-loaded BioPearl™ microspheres
33235272|NCT00586898|Experimental|1|
33235273|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
33235274|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
33235275|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
33235276|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
32750307|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
32750308|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
32750309|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
33235277|NCT04932135||Group Treatment|Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.
33235278|NCT04932135||Group Surveillance|Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.
33235279|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
32750310|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
32750311|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
32750312|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
33235280|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
33235281|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
33235282|NCT04099316|Experimental|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
33235283|NCT04099316|Experimental|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
33235284|NCT04099316|No Intervention|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
33235285|NCT04924101|Experimental|Pembrolizumab + MK-4830 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation, MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W, up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
33235286|NCT04924101|Experimental|Pembrolizumab + MK-5890 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, MK-5890 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W), up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
33235287|NCT04924101|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
33235288|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
33235289|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
33235290|NCT04101812|Experimental|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
33235291|NCT04101812|Active Comparator|Control group|PD-1 every 3 weeks, for 6 cycles.
33235292|NCT04923867||Supratentorial Procedure Group|Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.
33235293|NCT04923867||Infratentorial Procedure Group|Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.
33235294|NCT04923867||Spinal Procedure Group|Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.
33235295|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
33235296|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
33235297|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
33235298|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
33235299|NCT04916847||children with controlled HIV|Children over 0 days and under 16 years old, with controlled HIV
33235300|NCT04916847||children with hematologic Malignancy treated by conventional chemotherapy|Children over 0 days and under 16 years old, with Hematologic Malignancy treated by conventional chemotherapy
33235301|NCT04916847||Children with inflammatory bowel disease treated by anti-TNF at least 6 weeks|Children over 0 days and under 16 years old, with inflammatory bowel disease treated by anti-TNF
33235302|NCT04916847||Children with idiopathic juvenile arthritis|Children over 0 days and under 16 years old, with idiopathic juvenile arthritis treated by methotrexate:
33235303|NCT04916847||Children treated by renal transplantation|Children over 0 days and under 16 years old, treated by renal transplantation from more than 3 months:
33235304|NCT04916847||Children attending consultation|"Children over 0 days and under 16 years old, without immunodepression or chronic inflammation attending consultation for :~preoperative assessment~-congenital abnormalities of the kidney and urinary tract:~Nephropathies without renal impairment (eDFG > 45mL/min/1.73m2)~Non-inflammatory intestinal (polyposis, Chronic intestinal pseudo-obstruction, short bowel syndrome) or pancreatic (hereditary pancreatitis) pathologies This group of children will be a control group (age matched healthy children, non-immunosuppressed)."
32750313|NCT04406259|Other|Verapamil|administration of verapamil to treat cluster headache
33235305|NCT04912245|Other|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
32750314|NCT05500521||Patients with severe-to-profound hearing loss|Patients with severe-to-profound hearing loss will undergo investigation with caloric irrigation, video head impulse test and vestibular evoked myogenic potential. Patients will complete the Dizziness Handicap Inventory-questionnaire.
32750315|NCT05500521||Controls|Controls will undergo investigation with caloric irrigation, video head impuls test and vestibular evoked myogenic potential. Controls will complete the Dizziness Handicap Inventory-questionnaire.
32750316|NCT04077021|Experimental|Part 1a: Dose Escalation QOD|CCW702 administered subcutaneously QOD, dose escalating cohorts.
32750317|NCT04077021|Experimental|Part 1b: Dose Escalation Q7D|CCW702 administered subcutaneously Q7D, dose escalating cohorts.
32750318|NCT04077021|Experimental|Part 2: Dose Expansion|CCW702 administered subcutaneously Q7D at RP2D.
32750319|NCT05500287|Experimental|Virtual Care Group|Children in virtual care group (VCG) were given distance asthma education for the first month. The education was given in groups of 5-6 children. Also, short videos were taken by the researcher on how to use medications and nebulizers and were shown in Zoom meetings. The education and videos were prepared by scanning the current literature and expert opinion was obtained from 2 experts in nursing education, 2 experts in pediatric nursing and a expert in the pediatric allergy field. Children and families sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. The patients received support from the researcher on case management via telephone or video call 24/7. Case management was multidisciplinary (a nurse and a specialist).
32898251|NCT03507452|Experimental|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
32898252|NCT03507452|Experimental|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
33235306|NCT04884945|Active Comparator|Robotic Surgery|Robotic-Assisted Laparoscopic Pyeloplasty (RALP), standard of care treatment option for UPJ obstruction
33235307|NCT04884945|Active Comparator|Open Surgery|Open Pyeloplasty (OP), standard of care treatment option for UPJ obstruction
33235308|NCT04875975|Experimental|Rozanolixizumab|Participants will be randomized to receive a predefined dose of rozanolixizumab.
33235309|NCT04875975|Placebo Comparator|Placebo|Participants will be randomized to receive a dose of placebo.
33235310|NCT04870905|Experimental|ICRT arm|
33235311|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
33235312|NCT04082403|Active Comparator|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
33235313|NCT04082403|Experimental|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
33235314|NCT04862325|No Intervention|Usual care|"Control group will follow the standard preoperative measures Enhanced Recovery After Surgery (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them."
33235315|NCT04862325|Experimental|Multimodal prehabilitation|Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
33235316|NCT00919737|Experimental|NPC-08|
33235317|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
33235318|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
33235319|NCT04848051|Experimental|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
32750320|NCT05500287|No Intervention|Control Group|Children and families who in the control group (CG), sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. In the CG, the education routinely given by the physician during the outpatient clinic visits continued in the same way. In the name of equality of opportunity, training presentations and videos were shared with the CG at the end of the study. Also, the training presentation was converted into a booklet (videos were added to the booklet in the form of QR codes) and delivered to the clinic in printed form.
32750321|NCT04603911|Active Comparator|Control|Control arm will receive standard of care solution for the ESPB block
32750322|NCT04603911|Active Comparator|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
32750323|NCT05498025|Experimental|Activated charcoal pouch|The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.
32750324|NCT05497791|Experimental|Experimental Transcranial Laser and Electrical Stimulation|Hemiplegics treated with transcranial laser stimulation (on) associated with neuromuscular electrical stimulation (NMES) (on)
32750325|NCT05497791|Placebo Comparator|Placebo|Hemiplegics treated with placebo transcranial laser stimulation (off) associated with NMES (on)
32750326|NCT02699099|Experimental|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
32750327|NCT02699099|Experimental|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
32750328|NCT02699099|Experimental|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
32750329|NCT04399551|Experimental|Participants with HIV infection|HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
32750330|NCT04399551|Other|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
32750331|NCT05497713|No Intervention|Control Condition|No Mindset.
32750332|NCT05497713|Experimental|Egoistic x Proximal|"Mindset: This is my 5-minute exercise."
32750333|NCT05497713|Experimental|Egoistic x Distal|"Mindset: I am doing this for my health."
32750334|NCT05497713|Experimental|Altruistic x Proximal|"Mindset: I am saving one kilo of CO2: "
32908991|NCT05593718||FaceMask Ventilation (FMV)|During the period from January 1, 2015, to December 31, 2016, all panendoscopies performed with FMV, whether urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
33235320|NCT04848051|Experimental|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
33235321|NCT04848051|Experimental|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
32750335|NCT05497713|Experimental|Altruistic x Distal|"Mindset: I am doing this to fight climate change."
32750336|NCT03928587|Experimental|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
32750337|NCT03928587|Placebo Comparator|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
33235322|NCT04848051|Experimental|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
32908992|NCT05593718||HFNO|During the period from January 1, 2018, to December 31, 2019, all panendoscopies performed with HFNO, urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
32908993|NCT01003418|Experimental|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
33072437|NCT05086172|No Intervention|Control Arm|All subjects in this arm will complete all study assessment instruments collected in the interventional arm but will not receive an intervention.
33235323|NCT04847661|Active Comparator|Mefloquine arm|"Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.~30kg≤BW<45kg: 825mg followed by 275mg after 6-8 hours~45kg≤BW<60kg: 825mg followed by 550mg after 6-8 hours~60kg≤BW: 825mg followed by 550mg after 6-8 hours and then 275mg 6-8 hours after the second dose"
33235324|NCT04847661|Placebo Comparator|Control arm|A similar tablet of non-active gradients was specifically manufactured for the study by EVA Pharma company. The placebo tablets exactly resemble the active treatment mefloquine tablets (the same shape, size and color).
33235325|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
33235326|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
33235327|NCT02587377|Other|Cohort 1|single cohort of patient
33235328|NCT05682963|Active Comparator|Square-Stepping Exercise Program Group|Square stepping exercise is performed on a thin exercise mat divided into 40 small squares of 250 cm x 100 cm. Participants practice a set of step patterns on the mat. Square step exercises are a low-cost, highly accessible and fun exercise method. It is known that it improves motor performance and muscle strength in healthy young individuals, and has positive effects on functional fitness and gait parameters in individuals with osteoarthritis. It is known to have positive effects on balance, fall risk, walking ability, physical and cognitive function in elderly individuals. It will be applied to examine the effects on mobility, balance and position sense in individuals with multiple sclerosis.
33235329|NCT05682963|Active Comparator|Home Exercise Program Group|The home exercise program group will implement a protocol of frenkel's coordination exercises developed for balance and coordination therapy. The exercise protocol, which includes frenkel's coordination exercises, will be delivered to the patient in the form of a brochure and in the form of a Compact Disc (CD) with video images.
33235330|NCT04835805|Experimental|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
33235331|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
33235332|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib Plus Nivolumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus nivolumab IV infusion every 4 weeks (Q4W) in a run-in phase followed by an expansion phase
33235333|NCT04813263||Participants Treated With Venetoclax|Participants who are administrated venetoclax for treatment of AML under routine clinical practice.
33235334|NCT00796991|Active Comparator|Arm A|
33235335|NCT00796991|Active Comparator|Arm B|
33235336|NCT00796991|Active Comparator|Arm C|
33235337|NCT05682183|Active Comparator|Multi-domain Psychoeducation Self-management Programme|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre. Those who are randomised into the intervention arm will undergo 5-sessions of Multi-domain Psychoeducation Self-management Programme over 5 weeks.
33235338|NCT05682183|Active Comparator|Treatment as Usual|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre.
33235339|NCT04082247|Experimental|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
33235340|NCT04082247|No Intervention|Control group|Receive the standard care.
33235341|NCT05681949||Participants' cases discussed in tumor conference without ADBoard|Participants' cases are discussed in tumor conference without the use of ADBoard, according to conventional practice.
33235342|NCT05681949||Participants' cases discussed in tumor conference with ADBoard|Participants' cases will be evaluated by ADBoard directly before they are discussed in the tumor conference.
33235343|NCT04112225|Active Comparator|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
33235344|NCT04112225|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
33235345|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
33235346|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
33235347|NCT04787211|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
33235348|NCT05682989||mesh surgery|Data obtained before the operation
33235349|NCT05682989||Robotic-assisted sacrocolpopexy|Data obtained before the operation
33235350|NCT05678205|Experimental|Phase 1 Dose Confirmation|Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression
33235351|NCT05678205|Experimental|Phase 2 Cohort A|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC ≥2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
33235352|NCT05678205|Experimental|Phase 2 Cohort B|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) that is relapsed to, refractory to, or intolerant of previous trastuzumab deruxtecan (T-DXd) based therapy
33235353|NCT05678205|Experimental|Phase 2 Cohort C|AB-201 given to patients with advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression (IHC ≥ 2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
33235354|NCT04112147|Experimental|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
32750338|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
32750339|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
32750340|NCT05500131||Experimental group|All participants allowed three practice trials for each test in this order: the Weight-bearing lunge test and the Single-leg squat test. Both of them were evaluated through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain)
32750341|NCT02399891||Retrospective|MI prior to December 11, 2011
32750342|NCT02399891||Prospective|MI on or after December 11, 2011
32750343|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
32750344|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
32750345|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
32750346|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
32750347|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
32750348|NCT05497479|Experimental|Treatment with Schirmer test with no anesthetic|Both eyes will be treated.
32750349|NCT05497479|Experimental|Treatment with Schirmer test with anesthetic|Both eyes will be treated.
32750350|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
32750351|NCT03177785|No Intervention|Control|Wait-list control
32750352|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
32750353|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
32750354|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
32750355|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
32750356|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
33072438|NCT05085535|Active Comparator|Exercise|to which the treatment of therapeutic exercise and pain education will be applied,
32750357|NCT05497401|Experimental|treatment|
33072439|NCT05085535|Experimental|Manual Therapy|to which the same treatment as the control group will be applied, adding manual therapy sessions based on musculoskeletal rhythmic mobilizations.
33235355|NCT04112147|Experimental|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
33235356|NCT04112147|Placebo Comparator|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
33235357|NCT04779333|Experimental|LEAP Group|In addition to the components of the BMT group, the LEAP program includes an emphasis on supporting optimal physical activity, limiting screen time, and encouraging adequate sleep. The child and caregiver are also given a wrist-worn activity tracker and caregivers participate in a motivational Facebook group.
33235358|NCT04779333|Active Comparator|BMT Group|The BMT Group will take part in a family-based intervention within the context of evidence-based behavioral management training (BMT) for caregivers. Standard BMT represents the current standard of care for childhood ADHD.
33235359|NCT04081857|Experimental|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
33235360|NCT04081857|Experimental|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
32750358|NCT05497401|Placebo Comparator|control|
33235361|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
33235362|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
33235363|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
33235364|NCT04773171|Experimental|CACR Group|Participants of CACR group will attend individual computer-assisted cognitive remediation sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
33235365|NCT04773171|Active Comparator|TAU Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CACR training.
32750359|NCT02698865|Experimental|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
32750360|NCT02698865|Placebo Comparator|Saline|Physiologic saline
32750361|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
32898253|NCT03507452|Experimental|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
33235366|NCT02605109||RiskMERS|Exposed to case-patients
33235367|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
33235368|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
33235369|NCT04114331|Experimental|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).~Manual therapy:~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature~Therapeutic exercises:~Strengthening of mid and lower traps, lats, glut med, and glut max. Active & passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.~The treating therapists agreed on a protocol with treatment individualized to each patient."
33235370|NCT05651061|Experimental|Dose cohorts|Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.
33235371|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
33235372|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
33235373|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
33235374|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
33241627|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
32750362|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
32750363|NCT04497597||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
32750364|NCT02698787|Experimental|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
32750365|NCT02698787|Experimental|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
32750366|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
32750367|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
32750368|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
32750369|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
32750370|NCT05499897|Placebo Comparator|Group general anesthesia|(Patients who will be operated under general anesthesia): Standard ASA monitoring, induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 1µcg/kg fentanyl. Maintenance with 2MAC sevoflurane + 40% air mixture. Flow 2L/min. Before extubation, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
32750371|NCT05499897|Experimental|Group interscalene|(Patients who will undergo surgery with interscalen block): 20 ml of 0.25% bupivacaine for anesthesia. Before being taken to the postoperative unit, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
32750372|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
33235375|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
33235376|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.~Patients will be matched based upon the following details:~Age (within 5 years of matched case)~Surgical procedure (matched for the following elements:~Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)~+/- Sentinal lymph node biopsy or axillary dissection~+/- Reconstruction~Surgical procedure within 3-months of matched case.~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
33235377|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
32750373|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
32750374|NCT05497323|Experimental|Combination Cream Group|Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
32750375|NCT05497323|Other|Adapalene 0,1% cream|The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
32898254|NCT03507452|Experimental|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma~Dose / Regimen to be determined"
33072440|NCT05081557||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
33241628|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
33394111|NCT04488016|Experimental|Cohort 4 - Part 1|Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
33394112|NCT04488016|Experimental|Cohort 1- Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
33394113|NCT04488016|Experimental|Cohort 2 - Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
33394114|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
33394115|NCT03239704|Active Comparator|Minimal Intervention|
32750376|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
33235383|NCT05680415|Experimental|Treatment Group|"Mycobacterium vaccae for injection (Mica) :~Dosage form: injection. Main ingredients and contents:Mycobacterium protein 22.50μg/ bottle. Open the aluminum-plastic combination cap of the Xilin bottle, dilute it with 1.0ml sterilized water for injection, shake well, extract the liquid, and inject it deep into the buttocks muscle. Six times every two weeks."
33235384|NCT05680415|No Intervention|Blank Group|Non-injection drug.
33235385|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
33235386|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
33235387|NCT04745169|Other|Intervention|Participants will be asked to complete an 8-week home-based exercise intervention
33235388|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
33235389|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
33235390|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
33235391|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
33235392|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
33235393|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
33235394|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
33235395|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
33235396|NCT04081935|Experimental|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
33235397|NCT04081935|No Intervention|Compared|Normal treatment
33235398|NCT05616195||3D printed bone prosthesis replacement surgery|Patients undergoing 3D-printed bone prosthesis replacement surgery
33235399|NCT04713657|Active Comparator|Propranolol|The target dose of Propranolol hydrochloride for this study target dose for this study will be 4 mg/kg/day divided in 4 doses. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
33241629|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
33394116|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
33394117|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
33394118|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
33394119|NCT04486690|Experimental|propofol group|"Propofol infusion, 25-150mic/kg/min.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
33394120|NCT04486690|Active Comparator|ketofol group|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
33394121|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
33394122|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
33235400|NCT04713657|Placebo Comparator|Placebo|Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age. There is no current standard of care for pharmacologic therapy for infants with ToF. As such, there are no alternative treatments, and the placebo group is standard of care.
32898255|NCT03507452|Experimental|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
33235401|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
33235402|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
33235403|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
33235404|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
33235405|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
33235406|NCT04691739|Active Comparator|In-person occupational therapy|occupational therapy delivered in-person
33235407|NCT04691739|Active Comparator|Teletherapy|Video-conferencing occupational therapy
33235408|NCT04111679|Experimental|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
33235409|NCT04111679|No Intervention|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
33235410|NCT05678153||passive smokers children group (study group)|children whose parents reported having one or more family members smokes indoors in the presence of the child
33235411|NCT05678153||non-passive smokers children group (control group)|children whose parents reported not to have one or more family members smokes indoors in the presence of the child
33235412|NCT00920127|Placebo Comparator|Placebo|
33235413|NCT00920127|Active Comparator|AKL1|
33235414|NCT05607771|Experimental|Manual|Oocytes will be vitrified using the manual protocol
33235415|NCT05607771|Experimental|Automated|Oocytes will be vitrified using Davitri device
33235416|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
33235417|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
33235418|NCT01294007|Experimental|Study Graft Composite|"AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique.~Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator."
33235419|NCT01294007|Active Comparator|Control Graft Composite|"Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.~A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone~The graft composite is placed on the randomized control side using standard technique for PLF"
33235420|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
33235421|NCT04684641|Experimental|Phage therapy|Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
33235422|NCT04684641|Active Comparator|Placebo|Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
33235423|NCT05677763|Experimental|BV-12|Subjects will receive OM-85 treatment for 12 consecutive months. (10 days per month)
33235424|NCT05677763|Experimental|BV-3|Subjects will receive OM-85 treatment for 3 consecutive months, followed by matching placebo for 9 consecutive months. (10 days per month)
33235425|NCT05677763|Placebo Comparator|Placebo|Subjects will receive matching placebo for 12 consecutive months. (10 days per month)
33235426|NCT04684485|Placebo Comparator|Placebo of SCD-044 product|Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
33235427|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
33235428|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
33235429|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
33235430|NCT04111913|Experimental|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks."
33235431|NCT04081467|Experimental|bed rest condition|Bed rest condition without any additional intervention
33235432|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
33235433|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
33235434|NCT04682769||Patients with medically stable coronary heart disease and Depressive Disorder|
33235435|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
33235436|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
33235437|NCT04081623||Labor and Delivery|This group is in active labor.
33235438|NCT05561673|Active Comparator|HBs-alum Group|Participants receive three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, one each at Day 1, Day 31 and Day 181.
33235439|NCT05561673|Experimental|HBs-AS03 Group|Participants receive two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, one each at Day 1 and Day 31.
33235440|NCT05561673|Experimental|HBs-AS04 Group|Participants receive two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, one each at Day 1 and Day 31.
33235441|NCT05561673|Experimental|HBs-AS37_formulation 1 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1, one each at Day 1 and Day 31.
33235442|NCT05561673|Experimental|HBs-AS37_formulation 2 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2, one each at Day 1 and Day 31.
33235443|NCT04101500|Placebo Comparator|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
33235444|NCT04101500|Experimental|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
33235445|NCT05676515|Active Comparator|culture media of fabricant A|use of culture media of fabricant A
33235446|NCT05676515|Active Comparator|culture media of fabricant B|use of culture media of fabricant B
33235447|NCT05676515|Active Comparator|culture media of fabricant C|use of culture media of fabricant C
33235448|NCT04103060|Experimental|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
33235449|NCT04103060|Placebo Comparator|Vehicle gel|Vehicle gel applied topically twice daily
33235450|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.~Raw EEG in a steady state was collected for 5 minutes.~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)~Mechanical ventilation was initiated~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.~After extubation, BIS-VISTA TM monitoring was stopped."
33235451|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
33235452|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
33235453|NCT05558241|Experimental|Combined MRI and micro-ultrasound guided prostate biopsy.|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
33235454|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
33235455|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
33235456|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
33235457|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
33235458|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
33235459|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
32908994|NCT01003418|Experimental|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
33070792|NCT05013892|Experimental|NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine|"Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:~NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
33235460|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
33235461|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
33235462|NCT05326022|Experimental|medical therapy group|formed of 20 patients to whom ordinary medical therapy as the pervious groups and placebo shame laser had been applied.
33235463|NCT05326022|Experimental|medical therapy and Microcurrent group|formed of 20 patients to whom the microcurrent therapy had been applied with ordinary medical therapy.
33235464|NCT05326022|Experimental|medical therapy and Low-Level Laser Therapy group|formed of 20 patients to whom the Low Level Laser Therapy had been applied with ordinary medical therapy.
33235465|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
33235466|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
33235467|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
33235468|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
33235469|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
33235470|NCT04081077|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
33235471|NCT04081077|Experimental|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
33235472|NCT04081077|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
33235473|NCT04669665|Experimental|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
33235474|NCT04669665|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
33235475|NCT00764504|Experimental|Primary|Primary shoulder
33235476|NCT00764504|Experimental|Revision|Revision shoulder
33235477|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
33235478|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
33235479|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
33235480|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
33235481|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
33235482|NCT04662255|Experimental|Arm A (Pirtobrutinib)|Orally
33235483|NCT04662255|Active Comparator|Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)|Investigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
33235484|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
33235485|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
33235486|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)~Pre-Class Laryngectomy Survey (5-10 minutes to complete)~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
33072444|NCT05077865|Experimental|Cohort 1 - Active|6 subjects, randomized to receive 150mg MYMD1 (Isomyosamine), administered as one 150mg capsule on Day 1.
33235487|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
33235488|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
33235489|NCT02601482|Experimental|Control (CON)|No exercise intervention.
33235490|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
33235491|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
33235492|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
33235493|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
33235494|NCT00763256|Active Comparator|A|
33235495|NCT00763256|Placebo Comparator|B|
33235496|NCT05520554||Telerehabilitation Satisfaction|Telerehabilitation Satisfaction Group
33235497|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
33235498|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
33235499|NCT04098770|Experimental|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
33235500|NCT04098770|No Intervention|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
33235501|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
33235502|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
33235503|NCT04081311|Experimental|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
33235504|NCT04081311|Active Comparator|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
33235505|NCT04080921|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
33235506|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
33235507|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
33235508|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
33235509|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
33235510|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
33235511|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
33235512|NCT04080609|Experimental|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
33235513|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
33235514|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
33235515|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
33235516|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
33235517|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
33235518|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
33235519|NCT04649151|Experimental|mRNA-1273|"Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29.~Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29.~Part 2 (Open-Label): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29."
33235520|NCT04649151|Placebo Comparator|Placebo|Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
33235521|NCT04649151|Experimental|mRNA-1273 BD|"Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B.~Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose."
33235522|NCT04649151|Experimental|mRNA-1273.222|Part 3 (Open-Label): Participants will receive 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.
33235523|NCT00762476|Placebo Comparator|Placebo|
33235524|NCT00762476|Experimental|3804-250A|
33235525|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
33235526|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
33235527|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
33235528|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
33235529|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
33235530|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
33235531|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
33235532|NCT04098614|Experimental|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
33235533|NCT04098614|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
33235534|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
32750377|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
32750378|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
32750379|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
32750380|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
32750381|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
32908995|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
32750382|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
33235535|NCT00583791|Experimental|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
33235536|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
33235537|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
32750383|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
32750384|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
32750385|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
32750386|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
32750387|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
32750388|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
32750389|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
32750390|NCT04279119|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
32750391|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
32750392|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
32750393|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
32750394|NCT04278729|Experimental|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
32908996|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
32908997|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
32908998|NCT01004354|Experimental|Vitamin D|
32908999|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;~Aerobic exercise training for a 4-month period;"
32909000|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;~Aerobic exercise training for a 4- month period;"
33235538|NCT04080375|Experimental|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
33235539|NCT04080375|Placebo Comparator|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
33235540|NCT00781274|Experimental|MP-424|
33235541|NCT02585739|Experimental|patient|patient with Cluster headache
33235542|NCT02585739|Other|healthy subject|patient without Cluster headache
33235543|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
33235544|NCT04103294|Experimental|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
33235545|NCT04103294|Experimental|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
33235546|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
33235547|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
33235548|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
33235549|NCT04080765|Experimental|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
33235550|NCT04080765|Active Comparator|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
33235551|NCT04103372|Active Comparator|Low risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 0. (Margin Clear >0mm from the diathermy margin and Sm1/2 or Haggitt 1/2/3) Six monthly follow up from date of surgery.
33235552|NCT04103372|Active Comparator|Moderate Risk - RT&Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to receive radiotherapy (RT) and regular surveillance, with 3 monthly follow-up from the date of surgery.
33235553|NCT04103372|Active Comparator|Moderate Risk - Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to surveillance arm with regular surveillance, with 3 monthly follow-up from the date of surgery.
33235554|NCT04103372|Active Comparator|High Risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of >2. (Margin positive - 0mm to the diathermy margin, Margin positive/or unassessable due to piecemeal removal - 0mm to the tumour margin, Sm3 or Haggitt 4, Poorly differentiated/mucinous, LVI, T2) Patient is considered for surgery, receives radiotherapy and surveillance, with 3 monthly follow-up from date of surgery.
33235555|NCT04103372|Active Comparator|TME (Total mesorectal excision) Surgery|For patients where it is considered technically feasible to do LE but MR staged<1mm muscularis preserved, or it is considered not feasible to perform a local excision. Patients undergo TME surgery. Pathology assessment on sample with confirmation of adenocarcinoma. Patient receives 6 monthly follow-up from date of surgery.
33235556|NCT05538663|Experimental|Arm A|Gemcitabine + Docetaxel
33235557|NCT05538663|Experimental|Arm B|BCG
33235558|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
33235559|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
33235560|NCT05532657|Active Comparator|Hearing intervention (HI) group|Participants in this group were randomized to the hearing intervention (HI) group at ACHIEVE trial baseline and received a best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist. These participants will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
33235561|NCT05532657|Active Comparator|Successful aging/Delayed hearing intervention (SA/DHI) group|Participants in this active control group were randomized to the successful aging (SA) group at ACHIEVE trial baseline and received a successful aging health education program, following the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator to control for staff-participant time and attention between the two groups. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
33235562|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
33235563|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
33235564|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
33235565|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
33235566|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
33235567|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
33235568|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
33235569|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
33235570|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
33235571|NCT05520177|Experimental|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
33235572|NCT05520177|Active Comparator|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
33235573|NCT04625517|Experimental|Breast cancer patients|Patients with ipsilateral intact biopsy-proven breast cancer
33235574|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
33235575|NCT00780416|Experimental|TRV/PEG/RBV|
33235576|NCT00780416|Active Comparator|PEG/RBV|
33235577|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
33235578|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
33235579|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
33235580|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
33235581|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
33235582|NCT04098692|Experimental|Single-Arm: Derazantinib (Part 1 and Part 2)|"Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose~Part 2: 300 mg [14C]-Derazantinib oral administration"
33235583|NCT04080219||Normal|Patients with Oxygen desaturation index <5
33235584|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
33235585|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
33235586|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
33235587|NCT04080063|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
33235588|NCT04098536|Experimental|Diesel Exposure|
33235589|NCT04098536|Placebo Comparator|Filtered Air Exposure|
33235590|NCT04079985|Experimental|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
33235591|NCT04079985|Active Comparator|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
33235592|NCT05506059|Other|Healthy Volunteer|Healthy volunteers over the age of 18 who consent to two ultrasounds.
33235593|NCT05506059|Experimental|ED patient with planned heart echocardiogram|Patients in emergency department (ED) who have a heart echocardiogram scheduled as part of their routine clinical care
33235594|NCT04080141||PD+|Subjects with personality disorder
33235595|NCT04080141||PD-|Subjects without personality disorder
33235596|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
33235597|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
33235598|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
32750395|NCT04278729|Experimental|Healthy Arm|Healthy volunteers will be in this arm.
32750396|NCT02399423|Other|South Asian participants|30 South Asian male participants
33235599|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
33235600|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
32909001|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
33235601|NCT04607421|Experimental|Safety Lead-in Cohort 1|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
33235602|NCT04607421|Experimental|Safety Lead-in Cohort 2|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
32750397|NCT02399423|Other|European participants|30 European male participants
32750398|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
32909002|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
32909003|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
32909004|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
33072445|NCT05077865|Placebo Comparator|Cohort 1 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as one capsule matching the 150mg MYMD1 capsule in appearance.
33235603|NCT04607421|Experimental|Phase 3 Arm A|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
33235604|NCT04607421|Experimental|Phase 3 Arm B|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
33235605|NCT04607421|Active Comparator|Phase 3 Arm C|Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
33235606|NCT04607421|Experimental|Cohort 3 Arm D|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
33235607|NCT04607421|Active Comparator|Cohort 3 Arm E|Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
33235608|NCT04101032|Experimental|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
33235609|NCT04101032|No Intervention|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
33235610|NCT00761306|Experimental|Vortioxetine|
33235611|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
33235612|NCT04605549|Experimental|CIN-107 for dosing at 2, 4, or 8 mg|"Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk.~At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg."
33235613|NCT04079595|Experimental|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
33235614|NCT04079595|Active Comparator|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
33235615|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
33235616|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
33235617|NCT04079517|Experimental|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
33235618|NCT04079517|Active Comparator|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
33235619|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
33235620|NCT05493189|No Intervention|Control Group|Participants with no additional autonomous training sessions.
33235621|NCT05493189|Experimental|Intervention Group|Participants exposed to 2 additional autonomous training sessions (after 2 and 6 months).
33235622|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
32909005|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
33235623|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
32909006|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
33072446|NCT05077865|Experimental|Cohort 2 - Active|6 subjects, randomized to receive 300mg MYMD1 (Isomyosamine), administered as two 150mg capsules on Day 1.
33235624|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
33235625|NCT00760994|Experimental|1 - Experiential Accepatance|Experiential acceptance
33235626|NCT00760994|Active Comparator|2 - Cognitive Restructuring|Cognitive restructuring
33235627|NCT00760994|Placebo Comparator|3 - Control|No-intervention control: Nutrition information
33235628|NCT00583557|Experimental|Belimumab|
33235629|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
33235630|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
33235631|NCT04581681|Experimental|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
33235632|NCT04581681|Active Comparator|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
33235633|NCT04580121|Experimental|Part A: Single Participant Dose Escalation|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
33235634|NCT04580121|Experimental|Part B: Multiple Participant Dose Escalation|Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, every-2-weeks (Q2W), or once-a-week (QW) dosing regimens, respectively to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Additionally, step-up dosing regimens with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
33235635|NCT04580121|Experimental|Part C: Dose Expansion|Participants will receive the respective RP2D for Group I and Group II.
33235636|NCT04578093|Experimental|Intervention|Will receive adjusts curriculum
33235637|NCT04578093|No Intervention|Control|Will receive unadjusted curriculum
33235638|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
33235639|NCT00760838|Placebo Comparator|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
33235640|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
33235641|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
33235642|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
33235643|NCT00586664|Placebo Comparator|Placebo|
33235644|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
33235645|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
33235646|NCT00437281|Placebo Comparator|Placebo|
33235647|NCT00437281|Experimental|Pregabalin|
33235648|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
33235649|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
33235650|NCT05475236|Sham Comparator|Sham Stimulation|Participants will undergo 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
33235651|NCT05475236|Experimental|Transcranial Direct Current Simulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
33235652|NCT04566003|Experimental|[18F]PI-2620 PET, then [18F]GTP1 PET|Participants will undergo one [18F]PI-2620 PET imaging session, then one [18F]GTP1 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18F]PI-2620 or 7mCi of [18F]GTP1.
33235653|NCT04566003|Experimental|[18F]GTP1 PET, then [18F]MK-6240|Participants will undergo one [18F]GTP1 PET imaging session, then one [18F]MK-6240 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18 F]MK-6240 or 7mCi of [18F]GTP1.
33235654|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
33235655|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
33235656|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.~All men will have standard transrectal ultrasound guided biopsies"
32750399|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
32750400|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
32750401|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
32750402|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
32750403|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
33070793|NCT05013892|Experimental|HA-WBRT (hippocampal avoidance whole brain radiation Therapy) + Memantine|"Participants will be randomly assigned to HA-WBRT (hippocampal avoidance whole brain radiation Therapy) administration group and receive:~HA-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
32750404|NCT04480775|Experimental|bupivacaine group|28 Patients will receive 18 ml of bupivacaine 0.5 % plus 1ml 0.9% saline in TAP block divided equally on both sides
32750405|NCT04480775|Active Comparator|triamicinolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (20 mg of triamcinolone in 1ml 0.9% saline divided equally on both sides in TAP block
32750406|NCT04480775|Active Comparator|methylprednisolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (40 mg of methylprednisolone in 1ml 0.9% saline ) on both sides in TAP block.
32750407|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
32750408|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
32750409|NCT02417363||Group A|the control group,healthy individuals
32750410|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
33235657|NCT04102982|Active Comparator|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
33235658|NCT04102982|Placebo Comparator|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
32750411|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
32909007|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
32909008|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
32909009|NCT05593640||ThroboxaneOA|Patient with osteoarthritis and knee effusion
33070794|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
33235659|NCT04548999|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
33235660|NCT04548999|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
33235661|NCT04548609|Experimental|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33070795|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
33235662|NCT04548609|Experimental|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33235663|NCT04544007|Experimental|Administer Poly-ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
33394123|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
32750412|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
33235664|NCT05468073|Experimental|Treatment|Patient will be treated with low dose of Interleukin 2 (PROLEUKIN ®)
33235665|NCT05468073|Placebo Comparator|Placebo|Patient will receive sodium chloride solution (NaCl)
33235666|NCT04526847|Experimental|Intervention|"Intermittent energy restricted (IER) group:~IER group will receive 5:2 diet pattern (5 day without energy restriction and 2 days with 75% energy restriction, net weekly energy deficit ~25%)"
33235667|NCT04526847|Active Comparator|Calorie Restricted Diet (CER)|"Continuous energy restricted (CER) group:~CER group with a low-calorie diet (daily energy deficit ~25%) over the course of six months."
32750413|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
32750414|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
33235672|NCT04520061|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
33235673|NCT04520061|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
32750415|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
32750416|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles~Auto-HSCT conditioning regimen:~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
32750417|NCT03106493||Primary|Singletons and 1 twin of each pair
32750418|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
32750419|NCT03106493||Tertiary|Higher order multiples and siblings
33235674|NCT02584101|Experimental|ACT|ACT therapy
33235675|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
33235676|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
33235677|NCT05442255||Chemical Submission|Patients with a suspected chemical submission
33235678|NCT05674773||IBD patients with advanced neoplasia|"IBD patients with advanced neoplasia (high-grade dysplasia or colorectal cancer) treated with:~proctocolectomy~(sub)total colectomy~partial colectomy~endoscopic resection"
33235679|NCT04079205|Experimental|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
32750420|NCT03177161|Experimental|Postal Questionnaire|
33070796|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
33070797|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
33070798|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
33235680|NCT04079205|Active Comparator|Control|Standard home rehabilitation program
33235681|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
33235682|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
33235683|NCT04079049|Experimental|Surgical intervention|Surgical and oncological treatment
33235684|NCT04079049|Active Comparator|Control|Oncological treatment
33235685|NCT04078971|Experimental|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
33235686|NCT04078971|Active Comparator|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
32750421|NCT03177161|Experimental|Online Questionnaire|
32750422|NCT03177161|Experimental|Face-to-face Questionnaire|
33072447|NCT05077865|Placebo Comparator|Cohort 2 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as two capsules matching the 150mg MYMD1 capsules in appearance.
32750423|NCT03177161|Experimental|Telephone Questionnaire|
32750424|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
33235687|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
33235688|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
32750425|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
32750426|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
32750427|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
32750428|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
32750429|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
33235689|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
32750430|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
32750431|NCT03177083|Active Comparator|peginterferon beta-1a|
32750432|NCT03177083|Active Comparator|Current Therapy|
32750433|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
32750434|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
32750435|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
32750436|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
33235690|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
33235691|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
33072448|NCT05077865|Experimental|Cohort 3 - Active|6 subjects, randomized to receive 450mg MYMD1 (Isomyosamine), administered as three 150mg capsules on Day 1.
33235692|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
33235693|NCT04019769|Experimental|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
33235694|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
33235695|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
33394124|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33394125|NCT03255304|Experimental|health prime|
33394126|NCT03255304|Experimental|palatability prime|
33394127|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
33235700|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
33235701|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
33235702|NCT04454229|Experimental|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
33235703|NCT04454229|Active Comparator|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
33235704|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
33235705|NCT02583165|Experimental|Monotherapy arm|MEDI1873
33235706|NCT00772382|Experimental|MCI-196|
33235707|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
33235708|NCT04078581|Experimental|healthy controls|Questionnaire and fecal sample collection
33235709|NCT04102748|Active Comparator|Conventional|
33235710|NCT04102748|Active Comparator|I-incision|
33235711|NCT04102748|Active Comparator|M-flap|
32750437|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
33235712|NCT04078659|Experimental|Propofol infusion|Patients received intravenous Propofol infusion
32909010|NCT02357654|Experimental|GnRH agonist|
32909011|NCT02357654|Placebo Comparator|Placebo|
33072449|NCT05077865|Placebo Comparator|Cohort 3 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as three capsules matching the 150mg MYMD1 capsules in appearance.
33235713|NCT04078659|Experimental|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
32909012|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
32909013|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
33235714|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
32750438|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
32750439|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
32909014|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
32909015|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
32909016|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
32909017|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
32909018|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
32909019|NCT02266628|Experimental|Treatment Group A|RSV-F vaccine (0.5mL Injection)
32909020|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
32909021|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
32909022|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
32909023|NCT01004744|Experimental|Presurgical oral anastrozole|1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.
33072450|NCT05077865|Experimental|Cohort 4 - Active|6 subjects, randomized to receive 600mg MYMD1 (Isomyosamine), administered as four 150mg capsules each on Days 1, 2, 3, 4, and 5.
33235715|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
33235716|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
33235717|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
33235718|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
33235719|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
33235720|NCT00798707|Placebo Comparator|Placebo|
33235721|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.~Lumbar puncture Blood sample"
33235722|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
33235723|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
33235724|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
33235725|NCT00760214|Active Comparator|Ramipril 10 mg QD|
33235726|NCT04401267|Experimental|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
33235727|NCT04401267|Active Comparator|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
33235728|NCT04078425|Experimental|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
33235729|NCT04078425|Experimental|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
33235730|NCT04098380|Active Comparator|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
33235731|NCT04098380|Active Comparator|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
33235732|NCT05387889|Experimental|Treatment Arm|"This treatment Arm will receive MMPH intervention first, while the wait-listed group waits until this group is complete.~Then the wait-listed group will receive the same intervention after the first group completes it."
33394128|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
32750440|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
32750441|NCT04295811|Experimental|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
33235733|NCT05387889|Active Comparator|Comparison Arm or Waited List Arm|This active comparator Arm will not receive MMPH intervention at the beginning. They will receive the intervention once the Treatment Group completed the intervention.
33235734|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
33235735|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
33235736|NCT00638391||1|all patients treated with Anastrozole
33235737|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
33235738|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
33235739|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;~One softgel every 20 min (4 doses)~Two softgel every 6 hr (4 doses)~One softgel every 6 hr (4 doses)~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
33235740|NCT04447833|Experimental|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg.
33235741|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
33235742|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
33235743|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
33235744|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
33235745|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
33235746|NCT05353257|Experimental|HLX10 + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus HLX10 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
33235747|NCT05353257|Placebo Comparator|placebo + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
33235748|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
33235749|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
33235750|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
33235751|NCT00638469|Other|left/right|left or right body side
33235752|NCT02689011|Experimental|Group F|Femoral nerve Block Group
33235753|NCT02689011|Active Comparator|Group E|Epidural Group
33235754|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
33235755|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
33235756|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
33235757|NCT02689245|Active Comparator|Tenofovir|
32909024|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
33235758|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
32909025|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
32909026|NCT05593484|Other|Standard Referral|
32909027|NCT05593484|Other|Specialty Telemedicine Access for Referrals (STAR)|
32909028|NCT04494932|Experimental|Biceps Tenodesis|
32909029|NCT04494932|Active Comparator|SLAP Repair (Control)|
32909030|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
33235759|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
33235760|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
33235761|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
33235762|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
33235763|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
33235764|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
33235765|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
33235766|NCT05472038|Experimental|Cohort 1: BNT162b5 Bivalent (WT/OMI BA.2)|Participants will receive 30 µg of BNT162b5 Bivalent (WT/OMI BA.2) at Visit 1.
33235767|NCT05472038|Experimental|Cohort 1: BNT162b2 Bivalent (WT/OMI BA.1)|Participants will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.1) at Visit 1.
33235768|NCT05472038|Experimental|Cohort 2 -Group 1: 12-17 years; 30 µg|Participants 12-17 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
33235769|NCT05472038|Experimental|Cohort 2 - Group 2: 18-55 years; 30 µg|Participants 18-55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
33235770|NCT05472038|Experimental|Cohort 2 - Group 3: 18-55 years; 60 µg|Participants 18-55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
33235771|NCT05472038|Experimental|Cohort 2 - Group 4: >55 years; 30 µg|Participants over 55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
33235772|NCT05472038|Experimental|Cohort 2 - Group 5: >55 years; 60 µg|Participants over 55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
33235773|NCT05472038|Experimental|Cohort 3 - Group 1: 18-55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
33235774|NCT05472038|Experimental|Cohort 3 - Group 2: >55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
33235775|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
33235776|NCT01257269||2|Family members of patients with confirmed hereditary TTP
33235777|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
33235778|NCT02605889|Experimental|Group A|Laser acupuncture
33235779|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
33235780|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
33235781|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
33235782|NCT04077957|Experimental|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
33235783|NCT04077957|Active Comparator|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
33235784|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
33235785|NCT04102670|Experimental|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
33235786|NCT04114097|Experimental|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
33235787|NCT04114097|Active Comparator|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
33235788|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
33235789|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
33235790|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
33235791|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
33235792|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
33235793|NCT00796757|Experimental|1|
33235794|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
33235795|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
33235796|NCT04101266|Active Comparator|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
33394129|NCT04487626|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
33394130|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
33235797|NCT04101266|Active Comparator|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
32750442|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
32750443|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
32909031|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
33394131|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
33394132|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
33394133|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
32909035|NCT04488692|Experimental|Model 1|Participants will receive 2 sessions of functional training per day, 15-min per session.
33070799|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
33235798|NCT05637515|Active Comparator|Humira continuously|"Subjects receive Humira continuously both during Run-in period and Randomized interchangeable treatment period.~Run-in Period:~Subjects will receive Humira (initial dose of 80 mg [2 × 40 mg]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Randomized interchangeable treatment period:~Subjects continue to receive Humira (40 mg every other week) until Week 26"
33235799|NCT05637515|Experimental|Repeated switches Humira - Hulio|"Subjects will receive Humira in Run-in period & undergo repeated switches between Humira Hulio during randomized interchangeable treatment period~Randomized interchangeable treatment period:~Subjects undergo repeated switches between Humira and Hulio between week 12 to week 26.~Hulio (40 mg every other week) at Week 12 and Week 14~Humira (40 mg every other week) at Week 16 and Week 18, and~Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
33235800|NCT05470322|Experimental|Laser Treatment|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target HS scarring.
33235801|NCT04113941|Experimental|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
33235802|NCT04113941|Placebo Comparator|Placebo|Normal saline, same volume with Experimental arm
33235803|NCT04102592|Experimental|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
33235804|NCT04102592|Placebo Comparator|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
33235805|NCT04113473|Experimental|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
33235806|NCT04113473|No Intervention|Control Group|Control group were given education session and continued on usual care for 12-weeks.
33235807|NCT05675345|Active Comparator|HFNC only|
33235808|NCT05675345|Experimental|HFNC + CNEP10|
33235809|NCT05675345|Experimental|HFNC + CNEP20|
33235810|NCT05675345|Experimental|HFNC + CNEP30|
33235811|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
33235812|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235813|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33394134|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
33394135|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
33394136|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
33235814|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
33235815|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33070800|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft~Placebo lotion: liposome lotion with no DEET"
33070801|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
33235816|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235817|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
33235818|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
33235819|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235820|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235821|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235822|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
33235823|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
33235824|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
33235825|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
33235826|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
33235827|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
33235828|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
33235829|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
33235830|NCT05632601|Experimental|Sex-Specific Risk HDP Subgroup Factor Group and Age-Matched Control Group|"Blood sample~Questionnaires~Arterial stiffness assessment~Transthoracic Echocardiogram~Coronary Computed Tomography Angiography (CTA)~Cardiac Positron Emission Tomography (PET)"
33235831|NCT05632601|No Intervention|Sex-Specific Risk factor group and Age-Matched Control Group|"Blood sample~Questionnaires~Arterial stiffness assessment"
33235832|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
33235833|NCT05631197|Experimental|Trial group|
33235834|NCT05631197|Active Comparator|Control group|
33235835|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
33235836|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
33235837|NCT04113629|Other|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
33235838|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
33235839|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
33235840|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
33070802|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
33070803|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
33394137|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
33394138|NCT03254914||Control Site|Measure Clinic Blood Pressure
33070804|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
33235841|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
33070805|NCT02938936|No Intervention|Control|
33070806|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
33070807|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
33070808|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
33070809|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
33070810|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
33070811|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
33235842|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
33235843|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
33235844|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
33235845|NCT04307511|Experimental|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
33235846|NCT04307511|Active Comparator|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
33235847|NCT04078893|No Intervention|control group|
33235848|NCT04078893|Experimental|on need group|
33235849|NCT04078893|Experimental|communication group|
33235850|NCT04347759|Other|System with coaching messages|A telephone-computer interface IVR system to report symtopms and to receive coaching messages based on symptom severity.
33235851|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
33235852|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
33235853|NCT04078347||Successful Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
33235854|NCT04078347||Failed Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
33235855|NCT04342611|Experimental|Patients under the care of TA Oncologist|These patients will be under the care of an oncologist who will be randomized to training in the TA intervention.
33235856|NCT04342611|No Intervention|Patients under the care of Usual Care Oncologist|These patients will be under the care an oncologist who will be randomized to usual care.
33235857|NCT04300023|No Intervention|Study 1: Normal Care Control Group|Study 1: Normal Care Control Group [will crossover and complete the cycling intervention following the initial 6-months]
33235858|NCT04300023|Experimental|Study 1: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
33235859|NCT04300023|Experimental|Study 2: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
33235860|NCT04300023|Experimental|Study 2: Solo Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to cycling without a partner for a target duration and intensity.
33235861|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
33235862|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
33235863|NCT04078113|Experimental|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
33235864|NCT04078113|No Intervention|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
33235865|NCT04097990|Other|healthy participants|healthy participants
33235866|NCT04097990|Other|hypertriglyceridemia without prior pancreatit|
33235867|NCT04097990|Other|hypertriglyceridemia and at least one case of|
33235868|NCT04186533|Experimental|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
32750444|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
33235869|NCT04186533|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
32750445|NCT04280133|Experimental|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
32750446|NCT04280133|No Intervention|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
33235870|NCT04097756|Experimental|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
33235871|NCT04097756|Experimental|Part 2：dose expansion|2~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
32750447|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy~Ventral hernia repair - perioperative factors of interest:~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,~Pregnancy and delivery - factors of interest:~- vaginal vs caesearan section, single vs multiple pregnancy~Subgroup of patients with mesh repair:~- subanalysis on main attributes~Subgroup of patients with sutured repair:~- mono- vs multifilament, slowly vs rapidly absorbable"
32750448|NCT05499819|Experimental|Black beans|Canned black beans, drained and rinsed
32750449|NCT05499819|Experimental|Red kidney beans|Canned red kidney beans, drained and rinsed
32750450|NCT05499819|Experimental|Extra-lean ground beef|Extra-lean ground beef, pan-fried
32750451|NCT02398877|Experimental|Depression with early trauma|stress
32750452|NCT02398877|Experimental|Depression without early trauma|stress
32750453|NCT02398877|Experimental|Healthy with early trauma|stress
32750454|NCT02398877|Experimental|Healthy without early trauma|stress
32750455|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)~2.5 mg/kg UB-621"
32909036|NCT04488692|Active Comparator|Model 2|Participants will receive 1 session of functional training and 1 session of sham intervention (therapist visiting and education) per day, 15-min per session.
33235872|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
33235873|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
33235874|NCT04101344|Experimental|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
33235875|NCT04119999|Active Comparator|CPAP|Continuous Positive Airway Pressure
33235876|NCT04119999|Experimental|MAD|Mandibular Advancement Device
33235877|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
33235878|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
33235879|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
33235880|NCT05293821||Positive test subjects|documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.
33235881|NCT05293821||Control|no documented medical history of HIV, HBV or HCV and are considered normal.
32750456|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)~5 mg/kg UB-621"
32750457|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
32750458|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
32750459|NCT02398487|No Intervention|Usual smoking|
32909037|NCT05593172||Mild traumatic brain injury|15 consecutive patients presenting at the emergency departement with mild traumatic brain injury
32909038|NCT05593172||Minor orthopedic injury|15 patients, recruited during the same time-frame as the mTBI-patients, presenting at the emergency departement with a minor orthopedic injury
33235882|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
33235883|NCT02688699|No Intervention|control|
33235884|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
33235885|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
33235886|NCT02688465|Experimental|Apomorphine pump|
32750460|NCT05499585|Other|Arm One|Habitual diet for 12 weeks followed by experimental diet for 12 weeks
32750461|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
33394139|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
33394140|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
33394141|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
33394142|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
32750462|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
32750463|NCT05497245|Experimental|intervention group|mobile app-based breastfeeding education
32750464|NCT05497245|No Intervention|control group|rutin health care
32750465|NCT04480619|Experimental|Ga-68-PEG-Αvβ3-IAC PET/CT|Companion Ga-68 PET diagnostic for tumor targeted therapy
32750466|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
32750467|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
33394143|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
32750468|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
32750469|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
32750470|NCT02398253|Experimental|Hypo-energetic Diet only|
32750471|NCT05497167|Experimental|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
32750472|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
32750473|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
32750474|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
32750475|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
32750476|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
32750477|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
32750478|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
32750479|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
32750480|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
32750481|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
32750482|NCT05499429|Active Comparator|active stimulus group|Patients were assigned into active stimulus group according to random number table
32750483|NCT05499429|Sham Comparator|sham stimulus control group|Patients were assigned into sham stimulus control group according to random number table
32750484|NCT02868567|Experimental|Ampyra|Ampyra open label
32750485|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
32750486|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
32750487|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
32750488|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
33394144|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
33394145|NCT04427501|Experimental|LY3819253|700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
32750489|NCT05564481|Experimental|Immediate intervention|Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months).
32750490|NCT05564481|Active Comparator|Wait-list/delayed intervention|Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months).
32750491|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
32750492|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
32750493|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
32750494|NCT05496699|Experimental|mckenzie group|Mckenzie exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
32750495|NCT05496699|Experimental|mullgian group|Mulligan exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
32750496|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
32750497|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
32750498|NCT04272801|Experimental|Pre-operative endocrine therapy|All participants enrolled to the study will receive 3 months of pre-operative endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
32750499|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
32750500|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
33070812|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
32750501|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
33070813|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
32750502|NCT05496621|Experimental|Musculoskeletal Diseas|Questionnaires will be asked for the validity of the Turkish version of the Keel Start Tool.
32761962|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
32761963|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
32761964|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
32761965|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
33070814|NCT02938858||ATRA-chimio|according to usual practice center
32750503|NCT05564247|Experimental|Experimental Group (WSTP)|Participants will complete 12, 45-minute weekly sessions of WSTP delivered by clinicians with >5 years of experience working with children who use MWC. Trainers will customize each session based on the age group (child or adolescent) and training goals of each child as determined in session one. Subsequent sessions will begin with a 5-minute review of progress and socializing, followed by a 10-minute warm-up (random practice of the previously learned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment. Age-appropriate considerations are incorporated into training materials
32761966|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
33070815|NCT02938858||ATRA-ATO|according to usual practice center
33235887|NCT04186611|Experimental|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
32761967|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
33235888|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
33235889|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
33235890|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
32761968|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
32761969|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
33070816|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
33070817|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
33235891|NCT00758498|Placebo Comparator|3|matching placebo
33235892|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
33235893|NCT00798161|Placebo Comparator|matching placebo|matching placebo
33235894|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
33235895|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
33235896|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
33235897|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
33235898|NCT02688231|Experimental|High intensity group|
33235899|NCT02688231|Experimental|Low intensity group|
32761970|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
32761971|NCT02332447|Experimental|NALOXONE|
33070818|NCT00147095||COPD and smoking|Smoking participants with COPD
33070819|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
33070820|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
33235900|NCT02688231|Active Comparator|Control group - conventional treatment|
33235901|NCT04089579|Experimental|MSC|One dose of 6x10e6 cells/kg administered intravenously.
33235902|NCT04089579|Placebo Comparator|Placebo Infusion|Placebo infusion
33235903|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
33235904|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
33235905|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
33235906|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
33235907|NCT04170855|Other|Furosemide Injection|"Patients with diuretic resistance:~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:~Peripheral or sacral oedema~Jugular venous distension ≥ 7 cm~Radiographic pulmonary oedema or pleural effusion~Enlarged liver or ascites~Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea~Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
33235908|NCT04076709|No Intervention|Standard Care|
33235909|NCT04076709|Experimental|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
33235910|NCT04268121|Experimental|Phase II|Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
33235911|NCT04268121|Active Comparator|Prospective cohort|Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
33235912|NCT04111523|Experimental|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
33235913|NCT04111523|Experimental|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
33235914|NCT04111523|Experimental|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
33235915|NCT04111523|Experimental|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
33235916|NCT04111523|Experimental|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
33235917|NCT04111523|Experimental|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
32750504|NCT05564247|No Intervention|Control Group (Attention)|Participants will be attention-matched to mimic time and contacts ‬of‭ ‬the‭ experimental‭ ‬group. The control group will receive 12, 45-minute weekly sessions of 'Games and Activities' facilitated by healthcare professionals (e.g., occupational therapy/rehabilitation students) who will not be involved in the intervention or any other aspect of the study. The control group facilitator will mimic the same type of attention as the training at each site (i.e., sessions will be held at healthcare facilities and in the community (e.g., libraries, shopping centres, museums, parks). Facilitators will be equipped with current popular games and activities (according to social media and websites of popular children's stores) kits that include various board and card games, hand-eye coordination games, active games, cognitive activities, and arts and crafts suitable for children and adolescents to ensure interest and acceptability for all participants.
33235918|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
33235919|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
33235920|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
33235921|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
32750505|NCT01918527|Other|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
33235926|NCT04186299|Experimental|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
33235927|NCT04186299|Active Comparator|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
33235928|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
33235929|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
33235930|NCT04266249|Experimental|Arm A (pCR after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate."
32750506|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
33235931|NCT04266249|Experimental|Arm B (residual invasive disease after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate."
33235932|NCT04113005|Experimental|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
33235933|NCT05646485|Experimental|BCa Early Screening Group|"All participants undergo Urinalysis testing every 6 months for 2 years. Based on the RBC count, each participant will go through each of the screening procedures : [cystoscopy + Upper tract imaging] or [urine marker cancer testing with Cxbladder triage + Upper tract imaging] or [Repeat urinalysis]~Patients with suspicious findings on cystoscopy or imaging will get treatment as per standard of care.~Their outcomes will be compared to a historical control (bladder cancer detected by standard of care using SEER registries)."
32750507|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
32750508|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
33235934|NCT05646485|No Intervention|Historical Control Group|This will include historical control (bladder cancer detected in patients by standard of care) using SEER registries).
33235935|NCT00588341|Experimental|Treatment|
33235936|NCT00914693|Experimental|Arm 1|
33235937|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
33235938|NCT00802529|Experimental|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
33235939|NCT00802529|Active Comparator|Gentamicin|Gentamicin
33235940|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
33235941|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
33235942|NCT05671835|Experimental|TTI-101 400 mg/day|Participants will receive 400 mg/day of TTI-101 twice daily (BID) for 12 weeks.
33235943|NCT05671835|Experimental|TTI-101 800 mg/day|Participants will receive 800 mg/day of TTI-101 BID for 12 weeks.
33235944|NCT05671835|Experimental|TTI-101 1200 mg/day|Participants will receive 1200 mg/day of TTI-101 BID for 12 weeks.
33235945|NCT05671835|Placebo Comparator|Placebo|Participants will receive a matching placebo BID for 12 weeks.
33235946|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
33235947|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
33235948|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
33394146|NCT04427501|Experimental|LY3819253 + LY3832479|350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
33394147|NCT04427501|Experimental|LY3853113 Open Label Addenda Arm 23|Administered IV
32750509|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
32750510|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
33394148|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
33235952|NCT05670743|Experimental|Silver diamine fluoride|Silver diamine fluoride, 38%, topical, single application
32909039|NCT04481516||Yoga|Single arm only representing cohort of NHS health care workers with possible Covid-19 related stress and anxiety disorder. Participants act as their own controls pre and post regular practice of yoga technique.
32909040|NCT04478474||Eligible|Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). Children, adolescent, and young adult patients, ages 0-≤26 years, who have received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor, who received ganciclovir prophylaxis for ≥14 days.
32750511|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
32750512|NCT04283019|Experimental|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
32909041|NCT05592938|Experimental|rPBI|26Gy in 5 daily fractions over 1-week
32750513|NCT04283019|Experimental|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
32750514|NCT04283019|Experimental|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
32750515|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
33070821|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
33070822|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
33235953|NCT04027517|Experimental|JTZ-951|Oral doses once daily
33235954|NCT04027517|Active Comparator|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
33235955|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
33235956|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
33235957|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
33235958|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
33235959|NCT00588731|Experimental|Cannabidiol|
33235960|NCT00588731|Placebo Comparator|Placebo|
33235961|NCT04111367|Experimental|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
33235962|NCT04111367|Experimental|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
33235963|NCT05629949|Experimental|QL1701+Docetaxel|Participants received intravenous infusion of QL1701 with docetaxel. The initial load dose of QL1701 was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
33394149|NCT03237052|Experimental|model|model aided decision
33394150|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
32750516|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
32750517|NCT05496465|Active Comparator|ARS-1 1mg|1 mg per 100 µL dose of ARS-1
32750518|NCT05496465|Active Comparator|ARS-1 2mg|2 mg per 100 µL dose of ARS-1
32750519|NCT05496465|Placebo Comparator|Placebo|Placebo (100 µL)
33235964|NCT05629949|Active Comparator|Herceptin®+Docetaxel|Participants received intravenous infusion of Herceptin® with docetaxel. The initial load dose of Herceptin® was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
32909042|NCT04438460|Experimental|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
32909043|NCT04438460|Other|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
33235965|NCT04111445|Experimental|ADG116|
33235966|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
32750520|NCT04440215|Other|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
32750521|NCT04440215|Experimental|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
32750522|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
32750523|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
32750524|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
32750525|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
32750526|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
32750527|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
32750528|NCT04362111|Experimental|Anakinra Group|The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.
32750529|NCT04362111|Placebo Comparator|Control Group|The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete repsonse criteria at 5 days, dosing wll be decreased to twice daily for the remaining 5 days.
32750530|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
32750531|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
32750532|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
32750533|NCT04282473||with mesh|Placement of lightweight (<50g/m2) monofilament mesh during colostomy formation
32909044|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
32909045|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
32909046|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
32909047|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
32909048|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
32909049|NCT01051310|Experimental|CoreValve|
33235967|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
33235968|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
32750534|NCT04282473||no mesh|colostomy without mesh placement
32750535|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Peanut skin prick test wheal ≥ 8 mm."
32909050|NCT03015584||Septic patients admitted to the ICU|
32909051|NCT05592860|Experimental|Mobile application|Mobile application to enter glucose level
32909052|NCT05592860|Placebo Comparator|Daily Diary|Daily Diary to record glucose level
32909053|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
33235969|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
33235970|NCT05629481|Experimental|CO2 laser group|Participants in the CO2 laser group underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals.
33235971|NCT05629481|Sham Comparator|Sham group|Participants in the sham group underwent three sham treatment sessions with 4-6 weeks intervals.
33235972|NCT05628857|Experimental|Cohort 1|gastric cancer patients
33235973|NCT05628857|Experimental|cohort 2|colorectal cancer patients
32909054|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
33235974|NCT05628857|Experimental|cohort 3|liver cancer patients
33235975|NCT05628857|Experimental|cohort 4|other digestive system malignancies, including esophageal cancer, pancreatic cancer, gallbladder cancer, etc.
33235976|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
33235977|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
33235978|NCT04109573|Experimental|Anorectal function post anal laser|"Intervention:~Device: laser"
32750536|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
32750537|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
33235979|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
33235980|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
33235981|NCT04017533|Experimental|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
33235982|NCT05642273|Experimental|Intervention|Oxiris for 24 h
32750538|NCT04357587|Experimental|Pembrolizumab|Experimental pembrolizumab and SOC external beam radiation and capecitabine
33235983|NCT05642273|Active Comparator|Control|Usual care
33235984|NCT05628233|No Intervention|Study Arm A (control arm)|Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity.
32750539|NCT04058717|Experimental|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
32750540|NCT04058717|Experimental|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
32750541|NCT04058717|Experimental|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
33235985|NCT05628233|Experimental|Study Arm B (treatment arm)|Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity.
33235986|NCT04109261||Palbociclib treatment|
32761972|NCT02332447|Placebo Comparator|PLACEBO|
32761973|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
32761974|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
33070823|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
33235987|NCT04109339|No Intervention|group 1 with no oxytocin|
33235988|NCT04109339|Experimental|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
33235989|NCT04109339|Experimental|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
33235990|NCT04109339|Experimental|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
33235991|NCT05628077||PAIN|
33235992|NCT05628077||NO PAIN|
33235993|NCT04109495|Other|Smart phone application(NOOM)|
33235994|NCT04109495|Other|Non-user|
33235995|NCT04109417|Experimental|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
33235996|NCT04109417|Sham Comparator|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
33235997|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
33235998|NCT04097678|Experimental|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
33235999|NCT04097678|No Intervention|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
33394151|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
33236000|NCT00797225|Placebo Comparator|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
33236001|NCT00797225|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
33236002|NCT00797225|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
33236003|NCT00797225|Other|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
33236004|NCT04266093||Cohort 1|Subjects who have received treatment on an NCI GMB or GMB gene therapy protocol.
33236005|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
33236006|NCT05277285|No Intervention|Standard Treatment|The standard treatment includes the application of mechanical ventilation and / or support with the administration of inotropes and / or extracorporeal oxygenation (ECMO) and the intravenous administration of fluids and dexamethasone. The administration of any other immunosuppressive therapy, including tocilizumab and / or antimicrobials at the discretion of the therapists, is permitted.
33236007|NCT05277285|Experimental|One intravenous 12.5 gr STS - Treatment Group 1|Patients will receive standard treatment and one intravenous (iv)12.5 gr STS in 60 minutes continuous intravenous infusion. STS is dissolved in a final volume of 100ml N/S 0.9% w/v,
33236008|NCT05277285|Experimental|Three intravenous doses of 12.5 gr STS - Treatment Group 2|Patients will receive standard treatment and three intravenous doses of 12.5 g STS. STS is dissolved in a final volume of 100ml N/S 0.9% w/v. Each dose will be given in 60 minutes of continuous intravenous infusion with 48 hours intervals between each dose.
33236009|NCT04069143|Experimental|Part 1|
33236010|NCT04069143|Experimental|Part 2|
33236011|NCT04069143|Experimental|Part 3|
33236012|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
33236013|NCT04085523|Other|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg or placebo mimicking TransCon CNP 6 mcg delivered once weekly by subcutaneous injection
33236014|NCT04085523|Other|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg or placebo mimicking TransCon CNP 20 mcg delivered once weekly by subcutaneous injection
33236015|NCT04085523|Other|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
33236016|NCT04085523|Other|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
33236017|NCT04085523|Other|TransCon CNP >100 mcg|TransCon CNP >100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)
32909055|NCT05592782|Experimental|Study Arm|
33236018|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
33070824|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
33236019|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
33236020|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
33236021|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
33236022|NCT04077333|Experimental|MISA group|minimal invasive surfactant administration group
32750542|NCT04058717|Experimental|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
32750543|NCT05496387|Experimental|Study Group One|Sciatic nerve neuromobilization techniques (tension) was applied to the dominant side lower extremities of all participants in the study.
33070825|NCT04891393|Experimental|Caffeine|Single-dose, orally ingested, instant coffee.
33070826|NCT04891393|Placebo Comparator|Inactive Placebo|Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).
33236023|NCT04077333|No Intervention|EISA group|conventional treatment: endotracheal intubation surfactant administration group
33236024|NCT00778700|Placebo Comparator|Vehicle Cream|Vehicle cream, applied topically, once daily from Day 1 to Week 12.
33236025|NCT00778700|Experimental|Ruxolitinib Phosphate 0.5% Cream|Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
33236026|NCT00778700|Experimental|Ruxolitinib Phosphate 1.0% Cream|Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
33236027|NCT00778700|Experimental|Ruxolitinib Phosphate 1.5% Cream|Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.
32909056|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
33070827|NCT03458065||S-ICD|
33070828|NCT03458065||T-ICD|
33070829|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
33070830|NCT02938702||Active surveillance|Group with active surveillance of their PTC
33236028|NCT04077489|Other|MT|Macular thickness
33236029|NCT00793403||1|As per routine clinical care
33236030|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
33236031|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
33236032|NCT04110899|Experimental|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
33236033|NCT04100876||primary ITP patients .|60 primary ITP patients .
33236034|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
33236035|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
33236036|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
33236037|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
33236038|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
33236039|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
33236040|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
33236041|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
33236042|NCT04109183|Experimental|Active Comparator: FNC 2 mg+ TDF+EFV|
33236043|NCT04109183|Experimental|Active Comparator: FNC 3 mg+ TDF+EFV|
33236044|NCT04109183|Experimental|Active Comparator: FNC 4 mg+ TDF+EFV|
33236045|NCT04109183|Experimental|Postive Comparator: 3TC+ TDF+EFV|
33236046|NCT04055883|Experimental|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
33236047|NCT04055883|Experimental|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
33236048|NCT04055883|Placebo Comparator|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
33236049|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
33236050|NCT04036695|Experimental|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
33236051|NCT00793325||Somatropin|Patients administered Somatropin.
32761975|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
33236052|NCT04042701|Experimental|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
33236053|NCT04042701|Experimental|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
33236054|NCT04042701|Experimental|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
33236055|NCT04042701|Experimental|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
33236056|NCT04042701|Experimental|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
33236057|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
33236058|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
33236059|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
33236060|NCT04076553|Active Comparator|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
33236061|NCT04076553|Sham Comparator|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
33236062|NCT04077645|Experimental|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
33236063|NCT04077645|Active Comparator|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
33236064|NCT04077645|Other|Seated rest (attentional control)|Watching educational videos for 30 minutes.
33236065|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
33236066|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
33236067|NCT04237467||Older transgender men|This cohort will consist of transgender men aged 50-75 years old who have taken testosterone for at least one year.
33236068|NCT04237467||Younger transgender men|This cohort will consist of transgender men aged 18-40 years old who have taken testosterone for at least one year.
33236069|NCT04076475|Experimental|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
33236070|NCT04076475|Sham Comparator|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
33236071|NCT05121441|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
33236072|NCT05121441|Placebo Comparator|Placebo Comparator|Placebo arm matching active arm ARD-101, 200 mg BID
33236073|NCT04011267|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
32750544|NCT05496387|Experimental|Study Group Two|Sciatic nerve neuromobilization techniques (sliding) was applied to the dominant side lower extremities of all participants in the study.
33236074|NCT04011267|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
33070831|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
33236075|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
33236076|NCT00778622|Experimental|A2|Overweight by Body Weight Index
33236077|NCT00778622|Experimental|A3|Obese by Body Weight Index
33236078|NCT00915980||Patients without diabetes undergoing gastric bypass|
33236079|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
33236080|NCT04236141|Experimental|Polatuzumab Vedotin plus BR|
33236081|NCT04236141|Active Comparator|Placebo plus BR|
32909057|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
32909058|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
33236082|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
33236083|NCT00916682||Cystic Fibrosis|
32909059|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
33236084|NCT04097522|Active Comparator|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
33070832|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
33236085|NCT04097522|Sham Comparator|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
33236086|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
33070833|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
33236087|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
33236088|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
33236089|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
33236090|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
33236091|NCT04097444|Experimental|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.~[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
33236092|NCT04097444|Experimental|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: FOLFOXIRI+BEV] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
33241630|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
33241631|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
33236093|NCT04097444|Experimental|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
33236094|NCT04097288|Experimental|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
33236095|NCT04097288|Active Comparator|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
33236096|NCT04097288|Placebo Comparator|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
33236097|NCT04097288|Placebo Comparator|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
33236098|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
33236099|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
33236100|NCT05507138|Experimental|AKL-T01|Participants in the intervention group will complete 25 minutes of AKL-T01 per day, 5 days/week, for 6 weeks. AKL-T01 trains rapid multitasking on an iPad in an immersive videogame-like environment. Participants complete go/no-go + navigation exercises by moving the iPad to navigate a character on a path while tapping when a certain stimulus is presented and ignoring other stimuli. Participants will also receive weekly 45-minute metacognitive strategy coaching sessions delivered by a clinician. Sessions use guided questions and worksheets (shared virtually) to help participants reflect on their experience with AKL-T01 and link it to daily functioning, generate strategies for daily activities, and explore any emotional responses that arise during gameplay.
32750545|NCT05496387|Sham Comparator|Control Group|No application was applied to the sham group
33070834|NCT04690543|Active Comparator|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
32750546|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
33070835|NCT04690543|Experimental|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
33070836|NCT04839523|Experimental|Exufiber|Treatment with Exufiber gelling fiber dressing
33236101|NCT05507138|Placebo Comparator|Enhanced Metacognitive Strategy Training|"In the control group, participants will complete-at the same frequency and duration as the intervention group-iPad-based games designed to provide general cognitive stimulation (word searches, checkers, and spot the differences between two pictures). Concurrently with these cognitive stimulation games, participants will receive weekly metacognitive strategy coaching sessions akin to that described above."
33236102|NCT04076007|Active Comparator|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
33070837|NCT04839523|Experimental|Exufiber Ag+|Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing
33236103|NCT04076007|Placebo Comparator|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
33236104|NCT04005105|Active Comparator|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group~1 based on cardiac index and MPP will be followed for 24 hours."
33236105|NCT04005105|No Intervention|Standard management|MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
33070838|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
33236106|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
33236107|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
33236108|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
33236109|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
33236110|NCT03995901|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
33236111|NCT03995901|No Intervention|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and +/- corticosteroids after kidney transplant.~Control donors are not followed beyond randomization."
33236112|NCT04076085|Active Comparator|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
33236113|NCT04076085|Active Comparator|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
33236114|NCT04076085|No Intervention|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
33236115|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
33236116|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
33236117|NCT04231539|Experimental|Low Nicotine (nicotine vapor) 24 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
33236118|NCT04231539|Experimental|High Nicotine (nicotine vapor) 42 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
33236119|NCT04228419|Active Comparator|Total Shoulder Arthroplasty (anatomic)|TSA procedure involves replacing the worn-out ball and socket joint with prosthetic components.
33236120|NCT04228419|Active Comparator|Reverse Shoulder Arthroplasty|RSA procedure is similar to a TSA, however the orientation of the ball and socket joint is placed in the reverse position
33394152|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
33070839|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
33394153|NCT04487938||Tobacco use and/or alcohol consumption|
33394154|NCT04487938||No tobacco use and/or alcohol consumption|
33236121|NCT05674617|Experimental|Written Exposure Therapy (WET)|5 individual therapy sessions of WET via video telehealth
33236122|NCT05674617|Active Comparator|PTSD Education Control|5 individual sessions of PTSD psychoeducation via video telehealth
33236123|NCT05247957|Experimental|NKG2DL-specific CAR-NK cells|Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated
33236124|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
33236125|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
33236128|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
33236129|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
33236130|NCT04075773|Experimental|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
33236131|NCT04075773|Sham Comparator|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
33236132|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
33236133|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
32750547|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
33236134|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
33236135|NCT04075851||Healthy crowd|Draw 10 ml venous blood
33236136|NCT03799341|Experimental|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
32750548|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
32750549|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
33236137|NCT03799341|Experimental|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
33236138|NCT04108871|Experimental|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
33236139|NCT04108871|Active Comparator|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
33236140|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
33236141|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
33236142|NCT03941769|Experimental|Supportive care (recombinant interleukin-7)|Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.
32750550|NCT04480229|Experimental|Intervention Group|After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
33236143|NCT03939819|Experimental|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
33236144|NCT03939819|Active Comparator|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
32750551|NCT04480229|No Intervention|No Intervention: Control Group|"During their first treatment the Patient Identification Form was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the Symptom follow-up form, asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The Symptom Follow-up Form given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment"
32750552|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
32909060|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
33070840|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
33236145|NCT05674383|Experimental|Intervention group|The intervention group will recieve an axilliary plexus nerve block as pain reduction before the fracture repositioning.
33236146|NCT05674383|Active Comparator|Control group|The control group will recieve a fracture hematoma block as pain reduction before the fracture repositioning.
33236147|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
33236148|NCT04210089|Experimental|Soft Cast with a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast with removable cam boot.
32750553|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
32750554|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
32750555|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
32750556|NCT02395913|Active Comparator|R|
32750557|NCT02395913|Experimental|T1|
32750558|NCT02395913|Experimental|T3|
32750559|NCT02395913|Experimental|T4|
32750560|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
32750561|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
32750562|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
32750563|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
32750564|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
32750565|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
32750566|NCT04440293|Experimental|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
32750567|NCT04440293|Experimental|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
32750568|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
32750569|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
32750570|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
32909061|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
32909062|NCT05592704|Experimental|Intervention group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program using wearable device (heart rate monitor), which was connected to the smartphone via Bluetooth. A special smartphone application enabled participants to keep their training heart rate during home-based exercises (or workouts).
32909063|NCT05592704|No Intervention|Control group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program without wearable devices and smartphone application.
32750571|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
32750572|NCT05564013|No Intervention|Phase 1 - Patient feedback and needs analysis|To facilitate the development of virtual reality application that is suitable for perioperative care management, a survey will be conducted in 100 subjects to gather patient preference and feedback with needs analysis.
32750573|NCT05564013|Experimental|Phase 2 - Evaluation of prototype efficacy|Comparison of pre-operative anxiety and post-operative pain in 60 patients before and after intervention using the developed virtual reality application.
32750574|NCT05563935|Active Comparator|OCD group|OCD patients will receive rTMS treatment for 6 weeks.
32750575|NCT05563935|No Intervention|HC group|Health control will not receive any treatment.
32750576|NCT05496153|Experimental|Cardiovascular diseases Patients|Subjects were recruited from outpatients with CVDs, under 18 years of age. All pa-tients have been verified the willingness of participating before the experiment. Patients was excluded if having abnormal blood pressure response, unstable angina pectoris, acute heart failure, congenital heart disease, and severe musculoskeletal diseases limiting.
32750577|NCT05499351|Experimental|Adult group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
32750578|NCT05499351|Experimental|Elderly group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
32750579|NCT05499351|Experimental|Adult group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
32750580|NCT05499351|Experimental|Elderly group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
32750581|NCT05496075|Experimental|Orlistat group|Orlistat was administered orally on the basis of lifestyle guidance.
32750582|NCT05496075|Placebo Comparator|control group|Orlistat placebo was administered orally on the basis of lifestyle guidance.
32750583|NCT05495919|Experimental|Control Group|No intervention was performed to reduce anxiety in the control group
32750584|NCT05495919|Experimental|video interaction group|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
32750585|NCT05495919|Experimental|Flipped Training|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
32750586|NCT05563623||progression group|
32750587|NCT05563623||non-progression group|
32750588|NCT04280055|Experimental|Psilocybin|
32750589|NCT05495685||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
32750590|NCT05495685||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
32750591|NCT05495607||Patients|We have included 25 neonates and small infants having received CARPEDIEM® machine in France in a multicentric experience
32750592|NCT05499195||ESD group|ESD was performed by a highly experienced endoscopist who underwent systemic training. First, the endoscopist carried out chromoendoscopy by spraying 1.25% Lugol's iodine solution to identify the lesion and made dots with a dual-knife outside the margin of the lesion. Next, a forward-viewing endoscope was introduced with a transparent cap attachment on its tip. A saline solution with methylene blue and epinephrine was injected into the submucosa with an injection needle to create a liquid cushion separating the lesion and the muscle layer. Then, a mucosal incision at the periphery of the marking dots was performed with a dual-knife. After that, the submucosal connective tissue beneath the lesion was dissected using the same dual-knife, and the lesion was totally removed through dissection.
32750593|NCT05499195||ESD+adjuvant radiotherapy group|The process of ESD was the same as that of ESD group. A total dose of 41.4-60.0 Gy in common fractionation based on three-dimensional conformal radiotherapy or intensity modulated radiotherapy technology was prescribed.
32750594|NCT04424823|Experimental|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
32750595|NCT04424823|Sham Comparator|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
32750596|NCT04265781|Experimental|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
32750597|NCT04265781|Experimental|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
32750598|NCT04265781|Placebo Comparator|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
32750599|NCT04265781|Placebo Comparator|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
32750600|NCT05495529||Patients|Patients with single liver tumor traited by thermoablation with high iatrogenic risk, with biliary or digestive protection by ambiant air interposition
32750601|NCT05499117|Active Comparator|Antidepressant and light treatment group|
32750602|NCT05499117|Placebo Comparator|Antidepressants and pseudo-light therapy|
32750603|NCT05495451|Experimental|Mediterranean diet and Personalized training|"36 participants will participate to the following lifestyle changes for 6 months:~Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet.~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
32750604|NCT05495451|Active Comparator|Intermittent Fasting Intervention|Between 3 and 6 months, 24 participants (on a total of 36) will progressively integrate intermittent fasting 16:8 (5 times/week for 12 weeks) and 20:4 (2 times/week for 4 weeks)
32750605|NCT05495373||healthy cases|healthy children at ages between 4-12
32750606|NCT05563311|Experimental|high-intensity interval training|High-intensity interval training describes physical exercise that is characterized by brief, intermittent bursts of vigorous activity, interspersed with periods of rest or low-intensity exercise
32909064|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
32909065|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
32909066|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
32909067|NCT05592392|Experimental|Therapy|SDS system implanted and Therapy On for 6 months post randomization
32750607|NCT05499039|Active Comparator|Group A1 (NIVMV on hypoxemic)|Use of NIV on acute hypoxemic respiratory failure patients
32909068|NCT05592392|Sham Comparator|Control|SDS system implanted and Therapy Off for 6 months post randomization
32750608|NCT05499039|Experimental|Group A2 (HFNC on hypoxemic)|Use of HFNC on acute hypoxemic respiratory failure patients
32750609|NCT05499039|Active Comparator|Group B1 (NIVMV on hypercapneic)|Use of NIV on acute hypercapneic respiratory failure patients
32750610|NCT05499039|Experimental|Group B2 (HFNC on hypercapneic)|Use of HFNC on acute hypercapneic respiratory failure patients
32750611|NCT05495295|Experimental|Advanced Solid Tumours|"First-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours. The trial includes two parts, a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types:~Glioblastoma Multiforme (GBM)~Triple Negative Breast Cancer (TNBC)~Selected solid tumours"
32750612|NCT05495217|Experimental|Gasless Laparoscopy-assisted Gastrectomy|Patients receive Gasless Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
32750613|NCT05495217|Other|Conventional Laparoscopy-assisted Gastrectomy|Patients receive Conventional Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
32750614|NCT05495139|Experimental|A single arm study, only investigational product|To evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
32750615|NCT05498883|Other|patient requiring NIV|Clinical examination, completion of the ALS-FRS score, completion of the SRI score.
32750616|NCT05494983|Other|Session 1 : Peripheral Session (left) - session 2 Central Session (right)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
32750617|NCT05494983|Other|Session 1 : Peripheral Session (right) - session 2 Central Session (left)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
32750618|NCT05494983|Other|Session 1 : Central Session (left) - session 2 Peripheral Session (right)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
33070841|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
32750619|NCT05494983|Other|Session 1 : Central Session (right) - session 2 Peripheral Session (left)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
32761976|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
32761977|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
32909069|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
33070842|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
33072451|NCT05077865|Placebo Comparator|Cohort 4 - Placebo|2 subjects, randomized to receive placebo, administered on Days 1, 2, 3, 4, and 5 as four capsules each, matching the 150mg MYMD1 capsules in appearance.
33072452|NCT05075824|Experimental|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
33072453|NCT05075824|Placebo Comparator|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
33236149|NCT04210089|Experimental|Soft Cast without a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast.
33236150|NCT04210089|No Intervention|Conventional|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will use conventional offloading including total contact casting, removable cast boots (cam boots), CROW boots, bracing, AFO's, offloading shoes, insoles, padding, shoe modifications, crutches, wheelchairs, rollabout, and surgical correction.
33236151|NCT04209855|Experimental|mirvetuximab soravtansine (MIRV; IMGN853)|MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
33236152|NCT04209855|Active Comparator|Investigator's choice of chemotherapy|"Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle~Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)~Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)"
33236153|NCT04075929|Other|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
33236154|NCT04075929|Other|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
33236155|NCT04075929|Other|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
33236156|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
33236157|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
33236158|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
33236159|NCT04076865|Experimental|EMLA|
33236160|NCT00796367|Placebo Comparator|Placebo|Placebo
33236161|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
33236162|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
33236163|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
33236164|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
33236165|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
33236166|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
33236167|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
33072454|NCT05074420|Experimental|Baricitinib|Baricitinib given orally to participants daily
33236168|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
33236169|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.~Female~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0~Male~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.~Patients will take Phe for 4 weeks."
33236170|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.~Patients will take the Placebo for 4 weeks."
33236171|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
33236172|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
33236173|NCT03778827|Experimental|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
32750620|NCT05563233|Experimental|Helfer Skin Tap|"Helfer Skin Tap (rhythmic tapping of the skin at the injection site to relax the muscles during injection) is an effective method in reducing pain in intramuscular applications in studies performed with the injection technique.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined using the Helfer skin tap technique.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
33236174|NCT03778827|No Intervention|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
33236175|NCT04107233|Experimental|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
33236176|NCT04107233|No Intervention|Control|Usual care; may receive the intervention at the end of the study if successful
33236177|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
33236178|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
32750621|NCT05563233|Experimental|Shotblocker|"Shotblocker is a flat, horseshoe-shaped device with short, non-sharp 2 mm thick blunt protrusions that connect with the skin, and a hole in the middle to expose the injection site used to reduce pain during subcutaneous or intramuscular injection applications.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined by using Shot Blocker.~5 minutes after the injection, the pain and fear levels of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
32750622|NCT05563233|No Intervention|control group|"Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~The level of pain and fear will be examined during intramuscular injection into the ventrogluteal region without any intervention.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
32750623|NCT05498805|Experimental|experimental group|PD-1 inhibitor combined with radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator. According to the lesion sties, SBRT or hyperfractionated radiotherapy was used.
33072455|NCT05067790|Experimental|Higher Dose Nusinersen|There will be two groups of participants previously treated with risdiplam in the study (nusinersen-naive group and nusinersen-experienced group), who will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months.
33236179|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
33236180|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
33236181|NCT05604989|Experimental|Neovascular AMD patients with anti-VEGF treatment, oral probiotics supplement|"Treatment-naive neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~Oral probiotics (The Perfect Probiotics®) supplement will be given to the participants for 6 months."
33236182|NCT05604989|Sham Comparator|neovascular AMD patients with anti-VEGF treatment, no oral probiotics supplement|"Treatment-naive neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
33236183|NCT05604989|No Intervention|Control patients, no oral probiotics supplement|"Healthy, no retinal disease patients will be allocated. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
33236184|NCT03905031|Experimental|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
33236185|NCT00792935|Experimental|MK-0941|
33236186|NCT00792935|Active Comparator|Glimepiride|
33236187|NCT03904563|Experimental|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
33236188|NCT00770510|Experimental|Eszopiclone 1 mg|
33236189|NCT00770510|Experimental|Eszopiclone 2 mg|
33236190|NCT00770510|Experimental|Eszopiclone 3 mg|
33236191|NCT00770510|Placebo Comparator|Placebo|
33236192|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
33236193|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
33236194|NCT04077177|No Intervention|Assessment Only|
33236195|NCT04077177|Experimental|Intervention|
33236196|NCT04077255|Experimental|anti-EGFR|Participants will receive GC-1118 in combination with weekly paclitaxel.
33236197|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
32750624|NCT05498805|Active Comparator|controlled group|PD-1 inhibitor without radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator.
32750625|NCT05562921||Case|
33236198|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
33236199|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33236200|NCT03772353|Experimental|Dalpiciclib combined with Pyrotinib and Endocrine therapy|"Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.~Dalpiciclib combined with Pyrotinib and Endocrine therapy (treatment of physician's choice: letrozole or fulvestrant) ER+/HER2+ metastatic breast cancer patients eligible for first- or second-line treatment were enrolled to receive dalpiciclib combined with pyrotinib and endocrine therapy (treatment of physician's choice: letrozole or fulvestrant)"
33236201|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
33236202|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
33236203|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
33236204|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
33236205|NCT04192929|Placebo Comparator|High definition white light endoscopy|colonoscopy performed using high definition equipment
33236206|NCT04192929|Active Comparator|Chromoendoscopy|indigo carmine is sprayed on the colon mucosa during withdrawal phase
33236207|NCT04192929|Experimental|Narrow band imaging|Narrow band imaging is used during withdrawal phase
33236208|NCT05559983|Experimental|OSP:rTTHc Cholera Conjugate Vaccine|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
33236209|NCT05559983|Experimental|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
33236210|NCT05559983|Placebo Comparator|Placebo|2 doses @0.5 mL of Sterile 0.9% sodium chloride administered intramuscularly in deltoid region at 4 weeks apart
33236211|NCT03765567|Experimental|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
33236212|NCT03765567|No Intervention|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
33394155|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
33394156|NCT04876794|Experimental|Arm 1|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
33394157|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
33394158|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
33394159|NCT04830852||Recovery Group|Participants aged 21 years and younger and enrolled within 12 weeks after acute infection or positive test. These participants will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years.
33394160|NCT04830852||Convalescent Group|Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection or positive test. These participants will attend study visits at baseline and subsequently every 6 months for a total of 3 years.
33394161|NCT04830852||Healthy contacts|Individuals (aged ≤21 years) without a diagnosis of SARS-CoV-2 infection or current symptoms suggestive of COVID-19 will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years.
33394162|NCT04830852||Parents/guardians of participants|Parents or guardians of participants in all cohorts will also be enrolled for limited participation to complete questionnaires about how the family is impacted by the participant's health and SARS-CoV-2.
33394163|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
33236213|NCT03765567|No Intervention|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
33394164|NCT04809246|No Intervention|Standard of care|The first group (n=240) of participants enrolled in the study will be assigned to the control period to receive the standard of care.
32750626|NCT05562921||Control|
33236214|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
33236215|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
33394165|NCT04809246|Experimental|'One-stop-shop' intervention|Following the control period, the second group (n=300) of participants enrolled in the study will be assigned to the intervention period to receive the 'one-stop-shop' intervention.
33394166|NCT04486144|Experimental|COVID19 Positive: Intervention Group (Receive extract)|These are patients that are COVID19 positive who elect to try the extract.
33236216|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
33236217|NCT05559905|Experimental|Panel A: Molnupiravir Prophylaxis|Participants receive molnupiravir 800 mg every 12 hours for 5 days beginning on Day -1, and are inoculated with RSV-A Memphis 37b on Day 0. Participants then receive placebo on the evening of Day 4 to the morning of Day 10.
33236218|NCT05559905|Experimental|Panel B: Molnupiravir Triggered Treatment|Participants receive placebo on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue to receive placebo until testing positive for RSV. Participants then receive molnupiravir 800 mg every 12 hours for 5 days.
33236219|NCT05559905|Placebo Comparator|Panel C: Matched Placebo|Participants receive placebo from Day -1 to Day 10, and are inoculated with RSV-A Memphis 37b on Day 0.
33236220|NCT00777296|Experimental|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
33236221|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
33236222|NCT00777296|Experimental|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
33236223|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
33236224|NCT05186805|Experimental|tapinarof cream|Tapinarof (DMVT-505) cream, 1% applied topically once daily
33236225|NCT04106609|Experimental|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
33236226|NCT04106609|Active Comparator|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
33236227|NCT02603549||Surgery or Blood Patch|
33236228|NCT05084547||Case|Subjects with Bronchiectasis
33236229|NCT05084547||Control|Healthy Controls
33236230|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
33236231|NCT04076163|No Intervention|control group|group of students participating to a face-to-face learning
33236232|NCT04076163|Other|intervention group|group of students using serious game
32750627|NCT05494905|Experimental|Virtual Reality (VR)|
33236233|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
32750628|NCT05494905|Active Comparator|Functional Strength Training (FST)|
33236234|NCT05674071|Experimental|Articulation/HVT|This intervention will use articulation and high-velocity thrust techniques
33236235|NCT05674071|Experimental|Soft-tissue massage|This intervention will use soft-tissue massage
33236236|NCT05674071|Experimental|Craniosacral techniques|This intervention will use craniosacral techniques
33236237|NCT05674071|Experimental|Combination|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral
33236238|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
33236239|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
33236240|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
33236241|NCT05501678|Experimental|Diphenhydramine, then Placebo|"Participants will first receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
33236242|NCT05501678|Experimental|Placebo, then Diphenhydramine|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
33070843|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
33236243|NCT04106921|Experimental|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
33236244|NCT04106921|No Intervention|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
33070844|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
32750629|NCT05498571||Schizophrenia Patients|We collect relevant information, review cardiovascular events in schizophrenia patients.
32750630|NCT05494827|Experimental|Borjomi|Healthy volunteers (N16, 8 males and 8 females) 30.63±1.04 y.o. with BMI 22.17±0.75 kg/m2 were randomly allocated to Borjomi group. Participants received 30 bottles (500 ml) of natural mineral water Borjomi® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test
33236245|NCT05052567|Experimental|CEND-1|CEND-1+paclitaxel (albumin-bound type)+gemcitabine
33236246|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
33236247|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
33236248|NCT04108793|Experimental|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip & knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
32750631|NCT05494827|Active Comparator|Smart Spring|Healthy volunteers (N16, 8 males and 8 females) 28.56±1.61 y.o. with BMI 23.14±0.60 kg/m2 were randomly allocated to Smart Spring group. Participants received 30 bottles (500 ml) of processed drinking water Smart Spring® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
33236249|NCT04108793|No Intervention|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
33236250|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
33236251|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
33236252|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
33236253|NCT04170621|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
33236254|NCT04108715|Active Comparator|ESPB GROUP|Erector spina plane block group
33236255|NCT04108715|Active Comparator|SAPB group|Deep Serratus anterior plane block group
33236256|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
33236257|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
32750632|NCT05494827|Placebo Comparator|Control group|Healthy volunteers (N16, 8 males and 8 females) 30.69±1.74 y.o. with BMI 22.67±0.51 kg/m2 were randomly allocated to Control group. Participants received 30 bottles (500 ml) of steal drinking water Святой Источник® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
32761978|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals~Intervention-B: Drink extra water at anytime over 24 hours"
33241632|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
33236258|NCT03862131|Experimental|MyoStrain® unblinded treatment arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk Group~The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.~Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
33236259|NCT03862131|Active Comparator|MyoStrain® blinded control arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk group~The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care~Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
33070845|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
33070846|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
33236260|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
33236261|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
33236262|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
33236263|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
33236264|NCT05496374|Placebo Comparator|Double Blind: Placebo|Participants will receive matching placebo 4 capsules, orally once daily (QD) for 56 days.
33070847|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
33070848|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
32744967|NCT02610777|Experimental|Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2|Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
33236265|NCT05496374|Experimental|Double Blind: SPR720 Low Dose|Participants will receive SPR720 500 milligrams (mg) [250 mg × 2 capsules and 2 matching placebo capsules, orally QD for 56 days.
33236266|NCT05496374|Experimental|Double Blind: SPR720 High Dose|Participants will receive SPR720 1000 mg [250 mg × 4 capsules], orally QD for 56 days.
33236267|NCT05496374|Experimental|Open Label: SPR720 High Dose|Participants will receive SPR720 1000 mg [250 mg × 4 capsules], orally QD for 56 days.
33236268|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.~Two substudies will be proposed:~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
33236269|NCT04019730|Experimental|low carbohydrate diet|less than 10 En% carbohydrates
33236270|NCT04019730|Experimental|high carbohydrate diet|more than 50 En%carbohydrates
33236271|NCT05042583|Experimental|experimental group|The experimental group was injected with 0.5% ropivacaine 6ml
32744968|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
33236272|NCT05042583|Placebo Comparator|Control group|control group was injected with 6ml normal saline.
33236273|NCT00721578||1|
33236274|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
33236275|NCT00789737|Placebo Comparator|placebo|placebo
33236276|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
33236277|NCT04075617|Experimental|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
32909070|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
33236278|NCT04075617|Active Comparator|control group|palatal crib will be cemented after impression taking and fabrication
33236279|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
33236280|NCT02592252|Experimental|Microfinance only|Receive microfinance only
33236281|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
33236282|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
33236283|NCT04019574|Experimental|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
33236284|NCT04019574|Experimental|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
33236285|NCT04019574|Placebo Comparator|Placebo IV|
33236286|NCT04019574|Active Comparator|Moxifloxacin 400 mg|
33236287|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom~Evaluated items:~Number of seizures~Type of seizures~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before cognitive disorders"
33236288|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom~Evaluated items:~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before epileptic seizures"
33236289|NCT05082051|Active Comparator|CDX-7108|CDX-7108, an oral recombinant lipase. It is a modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovans (btLIP) and produced by fermentation of recombinant Escherichia coli.7
33236290|NCT05082051|Placebo Comparator|Placebo|Excipients only
33236291|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
33236292|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
33236293|NCT04106687|Active Comparator|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
32744969|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
32744970|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
33236294|NCT04106687|Active Comparator|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
33236295|NCT05374122|Experimental|DSOC + AI-biopsy guidance|"This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy. In this group, the investigators aim to use as a complement tool an AI model for the detection of features suggestive of malignancy to perform the biopsy on the detecting bounding box signal.~A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions."
32744971|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
33236296|NCT05374122|Active Comparator|DSOC biopsy without AI guidance|This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy without AI guidance. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
33236297|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
33236298|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
32750633|NCT05494593|Experimental|ITR + ELAPRASE|"Participants will receive prophylactic ITR which consist of rituximab, methotrexate and IVIG in a 5-week cycle. Following the completion of 1 cycle and at the Month 6, 12, and 18 study visits, an assessment will be made regarding the need for administering another 5-week cycle of the ITR depending on the trend of the participants anti-idursulfase antibody titers and lymphocyte quantitation and CD19 percent (%) recovery.~Elaprase treatment (IV, weekly) will start 1 day after the initiation of the first cycle of ITR and continue for 104 weeks.~The dose of ELAPRASE will be calculated based on the participant's weight at each visit."
33236299|NCT04110977|Experimental|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
32750634|NCT04311723|Active Comparator|Group I (conventional mechanical ventilation)|Patients receive anesthesia using a standard short breathing tube called LMA and then undergo standard of care bronchoscopy.
32750635|NCT04311723|Experimental|Group II (VESPA)|Patients receive anesthesia using a longer breathing tube called an endotracheal tube and then undergo standard of care bronchoscopy.
32750636|NCT04424433|Other|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
32750637|NCT04424433|Other|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
32750638|NCT05494515|Experimental|the early swallowing rehabilitation program|swallowing problem eveluated by high resolution impedance manometry (HRIM). The early swallowing rehabilitation program based on the results of HRIM evaluation
32909071|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
33070849|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
33236300|NCT04110977|Active Comparator|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
33236301|NCT05359146|Experimental|Phase 0a, Group 1|"The first test injection will be with 161Tb-DOTA-LM3; the second one will be with 177Lu-DOTATOC. The ~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq ~ 200 μg 177Lu-DOTATOC with renal protection Not more than 6 weeks later patients will receive ~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
33394167|NCT04486144|No Intervention|COVID19 Positive: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 positive who do NOT elect to try the extract
33236302|NCT05359146|Experimental|Phase 0a, Group 2|"The first test injection will be with 177Lu-DOTATOC; the second one will be with 161Tb-DOTA-LM3. The ~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: Group 2: 0.5 - 1 GBq ~ 200 μg 177Lu-DOTATOC with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
33236303|NCT05359146|Experimental|Phase 0b, Group 1|"Both test injections will be with 161Tb-DOTA-LM3 (with different peptide amounts). The ~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: ~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: ~ 2 GBq ~ 300 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 2 cycles with ~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if ~2 GBq is well tolerated"
33236304|NCT05359146|Experimental|Phase 0b, Group 2|"Start with the other peptide amount of 161Tb-DOTA-LM3. The ~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: ~ 2 GBq ~ 300 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: ~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 2 cycles with ~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if ~2 GBq is well tolerated"
33236305|NCT04166487|Experimental|Pembrolizumab Cycles 1-2|"For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.~InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.~At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;~PEMBROLIZUMAB Alone~PEMBROLIZUMAB + Doublet Chemotherapy"
33236306|NCT04166487|Experimental|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:~Response of Partial Response/Complete Response~Response of Stable Disease with plasma response~Response of Progressive Disease without worsening cancer symptoms AND plasma response"
33394168|NCT04486144|Experimental|COVID19 Exposed: Intervention Group (Receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.
33394169|NCT04486144|No Intervention|COVID19 Exposed: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.
33394170|NCT04760808||AIS group|
33394171|NCT04760808||Control Group|
33394172|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
32744972|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
32750639|NCT05494515|No Intervention|the routine care group|patients recieve swallowing education
32750640|NCT05498415|Active Comparator|Education|Participants will receive basic education information on physical activity, sedentary behavior, and sleep for 8 weeks.
33394173|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
33394174|NCT04693806|Experimental|Continuous CO2 Level|embryos will remain in a single incubator set at a continuousCO2 level
33394175|NCT04693806|No Intervention|Sequential CO2 Level|Current standard of care
33394176|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
33394177|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
32750641|NCT05498415|Experimental|Education + Health Coaching + Activity Monitor|Participants will receive education information on physical activity, sedentary behavior and sleep plus health coaching plus a Fitbit activity monitor for 8 weeks.
33236307|NCT04166487|Experimental|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.~PEMBROLIZUMAB~Chemotherapy multiple agents systemic~PEMETREXED~CARBOPLATIN~PACLITAXEL"
33236308|NCT04086498|Experimental|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
32750642|NCT05494359||ESCA group|"40 patients of ESCA were included through the diagnosis of gastroscopic biopsy positive.~Age, gender, esophageal cancer staging, tumor biomarkers and other laboratory test indicators, CT and other imaging examinations results, gastroscope and pathological examinations results have been collected."
33394178|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
33236309|NCT04086498|Active Comparator|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
33236310|NCT04086498|Active Comparator|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
33394179|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
32909072|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
33236311|NCT00792467|Experimental|ITF2357|"Patients received the following therapy cycle~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles.~The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles."
33236312|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
33236313|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
33236314|NCT05600777|Experimental|BLU-5937 25 mg|BLU-5937 oral dose 25 mg twice a day.
33236315|NCT05600777|Experimental|BLU-5937 50 mg|BLU-5937 oral dose 50 mg twice a day.
33236316|NCT05600777|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
33236317|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
33236318|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
33236319|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
33236320|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
33236321|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
33236322|NCT05600387|Experimental|Empagliflozin group|subjects in Empagliflozin group take 10mg Empagliflozin 10mg per day
33236323|NCT05600387|No Intervention|Control group|subjects in Control group will not receive Empagliflozin or other sglt-2 inhibitors
33236324|NCT04075305||Brain cancer|
33236325|NCT04075305||Lung cancer|
33236326|NCT04075305||Esophageal cancer|
32909073|NCT03015428|Experimental|Psychoeducation|"Interventions:~Give information Teach and train strategies"
33236327|NCT04075305||Breast Cancer|
33236328|NCT04075305||Head and Neck Cancer|
33236329|NCT04075305||Pancreatic cancer|
33236330|NCT04075305||Gynecological cancer|
33236331|NCT04075305||Rectal cancer|
33236332|NCT04075305||Prostate cancer|
33236333|NCT04075305||Bladder cancer|
33236334|NCT04075305||Oligometastases|
33236335|NCT04075305||Liver cancer|
33236336|NCT04075305||Other types of cancer|
33236337|NCT04087044|Experimental|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
33236338|NCT04087044|Other|Control|120 aged matched controls
33236339|NCT05557409|Experimental|AXS-05|Up to 5 weeks
33236340|NCT05557409|Placebo Comparator|Placebo|Up to 5 weeks
33236341|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
33236342|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
33236343|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
33236346|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
33236347|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
33236348|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to <18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
33236349|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to <18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
33236350|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to <12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
33236351|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to <6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
32750643|NCT05494359||Health control|"40 healthy people who experienced negative gastroscopy and tumor biomarkers were included as healthy control.~Age, gender, gastroscope, tumor biomarkers and other laboratory test results have been collected."
32750644|NCT05494359||Reflux esophagitis|40 patients of reflux esophagitis were included. Age, gender, tumor markers and other laboratory test indicators, gastroscope and pathological examinations results have been collected.
32750645|NCT05498337|Other|Examiner|Examiner
32750646|NCT05498337|No Intervention|Patient|Patient
32750647|NCT04424667|Active Comparator|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
32909074|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
33236352|NCT03725007|Experimental|Participants of age group 2 to <18 years receiving dose A|Participants of age group 2 to <18 years administered with upadacitinib dose A as described in the protocol.
33236353|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
32750648|NCT04424667|Experimental|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
32750649|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
32750650|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
32750651|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
32750652|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
32750653|NCT04046055|Experimental|Sham and Experimental Sessions|"50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.~A unilateral cerebellar montage will be applied. tDCS intensity will be 2 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 2 mA. A unilateral cerebellar montage will be applied. tDCS intensity will be 4 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 4 mA."
32750654|NCT05494281|Experimental|Placebo|
33236354|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
33236355|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
33236356|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
33236357|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
33236358|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
33236359|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
32750655|NCT05494281|Experimental|Serratus anterior plane block|
33394180|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
32750656|NCT05494203||spa|Untreated patients meeting the revised AS New York diagnostic criteria or the ASAS classification criteria for axial SpA. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
32750657|NCT05494203||HC|healthy control. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
32750658|NCT05486091|Experimental|App-Enhanced Brief Cognitive-Behavioral Therapy|Up to 4 in-person sessions
32750661|NCT05494047|Experimental|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine developed by Sinovac Biotech Co.(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
32750662|NCT05494047|Active Comparator|Vaxigrip Tetra TM|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine Vaxigrip Tetra TM(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
32750663|NCT05493969|Other|DTG/3TC|Subjects will switch to dolutegravir (DTG) plus lamivudine (3TC) or fixed dose combination DTG/3TC for 48 weeks.
32750664|NCT05491629||surgical team members|The aim of this study is to determine with a deep understanding the perceptions of the operating room nurses' competence and the surgical team's views on the competence of nurses and the factors affecting them. In the research, parallel data type in convergent parallel mixed design (convergent parallel) was used to obtain rigorous, valid and reliable data with survey questions and individual interviews. In the quantitative dimension of the study, it was aimed to determine the perceptions of the operating room nurses about their competencies, and in the qualitative aspect, the thoughts/opinions of the entire surgical team about the competency of the operating room nurses and the factors affecting them.
32750665|NCT05493891||Group A|22 participants have exposed to midline spinal anaesthesia for cesarean delivery
32750666|NCT05493891||Group B|22 participants who were in the control negative group (no previous pregnancy or anaesthesia),
32750667|NCT05491473||Control|Patients who did not receive the application of iNPWT at the donor site.
32750668|NCT05491473||Negative pressure|Patients who received the application of iNPWT at the donor site.
32750669|NCT05493813|Active Comparator|Intubated Sevoflurane-GA group|After preoxygenation for 3 minutes with 100% oxygen, anesthesia is induced with intravenous injection of propofol (1.5-2 mg/kg), remifentanil infusion (Ce value around 1-1.5 ng/kg), and cisatracurium (0.15-0.2 mg/kg), and followed by endotracheal intubation. General anesthesia is maintained with cisatracuirum (0.03 mg/kg every 45-50 min), remifentanil (Ce value around 1-1.5 ng/kg) and sevoflurane inhalation. Sevoflurane concentration will be adjusted to keep BIS value within the range of 40-60. Mechanical ventilation will be processed at volume-controlled mode with fraction of inspired oxygen (FiO2) 60%, tidal volume 6 ml/kg, and respiratory rate 9-12/min to keep normocapnia and avoid desaturation during the EVT procedure.
32909075|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
32909076|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
32909077|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
32909078|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
32909079|NCT05591612|Experimental|MSG (Monosodium Glutamate)|Vegetables and foods prepared with MSG
32909080|NCT05591612|Other|NaCl (sodium chloride/table salt)|Active control/Standard practice Vegetables and foods prepared with table salt
32909081|NCT05591612|Experimental|KCl (potassium chloride/salt substitute)|Vegetables and foods prepared with KCl
32909082|NCT04197596|Experimental|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
32909083|NCT05591456|Experimental|group 1|The first group 50 patient (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week,
32909084|NCT05591456|Active Comparator|group 2|the second group 50 patient (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
32909085|NCT05590208|Experimental|sleeve gastrectomy+ cruroplasty + omental rape|sleeve gastrectomy+ cruroplasty + omental rape
33394181|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
33394182|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
33236360|NCT05073237|Experimental|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. Recommended and only FDA approved dosage is one CE/BZA tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
33236361|NCT05073237|Placebo Comparator|Placebo|Participants assigned to placebo will receive a daily tablet. To assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication. Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about CE/BZA and its potential side effects and contraindications, again to maintain the blind.
32750670|NCT05493813|Active Comparator|Non-intubated TIVA-propofol group|With the application of Optiflow nasal high flow set at a flow rate of 20 L/min and 60% FiO2, total intravenous anesthesia is induced with target-controlled infusion of propofol (effect site (Ce) concentration around 1.5-2 μg/ml) and remifentanil (Ce value around 1.0-1.5 ng/ml), and adjusted as required.
32750671|NCT05491395|Experimental|Post Mastectomy Hypofractionated Radiotherapy Arm|Post Mastectomy Hypofractionated Radiotherapy Arm
32750672|NCT05491395|No Intervention|Post Mastectomy Conventional Radiotherapy|Post Mastectomy Conventional Radiotherapy
32750673|NCT05493657|Active Comparator|Aspirin group|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
33236362|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
32750674|NCT05493657|Experimental|Clopidogrel group|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
32750675|NCT05485701||Perinatal women|Women will be recruited in their first trimester of pregnancy and followed-up until 6 months post-partum. This is the 'exposed' group.
32750676|NCT05485701||Non-perinatal women|Non-perinatal women will be recruited as the 'non-exposed' group and followed-up over the same duration as the perinatal group.
32761979|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
32761980|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32909086|NCT04171466|Active Comparator|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
33236363|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
33236364|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
32761981|NCT05077813|Active Comparator|9 cis retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32761982|NCT05077813|Active Comparator|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32898256|NCT03507452|Experimental|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
32898257|NCT03497897|Experimental|LYS006 20 mg BID|LYS006, 20 mg, orally, twice daily (BID), for 12 weeks
32898258|NCT03497897|Experimental|LYS006 2 mg BID|LYS006, 2 mg, orally, BID, for 12 weeks
32898259|NCT03497897|Placebo Comparator|Placebo BID|Matching placebo, orally, BID, for 12 weeks
32750677|NCT05485623|Experimental|clinician guided scan comparing the device output to the in clinic scan (ground truth) output|2. Clinician guided scan: an ultrasound scan during a telehealth session using Pulsenmore platform which will take place in a clinic private room, with a professional sonographer, who will instruct and guide the patient how to operate the ultrasound prob, to acquire the required images. Later, on the same day, the patients will have an in-person clinic visit and will be scanned using a conventional sonographic equipment. The in-clinic scan will serve as Ground truth (GT). The images from the clinician guided scan will be automatically uploaded to the cloud from the patient's device and interpret by a physician The scan interpretation will include but not limited to visualization of the uterus and ovaries, number and size of follicles and endometrial thickness. The in-person scans will be read and interpreted immediately after the procedure by a physician blinded to the previous video guided/clinician guided sessions. The images will be downloaded and stored for documentation.
32750678|NCT05485623|Experimental|video guided scan comparing the device output to the in clinic scan (ground truth) output.|1. Video guided arm: Video guided scan which includes self-acquisition of ultrasound images of the ovaries/follicles and the endometrium performed initially independently by the patient (unassisted) guided by procedure's videos on Pulsenmore app, in a separate private room in the clinic. Later, on the same day, the patients will have an in-person clinic visit and will be scanned using a conventional sonographic equipment. The in-clinic scan serves as Ground truth (GT). The images from the video guided scan will be automatically uploaded to the cloud from the patient's device and interpreted by a physician.
32750679|NCT04201821|Experimental|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
32750680|NCT05493579|Experimental|Complete denture then complete implant supported overdenture|
32750681|NCT05491239|Active Comparator|Thoracic epidural analgesia|See intervention description
32750682|NCT05491239|Experimental|Continuous regional paravertebral block|See intervention description
32750683|NCT05491239|Experimental|Single shot intercostal nerve block|See intervention description
32750684|NCT05493423|Experimental|Standard of Care vs. V Needle Performance Assessment|Subjects will undergo three dialysis sessions using standard of care needles (control) and results will be compare to 6 dialysis sessions using the V Needle (experimental).
32750685|NCT05485545|Other|Fallot group|Patient with Fallot Tetralogy operated
32750686|NCT05485545|Other|Control group|Patient benefiting from electrophysiological exploration for a healthy heart arrhythmia
32750687|NCT05485467||Heart transplant recipients|All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, the patient will undergo a detailed clinical evaluation, and cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood
32750688|NCT05491005|Experimental|eHealth|
32750689|NCT05491005|Experimental|Face-to-face|
32750690|NCT05491005|No Intervention|Healthy control group|
32750691|NCT05485389|Experimental|Study group|At the beginning, knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the pre-test. Then, 6-hour theoretical course on the care of the elderly patient will be given to the participants included in the study. After the theoretical course, the knowledge test will be re-applied. After that, experience will be provided within the scope of first, second and third level simulation-based learning, one week apart. After the simulation experiences knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the post-test 1. Post-tests will be administered in the first (Post-test 2) and third (Post-test 3) months of the simulation experience.
32750692|NCT04277325|Experimental|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
32750693|NCT04277325|No Intervention|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
32750694|NCT04277091|No Intervention|Control|No exercise
32750695|NCT04277091|Experimental|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
32750696|NCT04277091|Experimental|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
32750697|NCT05493267|Experimental|Vγ2Vδ2 T lymphocyte-based immunotherapy +Treatment regimens for MDR-TB|Treatment was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis, with the addition of immunotherapy：zoledronic acid and recombinant human interleukin 2
32750698|NCT05493267|Active Comparator|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
32750699|NCT04180449||Dysphagia screening positive|
32750700|NCT04180449||Dysphagia screening negative|
32750701|NCT04239261|Active Comparator|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
32750702|NCT04239261|Placebo Comparator|Placebo|Hydrolyzed gelatin 10.0 grams once daily
32750703|NCT05485311||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
32750704|NCT05485311||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
32750705|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
32750706|NCT05493033|Experimental|Intracorporeal anastomotic after LRC|
32750707|NCT05493033|Active Comparator|Extracorporeal anastomotic after LRC|
32750708|NCT03994029|Experimental|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
32750709|NCT03994029|Placebo Comparator|Placebo|1 tab PO QD per day of placebo for 60 days
33236365|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
33236366|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
33070850|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
32909087|NCT04171466|Placebo Comparator|Broad Spectrum Antibiotic Therapy + Placebo|
33236367|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
33236368|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
33236369|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
33236370|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
33070851|NCT04836910||Study Group: Women with Polycystic Ovary Syndrome|Woen diagnosed with Polycystic Ovary Syndrome according to the Rotterdam Criteria (requires 2 out of 3 symptoms: 1. Hyperandrogenism or excess levels of androgen. 2. Oligo or anovulation. 3. Polycystic ovaries on ultrasound - over 12 follicles, 2-9 mm or increased ovarian volume),who haven't started any treatment
33070852|NCT04836910||Cohort Group: Women without Polycystic Ovary Syndrome|
33070853|NCT00147485|Experimental|1|
33236371|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
33236372|NCT04033263|Placebo Comparator|Placebo mouth rinse|Placebo: Deionized water (serving as negative control)
33236373|NCT04033263|Active Comparator|Elmex mouth rinse|Commercial mouth rinse used as gold standard in erosion studies: elmex® Erosion Protection solution (which contains 800 ppm Sn2+, as SnCl2, and 500 ppm F-, as NaF and AmF)
33236374|NCT04033263|Active Comparator|Fluoride mouth rinse|Fluoride solution similar to many other commercial mouth rinses containing sodium fluoride (NaF at 500 ppm F-)
32750710|NCT05485233||Presencial|At day 3th and 10th after surgery, each patient will undergo face-to-face examination of their surgical wound by a physician or a nurse, who will confirme the presence or absence of complications and they will fill in the questionnarie to compare the reponses with the aplication
32750711|NCT05485233||Telematic|At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge.
32750712|NCT05490849|Experimental|68Ga-HX01 PET scanning|Determine if 68Ga-HX01 PET is safe and effective method for imaging of malignant tumors
32750713|NCT05485077||Positive group|All the subjects who completed colorectal cancer polygene methylation test at baseline completed colonoscopy within 3 months. Colorectal cancer diagnosed by colonoscopy, adenoma or polyp lesions found after treatment will reach the end of the study. The tumor history of family members was tracked for patients who met the end point of the study. The positive subjects who did not reach the end point of the study underwent three center visits at 12, 36 and 60 months after enrollment respectively, including history taking, colonoscopy, FIT test and blood CEA test. Another telephone follow-up was conducted at 24 and 48 months, respectively.
32750714|NCT05485077||Negative group|The subjects who completed colorectal cancer polygene methylation test at baseline, and those with negative test results (n= 500, direct extraction method) completed colonoscopy within 3 months. The end points and follow-up were the same as those in the positive group. The negative group was compared with the positive group to observe the difference of negative predictive value and survival outcome.
32750715|NCT05492721|Active Comparator|Dermabond|Dermabond over incisions
32750716|NCT05492721|Active Comparator|Swiftset|Swiftset over incisions
32750717|NCT05492565||Men who have sex with men|Men who have sex with men at substantial risk for HIV infection due to high-risk sexual habits
32750718|NCT05492565||Transgender women|Transgender women at substantial risk for HIV infection due to high-risk sexual habits
32750719|NCT05492565||Sex workers|Sex workers at substantial risk for HIV infection due to high-risk sexual habits
32909088|NCT04171466|Active Comparator|No Antibiotic Therapy + Microbial Consortia|
32909089|NCT04171466|Placebo Comparator|No Antibiotic Therapy + Placebo|
33070854|NCT04825717|Experimental|Intervention group|Patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements
33070855|NCT04825717|No Intervention|Control group|Nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula.
33236375|NCT04033263|Experimental|Plant extract A|Plant Extract A
33236376|NCT04033263|Experimental|Plant extract A with fluoride|Plant Extract A + Fluoride
33236377|NCT04033263|Experimental|Plant extract B|Plant extract B
33236378|NCT04033263|Experimental|Plant extract B with fluoride|Plant Extract B + Fluoride
33236379|NCT04033263|Experimental|Plant extract C|Plant extract C
33236380|NCT04033263|Experimental|Plant extract C with fluoride|Plant Extract C + Fluoride
33236381|NCT04075227|Experimental|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
33236382|NCT04075227|Active Comparator|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
33236383|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
33394183|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
33070856|NCT04823455|Experimental|Allo Omero 2020|Humeral allograft group 12 patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.Included patients were clinically and radiographically re-evaluated for the purpose of this study by examiners not involved in the primary treatment at a mean of 66 months postoperatively. The clinical examination consisted of a physical examination and structured interview. Computed tomography (CT) was carried out at the medium follow-up of 66 months in all patients to evaluate OA progression and allograft resorption.
33236384|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
33236385|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
32909090|NCT05587634|Experimental|Peer Health Coaching Intervention|Intervention Arm - these participants receive individualized peer health coaching (intervention group only) and an adaptive physical activity guide of local resources (both groups)
33070857|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
33070858|NCT04773106|Other|Single-arm longterm Follow up ARGOS-SC Sensor Pressure system|The ARGOS-SC sensor was already implanted in a previous study as ARGOS-SC01.
32744973|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
32744974|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
32744975|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
32744976|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
32744977|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
32744978|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
32744979|NCT02503163|Experimental|KCT-0809|
32744980|NCT04496921|Active Comparator|Vitamin K supplement, dose #1|Vitamin K supplementation with dose #1
32744981|NCT04496921|Active Comparator|Vitamin K supplement, dose #2|Vitamin K supplementation with dose #2
32744982|NCT04860609|Active Comparator|Conventional Physiotherapy|It includes the pre-physiotherapy session by conventional physiotherapy
32744983|NCT04860609|Experimental|Lumber spinal decompression|It includes the pre-physiotherapy session iby lumber spinal decompression along with conventional therapy.
32744984|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
32744985|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
32744986|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
32744987|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)~LY3381916 administered orally and LY3300054 administered IV."
32744988|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)~LY3381916 administered orally and LY3300054 administered IV."
32744989|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)~LY3381916 administered orally and LY3300054 administered IV."
32744990|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
33236386|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
33236387|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
32750720|NCT05492565||HIV-uninfected people at substantial risk for HIV infection (other)|All HIV-uninfected people at substantial risk for HIV infection due to any other reason, including having an HIV-positive life partnerwith an HIV-positive life partner
32750721|NCT05492487|Experimental|Mirena Arm|The patients in the Mirena arm will have a Mirena inserted at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy. As Mirena can be used for treatment of atypical hyperplasia as well as endometrial protection (decreases the risk of endometrial hyperplasia recurrence), the option of keeping or changing the Mirena during biopsy will be discussed with the patient.
32750722|NCT05492487|Experimental|Megace Arm|The patients in the megace arm will have be prescribed 3 months of oral megace at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy.
32750723|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
32750724|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
32750725|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
32750726|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
32750727|NCT05492331|Experimental|Music Therapy during the IUI procedure|Subjects undergoing an intrauterine insemination (IUI) procedure will experience music therapy during the procedure.
32750728|NCT05492331|No Intervention|Standard of Care|Subjects will receive standard of care for intrauterine insemination (IUI) procedure.
32750729|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
32750730|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
32750731|NCT04176705|Experimental|Laser|
32750732|NCT04176705|Placebo Comparator|No laser|
32750733|NCT05492019|Experimental|Doxycyline- Patients receiving Doxycycline .|Drug generic name: Doxycycline Dosage form- oral capsule Dosage- (50mg) one capsule Frequency- twice daily Duration- 8 weeks.
32750734|NCT05492019|Placebo Comparator|Control- Patients receiving placebo|Patient will receive one capsule of placebo twice daily
32750735|NCT05484921||traumatic brain injury group|(1) age 18-80 years, (2) admission due to isolated head injury, (3) unconsciousness at the time of injury. Isolated head trauma was defined as CT scan-confirmed brain injury without other major extracranial injuries, such as pelvis fractures, femur fractures, and severe invasive abdominal or thoracic injuries. Other exclusion criteria for patients were infection within the most recent month, previous head trauma, neurological diseases including ischemic and hemorrhagic stroke, use of antiplatelet or anticoagulant medications, and other prior systemic diseases including uremia, liver cirrhosis, malignancy, chronic heart disease, and chronic lung disease.
32909091|NCT05587634|No Intervention|Control|Control arm - these participants receive only an adaptive physical activity local guide including information on local adaptive sports opportunities however no individualized peer health coaching
32909092|NCT05577338|Experimental|training group|group psychotherapy
32909093|NCT05577338|Active Comparator|active control group|receive disease-related health knowledge
32750736|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
32909094|NCT02246348|Experimental|Doppler ultrasound|
33070859|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
33236388|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
33236389|NCT04145037|Experimental|Switch Stable|Switch-stable arm: Subjects who have undergone ERT ≥15 U/kg and ≤60 U/kg every other week (or equivalent; ie, any combination of infusions resulting in a total monthly ERT dose of >30 U/kg and <120 U/kg) for ≥24 consecutive months for Type 1 Gaucher disease at the time of Screening. Switch-stable subjects must discontinue ERT at least 2 weeks before the scheduled transplant day. Switch-stable subjects who have been on ERT and substrate reduction therapy (SRT) must not have received SRT within 12 months of Screening.
33236390|NCT04145037|Experimental|Treatment-naïve|Treatment-naïve arm: Subjects with Type 1 Gaucher disease who have never received either ERT or SRT for Gaucher disease or have not received either ERT or SRT for Gaucher disease within 12 months of Screening (ie, treatment-naïve subjects). Enrollment will follow a similar scheme as for the switch-stable subjects.
32750737|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are >3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
32750738|NCT05484843|Experimental|Stroke patients_intervention group|"Inclusion criteria for the study:~Being over 18 years old~Being of all genders, male and female~Being able to communicate in Turkish~Having had a hemorrhagic or ischemic stroke~Not more than one month after the stroke event.~Being oriented to person, place and time~Not being aphasic~Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~Not having serious vision and hearing problems~Not having a psychiatric history~Being open to communication and cooperation~To be willing and voluntarily to participate in the study."
32750739|NCT05484843|Experimental|stroke patients_control group|"Inclusion criteria for the study:~Being over 18 years old~Being of all genders, male and female~Being able to communicate in Turkish~Having had a hemorrhagic or ischemic stroke~Not more than one month after the stroke event.~Being oriented to person, place and time~Not being aphasic~Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~Not having serious vision and hearing problems~Not having a psychiatric history~Being open to communication and cooperation~To be willing and voluntarily to participate in the study."
32750740|NCT05491941|Active Comparator|Hour-1 Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the Hour-1 bundle, all interventions in the bundle must be initiated within 1 hour.
32750741|NCT05491941|Active Comparator|3-Hour Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the 3-hour bundle, all elements must be completed by 3 hours.
32750742|NCT05491863|Active Comparator|conservative physiotherapy plan|Postural and Proprioceptive facilitation,walking ,jumping and staircase activity
32750743|NCT05491863|Experimental|Trunk stability exercise plan|Trunk stability exercises including proprioception,balance and stability.
32750744|NCT05491785|Experimental|Cebranopadol 600 µg|3 x 200 µg cebranopadol tablets
32750745|NCT05491785|Experimental|Cebranopadol 800 µg|4 x 200 µg cebranopadol tablets
32750746|NCT05491785|Experimental|Cebranopadol 1000 µg|5 x 200 µg cebranopadol tablets
32750747|NCT05491785|Active Comparator|Oxycodone 30 mg|3 x 10 mg Oxycodone tablets
32750748|NCT05491785|Active Comparator|Oxycodone 60 mg|3 x 20 mg Oxycodone tablets
32750749|NCT05491785|Placebo Comparator|Cebranopadol placebo tablets/ Oxycodone placebo capsules|Cebranopadol placebo tablets/ Oxycodone placebo capsules
32750750|NCT05490147|Experimental|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 10~12 throughout the surgery.
32909095|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
32909096|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
32909097|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
32909098|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
32909099|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
33070860|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
33394184|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
33394185|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
33236391|NCT04075071|Experimental|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
33236392|NCT04075071|No Intervention|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
33236393|NCT00717756|Experimental|Lenalidomide|
33236394|NCT00915629|Experimental|Probiotic|Dietary supplement
33236395|NCT04111289|Active Comparator|Patient received upstream high bolus dose of tirofiban|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
33236396|NCT04111289|Active Comparator|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
33236397|NCT04108637|Experimental|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2&3 of the PAAP pathway:~Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3~Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
33236398|NCT04108637|No Intervention|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
33236399|NCT05674539|Active Comparator|fludarabine and busulfan|fludarabine (30 mg/m^2/day, days -6 to days -2, the total dase is 150 mg/m^2) and busulfan (3.2 mg/kg/day, days -3 to days -2, the total dose is 6.4 mg/kg)
33236400|NCT05674539|Experimental|fludarabine and melphalan|fludarabine (30 mg/m^2/day, days -6 to days -2, the total dose is 150 mg/m^2) and melphalan (70 mg/m^2/day, days -3 to days -2, the total dose is 140 mg/m^2)
33236401|NCT04108559|Experimental|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
33236402|NCT04108559|Experimental|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
33236403|NCT04108559|Placebo Comparator|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
33070861|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
33070862|NCT03457870|No Intervention|Control|No intervention: Control
33236404|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
33236405|NCT04128189|Active Comparator|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
33236406|NCT04128189|Sham Comparator|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
33236407|NCT05014659|Experimental|Creatine monohydrate|Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days.
32750751|NCT05490147|Experimental|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 6~8 throughout the surgery.
32750752|NCT05491707|Experimental|Music|Patients in the intervention group will receive music after the ASA monitors are applied. The music will be played at a self-selected volume, on Pro Bass Swagger Series Aux disposable earphones and will be played for the duration of the surgical procedure. The music will be played from an iPhone which will be placed in a plastic bag for infection control purposes. These patients will receive standard anaesthetic care.
32750753|NCT05491707|No Intervention|Control|The control group will not receive music. These patients will receive standard anaesthetic care.
32750754|NCT05484687|Experimental|Lidocaine is used in radical resection of colorectal tumors.|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
33236408|NCT05014659|Placebo Comparator|Placebo|Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days.
32750755|NCT05490069|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
32750756|NCT05490069|No Intervention|Control group|Receive general mental health information through instant message.
32750757|NCT05484609|Experimental|OUD scenario|
32750758|NCT05484609|Active Comparator|Diabetes scenario|
32750759|NCT03889197|No Intervention|Control|Standard of care sodium supplementation as directed by the medical care team
32750760|NCT03889197|Active Comparator|Sodium supplementation algorithm|Beginning on the 14th -16th postnatal day and continuing until 36 weeks postmenstrual age, infants randomized to the algorithm will have a spot urine sodium concentration determined every two weeks and sodium supplementation provided according to the algorithm.
32901678|NCT05139654||Healthy climbers group|Healthy subjects will be included to compare the differences in shoulder kinematics and muscle activation between healthy subjects and subjects with shoulder pain. Subjects in this group will received the same assessments as the shoulder pain climbers group.
32901679|NCT05028504|Experimental|Penpulimab+Anlotinib|Penpulimab 200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
33236409|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
33236410|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
33236411|NCT05003115|No Intervention|Standard of Care|Standard of Care
33236412|NCT05003115|Experimental|Intervention|Motivational interviewing intervention
33236413|NCT04111055|Experimental|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
33236414|NCT02580123|Experimental|Experimental group|Received the intervention program.
33236415|NCT02580123|No Intervention|Control group|received the standard care
33236416|NCT04106843|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
33236417|NCT03657693||BPD|Infants born premature requiring oxygen
33236418|NCT03657693||Controls|
33236419|NCT04106453|Experimental|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
33236420|NCT04106453|Active Comparator|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
33236421|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236422|NCT03475953|Experimental|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236423|NCT03475953|Experimental|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
32750761|NCT04424589|Experimental|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
32750762|NCT04424589|Sham Comparator|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
32750763|NCT03873207|Experimental|Intervention|Pedal fat grafting followed by PopSole™ offloading device
32909100|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
32909101|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
33236424|NCT03475953|Experimental|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236425|NCT03475953|Experimental|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236426|NCT03475953|Experimental|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236427|NCT03475953|Experimental|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33394186|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
32750764|NCT03873207|Other|Standard of care|Pedal fat grafting followed by standard post-operative care with padding of the insoles
32750765|NCT04155723||Phase 1 group|During phase 1, Midlines are inserted only by doctors.
33236428|NCT03475953|Experimental|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236429|NCT03475953|Experimental|Phase 2 : cohort H Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236430|NCT03475953|Experimental|Phase 2 : cohort I Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
32750766|NCT04155723||Phase 2 group|During Phase 2, Midlines are preferentially inserted by ICU nurses, and if needed, by doctors.
32750767|NCT05484531||CLEAR|Adult subjects suffering from myopia AND/OR astigmatism treated with CLEAR.
32750768|NCT05484453||GoCheckKids screening|GoCheckKids screening at the Child And Family Agency at the age of 12-15 months (+- 1 month) are invited to undergo a complete eye examination by an ophthalmologist for evaluation of amblyopia risk factors.
32750769|NCT05489913|Experimental|Web based Cardiac Rehabilitation program and follow-up telephone|"The website was created under the name of Cardiac Rehabilitation Support Program. The language of the website is Turkish. Designed for computer, tablet and mobile phone use. Patients must be registered to access the website. After creating a six-digit password during registration, they log in to the website with their e-mail address and this password. The password is determined specifically for the patient. There is a welcome text on the home page of the website. The main headings in the menu section; trainings, disease management questions, questionnaires, ask questions to the researcher."
32750770|NCT05489913|No Intervention|Standard care|patients received their training before discharge from the hospital and no intervention was made for 12 weeks.
32750771|NCT05484375|Experimental|Capecitabine plus toripalimab maintenance therapy|capecitabine and toripalimab were used as maintenance therapy every 3 weeks until toxicity was unacceptable, disease progression, consent withdrawal, or withdrawal was determined by the investigator, or a maximum of 2 years of treatment had been reached.
32750772|NCT05480007|No Intervention|Control|did not take medicine
32750773|NCT05480007|Experimental|DPPVI|received sitagliptin treatment (100mg per day)
32750774|NCT05480007|Experimental|metformin|received metformin (500mg three times per day)
32750775|NCT05480007|Experimental|metformin +DPPVI|received sitagliptin (100mg per day) and metformin (500 mg three times per day)
32750776|NCT05479929||Patients with Respiratory Symptoms|The Canadian Triage Assessment Scale (CTAS) will be assessed via patient survey form and electronic chart review.
32750777|NCT05479851||UK National Health Service Patient Postal Survey Participants|Patients who have agreed to participate in the study after receiving a postal invitation
33236431|NCT03475953|Experimental|Phase 2 : cohort A' Regorafenib low-dose + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236432|NCT03475953|Experimental|Phase 2 : cohort J Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33394187|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
33394188|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
32750778|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
32750779|NCT05484063|Experimental|Intervention|Intervention group will receive a multicomponent, mobility-focused intervention during the course of inpatient admission.
32750780|NCT05484063|No Intervention|Control|The control group will receive usual care as per current ward practice.
32750781|NCT05489601||Participants|"Adults between 21 and 59 years of age.~Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD).~Subjects have taken an opioid prescription for pain management within the prior 24 months and have not used any opioids during the preceding 30 days.~Subjects are required to have a negative urine drug test. At any point during the study, If a subject is found to have a positive drug test, the subject will be discontinued from the study."
32750782|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~ibrutinib: dose tolerated by subject; to be administered daily"
32750783|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~venetoclax: dose tolerated by subject; to be administered daily"
32750784|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~acalabrutinib: previously tolerated dose; to be administered every 12 hours"
32750785|NCT05489367||Pre-vaccine ovarian reserve and fertility status|Before vaccination, ovarian reserve tests and fertility status of 64 women will be examined and results will be recorded.After 2 doses of vaccination, ovarian reserve and fertility status of same 64 women will be examined and results will be recorded
32750786|NCT05483985|No Intervention|Traditional Morphology|The embryo selection will be based on standard of care traditional morphology only.
32750787|NCT05483985|Experimental|Device: Hera System|For the Hera, the embryologist will use the consider both the standard morphology grade and the Hera System score on embryos that were already deemed suitable for transfer or freeze based on the standard morphology assessment to determine the most suitable embryo for transfer.
32750788|NCT05483829|Experimental|Long COVID prospective group|
32750789|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
32750790|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
32750791|NCT04424121|Active Comparator|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
32750792|NCT05479695|Experimental|Patient who use spinal orthoses and insoles|Spinal Orthoses: Devices that used in spinal deformities. Insoles: Devices that used in foot deformities.
32750793|NCT05479695|Other|Patient who use only spinal orthoses|Spinal Orthoses: Devices that used in spinal deformities.
32750794|NCT05479539|Experimental|AOT|
32750795|NCT05479539|No Intervention|Control|
32750796|NCT04013685|Experimental|Subjects with Acute Leukemia or Myelodysplasic Syndrome, Myelofibrosis, or BPDCN|This is a non-randomized, single-arm study. All enrolled subjects will receive an allogeneic HCT with the Orca-T product.
32750797|NCT04276155|Experimental|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
33236433|NCT03475953|Experimental|Phase 2 : cohort K Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
32750798|NCT04276155|No Intervention|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
33236434|NCT03475953|Experimental|Phase 2 : cohort L Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236435|NCT03475953|Experimental|Phase 2 : cohort M Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
32750799|NCT05489289|Active Comparator|AK104|AK104 IV every three weeks
32750800|NCT05489289|Placebo Comparator|placebo|Placebo IV every three weeks
32750801|NCT05479383||Tobacco users|"Tobacco users~Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers.~Never snus users (reference group) will also compare with never users, former users and current users."
32750802|NCT04139577|Experimental|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.~One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.~The maintenance weeks happen for 3 weeks after the induction week.~All doses will be administered in the clinic.~A second cycle of treatment as deemed appropriate"
32750803|NCT05479227||Patients with bile duct injuries during laparoscopic cholecystectomy|The data concerning 241 patients´ BDI emergence, severity, management, and outcomes was analyzed
32750804|NCT05479071||SLE patients WITH cardiovascular disease|Relation of antibodies against LDL to disease activity in pt with cardiovascular disease
32750805|NCT05479071||SLE Patients without cardiovascular disease|Relation of antibodies against LDL to disease activity in pt without cardiovascular disease
32750806|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
32750807|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
32750808|NCT05489055|Experimental|BBT-CM (basic body temperature) group|BBT-CM (basic body temperature) group received contrast media warmed to body temperature (37°C[99°F]) before coronary CTA.
32750809|NCT05489055|Active Comparator|RT-CM (room temperature) group|RT-CM (room temperature) group received contrast media at room temperature (~23°C [~73°F]) before coronary CTA.
32750810|NCT05478915|Experimental|patients with TMJ anterior disc displacement|patients had clinically limited mouth opening and by MRI we found anterior disc displacement
32750811|NCT04423965|Experimental|mFOLFOXIRI|Patients receive 6 cycles of mFOLFOXIRI
32750812|NCT04423965|Experimental|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
32901680|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
33236436|NCT03475953|Experimental|Phase 2 : cohort N Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236437|NCT03475953|Experimental|Phase 2 : cohort O Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236438|NCT03475953|Experimental|Phase 2 : cohort P Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
33236439|NCT04106375|Experimental|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
32750813|NCT05478681|Experimental|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
33236440|NCT04106375|No Intervention|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
33070863|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
33236441|NCT04108325|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
32909102|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
32909103|NCT05551988||diabetic foot ulcer patients|Diabetic foot ulcer patients with and without diabetic foot amputation
33236442|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
33236443|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
33236444|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
33236445|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
33236446|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
33236447|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
33236448|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
33236449|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
33236450|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
33236451|NCT05673837||Type 1 Diabetes|111 persons with Type 1 Diabetes since childhood
33236452|NCT05673837||Controls|37 persons without diabetes
33236453|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
33236454|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
33236455|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
33236456|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
33236457|NCT04968405|Other|Single Arm|Intervention with a 510k cleared shoulder arthroplasty device
33236458|NCT04967235|Active Comparator|Conventional Exercise-based Cardiac Rehabilitation|This interventional arm consists of a conventional exercise-based cardiac rehabilitation, composed of initial rest, warm-up, treadmill aerobic exercise, orthostatic passive recovery, and supine passive recovery.
32909104|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
33394189|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
33394190|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
32750814|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
32750817|NCT05483595|Other|FYTF-Placebo group|Subjects tasted FYTF-919 and then placebo: Oral liquid 10ml
32750818|NCT05483595|Other|Placebo-FYTF group|Subjects tasted placebo and then FYTF-919: Oral liquid 10ml
33394191|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
32750819|NCT03972501|Placebo Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
32750820|NCT03972501|Experimental|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
32750821|NCT05488899|Experimental|Half iodine - Spectral CT group|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 kiloelectronVolts (keV).
32750822|NCT05488899|Active Comparator|Standard iodine - Conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kiloVolts (kV) polychromatic CT images
32750823|NCT05483517|Experimental|physiotherapy and high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and high-PEMF therapy for three weeks, following two sessions a week.
32750824|NCT05483517|Sham Comparator|physiotherapy and sham high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and sham high-PEMF therapy for three weeks, following two sessions a week.
32750825|NCT05483439|Experimental|Immunotherapy and neoadjuvant therapy|Traditional herbal medicine twice daily combined with neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
32750826|NCT05483439|Other|neoadjuvant therapy|Only received neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
32750827|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Participants will receive a combination MK-8353 and selumetinib for 4 days on and 3 days off until disease progression or discontinuation. MK-8353 will be escalated sequentially from 50 mg to 250 mg based on pharmacokinetic and safety data. Selumetinib will be escalated sequentially from 25 mg to 75 mg based on pharmacokinetic and safety data. Doses may be adjusted downward sequentially based on tolerability
32750828|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
32750829|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
32750830|NCT04088799||FSGS requiring LDL-apheresis|Pediatric patients with FSGS requiring LDL-apheresis with the Liposorber
32750831|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
32750832|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
32750833|NCT04273269|Experimental|8x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8x10^12 vg/Kg LYS-GM101
33394192|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
33070864|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
33236459|NCT04967235|Experimental|Dance-Based Cardiac Rehabilitation|This interventional arm consists of a new dance-based cardiac rehabilitation, composed of initial rest, warm-up, dance therapy, orthostatic passive recovery and supine passive recovery.
32750834|NCT04058301|No Intervention|Handout|Participants receive a generic handout about resources in Boston
32750835|NCT04058301|Experimental|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
33236460|NCT03628677|Experimental|Domvanalimab Monotherapy|Varying Doses of domvanalimab Monotherapy
33236461|NCT03628677|Experimental|Domvanalimab + zimberelimab Q2W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
32750836|NCT05488821|Experimental|QLH11906|QLH11906 Tablets
32750837|NCT05488743||7th and 8th grade students (children age 12-15 years) from the elementary school|
32750838|NCT05478291|Experimental|Vitamin D supplementation|"Appropriate diet and physical activity counselling~Supplementation with Vitamin D and oral Calcium- Doses of cholecalciferol (commercial name, Calcirol) 60,000 international units (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer.~After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated. If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 international units per day will be given as a maintenance dose."
32750839|NCT05488665|Experimental|Crush technique group|Two stenting with the Crush technique
33236462|NCT03628677|Experimental|Domvanalimab + zimberelimab Q3W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
32750840|NCT05488665|Active Comparator|Culotte technique group|Two stenting with the Culotte technique
32750841|NCT05478057|Experimental|PD patients with speech disturbance treated with 10 Hz rTMS|
32750842|NCT05478057|Sham Comparator|PD patients with speech disturbance treated with sham rTMS|
32750843|NCT05478057|Experimental|PD patients without speech disturbance treated with 10 Hz rTMS|
32750844|NCT05478057|Sham Comparator|PD patients without speech disturbance with sham rTMS|
32750845|NCT05483361||smart phone addiction group|Smart phone addiction will be assessed using the Smart Phone Addiction Scale short version (SAS-SV) evaluation of pulmonary functions and functional capacity evaluation craniovertebral angle
32750846|NCT05488587||hepatocellular carcinoma|
32750847|NCT05488587||liver cirrhosis|
32750848|NCT05488587||healthy individuals|
32750849|NCT05488509|Experimental|Cannabis|Participants will inhale vapor from cannabis containing 20mg THC.
32750850|NCT05488509|Placebo Comparator|Placebo|Participants will inhale vapor from a placebo product.
32909105|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
32750851|NCT05488353|Experimental|Single Arm|Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
33236463|NCT03628677|Experimental|Domvanalimab + zimberelimab Q4W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
33236464|NCT03628677|Experimental|Domvanalimab and Zimberelimab Q6W combination therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
33236465|NCT03628677|Experimental|Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
33236466|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
33236467|NCT05016843|Experimental|CBT, 8 weeks and access to forum.|
33236468|NCT05016843|Experimental|CBT, 16 weeks and access to forum.|
32750852|NCT05488275|Active Comparator|MPFL static|Medial Patellofemoral Ligament reconstruction with hamstring graft - static procedure
32750853|NCT05488275|Active Comparator|Campbell|Medial Patellofemoral Ligament reconstruction using non-anatomic reconstruction (quadriceps femoris plasty - Campbell method)
32750854|NCT05488275|Active Comparator|MPFL dynamic|Medial Patellofemoral Ligament reconstruction with hamstring graft - dynamic procedure
32909106|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
32909107|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
33070865|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
33236469|NCT05016843|Experimental|CBT, 8 weeks and no access to forum.|
33236470|NCT05016843|Experimental|CBT, 16 weeks and no access to forum.|
33236471|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and access to forum.|
33236472|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and access to forum.|
33236473|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and no access to forum.|
33236474|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and no access to forum.|
33236475|NCT05016843|Experimental|Waitlist, 8 weeks and access to forum.|
33236476|NCT05016843|Experimental|Waitlist, 16 weeks and access to forum.|
32750855|NCT03947619|Experimental|Experimental|"Subjects randomized to the experimental arm will have their heart unloaded for 30 minutes on the Impella CP® device prior to PCI.~Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
33236477|NCT05016843|Experimental|Waitlist, 8 weeks and no access to forum.|
33236478|NCT05016843|Experimental|Waitlist, 16 weeks and no access to forum.|
33236479|NCT04108013|Experimental|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
33236480|NCT04108013|Active Comparator|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
33236481|NCT04105985|Experimental|Kovanaze Nasal Spray (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
33236482|NCT04105985|Active Comparator|Articaine Injections (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
33236483|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
33236484|NCT04110587|Placebo Comparator|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
33241633|NCT04223960|Experimental|Part B: FE/BA, in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
32750856|NCT03947619|No Intervention|Control|"Primary PCI. Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
32750857|NCT04549077||Cystic Fibrosis Patients|Patients with Cystic Fibrosis.
33236485|NCT04110587|Active Comparator|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
32750858|NCT04549077||Historical Controls|Patients diagnosed with solid tumors, who have had a normal chest CT scan during screening for possible metastasis
32750859|NCT04543305|Experimental|PRT1419|PRT1419 will be administered orally
32750860|NCT05488197||Group 1 participants with gestational diabetes|
32750861|NCT05488197||Group 2 participants without gestational diabetes|
32750862|NCT04543071|Experimental|Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel|Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified.
32750863|NCT05488041|Experimental|UC patients with anorectal symptoms|Patients with ulcerative colitis in remission who have anorectal symptoms will undergo an anal manometry test to characterize these symptoms.
32750864|NCT05488041|Active Comparator|UC patients without anorectal symptoms|Patients with ulcerative colitis in remission without anorectal symptoms will undergo an anal manometry test to characterize their anorectal function and to compare to those with symptoms
32750865|NCT05477745||The group that the sagittal flexion angle of the femoral component less than 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component less than 4° were categorized into this group.
33236486|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
32750866|NCT05477745||The group that the sagittal flexion angle of the femoral component over 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component over 4° were categorized into this group.
32750867|NCT05487963|Experimental|CGB-500 topical ointment, 1% tofacitinib|
32750868|NCT05487963|Placebo Comparator|Vehicle topical ointment|
32750869|NCT05487885|Experimental|TMS and PAT|All open label with no randomization to placebo
32750870|NCT05487885|Experimental|TMS and PAT, then Ketamine|All open label with no randomization to placebo
32750871|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
32750872|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 8 breaths/min, induction of general anesthesia and intubation will proceed.
32750873|NCT05487807|No Intervention|Standard of Care|This is the baseline group receiving advice to quit.
32750874|NCT05487807|Active Comparator|Nicotine Replacement|This group will receive the standard of care and be prescribed nicotine replacement therapy
33236487|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
33236488|NCT05594147||TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used Tyrosine kinase inhibitors (TKIs) within 30 days before COVID-19 diagnosis.
33236489|NCT05594147||Non-TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used other anti-cancer therapies 30 days before COVID-19 diagnosis
33236490|NCT03616587|Experimental|AZD9833 monotherapy dose escalation|
33236491|NCT03616587|Experimental|AZD9833 monotherapy dose expansion|
33236492|NCT03616587|Experimental|AZD9833 with palbociclib dose escalation|
32750875|NCT05487807|Active Comparator|Text Messaging|This group will receive the standard of care and receive text message support
33236493|NCT03616587|Experimental|AZD9833 with palbociclib dose expansion|
33236494|NCT03616587|Experimental|AZD9833 with everolimus dose expansion|
33236495|NCT03616587|Experimental|AZD9833 with everolimus dose escalation|
33236496|NCT03616587|Experimental|AZD9833 with abemaciclib (± anastrozole) dose escalation|
33236497|NCT03616587|Experimental|AZD9833 with abemaciclib (± anastrozole)dose expansion|
33236498|NCT03616587|Experimental|AZD9833 with capivasertib dose escalation|
33236499|NCT03616587|Experimental|AZD9833 with capivasertib dose expansion|
33236500|NCT03616587|Experimental|AZD9833 with ribociclib (± anastrozole) dose escalation|
33236501|NCT03616587|Experimental|AZD9833 with ribociclib (± anastrozole) dose expansion|
33236502|NCT03616587|Experimental|AZD9833 with anastrozole dose escalation|
33236503|NCT03616587|Experimental|AZD9833 with anastrozole dose expansion|
33236504|NCT05673915|Experimental|tDCS Treatment A (Low Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.
33236505|NCT05673915|Experimental|tDCS Treatment B (High Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.
33236506|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
33236507|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
33236508|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
33236509|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
33236510|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
33236511|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
33236512|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
33236513|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
33236514|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
33236515|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
33236516|NCT03578367|Experimental|Asciminib 80mg QD|Asciminib 80 mg taken once daily
33236517|NCT02626455|Experimental|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)
33236518|NCT02626455|Placebo Comparator|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
33236519|NCT03534453|Experimental|Olaparib 300mg tablets|Taken orally twice daily
33236520|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
33236521|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
32750876|NCT05487807|Active Comparator|Nicotine replacement and text messaging|This group will receive the standard of care, be prescribed nicotine replacement therapy, and receive text message support
32750877|NCT05487729||Young adults|Young adults without neurological and serious structural condition.
33236522|NCT04074915|Placebo Comparator|Placebo rinse|Normal saline
33236523|NCT04074915|Experimental|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
32750878|NCT05483049||grey zone 1|HBeAg (+), HBV DNA >20 but < 10000000IU/mL, ALT ≤40 U/L
33236524|NCT04074915|Experimental|Test group|Chamomile mouth rinse
33236525|NCT02595957||Cascade Testing|Family members of individuals who have received secondary genomic findings after exome/genome sequencing
33236526|NCT02595957||Secondary findings recipients|Individuals who have received secondary genomic findings after exome/genome sequencing
33236527|NCT05673525|Experimental|Treatment Group|
32750879|NCT05483049||grey zone 2|HBeAg (-), HBV DNA > 2000 IU/mL, ALT ≤40 U/L
32750880|NCT05477667|Active Comparator|control group|the patients with non-malignant hematological diseases
32750881|NCT05477667|Active Comparator|the cases (A)|NHL .
32750882|NCT05477667|Active Comparator|the cases (B)|acute leukemia
32750883|NCT05477511||Mother|Chinese mother in Hong Kong who had been assessed in HAPO follow-up study when their children was at either 7 or 11-14 years of age
32750884|NCT05477511||18 years old child of the enrolled mother|Children who had been assessed in HAPO follow-up study at either 7 or 11-14 years of age
32750885|NCT05487495|Experimental|CD5 CAR T (CT125B)|All patients who receive CD5 CAR T (CT125B) cell infusion.
32750886|NCT05487261|Experimental|Sacubitril and valsartan combination|Patient receive: 1 bottle with Sacubitril/Valsartan tablets and 2nd bottle with placebo to enalapril.
32750887|NCT05487261|Active Comparator|Enalapril|Patient receive: 1 bottle with placebo to Sacubitril/Valsartan and 2nd bottle with enalapril.
32750888|NCT05477355|Experimental|Intervention Arm|Participants will be provided the 5 session intervention.
32750889|NCT05477355|Active Comparator|Wait list control arm|Participants will not be provided Group PM+ in Phase 1 but will be provided the intervention after all participants in the initial intervention arm receive Group PM+.
32750890|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo.
32750891|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo.
32909108|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
33236528|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
33236529|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
33236530|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
33236531|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
33236532|NCT03522597||Obese|Obese (BMI) women and their infants
33236533|NCT03522597||Diabetic|Women with gestational diabetes and their infants
33236534|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
33236535|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
33236536|NCT04073199|Active Comparator|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
33236537|NCT04073199|Active Comparator|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
33236538|NCT04073199|No Intervention|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
33236539|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
33236540|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
33236541|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
33236542|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
33236543|NCT03222609|Experimental|Navitoclax + ruxolitinib|Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
33236544|NCT03222609|Experimental|Navitoclax|Participants will be administered various doses of navitoclax once daily (QD)
33236545|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
33236546|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
33236547|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
33236548|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
33236549|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
33236550|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
33236551|NCT00437203|Experimental|1|
33236552|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
33236553|NCT04072653|Experimental|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
33236554|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
33236555|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
32750892|NCT03602859|Experimental|Participants receiving SOC+dostarlimab+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab.
32750893|NCT05482815|Experimental|Voice Prosthesis|Subjects receive a Voice prosthesis using the Provox Puncture Set, then undergo an articulation training program (3 weeks). The voice prosthesis is replaced after 3 months and 6 months.
33236556|NCT02419287|Experimental|crizotinib|250mg BID
33236557|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
33236558|NCT03173937|Experimental|1|CordIn is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
33236559|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
33236560|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
33236561|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
33236562|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
33236563|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
33236564|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
33236565|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
33236566|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
33236567|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
33236568|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
32750894|NCT05487183|Experimental|Healthy Volunteers|QST devices and computer tasks are used to measure OA, OH, pain intensity, and other outcomes
32750895|NCT05482737||Reference group|Transfused RBC stored 8-35 days
32750896|NCT05482737||less than or equal 7 days|Transfused RBC stored =<7 days
32750897|NCT05482737||more than 7 days|Transfused RBC stored <7 days
32750898|NCT05482737||less that or equal 10 days|Transfused RBC stored =<10 days
32750899|NCT05482737||more that 10 days|Transfused RBC stored >10 days
32750900|NCT05482737||more than 35 days|Transfused RBC stored >35 days
32750901|NCT05482737||less than or equal 35 days|Transfused RBC stored =<35 days
32750902|NCT05482737||less than 18 days|Transfused RBC stored <18 days
33236569|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
33236570|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
33236571|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
33236572|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
33236573|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
33236574|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
33236575|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
33236576|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
33236577|NCT04698135||morbid obesity|Patients with morbid obesity
33236578|NCT04698135||Metabolically healthy obesity|Patients with metabolically healthy obesity
33236579|NCT04698135||Healthy volunteers|Healthy volunteers
33236580|NCT01028443|Active Comparator|Cyclosporine A 2%|
33236581|NCT01028443|Placebo Comparator|Artificial tears|
33236582|NCT05440214|Experimental|Dialectical Behavior Therapy - Skill Training|
33236583|NCT05440214|No Intervention|Treatment As Usual|
33236584|NCT04096976||Hospital survival|
33236585|NCT04096976||No hospital survival|
33236586|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
33236587|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
33236588|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
33236589|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
33236590|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
33236591|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
33236592|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
33236593|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
33236594|NCT00443053|Placebo Comparator|Placebo|
33236595|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
32750903|NCT05482737||more than or equal 18 days|Transfused RBC stored =>18 days
32750904|NCT05482659|Experimental|Experimental|Health education on healthy nutrition and regular physical activity based on the transtheoretic model was given to overweight university students in the experimental group once a week (every 4 weeks) using the online education method.
32750905|NCT05482659|No Intervention|control group|No attempt was made to the students in the control group during the intervention process. When the intervention process of the experimental group was finished, the materials used in health education were shared with the students.
33236596|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
33236597|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
33236598|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
33236599|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
32750906|NCT05477199|Experimental|Cognitive behavioral principles-based treatment program group|
32750907|NCT05477199|Active Comparator|Control group|
32750908|NCT04274985||1|Patients with temporomandibular disorders
32750909|NCT05477043||group of study|Patients ≥ 18 years old subjected to uterosacral ligaments suspension surgical procedures for pelvic organs prolapse.
33236600|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
32750910|NCT04274595|Experimental|Psoriasis patients|
32750911|NCT04274127|Other|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
32750912|NCT05486871|Active Comparator|renal cell carcinoma stages T1|laparoscopic partial nephrectomy in renal cell carcinoma stage T1
32909109|NCT05551832|Placebo Comparator|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months|Placebo beginning day of hospital discharge following PPPD for 6 months
33236601|NCT03995095|No Intervention|Control group|Group of participants that received usual psychological attention.
33236602|NCT03995095|Experimental|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
33236603|NCT03995329|Other|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
33236604|NCT02392455||A|
33236605|NCT03489187||VTTS as standard of care|VTTS as standard of care.
33236606|NCT04936893|Experimental|HeadSpace Mobile App|Mindfulness practice
33236607|NCT04936893|Active Comparator|Lumosity Mobile App|Cognitive games
33236608|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
32744991|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.~Intervention : PEEP INCREMENTAL"
32744992|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.~Intervention :PEEP DECREMENTAL"
32744993|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
32744994|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
32744995|NCT02502929|Active Comparator|Social Services|Participants in this arm will receive referrals for social services as indicated.
32744996|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
32744997|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
32744998|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
33236609|NCT04072965|Experimental|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
33236610|NCT04072965|Experimental|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
33236611|NCT04072965|No Intervention|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
33236612|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
32750913|NCT05486871|Active Comparator|renal cell carcinoma stages T2a|laparoscopic partial nephrectomy in renal cell carcinoma stage T2a
32909110|NCT05551832|Experimental|Esmesol 40mg after PPPD for 6 months|Esmesol 40mg beginning day of hospital discharge following PPPD for 6 months
32909111|NCT05551754|Active Comparator|ketone supplement|Subjects will drink single dose of ketone supplement 25g
32750914|NCT05476965|Experimental|Arm 1|De-escalation radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: De-escalation radiotherapy
32909112|NCT05551754|Placebo Comparator|Placebo beverage|Subjects will drink single dose of placebo beverage that will look and taste the same as ketone supplement.
32909113|NCT05536154|Experimental|EAP regimen|The combination regimen of etoposide, cytarabine and PEG-rhG-CSF.
32909114|NCT04124120|Experimental|Single Arterial Graft (SAG) group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
32909115|NCT04124120|Experimental|Multiple Arterial Graft (MAG) group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
32909116|NCT04099004|Other|Neural Imaging|Females with PFP attending a single study visit where neural imaging is acquired via MRI.
32750915|NCT05476965|Active Comparator|Arm 2|Arm 2 Standard radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: Standard radiotherapy
32750916|NCT05482503|Experimental|Atrial Fibrillation|
32909117|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
33394193|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~Cycle 1:~Rituximab : 375 mg/m² i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2~Cycle 2-6:~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
33394194|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~Prephase:~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase~Cycle 1-6 (cycle 1 beginning at D22):~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
33394195|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
33394196|NCT03254524||Patients visiting an emergency department in New York State|
33394197|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
32750917|NCT05482503|Experimental|Premature beats|
32750918|NCT05482503|Experimental|Sinus Rhythm|
32909118|NCT03014960|No Intervention|Control Condition|No intervention
32909119|NCT04098224|Experimental|Interventional Device - Treated|Subjects connected to the investigational device smART+
32744999|NCT04429737|Experimental|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
32745000|NCT04429737|Placebo Comparator|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
32745001|NCT03209843|Other|Successfully CTO recanalization|
32745002|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
32745003|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
32745004|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
32745005|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
32745006|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
32745007|NCT03209765|No Intervention|No reminder|
32745008|NCT04866537||Pregnant women who received a fetal heart ultrasound between 2015 and 2019.|Pregnant women who received a fetal heart ultrasound between 2015 and 2019.
32745009|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
32745010|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
32745011|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
32745012|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
32745013|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
32745014|NCT04866615||50 patients newly diagnosed SLE with no treatment|OCT & OCTA for newly diagnosed SLE patients
32745015|NCT04866615||50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years|OCT & OCTA for on treatment SLE patients
32745016|NCT04866615||50 normal subjects as control group of similar age and gender|OCT & OCTA for normal subjects
33394198|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
33394199|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
33394200|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
33394201|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
33394202|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
33394203|NCT01842282|Experimental|Amlexanox|
33394204|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
32750919|NCT04424043|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
32750920|NCT04424043|Active Comparator|surgery alone|hepatic resection remove the liver tumors
32750921|NCT05486715||65 rheumatoid arthritis patient|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
32750922|NCT05486715||65 healthy population|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
32750923|NCT05482347|Active Comparator|Control (knowledge assessment before video)|The patient will complete the knowledge assessment, then they will be presented with the educational video. After watching the video, they will complete the acceptability scale questionnaire and will be asked to select a gift card preference at the end of the survey.
32909120|NCT04098224|No Intervention|Control Group|treated according to local Standard of Care.
32909121|NCT05522426|Experimental|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
33394205|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
33394206|NCT03234634|No Intervention|Group 1: patients with good collateral|
33394207|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
33394208|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
33394209|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
33394210|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
33394211|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
33394212|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
33394213|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
33394214|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
33394215|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
33394216|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
32750924|NCT05482347|Experimental|Video (video before knowledge assessment)|The patient will be presented with the educational video, then they will complete the knowledge assessment and the acceptability scale questionnaire. They will be asked to select a gift card preference at the end of the survey.
32750925|NCT03560895||Group I|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Flexicare-UK) ) with its outer diameter determined by ultrasonography.
32750926|NCT03560895||Group II|Patients will be anesthetized using uncuffed endotracheal tube (Flexicare-UK) with its outer diameter determined by ultrasonography.
32909122|NCT04090268|Experimental|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
32909123|NCT04090268|No Intervention|Healthy children|Healthy children
33394217|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
33394218|NCT04360187|Experimental|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
33394219|NCT04360187|Placebo Comparator|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
33394220|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
33394221|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
33394222|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
33394223|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
33394224|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
33394225|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
33394226|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
33394227|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
33394228|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
33394229|NCT04498169|Experimental|Once Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
33394230|NCT04498169|Experimental|Twice Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
33394231|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
33394232|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
33394233|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
33394234|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
33394235|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
33394236|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
33394237|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
33394238|NCT03236584|Active Comparator|lamivudine adefovir|
33394239|NCT03236584|Experimental|tenofovir|
33394240|NCT01164228|Experimental|Arm A (Sunitinib + Gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
33394241|NCT01164228|Experimental|Arm B (Sunitinib)|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
33394242|NCT01562093|Experimental|local nasal steroids|
33394243|NCT01562093|Placebo Comparator|placebo|
33394244|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
33394245|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
33394246|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
33394247|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
33394248|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
33394249|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
33394250|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
33394251|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
33394252|NCT05321615|Other|Study arm|All patients will undergo a standard VATS pleuroscopy to visually search for the nodule and its position. Sequential assessment using a grasper, the Palpator, the VATS ultrasound probe, and then finger palpation will be done to detect the nodule.
33236613|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
33236614|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
33236615|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
33236616|NCT04086420|Experimental|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
33394253|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
33394254|NCT04614168|Active Comparator|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
33236617|NCT04086420|Active Comparator|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
33236618|NCT00756002|Experimental|Ramelteon 4 mg QD|
33236619|NCT00756002|Placebo Comparator|Placebo QD|
32750927|NCT04526145|Experimental|Stress and emotion Management for Black/African Americ|Four weekly sessions delivered in a group format via Zoom teleconference. The following topics are listed in the workbook: Planning Your Information Diet; My Spheres of Influence Worksheet; Practical Wisdom for Tolerating Uncertainty; Reducing Anxiety With Thought Challenging; Reducing Anxiety Through Distraction Activities; Starting a Planning Practice; Starting a Daily Gratitude Practice; Starting a Daily Breathing Practice; Improving the Quality of Your Social Connections; Developing a Regular Exercise Routine; and Creating Your Stress-Resilience Action Plan. Each session will begin with a 15-30 minute check in on what went well, challenges, and Coronavirus Anxiety workbook. The Coronavirus Anxiety Workbook topics are complementary and the sessions will tie together the themes of comprehensive stress and emotional management through blood pressure knowledge/self-monitoring, diet, interpersonal communication skills building, and sleep hygiene.
32750928|NCT05486637||Children with Cochlear Implants|Participants will be native speakers of American English and include pediatric cochlear implant recipients with unilateral or bilateral devices aged 6-19 years. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
32750929|NCT05486637||Children with Normal Hearing|Participants will be native speakers of American English who have normal hearing and are aged 6-19 years. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
32750930|NCT05486637||Adults with cochlear implants|Participants will be native speakers of American English and include adult cochlear implant recipients with unilateral or bilateral devices. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
32750931|NCT05486637||Adults with normal hearing|Participants will be native speakers of American English who have normal hearing. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
32750932|NCT05476731||case|
32750933|NCT05476731||control|
32750934|NCT05482113|Active Comparator|Control - Standard Bupivacaine|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of 0.25% bupivacaine injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
33236620|NCT04017403|Experimental|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
33236621|NCT04017403|Placebo Comparator|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
33236622|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
33394255|NCT04614168|Experimental|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
33394256|NCT04495829||Phorcides|Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.
33394257|NCT02453230|Active Comparator|light on|BPP done with lights on
33394258|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
33394259|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
33394260|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
33394261|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
33394262|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
33394263|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
33394264|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
33394265|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
33394266|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
33394267|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days"
33394268|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
33394269|NCT04258020|Experimental|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
33394270|NCT04258020|No Intervention|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
33394271|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
32750935|NCT05482113|Experimental|Experimental - Liposomal Bupivacaine (Exparel)|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of Exparel injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
32750936|NCT05486403|Experimental|Intervention|Preschool Educators deliver the Appetite Toolbox programme directly to children over a period of six weeks after the pre-test and before the post-test effectiveness measures.
32750937|NCT05486403|Other|Waitlist Control|Preschool Educators continue to deliver their usual preschool curriculum over a period of six weeks after the pre-test and before the post-test effectiveness measures. They will deliver the Appetite Toolbox programme directly to children after the post-test measures.
32750938|NCT05482035|Experimental|Blood pressure measured by wrist blood pressure monitor and mercury sphygmomanometer|
32750939|NCT05476653|Experimental|MRI exam|"Patients will be asked to perform a pulmonary MRI in addition to the usual chest CT can.~The chest CT scan will be performed according to the usual protocol of standard practices. No difference is expected for this research protocol."
32750940|NCT05476575|Experimental|Hydrogen inhalation group|Patients allocating to this group received hydrogen inhalation (4% hydrogen given via nasal cannula) with other normal intraoperative care throughout the whole procedure.
32750941|NCT05476575|No Intervention|Traditional care group|Patients allocating to this group received traditional intraoperative care.
32909124|NCT04079582|Experimental|Higher dialysate magnesium|
32909125|NCT04079582|Active Comparator|Lower dialysate magnesium|
32909126|NCT04069520|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
32909127|NCT04069520|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
32909128|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
33394272|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
33394273|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
33394274|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
33394275|NCT04495283|Experimental|PGB and APAP (Group A)|Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
33394276|NCT04495283|Experimental|APAP (Group B)|Group B receives placebo 2 prior to surgery and APAP post-surgery.
33394277|NCT04495283|Experimental|Placebo (Group C).|Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
32909129|NCT03987854|Experimental|complete diet and lifestyle program|
32909130|NCT05513300|Experimental|HIIT group|Participants randomized in this group will be assigned to 12 weeks high intensity interval training.
33236623|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
33236624|NCT04096664|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
33236625|NCT04096664|No Intervention|Control|Usual care
33236626|NCT02939989|Experimental|Glecaprevir/Pibrentasvir + SOF + RBV for 12 weeks|Participants without cirrhosis who had non-genotype 3 infection and were naïve to protease inhibitor (PI) and/or nonstructural viral protein 5A inhibitor (NS5Ai) prior to participation in AbbVie HCV parent study received daily treatment with glecaprevir/pibrentasvir (GLE/PIB) 300 mg/120 mg plus sofosbuvir (SOF) 400 mg plus twice-daily weight-based ribavirin (RBV) 600 mg - 1200 mg daily total for 12 weeks.
33236627|NCT02939989|Experimental|Glecaprevir/Pibrentasvir + SOF + RBV for 16 weeks|Participants with genotype 3, and/or compensated cirrhosis, and/or experience with PI and/or NS5Ai prior to participation in Abbvie HCV parent study received daily treatment with GLE/PIB 300 mg/120 mg plus SOF 400 mg plus twice-daily weight-based RBV 600 mg - 1200 mg daily total for 16 weeks.
33236628|NCT04096742|Experimental|Altreno|tretinoin 0.05% lotion (Altreno)
33236629|NCT04096742|Sham Comparator|Vehicle|Vehicle lotion not containing tretinoin
33236630|NCT04085640|Experimental|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
33236631|NCT04085640|Sham Comparator|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
33236632|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
33236633|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
33236634|NCT03994315|Experimental|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 [B. infantis + LNT (3 g/L then 8 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
33236635|NCT03994315|Experimental|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 [B. infantis + LNT (6 g/L then 12 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
33236636|NCT03994315|Active Comparator|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days.
33236637|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:~An angiographic stenosis of more than 50% and less than 90% of the left main~Any proximal descending anterior with a stenosis of more than 50% and less than 90%~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%~Single remaining patent coronary artery with stenosis >50% and less than 90%"
33236638|NCT04100642|Active Comparator|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
33236639|NCT04100642|Experimental|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
33236640|NCT04100642|Experimental|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
33236641|NCT04100642|Experimental|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
33236642|NCT04100642|Placebo Comparator|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
33236643|NCT04100642|Placebo Comparator|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
33236644|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
33236645|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
33236646|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
33236647|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
33236648|NCT00723606|Experimental|Intramuscular ziprasidone|
33236649|NCT00723606|Active Comparator|Intramuscular haloperidol|
33236650|NCT01028521|Experimental|CM3.1-AC100|
33236651|NCT01028521|Placebo Comparator|Placebo|
32750942|NCT05486325|Experimental|Bariatric Surgery|Up to twenty participants meeting inclusion criteria will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube. Up to ten participants meeting inclusion criteria will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
32750943|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
32750944|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
32909131|NCT05513300|Experimental|MICT group|Participants randomized in this group will be assigned to 12 weeks of moderate-intensity continuous training.
33236652|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
33236653|NCT01028599|Experimental|Exercise|
33236654|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
33236655|NCT04005001|Experimental|Experimental|The experimental arm will involve patients monitored by HindSight.
33236656|NCT04005001|Active Comparator|Control|The control arm will involve patients monitored by InSight.
33236657|NCT01031797||High SLEDAS|High SLE disease activity score
33236658|NCT01031797||Low SLEDAS|SLE patient with low score
33236659|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
33236660|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
33236661|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
33236662|NCT01021657||Glaucoma|
33236663|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
33236664|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
33236665|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
33236666|NCT00442351|Experimental|Asmanex Twisthaler|
33236667|NCT00442351|Placebo Comparator|Placebo inhaler|
33236668|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
33236669|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33236670|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
33236671|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
33236672|NCT00755846|Experimental|Alogliptin 25 mg QD|
33236673|NCT00755846|Experimental|Alogliptin 50 mg QD|
33236674|NCT00755846|Experimental|Alogliptin 100 mg QD|
33236675|NCT00755846|Placebo Comparator|Placebo QD|
33236676|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
33236677|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
33236678|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
33236679|NCT00442117|Experimental|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
33236680|NCT00442117|Active Comparator|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
33236681|NCT04096508|Experimental|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
33236682|NCT04096508|Experimental|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
33236683|NCT04096508|No Intervention|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
33236684|NCT05457998||Main study population: Cognitively unimpaired individuals (50-80 y)|"This study will be conducted in up to 200 subjects between the ages of 50-80 who are cognitively unimpaired with ongoing recruitment and enrollment for 2 years and participant follow-up for 4 years.~Following analysis of blood plasma at screening, all p-tau 217 plasma positive participants will be enrolled and scheduled for amyloid PET. A randomly selected 1/10 of all p-tau 217 plasma negative participants will also continue. We will enroll participants until we have reached a sample size where 3/4 of participants are amyloid positive.~FOLLOW-UP FOR 4 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months.~MRI and Amyloid PET scans will be performed at screening/baseline and 24 months. An additional amyloid PET scan will be performed at 48 months."
33236685|NCT05457998||Sub-group 1: Optional Tau PET imaging sub-study|"An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate.~If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with [18F]RO-948: at baseline, 24 months, and 48 months."
33236686|NCT05457998||Sub-group 2: Optional Tau PET tracer comparison sub-study|"An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate. These individuals will be amyloid positive as determined by Flutemetamol amyloid PET scan.~Tau PET scans with 2 tracers ([18F]RO-948 and [18F]MK-6240) will be performed at baseline and 24 months. An additional Tau PET scan with [18F]RO-948 will be performed at 48 months."
33236687|NCT04096352|Experimental|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
33236688|NCT04096352|Active Comparator|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
33236689|NCT02600702|No Intervention|usual care|quadricep exercise
33236690|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
33236691|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
33236692|NCT01796145|Experimental|TACE|
33236693|NCT01796145|Experimental|Systemic Therapy|
33236694|NCT01796145|Experimental|Surgery|
33236695|NCT04095962|Experimental|Experimental Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
33236696|NCT04095962|No Intervention|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
33236697|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
33236698|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):~Positive leukocytes, positive nitrites on dipstick~Negative leukocytes, Positive nitrites on dipstick~Positive leukocytes, negative nitrites, plus bacteriuria on microscopy~Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.~Exclusion criteria (one from the list below):~1. No evidence of UTI on dipstick"
32750945|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
33236699|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::~Evidence of nasal discharge AND/OR~Inflammation throat/ tonsils on direct examination AND/OR~Inflammation of middle or outer ear on direct examination~History of fever AND history of stridor/ barking cough~History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough~Exclusion criteria (one from the list below)::~Foreign body inserted in either nose/ ear~Traumatic perforation of ear drum~Allergic rhinitis i.e. good contact history~Evidence of LRTI"
33236700|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):~Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry~Fever > 38.5C AND chest recessions AND/OR raised respiratory rate~Radiological evidence of LRTI~Exclusion criteria (one from the list below):~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
33236701|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):~Abrupt onset of 3 or more loose/liquid stools/ day~Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting~Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI~Exclusion criteria (one from the list below):~Normal breast milk stool~Neurological cause of vomiting"
33236702|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
33236703|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
33394278|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
33394279|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
33394280|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
33394281|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
33394282|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
32750946|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
33394283|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
33394284|NCT03744845|No Intervention|Control group|Usual anesthetic care.
32750947|NCT05481957|Experimental|vortioxetine|participants given 5~10mg per day for 16 weeks
32750948|NCT05481957|Active Comparator|Sodium valproate|participants given 500~1000mg per day for 16 weeks
32750949|NCT05475561|Active Comparator|Group (P)|
32750950|NCT05475561|Active Comparator|Group (E)|
32750951|NCT05475405|Experimental|Scapulothoracic mobilization along with conventional physical therapy for mechanical neck pain.|"conventional physical therapy:~Scapulothoracic mobilization:~Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula."
32750952|NCT05475405|Active Comparator|IASTM with conventional physical therapy for mechanical neck pain|"Conventional Physical Therapy:~IASTM (Instrument Assisted Soft Tissue Technique):~Patient sitting or prone lying Restrictions and myofascial adhesions assessed prior to treatment fanning strokes at 45 degree angles to skin be applied using the tool"
32750953|NCT05476341|Experimental|Bevacizumab injection|On the first day, bevacizumab injection was given, 3mg/kg each time, diluted to 100ml of 0.9% sodium chloride injection, mixed evenly, and then intravenous infusion for 90 minutes (±15 minutes).
32750954|NCT05476341|Active Comparator|Bevacizumab injection（Avastin）|On the first day, Avastin injection was given, 3mg/kg of which was diluted to 100ml of 0.9% sodium chloride injection. After mixing evenly, it was infused intravenously for 90 minutes (±15 minutes).
32750955|NCT03476187|Experimental|µCor wearers|Wear the µCor device
32750956|NCT05481723|Active Comparator|Control group|The control group will be treated according to the usual protocol of the department (standard group)
32750957|NCT05481723|Experimental|pulmonary ultrasound group|the experimental group follows an algorithm incorporating the number of B-lines occurring after a filling test (pulmonary ultrasound group).
32750958|NCT05476185|Experimental|READY4Life Programming - classroom instruction|The intervention is an 16-hour classroom-based relationship education program taught by project staff. This instruction will strengthen and promote healthy marriages among young refugees and immigrants through education and comprehensive case management that will support an overall goal of helping youth build healthy relationship skills while supporting positive socio-emotional development and promoting successful transitions to young adulthood.
32750959|NCT05476185|No Intervention|No Intervention: Control|The control group does not receive any part of the classroom instruction that the intervention group receives. Like the intervention group, however, the control group does have access to case management.
32750960|NCT05475015||Training cohort|Training cohort was set to develop the novel non-invasive model for virtual HVPG
32750961|NCT05475015||Validation cohort|Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments
32909132|NCT05513300|No Intervention|Control group|
33394285|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
33394286|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
33394287|NCT03253666||Nurses' Health Study|"See Detailed Description"
33394288|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
33394289|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
33394290|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
33394291|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
33394292|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
33394293|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
33394294|NCT04466592|Experimental|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
33394295|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
33394296|NCT04445220|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
33394297|NCT04445220|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
33394298|NCT04445220|No Intervention|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
33394299|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
33394300|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
33394301|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
33236704|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
33236705|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
32750962|NCT05481645|Experimental|Group one|"First-line treatment: TQB2450 injection 1200mg,d1/Q3W+Carboplatin Injection, AUC=5 mg/ml.min,d1/Q3W + Paclitaxel Injection 175mg/m2,d1/Q3W;6-8 cycles;~Maintenance treatment: TQB2450 injection, 1200mg，d1/Q3W"
32750963|NCT05481645|Experimental|Group two|First-line treatment: TQB2450 Injection 1200mg, d1/Q3W + Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W + Carboplatin Injection AUC=5 mg/ml.min, d1/Q3W + Paclitaxel Injection 175mg/m2, d1/Q3W ; 6-8 cycles; Maintenance treatment: TQB2450 injection+ Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W
32750964|NCT05481567||Stage III|Patients diagnosed with periodontitis stage III
33236706|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
32750965|NCT05481567||Stage IV|Patients diagnosed with periodontitis stage IV
32750966|NCT05474703||AUK with Dydrogestrone|Patients who applied for abnormal uterine bleeding and received oral dydrogesterone therapy for at least 6 months
32750967|NCT05474703||AUK with Levonorgestrel releasing intrauterin device|Patients who applied for abnormal uterine bleeding and were administered levonorgestrel-releasing intrauterine device at least 6 months ago
32750968|NCT04272021|Experimental|ADHD sample|Children with a diagnosis of ADHD
32750969|NCT04423887|Active Comparator|Control|
32750970|NCT04423887|Experimental|Creatine Supplementation|
33236707|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
32750971|NCT05474313|Experimental|PrEP-3D|Use of Alto Pharmacy, PrEP-3D mobile app and home laboratory testing.
33236708|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
33236709|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
33236710|NCT04093544|Active Comparator|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
33236711|NCT04093544|Experimental|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
33236712|NCT04072497|Experimental|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
33236713|NCT04072497|Active Comparator|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=3.3 LgPFU per dose)
33236714|NCT04072497|Placebo Comparator|Placebo|Placebo with no live virus
33236715|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
33236716|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
33236717|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
33236718|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
33236719|NCT04072263|Experimental|Cohort 1|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
33236720|NCT04072263|Experimental|Cohort 2|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus~Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
33236721|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
33236722|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
33236723|NCT04072419||enhanced recovery after surgery group|"weaning mechanical ventilation after surgery (less than 48h),~no post-operative chest tube and urinary catheterization)~Establishment of early feeding (D3 post-operative)"
33236724|NCT04072419||control group|"the time of mechanical ventilation after surgery is more than 48 hours~routine postoperative indwelling chest tube and urinary catheterization)~Establishment of feeding after D3 post-operative"
33236725|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
33236726|NCT00755222|Placebo Comparator|Placebo|
33236727|NCT02956239|Experimental|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
33236728|NCT02956239|Active Comparator|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
33236729|NCT02956239|Active Comparator|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
33236730|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
33236731|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
33236732|NCT00441727|Placebo Comparator|Placebo|Placebo
33236733|NCT04095728|Experimental|Investigational Product|
33236734|NCT04095728|Placebo Comparator|Placebo|
33236735|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
33236736|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
32909133|NCT05509634|Experimental|Treatment group A|HR20013 for injection + simulant of fosaprepitant dimeglumine for injection + simulant of palonosetron hydrochloride injection + dexamethasone
32909134|NCT05509634|Active Comparator|Treatment group B|simulant of HR20013 for injection + fosaprepitant dimeglumine for injection + palonosetron hydrochloride injection + dexamethasone + simulant of dexamethasone
32909135|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
33070866|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
33070867|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
33394302|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
33394303|NCT01371084|Placebo Comparator|Wait List Control|
33394304|NCT03233386||Condition 1|Mexico City Cohort
33394305|NCT03233386||Condition 2|Monterrey Cohort
33394306|NCT03233386||Condition 3|Guadalajara Cohort
33394307|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
33394308|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
33394309|NCT04237116|Experimental|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
33394310|NCT04237116|Placebo Comparator|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
33394311|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
33394312|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
33394313|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
32750972|NCT05474313|Other|Control Arm|Participants in the control arm will receive standard of care PREP navigation.
32750973|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
32909136|NCT03937700|Experimental|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
32909137|NCT03930056|Experimental|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
32909138|NCT03930056|Active Comparator|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
32909139|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
32909140|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy"
33070868|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
33070869|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
33070870|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
32909141|NCT05419856|Experimental|4P-004 at 0.3 mg or placebo|4P-004 at 0.3 mg or placebo is administered once intraarticularly in the target knee joint
32909142|NCT05419856|Experimental|4P-004 at 1 mg or placebo|4P-004 at 1 mg or placebo is administered once intraarticularly in the target knee joint
32909143|NCT05419856|Experimental|4P-004 at 3mg or placebo|4P-004 at 3 mg or placebo is administered once intraarticularly in the target knee joint
32909144|NCT05419856|Experimental|4P-004 at 6 mg or placebo|4P-004 at 6 mg or placebo is administered once intraarticularly in the target knee joint
33236737|NCT04074057|Other|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
32750974|NCT03426891|Experimental|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
33236738|NCT04074057|Other|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
33236739|NCT04072185|Experimental|Physical activity group|
33236740|NCT04072185|No Intervention|Control group|
33236741|NCT05673447|Experimental|anti-CD19 CAR NK cells|CD19-CAR-NK is an allogenic CD19-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
32750975|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
33236742|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
32750976|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
32750977|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
32750978|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
32750979|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
32750980|NCT02395211|Active Comparator|Usual Physiotherapy|
32750981|NCT02395211|Experimental|Gloreha device|
32750982|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
32750983|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
33236743|NCT03996655|Experimental|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
33236744|NCT03996655|Active Comparator|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
33236745|NCT01032031|Active Comparator|Green tea + vit C high dose|
33236746|NCT01032031|Placebo Comparator|Placebo|
33236747|NCT03960619|Experimental|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
33236748|NCT01032109|Experimental|Bevacizumab|
32750984|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
32750985|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
32750986|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
32750987|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
32750988|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
32750989|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
32750990|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
32750991|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
32898260|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
32898261|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
32898262|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
32898263|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
32898264|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
32898265|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
32898266|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
32750992|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
32750993|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
33236749|NCT04100330|Experimental|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
33236750|NCT04100330|Active Comparator|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
33236751|NCT02600624||Participants|Women who are in active labor and their newborn infants.
32750994|NCT02394743||eGFR > 90|group whose eGFR is more than 90
32750995|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
32750996|NCT02394743||eGFR < 60|group whose eGFR is less than 60
32750997|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
32750998|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
32750999|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
32751000|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
32751001|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
32751002|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
32751003|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
33236752|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI<5 were enrolled in the Group 1.
33236753|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
33236754|NCT00436345|Experimental|Remifentanil|remifentanil
33236755|NCT00436345|Active Comparator|Propofol|Propofol infusion
33236756|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
33236757|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
33236758|NCT04095650|Experimental|Intervention|Participants will engage in a 7-week chronic pain self-management program.
33236759|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
33236760|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
33241634|NCT04223960|Experimental|Part B: FE/BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
32751004|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
32751005|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
32751006|NCT05745857|Experimental|Oral bevacizumab-800CW|Dose finding of oral bevacizumab-800CW and extend optimal dose group (n = 5 - 10)
32751007|NCT05745857|Experimental|Oral cetuximab-800CW and combined oral cetuximab-800CW and bevacizumab-800CW|"Dose finding of oral cetuximab-800CW in first five patients and combined oral bevacizumab-800CW and cetuximab-800CW if the investigators see good results with cetuximab-800CW. If not, they will add a control group of non-dysplastic BE patients and administer oral bevacizumab-800CW.~(n = 15)"
32751008|NCT05745857|Experimental|Combined topical tracer administration bevacizumab-800CW and cetuximab-800CW|"This arm will only be part of the study when oral administration is not feasible or safe.~Compare single topical tracer administration of bevacizumab-800CW with combined topical tracer administration of bevacizumab-800CW and cetuximab-800CW. Extend combined group when lesion detection is increased or add control group with non-dysplastic BE patients if not.~(n = 20)"
32751009|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
32751010|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
32751011|NCT05745779||Gingivitis|0% interdental bone loss
32751012|NCT05745779||Stage 1 periodontitis|0-15% interdental bone loss
32751013|NCT05745779||Stage 2 Periodontitis|15-33% interdental bone loss
33070871|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:~Day 1-7, 60 mg~Day 8-14, 120 mg~Day 15-21, 180 mg~Day 22-28, 300 mg~Day 29-186, 420 mg"
33394314|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
33241635|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
32751014|NCT05745779||Stage 3 Periodontitis|>33% interdental bone loss with potential for additional tooth loss
32751015|NCT05745779||Stage 4 Periodontitis|>%33 interdental bone loss with potantial for loss of dentition
32751016|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
32751017|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
32751018|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~When and how much: once; diluted in 1000 ml of normal saline."
32898267|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
32898268|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo twice daily (BID) + cabozantinib (60 mg once daily [QD]) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or unacceptable toxicity, whichever occurred first.
33070872|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
33236761|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
33236762|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
33236763|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
33236764|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
33236765|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
33236766|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
33236767|NCT04095338|Active Comparator|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
33236768|NCT04095338|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
33236769|NCT04095338|Experimental|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
33236770|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
33236771|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
33236772|NCT01028755|Experimental|Arm 1|
33236773|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
33236774|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
33236775|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
33236776|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
33236777|NCT03955627|No Intervention|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
33236778|NCT03955627|Experimental|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
33236779|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
33236780|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
33236781|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
33236782|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
33236783|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
33236784|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
33236785|NCT00754442|Active Comparator|teriparatide control|control subject
33236786|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
33236787|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
33236788|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
33236789|NCT00754052|Active Comparator|1|
32751019|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: the same as for Ofatumumab Arm~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
32751020|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
33236790|NCT00754052|Active Comparator|2|
33236791|NCT00754052|Placebo Comparator|3|
33236792|NCT04095182|Experimental|Zebinix 400mg|
33236793|NCT04095182|Placebo Comparator|Placebo for Zebinix 400mg|
33236794|NCT04095182|Experimental|Zebinix 800mg|
33236795|NCT04095182|Placebo Comparator|Placebo for Zebinix 800mg|
33236796|NCT04095182|Experimental|Zebinix 1600mg|
33236797|NCT04095182|Placebo Comparator|Placebo for Zebinix 1600mg|
33236798|NCT00753896|Experimental|1|
33236799|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
33236800|NCT04093154|Experimental|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
33236801|NCT04093154|No Intervention|Control|Standart Care Control group children did not receive any distraction techniques.
33236802|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
33236803|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
33236804|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
33236805|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
33236806|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
33236807|NCT04099784||Fresh|Children born from fresh embryo transfer
33236808|NCT05430152|Experimental|Low-Dose Naltrexone|The Low-Dose Naltrexone (LDN) will be provided as a compounded capsule starting at a strength of 1mg/day of naltrexone and increasing up to a maximum of 4.5 mg/day. The compounding pharmacy will compound the needed doses in Capsugel® empty gelatin based capsules using Naltrexone Hydrochloride Tablets and CELLULOSE.
33236809|NCT05430152|Placebo Comparator|Placebo|Matching placebo capsule will be created by compounding pharmacy to look exactly like the LDN doses. The compounding pharmacy will compound the placebo in Capsugel® empty gelatin based capsules using CELLULOSE.
33236810|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
33236811|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
33236812|NCT05428358|Experimental|+Preoperative MRI|Preoperative MRI
33236813|NCT05428358|No Intervention|-Preoperative MRI|No preoperative MRI, standard of care
33236814|NCT04092920|Experimental|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
33236815|NCT02927067|Active Comparator|Valganciclovir 900 mg BID|Participants received 900 milligrams (mg) of valganciclovir along with a placebo matched to maribavir, twice daily (BID) orally for 8 weeks. Valganciclovir dose was allowed to be adjusted to 450 mg BID or 450 mg QD based on renal function impairment assessed at baseline or development of neutropenia during the study.
33236816|NCT02927067|Experimental|Maribavir 400 mg BID|Participants received 400 mg of maribavir along with a placebo matched to valganciclovir, BID orally for 8 weeks.
33236817|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
33236818|NCT05457218|Experimental|Whey protein|This arm will be given a supplemental dose of whey protein (0.25 g/kg body weight)
33236819|NCT05457218|Experimental|IPC80|This arm will be given a supplemental dose of IPC80, an insect-derived protein source (0.25 g/kg body weight)
33236820|NCT05457218|Experimental|Whole Buffalo Powder|This arm will be given a supplemental dose of Whole Buffalo Powder, an insect-derived protein source (0.25 g/kg body weight)
33236821|NCT04094636|No Intervention|No intervention: Control|Control group
33236822|NCT04094636|Experimental|In-bed cycling|Supervised in-bed cycling
33236823|NCT04094636|Experimental|Exercise booklet|Supervised physical training with exercises from exercise booklet
33236824|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
33236825|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
32745017|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
33236826|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
33236827|NCT04094480|Active Comparator|endoloop ligation|securing appendicular base with endoloops
32745018|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
32745019|NCT04866225|Experimental|Study arm|One arm of healthy male participants administered a single oral dose of [14C]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of [14C]PF-06865571 three hours later.
33236828|NCT04094480|Active Comparator|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
32745020|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
32745021|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
32745022|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
32751021|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
33236829|NCT04073901|Experimental|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
33236830|NCT04073901|Active Comparator|Zirconia crowns|Prefabricated primary full coverage crown
33236831|NCT05447312|Experimental|Adaptive Music Intervention (AM)|The intervention will be an adaptive music program, in which participants will listen to music provided by the research team that has been enhanced with frequencies that elicit positive moods using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
33236832|NCT05447312|Active Comparator|Traditional Music Intervention (TM)|The intervention will be traditional music therapy, in which participants will listen to music provided by the research team that has not been enhanced with frequencies using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
33236833|NCT05447312|No Intervention|Control Group|The control intervention will be an audiobook provided by the research team that participants will listen to using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
33236834|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
33236835|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
33236836|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
33236837|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
33236838|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
33236839|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
33236840|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33236841|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
33236842|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
33236843|NCT00586508|Experimental|Enzastaurin + Bevacizumab|
33236844|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
33236845|NCT04094168|Experimental|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
33236846|NCT04094168|Active Comparator|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
33236847|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
33236848|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
33236849|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
33236850|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
33394315|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
33394316|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
33394317|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
33394318|NCT03117738|Experimental|AstroStem|
33394319|NCT03117738|Placebo Comparator|Placebo-Control|
33394320|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
32751022|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room."
32751023|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
32751024|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
32751025|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
32751026|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
32751027|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
32751028|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
32751029|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
32751030|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
32751031|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
32751032|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
32751033|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
32751034|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
32751035|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
32751036|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
32751037|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
33236851|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
33236852|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
33394321|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
33394322|NCT02855268|Experimental|lademirsen (SAR339375)|Eligible participants will receive subcutaneous injection every week for 48 weeks
33394323|NCT02855268|Placebo Comparator|Placebo|Eligible participants will receive subcutaneous injection every week for 48 weeks
33394324|NCT04292106|Placebo Comparator|Placebo|
32751038|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
32751039|NCT05745623|Experimental|ICP-723|
32751040|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
32751041|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
33394325|NCT04292106|Experimental|Red Spinach Extract (RSE)|
33394326|NCT03236272||case group|patients with ARDS
33394327|NCT03236272||control group|patients Without ARDS
33394328|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~a nasogastric tube inserted as part of routine management of preterm infants.~Written informed consent has been obtained"
33394329|NCT04285086|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
33394330|NCT04285086|Active Comparator|Anagrelide|Capsules, Daily, p.o.
33394331|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
33236853|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
33236854|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
33236855|NCT00751790|Experimental|Triptorelin|
33236856|NCT04092998|Experimental|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
33236857|NCT04086810|Experimental|DCCR|25 - 450 mg DCCR
33236858|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
33236859|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
33236860|NCT04020536||kala-azar group|
32751042|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
32751043|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
32751044|NCT05745467|Experimental|Povidone Iodine|5% povidone iodine will be swabbed in patients' nares (experimental group), one in each nostril, twice before incision.
32751045|NCT05745467|No Intervention|Usual Care|Half of the patients will not receive 5% povidone iodine and will proceed with usual care.
33236861|NCT04020536||epidemic hemorrhagic fever group|
33236862|NCT04020536||brucellosis group|
33236863|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
32751046|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
32751047|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
32751048|NCT05745389||Alopecia Areata|Pts presenting to enrolling sites across the US are invited to enroll if eligible
32751049|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
32751050|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
32751051|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
32751052|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
32751053|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
32751054|NCT05745233|Experimental|Checkpoint inhibitor (nivolumab or pembrolizumab)|Patients with malignant ascites will received either nivolumab or pembrolizumab intraperitoneally.
32751055|NCT02393027|Experimental|patients|10 idopathic parkinson disease
32751056|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
32751057|NCT04781231|Experimental|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
33070873|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
33070874|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
33236864|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
33241636|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
32751058|NCT04781231|Active Comparator|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
32751059|NCT04781231|Other|Usual management of anxiety|
32751060|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.~Arm A is closed to enrollment."
33236865|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
32751061|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
32751062|NCT05745155|Experimental|Senti-Wear with Senti-AI|Participants will wear the Senti-Wear smart garment up to twice per day (as tolerated) and complete a study journal detailing issues with the device and changes to their respiratory illness.
32751063|NCT05745077|Experimental|Telemedicine Consultation|Patient will schedule a Telemedicine Consultation in place of traditional in-person visit.
32751064|NCT05745077|Active Comparator|Traditional In-Person Care|Patient will schedule a traditional in-person visit as per usual care.
32751065|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
32751066|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
32751067|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
32751068|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
32751069|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
32751070|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
32751071|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
32751072|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
32751073|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
32751074|NCT05744921|Experimental|PNH Transition Patients|Patients with PNH who completed treatment/ protocol requirements (as applicable) in the parent studies (R3918-PNH-2021 [NCT05133531] or R3918-PNH-2022 [NCT05131204])
33236866|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
33236867|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
33236868|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
32751075|NCT05744921|Experimental|C5 Polymorphism Patients|Patients who have not been treated in either parent study but who have a documented complement component 5 (C5) polymorphism (eg, C5 variants p.Arg885His, p.Arg885R885Cys) rendering them refractory to eculizumab/ravulizumab.
32751076|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
32751077|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
32751078|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
32751079|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
32751080|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
32751081|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
33236869|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
33236870|NCT00916760|Placebo Comparator|2|
33236871|NCT05444894|Experimental|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
33236872|NCT05444192|Active Comparator|insoles manufactured from foam-box cast|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
32751082|NCT05744765|Experimental|Intervention group|First evaluation - breathing exercises (1 session) - second evaluation - breathing exercises (11 sessions) - third evaluation
32751083|NCT05744765|No Intervention|Control Group|First evaluation - no intervention (1 session) - second evaluation - no intervention (11 sessions) - third evaluation
33236873|NCT05444192|Active Comparator|insoles manufactured from direct 3D scan|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
33236874|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
33236875|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
32751084|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
32751085|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
32751086|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
33236876|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
33236877|NCT05442554|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.
33236878|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
33236879|NCT00723450|Experimental|lamictal|Flexible Dosing
33236880|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
33236881|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
33236882|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
33236883|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
33236884|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
33236885|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.~Three visits will take place:~V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.~V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated~V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
33236886|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
33236887|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
33236888|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
33236889|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
33236890|NCT02591550||patients with normal cough sensitivity|
33236891|NCT02591550||patients with high cough sensitivity|
33236892|NCT02591550||healty controls|
33236893|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
33236894|NCT04086342|Active Comparator|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
33236895|NCT04086342|Placebo Comparator|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
33236896|NCT05341362|No Intervention|Blank Group|In this group, the anesthesia management is conducted according to the anesthetists' experience, based on the regular monitor.
33236897|NCT05341362|Experimental|LiDCOrapid Group|In this group, the anesthesia management is conducted based on both the regular monitor and the hemodynamic figures on the LiDCOrapid.
33236898|NCT05420948|Experimental|Group 1: Participants Who Receive Pembrolizumab (Alone)|Participants in this group will receive pembrolizumab 200 mg through an intravenous (IV) needle inserted into the arm. Medications will be given on day 1 of each 21-day cycle for two cycles..
33394332|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
33394333|NCT04485988||No-beta blocker|
33394334|NCT04485988||beta blocker|
33394335|NCT04163484||Stable coronary artery disease|
33394336|NCT04163484||ST-elevation myocardial infarction|
33394337|NCT04163484||Non-ST-elevation myocardial infarction|
33394338|NCT04234464|Experimental|A/B - Treatment with BDA MDI 160/180 followed by treatment with Placebo MDI|Subjects randomized to receive a single dose of BDA MDI 160/180 in treatment period 1, and a single dose of Placebo MDI in treatment period 2.
33394339|NCT04234464|Experimental|B/A - Treatment with Placebo MDI followed by treatment with BDA MDI 160/180|Subjects randomized to receive a single dose of Placebo MDI in treatment period 1, and a single dose of BDA MDI 160/180 in treatment period 2.
33394340|NCT04485910|Active Comparator|Single step media|Embryos cultured in single step media
32751087|NCT04805177|Experimental|hematoma evacuation|Early minimally invasive image guided hematoma evacuation
32751088|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
33394341|NCT04485910|Active Comparator|Sequential media|Embryos cultured in sequential media
33394342|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
33394343|NCT01371162|Experimental|A1 Healthy Volunteers|
33394344|NCT01371162|Placebo Comparator|A2|
33394345|NCT01371162|Experimental|B1 HCV Infection|
32751089|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
32751090|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
32751091|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
32751092|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
32751093|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
33070875|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
33394346|NCT01371162|Placebo Comparator|B2|
33394347|NCT04485832|Active Comparator|Intervention|
33394348|NCT04485832|Active Comparator|Control|
33394349|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
33394350|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
32751094|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
32751096|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
32751097|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
32751098|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
32751099|NCT03167645|No Intervention|Control|Standard clinical care
32751100|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
32751101|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
32751102|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
33394351|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
33394352|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
33394353|NCT03123588|Experimental|Group A : Ruxolitinib and anagrelide placebo|Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
33394354|NCT03123588|Active Comparator|Group B : Anagrelide and Ruxolitinib PLacebo|Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
33394355|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
33394356|NCT04114812|Experimental|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
33394357|NCT04114812|Active Comparator|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
33394358|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
33070876|NCT05037877|Active Comparator|Intervention group|HUM supplement - 1 capsule per day
33070877|NCT05037877|Placebo Comparator|Placebo group|Placebo supplement - 1 capsule per day
33070878|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
33070879|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
33070880|NCT04690777|Experimental|VESTIBULAR EXERCISE|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~Head and eye movements while sitting.~Head and body movements while sitting.~Paused exercises.~Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
33394359|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
33236899|NCT05420948|Experimental|Group 2: Participants Who Receive Pembrolizumab + Chemotherapy with Carboplatin and Paclitaxel|Participants in this group will receive 200 mg of pembrolizumab through an intravenous (IV) needle inserted into the arm plus chemotherapy with carboplatin (AUC 6) on day 1 and paclitaxel (200 mg) on day 1 of each 21-day cycle for two cycles.
33236900|NCT04093778|Experimental|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
33236901|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
33236902|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
33236903|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
33394360|NCT01372722|Experimental|Sham then Stimulation|
32751103|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
33070881|NCT04690777|Active Comparator|MULTICOMPONENT EXERCISE|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
33070882|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
33070883|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
33070884|NCT05317585|Experimental|Continuous Glucose Monitoring (CGM)|Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.
33070885|NCT05317585|Active Comparator|Fingerstick Glucose Monitoring|Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.
33236904|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
33236905|NCT05406440|Experimental|MK-8189 Panel A|Participants will receive MK-8189 starting at 48 mg on Day 1 and 60 mg on Day 2.
32751104|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
32898269|NCT03428217|Experimental|CB-Cabo|CB-839 800 mg BID + cabozantinib (60 mg QD) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per RECIST v1.1 or unacceptable toxicity, whichever occurred first.
33236906|NCT05406440|Experimental|MK-8189 Panel A-1|Participants will receive MK-8189 48 mg on Day 1 and 80 mg on Day 2.
33236907|NCT05406440|Experimental|MK-8189 Panel C|Participants will receive MK-8189 48 mg on Days 1-2 and 80 mg on Day 3 based on safety and tolerability.
33236908|NCT05406440|Placebo Comparator|Placebo|Participants will receive MK-8189-matching placebo.
33236909|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
33236910|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
33236911|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
33236912|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
33236913|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
33236914|NCT04086108|Experimental|Tomato|Single oral administration
33236915|NCT04086108|Experimental|GABA supplement|Single oral administration
33236916|NCT04086108|Experimental|Glutamate supplement|Single oral administration
33236917|NCT04086108|No Intervention|Placebo|Single oral administration, same volume of water that is distributed in the other arms
33236918|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
33236919|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
33236920|NCT04089410|Active Comparator|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
33236921|NCT04089410|Placebo Comparator|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
33394361|NCT01372722|Experimental|Stimulation then Sham|
33394362|NCT02452918|Experimental|oritavancin|oritavancin, a single 1200mg IV dose, over 3 hours
33236922|NCT04092608|Active Comparator|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP < 7 mmHg during surgery.~Baseline of crystalloid of 2ml/kg/h max in all patients.~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)~UPi is blinded in all groups"
33070886|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
33070887|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
33236923|NCT04092608|Experimental|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~UPi is blinded in all groups"
33236924|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
32909145|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
33070888|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
33236925|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
33236926|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
33236927|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
33236928|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
33236929|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
33236930|NCT04092296|Experimental|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
33236931|NCT04092296|Active Comparator|remineralization|
33236932|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
33236933|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
33236934|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
33236935|NCT00918450|Experimental|1|
33236936|NCT04092374|Experimental|Case arm|
33236937|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
33236938|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
33236939|NCT04090112|Experimental|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
33236940|NCT04090112|Active Comparator|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
33236941|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
33236942|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
33236943|NCT04091906|Experimental|Healthy donor|
33236944|NCT04071717|Experimental|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
33236945|NCT04071717|Sham Comparator|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
33236946|NCT04071717|Other|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
33236947|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
32751105|NCT03166397|Experimental|ACT TIL + Anti PD-1|"Single dose of Nivolumab 480 mg fixed dose~Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.~Second dose of Nivolumab 480 mg fixed dose (at least 4 weeks from the first dose)"
33236948|NCT02597504|Experimental|Validity and Reliability|"Reliability:~Test-Retest~Validity:~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
33236949|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
32751106|NCT03166397|Experimental|ACT TIL FMT + Anti CTLA4|"FMT loading dose given via colonoscopy~FMT 12 oral capsules as maintenance - given 2 times~Single dose of Ipilimumab 1mg/kg up to 100 mg~Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
33236950|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
33236951|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
33236952|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
33236953|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
33236954|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
33236955|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
33236956|NCT04089878|Experimental|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
33236957|NCT04089878|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
33236958|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
33236959|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
33236960|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
33236961|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
33236962|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
33236963|NCT04071873|Experimental|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
33236964|NCT04071873|Active Comparator|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
33236965|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
33236966|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
33236967|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
33236968|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
33236969|NCT02577393|Experimental|prophylactic EGCG group|
33236970|NCT02577393|Experimental|therapeutic EGCG group|
33236971|NCT02577393|Placebo Comparator|conventional therapy group|
33236972|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
33236973|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
33236974|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
33236975|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
33236976|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
33070889|NCT02941354|Experimental|Turoctocog alfa|
32751107|NCT05744609||children hospitalized with community-acquired pneumonia|
32751108|NCT04480073|Other|edentulous patients with atrophic jaws|patients presenting with severely atrophic edentulous sites in the upper and lower jaw, and requesting implant-supported prosthetic restorations, will be enrolled in this study.
32751109|NCT05744531|Experimental|education group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was given to the pregnant women and their spouses in the education group .Internet-based Parenting education based on the Information-Motivation-Behavioral Skills (IMB) Model was given to the pregnant women and their spouses in the education group , once a week between 31 and 34 weeks of gestation, for a total of 4 times. . Internet-based counseling was given to the pregnant women and their spouses in the education group as part of the motivation step of the model,
32751110|NCT05744531|No Intervention|control group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was not given to the pregnant women and their spouses in the control group. No training was given to the pregnant women and their spouses in the control group.Counseling was not provided to the pregnant women and their spouses in the control group. .
32751111|NCT05746169||Pregnant women and their children|The DREAM cohort will recruit from University of California, San Francisco (UCSF) Mission Bay, Zuckerberg San Francisco General Hospital, and Fresno Community Medical Center locations to enroll an economically, geographically, ethnically and racially diverse cohort of pregnant women and their children for long term follow-up.
33070890|NCT05304403||Chronic Opioid User|Patients identified to have chronic opioid use (identified in chronic pain clinic)
33070891|NCT05304403||Healthy Control|These patients will not be actively recruited in this study. The investigators will use national microbiome dataset as a comparison.
33236977|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
33236978|NCT04852107|Active Comparator|SCS/ DRGS/DUAL /Dual*|
33236979|NCT04852107|Active Comparator|SCS/DUAL/DRGS/DRGS*|
33236980|NCT04852107|Active Comparator|DRGS/SCS/DUAL/DUAL*|
33236981|NCT04852107|Active Comparator|DRGS/DUAL/SCS/SCS*|
33236982|NCT04852107|Active Comparator|Dual/DRGS/SCS/SCS*|
33236983|NCT04852107|Active Comparator|Dual/SCS/DRGS/DRGS*|
33236984|NCT00743444|Experimental|1|AZD3355
33236985|NCT00743444|Placebo Comparator|2|
33236986|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
33236987|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
33236988|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
33236989|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
33236990|NCT05361174|Experimental|Cohort 1|Participants with unresectable or metastatic melanoma
33236991|NCT05361174|Experimental|Cohort 2|Participants with Stage III or IV non-small-cell lung cancer
33236992|NCT05673369|Experimental|Group 1|Period 1: Reference drug Period 2: Test drug
33236993|NCT05673369|Experimental|Group 2|Period 1: Test drug Period 2: Reference drug
33236994|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33236995|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
33070892|NCT02941432|Other|Black tea|Black tea compress treatment
33236996|NCT01760655|Experimental|Treatment (RIC and allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28"
33236997|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
33236998|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
33236999|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
33237000|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
33237001|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
33237002|NCT04073511|Experimental|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
33237003|NCT04073511|Experimental|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
33237004|NCT04073511|Placebo Comparator|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
33237005|NCT02591394|Experimental|STEP Clinic|
33237006|NCT02591394|Active Comparator|Usual Care|
33237007|NCT04089254|Active Comparator|Inpatient Psychiatry|Child and adolescent inpatient treatment
33237008|NCT04089254|Active Comparator|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
33237013|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
33237014|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
33237015|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
32751112|NCT04480151||IMPELLA™ alone as bridge to LVAD|patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)
32751113|NCT04480151||ECLS alone or with IMPELLA™ as bridge to LVAD|patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD
32751114|NCT05744453|Experimental|Olive Leaf Extract|Olive leaf extract supplementation
32751115|NCT05744453|Placebo Comparator|Control|Cellulose Supplementation
33237016|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
32751116|NCT05746091|Active Comparator|Hematoma distraction|open Hematoma distraction
32751117|NCT05746091|Active Comparator|Arthroscopic|Arthroscopic Partial Trapeziectomy with Hematoma Distraction
32751118|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
32751119|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
32751120|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
32751121|NCT05746013|Placebo Comparator|No Fat meal|
32909146|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
32751122|NCT05746013|Experimental|SFA meal|
32751123|NCT05746013|Experimental|MUFA meal|
32751124|NCT05746013|Experimental|PUFA meal|
32751125|NCT05745935|Experimental|Group A|About 50 Patients Will receive 20 units of local oxytocin infiltration before skin closure . 10 units of oxytocin will be infiltrated at the upper skin edge and 10 units of oxytocin will be infilterated at the lower skin edges at equal intervals of 2 cm in between infiltration points.
32751126|NCT05745935|Experimental|Group B|About 50 Patients Will receive the 10 units of local oxytocin infiltration before skin closure . 5 units will be infiltrated at the upper skin edge and 5 units will be infiltrated at the lower skin edge at equal intervals of approximately 2 cm in between infiltration points.
32751127|NCT05232227|Active Comparator|Standard regimen Primaquine single dose over 14 days|The standard regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 3.5 mg/kg divided over 14 days (0.25mg/kg/day)
32909147|NCT03014882|Other|Antioxidant treatment|
32909148|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
32909149|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
33237017|NCT04092062|Experimental|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
33237018|NCT04092062|Sham Comparator|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
33237019|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
33237020|NCT04019912|Experimental|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
33237021|NCT04019912|Active Comparator|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
33237022|NCT02579109|Other|autistic patient|patient with autistic trouble
33237023|NCT02579109|Other|healthy volunteers|healthy volunteers
33237024|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
33237025|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
33237026|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
32751128|NCT05232227|Experimental|Treatment regimen Primaquine double dose over 14 days|The treatment regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 7 mg/kg divided over 14 days
32751129|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
32751130|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
32751131|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
32751132|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
32751133|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
32751134|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
32898270|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle"
32898271|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
33237027|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
33237028|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
33237029|NCT00410241||A2|Individuals 45-65 at enrollment who self-identified as African, African-American, or Afro-Caribbean
33237030|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
33237031|NCT00410241||B|Family members of Group A1, A2, or A3
33237032|NCT05404880||EDWARDS INSPIRIS RESILIA Aortic Valve|Subjects who were treated with the INSPIRIS RESILIA aortic heart valve.
33237033|NCT04091594|Experimental|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
33237034|NCT04091594|Active Comparator|Standard of care|Standard of care solid ankle foot orthotic (AFO)
33237035|NCT02184663|Active Comparator|Standard care without APA program|
33237036|NCT02184663|Experimental|standard care with APA program|
33237037|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
33237038|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
33237039|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
33237040|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
33237041|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
33237042|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
33237043|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
33237044|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
33237045|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
33237046|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
33237047|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
33237048|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
33237049|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
33237050|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
32909150|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
33237051|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
33237052|NCT04091438|Experimental|TAK-925 Dose A + Placebo|TAK-925 Dose A, 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour IV infusion once on Day 3, Treatment Period 2.
33237053|NCT04091438|Placebo Comparator|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 Dose A, 9-hour IV infusion once on Day 3, Treatment Period 2.
33237054|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
33237055|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
33237056|NCT00750152|Placebo Comparator|2|placebo
33237057|NCT00750152|Experimental|1|NAFT-500
33237058|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
33237059|NCT02182089||Patients with less than 10% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
33237060|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any age|Participants may range from neurologically asymptomatic to severe and may have liver disease or unrelated comorbidities, but must be stable enough to safely travel and tolerate medical evaluations.
33237061|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
33237062|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
33237063|NCT05392790|Experimental|Aerobic exercise plus progressive resisted exercise group|Will receive aerobic exercise, progressive resisted exercise in addition to traditional care.
33237064|NCT05392790|Experimental|Aerobic exercise group|Will receive aerobic exercise plus traditional care.
33237065|NCT05392790|Experimental|Progressive resisted exercise group|Will receive progressive resisted exercise
33237066|NCT05392790|Other|Control group|Will receive traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
33237067|NCT04071483|Experimental|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was >50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
33237068|NCT04071483|Active Comparator|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
33237069|NCT05404802|Experimental|Experimental Group|"Training sessions~Each training session will last for 30-45 minutes, twice a week over a 10-week period in Week 1 to Week 10. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~Free-play sessions~Two 15-30 minutes free-play sessions in each week of the 10 weeks are conducted on days when there are no training sessions."
33237070|NCT05404802|Experimental|Control Group|"Training sessions~Each training session will last for 30-45 minutes, once a week over a 2-week period after all assessments are completed. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~There is no free-play sessions for control group."
33237071|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
33237072|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
33237073|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
33237074|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
33237075|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
33237076|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
32751135|NCT05744375|Experimental|Trastuzumab deruxtecan (T-DXd)|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
32751136|NCT05669183||Peripheral VA ECMO|Femoral artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
32909151|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
32751137|NCT05669183||Central VA ECMO|Axillary artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
32751138|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
32751139|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
32751140|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
32909152|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
32909153|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
32909154|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
32909155|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
33237077|NCT04073355|Experimental|Physical Activity|Smartphone-delivered physical activity intervention
33237078|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
32909156|NCT05343182|Active Comparator|Modified Vestibulectomy|
32909157|NCT05343182|Active Comparator|Traditional Vestibulectomy|
32909158|NCT01062230|Experimental|All patients|All participants enrolled.
33237079|NCT04071639|Experimental|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
33070893|NCT05301946||Stroke patients|The created-ICF Core Set for Stroke including activitiy, participation, and environmental factors was used show the meaningfulness of the clinical outcome measurements. The correlation of the created-ICF Core Set for Stroke's items and the outcome measurements were analyzed through Spearman or Pearson correlation analysis.
33237080|NCT04071639|Experimental|Group 2|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.
33237081|NCT04089176|Active Comparator|protocal A|Carbetocin versus placebo
33237082|NCT04089176|Active Comparator|protocal B|Oxytocin versus placebo
33237083|NCT05388032|Experimental|sodium reduction intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to <2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
33237084|NCT05388032|No Intervention|Usual Diet|Participants randomized to the usual diet group will receive standard care from their providers with no study intervention.
33237085|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
33237086|NCT02596646|Active Comparator|Group A|Early Precut
33237087|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
33237090|NCT04089020|Experimental|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 6 weeks.
33237091|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
33070894|NCT05291611|Experimental|Treatment with cbt|Treatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
33394363|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
33394364|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
33394365|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
33394366|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
33394367|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
33394368|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
32751141|NCT03484143|Active Comparator|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
32751142|NCT03484143|Sham Comparator|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
32751143|NCT05473611||closed reduction percutaneous fixation method|Patients with closed reduction percutaneous sacroiliac screw fixation of posterior pelvic ring due to unstable pelvic injury
32751144|NCT05473611||open reduction anterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction anterior approach due to unstable pelvic injury
32751145|NCT05473611||open reduction posterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction posterior approach due to unstable pelvic injury
32751146|NCT05476107|Experimental|AMT-126|oral AMT-126
32751147|NCT05476107|Placebo Comparator|Placebo|oral placebo
32751148|NCT05476107|Other|Radioactive Tablet (Part 2 only)|oral radioactive tablet for scintigraphic analysis
32751149|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
32751150|NCT05472987|Active Comparator|Open Ventral Hernia Repair|These patients will undergo open retromuscular ventral hernia repairs
32751151|NCT05472987|Active Comparator|Robotic Ventral Hernia Repair|These patients will undergo robotic retromuscular ventral hernia repairs.
32751152|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
32751153|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
33070895|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
33070896|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
33070897|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
32751154|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
32751155|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
32751156|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
33070898|NCT02941315|Placebo Comparator|etiology unconfirmed without acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
33070899|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
33070900|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
33070901|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
33070902|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
33394369|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
32751157|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
32751158|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
32751159|NCT04479657|Experimental|QingFei Granule+Cefuroxime group|Cefuroxime：30mg/kg/d,bid QingFei Granule: tid
32751160|NCT04479657|Active Comparator|Cefuroxime group|Cefuroxime：30mg/kg/d,bid
32751161|NCT05476029||Sepsis complicated with ARDS group|Blood samples and alveolar lavage fluid were collected within 24h after admission to ICU. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
32751162|NCT05476029||control group|Blood samples and alveolar lavage fluid were collected. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
32909159|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
33237092|NCT03972098||healthy control|healthy person, similar population
32909160|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
32909161|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
32909162|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
32909163|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
32909164|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
32909165|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
32909166|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
32909167|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
32909168|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
32751163|NCT05475951|Experimental|Normal Weight Pregnant Women|The women who had term pregnancy and had normal BMI.
32751164|NCT05475951|Experimental|Overweight Pregnant Women|The women who had term pregnancy and had BMI values between 25-30.
32909169|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
32751165|NCT05475951|Experimental|Obese Pregnant Women|The women who had term pregnancy, and had BMI values more than 30.
32751166|NCT05475873|Sham Comparator|Control group|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
32751167|NCT05475873|Experimental|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
32751168|NCT05475873|Experimental|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
32751169|NCT05475795|Active Comparator|Metapex group|Obturation of primary molars with calcium hydroxide and iodoform paste
32751170|NCT05475795|Experimental|Endoflas group|Obturation of primary molars with calcium hydroxide, eugenol and iodoform paste
32751171|NCT04270305|Experimental|orientation|Orientation training with GRAIL
32751172|NCT04270305|Active Comparator|walking|Walking training with GRAIL
32909170|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.~Procedure of TACE will be standardized.~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
32909171|NCT03811886|Experimental|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
33237093|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
33237094|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
33237095|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
33394370|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
33394371|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
32751173|NCT05481099|Experimental|Intervention|Cognitive-behavioural-based intervention combined with mindfulness, psychoeducation, and relaxation techniques
32751174|NCT05481099|No Intervention|Control|Care as usual
32751175|NCT05480787|Experimental|Remimazolam 0.1mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.1 mg/kg/h.
32751176|NCT05480787|Experimental|Remimazolam 0.3mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.3 mg/kg/h.
32751177|NCT05480787|Experimental|Remimazolam 0.5mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.5 mg/kg/h.
32751178|NCT05471661|Experimental|Penta-STs|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
33237096|NCT04818255|Experimental|Disclosure|Participants who demonstrated decisional capacity for and interest in disclosure (or whose care partner is able to do so) will receive the participant's personalized PET amyloid and tau biomarker status, as well as information about the meaning and clinical utility of this information and recommendations for next steps (e.g., discussing findings with his/her provider).
32751179|NCT03366129||Cohort|Stroke patients with white matter hyperintensities (WMH)
32751180|NCT05480631|Active Comparator|Group A|group A- autograft
32751181|NCT05480631|Experimental|group B|group B- concentrated growth factor with autograft
32751182|NCT05480631|Experimental|Group C|group C- concentrated growth factor with xenograft
32751183|NCT05480553|Experimental|NPC-06|
32751184|NCT05480553|Placebo Comparator|Placebo|
32751185|NCT05471193||Instability|
32751186|NCT05471193||No Instability|
32751187|NCT05480397|Experimental|• Group (1) will receive (TENS , cryotherapy and conventional physical therapy program).|
32751188|NCT05480397|Experimental|•Group (2) receive (distractive techniques , cryotherapy and conventional physical therapy)|
32751189|NCT05480397|Experimental|• Group (3) will receive (cryotherapy and conventional physical therapy program).|
32751190|NCT05480319|Experimental|EDICARS|
32751191|NCT05480319|Active Comparator|Usual care|
32909172|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
32909173|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
32909174|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
32909175|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
32909176|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
32909177|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled prior to July 2020 (Cohort 1)|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery
32909178|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled after July 2020 (Cohort 2)|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery
32909179|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
32909180|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
32909181|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
32909182|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
32909183|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
33237097|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
33237098|NCT00749996|Active Comparator|Control group|Single level herniectomy
33237099|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
33237100|NCT00916994|Experimental|SpaceGuard Balloon implantation|
33237101|NCT02143245|Other|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection. These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure. Diagnostic accuracy will be compared, and all participants will be tracked over time."
33237102|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~II and III (>/= 1.5 mm Breslow thickness without distant metastases~melanoma with lymph node metastases"
33237103|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
33237104|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
33394372|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
32751192|NCT05458869||Observational (survey, HPV self-collection, interview)|Participants complete a survey, use an HPV self-collection kit, and attend an interview over 30 minutes.
32909184|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
33070903|NCT00407979||People with Atopic Dermatitis|
32751193|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
32751194|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
32751195|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
32909185|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
33070904|NCT00407979||People with Psoriasis|
33237105|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
33237106|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
33237107|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
33237108|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
33237109|NCT04073277|Experimental|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
33237110|NCT04073277|Sham Comparator|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
33237111|NCT04073121|Experimental|Luminor DCB and Angiolite DES|Study Devices
33237112|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
33237113|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
33237114|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
33237115|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
33237116|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
33237117|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
33237118|NCT02125149|No Intervention|Control|Standard of care
33237119|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
33237120|NCT00746564|Experimental|Open Label|SJM Confirm Device
33237121|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
33237122|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
33237123|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).~Days 2 and 3 (Dexamethasone 16 mg).~If not complete response:~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
33237124|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
33237125|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
33237126|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
33237127|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
33237128|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
33237129|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
33237130|NCT04086264|Experimental|Regimen A|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azaciditine dose in subsequent cohorts may be reduced.
33394373|NCT04421027|Experimental|Baricitinib + Standard of Care (SOC)|4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.
32751196|NCT02723955|Experimental|Part 1A: Dose escalation feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
32751197|NCT02723955|Experimental|Part 1B: Expansion feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
32751198|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
32751199|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
32751200|NCT02723955|Experimental|Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
32751201|NCT02723955|Experimental|Part 2B: Expansion-feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
32751202|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
32751203|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
32751204|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
32751205|NCT05471037|Active Comparator|Long Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
32751206|NCT05471037|Active Comparator|Short Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
33237131|NCT04086264|Experimental|Regimen B|IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.
32751207|NCT05471037|No Intervention|Control|15 normal weight control group without surgery.
32751208|NCT05480241|Experimental|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
32751209|NCT05480241|Placebo Comparator|Placebo|Placebo + Omeprazole 20mg once daily on fasting
32751210|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
32751211|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
32898272|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle"
33070905|NCT00407979||Generally healthy people|
33070906|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
33237132|NCT04086264|Experimental|Regimen C|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.
33237133|NCT04086264|Experimental|Regimen D|IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients
33237134|NCT04756401|Experimental|Treatment (carfilzomib, daratumumab, dexamethasone, selinexor)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33237135|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
33237136|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
33237137|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
33237138|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
33237139|NCT04073589|Experimental|Treatment A|Single SC injection of Dose A
33237140|NCT04073589|Experimental|Treatment B|Single SC injection of Dose B
33237141|NCT04073589|Experimental|Treatment C|Single SC injection of Dose C
33237142|NCT04073589|Experimental|Treatment D|Single SC injection of Dose D
33237143|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
33241637|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
33237144|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
33237145|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
32745023|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
33237146|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
33237147|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
33237148|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
33237149|NCT04720911|Experimental|In-person TASCS|This intervention is designed to assess the TASCS app administered via an in-person clinician in the ED, with follow-up telephone calls by a clinician
33237150|NCT04720911|Active Comparator|Telehealth TASCS|This comparison condition is designed to assess the telehealth modality of TASCS in the ED (in contrast to in-person clinician modality), with follow-up telephone calls by a clinician
32745024|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
33237151|NCT04720911|Active Comparator|Self-administered TASCS|This comparison condition is designed to assess the self-administered modality of TASCS (in contrast to clinician modality), with follow-up telephone calls by a clinician
33237152|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
33237153|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
33237154|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
33237155|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
32745025|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
32745026|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
33237156|NCT02575443|Experimental|Moderate block (MB) group|
32745027|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
32745028|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
32745029|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
32745030|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
32745031|NCT04866381|Experimental|SHR-6390|SHR-6390
32745032|NCT04866381|Experimental|SHR-6390 combined with Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
32745033|NCT04866381|Experimental|Camrelizumab (SHR-1210) combined with SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
32745034|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
32745035|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
32745036|NCT04872231|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
33237157|NCT02575443|Experimental|Deep block (DB) group|
33237158|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
33237159|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
33237160|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
32745037|NCT04872231|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
32745038|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
32745039|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
32745040|NCT04861389|Experimental|Distal transradial access (dTRA)|Distal transradial access for primary percutaneous coronary intervention in STEMI patients
33237161|NCT05297448|Experimental|Rifaximin SSD-40mg IR|
33237162|NCT05297448|Placebo Comparator|Placebo|
33237163|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
33237164|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
32898273|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle~Trastuzumab is administered intravenously twice per cycle"
32901725|NCT05022498|Experimental|Exercise 2|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
32901726|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
33237165|NCT04071093|Other|Telemonitoring|
33237166|NCT04071093|No Intervention|Usual Care|
33237167|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
33237168|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
33237169|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
33237170|NCT00719706|Placebo Comparator|2|
33237171|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
33237172|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
33237173|NCT05684952|Experimental|Treatment group|Subjects need to take the Chinese herbal medicine (Shenlingcao oral liquid) 200 ml twice per day for 4 weeks. Shenlingcao oral solution is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
33237174|NCT05684952|Placebo Comparator|Control group|Subjects need to take the placebo of Shenlingcao oral liquid 200 ml twice per day for 4 weeks.
33237175|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
33237176|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
33237177|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
33237178|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
33237179|NCT00742274|Experimental|1|TAG+BMT
33237180|NCT00742274|Active Comparator|2|BMT alone
33237181|NCT04711473|Active Comparator|Colonoscopy Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in colonoscopy, and including a referral for the procedure at a local endoscopy center. Participants will be provided a phone number if interested in navigated colonoscopy scheduling.
33237182|NCT04711473|Experimental|Choice|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in their choice of either colonoscopy or mailed fecal immunochemical testing (FIT). The letter will include both a referral for the colonoscopy at a local endoscopy enter and a FIT kit with a lab requisition and instructions for completion.
33237183|NCT04711473|Experimental|FIT Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in FIT testing. The letter will include a FIT kit with lab requisition and instructions for completion.
33237184|NCT00917696|Active Comparator|1|ATP
33237185|NCT00917696|Placebo Comparator|2|Saline
33237186|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
33237187|NCT02576457|Other|Placebo|Placebo on specified days
33237188|NCT05276102|Active Comparator|Repated exposure to antiseptic and treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
33237189|NCT05276102|Active Comparator|Sham irritation and treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
33237190|NCT05276102|Active Comparator|No irritation and treatment|Intact skin on forearms Emollient cream treatment 3 times a day
33237191|NCT05276102|No Intervention|Repated exposure to antiseptic and no treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
33237192|NCT05276102|No Intervention|Sham irritation and no treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
33237193|NCT05276102|No Intervention|No irritation and no treatment|Intact skin on forearms No emollient cream treatment
33237194|NCT02596100|Experimental|Tablet|80mg immediate release tablet
33237195|NCT02596100|Experimental|Capsule|80mg immediate release capsule
33237196|NCT01192971|Experimental|A: 850mg|A: Experimental apatinib 850 mg qd p.o, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33237197|NCT01192971|Experimental|B: 750mg|B: Apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33237198|NCT04090814|Experimental|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
33237199|NCT04090814|No Intervention|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
32745041|NCT04861389|Active Comparator|Transradial access (TRA)|Transradial access for primary percutaneous coronary intervention in STEMI patients
32901727|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
33237200|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
33237201|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
33237202|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
33237203|NCT05412836|Experimental|One Treatment Arm|Subjects will receive a single intra-articular injection of AqueousJoint.
33237204|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
33237205|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
33237206|NCT05293158|Experimental|HBIG treatment|
33237207|NCT05410262||Mechanical power and risk of ventilator-induced lung injury in patients with ARDS|This study will prospectively evaluate patients consecutively admitted with ARDS, as defined according to the Berlin expert consensus
33237208|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
33237209|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
33237210|NCT02596178|Experimental|EIT Guided PEEP Therapy|
33237213|NCT04085952|Experimental|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
33237214|NCT04085952|Active Comparator|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
33237215|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
33237216|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
33237217|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
33237218|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
33237219|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
33237220|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
33237221|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
33237222|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
33237223|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
33237224|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
33237225|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
33237226|NCT00001503||1/All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCR Investigators.
33237227|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
33237228|NCT04019067|Experimental|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
33237229|NCT04019067|No Intervention|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
33394374|NCT04421027|Placebo Comparator|Placebo + SOC|Placebo (given as two placebo tablets) administered orally QD with standard of care.
33394375|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
33394376|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
33394377|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
33394378|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
33394379|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
33394380|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
33394381|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
33394382|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
33394383|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
33394384|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
33394385|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
33394386|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
33394387|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
32751212|NCT05480163|Experimental|Measurement records in COPD patients|"The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~Pre-session clinical assessment by the physiotherapist~Installation of the Sybille waistcoat on the patient~First measurement phase: Recording of spirometry parameters, acoustics, movements (thoracic volumetry) for forced vital capacity (FVC) and LVC manoeuvres.~Second phase of measurements:~Treatment: the physiotherapist performs the session in the classical way. Recording of acoustic parameters, movements (thoracic volumetry).~Third phase of measurements: Recording of spirometry, acoustics and movement parameters (thoracic volumetry) for FVC and LVC manoeuvres.~Removal of measurement devices~Post session evaluation by the physiotherapist."
32751213|NCT05480163|Other|Measurement records in control subject|"The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~Clinical assessment by the physiotherapist The subject answers the questionnaire~Installation of the Sybille waistcoat on the patient~Measurement phase: Recording of spirometry, acoustics, movements (thoracic volumetry) for FVC and LVC manoeuvres.~Removal of measurement devices"
32751214|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
32751215|NCT02706639||SVAS group|Children or adults must: be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
32751216|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85; have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
32751217|NCT02706639||WS region gene changes|Children or adults must: be between the ages of 0-85; have clinical or research genetic testing that reports gene variation in one or more genes in the WS region (ELN variants alone will be considered in the SVAS category but other changes to the region that include ELN plus other genes may be grouped in this category).
32751218|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
32751219|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
32751220|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
33070907|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
33394388|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
32745042|NCT04860531|Active Comparator|Group (I) Platelet Rich Plasma|The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
32745043|NCT04860531|Active Comparator|Group (II) Corticosteroids|The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .
32745044|NCT01594827|Experimental|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
32745045|NCT01594827|Active Comparator|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
32745046|NCT04858893||Subjects affected from Parkinsonims|Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator
32745047|NCT04858893||Health Controls|CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator
32745048|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
32745049|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
32901728|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 65 years of age, admitted to an intensive care unit in Sweden, for other reason than postoperative care or simple monitoring.
32745050|NCT04849845|Experimental|Afrezza|The test product is defined as Afrezza [insulin human] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
32745051|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
32901729|NCT04228380||Exclusion|Exclusion criteria: Declined consent to participate.
32901730|NCT04227678|Other|Control group- A0|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A0: without heparin administered"
33070908|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
32909186|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
32751221|NCT02702115|Experimental|Cohort 1: SB-318: Starting Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
32751222|NCT02702115|Experimental|Cohort 2: SB-318 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
32751223|NCT02702115|Experimental|Cohort 3: SB-318 at Next Ascending Dose 1.20E+14 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
33237230|NCT05684874|Experimental|Pre- and post- radiotherapy multiparametric quantitative MRI|"Patients with STS of the limbs and trunk will be accrued during the initial radiotherapy consultation radiotherapy (prior to receiving radiotherapy).~Two quantitative multiparametric MRI will be performed. The first one will be acquired less than 14 days before the dosimetric scan, the second one 4 to 6 weeks after the end of the radiotherapy.~A tumor resection will be performed 6 to 8 weeks post-RT and an anatomopathological observation of the surgical specimen will be performed."
32909187|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
33070909|NCT05273671|Experimental|nalbuphine|0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery
33237231|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
32751224|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
32909188|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
33394389|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
33394390|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
32751225|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
32751226|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
32751227|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
32751228|NCT05456139|Active Comparator|Treatment as Usual Only|"During 2 of the 3 six-month periods of participation, families will receive Treatment as Usual (TAU) only. Families in the TAU control condition will receive usual care and EI service in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
33394391|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
32901731|NCT04227678|Other|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A0: without heparin administered"
32751229|NCT05456139|Active Comparator|ESI-MC plus Treatment as Usual|During 1 of the 3 six-month periods of participation, families will receive 24 weekly sessions of Early Social Interaction via Mobile Coaching (ESI-MC) by a trained early intervention provider. ESI-MC is an evidence-based parent-implemented intervention for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Program planning entails building consensus with families on priority targets for the child and teaching strategies and supports for the parents using manualized conversational steps, Baby Navigator social communication milestones, and ESI content for families to practice 25 hours per week. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided web-based course and companion online group education meetings. Families will also receive Treatment as Usual (TAU).
32751230|NCT03290079|Experimental|Pembrolizumab & Lenvatinib treatment|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks, in addition to 20 mg Lenvatinib by mouth every day of each 3 week cycle. Estimated average length of treatment per participant: 4 months.
32751231|NCT05455905||Main Study Cohort|"A web-based audio recording tool will be used to record voice sample answering the prompt, How are you feeling today? Participants are asked to speak for 1-minute. Following the recording, participants are asked to complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questions."
32751232|NCT05455905||Selected Self-Reported Depression Cohort|The Researcher will review Patient Health Questionnaire-9 scores of all the participants and select the subset that self-reported a scored greater than 20, on a scale from 0 to 27. Participants will be approached via email to complete an additional administration of the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questionnaires and be offered resources for depression and anxiety and how to set up an appointment with a mental health professional.
32751233|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
32751234|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
32751235|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
32751236|NCT05455671||Cohort 1 - Healthy Controls|Persons, male or female, between the ages of 3 and 21 (inclusive) with healthy lungs, defined by no known or suspected chronic or temporary lung disease. A single study visit
32909189|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
33394392|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
33070910|NCT05273671|Experimental|dexmedetomedine|receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
33394393|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
33394394|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
32751237|NCT05455671||Cohort 2 - CF Longitudinal|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of >60mmol/L, between the ages of 3 and 21 (inclusive).
32751238|NCT05455671||Cohort 3 - CF Exacerbation|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of >60mmol/L, between the ages of 3 and 21 (inclusive), experiencing a pulmonary exacerbation requiring antibiotics.
33241638|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
32751239|NCT05469711|Experimental|Arm 1:|Gamification
32751240|NCT05469711|No Intervention|Arm 2|Monitoring
32909190|NCT05239130|Experimental|Auralya 1|Sixteen patients will be administered Auralya® 1 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
33070911|NCT05273671|Placebo Comparator|saline|receive a saline solution 10 min before the end of surgery
32751241|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
32751242|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
33394395|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
32751243|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
32751244|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
32751245|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
32751246|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
32751247|NCT03274479|Experimental|PBF-1129_40mg|
32751248|NCT03274479|Experimental|PBF-1129_80mg|
32751249|NCT03274479|Experimental|PBF-1129_160mg|
33237232|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
33237233|NCT04086186|Active Comparator|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
32751250|NCT03274479|Experimental|PBF-1129_320mg|
33237234|NCT04086186|Experimental|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
33237235|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
33241639|NCT00769587|Experimental|Thalidomide|Use of thalidomide
33241640|NCT00769665||Systane Ultra|Systane Ultra
32751251|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
32909191|NCT05239130|Experimental|Auralya 2|Sixteen patients will be administered Auralya® 2 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
33070912|NCT05245357|Experimental|Lentil, then Control|Participants first received a meal with 140 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 0 g of lentils in the morning.
33241641|NCT00769665||Sensitive Eyes|Sensitive Eyes
33241642|NCT04077320|Experimental|Memory Self-Efficacy Training|
33241643|NCT04077320|Active Comparator|General Education Group|
33241644|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
32751252|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
32909192|NCT05239130|Experimental|Auralya 3|Sixteen patients will be administered Auralya® 3 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
32751253|NCT05454891|Experimental|High Fat High Protein (HFHP) Meal- extended then standard insulin bolus arm|Subjects will receive extended meal bolus for breakfast on the first day and standard meal bolus on the second day of the study.
32751254|NCT05454891|Experimental|High Fat High Protein (HFHP) Meal- standard then extended insulin bolus arm|Subjects will receive standard meal bolus for breakfast on the first day and extended meal bolus on the second day.
32909193|NCT05227898|Active Comparator|Attune™|Attune™ is a completely digital therapeutic intervention.
32751255|NCT05433519||Pregnant Women|Pregnant women with gestational age established at less than 14 weeks of gestation
32909194|NCT05227898|Active Comparator|Cerena™|Cerena™ is a completely digital therapeutic intervention.
32909195|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
33070913|NCT05245357|Experimental|Control, then Lentil|Participants first received a meal with 0 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 140 g of lentils in the morning.
32751256|NCT04470921||Choice for Opportunistic Salpingectomy|Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
32909196|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
32751257|NCT02688647|Experimental|Belumosudil-R|"Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks.~No subject may receive more than 96 weeks of treatment with belumosudil"
32751258|NCT02688647|Active Comparator|BSC-R|Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.
32751259|NCT04469127|Experimental|Arm 1|"Single Arm study Lu-177-DOTAGA-PEG-IAC (intracutaneous)~Dosage and Dose Escalation Frequency:~Cohort 1: 75 mCi x 3 (maximum cumulative administered activity, 225mCi) + 100 μgr IAC Cohort 2: 150 mCi x 3 (maximum cumulative administered activity, 450mCi) + 100 μgr IAC Cohort 3: 200 mCi x 3 (maximum cumulative administered activity, 600mCi) + 100 μgr IAC~Three cycles each 8 weeks apart."
32751260|NCT05454267||Healthy Volunteer Group|Participants who have never smoked or vaped
32751261|NCT05454267||High Frequency Vaping Group|Participants who vape >20 days per month.
32751262|NCT05454267||Low-Frequency Vaping Group|Participants who vape < 20 days per month
32751263|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
32909197|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
33237236|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
33237237|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
33237238|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
33241645|NCT04048083|Experimental|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
32751264|NCT05743985|Experimental|50mg CBG Capsule|50mg cannabigerol (CBG) oil capsule taken daily for 8 weeks. Study surveys and bloodwork completed for 12 weeks total, including 8 weeks of CBG treatment and subsequent 4-week washout period
32751265|NCT05433285|Experimental|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
32909198|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
32751266|NCT05433285|Active Comparator|Active Comparator|2 doses of Covovax® - recombinant spike protein Nanoparticle Vaccine, administered with 28 days interval (0.5 mL per dose)
32909199|NCT05224388||Critically ill, prophylactic dose regimen|Prophylaxis of deep vein trombosis in critically ill patients
32909200|NCT05224388||Critically ill, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in critically ill patients
32751267|NCT05741957|Experimental|Once-a-week Exercise|Once-a-week vigorous-intensity exercise for 4 months.
32751268|NCT05741957|Experimental|Thrice-a-week Exercise|Thrice-a-week vigorous-intensity exercise for 4 months.
32751269|NCT05741957|Other|Usual Care Control|Bi-weekly health education for 4 months.
32751270|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
32751271|NCT04479839||Microcuff ETT|Patients intubated with microcuff ETT
32751272|NCT04479839||Non-microcuff ett|Patients intubated with regular ETT
32751273|NCT05432193|Experimental|Dose escalation|Up to 30 patients with FAP-avid solid tumors.
32751274|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
32751275|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
32751276|NCT05453799|Experimental|Treatment (vudalimab)|Patients receive vudalimab IV over 1 hour on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32751277|NCT05453721|Experimental|Indocyanine green fluorescence imaging method group|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
32751278|NCT05453721|Active Comparator|Modified inflation-deflation method group|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
32751279|NCT05453487|Experimental|Co-Ad group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine and three doses of rabies vaccine.~Participants received one dose of inactivated COVID-19 vaccine and rabies vaccine on Day 0, and one dose of rabies vaccine on Day 7 and Day 28.~Blood sampling was performed on Day 0, Day 28 and Day 42."
32751280|NCT05453487|Experimental|COVID-19 vaccine group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine on Day 0.~Blood sampling was performed on Day 0 and Day 28."
32751281|NCT05453487|Experimental|Rabies vaccine group|"A total of 120 participants received three doses of rabies vaccine on Day 0, Day 7 and Day 28.~Blood sampling was performed on Day 0 and Day 42."
32751282|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
32751283|NCT05741645|Experimental|Study group|Study group consists of 15 participants, where the elastic kinesiotaping is applied and evaluations are made before and after.
32751284|NCT05741645|Sham Comparator|Control Group|To the participants in the control group, the elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
32751285|NCT05740865||patients who developed deep surgical site infection after thoracolumbar surgery|this group included patients who developed deep surgical site infection after open posterior instrumented thoracolumbar surgery
32751286|NCT05740865||patients who did not develop deep surgical site infection after thoracolumbar surgery|this group included patients who did not develop deep surgical site infection after open posterior instrumented thoracolumbar surgery
32751287|NCT05739617|Sham Comparator|Sleep Hygiene Education|Participants will received once per month of sleep hygiene education for three months.
32751288|NCT05739617|Experimental|Comprehensive Respiratory Training Exercise Program|Participants will received Comprehensive Respiratory Training Exercise Program twice per weeks for three months.
32909201|NCT05224388||Covid, prophylactic dose regimen|Prophylaxis of deep vein trombosis in Covid patients
33070914|NCT05229484|Experimental|Intervention Group: an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
33070915|NCT05229484|No Intervention|Control group|The control group is the Treatment as Usual (TAU).
32909202|NCT05224388||Covid, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in Covid patients
33237239|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
33237240|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
33237241|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
32751292|NCT05646719|Experimental|Nyxol + low dose pilocarpine|
32751293|NCT05646719|Experimental|Nyxol + low dose pilocarpine vehicle|
32751294|NCT05646719|Experimental|Placebo + low dose pilocarpine|
32751295|NCT05646719|Placebo Comparator|Placebo + low dose pilocarpine vehicle|
32751296|NCT05738525||Automated peritoneal dialysis with remote patient management (APD-RPM)|APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD). Dialysis dose ranges from 5 to 10 liters per day and glucose concentration starts from low concentration (1.5%).
32751297|NCT05738525||Continuous ambulatory peritoneal dialysis (CAPD)|(1) Dialysis dose ranges from 5 to 10 liters per day at the run-in period. For those with regular peritoneal dialysis, the original dose can be used according to the volume status and solute clearance effect in the past 3 months; (2) Exchange time and abdominal retention time is generally 2-5 times and 1 time at daytime and night, separately; (3) Glucose concentration includes 1.5%, 2.5% or 4.25%; (4) The treatments can be adjusted according to the change of residual renal function, peritoneal transport characteristics, volume status, solute clearance, clinical status and peritonitis.
32751298|NCT05642507|Experimental|Active (AC01) Microtablets|Escalating doses of AC01
32751299|NCT05642507|Placebo Comparator|Placebo Microtablets|Matching placebo tablets
32751300|NCT05639543|Active Comparator|INT-787|Capsules
32751301|NCT05639543|Placebo Comparator|Placebo|Capsules
32751302|NCT04058639|Experimental|felt relief|"custom felt relief"
32751303|NCT04058639|Active Comparator|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
32751304|NCT05630807|Experimental|Bepirovirsen|
32751305|NCT05630807|Placebo Comparator|Placebo|
32751306|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
32751307|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
32751308|NCT05627999||patients candidate to the haemorrhoidal artery embolization|Consecutive patients assessed at the Division of General Surgery 1, Treviso Regional Hospital, from October to December 2021 and candidate to the haemorrhoidal artery embolization were included in the study. Indications to the procedure were symptomatic hemorrhoidal disease (French bleeding score [FBS] > 4), Goligher's classification score II or III, age >18 years, failure of non-operative management (change life style, dietary modification, supplemental fibers for constipation, over-the-counter treatments). Signed informed and research consents were obtained. Exclusion criteria were age < 18 years, Goligher prolapse score IV, pregnancy, previous haemorrhoidal surgery, inflammatory bowel disease. Use of anticoagulant or antiaggregant was not considered an exclusion criteria [stecca].
33237242|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
32751309|NCT05431725|Experimental|Sinovac-QIV group|800 subjects aged 3 years and older will receive one dose of Sinovac-QIV for vaccine-primed subjects or two doses of Sinovac-QIV for vaccine-unprimed subjects.
32909203|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
32751310|NCT05431725|Active Comparator|Vaxigrip Tetra-QIV group|800 subjects aged 3 years and older will receive one dose of Vaxigrip Tetra-QIV for vaccine-primed subjects or two doses of Vaxigrip Tetra-QIV for vaccine-unprimed subjects.
32751311|NCT05469009|Experimental|Infusion plus Exablate BBBO Treatment|Intravenous infusion of Aducanumab every 4 weeks followed by blood brain barrier opening by FUS.
33237243|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
32751312|NCT05453097||Perioperative Myocardial Injury Occured|Patients with troponin elevation from the preoperative basal level do not meet the criteria for myocardial infarction according to the fourth universal myocardial infarction guideline, do not describe active anginal complaints, and underwent surgery in the operating room.
32751313|NCT05453097||Perioperative Myocardial Injury Not Occured|Patients without troponin elevation from the preoperative basal level, do not describe active anginal complaints, and underwent surgery in the operating room.
32751314|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
32751315|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
32751316|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
32751317|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
32751318|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
32751319|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.~This group includes a sub-study of patients providing blood samples."
32751320|NCT05452005|Experimental|Experimental [18F]-αvβ6-BP|Patients receive [18F]-αvβ6-BP BP IV and then undergo a PET/CT scan over 30 minutes 60 minutes post-injection.
32751321|NCT05451615|Experimental|Abatacept|D2T RA patients receive Abatacept
33237244|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at TNO"
32751322|NCT05451615|Experimental|JAK inhibitor|D2T RA patients receive JAKi
32751323|NCT05451303||Oral Squamous Cell Carcinoma (OSCC)|OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from secondary care.
32751324|NCT05451303||OroPharyngeal Cancer (OPC)|OPC case cohort will consist of patients with OroPharyngeal cancer (all stages, locations), recruited from secondary care.
32751325|NCT05451303||Oral Potentially Malignant Disease (OPMD)|"OPMD cohort will consist of patients with both potential malignancies or benign conditions including, but not limited to:~Dysplasia~Hyperplasia~Leukoplakia~Erythroplasia~Lichenoid lesions~Actinic Keratosis~Lichenoid reaction~Aphthous ulcer/ Canker Sores~Gingival enlargement (side effect)~Lichen planus~Keratosis~Inflammatory reaction~Cheek bites"
32751326|NCT05451303||Cancer-free|Cancer free control cohort will be matched with cases. Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary care facilities.
32751327|NCT05731037|Active Comparator|Short restitution group (SR)|Resistance training for knee extensors three training session per week.
32751328|NCT05731037|Experimental|Extended restitution group (ER)|Resistance training for knee extensors on training session per week (greater restitution from loading).
32751329|NCT05727527|Active Comparator|Study group|Will initially receive the infiltration injection after applying a candy flavor first, followed by sterile water in the next visit
32751330|NCT05727527|Active Comparator|Control group|Will initially receive the infiltration injection after applying sterile water first, followed by candy flavor in the next visit
33237245|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
33237246|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
33237247|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
33237248|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
33237249|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at home"
33237250|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
33237251|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
33237252|NCT05285670|Experimental|Digital counseling plus interactive two-way SMS dialogue|Participants will receive initial counseling on a tablet followed by automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
33237253|NCT05285670|No Intervention|Control|Control receiving standard of care.
33237254|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
33237255|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
32751331|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
32751332|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
32751333|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
32751334|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
32751335|NCT05626439|Experimental|Treatment Sequence AB|Study participants randomized into this arm will receive single dose of Staccato alprazolam followed by single dose of oral alprazolam at pre-specified time points in the sequence AB.
32751336|NCT05626439|Experimental|Treatment Sequence BA|Study participants randomized into this arm will receive single dose of oral alprazolam followed by single dose of Staccato alprazolam at pre-specified time points in the sequence BA.
32751337|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
32751338|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
32901732|NCT04227678|Other|Control group-A1|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g OGTT glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
32909204|NCT03558464|Active Comparator|Control|(agriculture-focused package)
33241646|NCT04048083|Experimental|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
32909205|NCT05205980|Experimental|Training group|This arm will receive a single-session perturbation training treatment on a treadmill under the protection of a safety harness.
32751339|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
32751340|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
32751341|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
32751342|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
32909206|NCT05205980|Sham Comparator|Control group|This arm will not receive perturbation training but will go through harnessed walking on the same treadmill for the same time as the other group.
32751343|NCT03165227|Experimental|BI 685509 Dose 1|
32751344|NCT03165227|Experimental|BI 685509 Dose 2|
32751345|NCT03165227|Experimental|BI 685509 Dose 3|
32751346|NCT03165227|Placebo Comparator|Placebo|
32909207|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times/cycle.~Placebo is administered orally on a daily basis"
32909208|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered intravenously once weekly."
33237256|NCT05285358|Experimental|Treatment (gemcitabine, cisplatin, nab-paclitaxel PIPAC)|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8. Patients also receive nab-paclitaxel via PIPAC over 5-10 minutes on day 3 of cycles 1, 3, and 5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33237257|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
33237258|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
32751347|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
32751348|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
32751349|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
32751350|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
33241647|NCT04048083|Experimental|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
32751351|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
32751352|NCT05430009|Experimental|Arm 1|This is an open-label, single-arm, single center clinical trial to evaluate the feasibility of liver SBRT (up to 4 metastases) during the first cycle of physician's choice ICI for NSCLC.
32751353|NCT05429853|Experimental|Sondalis® HP 2 kcal (with or without fibre)|
32751354|NCT05429697|Experimental|Pembrolizumab+SMT-NK inj.|"Experimental:~Pembrolizumab + SMT-NK inj. Participants will be randomized to receive 200 mg pembrolizumab followed by 3*10^6cells/kg SMT-NK inj.~Interventions:~Drug: SMT-NK inj. Drug: Pembrolizumab"
32751355|NCT05429697|Placebo Comparator|Pembrolizumab|"Placebo Comparator: Pembrolizumb Participants will be randomized to receive 200 mg pembrolizumab.~Intervention:~Drug: Pembrolizumab"
33241648|NCT04048083|Active Comparator|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
32751356|NCT05450679||Cervical Radiofrequency Ablation (RFA)-treated group|Only patients who have already been deemed candidates by their primary pain physician for cervical RFA will be recruited to the study. During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.
32751357|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
33237259|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
32751358|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
32751359|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
32751360|NCT05450601|Experimental|Experimental|HCP2102
32751361|NCT05450601|Active Comparator|Active Comparator|RLD2106
32751362|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
32751363|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
32751364|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
32751365|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
32751366|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
32751367|NCT03207555|Experimental|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
32751368|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
32751369|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
32751370|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32751371|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32751372|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32751373|NCT05586191|Experimental|Action Observation therapy at home|In action observation therapy, patient will not come to hospital for treatment. He will see a video at home in which therapist will perform different activities then patient will also perform the same movements.
32751374|NCT05586191|Active Comparator|Action Observation therapy at hospital|In action observation therapy, patient will come to hospital for treatment. He will see a video in which therapist will perform different activities then patient will also perform the same movements.
32751375|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
32751376|NCT05578703|Experimental|Gastric Fundic Ablation plus Endoscopic Sleeve Gastroplasty|Subjects will undergo fundic mucosal ablation followed by endoscopic sleeve gastroplasty
32751377|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
32751378|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
32751379|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
32751380|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
32751381|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
32751382|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
32751383|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
32751384|NCT03165929|Placebo Comparator|placebo-free gingival graft|
32751385|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
32751386|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
32751387|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
32751388|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
32751389|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
32751390|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
32751391|NCT03206073|Experimental|1/Arm A1 Pexa-Vec + Durvalumab|Pexa-Vec escalation dose levels + Durvalumab
32751392|NCT03206073|Experimental|2/Arm A2 Pexa-Vec +Durvalumab|Maximum tolerated dose (MTD) of Pexa-Vec after the MTD is established +Durvalumab
32751393|NCT03206073|Experimental|3/Arm B1 Pexa-Vec + Durvalumab +Tremelimumab|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
32751394|NCT03206073|Experimental|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
32751395|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
32751396|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
32751397|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
32751398|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
32751399|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
32751400|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
32751401|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
32751402|NCT03106779|Experimental|Asciminib|Patients were randomized to asciminib 40mg BID
32751403|NCT03106779|Active Comparator|Bosutinib|Patients were randomized to bosutinib 500mg QD
32751404|NCT05428215|Active Comparator|PO then SL|Subjects will administer 17-beta-estradiol orally (PO) for Study Day 1-14, followed by administration of 17-beta-estradiol sublingually (SL) for Study Day 15-28.
32751405|NCT05428215|Active Comparator|SL then PO|Subjects will administer 17-beta-estradiol sublingually (SL) for Study Day 1-14, followed by administration of 17-beta-estradiol orally (PO) for Study Day 15-28.
32751406|NCT05428137|Active Comparator|Probiotic|Live bacteria strain in a form of a capsule with a daily dose of 1x10^10 Colony Forming Unit (CFU) per day for 16 weeks
32751407|NCT05428137|Active Comparator|Postbiotic|Heat treated bacteria strain in a form of a capsule with a daily dose of 1x10^10 CFU per day for 16 weeks
32751408|NCT05428137|Placebo Comparator|Placebo|Placebo in a form of a capsule administered for 16 weeks
32751409|NCT05468151|Experimental|Cold acclimation protocol|Participants with obesity (n = 20) will undergo weekly cold water immersions (water temperature 18ºC, two to three times a week, 30 minutes per day) for, at least, 12 weeks. Before and after the cold acclimation period, the participants will undergo PET/CT scans at room temperature and after controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
32751410|NCT05468151|Other|Acute cold exposure - control volunteers with obesity|"PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (n = 10) will undergo PET/CT scans at baseline and 12 weeks after the first scan.~The participants will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes."
32751411|NCT05468151|Other|Acute cold exposure - lean controls|PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (lean, n = 15) will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
32909209|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered orally on a daily basis"
33241649|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
32751412|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
32751413|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
32751414|NCT05448963|Experimental|Robotic mastectomy|Patients receive unilateral or bilateral robot-assisted nipple-sparing mastectomy with or without axillary lymph node dissection
32751415|NCT05448729|Sham Comparator|Strain ratio Elastography EUS|The solid pancreatic lesion will be assessed by using strain ratio elastography EUS
32751416|NCT05448729|Active Comparator|Shear Wave Elastography EUS|The solid pancreatic lesion will be assessed by using shear wave elastography EUS
32751417|NCT04423653|Experimental|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
32751418|NCT04423653|Active Comparator|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
32751419|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
32909210|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
32909211|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
33241650|NCT05674604||Participants|Adult inpatients who are referred to Victoria General Hospital for rehabilitation with the chief complaint of an acute neurological disorder such as stroke, within next 16 weeks, and suffer from shoulder and/or knee pain. All potential participants are already candidate for cryoneurolysis to mange their shoulder or knee pain.
32751420|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
32751421|NCT05467215|Experimental|Hyperoxia followed by room air|Group 1 will receive oxygen (99%) in Phase 1, and room air (placebo) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. In Phase 2, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. Both high oxygen and room air will be delivered through a face mask. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure. In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
32751422|NCT05467215|Placebo Comparator|Room air followed by hyperoxia|Group 2 will receive room air (placebo) in Phase 1, and oxygen (99%) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. In Phase 2, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. Both high oxygen and room air will be delivered through a face mask approved by Health Canada. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure.In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
32751423|NCT05447091|Active Comparator|Active high dose treatment|Active LOH game training- high dose
32751424|NCT05447091|Active Comparator|Active low dose treatment|Acrive LOH game training - low dose
32751425|NCT05447091|Sham Comparator|Sham treatment|Sham LOH game- high dose
32751426|NCT05446935|Other|HITOC|HITOC group contains all patients who undergo HIROC in this study.
32751427|NCT05465811|Experimental|Baseline|Before the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
32751428|NCT05465811|Experimental|Follow-up|After the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
32909212|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
32751429|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
32751430|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
32751431|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
32751432|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
32901733|NCT04227678|Other|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
32901734|NCT00508118|Experimental|1|Nicardipine
33241651|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
33394396|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
33394397|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
33394398|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
32901735|NCT00508118|Placebo Comparator|2|0.9% saline
32751433|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
32901736|NCT04222764||Real-time three-dimensional echocardiography|
33394399|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
33394400|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
32751434|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
32751435|NCT05465421|Active Comparator|socket preservation with platelet rich fibrin PRF alone the implant placement 3 months after|after extraction socket preservation will be done by using PRF only in the socket and closed the socket by flap advancement.
32751436|NCT05465421|Experimental|socket preservation with BMMNCs of bone marrow aspirated of maxillary tuberosity|after extraction socket preservation will be done by using bone marrow mononuclear cell layer seeded on PRF in the socket and close the socket by flap advancement
32751437|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
32751438|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
32751439|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
32751440|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
32901737|NCT04227054|Experimental|Intervention|
33394401|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
33394402|NCT03750617|No Intervention|routine screening|
33394403|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
32901738|NCT05622266|Experimental|Pulpotomy|The removal of a small portion of the vital coronal pulp as a means of preserving the remaining coronal and radicular pulp tissues.
33394404|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
32745234|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
32745235|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX（Phase 2）|
32745236|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX （Phase 3）|
32745237|NCT04856787|Placebo Comparator|placebo in combination with BP102 and XELOX|
32745238|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
32745239|NCT04846179|Experimental|Ginkgo biloba extract group|Group receiving ginkgo biloba extract supplementation
32745240|NCT04856553|Experimental|Handgrip exercise (morning)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the morning.
32745241|NCT04856553|No Intervention|Control|In the control session, the participants will remain at rest for the same period of time as in the handgrip exercise protocol.
33394405|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
32751441|NCT02227251|Experimental|Part 1: Selinexor 60 mg|Participants received fixed dose of 60 mg selinexor orally, twice weekly (BIW) on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (each cycle of 28 days) cycle (total of 8 doses per cycle).
32751442|NCT02227251|Experimental|Part 2: Arm A-Selinexor 40 mg|Participants received selinexor 40 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles (28 days) until disease progression (total of 8 doses per cycle).
32751443|NCT02227251|Experimental|Part 2: Arm B-Selinexor 60 mg|Participants received selinexor 60 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles) for 2 cycles (each cycle of 28 days) followed by 60 mg once weekly (QW) in the subsequent cycles until disease progression (total of 8 doses per cycle).
32751444|NCT02213133|Experimental|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than [<] 100*10^9 per litre [/L]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
32751445|NCT02213133|Experimental|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
32751446|NCT02213133|Experimental|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
32909213|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
32745242|NCT04856553|Experimental|Handgrip exercise (afternoon)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the afternoon.
32745243|NCT04845789||Family caregivers|Family caregivers who were main caregiver to the person with dementia and who spent at least 10 hours a week providing care to the person with dementia.
32745244|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
32745245|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
32745246|NCT04846101|Experimental|Anterior restorations using single shade OMNICHROMA composite|Anterior class III and Class IV cavities will be restored using single shade composite material according to standard protocols of etching, bonding and composite placement.
32745247|NCT04846101|Active Comparator|Anterior restorations using multi-shade composite|Shade selection for the tooth will be performed prior to the placement of the restoration. Anterior class III and Class IV cavities will be restored using multi-shade composite material according to standard protocols of etching, bonding and composite placement.
32745248|NCT04845867||Measurement and digital documentation|continuous measurement and digital documentation with alarms and display off
32745249|NCT04839939|Active Comparator|Control Group|Children in this group received conventional physical therapy program in form of Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training were all part of the treatment plan, which was based on the neurodevelopmental approach.
32745250|NCT04839939|Experimental|AFO Group|Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
32745251|NCT04839939|Experimental|Combination Taping Group|"Children in this group received the same conventional treatment plus the combination taping technique, which was performed by one qualified physical therapist with over five years of experience. The technique started with the application of two 5-cm wide Kinesio tape I straps. The first strap was applied from the lateral condyle of the tibia to the base of the first metatarsal bone with the ankle joint in plantar flexion. The tape was not stretched for 5 cm from the initial site and was then stretched up to 30% for the remaining parts15. The second I strap While the therapist holds the ankle in dorsiflexion, he applied the distal end of the tape 10 cm below the ankle joint. With almost 70% tension, the proximal end is applied 10 cm above the ankle joint. While one hand was holding each end of the tape, the child was asked to move the joint into plantar flexion. Finally, both hands moved towards the middle of the joint to apply the remaining tape."
32745252|NCT04845711|Placebo Comparator|Control group|patients will receive general anesthesia only.
32745253|NCT04845711|Experimental|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
32745254|NCT04845711|Experimental|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
32745255|NCT04839549|Experimental|Dextenza (Intracanalicular ) 0.4mg|Dextenza for the treatment of Ocular Rosacea
32745256|NCT04839549|Active Comparator|Fluoromethalone .01%|Fluoromethalone .1% BID for 2 weeks then once daily for 2 weeks for the treatment of Ocular Rosacea
32745257|NCT04839627||serum progesterone measurement|
32745258|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
32745259|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
32745260|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
32745261|NCT04845633|Other|Healthy children using conventional toothbrush|
32745262|NCT04845633|Experimental|Healthy children using toothbrush with Customized Handle|
32745263|NCT04845633|Other|Children with Down syndrome using conventional toothbrush|
32745264|NCT04845633|Experimental|Children with Down syndrome using toothbrush with Customized Handle|
32745265|NCT04809363|Experimental|CDPATH™|Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.
32745266|NCT04845243|Other|Emotion recognition training|All participants have to complete the online emotion recognition training E.V.A. as well as the pre- and post training tasks: GERT and social decision making task.
32745267|NCT04845399|Experimental|Arm 1|Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
32745268|NCT04804995||Heathy participants|
32745269|NCT04804995||migraine patients|
32745270|NCT04845009|Experimental|progressive muscle relaxation|progressive muscle relaxation tape guided
32745271|NCT04845009|Placebo Comparator|usual care|usual care
33394406|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
32745272|NCT04856397|Other|Control group|"Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN (as needed) treatment regimen post 5 monthly loading doses."
32745273|NCT04856397|Experimental|Early switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.
32745274|NCT04856397|Experimental|Late switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea
32745275|NCT04856397|Other|Non-switch|Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.
32745276|NCT04839471|Experimental|BI-754091 plus afatinib|BI-754091 plus afatinib
32745277|NCT04839237|Experimental|Liraglutide|Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
32745278|NCT04839237|Experimental|Liraglutide combined with metformin|Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
32745279|NCT04839081||RA patients|RA patients diagnosed according to the 1987 ACR Criteria
32745280|NCT04839081||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint other than in hand, lasting more than three months
32745281|NCT04839159|Experimental|SCD Patient|
32745282|NCT04845087|Experimental|Trial Group|Patients from this group will receive treatment with ozonized water.
32745283|NCT04845087|Placebo Comparator|Placebo Group|Patients from this group will receive placebo with water.
32745284|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
32745285|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
32745286|NCT04844775|Experimental|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
32745287|NCT04844775|Experimental|Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-L|"0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
32745288|NCT04844775|Experimental|DNA HIV PT123 4mg and CN54gp140/MPLA-L|"1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe.~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
32745289|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
32745290|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
32745291|NCT03038607|Active Comparator|Aspirin group|
32745292|NCT03038607|No Intervention|No intervention|
32751447|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
32751448|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
32751449|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
32751450|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
32751451|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
32751452|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
32751453|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
32751454|NCT05446155||Patients with a suspected primary melanoma or equivocal pigmented skin tumour|Patients, 18 years or older, in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour/normal skin biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
32751455|NCT05446155||Patients with secondary melanoma (metastatic disease)|Patients, 18 years or older, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
32751456|NCT05445999|Experimental|tES treatment|The stimulation type is cathode direct current stimulation and alternating current stimulation. The maximum stimulation current of a single channel is not more than 3mA. The frequency of electrical stimulation was 0-10Hz; DLPFC was preferentially selected for electrical stimulation, and other candidate brain regions were: orbitofrontal cortex premotor cortex, motor cortex, sensorimotor cortex, auditory cortex, posterior parietal cortex, and cerebellar cortex. The brain state changes caused by each stimulus parameter combination were compared with sleep state to determine the optimal stimulus parameters. Each cycle of stimulation was 2 weeks, once a night on weekdays, a total of 10 times
32751457|NCT05444595|Experimental|Behavioral and Plant-based Dietary Intervention|In this arm, participants will receive the behavioral plant-based intervention from community health workers.
32751458|NCT05444595|Active Comparator|Standard Care|In this arm, participants will receive the standard care intervention from community health workers.
32751459|NCT05465109|Experimental|TACSI|
32751460|NCT05465109|No Intervention|Usual care control group|The usual care control group would have continued receipt of standard services at either the Mayo Clinic or the MVAHCS. In addition, staff will offer participants the opportunity to request supportive/educational resources as needed after randomization.
32751461|NCT05426655|Experimental|Self management|Intervention group: education in pain neuroscience + self-massage + exercises + advice and recommendations.
32751462|NCT04262661|Experimental|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
32751463|NCT04262661|Placebo Comparator|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
32751464|NCT04262661|Experimental|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
32751465|NCT04262661|Active Comparator|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
32751466|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
32751467|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
32901739|NCT05622266|Active Comparator|Root Canal Therapy|The complete removal of the vital dental pulp. Any material or combination of materials placed inside a root canal for the purpose of obturating and sealing the canal space.
33394407|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
33394408|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
32751468|NCT05443347|Experimental|Structured exercise|Adolescents randomized to the exercise will participate in a supervised structured exercise program (walking on a treadmill, cycling on a stationary bicycle, etc.) and expend an equivalent of 400 kcals/session (approximately 45-60 min/session) on three days/week. We will follow the protocol of Mentor Dr. Joseph Donnelly, with exercise prescriptions progressing from 150 kcal/session at intervention onset to reach the target exercise energy expenditure (EEEx) (400 kcal/session) at the end of month 3. EEEx will be assessed at baseline and monthly during the intervention to determine the duration of treadmill exercise required to achieve the EEEx goals. All supervised exercise will occur at the CCHLN on a treadmill with heart rate, speed, and grade monitored by an exercise specialist every five minutes.
32751469|NCT05443347|Active Comparator|Newsletter control|"Adolescents randomized to the newsletter control will receive with biweekly newsletters with parenting tips, sample praise statements, and age-appropriate activities and recipes identical to what has been used by others (Epstein et al., 2008), including existing group-based interventions with overweight/obese adolescents."
32751470|NCT05426421||No actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Questionnaires will be filled in and dried blood spots collected at transition and at four weeks. Medical history as well as clinical and socio-demographic data will be collected.
32751471|NCT05426421||With actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Baseline actigraphy data will be collected for two weeks prior to transition (actigraphy period 1), and for four weeks after transition (actigraphy period 2 from 0-2 weeks after transition; actigraphy period 3 from 2-4 weeks after transition). Sleep diaries will be filled in during all actigraphy periods. Questionnaires will be filled in and dried blood spots taken at transition as well as two and four weeks after transition. Medical history as well as clinical and socio-demographic data will be collected.
32751472|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
32751473|NCT05686109||Monitoring device Biobeat®|"Biobeat® non-invasive monitoring devices can be used in an out-of-hospital perioperative setting to observe patients' vital signs up to 5 days postoperatively.~The Biobeat® portable adhesive device will be installed after the surgery, in the recovery room. All patients will be equipped with a portable single-use Biobeat® Bluetooth device that will be positioned at chest level and connected via Bluetooth to the patient's cell phone. These patches have been FDA approved since 2019 (new approval in 2022) for non-invasive (systolic, diastolic, and mean) blood pressure measurement without a cuff. The following other parameters will also be recorded: peripheral oxygen saturation, heart rate, respiratory rate and body temperature based on the analysis of the plethysmography wave. This data will be recorded as soon as the patches are installed."
32751474|NCT02689349|Experimental|Esteem Implant Prospective Subjects|Subjects followed through 1 year for both Safety and Efficacy endpoints
32751475|NCT02689349|Other|Esteem Implant Retrospective Chart Review Subjects|Subjects providing Safety-only endpoint data through retrospective chart review, to be added to Prospective Subjects' Safety data
32751476|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
32751477|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
32751478|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
32751479|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
32751480|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
32751481|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
32751482|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
32751483|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
32751484|NCT05364437|Active Comparator|Dietary Fibres Supplement|Dietary fibre mix comprising of inulin, pectin and oat beta-glucan. The mix comes in a powdered form which can be added to participants' food.
32751485|NCT05364437|Placebo Comparator|Placebo|Placebo comprising of cellulose which will come in a powdered form that can be added to participants' food.
32751486|NCT05357261|Active Comparator|Daily home delivered meals|A lunch-time meal delivered to participants' homes five days per week with wellness check and socialization.
32751487|NCT05357261|Experimental|Frozen, Drop-shipped Meals|Ten frozen meals that are mailed to participants every two weeks.
32751488|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
32751489|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
32751490|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
32751491|NCT03162029||control group|CBCT imaging of medically-free participants
32745293|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
32745294|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
32745295|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
32745296|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
32745297|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
32745298|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
32745299|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
32745300|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
32745301|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
32745302|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
32745303|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
32745304|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
32745305|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
32745306|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
32745307|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~Applying exercises 3 times per week."
32745308|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.~Applying exercises 3 times per week."
32745309|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
32745310|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
32745311|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
32745312|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
32745313|NCT04838847|Experimental|Participants / Healthy Participants Aged ≥65 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
32745314|NCT04838847|Experimental|Participants / Healthy Participants Aged 18-45 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
32745315|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
32745316|NCT04843839|Experimental|Test Eye|These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
32751492|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
32751493|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
32751494|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
32751495|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
32751496|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
32751497|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
32751498|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
32751499|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
32751500|NCT03161951||Control group|Control group of healthy persons
32751501|NCT02678351|Experimental|68Ga-PSMA PET/MRI|Patients receive 68Ga-PSMA-11 IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
32751502|NCT05324501|Experimental|MTX-110 monotherapy|
32751503|NCT05324501|Experimental|MTX-110 combined with lomustine|
32751504|NCT05426265|Experimental|MEL-T01|MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects.
32751505|NCT05426265|Active Comparator|MEL-S01|MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements.
32751506|NCT05426265|No Intervention|TAU|Treatment-as-usual.
32751507|NCT05286437|Experimental|Intervention|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
32751508|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
32751509|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
32751510|NCT05426031|Experimental|Fixed Dose Protamine group|Participants in the group will receive a one time dose of 250 mg Protamine to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
32751511|NCT05426031|Active Comparator|Ratio Dose Protamine Group|Participants in the group will receive a ratio dose of Protamine in a 1mg per 100 units of heparin ratio to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
32751512|NCT04440527|Experimental|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
32751513|NCT04440527|Active Comparator|Trabeculectomy|Patients will be treated with trabeculectomy.
32751514|NCT05442645||Participants with AD|Male or female, 18 years or older at the baseline visit initiated treatment with dupilumab for AD, who are eligible for dupilumab reimbursement according to the country-specific prescribing information
32751515|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
32751516|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
32751517|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
32751518|NCT05265299|Experimental|Sequence 1|"Week 1-2: aspirin 81mg~Week 5-6: aspirin 162mg~Week 9-10: aspirin 325mg"
32751519|NCT05265299|Experimental|Sequence 2|"Week 1-2: aspirin 162mg~Week 5-6: aspirin 81mg~Week 9-10: aspirin 325mg"
32751520|NCT05265299|Experimental|Sequence 3|"Week 1-2: aspirin 325mg~Week 5-6: aspirin 81mg~Week 9-10: aspirin 162mg"
32751521|NCT05265299|Experimental|Sequence 4|"Week 1-2: aspirin 325mg~Week 5-6: aspirin 162mg~Week 9-10: aspirin 81mg"
32751522|NCT05265299|Experimental|Sequence 5|"Week 1-2: aspirin 162mg~Week 5-6: aspirin 325mg~Week 9-10: aspirin 81mg"
32751523|NCT05265299|Experimental|Sequence 6|"Week 1-2: aspirin 81mg~Week 5-6: aspirin 325mg~Week 9-10: aspirin 162mg"
32751524|NCT05464251||Subjects with spinal epidural abscess with a history of drug abuse|
32751525|NCT05464251||Subjects with spinal epidural abscess with no history of drug abuse|
32751526|NCT05253209|Experimental|Active|"Patients will receive:~an L-citrulline bolus of 150 mg/kg at the initiation of cardiopulmonary bypass~the addition L-citrulline to maintain a steady state target concentration of approximately 100 μmol/L of L-citrulline during cardiopulmonary bypass~an L-citrulline bolus of 10 mg/kg 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 μmol/L.~Infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first."
32751527|NCT05253209|Placebo Comparator|Placebo|Plasmalyte A administered to the same schedule as the active treatment arm.
32751528|NCT05442099|Experimental|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
32751529|NCT05442099|Sham Comparator|Generic calm music playlist|Participants listen to the generic music playlist for 30 minutes.
32751530|NCT05242367|Active Comparator|Active VeNS|
32751531|NCT05242367|Sham Comparator|Sham VeNS|
32751532|NCT05425641|Experimental|Goal Setting and Action Planning and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751533|NCT05425641|Experimental|Goal Setting and Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751534|NCT05425641|Experimental|Goal Setting and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751535|NCT05425641|Experimental|Goal Setting and Action Planning, and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751536|NCT05425641|Experimental|Action Planning and Self-Monitoring, and Feedback|Participants in this arm will receive daily text messages that include the Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751537|NCT05425641|Experimental|Goal Setting and Action Planning|Participants in this arm will receive daily text messages that include the Goal Setting and Action Planning behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751538|NCT05425641|Experimental|Goal Setting and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751539|NCT05425641|Experimental|Goal Setting and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751540|NCT05425641|Experimental|Action Planning and Self-Monitoring|Participants in this arm will receive daily text messages that include the Action Planning and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751541|NCT05425641|Experimental|Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Action Planning and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751542|NCT05425641|Experimental|Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Self-Monitoring and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751543|NCT05425641|Experimental|Goal Setting|Participants in this arm will receive daily text messages with the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751544|NCT05425641|Experimental|Action Planning|Participants in this arm will receive daily text messages with the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751545|NCT05425641|Experimental|Self-Monitoring|Participants in this arm will receive daily text messages with the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751546|NCT05425641|Experimental|Feedback|Participants in this arm will receive daily text messages with the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
32751547|NCT05425641|No Intervention|Control|"Participants in this arm will not receive any daily BCT text messages. Instead, individuals receive daily text messages with the text Please acknowledge that you have received this text message."
33394409|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
33241652|NCT04077242|Active Comparator|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed."
33394410|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
33394411|NCT05359211|Experimental|Treatment (lymphodepletion, liso-cel, NKTR-255)|Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity.
32751548|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
32751549|NCT05554289|Experimental|Experimental group|Conventional Treatment + Depression Auxiliary Intervention Treatment Software.A software used to treat depression, used frequently once a day.
33394412|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
32751550|NCT05554289|Placebo Comparator|control group|Conventional treatment + auxiliary intervention treatment software for depression (placebo software)
32751551|NCT05464173|Experimental|SAF|Fulvestrant 500mg d1, 15, 29, and then q4w, abemaciclib 150mg or 100mg bid, Chidamide 10-30mg biw.
32751552|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
32751553|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
32751554|NCT05464095|Active Comparator|mHealth Intervention|Patients will be randomized to the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
32751555|NCT05464095|Other|Usual Care|Routine medical care
32751556|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
32751557|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
33394413|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
32751558|NCT05515601|Experimental|Mirikizumab Solution (Reference)|Mirikizumab administered subcutaneously (SC) via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
32751559|NCT05515601|Experimental|Mirikizumab Solution (Test)|Mirikizumab administered SC via an AI at 3 different injection sites (arm, thigh, and abdomen).
32751560|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
32751561|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
32751562|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
32751563|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
32751564|NCT05425563|Experimental|Pain: High Cue|"Prior to experiencing the pain stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no sensation to strongest sensation of any kind. In the high cue condition, 10 data points are randomly extracted from a beta distribution, Beta(ɑ = 0.6, β = 0.85), for the semi-circle."
32751565|NCT05425563|Experimental|Pain: Low Cue|"Prior to experiencing the pain stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no sensation to strongest sensation of any kind. In the low cue condition, 10 data points randomly extracted from a beta distribution, Beta(ɑ = 0.1, β = 2), for the semi-circle."
32751566|NCT05425563|Experimental|Vicarious: High Cue|"Prior to experiencing the vicarious stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no sensation to strongest sensation of any kind. In the high cue condition, 10 data points are randomly extracted from a beta distribution, Beta(ɑ = 0.6, β = 0.85), for the semi-circle."
33394414|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
33394415|NCT04948697|Experimental|Arm A: ociperlimab + tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks
33394416|NCT04948697|Experimental|Arm B: tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks
33394417|NCT04358549|Experimental|Favipiravir Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
33394418|NCT04358549|Other|Standard of Care Arm|Standard of Care for 14 days
33394419|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
33394420|NCT01562483|Placebo Comparator|Placebo|
33237260|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
33237261|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
32901740|NCT05139030|Experimental|Cohort 1: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
33237262|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
33237263|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
32751567|NCT05425563|Experimental|Vicarious: Low Cue|"Prior to experiencing the vicarious stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no sensation to strongest sensation of any kind. In the low cue condition, 10 data points randomly extracted from a beta distribution, Beta(ɑ = 0.1, β = 2), for the semi-circle."
32751568|NCT05425563|Experimental|Cognitive Effort: High Cue|"Prior to experiencing the cognitive effort stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no effort to strongest effort of any kind. In the high cue condition, 10 data points are randomly extracted from a beta distribution, Beta(ɑ = 0.6, β = 0.85), for the semi-circle."
32751569|NCT05425563|Experimental|Cognitive Effort: Low Cue|"Prior to experiencing the cognitive effort stimulus, the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no effort to strongest effort of any kind. In the low cue condition, 10 data points randomly extracted from a beta distribution, Beta(ɑ = 0.1, β = 2), for the semi-circle."
32901741|NCT05139030|Active Comparator|Cohort 1: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
32901742|NCT05139030|Experimental|Cohort 2: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
32901743|NCT05139030|Active Comparator|Cohort 2: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
32901744|NCT00440180|Placebo Comparator|Group B|Placebo
33070916|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
33394421|NCT00700180|Experimental|1|
33394422|NCT00700180|Experimental|2|
32751570|NCT05195723|Experimental|WP1122|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
33394423|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
32898274|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
32901745|NCT00440180|Experimental|Group A|Anastrozole
33394424|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
33237264|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
33237265|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
33237266|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
33237267|NCT00709449|Experimental|1|20 patients with age related macular degeneration
33237268|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
33237269|NCT00709449|Experimental|3|20 age and sex matched control subjects
33237270|NCT05340816|Experimental|Manual Lymphatic Drainage|5 days, 30 minutes, Manual Lymphatic Drainage
33237271|NCT05340816|Experimental|Transcutaneous Electrical Nerve Stimulation|5 days, 20 minutes, Transcutaneous Electrical Nerve Stimulation
33237272|NCT05340816|No Intervention|Control|no any intervention
33237273|NCT00746252|Experimental|1|risperidone
33237274|NCT00746252|Experimental|2|aripiprazole
33237275|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
32751571|NCT05195723|Placebo Comparator|Placebo|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
32751572|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
32751573|NCT05497037|Sham Comparator|Sham Control Group|Subject receiving fake stimulation (no stimulation but same device procedure with PRF group)
32751574|NCT05497037|Active Comparator|PRF Group|Subject receiving 500 KHz PRF stimulation for 15 min
32751575|NCT05441709|No Intervention|Standard of care|Standard lactation care is provided by postpartum RNs on the inpatient unit and RNs who are board certified in lactation (IBCLCs).Postpartum RNs provide support to all patients post delivery with direct breastfeeding, breast pump use, and addressing routine breastfeeding concerns. IBCLCs provide direct lactation care for more complicated lactation problems and is delivered in a dosed manner based on the nature of the lactation problem, with low-risk patients often having no encounters.
32898275|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
32751576|NCT05441709|Active Comparator|ci-BPC with Standard of Care|"In addtion to normal standard of care (as described above), patients will also receive clinically-integrated breastfeeding peer counseling (ci-BPC) from a Peer Counselor at four timepoints throughout the perinatal period. The encounters will take place either in person or virtually and include: an intake encounter between 2- and 30 weeks gestation, a dedicated prenatal infant feeding education encounter, at least one inpatient encounter post-delivery during the delivery admission, and at least one postpartum encounter. Patients will also have access to a warmline that will include phone follow up by the next business day."
32751577|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
32751578|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
32751579|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
32751580|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
32751581|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
32751582|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
32751583|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
32751584|NCT05181995|Experimental|50 mg NYX-783 QD|50 mg NYX-783 QD
32751585|NCT05181995|Placebo Comparator|Placebo|Placebo QD
32751586|NCT05441475|Experimental|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w.|During part a, all subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w). After the first subject (sentinel subject) in each dose cohort completed the first combined medication, follow-up subjects were administered at least 7 days later
32751587|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
32751588|NCT05441241|Experimental|Leap Motion Controller|
32751589|NCT05441241|Active Comparator|Standard care|
32751590|NCT05181449|Experimental|Twin Precision Treatment (TPT)|Twin Precision Treatment (combination of AI and lifestyle coaching)
32751591|NCT05181449|No Intervention|Usual Care (UC)|Usual care prescribed by Cleveland Clinic diabetes specialists and primary care physicians
32751592|NCT05462379|No Intervention|Standard treatment|10 patients: Pelvic Chemoradiotherapy
32751593|NCT05462379|Experimental|Ovarian Graft|10 patients: Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
32751594|NCT04440137|No Intervention|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
32751595|NCT04440137|Experimental|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
32751596|NCT05178173|Placebo Comparator|Sterile Water|Subject participants will rinse mouth one time for 60 seconds with 20 mL of sterile water.
32751597|NCT05178173|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 20 mL 27% ethanol plus essential oils.
32751598|NCT05178173|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 20 mL 0.075% Cetylpyridinium Chloride.
32751599|NCT05175755|Experimental|Patients|The procedure involves taking a total of 12 ml of blood.
32751600|NCT05169437|Experimental|Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations|
32751601|NCT04777565|Experimental|CI surgery|cochlear implant surgery
32751602|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
32751603|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
32751604|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
32751605|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
32751606|NCT02680847|Experimental|ALO-02|One arm, open label, active
32751607|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
32751608|NCT05440149|Active Comparator|The Control group|"If patients received mastectomy, post-mastectomy radiation therapy (PMRT) should be performed.~If patients received breast conserving surgery (BCS), whole breast irradiation (WBI) + Regional radiotherapy (RT) should be performed."
32751609|NCT05440149|Experimental|The Experimental group|"If patients received mastectomy, No PMRT should be performed.~If patients received BCS, WBI alone should be performed."
33237276|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
33237277|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
33237278|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
33237279|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
32751614|NCT03959241|Active Comparator|Tacrolimus/Methotrexate|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
32751615|NCT03959241|Experimental|Tacrolimus/MMF/PTCY|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
32751616|NCT04452825|Experimental|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
32751617|NCT04452825|Experimental|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
32751618|NCT05146973|Experimental|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.
33394425|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
32751620|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
32751621|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
32751622|NCT05122793|Experimental|Prevention Group|In addition to the usual treatment (SoC), the prevention group receives an innovative prevention offer tailored to the severity of the heart failure (telemedical connection via health app as well as additional therapy recommendations).
32751623|NCT05122793|No Intervention|Control Group|The control group receives the current standard treatment according to the valid guidelines (Standard of Care = SoC).
32751624|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
32901746|NCT05021484|Active Comparator|Felzartamab|9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
32901747|NCT05021484|Placebo Comparator|Placebo|9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
32901748|NCT05021094|Experimental|POI patients who taking Kuntai capsule|Patients in this group will take Kuntai capsule orally, 4 capsules each time, 3 times a day, and take the medicine for 3 courses.
33237280|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
32901749|NCT05021094|Active Comparator|POI patients who accepting hormone therapy|The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 2mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and 3 courses of treatment were taken.
33237281|NCT00714363|Active Comparator|1|LASIK
33237282|NCT00714363|Active Comparator|2|SBK
33237283|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
33394426|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
33394427|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
32751625|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
32751626|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
32751627|NCT05438667|Experimental|TCR-T treatment group|Within 3 ~ 5 days after pretreatment, subjects will receive a single TCR-T infusion with an infusion dose of about 1 × 10⁹～1 × 10¹¹.6-8 weeks after the first TCR-T treatment, if the disease progress is evaluated, the second TCR-T treatment will be given(marked Day0). The administration scheme of TCR-T cells is the same as that described above.Day1 received the first intradermal DC vaccine in the morning. Before DC vaccine injection, patients will receive intradermal test dose (DC of 10³). After half an hour of observation of possible allergic reactions, the full dose will be injected intradermal in the lower abdominal area above the groin (1 × 10⁷dc 0.2ml) DC vaccine. After the first DC vaccine injection, the patient will receive another two doses of DC vaccine every two weeks, a total of three doses.
32909214|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
32751628|NCT04262427|Experimental|Single Group Assignment|Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks
32898276|NCT03399851|Active Comparator|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
32898277|NCT03389698||Cohort A|Cognitively normal control participants aged 20 - 40 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
32751629|NCT04262349|Experimental|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
32751630|NCT04262349|No Intervention|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
32751631|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
32751632|NCT05436873|Experimental|Treatment Arm|This is a single arm study
32751633|NCT05422521|Experimental|identification of predictive and prognostic biomarkers|
32751634|NCT05422209|Active Comparator|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|
32751635|NCT05422209|Active Comparator|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|
32751636|NCT05409651|Experimental|Time restricted eating|Everyone in this arm will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
32751637|NCT05421819|Active Comparator|Calcium and vitamin D supplement|In this arm, 50 women will receive calcium and vitamin D supplement once per day.
32751638|NCT05421819|Active Comparator|Calcium, vitamin D and prebiotic supplement|In this arm, 50 women will receive calcium, vitamin D and prebiotic supplement once per day.
32751639|NCT05421819|Active Comparator|Calcium, vitamin D, prebiotic and flavonoid supplement|In this arm, 50 women will receive calcium, vitamin D, prebiotic and flavonoid supplement once per day.
32898278|NCT03389698||Cohort B|Cognitively normal control participants aged 65 - 85 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
33237284|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
33237285|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
33394428|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
33237286|NCT04561791|Experimental|Feasibility of TCE & Prevalence of BE|"Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment~Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
33241653|NCT04077242|Active Comparator|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
33241654|NCT04076930||ACEI/ARB users|
33241655|NCT04076930||ACEI/ARB non-users|
32751640|NCT05421585|Active Comparator|QL2 block|Posterior QLB process After aseptic conditions are provided, the convex US probe will be covered with a sterile sheath, and an 80-100 mm block needle will be used. After imaging the abdominal muscles with the anterior approach, the needle will be advanced in the Petit triangle and 1-2 ml of saline will be injected into the posterior border of the quadratus lumborum muscle. After the block location is confirmed, 20 ml of local anesthetic infiltration at a concentration of 0.25% will be applied. The same procedure will be applied to the other side. A total of 30 ml of local anesthetic solution will be used.
33394429|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
33241656|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
32751641|NCT05421585|Active Comparator|TLIP block|Classic TLIP block After providing aseptic conditions, the high frequency linear US probe will be covered with a sterile sheath, and a 50 mm block needle will be used. The ultrasound probe will be placed vertically at the level of the L3 vertebra. After visualizing the guiding point spinous process and interspinal muscles, the probe will be moved laterally to visualize the longissimus and multifidus muscles. By using the in-plane technique, the block needle will be directed from medial to lateral, and after reaching the interfacial area between the longissimus and multifidus muscles, the block area will be confirmed by administering 5 ml of serum physiologically. Then, 20 ml of 0.25% local anesthetic will be administered. The same procedure will be applied to the other side. A total of 40 ml of local anesthetic solution will be used.
32751642|NCT05436639|Experimental|SPI-62 dose 1|0.2mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
32751643|NCT05436639|Experimental|SPI-62 dose 2|0.6mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
32751644|NCT05436639|Experimental|SPI-62 dose 3|2mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
32751645|NCT05436639|Experimental|SPI-62 dose 4|6mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
33241657|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
33241658|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
32751646|NCT05436639|Placebo Comparator|Placebo|Placebo by mouth each morning for up to 12 weeks.
32751647|NCT05436327|Other|Geriatric Assessment (GA)|Clinical staff undergo training in GA and are provided with facilitation and support for one year as they implement GA among older adult patients (65+) considering chemotherapy and their care partners/caregivers.
32751648|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
32751649|NCT05436171||All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital|"All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital~The target sample size will be about 67,000 women who had delivered in our unit from 2011 to 2021. Among them, it is expected that 75-80% had vaginal deliveries, either normal vaginal delivery or instrumental delivery. 53,600 will be recruited in study site."
32901750|NCT05021094|Experimental|POI patients who taking Kuntai capsule combined with hormone therapy|Kuntai capsule was taken at the same dose as Kuntai group on the basis of hormone therapy for 3 courses.
33394430|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
32898279|NCT03389698||Cohort C|Amnestic mild cognitive impairment (aMCI) patients aged 65 and older. Participants in Cohort C will be matched by age and gender to participants in Cohort B. Participants in Cohort C will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 9 minutes of scan time.
32898280|NCT03377491|Experimental|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel
33394431|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
33394432|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
33394433|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
32751650|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
33394434|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
32751651|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
33241659|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
33241660|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
32898281|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
33241661|NCT05233826|Experimental|COVI-VAC|COVI-VAC Nose Drops
33241662|NCT00769899|Experimental|1|
33241663|NCT00769899|Placebo Comparator|2|
32898282|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
32898283|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
33241664|NCT04609904|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
32898284|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously~Each cycle contains 21 days~Dosing is per the FDA label for other cancers"
32898285|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
32751652|NCT05408559|Active Comparator|Avmacol ES|Processed SFN-rich extract will be purchased from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. SFN (Avmacol Extra Strength) will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
32909215|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
33241665|NCT04609904|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
33241666|NCT04609904|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
33241667|NCT04609904|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
32751653|NCT05408559|Placebo Comparator|Placebo|Placebo caplets containing microcrystalline cellulose will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. Placebo will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
32751654|NCT05435547|Experimental|Steroids|Will be given pre-operative corticosteroid regimen
32751655|NCT05435547|Placebo Comparator|placebo|Will be given Placebo
32751656|NCT05435469||Questionnaires assessed adolescents|① Teenagers aged 14-25. ② Chinese nationality, who has lived in China since the outbreak of the COVID-19 epidemic, and has experienced or is experiencing the epidemic and its normalization. ③ Have the normal cognitive ability, expression ability, and social participation ability.
32751657|NCT04258215|Experimental|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
32751658|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
32751659|NCT05408169|No Intervention|Control|
32751660|NCT05408169|Experimental|1-week deadline, no planning sheet|
32751661|NCT05408169|Experimental|2-week deadline, no planning sheet|
32751662|NCT05408169|Experimental|4-week deadline, no planning sheet|
32751663|NCT05408169|Experimental|No deadline, with planning sheet|
32751664|NCT05408169|Experimental|1-week deadline, with planning sheet|
32751665|NCT05408169|Experimental|2-week deadline, with planning sheet|
32751666|NCT05408169|Experimental|4-week deadline, with planning sheet|
32751667|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
32751668|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
32751669|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
32751670|NCT04693156|Active Comparator|oblique subcostal tap block|ultrasound-guided right oblique subcostal TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl (sodium chloride) 10ml and ultrasound-guided posterior TAP block with %0.9 NaCl 30ml
32751671|NCT04693156|Active Comparator|posterior tap block|ultrasound-guided right oblique subcostal TAP block with %0.9 NaCl 30ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
32751672|NCT04693156|Active Comparator|dual tap block|ultrasound-guided right oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
32751673|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
32751674|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
32751675|NCT05111249|Experimental|Treatment Arm A|Branaplam 56 mg oral solution once weekly
32751676|NCT05111249|Experimental|Treatment Arm B|Branaplam 112 mg oral solution once weekly
33241668|NCT00764127||Obese Control|
33241669|NCT00764127||Normal Control|
32751677|NCT05111249|Experimental|Treatment Arm C or X or Y|(C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly
32751678|NCT05111249|Placebo Comparator|Placebo|Matching placebo oral solution once weekly
32751679|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
32751680|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
32751681|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
32751682|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
32751683|NCT02085460|Placebo Comparator|Placebo|6 times daily
32751684|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
32751685|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
32751686|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
32751687|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
32751688|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
32751689|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
32751690|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
32751691|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
32751692|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
32751693|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
32751694|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
33241670|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
33241671|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
32751695|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
32751696|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
32751697|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
32751698|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
32751699|NCT05059691||Observational (transbronchial cryobiopsy)|Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
32751700|NCT05036681|Experimental|futibatini|
32751701|NCT05036681|Experimental|pembrolizumab|
32751702|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
32751703|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
32751704|NCT03163979|Active Comparator|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
32751705|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
32751706|NCT03114761|Experimental|CTA-IH|
32751707|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
32751708|NCT03114605|No Intervention|Control|Waiting List
32751709|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
32751710|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~Full medical History and physical examination~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~Abdominal Ultrasound~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
32901751|NCT05021094|Experimental|Subclinical POI patients who taking Kuntai capsule|Subclinical POI patients in this group which with Kuntai capsule intervention. This group is a self-controlled experiment before and after treatment
32751711|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
32751712|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
32751713|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
32751714|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
32751715|NCT04439903|Experimental|Web-based Simulation Tool (WST)|
32751716|NCT05419817|Experimental|Pembrolizumab + Sitravatinib|Standard of care pembrolizumab 200 mg IV combined with oral sitravatinib 100 mg oral QD every 21 days until disease progression, unacceptable toxicities or complete response.
32751717|NCT05411939|Other|Control|Patients in the control arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon.
32751718|NCT05411939|Experimental|Shared Decision-Making Tool|Patients in the treatment arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon that includes discussion of the shared decision-making tool.
32751719|NCT05401097|Experimental|Arm A (IDHi+Aza followed by Ven+aza)|For IDH1 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Ivosidenib 500mg po orally daily on Days 1-28 of each 28 day cycle. For IDH2 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Enasidenib 100mg po orally daily on Days 1-28 of each 28 day cycle. Azacitidine will be given to both groups intravenously at 75mg/m2 daily on days 1-7 of each 28 day cycle. Subsequent cycles may be adjusted in timing and dosing based off the FDA-label for the combination therapy based off cytopenias or other toxicities.
32751720|NCT05401097|Experimental|Arm B (Ven+aza followed by IDHi+aza)|For both IDH1 and IDH2 mutated AML patient randomized to first-line therapy with Ven+aza, patients will receive venetoclax dosing with the ramp-up and dosing per the FDA-label (based off of concurrent drug interactions). Azacitidine will be given intravenously at 75mg/m2 daily on days 1-7 of each 28-day cycle. Subsequent cycles may be adjusted in timing and dosing based off the FDA-label for the combination therapy based off cytopenias or other toxicities.
32751721|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
32751722|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
32751723|NCT03160391|Experimental|Music Training|Music Training
32751724|NCT03160391|Active Comparator|Dance Training|Dance Training
32751725|NCT03160391|No Intervention|Passive control group|Passive control group
32751726|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
32751727|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
33241672|NCT00764205||Study Group|Troponin measured prior to hospital arrival
32751728|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
32751729|NCT03163433|No Intervention|Control|Usual consultations
32751730|NCT04995419|Experimental|Enfortumab vedotin|Participants will receive enfortumab vedotin on Days 1, 8 and 15 of every 4-week (28 days) cycle.
32751731|NCT05676749|Experimental|C-TIL051|C-TIL051 plus IL-2 and Pembrolizumab
32751732|NCT05392205|Experimental|68Ga-FAP-2286|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time.
32751733|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
32751734|NCT05676671|Experimental|Self-etching adhesive Clearfil SE Bond|Group 1 received treatment with Clearfil SE Bond after selective caries removal
32751735|NCT05676671|Experimental|Self-etching adhesiveClearfil SE Protect containing MDPB|Group 2 received treatment with Clearfil SE Protect containing MDPB after selective caries removal
32751736|NCT05231759||Navigable Percutaneous Plasma Disc Decompression (L'DISQ)|The L'DISQ (U&I Co., Uijeongbu, Korea) is one of the minimally invasive disc decompression procedures which was introduced in 2011. The L'DISQ uses a navigable tip and flexible handle allowing resection of the posterolateral or posterior median disc tissue without thermal damage.
32751737|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
32751738|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
32751739|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
32751740|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
32751741|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
32751742|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
32751743|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
32751744|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
32751745|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
33241673|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
33394435|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
32751746|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
32751747|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
32751748|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
32751749|NCT03114293|No Intervention|Waiting group|Waiting group
32751750|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
32751751|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
32751752|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
32901752|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
33070917|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
33394436|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
32898286|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
33070918|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
33394437|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
33394438|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
32751753|NCT04905407|Experimental|Part 1: Tamibarotene/Venetoclax/Azacitidine|"Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination as follows: Azacitidine (intravenously or subcutaneously) at 75 milligrams (mg)/square meter (m^2) once daily, on Days 1 through 7 of each 28-day therapy cycle (per VIDAZA USPI). Alternative dosing of azacitidine (Days 1 through 5, 8, and 9) will be permitted throughout the study.~Venetoclax (orally) daily on Days 1 through 28 per standard of care. Standard of care daily dosing is 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and beyond.~Tamibarotene 6 mg twice daily (BID) orally, on Days 8 through 28 of each 28-day therapy cycle. Tamibarotene will only be administered to participants who have been confirmed as RARA-positive."
32751754|NCT04905407|Experimental|Part 2: Tamibarotene/Venetoclax/Azacitidine|Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination at the dose and regimen selected in Part 1.
32751755|NCT04905407|Active Comparator|Part 2: Venetoclax/Azacitidine|Participants will receive the venetoclax/azacitidine combination at the dose and regimen selected in Part 1.
33070919|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
33241674|NCT04048317|Experimental|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
32751756|NCT04905407|Experimental|Part 3: Tamibarotene/Venetoclax/Azacitidine|Part 2 participants treated with venetoclax/azacitidine who experience progressive disease, relapse after initial CR or CRi response, or treatment failure may begin subsequent treatment in Part 3, where tamibarotene will be added to their regimen.
32751757|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
32751758|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
32751759|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
32751760|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
32751761|NCT04903535||Healthy Volunteers|Study will enroll 5 healthy volunteers to test the assay
32751762|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
32751763|NCT04837547|Experimental|Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
32751764|NCT04837547|Experimental|Arm 2: Relapsed/Refractory Neuroblastoma (NB)|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
32901753|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
33241675|NCT04048317|Placebo Comparator|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
33241676|NCT00764283|Experimental|1|Tegaderm dressing
32751765|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
33241677|NCT00764283|Active Comparator|2|Epi-Fix dressing
33241678|NCT00764283|Active Comparator|3|Lockit-Plus dressing
32751766|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
32751767|NCT04811027|Experimental|(CPS ≥1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
32751768|NCT04811027|Active Comparator|(CPS ≥1): Pembro|Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
32751769|NCT04811027|Experimental|(CPS <1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
32751770|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
32751771|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
32751772|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
32751773|NCT04805489|Experimental|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
33241679|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
32751774|NCT03114137||sickle cell patients|"age: five-year-old or more~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
32751775|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients~hospital staff or their children matched on country and age +/- 3 ans with the patients"
32901754|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
33241680|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
33241681|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
32901755|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
33241682|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
33070920|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
32751776|NCT04708067|Experimental|Treatment (hypofractionated radiation, bintrafusp alfa)|Patients undergo hypofractionated radiation therapy QD on weekdays (Monday-Friday) for 15 fractions in the absence of disease progression or unacceptable toxicity. Beginning 1 week after completion of radiation therapy, patients receive bintrafusp alfa IV over 1 hour on day 1. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32751777|NCT04703387||Postextubation Success|
32751778|NCT04703387||Postextubation Distress|
32751779|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
32751780|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
32751781|NCT04439981|Placebo Comparator|Control Group|treated by ice cream without any Curcuma extract supplementation
32751782|NCT04439981|Experimental|Treatment Group|treated by ice cream supplemented by Curcuma extract
32751783|NCT04683731|Active Comparator|Group 1|Patients view decision aid without personalized message and whose providers do not receive the personalized message.
32751784|NCT04683731|Experimental|Group 2|Patients view decision aid with personalized message and whose providers do not receive the personalized message.
32751785|NCT04683731|Experimental|Group 3|Patient view decision aid without the personalized message and whose providers receive the personalized message.
32751786|NCT04683731|Experimental|Group 4|Patients view decision aid with the personalized message and whose providers receive the personalized message.
32751787|NCT04722887|Experimental|Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)|Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
32751788|NCT04722887|Experimental|Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)|Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
33070921|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
32751789|NCT04722887|Experimental|Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)|Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
33241683|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
32751790|NCT04722887|Experimental|Cohort 2: Treatment Period 1 (Alpha-1 15%, 144 mg/kg)|Participants will receive Alpha-1 15% 144 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.
32751791|NCT04722887|Experimental|Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)|Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
33241684|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
32751792|NCT04722887|Experimental|Cohort 2: Treatment Period 2 (Alpha-1 15%, 144 mg/kg)|Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 144 mg/kg, for 8 weekly SC infusions.
32751793|NCT03374267||aRCC|Patients with advanced renall cell carcinoma
32751794|NCT03374267||aUBC|Patients with advanced urothelial carcinoma
32751795|NCT04665479|Experimental|Intervention group|A total of 30 children with any progressively declining (acute or chronic) life-threatening diagnosis per parent report (aged 8 to 17) and their primary parent caregivers will be recruited as a dyad. Dyads will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
32751796|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells|
32751797|NCT04614467|Placebo Comparator|Placebo|
32751798|NCT05675891|Experimental|Supplemental Feeding System Group|3 feeding between 08-16:00 are carried out with the supplemental feeding system. The remaining 5 feedings continue with the bottle.
32751799|NCT05675891|No Intervention|Bottle Feeding Group (Control)|All feedings are made from a bottle.
32751800|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
32751801|NCT03206099||Healthy volunteers|Select internal controls
32751802|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
32751803|NCT05675813|Experimental|CHOP+selinexor+5-Azacitidine|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg in phase I triaI on days d1,d8 while selinexor RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
32751804|NCT05675813|Experimental|CHOP+duvelisib+5-Azacitidine|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg in phase I triaI on days d1-21 while duvelisib RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
32751805|NCT05675813|Experimental|CHOP+chidamide+tislelizumab|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive tislelizumab 200mg d1 ivgtt and chidamide 20mg or 30mg po in phase I triaI biw while chidamide RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
32751806|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
32751807|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
32751808|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
32751809|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
32751810|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
32751811|NCT03158129|Experimental|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
32751812|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
32751813|NCT05620043|Active Comparator|Poly L-Lactic Acid (PLLA)|Lyophilized PLLA with sodium carboxymethylcellulose, non-pyrogenic mannitol. Treatment needs to be reconstituted prior to injection, following product instruction.
32751814|NCT05620043|Active Comparator|Calcium Hydroxylapatite (CaHA)|Opaque, sterile, non-pyrogenic, semi-solid, cohesive implant whose component is synthetic CaHA suspended in a gel carrier of glycerin, sodium carboxymethylcellulose, 0.3% lidocaine hydrochloride, and sterile water. Treatment injection follows product instruction.
32751815|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
32751816|NCT03113903|Experimental|scheduled surgery|
32751817|NCT03113903|Other|healthy volunteers|
33237287|NCT04084158|Experimental|Toripalimab+chemoradiation|"Induction immunotherapy: Toripalimab injection (JS001) 3mg/kg IV q 14 days x 2 cycles.~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.~Adjuvant immunotherapy:Toripalimab injection (JS001) 3mg/kg IV q 14 days up to 1 year."
32751818|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
33237288|NCT04084158|Active Comparator|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
32751819|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~Systemic antibiotic therapy for preventing infectious complications;~Adequate analgesia and sedation;~Decompression necrotomy in the first 24 hours following the burn trauma;~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
32751820|NCT02742935|Experimental|camrelizumab|camrelizumab (SHR-1210) injection, 60,200,400mg/dose, intravenous infusion over 30 minutes, every 2 weeks.
33237289|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
32751821|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
32751822|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
33237290|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
32751825|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
32751826|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
32751827|NCT02673515|No Intervention|control group|control group
32751828|NCT02390765||All participants|All participants in the study will be evaluated as one group
32751829|NCT05675579|Experimental|Sacituzumab Govitecan and Pembrolizumab|"Participants will receive drug on Days 1 and 8 of Cycles 1-4, Participants will receive sacituzumab govitecan by vein.~Participants will receive drug on Days 1, 8, and 15 of each cycle, Participants will receive pembrolizumab by vein."
32751830|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
32751831|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
32751832|NCT04364789|Active Comparator|Pilot dose Cohort|A pilot dose of 20 mg will be evaluated in 2 subjects (all receiving TT-00920) for safety, tolerability, and PK profile before the initiation of dose escalation.
32751833|NCT04364789|Active Comparator|SAD Dose 1|
32751834|NCT04364789|Active Comparator|SAD Dose 2|
32751835|NCT04364789|Active Comparator|SAD Dose 3|
32751836|NCT04364789|Active Comparator|SAD Dose 4|
32751837|NCT04364789|Active Comparator|Food Effect Cohort|
32751838|NCT04364789|Placebo Comparator|Placebo|
32751839|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
32751840|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
32751841|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
32751842|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
32751843|NCT01932125|Experimental|Cohort|
33237291|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
33237292|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
33237293|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
33237294|NCT04084236|Active Comparator|Active TENS|
33237295|NCT04084236|Sham Comparator|Sham TENS|
33237296|NCT00714519|Experimental|1|
33237297|NCT00714519|Placebo Comparator|2|
32751844|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
32751845|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
32751846|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
32751847|NCT01740557|Experimental|Treatment (genetically modified T-cells, high-dose aldesleukin|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
33237298|NCT00709527|Experimental|1|
33237299|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
32751848|NCT01738139|Experimental|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32751849|NCT01729091|Experimental|Treatment (chemotherapy, UCB-derived NK cells, transplant)|Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.
32751850|NCT05605067||Cases|Participants will self-select into the study. All enrolled will meet study specific criteria and be considered cases.
32751851|NCT04205903|Experimental|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33237300|NCT04535661||non CRE|Children with a negative culture for CRE during their stay in PICU are defined as non CRE.
33237301|NCT04535661||CRE colonization|Children who have a positive culture for CRE during their stay in PICU but lack of clinical symptoms are defined as CRE colonization.
33237302|NCT04535661||CRE infection|Children who have a positive culture for CRE during their stay in PICU combined with clinical symptoms are defined as CRE infection.
32751852|NCT04205903|Placebo Comparator|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32751853|NCT05566691|Active Comparator|Positive thinking|Videos will describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
33394439|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
33394440|NCT03222700||robotic thyroidectomy group|
33394441|NCT03222700||open thyroidectomy group|
33394442|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
32901756|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
32901757|NCT01364298|Experimental|Gabapentin/B-complex|
33394443|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
33394444|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
32901758|NCT01364298|Active Comparator|Pregabalin|
33394445|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
33237303|NCT00714675|Experimental|1|Citrulline
33394446|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
32901759|NCT05020470|Experimental|Self-guided mAPA (S-mAPA)|S-mAPA group will be provided with instructions so that participants can learn to self-administer APA weekly for four weeks and then followed by weekly telecommunication for Q & As.
33070922|NCT02931487|Experimental|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
33237304|NCT00714675|Active Comparator|2|Amino acids
33237305|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
33237306|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
33237307|NCT00714831|Active Comparator|CG|Control Group
33237308|NCT00714831|Experimental|IG|Intervention Group
33237309|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
33237310|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
33237311|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
33237312|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
32751854|NCT05566691|Active Comparator|Positive thinking plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
33070923|NCT02931487|Sham Comparator|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
32751855|NCT05566691|Active Comparator|Thought reevaluation|Videos will describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
32751856|NCT05566691|Active Comparator|Thought reevaluation plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
32751857|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
32751858|NCT01515527|Experimental|Cladribine + Cytarabine Alt. with Decitabine|"Induction cycle: Cladribine intravenous (IV) over approximately 1 to 2 hours, daily on days 1-5 combined with Cytarabine subcutaneous (SQ) twice daily on days 1-10. Cytarabine should be administered approximately 3-6 hours following the start of the cladribine infusion.~Consolidation cycle: Cladribine IV over 1 to 2 hours, daily on days 1-3 combined with Cytarabine SQ twice daily on days 1-10. Cytarabine should be administered 3-6 hours following the start of the cladribine infusion.~Alternating with: Decitabine IV over 1 to 2 hours, daily on days 1-5."
32751859|NCT05675501|Experimental|Study Drug|Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2),
32751860|NCT05675501|Placebo Comparator|Vehicle|Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2),
32751861|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
33237313|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
33237314|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
33237315|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
33394447|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
32745317|NCT04843839|Placebo Comparator|Control Eye|These eyes will be given the placebo, that is Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v, at the same dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
32745318|NCT04838691|Experimental|interpersonal relations counseling applied|8 sessions of interpersonal relations counseling, each lasting 40 minutes, were applied for 2.
32745319|NCT04838691|No Intervention|no application|No action taken.
32745320|NCT04838535|Other|PCOS follicular fluid|
32745321|NCT04838379|Placebo Comparator|group Bupivacaine|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
32745322|NCT04838379|Active Comparator|group bupivacaine&dex|2 will include 30 patients: each one will receive 2.5mg/kg of 0.25% bupivacaine plus 2 µ/kg of dexmedetomidine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
32745323|NCT04369911|Experimental|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
32745324|NCT04369911|Experimental|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
32745325|NCT04369131|Experimental|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
32745326|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
32751862|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
32751863|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
32751864|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
32751865|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
32751866|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
32751867|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
32751868|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
32751869|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
32751870|NCT01430351|Experimental|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
32751871|NCT01430351|Experimental|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
33237316|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
32751872|NCT01430351|Experimental|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
33394448|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
32751873|NCT01430351|Experimental|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
32751874|NCT01430351|Experimental|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
33394449|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
32909216|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
33394450|NCT03222388||IIEF5 paper-electronic|
33394451|NCT03222388||IIEF5 electronic-paper|
32751875|NCT01430351|Experimental|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
32751876|NCT01430351|Experimental|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
33394452|NCT03222388||IIEF15 paper-electronic|
33394453|NCT03222388||IIEF15 electronic-paper|
33394454|NCT03222388||IIEF5 electronic-electronic|
32751877|NCT01430351|Experimental|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
32751878|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
32751879|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
32751880|NCT05675267||patient with chest pain|
32751881|NCT05675111||Nanjing|The First Affiliated Hospital of Nanjing Medical University
32751882|NCT05675111||Zhengzhou|Henan Provincial People's Hospital
32751883|NCT05675111||Qingdao|The Affiliated Hospital of Qingdao University
32751884|NCT05675111||Urumqi|People' s Hospital of Xinjiang Uygur Autonomous Region
32751885|NCT05675111||Jinan|Shandong Provincial Hospital Affiliated to Shandong First Medical University
32751886|NCT05549219|Experimental|10 mg/kg GLM101|GLM101 IV infusions, given weekly
32751887|NCT05549219|Experimental|20 mg/kg GLM101|GLM101 IV infusions, given weekly
32751888|NCT04439591|Experimental|Intervention group|Intervention group undergoes computerised brain training programme first.
32751889|NCT04439591|Other|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
33237317|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
33237318|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
33394455|NCT03222388||IIEF15 electronic-electronic|
32751890|NCT05675033|Other|study arm|This is a single arm study.
32751893|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
32751894|NCT02391935|Placebo Comparator|Placebo|cryomedium
33070924|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
33070925|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
32745327|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
32751895|NCT05674877|Placebo Comparator|Opioid-based group (OB)|".Patients in the opioid-based group will receive placebo boluses and infusions of saline.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg"
32751896|NCT05674877|Active Comparator|Opioid sparing group (OS)|"Patients in the Opioid Sparing group will receive a loading dose of dexmedetomidine (1µg/kg over 10 minutes). This will be followed by a fixed continuous maintenance infusion of 0.5µg/kg/hour. Furthermore, a single induction analgesic dose of 0.5 mg/kg ketamine will be given to all patients in the OS group. This will be followed by 0.25 mg/kg/h continuous maintenance infusion. Dexmedetomidine and ketamine infusions will be stopped 30 minutes prior to the conclusion of surgery.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg in the two study groups."
32745328|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
32745329|NCT04838145|Active Comparator|Active treatment|Pleconaril: 5 mg/kg x2 times a day for 26 weeks up to 40 kg. Max dose 300mg x2. Ribavirin:15 (7.5) mg/kg/day divided in two doses daily for 26 weeks: Max dose 1000mg/24h if body weight<75kg and 1200mg if body weight>75kg.
32745330|NCT04838145|Placebo Comparator|Placebo|Receives placebo, on a double blind basis
32745331|NCT04837911|Other|Patients using the Spirobank Smart|Use of a portable spirometry
32745332|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
32745333|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
32745334|NCT04855539||wave 1|
32745335|NCT04855539||wave 2|
32745336|NCT04855383|Experimental|The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
32751897|NCT04103489|Experimental|HELLP Syndrome at less than 30 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
32751898|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
33070926|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
32751899|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
32751900|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
32751901|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
33070927|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
33070928|NCT04597684|Active Comparator|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
32751902|NCT04075487|Experimental|User experiences with MEPS-Pain|This is a pilot study to assess user experience with MEPS-Pain App, there is only one arm.
32751903|NCT05545085||Group 1|All included patients meeting the eligibility criteria and scheduled to undergo a lobectomy in the Medical Centre Leeuwarden.
32751904|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751905|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751906|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751907|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751908|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751909|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
32751910|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
33070929|NCT04597684|Active Comparator|Control|Total Knee Arthroplasty (TKA) with cemented knees
32751911|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
33070930|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
32751912|NCT04038359|Experimental|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycles.
32751913|NCT04038359|Experimental|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed two weeks on and two weeks off.
32751914|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
32751915|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
32751916|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
32751917|NCT04029857|Active Comparator|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
32751918|NCT04029857|Experimental|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
32751919|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
32751920|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
33237319|NCT04084938|Active Comparator|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
32901760|NCT05020470|Experimental|In-Person Training + mAPA (IP-mAPA)|Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
33237320|NCT04084938|Active Comparator|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
33237321|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
33237322|NCT00578877|Experimental|Arm 2|Buffer Gel
33237323|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
33237324|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
33237325|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
33237326|NCT01032343|Placebo Comparator|Gelatine capsule|
33241685|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
32901380|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
33241686|NCT04353986|Experimental|Beta thalassemia|HCV infected Beta thalassemia major adolescents
33241687|NCT04353986|Active Comparator|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
32751921|NCT04479527|Experimental|the group of HAIC combined with carilizumab and apatinib mesylate treatment|"cTACE or DEBTACE+FOLFOX scheme HAIC, arterial chemotherapy scheme: OXA 65-85mg/m2 arterial H0-4 pump, calcium folinate 200mg/ m2 intravenous pump H2-4, 5-FU 1g-1.5g/ m2 arterial H4-24 pump, once every 6-8 weeks, the interventional treatment times are determined by researchers according to the patient's condition, and two times are adjacent.~Apatinib mesylate tablets, 250mg/ time, once a day. Take it about half an hour after a meal (the daily medication time should be as same as possible), and take it with warm boiled water.~Karelizumab, 200mg, was given intravenously for 30 minutes (including the flushing time, the whole infusion time was not shorter than 20 minutes and not longer than 60 minutes), and the medication period was q3w(±3 days)."
32751922|NCT05534945|Experimental|F5 ml PIEB|Female patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751923|NCT05534945|Experimental|F6 ml PIEB|Female patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751924|NCT05534945|Experimental|F7 ml PIEB|Female patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751925|NCT05534945|Experimental|F8 ml PIEB|Female patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751926|NCT05534945|Experimental|F9 ml PIEB|Female patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751927|NCT05534945|Experimental|F10 ml PIEB|Female patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751928|NCT05534945|Experimental|M5 ml PIEB|Male patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751929|NCT05534945|Experimental|M6 mL PIEB|Male patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751930|NCT05534945|Experimental|M7 mL PIEB|Male patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751931|NCT05534945|Experimental|M8 mL PIEB|Male patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751932|NCT05534945|Experimental|M9 mL PIEB|Male patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751933|NCT05534945|Experimental|M10 mL PIEB|Male patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
32751934|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
32751935|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
32751936|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
32751937|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
32751938|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
32751939|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
32751940|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
32751941|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
32751942|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
32751943|NCT05502029|Active Comparator|Control|Translator in preoperative area
32751944|NCT05502029|Experimental|Intervention|Translator in preoperative area, continued through transport to the operating room, and in the operating room until the patient is under general anesthesia
32751945|NCT05477069|Experimental|First intervention group|The volunteer ingests the medical device which passes through the body for a period of 12 to 24 hours. Capsules are collected and analysis on intestinal fluid and faeces are performed
32751947|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
32751948|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751949|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751950|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751951|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751952|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751953|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751954|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751955|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751956|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
32751957|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
32751958|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
32751959|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
32751960|NCT02390375|Experimental|A|DW-0929
32751961|NCT02390375|Active Comparator|B|Rosuvastatin
32751962|NCT03926507|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
32751963|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
32751964|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
32751965|NCT03921203||Type 2 diabetes patients|
32751966|NCT03921203||Healthy controls|
32751967|NCT02669849|Placebo Comparator|Placebo|
32751968|NCT02669849|Experimental|VX-210|
32751969|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
32751970|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
32751971|NCT03836963|Experimental|cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
32751972|NCT03836963|Active Comparator|cognitive and memory strategy control training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
32751973|NCT03836963|Active Comparator|active control for cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
32751974|NCT03813407|Experimental|Active Arm ( Sodium Zirconium Cyclosilicate SZC)|Dosage formulation: 5 g sachets 2.5 g sachets 0.25 g sprinkle capsules 0.125 g sprinkle capsules (can be manufactured to support participants <2 years of age) Route of administration: Oral Dosing instructions: SZC is provided as a powder. At the time of dosing SZC is mixed with a quantity of water or sprinkled onto semi-solid food (eg, milk, baby food, yogurt, or ice cream) within an hour of drug administration. Packaging and labelling: Study treatment will be provided in sachets packed in cartons or sprinkle capsules in high density polyethylene bottles, as appropriate for the dose. Each carton of sachets, individual sachets, and bottle of capsules will be labelled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Participant-specific dosing cards (diary) will be provided.
32751975|NCT03806309|Active Comparator|Arm A : maintenance with FOLFIRI|FOLFIRI (IV; folinic acid 400 mg/m^2, irinotecan 180 mg/m^2, 5-FU bolus 400 mg/m^2 and continuous infusion 2,400 mg/m^2/46h (dose adjustment will be accepted).
32751976|NCT03806309|Experimental|Arm B : maintenance with OSE2101 plus FOLFIRI|"OSE2101 - subcutaneous injection on day 1 and day 15, every 4 weeks for 6 doses then every 8 weeks until month 12 then every 12 weeks up to 24 months.~FOLFIRI - schedules as in Arm A until disease progression on unacceptable toxicity"
32751977|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
32751978|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
32751979|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
32751980|NCT03741023|Other|Trauma Patients|"During Hospitalization:~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
32751981|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
32751982|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
32751983|NCT03625895||Anagrelide hydrochloride|Participants who received treatment with Anagrelide hydrochloride will be evaluated for this study. Participants will receive interventions as part of routine medical care.
32751984|NCT05656235|Experimental|Enfortumab vedotin with Pembrolizumab|"The study population will include male and female patients over the age of 18 with high grade UTUC (cN0/xM0) and is ineligible for or refuses definitive radical nephroureterectomy (RNU).~Enfortumab vedotin will be administered on Days 1 and 8 at 1.25mg/kg of every 3-week cycle by intravenous (IV) infusion given over approximately 30 minutes. Pembrolizumab will be administered on Day 1 at 200mg of every 3-week cycle by IV infusion over approximately 30 minutes. Enfortumab vedotin and Pembrolizumab may be administered for up to total of 35 cycles (approximately 2 years)."
32751989|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
32751990|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
32751991|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
32751992|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
32751993|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
32751994|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
32751995|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
32751996|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
32751997|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
32751998|NCT02388503|Placebo Comparator|Reference|No added fruit extract
32751999|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
32752000|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
32752001|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
32752002|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
32752003|NCT04748939|Active Comparator|vaccine|Shingrix vaccine
32752004|NCT04748939|Placebo Comparator|placebo|normal saline injection (0.5mL)
32752005|NCT05345015|Experimental|Acute effects|The experimental group will receive one single session of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The control group will receive one 20-minute session of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f< 50Hz). Outcome measures will be measured prior to, immediately after, 24 and 48 hours after.
32752006|NCT05345015|Experimental|Chronic effects|The experimental group will receive 10 sessions of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The control group will receive 10 20-minute sessions of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f< 50Hz). Outcome measures will be measured prior to, immediately after, 3 and 6 months after.
33070931|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
32745052|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
32745337|NCT04855383|No Intervention|The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.
32745338|NCT04855149||WALANT|anesthesia performed with WALANT technique
32745339|NCT04855149||BAx|anesthesia performed with axillary block under ultrasound control
32745340|NCT04855071|Active Comparator|Interventional group|"The intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.~Furthemore, active RF will be applied intracavitary, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session)."
32745341|NCT04855071|Sham Comparator|Comparator group|The intervention will be the same that in IG (exercises to balance the pelvis and their muscles, etc) an also standards of water, urination, food, defecation, postural hygiene and physical activity for their generalization at home and life habit advices. The application of RF in the control group will follow the same application procedure as in the intervention group with the only difference that no parameter is applied to the RF device (in terms of temperature, power, frequency and dose); that is, it remains off for the entire duration of the session.
32745342|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
32745343|NCT03041493|Experimental|traditional cigarette (TC) smokers|
32745344|NCT03041493|Active Comparator|nonsmokers|
32745345|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
32745346|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
32745347|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
32745348|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
32745349|NCT04429035|Experimental|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
32745350|NCT04429035|Placebo Comparator|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
32745351|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
32745352|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
32909217|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
32909218|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
32745353|NCT04843449|Experimental|Inhibitor group|"ASC40 50mg, once daily on the 1st and 11th days before meal;~Itraconazole 200mg, once daily from the 6th day to the 15th day."
32745354|NCT04843449|Experimental|Inducer group|"ASC40 50mg, once daily on the 1st and 19th days before meal;~Rifampicin 600mg, once daily from the 6th day to the 19th day."
32745355|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
32745356|NCT03037593|No Intervention|Control|standard prenatal vitamin
32745357|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
32745358|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
32745359|NCT04838067|Experimental|Cefaly Intervention|Cefaly
32745360|NCT04843293|Experimental|Experimental Group: Olfactory stimulation group|Preterm newborns in the initiative group were sniffed the smell of breast milk before and during feeding, except for routine application
32745361|NCT04843293|No Intervention|Control Group|Premature newborns in the control group feeds gavage according to the routine of the clinic, and no attempt will be made during feeding.
32745362|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
32745363|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
32745364|NCT04843215|Experimental|Experimental group/D2 radical gastrectomy with partial omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.
32745365|NCT04843215|No Intervention|Control group/D2 radical gastrectomy with total omentectom|Control group with total omentectomy
32745366|NCT04803357|Experimental|Blinded Continuous Glucose Monitoring Devise|If you are in the control group, you will wear a continuous glucose monitor with the read out screen covered so you can not see your continuous glucose level. You will be taught how to test your blood sugar by pricking your finger and using a standard blood glucose meter as per the standard of care used by your provider in the obstetrics clinic.
32745367|NCT04837443|Experimental|Synchronous working group|
32745368|NCT04837443|Sham Comparator|Asynchronous working group|
32745369|NCT04842825|Experimental|kidney-tonifying and blood-regulating herbs treatment group|the treatment group will receive sequential treatment with the Chinese herbal formula for tonifying the kidney, nourishing the blood, and activating the blood 2 months before the proposed ET to regulate menstruation and improve ovarian reserve function. Treatment with the Chinese herbal formula will continue on the 5th day of menstruation after entering the super-ovulation cycle.
32745370|NCT04842825|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
32745371|NCT04837599|No Intervention|Pentax i 10|Patient gets normal colonoscopy without Endocuff or activation of artifical intelligence
32745372|NCT04837599|Active Comparator|Pentax i 10 with artificial intelligence Discovery TM|Normal Pentax i 10 colonoscope with on the special monitor acitvated artificial intelligence
32745373|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM|Endocuff cap is mounted on the tip of the endoscope a cheap assistance device proven in former studies to increase adenoma detection rate.
32745374|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM and artificial intelligence Discovery TM|Endocuff cap is mounted on the tip of the endoscope and artificial intelligence is activated on the monitor. hypothesis is that probably artificial intelligence and Endocuff combined potentiate their effect.
32745375|NCT04837131|Experimental|Ixazomib in patients with scleroderma-interstitial lung disease (ILD)|Participants will be administered oral ixazomib for six cycles (each cycle is 28 days duration).
32745376|NCT04854915|Active Comparator|Liverpool Overweight and Obesity Programme (LOOP) only|Patients will continue to follow the LOOP@ Alder Hey programme.
32745377|NCT04854915|Experimental|LOOP + mHealth technology assisted exercise counselling|Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
32745378|NCT04842903|Experimental|Experimental Group|Therapeutic touch and standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
32745379|NCT04842903|No Intervention|Control Group|Only standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
32752007|NCT05231291||Young Adults|"Skinfold thickness (SFT) at multiple marked sites on biceps, triceps, subscapular and suprailiac areas using a Harpenden Caliper (Baty, UK) for the non-dominant side.~Hand grip strength measurement Jamar Hydraulic Dynamometers (Hydraulic Hand Dynamometer Fabrication Enterprises Inc, NY) was used as the evaluation tool for measuring grip.~The handgrip measurement was carried out as per the recommendations laid by The National Institute of Health Research (NIHR).~The T score for hand grip strength was also calculated. Also the mean predicted handgrip strength for given height was calculated foe the given height Trunk muscle strength testing was done. An analogue hydraulic push-pull dynamometer (Model: FEI-12-0394) was used to evaluate. The trunk extensor and flexor muscle strength was evaluated using and was recorded in pounds (lbs.)."
32752008|NCT05442827|Experimental|Treatment group A: SHR7280 tablets|
32752009|NCT05442827|Experimental|Treatment group B:SHR7280 tablets|
32752010|NCT05442827|Placebo Comparator|Treatment group C:Intervention: Drug: PlaceboSHR7280 tablets blank preparation|
32752011|NCT02389751|Experimental|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
32752012|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
32752013|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
32752014|NCT04740047||Pulmonary Nodule|Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.
32752015|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
32752016|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
32752017|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
32752018|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
32752019|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
32752020|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
32752021|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
32752022|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
32752023|NCT05407025||Observational (questionnaire, biospecimen collection)|Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
32752024|NCT04439669|Active Comparator|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
32752025|NCT04439669|Placebo Comparator|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
32752026|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
32752027|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
32752028|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
32752029|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
32909219|NCT05187962||Women receiving epidural analgesia for labor|Sensory block level check Patients will have their sensory block level checked using 3 modalities: ice, pin prick and soft touch (cotton ball).
32752030|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
32752031|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
32752032|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
32752033|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
32752034|NCT02389595||HIV positive subjects|This group will provide a blood sample.
32752035|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
32752036|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
32909220|NCT01070810|Placebo Comparator|1|50 ml D5W
32745380|NCT04837287|Active Comparator|Static Stretching Exercise for 10 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
32745381|NCT04837287|Active Comparator|Static Stretching Exercise for 30 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
32745382|NCT04842669|Experimental|Low level laser therapy|Low level laser therapy
32745383|NCT04842669|Active Comparator|Conservative treatment|Conservative treatment
32745384|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
32745385|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
32745386|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
32745387|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
32745388|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
32745389|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
32745390|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
32745391|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
32745392|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
32745393|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
32745394|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
32745395|NCT04842357|Other|video - then self-study|Group A will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group A will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
32745396|NCT04842357|Other|self-study, then video|Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
32745397|NCT04779645|Experimental|GRA (REMD-477) Group|Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.
32745398|NCT04779645|Placebo Comparator|Placebo Group|Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.
32745399|NCT04854759|Experimental|Study group|
32745400|NCT04854759|Placebo Comparator|Control group|
32745401|NCT04428957|Experimental|Telemonitoring group|3 months home-based telemonitoring
32745402|NCT04428957|No Intervention|Control group|3 months standard care
32745403|NCT04842435|Experimental|Stage 1. Group 1|Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
32745404|NCT04842435|Experimental|Stage 1. Group 2|Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
32745405|NCT04842435|Experimental|Stage 1. Group 3|Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
32745406|NCT04842435|Placebo Comparator|Stage 1. Group 4|Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
32745407|NCT04842435|Active Comparator|Stage 2. Group 1|Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
32745408|NCT04842435|Placebo Comparator|Stage 2. Group 2|Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
32745409|NCT04854681|Experimental|TQB2928 injection|Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
32745410|NCT04774419|Experimental|Radiation and Dostarlimab|Patients will undergo standard intensity modulated radiation therapy (IMRT) to the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks and receive IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
32745411|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
32745412|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
32745413|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
32745414|NCT04772313|Experimental|Pegloticase plus Methotrexate (MTX)|Pegloticase (8mg) intravenous (IV every two weeks). Methotrexate (15 or 25 mg weekly) subcutaneous (SC).
32745415|NCT04770285|Other|Digital Therapeutic A|Digital Therapeutic Version A
32745416|NCT04770285|Other|Digital Therapeutic B|Digital Therapeutic Version B
32752037|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
32752038|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
32752039|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
32752040|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
32752041|NCT05283395|Other|Netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|
32752042|NCT02389205|Placebo Comparator|control group|physical therapy
32752043|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
32752044|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
32752045|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
32752046|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
32752047|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
32752048|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
32752049|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
32752050|NCT03106025|Active Comparator|Patients Receiving Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
32752051|NCT03106025|Experimental|Ocular Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis
32752052|NCT05359991|Active Comparator|Healthy Controls|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in healthy controls. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
32752053|NCT05359991|Experimental|Children With Documented History of SARS CoV-2 Infection|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with a documented history of SARS CoV-2 Infection. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
32905412|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
32909221|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
32909222|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
32745053|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
32745054|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
33070932|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
32745417|NCT04769973||Work Packages 1 - 3|"Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers.~Work Package 2: National Survey with up to 2000 participants~Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)"
32745418|NCT04769895|Experimental|MaaT013|"Route of administration: rectal (enema)~Study drug dose: 4 enemas in total:~Week 1:~D0-D1: vancomycin pre-treatment (250mg per os, 4 times a day for 2 days)~D2: 1 dose~Between D3 to D5: 1 dose Week 2: 1 dose (7 +/- 2 days after the last dose) Week 3: 1 dose (7 +/- 2 days after the last dose) A supplementary dose can be prescribed in case of GvHD relapse or massive antibiotic use during the study."
32745419|NCT04769037|Active Comparator|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
32745420|NCT04769037|Placebo Comparator|Placebo|Lactose identical in appearance and taste to the active supplement
32745421|NCT04836663|Experimental|TQ-B3525 tablet|
32745422|NCT04836741|Experimental|Micro Hand S robot-assisted surgery|This group is consisted of 40 cases performed using the Micro Hand S robot by one single surgeon for rectal cancer
32745423|NCT04836741|Active Comparator|Laparoscopic surgery|This group is consisted of 65 cases performed using the laparoscope by one single surgeon for rectal cancer
32745424|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
32745425|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
32745426|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
32745427|NCT04841811|Experimental|Postoperative Almonertinib continuous treatment group|Operable subjects were randomly assigned to groups A and B after surgery: Group A received 110 mg of Almonertinib once a day for 2 years.
32745428|NCT04841811|Experimental|Postoperative ctDNA dynamic monitoring guided the Almonertinib treatment group|Operable subjects were randomly assigned to groups A and B after surgery:Group B received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
32745429|NCT04841811|Experimental|Almonertinib continuous treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group C continued to receive Almonertinib 110 mg once a day for 2 years.
32745430|NCT04841811|Experimental|ctDNA dynamic monitoring guided the Almonertinib treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group D received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
32745431|NCT04854525||One Stage Reconstruction With pre-reconstruction Radiotherapy|
32745432|NCT04854525||Two Stage Reconstruction With pre-reconstruction Radiotherapy|
32745433|NCT04854525||Autologous Reconstruction With pre-reconstruction Radiotherapy|
32745434|NCT04854525||One Stage Reconstruction Without pre-reconstruction Radiotherapy|
32909223|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
32745435|NCT04854525||Two Stage Reconstruction Without pre-reconstruction Radiotherapy|
32745436|NCT04854525||Autologous Reconstruction Without pre-reconstruction Radiotherapy|
32745437|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
32745438|NCT04854135|Experimental|CGM Intervention|All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.
32745439|NCT04428879|Experimental|Phase I single arm trial|
32745440|NCT04836819|Active Comparator|Group L|IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.
32745441|NCT04836819|Active Comparator|Group K|IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
32745442|NCT04836819|Active Comparator|Group D|IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
32745443|NCT04836507|Experimental|CRC01|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.
32745444|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|Cognitive behavioral therapy based psychological intervention occurring every other week for 12 weeks.
32745445|NCT03039933|Other|Treatment As Usual|Control group completes questionnaires but does not receive any study intervention. Receives medical care as usual.
32745446|NCT04853745||sodium bicarbonate group|Sodium bicarbonate-based powder (CLASSIC®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
32745447|NCT04853745||glycine group|Glycine-based powder (PERIO®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
32745448|NCT04853745||erythritol group|Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
32745449|NCT04836351|Experimental|Concentrated rehabilitation|3+ 1-2 day concentrated rehabilitation for patients with persistent symptoms post COVID-19.
32752054|NCT05359991|Experimental|Children With Sickle Cell Disease (SCD)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Sickle Cell Disease (SCD). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
32752055|NCT05359991|Experimental|Children With Cystic Fibrosis (CF)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Cystic Fibrosis (CF). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
32752056|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
32752057|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
32752058|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
32752059|NCT02387489|Experimental|CBI|Computerized Brief Intervention
32752060|NCT05225207||All Participants|Participants with uHCC who are prescribed with Lenvima within the scope of the approved label for Korea under the medical judgment of the investigator will be enrolled and observed for up to 12 months.
32752061|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
32752062|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
32752063|NCT04439825|Active Comparator|Botox|
32752064|NCT04439825|Placebo Comparator|Placebo|
32752065|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
32752066|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
32752067|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
32752068|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
32752069|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
32752070|NCT02387411|Active Comparator|Combined group|combined exercise training
32752071|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
32752072|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
32752073|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
32752074|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
32752075|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
32752076|NCT04715386||Group 1- StrataXRT|
32752077|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
32752078|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
32752079|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Random glucose <200 mg/dL on at least 3 occasions~No use of insulin or any hypoglycemic agent~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
32752080|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
32752081|NCT02389127||Control|"Age 18 to 75~No known chronic liver disease~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent"
32752082|NCT02383121||No patients|Study has been withdrawn
32752083|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
32752084|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
32752085|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
32752086|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
32752087|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
32752088|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
32752089|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
32752090|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
32752091|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
32752092|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
32752093|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
32752094|NCT04714372|Experimental|Dose Level 1: FT538 at 1 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
32752095|NCT04714372|Experimental|Dose Level 2: FT538 at 3 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
32752096|NCT04714372|Experimental|Dose Level 3: FT538 at 1 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
32752097|NCT04714372|Experimental|Dose Level 4: FT538 at 1.5 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
32752098|NCT02386709|Experimental|Experimental Arm|"Diagnostic~PET1 : before the neoadjuvant treatment~start neoadjuvant treatment~PET2: two weeks after the start of the first course of chemotherapy~surgery"
32752099|NCT04787471|Active Comparator|30 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
32752100|NCT04787471|Active Comparator|10 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
32752101|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
32752102|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
32752103|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
32752104|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
32752105|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
32752106|NCT02386397|Other|Standard treatment|"mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
32752107|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
32752108|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
32752109|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
32752110|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
32752111|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
32752112|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
32752113|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
32752114|NCT05136443|Experimental|Preventative Treatment|Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.
32752115|NCT05134649|Experimental|BOTOX|BOTOX will be injected into the platysma muscle for up to 3 administrations.
32752116|NCT05101031||Denver Health Medical Center|SV machine will be attached if hypotensive and in the emergency department
32752117|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
32752118|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
32752119|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
32752120|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
32752121|NCT02382809|Placebo Comparator|Placebo|
32752122|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
32752123|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
32752124|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
32752125|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
32752126|NCT02386007|Experimental|DW-3101_150mg|150mg a day
32752127|NCT02386007|Experimental|DW-3101_300mg|300mg a day
32752128|NCT02386007|Experimental|DW-3101_600mg|600mg a day
32752129|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
32752130|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
32752131|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
32752132|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
32752133|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
32752134|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
32752135|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
32752136|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
32752137|NCT02385773|Experimental|PTM202|PTM202
32752138|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
32752139|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
32752140|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
32752141|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
32752142|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
32752143|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
32752144|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
32752145|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
32752146|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
32752147|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
32752148|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
32909224|NCT05150756|Active Comparator|Group Lidocaine|At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.
32752149|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
32752150|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
32752151|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
32752152|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
32752153|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
32752154|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
32752155|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
32752156|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
32752157|NCT02381951|Experimental|Spinal cord stimulation|
32752158|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
32752159|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
32752160|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
32752161|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
32752162|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
32752163|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
32752164|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
32752165|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
32752166|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
32752167|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
32752168|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
32752169|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
32752170|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
32752171|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
32752172|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
32752173|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
32752174|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
32752175|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
32752176|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
32752177|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
32752178|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
32752179|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
32752180|NCT05003687|Experimental|Part A: Single Dose of Lu AG06474 or Placebo|Participants will receive single oral dose of Lu AG06474 or placebo.
32752181|NCT05003687|Experimental|Part B: Repeated Dose of Lu AG06474 and Food Interaction|"Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:~Sequence B1: Fed - Fasting- Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
32752182|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
32752183|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
33394456|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
32752184|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
32752185|NCT02381483|Experimental|Lean|Cold exposure
32752186|NCT02381483|Experimental|Obese|Cold exposure
32909225|NCT05150756|Active Comparator|Group Morphine|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
32752187|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752188|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752189|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752190|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752191|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752192|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752193|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752194|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752195|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752196|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752197|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752198|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32752199|NCT02381405|Active Comparator|A|Enterade beverage
32752200|NCT02381405|No Intervention|B|Standard of care
32752201|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
32752202|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
32752203|NCT02384681||Exposed|Medical regulation assistants working with headset
32752204|NCT02384681||Non-Exposed|Participants working without headset
32752205|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
32752206|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
32752207|NCT04895735|Experimental|Treatment (pembrolizumab, pemetrexed)|Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
32752208|NCT04875377|Experimental|Reformulated pizza|Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks
32752209|NCT04875377|Placebo Comparator|Control pizza|Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks
32752210|NCT04875377|Experimental|Seaweed capsule|Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks
32752211|NCT04875377|Placebo Comparator|Control capsule|Participants must consume an empty capsule 3 times a week for 24 weeks
32752212|NCT04733495|Experimental|Supportive care (resistance exercise, counseling)|Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling BIW in weeks 1-8, QW in weeks 9-12, and then twice a month in weeks 13-24.
32752213|NCT04721327|Experimental|Pediatric Arm|Patient ages 1-17 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
32909226|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
32752214|NCT04721327|Experimental|Adult Arm|Patient ages 18-90 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
32752215|NCT04872101|Experimental|Delgocitinib 20 mg/g|Twice-daily topical application for 16 weeks
32752216|NCT04872101|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
32752217|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
32752218|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
32752219|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
32752220|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
32752221|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
32752222|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
32752223|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
32752224|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
32752225|NCT04729439|Experimental|Organizational/behavioral intervention + digital health tool|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills [HOPS]) plus the online digital health application during treatment
32752226|NCT04729439|Active Comparator|Organizational/behavioral intervention only|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills [HOPS]) only, without the online digital health application during treatment
32752227|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
32752228|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
32752229|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
32752230|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
32752231|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
32752232|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
32752233|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
32752234|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
32752235|NCT02384525|Experimental|clinical-based ultrafiltration|
32752236|NCT02384525|Active Comparator|BIA-based ultrafiltration|
32752237|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
32752238|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
32752239|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
32752240|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
32752241|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
32752242|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
32752243|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
32752244|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
32752245|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
32909227|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
32909228|NCT04352582||1|Survey respondants
32909229|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
33394457|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
32745450|NCT04372329|Experimental|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
32745451|NCT04372329|Experimental|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
32745452|NCT04841733|Experimental|Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Cold-Water Immersion (CWI)
32745453|NCT04841733|Experimental|Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)|Stretching (STR) Cold-Water Immersion (CWI)
32745454|NCT04841733|Experimental|Protocol III: Foam Roller (FR) + Stretching (STR)|Foam Roller (FR) Stretching (STR)
32745455|NCT04841733|Experimental|Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
32745456|NCT04835883|Experimental|Assigned interventions|Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks post-enrollment.
32745457|NCT04841421|Experimental|89Zr-CD147 1mCi±10% 10mg dose group|The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.
32745458|NCT04841421|Experimental|89Zr-CD147 3mCi±10% 10mg dose group|The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.
32745459|NCT04841421|Experimental|89Zr-CD147 5mCi±10% 10mg dose group|The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.
32745460|NCT04835337|Experimental|Air purifier|Participants in this group receive an intervention of real air purifiers placed in the indoor environment.
32745461|NCT04835337|Sham Comparator|Control|Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.
32745462|NCT04835259|Active Comparator|Group 1(treatment group)|"Topical application of a cream of a combination of antioxidants once daily at night for 6 months Name: Selenium ACE cream (Interpharma UK company, Egypt)~Ingredients:~Selenium (Selenium amino acid chelate) 0.5% Vitamin C (Sodium ascorbyl phosphate - stay C) %1 Vitamin E (Tocopheryl acetate) % 0.5 Vitamin A (Retinyl palmitate) %1 Emulsifiers ( Ceteareth 20 , Glycerol monostearate , Cetyl alcohol) Emollient(Caprylic capric triglycerides)"
32745463|NCT04835259|Active Comparator|Group 2 (positive control)|Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)
32745464|NCT04835259|Placebo Comparator|Group 3 (Negative control)|Topical application of a panthenol cream once daily at night for 6 months (panthenol 2% cream, El Nile company, Egypt)
32745465|NCT04368117|Active Comparator|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
32745466|NCT04368117|Experimental|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
32745467|NCT04853901|Experimental|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days
32745468|NCT04853901|Active Comparator|Standard of care therapy|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days
32745469|NCT04853823|Experimental|PDC-APB|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
32745470|NCT04853823|Placebo Comparator|Vehicle|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
32745471|NCT04853277|Experimental|Education Group|Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
32745472|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
32745473|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
32745474|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
32745475|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
32745476|NCT04836039||Physiotherapists|Individuals between the ages of 22-65 who continue to work as a self-employed or employee physiotherapist.
32745477|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
32745478|NCT04841031|Experimental|NET Treatment|Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
32745479|NCT04841031|Other|Control|This group contains eligible individuals who are randomly assigned to the control group and are part of the study sample. In every cohort, the control group contained 6 individuals.
32745480|NCT04834947||Prone position in non-intubated COVID19 , before and after.|Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement.
32745481|NCT04834791|Experimental|Letrozole|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
32752246|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
33237327|NCT05263050|Experimental|Cabozantinib|Cabozantinib treatment will start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg (table 1). The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met the established protocol criteria (outlined in Section 6.3) and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
33237328|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
32752247|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
32752248|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
32752249|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
32752250|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
32752251|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
32752252|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
32752253|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
32752254|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
32752255|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
32752256|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
32752257|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
32752258|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
32752259|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
32752260|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
32752261|NCT04835597||Observational (movement assessment, medical data collection)|Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
32752262|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
32752263|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
32752264|NCT04819841|Experimental|GPH101 Drug Product|GPH101 Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
32752265|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
32752266|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
32752267|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
32752268|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
32752269|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
32752270|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
32752271|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
32752272|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
32752273|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
32752274|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
32752275|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
32752276|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
32752277|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
32752278|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
32752279|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
32752280|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
32752281|NCT04796597|Experimental|Single-arm|Implantation of subcutaneous leads and connection to an external EEG amplifier
32752282|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
32752283|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
32752284|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
32752285|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
32752286|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
32752287|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
32752288|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
32752289|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
32752290|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
32752291|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
32752292|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
32752293|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
32752294|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
32752295|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
32752296|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
32752297|NCT02053792|Experimental|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
32752298|NCT02379455|Experimental|Comprehensive drug review|
32752299|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
32752300|NCT02379533|No Intervention|sedentary control|
32909230|NCT03359252|Active Comparator|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
32909231|NCT03359252|Experimental|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
32745482|NCT04834791|Active Comparator|Gonadotropins|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
32745483|NCT04835181|Experimental|Electroacupuncture combined with umbilical moxibustion|
32745484|NCT04835181|Active Comparator|Electroacupuncture|
32745485|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
32745486|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
32745487|NCT04835025||Control group (radiotherapy group)|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesion (without limitation of dose and treatment method for radiotherapy) , but not receiving immunotherapy. Those patients would enter the control group. After patients experiencing disease progression(PD) in this group, follow-up treatment does not include immunotherapy until tumor progression again or death.
32745488|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
32745489|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
32745490|NCT03997773|Experimental|Intervention|Will receive the intervention
32745491|NCT03997773|No Intervention|Usual care|Will receive usual care - will be the control group
32745492|NCT04852263|Other|Group I|Fiberoptic intubation was carried out without nasopharyngeal airway
32745493|NCT04852263|Other|Group II (NPA group)|Fiberoptic intubation was performed with a modified nasopharyngeal airway.
32745494|NCT04794153|Experimental|Pork|Locally sourced
32745495|NCT04794153|Experimental|Salmon|Locally sourced
32745496|NCT04794153|Experimental|Mycoprotein|Provided by Marlow Foods
32745497|NCT04794153|Experimental|Lentils|Red
32745498|NCT04794153|Experimental|Egg|Local supplier
32745499|NCT04794153|Active Comparator|Egg whites|Local Supplier
32745500|NCT04852341||Corneal horizontal diameter ≤9.00mm group|
32745501|NCT04852341||Corneal horizontal diameter 9.00mm~9.50mm group|
32745502|NCT04852341||Corneal horizontal diameter 9.50mm~10.00mm group|
32745503|NCT04852341||Corneal horizontal diameter >10.00mm group|
32745504|NCT04833543|Active Comparator|Tilt Table|
32745505|NCT04833543|Experimental|Robotic Mobility Device (REX)|
32745506|NCT04834713||Mild patients|defined as patients who had kidney injury without oliguria and hypotension
32745507|NCT04834713||moderate patients|defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria
32745508|NCT04834713||severe patients|defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50-500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days
32745509|NCT04834713||critical patients|defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50-500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days
32745510|NCT04834713||healthy control|defined as people without HFRS
32745511|NCT04833621|Active Comparator|NMES GROUP|NMES TREATMENT AND PHYSICAL TREATMENT
32745512|NCT04833621|Active Comparator|CONTROL GROUP|JUST PHYSICAL TREATMENT
32745513|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
32745514|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
32745515|NCT04834323|Active Comparator|group (1)|included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy
32745516|NCT04834323|No Intervention|group (2)|included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
32745517|NCT04851951||patients treated by one-shot PRP injection|
32745518|NCT04851561||Cases|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
32745519|NCT04851561||Controls|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
32745520|NCT01668147|Experimental|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
32745521|NCT01668147|Active Comparator|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
32752301|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
32752302|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
32752303|NCT02377115|Other|Study cohort|Tablet computer application
32752304|NCT04713592|Experimental|Risankizumab|Participants will receive risankizumab for 52 weeks
32752305|NCT04713592|Placebo Comparator|Placebo|Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
32752306|NCT04356287|Experimental|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
32752307|NCT04356287|Experimental|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
32752308|NCT04356287|Placebo Comparator|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
32752309|NCT04688021|Experimental|Tocilizumab cohort|Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.
32752310|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
32752311|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
32752312|NCT04349969|Experimental|Treatment|"Parts A and B: AK117 monotherapy intravenous (IV) infusion- weekly doses in a 28-day cycle.~Parts A2: AK117 (QW) + AK104 (Q3W) combination therapy intravenous (IV) infusion in a 21-day cycle."
32752313|NCT04712968|Experimental|Group 1 (intervention group)|Regular exposure to morning daylight
32752314|NCT04712968|No Intervention|Group 2 (control group)|Treatment as usual.
32752315|NCT04327505|Experimental|Hyperbaric oxygen|Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
32752316|NCT04327505|No Intervention|Control|Best practice
32752317|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
32752318|NCT04678661|Experimental|My Dose Coach (Insulin Dosing Support App)|"Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2.~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6. Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability."
32752319|NCT04678661|Active Comparator|Usual Care Group|A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants.
32752320|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
32752321|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
32752322|NCT04665245||COVID-19 Positive Patients|The study only includes one cohort: COVID-19 positive patients. Enrollees will not receive any therapeutic intervention; participants will simply report their temperature and any symptoms experienced twice per day for 10 days.
32752323|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
32752324|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
33394458|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
32752325|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
32909232|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
32909233|NCT03333356|No Intervention|Standard Arm|Surveillance
32909234|NCT01072136|Placebo Comparator|Placebo|Placebo.
32752326|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
32752327|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
32752328|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
32752329|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
32752330|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
32752331|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
32752332|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
32752333|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
32752334|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
32752335|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
32752336|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
32752337|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
32752338|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
32752339|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
32752340|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
32752341|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
32752342|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
33394459|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
32752343|NCT04697069|Experimental|ANB019|Participants received a starting dose of 400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
32752344|NCT04697069|Placebo Comparator|Placebo|Participants received imsidolimab matching placebo on Day 1 and thereafter, every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
32752345|NCT03113279||Obese older individuals|Obese older individuals
32752346|NCT03113279||Lean older individuals|Lean older individuals
32752347|NCT03113279||Young lean individuals|Young lean individuals
32752349|NCT04678427|Experimental|Supportive Care (TEAM Me)|Patients complete a 6-minute walk test and a timed get up and go test on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients also complete surveys over 10 minutes about quality of life and fatigue levels on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients who are able and allowed to, may also walk and participate in other intense physical activities to earn stickers. Patients who are unable to walk have tailored goals created by a physical/occupational therapist to earn stickers and participate in physical activity as prescribed by their therapist.
32752350|NCT04247243|Experimental|Rapid testing|Abbott ID NOW Strep A testing.
32752351|NCT04247243|Active Comparator|Reference testing|Culture-based testing.
32752352|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
32752353|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
32752354|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
32752355|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
32752356|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
32752357|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
32752358|NCT04210427|Experimental|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
32752359|NCT04189679||First line|20 patients in first line of treatment
32752360|NCT04189679||Second or third line|40 patients in second and third line of treatment
32752361|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
32752362|NCT04159415|Experimental|Treatment A|
32752363|NCT04159415|Experimental|Treatment B|
32752364|NCT04132427|Experimental|Group A: Treatment|Vancomycin, magnesium citrate, microbiota
32752365|NCT04132427|Placebo Comparator|Group B: Placebo|placebo vancomycin, real magnesium citrate (because it obviously empties the bowels) and placebo microbiota
32752366|NCT02378987||Typical developmental children|Normal children
32752367|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
32752368|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
32752369|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
32752370|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
32752371|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
32752372|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
32752373|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
32752374|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
32752375|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
32752376|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
32752377|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
32752378|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
32752379|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
32752380|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
32752381|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
32752382|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
32752383|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
32752384|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
32752385|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
32752386|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
32752387|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.~Superior pedicle mammoplasty / inverted T~Superior pedicle mammoplasty / V scar~Batwing~Inferior pedicle mammoplasty~Racquet mammoplasty/radial scar~vertical-scar mammoplasty"
33237329|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
33237330|NCT00709683||A|
32752388|NCT04688710|Active Comparator|Self-Hypnosis (HYP)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Self-Hypnosis. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
32909235|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
32909236|NCT05135858|Experimental|CPG2|6 infusions of glucarpidase
32909237|NCT05116904|Other|Children with Smith Magenis Syndrome|
32909238|NCT05106608|Experimental|Group PBM_1|Energy density 7.5 J / cm2 for group PBM_1
32745522|NCT01668147|Active Comparator|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
32745523|NCT04851639|Experimental|Proof of principle|Proof of principle of the efficacy and utility of the WATapp
32745524|NCT04833777|Active Comparator|Lidocaine|Administration of subcutaneous lidocaine as local anesthetic prior to carpal tunnel release (lidocaine intervention)
32745525|NCT04833777|Experimental|Bupivacaine|Administration of subcutaneous bupivacaine + lidocaine as local anesthetic prior to carpal tunnel release (bupivacaine intervention)
32745526|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
32745527|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
32909239|NCT05106608|Experimental|Group PBM_2|Energy density 3 J / cm2 for group PBM_2
32909240|NCT05106608|Placebo Comparator|Placebo Control|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective glasses) using the same laser device to imitate a real irradiation; however, the device will be turned off and a recording of the emission sounds will be used to give the patient the hearing sensation of the laser therapy.
32909241|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
32909242|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
32909243|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
32909244|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
32909245|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
32909246|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
32909247|NCT05070650|Experimental|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
32909248|NCT05070650|Active Comparator|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day
32909249|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
32745580|NCT04823793||Disease group : Stool specimens from participants with adenoma/colorectal cancer|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group.~Also, specimens from confirmed colorectal cancer patients are included in the disease group."
32745581|NCT04850235|Experimental|TPX neoadjuvant chemotherapy +CCRT|Patients receive neoadjuvant chemotherapy with Nab-PTX (150/175/200/225/250 mg/m2, D1) , cisplatin (75 mg/m2, D1) and capecitabine (1000 mg/m2, BID, D1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100 mg/m2) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT)
32745582|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
32745583|NCT04850001||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
32745584|NCT04850001||Healthy Control|Healthy control are free from intracranial stenosis
32745585|NCT04823715||TACE- hypofractionated radiation therapy|Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
32745586|NCT04823715||Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
32745587|NCT04823559|No Intervention|Usual practice|Usual practice
32745588|NCT04823559|Experimental|Intervention|Receives educational workshop
32745589|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
32745590|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
32745591|NCT05618379||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
32745592|NCT05618379||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
32745593|NCT04823325||Surgery patients|Otherwise healthy patients with Skeletal Class III problem
32745594|NCT04823169|Experimental|podobarometry|podobarometric measures at day7 and day 30
32745595|NCT04823013|Experimental|high power pain threshold ultrasound which the dose was kept constant group (HPPT-US 1)|Participants in HPPT-US 1 group received one session of HPPT-US treatment which the dose was kept constant. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
32745596|NCT04823013|Experimental|high power pain threshold ultrasound which the dose reduced to one half group (HPPT-US 2)|Participants in HPPT-US 2 group received one session of HPPT-US treatment which the dose reduced to one half. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
32745597|NCT04823013|Experimental|ischemic compression group|Participants in IC group received one session of ischemic compression therapy. Ischemic compression is a therapy technique used in manual therapy, where blockage of blood in an area of the body is deliberately made, so that a resurgence of local blood flow will occur upon release.
32745598|NCT04816695|Experimental|VOC analysis|VOC analysis in exhaled air in patients hospitalised for COPD exacerbation
32745599|NCT05617365|Experimental|Treatment|All subjects in the Treatment group will receive OMT a minimum 4 times and a maximum of 8 times at the physician's (JJR) discretion (Jull et al., 2002). All subjects in the Treatment group will be taught the THE. This voluntary head retraction/protrusion exercise protocol engages the RCPm muscles in eccentric and isometric contractions that should strengthen the muscles and thereby increase CSA.
32745600|NCT05617365|No Intervention|Control|All subjects assigned to the Control group will be allowed to continue to receive conservative care. It is understood that any care that they receive will be prescribed on an individual basis. A participant could therefore receive any combination of medical, physio therapeutic and psychological care. It would also be expected that some form of pain management will be a priority for participants with moderate to severe symptoms. Subjects assigned to the Control group will not receive OMT and will not be taught the THE protocol.
32745601|NCT04830579|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in Period 1 and a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32745602|NCT04830579|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in Period 1 and a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32745603|NCT04428021|Active Comparator|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
32745604|NCT04428021|Experimental|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
32745605|NCT04428021|Experimental|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
32745606|NCT04816461|Experimental|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive
32745607|NCT04816461|Experimental|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive
32745608|NCT04816461|Active Comparator|SMC alone|No roommates screening and treatment
32745609|NCT04427865|Experimental|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
32909250|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
32909251|NCT03041324|Experimental|Cohort 1 SB-913 Starting Dose 5.00E+12 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
32745610|NCT04427865|No Intervention|Control group|
32745611|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
32745612|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
32745614|NCT04822857||1|AMH > cut-off point
32745615|NCT04822857||2|AMH < cut-off point
32745616|NCT04822779|Active Comparator|Active Group|"This group will receive ultrasound therapy.~Respondents will conduct individual medical-gymnastics: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
32745617|NCT04822779|Sham Comparator|Control Group|"This group will receive sham ultrasound therapy.~Respondents will conduct the same individual medical-gymnastics, as in the active group: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
32745618|NCT04816305|Experimental|rTMSc + physiotherapy|A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
32745619|NCT04816305|Experimental|rTMSp + physiotherapy|A personalized high or low-frequency rTMS (rTMSp) will be applied to the lesioned or non-lesioned hemisphere depending on cortical biomarkers assessment guide a personalized stimulation for each patient in this group. After rTMSp, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
32745620|NCT04816305|Sham Comparator|tDCS sham + physiotherapy|The sham protocol will be delivered to each patient of this arm imitating the exat sound of the equipment and structure of the experimental arms. After rTMS sham, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
32745621|NCT04830657|Experimental|Distant reiki group|The application will be carried out by the researcher who has received level 2 reiki training. Reiki energy will be sent to the individuals who have undergone hemodialysis with the intention of healing. The Reiki practitioner is enabled to send the Reiki remotely in a quiet and lonely room. The practitioner moves to the right side of the individual, imagining as if he is next to the individual, and his aura (the energy that exists around the body) is corrected 3 times from above and from the head to the feet. The practitioner's hands are held side by side. Starting from the beginning of the application, reiki energy is sent to the 7 main chakras in an average of 3 minutes, from top to bottom. Each session is approximately 21-25 minutes. After the session, the chakra equalization process is applied to help the frequencies of the chakras to work in harmony with each other. 15 minutes in total. Balancing is done.
32745622|NCT04830657|Other|Control|Patients will receive routine treatment in accordance with the institution policy without any intervention in the control group.
32745623|NCT04830189|Experimental|shoulder slings|Patients were used shoulder sling in addition to conservative treatment.
32745624|NCT04830189|Active Comparator|forearm sling|Patients were used forearm sling in addition to conservative treatment.
32745625|NCT04427787|Experimental|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
32745626|NCT05617287|Experimental|Semaine Supplement|Participants are provided with a dietary supplement and are instructed to take 1 capsule per day. Participants are to take the supplement at the same time every day. If forgotten, they are to take it with the next meal. Participants will take a well-being assessment after each month (4 surveys total including the baseline.)
32745627|NCT04830267|Active Comparator|Camrelizumab alone|Camrelizumab 200mg IV every 2 weeks
32745628|NCT04830267|Experimental|Stereotactic body radiotherapy plus Camrelizumab|Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks
32752389|NCT04688710|Active Comparator|Mindfulness Meditation (MM)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Mindfulness Meditation. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
32752390|NCT04688710|No Intervention|Treatment as Usual (TAU)|Participants will not receive treatment from the study during the treatment phase. Participants will continue to receive their normal care outside of the study for MS and fatigue. Participants will have the option to access either the Self-Hypnosis or Mindfulness Meditation treatment after all study assessments have been completed.
32752391|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
32752392|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
32752393|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
33394460|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
32752394|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
32752395|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
32752396|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
32752397|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
32752398|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
32752399|NCT04072445|Experimental|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32752400|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
32752401|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
32898129|NCT04140526|Experimental|ONC-392 Treatment as single agent|"The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels from 0.1 mg/kg to 10 mg/kg ONC-392 as monotherapy every 21 days (Q3W). The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).~In Part C, Arms A-C, I-N monotherapy expansion cohorts will further assess the safety and efficacy of ONC-392 in different dose levels as monotherapy in pancreatic cancer, triple negative breast cancer, non small cell lung cancer with driver mutations, PD-1 resistant non small cell lung cancer, PD-1 resistant melanoma, head and neck cancer, ovarian cancer, renal cell carcinoma and other solid tumors.~Part D is a Phase II study on recurrent and/or metastatic adenoid cystic carcinoma."
32752402|NCT04600427|Experimental|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
32752403|NCT04595981|Experimental|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
32752404|NCT03985943|Placebo Comparator|Placebo|Placebo
32752405|NCT03985943|Experimental|Nemolizumab|Nemolizumab Active
32752406|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
32752407|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
32752408|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
32752409|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
32752410|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
32752411|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
32752412|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
32752413|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
32752414|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
32752415|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
32752416|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
32752417|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
32752418|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
32752419|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
32752420|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
32752421|NCT04540133|Experimental|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
32752422|NCT04540133|Active Comparator|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
32752423|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
32752424|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
32752425|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
32752426|NCT04448483|Experimental|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
32752427|NCT04448483|Experimental|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
32752428|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
32752429|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
32752430|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
32752431|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
32752432|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
32752433|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
32752434|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
32752435|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
32752436|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
32752437|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
32752438|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
32752439|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
32752440|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
32752441|NCT02377583||Diabetic children|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI"
32752442|NCT02377583||Controls|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI~Laboratory tests"
32752443|NCT02374619|Experimental|Iron supplement|Oral supplementation
32752444|NCT02374619|Placebo Comparator|Control|Oral supplementation
32752445|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
32752446|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
32752447|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
32752448|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
32752449|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
32752450|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
32752451|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
32752452|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
32752453|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
32752454|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
32752455|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
32909252|NCT03041324|Experimental|Cohort 2 SB-913 at Next Ascending Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
32909253|NCT03041324|Experimental|Cohort 3 SB-913 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
32752456|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
32752457|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
32752458|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
33237331|NCT05256888|Experimental|Time-restricted eating|Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times). Participants will also receive weekly tips to encourage a healthy lifestyle in cancer survivorship.
33394461|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
32752459|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
32752460|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
32752461|NCT03672773|Experimental|Treatment (temozolomide, talazoparib)|Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33394462|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
33394463|NCT03119974|Other|Tpo-RA discontinuation|
32752465|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
32752466|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
32752467|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
32752468|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
32752469|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
32752470|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
32752471|NCT02373917||study group|patient who in the biopsy showed lung cancer
32752472|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
32752473|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
32752474|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
32752475|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
32752476|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
32752477|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
32752478|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
32752479|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
32752480|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
32752481|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
32752482|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
32752483|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
32752484|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
32752485|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
32752486|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
32752487|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
32752488|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
32752489|NCT02371265|No Intervention|Control|Clusters continue without intervention package
32752490|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
32752491|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
32752492|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
32752493|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
32752494|NCT02371109||selftaken vs clinical taken swabs|
32752495|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
32752496|NCT03959891|Experimental|Fulvestrant + Ipatasertib|"Ipatasertib will be administered orally on a daily basis~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles."
32752497|NCT03959891|Experimental|Aromatase Inhibitor + Ipatasertib|"Ipatasertib will be administered orally on a daily basis~Aromatase inhibitors will be administered orally on a daily basis"
32752498|NCT03959891|Experimental|Fulvestrant + Ipatasertib +Palbociclib|"Ipatasertib will be administered orally on a 3 week on and 1 week off schedule~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles.~Palbociclib will be administered orally on a 3 week on and 1 week off schedule"
32752499|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
32752500|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
32752501|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
32752502|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
32752503|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
32752504|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
32752505|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
32752506|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
32752507|NCT02370719|No Intervention|Control Group|Standard of care
32752508|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
32752509|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
32752510|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
32752511|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
32752512|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
32752513|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
32752514|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
32752515|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
33237332|NCT05256888|Other|Control|Participants will receive weekly tips to encourage healthy lifestyle behaviors in cancer survivorship.
33237333|NCT04085874|Experimental|FBR group|weekly home visit and monthly group meeting for 12 weeks
32752516|NCT03785249|Experimental|Phase 2 Combination with Cetuximab|Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
32752517|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in NSCLC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
32752518|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in PDAC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)
32752519|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
32752520|NCT03773237|Active Comparator|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
32752521|NCT03773237|Active Comparator|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
32752522|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
32752523|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
32752524|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
32752525|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
32752526|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
32752527|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
32752528|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
32752529|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
32752530|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
33237334|NCT04085874|Active Comparator|non-FBR group|once nutrition counseling from standard health care services
33237335|NCT04510467||case group|RMD patients with COVID 19 infection
32752531|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
32752532|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
32752533|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
32752534|NCT02372591|Placebo Comparator|Placebo|
33237336|NCT04510467||control group|RMD patients without COVID 19 infection
33237337|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every 4 weeks~Duration: 8 weeks (3 DermaVir treatments)"
32752535|NCT02372591|Active Comparator|Hydromorphone|
32752536|NCT02372591|Experimental|Buprenorphine|
32752537|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
32752538|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
32752539|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
32752540|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
32752541|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
32752542|NCT02369861|Experimental|ST266|Eye drops
32752543|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
32752544|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
32909254|NCT05017532|Experimental|Intervention|Intervention with RC2S+ that consists of 24 biweekly sessions
33237338|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every four weeks~Duration: 8 weeks (3 Placebo treatments)"
33237339|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
33237340|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
33237341|NCT00714909||1|
33237342|NCT00918528|Active Comparator|1. Internal urethrotomy|
33237343|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
33237344|NCT00714987||1: High level PEEP|
33237345|NCT00714987||2: Low level PEEP|
32752545|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
32752546|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
32752547|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
32752548|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
32752549|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
32752550|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
32752551|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
32752552|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
32752553|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
32752554|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
32752555|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
32752556|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
32752557|NCT02372123|Other|control|lifestyle advice
32752558|NCT02372123|Active Comparator|intervention|connective tissue manipulation
32752559|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
32752560|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
33237346|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
33237347|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
33237348|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
32752561|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
32752562|NCT03603509|Active Comparator|Fluad vaccine|Subjects receive a single dose of the Fluad influenza vaccine.
32752563|NCT03603509|Active Comparator|Fluzone vaccine|Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
32752564|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
32752565|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
32752566|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
32752567|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
32752568|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
32752569|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
32752570|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
32752571|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
32752572|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
32752573|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
32752574|NCT02365415|No Intervention|Control|No treatment.
32752575|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
32752576|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
32752577|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
32752578|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
32752579|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
32752580|NCT02368769||Before tele-expertise|Usual (on site) frozen section
32752581|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
32901761|NCT05020470|Active Comparator|Usual Care Control (UC)|"Participants will receive usual care only for their pain; after enrolled, patients will receive weekly telecommunication to control for attention and time. The content of the phone/video call will focus on the pain problem they have and the investigators will provide additional information published by the National Center for Complementary and Integrative Health Chronic Pain: In-Depth (https://www.nccih.nih.gov/health/chronic-pain-in-depth) which the investigators used in the R01 study for participants enrolled in the control group"
32752582|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
32752583|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
32752584|NCT02365103|Other|Test meal I (given with water)|Test meal with water
32752585|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
32752586|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
32752587|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
32752588|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
32752589|NCT02365181|Active Comparator|ISB|interscalene block with catheter
32752590|NCT05653895|Active Comparator|Arm 1|Resveratrol (2 gm daily) 50 patients with PCOS will receive Resveratrol 1000mg BD daily
32752591|NCT05653895|Active Comparator|Arm 2|Metformin (1000mg daily),Resveratrol(2 gm daily) 50 patients with PCOS will receive Metformin 500mg,Resveratrol 1000 mg BD daily
32752592|NCT05653895|Active Comparator|Arm 3|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg ,COQ10 100mg BD daily respectively
32752593|NCT05653895|Active Comparator|Arm 4|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily),Metformin (1000mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg,COQ10 100mg BD daily respectively
32752594|NCT03589859||Normal Volunteers|Testing motor learning
32752595|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
32752596|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
32752597|NCT03589703|Active Comparator|T-APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
32752598|NCT03589703|Active Comparator|NT-APA|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.~These points are chosen for the non-target ear points of APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
32752599|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
32752600|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
32752601|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.~Step 5: 3 months follow up."
32752602|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
32752603|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
32752604|NCT02368613|Placebo Comparator|placebo group|Placebo
32752605|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
32752606|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
32752607|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
32752608|NCT02364479|Experimental|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
33237349|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
33237350|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
33237351|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
32752609|NCT02364479|Experimental|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
32752610|NCT02364479|Placebo Comparator|Placebo|Placebo, Subcutaneous injection per week
32752611|NCT05653817|Experimental|Advanced or metastatic cholangiocarcinoma|A multicenter clinical study of carralizumab combined with albumin paclitaxel and apatinib mesylate in the second-line treatment of advanced or metastatic cholangiocarcinoma.Albumin-bound paclitaxel 125 mg/m2 d1,8; Carrilizumab 200mg Q3W d1; Apatinib mesylate tablet treatment: 250mg orally, once a day, continuous administration. Treatment continued or was evaluated every 2 cycles until disease progression or toxic side effects of patient intolerance to the treatment regimen.
32752612|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
32752613|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
32752614|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
32752615|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
32752616|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
32752617|NCT02052310|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [≤70 kilograms (kg)] and high weight [>70 to 160 kg] participants will receive 70 and 100 milligrams [mg] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).
32752618|NCT02052310|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).
32752619|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
32752620|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
32752621|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
32752622|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
32752623|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
32752624|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
32752625|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
32752626|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
32752627|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
32752628|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
32752629|NCT02051764|Experimental|Follow-up Flortaucipir PET Scan|
32752630|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
32752631|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
32752632|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
32752633|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
32752634|NCT02051296|Placebo Comparator|Placebo|PLacebo
32752635|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
32752636|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
32752637|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
32752638|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
32752639|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
32752640|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
32752641|NCT04711954||ATHENA|Cohort of people living with HIV in the Netherlands
32752642|NCT04711954||LUKCY|Cohort of people living with HIV in the Lviv area, Ukraine
32752643|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
32752644|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
32752645|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
32752646|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
32752647|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
32752648|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
32752649|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
32752650|NCT04727944|Experimental|MEG and EEG recordings on Healthy volunteers|"All subjects can participate in experiment 1 and/or 2. All analyses are intra-subject (no analyses are between-subject).~Experiment 1 will test the functional role of beta bursts in naturalistic action preparation, using a combined anatomical MEG-MRI approach which will be conducted in 2 sessions.~Experiment 2 will study the relationship between beta bursts and naturalistic action preparation using EEG."
32752651|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
32752652|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
32752653|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
32752654|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
32752655|NCT02049814|Experimental|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
32752656|NCT02049814|Active Comparator|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
32752657|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
32752658|NCT04059809|No Intervention|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
32752659|NCT04059809|Experimental|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
32752660|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
32752661|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
32752662|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
32752663|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
32752664|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
32752665|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
32752666|NCT03344159|Experimental|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
32752667|NCT03344159|Placebo Comparator|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
32752668|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
32752669|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
32752670|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
32752671|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
32752672|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
32752673|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
32752674|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
32752675|NCT02363231||patients under mechanical ventilation|
32752676|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
32752677|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
32752678|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
32752679|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
32752680|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
32752681|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
32901762|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
32745629|NCT04816383|Experimental|Experimental Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the Apple breastfeeding application in the office once enrolled in the study between 32 to 36 weeks gestation. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
32745630|NCT04816383|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
32745631|NCT04815915|Experimental|Study Group|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
32745632|NCT04816071|Experimental|EAA - non-vaccinated|18 g/day
32745633|NCT04816071|Placebo Comparator|Placebo - non-vaccinated|18 g/day
32745634|NCT04816071|Experimental|EAA - vaccinated|18 g/day
32745635|NCT04816071|Placebo Comparator|Placebo - vaccinated|18 g/day
32745636|NCT04822623||MS|
32745637|NCT04822623||NMOSD|
32745638|NCT04822623||Control|
32745639|NCT04830111|Experimental|heart rate variability biofeedback training group|The goal of heart rate variability biofeedback is to increase heart rate variability through paced breathing exercises, which have shown to be effective in reducing stress and anxiety in general adult populations.
32745640|NCT04830111|No Intervention|Care as usual|In this condition, all of this group take care by hospital routine and the questionnaires were completed over a period with similar intervals.
32745641|NCT03987399|Experimental|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
32745642|NCT04822311|Experimental|Investigate the effects of an exercise intervention on retired APF players|20 retired APF players (≥ 18 years of age), who suffer from chronic pain, will be enrolled.
32745643|NCT04829253|Experimental|b-DBT (Brief Dialectical Behavioral Therapy)|3 months of and intensive modified DBT intervention.
32745644|NCT04829253|Active Comparator|s-DBT (standard Brief Dialectical Behavioral Therapy)|6 months of a standard DBT intervention (this is a shorter version of the original 12-month DBT, but includes all four active components delivered over 6 months)
32745645|NCT04822233|Experimental|Hall Technique (HT)|
32745646|NCT04822233|Experimental|Modified Hall Technique (MHT)|
32745647|NCT04822233|Active Comparator|Conventional Technique (CT)|
32745648|NCT04822077|Experimental|Proton radiotherapy|"Proton radiotherapy with RBE doses:~Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
32745649|NCT04821843|Experimental|(Neoadjuvant chemotherapy) nCT|This arm received chemotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
32745650|NCT04821843|Placebo Comparator|(Neoadjuvant Chemoradiation) nCRT|This arm received chemoradiotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
32745651|NCT04815837|Experimental|Intervention|"Participants received the following interventions:~Viewing a video promoting Human Papillomavirus (HPV) vaccination~Receiving discount coupons~Visiting the project webpage~Receiving follow-up reminders"
32745652|NCT04829487|Experimental|Vitamin D|Vitamin D 50,000 IU orally weekly for 8 weeks
32745653|NCT04829487|Placebo Comparator|Placebo|Placebo capsules orally weekly for 8 weeks
32745654|NCT04815603|Experimental|BGE-117|BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
32745655|NCT04815603|Placebo Comparator|Placebo|Placebo Capsules to be taken by mouth once a day for 84 days.
32745656|NCT04829565|Experimental|botulinum toxin|50 IU of botulinum toxin
32745657|NCT04829565|Placebo Comparator|placebo|50 IU of placebo
32745658|NCT04815447||CCS group|Patients under 25 were recruited in the pediatric CPET laboratory of Montpellier University Hospital after a regular paediatric cardiology outpatient visit.
32745659|NCT04815447||Control|The control group consisted in children referred for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certificate. These children were classified in the control group only after a completely normal check-up, including physical examination, electrocardiogram, echocardiography, and spirometry.
32752682|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
32752683|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
32752684|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
33237352|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
33237353|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
32752685|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
32752686|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
32752687|NCT03307343|Experimental|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
32752688|NCT03307343|No Intervention|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
32752689|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
32752690|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
32752691|NCT03097757|Active Comparator|Fracture reduction without ultrasound|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray. Closed reduction of a fractured bone. Closed reduction is a procedure to set (reduce) a broken bone without surgery. This allows the bone to grow back together. It works best when it is done as soon as possible after the bone breaks.
32752692|NCT03097757|Experimental|Fracture reduction with ultrasound|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
32752693|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
32752694|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
32752695|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32752696|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
32752697|NCT04417114|Experimental|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
32752698|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
32752699|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
32752700|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
32752701|NCT04417504|Experimental|MobFood breakfast kit|
32752702|NCT04417504|Experimental|Control isocaloric breakfast|
32752703|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
32752704|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
32752705|NCT04711486|Experimental|Contraloid acetate|"300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.~Other Name: PRI-002"
32752706|NCT04711486|Placebo Comparator|Placebo|300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.
32752707|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
33237354|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
32752708|NCT04711330||Patients treated with maintenance immunotherapy after concurrent chemo/RT|"Observation of response and response. The microbiome of the patients throat and stool will be analyzed before the standard treatment with IO is initiated after completion of the chemoradiation therapy.~No intervention is planned."
32752709|NCT01514669||No treatment|No Tx, this is observational
32752710|NCT04686292||Suspected infection|All patients admitted to the emergency department with suspected infections assessed by the receiving physician
32752711|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
32752712|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
32752713|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
32752714|NCT04479371|Experimental|Liposomal bupivacaine|a penile block administered with novel liposomal bupivacaine during hypospadias repair
32752715|NCT04479371|Active Comparator|Standard Penile Block|Standard weight based bupivacaine penile block during hypospadias repair
32752716|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
32752717|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
32752718|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
32752719|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
32752720|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
32752721|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
32752722|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
32752723|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
32752724|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
32752725|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
32752726|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
32752727|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
32752728|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
32752729|NCT02079532|Experimental|MabThera (Rituximab)|
32752730|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
32752731|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
32752732|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
32752733|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
32752734|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.~This training intervention will be applied to the facilities presenting half the patient sample size."
32752735|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
32752736|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
32752737|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
32752738|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
32752739|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
32752740|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
32752741|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
32752742|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
32752743|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
32752744|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
32752745|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
32752746|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
33237355|NCT00715065||1|People who faint at sight of blood
32752747|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
32752748|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
32752749|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
32752750|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
32752751|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
32752752|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
32752753|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
32752754|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
32752755|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
32752756|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
32752757|NCT02362295||census|qualitative interview
32752758|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: Tiragolumab|Cohorts of at least 3 participants each will be treated with escalating doses of tiragolumab.
32752759|NCT02794571|Experimental|Phase Ia Dose-Expansion Stage: Tiragolumab|Participants will be treated with tiragolumab at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
32752760|NCT02794571|Experimental|Phase Ib Q3W Dose-Escalation Stage: Tiragolumab+Atezolizumab|A minimum of 3 participants will be treated for each dose level of tiragolumab in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
33237356|NCT00713700|Experimental|Device|
33237357|NCT05673057|Experimental|Dose escalation|
33237358|NCT05673057|Experimental|Dose expansion|
32752761|NCT02794571|Experimental|Phase Ib Q3W Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with tiragolumab at or below the MTD or MAD in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
32752762|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and tiragolumab intravenous (IV) infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab in combination with pemetrexed on Day 1 of each 21-day cycle.
32752763|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle (participants enrolled under protocol version 4) or Day 1 of each 28-day cycle (participants enrolled under protocol version 5).
33237359|NCT03949153|Experimental|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
32752764|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 28-day cycle.
32752765|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort D|In Cohort D, participants will receive atezolizumab and tiragolumab on Day 1 and capecitabine on Day 1-14 of each 21-day cycle.
32752766|NCT02794571|Experimental|Phase Ib Q4W Sequential Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of tiragolumab and atezolizumab with tiragolumab being administered prior to atezolizumab.
32752767|NCT02794571|Experimental|Phase Ib Q4W Coinfusion Expansion Cohort Tiragolumab+Atezolizumab|Participants will be treated Q4W with fixed doses of tiragolumab and atezolizumab mixed and administered in one IV bag.
32752768|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC1|In Cohort NC1, participants will receive atezolizumab and tiragolumab in combination with bevacizumab on Day 1 of each 21-day cycle.
32752769|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC2|In Cohort NC2, participants will receive tiragolumab in combination with pembrolizumab on Day 1 of each 21-day cycle.
32752770|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
32752771|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
32909255|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32752772|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
32752773|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
32752774|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
32752775|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
32752776|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
32752777|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
32752778|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
32752779|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
32752780|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
32752781|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
32752782|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
32909256|NCT03005444|Experimental|Anticoagulation|Rivaroxaban：10mg/d for 2 years
32909257|NCT03005444|No Intervention|Non-anticoagulated|No anticoagulants will be used.
33237360|NCT00715221||1|Normal Weight
32752783|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
32752784|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
32752785|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
32752786|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.~Subjects: 16 healthy volunteers."
32752787|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
32752788|NCT02361827||A, Vitamin D deficient|Vitamin D level on the day of HCG administraion < 20 ng/mL Embryo transfer after oocyte retrieval.
32752789|NCT02361827||B, Vitamin D insufficient|Vitamin D level on the day of HCG administraion 20-29.9 ng/mL Embryo transfer after oocyte retrieval.
32752790|NCT02361827||C, Vitamin D replete|Vitamin D level on the day of HCG administraion > 30 ng/mL Embryo transfer after oocyte retrieval.
32752791|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
32752792|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
32752793|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
32752794|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
32752795|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
32752796|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
32752797|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
32752798|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
32752799|NCT04478825|Experimental|BBT-401-1S|BBT-401-1S, rectal administration
32752800|NCT04479059|Experimental|İntracavitary fluid flushing|
32752801|NCT04479059|No Intervention|Control group|
32752802|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
32752803|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
32752804|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
32752805|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
32752806|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
32752807|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
32752808|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
32752809|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
32752810|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
32752811|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
32752812|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
32752813|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
32752814|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
32752815|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
33070933|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
33237361|NCT00715221||2|Obese without diabetes
33237362|NCT00715221||3|Obese with diabetes
33237363|NCT05254002|Experimental|Finerenone and empagliflozin|Participants will take finerenone and empagliflozin for up to 180 days.
33237364|NCT05254002|Experimental|Finerenone and empagliflozin placebo|Participants will take finerenone and placebo to empagliflozin for up to 180 days.
33237365|NCT05254002|Experimental|Empagliflozin and finerenone placebo|Participants will take empagliflozin and placebo to finerenone for up to 180 days.
33237366|NCT00709917||A|
33237367|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
33237368|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
33237369|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
32752816|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
32752817|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
32752818|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
32752819|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
32752820|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
32752821|NCT04372433|Experimental|Dose Escalation of IO-202|Dose cohorts treated with intravenous (IV) IO-202 monotherapy in ascending doses.
32752822|NCT04372433|Experimental|Dose Escalation of IO-202 Plus Azacitidine|AZA Dose cohorts treated with intravenous (IV) IO-202 in ascending doses plus Azacitidine (IV or SC) on days 1-7 of each 28-day cycle.
32752823|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine AML|To enroll high LILRB4 expression monocytic AML patients refractory to or relapsed after available therapies known to be active in AML.
32752824|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine CMML|To enroll hypomethylating-agent naive CMML patients.
32752825|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)|To enroll newly diagnosed high LILRB4 expression AML patients who are unfit for intensive induction chemotherapy.
32752826|NCT02361203|No Intervention|No Exercise|
32752827|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
32752828|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
32752829|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
32752830|NCT02361437|Placebo Comparator|placebo|placebo
32752831|NCT02361437|Experimental|Vasculera|diosmin
32752832|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
32752833|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
32752834|NCT04349735|Experimental|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
32752835|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
32752836|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.~Half of the children will be assigned to NF training, the other half to CCT."
32752837|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).~Half of the children will be assigned to NF training, the other half to CCT."
32752838|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
33237370|NCT00468169|Experimental|A: Cetuximab+FHX|Cetuximab [250mg/m2 (day 1, weekly x10)] + FHX (5-FU [CI: 600mg/m2/day; days 0-5 (120h total) every other week x5], Hydroxyurea [500 mg PO BID, days 0-5 (=11 doses), every other week x5] and twice-daily radiation [150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)]). Total duration is 10 weeks.
32752839|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
32752840|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
32752841|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
32752842|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
32752843|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
32752844|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
32752845|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
32752846|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
33237371|NCT00468169|Experimental|B: Cetuximab + PX|Cetuximab [250 mg/m2 (day 1, weekly x7)] + PX (Cisplatin [100mg/m2 (week 1 & 4 on day 1 (or 2))], Accelerated fraction radiotherapy with concomitant boost [AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)]). Total duration: 7 weeks.
33237372|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
33237373|NCT04015830|Experimental|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
33237374|NCT00918606|Experimental|LIPO-102|
32752847|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
32752848|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
32752849|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
32752850|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
32752851|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
32752852|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
32752853|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
32752854|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
32752855|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
32752856|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
32752857|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
32752858|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
32752859|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
32752860|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
32752861|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
32752862|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
32752863|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
32752864|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
32752865|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
32752866|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
32752867|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
32752868|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
32752869|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
32752870|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
32752871|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
32752872|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
32752873|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
32752874|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
32752875|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
32752876|NCT02357927|Placebo Comparator|control|simple general telephone call
32752877|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
33237375|NCT05685108|Active Comparator|Group 1|"In Subgroup 1, individuals will receive pulsed ultrasound with a mechanical index of 0.6 and 1.4 delivered to the splenic hilum.~In Subgroup 2, individuals will receive pulsed ultrasound with a mechanical index of 1.0 and 1.8 delivered to the splenic hilum. The two doses will be administered in separate visits with min. 14 days between each stimulation.~In both Subgroups, the two doses will be administered in separate visits with min. 14 days between each stimulation."
32752878|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
32752879|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
32752880|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
32752881|NCT02360579|Experimental|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
32752882|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
32752883|NCT02360579|Experimental|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
32752884|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
32752885|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
32909258|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
33070934|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
33070935|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
33070936|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
33070937|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
32909259|NCT04937192||Kidney stone former|
33070938|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
33070939|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
33070940|NCT04690036|Experimental|one group|All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.
32752886|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
32909260|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
32909261|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
32909262|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
32909263|NCT04912050||Tablo Hemodialysis System|Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy > 12 hours on the Tablo Hemodialysis System
33394464|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
32752887|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
32752888|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
32752889|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
33237376|NCT05685108|Active Comparator|Group 2|Individuals will receive pulsed ultrasound with a mechanical index of 1.4 delivered to the splenic hilum and the cervical vagus nerve. The two doses will be administered in separate visits with min. 14 days between each stimulation.
32752890|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
33237377|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
33237378|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
33237379|NCT05685030|Placebo Comparator|Placebo|product vehicle (sunflower oil)
32752891|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
32752892|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
33237380|NCT05685030|Experimental|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ daY.
33237381|NCT05685030|Experimental|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Blend: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day.
33237382|NCT05334576|Other|Single Arm: Crizanlizumab|Single-arm: Patients with sickle cell disease and increased risk of silent cerebral infarcts
33237383|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
32901763|NCT05072808|Active Comparator|Intervention Group|ED Providers randomized to the Intervention Group will be able to view the results of the parent-completed questionnaire, the Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED), and outpatient referral recommendations aligned with asthma severity.
32909264|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
33237384|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
33237385|NCT05251974||Compliant with beta blocker therapy|Patients observed to be compliant with beta blocker therapy by blood assay
33237386|NCT05251974||Non-compliant with beta blocker therapy|Patients observed to be non-compliant with beta blocker therapy by blood assay
33237387|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
33237388|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
33237389|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
33237390|NCT05325684|Experimental|PD-L1 rechallenge|
33237391|NCT05241834|Experimental|Phase 1A: LOXO-260 Dose Escalation|LOXO-260 administered orally
33237392|NCT05241834|Experimental|Phase 1B: LOXO-260 Dose Expansion|LOXO-260 administered orally
33237393|NCT00435487|Experimental|A|
33237394|NCT00435487|Active Comparator|B|
33237395|NCT00918918|Experimental|Treatment B|Vodka + orange juice
33237396|NCT00918918|Placebo Comparator|Treatment A|Orange juice
33237397|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
33237398|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
33237399|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
33237400|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
33394465|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
32909265|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
32909266|NCT05458128|Other|pitolisant|"Open-label:~Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening."
33070941|NCT02931214|Experimental|GMI-1359|Dose escalation
33070942|NCT02931214|Experimental|Placebo|Dose escalation
32901764|NCT05072808|No Intervention|Control Group|ED providers randomized to the Control Group will neither receive the results of the parent-completed PACCI-ED or specific recommendations for outpatient referrals. Patients randomized to the control group will receive usual care.
32901765|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
32901766|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
33070943|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
33394466|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
33394467|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
32752893|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
32752894|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
32752895|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
32752896|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
32752897|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
32752898|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
32752899|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
32752900|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
32752901|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
32752902|NCT02359721|No Intervention|control|scaling and root planing
32752903|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
32752904|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
32752905|NCT04299191|Experimental|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant LAM561-related toxicities."
32752906|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
32752907|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
32752908|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
32752909|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
32752910|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
32752911|NCT03112811|Experimental|Intubated infant|
32752912|NCT03112811|Experimental|Extubated infant|
32752913|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
32752914|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
33394468|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
33394469|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
32752915|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
32752916|NCT02352935|No Intervention|Control|The patients without any treatment
32752917|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
32752918|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
32752919|NCT04478903||primary caregiver of patients aged 70 and over|
32752920|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
32752921|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
32752922|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
32752923|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
32752924|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
32752925|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
32752926|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
32752927|NCT02357069|Experimental|LBEC0101|Etanercept
32752928|NCT02357069|Active Comparator|Enbrel|Etanercept
32752929|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
32752930|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
32752931|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
32752932|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
33394470|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
32752933|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
32752934|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
32752935|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
32752936|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
32752937|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
32752938|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
32752939|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
32901767|NCT05072652|Experimental|Immobilization|Participants in the immobilization groups will undergo one week of unilateral knee joint immobilization of the left leg.
33394471|NCT04485520|Experimental|Carica Papaya extract|Carica Papaya at 3%
32901768|NCT05072652|No Intervention|Control|The control group will not undergo any intervention.
32901769|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
32752940|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
32752941|NCT04438655|Experimental|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.~Systemic antibiotic drugs:~Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
32752942|NCT04438655|Sham Comparator|Only parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
32752943|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
32752944|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
32752945|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
32752946|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
32752947|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
32752948|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
32752949|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
32752950|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
32752951|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
32752952|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
32752953|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
32752954|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
32752955|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
32752956|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
32752957|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
32752958|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
32752959|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
32901381|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
32752960|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
32752961|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
32752962|NCT03153215|Active Comparator|Control group|women with severe IUGR
33237401|NCT05234970|Active Comparator|Active Comparator: App 1 Study group (Wysa)|"Wysa App~Wysa provides free, 24/7, emotional support to users through an app-based AI chatbot system. All Wysa chats are anonymous. The AI-based bot responds to the users' emotions and uses CBT, DBT, meditation, breathing, yoga, motivational interviewing, and micro-actions to help the user manage their emotions and encourage mental well-being. In addition, there are over a hundred AI-guided self-care exercises which are backed by science and handpicked by therapists."
32752963|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
33237402|NCT05234970|Placebo Comparator|Placebo Comparator: App 2 Study Group (Harvard College Mobile)|"Harvard College Mobile App~Harvard College Mobile is an informational app developed by the Harvard University, and is designed to help students navigate resources on campus including professional and peer support groups, but does not allow direct messaging through the app. All Harvard students have full access to the contents of this application."
33237403|NCT05229900|Experimental|SGN-ALPV|SGN-ALPV monotherapy
33237404|NCT05328258|Experimental|Arm A: Triptorelin|"Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment, OR 3.75 mg for subjects during one-month of gonadotoxic treatment"
32752964|NCT02355431|Experimental|Itacitinib plus erlotinib|
33237405|NCT05328258|Placebo Comparator|Arm B: Placebo|"Placebo, 0.9% sodium chloride, given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind."
33237406|NCT05327946|Experimental|Monotherapy dose escalation|
33237407|NCT05327946|Experimental|Combination therapy dose escalation|
32752965|NCT02355431|Active Comparator|Placebo plus erlotinib|
32752966|NCT02355353|Experimental|Imaging arm|
32752967|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
32752968|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
32752969|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
32752970|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
32752971|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
33237408|NCT05319288|Active Comparator|Distal acupoints only group|The DPOG (n=51) will receive acupuncture of distal acupoints only(SI3, EX-UE7) for ALBP.
33237409|NCT05319288|Active Comparator|Local acupoints mainly combined with distal acupoints group|LPMG (n=51) will receive acupuncture of local acupoints mainly(BL23, BL25, BL32) combined with distal points(BL40) for ALBP.
33237410|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
33237411|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
33237412|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
32752972|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
32752973|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
33237413|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).~Doppler on fetal middle cerebral artery"
33237414|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.~Doppler on fetal middle cerebral artery"
33394472|NCT04485520|Active Comparator|Chlorhexidine|0.12% chlorhexidine mouthwash formulation (commercially available)
33394473|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
32752974|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
32752975|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
33394474|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
32752976|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
32752977|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
32752978|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
32752979|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
32752980|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
32752981|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
33394475|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
32752982|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
32752983|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
32752984|NCT02355119|Experimental|FOLFOXIRI|
32752985|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
32752986|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
32752987|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
32752988|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
32752989|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
32752990|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
32752991|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
32752992|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
32752993|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
32752994|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
32752995|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
32752996|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
32752997|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
32752998|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
32752999|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
32753000|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
32753001|NCT02351219|Experimental|FOLFOXIRI|
32753002|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
32753003|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.~Assessment of antral follicle count. IVF treatment."
32753004|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
32753005|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
32753006|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
32753007|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
32753008|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
32753009|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
32753010|NCT02354729|No Intervention|Control|Participants received text messages.
33394476|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
32753011|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
33394477|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
32753012|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
32753013|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
33394478|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
33394479|NCT02452450|Experimental|Ibuprofen lysine|
32753014|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
32753015|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
32753016|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
32753017|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
32753018|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
32753019|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
32753020|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
32753021|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
32753022|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
32753023|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
32753024|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
33394480|NCT02452450|Experimental|Ibuprofen sodium|
33394481|NCT02452450|Experimental|Ibuprofen liquid capsules|
32753025|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
33394482|NCT02452450|Active Comparator|Ibuprofen acid|
32753026|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
32753027|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
32753028|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
32753029|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
32753030|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
32753031|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
32753032|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
32753033|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
33394483|NCT02452450|Active Comparator|Paracetamol|
33394484|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
32753034|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
32753035|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
32753036|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
32753037|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
32753038|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
32753039|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
32901770|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
32901771|NCT05138796|Experimental|TP-05 SAD|Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order
33394485|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
32901772|NCT05138796|Experimental|Placebo SAD|Single dose of Placebo
33394486|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
33394487|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
33394488|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
33394489|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
33394490|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
33394491|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
33394492|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
33394493|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
33394494|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
33394495|NCT00594334|Experimental|E, I|
33394496|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
33394497|NCT00238420|Experimental|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
32901773|NCT05138796|Experimental|TP-05 MAD|Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order
33394498|NCT00238420|Experimental|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
33394499|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
33394500|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
33394501|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
32753040|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
32753041|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
33394502|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
33394503|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
33394504|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
33394505|NCT03231280|Experimental|SB-061|SB-061
32753042|NCT02353559|No Intervention|Usual Care|Usual care
33394506|NCT03231280|Placebo Comparator|Placebo|Placebo
33394507|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
33394508|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
32753043|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
32753044|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
32753045|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
32753046|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
32753047|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
32753048|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
32753049|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
32753050|NCT02349737||Electromagnetic Interference|
32901774|NCT05138796|Experimental|Placebo MAD|Four doses of Placebo
32753051|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
32753052|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
32753053|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
32753054|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
32753055|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
33237415|NCT05312736||Vision Cohort 1|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter 10 degrees or more in every meridian of the central field~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
33394509|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
32753056|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
33394510|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
33394511|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
33241688|NCT05208164|Experimental|Mindfulness Meditation Classes|"8 mindfulness classes: Participants will engage in 8 two-hour mind and body practice classes over 8 weeks in-person or online (during the pandemic). You will receive compensation for your participation and a yoga mat. You will need to wear comfortable clothing. These sessions can be done sitting in chair, sitting on the floor, or standing.~Text messaging., in between classes you will receive text messages to encourage mind and body practices at home. Text messaging may appear as the following:~1.Do you have time to meditate right now? Yes or No. 2.Did you practice your mindfulness today? Yes or no. 3.Remember to wind down this evening and do not drink any caffeinated beverages 4 hours before bed."
32753057|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
32753058|NCT02350049||Investigational|Cementless Medial Partial Knee
32753059|NCT02350049||Control|Cemented Medial Partial Knee
32753060|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
32753061|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
32753062|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
32753063|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
32753064|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
32753065|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
32753066|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
32753067|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
32753068|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
32753069|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
32753070|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
32753071|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
32753072|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
32753073|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
32753074|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
32753075|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
32753076|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
32753077|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
32753078|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
32753079|NCT03148925|Experimental|SELA-070|
32753080|NCT03148925|Placebo Comparator|Saline|
32753081|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
32753082|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
32753083|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
32753084|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
32753085|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
32753086|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
32753087|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
32753088|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
32753089|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
32753090|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
32753091|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
32753092|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
32753093|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
32753094|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
32753095|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
32753096|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
33241689|NCT05208164|No Intervention|Usual Care|
32753097|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
32753098|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
32753099|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
32901775|NCT05138796|Experimental|TP-05 Fasted|Single dose of TP-05 (lotilaner oral capsules) in a fasted state
32901776|NCT05138796|Experimental|Placebo Fasted|Single dose of placebo in a fasted state
33241690|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
33241691|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
33241692|NCT04077008|Other|Bilaterally Obstructed Kidneys by benign cause|
33241693|NCT04077008|Other|Bilaterally Obstructed Kidneys by malignant cause|
33241694|NCT05325554|Experimental|Research Group|multi-mode rehabilitation
33241695|NCT05325554|No Intervention|control group|control group
32753100|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
32753101|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
32753102|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
33070944|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
32753103|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
32753104|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
32753105|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
32753106|NCT03147599|Placebo Comparator|Placebo|Placebo
32753107|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
32753108|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
32753109|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
32753110|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
32753111|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
32753112|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
32753113|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
32753114|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
32753115|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
32753116|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
32753117|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
32753118|NCT02348411|Experimental|ExAblate Treatment group|
33070945|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.~Subjects will take 2 capsules three times a day, 30 mins before meals."
32753119|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
32753120|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
32753121|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
32753122|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
32753123|NCT02348879|Placebo Comparator|Placebo|No active drug
32753124|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
32753125|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
32753126|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
32753127|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
32753128|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
32753129|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
32753130|NCT03146975|No Intervention|Healthy|
32753131|NCT03146975|Experimental|Periodontitis without diabetes|
32753132|NCT03146975|Experimental|Periodontitis compensated diabetes|
32753133|NCT03146975|Experimental|Periodontitis decompensated diabetes|
32753134|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
32753135|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
32753136|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
33237416|NCT05312736||Vision Cohort 2|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 - 20/400) OR visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter less than 10 degrees in any meridian of the central field.~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
33241696|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
33241697|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
33241698|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
33241699|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
33241700|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
33394512|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
33394513|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
32753137|NCT04183205|Placebo Comparator|Placebo only arm|For individuals who are placebo responders during the 2 week placebo lead in phase, they will remain on placebo for the duration of the study (i.e., the 12 weeks where the placebo non-responders are taking sertraline).
33394514|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
33394515|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
33394516|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
33394517|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
32901382|NCT00471848|Experimental|Treatment Arm|Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
33394518|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
33394519|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
33394520|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
33394521|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
33394522|NCT03230812|Experimental|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
32901777|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 1|Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
32901778|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 2|Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
32901779|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 3|Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
32901780|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 1|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
32901781|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 2|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
33394523|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
33394524|NCT04936763|Experimental|Janesse 20|
32909267|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
33394525|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
33394526|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
33394527|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~working memory strategies~executive function program~divided attention program~environmental changes~identification of problematic cognitive-communication situations"
33394528|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
33394529|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
32909268|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
32909269|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
32901782|NCT05137236|Active Comparator|Part A: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1.
32901783|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 1|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
32901784|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 2|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
32901785|NCT05622110|Experimental|One abdominal side|Arm randomized for adhesive glue closure
32753138|NCT04183205|Active Comparator|Sertraline arm|After the 2-week placebo lead-in phase, placebo-non responders will receive sertraline 25 mg daily for 2 weeks. Thereafter, sertraline will be increased flexibly by 25 to 50 mg per day (at a rate no higher than 50 mg per week) to achieve a total daily dose of 50 to 200 mg, based on clinical response and tolerability, with a maximum dose of 200 mg/d. Subjects unable to tolerate higher doses may be dropped back to the previous dose and remain at that dose for the remainder of the study.
32753139|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
32753140|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
32753141|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
32753142|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
32753143|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
32753144|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
32753145|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
32909270|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
32753146|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
32753147|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
32909271|NCT04934306||Patients without cleft|Patients without developmental speech disorder (including articulation disorder) or hearing impairment
32909272|NCT04934306||Patients with a cleft|Patients with a hard and/or soft palate cleft and for whom the perceptual speech-language pathology evaluation revealed a velopharyngeal insufficiency
33394530|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
33070946|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
32753148|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
32753149|NCT02348333|Active Comparator|FYU-981|
32753150|NCT02348333|Placebo Comparator|Placebo|
32753151|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
32753152|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
32753153|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
32753154|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
32753155|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
32753156|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
32753157|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
32753158|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
32753159|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
32753160|NCT05255627|Experimental|Control Group|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
32753161|NCT05255627|Experimental|Mobile application group (Experimental Group)|"A mobile application program was installed on their phones for the experimental group students to benefit from. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
32753162|NCT05255549|Experimental|Group I|
33070947|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
32753163|NCT05255549|Sham Comparator|Group II|
32753164|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
32753165|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
32753166|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
32753167|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
32753168|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
32753169|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
32753170|NCT02343341|Other|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
32753171|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
32753172|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
32753173|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
32753174|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
32753175|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
32753176|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
32753177|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
32753178|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
32753179|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
32753180|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
32753181|NCT02342951|Other|LCI|Measure of lung clearance index
33070948|NCT00147914|Active Comparator|1|cefdinir
32753182|NCT02342717|Experimental|Reference|single dose BI 425809
32753183|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
32901786|NCT05622110|Experimental|Second abdominal side|Arm randomized for subcuticular suture closure
32901787|NCT04351321|Experimental|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
32901788|NCT04351321|Active Comparator|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
33070949|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
32753184|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
32753185|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
32753186|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
32753187|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
32753188|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
32753189|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
32753190|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
33394531|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
33394532|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
32753191|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
32753192|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
32753193|NCT04478435|Active Comparator|1 Hour post intervention|Ultrasound assessment done 1 hour after ingestion of glucose loaded drink
32753194|NCT04478435|Placebo Comparator|2 hours post intervention|Ultrasound assessment done 2 hour after ingestion of glucose loaded drink
32753195|NCT04478357|Other|Treatment A|4 mg fesoterodine ER tablet manufactured at Zwickau.
32753196|NCT04478357|Other|Treatment B|4 mg fesoterodine ER tablet manufactured at Freiburg
32753197|NCT04478357|Other|Treatment C|8 mg fesoterodine ER tablet manufactured at Zwickau
32753198|NCT04478357|Other|Treatment D|8 mg fesoterodine ER tablet manufactured at Freiburg.
32753199|NCT04478513|Experimental|Smokers|Pre-specified group of participants.
32753200|NCT04478513|Experimental|Non-smokers|Pre-specified group of participants.
32753201|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
33394533|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
32753202|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
32753203|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
32753204|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
32753205|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
32753206|NCT04478591||Patients with multiple sclerosis using ocrelizumab.|Patients with multiple sclerosis using ocrelizumab for a minimum of one year.
33394534|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
32753207|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
32753208|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
32753209|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
32753210|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
32753211|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
32753212|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
33070950|NCT04461691|Other|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
32753213|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
32753214|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
33394535|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
32909273|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
33070951|NCT04461691|Other|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
33394536|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
33394537|NCT04486235|No Intervention|Control|No materials, usual care
33394538|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
32753215|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
32753216|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
33394539|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
33394540|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
32753217|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
32753218|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
32753219|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
32753220|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
32753221|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
32753222|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
32901383|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
32901384|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
33394541|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
32901385|NCT00418574|Experimental|Abagovomab|
32909274|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
32901386|NCT00418574|Placebo Comparator|Placebo|
32901387|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
32901388|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
32901389|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
33070952|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32753223|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
32753224|NCT02346851|Experimental|triggered FES|
32753225|NCT02346851|Active Comparator|conventional FES|
32753226|NCT02346851|No Intervention|control group|
32753227|NCT02341469|No Intervention|Standard-of-care|
32909280|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
32909281|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
33070953|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
32753228|NCT02341469|Experimental|integrated ediagnostic approach|
32753229|NCT02347007|Experimental|Almond|
32753230|NCT02347007|Active Comparator|Cereal Bar|
33070954|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
33237417|NCT05312736||Vision Cohort 3|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse).~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
33237418|NCT05310786|Other|Site Staff|Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments
33237419|NCT05310786|Other|Patients|Subset of patients receiving PrIMO care to receive survey assessments
32901390|NCT00418964|Experimental|Single bundle hamstring|
33070955|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32753231|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
32753232|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
33237420|NCT04085562|Experimental|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
33237421|NCT04085562|Experimental|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
32753233|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
32753234|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
32753235|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
32753236|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
32753237|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
32753238|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
32753239|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
32753240|NCT02346695||Controls|Normotensive individuals
32753241|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
32901391|NCT00418964|Experimental|Double bundle hamstring|
32901392|NCT00418964|Active Comparator|Bone patellar tendon bone|
32901393|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
32753242|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
33070956|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
33237422|NCT05343000|Experimental|Severe Comorbid OSA|Newly-diagnosed severe comorbid obstructive sleep apnea subjects will use technology to facilitate remote health coaching through a home-based pulmonary rehabilitation (PR) system
32753243|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
32753244|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
33070957|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
32753245|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
32753246|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
32753247|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
33237423|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
33237424|NCT05307978|Experimental|Cohort 1|Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV.
32753248|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
32753249|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
32753250|NCT02340689||Genetic testing|Genetic Analysis
32753251|NCT04018859|Experimental|Platelet-Rich Plasma|Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
33237425|NCT05307978|Experimental|Cohort 2|Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
32753252|NCT04018859|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
33237426|NCT05307978|Experimental|Cohort 3|Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV.
33237427|NCT05307978|Experimental|Cohort 4|Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
33237428|NCT05307978|Experimental|Cohort 5|Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC.
33237429|NCT05307978|Experimental|Cohort 6|Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC.
33237430|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
33237431|NCT04084002||Control group|Healthy control group age and sex matched
33237432|NCT05048238|Experimental|Tofacinitib|10 participants receiving 11 mg of Tofacitinib administered orally and daily, from Day 2 to Day 26
32753253|NCT02346149|Other|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
32753255|NCT04091243|Experimental|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
33237433|NCT05047536|Experimental|KZR-261 with standard therapy: open-label|"Part 1 (Dose Escalation)~The initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.~___________________________________________~Part 2 (Dose Expansion)~Following safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:~melanoma (including uveal melanoma)~colorectal cancer~prostate cancer~mesothelioma"
33237434|NCT04082832|Active Comparator|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
32753256|NCT04091243|Active Comparator|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
32753257|NCT05254691|No Intervention|Standard care|All children are put on a time-cycled, pressure limited ventilation mode (AVEA, CareFusion, Yorba Linda, CA, USA). Inspiratory pressures are set to deliver a expiratory tidal volume of 5-7 ml/kg ideal bodyweight. The frequency of the delivered machine-breaths is set in accordance with age and disease condition of the patient. Then the patient set rate of breaths per minute delivered by the ventilator is reduced with 25%, allowing for more spontaneous breaths.
32901846|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
32901847|NCT05067894|Experimental|Adult - Vaccine candidate|50 µg dose, adult group (18-59 years)
32901848|NCT05067894|Active Comparator|Adult - Control|SARS-CoV-2 inactivated vaccine, adult group (18-59 years)
32901849|NCT05067894|Experimental|Elderly - Vaccine candidate|50 µg dose, elderly group (> 60 years)
32753258|NCT05254691|Experimental|Sprinting|The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing).
33070958|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
32901850|NCT05067894|Active Comparator|Elderly - Control|SARS-CoV-2 inactivated vaccine, elderly group (> 60 years)
33237435|NCT04082832|Placebo Comparator|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
33070959|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
33237436|NCT05038488|Experimental|MIB-626|Oral administration of MIB-626 substantially raises the intracellular NAD+ levels and activates signaling mechanisms that regulate inflammation and cell survival, downregulates the NLRP3 inflammasome, and attenuates the inflammatory response in a number of experimental models, and protects against tissue damage induced by pro-inflammatory cytokines.
33237437|NCT05038488|Placebo Comparator|Placebo Tablet|"A placebo control will be supplied. Participants randomized to placebo will receive matching tablet.~Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC."
32753259|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
33237438|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
32753260|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
32753261|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
33070960|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
33070961|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
33070962|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
33070963|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
32753262|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
32753263|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
32753264|NCT05254223|Experimental|Control Diet (NDA)|No dietary advice (NDA)
32753265|NCT05254223|Experimental|Anti-inflammatory Diet (AIDA)|Anti-inflammatory Dietary advice (AIDA)
32753266|NCT05254145||Group A|This group will include participants without an arthritic knee. These participants will be recruited from the Orthopedic Sports Medicine consultation
32753267|NCT05254145||Group B|This group will include participants undergoing primary knee arthroplasty (KA).
32753268|NCT05254145||Group C|This group will include participants undergoing a surgical procedure whose opposite knee has no history of arthritis
32753269|NCT05254145||Group D|This group will include participants undergoing knee revision surgery with no suspicion of infection (aseptic knee revision replacement)
32753270|NCT05254145||Group E|This group will include participants undergoing knee revision with a known infection (septic knee revision replacements)
32753271|NCT05254067||Device recipient|
32753272|NCT02345915|Other|Young adult acute leukemia-survivor|
32753273|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
32753274|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
32753275|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
33237439|NCT04082988|Other|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
33070964|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
33237440|NCT05038098|Experimental|Cohort I (preoperative injection)|Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
33237441|NCT05038098|Experimental|Cohort II (intraoperative)|Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
33237442|NCT05036850||Incident and Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
33237443|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
33237444|NCT05218044|Other|Cryoablation|Phase I, single-arm study to evaluate the ability of cryoablation to achieve complete ablation of DCIS in the cryoablation zone of necrosis as a potential alternative to surgery.
33237445|NCT00919230|No Intervention|no treatment|no iron given
33237446|NCT00919230|Experimental|ferrous sulphate|iron given
33237447|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
33237448|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
33237449|NCT05684562||Fontan group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
33237450|NCT05684562||Control Group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
33237451|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
33237452|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
33237453|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
33237454|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
33237455|NCT05168202|Experimental|CC-95251 monotherapy|
33237456|NCT05168202|Experimental|CC-95251 + azacitidine|
33237457|NCT02588196|Experimental|treatment of dexamethasone group|
33237458|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
33237459|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
33237460|NCT02588820|Experimental|Antiretroviral treatment|
33237461|NCT04083768|Placebo Comparator|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
33237462|NCT04083768|Active Comparator|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
33237463|NCT04083768|Active Comparator|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
33237464|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
33237465|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
33237466|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
33237467|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
33237468|NCT00715377|Experimental|1|
33237469|NCT04083924|Experimental|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
33237470|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
33237471|NCT05023980|Experimental|Arm A (Pirtobrutinib)|Pirtobrutinib administered orally
33237472|NCT05023980|Active Comparator|Arm B (BR)|Bendamustine plus rituximab administered intravenously (IV)
33237473|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
33237474|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
33237475|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
32753276|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
32753277|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
32753278|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
32753279|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
32753280|NCT02340455|Experimental|Pregabalin_male|
32753281|NCT02340455|Experimental|Pregabalin_female|
32753282|NCT02340455|Active Comparator|Placebo_male|
32753283|NCT02340455|Active Comparator|Placebo_female|
32753284|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
32753285|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
32753286|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
32753287|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
32753288|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
32753289|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
32753290|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
32753291|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
32753292|NCT05253989|No Intervention|Control|Regular assessments as outlined in the outcomes assessment section. No other change from standard of care.
32753293|NCT05253989|Active Comparator|VR Intervention Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions.
32753294|NCT05253989|Active Comparator|VR Intervention + FES Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions, with FES stimulation.
32753295|NCT05253599|Experimental|Isokinetic training|In the IKT group before isokinetic training, the subjects were asked to perform five minutes' warm-up followed by slow stretching of back extensors and flexors. The subject was asked to be in an isokinetic dynamometer (Biodex Corporation, New York, USA) in a vertical standing position.
32753296|NCT05253599|Experimental|Virtual reality training|The VRT group received virtual reality training with (Pro-Kin system PK 252 N Techno body, Pelvic Module balance trunk MF, Italy) focusing on the balance of core stability muscles.
32753297|NCT05253599|Active Comparator|Control group|The Control group focused on conventional balance training for core muscles. The training includes active isotonic and isometric exercise for abdominal muscles (Internal oblique, external oblique, transverse abdominus and Rectus abdominus) deep abdominal muscles (Psoas major, Psoas minor, Illiacus and Quadratus Lumborum) and back muscles (Erector spinae, Transverses spinalis, inter spinalis and Inter transverse).
32753298|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
32753299|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
32753300|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
32753301|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
32753302|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
32753303|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
32753304|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
32753305|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
32753306|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
32753307|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
32753308|NCT02345603|No Intervention|Control|No intervention in renal arteries
32753309|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
32753310|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
32753311|NCT03145883|No Intervention|Control group|Control group
33237476|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
33237477|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
33070965|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
33237478|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
33237479|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
33237480|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
33237481|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
33237482|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
33237483|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
33237484|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
33237485|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
33237486|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
33237487|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
33237488|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
33237489|NCT04199403||Single Group|
33237490|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
33237491|NCT04417959|Other|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
33237492|NCT04417959|Other|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
33237493|NCT00718653|Experimental|1|lutein
33070966|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
33237494|NCT00718653|Experimental|2|Lutein plus green tea extract
33237495|NCT00718731|Experimental|1|Subject on active drug
33237496|NCT00718731|Placebo Comparator|2|Subject on placebo
33237497|NCT04083846|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
33237498|NCT04083846|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
33237499|NCT04083846|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
33237500|NCT04083846|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
33237501|NCT04083846|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
33237502|NCT04083846|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
33237503|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
33237504|NCT04069845||liposomal doxorubicin treatment|intravenous liposomal doxorubicin
33237505|NCT05160480|Experimental|Total-body PET scan|All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
33237506|NCT04070625||Communication book group|Speech therapy with communication book
33237507|NCT04070625||Control group|Simple speech therapy
33237508|NCT05158140|Experimental|V110 + concomitant mRNA-1273|Single dose vaccination of V110 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V110 on Day 30
33237509|NCT05158140|Experimental|V110 + non-concomitant mRNA-1273|Single dose vaccination of placebo for V110 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V110 on Day 30
33237510|NCT05158140|Experimental|V114 + concomitant mRNA-1273|Single dose vaccination of V114 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V114 on Day 30
33237511|NCT05158140|Experimental|V114 + non-concomitant mRNA-1273|Single dose vaccination of placebo for V114 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V114 on Day 30
33237512|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
33237513|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire<22 Rigiscan test are performed for two nights
33237514|NCT04068987||Healthy Volunteers|"Healthy volunteers~Recruited from the public~Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
33237515|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
33237516|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
33237517|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
32753312|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
32753313|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
32753314|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
32753315|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
32753316|NCT03145649||Healthy|Healthy mother-infant dyads
32753317|NCT04086329|Other|Affected MM Cases|Key eligibility criteria for MM cases includes physically-capable adults (male and females, ages 18 to 65 years, inclusive) with genetically-confirmed MM with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
32753318|NCT04086329|Other|Healthy Controls|Adult healthy volunteers will be individually matched with corresponding MM cases based on age, biological sex, and body mass index.
32753319|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
32753320|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
32753321|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
32753322|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
33237518|NCT05198466|Active Comparator|Active E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
33237519|NCT05198466|Sham Comparator|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
33237520|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
33237521|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
32753323|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
32753324|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
32753325|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
32753326|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
32753327|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
32753328|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
32753329|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
32753330|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
32753331|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
33237522|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
33237523|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
33237524|NCT05196126|Active Comparator|Group A - PACEMAKER|According with ESC indications for elective pacemaker implantation due to SND will referred for PM implantation.
32753332|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
32753333|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
32753334|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
32753335|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
32753336|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
32753337|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
32753338|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
32753339|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
32753340|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
32753341|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
32753342|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
32753343|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
32753344|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
32753345|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
32753346|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
32753347|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
33070967|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
33237525|NCT05196126|Experimental|Group B - CARDIONEUROABLATION|According with ESC indications for elective PM implantation due to SND will referred for ICM/ILR implantation or prolonged ECG monitoring. Within 4 weeks patient will be screened by interdisciplinary team and autonomic tests (including atropine tests) will be performed. Than, based on atropine tests, electrophysiologic study and extracardiac vagal nerve stimulation, final indication for cardioneuroablation will be established. Biatrial, binodal cardioneuroablation will be performed with anatomical approach with bilateral extra cardiac vagal nerve stimulation during general anesthesia. Than, patient will be closely monitored and indication for PM implantation will be verified.
33237526|NCT05670951|Active Comparator|ELGN-2112|
33237527|NCT05670951|Placebo Comparator|Placebo|
33070968|NCT02930512||patients with idiopathic Parkinson's disease|
33237528|NCT05012592|Active Comparator|Intervention Group|Health assessment (health checkup) and health awareness program to reduce malnutrition and helminth infestation among primary school children
33237529|NCT05012592|No Intervention|Comparison group|Health assessment (health checkup) was provided but no health educational intervention during the intervention period
33237530|NCT00715689|Experimental|A|
33237531|NCT00715689|Experimental|B|
33237532|NCT00715689|Experimental|C|
33237533|NCT00715689|Experimental|D|
33237534|NCT05012046|Experimental|Orange juice|Treatment beverage
33237535|NCT05012046|Experimental|Orange flavoured drink|Treatment beverage
33237536|NCT05012046|Experimental|Water|Treatment beverage
33237537|NCT04069533|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
33237538|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
33070969|NCT02930395||professional rugby players|
33070970|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
33237539|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
33237540|NCT00715845|Experimental|2|
33237541|NCT04240626|Active Comparator|Standard of Care|The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.
33237542|NCT04240626|Experimental|Multi-Modal|Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
33237543|NCT00719121|No Intervention|A|No Treatment
32901394|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
33070971|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
33237544|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
32753348|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
32901395|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
32901396|NCT00419666|Experimental|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
33070972|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
32753349|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
32753350|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
32753351|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
32753352|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
32753353|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
32753354|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
32753355|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
32753356|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
32753357|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
32753358|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
32753359|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
32753360|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
32753361|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
32753362|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
32753363|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
32753364|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
32753365|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
32753366|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
32753367|NCT02338739|Active Comparator|REC; Outreach if Failure|
32753368|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
32753369|NCT02338739|Active Comparator|REC; Navigator if Failure|
32753370|NCT02338739|Active Comparator|SMS; Outreach if Failure|
32753371|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
32753372|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
32753373|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
32753374|NCT02338739|Active Comparator|SMS; Navigator if Failure|
32753375|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
32753376|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
32753377|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
32753378|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
32753379|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
33394542|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
33394543|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
32753380|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
32753381|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
33237545|NCT00719121|Active Comparator|C|R115866 Vehicle gel
33237546|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
33237547|NCT00715923|Experimental|1|Modified consent form
33237548|NCT00715923|Active Comparator|2|Standard consent form
33394544|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
32753382|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
33394545|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
32753383|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
32753384|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
32753385|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
33394546|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
33394547|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
33394548|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
33237549|NCT05138172|Placebo Comparator|Sedation without forced air heating temperature management|Sedation without forced air heating temperature management = present standard in sedation during endoscopic retrograde cholangiography (ERC)
32753387|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
32753388|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
32753389|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
32753390|NCT02338427|Experimental|proteomic|
32753391|NCT05002595||Modified quadruple therapy|pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days
32753392|NCT05002595||Tailored eradication|pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days
32753393|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
32753394|NCT02343965|No Intervention|without touch-massage group|
33070973|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
32753395|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
32753396|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
32753397|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
32753398|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
32753399|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
32753400|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
32753401|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and~Stop if the situation improves with neuropsychological assessment and monitoring to M12,~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
32753402|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
32753403|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
32753404|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
32753405|NCT02343809|Other|Control Group|Protocolized Physiotherapy
32753406|NCT03112109||Intervention Group|Patients receiving 'new care'
32753407|NCT03112109||Control group|Patients receiving 'old / usual care'
32753408|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
32753409|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
32753410|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
32753411|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
32753412|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
32753413|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
32753414|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
32753415|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
32753416|NCT02337569|Experimental|NPC-02|Oral dose
32753417|NCT02337569|Placebo Comparator|Placebo|Oral dose
32753418|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
32753419|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
32753420|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
32753421|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
32753422|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
32753423|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
32753424|NCT04852367|Active Comparator|Arm A (Doxorubicin)|a single intravenous dose of Doxorubicin, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered as per local practice.
33070974|NCT04438135|Active Comparator|active test|
33070975|NCT04438135|Placebo Comparator|placebo test|
33237550|NCT05138172|Experimental|Sedation with forced air heating temperature management|Sedation without forced air heating temperature management = proposed new standard in sedation during endoscopic retrograde cholangiography (ERC)
33237551|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
32753425|NCT04852367|Experimental|Arm B (ThermoDox + Focused Ultrasound)|under general anaesthetic, patients receive FUS, which is moved through the target tumour volume to raise the bulk tumour temperature above the thermal release threshold. At presumed target temperature, a single intravenous dose of ThermoDox®, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered concurrently to FUS, in line with the pharmacy manual provided by the manufacturer. FUS will continue following infusion, for no longer than two hours from infusion commencing.
32753426|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
32753427|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
32753428|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
32753429|NCT02332109||ODM 5-group|
32753430|NCT04850495|Experimental|Treatment (zanubrutinib, R-CHOP)|Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32753431|NCT02337023||healthy subjects|
32753432|NCT02337023||patients with Kleine-Levin Syndrome|
32753433|NCT04477811|Active Comparator|vitamin k1|vitamin k1 will be given 10 mg thrice a week for 3 months
32753434|NCT04477811|Active Comparator|vitamin k2|vitamin k2 (menaquinone) will be given 90 ug per day orally
32753435|NCT04477811|Placebo Comparator|placebo|placebo will be given daily per oral for 3 months
32753436|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
32753437|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
32753438|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
32753439|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
32753440|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
32753441|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
32753442|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
32753443|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
32753444|NCT02336867|Other|Control group|advancement flap technique
32753445|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
32753446|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
32753447|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
32753448|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
32753449|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
32753450|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
32753451|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
32753452|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
32753453|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
32753454|NCT02336711|Experimental|Dose escalation|Dose escalation
32753455|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
33070976|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
33237552|NCT05002998|Other|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~Placebo if a participant is a treatment responder at Week 12 or~Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
33237553|NCT05002998|Other|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
32753456|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
32753457|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
32753458|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
32753459|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
33237554|NCT05002998|Other|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
32753460|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
33237555|NCT04068675|Experimental|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
32753461|NCT02336477|Experimental|1|Mexiletine / Placebo
32753462|NCT02336477|Experimental|2|Placebo / Mexiletine
32753463|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
32753464|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
32753465|NCT02331953||delirium group|the patients with delirium after spine surgery
33237556|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
33237557|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
33237558|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
33237559|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
33237560|NCT00716001|Active Comparator|NAC|
33394549|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
33394550|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
32753466|NCT02331953||no delirium group|the patients without delirium after spine surgery
32753467|NCT04700891|Experimental|Patients scheduled for elective surgery aged 65 and +|
32753468|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
32753469|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
32753470|NCT03111563|Other|warm saline|case group ,
32753471|NCT03111563|Other|room temperature|control group
32753472|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
32753473|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
32753474|NCT02642315|Other|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
32753475|NCT02518139|Experimental|TD-4208-1|88 mcg
32753476|NCT02518139|Experimental|TD-4208-2|175 mcg
32753477|NCT02518139|Active Comparator|Tiotropium|18 mcg
32753478|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
32753479|NCT04477655|Active Comparator|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%. Prone positioning will be allowed as a rescue therapy.
32753480|NCT04477655|Experimental|Awake prone positioning|Oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%.
32753481|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
32753482|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
32753483|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
32753484|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
32753485|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
32753486|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
32753487|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
33394551|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
33394552|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
33394553|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
33394554|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
33394555|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
32753488|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
32753489|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
32753490|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
32753491|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
32753492|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
32753493|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
32753494|NCT02443129|Experimental|control group|"18-99 year old male + female~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
32753495|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
33070977|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
32753496|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
32753497|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment~Intervention:~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
32753498|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
32753499|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment~Intervention:~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
32753500|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).~Longitudinal arm with newly diagnosed patients for 2 years follow-up~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
32753501|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
32753502|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
32753503|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
32753504|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
32753505|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
32753506|NCT04483609||pre-test Group|10 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
32753507|NCT04483609||Validation and Reliability Group|80 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
32753508|NCT04483453|Experimental|EXPL feeding regimen|Lower protein / lower estimated glycemic index regimen
32753509|NCT04483453|Active Comparator|CTRL feeding regimen|Standard protein / standard glycemic index regimen
32753510|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
32753511|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
32753512|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
32753513|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
32753514|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
32753515|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
32753516|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
32753517|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
32753518|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
32753519|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
32753520|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
32753521|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
32753522|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
32753523|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
33070978|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
33070979|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
33237561|NCT00716001|Placebo Comparator|nonNAC|
32753524|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
32753525|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
32753526|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
32753527|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
32753528|NCT03192163||ResearchMatch Group|
32753529|NCT03192163||Northwestern Center for Ethnic Skin Group|
32753530|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
32753531|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
32753532|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
32753533|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
32753534|NCT03512197|Experimental|Midostaurin + chemotherapy|Participants will receive Midostaurin 50mg twice a day until not achieving CR nor CRi without adequate hematologic recovery for continuation of treatment, intolerable toxicity, relapse or consent withdrawal plus chemotherapy whichever occurs first during induction and consolidation followed by midostaurin monotherapy for 12 cycles of 28 days cycle duration.Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
32753535|NCT03512197|Placebo Comparator|Midostaurin Placebo + chemotherapy|Participants will receive matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
32753536|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
32753537|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
32753538|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
32753539|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
32753540|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
32753541|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
32753542|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
32753543|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
32753544|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
32753545|NCT02437591|Experimental|fidaxomicin|tablet twice daily
32753546|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
32753547|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
32753548|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with Drug-coated balloon"
32753549|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with additional Plain balloon angioplasty:"
33394556|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
33394557|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
32753550|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
32753551|NCT02437201|No Intervention|Control group|
32753552|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
32753553|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
32753554|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
33070980|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
33394558|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
33394559|NCT03226444|Placebo Comparator|placebo|placebo solution
32753555|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
32753556|NCT03022903|Other|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
32753557|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
32753558|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
32753559|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
32753560|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
32753561|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
32753562|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
32753563|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
32753564|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
32753565|NCT04483687|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
32753566|NCT04483687|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
32753567|NCT04483687|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
32753568|NCT04483687|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.~After study-wide unblinding, participants will receive filgotinib 200 mg."
32753569|NCT04483687|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.~After study-wide unblinding, participants will receive filgotinib 100 mg."
32753570|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day: stable isotope infusions with blood draws, sip feed"
32753571|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
32753572|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
32753573|NCT03189043|Experimental|Test|Use of antimicrobial surface
32753574|NCT03189043|No Intervention|Control|No antimicrobial surface
32753575|NCT01762579|Active Comparator|wheat flour|wheat flour is administered blindly versus placebo for 15 days
32753576|NCT01762579|Placebo Comparator|Xylose|placebo will be administered blindly versus wheat flour for 15 days
32753577|NCT01654315|Experimental|Experimental: Myomo Only Group|"Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as repetitive task specific practice (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period."
32753578|NCT01654315|Experimental|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
32753579|NCT01654315|Active Comparator|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
32753580|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
32753581|NCT03188575|Active Comparator|Waiting List|Waiting list control
32753582|NCT05233735|Other|topical treatment|Topical Betamethasone for the Treatment of Vitiligo Disease
32753583|NCT05233735|Experimental|Enhanced Transcutaneous Delivery|Enhanced Transcutaneous Delivery of Topical Betamethasone after a treatment with Tixel device for the Treatment of Vitiligo Disease
32753584|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure~clinically disclosed cardiac complications during and after vascular surgery procedure"
32753585|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
32753586|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
32753587|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
32753588|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
32753589|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
32753590|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
32753591|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
32753592|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.2 μg/d)|
32753593|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.4 μg/d)|
32753594|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.8 μg/d)|
32753595|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (1.6 μg/d)|
32753596|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (3.2 μg/d)|
32753597|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (6.5 μg/d)|
32753598|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (13 μg/d)|
32753599|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (25 μg/d)|
32753600|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (50 μg/d)|
32753601|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (100 μg/d)|
32753602|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (200 μg/d)|
32753603|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (400 μg/d)|
32753604|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (800 μg/d)|
32753605|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
32753606|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
32753607|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
32753608|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
32753609|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
32753610|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
32753611|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
32753612|NCT02441647|Experimental|Experimental group|
32753613|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
32753614|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
32753615|NCT04483271|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
32753616|NCT04483271|No Intervention|Control group|No intervention was given
32753617|NCT02434237||patients|
32753618|NCT02434237||healthy subjects|
32753619|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
32753620|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
32753621|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
32753622|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
32753623|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
32753624|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
32753625|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
33070981|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
33070982|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
32753626|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
33070983|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
33070984|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
33070985|NCT00170001|Placebo Comparator|Sugar pill|
32753627|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
32753628|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
32753629|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
32753630|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
32753631|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
32753632|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
32753633|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
33237562|NCT05136846|Experimental|Treatment (papaverine, RT, paclitaxel, carboplatin)|Patients receive PPV IV or SC and undergo 5 fractions of RT per week. Patients also receive paclitaxel IV over 1 hour and carboplatin IV QW over 1-6 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 month of completing CRT, patients with PD-L1 positive disease receive durvalumab IV Q2W for 12 months.
32753634|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
32753635|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
32753636|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
32753637|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
32753638|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
32753639|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
32753640|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
32753641|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.~Administration of Speech perception tests and self-rating questionnaire"
33237563|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
32753642|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
32753643|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
32753644|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
32753645|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
32753646|NCT04461899|Other|sclerotherapy|a sclerotherapy will be done in patients
32753647|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:~Abdominal obesity, defined as a waist circumference in men ≥88 cm~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
32753648|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
33070986|NCT00170001|Active Comparator|Active Comparator|
33070987|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
32753649|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
32753650|NCT02709109|Experimental|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
32753651|NCT02709109|Experimental|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
32753652|NCT02709109|Experimental|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
32753653|NCT02709109|Experimental|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
32753654|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
33237564|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
33237565|NCT05684406||Group I|patients with type 2 diabetes mellitus
33237566|NCT05684406||Group II|apparently healthy controls with no chronic illness of matched age and sex
32753655|NCT02436109||study group|elective cesarean delivery patients
32753656|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
32753657|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
32753658|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
32753659|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
32753660|NCT04289051|Experimental|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
32753661|NCT04289051|Active Comparator|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
32753662|NCT04289051|Placebo Comparator|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
32753663|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
32753664|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
32753665|NCT04233749|Experimental|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
32753666|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
32753667|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
33070988|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
32753670|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
32753671|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
32753672|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.~Procedure for the application of the treatment:~1. Study Group or PRGF group~Blood sample :~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.~Spinning of the sample:~8 minutes at 1800 rpm .~getting the blood fraction containing the PRGF~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
32753673|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
32753674|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
32753675|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
32753676|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
32753677|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
32753678|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
32753679|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
32753680|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
32753681|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
32753682|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
32753683|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
32753684|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
32753685|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
32753686|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
32753687|NCT02435797|Placebo Comparator|normal saline|normal saline
32753688|NCT02330861|Other|Normal coronary artery|
32753689|NCT02335697|Other|Intervention|Attitude change towards female circumcision
32753690|NCT02335697|Other|No intervention|No intervention
32753691|NCT05230745|Experimental|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
32753692|NCT02330705|Active Comparator|Group A|IUI at time of HCG
32753693|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
32753694|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
32753695|NCT04174625|Experimental|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
32753696|NCT04174625|Experimental|Control group|VD3 group 50,000 IU/week
32753697|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
32753698|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
32753699|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
32753700|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
32753701|NCT03105089|No Intervention|control|no intervention will be done
32753706|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
32753707|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
32753708|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
33070989|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
32753709|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
32753710|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
32753711|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
32753712|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
32753713|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
32753714|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
32753715|NCT02330237|Active Comparator|patients|natural gels
32753716|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
32753717|NCT03890237|No Intervention|Control|Business as usual, no intervention
32753718|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
32753719|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
32753720|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
32753721|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
32753722|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
32753723|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
32753724|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
32753725|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
32753726|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
33070990|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
33070991|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
32753727|NCT02334839||healthy|women without gestational hypertension or preeclampsia
32753728|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
32753729|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
32753730|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
32753731|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
32753732|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
32753733|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
32753734|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.65 mL normal saline
32753735|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
32753736|NCT02709655|Experimental|Vortioxetine 10 mg/day|
32753737|NCT02709655|Experimental|Vortioxetine 20 mg/day|
32753738|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
32753739|NCT02709655|Placebo Comparator|Placebo|
32753740|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
32753741|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
32753742|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
33070992|NCT04426201|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
33070993|NCT04426201|Placebo Comparator|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
32753743|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
32753744|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.~Intervention: Standard evening meals."
32753745|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.~Intervention: Improved evening meal"
32753746|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
32753747|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
32753748|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
32753749|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
32753750|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
32753751|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
32753752|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
32753753|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
32753754|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
32753755|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
32753756|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
32753757|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
32753758|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
32753759|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
32753760|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
32753761|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
32753762|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
32753763|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
32753764|NCT02334293|Other|Omegaven|
32753765|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
32753766|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
32753767|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
32753768|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
32753769|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
32753770|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
32753771|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
32753772|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
32753773|NCT02329145|Experimental|Active treatment|Renal denervation
32753774|NCT02329145|No Intervention|Observational|
33237567|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
33237568|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
32753775|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
33237569|NCT04994808|Experimental|Arm A (treosulfan, fludarabine, TBI, HCT)|Patients receive treosulfan IV over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
32753776|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
32753777|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
33237570|NCT04994808|Experimental|Arm B (clofarabine, TBI, HCT)|Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
33237571|NCT00710619||A|
32753778|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
32753779|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
33237572|NCT00710697|Experimental|Single Arm|Picoplatin
33237573|NCT05684250|Experimental|The time course group|The time course of the effect of biofeedback training in young adults wearing MFCLs. Subjects will receive one episode of auditory biofeedback training and accommodation will be measured before the training and after the training on a weekly basis for 3 weeks.
33237574|NCT05684250|Experimental|The repetition group|Subjects will receive one episode of auditory biofeedback training every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
33237575|NCT05684250|Experimental|The longer duration group|Subjects will receive one episode of auditory biofeedback training for twice as long every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
33237576|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
33237577|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
33237578|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
33237579|NCT05192460|Experimental|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subject will only receive neoantigen tumor vaccine. In dose expansion phase, subject will receive neoantigen tumor vaccine combination with PD-1/L1.
33237580|NCT00719433|Experimental|1|
33237581|NCT00719433|Active Comparator|2|
33237582|NCT05128344|Experimental|AMZ002|
33237583|NCT05128344|Active Comparator|Vigabatrin|
33237584|NCT02589054||Patients|
33237585|NCT05189106|Experimental|Baricitinib|Baricitinib 2mg administered by mouth once daily for the first 8 weeks, followed by baricitinib 4mg administered by mouth once daily for 16 weeks.
33237586|NCT03897699|Experimental|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
33237587|NCT03897699|Sham Comparator|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
32909282|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
33237588|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
33237589|NCT04069689|Experimental|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
33237590|NCT04069689|Placebo Comparator|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
33237591|NCT04985994||Tuberculosis Patients|"Diagnosed with pulmonary TB after detailed history collection, clinical examination, and laboratory assessment (sputum culture positive).~Aged 18 years or above.~Willing to participate in the study."
33070994|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
33237592|NCT04985994||Healthy Volunteers|"Healthy subjects with no symptoms or history of pulmonary TB~Negative sputum culture~Matched for sex and age (±5 years) with the TB patient group."
32753780|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
32753781|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
32753782|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
32753783|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
32753784|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
32753785|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
33237593|NCT00719511|Experimental|1|Patch allergen dose 1
33237594|NCT00719511|Experimental|2|Patch allergen dose 2
33237595|NCT00719511|Experimental|3|Patch allergen dose 3
33237596|NCT00719511|Experimental|4|Placebo
33237597|NCT04984122|Other|Control|GA group intravenous 2-3 μ/kg fentanyl followed by 2 mg/kg propofol. were administered for anesthesia induction. After a laryngeal mask insertion anesthesia was maintained by inhalation of sevoflurane in an oxygen (60%) and nitrous oxide (40%) mixture to maintain a minimal alveolar concentration (MAC) of 0.8%-1.3%.
33237598|NCT04984122|Other|Study|In the LA group, after positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) were applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix.
33237599|NCT00719589||1|Patient who have had implantation of an interstim.
33394560|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
33237601|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
33237602|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
32753786|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
32753787|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
32753788|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
33237603|NCT04068441||Regular treatment|
33237604|NCT04068441||Treatment interruption|
32753789|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
32753790|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
32753791|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
32753792|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
32753793|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
32753794|NCT04031729|Experimental|Aspirin|Low-dose (81mg) aspirin tablets
32753795|NCT04031729|Placebo Comparator|Placebo|Placebo tablets
32753796|NCT02708485|No Intervention|Control group|No intervention
32753797|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
32753798|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
32753799|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
32753800|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
32753801|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
33237605|NCT04978506|Experimental|BI 1569912 MRD: treatment group 1|Multiple rising dose (MRD) part
33237606|NCT04978506|Experimental|BI 1569912 POSO treatment group|Posology part (optional)
33237607|NCT04978506|Placebo Comparator|Placebo|
32753802|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
32753803|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
32753804|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
32753805|NCT02433847|Experimental|mosapride|
32753806|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
33237608|NCT04978506|Experimental|BI 1569912 MRD: treatment group 2|Multiple rising dose (MRD) part
32753807|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
32753808|NCT02435329||Healthy volunteers|"10 healthy volunteers~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
32753809|NCT02435329||Type 2 diabetes without neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
32753810|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
32753811|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
33237609|NCT04978506|Experimental|BI 1569912 MRD: treatment group 3|Multiple rising dose (MRD) part
33237610|NCT04978506|Experimental|BI 1569912 MRD: treatment group 4|Multiple rising dose (MRD) part
33394561|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
32753812|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
32753813|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=679
32753814|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=895
32753815|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=721
32753816|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=394
32753817|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=234
32753818|NCT02328677||Washington University School of Medicine in St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=232
32753819|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=183
32753820|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
32753821|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
32753822|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
32753823|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
32753824|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
33237611|NCT04068519|Experimental|Tislelizumab|Tislelizumab will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
33237612|NCT04978272|Active Comparator|IPTc DP 1 year|DP given from 8 weeks to 52 weeks of age; DP placebo given from 52 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
32753825|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
33237613|NCT04978272|Active Comparator|IPTc DP 2 years|DP given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
33237614|NCT04978272|Placebo Comparator|No IPTc|DP placebo given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
33237615|NCT05684094|Experimental|"Sleep extension and advance Lark Routine"|Participants go to bed 90 minutes earlier than their typical average bedtime to extend sleep duration and advance sleep timing
33237616|NCT05684094|Active Comparator|"Regular sleep duration and timing Owl Routine"|Participants go to bed at their typical average bedtime
33237617|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
33237618|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
33237619|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
33237620|NCT04973124|Active Comparator|SEVODEX Group|The SEVODEX group will receive intraoperative dexmedetomidine at a fixed infusion rate of 0.25 mcg/kg/h
33237621|NCT04973124|Placebo Comparator|SEVO Group|The SEVO group will not receive dexmedetomidine during surgery.
32909283|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
32909284|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
32909285|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
32909286|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
32909287|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
32753826|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
32753827|NCT04477421|Active Comparator|FS-LASIK Group|100 eyes of 50 patients underwent bilateral FS-LASIK (Femtosecond laser Insitu Keratomileusis)
32753828|NCT04477421|Experimental|FS-SMILE|100 eyes of 50 patients who underwent bilateral FS-SMILE (femtosecond small incision lenticule extraction)
33394562|NCT04358081|Placebo Comparator|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
33394563|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
32753829|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
32753830|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
33394564|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
33394565|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
32753831|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
32753832|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
32753833|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
32753834|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
32753835|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
32753836|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
32753837|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
32753838|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
32753839|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
32753840|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
32909288|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
32909289|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
32753841|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
32753842|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
32753843|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
32753844|NCT03192241|Active Comparator|book|Mothers provided with a children's book
32753845|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
32753846|NCT03831503|Experimental|Cohort A - 0.5mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 0.5 mg DNA/dose. Inoculation will be administered as 0.5 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
32753847|NCT03831503|Experimental|Cohort B - 1mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 1 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
32909290|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
32753848|NCT03831503|Experimental|Cohort C - 2mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
32753849|NCT03831503|Experimental|Cohort D - 4mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
33237622|NCT00716235||DCD|Children with a diagnosis of DCD
32753850|NCT03831503|Experimental|Cohort E - 4mg Side Port|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device with Side Port needle.
32753851|NCT03187093|Active Comparator|Vortioxetine|
32753852|NCT03187093|Active Comparator|Escitalopram|
32753853|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
33237623|NCT00716235||Autism|Children with a diagnosis of Autism disorder
33237624|NCT00716235||ADHD|Children with a diagnosis of ADHD
33237625|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
33237626|NCT04971720|Experimental|Sacubitril/Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
33237627|NCT04971720|Experimental|Sacubitril/Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
32753854|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
32753855|NCT02078752|Experimental|Part 1|
32753856|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
33237628|NCT04971720|Active Comparator|Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
33237629|NCT04971720|Active Comparator|Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
33237630|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
33237631|NCT00711165|Experimental|Memetasone|Mometasone
33237632|NCT00719745|Active Comparator|1|
33237633|NCT00719745|Experimental|2|
33237634|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
33237635|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
33237636|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
33237637|NCT00719823|Other|1|
33237638|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
33237639|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
32753857|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
33237640|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
33237641|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
32753858|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
32753859|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
32753860|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
33070995|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
32909291|NCT04352894|Experimental|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
32909292|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
32909293|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
32909294|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
32909295|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
33237642|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
33237643|NCT05127486|Experimental|Galcanezumab|"Galcanezumab administered subcutaneously (SC).~Placebo for rimegepant will be used for blinding."
33237644|NCT05127486|Active Comparator|Rimegepant|"Rimegepant administered oral disintegrating tablets (ODT).~Placebo for galcanezumab will be used for blinding."
33237645|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
33237646|NCT04850274|Experimental|Remote Therapy Intervention|Youth will receive the maximal dose of six S-RTI therapy sessions delivered by a remote therapist with no alteration in intensity
33237647|NCT04850274|Experimental|Artificial Intelligence Remote Therapy Intervention|Youth will first receive a remote therapy session in the Emergency Department (ED). The RL system will then make decisions about the intensity of each subsequent therapy session (the initial decision is seven days post ED visit and bi-weekly [i.e., every other two weeks] thereafter) for the next 11 weeks. Potential treatment decisions include a 30-minute remote therapy session delivered via phone or video chat (mirroring the S-RTI), a less intensive tailored Motivational Interviewing (MI)-adherent electronic remote therapy (delivered by an electronic robot), or an assessment only without intervention.
33237648|NCT04850274|No Intervention|Enhanced Usual Care|The youth's retaliatory risk will be assessed and a pamphlet with referrals for violence, substance use, and mental health services will be provided.
33241701|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
33237649|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
33237650|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
33237651|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
33237652|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
33237653|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
33237654|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
33241702|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
32909296|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
32909297|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
32909298|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
32909299|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
33237655|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
32909300|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
33070996|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
33070997|NCT02929615|Experimental|Treatment group|
33237656|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
33237657|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
33237658|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
33237659|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
33394566|NCT03934931|Experimental|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
33394567|NCT03934931|Experimental|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
33394568|NCT03934931|Experimental|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
33394569|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
33394570|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
33394571|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
33394572|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
33394573|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
32753861|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
32753862|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
32753863|NCT03191851|Active Comparator|Standard Device|Standard device
32753864|NCT03191851|Experimental|Melody Device|Melody device without Pump
32753865|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
32753866|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
32753867|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
32753868|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
32753869|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
32753870|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
32753871|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
33070998|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
33070999|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
33071000|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
33071001|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
33237660|NCT04068129||Burma|Patients from remote Burma clinic
33394574|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
33394575|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
33071002|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
33237661|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
33071003|NCT00148304||Group 1|
33071004|NCT02929693|Experimental|combination|YYJD plus gefitinib
33237662|NCT05123586|Experimental|LY3361237|Participants are administered LY3361237 subcutaneously (SC) and standard of care (SOC)
33071005|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
33237663|NCT05123586|Placebo Comparator|Placebo|Placebo administered SC and SOC given at matching intervals
33241703|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
33241704|NCT00771147||Group 1|
33241705|NCT00771225|Other|prolapse surgery with fascial repair|
33241706|NCT00771225|Other|prolapse surgery with mesh repair|
33241707|NCT04155710|Experimental|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
33241708|NCT04155710|Experimental|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
33237664|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
33237665|NCT04068207|Experimental|Minocycline|Tablets Minocycline 100mg po per day for 24 weeks
33237666|NCT00711321||2|AFFITOPE AD02 with adjuvant
33237667|NCT00711321||1|AFFITOPE AD02 without adjuvant
33237668|NCT04082598|Experimental|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
33237669|NCT04082598|Experimental|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
33237670|NCT04082598|No Intervention|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
33237671|NCT03895203|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
33237672|NCT03895203|Active Comparator|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
33237673|NCT03895203|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
33237674|NCT04958226|Experimental|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
33241709|NCT04155710|Experimental|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
33237675|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
33237676|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
32753874|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
32753875|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
32753876|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
32753877|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
32753878|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
32753879|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
32753880|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
33237677|NCT04847232|Experimental|Sodium Zirconium Cyclosilicate|
33237678|NCT04847232|Placebo Comparator|Placebo|
33237679|NCT04095195||Familial pancreatic cancer relatives|
33237680|NCT04095195||Peutz-Jeghers syndrome|
33237681|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
33237682|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
33237683|NCT04095195||FAMMM syndrome|
33237684|NCT04095195||Hereditary and genetic pancreatitis|
33237685|NCT00716547|Experimental|1|
33237686|NCT00716547|Experimental|2|
33237687|NCT00716547|Active Comparator|3|
33237688|NCT00716547|Placebo Comparator|4|
32753881|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
33237689|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
33237690|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
33394576|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
33237691|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
33237692|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
33237693|NCT00711399||group A|Study group
33237694|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
33237695|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
33241710|NCT04155710|Experimental|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
33241711|NCT04140500|Experimental|Part A: Single-Agent Dose Escalation|Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
33241712|NCT04140500|Experimental|Part B: Tumor Specific Expansion Cohorts|Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
33241713|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
33241714|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
33241715|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
32905322|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|Each participant will be given a supplement log at the end of visit 1. They will be asked to complete the log during the 28 days to indicate that the daily dose of supplements were taken according to instructions. The study coordinator will check the log on the second and third visits as well as count the remaining supplement pills. If participants do not comply with the daily supplement schedule, then the PI will determine if the participant should be withdrawn from the study.
33241716|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
32909303|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
33241717|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
33241718|NCT00764439|Active Comparator|1|Standard NRT user direction
33241719|NCT00764439|Experimental|2|Novel NRT user direction
33241720|NCT04130516|Other|Active|Phase 1/2 open-label
33241721|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
33241722|NCT05674526|Experimental|WU-NK-101 Monotherapy/Cetuximab combo Run-in|"WU-NK-101 is a non-engineered Natural Killer (NK) cell derived from peripheral blood mononuclear cells (PBMC) that is cytokine-reprogrammed, expanded, and cryopreserved to create an allogeneic enhanced memory-like anti-tumor NK cell therapy product.~Each 8 week cycle in dose escalation is divided into two 28- days segments. Patients will receive WU-NK-101 (Days 1 and 15) in the first segment and a combination of cetuximab (500mg/m2 on Days 29 and 43) plus WU-NK-101 (Days 30 and 44) in the second segment."
32753882|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
32909304|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
32909305|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
32909306|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
32909307|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
32909308|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
32909309|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
32909310|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
33241723|NCT05674526|Experimental|WU-NK-101 /Cetuximab Combo|Patients will receive cetuximab dosed at 500 mg/m2 on Days 1 and 15, and WU-NK-101 on Days 2 and 16, in each 4-week cycle. Depending on response patients may receive up to 6 cycles of treatment.
32909311|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.~Non-selective beta blockers.~Anticoagulation therapy."
32909312|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
32909313|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
32909314|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
32909315|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
32909316|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
32753883|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
32753884|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
32753885|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
32753886|NCT02333513|Experimental|case group|
32753887|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
32909317|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
32909318|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
32909319|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
33394577|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
32753888|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
33394578|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
33394579|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
33394580|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
32753889|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
33394581|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
32753890|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
33241724|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
33241725|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
32753891|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
32753892|NCT02328287|Experimental|ALLOB® Implantation|
32753893|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
32753894|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
32753895|NCT02328209|Experimental|ranibizumab|ranibizumab
32753896|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
32753897|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
32753898|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
32753899|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
32753900|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
32753901|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
32753902|NCT02434783||No arterial insufficiency|Healthy individuals (control)
32753903|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
32753904|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
32753905|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
32753906|NCT02328443|Experimental|midazolam alone|midazolam administration alone
32753907|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
33237696|NCT05684016|Active Comparator|Control|A control population (Non RRMS) will include a minimum of 20 age and gender matched healthy patients from the George Washington University (GWU) neurology outpatient clinic (being compared with those RRMS patients being treated with Gilenya® ) for whom Brain MRI's are being ordered as a result of their having headaches, dizziness, or other conditions where there is no physical evidence for neurologic impairment. All control patients will only be recruited by the full time Neurology Faculty at the GWU Medical Faculty Associates (MFA). Control patients will be asked to consent to have NeuroQuant added to their routine Brain MRI which will add 7 minutes to their time in the MRI scanner to obtain additional image data.
33237697|NCT05684016|Active Comparator|MS Subject on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant. The 30 patients that are taking Gilenya® will have serial NeuroQuant/MRI and Neuropsychological testing (which is like an IQ test) using Automated Neuropsychological Assessment Matrices (ANAM) whether they are or are not experiencing cognitive issues. In addition, each study patient will undergo Extended Disability Status Score (EDSS) evaluation by a physician or a physician assistant at baseline and at 1 and 2 years. A group of 20 RRMS patients will undergo a second Brain MRI (not standard of care) with NeuroQuant evaluation 7 to 14 days after the initial study in order to confirm the reproducibility of this imaging technique. The cost for this repeat MRI will not be charged to you but will be borne by the sponsors of this study
33237698|NCT05684016|Active Comparator|MS Subject not on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant.
33237699|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
33237700|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
33237701|NCT04842006|Experimental|TNT + precision|
32909320|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
32909321|NCT04802876|Experimental|Spartalizumab (PDR001)|400mg/intravenous every 28 days
32909322|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
32909323|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
32909324|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
33237702|NCT04842006|Active Comparator|Conventional|
32909325|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
32909326|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
33237703|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
33237704|NCT04082286|Experimental|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
33237705|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
33237706|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
32753908|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
33237707|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
32753909|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
33237708|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
33237709|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
33237710|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
33237711|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
33237712|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
33394582|NCT04482647|Experimental|Supportive Care (video, breathing techniques, meditation)|Patients view an instructional video on breathing techniques and meditation. Patients then perform breathing techniques over 3 minutes and meditation over 2 minutes BID for 28 days.
32753910|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
33237713|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
33237714|NCT00720525||1|Patients with diastolic heart failure
33237715|NCT00720525||2|Patients without diastolic heart failure
33237716|NCT04828824|Experimental|COCR Arm|Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.
32753911|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
33237717|NCT04828824|No Intervention|SOC Arm|Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.
33237718|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
33237719|NCT04082208|Experimental|Intervention Group|High Flow nasal cannula (HF)
33237720|NCT04082208|Active Comparator|Standar Care Group|Standar Care: low flow device (LF)
33237721|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
32753912|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
33394583|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
32753913|NCT05150197|Experimental|Patient (pathology) group|This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
32753914|NCT05150197|Other|Control group|This group will only perform the VisuALL Virtual Reality Visual Field.
32909327|NCT02119988|Experimental|TIPS combined with variceal embolization|"The covered stents will be used for TIPS~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
32909328|NCT02119988|Active Comparator|TIPS alone|"The covered stents will be used for TIPS~No embolization of any collateral will be performed during TIPS"
33394584|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
33237722|NCT00716937|Experimental|2|Excision of the cyst and laying open
32753915|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
33237723|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
33237724|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
33237725|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
33237726|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
33237727|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
33237728|NCT04819386|Experimental|Active group|18 half-hour in-office active vision therapy sessions with the NEIVATECH Virtual Reality-based system
33237729|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
33237730|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
33237731|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
33237732|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
32753916|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
33237733|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
33237734|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
33237735|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
33237736|NCT05108688|Active Comparator|Mirtazapine Therapy group (M group)|
33237737|NCT05108688|Active Comparator|Sumatriptan Therapy group (S group)|
33237738|NCT05108688|Placebo Comparator|Control group ( C group)|
32753917|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
33237739|NCT04936854|Active Comparator|Sirolimus|Patients with active thyroid eye disease will receive 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
32753918|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
32753919|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
32909329|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
33237740|NCT04936854|Active Comparator|Corticosteroids|Patients with active thyroid eye disease will receive 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks.
33237741|NCT00711789|Active Comparator|Angiotensin II|
33237742|NCT00711789|Placebo Comparator|Placebo|
32905323|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
32909330|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
33237743|NCT04082052|Experimental|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
33237744|NCT04082052|Placebo Comparator|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
33237745|NCT00717171|Placebo Comparator|1|
33237746|NCT00717171|Experimental|2|
32905324|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
33237747|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
33237748|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
33394585|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
32905325|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
32905326|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
33394586|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
32909331|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
33394587|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
33394588|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
33394589|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
33237749|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
33237750|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
33394590|NCT03220438|Active Comparator|TMS|rTMS
33394591|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
33394592|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
33394593|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
33394594|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
33394595|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
33394596|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
33237751|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
33237752|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
32905327|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
32909332|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
33394597|NCT04901273|Experimental|Homologous PRP|This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
33394598|NCT04901273|Placebo Comparator|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
33394599|NCT03226210|Experimental|NovoRapid group (group Asp)|
33394600|NCT03226210|Experimental|Prandilin group (group Lis)|
33237753|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
33237754|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
33237755|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
33237756|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
33237757|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
33237758|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
33237759|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
32909333|NCT04922346||Healthy Pregnant|All volunteer pregnant women who were in the 2nd and 3rd trimesters (between 14-40 weeks) and who met the inclusion criteria in the study
32909334|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
32909335|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
33237760|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
33237761|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
33237762|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
33237763|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
33237764|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
33237765|NCT04806282||1/All Patients|Documented hearing instability
33237766|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
32909336|NCT04926168||Adjuvant TMZ (Treatment group):|"Adjuvant TMZ (temozolomide) will be given to patients as standard of Care (SOC) treatment is administered on an outpatient basis.~Patients will be provided with medication diaries and instructed in their use. TMZ will be dispensed as SOC."
33237767|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
33237768|NCT00717483||Type 1 diabetes|children with type 1 diabetes
32909337|NCT04926168||Delay TMZ (Observation group):|"Patients in this cohort will have their TMZ in the adjuvant setting delayed and they will be observed with SOC procedures. Once the patient recurs, will be off observation and will be able to either have TMZ prescribed or something other."
33394601|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
33241726|NCT04125836|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
33241727|NCT00771459|Active Comparator|Ropivacaine|
33241728|NCT00771459|Placebo Comparator|Placebo|
32909338|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
32909339|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
33237769|NCT04934358|Experimental|Physical activity program and motivational intervention|Physical activity program agreed with the patient / family and according to functional status (based on the 6-minute walk test) and motivational intervention. In addition to the care provided in usual care, a progressive physical exercise program based on basal functional capacity is prescribed. The exercise will be developed at home.
33237770|NCT04934358|Active Comparator|Treatment as usual|Multidisciplinary rehabilitation provided by professionals in the hospital and primary care settings, according to the individual needs of patients at different times of their recovery and the accessibility and availability of services in the different care settings.
33237771|NCT04090580|Experimental|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
33237772|NCT04090580|Experimental|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
33237773|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
33237774|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
33394602|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
33394603|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
32744600|NCT04873791||Group 1|"Assessment Geriatric Individuals Living at Home were joined in Group 1.~Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
33241729|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
33241730|NCT00775281||1|
32909340|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
32753920|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
32753921|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
32753922|NCT02327975|Other|Control group|No received intervention.
32753923|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
32753924|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
32753925|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
33241731|NCT00775281||2|
33241732|NCT00775281||3|
32745055|NCT04429191|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|"The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.~The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose."
33241733|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
32745056|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
32745057|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
32909341|NCT01083368|Experimental|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
32745058|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
32745059|NCT04850157|Experimental|Tislelizumab+IMRT|
32909342|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
32909343|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
32745060|NCT04849533|Experimental|Group D Bela/EVR|rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
33241734|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
33241735|NCT04349072|Experimental|Drug: Mavacamten|"Mavacamten Capsules~Other names:~MYK-461"
33241736|NCT04349072|Placebo Comparator|Drug: Placebo|Matching Placebo Capsules
32753926|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
33394604|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
33394605|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
33394606|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
33394607|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
33394608|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
33394609|NCT05351489|Experimental|Dexmedetomidine 5 μg group (D5 group )|Dexmedetomidine 5 μg group (D5 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 5 μg intrathecal.
33394610|NCT05351489|Active Comparator|Dexmedetomidine 10 μg group (D10 group )|dexmedetomidine 10 μg group (D10 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 10 μg intrathecal .
33394611|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
33394612|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
33237775|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
33237776|NCT04089722|Other|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
33241737|NCT02557347|Experimental|Intervention|Aggressive fluid management
33394613|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
33241738|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
33394614|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
33394615|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
32753927|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
33237777|NCT05093166|Experimental|Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure|"The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted.~The treatment for urethra reconstruction required a two stage urethroplasty:~First stage: application of Holour on the wound bed prepared according to standard surgery The penis will be immobilized for some days after this operation.~Second stage: surgical procedure for urethral tubularization and penile reconstruction according to standard surgical procedure.~The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics."
33237778|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
33394616|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
32753928|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
33237779|NCT00712023|Active Comparator|1|warming by circulating-water mattress
33237780|NCT00712023|No Intervention|2|Forced-air warming mattress
33237781|NCT05683314||Acetabular_Pelvic_Sacral fracture with open reduction and internal fixation|
33237782|NCT05683314||Acetabular_Pelvic_Sacral fracture with minimally invasive internal fixation|
33237783|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
33237784|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
33237785|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
33237786|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
33237787|NCT00717561|Experimental|Arm 1|
33394617|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
33394618|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
33071006|NCT04376476|Experimental|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
33237788|NCT00717561|Active Comparator|Arm 2|
33237789|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
33237790|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
33237791|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
32745061|NCT04849533|Active Comparator|Group E Bela/MMF|rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
33394619|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
33394620|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
33237792|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
33237793|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
33237794|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
33237795|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
33237796|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
33237797|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
32744601|NCT04873791||Group 2|"Assessment Geriatric Individuals Living in Nursing Home were joined in Group 2. Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
33071007|NCT04376476|Experimental|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
33071008|NCT04376476|Experimental|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
33237798|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
33237799|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
32745062|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
33071009|NCT04331275|Experimental|Viral Specific T-cells (VSTs)|
33071010|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
33071011|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
33237800|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
33237801|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
33237802|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
33237803|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
33237804|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
33394621|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
33394622|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
33394623|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
33071012|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
33394624|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
33241739|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
33241740|NCT00775515|Experimental|one|laparoscopic prostatectomy
33241741|NCT05338502|Experimental|160 milligram (mg) Selpercatinib|Participants received a single oral dose of 160 mg Selpercatinib.
32745063|NCT03040635|Experimental|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
33394625|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
32753929|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
32745064|NCT03040635|Experimental|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
32745065|NCT03040635|Experimental|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
32745066|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
33241742|NCT05338502|Experimental|150 mg Ranitidine and 160 mg Selpercatinib|Participants received 150 mg ranitidine twice a day orally for 11 days and a single oral dose of 160 mg Selpercatinib.
33241743|NCT05338502|Experimental|40 mg Omeprazole and 160 mg Selpercatinib|Participants received 40 mg omeprazole once daily for 11 days and a single oral dose of 160 mg Selpercatinib.
33241744|NCT04078334|Experimental|Group 1|PATH Tool : Prescription of exercise programs at discharge
33241745|NCT04078334|Experimental|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
33241746|NCT04078334|Experimental|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
33241747|NCT04078334|No Intervention|Group 4|Control group: Usual care by the clinical teams
33241748|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
33394626|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
33071013|NCT04689841|Experimental|Vojta Therapy|In Vojta therapy, the therapist selectively presses certain areas of the body, with the patient lying prone, - supine or - lateral. These types of stimuli, in humans of any age, provoke automatically and without their own initiative, that is, without the active voluntary collaboration of the person
33071014|NCT04689841|Placebo Comparator|Control Group|In the control group, a placebo intervention is administered, similar to an experimental intervention
33394627|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
32745067|NCT02178358|Experimental|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
32753930|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
33241749|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
32753931|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
32753932|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
32753933|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
32753934|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
32753935|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
32753936|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
32753937|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
32753938|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
32753939|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
32753940|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade or SGLT2i.
32753941|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade or SGLT2i treatment. Drug injection (intravenous) + tablets
32753942|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
32745068|NCT02178358|Experimental|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
32744602|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
33237805|NCT04082130|Experimental|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:~After local anesthetizing the recipient site,CAF elevation will be done using (De Sanctis & Zucchelli 2007) design.Horizontal incisions will be done at the recession site,another two slightly divergent vertical incisions will be done at the end of previous incisions extending to the mucogingival junction.The resulting flap will be split thickness in the surgical papillae area,then will be full thickness exposing 3-4 mm of the bone apically of the dehiscence and after that it will be split thickness in the apical direction,all the muscle insertions will be eliminated,the root surface will be prepared by curettes and chemically treated with 24% EDTA gel.De-epithelialization of the interdental papillae will be done.The XCM will be trimmed and fix onto the root surface 1-2mm coronally of the CEJ using absorbable sutures,and the flap will be coronally advanced to fully cover the XCM and then sutured to the de-epithelialized papillae."
33237806|NCT04082130|Active Comparator|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these exceptions:~The entire flap will be elevated as split thickness instead of split-full-split thickness flap.~A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And absorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.~As in the test group the mucosal flap will coronally advanced to completely cover the SCTG then sutured to the de-epithelialized papillae."
33237807|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
33237808|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
33237809|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
33237810|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
33237811|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
32744603|NCT04868487|Experimental|Intervention|The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
33237812|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
33237813|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
33071015|NCT04321759|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
33237814|NCT00740792|Active Comparator|azelastine HCL|nasal spray
33237815|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
33394628|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
32744604|NCT04868487|No Intervention|Control|The control group had no educational interaction with the researcher after the pre-test. The control group was administered the one-week and three-month posttest THLS-32 by the researcher simultaneously with the intervention group.
32753943|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
33071016|NCT04321759|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
32744605|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
32744606|NCT04379973|Experimental|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
32744607|NCT04379973|No Intervention|No tubal flush after Hyfosy|
33394629|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
33394630|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
33394631|NCT03119506||Long Recess Duration/Before Lunch|
33394632|NCT03119506||Short Recess Duration/Before Lunch|
33394633|NCT03119506||Long Recess Duration/After Lunch|
33394634|NCT03119506||Short Recess Duration/After Lunch|
32753944|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
33394635|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
32753945|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
33071017|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
32753946|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
33237816|NCT00740792|Placebo Comparator|placebo|nasal spray
33237817|NCT00919698||Sedated mechanically ventilated patients|
32744608|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
33071018|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
33071019|NCT04689763|Experimental|Lifestyle Redesign Training|The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training.
33237818|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
33237819|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
33237820|NCT04895436|Experimental|Cohort 1 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.
32744609|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
32744610|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
32753947|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
33071020|NCT04689412||Cases|Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
33237821|NCT04895436|Experimental|Cohort 2 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.
33241750|NCT05337722|Experimental|App+fixed MI|The participants will use the SFT2.0 app and receive a fixed number of 4 counseling video sessions during pregnancy up to 1-month postpartum.
33394636|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
32745069|NCT02178358|Placebo Comparator|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
32909344|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
32909345|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
32909346|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
33071021|NCT04689412||Controls|Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
33071022|NCT04689451||Perclose ProGlide|Perclose ProGlide group: use Perclose ProGlide to suture the artery
33071023|NCT04689451||Surgical Arterial Repair|Surgical Arterial Repair group : suture the artery by surgery
33071024|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
33071025|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
33071026|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
33071027|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
33071028|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
33071029|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
33071030|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
33071031|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
32745070|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
32909347|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
33241751|NCT05337722|Experimental|Adaptive app + as-needed MI|The participants will use the SFT2.0 app and receive as-needed prenatal and postnatal video counseling sessions (between 1 and 10 sessions) during pregnancy up to 1-month postpartum.
33241752|NCT05337722|Active Comparator|Control|Participants will receive low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session.
33071032|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
32909348|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
33071033|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
32909349|NCT02440854||Patients with non-small cell lung cancer (NSCLC) treated with afatinib|Patients with advanced/metastatic non-small cell lung cancer (NSCLC) in Greece treated with afatinib. Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib. Patients were observed in the context of the study until the end of study participation, defined as a maximum of 48 months after afatinib treatment initiation or until disease progression, death, withdrawal of consent, unacceptable toxicity, study completion or physician's decision whichever occurred earlier.
32909350|NCT01084148|Experimental|V0034CR01B|cream
33071034|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
33071035|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
33394637|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
33394638|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
32909351|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
32909352|NCT04672226|Experimental|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
33071036|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
33071037|NCT04283578|Experimental|Oxytocin|intranasal administration of OT
33071038|NCT04283578|Placebo Comparator|Placebo|intranasal administration of placebo
33071039|NCT00148538|Active Comparator|1|resistance exercise
33071040|NCT00148538|Active Comparator|2|Aerobic and Resistance exercise
32909353|NCT01085006|Experimental|Tranexamic acid|
33071041|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
33071042|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
33071043|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
33071044|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
33071045|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
33071046|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
33394639|NCT04345367|Experimental|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
32909354|NCT01085006|Placebo Comparator|normal saline infusion|
32909355|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
33071047|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
33071048|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
33071049|NCT02929264|No Intervention|Control|No Intervention
33071050|NCT02929186|Experimental|Opt-In|Opt-In Outreach
33071051|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
33071052|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
33071053|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
33071054|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
33071055|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
33394640|NCT04345367|Active Comparator|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
33071056|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
33394641|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
33071057|NCT00148616|Active Comparator|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
33394642|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
32745071|NCT04849767||Transgender people living with HIV|Transgender person Living with HIV Followed in clinical service
33071058|NCT00148616|Placebo Comparator|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
33071059|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
32909356|NCT01085318|No Intervention|Arm 2 Healthy Control|
33071060|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
33071061|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
33071062|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
33071063|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
33237822|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
33394643|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
33071064|NCT02928796||Trainees|Registrar Cardiologists
33071065|NCT02928796||Trainers|Consultant Cardiologists
33394644|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
33071066|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
33071067|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
33071068|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
33071069|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
33394645|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
32745072|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
32745073|NCT01598896|Placebo Comparator|Placebo|Placebo
33394646|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
33394647|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
32745074|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
32745075|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
33394648|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
33394649|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
33394650|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
33394651|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
33394652|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
33394653|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
33394654|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
33394655|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
33394656|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
33394657|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
33394658|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
33394659|NCT03120208|Experimental|Partners|
33394660|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
33394661|NCT04404725|Experimental|comfilcon A then samfilcon A|Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.
33394662|NCT04404725|Active Comparator|samfilcon A then comfilcon A|Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.
33394663|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
33394664|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
33394665|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
33394666|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
33394667|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
33394668|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
33394669|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
33394670|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
33394671|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
33394672|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
33394673|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
33394674|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
33237823|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
33237824|NCT02595788||Supine position|Examination in the supine position
33237825|NCT02595788||Prone position|Change from supine to prone position
33237826|NCT00721071|Experimental|1|
32745076|NCT03042351|Other|Unique arm|Magic Kegel app
32745077|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
33071070|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
33071071|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
33237827|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
33237828|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
33237829|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
33237830|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
33237831|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
33237832|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
33237833|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
33237834|NCT00721383|Active Comparator|Control|caregiver skill-building
33237835|NCT00721461|Experimental|1|V930
33394675|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
33394676|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
33394677|NCT03207646|No Intervention|Control|Standard-of-care alone.
33394678|NCT05115383|Active Comparator|Sedentary Group|Individuals who are physically active for less than 75 minutes of moderate to vigorous physical activity a week will be placed in the sedentary group.
33394679|NCT05115383|Active Comparator|Active Group|Individuals who are physically active for greater than 150 minutes of moderate to vigorous physical activity will be placed in the active group.
33394680|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
33394681|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
33394682|NCT03749993|Other|Screening Arm|Screening
33237836|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
33237837|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
33237838|NCT00712491|Experimental|1|
33237839|NCT00712491|Experimental|2|
33237840|NCT04083066|Experimental|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
33237841|NCT04070547|Experimental|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
33237842|NCT04070547|Experimental|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
33237843|NCT04070547|Experimental|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
33237844|NCT04070547|Experimental|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
33237845|NCT05082402|Experimental|All Participants|50 participants identified in the Northwestern Medicine Division of Vascular Surgery.
33237846|NCT04069455|Experimental|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
33237847|NCT04069455|No Intervention|Control group|Clinical usual care during postoperative adjuvant chemotherapy
33394683|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
33394684|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
33394685|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
33394686|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
32753948|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
33237848|NCT05683782|Active Comparator|Test Group|"Split-thickness Apically Positioned Flap with topical Erythropoietin (Test group):~A split thickness horizontal incision will be done at the mucogingival junction of the targeted area to be augmented with a scalpel with blade number 15C. Around the teeth, the gingiva stays intact coronal to the horizontal incision. The horizontal incision will extend mesio-distally in accordance with the area to be augmented.(Mandibular anterior or premolar teeth).~A split-thickness flap is elevated, and the dissection is extended as far as necessary in the apical direction. The flap is secured to the periosteum with simple interrupted bio absorbable sutures.~A Chitosan based Erythropoietin gel will be prepared. 1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used. The patient will be instructed to use the gel on the surgical site two times daily for 14 days."
33237849|NCT05683782|Active Comparator|Control Group|"Split-thickness Apically Positioned Flap without Erythropoietin :~Local anesthesia is administered by infiltration technique. The same surgical procedure is performed with the application of Chitosan gel without being loaded with erythropoietin."
33237850|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
33071072|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
33071073|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
33071074|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
33071075|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
33071076|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
33071077|NCT02928601|Experimental|Ondansetron|
33071078|NCT02928601|Active Comparator|Saline|
33394687|NCT05064371|Experimental|Eptinezumab|Participants will receive eptinezumab 100 milligrams (mg) at the Baseline visit (Week 0) and eptinezumab 100 mg or 300 mg (depending upon the treatment response) at Weeks 12, 24, 36, and 48 by intravenous (IV) infusions.
33071079|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
33237851|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
33237852|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
33237853|NCT04877184|Experimental|Transcranial ultrasound stimulation and rehabilitation|The investigators expect to enroll 10 people in the experimental group.
33237854|NCT04877184|Active Comparator|Rehabilitation|The investigators expect to enroll 10 people in the control group.
33237855|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
33237856|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
33237857|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
33237858|NCT04068285|Active Comparator|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.~exercise"
33237859|NCT04068285|Active Comparator|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.~exercise"
33237860|NCT04068285|No Intervention|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
33237861|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
33237862|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
33237863|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
33237864|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
33071080|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
33237865|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
33237866|NCT05676684|Experimental|[Dapagliflozin] - [Spironolactone] - [Dapagliflozin + Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin + Spironolactone [week 33-44]"
33237867|NCT05676684|Experimental|[Dapagliflozin] - [Dapagliflozin + Spironolactone] - [Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Spironolactone [week 33-44]"
33071081|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
33071082|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
33071083|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
33071084|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
33071085|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
33071086|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
33071087|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
33071088|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
33071089|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
33071090|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
33071091|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
33071092|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
33071093|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
33394688|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
33071094|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
33071095|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
33237868|NCT05676684|Experimental|[Spironolactone] - [Dapagliflozin] - [Dapagliflozin + Spironolactone]|"Drug will be administered according to sequence:~Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Dapagliflozin + Spironolactone [week 33-44]"
33237869|NCT05676684|Experimental|[Spironolactone] - [Dapagliflozin + Spironolactone] - [Dapagliflozin]|"Drug will be administered according to sequence:~Spironolactone [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Dapagliflozin [week 33-44]"
33237870|NCT05676684|Experimental|[Dapagliflozin + Spironolactone] - [Spironolactone] - [Dapagliflozin]|"Drug will be administered according to sequence:~Dapagliflozin + Spironolactone [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin [week 33-44]"
33237871|NCT05676684|Experimental|[Dapagliflozin + Spironolactone] - [Dapagliflozin] - [Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin + Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Spironolactone [week 33-44]"
33237872|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
32753949|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
33237873|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
33237874|NCT04377945|Experimental|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
33237875|NCT04377945|Experimental|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
33237876|NCT04377945|Experimental|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
33237877|NCT04377945|Placebo Comparator|Part 1, Placebo Group|Part 1, Placebo Group
33237878|NCT04377945|Experimental|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
33237879|NCT04377945|Experimental|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
33237880|NCT04377945|Experimental|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
33237881|NCT04377945|Placebo Comparator|Part 2, Placebo Group|Part 2, Placebo Group
33237882|NCT00718185||A|Patients receiving sildenafil as standard of care
33237883|NCT04070469|Experimental|Patient reveiving amoxycillin|all patient included in this study
32753950|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
33237884|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
33237885|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
33237886|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
33237887|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
33394689|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
33394690|NCT05050409|Experimental|Brief mindfulness followed by brief mindfulness for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive another single session of brief mindfulness. Responders will continue to receive standard of care.
33237888|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
33394691|NCT05050409|Experimental|Standard care followed by brief mindfulness for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive one session of brief mindfulness. Responders will continue to receive standard of care.
33237889|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
33237890|NCT04067817|Experimental|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
33394692|NCT05050409|Experimental|Brief mindfulness followed by MORE for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
32909357|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
33394693|NCT05050409|Experimental|Standard care followed by MORE for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
33394694|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
32909358|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
32909359|NCT04670822|Experimental|Breastfeeding intervention group|A multicomponent behavioral intervention to promote breastfeeding
33237891|NCT04067817|Experimental|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
33237892|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
33237893|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
33237894|NCT00718341|Active Comparator|1|
33237895|NCT00718341|Placebo Comparator|2|
33237896|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
33394695|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
33394696|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
33394697|NCT04333199|No Intervention|Control|Patients do not receive an email
33394698|NCT04333199|Experimental|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
33237897|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
33237898|NCT00721929|Experimental|adrenal mass group|
33237899|NCT05592665|Other|Patient Perspective|Study participants will complete several questionnaires/assessments related to adverse events and quality of life.
32909360|NCT04670822|Placebo Comparator|Attention placebo control group|General infant care counseling and support
32909361|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
32909362|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
32909363|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
32909364|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
32909365|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
33237900|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
33237901|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
33237902|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
33237903|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
33237904|NCT02572635|Placebo Comparator|Placebo|Placebo
33237905|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
33237906|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
33237907|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
33237908|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
33237909|NCT04069065|Experimental|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
33237910|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
32909366|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
32909367|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
33237911|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
33237912|NCT00722085||Observational|
32909368|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
32909369|NCT01036490|No Intervention|Control|Control group
32909370|NCT01036490|Experimental|Exercise|Exercise Group
32909371|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
32909372|NCT01036802|Placebo Comparator|Placebo|matching active products
32909373|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
32909374|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
33237913|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
33237914|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
33237915|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
33237916|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
33237917|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
33237918|NCT05615363|Experimental|OPC 131461 10mg group|OPC-131461 5 mg tablet ｘ 2
33237919|NCT05615363|Experimental|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet
33237920|NCT05615363|Experimental|OPC 131461 2mg group|OPC-131461 1 mg tablet ｘ 2
33237921|NCT05615363|Experimental|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet
33237922|NCT05615363|Placebo Comparator|Placebo|Placebo tablet
33237923|NCT04070391|Experimental|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
33237924|NCT04070391|Placebo Comparator|control|One vinegar pill ingested daily for 4 weeks
33237925|NCT04089800|Experimental|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
33237926|NCT04089800|No Intervention|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
33237927|NCT05615051|Experimental|Group electrolytic approach (EA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) during 2 minutes
33237928|NCT05615051|Active Comparator|Group hydrogen peroxide (HP)|Group hydrogen peroxide (HP): Mechanical detoxification using curettes + NiTi brushes + hydrogen peroxide 5% for 2 minutes soaked in a gauze
33237929|NCT04070235|Experimental|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
33071096|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
33071097|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
33237930|NCT04070235|Experimental|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
33237931|NCT04070235|Experimental|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
33237932|NCT04070235|Experimental|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
33237933|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
33237934|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
32753951|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
32753952|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
32753953|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
33237935|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
33237936|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
33237937|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
33237938|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
33237939|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
33237940|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
33237941|NCT02603003|Experimental|Jinfukang|Jinfukang
33237942|NCT00722163|Experimental|1|behavioural
33237943|NCT00722163|Active Comparator|2|befriending
33237944|NCT00722163|No Intervention|3|TAU
33237945|NCT04106141|Other|control group|
33237946|NCT04106141|Active Comparator|intervention group|
33237947|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
33237948|NCT04106297|Experimental|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
33237949|NCT04106297|Placebo Comparator|Placebo SAD|Single doses of placebo
33237950|NCT04106297|Experimental|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
33237951|NCT04106297|Placebo Comparator|Placebo MAD|Multiple doses of placebo
33237952|NCT04106297|Experimental|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
33237953|NCT04106297|Experimental|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
33237954|NCT04106297|Experimental|GLPG3970 in psoriasis subjects|
33237955|NCT04106297|Experimental|Placebo in psoriasis subjects|
33394699|NCT04333199|Experimental|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
33237956|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
33237957|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
33237958|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
33237959|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
33237960|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
32753954|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
32753955|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
33237961|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
33237962|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
33237963|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
33237964|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
33237965|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
33237966|NCT05656599||Letermovir Group|HSCT recipients who received letermovir prophylaxis
33237967|NCT05656599||Preemptive therapy Group|HSCT recipients who received PCR-guided preemptive therapy
33237968|NCT04105829|Experimental|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
33237969|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
33237970|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
32753956|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
33237971|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
33394700|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
32753957|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
33394701|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
33394702|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
33394703|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
33237972|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
33237973|NCT05590793|Experimental|Triptorelin pamoate 22.5 mg 6-month formulation|All enrolled participants will receive one intramuscular (i.m.) injection of containing 22.5 mg 6-month formulation triptorelin pamoate on Day 1.
33237974|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;~Lung function testing with Bluetooth connection of external spirometry~Symptom evaluation~Actual treatment plan, based om lung function and symptoms~Trend views of lung function, symptoms and asthma control"
32753958|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
33237975|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
33237976|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
33237977|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
33237978|NCT04108169|Active Comparator|Active Comparator|
33237979|NCT04108169|No Intervention|Sham Comparator|
33237980|NCT05549297|Experimental|Arm A|Tebentafusp as single agent
33237981|NCT05549297|Experimental|Arm B|Tebentafusp in combination with Pembrolizumab
33237982|NCT05549297|Experimental|Arm C|Straight to on protocol survival follow up including investigators choice of therapy
33237983|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
33237984|NCT04067349|Active Comparator|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
33237985|NCT04067349|Active Comparator|open liver resection|Patients undergoing open liver resection
33237986|NCT00787319||AMD|
33237987|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
33237988|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
33237989|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
33237990|NCT02571231|Experimental|HFV+vg|volume guarantee given
33237991|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
33237992|NCT00915239|Active Comparator|Pantoprazole|
33237993|NCT00915239|Placebo Comparator|Placebo|
33237994|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
33237995|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
33237996|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
33237997|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
33237998|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
33394704|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
32753959|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
32753960|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
32753961|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
32753962|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
32753963|NCT02440555||patients included|fulfill the self-administered questionnaire.
32753964|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
32753965|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
32753966|NCT02039843|Active Comparator|1|Emotional Support Dogs
33394705|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
33394706|NCT03224806|Other|Wholegrain bread|
32753967|NCT02039843|Active Comparator|2|Service Dogs
32753968|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
32753969|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
32753970|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
32753971|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
33394707|NCT03224806|Other|White bread|
33394708|NCT03224806|Other|15% fiber-rich bread|
33394709|NCT03224806|Other|30% fiber-rich bread|
33237999|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
33238000|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
33238001|NCT05583617|Experimental|Substudy 2: Escalation Phase|In Cycle 1, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Cycle(C) 1 Day(D)1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on D1 and D15 for cycles 2-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle.
33238002|NCT05583617|Experimental|Substudy 2: Expansion Phase|During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle.
33238003|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
33238004|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
33238005|NCT05580653|Experimental|1) Beef then half beef and half pinto bean then pinto bean|
33238006|NCT05580653|Experimental|2) Half pinto bean and half beef then pinto bean then beef|
33238007|NCT05580653|Experimental|3) Pinto Bean then Beef then half pinto bean and half beef|
33238008|NCT05580653|Experimental|4) Egg then half Egg and half black bean then black bean|
33238009|NCT05580653|Experimental|5) Half egg and half black bean, then black bean then egg|
33071098|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
32753972|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
33071099|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
33071100|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
33071101|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
33071102|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
33071103|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
33071104|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
33071105|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
33071106|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
33394710|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
33394711|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
33394712|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
33238010|NCT05580653|Experimental|6) Black bean then egg then half black bean and half egg|
33238011|NCT00713193|Experimental|1|Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.
33238012|NCT00713193|Active Comparator|2|Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.
33238013|NCT04107779|Experimental|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product [6 days] in confinement.
33238014|NCT04107779|Experimental|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product [6 days] in confinement.
33238015|NCT04107779|Experimental|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product [6 days] in confinement.
32753973|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
32753974|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
32905328|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
32905329|NCT00867932|Experimental|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
32905330|NCT05236088|Experimental|NMES group|Neuromuscular electrical stimulation (NMES) will be applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device for 30 minutes 3 days a week during 4 weeks
33071107|NCT03457480|Experimental|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
33071108|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
33071109|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
33071110|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
33238016|NCT04107779|Experimental|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product [6 days] in confinement.
33238017|NCT04107779|Experimental|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product [6 days] in confinement.
33238018|NCT04107779|Experimental|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product [6 days] in confinement.
33238019|NCT04107779|Experimental|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product [6 days] in confinement.
33238020|NCT04107779|Experimental|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product [6 days] in confinement.
33238021|NCT04107779|Experimental|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette [6 days] in confinement.
33238022|NCT04107779|Active Comparator|UB of Combustible Cigarette|Usual brand combustible cigarette [6 days] in confinement.
32744611|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
33238023|NCT04107779|Other|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) [6 days] in confinement.
33238024|NCT04067505|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
33238025|NCT04067505|Active Comparator|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
33238026|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
33394713|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
33071111|NCT02927626|Placebo Comparator|Routine medical care|
33071112|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
33394714|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
33394715|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
33071113|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
33071114|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
33071115|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
33071116|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
33071117|NCT02927353|Active Comparator|adalimumab|adalimumab
33071118|NCT00176085||healthy|healthy volunteers
33071119|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
33071120|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
33071121|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
33071122|NCT00148889|Sham Comparator|2|Sham-stimulation
33394716|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
33071123|NCT00148889|Active Comparator|1|Active GPI-DBS
33071124|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
33071125|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
33071126|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
33238027|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
33071127|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
33238028|NCT00713271|Experimental|1|Low dose
33238029|NCT00713271|Experimental|2|intermediate dose
33238030|NCT00713271|Experimental|3|high dose
33238031|NCT00713271|Placebo Comparator|4|
33238032|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
33238033|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
33071128|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
33071129|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
33394717|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
33071130|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
33071131|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
33394718|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
32909375|NCT04498208|Experimental|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 14 days to a maximum of 42 days before surgery
33394719|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
32909376|NCT04498208|No Intervention|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 14 days prior to surgery.
33394720|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
32909377|NCT03014258|Active Comparator|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
33394721|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
33238034|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
33238035|NCT04105361|Experimental|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
33238036|NCT04105361|Experimental|Control group|We will do FESS only in the other side of the nose
33238037|NCT05673135|Other|Non-obese hypertensive pregnant women|
33238038|NCT05673135|Other|Obese hypertensive pregnant women|
33238039|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
33394722|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
33394723|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
33394724|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
33071132|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
33071133|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
33238040|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
33071134|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
33071135|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
33071136|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
33238041|NCT00722709|Experimental|LA|Use of Ropivacaine
33238042|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
33238043|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
33238044|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
33238045|NCT04105205|Experimental|Apramycin injection in escalating doses|Apramycin, solution for infusion.
33238046|NCT04105205|Placebo Comparator|Placebo|Physiological saline, solution for infusion.
32909378|NCT03014258|Active Comparator|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
33394725|NCT04403399|Experimental|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
33394726|NCT04403399|Experimental|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
33394727|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
33394728|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
33238047|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
33238048|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
33238049|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
33238050|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
33238051|NCT05683236|Experimental|intervention group|The patients in the intervention group received multidisciplinary collaborative team care combined with palliative care.
33238052|NCT05683236|Active Comparator|control group|The control group was given routine nursing intervention.
33238053|NCT05068908||Low-impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be low-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
33238054|NCT05068908||High- impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be high-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
33238055|NCT05068908||Pain-free controls|Participants without chronic painful TMD. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
33238056|NCT05068908||Pilot study-MRI optimization group|"A pilot study will be conducted separately from the main project for optimization of MRI parameters, where up to five participants will be recruited as a separate group to undergo only MRI sessions (single study visit). The goal is to optimize the parameters of the main project's MR imaging protocol in order to minimize imaging distortions related to the presence of the thermodes in close proximity to the field of view for the brain."
33238057|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
33238058|NCT00919464|Other|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
33238059|NCT04857372|Experimental|Group 1|Malignant pleural mesothelioma
33071137|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
33071138|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
33071139|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
33238060|NCT04857372|Experimental|Group 2|NF2 truncating mutations or deletions
33238061|NCT04857372|Experimental|Group 3|Solid tumors with functional YAP/TAZ fusions
33238062|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
33238063|NCT05373693|Placebo Comparator|Control group|The subjects are randomized to wear SV lens
33238064|NCT05373693|Experimental|experimental group +2D|The subjects are randomized to wear special designed lens with +2D Peripheral Defocus.
33238065|NCT05373693|Experimental|experimental group +3D|The subjects are randomized to wear special designed lens with +3D Peripheral Defocus.
33238066|NCT05373693|Experimental|experimental group +4D|The subjects are randomized to wear special designed lens with +4D Peripheral Defocus.
33238067|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
33071140|NCT00170235|Active Comparator|2|Usual care as provided by the institution
33071141|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
33071142|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
33071143|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
33071144|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
33071145|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
33238068|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
33238069|NCT05667792|Experimental|Study Group- 4-11 age|
33238070|NCT05667792|Placebo Comparator|Control Group-4-11 age|
33238071|NCT05667792|Experimental|Study Group- 11-18 age|
33238072|NCT05667792|Placebo Comparator|Control Group-11-18 age|
33238073|NCT04018911|Active Comparator|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
33238074|NCT04018911|Experimental|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
33238075|NCT04018911|Experimental|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
33238076|NCT04018911|Experimental|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
33238077|NCT05061654|Experimental|Treatment arm|Eligible patients will be started on empiric ceftolozane-tazobactam in addition to standard care.
33238078|NCT04070079|Other|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
33238079|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
33238080|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
33238081|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
33071146|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
33071147|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
33071148|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
33071149|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
33071150|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
33071151|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
33071152|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
33238082|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
33071153|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
33071154|NCT02926495|Active Comparator|Treatment (ON)|
33071155|NCT02926495|Sham Comparator|Control (OFF)|
33071156|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~Level medium~Max. Rate: 110ppm VSR: Off"
33071157|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
33238083|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
33238084|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
33238085|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
33238086|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
33238087|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
33238088|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
33238089|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
32744612|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
33238090|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
33238091|NCT04089644|Active Comparator|manual group|Hypotension will be corrected by manual infusion of norepinephrine
33238092|NCT04089644|Experimental|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
33238093|NCT00713739|Experimental|1|Alfuzosin 10mg daily
33238094|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
33238095|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
33238096|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
32744613|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
33394729|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
33394730|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
32745078|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
33071158|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
33071159|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
33071160|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
33071161|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
33071162|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
33071163|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
33071164|NCT02926105|Experimental|Otago|Individually tailored exercise programme
33071165|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
33071166|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
33394731|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
32745079|NCT04849065|Experimental|MNC (Mononuclear cells)|"MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).~This group would consist of 74 patients."
32745080|NCT04849065|Placebo Comparator|Saline|(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.
33071167|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
33071168|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
33071169|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
33394732|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
33394733|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
33071170|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
33238097|NCT04081662|Experimental|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
33238098|NCT05379920|Experimental|Concussed Participants Group 1|High Volume Group
33238099|NCT05379920|Experimental|Concussed Participants Group 2|Low Volume Group
33238100|NCT05379920|Active Comparator|Healthy controls Group 1|High Volume Group
33238101|NCT05379920|Active Comparator|Healthy Controls Group 2|Low Volume Group
33238102|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
33238103|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age~Venography with balloon occlusion test will be performed."
33394734|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
33238104|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
33238105|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
33238106|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
33238107|NCT05566704||Modulus ALIF System|
33238108|NCT05373069|Experimental|Group intervention|PIM - DIEP
33238109|NCT02595476|Experimental|BIS 55|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 55~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
33394735|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
33238110|NCT02595476|Active Comparator|BIS 25|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 25~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
33238111|NCT05563038|Experimental|Scrambler Therapy Group|Patients undergoing treatment by Scrambler Therapy will begin by describing the areas and levels of pain along the Numerical Rating Scale (NRS) from 0-10. After the Scrambler treatment, patients will again be asked to describe the areas and levels of pain using the NRS. Each patient undergoing Scrambler Therapy will undergo this process for 5 consecutive days, following the same procedure every day of treatment. After completion of treatment, participants will be asked to complete monthly ratings of their pain for three months, and to follow-up in clinic at 3-6 month intervals (standard of care).
33238112|NCT05563038|Active Comparator|Non-Scrambler Therapy Group|For patients electing to start or continue pharmacotherapy, doses will be up-titrated as per standard of care. Pain will be assessed using the NRS monthly by phone as well as regularly scheduled follow-up appointments (typically 3-6 months apart).
33238113|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
33238114|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
33238115|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
33238116|NCT00713895|Active Comparator|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
33238117|NCT00713895|Experimental|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
33238118|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
33238119|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
33238120|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
33238121|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
33238122|NCT05636514|Experimental|Decitabine/cedazuridine + defactinib|"Decitabine/cedazuridine taken days 1-5 of each 28 day treatment cycle, cycle 1 to 6~Defactinib taken on days 1-5 of each 28 treatment day cycle from cycle 2 to cycle 6."
33238123|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
33238124|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
33238125|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
33238126|NCT05635032||IPF|Patients with Idiophatic Pulmonary Fibrosis (IPF), serving as a prototype of a progressive fibroproliferative disorder.
33238127|NCT05635032||Progressive Pulmonary Fibrosis (non-IPF)|Patients with non-IPF interstitial lung diseases, presenting a progressive fibrosing phenotype, or acute exacerbations.
33238128|NCT05635032||Non-Progressive Pulmonary Fibrosis (non-IPF)|Patients with fibrotic non-IPF interstitial lung diseases that are stable during a minimum follow-up of 24 months.
33238129|NCT02570529|Experimental|Albis®|The intervention group
33238130|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
33238131|NCT05372835|Experimental|mouthwash|The 15 mL of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) was used for intervention to rinse in mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
33394736|NCT04459715|Experimental|Xevinapant (Debio 1143)|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Xevinapant (Debio 1143)~Monotherapy period (Cycles 4-6):~• Xevinapant (Debio 1143)"
33238132|NCT05372835|Experimental|mouthwash and periodontal flosser|The 15 ml of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) in conjunction with the La Chlogen periodontal flosser (Republic of China Patent No. M590033) were used for intervention in the mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
33238133|NCT05372835|Placebo Comparator|control|The pure water without HOCl chemical was applied in this intervention to rinse in mouth for 5 minutes.
33238134|NCT05372757|Experimental|Partial Heart Transplantation Arm|
33238135|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
33238136|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
33238137|NCT04079556|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
33238138|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
33238139|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
33238140|NCT04081194||control group|"10 Persons without Melanoma, age > 40 years~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
33238141|NCT02586324|Other|global medium|
33238142|NCT02586324|Experimental|SSM|
33238143|NCT04586010|Experimental|Fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
33238144|NCT04586010|Active Comparator|Teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
33238145|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
33238146|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
33238147|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
33238148|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
33238149|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
33238150|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
33238151|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
32898130|NCT04140526|Experimental|ONC-392 in combination with pembrolizumab|"The Part B1 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).~The Part B1 will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.~In Part C, the expansion cohorts Arm D to G will assess the safety and efficacy of ONC-392 in different dose levels and Pembrolizumab combination therapy in non small cell lung cancer, and metastatic melanoma."
33238152|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
32898131|NCT04115371|No Intervention|Control|Standard emergency department care
33238153|NCT00435409|Experimental|A|
33238154|NCT00435409|Active Comparator|B|
33238155|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
33238156|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
33238157|NCT04335591|Experimental|Linzagolix 75 mg|
33238158|NCT04335591|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
33238159|NCT04126824|Active Comparator|Bupivacaine|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.
33238160|NCT04126824|Experimental|Bupivacaine and Triamcinolone|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.
33238161|NCT00724113|Active Comparator|1|infiltration intra articular
33238162|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
33238163|NCT04581330|Experimental|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
33238164|NCT04581330|No Intervention|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
33238165|NCT04070001|Active Comparator|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
33238166|NCT04070001|Active Comparator|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
33238167|NCT04070001|Placebo Comparator|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
33238168|NCT04081506|Experimental|Group A|Individualized care
33238169|NCT04081506|No Intervention|Group B|Conventional care
33238170|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
33238171|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
33238172|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
33238173|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
33238174|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
33238175|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
33238176|NCT05328219|Experimental|Chewing gums with PEG solution|The investigator provide the chewing gums with PEG solution to the experimental group.
33238177|NCT05328219|Active Comparator|Standard of Care|Care provided as per the standard existing routine.
33394737|NCT04459715|Active Comparator|Placebo|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Matched placebo~Monotherapy period (Cycles 4-6):~• Matched placebo"
33394738|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
33394739|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
33238181|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
33238182|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
33238183|NCT05315661|Experimental|Treatment Arm|injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals
32898132|NCT04115371|Other|Intervention|Standard emergency department are plus GEDI consult
33071171|NCT04257526|Active Comparator|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
33071172|NCT04257526|No Intervention|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
33071173|NCT00170469|Experimental|1|Low dose rPA vaccine
33071174|NCT00170469|Experimental|2|High dose rPA vaccine
33071175|NCT00170469|Active Comparator|3|Active vaccine control
33071176|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
33071177|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
33071178|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
32909379|NCT03014258|Active Comparator|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
32909380|NCT03014258|Active Comparator|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
32909381|NCT03014258|Experimental|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
33238184|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
33394740|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
33238185|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
33238186|NCT00714129|Experimental|1|Weight loss diet - normal diet
33238187|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
33238188|NCT03635073|Experimental|Soticlestat|Treatment: Soticlestat, tablets orally twice daily at optimized dose, titrated in up to 2 weeks of Dose Optimization Period, followed by Maintenance Period, which lasts until development is stopped by the sponsor, or the product is approved for marketing, or at any time at the discretion of the sponsor.
33238189|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
33238190|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
33394741|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
33394742|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
33394743|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
32905331|NCT05236088|Sham Comparator|Sham group|Sham group will be applied from the same device (INNOVO brand (Atlantic Therapeutics, Galway, Ireland)), for 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
33394744|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
33394745|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
33394746|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
33394747|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=low dose buprenorphine + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
33071179|NCT04689607|Experimental|Mulligan Traction Straight Leg Raise (TSLR)|This technique involves sustained traction applied to the limb. Patient actively does the SLR and both the therapist and the patient note the range. Therapist now grasp patient lower leg proximal to the ankle joint and raise it off the bed to a position just short of the painful range. Therapist flexes his knees and holds the clasped leg to his (therapist's) chest. When the therapist extends his knees this will effectively apply a longitudinal traction to the leg provided the bed is low enough and the therapist is tall enough. Sustain this traction and undertake a straight leg raise as far as it will go provided there is no pain.When pain free SLR with traction is given for three times.
33071180|NCT04689607|Active Comparator|Post Isometric Relaxation technique (PIR):|The patient is placed in the supine position with the non-affected leg lying flat on the table. The knee of the affected leg is gently placed in extension, and the affected hip is then flexed. The calf of the patient is then placed on the shoulder of the practitioner The practitioner stands on the side of the affected leg. The hands of the practitioner are then placed over the upper leg, just proximal to the knee. The hip of the affected leg is then passively flexed until resistance is felt. The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance. The practitioner resists hip extension to create an isometric contraction and then, after appropriate time and breathing instructions. The patient is instructed to relax and the practitioner gently flexes the hip until the next barrier is reached. After a period of relaxation, the technique will be repeated three to four times.
33394748|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=high dose buprenorphine + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
33238191|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
33394749|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=low dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
33394750|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=high dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
33394751|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=low dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
33071181|NCT04689217|Experimental|Group F|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml fentanyl (25 μg)
33071182|NCT04689217|Experimental|Group N|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.8 mg nalbuphine hydrochloride
33071183|NCT04689217|Placebo Comparator|Group C|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml normal saline
33071184|NCT00149162|Active Comparator|1|Patients treated by Proleukin
33071185|NCT00149162|No Intervention|2|Without Proleukin
33394752|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=mid dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
32909382|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
32909383|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
32909384|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
32909385|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
32909386|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
32909387|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
32909388|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
33071186|NCT02925637|Experimental|FACoT group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
33071187|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
33071188|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
32909389|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
32909390|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
33071189|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
33071190|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
32745081|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
33238192|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
33238193|NCT05188599||Amputee patients|age between 18-65 years, (b) time after amputation ≥ 6 months, (c) unilateral or bilateral amputation above the ankle level
33238194|NCT00724581|Experimental|A|
33238195|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
33238196|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
33238197|NCT04736628|Experimental|Dose group 1: BI 685509|Low dose.
33238198|NCT04736628|Placebo Comparator|Dose group 1: Matching placebo|Matching placebo for low dose.
33238199|NCT04736628|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
33238200|NCT04736628|Placebo Comparator|Dose group 2: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose.
33238201|NCT04736628|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
33238202|NCT04736628|Placebo Comparator|Dose group 3: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.
33238203|NCT05079009|Experimental|ECCO2R pulsatile configuration|Adult patients hospitalized in the medical ICU for whom a treatment by ECCO2R has been indicated.
33238204|NCT04067037|Experimental|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
33238205|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
33238206|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
33238207|NCT04732416|Experimental|HM15136 active|Cohort A / Cohort C
33238208|NCT05045079|Other|Severe tricuspid regurgitation due to atrial fibrillation|Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.
33238209|NCT04730544|Experimental|Experimental Arm A|"Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):~Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
33238210|NCT04730544|Active Comparator|Control Arm B|"Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):~Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
33238211|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
33238212|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
33238213|NCT05021757||Disrupt CAD III PAS Cohort|Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort. A minimum of 150 patients with 30-day follow-up will be included in the PAS cohort.
33238214|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
33238215|NCT02586168|Placebo Comparator|Placebo|Placebo
33238216|NCT04079478||AI|Artificial Intelligence colonoscopy
33238217|NCT04079478||Control|White light colonoscopy
33071191|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
33238218|NCT04081116|Experimental|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
33238219|NCT04081116|Experimental|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
33238220|NCT04081116|Sham Comparator|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
33238221|NCT04666038|Experimental|Arm A (LOXO-305)|Orally
33238222|NCT04666038|Active Comparator|Arm B (Idelalisib plus rituximab [IdelaR] or bendamustine plus rituximab [BR])|Investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
33238223|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
33238224|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
33071192|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
33071193|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
32745082|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
33071194|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
32753975|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
32753976|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
32753977|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
33071195|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
32753978|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
33238225|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.~Determine how the Evolut PRO conforms to LVOT calcification.~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
33394753|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=high dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
32753979|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
32753980|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
32753981|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
33071196|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
33394754|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
33394755|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
32753982|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
33394756|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
33394757|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
33394758|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
33394759|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
33394760|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
33394761|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
33394762|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
33394763|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
33394764|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
32753983|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
32753984|NCT03111641|Experimental|Lung ultrasonography|
33394765|NCT04484740|Experimental|Gepotidacin|
33071197|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
33071198|NCT02925247|Other|patient with atrial fibrillation|
33071199|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
33071200|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
32753985|NCT04682392|Active Comparator|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|This group will use Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction for rehab.
33394766|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
32753986|NCT04682392|Active Comparator|Non Delfi PTS Personalized Tourniquet System for Blood Flow Restriction Group|Standard post operative ACL rehab without Blood flow restriction
32753987|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
32753988|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
32753989|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
33394767|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
33394768|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single Photodynamic therapy (PDT)."
33394769|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
32905332|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
33394770|NCT02451904||Uncomplicated Malaria|Intensive monitoring
33394771|NCT02451904||Sepsis|Intensive monitoring
33394772|NCT02451904||Acidosis|Intensive monitoring
32905333|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
33394773|NCT02451904||Encephalitis|Intensive monitoring
33394774|NCT02451904||Healthy Individuals|Monitoring
33394775|NCT03224338|Experimental|: Dolutegravir (DTG)|
33394776|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
33394777|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
33071201|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
33394778|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
32905334|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
32905335|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
32745083|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
32909391|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
32745084|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
32745085|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
32745086|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
32745087|NCT02153086||Ramelteon 8 mg Tablets|
32745088|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (simultaneous)|n=12
32745089|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (staggered)|n=12
32909392|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
32909393|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
32909394|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
32909395|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
32909396|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
32745090|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
32745091|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
32745092|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
32745093|NCT04858659|Experimental|PK101 group|
33238226|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
32745094|NCT04858659|Active Comparator|PK101-002 group|
32909397|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
33238227|NCT04663308|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
33238228|NCT04663308|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
33238229|NCT04663308|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
32905336|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
32905337|NCT05236010|Active Comparator|Active rTMS with Attention Process Training|Subjects in this arm will receive active rTMS and then complete the assigned Attention Process Training battery immediately following active rTMS.
33394779|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
33394780|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
33394781|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
32745095|NCT04848987|Active Comparator|Etch-and-rinse (Variolink N) resin cement|For etch-and-rinse resin cement, 40 inlays were cemented by Variolink N resin cement.
33071202|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
32745096|NCT04848987|Placebo Comparator|Self-etch (Panavia F2.0) resin cement|Regarding self-etch resin cement, 40 inlays were cemented by Panavia F2.0 resin cement.
33071203|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
32745097|NCT04848987|No Intervention|Self-adhesive (RelyX Unicem) resin cement|For self-adhesive resin cement, 40 inlays were cemented by RelyX Unicem resin cement.
32745098|NCT04858581|Other|Healthcare workers who had a diagnosis confirmed by a nasopharyngeal RT-PCR test with SARS-CoV-2|Survey, RT-PCR test and blood test.
32745099|NCT04859751|Experimental|VB4-845 Injection|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
32745100|NCT04860063|Placebo Comparator|Placebo|Placebo three times daily for 6 months
32745101|NCT04860063|Experimental|Berberine|Berberine 500 mg three times daily for 6 months
32745102|NCT04860219|No Intervention|Control Group|None of the participants in the Control Group received lactoferrin
32745103|NCT04860219|Active Comparator|200 mg lactoferrin orally once daily Group|received 200 mg lactoferrin orally once daily
32745104|NCT04860219|Active Comparator|200 mg lactoferrin orally twice daily Group|received 200 mg lactoferrin orally twice daily
32745105|NCT04848207|Other|Digital impression technique|- 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
33394782|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
33071204|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
32909398|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
33394783|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
33394784|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
33071205|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
32909399|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
32909400|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
32905338|NCT05236010|Sham Comparator|Sham rTMS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training immediately following sham rTMS.
33394785|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
33238230|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer > 8 U/mL).
33238231|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
33238232|NCT04962789||with compaction|those whose endometrial thickness is calculated to decrease by the time of embryo transfer compared with the thickness at the day of ovulation trigger, analyzed according to the degree of compaction, i.e., 5%, 10%, 15%, or 20% decrease thickness
33238233|NCT04962789||without compaction|those who had an increase in their endometrial thickness or whose thickness decreased less than 5%
33238234|NCT04956627|Experimental|BMS-986166|
33238235|NCT04956627|Experimental|BMS-986166 + Itraconazole|
33238236|NCT04956627|Experimental|BMS-986166 + Phenytoin|
33238237|NCT04956627|Experimental|BMS-986166 + Gemfibrozil|
33238238|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
33238239|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
33238240|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
33238241|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
33238242|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
33238243|NCT04710420||WIfI composite 1-4|Summing the three individual WIfI components together, the WIfI composite score 1-4.
33238244|NCT04710420||WIfI composite 5-9|Summing the three individual WIfI components together, the WIfI composite score 5-9.
33238245|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
33238246|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
33238247|NCT04066803|Experimental|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
33238248|NCT04066803|Active Comparator|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
33238249|NCT04701684|Experimental|Direct tot Angiography Suite (DTAS) triage workflow|
33238250|NCT04701684|Active Comparator|Conventional CT/MR triage workflow|
33238251|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
33238252|NCT04921371|Other|Healthy Reference Group|Participants who are identified as healthy will be a comparison group. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product.
33238253|NCT04921371|Experimental|5% Hydroalcohol Mouthrinse (Negative control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks.
33238254|NCT04921371|Experimental|Listerine® Cool Mint® (Positive control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks.
33238255|NCT04921371|Experimental|Mouthrinse Prototype 1|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks.
33238256|NCT04921371|Experimental|Mouthrinse Prototype 2|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks.
33238257|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
33238258|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
33238259|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
33238260|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
33394786|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
33394787|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
32909401|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
32909402|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
32909403|NCT01041248|Experimental|Tocilizumab|Single arm open label study. In this arm patient will receive 8mg/kg of Tocilizumab q 2 weeks iv.
32909404|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
32909405|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
32909406|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
32909407|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
32909408|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
32909409|NCT01110434|Placebo Comparator|Sugar pill|
32909410|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
32909411|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
32909412|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
32909413|NCT01111058|Experimental|Placebo|Subjects will receive double-blind placebo
32909414|NCT02246738||Cohort1|
32909415|NCT02246738||Cohort 2|
32905339|NCT05236010|Active Comparator|Active HD-tDCS with Attention Process Training|Subjects in this arm will receive active HD-tDCS and complete the assigned Attention Process Training battery during active HD-tDCS.
32909416|NCT02246738||Cohort 3|
32909417|NCT02246738||Cohort 4|
32909418|NCT02246738||Cohort 5|
32909419|NCT02246738||Cohort 6|
32909420|NCT02246738||Cohort 7|
32905340|NCT05236010|Sham Comparator|Sham HD-tDCS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training during sham HD-tDCS.
32909421|NCT02246738||Cohort 8|
32909422|NCT02246738||Cohort 9|
32909423|NCT01111370|Experimental|CGM|continuous glucose monitoring system
33394788|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
33394789|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
33394790|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
33394792|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
33394793|NCT03223792|Active Comparator|Control|
33394794|NCT03223792|Experimental|Investigational|
32909424|NCT01112228||Obese patients|Obese patients for Bariatric surgery
33238261|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
33238262|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
33238263|NCT05648565|Experimental|Radiofrequency ablation (RFA)|
33238264|NCT04837833|Experimental|research ultrasound (rUS1)|Participants will undergo research ultrasound (rUS1) within three days of their routine contrast enhanced CT scan (CECT). A subset of participants will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.
33238265|NCT00725439|Experimental|A|Talarozole
33238266|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
33238267|NCT00920166|Active Comparator|Modilac 1|Regular milk
33238268|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
33238269|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
33238270|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
33238271|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
33238272|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
33238273|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
33238274|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
33238275|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
32905341|NCT05235932|Experimental|Robotic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received robotic radical total gastrectomy with D2 lymphadenectomy
32909425|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
32909426|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
33238276|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
33238277|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.~No intervention is included in this study."
32909427|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
32905342|NCT05235932|Active Comparator|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received laparoscopic radical total gastrectomy with D2 lymphadenectomy
32905343|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
32905344|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
32905345|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
32905346|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
33238278|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
33394795|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
32905347|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
33394796|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
33394797|NCT01562561|Experimental|Rep + NPH|
33394798|NCT01562561|Active Comparator|NPH|
32909428|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
33394799|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
33394800|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
33394801|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
32898133|NCT04110236|Experimental|Immediate PriCARE|Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 1-2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
32905348|NCT05235620||Pharmacy staff|Pharmacy staff working at pharmacies which have chosen to implement PatientToc software for this implementation science project and evaluation. Pharmacy staff will be observed and participate in interviews pertaining to their experiences using PatientToc.
32745106|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
32745107|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
32909429|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
32745108|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
32909430|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
32909431|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
32909432|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
32909433|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
32909434|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
32909435|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
32745109|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
32909436|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
32909437|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
32909438|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
32909439|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
32909440|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
32909441|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
33238279|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
33238280|NCT00725517|Experimental|1|Icodextrin group
33238281|NCT00725517|No Intervention|2|Glucose group
33238282|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
33238283|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
33238284|NCT04066881|Experimental|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Truvada (0-26 weeks)"
33238285|NCT04066881|Experimental|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Truvada (0-26 weeks)"
33238286|NCT04066881|Placebo Comparator|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Truvada (0-26 weeks)"
33238287|NCT04066881|Active Comparator|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Descovy (0-26 weeks)"
33238288|NCT04066881|Experimental|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Descovy (0-26 weeks)"
33394802|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
33394803|NCT04454567|Experimental|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
33394804|NCT04454567|Placebo Comparator|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
33394805|NCT03206632|Experimental|BI 690517 dose group 1|
33394806|NCT03206632|Experimental|BI 690517 dose group 2|
33394807|NCT03206632|Experimental|BI 690517 dose group 3|
33394808|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
33394809|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
33394810|NCT03206554|Sham Comparator|sham LIA|Saline injections
33238289|NCT04066881|Placebo Comparator|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Descovy (0-26 weeks)"
33238290|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
33238291|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
33238292|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
33238293|NCT04620291|Experimental|Cohort A|250 mg UB-421 SC: ART-treated subjects
33238294|NCT04620291|Experimental|Cohort B|500 mg UB-421 SC: ART-treated subjects
33238295|NCT04620291|Experimental|Cohort C|700 mg UB-421 SC: ART-treated subjects
33238296|NCT04620291|Experimental|Cohort D|500 mg UB-421 SC: Treatment naive subjects
32745110|NCT04848363|Experimental|Study group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
33238297|NCT04620291|Experimental|Cohort E|700 mg UB-421 SC: Treatment naive subjects
33238298|NCT04657068|Experimental|Part A1|Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.
33238299|NCT04657068|Experimental|Part A2|Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
32909442|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
32909443|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
33238300|NCT04657068|Experimental|Part A3|Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 12 participants will participate in this dose escalation arm.
32909444|NCT01113008|Placebo Comparator|Control group|
32909445|NCT00585195|Experimental|1|
32909446|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
32909447|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
32909448|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
32909449|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
32909450|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
32898134|NCT04110236|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
32898135|NCT04110236|Experimental|Immediate PriCARE Positive Discipline Module|A subset of participants (up to 40 caregiver-child pairs) who were assigned to the immediate PriCARE group will be offered to participate in the PriCARE Positive Discipline Module if they attended at least 4 PriCARE sessions and completed both main study interviews. If they are randomized to the immediate PriCARE Positive Discipline group, they will attend an additional 4-6 sessions 4-6 weeks after completion of the 6-week PriCARE intervention. This module teaches techniques related to behavior reward charts, appropriate timeout protocol, and other positive discipline techniques for handling persistent behaviors not addressed by the other PriCARE skills.
32909451|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
32909452|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
32909453|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
32909454|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via aqueous nasal spray|
33238301|NCT04657068|Experimental|Part B1|"In Part B1, up to 3 cohorts making up to a total of approximately 90 participants with solid cancers with alterations in the ATM (ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein will be treated with either~ART0380 monotherapy Or~ART0380 in combination with irinotecan Or~ART0380 in combination with gemcitabine"
32909455|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via HFA nasal aerosol|
32909456|NCT00458835|Active Comparator|Ciclesonide 320 mcg orally inhaled via HFA MDI|
32909457|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
33238302|NCT04657068|Experimental|Part B2|In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open-label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
33238303|NCT00725673||1|GOLD II COPD patients with osteoporosis
33238304|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
33238305|NCT04689828|Experimental|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
32909458|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
33394811|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
33394812|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
33394813|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
33394814|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
33238306|NCT04689828|Active Comparator|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
33238307|NCT04434417||Cohort tested|The cohort will include patients or health professionals who patients who were suspected of being infected with 2019-nCoV
33238308|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
33238309|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
33238310|NCT02586714||Normal weight|
33238311|NCT02586714||Overweight|
33238312|NCT02586714||Obese|
33238313|NCT04819425|Experimental|Elastic Adhesive Strips|"Endotracheal tube fixed by elastic adhesive tape (Tensoplast type adhesive tape):~The adhesive tape will be attached to the patient's face (opposite side to the endotracheal tube) and then two turns around the endotracheal tube will be made. The rest of the adhesive tape will be attached to the other side of the face (side of the endotracheal tube).~The laminated tape will be kept on the adhesive tape until it passes over the neck in order to avoid adhering to the hair.~Finally, the end of the adhesive tape will be replaced on the part already attached to the patient.~It will be changed daily and after stain or examinations if necessary."
33238314|NCT04819425|Active Comparator|Lace in A Protective Sheath|"A loop is made with the lace then the endotracheal tube is passed through the loop. The loop is tightened by pulling each side on the remaining cords and a knot is made on one side of the fastener.~It will be changed daily and after stain or examinations if necessary."
33238315|NCT04562688|Experimental|Arm A|Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
33238316|NCT04562688|Experimental|Arm B|Participants assigned to Arm B will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
33238317|NCT04562688|Experimental|Arm C|Participants assigned to Arm C will engage in PEERS + Active Comparator for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
33238318|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
32909459|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
32909460|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
33394815|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
32753990|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
32753991|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
32753992|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
32753993|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
32753994|NCT04682158|Active Comparator|Chemoradiation Therapy - Group I|Patients receiving beta-blockers undergo radiation therapy in the form of IMRT or 3D CRT over 23-28 fractions for 5 days per week (Monday-Friday) for 5 weeks, and receive paclitaxel IV QW and carboplatin IV QW for 5 weeks in the absence of disease progression or unacceptable toxicity.
32753995|NCT04682158|Active Comparator|Chemoradiation Therapy - Group II|Patients undergo CRT as in Group I in the absence of disease progression or unacceptable toxicity.
32753996|NCT04682158|Experimental|Chemoradiation Therapy plus Propanolol|Patients undergo radiation therapy as in Group I. Patients receive propranolol PO BID for 4-6 weeks while receiving CRT in the absence of disease progression or unacceptable toxicity.
32753997|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
32753998|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
32753999|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
32754000|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
32754001|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
32754002|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
32754003|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
32754004|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
32754005|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
32909461|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
33394816|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
32754006|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
32754007|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
33238319|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
33394817|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
32754008|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
33238320|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
33394818|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
33394819|NCT03223636||Healthy Volunteers|Healthy Volunteers
32909462|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
32909463|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
33394820|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
33394821|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
33394822|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
33238321|NCT00794417|Experimental|Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
32754009|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
32909464|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
33238322|NCT00794417|Experimental|Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m^2) and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
32754010|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
32754011|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
33238323|NCT00794417|Experimental|Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
33394823|NCT04638647|Experimental|Secukinumab s.c.|Participants will be started on 75 mg, 150 mg or 300 mg s.c. Q4W depending on what dose the participant was receiving in the parent trial (for trials with i.v. formulation the starting dose will be 300 mg s.c.). The study medication dose may be modified basedu pon clinical need, the judgement of the investigator and health authority guidelines (if applicable). For pediatric participants, the dose should not be increased beyond the maximum dose evaluated in the respective weight category in the parent protocol.
32909465|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
32754012|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
32909466|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
32909467|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
32909468|NCT02439216|Placebo Comparator|Placebo|Matching placebo
32909469|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
32909470|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
32909471|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
33394824|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
32909472|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
32909473|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
32909474|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
32909475|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
32909476|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
33394825|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
33394826|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
33394827|NCT03206866||patients with HCC|
32754013|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32754014|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33394828|NCT03206866||patients with hepatitis C Ab positive|
33394829|NCT03206866||patients with hepatitis C Ab negative|
33394830|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
33394831|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
33394832|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
33071206|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
33394833|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
32754015|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
32909477|NCT02442687|Placebo Comparator|C|Identical appearing placebo
32754016|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
32754017|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
32754018|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
32754019|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
33238324|NCT00794417|Experimental|Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
33238325|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
33238326|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
33238327|NCT04559256|Other|Tricuspid Cardiopulmonary Exercise testing|Patient receiving cardiopulmonary exercise testing
32909478|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
32909479|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
32909480|NCT00841178|Active Comparator|Surgery|Patients undergo Surgery under a general anaesthetic.
32909481|NCT00841178|Experimental|EVLT|Patients undergo EVLT under a local anaesthetic.
32909482|NCT04341519||Family members|"Age>18y~Non-opposition to participate to the telephone interviews~One family member per patient: the family member the most implicated in the patient's care~3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
33238328|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
32754020|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
33238329|NCT04406727|Experimental|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
32754021|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
32754022|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
33238330|NCT04406727|Active Comparator|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
33238331|NCT04557618|Experimental|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
33238332|NCT04557618|Sham Comparator|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
32754023|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
32754024|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
32754025|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
32754026|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
33238333|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
33238334|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
33238335|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
33238336|NCT04391907|Active Comparator|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
33238337|NCT04391907|No Intervention|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
32909483|NCT04341519||Patients|"Patients:~Age>18y~Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic~Having received invasive or noninvasive mechanical ventilation~Non-opposition to participate to the telephone interviews.~3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.~COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)~Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia~Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
33238338|NCT04483206|Experimental|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
33238339|NCT04107545|Experimental|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
33238340|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
33238341|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
33238342|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
33071207|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
33071208|NCT00170664|Experimental|Paclitaxel, Carboplatin|
33238343|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
33071209|NCT04725617|Active Comparator|Health Intervention Approach 1|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
33071210|NCT04725617|Active Comparator|Health Intervention Approach 2|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
33238344|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
33238345|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
33238346|NCT04321317|Other|Undernourished Patients|All patients included will be included in the unique arm of the study
33238347|NCT04079322|Experimental|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
33238348|NCT04079322|Experimental|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described easy pace) later in the afternoon."
33238349|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
33238350|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
33238351|NCT02583438|Experimental|Lifestyle intervention|
33238352|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
33238353|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
33238354|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
33238355|NCT03929874||age ≥ 60|age ≥ 60
33238356|NCT00725907|Experimental|1|PGRF
33238357|NCT00725907|Placebo Comparator|2|saline
33238358|NCT04476654|No Intervention|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
33238359|NCT04476654|Active Comparator|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
33238360|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
33238361|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
33238362|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
33238363|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
33238364|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
33238365|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
33238366|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
33238367|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
33071211|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
32745111|NCT04848363|Placebo Comparator|Control group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
32745112|NCT04847895||Lucentis|Patients administered Lucentis by prescription
33238368|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
32909484|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
32909485|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
32909486|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
32909487|NCT02444715|Active Comparator|Standard care (SC)|
33238369|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
33238370|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants will receive atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on days 1-21 of each cycle.
32745113|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
32909488|NCT02444715|Experimental|Interventional care (IC)|
32909489|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
32909490|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
33238371|NCT04471428|Active Comparator|Docetaxel|Participants will receive docetaxel on Day 1 of each 21-day cycle.
33071212|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
33071213|NCT02917837|Active Comparator|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
33071214|NCT02917837|Experimental|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
32909491|NCT04341675|Active Comparator|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
33238372|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
33238373|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
32909492|NCT04341675|Placebo Comparator|Placebo|Matching placebo
32909493|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
33394834|NCT02451748|Other|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
32909494|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
32909495|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
32909496|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
32909497|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
32909498|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33394835|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
33394836|NCT03208894|Experimental|with salbutamol|
33394837|NCT03208894|Experimental|with furosemide|
33394838|NCT03208894|Experimental|both furosemide and salbutamol|
33394839|NCT03208894|No Intervention|no inervention|
32909499|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909500|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238374|NCT04254627|Experimental|Mifepristone 300 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 1 will receive one week of mifepristone at 300 mg daily.
32745114|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
33238375|NCT04254627|Experimental|Mifepristone 600 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 2 will receive one week of mifepristone at 600 mg (2x300 mg) daily.
33238376|NCT04110275|Experimental|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
33238377|NCT04110275|Experimental|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
33238378|NCT04110275|Active Comparator|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
33238379|NCT04250883|Experimental|Experimental group: Low Impact laparoscopy|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)
33238380|NCT04250883|Active Comparator|Control group: Standard laparoscopy|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)
33238381|NCT04469634|Experimental|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
33238382|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
33238383|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
33238384|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
33238385|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
33238386|NCT04465500|Other|Treatment|
33238387|NCT05432076||experimental group|In the study, sleep bands and white noise will be used for sleep for the babies in the experimental group
33238388|NCT05432076||control group|while the control group will not be interfered with
33238389|NCT04080726|Experimental|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
33238390|NCT04080726|Experimental|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
33238391|NCT04646226|Experimental|fistula surgically placed|Randomized group to have surgically placed fistula for permanent hemodialysis access
33238392|NCT04646226|Active Comparator|graft surgically placed|Randomized group to have surgically placed graft for permanent hemodialysis access
33238393|NCT04080570|Experimental|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
33238394|NCT04080570|No Intervention|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
33238395|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
33238396|NCT04639986|Experimental|Sacituzumab Govitecan-hziy|Participants will receive Sacituzumab Govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle.
33238397|NCT04639986|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive recommended doses and schedules as per package insert depending on region.~Eribulin (1.4 mg/m^2 of eribulin mesylate or 1.23 mg/m^2 of eribulin on Days 1 and 8 of a 21-day cycle)~Capecitabine (1000 to 1250 mg/m^2 twice daily on Days 1 to 14 of a 21-day cycle)~Gemcitabine (800 to 1200 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle)~Vinorelbine (25 mg/m^2 on Day 1 weekly)"
33238398|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
33238399|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
33238400|NCT04126317|Experimental|intravitreal aflibercept injection (IAI)|"Treatment-naïve patients with neovascular wet age-related macular degeneration (nAMD) randomized in a 1:1 ratio"
33238401|NCT04126317|Experimental|High-dose aflibercept (HD)|Treatment-naïve patients with nAMD randomized in a 1:1 ratio
33238402|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
33238403|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
33238404|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
33238405|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
33238406|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
33238407|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
33238408|NCT05539326||PIQ Patients|"Patient is scheduled for or has undergone primary total knee arthroplasty (TKA) using a Persona Personalized Knee System with Canary Tibial Extension (PIQ) TKA implant according to the appropriate surgical technique and IFU. If you decide to take part in this research study, the general procedures include one follow-up visit where you will be asked to complete two performance-based tests that are used to assess your physical function following Total Knee Arthroplasty (TKA). As part of your standard of care, you will receive a Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension. As part of this study, subjects will be asked to perform two performance based tests called the 4 meter walk test and the timed up and go test. Subjects will also be asked to complete a series of patient questionnaires that will assess their post-operative function."
33238409|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
33238410|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
33238411|NCT00726531|No Intervention|TAU|Treatment as usual
33238412|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
33238413|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
33238414|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
33238415|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
33238416|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
33238417|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
33238418|NCT05472714|No Intervention|Without Video|In year 1, we will recruit families of patients receiving the current standard-of-care approach to tumor-normal genetic testing with provider based education.
33238419|NCT05472714|Experimental|With Video|In year 2, we will recruit families of patients receiving the updated standard-of-care approach to tumor-normal genetic testing with provider based education and an educational video.
33238420|NCT05429268|Experimental|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
33238421|NCT03109353|Experimental|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
33238422|NCT04066569|Active Comparator|OGTT Tests and Placebo Test|Patients with acromegaly
33238423|NCT04066569|Active Comparator|OGTT Tests|age and sex matched healthy volunteers
33238424|NCT04071795|Experimental|Opt Out|Training and Academic Detailing
33238425|NCT04071795|Experimental|Opt In|Training and Academic Detailing
33238426|NCT05413434|Experimental|HIIT with a supervisor|These individuals will be given HIIT training on the treadmill, accompanied by a physiotherapist, 3 days a week for 8 weeks.
33238427|NCT05413434|Experimental|Hiit and respiratory muscle training with a supervisor|HIIT program and respiratory muscle training will be applied to these individuals 3 days a week for 8 weeks.
33238428|NCT05413434|No Intervention|control group|The importance of physical activity will be explained and appropriate physical activity recommendations will be made.
33238429|NCT04066179|Experimental|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
33238430|NCT04066179|Active Comparator|Prednisolone|Prednisolone 40 mg/day for 7 days
33238431|NCT04066179|Experimental|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
33238432|NCT04110119|Active Comparator|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (49 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
33394840|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
33394841|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
33394842|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
33394843|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
33394844|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
33394845|NCT03206242||initial|0 month begin physiotherapy
33394846|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
33394847|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
33394848|NCT03206320|No Intervention|Control|
33394849|NCT03206320|Active Comparator|Reference|
33394850|NCT03206320|Experimental|New|
32754027|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
32754028|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
33071215|NCT02917837|Experimental|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
32754029|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
32754030|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
32754031|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
33071216|NCT02917837|Experimental|New utilization report plus detailing|New type of report plus detailing as described above.
33238433|NCT04110119|Experimental|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (49 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
33238434|NCT05409846||Group A|Idiopathic hypertrophic cardiomyopathy
33238435|NCT05409846||Group B|Idiopathic left ventricle hypertrophy
33238436|NCT05409846||Group C|Idiopathic burned-out hypertrophic cardiomyopathy
32754032|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
32754033|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
32754034|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
33394851|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
32754035|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
32754036|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
33238437|NCT05409846||Group D|Idiopathic dilated cardiomyopathy
33238438|NCT04052061|Experimental|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
33238439|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
33238440|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
33238441|NCT04630392|Experimental|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
32754037|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
32754038|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
32754039|NCT05078099|Experimental|Study arm - Binocular CureSight|Using binocular treatment device 90 min a day 5 times a week for 12 weeks following by 90 min a day 3 times a week for additional 12 weeks
32754040|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
33238442|NCT04019691|Active Comparator|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
33238443|NCT04019691|Active Comparator|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
33238444|NCT04019691|Active Comparator|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
33238445|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
33238446|NCT04101396|Other|4 points blood glucose monitoring|4 points of self monitoring blood glucose which comprises of fasting, 1 hour post breakfast, 1 hour post lunch and 1 hour post dinner
33238447|NCT04101396|Other|7 points blood glucose monitoring|7 points of self monitoring blood glucose which comprises of fasting,1 hour post breakfast, 1 hour pre and post lunch, 1 hour pre and post dinner, pre bed at 10 pm
33238448|NCT03950115|Experimental|Group 1|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
33238449|NCT04532424|Experimental|Targeting insistence on sameness|
33238450|NCT04532424|Experimental|Targeting stereotyped motor behaviors|
33238451|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
33238452|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
33394852|NCT04448561|Placebo Comparator|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
32744614|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
33394853|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
33394854|NCT03208738|No Intervention|Assessment only|
33394855|NCT03208738|Experimental|VetChange mobile app|
33394856|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
33394857|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
33394858|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
33394859|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
33394860|NCT04978259|Experimental|Standard of care plus remdesivir|Local standard of care plus daily remdesivir infusion for up to 10 days (or until discharge)
32909501|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909502|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33394861|NCT04978259|No Intervention|Standard of care|Local standard of care
32909503|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33394862|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
33394863|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
32744615|NCT04868331|Experimental|AIS girls|Girls between the ages of 10-16 will be recruited if they have a diagnosis of AIS.
32909504|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33238453|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.~And:~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
33238454|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~Inflammatory back pain~Human leukocyte antigen B27 (HLA-B27)~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
32744616|NCT04868331|Active Comparator|Healthy Controls|Healthy adolescent girls matched in age and puberty maturity without spinal deformity
32744617|NCT04863417|Experimental|Cohort 1 (2000 cm2 Body Surface Area)|
32744618|NCT04863417|Experimental|Cohort 2 (4000 cm2 Body Surface Area)|
33238455|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~Inflammatory back pain~HLA-B27~Sacroiliitis (on imaging)~Family history of AS~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
33238456|NCT02653287|Experimental|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual for a caseload of participants. There are no drugs involved in the intervention.
33238457|NCT02653287|Active Comparator|Control|The control group intervention will receive four individual phone calls checking in with participants regarding questions about the study or from the educational sessions focusing on SLE disease management, each lasting approximately 10-15 minutes.
33238458|NCT04080336|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
33238459|NCT04080336|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
33238460|NCT04080336|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
33238461|NCT00727155|Experimental|1|Treatment
33238462|NCT00727155|No Intervention|2|Waitlist
33238463|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
33238464|NCT05466474|Experimental|Tislelizumab combined with dacarbazine|Tislelizumab combined with dacarbazine in the treatment of advanced melanoma.
33238465|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
33238466|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
33238467|NCT02585154|Experimental|Closed-loop Deep Brain Stimulation|Closed-loop Deep Brain Stimulation
33238468|NCT02585154|Active Comparator|Open loop Deep Brain stimulation|Open loop Deep Brain stimulation
33238469|NCT02585154|Other|No Deep Brain Stimulation|No Deep Brain Stimulation
33238470|NCT04105283|Experimental|Tc99m-MAA|"Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.~Administration will occur over a period of 30-240 seconds"
33238471|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
33238472|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
33238473|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
33238474|NCT04105127|Active Comparator|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
33238475|NCT04105127|Active Comparator|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
33238476|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
33238477|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
33238478|NCT04066257|Active Comparator|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
33238479|NCT04066257|Active Comparator|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
32754041|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
33238480|NCT04066257|Active Comparator|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
33238481|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
33238482|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
33238483|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
33238484|NCT04080102|Experimental|High intensity interval training (HIIT)|
33238485|NCT04080102|Experimental|Essential Amino Acid Supplement|
33238486|NCT04080102|Experimental|High intensity interval training + Essential Amino Acid|
33238487|NCT04080102|No Intervention|Control|
33238488|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
33238489|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
33238490|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
33238491|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
33238492|NCT00730119||Neonates|Subjects ages birth to 30 days
33238493|NCT00730119||Infants|Subjects aged >30 days to 2 years
33238494|NCT00730119||Adults|Subjects aged 18 years of age or older
33238495|NCT05571839|Experimental|SGN-BB228|SGN-BB228 monotherapy
33238496|NCT00920712|Experimental|Weiqi decoction|
33238497|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
33238498|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
33238499|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
33238500|NCT04104971||with complications|children who did liver transplantation and develop complications
33238501|NCT04104971||without complications|children who did liver transplantation and do not develop complications
33238502|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
33238503|NCT00733863|Experimental|1|
33238504|NCT00733863|Placebo Comparator|2|
33238505|NCT04524702|Experimental|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33238506|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
33238507|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
33238508|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
33238509|NCT04421040|Experimental|Biomonitor 3|Placement of Biotronic 3 Device for a 6 month period. After the 6 month monitoring period, the patient will have the Biotronic 3 device removed.
33238510|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
33238511|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
33238512|NCT04080258|Experimental|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
33238513|NCT04080258|Sham Comparator|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
33238514|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
33238515|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
33394864|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
32754042|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
33238516|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
33238517|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
33238518|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
32745115|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
32745116|NCT04496531|Experimental|Active|Active group members use a device providing perceivable electrical stimulation
33238519|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
33238520|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
33238521|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
33238522|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
33238523|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
33238524|NCT00727545|Experimental|1|
33238525|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
33238526|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Normal Liver function|Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
33238527|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
33238528|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
33238529|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
33238530|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
33238531|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
33238532|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
33238533|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
33238534|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
33238535|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
33238536|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
33238537|NCT04517370|Active Comparator|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
33238538|NCT04517370|Sham Comparator|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
33238539|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
33238540|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
33238541|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
33238542|NCT02582892|Other|Vit D|Vit D 20 mg/day
32745117|NCT04496531|Sham Comparator|Sham|Group members use a device providing a non-perceivable stimulus
32745118|NCT02502383|Experimental|ACTION PAC|
32745119|NCT02502383|Active Comparator|Comparison|
33238543|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
33238544|NCT04079946|Active Comparator|patients for whom Complete mesocolic excision will be done|
33238545|NCT04079946|Active Comparator|patients had conventional surgery before|
33238546|NCT00734331||IBD|Inflammatory bowel disease patients
33238547|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
33238548|NCT04512456|Experimental|Active HIV-infected patients|Exercise training
33238549|NCT04512456|No Intervention|Inactive HIV-infected patients|No intervention.
33238550|NCT04512456|No Intervention|Healthy subjects|No intervention.
33238551|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
33238552|NCT04764513|Experimental|Patients with hematological malignancies after allo-HSCT|"Patients with negative minimal residual disease or stable disease:~After inclusion, patients will receive or not receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~Patients with positive minimal residual disease but not hematologic relapse:~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~Patients with hematologic relapse:~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell."
33238553|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
33238554|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
33238555|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
33238556|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
33238557|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
33238558|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
33238559|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
33238560|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
33238561|NCT02549937|Experimental|Escalation 50 mg|Escalation cohort at 50 mg/day
33238562|NCT02549937|Experimental|Escalation 100mg|Escalation cohort at 100 mg/day
33238563|NCT02549937|Experimental|Escalation 200 mg|Escalation cohort at 200 mg/day
33238564|NCT02549937|Experimental|Escalation 300 mg|Escalation cohort at 300 mg/day
33238565|NCT02549937|Experimental|Escalation 400 mg|Escalation cohort at 400 mg/day
33238566|NCT02549937|Experimental|Expansion|Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively.
33394865|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
33394866|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
33394867|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
32745120|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
32745121|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
32744619|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
32744620|NCT04868175|Active Comparator|Group 1|control (hypromellose), then Timolol, then Travatan
32744621|NCT04868175|Active Comparator|Group 2|Timolol, then Travatan, Hypromellose
32745122|NCT04857957|Experimental|Cohort 1|300 mg oral dose TID
32744622|NCT04868175|Active Comparator|Group 3|Travatan, then Hypromellose, Timolol
32745123|NCT04857957|Experimental|Cohort 2|600 mg oral dose TID
32909505|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909506|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909507|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32745124|NCT04857957|Experimental|Cohort 3|800 mg oral dose TID
33238567|NCT04512144|Experimental|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
32744623|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
32744624|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
33394868|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~Reactive balance training involved both slip and trip training.~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
33394869|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
33394870|NCT03201328|Active Comparator|healthy subjects|
33394871|NCT03201328|Experimental|patients with unilateral cochlear implants|
33394872|NCT03201328|Experimental|patients with bilateral cochlear implants|
33394873|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
33394874|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
33394875|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
33394876|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
33394877|NCT03201172||Univation® X|
33394878|NCT03201172||iUni®|
32744625|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
32744626|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
32744627|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
33394879|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
33394880|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
33394881|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
33238568|NCT04512144|No Intervention|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
33238569|NCT00734565|Experimental|1|
33238570|NCT04503564|Experimental|Achilles Infusion Set|Coil-reinforced soft polymer indwelling cannula
33238571|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
33238572|NCT04019652|Experimental|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
33238573|NCT04019652|Experimental|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
33238574|NCT04019652|Experimental|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
33238575|NCT04019652|Experimental|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
33238576|NCT00734721|Active Comparator|A|Presentation of factual information video
33238577|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
33238578|NCT00734721|Active Comparator|C|Presentation of emotional information video
33238579|NCT00734721|Active Comparator|D|Stress relaxation music
33238580|NCT04400370||Pediatric patients undergoing lung resection|
33238581|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
33238582|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
33238583|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
33238584|NCT04078464|Experimental|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
33238585|NCT04078464|Experimental|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
33238586|NCT04078464|Experimental|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
33238587|NCT04396236|Experimental|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
33238588|NCT04396236|Experimental|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
33238589|NCT04396236|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
33238590|NCT04396236|Placebo Comparator|Placebo|Placebo administered orally.
33238591|NCT00735111|Experimental|Karnofsky Performance Status Score|
33238592|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
33238593|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
33238594|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
33238595|NCT00735501||A|
33238596|NCT00728013|Experimental|A|intensive statin group
33238597|NCT00728013|Experimental|B|moderate statin group
33238598|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
33238599|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
33238600|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
33238601|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
33238602|NCT00735579||Study group|Patients undergoing major abdominal surgery
33238603|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
33238604|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
33238605|NCT00728325|Experimental|2|Supported Employment (SE)
33238606|NCT00730743|Experimental|1|Intermittent clamp group
33238607|NCT00730743|No Intervention|2|No clamp group
33238608|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
33238609|NCT00728403|Experimental|2|American Ginseng Capsules
33238610|NCT00728403|Placebo Comparator|3|Placebo Capsules
33238611|NCT00730821|Experimental|1|
33238612|NCT00728559|Experimental|1|preemptive trocar site analgesia
33238613|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
33238614|NCT00728559|No Intervention|3|control
33238615|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
33238616|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
33238617|NCT00736047|Active Comparator|1|
33238618|NCT00736047|Placebo Comparator|2|
33238619|NCT04064775|Experimental|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
32744628|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
33238620|NCT04064775|No Intervention|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
33238621|NCT04064619|Active Comparator|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
33238622|NCT04064619|Experimental|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
33238623|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
33238624|NCT00728637|Active Comparator|2|Participants took part in a control group.
33238625|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
33238626|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
33238627|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
33238628|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
33238629|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
33238630|NCT05617833|Experimental|MLT+EPO|"Melatonin 3 mg/mL oral syringe enterally every evening. For neonates weighing less than 1200 g, divide the dose in half and administer each half 30 minutes apart.~High dose epoetin alfa epbx recombinant (1000 units/kg) syringe IV every 48 hours for 10 doses.~Low dose epoetin alfa-epbx recombinant (400 units/kg) subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
33238631|NCT05617833|Placebo Comparator|Placebo|"Placebo oral syringe enterally every evening.~Placebo syringe IV every 48 hours for 10 doses.~Placebo subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
33238632|NCT00736203||A|non-smokers
33238633|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
33238634|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
33238635|NCT00736437|Experimental|1|ME-609
33238636|NCT00736437|Placebo Comparator|2|Vehicle
33238637|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
33238638|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
33238639|NCT00045201|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33238640|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
33238641|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
33238642|NCT00736593|Experimental|1|
33238643|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
33238644|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
33238645|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
33394882|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
32744629|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
32744630|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
32745125|NCT04857957|Experimental|PDN cohort|Dose based on safety in healthy Cohorts 1-3
33238646|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
33238647|NCT00731523|Experimental|1|
33238648|NCT05601531|Experimental|Autologous Tooth Root+Vit.D3+Bone graft|Placement of bone graft and local administration of Vit.D3, and placement of autologous root slices
32754043|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
32754044|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
32754045|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
32754046|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
32898136|NCT04110236|No Intervention|Delayed PriCARE Positive Discipline Module|The delayed Positive Discipline group will not receive the Positive Discipline Module intervention until after their third interview data collection is complete (in 2-3 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
32898137|NCT04097717|Experimental|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
33394883|NCT04484896|Experimental|Gain-frame Message|"Short messaging service (SMS) message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to save lives. Thank you for your support.~Please bring your identification (ID) card and show this message to our staff. Thank you."
32898138|NCT04097717|Other|Usual Care Arm|Participants will receive usual medical care.
33238649|NCT05601531|Experimental|Autologous Tooth Root+ Bone graft|Placement of bone graft without local administration of Vit.D3 and placement of autogenous root slices
33238650|NCT05601531|Experimental|Bone graft|Only bone graft materials were placed, no local administration of Vit.D3, and no autologous root slices were placed
33238651|NCT05601531|No Intervention|Natural healing|After the wound healed naturally, no bone graft material was filled, and Vit.D3 was not administered locally, and autologous tooth root slices were not placed.
33238652|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
33238653|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
33238654|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
33238655|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
33238656|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
33238657|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
33394884|NCT04484896|Experimental|Loss-frame Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to prevent the loss of life. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
33394885|NCT04484896|Experimental|Information Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, if you can, please consider donating blood again. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
33394886|NCT04484896|No Intervention|Control group|Donors in this group were not received SMS reminders.
33394887|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
33394888|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
33394889|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
33394890|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
33394891|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
33394892|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
33394893|NCT03749525|Placebo Comparator|placebo group|5% GS solution
33394894|NCT03749525|Active Comparator|control group|shenfu injection
33394895|NCT04578665|Experimental|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
33394896|NCT04578665|Experimental|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
33394897|NCT04578665|Experimental|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
33394898|NCT04578665|Experimental|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
33394899|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
33394900|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
33238658|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
33238659|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
33238660|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
32744631|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
32744632|NCT03224897|Active Comparator|Cathodal tDCS|
32744633|NCT03224897|Active Comparator|Anodal tDCS|
32744634|NCT03224897|Sham Comparator|Sham tDCS|
33238661|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
33238662|NCT02568813|Experimental|Scales passation|
33238663|NCT04065633|Experimental|Part A sequence 1|
33238664|NCT04065633|Experimental|Part A sequence 2|
33238665|NCT04065633|Experimental|Part B sequence 1|
33238666|NCT04065633|Experimental|Part B sequence 2|
33238667|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
33238668|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
33238669|NCT00736983|Active Comparator|1|Adalimumab
33238670|NCT00736983|Placebo Comparator|2|ciprofloxacin
33238671|NCT00713349|Other|1|Xenaderm Vehicle
33238672|NCT00713349|Placebo Comparator|2|Placebo Comparator
33238673|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
33238674|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
33238675|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
33238676|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
33238677|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
33238678|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
32909508|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909509|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33394901|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
33394902|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
33394903|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
33394904|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
33394905|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
33394906|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
33394907|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
33394908|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
33394909|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
33394910|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
33394911|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
33394912|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
33394913|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
33394914|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
33394915|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
33394916|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
33394917|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
33394918|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
33394919|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
33394920|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
33394921|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
33394922|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
33394923|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
33394924|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
33394925|NCT04285229|Experimental|Ixekizumab|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection.
33394926|NCT04285229|Placebo Comparator|Placebo|Participants received placebo every four weeks (Q4W) by subcutaneous (SC)injection.
33394927|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
32909510|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33238679|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
33238680|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
33238681|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
33238682|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
33238683|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
33238685|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
33238686|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
33394928|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
33394929|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
33394930|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
33394931|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
33394932|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
33238687|NCT00737217||Parkinson's disease|
33238688|NCT00737217||Normal Controls|
33238689|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
33238690|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
33238691|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
32909511|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238692|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
33238693|NCT00737373|Experimental|1|FLOT
32898139|NCT04091347|Experimental|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
32898140|NCT04091347|Active Comparator|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
32898141|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
32898142|NCT04041128|Experimental|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
32898143|NCT04037358|Experimental|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
32898144|NCT04037358|Active Comparator|SABR|SABR(1-5 fractions) will be administered for all men
32898145|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
32898146|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
32898147|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
33394933|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
33394934|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
33394935|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
33394936|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.~."
32898148|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
32898149|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
32898150|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
32898151|NCT04030962|Placebo Comparator|Stage 1: AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
32898152|NCT04030962|Placebo Comparator|Stage 1: AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
32898153|NCT04030962|Experimental|Stage 2: AGN-242428 Group 1|Administration of AGN-242428 ophthalmic solution
33071217|NCT04689022|Other|Group І received general anesthesia (n=53)|"The sedation with constant rate infusion of 1% propofol, 1-4mg/kg/h, guided by Bispectral analysis (60-70 - for regional anesthesia and 40-60 - for the general one). 0.005% fentanyl analgesia was injected, 3-10 mkg/kg or 0.05-0.2 mkg/kg/min during induction; and 2-10 mkg/kg/h for maintaining analgesia, by periodic bolus injection 25-100 mkg or by permanent infusion.~The postoperative pain management of the I group patients was provided according to the local clinical protocol: paracetamol+/-non-steroid anti-inflammatory drugs +/-opioids.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
33238694|NCT00737373|Active Comparator|2|FLO
33394937|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~No intervention is provided."
33394938|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
33394939|NCT04496453|Experimental|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
33394940|NCT03118882|Active Comparator|Diet Group|
33394941|NCT03118882|Active Comparator|Physical activity group|
33394942|NCT03118882|Active Comparator|Physical activity and diet group|
33394943|NCT03118882|No Intervention|Control group|
33394944|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
33394945|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
33394946|NCT04484194|Experimental|eHA Screening|Patients receiving eHA screening tool.
33394947|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
33394948|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home~First stroke deficit with non-regressive clinical expression in 24 hours~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~No psychiatric history that led to hospitalization for more than six months~Written informed consent after reading the briefing note~Patient affiliated or beneficiary of a social security scheme."
33394949|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
33394950|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
33394951|NCT03200470||Suspected PJI|
33394952|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
33394953|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
33394954|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
33394955|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
33394956|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
33394957|NCT04484662|Other|Potted Mint Plants Intervention|We will measure 2 indoor environments (living room and bedroom) for placing potted plants. We will analyze the effect of potted mint plants on indoor air quality, fungal and bacterial concentration, and explore the correlation between the intervention of potted mint plants and cardiovascular health.
33394958|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
33394959|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
33394960|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
33394961|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
33394962|NCT03204370||MPS4A patients|
33394963|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
32909512|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238695|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
33238696|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
33238697|NCT00729495|Active Comparator|1|marketed celecoxib
33238698|NCT00729495|Experimental|2|overencapsulated celecoxib
33238699|NCT00737451||skin itching|
33238700|NCT00737685|Experimental|Fludarabine|
32909513|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33238701|NCT00732459||1|electro-acupuncture preconditioning group
33238702|NCT00732459||2|control group
33238703|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
32744635|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
33238704|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
33394964|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
32898154|NCT04030962|Experimental|Stage 2: AGN-242428 Vehicle Group 2|Administration of matching placebo (vehicle) ophthalmic solution
33238705|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
33238706|NCT00729729|Placebo Comparator|1|Placebo
33238707|NCT00729729|Experimental|2|Slow release PCA derivative
33238708|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
33238709|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
32898155|NCT04030962|Experimental|Stage 2: AGN-231868 Group 3|Administration of AGN-231868 ophthalmic solution
33238710|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
33238711|NCT00712725|Experimental|1|MK3207- 2.5 mg
33238712|NCT00712725|Experimental|2|MK3207- 5 mg
33238713|NCT00712725|Experimental|3|MK3207- 10 mg
32754047|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
32898156|NCT04030962|Experimental|Stage 2: AGN-231868 Vehicle Group 4|Administration of matching placebo (vehicle) ophthalmic solution
32898157|NCT04030962|Active Comparator|Lifitegrast|Administration of Lifitegrast ophthalmic solution
32898158|NCT04024059|Experimental|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
32898159|NCT04024059|Experimental|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
32898160|NCT04024059|No Intervention|Control|Participants will not receive any intervention.
32898161|NCT04022590|Experimental|E-clothes|The participants with E-clothes do aerobic training at home
32898162|NCT04022590|Active Comparator|Home exercise|The participants with healthy consultation do aerobic training at home.
32898163|NCT04009837|Experimental|Hip-focused|Hip-focused rehabilitation intervention
32898164|NCT04009837|Active Comparator|Spine-focused|Spine-focused rehabilitation intervention
33238714|NCT00712725|Experimental|4|MK3207- 20 mg
33238715|NCT00712725|Experimental|5|MK3207- 50 mg
33238716|NCT00712725|Experimental|6|MK3207- 100 mg
33238717|NCT00712725|Placebo Comparator|7|Placebo
33238718|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
33238719|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
33238720|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
33238721|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
33238722|NCT00737841|Experimental|A|Bifidobacterium breve
33238723|NCT00737841|Placebo Comparator|B|Placebo
33238724|NCT00732771|Experimental|LCI696 1mg bid|
33238725|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
33238726|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
33238727|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
33238728|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
33238729|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
33238730|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
33238731|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
33238732|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
33238733|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
33238734|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
33238735|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
33238736|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
33238737|NCT00737997|Placebo Comparator|1|
33238738|NCT00737997|Experimental|2|
33238739|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
33238740|NCT00732927|Active Comparator|2|aspirin
33238741|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
33238742|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
33238743|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
33238744|NCT00733083|Placebo Comparator|4|NaCl 0,9%
33238745|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
33238746|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
33238747|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
33238748|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
32909514|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238749|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
33238750|NCT00712335|No Intervention|5|Normal controls
32909515|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33238751|NCT04065711|Experimental|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
33238752|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
33238753|NCT00733161|Active Comparator|2|Stretching and resistance training
33394965|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
33394966|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
32909516|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909517|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
33394967|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
32744636|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
33394968|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
32909518|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909519|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909520|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909521|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909522|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33394969|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
33394970|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
33238754|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
33238755|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
33238756|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
33238757|NCT00738153||A|
33238758|NCT04065165|Experimental|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
33238759|NCT04065165|Placebo Comparator|Control arm|Lanreotide 120 mg q4w Placebo TID
33238760|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
33238761|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
33238762|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
33238763|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
33238764|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
33238765|NCT00733395|Experimental|1|Tart cherry juice
33238766|NCT00733395|Placebo Comparator|2|Fruit juice
33238767|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
33238768|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
33238769|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
33238770|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
33238771|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
33238772|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
33394971|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
33238773|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
33238774|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
33238775|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
33238776|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
33238777|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33238778|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33238779|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33238780|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33238781|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33394972|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
32744637|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
33238782|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33394973|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
33238783|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
33238784|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
33238785|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
33238786|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
33238787|NCT04063527|No Intervention|Observation|Observation
33238788|NCT00738777|Active Comparator|1|Anastrozole
33238789|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
33238790|NCT00738777|Active Comparator|3|Tamoxifen
33238791|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
32909523|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238792|NCT00733707|Experimental|1|Text messaging reminders
33238793|NCT00733707|No Intervention|2|No text messaging reminder
33238794|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
32909524|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
32909525|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
32909526|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238795|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
33238796|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
33238797|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
33238798|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
33238799|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
33238800|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
32744638|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
32744639|NCT04868019|Experimental|Group A|Groups A will receive solution A .i.e fenofibrate suspension
32744640|NCT04868019|Placebo Comparator|Group B|Group B will receive solution B i.e placebo.
33238801|NCT00738855|Active Comparator|1|Gastrografin group
33238802|NCT00738855|Placebo Comparator|2|Control group
33238803|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
33238804|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
33238805|NCT00738933|Placebo Comparator|C|
33238806|NCT05741073||resected HR-cSCC|Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting
33238807|NCT05741073||advanced cSCC|Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2)
33238808|NCT05741073||advanced BCC|Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)
33238809|NCT05549661|Experimental|Treatment (onvansertib)|Patients receive onvansertib PO QD on study. Patients also undergo bone marrow aspiration and biopsy, collection of blood samples, and ultrasound imaging during screening and throughout the trial.
32745126|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
32745127|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
32745128|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
32745129|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
32745130|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
32745131|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
32745132|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
32745133|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
32745134|NCT04859283|Active Comparator|DEX-group|intranasal dexmedetomidine 1 µg/kg
32745135|NCT04859283|Placebo Comparator|PLACEBO-group|intranasal saline 10 µL/kg
32745136|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
32745137|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
33238810|NCT05555589|Experimental|0.1% RGN-259 Opthalmic Solution|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
33238811|NCT05555589|Placebo Comparator|Placebo Ophthalmic Solution (Vehicle for RGN-259 Ophthalmic Solution)|It is composed of the same excipients as RGN-259 but does not contain Tβ4
33238812|NCT05740917|Experimental|Part 1: XZB-0004|
32744641|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~Clinical diagnosis of Posner-Schlossman Syndrome~Able to communicate with doctor and understand this study~Exclusion criteria:~Not be able to communicate with doctor and understand this study~One or more authorized investigators think he or she will suffer from any severe risks from the study"
32744642|NCT03233477||cataract|"Inclusion criteria：~Clinical diagnosis of age-related cataract~Prepare for cataract operation~Open angle and intraocular pressure is normally at anytime~No family history of glaucoma~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
32909527|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33394974|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
32745138|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
33394975|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
32909528|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
33394976|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
33394977|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
32898165|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior Bruton tyrosine kinase inhibitor (BTKi) therapy cohort, approximately 40 participants with Prior BTKi therapy will be enrolled.
32898166|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
32898167|NCT03991962|Experimental|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
32898168|NCT03951753|Experimental|Tirzepatide 15 mg|Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.
32898169|NCT03951753|Active Comparator|Semaglutide 1 mg|Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.
32909529|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
33238813|NCT05529459|Experimental|angiography-guided percutaneous coronary intervention|If the patient is assigned to the QCA-guided strategy, quantitative diameter stenosis is measured for lesions with diameter stenosis of 50% to 90% on angiographic visual estimation. The operator evaluates coronary artery through routine angiography, and measure diameter stenosis based on the narrowest view of the interest lesion on the CAG. The operator determines the range to be covered with the stent, sets the virtual stent distal edge as the distal reference, and the virtual stent proximal edge as the proximal reference, then creates a interpolate line. Calculate the degree of stenosis by the ratio of the diameter of the lesion to the interpolate line. PCI is performed
33238814|NCT05529459|Active Comparator|fractional flow reserve-guided PCI|If the patient is assigned to the FFR-guided strategy, FFR is measured for lesions with diameter stenosis of 50% to 90% on angiographic visual estimation. FFR is measured with a standard coronary pressure wire and after complete hyperemia has been achieved with intravenous adenosine, administered at 140 μg/(kg·min) via a peripheral vein. The investigator can decide not to perform PCI despite an FFR ≤0.80 if the pressure gradient is found on slow pullback of the pressure wire as a result of diffuse CAD and not a focal lesion. In the setting of serial stenoses, PCI is performed
32909531|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
32909532|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
32909533|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
32898170|NCT03951753|Placebo Comparator|Placebo|Participants received Placebo administered SC once weekly for 28 weeks.
32898171|NCT03948971|Other|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
32898172|NCT03947671|Experimental|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
32898173|NCT03947671|Active Comparator|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
32898174|NCT03947671|Experimental|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
33238815|NCT05740839|Experimental|HIIT Exercise Program Group|"Participants will be randomly assigned to the HIIT exercise group and receive:~3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.~16-week self-directed exercise follow up period.~3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires"
33238816|NCT05740839|Active Comparator|Control Group|"Participants will be randomly assigned to the HIIT waitlist control group and receive:~Daily usual activities~2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires~Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period."
33238817|NCT00739011|Experimental|1|
33238818|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
33238819|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
33238820|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
32909534|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
32909535|NCT01099202|No Intervention|No Procrit|No intervention.
32909536|NCT02448303|Experimental|Arm 1|pembrolizumab
33238821|NCT05528133|Experimental|Radiosensitivity Index optimized|Participants will be assigned to optimized arm based on their RSI score. Participants will receive whole breast radiation therapy with or without regional lymph node irradiation as appropriate with or without a boost to the lumpectomy cavity.
32909537|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
32909538|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
32909539|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
32909540|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
32909541|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
32909542|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
32909543|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
32909544|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
32909545|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
32909546|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
32909547|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
32909548|NCT00363363|Experimental|1|
32909549|NCT00363363|Active Comparator|2|
32909550|NCT02423577|Experimental|FF-3 dry powder|FF-3
32909551|NCT02423577|Placebo Comparator|Placebo|
32909552|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
33238822|NCT05528133|Active Comparator|Radiosensitivity Index not optimized|Participants will receive standard of care whole breast radiation therapy with or without regional lymph node irradiation as appropriate with a boost to the lumpectomy cavity.
32745139|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
32745140|NCT04377087|Experimental|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
32745141|NCT03343535|Experimental|OCS|OCS Lung Preservation
32745142|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
32745143|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
32745144|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
32745145|NCT03343457|No Intervention|Control|Control group
32745146|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
32745147|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
32909553|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
33238823|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
33238824|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
33238825|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
33238826|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
33238827|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
33238828|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
32909554|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
32909555|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
32909556|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
32909557|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
32909558|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
33238829|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
33394978|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
32909559|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
32909560|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
32909561|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
32909562|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
32909563|NCT02454153|Active Comparator|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
32745148|NCT04857879|Experimental|Good Life with Osteoarthritis (GLA:D) Program|Participants will attend 2 sessions aimed at providing disease-specific education followed by 12 sessions of neuromuscular exercises, each 1 hour in length, delivered twice a week over 6 weeks.
32745149|NCT04857879|Active Comparator|Control intervention group|Participants allocated to the control intervention will receive disease-specific education and training to learn home exercises in a 1-hour group session. They will receive a booster session 4-weeks after the first session.
32909564|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
32745150|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
33394979|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
33394980|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
33394981|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
33238830|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
33238831|NCT05740683||People with idiopathic olfactory dysfunction|
33238832|NCT05740683||People without olfactory dysfunction|
33394982|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
33394983|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
33394984|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
33394985|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
32745151|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
32745152|NCT04847115|Active Comparator|Operative|The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.
32909565|NCT04744233|Active Comparator|Freshly squeezed orange juice (FS)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juice assayed was freshly squeezed (FS). Six subjects consumed FS-orange juice.
33238833|NCT04064541|Other|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders & Mini Cog) and Functional Assessments (Timed Up & Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ & Frailty Index) and Functional Assessments(Timed Up & Go and 6MWT) will be completed."
32745153|NCT04847115|Active Comparator|Non-operative|The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated
32745154|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
33238834|NCT05512767|Experimental|Group I (pneumatic therapy, lymphedema management)|Patients undergo 32 minute treatments twice daily for 12 weeks using the FlexiTouch Plus System and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
32745155|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
32745156|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
32745157|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
32745158|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
33238835|NCT05512767|Active Comparator|Group II (standard of care, lymphedema management)|Patients undergo standard of care self-manual lymphatic drainage (technique instructions provided) twice daily for 12 weeks and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
32745159|NCT03343379|Other|Healthy cohort|Core stability test
32745160|NCT04857567|Experimental|Three Self-Commitment (TSC) program|
32909566|NCT04744233|Active Comparator|Commercially available low pasteurized orange juice (LP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was commercially available low pasteurized juice (LP). All participants consumed the LP orange juices.
32909567|NCT04744233|Active Comparator|High-pressure processed orange juice(HPP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was high-pressure processed (HPP). All participants consumed the HPP orange juices.
33394986|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
32745161|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
32909568|NCT04744233|Active Comparator|Pulsed electric fields treated orange juice (PEF)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was those treated with pulsed electric fields (PEF). Six participants consumed the PEF-orange juice.
32909569|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
32909570|NCT02457897|Experimental|Patients with insulin receptor mutation|
33238836|NCT05740527|Other|Testing closed-loop system in an ambulatory setting|Closed-loop system feasibility testing
33394987|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
33394988|NCT03203902|No Intervention|Control|No intervention
33394989|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
33394990|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
33394991|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
33394992|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
33394993|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
33394994|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
33394995|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
33394996|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
33394997|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
33394998|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
33394999|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
33395000|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
33395001|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
33395002|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
33395003|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
33395004|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
33395005|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
33395006|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
33395007|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
33395008|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
33395009|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
33395010|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
33395011|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
33395012|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
33395013|NCT02447146|Experimental|Training group|9-week resistance training program
33395014|NCT02447146|Other|Control group|'Lectures on the disease'
33395015|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
33395016|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
33395017|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
33395018|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
33395019|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
33395020|NCT03203434||Esophageal anastomotic leakage|
32909571|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
33395021|NCT03203434||Esophageal uncomplicated controls|
33395022|NCT03203434||Pancreatic anastomotic leakage|
32909572|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
33395023|NCT03203434||Pancreatic uncomplicated controls|
33395024|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
33395025|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
33395026|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
33395027|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
33395028|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
33395029|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
33395030|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
33395031|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
33395032|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
33395033|NCT03199378||Caucasian|English speaking Caucasian individuals
33395034|NCT03199378||African American|English speaking African American individuals
33395035|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
33395036|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
33395037|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
33395038|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
33395039|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
33395040|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
33395041|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
33395042|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
33395043|NCT03203278|No Intervention|Control group|Usual care
33395044|NCT02450344|Experimental|Internet intervention|Interactive health promotion
33395045|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
33395046|NCT04362449|Experimental|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
33395047|NCT04362449|Active Comparator|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
33395048|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
33395049|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
33395050|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)|Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
33395051|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)|De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395052|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)|Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395053|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395054|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395055|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 20 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395056|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 25 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
33395057|NCT05186350|Active Comparator|SpyGlass group|ERCP plus SpyGlass group
33395058|NCT05186350|Active Comparator|ESWL group|ERCP plus ESWL
33395059|NCT03199066||All NHL subtypes|no interventions
33395060|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
33395061|NCT03199066||FL|only patients with follicular lymphoma
33395062|NCT03199066||MCL|only patients with mantle cell lymphoma
33395063|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
33395064|NCT03199066||MZL|only patients with marginal zone lymphoma
33395065|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
33395066|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
33395067|NCT03198910||Pulmonary arterial hypertension|
33395068|NCT03198910||Chronic thromboembolic pulmonary hypertension|
33395069|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
33071218|NCT04689022|Other|Group II received regional anesthesia: peripheral block was performed (n=73)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
33395070|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
33395071|NCT04273217|Experimental|AV-1 30 mg|Participants received a single intravenous (IV) infusion (infusion duration: 1 hour) of AV-1 30 mg on Day 1.
33395072|NCT04273217|Experimental|AV-1 90 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 90 mg on Day 1.
33395073|NCT04273217|Experimental|AV-1 250 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 250 mg on Day 1.
33395074|NCT04273217|Experimental|AV-1 500 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 500 mg on Day 1.
33395075|NCT04273217|Experimental|AV-1 1000 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 1000 mg on Day 1.
33395076|NCT04273217|Placebo Comparator|Placebo|Participants received a single IV infusion (infusion duration: 1 hour) of placebo matched to AV-1 on Day 1.
33395077|NCT05234086|Active Comparator|Advanced Healing|Activities related to wound washing, microbiological load control, care of peri-ulcer tissue and application of wound healing products in accordance to condition of the ulcer
33395078|NCT05234086|Experimental|InbioDerm + C plus advanced healing|For patient who are assigned treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section and through an enzymatic process with cell proliferation, skin cells will be obtained that will be integrated into de the InbioDerm+C, then will be apply to the patients with the advanced wound healing every fourteen days in accordance application program.
33395079|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
33395080|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
33395081|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
33395082|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
33395083|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
33395084|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
33395085|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
33395086|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
33395087|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
33395088|NCT04264949|Experimental|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
33395089|NCT04264949|Active Comparator|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
33395090|NCT04484506|Experimental|Stage I/II nasal ENKTL|2-3 cycles of induction pegaspargase-COEP chemotherapy followed by concurrent chemoradiotherapy, then by 1-2 cycles of pegaspargase-COEP chemotherapy as consolidation
33395091|NCT04484506|Experimental|Stage III/IV or primary extra-nasal ENKTL|6-8 cycles of pegaspargase-COEP chemotherapy with or without local radiotherapy and/or consolidative autologous stem cell transplantation
33395092|NCT04332653|Experimental|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395093|NCT04332653|Experimental|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395094|NCT04332653|Experimental|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395095|NCT04332653|Experimental|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395096|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395097|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395098|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive 1200 µg/kg of NT-I7 and and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395099|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC).Participants will receive 1200 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395100|NCT04332653|Experimental|Biomarker Cohort: CPI Naïve Ovarian Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
33395101|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
33395102|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
33395103|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
33395104|NCT05668871|Experimental|Danning Tablet and lifestyle intervention group|Under lifestyle intervention, Danning Tablet will be taken orally from baseline to weeks 12±1.
33395105|NCT05668871|No Intervention|Lifestyle intervention group|Lifestyle intervention only.
33395106|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
33395107|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
33395108|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
33395109|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
33395110|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
33395111|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
33395112|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
33395113|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
33395114|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
33395115|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
33395116|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
33395117|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
33395118|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
33395119|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
33395120|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
33395121|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
33395122|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
33395123|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
33395124|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
33395125|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
32745162|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
32909573|NCT04341753|Experimental|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:~the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
32909574|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
32909575|NCT02458365|Other|Comparison|Health In Motion
32909576|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
32909577|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
32909578|NCT04744077|Sham Comparator|Control|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
32898175|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
32744643|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~Both eyes involved~Open angle~Progressive glaucomatous optic neuropathy~Specific visual field loss of glaucoma~Intraocular pressure above the up limit of normal people~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
32744644|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
33071219|NCT04689022|Other|Group III received regional anesthesia with sedation (n=92)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
32744645|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
32744646|NCT03224741|Placebo Comparator|Information|
32744647|NCT03224741|Active Comparator|Active Choice|
33395126|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
33395127|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
33395128|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
33395129|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
33395130|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
33395131|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
33395132|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
33395133|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
33395134|NCT03198208||Reference group|No fentanyl dose administered during surgery
33395135|NCT03198208||Comparative group|Fentanyl dose administered during surgery
33395136|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
33395137|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
33395138|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
33395139|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
33395140|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
33395141|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
33395142|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
33395143|NCT04796714|Sham Comparator|Double antiplatelet therapy group|Patient randomized in this group will receive 1 tablet containing clopidogrel 75 mg and 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
33395144|NCT04796714|Experimental|Aspirin group|Patients randomized in this group: will receive 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
33395145|NCT04382651|Experimental|MAS825 + SoC|Single dose of MAS825 10 mg/kg by intravenous infusion in addition to SoC
33395146|NCT04382651|Placebo Comparator|Placebo + SoC|Single dose of matching Placebo by intravenous infusion in addition to SoC
33395147|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
33395148|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
33395149|NCT04762706|Experimental|CRUTCH Pathway|A novel behavioral health program.
33395150|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
33395151|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
33395152|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
33395153|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
33395154|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
33395155|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
33395156|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
33395157|NCT04673630|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
32744648|NCT03224741|Experimental|Monetary incentive|
32744649|NCT04863105|Experimental|Conference-Abiraterone acetate tablet|Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)
32909579|NCT04744077|Experimental|Student|Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
33395158|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
33395159|NCT04484116||Succesful surgery|PTH 24 hours after surgery <150pg/mL
33395160|NCT04484116||Unsuccessful surgery|PTH 24 hours after surgery >150pg/mL
33395161|NCT04614428|No Intervention|Standard Care Group|Participants will receive the standard care provided by their institution.
33395162|NCT04614428|Active Comparator|RESILIENCE Program group|Participants will receive the RESILIENCE Program on top of the standard care provided by their institution.
33395163|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
33395164|NCT04611854|Active Comparator|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
33395165|NCT04611854|Experimental|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
33395166|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
33395167|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
32744650|NCT04863105|Experimental|test-Abiraterone acetate tablet|Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd)
33395168|NCT04238780|Active Comparator|ESP( Erector Spinae Plane Block)|"After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
33395169|NCT04238780|Active Comparator|control group|"No regional anesthesia technique will be applied to the control group.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
33395170|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
33395171|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
33395172|NCT00944216|Experimental|Salkera Emollient Foam Treatment|All participants will receive this intervention.
33395173|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
33395174|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
33395175|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
33395176|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
33395177|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
33395178|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
33395179|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
33395180|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
33395181|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
33395182|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
33395183|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
32744651|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
33395184|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
33395185|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
33395186|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
33395187|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
33395188|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
33395189|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
33395190|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
33395191|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
33395192|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
33395193|NCT03442088|Experimental|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
33395194|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
33395195|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
33395196|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
33395197|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
33395198|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
33395199|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
33395200|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
33395201|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
33395202|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
33395203|NCT03194386|No Intervention|Control|usual care
33395204|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
33395205|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
33395206|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
33395207|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
33395208|NCT03298334|Active Comparator|Receives Vaginal Seeding|
33395209|NCT03298334|Sham Comparator|No Vaginal Seeding|
33395210|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
33395211|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
33395212|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
33395213|NCT03746717|Active Comparator|Staples|Skin closure with staples
33395214|NCT05582642|Active Comparator|Diaphragm Strength Training|
33395215|NCT05582642|Sham Comparator|Diaphragm Endurance Training|
33395216|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
33395217|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
33395218|NCT05582564|Other|concrete text|Italian and French unvaccinated cohorts (n= 164; n=163)
33395219|NCT05582564|Other|abstract text|Italian and French unvaccinated cohorts (n=155; n=153)
33395220|NCT05582564|Other|abstract task|Italian and French unvaccinated cohorts (n=54; n=55)
33395221|NCT05582564|Other|concrete task|Italian and French unvaccinated cohorts (n=55; n=56)
33395222|NCT05582564|Other|control|Italian and French unvaccinated cohorts (n=103; n=110)
33071220|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
32754048|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
33395223|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
33395224|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
33395225|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
33395226|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
32754049|NCT05077475|Experimental|Sequence A|Period 1: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
33395227|NCT05581940||Pediatric caudal anesthesia block.|caudal epidural block is a neuraxial block to provide effective pain relief and analgesia in pediatrics undergoing infra-umbilical pediatric surgery this study aimed to compare the effectiveness of adding to general anesthesia in terms of Intra and post-op pain management. A prospective, randomized case-controlled.A total of 72 patients aged two months to six years with (ASA PS) I (ASA I) were recruited over a six-month period between December 2019 and May 2020. Patients were allocated into two groups A performed under general anesthesia with caudal block and group B performed under general anesthesia alone. Both groups were compared based on hemodynamic stability, analgesia need, pain score, and parental satisfaction. Postoperative pain was evaluated by the Pain Scale- Categorical and numerical variables of both groups were compared. Results:
33395228|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
33395229|NCT04223687|Other|Neutral label|
33395230|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
33395231|NCT05579132|Experimental|CN201|"By study design, four planned target CN201 dose levels are600ug, 1200 ug, 2500 ug and 5000 ug.~Subjects will receive CN201 by intravenous infusion (IV), once per week, four weeks per treatment cycle."
32754050|NCT05077475|Experimental|Sequence B|Period 1: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
33395232|NCT05549648|Other|Aged group|50-65 y.o.
32754051|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
32754052|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
32754053|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
33395233|NCT05549648|Other|Super-aged group|65+ y.o.
33395234|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
33395235|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
33395236|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
33395237|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
33395238|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
33395239|NCT03942770|Active Comparator|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
33395240|NCT03942770|Active Comparator|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
33395241|NCT03942770|Sham Comparator|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
33395242|NCT03942770|Sham Comparator|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
33395243|NCT03942770|No Intervention|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
33395244|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
33395245|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
33395246|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
33395247|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
33395248|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
32754054|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
33395249|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
32909580|NCT04744077|Experimental|Scientist|"The PI will manage this Instagram account created for the study. The PI is a certified exercise physiologist and holds a PhD in Rehabilitation Sciences. She will disclose this information on the account. This group is the study's gold standard because it will provide evidence-based content delivered by an exercise scientist."
32909581|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
32909582|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
32909583|NCT04920630|Experimental|CBT-I|5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.
33395250|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
33395251|NCT03722576|Experimental|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
33395252|NCT04084067|Experimental|Indocyanine green (ICG)|Participants will receive a single dose of 1.5 mg/kg of ICG intravenously over 15 minutes prior to surgery.
33395253|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
33395254|NCT02445664|No Intervention|Control|No intervention (no video)
33395255|NCT04221815|Active Comparator|IVUS guided PCI|Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
33395256|NCT04221815|Placebo Comparator|Angiographic-guided PCI|Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
33395257|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
33395258|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
33395259|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
33395260|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
33395261|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
33395262|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
33395263|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
33395264|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
33395265|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
33395266|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
33395267|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
33395268|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
33395269|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
33395270|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
33395271|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
33395272|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
33395273|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
33395274|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
33395275|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
33395276|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
32909584|NCT05370066|Experimental|CS6BP and cuff|CS6BP watches will be used in the study with Commercially available FDA approved Blood pressure monitors:
33395277|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
33395278|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
33395279|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
32909585|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
33395280|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
33395281|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
33395282|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
33395283|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
33395284|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
33395285|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
33395286|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
33395287|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
33395288|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
33395289|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
33395290|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
33395291|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
33395292|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
33395293|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
33395294|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
33395295|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
33395296|NCT02786186||Secikinumab|Patients treated with secukinumab
33395297|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
33395298|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
33395299|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
33395300|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
33395301|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
33395302|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
33395303|NCT05234242||stationary/inpatient|
33395304|NCT05234242||ambulatory/outpatient|
33395305|NCT04206293|Experimental|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
33395306|NCT05520476||20 patients with at least two seizures per week.|The device collects vital signs and EEG data as well as caregiver information associated with seizure episodes.
33395307|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
33395308|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
33395309|NCT04939532|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants with high risk for either infection or severe disease and proactivity reaches those participants via text message for testing needs (as advised by state and/or federal guidelines) and testing recommendation when applicable. This is a bi-directional text messaging system.
33395310|NCT04939532|Active Comparator|Text-Messaging plus Patient Navigation (TM+PN)|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD testing.
33395311|NCT03197740|Active Comparator|aricept Tab 5mg|
33395312|NCT03197740|Experimental|donepezil patch 25cm2|
33395313|NCT03197740|Active Comparator|aricept Tab 10mg|
33395314|NCT03197740|Experimental|donepezil patch 50cm2|
32909586|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
33395315|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
32909587|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
32909588|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
32909589|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
32909590|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
33071221|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
32909591|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
33071222|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
33071223|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
33071224|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
33395316|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
32754055|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
32754056|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one <50% stenotic lesion on coronary angiography.
33395317|NCT04050878|Experimental|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
33395318|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
33071225|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
32909592|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
33071226|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
32754057|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
32754058|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
32754059|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
32754060|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
33071227|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
33071228|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
33395319|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
33395320|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
33395321|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
33395322|NCT02444962|Experimental|HAVD implant|
33395323|NCT04200989|Experimental|Treatment|Peanut ILIT
33395324|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
33395325|NCT02450110|No Intervention|Control|Standard treatment
33395326|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
33395327|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
33395328|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
33395329|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
33395330|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
33395331|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
33395332|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
33395333|NCT02727998|Experimental|Single infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
33395334|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
33395335|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
33395336|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
33395337|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
33395338|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 70 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
33395339|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 140 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
33395340|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
33395341|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
33395342|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
33395343|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
33395344|NCT01562639||Nexium|
33395345|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
33395346|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
33395347|NCT01766648|Active Comparator|Standard screw fixation|Standard screw fixation
33395348|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
33395349|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
33395350|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
33395351|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
33395352|NCT01163864|Experimental|affect regulation training|
33395353|NCT01163864|Active Comparator|health and lifestyle|
33395354|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
33395355|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
32754061|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
32754062|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
32754063|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
33395356|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
32754064|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
32754065|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
32754066|NCT05077241|Experimental|Experimental group - inspiratory muscle training group with load|Experimental group: Inspiratory muscle training with POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) with 30% of Pimax. with weekly load increment of 10% of the Pimax value. initial. The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication.
32905349|NCT05235620||Pharmacy patients|Patients engaged in completing medication adherence-related questionnaires in the PatientToc software at their pharmacies. Patient-level medication, health history, and self-reported adherence information will be collected from patients meeting eligibility criteria. Patients will also be observed and interviewed about their experiences using PatientToc.
33395357|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
33395358|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
33395359|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
33395360|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
33395361|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
33395362|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
33395363|NCT04844528|Experimental|Treatment: all patients|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
33395364|NCT04844528|Placebo Comparator|Arm 2: Placebo|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
33395365|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
33395366|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
33395367|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
33395368|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
33395369|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
33395370|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
33395371|NCT04172831|Experimental|TNX-102 SL Tablets, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
33395372|NCT04172831|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
33395373|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
33395374|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
33395375|NCT04839770|Experimental|Axonpen|Subjects will receive minimally invasive endoscopic surgery using the Axonpen™ system for early hematoma evacuation (within 48 hours post-ictus).
33395376|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
33395377|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
33395378|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
33395379|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
33395380|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
33395381|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
33395382|NCT01562717|Experimental|Ibuprofen|
33395383|NCT01562717|Placebo Comparator|Placebo|
33395384|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
33395385|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
33395386|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
33395387|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
33395388|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
33395389|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
33395390|NCT03744923|No Intervention|control group|the patients will not receive any blocks
33395391|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
33395392|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
33395393|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
33395394|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
33395395|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
33395396|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
33395397|NCT05058404|Experimental|Standard arm (A)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).~After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
33395398|NCT05058404|Experimental|Experimental arm (B)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:~Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;~In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
33395399|NCT03118336|Placebo Comparator|placebo group|
33395400|NCT03118336|Experimental|empaglifozine group|
33395401|NCT02444572|Experimental|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:~Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer ENOXA® subcutaneously~The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
33395402|NCT02444572|Active Comparator|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:~Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer LOVENOX® subcutaneously~The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
33395403|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
33395404|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
33395405|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A1 High Dose|Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.
33395406|NCT04165031|Experimental|LY3499446 Phase 1 Cohort AO Mid Dose|Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
33395407|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A-2 Low Dose|Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles.
33395408|NCT04165031|Experimental|LY3499446 + Combination Drugs Phase 1|"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~This trial was terminated prior to initiation of combination therapy cohorts."
33395409|NCT04165031|Experimental|LY3499446 Monotherapy + Combination Drugs Phase 2|"LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~The trial was terminated prior to initiation of Phase 2 of this study."
33395410|NCT04165031|Active Comparator|Docetaxel Phase 2|"Docetaxel IV infusion.~The trial was terminated prior to initiation of Phase 2 of this study."
33395411|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
33395412|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
33395413|NCT05480930|Active Comparator|paper-based clinical decision support tool|Providers at the TMDS will use the existing paper-based clinical decision support tools to consult/examine patients.
33395414|NCT05480930|Experimental|digital clinical decision support (dCDS) tool|Providers at the TMDS will use the new digital clinical decision support (dCDS) tool to consult/examine patients.
33395415|NCT05480150|Experimental|bipolar disorder|Patients with BD depressive episode received standard treatment with quetiapine fumarate tablets, starting from 50mg/ night, titrated to a therapeutic dose of 300-400mg/ night within 10 days, and maintained treatment for 4 weeks. According to the patient's condition, patients with BD depressive episode could receive another standard treatment with lurasidone, starting from 20mg/ night, titrated to a therapeutic dose of 40mg/ night within 6 days, and maintained treatment for 4 weeks. Adverse reactions and changes in condition of all patients were recorded
33395416|NCT05480150|Experimental|major depressive disorder|MDD depressive episode patients received standard treatment with escitalopram oxalate tablets, starting from 5mg/ day once, titrated to a therapeutic dose of 10-20mg/ day within 1 week, and maintained treatment for 4 weeks
33395417|NCT05480150|No Intervention|healthy control|no interventions
32909593|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
32909594|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
32909595|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
32909596|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
32901397|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
33071229|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
33071230|NCT00149318||Patients with Fabry disease|
32901398|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
32901399|NCT00541190|Experimental|healthy controls|Healthy control subjects
33071231|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
32901400|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
32901401|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
32901402|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
32901403|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
32754067|NCT05077241|Placebo Comparator|Control group - inspiratory muscle training group without load|Subjects will use a IMT POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) device without any load and will receive the same guidelines as experimental group (The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication). At the end of the research, the control group will have the right to experimental treatment with the IMT protocol, if this is effective.
32901404|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
32901405|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
33395418|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
33395419|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
33395420|NCT05464628|Experimental|Atorvastatin and ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin.
33395421|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
33395422|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
33395423|NCT04829630|Other|subjects who received three vs. four ID PEP at least two, five or 10 years earlier|"30 subjects who received three ID PEP at least two years earlier in Cambodia~30 subjects who received three ID PEP at least five years earlier in Cambodia~30 subjects who received three ID PEP at least 10 years earlier in Cambodia~30 subjects who received four ID PEP at least two years earlier in Madagascar~30 subjects who received four ID PEP at least five years earlier in Madagascar~30 subjects who received four ID PEP at least 10 years earlier in Madagascar"
33395424|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
33395425|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
33395426|NCT03196414|Experimental|CART-138/BCMA/19/more|
33395427|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
33395428|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
33395429|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
33395430|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
33395431|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
33395432|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
33395433|NCT03766516||Cohort|"Any patient planning to administer BrentuximabVedotin to treat the target disease.~Any patient administering BrentuximabVedotin to treat the target disease.~Any patient tracing BrentuximabVedotin after treating the target disease.~Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
33395434|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
33395435|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
33395436|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
33395437|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
33395438|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
33395439|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
33395440|NCT05234164|Experimental|EXIST 6F NiTi Stent System FLEX|Stent implantation of lesions in the SFA graded with Fanelli 1 and 2, and lesions in the P1 segment of the proximal popliteal artery.
33395441|NCT05234164|Experimental|EXIST 6F NiTi Stent System PULL|Stent implantation of lesions in the SFA graded with 3 and 4.
33395442|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
33395443|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
33071232|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
33395444|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
33395445|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
33395446|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
33395447|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
33395448|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
33395449|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
33395450|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
33395451|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
33395452|NCT05461352|Experimental|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
33395453|NCT05461352|Experimental|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
33395454|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
33395455|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
33395456|NCT05455502|Experimental|Sequence 1|Participants will receive VX-548 reference tablet (TF1) under fasted condition in dosing period 1, then VX-548 test tablet (TF2) under fasted condition in dosing period 2, and finally VX-548 test tablet (TF2) under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395457|NCT05455502|Experimental|Sequence 2|Participants will receive VX-548 TF1 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395458|NCT05455502|Experimental|Sequence 3|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395459|NCT05455502|Experimental|Sequence 4|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395460|NCT05455502|Experimental|Sequence 5|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395461|NCT05455502|Experimental|Sequence 6|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF2 under fasted condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
33395462|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
33395463|NCT05427812|Experimental|Phase 1: Dose escalation|Participants with R/R multiple myeloma (MM) will be administered ISB 1442 weekly by subcutaneous (SC) injection in each 28-day cycle. Dose escalation will begin with an accelerated titration dose escalation and should certain conversion criteria be met, escalation will convert to the standard (3 + 3) dose escalation
33395464|NCT05427812|Experimental|Phase 2 (Dose Expansion): Cohort A: R/R Multiple Myeloma|This cohort includes the participants with pathologically confirmed R/R MM and must have received at least 3 prior lines of therapy, including proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. Participants will receive the recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection determined in Phase 1 of the study for treatment of R/R MM. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
33395465|NCT05427812|Experimental|Phase 2 (Dose Expansion): Cohort B: R/R MM Post-T-cell-Directed Therapy|This cohort includes the participants with pathologically confirmed R/R MM post T cell-directed therapy and have received prior treatment with proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti-CD38 therapies either in combination or as a single agent; and must have failed at least 3 prior lines of treatment. Participants will receive the RP2D of ISB 1442 SC injection determined in Phase 1 of the study. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
32909597|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
33071233|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
33395466|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation~All Patients will be operated following a standardized protocol of our foot and ankle department:~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
33395467|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
33395468|NCT02912312|Experimental|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
33395469|NCT02912312|Active Comparator|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
33395470|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
33395471|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
33395472|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
33395473|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
33395474|NCT05387720|Active Comparator|Study Group A|Study Group A (25 patients) will receive manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy
33395475|NCT05387720|Active Comparator|Study Group B|Study Group B (25 patients) will receive trigger sensitivity adjustment on mechanical ventilator in addition to traditional chest physiotherapy.
33395476|NCT05387720|Active Comparator|Study Group C|Study Group C (25 patients) will receive a concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy.
33395477|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
33395478|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
33395479|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
33395480|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
33395481|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
33395482|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
33395483|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
33395484|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
33395485|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
33395486|NCT03704870|Experimental|Chest Xray post chest tube removal only|
33395487|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
33395488|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
33395489|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
33395490|NCT04794218|Experimental|Study Group 1|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^4 or Placebo
33395491|NCT04794218|Experimental|Study Group 2|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
33395492|NCT04794218|Experimental|Study Group 3|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
33395493|NCT04794218|Experimental|Study Group 4A|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
33395494|NCT04794218|Experimental|Study Group 5|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
32901406|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
32901407|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
32901408|NCT00478556|Active Comparator|1|Gastroview
32901409|NCT00478556|Experimental|2|Omnipaque
33071234|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
32909598|NCT01118624|Experimental|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
33071235|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
33071236|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
33071237|NCT02917330|No Intervention|Control group|Treatment as usual
33071238|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
32909599|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
33071239|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
33395495|NCT04794218|Experimental|Study Group 6|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
32901410|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
32901411|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
33395496|NCT04794218|Experimental|Study Group 7|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
33395497|NCT04794218|Experimental|Study Group 4B|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 and Day 42 2 X 10^7 or Placebo
32909600|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
32744229|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
32909601|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
32909602|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
33071240|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
33395498|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
33395499|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
33071241|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
33395500|NCT05374460|Sham Comparator|Conscious awareness: No information|Told nothing about the visuo-proprioceptive mismatch. Hand remains hidden beneath mirror that shows visual display. (control)
33395501|NCT05374460|Experimental|Conscious awareness: Explanatory diagram|Told in advance about the visuo-proprioceptive mismatch, which will be explained with a diagram. Hand remains hidden.
33395502|NCT05374460|Experimental|Conscious awareness: Direct vision of hand|Foamboard under mirror removed, making the mirror see-through and the hand directly visible.
33395503|NCT05374460|Sham Comparator|Movement feedback: No feedback|No movement feedback (control)
33395504|NCT05374460|Experimental|Movement feedback: Target hand|Movement feedback about the target hand.
33395505|NCT05374460|Experimental|Movement feedback: Pointing hand|Movement feedback about the pointing hand.
33071242|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
33071243|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
33071244|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
33395506|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
33395507|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
33071245|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
33071246|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
32901412|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
33071247|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
33071248|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
33071249|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
33071250|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
33071251|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
33071252|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
33071253|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
32901413|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
33071254|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
33071255|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
33395508|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
33395509|NCT02644460|Experimental|Stratum B - enrollment is closed for this study arm|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
33071256|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
32901414|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
32909603|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
32754068|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
32754069|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
32754070|NCT03574571|Experimental|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
32754071|NCT03574571|Experimental|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
32754072|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
32754073|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
32754074|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
33395510|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
33395511|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
33395512|NCT05358548|Experimental|Squamous Lung Cancer|"A Cycles consist of either:~Paclitaxel Based: Carboplatin/Paclitaxel/Pembrolizumab OR~nab-Paclitaxel Based: Carboplatin/nab Paclitaxel/Pembrolizumab These A Cycles will be given for up to four cycles (standard)~B Cycles consist of Pembrolizumab alone"
33395513|NCT05358548|Experimental|Non-Squamous Lung Cancer|"A Cycles consist of Carboplatin/Pemetrexed/Pembrolizumab (up to four cycles standard)~B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 5 and beyond): Pemetrexed in combination with Pembrolizumab; Alternatively, Pembrolizumab alone, for up to 2 years since enrollment (standard)"
33395514|NCT05358548|Experimental|Head and Neck Squamous Cell Carcinoma|"A Cycles consist of Carboplatin/5-Fluorouracil/Pembrolizumab (up to six cycles standard)~B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 7 and beyond): Pembrolizumab alone, for up to two years since enrollment (standard)"
33395515|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
33395516|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
33395517|NCT05302154|Active Comparator|Standard treatment group|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
33395518|NCT05302154|Experimental|Cartoon movie- passive distraction group|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
33395519|NCT05302154|Experimental|VR-active distraction group|The active distraction group is treated while wearing the VR headset and interacting with the designed application.
33395520|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
33395521|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
33395522|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
33395523|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
33395524|NCT04050488|Active Comparator|Treatment Group|Participants who receive the intervention.
33395525|NCT04050488|Placebo Comparator|Control Group|Participants who receive the placebo.
33395526|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
33395527|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
33395528|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
33395529|NCT02584478|Experimental|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
33395530|NCT02584478|Other|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
33395531|NCT02584478|Experimental|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
33395532|NCT02584478|Experimental|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
33395533|NCT03490318||Patients with DMO and/or PDR|
33395534|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
33395535|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
33395536|NCT04779554|Experimental|Flat Dose Mitomycin C|Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
33395537|NCT04779554|Experimental|Weight-Based Mitomycin C|Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
33395538|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
33395539|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
33395540|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
33395541|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
33395542|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
33395543|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
33395544|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
33395545|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
33395546|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
33395547|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
33395548|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
33395549|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
33395550|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
32909604|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
32909605|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
32909606|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
32909607|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
32909608|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
32909609|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
32909610|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
32909611|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
33071257|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
33395551|NCT02431364|Placebo Comparator|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
33395552|NCT02431364|Experimental|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
33395553|NCT02431364|Experimental|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
33395554|NCT02431364|Experimental|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
33395555|NCT02431364|Experimental|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
33395556|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
33395557|NCT03701750|No Intervention|Control Arm|routine luteal phase support
33395558|NCT03704402||alcohol policy group|High schools that introduced the policy
33395559|NCT03704402||control group|High schools that did not introduce the policy
33395560|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
33395561|NCT05273684|Experimental|4*4 followed by 10*1 or 10*1 followed by 4*4|Following baseline measurements, participants are allocated to the random sequence, by which they will complete the two HIIT protocols ⟨http://www.randomization.com⟩ and based on this, patients are randomized to a specific testing sequence.
33395562|NCT05272592||Nursing staff|Certified local-and-international inpatient-and-outpatient nurses specialised in urology, perioperative nurses, and urology-specific advanced practice nurses/nurse practitioners will be included.
33395563|NCT05260892||Narrow GM|Patients presenting at least onde edentulous site rehabilitated with Narrow GM implant
33395564|NCT05239910|Experimental|Tenalisib 400 mg BID and CHOP|
33395565|NCT05239910|Experimental|Tenalisib 800 mg BID and CHOP|
33395566|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
33395567|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
33395568|NCT04764656||Brolucizumab|Naïve (Patients being the first time treated) and pre-treated patients
33395569|NCT04594694|Active Comparator|Treatment A: BZF 200 mg IR|Bezafibrate (BZF): 200 mg IR Ocaliva (OCA) Placebo Bezafibrate (BZF) 400 mg Placebo
33395570|NCT04594694|Active Comparator|Treatment B: BZF 400 mg SR|Bezafibrate (BZF): 400 mg SR Ocaliva (OCA) Placebo Bezafibrate (BZF) 200 mg Placebo
33395571|NCT04594694|Experimental|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 200 mg IR Bezafibrate (BZF) 400 mg Placebo
33395572|NCT04594694|Experimental|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 400 mg SR Bezafibrate (BZF) 200 mg Placebo
33395573|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
33395574|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
33395575|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
33395576|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
33395577|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
33395578|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
33395579|NCT03703934||Healthy Controls|Patients without a painful condition
33395580|NCT03034460|Experimental|CD5024 1% cream|Active drug;
33395581|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
33395582|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
33395583|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
33395584|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod 1 milligrams (mg)|
32909612|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
33071258|NCT00149513|Experimental|1|Targeted nurse case management
33395585|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod 2 mg|
33395586|NCT04162769|Placebo Comparator|12-Week Double-Blind Treatment Period: Placebo|
33395587|NCT04162769|Experimental|52-Week Open-Label Extension Period: Etrasimod 2 mg|
32744652|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
33071259|NCT00149513|Active Comparator|2|Usual Care
33071260|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
33071261|NCT02916901|Placebo Comparator|Placebo|placebo
32744653|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
32909613|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
32909614|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
32909615|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
32909616|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
32909617|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
32909618|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~5 weeks preoperative chemoradiotherapy.~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
32909619|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
32754075|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
32754076|NCT03565445|Experimental|ASP1948 Dose Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1948. Each dose level will enroll approximately 3 or 4 participants. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM). Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
33071262|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
33071263|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
32905350|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
32905351|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
33395588|NCT04593602|Experimental|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
33395589|NCT04593602|Active Comparator|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
33395590|NCT04751942|Experimental|Non-compressive Bioactive Garment|The non-compressive bioactive garment is a commercially available garment that is designed to reflect infrared waves generated by the wearer back into the soft tissue surrounded by the garment. The reflection of the infrared waves is intended to improve pain and swelling at the site. Patients following Total knee replacement are intended to wear morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
33395591|NCT04751942|Active Comparator|Thrombo-Embolic Deterrent|a gradient compression stocking that is currently the gold standard for deterring thromboembolic events and assisting with post-operative swelling after total knee replacements. Patients following Total knee replacement are intended to wear the TED hose morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
33395592|NCT04589468|Experimental|Dose-Finding/Escalation|Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
33395593|NCT04589468|Experimental|Dose Expansion|An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
33395594|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
33395595|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
33395596|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
33395597|NCT04743518|Active Comparator|anti-TNF|
33395598|NCT04743518|Active Comparator|vedolizumab|
33395599|NCT04743518|Active Comparator|tofacitinib|
33395600|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
33395601|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
33395602|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
33395603|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
33395604|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
33395605|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
33395606|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
33395607|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
33395608|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
33395609|NCT04585802||Control Group (3)|patients without suicide attempt and without suicide ideation
33395610|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33395611|NCT03624686||healthy volunteer|
33395612|NCT03624686||luekemia patient|
33395613|NCT04152083|Experimental|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
33238837|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
33238838|NCT04064385|Experimental|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
33238839|NCT04064385|No Intervention|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
33238840|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
33238841|NCT04063059|No Intervention|Control|Usual care
33238842|NCT02567955|Active Comparator|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
33238843|NCT02567955|Experimental|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
33238845|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
33238846|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
33238847|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
33238848|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
33238849|NCT02568423|Experimental|Mirikizumab IV|Mirikizumab given by intravenous (IV) infusion once.
33238850|NCT02568423|Experimental|Mirikizumab SC|Mirikizumab given by subcutaneous (SC) injection once.
33238851|NCT02568423|Placebo Comparator|Placebo IV|Placebo given by IV infusion once.
33238852|NCT02568423|Placebo Comparator|Placebo SC|Placebo given by SC injection once.
33395614|NCT04152083|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
33395615|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
33395616|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
33395617|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
33071264|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
33238853|NCT00921063|Experimental|PD 0332334 250 mg|
33238854|NCT00921063|Experimental|PD 0332334 100 mg|
33395618|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
33071265|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
33071266|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
33071267|NCT00149552|Placebo Comparator|Placebo|Placebo
33395619|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
33238855|NCT00921063|Placebo Comparator|placebo|
32909620|NCT01100762|Experimental|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
33238856|NCT00921063|Active Comparator|Alprazolam extended release|
33238857|NCT05738967|Experimental|Transdiagnostic cognitive behavioral therapy|
33238858|NCT05738967|Active Comparator|Treatment as usual|
33238859|NCT05738811|Experimental|TENS treatment group|Group A would be given exercise protocol along with TENS treatment protocol.
33238860|NCT05738811|Experimental|EMS treatment group|Group B would receive exercise protocol along with EMS treatment protocol.
33238861|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
33238862|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
32909621|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
32909622|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
33238863|NCT00739635|Experimental|1|
33238864|NCT00739635|Placebo Comparator|2|
33238865|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
32909623|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
32909624|NCT03013166||Cohort 1|IR hydrocortisone
33238866|NCT00739713|Experimental|SB|Sea buckthorn oil group
33238867|NCT00739713|Placebo Comparator|PL|Placebo group
32909625|NCT03013166||Cohort 2|IR prednisolone
32909626|NCT03013166||Cohort 3|MR hydrocortisone
32909627|NCT03013166||Cohort 4|IR to MR hydrocortisone
32909628|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
32909629|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
32909630|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
33238868|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
32905352|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
32905353|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
32905354|NCT00868712||1|Warfarin use < 6 months
32909631|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
32909632|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
33238869|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
32754077|NCT03565445|Experimental|ASP1948 Dose Expansion|If a confirmed response (partial response [PR] or confirmed response [CR]) per iRECIST occurs in a monotherapy escalation cohort, a tumor specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been cleared. Up to 5 expansion cohorts may be opened. Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
32754078|NCT03565445|Experimental|ASP1948 plus nivolumab Combination Therapy Dose Escalation|ASP1948 will be administered in combination with a fixed dose of nivolumab every 2 weeks. Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
32754079|NCT03565445|Experimental|ASP1948 plus nivolumab Combination Therapy Dose Expansion|If a confirmed response (PR or CR) is observed, a combination expansion cohort may be opened in a tumor type with response. Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
32754080|NCT03565445|Experimental|ASP1948 plus pembrolizumab Combination Therapy Dose Escalation|After the completion of the nivolumab combination escalation, a fixed dose of ASP1948 will be administered every 2 weeks in combination with a fixed dose of pembrolizumab every 6 weeks. An every 3 week schedule will also be evaluated with the highest fixed dose of ASP1948 in combination with fixed dose of pembrolizumab after the monotherapy cohort is cleared. Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
32754081|NCT03565445|Experimental|ASP1948 plus pembrolizumab Combination Therapy Dose Expansion|If a confirmed response (PR or CR) per iRECIST occurs in a combination therapy escalation cohort, a tumor specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been cleared. Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
32754082|NCT03184909|Experimental|Tulsi active|
32754083|NCT03184909|Placebo Comparator|Tulsi placebo|
32754084|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
32754085|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
32754086|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
32754087|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
32754088|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
32754089|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
32754090|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
33395620|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
32754091|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
32754092|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
32754093|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
32754094|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
32754095|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
32754096|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
32754097|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
32754098|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
32754099|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
32905355|NCT00868712||2|Warfarin use 6-24 months
32905356|NCT00868712||3|Warfarin use >24 months
32909633|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
32909634|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
33238870|NCT05388825|Experimental|Sequence 1|N=14 subjects receive 2.5 mg TPN171H and 10 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2 ; 10 mg Placebo and 5 mg Placebo for Period 3.
32909635|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
32754100|NCT04483765||post-spinal hypotension|Patients with a fall in SBP by 25% of the preoperative baseline or an absolute value <90 mm of Hg; MAP ≤65 mmHg after spinal anesthesia
32754101|NCT04483765||post-spinal normotension|Patients with Fall of SBP<%25 of the preoperative value or absolute value >90 mm Hg, MAP>65 mmHg
32754102|NCT05054231|Experimental|Patient treated with CAR-T cells|
32754103|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
32909636|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
32909637|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
32909638|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
32754104|NCT02326571||spontaneous intracerebral hemorrhage|
32909639|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
32909640|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
32909641|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
32909642|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
32909643|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
32754105|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
32754106|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
32754107|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
32754108|NCT03142217|Other|Patient with Huntington's Disease|
32754109|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
33395621|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
32754110|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
32754111|NCT03117907||Infants with low infectious status|
32754112|NCT03117907||Infants with high infectious status|
33238871|NCT05388825|Experimental|Sequence 2|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2 ; 2.5 mg TPN171H and 10 mg Placebo for Period 3.
33238872|NCT05388825|Experimental|Sequence 3|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 2.5 mg TPN171H and 10 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
33238873|NCT05388825|Experimental|Sequence 4|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg TPN171H and 5 mg Placebo for Period 2; 10 mg Placebo and 5 mg Placebo for Period 3.
33238874|NCT05388825|Experimental|Sequence 5|N=14 subjects receive 10 mg TPN171H and 5 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
33238875|NCT05388825|Experimental|Sequence 6|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2; 10 mg TPN171H and 5 mg Placebo for Period 3.
33238876|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
33238877|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
33238878|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
33238879|NCT05372913|Experimental|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
33238880|NCT05372913|Active Comparator|CBT-Light Teletherapy Group|Participants assigned to the CBT-light teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
33238881|NCT05371509|Experimental|Myofunctional therapy (MT) nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a myofunctional therapy (MT) nozzle to use daily
33238882|NCT05371509|Placebo Comparator|Placebo nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a placebo nozzle to use daily
33238883|NCT00739947||1|Standard of Care
33238884|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238885|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238886|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238887|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238888|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238889|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238890|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
33238891|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
33238892|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
33238893|NCT00740025||QD|Women who received their meds as QD administration
33238894|NCT00740025||BID|Women who received their gonadotropins as a BID dose
33238895|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
33238896|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
33238897|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
33238898|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
33238899|NCT05722665||Normal chest radiographs|X-rays without alterations in the lung parenchyma
33238900|NCT05722665||COVID-19 chest radiographs|X-rays belonging to patients with a diagnosis of COVID-19 confirmed by positive Reverse Transcriptase polymerase chain reaction (RT-PCR) and/or presence of antibodies to COVID-19 and/or positive COVID-19 viral antigen.
33238901|NCT05722665||Other pneumonia chest radiographs|X-rays belonging to patients with a diagnosis of pneumonia other than COVID-19
32909644|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
32909645|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
32909646|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
33238902|NCT05714865|Experimental|LISA Arm|Eligible subjects who have respiratory distress syndrome (Anderson Silverman Score >4) managed on continuous positive airway pressure (CPAP) will receive surfactant via a thin catheter while on CPAP.
32909647|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
32754113|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
32754114|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
32754115|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
32754116|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
33395622|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
33395623|NCT04736030|Experimental|Conmigo PA Intervention|12-week program (90 minutes/week)
33395624|NCT04736030|No Intervention|Delayed Abbreviated Intervention|No intervention during experimental phase; participants in control group receive abridged program after the final measurement point (wait list control).
33395625|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
33395626|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
33395627|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
33395628|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
33395629|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
33395630|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
33395631|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
33395632|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
33395633|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
33395634|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
33395635|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
33395636|NCT04712474|Experimental|In-home decluttering|Study participants receive weekly sessions of in-home decluttering for 10 weeks.
33395637|NCT04712474|No Intervention|Delayed treatment|Study participants receive weekly session of in-home decluttering after a 10 week delay.
33395638|NCT04710368|Experimental|Treatment|Evolocumab subcutaneously administered 140 mg every 2 weeks for 26 weeks
33395639|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
33395640|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
32754117|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
32754118|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
32754119|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
32754120|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
32754121|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
32754122|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
32754123|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
32754124|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
32754125|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
32754126|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
32754127|NCT04996199|Experimental|Oxcarbazepine GROUP|Oxcarabazepine 150mg BD starting dose & will be increased if the patient is not relieved
33395641|NCT04709276|Experimental|Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)|"Subjects with neuroendocrine prostate cancer (NEPC) or aggressive variant prostate cancer (AVPC) will receive a combination of nivolumab, ipilimumab, carboplatin and cabazitaxel for up to 10 cycles of 21 days each. After carboplatin and cabazitaxel are discontinued, a combination of nivolumab and ipilimumab will be administered.~Nivolumab will be administered intravenously at a dose of 360 mg every 3 weeks.~Ipilimumab will be administered intravenously at a dose of 1 mg/kg every 6 weeks.~Carboplatin will be administered intravenously at a dose of AUC 4 mg/ml per minute.~Cabazitaxel will be administered intravenously at a dose of 20 or 25 mg/m2."
33395642|NCT01526668|Active Comparator|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
33395643|NCT01526668|Active Comparator|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
33395644|NCT01526668|Active Comparator|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
33395645|NCT01526668|Active Comparator|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
33395646|NCT04706624|Active Comparator|A - High intensity Contingency management + SMS reminders|Participants who respond to the high intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
33395647|NCT04706624|Active Comparator|B - High intensity Contingency management + Matrix only|Participants who do not respond to the high intensity contingency management are randomized into the Matrix only group.
33395648|NCT04706624|Active Comparator|C - High intensity Contingency management + (Matrix + CM)|Participants who do not respond to the high intensity contingency management are randomized into the Matrix plus contingency management group.
33395649|NCT04706624|Active Comparator|D - Low intensity Contingency management + SMS reminders|Participants who respond to the low intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
33395650|NCT04706624|Active Comparator|E - Low intensity Contingency management + Matrix only|Participants who do not respond to the who intensity contingency management are randomized into the Matrix only group.
33395651|NCT04706624|Active Comparator|F - Low intensity Contingency management + (Matrix+CM)|Participants who do not respond to the who intensity contingency management are randomized into the Matrix plus contingency management group.
33395652|NCT01194622|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
33395653|NCT01194622|Active Comparator|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
33395654|NCT01194622|Active Comparator|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
33395655|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
33395656|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
33395657|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395658|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395659|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395660|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395661|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395662|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33238903|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
33238904|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
33238905|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
33238906|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
33395663|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395664|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395665|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395666|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
33395667|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
33395668|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
32754128|NCT04996199|Active Comparator|Carbamzepine GROUP|carbamazepine 100mg BD initial dose & will be increased if the patient is not relieved
32754129|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
33395669|NCT05200858|Active Comparator|Active Group (AG)|Active group (AG). The AG (n=20) will be undergoing TENS therapy with an active device during 4 weeks. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis.
33071268|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
33071269|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
33071270|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
33071271|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
33238907|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
33071272|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
33071273|NCT02916628|No Intervention|Group 3|self-help smoking cessation
33071274|NCT02916628|No Intervention|Group 4|Non-smokers
32754130|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
32754131|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.~Other Names:~Topical Wound Oxygen Therapy~TWO2"
32754132|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
32754133|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
33238908|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
33238909|NCT05711667|Experimental|ARM I (Letermovir prophylaxis)|Patients receive letermovir PO or IV over 60 minutes QD starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
33238910|NCT05711667|Active Comparator|ARM II (No prophylaxis)|Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
33238911|NCT04384692|Experimental|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
33395670|NCT05200858|Placebo Comparator|Placebo Group (PG)|Placebo Group (PG) The PG (n=20) will be undergoing TENS therapy with a sham device as described in the AG. The sham device is identical to the active device in all respects except that it stimulates for 6 minutes during each therapy session instead of 60 minutes, and is therefore 10% of the dose.
33395671|NCT04564898|Experimental|trifluridine/tipiracil plus capecitabine and bevacizumab|
33395672|NCT05178238||Patients with high viral load of SARS-CoV-2 in feces|
33395673|NCT05178238||Patients with low viral load of SARS-CoV-2 in feces|
33238912|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
33071275|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
33071276|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
33071277|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
33071278|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
33071279|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
33071280|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
33071281|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
33395674|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.~Subjects will be classified as trained, physical active and untrained according to their VO2max.~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
33395675|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
33395676|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
33395677|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
33395678|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
33395679|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
33395680|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
32754134|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
32754135|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
32754136|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
33395681|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
33071282|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
33071283|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
32909648|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
33395682|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
33395683|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
32909649|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
32909650|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
32909651|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
33395684|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
32909652|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
33238913|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
33238914|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
33238915|NCT05501769|Experimental|ARV-471 and Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
33238916|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
33238917|NCT04063137|Placebo Comparator|White bread|
33238918|NCT04609878|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
32909653|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
32909654|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
33238919|NCT04609878|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
32909655|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
33238920|NCT04609878|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
33238921|NCT04609878|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
33238922|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
33238923|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
33238924|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
33238925|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
32909656|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
33238926|NCT04609566|Experimental|Combination Therapy|brentuximab vedotin + pembrolizumab
32909657|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
33238927|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
33238928|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
33238929|NCT04655157|Experimental|Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab|Patients will be treated with 300mg encorafenib and 3mg/kg nivolumab and 1 mg/kg ipilimumab (triple therapy).
33238930|NCT04655157|Experimental|Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumab|Patients will be treated with 450mg encorafenib, 45mg binimetinib, 3mg/kg nivolumab and 1mg/kg ipilimumab (quadruple therapy).
33238931|NCT00583596|Experimental|implant to close PDA|
33238932|NCT05700279|Active Comparator|Stellate Ganglion Block Treatment|Participants randomly assigned to the Stellate Ganglion Block (SGB) condition will receive 2 SGB treatments separated by 2 weeks.
33238933|NCT05700279|Active Comparator|Cognitive Processing Therapy|Participants randomly assigned to the Cognitive Processing Therapy (CPT) condition will receive 1-week massed CPT treatment consisting of 10 CPT sessions given within a single 5-day period via telehealth.
33238934|NCT05700279|No Intervention|Usual Care|Participants randomly assigned to the Usual Care condition will not receive any active intervention.
33238935|NCT04079010|Placebo Comparator|Control|Participants will adhere to resistance training protocol.
33238936|NCT04079010|Active Comparator|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
33238937|NCT04079010|Active Comparator|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
33238938|NCT04555161|Experimental|Aria CV Pulmonary Hypertension System|Treatment with the Aria CV Pulmonary Hypertension System
33238939|NCT05541029|Experimental|Live music > Recorded music > Usual Care|Order of conditions for the day
33238940|NCT05541029|Experimental|Recorded music > Usual care > Live music|Order of conditions for the day
33238941|NCT05541029|Experimental|Usual Care > Live music > Recorded music|Order of conditions for the day
33238942|NCT05541029|Experimental|Live music > Usual Care > Recorded music|Order of conditions for the day
33238943|NCT05541029|Experimental|Recorded music > Live music > Usual care|Order of conditions for the day
33238944|NCT05541029|Experimental|Usual care > Recorded music > Live music|Order of conditions for the day
33238945|NCT02581878|Experimental|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
33238946|NCT02581878|Experimental|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
33238947|NCT02581878|Experimental|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
33238948|NCT02581878|Experimental|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
33238949|NCT02581878|Experimental|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
33238950|NCT05700045|Experimental|dexmedetomidine + ropivacaine|each side dexmedetomidine 0.5ug/kg+0.25% ropivacaine 20ml TAP block
33238951|NCT05700045|No Intervention|ropivacaine|each side 0.25% ropivacaine 20ml TAP block
33238952|NCT04109651|Experimental|Nursing İntervention|Intervention: Other: Nursing intervention
33238953|NCT04109651|Other|No Intervention: Control Group|Receive routine nursing care
33238954|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
33238955|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
33238956|NCT05609825|Experimental|LY3875383 (Part A)|Single-ascending doses of LY3875383 administered subcutaneously (SC).
33238957|NCT05609825|Experimental|LY3875383 (Part B)|Single doses of LY3875383 administered SC.
33238958|NCT05609825|Experimental|LY3875383 (Part C)|Single doses of LY3875383 administered SC.
33238959|NCT05609825|Experimental|LY3875383 (Part D)|Single doses of LY3875383 administered SC.
33238960|NCT05609825|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
33238961|NCT05609825|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
33238962|NCT05609825|Placebo Comparator|Placebo (Part C)|Placebo administered SC.
33238963|NCT05609825|Placebo Comparator|Placebo (Part D)|Placebo administered SC.
33238964|NCT05393232|Experimental|Dietitian-Assisted DASH groceries|Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
33238965|NCT05393232|Active Comparator|Self-directed shopping (referent assignment)|Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
33238966|NCT04079088|Placebo Comparator|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
33238967|NCT04079088|Experimental|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
32909658|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
32909659|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
32909660|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
32909661|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
32909662|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
32909663|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
32909664|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
32909665|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
32909666|NCT02466087|No Intervention|Control|No intervention
33071284|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
33071285|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
33071286|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
33071287|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
32909667|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
32909668|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
33238968|NCT04079088|Experimental|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
33238969|NCT04079088|Experimental|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
33238970|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
33238971|NCT04078074|Experimental|Maxillary OSS|
33238972|NCT04078074|Experimental|Mandibular OSS|
33238973|NCT04078074|Experimental|Modified farrar splint|
33238974|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
33238975|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
33238976|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
33238977|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
33238978|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
33238979|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
33238980|NCT05571761|Experimental|Study group|Refers to the experimental group that will receive the cognitive stimulation program intervention.
33238981|NCT05571761|Other|Waiting list control group|Will be the control group that remains without intervention until the study group completes the cognitive stimulation program and the subsequent neuropsychological assessment has been done. Once the intervention is completed with the study group, the same program will be applied to the control group.
33238982|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~Rituximab /Mabthera®, 375 mg/m2 en IV~Bendamustine, 90 mg/m2 en IVD~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
33238983|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
33238984|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
33238985|NCT00734162|Placebo Comparator|Placebo|
33238986|NCT04342572|Experimental|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
33238987|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
33238988|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
33238989|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
33238990|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
33238991|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
33238992|NCT00790751|Placebo Comparator|placebo|
33238993|NCT00790751|Experimental|avanafil 50 mg|
33238994|NCT00790751|Experimental|avanafil 100 mg|
33238995|NCT00790751|Experimental|avanafil 200 mg|
33238996|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
33238997|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
33238998|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
33238999|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
33239000|NCT00740649|Experimental|1|HSD-016
33239001|NCT00740649|Other|2|placebo
33239002|NCT04107155|Experimental|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
32909669|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
32909670|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
33071288|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
33071289|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
33071290|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
33071291|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
33239003|NCT04107155|Placebo Comparator|Placebo|Placebo and handout with suggestions for healthy eating and overall health
33239004|NCT05262387|Experimental|Lyumjev|Lyumjev administered subcutaneously (SC) during a meal and following different approaches for basal reduction prior to exercise
33239005|NCT05262387|Active Comparator|Humalog|Humalog administered SC during a meal and following different approaches for basal reduction prior to exercise
33071292|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
33071293|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
33071294|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
32909672|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
33071295|NCT02916121|Placebo Comparator|placebo|placebo
32909673|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
32909674|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
32909675|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
32909676|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
32909677|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
32909678|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
32909679|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
32909680|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
33239006|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
33239007|NCT02582424|Placebo Comparator|placebo|olive oil
32909681|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
33239008|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
33239009|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
33239010|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
32909682|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
32909683|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
33239011|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
33239012|NCT05248893|Experimental|AGN-151586|Participants will receive 5 intramuscular injections in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may receive up to 2 additional cycles of open-label treatments.
33239013|NCT04339140|Experimental|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
33239014|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
33239015|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
33239016|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
32909684|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
33239017|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
33239018|NCT04487106|Experimental|Treatment (azacitidine, venetoclax, trametinib)|"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
32909685|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
33239019|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
32905357|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
32905358|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
33239020|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
33239021|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
33239022|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
33239023|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
32909686|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
32909687|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
33395685|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
33239024|NCT02568033|Experimental|A|"Chemotherapy:~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions~Schedule is:~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
33239025|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
33239026|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
32909688|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
33395686|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
33395687|NCT03190408||Shock|
32909689|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
33395688|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
33395689|NCT04483570||Secondary Tethered Cord Syndrome|Children with signs of progressive deterioration in urological or neuroorthopedic system, and suspected Secondary Tethered Cord Syndrome (STCS) following primary untethering surgery.
32909690|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
32909691|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
33239027|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
33239028|NCT05236413|Experimental|High Intensity Interval Exercise|Enrolled patients will perform supervised exercise on 3 nonconsecutive days of the week for 4 weeks.
33239029|NCT05236413|Experimental|Dietary Approaches to Stop Hypertension (DASH) Diet|Enrolled patients will have all of their food prepared for them by a registered dietician for the duration of the study period. The diet will consist of a high fiber content DASH diet.
33239030|NCT05236413|Experimental|Exercise + DASH Diet|Enrolled subjects will undergo both the exercise training visits and be provided with the DASH diet.
33239031|NCT04484220|Experimental|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients who have chronic kidney disease requiring dialysis.
33239032|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
33239033|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
33239034|NCT05224401|Experimental|PAC treatment|
33239035|NCT05224401|Active Comparator|Standard treatment|
33239036|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:~A - B B - A"
33239037|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
33239038|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
33239039|NCT04319718|Active Comparator|High Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)."
33239040|NCT04319718|Active Comparator|Low Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)."
33239041|NCT00918086|Experimental|Vitamin D pill|
33239042|NCT00918086|Placebo Comparator|Placebo|
33239043|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
33239044|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
33239045|NCT02598050||older surgical patients|Patients 65 years of age and older having lower extremity joint replacement surgery.
33239046|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
33239047|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
33239048|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
33239049|NCT04317066|Experimental|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
33239050|NCT04311996|Experimental|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
33239051|NCT04311996|Experimental|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
33239052|NCT04311996|Experimental|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
33239053|NCT04311996|Experimental|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
33239054|NCT04375800|Experimental|Doravirine + 2 NRTIs|Participants receive DOR (3.2 mg to 100 mg based on weight) in combination with 2 NRTIs (based on local label) for 96 weeks.
33239055|NCT04372602|Experimental|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days.
33239056|NCT04372602|Sham Comparator|Placebo|-Placebo 25 mg twice daily for up to 10 days.
33239057|NCT04118088|Experimental|Darvadstrocel|Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.
33239058|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
33071296|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
33239059|NCT04077996|Active Comparator|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
33239060|NCT04077996|Experimental|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
33239061|NCT04366908|Active Comparator|Control - best available therapy|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
32909692|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
32909693|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
32909694|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
33395690|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
32909695|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
32909696|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
32909697|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
32909698|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
33395691|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
33071297|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
32909699|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
32909700|NCT01123928|No Intervention|Non-counseling|
32909701|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
32909702|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
32909703|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
32909704|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
33071298|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
33071299|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
33395692|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
33395693|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
32909705|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
33071300|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
33071301|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
33239062|NCT04366908|Experimental|Treatment|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules~Days 3, 7, 14, 21, 28: 1 capsule"
33239063|NCT04102020|Experimental|Part 1: Dose Confirmation|Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
33239064|NCT04102020|Experimental|Part 3 (Dose Finding): Dose Escalation|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
32909706|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
32909707|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
33071302|NCT04688632|Active Comparator|Group 1a|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin <Dose A>
33071303|NCT04688632|Active Comparator|Group 1b|Day 1: Single dose of Moxifloxacin <Dose A>; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin Placebo
33239065|NCT04102020|Experimental|Part 3 (Dose Finding): Safety Expansion|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
33239066|NCT04102020|Experimental|Part 3 (Randomization): Venetoclax + CC-486|Participants will receive venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
32909708|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
33239067|NCT04102020|Experimental|Part 3 (Randomization): Placebo + CC-486|Participants will receive Placebo for venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
33071304|NCT04688632|Experimental|Group 2 - Treatment|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 7: Single daily dose of Ampreloxetine <Dose A>; Day 8 - Day 14: Single daily dose of Ampreloxetine <Dose B>; Day 15: Single dose of Moxifloxacin Placebo; Day 15: Single dose of Ampreloxetine Placebo;
33071305|NCT05786690||Group 1|17 patients with MIC prosthesis,
33071306|NCT05786690||Group 2|17 patients with non-MIC prosthesis,
33071307|NCT05786677|Experimental|Patients with fibromyalgia and depression (1)|Patients in this group will receive physiotherapy protocol and medications.
33071308|NCT05786677|Active Comparator|Patients with fibromyalgia and depression (2)|Patients in this group will receive medications only.
33071309|NCT05786677|Experimental|Patients with depression only (1)|Patients in this group will receive physiotherapy protocol and medications.
33071310|NCT05786677|Active Comparator|Patients with depression only (2)|Patients in this group will receive medications only.
33071311|NCT05786664||Observational (survey, biospecimen collection, record review)|Patients complete surveys, undergo collection of blood samples, and review of medical records on study.
33239068|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
33239069|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
33239070|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
33239071|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
33239072|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
33239073|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
33239074|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
33071312|NCT05786651|Experimental|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
33239075|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
33239076|NCT04366518|Experimental|Aim 2: Those with psychosis/hallucinations|Participants who have a psychosis spectrum diagnosis and frequent auditory hallucinations will be given Rivastigmine capsule versus placebo capsule.
33239077|NCT04366518|Placebo Comparator|Aim 1: Healthy Controls|Healthy controls will be given scopolamine patches versus placebo patch.
33239078|NCT04088240|Experimental|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
33239079|NCT04088240|Active Comparator|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
33071315|NCT05786625||Microwave ablation|Patients with a single or multiple soft tissue lung lesions that is medically inoperable or for which the patient has declined surgical resection.
33239080|NCT04088240|Placebo Comparator|Placebo|"4 g/d placebo control (light olive oil)"
33239081|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
33239082|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
33239083|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
33239084|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
33239085|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
33239086|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
33239087|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
33071316|NCT05786612|Active Comparator|Mepilex Border with Aquacel Extra Hydrofiber|Standard of care (filler, that functions as a primary dressing to manage exudate and the gap/space between the wound bed and the dressing, covered by a secondary dressing on top) defined in this study as Mepilex® Border with AQUACEL® Extra Hydrofiber Dressing
33071317|NCT05786612|Experimental|Biatain® Silicone|The investigational test product is Biatain® Silicone. Biatain® Silicone is intended to be used for moist wound healing and exudate management.
33071319|NCT05786586|Experimental|650 nm low-level red-light, plus single vision spectacle lenses|Children in the treatment group are expected to receive 6 minutes irradiation of 650 nm low-level red-light daily, divided into two times a day, each lasting for 3 minutes. Single vision spectacle lenses are allowed for myopic children.
33071320|NCT05786586|No Intervention|Control|Single vision spectacle lenses are allowed for myopic children. No intervention was given.
33071321|NCT05786573|Experimental|Part A: Obexelimab|Obexelimab will be administered as an SC injection for 24 weeks (Safety and Dose Confirmation Run-In Period). Participants may then continue to receive Obexelimab in the Open Label Extension (OLE) Period.
33239088|NCT05526417|Experimental|Arm I (prehabilitation physical therapy)|Patients perform personalized prehabilitation physical therapy exercises BID 5 days per week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery, attend telemedicine visits with a physical therapist once a week for 9 weeks, and receive educational materials. Patients undergo MRI and CT at week 9.
33239089|NCT05526417|Active Comparator|Arm II (educational materials)|Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery. Patients undergo MRI and CT at week 9.
33071322|NCT05786573|Experimental|Part B: Obexelimab or Placebo|Obexelimab or Placebo will be administered as an SC injection for 24 weeks (Double-Blinded Period). Participants may then continue to receive Obexelimab in the Open Label Extension (OLE) Period.
33071323|NCT05786573|Placebo Comparator|Placebo|Placebo administered as an SC injection.
32909709|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
32909710|NCT00363519|Placebo Comparator|P|
32909711|NCT00363519|Experimental|E|
32909712|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
32909713|NCT04743687|Experimental|Zanuburutinib|Oral Zanuburutinib 160mg twice a day
32909714|NCT04341285|Active Comparator|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
32909715|NCT04341285|Active Comparator|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
32909716|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
32909717|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
33239090|NCT04364178|Experimental|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
32909718|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
32909719|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
33239091|NCT05623839|Experimental|LY3305677|LY3305677 administered subcutaneously (SC)
32909720|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
33239092|NCT05623839|Placebo Comparator|Placebo|Placebo administered SC
32754137|NCT04984733|Experimental|Treatment|"Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV until progression.~Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression. Patients who progress on TMZ will start monotherapy with nivolumab.~Metronomic TMZ50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until progression. Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths until they progress~Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until 24 months. Patients will remain on combination therapy up to a maximum of 24mths."
32754138|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
32754139|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
32754140|NCT04908137|Experimental|2-Octyl Cyanoacrylate (Dermabond) Group|2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks topical application around post-circumcision site subcoronal area immediately after the circumcision devise is removed and circumcision procedure was done
32754141|NCT04908137|No Intervention|Control Group|will receive Vaseline cream application around the post-circumcision site immediately after circumcision
32754142|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
32754143|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
32754144|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
32754145|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
32754146|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
32754147|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
32754148|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
32754149|NCT04904705|Active Comparator|Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"It will be given a home program. Then The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach will be applied by video conferencing method in a total of 10 sessions, 2 sessions per week, through 5 weeks, and a total of 12 sessions with initial and final evaluations.~The Cognitive Orientation for Daily Activity Performance (CO-OP) approach is a person-oriented, performance-solving. and problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills."
32754150|NCT04904705|Active Comparator|Home Program|It will be given a home program only.
32754151|NCT02429401|Experimental|Culturally adapted brief intervention|
32754152|NCT02429401|Active Comparator|Non-adapted brief intervention|
32754153|NCT05076851|Placebo Comparator|placebo group|placebo+ADT
32754154|NCT05076851|Experimental|Proxalutamide|Proxalutamide +ADT
32754155|NCT04890509|Experimental|Standard of Care + Bemcentinib|Bemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.
32754156|NCT04890509|Active Comparator|Standard of Care|The SoC will be administered based on local guidelines in place at the time of treatment during the study.
32754157|NCT03185143|Experimental|Naltrexone and Acetaminophen Combination|
32754158|NCT03185143|Active Comparator|Sumatriptan 100 mg|
32754159|NCT03185143|Placebo Comparator|Placebo|
32754160|NCT05076773|Placebo Comparator|Control Group (D)|Patient will receive opioid only for management of their perioperative pain
32754161|NCT05076773|Active Comparator|Paravertebral block Group (A)|Will receive thoracic paravertebral block
32754162|NCT05076773|Active Comparator|Pectoral block Group (B)|Will receive pectoral 1 and 2 block
32754163|NCT05076773|Active Comparator|Erector spinae block Group (C)|Will receive erector spinae block
32754164|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
32909721|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
33239093|NCT04096170|Experimental|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
32909722|NCT02477319||Part A|"Cohort 1: Healthy Controls~Cohort 2: Partial CFTR function CF (class IV/V)~Cohort 3: Absent CFTR function CF (Class I/II)"
32909723|NCT02477319||Part B|CF patients who are homozygous for the F508del
33239094|NCT04096170|Placebo Comparator|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
32909724|NCT01124786|Experimental|CO-1.01|
32909725|NCT01124786|Active Comparator|gemcitabine|
32909726|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
32909727|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
33239095|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
33239096|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
33239097|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
33239098|NCT04091724||Delirium is determined by PAED score|
33239099|NCT04091724||No delirium is determined by PAED score|
33239100|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
33239101|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
33239102|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
33239103|NCT04295538|Experimental|Elezanumab|Participants will receive elezanumab dose A
33239104|NCT04295538|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
33239105|NCT04283994|Experimental|Survey-based Patient/Clinician Jumpstart|The Survey-based Patient/Clinician Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed by patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
33239106|NCT04283994|Active Comparator|EHR-based Clinician Jumpstart|The EHR-based Clinician Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
32909728|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
33239107|NCT04283994|No Intervention|Usual care|Patients in this arm receive usual care; neither subjects nor providers will receive either version of the Jumpstart Guide.
32909729|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
33239108|NCT05288556|Experimental|Stoma Site Accessory|Stoma site accessory with enteral tube replacement procedure.
33239109|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
33239110|NCT00732992|Experimental|CDD|
33239111|NCT00732992|Experimental|2/1|
33239112|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
33239113|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
33239114|NCT05338632|Experimental|Intravenous fentanyl year 1|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
33239115|NCT05338632|Experimental|Intravenous sufentanil year 1|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
33239116|NCT05338632|Experimental|Intravenous sufentanil year 2|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
33239117|NCT05338632|Experimental|Intravenous fentanyl year 2|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
32909730|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
33071326|NCT05786547|Experimental|Varenicline + Positively Smoke Free - Mobile|"Offer of varenicline per package dosing with dose escalation over week 1: 0.5 mg once daily on days 1 - 3, 0.5 mg twice daily on days 4 -7, followed by 1.0 mg twice daily on days 8 to 84.~Offer of Positively Smoke Free Mobile delivered by mobile phone including 42 days of content, tailored to individual quit date."
32909731|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
33071327|NCT05786547|Active Comparator|Standard Care|Brief advice to quit tobacco Offer of referral to the national tobacco quitline
33071328|NCT05786534|Experimental|Metabolic Syndrome patients|Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients
33071329|NCT05786521|Experimental|Semaglutide and lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
32744230|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
32909732|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
32909733|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
32909734|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
33071330|NCT05786521|Active Comparator|Lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
32909735|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
32909736|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
32909737|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
33071331|NCT05786508|Experimental|Partners4Pain program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
32909738|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
32909739|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
32909740|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
32909741|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
32909742|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
32909743|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
32909744|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
32909745|NCT05308160|Active Comparator|Dapagliflozin|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
32909746|NCT05308160|Placebo Comparator|Non-used drug|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
32909747|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
33071332|NCT05786508|Active Comparator|Key to Wellbeing program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
33071333|NCT05786495|Experimental|Short treatment|Antibiotic treatment will be stopped at the time of allocation to the intervention group
32909748|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
32909749|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
33239118|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
33239119|NCT05217927|Experimental|Rimegepant 75mg daily dosing|
33239120|NCT05217927|Experimental|Rimegepant 75mg every other day dosing|
33239121|NCT05217927|Placebo Comparator|Placebo comparator dosing|
32909750|NCT05307848||Female patients with bipolar disorder without medication|
32909751|NCT05307848||Female patients with bipolar disorder after stable prescription for ≥6 months|
32909752|NCT05307848||Age and BMI-matched healthy controls|
32909753|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
32909754|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
33239122|NCT04078932|Experimental|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
32909755|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
32909756|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
32909757|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
32909758|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
33071334|NCT05786495|Active Comparator|Prolonged treatment|Antibiotic treatment will be continued until the resolution of neutropenia (ANC > 0.5x109/L)
33239123|NCT04078932|No Intervention|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
33239124|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
33239125|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
33239126|NCT04082754|Experimental|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
33239127|NCT04082754|Experimental|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239128|NCT04082754|Experimental|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239129|NCT04082754|Experimental|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239130|NCT04082754|Experimental|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239131|NCT04082754|Experimental|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239132|NCT04082754|Experimental|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239133|NCT04082754|Experimental|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
33239134|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
33239135|NCT04082754|Placebo Comparator|Placebo|0.9% sodium chloride solution administered intravenously
33395694|NCT04561232|Other|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
32909759|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
33395695|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
33395696|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
33395697|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
33395698|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
33395699|NCT04701164|Experimental|ANX005 Treatment Group - Dose 1|Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
33395700|NCT04701164|Experimental|ANX005 Treatment Group - Dose 2|Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
33239136|NCT04082754|Placebo Comparator|Placebo (2)|0.9% sodium chloride solution administered subcutaneously
33239137|NCT04082754|Experimental|CSL311 Cohort C1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously (SC)
33239138|NCT04082754|Experimental|CSL311 Cohort C2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
33239139|NCT04082754|Experimental|CSL311 Cohort C3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
33239140|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
33239141|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
33239142|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
33239143|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
33239144|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
33395701|NCT04701164|Placebo Comparator|Placebo Group|Participants will receive a single IV infusion of placebo on Day 1.
33239145|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
32909760|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
32909761|NCT05307614|Experimental|Moksi® 400mg Tablet of Abbott|Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition
32909762|NCT05307614|Active Comparator|Avelox® 400mg Tablet of Bayer|Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition.
33239146|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
33239147|NCT05207865|Experimental|Rimegepant|rimegepant 75 mg ODT daily
32909763|NCT05307458||Buprenorphine Microdosing|Participants transitioning to buprenorphine from methadone using a microdosing protocol.
33239148|NCT05580003|Experimental|PF-07817883 Dose 1 in PART-1|
32909764|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
32909765|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
33239149|NCT05580003|Experimental|PF-07817883 Dose 2 in PART-1|
33071338|NCT05786469|Experimental|IMP|Patiromer is an organic, non-absorbed, sodium-free, potassium-binding polymer that exchanges potassium for calcium in the gastrointestinal tract.
33239150|NCT05580003|Experimental|PF-07817883 Dose 3 in PART-1|
33239151|NCT05580003|Experimental|PF-07817883 Dose 4 in PART-1|
33239152|NCT05580003|Experimental|PF-07817883 Dose 5 in PART-1|Optional dose levels
33239153|NCT05580003|Experimental|PF-07817883 Dose 6 in PART-1|Optional dose levels
33239154|NCT05580003|Placebo Comparator|Placebo in PART-1|A single dose of placebo
33239155|NCT05580003|Experimental|PF-07817883 DR1 in PART-2|DR=Dosing regimen; twice a day
33239156|NCT05580003|Experimental|PF-07817883 DR2 in PART-2|
33239157|NCT05580003|Experimental|PF-07817883 DR3 in PART-2|Optional dosing regimen
33239158|NCT05580003|Experimental|PF-07817883 DR4 in PART-2|Optional dosing regimen
33239159|NCT05580003|Experimental|PF-07817883 in Japanese in PART-2|Optional dosing regimen to be studied in Japanese population
33239160|NCT05580003|Experimental|PF-07817883 in Chinese in PART-2|Optional dosing regimen to be studied in Chinese population
33239161|NCT05580003|Placebo Comparator|Placebo in PART-2|
33239162|NCT05580003|Experimental|PF-07817883 Suspension Fasted in PART-3|PART-3 is optional
33239163|NCT05580003|Experimental|PF-07817883 FORM-1 Fasted in PART-3|First solid oral formulation (FORM1)
33239164|NCT05580003|Experimental|PF-07817883 FORM-2 Fasted in PART-3|Second solid oral formulations (FORM-2) is optional
33239165|NCT05580003|Experimental|PF-07817883 FORM-1 Fed in PART-3|
33239166|NCT05580003|Experimental|PF-07817883 FORM-2 Fed in PART-3|
33239167|NCT05580003|Experimental|PF-07817883 in PART-4|PART-4 is optional
33239168|NCT05580003|Experimental|Midazolam 5 mg in PART-5|Single dose of 5 mg alone
33071339|NCT05786469|Placebo Comparator|Placebo|Active study treatment and placebo will be provided by Vifor Pharma and will be indistinguishable from one another in terms of labelling and instructions
33239169|NCT05580003|Experimental|Midazolam 5 mg with PF-07817883 in PART-5|Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883
33239170|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
33239171|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
33239172|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
33071340|NCT05786456|Experimental|Supportive Care (DBD)|Patients receive DBD intervention consisting of group and web-based self-study sessions and check-in calls on study. Patients also watch videos and receive handouts to reinforce the group sessions.
32909766|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
33239173|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
33239174|NCT02582112|Placebo Comparator|Control group|Control group
33239175|NCT05742321||Patients with FECD|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of data and a blood sample
33071341|NCT05786443|Experimental|Empagliflozin|Participants with end-stage kidney disease (ESRD) initiating hemodialysis will receive Empagliflozin 10 mg daily for 12 weeks.
33395702|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
33395703|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
33239176|NCT04277442|Experimental|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32909767|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
32909768|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
33239177|NCT05742243|Active Comparator|Abatacept and nasal insulin|Abatacept (CTLA4-Ig; 50 mg for participant weight <25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight >50 kg) will be injected subcutaneously once per week and nasal insulin (Humulin R®, 100 Units/mL) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
33239178|NCT05742243|Placebo Comparator|Abatacept and nasal placebo|Abatacept (CTLA4-Ig; 50 mg for participant weight <25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight >50 kg) will be injected subcutaneously once per week and nasal placebo (0.9% sodium chloride) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
33071342|NCT05786443|Placebo Comparator|Placebo|Participants with ESRD initiating hemodialysis will receive Empagliflozin-matching placebo daily for 12 weeks.
33071343|NCT05786430|Experimental|experimental arm|
32909769|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
32909770|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
32909771|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
32909772|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
32909773|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
32909774|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
32909775|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
32909776|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
32909777|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
32909778|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
32909779|NCT05307380||patients with pain|patients with acute postoperative or post-traumatic pain or chronic pain
32909780|NCT02551887|No Intervention|Usual Care|Usual Care Only
33071344|NCT05786417|Experimental|Beta-Blockers (BB) Therapy|Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).
32909781|NCT02551887|Active Comparator|Automated Reminder|Reminder
32909782|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
32909783|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
32909784|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
32909785|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
33071345|NCT05786417|Experimental|Calcium Channel Blockers (CCB) Therapy|Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).
33071346|NCT05786404|Experimental|Experimental: PRIM-DJ2727 - FROZEN|
33071347|NCT05786404|Experimental|Experimental: PRIM-DJ2727 - CAPSULES|
33071348|NCT05786391|Experimental|Flat position with no Insufflation|
33071349|NCT05786391|Experimental|Trendelenburg position and Insufflation|insufflation to 15 mm Hg
33071350|NCT05786391|Experimental|Flat position and Insufflation|
33071351|NCT05786391|Experimental|Trendelenburg position with no Insufflation|
33071352|NCT05786378|Experimental|platlet rich plasma|
33071353|NCT05786365||The group given 0.5 mg/kg ketamine|In this group we will give 0.5 mg/kg ketamine and we observe for disphoric reaction
33071354|NCT05786365||The group given 1 mg/kg ketamine|In this group we will give 1 mg/kg ketamine and we observe for disphoric reaction
33239179|NCT04077918|Active Comparator|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
33239180|NCT04077918|Active Comparator|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
32909786|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
32909787|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
32909788|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
32909789|NCT05307224|Experimental|intervention group|In the experimental group, patients will receive both routine care and mandala painting. Experimental group will paint mandala for 30 minutes/day in the evening for six consecutive days.
32909790|NCT05307224|No Intervention|control group|The control group will receive the usual care.
32909791|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
32909792|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
32909793|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
32909794|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
32909795|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
32909796|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
32909797|NCT05307146|Experimental|micro/macro electrode|
33239181|NCT04076748|Experimental|Experimental|"* Intra Nasal Sufentanil (50 µg.ml-1): Load dose : 0.3 µg. kg-1, Followed by bolus : 5 µg / 10 minutes with 2 bolus maximum.~As soon as the venous route and ten minutes after the last administration of sufentanil:~Morphine IV: 3 mg / 5 minutes.~Objective: numeric rating scale (NRS) ≤ 3/10."
33239182|NCT04076748|Active Comparator|Control|"* EMONO : Given by respiratory administration via a face mask at a rate suitable for patient ventilation (generally at least 9l.min-1), Until a venous route is obtained and without exceeding 30 minutes.~* Morphine IV: Load dose: 0.1mg. kg-1 as soon as possible; Then bolus: 3mg / 5 minutes.~* Objective: NRS ≤ 3/10"
32909798|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
32744654|NCT04868253|Experimental|EMB-001|EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
33239183|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
32744655|NCT04486157|Experimental|IN-A012|Intravenous administration of IN-A012
32744656|NCT04486157|Active Comparator|Akynzeo capsules|Single oral administration of Akynzeo capsules
32744657|NCT02452073||CRE group|patients with chronic radiation enteritis
32744658|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
32744659|NCT02452073||control group|age-matched healthy volunteers
33239184|NCT00698997|Other|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
33395704|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
32744660|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
32744661|NCT04862637|Experimental|pull through group|the patients receiving the pull though method during the tongue cancer surgery
32744662|NCT04862637|Placebo Comparator|mandibular-lip split group|the patients receiving the traditional mandibular lip split method during the tongue cancer surgery
32744663|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
32744664|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
32744665|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
32744666|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
32744667|NCT03224117|Placebo Comparator|Placebo|SQ injection
32744668|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
32744669|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
32744670|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
32744671|NCT04862793|Experimental|Feedback|Feedback system through CoPS and CoRS
32744672|NCT04862793|No Intervention|Standard procedure|Performing the standard procedure in accordance with the departments usual conduct.
32744673|NCT04862559|Experimental|NovaCross|Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)
32744674|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
32744675|NCT04867629|Experimental|Rapeseed oil|Participants asked to consume 20mL of rapeseed oil raw every day for 12 weeks
32744676|NCT04867629|Active Comparator|Sunflower oil|Participants asked to consume 20mL of sunflower oil raw every day for 12 weeks
32744677|NCT04867629|No Intervention|Habitual diet|Participants asked to maintain their habitual diet for 12 weeks
32744678|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
32744679|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
32744680|NCT04862403|Experimental|Intervention group I|In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
32744681|NCT04862403|Experimental|Intervention group II|In intervention group II - clamped at a distance of 3 cm - umbilical cord was measured 3 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 3 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group II.
32744682|NCT04862403|No Intervention|Control group|Control group - clamped without measuring - no intervention was made in defining the distance at which the umbilical cord of the newborn would be clamped. Another healthcare workers measured the distance at which the umbilical cord had been clamped. The same researcher used a standard measuring tape to measure the distance between the umbilical cord to the clamping point.
32744683|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~Normal saline 1ml intravenous (IV) push x 1 dose"
32744684|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:~Normal saline 0.3 mL IN x 1 dose~Morphine 0.1 mg/kg IV push x 1 dose"
32744685|NCT04862091|Experimental|Abiraterone Acetate Tablets (I)|
32744686|NCT04862091|Active Comparator|ZYTIGA®.|
32744687|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
32744688|NCT04873635||Patients who had excised pathological jaw lesions and will receive implant rehabilitation|
32744689|NCT04485143||experimental group|Non-invasive Wearable Device
32744690|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
32744691|NCT03119441|Active Comparator|Dental floss|Dental floss
32744692|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
32744693|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
33239185|NCT04075266|Experimental|Cohort 1|Participants with a body weight from >/= 25 kg to < 40 kg (with at least 2 participants with a body weight from >/= 25 kg to </= 35 kg) will receive 300 milligram (mg) ocrelizumab
33239186|NCT04075266|Experimental|Cohort 2|Participants with a body weight >/= 40 kg (with at least 2 participants with a body weight >/= 40 kg but </= 50 kg) will receive 600 mg ocrelizumab
33239187|NCT04075266|Experimental|Cohort 3 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from >/= 25 kg to < 40 kg may be enrolled and receive another dose level of ocrelizumab
33239188|NCT04075266|Experimental|Cohort 4 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight >/= 40 kg may be enrolled and receive another dose level of ocrelizumab
33239189|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
33239190|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
33239191|NCT04272606|Active Comparator|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
33239192|NCT04272606|Placebo Comparator|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
33239193|NCT04078308|Experimental|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
33239194|NCT04078308|Placebo Comparator|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
33239195|NCT05137782|Experimental|Arm 1|Patients and care partners receive specialty primary care and participate in pre- and post- functional MRI scans to measure the effects of the specialty palliative care intervention.
33239196|NCT05126862|Experimental|MindTrails pilot|This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
33239197|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
33239198|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
33239199|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
33239200|NCT02581956|Placebo Comparator|No Intervention|No exercise required
33239201|NCT04262466|Experimental|IMC-F106C - Arm A - Phase 1 and Phase 2|Phase 1 dose escalation and Phase 2 monotherapy dose expansion
33239202|NCT04262466|Experimental|IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1|Dose Escalation
33239203|NCT04262466|Experimental|IMC-F106C and chemotherapy - Arm C - Phase 1|Dose Escalation
33239204|NCT04262466|Experimental|IMC-F106C and another ImmTAC - Arm D - Phase 1|Dose Escalation
33239205|NCT04255602|Experimental|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
33239206|NCT04255602|Active Comparator|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
33239207|NCT05275920|Experimental|Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
33239208|NCT05275920|Experimental|In-Basket Message group|Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
33239209|NCT05275920|No Intervention|Control group|Patients who will receive the current standard practice of care (no BPA or in-basket message)
33239210|NCT04250688|Experimental|Esko Bionics Suit + Functional Electrical Stimulation|
33239211|NCT04250688|No Intervention|Control|
33239212|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
33239213|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
33239214|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
33239215|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
33239216|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
33239217|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
33239218|NCT04077684|Placebo Comparator|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
33239219|NCT04077684|Active Comparator|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
33239220|NCT04077684|Active Comparator|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
33239221|NCT04077684|Active Comparator|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
32909799|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met.~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
32909800|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met."
32909801|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.~Ramucirumab and gefitinib administered during period 1.~Ramucirumab and osimertinib administered during period 2."
32744231|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
32744694|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
33239222|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
33239223|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
33239224|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
33239225|NCT05674656|Experimental|Dolutegravir(DTG)/Rilpivirine (RPV)|
33239226|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
33239227|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
33239228|NCT03838536|Experimental|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
33239229|NCT03838536|Placebo Comparator|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
33239230|NCT04076124|Experimental|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
33239231|NCT04076124|Experimental|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
33239232|NCT04076124|Sham Comparator|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
33239233|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
33239234|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
33239235|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
32744695|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
32744696|NCT03045471||R-EPOCH|
32744697|NCT03045471||R-CHOP|
32744698|NCT04873713|No Intervention|No Intervention: internal hip rotation|internal hip rotation pre measurement with knee and hip flexion at 90º, internal hip rotation will be performed
33395705|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
33395706|NCT04545554|Experimental|Romosozumab|
33395707|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
33395708|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
33395709|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
33395710|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
33395711|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
33395712|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
33395713|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
33395714|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
33395715|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
33395716|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
33395717|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
33395718|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
33395719|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
33395720|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
33395721|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
33395722|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
33395723|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
33395724|NCT04050332|Experimental|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
33395725|NCT04050332|No Intervention|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
33395726|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
33395727|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
33395728|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
33395729|NCT02443246|Experimental|Vitamin D deficiency|Group 1
33395730|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
33395731|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
33395732|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
33395733|NCT03188302|Other|Specimen collection|Collection of stool samples
33395734|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
33395735|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
33395736|NCT02443948||adjuvant/follow up setting|
33395737|NCT02443948||neo-adjuvant setting|
33395738|NCT02443948||advanced disease|
33395739|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
33395740|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
33395741|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
33395742|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
33239236|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
33239237|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
33395743|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
33239238|NCT04075890|Active Comparator|Healthy subjects|
33395744|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
33395745|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
33239239|NCT04075890|Active Comparator|OCD subjects|
33239240|NCT04087850|Experimental|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
33239241|NCT04087850|No Intervention|Typical Practice Control|
33239242|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
33239243|NCT03825510|Experimental|Treatment Arm|
32744699|NCT04873713|Experimental|Experimental: internal hip rotation|internal hip rotation post experimental application measurement with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
32744700|NCT04873713|Placebo Comparator|Placebo Comparator: internal hip rotation|internal hip rotation post placebo application measurement with Placebo tape Application with knee and hip flexion at 90o, internal hip rotation will be performed
32744701|NCT03045315|Experimental|women included in a IVF program|
32744702|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
32744703|NCT03223571||Controls|Healthy people with no history of neurological pathologies
32744704|NCT04862169|Placebo Comparator|Control group|"In the control group, they will only receive electronic version of the modules. They are able to access the module on their own devices.~The observation arm will receive the link of eLOK at the end of data collection and follow-ups (week 14). With this link, then they are able to access modules, videos and case studies provide in SPARK."
32744705|NCT04862169|Experimental|Intervention group|The intervention on this RCT is an educational training program: SPARK (Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos) and some synchronous meetings.
32744706|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
33395746|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
32744707|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
33239244|NCT04032990|Experimental|Transcutaneous spinal stimulation - Acute and Training|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while upper extremity function is assessed at 3 time points (acute) and/or in combination with activity-based upper extremity training (40 sessions, 1.5 hours/day, 5 days/week); stimulation will be applied intermittently for no more than 10 minutes at a time. Upper extremity training is based on usual care activities to challenge use of the hands and arms, e.g. reaching, grasping, manipulating objects.
33239245|NCT00921219|Experimental|Ivermectin|ivermectin
33239246|NCT04076514||patients with node negative papillary thyroid carcinoma|
33239247|NCT04014348||Female|Diagnostic
33239248|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
33072456|NCT05063552|Active Comparator|Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 of each cycle, and cisplatin IV or carboplatin IV on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial.
33395747|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
33239249|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
32744708|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
33072457|NCT05063552|Experimental|Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 of each cycle, and cisplatin IV or carboplatin IV on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial.
33072458|NCT05063552|Experimental|Phase II, Arm C (Bevacizumab, Atezolizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial.
33395748|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
32744709|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
32744710|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
33395749|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
33395750|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
33239250|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
32744711|NCT04861857|Experimental|Parmigiano Reggiano|participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
33395751|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
33395752|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
32744712|NCT04861857|Active Comparator|Whey Protein|participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
32744713|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
33395753|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
33239251|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
33239252|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of cobomarsen
33239253|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
33239254|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
33239255|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
33395754|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
33395755|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
33395756|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
33239256|NCT02580552|Experimental|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
33239257|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
33239258|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
33239259|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
33239260|NCT05179863||Patient population|Children, adolescents, and adults with a high suspicion, or a confirmed diagnosis of a rare disease who are treated or living in Switzerland.
33239261|NCT03793140|Experimental|CPI-613|CPI-613 IV induction (Days 1-5 for first 2 Cycles [14-day cycles]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter [21-day cycles].
33395757|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
33395758|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
33395759|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
32909802|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
32909803|NCT05306990|Active Comparator|Atorvastatin|Atorvastatin tablets Dosage and frequency: 40mg orally once daily
32744714|NCT04861701|Experimental|Stretching exercise group (SE)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
32909804|NCT05306990|Active Comparator|Rosuvastatin|Rosuvastatin tablets Dosage and frequency: 20mg orally once daily
32909805|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
33395760|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
33395761|NCT03701204|No Intervention|Control|Treatment as usual
33395762|NCT03188224|Experimental|Intervention|MyTransition app
33395763|NCT03188224|No Intervention|Control|Usual care
33395764|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
33395765|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
33395766|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
33395767|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
33395768|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
33395769|NCT03189940|Active Comparator|App user group|
32754165|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
32754166|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
32744461|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
32754167|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
32754168|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
32754169|NCT04777799|Experimental|URGOnight|Use of the URGOnight neurofeedback training headband and its associated application
32754170|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
32754171|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
33239262|NCT05742165|Experimental|Time-Restricted Eating - 6 Hours (TRE6)|Participants will be instructed to consume all daily food and beverages during their allotted 6-hour time period.
33239263|NCT05742165|Experimental|Time-Restricted Eating - 10 Hours (TRE10)|Participants will be instructed to consume all daily food and beverages during their allotted 10-hour time period.
33395770|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
33395771|NCT04681742|Experimental|CO-OP Group|10, 45-60 minute Cognitive Orientation to daily Occupational Performance intervention sessions
33395772|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
33239264|NCT04077606|Active Comparator|ceramo-metallic crown|ceramo-metallic crown preparation
32744715|NCT04861701|No Intervention|Control group (CON)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
32744716|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
32744717|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
32744718|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
32744719|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
32744720|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
32744721|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
32744722|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
32744723|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
32744724|NCT03045159|Experimental|Strong Families|parenting program
32744725|NCT03045159|Active Comparator|Strong Parents|self-care program
32744726|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
32744727|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
32744728|NCT03047499||Scar Length|
32744729|NCT03047499||Vancouver scar scale|
32744730|NCT03047499||Scar width|
32744731|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
33239265|NCT04077606|Active Comparator|monolithic zirconia crown|monolithic zirconia crown preparation
32744732|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
32744733|NCT04867941|Experimental|Part1: Mild hepatic insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
32909806|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
33395773|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
33395774|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
33395775|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
32744734|NCT04867941|Experimental|Part 1: Moderate hepatic insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
32744735|NCT04867941|Experimental|Part 1: Normal hepatic function|Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.
33395776|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
32909807|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
32909808|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
32909809|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
32909810|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
32909811|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
32909812|NCT04341207|Experimental|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test & Covid19 symptoms
32744736|NCT04867941|Experimental|Part 2: Severe hepatic insufficiency|Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
33239266|NCT04077450|No Intervention|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
33395777|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
33395778|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
32909813|NCT04341207|No Intervention|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test & Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
32909814|NCT04341207|No Intervention|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test & no Covid19 symptoms
32909815|NCT04341207|Experimental|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease & no Covid19 symptoms & Pretreated or with frail conditions following the HCSP definition
32909816|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
32909817|NCT01166984|Experimental|AB103 7.5 µg/kg|AB103 7.5 µg/kg administered as a single IV infusion
32909818|NCT01166984|Experimental|AB103 37.5 µg/kg|AB103 37.5 µg/kg administered as a single IV infusion
32909819|NCT01166984|Experimental|AB103 150 µg/kg|AB103 150 µg/kg administered as a single IV infusion
32909820|NCT01166984|Experimental|AB103 450 µg/kg|AB103 450 µg/kg administered as a single IV infusion
32909821|NCT01166984|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
32909822|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
32909823|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
32909824|NCT04743531|Experimental|Intervention|Families living in rural Colorado will participate in the HEROs intervention in Fall 2019.
32909825|NCT04743531|Experimental|Staggered Intervention|Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
32909826|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
32909827|NCT04352192|Experimental|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
32909828|NCT04352192|No Intervention|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
32909829|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
32909830|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
32909831|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
32909832|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
33395779|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
33395780|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
32744737|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
33072459|NCT05063552|Experimental|Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 of each cycle, and cisplatin IV or carboplatin IV on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial.
33072460|NCT05063552|Experimental|Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)|Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
32744738|NCT04752592|Experimental|SeroSelectTB|The participants in this arm, after providing informed concent, will be tested using the SeroSelectTB rapid assay.
33395781|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
32909833|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
33395782|NCT04670432|Experimental|Treatment group|Hydroxyethylrutoside oral tablet twice daily for 8 weeks starting at the time of randomization, in addition to usual care.
33395783|NCT04670432|No Intervention|Control group|Usual care, consisting of anticoagulant treatment and elastic compression therapy for full study duration.
33395784|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
33395785|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
33395786|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
33395787|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
33395788|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
33395789|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
33395790|NCT02439736||CT positive for acute intracranial lesion|
33395791|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
33395792|NCT02442934|Active Comparator|Standard Care|Standard care
33395793|NCT04668326|Active Comparator|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
33395794|NCT04668326|Experimental|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
33395795|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
33395796|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
33395797|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
33395798|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
33395799|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
33395800|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
33395801|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
33395802|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
33395803|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
33395804|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
33395805|NCT04370054|Experimental|PF-07055480 (giroctocogene fitelparvovec)|Single administration of PF-07055480
33395806|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
33395807|NCT03702140|Active Comparator|TPTD 6M|
33395808|NCT03702140|Active Comparator|TPTD 6-12M|
33395809|NCT03702140|Active Comparator|TPTD 12-24M|
33395810|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
33395811|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
33395812|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
33072461|NCT05060497||Covid patients|Participants who were treated in hospital with laboratory diagnosed Covid-19 requiring high flow oxygen, non invasive ventilation or intubation and have now recovered. They will be recruited 5-7 months post discharge from their local hospital Trust
32744739|NCT04752592|No Intervention|Standard of Care|The participants in this arm, after providing informed consent, will receive the established standard of care.
33072462|NCT05060497||Healthy control volunteers|Participants who are otherwise healthy, who have not had Covid-19 infection and are age, gender, BMI and ethnicity matched to patients
32909834|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
32909835|NCT01132508||Treatment|
32909836|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
32909837|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
32909838|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
33072463|NCT05059522|Experimental|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
33072464|NCT05059522|Experimental|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
33072465|NCT05059522|Experimental|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
32754172|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
32754173|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
33239267|NCT04077450|Experimental|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
33239268|NCT00577005|Experimental|1|Levetiracetam tablets
33239269|NCT00577005|Placebo Comparator|2|matching placebo
33239270|NCT05162157||at-home spirometry|This group performs spirometry at home with the Nuvoair spirometer
33239271|NCT04077060|Experimental|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.
32754174|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
33072466|NCT05059522|Experimental|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
33239272|NCT04077060|Other|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
33239273|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
33239274|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
33239275|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
33239276|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
33239277|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
33239278|NCT05237076|Experimental|Diabetes Type 2|Patients with DM Type 2 using Oral Diabetes Medications only.
33239279|NCT05237076|Active Comparator|Healthy controls|Healthy controls without comorbidities.
33239280|NCT04077216|Experimental|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
33239281|NCT04077216|No Intervention|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
33239282|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
33239283|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
33239284|NCT04209192|Active Comparator|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
33239285|NCT04209192|Experimental|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
33239286|NCT05742087||Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the iological Resource Center of the Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids).~The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF."
33239287|NCT04003506|Experimental|Group LB|local infiltration of analgesia (LIA) with adductor canal block (ACB) will be given using 10ml of 1.33% liposomal bupivacaine with 10ml 0.9% normal saline
33239288|NCT04003506|Active Comparator|group S|LIA with ACB will be given using 20ml 0.9% normal saline
33239289|NCT05674578|Experimental|Health services research (patient navigator)|Patients are assigned a Black patient navigator for racial concordance and receive coaching from patient navigator over 30 minutes every other week for 3 months and then monthly for 3 months.
33072467|NCT05059522|Experimental|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
33395813|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
33395814|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
33395815|NCT04658186|Experimental|UCB0599 High Dose Arm|Participants will be randomized to receive a predefined high dosage of UCB0599 during the Treatment Period.
33395816|NCT04658186|Placebo Comparator|Placebo Arm|Participants will be randomized to receive a predefined dosage of Placebo during the Treatment Period.
33395817|NCT04658186|Experimental|UCB0599 Low Dose Arm|Participants will be randomized to receive a predefined low dosage of UCB0599 during the Treatment Period.
33395818|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
33395819|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
33395820|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
33395821|NCT02434042|Placebo Comparator|Placebo|100% dextrin
33395822|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
33395823|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
33395824|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
33395825|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
33395826|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
33395827|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
33395828|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
33395829|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
33395830|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
33395831|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
33395832|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
33395833|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
33072468|NCT05059522|Experimental|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
32754175|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
33072469|NCT05059522|Experimental|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
33395834|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
33395835|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
33395836|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
33395837|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
33395838|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
33395839|NCT04336982|Experimental|CC-90009 in combination with venetoclax and azacitidine|"CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.~Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle."
33395840|NCT04336982|Experimental|CC-90009 in combination with gilteritinib|CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.
33395841|NCT02439034|Active Comparator|Arm A|Paracetamol
33395842|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
33395843|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
33395844|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
33395845|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
33395846|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
33395847|NCT03696602||test with methacholine|
33395848|NCT03696602||test with exercise|
33395849|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
33395850|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
33395851|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
33395852|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
33395853|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
33395854|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
33395855|NCT03692858|Active Comparator|Group A|
33395856|NCT03692858|Active Comparator|Group B|
33395857|NCT04239092|Experimental|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
33395858|NCT04239092|Experimental|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
33395859|NCT04239092|Experimental|9-ING-41 plus Irinotecan plus Temozolomide|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days. Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 ((cycle duration is 21 days).
33395860|NCT04239092|Experimental|9-ING-41 plus Cyclophosphamide plus Topotecan|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5. Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5. 9-ING-41 intravenous infusion twice weekly (cycle duration is 21 days).
33395861|NCT02442232||Normotensive|
33395862|NCT02442232||Hypertensive taking ACEi|
33395863|NCT02442232||Hypertensive not taking ACEi|
33395864|NCT03692780|Experimental|Careseng 1370|
33395865|NCT03692780|Placebo Comparator|Matched Placebo|
33395866|NCT04483492||1|newborns under 32 weeks with respiratory support if they are decided to start caffeine treatment
33395867|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
33395868|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
33395869|NCT04483336|Experimental|Virtual reality Distraction.|Subjects watched a video cartoon using virtual reality goggles as a distraction technique during the administration of local anesthesia.
33395870|NCT04483336|Active Comparator|TV screen Distraction|Subjects watched a video cartoon on a regular TV screen as a distraction technique during the administration of local anesthesia.
32754176|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
33239290|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
33395871|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
33395872|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
33395873|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
33395874|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
33395875|NCT02442388|Experimental|Hand file|Instrumentation technique
33395876|NCT02442388|Experimental|ProTaper file|Instrumentation technique
33395877|NCT02442388|Experimental|Wave-One file|Instrumentation technique
33395878|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
33395879|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
33395880|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
33395881|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
33395882|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
33395883|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
33395884|NCT03189784|No Intervention|Control group|The control group will receive no intervention
33395885|NCT05163808|Active Comparator|Study Drug|Subjects will 25mg BID dose of BPN14770
33395886|NCT05163808|Placebo Comparator|Placebo Arm|Subjects will receive Placebo
33395887|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
33395888|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
33395889|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
33395890|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
33395891|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
33395892|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
33395893|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
33395894|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
33395895|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
33395896|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
33395897|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
33395898|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
33395899|NCT02438176|Experimental|single puncture group|single trans-septal puncture
33395900|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
32754177|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
32754178|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
32754179|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
32754180|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
32754181|NCT04741841|Placebo Comparator|Placebo|The placebo product is identical to active product in taste and appearance but without probiotic
32754182|NCT04741841|Active Comparator|Treatment high dose|High dose GutMagnific™
32754183|NCT04741841|Active Comparator|Treatment low dose|Low dose GutMagnific™
32754184|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
32754185|NCT05076695|Experimental|TPPF group|Patients will be treated with Trastuzumab, Pyrotinib, Palbociclib plus Fulvestrant(TPPF).
32754186|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
32754187|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
32754188|NCT02440243|Active Comparator|Patients active|Purethal Grass
32754189|NCT02440243|Placebo Comparator|Patients placebo|Placebo
33395901|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
33239291|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
33239292|NCT00698841|Experimental|Cetuximab|
33239293|NCT03789240|Experimental|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1 week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
33239294|NCT03787290|Experimental|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
33239295|NCT03787290|Active Comparator|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
33239296|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
33239297|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
33239298|NCT05674110|Experimental|Education and Support|online education and support meetings
33239299|NCT05055843|Experimental|Screening (3D MRI)|Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.
33239300|NCT03998202||Adults 60-74 years|
33239301|NCT03998202||Adults >= 75 years|
33239302|NCT04062357|Active Comparator|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
33239303|NCT04062357|Placebo Comparator|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
33239304|NCT05133141||Echelon Contour|This prospective study will include the participants who plan to have an elective colorectal surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the Echelon Contour instruction for use (IFU).
33239305|NCT05104125|Experimental|Experimental group 1|ASC40 25mg for 12 weeks
33239306|NCT05104125|Experimental|Experimental group 2|ASC40 50mg for 12 weeks
33239307|NCT05104125|Experimental|Experimental group 3|ASC40 75mg for 12 weeks
33239308|NCT05104125|Placebo Comparator|Placebo group|Placebo for 12 weeks
33239309|NCT05047185|Experimental|Part 1: Low dose|BID low dose of PHA-022121
33239310|NCT05047185|Experimental|Part 1: High dose|BID high dose of PHA-022121
33239311|NCT05047185|Placebo Comparator|Part 1: Placebo|BID placebo
33239312|NCT05047185|Experimental|Part 2: Open-label|BID high dose of PHA-022121
33239313|NCT04482309|Experimental|Arm 1|Cohort 1: Biliary tract cancer
33239314|NCT04482309|Experimental|Arm 2|Cohort 2: Bladder cancer
33239315|NCT04482309|Experimental|Arm 3|Cohort 3: Cervical cancer
33239316|NCT04482309|Experimental|Arm 4|Cohort 4: Endometrial cancer
33239317|NCT04482309|Experimental|Arm 5|Cohort 5: Ovarian cancer
33239318|NCT04482309|Experimental|Arm 6|Cohort 6: Pancreatic cancer
33239319|NCT04482309|Experimental|Arm 7|Cohort 7: Rare tumors
33239320|NCT05190120|Active Comparator|Femoral Block|Patients scheduled for knee arthroscopy will have a femoral nerve block done using 0.5% ropivacaine 20ml before surgery.
33239321|NCT05190120|Experimental|Adductor Canal Block|Patients scheduled for knee arthroscopy will have an adductor canal block done using 0.75% ropivacaine 13.3ml before surgery.
33239322|NCT05742009|Experimental|iCare ST500 vs GAT and iCare IC200|Measurement of intraocular pressure (IOP) with iCare ST500 compared to GAT and iCare IC200. Measurements will be performed in three categories: Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).
32754190|NCT04723043|Active Comparator|v group|patients will ventilate with volume controlled mode
32754191|NCT04723043|Active Comparator|p group|patients will ventilate with pressure controlled mode
33072470|NCT05059522|Experimental|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
32754192|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
32754193|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
32754194|NCT04705259|Active Comparator|ENGAGEMENT bundle|A multimodal bundle of interventions to optimise antibiotic prescribing in residential aged care facilities. The bundle includes education for nurses and general practitioners caring for residents, telehealth support and implementation of state-wide guidelines.
32754195|NCT04705259|Placebo Comparator|Usual care|Usual facility practices with regards to antibiotic prescribing and review
32754196|NCT05076461|Experimental|ondansetron group|Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
32754197|NCT05076461|Experimental|Domperidone group|Children in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight
32754198|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
32754199|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
32754200|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
32754201|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
32754202|NCT03142373|Experimental|CV4 group|CV4 technique
32754203|NCT03142373|Experimental|RR group|Rib Raising technique
32754204|NCT03142373|Placebo Comparator|Placebo group|Light touch
32754205|NCT02429011||MDD|patients with current MDD
32754206|NCT02429011||Healthy Control (HC)|healthy control volunteers
32754207|NCT05233657|Experimental|JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.
32754208|NCT05233657|Placebo Comparator|Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..
32754209|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
32754210|NCT02432131||Divers with PFO|
32754211|NCT02432131||Divers without PFO|
32754212|NCT02030327||No trauma|n=5 patients
32754213|NCT02030327||trauma without organ dysfunction|n=40 patients
32754214|NCT02030327||trauma with organ dysfunction|n=40 patients
32754215|NCT02432053|Experimental|Transplantation|Advagraf
32754216|NCT04624919|Active Comparator|Hot/Dry|
32754217|NCT04624919|Experimental|Warm/Humid|
32754218|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
32754219|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
32754220|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
32754221|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
32754222|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
32754223|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
32754224|NCT03190681|Experimental|methylphenidate|
32754225|NCT03190681|Placebo Comparator|inactive pill|
32754226|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
32754227|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
32754228|NCT04604405|Experimental|photobiomodulation|Eyes are irradiated with 650nm low energy red light
33072471|NCT05052138|Experimental|Tactile massage|Tactile massage 1 will receivetwo 15-min tactile massages (hand massage) per week for 4 weeks
32754229|NCT04604405|No Intervention|blank|no intervention except for wear glasses
32754230|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
32754231|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
33072472|NCT05052138|No Intervention|comparison group|The comparison group will receive regular care and activities.
33072473|NCT05045976|Experimental|Experimental group|The experimental group will receive the web-based interactive self-management support intervention.
33239323|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
33239324|NCT04477785||Clinical Observation|Up to 4500 participants will be followed clinically once identified, over the course of 5-8 years.
33239325|NCT00738374|Experimental|1|
33239326|NCT05325450|Experimental|Training A|Training A in Unilaterally postlingually-deafened adult cochlear implanted candidates
33239327|NCT05325450|Experimental|Training B|Training B in Unilaterally postlingually-deafened adult cochlear implanted candidates
33239328|NCT05325450|Active Comparator|Control|Training in bilaterally postlingually-deafened adult cochlear implanted candidates
33239329|NCT04076982|Experimental|mung bean|daily oral administration of protein supplement
33239330|NCT04076982|Placebo Comparator|biscuit|daily oral administration of control supplement
33239331|NCT03986190|Experimental|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
33239332|NCT03986190|No Intervention|Control Group|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites which they may access at their discretion.
33239333|NCT04088474|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
33239334|NCT04088474|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
33239335|NCT04190628|Experimental|Monotherapy Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
33239336|NCT04190628|Experimental|Combination Therapy Dose Escalation|"A classic 3+3 design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy."
33239337|NCT04190628|Experimental|Monotherapy Therapy Dose Expansion-1|- In C-1(Monotherapy - CNS Tumors), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
33239338|NCT04190628|Experimental|Monotherapy Therapy Dose Expansion-2|- In C-2 (Monotherapy - Melanoma w/ Brain Mets), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
33239339|NCT04190628|Experimental|Combination Therapy Dose Expansion-1|- In C-3 (Combotherapy - Advanced/Metatatic Solid Tumors), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
33239340|NCT04190628|Experimental|Combination Therapy Dose Expansion-2|- In C-4 (Combotherapy - Melanoma w/ Brain Mets), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
33239341|NCT05016999|No Intervention|Control|Volunteers in this group will not take any products.
33239342|NCT05016999|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
33239343|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
33239344|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
33239345|NCT03746184||Knee osteoarthritis|Treatment course
33239346|NCT04075500|No Intervention|Arm 1|Control arm, 24-h Holter monitoring
33239347|NCT04075500|Other|Arm 2|Interventional arms, prolonged cardiac monitoring
33239348|NCT03967626|Experimental|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
32909839|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
32909840|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
32909841|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
33072474|NCT05045976|No Intervention|Control group|The control group will receive usual care and regular patients education.
33239349|NCT03967626|Active Comparator|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
33239350|NCT05119608|Experimental|CBT/ACT|Cognitive-behavioral therapy intervention with principal components of acceptance and commitment therapy (ACT)
33239351|NCT05119608|Active Comparator|TAU|Treatment as usual, defined by standard care, i.e. referral to relevant health care provider (typically primary care).
33072476|NCT05039099|Experimental|AP-101|AP-101 is administered by IV.
33239352|NCT00697593|Experimental|Efalizumab|
33239353|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
33239354|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
33239355|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
33239356|NCT05012475|Experimental|Participants|The study involves a pre-intervention phase (4 weeks long), followed by a cause and effect training phase (1 week long), followed by an intervention phase (12 weeks long), and ending with a post-intervention phase (4-weeks long) for a total of 5-6 months from start to finish.
33239357|NCT05325021||Axial myopia|children have anisometropia due to axial myopia, axial length will be measured by optical biometry device in millimeter (mm).
33239358|NCT05325021||Refractive myopia|children have anisometropia due to refractive myopia, axial length will be measured by optical biometry device in mm.
33239359|NCT05325021||Axial hyperopia|children have anisometropia due to axial hyperopia, axial length will be measured by optical biometry device in mm.
33239360|NCT05325021||Refractive hyperopia|children have anisometropia due to refractive hyperopia, axial length will be measured by optical biometry device in mm.
33239361|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
33239362|NCT05741931|Experimental|Intervention Group|Pregnant women and midwives will use the REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting) mobile application to monitor the condition of maternal pregnancy. Mothers and midwives will implementation 3 times of pregnancy class until mothers give birth
33239363|NCT05741931|No Intervention|Control Group|Pregnant women and midwives will conduct pregnancy monitoring as usual. The pregnancy class will be implemented in accordance with government program standards. Mothers will take pregnancy class 3 times until the mother gives birth
33239364|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
33239365|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
33239366|NCT04445025|Experimental|Test group|Subjects will receive the medication elagolix
33239367|NCT04445025|Active Comparator|Control group|Subjects will receive leuprolide acetate
33239368|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
33239369|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
33239370|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
33239371|NCT04166604|Experimental|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
33239372|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
33239373|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
33239374|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
33239375|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
33239376|NCT00697515|Placebo Comparator|Placebo|
33239377|NCT04163640|Experimental|Intervention Group|Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection
33239378|NCT04163640|No Intervention|Control Group|Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection
33239379|NCT04160910|Active Comparator|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
33239380|NCT04160910|Placebo Comparator|Placebo|"Dosage of placebo will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
33239381|NCT03951636|Sham Comparator|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
33239382|NCT03951636|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
33239383|NCT03951636|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
33239384|NCT00738062|Active Comparator|Droxidopa|Study medication
33239385|NCT00738062|Placebo Comparator|Placebo|Placebo
33239386|NCT04156074|Experimental|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
33239387|NCT04156074|Active Comparator|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
33072477|NCT05039099|Placebo Comparator|Placebo|Placebo is administered by IV.
33072478|NCT05036447|Experimental|DM1-Ex|Moderate-heavy resistance exercise of one leg in DM1-patients
32754232|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
32754233|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
32754234|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
32754235|NCT05068115||1|Young breast cancer patients in China from 2000 to 2015, of whom the clinical features, diagnosis and treatment models and survival status are described.
33395902|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
33395903|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
33395904|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
33395905|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
33395906|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
33395907|NCT02433418|No Intervention|Control group|Women will not receive any intervention
33395908|NCT04484038|Other|IMRT, any mode|"External radiation therapy with 6-18 MV photons on the 62.5 Gy prostate bed in 25 2.5 Gy fractions (EQD2 71 Gy).~Serving per fraction: 2.5 Gy Total fractions: 25 No. fractions / week: 5 Total treatment time: 5 weeks Total nominal dose: 62.5 Gy EQD3 (TRT): 68.75 Gy EQD1.5 (CaP): 71.43 Gy EQD2 (CaP): 68.75 Gy EQD10 (TRA): 65.10 Gy"
33395909|NCT02433730|Active Comparator|placebo|intramuscular injection
33395910|NCT02433730|Active Comparator|testosterone|intramuscular injection
33395911|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
33395912|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
33395913|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
33395914|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:~Fasting glucose >6 2 hour glucose >7.7"
33395915|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
33395916|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
33395917|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
33395918|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
33395919|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
33395920|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
33395921|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
33395922|NCT02433106|Active Comparator|Control|Control Usual training
33395923|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
33395924|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
33395925|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
33395926|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
33395927|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
33395928|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~During Surgery:~Blood Collection~Vaginal Swab~Chromopertubation~Culdocentesis~Tissue Collection"
33395929|NCT02437786|Experimental|GRAZAX|GRAZAX
33395930|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
33072479|NCT05036447|No Intervention|DM1-Rest|Control leg (i.e. no exercise) in DM1-patients
33072480|NCT05036447|Experimental|Ctrl-Ex|Moderate-heavy resistance exercise of one leg in healthy participants
32909842|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
32909843|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
33239388|NCT04156074|Placebo Comparator|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
32909844|NCT05305508|Placebo Comparator|placebo|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
32909845|NCT05305508|Experimental|Calcium Dobesilate|The CaD (Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
32909846|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
32909847|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
33072481|NCT05036447|No Intervention|Ctrl-Rest|Control leg (i.e. no exercise) in healthy participants
33072482|NCT05032859|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
33072483|NCT05032859|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
33072484|NCT05029128|Other|Exercise|All participants engage in exercise training
33239389|NCT04156074|Active Comparator|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
32909848|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
32909849|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
32909850|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
32909851|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
32909852|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
33239390|NCT04076670|No Intervention|Control group|Group pf participants that received usual psychological attention.
32744740|NCT04873479|Experimental|test group|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
32909853|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
32909854|NCT05296460|Experimental|dapsone gel and trichloroacetic acid|trichloroacetic acid peeling on right side of face and dapsone gel on left side
32909855|NCT05288894||Repaired Tetralogy of Fallot|A patient affected by Tetralogy of Fallot (right ventricle outflow obstruction, right ventricle hypertrophy, ventricular septal defect, aortic overriding of the ventricular defect) that already underwent cardiac surgery for the correction.
32909856|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
32909857|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
32909858|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
32909859|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
32909860|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
32909861|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
32909862|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
32909863|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
32909864|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
32909865|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
32909866|NCT05269628|Experimental|Cannabidiol (CBD)|"Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~PLUS Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol."
32909867|NCT05269628|Active Comparator|Tetrahydrocannabinol (THC)|"The drug dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment.~PLUS Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as active Epidiolex®."
32909868|NCT05269628|Active Comparator|CBD + THC|
32909869|NCT05269628|Placebo Comparator|Placebo CBD + Placebo THC|
33072485|NCT05028751|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of lanraplenib (LANRA) once daily (QD) + gilteritinib QD in each 28 day cycle for determination of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of LANRA in combination with gilteritinib.
33239391|NCT04076670|Experimental|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
33395931|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
33239392|NCT04062045|Experimental|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
33239393|NCT04062045|Placebo Comparator|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
33395932|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
33395933|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
33395934|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
33395935|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
32909870|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
32909871|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).~***~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
33395936|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
32909872|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
33072486|NCT05028751|Experimental|Part 2: Expansion Cohort|Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of lanraplenib (LANRA) in combination with gilteritinib in Part 1, an expansion cohort will enroll. The expansion cohort will receive LANRA in combination with gilteritinib at the MTD / RP2D once daily (QD) in each 28 day cycle.
33395937|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
33395938|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
33395939|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
33395940|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
32909873|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
32909874|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
32909875|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
32744741|NCT04873479|Other|control group|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
32909876|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
32909877|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
33395941|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
32909878|NCT01138514|Active Comparator|Reference Product|
33395942|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
33395943|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
33395944|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
32909879|NCT01138514|Placebo Comparator|Vehicle|
33395945|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
33072487|NCT05028140|Experimental|Piemonte association|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 tablet Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
33395946|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
33239394|NCT03740256|Experimental|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
32744742|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
32744743|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
32744744|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
32744745|NCT04744324|Experimental|Self-supporting Care Group|Self-supporting Care in home
32744746|NCT04744324|Active Comparator|Control group|Home Health Education
33072488|NCT05028140|Active Comparator|Empagliflozin|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
33072489|NCT05028140|Active Comparator|Pioglitazone|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 tablet of piglitazone, oral."
32754236|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
32754237|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
32754238|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
32754239|NCT04593563|Experimental|Psilocybin 25mg|Psilocybin 25mg Single does with supportive conditions.
32754240|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
32754241|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
32754242|NCT04568759|Active Comparator|Standard care group|Observation or brace plus conventional physiotherapy exercises on video
32754243|NCT04568759|Experimental|GPR group|GPR interventions added to standard care (observation or brace)
32754244|NCT04551911|Experimental|30 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
32754245|NCT04551911|Placebo Comparator|0 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
32754246|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
32754247|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
32754248|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
32754249|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
32754250|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
32754251|NCT03143465|Experimental|CGRP|
32754252|NCT03143465|Experimental|Sildenafil|
32754253|NCT03143465|Placebo Comparator|Placebo|
32754254|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
32754255|NCT05034809|Experimental|Treatment Group|Other than the guided management of Dengue Fever with warning signs, the treatment group will receive a standard dose of 20mg/day of melatonin20-21 for 5 days. The dosing was based on the study by Leiberman et al and Malhotra et al. If a patient is unable to tolerate the whole or punctured tablet, it will be given with milk or water. There is no known interaction between melatonin and milk known to date. Daily complete blood count will be done and be recording in an electronic record using Microsoft Excel.
32754256|NCT05034809|No Intervention|Control Group|Other than the guided management of Dengue Fever with warning signs, the control group will be manage according the Department of Health Dengue Management Guideline. No placebo will be given.
32754257|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
32754258|NCT04428203|Experimental|single arm|A Phase I/Ib on the Safety of Epidiolex in Patients with Prostate Cancer with Rising PSA after Localized Therapy with either Surgery or Radiation
32901415|NCT02889458||Case|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)~Able to speak Cantonese~Newly diagnosed with breast cancer or DCIS in 24 weeks~Exclusion Criteria~- Undergoing treatment for any non-breast cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
32909880|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
33072490|NCT05027516|Active Comparator|Rocephine®|ceftriaxone 1g + lidocaine 35mg; intramuscular injection
33072491|NCT05027516|Active Comparator|Rocephine® + Azithromycin|ceftriaxone 1g + lidocaine 35mg intramuscular injection + azithromycin 2g orally
33072492|NCT05016882|Experimental|NNC0194-0499 7.5 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
32909881|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
32909882|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
32909883|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
32909884|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
32909885|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
32909886|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
32909887|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
33395947|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
33395948|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
33395949|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
33395950|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
32909888|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
33239395|NCT05007015|Experimental|Transanal Irrigation|This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
32909889|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
32754259|NCT04381325|Experimental|MSB0254 Injection|This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration. An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
32754260|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
32754261|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours."
32754262|NCT05014217||Mentalization-based Treatment|Participants who have been oriented to the mentalization-based treatment among the clinical adult population with a cluster B personality disorder.
32909890|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
32754263|NCT05014217||Dialectical Behavior Therapy-inspired Treatment|Participants who have been oriented to the dialectical behavior therapy-inspired treatment among the clinical adult population with a cluster B personality disorder.
32754264|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
32754265|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
32754266|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
32909891|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
32754267|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
32754268|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
32754269|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
32754270|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
33395951|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
33395952|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
33395953|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
33395954|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
33395955|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
32754271|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
32754272|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
32754273|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
32754274|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
32754275|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
33395956|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
32754276|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
32754277|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
33395957|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
33395958|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
33395959|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
33395960|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
33395961|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
33395962|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
33395963|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
33395964|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
33395965|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
33395966|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
33395967|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
33395968|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers~offer of nicotine patches"
33395969|NCT05145478||Shockwave Intravascular Lithotripsy (IVL)|Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
33395970|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
33395971|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
33395972|NCT03189472|Experimental|active tDCS|
33395973|NCT03189472|Sham Comparator|sham tDCS|
33395974|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
33395975|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
33395976|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
33395977|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
33395978|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
33395979|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
33395980|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
33395981|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
33395982|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
33395983|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
33395984|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
33395985|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
33395986|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
33395987|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
33395988|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
33395989|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
33072493|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
32754278|NCT04327193|Experimental|Driving pressure|The selected PEEP which makes the driving pressure lowest is applied during the operation.
32754279|NCT04327193|Active Comparator|Conventional|Conventional PEEP (5cmH2O) is applied.
33072494|NCT05016882|Experimental|NNC0194-0499 15 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
33395990|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
32754280|NCT04293029|Experimental|Normal liver function|Patients will receive single dose of SHR0302
32909892|NCT05254418|Experimental|dulagutide arm|Patient will receive 1.5 mg injections per week for 12 weeks.
33395991|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
33395992|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
32909893|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
32744747|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
32754281|NCT04293029|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR0302
32909894|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
33072495|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
33395993|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
33395994|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
32754282|NCT04293029|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR0302
32754283|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
33072496|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
33395995|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
33395996|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
33072497|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
33072498|NCT05016882|Active Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
33072499|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
32909895|NCT05185778||parasitic infected individuals received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who received COVID-19 vaccines of any type
33395997|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
33395998|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
33395999|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
33396000|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
33396001|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
33396002|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
33396003|NCT03186040|Other|Lacosamide|
33396004|NCT03185962||Successful extubation|extubated successfully
33396005|NCT03185962||Extubation failure|reintubated within 48 hours
33396006|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
33396007|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
33396008|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
33239396|NCT05007015|No Intervention|Tradition care Control arm|This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
33239397|NCT03733314|Experimental|E6011|
33239398|NCT03733314|Placebo Comparator|Placebo|
33239399|NCT04064073|Experimental|1|
33239400|NCT04064073|Experimental|2|
33239401|NCT04064073|Experimental|3|
33072500|NCT05016882|Experimental|NNC0174-0833 2.4 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
32909896|NCT05185778||parasitic infected individuals not received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who don't receive COVID-19 vaccines of any type
32909897|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32909898|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
32909899|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
33072501|NCT05016882|Placebo Comparator|Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
32909900|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
32909901|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
32909902|NCT05177510|Experimental|Mifepristone and standard of care|Mifepristone 300mg once only and standard of care
32909903|NCT05177510|Placebo Comparator|Placebo|Placebo 300mg once only and standard of care
32909904|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
32909905|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
32909906|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
32909907|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
32909908|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
33239402|NCT04075344|Experimental|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
33239403|NCT04075344|No Intervention|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
33239404|NCT05741853|Experimental|Lexical Retrieval Training|Naming intervention for individuals with logopenic or semantic variant PPA.
33239405|NCT05741853|Experimental|Video Implemented Script Training for Aphasia|Script training intervention for individuals with nonfluent/agrammatic PPA.
33239406|NCT03728400||Patients in neurovascular intensive care|During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.
33239407|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
33239408|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
33239409|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
32909909|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
32909910|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
33396009|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
32909911|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
32909912|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
32909913|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
32909914|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
32909915|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
32909916|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
33072502|NCT05013229|Experimental|IcoSema|Participants will receive once weekly subcutaneous (s.c) injections of IcoSema during the 52-week treatment period.
33239410|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
33239411|NCT04137354|Placebo Comparator|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron & vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
33239412|NCT04137354|Experimental|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
33239413|NCT04137354|Experimental|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
32901416|NCT02889458||Control|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong~Able to speak Cantonese~Exclusion Criteria~- History of any cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
33239414|NCT04137354|Experimental|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
33239415|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
33239416|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
33239417|NCT02566629||healthy controls|collect faeces from healthy controls
33239418|NCT03928704|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
33239419|NCT03928704|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
33239420|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
33239421|NCT02566941|No Intervention|Control|
33239422|NCT05000073|Experimental|Experimental Arm|
33239423|NCT05000073|Active Comparator|Control arm|
33239424|NCT04368195|No Intervention|Control group|This group will not receive any regional block
33239425|NCT04368195|Experimental|Erector spinae block group|This group will receive erector spinae block
33239426|NCT04130958|Experimental|MDD and Active iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving active iTBS-TMS.
33239427|NCT04130958|Experimental|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
33239428|NCT04130958|Sham Comparator|MDD and Sham iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving sham iTBS-TMS.
33239429|NCT04130958|Sham Comparator|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
33239430|NCT03709680|Experimental|Phase 2 Arm A|Palbociclib in combination with irinotecan and temozolomide.
33239431|NCT03709680|Experimental|Phase 1|Palbociclib in combination with temozolomide and irinotecan and/or with topotecan and cyclophosphamide.
33239432|NCT03709680|Active Comparator|Phase 2 Arm B|Irinotecan and temozolomide alone.
33239433|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
33239434|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
33239435|NCT04075032|Experimental|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
33239436|NCT04075032|Placebo Comparator|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
33239437|NCT04075032|Placebo Comparator|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
33239438|NCT04075032|Experimental|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
33239439|NCT04245345|Other|Single-arm|Subjects implanted with the Medtronic Micra AV device
33239440|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
33239441|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
33239442|NCT05741775|Experimental|Aerobic training|Participants in the aerobic group will undergo a training that includes walking, static bicycle, and neck exercise. The participants start the session with a warm-up for 5 minutes followed by 30 minutes of aerobic exercise and end with 5 minutes of cool-down exercise. 40 minutes/ session, 3 times per week for 6 weeks.
33239443|NCT05741775|Experimental|Biofeedback training|Participants in this group will undergo an electromyography (EMG) biofeedback training for trapezius and frontalis using rose for relaxation 3 times per week for 6 weeks. Each session will be for 30 minutes with a 5-minute resting period between each muscle session.
33239444|NCT05741775|No Intervention|Waitlist Control group|"The control group will receive the patient education sheet with the basic information about migraine in terms of symptoms, triggers, and prevention tips. This group is also called as waitlist control group who will receive intervention after the active treatment group."
33239445|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
33239446|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.~If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card~In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
33239447|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
33239448|NCT05741619||Anti-GABABr encephalitis|This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
33239449|NCT04995003|Experimental|Arm A|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab
32909917|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
32909918|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
32909919|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
32909920|NCT01178528|Experimental|Ivabradine|7.5 mg bd
32909921|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
32909922|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
33072503|NCT05013229|Active Comparator|Insuling glargine/insulin aspart|Participants will receive subcutaneous (s.c) injections of insulin glargine once daily combined with 2-4 times daily injections of insulin aspart.
33396010|NCT05233540||Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy|Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
33396011|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
33396012|NCT02440516|Placebo Comparator|Waiting list|Waiting list
33396013|NCT02659020|Experimental|Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 15 milligrams per kilogram (mg/kg) on days 1, 8 plus gemcitabine 900 milligrams per meter square (mg/m^2) on days 1, 8 plus docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met.
32909923|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
32909924|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
32909925|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
33396014|NCT02659020|Experimental|Phase 1b: Cohort 2 overall - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 20 mg/kg on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met (cohort 2). Following a protocol amendment, additional participants were enrolled into this group to confirm the safety of the 20 mg/kg dose level prior to opening the Phase 2 (cohort 2 expansion).
33396015|NCT02659020|Experimental|Phase 2: Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
32901417|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
32901418|NCT00424268|Placebo Comparator|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
32901419|NCT00424502|Experimental|1|
32901420|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32901421|NCT00543764||Pre pathway|Pre pathway
32901422|NCT00543764||Post pathway|Post pathway
32901423|NCT00544076|Experimental|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
32901424|NCT00544076|Active Comparator|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
32901425|NCT00544076|Experimental|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
32901426|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
32901427|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
32901428|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
32901429|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
32901430|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
32901431|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
32901432|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
32901433|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
33239450|NCT04995003|Experimental|Arm 2|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody nivolumab
32909926|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
32909927|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
32909928|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
32909929|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
33239451|NCT04223193|Experimental|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
33239452|NCT04223193|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
32901434|NCT00489086|Other|Tazarotene Cream|Open label
32901435|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
32901436|NCT00489866|Experimental|Aripiprazole|
32901437|NCT00489866|Placebo Comparator|Placebo|
32901438|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
32901439|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
32901440|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
32909930|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
32909931|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
32901441|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
32901442|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
32901443|NCT00547586|Placebo Comparator|Placebo|
32901444|NCT00547586|Experimental|150 mg|
32901445|NCT00547586|Experimental|300 mg|
32901446|NCT00547586|Experimental|450 mg|
32901447|NCT00547586|Experimental|600 mg|
32901448|NCT00547898|Experimental|Placebo|
32901449|NCT00547898|Experimental|Crofelemer 125 mg|
32901450|NCT00547898|Experimental|Crofelemer 250 mg|
32901451|NCT00547898|Experimental|Crofelemer 500 mg|
32901452|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
32909932|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
32909933|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
32909934|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
32909935|NCT04919772||Stroke survivors|Chronic stroke, generally speaking chronic stroke refers to the period of recovery that takes place at least six months after the initial stroke event
32909936|NCT05071196|Experimental|Facilitated Vegan Diet|The facilitated vegan participants will self-prepare and consume 2 vegan meal kits per day for 4 weeks
32909937|NCT05071196|Active Comparator|Standard Omnivorous Diet|The standard omnivorous arm will self-prepare and consume 2 non-vegan meal kits per day for 4 weeks
33239453|NCT03505320|Experimental|zolbetuximab (Cohort 1A)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.
32754284|NCT04261127|Experimental|experimental arm|"The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:~Control group: interpretation of genetic analyzes without the use of RADIAL;~Experimental group: interpretation of genetic analyzes using RADIAL. Exome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available."
32754285|NCT03185767|Other|SLE group|
32754286|NCT03185767|Other|control group|
32754287|NCT03184675|Experimental|Functional action observation training|
32754288|NCT03184675|Other|General action observation training group|
32754289|NCT04747457|Experimental|Adults and pediatric patients, all etiologies combined|
32754290|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
32754291|NCT04596917|Experimental|Preferred music listening|Patients will be randomized to listen to music with iPod that has preferred music selections that patients can choose.
32754292|NCT04596917|Experimental|Hypnotic music with relaxation breathing|Patients will be randomized to listen to hypnotic music with relaxation breathing narrative.
32754293|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
32754294|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
32754295|NCT04199897|Experimental|Intervention group (sucrose + probiotics)|Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
32754296|NCT04199897|Active Comparator|Intervention group (sucrose + placebo|Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
32754297|NCT04199897|Placebo Comparator|Control group (xylitol + probiotics)|Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
32754298|NCT04199897|Placebo Comparator|Control group (xylitol + placebo|Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
32754299|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
32754300|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
32754301|NCT03547973|Experimental|Cohort 1: Sacituzumab Govitecan-hziy|Participants with urothelial cancer (UC) previously treated with platinum-based and/or checkpoint inhibitors (CPIs) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
32754302|NCT03547973|Experimental|Cohort 2: Sacituzumab Govitecan-hziy|Participants with UC who are ineligible for platinum-based therapy and failed therapy with previous immune CPI therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
32754303|NCT03547973|Experimental|Cohort 3: Sacituzumab Govitecan-hziy + Pembrolizumab|Participants who have had progression or recurrence of UC following a platinum-containing regimen in the metastatic setting, or progression or recurrence of UC within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle and pembrolizumab at the standard approved dose (200 mg) only on Day 1 of a 21-day cycle. Lower doses of sacituzumab govitecan-hziy may be tested based on dose-limiting toxicities (DLTs) observed to determine the Recommended Phase 2 Dose (RP2D) of sacituzumab govitecan-hziy in combination with pembrolizumab.
32754304|NCT03547973|Experimental|Cohort 4: Sacituzumab Govitecan-hziy + Cisplatin + Avelumab (Dose Escalation Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. Based on DLTs observed, two additional lower doses may be tested to determine RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days.
32754305|NCT03547973|Experimental|Cohort 4: Sacituzumab Govitecan-hziy + Cisplatin + Zimberelimab (Dose Expansion Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days and zimberelimab 360 mg every 3 weeks (Day 1 of a 21-day cycle).
32901453|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
32901454|NCT00490100|Experimental|Treatment|Treatment
32901455|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
33072504|NCT05006729||RURAL cohort study|A longitudinal research project in ten rural counties in Alabama, Kentucky, Louisiana, and Mississippi enrolling approximately 4,600 participants from these communities, examining several different aspects of their health, including heart and lung function.
32745163|NCT04859361|Experimental|Treatment with imiquimod|Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
33072505|NCT05000216|Experimental|Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32909938|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
32909939|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
32744748|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
32909940|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
32909941|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
32909942|NCT02492451|No Intervention|Control group|Only IUI
32909943|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
32909944|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
32909945|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
32754306|NCT03547973|Experimental|Cohort 5 (Arm 1): Sacituzumab Govitecan-hziy + ZIM|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will receive SG 10 mg/kg IV on Days 1 and 8 of a 21-day cycle followed by ZIM 360 mg IV, Q3W (Day 1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit. participants who must discontinue 1 agent may continue the other until PD, unacceptable toxicity, or loss of clinical benefit."
32754307|NCT03547973|Experimental|Cohort 5 (Arm 2): Avelumab|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will be randomized to receive avelumab 800 mg IV Q2W until PD, unacceptable toxicity, or loss of clinical benefit."
32754308|NCT03547973|Experimental|Cohort 5 (Arm 3): ZIM|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will be randomized to receive ZIM 360 mg IV Q3W (Day 1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit."
32754309|NCT03547973|Experimental|Cohort 6 (Arm 1): Sacituzumab Govitecan-hziy|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented, and alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
32754310|NCT03547973|Experimental|Cohort 6 (Arm 2): Sacituzumab Govitecan-hziy + ZIM|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. The standard approved dose of SG will be used in combination with ZIM. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented or alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
32754311|NCT03547973|Experimental|Cohort 6 (Arm 3): Sacituzumab Govitecan-hziy + ZIM + Domvanalimab|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM and DOM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease.
32754312|NCT03547973|Experimental|Cohort 6 (Arm 4): Carboplatin + Gemcitabine|"Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and CARBO in combination with GEM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease.~Participants without disease progression as assessed by the investigator after completion of 4 to 6 cycles of therapy may continue with maintenance therapy (avelumab 800 mg every 2 weeks) until loss of clinical benefit."
32754313|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
32754314|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
32754315|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
32754316|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
32754317|NCT04158245|Experimental|18F-fluciclovine PET Scan|Single intravenous administration of 18F-fluciclovine for PET Scan.
32754318|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
32754319|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
32754320|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
32754321|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
32754322|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
33396016|NCT02659020|Placebo Comparator|Phase 2: Placebo + Gemcitabine + Docetaxel|Participants received intravenous infusions of placebo on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
32745164|NCT04859361|Active Comparator|Treatment with LLETZ|Standard treatment will be scheduled after patients' first period.
32754323|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
32754324|NCT02428075|Experimental|FCHV visit-normotensive|
32754325|NCT02428075|No Intervention|FCHV no visit-normotensive|
32754326|NCT02428075|Experimental|FCHV visit-prehypertensive|
32754327|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
32754328|NCT02428075|Experimental|FCHV visit-hypertensive|
32754329|NCT02428075|No Intervention|FCHV no visit-hypertensive|
32754330|NCT02428153|Experimental|cases|static and dynamic stretching exercises
32754331|NCT03142061|Experimental|ECT|
32754332|NCT04402307|No Intervention|Usual care|Usual care to patients with dysphagia
32754333|NCT04402307|Experimental|Training|Chin Tuck Against Resistance to patients with dysphagia
32754334|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
32754335|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
32754336|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
32754337|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
32754338|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
32754339|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
32754340|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
32754341|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
32754342|NCT03182647||Non surgery|Patients were not treated with surgery initially
32754343|NCT03182647||Surgery|Patients had an initial surgical treatment
32754344|NCT04016363|Experimental|ProbeFix arm|The echocardiography probe is fixated on the patient's thorax using the ProbeFix
32754345|NCT04016363|Active Comparator|Controll arm|The sonographer manually holds the probe on the patient's thorax
32754346|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
32754347|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
32754348|NCT03857165|Experimental|Low dose SAP-001|SAP-001 (Experimental drug) low dose versus placebo
32754349|NCT03857165|Experimental|Mid dose SAP-001|SAP-001 (Experimental drug) mid dose versus placebo
32754350|NCT03857165|Experimental|High dose SAP-001|SAP-001 (Experimental drug) high dose versus placebo
32754351|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
32754352|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
32754353|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
32754354|NCT04346693|Active Comparator|group 1|80 patients with moderate and critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). Standard therapy is prescribed recommended by the Ministry of Health of the Russian Federation.
32754355|NCT04346693|Experimental|group 2|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days).
32754356|NCT04346693|Experimental|group 3|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
32901456|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
32901457|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
32909946|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
32909947|NCT02566239|Experimental|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
33396017|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
32744749|NCT04861467|Experimental|Experimental: Camrelizumab|camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)
32744750|NCT04861467|No Intervention|observation|observation after Chemoradiation
32744751|NCT04861467|Experimental|Exploration：Camrelizumab|camrelizumab for maintenance after chemoradiation( evaluation results：CR)
32745165|NCT04840485|Experimental|Treatment group A|
33071355|NCT05786352|Experimental|ERAS|"ERAS Protocol~Preoperative:~Clear carbohydrate ( pulp free juice) drink 4 hours before cesarean. Water drinking is allowed until 4 hours before cesarean.~Prophylactic antibiotics 1 hour before cesarean ( Cephazole 2 g iv)~Intraoperative:~Hypothermia prevention (warming devices)~Pneuomatic compression stockings~Skin preparation with clorhexidine-alcohol~Vaginal preparation with povidone-iodine solution~Postoperative:~Regular diet within 2 hours after cesarean~Sugar-free gum chewing at postoperative 3rd, 5th and 7th hours, for 20 minutes~Tight control of capillary blood glucose~Mobilization at postoperative 4th hour.~Urinary catheter removal at postoperative 4th hour~Pneuomatic compression stockings~Prevention of nausea and vomiting with routine use of Metoclopramide.~Routine analgesia with Diclofenac sodium suppository application and oral Paracetamole."
33396018|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
32754357|NCT04346693|Experimental|group 4|80 patients with moderate to critical severity of the disease with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular administration of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days) in conjunction with inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
32754358|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
32754359|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
32754360|NCT04483141||non-communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (hetero-assessment of pain).
33396019|NCT03482011|Experimental|Mirikizumab|"Induction Period:~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).~Maintenance Period:~Participants received one of the four options below:~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
32754361|NCT04483141||communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (including hetero-assessment and auto-assessment of pain)
32754362|NCT04683718|Experimental|BIOTRONIK Prospera™ SCS (Spinal Cord Stimulation) System|Eligible participants will be permanently implanted with a BIOTRONIK Prospera™ SCS (Spinal Cord Stimulation) System with HomeStream™ Remote Management.
32754363|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
32754364|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
32754365|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
32754366|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
32754367|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
32754368|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
32754369|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
32754370|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
32754371|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
32754372|NCT04680832|Experimental|ILD patients|Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).
32754373|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
32754374|NCT03183973|Experimental|placebo group|
32754375|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
32754376|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
32754377|NCT04102241|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
32754378|NCT04102241|Experimental|15mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
32754379|NCT04102241|Experimental|30mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
32754380|NCT04102241|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
32754381|NCT01994902|Experimental|First Coloplast test product|"The subjects test:~test period 1: Coloplast test product test period 2: SenSura Convex Light"
32754382|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:~test period 1: SenSura Convex Light test period 2: Coloplast test product"
32754383|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
32744752|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
32909948|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
32909949|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
32745166|NCT04840485|Experimental|Treatment group B|
32909950|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
32909951|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
32909952|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
32909953|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
32745167|NCT04840485|Placebo Comparator|Treatment group C|
32745168|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
32909954|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
32909955|NCT03010124|Other|Patients with ovarian cancer|
32909956|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
33239454|NCT03505320|Experimental|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive up to 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous [IV] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
32744462|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
32909957|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
32909958|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
33396020|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.~Maintenance Period:~Participants received one of the two options below:~Placebo administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
33396021|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
33396022|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
32744463|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
33239455|NCT03505320|Experimental|Pembrolizumab plus zolbetuximab (Cohort 3A)|Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.
33396023|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
32744464|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
32745169|NCT03207659|Experimental|Basketing|stones will be actively extracted.
32744465|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
32909959|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
32909960|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
32909961|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
32754384|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
32754385|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
32754386|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
32754387|NCT03777137||TMS during heat pain stimuli|This is a single institution, single-blinded, long-term exploratory study using participant as his/her own control to evaluate and compare the analgesic effect of experimental heat pain of TMS during early versus late times on a vigilance behaviors toward pain (CPT, Continuous Performance Task). Vigilance behaviors include errors, reaction times and activation.
32901458|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
32909962|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
32909963|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
32909964|NCT05042648|No Intervention|Control group (Group A)|Group A will receive no intervention
32909965|NCT05042648|Experimental|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
32901459|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
32901460|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
32901461|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
32901462|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
32901463|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
32909966|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
32909967|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
32909968|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
32909969|NCT01650636|Active Comparator|Health Information|
32909970|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
32909971|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
32909972|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
32909973|NCT02495103|Experimental|Phase I Component - Vandetanib|Phase I Component
32901464|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
32901465|NCT00551174|Experimental|1|
32901466|NCT00551174|Active Comparator|2|
32901467|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
32901468|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
33396024|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
33396025|NCT03189238|Placebo Comparator|Placebo|
32909974|NCT02495103|Experimental|Phase II Component- Vandetanib/Metformin|Phase II Component
33396026|NCT03189238|Active Comparator|PRP|
33396027|NCT03189082|Experimental|Intervention group|
32909975|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
32909976|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
32909977|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
32909978|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
32909979|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
32909980|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
33396028|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
32744753|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
32909981|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
32909982|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
32909983|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
33396029|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
33396030|NCT01374126|Experimental|Azithromycin-Artesunate|
32909984|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
33396031|NCT01374126|Active Comparator|Control (artesunate alone)|
32909985|NCT04573322|Experimental|Lead-in 0.25 mg/kg|0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
32909986|NCT04573322|Experimental|Lead-in 0.50 mg/kg|0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
32909987|NCT04573322|Experimental|Lead-in 1.0 mg/kg|1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
33396032|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
33396033|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
33396034|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
33396035|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
33396036|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
32909988|NCT04573322|Experimental|Lead-in 1.5 mg/kg|1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
33396037|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
33396038|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
32909989|NCT04573322|Experimental|Randomized Active TSC|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
32909990|NCT04573322|Placebo Comparator|Randomized Placebo|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
33396039|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
32909991|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
32909992|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
33396040|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
33396041|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
33396042|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
32909993|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
32909994|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
33396043|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
33396044|NCT03916770|Active Comparator|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 3 days a week, a total of 12 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm at progressively increasing duration)
32909995|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
32909996|NCT02974491|Experimental|Apple Juice|
33072506|NCT05000216|Experimental|Cohort A, Arm A2: BNT162b2 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32909997|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
33072507|NCT05000216|Experimental|Cohort A, Arm A3: Ad26.COV2.S + Continue IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32744466|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
32744467|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
32744468|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
33396045|NCT03916770|Sham Comparator|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be same as WBV in the treatment group ).
33072508|NCT05000216|Experimental|Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
33396046|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
33396047|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
33396048|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
32744469|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
32744470|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
33239456|NCT03505320|Experimental|Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B)|Participants will be treated with zolbetuximab and mFOLFOX6, nivolumab on a 42-day cycle. Cohort 4A: Loading dose of zolbetuximab in combination with nivolumab and mFOLFOX6 on cycle 1 day 1, followed by zolbetuximab in combination with nivolumab and mFOLFOX6 q2w [days 15 and 29] (1 cycle = 6 weeks). Tolerability and safety of zolbetuximab in combination with nivolumab, mFOLFOX6 will be evaluated during the 3-week DLT assessment period. If cycle 1 dose is not tolerable, a lower dose of dose zolbetuximab in combination with nivolumab and mFOLFOX6 will be subsequently evaluated. Cohort 4B: Subjects will be treated with the combination of zolbetuximab, mFOLFOX6 and nivolumab at the dose deemed tolerable in Cohort 4A. Subjects will receive up to 12 mFOLFOX6 treatments (4 cycles). For Cohorts 4A and 4B, beginning at cycle 5, subjects may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab and nivolumab for the remainder of the study per investigator's discretion.
32744471|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
32744754|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
32744472|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
32744755|NCT04873167|Experimental|Low Fat Diet|subjects subjected to a low-fat dietary regime
32744756|NCT04873167|Experimental|Mediterranean Diet|subjects subjected to a mediterranean dietary regime
33239457|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
33396049|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
33072509|NCT05000216|Experimental|Cohort A, Arm A5: BNT162b2 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
32744757|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
33239458|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
33396050|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
32744758|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
33239459|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
32909998|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
32909999|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
32910000|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
32910001|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
32910002|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
32910003|NCT02579343|Experimental|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
32910004|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
32910005|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
32910006|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
32910007|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
32910008|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
33396051|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
33396052|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
33396053|NCT01372800||volunteer|
33396054|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
33396055|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
33396056|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
33071356|NCT05786352|No Intervention|SOC (Standard of Care)|"Preoperative:~Fasting until 6 hours before cesarean.~Prophylactic antibiotics post-delivery during cesarean per institutional protocol ( Cephazole 2 g iv)~Intraoperative:~Pneuomatic compression stockings as needed~Skin preparation with povidone-iodine solution~Postoperative:~Water intake at 4th hour after cesarean, traditional delayed feeding until return of intestinal function (bowel sounds or flatus)~Capillary glucose control~Mobilization at postoperative 6th hour.~Urinary catheter removal at postoperative 6th hour~Pneuomatic compression stockings as needed.~Analgesia with Diclofenac sodium intramuscular and oral Paracetamole as needed."
32910009|NCT04436601|Active Comparator|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
32910010|NCT04436601|Experimental|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
32910011|NCT04900974|Experimental|Doravirine|100mg doravirine given by mouth once at each sampling visit.
32910012|NCT01144442|Experimental|HIPC Treatment|
33071357|NCT05786339|Experimental|Reference formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Sanofi Clir SNC
33239460|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
33239461|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
32910013|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
32910014|NCT01144598||Turkish patients with rheumatoid arthritis|
32910015|NCT04909788||Healthy adults with regular exercise|Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km).
32910016|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
32910017|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
32910018|NCT01146704|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
32910019|NCT01146704|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
32910020|NCT04909320|Experimental|Intervention group|
33396057|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
33239462|NCT04902729|Active Comparator|Oxytocin 1IU|Oxytocin 1IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
32910021|NCT04909320|Active Comparator|Control group|
33071358|NCT05786339|Experimental|Test formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Shenzhen Haibin Pharmaceutical Co., Ltd.
32910022|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
33071359|NCT05786326|Experimental|multiholes fully covered metaalic stents group|Insertion of multiholes fully covered self-expandable metallic stents in the biliary tree through Endoscopic retrogrades cholangiopancreatography (ERCP)patients with malignant biliary obstruction.
32744759|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
33071360|NCT05786326|Active Comparator|parially covered metallic stents group|Insertion of partially covered metallic stents in patients with malignant biliary obstruction.
33071361|NCT05786326|Active Comparator|unocoered metaalic stents group|Insertion of uncovered metallic stents in patients with malignant biliary obstruction.
33239463|NCT04902729|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
32910023|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
33071362|NCT05786313|Active Comparator|Centerpiece titanium plate|All surgical operations were performed by the same group of senior spine surgeons. The range of open door decompression involved C3 ~ C7. For convenient operation and more accurate statistics, the right side of the door axis and the left side of the door seam were selected for all operations. Centerpiece titanium plates were used for intraoperative fixation.
33239464|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
33239465|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
33239466|NCT04877691|Experimental|Anifrolumab|Solution for injection in aPFS
33072510|NCT05000216|Experimental|Cohort A, Arm A6: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
33239467|NCT04877691|Placebo Comparator|Placebo|Solution for injection in aPFS
33239468|NCT03912558|Experimental|Butterfly device implantation|"Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.~Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position."
32744760|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
33239469|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
33239470|NCT03911700|Experimental|Phasix™ Mesh|Prophylactic onlay placement of mesh.
33239471|NCT03911700|No Intervention|Primary Suture Closure|Standard Fascial closure.
32910024|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
32744473|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
32744474|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
32744761|NCT04872933|Other|Non-Waitlist|Patient will attend a total of 3 virtual assessments whilst in the study: at baseline, at 12 weeks then at 6 months. The online intervention will commence straight after completing the baseline visit.
32744762|NCT04872933|Other|Waitlist|Patient will be complete assessments at baseline and 12 weeks but will only start the online intervention after the 12-week assessment.
33396058|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
33072511|NCT05000216|Experimental|Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32910025|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
32910026|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
33396059|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
33396060|NCT02440282||Group A|patients undergo general anesthesia
33396061|NCT02440282||Group B|spinal anesthesia
33396062|NCT02440282||Group C|ultrasound-guided sciatic nerve block
32910027|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
32910028|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
32910029|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
32910030|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
32910031|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
32910032|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
32910033|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
32910034|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
32910035|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
32910036|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
32910037|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
32910038|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
33396063|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
32910039|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
32910040|NCT00363987|Experimental|1|
32910041|NCT00363987|Other|2|
32910042|NCT04352114|Experimental|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
32910043|NCT04352114|Placebo Comparator|Placebo - SC|Placebo administered SC.
32910044|NCT04352114|Experimental|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
32910045|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
32910046|NCT01186250|Placebo Comparator|Placebo|Placebo
33396064|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
33396065|NCT02440438|Experimental|Clostridium difficile infection|
32910047|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
32910048|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
33239472|NCT04211259|Experimental|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
33239473|NCT04211259|Placebo Comparator|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
33239474|NCT03490812|Experimental|Prospective population|
33239475|NCT03490812|Experimental|Retrospective population|
33239476|NCT05674032||Cases|In-patients with AP or cUTI admitted for treatment to the hospital.
32744763|NCT04867239|Other|A two-day education program|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise for metabolic syndrome. Participants visited at 3- and 6-month after camp for follow-up.
32744764|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
33239477|NCT05674032||Control group 1|Out-patients seeking treatment for uncomplicated acute cystitis.
33239478|NCT05674032||Control group 2|In-patients admitted to the ward without signs and symptoms of a urinary tract infection and with a negative urine culture result.
33239480|NCT03650712|Other|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
33239481|NCT03650712|Other|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
33239482|NCT03650712|Other|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
33239483|NCT03650712|Other|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
33239484|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
32744475|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
32744765|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
32744766|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
32744767|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
32910049|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
32910050|NCT04743375|Experimental|Sericin dressing with collagen|Sericin dressing with collagen
32910051|NCT04743375|Active Comparator|Bactigras|Commercial dressing
32910052|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
32910053|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
32910054|NCT02504619|Experimental|CordIn|Transplantation of CordIn
32910055|NCT04431843|Experimental|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
32910056|NCT04431843|Placebo Comparator|Placebo|Spirulina maxima extract for 0 g/day
33239485|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
32910057|NCT04431765|Active Comparator|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
32910058|NCT04431765|Placebo Comparator|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
32910059|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
32910060|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
32910061|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
32910062|NCT04430049||no visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
32910063|NCT04430049||restrictive visitation group|relatives have restriction to visit ICU patient during Covid pandemic period in France
32910064|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
32910065|NCT05455710|Experimental|VigiApp|"the intervention group, which will use the mobile application to detect SSI, which has interoperability with the hospital's hospital infection control service information system. The Vigi-App application will be installed on the Smartphone of the selected patients, who will receive training on how to use the application; should access it on days seven, 14, 21 and 30 after the surgical procedure, they will additionally be evaluated in person in an outpatient consultation, according to the hospital routine.~The patients in the intervention group will receive notices the day before, through reminders issued by the application, reminding them that they must access and complete the requested information. If the patient presents signs and symptoms of infection on dates other than filling out the application, he can access the application and send his data normally as an extra access."
32910066|NCT05455710|Sham Comparator|telephone call|the called control, consisting of the standard infection surgical site post-discharge surveillance the developed infection of the surgical site procedure, by means of a telephone call. You will receive guidance on phone calls; will follow the standard SSI post-discharge surveillance procedure, by means of a telephone call on days seven, 14, 21 and 30 after the date of surgery, being asked about the presence of signs and symptoms of infection according to the instrument previously validated in previous investigation and will be evaluated in person in an outpatient consultation, according to the hospital routine.
32910067|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
32910068|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
32910069|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
32910070|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
33239486|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
33239487|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
33239488|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
32744476|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
32744477|NCT03228485||MyBPH Care|All patients enrolled in this study.
32744478|NCT04864197|Experimental|prf group|prf membrane placement over implant site for gingival thickening
32744479|NCT04864197|Experimental|control group|no prf placement
33072512|NCT05000216|Experimental|Cohort B, Arm B2: BNT162b2 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32744480|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
32744481|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
32744482|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
32744483|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
32744484|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
32744485|NCT04864509|Active Comparator|Melatonin 10mg|Nightly oral dose
32910071|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
32910072|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
32910073|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
32910074|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
32744486|NCT04864509|Placebo Comparator|Placebo|nightly oral dose
32744487|NCT04864353|Experimental|Experimental: Intervention|Participants will after baseline receive a guided intervention with weekly therapist support.
32910075|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
32744488|NCT04864353|No Intervention|Control: Waitlist|Participants will not receive intervention until 7 weeks after baseline.
33396066|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
32744489|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
32910076|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
32754388|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
33396067|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
33396068|NCT03191110||Colorectal cancer patients|
33396069|NCT02431312|Experimental|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
33396070|NCT02431312|Experimental|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
32754389|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
32754390|NCT05129683|Experimental|Anodal tDCS cerebellar stimulation group:|Anodal tDCS cerebellar stimulation
32754391|NCT05129683|Experimental|Anodal tDCS cerebral (M1) stimulation group:|Anodal tDCS cerebral (M1) stimulation
32754392|NCT05129683|Sham Comparator|Sham Group|Sham: Single-session a-tDCS (2 mA, 20 min),
32754393|NCT03576443|Experimental|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
32910077|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
32910078|NCT04423029|Experimental|Monotherapy Dose Escalation|
32910079|NCT04423029|Experimental|Monotherapy Dose Expansion (Melanoma)|
32910080|NCT04423029|Experimental|Monotherapy Dose Expansion (NSCLC)|
33396071|NCT02431312|Experimental|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
32910081|NCT04423029|Experimental|Combination Dose Escalation|
32910082|NCT04423029|Experimental|Combination Dose Expansion (Melanoma)|
32910083|NCT04423029|Experimental|Combination Dose Expansion (NSCLC)|
32910084|NCT01186562|Active Comparator|Sitagliptin|
32910085|NCT01186562|Placebo Comparator|Placebo|
32754394|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
32754395|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
32754396|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
32754397|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
32754398|NCT03336671|Active Comparator|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
32754399|NCT03336671|Experimental|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
33396072|NCT02431312|Experimental|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
32754400|NCT04667572|Experimental|Pulsed 5mW/cm2|5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
32754401|NCT04667572|Experimental|Pulsed 8mW/cm2|8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time
32754402|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
32754403|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
32754404|NCT04438733|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
32754405|NCT04438733|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
32754406|NCT04438811|Other|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
32754407|NCT04438811|Other|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
32754408|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml~medical treatment : Sandostatin (Octreotide Acetate)"
32754409|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
32754410|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation~and IGF-1 <600ng/ml"
32754411|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.~Participant to take 5 mg oral prednisone, twice daily."
32754412|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
32754413|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
32754414|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
32754415|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
32754416|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.~The control intervention focuses on job skills development."
32754417|NCT05387603|Experimental|177Lu-DOTATOC + Capecitabine|"Patients with 68Ga-DOTA- and 18F-FDG-PET-positive NET will receive a combination of intravenous 7.5 GBG (gigabequerel) 177Lu-DOTATOC for about 7 cycles in combination with capecitabine (4 cycles, cycle length 3 weeks, with one week without capecitabine, dosing 825 mg twice daily) and PRRT to a cumulative renal AD (absorbed dose) limit of 30 Gy and dosimetry-based PRRT.~."
32754418|NCT05387603|Experimental|177Lu-DOTATOC|Intravenous infusion for about 7 treatment cycles with 7.5 GBq 177Lu-DOTATOC with an interval of 10 ± 2 weeks and PRRT to a cumulative renal AD limit of 30 Gy and dosimetry-based PRRT.
32754419|NCT05387603|Active Comparator|Standard 177Lu-DOTATOC|Standard treatment of 177Lu-DOTATOC with treatment for 4 cycles.
32754420|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
32754421|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
32754422|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
32754423|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
32754424|NCT03430115||Control|This group was randomized and previously assigned to control.
32910086|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
32744490|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
32744491|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
32910087|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
32910088|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
32754425|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
32754426|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
32754427|NCT03306173|Experimental|Ventilated cigarettes|Participants in this ARM will be assigned to ~25% filter ventilation commercially available cigarettes.
32754428|NCT03306173|Experimental|Unventilated cigarettes|Participants in this ARM will be assigned to ~0% filter ventilation commercially available cigarettes.
32754429|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
32754430|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
32754431|NCT03182413|Placebo Comparator|PBO|Placebo
32754432|NCT03182413|Active Comparator|MOD|Modafinil 100mg
32754433|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
32754434|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
32754435|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
32754436|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
32754437|NCT02430649|No Intervention|Control|The patients without treatment
32754438|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
32910089|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
32754439|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
32754440|NCT03166631|Experimental|Part A|BI 891065 alone (Solid Tumours)
32754441|NCT03166631|Experimental|Part B|BI 891065 in combination with BI 754091 (Solid Tumours)
32754442|NCT03166631|Experimental|Part C|BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
32754443|NCT05117827|Experimental|Power Wheelchair Standing Device User|
32754444|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
32754445|NCT02980367|Experimental|ACL Rehabilitation Group|Non-surgical management [Rehabilitation] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
32754446|NCT02980367|Active Comparator|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
32754447|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
32754448|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
32754449|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
32754450|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
32754451|NCT02507765|Experimental|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
32754452|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
32754453|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
32754454|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
32754455|NCT03183817|No Intervention|Usual Care|Evidence-based care
32754456|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
32754457|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
32754458|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
32754459|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
32754460|NCT02862119|Experimental|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of >0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
32910090|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
33396073|NCT02431312|Experimental|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
32910091|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
32754461|NCT02862119|Active Comparator|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
32754462|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
32754463|NCT05080361||Reports of adverse events associated with the use of BRAF +/- MEK inhibitors|"Reports of adverse event (individual case safety reports) from Vigibase, the World Health Organization pharmacovigilance database related to the use of BRAF +/- MEK inhibitors from inception (1986) until March, 1, 2021 will be extracted.~Cases concurrently reporting on immune checkpoint inhibitor therapies will be excluded."
32754464|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
32754465|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
32754466|NCT05080205|Experimental|Morbidly obese subjects|Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)
32754467|NCT05080205|No Intervention|Control subjects|Non-obese controls are only studied at baseline
32754468|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
32754469|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
32754470|NCT02741141|Active Comparator|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
32754471|NCT02741141|Experimental|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
32754472|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
32754473|NCT05079971|Active Comparator|Group A is a control group with aEEG monitoring only, and with retrospective cEEG review|
32754474|NCT05079971|Experimental|Group B is undergoing aEEG monitoring with concurrent full EEG review|
32754475|NCT02616263|Experimental|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
32754476|NCT02616263|Active Comparator|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
32754477|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
32754478|NCT02544035|Experimental|1|6-11 month-olds
32754479|NCT02544035|Experimental|10|36-71 month-olds (1.5-2 year olds)
32754480|NCT02544035|Experimental|11|72-107 month-olds (6-8 year-olds)
32754481|NCT02544035|Experimental|12|108-144 month-olds (9-12 year-olds)
32754482|NCT02544035|Experimental|2|12-18 month-olds (1-1.5 year olds)
32754483|NCT02544035|Experimental|3|19-35 month-olds (1.5-2 year-olds)
32754484|NCT02544035|Experimental|4|36-71 month-olds (3-5 year-olds)
32754485|NCT02544035|Experimental|5|72-107 month-olds (6-8 year-olds)
32754486|NCT02544035|Experimental|6|108-144 month-olds (9-12 year-olds)
32754487|NCT02544035|Experimental|7|6-11 month-olds
32754488|NCT02544035|Experimental|8|12-18 month-olds (1-1.5 year olds)
32754489|NCT02544035|Experimental|9|19-35 month-olds (1.5-2 year olds)
32754490|NCT02426905|No Intervention|Retrospective|
32754491|NCT02426905|Other|Prospective|
32754492|NCT05079893||Cases|The cases will be the patients suffering from low back pain for at least three months and referred by an orthopedic doctor or general physician.
32754493|NCT05079893||Controls|The controls will be the patients matched for age, sex, handedness who had no complaints of lower back pain
32754494|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
32754495|NCT05079737||Subjects with Fitzpatrick Skin Type I-III|Subjects 21 years of age or older with Fitzpatrick Skin Type I-III will be enrolled and analyzed by age.
32754496|NCT05079737||Subjects with Fitzpatrick Skin Type IV-VII|Subjects 21 years of age or older with Fitzpatrick Skin Type IV-VII will be enrolled and analyzed by age.
32754497|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
32910092|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
32910093|NCT01147406|Experimental|Active|N6022
32910094|NCT01147406|Placebo Comparator|Placebo|Placebo
32910095|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
32910096|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
32910097|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
32910098|NCT04375124|No Intervention|non-peptide group|This group will receive routine treatment and care for COVID-19.
32910099|NCT04375124|Active Comparator|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
32910100|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
32910101|NCT03012698|Experimental|RMS treatment|
32910102|NCT04352348|Other|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
32910103|NCT04352348|Other|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
32910104|NCT04352348|Other|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
32910105|NCT04352348|Other|Follow-up after COVID-19 hospitalization|"Patients previously hospitalized for COVID-19 infection but not recruited for the study can be recruited during a follow-up visit in hospital scheduled in standard care at 3 to 6 months after the hospitalization.~For this arm, T0 = 3 to 6 months post-COVID-19 follow-up visit"
32910106|NCT01150760||Alvimopan Users|
32910107|NCT01150760||Matched controls|
32910108|NCT01150838|Experimental|Propofol administration|"For each of the 6 groups, propofol 2 mg/kg will be administered to first subject. The propofol dose will move separately for each of the 6 groups, and be increased by 0.3 mg/kg for the next subject if intubation score is not excellent and decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued until there are 6 crossovers as described above."
32910109|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
33396074|NCT02431312|Active Comparator|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
33396075|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
33396076|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
33396077|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
33396078|NCT02709538|Experimental|GSP 301 NS|
33396079|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
33396080|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
32754498|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
32754499|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
32754500|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
32910110|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
32910111|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
32910112|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
32744492|NCT04863963||Milligan Morgan|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Milligan-Morgan hemorrhoidectomy surgery.
32910113|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
32910114|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
32910115|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
32910116|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
33396081|NCT03789318|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (CA-008 5 mg): the surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
33396082|NCT03789318|Placebo Comparator|Placebo for Cohort 1|"Cohort 1:~Placebo comparator is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
33396083|NCT03789318|Active Comparator|CA-008 10 mg (0.1 mg/mL)|Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
33396084|NCT03789318|Active Comparator|CA-008 15 mg (0.15 mg/mL)|Cohort 3 (CA-008 15 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
32744493|NCT04863963||Dearterialization with mucopexy|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy
32744494|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
32910117|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
32910118|NCT04352504|Experimental|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
32910119|NCT04352504|Active Comparator|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
32744495|NCT04864041||Patients hospitalised in ICU for vaso-occlusive crisis|
32910120|NCT04187378|No Intervention|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
32754501|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
32754502|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
32754503|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
32754504|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
32754505|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
32754506|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
33396085|NCT03789318|Placebo Comparator|Placebo for Cohorts 2 and 3|"Cohorts 2 & 3:~Placebo comparator in each cohort is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
33396086|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
33396087|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
33396088|NCT05226468|Experimental|NEI-01|Single Arm
33396089|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy~Biopsy at the visually abnormal lesions~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
33396090|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy~Biopsy at the unstained lesions >= 5 mm diameter~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
33396091|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
33396092|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
33396093|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.~This is a prospective observational cohort study."
32754507|NCT03142997||group S|anesthetized children on spontaneous ventilation.
32754508|NCT03142997||group C|anesthetized children on controlled ventilation.
32754509|NCT02389517|Experimental|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
32754510|NCT02389517|Active Comparator|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
32754511|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
32754512|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
32754513|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
32754514|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
32754515|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
32754516|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
32754517|NCT02424877|Experimental|SandRA|cell phone monitoring
32754518|NCT02424877|No Intervention|Control|conventional monitoring
32754519|NCT05079503|Experimental|TNT plus GEN-001|Total neoadjuvant therapy (TNT) includes short-course radiotherapy (25 Gy/5fx), followed by systemic chemotherapy with FOLFOX regimen for 3-6 months. GEN-001 is orally administered once daily during total TNT periods and surgery will be performed 1 month after systemic chemotherapy.
32754520|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
32754521|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
32754522|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
32910121|NCT04187378|Experimental|Underbody Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
33396094|NCT05212428|Experimental|Screening (biospecimen collection, genetic analysis)|Participants receive a saliva kit, register with Helix then undergo collection of saliva sample which is returned o Helix. Participants also receive an online link to complete the About Me family history. Once sequencing is completed by Helix, ancestry/trait information and genetic findings are shared with participants and their primary provider, if applicable. Participants with positive results are offered genetic counseling and are encouraged to seek clinical confirmatory testing. Following clinical confirmation, results are scanned into the electronic health record. Participants may also undergo the collection of blood, urine, and stool samples for future studies.
32754523|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
32754524|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
32754525|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
32754526|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
32754527|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
32754528|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
33396095|NCT03191188|Experimental|Levothyroxine|
32754529|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
32754530|NCT02426827|Experimental|SCS in CV|
32754531|NCT05078801||Endoscopic drainage|All patients with perihilar malignant biliary obstruction treated with endoscopic drainage. This drainage can be multimodal using endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS)-guided biliary drainage.
32754532|NCT05078801||Radiologic percutaneous drainage|All patients with perihilar malignant biliary obstruction treated with percutaneous drainage
32754533|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
32754534|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
32754535|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
33396096|NCT03191188|Placebo Comparator|Placebo|
33396097|NCT04518410|Experimental|Bamlanivimab 7000 mg (Phase 2)|Administered by IV infusion.
33396098|NCT04518410|Placebo Comparator|Bamlanivimab 7000mg Placebo (Phase 2)|Administered by IV infusion
33396099|NCT04518410|Experimental|Bamlanivimab 700mg (Phase 2)|Administered by IV infusion
33396100|NCT04518410|Placebo Comparator|Bamlanivimab 700mg Placebo (Phase 2)|Administered by IV infusion
33396101|NCT04518410|Experimental|Bamlanivimab 700mg (Phase 3)|Administered by IV infusion
33396102|NCT04518410|Experimental|BRII-196+BRII-198 (Phase 2)|Administered by IV infusion
33396103|NCT04518410|Placebo Comparator|BRII-196+BRII-198 Placebo (Phase 2)|Administered by IV infusion
33396104|NCT04518410|Experimental|BRII-196+BRII-198 (Pooled Phase 2/3)|Administered by IV infusion
33396105|NCT04518410|Placebo Comparator|BRII-196+BRII-198 Placebo (Pooled Phase 2/3)|Administered by IV infusion
33396106|NCT04518410|Experimental|AZD7442 (IV) (Phase 2)|Administered by IV infusion
33396107|NCT04518410|Placebo Comparator|AZD7442 (IV) Placebo (Phase 2)|Administered by IV infusion; shared placebo includes AZD7442 (IM) placebo and placebo from other comparator arms in the study.
33396108|NCT04518410|Experimental|AZD7442 (IM) (Phase 2)|Administered by IM injection
33396109|NCT04518410|Placebo Comparator|AZD7442 (IM) Placebo (Phase 2)|Administered by IM injection; shared placebo includes AZD7442 (IV) placebo and placebo from other comparator arms in the study.
32754536|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
32754537|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
32754538|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
32754539|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
32754540|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
32754541|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
32754542|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
32754543|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
33071363|NCT05786313|Experimental|3D printed arch titanium plate|Before surgery, according to the imaging results, according to the effective imaging indicators screened in the early stage and the calculated door opening Angle formula, the door opening Angle of the patient's posterior cervical vertebra and the size of the fitted arch titanium plate were designed by mimics 10.0 software, and the titanium plate was printed using 3D printing technology. During the operation, the developed laminae opener was used to accurately control the door opening Angle and appropriate size titanium plate was installed for internal fixation. The standardized laminae door opening guide was used to complete the preparation of the door shaft side and door opening side of the lamina
33239489|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
33239490|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
33239491|NCT05673954||Case group|Patients with primary open angle glaucoma
32754544|NCT05653505||Endovascular therapy|According to current guideline recommendations, patients enrolled in this cohort will receive standardized perioperative management, endovascular therapy, and postoperative medical therapy.
33239492|NCT05673954||Control group|Healthy people
32754545|NCT05653505||Endovascular therapy+Remote ischemic conditioning|"Patients enrolled in this cohort will receive the same treatment as those in the endovascular therapy alone cohort as well as additional remote ischemic conditioning treatment.~Remote ischemic conditioning treatment protocol: RIC will be applied immediately after admission to the integrated neurovascular ward and the treatment continues until the patient is discharged, Once the patient is discharged, the choice of whether to continue RIC treatment depends on the patient's preference. RIC was induced through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 5 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure), and 5 minutes of deflation twice a day."
32754546|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
32754547|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
33396110|NCT04518410|Experimental|SNG001 (Phase 2)|Administered by inhalation
32754548|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
32754549|NCT05078645|Other|Group 1: Maya use on 1st, 3th and 5th day|Group 1 uses the Maya on the 1st, 3th and 5th day and not on the 2nd, 4th and 6th day of their admission to either the ICU, MC or CCU.
32754550|NCT05078645|Other|Group 2: Maya use on the 2nd, 4th, and 6th day|Group 2 uses the Maya on the 2nd, 4th and 6th day and not on the 1st, 3th, and 5th day of their admission to either the ICU, MC or CCU.
32754551|NCT02426593||Subjects without heart failure|
32754552|NCT05078567|Experimental|Single arm open label study|Topical used natural lactic acid-enriched cream twice daily.
32754553|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
32754554|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
32754555|NCT05081765||Patients with diabetes mellitus|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
32754556|NCT05081765||Patients with hyperglycemia,|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
32754557|NCT05081765||Patient with normal glucose level|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
32754558|NCT04482829|Experimental|Experimental Group|On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
32754559|NCT04482829|Other|Control Group|All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
32754560|NCT02426359|Experimental|Q301 Cream|Q301 Cream
32754561|NCT02426359|Placebo Comparator|Vehicle|Vehicle
32754562|NCT05078177|Experimental|AHSCT + intrathecal Rituximab|AHSCT with reduced intensity condition regimen (RIC). Lumbar puncture with intrathecal injection of 25 mg Rituximab will be performed once from about D+12 to D+14 AHSCT, depending on the duration of cytopenia.
32754563|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
32754564|NCT03183427||Control group|Group of subjects without pineal cyst
32754565|NCT05081687|Experimental|Total neoadjuvant therapy (TNT)|"4 cycles of mFOLFIRINOX every 14 days:~Oxaliplatin 85 mg/m2~Irinotecan 150mg/m2~5-FU 2.400mg/m2~Dexamethasone 12mg~Atropine 0.5mg~Netupitant/palonosetron"
32754566|NCT05081687|No Intervention|Standard of care|Standard post-radiation care
32754567|NCT05387369||Paxlovid|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
32754568|NCT05387369||Routine therapy|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid
32754569|NCT05387213|Experimental|Huddle attendees|Participants in this arm participated in huddles
32754570|NCT05387213|No Intervention|Huddle non-attendees|Participants in this arm did not participate in huddles
32754571|NCT05387135|Sham Comparator|sham Transcutaneous Vagus Nerve Stimulation|For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used.
32901469|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
32901470|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
32910122|NCT04187378|Experimental|Surgical Access Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
33396111|NCT04518410|Placebo Comparator|SNG001 Placebo (Phase 2)|Administered by inhalation; shared placebo includes placebo from other comparator arms in the study.
33396112|NCT04518410|Experimental|Camostat (Phase 2)|Administered as oral tablets
33396113|NCT04518410|Placebo Comparator|Camostat Placebo (Phase 2)|Administered as oral tablets; shared placebo includes placebo from other comparator arms in the study.
33071364|NCT05786300|Experimental|Treatment Group|"The Treatment Group will follow the rehabilitation protocol with the addition of the Neuromuscular Electrical Stimulation Superimposed onto Movement (NMES+).~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz"
33396114|NCT04518410|Experimental|SAB-185 (low dose) (Phase 2)|Administered by IV infusion
32910123|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
33071365|NCT05786300|Active Comparator|Control Group|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
33071366|NCT05786287||Conditioned Medium (CM)|2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell injected into peribulbar
32910124|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
33396115|NCT04518410|Placebo Comparator|SAB-185 (low dose) Placebo|Administered by IV infusion; includes SAB-185 (high dose) and placebo from other comparator arms in the study.
33396116|NCT04518410|Experimental|SAB-185 (low dose) (Phase 3)|Administered by IV infusion
33396117|NCT04518410|Active Comparator|Casirivimab and Imdevimab (Phase 3)|Administered by IV infusion
33396118|NCT04518410|Experimental|SAB-185 (high dose) (Phase 2)|Administered by IV infusion
33396119|NCT04518410|Placebo Comparator|SAB-185 (high dose) Placebo|Administered by IV infusion; includes SAB-185 (low dose) and placebo from other comparator arms in the study.
33396120|NCT04518410|Experimental|BMS 986414+BMS 986413 (Phase 2)|Administered as subcutaneous (SC) injections
33396121|NCT04518410|Placebo Comparator|BMS 986414+BMS 986413 Placebo (Phase 2)|Administered as subcutaneous (SC) injections; shared placebo includes placebo from other comparator arms in the study.
33396122|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
33396123|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
33239493|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
33239494|NCT04972968|Experimental|ABBV-154 Dose A|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
33239495|NCT04972968|Experimental|ABBV-154 Dose B|Participants in this group will receive dose B of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
33239496|NCT04972968|Experimental|ABBV-154 Dose C|Participants in this group will receive dose C of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
33239497|NCT04972968|Placebo Comparator|Placebo|Participants will receive placebo SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
33396124|NCT03613662|Experimental|SP-102|SP-102
32910125|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
32910126|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
33396125|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
32910127|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
32910128|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
32901471|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
32901472|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
32901473|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
32901474|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
32901475|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
32901476|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
32754572|NCT05387135|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM) made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz.
32754573|NCT05080985|Experimental|Group P : TPVB|Thoracic paravertebral block
32754574|NCT05080985|Experimental|Group E : ESPB|Erector spinae plane block
32754575|NCT05275205|Experimental|UBX1325|
32754576|NCT05275205|Active Comparator|Aflibercept (EYLEA ®)|
32754577|NCT05080829|Experimental|Mutation Register|Measure of myeloid mutations after detection of relapse or refractoriness to ITK treatment
33396126|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
33396127|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
32754578|NCT05267639|No Intervention|Comparator Baseline|The subject will wear their usual Microprocessor Knee (MPK) for 3 months, as well as in the lab to complete outcome measures.
32754579|NCT05267639|Experimental|Power Knee|The subject will wear the Ossur PK in place of their usual MPK for 3 months, as well as in the lab to complete outcome measures.
32754580|NCT05258591|Experimental|Axem Home|Patients receive at-home access to Axem Home system for duration of the study period.
32754581|NCT05258357|Active Comparator|Landmark|For a landmark bone marrow biopsy procedure, the patient is first positioned either prone or lateral decubitus. The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
32754582|NCT05258357|Experimental|Ultrasound-Assisted|"After the usual landmark technique is performed and the potential site has been marked, procedure team physician will use the ultrasound machine to fine tune the drill site location."
33396128|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
32754583|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
32754584|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
32754585|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
32754586|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the short term|3 patients biopsied 3-5 weeks post implantation of ProFlor
32754587|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the midterm|5 patients biopsied 3-4 months post implantation of ProFlor
32754588|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the long term|4 patients biopsied between 3-4 months post implantation of ProFlor
32754589|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the extra long term|3 patients biopsied more than 3 years after implantation of ProFlor
32754590|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
32754591|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
32754592|NCT04976387|Experimental|Group 1: Hydrocodone/Acetaminophen and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
32754593|NCT04976387|Experimental|Group 2: Ibuprofen and Hydrocodone/acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
32754594|NCT04976387|Experimental|Group 3: Ibuprofen and Acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Acetaminophen 650mg every 6 hours as needed for additional pain control."
32754595|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
32754596|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
32754597|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
32754598|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
32754599|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
32754600|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
33396129|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
33396130|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
33396131|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
33396132|NCT05160090|Active Comparator|Test- BUPROPION HCl MR TABLETS 300mg|Single dose of Test- BUPROPION HCl MR TABLETS 300mg
33396133|NCT05160090|Active Comparator|Reference-Elontril 300 mg|Elontril 300 mg (Bupropion HCl MR tablets 300mg)
33396134|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
33396135|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
33396136|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
33396137|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
33396138|NCT05144308|Experimental|Patients operated with a TECNIS® Eyhance Toric II 1-piece posterior chamber lens|For at least one eye : Planned cataract surgery with placement of a TECNIS® Eyhance Toric II 1-piece posterior chamber lens
33396139|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
33396140|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
33396141|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
33396142|NCT04332692|Experimental|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
33396143|NCT00695214|Other|1|OSA Patients considering surgical treatment
33396144|NCT05121376|Experimental|BMN 331|AAV Gene Therapy Infusion
32754601|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
32910129|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
33239498|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
33239499|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
33239500|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
32910130|NCT01191320|Placebo Comparator|Placebo|Placebo
33396145|NCT04516616|Experimental|Study group|Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.
32910131|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
32910132|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
33396146|NCT04322318|Experimental|Arm I (Regimen UH-3)|See outline in detailed description section.
32754602|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
32754603|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
33396147|NCT04322318|Experimental|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery and/or RT during cycles 4, 7, and 10 as clinically indicated. Patients undergo a CT scan, a PET scan, a chest x-ray, MRI, an abdominal ultrasound, and/or a bone scan throughout the trial. Patients may also undergo blood specimen collection and biopsy throughout the trial."
33396148|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
32901477|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
33396149|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
33396150|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
33396151|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
33396152|NCT02435134||Healthy participants|
33396153|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
33396154|NCT03634722|No Intervention|The observational group|routine nursing
33396155|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
33396156|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
33396157|NCT01372956||Dyslipidemia|
33396158|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
33396159|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
33396160|NCT05103228|Experimental|Lower gonadotropin dose stimulation|"Low-dose group:~150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)~10 mcg follitropin delta + 75 IU hpHMG"
33396161|NCT05103228|Experimental|Higher gonadotropin dose stimulation|"High-dose group:~225 IU follitropin alpha + 150 IU highly purified human menopausal gonadotropin (hpHMG)~15 mcg follitropin delta + 150 IU hpHMG"
33396162|NCT01372384|Experimental|Single Arm|
33396163|NCT05082480|Experimental|Hyaluronic acid (HA)|Hyaluronic acid (HA)
33396164|NCT05082480|Placebo Comparator|Saline|Saline
33396165|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
33396166|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
33396167|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
33396168|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
33396169|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
33396170|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
33396171|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
33396172|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
33396173|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
33396174|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
33396175|NCT03115476|Placebo Comparator|Vehicle gel|
33396176|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
33396177|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
32901478|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
33396178|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
32901479|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
32901480|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
33396179|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
33396180|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
33396181|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
33396182|NCT04506320||Patients with Multiple myeloma|Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
33396183|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
33396184|NCT02434978|Placebo Comparator|control group|
33396185|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
33396186|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
33396187|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
33396188|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
33396189|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
33396190|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
33396191|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
33396192|NCT02434666|Experimental|CPC-201|
33396193|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
33396194|NCT05048160|Experimental|6MW3211|"Dosage form: injection~Specification: 240 mg / 8 ml/Vial"
33396195|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
33396196|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
33396197|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
33396198|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
33396199|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
33396200|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
33396201|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
33396202|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
33396203|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
33396204|NCT02434588|Experimental|Bhattacharjee ring|
32901481|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
32901482|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
33396205|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
33396206|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
33071367|NCT05786287||UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension injected into peribulbar
33071368|NCT05786287||UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension injected into peribulbar
33072513|NCT05000216|Experimental|Cohort B, Arm B3: Ad26.COV2.S + Continue IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33239501|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
33396207|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
33072514|NCT05000216|Experimental|Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX)|Adult Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
33396208|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
33396209|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
33396210|NCT04223804|Placebo Comparator|Stage 1: Arm A|Participants will receive placebo.
33396211|NCT04223804|Experimental|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
33396212|NCT04223804|Experimental|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
33396213|NCT04223804|Placebo Comparator|Stage 2: Arm D|Participants will receive Placebo.
33396214|NCT04223804|Experimental|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
33396215|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
33396216|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
33396217|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
33396218|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
33396219|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
33396220|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
33396221|NCT02430766|No Intervention|Control|The patients without treatment
33396222|NCT03700502||patients with painful diabetic neuropathy|
33396223|NCT03700502||diabetics with non-pain neuropathy|
33396224|NCT03700502||gender and age matched healthy controls|
33396225|NCT03123120|Experimental|Spesolimab|1200 milligrams (mg) of Spesolimab (BI 655130) were administered every 4 weeks (q4w) via intravenous infusion over 12 weeks of treatment (3 injections of Spesolimab 1200 mg in total during the 12 weeks: at Week 0, 4, and 8 respectively).
33396226|NCT03123120|Placebo Comparator|Placebo|Matching placebo was administered via intravenous infusion over 12 weeks of treatment.
33396227|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
33396228|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
33396229|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
33396230|NCT02430688|No Intervention|Control|The patients without treatment
33396231|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
33396232|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
33396233|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
33396234|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
33396235|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
33396236|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
33396237|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
33396238|NCT03692832|Experimental|Group L|40 patients undergoing laparoscopic hysterectomy
33396239|NCT03692832|Active Comparator|Group V|40 patients undergoing vaginal hysterectomy
32910133|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
33396240|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
33072515|NCT05000216|Experimental|Cohort B, Arm B5: BNT162b2 + Withhold IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
33396241|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
32754604|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
33396242|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
33396243|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~*No individual participants are recruited for this study."
33396244|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
33396245|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
33396246|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
33396247|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
33396248|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
33396249|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
33396250|NCT01319994|Experimental|Metformin|Metformin 850mg TDS (12 weeks)
33396251|NCT01319994|Placebo Comparator|Placebo|Placebo 850mg TDS (12 weeks)
33396252|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
33396253|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
33396254|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
33396255|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
33396256|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
33396257|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
33396258|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
33396259|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
33396260|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
33396261|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
33396262|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
33396263|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
33396264|NCT01373034|Experimental|Soy Dietary Fiber|
33396265|NCT01373034|Placebo Comparator|Rice powder|
33396266|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
33396267|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
33396268|NCT05631613||Water for Injection -Idarubicin -Lipiodol|"Idarubicin is first dissolved in water for injection to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
33396269|NCT05631613||Nonionic Contrast Agent -Idarubicin -Lipiodol|"Idarubicin is first dissolved in nonionic contrast agent to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
33396270|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
33396271|NCT05007522|Experimental|Study Drug|Ketotifen 2 mg administered in tablet form twice a day (every 12 hr). Indomethacin sustained-release (SR) 75 mg, twice a day (every 12 hr). Patients will be administered 28 doses in total of ketotifen/indomethacin combination.
33396272|NCT05007522|Placebo Comparator|Placebo|Placebo pills matching in appearance to study drug twice a day for 28 doses total.
33396273|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
33396274|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
33396275|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
32910134|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
33396276|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
33396277|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
33396278|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
33396279|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
32754605|NCT05095649|Experimental|Regulatory T-cell enriched infusion|The doses of Regulatory T-cell enriched infusion will be 2x10^6 cells/kg
32754606|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
33396280|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
33396281|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
32754607|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
32754608|NCT04665557|Experimental|Dove Confident Me Indonesia - Single Session|Dove Confident Me Indonesia Single Session is school-based, body image curriculum.
32754609|NCT04665557|No Intervention|Lessons As Usual Control|School lessons as usual.
33396282|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
32754610|NCT04587245||Physicians|Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients
32754611|NCT05092061|Experimental|Moderate-repetition resistance training|The participants will undergo a full-body resistance training protocol with moderate repetitions (6-12), moderate load (70-85% of 1RM), and moderate rest between sets (60-90s). Training will be undertaken three times per week.
32754612|NCT05092061|Experimental|High-repetition resistance training|The participants will undergo a full-body resistance training protocol with high repetitions (15+), low load (<60% of 1RM), and short rest between sets (30s). Training will be undertaken three times per week.
32754613|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
33396283|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
33396284|NCT03189160|No Intervention|Non-treatment control group|
33396285|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
33396286|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
33396287|NCT03718507|Active Comparator|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
33396288|NCT03718507|Experimental|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
32754614|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
32754615|NCT04566185||Patients with recurrent glioblastoma|
32754616|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
32754617|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
32754618|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
32901483|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
32901484|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
33396289|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
33396290|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
33396291|NCT03188692|Experimental|BK1310|
33396292|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
33396293|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
33396294|NCT04940832|Active Comparator|radiofrequency with corticosteroids|corticosteroids- 80mg depo-medrol Pulsed radiofrequency to 42 derees celsius for 6 minutes
33396295|NCT04940832|Active Comparator|radiofrequency without corticosteroids|Pulsed radiofrequency to 42 derees celsius for 6 minutes
33396296|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
33396297|NCT02430610|No Intervention|Control|The patients without treatment
33396298|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
33396299|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
32901485|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
33396300|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
33396301|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
33396302|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
33396303|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
33396304|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
33396305|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
33396306|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
33396307|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
33396308|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
33396309|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
33396310|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
33396311|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
33396312|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
33396313|NCT03453151|Experimental|Regional nerve anesthesia|
33396314|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
33396315|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
33396316|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
33396317|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
33396318|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
33396319|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
33396320|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
33396321|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
33396322|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
33396323|NCT03691688||Aspirin|Aspirin 100mg
33396324|NCT03691688||Clopidogrel|Clopidogrel 75mg
33396325|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
33396326|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
33396327|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
33396328|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
33396329|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
33396330|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
33396331|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
33396332|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
33396333|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
33396334|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
33396335|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
32754619|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
32754620|NCT04423601|Experimental|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then itraconazole capsules 200 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
33072516|NCT05000216|Experimental|Cohort B, Arm B6: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
33396336|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
33072517|NCT05000216|Experimental|Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33396337|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
33396338|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
33396339|NCT04482868|Placebo Comparator|open reduction group|
33396340|NCT04482868|Experimental|percutaneous group|
33396341|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
33396342|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
33396343|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
33396344|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
32754621|NCT04418141|Experimental|Single Arm|"Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.~Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle)."
32754622|NCT05022563||Parenteral anticoagulant only|LMWH, UFH
32754623|NCT05022563||Warfarin-based|Warfarin only + parenteral anticoagulant bridged warfarin
32754624|NCT05022563||NOAC-based|"NOAC only + parenteral anticoagulant bridged NOAC~NOAC: apixaban, rivaroxaban, dabigatran, edoxaban"
32754625|NCT04345991|Experimental|COVID-19 convalescent plasma|A plasma unit provided by a COVID-19 convalescent pathogen-reduced plasma will be used for the treatment of the patients.
32754626|NCT04345991|No Intervention|Control patients|Control patients will receive the best standard of care
32754627|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
32754628|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
32754629|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
32754630|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
32754631|NCT04085705||Patients with diabetic foot ulcers|All patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings.
32754632|NCT04983095|Active Comparator|Standard treatment|ADT and local RT to de novo patients
32754633|NCT04983095|Experimental|SBRT+Standard treatment|SBRT to all PSMA+ lesions in addition to ADT and local RT to de novo patients
32754634|NCT04902287|Experimental|TIES Engagement Strategies|Participants in this arm will receive a 30-minute TIES engagement intervention during their referral phone call.
32754635|NCT04902287|No Intervention|Referral as Usual|Participants in this arm will receive a standard call to schedule an intake appointment by an administrative assistant with no clinical training.
32754636|NCT04880759|Experimental|Bike desks in classroom|All participants receive the same intervention: the use of bike desks during school.
32754637|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
32754638|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
33072518|NCT05000216|Experimental|Cohort C, Arm C2: BNT162b2 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32754639|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
32754640|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
32754641|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
32754642|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
32754643|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
32754644|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
32754645|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
32754646|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
33396345|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
33396346|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
33396347|NCT04878510|Experimental|Dexmedetomidine Intervention|Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale [RASS] = -2 to +1 or Riker Sedation-Agitation Scale [SAS] 3-4).
33396348|NCT04878510|Placebo Comparator|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
33396349|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
33396350|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
33396351|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
33396352|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
33396353|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
33396354|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
33396355|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
32754647|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
32754648|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
32754649|NCT04877405||Intracerebral hemorraghe|Patients that suffered an intracerebral hemorraghe and that have been subjected to CT and MRI scans
33396356|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
33396357|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
33396358|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
33396359|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
33396360|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
33396361|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
33396362|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
33396363|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
33396364|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
33396365|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
33396366|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
33396367|NCT02800824|Experimental|Budesonide rectal foam|
33396368|NCT02800824|Active Comparator|Uceris rectal foam|
33396369|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
33396370|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
33396371|NCT04806360|Experimental|ACRF group|ACRF is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. Eligible patients in this group will receive ACRF surgery.
33396372|NCT04806360|Active Comparator|conventional anterior surgery group|Eligible patients in this group will receive conventional anterior surgery, including anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
33396373|NCT04806360|Active Comparator|conventional posterior surgery group|Eligible patients in this group will receive conventional posterior surgery, including laminectomy and fusion surgery or laminoplasty surgery.
33396374|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
33396375|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
33396376|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.~Subcutaneous injection"
33396377|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
33396378|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
33396379|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
33396380|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
33396381|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.~Name of each active substance (INN or proposed INN if available):~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
33396382|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
33396383|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
33396384|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
33396385|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
33396386|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
33396387|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
33396388|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
32754650|NCT03495479||OMN54 -Treated|Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
32754651|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
32754652|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
33239502|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
33239503|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
32754653|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
32754654|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
32754655|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
32754656|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
32898287|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
32910135|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
33072519|NCT05000216|Experimental|Cohort C, Arm C3: Ad26.COV2.S + Continue IS (B cell depletion therapy)|Arm closed, effective protocol version 3.0. Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32754657|NCT04870307|Other|Primary Care Practices|A practice-based implementation study will be conducted with 50 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members.
32754658|NCT04792931|Other|Adult Autoimmune Myopathies|It is a description Autoimmune Myopathie cohort
32754659|NCT02936687|Experimental|Metabolic Syndrome NOS Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
32754660|NCT02936687|Experimental|Metabolic Syndrome ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male subjects with MetSyn will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
32754661|NCT02936687|Experimental|Control NOS Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
32754662|NCT02936687|Experimental|Control ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male control subjects will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
32754663|NCT04728737|Experimental|combined swallowing and IOPI group|the patients will receive swallowing therapy and IOPI biofeedback exercise program
32754664|NCT04728737|Active Comparator|combined swallowing and NMES group|the patients will receive swallowing therapy and neuromuscular electrical stimulation
32754665|NCT04728737|No Intervention|Normal group|20 normal people will receive sonography evaluations to verify the inter-rater and intra-rater reliability of sonography, and use IOPI to assess maximal muscle strength and endurance of oropharyngeal muscles.
32754666|NCT04722809|Experimental|Symptomatic patients in the context of bruxism|
32754667|NCT04709861||Retrospective 6 week Weight-Bearing|Delayed weight-bearing 6 weeks after total ankle replacement
32754668|NCT04709861||Prospective 2 week Weight-Bearing|Early weight-bearing 2 weeks after total ankle replacement
32754669|NCT04654013|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
32754670|NCT04654013|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
32754671|NCT05083793|Experimental|Study group|patients have spine surgery receive oral pregabalin 150 mg 1 hour before surgery
32754672|NCT05083793|Placebo Comparator|Placebo group|patients will receive placebo 1 hour before surgery with a sip of water.
32754673|NCT04642079|Experimental|Cohort 1: =>15 through 23 months of age|20vPnC
32754674|NCT04642079|Experimental|Cohort 2: 2 through 4 years of age|20vPnC
32754675|NCT04642079|Experimental|Cohort 3: 5 through 9 years of age|20vPnC
32754676|NCT04642079|Experimental|Cohort 4: 10 through 17 years of age|20vPnC
32754677|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
32754678|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
32754679|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
32754680|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
32754681|NCT04525703|Experimental|Pathways for Parents|
32754682|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
32754683|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
32754684|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
32754685|NCT04415021|Experimental|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
32754686|NCT04415021|Sham Comparator|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
32754687|NCT04399967|Experimental|Intervention Group|Chat-based support+ COVID-19 specific advice + AWARD advice + COVID-related health warning leaflet + referral card + COSH booklet
32754688|NCT04399967|Experimental|Control Group|Text-based support + AWARD advice + warning leaflet + referral card + COSH booklet
32754689|NCT04332029|Experimental|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
32898288|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
32754690|NCT04332029|Active Comparator|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
32754691|NCT05083013||COVID-19 with DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
32754692|NCT05083013||COVID-19 without DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
32754693|NCT03140735|Other|Control group of 150 heart disease-free individuals|
32754694|NCT03140735|Other|Patients with aortic sclerosis|
32754695|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
32754696|NCT03140735|Other|Patients with Serious Aortic Retention|
32754697|NCT05082623|Experimental|Music group|"MusiCure® compositions specially composed for the music group will be performed twice a day, between 10.00-11.00 a.m. and 14.00-15.00 p.m., for five days with headphones and a music player. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the music application, at the 30th minute after starting the music, and at the 60th minute after the end of the music, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools."
32754698|NCT05082623|Active Comparator|Earplug group|In this group, patients will be given only earplugs. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the intervention, at the 30th minute after starting intervention, and at the 60th minute after the end of the intervention, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools.
32754699|NCT05082623|No Intervention|Control group|The control group involves neither music intervention nor using earplug.
32754700|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
32754701|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
32754702|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
32754703|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
32754704|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
32754705|NCT05073653|Other|68Ga-PSMA PET/CT Imaging|Injection of the radioligand 68Ga-PSMA; Device: PET/CT; Following injection of 68Ga-PSMA, the participants will be subjected to whole body PET/CT.
32754706|NCT05073653|Other|68Ga-GRP PET/CT Imaging|Injection of the radioligand 68Ga-GRP; Device: PET/CT; Following injection of 68Ga-GRP, the participants will be subjected to whole body PET/CT.
32754707|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
32754708|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
32754709|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
32754710|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
32754711|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
32754712|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
32754713|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
32754714|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
32898289|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
32898290|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
32898291|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
32901486|NCT01482715|Experimental|Part 1 (Phase 1)|Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond).
32910136|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
32910137|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
33072520|NCT05000216|Experimental|Cohort D, Arm D1: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
32910138|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
33396389|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
32754715|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
32754716|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
32754717|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
32754718|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
32754719|NCT05042141|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days
32754720|NCT05042141|Placebo Comparator|Placebo|Placebo, 3 capsules/time x 3 times/day x 14 days
32754721|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
32754722|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
32754723|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
32754724|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
32754725|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
32754726|NCT03117205|Experimental|Kinesio Taping® group|
32754727|NCT03117205|Placebo Comparator|placebo group|
32754728|NCT04065113|Experimental|Embolization Only|Medically managed patient receives middle meningeal artery embolization
32754729|NCT04065113|Experimental|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
32754730|NCT04065113|No Intervention|Medical Management|Historical control of medically managed patients
32754731|NCT04065113|Active Comparator|Surgical Patients|Historical control of patients receiving standard surgery alone
32754732|NCT03366155|Experimental|1/ Arm 1|HAIP chemotherapy + Systemic chemotherapy
32754733|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
32754734|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
32754735|NCT05005871|Active Comparator|Quadratus lumborum intramuscular block|The quadratus lumborum intramuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
32754736|NCT05005871|Active Comparator|Quadratus lumborum transmucular block|The quadratus lumborum transmuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
32754737|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
32754738|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
32754739|NCT04029155|Active Comparator|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
32754740|NCT04029155|Experimental|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
32754741|NCT03116737|Experimental|Benzocaine Otic Solution|
32754742|NCT03116737|Placebo Comparator|Placebo|
32754743|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
32754744|NCT04910243||Physicians|Physicians managing patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
32754745|NCT04910243||Nurses|Nurses providing care to patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
32754746|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
32754747|NCT04889573|Experimental|Blood sample|
32754748|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
32754749|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
32898292|NCT03213652|Experimental|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
32898293|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
32910139|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
32910140|NCT04073810||Myocardial infarction|Patients with recent MI
33239504|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
33239505|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
32901487|NCT01482715|Experimental|Part 2A (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
32901488|NCT01482715|Experimental|Part 2B (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
32901489|NCT01482715|Experimental|Part 3 (Phase 2)|Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
32910141|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
32910142|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
32910143|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
32910144|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
32910145|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
32910146|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
32898294|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
32901490|NCT05046600||All Products listed in Descriptions|Biocomposite™ or PEEK PushLock, DX SwiveLock SL, Headless Compression Screws, Tenodesis Screw (Biocomposite and PEEK), Corkscrew® Titanium (Nano and Micro-Corkscrew), DynaNite Nitinol Staples
32910147|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
33239506|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
33239507|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
33239508|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
33239509|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
33396390|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
33239510|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
33239511|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
33239512|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
33239513|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
33239514|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
33239515|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
33239516|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
33072521|NCT05000216|Experimental|Cohort D, Arm D2: Alternative mRNA Vaccine + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
33239517|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
33396391|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
32910148|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
33239518|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
32901491|NCT05045196|Experimental|Patient and family member of patient undergoing elective open heart surgery- Intervention|Family randomized to the intervention group receiving Health-promoting conversation intervention
33239519|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
33239520|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
33239521|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
33239522|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
33239523|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
33239524|NCT04076358|Experimental|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
33239525|NCT04076358|No Intervention|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
33239526|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
33239527|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
33239528|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
33239529|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
33239530|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
33239531|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
33239532|NCT05015166|Experimental|Internet delivered self-help program with therapist support|"The intervention consists of 8 therapist-supported self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which they send to their therapist and receive feedback within a few days.~The treatment is based on principles from affect-focused psychodynamic psychotherapy."
33239533|NCT05015166|Active Comparator|Internet delivered self-help program without therapist support|The intervention consists of 8 self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which the participants are encouraged to try. The treatment is based on principles from affect-focused psychodynamic psychotherapy.
33239534|NCT05015166|No Intervention|Waitlist|Participants will receive no intervention for 8 weeks.
33239535|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
33239536|NCT02592746|Active Comparator|Capecitabine|
33239537|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
33239538|NCT03375216|Active Comparator|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
33239539|NCT03375216|Placebo Comparator|non taper systemic <90|participants on systemic opioids < 90 MEDD (morphine equivalent daily dose) and no taper
33239540|NCT03375216|Placebo Comparator|non taper systemic >90|participants on systemic opioids > 90 MEDD and no taper
33239541|NCT03375216|Placebo Comparator|non taper intrathecal|Participants on intrathecal therapy and no taper
33239542|NCT03375216|Sham Comparator|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
33239543|NCT03366168||Group 1|Ages 18-39 years
33239544|NCT03366168||Group 2|Ages 40-59 years
33239545|NCT03366168||Group 3|Ages 60 years old or older
33239546|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
33239547|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
33239548|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
33239549|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
33239550|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
33239551|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
33239552|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
32910149|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
32910150|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
33396392|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
32910151|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
32910152|NCT04418271|Experimental|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
33396393|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
33396394|NCT04776408|Active Comparator|Control group_Use Lung recruitment|Use the Lung recruitment,
33396395|NCT04776408|Experimental|Study group_Use Lung recruitment combined inhaled Nitric oxide|Use the Lung recruitment combined inhaled Nitric oxide,
33396396|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
33396397|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
33396398|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
33396399|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
33396400|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
33396401|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
33396402|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
33396403|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
33396404|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
33396405|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
33396406|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
33396407|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
33396408|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
33396409|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
33396410|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
33396411|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
33396412|NCT02653092|Active Comparator|Aim 1|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:~infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response; and~inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
33396413|NCT02653092|Experimental|Aim 2|Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.
33396414|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
33396415|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
33396416|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
33396417|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
33396418|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
33396419|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
32910153|NCT04418271|No Intervention|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
33396420|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
33396421|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
33396422|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
33396423|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
33396424|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
33396425|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
33396426|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
32910154|NCT05249595|Experimental|Group A - Particiapnts without neurological disorders|Individuals without neurological disorders will be recruited (Group A).
33239553|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT).
33239554|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
33239555|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
33239556|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
33239557|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
33239558|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
33239559|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
33239560|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
33239561|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
33239562|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
33239563|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
33239564|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
33239565|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
33396427|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
33396428|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
33396429|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
33396430|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
33396431|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
33396432|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
33396433|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
33396434|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
33396435|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
33396436|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
33396437|NCT04166318|Active Comparator|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
33396438|NCT04166318|Experimental|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
33396439|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
33396440|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
33396441|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
33396442|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
33396443|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
33396444|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
33396445|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
33396446|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
33396447|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
33396448|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
33396449|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
33396450|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
33396451|NCT03715309|Experimental|Revlimd|
33396452|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
33396453|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
33396454|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
33396455|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
33396456|NCT03182530|Active Comparator|ULTRA method group|
33396457|NCT03182530|Active Comparator|standard patent hemostasis group|
33396458|NCT03182530|Experimental|control group|
33396459|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
33396460|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
33396461|NCT02953639|Placebo Comparator|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
33396462|NCT02953639|Experimental|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
33396463|NCT02953639|Experimental|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
33396464|NCT04147715|Placebo Comparator|Part 1: Placebo|Participants received a single oral dose of matching placebo in a fasted state on Day 1.
33396465|NCT04147715|Experimental|Part 1: 10 mg S-648414|Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.
33396466|NCT04147715|Experimental|Part 1: 30 mg S-648414|Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.
33396467|NCT04147715|Experimental|Part 1: 100 mg S-648414|Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.
33396468|NCT04147715|Experimental|Part 1: 250 mg S-648414|Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.
32901492|NCT05045196|No Intervention|Patient and family member of patient undergoing elective open heart surgery- Control|Family of a patient undergoing elective open-heart surgery randomized to the intervention group receiving standard care
32901493|NCT05095272|Experimental|Healthy malaria-naive US adults|A single dose of cryopreserved inoculum containing blood-stage P. vivax will be administered IV
32901494|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
32901495|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
32901496|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
32901497|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
32901498|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
32754750|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
32754751|NCT04862429|Experimental|Contrast enhanced mammography guided biopsy|"Patients will be subjected to CESM; the two orthogonal mammographic projections, after intravenous administration of iodized contrast-enhancement (Omnipaque), will be performed.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the experimental procedure."
32754752|NCT04862429|Active Comparator|mammography guided biopsy|"Patients will be subjected to stereotactic biopsy Mammotome as normal clinical practice.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the standard procedure."
32754753|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
32754754|NCT04852133||Burn subjects|exposure to burn injury
32754755|NCT04852133||Non-burned control|no exposure to burn injury
32754756|NCT04683562|Other|Normal pregnancy group|
32754757|NCT04683562|Other|Placenta accreta group|
33396469|NCT04147715|Experimental|Part 1: 500 mg S-648414|Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.
33396470|NCT04147715|Experimental|Part 1: 1000 mg S-648414|Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.
32754758|NCT04804787|Experimental|Experimental group : patients with multiple sclerosis|The experimental group will be constituted of patients with multiple sclerosis.
32754759|NCT04804787|Active Comparator|Control group : volunteers|The control group will be constituted of healthy volunteers with the same characteristics concerning age, sex, education's level as experimental group's patients
33396471|NCT04147715|Placebo Comparator|Part 2: Placebo + Midazolam|Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.
32754760|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
32754761|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
32754762|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
33396472|NCT04147715|Experimental|Part 2: 50 mg S-648414 + Midazolam|Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
33396473|NCT04147715|Experimental|Part 2: 30 mg S-648414 + Midazolam|Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
32754763|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
32754764|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
32754765|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
32754766|NCT03891875|Experimental|Elamipretide|40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
32754767|NCT03891875|Placebo Comparator|Placebo|subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
32754768|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
33396474|NCT04147715|Experimental|Part 3: 100 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.
33396475|NCT04147715|Experimental|Part 3: 200 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.
33396476|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
33396477|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
33396478|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
33396479|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
33396480|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
33396481|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
33396482|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
33396483|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
33396484|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
33396485|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
33396486|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:~PIEB flow rate = high; interval = 60 min"
33396487|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
33396488|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
33396489|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
33396490|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
33396491|NCT02428816|Experimental|Controls|30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
33396492|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
33396493|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33396494|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
33396495|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
33396496|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
33396497|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
33396498|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
33396499|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
33396500|NCT03718039|Experimental|Treatment Group 1|HTX-011
33396501|NCT03718039|Experimental|Treatment Group 2|aprepitant
33396502|NCT03718039|Experimental|Treatment Group 3|HTX-011 and a scheduled multimodal analgesic regimen (oral ibuprofen and acetaminophen).
33396503|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
33396504|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
33396505|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
33396506|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
33396507|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
33396508|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
33396509|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
33396510|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
33396511|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
33396512|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
33396513|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
33396514|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
33396515|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
33396516|NCT03717883||Healthy subjects|
33396517|NCT03717883||Subjects with ADPKD|
33396518|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
32754769|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
33396519|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
33396520|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
33396521|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
33239566|NCT04075188|Experimental|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
33239567|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
33396522|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
33071369|NCT05786274|Other|Cardiac surgery with cardiopulmonary bypass patients|Patients will be enrolled before cardiac surgery with cardiopulmonary bypass (CPB) and monitored until after the surgery. Patients enrolled will undergo diffusion weighted magnetic resonance imaging and will be administered with cognitive tests one day before surgery and within one week after surgery. Cerebral blood flow velocity as derived from transcranial Doppler recordings will be acquired from the middle cerebral artery synchronously with arterial pressure, invasively derived from the radial artery, and with the electrocardiogram as derived from patient's monitor. Signals will be acquired before anesthesia induction (BASAL), after anesthesia induction and intubation of the chest (ANESTH) and during CPB (CPB). Each acquisition will last at least 5 minutes and will be prolonged to the maximum possible length in keeping with clinical scheduling. Partial pressure of carbon dioxide and other clinical parameters will be acquired too during the intervention.
33396523|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
33396524|NCT02176668|Experimental|Cohort1-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
32754770|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
32754771|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
32901499|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
32744768|NCT04873011|Experimental|Quinine hydrochloride|The bitter tastant, quinine hydrochloride, will be acutely infused via a nasogastric feeding tube into the stomach. 320 mg of quinine hydrochloride is dissolved in 10 mL of water and all is infused.
33239568|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
33239569|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
32744769|NCT04873011|Placebo Comparator|Placebo|10 mL of water is infused via a nasogastric feeding tube into the stomach.
32901500|NCT05153226|Experimental|Cyclophosphamide|Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
32754772|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
33396525|NCT02176668|Experimental|Cohort1-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal
33396526|NCT02176668|Experimental|Cohort1-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
33071372|NCT05786248|Other|Impedancemtry|measurement of fluid shift by impedancemetry, recording by polysomnography, measurement of neck, calf and ankle perimeters, at different times: 0 min (T0), 30min (T30), 90min (T90), and the next day on waking
33239570|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33239571|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33071375|NCT05786222|Experimental|Cluster 1|"Buildings randomized to Cluster 1 will receive the CSH-delivered intervention at Months 2-7. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders 12 months following the end of the intervention period."
33239572|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33239573|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33239574|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
32754773|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Varian Truebeam Radiotherapy System)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
33239575|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33396527|NCT02176668|Experimental|Cohort1-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
33396528|NCT02176668|Experimental|Cohort2-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
33071376|NCT05786222|Experimental|Cluster 2|"Buildings randomized to Cluster 2 will receive the CSH-delivered intervention at Months 9-14. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders 12 months following the end of the intervention period."
33071377|NCT05786222|Experimental|Cluster 3|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 16-21. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders 12 months following the end of the intervention period."
32754774|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
32754775|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
32754776|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
32754777|NCT05393843|Active Comparator|intervention|"patients receiving~diet~Omega-3 fatty acids (EnerZona Omega3Rx®, Enervit, Italia), at a daily dosage of 2.4 gr at breakfast.~Anthocyanins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 108 mg divided into three equal intakes at breakfast, lunch and dinner.~Alpha-cyclodextrins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 15 gr divided into three equal intakes at breakfast, lunch and din-ner"
32754778|NCT05393843|Placebo Comparator|placebo|"patients receiving~diet~placebo (sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins)"
32754779|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
32754780|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
32754781|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
32754782|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
32754783|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
32754784|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
32754785|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
32754786|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
32754787|NCT05112679|Active Comparator|Proprio Foot|microprocessor-controlled prosthesis that regulates the angle of ankle dorsiflexion during the swing phase
32754788|NCT05112679|Active Comparator|Empower Ankle|a powered prosthesis that provides active propulsion in late stance to mimic the positive work performed by the ankle plantar-flexors in push-off. The Empower has been shown to improve affected leg kinematics (increased ankle range of motion and reduced knee flexion) on smooth flat ground, ramp ascent, and gravel
32754789|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
32754790|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
32754791|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
32754792|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
32754793|NCT05393687|Experimental|eccentric exercise group|8 weeks of progressive eccentric ankle muscle strengthening program with elastic bands. Regular swimming training program five times a week.
32754794|NCT05393687|No Intervention|Control group|Regular swimming training program five times a week.
32754795|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
32754796|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
33071378|NCT05786222|Experimental|Cluster 4|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 23-28. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders 12 months following the end of the intervention period."
33071379|NCT05786209|Experimental|Whole-body Balm + Wash and Shampoo|Parent participant will be instructed to apply the whole-body balm on the newborn baby's whole body (excluding the mouth, eyes, diaper area, and scalp) two times per day (morning and evening), and to cleanse the newborn baby with the wash and shampoo at least once per week and no more than three times per week up to Day 28.
32754797|NCT05393609||Sigmoidectomy|Patients with diverticular disease undergoing elective resection of the sigmoid colon
33071380|NCT05786196|Active Comparator|iTrack Advance|Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)
33071381|NCT05786196|Active Comparator|OMNI Surgical System|Ab-interno canaloplasty utilizing the OMNI Surgical System
33071382|NCT05786170|Experimental|magnetic resonance imaging|DW-MRI after ischemic stroke
33071383|NCT05786157|Experimental|alcohol administration paradigm|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
33396529|NCT02176668|Experimental|Cohort2-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
33396530|NCT02176668|Experimental|Cohort2-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
33239576|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33239577|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
33239578|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239579|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239580|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239581|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
33239582|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239583|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239584|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
33239585|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
33239586|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
33239587|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
33239588|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
33239589|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
33396531|NCT02176668|Experimental|Cohort2-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
32745170|NCT04846725||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) inserted between April 2012 and November 2019. Follow up data is collected up to July 2020.
33396532|NCT02176668|Experimental|Cohort3-YH4808 OF 200|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 200mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before dinner~7 days repeat administration of YH4808 Old Formulation 200mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before bed"
33396533|NCT02176668|Experimental|Cohort3-YH4808 OF 400|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 400mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before dinner~7 days repeat administration of YH4808 Old Formulation 400mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before bed"
33396534|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
33396535|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
33396536|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
32910155|NCT05249595|Experimental|Group S - Participants with iSCI or transverse myelitis|Individuals with neurological disorders, like iSCI or transverse myelitis, will be recruited (Group S). These individuals usually have weakened ankle joint functionalities but can walk independently.
32910156|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
32910157|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
33239590|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
33239591|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
33239592|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
33239593|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
33396537|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
33396538|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
32910158|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
33071386|NCT05786118||SIJ Group|Individuals with sacroiliac joint dysfunction: Participants will be grouped as positive sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
33396539|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
32910159|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
32745171|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
32910160|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
32910161|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
33071387|NCT05786118||Control Group|Individuals with no sacroiliac joint dysfunction: Individuals with sacroiliac joint dysfunction: Participants will be grouped as negative sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
33396540|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
33396541|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
33396542|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
33396543|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
33396544|NCT04640532|Experimental|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
33396545|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
33396546|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
33396547|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
33396548|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
32745172|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
33071388|NCT05786092|Experimental|treatment|
33396549|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
33396550|NCT04620252|Experimental|Chewing calcium supplements|"Participants were given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.~Participants were randomized to determine the sequence of exposure to the different treatments."
33396551|NCT04620252|Experimental|Fluoride rinse|Participants rinsed with an over the counter sodium fluoride rinse for 1 min, after having chewed a candy (negative control), a calcium calcium carbonate or a calcium citrate supplement.
33396552|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
33396553|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
33396554|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
33396555|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
33396556|NCT04146467|Experimental|Study Phase I|Subjects will be treated with the Renuvion APR device in the neck and submental region.
33396557|NCT04146467|Experimental|Study Phase II|Subjects will be treated with the Renuvion APR device in the neck and submental region.
33396558|NCT05602675|Experimental|LY3871801 + Methotrexate (Part 1)|LY3871801 administered orally in combination with methotrexate given orally.
33396559|NCT05602675|Experimental|LY3871801 + Repaglinide + Drug Cocktail (Part 2)|LY3871801 administered orally in combination with repaglinide given orally and drug cocktail which includes warfarin, dextromethorphan and midazolam administered orally.
33071389|NCT05786092|No Intervention|control|
33396560|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
33396561|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
32910162|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
33071392|NCT05786066|Experimental|Perampanel + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
32745173|NCT04496141||With COVID-19 infection|Subjects with a positive SARS-CoV-2 PCR
33239594|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
33239595|NCT00696657|Experimental|A|
33239596|NCT00696657|Experimental|B|
33239597|NCT00696657|Experimental|C|
33239598|NCT00696657|Experimental|D|
33239599|NCT00696657|Experimental|E|
33239600|NCT00696657|Experimental|F|
33239601|NCT00696657|Placebo Comparator|G1|
33239602|NCT00696657|Placebo Comparator|G2|
33239603|NCT00696657|Placebo Comparator|G3|
33239604|NCT00696657|Placebo Comparator|G4|
33239605|NCT00696657|Placebo Comparator|G5|
33239606|NCT00696657|Placebo Comparator|G6|
33239607|NCT00696657|Experimental|H|
33239608|NCT00696657|Experimental|I|
33239609|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
33239610|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
33239611|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
33239612|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
33239613|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
33396562|NCT04602468|Other|Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
33396563|NCT04602468|Other|Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
33396564|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
33396565|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
33239614|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
33239615|NCT02592590|Experimental|Group A|
33239616|NCT02592590|Experimental|Group B|
33239617|NCT02592590|Experimental|Group C|
33239618|NCT02592590|Active Comparator|Group D|
33239619|NCT03307980|Experimental|PF-06838435 Dose-Escalation|Single intravaneous infusion of PF-06838435. After 2 participants receive initial dose, data will be evaluated and a decision will be made to escalate or reduce the dose being evaluated, increase the number of participants receiving the dose, or stop dosing. Multiple iterations may be undertaken.
33396566|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
33396567|NCT03714607|No Intervention|Control|No intervention
33396568|NCT01374594||Healthy adults|
33396569|NCT01374594||Type 2 diabetes|
33396570|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
33396571|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
33396572|NCT03444181|Experimental|Music lessons|
33396573|NCT03444181|Active Comparator|Training intervention|
33396574|NCT03444181|No Intervention|No intervention|
33396575|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
33396576|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
33396577|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
33396578|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
33396579|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
33396580|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
33396581|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
33396582|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
33396583|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
33396584|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
33396585|NCT04138043|Experimental|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
33396586|NCT04138043|Placebo Comparator|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
33396587|NCT05579587||LPR Patients|Adults with a confirmed diagnosis of LPR with HEMII-pH (≥2 LPR events in 24 hr period), Esophageal manometry and Laryngoscopy undergoing endoscopic transoral incisionless fundoplication (TIF).
33396588|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
33396589|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
33396590|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
33396591|NCT02429050|Active Comparator|intervention|sustained release morphine
33396592|NCT02429050|Placebo Comparator|control|placebo
33396593|NCT04479488||Hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection need hospitalization.
33396594|NCT04479488||Non-hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection non-hospitalized.
33396595|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
33396596|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
33396597|NCT02417142|Experimental|Experimental|Exenatide 2mg subcutaneous injection, once weekly
33396598|NCT02417142|Placebo Comparator|Placebo|Placebo
32745174|NCT04496141||Without COVID-19 infection|Subjects with COVID-19 negative serum
33071393|NCT05786066|Placebo Comparator|Placebo + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
33239620|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
33071394|NCT05786053|Active Comparator|v pattern exotropia|v pattern exotropia patients with associated inferior oblique overreaction
33071395|NCT05786053|Active Comparator|Pattern esotropia|v pattern esotropia patients with inferior oblique overreaction
32901501|NCT05153226|Active Comparator|ATG|ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
32754798|NCT05393609||Conservative|Patients with diverticular disease not referred to surgery, but conservative treatment
32754799|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion)
32754800|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion)
32754801|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion)
33396599|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
33396600|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
33071396|NCT05786040|Experimental|Treatment (tafasitamab, rituximab)|Patients receive tafasitamab IV and rituximab IV or SC on study. Patients who have CR or PR after 4 cycles may receive additional tafasitamab and rituximab on study. Patients also undergo PET or CT, biopsy, and collection of blood samples throughout the trial.
33396601|NCT04135937|Experimental|MESH|Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.
32745175|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
33396602|NCT04477928||Study Group|Children receiving routine care at a Sanford facility
33396603|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
33396604|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
32745176|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
32745177|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
32910163|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
33071397|NCT05786027|Experimental|Peer Driven Intervention (PDI)|Participants from two experimental (E) prisons that are HIV-negative will be assigned to this arm. Participants will receive 12 weeks of PDI and weekly opioid urine tests. Prior to intervention participants will receive training by a Health Educator (HE) in Health Advocate (HA) and Peer roles.
33396605|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
33396606|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
32910164|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
32910165|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
32910166|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
32910167|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
32745178|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
33071398|NCT05786027|No Intervention|Treatment As Usual (TAU)|Participants from two control (C) prisons that are HIV-negative will be assigned to this arm. Participants will receive treatment as usual (which includes universal access to SSP, MMT, and Atlantis program for individuals with opioid dependence) and weekly urine opioid tests for 12 weeks.
32754802|NCT02423083|Experimental|Treatment arm|
32754803|NCT05393531|Other|Mandibular advancement device|Active therapy
32754804|NCT05393531|Other|Continuous positive airway pressure|Active therapy
32754805|NCT02017444|Placebo Comparator|Placebo|Matched placebo tablet B.D for 12 weeks
32754806|NCT02017444|Active Comparator|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
33396607|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
32910168|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
32910169|NCT05249439|Experimental|I-SatPro|Patients in the I-SatPro group will attend I-SatPro patient group sessions and follow the I-SatPro weight loss programme
33071399|NCT05786014|Experimental|Moderate Intensity Walking|Subjects allocated to moderate intensity walking will be given running shoes, a chest-based heart rate monitor, and an activity tracker watch. Subjects will aim to achieve 150 minutes a week of moderate intensity walking. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
33071400|NCT05786014|Experimental|High Intensity Interval Exercise|Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker. Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
33071401|NCT05786001||Unhealthy group|Individuals with CLTI
32910170|NCT05249439|Active Comparator|Control|Patients in the control group will attend NHS Tier 3 patient group sessions and follow the NHS Tier 3 weight loss programme
32910171|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
32910172|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
32910173|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
33071402|NCT05786001||Age control group|Healthy individuals over the age of 50
33071403|NCT05786001||Healthy group|Healthy and young individuals
32910174|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
32910175|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
33396608|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
32910176|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
32910177|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
33239621|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
32910178|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
32910179|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
33239622|NCT00726752|Experimental|Axitinib|
33239623|NCT00917930||physical training|
33239624|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
33239625|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
33239626|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
33239627|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
33239628|NCT04063683|Experimental|Anlotinib with chemotherapy|
33239629|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
33239630|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
33239631|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
32745179|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
33239632|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
33239633|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
33239634|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
32744496|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
32754807|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
32754808|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
32754809|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
32754810|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
33071404|NCT05785988||Patients with migraine treated with a second anti-CGRP|Patients with migraine treated with a second anti-CGRP monoclonal antibody as per responsible physician criteria in routine clinical practice.
33396609|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
33396610|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
33396611|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
33396612|NCT03106558|Active Comparator|Manual instrument total knee replacement|
33396613|NCT03106558|Active Comparator|Robitic arm total knee replacement|
33396614|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
33396615|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
33396616|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
33396617|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
33396618|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
33396619|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
33396620|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
33396621|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
33396622|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
33396623|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
33396624|NCT01374828|Experimental|Ketolorac|
33396625|NCT04133519|Active Comparator|Arm 1|Arm 1 is an active behavioral treatment for IBS (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD).
33396626|NCT04133519|Active Comparator|Arm 2|Arm 2 is a behavioral treatment (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
33396627|NCT05567497|Active Comparator|Trigeminal Nerve Block (TNB)|patients will receive general anesthesia followed 5 ml of 0.25% Bupivacaine for TGB under USG after induction of anesthesia (Block Group).
33396628|NCT05567497|No Intervention|control|patients will receive general anesthesia only (Control Group).
33396629|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
33396630|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
33396631|NCT05197764||Children with spastic cerebral palsy|Children between 6 months and 9 years old.
33396632|NCT05197764||Typically developing children|Children between 6 months and 9 years old.
33396633|NCT05197764||Children with an acquired brain injury|Children between 1,5 years and 9 years.
33396634|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
33396635|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
33396636|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
33396637|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
33396638|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
33396639|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
33396640|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
33396641|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
32745180|NCT04857177|Experimental|CKD-701|Drug: CKD-701 (proposed ranibizumab biosimilar)
32745181|NCT04857177|Active Comparator|Lucentis®|Drug: Lucentis® (ranibizumab)
32910180|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
32910181|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
32910182|NCT01194674|Experimental|Microplasmin|
32910183|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
32910184|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
32910185|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
32910186|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
32910187|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
32910188|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
32910189|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
33239635|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
33239636|NCT02627508|Placebo Comparator|Placebo|Placebo
33239637|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
33239638|NCT00921531|Active Comparator|TACE only|
32745182|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
32745183|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
32910190|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
33239639|NCT04072692|No Intervention|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
33239640|NCT04072692|No Intervention|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
33396642|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
33396643|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
33396644|NCT03714217|Experimental|Intervention|Telenutrition counseling
33396645|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
33396646|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
33396647|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
33396648|NCT04477694||type II diabetic patients|
33396649|NCT04477694||non-diabetic patients|
33396650|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
33396651|NCT03744767|Experimental|Single treatment arm|
33396652|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
33396653|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
33396654|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
33396655|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
33396656|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
33396657|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
33396658|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
33396659|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
33396660|NCT03179176|Experimental|HFUD utilisation|
33396661|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
33396662|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
33396663|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
32745186|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
32745187|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
32745188|NCT04496375||Institut Paoli Calmettes Outpatients|Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic
32745189|NCT04017351|Experimental|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
32745190|NCT04017351|No Intervention|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
32745191|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
32745192|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
32745193|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
32745194|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
32745195|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
32910191|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
33396664|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
33396665|NCT04483024|Placebo Comparator|Placebo|Maltodextrin
33396666|NCT04483024|Active Comparator|Glucosamine|Glucosamine hydrochloride
33396667|NCT04483024|Experimental|Collagen hydrolysate|2g of hydrolyzed collagen II
33396668|NCT04483024|Experimental|Collagen hydrolysate + chicken extract|2g of hydrolyzed collagen II with chicken extract
33396669|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
33396670|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
33396671|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
33396672|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
33396673|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
32910192|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
32910193|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
33396674|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
32910194|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
32910195|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
32910196|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
32910197|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
32910198|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
32910199|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
32910200|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
32910201|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
32910202|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
32910203|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
32910204|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
32910205|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
32910206|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
32910207|NCT03809780|Experimental|Lenalidomide,dexamethasone|"high dose: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly~low dose: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly Schedule"
32910208|NCT03713528|Other|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
32910209|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).~In Part B: one cohort with a single dose"
32910210|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
32910211|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
32910212|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
32910213|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
33396675|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
32910214|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
33239641|NCT04072692|Experimental|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
33071407|NCT05785962|Experimental|Intervention group for people with brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
33071408|NCT05785962|Experimental|Intervention group for people without brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
32910215|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
32910216|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
32910217|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
32744497|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
33071409|NCT05785949|Experimental|Microfracture + Chondro-Gide®|Microfracture + Chondro-Gide® bilayer collagen membrane
33071410|NCT05785949|Active Comparator|Microfracture|Microfracture
33396676|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
32910218|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
32910219|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
33071414|NCT05785923|Experimental|Echo Arm|Chest pain patients identified by their treating physician as being low-risk chest pain will undergo a point-of-care echocardiogram performed by a trained emergency medicine attending or resident prior to discharge from the emergency department. The physician of record will review this ultrasound and it will be documented whether the findings on the ultrasound changed the physician of record's disposition decision for the patient or the follow up instructions or medications.
33071415|NCT05785923|No Intervention|Usual Care|Chest pain patients identified by their treating physician as being low-risk chest pain will receive the usual care for their condition.
33071416|NCT05785910|Experimental|Normal subjects|
33396677|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
33396678|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
33396679|NCT02424292||Physical activity|Physical activity in a personalised program
32910220|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
32910221|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
32910222|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
32910223|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
32910224|NCT02513121|No Intervention|Observational Arm|Standard of care
32910225|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
32910226|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
32910227|NCT04411641|Experimental|SAR442168|Dose 1 of oral SAR442168 once daily
32910228|NCT04411641|Placebo Comparator|Placebo|Placebo tablet to match SAR442168 once daily
33396680|NCT04473872|Active Comparator|Neurodevelopmental treatment program group|"When applying NGT, which is described as a problem solving approach, the treatment program appropriate for their functional levels will be determined for each patient, taking into account the individual needs and wishes of the patient. Principles to be considered while applying the treatment program:~Inhibition of normal / ineffective movements~Facility of normal / effective movements Sensory-motor stimulation~Correct placement of body segments Neurodevelopmental treatment physiotherapy session for 5-days in a week, over 6-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities."
33396681|NCT04473872|Experimental|diaphragmatic breathing|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
32910229|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
32910230|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
32910231|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
32910232|NCT01158716|No Intervention|Control|
32910233|NCT04405479||Patients with multiple sclerosis|MS patients will be chosen by an independent neurologist.
32910234|NCT04405479||Healthy volunteers|Healthy controls will be paired by age and sex with MS patients.
33239642|NCT04072692|Experimental|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
32744770|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
32910236|NCT04380987||Predicovid|
32910237|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
32910238|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
32910239|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
32744771|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
32744772|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
32744773|NCT04873089||RV3278A arm|RV3278A study product is applied twice a day (morning and evening) on the face during the whole study.
32744774|NCT04873089||Control Group|Subjects included in the control group did not receive the test product or other associated product
32744775|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
32744776|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
32744777|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
32744778|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
32744779|NCT03043677||Non-inflamed|
32744780|NCT03043677||Inflamed ulcerative colitis|
32744781|NCT03043677||inflamed Crohn´s disease|
32744782|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
32910240|NCT04378959|Experimental|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
32910241|NCT04378959|Placebo Comparator|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
33396682|NCT04473872|Experimental|respiratory muscle training with the THRESHOLD IMT device|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device. T-IMT is an instrument that provides the same pressure in each breath for the strength and endurance of the inspiratory muscles, regardless of the patient's rapid or slow breathing. This device provides a constant pressure in inspiration with its flow-free one-way valve. It also has an adjustable device pressure. The tool consists of pressure section, mouthpiece and nose clip. During application, constant pressure is applied to the inspiration phase. The training group is started from 40% of MIP and inspiratory muscle training is given. In practice, patients are asked to sit in a loose position on the upper chest and shoulders. After eight breathing cycles, 1-2 respiratory controls are requested
33396683|NCT01373658|Experimental|Yinyi stent|
33396684|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
32754811|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
32910242|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
32910243|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
32744783|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
32910244|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
32754812|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
32754813|NCT05393063|Experimental|AK127|Subjects will receive AK127 by intravenous administration
32754814|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
32754815|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
32754816|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
32754817|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
32754818|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
32754819|NCT02423863|Experimental|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
32754820|NCT03586739|Experimental|"Covered stents strategy"|
32754821|NCT03586739|Active Comparator|"Bare metal stents strategy"|
32910245|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
32744498|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
33239643|NCT04072692|No Intervention|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
33396685|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33071421|NCT05785871||Untreated Hypertension|in office SBP ≥140 at two separate occasions and currently treated with antihypertensive medications (uncontrolled), or in office SBP ≥ 140 at two different occasions and no current treatment (untreated).
33071422|NCT05785871||Normotensive|in office SBP<140 mmHg, no treatment with antihypertensive medications
33071423|NCT05785871||Controlled Hypertension|in office SBP <140 and current treatment with antihypertensive medications
33071424|NCT05785845|Experimental|Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)|In this study, consenting and eligible patients will receive a prescription dose of 55 Gy in 5 fractions delivered on consecutive business days with adaptation based on daily anatomic changes as per clinical standard of care.
33071425|NCT05785832|Experimental|Intervention group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the Intervention group using t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM for 13 weeks.
33071426|NCT05785832|Active Comparator|Control group|Continuation of pre-study basal-bolus insulin delivery method, plus use of study CGM (Dexcom G6).
33071429|NCT05785806|Experimental|Skin to skin contact and co-parenting theory course|"Skin to skin contact and co-parenting theory course~Skin to skin contact instruction manual and co-parenting theory brochure~Daily face-to-face skin to skin contact guidance during hospitalization~Online punching skin to skin contact"
33071430|NCT05785806|Other|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
33071431|NCT05785780|Experimental|Targeted CRC Screening Toolkit|Based on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.
32910246|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
33071435|NCT05785754|Experimental|Part 1B Dose Escalation|Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCSZ11.
33071436|NCT05785754|Experimental|Part 2B Dose Expansion|Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity. In addition to antitumor activity, PK and PD analysis may be used to support RP2D confirmation.
33071437|NCT05785741|Experimental|DB-1310 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 1 on Day 1 of each cycle Q3W
33071438|NCT05785741|Experimental|DB-1310 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 2 on Day 1 of each cycle Q3W
33071439|NCT05785741|Experimental|DB-1310 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 3 on Day 1 of each cycle Q3W
32744784|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
33396686|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
32910247|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
32910248|NCT04377711|Active Comparator|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
32910249|NCT04377711|Placebo Comparator|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
33071440|NCT05785741|Experimental|DB-1310 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 4 on Day 1 of each cycle Q3W
32754822|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
32754823|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
32754824|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
32754825|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
32754826|NCT02425423|Experimental|New thickened infant formula|
32754827|NCT05392673|Experimental|comprehensive medical treatment|All the 62 patients enrolled received comprehensive medical treatment after admission to the hospital, including anti-viral treatment, general supportive treatment, supplementation of blood products, such as albumin and plasma, and symptomatic treatment.
33071441|NCT05785741|Experimental|DB-1310 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 5 on Day 1 of each cycle Q3W
33396687|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33396688|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
33396689|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
32744785|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
32744786|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
33239644|NCT04072692|Experimental|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
33239645|NCT05673330|Active Comparator|Spinal Mobilizations|"Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
33396690|NCT05197686|Experimental|HFNC|
33396691|NCT05197686|Active Comparator|COT|
33396692|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
33396693|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
32754828|NCT05392673|Experimental|PE(plasma exchange)|In addition to comprehensive medical treatment, the PE groups were treated with PE or PE plus half-dose sequential PE. In the current study, PE was carried out using the KM-8800 plasma exchange device (Kuraray, Tokyo, Japan). The device was pre-flushed with 2000 mL of normal saline and 20 U/mL heparin dilution. And the blood pump speed was 100 to 120 mL/min and the plasma exchange speed was 25 to 30 mL/min. Before PE, calcium gluconate and diphenhydramine were routinely administrated to prevent an allergic reaction. For each time of plasma exchange,2800 mL fresh frozen plasma was administrated.
33396694|NCT05197608|Experimental|Intervention - System Navigator|"The intervention group will be connected to a system navigator who is a trained staff member embedded within the primary health clinic team with a focus to address participant's biological, psychological and social needs.~Working with the System Navigator will mean:~Discussing patients' current health status and concerns~Receiving support on management of chronic diseases and mental health including connection to local resources e.g. counseling, harm reduction, crisis support services~Receiving information about benefits that they may be entitled to and learning about free services~Receiving help from the System Navigator on forms or letters that are required to access resources"
33396695|NCT05197608|Active Comparator|Tailored list of community resources|Control group will be provided a tailored list of community resources.
33396696|NCT02428894||LVAD recipients|
33396697|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
33396698|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
33396699|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
33396700|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
33396701|NCT02428504||End of life decision|
33396702|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
33396703|NCT03711487|No Intervention|No intervention|No intervention.
33396704|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
33396705|NCT05560555||Retrospective cohort ATTRv and ATTRwt patients enrolled in B3461028 and B3461045 studies in Spain|
33396706|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
33396707|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
33396708|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
33396709|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
33396710|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
33396711|NCT05559541|Experimental|AK119+AK104|AK119 and AK104 IV every 2 or every 3 weeks.
33396712|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
33396713|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
33396714|NCT03691571|Experimental|Esophageal Cooling|Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).
33396715|NCT03691571|Active Comparator|Control|Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).
33396716|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
33396717|NCT03113916|No Intervention|Enhanced usual care|Printed materials
33396718|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
33396719|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
33396720|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
33396721|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
33396722|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
33396723|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
33396724|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
33396725|NCT03744533|Experimental|head-down position treatment|
33396726|NCT03744533|Active Comparator|guideline-based treatment|
33396727|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
33396728|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
33239646|NCT05673330|Active Comparator|Myofascial Release technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
33239647|NCT04114851|Experimental|Active|Patients who get active monitor NoL
33239648|NCT04114851|No Intervention|control|control no NoL
33396729|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
33071442|NCT05785741|Experimental|DB-1310 Dose Expansion 1|Enrolled Subjects with advanced/unresectable, or metastatic adenocarcinoma NSCLC with EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33239649|NCT04094415||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
33396730|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
32754829|NCT05392673|Experimental|DPMAS+half-dose sequential PE|DPMAS with half-dose sequential PE was applied using the EC-40W plasma separator (Asahi Kasei Medical, Tokyo, Japan), BS330 bilirubin adsorption column (Jianfan Biotechnology, Zhuhai, China), and the neutral microporous adsorption resin HA330-Ⅱ (Jianfan Biotechnology). After the bilirubin adsorption and hemoperfusion treatment, sequential half-dose PE treatment begins. 1400 mL plasma replacement was conducted each time.
32754830|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
32754831|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
32754832|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
32754833|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
32754834|NCT05392595|Experimental|Group A|Caw-throne and Cooksey exercise, Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
32754835|NCT05392595|Other|Group B|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
32754836|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
32754837|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
32754838|NCT01993186|Experimental|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
32754839|NCT01993186|Placebo Comparator|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
32754840|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
32754841|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
32754842|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
32754843|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
32754844|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
32754845|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
32754846|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
32754847|NCT02416375||Observation|Adult Cystic Fibrosis patients
32754848|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks for up to 5 years.
32754849|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks for up to 5 years.
32754850|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
32754851|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
32754852|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
33396731|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
32754853|NCT04482907|Active Comparator|Group receiving dill|They took 3 meals a day, 3x300 mg dry dill powder by mouth. They bought dry dill powder for 90 days.
32754854|NCT04482907|Placebo Comparator|Group receiving placebo|They took 3 meals a day and 3 cellulose placebo capsules by mouth. They took placebo capsules for 90 days.
32754855|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
32754856|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
32754857|NCT04682938||adrenal incidentalomas in Chinese community adults|On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.
33396732|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
33396733|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
33396734|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin~Triple-negative breast cancer~Platinum-sensitive Ovarian cancer~Mesothelioma"
33239650|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
33239651|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
33396735|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
33396736|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
33396737|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
33071443|NCT05785741|Experimental|DB-1310 Dose Expansion 2|Enrolled Subjects with advanced/unresectable, or metastatic NSCLC without EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33396738|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
33071444|NCT05785741|Experimental|DB-1310 Dose Expansion 3|Enrolled Subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33239652|NCT02332668|Experimental|Melanoma|Participants aged 6 months to <18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to <12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues.
33396739|NCT05658445||cases|Female with recurrent unexplained abortion
33396740|NCT05658445||control|female with normal labour
33396741|NCT05469841|Experimental|Pupillometry|Pain will be evaluated via pupillometry with 3 successive measurements
33071445|NCT05785741|Experimental|DB-1310 Dose Expansion 4|Enrolled Subjects with advanced/unresectable, or metastatic HNSCC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33071446|NCT05785741|Experimental|DB-1310 Dose Expansion 5|Enrolled Subjects with advanced/unresectable, or metastatic BC with HER2-positive (IHC3+, or IHC2+ and ISH+) who have progressed on or after HER2 targeted systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33071447|NCT05785741|Experimental|DB-1310 Dose Expansion 6|Enrolled Subject with other advanced/unresectable, or metastatic solid tumors who have progressed on or after standard systemic treatment, or for which no standard systemic treatment is available will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
33071448|NCT05785728|Experimental|DB-1202 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 1 on Day 1 of each cycle Q3W
33071449|NCT05785728|Experimental|DB-1202 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 2 on Day 1 of each cycle Q3W
33071450|NCT05785728|Experimental|DB-1202 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 3 on Day 1 of each cycle Q3W
33239653|NCT02332668|Experimental|Solid Tumors and Other Lymphomas|Participants aged 6 months to <18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.
33239654|NCT02332668|Experimental|rrcHL|Participants aged 3 years to <18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
33396742|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~420 mg (140 mg capsule x3) by mouth daily~May be given beyond 3-6 months (for maintenance)."
33396743|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
33396744|NCT04006145|Placebo Comparator|Placebo|Placebo
33396745|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
33396746|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
33396747|NCT03689816|Experimental|bone density|bone density
33396748|NCT04471844|Experimental|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
33396749|NCT04471844|Active Comparator|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
33396750|NCT04362852||Cancer|No intervention
33396751|NCT04362852||Atopic Dermatitis/Eczema|No intervention
33396752|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
33396753|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
33396754|NCT04207866|Experimental|Remote AT services|Experimental group will consist of participants who access auditory therapy services from a remote location. Services will be conducted with this group via teleconferencing over the Ontario Health Network.
33396755|NCT04207866|Active Comparator|In House AT|This group will receive auditory therapy services face-to-face at the treatment site.
33396756|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
33396757|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
33396758|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
33396759|NCT04207710|Experimental|Microbial growth after application of Pain Ease|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Pain Ease numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
33396760|NCT04207710|Experimental|Microbial growth after application of Ethyl Chloride|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Ethyl Chloride numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
33396761|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
33396762|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
33396763|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
33396764|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
33396765|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
33071451|NCT05785728|Experimental|DB-1202 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 4 on Day 1 of each cycle Q3W
33239655|NCT02332668|Experimental|MSI-H|Participants aged 6 months to <18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
33396766|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
33071452|NCT05785728|Experimental|DB-1202 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 5 on Day 1 of each cycle Q3W
33396767|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
33396768|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
33396769|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
33396770|NCT04106544|Other|Acid Sphingomyelinase Deficiency (ASMD) Cohort|Patients across the full spectrum of chronic ASMD who have fulfilled the eligibility criteria and who have performed the inclusion visit
33071453|NCT05785728|Experimental|DB-1202 Dose Level 6|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 6 on Day 1 of each cycle Q3W
33239656|NCT02332668|Experimental|TMB-H|Participants aged 6 months to <18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
32754858|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
32754859|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
32754860|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
32754861|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
32754862|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
32754863|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
32754864|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
32754865|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
32754866|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
32754867|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
32754868|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
32754869|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
33239657|NCT02332668|Experimental|Adjuvant Melanoma|Participants aged 12 years to <18 years with resected high-risk Stage IIB, IIC, III, or IV melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W).
33239658|NCT04074642|No Intervention|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
33239659|NCT04074642|Experimental|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
33239660|NCT04083495|Experimental|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
33239661|NCT05673642|Experimental|Working group|A total of 10 sessions will be applied myofascial release technique for 4 weeks, 3 times a week for the first 2 weeks, and 2 times a week for the next 2 weeks. Evaluations will be made at the beginning of the study and at the end of 4 weeks
33239662|NCT05673642|Experimental|Exercise group|The stretching exercises that we planned to give to the exercise group were planned for the muscles to which we will apply myofascial technique. Evaluations will be made at the beginning of the study and at the end of 4 weeks
33239663|NCT05673642|Experimental|Control group|No application will be made to the control group. Evaluations will be made at the beginning of the study and at the end of 4 weeks
33239664|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
33239665|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
33239666|NCT03356223|Experimental|Abemaciclib|
33239667|NCT04087694|Other|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
33239668|NCT04087694|Other|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
33239669|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
33239670|NCT04760769|Experimental|Tavapadon|Participants will receive a Tavapadon tablet at a dose of 5 milligrams (mg) to 15 mg once daily (QD) orally during 58-week treatment period.
33239671|NCT00736502||Patients HIV-1 positive|
33239672|NCT04088084|Experimental|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
33239673|NCT04088084|No Intervention|standard of care|patients were only on topical IOP lowering therapy (SOC)
33239674|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
33239675|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
33239676|NCT04061109|Experimental|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
33239677|NCT04087616|Experimental|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
33239678|NCT04087616|Placebo Comparator|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
33239679|NCT00918320|Experimental|Toptecan + temozolomide|
33239680|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
33239681|NCT02593292|Placebo Comparator|control group|
33239682|NCT05478759|Experimental|MMART and attention training|Training to recognize affect and prosodic expressions of emotions combined with attention training.
33239683|NCT05478759|Placebo Comparator|Brain Health Workshop and National Geographic Movies|an inactive arm that matches sessions of intervention. BHW is education about the brain and cognition. National Geographic movies are viewed with the clinician and the participant answers questions about the movies.
33239684|NCT00729560|Experimental|1|Flutamide
33239685|NCT00729560|Placebo Comparator|2|control to arm 1
33239686|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
33239687|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
33239688|NCT00918008||Blood sample|the blood sample only collected prior to surgery
33239689|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
33239690|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
33239691|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
33239692|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
33239693|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
33239694|NCT04088162|No Intervention|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
33239695|NCT04088162|Experimental|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
33239696|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
33239697|NCT04060797|Experimental|endovascular denervation|endovascular denervation
33239698|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
32754870|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
32754871|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
33071454|NCT05785728|Experimental|DB-1202 Dose Expansion 1|Enrolled Subjects with locally advanced or metastatic primary thyroid cancers with pathology of epithelial tumors that originated from thyroid follicular cells will be enrolled regardless of PD-L1 expression will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
32754872|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
32754873|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
32754874|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
32754875|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
32754876|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
32754877|NCT04483063|Experimental|Extended shoulder group|2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face
32754878|NCT04483063|Experimental|Shoulder group|2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla
32754879|NCT04483063|No Intervention|Control group|Skin prepare with soap as usual
32754880|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
32754881|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
32754882|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
32754883|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
32754884|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :~Pre-implant evaluations (6-8 weeks)~Device implantation and stimulation optimization (6-8 weeks)~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
33396771|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
33396772|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
32754887|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
33396773|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
33396774|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
33396775|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
33396776|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
33396777|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
32754888|NCT05392049|Experimental|Bowen's therapy|Bowens therapy will be given to 12 patients of temporomandibular joint disorder .
32754889|NCT05392049|Experimental|Post isometric relaxation|post isometric relaxation technique will be given to12 patients of temporomandibular joint disorder.
32754890|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of fast release oro dispersible tramadol 50 mg"
33071455|NCT05785728|Experimental|DB-1202 Dose Expansion 2|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
33396778|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
33396779|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
33396780|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
33396781|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
33396782|NCT01375062|No Intervention|tissue from biopsies|
33396783|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
32754891|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of placebo"
32754892|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)~4 patients who have tested at staging, will be tested again after treatment.~4 patients with treatment failure or recurrence."
32754893|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
32754894|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
32754895|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
32754896|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
32754897|NCT05391659|Active Comparator|current workflow in Flanders|patient visits ophthalmologist
32754898|NCT05391659|Active Comparator|AI-only workflow|patient is imaged, images are interpreted by DR AI tool, only referrable cases identified by DR AI tool will visit ophthalmologist
32754899|NCT05391659|Active Comparator|AI-human workflow|patient is imaged, images are interpreted by DR AI tool, referrable cases identified by DR AI tool will be remotely graded by a human, only the high risk patients will visit ophthalmologist
32754900|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
32754901|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .~Drug:caudal Dexmedetomidine 1μg /kg.~Intravenous :10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
32754902|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline~Anesthesia was induced and maintained with sevoflurane"
32754903|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .~Intravenous: 10 ml Normal saline~Anesthesia was induced and maintained with sevoflurane"
32754904|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~Fixed low dose nadroparin, or;~Fixed low dose enoxaparin, or;~Fixed low dose dalteparin, or;~Fixed low dose tinzaparin."
32754905|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~Intermediate dose nadroparin, or;~Intermediate dose enoxaparin, or;~Intermediate dose dalteparin, or;~Intermediate dose tinzaparin."
32754906|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
32754907|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
32754908|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
32754909|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
32754910|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
33239699|NCT04705779|Experimental|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
33239700|NCT04705779|Active Comparator|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
33239701|NCT04686279|Experimental|TFV Medicated Douche|Once enrolled, participants will complete a baseline sampling session and then a single dose of study product administration. Post-dose observations and data collection will follow at 1, 6, 24, and 72 hours, using a sparse PK sampling design in which plasma and peripheral blood mononuclear cells (PBMC) are collected at each designated time. Between sampling windows, YMSM will complete a web-survey examining their perceived reactions and comfort using the study douche, factors influencing product use in the future, and comfort with the trial procedures. The survey will be administered after dosing but scheduled not to interfere with other study assessments. Sampling for safety, PK, PD, and acceptability assessments will be collected according to the schedule of events. Phase I Trial participants will complete an in-depth interview as part of their Termination visit.
33239702|NCT00729326|Experimental|Sequence A|
33239703|NCT00729326|Experimental|Sequence B|
33239704|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
33239705|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
33239706|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
33239707|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
33239708|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
33396784|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
33396785|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
33396786|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
33396787|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
33396788|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
33396789|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
33396790|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
33396791|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
33396792|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
33396793|NCT05193162||Pancreatic ductal adenocarcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396794|NCT05193162||Chronic pancreatitis|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396795|NCT05193162||Pancreatic serous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396796|NCT05193162||Pancreatic mucinous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396797|NCT05193162||Intraductal papillary mucinous tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396798|NCT05193162||Pancreatic neuroendocrine tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396799|NCT05193162||Pancreatic acinar cell carcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396800|NCT05193162||Solid pseudopapillary tumor of pancreas|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
33396801|NCT05193162||Blank paraffin section|
33396802|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
33396803|NCT04040946|Other|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
33396804|NCT04040946|Other|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
33396805|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
33396806|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
33396807|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
33396808|NCT05196594||Affected group by transthyretinal amyloidosis with cardiac involvement|collection of stools
33396809|NCT05196594||Affected group by transthyretinal amyloidosis without cardiac involvement|collection of stools
33396810|NCT05196594||healthy control group|collection of stools
33396811|NCT04050176|Experimental|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
33396812|NCT04050176|Active Comparator|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
33396813|NCT01372020|Sham Comparator|control group|
33396814|NCT01372020|Experimental|neuromuscular electrical therapy|
33396815|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
33396816|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
33396817|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
32754911|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8.
32754912|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
32754913|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
32754914|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
32754915|NCT03358979||Severe eye dryness|
32754916|NCT03358979||absence of eye dryness|
32754917|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.~Period II: Administration of Lu AF67708 single dose (week 4)"
32754918|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
32754919|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
32754920|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
32754921|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
32754922|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
32754923|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
33071456|NCT05785728|Experimental|DB-1202 Dose Expansion 3|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
33396818|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
33396819|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
33396820|NCT03744221|Experimental|Corn protein|Corn protein powder
33396821|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
33396822|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
33396823|NCT05507359|Experimental|Clove Gel|"Group 1: a. The heart rate will be measured using the pulse oximeter before topical application of clove gel.~b. The site where the rubber dam\ matrix band will be applied will be dried, then topically anesthetized with 4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel for 30-60 seconds.~c. During rubber dam clamp\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~d. After the rubber dam clamp\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~e. The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
33396824|NCT05507359|Active Comparator|Benzocaine Gel|"The heart rate will be measured using the pulse oximeter before topical application of benzocaine gel.~The site where the rubber dam\ matrix band will be applied will be dried, then topically anesthetized with 20% benzocaine gel for 30-60 seconds (Opahl Gel).~During rubber dam clamp\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~After the rubber dam clamp\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
33396825|NCT05196360|Experimental|MAX-10181|tables
33396826|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
33396827|NCT04123067|Experimental|Pioglitazone treatment group|oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
33396828|NCT04123067|Placebo Comparator|Placebo group|Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
33396829|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
33396830|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
33396831|NCT05193006||peritoneal malignant mesothelioma of grade 1|peritoneal malignant mesothelioma of grade 1
33396832|NCT05193006||peritoneal malignant mesothelioma of grade 2|peritoneal malignant mesothelioma of grade 2
33396833|NCT05193006||peritoneal malignant mesothelioma of grade 3|peritoneal malignant mesothelioma of grade 3
33239709|NCT05476809|Experimental|smart-cloth|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
33239710|NCT05476809|No Intervention|usual care|Routine clinical care will be provided to the participants.
33239711|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
33239712|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
33239713|NCT05325944|Experimental|Self-guided digital intervention for NSSI|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface.
33239714|NCT05325944|Experimental|Digital intervention for NSSI with coaching|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface. This arm will additionally receive lightweight coaching which consists of a one 20-30 minute engagement call at the beginning of treatment. Thereafter, coaches will check in with participants via medium of participants choice twice per week and respond to patient texts, calls, or emails.
33239715|NCT05325944|Active Comparator|Active control|The active control arm will receive 8 weekly modules with psychoeducational components only, without the interaction features or EMA for personalization.
33239716|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
33239717|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
33239718|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
33396834|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
33396835|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
33396836|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
33396837|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
33396838|NCT05192928|Experimental|All Patients using the Ripple Health Smart Pill Cap|In this single-arm trial, all patients will be using the Ripple Health Smart Pill Cap as a method of medication administration
33396839|NCT01375218|Active Comparator|Plastizote Brace|
33396840|NCT01375218|Active Comparator|Pavlik Brace|
33396841|NCT05196282||UC, Smoker|
33396842|NCT05196282||UC, Smoking cessation|
33396843|NCT05196282||UC, THS user|
33396844|NCT05196282||CD, Smoker|
33396845|NCT05196282||CD, Smoking cessation|
33396846|NCT05196282||CD, THS user|
33396847|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
33396848|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
33396849|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
33396850|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
33396851|NCT05192616||iCover covered stent|Percutaneous transluminal angioplasty (PTA)
33396852|NCT05196204|Experimental|Trunk-oriented task combined with functional electrical stimulation training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training combined with functional electrical stimulation.
33396853|NCT05196204|Active Comparator|Trunk-oriented task training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training.
33396854|NCT05196204|No Intervention|Control group|Healthy participants will be recruited based on the age and sex of the participants with spinal cord injury to realize clinical, biomechanical and cortical evaluations
33396855|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
33396856|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
33396857|NCT05196048||No Intervention|No Intervention
33396858|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
33396859|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
33396860|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
33396861|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
33396862|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
33239719|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
33239720|NCT04677465|Experimental|RheOx Treatment|
33239721|NCT04677465|Sham Comparator|Sham Procedure|
33239722|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
33239723|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
33239724|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
33239725|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
33239726|NCT04035837|Experimental|short-course combination group|Nucleoside analogue is used during the first 3 months.
33239727|NCT04035837|Experimental|full-course combination group|Nucleoside analogue is used during all the course of study.
33239728|NCT00697827|Experimental|1|In-Space
33239729|NCT00697827|Active Comparator|2|X STOP
33239730|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
33239731|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
33239732|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
33239733|NCT00728936|Experimental|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
33239734|NCT00728936|Experimental|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
33239735|NCT00728936|Experimental|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
33239736|NCT00728936|Experimental|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
33239737|NCT00728936|Experimental|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
33239738|NCT00728936|Placebo Comparator|Placebo|Weekly saline placebo
33239739|NCT00728936|Experimental|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
33239740|NCT03980925|Experimental|Nivolumab + platinum-doublet chemotherapy|"Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.~Order of administration: Nivolumab, Carboplatin, Etoposide~Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
33239741|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
33239742|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
33239743|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
33239744|NCT03966807||Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
33239745|NCT03966807||traditional-based support +nicotine replacement therapy(NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
33239746|NCT04620681|Experimental|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg
33239747|NCT04620681|Experimental|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg
33239748|NCT04620681|Experimental|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg
33239749|NCT04620681|Experimental|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
33239750|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:~Age ≥ 80 years~Body weight ≤ 60 kg~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
33239751|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:~- No antithrombotic treatment~or:~Acetylsalicylic acid 80 mg once daily~Carbasalate calcium 100 mg once daily~Clopidogrel 75 mg once daily~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
33239752|NCT04603989|Experimental|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
32754924|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
32754925|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
32754926|NCT04482725|Experimental|S1|"Day 1: Trial products 1-2-12-3-11-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 10-5-9-6-8-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754927|NCT04482725|Experimental|S2|"Day 1: Trial products 2-3-1-4-12-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 11-6-10-7-9-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
33239753|NCT04603989|Placebo Comparator|Placebo|Placebo, multiple ascending doses, Intravenous route
33239754|NCT00728468|Experimental|Treatment arm|
33239755|NCT04061655|Active Comparator|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
32910250|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
33239756|NCT04061655|Placebo Comparator|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
32910251|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
32910252|NCT04366713|Experimental|Neratinib|Neratinib with loperamide prophylaxis, and capecitabine for participants treated for metastatic breast cancer
32910253|NCT05249361||Duchenne Muscular Dystrophy|Children aged 5 to 18 years with Duchenne muscular dystrophy
32910254|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone~Dosage form: crystalline powder for intramuscular injection~Dose(s): 1 g~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
33396863|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
33396864|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
33396865|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
33396866|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
33396867|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
33396868|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
33396869|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
33396870|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
33396871|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
33396872|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
33396873|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
33396874|NCT05192304|Experimental|0.2mg single dose|single dose of TPN-672 0.2mg, 2 subjects
33396875|NCT05192304|Experimental|0.3mg single dose|single dose of TPN-672 0.3mg, 12 subjects（9 for TPN-672, 3 for placebo）
33396876|NCT05192304|Experimental|0.4mg single dose|single dose of TPN-672 0.4mg, 12 subjects（9 for TPN-672, 3 for placebo）
33396877|NCT05192304|Experimental|0.5mg single dose|single dose of TPN-672 0.5mg, 12 subjects（9 for TPN-672, 3 for placebo）
33396878|NCT05192304|Experimental|0.6mg single dose|single dose of TPN-672 0.6mg, 12 subjects（9 for TPN-672, 3 for placebo）
33396879|NCT05192304|Experimental|0.7mg single dose|single dose of TPN-672 0.7mg, 12 subjects（9 for TPN-672, 3 for placebo）
33396880|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
33396881|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
33396882|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
33396883|NCT01375296|Other|medicine|
33396884|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
33396885|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
33396886|NCT04430660|Other|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for ~4 weeks.
33396887|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
33396888|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
33396889|NCT05191992|Experimental|experimental|The group will receive CPR training with the e-learning method and will learn skills with a handmade mannequin.
33396890|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
33396891|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
33396892|NCT04112303|Experimental|SOF/VEL|Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.
33396893|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
33396894|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
33396895|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
33396896|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
33396897|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
33396898|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
33396899|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
32910255|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
32910256|NCT05249049|Experimental|e-OPRA Implant System for Transtibial Amputees|Implantation of e-OPRA Implant System in lower limb.
32910257|NCT03012152|Active Comparator|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .~."
32910258|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
33239757|NCT04061265|Active Comparator|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
33239758|NCT04061265|Experimental|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
32910259|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide~Focal radiation therapy: standard of care dose daily for approximately 6 weeks~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
32910260|NCT03010826||40 Demyelinating Disease patients|
32910261|NCT03010826||40 Non-patient participants|
32910262|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
33239759|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
33239760|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
32910263|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
33071460|NCT05785702|Experimental|The anti-wandering system|The experimental group will use the anti-wandering system 4-6-week of pre-test and 12-week of test trial.
33071461|NCT05785689|Experimental|DEX: Bolus dexmedetomidine 0,5 mcg/kg|Intravenous infusion during first 10 minutes of anesthesia
32910264|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
32910265|NCT05248971||Children screened for trauma and/or posttraumatic stress|Children were screened for trauma exposure and posttraumatic stress at one of the first meetings at the child and adolescent mental health clinic. For participants receiving TF-CBT, posttraumatic stress was also assessed during and after therapy.
32910266|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
32910267|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
33239761|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
32910268|NCT05248815||Study group|Patients scheduled for total knee replacement.
32910269|NCT05248815||Control|Healthy age-matched controls.
32910270|NCT00363831|Experimental|1|Oxaliplatin
32910271|NCT01220726|Active Comparator|Botox|200U onabotulinumtoxinA (botox)
32910272|NCT01220726|Placebo Comparator|Placebo|200U Saline
32910273|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
32910274|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
32910275|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
32910276|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
33239762|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
32910277|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
32910278|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
33239763|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
32910279|NCT02433834|Placebo Comparator|Placebo|Placebo
33396900|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
33396901|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
33396902|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
33239764|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
33396903|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
33396904|NCT01373892|No Intervention|Healthy lean volunteers|
32910280|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
33396905|NCT04103567|Experimental|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, after neoadjuvant treatment and before surgery,~In parallel to this fecal collection, standardized clinical data will be entered into a database"
33396906|NCT03355872|Experimental|HLX01|
33396907|NCT03355872|Active Comparator|Rituximab|
33071462|NCT05785689|Placebo Comparator|Placebo (PCB): Bolus isotonic saline|Intravenous infusion during first 10 minutes of anesthesia
33071463|NCT05785676||Vena Cava Filter|Participants implanted with the vena cava filter OATF (ALN)
33396908|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
33396909|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
33396910|NCT05191914|Experimental|chidamide + fulvestrant|
33396911|NCT04060394|Experimental|Phase I Cohort 1|LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
33396912|NCT04060394|Experimental|Phase I Cohort 2|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
33396913|NCT04060394|Experimental|Phase I Cohort 3|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
33396914|NCT04060394|Experimental|Phase I Cohort 4|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
33396915|NCT04060394|Experimental|Phase II Cohort 1|LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
33396916|NCT04060394|Experimental|Phase II Cohort 2|Docetaxel/prednisone + afuresertib
33396917|NCT03345654|Placebo Comparator|Standard-of-care hearing aid fit|
33396918|NCT03345654|Experimental|Toolset-directed hearing aid fit|
33396919|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
33396920|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
33396921|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using video game distraction.|
33396922|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using audio visual distraction.|
33396923|NCT05191836|Other|Pulpotomy in primary mandibular molars without using any type of distraction aids|
33396924|NCT04099277|Experimental|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
33396925|NCT04099277|Experimental|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
33396926|NCT04099277|Experimental|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
33396927|NCT04099277|Experimental|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
33396928|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
32754928|NCT04482725|Experimental|S3|"Day 1: Trial products 3-4-2-5-1-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 12-7-11-8-10-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754929|NCT04482725|Experimental|S4|"Day 1: Trial products 4-5-3-6-2-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 1-8-12-9-11-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754930|NCT04482725|Experimental|S5|"Day 1: Trial products 5-6-4-7-3-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 2-9-1-10-12-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754931|NCT04482725|Experimental|S6|"Day 1: Trial products 6-7-5-8-4-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 3-10-2-11-1-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754932|NCT04482725|Experimental|S7|"Day 1: Trial products 7-8-6-9-5-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 4-11-3-12-2-1-given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754933|NCT04482725|Experimental|S8|"Day 1: Trial products 8-9-7-10-6-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 5-12-4-1-3-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
33071464|NCT05785663||I|Subjects received Lysine hydrochloride 26 g ± 5% Arginine hydrochlordie 26 g ± 5% Amifostine trihydrate 0.65 g ± 5%
33071465|NCT05785663||II|Subjects received Lysine hydrochloride 39 g ± 5% Arginine hydrochlordie 39 g ± 5% Amifostine trihydrate 0.98 g ± 5%
33396929|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
33396930|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
33396931|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
33071466|NCT05785663||III|Subjects received Lysine hydrochloride 52 g ± 5% Arginine hydrochlordie 52 g ± 5% Amifostine trihydrate 1.3 ± 5%
33071467|NCT05785663||IV|Subjects received Lysine hydrochloride 60 g ± 5% Arginine hydrochlordie 60 g ± 5% Amifostine trihydrate 1.5 ± 5%
33071468|NCT05785637||Initiation a non-invasive ventilation at night|Neuromuscular patients with chronic respiratory failure who initiate a non-invasive ventilation at night.
33071469|NCT05785624|Experimental|DBT: Cohort 1: Vixarelimab|Participants with IPF will receive vixarelimab, subcutaneously (SC), once every two weeks (Q2W) for 52 weeks in the DBT period.
33396932|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
33071470|NCT05785624|Placebo Comparator|DBT: Cohort 1: Placebo|Participants with IPF will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
33071471|NCT05785624|Experimental|DBT: Cohort 2: Vixarelimab|Participants with SSC-ILD will receive vixarelimab, SC, Q2W for 52 weeks in the DBT period.
32910281|NCT05248737||Group 1 - DHA/EPA bioenhanced poultry (n=24)|Participants will be asked to consume two meals of chicken, one meal will contain chicken that has been fed omega-3 fatty acids so the chicken contains omega 3 (DHA/EPA) fatty acids and the other meal will consist of non enhanced chicken and a DHA supplement. Each participant will be asked to eat both of these forms of chicken in random order. Each study is expected to take 9-hours and the two visits will be separated by a period of two weeks. A total of 5 blood samples will be collected over a 9-h period.
32910282|NCT05248737||Group 2 - 25(OH)D bioenhanced poultry (n=36)|Participants will be asked to consume 1 serving of 25-hydroxyvitamin D (25(OH)D enhanced chicken or non-fortified chicken that does not contain additional 25(OH)D and a vitamin D supplement every day for 21 days. Your participation in the study is expected to last 3 weeks. On Monday-Friday you will be asked to eat lunch in the HMRU on the Cornell campus. On weekends you will be given packaged chicken to eat at home. At 4 timepoints over the 3-week study, a blood draw will be collected to measure vitamin D status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit should last about 30 minutes. The total time needed to complete study visits in the HMRU is 10 hours over the 21-day period.
33071472|NCT05785624|Placebo Comparator|DBT: Cohort 2: Placebo|Participants with SSC-ILD will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
33396933|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
33071473|NCT05785624|Experimental|OLE Period: Cohort 1: Vixarelimab|Participants with IPF who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
32910283|NCT05248737||Group 3 - DHA/EPA and 25(OH)D bioenhanced poultry (n=24)|Participants will be asked to consume chicken that contains both omega3 (DHA/EPA) fatty acids and vitamin D (25(OH)D) for a 3week period. On the first day, you will be asked to spend around 9h in the HMRU, and will be fed a breakfast containing this chicken. A total of 5 blood samples will be collected over the 9h period. You will be asked to stay in the HMRU for this 9h study and will be fed breakfast, lunch and dinner. For the next 3w you will be asked to eat this chicken at lunch in the HMRU on the Cornell campus on weekdays (Monday-Friday). On weekends you will be given two packaged frozen chicken servings to eat at home (one serving per day). At 4 timepoints over the 3-week study, a blood draw will be collected to measure (25(OH)D) status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit to the HMRU should last about 30 minutes. The time needed to complete this study in the HMRU is 10 hours over the 3w period.
32910284|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
32910285|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
32910286|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
32910287|NCT01204736||Group 4|Unimpaired control subjects
33396934|NCT05171322||All patients|All patients included were set up with the WARD monitoring devices.
32910288|NCT05248581||All Participants|Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by the Liver transplantation team. Patients must demonstrate favorable tumor biology and no evidence of extra hepatic disease.
32910289|NCT04346745|Experimental|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
32910290|NCT04346745|No Intervention|Control group|The control group will receive usual services they could receive from community agencies.
33239765|NCT05464329|Experimental|Arm A: Mosunetuzumab + DHAX|"3 cycles (cycle=21 days) of mosunetuzumab with DHAX salvage chemotherapy (selected at the discretion of the treating physician).~The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of DHAX. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with DHAX. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and DHAX, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
33396935|NCT04053842|Experimental|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
32910291|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
32910292|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
32910293|NCT04341597|Experimental|transperineal sonographic cervix assessment|
32910294|NCT04341597|Active Comparator|endovaginal sonographic cervix assessment|
32910295|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
32910296|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
32910297|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
33396936|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
32910298|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
32910299|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
33396937|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.~A repeat [18F]FP-R01-MG-F2 PET/CT scan will be performed within 3-8 weeks post initial scan if a signal is present in the first scan."
32910300|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
32910301|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
32910302|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
32910303|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
32910304|NCT05248347|Active Comparator|Bronchoscopy training simulator|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan) was used to train the participants.
32910305|NCT05248347|Experimental|The BRONCH Mentor|Group B: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA) was used.
33239766|NCT05464329|Experimental|Arm B: Mosunetuzumab + ICE|"3 cycles (cycle=21 days) of mosunetuzumab with ICE salvage chemotherapy (selected at the discretion of the treating physician).~The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of ICE. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with ICE. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and ICE, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
33239767|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
33239768|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
33239769|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
33239770|NCT00735878|Experimental|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
33239771|NCT00735878|Experimental|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
33239772|NCT00735878|Experimental|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
33239773|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
33239774|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
33239775|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
33239776|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
33239777|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
33239778|NCT05376800|Experimental|Phase 0 Part: BI 907828|
33239779|NCT05376800|Experimental|Phase Ia Part: BI 907828|
32910306|NCT04333017|Experimental|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
33239780|NCT00695955|Experimental|Azilsartan Medoxomil|
33239781|NCT04547205|Experimental|AK109|
33239782|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
33239783|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
33239784|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
33071474|NCT05785624|Experimental|OLE Period: Cohort 2: Vixarelimab|Participants with SSC-ILD who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
33239785|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
33396938|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
32910307|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
32910308|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
32910309|NCT05248269|Experimental|Thermocoagulation of epileptogenic zone|
32910310|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
32910311|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
32910312|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
32910313|NCT04328103||Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
32910314|NCT04328103||Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
32910315|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
32910316|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
32910317|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
32910318|NCT02515305|Experimental|Test product|
32910319|NCT02515305|Active Comparator|Reference product|
33239786|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
33239787|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
33071475|NCT05785611|Experimental|Radiographic Part (Study A) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16, after that participants will enter open label period and all participants will receive filgotinib 200 mg until Week 52. When a participant reaches an Ankylosing Spondylitis Disease Activity Score (ASDAS) <2.1, he will enter dose de-escalation phase and will be randomized to filgotinib 200 or 100 mg until Week 104. The maximum duration of treatment period will be up to Week 104.
32910320|NCT02515305|Placebo Comparator|Placebo product|
33071476|NCT05785611|Experimental|Non-radiographic Part (Study B) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16, after that participants will enter open label period and all participants will receive filgotinib until Week 52. When a participant reaches an ASDAS <2.1, he will enter dose de-escalation phase and will be randomized to filgotinib 200 mg or 100 mg until Week 104. The maximum duration of treatment period will be up to Week 104.
33239788|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
33239789|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
33071477|NCT05785585|Experimental|Methylcobalamin group|One capsule daily with 500 µg of methylcobalamin for 12 weeks
33071478|NCT05785585|Active Comparator|Cyanocobalamin group|One capsule daily with 500 µg of Cyanocobalamin for 12 weeks
33071479|NCT05785585|Placebo Comparator|Control group|One capsule daily with microcrystalline cellulose for 12 weeks
33239790|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
33239791|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
33239792|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
33239793|NCT03718299|Other|tildrakizumab 100 mg|
33071480|NCT05785572|Experimental|Radiofrequency group|Patient group that undergoes Radiofrequency of supraescapular nerve before shoulder arthroplasty surgery
33239794|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
32910321|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
33239795|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
33239796|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
33239797|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
33239798|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
33239799|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
33239800|NCT04088006|Experimental|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
32754934|NCT04482725|Experimental|S9|"Day 1: Trial products 9-10-8-11-7-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 6-1-5-2-4-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754935|NCT04482725|Experimental|S10|"Day 1: Trial products 10-11-9-12-8-1 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 7-2-6-3-5-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754936|NCT04482725|Experimental|S11|"Day 1: Trial products 11-12-10-1-9-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 8-3-7-4-6-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754937|NCT04482725|Experimental|S12|"Day 1: Trial products 12-1-11-2-10-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 9-4-8-5-7-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
32754938|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
32754939|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
32754940|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
32754941|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
32754942|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
32754943|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
32754944|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
32754945|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
32754946|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
33071481|NCT05785572|Active Comparator|Interscalenic braquial plexus block group|Interscalenic braquial plexus block done at the moment of the surgery.
33071482|NCT05785559|Experimental|Scarred uterus|Patients who have already undergone one or more cesarean section(s) during a previous pregnancy and for whom a cesarean section is indicated on a scheduled or emergency basis.
33071483|NCT05785559|Experimental|Scar dehiscence surgery|Patients who have already undergone one or more caesarean section(s) and for whom the surgical management of a dehiscence of a caesarean section scar is indicated outside of pregnancy.
33071484|NCT05785559|Experimental|Healthy uterus|"Patients with no history of caesarean section, pregnant with an indication for caesarean section: patients who have never had a caesarean section during a previous pregnancy or who are pregnant with their first pregnancy and for whom a caesarean section is indicated scheduled or urgently"
33071485|NCT05785546||development cohort|Neuromuscular diseases
32754947|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
32754948|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
32754949|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
32754950|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
32754951|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
32754952|NCT04441775||All patients for enrollment and analysis|Patients previously treated with RT for prostate cancer who are now being enrolled into this study for data analysis and incorporation into Artificial Intelligence (AI) models
32754953|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
32754954|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~live in areas where no DBT intervention is currently available OR~were offered a place on the DBT programme but decided not to partake at that time"
32754955|NCT05391425||premenopausal|Premenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
32754956|NCT05391425||postmenopausal|Postmenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
32910322|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
33071486|NCT05785546||validation cohort|Neuromuscular diseases
33239801|NCT04088006|No Intervention|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
33239802|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
32754957|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
32754958|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
32754959|NCT05390099|Experimental|moringa plant toothpaste|
32754960|NCT05390099|Active Comparator|Fluoride toothpaste|
32754961|NCT02415751||self-care education|All patients in the study will receive self-care education
32910323|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
32910324|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
32910325|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
32910326|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
32910327|NCT04917042|Experimental|tazemetostat|
32910328|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
32910329|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
32910330|NCT04916496|Experimental|ACT-LCP Group|An Acceptance and Commitment Therapy-based healthy lifestyle counselling programme (ACT-LCP) and routine psychiatric outpatient/rehabilitation services of the study hospital.
32910331|NCT04916496|Placebo Comparator|Control Group|A healthy lifestyle talk and routine psychiatric outpatient/rehabilitation services of the study hospital.
32910332|NCT03010514||case|
32910333|NCT03010514||control|
32910334|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
32910335|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
32910336|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
32910337|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
33239803|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
32754962|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
33239804|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
32754963|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
32910338|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
33239805|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
33239806|NCT04087928|Experimental|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
32754964|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
32754965|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
33396939|NCT03990389|No Intervention|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
33396940|NCT03990389|Experimental|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
33396941|NCT03990389|No Intervention|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
33396942|NCT04044794|Active Comparator|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
32910339|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
32910340|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
32910341|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
32910342|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
32910343|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
32910344|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
32910345|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
32910346|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
32910347|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
32910348|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
33239807|NCT04087928|Experimental|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
33239808|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
33239809|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
32910349|NCT05247801|Experimental|Experimental Group (Psychoeducational Intervention)|Two hundred and sixteen caregivers of multi-pathological and polypharmacy patients will receive psychoeducational intervention based on virtual reality and a dosing device for safer medication use at home. The intervention will be developed in a previous project phase using a mixed methodology (observational study and qualitative techniques). The intervention will be group-based and consist of motivational discussions and a review of audiovisual materials to promote self-efficacy and health literacy on the safe use of medication at home (most frequent errors, preventive strategies, etc.). Study period: 15 days intervention and follow-up 12 months.
32910350|NCT05247801|Active Comparator|Control Group (Dosing Device)|The 216 subjects assigned to the control group will use a medication dosing device and will receive information on how to use it for medication errors. Study period: 15 days intervention and follow-up 12 months.
32910351|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
32910352|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
32910353|NCT05221983||Patients with COVID-19 + with vitamin D levels|Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.
33239810|NCT00727532|Experimental|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
33239811|NCT00742599|Active Comparator|N|
33239812|NCT00742599|Placebo Comparator|P|
33239813|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
33239814|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
33239815|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
33239816|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
33239817|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
33239818|NCT02565459|No Intervention|No intervention|
33239819|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
33239820|NCT03567213|Experimental|Surgical implantation of the CortiCom system|
33239821|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
33396943|NCT04044794|Experimental|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
33396944|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
33071487|NCT05785533|Experimental|Smartphone App|The mobile app will allow recording of study outcomes (pain using the vNRS and functional outcomes using the ASKp) and house an interactive educational component to provide daily reminders on pharmacological (ibuprofen and acetaminophen) and non-pharmacological (ice, elevation, and range of motion exercises) for pain management and when to return to activity. The app will collect pain scores using the verbal Numeric Rating Scale (vNRS) and functional outcomes using the Activities Scale for Kids (ASKp) scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
33396945|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
32754966|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
32754967|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
32754968|NCT04482985|Active Comparator|Meclizine responders|
32754969|NCT04482985|Active Comparator|Meclizine non responders|
32754970|NCT05388305|Experimental|CAR--γδT|
32754971|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
32754972|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
32754973|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
32910354|NCT05159193|Experimental|PLD + C + HP followed by THP|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90~100 mg/m^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
32910355|NCT05159193|Active Comparator|TCbHP|docetaxel (T) 75 mg/m^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
32910356|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
32910357|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
32910358|NCT04916340|Experimental|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
32910359|NCT04916340|Experimental|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
33239822|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
33396946|NCT04037462|Experimental|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
33396947|NCT05194878|Experimental|Neoadjuvant chemotherapy|12 weeks of FOLFOXIRI neuoadjuvantly followed by surgery and adjuvant chemotherapy
33396948|NCT05194878|Active Comparator|Postoperative chemotherapy|surgery followed by 24 weeks of FOLFOX or CapeOX or Cape
32910360|NCT04314375|Experimental|Low Dose Budesonide|
33396949|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
33396950|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
33071488|NCT05785533|Active Comparator|Standard of Care|The standard of care group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity identical to the information contained in the mobile app. They will download onto their smartphone device a Data Collection App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, and pain using the vNRS and ASKp scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
33396951|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
33071489|NCT05785520|Other|ST500 single-dose gel|The treatment is performed twice weekly for 6 weeks.
33071490|NCT05785507||Cases|Women with PCOS according to the Rotterdam criteria.
33071491|NCT05785507||Controls|Women with PCOS.
32910361|NCT04314375|Experimental|High Dose Budesonide|
32910362|NCT04314375|Placebo Comparator|Placebo|
32910363|NCT05220813|Active Comparator|local anesthetic group (control group)|44 patients will receive local infiltration anesthesia.
32910364|NCT05220813|Active Comparator|ilioinguinal iliohypogastric group|44patients will receive ilioinguinal iliohypogastric nerve blocks
32754974|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
32754975|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
32754976|NCT04286789|Experimental|ORTD-1-Low Dose|5.6 mg/0.45 mL of active study drug
32754977|NCT04286789|Placebo Comparator|Vehicle Control -Low Dose|Vehicle (Identical formulation without the active DP)
32754978|NCT04286789|Experimental|ORTD 1-High Dose|22.5 mg/1.8 mL of active study drug
32754979|NCT04286789|Placebo Comparator|Vehicle Control -High Dose|Vehicle (Identical formulation without the active DP)
32754980|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
33396952|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
33396953|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
32754981|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
32754982|NCT02415517|No Intervention|Passive control group|No intervention
32754983|NCT04253327||BOT|Patients diagnosed and treated by surgery for borderline ovarian tumor
32754984|NCT04253327||controls|Patients after surgical treatment of benign ovarian tumor
32754985|NCT05385263|Experimental|NIVOLUMAB|All patients enrolled will be given nivolumab ( 3mg/kg IV) on day +5 Patients with CAR-T expansion<100 cells/microL on day +7 will be given 1 additional dose of nivolumab (3mg/kg IV) on day +19 (two weeks after first dose of nivolumab).
32754986|NCT00706147|Placebo Comparator|1|
32754987|NCT00706147|Active Comparator|2|
33396954|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
33396955|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
33396956|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
33396957|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
32754988|NCT05384561|Experimental|Chemosensory training group 1|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, Orange, and eugenol, for a total of five minutes per session.
32754989|NCT05384561|Experimental|Chemosensory training group 2|For 12 weeks, morning and evening, smell four odors namely coffee aroma, cheese aroma, strawberries, and limon, for a total of five minutes per session.
32754990|NCT05384561|Placebo Comparator|Chemosensory training group 3|For 12 weeks, morning and evening, smell four same odorless substance.
32754991|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
32754992|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
32754993|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
32754994|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
32754995|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
32754996|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
32754997|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
32754998|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
32754999|NCT05375435|Experimental|experimental group|
32755000|NCT05375435|Experimental|control group|
32755001|NCT05091619|Experimental|A1|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
32755002|NCT05091619|Active Comparator|A2|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
32755003|NCT05091619|Active Comparator|A3|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
32755004|NCT05091619|Experimental|B1|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
32755005|NCT05091619|Active Comparator|B2|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
32755006|NCT05091619|Experimental|B3|subjects aged 2 months receive 3 doses of vaccines with a interval of 2 months for primary immunization, and a booster dose at 18 month old
32755007|NCT05091619|Experimental|C1|subjects aged 3 months receive 3 doses of lot-1 vaccines with a interval of 30 days for primary immunization
32755008|NCT05091619|Experimental|C2|subjects aged 3 months receive 3 doses of lot-2 vaccines with a interval of 30 days for primary immunization
32755009|NCT05091619|Experimental|C3|subjects aged 3 months receive 3 doses of lot-3 vaccines with a interval of 30 days for primary immunization
32910365|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
33071492|NCT05785494|Experimental|Intervention|Access to web-site
32755010|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
32755011|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
32755012|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
32755013|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
32755014|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
32755015|NCT03836417||Idiopathic interstitial pneumonias|Patients with idiopathic interstitial pneumonias undergoing surgical lung biopsy
32755016|NCT02423551|No Intervention|Control|Usual diet
32755017|NCT02423551|Experimental|MRE|MRE consumption
32755018|NCT03820817|Experimental|Treatment (rifaximin)|Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
32755019|NCT05111509|Experimental|[203Pb]VMT-α-NET SPECT/CT|injection of [203Pb]VMT-α-NET with serialized imaging and dosimetry measurements
32755020|NCT05111197|Experimental|A. (Immunotherapy + SRT)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy, started at least 6 months ago, associated with Stereotactic Radiation Therapy (SRT)
32755021|NCT05111197|Active Comparator|B (Immunotherapy alone)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy alone (started at least 6 months ago)
32755022|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
32755023|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
32755024|NCT05106517|Experimental|denosumab|Denosumab 60mg/6 months subcutaneously + placebo intravenous
32755025|NCT05106517|Experimental|zoledronic acid|intravenous zoledronic acid and placebo /6 months subcutaneously
32755026|NCT02415361|No Intervention|Arm A|"Standard care consists of:~a phone call from a CLP-nurse after the referral from the local birth hospital has been received~telephone service at parents request and at the staffs availability~invitation to a one-day-information course before surgery"
32755027|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:~telephone contact with the parents shortly after birth~visit at the maternity ward within 36 hours after the referral has been received~telephone follow ups at specific times and at parents request~guidance and support in feeding and treatment~written information~cooperation with the staff at the maternity unit and the health centre~follow up in accordance with a check-list and log~invitation to a one-day-information course before surgery"
32755028|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
32755029|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
32755030|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
32755031|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
32755032|NCT03622697|Experimental|Mindfulness Meditation Arm|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation phone application intervention.
32755033|NCT03622697|No Intervention|Non-Intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
32755034|NCT01992094|Experimental|QIVc|Influenza vaccine
32755035|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
32755036|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
32755037|NCT05347043|Experimental|Intervention|All patients will undergo both the MoCA test and the standardized neuropsychological evaluation Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
32755038|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
32755039|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
32755040|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
32755041|NCT05338931|Experimental|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
32755042|NCT02414893||Non obese|
32755043|NCT02414893||Morbidly obese|
32755044|NCT02414893||Sleeve gastrectomy|
32755045|NCT03507101||Invasive GAS infection study patients|
33071493|NCT05785494|No Intervention|Control|Standard care
33071494|NCT05785481||Patients with early diagnosis (within 6 hours of life) of mild HIE|
32744787|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
33396958|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
32744499|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
32744788|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
32910366|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
32910367|NCT01650246|Experimental|lesinurad 400 mg|
32910368|NCT05204199||Group A|Patients without a urological or gastrointestinal malignancy undergoing non-oncological bladder surgery or transurethral resection of the prostate (TUR-P)
32910369|NCT05204199||Group B|Low Risk NMIBC (primary, solitary, Ta / low grad < 3cm, no carcinoma in situ (CIS))
32910370|NCT05204199||Group C|NMIBC patients, BCG candidates, assessed as intermediate (between the category of low- and high risk) or high risk (T1 or high grade or CIS or multiple, recurrent and large (> 3 cm) Ta/ low grade tumours).
32744789|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
32744790|NCT04484831|Experimental|ABT Weight Loss Intervention|Adolescent participants will attend sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
32744791|NCT04484831|Placebo Comparator|Enhanced Care|Adolescent participants will receive handouts on elements of a healthy lifestyle and will participate in a midpoint one-on-one nutrition consultation with a registered dietitian.
32744792|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
32744793|NCT04860999|Experimental|Somatic Dysfunction|This is the single study arm. All participants completed an osteopathic postural examination and an osteopathic manipulative treatment. Participants also completed a biomechanical assessment prior to and following the osteopathic manipulative treatment to evaluate effects of the treatment on the gait asymmetry.
32744794|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
32744795|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
32744796|NCT04867005|Active Comparator|Online traininig group. A|This arm included 5 primary care teams, that carried out a 10 hours online course.
32744797|NCT04867005|Experimental|online and face-to-face training group. B|This arm included 5 primary care teams, that carried out a 10 hours online course plus a 6h hours face-to-face course
32744798|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
32744799|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
32744800|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
32744801|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
32744802|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
32744803|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
32744804|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
32744805|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
32744806|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
32744807|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
32744808|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
32744809|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
33239823|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
33239824|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
33239825|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
33239826|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
32910371|NCT04313985|Active Comparator|Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
33239827|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
33239828|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
33239829|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
33239830|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
32910372|NCT04313985|Sham Comparator|Sham Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
33071495|NCT05785455|Active Comparator|Usual care|"Subjects will receive a health education program during 5 group sessions of 60 minutes, taught by physical therapists without training in pain neuroscience education.~All patients will receive 5 sessions, regardless of the group they belong to. Group education sessions will be in groups (of 5-6 patients), respecting the safety distance. Group sessions will be held in person, in small groups, at the health center, on a weekly basis. Both groups will receive online monitoring of the exercise program. An image with more information about the intervention and control is attached in Annex 2."
33071496|NCT05785455|Experimental|COGMO Intervention|Each subject will receive. a first individual session to assess their beliefs about pain and coping strategies, combining motivational interviewing and pain neuroscience education techniques, followed by 4 group sessions of 60 minutes, focused on the neurophysiology of pain and self-efficacy techniques in pain control, emphasizing . in two-way communication and followed by cognition targeted exercise therapy. These sessions will be taught by physiotherapists with specific training in motivational interviewing, pain neuroscience education and cognition targeted exercise
33071497|NCT05785442|Placebo Comparator|Placebo|Treatment Arm 1: patients receiving placebo (N/S 0.9% w/v) subcutaneously once daily for 10 days plus Standard of Care
33071498|NCT05785442|Active Comparator|Anakinra|Treatment Arm 2: patients receiving anakinra subcutaneously 100 mg once daily for 10 days plus Standard of Care
33071499|NCT05785429|Experimental|Colchicine|One tablet of colchicine 0.5 mg per day
32744810|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
32744811|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
32744812|NCT03221699|Placebo Comparator|control|Formula without ZnO
32744813|NCT03221699|Active Comparator|intervention|Formula with ZnO
32744814|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
33071500|NCT05785429|Placebo Comparator|Placebo|One tablet of microcrystalline cellulose per day
32755046|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
32755047|NCT03504137|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
32901502|NCT05044104|Experimental|Wearable technology in endoscopic gastrointestinal procedures with sedation|Subjects undergoing a endoscopic gastrointestinal procedure with sedation as part of standard of care will wear a consumer-facing wearable smart watch for the duration of the procedure.
32755048|NCT03504137|No Intervention|Standard of Care|Participants will not download the mHealth application. They will continue with their standard of care. Study personnel will send out surveys about general adherence. Participants will take their medications according to the instructions given by their transplant team and without any aid of the mHealth application.
32910373|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
32910374|NCT05110677||Study group|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gastrocnemius of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~Physical assessment: Color-Coded Duplex Sonography/treadmill examination to determine actual walking distance/Ankle-Brachial-Index/defined walking distance of 150 meters under medical supervision"
33239831|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
33239832|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
33239833|NCT00720902|Active Comparator|A - Normal growth hormone secretion|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
33239834|NCT00720902|Active Comparator|B - Growth hormone deficient|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
33239835|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
33239836|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
33239837|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
33239838|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
33239839|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
33239840|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
33239841|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
33071501|NCT05785416|Experimental|PNF- CR Group|The participants in the group were given PNF contract- relax stretching using the standard protocol. One trial had two isometric contractions each followed by five seconds muscle stretch and there was a total of four trials. Total of 12 sessions in 4 weeks (3sessions/week).
33239842|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
33071502|NCT05785416|Experimental|Static Stretching Group|"The participants in the group were given sustained stretching for a period of 80s at a stretch.~Total of 12 sessions in 4 weeks (3sessions/week)."
33071503|NCT05785416|No Intervention|Control Group|No intervention was given in this group
33239843|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
33239844|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
33239845|NCT04086602|Experimental|Single Ascending Dose|Once daily oral IZD334 or Placebo
32755049|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
33071504|NCT05785390|Experimental|Active Drug Treatment|Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
33071505|NCT05785390|Placebo Comparator|Placebo|As above, except dosed with matching placebo capsules.
33071506|NCT05785377|Placebo Comparator|Bupivacaine group (Group-B)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of normal saline (Total volume of 21mL in each side
33071507|NCT05785377|Active Comparator|Bupivacaine-Neostigmine group (Group-BN)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of 500 mcg neostigmine (Total volume of 21mL in each side
33239846|NCT04086602|Experimental|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
33239847|NCT00742833|Experimental|3|
33239848|NCT00742833|Placebo Comparator|1|
33239849|NCT04060953|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
33239850|NCT04060953|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
33239851|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
33239852|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
33239853|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
33239854|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
33239855|NCT00742911|Experimental|1|
33239856|NCT00742989|Experimental|A|OLT administration
33239857|NCT00742989|Sham Comparator|B|placebo-OLT
33239858|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
33239859|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
33239860|NCT00694707|Placebo Comparator|Placebo|Participants received placebo orally once a day for 6 weeks.
33239861|NCT00694707|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
33239862|NCT00694707|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
33239863|NCT00694707|Experimental|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
33239864|NCT00694707|Active Comparator|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
33239865|NCT00692913|Experimental|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
33239866|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
33239867|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
33239868|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
33239869|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
33239870|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
33239871|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
33239872|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
33239873|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
33239874|NCT00743301|Active Comparator|Olive oil|
33239875|NCT00743301|Experimental|Palm olein|
33239876|NCT00743301|Active Comparator|Lard|
33239877|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
33239878|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
33239879|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
33239880|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
33239881|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
33239882|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
33239883|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
33239884|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
33239885|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
33239886|NCT00689871|Experimental|1|Primary augmentation
33239887|NCT00689871|Experimental|2|Primary reconstruction
33239888|NCT00689871|Experimental|3|Revision-augmentation
33239889|NCT00689871|Experimental|4|Revision-reconstruction
33239890|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
33239891|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
33239892|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
33239893|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
33239894|NCT00793793|Placebo Comparator|Placebo|
33239895|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
33239896|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
33071510|NCT05785325|Experimental|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.
33239897|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
32755050|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
32755051|NCT02910791||atopic dermatitis|up to 40 subjects with atopic dermatitis will be enrolled into study.
32755052|NCT02910791||psoriasis|up to 20 subjects with psoriasis will be enrolled into study.
32755053|NCT02910791||people without skin conditions|Up to 40 subjects without skin conditions will be enrolled into study.
32755054|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
32755055|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
32755056|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
32755057|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
32755058|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
32755059|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
32755060|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
32755061|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
32755062|NCT03697031||REKOVELLE®|Follitropin Delta
32755063|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
32755064|NCT02729207|Active Comparator|Esflurbiprofen 1.5% Hydrogel Patch|One patch per 24hr for 7 days
32755065|NCT02729207|Placebo Comparator|Placebo comparator|Placebo One patch per 24hr for 7 days
32755066|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
32755067|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
32755068|NCT02709239|Active Comparator|DHA 200mg|Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
32755069|NCT02709239|Experimental|DHA 800mg|Participants will receive 800mg DHA to take per day. Participants will be asked to take four capsules containing 200mg DHA each.
32755070|NCT01991470|Experimental|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
32755071|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
32755072|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
32755073|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
32755074|NCT02488655|Experimental|Echopulse|Echopulse HIFU
32755075|NCT02414815|Experimental|AF group|Atrial fibrillation
32755076|NCT05088239||PAD|In prophylactic antibiotics for drain group (PAD) (n = 15), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative for 10-14 days when the drains were removed from the breast and abdomen.
32755077|NCT05088239||PA3|In the 3-day prophylactic antibiotics group (PA3) (n = 11), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in peri-operative period, and 6-hourly thereafter for 3 days.
32755078|NCT05088239||PA1|In the 1-day prophylactic antibiotics group (PA1) (n = 82), patients received prophylactic cefazolin 1000 mg 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative period and antibiotics were discontinued within 24 hours of surgery.
32755079|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
32755080|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
32755081|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
32755082|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
32755083|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
32755084|NCT03500471||Experimental: Robotic surgery|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
32755085|NCT03500471||Compared: Laparoscopic surgery|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
32755086|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
32755087|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
32755088|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
32755089|NCT03474497|Experimental|Pembrolizumab/IL-2/Radiotherapy|All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
32755090|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
32755091|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
33239898|NCT04000997||Failure group|Patients with a failure endotracheal extubation
33239899|NCT04000997||Success group|Patients with a successful endotracheal extubation
32755092|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
32755093|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
32755094|NCT03415061|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7
32755095|NCT03415061|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7
32755096|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
32755097|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
32755098|NCT03275831|Active Comparator|Intrasite Gel|Intrasite Gel is an effective method for hydrating dry necrotic and sloughy wounds. It is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound, encouraging moist wound healing through autolytic debridement.
32755099|NCT03275831|Experimental|PluroGel Burn and Wound Dressing|PluroGel contains a surfactant-based cleanser to assist wound debridement and cleansing
32755100|NCT03160235|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
32755101|NCT03160235|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
32755102|NCT03160235|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
32755103|NCT05088083|Experimental|DCB Treatment Group|Subjects treated with DCB
32755104|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
32755105|NCT05088005||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
32755106|NCT05087693|Experimental|Exercising in ozone following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling 200ug of salbutamol.
32755107|NCT05087693|Active Comparator|Exercising in filtered air following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered air after inhaling 200ug of salbutamol.
32755108|NCT05087693|Placebo Comparator|Exercising in ozone following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling placebo medication.
32755109|NCT05087693|Placebo Comparator|Exercising in filtered air following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered after inhaling placebo medication.
32755110|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
32755111|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
32755112|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
32755113|NCT03002207|Experimental|The defect is repaired and sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.
32755114|NCT03002207|Experimental|The defect is repaired but not sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.
32755115|NCT03002207|Experimental|The defect is sutured but not repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
32901503|NCT05043402|Experimental|Combination navicixizumab + paclitaxel|Combination navicixizumab + paclitaxel: navicixizumab 3 mg/kg Q2W of a 28 day cycle (i.e., Days 1 and 15); paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28 day cycle
33239900|NCT02602613|Experimental|AMEND|
33071511|NCT05785312|Experimental|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The standard Face to Face Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through in person face to face sessions.
32755116|NCT03002207|No Intervention|The defect is neither sutured nor repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
32755117|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
32755118|NCT05087459||patients with primary hepatocellular carcinoma undergoing elective hepatectomy|The baseline platelet count before enrollment was < 75×10^9/L and > 30×10^9/L.The primary clinical diagnosis of hepatocellular carcinoma was confirmed, and the CNLC stages were Ia and Ib.An elective hepatectomy, including laparotomy or laparoscopic hepatectomy, except hepatectomy combined with splenectomy or radiofrequency ablation.
32755119|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
32755120|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
32755121|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
32755122|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
32755123|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
32755124|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
32755125|NCT05086991||Group Study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, cardiac holter) and self analysis (hemoglobin, hematocrit, creatinine).
32755126|NCT05228327|Active Comparator|Occlusal Splint Group|Only occlusal splint was made for this patients.
32755127|NCT05228327|Active Comparator|Masticatory muscle injection group|Only intramuscular injection was applied to this patients. Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points.
32755128|NCT05228327|Active Comparator|Occlusal splint and masticatory muscle injection combination group|Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points. Patients were started to use their occlusal splints in the evening of the injection day.
32755129|NCT05228327|No Intervention|Control group|16 healthy volunteers was involved. Not given any treatment to these volunteers.
32755130|NCT02624765|Active Comparator|RCT A (1st arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Digoxin as monotherapy.
32755131|NCT02624765|Active Comparator|RCT A (2nd arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Sotalol as monotherapy.
32755132|NCT02624765|Active Comparator|RCT B (1st arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Digoxin as monotherapy.
32755133|NCT02624765|Active Comparator|RCT B (2nd arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Flecainide as monotherapy.
32755134|NCT02624765|Active Comparator|RCT C (1st arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Sotalol.
32755135|NCT02624765|Active Comparator|RCT C (2nd arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Flecainide.
32755136|NCT02414321||Fontan group|"Right heart catheterization:~pulmonary artery OCT analysis~dobutamine stress test~pulmonary vascular response test (nitric oxide)~trans-thoracic echocardiography"
32755137|NCT02414321||Control group|"Right heart catheterization:~- pulmonary artery OCT analysis"
32755138|NCT02414321||PAH group|"Right heart catheterization:~- pulmonary artery OCT analysis"
32755139|NCT05086367|Active Comparator|Routine Physical Therapy|This group received only routine physical therapy. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week)
32755140|NCT05086367|Experimental|Breathing Exercises along with routine physical therapy|This group received routine physical therapy along with breathing exercises. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week).
32755141|NCT05090189|Experimental|Exercise training|The experimental arm will enroll in a 6-month, twice-weekly, home-based, remotely monitored exercise training program, the emphasis of which will be to improve musculoskeletal health and function.
33239901|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
33239902|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
32755142|NCT05090189|No Intervention|Control|The control group will receive standard medical care.
32755143|NCT05086211|Experimental|proprioceptive neuromuscular facilitation|"Each session including three PNF techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
32755144|NCT05086211|Experimental|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects.
32755145|NCT05085743||Training|Images and related clinical data along with the measured lip to carina length of the training group are fed into and used to fit out deep convolutional neural networks model.
32755146|NCT05085743||Validation|We evaluate the model accuracy and efficacy of predicting the lip to carina length with images and clinical data of those unforeseen cases in the validation group.
32755147|NCT05089721||Anesthesiologist|
32755148|NCT05089721||Obstetricians|
33071512|NCT05785312|Active Comparator|Online Eye Movement Desensitization & Reprocessing Therapy|The Online Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through computer system by connecting through internet. For this purpose the online EMDR therapy application software will be installed
33071513|NCT05785299|Active Comparator|Double blind placebo controlled challenge test|Introduction of cow's milk by means of an adjusted double blind placebo controlled challenge test
33071514|NCT05785299|Active Comparator|Home introduction test|Introduction of cow's milk by means of a standardized schedule
33071515|NCT05785286||Subject with male LUTS|Male subjects who have been bothered by male LUTS for at least 4 weeks and are still able to pass urine on their own without the need of assistance or urethral catheterization.
33071516|NCT05785286||Subject who is waiting for their transurethral ablative prostate surgery|Male subjects who are waiting for BPH surgery and are still able to pass urine on their own without the need of assistance or urethral catheterization.
33071517|NCT05785273||Dexmedetomidine|Patient undergoing general anesthesia receving initial administration of dexmedetomidine loading dose of 0.5-1 μg/kg (ADJUSTED weight) over 15 minutes. After intubation maintenance of general anesthesia is administrated with desflurane or sevoflurane (MAC 0.6 - 1, according to Bispectral Index (BIS) or Patient State Index (Psi)), dexmedetomidine (0.2- 0.4 μg/kg/h (Lean Body Weight)) with constant infusion rate unless hypotension or bradycardia not responsive to standard treatments (filling, atropine, ephedrine, ethylephrine) occurred, and remifentanil (0.02 - 0.2 μg/kg/min (LBW)) based on clinical and instrumental assessment (Heart Rate, Blood Pressure, BIS or Psi).
33071518|NCT05785273||No Dexmedetomidine|Patients in this group receive an eventual premedication with benzodiazepines according to anaesthesiologist assessment and patient condition. After intubation general anesthesia is administrated with inhaled (desflurane or sevoflurane; MAC 0.6 - 1) or intravenous (propofol) anesthetics (according to BIS or Psi) and remifentanil (0.02 - 0.2 μg/kg/min (LBW) based on clinical and instrumental assessment (HR, BP, BIS or Psi)).
32755149|NCT05085587|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
32755150|NCT05085587|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
32755151|NCT01990534|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
33071519|NCT05785260||Group 1|All patients are assessed. The neuropsychologist assessed global cognitive status and disposition to Mindfulness. Engineered bands for multi-parameter heart rate monitoring were delivered.From the time of delivery, for 9 consecutive days the patient received a reminder via WhatsApp at the most convenient time slot. At this point, he would wear the supplied chest strap by wetting it appropriately so that it adhered perfectly to the skin. The heart rate App was accessed via Bluetooth and recorded the basal heart rate for about 10 minutes.Then the Mindfulness session was carried out. At the end of 9 days, the completed input tests plus the heart rate measurement were sent on day 10, except for the Mindfulness session, which was not scheduled. After two weeks, the measurement was repeated with the same procedure.
33071520|NCT05785260||Group 2|Patients in this group met the inclusion criteria and did not take any measurements. They underwent only the neuropsychological evaluation
33071521|NCT05785234|Experimental|Sufentanil-remimazolam group|The sufentanil-remimazolam group receives total intravenous anesthesia with sufentanil-remimazolam.
33071522|NCT05785234|Active Comparator|Remifentanil-remimazolam group|The remifentanil-remimazolam group receives total intravenous anesthesia with remifentanil-remimazolam.
33071523|NCT05785221|Placebo Comparator|Healthy Comparators|They will receive general lifestyle and nutritional education.
33071524|NCT05785221|Experimental|Overweight/Obese Group|They will receive personalized nutritional and lifestyle weight reduction intervention including dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.
33071525|NCT05785208|Experimental|ARM A: TP53 wilde-type|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
33071526|NCT05785208|Experimental|ARM B: TP53 mutant|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
33071527|NCT05785195|Experimental|Inhaled Nitric Oxide (iNO)|iNO 20ppm，≥8 hours/day for 3 days
33071528|NCT05785182||Open Fracture|High energy open fracture.
33071529|NCT05785182||Infected Fracture|Infected open or closed fracture.
33071530|NCT05785169|Experimental|Cluster 1|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
33071531|NCT05785169|Experimental|Cluster 2|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
33072522|NCT05000216|Experimental|Cohort D, Arm D3: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
32755152|NCT05085509|Experimental|Ultrasound|Ultrasound guidance and methylene blue staining
32755153|NCT05085509|Active Comparator|Open surgery|Open surgery without ultrasound guidance and methylene blue staining
32755154|NCT05085431|Experimental|Treatment of Sjogren's Syndrome|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
32755155|NCT05084807|Other|Healthy group|A group of healthy, strictly asymptomatic individuals of both sexes and different age groups.
32755156|NCT05089097||Inhibitors of serotoninergic reuptake on|"patients with a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and on treatment with antidepressants for more than three months.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
32755157|NCT05089097||Inhibitors of serotoninergic reuptake off|"patients without a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and not in treatment with antidepressants.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
32755158|NCT05084573|Experimental|Liposomal bupivacaine|Patients will receive a single bolus interscalene injection of 10mL 1.33% LB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL normal saline (NS) at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the milky appearance of LB. The catheter will be removed on postoperative day 2.
32901504|NCT05043402|Active Comparator|Paclitaxel monotherapy|Paclitaxel monotherapy: paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
32901505|NCT05043402|Experimental|Navicixizumab monotherapy|Navicixizumab monotherapy: navicixizumab 3 mg/kg Q2W of a 28-day cycle (i.e., Days 1 and 15)
32901506|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
32755159|NCT05084573|Active Comparator|Standard bupivacaine CISB|Patients will receive a single bolus interscalene injection of 10mL 0.25% SB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL 0.2% SB at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the drug appearance. The catheter will be removed on postoperative day 2.
32755160|NCT05069753|Active Comparator|Immediate sequential bilateral cataract surgery (ISBCS)|
32755161|NCT05069753|Active Comparator|Delayed sequential bilateral cataract surgery (DSBCS)|
32755162|NCT05088707|Experimental|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
32755163|NCT05088707|Active Comparator|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
32755164|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
32755165|NCT01967134|Experimental|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
32755166|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
32755167|NCT05088551|No Intervention|Control group|When the patients were admitted to the clinic,and the face-to-face interview method and the Patient Information Form,Turkey Health Literacy Scale-32,Patient Learning Needs Scale,Functional Assessment Form and Quality of Life Scale Form were filled.The second interview was conducted on the second or third day after the surgery, just before the patients were discharged.The Functional Assessment Form,Discharge Data Collection Form, and Quality of Life Questionnaire were applied.The third interview was performed 15 days after the surgery when the patients came for control or by phone.The 15th Day Recovery Process Data Collection Form were applied.The last interview was carried out six weeks after the surgery,either face-to-face or by phone,and the Functional Assessment Form,6th Week Post-Discharge Recovery Process Data Collection Form,and Quality of Life Questionnaire were applied again.Except for the routine practices of the service,no intervention was made to the control group patients.
32755168|NCT05088551|Experimental|Intervention group|Unlike the control group, the intervention group was given the education plan prepared by the researcher after filling out the forms when the patients were first encountered, and the education was carried out using various training methods such as lecture, question-answer, demonstration, and practice.Patients whose check-up time after discharge was nearing (15 days after the operation) were called a few days before and their visit time was learned. The forms were filled in by interviewing the patients face-to-face by the researcher on the 15th day and the 6th week after the operation or making a phone call on the same day with the patients who could not be reached.
32755169|NCT05028257|Experimental|COVID-19 Vaccinated Patients|
32755170|NCT04678882|Experimental|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
32755171|NCT04678882|Placebo Comparator|Placebo|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
32755172|NCT05075057|Experimental|Experimental Group|A total 400 subjects aged ≥60 years with chronic bronchitis and COPD receive three doses inactivated COVID-19 vaccine on Day 0, Day 21, Day 111, respectively.
32755173|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
32755174|NCT05072639|Experimental|Meditation|Participants randomized to the meditation arm will receive an mp3 audio recording of the visual guided meditation will be sent an additional mp3 file specifically for the recovery phase of surgery. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation.
32755175|NCT05072639|No Intervention|Control group|"Participants received standard of care, including the option to attend a free Prepare for Surgery workshop. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation."
32755176|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
32755177|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
32755178|NCT04937231|Experimental|Aerobic exercises|Treadmill and Cycle ergometer
32755179|NCT04937231|Experimental|Resistance exercises|unilateral leg press, Bilateral leg press, unilateral arm curls
32755180|NCT04937231|Experimental|Combined training|Treadmill and Cycle ergometer along with resistive Training
32755181|NCT03136133|Active Comparator|Active protein drink|Active protein drink
32755182|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
32755183|NCT05036291|Experimental|NB004|"NB004 dose escalation cohort:~NB004 tablets will be administered orally once a daily for repeated 28-day cycles until discontinuation criteria are met."
33239903|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
33239904|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
33239905|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
33239906|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
32901507|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
32901508|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
32901509|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
32901510|NCT00496262|Experimental|Human Fibrinogen Concentrate|
32901511|NCT05043246||Basic diseases Patients/Healthy People|Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease,Chronic Liver Diseases, Cancer diseases Patients
32901512|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
32901513|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
33396959|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
32910375|NCT05107479|Experimental|Treatment|The participants in the treatment group will be invited to participate in a 5-module IVR training covering an overview of available COVID-19 vaccines and best practices for vaccine administration.
32910376|NCT05107479|Active Comparator|Control|Participants in the control group will receive the intervention following a one-month delay allowing for a comparison of outcomes with the treatment group.
32910377|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
32910378|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
33396960|NCT03745781|Experimental|open-label placebo|open-label placebo
33396961|NCT03745781|No Intervention|treatment as usual|
33396962|NCT01372176|Experimental|Early Goal-Directed Nutrition|
32755184|NCT05002439|Experimental|Group multicomponent physical exercise program and a nutritional intervention|Group multicomponent physical exercise program and a nutritional intervention. The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
32755185|NCT05002439|No Intervention|Control group|Control group will receive usual care by their Primary Care Physicians. Healthy lifestyle recommendations including exercise and nutritional recommendations will be offered
32755186|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
32755187|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
32755188|NCT05378087|Active Comparator|Image staging group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
32755189|NCT05378087|Experimental|Surgery staging group|Open/minimally invasive para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
32755190|NCT04928729|Experimental|Pursed Lip Breathing|
32755191|NCT04928729|Experimental|Pursed Lip Breathing +DB|
32755192|NCT04928729|Experimental|Conservative care|
32755193|NCT04877327|Experimental|Cross-over of ablation technique|Cross-over of cardiac ablation procedures (cryotherapy and radiofrequency; radiofrequency and cryotherapy)
32755194|NCT04877327|No Intervention|Repetition of the same technique|Repeat the same procedure (cryotherapy and cryotherapy; radiofrequency and radiofrequency)
32755195|NCT04850651|Experimental|Pyrotinib/Fluconazole|Durg: Pyrotinib Durg: Pyrotinib/Fluconazole Participants received a single oral dose of pyrotinib 80 milligram (mg) on day1 and day9. Participants received a loading dose of fluconazole 400 mg on day6 followed by single dose of fluconazole 200 mg for oral administration from D7 to D18.
32755196|NCT04837235|Experimental|75mg group|15mg/tablet. Five tablets (75mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
32755197|NCT04837235|Experimental|90mg group|15mg/tablet. Six tablets (90mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
32755198|NCT04837235|Experimental|105mg group|15mg/tablet. Seven tablets (105mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
32755199|NCT04767971||Standard Colonoscopy|Colonoscopy with a standard colonoscope
32755200|NCT04767971||G-EYE® Colonoscopy|Colonoscopy with a G-EYE Colonoscopy
32755201|NCT04755101|Active Comparator|Righ-sided ARGP ablation|two-thirds of the patients will be randomized to procedural arm A: a diagnostic evaluation followed by cardio-neuromodulation (CardNM) and a pharmacological evaluation
32755202|NCT04755101|Sham Comparator|Placebo|one-third of the patients will be randomized to procedural arm B: a diagnostic evaluation followed by a pharmacological evaluation.
32755203|NCT04829981|Experimental|Intervention community|Two communities in rural Colombia
32755204|NCT04829981|No Intervention|Control community|One community in rural Colombia
32755205|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
32755206|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
32755207|NCT04736615|Experimental|Intervention community|Households will be randomly allocated to the intervention every 1-2 months over the12 month intervention
32755208|NCT05738213|Active Comparator|Migraine|Adolescents with a migraine diagnosis
32755209|NCT05738213|Placebo Comparator|Healthy control|Adolescents without a migraine diagnosis
32755210|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
32755211|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
32755212|NCT05738057|Experimental|Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab|"D-TACE with cisplatin-eluting beads. More TACE can be done if clinically necessary.~Camrelizumab (200 mg, Intravenous drips (ivd), D1/3W) plus Gem (1000 mg/m2, ivd, D1&8/3W) and Cis (25 mg/m2, ivd, D1&8/3W). Three weeks are one cycle of treatment. Chemotherapy lasted for no more than 12 cycles."
32755213|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
32755214|NCT04729829|Active Comparator|FAD + SBC|Community will be exposed to increased availability of fish from a fish aggregating device and will receive information and messaging as part of a social and behaviour change communication about consuming fish.
32755215|NCT04729829|Active Comparator|FAD only|Community will be exposed to increased availability of fish from a fish aggregating device only
32755216|NCT04729829|Active Comparator|SBC only|Community will receive information and messaging as part of a social and behaviour change communication about consuming fish.
32755217|NCT04729829|No Intervention|Control|Control (No FAD or SBC)
33396963|NCT01372176|Active Comparator|ASPEN-guidelines|
33396964|NCT04396106|Active Comparator|AT-527 - 550 mg BID|Part A
33396965|NCT04396106|Placebo Comparator|Placebo for 550 mg BID|Part A
32755218|NCT04719533|Experimental|Pre-marked episiotomy location|Women in this group will undergo pre-marking of episiotomy location
33396966|NCT04396106|Active Comparator|AT-527 - 1100 mg BID|Part B
33396967|NCT04396106|Placebo Comparator|Placebo for 1100 mg BID|Part B
33396968|NCT03743831|Other|orotracheal intubation direct|
33396969|NCT03743831|Other|orotracheal intubation indirect|
33396970|NCT01373970|Placebo Comparator|Placebo|
33396971|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
33396972|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
33396973|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
32755219|NCT04719533|No Intervention|No pre-marked episiotomy location|Women in this group will not undergo pre-marking of episiotomy location
32755220|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
32755221|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
33396974|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
33396975|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
33396976|NCT04050098|Active Comparator|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
32755222|NCT05737979||Women undergoing IVF|Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation
32755223|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
32755224|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
32755225|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
32755226|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
32755227|NCT05737901|No Intervention|Standard care group|The standard discharge training of the clinic was carried out in the patient's room on the day of discharge in an average of 5 minutes, in the form of verbally explaining the information deemed important by the physician and/or nurse to the patient. No intervention was made in this group.
32755228|NCT05737901|Experimental|Education Booklet Group|Discharge training was given by the researcher the day before the surgery in an average of 60 minutes in the meeting room of the clinic through the booklet.
32755229|NCT05737901|Experimental|Mobile Application Group|The mobile application was introduced to the patient by the researcher the day before the surgery. During the presentation phase, the patient was informed about the titles and contents of the training videos, and after explaining the technical features related to turning the tablet on and off, raising and lowering the volume, logging into the account using the username and password for training, using the buttons on the main screen and the keyboard, the patient was asked to apply them. All these stages took an average of 20 minutes. In addition, information about logging in, such as how to switch on and off the device, the patient's user name and password, were added to the back of the tablet in writing.
32755230|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
32755231|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
32755232|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
32755233|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
32755234|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
32755235|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
32755236|NCT04700267|Experimental|GLPG3970|One dose level of GLPG3970
32755237|NCT04700267|Placebo Comparator|Placebo|One dose level of Placebo
32755238|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
32755239|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
32755240|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
32755241|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
32755242|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
32755243|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
32755244|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
32755245|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
32755246|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
33396977|NCT04050098|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
33396978|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
32755247|NCT04643249|Experimental|Active|Daily treatment
33072523|NCT05000216|Experimental|Cohort E, Arm E1: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
32755248|NCT04482517|Other|Density Gradient Centrifugation (DGC)|Using the routine DGC sperm processing only
32755249|NCT04482517|Active Comparator|Physiological ICSI (PICSI)|Using PICSI dish for selecting sperm with lower sperm DNA fragmentation
32755250|NCT04482517|Active Comparator|Magnetic Activated Cell Sorting (MACS)|Using MACS for selecting sperm with lower sperm DNA fragmentation
32755251|NCT04482517|Active Comparator|Testicular sperm (Testi)|Using testicular sperm not ejaculated sperm
32755252|NCT02418871|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
32755253|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
32755254|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of placebo"
32755255|NCT04524143|Other|control group|There was no intervention in the control group during the study (At the end of study all patients were received home-based exercise)
32755256|NCT04524143|Experimental|mobilization group|Cervical mobilization was applied to the mobilization group. Cervical mobilization techniques were applied for 10 minutes in the supine position. (At the end of study all patients were received home- based exercise)
32755257|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
32755258|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
32755259|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
32755260|NCT05737589||Observation group|This is an observational study, no interventions will be applied to patients in the observation group, and only blood and cerebrospinal fluid ctDNA and TCR data of patients with brain metastases from non-small cell lung cancer treated with radiotherapy will be recorded to predict patient prognosis. Peripheral blood and CSF samples were collected at baseline, 24 h (T0), and 28 days (T28) after completion of radiotherapy and underwent deep sequencing of ctDNA and TCR. The 6-month response rates of brain metastases and systemic lesions were evaluated based on Response Evaluation Criteria in Solid Tumors version 1.1 for further study.
32755261|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
32755262|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
32755263|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
32755264|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
32755265|NCT05737511|Experimental|Hydroxyzine|Hydroxyzine (25 mg/day) for eight weeks, the dose of hydroxyzine may be adjusted based on tolerability and clinical judgment, max 100mg/day
32755266|NCT05737511|Active Comparator|Treatment as Usual|Treatment as usual includes the currently approved treatment according to CANMAT and Muadesly guidelines
32755267|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
32755268|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
32755269|NCT04310423|Placebo Comparator|Placebo|Matched to endotoxin
32755270|NCT04310423|Experimental|Endotoxin|Bolus dose of endotoxin (0.8 ng/kg)
32755271|NCT05737277|Experimental|GABAPRAL|Children with irritative bowel sindrome who received 20 Mld UFC of Bifidobacterium adolescentis PRL 2019 once a day for 12 weeks
32755272|NCT05737277|Placebo Comparator|Placebo|Children with irritative bowel sindrome who received placebo once a day for 12 weeks
32755273|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
32755274|NCT04301687|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
33239908|NCT05538533|Experimental|46 Gray (Gy)|46 gy of radiation therapy will be administered in 10 fractions.
32755275|NCT04301687|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
32755276|NCT04187027|No Intervention|the medical care and standard care only group|Group (A) received medical care and standard urotherapy only.
32755277|NCT04187027|Experimental|the medical care and standard care + P.E.M.F group|Group (B) which received the same medical care and standard urotherapy in addition to pulsed electromagnetic field therapy that applied for 20 min, ,three times / weak for three successful months.
32755278|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
32755279|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
32755280|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
32755281|NCT05737043|Placebo Comparator|myocardial performance and epicard thickness in case with polyhidramnios|we will do a fetal echo, and fetal screening with ultrasonography
32755282|NCT05737043|Active Comparator|pregnant women with polyhidramios|
32755283|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
32905398|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
32755284|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
32755285|NCT05021497|Experimental|Global Positional Re-education|Global Positional Re-education
32755286|NCT05021497|Active Comparator|Conventional Physical Therapy Program|Conventional therapy will consist of a combination of manual techniques
32755287|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
32755288|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
32755289|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
32755290|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
32755291|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
32755292|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
32755293|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
32755294|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
32755295|NCT05736887|Experimental|N-Acetylcysteine arm|Subjects with recent history of COVID-19 infection randomized to receive N-Acetylcysteine.
32755296|NCT05736887|Placebo Comparator|Placebo arm|Subjects with recent history of COVID-19 infection randomized to receive placebo.
32755297|NCT04074083|Experimental|Intervention electronic IMCI group|15 primary health care clinics will be randomly allocated to intervention group. One IMCI trained HW will be selected in each intervention facility to be trained in electronic IMCI.
32755298|NCT04074083|Active Comparator|Control paper IMCI group|15 primary health care clinics will be randomly allocated to the control group. One IMCI trained HW will be selected in each control facility to receive an IMCI update (designed to mirror eIMCI training).
32755299|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
32755300|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
32755301|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
32755302|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
32755303|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
32755304|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
32755305|NCT05736809|Experimental|Low-Dye taping|out of 21 participants 7 will be included in the study design as an experimental group using low-dye taping in acute stage
32755306|NCT05736809|Active Comparator|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
32755307|NCT05736809|Placebo Comparator|Sham taping|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
32755308|NCT05736731|Experimental|A2530|Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B530 intravenously on day 0
32755309|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
32755310|NCT02418715|No Intervention|Control|No training, no intervention.
32755311|NCT02414113||Low GNOS donors|
32755312|NCT02414113||High GNOS donors|
32755313|NCT03976895|Other|Supine position (SP)|Supine position (SP) combined with HFNC
32755314|NCT03976895|Experimental|Prone position (PP)|Prone position (SP) combined with HFNC
32755315|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
32755316|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
32755317|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
32755318|NCT03179683|No Intervention|No application|no treatment were aplied
32755319|NCT05735639|No Intervention|Compression therapy alone|
32755320|NCT05735639|Experimental|Compression therapy + single dose of low-molecular weight heparin at time of procedure|A single prophylactic dose of low molecular weight heparin (LMWH) (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) will be prescribed as per standard practice and administered in accordance with the relevant Summary of Product Characteristics (SmPC), manufacturer's recommendations and instructions for use.
32755321|NCT05735639|Experimental|Compression therapy + single dose of LMWH at time of procedure + extended course of LMWH or DOAC|An extended duration of LMWH (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) or an extended duration of a direct oral anticoagulant (DOAC) (e.g., rivaroxaban, apixaban, dabigatran etexilate) will be prescribed as per current local practice and administered in accordance with the relevant SmPC, manufacturer's recommendations and instructions for use. The duration of this must be at least 7 days, but can be in line with local practice i.e., 7, 10 or 14 days.
33071532|NCT05785169|Experimental|Cluster 3|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
33071533|NCT05785156||acute stroke patients|
32755322|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
32755323|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
32755324|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
32755325|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
32755326|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
32755327|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
33071534|NCT05785156||cognitive neurodegenerative disorders|cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), FrontoTemporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)
33396979|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
33396980|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
33071537|NCT05785117|Experimental|Vagus nerve stimulation group|Vagus nerve stimulation group
33071538|NCT05785117|Experimental|Circuit weight training group Group|Circuit weight training group Group
33396981|NCT04021706|Active Comparator|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
33071541|NCT05785091||1|forward head posture with hamstring muscles tightness
33239909|NCT05538533|Experimental|40 Gray (Gy)|40 gy of radiation therapy will be administered in 7 fractions.
33239910|NCT05538533|Experimental|35 Gray (Gy)|35 gy of radiation therapy will be administered in 5 fractions.
33071542|NCT05785091||2|forward head posture with calf muscles tightness
33071543|NCT05785091||3|forward head posture and hamstring- calf muscles tightness
33071544|NCT05785091||4|forward head posture and lumber inflexibility
33071545|NCT05785091||5|forward head posture and hamstring- calf muscles tightness, lumber inflexibility
33071546|NCT05785065|Experimental|Mycophenolate mofetil|2 to 4 capsules of mycophenolate mofetil twice daily.
33071547|NCT05785065|Placebo Comparator|Placebo|2 to 4 capsules of placebo twice daily.
33239911|NCT00915785|Experimental|5 azacytidine|
33239912|NCT04104581|Placebo Comparator|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
33239913|NCT04104581|Experimental|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
33239914|NCT04104581|Experimental|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
32910379|NCT04908072|Active Comparator|Virtual Reality Training|Will participate in an Intensive virtual reality (R) cataract simulation course that includes a five day instructor led VR course using the Orbis-FundamentalVR cataract surgical simulator, in addition to standard resident training at the training facility.
33071548|NCT05785052||Renal-mass patients|Patients diagnosed with a first episode of renal mass attending the urology department.
33071549|NCT05785052||Control subjects|Patients affected by urological functional diseases or living kidney donor.
33239915|NCT04104581|Experimental|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
33071551|NCT05785026|Experimental|WP 1a|Menthol inhalation during resistive loaded breathing trials in healthy participants.
33239916|NCT04104581|Experimental|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
33239917|NCT04104737|Experimental|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
33239918|NCT00720434|Experimental|A|500 mg BID
33239919|NCT00720434|Experimental|B|300 mg BID
33239920|NCT00720434|Experimental|C|200 mg BID
33239921|NCT00720434|Placebo Comparator|D|Placebo
32755328|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
32755329|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
33071552|NCT05785026|Placebo Comparator|WP 1b|Strawberry scent during resistive loaded breathing trials in healthy participants.
33071553|NCT05785026|Experimental|WP 2a|Menthol inhalation during cycle exercise in healthy participants.
33071554|NCT05785026|Placebo Comparator|WP 2b|Strawberry scent during cycle exercise in healthy participants.
33071555|NCT05785026|Experimental|WP 3a|Menthol inhalation during resting breathing in dyspneic COPD participants.
33071556|NCT05785026|Placebo Comparator|WP 3b|Strawberry scent during resting breathing in dyspneic COPD participants.
33071557|NCT05785026|No Intervention|WP 3c|Resting breathing in dyspneic COPD participants.
33071558|NCT05785026|Experimental|WP 4a|Menthol inhalation during cycle exercise in COPD participants.
33071559|NCT05785026|Placebo Comparator|WP 4b|Strawberry scent during cycle exercise in COPD participants.
32755330|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
32755331|NCT05734781||1|Interviewees: terminally ill patients, families and healthcare providers of such patients
32755332|NCT05733377||Pregnant|Pregnant >36 weeks gestation, 20 to 40 years old, without significant lumbar pathology, or intense labor pain, or percentile p>97 or <p3, or with a result of delivery-cesarean section due to risk of loss of fetal well-being
32755333|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
32755334|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
32755335|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
32755336|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
32755337|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
32755338|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
32755339|NCT05732831|Experimental|Dose Escalation|Participants with MTAP-deleted solid tumors will receive escalating doses of TNG462 to estimate the MTD
33071560|NCT05785013|Experimental|Interventional|25 children diagnosed with Hirschsprung disease and planned for elective surgery will be supplemented with Zinc 7 days before the operation . Outcomes will be evaluated thorugh measuring the hospital length stay. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
32755340|NCT05732831|Experimental|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG462 at the identified RP2D
33239922|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
33239923|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
32755341|NCT05732831|Experimental|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG462 at the identified RP2D
32755342|NCT05732831|Experimental|Dose Expansion in Cholangiocarcinoma|Participants with MTAP-deleted cholangiocarcinoma will receive TNG462 at the identified RP2D
32755343|NCT05732831|Experimental|Dose Expansion in MPNST|Participants with MTAP-deleted malignant peripheral nerve sheath tumor (MPNST) will receive TNG462 at the identified RP2D
32755344|NCT05732831|Experimental|Dose Expansion in solid tumors|Participants with MTAP-deleted solid tumors will receive TNG462 at the identified RP2D
32755345|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
32755346|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
32755347|NCT04483219|Experimental|TKI ± anti-PD-1 antibody|According to response to TKI, the combination of anti-PD-1 treatment would be determined.
33071561|NCT05785013|No Intervention|Control|25 children diagnosed with Hirschsprung disease and planned for elective surgery will recieve the standard care provided for the cases and will not be supplemented with Zinc . Outcomes will be evaluated thorugh measuring the hospital length. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
33071562|NCT05785000|Experimental|Aerobe graded physical exercise intervention and usual care|Physical exercise program. The experimental programme is an add-on to usual care and consists of an aerobe graded exercise program performed twice a week for 12 weeks. Usual care includes all public treatments that each patient is assigned to at entry to REPCon. The provision of officially available treatments follow the Danish Health Care Act.
33071563|NCT05785000|Placebo Comparator|Usual care|No physical exercise program in a patient control group with PCS. This group continues with usual care, but all clinical test, interviews and MRI protocol are the same.
33071564|NCT05784987|Experimental|R-MINE+X|"R-MINE: Rituximab, Isophosphamide, Mitoxantrone hydrochloride liposome, Etoposide~X: Orelabrutinib, Chidamide, Penpulimab, Lenalidomide"
32755348|NCT03975179|Experimental|Frozen section omission|Intraoperative frozen section biopsy of resection margin will not be performed
32755349|NCT03975179|Active Comparator|Frozen section|Intraoperative frozen section biopsy of resection margin will be performed. Margin evaluation of superior, medial, lateral, inferior margin is recommended but will follow surgeon's discretion.
32755350|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
32755351|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
32755352|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
32755353|NCT05732753|Experimental|Experimental group|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
32755354|NCT05732753|Active Comparator|Control group|The control group (CG) will receive an Education intervention, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive 8 sessions, 60' long, with a frequency of one session per week.
32755355|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
32755356|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
32910380|NCT04908072|No Intervention|Traditional Training|Will receive standard resident training at the training facility.
33239924|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
33396982|NCT04021706|Placebo Comparator|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
33239925|NCT00694161|Experimental|Fx-1006A|
33396983|NCT05194332|Experimental|LIFUP sonication to the amygdala|
33396984|NCT05194020|Experimental|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
33396985|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
33071565|NCT05784974|Experimental|Cadonilimab|Participants receive two cycles of Cadonilimab as neoadjuvant therapy prior to surgery; followed by surgery; followed by standard adjuvant chemotherapy +/- adjuvant Cadonilimab for 6 months.
32744815|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
33239926|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
32910382|NCT01284296|Experimental|Digital block|
32910383|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
33396986|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
33396987|NCT01375452|Active Comparator|Femara|
33396988|NCT01375452|Experimental|Letrozole|
33396989|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
32910384|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
33396990|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
33396991|NCT03053466|Experimental|Single-Arm|APL-501
33396992|NCT05131308||Detachable embolization coils group|Patients who have an intervention for leak closure with detachable embolization coils
33396993|NCT05131308||Vascular plugs/septal occluders group|Patients who have an intervention for leak closure with vascular plugs/CSO
33396994|NCT05131308||RF Ablation group|Patients who have an intervention for leak closure with Radio Frequency Ablation (RFA)
33396995|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
33396996|NCT04091087|Experimental|crisaborole ointment|crisaborole ointment
33396997|NCT04091087|Sham Comparator|vehicle ointment|vehicle ointment
33396998|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 international units (IU) intranasal Oxytocin
33396999|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
33397000|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
33071566|NCT05784961|Experimental|Active transcranial direct current stimulation (active tDCS)|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the L DLPFG and the cathode over the left temporo-parietal junction (L TPJ)
33239927|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
32910385|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
32910386|NCT04308759|Experimental|Group I (QuitBot Experimental)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
32910387|NCT04308759|Active Comparator|Group II (QuitBot Control)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
33397001|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
33239928|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
33239929|NCT02564913||control group|
33239930|NCT02564913||pre-DM group|
33239931|NCT02564913||DM group|
32755357|NCT03955835|Other|ACUTE|Patients with acute ischemic stroke and proven large vessel occlusion (e.g. intracranial internal carotid artery or middle cerebral artery) with unsuccessful recanalization after endovascular treatment with mechanical thrombectomy and suspected underlying stenosis of the occluded intracranial artery amenable to stenting based on judgment by the treating neurointerventionalist.
32755358|NCT03925961|No Intervention|control arm|All subjects in the control arm will receive the current preoperative and post operative instructions.
32755359|NCT03925961|Experimental|'education booklet' arm|All subjects in the 'education booklet' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery
32755360|NCT03925961|Experimental|'education booklet and preoperative' arm|All subjects in the 'education booklet and preoperative' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery. Those subjects randomized to the 'education booklet and preoperative' arm will receive a pre-operative phone call by the research study's lead nurse, Catherine Davidson, approximately 1 week after participants enroll in the study. She will review pre-operative and post-operative guidelines pertinent to participants' operative as outlined in the patient information booklet. The amount of time (in minutes) that this phone call takes will be recorded in an excel file sheet.
32755361|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
32755362|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
32755363|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
32755364|NCT05731193|Experimental|Exposed group (EXP)|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.
32755365|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
32755366|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
32755367|NCT03909503|Experimental|Porcine-derived collagen wound dressing|The dressing is a sheet of collagen composed of type I collagen derived from porcine peritoneal membrane. The dressing also contains additional components from the procine extracellular matrix. The dressing is a currently marketed, cleared device in the United States indicated for the management of full- and partial-thickness wounds, including: pressure ulcers, diabetic ulcers, venous ulcers, and several other wound types.
32755368|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
32755369|NCT03877133|Other|Regional oxygen saturation group|Near-infrared spectroscopy application to the skin near the kidney
32755370|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
32755371|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
32755372|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
32755373|NCT03827447|Active Comparator|Drug: Vancomycin Group|Subjects will receive oral vancomycin capsules by mouth, 125 mg every 6 hours for 14 days.
32755374|NCT03827447|Placebo Comparator|Drug: Placebo Group|Subjects will receive a placebo oral capsule by mouth every 6 hours for 14 days. The placebo oral capsule is manufactured by Study Site's pharmacy to be identical in size, shape, color, appearance and taste as the drug comparator
32755375|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
32755376|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
32755377|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
32755378|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
32755379|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
32755380|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
33397002|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
32745196|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
32745197|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
32745198|NCT03207425|Experimental|Mild hepatic impairment group|
32910388|NCT04055649|Experimental|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
32910389|NCT04899492|Active Comparator|Group 1:Nicotine Replacement Therapy (NRT)|Patients enrolled in group 1 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study
32910390|NCT04899492|Experimental|Group 2:Motivational Interviewing (MI)|Patients enrolled in group 2 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization
32910391|NCT04899492|Experimental|Group 3:Cognitive Behavioural Therapy (CBT)|Patients enrolled in group 3 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and 6 sessions of CBT after Motivational Interviewing up to 6 months after
32910392|NCT04899492|Experimental|Group 4: Hypnotherapy|Patients enrolled in group 4 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and about 3 sessions of hypnotherapy up to 6 months after
32910393|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
32910394|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
32910395|NCT03996291|Experimental|SAR442168|"SAR442168 : Experimental - Part A: Double-blind period of continued treatment with the respective SAR442168 dose administered in the DRI15928 study until selection of Phase 3 dose.~Part B: Open-label period of a single-group treatment with SAR442168 selected Phase 3 dose of 60 mg. All participants will be switched to this 60 mg dose."
33397003|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
33397004|NCT02995902|Experimental|FLT-PET/MRI|
33397005|NCT05123820|Experimental|ACT-1014-6470, Midazolam and Omeprazole|"Treatment Period A (Day 1 to Day 2) The plan is that all participants will receive treatment A and then treatment B.~A single oral dose of midazolam 2 mg and a single oral dose of omeprazole 20 mg on Day 1.~Treatment Period B (Day 8 to Day 11)~A single oral dose of 100 mg ACT-1014-6470, a single oral dose of 20 mg omeprazole, and a single oral dose of 2 mg midazolam on Day 8."
32745199|NCT03207425|Experimental|Moderate hepatic impairment group|
33397006|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
33397007|NCT03118518|Active Comparator|Anti-arrhythmic drug|
33397008|NCT03118518|Experimental|Cryoablation|
32745200|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
33071567|NCT05784961|Placebo Comparator|Sham tDCS|"Sham Comparator: sham transcranial direct current stimulation tDCS device allows sham stimulation. tDCS device sham technology allows optimum placebo stimulation via the same stimulation impresssion than active stimulation.~Electrode placement is the same than the active arm"
33071568|NCT05784948|Experimental|Virtual Reality Mindfulness Treatment|Experience virtual reality mindfulness treatment with a screen from a head-mounted display for 16 minutes in a comfortable sitting position.
33071569|NCT05784948|Sham Comparator|Relaxing scenery and music experience|Experience relaxing scenery and music with a screen from a head-mounted display for 16 minutes in a comfortable sitting position.
33397009|NCT03984305|Experimental|PKG+ Group|"For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is controlled or uncontrolled based on scores provided by the PKG."
32910403|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
32910404|NCT01286402|Placebo Comparator|Placebo|
32755381|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
32755382|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
32755383|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
32755384|NCT02423395|Experimental|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
32755385|NCT02423395|Placebo Comparator|Placebo|50 patients will be given placebo
32755386|NCT05712083|Experimental|Treatment Group|This is a single arm clinical trial.
32755387|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
32755388|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
32755389|NCT05711147|Experimental|Definitive abutment|Definitive prosthetic abutment placed at the moment of implant placement
32755390|NCT05711147|Active Comparator|Healing abutment|Conventional healing abutment placed at the moment of implant placement and removed 4 times during prosthesis making
32755391|NCT05694689|Active Comparator|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
32755392|NCT05694689|Experimental|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day. At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
32755393|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
32755394|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
32755395|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
32755396|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
32755397|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
32755398|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
32755399|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
32755400|NCT05082493|Experimental|Berubicin HCL - MTD phase|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
32755401|NCT05377853|Experimental|Blindness history|Since this is a regression analysis, all participants are assigned to the same Arm with blindness history and the demographics as covariates.
32755402|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
32755403|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
32755404|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
32755405|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
32755406|NCT05377775|Experimental|Conventional Implantation of mesh stent|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
32755407|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
32755408|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
32755409|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
32755410|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
32755411|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
32755412|NCT05377931||Normal subjects users of battle ground games (Group 1)|Subjects with no history of any medical diseases that are using mobile battle ground games for average 2 hours per day.
32755413|NCT05377931||Post COVID-19 users of battle ground games (Group 2)|Adults with a recent history of COVID-19 (average of 6 months after onset of the disease) that returned to their normal life style and are using mobile battle ground games.
33397010|NCT03984305|Placebo Comparator|PKG- Group|For subjects in the PKG- Group (SOC control group), participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
33397011|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
32755414|NCT05377931||Normal subjects not playing mobile games (Groups 3)|Normal subjects that are not using any action mobile games.
32755415|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
32755416|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
32755417|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD
32755418|NCT04543331||pre-treated patients|Patients already being treated for nAMD
32755419|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
32755420|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
32755421|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
32755422|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
32755423|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
32755424|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
32755425|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
32755426|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
32755427|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
32755428|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
32755429|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
32755430|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
32755431|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
32755432|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
33397012|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
33397013|NCT05009160||Patients with Multiple Sclerosis (PwMS)|PwMS will download the Healios+Me platform App which contains the dreaMS App and will follow the study schedule.
33397014|NCT05009160||Healthy Control Persons (HC)|HC will download the Healios+Me platform App which contains the dreaMS App and will follow the same study schedule as PwMS.
33397015|NCT03711721|Experimental|Food basket|
33397016|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
33397017|NCT05166954||LSG group|Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity
33397018|NCT05166954||RYGB group|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity
33397019|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
33397020|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
32755433|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
32755434|NCT05233501|Sham Comparator|non-surgical perıodontal treatment|
32755435|NCT05233501|Experimental|non-surgical treatment+ low level laser therapy|
32755436|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
32755437|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
33397021|NCT04086641|Experimental|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
32755438|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
32755439|NCT04542707|Active Comparator|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of T7, MTP 2 and MCP2 joints.
32755440|NCT04542707|Active Comparator|Exercise|Aerobic, anaerobic, and yoga exercises
32755441|NCT04542707|Active Comparator|Soft tissue massage|Instrument assisted soft tissue massage
32755442|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
32755443|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
32755444|NCT02607449|Experimental|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
32755445|NCT02607449|Placebo Comparator|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
32755446|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
32755447|NCT04928963|Experimental|Fasting mimicking diet|Fasting mimicking diet will be provided with all food to be consumed during each of the 2 cycles. The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective.
32755448|NCT04928963|Placebo Comparator|Placebo diet|One meal which substitute or lunch or dinner for 5 days, without calories restriction.
32755449|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
32755450|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
32755451|NCT03177655|Active Comparator|Journaling|Keeping a journal
32755452|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
32755453|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
32755454|NCT01680341|Experimental|IDegAsp Simple|
32755455|NCT01680341|Experimental|IDegAsp Step wise|
33397022|NCT04086641|Experimental|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
32755456|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
32755457|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
33397023|NCT03503318|Placebo Comparator|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
32755458|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
32755459|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
32755460|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
32755461|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
32755462|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
32755463|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
32755464|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
32755465|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
32755466|NCT02412865|Experimental|Intervention|quit4baby + text4baby
32755467|NCT02412865|Other|Control|text4baby
32755468|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
32755469|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
32755470|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
32755471|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
32755472|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
32755473|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
32755474|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
32755475|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
32755476|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
32755477|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
33239932|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
33397024|NCT03503318|Experimental|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
33239933|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
33239934|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
33239935|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
33239936|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
32910405|NCT03940677|Other|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
32910406|NCT03940677|Other|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
32910407|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
32910408|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
33071570|NCT05784922||Digital Outreach: Patient Gateway|"Participants who list Patient Gateway as the preferred mode of contact in the electronic health record (EHR) system. Patient Gateway is an online patient portal that gives patients access to securely message their Mass General Brigham provider, request routine appointments, prescriptions and referral authorizations as well as view test results that were processed at a Mass General Brigham facility. Participants will receive the digital educational lung cancer screening video via their patient gateway account."
33239937|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
32755478|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
32755479|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
32755480|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
32755481|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
33071571|NCT05784922||Digital Outreach: Text|"Participants who list Text as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video via a text message sent directly to their cell phone."
33071572|NCT05784922||Digital Outreach: Email|"Participants who list Email as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video directly to the email they have listed."
33239938|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
33239939|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
33239940|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
33239941|NCT00746031|No Intervention|3|
33239942|NCT03881241||Study Treatment|EVOS SMALL PLating System
33239943|NCT00720122|Experimental|Anorexia Nervosa Females|
33239944|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
33239945|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
33239946|NCT02564133|Experimental|detection of a patent foramen ovale|
32755485|NCT03179371||1|Mothers whose fetus has CDH
32755486|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
33239947|NCT04087382|Active Comparator|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
33239948|NCT04087382|Other|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
33239949|NCT04085744|No Intervention|control group|In this group any drug will be applied on the cuff of the intubation tube
33239950|NCT04085744|Active Comparator|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
33239951|NCT04085744|Active Comparator|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
33239952|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
32910409|NCT04298229|Active Comparator|Protocolized diuretic therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
32910410|NCT04298229|Experimental|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
32910411|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
33071573|NCT05784909|Experimental|patients diagnosed with bladder outlet obstruction due to BPH|all symptomatic patients with BPH with failure medical management or prefer minimal invasive procedure from the start.
33071574|NCT05784883||Consecutive patients ≥60-year-old presenting to the echocardiography clinic|
32755487|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
32755488|NCT04858061|Experimental|Virtual Reality Cue Exposure Therapy|Virtual Reality Cue Exposure Therapy
32755489|NCT04858061|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
32755490|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
32755491|NCT04798625||Rheumatoid arthritis|Patients with a clinical diagnosis of rheumatoid arthritis and treated with immunosuppressive medication
32755492|NCT04798625||Psoriatic arthritis|Patients with a clinical diagnosis of psoriatic arthritis and treated with immunosuppressive medication
32755493|NCT04798625||Spondyloarthritis|Patients with a clinical diagnosis of spondyloarthritis and treated with immunosuppressive medication
32755494|NCT04798625||Crohn disease|Patients with a clinical diagnosis of Crohn disease and treated with immunosuppressive medication
32755495|NCT04798625||Ulcerative colitis|Patients with a clinical diagnosis of ulcerative colitis and treated with immunosuppressive medication
32755496|NCT04798625||Autoimmune hepatitis|Patients with a diagnosis of autoimmune hepatitis and treated with immunosuppressive medication
32755497|NCT04798625||Liver transplant|Patients who have undergone liver transplantation and are treated with immunosuppressive drugs
32755498|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
32755499|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
32755500|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
32755501|NCT04543643|Experimental|Carvedilol+ berberine|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85mm Hg and HR 55/min. Berberine is started at a dose of 0.3g twice per day.
32755502|NCT04543643|Active Comparator|Carvedilol|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85 mm Hg and HR 55/min.
32755503|NCT02417155|Experimental|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
32755504|NCT02417155|Active Comparator|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
32755505|NCT02417155|Active Comparator|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
32755506|NCT02417155|Active Comparator|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
32755507|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
32755508|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
32755509|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
32755510|NCT05377619|Experimental|prucalopride|prucalopride 2 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
32755511|NCT05377619|Experimental|buspirone|buspirone 10 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
32755512|NCT05377619|Placebo Comparator|placebo|placebo 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
32755513|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
32755514|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
32755515|NCT04393337|Experimental|Gestational Age Chart Method|In this method, the endotracheal tube insertion depth is obtained from the gestational age chart provided in the 7th edition textbook of neonatal resuscitation program (adapted from Kempley et al. PubMed identifier number: 18372092)
32755516|NCT04393337|Active Comparator|Nasal-Tragus Length Method|In this method, the endotracheal tube insertion depth is calculated based on the formula-the distance from nasal septum tip to ear tragus+1 cm
32755517|NCT04322513||Covid-19 positive patients|all drugs used for standard treatment
32755518|NCT04322513||Covid-19 negative patients|
32755519|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
32755520|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
32755521|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
32755522|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
32755523|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
32755524|NCT03199157|No Intervention|Control group|
32755525|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
32910412|NCT04297605|Experimental|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
32755526|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
32755527|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
33239953|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
33071575|NCT05784870|Experimental|Shengxuening Tablets|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
32744500|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
32755528|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
33071576|NCT05784870|Active Comparator|ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
33239954|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
33239955|NCT04085666|Experimental|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
33239956|NCT04085666|Experimental|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
33239957|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
33239958|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
33239959|NCT00743769|Active Comparator|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
33239960|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
33239961|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
33239962|NCT00743847|Placebo Comparator|placebo|
33239963|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
33239964|NCT00743847|Active Comparator|varenicline 1mg BID|
32742742|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
32910413|NCT04297605|Experimental|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
32910414|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
33397025|NCT03503318|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
32910415|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
33397026|NCT04971408|Other|control|passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.
33397027|NCT04971408|Experimental|Passive heat stress|After arm 1, passive heat stress 3x/week x8 weeks.
32742743|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
32742744|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
32742745|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
32755529|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
32755530|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
32755531|NCT02416999|Experimental|patient group|
32755532|NCT04194671|Experimental|Mesenchymal stem cells cohort|
32755533|NCT04194671|Placebo Comparator|Saline cohort|
32755534|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
32755535|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
32755536|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
32755537|NCT02465333|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A~Heel fat grafting procedure and local anesthetic and visits at:~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
32755538|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
32755539|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to~Passive stretching exercises for spasticity reduction~Gait exercises~Walking on treadmill~Lower limb strengthening exercises~Exercises for balance improvenet"
32755540|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
32755541|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
32755542|NCT01679405|Experimental|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
32755543|NCT01679405|Experimental|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
32755544|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
32755545|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
32755546|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
32755547|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
32755548|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
32755549|NCT03175393||postprandial dyslipidemia|
32755550|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
32755551|NCT02422459|No Intervention|Wait-list control|No treatment assigned
32755552|NCT03270527|Experimental|High SFA diet to low SFA diet|Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain ~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of ~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed and peer-reviewed for a previous dietary intervention study ('DIVAS') at the University of Reading, U.K.
32755553|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
32755554|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
32755555|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
32755556|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
32755557|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
32755558|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
32755559|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
32755560|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
32755561|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
32755562|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
32910416|NCT03904251|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
32910417|NCT04742517|Experimental|Single ascending dose of ASP1128|Participants (6 for each cohort) will receive a single dose of ASP1128.
33397028|NCT03396913|Experimental|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
32910418|NCT04742517|Placebo Comparator|Single ascending dose of Placebo|Participants (2 for each cohort) will receive a single dose of matching Placebo.
33397029|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
33397030|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
32910419|NCT04742517|Experimental|Multiple ascending dose of ASP1128|Participants (9 for each cohort) will receive daily doses of ASP1128 for 7 consecutive days.
32910420|NCT04742517|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort) will receive matching Placebo for 7 consecutive days.
32910421|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
33071577|NCT05784857|Other|No Intervention and Touch Group|"Each intubated infant will be follewed up during 3 aspiration procedures. Different touching techniques will be used for preterm infants in each aspiration application.~The first aspiration procedure will be performed without intervention. During the second aspiration procedure, yakson touch will be applied.Third aspiration procedure, gentle human touch will be applied."
33397031|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
33071578|NCT05784844|Active Comparator|Meropenem Arm|Patients who meet inclusion criteria may be randomized to meropenem (routine standard of care) dose according to local dosing guidelines to include the use of extended-infusions and adjustments to account for renal function. Duration will be managed by the primary team.
32742746|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
32742747|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
32742748|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
32742749|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
32910422|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
33071579|NCT05784844|Active Comparator|Micafungin Arm|Patients who meet inclusion criteria may be randomized to micafungin dosed as 150mg intravenously every 24 hours according to local dosing guidelines. Duration will be managed by the primary team.
33239965|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~psychiatric treatment by a study psychiatrist~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
33397032|NCT03982433|Experimental|Intervention|participants all receive the intervention
32910423|NCT04708197|Other|aphasic patients|post stroke aphasic patients will receive 10 sessions of high frequency rTMS 3 times per week over the damaged hemisphere without language therapy
32910424|NCT04290663|Active Comparator|RAI group|
32910425|NCT04290663|Experimental|GUIDED FOLLOW-UP group|
33397033|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
33397034|NCT01375998||Group 1|
33397035|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
33397036|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
33397037|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
33397038|NCT03683108|Placebo Comparator|Saline solution|
33397039|NCT05137860|No Intervention|Standard Care Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
33397040|NCT05137860|Experimental|Bortezomib Treatment Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
33397041|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
32910426|NCT04932915|Experimental|UNI91103 intranasal spray 1%|UNI91103 intranasal spray 1%, BID, 10 consecutive days
32910427|NCT04932915|Placebo Comparator|Placebo|Placebo intranasal spray, BID, 10 consecutive days
33397042|NCT03682952|No Intervention|Anemia control group|Anemia patients
33397043|NCT03682952|No Intervention|Control group|Healthy person
33397044|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
33397045|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
33397046|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
33071580|NCT05784831|Experimental|Regular Intervention Group|Group using the app delivering reappraisal training for 21 consecutive days.
33071581|NCT05784831|Experimental|Burst Intervention Group|Group using the app delivering reappraisal training for 7 consecutive days, then having 7 days break and again using the app 7 consecutive days.
33071582|NCT05784831|Active Comparator|Active Control Group|Group using the ecological momentary assessment app for 21 consecutive days.
33071583|NCT05784818|Experimental|Intervention + No Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook.
33071584|NCT05784818|Experimental|Intervention + Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook. Additionally, participants randomized to this arm will complete an additional session 4 weeks after the third session of the intervention.
32910428|NCT04926051|Experimental|Part A: SAD|SAD = Single Ascending Dose
32910429|NCT04926051|Experimental|Part B: MAD|MAD = Multiple Ascending Dose
32910430|NCT04926051|Experimental|Part C: JMAD|JMAD= Japanese Multiple Ascending Dose
32910431|NCT04926051|Experimental|Part D: FE/BA|FE/BA = Food Effect/Relative Bioavailability
32910432|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
32910433|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
32910434|NCT04708119|Other|histopathological evaluation|angulation of impacted lower mandibular third molar and histopathological evaluation
33071585|NCT05784818|No Intervention|Waitlist Control|"This arm will have n=67 participants. Those randomized to this arm will be engaged in treatment as usual, participating in the same services and activities that they were engaged with prior to recruitment into the study."
32742750|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
32910435|NCT04844307|Active Comparator|Standard PT group|The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week. There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
32910436|NCT04844307|Experimental|Divided session PT group|The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week. The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
33071586|NCT05784805|Experimental|Participants with ongoing non-convulsive or focal motor SE|Adult patients with ongoing non-convulsive or focal motor SE despite treatment with at least 2 ASMs and who are monitored with surface EEG will be screened and enrolled to receive up to 2 sessions of PLIFU.
33071587|NCT05784792|No Intervention|Lugol -|No pre-operative Lugol Solution preparation
33071588|NCT05784792|Active Comparator|Lugol +|Pre-operative Lugol preparation (10 drops per day orally three times a day for 7 days for an amount of 10,5 ml of Lugol solution that contains 1,68 gr of Iodine).
33071591|NCT05784766|Active Comparator|Screen group|Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
32910437|NCT04285983||Trelagliptin 25 mg|Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.
32910438|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
33071592|NCT05784766|Active Comparator|Usual Care|For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.
32910439|NCT01224236|Sham Comparator|control|multivitamin solution without iron
32910440|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
32910441|NCT03780075|Experimental|2.00 GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
32744501|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
32910442|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
32910443|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
32910444|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
32910445|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
33071593|NCT05784753|Experimental|HEART Camp|Participants in the HEART Camp group will be provided paid, in-person access to the medical fitness center and in-person coaching by a trained coach.
32910446|NCT03700437|Experimental|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
32910447|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
32910448|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
33397047|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
33397048|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
32755563|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
32755564|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
32755565|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
32755566|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
33397049|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
32755567|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~Mitral lateral annulus e' in tissue Doppler < 10 cm/s~American society of echocardiography (ASE) criteria 2009~ASE criteria 2016"
32755568|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
32744502|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
32910452|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
32910453|NCT03547245|Active Comparator|HIV-uninfected, healthy adults|
32910454|NCT03547245|Placebo Comparator|HIV-uninfected, healthy adults - placebo|
32910455|NCT01226420|Experimental|Alefacept|Alefacept iv
32910456|NCT05440227|Experimental|PG2 treatment group|500 mg PG2 injection will be administered to this group once per week for 8 weeks.
32910457|NCT05440227|Experimental|Placebo-controlled group|Placebo injection will be administered to this group once per week for 8 weeks.
33071594|NCT05784753|Experimental|HEART Camp Connect|Participants in the HEART Camp Connect group will be provided paid, virtual access to the medical fitness center and virtual coaching by a trained coach via videoconference. Participants will also receive automated, asynchronous motivational electronic messaging if they are below the weekly adherence threshold.
33397050|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
32755569|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
32755570|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
32755571|NCT03185897||Hemophilia A|Participants with hemophilia A
32755572|NCT03185897||Hemophilia B|Participants with hemophilia B
32755573|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
32910458|NCT04277637|Experimental|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
32910459|NCT04277637|Experimental|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
32910460|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib
32755574|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
32755575|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
32755576|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
32755577|NCT01603355|Experimental|Tocilizumab|
32755578|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
32755579|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
33397051|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
33397052|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
32755581|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
32755582|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
32755583|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
32755584|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
32755585|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
32755586|NCT05094947|Experimental|intermittent catheterization (group B)|Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.
32755587|NCT05094947|Active Comparator|Catheter Foley (group A)|The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.
32755588|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
32755589|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
32910461|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with zanubrutinib
32755590|NCT05094869||APP self-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (manually set up by the patients on the APP), medication reminder, health education knowledge, etc.
32755591|NCT05094869||APP intelligent-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (automatically set up by the APP), medication reminder, health education knowledge, etc. The doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
32755592|NCT05094869||Control group|History data of another 4000 Patients who have been on the platform of China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B cirrhosis would be extracted and serve as the control group (No APP, no follow-up reminders, no online interaction).
32755593|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
32755594|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
32755598|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
32755599|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
32755600|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
32755601|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
32910462|NCT04277637|Experimental|: BGB-11417 + Zanubrutinib Combination Therapy Dose Escalation: Part 5|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with obinutuzumab without and with zanubrutinib.
32910463|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 6|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with obinutuzumab without and with zanubrutinib
33397053|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
33397054|NCT03682562||Normal Subjects|"Patients who give a history of:~No smoking~No alcohol~No systemic disease; and who on conventional oral examination have:~No visible oral lesions on conventional oral examination .~Good oral hygiene."
32755602|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
32755603|NCT05094479|Experimental|Health information delivered via health app|Use of a health app with health information
32755604|NCT05094479|No Intervention|Control|Use of a health app without health information
32755605|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
32755606|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
32755607|NCT05094167|Experimental|probiotics group|"The oral probiotic (Lactobacillus Bifidobacterium V9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
32755608|NCT05094167|Placebo Comparator|placebo group|Immunotherapy with placebo alone
32755609|NCT05094167|No Intervention|healthy control group|healthy control group
32755610|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
32755611|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
32755612|NCT05093465|Active Comparator|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
32755613|NCT05093465|Experimental|Technology Intervention|Participants were given the same intervention materials as the active control condition plus procedures to change technology use.
32755614|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
32755615|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
32755616|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
32755617|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
32755618|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
32755619|NCT05093309|Experimental|Intervention|The intervention group received naloxone resources + monthly reminders + educational webinar.
32755620|NCT05093309|No Intervention|Control|The control group received naloxone resources + monthly reminders + delayed educational webinar (after the 3-month study period).
32755621|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
32755622|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
32755623|NCT05093231|Experimental|Pembrolizumab and olaparib|"Pembrolizumab will be given as a fixed dose of 200mg standard dose on Day 1 (+/-3 days) of every 3 weeks cycle , administered intravenously as a ~30 minute infusion, as per standard clinical practice. Patients continuing beyond 27 weeks can switch to pembrolizumab 400mg every 6 weeks (as per standard clinical practice).~Olaparib dose is 300mg given orally, twice daily, from Day 1 to Day 21 continuously of each 3-week cycle. Dosing will start on day 1 of each cycle."
32755624|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
32755625|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
32755626|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
32755627|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
32755628|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
32755629|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
32755630|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
32910464|NCT04743453|Experimental|Dapagliflozin|
32910465|NCT04743453|Placebo Comparator|Placebo|
32755631|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
32755632|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
32755633|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
32755634|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
32755635|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
32755636|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
32755637|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
32755638|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
32755639|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
32755640|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
32755641|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
32755642|NCT04542395|Experimental|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
32755643|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
32755644|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
32755645|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
32755646|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
32755647|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
32755648|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
32755649|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
32755650|NCT02411227|Experimental|1|Immediate Intervention
32755651|NCT02411227|No Intervention|2|Wait list
32755652|NCT05093075|Experimental|Treatment Arm|Participants randomized to treatment will received 1.0 plasma volume exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 treatments. The management of septic shock, including but not limited to, antibiotic therapy, infection source control, fluid therapy, mechanical ventilation, and nutrition, will be at the discretion of the treating medical team, and will be recorded and reported.
32755653|NCT05093075|No Intervention|Standard of Care Arm|Participants randomized to Standard-of-Care will be treated at the discretion of the treating medical team. The management of septic shock, including but not limited to, antibiotic therapy, infection source control, fluid therapy, mechanical ventilation, and nutrition, will be at the discretion of the treating medical team, and will be recorded and reported.
32755654|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:~30 ml normal saline~3ml 0.5% preservative-free bupivacaine"
32755655|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine"
32755656|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
32755657|NCT04413227|Experimental|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
32755658|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
32910466|NCT04678557|Experimental|Sentinel units (aka Cohort 1)|VC-01 Combination Product; Up to ten (10) VC-01 sentinels
32755659|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
32755660|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
32755661|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
32755662|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
32755663|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
32755664|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
32755665|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
32755666|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
32755667|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
32755668|NCT05233423|Experimental|Intervention Group|The patients in the intervention group were applied 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
32755669|NCT05233423|No Intervention|Control Group|The patients in the control group were applied 9 times of cold gel in the form of 20 minutes of application and 40 minutes of rest after surgery.
32755670|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
32755671|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
32755672|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
32755673|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
32755674|NCT02411305||PCRC Palliative Care Clinicians|
32755675|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
32755676|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
32755677|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
32755678|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
32755679|NCT05080127|Experimental|study subjects|"Children with proven IgE-mediated food allergy to one of the allergenic foods described.~Parallel to the skin tests that are done as part of the accepted follow-up:~The parents will fill a questionnaire regarding the quality of life (QOL) and another questionnaire regards family and personal relevant medical history.~Patch test sticker with the allergenic food will be placed on the forearm for 15 minutes.~A week later and 2 months later, the same QOL questionnaire will be sent by e-mail."
32755680|NCT05080127|Active Comparator|Control - atopic children|"Children with atopic comorbidities except for food allergy (ie. atopic dermatitis, asthma, allergic rhinitis).~The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
32755681|NCT05080127|Active Comparator|Control - healthy children|"Children without any atopic comorbidity (ie. atopic dermatitis, asthma, allergic rhinitis, and food allergy).~The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
32755682|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
32755683|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
32755684|NCT05054621|Experimental|Heterologous group|1st dose AZD1222, 2nd dose MVC-COV1901
32755685|NCT05054621|Active Comparator|Homologous group (control)|1st dose AZD1222, 2nd dose AZD1222
32755686|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
32755687|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
32755688|NCT04459091|Experimental|Amino essential acids|oral supplementation with a mixture of amino essential acids 8 gr die in two administrations for six weeks
32755689|NCT04459091|Placebo Comparator|Placebo|placebo consisting in isocaloric product containing maltodextrins in two administrations for six weeks
32755690|NCT03175081|Experimental|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
32755691|NCT03175081|Experimental|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
32755692|NCT05016479|Experimental|Active arTMS (15 Hz)|The treatment involves 15 Repetitive Transcranial Magnetic Stimlation sessions (3/daily for 5 consecutive days, each session lasts 13 min with an interval of 50 min). Coil is placed on the left dorsolateral prefrontal cortex (LDLPFC).The stimulation has a frequency of 15 Hz and a intensity of 120% of the individual resting motor threshold.
32755693|NCT05016479|Sham Comparator|Sham arTMS|Sham group receives the same Repetitive Transcranial Magnetic Stimlation sessions of active compactors. However the interventions in the place group are with a superficial stimulation of scalp muscles only, in order to induce a sensation close to the one experienced with the real rTMS stimulation.
32755694|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
32755695|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
32755696|NCT03175003|Experimental|Food Product 3|Experimental 1
32755697|NCT03175003|Experimental|Food Product 4|Experimental 2
32755698|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
32755699|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
32755700|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
32755701|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
32755702|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
32755703|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
32755704|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
33071595|NCT05784753|No Intervention|Enhanced Usual Care|Participants in the Enhanced Usual Care group will be provided paid virtual access to the medical fitness center and virtual availability of the medical fitness center staff and study personnel for participant-initiated questions.
33071596|NCT05784740|Experimental|Exercise Intervention|Patients will participate in a 12-week (36 sessions) precision exercise training intervention
32755705|NCT02409901|No Intervention|Control|Standard clinical care only
32755706|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
32755707|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
32755708|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
32755709|NCT02409823||patients on atypical antipsychotics|
32755710|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
32755711|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
32755712|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
32755713|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
32755714|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
32755715|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
32755716|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
32755717|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
32755718|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
32755719|NCT04481269|Experimental|Research Group|Research group uses surface-modified composite coated orthopedic implants
33071597|NCT05784740|No Intervention|Attention Control|Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.
32755720|NCT04481269|Active Comparator|Controls Group|Controls group uses conventional orthopedic implants
32755721|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
32755722|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
32755723|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
32755724|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
32755725|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
32755726|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
32755727|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
32755728|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
32755729|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
32755730|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
32755731|NCT00701701|Experimental|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to [>=] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than [<6] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
32755732|NCT00701701|Experimental|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers >=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was <6 months of age at time of enrollment). In addition,rituximab 375 mg/m^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m^2 subcutaneous on the day after Myozyme® infusion for 6 months.
32755733|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
32755734|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
32755735|NCT03174613|Experimental|LC51-0255|tablets, PO
32755736|NCT03174613|Placebo Comparator|Placebo|tablets, PO
32755737|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
32755738|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
32755739|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
32755740|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
32755741|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
32755742|NCT03174145|Active Comparator|Active group|
32755743|NCT03174145|Sham Comparator|Control group|
32755744|NCT04480957|Experimental|Escalation Cohort dose 1 of ARCT-021, 21 - 55 years|Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755745|NCT04480957|Experimental|Escalation Cohort dose 2 of ARCT-021, 21 -55 years|Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755746|NCT04480957|Experimental|Escalation Cohort dose 3 of ARCT-021, 21 - 55 years|Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755747|NCT04480957|Experimental|Escalation Cohort dose 4 of ARCT-021, 21 - 55 years|Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755748|NCT04480957|Experimental|Expansion cohort dose regimen 1, 21 - 55 years.|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755749|NCT04480957|Experimental|Expansion cohort dose regimen 2, 21 - 55 years.|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
33397055|NCT04084769|Experimental|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
32742751|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
33071598|NCT05784727|Other|Earswitch Robustness|Participants will wear the Earswitch device and voluntarily contract their TT to complete a series of tasks shown on screen and/or explained audibly. We will also ask participants to complete questionnaires to understand participant opinions about the effectiveness, usability, and comfort of both their current device (if applicable) and the Earswitch.
32755750|NCT04480957|Experimental|Expansion cohort dose regimen 1, 56 - 80 years|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
32742752|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
32742753|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
32742754|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
32742755|NCT03058887|No Intervention|Control group|No exercise intervention.
33071599|NCT05784714|Experimental|Intervention|This arm will include daily diary assessment and GPS phone tracking, access to psychoeducational modules, skills practice, and tools to help with coping and stress reduction. Enhancements include geofencing alerts for risky environments; progress tracking and feedback reports; self-initiated tool engagement (e.g. push button to engage in coping exercise), robust JITAI programming that recommends skills for participants to use in the moment based on daily diary responses, positive mood building exercises, and support.
33071600|NCT05784714|No Intervention|GEMA|This arm will include daily diary and phone tracking. Participants in this arm will also respond to daily diary assessments twice daily but will not receive the psychoeducation interactive components such as tracking and feedback, alerts, or capacity to send alerts that connect them to tools. This arm will have access to resources.
33397056|NCT04084769|Experimental|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
33397057|NCT04084769|Experimental|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
33397058|NCT04084769|Experimental|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
32742756|NCT03606161|Experimental|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
33397059|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
32742757|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
32742758|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
32742759|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
32742760|NCT04962555||Meniscus Suture|The patient underwent meniscus suture surgery
32742761|NCT04962555||Partial meniscus resection|The patient underwent partial meniscus resection
32742762|NCT04962555||Subtotal meniscus resection|The patient underwent Subtotal meniscus resection
32742763|NCT04962555||Complete meniscectomy|The patient underwent complete meniscectomy
32742764|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
32742765|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
32742766|NCT03252821|No Intervention|Control group|Usual care
33397060|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
33397061|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
33397062|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
32755751|NCT04480957|Experimental|Expansion cohort dose regimen 2, 56 - 80 years|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
32755752|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
33397063|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
33397064|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
32755753|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
32755754|NCT02406079|Experimental|tracheotomy|
32755755|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
32755756|NCT02406001|Other|Control|Surgical intervention: open flap debridement
32755757|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
32755758|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
32755759|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
32755760|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
32755761|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age >28 days."
32755762|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10^9 pfu SQ at weeks 3, 7, 11, and 15
32755763|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
32755764|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
32755765|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
32755766|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
32755767|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
32755768|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
32755769|NCT01619410|Active Comparator|linezolid|
32755770|NCT01619410|Active Comparator|Clindamycin|
32755771|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
32755772|NCT04416724|Experimental|Phacoemulsification|Main study intervention will be Phacoemulsification
33239966|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~psychiatric treatment by a study psychiatrist~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
33239967|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
32755773|NCT04416724|Experimental|SLT|Main study intervention will be Selective Laser Trabeculoplasty
32755774|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
32755775|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
32755776|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
32755777|NCT04666714|Experimental|Praga formulation|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral"
32755778|NCT04666714|Active Comparator|Pregabalin|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral"
32755779|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32755780|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32755781|NCT05016167|Other|Control group (replacement every 24 hours)|The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours (the protocol currently used in the institution) in control group.
32755782|NCT05016167|Experimental|Experimental Group (replacement every 12 hours)|In the experimental group, the monitoring electrodes were replacement every 12 hours within 24 hours.
32755783|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33239968|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
32910467|NCT04678557|Experimental|Dose-finding units (aka Cohort 2)|VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
32910468|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
32910469|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
33397065|NCT03687398||patient|has laparoscopically proven endometriosis
33397066|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
32910470|NCT04274517|Experimental|Sterile Water|
32910471|NCT04274517|Experimental|3.5% betadine|
32910472|NCT04274517|Experimental|0.05% chlorhexidine gluconate|
32910473|NCT00365001|Experimental|1|
32910474|NCT00365001|Active Comparator|2|
32910475|NCT04741971|Experimental|Probiotics group|Will give Probiotics with Vit.D 3
32910476|NCT04741971|Placebo Comparator|Non-probiotics group|Will give Vit. D3 as placebo
32910477|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
32910478|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
32910479|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
33397067|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
32910480|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
32910481|NCT03192345|Experimental|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
32910482|NCT03192345|Experimental|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
32910483|NCT04246047|Experimental|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
32910484|NCT04246047|Active Comparator|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
32910485|NCT04392453|Experimental|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
32910486|NCT04250805|Active Comparator|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
32910487|NCT04250805|Experimental|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
33397068|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
33397069|NCT03687242|Experimental|SPR001|SPR001 at Dose A
33397070|NCT05760066|Experimental|Resistance Training Preconditioning (PRECON)|"This group will perform:~6 weeks of lower body focused resistance training~2 weeks of locking brace-induced immobilization of a randomized leg~6 weeks of lower body focused resistance training"
32910488|NCT04742127||Patients with septic arthritis of the native hip|
32910489|NCT04240665|Experimental|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
32910490|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
33397071|NCT05760066|Active Comparator|Control (CTL)|"This group will perform:~6 weeks of activities of daily living (no training)~2 weeks of locking brace-induced immobilization of a randomized leg~6 weeks of lower body focused resistance training"
33397072|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
33397073|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
32910491|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
32910492|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
32910493|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
32910494|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
32742767|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
32910495|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
33239969|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
33071609|NCT05784675|Experimental|MOBI-CPR|Participants use MOBI-CPR game at home environment.
33071610|NCT05784675|No Intervention|No MOBI-CPR|Participants do not use MOBI-CPR game at home environment.
33397074|NCT05074758||non-COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19
33397075|NCT05074758||COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19
33397076|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
33397077|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
33397078|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
33397079|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
32742768|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
32755784|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755785|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755786|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755787|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755788|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755789|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755790|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755791|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755792|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755793|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755794|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
32755795|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
32755796|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
32755797|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
32755798|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
32755799|NCT04400123|Experimental|Treatment group TR|Intervention: Drug: famitinib malate, new formulation; Intervention: Drug: famitinib malate, old formulation.
32755800|NCT04400123|Experimental|Treatment group RT|Intervention: Drug: famitinib malate, old formulation; Intervention: Drug: famitinib malate, new formulation.
32755801|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
32755802|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
32755803|NCT04916795|Experimental|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
32755804|NCT04916795|Experimental|Vupanorsen 160 milligram (mg)|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
32755805|NCT01677767||Cohort|
32755806|NCT04373837|Experimental|Group 1: Without pre - With post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic adaptation (PA) + VR task (5 sessions)."
32755807|NCT04373837|Experimental|Group 2: With pre - Without post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic (PA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + VR task (5 sessions)."
32755808|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
32755809|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
32755810|NCT04897295|Active Comparator|Active tDCS|The intervention will be the stimulation with transcranial Direct Current Stimulation (tDCS). Each patient will undergo a 20 minutes session with anode placed on the right Dorso-Lateral Prefrontal Cortex (RDLPFC) and the cathode on the left DLPFC (LDLPFC); the tDCS will administrate a 1 mA stimulation. During the intensive treatment phase participant will undergo one stimulation/day for 5 consecutive days. After this, participants will receive one stimulation per week for 3 months with the same parameters. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
32755811|NCT04897295|Sham Comparator|Sham tDCS|The intervention will be the stimulation with sham transcranial Direct Current Stimulation (sham tDCS). The device will be set by staff member not involved with data collection analysis to ensure the blinding of assessors. The device will be set to give a weak amperage for the first and the last 20 second of stimulation to ensure the blinding of participant giving them a similar sensation experienced by the active tDCS participants without stimulate brain tissues. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
32755812|NCT03189563|Placebo Comparator|Placebo|placebo, tid
32755813|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
32755814|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
32755815|NCT04254731|Other|Cross over study before and after drug switch|Stabilized on racemic methadone dose, switched to R-methadone of half racemic methadone dose. Cross over study, own control
32755816|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
32755817|NCT01603277|Placebo Comparator|Normal Saline|
32755818|NCT04192487|Experimental|Healthy Volunteers (HIV-negative)|Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days
32755819|NCT04192487|Experimental|HIV+ Patients (Fully Suppressed, Viral Load < 50c/mL)|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
32755820|NCT04192487|Experimental|HIV+ Patients (Not fully suppressed viral load > 1000c/mL|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
32755821|NCT04107623|Active Comparator|Grupp 1|Patients will be allocated to preserving the right gastric artery during the resection of GEJ cancer.
32755822|NCT04107623|Active Comparator|Grupp 2|Patients will be allocated to an extensive lymphatic resection (ligating the right gastric artery) during the resection of GEJ cancer.
32755823|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
32755824|NCT04655027|Experimental|Roxadustat|Patients will receive oral dose of roxadustat three times a week (TIW) for 2- weeks during treatment period.
32755825|NCT04655027|Active Comparator|rHuEPO|Patients will receive uniform brand of short acting intravenous or subcutaneous dose of rHuEPO two times a week (BIW) or TIW based upon their previous dose of rHuEPO for 2- weeks during treatment period.
32755826|NCT04631705|Experimental|Group 1A (uninfected) - low dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
32755827|NCT04631705|Experimental|Group 1B (uninfected) - mid dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
32755828|NCT04631705|Experimental|Group 1C (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
32755829|NCT04631705|Experimental|Group 2A (infected) - low dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
32755830|NCT04631705|Experimental|Group 2B (infected) - mid dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
32755831|NCT04631705|Experimental|Group 2C (infected) - high dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
32755832|NCT04631705|Experimental|Group 2D (infected)|SARS-CoV-2-infected volunteers will be randomized 1:1:1 to receive DZIF-10c by inhalation and infusion, DZIF-10c by inhalation and placebo by infusion, or placebo by inhalation and infusion
32755833|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
32755834|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
32755835|NCT03965897|Active Comparator|Attention Control (AC)|The primary purpose of this workshop is to provide attention and education to participants. Topics of discussion will include: a) the pathophysiology of postoperative pain and how it differs from preoperative pain, b) the role of contextual factors (e.g., depressive or anxiety symptoms, expectation) on the experience of pain, d) the role of inflammation in pain and healing, e) types of pain medications and other pain relief strategies provided following surgery, and f) goals of pain medications. Additionally, deep (diaphragmatic) breathing strategies will be taught and a progressive muscle relaxation exercise will be performed in the workshop at strategic times to maintain Veteran engagement.
32755836|NCT03965897|Experimental|Acceptance and Commitment Therapy (ACT)|"The ACT intervention will include: 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts such as I can't take this pain anymore or This is unfair) and learning how to willingly face experiences that cannot be changed; and 2) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise. The workshop will also include information on pain and pain control post-TKA."
32755837|NCT03876977|No Intervention|Non-invasive|Neuropathic drugs Pudendal infiltration
32755838|NCT03876977|Experimental|Robotic laparoscopic decompression|Robotic laparoscopic decompression of pudendal nerve entrapment.
32755839|NCT04508933||Typical ARDS|ARDS due to non Covid19 causes
32755840|NCT04508933||C-ARDS|ARDS due to Covid19
32755841|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
32755842|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
32755843|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
32755844|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
32755845|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
32755846|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
32755847|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
32755848|NCT03409991|Experimental|Experimental|Receives the 12-week Opening Doors group sessions, and up to 8 individual career counseling sessions.
32755849|NCT03409991|No Intervention|Waitlist Control|Offered non-vocational classes at the Boston University Center for Psychiatric Rehabilitation, and offered the chance to attend the Opening Doors program at the end of their enrolled 12-month study period.
32755850|NCT04435379|Experimental|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
32755851|NCT04435379|Placebo Comparator|Placebo|Physiological saline 0.1ml
32755852|NCT03407495|Experimental|single arm: IOP injection (MPB-1523)|single group treatment
32755853|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
32755854|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
32755855|NCT04365803||patient with radiological complete response|patient with radiological complete response after neoadjuvant chemotherapy
32755856|NCT04413383|Active Comparator|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
32755857|NCT04413383|Experimental|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
32755858|NCT04413383|Other|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
32755859|NCT03246425|Active Comparator|1. Volume control- Pressure control- APRV- VPA group|
32755860|NCT03246425|Active Comparator|2. Pressure control- APRV- Volume control- PAV group|
32755861|NCT03246425|Active Comparator|3. APRV- Volume control- pressure control- AVP group|
32755862|NCT03139721||Primary cohort|Subjects requiring aortic or mitral valve replacement
32755863|NCT04325789|No Intervention|Group 1 Control|Group 1 will serve as the control and undergo routine rotator cuff repair with suture anchors without the nanofiber scaffold.
32755864|NCT04325789|Active Comparator|Group 2 Scaffold|Group 2 will undergo rotator cuff repair with suture anchors and incorporation of the nanofiber scaffold.
33239970|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, & Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
33239971|NCT05341700|Experimental|Endurance and Jumping Exercises|5 days of endurance treadmill running and 5 sets of 10 jumping exercises
33239972|NCT05341700|Active Comparator|Endurance Exercise Only|5 days of endurance treadmill running
33397080|NCT05174364||Epidural Block|Epidural block for the control group will be done before induction of general anesthesia. Patients will be positioned in the sitting position, an 18-gauge Tuohy needle will be inserted into epidural space of Th 11-12 intervertebral space under aseptic condition. In the medial approach, the site of the insertion of the needle is between the spaces created by the vertebral spinous processes. Upon locating the desired spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle
33397081|NCT05174364||Quadratus Lumborum Block|Bilateral QL block type 3 (anterior) for the intervention group will be performed on both sides of the patient after induction of general anesthesia. Patient will be positioned in semi-lateral decubitus and using low-frequency ultrasonography (USG) guidance attached to inferior lumbar region (Petit's triangle) that is consisted of inferior iliac crest and bordered by two muscles such as latissimus dorsi muscle in the posterior, abdominal external oblique muscle in the anterior. The USG will display the Shamrock sign, where the transverse process of vertebrae L4 role as the trunk, erector spinae muscle on the posterior side, psoas major (PM) on the anterior side, and QL muscle on the lateral side. After the visualization of QL and PM muscles, the Contiplex R needle will be directed parallel to the posterior side of the ultrasound probe until the tip of needle is confirmed in the border of QL and PM muscle
33239973|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
33239974|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
33239975|NCT05365802|Experimental|68Ga-FAPi-46|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes
33239976|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
33239977|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
33239978|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
33239979|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
33239980|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
33239981|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
33239982|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
33239983|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
33397082|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
33397083|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
32755865|NCT02356757|Experimental|Personalized Behavioral Intervention (PBI)|The PBI is a 12-month long integrated, multicomponent counseling and dermal thermometry intervention targeting foot self-care, foot self-monitoring, diet, medication and physical activity. The intervention is based on self-regulation theory, the Transtheoretical Model and
33239984|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
33397084|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
33397085|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
33239985|NCT02564367|Experimental|Treatment|"First Cohort 1:~(n = 30 patients) 18 cycles S-1"
33239986|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
33239987|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
33239988|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
33239989|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
33239990|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
33239991|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
33239992|NCT00689793|Active Comparator|1|
33239993|NCT00689793|Placebo Comparator|2|
33239994|NCT04086290|Experimental|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
33239995|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:~The patients who have distant metastatic sites at first and recur from surgery:~The patients who are going to receive first-line chemotherapy:"
33239996|NCT05431491|Experimental|Ultrafiltration cohort|These patients will be recruited into the study to assess the feasibility of slow continuous ultrafiltration through either a standard central venous catheter, or peripheral intravenous cannula.
33239997|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
33239998|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
33239999|NCT00744159||OC|Open colorectal resection
33240000|NCT00744159||LC|Laparoscopic colorectal resection
33397086|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
33397087|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
32755866|NCT02356757|Placebo Comparator|Current Best Practice (CBP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes and foot care, and will also receive counseling regarding preventing general health conditions.
33240001|NCT04086134|Experimental|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
33240002|NCT04086134|Experimental|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
32755867|NCT03196895|Active Comparator|WR|Weight reduction training
33240003|NCT04086134|Placebo Comparator|Control fruit products|Three servings of control fruit products per day for 4 weeks.
33240004|NCT04060329|No Intervention|Phase 1|Usual care
33240005|NCT04060329|Experimental|Phase 2|Usual care + coopeRATE Prompt intervention
33240006|NCT04060329|Other|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
33240007|NCT04060563|Sham Comparator|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
33240008|NCT04060563|Experimental|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
33240009|NCT02591576||ST-elevation myocardial infarction (STEMI)|
33240010|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
33240011|NCT00744315|Other|1|Controlled
33240012|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
33240013|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
33240014|NCT00744393|Active Comparator|A|Active drug
32742769|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
33240015|NCT00744393|Placebo Comparator|P|Placebo drug
33240016|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
33240017|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms."
33240018|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms"
33240019|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
33240020|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
33240021|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
33240022|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
33240023|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
33397088|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
32755868|NCT03196895|Active Comparator|GE|PPG training
33240024|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
33240025|NCT00999609|Experimental|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
33240026|NCT00999609|No Intervention|Control|No intervention
33240027|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
33240028|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
32755869|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
33240029|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
33240030|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
32755870|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
32910496|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
33240031|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
33240032|NCT00746655|Other|SBRT / TACE|
33240033|NCT04060719|Experimental|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
33240034|NCT04060719|Experimental|Test (Period 2) - BI 894416 + Rifampicin|
33240035|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
33240036|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
33240037|NCT04060173|Experimental|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
33240038|NCT04060173|Placebo Comparator|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
33071611|NCT05784662|Experimental|Social Workers Addressing Firearm Risk|The Social workers Addressing Firearm Risk (SAFR) intervention is fully-online intervention that contains four modules. Each module includes interviews with experts, didactic content, handouts, and brief quizzes to check learning (required by New York State for continuing education credit).
33240039|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
32755871|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
32755872|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
32755873|NCT05092685|Experimental|AAVLK03hOTC (also known as ssAAV-LK03.hAAT.hcoOTC)|Dose escalation in three groups from 6x10^11vg/kg (low dose), 2x10^12vg/kg (intermediate dose) to 6x10^12vg/kg (high dose). Dose expansion in a fourth group with the best acceptable safety:efficacy ratio
32755874|NCT05092217|Experimental|Tirelizumab plus salvage surgery|Tirelizumab: Tirelizumab treatment after salvage surgery. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
32755875|NCT05092217|Active Comparator|salvage surgery alone|Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
32755876|NCT04413305|Experimental|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
32755877|NCT04413305|No Intervention|Non-intervention|Non-intervention
32755878|NCT03854747|No Intervention|control group|
32755879|NCT03854747|Experimental|working group|
32755880|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
32755881|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
32755882|NCT05091827||Pregnant women with pre-eclampsia|Pre-eclamptic pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study.
32755883|NCT05091827||Normotensive pregnant women|Normotensive pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study
32755884|NCT05091827||Offspring of pre-eclamptic women|Both male and female offspring of pre-eclamptic women recruited in this study will be recruited into this study group.
32755885|NCT05091827||Offspring of normotensive pregnant women|Both male and female offspring of from normotensive pregnant women recruited in this study will be recruited into this study group.
33071612|NCT05784662|No Intervention|Control|Wait list control. Will receive access to SAFR intervention at conclusion of the study.
33071613|NCT05784649|Other|control group|The interventions of the control group will receive the routine health education proposed by relevant experts in China which are chosen by the Chinese Medical Association.
32755886|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
32755887|NCT04534907|Active Comparator|VR(ERP）|The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
32755888|NCT04534907|Active Comparator|traditional ERP|The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
32755889|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
32755890|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
32755891|NCT05091515||Health workers|Medical personnel: doctors, nurses.
32755892|NCT05091359|Experimental|Study group|Participants in which absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste at the time of the placement of the hip implant to prevent loosening of it's unstable trans-trochanteric fractures of the proximal femur, were applied.
32755893|NCT05091359|No Intervention|Control Group|Participants without application of graft during hip implant.
32755894|NCT03670745|Experimental|Pre-visit Planning Tool|To determine the effectiveness an electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit. Interviews will also explore approaches to implement and evaluate such a tool.
32755895|NCT03670745|Active Comparator|control group|Will not be receiving an electronic self-administered pre-visit planning tool.
32755896|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
32755897|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
32755898|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
32755899|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
33240040|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
33240041|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
33240042|NCT00741507|Active Comparator|1|No alcohol drinking
33240043|NCT00741507|Active Comparator|2|Mild alcohol drinking
33240044|NCT00741507|Active Comparator|3|Moderate alcohol drinking
33240045|NCT00741507|Active Comparator|4|Severe over alcohol drinking
33240046|NCT00741507|Active Comparator|5|Alcohol-dependent
33240047|NCT00688623|Experimental|Everolimus|Everolimus
33240048|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
33240049|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loading dose (8mL).~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
33240050|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loadind dose (8 mL)~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
33240051|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
33240052|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
33240053|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
33240054|NCT00717236|Experimental|Certolizumab pegol (CZP)|
33240055|NCT00717236|Placebo Comparator|Placebo|
33240056|NCT04085354|Placebo Comparator|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
33240057|NCT04085354|Active Comparator|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
33240058|NCT04085354|Active Comparator|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
33240059|NCT04085354|Active Comparator|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
33240060|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
33240061|NCT00719810|Experimental|1|
33240062|NCT00719810|Experimental|2|
33240063|NCT00719810|Active Comparator|3|
33240064|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This cohort will complete a first round of interviews to assess measure content."
33071614|NCT05784649|Experimental|intervention group|The interventions of the intervention group will include routine health education. And then the participants will have individual counsel about health-promoting behaviors with a midwife and a doctor. The counseling will be based on the procedure of the health promotion model.
33240065|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
33240066|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
33240067|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
33240068|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
32742770|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
33071615|NCT05784636|Experimental|Non-invasive BiPAP ventilation treatment group|Patients were first treated with HFNC on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40 L/min, maintaining SpO2>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge
33240069|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
33240070|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
33240071|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
32910497|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
32910498|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
33240072|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
33397089|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
33397090|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
33397091|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
32910499|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
32910500|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
32755900|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
32755901|NCT05091125||Patients over 65 years old who have undergone a mild head trauma.|
32755902|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
32755903|NCT03593759|Active Comparator|Prednisone (or Prednisolone)|"[Dose everywhere except Japan] Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)~[Dose in Japan] Prednisone or prednisolone 0.5 mg/kg po (max 30mg) for one month then reduce by 5 mg per month for five months"
32755904|NCT03593759|Experimental|Methotrexate|"[Dose everywhere except Japan] Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + Prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid 2 mg po daily for 6 months.~[Dose in Japan] Methotrexate 5-20mg mg orally, sc, or IM once a week for 6 months+ Prednisone or Prednisolone 20mg OD for 1 month then 10mg OD for 1 month then 5 mg OD one month. Also Folic Acid 2 mg po daily for 6 months."
32755905|NCT03564821|Experimental|Ivosidenib (500mg/day)|-Ivosidenib will be administered orally every day
32755906|NCT03564821|Experimental|Ivosidenib (250mg/day)|-Ivosidenib will be administered orally every day
32755907|NCT03364283||Sitting Position|Sitting and semi-sitting
32755908|NCT03364283||Horizontal Position|Prone, lateral and park bench.
32755909|NCT03328013||Women aged 25 to 33 years in 2017|"Women aged 25 to 33 years in 2017 and having performed an analyzed smear at the Brest University Hospital.~They are invited to fill out an online questionnaire asking them about :~vaccine status against HPV~if vaccinated, the name of the vaccine and the number of injection~age of first sexual intercourse~do they have a gynecological pathology"
32755910|NCT02014402|Experimental|IG1202-A (Vascular)|
32755911|NCT02014402|Experimental|IG1202-B (Hepatic)|
32755912|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
32755913|NCT02014402|Experimental|IG1202-D (Spinal)|
32755914|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
32755915|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
32755916|NCT02839343|Experimental|mFOLFIRINOX + surgery + FOLFOX|Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
32755917|NCT02839343|Experimental|mFOLFIRINOX + radiation + surgery + FOLFOX|Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
32755918|NCT00127673|Active Comparator|CBT no choice|Participants will receive no choice cognitive behavioral therapy (CBT no choice)
32755919|NCT00127673|Active Comparator|CBT choice|Participants will receive choice cognitive behavioral therapy (CBT choice)
32755920|NCT00127673|Active Comparator|sertraline no choice|Participants will receive no choice sertraline (sertraline no choice)
32755921|NCT00127673|Active Comparator|sertraline choice|Participants will receive choice sertraline (sertraline choice)
32755922|NCT05377463|Experimental|Condition 1: Components 1, 2, 3 and 4|"Participants will be assigned to receive all of the four intervention programs:~Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~Patient Navigation for HIV Care~Life Steps Program for Medication Adherence"
32755923|NCT05377463|Experimental|Condition 2: Components 1, 2, 3|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~Patient Navigation for HIV Care"
32755924|NCT05377463|Experimental|Condition 3: Components 1, 2 and 4|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~4) Life Steps Program for Medication Adherence"
32755925|NCT05377463|Experimental|Condition 4: Components 1 and 2|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy"
32755926|NCT05377463|Experimental|Condition 5: Component 1, 3, and 4|"1) Peer-Support for Medication-Assisted Treatment~3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
32755927|NCT05377463|Experimental|Condition 6: Component 1 and 3|"1) Peer-Support for Medication-Assisted Treatment~3) Patient Navigation for HIV Care"
32755928|NCT05377463|Experimental|Condition 7: Component 1 and 4|"1) Peer-Support for Medication-Assisted Treatment~4) Life Steps Program for Medication Adherence"
32755929|NCT05377463|Experimental|Condition 8: Component 1|1) Peer-Support for Medication-Assisted Treatment
32755930|NCT05377463|Experimental|Condition 9: Components 2, 3, and 4|"2) Behavioral Activation Therapy~3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
32755931|NCT05377463|Experimental|Condition 10: Components 2 and 3|"2) Behavioral Activation Therapy~3) Patient Navigation for HIV Care"
32755932|NCT05377463|Experimental|Condition 11: Component 2 and 4|"2) Behavioral Activation Therapy~4) Life Steps Program for Medication Adherence"
32755933|NCT05377463|Experimental|Condition 12: Component 2|2) Behavioral Activation Therapy
32755934|NCT05377463|Experimental|Condition 13: Component 3 and 4|"3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
32755935|NCT05377463|Experimental|Condition 14: Component 3|3) Patient Navigation for HIV Care
32755936|NCT05377463|Experimental|Condition 15: Component 4|4) Life Steps Program for Medication Adherence
32755937|NCT05377463|Experimental|Condition 16: No Components|Participants not assigned to any of the 4 components. They are placed on a wait list and will receive components after the primary data collection period.
32755938|NCT05377073|Experimental|Hatha Yoga|Participants performed 1 hour supervised Yoga sessions once a week for a total of eight weeks.
32755939|NCT05377073|Experimental|Stretching|Participants performed 1 hour supervised Stretching sessions once a week for a total of eight weeks.
32755940|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
32755941|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
32755942|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
32755943|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
32755944|NCT05376995|Experimental|Graston technique.|The Graston Technique is a form of manual therapy known as soft-tissue instrument-assisted mobilization
32755945|NCT05376995|Experimental|muscle energy technique|Muscle Energy Technique (MET), uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle
32755946|NCT05090735|Active Comparator|SPIP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
32755947|NCT05090735|Active Comparator|SPIP Block with TAP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib. This group of patients will also receive unilateral TAP block by injecting 20 mL of 0.25% bupivacaine in the plane between the internal oblique and transversus abdominis muscles.
32755948|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
32755949|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
32755950|NCT02761499||Total Hip Arthroplasty|The United Hip System consist of several components, and for this clinical evaluation it includes the U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem.
32755951|NCT02379611|Active Comparator|normally hearing children|
32755952|NCT02379611|Experimental|Congenital profound deaf children|
32755953|NCT05376605||lung transplant|Patients who have passed at least 3 months after lung transplantation
32755954|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
32755955|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
32755956|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32755957|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33240073|NCT04085198|Active Comparator|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
32755958|NCT05376527|Experimental|VV-GMCSF-Lact|Double Recombinant Vaccinia Virus VV-GMCSF-Lact
32755959|NCT05090579|Active Comparator|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine , 1 mL of 10 mg of nulbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
32755960|NCT05090579|Active Comparator|Group II (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine ,2 mL of 20 mg of nulbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
32755961|NCT05090579|Active Comparator|Group lll(B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
32755962|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
32755963|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
32755964|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
32755965|NCT05087537|Active Comparator|Valve ablation|Valve ablation
32755966|NCT05087537|Active Comparator|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
33240074|NCT04085198|Placebo Comparator|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
33240075|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
33240076|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
33240077|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
33240078|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
33240079|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
33240080|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
33240081|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
33240082|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
33240083|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
33240084|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
33240085|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
33240086|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
33240087|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
33240088|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
33240089|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
33240090|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
33240091|NCT04060407|Experimental|Advanced Melanoma|Patients with advanced melanoma.
33240092|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
33240093|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
33240094|NCT00746967|Other|Arm 1|
32742771|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
32742772|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
33240095|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
33240096|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
33240097|NCT00741663|Active Comparator|A|
33240098|NCT00741663|Experimental|B|
33240099|NCT00745017|Experimental|1|
33240100|NCT00745017|Experimental|2|
33240101|NCT00745017|Experimental|3|
33240102|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
32742773|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
33240103|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
33240104|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
33240105|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
32742774|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
32742775|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
33071616|NCT05784636|Experimental|HFNC treatment group|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC until discharge.
32742776|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
33240106|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
33240107|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
33240108|NCT00745173|Other|1|
33240109|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
33240110|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
33240111|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
33240112|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:~15 minutes without acoustic pulses~15 minutes with acoustic pulses~15 minutes without acoustic pulses~Two different protocols are applied:~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.~Participants with ESES/CSWS: only Protocol A."
32755977|NCT05095571|Other|NO-ALS Extension Study High Dose EH301|
32755978|NCT05095493|Experimental|zinc, then placebo|Participants first received oral zinc acetate 50 mg tab each day for 7 days before scheduled BoNT injection. 3 months later participants received oral placebo (matching oral zinc) tablet each day for 7 days before scheduled BoNT injection.
32755979|NCT05095493|Experimental|placebo, then zinc|Participants first received placebo tablet (matching oral zinc) each day for 7 days before scheduled BoNT injection. 3 months later participants received oral zinc acetate 50 mg tablet each day for 7 days before scheduled BoNT injection.
32755980|NCT05095415|Active Comparator|Typical Pre-operative Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
32755981|NCT05095415|Experimental|Occupational Therapy Consult Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
32755982|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
32755983|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
32755984|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
32755985|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
32755986|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
32755987|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
33240113|NCT00745329||2|"patients~healthy volunteers"
32755988|NCT05095103||Stable Immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on prednsiolone <5mg/day and azathioprine or mycophenolate.
32755989|NCT05095103||Stable Non-immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on ≤120mg pyridostigmine/day and no immunosuppression.
32755990|NCT05095103||Refractory|Acetylcholine repector antibody positvie myasthenia gravis, meeting the NHS England criteria for Rituximab
32755991|NCT05095103||Healthy Controls|No autoimmune disease or current solid organ or haematological malignancy.
32755992|NCT05095025|Experimental|Bupivacaine dose finding|Sequential up and down dose modification based on the outcome of the intervention in the preceding participant
32755993|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
32755994|NCT05065073|Active Comparator|Iso-Osmolar Contrast Media|Will receive iso-osmolar media first, low-osmolar media second
32755995|NCT05065073|Active Comparator|Low-Osmolar Contrast Media|Will receive low-osmolar media first, iso-osmolar media second
32755996|NCT05059379|Active Comparator|Breast/chest wall+undisseted axillary+IMN+medial SCL ( medial SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and medial supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
32910501|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
32910502|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
33240114|NCT00741897|Experimental|1|Fexofenadine
33240115|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
33240116|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
33240117|NCT00688155|Experimental|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.~."
32910503|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
32742777|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
32755997|NCT05059379|Experimental|Breast/chest wall+undisseted axillary+IMN+entie SCL (entire SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
32755998|NCT05056259||newly diagnosed endometrial cancer|
32755999|NCT05056259||Recurrent cases of endometrial cancer|
32756000|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
32756001|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
32756002|NCT05084027|Experimental|treatment group|older patients accepting venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation treatment
32756003|NCT02013778|Experimental|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
32756004|NCT05374889|Experimental|Exercise Group|Athletes were asked to throw the ball at predetermined targets in different positions with their eyes closed. In the first exercise, the athlete was positioned 2 m from the target in a sitting position, facing the marked lines on the wall. It was asked to make 3 trial shots with a basketball ball while the eyes were open, from the bottom up to the 3 lines on the wall. Then the shots were made while the eyes were closed. In the next exercise, it was requested to make 3 trial shots from the bottom up by looking at the same 3 lines marked in the supine position at the distance of 1 m from the target. Then the shots were made with the eyes facing the ceiling. The last exercise was in a standing position, from the line marked 5 m from the target to the basket, it was requested to make 3 trial free throw with eyes open to the basket. Then, after each throw, the athlete was asked to turn around his own axis and continue to next throw, with eyes closed.
32756005|NCT05374889|No Intervention|Control Group|Control group did not participate in any exercise program.
32756006|NCT04676308||AI arm|Standard colonoscopy with Artificial Intelligence-GI GeniusTM
32756007|NCT04676308||Cuff arm|Endo-cuff Vision aided colonoscopy with Artificial Intelligence -GI GeniusTM
32756008|NCT05074745|Experimental|Buccal and nasopharyngeal swabs|One patient will have 3 swabs taken, 2 buccal for PCR and ELISA POCT, 1 nasopharyngeal for PCR
32756009|NCT05374811||Multiple sclerosis.|Those diagnosed with Multiple Sclerosis according to the 2017 Revised McDonald criteria
32756010|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
32756011|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
32756012|NCT02448797|Active Comparator|standard chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
32756013|NCT05374733|Other|Single arm|Coronary physiology measurements both pre- and post- transcatheter left-sided valvular intervention.
32756014|NCT04438421|Experimental|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
32756015|NCT04438421|Active Comparator|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
32756016|NCT04438421|Placebo Comparator|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
32756017|NCT05099081|Experimental|diode laser|diode laser application
32756018|NCT05099081|Active Comparator|sclerotherapy|intra-lesional injection of ethanolamine oleate
32756019|NCT04438577|Experimental|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
32756020|NCT05374655|Experimental|Preoperative blood glucose control|Under the guidance of endocrinologists, the patient's hypoglycemic strategy is formulated, follow-up guidance is guided by the patient to take the drug, the HbA1c level is reviewed after 6 weeks, the preoperative HbA1c < 7.5% is performed surgically, and if it is still above the standard, the hypoglycemic therapy is continued, during which the patient is administered according to the corresponding heart disease type.
32756021|NCT05374655|No Intervention|Preoperative blood glucose uncontrol|Patients included in this group ≥ 7.5% preoperative HbA1c and underwent surgery directly
32756022|NCT04846439|Experimental|CAR-T infusion|CD19 and BCMA CAR-T cells were infused into complete remission acute leukemia patients with PTR sequentially, with（1.0-2.0）×10e7/kg respectively. Each patient was followed up for 1 years.
32756023|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
32756024|NCT05087615|No Intervention|Control|Patients who did not receive any antiemetic during hospitalization (NA).
32756025|NCT05087615|Experimental|MA|Patients receiving metoclopramide alone (MA).
32756026|NCT05087615|Experimental|OA|Patients who received ondansetron only (OA).
32756027|NCT05087615|Experimental|MO|Patients receiving a combination of metoclopramide and ondansetron (MO).
32756028|NCT05087615|Experimental|GA|Patients who received granisetron alone (GA).
32756029|NCT01987102|Experimental|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
32910504|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
32910505|NCT05440383|Experimental|KLH-2109|Oral administration
33240118|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
33240119|NCT00741975|Experimental|1|Affect Management
33240120|NCT00741975|Active Comparator|2|General Health Promotion
33240121|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
33240122|NCT00745485|Experimental|Zoldronic|
32910506|NCT05440383|Active Comparator|Leuprorelin|Subcutaneous administration
32742778|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~or re-induction by carboplatin - etoposide chemotherapy."
32742779|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
32742780|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
32910507|NCT01290614|Experimental|Pharmacist intervention|
33240123|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
33240124|NCT00745563|Experimental|A|
32910508|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
32910509|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
32910510|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
32910511|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
33240125|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
33240126|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
33240127|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
32742781|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
32910512|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
32910513|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
32910514|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
33240128|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
33240129|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
33240130|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
32756030|NCT01987102|Experimental|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2*)~*Dose will depend on outcome from Cohort 1"
32756031|NCT05374577||Patients with a suspected diagnosis of post/long-COVID-19|Patients with a suspected post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after severe acute respiratory syndrome coronavirus(CoV) type 2 (SARS-CoV-2) infection (symptomatic or asymptomatic)
32756032|NCT05374577||Patients without post/long-COVID-19 Syndrome|Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19.
32756033|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
32756034|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
32756035|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
32756036|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
32756037|NCT05374499|Experimental|Liposomal bupivacaine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the mandibular third molar extraction surgical procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel).
32756038|NCT05374499|Active Comparator|0.5% bupivacaine with 1:200,000 epinephrine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine.
32756039|NCT04284605|Experimental|Group1|
32756040|NCT04284605|Experimental|Group2|
32756041|NCT03968939|No Intervention|Control group (Usual Care)|Usual care
32756042|NCT03968939|Active Comparator|Sleep Hygiene Education|Sleep Hygiene Education
32756043|NCT03968939|Active Comparator|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin)|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin) and Sleep Hygiene Education
32756044|NCT03856619|Experimental|Aubagio®/Teriflunomide|Single dose of Aubagio® to be taken orally, once daily in the morning
32756045|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
32756046|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
32756047|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
32756048|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
32756049|NCT05374343|Active Comparator|Group A and C (normal kidney function)|Each subject will receive a single dose of rongliflozin on Day 1
32756050|NCT05374343|Experimental|Group B (mild renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
32756051|NCT05374343|Experimental|Group D (moderate renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
32756052|NCT05374265|No Intervention|Registry|Patients with non-viable myocardium will be treated with standard clinical care.
32756053|NCT05374265|Other|OMT with revascularization|Patients with viable myocadium will be randomised to OMT with revascularization. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
32756054|NCT05374265|Other|OMT alone|Patients with viable myocardium will be radomised to OMT alone. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
33397092|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
32756055|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
32756056|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
32756057|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
32756058|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
32756059|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
32756060|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
32756061|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
32756062|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
32756063|NCT05099471|Experimental|Venetoclax / Rituximab|"Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of 800 mg/d QD PO.~Day 1-7: Venetoclax 200 mg/d QD PO Day 8-14: Venetoclax 400 mg/d QD PO Day 15-28: Venetoclax 800 mg/d QD PO~Cycle 2-12:~Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax 800 mg/d QD PO"
32756064|NCT05099471|Active Comparator|Dexamethasone / Rituximab / Cyclophosphamide|"Cycle 1-6:~Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO"
32756065|NCT05200715||Patients affected by autoinflammatory diseases|
32756066|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
32756067|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
32756068|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
32756069|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
32756070|NCT05098847|Experimental|Cryoablation in combination with Sintilimab plus lenvatinib|
32756071|NCT03195179||Suprapubic tube placement|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will have a suprapubic tube placed to manage the acute urethral injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
32756072|NCT03195179||Urethral realignment|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will undergo urethral realignment with a combined antegrade / retrograde approach within 7 days of injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
32756073|NCT01676909|Experimental|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
32756074|NCT01676909|Active Comparator|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
32756075|NCT04437953|Experimental|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
32756076|NCT03051971|Active Comparator|Jet nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a jet nebulizer
32756077|NCT03051971|Active Comparator|Vibrating Mesh Nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a vibrating mesh nebulizer
32756078|NCT04517357|Experimental|Safety Lead-in or Parallel， Fluzoparib+Apatinib|Participants will receive Fluzoparib-Apatinib combination until progression
32756079|NCT04517357|Active Comparator|Fluzoparib monotherapy|Participants will receive Fluzoparib monotherapy until progression
32756080|NCT04517357|Other|Exploratory cohort: Fluzoparib+Apatinib|Participants who has previously received PARP inhibitor, will receive Fluzoparib-Apatinib combination until progression
32756081|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
32756082|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
32756083|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
32756084|NCT04177498|Experimental|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
32756085|NCT04658836|Experimental|Triamcinolone application|Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery
32756086|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
32756087|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
32756088|NCT01677377|Experimental|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
32756089|NCT01677377|Experimental|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
32756090|NCT01677377|Experimental|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
32756091|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
32756092|NCT02893865|Experimental|Experimental|Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
32756093|NCT02893865|Sham Comparator|Sham Comparator|Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
32756094|NCT05104151|Experimental|Group with nutritional bar|Participants will recieve two nutritional bars per day during eight weeks, and will receive a healthy habits intervention wich includes: nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily.
33240131|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
33240132|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
33240133|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
33240134|NCT00747279|Active Comparator|2|Intensive insulin therapy
33240135|NCT00747357|Experimental|1|Balloon first
33240136|NCT00747357|Experimental|2|Stent First
33240137|NCT00747513|Experimental|I|intervention group
33240138|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
33240139|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
32742782|NCT04952649||pacemaker dependent patients after cardiac surgery|Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
33240140|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
33240141|NCT00742287|Placebo Comparator|1|placebo
33240142|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
33240143|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
33240144|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
33240145|NCT00690573|Experimental|Adalimumab|
33240146|NCT00742443|Other|1|Active versus Placebo within patient
33240147|NCT00742443|Other|2|Active vs. Placebo within patient
33240148|NCT00742443|Other|3|Active vs. Active within patient
33240149|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
33240150|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
33240151|NCT00749151|No Intervention|Literature|
33240152|NCT00749151|Experimental|Lit + Counseling|
33240153|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
33240154|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
33240155|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
33240156|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
33240157|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
33240158|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
33240159|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
33240160|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
33240161|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
33240162|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
33240163|NCT00749229|Other|1|Balloon kyphoplasty
32910515|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
32910516|NCT05459207|Experimental|Moderate Fat Meal, Followed by High Fat Meal Group|Participants will receive a moderate fat meal, followed by a high fat meal approximately seven days apart.
32742783|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
33240164|NCT04085120|Experimental|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
33240165|NCT04085120|Experimental|10% lignocaine injection group|4 ml of 10% lignocaine
33240166|NCT00749307|Experimental|1|
33240167|NCT00749307|Placebo Comparator|2|
32742784|NCT04965051|Experimental|IDegAsp group|IDegAsp twice daily
33240168|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
33240169|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
33397093|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
33397094|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
33240170|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
33240171|NCT00723398|No Intervention|Group 1: Control|Control, no intervention
33240172|NCT00723398|Experimental|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
33071617|NCT05784610|Active Comparator|TOF/PTC|Non-automated neuromuscular blockade monitoring (TOF/PTC). As the NMB monitoring is depending on anesthesiologist usual practice and so only TOF measure is systematic, it is necessary to include a blind anesthesiologist measurement with the ATP mode in order to compare with data obtained during Time 2.
33071618|NCT05784610|Experimental|ATP|Automated neuromuscular blockade monitoring (ATP). TOF and PTC stimulations are regularly performed, and PTC is systematically performed if TOF = 0/4. If PTC = 10/10, a TOF stimulation is automatically performed.
33240173|NCT00723398|Experimental|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
33071619|NCT05784597|Experimental|Cohort A|3 female + 3 male patients with a primary tumor only
33071620|NCT05784597|Experimental|Cohort B|Patients with a primary tumor and/or advanced/metastatic disease with a quantifiable number of lesions
33071621|NCT05784584||Infants infected through breast-feeding and perinatally|Infants infected through breast-feeding and perinatally diagnosed with HIV ≤90 days of age and starting ART ≤90 days after diagnosis. For these patients clinical data and blood for viral load, immunology and serology will be collected in the 11 visits.
33071622|NCT05784571||Older Adults|Adults 60-80 years of age with body mass index > 30kg/m2
32742785|NCT04965051|Active Comparator|basal insulin plus pre-prandial insulin group|basal insulin once or twice daily plus pre-prandial insulin
33071623|NCT05784558||UroLift System|Therapy to be treatment with the UroLift System.
33240174|NCT00723398|Experimental|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
33240175|NCT00723398|Experimental|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
33397095|NCT05170464|Experimental|Acute Exercise|20 minutes of moderate intensity acute exercise (treadmill speed to achieve ⅔ of maximum heart rate).
33240176|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
33240177|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
33397096|NCT05170464|Active Comparator|Caffeine Ingestion|1.2mg/kg of powdered caffeine (Caffeine powder, ReagentPlus® from Sigma-Aldrich) dissolved in 1 cup of water then sitting for 20 minutes.
33397097|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
33397098|NCT03677492|No Intervention|Handling Medium as it is.|
33397099|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
32910517|NCT05459207|Experimental|High Fat Meal, Followed by Moderate Fat Meal Group|Participants will receive a high fat meal, followed by a moderate fat meal approximately seven days apart.
33397100|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
33240178|NCT04054869|Experimental|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
33397101|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
33397102|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
33397103|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
32910518|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
32910519|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
33397104|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
32910520|NCT03866655|Experimental|Intervention|
32910521|NCT03866655|No Intervention|Control|
32742786|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
32742787|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
32742788|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
32742789|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
32742790|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
32742791|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
32742792|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
32742793|NCT04953195|Experimental|levothyroxine sodium|levothyroxine sodium
32742794|NCT03253523|No Intervention|Continued maximal medical management|
32742795|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
32742796|NCT04952883||COPD patients|The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
32742797|NCT03253211||State|North Carolina
32742798|NCT03253211||SCD Patients|
32742799|NCT03253211||Providers|Primary care and emergency department clinicians
32742800|NCT03253211||Year|Baseline, year 2, year 3
32742801|NCT04952571|Experimental|GBM at first relapse|
32742802|NCT04952571|Experimental|GBM at second relapse|
32742803|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
32742804|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
32742805|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
32910522|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
32910523|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
32910524|NCT00622557||Surgical|All patients having surgery procedures
32910525|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
32910526|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
32910527|NCT02595567|Other|ITPC|
33240179|NCT04054869|Experimental|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
33071624|NCT05784558||Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
33071625|NCT05784558||Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
33240180|NCT00752037|Other|1|open label single arm
33240181|NCT00747981|Experimental|A|Thoracic CT Scan
33240182|NCT05416983||Observational (discussion)|Patient and clinician discussions are observed to support refinement of a decision aid. Clinicians may use a prototype of the decision aid in discussions with their patients and may complete a questionnaire.
33071626|NCT05784545|Placebo Comparator|Placebo|
33071627|NCT05784545|Experimental|Blueberry Supplementation|
32742806|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
32742807|NCT04952259|Experimental|Intervention group|Shexiang Tongxin dripping pills + routine treatment
32742808|NCT04952259|Active Comparator|Control group|routine treatment
33240183|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
33397105|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
33397106|NCT05168592|Experimental|Imaginal extinction|Conditioned fear will be diminished using imaginal extinction.
33397107|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
33397108|NCT01361373|Placebo Comparator|Placebo|placebo
33071628|NCT05784532||STERN FIX|Patients undergoing cardiothoracic surgery through median sternotomy, once the main intervention is finished, will have their sternum closed using the sternal stabilization system STERN FIX in combination with wires according to the STERN FIX instructions for use.
33240184|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
33240185|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
33240186|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
33240187|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
33240188|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
33240189|NCT02562261||Healthy|
33240190|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
33240191|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)~Heart rate >90bpm~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
33071629|NCT05784519|Experimental|experimental group|The MSCs eye drops was administered to enrolled patients with 5×10^5 /50μl in each eye, twice a day for 2 weeks.
33240192|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
33240193|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
33240194|NCT00749385|Experimental|1|PN 400
33240195|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
32742809|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
32742810|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
32742811|NCT04962399||DKD group|Patients with type 2 diabetes mellitus complicated with diabetic nephropathy diagnosed by the second hospital of Shanxi Medical University
32742812|NCT04962399||TDM group|Type 2 diabetes mellitus without diabetic nephropathy
32742813|NCT04962399||control group|Health examination population in the same period
33240196|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
33240197|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
33240198|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
33240199|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
33240200|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
33240201|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
33240202|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
33240203|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
33240204|NCT00749541||1normal catheter.|
33240205|NCT00749541||abnormal catheter.|
33240206|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
33240207|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
33240208|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
32742814|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
32742815|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
33240209|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
33240210|NCT00749619|Experimental|A|
33240211|NCT00749619|Experimental|B|
32742816|NCT04962243||Patients undergoing repair of Achilles tendon rupture|Patients undergoing repair of Achilles tendon rupture
32742817|NCT04962243||Subjects who underwent physical examination during the same period|Subjects who underwent physical examination in the Physical Examination Center of Peking University Third Hospital during the same period
32742818|NCT04487483|Experimental|Sleep App|"Participants in this condition will receive full free access to the Pro version of the sleep app and asked to use the app every day for three months."
32742819|NCT04487483|No Intervention|Control|Participants in this condition will be asked to continue their life as normal and abstain from downloading or using any sleep aid and/or sleep tracker app for three months.
32742820|NCT03253367||Current/former clozapine users|This group has only one visit.
32742821|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
32742822|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
32742823|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
32742824|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
32742825|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
32742826|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
32742827|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
32742828|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
32742829|NCT03251885||women with preterm labor|pregnant women < 37 weeks of gestations with regular uterine contractions and > 3 cm dilation, > 80% effacement
32742830|NCT03251885||women with term pregnancy|pregnant women > 37 weeks of gestation
32756095|NCT05104151|Active Comparator|Group without nutritional bar|Participants will receive a healthy habits intervention wich includes nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily during eight weeks.
32756096|NCT02492009|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
32756097|NCT02492009|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
32756098|NCT04458623|Active Comparator|positive air test|postoperative in the recovery room.patients received supplemental oxygen through a venture mask with a jet and flow adjusted to a theoretical fio2 of 100% for 10 min. The Air-Test was then performed by removing the oxygen mask and leaving the patients breathing room air for 10 min while continuously monitoring SpO2 with a pulse oximeter finger probe. The Air-Test result was considered positive when the recorded SpO2 was ≤96%.
32756099|NCT04458623|Active Comparator|negative air test|negative when SpO2 was >96 %.
32756100|NCT05098691||Group 1 (Early onset Preeclampsia )|43 cases The groups were matched for gestational age and gravidity.
32756101|NCT05098691||Group 2 ( Healthy pregnant woman) control group|41 cases The groups were matched for gestational age and gravidity
32756102|NCT04430387|Active Comparator|Group 1- The saliva ejector|
32756103|NCT04430387|Active Comparator|Group 2- The high-volume evacuator|
32756104|NCT04430387|Active Comparator|Group 3- The DryShield|
32756105|NCT04066205|Experimental|SLEEPSMART PROGRAM|"Arm: Placebo Comparator (Usual care)-This treatment arm will receive usual JIA care, including annual Rheumatology clinic visits, medications, routine clinical and laboratory tests, physical therapy, follow-up appointments, and no sleep intervention.~Arm: Experimental -Each child and parent will create a login, choose treatment goals, and interact with fields in the Web site. The modules will focus on improving sleep hygiene, relaxation, or increasing sleep duration. The intervention will last 6 to 8 weeks."
32756106|NCT05098535|Experimental|Visual Aid + Scripted Risk Discussion|This will involve the group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
32756107|NCT05098535|Active Comparator|Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
32756108|NCT05375513|Active Comparator|SYNERGIC 2|"Personalized multidomain coached 1-to-1 interventions at home (PMI@Home) including:~Physical Exercise~Cognitive Training~Diet~Sleep~Vascular Risk Factors Control"
32756109|NCT05375513|Placebo Comparator|Brain Health PRO (BHPro)|"Brain Health PRO (BHPROBHPRO) is an independent, educational program with content also related to:~Physical Exercise~Cognitive Training~Diet~Sleep~Vascular Risk Factors"
32756110|NCT05103995||ABO matched|Donor-recipient ABO matched
32756111|NCT05103995||Minor incompatibility|Donor-recipient minor incompatibility
32756112|NCT05103995||Major incompatibility|Donor-recipient major incompatibility
32756113|NCT05103995||Bidirectional incompatibility|Donor-recipient bidirectional incompatibility
32756114|NCT05103917|Experimental|X4P-001-201|trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination with Toripalimab in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
32756115|NCT03997409|Experimental|Low Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.
32756116|NCT03997409|Active Comparator|Standard Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the SCD intervention will consume 45-65% of total daily caloric intake from carbohydrates, 25-35% from fat and 10-30% from protein.
32756117|NCT03997409|No Intervention|No Dietary Recommendations|This group will serve as a control that receives the same number of education sessions as LCD and SCD group to teach general diabetes management but without specific dietary recommendations.
32756118|NCT03861221|Experimental|Conebeam Breast Computed Tomography|
32756119|NCT05098223|No Intervention|Promotions|Participants in this group will see a version of the website which will reproduce the types and frequency of promotions that can be found in any online supermarket, for example multi-buy offers and temporary price reductions will be applied to a pre-determined percentage of food products within the target categories [confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts]. Promotions will be applied to match the current levels and types of promotions on the website of the largest UK retailer present in a specific week, shortly before the study launch.
32756120|NCT05098223|Experimental|No promotions|All price promotions will be removed so no promotions will be present on any of the products within the target food categories [confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts] offered to participants when searching for products.
32756121|NCT05097911|Experimental|Advanced HCC patients|Patients will receive treatment as outlined until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. If scheduled dosing and study assessments are precluded because of a holiday, weekend, or other event, then dosing may be postponed to the soonest following date, with subsequent dosing continuing on a 21-day schedule. If treatment was postponed for fewer than 3 days, the patient can resume the original schedule.
32756122|NCT03739775|Other|Blood sampling|
33071630|NCT05784506|Experimental|Macronutrients loading test for healthy group|A total of 30 subjects with normal metabolic status underwent three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
32756123|NCT03732209|Experimental|Episodic future thinking|Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
32756124|NCT03732209|Sham Comparator|Control thinking|Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
32756125|NCT05097365|Experimental|Supplemented Lean Group|
32756126|NCT05097365|Experimental|Supplemented Obese Group|
32756127|NCT05097365|Placebo Comparator|Control Lean Group|
32756128|NCT05097365|Placebo Comparator|Control Obese Group|
32756129|NCT03507647|Experimental|Mindfulness Based Cognitive Therapy added to usual care|Patients in the MBCT arm will be invited to participate in MBCT added to their usual care.
32756130|NCT03507647|Active Comparator|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse).
32756131|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
32756132|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
32756133|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
32756134|NCT02659943|Experimental|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells only
33240212|NCT00749619|No Intervention|C|
33240213|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
33240214|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
33240215|NCT02561403|Experimental|EVO multitask video game|
33240216|NCT02561403|Experimental|EVO words video game|
33240217|NCT02561403|No Intervention|Assessment Only|
33240218|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
33240219|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
33240220|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
33071631|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for healthy group|A total of 40 subjects with normal weight and plasma glucose levels underwent MMTT.
33071632|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for overweight subjects with normal plasma glucose|A total of 40 overweight subjects without a history of diabetes underwent MMTT.
33071633|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for obese subjects with abnormal plasma glucose|A total of 40 obese subjects without a history of diabetes underwent MMTT.
33071634|NCT05784493|Experimental|Washing by heated saline group|
32756135|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10^6 CAR T cells
32756136|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
32756137|NCT02659943|Experimental|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells only
32756138|NCT02659943|Experimental|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
32756139|NCT02659943|Experimental|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10^6 Chimeric Antigen Receptor (CAR) T cells only
32756140|NCT03257969|Experimental|The DROP program|
32756141|NCT03257969|Other|Standard of care|
32756142|NCT05103371|Experimental|"Mili prevention program, adolescents and active parents"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
32756143|NCT05103371|Active Comparator|"Mili prevention program, adolescents only"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image, no parental involvement in the program. Adolescents will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
33071635|NCT05784493|Active Comparator|Washing by normal room temperature saline group|
32756144|NCT05103371|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program
32756145|NCT05103293|Experimental|PTC group|Patients randomized into this group receiving PTC test and choose regimens according to this test results
32756146|NCT05103293|No Intervention|Control group|Patients randomized into this group receiving routine regimens according to subtypes
32756147|NCT05369663||no mask|no mask use
32756148|NCT05369663||surgical mask|surgical mask use
32756149|NCT05369663||N99 mask|N99 mask use
32756150|NCT05369663||face shield|face shield use
32756151|NCT05369663||surgical mask+ faceshield|surgical mask+ faceshield use
32756152|NCT05369663||N99 mask+ faceshield|N99 mask+ faceshield use
32756153|NCT05083325|Experimental|Oseltamivir Phosphate Test Product|Participants will receive one capsule of the test formulation containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
32756154|NCT05083325|Active Comparator|Oseltamivir Phosphate Referent Product|Participants will receive one capsule of the marketed reference containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
32756155|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
32756156|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
32756157|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
32756158|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
32756159|NCT04436783|Experimental|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
32756160|NCT04436783|Active Comparator|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
32756161|NCT05102903|Other|A(RT)|"Reference drug BR1016B 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug BR1016A 1 tablet is administered once in fasted state."
32756162|NCT05102903|Other|B(TR)|"Study drug BR1016A 1 tablet is administered once in fasted state. After having a break of 7 days or more, reference drug BR1016B 1 tablet is administered once in fasted state."
32756163|NCT03185117||All patients|Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.
32756164|NCT05102825||Respiratory Disease|Any physician-diagnosed lung disease
32756165|NCT05102825||Healthy|Healthy control with no physician-diagnosed lung disease
32756166|NCT05012267|No Intervention|Control group|48 hours of PP
32756167|NCT05012267|Experimental|Experimental group|Anytime from 16 hours when PaO2/FiO2 ≥ 150 mmHg with a FiO2 < 60%
32756168|NCT04999631|Experimental|Squaric Acid Dibutyl Ester (SADBE)|Following sensitization, subjects will apply 0.2% SADBE in ethanol to a predetermined area of their nevus 3 times per week for 12 weeks, with adjustment of frequency depending on response.
32756169|NCT04999631|Placebo Comparator|Control|Subject will apply an ethanol solution to a specified area of the nevus.
32756170|NCT05337761|Experimental|Intervention|The peers will be trained to train their colleagues (fellow boaters) on proper lifejacket use. A training manual has been developed for this.
33071636|NCT05784480|Other|Evaluation of reversible causes using digital checklist and diagnostic support|
33240221|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
33071637|NCT05784467|Other|English|Participants in the English arm will receive the eMPrISe intervention materials in English.
33240222|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
33240223|NCT00748449|Active Comparator|1|CT Colonography
33240224|NCT00748449|Active Comparator|2|Colonoscopy
33071638|NCT05784467|Other|Spanish|Participants in the English arm will receive the eMPrISe intervention materials in Spanish.
33071639|NCT05784246|Experimental|Mirikizumab Weight-Based Group 1|Experimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
33240225|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
33240226|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
33240227|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
33240228|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
33240229|NCT04053621|Experimental|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
33240230|NCT04053621|Placebo Comparator|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
33240231|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
33240232|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
33240233|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
33240234|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
33240235|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
33240236|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
33240237|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
33240238|NCT00686829|Experimental|VCV 30 mg|Participants take VCV 30 mg once daily.
33240239|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
32756171|NCT05337761|Placebo Comparator|Control|The Marine Police will be encouraged to continue conducting their community policing on water safety and emphasize lifejacket wear.
32756172|NCT04437875|Experimental|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
32756173|NCT04437875|Experimental|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
32756174|NCT04437875|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
32756175|NCT02718833|Experimental|Elotuzumab, pomalidomide, bortezomib, dex|"Each cycle is 28 days.~Elotuzumab will be administered by intravenous infusion. For cycles 1-2, elotuzumab will ge given weekly. For cycles 3-8, elotuzumab will be given every other week. For cycles 9+, elotuzumab will be given on day 1.~Pomalidomide will be given orally on days 1-21.~Bortezomib will be given weekly subcutaneously on days 1, 8, 15.~Dexamethasone will be given as a combination orally and intravenously."
32756176|NCT04908293|Experimental|Trial Group|Use of New Biorepair Advanced Sensitive toothpaste for home oral care.
32756177|NCT04908293|Active Comparator|Control Group|Use of Colgate toothpaste for home oral care.
33071640|NCT05784246|Experimental|Mirikizumab Weight-Based Group 2|Experimental: Participants will receive mirikizumab weight-based dosing IV or SC.
33071641|NCT05784246|Experimental|Mirikizumab Weight-Based Group 3|Experimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
32742253|NCT05075369|Active Comparator|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
32742254|NCT05074901|Experimental|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
32756178|NCT04437797|Experimental|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
32756179|NCT04437797|Active Comparator|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
32756180|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
32756181|NCT04786457|Experimental|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|open-label injection of DENV-1-LVHC to 15-20 adults who were previously vaccinated and 5 adults who have never received a dengue vaccination
32756182|NCT05047757|Experimental|Fava bean|The intervention consists in a test meal containing 250 g of cooked and peeled favabean, to provide 20 g protein. Fava bean are intrinsically labelled with 15N.
32756183|NCT04436705|Experimental|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
32756184|NCT04436705|No Intervention|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
32756185|NCT05102045|Experimental|TMS group|In the TMS group (n=10) rTMS was applied to the bilateral dorsolateral prefrontal cortex (DLPFC) at 20 Hz, for 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
32756186|NCT05102045|Experimental|AE group|AE group (n=9) received a moderate- intensity aerobic exercise program lasting 50 minutes per session, 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
32756187|NCT05102045|Active Comparator|Control group|No additional intervention was given to the patients in the control group (n=8) and participants were only treated pharmacologically.
32756188|NCT04934267|Experimental|Eccentric exercise of elbow in order to induce Delayed Onset of Muscle Soreness|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1RM).Both groups will perform 1 set of standing eccentric bicep curls based on their 1RM to failure in order to induce DOMS.The exercise will stop when the participant cannot volitionally keep up with the 5 second count lowering the weight. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
32756189|NCT04867655|Experimental|Orange juice only|Experimental test for 24 hours after consumption of orange juice only (Tropicana 'with bits').
32756190|NCT04867655|Experimental|Orange Juice mixed with either 6g or 3 g of β-Glucan|Experimental test for 24 hours after consumption of orange juice (Tropicana 'with bits') with either 6g or 3 g of β-Glucan.
32756191|NCT04855019|Active Comparator|periarticular injection group (PI)|the group to be given a periarticular injection by an orthopedist
32756192|NCT04855019|Active Comparator|Combined suprascapular-axillary nerve block group (CSAB)|the group in which an anesthesiologist will perform combined suprascapular axillar border block under ultrasound guidance
33240240|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
33240241|NCT00684177|Experimental|Retapamulin Ointment, 1%|
33240242|NCT00684177|Placebo Comparator|Placebo Ointment|
33240243|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
33240244|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
33240245|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
33240246|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
33240247|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
33240248|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
32756193|NCT04414241|Experimental|Hydroxychloroquine|Hydroxychloroquine prophylaxis plus standard measures of personal protection.
32756194|NCT04414241|No Intervention|Control|Standard measures of personal protection.
32756195|NCT05101967|Experimental|Dynamic Cervical Implant|
32756196|NCT05101967|Active Comparator|Anterior Cervical Discectomt and Fusion|
32756197|NCT04779905||Non-alcoholic Fatty Liver Diseases|patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital
32756198|NCT04779905||control|healthy volunteers who looks normal on ultrasonography
32756199|NCT04764773||Case|Patient who had COVID19 infection
32756200|NCT04764773||control|healthy volunteer who were age and sex matched with our patients
32756201|NCT04758377|Experimental|Arm 1|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
33240249|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
33240250|NCT04057911|Experimental|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
33240251|NCT04057911|Sham Comparator|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
32742255|NCT05074901|No Intervention|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
32742256|NCT03961919|Experimental|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
33071642|NCT05783700||DIABETIC|"PERFORMANCE OF BIOIMPEDANCIOMETRY WITH DETERMINATION OF:~Daily calorie intake~Body fat mass and percentage~Segmental body fat percentage~Resting Heart Rate~Lean Mass~Risk of sarcopenia~Proteins~Extra Cellular Water~Intracellular Water~Phase Angle~Visceral fat~Muscle mass~Segmental muscle mass~Muscle quality score~Total body water (%)~Metabolic age"
32742257|NCT03938987|Experimental|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
33071643|NCT05783622|Experimental|Dose Escalation|Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose.
33071644|NCT05783622|Experimental|Backfill Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable.
33071645|NCT05783622|Experimental|Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D).
33071646|NCT05783583||Enrolled participants|Adult human subjects showing either healthy eyes or specific ocular pathologies.
33071647|NCT05783206|Experimental|MIR 19 ®|"MIR 19 ® was used in a single dose of 1.85 mg for 3 inhalations per day at intervals of 6-7 hours for 7 days in addition to standard therapy without use of any etiotropic drugs.~Standard therapy included:~- paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
33071648|NCT05783206|Active Comparator|Standard therapy|"Standard therapy included:~umifenovir (Arbidol®) - 200 mg 4 times per day for 7 days~interferon-α, intranasal forms (Grippferon®),spray - in accordance with the instructions.~paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
33240252|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
32910528|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
32910529|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
33240253|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
32910530|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
32910531|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
32910532|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
32910533|NCT04205409|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32910534|NCT04340661|Experimental|Bionocol arm|
33071649|NCT05782985||Myeloproliferative neoplasms Cases|The myeloproliferative neoplasms Cases will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
32910535|NCT04340661|Placebo Comparator|Placebo arm|
32910536|NCT00609791|Experimental|nab-paclitaxel|
32910537|NCT04201119|Experimental|With Oxiris|
32910538|NCT04201119|No Intervention|Without Oxiris|
32910539|NCT05457959|Placebo Comparator|Cohort I Arm A (ppDC, placebo)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID in both arms with poly ICLC IM on day -10 and placebo IV on day -9 prior to standard of care surgical resection.
33071650|NCT05782985||Controls|Healthy controls will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
33071651|NCT05782894|Experimental|Remimazolam besylate|Remimazolam besylate
33071652|NCT05782894|Active Comparator|Propofol|Propofol
33071653|NCT05782712||Syncope|patients referred for syncope evaluation
33071654|NCT05782712||No syncope|Subjects without syncope
33071655|NCT05782699|Experimental|patch monitoring|
33071656|NCT05782699|Active Comparator|standard BP monitoring|
33071657|NCT05782660|Experimental|Treatment Group|Participants in the treatment group received up to $400 per month.
33071658|NCT05782660|Active Comparator|Control Group|Participants in the control group did not receive monthly cash benefits.
33071659|NCT05782647|Experimental|Cuffless BP monitoring|Investigational device Omron HeartGuide® 6410T
33071660|NCT05782647|Active Comparator|Beat-to-beat BP monitoring|Continuous finger BP monitoring (Finometer®, Finapres Medical Systems, Enchede, The Netherlands, and Task Force® monitor, CNSystem, Graz, Austria), based on the photoplethysmographic volume clamp method
32910540|NCT05457959|Placebo Comparator|Cohort I Arm B (placebo, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive placebo ID in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
32910541|NCT05457959|Experimental|Cohort I Arm C (ppDC, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID divided in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
33240254|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
33071663|NCT05781919|Experimental|Branch A: L1 2D + iRV|Patients with L1 neuroblastoma that will be planned using gold standard imaging (TC and/or MRI) and immersive virtual reality
33071664|NCT05781919|Active Comparator|Branch B: L1 2D|Patients with L1 neuroblastoma that will be planned using only gold standard imaging (TC and/or MRI)
33071665|NCT05781919|Experimental|Branch C: L2 2D + iVR|Patients with L2 neuroblastoma that will be planned using gold standard imaging (TC and/or MRI) and immersive virtual reality
33071666|NCT05781919|Active Comparator|Branch D: L2 2D|Patients with L2 neuroblastoma that will be planned using only gold standard imaging (TC and/or MRI)
32756202|NCT05101889|Experimental|Immunonutrition|"Oral immunomodulating formula (Oral Impact®, Nestle) One sachet of Oral Impact® consisted of 74 g of powder providing 303 kilocalories.~Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session."
32756203|NCT05101889|Active Comparator|Control|An isocaloric isonitrogenous standard enteral nutrition formula. Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session.
32756204|NCT04532177|Experimental|Active|
32756205|NCT04531553|Active Comparator|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/h until chest tube removal ( 5-6 days).
32756206|NCT04531553|Active Comparator|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
32756207|NCT04531553|Active Comparator|ESPB with levobupivacaine and dexmedetomidine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
32756208|NCT05101811|Experimental|Control women without polycystic ovary syndrome|Normal fertile women without polycystic ovary syndrome
32756209|NCT05101811|Experimental|Case women with polycystic ovary syndrome|Women with polycystic ovary syndrome
32756210|NCT05323409|Experimental|OPTIMISE|OPTIMISE components to facilitate Patient self-management support are: 1) a bilingual oncology nurse navigator (ONN) and care coordination; 2) distress screening; 3) tailored comorbidity self-management action planning, 4) tailored survivorship action planning, and 5) surveillance reminders and follow-up. OPTIMISE components to facilitate provider decision support are: 1) when the initial referral is made, the ONN will send the PCP treatment plan summary (based on the ASCO treatment plan template) and standardized fact sheets on treatment toxicities; 2) throughout treatment, there will be bi-directional and structured communication between oncologist and PCP facilitated by the ONN; 3) The ONN will send the SCP to the PCP describing surveillance guidelines and summary of late effects. Finally, OPTIMISE will adopt a risk-stratified shared care model of post-treatment survivorship care.
32756211|NCT05323409|No Intervention|Usual Medical Care (UMC)|UMC consists of standard oncologic care from point of diagnosis. Cancer patients with comorbidities are encouraged by their oncologist to follow up with their PCP regarding comorbidity management but no formal referral process is in place. At the end of cancer treatment (with standard, definitive therapies), patients meet with a nurse (Survivorship Nurse Practitioner, NP) to review the SCP, which is based on ASCO templates and populated from the EHR. The Survivorship NP also reviews therapies received, recommended surveillance, common late effects, and recommended lifestyle behaviors. Patients are given a printed copy of the SCP and are encouraged to share this information with their PCP. Cancer surveillance follows the traditional oncologist led model regardless of patient risk for recurrence.
32756212|NCT04088123||Healthy Patients|The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.
32756213|NCT05308355||OFA : Opioid Free Anesthesia|Opioid-free surgery. Analgesia provided by attenuation analgesic 1, dexmedetomidine, ketamine and general anesthesia by propofol. Regional loco anesthesia is performed in the OFA group and possible in the OBA group. It's local service protocol used since 1 year.
32756214|NCT05308355||OBA : Opioid Based Anesthesia|Conventional anesthesia with Propofol and Sufentanil boli with the possibility of regional loco anesthesia.
32756215|NCT05307419|Active Comparator|Rectal suction biopsy first|Children randomised for pahtological evaluation of rectal suction biopsy tissue first.
32756216|NCT05307419|Active Comparator|Full thickness biopsy first|Children randomised for pathological evaluation of full thickness biopsy tissue first.
32756217|NCT05199779|Experimental|Self-Compassion Intervention (SCI)|First, participants will be taught to implement a 20-second self-compassion induction via video recording. Second, participants will be taught to choose a cue that will precede their daily use of the self-compassion induction. Participants will document the cue they chose, and will be emailed a record of their selected cue, along with the recording and transcript of the self-compassion induction that they can refer back to for reference. Third, participants will be asked to use the self-compassion induction as much as they can and at least once during their daily routine following exposure to their chosen cue.
32756218|NCT05199779|Active Comparator|Finger-Tapping Active Control (AC)|The active control will receive the same procedures as described above, except for receiving a different video containing different instructions describing a finger-tapping exercise. The videos will be virtually identical in length, quality, instructor/their outfit, and lighting.
32756219|NCT05164367|Experimental|0.1 mg of atropine|1 gram of gel by topical application in the oral cavity once.
32756220|NCT03896711|Experimental|Active Intervention|Intervention arm with MEMORI Corps program
32756221|NCT03896711|Other|Control|Augmented waitlist control.
32756222|NCT03847181||NVAF-patients_1|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
32756223|NCT03847181||NVAF-patients_2|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
32756224|NCT03847181||NVAF-patients_3|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
32756225|NCT03825107|Active Comparator|Patching|2 hours per day 7 days per week patching of the fellow eye
33071667|NCT05781802||Adult mechanically ventilated patients with ARDS|Adult mechanically ventilated patients with ARDS (see inclusion/exclusion criteria)
32756226|NCT03825107|Experimental|Dichoptic Videos|watching 6 dichoptic videos during each 2 week period
33071668|NCT05781776|Experimental|Otago exercise program group|Participants performed Otago exercise program and core muscle strengthening exercises for eight weeks (thrice a week).
33071669|NCT05781776|Active Comparator|Gaze stability exercises group|Participants performed Gaze stability exercises and core muscle strengthening exercises for eight weeks (thrice a week).
33071670|NCT05781672|Experimental|Anthra2|"Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to SpeckleAnthra study (NCT02893787)"
33071671|NCT05781672|Active Comparator|Control|Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group
33071672|NCT05781568||Control Group|"The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution.~Included in this group are:~Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP."
33071673|NCT05781568||Case Group|"The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period. This group will include:~Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP at the time of tumor diagnosis."
33071674|NCT05781516|Placebo Comparator|Prednisolone monotherapy|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
33071675|NCT05781516|Experimental|Prednisolone plus Baricitinib|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months. Oral Baricitinib 2mg daily for 12 months.
33071676|NCT05781321|Experimental|Arm A (short course RT)|Patients undergo short course RT over 1-2 weeks on study. Patients also receive temozolomide PO on study, undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI throughout the trial.
33071677|NCT05781321|Active Comparator|Arm B (standard course RT)|Patients undergo standard course RT over 3-6 weeks on study. Patients also receive temozolomide PO on study, undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI throughout the trial.
33071678|NCT05780892|Experimental|Emotional Wellbeing|This arm consists of 6 30-minute group sessions taking place every 2 weeks for a total of 12 weeks. The sessions will be led by licensed therapists based on cognitive behavioral therapy and acceptance and commitment therapy. Session topics are sequential in nature such that each session builds on the previous session. Between sessions, participants will complete worksheets based on the material covered in the previous session. If a participant misses a session, they will be provided with a pre-recording with the content they missed.
33071679|NCT05780892|Experimental|EHR Skills Optimization|This arm consists of 6 individual educational sessions taking place every 2 weeks for a total of 12 weeks which will be scheduled to accommodate clinicians schedule and preferences. These sessions will be led by a member of the clinical informatics team and target optimization of the EHR. The sessions will be conducted on site, virtually, or a combination of both onsite and virtual. Between sessions participants are to note any challenges, questions, or recommendations related to the EHR. If participant misses 2 sessions, they will be asked to reschedule, but if they miss 3 sessions they may be asked to withdraw from the intervention.
33240255|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
33240256|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
33240257|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
32756227|NCT03582371|Experimental|Aqua SUP|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
32756228|NCT03582371|Active Comparator|Physiotherapy|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
32756229|NCT05101499|Experimental|AKIN osteotomy with screw fixation|
32756230|NCT05101499|Active Comparator|AKIN osteotomy without screw fixation|
32756231|NCT03477851|Placebo Comparator|Placebo|Patients randomized to receive 0,9% sodium hydrochloride solution 5ml i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
32756232|NCT03477851|Experimental|Tramadol|Patients randomized to receive 100mg of Tramadol hydrochloride in 5ml 0,9% sodium hydrochloride i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
32910542|NCT05457959|Experimental|Cohort II Arm A (ppDC, placebo)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and placebo IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
32910543|NCT05457959|Placebo Comparator|Cohort II Arm B (placebo, nivolumab)|Within 30 days of surgical resection, patients receive placebo ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
32910544|NCT05457959|Experimental|Cohort II Arm C (ppDC, nivolumab)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
33240258|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
33240259|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
33240260|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
33240261|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
33240262|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
33240263|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
33240264|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
33240265|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
33397109|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
32910545|NCT05457647|Experimental|Riboflavin/UV-A corneal cross-linking monitored by theranostic software module|One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.
32756233|NCT05101343|No Intervention|Control|Uses Fitbit, does not participate in breathing meditation.
32756234|NCT05101343|Experimental|Meditation|Uses Fitbit and participates in brief, daily breathing meditation.
32756235|NCT05122871|Experimental|Scape room|
32756236|NCT05122871|Active Comparator|Simulation|
32756237|NCT04437407|Other|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
32756238|NCT04437407|Experimental|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
32756239|NCT04437407|Experimental|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
32756240|NCT04437407|Experimental|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
32756241|NCT04437407|Experimental|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
32756242|NCT04437407|Experimental|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
32756243|NCT05101265|Experimental|Normal Hepatic function cohort|"Patients in the control cohort must meet the following criteria:~Total bilirubin ≤ 1.0 x upper limit of normal (ULN) and no clinical (or histological) evidence of liver disease.~Aspartate aminotransferase (AST) ≤ 1.0 x ULN and alanine aminotransferase (ALT) ≤ 1.0 x ULN.~Albumin ≥ 3.5 g/dL.~The age, weight and CLcr should be within ±10 years, ±15 kg and ±20 mL/min of the mean of pooled HI cohort, respectively; and with a similar male/female ratio."
32756244|NCT05101265|Experimental|Mild Hepatic impairment cohort|"Patients with Mild Hepatic impairment must meet the following additional criteria~Total bilirubin ≤ 1.0 x ULN and AST > 1.0 x ULN, or~Total bilirubin > 1.0 - ≤ 1.5 x ULN and any AST, and~Albumin ≥ 3.0 g/dL"
32756245|NCT05101265|Experimental|Moderate Hepatic impairment cohort|"Patients with Moderate Hepatic impairment must meet the following additional criteria~Total bilirubin >1.5 - ≤ 3.0 x ULN and any AST, and~Albumin ≥ 2.8 g/dL"
32756246|NCT05101265|Experimental|Severe Hepatic impairment cohort|"Patients with Severe Hepatic impairment must meet the following additional criteria:~Total bilirubin >3.0 x ULN and any AST, and~Albumin ≥ 2.5 g/dL"
32756247|NCT05375201|Experimental|VR skateboarding training|specific rehabilitation exercise for improving postural balance
32756248|NCT05375045||prospective|A prospective cohort will be recruited into the study to meet the secondary objective of improving quality of life. In fact, to measure the improvement in quality of life, a questionnaire must be completed by the patient before the implant is placed. Answers to this questionnaire preoperatively cannot be collected for patients recruited retrospectively.
32756249|NCT05375045||retrospective|Patients who received one or more EUROTEKNIKA implants before 2017 may be included in the study for the retrospective cohort
32756250|NCT04437251|Experimental|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
32756251|NCT04437251|Experimental|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
32756252|NCT04437251|Sham Comparator|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
32756253|NCT05098769||Acute pulmonary embolism|an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
32756254|NCT03310697|Experimental|Children with afebrile seizure|"For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.~Intervention : Collection of blood and urine samples, and Clinical examination"
32756255|NCT05281211|Experimental|Preoperative Nutrition+Exercise|Preoperative nutrition and exercise pre-habilitation followed by major liver resection.
32756256|NCT05281211|No Intervention|Upfront Surgery|Upfront major liver resection.
32756257|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
32756258|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32756259|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32756260|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
32756261|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
32756262|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
32756263|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
32756264|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
32756265|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
32756266|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
32756267|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
32756268|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
32756269|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
32756270|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
32756271|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
32756272|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
32756273|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
32756274|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
32756275|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
32756276|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
32756277|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
32756278|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
32756279|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
32756280|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
32756281|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
32756282|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
32756283|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
32756284|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
32756285|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
32756286|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
32756287|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
32756288|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
32756289|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
32756290|NCT02408809|Active Comparator|Control|
32756291|NCT02408809|Active Comparator|Intervention|
32756292|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
32756293|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
32756294|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
32756295|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
32756296|NCT02401165|Other|patient|patient
32756297|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
32756298|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
32756299|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
32756300|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
32756301|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
32756302|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
32756303|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
32756304|NCT03116191|Experimental|SK-1404 high dose|
32756305|NCT03116191|Experimental|SK-1404 middle dose|
32756306|NCT03116191|Experimental|SK-1404 low dose|
32756307|NCT03116191|Placebo Comparator|Placebo|
32756308|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
32756309|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
32756310|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
32756311|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
32756312|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
32756313|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
32756314|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
32756315|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
32756316|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
32756317|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
32756318|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
32756319|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
32756320|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
32756321|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
32756322|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
32756323|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
32756324|NCT03168685|Experimental|Experimental|"Multiple device intervention~SureSource Engage mobile application~ActiGraph Link~weight scale"
32756325|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
32756326|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
32756327|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
32756328|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
32756329|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
32756330|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
32756331|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
32756332|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
32756333|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
32756334|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
32756335|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
32756336|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
32756337|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
32756338|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
32756339|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
32756340|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
32756341|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
32756342|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
32756343|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
32756344|NCT02405455|Experimental|Cerclage|Cervical cerclage.
32756345|NCT02405455|Experimental|Cervical pessary|Cervical pessary
32756346|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
32756347|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
32756348|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
32756349|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
32756350|NCT03173755||People with normal weight|
32756351|NCT03173755||people with overweight and obesity|
32756352|NCT02659631|Experimental|PF-06671008|
32756353|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
32756354|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
32756355|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
32756356|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
32756357|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
32756358|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
32756359|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
32756360|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
32756361|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
32756362|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
32756363|NCT04459247|Experimental|Intervention|Vitamin D high dose
32756364|NCT04459247|No Intervention|Control arm|No Vitamin D supplementation
32756365|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
32756366|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
32901378|NCT05047068||OCS DCD Heart Primary Analysis Population|"150 adult primary heart transplant recipients of OCS perfused DCD donor hearts that meet the FDA-approved indication for use except for the following recipient exclusion criteria:~Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or~On renal dialysis at time of transplant~Transplanted with DCD heart with warm ischemic time > 30 minutes (warm ischemic time is defined as: Time from when mean systolic blood pressure (SBP) is < 50 mmHg or peripheral saturation < 70% to aortic cross-clamp and administration of cold cardioplegia in the donor)."
32756367|NCT04402463|Experimental|GPR Group|"Global Postural Reeducation with 2 parts in each session:~st: 2 postures in lying position - without gravity load (15 minutes each posture): The aim of these postures is to achieve and maintain postural balance and to stretch the posterior muscle chain. In order to achieve this, specific exercises in the lying position are used. That exercises involve a precise use of contractions, stretch reflexes, light and controlled manual tractions and sustained elongations.~The maintenance of alignment during posture will be achieved by verbal commands and manual contact of the therapist, guaranteeing the active engagement of patient to reach the correct posture.~st: Standing posture - integration under gravity load (10 minutes): With the participant standing the physiotherapist makes final corrections for postural integration."
32756368|NCT04402463|Experimental|Exercise Group|"Therapeutic exercises. That they will be divided into 3 phases:~The exercises in these phases will consist in active exercises of the cervical spine and shoulder girdle, motor control exercises, and finally strength and endurance of the cervical flexors and extensors and of the musculature of the shoulder girdle."
32756369|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
32756370|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
32756371|NCT04342871|Experimental|Fam-CT|Patients will receive access to intervention materials.
32756372|NCT04480879|Experimental|AZD8154 nebuliser suspension|The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension
32756373|NCT04480879|Experimental|AZD8154 Monodose|The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation
32756374|NCT04480879|Placebo Comparator|AZD8154 Placebo Monodose DPI|The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation
32756375|NCT05088317||Obese group|Volunteer female and male individuals aged 20-65 years, followed in an Internal Diseases unit of a state hospital in Turkey, diagnosed with obesity (BMI> 30 kg/m^2), who met the inclusion criteria of the study.
32756376|NCT05088317||Healthy group|Healthy male and female individuals between the ages of 20-65 who were not diagnosed with obesity and volunteered to participate in the study.
32756377|NCT05083949|Experimental|Test: empagliflozin/metformin, fixed dose combination|
32756378|NCT05083949|Active Comparator|Reference: Jardiance® and Glifage® single dose each|
32756379|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
32756380|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
32756381|NCT02717663|Experimental|Static goals with delayed incentives|Participants will receive static physical activity goals with delayed, non-contingent incentives
32756382|NCT02717663|Experimental|Adaptive goals with delayed incentives|Participants will receive adaptive physical activity goals with delayed, non-contingent incentives
32756383|NCT02717663|Experimental|Static goals with immediate rewards|Participants will receive static physical activity goals with immediate rewards
32756384|NCT02717663|Experimental|Adaptive goals with immediate rewards|Participants will receive adaptive physical activity goals with immediate rewards
32756385|NCT05080751|No Intervention|Control|In this modality of intervention, the focus will be on the development of skills through educational actions in health, using the pedagogy of transmission. The focus will be based on content related to food, nutrition and quality of life. Materials like videos, áudios (podcasts), booklets and short films will be available weekly, following a schedule of sessions.
32756386|NCT05080751|Experimental|Eating Behaviors|In the intervention group, the focus will be the development of skills through educational health actions that provide the development of autonomy and empowerment for behavior change, based on cognitive behavioral interventions, which involve eating behavior and impact on quality of life. Cognitive behavioral therapy (CBT) is based on ten principles that influence and / or determine treatment attitude and approach. Intervention group sessions will be based on principles.
32756387|NCT02699125|Experimental|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
32756388|NCT02699125|Experimental|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
32756389|NCT04279535|Experimental|ascorbic acid|Participants applied topical solution of ascorbic acid twice daily for 8 weeks
32756390|NCT04279535|Active Comparator|Imiquimod|Participants applied 5% imiquimod cream topically 5x/week
32756391|NCT05049317|Experimental|FTME group|Participants will undergo laparoscopic FTME surgery.
32756392|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.~Intervention: Normal control"
32756393|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
32756394|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
32756395|NCT04845893||Skeletal Ewing Sarcoma|This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.
32756396|NCT02407951|Experimental|CBIT group|
32756397|NCT02407951|Placebo Comparator|Psycho-Educational group|
32756398|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
32756399|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
32742258|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
32756400|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
32756401|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
32756402|NCT04138433|Experimental|Real tDCS|fMRI task plus anodal tDCS
32756403|NCT04138433|Sham Comparator|Sham tDCS|fMRI task plus sham tDCS
32756404|NCT04072991|Active Comparator|Low FODMAP diet|As part of their treatment for IBS participants may be randomised to a low FODMAP diet
32756405|NCT04072991|Active Comparator|Gluten Free Diet|As part of their treatment for IBS participants may be randomised to a gluten free diet
32756406|NCT04072991|Active Comparator|British Dietetic Association diet|As part of their treatment for IBS participants may be randomised to the BDA diet
32756407|NCT02405065|Experimental|HM95573|single arm
32756408|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
32756409|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
32756410|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
32756411|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
32756412|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
32756413|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
32756414|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
32756415|NCT04004741|Experimental|Osteopathic Manipulative Treatment|Group A will receive osteopathic treatment by NMM/OMM board certified attending physicians. The protocol for the OMT intervention group is based on the guidelines set forth previously in textbooks. The protocol will last 25 minutes total, with 10 minutes for the evaluation and 15 minutes for treatment. The protocol will start in ribs so as to not exacerbate any tachyarrhythmias with rib raising, thoracic myofascial release, and a pectoralis lift. The investigator will then proceed with opening the thoracic inlet, cervical myofascial release, suboccipital release, and then end by checking for and treating Chapman's points. The physician will submit their osteopathic evaluation and fill out a form in order to determine if certain arrhythmias have an associated trigger point.
32756416|NCT04004741|Sham Comparator|Light Touch Treatment|Group B will receive a light touch treatment, based on previous research done studying heart rate variability and OMM, where sham treatment was utilized. The protocol consisted of contacting the right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium for precisely two minutes each, with the goal of preventing placebo autonomic nervous system stimulation. The protocol is 25 minutes long, with 10 minutes for the evaluation and 15 minutes for treatment.
32756417|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
32756418|NCT02425787||Parents of deceased children (no BMT)|"Participants will be parents who have lost a child at St. Jude Children's Research Hospital (SJCRH). They will participate in a 60-90 minute interview.~(Not recruiting)"
32756419|NCT02425787||Parents of deceased children (haploidentical BMT)|Participants will be parents whose child died after receiving a haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
32756420|NCT02425787||Parents of deceased children (non-haploidentical BMT)|Participants will be parents whose child died after receiving a non-haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
32756421|NCT02425787||Parents of deceased children (not interviewed)|Participants will be parents who have lost a child at SJCRH, who have not previously participated in an interview through this study.They will participate in a 30-90 minute focus group.
32756422|NCT02425787||Hematology/Oncology Fellows|Participants will be Hematology/Oncology Fellows at SJCRH. They will participate in a 30-90 minute focus group.
32756423|NCT02425787||Legacy-Building|Participants will be parents who have lost a child at SJCRH and received legacy items. They will participate in a 30-90 minute interview.
32756424|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
32756425|NCT05100953|Experimental|Experimental Group|After informing about the benefits of physical activity at the beginning of the study, physical activity counseling will be applied once a week for two months via videoconference.
32756426|NCT05100953|No Intervention|Control Group|At the beginning of the study, a one-session briefing will be given on the benefits of physical activity.
32756427|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
32756428|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
32756429|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
32756430|NCT05374967|Other|Control group|The control group will receive the current standard of care: an informational brochure on how to cope with fatigue.
32742259|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
32742260|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
32756431|NCT05374967|Experimental|Lifestyle intervention|Participants will undergo a multimodal lifestyle intervention, which focuses on nutrition, sleep, stress, and exercise. The lifestyle intervention includes digital lessons/webinars and online counseling by a nutritionist and a lifestyle coach.
32756432|NCT05100719|Active Comparator|alverine-citrate + simethicone and lactase|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone and lactase.
32756433|NCT05100719|Placebo Comparator|alverin-citrate + simethicone with placebo|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone with placebo.
32756434|NCT05100485||Training cohort|Training cohort was used to developement the new algorithm for predicting liver decompensation.
32756435|NCT05100485||Validation cohort|Validation cohort was used to test the performance of the new algorithm in predicting liver decompensation.
32756436|NCT05100485||HVPG cohort|HVPG cohort, a cross-section cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension.
32756437|NCT04828109|Active Comparator|VR and Fitbit|Daily VR use every 3 hours up to 30 minutes at a time and Fitbit daily step goal of 2,000 steps
32756438|NCT04828109|Active Comparator|VR Only|Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.
32756439|NCT04828109|Active Comparator|Fitbit Only|Fitbit daily step goal of 2,000 steps.
32756440|NCT04828109|No Intervention|Control|Standard of care
32756441|NCT05100329|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients will receive mitoxantrone hydrochloride liposome injection every 3 weeks (q3w, a cycle).
32756442|NCT04530539|Experimental|Experimental- Melatonin|Patients will receive melatonin
32756443|NCT04530539|Experimental|Experimental- Vit C|Patients will receive vitamin C
32756444|NCT04530539|Placebo Comparator|Control|Patients will receive placebo
32756445|NCT02698891|Experimental|Paclitaxel|"After the screening procedures confirm participation in the research study:~175 mg/m^2 Paclitaxel via IV, once every 2 weeks x 4 cycles. (1 cycle = 2 weeks)~-- Neulasta™ (Pegfilgrastim) 6 mg SQ x1 is administered on day 2 of each treatment cycle, approximately 24 hours after the chemotherapy treatment, if:~The patient experiences a prior episode of fever and neutropenia.~If the patient has an active infection this decision will be at provider discretion.~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
32756446|NCT04719065|Experimental|Group A, Mitoxantrone Hydrochloride Liposome Injection, q4w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
32756447|NCT04719065|Experimental|Group B, Mitoxantrone Hydrochloride Liposome Injection, q3w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
32756448|NCT04688255|Experimental|Intervention group (MSTEP)|REHABILITATIVE EXERCISE: Participants will be asked to exercise at home daily for 6 weeks, meeting with an RA weekly via video conference to gradually increase the intensity and duration of exercise based on symptom tolerance. The eventual goal will be to achieve 60 minutes of MVPA daily (US Federal recommendations). They will wear a personal fitness device (Fitbit) to track whether they are achieving their HR goals.
32756449|NCT04688255|Active Comparator|Control group (Stretching)|STRETCHING: Participants will be asked to complete stretches daily. They will initially be given two stretches, primarily focused on the neck and upper back. Additional stretches will be added through weekly discussions with the study RA.
32756450|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
32756451|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
32756452|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
32756453|NCT04567745|Other|Cognitive diagnosis|
32756454|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
32756455|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
32756456|NCT05087147|Experimental|Bonded space maintainer|Wire bonded with composite to abutment teeth
32756457|NCT05087147|Active Comparator|Banded space maintainer|Band and loop space maintainer
32756458|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
32756459|NCT05099627||Prospective cohort study arm|"The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up.~The mJOA score and JOACMEQ score are the outcome measures for the prospective arm of the study. Good response to surgery is a 1-point improvement in mJOA score at 3 and 6 months."
32901379|NCT05047068||Other OCS Heart Analysis Population|Any/all other recipients of OCS Heart perfused donor hearts outside of the DBD and DCD indications above will be collected in the respective arm of this registry until the enrollment of the PAP of that arm is completed (200 for DBD and 150 for DCD).
33240266|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
32742261|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
32742262|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
32742263|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
32742264|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
32756460|NCT05099627||Retrospective cohort study arm|"The retrospective questionnaire CSM early diagnosis questionnaire contains all the questions which will be collected retrospectively via telephone. Furthermore patients from the community MSK team, those diagnosed with CM eventually and those examined for CM query, their clinical, biochemical and radiological data from the local SystemOne Databases will be collected for analysis and comparison.~Radiological confirmation of cervical myelopathy is the outcome measure for the retrospective arm."
32756461|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
32756462|NCT05264207|Experimental|Intervention group|Participants allocated to the 'intervention group' arm will receive the usual care offered by the Public Andalusian Healthcare Service in conjunction with a 12-week nursing students' home-visit programme.
32756463|NCT05264207|Active Comparator|Control group|Participants allocated to the 'control group' arm will only receive the usual care offered by the Public Andalusian Healthcare Service for 12 weeks.
32756464|NCT02407873||Cardiac surgery|
32756465|NCT02399605|No Intervention|Control|No intervention, group control.
32756466|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
32756467|NCT05076383|Experimental|Motor relearning program (MRP)|
32756468|NCT05076383|Active Comparator|Conventional physical therapy program (CPT)|
32756469|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
32756470|NCT04442711||PFBIO-EXA|All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
32756471|NCT05108207|Placebo Comparator|Control Group|will receive the standard delirium prevention measures outlined above, plus the use of a mobile device without delirium prevention software for 5 days (Control Group: nPPD package, without PREVEDEL).
32756472|NCT05108207|Experimental|Experimental Group|will receive the standard delirium prevention measures, plus the use of a mobile device with PREVEDEL software for 5 days (Experimental Group: nPPD package, with PREVEDEL).
32756473|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
32756474|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
32756475|NCT05108051|Experimental|sequence 1|Period 1: study of ZSP1273's pharmacokinetics at steady state； Period 2: study of Oseltamivir's pharmacokineticsat at steady state； Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.
32756476|NCT05108051|Experimental|sequence 2|Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.
32756477|NCT05108051|Experimental|sequence 3|Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.
32756478|NCT02404909||Patients with liver tumors candidate to hepatectomy|
32756479|NCT03765359|Active Comparator|metforminhydrochloride|Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
32756480|NCT03765359|Placebo Comparator|Placebo Oral Tablet|Placebo tablets starts on 12-14 weeks of gestation. The starting dosage is 1 tablet x1 and it is increased gradually 1 tablet a week up to 2+2 tablets daily. Duration of the treatment is approximately until one week before delivery. Otherwise placebo treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
32756481|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
32756482|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
32756483|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
32756484|NCT04351295|Experimental|Faviprevir|Faviprevir
32756485|NCT04351295|Active Comparator|chloroquine|chloroquine
32756486|NCT05107895|Experimental|Experimental: Intervention group|A 10-week coping skills training was given to the training group from the randomly separated groups. The Coping Skills Training program will take place in a total of 10 online sessions, and the entire program was implemented in 10 weeks. The duration of each session is between 40 and 50 minutes, and it is determined as 5 minutes of introduction to the session, recognizing the general topics, 5 minutes of briefly summarizing the previous session, and the subject of the session for 30-40 minutes. In all sessions, reflections previously prepared with the power point program were used. In the sessions, question-answer method, audio-visual (audio-visual) method, role-playing and performance feedback phases were used when necessary. In addition to knowledge, experiences were also emphasized in education and it was possible to make comparisons with the subject learned in education.
32756487|NCT05107895|Active Comparator|Comparator: Control group|The control group will be informed about their coping skills for a week. Both groups will receive a final evaluation 10 weeks later and a follow-up evaluation 1 month after the last evaluation.
32756488|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
32756489|NCT02407639|Placebo Comparator|air arm|insufflation with air
32756490|NCT04344587|Experimental|Intervention group|Participants in the intervention arm will receive a text message on their smartphones linking to the Qualtrics intervention website
32756491|NCT04344587|Active Comparator|Usual care group|Participants in the usual care arm will receive a text message on their smartphone linking to the Qualtrics usual care website
32756492|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
32756493|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
32756494|NCT02399137|No Intervention|Observational Group|
32756495|NCT05236205|Experimental|Control Group|This group will receive the treatment of caries removal with a lowspeed drill (conventional treatment).
32756496|NCT05236205|Experimental|Papacarie|In this group, partial caries removal with Papacarie will be performed.
32756497|NCT05236205|Experimental|Papacarie and Bixa orellana extract|In this group, partial caries removal with Papacarie and the application of Bixa orellana extract (20%) will be performed.
32742265|NCT05074589|Experimental|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
32756498|NCT05236205|Experimental|Partial removal with aPDT|In this group, partial removal of the carious tissue will be performed, with Papacarie and the application of Bixa orellana extract (20%) with blue LED (aPDT).
32756499|NCT05093387|Experimental|Interventional (SGT-53, pembrolizumab, carboplatin)|Patients receive SGT-53 IV over 90-120 minutes on days 1, 8, and 15, pembrolizumab IV over 30 minutes on day 3, and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
32756500|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
32756501|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
32756502|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
32756503|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
32756504|NCT05107349|Other|1|
32756505|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
32756506|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
32756507|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
32756508|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
32756509|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
32756510|NCT03952793|Experimental|Experimental|Extended biopsy
32756511|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
32756512|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
32756513|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biological samples will be collected for each patient.
32756514|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
32756515|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
32756516|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
32756517|NCT04481815|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
32756518|NCT04481815|Sham Comparator|R-MTX|Control arm will be treated with R-MTX regimen(Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved CR or PR with additional WBRT, they processed to Lenalidomide maintenance for 4 cycles.
32756519|NCT05107037|Experimental|TQ-B3234 capsule|"In the dose escalation phase, enrolled subjects first received a single dose on an empty stomach for a 3-day observation period. If Dose limiting toxicity (DLT) did not occur, continuous multiple doses were continued, once a day on an empty stomach for a treatment cycle of 28 days.~After the dose escalation phase was completed, cohort extension studies were conducted according to the identified phase ii clinical recommended doses.type I neurofibromatosis （NF1） patients and malignant peripheral nerve sheath tumors （MPNST） patients were selected."
32756520|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
32756521|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
32756522|NCT05106959|Experimental|Pilot Training|In this arm participants will complete a variety of baseline assessments then participate in 15-20 minute conversation based on motivational interviewing principles in which they are trained in shame resilience. Follow-ups will be conducted a month later. Assessments will be repeated and then participants will engage in a qualitative interview regarding the training.
32756523|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
32756524|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
32756525|NCT05106803||Wound infection|Patients with surgical site infection as diagnosed by the attending physician
33240267|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
32742266|NCT05074589|Active Comparator|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
32742267|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
33240268|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
33240269|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
33240270|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
33240271|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
33240272|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
32742268|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
33240273|NCT00755859|Active Comparator|2|six month steroid course
33240274|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
33240275|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
33240276|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
32910546|NCT05455697|Experimental|Treatment (TRR, CHOP)|"PREPHASE THERAPY: Patients receive tafasitamab IV over 30 minutes on days 1, 8, and 15 of each cycle, rituximab and hyaluronidase human SC on day 1 of each cycle, and retifanlimab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~COMBINATION THERAPY: After completion of prephase therapy or if patients progress during prephase therapy, patients receive tafasitamab IV over 30 minutes, retifanlimab IV over 30 minutes, rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 of each cycle. Patients also receive prednisone PO on days 1-5 of each cycle. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity."
32910547|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
32742269|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
32742270|NCT03266939|Placebo Comparator|Placebo|
32742271|NCT03266939|Active Comparator|Active Medication|
32742272|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
32910548|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
32910549|NCT05446025||pregnant women with a diagnosis of hyperemesis gravidarum( n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in patients with hyperemesis gravidarum.
32756526|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
32756527|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
32756528|NCT03780803|Experimental|Patients with PAH|home cardiac rehabilitation and respiratory rehabilitation
32756529|NCT03780803|Experimental|Patients with HFREF|home cardiac rehabilitation and respiratory rehabilitation
32756530|NCT03780803|Experimental|Patients with IHD|home cardiac rehabilitation and respiratory rehabilitation
32756531|NCT03780803|No Intervention|Control group|No rehabilitation
32756532|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
32756533|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
32756534|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
32756535|NCT05025761|Experimental|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN),insect repellent (DEET), Insecticide-treated clothes (ITC), and mobile and migrant population-tailored behavioural change communication (BCC) package
32756536|NCT05025761|No Intervention|Control|No personal protection package
33240277|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
32756537|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
32756538|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
32756539|NCT05017883|Experimental|TAA05 cell injection|TAA6 cell injection#Targeting FLT3 autologous chimeric antigen receptor T cells#
32756540|NCT05008991||Study group|The study group will consist of (20) obese menopausal women whom are recently recovered from mild-moderate COVID-19 after one month.
32756541|NCT05008991||Control group|The control group will consist of (20) obese menopausal women; whom are not be affected by COVID-19.
32756542|NCT05106569||SUNY Upstate|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
32756543|NCT05106569||Atrium Health|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
32756544|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
32756545|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
32756546|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
32756547|NCT03647501|Active Comparator|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
32756548|NCT03647501|Active Comparator|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
32756549|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
32756550|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
32756551|NCT04481659|Experimental|A group|Patients who are initially staged as T1-2, according to MRI and intraluminal ultrasound, are assigned to the direct surgery group (determined by the multidisciplnary team [MDT] group)
32756552|NCT04481659|Experimental|B group|Patients who are initially staged as T3M0, according to MRI and intraluminal ultrasound, should undertake preoperative chemoradiotherapy (determined by the MDT group). The operation was performed 8-12 weeks after the end of the chemoradiotherapy.
32756553|NCT04876625|Experimental|OA plus MS 8wk|Oral Appliance plus Mouth Shield for 8-weeks
32756554|NCT04876625|Active Comparator|OA Alone 4wk|Oral Appliance is used alone for first 4 weeks followed by 4 weeks of Oral Appliance plus Mouth Shield
32756555|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
32756556|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
32756557|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
32756558|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
32756559|NCT04826081||Case|women who contracted symptomatic dengue fever during pregnancy
32756560|NCT04826081||Control|women who did not contract symptomatic dengue fever during pregnancy
32756561|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
32756562|NCT02398903||Normal weight women|Normal weight women
32756563|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
33240278|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
32756564|NCT04923971|Active Comparator|0C Trial|Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
32756565|NCT04923971|Active Comparator|-10C Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C (14F) conditions.Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
32756566|NCT04923971|Active Comparator|-20C Surrogate Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C + 3m/s wind (14F+6 mph wind) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
32756567|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
32756568|NCT05041751|Active Comparator|Arm I (trigger point injections)|Patients receive standard of care trigger point injections at baseline
32756569|NCT05041751|Experimental|Arm II (myofascial release)|Patients perform myofascial release for 10 minutes each day.
32756570|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
32756571|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
32756572|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
32756573|NCT05031845||COVID-19 positive, Hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
32756574|NCT05031845||COVID-19 positive, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
32756575|NCT05031845||COVID-19 negative, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
32756576|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
32756577|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
32756578|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
32756579|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
32756580|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
32756581|NCT05090111|Experimental|ALG-055009|Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
32756582|NCT05090111|Placebo Comparator|Placebo|Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
32756583|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
32756584|NCT04436939|Experimental|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
32756585|NCT04436939|Active Comparator|Ti healing abutment|Healing abutment made of titanium (Ti)
32756586|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
32756587|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
32756588|NCT04611425|Experimental|Remimazolam|"Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours.~The dose of Remimazolam will be adapted according to our ICU protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale)"
32756589|NCT04436471|Experimental|Component 1|"rAd26 Component, 1 vaccination~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
32756590|NCT04436471|Experimental|Component 2|"rAd5 Component, 1 vaccination~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
32756591|NCT04436471|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
32756592|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
33071680|NCT05780892|Experimental|Performance Improvement|This arm consists of 6 virtual group sessions taking place over every 2 weeks for a total of 12 weeks. The sessions target improving perceptions of the work environment through foundational performance improvement knowledge and skills, and they will be led by a member of the systems-reengineering team. Between sessions, participants will be asked to follow through on tasks outlined in the learning sessions and share in the next session. If a session is missed, they will be provided with a prerecording of the didactic material presented in the learning sessions.
33071681|NCT05780892|Active Comparator|Control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
33240279|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
33240280|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
32742273|NCT05074199|Active Comparator|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
32742274|NCT05074199|Active Comparator|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
32742275|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
32742276|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
32742277|NCT03267017||Patient scheduled for surgery under general anesthesia|
32742278|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
32742279|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
32742280|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
32742281|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
32742282|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
32742283|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
32742284|NCT05073965|Experimental|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
32742285|NCT05073965|Placebo Comparator|Placebo group|Subject receive a placebo daily for 6 months
32742286|NCT03266549|Experimental|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
32742287|NCT03266549|Active Comparator|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
32742288|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
32742289|NCT05065775|Experimental|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
32742290|NCT05016323|Experimental|HR19042 Capsules|
32742291|NCT05016323|Placebo Comparator|Placebo|
32742292|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
32742293|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
32742294|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
32742295|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
32742296|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
32742297|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
32742298|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
32742299|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
32742300|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
32742301|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
32742302|NCT04800887|Active Comparator|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
32742303|NCT04800887|Active Comparator|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
32742304|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
32742305|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
32742306|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
32742307|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
32742308|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.~An App for field supervisor to monitor ASHAs~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
33240281|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
32742309|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
32742310|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
32910550|NCT05446025||Control group pregnants (n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in the patients of the control group .
32756593|NCT05106179|Active Comparator|Previously treated + Atenolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
32756594|NCT05106179|Active Comparator|Previously treated + Propranolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
32756595|NCT04480567|Experimental|Dose 1 of BMN 307|
32756596|NCT04480567|Experimental|Dose 2 of BMN 307|
32756597|NCT04480567|Experimental|Dose 3 of BMN 307|
32756598|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 2.0 ng/mL|
32756599|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 4.0 ng/mL|
32756600|NCT02406781|Experimental|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
32756601|NCT02406781|Experimental|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
32756602|NCT05106023|Experimental|SHR-1701 combined with temozolomide|SHR-1701 combined with temozolomide
32756603|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
32756604|NCT02398123|Placebo Comparator|Caudal block|Caudal block
32756605|NCT05105945|Experimental|Single port inflatable mediastinoscope and synchronized laparoscopic radical resection|"Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
32756606|NCT05105945|Active Comparator|Thoracoscopy combined with laparoscopic radical resection|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
32756607|NCT04480801|Experimental|thermal evaluation and foot care|Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
32756608|NCT04480801|Other|foot care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone.While the participants in the control group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions will be provided and participants will be invited to check every 2 months.
32756609|NCT04486625|Experimental|Cohort 1|Normal renal function
32756610|NCT04486625|Experimental|Cohort 2|Severe renal impairment (not on dialysis)
32756611|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
32756612|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
32756613|NCT04458077|Experimental|Mobile-phone-based SEIL Intervention|This group will receive the Discover Learning 10-session intervention through a mobile-phone based platform over the course of 10 weeks (1 session per week).
32756614|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
32756615|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
32756616|NCT04872569|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
32756617|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
32756618|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
32756619|NCT04647851|Experimental|Remote exercise intervention Down syndrome|Intervention: The program we will be using is specifically developed for individuals with Down syndrome based on the Mann Method PT Principles. The MMPT Principles TM focus on a progressive program of therapeutic activity (cardiovascular activity), therapeutic exercise (foundational strengthening and hip strengthening activities), and neuromuscular rehabilitation (visual/vestibular and balance activities) to address the unique needs of individuals with Down syndrome. This program has been developed and successfully implemented in Down syndrome activity centers across the country. This program will be offered through Zoom. Intensity will be submaximal for both data collection and during the exercise sessions, and recorded with Polar heart rate monitors.
32756620|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
32756621|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
32756622|NCT04524611|Experimental|Risankizumab Dose A Followed by Dose B|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous (SC) risankizumab dose B every 8 weeks through Week 48. Participants who complete the Week 48 visit will continue SC risankizumab for up to an additional 220 weeks.
32756623|NCT04524611|Active Comparator|Ustekinumab|Participants will receive weight-based intravenous ustekinumab at Week 0 followed by subcutaneous ustekinumab every 8 weeks through Week 48.
32756624|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
32756625|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
32756626|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
32756627|NCT03701711|Experimental|Lenalidomide escalation and expansion|Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.
32756628|NCT04522895|Experimental|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
32756629|NCT03511079|Experimental|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
32756630|NCT03511079|No Intervention|Control|This group will not listen to music each night for the duration of the study.
32756631|NCT03458195|Experimental|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
32756632|NCT05111873||waiting-list control|Participants enquired prior to the treatment appointment in the neurological day clinic service, no intervention
32756633|NCT05111873||post-treatment group|Participants enquired after the treatment in the Neurological day clinic service
32756634|NCT05111405|Other|Trapezial excision with or without soft tissue interposition and /or ligament reconstruction|The participating surgeon will perform their usual version of a trapeziectomy and thumb metacarpal using either FCR tendon or abductor hallucis longs (APL) tendon. Tendon interposition will be left to the surgeon's discretion.
32756635|NCT05111405|Other|Suture button suspension arthroplasty (SBS)|Dorso-radial incision, capsulotomy between extensor pollicis brevis (EPB) and APL protecting the radial artery. A second incision is made on dorsum of hand between the 2nd and 3rd MCs. A cannulated drill with suture passer is passed from base of 1st MC to mid 2nd MC. The TightropeTM is passed from 1st to second MC with one button on the base of the 1st MC. Trapeziectomy is then performed using a cruciate osteotomy and rongeurs. The thumb is adducted against index MC to avoid excessive tightening and the suture is tied over a second button on the 2nd MC. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
32756636|NCT05105321|Placebo Comparator|Placebo Group|Placebo plus healthy lifestyle intervention. Placebo with same appearance of berberine tablet will be orally taken twice daily and maintained until the last subject completes 3-year intervention.
32756637|NCT05105321|Experimental|Berberine Group|Berberine plus healthy lifestyle intervention. Berberine dose is 500mg twice daily and maintained until the last subject completes 3-year intervention.
32756638|NCT02698189|Experimental|Birabresib 20 mg AML Cohort|Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
32756639|NCT02698189|Experimental|Birabresib 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
32756640|NCT03172663|Experimental|group 1|
32756641|NCT03172663|Active Comparator|group 2|
32756642|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
32756643|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
32756644|NCT04482127|Experimental|SubEpithelial connective graft|"SCTG harvested from palatal tissue by single line incision technique, blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.~The fatty tissue (yellow in color) will be eliminated and some contouring of the graft will be done to fit the prepared envelope. The harvested SCTG will be placed at the extraction sites in a supra-periosteal partial dissection (pouch II technique) prepared at the buccal aspect without using vertical incisions and without flap elevation."
32756645|NCT04482127|No Intervention|Atraumatic extraction|Extraction with Periotomes and Luxators keeping the buccal plate of bone intact
32756646|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
32756647|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
32756648|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
32756649|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
32756650|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
32756651|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
32756652|NCT04481971|Experimental|40 mg|
32756653|NCT04481971|Experimental|20 mg|
32756654|NCT04481971|Placebo Comparator|Placebo|
32756655|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
32756656|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
32756657|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
33240282|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
33240283|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
33240284|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
32742311|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
32742312|NCT03265925||Healthy|Healthy controls
32756658|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
32756659|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
32756660|NCT02702011|Experimental|empagliflozin low dose|
32756661|NCT02702011|Experimental|empagliflozin medium dose|
32756662|NCT02702011|Experimental|empagliflozin high dose|
32756663|NCT02702011|Placebo Comparator|placebo|
32756664|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
32756665|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
32756666|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
32756667|NCT02404207|Active Comparator|Soybean oil|
32756668|NCT02404207|Experimental|High-oleic soybean oil|
32756669|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
32756670|NCT02404207|Active Comparator|Palm olein + palm stearin|
32756671|NCT04959175|No Intervention|Donors|Collection of research samples on bone marrow donors
32756672|NCT04959175|Experimental|Older, HLA-matched|Subjects age 60-85 with hematologic malignancies and an HLA-matched related or unrelated donor
32756673|NCT04959175|Experimental|Older, HLA-mismatched|Subjects age 60-85 with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
32756674|NCT04959175|Experimental|Younger, HLA-matched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-matched related or unrelated donor
32756675|NCT04959175|Experimental|Younger, HLA-mismatched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
32756676|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
32756677|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
32756678|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
32756679|NCT04952779||Xultophy®|Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
32756680|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
32756681|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy|acute stroke patients treated with or without thrombolysis
32756682|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
32756683|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
32756684|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
32756685|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
32756686|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
32756687|NCT05110859||first work experience nurses|
32756688|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
32756689|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
32756690|NCT04850339|Active Comparator|ANXV single dose|ANXV in a single ascending dose pattern in four dose levels.
32756691|NCT04850339|Placebo Comparator|Placebo single dose|Placebo in a single ascending dose pattern in four dose levels.
32756692|NCT04850339|Active Comparator|ANXV multiple dose|ANXV in a multiple ascending dose pattern in three dose levels.
32756693|NCT04850339|Placebo Comparator|Placebo multiple dose|Placebo in a multiple ascending dose pattern in four dose levels.
32756694|NCT02403973|Other|Patient hotel group|
32756695|NCT02403973|Other|Ward group|
32756696|NCT04832009|Experimental|Glucose Infusion|Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
32756697|NCT04832009|Experimental|Lipid Infusion|Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
32756698|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
32756699|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
32756700|NCT03129113|Experimental|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
32756701|NCT03129113|Experimental|metformin (Arm B)|metformin 500mg BID p/o.
32756702|NCT03129113|Experimental|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
32756703|NCT03129113|No Intervention|no adjunctive therapy (Arm D)|no adjunctive therapy
32756704|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
32910551|NCT05439629|Experimental|Experimental group：BAT5906|Intravitreal injection; Dosage: 4.0 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
32910552|NCT05439629|Active Comparator|Control group：Lucentis®|Intravitreal injection; Dosage: 0.5 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
32910553|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
33397110|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
33397111|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
33397112|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
33397113|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
32910554|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
32910555|NCT01229228|Active Comparator|Naprosyn 250 mg|
32910556|NCT01229228|Active Comparator|Naprosyn 500 mg|
32910557|NCT01229228|Placebo Comparator|Placebo|
32756705|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
32756706|NCT05105165||Antibody positive group|
32756707|NCT05105165||Antibody negative group|
32742313|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
32756708|NCT05105165||Health Group|
33240285|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
33240286|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
33240287|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
33240288|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
33240289|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
32910558|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
32742314|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
32742315|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
32910559|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
32910560|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
32910561|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
32910562|NCT01292252|Experimental|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
32910563|NCT01292252|Placebo Comparator|Control|Saline placebo
32910564|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
32910565|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
32910566|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
32910567|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
32910568|NCT00003407|Experimental|Effectiveness of amifostine &high-dose combination chemotherapy in treating patients with AML or CML|Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantroni, followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin, and Decadron
33240290|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
32756709|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
32756710|NCT05110547||Idiopathic Parkinson's disease|patients meeting the current clinical criteria whose disorders have progressed for strictly more than 2 years and strictly less than 7 years.
32756711|NCT05110547||atypical Parkinsonian syndromes|including the subgroups: multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration with a duration of disease progression strictly greater than 2 years and strictly less than 7 years, and meeting the current clinical criteria for each
32756712|NCT02397577|Other|gastric emptying measurements|
32756713|NCT05105009|Active Comparator|Healthy Kidney Donors|12 Healthy Kidney Organ Donors
32756714|NCT05105009|Experimental|CKD Patients|12 patients for each CKD Stage
32756715|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
32756716|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
32756717|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
32756718|NCT03115879|Experimental|Manipulation Group|Hip manipulation
32756719|NCT05104931|Experimental|Nanoformed Piroxicam IR Tablet|orally delivered nanoformed piroxicam immediate release tablets (20mg)
32756720|NCT05104931|Active Comparator|Felden (piroxicam) Tablets|orally delivered Felden (piroxicam) tablets (20mg)
32756721|NCT05104931|Active Comparator|Brexidol (piroxicam) Tablets|orally delivered Brexidol (piroxicam) tablets (20mg)
32756722|NCT02397499|Experimental|LIPO-202|Experimental arm
32756723|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
32756724|NCT02847689|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
32756725|NCT02847689|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
32756726|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
32756727|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
32756728|NCT02682641|Experimental|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:~Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.~Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
32756729|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
32756730|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
32756731|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
32756732|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
32756733|NCT05110469|Experimental|Group M|IV Magnesium sulphate 30 mg/kg in 100 ml NaCl 0.9%
32756734|NCT05110469|Experimental|Group P|IV Meperidine 0.5 mg/kg in 100 ml NaCl 0.9%
32756735|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
32756736|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
32756737|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
32756738|NCT04831775|Experimental|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice over 8 weeks. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on. The intervention group will be asked to practice 20 minutes, 7 days a week.
32905399|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
32910569|NCT04838717|Active Comparator|BPG Arm|BPG injections will be performed at the participating center
33071682|NCT05780684|Experimental|Study Arm|All patients in this single-study arm will be exposed to the FOX regimen, an adaptively dose-escalated chemotherapy regimen. The FOX regimen is comprised of oxaliplatin 85 mg/m2 IV on Day 1; leucovorin calcium 350 mg IV on Day 1; and infusional 5-FU IV over 46 hours (Days 1 and 2) - starting at a dose of 2,400 mg/m2 and adaptively adjusted toward a maximum dose of 3,200 mg/m2 over Cycles 2-4 using a clinical algorithm.
33240291|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
32910570|NCT04838717|Experimental|Doxycycline Arm|Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.
32910571|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
32910572|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
33240292|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
33240293|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
32905400|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
32905401|NCT00875342|Experimental|D-cycloserine|100 mg on days of therapy session
32756739|NCT04831775|Active Comparator|Brain Games Only|An active control group will be used. The differing variable between the two groups is the class sessions. Those randomized to the control group will only receive a link to the BrainHQ games site. A specific amount of practice will not be prescribed, but the frequency and duration of participant's practice will be obtained from BrainHQ. Participants will receive a weekly phone call to maintain connection to the study. Data collection will be on the same schedule as the intervention group.
32756740|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
32756741|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
32756742|NCT05101109|Experimental|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation.
32756743|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
32756744|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
33240294|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
32756745|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
32756746|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
32756747|NCT05094323|Active Comparator|Group I|Patients will receive ultrasound-guided deep serratus anterior plane block.
32756748|NCT05094323|Active Comparator|Group II|Patients will receive local wound infiltration (LWI).
32756749|NCT05094323|Placebo Comparator|Group III|Patients will receive ultrasound-guided thoracic paravertebral block.
32756750|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
32756751|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
32756752|NCT04480489|Experimental|Group A|In Group A, students will first perform Task 1 (walk from anesthesia lounge to the day surgery unit) using intervention 1 (using the virtual reality video) first, then Task 2 (walk from anesthesia lounge to the pre-operative clinic) using intervention 2 (using the traditional 2D video).
32756753|NCT04480489|Active Comparator|group B|In Group B, students will first perform Task 1 (follow route 1: walk from anesthesia lounge to the day surgery unit) using intervention 2 (using the traditional 2D video) first, then Task 2 (follow route 2: walk from anesthesia lounge to the pre-operative clinic) using intervention 1 (using the virtual reality video).
32756754|NCT04961177|Other|EITC & ACEs Training|Trainings for frontline health workers about EITC and ACEs.
32756755|NCT04961177|Other|EITC Outreach and Screening|Our partners will implement EITC outreach events and EITC screening with clients.
32756756|NCT04961177|Other|EITC Assistance|Our partners will screen clients for EITC and refer those who qualify for free tax preparation assistance and assistance submitting their tax returns.
32756757|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
32756758|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
32756759|NCT04788875|Active Comparator|Small Bite Technique Group|closure of laparotomy by small bites technique using PDS 2.0
32756760|NCT04788875|Other|Standardised Large Bites Technique Group|usual practice closure of laparotomy by standardised large bites technique using PDS 2.0
32756761|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
32756762|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
32756763|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
32756764|NCT02396875|Experimental|Group A|"10 patients from Group 1~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
33240295|NCT04087226|Active Comparator|Conventional Retraction Cord|
33240296|NCT04087226|Experimental|PTFE Retraction Cord|
33240297|NCT04085822|Experimental|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
33240298|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
32910573|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
33397114|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
33397115|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
33397116|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
33397117|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
33397118|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
33397119|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
33397120|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
32756765|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
32756766|NCT02396875|Active Comparator|Group C|"5 patients form Group 3~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
32756767|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
32756768|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
32756769|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
32756770|NCT05109923|Experimental|New Mood Supplementation|The New Mood herbal supplement includes lemon balm, 5-HPT, L-Tryptophan and valerian root.
32756771|NCT05109923|Placebo Comparator|Placebo Supplementation|The placebo includes rice bran and maltodextrin.
32756772|NCT02396563||epidural analgesia|women in labor with epidural analgesia
32756773|NCT02396563||no epidural analgesia|
32756774|NCT05109767|Experimental|Virtual reality glass game application|
32756775|NCT05109767|Active Comparator|Smartphone game application|
32756776|NCT05109767|No Intervention|Control group|
32756777|NCT03170245||B thalassemia group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
32756778|NCT03170245||Control group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
32756779|NCT05109689|Experimental|ACT-P|ACT-P is a cognitive behavioral program based on acceptance and commitment therapy, and it has been modified for use in the prison setting.
32756780|NCT05109689|Active Comparator|T4C|Thinking for Change (T4C) is an evidence-based cognitive behavioral program focused on changing criminal thinking.
32756781|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
32756782|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
32756783|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
32756784|NCT02701777|Other|Multisite-STDP + Training|Prospective Single Cohort Multisite-Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
32756785|NCT05109533|No Intervention|Group 1 - ARM WITH STANDARD TREATMENT|Standard specific treatment for vaginal infections following latest version of CDC guidelines
32756786|NCT05109533|Experimental|Group 2 - ARM WITH STANDARD TREATMENT PLUS PROBIOTICS IMPLEMENTATION|Standard specific treatment for vaginal infections plus long-lasting (9 months) vaginal and oral probiotics implementation (Lactobacillus rhamnosus BMX 54 vaginally and Lactobacillus reuteri RC-14/Lactobaciullus rhamnosus GR-1 combination orally)
32756787|NCT05109377|Other|5mg tadalafil|5mg tadalafil
32756788|NCT05109377|Other|20mg tadalafil|20 mg tadalafil
32756789|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
32756790|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
32756791|NCT05109299|Experimental|Miswak toothpaste|Dabur meswak herpal toothpaste
32756792|NCT05109299|Active Comparator|Fluoride toothpaste|Signal fluoride toothpaste, containing 1450 ppm of fluoride
32756793|NCT03172351|Experimental|EDoF1|
32756794|NCT03172351|Active Comparator|Monofocal|
32756795|NCT03172351|Active Comparator|EDoF2|
32756796|NCT05108753||Group 1|5 patients underwent TaTME under proctoring
32756797|NCT05108753||Group 2|the first 10 patients underwent TaTME without proctoring
32756798|NCT05108753||Group 3|the second 10 patients underwent TaTME without proctoring
32756799|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
32756800|NCT03170089|No Intervention|Control|NO program or scaling done
32756801|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
32756802|NCT04673591|Experimental|Tregalizumab|
32756803|NCT04673591|Placebo Comparator|Matched placebo|
32756804|NCT05108597|Experimental|Misoprostol (Study Group)|In study group, 400ug misoprostol will be administered through rectal route, 1 hour before surgery.
32756805|NCT05108597|No Intervention|No drug|In control group no dose will be administered
32756806|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
32756807|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
32756808|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
32756809|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
32756810|NCT05108519||Observational (medical records review)|Patients' medical records are reviewed.
32905402|NCT00875342|Placebo Comparator|Placebo|Sugar pill
33240299|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
33240300|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
32905403|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
33397121|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
32742316|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
32742317|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
32742318|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
32742319|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
32742320|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
32742321|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
32742322|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
32742323|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
32742324|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
32742325|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
32756812|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
32756813|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
32756814|NCT04524767|Experimental|SBIRT|SBIRT will involve screening with the Patient Health Questionnaire-9 (PHQ-9); brief intervention with Motivational Interviewing (MI); and referral to specialty treatment, as needed for subjects with persistent depressive symptoms.
32756815|NCT04524767|Active Comparator|Referral As Usual|Referral as Usual will involve distributing depression educational materials (e.g., from the National Institute of Mental Health) and contact information for treatment providers in our target community
32756816|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
32756817|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
32756818|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
32756819|NCT05086913|Experimental|Lifestyle medicine smartphone app|The app group will receive an app to facilitate lifestyle modification such as video demonstrations of physical activity, diet recommendations, stress and sleep management.
32756820|NCT05086913|Experimental|lifestyle medicine booklets|The booklet group will receive 8 lifestyle medicine and psychoeducation booklets with identical content with the lifestyle medicine app.
33397122|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
32756821|NCT05086913|Sham Comparator|waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
32756822|NCT05745805||Mild COVID-19 group|Confirmed diagnosis of mild Covid-19 (WHO criteria)
32756823|NCT05745805||Moderate COVID-19 group|Confirmed diagnosis of moderate Covid-19 (WHO criteria)
32756824|NCT05745805||Uninfected Healthy controls|Healthy people who have not had COVID-19
32756825|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
32756826|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
32756827|NCT04436627|Experimental|Mild severity:|Brunnstrom stage of distal part: 5-6
32756828|NCT04436627|Experimental|Moderate severity:|Brunnstrom stage of distal part: 4
32756829|NCT04436627|Experimental|severe severity:|Brunnstrom stage of distal part: 2-3
32756830|NCT02396329|Experimental|chlorhexidine _based antisepsis|"Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.~."
32756831|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
33397123|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
32756832|NCT04967651||Patients with pulmonary complications following cardiac surgery|
32756833|NCT04967651||Patients without pulmonary complications following cardiac surgery|
32756834|NCT04964921||Impaired Fasting Glucose Individuals|The group contains subjects with various stages of impaired fasting glucose tolerance levels and diabetes (with or without complications). All subjects will be considered in one group since the heart rate variability and vital signs are monitored in a single visit.
32756835|NCT05745727|Experimental|PRX-115|Participants will receive a single dose of PRX-115 by IV infusion
32756836|NCT05745727|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion
32756837|NCT04053049|Active Comparator|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
32756838|NCT04053049|Active Comparator|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
32756839|NCT04053049|Active Comparator|High fat/ solid|Subject will receive a high fat/solid meal.
32756840|NCT04053049|Active Comparator|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
32756841|NCT04648553|Experimental|Task-Based Grounding|Participating parents will be provided with three 50-minute Task Based Grounding sessions using a standardized manual over 6 weeks.
32756842|NCT04648553|Sham Comparator|Connected Care (Enhanced treatment as usual)|"Participating parents will be provided with two sessions and one phone check-in call over 6 weeks. They will work with a care navigator to assess their child's needs, find them an appropriate referral for care, and help problem solve barriers to finding a therapist."
32756843|NCT03167515|Experimental|074-6751 Lotion|
32756844|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
32756845|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
32756846|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
32905404|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
32905405|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
33240301|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
33240302|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
33240303|NCT05393271|Experimental|Part 1 (SAD): Participants receiving VH4011499|
33240304|NCT05393271|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
33240305|NCT05393271|Experimental|Part 2 (MAD) Drug-Drug Interaction (DDI) cohort: Participants receiving VH4011499 + Midazolam|
33071683|NCT05780437|Experimental|AZD7442 plus SOC|"AZD7442 600 mg solution (separate vials containing 300 mg each of AZD88995 and AZD1061); administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
33071684|NCT05780437|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
33240306|NCT05393271|Placebo Comparator|Part 2 (MAD) DDI cohort: Participants receiving placebo + Midazolam|
33240307|NCT05393271|Experimental|Part 2 (MAD) Non DDI cohort: Participants receiving VH4011499|
33240308|NCT05393271|Placebo Comparator|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
33240309|NCT05393271|Experimental|Part 3 (Single dose): Participants receiving VH4011499 (new formulation)|
33240310|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
32756847|NCT04515407|Other|Order 1|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
32756848|NCT04515407|Other|Order 2|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 2 will be: Seated@Active, Walking, Seated@Rest.
32756849|NCT04515407|Other|Order 3|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 3 will be: Walking, Seated@Rest, Seated@Active.
32756850|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
32756851|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
32756852|NCT04666571|Experimental|Personalised (TOKA)|"During HTO surgery, the personalised plate will be inserted below the knee.~The investigational device and comparator are two types of metal plate used to fix the bone in place during a high tibial osteotomy (HTO)."
32756853|NCT04666571|Active Comparator|Standard (Tomofix)|During HTO surgery, the standard plate will be inserted below the knee.
32756854|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
32756855|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
32756856|NCT02395783|Placebo Comparator|Placebo|Placebo
32756857|NCT04470713||Group A - Retrospective data collection|Participants with a confirmed diagnosis, either deceased patients or patients whose survival status is not known at enrollment.
32756858|NCT04470713||Group B - Prospective data collection|Participants who are alive at enrollment. Data collection is retrospective for the time between birth and enrollment visit, and data collection is prospective from the enrollment visit onwards. Visits are performed as per local standard of care.
32756859|NCT04604015|Experimental|NeuralBot Investigational System|Robotic TCD monitoring during bubble exam
32756860|NCT04569383|Experimental|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
32756861|NCT04569383|Experimental|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
32756862|NCT04555343|Experimental|Intervention- TXA|"Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings.~1gm of TXA will be mixed with 100cc NS"
32756863|NCT04450667|No Intervention|Fasting|"Patient will be nil per os from midnight before their cesarean section"
32756864|NCT04450667|Active Comparator|Rehydration|Patient will receive 400 mL of Nutricia Preop ® 2 hours before their cesarean section
32756865|NCT04436237|Experimental|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
32756866|NCT04436237|Active Comparator|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
32756867|NCT04466657|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
32756868|NCT04466657|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus daily antioxidant supplement composed of two proprietary formulations that include reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
32756869|NCT04546451|Experimental|Music practice|Patients will receive Music Practice interventions of 45 minutes twice a week over 6 months, provided by a professional musician
32756870|NCT04546451|Experimental|Psychomotor therapy|Patients will receive Psychomotor interventions of 45 minutes twice a week over 6 months, provided by a professional psychomotor therapist
32756871|NCT04546451|No Intervention|Passive control group|Healthy passive controls will pass all measurements without any intervention. The control group participants must adhere to the same inclusion and exclusion criteria as the experimental groups, except for an MCI diagnosis. Control participants will be matched to the experimental groups for age, gender and education level.
32756872|NCT04392323|Experimental|Study Group|Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
32756873|NCT04528667|Experimental|STI-5656|STI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
32756874|NCT04528667|Placebo Comparator|Placebo|Placebo capsules administered orally daily for 7 days, in addition to standard of care
32756875|NCT04383119|Experimental|Arm A|Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles
32756876|NCT04383119|Active Comparator|Arm B|Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days
32756877|NCT04383119|Active Comparator|Observational Cohort|Treatmen according clinical practice (not defined in advance). The patient who will refuse randomization between Arm A and B can choose to participate to the observational cohort to the study, where they will be treated according clinical practice
32756878|NCT04522739|Experimental|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
32756879|NCT04522739|Placebo Comparator|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
32756880|NCT04309877|Experimental|PO theophylline & IV LPS|Oral (PO) theophylline 400 mg/day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
32756881|NCT04309877|Experimental|PO placebo & IV LPS|PO methylcellulose (placebo) daily for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
32756882|NCT04309877|Experimental|PO theophylline & IV placebo|PO theophylline 400 mg/day for 2 weeks followed by a single IV bolus of 0.9% saline
32756883|NCT04309877|Placebo Comparator|PO placebo & IV placebo|PO methylcellulose (placebo) daily for 2 weeks followed by a single IV bolus of 0.9% saline
32756884|NCT04367909|Experimental|Nimotuzumab plus TC Regimen chemotherapy|Nimotuzumab (200 mg) plus TC Regimen chemotherapy every 3 weeks
32756885|NCT04367909|Active Comparator|TC Regimen chemotherapy|TC Regimen chemotherapy every 3 weeks
32756886|NCT04221425|Experimental|VRRS GROUP|Home rehabilitation program is provided through a virtual reality based telerehabilitation system
33397124|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
33071685|NCT05780424|Experimental|BRII-196/BRII-198 plus SOC|"BRII-196 1000 mg solution; administered as IV infusion~BRII-198 1000 mg solution; administered as IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
32756887|NCT04221425|Active Comparator|CONTROL GROUP|Home rehabilitation program is provided through illustrative booklet containing characteristics of exercises and indications for recovery
32756888|NCT04942613|Experimental|Multicomponent Telehealth Intervention (Group1)|This group will be randomized to receive the 12-week multicomponent intervention first. They will receive individual physical therapy sessions, group physical therapy sessions, and biobehavioral interventions emphasizing program engagement and increased daily physical activity. Most interventions will be provided synchronously through videoconferencing. Each participant will receive an individualized home exercise program.
32756889|NCT04942613|Other|Education (Group2)|This group will be randomized to 12-week waitlist control condition. They will receive a one-hour education session every 2 weeks (6 sessions total) on general health topics (e.g., basic nutrition, stress reduction, sleep hygiene). At the end of 12 weeks, they will transition to the 12-week multicomponent intervention
32756890|NCT04942613|Other|Research Participants|Participants will be asked to complete up to 2 semi-structured interviews following completion of the 12-week multicomponent intervention. The first interview will occur within 3 weeks of program completion (by week 15 for Group 1 and by week 27 for Group 2). The second interview will occur between 3 to 6 months after the first interview.
32756891|NCT04196075|Experimental|Andrographis Paniculata treatment|Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
32756892|NCT04142255|Experimental|FMT|20 subjects will be enrolled in this arm to receive FMT treatment.
32756893|NCT03863483|Experimental|Sintilimab plus chemotherapy|Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
32756894|NCT03863483|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
32756895|NCT04031339||Patients diagnosed with thyroid cancer|Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer
32756896|NCT04000763|Experimental|Transcutaneous Nerve Stimulator(TENS)|Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.
32756897|NCT03871595|Experimental|Test Treatment|Non-fasting state
32756898|NCT03871595|Experimental|Reference Treatment|Fasting state
32756899|NCT03840005|Placebo Comparator|Placebo|2:1 in favour of UDCA
32756900|NCT03840005|Experimental|Ursonorm (Ursodeoxycholic acid)|UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.
32756901|NCT03780725|Experimental|Part 1: Ezabenlimab 240mg + BI 754111 600mg|
32756902|NCT03780725|Experimental|Part 2: Ezabenlimab 240mg + BI 754111 40mg|
32756903|NCT03830411|Experimental|Arm A: Sintilimab|Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
32756904|NCT03830411|Active Comparator|Arm B: Chemotherapy (Docetaxel or Pemetrexed)|Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
32756905|NCT03300479|Experimental|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
32756906|NCT03300479|Active Comparator|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
32756907|NCT04758065|Active Comparator|1-Goup: Control group|Home-based cervical therapeutic exercise and manual therapy.
32756908|NCT04758065|Experimental|2-Group: Radial pressure waves Group|Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.
32756909|NCT04718987|Experimental|Prostate Cancer Patients|Low- or favourable intermediate-risk prostate cancer patients
32756910|NCT04708379|Experimental|Intervention group|Nutrition education and physical activity education.
32756911|NCT04708379|No Intervention|Control group|No specific intervention.
32905406|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
32905407|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
32756912|NCT04698785|Experimental|Regorafenib and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
32756913|NCT04698785|Placebo Comparator|Placebo and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
32756914|NCT03702569||Patients needing a volume expansion|
32756915|NCT04685447|Experimental|Expanded Hemodialysis|Hemodialysis modality performed by using a medium cut-off membrane
32756916|NCT04685447|Experimental|Protein-leaking hemodialysis|Hemodialysis modality performed by using a membrane with accentuated absorption capacities.
32756917|NCT03012425|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation & compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction & Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control & sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control & sleep restriction procedures, introduce & practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control & sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control & sleep restriction procedures Session 7- Review of sleep diary & overall progress, discuss relapse prevention, further sleep restriction guidelines & prophylaxis.
32756918|NCT03012425|Experimental|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
32756919|NCT03587675|Other|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
32756920|NCT05115929|Active Comparator|Decompressive Craniectomy Group|participants with severe TBI randomly assigned as described in the study protocol
32756921|NCT05115929|Active Comparator|Decompressive Laparotomy Group|participants with severe TBI randomly assigned as described in the study protocol
32756922|NCT03540875|Experimental|Full automation group|Full automation control of propofol and remifentanil
32756923|NCT03540875|Other|Control group|Manual control of of propofol and remifentanil using TCI system
32756924|NCT03536507|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
32756925|NCT03536507|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
32756926|NCT03220685||1.normal persons|normal persons include 25 person
32756927|NCT03220685||2.CKD pt with anemia|includes 25 previously diagnosed CKD patients with or without treatment of anemia.
32756928|NCT04819373|Experimental|BDB001|BDB001 will be administered intravenously as monotherapy in subjects with histologically-confirmed unresectable or metastatic solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment either as monotherapy or in combination with other therapies.
32756929|NCT04765787||Painful musculoskeletal disorders in random order|Nuberol Forte® (Paracetamol 650 mg + Orphenadrine 50 mg) for the symptomatic management of the painful musculoskeletal disorders one tablet three times a day or as per physician discretion or as per severity of pain and treatment duration is 7-10 days
32756930|NCT05115617||Pregnant individuals|Pregnant individuals who have previously received one-dose of COVID-19 vaccine, or who are planning to receive a COVID-19 vaccine in pregnancy.
33071686|NCT05780424|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
32756931|NCT04672967||Autism Spectrum Disorder|Children diagnosed with ASD between the ages of 18-60 months
32756932|NCT04672967||Non-ASD (developmental delay or typically developing)|Children diagnosed with non-ASD between the ages of 18-60 months
32756933|NCT04663217||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
33240311|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
32756934|NCT04663217||Pulmonary hypertension due to left heart disease|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.
32756935|NCT04663217||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
32756936|NCT04663217||Control|Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.
32756937|NCT02944799|Active Comparator|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
32756938|NCT02944799|Placebo Comparator|Placebo|Placebo tablets, one every week
32905408|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
32905409|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
32905410|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
32905411|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
32910574|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
33071687|NCT05780333|Other|tap block|"Tap block is one of the frequently used field blocks for analgesia management of abdominal surgery.~At the end of surgery and general anesthesia, transversus abdominis fascial plane will be detected with using lineer usg probe. With in-plane tecnique after placement of the needle in the transversus abdominis fascial plane, and careful aspiration to exclude vascular puncture, a test dose of 1 mL will be injected to determine resistance to flow, and confirm needle tip placement within the fascial plane. After this, 20 ml local anaestetic mixture will be injected through the needle. The TAP block will be then performed on the opposite side using an identical technique."
33071688|NCT05780333|Active Comparator|esp block|"The effectiveness of esp block is also evaluated in abdominal surgery after spinal surgery, thoracic and cardiovascular surgery.~At the end of surgery and general anesthesia, in the lateral decubitus position, the linear probe will be placed approximately 3 cm lateral to the T10 spinous process, in the parasagittal plane. With the in-plane technique, when the block needle rests on the transverse process (approximately 3cm in depth), the erector spina plan will be confirmed with a 0.5-1 mL 0.9% NaCl test dose. 20 ml of local anesthetic mixture will be applied to the confirmed area. The procedure will be applied bilaterally."
33071689|NCT05779839|Experimental|Algorithmically Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be matched to other caregivers using an algorithm that matches a caregiver to another caregiver based on specific preferences each caregiver identifies in a questionnaire.
33071690|NCT05779839|Active Comparator|Randomly Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be randomly matched to other caregivers not based on the preferences they identified in a questionnaire.
33071691|NCT05779631|Experimental|mpMRI plus a same-day cystoscopic bladder biopsy|multiparametric MRI plus same-day cystoscopic bladder biopsy
33071692|NCT05779631|Active Comparator|TURBT|Transurethral resection of the bladder tumor
33071693|NCT05779293|Experimental|non-invasive auricular vagus nerve stimulation|non-invasive auricular vagus nerve stimulation + Neuromuscular Electrical Stimulation (NMES) exercise under the supervision of a physiotherapist
33071694|NCT05779293|Active Comparator|Conventional physical therapy|NMES exercise under the supervision of a physiotherapist
33071695|NCT05779007||Pirfenidone initiators|Patients who initiated pirfenidone treatment
33240312|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
33240313|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
33240314|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
33240315|NCT00756171|Experimental|1|Verum; colesevelam
33240316|NCT00756171|Placebo Comparator|2|placebo
33240317|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
33240318|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
32744503|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
32910575|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
33071696|NCT05779007||Nintedanib initiators|Patients who initiated nintedanib treatment
33071697|NCT05778266|Active Comparator|L-Cit + HIIT|adolescents will be supplemented with 6 g/day of L-citrulline and 3 sessions per week of HIIT for 12 weeks
33071698|NCT05778266|Active Comparator|L-Cit|adolescents will be supplemented with 6 g/day of L-citrulline but without do exercise for 12 weeks
33397125|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
33397126|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
33397127|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
33397128|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
33397129|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
33397130|NCT01318239|Active Comparator|Standard Chemotherapy only|
33397131|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
33397132|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
33397133|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
32756939|NCT02749331|Experimental|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:~10 000 000 000 virus particles~100 000 000 000 virus particles~300 000 000 000 virus particles~1000 000 000 000 virus particles~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
32756940|NCT05115149|Experimental|Volga: tSCS during the exercise|Stimulation during the excercise
32756941|NCT05115149|Experimental|Neva: tSCS prior to the exercise|Stimulation prior to the action
32756942|NCT05112341||group 1 standared hypofractonation|
32756943|NCT05112341||group 2 fast forward group|
32756944|NCT04638803|Experimental|Crossover (fasted)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
32756945|NCT04638803|Experimental|Single Group (fed)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
32756946|NCT04592783|Experimental|Tight Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 140/90 mmHg
32756947|NCT04592783|Experimental|Liberal Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 150/95 mmHg
32756948|NCT05114525|Experimental|Patients Who are Anticipated to Receive Definitive Treatment|
32756949|NCT05112107|No Intervention|Control|
32756950|NCT05112107|Experimental|Intervention|
32756951|NCT04521881|Active Comparator|Active|A single dose of Tranexamic acid 500mg given by intramuscular injection
32756952|NCT04521881|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
32756953|NCT04570787|Active Comparator|No Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.
32756954|NCT04570787|Active Comparator|Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.
32756955|NCT05114369||Early (<4weeks), Intermediate (4-12 weeks) and Late (>12 weeks)|Interval between index cholecystectomy and radical re-resection with curative intent
32756956|NCT04316585|Experimental|Participants receiving GSK2982772 960 mg|Participants will receive GSK2982772 960 mg oral tablets once daily for 12 weeks.
32756957|NCT04316585|Placebo Comparator|Participants receiving placebo|Participants will receive GSK2982772 matching placebo oral tablets once daily for 12 weeks.
32756958|NCT04305899|Experimental|Treatment Group 1|
32756959|NCT04305899|Experimental|Treatment Group 2|
32756960|NCT04305899|Experimental|Treatment Group 3|
32756961|NCT04305899|Experimental|Treatment Group 4|
32756962|NCT04305899|Experimental|Treatment Group 5|
32756963|NCT04305899|Experimental|Treatment Group 6|
32756964|NCT04305899|Experimental|Treatment Group 7|
32756965|NCT04305899|Experimental|Treatment Group 8|
32756966|NCT04305899|Experimental|Treatment Group 9|
32756967|NCT04305899|Experimental|Treatment Group 10|
32756968|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
32756969|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
32756970|NCT04463693|Experimental|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
32756971|NCT04462289|No Intervention|Usual Care|Randomly assigned sample who will receive usual care for tobacco cessation treatment
32756972|NCT04462289|Experimental|Proactive Outreach|Randomly assigned sample who will receive a proactive offer of tobacco treatment
32756973|NCT04453709|Experimental|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
32756974|NCT04453709|Active Comparator|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
32756975|NCT05113823|Active Comparator|High Fidelity Simulator|Subjects will receive training using high fidelity simulator
32756976|NCT05113823|Active Comparator|Low Fidelity Simulator|Subjects will receive training using low fidelity simulator
32756977|NCT04425395|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
32756978|NCT04014803|Active Comparator|Prasugrel plus Aspirin arm|"Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily* will be given for one year.~* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement."
33071699|NCT05778266|Placebo Comparator|Placebo + HIIT|adolescents will be supplemented with 6 g/day of Carboxymethyl cellulose and 3 sessions per week of HIIT for 12 weeks
32756979|NCT04014803|Active Comparator|Clopidogrel plus Aspirin arm|Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
32756980|NCT04003493|Experimental|Intervention group of nutrition|On the basis of a blood test, Mini Nutritional Assessment, food diary and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the caregivers. If the caregivers seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
32756981|NCT04003493|No Intervention|Control group of nutrition|The control group has the same examinations as the intervention group, they do not get dietary counseling.
32756982|NCT04003493|Experimental|Intervention group of oral health|After the dental hygienist interview and oral health examination, the caregivers in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
32756983|NCT04003493|No Intervention|Control group of oral health|The control group has the same examinations as the intervention group, they do not get oral health counseling.
32756984|NCT03956849||Professionals working with children|The studypopulation for this mixed-methods study is consisting of healthcareprofessionals working with children (with overweight or obesity), such as pediatric residents, paediatricians and youth health care professionals. Also other professionals working with children, not working in the field of healthcare, such as teachers, can be included in the study population.
32756985|NCT05113511|Experimental|SCT510|SCT510
32756986|NCT05113511|Active Comparator|bevacizumab|bevacizumab
32756987|NCT04163081|Experimental|Quit Card Intervention (QCI)|Study intervention group.
32756988|NCT04163081|No Intervention|Usual Care (UC)|Study control group.
32756992|NCT05113433|Experimental|group a|15 minute on standing frame .
32756993|NCT05113433|Experimental|group b|30 minute on standing frame .
32756994|NCT05113433|Experimental|group c|45 minute on standing frame.
32756995|NCT05113433|Experimental|group d|60 minute on standing frame.
32756996|NCT05112887|Experimental|OMT Group|"The OMT protocol treatment sequence was performed in the following order:~1. Rib raising from a seated position 2. Suboccipital Release from a supine position 3. Thoracic Inlet Release 4. Miller Lymphatic Pump 5. Pedal Pump 6. Suboccipital Release 7. Cranial Sinus Effleurage~Engaging the sagittal midline of occiput with pressure until release of the tissue is palpated~Direct pressure along the external region of the transverse sinus until release of the tissue is palpated.~Pressure on sagittal suture with transverse traction until release of the tissue is palpated~Pressure on metopic suture with transverse traction in a pulsatile manner~Vault hold~1. Appreciate cranial respiratory motion 2. Diagnose cranial strain pattern 3. Place cranial strain pattern into position of ease"
32756997|NCT05112887|Placebo Comparator|Placebo/Light Touch/Sham Group|Participants in the sham/placebo group were lightly touched in equivalent positions to the OMT treatments. First, sham participants were lightly touched on the thoracic cage while seated, followed by light touch of the neck, chest, feet, and cranium while supine. The length of light touch was modeled after the approximate time needed for the OMT matching each treatment region. Each treatment sequence lasted about 20 minutes in total.
32756998|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
32756999|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
32757000|NCT05112653||2|"Group of Philadelphia positive leukemic patients will included in the study who divide into:~patient newly diagnosed CML treated with first line of tyrosine kinase inhibitors therapy.~Philadelphia positive acute leukemic patients(ALL, mixed-phenotype acute leukemia) on TKI therapy who achieved complete hematological remission(CHR) and who failed to achieve CHR."
32757001|NCT05111171||6F sheath CAG group|No PCI is required, only diagnostic CAG is required.
32757002|NCT05111171||6F sheath PCI group|PCI is required, simple lesions are group.
32757003|NCT05111171||7F sheath PCI group|PCI is required for the complicated disease.
32757004|NCT03330197|Experimental|Arm 1 - Closed|Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
32757005|NCT03330197|Experimental|Arm 2 - Open|Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
32757006|NCT03169985|Active Comparator|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
32757007|NCT03169985|Active Comparator|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
32757008|NCT03155399|Experimental|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
32757009|NCT03155399|Other|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
33240319|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
33240320|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
33240321|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
33240322|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
33240323|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
33240324|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
33240325|NCT00756249|Placebo Comparator|Placebo|
33240326|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
33240327|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
33071701|NCT05777135|Experimental|Group I (Preloading with Ringer Lactate)|Preloading with Ringer lactate 30ml/kg over 30 minutes prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
33240328|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
33240329|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
33240330|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
33071702|NCT05777135|No Intervention|Group II (No preloading)|No preloading will be done and Propofol dose requirement for induction of anaesthesia will be noted
33071703|NCT05775029||Study group 1|Short term compliance group
33071704|NCT05775029||Study group 2|Long term compliance group
33071705|NCT05774405|Experimental|Experimental|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Estradiol patch (Climara 7.8 mg patch/week, Bayer, Germany) for 14 days.
33071706|NCT05774405|Placebo Comparator|Placebo|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Hydrogel patch (Adhesive Hydrogel patch/week, Rebul Pharmacy, Turkey) for 14 days.
33071707|NCT05773586|Experimental|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of APG-5918 or placebo.
33071708|NCT05773586|Experimental|Multiple Ascending Dose (MAD) cohorts in Anemic Patients (Part B)|Subjects will be randomized to receive once daily APG-5918 or placebo for 28 days.
33071709|NCT05773066|Experimental|Belotero® Intense Lidocaine|Lips injected with BIL.
33071710|NCT05773066|Active Comparator|Restylane® Silk|Lips injected with RS.
32757010|NCT05108363|Other|Lifestyle modification program|Patients with obstructive sleep apnea and prediabetes will have lifestyle modification program for 12 months
32757011|NCT05065307|Experimental|Video game in Virtual reality|The study subject will be playing a video game during the venipuncture, in virtual reality
32757012|NCT05065307|Active Comparator|Video game on a tablet|The study subject will be playing a video game during the venipuncture, on a tablet
32757013|NCT05104385||Hacettepe University Health Cohort- Students of Health Sciences|"Students of medical school (grades 4,5, and 6) in 2021 Spring Students of dental school (grades 4 and 5) in 2021 Spring New comers of grade 4 in both medical and dental school will be recruited early in October 2021.~There is no intervention. Vaccinations for COVID-19 have been provided by the Turkish Ministry of Health, in a pre-planned schedule. The study will follow students after vaccination, regardless of the type and dose administered."
32757014|NCT01013129||Probands|
32757015|NCT05103761|Active Comparator|Ketogenic diet|Diet administered to induce ketosis.
33071711|NCT05768776||HoLEP patients without MOSESTM 2.0 effect (open label)|control retrospective open label
33071712|NCT05768776||HoLEP patients with MOSESTM 2.0 effect (open label)|prospective open label
33071713|NCT05767970|Experimental|Integrated Stress Toolbox for Healthcare Providers (ISTH)|A 12-week synchronous and app-based well-being training that involves weekly 2-hour sessions for weeks 1-8 and at week 12, along with 12-weeks of app-based content delivered through a special version of the Healthy Minds Program app.
33071714|NCT05767970|No Intervention|Wait-list control|The wait-list control group will continue with business as usual and receive the ISTH after the last data collection point.
33071715|NCT05766683|Experimental|2mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 2mm
33071716|NCT05766683|Experimental|4mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 4mm
33071717|NCT05764941||Observational Group|Patients receive initetamab combined with pyrotinib and vinorelbine after trastuzumab progression.
33240331|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
32757016|NCT05103761|Placebo Comparator|Low glycemic index treatment diet|Diet matched with a ketogenic diet with added carbohydrates to avoid ketosis.
32757017|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
32757018|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
32757019|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
32757020|NCT05088473||Mutliple sclerosis|
32757021|NCT05088473||CIS/RIS|
32757022|NCT05088473||Other CNS inflammatory diseases|
32757023|NCT05088473||Non inflammatory CNS diseases|
32757024|NCT05119127|Experimental|vivity toric IOL implantation arm|vivity toric intraocular lens will be implanted in one eye and undergo digital imaging intra op and post op to evaluate for toric intraocular lens rotational stability.
32757025|NCT04161989|Other|Group I (omega-3 fatty acids group)|received omega 3 (Omega 3 plus, SEDICO, Egypt); once daily from 28-30 weeks till delivery. The omega 3 plus capsule contains 1000 mg Fish Oil plus 100 mg Wheat Germ Oil is a natural source of Vitamin E.
32757026|NCT04161989|Other|Group II (vaginal progesterone plus omega-3 group)|received vaginal progesterone (Prontogest 400 mg vaginal suppository, Marcyrl Pharmaceutical Industries, Egypt) and omega 3 once daily from 28-30 weeks till delivery.
33071718|NCT05761782||University of California, Davis Comprehensive Cancer Center's Catchment Area Population|Behavioral Intervention: Education and Training on Cancer Prevention and Education
33071719|NCT05760300|Experimental|Group A: Bulevirtide (BLV), Severe Renal Impaired Participants|"Participants with severe renal impairment will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of pharmacokinetics (PK) and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
32757027|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757028|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757029|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757030|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757031|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757032|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
32757033|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
33071720|NCT05760300|Experimental|Group A: BLV, Normal Renal Function (Matched Control Participants)|"Participants with normal renal function will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of PK and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
33071721|NCT05757869|Experimental|Milvexian|Participant will receive milvexian and a capsule containing placebo beginning on Day 1 through end of treatment (EOT). Participants after the EOT visit may have an option to receive open-label apixaban at the appropriate dose, for which the sponsor provides a 30-day supply.
32757034|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
32757035|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
32757036|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
32757037|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
33240332|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
32757038|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
32757039|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
32757040|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
32757041|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
32757042|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
32757043|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
32757044|NCT02700841|Experimental|Arm I (vaccine, CD34 transplant, DLI)|ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.
32757045|NCT02700841|Active Comparator|Arm II (vaccine, stem cell transplant)|Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
32757046|NCT04160117|Experimental|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
32757047|NCT04160117|Placebo Comparator|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
32757048|NCT04414631|Active Comparator|active treatment arm|treatment with conestat alfa in addition to standarf of care
32757049|NCT04414631|No Intervention|Standard of care treatment arm|Standard of care treatment established at the centers
33240333|NCT00756483||M, 1|Male patients that have undergone total knee replacement
32757050|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
33240334|NCT00756483||F, 1|Female patients that have undergone total knee replacement
32757051|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
33240335|NCT00756483||M, 2|Male patients that have undergone total hip replacement
33240336|NCT00756483||F, 2|Female patients that have undergone total hip replacement
32757052|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
32757053|NCT05042063||Participants with cough as a symptom|This group will be composed of patients at the Clínica Universidad de Navarra that complain of having cough as a remarkable symptom.
32757054|NCT05042063||Validation subgroup 1|This subgroup will be composed by both, patients belonging to the main study group, as well as voluntaries, who will be asked to provide a series of elicited cough and non-cough sounds for validation purposes.
32757055|NCT05042063||Validation subgroup 2|This subgroup will be composed by inpatients admitted to the Clínica Universidad de Navarra with a diagnosis of respiratory disease, or presenting cough as a symptom, as well as healthy individuals. This group will be monitored with Hyfe Cough Tracker and Hyfe Air for a variable period of 6-24 hours, while they are recorded with a MP3 recorder connected to a lapel microphone.
33071722|NCT05757869|Active Comparator|Apixaban|Participants will receive a placebo that matches milvexian and a capsule containing apixaban. Participants after the EOT visit may have an option to receive open-label apixaban at the appropriate dose, for which the sponsor provides a 30-day supply.
33071723|NCT05756192|Experimental|Video and physician counseling arm|This groups will complete a pre survey and will then watch the 10-minute educational video on cervical cancer screening and prevention prior to seeing their provider. Patients will then see the provider and will complete a post survey following appointment.
33071724|NCT05756192|No Intervention|Physician counseling arm|This group will complete a pre survey and will then see their provider. Following provider visit patients will complete a post survey.
33071725|NCT05755360||Participants with T2D|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician.
32757056|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
33071726|NCT05754658||Breast Cancer|Female patients
33071727|NCT05754658||Prostate Cancer|Male patients
33071728|NCT05750017|Experimental|Cohort1: Low dose sentinel group|Three subjects will be first enrolled into low dose sentinel group in open-label, prior to initiation of dosing in each dose level main group.
32757057|NCT04278131|Experimental|Cohort 1|BSO1 Cohort 1 dose
32757058|NCT04278131|Experimental|Cohort 2|BS01 Cohort 2 dose
32757059|NCT04278131|Experimental|Cohort 3|BS01 Cohort 3 dose
32757060|NCT04278131|Experimental|Cohort 4|BS01 Cohort4 dose
32757061|NCT01963780|Experimental|OCS Lung Tx.|A prospective, pivotal single arm trial.
32757062|NCT03167983||dementia|patients with dementia
32757063|NCT03167983||control|healthy control
32757064|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
32757065|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
32757066|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
32757067|NCT04439968|Active Comparator|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
32757068|NCT04439968|No Intervention|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
32757069|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
32757070|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
32757071|NCT04416880|Experimental|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
32757072|NCT04416880|Sham Comparator|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
32757073|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
32757074|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
32757075|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
33071729|NCT05750017|Experimental|Cohort2: High dose sentinel group|After reviewing the safety through 7 days after the first dose of LZ901, if no safety signals occur, another 3 subjects will be enrolled into high dose sentinel group in open-label.
33071730|NCT05750017|Placebo Comparator|Cohort3: Low dose main group|If also no safety signals occur through 7 days after the first dose of LZ901 in high dose sentinel group, 30 subjects will be randomized in a 2:1 ratio to receive two doses of LZ901 or placebo in a double-blind fashion in low dose main group.
33071731|NCT05750017|Placebo Comparator|Cohort4: High dose main group|Subjects will be enrolled in high dose main group also after the safety review through 7 days after the first dose of LZ901 or placebo in low dose main group.
32757076|NCT04198961|Experimental|Electronic Intervention|Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
32757077|NCT05118971||elliptical (GE)|The patient is suspended supported by the hip positioner, secured by nylon straps to a galvanic iron grid fixed to the ceiling with parabolts. The height of the seat belts will be measured according to the patient's proper position in the device. The weight support belt will be adjusted to maximize load bilaterally without knee deformation during correct posture, manual assistance will be provided by physical therapists on each leg. A physical therapist's hand will be placed on the anterior surface of the leg below the patella to aid in knee extension during the elliptical gait simulation. The other hand will be placed on the ankle to aid in the movement of the feet during the alternating movement of the legs and the return of the heel placement to the starting position. The patient performs the movements at the maximum speed he can, recording the electromyographic signal of the selected muscles for 20 seconds.
32757078|NCT05118971||elliptical with biofeedback (GEB)|The same described in the elliptical group adding biofeedback.
32757079|NCT05118971||bicycle (GB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal of the same selected muscles for 20 seconds.
32757080|NCT05118971||bike with biofeedback (GBB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal from the same selected muscles for 20 seconds, adding biofeedback.
32757081|NCT04436315|Experimental|Intervention|Exergame intervention
32757082|NCT04436315|Sham Comparator|Control|Active control condition
32757083|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
32757084|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
32757085|NCT05029739|Experimental|E-intervention group|Participants will be instructed to download a life-style-changing mobile app to which they will have access for 12 weeks. After the first week of the program, participants who smoke will be offered to incorporate smoking cessation support into their PAD program. These changes are minor and not intended to divide the intervention group in two but instead to personalize the study experience. The program aims to empower positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
32757086|NCT05029739|Active Comparator|Standard of care - control group.|All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors. The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD. After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
32757087|NCT05118659|Experimental|SNAG GROUP|The SNAG group received a treatment based on sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each, combined with active cervical extension.
32757088|NCT05118659|Sham Comparator|SHAM SNAG GROUP|The placebo SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension.
32757089|NCT05118659|No Intervention|CONTROL GROUP|The control group did not receive any type of intervention, they only waited for four minutes, sat down on a chair
32757090|NCT05017649|Other|Healthy volunteers|volunteers showing no hypercholesterolemia
32757091|NCT05017649|Experimental|Patients with untreated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia with no treatment at the time of inclusion
32757092|NCT05017649|Experimental|Patients with treated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia and treated at the time of inclusion
32757093|NCT04999553|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
32757094|NCT04999553|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
32757095|NCT04657588|Experimental|Anal insert|This group will be asked to use anal inserts to help manage their faecal incontinence during the treatment period
32757096|NCT04657588|Sham Comparator|Care as usual|This group will be asked to continue with their care as usual (e.g. incontinence pads)
32757097|NCT04589663|Experimental|Mometasone furoate followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 followed by a single inhaled dose of QMF149 on Day 6
32757098|NCT05118347|Experimental|Buteyko Breathing Technique|Buteyko Breathing Method teaches you how to bring your breathing volume back toward normal or, in other words, reverse what's called chronic hyperventilation or chronic over-breathing. When your breathing is normal (ideally it is shown you should breathe lightly, in a calm fashion, and only through the nose, not mouth), you have better oxygenation of tissues and organs, including your brain.
32757099|NCT05118347|Experimental|Incentive Spirometer|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
32757100|NCT05109845||Control group|Healthy volunteers
32757101|NCT05109845||Suicidal patients|Patients with a history of suicidal thoughts or behaviors
32757102|NCT05109845||Non-suicidal patients|Patients without a history of suicidal thoughts or behaviors
32757103|NCT04585841|Experimental|Intervention group|Cancer patients receiving cannabidiol
32757104|NCT04585841|No Intervention|Control group|Cancer patients not receiving cannabidiol
32757105|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
32757106|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
32757107|NCT05038475||Mild group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
32757108|NCT05038475||Moderately-severe group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
32757109|NCT02395861|Experimental|Electrophysiologic analyses|
32757110|NCT04518917|Other|Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
32757111|NCT04848935|Experimental|CURATE.AI|A cognitive evaluation and a Digital Diagnostic (DD) session performed anytime before radiotherapy will serve as the baseline. After the radiotherapy treatment, which can last between 1 to 6.5 weeks, patients will have a variable recovery time (0 to 4 weeks). Subsequently, patients will be subject to a cognitive evaluation and a DD session, right before starting the Digital Intervention (DI) training. This training will comprise ten weeks of DI (three 10-15 minute sessions per week). Patients will complete cognitive evaluations and DD sessions at the end of DI, and 16 and 32 weeks after the end of DI.
32757112|NCT04827095|Experimental|Web-Based Support and Education Program 1|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
32757113|NCT04827095|Experimental|Web-Based Education and Support Program 2|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
32757114|NCT01353703|Experimental|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
32757115|NCT01353703|Active Comparator|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
32757116|NCT04096703|No Intervention|Expectant management of EGJOO Group|The participants randomized to this group will receive expectant management of EGJOO. Expectant management is evaluating whether symptoms improve over time without an intervention
32757117|NCT04096703|Experimental|Pneumatic dilation of EGJOO Group|The participants randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific).
32757118|NCT02009332|Experimental|Phase 1: ABI-009 100 mg/week|Phase 1, Cohort 1: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
32757119|NCT02009332|Experimental|Phase 1: ABI-009 200 mg/week|Phase 1, Cohort 2: ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
32757120|NCT02009332|Experimental|Phase 1: ABI-009 100 mg 2×/week|Phase 1, Cohort 2b: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, twice per week (total dose 200 mg per week) for 6 weeks
32757121|NCT02009332|Experimental|Phase 1: ABI-009 300 mg/week|Phase 1, Cohort 3: ABI-009 injectable suspension, 300 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
32757122|NCT02009332|Experimental|Phase 1: ABI-009 400 mg/week|Phase 1, Cohort 4: ABI-009 injectable suspension, 400 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
32757123|NCT02009332|Experimental|Phase 2: ABI-009 400 mg/week + Gemcitabine 2000 mg/week|ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 1 hour, once per week for 6 weeks; Gemcitabine, 2000 mg in 100 mL saline, administered intravesically after voiding of ABI-009 and retained for 1 hour, once per week for 6 weeks
32757124|NCT04518293|Experimental|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
32757125|NCT04518293|Active Comparator|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
32757126|NCT04518293|Active Comparator|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
32757127|NCT04518293|Active Comparator|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
32757128|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
32757129|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
32757130|NCT04480021|Experimental|Multiuser Interactive Health Response Application (MITHRA)|Randomization is at the level of the Community Based Organization (CBO). CBOs randomized to MITHRA will have access to the MITHRA app on tablets. MITHRA app will include depression screening and behavioral activation modules.
32757131|NCT04480021|Placebo Comparator|Enhanced Usual Care (EUC)|CBOs randomized to EUC will receive standardized monthly group education (45 min) regarding the symptoms of depression
32757132|NCT04480177|Other|insole group|the control group receives insole only.
32757133|NCT04480177|Experimental|exercise group|the experimental group receives exercise and insole.
32757134|NCT03166969|Experimental|Patients taken care in neurovascular unit|
32757135|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
32757136|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
32757137|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
32757138|NCT04932707|Experimental|Study group 1|sub-occipital muscle inhibition applied plus passive stretch of hamstring muscle
32757139|NCT04932707|Experimental|Study group 2|Received neural slump sliding stretch plus passive stretch of hamstring muscle
32757140|NCT04932707|Active Comparator|control group|Received passive stretch of hamstring muscle
33071732|NCT05747924|Experimental|AOC 1020 Regimen 1|Part A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
33071733|NCT05747924|Experimental|AOC 1020 Regimen 2|Part B1 & C: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
33240337|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
33240338|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
33071734|NCT05747924|Experimental|AOC 1020 Regimen 3|Part B2 & C: AOC 1020 Dose Regimen 3; Five doses administered intravenously over 9 months
33071735|NCT05747924|Placebo Comparator|Placebo (Saline)|Part A, B & C: Placebo; Five doses administered intravenously over 9 months
33240339|NCT05410977||Observational (biospecimen collection, record review)|Patients undergo collection of blood and stool samples no more than 90 days prior to or between 7-90 days after standard of care colonoscopy or flexible sigmoidoscopy. Patients' medical records are also reviewed.
33240340|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
32757141|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
32757142|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
32757143|NCT03953027||Health Services Research (surveys about drug shortages)|At baseline, practice sites complete a Baseline Drug Shortage Survey and Pharmacy Baseline Survey; Drug Shortage Incident Reports are completed in real time as cancer care delivery problems occur; and the Quarterly Follow-Up Survey Number Treated Report every 3 months for one year (4 total).
32757144|NCT05745493|Experimental|Social Engage Coaching (S-ENG)|Social Engage Coaching is 10 individual sessions of coaching to increase social connection.
32757145|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
32757146|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
32757147|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
32757148|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
32757149|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
32757150|NCT04418921|Experimental|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
32757151|NCT04418921|Active Comparator|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
32757152|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
32757153|NCT04342325|Experimental|ADR-001|Intravenous infusion of ADR-001 (Mesenchymal stem cell)
32757154|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
32757155|NCT04416334|Experimental|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
32757156|NCT04416334|Active Comparator|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
32757157|NCT05745415||pancreatic cancer patients|
32757158|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757159|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757160|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757161|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
33071740|NCT05746559|Placebo Comparator|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.
33071741|NCT05746559|Experimental|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.
33071742|NCT05745675||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
33071743|NCT05745662||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
32757162|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
33071744|NCT05745558|Experimental|Prehabilitation|A 3-to-6-week prehabilitation program consisting of training and nutritional, smoking cessation and psychosocial counselling.
33071745|NCT05743621|Experimental|TVB-2640 in combination with Enzalutamide|
32757163|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757164|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757165|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757166|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757167|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757168|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757169|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757170|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
33240341|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
32757171|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757172|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757173|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757174|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757175|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
32757176|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
32757177|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
32757178|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
32757179|NCT04735822|Experimental|Part 1: Belumosudil Sequence ABFCED|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);
32757180|NCT04735822|Experimental|Part 1: Belumosudil Sequence BCADFE|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)
32757181|NCT04735822|Experimental|Part 1: Belumosudil Sequence CDBEAF|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)
32757182|NCT04735822|Experimental|Part 1: Belumosudil Sequence DECFBA|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)
32757183|NCT04735822|Experimental|Part 1: Belumosudil Sequence EFDACB|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)
32757184|NCT04735822|Experimental|Part 1: Belumosudil Sequence FAEBDC|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).
33240342|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
32757185|NCT04735822|Experimental|Part 2: Belumosudil Sequence GHI|Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)
33240343|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
33240344|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
33240345|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
33240346|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
33240347|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
32757186|NCT04735822|Experimental|Part 2: Belumosudil Sequence HIG|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)
32757187|NCT04735822|Experimental|Part 2: Belumosudil Sequence IGH|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
32757188|NCT04735822|Experimental|Part 2: Belumosudil Sequence IHG|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)
32757189|NCT04735822|Experimental|Part 2: Belumosudil Sequence GIH|Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
32757190|NCT04735822|Experimental|Part 2: Belumosudil Sequence HGI|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);
32757191|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
32757192|NCT01984138|Experimental|Estring|ESTRING
32757193|NCT01984138|Active Comparator|REPLENS|Replens
32757194|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
32757195|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
33397134|NCT03112590|Experimental|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.~Phase 2: Post therapy surgery."
33397135|NCT02809131|Experimental|Saline irrigation|Saline irrigation
32757200|NCT02008396|Placebo Comparator|Inactive Placebo with Psychotherapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
32757201|NCT02008396|Experimental|75 mg to 125 mg MDMA with Psychotherapy|Participants will receive 75 to 125 mg during two psychotherapy sessions lasting approximately 7 hours; first session dose lower than second session dose.
32757202|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
32757203|NCT02008318|Experimental|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
32757204|NCT02008318|Placebo Comparator|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
32757205|NCT02008318|Experimental|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
32757206|NCT04299113|Experimental|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
32757207|NCT04009265|Experimental|Chemotherapy|Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.
32757208|NCT04009265|Experimental|Chemoradiotherapy|5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles
32757209|NCT04009265|No Intervention|Surgery alone|Surgery alone, no adjuvant treatment.
32757210|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
32757211|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
32757212|NCT03996785|Active Comparator|Urban|"Patients will go for a silent 60-minute walk in an urban setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology). The urban walk will be located on Boulevard de la Vérendrye with large arteries with three to four lanes."
33071748|NCT05739383|Experimental|Inclisiran Sodium 300mg|"Inclisiran sodium 300 mg in 1.5 mL Solution for injection (subcutaneous) in pre-filled syringe.~Randomized in a 1:1 ratio with matching placebo"
33071749|NCT05739383|Placebo Comparator|Placebo|Matching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ration with Inclisiran.
32757213|NCT03996785|Experimental|Nature|"Patients will go for a silent 60-minute walk in a nature park setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology).~The nature walk will take place at Parc Angrignon, an area of 96 hectares, one of Montreal's largest green and biodiverse spaces with a forest of 20 000 trees and a pond surrounded by willow trees."
32757214|NCT04541693|Other|Hip revision|Revision to cup and stem, cup only or stem only.
32757215|NCT04534985|Experimental|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
32757216|NCT04534985|Active Comparator|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
32757217|NCT04910087|Active Comparator|Group K: Ketofol|"A ketofol mixture of 15 cc propofol 2%, 2 cc ketamine 50 mg/ml, and 13 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through perfuser device. (at a ratio of 100 mg ketamine/300 mg propofol) After the loading dose is administered at 1 mg/kg IV in 5 minutes based on propofol, 0.5 cc/kg/hour ketofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push."
32757218|NCT04910087|Active Comparator|Group P: Propofol|"A propofol mixture of 15 cc propofol 2% and 15 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through the perfuser device.~After the loading dose is administered at 1 mg/kg IV propofol in 5 minutes ,0.5 cc/kg/hour propofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push"
32757219|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
32757220|NCT03906617|Experimental|Bupivacaine/epinephrine + dexamethasone|
32757221|NCT03906617|Active Comparator|Liposomal bupivacaine|
32757222|NCT03897725|Experimental|Telehealth Intervention|Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.
32757223|NCT03897725|No Intervention|Routine Care|The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.
32757224|NCT03844919|Experimental|rTMS + CBIT|Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
32757225|NCT03844919|Active Comparator|Sham rTMS + CBIT|Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
32757226|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
32757227|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
32757228|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
32757229|NCT04655482|Experimental|Treatment arm|"Patients treated with aflibercept (2.0ml/0.05cc) using treat-and-extend regimen.~Three monthly loading injections followed by proactive treatment using treat-and-extend regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
32757230|NCT04866173|Experimental|Dog|Being subjected to two standardised stress situations with a dog and its handler present
32757231|NCT04866173|Experimental|No Dog|Being subjected to two standardised stress situations without a dog present, but in the presence of a person (dog handler)
32757232|NCT04515797|Experimental|Treatment with Direct Acting Antiviral for HCV|4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant
32757233|NCT03571841|Experimental|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.~Group Session~Telephone Booster Session"
32757234|NCT04866095|Experimental|Surgery|All patients, who have given their consent, aged over 18 years, with a sinus rhythm, requiring a surgical procedure that allows obtaining high quality transthoracic echocardiogram imaging without pain and discomfort.
32757235|NCT01959815||Scleroderma and diagnosed PAH|
32757236|NCT01959815||"Low risk scleroderma"|
32757237|NCT01959815||Healthy volunteers|
32757238|NCT01959815||"High risk scleroderma"|
32757239|NCT02184767|Experimental|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
32757240|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
32757241|NCT04258709|Experimental|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
32757242|NCT04258709|Active Comparator|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
32757243|NCT04248413|Other|Standard rehabilitation protocol|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution.
32757244|NCT04248413|Experimental|Standard rehabilitation plus Blood Flow Restriction Therapy|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution in addition to the BFR therapy. Per recommendations of Owens Recovery Science, the organization responsible for certifying physical therapists in BFR therapy, the therapy will take place concurrently throughout the duration of the rehabilitation.
32757245|NCT03727139||Rasagiline 1 mg|Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
32757246|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
32757247|NCT03514043||Surgical assessment unit staff|Staff who are involved in the care of patients on the surgical assessment unit. This includes senior and junior doctors, nurses, healthcare assistants and ward receptionists.
32757248|NCT05122403||FUS Thalamotomy|The cohort includes patients with neuropathic pain who underwent MRgFUS central lateral thalamotomy.
32757249|NCT05122403||Sham Procedure|The cohort includes patients with neuropathic pain who underwent sham MRgFUS central lateral thalamotomy.
32757250|NCT05120687||Corticosteroid group|Patients in corticosteroid group will receive systemic corticosteroid. In case of severe, the patients may receive methylprednisolone (no more than 1 gram/day) followed by gradual taper of oral prednisone.
32757251|NCT05120687||Corticosteroid + NCSIT group|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate or Adalimumab or other noncorticosteroid systemic immunomodulatory such as cyclophosphamide.
32757252|NCT05122325|Experimental|Intervention group 1: Transcutaneous tibial nerve stimulation (TTNS)|"Transcutaneous application of low frequency electrical current over the tibial nerve TENS® EMS NMS60 for a 30 minutes session, twice a week.~Placing a small electrode 3 fingers up to the internal malleolus and 1 cm posterior (adjusting its placement with a point finder or testing with low frequencies of 2-3 Hz). A large electrode placed in the calcaneus."
32757253|NCT05122325|Experimental|Intervention group 2: Genital vibration|Women will be instructed in the use of the Ferticare 2.0® vibrator with a frequency of 70 Hz, amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
32757254|NCT05122325|Sham Comparator|Control group|A sham of TTNS intervention with the device turned off, twice a week.
33240348|NCT04056663|Experimental|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
33240349|NCT04056663|No Intervention|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
33240350|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
33240351|NCT02591732||Patient treated with Apixaban|
33240352|NCT02591732||Patient treated with Rivaroxaban|
33240353|NCT02591732||Patient treated with Dabigatran|
33240354|NCT02591732||Patient treated with vitamin K antagonists|
32757255|NCT05120609|Experimental|Parkinson's Application|Subjects will complete at-home allied health therapy exercises delivered through a smartphone application. Subjects will use the application daily for 4 weeks, each daily session takes up to 30 minutes to complete.
33071752|NCT05738096|Experimental|TGN patients|Patients with TGN who will undergo rhizotomy surgery as the standard of care
33071753|NCT05738096|Active Comparator|Healthy volunteers|Healthy volunteers for whom TSEPS will be recorded in a lab setting
33071754|NCT05736705|Active Comparator|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their endoscopic submucosal dissection procedure.
33071755|NCT05736705|Experimental|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their endoscopic submucosal dissection procedure.
33071756|NCT05735600|Experimental|Virtual|This group will participate in weekly virtual group sessions facilitated by a culturally similar and trained health educator (Promotora). The virtual modules will be on a platform such as Zoom and will last approximately 90 minutes each. Each module will last 60 minutes with the following three components: 1) 15-minute video on behavior change-related module objective, 2) 15-minute vignette/story depicting a family implementing behavior change, and 3) 15-minute discussion on creating goals and overcoming barriers for behavior change pertaining to the module. The remaining 15-minutes will ask participants to share what worked well towards achieving goals set in the prior module
33071757|NCT05735600|Active Comparator|Traditional|This group will get the same educational materials in writing (slides with information from video, written story, and instructions on goal setting and overcoming barriers) and receive a phone call from one of the researchers each week (5 weeks in a row) to provide an opportunity to respond questions, comments, and provide guidance about following the recommendations of the written material
33071758|NCT05735119||Subscapularis Tendon Injuries|Tapestry Biointegrative Implant
33240355|NCT04086914|No Intervention|Non nerve block|Receives no nerve block
33071760|NCT05734105|Experimental|Ripretinib|150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles.
33071761|NCT05734105|Active Comparator|Sunitinib|50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles. Sunitinib will be given continuously for 4 weeks with a 2-week break.
33071762|NCT05732402|Experimental|povetacicept 80mg|
33071763|NCT05732402|Experimental|povetacicept 240mg|
33071764|NCT05732285|Experimental|CRT plus CBT and Lifestyle modifications|
33071765|NCT05732285|Active Comparator|Usual care|
32757256|NCT05120609|Placebo Comparator|Digital Placebo|Subjects will have access to a digital placebo application and continue usual care.
32757257|NCT05121935||MAL-ED cohort|Children initially followed from birth through 2 years old in the MAL-ED study (with some additional assessments in follow-up studies since then).
32757258|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
32757259|NCT05121779|Experimental|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
32757260|NCT05120063|Experimental|3D anatomical stem|3-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
32757261|NCT05120063|Experimental|3D non-anatomical stem|3-D-Planing with non anatomical stem (Quadra-H, Medacta)
33071766|NCT05732038|Experimental|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to practice 10 minutes per day for 12 weeks. The first four weeks will be prescribed. Weeks 5-12 will allow full access to the app's library.
32757262|NCT05120063|Experimental|2D anatomical stem|2-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
32757263|NCT05120063|Experimental|2D non anatomical stem|2-D-Planning with non anatomical Stem (Quadra-H, Medacta)
32757264|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
32757265|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
32757266|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
32757267|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
32757268|NCT05119673|No Intervention|mono-plane sonographic view|Usual standard of care, in our institution, for difficult peripheral vascular access in the Emergency Department.
32757269|NCT05119673|Active Comparator|bi-plane sonographic view|
32757270|NCT04224545|Experimental|Colchicine|Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)
32757271|NCT04224545|Placebo Comparator|Placebo|Sugar pill
33071767|NCT05732038|Experimental|Wellness App (WA)|Participants in the WA group will be asked to listen to the app content for 10 minutes per day for the entire 12 weeks.
33240356|NCT04086914|Experimental|Nerve block|Receives nerve block
33240357|NCT00715676|Placebo Comparator|Group 1|
32757272|NCT04224311|Active Comparator|Low number plateletpheresis donations|Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
32757273|NCT04224311|Active Comparator|Medium number plateletpheresis donations|Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
33240358|NCT00715676|Experimental|Group 2|220 ng
32757274|NCT04224311|Active Comparator|High number plateletpheresis donations|Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
32757275|NCT05121389|Experimental|study group|Patients of study group will receive intravenous normal saline 30cc per kilogram of body weight, one fifth of which will be given as a bolus followed by delivery of the remaining four fifth as a constant infusion over a period of 12 hours.
32757276|NCT05121389|Sham Comparator|control group|Patients of control group will receive intravenous normal saline 10cc per kilogram of body weight as a constant infusion in the first 12 hours.
32757277|NCT03096041|Experimental|Experimental arm|Auriculotherapy for analgesic use
32757278|NCT03096041|Placebo Comparator|Controle arm|Placebo auriculotherapy
32757279|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
32757280|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
32757281|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
33071768|NCT05730153|Active Comparator|group 1|
33071769|NCT05730153|Sham Comparator|group 2|
33240359|NCT00715676|Experimental|Group 3|440 ng
33240360|NCT05163470|Experimental|On Fi.RE. framework|Men football professional players
33071772|NCT05725733|Experimental|children with ASD group.|ASD groups will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old). Also, ASD group will be categorized according to the symptoms severity using the childhood autism rating scale (CARS).
33071773|NCT05725733|Active Comparator|One hundred typically developed children or control group|They will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old)
33071774|NCT05724316|Experimental|Vitamin D Group|All participants in this group will receive cholecalciferol (VD3 25μg) tablets, one to be taken per day.
33240361|NCT05163470|Active Comparator|Traditional rehabilitation|Men football professional players
33240362|NCT00718328|Experimental|I|Simvastatin Group
32757282|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
32757283|NCT05121233|Active Comparator|Diclofenac|Group A will receive a single dose 75 mg IV diclofenac by infusion prior to the procedure
32757284|NCT05121233|Placebo Comparator|Placebo|Group B who will receive placebo
32757285|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
32757286|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
32757287|NCT05120921|Active Comparator|standard osteopathic manual treatment|Pragmatic individualised osteopathic manual treatment which is a system of diagnosis and treatment for a wide range of musculoskeletal conditions. Osteopaths take a detailed case history and perform a thorough clinical examination to help understand the nature of patients' pain and symptoms so that they can arrive at a diagnosis. Practitioners use touch, physical manipulation, stretching and massage to help increase the mobility of joints, to relieve muscle/joint tension and pain. Osteopaths often combine a range of other treatment techniques in their approach, such as rehabilitative exercises, advice about how patients can self-manage their condition and educational approaches to help them understand their pain. Osteopathy is a regulated profession (regulated by the General Osteopathic Council) in the UK
32757288|NCT05120921|Active Comparator|biopsychosocially informed osteopathic manual treatment|As for the active comparator + biopsychosocial management: after having a completed a 8-10 hour e-learning on the biopsychosocial model for the management of low back pain, osteopaths will use the same approaches as in the active comparator group, plus techniques to help patients making sense of their symptoms, to develop patients' self-efficacy, and psychosocial management skills.
32757289|NCT05745259|Active Comparator|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
32757290|NCT05745259|Experimental|Tenecteplase|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5~10 seconds
32757291|NCT05118581|Experimental|patients need vascular access|Arterial or venous cathetrization guided by ultrasound
32757292|NCT02928107|Experimental|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS
32757293|NCT02928107|Experimental|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
32757294|NCT02928107|Experimental|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
32757295|NCT02928107|No Intervention|CHEER Cohort (non-randomized)|Participants will complete a one page questionnaire related to Red Flag conditions during a routine Otolaryngology appointment for suspected hearing loss. The audiologist will be complete a questionnaire about the participants audiological assessment including Red Flag conditions. The Otolaryngology provider will complete a questionnaire about the participants otoscopic exam findings, Red Flag conditions, and indicate if any other conditions exist that me be considered a medical contraindication to hearing aid fitting.
32757296|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
32757297|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
32757298|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
32757299|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
32757300|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
32757301|NCT05119283|Experimental|Phtalox|Patients will undergo scaling and coronal-radicular smoothing and rinses with PHTALOX mouthwashes.
32757302|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
32757303|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
32757304|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
32757305|NCT05745181|Experimental|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
33071775|NCT05724316|No Intervention|Control Group|Will receive no vitamin D supplements.
32757306|NCT05745103|Experimental|The Eleos Health Platform|Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.
33071776|NCT05723835|Experimental|Somapacitan|Participants will receive Somapacitan for 26-week main phase followed by 130-week extension phase.
33240363|NCT00718328|Placebo Comparator|II|Placebo Group
32757307|NCT05745103|Active Comparator|Treatment as Usual|Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful.
32757308|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
32757309|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
32757310|NCT04508699|Experimental|Developmental language disorder|Children with language impairment but in the absence of cognitive deficits
32757311|NCT04508699|Active Comparator|Typical language|Children with typical language development and typical cognitive development
32757312|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
32757313|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
32757314|NCT05021861||Test group 1|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS.
32757315|NCT05021861||Test group 2|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
32757316|NCT05021861||Control group|SYSTEMICALLY HEALTHY FEMALES
32757317|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
32757318|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
33071777|NCT05723159||Clínica Universidad Navarra site|Research subjects will be enrolled at Clínica Universidad Navarra. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
32757319|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
32757320|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
32757321|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
32757322|NCT05230355|Active Comparator|group A the standard technique|cyclophotocoagulation is applied along the upper and lower hemispheres over pars plana -3 mm behind the limbus
32757323|NCT05230355|Active Comparator|Group B a modified technique|cyclophotocoagulation is applied over one hemisphere only (180 degrees) along pars plana-3 mm behind the limbus- followed by a second application over pars plicata-1.2 mm behind the limbus- along the same hemisphere (ie, in a double arc fashion).
32757324|NCT04664062|Active Comparator|Home|This induction arm is asynchronous and unobserved. The home induction is done primarily by the participant in their home or current residence. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. Home induction is initiated by the participant at a time and place (other than the practice) determined by the participant. The participant determines when to stop taking opioids, begins withdrawal, monitors symptoms, administers the SOWS, and determines when to take first dose of medication, per the instructions and protocol provided. The clinic team does not observe or have contact with the participant while the participant undergoes these steps or takes the first dose. The participant continues this process for additional doses. Follow-up contact with clinic team may occur after the first or second day, typically within a week.
32757325|NCT04664062|Active Comparator|Office|This induction arm is synchronous and observed by the clinical team. The participant receives instruction from clinic team at an in-person or telehealth visit. On a pre-determined day, the participant stops taking opioids and comes to office with mild to moderate withdrawal. The clinic team monitors the participant, assesses symptoms, administers COWS to determine time of first dose of medication, and administers first dose with the participant. The clinic team observes and has in-person contact with the participant. Office induction includes the observed administration of the first dose, followed by observation and evaluation 30-60 minutes after the first dose. After 30-60 minutes of observation, the clinic team and participant decide whether to administer the second dose in the office or for the participant to leave the clinic to administer subsequent doses. On rare occasions, a second dose may not be needed (if the participant has a low COWS score after just one dose).
32757326|NCT04664062|Active Comparator|Telehealth|This induction arm is synchronous via phone or video contact and observed. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. The participant undergoes the same process as an office induction but from a location other than the clinic. Like an office induction, the participant has regular contact with someone from the practice team on Day 1 of induction. Prior to initiating the first dose, the participant has contact by phone or video with the clinic team to assess symptoms and determine level of withdrawal (using COWS or SOWS). The administration of the first dose of medication is determine by the clinic team during phone or video contact, and the clinic team is in contact with the participant by phone or video when the first dose is taken. This process continues through the second and possible third dose. The participant is re-assessed via video or phone regularly by clinic staff and prescriber throughout this process.
32757327|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
32757328|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
32757329|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
32757330|NCT04652908|Experimental|Treatment with PMSC-ECM|One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered
32757331|NCT04652908|Other|non-PMSC untreated contemporaneous cohort|Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort).
32757332|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
32757333|NCT05745025|Experimental|rTMS and Rehabilitation|Subjects in this arm will get rTMS to the contralateral motor cortex and best practice rehabilitation.
32757334|NCT05745025|Sham Comparator|Sham rTMS and Rehabilitation|Subjects in this arm will get sham rTMS to the contralateral motor cortex and best practice rehabilitation.
33397136|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
33397137|NCT05046054|Active Comparator|transcutaneous electrical nerve stimulation group|Transcutaneous electrical nerve stimulation was givent via two electrodes on the venous cannulation site 20 min before propofol injection
33397138|NCT05046054|Placebo Comparator|control group|No transcutaneous electrical nerve stimulation was not given via two electrodes on the venous cannulation site 20 min before propofol injection
33397139|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
33397140|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
33397141|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
33397142|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
33397143|NCT05032950|Active Comparator|Treatment A|Midazolam orally
33397144|NCT05032950|Experimental|Treatment B|PF-07321332/ritonavir orally + Midazolam orally
33397145|NCT05032950|Active Comparator|Treatment C|Ritonavir orally + Midazolam orally
32757335|NCT04672798|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinical trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
32757336|NCT04672798|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive treatment from their mental health clinician which may include safety planning.
32757337|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
32757338|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
32757339|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
32757340|NCT04652596|Active Comparator|Fresh Connect Produce Prescription Program|Investigators will partner with a community organization, About Fresh, that administers a produce prescription program (PPR) and operates mobile fresh foods markets. Participants randomized to this comparator will receive a stipend to Fresh Connect PPR to purchase fresh food items available at mobile markets and at independent farmers markets throughout Boston.
32757341|NCT04652596|Active Comparator|Grocery store gift cards|Participants randomized to this comparator will receive grocery gift cards redeemable at conventional grocery stores.
32757342|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
32757343|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
32757344|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
32757345|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
32757346|NCT04480333|Experimental|Drug: NA-831 - 0.10 mg/kg|3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
32757347|NCT04480333|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
32757348|NCT04480333|Experimental|Drug: NA-831 - 0.20 mg/kg|6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
32757349|NCT04480333|Placebo Comparator|Comparable Placebo- 0.20 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
32757350|NCT04480333|Experimental|Drug: GS-5734 - 1.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
32757351|NCT04480333|Placebo Comparator|Comparable Placebo- 1.00 mg.kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
32757352|NCT04480333|Experimental|Drug: GS-5734 - 2.00 mg/kg|6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
32757353|NCT04480333|Placebo Comparator|Comparable Placebo - 2.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
33397146|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
33397147|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
33397148|NCT05009628|Experimental|automated oxygenation with a sitting patient position in the ICU|
33397149|NCT05009628|No Intervention|controlled oxygenation with a lying patient position in the ICU|
33397150|NCT05009628|Experimental|automated oxygenation with the patient lying down in the ICU|
33397151|NCT05009628|Experimental|control oxygenation with the patient in a sitting position in the ICU|
33397152|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
33397153|NCT04074161|Experimental|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
33397154|NCT04074161|Placebo Comparator|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
33397155|NCT04074161|Active Comparator|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
32757354|NCT04480333|Experimental|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
33397156|NCT04074161|Placebo Comparator|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
32757355|NCT04480333|Placebo Comparator|Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg|3 Subjects - inhaled formulation of placebo once/day for 5 days
32757356|NCT04480333|Experimental|Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)|6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
32757357|NCT04480333|Placebo Comparator|Placebo- 0.20 mg/kg + 2.00mg/kg|3 Subjects- inhaled formulation of placebo once/day for 5 days
32757358|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
32757359|NCT04969601|Experimental|Anti Covid with COMIRNATY® (BNT162b2) vaccine|Two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart
32757360|NCT05744869|Experimental|SB-CAP|"For schools randomized to the SB-CAP program, the following core elements will be implemented:~systematic asthma assessment~telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT~school-based DOT of preventive asthma medications~centralized case management support as needed"
32757361|NCT05744869|No Intervention|Control Comparison|While all schools in the district have the opportunity to utilize telemedicine visits and a protocol for initiating DOT of medications, these strategies will not be implemented for the control comparison schools.
32757362|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
32757363|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
32757364|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
32757365|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
32757366|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
32757367|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
32757368|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
32757369|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
32757370|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
32757371|NCT04857437|Experimental|Part 1|Single, Escalating Doses of PF-07202954 or Placebo (Cohorts 1 and 2)
32757372|NCT04857437|Experimental|Part 2|Repeated, Escalating Doses of PF-07202954 or placebo from Day 1 to Day 14, inclusive (Cohorts 3, 4, 5, 6 7, and optional Cohort 8)
32757373|NCT04857437|Experimental|Part 3|Single dose of PF-07202954 with a high-fat/high-caloric meal and a single dose following an overnight fast of ≥10 hours
32757374|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
32757375|NCT05229575|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 5 fractions of image-guided stereotactic body radiation therapy to primary breast tumor over 2 weeks
32757376|NCT04842929|Active Comparator|Active Stimulation|Active Comparator: Active stimulation with pulses emitted according to intervention description
32757377|NCT04842929|Sham Comparator|Sham Stimulation|Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.
32757378|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
32757379|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
32757380|NCT01960114|Experimental|Acetaminophen ER|
32757381|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
32757382|NCT04752527|Experimental|Treatment regime|combination of venetoclax plus azacitidine, and Sorafenib for patients with high FLT3-ITD allelic ratio
32757383|NCT05229497|Experimental|Phase Ib#Dosage regimen 1#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (30 mg/kg QW)
32757384|NCT05229497|Experimental|Phase Ib#Dosage regimen 2#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (45 mg/kg QW)
32757385|NCT05229497|Experimental|Phase II#Cohort 1#|Head and neck squamous cell carcinoma (HNSCC): AK112 (20 mg/kg Q3W)
33071778|NCT05723159||OHSU site|Research subjects will be enrolled at OHSU. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
32757386|NCT05229497|Experimental|Phase II#Cohort 2#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)
32757387|NCT05229497|Experimental|Phase II#Cohort 3#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)+Carboplatin/cisplatin+5-fluorouracil
32757388|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
32757389|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
32757390|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
32757391|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
32757392|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
32757393|NCT02306915|Experimental|lipegfilgrastim 30|
32757394|NCT02306915|Experimental|lipegfilgrastim 60|
32757395|NCT02306915|Experimental|lipegfilgrastim 100|
32757396|NCT04105907|Experimental|Partial root canal treatment with the Sonendo GentleWave|
33397157|NCT05002062|Sham Comparator|G1 ( Conventional Physical Therapy Program group)|"Patients in G1 underwent conventional physical therapy program continued for 3 months, included (aerobic training 20 minutes, resistive training for 15 minutes and flexibility program for 15 minutes).~The whole treatment session lasted from 50 minutes to one hour, 3 times per week for 3 consecutive months."
32757397|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
32757398|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
32757399|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
32757400|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
32757401|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
32757402|NCT05229029|Experimental|TCM decoction|Compound granules of Traditional Chinese Medicine
32757403|NCT05229029|Placebo Comparator|placebo|Placebo only
32757404|NCT02092571|Experimental|Treatment A|1 ring intravaginal for 7 days, produced from the new process
32757405|NCT02092571|Experimental|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
32757406|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
33397158|NCT05002062|Active Comparator|G2 ( Computer-based Cognitive Therapy group)|"Patients in G2 underwent Computer-based cognitive training continued for 3 months, included (attention/concentration, memory and reaction behavior training).~The whole treatment session timing lasted 50 minutes to one hour, 3 times per week for 3 consecutive months."
32757407|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757408|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757409|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32742326|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
32757410|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757411|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757412|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757413|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757414|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757415|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
32757416|NCT02085863|Experimental|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
32757417|NCT02085863|Placebo Comparator|Placebo|Matching placebo (with combination oral contraceptives)
32757418|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
32757419|NCT02054351|Experimental|IMAB027 administration|Monotherapy - different dose Levels.
32757420|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
32757421|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
32757422|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
32757423|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
32757424|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
32757425|NCT04542083||COVID-19 period|Admissions from January to December 2020
32757426|NCT04542083||Control period|Admissions from January 2018 to December 2019
32757427|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
32757428|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
33240364|NCT05346848|Experimental|Experimental Arm A: combination of radiotherapy and darolutamide|Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy
32744504|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
33397159|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
33071782|NCT05714969|Experimental|TAK-755 Dose 1 in Acute Phase and Dose 2 in Post-acute Phase|TAK-755 Dose 1, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
32757429|NCT04101695|Active Comparator|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
33071783|NCT05714969|Experimental|TAK-755 Dose 2 in Both Acute and Post-Acute Phase|TAK-755 Dose 2, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
33240365|NCT05346848|Other|Standard Arm B: combination of radiotherapy and androgen deprivation therapy|Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy
33240366|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
33071786|NCT05712200|Experimental|Abelacimab (MAA868)|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
33071787|NCT05712200|Placebo Comparator|Placebo|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
33240367|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
32757430|NCT04101695|Active Comparator|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
32757431|NCT04103099|Other|HLNatural Immune Cohort|Observational one arm virtual study of HLNatural Immune supplement
32757432|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
32757433|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
32757434|NCT04091555|Other|Adult patients who suffer from symptoms of tension headaches|Patients will begin taking the capsules at the onset of headache symptoms.
32757435|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
32757436|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
32757437|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
33240368|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
32757438|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
32757439|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
32757440|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
32757441|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
32757442|NCT02393989|Experimental|Active comparator|posterior restorations
32757443|NCT04065893||Catheter ablation group|Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices
32757444|NCT04065893||Medical treatment group|Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices
32757445|NCT05744713||Disease Cohort|
32757446|NCT05744713||Engaged Cohort|
33240369|NCT02590874|Experimental|Duloxetine group|Active drug group
33240370|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
33240371|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
33240372|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
33240373|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
33240374|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
33240375|NCT05306132|Experimental|ASKC202|Participants received ASKC2020 50mg~600mg orally
33071788|NCT05712057|Experimental|Cognitive Restructuring + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 1 (G1)- 80 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while receiving rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
33397160|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
33397161|NCT05199792||2x dose of Dotarem|qualifying MRA
33397162|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
33397163|NCT04995120|Experimental|Induction chemotherapy and Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
33397164|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
33240376|NCT05684978|Experimental|Single arm prospective study|"Adults patients equal or greater than 18 years~Patients in RSE that require IV anesthetic infusions. Note: RSE is defined as status epilepticus that fails to terminate after an adequate dose of benzodiazepines (1st line agents) and an AED (2nd line agent). Adequate doses have been defined in the screening (below).~Patients taking oral contraception who will be on the study long term should be informed about additional alternative methods of contraception."
33071789|NCT05712057|Active Comparator|Cognitive Restructuring + scalp electrical stimulation|Group 2 (G2) - 80 eligible participants will receive training in CR. These participants will use CR while receiving scalp electrical stimulation over their individual dlPFC target and will partake in short term and long term follow up testing.
33071790|NCT05712057|Active Comparator|Emotional Awareness Training + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 3 (G3) - 80 eligible participants will receive emotional awareness training. These participants will receive rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
33071791|NCT05709860|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote PrEP knowledge or uptake among women in primary care, and 2) variable physician counseling on PrEP among women with increased vulnerability to HIV.
32757447|NCT05228561|No Intervention|Control Group|After the physician involved in the study asks the participants for their biochemical tests (FBC, HbA1C, LDL-C, HDL-C, Total K, Triglyceride), the outpatient dietitian will give routine nutrition education to the participants. In addition, a data collection form including socio-demographic information, health history, nutrition history and height, weight, waist circumference measurements will be made and filled by the thesis student.
32757448|NCT05228561|Experimental|Study Group|The software developed for this research will be downloaded to the phones of the participants in the intervention group. With this software prepared, written and visual information (pictures, mini-videos) will be given to participants every day for 3 months on diabetes, self-management of diabetes and nutrition. Whether the participants read the messages or not will also be monitored through this software. At the end of 3 months, the participants in the intervention and control groups will be invited again, and their biochemical parameters and self-management status will be measured according to the diabetes self-management scale. Data will be collected through face-to-face interviews in the outpatient clinic, and weight will be measured with the bioelectrical impedance analyzer in the outpatient clinic, height will be measured with a height meter fixed to the wall, and waist circumference will be measured with a non-stretchable measuring tape.
32757449|NCT05228483|Experimental|Photodynamic treatment monotherapy or combined with CO2 fractional laser|For patients who receive photodynamic therapy, lesions will be symmetrically randomized into two sides. One side will receive 5-aminolevulinic acid (5-ALA) with a red light illumination(80mW/cm2, and 120J/ cm2); while the other side will receive CO2 fractional laser(parameter: 20mm *20mm, spot coverage rate 10%, and 18-25mJ/cm2) before photodynamic therapy. Treating area should cover 0.5cm beyond the visible boundary of the lesion. In total 6 therapies will be given for each patient, with 14±3d intervals.
32757450|NCT05228483|Active Comparator|Mometasone furoate cream|Mometasone furoate cream (0.1%) for topical application, frequency: once daily, 5 days/week, for the first month; once every other day, for the second month; twice a week for the third month; the area of application should cover 0.5cm beyond the visible boundary of the lesion.
32757451|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
32757452|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
32757453|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
32757454|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
32757455|NCT05228405||1/caregivers of disabled children|1/Caregivers of disabled children will be assessed by the questionnaire of the Disease, Physiotherapy and Sports Awareness
32757456|NCT04259801|Experimental|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
32757457|NCT04259801|Experimental|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
32757458|NCT04259801|Active Comparator|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
33071792|NCT05709860|Active Comparator|The EMC2 PrEP Strategy|The EMC2 PrEP Strategy will utilize health information and consumer technologies to automatically deposit an interactive PrEP educational material into the patient portal of women with clinically indicated increased vulnerability to HIV. The material will: 1) promote PrEP knowledge, and 2) prompt discrete scheduling of a dedicated PrEP visit among those interested.
32757459|NCT04259801|Placebo Comparator|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
32757460|NCT04255277|Other|Period 1: First administration of combined oral contraceptives|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.
32757461|NCT04255277|Other|Period 2: Second administration of Combined Oral Contraceptive|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.
32757462|NCT04255277|Experimental|Period 2: Cenerimod 0.5 mg|Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.
32757463|NCT04255277|Experimental|Period 2: Cenerimod 4 mg|Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.
32757464|NCT04255277|Other|Period 2: Moxifloxacin|Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.
32757465|NCT04255277|Placebo Comparator|Period 2: Placebo|Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.
32757466|NCT04255277|Experimental|Period 3: Cenerimod 0.5 mg and charcoal|Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
33071793|NCT05708846||Heart Failure patients telemonitored|Patients will be monitored with the HumanITcare app and platform
33240377|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
33240378|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
33071796|NCT05701657|Other|Module 1|"Module 1 is approximately 10 days (minimum of 8 days) and includes two study visits and remote data collection. Visit 1 will include application of an accelerometer and continuous glucose monitoring device for remote data collection over the next 8 to 10 days. A stool sample collection kit and instructions for stool collection and completion of dietary assessments during the observation period will be provided.~At Visit 2, anthropometry (height, weight and body circumferences), body composition by bioelectrical impedance (BIA), vital signs (temperature, respiratory rate and blood pressure), resting heart rate variability and grip strength will be measured. Medications will be recorded. A liquid MMTT with timed biospecimen collection (blood, urine, saliva, hair, and nails) and visual analogue assessments will be completed.~Participants in Module 1 will be asked to adhere to their usual routine (e.g., diet, exercise, sleep, supplements, medication use, etc.) throughout the study."
33071797|NCT05701657|Other|Module 2|"Module 2 is a minimum of 10 weeks long. It includes a total of six (6) study visits that occur before and after each of the three (3), 14-day dietary intervention periods (i.e., Diets A, B, and C), separated by washout periods of at least 14 days. Participants will be asked to consume only the foods provided and to adhere to their other usual routines throughout the study.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied for remote data collection. A stool sample collection kit will be provided together with instructions for stool collection and dietary assessments. At the end of each diet, a diet-specific meal test with timed biospecimen blood collection and visual analogue assessments will be completed."
33071798|NCT05701657|Other|Module 3|"Module 3 is a minimum of 10 weeks long. It includes three (3), 14-day dietary interventions (i.e. Diets A, B, and C) completed while participants are domiciled under the supervision of study staff. At the end of each dietary intervention period, participants return to their usual residence and routine for a minimum of 2 weeks.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA and DXA, and physical measures will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied. Excluding pregnant females, participants will receive a dose of doubly labeled water. Weight and vital signs will be measured daily and questionnaires administered.~A diet-specific meal test and a separate liquid MMTT with timed blood biospecimen collection and visual analogue assessments will be completed."
33071799|NCT05701306|Experimental|APG-115 monotherapy in part1|Multiple dose cohorts, to determine the RP2D of APG-115.
33071800|NCT05701306|Experimental|APG-115 combined with APG-2575 in part2|Multiple dose cohorts of APG-2575, to determine the RP2D of APG-2575 combined with APG-115.
33071801|NCT05700734|Experimental|Panel A: MK-8510 at dose level 1|Single oral dose of MK-8510 administered at dose level 1 (≤1800 mg) following a 10-hour fast. Dose level 1 shall not exceed 1800 mg.
33071802|NCT05700734|Experimental|Panel B: MK-8510 at dose level 2|Single oral dose of MK-8510 administered at dose level 2 (≤2200 mg) following a 10-hour fast. Dose level 2 shall not exceed 2200 mg.
33071803|NCT05700734|Experimental|Panel C: MK-8510 at dose level 3|Single oral dose of MK-8510 administered at dose level 3 (≤2200 mg) following a 10-hour fast. Dose level 3 shall not exceed 2200 mg.
33240379|NCT00756873|Placebo Comparator|1|
33240380|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
33240381|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
33240382|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
33240383|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
33240384|NCT04056039|Active Comparator|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
32757467|NCT04255277|Experimental|Period 3: Cenerimod 4 mg and charcoal|Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
32757468|NCT04255277|No Intervention|Period 3: Cenerimod elimination period|Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.
32757470|NCT05228093|Experimental|Surgery group|Prior to surgery, a bacterial cultivation for purulent nasopharyngeal secretions and drug sensitivity assays were performed to identify sensitive antibiotics to be used postoperatively. Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. One side flap, typically the ipsilateral side, was harvested after complete radical endoscopic necrectomy.
32757471|NCT05228093|Active Comparator|Conservative group|"Patients receive debridement treatment of the necrotic tissues guided by endoscope and systematic antibiotic therapy partly under the guidance of nasopharyngeal secretion drug sensitivity test.~Patients could use a common nasopharyngeal irrigation pot to wash the nasopharynx three times a day with warm boiled water or light saltwater (500 ml). If possible, patients could also received direct irrigation with an electronic nasopharyngoscopy operated by a physician.~In addition, patients can receive hyperbaric oxygen therapy when conditions permit."
32757472|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
32757473|NCT01255943||prevalent hemodialysis patients|These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
32757474|NCT05057975|Experimental|Sunrise|Home Sleep Test, OSA diagnosis based on mandibular movements recording
32757475|NCT05057975|Active Comparator|PSG|Polysomnography, OSA diagnosis based on local scoring by center
33071804|NCT05700734|Experimental|Panel D: MK-8510 at dose level 4|Single oral dose of MK-8510 administered at dose level 4 (≤2200 mg) following a 10-hour fast. Dose level 4 shall not exceed 2200 mg.
33071805|NCT05700422|Experimental|OC-01 (varenicline solution) 0.03 mg nasal spray|
33071806|NCT05697380|Experimental|Experimental: Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
33071807|NCT05697146||ribociclib + ET|Women prescribed ribociclib + Endocrine Therapy (ET)
32757476|NCT04007705|Experimental|Anti-inflammatory and low FODMAPs diet|The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
32757477|NCT04007705|Active Comparator|Control|Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
32757478|NCT03978533|Experimental|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
32757479|NCT03840707|Experimental|Experimental group|"LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants).~Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital."
32757480|NCT03840707|No Intervention|Control group|Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
32757481|NCT04221893|Experimental|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
32757482|NCT03670121|Experimental|BTVA Treatment|All patients that will receive Bronchoscopic Thermal Vapor Ablation (BTVA) Treatment
32757483|NCT04435925|Active Comparator|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
32757484|NCT04435925|Placebo Comparator|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
32757485|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
32757486|NCT01979614|Experimental|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
32757487|NCT01979614|Placebo Comparator|Placebo|Placebo was administered by intravenous infusion for 48 hours
32757488|NCT00001349||1|Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.
32757489|NCT05205707||Covid-19 Patients|Blood sample from admitted patients will be drawn
32757490|NCT05205707||Control Patients|Blood sample from control group will be drawn
32757491|NCT04649476|Experimental|Neoadjuvant PD-1 blockade alone|The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
32757492|NCT04649476|Experimental|Neoadjuvant PD-1 blockade plus TPF induction chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
32757493|NCT04671784||Enlarged mediastinal or abdominal|Consecutive patients with enlarged mediastinal or abdominal detected by cross-sectional imaging and confirmed at EUS will be enrolled.
32757494|NCT05117957|Experimental|Sorafenib|Sorafenib will be administered orally at a dose of 600mg (3 tablets; 400mg orally in the morning and 200mg orally in the evening about 12 hours apart or 200mg orally in the morning and 400mg orally in the evening about 12 hours apart) daily without food (at least 1 hour before or 2 hours after a meal).
32757495|NCT04671628|Experimental|Relaxing music|
32757496|NCT04671628|No Intervention|Control|
32757497|NCT04671238||Patient for SPECT/CT scan|Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.
32757498|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
32757499|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
32757500|NCT05198063|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
32757501|NCT05117879|Other|Cold snaring polypectomy|The sessile serrated adenoma size between 10-20mm would be resected by cold snaring polypectomy
32757502|NCT05117879|Other|Non-electrocautery Endoscopic Mucosal Resection (Cold EMR)|The sessile serrated adenoma size between 10-20mm would be resected by cold EMR
32757503|NCT05117879|Other|Electrocautery Endoscopic Mucosal Resection( Hot EMR)|The sessile serrated adenoma size between 10-20mm would be resected by Hot EMR
32757504|NCT05117801|Experimental|children at the general practitioner or pediatrician|Children between 9 months and 3 years-old coming to their doctor for any consultation
33397165|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
32757505|NCT03094871|Experimental|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
32757506|NCT03094871|No Intervention|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
32757507|NCT04236167|No Intervention|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
32757508|NCT04236167|Experimental|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
32757509|NCT02969837|Experimental|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
32757510|NCT02969837|Experimental|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
32757511|NCT05191043|Experimental|Group A/ kinesio taping group|Routine physical therapy along with Kinesio Taping
32757512|NCT05191043|Active Comparator|Group B/ routine physical therapy|routine physical therapy
32757513|NCT05190029|Experimental|Complete sample|Group of 120 children evaluated by craniosacral therapy for cranial blocks and primitive reflexes.
32757514|NCT04508543||Minority (Case)|Self-identified as being a member of group traditionally underrepresented in the medical profession relative to the proportion in the general population: African-American/Black, Mexican-American, Native American (American Indians, Alaska Natives, and Native Hawaiians), and mainland Puerto Rican.
32757515|NCT04508543||Caucasian (Control)|Self-identified as Caucasian and Non-Hispanic
32757516|NCT05117645||Cases|patients come to surgical emergency unit and complaining of intestinal obstruction and CT Abdomen and pelvis will be done to detect the cause then will be compared with operative findings .
32757517|NCT03343301|Experimental|Bemarituzumab 6 mg/kg + mFOLFOX6|Participants received 6 mg/kg bemarituzumab administered every 2 weeks (Q2W) and mFOLFOX6 chemotherapy administered Q2W until unacceptable toxicity, disease progression, or death.
32757518|NCT03343301|Experimental|Bemarituzumab 15 mg/kg + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered Q2W with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
32757519|NCT03930251|No Intervention|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
32757520|NCT03930251|Experimental|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
32757521|NCT03930251|Experimental|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
32757522|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
32757523|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
32757524|NCT05136365|Experimental|Xiongdan Wan group|Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder. The daily dose (1350mg per day) should be strictly controlled according to the experimental design.
32757525|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
32757526|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
32757527|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
32757528|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
32757529|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
32757530|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
32757531|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
32757532|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
32757533|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
32757534|NCT05117567|Experimental|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and mobile and migrant population-tailored behavioural change communication (BCC) package
32757535|NCT05117567|No Intervention|Control|No personal protection package
32757536|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
32757537|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
32757538|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
32757539|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
32757540|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
32757541|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
32757542|NCT05117411||Patients group|Subjects over 18 years that after cataract surgery, showed pseudophakic cystoid macula edema.
32757543|NCT05117411||Control Group|Normal subjects over 18 years that did not show pseudophakic cystoid macula edema.
32757544|NCT01675427|Experimental|Chronic hepatitis C patients|
32757545|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
32757546|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
32757547|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
32757548|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
32757549|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
32757550|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
32757551|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
32757552|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
33071808|NCT05696301|Experimental|Interventionnal Group|These women will receive Tecar by Winback® technology [CE medical 1984, Norma 60601-2, ISO9001, ISO13485, CET 400 VA and RET 100 Watts, weight 4 Kg]. Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks
33397166|NCT03988998|Experimental|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
33397167|NCT03988998|Active Comparator|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
33397168|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
33397169|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
33397170|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
33397171|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
33397172|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
33397173|NCT01354665||Group 1|
33397174|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
33397175|NCT05759910|Placebo Comparator|Placebo group|4 capsules per day containing 275mg of Maltodextrin
33397176|NCT05759910|Experimental|BrainPhyt High dose|4 capsules per day containing 275mg of BrainPhyt
33397177|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
33397178|NCT05018403|Experimental|AON-D21|Single ascending doses by iv infusion.
33397179|NCT05018403|Placebo Comparator|Placebo|Placebo medication identical in appearance to active.
33397180|NCT04944108|Experimental|Surfactant administration with less invasive surfactant administration (LISA) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter)
33397181|NCT04944108|Active Comparator|Surfactant administration with intubation (INSURE) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
33397182|NCT05008575|Experimental|antiCD33 CAR NK cells|After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated
33397183|NCT03971994|Active Comparator|Young adults|Participants aged between 18 and 40 years old.
33397184|NCT03971994|Active Comparator|Healthy old adults|Participants aged between 65 and 95 years old.
33397185|NCT03971994|Experimental|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
32757553|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
32757554|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
32757555|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
32757556|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
32757557|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
32757558|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
32757559|NCT02402413|Experimental|PCOS women|
32757560|NCT04440241|Experimental|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
32757561|NCT04440241|Experimental|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
32757562|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
33071809|NCT05696301|Sham Comparator|Control|The women will follow the same study design as the experimental group but the portable instrument will not be activated, and this difference will not be visible to patients, as the instrument will be blocked from their view by an opaque drape. Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks.
32757563|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
33397186|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
33397187|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
32757564|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
32757565|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
33397188|NCT05759754|Experimental|Traditional Chinese Medicine treatment group|"Patients will receive Gushen Juanyu Formula, 30 ml or 60ml each time based on weight (30 mL for W≤30kg, or 60ml for W>30kg), 2 times a day for 12 weeks, orally, as an add-on to any ongoing treatment, including ACE inhibitors/ angiotensin II receptor blocker.~Patients receiving a stable dose of ACEI/ARB will be continued."
33397189|NCT05759754|Other|Control group|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
32757566|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
32757567|NCT01978912|Experimental|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
32757568|NCT01978912|Experimental|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
32757569|NCT01978912|Experimental|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
32757570|NCT01978912|Experimental|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
32757571|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
32757572|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
32757573|NCT05744635||Liver transplant patients, receiving tacrolimus containing immunosuppression|"Patients ≥ 18 years of age~Patients after liver- or simultaneous liver and kidney transplantation~Having received a tacrolimus containing immunosuppressant therapeutic regimen at least for four weeks (induction therapy), and TL is within 5-20 ng/ml before inclusion. Possible medications are the following (dosages and administration according to local (European) SmPC~Envarsus prolonged release tablet~Adport hard capsule~Advagraf prolonged-release hard capsule~Modigraf granule for oral suspension~Prograf hard capsule~Tacforius hard capsule"
32757574|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
32757575|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
32757576|NCT02393287||Reproline|this is an observational trial ; there is no intervention
32757577|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
32757578|NCT05744479|Experimental|Metformin (Oral)|50 participants will be administered oral metformin titrated to a maximum dose of 2000mg/day for 24 weeks.
32757579|NCT05744479|Placebo Comparator|Placebo|50 participants will be administered an identical oral placebo for 24 weeks.
33397190|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
33397191|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
33397192|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
33397193|NCT03681119|Experimental|Advanced Demential Patients|
32757580|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
32757581|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
32757582|NCT05232253|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
32757583|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
32757584|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
32757585|NCT04670536||PASS LP implants|Patient suffering from a spinal degenerative disease and who is operated with PASS LP
32757586|NCT04670536||PASS Degen implants|Patient suffering from a spinal degenerative disease and who is operated with PASS DEGEN
32757587|NCT04670536||PASS Tulip PRIME implants|Patient suffering from a spinal degenerative disease and who is operated with PASS TULIP PRIME
32757588|NCT04649398||oral nimodipine|60mg of nimodipine is orally administered every 4 h,
32757589|NCT04649398||intra-venous nimodipine|nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
32757590|NCT04649398||intra-arterial nimodipine|during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
32757591|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
32757592|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
32757593|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
32757594|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
32757595|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
32757596|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
32757597|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
32757598|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
32757599|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
32757600|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
32757601|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
32757602|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
32757603|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
32757604|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
32757605|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
32757606|NCT01977820|Experimental|Sapropterin|
32757607|NCT01977820|Placebo Comparator|Placebo|
32757608|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
32757609|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
32757610|NCT05744401|Experimental|AL002 Dose 1|AL002 every 4 weeks
32757611|NCT05744401|Experimental|AL002 Dose 2|AL002 every 4 weeks
32757612|NCT05744401|Experimental|AL002 Dose 3|AL002 every 4 weeks
32757613|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
32757614|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
32757615|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
32757616|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
32757617|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
32757618|NCT03166345|No Intervention|No intervention|The control arm.
32757619|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
32757620|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases [undiagnosed connective tissue diseases and additional rheumatological diseases] that may accompany secondary FMS exclusion.
32757621|NCT02392819|Experimental|test product|Arm: Panax ginseng
32757622|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
33397194|NCT03681119|Experimental|Hospice IDT Members|
33397195|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
32757625|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
32757626|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
32757627|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
32757628|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
32757629|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
32757630|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
32757631|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
32757632|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
32757633|NCT02001688|Experimental|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
32757634|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
32757635|NCT02001688|Experimental|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
32757636|NCT05668507|Experimental|REACHOUT|The REACHOUT intervention arm will receive access to the REACHOUT mobile app through which they will be able to review profiles of Peer Supporters and connect with one of their choosing. They will also have access to the other app features including a 24/7 chat room and face-to-face support via virtual happy hours. Participants will complete questionnaires (baseline, 1 month, 3 months, 6 months) and a blood draw (baseline and 6 months). Monetary compensation will be provided for their time and effort.
32757637|NCT05668507|No Intervention|Wait-list|The wait-list control group will receive access to the mobile app/support program after six (6) months. They will complete questionnaires and a blood draw at baseline and 6 months. Monetary compensation will be provided for their time and effort.
32757638|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
32757639|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
32757640|NCT04030325|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
32757641|NCT04030325|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
32757642|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
32757643|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
32757644|NCT04030325|No Intervention|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
33397196|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
33397197|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
32757645|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
32757646|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
32757647|NCT05117021|Experimental|Group of Bupivacaine injection in Caudal block group|The children will receive of 0.25% plain bupivacaine infiltration as caudal block for post operative analgesia in infraumblical surgeries
32757648|NCT05117021|Experimental|Group 2 : Group of Bupivacaine injection in TAP block group|The children will receive of 0.25% plain bupivacaine infiltration as Transversus Abdominis Plane Block for post operative analgesia in infraumblical surgeries
32757649|NCT02001064|Experimental|Care4Today v2.0 mobile application + electronic monitoring of adherence|"Care4Today v2.0 mobile application~Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.~Electronic monitoring of adherence:~Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap."
32757650|NCT02001064|No Intervention|Electronic monitoring of adherence|Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap.
32757651|NCT02392585|Active Comparator|Single tourniquet|
32757652|NCT02392585|Active Comparator|Triple tourniquet|
32757653|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
32757654|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
32757655|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
32757656|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
32757657|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
32757658|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
32757659|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
32757660|NCT05744323|Experimental|Experimental group|The experimental group will engage in functional training
32757661|NCT05744323|No Intervention|Control group|the control group will follow the state-mandated physical education curriculum.
32757662|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
32757663|NCT02392117||Insulin degludec|
32757664|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
32757665|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
32757666|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
32757667|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
32757668|NCT03995693|Experimental|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
33071811|NCT05693272|Experimental|COVAC-01 10µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
32910576|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
32910577|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
32910578|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
32910579|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
32910580|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
32910581|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
33071812|NCT05693272|Experimental|COVAC-01 25µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
33071813|NCT05693272|Experimental|COVAC-01 50µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
33071814|NCT05693272|Placebo Comparator|Placebo Control|12 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
32910582|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
32910583|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
32910584|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
33397198|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
33397199|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
33397200|NCT05198856|Experimental|Thalidomide|"The study is divided into two phases:~The first phase is a combination phase (chemotherapy +T) : Oxaliplatin (130mg/m2 iv d1) and capecitabine (1000mg/m2 d1-14 po bid) repeated every 21 days for a total of 4-6 cycles. Thalidomide tablet: 100 mg/d, qn, orally.~The second stage is maintenance stage: Patients who have obtained CR, PR or SD in the first stage enter the maintenance stage and receive maintenance treatment with thalidomide tablets: 100mg/d, qn, orally. Maintained until disease progression or adverse reactions are intolerable."
32757669|NCT03995693|Experimental|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
32757670|NCT03995693|Experimental|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
32757671|NCT03995693|Experimental|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
32757673|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
32757674|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
32757675|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
32757676|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
32757677|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
32757678|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
32757679|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
32757680|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
32757681|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
32757682|NCT04965935|Experimental|Dapagliflozin Tablets|Patients will be randomized to therapy with dapagliflozin 10mg PO daily for 12 weeks.
32757683|NCT04965935|Placebo Comparator|Placebo Matching Dapagliflozin Tablets|Patients will be randomized to therapy with placebo matching dapagliflozin tablets PO daily for 12 weeks.
32757684|NCT05657587||PNS Group|All subjects will receive the PNS device. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
32757685|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
32757686|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
32757687|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
32757688|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
32757689|NCT05742451|Active Comparator|intervention group|The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.
32757690|NCT05742451|No Intervention|Control group|The control group was evaluated at 8-week intervals.
32757691|NCT03916133|Other|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
32757692|NCT03915665|Active Comparator|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
32757693|NCT03915665|Experimental|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
32757694|NCT01959334|Active Comparator|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
32757695|NCT01959334|Experimental|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
33071815|NCT05691712|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
33071816|NCT05691712|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
32757696|NCT04722419|Experimental|Functional dyspepsia|
32757697|NCT04722419|Active Comparator|Healthy subjects|
32757698|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
32757699|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
32757700|NCT04173754||MSAT Group|"The MSAT group who are treated with korean medical treatment including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
32757701|NCT04173754||Control Group|"The control group who are treated with Korean medical treatment not including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
32757702|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
32757703|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
33397201|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
33397202|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
32757704|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
32757705|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
32757706|NCT05737849||Cohort 1: Participants With Positive EGFR ex20ins Detection|Participants with NSCLC having positive EGFR ex20ins detected by NGS were observed retrospectively for three years prior to leading site initiation.
32757707|NCT05737849||Cohort 2: Participants With Positive and Negative EGFR ex20ins Detection|Participants with NSCLC having positive and negative EGFR ex20ins NGS testing results were observed retrospectively for three years prior to leading site initiation.
32757708|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
32757709|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
32757710|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
32757711|NCT05652439||Fixed triple therapy BDP/FF/GB via DPI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via DPI formulation according to local clinical practice
32757712|NCT05652439||Fixed triple therapy BDP/FF/GB via pMDI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via pMDI formulation according to local clinical practice
32757713|NCT04813705|Experimental|Reduced dose group|The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
32757714|NCT04813705|Active Comparator|Conventional dose group|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
32757715|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
32757716|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
32757717|NCT04809181|Experimental|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
32757718|NCT05737381|No Intervention|Control group|"The oocytes from a patient, retrieving more than 8 oocytes will be divided into 2 sibling groups. The control group and the study group.~The first part of the collected oocytes, will be included as controls. If an unequal numbers of oocytes are collected, the extra oocyte will be included into the control group.~Control oocytes are, after fertilization, placed in conventional 5% O2 incubators and cultured herein for 5 days."
32757719|NCT05737381|Experimental|Study group|"The second part of the collected oocytes, from a patient retrieving more than 8 oocytes, will be included as study group.~Study oocytes, are after fertilization, placed and cultured in conventional 5% O2 incubators for the first 3 days. At day 3, the embryos are moved to an incubator with 2% O2 tension and cultured until day 5."
32757720|NCT05736679|Experimental|In2Care EaveTube|EaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets)
32757721|NCT05736679|No Intervention|Control|Standard of care (standard pyrethroid-only bednets)
32757722|NCT05734807|Active Comparator|NrtIs|
32757723|NCT05734807|Experimental|HH-003+NrtIs|
32757724|NCT05734807|Experimental|HH-003+NrtIs+PEG-IFN-α|
32910585|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
32757725|NCT05746585|Experimental|The TALK intervention for Black male adolescents and young adults (AYA)|The TALK, a parent-centered, adolescent-involved health promotion intervention for Black male adolescents and young adults (AYA). Through the use of entertainment videos and educational modules, investigators will provide parents with resources and tools for communicating with their adolescents about sexual health and experiences of racial discrimination, and how these experiences impact sexual health.
33397203|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
32757726|NCT01057121|Experimental|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32757727|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
32757728|NCT05106647|No Intervention|Control|This group would complete a survey that measures stress before and after leisure time with no added instructions.
32757729|NCT05106647|Experimental|Reduce screen time|Participants randomized to the intervention group are encouraged to set up an automated response to emails received during their weekend off, reduce their screen time for duration of leisure time, and uninstall work applications from their mobile device. Surveys are sent prior to and after leisure time.
32757730|NCT04692389|Experimental|Jalosome® Soothing gel|"The medical device will be applied by the patient himself, after appropriate training carried out by the nurse, twice a day, in the quantity necessary to cover the lesion (0.2g of gel /16 cm2 of skin (one spray), repeated as many times as necessary to cover the entire lesion). The treatment will last 8 weeks.~The medical device will be delivered in the quantity strictly necessary to carry out the therapies between visits, in order to monitor its use. Patients will be seen weekly by the nurse, in order to ensure the best continuity of care and promote adherence to the study. Patients will be asked to keep a weekly diary, in which they will report their level of pain, analgesic therapy and medication. Nurses will be available for telephone counselling, if necessary."
32757731|NCT04679909|Experimental|Single Low Dose AdCOVID|
32757732|NCT04679909|Experimental|Single Medium Dose AdCOVID|
32757733|NCT04679909|Experimental|Single High Dose AdCOVID|
32757734|NCT04679909|Experimental|Two Low Doses AdCOVID|
32757735|NCT04679909|Experimental|Two Medium Doses AdCOVID|
32757736|NCT04679909|Experimental|Two High Doses AdCOVID|
32757737|NCT04679909|Placebo Comparator|Single Dose Placebo|
32757738|NCT04679909|Placebo Comparator|Two Dose Placebo|
32757739|NCT04620941||ventilator-associated pneumonia|Ret-He values will be studied on the day (1st day), 4th and 7th days of VID diagnosis in patients receiving mechanical ventilation support in the intensive care unit. The hemogram, CRP, and NLR values that are routinely studied in the intensive care unit will be recorded. In addition, in case of infection, the routinely studied procalcitonin value will also be recorded. The patient's age, gender, APACHE II, SOFA scores will be recorded; respiratory system examination, fever, the mental status evaluation will be done daily.
32757740|NCT04615871|Experimental|semaglutide|Eligible subjects randomized to this arm will receive semaglutide 0.25 mg s.c. after randomization (Day 0), then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21 in addition to standard of care.
32757741|NCT04615871|No Intervention|control|Eligible subjects randomized to the control arm will receive no active treatment, only standard of care.
32757742|NCT04210349|Experimental|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
32757743|NCT04210349|Experimental|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
32757744|NCT04210349|Experimental|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
32757745|NCT04210349|Experimental|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
32757746|NCT04210349|Experimental|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
32757747|NCT04210349|Experimental|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
32757748|NCT01353313|Placebo Comparator|Placebo|Saline placebo
32757749|NCT01353313|Experimental|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
32757750|NCT04991129|Experimental|WJ01024 5mg repeat dose every 28 days|
32757751|NCT04991129|Experimental|WJ01024 10mg repeat dose every 28 days|
32757752|NCT04991129|Experimental|WJ01024 20mg repeat dose every 28 days|
32757753|NCT04991129|Experimental|WJ01024 40mg repeat dose every 28 days|
32757754|NCT04991129|Experimental|WJ01024 60mg repeat dose every 28 days|
32757755|NCT04991129|Experimental|WJ01024 80mg repeat dose every 28 days|
32757756|NCT04991129|Experimental|WJ01024 100mg repeat dose every 28 days|
32757757|NCT04991129|Experimental|WJ01024 120mg repeat dose every 28 days|
32757758|NCT04991129|Experimental|WJ01024 140mg repeat dose every 28 days|
33397204|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
33397205|NCT03887910|No Intervention|Control|Usual care with developmental toys.
33397206|NCT03184714|No Intervention|Control|
32757759|NCT04991129|Experimental|WJ01024 160mg repeat dose every 28 days|
32757760|NCT04888793||Cancer Patients on active treatment|
32757761|NCT04888793||Bone marrow transplant patients|
32757762|NCT04888793||Solid organ transplant recipients|
32757763|NCT04888793||HIV patients|
32757764|NCT04888793||Rheumatic disease patients|
32757765|NCT04888793||Healthy controls|
32757766|NCT04746989||Probenecid|Exposure group
32757767|NCT04746989||Allopurinol|Reference group
32757768|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
32757769|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
32757770|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
32757771|NCT04542551|Active Comparator|Without stricture - dilation with 60-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 60-Fr dilator
32757772|NCT04542551|Sham Comparator|Without stricture - dilation with 15-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 15-Fr dilator (sham)
32757773|NCT04542551|Active Comparator|Non severe stricture - dilation with 60-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
32757774|NCT04542551|Active Comparator|Non severe stricture - dilation with 46-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
32757775|NCT04542551|Active Comparator|Severe stricture - dilation with 51-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 51-Fr dilator
33397207|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
32744505|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
32757776|NCT04542551|Active Comparator|Severe stricture - dilation with 42-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 42-Fr dilator
32757777|NCT04806269||Thyroid dysfunction group|"Subjects with thyroid dysfunction including thyrotoxicosis and hypothyroidism Subjects who were newly diagnosed or undergoing treatment for thyroid dysfunction can be included in the study.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
32757778|NCT04806269||Control group|"Subjects without thyroid dysfunction including thyrotoxicosis and hypothyroidism.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
32757779|NCT04383821|Experimental|Double-Trunk Mask|The oxygen delivery system is the DTM
32757780|NCT04383821|Active Comparator|Non-Rebreather Mask|The oxygen delivery system is the NRM
32757781|NCT04520009||Activity Restriction|Discharge orders for activity restriction
32757782|NCT04520009||Activity As Tolerated|Discharge orders written for activity as tolerated
32757783|NCT04349423|Experimental|No Social Media Use|Participants will be asked to refrain from using all social media
32757784|NCT04349423|Experimental|Maximum 30 minutes of use|Participants will be asked to only use social media at most 30 minutes a day.
32757785|NCT04349423|Experimental|Maximum 1 hour of use|Participants will be asked to only use social media at most 60 minutes a day.
32757786|NCT04349423|Experimental|Control|Control Group
32757787|NCT03988985|Experimental|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
32757788|NCT03988985|Active Comparator|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
32757789|NCT03988985|No Intervention|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
32757790|NCT04163393|Experimental|R-One|Patients treated with robotic assistance
32757791|NCT04428749||Study group|"Participants are screened using the Yale Swallow Protocol (YSP) 2-4 hours after extubation:~Ability to swallow is assessed by an ICU nurse using the YSP. If the YSP is negative, the patient may start oral feeding and drinking. In case of a positive YSP, the screening may be repeated within the next 24 hours provided the patient improves clinically. If YSP continues to be positive the patient is referred to assessment by a speech language pathologist (SLP).~Participants are screened within 24 hours:~To evaluate YSP against the FEES, the patient undergoes 1) YSP performed by an ICU nurse followed by 2) FEES performed by a SLP (until PAS>6 (aspiration on any food consistency on the Penetration Aspiration Scale (20)). The SLP will be blinded to the assessment made by the ICU nurses. Patients will follow recommendations for oral feeding and drinking as given by the SLP."
32757792|NCT04402385|Experimental|Aspirin|Participants randomized to 81 mg of Aspirin daily
32757793|NCT04402385|Placebo Comparator|Placebo|Participants randomized to placebo daily
32757794|NCT04393103|Other|Follow up|Follow Up of 30 patients after administration of atropine.
32757795|NCT04393103|Experimental|intralipid 20% adjuvant|30 patients will receive atropine and intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
32757796|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
32757797|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
32757798|NCT04238585|Active Comparator|Negative message frames|Participants will receive messages framed in a negative manner to avoid sugar-sweetened beverages
32757799|NCT04238585|Active Comparator|Sugar content information messages|Participants will receive messages framed in a positive manner to promote healthy beverage consumption
32757800|NCT04238585|Placebo Comparator|Attention Control-Infant Safety|Participants will receive messages with infant safety education materials-attention control group
32757801|NCT04677803|Experimental|Treatment|"Subcutaneous (SC) injection:~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21."
32757802|NCT04671953|Experimental|Arm 1: BMS-986165 Dose 1 + Metformin|
32757803|NCT04671953|Experimental|Arm 2: BMS-986165 Dose 2 + Metformin|
32757804|NCT04616105|Experimental|Cohort 1|Single ascending subcutaneous (SC) dose 1 of REGN6490 or matching placebo
32757805|NCT04616105|Experimental|Cohort 2|Single ascending subcutaneous (SC) dose 2 of REGN6490 or matching placebo
32757806|NCT04616105|Experimental|Cohort 3|Single ascending subcutaneous (SC) dose 3 of REGN6490 or matching placebo
32757807|NCT04616105|Experimental|Cohort 4|Single ascending intravenous (IV) dose 4 of REGN6490 or matching placebo
32757808|NCT03950453|Experimental|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
32757809|NCT03950453|Active Comparator|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
32757810|NCT04585061|Active Comparator|sweet test group|Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
32757811|NCT04585061|Active Comparator|Virtual reality group|"Local anesthesia with conventional syringe + VR device Device: Local anesthesia with conventional syringe + VR device Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized."
32757812|NCT04531007|Experimental|Intermediate LMS stenosis|Patients with intermediate left main stem stenosis with additional severe downstream lesion will be subject to physiology (FFR and iFR) at multiple sites along the target vessels before and after PCI of the severe lesion located in the downstream vessel. Intravascular imaging (IVUS and OCT) will be performed for additional evaluation of the left main stem stenosis.
32757813|NCT03902717||minimally invasive cardiac surgery|Group of patients that will undergo minimally invasive cardiac surgery
32757814|NCT04349501|Experimental|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
32757815|NCT04512365|Placebo Comparator|Placebo oral capsule|Participants will receive a placebo at their first or second laboratory visit.
32757816|NCT04512365|Experimental|THC|Participants will receive THC (7.5 mg) at their first or second laboratory visit.
32757817|NCT03874091|Active Comparator|GA group|Patients will receive general anaesthesia for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
32757818|NCT03874091|Experimental|ESP group|Patients will receive general anaesthesia with bilateral ESP block for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
32757819|NCT03786965|Other|On-pump CABG.|On-pump CABG.
32757820|NCT03786965|Other|Off-pump CABG.|Off-pump CABG.
32757821|NCT03786965|Other|Pump-assisted CABG.|Pump-assisted CABG.
32757822|NCT03786965|Other|Heart Valve Procedure without CABG.|Heart Valve Procedure without CABG.
32757823|NCT03786965|Other|Heart Valve Procedure with CABG.|Heart Valve Procedure with CABG.
32757824|NCT03735017|Active Comparator|Non-Interactive|Participants will receive non-interactive virtual reality walking sessions.
32757825|NCT03735017|Experimental|Interactive|Participants will receive interactive virtual reality walking sessions.
32757826|NCT03729557||Kidney Donors|
32757827|NCT03729557||Control group|
32757828|NCT03722693||Experimental group|Experimental group included subacute stroke patients with initial wrist extension. Each participant will receive 28 therapy sessions in total, that are divided into four blocks of 7 sessions. During the first 7 sessions the participant will receive standard care treatment (S), this block will be followed by first Functional electrical stimulation based treatment (FES intervention) block with 7 sessions of protocol A (AUTO or FUNCTION). Third block will consider additional 7 sessions of standard care (S). Fourth block will include 7 sessions of Functional electrical stimulation based treatment (FES intervention) with other type of treatment B (FUNCTION or AUTO).
32757829|NCT01362491|Experimental|Treatment A|
32757830|NCT01362491|Active Comparator|Treatment B|
33071817|NCT05691712|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
32757831|NCT01362491|Placebo Comparator|Treatment C|
32757832|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
32757833|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
32757834|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
32757835|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
32757836|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
32757837|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
32757838|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
32757839|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
32757840|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
32757841|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
32757842|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
32757843|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
32757844|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
32757845|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
32757846|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
32757847|NCT02687035|Experimental|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
32757848|NCT03701555|Experimental|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
32757849|NCT03701555|Experimental|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
32757850|NCT03701555|Experimental|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
32757851|NCT03701555|Experimental|Part 1, Cohort 1E-2 CeD|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
32757852|NCT03701555|Experimental|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
32757853|NCT03701555|Experimental|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
33071818|NCT05691712|Placebo Comparator|Placebo|Participants will receive a tirzepatide matched placebo.
33240385|NCT04056039|Active Comparator|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
33397208|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
32757854|NCT03701555|Experimental|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
32757855|NCT03701555|Experimental|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
32757856|NCT03701555|Experimental|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
32757857|NCT03701555|Experimental|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
32757858|NCT03701555|Experimental|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
32757859|NCT03701555|Experimental|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
32757860|NCT03701555|Experimental|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
32757861|NCT03701555|Experimental|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
32757862|NCT03701555|Experimental|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
33071823|NCT05686226|Experimental|E7 TCR-T cells|Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
33240386|NCT00750945|Experimental|A|Treadmill with Music cueing group
33240387|NCT00750945|Active Comparator|B|Treadmill group
33240388|NCT00750945|Placebo Comparator|C|Home walking group
33240389|NCT04104815|Experimental|Experimental Thickener|Powder thickener
33071825|NCT05685082|Experimental|Standardized patient group|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
33071826|NCT05685082|Experimental|Manikin-based group|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
33240390|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
33240391|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
33240392|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
33240393|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
33240394|NCT04104503|Experimental|Part A|
32757863|NCT04515563|Placebo Comparator|Control Group|Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
32757864|NCT04515563|Experimental|Low-frequency, moderate-intensity walking group|A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 150-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 150 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
33240395|NCT04104503|Experimental|Part B group 1|"Treatment period 1: Fasted + iv;~Treatment period 2: Fasted;~Treatment period 3: High-fat meal"
33240396|NCT04104503|Experimental|Part B group 2|"Treatment period 1: High-fat meal;~Treatment period 2: Fasted + iv;~Treatment period 3: Fasted"
32910586|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
32910587|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
32910588|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
33240397|NCT04104503|Experimental|Part B group 3|"Treatment period 1: Fasted;~Treatment period 2: High-fat meal;~Treatment period 3: Fasted + iv"
32910589|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
32910590|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
32910591|NCT03994367|No Intervention|Standard protein (control)|
32910592|NCT03994367|Experimental|High animal protein isolate|
32910593|NCT03994367|Experimental|High animal protein whole food|
32910594|NCT03994367|Experimental|High plant protein isolate|
32910595|NCT03994367|Experimental|High plant protein whole food|
32744506|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
32744507|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
32910597|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
32910598|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
32910599|NCT04771481|Experimental|metoclopramide|Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.
33240398|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
32910600|NCT04771481|Placebo Comparator|placebo|Normal saline 10 ml IV slowly push in 5 minutes.
33240399|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
33240400|NCT05184140|Experimental|Adnexal mass with high suspicion of malignancy|An ovarian lymphatic map will be performed in patients with adnexal masses suspected of malignancy. Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer confirmation including restaging surgeries.
32757865|NCT04515563|Experimental|High-frequency, moderate-intensity walking group|Intervention of high-frequency, moderate-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 50-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 50 minutes of exercise time. If needed, there will be one 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
32757866|NCT04515563|Experimental|Low-frequency, vigorous-intensity walking group|Intervention of low-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 75-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 75 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
32757867|NCT04515563|Experimental|High-frequency, vigorous-intensity walking group|Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
32757868|NCT05746507|Experimental|Night Respite Care|18 overnight night respite care sessions over six weeks with parental skills provided through teachable moments before and after respite care supports
32757869|NCT04477889||COVID-19 Cohort|Patients treated at MHS facilites for COVID-19
32757870|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
32757871|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
32757872|NCT03684473|Experimental|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
32757873|NCT05726461|Experimental|AndroidAPS-rt-CGM|1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone
32757874|NCT05726461|Active Comparator|sensor augmented pump(SAP)|SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
32757875|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
32757876|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
32757877|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
32757878|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
33397209|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
33397210|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
32757882|NCT03423407||PET/MR|"Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.~Participants will be asked to lie still within the scanner for up to 90 minutes"
32757883|NCT04256759|Experimental|Dupilumab|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
32757884|NCT03342989|Experimental|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
32757885|NCT03342989|Active Comparator|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
32757886|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
32757887|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
32757888|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
32910601|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
32757889|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
32757890|NCT04965389|Experimental|Sequence 1|
32757891|NCT04965389|Experimental|Sequence 2|
32757892|NCT04965389|Experimental|Sequence 3|
32757893|NCT04965389|Experimental|Sequence 4|
32757894|NCT04957745|Other|Visual confusion|The study participants will respond to various visual confusion stimuli presented on a stereoscopic display designed to simulate binocular/monocular visual confusions
32757895|NCT04122287|Experimental|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
32757896|NCT04122287|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
32757897|NCT05746351|Active Comparator|epidural Bupivacaine with Dexmedetomidine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with Dexmedetomidine 0.5 μg/ml
32757898|NCT05746351|Active Comparator|epidural Bupivacaine with fentanyl in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with fentanyl 2 μg/ml.
32757899|NCT05746351|Active Comparator|epidural Bupivacaine with Nalbuphine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with 0.2 mg/ml Nalbuphine.
32757900|NCT05403437||Group 1: Pregnant women with PGP and newly diagnosed with GDM|Pregnant women with PGP who were newly diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment for diabetes was not started
33397211|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
32757901|NCT05403437||Group 2: Pregnant women with PGP and diagnosed with GDM|Pregnant women with PGP who were diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment has been already started for diabetes
32757902|NCT05403437||Group 3: Pregnant women with PGP|Pregnant women with PGP who were not diagnosed with GDM according to routine control examinations
32757903|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
32757904|NCT04760795||coping strategy based on problem|59 geriatric patients will be included on the group: coping strategy based on problem
32757905|NCT04760795||coping strategy based on emotion|59 geriatric patients will be included on the group: coping strategy based on emotion
32901514|NCT05151900|Experimental|Stakeholder Perspectives and Virtual Parent-Led Peer Support Group|Qualitative interviews regarding the impact of COVID-19 will be conducted with youth who have an eating disorder (ED), parents of youth who have an ED, ED clinicians and ED program administrators, as well as get their perspectives on parent-led peer support groups. Three parent-led peer support groups will be started, including psychoeducation in a virtual group setting for parents who have a child or adolescent with an eating disorder.
33397212|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
33240401|NCT04083872|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
33240402|NCT04083872|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
33240403|NCT05183672|Experimental|Intervention group|Participants will receive three tertiary stroke care consultations provided by stroke nurses via telecare in 3 months.
33240404|NCT05183672|Placebo Comparator|Control group|Participants will receive three usual face-to-face consultations provided by stroke nurses in 3 months
33240405|NCT05183360|Experimental|BI 706321 single dose|
33240406|NCT05183360|Experimental|BI 706321 multiple dose|
33240407|NCT05183360|Placebo Comparator|Placebo|
32910602|NCT04751201|Experimental|Receiving mindfulness open and circular program|
33397213|NCT05714982|Experimental|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills.
32742327|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
32742328|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
32742329|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
32742330|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
32742331|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
32744508|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
33397214|NCT05714982|Experimental|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills.
32757906|NCT05720611|Active Comparator|Intervention group|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden. Participants will be asked to engage in a closed Facebook group.
32757907|NCT05720611|Placebo Comparator|Control Group|Participants in this group will complete all questionnaires but will not receive the digitally delivered course or access to Facebook.
32757908|NCT05403281|Experimental|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: DW6012
32757909|NCT05403281|Experimental|Sequence B|Period 1: DW6012/ Period 2: Dapagliflozin and Sitagliptin
32757910|NCT03158831|Other|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
32757911|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
32757912|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
32757913|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
32757914|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
32757915|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
32757916|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
32757917|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
33071829|NCT05677906|Active Comparator|Walking only (Step It Up!)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes.
32757918|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
32757919|NCT03037931|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.
32757920|NCT03037931|Placebo Comparator|Placebo|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
32757921|NCT05746117|Experimental|Continuous Blood Pressure Monitoring (CBPM)|Participants will wear the Aktiia Bracelet for 6-months and potentially receive blood pressure medication titrations during the 6-month period.
32757922|NCT05746117|Active Comparator|Home Blood Pressure Monitoring (HBPM)|Participants will receive an upper arm cuff and standard hypertension care from their primary care physician.
32757923|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
32757924|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
32757925|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
32757926|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
32757927|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
32757928|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
32757929|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
32910603|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
32757930|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
32757931|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
32757932|NCT05746039|Experimental|Study Drug (semaglutide)|Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy
32757933|NCT05745961||PAH|
32757934|NCT05745961||Healthy volunteer|
32757935|NCT03165643||NGT-normal birth weight|
32757936|NCT03165643||NGT-macrosomia|
32757937|NCT03165643||GDM-normal birth weight|
32757938|NCT03165643||GDM-macrosomia|
32757939|NCT04436003|Experimental|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
32757940|NCT04436003|No Intervention|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
32757941|NCT05598151|Experimental|HM97662|Tablet, oral administration, once daily (QD), continuous dosing
32757942|NCT04436159|Active Comparator|Nissen fundoplication|Addition of 360 fundoplication after crural closure
32757943|NCT04436159|Active Comparator|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
32757944|NCT05403125|Experimental|Package|Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
32757945|NCT05403125|Active Comparator|Gel Alone|Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
32757946|NCT05701423||Natalizumab (NTZ)|Participants who receive NTZ intravenously (IV) or subcutaneously (SC) as standard interval dosing (SID), or as SC extended interval dosing (EID) will be followed prospectively for up to 30 weeks.
32757947|NCT02795351|Experimental|Active|Sildenafil 100 mg single dose
32757948|NCT02795351|Placebo Comparator|Placebo|Placebo capsule
32757949|NCT04657835|Experimental|Coronary Artery Bypass Grafting|"Patient with indication of Coronary Artery Bypass Grafting will be included. They will have:~before surgery : cardiac Magnetic Resonance Imaging (MRI), Blood sample~during surgery : Cardiac muscle biopsy~after surgery : Holter-electrocardiogram (ECG), medical examination"
32757950|NCT05403047|Other|pregnant woman - tenofovir|Participants will be started on tenofovir disoproxil fumarate (TDF) 245 mg one tablet per day from week 28 of pregnancy until 6 weeks postpartum.
32757951|NCT04626713|Experimental|Intervention|Participants will undergo a brief interactive psychoeducation session four times a week for two weeks. For each session, participants will wear a commercially available Electroencephalography (EEG) headset and play a downloaded online game for a total of 30 minutes. Participants can feel free to play the game for more than the instructed frequency during their 2-week intervention participation.
32757952|NCT04626713|No Intervention|Waitlist control|Participants in Waitlist Control will receive no intervention in the first four weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
33071830|NCT05677906|Experimental|Combined (Step It Up! plus Change Club)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes. Participants also spend 30 minutes each week in a civic engagement program (the Change Club) improving walkability in the community
32757953|NCT05399303|Experimental|bioceramic sealer obturation|
32757954|NCT05399303|Experimental|resin sealer|
32757955|NCT04563845|Experimental|Part 1: Sentinal Cohort 1|Participants will be randomized in a 3:1 ratio to evaluate QD dosing of GSK3640254 or placebo. Participants will be administered GSK3640254 500 milligram (mg) or placebo with approximately 240 milliliters (mL) of water following ingestion of a moderate fat meal.
32757956|NCT04563845|Experimental|Part 1: Sentinal Cohort 2|Participants will be randomized in a 3:1 ratio to evaluate BID dosing of GSK3640254 or placebo. The maximum dose would be GSK3640254 500 mg BID or placebo BID with approximately 240 mL of water following ingestion of a moderate fat meal.
32757957|NCT04563845|Placebo Comparator|Part 2: Main QTc Study|Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin [400 mg] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
32757958|NCT01979315||patients with LBP|
32757959|NCT01979315||healthy individulas|
32757960|NCT03927443|Experimental|Test|
32757961|NCT03927443|Active Comparator|Reference|
32757962|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
32757963|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
32757964|NCT05124353|Active Comparator|G1 : Treatment Group (TG)r|Patients in TG receive neuroprotective drug: standard dose of Cerebrolysin 30ml i.v. in the first 6 hours after first symptoms. After EVT the administration is continued for 10 days.
32757965|NCT05124353|No Intervention|G2 : Control Group (CG)|Patients in CG receive no additional i.v. treatment.
32757966|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).~The embryo culture media will be collected at day 2-5."
32757967|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.~The embryo culture media will be collected at day 2-5."
32757968|NCT05124197||Cohort of ICU patients with COVID-19 related ARDS requiring at least one extended PP session|patients with COVID-19 related ARDS requiring prone position because of profound hypoxemia were applied the investigators' strategy to extend duration of prone position: after being turned prone, they spent at least two complete nights in prone position before being turned to supine position
32757969|NCT03913247||Group with different size measures|Each patient included in the study will have different measure of size.
32757970|NCT03805841|Experimental|Active|tarloxotinib bromide
32757971|NCT02816099|Experimental|Type-1 diabetes patients|
32757972|NCT02816099|Other|Controls|
32757973|NCT02815943|Other|Before DBP-DS surgery|
32757974|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
32757975|NCT02815943|Other|Before SG surgery|
32757976|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
32757977|NCT04440995|Experimental|PECS block(P) group|PECS group (P) received general anesthesia and pectoral nerve block(PECS block) with 025% ropivacaine after surgical resection of breast by operator.
32757978|NCT04440995|No Intervention|Control(c) group|only received general anesthesia
32757979|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
32757980|NCT03560765|Experimental|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
32757981|NCT03560765|Active Comparator|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
32757982|NCT03560765|Active Comparator|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
32757983|NCT03560765|No Intervention|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
32757984|NCT04207073|No Intervention|Control group|No intervention.
32757985|NCT04207073|Experimental|Exercise group|Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days.
32757986|NCT04435847|Experimental|HST 001|HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
32757987|NCT04435847|Placebo Comparator|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
32757988|NCT05123651|Placebo Comparator|Control group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge Supplement looking and tasting placebo.
32757989|NCT05123651|Experimental|Viable group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing active L.r X253).
32757990|NCT05123651|Experimental|Inactivated group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing inactive L.r X253).
32757991|NCT02811887|Active Comparator|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
32910604|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
32910605|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
32910606|NCT04733417|Experimental|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
32910607|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
32744509|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
32744510|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
32744511|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
32744512|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
32744513|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
32757992|NCT02811887|Experimental|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
32757993|NCT03995303|Active Comparator|NCP and home-delivered meals|Preventing malnutrition with NCP by a registered dietician and home-delivered meals
32757994|NCT03995303|No Intervention|Current practice|Current practice after discharge from the University Hospital of Iceland.
32757995|NCT03957707|Experimental|stereotactic surgery with drugs treatment|
32757996|NCT03957707|Sham Comparator|drugs treatment alone|
32757997|NCT02739659|Experimental|carbon-ion radiotherapy|Five dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx and 65.6 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65.6 GyE/16Fx are safely delivered, the recommended dose (or 65.6 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
32757998|NCT02386553|Experimental|Nusinersen|Nusinersen administered as an intrathecal injection
32757999|NCT05123261|Experimental|the mindfulness-based elder care (MBEC) therapy|The experimental group was offered eight 50-minute courses once a week.
32758000|NCT05123261|No Intervention|the routine activities|The control group maintained routine activities.
32758001|NCT05123105|Experimental|Experimental|Each person participated in three tests with an interval of approximately one week between them.
32758002|NCT05122949|Experimental|Adults with neurological disorders|
32758003|NCT02684617|Experimental|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
32758004|NCT02684617|Experimental|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
32758005|NCT02684617|Experimental|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
32758006|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
32758007|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
32758008|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
32758009|NCT04055389|Experimental|AT-III treatment|
32758010|NCT04055389|Placebo Comparator|Placebo|
32758011|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
32758012|NCT05697055|Experimental|Azvudine|
32758013|NCT05697055|Active Comparator|Nirmatrelvir-Ritonavir|
32758014|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
32758015|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
32758016|NCT04053361|Active Comparator|Group A: Clinical ablation|"Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.~If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.~If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.~If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.~If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.~No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
32758017|NCT04053361|Experimental|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.~Supplemental ablation will consist of:~Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)~AND~Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage <0.5 mV in sinus rhythm or <0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (<20% of atrial surface) achievable to ablate.~Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.~Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
32758018|NCT03162367|Experimental|Autologous epidermal cell suspension group|
32758019|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
32758020|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
32758021|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
32758022|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
32910608|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
33240408|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
33240409|NCT05293418||ICU mechanically ventilated COVID-19 patients|Patients admitted to Milano Fiera ICU for COVID-19 requiring mechanical ventilation from October 2020 through May 2021
33240410|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
32758023|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
32758024|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
32758025|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
32758026|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
32758027|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
32758028|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
32758029|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
32758030|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
32758031|NCT01976728|Experimental|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
32758032|NCT01976728|Experimental|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
32758033|NCT01976728|Experimental|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
32758034|NCT01976728|Placebo Comparator|Placebo|Placebo
32758035|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
32758036|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
32758037|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
32758038|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.~After their post-assessment they were able to attend the Baduanjin classes."
32758039|NCT05673733|Experimental|Group A|Exergaming training combined with Scapular stabilization exercises will be performed for 6 weeks for 3 times per week.
32758040|NCT05673733|Active Comparator|Group B|Exergaming training will be performed for 6 weeks for 3 times per week.
32758041|NCT05550727|Experimental|PorchLight|
32758042|NCT05550727|No Intervention|Control|
32758043|NCT05673421|Experimental|Exergaming Training Group|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks.
32758044|NCT05673421|Active Comparator|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb. Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
32758045|NCT04055467|Other|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
32758046|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
32758047|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
32758048|NCT05543317|Experimental|68Ga-FAPI-RGD|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAPI-RGD, and undergo PET/CT imaging within the specified time.
32758049|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
32758050|NCT03114241|No Intervention|Control|Usual care.
32758051|NCT04718389|Experimental|Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment|Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
32758052|NCT04718389|Active Comparator|Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)|Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
32758053|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
32758054|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
33240411|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
33397215|NCT05714982|Other|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills.
33397216|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
32744514|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
32758055|NCT04703413|Experimental|LoFric® OrigoTM or LoFric® SenseTM|Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).
32758056|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
32758057|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
32742332|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
32758058|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
32758059|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
32758060|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
32742333|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
32742334|NCT02457533|No Intervention|Control|Only SF-36 and CAT
32742335|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
32742336|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
32742337|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
32742338|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
32742339|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
32742340|NCT03265457||Normal people at same age|
32742341|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
32742342|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
32742343|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
32742344|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
32742345|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
32742346|NCT02458079|Experimental|Pentoxiphylline|
32742347|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
32742348|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
32742349|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
32742350|NCT03264755|Active Comparator|cortical excitability in smokers|
32742351|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
32742352|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
32744515|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
32744516|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
32742353|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
32744517|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
32742354|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
32742355|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
32744518|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
33071843|NCT05674188|Experimental|Augmented Reality Enhanced Simulation (Treatment group)|Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical error and workplace harassment via Augmented Reality (AR) headset.
33071844|NCT05674188|No Intervention|Traditional In Situ Simulation (Control group)|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
33071845|NCT05672615||Non-Muscle Invasive Bladder Cancer - Bacillus Calmete-Guerin (BCG) intravesical treatments|Participants who are receiving BCG intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
33071846|NCT05672615||Non-Muscle Invasive Bladder Cancer - Chemotherapy intravesical treatments|Participants who are receiving chemotherapy intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
33071847|NCT05672576|Experimental|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
33071848|NCT05672576|Placebo Comparator|Placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
33071849|NCT05671887||Cohort A: Primary lung cancers|- Examples include invasive mucinous/non-mucinous non-small cell lung cancers and multifocal carcinomas
33071850|NCT05671887||Cohort B: Metastatic cancers to the lung only|- Examples include germ cell tumors, head & neck tumors, colorectal tumors, renal cell tumors
33240412|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
32758061|NCT05676307|Experimental|Bilateral Vestibular Hypofunction|Vestibular Rehabilitation in Bilateral Vestibular Hypofunction
32758062|NCT05115773|Experimental|Intraligamentary Anaesthesia|Before the restorative treatment of mandibular first molar, SOPIRA® 30 gauge extra-short cartridge needle attached to the tip of the SOPIRA® Citoject (SOPIRA® Heraeus Kulzer, Hanau, Almanya) pressure injector will be inserted into the periodontal sulcus 1-2 mm until resistance. The needle will be at an angle of 30 degrees to the long axis of the tooth. As recommended by the manufacturer, a total of 0.36 ml (mesiobuccal and distobuccal) 4% articaine solution containing 1:100,000 epinephrine (Ultracaine DS forte cartridge, Sanofi-Aventis GmbH, Almanya) will be injected slowly over 42 seconds by pressing the dosing lever 3 times for each root. If the anaesthesia will be failed, we would use the 4-point IL injection by injecting the mesiolingual sulcus and distolingual sulcus with the same technique.
32758063|NCT05115773|Active Comparator|Mandibular Anaesthesia|Before the restorative treatment of mandibular first molar, inferior alveolar nerve block will be provided using the direct standard method. The 27 gauge needle of a 2ml disposable plastic syringe (Ayset, Adana, Turkey) enters from the intersection of the internal oblique edge and the midline of the pterygomandibular raphe, and 1 ml of 4% articaine solution containing1:100,000 epinephrine (Ultracaine DS Forte ampul, Sanofi-Aventis GmbH, Almanya) will be injected slowly in 60 seconds. 15 minutes after the injection the anaesthesia of the lip/tongue will be checked by probing the labial mucosa of the ipsilateral canine tooth.
32758064|NCT05108285||MNV group|Eyes affected by MNV. The dark halo of MNV was evaluated by OCTA and ICGA
32758065|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
32758066|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
32758067|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
32758068|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
32758069|NCT05287711|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy for alcohol use problems, which includes empathic support, feedback and advice, strategies for enhancing self-efficacy, techniques for eliciting self-motivational statements from the participant, strategies for addressing participant ambivalence about change and participant resistance to change, and methods for eliciting and affirming commitment to a specific change plan (active intervention).
32758070|NCT05287711|Experimental|Alcohol Education Control|Psychoeducational intervention intended to: (1) dispel myths about the effects of alcohol, (2) provide information about the general risks of drinking and process of recovery from alcohol problems, (3) provide information about the specific risks related to family relationships and IPV, (4) offer self-help program information and related strategies to address drinking problems, (5) promote and encourage healthy decision-making, and (6) reinforce the benefits of abstinence or controlled drinking.
32758071|NCT05287711|Other|Telephone Monitoring|Brief supportive telephone monitoring sessions that are commonly delivered while Veterans wait to begin their groups (treatment as usual).
32758072|NCT03723473||PAOD patients statin (+)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment.~They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
32758073|NCT03723473||PAOD patients statin (-)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment .~They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
32744519|NCT04875117||Intervention|Participants who are due to receive their first-ever hearing aid(s) as part of their routine audiological care.
32758074|NCT05676151|Experimental|Music Therapy in Pain Rehabilitation|Subjects undergoing care at the Mayo Clinic Florida Pain Rehabilitation Center (PRC) to address pain will receive a 20-minute music therapy intervention
32758075|NCT03054155|Experimental|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
32758076|NCT03054155|No Intervention|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
32758077|NCT04701853|Experimental|Specific abdominal muscle training|Specific abdominal muscle training which is introduced preoperatively and performed the first year after surgery
32758078|NCT04701853|Active Comparator|Usual care treatment|No specific abdominal muscle training
32758079|NCT03049397|Experimental|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
32758080|NCT04657939|Active Comparator|Liraglutide-Pioglitazone|Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
32758081|NCT04657939|Active Comparator|Pioglitazone-Liraglutide|Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.
32758082|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
32758083|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
32758084|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
32758085|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
32758086|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
32758087|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
32758088|NCT04500275|Experimental|Vancomycin group|"i. Timing of application: the Vancomycin (China Chemical & Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.~ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery."
32758089|NCT04500275|Placebo Comparator|Placebo group|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.
32758090|NCT02783105|Experimental|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.~Both have inverted U shape."
32758091|NCT02783105|Sham Comparator|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
32758092|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
32758093|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
32758094|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
32758095|NCT02666339|Experimental|Hortitherapy group|Hortitherapy + Usual care
32758096|NCT02666339|Active Comparator|Control group|Usual care
32758097|NCT05062421||Cases 1|Patients treated with JAK-type kinase inhibitors.
32758098|NCT05062421||Cases 2|Patients treated with monoclonal antibodies against TNF.
32758099|NCT05062421||Cases 3|Patients treated with soluble receptor against TNF.
32758100|NCT05062421||Cases 4|Patients treated with FAME group biosimilars.
32758101|NCT05062421||Cases 5|Patients treated with rituximab.
32758102|NCT05062421||Cases 6|Patients treated with abatacept.
32758103|NCT05062421||Cases 7|Patients treated with drugs that block the IL6.
32758104|NCT02382497|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
32758105|NCT02382497|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
32758106|NCT02382497|Experimental|BED Active tDCS|"Treatment as usual plus experimental treatment"
32758107|NCT02382497|Sham Comparator|BED Sham tDCS|"Treatment as usual plus placebo treatment"
32758108|NCT05061875||Cases|Patients treated with ceftriaxone doses equal to or higher 4 grams / day.
32758109|NCT04503161|Experimental|Hydrogel recipient|
32758110|NCT02214407|Experimental|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.~Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
32742356|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
32744520|NCT04875117||Control|Participants with hearing loss who have not experienced any change in hearing aid status for at least 1 year.
32742357|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
32744521|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.~Current intensity: 2mA, 20min/day"
33240413|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
33071856|NCT05667506|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
33240414|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
33240415|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
33240416|NCT05684900||reservoir oxygen mask|During the sedation procedure in the endoscopy unit, patients who used a reservoir oxygen mask will be examined. No premedication will be applied to patients admitted to the endoscopy unit. As a standard, intravenous vascular access will be established with a 22 gauge intraket on the back of the left hand in all patients, 6-10 lt/minute oxygen therapy will be started with a reservoir mask, and peripheral oxygen saturation, end-tidal CO2, blood pressure arterial values will be monitored and recorded. These parameters will be monitored and recorded every five minutes during the procedure. In addition, the sedative agents applied to the patients and their doses will be recorded. After the procedure, all patients will be taken to the recovery room, where they will be observed until the modified aldrete score is 9 or higher. The recovery times of the patients, nausea, vomiting and similar symptoms will be followed and recorded.
33240417|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
33240418|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
33240419|NCT05169320||Case group|Patients with symptomatic persistent AF episodes after previous failure of ≥2 pulmonary vein isolation procedures
33240420|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
33071864|NCT05665738|Experimental|HDR brachytherapy|Participants will receive the same radiotherapy technique, methods, and delivery will as standard of care 3 hours apart instead of receiving the radiotherapy on separate days.
33240421|NCT05167526|Experimental|Part 1: Single ascending dose of ASP8731|This is composed of 10 sequential cohorts (cohorts 1.1 to 1.10). Participants (6 for each cohort) will receive a single dose of ASP8731 under fasting conditions.
33240422|NCT05167526|Placebo Comparator|Part 1: Single ascending dose of placebo|Participants (2 for each cohort, cohorts 1.1 to 1.10) will receive a single dose of matching placebo under fasting conditions.
33240423|NCT05167526|Experimental|Part 1: Single dose of ASP8731 (Food effect)|Participants (8) will receive a single dose of ASP8731 with a high-fat meal.
33240424|NCT05167526|Experimental|Part 2: Multiple ascending dose of ASP8731|"This is composed of 6 sequential cohorts (cohorts 2.1 to 2.6). Participants (9 for each cohort) will receive ASP8731 for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
33071869|NCT05662332|Experimental|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
32758111|NCT02214407|Experimental|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
33071870|NCT05662332|Active Comparator|Insulin Glargine|Participants will receive insulin glargine SC once daily.
33071874|NCT05656313|Experimental|Narrow reference beamformer|
33071875|NCT05656313|Active Comparator|Novel beamformer approach|
33071876|NCT05655507|Experimental|Part A: SAGE-217|Adolescents (12-17 years of age) will be enrolled to receive SAGE-217 orally in the morning on Day 1 and in the evening on Days 2 to 14. Participants with a body weight of greater than or equal to 54 kilograms (kg) will receive 50 mg, and participants with a body weight less than 54 kg will receive 40 mg.
33071877|NCT05655507|Experimental|Part B: SAGE-217|Children (7-11 years of age) will be enrolled to receive SAGE-217 orally in the morning on Day 1 and in the evening on Days 2 to 14. The dose to be administered will be determined after review of safety and PK data in Part A.
32758112|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
32758113|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
32758114|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
32758115|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
33240425|NCT05167526|Placebo Comparator|Part 2: Multiple Ascending Dose of Placebo|Participants (3 for each cohort) will receive matching placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.6.
33240426|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
33240427|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
33240428|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
33240429|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
33240430|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
33240431|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
33240432|NCT05163782|Experimental|People with foot drop|People with left or right foot drop
32758116|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
32744522|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
32744523|NCT04875039|Active Comparator|Perineural dexamethasone|Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
32744524|NCT04875039|Experimental|Perineural dexamethasone plus dexmedetomidine|Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
32744525|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
32744526|NCT03227939|Active Comparator|LSG Group|LSG only
32744527|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
32744528|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
32744529|NCT04874883|Active Comparator|Intervention Group|You will receive 6 grams of the symbiotic (association of fructooligosaccharides, prebiotics, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) either enterally or twice a day.
32744530|NCT04874883|Placebo Comparator|Control Group|Will receive 6 grams of the maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in two sachets times a day
32744531|NCT04874727||Study Population|The five or six individual patients enrolled are the members of the sole group, the study population. These individuals all have been diagnosed with obstructive sleep apnea and have take a Cone-beam CT scan with and without the new bite technique.
32744532|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
32744533|NCT04874649|Experimental|Balloon-blowing breathing|"Start by measuring the vital capacity using a balloon to determine. The width of the balloon diameter for each blow and used the value to make a balloon size control device to give to the sample group and parents to use it for home training.~Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks"
32744534|NCT04874649|Experimental|Sustained maximal inspiration breathing|Participants sitting in a chair, back and head close to the wall. Inhale through their nose fully and hold for 3 seconds for a full breath, then slowly exhale through their mouth and hold for 1 second of exhalation, counted as 1 breathing cycle.Do this 3 times in a row for 1 set. Practice each time doing a total of 3 sets, with 1 minute rest between sets. Participants were required to complete breathing exercise 5 times per week for 8 weeks.
33071885|NCT05652205|Experimental|Part 1 Linaclotide|Participants will receive linaclotide for 12 weeks.
33071886|NCT05652205|Experimental|Part 1 Placebo|Participants will receive placebo for 12 weeks.
33071887|NCT05652205|Experimental|Part 2 Linaclotide|Participants who completed study intervention in Part 1 of this study or the Phase 2 Study LIN-MD-67 will receive 24 weeks of linaclotide exposure.
32758117|NCT01899989|Experimental|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
32758118|NCT01899989|Experimental|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
32758119|NCT01634711|Experimental|The L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
32758120|NCT01478555|Experimental|Dose 1 of Bromfenac in DuraSite|
32758121|NCT01478555|Experimental|Dose 2 of Bromfenac in DuraSite|
32758122|NCT01478555|Experimental|Dose 3 of Bromfenac in DuraSite|
32758123|NCT01478555|Active Comparator|DuraSite|
32758124|NCT01478555|Active Comparator|Vehicle|
32758125|NCT02261285|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
32758126|NCT02261285|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
32758127|NCT02261285|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
32758128|NCT01422083|No Intervention|Control group|This group of athletes do not perform a 6-week stretching program.
32758129|NCT01422083|Experimental|Home stretching program|These athletes take on a home stretching program (sleeper's stretch).
32758130|NCT05130125||fresh embryo|fresh embryo transfer after ovarian hyperstimulation
32758131|NCT05130125||frozen embryo|frozen embryo transfer after ovarian hyperstimulation
32758132|NCT01288625|Experimental|Cytofos group A|Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
32758133|NCT01288625|Experimental|Cytofos group B|Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
32758134|NCT01288625|Active Comparator|Control group|Radiation treatment 1.8-2.0 Gy/day × 30-35 times
32758135|NCT05041829|Experimental|lowsodium|Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.
32758136|NCT05041829|Active Comparator|highsodium|Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.
32758137|NCT05129813||Buprenorphine MOUD in FQHC|Participants receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center. Recovery Guide counseling is provided weekly.
32758138|NCT05129813||Telemedicine Provision of Buprenorphine MOUD in a community site|Participants receiving buprenorphine treatment provided by telemedicine from a hub clinic and Recovery Guide counseling in a church or faith-based community organization. Recovery Guide counseling is provided weekly.
32758139|NCT04968899|Experimental|Experimental group|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21
32758140|NCT04968899|Active Comparator|Control|IVIg (1g/kg D1-D2) plus prednisone (1 mg/kg/day x 21 days (3 weeks))
32758141|NCT05129579|Experimental|MBRSEG|The group in which the mindfulness-based stress reduction intervention will be implemented.
32758142|NCT05129579|Other|control group|The group to which mindfulness-based stress reduction intervention will not be applied
32758143|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
32758144|NCT05129267|Active Comparator|Group B|Scaling and Root Debridement + iPRF
32758145|NCT05129267|Active Comparator|Group C|Scaling and Root Debridement + iPRF +Vitamin C
32758146|NCT05129267|No Intervention|Group A|Scaling and Root Debridement
32758147|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
32758148|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
32758149|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
32758150|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
32758151|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
32758152|NCT05676073|Experimental|SHEN26 dose 1|SHEN26 capsule 200mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
32758153|NCT05676073|Experimental|SHEN26 dose 2|SHEN26 capsule 400mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
32758154|NCT05676073|Placebo Comparator|SHEN26 placebo|Placebo matching the SHEN26 capsule. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
32758155|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
33071888|NCT05650879|Experimental|Phase 1a Monotherapy Dose Escalation|ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
33071889|NCT05650879|Experimental|Phase 1a Monotherapy Dose Exploration|ELVN-002 will be administered either once or twice daily. A maximum of 30 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
33071890|NCT05650879|Experimental|Phase 1b Monotherapy Dose Expansion|"ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels.~ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason."
33397217|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
32758156|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
32758157|NCT01352845|Experimental|rLP2086|
32758158|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
32758159|NCT05675995|Experimental|Immediate|Receives 6 sessions of qigong first.
32758160|NCT05675995|Other|Waitlist Control|Receives 6 sessions of qigong after the immediate group
32758161|NCT05675917|Experimental|MacuTest website|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
32758162|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
32758163|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
32758164|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
32758165|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
32758166|NCT05675839|Experimental|Experimental|"Before the intervention, students filled the Nursing Professional Pride Scale. Nursing students watched a documentary and a movie about nursing profession. After the intervention, students filled the Nursing Professional Pride Scale."
32758167|NCT05675839|No Intervention|Control|"First of all, Control group filled the Nursing Professional Pride Scale. The control group have no intervention. They filled the scale again, after 2 week."
32758168|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
32758169|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
32758170|NCT04587193|Experimental|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
32758171|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
32758172|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
32758173|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
32758174|NCT05235451|Experimental|Intervention group|The 2 HAI intervention reading groups will receive visits from a registered canine team during children's small group reading sessions twice a week over 12 weeks.
32758175|NCT05235451|No Intervention|Control group|The 2 control reading groups will receive care as usual and offered a 1-time visit from the dog at the end of the study (after T3 completed).
32758176|NCT05461495|Experimental|Treatment Group|"Treatment group will receive 6 counseling sessions, participate in local support group and on-line chat group, and receive ad hoc' counseling."
32758177|NCT05461495|No Intervention|Control Group|Control group will participate in on-line chat group, and call the counselor for resource information and support as needed.
32758178|NCT05675683||Asymptomatic Brain Metastases|Patients with Asymptomatic Brain Metastases
32758179|NCT05675683||Symptomatic Brain Metastases|Patient with Symptomatic Brain Metastases
33397218|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
32758180|NCT04691999|Experimental|Intermittent Fasting|All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.
32758181|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
32758182|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
32758183|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
32758184|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
32758185|NCT04440085|Active Comparator|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
32758186|NCT04440085|Placebo Comparator|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
32758187|NCT05129033|Active Comparator|anti-fungal agent plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Itraconazole is given orally 200mg bid for 8 months and 100mg bid for another 8 months
32758188|NCT05129033|Active Comparator|anti-IgE mAb plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Omalizumab is given by subcutaneous injection of 600mg q4w for at least 6 months
32758189|NCT05675605|Experimental|Phase 1 Dose Escalation|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
32758190|NCT05675605|Experimental|Phase 2 Dose Expansion|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
32758191|NCT04780399|Experimental|Yangxue Qingnao pills high dose group|Yangxue Qingnao pills 7.5 g per time,2 times per day.
32758192|NCT04780399|Experimental|Yangxue Qingnao pills lower dose group|Yangxue Qingnao pills 5 g per time,2 times per day, and placebo identified to Yangxue Qingnao pills 2.5 g per time, 2 times per day.
32758193|NCT04780399|Placebo Comparator|Placebo group|Placebo identified to Yangxue Qingnao pills 7.5 g per time,2 times per day
32758194|NCT05404997|Experimental|Shockwave Therapy|Common Treatment : Conventional physical therapy (lumbar stretching exercises and core strengthening exercises) Group A: Shockwave Therapy
32758195|NCT05404997|Experimental|Maitland's Lumbar Mobilizations|Common Treatment: Conventional Physical Therapy (lumbar stretching exercises and core strengthening exercises) Group B: Maitland's Lumbar mobilizations
32758196|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
32758197|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
32758198|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
32758199|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
32758200|NCT03114007|No Intervention|Control|Treatment as usual
32758201|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
32758202|NCT04588025|Active Comparator|Healthy Volunteers|
32758203|NCT04588025|Active Comparator|Pancreatic Cancer Participants|
32758204|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
32758205|NCT05128721|Active Comparator|NRC-VACC-101 vaccine 3 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
32758206|NCT05128721|Active Comparator|NRC-VACC-101 vaccine 6 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
32758207|NCT05128721|Placebo Comparator|Control arm|Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
32758208|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
32758209|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
32758210|NCT05128565||Females under 40|females from 18 years old to 40 years old
32758211|NCT05128565||Males under 40|males from 18 years old to 40 years old
32758212|NCT05128565||Females above 40|females older than 40 years old
32758213|NCT05128565||Males above 40|males older than 40 years old
32758214|NCT04546399|Experimental|Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2, and MTX IT, cytarabine IT, or ITT IT on days 1,15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start this cycle 1), MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2, and leucovorin calcium IV or PO q6h for 2 doses on days 2, 16 and 37 of cycle 1 and q6h for 2 doses on days 16 and 37 of cycle 2.
32758215|NCT04546399|Experimental|Group 1, Arm A (dexamethasone, blinatumomab, MTX)|ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
32758216|NCT04546399|Experimental|Group 1, Arm B (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
32758217|NCT04546399|Experimental|Group 2, Arm C (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
32758218|NCT04546399|Experimental|Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
32758219|NCT04546399|Experimental|Group 3, Arm E (dexamethasone, blinatumomab, MTX)|See Outline section
32758220|NCT04546399|Experimental|Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)|See Outline section
32758221|NCT04496609|Experimental|Stimulation-automated rehabilitation/automated rehabilitation|"Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~Washout 30 days~Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
32758222|NCT04496609|Experimental|Automated rehabilitation/Stimulation-automated rehabilitation|"Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~Washout 30 days~Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
32758223|NCT05128175|Experimental|25 mg /100 mg treatment A group|Treatment A: carbidopa/levodopa (25 mg /100 mg)
32758224|NCT05128175|Experimental|25 mg /150 mg treatment B group|Treatment B: carbidopa/levodopa (25 mg/150mg)
32758225|NCT05128175|Experimental|25 mg /150 mg treatment C group|Treatment C: carbidopa/levodopa (25 mg /150 mg)
32758226|NCT05128175|Experimental|25 mg /150 mg treatment D group|Treatment D: carbidopa/levodopa (25 mg /150 mg)
32758227|NCT05128175|Placebo Comparator|25 mg /100 mg placebo group|Treatment E(Reference): Carbidopa and Levodopa tablets (a generic version of Sinemet® IR) 25 mg/100 mg
32758228|NCT05341427|Experimental|burn wound receiving electromagnetic therapy|There will be only one intervention group. The duration of the study will be 6 weeks divided to 18 sessions (three sessions per week). Sixty patients (male and female) will be recruited from the burn units of Cairo university hospitals
32758229|NCT04184453|Experimental|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
32758230|NCT05127707|No Intervention|No exposure control group|This group was not exposed to any message frame.
32758231|NCT05127707|Experimental|Words Matter - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
32758232|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
32758233|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
32758234|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
32742358|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
33398756|NCT05194176|Experimental|Virtual Reality|The intervention group will be instructed to perform the respiratory exercises using the VR-intervention 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. The respiratory exercises in VR are comparable to the exercises in usual care but performed in a virtual environment and without incentive spirometry. The physical exercises consist of several games through which patients are challenged to reach out to objects while engaging their core. Patients are allowed to continue these exercises or play some relaxation games for up to 30 minutes per session in total. The exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
32758235|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
32758236|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
32758237|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
32758238|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
32758239|NCT05018975|Experimental|Tazemetostat|Subjects will receive tazemetostat 800mg BID for 15 days in addition to standard of care treatment. The duration of the interventional part of the study will last 15 days.
32758240|NCT05018975|No Intervention|Control|Subjects receiving standard of care treatment
32758241|NCT03741881||Patients with haemophilia|Patients with haemophilia A or B and with or without inhibitors
32758242|NCT05217667|Experimental|ARO-ANG3 Dose 1|ARO-ANG3 Dose Level 1 subcutaneous (SC)
32758243|NCT05217667|Experimental|ARO-ANG3 Dose 2|ARO-ANG3 Dose Level 2 SC
32758244|NCT05216029|Experimental|Group I (oncology dashboard)|Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.
32758245|NCT05216029|Experimental|Group II (standard of care)|Patients receive standard of care.
32758246|NCT04680455|Experimental|Resistance Training + (RT+)|"Participants in RT+ group will be asked to exercise three times per week and perform four basic RT exercises in a circuit manner for 12 weeks while supervised via an online platform such as Skype or TEAM.~The first four weeks of sessions will be fully supervised. Participants will be eased into the program using a three-week progressive start, completing 120 minutes of exercise in week one, 150 minutes in week two, 180 minutes in week three and week four. Participants will be supervised 3X/week for the first four weeks, then 2X/week for the next four weeks and 1X/week for the remaining four weeks.~At each session, a participant will perform the four prescribed exercises (i.e., squats, tricep dips, lunges, and push-ups) for 45 seconds each, then switch immediately (15 seconds) to the next exercise followed by one-minute of rest at the end of each circuit. The circuit will repeat until the session is complete."
32758247|NCT04680455|No Intervention|Standard care|Participants allocated to the control standard care group will receive free access to an exercise platform (V-Shred-Ripped-in-90-days) for the same period of time (12 weeks) to become more active. It will be recommended that they do a minimum of 150 minutes of moderate to vigorous aerobic activities and two resistance training sessions using the platform.
32758248|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
32758249|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
32758250|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
32758251|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.~The clinical team will view reports detailing their patients' symptom burden~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
32758252|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer~Patients will report their symptoms to their clinicians as they usually would~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
32758253|NCT02433509|Experimental|HUCB monocyte cells w/ Mannitol in acute ischemic stroke|"The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
32758254|NCT05205109|Experimental|ATG-037+Pembrolizumab|Part I: Dose Escalation Phase of ATG-037 Monotherapy PartII: Dose Escalation Phase and Dose Expansion Phase of ATG-037 in Upfront Combination with Pembrolizumab
32758255|NCT02207465|Experimental|Subtrial 1-Arm A (Dose Level 1 of Abraxane)|Determine if it is safe or not (via occurrence of dose limiting toxicities) for patients to receive both Abraxane and radiation therapy.
32758256|NCT02207465|Experimental|Subtrial 1-Arm B (Dose Level 2 of Abraxane: 3+4 enrollment)|Determine the maximum dose of Abraxane that is allowable and safe for patients receiving both Abraxane and radiation therapy.
32758257|NCT02207465|Experimental|Subtrial 2- Abraxane 125mg; Borderline get 55cGY, unresectable get 57.5cGY until next escalation|
32758258|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
33398757|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
32742359|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
32742360|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
32742361|NCT03938129||Group 1|Pregnant women and their baby
32742362|NCT03851237|Experimental|Cohort 1a: Any Treatment Group|"Early-staged localized pancreatic cancer~Standard of care diagnostic biopsy~64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study~Receive treatment with upfront surgery such as whipple procedure"
32742363|NCT03851237|Experimental|Cohort 1b: Standard of Care Treatment Chemotherapy|"Borderline resectable, locally advanced/metastatic or recurrent pancreatic cancer~Standard of care diagnostic biopsy (if available tissue to be used for CCR2 expression)~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~Treatment with any standard of care (SOC) chemotherapy~Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with positive scan at baseline/early therapy at the time of standard of care follow-up imaging appointment --Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with negative scan at baseline/early therapy at time recurrence is diagnosed by any standard imaging modality"
32742364|NCT03851237|Experimental|Cohort 2: CCR2-Targeted Therapy|"Locally advanced or borderline resectable pancreatic cancer~Biopsy per therapeutic protocol (if available tissue to be used for CCR2 expression)~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~2 cycles of CCR2-targeted therapy~Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy"
32742365|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
32742366|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
32742367|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
32742368|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
32742369|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
32742370|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
32742371|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
32742372|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
32742373|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
32742374|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
32742375|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
32742376|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
32742377|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
32742378|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
32742379|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
32742380|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
32742381|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
32742382|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
32742383|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
33398758|NCT05183412|Active Comparator|Ultrasound-guided regional nerve block and hand surgery without VR glasses|Patients will not receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
32742384|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
33071891|NCT05650879|Experimental|Phase 1a Combination Dose Escalation with T-DXd|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
33071892|NCT05650879|Experimental|Phase 1a Combination Dose Escalation with T-DM1|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
33398759|NCT05183412|Experimental|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Patients will receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
33398760|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
32758259|NCT05168579|Experimental|Deliberate practice|Trainees will be paired with a coach, and will meet, once per week for thirty minutes, over a three week period. During the training session, coach-trainee dyads will play a puzzle video game, and will discuss contextual cues that should inform triage decisions. At the completion of the three weeks, trainees will complete a semi-structured, debriefing interview and a virtual simulation to assess triage performance.
32758260|NCT05168579|No Intervention|Control|Participants in the control group will complete a virtual simulation.
32758261|NCT05404607|Experimental|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive the fascial distortion method followed by the neuromuscular inhibition technique for trigger points. After this, neural mobilization will be given as stander treatment.
32758262|NCT05404607|Active Comparator|Fascial distortion method|Fascial distortion will be applied to 27 participants where the tip of the thumb worms its way through the peripheral tissue until it rests on the distortion. Force is focused directly on the most painful spot until the provider feels like a button-slipping-into-a-buttonhole. After this, neural mobilization will be given as a stander treatment.
32758263|NCT05404451|Experimental|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
32758264|NCT05404451|Experimental|Mckenzie Exercises|Using Mckenzie Exercises
32758265|NCT05127239|Experimental|smartphone application with education|participants were provides 3 times lifestyle modification education and using smartphone app program
32758266|NCT05127239|Experimental|smartphone application|participants were only provided smartphone app program
32758267|NCT05127239|No Intervention|waiting list|No intervention was provided, but researchers explained the results of OSA screening for participants after every examination
32758268|NCT05127083|Experimental|toluidine blue-mediated photodynamic therapy|The number of points will be variable according to the lesion size. Patients will be treated with localized PBM with a diode laser with continuous wave +toluidine blue
32758269|NCT05127083|Active Comparator|photodynamic therapy + gel|The number of points will be variable according to the lesion size.atients will be treated with localized PBM with a diode laser with continuous wave
32758270|NCT05127083|Sham Comparator|acetonide triamcinolone 0.2%+sham|Patients will be treated with acetonide triamcinolone 0.2% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the gel in the entire lesion three times/days.The number of points will be variable according to the lesion size.
32758271|NCT04566497|Experimental|Experimental|no systematic stress testing during follow-up
32758272|NCT04566497|Active Comparator|Active Comparator|systematic annual stress testing during follow-up
32758273|NCT05134337|Experimental|Part 1 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
32758274|NCT05134337|Experimental|Part 1 Period 2 (Itraconazole + LOXO-305)|Itraconazole + LOXO-305 co-administered orally
32758275|NCT05134337|Experimental|Part 2 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
32758276|NCT05134337|Experimental|Part 2 Period 2 (Rifampin + LOXO-305)|Rifampin + LOXO-305 co-administered orally
32758277|NCT04535219|Experimental|Group A|Participants will have vascular function assessed following total sleep deprivation
32758278|NCT04535219|No Intervention|Group B|Participants will have vascular function assessed following a full night of sleep
32758279|NCT04535219|Experimental|Group C|Participants will have vascular function assessed following total sleep deprivation preceded by exercise
32758280|NCT04535219|No Intervention|Group D|Participants will have vascular function assessed following a full night of sleep
32758281|NCT05134181|Active Comparator|Group MTP|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.
32758282|NCT05134181|Active Comparator|- Group TMC|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of Triamcinolone acetonide with a uniform dose of 2 mL of 2% lidocaine hydrochloride .
32758283|NCT05323175|Active Comparator|ESP Nerve Block for Renal colic|On top of receiving standard of care, At T8 nerve level, with ultrasound guidance to bathe the nerve
32758284|NCT05323175|Active Comparator|Standard of care|Whatever medications the clinician normally treats renal colic with
32758285|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
32758286|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
32758287|NCT05134103|Experimental|Mindbeacon TAI-CBT for Depression group|Participants randomized to this condition will receive immediate Therapist-Guided Internet-CBT for Depression for 12 weeks.
32758288|NCT05134103|Other|Waitlist Control Group|Participants randomized to this condition will remain on the waitlist for 12 weeks before crossing over and receiving Therapist-Guided Internet-CBT for Depression for 12 weeks.
32758289|NCT05126849|Experimental|Haploidentical allogeneic hematopoietic stem cell transplantation.|"Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~Stem cell source Bone Marrow~GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
32758290|NCT05279963|Active Comparator|medication group|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of participants will be recorded on diary cards.
32758291|NCT05279963|Experimental|EA group|Patients allocated to this group will receive treatment with electroacupuncture. The location of acupoints will be determined based on the National Standard Nomenclature and Location of Acupoints. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks.
33071893|NCT05649852|Other|Chemotherapy|Adjuvant chemotherapy treatment
33071894|NCT05643209|Other|consecutive patients|20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia/ ventricular fibrillation substrate
33071895|NCT05643079||metal/Bio-Tenodesis group|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Metal-/Bio-Tenodesis screw (Arthrex, Naples, Florida, USA)~Metal-Screw:~ø 6,7 mm length: 40-60 mm~Bio-Tenodesis screw:~ø 4,00 mm, length: 10 mm ø 4,75 mm, length: 15 mm ø 5,50 mm, length: 15 mm"
32758292|NCT05279963|Sham Comparator|SA group|Patients allocated to this group will receive acupuncture in non-meridian and non-acupoints regions. The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the EA group.
32758293|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
32758294|NCT05133947||CIPN patient|Patient with CIPN symptom
32758295|NCT05133947||Healthy subject|Healthy subject
32758296|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
32758297|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
32758298|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
32758299|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
32758300|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
32758301|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
32758302|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
32758303|NCT05274659|Active Comparator|KJ103 dose group 1|KJ103 single dose
32758304|NCT05274659|Active Comparator|KJ103 dose group 2|KJ103 single dose
32758305|NCT05274659|Active Comparator|KJ103 dose group 3|KJ103 single dose
32758306|NCT05274659|Active Comparator|KJ103 dose group 4|KJ103 single dose
32758307|NCT05274659|Active Comparator|KJ103 dose group 5|KJ103 single dose
32758308|NCT05274659|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
32758309|NCT04310995|Experimental|Nicorandil|
32758310|NCT04310995|Experimental|Diltiazem|
32758311|NCT04310995|Experimental|Isosorbide Mononitrate|
32758312|NCT05158543|Active Comparator|Control Group|the control group will receive conventional intervention for upper and lower limb motor function & balance.
32758313|NCT05158543|Experimental|moderate intensity group|this group will get task-oriented training with moderate intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
32758314|NCT05158543|Experimental|high intensity group|this group will get task-oriented training with high intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
32758315|NCT05235659|Experimental|Condition 1|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
32758316|NCT05235659|Experimental|Condition 2|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
32758317|NCT05235659|Experimental|Condition 3|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
32758318|NCT05235659|Experimental|Condition 4|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
32758319|NCT05235659|Experimental|Condition 5|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
32758320|NCT05235659|Experimental|Condition 6|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
32758321|NCT05235659|Experimental|Condition 7|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
32758322|NCT05235659|Experimental|Condition 8|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
32758323|NCT05235659|Experimental|Condition 9|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
32758324|NCT05235659|Experimental|Condition 10|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
32758325|NCT05235659|Experimental|Condition 11|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
32758326|NCT05235659|Experimental|Condition 12|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
32758327|NCT05235659|Experimental|Condition 13|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
32758328|NCT05235659|Experimental|Condition 14|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
32758329|NCT05235659|Experimental|Condition 15|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
32758330|NCT05235659|Experimental|Condition 16|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
32758331|NCT05146297|Active Comparator|Patient Participants|Patients with invasive breast, prostate or liver cancer, who face a treatment decision
32758332|NCT05146297|Active Comparator|Physician Participants|Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists & hepatologists
32901515|NCT01483807|Experimental|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
33071896|NCT05643079||human, allogeneic cortical bone screw (Shark Screw®)|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Shark Screw® (Surgebright-GmbH, 4040 Lichtenberg, Austria)~Versions used:~Shark Screw® diver ø: 5,0 mm, length: 35 mm Shark Screw® diver ø: 5,0 mm, length: 45 mm Shark Screw® tendon ø: 5,0 mm, length: 15 mm"
33240433|NCT05565833|Experimental|SHUTi OASIS|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) for Older Adult Sufferers of Insomnia and Sleeplessness (OASIS) online intervention optimized for older adults. CBTi will be delivered online and metered out over time with each new core becoming available one week after the completion of the previous core. The intervention period is 9 weeks. They will spend 1-2 hours during the intervention period completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions on how to improve their sleep.
33071899|NCT05635110|Experimental|Part A|Participants will receive a single dose of VX-548 on Day 1 and a single dose of omeprazole once daily (qd) on Days 10 through Day 12. On Day 13, participants will receive omeprazole followed by VX-548 under fasted conditions.
33071900|NCT05635110|Experimental|Part B|Participants will receive a single dose of VX-548 on Day 1 followed by rifampin qd on Days 10 through Day 27. On Day 19, participants will be co-administered rifampin and VX-548 under fasted conditions.
33071901|NCT05634577|Experimental|Lead-in Phase|Participants will first have a Lead-in Phase in which participants receive only mitotane. This will be 4 weeks long in most participants. Participants will then begin receiving pembrolizumab.
33071902|NCT05634369|Experimental|Treatment|"Part 1: Enrollment of 5 patients in each cohort (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and non-rhabdomyosarcoma).~Part 2: Enrollment of 2 cohorts in 2 stages for a total of 40 patients."
33071903|NCT05633628|Experimental|Periodic CGM- Intervention group|The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-management care of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning.
33071904|NCT05633628|No Intervention|Self-monitoring of blood glucose, SMBG and usual care - Control Group|The participants in the control group perform SMBG testing as usual including fasting, pre- or post-prandial measurements. They also receive usual care which comprises consultation with physician diabetes specialist or diabetes nurse depending on individual health care needs.
33071905|NCT05633407|Experimental|Efgartigimod|Receive efgartigimod IV 10mg/kg during weekly infusions during a treatment period of 24 weeks
33071906|NCT05633407|Placebo Comparator|Placebo|Receive a matching placebo during weekly infusions during a treatment period of 24 weeks
33071907|NCT05632471|Experimental|web-based training for parents in the intervention group|"Parents were given I know digital games training with 10 videos from the website."
33071908|NCT05632471|Other|parents in the control group|No intervention was applied to the parents in the control group.
33071911|NCT05630716|Experimental|Non-Invasive Cardiac Output Monitor (NICOM)|adult inpatients with sepsis associated with acute hypotension and/or evidence of septic shock
32742385|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
32742386|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
32742387|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
32742388|NCT03259217|Experimental|stem cell product|stem cell transplant
32742389|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
32742390|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
32742391|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
32742392|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
32742393|NCT03258983||The Diet, Cancer and Health cohort|
32742394|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
32742395|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
32742396|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
32742397|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
32742398|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
32742399|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
32758333|NCT05133869|Experimental|Baseline + intervention + follow up|All participants receive the same treatment in the same order. First there is a phase without treatment, the baseline phase. The length of this phase is randomly assigned to each participant. Then all participants follow a 42 day intervention, in which direct training and metacognitive training is combined. Afterwards they have a follow-up period, this length of this period is counterbalanced with the length of the baseline period so that the full study adds up to 150 days.
33071912|NCT05626491|Experimental|Active SAVIR Alpha Synch Mobile device (SASm)|Patients will receive active treatment with the device every other day over 8 weeks.
33071913|NCT05626491|Sham Comparator|Sham SAVIR Alpha Synch Mobile device (SASm)|Patients will receive sham treatment (no active stimulation) with the device every other day over 8 weeks.
32758334|NCT05231863||Observational Group|Patients receive TKIs after T-DM1 progression.
32758335|NCT05126693|Experimental|Intervention group|The children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s). As part of the standard treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of ankle foot orthoses following BoNT injections. The follow-up period for the current study is 8-10 weeks. During this intensive physical therapy period post-BoNT, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (that is scheduled prior to the BoNT injections).
32758336|NCT05126693|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic management during a period of 8-10 weeks.
32758337|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
32758338|NCT03164317|Other|Control|No trained NCC and electronic decision support system
32758339|NCT04300855|Experimental|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
32758340|NCT04300855|Placebo Comparator|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
32758341|NCT05133791|Active Comparator|0.5 mg|Annexin A5-CW800, 0.5 mg, 1 dose
32758342|NCT05133791|Active Comparator|1.0 mg|Annexin A5-CW800, 1.0 mg, 1 dose
32758343|NCT05133791|Active Comparator|2.0 mg|Annexin A5-CW800, 2.0 mg, 1 dose
32758344|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
32758345|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
32758346|NCT05133635|Active Comparator|Pulse methylprednisolone|250 mg methylprednisolone for 3 days
32758347|NCT05133635|Active Comparator|Tocilizumab|Tocilizumab 400-800 mg for one time
32758348|NCT05133557|Placebo Comparator|Placebo|Half the participants receiving placebo gum (2 gram; 1 gram xylitol) first,
32758349|NCT05133557|Experimental|BBE gum|Half receiving first the BBE gum (2 gram; 1 gram xylitol and 100 mg BBE) that were identical in size, shape, color and flavor. After 1 week the groups cross-over and chewed the other gum.
32758350|NCT04094675|Experimental|Treatment arm|"There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).~Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.~Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy~Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.~Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps."
33071914|NCT05626296||Phlegm-heat syndrome in ischemic stroke|"Phlegm-heat syndrome: the score of Phlegm-dampness syndrome ≥10 with the score of Internal fire syndrome ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
32758351|NCT04253587|Experimental|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
32758352|NCT04253587|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
33071915|NCT05626296||Non-phlegm-heat syndrome in ischemic stroke|"Non-phlegm-heat syndrome: the score of Phlegm-dampness syndrome <10 with the score of Internal fire syndrome <10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
33071916|NCT05626296||Healthy subjects|
33071917|NCT05624450|Experimental|Tozorakimab|Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 1176) will receive a single dose of tozorakimab.
33071918|NCT05624450|Placebo Comparator|Placebo|Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 1176) will receive matching placebo.
33071919|NCT05622201|Experimental|Rituximab|Rituximab 1000 mg, infusion
32758353|NCT04253587|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
33071920|NCT05622201|Placebo Comparator|Placebo|Saline infusion
33071921|NCT05621564||early breast cancer|no requirements for therapy
33071922|NCT05621564||advanced breast cancer|no requirements for therapy
33240434|NCT05565833|Placebo Comparator|Patient Education Website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
33071924|NCT05619952|Experimental|White Button Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams white button mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
33071925|NCT05619952|Experimental|Shiitake Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams Shiitake mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
33071926|NCT05619952|No Intervention|Control|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) and a Wegmans Food Market Brand Big Hawaiian bun.
33071927|NCT05617183|Experimental|CT-P47 Auto-injector|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
33071928|NCT05617183|Active Comparator|CT-P47 Pre-filled Syringe|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33240435|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
33240436|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
33071929|NCT05617027|Experimental|actual tDCS|"The actual transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of actual tDCS , 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for the whole 20-minute session."
33071930|NCT05617027|Placebo Comparator|placebo tDCS|"The placebo transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of placebo tDCS, 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for 30 secondes, and then will strop for the rest of the 20-minute session (programming of the equipment)."
33240437|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
33240438|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
33240439|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
33240440|NCT00918554|Experimental|Methotrexate|
33240441|NCT00918554|Placebo Comparator|Placebo|
33240442|NCT05684822|Experimental|The experimental group received acupuncture treatment|The experimental group received acupuncture treatment (Taichong, Shenmen, Neiguan points) twice a week, total three weeks, plus sleep hygiene guidance
33240443|NCT05684822|Sham Comparator|The control group received subcutaneous sham acupuncture|The control group received subcutaneous acupuncture (non-therapeutic acupuncture points) twice a week, total three weeks and given sleep Health guidance.
33240444|NCT05533775|Experimental|Arm A|Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days).
33240445|NCT05533775|Experimental|Arm B|Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).
33240446|NCT04104113|Experimental|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
33240447|NCT04104113|Placebo Comparator|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
33240448|NCT00713648|Experimental|rFXIII|
33240449|NCT04102085||Mothers under 30|no intervention will be administered
32742400|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
32742401|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
32742402|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
33240450|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
33071932|NCT05616260|Experimental|Acetazolamide, then Placebo, then optional open-label CPAP-therapy|"Subjects will start with a 2-week ACETAZOLAMIDE regimen~Day 1-13: Acetazolamide 500mg at bedtime at home~Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week PLACEBO regimen:~Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
33240451|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
33240452|NCT00768053|Experimental|1|
33240453|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
33240454|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
33240455|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
33240456|NCT04083482|Experimental|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
33240457|NCT04083716|Experimental|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
33240458|NCT04083716|Experimental|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
33240459|NCT04083716|Experimental|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
33240460|NCT00756951|Placebo Comparator|1|Placebo
33240461|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
33240462|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
33240463|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
33240464|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
33240465|NCT00916253|No Intervention|H|Healthy Volunteers
32758354|NCT04253587|Active Comparator|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
32758355|NCT04253587|Experimental|Labyrinth Tablet|Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
32758356|NCT04253587|Experimental|Labyrinth VR wireless|Multi-session cognitive intervention with head-mounted display virtual reality computer game using wireless, narrower filed technology to presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
32758357|NCT05133167|Experimental|GROUP A|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage.
32758358|NCT05133167|Experimental|GROUP B|In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage.
32758359|NCT05118529|Active Comparator|Sitting in bed|Sitting in bed with 60 degrees elevated back-rest during 20 minutes
33240466|NCT05150210|Experimental|SP Surgical System|Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.
33398761|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
33398762|NCT05417412|Experimental|STEP-UP (brief behavioral therapy)|Intervention arm of open trial
33398763|NCT03173326|Experimental|Subarachnoid block|
33398764|NCT03173326|Active Comparator|General anesthesia|
32758360|NCT05118529|Experimental|Sitting in chair|Sitting in chair during 20 minutes
32758361|NCT04219969|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
32758362|NCT05132933|Experimental|Shunt-group|Test of three different levels of positive end-expiratory pressure (PEEP)
32758363|NCT05132777|Experimental|JMT101 in combination with Osimertinib|
32758364|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
32758365|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
32758366|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
32758367|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
32758368|NCT05126615|Experimental|Patients with auriculotherapy|Mastectomy operated patient then, auriculotherapy
32758369|NCT05126615|Placebo Comparator|Patient with placebo|Mastectomy operated patient then, they received placebo
32758370|NCT03953417|Experimental|Bilateral accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
32758371|NCT05126069||Standalone Xen45|consecutive patients from June 2012 - July 2017 who received standalone Xen45®
32758372|NCT05126069||Standalone Trabeculectomy|consecutive patients from June 2012 - July 2017 who received standalone trabeculectomy
32758373|NCT05422027|Experimental|Selinexor-VRd（XVRd）|bortezomib SC 1.3mg/sqm on day 1,4,8,11, lenalidomide oral 25 mg on day 1-14, and dexamethasone 40mg on day 1,8,15 in a 21-day cycle; Selinexor dose escalation: 40，60mg respectively on day 1,8,15 for 21-days cycles. Then Selinexor will be given at the recommended dose level on phase II.
32758374|NCT05132621||Participants diagnosed with SLE|
32758375|NCT05132621||Participants diagnosed with IgA nephropathy|
32758376|NCT05132621||Healthy Participants|
32758377|NCT05080777|Experimental|Tele-Savvy Group|The participants will be enrolled into the Tele-Savvy group. Software analytics monitor caregivers' use of asynchronous material each week.
32758378|NCT05080777|Active Comparator|Attention Control Group|The participants will be enrolled in the Caregiving During Crisis program. Software analytics monitor caregivers' use of asynchronous material each week.
32758379|NCT05132309||Chronic pancreatitis without pancreatic external insufficiency|
33240467|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
32758380|NCT05132309||Chronic pancreatitis with mild pancreatic external insufficiency|
32758381|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency|
32758382|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency who underwent pancreatic surger|
32758383|NCT05072821|Experimental|Botulinum Toxin type A injection side|The Botulinum Toxin type A will be injected into the dermal layer before skin closure in keloid excision surgery. The concentration of Botulinum Toxin type A is 100 units in 2 mL and dosage is 8 units/cm. The maximal dose is 100 units for each participant.
32758384|NCT05072821|Placebo Comparator|0.9% saline injection side|The 0.9% saline will be injected into the dermal layer before skin closure in keloid excision surgery. The dosage is 0.16 mL/cm.
32758385|NCT05125991|Experimental|Prepectoral reconstruction|Prepectoral breast reconstruction with Braxon dermal matrix
32758386|NCT05125991|Active Comparator|Submuscular reconstruction|Submuscolar breast reconstruction
32758387|NCT04149691|Experimental|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
32758388|NCT03164005||Group 1|subjects without metabolic diseases
32758389|NCT03164005||Group 2|subjects with metabolic diseases
32758390|NCT04140487|Experimental|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32758391|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32758392|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
32758393|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
32758394|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
32758395|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
32758396|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
32758397|NCT05404061|No Intervention|Gut hormone secretion study|"This will be a retrospective study of participants who have undergone bariatric surgery. On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~Body weight and bioelectrical impedance analysis~Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~Metabolomic and Metagenomic Assessment"
32758398|NCT05404061|Placebo Comparator|Gut hormone sensitivity study|This will be a single blinded study with participants attending three visits. Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones. Occasionally some volunteers are more sensitive to the gut hormone infusion and the doses needs to be titrated down. The doses used will be established doses of the gut hormones infused previously and which have been shown to be safe and tolerated, and to reduce appetite (In house data).
33240468|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
33240469|NCT00757029|Other|open label|
33240470|NCT05147324|Experimental|"MyPlan - Individualized Eating Pattern"|All youth enrolled in the study will receive the 6-month MyPlan behavioral intervention. Youth will be paired with a dietitian to individualize the eating plan and receive support in setting and refining action plans focused on adhering to the five eating behavior goals that define the eating plan.
33398765|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
32742403|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
32742404|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
32758399|NCT05404061|No Intervention|Prospective assessment of gut hormone response pre and post-surgery|"This will be a prospective study assessing the gut hormone response pre and post bariatric surgery.~On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~Body weight and bioelectrical impedance analysis~Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~Metabolomic and Metagenomic Assessment"
32758400|NCT05051293||male cirrhotic with hypotension|Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension.
32758401|NCT05051293||male cirrhotic without hypotension|The concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis.
32758402|NCT05199233|Experimental|Muse S™ Headband system for post-Covid Syndrome|Subjects will utilize the Muse S™ Headband system at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
32758403|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
32758404|NCT05123495||Device Briefing Tool Implementation|Surgical departments which receive training on use of the Device Briefing Tool
32758405|NCT05123495||Comparator|Surgical departments that do not receive training on use of the Device Briefing Tool
32758406|NCT04139317|Experimental|Combination arm|Capmatinib 400 mg twice a day Pembrolizumab 200mg every 3 weeks
32758407|NCT04139317|Active Comparator|monotherapy|Pembrolizumab 200mg every 3 weeks
32758408|NCT05120219|Experimental|food effect cohort A|
32758409|NCT05120219|Experimental|food effect cohort B|
32758410|NCT05120219|Experimental|multiple dose pharmacokinetics|
32758412|NCT05119517|Experimental|Osteopathic manipulative medicine pedal pump|
32758413|NCT05119049|Experimental|Aquatic exercise plan in the pool.|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department.
32758414|NCT05119049|Active Comparator|Exercises in a rehabilitation room.|The control group did the same exercises and sessions in one of the rooms in the rehabilitation department.
32758415|NCT05046613||Pregnant women with migraine exposed to Rimegepant|
32758416|NCT05046613||Pregnant women with migraine not exposed to Rimegepant|
32758417|NCT05113355|Experimental|Chidamide + Sintilimab|Experimental arm will be treated by chidamide combined with sintilimab for up to 24 months.
32758418|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
32758419|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
32758420|NCT05054543|Experimental|Uproleselan|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
32758421|NCT05054543|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
32758422|NCT05044507|Sham Comparator|BQ 2.0 sham stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
32758423|NCT05044507|Active Comparator|BQ 2.0 active stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
32758424|NCT05125757|Experimental|intervention group|The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
33240471|NCT04101929|Experimental|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
32758425|NCT05125757|Active Comparator|control group|The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities
32758426|NCT04439617||sepsis patient|
32758427|NCT04439617||Sepsis-free patient|
32758428|NCT04186637|Experimental|Dose escalation and expansion|ALPN-202
32758429|NCT05030545|Experimental|Eplerenone Treatment|Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months
33240472|NCT04083638||Group 1|Control group
33240473|NCT04083638||Group 2|Feeding will not stop during the transfusion
32758432|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
32758433|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
32758434|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
32758435|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
32758436|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
32758437|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
32758438|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
33240474|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
32758439|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
32758440|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
32758441|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
32758442|NCT04960475||A/D group|Chronic ankle sprain patient with anxity or depression
32758443|NCT04960475||Control group|Chronic ankle sprain patient with no emotional issues
32758444|NCT03163615|Experimental|Tibet Rhodiola Capsule|
32758445|NCT03163615|Placebo Comparator|Placebo oral capsule|
32758446|NCT01712633||Volunteers|Healthy Volunteers
32758447|NCT04439695|Experimental|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
32758448|NCT04439695|Experimental|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
32758449|NCT04439695|Experimental|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
32758450|NCT04439695|Placebo Comparator|Placebo|Subjects in this group will receive placebo
32758451|NCT04799795||healthy subjects|Age-matched healthy participants will be recruited via flyers at public education facilities and online advertisement. Participants need to be healthy and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
32758452|NCT04799795||patients with absence epilepsy|Apart from the diagnosis of epilepsy, patients need to be of good health and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
32758453|NCT05675215||Normal subjects with suspicion of psychopathological disorder|Adults over 18 years old who are fluent in French (oral and written). Participant with neurological or organic mental disorder (not induced by substances) including dementia, organic amnesic syndrome, delirium, other mental, personality or behavioural disorders due to brain damage, dysfunction or to physical disease.
32758454|NCT03114787|Other|Patient receiving respiratory physiotherapy|
32758455|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
32758456|NCT05125445|Experimental|Crestally positioned implants|
32758457|NCT05125445|Active Comparator|Subcrestally positioned implants|
32758458|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
32758459|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
32758460|NCT00754949|Experimental|1|
32758461|NCT00754949|Active Comparator|2|
32758462|NCT00754949|Active Comparator|3|
32758463|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
32758464|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
32758465|NCT05058911|Experimental|Internet-delivered exposure-based cognitive behavior therapy (Exp-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
32758466|NCT05058911|Active Comparator|Internet-delivered traditional cognitive behavior therapy (T-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
32758467|NCT05022121|Experimental|Supported Biopsychosocial Self-Management (SBSM)|Supported Biopsychosocial Self-Management (SBSM)
32758468|NCT05022121|Active Comparator|Medical Care|Medical Care
32758469|NCT00406445||carrier LFS family members|96 carrier LFS family members
32758470|NCT00406445||non-carrier LFS family members or normal|60 non-carrier LFS family members or normal
32758471|NCT00406445||non-carrier mitochondrial disorder family members or normal controls|20 non-carrier mitochondrial disorder family members or normal controls
32758472|NCT00406445||normal controls for MR spectroscopy study|30 normal controls for MR spectroscopy study
33240475|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
32758473|NCT00406445||subjects with mitochondrial disorders|20 subjects with mitochondrial disorders
32758474|NCT05011045||Observational (neurocognitive assessment, questionnaires, MRI)|Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.
32758475|NCT05675137|Experimental|Mobile-based multidomain intervention|
32758476|NCT05675137|Active Comparator|paper-based intervention group|
32758477|NCT04620707|Experimental|RGS based therapy|
32758478|NCT04620707|Active Comparator|Treatment as usual|
32758479|NCT05674981|Experimental|Probiotic group|Subjects received two probiotic sachets per day
32758480|NCT05674981|Placebo Comparator|Placebo group|Subjects received two placebo sachets per day
32758481|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
32758482|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
32758483|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
32758484|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
32758485|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
32758486|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
32758487|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
32758488|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
32758489|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
32758490|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
32758491|NCT04589117|Experimental|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to cultivate compassion & forgiveness~Week 3: Writing to nurture positive emotions~Week 4: Writing to invite insight, perspective, & growth"
32758492|NCT04439929|Experimental|Adalimumab-TUR01|
32758493|NCT04439929|Active Comparator|Adalimumab-EU|
32758494|NCT05131841|Active Comparator|One-week group|Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer
32758495|NCT05131841|Experimental|Three-week group|Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
32758496|NCT03163849|Placebo Comparator|control group|oral tablets
32758497|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
32758498|NCT04520867||Qualifying Subjects|Patients seen in the EGMDC for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro
32758499|NCT05674903|Experimental|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets involved in pain perception Intervention: Device: Diadem prototype
32758500|NCT05674903|Sham Comparator|Sham stimulation|Low-intensity transcranial focused ultrasound stimulation using unfocused wave Intervention: Device: Diadem prototype
32758501|NCT04509947|Experimental|Ad26.COV2.S: High Dose|Participants (healthy adults aged greater than or equal to (>=) 20 to less than or equal to (<=) 55 years [cohort 1] and >= 65 years [cohort 2]) will receive intramuscular (IM) injection of Ad26.COV2.S at high dose, as 2-dose schedule on Day 1 and Day 57.
32758502|NCT04509947|Experimental|Ad26.COV2.S: Low Dose|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of Ad26.COV2.S at low dose, as 2-dose schedule on Day 1 and Day 57.
32758503|NCT04509947|Placebo Comparator|Placebo|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of placebo on Day 1 and Day 57.
32758504|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
32758505|NCT05131763|Experimental|KD-025|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
32758506|NCT05131685|Experimental|Non-sedated Immobilization|Immobilization in a cast without reduction
32758507|NCT05131685|Active Comparator|Formal Reduction|closed reduction under conscious sedation followed by casting
32758508|NCT04160039|Experimental|Cycle Ergometry + Standard PT/OT|The study intervention will include the same standard PT/OT procedures as the control arm (Standard PT/OT alone) with the addition of the Motomed Letto 2 lower extremity cycle ergometry sessions.
32758509|NCT04160039|No Intervention|Standard PT/OT alone|"The control arm will involve standard PT/OT procedures that patients in the transplant intensive care unit receive routinely, with frequency to be determined by a physical and/or occupational therapist, and may include but are not limited to the following:~Passive and active upper and lower extremity strength exercises, while in bed, sitting upright, and standing; stretching various muscle groups while supine in bed, sitting upright, and standing; in-bed mobility training including rolling and boosting; transfer training with and without an assistive device; gait training with and without an assistive device; balance exercises while sitting and standing; activities of daily living while sitting and standing; cognitive retraining"
32758510|NCT05676853|Experimental|Pegzilarginase|Weekly subcutaneous dosing of pegzilarginase plus individualized disease management for 52 weeks
32758511|NCT05178641|Experimental|Ninjamas Pyjama Pant, Then Participant's Overnight Current Standard of Care|For the first 3 weeks participants use Ninjamas Pyjama Pants, then for the next 3 weeks they switch to the Overnight Current Standard of Care.
32758512|NCT05178641|Experimental|Participant's Overnight Current Standard of Care, Then Ninjamas Pyjama Pant|For the first 3 weeks participants use their Overnight Current Standard of Care, then for the next 3 weeks they switch to Ninjamas Pyjama Pants.
32758513|NCT04501913||Observational (remote telemonitoring)|Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
32758514|NCT03163537||Kidney transplantation, postmortal, day|
32758515|NCT03163537||Kidney transplantation, postmortal, night|
32758516|NCT03163537||Kidney transplantation, living donor|
32758517|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
32758518|NCT05131295|Experimental|Dapsone|Besides the standard of care, those assigned to the dapsone group received orally 100mg (2.5 ml) of dapsone suspension daily, from the admission day until the 15th-day post-ictus.
32758519|NCT05131295|Placebo Comparator|Placebo|Besides the standard of care, those assigned to the placebo group received orally 2.5 ml of aluminum hydroxide gel daily, from the admission day until the 15th-day post-ictus.
32758520|NCT04028167|Experimental|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
32758521|NCT05130905|Experimental|Supplementation with RiteStart|Once enrolled into the study, participants were instructed to take RiteStart Supplement daily for 12 weeks.
32758522|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
32758523|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
32758524|NCT05130749||Primary Healthcare Nurses|Nurses allocated in primary Healthcare settings
32758525|NCT05130749||Non Nurses Primary Healthcare|Other Healthcare providers allocated in primary health care settings
32758526|NCT05130203|Experimental|MouvMat Exergaming|Older adults in the intervention group will participate in a 6-week, 3 times per week, 45 minutes per session exercise program involving use of the MouvMat. Each resident from the intervention group will engage with the exergame supervised by a qualified and trained RA. Each intervention session will involve groups of 4-5 participants, with participants taking turns. An RA blinded to participants' condition will collect the outcome data.
32758527|NCT05130203|Other|Standard Recreational Programming|A control group will meet on a similar schedule as the MouvMat group for standard recreational programming conducted by onsite recreational therapists. The same RA from the experimental group will collect outcome measurements from control group participants.
32758528|NCT05124587||Patients with confirmed COVID-19 in the hospital setting|
32758529|NCT01374217|Experimental|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
32758530|NCT04494815|Experimental|Treatment A|Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.
32758531|NCT04494815|Active Comparator|Treatment B|Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.
32758532|NCT04494815|Placebo Comparator|Treatment C|Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule.
32758533|NCT05676619|Other|Single cohort of healthy volunteers|Single cohort of healthy volunteers
32758534|NCT04494737|Active Comparator|Active Comparator: Program 1|Mindfulness Training program is based on mindfulness based stress reduction developed by Kabat-Zinn, but the didactic content is focused on attention training and meta-awareness. Participants will be taught formal open awareness meditation, gentle yoga, and a 'body scan' meditation during weekly classes. Importantly, there is no retreat day included in the program.
32758535|NCT04494737|Active Comparator|Active Comparator: Program 2|Stress Management Education (SME) is designed to control for non-specific factors such as contact hours, stress education, and gentle exercise. Stress education classes will consist of teaching about the effects of stress on health and optimizing one's personal health care, understanding positive coping behavior, optimizing nutrition to decrease stress, and exercise and strength training.
32758536|NCT04993261|Experimental|Diagnostic (dual energy CT scan)|Patients undergo one dual energy CT scan during scheduled CT scan.
32758537|NCT04494503|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 400mg, 600mg, 800mg dose levels respectively, every 28 days as a cycle.
32758538|NCT04494503|Experimental|APG-2575+Rituximab in Relapse/Refractory CLL/SLL|"Stage 1:APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg. Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with rituximab. Every 28 days as a cycle."
32758539|NCT04494503|Experimental|APG-2575+ibrutinib in Relapse/Refractory CLL/SLL|"Stage 1: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg.Ibrutinib 420mg orally once daily during C1D8-28 and following cycles. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with ibrutinib. Every 28 days as a cycle."
32758540|NCT05676541|Experimental|Intervention|
32758541|NCT05676541|No Intervention|Control|
32758542|NCT04012567|Experimental|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
32758543|NCT04012567|Active Comparator|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
32758544|NCT03688763|Other|Digital CBTi administered|Participants will receive 6 sessions of digitally administered CBTi using the Sleepio platform over the course of 12 weeks. Each session lasts on average 30-60 minutes, and is tailored to participant's progress and problems. During the treatment phase, between sessions, participants complete the Consensus Sleep Diary to track their progress.
32758545|NCT05051501|Experimental|Probiotics C2P/Placebo|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
32758546|NCT05051501|Experimental|Placebo/Probiotics C2P|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
32758547|NCT03906253|Experimental|Factionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
32758548|NCT03906253|Experimental|Factionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
32758549|NCT03278249|Experimental|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
32758550|NCT04941937|Experimental|Arm I: Selinexor+Thalidomide+Dexamethasone|Arm I is given XTd regimen Selinexor 60mg/d QW, Thalidomide 100mg/d, d1-28 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
33240476|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
32758551|NCT04941937|Experimental|Arm II: Selinexor+Lenalidomide+Dexamethasone|Arm II is given XRd regimen Selinexor 60mg/d QW, Lenalidomide 25mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
32758552|NCT04941937|Experimental|Arm III: Selinexor+Pomalidomide+Dexamethasone|Arm III is given XPd regimen Selinexor 60mg/d QW, Pomalidomide 4mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
32758553|NCT02959619|Experimental|Ensartinib|Escalating dose of ensartinib was orally given once er day
32758554|NCT04935931|Experimental|Pilot|Pre/post fMRI
32758555|NCT05124431|Experimental|Anlotinib hydrochloride+Everolimus|"Anlotinib hydrochloride: ,12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).~Everolimus:5mg po. qd in 21-day cycle"
32758556|NCT04435613|Other|protective mechanical ventilation|Ten patients with moderate to severe ARDS were subjected to a nearly ultra-protective ventilation strategy generating a reduction in minute ventilation (Tidal volume of 5 ml/kg of predicted body weight together with a 20% reduction in respiratory rate). In addition to end-inspiratory pause, prolongation was set to avoid hypercapnia. Protocol phases: Baseline conditions: Tidal volume of 7 ml/kg. I: Tidal volume of 6 ml/kg. II: Tidal volume of 5 ml/kg. III: Increase end-inspiratory pause until achieving an I:E ratio equal to 1. IV: Respiratory rate reduction until 20% of the basal condition keeping constant I:E ratio equal to 1
32758557|NCT04877275|Experimental|Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone|Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
32758558|NCT04877275|Experimental|Arm II: Selinexor+Cyclophosphamide+Dexamethasone|Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
32758559|NCT04955249|Experimental|Dexmedetomidine group|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
32758560|NCT04955249|Placebo Comparator|Control group|Patients in this group receive routine patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
32758561|NCT04876417|Active Comparator|tDCS and fatigue|This group will receive the active form of tDCS.
32758562|NCT04876417|Sham Comparator|Sham and fatigue|This group will receive the sham form of tDCS.
32758563|NCT05097443|Experimental|Orelabrutinib+R+chemotherapy|Orelabrutinib+R-CHOP;Orelabrutinib+R-DA-EPOCH;Orelabrutinib+R-HD MTX；Orelabrutinib+R+other regimens
32758564|NCT05676463|Experimental|Treatment (MRI-guided IMRT, ADT)|Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.
32758565|NCT02285621|Experimental|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
32758566|NCT02285621|Active Comparator|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
32758567|NCT00197873|Active Comparator|Lactophilus|Lactophilus supplementation
32758568|NCT00197873|Placebo Comparator|Placebo|Placebo is administered during chemotherapy.
32758572|NCT04899323||Cohort|Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
32758573|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
32758574|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
32758575|NCT04854317||Patients undergoing adjustable or nonadjustable fluid-filled intragastric balloon placement|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
32758576|NCT04854317||Patients undergoing Endoscopic Sleeve Gastroplasty|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
32758577|NCT04854317||Patients undergoing Endoluminal Vertical Gastroplasty|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
32758578|NCT04854317||Patients undergoing Primary Obesity Surgical Endolumenal 2|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
32758579|NCT04440553|Active Comparator|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
32758580|NCT04440553|Experimental|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
33240477|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
33071933|NCT05616260|Experimental|Placebo, then Acetazolamide, then optional open-label CPAP-therapy|"Subjects will start with a 2-week PLACEBO regimen~Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week ACETAZOLAMIDE regimen:~Day 1-13: Acetazolamide 500mg at bedtime at home~Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
33071934|NCT05615753|Experimental|Acupuncture group|Participants will receive 2 acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each acupuncture treatment will take 30 minutes.
33071935|NCT05615753|No Intervention|Usual care group|Participants will continue to receive their usual care.
33071936|NCT05614895|Experimental|Cohort A|Bacteremia participants without pneumonia and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
32758581|NCT05057897|Other|Cohort 1 - immunocompromised participants with solid organ transplant|Previously unvaccinated immunocompromised participants with solid organ transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
32758582|NCT05057897|Other|Cohort 2 - immunocompromised participants with hematopoietic stem cell transplant|Previously unvaccinated immunocompromised participants with hematopoietic stem cell transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
32758583|NCT05057897|Other|Cohort 3 - immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy|Previously unvaccinated immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
32758584|NCT05057897|Other|Cohort 4 - immunocompromised participants with chronic inflammatory disorders|Previously unvaccinated immunocompromised participants with chronic inflammatory disorders will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
32758585|NCT05057897|Other|Cohort 5 - immunocompromised participants with primary immunodeficiency|Previously unvaccinated immunocompromised participants with primary immunodeficiency will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
32758586|NCT05057897|Other|Cohort 6 - immunocompetent participants|Previously unvaccinated immunocompetent participants will receive a primary vaccination series with 2 IM doses of AZD1222 separated by 4 weeks, followed by a booster dose of AZD1222 administered 6 months after the first dose. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1. Participants will receive a third dose booster 6 months after dose 1 and will continue to be followed to the end of the study.
32758587|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
32758588|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
32758589|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
32758590|NCT05403983|Experimental|In person movement intervention|In person yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
32758591|NCT05403983|Active Comparator|Online yoga movement intervention|Pre-recorded video of yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
32758592|NCT05403983|Active Comparator|Education|Education control group using a recently published postpartum physical activity guidebook through the Sport Information Resource Center
32758593|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
32758594|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
32758595|NCT04918511|Experimental|Dose cohort 1|In dose cohort 1, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level of 30 mg/m2 (dose based on body surface area)
32758596|NCT04918511|Experimental|Dose cohort 2|In dose cohort 2, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 1
32758597|NCT04918511|Experimental|Dose cohort 3|In dose cohort 3, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 2
32758598|NCT04918511|Experimental|Dose cohort 4|In dose cohort 4, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 3
33071937|NCT05614895|Experimental|Cohort B|Participants with hospital-acquired bacterial pneumonia (HABP) and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
33071938|NCT05614895|Experimental|Cohort C|Participants with mechanical ventilation at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
33397219|NCT05711628|Active Comparator|Arm A (chemotherapy regimen, HDT-ASCT)|"SALVAGE THERAPY: Patients receive 1 of 3 chemotherapy regimens as clinically indicated: 1) ifosfamide IV, carboplatin IV, and etoposide IV; 2) gemcitabine IV, vinorelbine IV, and pegylated liposomal doxorubicin IV; or 3) brentuximab vedotin IV and bendamustine IV. Patients then undergo a PET/CT scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
32758599|NCT04918511|Experimental|Dose cohort 5|In dose cohort 5, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 4
32758600|NCT04918511|Experimental|Dose cohort 6|In dose cohort 6, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 5
32758601|NCT04918511|Experimental|Dose cohort 7|In dose cohort 7, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 6
32758602|NCT03162757|Experimental|Subclavian vein access|
32758603|NCT03162757|Experimental|Internal jugular vein access|
32758604|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
32758605|NCT03162991|No Intervention|12-Week Control Period|
32758606|NCT05056415|Active Comparator|Treatment as Usual (TAU)|"In the involved municipalities, TAU mainly consists of short-term efforts, such as Occupational Therapist (OT) prescribing technical aids, often initiated by the housing staff (HS). Daily support provided by HS varies, depending on the approach and commitment of individual staff and the norms that prevail in different housing units, as well as variations between municipalities. Co-planning on long-term rehabilitation efforts does not exist or is weak, and collaboration between OT and HS is, as described by staff from both parties, difficult to achieve.~After a control-period of 6 month, house facilities within the TAU-group will also be offered ELR."
32758607|NCT05056415|Experimental|Everyday Life Rehabilitation (ELR) plus TAU|"ELR is a model for long-term, outreach, and personalized rehabilitation for persons with SPD living in sheltered or supported housing facilities, in close collaboration between resident, OT, and HS.~ELR includes personcentred, motivational-, recovery- and activity-based methods, built on certain process steps. The focus is to promote personal recovery, while targeting meaningful daily activities, through person-driven goals, negotiated expectations, exploration and activity-training in real-life situations, and a maintenance phase. ELR includes a web-based educational package, and devices for reflective collaborative learning.~ELR consists of a weekly session with an OT, followed by regular collaboration with HS, who support the resident on a daily basis, in line with guidance given by the OT and input shared from the HS. The intervention period will last for 6 months.~Prior to the intervention, OT, HS, and HM will partake in web-based training, with associated manuals, and tools."
32758608|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
32758609|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
32758610|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
32758611|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 1|Challenge dose of 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758612|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 2|Challenge dose of 5 x 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758613|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 3|Challenge dose of 10^4 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758614|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 4|Challenge dose of 5 x 10^4 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758615|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 5|Challenge dose of 10^5 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758616|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 6|Challenge dose of 5 x 10^5 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758617|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 7|Challenge dose of 10^6 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
32758618|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
32758619|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
32758620|NCT04886453|Experimental|Intervention|
32758621|NCT04886453|Active Comparator|Controle|
32758622|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
32758623|NCT05136521|Experimental|300 mg trazodone hydrochloride (HCl) prolonged-release tablets (new polymer)|Subjects treated with 300 mg trazodone HCl prolonged-release tablets containing a new polymer,
32758624|NCT05136521|Active Comparator|Trittico®, 300 mg trazodone HCl prolonged-release tablets (Contramid®)|Subjects treated with Trittico®, 300 mg trazodone HCl prolonged-release tablets containing Contramid®
32758625|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
32758626|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
32758627|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
32758628|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
32758629|NCT05136209|Experimental|PCCC procedure without A-vit|Procedure/Surgery: PCCC procedure without A-vit ACCC + I / A + PCCC or ACCC + I / A +PCCC + IOL
32758630|NCT05136209|Active Comparator|PCCC+A-Vit procedure|Procedure/Surgery: PCCC+A-Vit procedure ACCC + I / A + PCCC + A-vit or ACCC + I / A +PCCC + IOL + A-vit
32758631|NCT05135897||Patients, depression, ECT|Patients in major depressive episode undergoing ECT
32758632|NCT05135897||Patients, depression, TMS|Patients in major depressive episode undergoing TMS
32758633|NCT05135897||Healthy|Healthy controls who do not receive ECT nor TMS but otherwise the same assessments.
32758634|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
32758635|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
32758636|NCT04937465||Elderly|Elderly (> 70 yrs) eligible for a short term rehabilitation
32758637|NCT04725877|Experimental|VIR-1111|
32758638|NCT04725877|Placebo Comparator|Placebo|
32758639|NCT02388529|Experimental|Low dose|
32758640|NCT02388529|Experimental|Intermediate dose|
32758641|NCT02388529|Experimental|High dose|
32758642|NCT02388529|Placebo Comparator|Placebo|
33071941|NCT05611034|Experimental|IVLP in single lung|
33240478|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
33240479|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
32758643|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
32758644|NCT05343013|Experimental|TAS-102|TAS-102 should be taken by mouth 2 times a day, within 1 hour after your morning and evening meals (about 12 hours apart).
33397220|NCT05711628|Experimental|Arm B (chemotherapy regimens+pembrolizumab, HD-ASCT)|"SALVAGE THERAPY: Patients receive pembrolizumab IV plus 1 of 3 chemotherapy regimens specified in Arm A as clinically indicated. Patients then undergo a PET scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
33397221|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
33397222|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
33397223|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
33397224|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
33397225|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
33071942|NCT05610189|Experimental|Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg|"Participants will receive tavapadon 1x15 mg tablet, orally, once daily (QD) from Day 15 to 21.~Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 22 to 28."
33397226|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
32758645|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
32758646|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
32758647|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
32758648|NCT05231239|Active Comparator|Active tDCS|tDCS will be applied for 20 min with 2 mA
33071943|NCT05610189|Experimental|Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg|"Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 15 to 21.~Participants will receive tavapadon 1x15 mg tablet, orally, QD from Day 22 to 28."
33240480|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
33240481|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
33397227|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
33397228|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
33240482|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
33240483|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
33240484|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
33240485|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
33240486|NCT05685134|Experimental|Ablation|Radiofrequency catheter ablation of the abnormal - prolonged and fragmented - electrophysiologic substrate of Brugada syndrome
33071948|NCT05601544|Experimental|Sphere TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.
33071949|NCT05601544|Experimental|Sphere CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.
33071950|NCT05601544|Experimental|Multifocal TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.
33071951|NCT05601544|Experimental|Multifocal CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.
33071952|NCT05601544|Experimental|Toric TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.
33071953|NCT05601544|Experimental|Toric CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.
33240487|NCT05685134|Sham Comparator|Control|Femoral venous punctions, catheter insertion, programmed electrical stimulation and electroanatomic mapping, with a similar duration to the ablation procedure
33240488|NCT00757185|Experimental|1|GNRH antagonist alone
33240489|NCT00757185|Experimental|2|GnRH with Testosterone
33071957|NCT05595434|Experimental|active stress group|20 healthy subjects will be subject to the active condition of a standardized stress protocol
33397229|NCT01361763|Experimental|Dabigatran|
32758649|NCT05231239|Placebo Comparator|Placebo tDCS|tDCS will be applied for only 20 sec, monatge will be left on the head for 20 min
33071958|NCT05595434|Placebo Comparator|placebo stress group|20 healthy subjects will be subject to the placebo condition of a standardized stress protocol.
33071959|NCT05592509|Active Comparator|Supplement|This arm will take dietary supplement
33071960|NCT05592509|Placebo Comparator|Placebo|Placebo will take the placebo
33071961|NCT05592275|Experimental|LY3540378 Dose 1|Participants will receive LY3540378 subcutaneously (SC).
33071962|NCT05592275|Experimental|LY3540378 Dose 2|Participants will receive LY3540378 SC.
33397230|NCT01361763|Active Comparator|Antiplatelets|
33397231|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
33397232|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
32758650|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
33071963|NCT05592275|Experimental|LY3540378 Dose 3|Participants will receive LY3540378 SC.
33071964|NCT05592275|Placebo Comparator|Placebo|Participants will be given placebo SC.
32758651|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
32758652|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Participants complete 2 questionnaires about anxiety and stress levels."
32758653|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Participants complete 2 questionnaires about anxiety and stress levels."
32758654|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
32758655|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
32758656|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
32758657|NCT04776005||Patients with malignant disease undergoing chemotherapy|Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
32758658|NCT04776005||Patients with malignant disease undergoing chemotherapy + immunotherapy|Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
32758659|NCT04776005||Patients with malignant disease undergoing immunotherapy|Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
32758660|NCT04776005||Patients with malignant disease treated with targeted therapies|Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
32758661|NCT04776005||Patients with malignant disease undergoing radiotherapy|Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
32758662|NCT03737695||Observational (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
32758663|NCT04909853|Experimental|PF-07321332|PF 07321332/ritonavir
32758664|NCT05135819|Experimental|Intergenerational educational program|
32758665|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
32758666|NCT05135741|Experimental|pressure bio feedback|Experimental
32758667|NCT05135741|Experimental|deep cervical exercises|comparative
32758668|NCT04645979||Participants|Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
33071965|NCT05591092||Observational (I-123, planar imaging, SPECT/CT scan)|Patients receive iodine-123 PO and then undergo planar imaging and a SPECT/CT scan on study.
33240490|NCT04084808|Experimental|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
32758669|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
32758670|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
32758671|NCT05135507|Experimental|An interactive stress reduction and behavioral parent training program|This feasibility evaluation will track and analyze individual program usage and examine changes in parents' psychological flexibility, parents' stress, parenting self-efficacy, parents' mindfulness and child behavior in a within subject pretest and posttest design with 50 parents of children who have DD
33071967|NCT05588141|Experimental|1|Escalation/de-escalation dose levels of zotiraciclib given in 28 day cycles
33071968|NCT05588141|Experimental|2|Estimated RP2D of zotiraciclib given in 28 day cycles
33397233|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
32742405|NCT03913637|Experimental|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
33397234|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
33397235|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
32758672|NCT05135429|Experimental|Bathing group|Newborn bathing will be done by the same nurse for each newborn in the study group. Since the evening hours are thought to be calmer for the baby bath, the hours between 22:00-24:00 will be chosen. Each newborn will be disinfected with only water beforehand and showered in the sinks used to wash the baby in the clinic. Bath time will be limited to two minutes. Newborns will be dried and dressed immediately after bathing. Monitor probes for monitor follow-ups and blood pressure cuffs will be connected to prevent extra touching during measurements.
32758673|NCT05135429|No Intervention|control group|Newborns in the control group will not receive any intervention. However, body temperature, pulse, respiration, systolic and diastolic blood pressure, saturation, oxygen demand and N-PASS scores will be evaluated and recorded in accordance with the measurement intervals of the newborns in the study group.
32758674|NCT05403905|Experimental|non-surgical treatment|The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that the ACL may grow back after 6 weeks of strict bracing.
32758675|NCT05403905|Active Comparator|surgical treatment|"The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that after 6 weeks of strict brace immobilization, the ACL may grow back without surgery. However, the choice was still made for immediate ACL reconstruction.~This group of patients underwent anterior cruciate ligament reconstruction surgery in the Third Hospital of Peking University."
32758676|NCT04893707|Experimental|CM310|"adults and teenagers (12 ~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 ~ 18 years) with weight ≥30 kg and <60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
32758677|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
32758678|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
32758679|NCT04637555|Experimental|LCZ696 (sacubitril/valsartan)|Following start of treatment, patients will receive LCZ696. Possible doses are level 1, 2, and 3 (50, 100 and 200 mg twice daily respectively)
32758680|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
32758681|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
32758682|NCT05134961||Patients undergoing resection of primary duodenal cancer|Tumors comprised histologically confirmed adenocarcinomas in the duodenum excluding adenocarcinoma of the ampulla of Vater and adenocarcinomas with gastric and pancreato-biliary morphology and immunohistochemistry.
32758683|NCT05668117||Control|Historical patient data from other published studies in the literature
32758684|NCT05668117||Study participants|Adult patients with non-pathologic distal femur and femoral shaft fractures treated with the Depuy Synthes Advanced Retrograde femoral nail who had at least 6 months of follow up.
32758685|NCT04587635|Active Comparator|PHGG fiber|PHGG Fiber
32758686|NCT04587635|Placebo Comparator|Placebo Maltodextrin|Maltodextrin
32758687|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
32758688|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
32758689|NCT04556357|Active Comparator|Control group|Phenylephrine infusion simultaneous with subarachnoid block
32758690|NCT04556357|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with subarachnoid block
32758691|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
32758692|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
32758693|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
32758694|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
32758695|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
32758696|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
32758697|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
32758698|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
32758699|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
32758700|NCT05134883|Experimental|Propioceptive neuromuscular facilitation (PNF)|This group will undergo a PNF stretching on the hamstring muscles.
32758701|NCT05134883|Active Comparator|self myo-fascial release (SMR)|This group will undergo a SMR stretching on the hamstring muscles.
33240491|NCT04084808|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
33397236|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
32758704|NCT05134805|Other|BHA group|Patients will undergo Bipolar hemiarthroplasty operation
32758705|NCT05134805|Other|PFN group|Patients will undergo cehphalo-medullary fixation (Proximal femoral nail)
32758706|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~The patient is subjected to tympanometry test on the specific ear,~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
33397237|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
33397238|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
33397239|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
33397240|NCT02420782|Other|Placebo and pilocarpine|Part 3
33071969|NCT05588141|Experimental|3|One RP2D dose of zotiraciclib given on the day prior to brain tumor biopsy or resection, a continuation of treatment with estimated RP2D of zotiraciclib given in 28 days cycles following the recovery of the surgery
33071970|NCT05588128||Cohort 1|Participants with biochemically recurrent prostate cancer
33071971|NCT05586269|Experimental|Meal Kits|Families receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration), followed by a washout period of 2 weeks, and then receive a newsletter and food pantry referral.
33240492|NCT04084808|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
33240493|NCT04084808|Active Comparator|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
32758707|NCT04180709|Experimental|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis CPFT or Early Intervention in Psychosis Services NSFT care team.
32758708|NCT04180709|No Intervention|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with their Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
32758709|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
32758710|NCT04553939|Experimental|Toripalimab in Combination With Gemcitabine Therapy|
32758711|NCT02790853|Experimental|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
32758712|NCT04500977|Experimental|Training community health promotion leaderss|Community women are trained in leadership and community-based health promotion skills
32758713|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
32758714|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
32758715|NCT05306041|Experimental|Inavolisib|Inavolisib for 6 cycles (18 weeks) Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
32758716|NCT05306041|Other|without Inavolisib|Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
32758717|NCT04874831|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
32758718|NCT04454879|Experimental|standard roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
32758719|NCT04454879|Experimental|lower roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.
32758720|NCT04859153||Sprinter|All sex of healthy adolescent athletes of the athletics sprint
32758721|NCT04859153||Non-sprinter|All sex of healthy adolescent athletes of other kinds of sports
32758722|NCT05122169|Experimental|chlorhexidine|Pre-vaginal delivery skip prep using chlorhexidine-alcohol
32758723|NCT05122169|Active Comparator|Povidone-iodine|Pre-vaginal delivery skip prep using Povidone-iodine
32758724|NCT04387955|Other|Acrovid|Cohort
32758725|NCT04359329|Experimental|Active|Estradiol Patch
32758726|NCT04359329|No Intervention|Control|No intervention
32758727|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
32758728|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
32758729|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
32758730|NCT04794023|Experimental|Intervention_Corneal Ablation|
32758731|NCT04256681|Experimental|patients affected by hereditary spastic paraplegia|40 subjects affected by genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show a dominant or recessive familiarity with exclusive involvement of the pyramidal system.
32758732|NCT04256681|Active Comparator|healthy subjects|40 healthy subjects will also be recruited to whom the questionnaire will be submitted to assess the variability of the score within a healthy population.
33071972|NCT05586269|Experimental|Delayed Meal Kits|Families receive a newsletter and food pantry referral. After 8 weeks, families will receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration).
33071973|NCT05583227|Experimental|Tezepelumab Low Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
33071974|NCT05583227|Experimental|Tezepelumab High Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
33071975|NCT05583227|Placebo Comparator|Placebo|Placebo subcutaneous injections, in accessorised pre-filled syringes
32758733|NCT05403749|Experimental|IBI302 dose 2 group|Drug: Aflibercept 8mg/eye;Intraocular injection
32758734|NCT05403749|Active Comparator|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
32758735|NCT05403749|Experimental|IBI302 dose 1 group|Drug: Aflibercept 6.4mg/eye;Intraocular injection
32758736|NCT04766645||Covid patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with covid symptoms
32758737|NCT05301725||PPI group|PPI regimen
32758738|NCT05301725||P-CAB group|P-CAB regimen
32758739|NCT05301647||Active Group|
32758740|NCT05301647||Control Group|
32758744|NCT04745351|Experimental|Remdesivir (RDV)|Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.
32758745|NCT04745351|Placebo Comparator|Placebo|Participants will receive continued SOC therapy together with RDV placebo on Day 1 followed by RDV placebo from Day 2 up to Day 5.
32758746|NCT04412759|No Intervention|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
32758747|NCT04412759|Experimental|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
32758748|NCT04203875|Experimental|Orencia® (Abatacept)|Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response
32758749|NCT05285111|Experimental|Interoceptive Awareness|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
32758750|NCT05285111|Active Comparator|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
32758751|NCT05283785||( group 1)|End to End sutures
32758752|NCT05283785||( group 2 )|End to Side sutures
32758753|NCT04491461|Active Comparator|Herbal tea blend|1 cup of herbal tea blend containing Rosehip and other berry extracts.
32758754|NCT04491461|Sham Comparator|Warm water|1 cup of warm water.
32758755|NCT04151927|Experimental|Normobaric Hypoxia (NH)|Overnight exposure (8 hours) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
32758756|NCT04151927|Sham Comparator|Normobaric Normoxia (NN)|Overnight exposure (8 hours) to NN conditions (~20% oxygen; achieved with nitrogen dilution, equivalent to ~1000 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
32758757|NCT04491383|Experimental|Tocovid Suprabio (HOV-12020)|200mg, twice 1 day, 12 months
32758758|NCT04491383|Placebo Comparator|Placebo|200mg, twice 1 day, 12 months
32758759|NCT04142645|Experimental|Intervention|The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
32758760|NCT04142645|No Intervention|Control|The control group (i.e. all eligible and consented residents of one control NH) will receive usual care .
32758761|NCT04089917||Q Aspiration Catheter|mechanical thrombectomy for acute ischemic stroke
32758762|NCT04089137|No Intervention|Control|This is an assessment only control condition.
32758763|NCT04089137|Experimental|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
32758764|NCT04004429|Experimental|50 mg AP1189|50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
32758765|NCT04004429|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
32758766|NCT04004429|Placebo Comparator|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
32758767|NCT03901235|Experimental|Mesenchymal Stromal Cells|
32758768|NCT05260073||Tirbanibulin (Klisyri®)|Participants will receive tirbanibulin ointment 2.5 mg in 250 mg (single dose packet). The participants will be observed for 24 weeks to gather participant reported outcomes (PROs) and clinical profile.
32758769|NCT03882203|Experimental|treatment|Patients receive the study protocol: CLAGE sequential with Flu-Bu as conditioning regimen followed by low-dose decitabine maintenance
32758770|NCT03826901|Experimental|Part 1: adults and adolescents (12 years and above)|Delgocitinib cream (dosage: A mg/g).
32758771|NCT03826901|Experimental|Part 2: children (2-11 years)|Delgocitinib cream (dosage: B mg/g).
32758772|NCT04590443|Experimental|NMP in Infrapiriformis level|Participants in this group received NMP of the sciatic nerve in the gluteus region
32758773|NCT04590443|Experimental|NMP in middle thigh level|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
32758774|NCT04590443|Experimental|NMP in middle distal level|Participants in this group received NMP of the sciatic nerve before popliteus region
32758775|NCT03476759|Active Comparator|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\or tuboplasty
32758776|NCT03476759|Active Comparator|IVF/ICSI|These patients will undergo IVF/ICSI
32758777|NCT04582643|Experimental|6P intervention|6P assessment along with education provided based on the 6P components.
32758778|NCT04576325|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
32758779|NCT04576325|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
32758780|NCT04566263|Other|Successful embolization of intracranial aneurysms|Successful embolization of intracranial aneurysms defined by angiographic occlusion of greater than or equal to 90% at 6 months.
32758781|NCT04564625||Fracture and Vitamin D assessment|All patients between 18 and 25 years treated for fractures at Methodist Dallas Medical Center (MDMC) with an index admission vitamin D assessment will be enrolled. This study will consider any patients with an index admission occurring between February 2016 and February 2020. No changes to care or intervention will occur and this study will be conducted completely via chart review. The aim is to identify 100 subjects with a one-year follow-up appointment for their injury to determine the rate of nonunion and vitamin D levels. As patients receive vitamin D supplementation as standard of care if index values are low, impact will be assessed through relative deficiency and clinical outcomes. Data collected from subjects without need for supplementation may be used to generate a threshold.
32758782|NCT04520711|Experimental|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
32758783|NCT05231993|Active Comparator|Active comparator|"All women ages <41, women ages ≥41 with TZ1 and TZ2, and women ages ≥41 with a desire for further childbearing Clinical management and follow-up according to the national screening guidelines published in 2017 (same as for the comparator group, see below).~Women with TZ3 and women ages ≥41 with no desire for further childbearing a. Referral to (diagnostic) excision. The depth of the diagnostic excision will be clinically determined in the trial. It should be with the intent to treat but no so extensive that the risk for side effects increases.~The excision should include a cervical abrasion and endometrial sampling."
32758784|NCT05231993|Placebo Comparator|Placebo comparator|"Clinical management and follow-up according to the national screening guidelines published in 2017:~Colposcopy with biopsy within 3 months, endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~Colposcopy after 12 months if the first colposcopy and biopsies are normal~Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
32758785|NCT05223257|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
32758786|NCT05223257|No Intervention|Control group|"Children will continue standard care for 8 weeks~Subject allocated to standard care group will have to continue what they normally do; they (if > 13 years) or their parents will have to fill a diary in which they will write the rehabilitative activities they do, specifying their intensity and whether these activities are more focused on the lower limbs or upper limbs."
32758787|NCT03390491|Experimental|OnTrack>TheGame (OTG)|Participants randomized to the OTG group (n=100) will have the option to play the online role-playing game for a period of 2 months. They will receive weekly email reminders that the game remains available to them.
32758788|NCT03390491|Other|Recovery Videos (RV)|Participants randomized to the RV group (n=100) will have the option to visit a website that will contain the recovery videos and the static information that is contained in the game. The RV group will also have 2 months to view the materials on the website and will receive weekly email reminders that the website/videos remain available to them. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
32758789|NCT04422743|Experimental|standard of care + citicoline plus homotaurine (CIT/HOMO)|CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)
32758790|NCT04422743|No Intervention|standard of care|only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months
32758791|NCT04421417|Active Comparator|Standard Arthroscopic Rotator Cuff Repair|
32758792|NCT04421417|Experimental|Microfracture and Arthroscopic Rotator Cuff Repair|
32758793|NCT04639973|Experimental|Group 1 (First trimester ultrasound)|
32758794|NCT04639973|Active Comparator|Group 2 (Second trimester anatomy ultrasound)|
32758795|NCT04401371||Hybrid learning group|students enrolled in hybrid learning pediatric dentistry course
32758796|NCT04401371||distance learning group|students enrolled in distance learning pediatric dentistry course
32758797|NCT05403515|No Intervention|Control group|Routine nursing interventions were performed on the patients.
32758798|NCT05403515|Experimental|Foot massage group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. For the patients in foot massage group, 30-min foot massage sessions (15 min for each foot, 3 sessions per week for 1 month) were performed in a special room of rehabilitation center, in a quiet atmosphere at suitable temperature and without environmental stimulants.
33397241|NCT03677024|Experimental|SLN arm|"Experimental:~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
32758799|NCT05403515|Experimental|Foot massage +Aromatherapy group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. During the foot massage + aromatherapy lavender inhalation intervention, the patients were given lavender oil for 30 minutes by using a censer. The intervention protocol was developed reviewing the literature about lavender oil inhalation
32758800|NCT05140421|Experimental|Early Implementation|This arm will receive D2S intervention components during Period 1 (Early Implementation) as well as throughout Period 2 of the stepped-wedge trial.
32758801|NCT05140421|Active Comparator|Delayed Implementation|This arm will receive no D2S intervention components during Period 1 (Early Implementation), but will then receive all D2S intervention components in Period 2, starting 12 months later.
32758802|NCT05127629|Placebo Comparator|Control|
32758803|NCT05127629|Experimental|Collagen matrix|
32758804|NCT02535221|Experimental|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
32758805|NCT02535221|Active Comparator|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
32758806|NCT05104307||Cardiac Performance System (NSR)|Subjects will wear Cardiac Performance System (CPS) non-invasive device during their standard echocardiogram
32758807|NCT02012153|Experimental|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
32758808|NCT04574609|No Intervention|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
32758809|NCT04574609|Experimental|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
32758810|NCT01071941|Experimental|Group 1|The first subjects will receive a single infusion of rRp450. Subsequent subjects will receive rRp450 as four doses administered every 1-2 weeks.
32758811|NCT05138237|Active Comparator|benign stricture|"no of cases suspected to be benign by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
32758812|NCT05138237|Active Comparator|malignant stricture|"no of cases suspected to be malignant by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
32758813|NCT05089253|Active Comparator|Dry needling|The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks.
32758814|NCT05089253|Active Comparator|kinesio taping|The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks
32758815|NCT04567121|Other|Intensive intervention group|intensive life-style and care intervention
32758816|NCT04567121|Other|Standard intervention group|standard life-style and care intervention
32758817|NCT05083403|Experimental|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in cardiac surgery post-CPB
32758818|NCT05083403|Placebo Comparator|Non-HPI Arm|Non-protocolized standard of care management per clinician and provider judgement.
32758819|NCT04493411|Experimental|Multiple Myeloma Patients|Patients with pathologically confirmed myeloma for cross-sectional study (detection) or scheduled to undergo induction therapy (or have gone 1-2 cycles of induction therapy), followed by either bone marrow transplantation or consolidation therapy for longitudinal study (therapy response assessment).
32758820|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
32758821|NCT05081921|Active Comparator|Control Patients with type 2 diabetes and obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
32758822|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
32758823|NCT05081921|Active Comparator|Control Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
32758824|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
32758825|NCT05081921|Active Comparator|Control Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
32758826|NCT04492007|Experimental|PRISMS|In addition to usual care, participants assigned to this arm will have access to our Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) program.
32758827|NCT04492007|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
32758828|NCT04561661|Active Comparator|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
32758829|NCT04561661|Active Comparator|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
32758830|NCT04553237||Patients over 90 years old|
32758831|NCT04553237||Patients between 70 and 89 years of age.|
32758832|NCT05138159|Experimental|Experimental: Donafenib + S-1|Donafenib: 200mg po bid； S-1 capsule: According to the body surface area <1.25m2 40mg/d, 1.25 ~ 1.5 m2 50 mg/d, > 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
32758833|NCT05066087|Experimental|DAHLIA treatment|6 weeks of online behavioural treatment; mainly self-guided and weekly contact with their therapist
32758834|NCT05066087|Other|Treatment as usual|receive usual treatment at their rehabilitation centre; detailed information will be collected to define what treatment as usual means in clinical settings.
32758835|NCT05064293|Other|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.~Control arm participants do not receive navigation."
32758836|NCT05064293|Experimental|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.~The navigator model and implementation to be tested include:~Automated identification of early symptoms for children~Virtual collection of self-reported, standardized assessment scores~Psychologists interpreting assessment scores and providing feedback to families and PCPs~Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months~Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
32758837|NCT04592159|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
32758838|NCT04592159|Placebo Comparator|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
32758839|NCT05061485|Experimental|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
33240494|NCT04084808|Placebo Comparator|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
33240495|NCT00751413|Experimental|1|MK0633
33240496|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
33397242|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
33240497|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
33240498|NCT00751491|Active Comparator|III|
33240499|NCT00751491|Active Comparator|A|
33240500|NCT00751491|Placebo Comparator|placebo|
33240501|NCT05685056|No Intervention|Control group|The control group will receive no intervention, and will be receiving only text reminders regarding the study, the following visits and study logistics in order to limit dropout rate.
33071977|NCT05582213|Other|classic group (CL group)|20 patients will be enrolled to induction with sevofloran as inhalational anesthetics
33071978|NCT05582213|Other|Group ketamine:|This group includes (20) patients will receive ketamine 2 mg/kg intravenous for induction of sedation and unconsciousness
33240502|NCT05685056|Experimental|Intervention group|Intervention will happen with weekly text messages during the study period, focusing on pregnancy nutrition and iodine rich foods. The texts will be based on the taxonomy of behavior change techniques used in interventions, the nudge theory and will be covering themes identified on our previous research.
33240503|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
32758840|NCT05061485|Experimental|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal protein (whey protein)
32758841|NCT05061485|Experimental|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal fat (cream)
32758842|NCT05138081|Experimental|PNF Stretching: Group A|Routine physical therapy treatment
33240504|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
33240505|NCT00753597|Experimental|1|Receiving active treatment
32758843|NCT05138081|Experimental|Stabilization Exercises: Group B|Routine physical therapy treatment
32758844|NCT05137613|Active Comparator|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
32758845|NCT05137613|Active Comparator|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
33071982|NCT05579158|Experimental|Mobile application-supported both calorie restriction and time-restricted eating (mCR/TRE)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of both calorie restriction (500kcal below estimated energy requirement) and time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day).
33071983|NCT05579158|Active Comparator|Mobile application-supported calorie restriction (mCR)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of only calorie restriction (500kcal below estimated energy requirement).
33071984|NCT05579158|No Intervention|Calorie restriction (CR)|Standard of care. This arm receives a brief counseling of calorie restriction.
33071985|NCT05579080||NIV group|group that performed only non-invasive ventilation
33071986|NCT05579080||HFNC group|group that performed only oxygen therapy by high flow nasal cannula
33071987|NCT05579080||NIV and HFNC group|group that used non-invasive ventilation and oxygen therapy by high flow nasal cannula
33071988|NCT05579080||conventional oxygen therapy group|group that used only conventional oxygen therapy low-flow oxygen therapy.
33071989|NCT05572021|Experimental|Prospective|Participants enrolled to ventral hernia repair with Fortiva mesh
33071990|NCT05572021|Active Comparator|Retrospective|Retrospective participants with ventral hernia repair using Strattice mesh
33240506|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
33240507|NCT00757341|Experimental|SKI-606|
33240508|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
33240509|NCT05338970|Experimental|Patritumab deruxtecan|Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.
33071994|NCT05566730|Experimental|CT-MICART App|Participants in this arm will receive daily EMAs for 6 weeks.
33071995|NCT05564728||Intervention|All participants will receive a conversational agent app, Well Feet, to support them in learning foot care self-management.
33397243|NCT04054193|Experimental|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine [5-HT3]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
33397244|NCT03394027|Experimental|Arm 1-ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: estrogen receptor (ER) + breast cancer, triple negative breast cancer, and endometrial cancer
33397245|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
33397246|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
33240510|NCT05338970|Active Comparator|Platinum-based chemotherapy|Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
33240511|NCT00757419|Experimental|1|
33240512|NCT00757419|Placebo Comparator|2|
33240513|NCT00757575||1|
33397247|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
33397248|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
33240514|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
33240515|NCT00757653|Experimental|2|
33240516|NCT00757653|Active Comparator|3|
33240517|NCT00757731|Experimental|Minalcipran 100 mg|
33240518|NCT00757731|Experimental|Minalcipran 150 mg|
33240519|NCT00757731|Experimental|Minalcipran 200 mg|
32758846|NCT05137535||Children diagnosed with Covid-19|Pediatric patients enrolled by the family pediatricians participating in this study, affected by Covid-19 disease whose diagnosis was confirmed by SARS-Cov-2 molecular test
33397249|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
33240520|NCT05338892||Cohort 1|Participants with r/r DLBCL who were treated with at least 2 prior systemic therapies in the real-world setting
33240521|NCT00757809|Experimental|QD|Once daily
32758847|NCT05137457|Experimental|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The mobile Cognitive Behavioral Therapy for insomnia (CBTi) will be offered using the Delivering Online ZZZ's with Empirical support (DOZE) app. Patients assigned to the intervention group will be given the DOZE app which is an integrated smart phone app and web based self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected application. Participants will be encouraged to log onto the sleep dairy once a day over 10-weeks to complete sleep diary, develop and track their goals, and receive sleep health education tailored sleep health interventions. After 10-weeks, participants will complete questionnaires on sleep health, pain, and Health Related Quality of Life (HQRL). The use of actigraphy will be optional in view of the COVID19 pandemic."
32758848|NCT05137457|Active Comparator|Sleep Diary Only Attention Control|"The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.~After the 10-week intervention period, participants will again complete a battery of questionnaires on sleep health, pain, and HRQL. The use of actigraphy will be optional in view of the COVID19 pandemic."
32758849|NCT05137145|Experimental|The control group|The control group was given 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestines
32758850|NCT05137145|Experimental|the observation group 1|the observation group 1 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
32758851|NCT05137145|Experimental|the observation group 2|the observation group 2 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
32758852|NCT05137145|Experimental|the observation group 3|the observation group 3 was given Linaclotide(290 ug) in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine.
32758853|NCT05136989||Professionals from the seven least coercive facilities|Volunteer professionals selected on the basis of their experience in reducing the use of coercion.
32758854|NCT05136989||Voluntary ex-patients|Voluntary ex-patients who were hospitalized in these establishments in the two years preceding the survey and whose condition is stabilized
32758855|NCT05136911|Experimental|Intervention Group|The intervention group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care or walk-in clinic and the Salt Intervention (Salt Intervention Manual, five weekly online modules and five weekly telephone calls.
32758856|NCT05136911|No Intervention|Usual Care Group|All participants in the usual care group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care of walk-in clinic.
32758857|NCT05123963|Active Comparator|Morning exercise|Participant to perform high-intensity interval training in the morning (~9 am)
32758858|NCT05123963|Experimental|Afternoon exercise|Participant to perform high-intensity interval training in the morning (~4 pm)
32758859|NCT05121467||Patients with Cervical Disc Herniation|Endurance tests were performed for 9 muscles/muscle groups in the cervical and scapular regions, upper limb, and trunk Visual Analogue Scale (VAS) and Neck Disability Index (NDI) Fremantle Neck Awareness Questionnaire (FreNAQ) Tampa Scale of Kinesiophobia (TSK)
32758860|NCT04971863||Clareon Monofocal IOL|Patients bilaterally implanted with the Clareon monofocal IOL
32758861|NCT04971863||Asqelio Monofocal IOL|Patients bilaterally implanted with the Asqelio monofocal IOL
32758862|NCT05306171|Experimental|Intervention group (I)|Online training for healthcare professionals which will follow a protocol made especially for this research. The online training is composed by 4 modules and each module has 3 meetings. Each meeting has 35 minutes long.
32758863|NCT05306171|No Intervention|Control group (C)|No intervention. The control group will receive the intervention after study is completed.
32758864|NCT05305937|Experimental|One arm - all patients|
32758865|NCT05305703|Experimental|Cervical muscles Stretching|Stretching is applied to the effected muscles in order to increase the muscle length and flexibility by breaking adhesions. Stretching exercises considerably decrease neck pain and improve range of motion
32758866|NCT05305703|Experimental|Soft tissue mobilization with trigger point release.|Soft tissue mobilization increases skin temperature, a rise in skin temperature indicates increase blood flow of involved area, provide relaxation and reduce muscle tension.Trigger point therapy is consisting of rubbing and pressing on trigger points.Heavy pressure must be applied to release trigger, light pressure is not effective. Pressure should be applied slowly and released slowly for best results and the pressure should be maintained until there is a change in pain
32758867|NCT04446845|Experimental|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
32758868|NCT04446845|Active Comparator|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
32758869|NCT05305625|Experimental|standard therapy|Patients will be treated with Guideline standard
32758870|NCT05305625|Experimental|remote ischemic postcondioning and standard therapy|Patients will be treated with remote ischemic postcondioning and Guideline standard , remote ischemic postcondioning twice a day for a total of 3 days.
32758871|NCT05305469||GN|Gram-negative bacteria infection group
33240522|NCT00757809|Experimental|BID|Twice daily
33240523|NCT05140382|Experimental|Cohort 1: non-natural killer (NK) PTCL (Non-NK PTCL)|Eligible participants with PTCL, all comers (excluding NKTCL) will receive AZD4573 monotherapy
32758872|NCT05305469||GP|Gram-positive bacteria infection group
32758873|NCT05305469||Fungal|Fungal infection group
32758874|NCT05305469||Viral|Viral infection group
32758875|NCT05305469||Control|Non-sepsis group
32758876|NCT05305157||Experts on forensic odontology|Experts on forensic odontology, members of AFIO (French Association of odontological identification) and UIO (Odontological identification Unit)
32758877|NCT04396613|Active Comparator|Running Subcuticular Suture|
32758878|NCT04396613|Active Comparator|Interrupted Vertical Mattress Suture|
32758879|NCT04396613|Active Comparator|Staple Closure Techniques|
32758880|NCT04938791|Experimental|Isometric activity|All participants will be included in this arm
32758881|NCT04457141|Other|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9 km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
32758882|NCT04457141|Other|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
32758883|NCT05305079||ODD-AION|NA-AION patients with ODD aka. Optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
32758884|NCT05305079||nODD-AION|NA-AION patients without ODD aka Non-optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
32758885|NCT04419389|Experimental|Safety Lead-In Cohort 1|APR-246 + Acalabrutinib in Subjects with R/R CLL.
32758886|NCT04419389|Experimental|Safety Lead-In Cohort 2|APR-246 + Venetoclax + Rituximab in Subjects with R/R CLL.
32758887|NCT04419389|Experimental|Expansion Cohorts|APR-246 + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT
32758888|NCT04419389|Experimental|Safety Lead-In Cohort 3|APR-246 + Venetoclax + Rituximab in Subjects with RT
32758889|NCT05304845|Experimental|Cohort 1|Aspirin (substrate), DWP14012 (Perpetrator)
32758890|NCT05304845|Experimental|Cohort 2|DWP14012 (substrate), Aspirin (Perpetrator)
32758891|NCT04407143||lung cancer+COVID-19|Lung cancer patients infected by COVID-19
32758892|NCT04390451|Experimental|Whole Health STEPS|Participants will immediately receive Whole Health STEPS.
32758893|NCT04390451|Other|Waitlist|Participants will receive Whole Health STEPS after a defined waiting period.
32758894|NCT04386005|Experimental|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
32758895|NCT04385927|Experimental|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
32758896|NCT04385927|Experimental|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
32758897|NCT05304299|Experimental|Cordyceps Cicadae Mycelia only|Only Cordyceps Cicadae Mycelia will be given.
32758898|NCT05304299|Experimental|Cordyceps Cicadae Mycelia with Taflotan (saflutan)|Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.
32758899|NCT04936451|Other|TENS / TENS ECOMODYN|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS / TENS ECOMODYN Patients first start with TENS during 2 months puis change with TENS ECOMODYN during 2 months with a wash-out period of 15 days
32758900|NCT04936451|Other|TENS ECOMODYN / TENS|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS ECOMODYN / TENS Patients first start with TENS ECOMODYN during 2 months puis change with TENS during 2 months with a wash-out period of 15 days
32758901|NCT04924517|Experimental|Extended Evening Fasting|Participants will eat between 8am-4pm
32758902|NCT04924517|Active Comparator|Control|Participants will eat between 8am-8pm
32758903|NCT04921787|Active Comparator|Low Intensity|MOUD training and support through the use of educational materials.
32758904|NCT04921787|Experimental|High Intensity|MOUD training and support through the use of educational materials in addition to practice facilitation.
32758905|NCT05303597|Other|diagnostic superior cluneal nerve block|Patients with low back pain will be evaluated by two physicians. The clinical history and physical examination of all patients with low back pain will be taken by the first physician. Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment. Patients who have had a diagnostic injection will be re-evaluated 1 hour later. Patients whose pain is reduced by more than 50% will be diagnosed with superior cluneal nerve entrapment.
32758906|NCT04898543|Experimental|Cohort 1: Subjects newly diagnosed|Cohort 1: Subjects newly diagnosed with high-risk solid tumors who have not received treatment.
32758907|NCT04898543|Experimental|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies.
32758908|NCT04892459|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
32758909|NCT04892459|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
32758910|NCT04892459|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months.
32758911|NCT04892459|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
32758912|NCT04890431|Experimental|Oxygen|
32758913|NCT04890431|Placebo Comparator|Placebo|
32758914|NCT04881539|Experimental|Cannabidiol (CBD)|Each group member will receive one dose of CBD daily for 8 weeks.
33240524|NCT05140382|Experimental|Cohort 2: NK PTCL|Eligible participants with PTCL (NKTCL only) will receive AZD4573 monotherapy
32758915|NCT04881539|Placebo Comparator|Placebo|Each group member will receive a calorie matched placebo daily for 8 weeks.
33240525|NCT05140382|Experimental|Cohort 3: cHL|Eligible participants with cHL will receive AZD4573 monotherapy
33240526|NCT00753831|Experimental|1|Aurosling
32758918|NCT05303519|Experimental|AB-218 125mg bid|AB-218 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AB-218 until disease progression or development of other unacceptable toxicity.
32758919|NCT05303519|Experimental|AB-218 250mg bid|AB-218 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AB-218 until disease progression or development of other unacceptable toxicity.
32758920|NCT05303519|Experimental|AB-218 500mg qd|AB-218 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AB-218 until disease progression or development of other unacceptable toxicity.
32758921|NCT05303519|Experimental|AB-218 375mg bid|AB-218 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AB-218 until disease progression or development of other unacceptable toxicity.
32758922|NCT05303519|Experimental|AB-218 700mg bid|AB-218 700mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AB-218 until disease progression or development of other unacceptable toxicity.
32758923|NCT04854083|Experimental|Semaglutide|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
33240527|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
32758924|NCT04854083|Placebo Comparator|Placebo|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to placebo treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
32758925|NCT05303441||patients with acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels compatible with ACS
32758926|NCT05303441||patients without acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels NONcompatible with ACS
32758927|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
32758928|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
32758929|NCT05303363||VV-ECMO|Critically ill patients with a suspected indication for VV-ECMO. ECMO will be provided according to local guidelines. In the Amsterdam UMC, location AMC, next to VV-ECMO, veno-arterial (VA-ECMO) is also provided. For this study, only patients on VV-ECMO will be included.
32758930|NCT05303285|Experimental|Secukinumab 300mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 300 mg s.c. every 4 weeks for an additional 48 weeks.
32758931|NCT05303285|Active Comparator|Secukinumab 150 mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks for an additional 48 weeks.
32758932|NCT05302973|Active Comparator|Conventional rehabilitation|Inpatient rehabilitation - person-centred and tailored to individual participant needs - which take into account the different sequelae associated with the severity of COVID-19, the prolonged stay of people in the acute hospital or in the intensive care unit, and the pre-existing comorbidities.
32758933|NCT05302973|Active Comparator|Aerobic exercise|Addition of aerobic exercise to conventional inpatient rehabilitation treatment for people wtih post-COVID-19.
32758934|NCT04288661|No Intervention|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
32758935|NCT04288661|Experimental|No drain|The patients of this arm do not undergo perianastomotic drain placement.
32758936|NCT04280939|Active Comparator|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
32758937|NCT04280939|Experimental|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
32758938|NCT04280939|Experimental|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
32758939|NCT04276571|Experimental|GRAIL|
32758940|NCT04276571|No Intervention|No treatment|
33240532|NCT04015544|Experimental|Watermelon|Watermelon puree 710 mL per day for six weeks
33240533|NCT04015544|No Intervention|Control|No intervention
32758941|NCT04831385|Experimental|CBT-i|
32758942|NCT04831385|No Intervention|Control (Usual Care)|Control
32758943|NCT04823273|Experimental|General improvement|"Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the prepare and transfuse orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians."
33397250|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
33397251|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
33397252|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
33397253|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
32901516|NCT01483807|Experimental|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
33397254|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
33397255|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
33397256|NCT03184402|Experimental|DWJ1252|
33397257|NCT03184402|Active Comparator|Gasmotin|
32901517|NCT05042076|Experimental|BK with VST|Adult patients with BKV infection and nephropathy (BKN) following kidney transplantation.
33397258|NCT01318395|Active Comparator|Aliskiren|
33240534|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
33240535|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
33240536|NCT05132582|Experimental|Tucatinib + trastuzumab + pertuzumab|Tucatinib + trastuzumab + pertuzumab
33240537|NCT05132582|Active Comparator|Placebo + trastuzumab + pertuzumab|Placebo + trastuzumab + pertuzumab
33240538|NCT00753987|Experimental|1|
33240539|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
33240540|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
33397259|NCT01318395|Placebo Comparator|Placebo|
33397260|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
33397261|NCT01376544|Active Comparator|Pressure support ventilation|
33397262|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
32758944|NCT04823273|Experimental|In-line help text|In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
32758945|NCT04823273|Experimental|Interruptive alert|In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
32758946|NCT05302817|Experimental|Standard-of-care Radiation Therapy for lung cancer using HXe MRI for diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study, where they will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. However, for this part of the study, subjects will still follow the standard-of-care radiation treatment plan. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
32758947|NCT05302817|Experimental|Guided Radiation Therapy for lung cancer using HXe MRI for functional lung avoidance and diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
32758948|NCT04489589|Experimental|Midodrine|Midodrine 10mg PO/NG q8h
32758949|NCT04489589|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
33397263|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
32758950|NCT04328441|Experimental|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
32758951|NCT04328441|Placebo Comparator|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
32758952|NCT04485611|Experimental|Prehabilitation|This pilot cohort will undergo an intervention and will be followed for up to 6 months. The study does not include a comparator group.
32758953|NCT05302739|Experimental|Facial cooling|Between each simulated fencing match participants will spend the first 30 s of rest having a facial water mist sprayed onto the face with accompanying fanning from 50 cm away from the face.
32758954|NCT05302739|No Intervention|Placebo|
32758955|NCT05302661|Experimental|case group will receive re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. The re-education group will receive regular re-education not noly when they leave hospital but also after leave hospital in our preset time by telephone or wechat. The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
33397264|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
33397265|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
33397266|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
33397267|NCT01318551|Experimental|Arm 1|
33397268|NCT01318551|Experimental|Arm 2|
33397269|NCT01318551|Experimental|Arm 3|
32758956|NCT05302661|No Intervention|control case group will receive no re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. without re-education group will receive regular re-education when they leave hospital.The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
32758957|NCT05302349|Experimental|Core Exercise Group|Core Exercise Group will performe core stabilization exercises and routine physiotherapy exercises.
32758958|NCT05302349|Active Comparator|Routine Therapy Group|Routine Therapy Group will performe routine physiotherapy exercises.
32758959|NCT04314713|Placebo Comparator|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
32758960|NCT04314713|Placebo Comparator|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
32758961|NCT04314713|Placebo Comparator|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
32758962|NCT04314713|Placebo Comparator|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
32758963|NCT04314713|Placebo Comparator|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
32758964|NCT04314713|No Intervention|Placebo|Placebo controlled
32758965|NCT05302193|Experimental|Blood pressure and heart rate measurement|Calm measurement of blood pressure and heart rate simultaneously by smartwatch and vital signs monitor. Each participant will undergo this measurement a total of 6 times.
32758966|NCT04777253|Experimental|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
32758967|NCT04777253|Other|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
32758968|NCT04775771|Experimental|Animal Assisted Practice (Experimental) Group|
32758969|NCT04775771|No Intervention|Control Group|
32758970|NCT05302037|Experimental|Dose-Escalation Arm|Four infusions of CTM-N2D at escalating doses: 1x10^7, 1x10^8, 3x10^8 or 1x10^9 per infusion at an interval of one infusion every 7 days.
32758971|NCT05302037|Experimental|Optimal Dose Arm|Four infusions of CTM-N2D at the optimal dose (expected to be 1x10^9) at an interval of one infusion every 7 days.
32758972|NCT04121507|Experimental|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
32758973|NCT04762043|Experimental|MyoVoice Device|MyoVoice Device for individuals with total laryngectomy
32758974|NCT04261595|Active Comparator|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
32758975|NCT04261595|Active Comparator|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
32758976|NCT04261595|Active Comparator|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
32758977|NCT04209725|Experimental|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
32758978|NCT04156373|Experimental|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
32758979|NCT04156373|No Intervention|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
32758980|NCT04743167|Active Comparator|Surgery|Patients undergoing surgery for endometriosis, after surgery, will receive indications for seeking for a natural pregnancy up to 12 months from the time of randomization
32758981|NCT04743167|Active Comparator|In Vitro Fertilization|Patients included in the IVF arm will undergo three complete cycles of IVF (i.e. three oocytes retrievals regardless of the number of embryo transfers)
32758982|NCT04082117|Other|Open Label|Educational genetic counseling video
32758983|NCT01449149|Experimental|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
32758984|NCT04719221|Placebo Comparator|Statin+Ezetimibe|Drug: Statin + Ezetimibe (combined cholesterol therapy)
32758985|NCT04719221|Active Comparator|Statin+Ezetimibe+Evolocumab|Drug: Statin + Ezetimibe (combined cholesterol therapy) and Drug: Evolocumab
32758986|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
32758987|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
32758988|NCT04704479|Experimental|combined Russian and EMT|Russian current will be applied over the participant expiratory muscles in addition to application of EMT for more enhancement and strengthening of the expiratory muscles.
32758989|NCT04704479|Active Comparator|EMT only|the participant receives EMT only over the whole study period
32758990|NCT04039763|Experimental|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
32758991|NCT04039763|Placebo Comparator|Standard care|Standard care - finger prick self monitoring of blood glucose.
32758992|NCT04033679|Experimental|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
32758993|NCT04033679|Sham Comparator|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
32758994|NCT04006925|Active Comparator|Sodium Oxybate (SXB) arm|Sodium Oxybate (SXB) will be dispensed to the participants.
32758995|NCT04006925|Placebo Comparator|Placebo (PBO) arm|Placebo will be dispensed to the participants.
33397270|NCT01562795|Experimental|group 1|
33397271|NCT01562795|Experimental|group 2|
32758996|NCT03982043|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
32758997|NCT03948503|Experimental|Mobilization with movement (MWM) group|Application of the Mulligan concept
32758998|NCT03948503|Placebo Comparator|Sham group|Sham treatment
32758999|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
32759000|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
32759001|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
32759002|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
32759003|NCT03718559|Experimental|Edoxaban alone|
32759004|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
32759005|NCT04684589|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
32759006|NCT04684589|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
32759007|NCT04677257|Experimental|STEMI acute myocardial infarction treated with effective primary PCI|STEMI patients treated with effective primary PCI to assess the ability of coronary physiology parameters (CFR and IMR) measured soon after recanalization to predict myocardial tissue characterization assessed with cardiac magnetic resonance (CMR) within a week of the acute event.
32759008|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
32759009|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
32759010|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
32759011|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
32759012|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
32759013|NCT03428165|No Intervention|spontaneous|
32759014|NCT04674761|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 24 weeks.
32759015|NCT04674761|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks.
32759016|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
32759017|NCT01171937|Placebo Comparator|Placebo|Placebo
32759018|NCT03416933|Experimental|Biological|
32759019|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
32759020|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
33397272|NCT01562795|Experimental|group 3|
32759021|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
32759022|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
32759023|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
32759024|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
32759025|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
32759026|NCT04481399|Experimental|FSI-ECD|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. The FSI-ECD will be delivered in weekly 90-minute home visiting sessions for 12 consecutive weeks.
32759027|NCT04481399|Other|Control|The control is standard maternal and child health home visiting delivered by community health workers. Families will receive three 90-minute home visiting educational sessions focused on nutrition, hygiene, and post-natal care.
32759028|NCT03102983|Experimental|Healthy Volonteers|
32759029|NCT04483349||Observational (survey administration)|Patients and healthcare providers complete a survey over 10-15 minutes.
32759030|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
32759031|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
32759032|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
32759033|NCT00887783|Experimental|B: 66Gy/33F+Navelbine oral 150 mg q3w|"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).~Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization"
32759034|NCT00887783|Active Comparator|A: 60Gy/30F+Navelbine oral 150 mg q3w|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization
32759035|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
32759036|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
32759037|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
32759038|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
32759039|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
32759040|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
32759041|NCT01125371|Placebo Comparator|Attention Control|Attention control
32759042|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
32759043|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
32759044|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
32759045|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
32759046|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
32759047|NCT04042571|Experimental|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
32759048|NCT04038593|No Intervention|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
32759049|NCT04038593|Active Comparator|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
32759050|NCT04038593|Experimental|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
32759051|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
32759052|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
32759053|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
32759054|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
32759055|NCT04012151||Pregnant cohort|Parturients of gestational age >= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
32759056|NCT03965273|Experimental|Full TP|Full TP intervention including emphasized social norms change
32759057|NCT03965273|Experimental|Light TP|Light TP intervention without emphasized social norms change
32759058|NCT03965273|No Intervention|Pure control|Pure control
33397273|NCT01562795|Other|group 4|
32742406|NCT03913637|Active Comparator|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
33397274|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
33397275|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
33397276|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
32742407|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
32742408|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
32742409|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
33397277|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
33397278|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
32742410|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
32742411|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
32742412|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
32742413|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
33397279|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
32742414|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
32742415|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
32759059|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
32759060|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
32759061|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
32759062|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
32759063|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
32759064|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
32759065|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
32759066|NCT03947333|Experimental|Intervention|Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the My Diabetes Care.
32759067|NCT03947333|No Intervention|Control|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the My Diabetes Care (i.e., usual care).
32759068|NCT03938831|Experimental|dexmedetomidine group|dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
32759069|NCT03938831|Placebo Comparator|control group|Fentanyl-based PCA infusion for 2 days
32759070|NCT02748941|Experimental|symptomatic and asymptomatic patients|
32759071|NCT03909815|Experimental|Intervention|Insertion of dual mobility cup
32759072|NCT03909815|Active Comparator|Control|Insertion of standard cup
32759073|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
32759074|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
32759075|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
32759076|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
32759077|NCT03872375|Experimental|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.~Subjects are also asked to follow RDN dietary recommendations."
32759078|NCT03872375|Active Comparator|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
33397280|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
33397281|NCT05450809||Ambulatory, outpatient Mayo Clinic ECG lab patients|Patients who are undergoing routine clinical evaluation with a 12 lead ECG recording ordered at the Mayo Clinic ECG lab.
32759081|NCT02592707|Experimental|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
32759082|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
32759083|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
32759084|NCT03855917|Experimental|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
32759085|NCT03104855|Experimental|Single pharmacokinetics arm|
32759086|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
32759087|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
32759088|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
32759089|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
32759090|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
32759091|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
32759092|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
32759093|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
32759094|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
32759095|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
32759096|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
32759097|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
32759098|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
32759099|NCT03102359|No Intervention|Control|No intervention in this group
32759100|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
32759101|NCT03104309|Other|Levonorgestrel intrauterine system|
32759102|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
32759103|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
32759104|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
32759105|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
32759106|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
32759107|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
32759108|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
32759109|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
32759110|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
32759111|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
32759112|NCT03104153|No Intervention|Output-based|
32759113|NCT03104153|Active Comparator|Early-removal|
32759114|NCT04482413|Experimental|Treatment|Treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.
32759115|NCT04482413|Placebo Comparator|Placebo Control|Placebo control group will receive AstroStem Placebo.
32759116|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
32759117|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
32759118|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
32759119|NCT04435223||COVID-19 severe pneumonia|
32759120|NCT04435223||Severe pneumonia due to other pathogene|
32759121|NCT04412603|Experimental|Conventional Mirror Therapy group|"Therapy:~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
32759122|NCT04412603|Experimental|Mirror Therapy Virtual Reality group|"Therapy:~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
32759123|NCT03817229|Active Comparator|Control Group|mHealth education module and automated digital reminders
32901518|NCT05041998|Experimental|Unmodified Socket + 8 Socket Modifications in Random Order|The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
33240541|NCT05435079|Experimental|new type of tracheotomy high-flow oxygen therapy (NTHF)|NTHF (connect the oxygen suction tube, Venturi, Fisher & Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, airtight suction tube and tracheotomy in sequence from the output end of the automatic pressure-adjustable oxygen flow meter Catheter), adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy catheter at 37°C according to the feedback temperature, and adjusts according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate of the oxygen therapy device is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
32742416|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
32759124|NCT03817229|Experimental|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence > 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence < 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
32759125|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
33397282|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
33397283|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
32759126|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
32759127|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
32759128|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
32759129|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
32759130|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
32759131|NCT03748433|Experimental|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
32759132|NCT03748433|No Intervention|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
32759133|NCT03748433|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
32759134|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
32759135|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
32759136|NCT00540995|Experimental|Arm I: 1200cGy|"1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
32759137|NCT00540995|Experimental|Arm II: 1350cGy|1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
32759138|NCT00418301|Experimental|Precision Spinal Cord Stimulation and PET Scan|Positron emission tomography (PET) scan imaging procedures to assess Spinal Cord Stimulation.
32759139|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759140|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759141|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759142|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759143|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759144|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759145|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
32759146|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
32759147|NCT05103215|Experimental|lidocaine group|Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
32759148|NCT05103215|Placebo Comparator|control group|Patients in control group receive the same volume of saline injection.
32759149|NCT03656159|Active Comparator|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
32901519|NCT05041842|Experimental|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy.
33397284|NCT03857256|Experimental|Active Treatment|CP105F (Oat beta-glucan), 0.5g TID (3, 6 or 12 tablets per day for a dose of either 1.5g, 3g or 6gr) for 12 weeks.
32742417|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
33397285|NCT03857256|Placebo Comparator|Placebo|matching placebo 3, 6 or 12 tablets per day for 12 weeks.
33397286|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
33240542|NCT05435079|Active Comparator|Respiratory Humidification Treatment（ AIRVO TM 2）|AIRVOTM 2 (Fisher & Paykel, Auckland, New Zealand), connect the special breathing circuit, tracheostomy joint and tracheostomy tube in sequence from the output end of the oxygen flow meter. The gas outflow from the mouth is the standard, adjust the output gas flow rate of the therapy device to 40-60L/min, adjust the oxygen concentration according to the monitored pulse oxygen saturation (SpO 2 ), and maintain the SpO 2 between 94% and 100%. .
33240543|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
33240544|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
33240545|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
33240546|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
33397287|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
33397288|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
32759150|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
32759151|NCT05033483|Experimental|Iron Supplement|65.7 mg of iron as ferrous fumarate
32759152|NCT05033483|Active Comparator|Placebo|0 mg of iron
32759153|NCT05001815|Experimental|Continuous subcutaneous insulin infusion (CSII)|Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
32759154|NCT05001815|Active Comparator|Multiple daily insulin injection (MDI)|Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
32759155|NCT02644967|Experimental|Phase 2, 8 mg Tilso/Ipi|IMO-2125 intratumoral injection plus ipilimumab
32759156|NCT04435535|Other|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
32759157|NCT04964453|Experimental|Dose group 1|
32759158|NCT04964453|Experimental|Dose group 2|
32759159|NCT04964453|Experimental|Dose group 3|
32759160|NCT04964453|Experimental|Dose group 4|
32759161|NCT04964453|Placebo Comparator|Placebo|
32759162|NCT04945109|Experimental|Mankai beverage first|Two weeks of Mankai supplementation followed by two weeks of water supplement
32759163|NCT04945109|Experimental|Mankai beverage last|Two weeks of water supplementation followed by two weeks of Mankai supplement
32759164|NCT04896749|Experimental|Group A/ Nerve mobilization group|In this group, patients will receive nerve mobilization exercises along with routine physical therapy. Patients will also be given home plan for cervical isometric exercises.
32759165|NCT04896749|Active Comparator|Group B/ Conventional physical therapy group|In this group, patients will receive routine physical therapy and also given home plan for cervical isometric exercises
32759166|NCT04890821|Experimental|CI Percutaneous Ring Annuloplasty System|Patients treated with the CI Percutaneous Ring Annuloplasty System
32759167|NCT04771637|Placebo Comparator|control with normal saline|
32759168|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h|
32759169|NCT04771637|Experimental|dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h|
32759170|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h|
32759171|NCT04751591|Experimental|Endoscopic resection|The endoscopist will perform endoscopic resection for patients enrolled in this group.
32759172|NCT04751591|Other|Laparoscopic partial gastrectomy|The endoscopist will perform laparoscopic partial gastrectomy for patients enrolled in this group.
32759173|NCT04731389|Experimental|internet CBT|Intervention with remote and self-applicable cognitive behavioral therapy, during 4 weeks.
32759174|NCT04731389|Active Comparator|Quality of life promotion|Control intervention, during 4 weeks.
32759175|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
32759176|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
32759177|NCT03103217|Experimental|Brief CBT intervention|
32759178|NCT04166591|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
32759179|NCT04166591|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
32759180|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
32759181|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
32759182|NCT04695041|Experimental|Cohort A: 1200 mg PBI-4050|
32759183|NCT04695041|Experimental|Cohort B: 1600 mg PBI-4050|
32759184|NCT04695041|Experimental|Cohort C: 2000 mg PBI-4050|
32759185|NCT04695041|Experimental|Cohort D: 2400 mg PBI-4050|
32759186|NCT04695041|Experimental|Cohort E: 2400 mg PBI-4050|
32759187|NCT04695041|Experimental|Cohort F (Supplemental): 1600 mg PBI-4050|
32759188|NCT04626869|Active Comparator|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
32759189|NCT04626869|Active Comparator|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
32759190|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
32759191|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
32759192|NCT04435145|Experimental|Intervention|Sugar-sweetened beverage warning label
32759193|NCT04435145|No Intervention|Control|No label
32759194|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
32759195|NCT04435301|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3), respectively. 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
32759196|NCT04435301|Experimental|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3). 28Hz acoustic stimuli and 28Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
32759197|NCT04435301|Sham Comparator|Sham modulation group|Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
32759198|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
32759199|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
32759200|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
32759201|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
32759202|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
32759203|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
32759204|NCT05244941||Cross site-case study|Qualitative methods: semi-structured interviews for patients, front line clinical practitioners, and health system stakeholders, case study building across sites
32759205|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
32759206|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
32759207|NCT03464669||Control group|Absence of prenatal education
32759208|NCT05244863||One group|Geriatric individuals
32759209|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
32759210|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
32759211|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
32759212|NCT04482179|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
32759213|NCT04482179|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
32759214|NCT05244707|Experimental|Mediterranean style diet|Mediterranean style diet.
32759215|NCT05244707|Active Comparator|Standard of care|Standard of care.
32759216|NCT05244629|Active Comparator|Bare Metal Stent|
32759217|NCT05244629|Active Comparator|Covered Stent|
32759218|NCT05055011||Observational (survey, medical record review)|Parents complete survey over 20 minutes. Patients' medical records are reviewed.
32759219|NCT04479995|Experimental|Horizon Program|"Eight weekly, audio recorded telehealth videoconferencing sessions. Sessions are 90 minutes.~Questionnaire assessments at 8 and 16 weeks after end of videoconferencing sessions"
32759220|NCT04479995|Experimental|Usual Care|"Standard medical visits to address chronic GVHD, with an additional standardized booklet, in electronic or paper format, containing information on the management of chronic GVHD and stem cell transplant survivorship recommendations.~Questionnaire assessment at 8 weeks and 16 weeks after Horizons Program group starts"
32759221|NCT05244317|Placebo Comparator|cast group|treatment of the participant of this group will be by the standard method which is by casting
32759222|NCT05244317|Experimental|splint group|treatment of the participant of this group will be by the removable splint
32759223|NCT04479683|Other|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
32759224|NCT04479683|Experimental|FTH (full-time hospitalisation) then day hospitalization)|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
32759225|NCT05244161|No Intervention|Radio messaging (RM)|Radio messaging only (RM)
32759226|NCT05244161|Active Comparator|RM, Video job aids, Early Childhood Development program (RMV-ECD)|Radio messaging, short video job aids primarily for CHW use, and the UNICEF Care for Childhood Development program (RMV-ECD)
33240547|NCT05331638|Experimental|Prostate Cancer Genius app|The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.
33397289|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of 0.375% ropivacaine"
33397290|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of Saline"
33397291|NCT04860804|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
33397292|NCT04860804|Active Comparator|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
33397293|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
33240548|NCT05331638|Active Comparator|Prevention Taskforce app|The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).
33240549|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
33240550|NCT04084340|Experimental|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA"
33397294|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
33397295|NCT02428114||5 days of filgrastim|Standard of care
32759227|NCT05244083|Experimental|Experimental Group|The experimental group will perform a 5-week motor program consisting of 4 bimanual exercises with mirror therapy, to be done at home 30 minutes a day, 5 days a week.
32759228|NCT05244083|Active Comparator|Control Group|The control group will perform a 5-week motor program consisting of 4 bimanual exercises without mirror therapy, to be done at home 30 minutes a day, 5 days a week.
32759229|NCT05243927|Experimental|Aerobic exercise group|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes, 3 days a week for 8 weeks.
32759230|NCT05243927|Active Comparator|Stabilization exercise group|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes, 3 days a week for 8 weeks.
32759231|NCT04961879|Active Comparator|Reversed Cross Finger Flap group 1|
32759232|NCT04961879|Active Comparator|Reversed island Homo-digital Flap group 2|
32759233|NCT05243849||Ischemic Stroke|The diagnosis of ischemic stroke was obtained from previous diagnostic reports or electronic medical records, according to the diagnostic criteria from the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
32759234|NCT05243849||Control|Inclusion criteria for healthy controls were no history of ischemic stroke or other neurological and ocular diseases.
32759235|NCT04937075||Before period without multiplex PCR identification|
32759236|NCT04937075||After period with multiplex PCR identification|
32759237|NCT05243771||Rectal resection with diverting stoma|Patients operated for rectal cancer with rectal resection and diverting stoma.
32759238|NCT05243771||Rectal resection without diverting stoma|Patients operated for rectal cancer with rectal resection without diverting stoma.
32759239|NCT05243771||Rectal resection with primary colostomy|Patients operated for rectal cancer with rectal resection with primary colostomy.
32759240|NCT04701593|No Intervention|Control|No additional drug given
32759241|NCT04701593|Experimental|Experimental (Triamcinolone Acetonide)|receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation
33397296|NCT02428114||7 days of filgrastim|Standard of care
32759242|NCT05243693|Experimental|Brentuximab vedotin and DHAP|A clinical study of safety and efficacy of treatment with Brentuximab vedotin and DHAP in patients with relapsed/refractory Hodgkin lymphoma
32759243|NCT05243459|Experimental|Gaze-Contingent Feedback Training|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.
33397297|NCT02428114||10 days of filgrastim|Standard of care
33397298|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
32759244|NCT05243459|Active Comparator|RT-Based Attention Bias Modification|"The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns."
32759245|NCT05243459|Placebo Comparator|Non-Contingent Feedback Training|This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.
32759246|NCT05243225||laparoscopic management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, trocars are inserted in the abdomen, insufflation by CO2 adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram then according to the site and the size of the injury repair will done. If the injury is small simple repair or repair on T-tube will be done. If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done. Intra-abdominal drains insertion
32759247|NCT05243225||open surgical management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram according to the site and the size of the injury repair will be done. If the injury is small simple repair or repair on T-tube will be done . If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done .Intra-abdominal drains insertion.
32759248|NCT04640987|Experimental|Experimental: Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.
32759249|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
32759250|NCT04552847|Experimental|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
32759251|NCT05204537||Patients who developed in-hospital COVID-19 thoracic complications, surgically managed.|"The study population consists of patients who have been surgically treated for COVID-19 thoracic complications.~Thoracic complications have been defined as any condition involving the thorax, directly or indirectly consequence of COVID-19, including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it. Since the wide span of diagnosis, the novelty of this pathology and the different protocols adopted by participating centers, it is not possible to identify common criteria for surgical indications. A wide variety of pleuro/parenchimal surgical procedures are included. Patients undergone chest tube placement alone are not included in the study."
32759252|NCT05183321|No Intervention|Control Group|Group will not receive treatment: periodontal therapy
32759253|NCT05183321|Experimental|Periodontal therapy|Group will receive treatment: periodontal therapy
32759254|NCT05167331|Active Comparator|Virtual Reality|"(T1) after fitting the headset to the child's face, the assistant starts the VR program chosen by the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
32759255|NCT05167331|Active Comparator|Nitrous oxide sedation|"(T1) With the nitrous oxide/oxygen inhalation system titrated to 50%/50% whose flow rate is adapted to the child's respiratory flow. The assistant is responsible for controlling the sedation. Verbal encouragement is always present to reassure the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
32759256|NCT04509401|Active Comparator|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
32759257|NCT04509401|Placebo Comparator|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
32901520|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
33240551|NCT04084340|Sham Comparator|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA"
33240552|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
33240553|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
33240554|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
32742418|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
32742419|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
32901521|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
32742420|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
32742421|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
32742422|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
32742423|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
32742424|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
32759258|NCT05155007|Experimental|Treatment Sequence ABC|Participants will receive a single oral dose of rilematovir (Treatment A) in Treatment Period 1, followed by a single oral dose of ciclosporin (Treatment B) in Treatment Period 2 and then single oral dose of ciclosporin plus single oral dose of rilematovir (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759259|NCT05155007|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759260|NCT05155007|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759261|NCT05155007|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759262|NCT05155007|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759263|NCT05155007|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
32759264|NCT01641107|Experimental|Ponatinib|
32759265|NCT04425317|Other|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
33072010|NCT05564039|Experimental|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC)
32759266|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
32759267|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
33072011|NCT05564039|Active Comparator|Dulaglutide|Participants will escalate their dulaglutide dose SC.
32759268|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
32759269|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
32759270|NCT04409405||Cured population|• Age ≥ 5 year old
32759271|NCT04409405||Contact population|"Age ≥ 5 year old~Contact of a participant included in cured-population cohort~Not diagnosed with EVD"
32759272|NCT04309799|Other|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
32759273|NCT04309799|Other|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
32759274|NCT05073263|Active Comparator|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
32759275|NCT05073263|Experimental|Full weight -bearing for the first six weeks after surgery|If the patient is randomized to the full weightbearing group, the patient will be instructed about acceptable exercises and activities.
32759276|NCT05073029|Active Comparator|standard care group|3-month course of individually selected nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
32759277|NCT05073029|Experimental|intervention group|additionally to previous group recieved treatment with synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103) and vitamin D3 - 2000 IU. The students were instructed to take vitamin D3 and synbiotic sachets twice a day for 3 months.
32901522|NCT05150496|Experimental|Two doses CoronaVac® + one dose medium-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using medium-dose CoronaVac®3-8 months after their second dose
33397299|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
33397300|NCT04854642|Experimental|T - R (fed then fasting condition)|Subjects were assigned to the sequence of treatments TR to receive Ladarixin in fed conditions (T treatment) during period 1 and in fasting conditions (R treatment) in period 2.
33397301|NCT04854642|Experimental|R - T (fasting then fed condition)|Subjects were assigned to the sequence of treatments RT to receive Ladarixin ini fasting conditions (R treatment) in period 1 and in fed conditions (T treatment) during period 2.
33397302|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
33240555|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
33240556|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
33240557|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
33240558|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
33240559|NCT05273762|Experimental|FlowTriever|
33240560|NCT00754143|Placebo Comparator|A|Placebo
33240561|NCT00754143|Experimental|B|FG-3019 5 mg/kg
33240562|NCT00754143|Experimental|C|FG-3019 10 mg/kg
33397303|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
32759278|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
32759279|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
32759280|NCT04268849|Active Comparator|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
32759281|NCT04268849|Active Comparator|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
32759282|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
32759283|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
32759284|NCT05072873|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
32759285|NCT05072873|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
32759286|NCT03970967|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
32759287|NCT05072405|Other|simvastatin 20 mg (Zocor®, MSD)|simvastatin 20 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases.
32759288|NCT05072405|Other|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases
32759289|NCT05072327|Experimental|Mohs surgery conbind with cryotherapy|patients in this group received both Mohs surgery and cryotherapy.
32759290|NCT05072327|Active Comparator|Mohs surgery|patients in this group received only Mohs surgery.
32759292|NCT03962855|Active Comparator|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
32759293|NCT03962855|Placebo Comparator|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
32759294|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
32759295|NCT05071547|Experimental|Internet-delivered acceptance and commitment therapy addition|The IACT addition supplies participants with weekly educational material and additional exercises in line with live IRPR, although enriched with multimedia. Participants will have access to their rehabilitation content via the web-site and can practice in their homes in-between live sessions of IRPR.
32759296|NCT05071547|Active Comparator|Interdisciplinary pain rehabilitation program|A 6-week long multimodal treatment including approximately 108 hours on site, focusing on return to work. Psychologists, physicians, physiotherapists (PT) and occupational therapists (OT) give synchronized treatments with a CBT/ACT approach.
32759297|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
32759298|NCT05071391||Obese|Obese patients undergoing Roux-en-Y gastric bypass
32759299|NCT05071781|Active Comparator|Cortisol releasing hormone group|HVs will start with CRH infusion.
32759300|NCT05071781|Placebo Comparator|Placebo (sodium choride) group|HVs will start with NaCl 0.9% (placebo) infusion
32759301|NCT05071001|Experimental|A|
32742425|NCT04427007|Experimental|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
32759302|NCT05071001|Experimental|B|
32759303|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
32759304|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
32759305|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
32759306|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
32759307|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
32759308|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
32759309|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
32759310|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
32759311|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
32759312|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency
32759313|NCT02481349|Experimental|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
32759314|NCT02481349|Active Comparator|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
32759315|NCT04479865|Experimental|Sequence 1|Period 1, Aricept 5mg → DA-5207 150mg; Period 2, Aricept 5mg → Aricept 10mg
32759316|NCT04479865|Experimental|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 150mg
32759317|NCT04479865|Experimental|Sequence 3|Period 1, Aricept 5mg → DA-5207 170mg; Period 2, Aricept 5mg → Aricept 10mg
32759318|NCT04479865|Experimental|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 170mg
32759319|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
32759320|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
32759321|NCT03494335||Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
32759322|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
32759323|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
32759324|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
32759325|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
32759326|NCT03491059|Experimental|Full Study - Radiation|
32759327|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
32759328|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
32759329|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
32759330|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
32759331|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
32759332|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
32759333|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
32759334|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
32759335|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
33397304|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
33240563|NCT05684198|Experimental|subcutaneous NPWT|The peritoneum and fascia will be closed as in the PC arm. Subsequently, patients will be treated with commercially available vacuum-assisted closure systems (provided by Smith&Nephew or Hartmann) according to the manufacturer's instructions. Following fascia closure, the NPWT foam will be adjusted to the wound size to fill the wound cavity without causing excessive wound dehiscence. Subsequently, the foam will be placed in the subcutaneous tissue. The foam will not be fixated on the skin with sutures. The wound will be sealed with adhesive film. In case of air leak in problematic areas such as the navel or ostomy, ostomy paste will be used to create a tighter seal. Continuous pressure of 120 mmHg will be applied. On the 3rd day postop, the dressing will be removed and closure by secondary intention will be performed.
32742426|NCT04427007|Other|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
32742427|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
32742428|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
32742429|NCT04977141||Under-represented minority|Non-English speaking and/or non-White
32742430|NCT04977141||Non-under-represented minority|English-speaking and/or White
32742431|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
33397305|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
33397306|NCT01358019|Experimental|LY2523355|
33072012|NCT05559359|Experimental|Lebrikizumab (Cohort 1)|"Participants who are 6 years to <18 years of age, 12 years to <18 years of age who weigh <40 kilogram (kg) or 6 years to <12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).~Dosing will be based on weight."
33397307|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
32742432|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
33397308|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
33397309|NCT01355367|Experimental|Arm 1|
33397310|NCT05759520|Experimental|2-month-old experimental group|Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)
33397311|NCT05759520|Active Comparator|2-month-old control group|Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)
33397312|NCT05759520|Experimental|3-month-old group|Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)
33397313|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
32742433|NCT04976673|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
32742434|NCT04976673|Active Comparator|Steroid side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
33240564|NCT05684198|No Intervention|primary closure|The peritoneum will be closed as a separate layer with a 2-0 multifilament absorbable suture. Subsequently, the fascia will be closed with a continuous suture using absorbable monofilament 0 sutures. Subcutaneous tissue will be rinsed twice with hypochlorite solution following peritoneal closure and fascial closure. Interrupted subcutaneous closure will be performed with absorbable multifilament 2-0 sutures. Following skin disinfection with an alcohol solution, the skin will be closed with non-absorbable monofilament 2-0 or 3-0 sutures using the interrupted mattress technique. Conventional Cosmopor® sterile gauze dressings will be applied. Unless the dressing material will be saturated, the dressing will remain unchanged until 3rd day post-op.
32759336|NCT03473821|Experimental|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
32759337|NCT05263843||Patients|Patients with a complex congenital heart disease
32759338|NCT05263843||controls|healthy subjects
32759339|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
32759340|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
32759341|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
32759342|NCT05251129|Experimental|Higher Intensity Statin|Atorvastatin 80 mg daily
32759343|NCT05251129|Active Comparator|Lower Intensity Statin|Pravastatin 40 mg daily
33240565|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
33240566|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
33240567|NCT04083248|Experimental|Feasibility group|"Intervention components:~Personalized group diabetes education.~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
33240568|NCT05266040|Experimental|valacyclovir group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
33240569|NCT05266040|Placebo Comparator|Control group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
33240570|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
33397314|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
32759346|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
32759347|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
32759348|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
32759349|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
32759350|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
32759351|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
32759352|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
32759353|NCT03412591|Other|Open label trial of suvorexant in SUDs|It is an open label trial to study the efficacy of suvorexant in a group of opioid use and alcohol use disorder subjects.
32759354|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.~Nivolumab: 3 mg/kg IV Q2 weeks.~Ipilimumab: 1 mg/kg Q6 weeks.~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
32759355|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
33240571|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
33240572|NCT05325710|Active Comparator|TD2 standard|Standard TD2 follow-up
33240573|NCT05325710|Experimental|TD2+ study Nurse|Specific study nurse follow-up every 4 months in addition of standard FU.
32759356|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
32742435|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~Prolonged mechanical ventilation (longer than 96 hours)~Tracheostomy~Sepsis~Serious injury (burn)~Stroke (hemorhagic or ischemic)~Traumatic brain injury"
33240574|NCT00773747|Experimental|Vorinostat + Bortezomib|Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
33240575|NCT00773747|Placebo Comparator|Placebo + Bortezomib|Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
33240576|NCT05123222|Experimental|ZIKV-SJRP/2016-184 Strain|Dose of 10ˆ2 PFU Dose escalation of 10ˆ3 PFU Dose escalation of 10ˆ4 PFU
33240577|NCT05123222|Experimental|ZIKV-Nicaragua/2016 Strain|Dose of 10ˆ2 PFU Dose escalation of Dose of 10ˆ3 PFU Dose escalation of 10ˆ4 PFU
33240578|NCT05123222|Placebo Comparator|Placebo|
33240579|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
32742436|NCT04969497|Experimental|Sequence ABC|Receives interventions in the sequence, A, B, C.
33240580|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
32759357|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
32759358|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
32759359|NCT05206591|Experimental|Secukinumab|Secukinumab 300 mg s.c
32759360|NCT05206591|Placebo Comparator|Placebo|Placebo s.c.
32759361|NCT05168449|No Intervention|Control Group|Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, with an access to the previously described mobile application
32759362|NCT05168449|Experimental|Intervention Group|Intervention group will be provided in addition to the usual care, with an access to the mobile application
32759363|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
32759364|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
32759365|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
32759366|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
32759367|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
32759368|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
32759369|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
32759370|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
32759371|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
32759372|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
32759373|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
32759374|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
33240581|NCT05329220|Experimental|ABNCoV2 100μg single dose|ABNCoV2 100μg single dose
33240582|NCT05329220|Active Comparator|Comirnaty|Comirnaty
33240583|NCT04104191|Experimental|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
32759375|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
32759376|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
32759377|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
32759378|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
32759379|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
32759380|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
32759381|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
32759382|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
32759383|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
32759384|NCT02382757||Children|
32759385|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
32759386|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
32759387|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
33240586|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
33240587|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
33240588|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
33240589|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
32742437|NCT04969497|Experimental|Sequence CAB|Receives interventions in the sequence, C, A, B.
32742438|NCT04969497|Experimental|Sequence BCA|Receives interventions in the sequence, B, C, A.
33240590|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
33240591|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
33240592|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
33240593|NCT05116748||LuTx recipients|Lung Transplant recipients
33240594|NCT05116748||OLT recipients|Orthotopic Liver Transplant recipients
32742439|NCT04969497|Experimental|Sequence CBA|Receives interventions in the sequence, C, B, A.
33397315|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
32742440|NCT04969497|Experimental|Sequence BAC|Receives interventions in the sequence, B, A, C.
32759388|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
32759389|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
32759390|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
32759391|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
32759392|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
32759393|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;~Patients treated with non-anthracycline based therapy as an initial treatment."
32759394|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;~Patients treated with non-anthracycline based therapy as an initial treatment."
32759395|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
32759396|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
32759397|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
32759398|NCT02382835||Metal-on-Metal Hip Replacement|
32759399|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
32759400|NCT05231317|Experimental|Experimental: Plant-based diet|Diet rich in fruit and vegetables (42% carbohydrates, 17.2% fibres; 15% proteins and 43% fats).
32759401|NCT05231317|Active Comparator|Active Comparator: Western diet|Diet Rich in Processed Foods (48% carbohydrates, 10.4% fibres; 14% proteins and 39% fats).
33240595|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
32759402|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
32759403|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
32759404|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
32759405|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
32759406|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
32759407|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
32759408|NCT02386501|Experimental|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
33240596|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
33240597|NCT05254964|Experimental|Intensive cognitive rehabilitation group|Participants receive intensive cognitive rehabilitation for 20 hours for 4 weeks.
33240598|NCT05071274|Experimental|SkinPen Precision System|"After a 15-minute acclimation to ambient temperature and humidity conditions, subjects will participate in bio instrumentation to assess for erythema and will participate in standard photography.~The Investigator will treat each subject's face from hairline to jawline with the SkinPen Precision System following instructions in the SKINPEN PRECISION SYSTEM INSTRUCTIONS with the following treatment of the face at depths of up to 1.5mm. Treatment depth will be recorded for each subject at every visit. Subjects will be dispensed a study provided diary and trained on compliance."
33240599|NCT05114252|Experimental|Participants with amblyopia in the serious games intervention|Participants with amblyopia receiving the experimental intervention consisting of serious videogames focusing on binocular function (with image modification) in a virtual reality environment.
33240600|NCT05114252|Active Comparator|Participants with amblyopia in the standard care intervention|Participants with amblyopia receiving the standard care intervention consisting of wearing spectacles with individualized refractive correction.
33240601|NCT05114252|Active Comparator|Healthy participants|Participants without amblyopia or other conditions receiving the experimental intervention consisting of serious videogames focusing on binocular function (without any image modification) in a virtual reality environment.
33240602|NCT05113784|Experimental|Meplazumab for Injection|First dose: 0.2 mg/kg - Day 1; Second dose: 0.2 mg/kg - Day 8
33240603|NCT05113784|Placebo Comparator|Placebo|First dose: control - Day 1; Second dose: control -Day 8
33240604|NCT05684744|Experimental|Roflumilast|oral roflumilast in a dose of 500 mcg per day
32759409|NCT05547841||Trial group|A total of 680 singleton pregnant women in the first trimester (gestational age of 6-13 weeks + 6 days), who had normal results in various examinations and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 34 centers, with 20 cases in each center.
32759410|NCT02391727|Other|SYN004|open label study
33240605|NCT05684744|Active Comparator|Methotrexate|oral methotrexate in a dose of 0.2- 0.4 mg/kg/week
33240606|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
33240607|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
33240608|NCT02588456|Experimental|Single Arm|
33240609|NCT05252702|Other|Single Arm|Non randomized arm
32742441|NCT04969497|Experimental|Sequence ACB|Receives interventions in the sequence, A, C, B.
32742442|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
33397316|NCT03729648|Experimental|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
32742443|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
32742444|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
32759411|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
33240610|NCT05109728|Experimental|Group 1 - Newly diagnosed GB (methylated MGMT)|Participants with newly diagnosed glioblastoma with methylated MGMT, will receive [177Lu]Lu-DOTA-TATE every 4 weeks +/- 2 days, starting 7 to 10 days prior to initiation of Radiotherapy (RT) and Temozolomide (TMZ)
33072013|NCT05559359|Experimental|Lebrikizumab (Cohort 2)|"Participants who are 6 months to <6 years of age, 2 years to <6 years of age or 6 months to <2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.~Dosing will be based on weight."
33240611|NCT05109728|Experimental|Group 2 - Newly diagnosed GB (unmethylated MGMT)|Participants with newly diagnosed glioblastoma with unmethylated MGMT, will receive [177Lu]Lu-DOTA-TATE every 4 weeks +/- 2 days for the first 3 doses (starting 7 to 10 days prior to initiation of Radiotherapy (RT) and at week 4 and week 8 after Radiotherapy (RT) initiated) and every 3 weeks +/- 2 days for the following doses
33240612|NCT05109728|Experimental|Group 3 - Recurrent GB|Participants with recurrent glioblastoma will receive [177Lu]Lu-DOTA-TATE as single agent therapy every 3 weeks +/- 2 days
33240613|NCT05107544|Experimental|High Intensity Interval Training|The entire group is going to be undergo the intervention
33072014|NCT05559359|Placebo Comparator|Placebo|Participants will receive placebo matching lebrikizumab by SC injections with a TCS.
33072015|NCT05558566|Experimental|Neurofeedback from the SMA|
33072016|NCT05558566|Active Comparator|Neurofeedback from control region|
33072017|NCT05557942|Experimental|low dose AV-101|
32759412|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
32759413|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
33240614|NCT05099822|Experimental|Administration of CC-97489|
33240615|NCT05099822|Experimental|Administration of Placebo|
33240616|NCT05099276|Experimental|Oral TXA|1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
33240617|NCT05099276|Placebo Comparator|Oral placebo|Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
33240618|NCT05103878|Experimental|BT051 100 mg|Participants will receive a single oral dose of 100mg BT051.
33240619|NCT05103878|Experimental|BT051 300 mg|Participants will receive a single oral dose of 300mg BT051.
33240620|NCT05103878|Experimental|BT051 700 mg|Participants will receive a single oral dose of 700mg BT051.
32759414|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
32759415|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
32759416|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
32759417|NCT02391649|Experimental|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
32759418|NCT02391649|Active Comparator|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
32759419|NCT02391649|No Intervention|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
33072018|NCT05557942|Experimental|medium dose AV-101|
33072019|NCT05557942|Experimental|high dose AV-101|
33240621|NCT05103878|Experimental|BT051 1500 mg|Participants will receive a single oral dose of 1500mg BT051.
33072021|NCT05552989||Key stakeholders of the local disaster relief community|
33240622|NCT05103878|Experimental|BT051 3500 mg|Participants will receive a single oral dose of 3500mg BT051.
33240623|NCT05103878|Placebo Comparator|Placebo|Participants will receive a single oral dose of Placebo matching BT051 dose.
33240624|NCT05307692|Experimental|Seltorexant|Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.
33240625|NCT05307692|Placebo Comparator|Placebo|Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.
33240626|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
33240627|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
33240628|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
33240629|NCT05094206|Experimental|Indolent B-cell NHL Dose Level -2: 0.75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240630|NCT05094206|Experimental|Indolent B-cell NHL Dose Level -1: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240631|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 0: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240632|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 1: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33397317|NCT03729648|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
33240633|NCT05094206|Experimental|Indolent B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
33240634|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level -1: .75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240635|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240636|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240637|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 2: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
33240638|NCT05094206|Experimental|Aggressive B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
33072024|NCT05550922|Experimental|Healthcare transition based education|The content of the education program and interviews include: the importance of transition readiness from pediatric to adult care; asthma, asthma management, asthma support groups and literature; asthma self-management skills (making appointments, taking medications regularly, knowing the risks and what to do during an asthma attack, visiting doctors alone, getting a prescription, communicating with health care professionals); filling out medical forms; insurance; decision making, autonomy, career plans; characteristics of adolescence; pediatrics and adult care differences; transition planning; discussions on case studies; knowledge and skills related to adult pulmonology service procedures; interview with pediatric and adult pulmonologists.
33072025|NCT05550922|No Intervention|No Intervention|Control: Not all control group participants will receive health care transition-based training. The control group will receive standard outpatient clinic asthma treatment during this process.
33072026|NCT05550818|Experimental|High Ultra Processed Food Diet|Participants will consume a diet containing 81% total energy from UPF for 2 weeks.
33240639|NCT05237648|Experimental|Experimental Group|Participants will complete an online module with content focusing on patient self-rating of vocal quality within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session;
33240640|NCT05237648|Sham Comparator|Sham Control Group|Participants will complete an online module within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session with content focusing on vocal hygiene.
32759420|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
33072027|NCT05550818|Experimental|No Ultra Processed Food Diet|Participants will consume a diet containing 0% total energy from UPF for 2 weeks.
33072028|NCT05550597|Experimental|Group F|The intrathecal additive Fentanyl with hyperbaric bupivacaine
33072029|NCT05550597|Experimental|Group FT|The intrathecal additive of fentanyl with hyperbaric bupivacaine along with Ultrasound-guided TAP block
33072030|NCT05550597|Experimental|Group T|Hyperbaric bupivacaine along with Ultrasound-guided TAP block without the intrathecal addition of fentanyl
33240641|NCT05237648|No Intervention|Control group|Participants will not complete an online module. The groups will be compared in terms of attendance, self-efficacy, and treatment outcome measures based on the data collected within the NYU Voice Center standard of care
33240642|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
33072033|NCT05548140|Experimental|NOVEL MOTORIZED SPIRAL ENTEROSCOPY|This arm involves performance of spiral enteroscopy using a specialized enteroscope under general anaesthesia in patients who fulfill the inclusion criteria.
33072034|NCT05548140|Active Comparator|SINGLE BALLOON ENTEROSCOPY|This arm involves performance of single balloon enteroscopy using a specialized single balloon enteroscope in patients who fulfill inclusion criteria.
33240643|NCT00758199|Active Comparator|2|Moxifloxacin
33240644|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
33240645|NCT00758199|Active Comparator|1|Bromfenac
33240646|NCT00919412||Preterm delivery (< 37 weeks)|
33240647|NCT00919412||Term delivery (>=37 weeks)|
33240648|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
33240649|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
33240650|NCT00919490|Experimental|Group 1|Single dose of 400 mg
33240651|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
33072045|NCT05541276|Experimental|Melatonin|Participants receive melatonin solution for injection 1 mg/mL in a dosage of 0.15 mg/kg body weight as a single intravenous injection approximately 30 minutes before end of surgical procedure.
33072046|NCT05541276|Placebo Comparator|Placebo|Participants receive isotonic sodium chloride (9mg/mL) intravenously once approximately 30 minutes before end of surgical procedure in a volume equivalent to the melatonin group for the same weight.
33072049|NCT05537753|Experimental|Encore PFO closure device|
33072050|NCT05537753|Active Comparator|Any FDA-approved PFO closure device chosen by the investigator|
33072051|NCT05537662|Experimental|Subjects using Neuromodulation Therapy (SCS or DRG)|Patients will trial standard of care neuromodulation therapy (SCS or DRG), and if successful will proceed to a permanent implant.
33072053|NCT05536804|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
33072054|NCT05536804|Placebo Comparator|Placebo|Placebo administered SC
33240652|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
33240653|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
32759421|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
32759422|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
32759423|NCT02386579||Diabetics with Charcot foot|
32759424|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
32759425|NCT05146453|Experimental|Intervention|This group of patients will undergo placement of US guided pectointercostal fascia blocks.
32759426|NCT05146453|Placebo Comparator|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
32759427|NCT05104489|Experimental|Low Dose|50 mcg of antigen with 250 mcg of Al(OH)3
32759428|NCT05104489|Experimental|Median Dose|100 mcg of antigen with 250 mcg of Al(OH)3
32759429|NCT05104489|Experimental|High Dose|100 mcg of antigen with 500 mcg of Al(OH)3
33240654|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
32759430|NCT05104489|Placebo Comparator|Placebo|250 mcg of Al(OH)3
32759431|NCT05101213|Experimental|Treatment for viral infections (virus-specific CTLs)|Patients receive virus-specific CTLs intravenously (IV) over 30 minutes. Patients with partial response, stable disease, or progressive disease may receive up to 8 additional infusions of virus-specific CTL at least 2 weeks between each infusion.
32759432|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
32759433|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
32759434|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
32759435|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
32759436|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
32759437|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
32759438|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
33072055|NCT05535842|Experimental|Intervention|Participants in the intervention group will use GLOW the conversational agent/app for 6 months in addition to their usual diabetes care offered by their attending doctor or endocrinologist.
32759439|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
32759440|NCT02382055|Experimental|REACH|Psychotherapy
33072056|NCT05535842|No Intervention|Control|The control group will continue with their usual care, i.e., scheduled consultations with their diabetes team at TTSH and any consultations with healthcare professionals and diabetes education support received either during the consultations or during dedicated times if there are any. They will not be asked to use GLOW during the trial.
33072057|NCT05535764|Experimental|Treatment: All Patients|A 3+3 dose de-escalation design will be used to determine the recommended phase 2 dose,while ensuring the safety and tolerability of the treatment. In this trial, the dose determined to be the maximum tolerated dose will be the recommended phase 2 dose and will be utilized in the cohort expansion.
33072058|NCT05524883|Experimental|Placebo-Controlled MAD Period - DYNE-251|DYNE-251 will be administered 6 times over 24 weeks.
33072059|NCT05524883|Experimental|Placebo-Controlled MAD Period - Placebo|Placebo will be administered 6 times over 24 weeks.
33072060|NCT05524883|Experimental|Open-Label and Long-Term Extension Period - DYNE-251|DYNE-251 will be administered up to 30 times (over 120 weeks) after participants complete the Placebo-Controlled MAD Period of the study.
33072061|NCT05522855|Experimental|Intervention Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion.
33240655|NCT05434767|Active Comparator|Standard rehabilitation program|
33240656|NCT05434767|Experimental|Mobile application|
33240657|NCT05434611||Kawasaki disease|All children with Kawasaki disease met the diagnostic criteria for Kawasaki disease revised by the American Heart Association in 2017.
33240658|NCT05434611||Healthy controls|Healthy control group were healthy children who underwent outpatient physical examination.
33397318|NCT02567643|Experimental|Stereotactic Radiosurgery|
33397319|NCT04789200|Experimental|NX9 oral contrast agent|Subjects will be given a 9% w/w HBGM concentration of NX9 provided as 1.2L of liquid.
32759441|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
32759442|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
32759443|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
32759444|NCT02381821||pregnant|women undergoing ICSI who became pregnant
32759445|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
32759446|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
32901523|NCT05150496|Experimental|Two doses CoronaVac® + one dose high-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using high-dose CoronaVac® 3-8 months after their second dose
33072062|NCT05522855|Active Comparator|Control Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server like the Intervention version, but no mental workload or brain energy data will be displayed.
33072063|NCT05520567|Experimental|Dose Ranging Phase (Phase 1)|Participants will receive daily dose of gilteritinib and venetoclax for 28 days, and azacitidine for 7 days in each 28-day cycle.
33072064|NCT05520567|Experimental|Dose Expansion Phase (Phase 2)|Participants will receive daily dose of gilteritinib, venetoclax, and azacitidine at an optimized dose established from dose ranging phase (Phase 1)
33240659|NCT05082116|Experimental|N8-GP prophylaxis|All patients will receive prophylaxis with 50 IU/kg N8-GP every 4 days for a treatment period of at least 28 weeks (with the possibility of switching to twice-weekly dosing during the treatment period at the discretion of the investigator).
33240660|NCT05081570|Experimental|Intervention group|The participants will receive two tertiary stroke care consultations provided by stroke nurses via telecare in 2 months.
33072065|NCT05519475|Active Comparator|Study 1 ALN-HSD Low Dose|
33072066|NCT05519475|Active Comparator|Study 1 ALN-HSD High Dose|
33240661|NCT05077904|Experimental|Staccato alprazolam Arm|Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
33240662|NCT05077904|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive a single dose of placebo by inhalation.
33240663|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
33240664|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
33072067|NCT05519475|Placebo Comparator|Study 1 Placebo|
33072068|NCT05519475|Active Comparator|Study 2 ALN-HSD Low Dose|
33072069|NCT05519475|Active Comparator|Study 2 ALN-HSD High Dose|
33072070|NCT05519475|Placebo Comparator|Study 2 Placebo|
33072071|NCT05519085|Experimental|480Vd (CC-92480, bortezomib and dexamethasone)|
33072072|NCT05519085|Experimental|PVd (pomalidomide, bortezomib and dexamethasone)|
33240665|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
33240666|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
33072073|NCT05514054|Experimental|Imlunestrant|Imlunestrant administered orally.
33072074|NCT05514054|Active Comparator|Investigator's Choice of Endocrine Therapy|Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.
33072075|NCT05512949|Experimental|Arm 1|0.1 mL of 2 x 10^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
33072076|NCT05512949|Experimental|Arm 2|0.05 mL of 1 x 10^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
33072077|NCT05512949|Active Comparator|Arm 3|0.5 mL of 1 x 10^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on Days 1 and 29. N=70
33072078|NCT05511922|Experimental|KVD900 600 mg|
33072079|NCT05509790|Experimental|LY3484356 Dose Level 1|Administered orally.
33072080|NCT05509790|Experimental|LY3484356 Dose Level 2|Administered orally.
33240667|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
33072082|NCT05508789|Experimental|Donanemab|Participants will receive donanemab intravenously (IV)
33072083|NCT05508789|Placebo Comparator|Placebo|Participants will receive placebo IV
33072084|NCT05505916|Experimental|KVD900 600 mg|
33240668|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
33240669|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
33240670|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
33240671|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
33240672|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
33240673|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
33240674|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
33072085|NCT05502861|Experimental|Intervention|The study's intervention is a prognostic-triggered EHR alert to nudge clinicians to provide generalist or specialist PC. The alert notifies the clinician that the patient is likely to benefit from PC, and requires clinicians to actively choose to provide generalist PC themselves, consult PC specialist, or to defer PC. If a clinician chooses to consult specialist PC, a second alert will fire that enables them to easily and quickly place the consult order. The alert will trigger for all patients with moderate or higher 6-month mortality risk on second full hospital day at 8AM.
33072086|NCT05502861|Active Comparator|Control/Usual Care|During the control phase, patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care. The length of the control phase will differ at each hospital dependent on the sequence in which hospitals are randomly assigned to switch to the intervention phase. All hospitals contribute a minimum of 4 months of outcomes data prior to adopting the intervention.
33072087|NCT05496062|Experimental|F&P Toffee Nasal and Toffee Nasal Pillows Mask|Participants will be placed in the experimental arm for 14 days, during which they will be using either the Toffee Nasal or Toffee Nasal Pillows mask for PAP therapy.
33072088|NCT05495269|Experimental|QLS-101, 2.0%|Qlaris' investigational product, QLS-101, 2.0% concentration, ocular administration (eye drop), given once daily in the morning to both eyes
33240675|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
33240676|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
33240677|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
33240678|NCT05434377|Active Comparator|Vitamin D supplementation using titration regimen|"Patients will receive ergocalciferol orally depending on serum 25(OH)D level as described~serum 25(OH)D < 5 ng/ml --> receive ergocalciferol 50,000 IU/week for 3 months followed by 50,000 IU monthly for 3 months~serum 25(OH)D 5-15 ng/ml--> receive ergocalciferol 50,000 IU/week for 1 month followed by 50,000 IU monthly for 5 months~serum 25(OH)D 16-30 ng/ml--> receive ergocalciferol 50,000 IU monthly for 6 months"
33240679|NCT05434377|Experimental|Vitamin D supplementation using fixed dose regimen|Patients will receive ergocalciferol 20,000 unit orally per week for 6 months.
33240680|NCT05428293|Experimental|Group A: Ibuprofen/ Acetaminophen oral suspension in fixed dose|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 100 mg/ Acetaminophen 125 mg/ 5 mL Dosage: 5 mL Administration way: oral
33240681|NCT05428293|Active Comparator|Group B: Ibuprofen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 2 g/100 mL Dosage: 5 mL (100 mg of ibuprofen) Administration way: oral
33240682|NCT05428293|Active Comparator|Group C: Acetaminophen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Acetaminophen 3.2 g/100 mL Dosage: 3.9 mL (125 mg of acetaminophen) Administration way: oral
33240683|NCT05427825|Experimental|ERAS group|Patients in the experimental group receive the protocolized anesthetic care bundle including EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
33240684|NCT05427825|Active Comparator|Control|Patients in the control group receive standard anesthetic care including bispetral index-guided balanced anesthesia and regular hemodynamic care protocols.
33240685|NCT05424237|No Intervention|Control group|"Sign consent form and baseline assessments~Usual care~Post intervention assessments"
33240686|NCT05424237|Experimental|Interention group|"Sign consent form and baseline assessments~Usual care + app iNATAL~Post intervention assessments"
33240687|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
32910609|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
32910610|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
32910611|NCT03901469|Experimental|Part 1 and Part 2|ZEN003694 will be administered PO QD with Talazoparib PO QD in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
32910612|NCT03901469|Experimental|Expansion Cohort A - Combination Treatment in post-TROP2-ADC patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
32910613|NCT03901469|Experimental|Expansion Cohort B - ZEN003694 Monotherapy|ZEN003694 will be administered PO QD as monotherapy at the RP2D in 28-day cycles with the option to cross-over to combination treatment of ZEN003694 PO QD with Talazoparib PO QD at the time of disease progression (but no sooner than after 6 weeks of monotherapy). Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
32910614|NCT03901469|Experimental|Expansion Cohort C - Combination Treatment in TROP2-ADC-naïve patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in China only.
32910615|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
32910616|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
32910617|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
32910618|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
33397320|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
32742445|NCT04976751|Experimental|Electrophysiological treatment group|Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
32910619|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
32910620|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
32742446|NCT04976751|No Intervention|Regular treatment group|Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
32742447|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
32742448|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
32742449|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
32742450|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
32742451|NCT04976829||adult (≥ 18 years) inpatients (hospitalised ≥ 48h)|
33240688|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
32742452|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
33240689|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
33240690|NCT00680121|Placebo Comparator|Control Group|Placebo
33240691|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
33240692|NCT00754533|Other|1|Continuous training
33240693|NCT00754533|Other|2|Interval training
33240694|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
33240695|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
33240696|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
33072091|NCT05494229|Experimental|Utilizing autologous whole blood for the full thickness macular hole|It is an interventional study by performing pars-plana vitrectomy
32742453|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
32742454|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
32742455|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
32742456|NCT04969029|Experimental|immunotherapy|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
33240697|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
33240698|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
33240699|NCT05375175|Experimental|Hybrid Snack|Hybrid Snack: combination of legumes, in the highest proportion, and lean meat.
33240700|NCT05375175|Active Comparator|Meat snack|Meat snack: composed of meat from loin tape
33240701|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
33240702|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
33240703|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
33240704|NCT00758277|Active Comparator|Levetiracetam|
33240705|NCT00758277|Placebo Comparator|Placebo|
33240706|NCT00584870|Active Comparator|Naproxen|
33240707|NCT00584870|Placebo Comparator|Placebo|
33240708|NCT00584870|Experimental|RN624|
33240709|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
33240710|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
33072092|NCT05487027|No Intervention|Control|This arm will have no intervention or instructions from researchers. Participants in this arm will perform their work planning as normal.
32901524|NCT05150496|Experimental|Two doses Comirnaty + one dose medium-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using medium-dose CoronaVac® 6-8 months after their second dose
33240711|NCT05683730|Experimental|Intermittent caloric restriction|Intermittent caloric restriction during 16 weeks.
33240712|NCT05683730|No Intervention|Routine practice|Routine practice
33240713|NCT05075408|Experimental|Nemolizumab 30 mg|
33240714|NCT05075408|Experimental|Nemolizumab 60 mg|
33240715|NCT05075408|Placebo Comparator|Placebo|
33240716|NCT00679263|Experimental|MN-221|
32910621|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
32910622|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
32910623|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
32910624|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
32910625|NCT04618055|Experimental|NiTiDent Tuah Porous NiTi Dental Implants|
32910626|NCT04618055|Active Comparator|Control Implant|
32910627|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
32910628|NCT01717001||ConforMIS|Patients with ConforMIS implants
32910629|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
32910630|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
33072093|NCT05487027|Experimental|Intervention|Introduce a deliberate variation between workers in how much they care for physically strenuous users. Some workers may receive more strenuous work compared to before, some less.
32901525|NCT05150496|Experimental|Two doses Comirnaty + one dose high-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using one dose high-dose CoronaVac® 6-8 months after their second dose
33240717|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
33240718|NCT05071586|Experimental|Children diagnosed with stroke/brain bleed|Male and females aged 8 to 21 with established diagnosis of stroke/brain bleed who are US residents.
33240719|NCT05067686||Mental Health Professionals|
33240720|NCT05067686||Non Mental Health Professionals|
33240721|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
33240722|NCT05228210||Partners of breast cancer survivors|Convenience sample of partners/significant others/spouses of breast cancer survivors
33240723|NCT05227352|Experimental|Biophilic experience|Healthcare workers will experience the biophilic-designed room
32901526|NCT04421586|Experimental|Pregnant women receiving VISTA counseling|Up to 30 pregnant women are screened and counseled for vaccine concerns using VISTA
33240724|NCT05227196|Experimental|Group 1 Sequence 1|Crossover arm
32901527|NCT04421586|No Intervention|Pregnant women receiving usual care|Up to 30 pregnant women receiving usual care
32901528|NCT05149872|Other|TOF ratio 0.9 spontaneous recovery|TOF ratio maintained at 0.9, spontaneous recovery
32901529|NCT05149872|Other|TOF ratio 0.7 spontaneous recovery|TOF ratio maintained at 0.7, spontaneous recovery
33072094|NCT05486208|Experimental|LY3844583 (Part A)|Single doses of LY3844583 administered subcutaneously (SC) and/or intravenously (IV).
33072095|NCT05486208|Experimental|LY3844583 (Part B)|Multiple doses of LY3844583 administered SC and/or IV.
33240725|NCT05227196|Experimental|Group 1 Sequence 2|Crossover arm
33240726|NCT05227196|Experimental|Group 2 Sequence 1|Crossover arm
33240727|NCT05227196|Experimental|Group 2 Sequence 2|Crossover arm
33240728|NCT05227196|Experimental|Group 3 Sequence 1|Crossover arm
33240729|NCT05227196|Experimental|Group 3 Sequence 2|Crossover arm
33240730|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
33240731|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
33240732|NCT00680043|Active Comparator|Epoetin Alfa|
32901530|NCT05149872|Other|TOF ratio 0.7 low dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 2 mg/kg
33240733|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
32901531|NCT05149872|Other|TOF ratio 0.7 high dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 4 mg/kg
33072096|NCT05486208|Experimental|LY3844583 (Part C)|Repeat doses of LY3844583 administered SC and/or IV.
33072097|NCT05486208|Placebo Comparator|Placebo (Part A)|Placebo administered SC and/or IV.
33072098|NCT05486208|Placebo Comparator|Placebo (Part B)|Placebo administered SC and/or IV.
33072099|NCT05486208|Placebo Comparator|Placebo (Part C)|Placebo administered SC and/or IV.
32910631|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
33240734|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
33240735|NCT05065190|Experimental|nintedanib|
33240736|NCT05065190|Placebo Comparator|Placebo|
33240737|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
33240738|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
33397321|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
33240739|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
33240740|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
33240741|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
33240742|NCT02560545|Placebo Comparator|Placebo|Oil
32910632|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
32910633|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
32910634|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
32742457|NCT04969029|No Intervention|chemotherapy|The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).
32742458|NCT04968795||Control|Participate in filling the questionnaire but NOT the meditation/wellness session (control).
32742459|NCT04968795||Wellness Group|Participate in filling the questionnaire and the meditation/wellness session
32742460|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
32742461|NCT04976907||Perioperative patients|Patients undergoing perioperative assessment of vital signs.
32742462|NCT04432389|Experimental|ALLOB|Single injection of ALLOB at fracture site (4 ml)
32742463|NCT04432389|Placebo Comparator|placebo|Single injection of Placebo at fracture site (4 ml)
32742464|NCT03262805|Placebo Comparator|Placebo|Placebo
32742465|NCT03262805|Active Comparator|Active|Lanconone(R)
32742466|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
32742467|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
32742468|NCT04968873|Experimental|Patients with Choledocholithiasis|Patients were managed by elective open cholecystectomy and operative exploration of the common bile duct.
32742469|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
32742470|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
32742471|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
32742472|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
32742473|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
33397322|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
33072101|NCT05481151|Experimental|P1101 250-350-500mcg|Pre-filled Syringe, Q2W starting at 250-350-500, SC injection
32910635|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
32910636|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
33397323|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
33072102|NCT05481151|Active Comparator|Ropeginterferon alfa-2b-njft|Pre-filled Syringe, Q2W starting at 100 up to 500 (50mcg increases), SC injection
33240743|NCT03877029||Study II|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women who have never attended BreastScreen Norway despite of several invitation, and who are diagnosed with symtomatic breast cancer.~Both groups of women will receive the questionnaire."
33240744|NCT03877029||Study III|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway~Women free from breast cancer"
33397324|NCT05759442|Active Comparator|Metformin|Tablet Metformin HCl 500 mg per oral twice daily for 12 weeks
33397325|NCT05759442|Active Comparator|Apple cider vinegar|Apple Cider Vinegar 15ml per day diluted in 200 ml of water for 12 weeks
33397326|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:~Clinical progression to probable or definitive disseminated AdV disease Death"
33397327|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
33397328|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
33397329|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
33397330|NCT04483258|Active Comparator|Sedation with Insufflation|Sedation induction via oxygen mask %8 sevoflurane and reducing %3 concentration after rediotherapy start
33397331|NCT04483258|Active Comparator|İntravenous sedation|Midazolam+ Ketamine sedation
32759447|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
32759448|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
32759449|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
32759450|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
32759451|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
32759452|NCT02386111|Experimental|Varlilumab and Sunitinib|
32759453|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
32759454|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
32759455|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
32759456|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
32759457|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
32759458|NCT05233345|Experimental|Experimental group: web based occupational therapy program|"Web-based occupational therapy classes were carried out as 5 sessions per week, each session lasting 1 hour, for 3 weeks. In total, 15 sessions were performed during the study period.~Group activities were performed through the Zoom application by means of a video camera. Included painting and cake making together, sports activities to be performed simultaneously with the movements shown by the researcher, memory games, and games that can be played with the group, such as the categories game. Sports activities were performed in the last 15 minutes of group activities, 5 days a week, in order to increase the physical activity level of children whose physical activities decreased during the lockdown period at home.~Also, all study participants continued taking classes from the EBA program as part of their routine education plan while taking occupational therapy program. EBA program is online classes given by government on local television."
32759459|NCT05233345|No Intervention|Control Group|There are no interventions except EBA which all study participants are already taking classes from as part of their routine education plan. EBA program is online classes given by government on local television. This program is out of our study.
32759460|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
32759461|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
32759462|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
32759463|NCT05540665|Experimental|Daxdilimab Arm 1|Daxdilimab injections over a total of 104 weeks
32759464|NCT05540665|Experimental|Daxdilimab Arm 2|Daxdilimab injections over a total of 104 weeks
32759465|NCT05540665|Placebo Comparator|Placebo|Placebo injections over a total of 104 weeks
32759466|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
32759467|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
32759468|NCT04821154||1) Revision Splined CCK|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, constrained condylar knee (CCK) articular surface, Persona Revision femoral component, and splined femoral stem.
32759469|NCT04821154||2) Revision Cemented CCK|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
32759470|NCT04821154||3) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, posterior stabilized/constrained posterior stabilized (PS/CPS) articular surface, Persona Revision femoral component, and splined femoral stem.
32759471|NCT04821154||4) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
32759472|NCT04821154||5) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
32759473|NCT04821154||6) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
32759474|NCT04821154||7) Revision Cemented CCK with 5 Degree Primary Tibia|Patients who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
32759475|NCT04821154||8) Primary Splined CCK/CPS/PS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and splined femoral stem.
32759476|NCT04821154||9) Primary Cemented CCK/PS/CPS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
33397332|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
33397333|NCT04770480|Active Comparator|Standard Care (SC)|Standard Post-Surgical Care utilizing opioids.
32759477|NCT04821154||10) Primary Cemented CCK/PS/CPS with 5 Degree Primary Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
33397334|NCT04770480|Active Comparator|Enriched Surgical Management Pathway (EMP)|Enriched Surgical Management Pathway utilizing Physical Therapy and Mindfulness in addition to Standard Protocol.
32759479|NCT05069623|Experimental|VB10.2129 Part 1 Dose escalaton|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
32759480|NCT05069623|Experimental|VB10.2210 Part 1 Dose escalation|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
32759481|NCT05069623|Experimental|VB10.2129 Part 2 Dose expansion|The seleceted dose from Part 1 will be administered IM in a two-dose schedule.
32759482|NCT05069623|Experimental|VB10.2210 Part 2 Dose expansion|The seleceted dose from Part 1 will be administed IM in a two-dose schedule.
32759483|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
32759484|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
32759485|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
32759486|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
32759487|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
32759488|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
32759489|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
32759490|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
32759491|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
32759492|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
32759493|NCT02391259|Placebo Comparator|Placebo|No active drug
32759494|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
32759495|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
32759496|NCT04743505|Experimental|Phase I Dose Level 1: APL-101 + Standard of Care Osimertinib|"After 8-12 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
32759497|NCT04743505|Experimental|Phase I Dose Level 2: APL-101 + Standard of Care Osimertinib|"After 8-12 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
32759498|NCT04743505|Experimental|Phase II: APL-101 + Standard of Care Osimertinib|"After 8-12 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose (this dose will be determined in Phase I of the study) twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
32759499|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
32759500|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
32759501|NCT02391025|Experimental|Gallium-68 citrate|
32759502|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
32759503|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
32759504|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
32759505|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
33240745|NCT03877029||Study IV|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
33397335|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
33397336|NCT02419768|No Intervention|Control|All patients will not change their physical activities
33397337|NCT01358097||Patients with HPV positive tumors|
33397338|NCT01358097||Patients with HPV negative tumors|
33397339|NCT01358097||Control|
33397340|NCT05687916|Experimental|TAK-861 Dose 1|TAK-861 dose 1, orally for 8 weeks.
33397341|NCT05687916|Experimental|TAK-861 Dose 2|TAK-861 dose 2, orally for 8 weeks.
33240746|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
33240747|NCT05352633|Experimental|Intensive BP Arm|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
33397342|NCT05687916|Placebo Comparator|Placebo|TAK-861 matching placebo tablets, orally for 8 weeks.
32759506|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
32759507|NCT04479163|Experimental|Plasma|Convalescent plasma with an IgG titer against SARS-CoV2
32759508|NCT04479163|Placebo Comparator|Placebo|Normal Saline 0.9%
32759509|NCT04645264|Experimental|Indwelling Foley|Indwelling Foley placed during surgery
32759510|NCT04645264|Active Comparator|Straight Catheter|straight catheterization (in-and-out straight catheterization) will take place at the end of the surgery
32759511|NCT04645264|No Intervention|No Catheter|Patient is not catheterized
32759512|NCT02380963|Experimental|Colorado Diet with soy protein|
32759513|NCT02380963|Active Comparator|Colorado Diet|
32759514|NCT02381509||IVC Filter|IVC filter for the prevention of PE
32759515|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
32759516|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
32759517|NCT04694287||Volume flow group|The study will include consecutive patients undergoing standard fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after final balloon dilation.
32759518|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
32759519|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
32759520|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
32759521|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
32759522|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
32759523|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
32759524|NCT04693507|Experimental|Teverelix TFA 120 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (120 mg SC + 120 mg IM) and teverelix TFA maintenance doses of 120 mg SC at week 6 and 6-weekly thereafter up to week 24
32759525|NCT04693507|Experimental|Teverelix TFA 180 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (180 mg SC + 180 mg IM) and teverelix TFA maintenance doses of 180 mg SC at week 6 and 6-weekly thereafter up to week 24
32759526|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
32759527|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
32759528|NCT05482789|Experimental|Exenatide|Participant receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
32759529|NCT04985695|Active Comparator|Thoracic epidural anesthesia|Epidural analgesia during midline laparotomy
32759530|NCT04985695|Experimental|Bilateral rectus sheath block|Bilateral rectus sheath block during midline laparotomy
32759531|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
32759532|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
32759533|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
32910637|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
33397343|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
33397344|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
33397345|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
33397346|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
33397347|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
33397348|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
33397349|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
33397350|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
32759534|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
33397351|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
33397352|NCT04769856|Experimental|Non-fasting group|
33397353|NCT04769856|Experimental|Fasting group|
33397354|NCT05759364|Active Comparator|Intervention group- IV PAPAVERINE 80 mg|Administration of IV PAPAVERINE 80 mg in 100 ml of saline, once within half an hour before inserting a single-balloon balloon catheter
33397355|NCT05759364|Placebo Comparator|Conrol group- Placebo group.|Administration of 100 ml of saline within half an hour before the insertion of a single-balloon catheter
33397356|NCT04275531||regional anesthesia|surgical procedures which will be performed under intrathecal anesthesia without sedation
33397357|NCT04275531||sevoflurane|surgical procedures which will be performed under general anesthesia and sevoflurane will be used for maintenance of anesthesia
32759536|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
32759537|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
32759538|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
32759539|NCT02380885|No Intervention|TAU|Treatment as Usual
33397358|NCT04275531||isoflurane|surgical procedures which will be performed under general anesthesia and isoflurane will be used for maintenance of anesthesia
32759540|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
33397359|NCT04275531||propofol|surgical procedures which will be performed under general anesthesia and propofol infusion will be used for maintenance of anesthesia
33397360|NCT04764864|Active Comparator|Angioembolization|
32759541|NCT02380729||Parents of the index patient|"Both parents of the index patient.~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
32759542|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
33397361|NCT04764864|Active Comparator|Preperitoneal Pelvic Packing|
32759543|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
32759544|NCT04903327|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
32759545|NCT04903327|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
33397362|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
33397363|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
33397364|NCT03689712|Experimental|GC4419|
33397365|NCT03689712|Placebo Comparator|Placebo|
33397366|NCT04804527|Experimental|Intensified physiotherapy|In addition to usual care physiotherapy patients in the intensified physiotherapy group will receive an extra physiotherapy session of up to 30 minutes on every weekday starting on the first postoperative day. The session will include progressive functional training of basic mobility and walking in the ward delivered by an experienced physiotherapist affiliated with the trial. The aim of this additional session is to improve the functional advances achieved during the earlier physiotherapy session.
32759546|NCT04897009||Basic science (biospecimen collection)|Patients undergo blood sample collection at baseline (prior to first NAC treatment), after taxane and prior to first dose of A/C (for patients receiving a taxane), end of NAC, 1-4 weeks and 6 months post-surgery. Patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery.
32759547|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
32759548|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
32759549|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
32759550|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
32759551|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
33072103|NCT05480449|Experimental|Dose Escalation Arm|"The phase 1 dose escalation portion of the trial will use a standard 3+3 design to establish the recommended phase 2 dose of huCART19 cells in patients with subjects with prior treatment with CD19-directed CAR T cells. Two dose escalations of huCART19 are planned for the dose escalation phase."
32759552|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
33072104|NCT05480449|Experimental|Dose Expansion Arms|"If at least one dose level of the dose escalation phase is determined to be safe, the phase 2b dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of huCART19 cells that were determined to be safe in the dose escalation part of the trial. 2 cohorts are planned:~Cohort A (relapsed/refractory, CAR T cell naïve)~Cohort B (prior treatment with CD19-directed CAR T cells)"
33072105|NCT05474638|Other|Controlateral and simultaneous comparison of neuromuscular transmission monitors|Controlateral and simultaneous comparison of responses from acceleromyography- and mechanomyography-based neuromuscular transmission monitors in the same patients.
32759553|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
32759554|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
32759555|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
32759556|NCT04747561|Experimental|18F-PEG3-FPN PET|A positron probe for the targeted melanin
32759557|NCT04745221|Experimental|with auto-FMT|The patients in the experimental group took autologous fecal bacteria capsule about 3 weeks after bone marrow transplantation.
32759558|NCT04745221|No Intervention|empty capsule|The patients in this group took empty capsule about 3 weeks after bone marrow transplantation
32759559|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
32759560|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
32759561|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
32759562|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
32759563|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
32759564|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
32759565|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
32759566|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
32759567|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :~Administration of the first dose the first dose must be allergic food or placebo~Clinical monitoring for 45 minutes~Administration of the second dose"
32759568|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
32759569|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
32759570|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
32759571|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
32759572|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
32759573|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
32759574|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
32759575|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
32759576|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
32759577|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
32759578|NCT02384317|Experimental|CCX168|BID for 84 days
32759579|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
32759580|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
32759581|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
32759582|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
32759583|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
32759584|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
32759585|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
32759586|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
32759587|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
32759588|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
32759589|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
32759590|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
32759591|NCT04644640|Active Comparator|Telerehabilitation|
32759592|NCT04644640|Active Comparator|In-Person Rehabilitation|
32759593|NCT04669834|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program based on a recent systematic review in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators using clamshell exercise . No emphasis will be placed on stabilizing the core musculature before initiating any of those exercises.
32759594|NCT04669834|Experimental|group B|Patients in this group will receive the same program as group (A) plus core stability exercise , but the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
32759595|NCT01621126|Experimental|Intra-op neuromonitoring|
32759596|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
32759597|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
32759598|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
32759599|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
33240748|NCT05352633|Active Comparator|Standard BP Arm|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
33240749|NCT05436093|Experimental|68Ga-ACN376|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET/CT scan.
32910638|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
32910639|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
32910640|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
33240750|NCT05436015|Experimental|Intervention Group|In addition to usual standard care during childbirth in hospital, the intervention group will receive a virtual nature-based intervention
32910641|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
33240751|NCT05436015|No Intervention|Control Group|The control group receives the usual standard care during childbirth in hospital
33240752|NCT05058092|Experimental|Intervention|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at the randomization day (D0)"
32759600|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
32759601|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
32759602|NCT04668898||LRRK2 Parkinson Disease|Individuals with LRRK2-related Parkinson Disease
32759603|NCT04668898||GBA Parkinson Disease|Individuals with GBA-related Parkinson Disease
32759604|NCT04668898||Idiopathic Parkinson Disease|Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
32759605|NCT04668898||LRRK2 non-manifesting carriers|Individuals without Parkinson Disease who have a LRRK2 mutation
32759606|NCT04668898||GBA non-manifesting carriers|Individuals without Parkinson Disease who have a GBA mutation
32759607|NCT04668898||Healthy control|Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
32759608|NCT02389387|No Intervention|Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
32759609|NCT02389387|Experimental|Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
32759610|NCT05406739|Experimental|Spinal Cord Injury Group|Participants who have a spinal cord injury will receive two meals on two separate visits between five to seven days.
32759611|NCT05406739|Active Comparator|Control Group|Participants without a spinal cord injury will receive two meals on two separate visits between five to seven days.
32759612|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
33072108|NCT05468112|Experimental|Sky Meditation and Mindfulness Intervention|In person meditation classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions. An additional 7 online sessions will be delivered to participants in successive days after the initial in-person intervention. Participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. To support participants stabilization of the practices, optional daily guided practice will be offered online at a determined convenient time for all participants to allow full participation. The breathing techniques will be taught by certified instructors.
32759613|NCT02383849||Arm 2|Breastfeeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
32759614|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
32759615|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
32759616|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 4000 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
32759617|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
32759618|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
32759619|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
32759620|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
32759621|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
32759622|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
32759623|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
32759624|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
32759625|NCT04849741|Experimental|ION373|ION373 will be administered by intrathecal bolus (ITB) injection once every 12 weeks through Week 109.
32759626|NCT04849741|Placebo Comparator|Placebo|Matching placebo will be administered by ITB injection once every 12 weeks through Week 109.
32910642|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
32910643|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
32910644|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
33072109|NCT05463744|Experimental|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa by subcutaneously (SC)
33072110|NCT05463744|Active Comparator|Insulin Degludec|Participants will receive insulin degludec SC
33240753|NCT05058092|Other|Control|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at three months (M3) after randomization day"
33072112|NCT05462730|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory damage following ST-segment elevation myocardial infarction. The infusion of methylprednisolone will be given in the pre-hospital setting prior to primary PCI.
33072113|NCT05462730|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
33072114|NCT05461547|Other|Usual Care|
33240754|NCT05435937|Experimental|P4C-Swe intervention|Pupils in participating classes will receive the Partnering for change (P4C) intervention
33240755|NCT05435937|Active Comparator|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
33072115|NCT05461547|Experimental|Lung Ultrasound|
33072116|NCT05459181|No Intervention|Control arm|465 participants undergoing standard of care post-transplant surveillance
33240756|NCT05057078|Experimental|Intervention group|A mindfulness-based stress reduction program will be done once a week for eight weeks
33240757|NCT05057078|No Intervention|Control group|During study process, no application will be made to the control group.
33240758|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
33240759|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
32759627|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
32759628|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
32759629|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
32759630|NCT04835779||SFN Patients|Patients with diagnosed Small Fibre Neuropathy
32759631|NCT04835779||Patients undergoing chemotherapy|Patients undergoing chemotherapy and are expected to develop SFN as a result
32759632|NCT04835779||Healthy Volunteer|Healthy test person
32759633|NCT04835779||Healthy Volunteer PREPs|For the pain-evoked potentials (PREPs), 20 additional healthy control subjects are to be included. Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
32759634|NCT04823923|Other|Patients without renal insufficiency under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759635|NCT04823923|Other|Patients without renal insufficiency under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759636|NCT04823923|Other|Patients with moderate renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759637|NCT04823923|Other|Patients with moderate renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759638|NCT04823923|Other|Patients with severe or terminal stage renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759639|NCT04823923|Other|Patients with severe or terminal stage renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
32759640|NCT04820023|Experimental|BBT-176|
32759641|NCT02379481|Experimental|NS 550mg|NS 550mg/day
32759642|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
32759643|NCT02379481|Placebo Comparator|placebo|placebo
32759644|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
32759645|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
32759646|NCT04439773|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
32759647|NCT04439773|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
32759648|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
32759649|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
32759650|NCT05387083|Experimental|Low Dose of TP-05 (lotilaner)|Single Oral Low Dose of TP-05 tablet.
33072117|NCT05459181|Experimental|Intervention arm|465 participants undergoing HeartCare protocol surveillance
33072118|NCT05457842|Experimental|Breast Cancer|Participants will receive a single dose of ASP5354. Up to 6 dose levels will be administered.
32759651|NCT05387083|Experimental|High Dose of TP-05 (lotilaner)|Single Oral High Dose of TP-05 tablet.
32759652|NCT05387083|Placebo Comparator|Placebo|Single Oral Dose of placebo tablet.
32759653|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
32759654|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
32759655|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
32759656|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
32759657|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
32759658|NCT02379325|Experimental|Lets Quit|Given text message
32759659|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
32759660|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
32759661|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
32759662|NCT02383771|Sham Comparator|Control|No Drug
32759663|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
32759664|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
32759665|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
33072119|NCT05457842|Experimental|Melanoma|Participants will receive a single dose of ASP5354. Up to 5 dose levels will be administered.
33240760|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
32759666|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
32759667|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
32759668|NCT04685317|Experimental|Sentinel® Cerebral Protection System Group|Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation
32759669|NCT04685317|No Intervention|Standard of Care Group|Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation
32759670|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
32759671|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
32759672|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
32759673|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
32759674|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
32759675|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
32759676|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
32759677|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
32759678|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
32759679|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
32759680|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
33240761|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
32759683|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
32759684|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
32759685|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
32759686|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
32759687|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
32759688|NCT04305925|Experimental|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
32759689|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)~Washout period~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
32759690|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4~Washout period~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
32759691|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
32759692|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
32759693|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
32759694|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
32759695|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
32759696|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
32759697|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
32759698|NCT02371837|No Intervention|control group|No treatment group
32759699|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
33240762|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
32759700|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
32759701|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
32759702|NCT02378857||Control group|Age- and gender-matched healthy individuals
32759703|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
32759704|NCT02371993|Experimental|Choline 650 mg twice daily|See above
32759705|NCT02371993|Placebo Comparator|Placebo|See above
32759706|NCT02378779|Other|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
32759707|NCT02378779|Other|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
32759708|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
32759709|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
32759710|NCT02371525|No Intervention|Standard of Care|
32759711|NCT02371525|Experimental|Prepmate|
32759712|NCT04230109|Experimental|Sacituzumab Govitecan (monotherapy cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~This can be followed by standard chemotherapy at the discretion of treating physician."
32759713|NCT04230109|Experimental|Sacituzumab Govitecan and Pembrolizumab (combination cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~Pembrolizumab via iv, predetermined dosage per protocol, IV, 1 day per each 21-day cycle, for 4 cycles.~This can be followed by standard chemotherapy at the discretion of treating physician."
32759714|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
32759715|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
32759716|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
32759717|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
32759718|NCT04175431|Active Comparator|Group I (fluciclovine PET/CT)|Patients undergo fluciclovine PET/CT and who do not have any abnormalities outside the prostatic fossa by fluciclovine PET/CT imaging undergo PSA recheckes every 3 months, and undergo fluciclovine PET/CT once PSA is > 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA recheckes every 3 months, and undergo fluciclovine PET/CT once PSA is > 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.
32759719|NCT04175431|Experimental|Group II (surgery, radiotherapy, abiraterone, prednisone)|Patients undergo fluciclovine PET/CT and who have =< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. 6 weeks after surgery, patients receive abiraterone acetate PO QD and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles abiraterone acetate and prednisone.
32759720|NCT04175431|Experimental|Group III (abiraterone, prednisone)|Patients undergo fluciclovine PET/CT and who have > 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.
32759721|NCT04149145|Experimental|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
32759722|NCT04148287|Experimental|APX001|APX001 IV or oral for up to 42 days
32910645|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
32910646|NCT04580771|Experimental|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
32910647|NCT04568993|Experimental|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
32910648|NCT04568993|Active Comparator|volar MCP level|injection above the A1 pulley volar to the MCP joint
32910649|NCT04559711|Experimental|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
32910650|NCT04559711|No Intervention|Comparison arm|Existing provision of nutrition services during ANC.
32910651|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
32910652|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
32910653|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
32910654|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
32910655|NCT01231646||Lamotrigine|No intervention
32910656|NCT01231646||Valproate|No intervention
32910657|NCT04539665|Experimental|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
32910658|NCT04539665|No Intervention|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
32910659|NCT04533659|Active Comparator|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
32910660|NCT04533659|Experimental|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
32910661|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
32910662|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
32910663|NCT04514393|Experimental|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
32910664|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
32910665|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
32910666|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
32910667|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
32759723|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
32759724|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
32759725|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
32759726|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
32759727|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
32759728|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
32759729|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
32759730|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
32759731|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
32759732|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
32759733|NCT02370979|Experimental|Dolutegravir|
32759734|NCT02371057||patients under follow-up known to have sleep apnoea|
32759735|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
32759736|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
32759737|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
32910668|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
33072122|NCT05456880|Experimental|BEAM-101|BEAM-101 manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and edited ex vivo. No maximum dose has been set for BEAM-101; all of the gene edited cells that pass release specifications will be administered to the patient. BEAM 101 will be administered as a single dose by IV infusion.
33072123|NCT05456100|Experimental|Expressive Helping|Participants complete a 20-minute expressive writing session once per week for the first three weeks. During Week 4, participants complete a 20-minute peer support writing session.
33072124|NCT05456100|Active Comparator|Expressive Writing|Participants complete a 20-minute expressive writing session once per week for four weeks.
33072125|NCT05456100|Active Comparator|Factual Writing|Participants complete a 20-minute factual writing about their cancer diagnosis and treatment every week for four weeks.
33072126|NCT05453578|Active Comparator|Stage 1/2a Arm 2|4x10^7 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
33072127|NCT05453578|Active Comparator|Stage 1/2a Arm 3|4x10^8 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
32759738|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
32759739|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
32759740|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
32759741|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
32759742|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
32759743|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
32759744|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
32759745|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
32759746|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
32759747|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
32759748|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
32759749|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
32759750|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink."
32759751|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
32759752|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
32759753|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
32759754|NCT02377999|Experimental|Treatment of genetial warts with Picato|
32759755|NCT04072783|Other|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
32759756|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
32759757|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
32759758|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
32759759|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
32759760|NCT04019275|Experimental|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
32910669|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
32910670|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
32910671|NCT01737281|Experimental|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
32742474|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
32910672|NCT01737281|Active Comparator|Usual care|Usual smoking cessation care from clinical staff
32759761|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
32759762|NCT04589377|Experimental|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
32759763|NCT04589377|No Intervention|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
32759764|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
32759765|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
32759766|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
32759767|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
32759768|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
32759769|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
32759770|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
32759771|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
32759772|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
32759773|NCT03611335||Site 2 H+H|Bellevue Hospital
32759774|NCT03611335||Site 3 H+H|Metropolitan Hospital
32759775|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
32759776|NCT03611335||Site 5 H+H|Coney Island Hospital
32759777|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
32759778|NCT04567771|Experimental|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
32759779|NCT04529707|Experimental|Sleep Intervention|All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
32759780|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
32759781|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
32759782|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
32759783|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
32759784|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
32759785|NCT04661332||Endoscopic retrograde cholangio-pancreatography|Endoscopic retrograde cholangio-pancreatography procedure
32759786|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
32759787|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
33397367|NCT04804527|Active Comparator|Usual care physiotherapy|Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
33397368|NCT03384745|Experimental|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
33397369|NCT03384745|Experimental|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
33397370|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
33397371|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
33397372|NCT03384745|Placebo Comparator|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
33397373|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
33397374|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
33397375|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
33397376|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
32759788|NCT01995526|Experimental|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
32759789|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
33397377|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
32759790|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
32759791|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
32759792|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
32759793|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
32759794|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
32759795|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
32759796|NCT01954342||Pregnant|Obese pregnant women
32759797|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
32759798|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
32759799|NCT01946152|Experimental|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32759800|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
32759801|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
32759802|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
32759803|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
32759804|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
32759805|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
32759806|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
32759807|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
32759808|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
32759809|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
32759810|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
32759811|NCT05070611|Experimental|Recurrent chalazia with IPL-MGX|The patients whose lesions had failed to respond to warm compresses and antibiotic and steroid treatment underwent incision and curettage. One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid. After removal of the ultrasound gel, meibomian gland expression (MGX) was performed with forceps-shaped meibomian gland compressor.
32759812|NCT05070221|Experimental|Arm A|Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
32759813|NCT05070221|Experimental|Arm B|Patients histologically confirmed non-mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
32759814|NCT05069909|Active Comparator|Conventional technique|The group of patients who received dentures fabricated with conventional technique first
32759815|NCT05069909|Active Comparator|Simplified technique|The group of patients who received dentures fabricated with simplified technique first
32759816|NCT04509037||Liposuction Assisted Breast Reduction|
32759817|NCT04509037||Open Incision Breast Reduction|
32759818|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
32759819|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
33397378|NCT04750824||Afatinib cohort|Afatinib cohort
33397379|NCT04750824||other systemic therapy cohort|other systemic therapy cohort
33397380|NCT01362075|Experimental|Local infiltration analgesia|
33397381|NCT01362075|Active Comparator|Interscalene catheter|
33397382|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
32759820|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
32759821|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
32759822|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
32759823|NCT04479397|Active Comparator|Sling Arm|This arm of the study will receive a sling for 3 weeks in postoperative care.
32759824|NCT04479397|Experimental|No Sling Arm|This arm of the study will not receive a sling during the postoperative care,
32759825|NCT03099629|Experimental|IMT|inspiratory muscle training
32759826|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
32759827|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
32759828|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
32759829|NCT05068895||Group1|Volunteers with normal glucose tolerance.
32759830|NCT05068895||Group2|type 2 diabetic patients without microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or lower extremity arterial disease) complications.
32759831|NCT05068895||Group3|type 2 diabetic patients with lower extremity artery disease diagnosed through the measurement of ABI (the ratio of ankle-to-brachial systolic blood pressure).
32759832|NCT02375815|Experimental|Statin Choice Implementation|
32759833|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
32759834|NCT05067881||Pneumohematocele|Patients with SARS CoV-2 diagnosis and PHC on imaging studies
32759835|NCT04404439|Experimental|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
32759836|NCT04404439|Experimental|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
32759837|NCT04404439|Placebo Comparator|Placebo|Placebo pill.
32759838|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
32759839|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
32759840|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32759841|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
33397383|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
32759842|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
32759843|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
33397384|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
32759844|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32759845|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
32759846|NCT05067959||IBD patients|patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy
33397385|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
32759847|NCT05067959||Controls|healthy volunteers
32759848|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
32759849|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
33397386|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
33397387|NCT05676528|Experimental|Intervention|Exercise intervention
33397388|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
33397389|NCT03631446||Patients administered Picoprep® for bowel cleansing|Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing
33397390|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
33397391|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
32759850|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
32759851|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
33240763|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
33240764|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
33240765|NCT05222906|Experimental|Venglustat|Venglustat
33240766|NCT05222906|Active Comparator|Cerezyme|Cerezyme
33240767|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
33240768|NCT00682461|Experimental|prototype|Nicotine prototype
33240769|NCT05684588|Other|Instrumental diagnostic evaluation|After enrollment all patients will undergo an instrumental evaluation including a radiography (according to clinical practice) and a magnetic resonance (experimental procedure outside clinical practice), at 1 year from previous hospitalization
33240770|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
33240771|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
33240772|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
33240773|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
33240774|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
33240775|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
33240776|NCT02560311||HER2+ metastatic breast cancer|
33240777|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
33240778|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
33240779|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
33240780|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
33240781|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
33240782|NCT02587364|Placebo Comparator|Placebo|Placebo
33240783|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
33240784|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
33240785|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
33240786|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
33240787|NCT05435781|Active Comparator|RCT group - hydrocortisone|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response <420 nmol/l) that are randomised to receive hydrocortisone
33240788|NCT05435781|Placebo Comparator|RCT group - placebo|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response <420 nmol/l) that are randomised to receive placebo
33240789|NCT05435781|No Intervention|Control group|Patients with polymyalgia rheumatica/giant cell arteritis with normal adrenal function (Synacthen test response ≥420 nmol/l)
33240790|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
33240791|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
33240792|NCT05435625|Active Comparator|FCO2|Fractional Carbon dioxide laser
33240793|NCT05435625|Active Comparator|FRF|Fractional Microneedling Radiofrequency
33240794|NCT05435391||Group 1|Patients with chest pain or who are clinically suspected as acute myocardial infarction with equivalent symptoms.
33240795|NCT05217914||r/r iNHL Patients: Copanlisib treatment|"The data in patients who received at least one dose of copanlisib before 01-May-2022 will be included for interim analysis. All study data collection will end in Q2 2024, or when the data collection of maximal 50 enrolled patients is completed, whenever comes first.~Subgroup analysis: r/r iNHL Patients: Copanlisib 2nd line treatment Subgroup analysis: r/r iNHL Patients: Copanlisib 3rd line treatment"
33240796|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
33240797|NCT00919880|Experimental|Experimental|
33240798|NCT00919880|Active Comparator|Active Comparator|
33240799|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
33240800|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
33240801|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
33240802|NCT04844606|Experimental|Mirikizumab Dose 1 for UC|"Dose 1 of Mirikizumab is administered subcutaneously (SC)~Dosing is based on the participant's weight."
33240803|NCT04844606|Experimental|Mirikizumab Dose 2 for UC|"Dose 2 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
33240804|NCT04844606|Experimental|Mirikizumab Dose 3 for UC|"Dose 3 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
33240805|NCT04844606|Experimental|Mirikizumab Dose 4 for CD|"Dose 4 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
33240806|NCT04844606|Experimental|Mirikizumab Dose 5 for CD|"Dose 5 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
33072128|NCT05453578|Active Comparator|Stage 1/2a Arm 4|4x10^9 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
33072129|NCT05453578|Placebo Comparator|Stage 2a Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=8
33072130|NCT05453578|Placebo Comparator|Stage 2b Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=17
32759852|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
32759853|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
32759854|NCT05067413|Sham Comparator|Total mesorectal excision approach|Patients of the control group who are to receive the traditional approach-- total mesorectal excision approach to transect the distal rectum are assigned into this arm.
32759855|NCT05067413|Experimental|Transanterior obturator nerve gateway approach|Patients of the experimental group who are to receive the novel approach-- transanterior obturator nerve gateway approach to transect the distal rectum are assigned into this arm.
32759856|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
32759857|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
32759858|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
32759859|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
32759860|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
32759861|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
32759862|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
32759863|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
33397392|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
33397393|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
33397394|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
33397395|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
33397396|NCT03184168|Experimental|treatment|[14C]lorlatinib
33397397|NCT04709874|Experimental|Paravertebral block|Patients will receive paravertebral block guided by a nerve stimulator.
33397398|NCT04709874|Active Comparator|Suprascapular block|Patients will receive suprascapular block
33397399|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
33397400|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
33397401|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
33397402|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
33397403|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
33397404|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
33397405|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
33397406|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
33397407|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
33397408|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
33397409|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
33397410|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
33397411|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
33397412|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
33397413|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
33397414|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
33397415|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
33397416|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
33397417|NCT01355991|Active Comparator|Anticholinergic Agent|
33397418|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
33240807|NCT04844606|Experimental|Mirikizumab Dose 6 for CD|"Dose 6 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
33240808|NCT04844606|Experimental|Mirikizumab Dose 7 for UC or CD|Intravenous (IV) rescue dosing, if response is lost.
33240809|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
33240810|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
33240811|NCT04082858|Experimental|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
33240812|NCT04082858|Active Comparator|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
33240813|NCT05273307|Experimental|Miracle Fruit|Participants will receive 1 Miracle Fruit Farm miracle fruit cube by mouth three times a day before meals
33240814|NCT05273307|Placebo Comparator|Miracle Fruit Placebo|Participants will receive 1 placebo cube by mouth three times a day before meals
33240815|NCT05683574|Experimental|etoricoxib 90 mg + cyclobenzaprine 15 mg|Investigational group: FDC of etoricoxib 90 mg + cyclobenzaprine 15 mg from Eurofarma Laboratórios SA
33240816|NCT05683574|Active Comparator|etoricoxib 90 mg|Comparator group: etoricoxib 90 mg (Arcoxia®)
33240817|NCT05683574|Active Comparator|cyclobenzaprine hydrochloride 15 mg|Comparator group: cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®)
33240818|NCT05209815||Group 1|continuation of NTZ throughout pregnancy and postpartum
33240819|NCT05209815||Group 2|exposure during the first trimester
33240820|NCT05209815||Group 3|exposure during the first and the second trimester
33240821|NCT05005442|Experimental|Pembrolizumab/vibostolimab coformulation|Participants will receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.
33240822|NCT05198817|Experimental|Single Group|
33240823|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
33240824|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
33240825|NCT00679029|Experimental|Chemotherapy with Bevacizumab|"AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.~TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
33240826|NCT00919022||Group 1|
33240827|NCT04082156|Active Comparator|Active TENS|
33240828|NCT04082156|Sham Comparator|Sham TENS|
33240829|NCT03938571|Experimental|Standard DS|"Standard duodenal switch:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Entero-entero-anastomosis linear stapled and handsewn.~Division between the two anastomosis.~Closure of the mesenteric defects."
33240830|NCT03938571|Active Comparator|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 250 cm alimentary limb/common channel.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Closure of the mesenteric defects."
33240831|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
33240832|NCT05191953|Active Comparator|Group ESPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
33240833|NCT05191953|Active Comparator|Group ESPB+Superficial PIPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) and a bilateral superficial PIPB (20 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
33240834|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
33240835|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
33240836|NCT05004350|Experimental|Encorafenib and cetuximab|"Safety Lead-in (SLI) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~Randomized (Phase II) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
33240837|NCT05004350|Experimental|Irinotecan and cetuximab or FOLFIRI and cetuximab|"Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles.~Irinotecan and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~OR~FOLFIRI and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks~Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks~5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
33240838|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
33240839|NCT05141955|Active Comparator|Group Erector Spinae Plane Block (ESPB)|
33240840|NCT05141955|Active Comparator|Group Quadratus Lumborum Block (QLB)|
33240841|NCT05141955|Other|Group (C) (Control group)|
33240842|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
33240843|NCT05122221|Experimental|CRTE7A2-01 TCR-T cell therapy|Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2
33240844|NCT05119647|Other|Patient Recruited|Since this is a single-arm objective performance criteria trial, patients with acute stoke caused by artery occlusion shall not be divided into two groups.
33240845|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
32910673|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
32910674|NCT01233518|Other|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
32910675|NCT01737593|Active Comparator|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
32910676|NCT01737593|Active Comparator|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
32759864|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
32759865|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
33397419|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
33397420|NCT03180658|Active Comparator|controlled|CGF+bone graft
33397421|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
33397422|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
33397423|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
33397424|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
33397425|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
33397426|NCT01319175|Experimental|Training group|
33397427|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
33397428|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
33397429|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
33397430|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
33397431|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
33397432|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
33397433|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
33397434|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
33397435|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
33397436|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
33397437|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
33397438|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
33397439|NCT03180346|Active Comparator|Standard of Care|
33397440|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
33397441|NCT03180112||control group|Healthy children of matching age and sex.
33397442|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
33397443|NCT01356225|Placebo Comparator|Intranasal placebo|
33397444|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
33397445|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
33397446|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
33397447|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
33397448|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
33397449|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
32759866|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
32759867|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
32759868|NCT02377453||Control|Control: Healthy adult
32759869|NCT02377453||Experimental|Experimental: patients with stroke
32759870|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
32759871|NCT02369809|Active Comparator|standard care|
32759872|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
32759873|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
32759874|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
32759875|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
32759876|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
32759877|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
32759878|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
32759879|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
32759880|NCT04400539|Experimental|Malignant Pleural Mesothelioma patients|
32759881|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
32759882|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
32759883|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
32759884|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
32759885|NCT02389075||Ankylosing Spondylitis|Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
32759886|NCT02389075||Inflammatory Bowel Disease|Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
32759887|NCT02389075||Healthy Controls|Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
32759888|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
32759889|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
32759890|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
32759891|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
32759892|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
32759893|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
32759894|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
32759895|NCT05067023|Experimental|MRI scan|All participants will undergo 1 DCE-MRI scan before surgery or puncture.
32759896|NCT00834119|Experimental|Mometasone furoate|
32759897|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
32759898|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
32759899|NCT05653921||Dry Eye Disease Group|Symptoms of ocular surface discomfort or dry eye disease for at least 3 months, supported by clinical exam findings. Reported quality of life is not effected by ocular pain.
32759900|NCT05653921||Neuropathic Corneal Pain Group|Symptoms of ocular surface discomfort or pain for at least 3 months, that are reported to have a significant impact on quality of life and ability to perform daily activities.
32759901|NCT05653921||Control Group|No symptoms of ocular surface discomfort or dry eye disease.
32759902|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
32759903|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
32759904|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
32759905|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
32759906|NCT04477187|Experimental|Single Group|All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
32759907|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
33240846|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
33240847|NCT03802305|Experimental|Computerized intraosseous technique (Quicksleeper™)|patients will receive the anesthetic solution with computerized intraosseous technique anesthesia near the tooth roots involved.
33397450|NCT05760846|Experimental|Bimanual Circuit version 1|Training on the REAplan® robot with a serious game based on proximal motor skill learning (bim-MSkL) with the bimanual version 1 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
33397451|NCT05760846|Experimental|Bimanual Circuit version 2|Training on the REAplan® robot with a serious game based on motor skill learning (MSkL) with bimanual version 2 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
33397452|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
32759908|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
32759909|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
32759910|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
33240848|NCT03802305|Active Comparator|loco-regional anesthesia (IANB technique)|patients will receive the anesthetic solution with the loco-regional anesthesia technique: near the place where the nerve goes into the jaw, based on osteo muscular markers.
33240849|NCT00755469|Experimental|1|
33240850|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
33240851|NCT03724149|Experimental|Direct-acting antiviral treatment for HCV|
33240852|NCT04084184|Experimental|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
33240853|NCT04084184|Experimental|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
33240854|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
33240855|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
32759911|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
32759912|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
32759913|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
32759914|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
32759915|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
32759916|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
32759917|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
32759918|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
32759919|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32759920|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32759921|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
32759922|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
32759923|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
32759924|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
32759925|NCT04157075|Placebo Comparator|No injection|No injection will be performed
32759926|NCT04157075|Sham Comparator|Normal Saline Injection|Normal saline will be injected into the uterosacral ligaments prior to colpotomy
32759927|NCT04157075|Active Comparator|Bupivacaine Injection|Bupivacaine will be injected into the uterosacral ligaments prior to colpotomy
32759928|NCT00763529|Experimental|Arm 1|
32759929|NCT00763529|Active Comparator|Arm 2|
32759930|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
32759931|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
32759932|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
32759933|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
32759934|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
32759935|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
32759936|NCT05066633|Placebo Comparator|Control Group|Matching placebo will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
32759937|NCT05066633|Experimental|Treatment Group|Metoprolol succinate will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
32910677|NCT01737593|Active Comparator|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
33072131|NCT05453578|Active Comparator|Stage 2b Arm 2|WRAIR-PAM-CF1 concentration determined after post stage 2a analysis, administered intravenously with 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. N=17
33072132|NCT05451953|Experimental|Apneic Oxygenation|
33072133|NCT05451953|Active Comparator|Standard of Care|
33240856|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
33240857|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
33240858|NCT02587052||Prograf|100 patients treated with Prograf
32742475|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
33240859|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
33240860|NCT04787042|Experimental|Phase 1a, Dose Escalation|In phase 1 dose escalation will start at a dose level of 30ug/kg . Patients will be treated every week and the DLT evaluation period is 28 days. According to the mTPI schema initially there will be 2 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D
33397453|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
33397454|NCT02220309||Anxiety and mood disorders|
33240861|NCT04787042|Experimental|Phase 2, Expansion|Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
33240862|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
33240863|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
33240864|NCT04084418|Experimental|Control diet followed by VLCHF diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
33240865|NCT04084418|Experimental|VLCHF diet followed by Control diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
33240866|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:~Arterial line~Nexfin Monitoring System~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)~Baseline blood samples. Induction of anaesthesia~Study Group:~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
33240867|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg~CVP ≤12 mmHg~Haemoglobin level ≥8 g/dl.~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
32910678|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
32742476|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
32910679|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
33397455|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
33397456|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
32759938|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
32759939|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
32759940|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
32759941|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
32759942|NCT04439305|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32759943|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.~MTD expansion phase:~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
32759944|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
32759945|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
32759946|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
32759947|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
32759948|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
32759949|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
32759950|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
32759951|NCT05066243||focus group|15 service users for focus group
32759952|NCT05066243||questionnaire|150 patients to test questionnaire
32759953|NCT00650663|Experimental|Ezetimibe + Simvastatin|
32759954|NCT00650663|Active Comparator|Simvastatin|
32759955|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
32759956|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
32759957|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
32759958|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
32759959|NCT04231565|Active Comparator|TAF group|50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.
32759960|NCT04231565|No Intervention|Observation group|50 patients would not receive treatment from baseline to life-long.
32759961|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
32759962|NCT05065931||Before|before CDSS on-line
32759963|NCT05065931||After|after CDSS on-line
32759964|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
32759965|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
32759966|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
32759967|NCT05065229|Experimental|A|Right foot no.520 Left foot no.521
32759968|NCT05065229|Experimental|B|Right foot no.521 Left foot no.520
32759969|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
32759970|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
32759971|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
32759972|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
32759973|NCT04564027|Experimental|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
32759974|NCT04564027|Experimental|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
32759975|NCT05064995||Patients|Patients with the Diagnosis of a Bipolar Disorder
32759976|NCT05064995||Healthy Controls|Individuals with no diagnosis of Bipolar Disorder
32759977|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
32759978|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
32759979|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
32759980|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
32759981|NCT05035277|Active Comparator|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
32759982|NCT05035277|Experimental|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
32759983|NCT02374645|Experimental|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
32759984|NCT02374645|Experimental|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
32759985|NCT05064839|Experimental|Bony scintigraphy|Bony scintigraphy within 1 to 4 months after inclusion
32759986|NCT02368483|Experimental|Neuromuscular training|
32759987|NCT05030207|Experimental|Real-Time Gated 4DCT and Conventional 4DCT|During the simulation (radiotherapy planning) session, the participant will undergo both the experimental 'Real-Time Gated 4DCT' and standard 'Conventional 4DCT'.
32759988|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
32759989|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
32759990|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
32759991|NCT04147247|Experimental|BI 905681|
32759992|NCT05001347|Experimental|TJ004309 and Atezolizumab|TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W
32759993|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
32759994|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
32759995|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
32759996|NCT04095845|Active Comparator|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
32759997|NCT04095845|Experimental|Mako THA|Mako robotic-arm assisted total hip arthroplasty
32759998|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
32759999|NCT04050293|Experimental|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
32760000|NCT04050293|Placebo Comparator|Placebo|Patients will be treated with Placebo once a day
32760001|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
32760002|NCT04989725|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
32760003|NCT04989725|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
32760004|NCT02374567|Experimental|Psychiatric drugs|
32760005|NCT04981535|Experimental|Patients undergoing upper gastrointestinal endoscopy with head box|experimental group
32760006|NCT04981535|No Intervention|Patients undergoing upper gastrointestinal endoscopy without head box|standard of care group
32760007|NCT04434989|Experimental|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
32760008|NCT04434989|Active Comparator|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
32760009|NCT05064215||injection behind NAC|in 7 breasts dye was injected behind the nipple areola complex before breast reduction
32760010|NCT05064215||Injection into lateral upper quadrant|in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction
32760011|NCT05064215||injection into medial upper quadrant|in 2 breasts dye was injected into upper medial glandular tissue before breast reduction
32760012|NCT03965741||Men with Prostate Cancer (PCa)|
32760013|NCT03965741||Men without PCa|
32760014|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
32760015|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
32760016|NCT04478201|Experimental|Back lying sleep position|sleep on the back
32760017|NCT04478201|Experimental|Side lying sleep position|sleep on the side
32760018|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
32760019|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
32760020|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
33240868|NCT05679440|No Intervention|Control group|Patients in the control group are ventilated in a comfortable position according to the principles of treatment and their wishes
33240869|NCT05679440|Experimental|Intervention group|Patients are ventilated in prone position (for patients with bilateral lung lesions), left/right lateral position, semi-prone position (for patients with unilateral lung lesions or those who cannot tolerate prone ventilation, so that the diseased lung is above and the healthy lung is below), supine position (for patients who cannot tolerate prone ventilation or lateral ventilation, etc.) according to the pulmonary imaging data.
33240870|NCT04969965|Experimental|Aumolertinib|single dose oral 110mg of aumolertinib
33240871|NCT03680625|Active Comparator|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
33240872|NCT03680625|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
33240873|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
33240874|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
33240875|NCT04081844|Experimental|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
33240876|NCT04779242|Experimental|Omadacycline|Omadacycline 100 mg IV; Omadacycline 300 mg PO (2 x 150 mg tablets); QD Dosing; 7-10 day duration.
33240877|NCT04779242|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg IV; Moxifloxacin 400 mg tablets; QD Dosing; 7-10 day duration
33240878|NCT05683496|Experimental|Cohort 1|Single SC injection of 20mg of VB421 or placebo at Day 1 and Day 21
33240879|NCT05683496|Experimental|Cohort 2|Single SC injection of 125mg of VB421 or placebo at Day 1 and Day 21
33240880|NCT05683496|Experimental|Cohort 3|Single SC injection of 250mg of VB421 or placebo at Day 1 and Day 21
33240881|NCT00676689|Experimental|SAPIEN THV|
33240882|NCT02589314||root planning|
33072524|NCT05000216|Experimental|Cohort E, Arm E2: Alternative mRNA Vaccine + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
33397457|NCT04674852|Other|Marking cN+ nodes|These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.
33397458|NCT01362231|Experimental|GS-6624 125mg|
33397459|NCT01362231|Experimental|Experimental: GS-6624 200mg|
33240883|NCT04978844|Active Comparator|I-WotCH|I-WotCH- Inner World of the Child- is a novel innovative therapy developed in our clinic. The therapy is based on modern concepts of early childhood developments emphasizing themes related to emotional regulation, processes of socialization, observational research on interpersonal and behavior as well as recent developments on affiliative neuroscience. More specifically, the therapist, through play, identifies themes and emotions the child is preoccupied with. The therapist then assists the child in naming these emotions, validating them, exploring their nature and consequences. The therapists discussed ways of managing and self-regulating these emotions. These methods would include behavioral techniques, the ability to enlist help from others and reframing. In addition, the therapy will address dealing with complexed emotions and enhancing symbolic play and joyfulness.
33397460|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
33397461|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
33397462|NCT03184246|Experimental|GlideScope|intubation with GlideScope
33397463|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
33397464|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
33397465|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
33397466|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
33397467|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
33397468|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
33397469|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
33397470|NCT05759286|Experimental|aromatherapy group|Children in this group will receive IANB injection with a nasal mask (similar to a nitrous oxide mask), the way the mask work is by putting on its circular hole a 3d printed perforated box containing cotton balls loaded with lavender-neroli oils blend
32742477|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
33397471|NCT05759286|Experimental|music group|children in this group will receive IANB injections by listening to music as background from a recorder.
33397472|NCT05759286|Experimental|combination group music and aromatherapy|children in this group will receive aromatherapy using the nasal mask with an aromatherapy box as well as music for 5 minutes and through the injection
33397473|NCT05759286|Placebo Comparator|control group|children in this group will receive IANB injections with behavioral management techniques l
33397474|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
33397475|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
33397476|NCT05114356||Study group|Patients being treated for degenerative disc disease
33397477|NCT05760768|Experimental|Individualized exercise guidance group|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
33397478|NCT05760768|No Intervention|Standard clinic prenatal care (control) group|Participants accept regular routine prenatal care following Chinese standard.
33397479|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
33397480|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization is a surgical procedure to relieve symptoms of Benign Prostatic Hyperplasia (BPH). Embolizing particles are injected into a target blood vessel to occlude blood flow.
33397481|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
33397482|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
33397483|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
33397484|NCT04604496|Experimental|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
33397485|NCT04604496|Experimental|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
33397486|NCT04604496|Experimental|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
33397487|NCT04604496|Experimental|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
33397488|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
33397489|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
33397490|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
33397491|NCT05129202||Chemotherapy alone or chemotherapy combined with anti-angiogenesis|patients with Chemotherapy
33397492|NCT05129202||immuntherapy|patients treated with immune checkpoint inhibitor monotherapy or combination therapy.
33397493|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
33397494|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
33397495|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
33397496|NCT05122572|Experimental|Intravenous Injection|Intravenous with or without Intratumoral RT-01 in the treatment of patients with advanced solid tumors combined with or without Nivolumab in the treatment of patients with advanced solid tumors
33397497|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
33397498|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
33397499|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
33397500|NCT01356381|Experimental|vildagliptin|
33397501|NCT01356381|Experimental|Placebo|
33397502|NCT03117166|Experimental|Lidocaine|treatment arm
33397503|NCT03117166|Placebo Comparator|Saline|placebo arm
32760021|NCT04412447|Experimental|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.~Optional (only for selected pilot):~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.~Phase V5: Participation on Cybathlon 2020"
32760022|NCT02364739|Experimental|Written information|Written information
33397504|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
33397505|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
33397506|NCT05189613|Experimental|Severe Asthma+BE|Patients with severe eosinophilic asthma with co-presence of Bronchiectasis (BE) in treatment with Mepolizumab
33397507|NCT05189613|Active Comparator|Severe Asthma without BE|Patients with severe eosinophilic asthma without Bronchiectasis (BE) in treatment with Mepolizumab
33397508|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
33397509|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
32760023|NCT02364739|Experimental|Written and oral information|Written and oral information
32760024|NCT02364739|No Intervention|No intervention|Control
32760025|NCT02374411||HIPEC surgeons|
32760026|NCT05063513|Experimental|Transplant arm|Experimental arm will undergo mobilisation with cyclophosphamide (CY) 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
32760027|NCT05063513|Active Comparator|Rituximab arm|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
32760028|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
32898176|NCT03944499|Experimental|FS-1502|"Phase Ia:~Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle;~Phase Ib:~FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D). All patients will continue treatment until no clinical benefit occurs, or intolerable toxicity occurs, or death occurs, or the investigator decides, or patients voluntarily withdraw from the study.~Study end is defined as the last patient's treatment ended or 2 years after the last patient's treatment began(depending on which happens earlier)."
33397510|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
33397511|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
33397512|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
33397513|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
33397514|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
33397515|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
33397516|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
33397517|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
33397518|NCT01356537||Gaucher's Disease under VPRIV|
33397519|NCT05669664|Experimental|Treatment (darolutamide, leuprolide acetate)|Patients receive darolutamide PO and leuprolide acetate IM on study. Patients also undergo a tumor biopsy at baseline and on study, and collection of blood throughout the study.
33397520|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
33397521|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
33397522|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:~agave inulin (4 g) in powder~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
33397523|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
33397524|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
33397525|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
33397526|NCT04591002|Active Comparator|Osemertinib|
33397527|NCT04591002|No Intervention|Observation|
33397528|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
33397529|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
33397530|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
33397531|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
32898177|NCT03941964|Experimental|Venetoclax 400 mg + azacitidine 75 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Azacitidine (75 mg/m^2) was administered subcutaneously or intravenously per investigator's choice and institutional practice for 7 days beginning on Day 1 of each 28-day cycle.
33397532|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
33397533|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
33397534|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
33397535|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
33397536|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
33397537|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
33397538|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
33397539|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
33397540|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
33397541|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
33397542|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
33397543|NCT03179878|Experimental|SYNB1020|SYNB1020
33397544|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
33397545|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
33397546|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
33397547|NCT04583592|Experimental|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
33397548|NCT04583592|Placebo Comparator|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
33397549|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
33397550|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
33397551|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
33397552|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
33397553|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
33397554|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
33397555|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
33397556|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
33397557|NCT05760690|Experimental|Retro-Auricular Single-Site Endoscopic Thyroidectomy group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
33397558|NCT05760690|Active Comparator|Transoral Endoscopic Thyroidectomy Vestibular Approach group|Patients in the Transoral Endoscopic Thyroidectomy Vestibular Approach group will receive endoscopic thyroid lobectomy and central lymph node dissection.
33397559|NCT05760690|Active Comparator|Transareola Endoscopic Thyroidectomy group|Patients in the Transareola Endoscopic Thyroidectomy group will receive endoscopic thyroid lobectomy and central lymph node dissection.
33397560|NCT01362543|Active Comparator|Stress Management|
33397561|NCT01362543|Active Comparator|Cognitive restructuring|
33397562|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
33397563|NCT02418988|Active Comparator|TACE|TACE will be applied alone
33397564|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
33397565|NCT01356771|Other|Control Group|
33397566|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
33397567|NCT05189301||CHF|CHF for chronic heart failure
32760029|NCT05063669|Experimental|Cognitive Occupational Therapy|Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
32760030|NCT05063669|No Intervention|Control|No intervention was performed in this group.
32760031|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
32760032|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
32760033|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
32760034|NCT05062967||HAOD Cohort|"This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.~The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection"
32760035|NCT05062967||OrthoC-Tx Cohort|This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection
32760036|NCT05062967||Ortho-CoRIS Cohort|"This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.~The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection."
32760037|NCT05062967||TrazHE Cohort|"This cohort includes patients whose clinical picture is compatible with HAE infection.~The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE."
32760038|NCT05062967||Ortho-C-Rodent Cohort|This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).
32760039|NCT05062967||Ortho-C-Domestic Rodent Cohort|This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.
32760040|NCT05062967||Ortho-C-Carnivore Cohort|"This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.~Feces, liver and serum samples will be taken to study the transmission of Ortho-C."
32760041|NCT02374177||Propofol group|Patient anesthetized using propofol
32760042|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
32760043|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
32760044|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
32760045|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
32760046|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
32760047|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
32760048|NCT04474691|Experimental|Visual-acoustic biofeedback|
32760049|NCT04474691|Active Comparator|Traditional articulation treatment|
32760050|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
32760051|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
32760052|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
32760053|NCT05062499|Active Comparator|Active TENS|electrical stimulation
32760054|NCT05062499|Sham Comparator|Sham TENS|no stimulation
32760055|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.~CO, phase contrast angiography.~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
32760056|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
32760057|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
33397568|NCT05189301||COPD|COPD for chronic obstructive pulmonary disease
33397569|NCT05189301||control|control for normal controls
33397570|NCT05005182|Experimental|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
33397571|NCT05005182|Experimental|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
33397572|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
33397573|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
33397574|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
33397575|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
33397576|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
33397577|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
33397578|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
33397579|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
33397580|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
33397581|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
33397582|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
33397583|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
33397584|NCT01357005||Schizophrenia Family|
32760058|NCT04632433|Experimental|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
32760059|NCT04473599|Active Comparator|Uniform Random|Participants will receive supportive text-messages for a period of 2 months. These text-messages have two categories: behavioral activation (BA) and coping skills. In this arm, participants will receive one of these types of messages daily on a random schedule in random time periods throughout the day.
32760060|NCT04473599|Experimental|Reinforcement Learning|In this arm we will test a reinforcement learning (RL) algorithm with a learned decision mechanism for the timing and type of text-messages. The algorithm learns from previous data (which messages were sent, what was the participants' mood) to maximize an increase in participants' mood.
32760061|NCT04473599|Active Comparator|Mood ratings only|In this arm, participants will monitor their mood and receive random feedback based on mood responses.
32760062|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
32760063|NCT03100097|No Intervention|Medical Management|Normal medical management
32760064|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
32760065|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
32760066|NCT04473443||Cohort A|Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots
32760067|NCT04473443||Cohort B|Consecutive patients eligible for TAVI with ACURATE-NEO2 valve
32760068|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
32760069|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
32760070|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
33397585|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
33397586|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
33397587|NCT03681938||Intensification treatment: Autograft|
33397588|NCT03681938||Standard chemotherapy (without autograft)|
33397589|NCT01362621||Children 6 to less than 12 years of age|
33397590|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
33397591|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
33397592|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
33397593|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
33397594|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
33397595|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
33397596|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
33397597|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
33397598|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
33397599|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
33397600|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
32910680|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
33397601|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
33397602|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
33397603|NCT04960722|Active Comparator|Control|autogenous bone graft
32910681|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
32910682|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
32910683|NCT01296542|Active Comparator|VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
32910684|NCT01296542|Active Comparator|Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
32910685|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
32910686|NCT04346420|Experimental|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
32910687|NCT04346420|Active Comparator|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
32910688|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
33397604|NCT04960722|Experimental|1.5 mg/g OIF/β-TCP|1.5 mg/g OIF/β-TCP
33397605|NCT04960722|Experimental|2 mg/g OIF/β-TCP|2 mg/g OIF/β-TCP
33397606|NCT04960722|Experimental|3 mg/g OIF/β-TCP|3 mg/g OIF/β-TCP
32910689|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
33397607|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
32760071|NCT05011487|Experimental|osimertinib plus chemotherapy|Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles
32760072|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
32910690|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
32910691|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
32910692|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
32910693|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
32910694|NCT01338506|Active Comparator|Treatment as usual|CBT for substance use disorder.
32910695|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
32910696|NCT01236326|Active Comparator|LESS-DN|
32910697|NCT01236326|Active Comparator|Conventional LDN|
32910698|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
32910699|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
32910700|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
32910701|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
32910702|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
32910703|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
32910704|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
32760073|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
32760074|NCT05062187||Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
32760075|NCT05062187||Healthy Individual|Proprioception on balance and gait functions in healthy individuals
32760076|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
32760077|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
32760078|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
32760079|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
32760080|NCT05061329||Normal individuals|no sino-nasal disease - no upper airway allergies - no intra nasal medication - normal sense of smell
32760081|NCT05061329||COVID-19 positive patient|
32760082|NCT05061329||Post-COVID-19 patients|Previous COVID-19 positive patients with prolonged olfactory dysfunction
32760083|NCT05061329||Patients with chronic rhinosinusitis with and without nasal polyps|
32760084|NCT05061329||Patients with smell loss|
32760085|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
32760086|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
32760087|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
32760088|NCT05061641|Active Comparator|progesterone 200mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg
32760089|NCT05061641|Experimental|progesterone 400mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg
32760090|NCT05061641|Experimental|progesterone 600mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg
32760091|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
32760092|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
32760093|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
32760094|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
32760095|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
33397608|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
32760096|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
32760097|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
32760098|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
32910705|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
32910706|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
33397609|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
33397610|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
33397611|NCT04874922|Experimental|Case group|The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
32742478|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
33397612|NCT04874922|Other|Control Group|The control group will only receive standart diabetes training from the hospital. Then, only follow-up will be done and the data will be evaluated.
32760099|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
32760100|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
32760101|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):~Double anti-aggregation~IEC (or sartan) at best tolerated dose~Beta-blocker at best tolerated dose~High dose statin (usually atorvastatin 80 mg daily)~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)~Any other treatment will be logged."
32760102|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
32760103|NCT05060393|Experimental|Intervention group|Daily use of mindfulness-based mobile application for 30 days.
32760104|NCT05060393|No Intervention|Control group|Treatment as usual
32760105|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
32760106|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
32760107|NCT02373631|Experimental|Dry Needling, Conventional PT|
32760108|NCT02373631|Active Comparator|Conventional PT|
32760109|NCT05060471|Experimental|Intervetional group|Neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and concurrent toripalimab
32760110|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
32760111|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
32760112|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
32760113|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
32760114|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
32760115|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
32760116|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
32760117|NCT05059613|Experimental|probiotics group|Use thalidomide in combination with probiotics during radiotherapy and chemotherapy
32760118|NCT05059613|No Intervention|thalidomide group|Thalidomide is used only during radiotherapy and chemotherapy
32760119|NCT05059613|No Intervention|healthy control group|healthy control group
32760120|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
32760121|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
32760122|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
32760123|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
32760124|NCT03098849|No Intervention|Control Group|Standard care as usual
32760125|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
32760126|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
32760127|NCT05059847|No Intervention|Standard Care Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus the World Health Organization recommendation that indicates at least 150 min a week of moderate physical activity, equivalent to walking 30 minutes a day for 5 days at an intensity between 60 and 70% of your maximum heart rate.
32760128|NCT05059847|Active Comparator|Resistance Training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a resistance exercise routine using weights. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
32760129|NCT05059847|Experimental|Cross-training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a cross-training routine using implements without any extra weight to improve stability, joint mobility and general strength of the body. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
32760130|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
32760131|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
32760132|NCT05060159|No Intervention|Hemodialysis|Conventional hemodialysis
32760133|NCT05060159|Experimental|Hemofiltration|Postdilutional hemofiltration
32760134|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
32760135|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
32760136|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
32910707|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
32910708|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
32910709|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
32910710|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
32910711|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
32742479|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
32910712|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
32910713|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
32910714|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
32910715|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
33072525|NCT05000216|Experimental|Cohort E, Arm E3: Moderna mRNA-1273 + Withhold IS (MTX)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
32910716|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
32910717|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
33397613|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
32742480|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
32760137|NCT05047055||Single Group - 4 months moxifloxacin group|"Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Moxifloxacin (M)~Isoniazid, rifampicin, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by isoniazid, rifampicin, ethambutol and moxifloxacin daily for 2 months (2 HRZEM daily / 2HREM daily) - Duration 4 months~Drug dosages The Fixed-dose Combination (FDC) for HRZE(75/150/400/275mg) used under NTEP according to weight category will be used.~The patients enrolled in the study will receive an additional tablet of moxifloxacin(M) 400mg (body weight <64 Kg) / 600mg (body weight >65 Kg) along with the FDC both in the intensive and continuation phase."
32760138|NCT03098537|Active Comparator|Enteral nutrion only|
32760139|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
32760140|NCT05046665|Other|Staging cohort|Eligible participants recruited to the staging cohort
32760141|NCT05046665|Other|Metastatic cohort|Eligible participants recruited from the metastatic cohort
32760142|NCT05046041|Experimental|Mifepristone + Misoprostol|200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
32760143|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
32760144|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
32760145|NCT04434833||Relapse|Patients with high risk of relapse.
32760146|NCT05045729||OHCA SPORTS|All OHCA, where the patient was engaged in sports at the time of the event
33240884|NCT04978844|Active Comparator|Dyadic therapy|"Child parent psychotherapy: CPP consists of joint parent-child sessions that focus on the child's free play and spontaneous parent-child interaction. The CPP therapist acts to translate the developmental and emotional meaning of a child's emotions and actions to the parent. The target of treatment includes the both the child's and the caregiver's adaptive conflicts, including a parent's difficulty in providing sensitive and developmentally appropriate care. CPP fosters parent-child activities that foster mutual pleasure, interpersonal trust and understanding. In the purpose of this study only mothers will be included."
32760147|NCT01970878|Experimental|GFF MDI (PT003)|
32760148|NCT01970878|Experimental|GP MDI (PT001)|
32760149|NCT01970878|Experimental|FF MDI (PT005)|
32760150|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
32760151|NCT05045651|Experimental|patient specific knee prosthesis|TKA with Gender Solution® posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
32760152|NCT05045651|Experimental|Unisex knee prosthesis|TKA with posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
32760153|NCT05045417||Cases with SLE|"110 patients with SLE will be divided to :~40 patients with lupus nephritis~40 patients interstitial lung disease~30 SLE patients without internal organ affection)"
32760154|NCT05045417||control group|30 sex and age matched healthy individuals as a control group
32760155|NCT05045339|Experimental|Exercise Group|Five different ball exercises were implemented for 35 minutes, 3 sessions per week for 2 months.
32760156|NCT05045339|No Intervention|Control Group|No exercises were performed in control group
33240885|NCT04978844|No Intervention|Control|Healthy control.
33240886|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
32760157|NCT05059145|Experimental|Chlorhexidine gluconate, 1% vaginal cream|8 ml vaginal cream every night for a week and then prophylactic treatment with 8 ml/week for another 11 weeks
33240887|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
33240888|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
32760158|NCT05059145|Active Comparator|Fluconazole, 150 mg oral capsule|Fluconazole150 mg (oral capsule) every 3 days for the first 3 doses, then prophylactic treatment with 150 mg/week for another 11 weeks
32760159|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
32760160|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
32760161|NCT05058989||Pregnant women who are aged between 18 to 47 years old (childbearing age).|These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
32760162|NCT05045105||ICU physicians|Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
32760163|NCT05045105||Neurosurgeons|Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
32760164|NCT05059067||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
32760165|NCT05059067||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
32760166|NCT05058677|Experimental|aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution|Treatment will be performed before the endotracheal suctioning
32760167|NCT05058677|Experimental|aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
32760168|NCT05058677|Experimental|Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution|Treatment will be performed before the endotracheal suctioning
32760169|NCT05058677|Experimental|Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
32760170|NCT05058677|Experimental|Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
32760171|NCT05058677|Experimental|Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
32760172|NCT05058599||facial videos dataset|facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University.
32760173|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
32760174|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
32760175|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
32760176|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
32760177|NCT05058521||In-hospital VTE group|In-hospital VTE group includes patients who were with a hospital stay over 3 days and new-onset of VTE during their stay. Patients who presented for VTE were excluded.
32760178|NCT05058521||Negative group|Negative group includes patients who were with a hospital stay over 3 days and did not have a VTE during their hospital stay.
32760179|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
32760180|NCT05058755|Experimental|TALE regimen|tislelizumab plus azacytidine and lenalidomide
32760181|NCT05058755|Experimental|TEPA regimen|tislelizumab plus etoposide and pegaspargase
32760182|NCT05044247|Experimental|ESP block|ESP block under mixed local anesthetics, betamethasone agent
32760183|NCT05044169|Experimental|Broncho-Vaxom|Intervention
32760184|NCT05058365|Experimental|Intervention group|
32760185|NCT05058365|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
32760186|NCT05044559|Experimental|Continuous Positive Air Way Group|"Day 1: Use of CPAP between 10 and 12 cmH2O according to tolerance for 20 minutes two time a day at first day of post surgery bed mobility chest physiotherapy ,active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise. and vital was record after exercise.~Day 2: Active ROM exercise progress of 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time was increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
32760187|NCT05044559|Active Comparator|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
32760188|NCT05058053|Experimental|Cold application group|"After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the Visual Infusion Phlebitis Scale and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
33240889|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
33240890|NCT04774952|Experimental|RMC-5552|RMC-5552 for IV administration
33240891|NCT04774718|Experimental|ALK-Fusion Positive|Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
33240892|NCT04774406||parp inhibitors|All patients treated at least with 1 PARPi
33397614|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
33397615|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
32910718|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
32910719|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
32910720|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
32910721|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
32910722|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
32910723|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
33397616|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
32910724|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
32910725|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
32910726|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
32910727|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
33397617|NCT03425786|Experimental|Early BPPV Management|Diagnostic and treatment training for BPPV.
33397618|NCT03425786|Active Comparator|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
33397619|NCT04548570||approximation of both recti group|
33397620|NCT04548570||non approximation of both recti group|
32742481|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
32910728|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
32910729|NCT03498729||Persistent AF|
32910730|NCT03498729||Paroxysmal AF|
32910731|NCT03498729||Psoriasis|
32910732|NCT03498729||Healthy Controls|
32910733|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
32910734|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
32910735|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
32910736|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
32910737|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
32910738|NCT04340973|Active Comparator|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32910739|NCT04340973|Active Comparator|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32910740|NCT04340973|Active Comparator|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32910741|NCT04340973|Active Comparator|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32910742|NCT04340973|Placebo Comparator|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
33397621|NCT02423434||Corneal Confocal Microscopy subjects|
33240893|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
32760189|NCT05058053|No Intervention|Control group|"the patients who were started on amiodarone infusion were observed for the development of phlebitis, receiving no intervention. During the treatment, phlebitis development was evaluated and recorded by the researcher using the Visual Infusion Phlebitis Scale every 2 hours during the 24-hour infusion. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
32760190|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
32760191|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
32760192|NCT05058209|Active Comparator|Arm 1|Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.
32760193|NCT05058209|Active Comparator|Arm 2|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.
32760194|NCT05057663|Active Comparator|Bleomycin group|
32760195|NCT05057663|Active Comparator|5-Fluorouracil group|
32760196|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
32760197|NCT03097445|No Intervention|Control|No intervention control group
32760198|NCT05057351|Experimental|Active ingredient|Isopentenyltheophylline 0.44% + Glycerin 4.56%
32760199|NCT05057351|Placebo Comparator|Placebo|Glycerin 4.56%
32760200|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
32760201|NCT05057039||hypertensive group|SBP >=140mmHg, DBP >=90mmHg, or use of antihypertensive drug
32760202|NCT05057039||normotensive group|SBP <=140mmHg and DBP <=90mmHg without use of antihypertensive drug
32760203|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
32760204|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
32760205|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
32760206|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
32760207|NCT05056961|Other|Large tidal volumes without respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, without respiratory distress symptoms
32760208|NCT05056961|Other|Large tidal volumes with respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)
32760209|NCT05044403|Active Comparator|Conventional treatment|Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
32760210|NCT05044403|Experimental|Extracorporeal support with haemoperfusion treatment|Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
32760211|NCT05056649||Heart Failure Patients with impaired ejection fraction|
32760212|NCT04434443|Experimental|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
32760213|NCT04434443|Sham Comparator|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
32760214|NCT05043935|Experimental|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
32760215|NCT05043935|Active Comparator|antimicrobial photodynamic therapy|Application antimicrobial photodynamic therapy in the defect
32760216|NCT05056571|Experimental|Relaxation exercise|Intensive care nurses will apply 20 minutes of online (zoom meeting) progressive muscle relaxation exercise twice a week, for 8 weeks, for a total of 16 group sessions. In order to support nurses' adaptation to the research, the group counselor will remind the nurses by phone twice a week during the implementation process, and their regular participation in online sessions will be supported.
32760217|NCT05056571|No Intervention|Control|No attempt will be made during the research.
33397622|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
33397623|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
33397624|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
32760218|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
32760219|NCT05056181|Experimental|PAI|Participants assigned to the PAI arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will receive conventional medical treatment. They will also participate in 2 weeks of training (12 sessions), plus telematic assistance of a specialized practitioner who will follow them during the post-discharge training sessions for a period of 12 weeks, with 3 workouts per week.
32760220|NCT05056181|No Intervention|TAU|Participants assigned to the TAU arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will also receive conventional medical treatment.
32760221|NCT05056337|Experimental|Treatment group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with lenvatinib(8mg/d for BW<60kg and 12mg for BW≥60kg) in combination with toripalimab(240mg iv Q3W) and TACE (on demand). Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the conversion resection rate will be calculated, and patient survival will be assessed.
32760222|NCT05056337|Active Comparator|Control group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with TACE alone. Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the translational resection rate will be calculated, and patient survival will be assessed.
32760223|NCT05056025|Experimental|postbiotics with vitamins|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
32760224|NCT05056025|Placebo Comparator|vitamins|vitamins (AREDS formulation and recommended daily dose)
32760225|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
32760226|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
32760227|NCT02661217|Other|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
32760228|NCT02661217|Other|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
32760229|NCT05044091||ovarian/fallopian tube/primary peritoneal cancer patients|ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks
32760230|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
33397625|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
32760231|NCT01952080|No Intervention|Standard of Care|
32760232|NCT05043779|Other|Preoperative Awake Airway Nasoendoscopy|only one arm
32760233|NCT05055791|Experimental|Arm 1|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
32760234|NCT05055791|Experimental|Arm 2|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
32760235|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
32760236|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
32760237|NCT05055635|Experimental|Doseescalated pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.
32760238|NCT05055557||ARDS group|"1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).~3.Diagnosis of ARDS less than 72 hours. 4.Just observation"
32760239|NCT05055557||Critically ill patients without ARDS group|Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
32760240|NCT05055557||healthy adult group|Healthy adults, voluntarily join the study.
32760241|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
32760242|NCT05043467||Duvie(Lobeglitazone)|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
32760243|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
32760244|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
32760245|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
32760246|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
32760247|NCT05055245||Patients undergoing assisted reproductive technology|Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
32760248|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
32760249|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
32760250|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
32760251|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
32760252|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
32910743|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
32910744|NCT02600637|Active Comparator|Education|Educational group program
33397626|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
33397627|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
33240894|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
32760253|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
32760254|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
32760255|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
32760256|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
32760257|NCT05055167|Experimental|Envafolimab|Elderly NSCLC Patients with high PD-L1 expression
32760258|NCT05043233||Patients with Graves' disease|Graves' disease was diagnosed based on clinical symptoms and laboratory findings. The clinical symptoms included heat intolerance, fatigue, increased appetite, increased sweating, weight loss, muscle weakness, tremors, and diffusely enlarged thyroid glands. The laboratory results included increased serum concentrations of free thyroxine (FT4) and/ or free triiodothyronine (FT3), decreased basal thyroid-stimulating hormone (TSH) level, and TRAb positivity. All participants in this study would be treated with anti-thyroid drugs(MMI: methimazole) according to the 2016 ATA guildline.
32760259|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
32760260|NCT03258853|Active Comparator|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 14 days. Patients will wear a continuous glucose monitor (CGM) during this arm
32760261|NCT03258853|Experimental|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin using a continuous glucose monitoring (CGM) device, for 14 days.
32760262|NCT05054855|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention.
32760263|NCT05054855|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an inperson session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
32760264|NCT05054933|Other|ultrasound capsule endoscopy examination|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
32760265|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
32760266|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
32760267|NCT05054777||oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques
32760268|NCT05054777||conventional breast-conserving surgery|The conventional breast-conserving surgery were performed without any oncoplastic operations
32760269|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
32760270|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
32760271|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
32760272|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
32760273|NCT05054465|Experimental|Pre-transplant consolidation and post-transplant maintnance with navitoclax and venetoclax.|Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol.Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.
32760274|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : Normal invitation"
32760275|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : revised invitation signed by the coordinating doctor"
32760276|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)~Intervention : Revised invitation signed by the attending physician"
33397628|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
32760277|NCT05054699|Experimental|MST|Subjects will receive 12-18 sessions of frontal Magnetic Seizure Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
32760278|NCT05054699|Active Comparator|ECT|Subjects will receive 12-18 sessions of bilateral Electroconvulsive Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
32760279|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
32760280|NCT02367157|No Intervention|No intervention: Control|
32760281|NCT05043389|Experimental|Obstructive sleep apnea|myofunctional therapy program
32760282|NCT05043389|No Intervention|control|standard treatment
32760283|NCT05042921||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 21 months and the available data is collected retrospectively.
32760284|NCT05042921||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 21 months.
32760285|NCT04059835|Active Comparator|standard|Standard bra, soft
32760286|NCT04059835|Experimental|compression bra|experimental bra, compression and stabile
32760287|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
32760288|NCT04472195|Experimental|Experimental|The experimental group will review a pre-induction airway management plan for their upcoming case and undergo a scripted 10-minute RCDP session with an airway coach within 1 hour of patient intubation. The intubation approach (DL vs. video assisted DL) will be chosen by the primary case attending and communicated to the airway coach to simulate the planned laryngoscopy attempt. The experimental group will then proceed with their scheduled case with a member of the research team observing the laryngoscopy attempt(s) to capture data.
32760289|NCT04472195|No Intervention|Control|The trainees in the control group will have no interventions by the research team, only observation of the intubation and documentation of the same details.
32760290|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
32760291|NCT04472117|Experimental|Usual care and usual care plus video|Phase I (completed 3/31/2021): A sample of patients in phase I will complete a qualitative interview prior to or after surgery. Twenty-five patients (15 pre-operatively and a separate 10 post-operatively) will be selected to participate in an in-person/phone interview. Phase II: A separate group of women will compose phase II. All patients (N = 100) in phase II will complete discrete-choice surveys. Patients in phase III of the study will be randomized evenly to usual care plus video or usual care only. Phase III: One hundred participants will be randomized via CRDB to receive standard pre-operative counseling or standard pre-operative counseling with the additional of an educational video. Those randomized to view the video will also complete the post-video survey. All patients will complete the Decision Regret Scale.
32760292|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
32760293|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
32760294|NCT04154189|Experimental|Randomization Phase: Lenvatinib + Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
32760295|NCT04154189|Active Comparator|Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)|Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
32760296|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
32760297|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
32760298|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
32760299|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
32760300|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
32760301|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
32760302|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
32760303|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
32760304|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
33397629|NCT05759052||Cohort of adult survivors having been treated by vincristine|Cohort of adult survivors having been treated by vincristine for a childhood leukemia
32760305|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
32760306|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
32760307|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
32760308|NCT04154111|Experimental|Real TBS to the vmPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
32760309|NCT04154111|Sham Comparator|Sham TBS to the vmPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
32760310|NCT04154111|Experimental|Real TBS to the dlPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
32760311|NCT04154111|Sham Comparator|Sham TBS to the dlPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC
32760312|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
32760313|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
32760314|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
32760315|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
32760316|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
32760317|NCT05053685||Obstructive Sleep Apnoea (OSA)|Subjects with OSA
32760318|NCT05053685||Elevated Urine Metanephrines|Subjects with elevated metanephrines
33240895|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
33397630|NCT03424850|Experimental|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
32742482|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
32760319|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
33240896|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
33397631|NCT03424850|Experimental|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
32760320|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
33240897|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
33397632|NCT03424850|Experimental|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
33397633|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
32910745|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
32910746|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
32910747|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
32742483|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
32742484|NCT04488341|Other|aerobic exercises in addition to diet|The study group will receive aerobic exercises in addition to diet recommendations
32742485|NCT04488341|Other|diet recommendations|control group will receive diet recommendations
32910748|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
32760321|NCT05042297|Active Comparator|Combined Posterior and anterior ring fixation|Posterior ring fixation via a single posterior Sacroiliac screw or two Iliac wing plates. While anterior ring fixation was via a single para-symphyseal plate in Tile B2 injuries. Meanwhile, we used double superior and anterior symphyseal plates in Tile C1 injuries.
32760322|NCT05042297|Experimental|Isolated Posterior ring fixation|We used either two Sacroiliac screws in S1 and S2, or two Iliac wing plates.
33397634|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
32760323|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
32760324|NCT05053919|Experimental|SR device group|
32760325|NCT05053919|Placebo Comparator|placebo device group|
32760326|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
32760327|NCT05041985|Experimental|group A (the Test group)|arm which received Diazepam 5 mg therapy for 7 days after whiplash
32760328|NCT05041985|No Intervention|group B (the control group)|a group which did not receive Diazepam 5 mg therapy
32760329|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
32760330|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
32760331|NCT05053841|No Intervention|Control group|fifteen obese females who received letrozole only
32760332|NCT05053841|Active Comparator|metformin group|fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
32760333|NCT05053841|No Intervention|lean group|fifteen non- obese breast cancer females who received letozole for six months, treatment period
32760334|NCT02372461|Placebo Comparator|Experimental|Placebo
32760335|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
32760336|NCT05053529|Experimental|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
32760337|NCT05053529|Experimental|Constrained induced movement therapy (CIMT)|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
32760338|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
32760339|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
32760340|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
32760341|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
32760342|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
32760343|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
32760344|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
32760345|NCT02372617||Group A|bone graft - autologous
32760346|NCT02372617||Group B|bone graft - ceramic
32760347|NCT05053373|Experimental|Electroacupuncture Added to Pelvic Floor Muscle Training|Patients will be in a prone position. Bilateral Zhongliao (BL33) and Huiyangacupoint (BL35) will be identified and punctured by an acupuncturist. The electrodes will be placed on the needle handles, and stimulate for 30 minutes at 50 Hz with a current intensity between 1 to 5 mA. PFMT will be performed 3 sets a day (morning, around noon, and night).
32760348|NCT05053373|Experimental|Sham Electroacupuncture Added to Pelvic Floor Muscle Training|The preparation for the patients will be the same as that for the patients who will receive EA. Whereas, instead of using real acupuncture needles, special designed placebo needles (size 0.30 × 25 mm) with the blunt-head will be used in the PFMT+sham EA group to penetrate the fixed pad to the skin surface but without skin penetration. The same procedure for deqi will be performed as in the PFMT+EA group. A special-designed cable (the intermediate wire of the cable is cut off but the appearance is normal) will be used to connect the electrodes to the electroacupuncture machine. Therefore, the electroacupuncture machine appears to work, but does not actually stimulated acupoints. The sham EA treatment will also be maintained for 30 minutes. PFMT will be performed 3 sets a day (morning, around noon, and night),
32910749|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
32742486|NCT04976517||non-diabetes group|patients who underwent heart tranplantation without diabetes
32742487|NCT04976517||pre-transplant diabetes group|patients who underwent heart tranplantation with diabetes before the transplantation
32742488|NCT04976517||post transplant daibetes group|patients who underwent heart tranplantation without diabetes until after the transplantation
32910750|NCT02601105|Experimental|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
32910751|NCT02603211||Women with Breast Tumors|Women with breast tumors.
32910752|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
32910753|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
33397635|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
32910754|NCT04743297|Active Comparator|Propess Vaginal Delivery System|Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
32910755|NCT04743297|Active Comparator|Prostin Tablet|Prostaglandin E2 Vaginal Tablet 3 mg dinoprostone
32910756|NCT04180371|Experimental|Part A-1 Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 48 participants will participate in this dose escalation arm.
32910757|NCT04180371|Experimental|Part A-2 - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose-escalation combination arm.
33398766|NCT04481776|Experimental|Breakfast consumption|Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
32910758|NCT04180371|Experimental|Part B - Dose expansion 1 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 240 patients have solid tumors (Cohort 1: urothelial cancers, Cohort 2: ovarian cancer, Cohort 3: non-small cell lung cancer, Cohort 4: head and neck cancer, Cohort 5: triple-negative breast cancer, and Cohort 6: gastric/upper gastrointestinal cancer) historically known for high expression of EphA2 will participate in this dose-expansion arm
32910759|NCT04176783|Active Comparator|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
32910760|NCT04176783|Active Comparator|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
32742489|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
32742490|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
32742491|NCT04976439||Age|
32742492|NCT04976439||Grade|
33397636|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
33397637|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
33397638|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
32742493|NCT04976439||Tumor location|
32742494|NCT04976439||Stage|
32742495|NCT04976439||Lymphovascular invasion|
33397639|NCT04437732|Other|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
32742496|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
33397640|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
33397641|NCT05760534|Experimental|Ideal body weight group|
33397642|NCT05760534|Active Comparator|Total body weight group|
33397643|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
33397644|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
33397645|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
33397646|NCT01362699|Experimental|JNJ-31001074|
33397647|NCT01362699|Placebo Comparator|Placebo|
33397648|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
33397649|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
33397650|NCT05649540|Active Comparator|high dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
32742497|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
32742498|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
32742499|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
32742500|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
33397651|NCT05649540|Experimental|standard dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg bid for 14 days
33397652|NCT05649540|Experimental|low dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 500mg tid for 14 days
33397653|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
33397654|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
33397655|NCT03686072|Other|Cataract surgery with goniosynechialysis|
32742501|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
32742502|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
33397656|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.~Under this arm, main therapeutic measures are listed as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D4 lymphadenectomy~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
32760349|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
33397657|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.~Under this arm, main therapeutic measures are included as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
32742503|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
33397658|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
32742504|NCT04968561||cohort 1|"Adult patients~Admitted in the ENT and Cervico-Facial Surgery department of the Gabriel Montpied University Hospital in Clermont-Ferrand.~From November 2020 to October 2021,~Requiring endoscopic sinus surgery~With good quality imaging (CT scan and/or MRI)"
33397659|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
32910761|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
32910762|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
32910763|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
32760350|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
32760351|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
32760352|NCT05053061|Experimental|Telerehabilitation Arm|
32760353|NCT04499131|Experimental|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
32760354|NCT04499131|Experimental|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
32760355|NCT04499131|Experimental|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
32760356|NCT04499131|Experimental|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
32760357|NCT04499131|Experimental|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
32760358|NCT04499131|Active Comparator|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
32760359|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
32760360|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
32760361|NCT02805595|Experimental|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.4cc per treatment. If necessary every two weeks, with a maximum of three treatments.
32760362|NCT05053295|Experimental|Immuncell-LC/Nivolumab group|Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
32760363|NCT02372227|Experimental|VS-5584 and VS-6063|
32760364|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
32760365|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
32760366|NCT05653687|Experimental|Fluoroscopy|
32760367|NCT05653687|No Intervention|Freehand|
32760368|NCT05053217|Active Comparator|Patients diagnosed with fibromyalgia|
32760369|NCT05053217|Active Comparator|Patients without a diagnosis of fibromyalgia|
32760370|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
32760371|NCT05052593|Experimental|Compressive myofascial release|". patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. with pressure directed from distal to proximal.~Conventional treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)"
32760372|NCT05052593|Active Comparator|Conventional treatment|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
32760373|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
32760374|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
32760375|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
32760376|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
32760377|NCT05052515|Placebo Comparator|Placebo|Oral treatment Two tablets twice a day for one year
32760378|NCT05052515|Experimental|Nutritional Supplementation|Oral treatment Two tablets twice a day for one year
32760379|NCT05041595||Sick Cohort|Borreliosis Subjects - established diagnosis of early Borreliosis expressing EM Rash Borreliosis Subjects - expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease
32760380|NCT05041595||Apparently Healthy|Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease
33240898|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
33240899|NCT04836897|Experimental|Treatment|Transcatheter aortic valve replacement
33240900|NCT04190342|Other|control group|standard care (intervention provided after the completion of the trial)
33240901|NCT04190342|Experimental|tai chi group|Tai chi intervention + standard care
33240902|NCT04772690|Experimental|BAL|A resource-orientered, individual and group-based intervention addressing balance in everyday life, activities and QoL among people with chronic or advanced cancer.
33072138|NCT05444582||Observational: 52 mg LNG IUD Same Day Start or EC|"Week 1: Text daily for seven days. Report occurrences of the following in the last day: presence or absence of bleeding, spotting, pain, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, and report any additional medical care received.~Weeks 2 & 3: Weekly text survey assessing on which days of the previous week participants experienced bleeding and spotting, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, or experienced adverse events.~Week 4 Survey: At 28 days, participants will be asked about pregnancy symptoms, concern about pregnancy, and the result of their urine pregnancy test including a prompt to upload a photo of the test."
33072139|NCT05442671|Other|Home exercise intervention|"Participants will be instructed in performing aerobic exercise for 20 minutes per day, 5 days per week, and light resistance exercises 2 days per week. Aerobic sessions will start with stretching followed by walking, biking, or light jogging, depending on access to facilities/equipment and weather. Participants will increase their heart rate on the smartwatch to a goal of 80% that achieved on their 6-minute walk test (at most 150 beats/min). Participants will perform light resistance exercises using resistance bands. Participants will be advised to avoid heavy exercise.~Participants will wear the smartwatch for the length of the intervention. This will synch with a mobile device application to support at-home symptom assessment, recording of resistance exercise, and protocol adherence. There will be multiple ways (videochat, telephone ChatBot) by which participants can contact the study team with questions or concerns."
33072140|NCT05440786|Experimental|Abemaciclib + Irinotecan +Temozolomide|Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally.
33240903|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
33072141|NCT05440786|Experimental|Irinotecan +Temozolomide|Irinotecan given IV and temozolomide orally.
33240904|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
33240905|NCT04767698|Experimental|Belimumab + short-term Ocrelizumab|Participants will receive Belimumab and Ocrelizumab.
33240906|NCT04767698|Active Comparator|Continued Ocrelizumab|Participants will receive Ocrelizumab only.
33072142|NCT05440643|Experimental|Cohort 1|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
33072143|NCT05440643|Experimental|Cohort 2|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
33240907|NCT05674994|Experimental|MethylPrednisone/Prednisone|"Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d) Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes. The commercialized form for methylprednisolone injectable solution is not imposed and is taken from the stock of each pharmacy of the participating centers.~From day 4 to Day 30: Oral Prednisone slow tappering~1 mg/kg/d for 7 days~0.5 mg/kg/d for 7 days~0.25 mg/kg/d for 7 days,~10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
33240908|NCT05674994|Placebo Comparator|Placebo|"Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo~From Day 4 to Day 30: Oral Prednisone-Placebo"
33240909|NCT04785807|Experimental|Evaluation arm|
33240910|NCT04962776|Active Comparator|Low-concentration carbohydrate and nitrates group (CHON group )|
33240911|NCT04962776|Active Comparator|Low-concentration carbohydrate group (CHO group)|
33240912|NCT04962776|Placebo Comparator|W group|
33240913|NCT04707573|Experimental|CKD, Stage 3|Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate [eGFR] 30 - 59 milliliters [mL]/minute) received a single 500 milligram (mg) oral dose of Vadadustat after fasting for at least 4 hours.
33240914|NCT04707573|Experimental|CKD, Stage 4|Participants with Stage 4 CKD (eGFR <30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of Vadadustat after fasting for at least 4 hours.
33072144|NCT05440643|Experimental|Cohort 3|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
33072145|NCT05440643|Experimental|Cohort 4|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
33072146|NCT05440643|Experimental|Cohort 5|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
33072147|NCT05440643|Experimental|Cohort 6|Adults and adolescents - UDR with once daily peanut SLIT-tablet
33072148|NCT05440643|Experimental|Cohort 7|Adolescents - UDR with once daily peanut SLIT-tablet
33072149|NCT05440643|Experimental|Cohort 8|Children - UDR with once daily peanut SLIT-tablet
33072150|NCT05440643|Experimental|Cohort 9|Highly sensitized Adults/Adolescents - UDR with once daily peanut SLIT-tablet
33072151|NCT05440643|Experimental|Cohort 10|Highly sensitized Children - UDR with once daily peanut SLIT-tablet
33240915|NCT02589080|Experimental|Non-invasive sensory feedback|
33072155|NCT05435443|Experimental|the PowerBreathe and PEP Therosold tools group|
32910764|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
33072156|NCT05435443|Active Comparator|perform diaphragmatic breathing, series of abdominal crunches and expiratory exercises group.|
32760381|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
32910765|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
33240916|NCT04082702|Experimental|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
32742505|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
32910766|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
32910767|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
33072158|NCT05427253|Experimental|C106 solution|Part A: Oral administration start dose, Single dose 5 mg Part B: Oral administration start dose 20 mg twice daily for 8 days
33072159|NCT05427253|Placebo Comparator|Placebo|Part A and B: Placebo to C106 without the active pharmaceutical ingredient
33072160|NCT05425940|Experimental|Experimental Arm|Subjects with mCRC will receive XL092 + atezolizumab
33072161|NCT05425940|Active Comparator|Control Arm|Subjects with mCRC will receive active comparator of regorafenib
33240917|NCT04082702|Active Comparator|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
33072162|NCT05425719|Experimental|eGFR ≥ 70 mL/min/1.73 m^2|Participants with eGFR ≥ 70 mL/min/1.73 m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest. Blood samples and fluorescent measurements will be collected over 12 hours.
32760382|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
33397660|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
32760383|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
32744535|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
32744536|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
32744537|NCT04874337|Experimental|Experimental group|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
32744538|NCT04874337|No Intervention|Control Group|
32760384|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
32744539|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
32760385|NCT05052437|Experimental|Utidelone|
32760386|NCT05052437|Experimental|Utidelone plus capecitabine|
32760387|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
33240918|NCT05309577|Active Comparator|Caregiver Intervention|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors for 6 weeks, into an electronic tablet or device; and behavioral self monitoring + motivational interviewing health coaching.
33240919|NCT05309577|Active Comparator|Enhanced Usual Care|Participants randomized to this condition will receive the written education provided to all participants, along with weekly check-in calls.
32760388|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
33398767|NCT04481776|Experimental|Breakfast omission|Participants were asked to abstain from all energy-providing nutrients before 10:30 for seven consecutive days.
32760389|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
32760390|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
32760391|NCT05041517|No Intervention|Control|No intervention
32760392|NCT05041517|Experimental|BOLT + 1 PTC|BOLT Training + 1 PTC Call
32760393|NCT05041517|Experimental|BOLT + 2 PTC|BOLT Training + 2 PTC Calls
32760394|NCT05041517|Experimental|BOLT + 4 PTC|BOLT Training + 4 PTC Calls
32760395|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
32760396|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
32760397|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
33397661|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
33240920|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
32760398|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
32910768|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
32910769|NCT04166721|Experimental|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
32910770|NCT04343001|No Intervention|Standard care|Usual standard of care at the study hospital
32910771|NCT04343001|Experimental|Aspirin|Aspirin 150mg once daily
32910772|NCT04343001|Experimental|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
32910773|NCT04343001|Experimental|Simvastatin|Simvastatin 80mg once daily
33397662|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
33397663|NCT03183466|Experimental|Patients included in inclusion criteria|
33397664|NCT05189067|Active Comparator|paclitaxel + trastuzumab|"paclitaxel × 12, every week a cycle, trastuzumab × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Paclitaxel i.v. 80mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
33397665|NCT05189067|Experimental|docetaxel + trastuzumab|"(docetaxel + trastuzumab) × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Docetaxel i.v. 100mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
33397666|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
33397667|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
33397668|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
33397669|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
33397670|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
33397671|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
33397672|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~Individualized exercise training~Educational activities~Dietary advices"
33397673|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
33397674|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
33397675|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
33397676|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
33397677|NCT03711643|Active Comparator|standard pain management|
33397678|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
33397679|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
33397680|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
33397681|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
33397682|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
33397683|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
33397684|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
33397685|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
33397686|NCT05647122|Experimental|Module 1 AZD9592 Monotherapy|"Module 1 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors"
33240921|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
32760401|NCT05051423||Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.|"Patients will be included or excluded according to the following criteria used throughout the study:~Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling~Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy.~Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings."
33240922|NCT04082624|Active Comparator|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
32760402|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
32760403|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
32760404|NCT05041283|No Intervention|Standard Preparation|Control arm; patients receive a standard support for bowel preparation consisting of a explanatory dialogue with a gastroenterologist and a brochure with a structurated description of bowel preparation and colonoscopy conduct
32760405|NCT05041283|Active Comparator|Phone-call Supported Preparation|In addition to standard preparation, patients receive a phone call every day starting at 3 days before colonoscopy in which a investigator explains key points of bowel preparation and patients can ask questions concerning bowel preparation and colonoscopy conduct.
32760406|NCT05041283|Experimental|Chatbot Supported Preparation|In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
32760407|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
32760408|NCT05041205|Placebo Comparator|Placebo control group|placebo drink powder without active ingredients, 1 sachet per day with 50 ml water for 12 weeks
32760409|NCT05041205|Experimental|Beauty drink powder group|Beauty drink powder is the test article provide to participants, 1 sachet per day with 50 ml water for 12 weeks
32760410|NCT05041205|Placebo Comparator|cosmetic apparatus group|This group is designed for a cosmetic apparatus control group without consumption of placebo or test article. Together with the specified cleanser, the apparatus is used for daily facial cleaning, two times in the morning and evening for 12 weeks.
32760411|NCT05041205|Experimental|Beauty drink powder + cosmetic apparatus group|In this group, Beauty drink powder is consumed 1 sachet daily with 50 ml water and the cosmetic apparatus is used together with the specified cleanser for daily facial cleaning, two times in the morning and evening for 12 weeks.
32760412|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
32760413|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
32760414|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
32760415|NCT05041439|Experimental|Community health worker (CHW) group|Participants in the intervention arm will receive 5 one-on-one sessions over 6 months with a CHW, as well as a manual and written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
32760416|NCT05041439|No Intervention|Enhanced care condition (ECC)|Participants in this arm will receive 5 outreach calls at the same interval as the intervention arm, as well as written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
32760417|NCT04434677|Active Comparator|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
32760418|NCT04434677|Experimental|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
32760419|NCT01944046|Placebo Comparator|DB Placebo Nasal Spray|Placebo treatment during weeks 0-24 double blind phase
32760420|NCT01944046|Active Comparator|DB Oxytocin Nasal Spray|DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study
32760421|NCT01944046|Active Comparator|open label intranasal oxytocin|non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment
32760422|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
32760423|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
32760424|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
32760425|NCT05040737|Experimental|Study Arm|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
32760426|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
32760427|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
32760428|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
32760429|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
32760430|NCT00773695|Active Comparator|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
32760431|NCT00773695|Experimental|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
32760432|NCT00773695|Active Comparator|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
32760433|NCT00773695|Experimental|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
32760434|NCT05040815|Experimental|chemo-radiation treatment|"Radiotherapy with concurrent 5-fluorouracil and mitomycin-C combination treatment.~Radiotherapy consists of 5400 cGy delivered in 30 fractions over 6 weeks. The investigators will be using the current standard regimen for the study or no change in the current CCI treatment regimen. However, the radiotherapy target will be smaller than current practice since the investigators will be omitting prophylactic inguinal irradiation."
32760435|NCT04643704||FPIES|100 patients
32760436|NCT04643704||IgE mediated food allergy|100 patients
32760437|NCT04643704||Celiac disease|100 patients
32760438|NCT04643704||Control group|100 patients
32760439|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
32760440|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
32760441|NCT03112525||Patient under Rivaroxaban|
32760442|NCT03112525||Patient under Apixaban|
32760443|NCT05040425|Experimental|Chinese herbal medicine treatment|
32760444|NCT05040425|No Intervention|Non-Chinese herbal medicine treatment|
32760445|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
32760446|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
32760447|NCT03112837|No Intervention|healthy control group|
32760448|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
32760449|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
32760450|NCT05040347||PVTT group|The diagnosis of portal vein tumor thrombosis was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
32760451|NCT05040347||HCC group|The diagnosis of HCC was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
32760452|NCT05040347||control group|The presence of PVTT or HCC was confirmed by medical record review and all the recorded events were confirmed by a radiologist using imaging studies, ultrasound, contrast-enhanced, or MR.
32760453|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
32760454|NCT05040503|Active Comparator|Patients without sepsis|patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
32760455|NCT05040503|Experimental|Patients with sepsis|Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
32760456|NCT05040503|Experimental|Patients with septic shock|Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
32760457|NCT05040503|Active Comparator|Healthy volunteers|
32760458|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
32760459|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
32760460|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
32760461|NCT05040191|Experimental|Control Group|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of Checklist for Teaching Nasogastric Tube Application Skills was watched and preliminary information was given. The questions were answered by allowing the students to ask questions."
32760462|NCT05040191|Experimental|Haptic Interactive Virtual Reality Simulation(Experiment 1 group)|Application in the Experiment-1 Group: After the theoretical lesson, the students in the Experiment-1 group were taken to the computer laboratory room where the haptic interactive virtual reality application was installed. The Nasogastric Tube Application with Haptic Interactive Virtual Reality Simulation was applied and explained by the researcher and preliminary information was given. The questions were answered by allowing the students to ask questions.
32898178|NCT03941964|Experimental|Venetoclax 400 mg + decitabine 20 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Decitabine (20 mg/m^2) was administered intravenously per investigator's choice and institutional practice for 5 days beginning on Day 1 of each cycle.
33240923|NCT04082624|Experimental|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
33397687|NCT05647122|Experimental|Module 2 AZD9592 Combination with Osimertinib|"Module 2 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm"
33397688|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
33397689|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
33397690|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
33397691|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
32910774|NCT04343001|Experimental|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
32910775|NCT04343001|Experimental|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
32744540|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
32744541|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
33397692|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
33240924|NCT04082624|Experimental|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
33240925|NCT04082624|Experimental|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
33240926|NCT04049253|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
32910776|NCT04343001|Experimental|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
33240927|NCT04049253|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
33240928|NCT00919958|Experimental|PLX-PAD low dose|
33240929|NCT00919958|Experimental|PLX-PAD intermediate dose|
33240930|NCT00919958|Experimental|PLX-PAD high dose|
32744542|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
33240931|NCT03217851||Patients Presenting P. falciparum Malaria|
33240932|NCT04082000|Experimental|BOL-DP-o-04|
33240933|NCT04082000|Placebo Comparator|Placebo|
33240934|NCT03205137||Telmisartan and hydrochlorothiazide group|
33240935|NCT03205137||Telmisartan and amlodipine group|
33240936|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
33240937|NCT03205137||telmisartan+amlodipine double-pill combination group|
32910777|NCT04343001|Experimental|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
33397693|NCT05641350|Experimental|Emotional eating intervention|Emotional eating intervention
33397694|NCT05641350|No Intervention|Waiting list|Waiting list
33397695|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
33397696|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
33397697|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397698|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397699|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397700|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397701|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397702|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
33397703|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397704|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397705|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397706|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397707|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397708|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
33397709|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
33397710|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
33397711|NCT05760456|Experimental|DIDALA|DIDALA is a herbal medicine, produced from dried mulberry leaves. The drug has been approved by the Drug Administration of Vietnam.
33397712|NCT05760456|Active Comparator|METFORMIN|
33397713|NCT02418130|Experimental|UDCA004|UDCA004
33397714|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
33397715|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
33397716|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
33397717|NCT03179956|Experimental|Ribociclib|
33397718|NCT03391765|Experimental|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
33397719|NCT03391765|Experimental|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
33397720|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
33397721|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
33397722|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
33397723|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of 5% dextrose in water (D5W)
33397724|NCT02426554|Active Comparator|Group 1|
33397725|NCT02426554|Placebo Comparator|Group 2|
33397726|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
32760463|NCT05040191|Experimental|Haptic Interactive Computer Based Simulation(Experiment 2 group)|Application in the Experiment-2 Group: After the theoretical lesson, the students in the Experiment-2 group were taken to the laboratory room where the haptic interactive computer-based simulation was located. This computer-assisted simulation allows us to see the application on the computer screen while performing an application with a haptic arm. It gives feedback on hand manipulations similar to reality. It was explained by the researcher by applying the nasogastric tube application skill with haptic interactive computer-based simulation and preliminary information was given. The questions were answered by allowing the students to ask questions.
32760464|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
32760465|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
32760466|NCT04636840|No Intervention|Control Group|Access to a self-help version of Space From Body and Eating Concerns Program on SilverCloud Health App
32760467|NCT04636840|Experimental|Experimental Group A- Mobile App with Social Networking Feature|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App with private social media group for social networking support.
32760468|NCT04636840|Experimental|Experimental Group B- Mobile App Only|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App.
32760469|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
32760470|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
32760471|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
32760472|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
32760473|NCT05039957|Active Comparator|A|
32760474|NCT05039957|Experimental|B|
32760475|NCT01942486|Experimental|Investigational Coating|
32760476|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
33397727|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
32760477|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
32760478|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
32760479|NCT04660084|Other|Ultra-rapid molecular point-of-care testing|Extended and more rapid diagnostics on microbiological specimens and an active feedback to treating staff with results.
32760480|NCT04660084|No Intervention|Standard of care|Standard collection of microbiological specimens and standard reply to treating staff.
32760481|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
32760482|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
32760483|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
33397728|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
33397729|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
32760484|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
33397730|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
33397731|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
33397732|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
33397733|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
33397734|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
33397735|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
33397736|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
33397737|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
33397738|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
33397739|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
33397740|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
33397741|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
32760485|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
32760486|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
32760487|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
32760488|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
32744543|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
32744544|NCT03227549|Active Comparator|Posterior Approach|
32744545|NCT04869033|Experimental|Farinelli's breathing group|Complete Farinelli's breathing exercise 5 times per week for 8 weeks.
32744546|NCT04869033|Other|Diaphragmatic breathing group (control group)|Complete Diaphragmatic breathing exercise 5 times per week for 8 weeks.
32760489|NCT05050877||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
33397742|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
33397743|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
33397744|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
32760490|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
32744197|NCT04464993|Experimental|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
32760491|NCT02362399|Active Comparator|placebo|single tablet of placebo
32910780|NCT02865135|Experimental|DPX-E7 Vaccine|Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.
32910781|NCT01739231|Experimental|ACE527 alone|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
32910782|NCT01739231|Experimental|ACE527 plus dmLT|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT) at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
32744198|NCT04464993|Experimental|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout and time of day. These prompts will specifically target outcome expectations around SST and MVPA.
33397745|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
32898179|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
32898180|NCT03935100|Experimental|Treatment Group|All visible diverticula clipped during index colonoscopy
33397746|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
33397747|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
33397748|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
32898181|NCT03935100|Placebo Comparator|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
33397749|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
33397750|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
33397751|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
33397752|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
33397753|NCT01365663|Placebo Comparator|Saline 0.9%|
33397754|NCT05488483||Breast and Melanoma Cohort|Participants with a suspicious finding at breast ultrasonography (BI-RADS 4 suspicious abnormality; BI-RADS 5, highly suggestive for malignancy) who are scheduled for ultrasound-guided breast biopsy will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. We will evaluate MSOT in 10 patients from the Melanoma Surgical Oncology Clinics (Dr. Ariyan, Co-I) with pathologically confirmed ITM following physical exam and biopsy. We will also evaluate MSOT in five melanoma patients with pathologically confirmed IT metastases scheduled for neoadjuvant immunotherapy prior to surgical resection.
33397755|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
33397756|NCT04380090|Active Comparator|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
33397757|NCT04380090|Experimental|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
33397758|NCT05191563|Experimental|Sequence 1 (Reference-Test)|Period 1: RLD2001-2 + RLD2006, Period2: HCP1904-1
33397759|NCT05191563|Experimental|Sequence 2 (Test-Reference)|Period 1:HCP1904-1, Period 2: RLD2001-2 + RLD2006
33397760|NCT03685994||the patients who will undergo TIPS|
32910783|NCT01739231|Active Comparator|Control: Part A and B|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of CeraVacx placebo at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
32910784|NCT01739231|Active Comparator|Control: Part B only|Eligible participants were screened and administered H10407 challenge strain concurrently with other arms in Part B of the study. Their results for Part B are combined with that of the Control Arm in Part A, which received three oral doses of CeraVacx placebo.
32910785|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
32910786|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
33397761|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
33397762|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
33397763|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
33397764|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
33397765|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
33240938|NCT04953884|Experimental|wilate treatment|PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of >30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of >50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels >30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels >50% during maintenance
33397766|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
32901532|NCT05090514|Experimental|Reading and Growth Mindset Intervention Group|Parents and students receive a packet of age-appropriate books and educational materials on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
32901533|NCT05090514|Active Comparator|Wait-list Control Group|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read.
33240939|NCT04953650|Experimental|intervention group|two fasting days and five ad-libitum days followed by usual exercise.
33240940|NCT04953650|Sham Comparator|Control group|Usual diet and usual exercise prior to the intervention.
32910787|NCT04742205|Active Comparator|tranexamic acid|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
33397767|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
33072163|NCT05425719|Experimental|eGFR < 70 mL/min/1.73 m^2|Participants with eGFR < 70 mL/min/1.73 m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest. Blood samples and fluorescent measurements will be collected over 24 hours.
33072164|NCT05425511|Experimental|intervention group|The intervention group will have a longitudinal follow-up of seven months in total (a control period of 1 month, then 6 to 8 sophrology sessions during two months, then a 4-month follow-up).
33072165|NCT05425511|Active Comparator|control group|The control group will have a differed intervention (longitudinal follow-up of seven months in total beginning by a control period without intervention of 3 months, then 6 to 8 sophrology sessions during two months, then a 2-month follow-up).
33397768|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
33397769|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
33397770|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
33072166|NCT05423496|Active Comparator|Steroid Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
33397771|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
33397772|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
33397773|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
33397774|NCT05758896|Experimental|Isuzinaxib (APX-115)|4 x Isuzinaxib 88 mg calculated as free base (4 x 100mg APX-115(Isuzinaxib hydrocloride) capsules as salt form) administered QD, orally, for up to 5 consecutive days
33397775|NCT05758896|Placebo Comparator|Placebo|4 x Placebo capsules administered QD, orally, for up to 5 consecutive days
33397776|NCT03745235|Experimental|"Mindfulness group"|
33397777|NCT03745235|Other|Control group|Treatment as Usual
33397778|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
32910788|NCT04742205|Placebo Comparator|Sodium Chloride|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
32910789|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
33072167|NCT05423496|Experimental|Steroid Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of steroids/CNI
32910790|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
32910791|NCT04743063||New users of angiotensin receptor neprilysin inhibitor|
32910792|NCT04743063||New users of angiotensin II receptor blockers|
32760492|NCT04410887|Experimental|PISOXO|"st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX~nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
33072168|NCT05423496|Active Comparator|Tacrolimus and mycophenolate mofetil (MMF) Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
32760493|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
32760494|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
32760495|NCT05050331|Experimental|Muscle Energy Technique (MET) Group|Post-isometric relaxation was given as the form of MET. It was applied to gastrocnemius and soleus with patient supine and foot extended, knee was flexed for soleus and extended for gastrocnemius muscle. The patient ankle was dorsiflexed by the therapist until the point of discomfort or resistance, and the patient was instructed to exert pressure using 20% force for 5-7 seconds toward plantar flexion. Relaxation was given for 5 seconds and the therapist passively dorsiflex the ankle to a new barrier. Gastrocnemius and soleus both received a single set of 5 repetitions separately. Treatment was given for 4 weeks, 3 sessions per week.
32760496|NCT05050331|Experimental|Trigger Point Release Group|Trigger points of gastrocnemius muscle was released. The patient in prone lying with legs extended and the therapist in walk standing position, applied vertical downward pressure toward the trigger points for 90 seconds with the therapist's thumb. Three repetitions was given with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction was given by the therapist's thumb over the taut band. Treatment was provided for 4 weeks, 3 sessions per week.
32760497|NCT05039333||RUS (Surgical navigation, anatomy 3D-reconstruction)|single-arm study : prospective observational 1-arm (RUS group)
32760498|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
32760499|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
32760500|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
32760501|NCT05038865||Malocclusion group|500 12-19 year olds with malocclusion, defined as IOTN-DHC grade 3, 4 or 5. The adolescents are consecutively recruited new patients at three orthodontic centers; Center for Orthodontics and Pediatric Dentistry, Norrköping, Public Dental Service Östergötland; Department of Orthodontics, Folktandvården Stockholms län AB, Folktandvården Eastmaninstitutet, Stockholm, Sweden and Department of Orthodontics, Malmö University, Malmö, Sweden. Patients are examined at the first visit at the orthodontic department, before any orthodontic treatment is begun.
32760502|NCT05038865||No malocclusion group|175 12-19 year olds without malocclusion, defined as IOTN-DHC grade 1 or 2. Patients are consectively recruited adolescents examined at their general dentistry clinic.
32760503|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
32760504|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
32760505|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
32760506|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
32760507|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
32760508|NCT03095807|Experimental|NNC9204-1706 A|
32760509|NCT03095807|Placebo Comparator|Placebo|
32760510|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
32760511|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
32760512|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
32760513|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
32760514|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
32760515|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
32760516|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
32760517|NCT05038397|Experimental|Therasphere|
32760518|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
32760519|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
32760520|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
32760521|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
32760522|NCT05049941||group1|Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
32760523|NCT05049941||group 2|Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation [(lactate(T0)- lactate(T8))/lactate(T0)] × 100%.
32760524|NCT05049941||group 3|"Group (3):~veno-arterial carbon dioxide tension group; P(v-a)co2 difference"
32760525|NCT04639414|Experimental|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
32760526|NCT04639414|Experimental|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
32760527|NCT04639414|Placebo Comparator|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
32760528|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
32760529|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
32760530|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
32760531|NCT05038007|Active Comparator|Control|Bupivacaine Hydrochloride in perioperative intercostal blockades
32910793|NCT04742985|Experimental|Green tea combined extracts group A|This group takes Green tea combined extracts (62.5 mg) for 8 weeks.
33397779|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
33397780|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
33397781|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
33397782|NCT01359267|Experimental|Imaging|
33397783|NCT03921944|Other|one year post total shoulder surgery|
33397784|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
33397785|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
33397786|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
32760532|NCT05038007|Experimental|Intervention|Liposomal bupivacaine in perioperative intercostal blockades
32910794|NCT04742985|Experimental|Green tea combined extracts group B|This group takes Green tea combined extracts (125 mg) for 8 weeks.
32910795|NCT04742985|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
32760533|NCT04639102|Experimental|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
32910796|NCT01739699|Experimental|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
33397787|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
33397788|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
32910797|NCT01739699|Other|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
32910798|NCT02633943||Subjects with Transfusion-Dependent β-Thalassemia|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
32910799|NCT04428905|Experimental|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
33072169|NCT05423496|Experimental|MMF Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of MMF/CNI
33397789|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
33397790|NCT05056714||patients with Nasosinus Polyposis|patients with Nasosinus Polyposis included in the study
33397791|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
32910800|NCT04428905|Active Comparator|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
32910801|NCT04154787|Experimental|LNP023|LNP023
32910802|NCT04154787|Active Comparator|Rituximab|Rituximab
33397792|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
33397793|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
33397794|NCT04351698|Active Comparator|Investigation|Montelukast
33397795|NCT04351698|Placebo Comparator|Match Placebo|Matched Placebo
33397796|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
32910803|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
32910804|NCT04742049|Experimental|Telerehabilitation|Telerehabilitation based exercise training will be given to the study group.
32910805|NCT04742049|Experimental|Exercise brochure|Exercise training will be provided by sending a document to the control group
32910806|NCT04741893|Experimental|faecally incontinent patients|faecally incontinent patients are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
33397797|NCT02426398||Healthy volunteers|Healthy volunteers
33397798|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
33397799|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
33397800|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
33397801|NCT01359423|Active Comparator|short spot|primary short spot stenting
33397802|NCT04330716|Active Comparator|Group A: Standard genetic counseling|Will receive standard genetic counseling prior to genetic testing.
33240941|NCT05189522|Experimental|Innova Breeze®-based roadmap|"An Innova Breeze® bolus chase acquisition is realized prior to the revascularization to assess the lesions of the entire target limb. Guidance to the different lesions is done using a 2D roadmap based on the Innova Breeze® bolus acquisition frames if the patient position has not moved on the table.~An Innova Breeze® bolus chase acquisition is realized to assess the final result of the revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm. Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. Innova Breeze® bolus chase acquisitions are performed with the injector set at 4mL/s and the volume at 24mL (pressure limit 1000psi). An injector with iodinated contrast (50% of dilution) will be used."
33397803|NCT04330716|Experimental|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
33397804|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
33397805|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
33397806|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
33397807|NCT01363089|Experimental|Ketorolac tromethamine|
33397808|NCT01363089|Experimental|Oxymetazoline hydrochloride|
33397809|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
33397810|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
33397811|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
32760534|NCT04639102|No Intervention|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
32760535|NCT04479007||Mechanically ventilated patients|Critically ill patients of 18 years or older who receive invasive mechanical ventilation for acute respiratory failure and have an indication for an intervention in the airways.
32760536|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
32760537|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
32760538|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
32910807|NCT04741893|Experimental|Asymptomatic individuals|asymptomatic individuals are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
33397812|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
33397813|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
32910808|NCT01740713|Experimental|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
32910809|NCT01740713|Experimental|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
32910810|NCT01740713|Experimental|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
33397814|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
33397815|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
33397816|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
32910811|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
33397817|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
32910812|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
33397818|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
33397819|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
33397820|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
33397821|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
33397822|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
32910813|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
33397823|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
33397824|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
33397825|NCT05627232|Experimental|Treatment (palbociclib, tazemetostat, CPX-351)|Patients receive palbociclib and tazemetostat PO and CPX-351 IV on study. Patients undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.
33397826|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
33397827|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
33241753|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
33241754|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
32901558|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
32910814|NCT01742117|Experimental|Genotype-Guided Therapy|Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.
33241755|NCT04344392|Other|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
33241756|NCT04344392|Other|Control|Volunteers which do not have an active swallowing dysfunction.
32901559|NCT04225260|Experimental|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
32901560|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
32901561|NCT05037318|Experimental|Stress arousal reappraisal|
32901562|NCT05037318|Experimental|Worked examples|
32901563|NCT05037318|Experimental|Stress arousal reappraisal + Worked examples|
32901564|NCT05037318|No Intervention|Control|
32901565|NCT05148000|Experimental|QM1114-DP|QM1114-DP
32910815|NCT01742117|Active Comparator|Conventional Therapy|Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.
32910816|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
32910817|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
32901566|NCT05146284|Experimental|PXL770 500 mg QD|
32901567|NCT05146284|Experimental|PXL770 250 mg BID|
32910818|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
33241757|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
33241758|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
33241759|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
33241760|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
33397828|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
32901568|NCT05087238|Other|PVC-specific CBT|This novel CBT treatment for symptomatic PVC targets cardiac anxiety and symptom preoccupation related to PVC. Treatment is developed from the research groups treatment for Atrial Fibrillation and may be altered during the treatment period to better meet the needs of the patients. Patients receive 10 weeks of CBT delivered through face to face digital video sessions.
33397829|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
33397830|NCT05416788|Experimental|Cervical manipulation group|high-velocity, low-amplitude cervical manipulation
33397831|NCT05416788|Sham Comparator|Control group|placebo manipulation, the cervical spine will be tilted and rotated without reaching the end feel or the pump
33397832|NCT01359501|Experimental|Chinese medical treatment|
32910819|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
33397833|NCT01359501|Placebo Comparator|Placebo|
33397834|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
33240942|NCT05189522|Other|control group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
33397835|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
32901569|NCT05085990|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
33397836|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
33397837|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
32901570|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
32760539|NCT05038319|Active Comparator|Cyanoacrylate injection and EUS guided coil and glue injection|The procedure would be performed under conscious sedation.The endoscope would be used to reach the site of Varices. In Conventional technique treatment with cyanoacrylate the injection was performed using a 23-G sclerotherapy needle catheter . One vial of N-butyl-2-cyanoacrylate (0.5 mL) was mixed with Lipiodol) in a 1:1 ratio, and injected intravesically as a 1 mL bolus. The injection was repeated until total hardening of the varix. In treatment with coil and cyanoacrylate once the gastric varix was identified, the total diameter of the vascular pseudotumor was measured and the puncture was made at the site of the widest varix. The puncture was performed using a 19 G needle . the size of the coil after release should not be greater than the caliber of the vessel. Following coil deployment, 2 mL of distilled water was injected, followed by one vial (0.5 mL) of N-butyl-2-cyanoacrylate mixed with Lipiodol in 1:1 ratio.
32760540|NCT05038319|Placebo Comparator|COIL and GLUE|"Cyanoacrylate injection, first published by Soehendra in 1986, remains the conventional treatment method.~Since coils were first used to treat ectopic varices by Levy in 2008(6), this technique has been increasingly implemented into clinical practice. However, its higher cost has been a limiting factor in more widespread use.~Depending on the ectasia of the varix the following coil was deployed: 8 mm x 20 cm, 10 mm x 20 cm, or 10 mm x 30 cm (Interlock-18 Fibered IDC Occlusion System,Cook)."
32760541|NCT05049629|Experimental|Eye 1|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
32760542|NCT05049629|Active Comparator|Eye 2|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
33240943|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
32760543|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
32760544|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
32760545|NCT05049785|Active Comparator|Arm I (counseling)|Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
32760546|NCT05049785|Experimental|Arm II (nutrition and PA intervention)|Patients attend 2 tasting sessions for low-fat and low-sugar recipes and complete 2 PA sessions over 1 hour for each session.
32760547|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
33240944|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
33240945|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
32760548|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
32760549|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
32760550|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
32901571|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
33240946|NCT04751162||Phase I|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones for tracking PA, SQ and symptoms for 3 weeks The ECOG-PS will be assessed by clinician at both, baseline and subsequent visit after the 3 weeks.
33240947|NCT04751162||Phase II|"Participants will be equipped with both devices (wearable and mobile application) for further monitoring during the following 9 weeks. Study participants will undergo scheduled visits according to local standard practice. The study will progress to Phase II just in case any of the following conditions are met at the end of Phase I:~The average time of use of the wearable device is equal or over 96 hours/week/participant, OR~The average SUS score is equal or above 68, OR~The average adherence to the app is equal or above 80%, measured as the rate of submitted ePROMs through the app."
33397838|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
32901572|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
33240951|NCT04745234|Experimental|Mogamulizumab|
33240952|NCT04951544|Experimental|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
33240953|NCT04951544|Active Comparator|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
33240954|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
33240955|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
33240956|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
33240957|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
33240958|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
32760551|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
33397839|NCT05626452|No Intervention|Usual Care|The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
33397840|NCT05626452|Experimental|Intervention|Implementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
32760552|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
33397841|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
32901573|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
32910820|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
32910821|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
33397842|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
33397843|NCT05188911||mCRPC|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 5mg prednisone bid. Patients would get medical or surgical castration.
33397844|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
33397845|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
33397846|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
33397847|NCT02426242||ICU PATIENTS|Patients with brain-injury
33397848|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
33397849|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
33397850|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
33397851|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
33397852|NCT03128931|Experimental|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
33397853|NCT02417662|Active Comparator|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
33397854|NCT02417662|Experimental|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
33397855|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
33397856|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
33397857|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
33397858|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
33397859|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
33397860|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
33397861|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
33397862|NCT03710707|Experimental|DNL201 low dose|
33397863|NCT03710707|Experimental|DNL201 high dose|
33397864|NCT03710707|Placebo Comparator|Placebo|
33397865|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
33397866|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
33397867|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
33397868|NCT01359579|Experimental|Subjects with mild renal impairment|
33397869|NCT01359579|Experimental|Subjects with moderate renal impairment|
33397870|NCT01359579|Experimental|Subjects with normal renal function|
33397871|NCT01359579|Experimental|Subjects with severe renal impairment|
33397872|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
33397873|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
33397874|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
32760553|NCT05037773|Experimental|Group 1|In this condition, the intervention is administered immediately after the baseline.
32901574|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
32910822|NCT01305356|Experimental|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
33240959|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
32760554|NCT05037773|Experimental|Group 2 (waiting-list group)|This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
32760555|NCT05049239|Experimental|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
32760556|NCT05049239|Active Comparator|Physical training combined with cognitive support|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.~The cognitive support consists of person centred individual occupational therapy."
32760557|NCT05049239|No Intervention|Control group|The control group receive no intervention.
32760558|NCT05049473|Experimental|Chemotherapy|"Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.~In pts with biological age >55 y with advanced stage block will receive A and B with attenuated doses (A1*-B1*-A2*-B2*-A3*-B3*).~Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.~Pts with a biological age >55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1*-B1*-A2*-B2*). If CR is not reached, patients will complete the 6 cycles of treatment."
32760559|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
32760560|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
32760561|NCT02361931|Experimental|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
32760562|NCT02361931|Placebo Comparator|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
32760563|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
32760564|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
32760565|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
32760566|NCT05037695|Experimental|empagliflozin + OMT|empagliflozin 25mg - Daily - at least 15 days before the PCI procedure OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
32760567|NCT05037695|No Intervention|OMT|OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
32760568|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
32760569|NCT05049395|Active Comparator|Control group|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
32760570|NCT05049395|Experimental|HFNO group|The patients are administered oxygen of 30L-60L/min until the end of the hysteroscopy operation.
32760571|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
32760572|NCT05048771||FERTITOP|300 patients (15-25 years) from 5 different hospitals (University Hospitals of Nancy, Strasbourg, Reims, Besançon, Dijon (France)) who have finished all cancer treatments for at least 2 years.
32760573|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
32760574|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
32760575|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
32760576|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
32910823|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
33397875|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
33397876|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
33397877|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397878|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397879|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397880|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397881|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397882|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397883|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397884|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397885|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397886|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
33397887|NCT03729596|Experimental|Cohort 1|0.5 mg/kg IV every 3 weeks
33397888|NCT03729596|Experimental|Cohort 2|1.0 mg/kg IV every 3 weeks
33397889|NCT03729596|Experimental|Cohort 3|2.0 mg/kg IV every 3 weeks
33397890|NCT03729596|Experimental|Cohort 4|3.0 mg/kg IV every 3 weeks
33397891|NCT03729596|Experimental|Cohort 5|4.0 mg/kg IV every 3 weeks
33397892|NCT03729596|Experimental|mCRPC expansion|3.0 mg/kg IV every 3 weeks
33397893|NCT03729596|Experimental|NSCLC expansion|3.0 mg/kg IV every 3 weeks
33397894|NCT03729596|Experimental|TNBC expansion|3.0 mg/kg IV every 3 weeks
33397895|NCT03729596|Experimental|Melanoma expansion|3.0 mg/kg IV every 3 weeks
33397896|NCT03729596|Experimental|SCCHN expansion|3.0 mg/kg IV every 3 weeks
33397897|NCT03729596|Experimental|vobramitamab duocarmazine plus retifanlimab|vobramitamab duocarmazine: Anti-B7-H3 antibody drug conjugate; retifanlimab: Anti-PD-1 antibody
33397898|NCT05197309|Active Comparator|Women with anorexia nervosa|adult women with anorexia nervosa who have been recently restored to normal weight
33397899|NCT05197309|Active Comparator|Women with no history of eating disorders|adult women with no history of eating disorders
33397900|NCT05668793||Positive group|The positive group is composed of patients with hepatocellular carcinoma of different stages and pathological types.
33397901|NCT05668793||Negative group|"Patients with other digestive system malignancies (including stomach cancer, esophageal cancer, colorectal cancer, pancreatic cancer, gallbladder/duct cancer, etc.), patients with non-digestive system malignancies (including lung cancer, thyroid cancer, cervical cancer, endometrial cancer, breast cancer, prostate cancer, urothelial cancer, etc.).~Patients with benign liver diseases (such as cirrhosis, hepatitis, fatty liver, liver adenoma, liver cyst, etc.)."
33397902|NCT05188833|Active Comparator|Deep Transcranial Magnetic Stimulation|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string.
33397903|NCT05188833|Experimental|Deep Transcranial Magnetic Stimulation and Paroxetine|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string. In addtion to DTMMS, paroxetine will applied.
33397904|NCT05188833|Active Comparator|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression in OCD.
33397905|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
33397906|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
33397907|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
33397908|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
33397909|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
32910824|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
33397910|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
33397911|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
33397912|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
33397913|NCT02015897|Active Comparator|Physical TherapyB|Group B
33397914|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
33397915|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
33397916|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
33397917|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
33397918|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
33397919|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
33397920|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
33397921|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
33397922|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
33397923|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
33397924|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
33397925|NCT04189536|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
33397926|NCT04183764|Experimental|MAX-40279-01|capsule, 5mg and 25mg
33397927|NCT04447287|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
33397928|NCT04447287|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of placebo concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
33397929|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
33397930|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
33397931|NCT04165122|Experimental|HDIT101 + Valaciclovir placebo|"Group A:~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
33397932|NCT04165122|Active Comparator|HDIT101 placebo + Valaciclovir|"Group B:~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
33397933|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
33397934|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
33397935|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397936|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397937|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397938|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397939|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397940|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
33397941|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Feasibility|Feasibility Phase.
33397942|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Validation|Validation Phase.
33240960|NCT04739072||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.
33240961|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
33240962|NCT00920036|No Intervention|Arm 2|usual care
33240963|NCT04684550|Placebo Comparator|Placebo|Health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).
33240964|NCT04684550|Experimental|Experimental|Health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
33240965|NCT00678561|Experimental|2% CP-690,550 QD|
33240966|NCT00678561|Experimental|0.2% CP-690,550 QD|
33240967|NCT00678561|Experimental|0.02% CP-690,550 QD|
33240968|NCT00678561|Experimental|2% CP-690,550 BID|
33240969|NCT00678561|Experimental|0.2% CP-690,550 BID|
33240970|NCT00678561|Experimental|0.02% CP-690,550 BID|
33240971|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
33240972|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
33240973|NCT05613296||Study group|All patients being observed during the study duration.
33240974|NCT04081532|Active Comparator|Surgical treatment|
33240975|NCT04081532|No Intervention|No surgical treatment|
33240976|NCT04732286|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
33240977|NCT04731350|Experimental|Shock wave(A)|subjects will recive radial extracorporeal shock wave (2000 shock/session, 10Hz and EFD 0.178 mJ/mm²) on knee joints once per week for four weeks in addition to strengthening exercise
33240978|NCT04731350|Experimental|Iontophoresis (B)|subjects will recive dexamethasone iontophoresis on knee joints once per week for four weeks in addition to strengthening exercise
33240979|NCT04731350|Other|Control (C)|stregnthening exercise;straight leg raising exercisein which the patients were positioned in the crook lying position with the unexercised limb was the flexed one then the patients were asked to contract the quadriceps muscle and elevate the limb to 45º and hold for 6 seconds, slowly lower the limb and then relax for 6 seconds, three sets of 10 repetitions were don ,Isometric quadriceps contraction (quadriceps drill) in full knee extension maintained for 5 seconds, followed by a 5-second rest; the exercise was performed for 20 repetitions per session .treatment once per week for four weeks
33241761|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
32760577|NCT04478929||gastroscopy clinic patients|NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study.
32760578|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
32760579|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
32760580|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
32760581|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
32910825|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
33397943|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
33397944|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
33397945|NCT05668715|Experimental|Group 1: Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
33397946|NCT05668715|Active Comparator|Group 2: Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
33397947|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
33397948|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
33397949|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
33397950|NCT01365897|Placebo Comparator|Placebo|Control Group
33397951|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
33397952|NCT04109820|Experimental|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
33397953|NCT04109820|Active Comparator|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
33397954|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
33397955|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
33397956|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
33397957|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
33397958|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
33397959|NCT05625204|Experimental|Center based attention control|Center based attention control
33397960|NCT05625204|Experimental|Center based HIIT|Center based HIIT
33397961|NCT05625204|Experimental|Home based HIIT|Home based HIIT
33397962|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
33397963|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
33397964|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
33397965|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
33397966|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
33397967|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
33397968|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
33397969|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
33397970|NCT05416398|No Intervention|Control|They will only receive standard medical treatment. In addition to the evaluation parameters applied, no additional information and/or exercise will be recommended other than routine clinical treatment and recommendations.
32910826|NCT05732181|Experimental|Lidocaine patch|
33397971|NCT05416398|Experimental|Aerobic Exercise|Aerobic exercise group; 3 days a week, 45-60 minutes will be carried out in the form of walking and jogging on the treadmill. Initially, warm-up exercises (10 minutes) will perform walking at 35-70% of maximum heart rate (HRmax). Then, aerobic exercises, the resistance and duration of which are increased according to the tolerance of the patient on the treadmill for 30-35 minutes, and at 60-70% of the HRmax, attention will be paid to ensure that the fatigue severity perceived by the patients is within the range of 12-14 according to the Modified Borg scale. Afterwards, the exercise program will be terminated with a cooling period (10 minutes) consisting of walking at a light pace.
33241762|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
32760582|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
32760583|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
32760584|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
32760585|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
32760586|NCT05036837|Experimental|OZOPROMAF_SEQ1|"OZOPROMAF consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into mucosal margin surrounding bone exposure or around situs evidenced by CT scans.~Pain intensity and/or other symptoms are assessed at each visit and the day after by a questionnaire (numerical rating scale).~OZOPROMAF is applied on 7-15 days, depending on patient compliance, until the resolution (i.e. formation of sequestrum and clinical healing -T1).~Follow-up visits are scheduled to confirm healing at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3/ T4/T5.~Positive outcomes~at T1/T2 clinical healing (no signs of acute phlogosis and no symptoms compatible with MRONJ);~at T3/ T4/T5 clinical healing and no radiological signs of MRONJ."
32760587|NCT04478617|Experimental|Metronidazole|
32760588|NCT04478617|No Intervention|Control|
32760589|NCT05048225||Low-salt (LS) group|intake of < 5 g of salt per day
32760590|NCT05048225||Normal-salt (NS) group|intake of 5 - 7.5 g of salt per day
32760591|NCT05048225||High-salt (HS) group|intake of 7.5 - 10 g of salt per day
32760592|NCT05048225||Very high-salt (VHS) group|intake of > 10 g of salt per day
32760593|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
32760594|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
32760595|NCT05036759|Experimental|68Ga-FAPI, PET/MR|inject 68Ga-FAPI，and then perform PET/MR
32760596|NCT02361619|Experimental|1|
32760597|NCT05036369|Experimental|Active capsule|The Vibrant non-biodegradable capsule administrated twice a week
32760598|NCT05036369|Placebo Comparator|Placebo|The placebo capsule is a white colored, softgel biodegradable capsule filled with soybean oil, beeswax and Calcium Carbonate, Gelatin, Glycerin or Titanium dioxide which is visually similar to the Vibrant active capsule
32760599|NCT05231083|Experimental|Arm A - 20Hz Stimulation|Transcutaneous stimulation of the genital nerves at 20Hz
32760600|NCT05231083|Experimental|Arm B - 60Hz Stimulation|Transcutaneous stimulation of the genital nerves at 60Hz
33241763|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
33241764|NCT00772083|Experimental|1|
33241765|NCT00772083|Active Comparator|2|standard approach currently being used
33241766|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
32760605|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
32760606|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
32760607|NCT05048303|Experimental|Individualized Lutajet operative group|Arthroscopic modified individualized flexible Latarjet procedure with preservation of the coracoacromial arch. During the procedure, we perform coracoid osteotomy with preservation of coracoacromial arch, then split subscapular tendon, transfer the bone graft and fix it with double button under arthroscopy.
32760608|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
32760609|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
32760610|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
32760611|NCT05047991|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV + Oxaliplatin|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin(LV) and oxaliplatin intravenously on day 1 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
32760612|NCT05047991|Active Comparator|Cohort 2: Nab-paclitaxel + Gemcitabine|The patients in cohort 2 will receive nab-paclitaxel and gemcitabine intravenously on day 1、day 8 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
32760613|NCT05035979|Experimental|TCM comprehensive treatment group|Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.
32760614|NCT05035979|Active Comparator|TCM internal treatment group|Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.
32760615|NCT05035979|Active Comparator|TCM external treatment group|Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.
32760616|NCT05035979|Placebo Comparator|Placebo group|Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.
32910827|NCT05732181|No Intervention|Placebo|
33241767|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
32910828|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
33241768|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
32910829|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
32910830|NCT02589171|Experimental|Neo Close Abdominal Closure|
32910831|NCT02589171|Active Comparator|Carter Thomason Device|
33241769|NCT00779181|Placebo Comparator|Placebo|
33241770|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
33241771|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
33241772|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
33241773|NCT04085276|Experimental|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
33241774|NCT04085276|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
32910832|NCT05732103|Experimental|Dose Escalation Cohort|Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly
32910833|NCT05732103|Experimental|Dose Expansion Cohort|Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort
32910834|NCT05732103|Experimental|Phase 2|CTX-712 administered at the recommended dose by the expansion cohort
32910835|NCT05732025|Experimental|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
33241775|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
33241776|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
33397972|NCT05416398|Experimental|High-İntensity İnterval Training|The high-intensity interval training (HIIT) group, it will be performed as walking or jogging on the treadmill for 4X4 minutes (16 minutes in total) at ≥ 80% of HRmax, three times a week, with each session lasting a total of 38 minutes. Each training session will begin with a 10-minute warm-up period at 70% of HRmax. Between each 4-minute interval and after the last interval, patients will walk at 70% of HRmax for 3 minutes. Patients will check heart rate and target heart rate to control exercise intensity and will aim to reach their individual target heart rate after 1-1.5 minutes of exercise in each interval. The physical therapist, who oversees all training sessions, will check the patients' target heart rates.
33397973|NCT03685292||Group A|Subject(s): A Subgroup
33397974|NCT03685292||Group B|Subject(s): B Subgroup
33241777|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
33241778|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
33241779|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
33241780|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
33241781|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
33241782|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
33241783|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
33241784|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
33241785|NCT05674448|Experimental|HH-003 20mg/kg|HH-003 20mg/kg, intravenously, Q2W
33241786|NCT05674448|Experimental|HH-003 3mg/kg|HH-003 3mg/kg, intravenously, Q2W
33241787|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
33241788|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
33241789|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
33241790|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
33241791|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
33241792|NCT05153408|Experimental|Part 1A: BLU-701 as monotherapy|Phase 1 dose escalation of BLU-701 as monotherapy at various dose levels
33241793|NCT05153408|Experimental|Part 1B: BLU-701 with osimertinib|BLU-701 in combination with osimertinib 40 mg or 80 mg tablets for oral administration
33241794|NCT05153408|Experimental|Part 1C: BLU-701 with platinum-based chemotherapy|"BLU-701 in combination with platinum-based chemotherapy (carboplatin and pemetrexed):~Carboplatin - IV infusion dosed to target AUC of 5-6 mg/mL min q3w~Pemetrexed - IV infusion dosed to 500 mg/m2 q3w"
33241795|NCT05153408|Experimental|Part 2A: BLU-701 as monotherapy|Phase 2 expansion group for BLU-701 as monotherapy at a dose determined during Part 1A in patients harboring the EGFR C797X resistance mutation
33241796|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
33241797|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
33241798|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
33241799|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
33241800|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
33241801|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
33241802|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
33241803|NCT03803774|Experimental|Treatment (IMRRT, birinapant)|Beginning on day 1, patients undergo IMRRT 5 days a week (Monday-Friday). Patients also receive birinapant IV over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
33241804|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
33241805|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
33241806|NCT02580344|Other|Ibuprofen|
33241807|NCT00779649|Active Comparator|MoviPrep|
33241808|NCT00779649|Active Comparator|HalfLytely|
33241809|NCT04074980|Experimental|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
32760617|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
32760618|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
32760619|NCT05035745|Experimental|Patients with refractory solid tumors|Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.
32760620|NCT05047367||single-group studies|A total of 149 patients diagnosed with CTS, 126 female and 23 male, were included in the study
32760621|NCT05036057||COPD patients and their proxies|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
32760622|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
32760623|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
32760624|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
32760625|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
32760626|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
32760627|NCT05047133|Experimental|Early Adminstration of TXA + Intraoperative TXA|This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
32760628|NCT05047133|Other|Intraoperative only TXA|This group will only receive the intraoperative TXA.
32760629|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
32760630|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
32760631|NCT05035355|Experimental|weaning protocol group|spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group
32760632|NCT05035355|No Intervention|routine SBT weaning group|
32760633|NCT04334863|Experimental|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
32760634|NCT05035589||TCZ|The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
32760635|NCT05035589||Control|50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
32760636|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
32760637|NCT05047211|Active Comparator|Oral Iron group|"Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.~Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride."
32760638|NCT05047211|Experimental|IV Iron group|"Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.~Oral placebo will be given by mouth for a total of 6 weeks TID."
32760639|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
32760640|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
32760641|NCT05035433|Experimental|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
32760642|NCT05035433|Experimental|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
32760643|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
32760644|NCT05046743|Experimental|Colonic gas load|
33241810|NCT04074980|Experimental|Fingerstick and Venous|One finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
33397975|NCT03685292||Group C|Subject(s): C Sub Group
33397976|NCT05416164|Experimental|Omission of radiotherapy|
33397977|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
32760645|NCT05046743|Sham Comparator|Sham|
32760646|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
32760647|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
32760648|NCT05046977|Active Comparator|Single tibial osteotomy|Single tibial osteotomy done to achieve correction
32760649|NCT05046977|Active Comparator|Double tibial osteotomy|Double tibial osteotomy done to achieve correction
33397978|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
33397979|NCT05416086|Other|iCLAS Cryoablation arm|all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month
33397980|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
33397981|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
33397982|NCT02425696||group 1|Normal individuals without migraine
33397983|NCT02425696||group 2|Migraineurs
33397984|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
33397985|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
33397986|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
33397987|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
33397988|NCT05416008||Group 1: treatment with ETV|"The patients in this group were composed of patients with chronic hepatitis B who firstly take entecavir for the treatment of chronic hepatitis B.~Take Entecavir capsule orally for a long time, once a day, 0.5mg each time."
33397989|NCT05416008||Group 2: treatment with TAF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir alafenamide Fumarate for the treatment of chronic hepatitis B.~Take Tenofovir alafenamide Fumarate tablets orally for a long time, 25mg once a day."
33397990|NCT05416008||Group 3: treatment with TDF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir disoproxil Fumarate for the treatment of chronic hepatitis B.~Tenofovir disoproxil fumarate was orally administered for a long time, once a day, 300mg each time."
33397991|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
33397992|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
33397993|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
33397994|NCT03178006||obese|BMI 30-40kg/m2
33397995|NCT03178006||control|BMI 20-27,5kg/m2
33397996|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
33397997|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
33397998|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
33397999|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
33398000|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
33398001|NCT03102918|Placebo Comparator|Placebo|Placebo
33398002|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
33398003|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
33398004|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
33398005|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
33398006|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
33398007|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
33398008|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
33398009|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
33398010|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
33398011|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
32760650|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
33241811|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
33241812|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
33398012|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
33398013|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
33398014|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
33398015|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
33398016|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
33398017|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
33398018|NCT05756088||Low MFR (less than or equal to 1.5)|Subjects who are found to have a low MFR of less than or equal to 1.5.
33398019|NCT05756088||Normal MFR (greater than 1.5)|Subjects who are found to have normal MFR of greater than 1.5.
33398020|NCT01363323|Experimental|Arm 1|
32760651|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
33398021|NCT01363323|Experimental|Arm 2|
33398022|NCT01363323|Experimental|Arm 3|
33398023|NCT01363323|Placebo Comparator|Arm 4|
33398024|NCT01363323|Active Comparator|Arm 5|
33398025|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
33398026|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
33398027|NCT01360047||Cases|Cases with nonfatal MI or coronary death
33398028|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
33398029|NCT05609292||Study group|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
33398030|NCT04388553|Experimental|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
33398031|NCT04388553|No Intervention|Control|no regional anaesthesia is performed nor saline is injected into the ESP
33398032|NCT05415852|Active Comparator|fractional CO2 laser|Laser
33398033|NCT05415852|Active Comparator|Pulsed dye laser|Laser
33398034|NCT05415852|Active Comparator|Nd Yag|Laser
33398035|NCT05415852|Active Comparator|Q switched Nd Yag|Laser
33398036|NCT03117244|Experimental|Exercise Group|
33398037|NCT03117244|Active Comparator|Exercise and NMES Group|
33398038|NCT03117244|No Intervention|Control Group|
33398039|NCT01366287|Experimental|Suspension/fasted|
33398040|NCT01366287|Experimental|Tablet/fasted|
33398041|NCT01366287|Experimental|Tablet/fed|
33398042|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
33398043|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
33398044|NCT05190861|Experimental|droplet digital PCR method|Pathogen detection by droplet digital PCR method as an adjunct to traditional microbiological assessments including blood culture
33398045|NCT05190861|Active Comparator|blood culture only|Pathogen detection by microbiological assessments including blood culture
33241813|NCT04990232|Placebo Comparator|Standard of care|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.
32760652|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
32760653|NCT05026307|Experimental|Pterygium|Simple surgical excision of pterygium withe bare sclera
32760654|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
32760655|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
32760656|NCT02351713|No Intervention|Control|Non-exercise control group
32760657|NCT05034965|Active Comparator|deep injection of hyaluronic acid fillers|Each female will receive filler injection deep to the muscle (supraperiosteal) on one side of the face.
32760658|NCT05034965|Active Comparator|superficial injection of hyaluronic acid fillers|Each female will receive filler injection at superficial level to the muscle (subcutaneous) on the contralateral side(same dose and same site).
32760659|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
33398046|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
33398047|NCT05760222|Experimental|Acupuncture arm|Intervention with 10 acupuncture sessions twice per week for 4 weeks followed by 2 more sessions once per week
33398048|NCT05760222|No Intervention|Usual care arm|Lifestyle recommendations
33398049|NCT05188443||COVID-19|Patients tested for COVID-19 with current or previous (last 3 years) radiological imaging
33398050|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
33398051|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
33398052|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
33398053|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
33398054|NCT01366365|Placebo Comparator|Arm 2|placebo
33398055|NCT01881048|No Intervention|Arm I|Patients undergo observation.
33398056|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
33398057|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
33398058|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~NO active enrollment of parents~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
33398059|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~Enroll 35 eligible parents per practice~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
33398060|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
33398061|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
33398062|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol~Localize SLN with the Gamma Probe for In vivo count~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)~Surgically remove/excise localized SLN~Ex vivo count - excised SLN with Gamma Probe~In vivo background/roaming count with Gamma Probe~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)~Sentinella intraoperative imaging protocol~Survey surgical field/Post-excision control with Sentinella for remaining SLNs~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
33398063|NCT02425540||patients with unclassified ovarian mass|
33398064|NCT01804296|Experimental|Part 2 Active|Open-label, active repetitive transcranial magnetic stimulation
33398065|NCT01346475|Active Comparator|valacyclovir|
33398066|NCT01346475|Experimental|high dose valacyclovir|
33398067|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
33398068|NCT02416414||Healthy Controls|Healthy individuals.
33398069|NCT05415306|Experimental|Attention Bias Modification Training|Participants randomized to the ABMT group will undergo active attention bias modification training. The emoji-based ABMT protocol will be adapted from the attention bias modification task from Browning et al., 2012. The stimuli used during the task are pictures of emoji displaying emotional expressions that have valences that are either positive, neutral, or negative. The positive, negative and neutral emojis will be chosen from the outcome of a preliminary rating questionnaire.
33398070|NCT05415306|Sham Comparator|Sham Training|Participants in the sham control group will receive a sham version of the ABMT task. This condition is identical to the active ABM condition except for the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
32760660|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
32760661|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
33398071|NCT05415306|Active Comparator|Deep-breathing training|The protocol for the deep breathing practice will be adapted from the procedure outlined in (Cheng et al., 2019). Participants randomized to the deep breathing group will undergo mindful deep breathing practice. Participants will be required to follow an instructional video and perform mindful deep breathing. The video guide will be sent to each participant in the deep breathing group, and they will be instructed to perform the exercise once a day at any time of their choice for the 14-day period.
33398072|NCT05415306|No Intervention|No-intervention control|Participants in the no-intervention control group will not be required to undergo any intervention.
32760662|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
32760663|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
32760664|NCT02351791|Experimental|Patch 2, 4 and 6|"Patch 2, Patch 4 and Patch 6 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
33398073|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
33398074|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
33240980|NCT04081766|Active Comparator|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
33398075|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
33398076|NCT05754060||Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) is composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
33398077|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
33398078|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
33398079|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
33398080|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
33398081|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
33398082|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
33398083|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
33398084|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
33398085|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
32760665|NCT05025839||C healthy|Healthy control group
32760666|NCT05025839||C pneum|Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
32760667|NCT05025839||Mild|Outpatients presenting to the hospital with COVID-19
32760668|NCT05025839||Moderate|In-patients with COVID-19 not requiring ICU admission
32760669|NCT05025839||Severe|Patients with COVID-19 admitted to the ICU
32760670|NCT05034887|Experimental|Trastuzumab Deruxtecan (T-DXd)|One cycle is 21 days, with T-DXd repeated 3 cycles before surgery as the neo adjuvant treatment.
32910836|NCT05732025|Active Comparator|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with Rotary atherectomy
33398086|NCT05753670|Experimental|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
33398087|NCT05753670|Placebo Comparator|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
33398088|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
33398089|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
33398090|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
33398091|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
33398092|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
33398093|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
33398094|NCT00592254||A|
32760671|NCT05035121|Experimental|milk supplement|The milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
32760672|NCT05035121|Experimental|soy milk supplement|The soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
32760673|NCT05035121|Placebo Comparator|control|The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
32760674|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
32760675|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
32760676|NCT05034653|Experimental|Intermittent Fasting Healthy Plate (IFHP)|Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
32760677|NCT05034653|Active Comparator|Healthy Plate|Practice the Healthy Plate concept in at least one meal every day
32760678|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
32760679|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
32760680|NCT05025917|Experimental|Shatavari|1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks.
32760681|NCT05025917|Placebo Comparator|Placebo|1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks.
32760682|NCT02039011|Active Comparator|Indacaterol|
32760683|NCT02039011|Experimental|Indacaterol & tiotropium|
32760684|NCT04449055|Experimental|DPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
32760685|NCT04449055|Experimental|MPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
32760686|NCT05025215|Experimental|Group A： Precise|The experimental group accepts improved precise aerosol inhalation nursing program，which was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc. This group is planned to enroll 100 patients.
32760687|NCT05025215|Experimental|Group B：Traditional|The control group accepts traditional aerosol inhalation nursing method. This group is planned to enroll 100 patients.
32760688|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
32760689|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:~prioritisation of resources and everyday activities~adaptation of activities~adaptation of posture and seating positioning~provision of assistive devices~modification of the physical home environment And usual care from hospital and municipality"
32760690|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
32760691|NCT05025137|Experimental|Flexi-Bar group|Participants in the Flexi-Bar group performed a 60-minute Flexi-Bar exercise every week for 12 consecutive weeks.
32760692|NCT05025137|Experimental|Multi-Component exercise group|Participants in the Multi-Component exercise group performed a 60-minute Multi-Component exercise every week for 12 consecutive weeks.
32760693|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
32760694|NCT05024669|No Intervention|Control Group|where no desensitizer application was done,
32760695|NCT05024669|Experimental|Group GL|applied with Gluma dentin desensitizer
32760696|NCT05024669|Experimental|Group SF|applied with Shieldforce desensitizer
32760697|NCT05024669|Experimental|Group TC|applied with Telio CS desensitizer
32760698|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
33398095|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
33398096|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
32910837|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
32910838|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
33398097|NCT05403996|Experimental|Activa-Mente (Intervention)|The active break program involves the presentation of video (4.5 min) with moderate-to-vigorous physical activities. These active breaks will be performed 6 times per day during 6 weeks.
32760699|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
33398098|NCT05403996|No Intervention|Control group|This group of students will not be exposed to the intervention.
33398099|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
33398100|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
33398101|NCT05357898|Experimental|Part 1A Monotherapy Dose Escalation Phase|"In Part 1A, SQZ-eAPC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~Cohort 1: low dose SQZ-eAPC-HPV~Cohort 2: intermediate dose SQZ-eAPC-HPV~Cohort 3: high dose SQZ-eAPC-HPV~Additional provisional cohorts may be opened prior to starting Part 1B."
33398102|NCT05357898|Experimental|Part 1B Combination Phase|In Part 1B, SQZ-eAPC-HPV is administered in combination with immune checkpoint inhibitor pembrolizumab. SQZ-eAPC-HPV will be administered on Day 1 of Cycle 1 and 200 mg of pembrolizumab will be administered on Day 8 of Cycle 1. In future cycles, patients will be first administered SQZ-eAPC-HPV and then pembrolizumab on the first day of each cycle, every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
33398103|NCT05357898|Experimental|Part 2 Lead-in Combination Phase|In Part 2, SQZ-eAPC-HPV will be administered on Day 1 of each treatment cycle. Treatment with 200 mg of pembrolizumab will begin in Cycle 3. Starting at Cycle 3, patients will be administered SQZ-eAPC-HPV and then pembrolizumab every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
33398104|NCT05599308|Active Comparator|Atrial fibrillation (AFib)|Patient with known history of AFib who are in AFib at the time of study screening.
33398105|NCT05599308|Active Comparator|Non-Afib|Patient with no known diagnosis of AFib
33398106|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
33398107|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
33398108|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
33398109|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
33398110|NCT00322218|Experimental|Zevalin|"Patients received Zevalin.~Zevalin Therapeutic Regimen:~Day 1: Initial administration of 250 mg/m^2 rituximab, followed immediately by administration of 185 MBq of [111In]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.~- Day 7-9: Rituximab 250 mg/m^2, followed immediately by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes.~Two treatment days one week apart were followed by a 12-week safety period."
33398111|NCT00322218|No Intervention|Observational|Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).
33398112|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
33398113|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
33398114|NCT05046730|Experimental|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
33398115|NCT05046730|Active Comparator|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
33398116|NCT05200494|No Intervention|Flexible Bronchoscopy without Recruiting Maneuver|At the end of the bronchoscopy, no further interventions or ventilator maneuvers will be done.
33398117|NCT05200494|Experimental|Flexible Bronchoscopy with Recruiting Maneuver|At the end of the bronchoscopy, a recruiting maneuver will be applied to the patients. Recruiting Maneuver consists in the application of an airway pressure of 30 cmH2O for a period of 30 seconds.
33398118|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
33398119|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
32760700|NCT05024825|Experimental|Gabapentin|Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
32910839|NCT05731869||Control group|The group measured without the use of orthoses and tapes
33398120|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
33398121|NCT05328336|Experimental|Experimental: Tislelizumab and Nab Paclitaxel|Experimental: Tislelizumab and Nab Paclitaxel Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
33398122|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
33398123|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
33398124|NCT05298774|Experimental|Postoperative recovery with G-tech WPS|
33398125|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
33398126|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
33398127|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
33398128|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
33398129|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
33398130|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
33398131|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
33398132|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
33398133|NCT03287414|Experimental|VAY736|Participants received 300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
33398134|NCT03287414|Placebo Comparator|Placebo|Participants received placebo administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
33398135|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
33398136|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
33398137|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
33398138|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
33398139|NCT05348460|Other|Ketone - Placebo treatment|Patients will first receive a supplemental drink containing a ketone ester before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the placebo treatment.
33398140|NCT05348460|Other|Placebo - Ketone treatment|Patients will first receive a placebodrink before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the supplemental drink containing a ketone ester.
33398141|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
33398142|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
33398143|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
33398144|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
33398145|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
33398146|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
33398147|NCT03669614|Experimental|AR-501 inhaled|Four doses (low, medium, high, top) of inhaled AR-501 will be used.
33398148|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|Four doses (low, medium, high, top) of inhaled placebo will be used
33398149|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
33398150|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
33398151|NCT05200260|Experimental|Upfront cytoreductive surgery with maintenance therapy|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
33240981|NCT04081766|No Intervention|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
33240982|NCT04951154||Participants with Suspected Lung Cancer|Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.
33240983|NCT04950686|Experimental|Intervention - Media Aware for Young Adults|This arm will receive Media Aware for Young Adults between the pretest and posttest questionnaire. Media Aware for Young Adults is a web-based sexual and relationship health promotion program that uses a media literacy education (MLE) approach. The program is self-paced and includes four modules.
33240984|NCT04950686|Active Comparator|Active Control - Health Aware for Young Adults|This arm will receive Health Aware for Young Adults in between the pretest and posttest questionnaire. Health Aware for Young Adults is a web-based sexual and relationship health promotion program. The program contains the same health content as Media Aware for Young Adults but without the media literacy education components. The program is self-paced and includes four modules.
33240985|NCT04950686|No Intervention|Delayed Intervention Control|Participants in this condition will not receive a sexual or relationship health promotion program until after the 12-month follow-up survey. After that survey is complete, they will receive access to the Media Aware for Young Adults program.
33240986|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
33240987|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
33240988|NCT04949828||Participants on CREON|
33240989|NCT04945460|Placebo Comparator|Placebo|Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, placebo participants will enter into 1 of the 2 sotatercept dose groups in an extension period.
33240990|NCT04945460|Experimental|Sotatercept 0.3 mg/kg|Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, participants will continue to receive sotatercept SC at a dose level of 0.3 mg/kg Q3W in an extension period for up to 18 months.
33240991|NCT04945460|Experimental|Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.
32910840|NCT05731869||Epicondylitis Band Group|Group measured with epicondylitis band
32910841|NCT05731869||Wrist Orthosis Group|Group measured with wrist orthosis
33240992|NCT04945460|Experimental|Extension Period: Placebo Crossed Over to Sotatercept 0.3 mg/kg|After the placebo-controlled treatment period, placebo participants will cross over to receive sotatercept SC at a dose of 0.3 mg/kg Q3W for up to 18 months in an extension period.
33240993|NCT04945460|Experimental|Extension Period: Placebo Crossed Over to Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|After the placebo-controlled treatment period, placebo participants will cross over to receive sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and then Q3W for up to 18 months in an extension period.
33240994|NCT04941716|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28. Patients receive acalabrutinib alone for the first three 28 day cycles. Venetoclax is added beginning with Cycle 4. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
33240995|NCT04939142|Experimental|SVd (Selinexor+Bortezomib+dexamethasone)|Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.
33240996|NCT04939142|Experimental|Vd(Bortezomib+dexamethasone)|Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.
33240997|NCT05683340|Experimental|ETC-1002 180mg|
33240998|NCT05683340|Placebo Comparator|Placebo|
33240999|NCT04931420|Experimental|Arm A - Participants Who Receive Sequential Procedures|"If you are assigned to this arm, study doctors will sequentially remove and treat all visible cancer spots with surgery, radiation, ablation, or other procedures. These interventions might include surgical removal of the diseased part of your lung, liver, lymph nodes, and/or the lining of your belly. In addition, if surgery could not be done, we could treat these diseased spots with other modalities such as radiation and/or radiofrequency/microwave ablation.~If you're selected to be in this arm, the type of procedure you receive will vary based on your cancer and what the study doctor recommends for treatment."
33241000|NCT04931420|Other|Arm B (Control) - Participants Who Receive Standard of Care Chemotherapy|Participants in this arm receive the current standard of care chemotherapy for their specific type of gastrointestinal cancer. This treatment may include the continuation of chemotherapy and a few procedures which may improve your quality of life.
33241001|NCT04714892||Healthy control|BMI of 18.5-29.9 kg/m2
33241002|NCT04714892||Obese|BMI of 30-39.9 kg/m2
33241003|NCT00920114|Experimental|Lupus disease|
33241004|NCT00920114|Active Comparator|Healthy witnesses|
33241005|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
33241006|NCT04081454||Children with chronic pain|
33241007|NCT04081454||Caregivers of children with chronic pain|
33241008|NCT04691570|Experimental|ANX005|Participants will receive two once-weekly doses of ANX005 at specific time points
33241009|NCT04691180|Experimental|Cohort 1|BRII-196 and BRII-198 dose level 1 or placebo
33241010|NCT04691180|Experimental|Cohort 2|BRII-196 and BRII-198 dose level 2 or placebo
33241011|NCT05585528|Other|Type of management, surgical or functional, after rupture of the anterior cruciate ligament|Patients will choose the type of management, surgical or functional, after rupture of the anterior cruciate ligament.
33241012|NCT05584280|Active Comparator|Promus stent|Control
33241013|NCT05584280|Experimental|Orsiro stent|Treatment
33241014|NCT04912622|Experimental|Control|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
32910842|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
32760701|NCT05024825|Active Comparator|Hydrocodone|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
33241015|NCT04912622|Experimental|Patient|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
33398152|NCT05200260|Active Comparator|Neoadjuvant chemotherapy with maintenance therapy|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
33398153|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
33398154|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
33398155|NCT05579106||Covid-19 patients|Mechanically ventilated and sedated adult patients with proven COVID-19 infection by PCR of nose- or airway sample. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
33398156|NCT05579106||non-COVID-19 patients|Mechanically ventilated and sedated adult patients not infected with COVID-19 infection. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
33398157|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
33398158|NCT03684746||Care specialist|including nurses - before/after care staff
33398159|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
33398160|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
33398161|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
33398162|NCT05745168||MSM-TGW|
33398163|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
33398164|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
33398165|NCT03174964|Experimental|Treatment group|IVIg group
33398166|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
33398167|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
33398168|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
33398169|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
33398170|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
33398171|NCT04933812|Other|Group Social Support Meetings and Facebook Group|Facebook group where community doulas will be providing information on various pregnancy and support topics in addition to 8 possible group Zoom meetings that will include pregnancy-related/reflection topics.
33398172|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
33398173|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
33398174|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
33398175|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
33398176|NCT04792320|Experimental|Active bamboo charcoal|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The participants will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
33398177|NCT04792320|Experimental|Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
32760702|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
32910843|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
32910844|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
32760703|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
32760704|NCT05033795|Experimental|Water A|2 L of water A per day
32760705|NCT05033795|Other|Water B|2 L of water B per day
32760706|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
32760707|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
32760708|NCT05024981|Active Comparator|Classic reeducation|
32760709|NCT05024981|Experimental|Classic reeducation + videographic feedback|
32760710|NCT02361073||Takotsubo|
32760711|NCT02361073||Healthy|
32760712|NCT02361073||ACS|
32760713|NCT05024591||same as study population|Use of AI-based CADe/x by breast radiologists
32760714|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
32760715|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
32760716|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
32760717|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
32760718|NCT05024435|Experimental|Nasogastric Tube|
32760719|NCT05024435|Experimental|Lisacath|
32760720|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
32760721|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
32910845|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
32910846|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
33241016|NCT05564936|Experimental|MG patients|MG patients will perform 2 in-clinic visits and use the ME&MG app at-home during 12 months
32910847|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
32910848|NCT05372523||Trauma+ & PTSD|Patients diagnosed with significant trauma exposure and PTSD
32910849|NCT05372523||Trauma+ & No PTSD|Patients diagnosed with significant trauma exposure but no PTSD
32910850|NCT05372523||No trauma or PTSD|Healthy adults without known major psychiatric disorders
33241017|NCT05564936|Other|Healthy volunteers|Healthy volunteers will perform one in-clinic visit and will use the app at-home once
33398178|NCT04792320|Experimental|Active bamboo charcoal+Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
32760722|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
32760723|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
32760724|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
32760725|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
32760726|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
32760727|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
32760728|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
32760729|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
32760730|NCT03149653|No Intervention|Comparator3|Healthy Control
32760731|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
32760732|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
32760733|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
32760734|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
32760735|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
32760736|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
32760737|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
32760738|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
32760739|NCT05024357|Experimental|Dasatinib for 1 year|After the allo-HSCT treatment, the patients in this group will continue to take dasatinib orally for 1 year.
32760740|NCT05024357|Experimental|Dasatinib for 6 months|After the allo-HSCT treatment, the patients in this group will receive dasatinib for 6 months.
32760741|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
32760742|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
32760743|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
32760744|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
32760745|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
32760746|NCT03095339|No Intervention|Control|The control group did not receive any intervention
32760747|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
32910852|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
33398179|NCT04792320|No Intervention|No invervention|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
32910853|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
33398180|NCT03896750|Active Comparator|Part A Group 1A|6 healthy participants with normal estimated Glomerular Filtration Rate (eGFR > / = 90 mL/min) matched to Group 2 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight) will receive a single oral dose of 200 mg pretomanid
33398181|NCT03896750|Experimental|Part A Group 2|6 participants with Severe renal impairment; Stage 4, Modification of Diet in Renal Disease (MDRD) (eGFR 15-29 mL/min) and End Stage Renal Disease (ESRD) not on dialysis: Stage 5, Modification of Diet in Renal Disease (MDRD) with estimated Glomerular Filtration Rate (eGFR < 15 mL/min) matched to Group 1A will receive a single oral dose of 200 mg pretomanid
33398182|NCT03896750|Active Comparator|Part B Group 1B|6 healthy participants with normal eGFR of > / = 90 mL/min matched to Group 3 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight ) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
33398183|NCT03896750|Active Comparator|Part B Group 1C|6 healthy participants with normal eGFR > / = 90 mL/min matched to Group 4 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
33398184|NCT03896750|Experimental|Part B Group 3|6 participants with mild renal impairment: Stage 2, MDRD (eGFR 60-89 mL/min) matched to Group 1B will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
33398185|NCT03896750|Experimental|Part B Group 4|6 participants with moderate renal impairment: Stage 3, MDRD (eGFR = 30-59 mL/min) matched to Group 1C will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
33398186|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
33398187|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
33398188|NCT04203537|Active Comparator|CA-008 36 mg|Single administration (0.3 mg/mL concentration)
33398189|NCT04203537|Active Comparator|CA-008 60 mg|Single administration (0.5 mg/mL concentration)
33398190|NCT04203537|Active Comparator|CA-008 90 mg|Single administration (0.75 mg/mL concentration)
33398191|NCT04203537|Placebo Comparator|Placebo|Single administration
33398192|NCT05565612|Experimental|Probiotic group|"Normodigest Classic~Multi-strain probiotic mixture (15 strains) with a concentration of 7,5 x 10^9 + fructooligosaccharides~1 vial of 10 ml per day for 12 weeks"
33398193|NCT05565612|Placebo Comparator|Placebo group|"Maltodextrin-based placebo~1 vial of 10 ml per day for 12 weeks"
33398194|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
33398195|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
33398196|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
33398197|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
33398198|NCT05190393||Convex resection group|Patients were used hemivertebra resection procedure on convex side to treat congenital cervical scoliosis.
33398199|NCT05190393||Concave distraction group|Patients were used distraction and lateral opening procedure on concave side to treat congenital cervical scoliosis, without hemivertebra resection.
33398200|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
33398201|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
33398202|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
33398203|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
33398204|NCT03275402|Experimental|131I-omburtamab|"One treatment cycle of 131I-omburtamab consists of 1 dose at 50mCi at week 1. For Japan only one treatment cycle of 131I-omburtamab consists of 2 doses: 2mCi at week 1 and 50mCi at week 2. First cycle is initiated right after confirmation of eligibility at week 1. At week 5 (week 6 for Japan) the participant will be evaluated for safety and if eligible, receive a second cycle of 131I-omburtamab.~Secondary efficacy endpoints will be evaluated at week 26 and primary efficacy endpoint will be evaluated at week 156."
33398205|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
32910854|NCT02975817|Experimental|Hibler's|Insert description from protocol
32910855|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
32760748|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
32760749|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
32760750|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
32760751|NCT05024123|Placebo Comparator|Placebo|
32760752|NCT05024123|Experimental|Experimental|
32760753|NCT02360449|No Intervention|Wait List|
32760754|NCT02360449|Experimental|Social Initiation Motivation Intervention|
32760755|NCT05033951||Cohort 1|Patients who start NIV in the first two months after the first visit to the HMV
32760756|NCT05033951||Cohort 2|Patients who do not start NIV in the first two months after the first visit to the HMV.
32760757|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
32760758|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
32760759|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
32760760|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
32760761|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
32760762|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
32760763|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
32760764|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
32760765|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
32760766|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
32760767|NCT02351245||lip hemangiomas|
32760768|NCT05033405|Experimental|Experimental:Neuro Linguistic Programming|One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field.
32760769|NCT05033405|No Intervention|control group|No NLP was applied on the control group patients.
32760770|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
32760771|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
32760772|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
32760773|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~Association of hematoma evacuation surgery with clinical outcomes~Associations of antithrombotic management with ischemic and hemorrhagic complications~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
32760774|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
32760775|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
32760776|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
32760777|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
32760778|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
32760779|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
32760780|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
32760781|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
32760782|NCT05033249||Normal|Alvarado Score 4 - 7 Normal according to the initial computed tomographic evaluation
32760783|NCT05033249||Patient|Alvarado Score 4 - 7 Acute appendicitis according to the initial computed tomographic evaluation
32760784|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
32760785|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
32760786|NCT01918774|Other|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
32760787|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
32760788|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
32760789|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
32760790|NCT03092999|Experimental|Healthy subjects|healthy subjects
33398206|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
32760791|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
32910856|NCT05372211||General hospital group|Questionnaires collected from general hospitals in China
32744199|NCT04464993|Experimental|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
32760792|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
33241018|NCT04904588|Experimental|Regimen A (MAC: busulfan and fludarabine, PBSC HCT)|"Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0."
33241019|NCT04904588|Experimental|Regimen B (MAC: Fludarabine and TBI; PBSC HCT)|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5~Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
32760793|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
32760794|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
32910857|NCT05372211||Maternity and infant hospital group|Questionnaires collected from Maternity and infant hospitals in China
33241020|NCT04904588|Experimental|Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2~Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
32760795|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
32760796|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
32742506|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
32742507|NCT04976361|Experimental|Diabetic Patients with PDR|PRP for each diabetic patient included in this study.
32742508|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
32742509|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
32742510|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
32742511|NCT04968327|Experimental|Micro-osteoperforations|
32742512|NCT04968327|Active Comparator|Canine retraction|
32742513|NCT05234645|Experimental|Younger group|Fifteen participants, between 18 and 35 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
32742514|NCT05234645|Experimental|Older group|Fourteen participants, between 55 and 75 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
32742515|NCT04968171||People with newly diagnosed diabetes mellitus type 1|"People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years."
32742516|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
32742517|NCT04975971||Dextenza recepient|A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery
32742518|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
32742519|NCT04968483||Study group|Patients with spine deformity undergoing surgical treatment
32742520|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
32742521|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
32742522|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
33241021|NCT04904588|Experimental|Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3~Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
32742523|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
32742524|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
32742525|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
32742526|NCT03256877||All participants|Patients with haematuria.
32742527|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
33241022|NCT04904588|Experimental|Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)|"Patients receive:~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5~TBI (200 cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
32742528|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
32760797|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
33398207|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
33398208|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
33398209|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
33398210|NCT05560932|Experimental|HIV Medications and Alcohol Use|Participants with HIV who take 5 or more medications and currently (within the past month) consume alcohol
33398211|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
33398212|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
33398213|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
33398214|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
33398215|NCT01360281|Experimental|ECR|
33398216|NCT01360281|No Intervention|Control|
33398217|NCT01360281|Experimental|NMES|
33398218|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
33398219|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
33398220|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
33398221|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of 4.000 kCal in the immediate postoperative course.
33398222|NCT01366677|Experimental|Yoga Therapy|
33398223|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
33398224|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
33398225|NCT05188209|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
33398226|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
33398227|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
33398228|NCT04046939|Placebo Comparator|placebo BID|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
33398229|NCT04046939|Active Comparator|37.5 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
33398230|NCT04046939|Active Comparator|75 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
33398231|NCT04046939|Active Comparator|150 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.
33398232|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
33398233|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
32760798|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
32760799|NCT02360527||Type 2 diabetic patients with AD|35 patients
33241023|NCT04904588|Experimental|Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)|"Patients receive:~Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3~Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1~Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0."
32742529|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
32742530|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
32742531|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
32742532|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
32742533|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
32742534|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
32742535|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
32742536|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
32742537|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
32742538|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
32742539|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
32742540|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
32742541|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
32742542|NCT03904589||Coronary Heart Disease|
32742543|NCT04967859|Placebo Comparator|Group 1 (control):|Patients using placebo ointment at the exit site of the hemodialysis catheter
32742544|NCT04967859|Experimental|Group 2 (intervention)|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
32742545|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
32742546|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
32742547|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
32742548|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
32742549|NCT04968093|Other|Group sessions of mindfulness-based therapy|Education of patients followed by seven group sessions of mindfulness-based therapy
32742550|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
32742551|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
32742552|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
32742553|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
32760800|NCT02360527||Type 2 diabetic patients with MCI|35 patients
32760801|NCT02360527||Type 2 diabetic patients controls|35 patients
32760802|NCT02360527||Non-diabetic patients with AD|35 patients
32760803|NCT05024201|Experimental|experimental group for effect of therapeutic touch|Therapeutic touch was applied to the experimental group for three days every other day.
32760804|NCT05024201|No Intervention|control group for effect of therapeutic touch|No application was applied to the control group. Only pretest and posttest were done.
32760805|NCT04408183|Experimental|GLS-1200|1 mL of GLS-1200 per nostril, TID
32760806|NCT04408183|Placebo Comparator|0.9 %Saline|1 mL of 0.9% Saline per nostril, TID
32760807|NCT03094793|Experimental|abnormal EEGs|
32760808|NCT04259905|Experimental|Active video game teleconference support group|Participants will attend enhanced support group meetings via zoom teleconferencing software. Support group meetings will include group play of active video games and discussion of survivorship topics. Participants will self-monitor physical activity using Fitbit wearable activity monitors and will receive a water bottle and tote bag.
32760809|NCT04259905|Active Comparator|Standard support group + pedometer|Participants will attend standard in-person support groups currently offered by the UTMB Breast Health Center. They will also receive a standard pedometer and a water bottle and tote bag.
32760810|NCT05023889|Other|open label|single open arm label
32760811|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
32760812|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
32760813|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
32760814|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
32760815|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
32760816|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
33398234|NCT05188131|Experimental|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium in healthy subjects.
33398235|NCT05188131|Placebo Comparator|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (isotonic saline) in healthy subjects.
33398236|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
33398237|NCT03174496||Children aged 4-7 years|
33398238|NCT03174496||Children and adolescents aged 8-16 years|
33398239|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
33398240|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
33398241|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
33398242|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
32760817|NCT05033015|Experimental|Test|Mouth rinse containing enzymes
32760818|NCT05033015|Active Comparator|Placebo|Control, same content as test, without enzymes
32760819|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
32910858|NCT05372211||Children's hospital|Questionnaires collected from Children's hospitals in China
33398243|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
33398244|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
33398245|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
33398246|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
33398247|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
33398248|NCT01366833|Experimental|Brachytherapy and Stent therapy|
33398249|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
33241024|NCT04904588|Experimental|Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)|"Patients receive:~Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4~TBI (1200 cGy total dose) on days -3, -2 and -1~Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0."
33241025|NCT04900376||vaccinated group|
33241026|NCT04900376||unvaccinated group|
33241027|NCT04896008|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
33241028|NCT04896008|Experimental|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
32742554|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
32742555|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
32742556|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
32742557|NCT04975659|Active Comparator|Nocebo|"We informed subjects in the N group a negative suggestion, using the following script: During the local anaesthetic injection, you are going to feel a sharp prick at your back; this is usually the painful part of the procedure"
32742558|NCT04975659|Placebo Comparator|Placebo|"We informed subjects in the P group a positive suggestion, using the following script: We will administer some local anaesthetic to numb your back; this will allow the procedure to be more comfortable and tolerable for you."
32742559|NCT04964349|Experimental|Intralesional cortisosteroid injection|Intralesional corticosteroid injection
32742560|NCT04964349|Experimental|jessener solution|topical jessener solution
32742561|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
32742562|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
32742563|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
32742564|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
32742565|NCT04975113|Experimental|Exercise group|Patients were given a progressive neuromuscular exercise program that included stabilization of the knee and hip joint . Green color elastic band was used in resistant exercises. When subjects used the green color Thera-Band®, they started with an easy length and increased relative to the Omni Scale .
32742566|NCT04975113|Experimental|Exercise and Taping group|"Patients in this group received the same exercises given in the exercise group for 12 weeks. In addition to these exercises, mechanical correction tape (5cm, Kinesio Tex Gold®) was applied for the knee and foot."
32742567|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
32742568|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
32742569|NCT04967625|Experimental|Sintilimab + Anlotinib|sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death
32742570|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
32742571|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
32742572|NCT04975035|Experimental|Zolodine group|
32742573|NCT04964271||Low risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) <10 ng/ml, and stage T1/T2a and Gleason score 3+3).
32742574|NCT04964271||High risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) >20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).
32742575|NCT04964271||Healthy donor|Participants who are in good health and without history of cancer disease.
32742576|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
32742577|NCT04967937|Experimental|Single-Group|The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
32742578|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
32742579|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
32742580|NCT04967781||"Group Severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), severe and critical types were grouped into case group as Severe."
32742581|NCT04967781||"Group Non-severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), mild and moderate types were grouped into control group as Non-severe."
32742582|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
32742583|NCT03261245||Controls|No hypertension disorder during pregnancy
32742584|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
32910859|NCT01743131|Placebo Comparator|Standard GVHD Prophylxis + Placebo|"Standard GVHD prophylaxis and placebo.~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
32910860|NCT01743131|Experimental|Standard GVHD Prophylxis + Abatacept|"Standard GVHD prophylaxis and abatacept (investigational product).~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
32910861|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
32910862|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
32910863|NCT05372133|Experimental|Split Script|Participants will receive four doses initially, with opportunity to obtain four additional doses if required
32910864|NCT05372055||Indwelling Pleural Catheter|Patients with malignant pleural effusions managed by IPC insertion as per standard of care
32910865|NCT01743521|Experimental|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
32910866|NCT01743521|Experimental|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
32910867|NCT01743521|Experimental|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
32910868|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
32910869|NCT00365703|Experimental|1|Orogastric feeding tube.
32910870|NCT00365703|Experimental|2|Nasogastric feeding tube.
32910871|NCT00361881|Experimental|1|ME-609
32910872|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
32760820|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
32760821|NCT05023499||With glutamine supplementation|perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
32760822|NCT05023499||Without glutamine supplementation|no glutamine use
32910873|NCT00361881|Placebo Comparator|3|Vehicle
32910874|NCT05371743||ITP patients|"Patients will be recruited from the internal department- hematology unit outpatient clinic of El Minia University Hospital in collaboration with the clinical pathology department of El Minia University Hospital and the biochemistry department of Minia and Sohag University. Exclusion criteria:~Secondary causes of ITP as systemic lupus erythematous (SLE), viral infections (HIV, hepatitis B or C infections)~Other underlying medical diseases that may cause thrombocytopenia as:~malignancy~megaloblastic anemia~aplastic anemia~lymphoproliferative disorders~liver disease~renal impairment~pregnancy~Organomegally and/or lymphadenopathy.~Recent history of vaccination.~Recent evidence of bacterial infection."
32910875|NCT05371743||normal individuals|Blood samples will be taken from normal individuals.
32910876|NCT01743677|Experimental|CP-690,550 100 mg|
32910877|NCT01743677|Placebo Comparator|Placebo|
32910878|NCT01743677|Active Comparator|Moxifloxacin hydrochloride|
32910879|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
32910880|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
32910881|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
32910882|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
32910883|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
32910884|NCT04080531|Experimental|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
32910885|NCT04080531|Experimental|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
33241029|NCT04081376|Experimental|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
32910886|NCT01745627|Experimental|Laser Treatment|
33241030|NCT04890158|Experimental|Prone positioning for a total of 6 hours daily by study protocol|Patients will be positioned prone for 3 hours then placed supine for 3 hours then prone again for 3 additional hours. The change in position from prone to supine and back is to more reliably document possible changes in ventilation, oxygenation, other vital signs and respiratory support required.
33241031|NCT04890158|No Intervention|usual positioning|"Patients in the newborn intensive care unit are physically handled usually every 3-4 hours. Those study participants who are randomly assigned to usual position may rest in a variety of positions in any order based on nursing or perceived patient preference. Positions may include supine, right lateral, left lateral, and prone as well."
32760823|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
32760824|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
32760825|NCT05023421||Problematic media use of children with CP|The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
32760826|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
32760827|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
32760828|NCT05033093|Active Comparator|Ah Plus|All samples will be filled with Ah Plus root canal sealer and gutta percha
32760829|NCT05033093|Active Comparator|I Root SP|All samples will be filled with I Root SP root canal sealer and gutta percha
32760830|NCT05033093|Active Comparator|GuttaFlow Bioseal|All samples will be filled with GuttaFlow Bioseal canal sealer and gutta percha
32760831|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
33398250|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
33398251|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
33398252|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
33398253|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
33398254|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
33398255|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
33398256|NCT01360437|Active Comparator|Prasugrel|
33398257|NCT01360437|Experimental|Ticagrelor|
33398258|NCT04042103|Experimental|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
33398259|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
33398260|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
33398261|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
33398262|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
33398263|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
33398264|NCT03883646|Experimental|Mindfulness|Mindfulness
33398265|NCT03883646|Experimental|Relapse Prevention|
33398266|NCT03883646|No Intervention|Waitlist Control|
33398267|NCT03883646|No Intervention|Treatment as Usual|
33398268|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
33398269|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
33398270|NCT03676322|Experimental|Part A: M5049|
32760832|NCT05023577|Experimental|CL group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levoflaxacin 0.5 g qd for 14 days
32760833|NCT05023577|Experimental|LM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levoflaxacin 0.5 g bid for 14 days
32760834|NCT05023577|Active Comparator|CM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
32760835|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
32760836|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
32760837|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
33398271|NCT03676322|Placebo Comparator|Part A: Placebo|
33398272|NCT03676322|Experimental|Part B: M5049|
33398273|NCT03676322|Placebo Comparator|Part B: Placebo|
33398274|NCT03676322|Experimental|Part C: M5049|
33398275|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
33398276|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
33398277|NCT01366911||stem cell QCT testing|
33398278|NCT05187897|No Intervention|Standard Care Control|CHVs based at facilities in the control arm will continue to implement the standard of care.
33398279|NCT05187897|Experimental|CHV-NEO Intervention|CHVs based at facilities in the Intervention arm will implement the integrated CHV-NEO two-way SMS messaging intervention with their clients.
33398280|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
33398281|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
33398282|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
33241032|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
33398283|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
32760838|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
32742585|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
33398284|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
33398285|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
33398286|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
33398287|NCT01360671|Experimental|Sildenafil|iv sildenafil
33398288|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
33398289|NCT04927884|Experimental|All subjects|Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
33398290|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
33398291|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
33398292|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
33398293|NCT02955797|Experimental|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
33398294|NCT02955797|Experimental|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
33398295|NCT02955797|Experimental|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
33398296|NCT02955797|Experimental|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
33398297|NCT05554068|Experimental|Shingrix|Patients 1-3 years post transplant will receive the Shingrix vaccine in standard dosing and schedule.
33398298|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
33398299|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
33398300|NCT04913298|Other|Cytosorb therapy|blood samples are taken before and after the cytokine adsorber at given times
32742586|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
32742587|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
32742588|NCT04833153|Experimental|PFP intervention|PFP 10 week continuing education intervention
32742589|NCT04833153|No Intervention|Control arm|Usual care
33398301|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
33398302|NCT03822650||Prospective|"Subjects who meet eligibility criteria and enroll in the prospective arm will be assessed every 6 months ± 4 weeks for a period of up to 3 years, according to the Schedule of Assessments.~Subjects in the Prospective arm may also participate in the Retrospective arm."
32742590|NCT04488107|Experimental|Dose escalation cohort of FCN-437c|"This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.~Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.~Participants must be histologically or cytologically diagnosed with ER+/ HER2- advanced breast cancer."
32760839|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760840|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760841|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760842|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760843|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760844|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760845|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760846|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
32760847|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
32760848|NCT05032391|Experimental|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
32760849|NCT05032391|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
32760850|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
32760851|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
32760852|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
32760853|NCT03092687||substance disorders|decedents with and without substance use disorders
32760854|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
32760855|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
32760856|NCT01939366|Experimental|Cebranopadol 300 µg|
32760857|NCT01939366|Experimental|Cebranopadol 600 µg|
32760858|NCT01939366|Active Comparator|Pregabalin|
32760859|NCT01939366|Placebo Comparator|Matching Placebo|
32760860|NCT01939366|Experimental|Cebranopadol 100 µg|
32760861|NCT04434365|Experimental|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
32760862|NCT04434365|Active Comparator|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
32760863|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
32760864|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
32760865|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
32760866|NCT05032469|Experimental|Refloxology Intervention|The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
32760867|NCT05032469|No Intervention|Standart Care|Participants in the control group will receive standart postoperative care.
32760868|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
32760869|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
32760870|NCT05032235|Experimental|Group A|
32760871|NCT05032235|Experimental|Group B|
32760872|NCT05032235|Experimental|Group C|
32760873|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
32760874|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
32760875|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
32760876|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
32760877|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
32760878|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
32760879|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
32760880|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
32760881|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
32760882|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
32760883|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760884|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760885|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760886|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760887|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
32760888|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
32760889|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
32760890|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760891|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760892|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760893|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760894|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760895|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
32760896|NCT05023265|Experimental|SBRT for Medically Inoperable RCC|35-40 Gy in five fractions (7-8 Gy/day)
32760897|NCT05031923|Experimental|SMV and antimicrobial photodynamic therapy|Application SMV and antimicrobial photodynamic therapy in intrabony defect
32760898|NCT05031923|Active Comparator|SMV application|Application SMV in intrabony defect
32760899|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
32760900|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
32760901|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
32760902|NCT04468919|Experimental|BCI-FIT multi-modal configuration|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with a standard P300 matrix speller layout and with the multi-modal configurations optimized from the BCI-FIT algorithms. Outcome measures are typing accuracy, typing speed and user experience.
32760903|NCT04468919|Experimental|Adaptive signal modeling|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with 3 signal adaptive modeling configurations. Outcome measures are typing accuracy, typing speed and user experience.
32760904|NCT04468919|Experimental|Active querying techniques|For this single case research design with alternating treatments without baseline, 5 control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 70-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
32760905|NCT04468919|Experimental|Language modeling|For this single case research design with alternating treatments, 5 control volunteers and 5 participants with severe speech and physical impairment, each with a control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
32760906|NCT02354989|Active Comparator|RR on first|Rate Response on first
32760907|NCT02354989|Active Comparator|RR off first|Rate Response off first
32760908|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
32760909|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
32760910|NCT04467749|Experimental|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
32760911|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
32760912|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
32760913|NCT05023187|Experimental|Social and Cognitive Online Training Group (SCOT)|A group of participants randomly assigned to a social-cognitive online training through individual cognitive training sessions and group sessions to improve social functioning.
32760914|NCT05023187|Active Comparator|Control Group (CON)|A group of participants randomly assigned to receive an active control intervention to compare performances with the experimental group.
32760915|NCT05032001|Experimental|Metformin|Metformin 1.7-2.5mg per day during twelve weeks
32760916|NCT05032001|Experimental|Metformina + IDDP-4|Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
32760917|NCT05032001|Experimental|Metformina + ISGLT-2|Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
32760918|NCT03147859|Experimental|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
32760919|NCT03147859|Experimental|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
32760920|NCT03147859|Experimental|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
32760921|NCT05022875|Experimental|Experimental app intervention|The complete Healthcare CEO app will be used for intervention in the experimental group.
32760922|NCT05022875|Sham Comparator|Control app intervention|"Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare CEO app."
32760923|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
32760924|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
32760925|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
32760926|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
32760927|NCT04963517|Experimental|Exercise therapy|"8 weeks personalized, multi-modal exercise with focus on lower extremity~Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations~2x per week multi-modal group-based and supervised exercise (endurance, strength, mobility, coordination)~week 1 and 2 supervised, week 3 and 4 partially supervised, week 5 and 6 only one supervised session, week 7 and 8 last two sessions supervised"
32760928|NCT04963517|Active Comparator|Information group|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
32760929|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
32760930|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
32760931|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
32760932|NCT05031689|Placebo Comparator|SPF 30 and Placebo|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
32760933|NCT05031689|Active Comparator|SPF 30 and pharmaceutical formulation with green banana peel|In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
32760934|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
33241033|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
32760935|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
32760936|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
33241034|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
33398303|NCT03822650||Retrospective|Upon confirmation of eligibility criteria, the site will obtain an Informed Consent/Assent form and release of medical records from the subject/legally authorized representative to allow review of the medical records from the subject's primary care physician and/or specialists to confirm the CLN5 diagnosis and disease course. To facilitate collection of the medical records, a caregiver interview will be completed at initial enrollment then once yearly for up to 3 years.
33398304|NCT05418348|Experimental|Treatment A (GTX-104 IV, Test):|Nimodipine was administered by infusion over 72 hours.
33398305|NCT05418348|Experimental|Treatment B (NIMOTOP, RLD):|Nimodipine capsules (RS) administered orally with 240 mL of water at a dose level of 60 mg (two 30 mg capsules) q4h for 72 hours.
33398306|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
33398307|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
33398308|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
33398309|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
33398310|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
33398311|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
33398312|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
33398313|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
33398314|NCT03258554|Active Comparator|Arm I (cetuximab, radiation therapy)|Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
33398315|NCT03258554|Experimental|Arm II (durvalumab, radiation therapy)|Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
33398316|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
33398317|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
33398318|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
33398319|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
33398320|NCT03010176|Experimental|Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions receive escalating doses of ulevostinag monotherapy via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
33398321|NCT03010176|Experimental|Part 1 Arm 2: Ulevostinag +Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions receive escalating doses of ulevostinag via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
32760937|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
32760938|NCT05022953|Experimental|Digital Story Group|"Digital Story Group: One of the researchers gave the experimental group participants a 15-minute briefing on how to perform digital storytelling. She also told them not to talk to the control group participants about the content of the briefing. She created a Pixton account (https://edu.pixton.com/educators/) and a class named Isolation. She sent the link (https://join.pixton.com/x5xb6) to the experimental group participants. She asked them to click on the link and make stories out of their knowledge of isolation in four weeks."
32760939|NCT05022953|No Intervention|Control Group|Control group participants did not go through any training in isolation.
32760940|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
32760941|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
32760942|NCT05031377|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
32760943|NCT05031377|Sham Comparator|Control|Receive usual care
32760944|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
32760945|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
32760946|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
32760947|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
32760948|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
32760949|NCT05031299|Active Comparator|Control group (Standard care)|Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.
32760950|NCT05031299|Experimental|Intervention group 1 (Application)|Participants will will be additionally provided with a health-promotion application for self-management for 3 months.
32760951|NCT05031299|Experimental|Intervention group 2 (Devices)|"Participants will be additionally provided with wearables and devices for 3 months including:~A weighing scale (assessing also body composition) device~A smartwatch/wristband to assess physical activity but also sleep pattern."
32760952|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
32760953|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
32760954|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
32760955|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.~Cohort 1, 3 of 3 patients received:~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
32760956|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.~Determination of the maximally tolerated dose (MTD) of GDC-0941."
32760957|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 1 Cisplatin Only Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
32760958|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 2 Cisplatin + GDC-0941 Patients received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
32760959|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.~Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
33241035|NCT00676143|Placebo Comparator|Placebo|
33241036|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
32910887|NCT05731245|Experimental|Ropeginterferon alfa-2b|"Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.~Intervention: Drug: Ropeginterferon alfa-2b"
32910888|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
32760960|NCT05031611|Experimental|Intuitive Eating Treatment|"The intervention was a novel 10-week program aimed at promoting IE through pre-recorded videos, reading material, and bi-weekly discussion sessions. The intervention introduced the following modules sequentially: Unconditional Permission to Eat, Reliance to Hunger and Fullness Cues, Body-Food Choice Congruence, Gentle Nutrition, and Joyful Movement.~Every other week, a new module was introduced. Participants were taught the concept of this module through video and reading, then prompted to practice it over the week. On opposite weeks, the module last introduced was discussed in greater detail through video, and participants were given the opportunity to discuss amongst one another and have all questions answered by the researchers."
32760961|NCT05031611|No Intervention|Waitlist Control|Waitlist control group participants completed a series of questionnaires at the beginning and end of a 10-week interval, to compare changes in those who completed the intervention versus those who did not. This group was subsequently invited to participate in the intervention after their time on the wait-list.
32760962|NCT05031533|Experimental|Assigned Interventions|"Radiation therapy: Dose-painting radiation~Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status~(1) Chemotherapy~Squamous cell carcinoma: Paclitaxel 135mg/m2 D1 + Cisplatin 25mg/m2 D1-3, every 21 days, a total of 2-4 cycles.~Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma): Pemetrexed 500mg/m2 d1 + Cisplatin 75 mg/m2 d1-3, a total of 2-4 cycles.~(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected;"
32760963|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
32760964|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
32760965|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
32760966|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
32760967|NCT05022797|Experimental|Glucarpidase, methotrexate, R-CHOP|Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.
32760968|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
32760969|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
32760970|NCT05031143|Active Comparator|SCTA injection (n=6 eyes)|Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.
32760971|NCT05031143|No Intervention|Non-injected eyes (Standard Treatment) (n=6 eyes)|Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months
32760972|NCT05022407||Cohort 1 (SARS-CoV-2 uninfected)|Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline.
32760973|NCT05022407||Cohort 2 (SARS-CoV-2 infected)|Participants who test positive on RNA-PCR SARS-CoV-2.
32760974|NCT05022407||Cohort 3 (SARS-CoV-2 exposed)|Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test.
32760975|NCT01948258|Other|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
32760976|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
32760977|NCT05030987|Experimental|RDN|Renal Denervation
32760978|NCT05030987|Sham Comparator|Sham|Sham Procedure
32760979|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
32760980|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
32760981|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
32760982|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
32760983|NCT05021627|Experimental|Cardiac autonomic nerve modification|
32760984|NCT05021627|Active Comparator|Pacemaker|
32760985|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
32760986|NCT05021783||Patients|Patients with Axial SpondyloArthritis
32760987|NCT03147313|Sham Comparator|Sham|
32760988|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
32760989|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
32760990|NCT04638400|Active Comparator|Simvastatin|Obese subjects with elevated cholesterol
32760991|NCT04638400|Active Comparator|Ezetimibe|Obese subjects with elevated cholesterol
32760992|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
32760993|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
32760994|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
32760995|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
32760996|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
32760997|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield & Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
32760998|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield & PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
32760999|NCT04974047|Experimental|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams [mg]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
32761000|NCT04974047|Experimental|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax < 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
32761001|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
32761002|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
32761003|NCT03147079|Experimental|Intervention|Lifestyle intervention
32761004|NCT03147079|Experimental|Internal controls|
32761005|NCT03147079|Experimental|External controls|
32761006|NCT04972721||Questionnaire survey|Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
32761007|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
32761008|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
32761009|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
32761010|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
32761011|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
32761012|NCT04971629||Cohort 1|Patients with knee osteoarthritis who use medical cannabis to manage MSK symptoms.
32761013|NCT04971629||Cohort 2|Patients with knee osteoarthritis who do not use medical cannabis.
32761014|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
32761015|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
32761016|NCT05020925|Experimental|SHR-1701 plus Famitinib|SHR-1701+Famitinib for R/M NPC failure after platinum-based chemotherapy and anti PD-1/PD-L1 antibody therapy
32761017|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
32761018|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
32761019|NCT05029583|Experimental|routine screening group|consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)
32761020|NCT05029583|Active Comparator|physician-driven screening group|consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)
32761021|NCT02349529|Experimental|Psychosocial group intervention|
32761022|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
32761023|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.~The following procedures will be carried out:~Questionnaire on compliance and adherence~Clinic Visit~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
32761024|NCT05021159||Methotrexate Group|20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)
32761025|NCT05021159||Healthy control group|20 healthy pediatric subjects not receiving any treatment
32761026|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
32761027|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
32761028|NCT05020613|Other|Early group|Patients whose catheters are removed within the first 48 hours after surgery will form the early group.
32761029|NCT05020613|Other|Late group|Patients whose catheters are removed after the first 48 hours of surgery will form the early group.
32761030|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
32761031|NCT03094559|Experimental|FlowMet device|This is a feasibility study
32761032|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
32761033|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
32761034|NCT05029037|Experimental|Group A|80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.
32761035|NCT05029037|Placebo Comparator|Group B|80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.
33241037|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
32761036|NCT03091907||Case|Children with a history of necrotizing enterocolitis
32761037|NCT03091907||control|Children with no history of necrotizing enterocolitis
32761038|NCT05028959|Experimental|Female athletes|highly trained subjects
32744200|NCT04464993|Active Comparator|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
32761039|NCT05028959|Experimental|Leisure sport women|recreational sportswomen practicing regular physical activity
32910889|NCT04071951|Experimental|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
33398322|NCT03010176|Experimental|Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)|Participants with visceral lesions receive escalating dose frequencies of ulevostinag via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8 and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
32761040|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
32761041|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
32761042|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
32761043|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
32761044|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
32761045|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
32761046|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
32761047|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
32761048|NCT02347969|Experimental|X34|Arm supplemented with X34
32761049|NCT05028803|Experimental|Phenylbutyrate|Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day.
32761050|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
32761051|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
32761052|NCT05020223|Experimental|MTA pulpotomy|Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure
32761053|NCT05020223|Experimental|MTA direct pulp capping|Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure
32761054|NCT05020223|Experimental|MTA indirect pulp capping|Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis
32761055|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
32761056|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
32761057|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
32761058|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
32761059|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
32761060|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
32761061|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
32761062|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
32761063|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
32761064|NCT03146845|Other|Standard care|Standard care dressing
32761065|NCT04438837|No Intervention|control group|no intervention
32761066|NCT04438837|Active Comparator|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
32761067|NCT05020067|Experimental|SPLS-IMRT|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%
32761068|NCT05020067|No Intervention|C-IMRT|The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%
32761069|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:~ubiquinol (liquid form, 150 mg/kg subject weight/day~carnitine, 50 mg/kg subject weight/day~alpha-lipoic acid, 100 mg/ day"
32761070|NCT05019911||Patients with COPD alone|In the cross-sectional part, the group of patients with COPD alone will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
32761071|NCT05019911||Patients with COPD combined with sleep apnea hypopnea syndrome|In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
32761072|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
32761073|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
32761074|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
32761075|NCT05028335|Other|Group G1|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + placebo gel
32761076|NCT05028335|Experimental|Group G2|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + 1.5% Potassium Oxalate gel
32761077|NCT04434053|Experimental|MIETHKE M.blue®|
32761078|NCT04434053|Active Comparator|MIETHKE proGAV 2.0® (with SA 2.0®)|
32761079|NCT04310345|Experimental|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
32761080|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
32761081|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
32761082|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
32761083|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
32761084|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
32761085|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
32761086|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
32761087|NCT05028179|No Intervention|Standard Care (comparator)|Patients will receive standard care
32761088|NCT05028179|Experimental|Standard Care plus AI platform (EchoGo)|Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
33398323|NCT03010176|Experimental|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory receive ulevostinag at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
32761089|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
32761090|NCT04467671|Experimental|Tissue Engineered Vascular Grafts|
32761091|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
32761092|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
32761093|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
32761094|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
32761095|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
32761096|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
32761097|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
32761098|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
32761099|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
33241038|NCT05683262|Active Comparator|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection is applied to patients in this group
32761100|NCT05028023|Experimental|Pediatric patients with tracheal stenosis undergoing tracheal balloon dilatation|Pediatric patients with severe to median acquired tracheal stenosis undergoing tracheal balloon dilatation, and the effects of apneic oxygenation on regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, and arterial oxygen partial pressure PaO2
32761101|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
32761102|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
32761103|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
32761104|NCT02347579||Patients with CLBP|Patients with chronic low back pain
32761105|NCT02347579||Healthy controls|
32761106|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
32761107|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
32761108|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
32761109|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
32761110|NCT05020301|Experimental|Control group|Participants who have never practiced mindfulness
32761111|NCT05020301|Experimental|Beginner Practitioner|Participants with less than two years of mindfulness practice
32761112|NCT05020301|Experimental|Advanced Practitioner|Participants with more than two years of mindfulness practice
32761113|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
32761114|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
32761115|NCT04130165|Experimental|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
32761116|NCT04130165|No Intervention|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
32761117|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
32761118|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
32761119|NCT04128995|Active Comparator|Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes|Youth with type 2 diabetes undergoing bariatric surgery, n=45
32761120|NCT04128995|Active Comparator|Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes|Youth with type 2 diabetes receiving medical management, n=45
32761121|NCT04128995|Active Comparator|Bariatric Surgery in Youth with Obesity|Youth with no obesity undergoing bariatric surgery, n=10
32761122|NCT02349607|Experimental|PF-05089771 300 mg|
32761123|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
32761124|NCT02349607|Placebo Comparator|Placebo|
32761125|NCT02349607|Active Comparator|pregabalin 300 mg|
32761126|NCT02349607|Active Comparator|ibuprofen 600 mg|
32761127|NCT05019755|Experimental|A(First period) to B(Second period) order|"A: Oral Administration of IN-A002(IN-115314) in fasting status~B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~There will be a wash out period of 7days between period"
32761128|NCT05019755|Experimental|B(First period) to A(Second period) order|"B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~A: Oral Administration of IN-A002(IN-115314) in fasting status~There will be a wash out period of 7days between period"
32761129|NCT04478461|Experimental|MW11 injection|1, 3, 10 mg/kg and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W.
32761130|NCT04115501|Experimental|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
32761131|NCT04115501|No Intervention|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
32761132|NCT04108481|Experimental|Y90-RE in combination with immunotherapy (durvalumab)|"The treatment phase starts of with the immunotherapy drug (durvalumab) - priming doses every 2 weeks prior to patient getting mapped and ready for treatment with Y90-RadioEmbolization.~Post-Y90-RE, treatment is approximately 2 months in combination with fixed doses (750 mg) of durvalumab. The number and timing of doses of durvalumab each patient will receive will depend on the dose level the patient is assigned to (range 2-5 doses of immunotherapy).~A single patient will be treated per dose level until the first dose limiting toxicity (DLT) is recorded. Once the first DLT is recorded, two additional patients are treated at the same dose level and the trial reverts to a standard 3+3 design. Up to 6 patients will be treated at each dose level. The maximum tolerated dose (MTD) will be defined as the highest dose level for which at most 1 out of 6 patients experience a DLT."
32761133|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
32761134|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
32761135|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
32761136|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
33241039|NCT05683262|Active Comparator|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection with coccygeal nerve block|Ultrasound-guided coccygeal nerve blockade is done before the application of ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection to patients in this group
33241040|NCT04082390|Experimental|RELEASE Supplement|
33241041|NCT04082390|Placebo Comparator|Placebo|
33241042|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
33241043|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
33241044|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
33241045|NCT04585022|Active Comparator|Magnum|A metal-on-metal large diameter head total hip arthroplasty
33398324|NCT03010176|Experimental|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC receive ulevostinag at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
33398325|NCT03010176|Experimental|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve receive ulevostinag at the preliminary RP2D based on Part 1: ulevostinag +pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
33241046|NCT04585022|Active Comparator|Recap|A metal-on-metal hip resurfacing arthroplasty
33241047|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
33241048|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
33241049|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
32761137|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
32761138|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
32761139|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
32761140|NCT05027555|Experimental|Multisensory training group|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
32761141|NCT05027555|Active Comparator|Conventional training group.|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
32761142|NCT05231005|Experimental|4th dose BNT162b2 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (30 microgram) of the BNT162b2 vaccine
32761143|NCT05231005|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
32761144|NCT05027321|No Intervention|Control|control
32761145|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring|1-hour consultation with a hypnopractor just before the examination
32761146|NCT05027321|Experimental|Conversational Hypnosis|conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
32761147|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|1-hour consultation with a hypnopractor just before the examination and conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
32761148|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
32761149|NCT05027711|Experimental|A|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
32761150|NCT05027711|Experimental|B|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
32761151|NCT05027711|Experimental|C|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist
32761152|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
32761153|NCT05019989|Experimental|Intervention group: on diet and physical activity|"Individual advice on diet and on physical activity Kitchen courses to teach basic Mediterranean and macrobiotic recipes (two 1-day course plus ten 3-h courses associated with common dinner) (15-20 participants at a time) Fortnightly common lunch or dinner (50-60 participant at a time) Basic gymnastic course (twelve - monthly- 2-hour courses)~Study newsletter, with scientific information, kitchen recipes, study facilities~Periodic conferences on diet and health~Periodic reinforcement meetings with common meals, gymnastic sessions, and dancing, after the first year~Periodic body weight assessment (weekly self-measurement and monthly measurement at the study center)~Discounted rate for advanced kitchen courses~Psychological support groups"
32761154|NCT05019989|Experimental|Control group: only public recommendations on lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
32761155|NCT04478305|Other|Intervention group|Patient will be provided with study medication. To be taken once a day for 16 weeks (112 days). Active drug brand name - Duavive/Duavee. Dose consisting of 1 pill of 0.45mg conjugated estrogens and 20mg bazedoxifene as bazedoxifene acetate.
32761156|NCT05027243|Experimental|bilateral temporomandibular joint arthroscopy|
32761157|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
32761158|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
32761159|NCT05019599|No Intervention|normal controls|subjects with normal renal function
32761160|NCT05019599|Experimental|CKD_Low protein diet|CKD patient with low protein diet (<0.8g/kg/BW)
32761161|NCT05019599|Active Comparator|CKD_normal protein diet|CKD patient with normal protein diet
32761162|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
32761163|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
32761164|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
32761165|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
32761166|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
32761167|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
32761168|NCT05019287|Experimental|Menstrual blood stem cell secretome group|Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
32761169|NCT05019287|Placebo Comparator|Control group|Intravenous saline injection (Placebo)+Routine treatment
32761170|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
32910890|NCT04071951|No Intervention|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
32761171|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
32761172|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
32761173|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
32761174|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
32761175|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
32761176|NCT04477993|Experimental|Experimental Group - ruxolitinib|Ruxolitinib 5 mg PO b.i.d. for 14 days
32761177|NCT04477993|Placebo Comparator|Placebo Group|
32761178|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
32761179|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
32761180|NCT05019443|Active Comparator|Conventional balloon predilation|the target lesion can be prepared according to standard clinical practice using SC balloons sized 0.8-1:1. Stenting using a drug-eluting stent (DES) is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
32761181|NCT05019443|Experimental|Scoring balloon predilation|the target lesion must be prepared with a scoring balloon (SC) inflated 3 times at nominal pressure. To allow the scoring balloon to cross the lesion, it might be necessary to predilate with a small compliant balloon. The size of the scoring balloon to be used for is based on the size of the vessel. Stenting using a DES is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
32761182|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
32761183|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
32761184|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
32761185|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
32761186|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
32761187|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
32761188|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
32761189|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
32761190|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
32761191|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
32761192|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
32761193|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
32761194|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
32761195|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
32761196|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
32761197|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
32761198|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
32761199|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
32761200|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
32761201|NCT05019365||Participants with previous HER2 breast cancer|
32761202|NCT05019365||Healthy Volunteers|
32761203|NCT05018741||Liver transplant|
32761204|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
32761205|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
32761206|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
32761207|NCT02347267|No Intervention|All beverages|Beverages were not restricted
32761208|NCT05025995|Experimental|Serious health game|Children played a serious health game with Garfield promoting health behavior, such as less intake of energy dense snacks, drink more water, and exercise more often.
32761209|NCT05025995|Experimental|control|Children in this condition did not play a serious health game and were in control condition.
32761210|NCT05255575||ertapenem treatment|
32761211|NCT05026229|Experimental|Dasatinib, Vincristine and Prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
32761212|NCT05026229|Experimental|Dasatinib, Methotrexate and Cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
32761213|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
32761214|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
32761215|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
32761216|NCT05026073||Group 1 Endometrial Cancer:|Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
32761217|NCT05026073||Group 2 Endometrial Hyperplasia:|Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
32761218|NCT05026073||Group 3 Controls:|Healthy women undergoing hysterectomy for a benign reason
32761219|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
32761220|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
32761221|NCT04478149|Experimental|Active Cameras|active cameras in the room
32761222|NCT04478149|Sham Comparator|Inactive Cameras|camera in the room, not activated
32761223|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
32761224|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
32761225|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
32761226|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
32761227|NCT05018429||nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
32761228|NCT05018429||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles) during the operation.
32761229|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
32761230|NCT03146611||control|healthy sex and age matched group
32761231|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
32761232|NCT03146299|Active Comparator|Group A: TLH|
32761233|NCT03146299|Active Comparator|Group B: LAVH|
32910891|NCT04340427|Experimental|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
32910892|NCT05731167|Active Comparator|Regular follow up|Subjects underwent routine outpatient care after assessment and will receive outcomes follow up for 1 year.
32761234|NCT05009693|Experimental|white light intervention group|Between the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
32761235|NCT05009693|No Intervention|Control group|
32761236|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
32761237|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
32761238|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
32761239|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
32761240|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
32761241|NCT04954781|Experimental|TACE in combination with Tislelizumab|
32761242|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
32761243|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
32761244|NCT04954157|Placebo Comparator|Healthy Subjects|This arm will consist of health subjects, not infected with COVID-19
32761245|NCT04954157|Active Comparator|COVID 19 Subjects|This arm will consist of subjects who are currently diagnosed with COVID-19 and fit all other criteria to be enrolled in this study.
32761246|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
32761247|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
32761248|NCT04949633|Experimental|Induction of labor|women randomized in the experimental group will be admitted to the labor ward to undergo induction of labor with intra-veinous oxytocin and early amniotomy. Oxytocin will be administered according to the French guidelines for induction of labor. Maximum oxytocin used should not exceed 10 UI.
32761249|NCT04949633|Active Comparator|Second cervical ripening|"women randomized in the control group will undergo a second cervical ripening lasting a maximum of 24 hours with either:~Vaginal slow releasing system of dinoprostone PROPESS® which is inserted in the vagina, against the cervix and left in place during 24 hours.~Oral misoprostol (ANGUSTA®) 25 µg every 2 hours, 8 times (maximum dosage should not exceed 200µg). Tablets will be given one at the time by midwives.~Vaginal gel of dinoprostone (2 mg PROSTINE®) every 6 hours, maximum dose of 6 mg.~The choice of the cervical ripening agent will depend of the local protocol of the participating maternity unit. The choice between ANGUSTA®, PROPESS® and PROSTINE® will be made by investigators of each participating unit at the beginning of the trial.~At the end of the second cervical ripening procedure women not in labor will be transferred to the labor ward for induction of labor with oxytocin."
32761250|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
32761251|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
32761252|NCT03146377|Experimental|Xeloxiri|
32761253|NCT05018195|Active Comparator|Benign|Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
32761254|NCT05018195|Experimental|Endometrial cancer|Women who receive surgery(staging or cytoreductive surgery) for endometrial cancer. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
32761255|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
32761256|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
32761257|NCT05009615|Experimental|Green coffee extract|Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
32761258|NCT05009615|Experimental|Beta-glucan|Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
32761259|NCT05009615|Experimental|Green coffee + Beta-glucan|Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
32761260|NCT02343133|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
32761261|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose
32761262|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
32761263|NCT04465721|Active Comparator|HABIT Group|Participants randomized to the HABIT group will maintain their habitual eating schedule (≥13-h).
32761264|NCT04465721|Experimental|TRE Group|Participants randomized to TRE will reduce their eating window to a self-selected eating window (≤10-h).
32761265|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
32761266|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
32761267|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
32761268|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
32761269|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
32761270|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
32761271|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
32761272|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
32761273|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
32761274|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
32761275|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
32761276|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
32761277|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
32761278|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
32761279|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
32761280|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
32761281|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
32761282|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
32761283|NCT02343211|Experimental|immunoglobulin|
32761284|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
32761285|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
32761286|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
32761287|NCT05008523|Experimental|Opioids and Police Safety Occupational Risk Reduction Training|Provides occupational risk reduction training for police in 49 slides including 8 filmed videos (police officers, MDs, SSP staff, a person in recovery). The training is delivered online with secure access only for enrolled study participants.
32761288|NCT05008523|Active Comparator|COVID Occupational Risk Reduction Training|The COVID-19 and Police Safety training (Control only) includes 22 slides, also narrated by a professional voice narrator.
32761289|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
32761290|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
32761291|NCT04477681||Patients in therapeutic failure or relapse|Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
32761292|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
32761293|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
32761294|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
32761295|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
32761296|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
32761297|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
32761298|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
32761299|NCT03146221|Other|Person to be surgically treated for arteritis|
32761300|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
32761301|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
32761302|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
32761303|NCT05008679|No Intervention|Control|patients with heart failure to receive standard HF therapy
32761304|NCT05008679|Experimental|Oseltamivir|patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy
32761305|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
32761306|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
32761307|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
32761308|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
32761309|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
32761310|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
32761311|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
32761312|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
32761313|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
32761314|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
32761315|NCT05017961|Active Comparator|Autograft|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group an autograft will be used to fill the void. For the purpose of autologous grafting, cancellous strips of bone will be harvested from the posterior superior iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s). This will be the control arm.
32761316|NCT05017961|Other|Allograft only|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) will be used to fill the void. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
32910893|NCT05731167|Experimental|Multidomain intervention|The intervention group will receive multi-faceted frailty prevention programs such as physical training, nutritional advice, cognitive training, and drug education and receive outcomes follow up for 1 year.
32761317|NCT05017961|Other|Allograft combined with BMAC|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) combined with BMAC will be used to fill the void. For the purpose of BMAC preparation, bone marrow will be collected from iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
32761318|NCT05008367|Active Comparator|Treatment A|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
32761319|NCT05008367|Active Comparator|Treatment B|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
32761320|NCT05008367|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
32761321|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
32761322|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
32761323|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
32761324|NCT05008211|Experimental|Intervention|"There will be a respiratory team, same as the usual care, responsible for patients requiring domiciliary NIV in the intervention group.~The IMB model-based intervention of this study is a six-week program consisted of a one-hour face-to-face home visit in the first week, two 20-minute telephone follow-ups in the second and fourth weeks, and a half-hour face-to-face follow-up at hospital in the sixth week, and a telephone consultation hotline during office hours.~There are three major components including information, motivation and behavioral skill interventions as proposed by the IMB model and will be deliberately arranged in the different sessions."
32761325|NCT05008211|Placebo Comparator|Control - usual care|There is a respiratory team of health care professionals responsible for patients requiring domiciliary NIV. The team is led by a Medical Consultant and with respiratory nurse(s) as team members who are responsible for assisting patients or their family to initiate domiciliary NIV and teaching the relevant technical skills. The nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems such as leakage and pressure sore in hospital before discharge. Commercial leaflet or booklet according to the choice of ventilator with information of the ventilator, interface, accessories and the ventilator company will be provided to the patient.
32761326|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
32761327|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
32761328|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
32761329|NCT05017259|Experimental|low carbohydrate trial|The energy distribution was carbohydrate 10%, protein 40-50%, fat 40-50% in the LC trial.
32761330|NCT05017259|Active Comparator|high carbohydrate trial|The energy distribution was carbohydrate 60-65%, protein 30-40%, fat 5-10% in the HC trial.
32761331|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
32761332|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
32761333|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
32761334|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
32761335|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
32761336|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
32761337|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
32761338|NCT03079271|Other|open label|
32761339|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
32761340|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
32761341|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
32761342|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
32761343|NCT05007743|Active Comparator|Stimulation of inner tragus|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
32761344|NCT05007743|Sham Comparator|Stimulation of ear lobe|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
32761345|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
33398326|NCT04040933|Active Comparator|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
32744201|NCT04464993|Active Comparator|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise based on 3:1 ratio , simple adaptive content (by SST bout, time of day). Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation."
32761346|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
32761347|NCT05016635||Sub-arachnoid Hemorrhage Patients|
32761348|NCT02337205|Experimental|KX2-391 Ointment|
32761349|NCT05007587|Experimental|Lenvatinib，Then HAIC of mFOLFOX regimen|Cohort1：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.
32761350|NCT05007587|Experimental|Lenvatinib，Then HAIC of ROX regimen|Cohort2：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
32761351|NCT04148911|Experimental|Atezolizumab plus Nab-Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
32761352|NCT05016557|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g protein
32761353|NCT05016557|Experimental|Spirulina|Bolus ingestion of spirulina providing 25g protein
32761354|NCT05016557|Experimental|Chlorella|Bolus ingestion of chlorella providing 25g protein
32761355|NCT05015933|Experimental|Refill at home|Patients will have one pump refill at home instead of at the hospital.
32761356|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
32761357|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
32761358|NCT05016011|Experimental|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.
33241050|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
33241051|NCT04504071|Other|Dacomitinib Arm|This is a single arm study.
33241052|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
33241053|NCT02586194|Experimental|Mild hepatic impairment|Oral
32761359|NCT05016011|Active Comparator|Marrow cellution (standard treatment)|Patients will undergo marrow cellution surgical procedure.
32761360|NCT03953677|Experimental|Dexmedetomidine|
33241054|NCT02586194|Experimental|Moderate hepatic impairment|Oral
33241055|NCT04483713|Active Comparator|Educational Workshop|Will receive theoretical and practical training in EBP through a workshop in a structured model with themes related to the introduction to EBP, with the final proposal of a practical class that aims to structure and describe an individual case through an exercise formulated to go through the phases of a project of EBP, to base this exercise we will use a finished and consolidated project, this will be used as a template of the exercise, the description of this exercise is in the programmatic content.
33241056|NCT04483713|Active Comparator|Educational Workshop plus J. H. N. EBP Guide Tools|"Will receive the same training as group Educational Workshop, plus the presentation and availability of the Johns Hopkins Nursing Evidence-based Practice guide tools to be used in the practice class for the structuring and individual description of the EBP exercise case. The same theme of the case will be used in both groups."
33241057|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
33241058|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
33241059|NCT02584166||Control group|No intervention in 57 maternity units
33241060|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
33241061|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
33241062|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
33241063|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
33241064|NCT00761163|Experimental|1|
33241065|NCT00761163|Experimental|2|
33241066|NCT00761163|Experimental|3|
33241067|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
33241068|NCT04569032|Experimental|CD30-negative Cohort|Participants with CD30 expression level < 1%
33241069|NCT04569032|Experimental|CD30-positive Cohort|Participants with CD30 expression level ≥1% to < 10%
32761361|NCT03953677|Placebo Comparator|Placebo|
32761362|NCT05015465||70 patients with juvenile SLE.|Anterior segment OCT for juvenile SLE patients.
32761363|NCT05015465||70 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
32761364|NCT03945643|Active Comparator|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
32761365|NCT03945643|Placebo Comparator|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
32761366|NCT05015777|Experimental|Intervention Group|Participated in the exercise programme
32761367|NCT05015777|No Intervention|Control Group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
32761368|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
32761369|NCT05015699|Experimental|HT Supreme|Device: HT Supreme ( R&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
32761370|NCT04958161|Experimental|Exercise Therapy|Exercise therapy will be performed three times per week for 12 weeks.
32761371|NCT04958161|No Intervention|Wait List Control|Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
32761372|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
32761373|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
32761374|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
32761375|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
32761376|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
32761377|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
32761378|NCT05014997||Patient|30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
32761379|NCT05014997||Control|30 healthy control subject without diagnosis of any chronic disease
32761380|NCT05255185|Experimental|All the patients|domino therapy treat the infection around the prosthesis after the limb salvage surgery of bone tumor
32761381|NCT05015075|Experimental|CR group|participants who have exercise-based cardiac rehabilitation program after PM.
32761382|NCT05015075|Placebo Comparator|non-CR group|participants who have only routine regular follow-up after PM instead of CR program
32761383|NCT04919863|Experimental|NTP42:KVA4|
32761384|NCT04919863|Placebo Comparator|Placebo|
32761385|NCT04909177|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
32761386|NCT04909177|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
32761387|NCT05007431||Women asylum seekers|
32761388|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
32761389|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
32761390|NCT05007665||Chronic Liver Diseases Patients/Healthy People|Chronic hepatitis (B OR C) , autoimmune hepatitis, liver cirrhosis, primary hepatocellular carcinoma
32761391|NCT04477915|Experimental|Core stabilization Exercise|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises. Exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
32761392|NCT04477915|Experimental|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles. exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
32761393|NCT04477915|No Intervention|Control|Control Group
32761394|NCT05007353|Experimental|Structured Lifestyle Intervention|Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
32761395|NCT05007353|Experimental|Self-Guided Intervention|General health information provided to participants.
32761396|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
32761397|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
32761398|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
32761399|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
32761400|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
32761401|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
32761402|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
32761403|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
33241070|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
33241071|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
33241072|NCT04081064|Experimental|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >18.5 and <30.0 kg/m2
33241073|NCT04081064|Experimental|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >30.0 to <40.0 kg/m2
33241074|NCT04049409|Experimental|CMAB809|
33241075|NCT04049409|Active Comparator|Trastuzumab|
33241076|NCT04568252|Experimental|Intervention|Millimetric wave emission bracelet.
33241077|NCT04568252|Sham Comparator|Control|Placebo bracelet.
33241078|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
33241079|NCT04564742|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
33241080|NCT04564742|Placebo Comparator|Placebo|Placebo matching dapagliflozin
33398327|NCT04040933|Active Comparator|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398328|NCT04040933|Active Comparator|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398329|NCT04040933|Experimental|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398330|NCT04040933|Experimental|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398331|NCT04040933|Experimental|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398332|NCT04040933|Experimental|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
33398333|NCT04040933|No Intervention|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
33398334|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
33398335|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
33398336|NCT04897698|Placebo Comparator|Placebo|Four capsules containing rice flour will be given to the placebo group daily.
33398337|NCT04897698|Experimental|Single dose|"Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.~The placebo is made of rice flour."
33398338|NCT04897698|Experimental|Double dose|Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
33398339|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
33398340|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
32761404|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
32761405|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
32761406|NCT05007119|Active Comparator|Control Group|"It includes participants receiving conventional physical therapy for low back pain female patients for a period of 6 months.~McKenzie extension exercise Protocol Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
32761407|NCT05007119|Experimental|Experimental Group|"Group (A) Involves participants receiving cupping therapy along with conventional physicla therapy for a period of 6 months .~Moist Heat Pack for 10 mins McKenzie Extension Exercise Protocol"
32761408|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
32761409|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
32761410|NCT03086837|No Intervention|Control|No information
32761411|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
32761412|NCT05007197|Experimental|Intervention Group|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people.~Group-specific diabetes trainings were completed in two training sessions. Each training session lasted an average of one and a half hours and a fifteen minute break was given.~The auditory group in the intervention group, calling by phone; visual group by SMS and WhatsApp tactile group, reminder alerts were made by phone+SMS+WhatsApp."
32761413|NCT05007197|No Intervention|Control Group|The learning modality of the control group were determined and standard group training was provided with the education booklet.
32761414|NCT05255029|Experimental|PODEYE Toric Intra Ocular Lens Implantation experimental|Implantation of PODEYE toric intraocular lenses.
32761415|NCT05006651|No Intervention|Laryngoscope|Intubation with traditional laryngoscope
32761416|NCT05006651|Active Comparator|McGrath MAC|Intubation with video laryngoscope
33398341|NCT04935060|Active Comparator|Usual Care Dementia assessment|Clinicians will conduct the assessment and outcome process as per their usual practice.
33398342|NCT04935060|Experimental|Guide informed dementia assessment|The guide will be used by both clinicians, patients and their companions to inform the approach to the dementia assessment process.
33398343|NCT04885530|Experimental|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
33398344|NCT04885530|Placebo Comparator|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
33398345|NCT04885530|Experimental|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
33398346|NCT04885530|Placebo Comparator|Arm B- Placebo|Placebo - appearance and size matched to active study drug. Placebo will be self-administered orally by each participant twice a day for 10 days.
33398347|NCT04885530|Experimental|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
33398348|NCT04885530|Placebo Comparator|Arm C - Placebo|Placebo is a self-administered by inhalation. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
33398349|NCT04885530|Experimental|Arm D - Ivermectin 600|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight for a daily dose of approximately 400-600 µg/kg."
33398350|NCT04885530|Placebo Comparator|Arm D - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight, matched to active study drug dosing."
33398351|NCT04885530|Experimental|Arm E - Fluvoxamine 100|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.
33398352|NCT04885530|Placebo Comparator|Arm E - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
33398353|NCT04885530|Experimental|Arm F - Montelukast|Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
33398354|NCT04885530|Placebo Comparator|Arm F - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
33398355|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
33398356|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
33241081|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
33241082|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
33241083|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
33241084|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
33241085|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
33241086|NCT04482062|Experimental|Edwards EVOQUE System & OMT|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation
33241087|NCT04482062|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
33241088|NCT04482062|Experimental|Single-Arm Registry|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
33241089|NCT00761397||Study Program Group|
33241090|NCT00761397||Usual Care Group|
33241091|NCT04292301|Experimental|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
33241092|NCT05436236||Control|People who self-report that they do not use cannabis.
33241093|NCT05436236||Cannabis|People who self-report that they use cannabis.
33241094|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
33241095|NCT04078646|Experimental|Dietary intervention|Intervention with test meal only
33241096|NCT04078646|Experimental|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
33241097|NCT04078646|Experimental|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
33241098|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
33241099|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
33241100|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
33241101|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
33241102|NCT04479644|Experimental|Cohort 1|BRII-198 dose level 1 or placebo
33241103|NCT04479644|Experimental|Cohort 2|BRII-198 dose level 2 or placebo
33241104|NCT04479644|Experimental|Cohort 3|BRII-198 dose level 3 or placebo
33241105|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
33241106|NCT00921921|Placebo Comparator|Placebo control|
33241107|NCT04557020|Experimental|Arm A|
33241108|NCT04557020|Active Comparator|Arm B|
33241109|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
33241110|NCT00761475|Placebo Comparator|1|primary closure of the midline
33241111|NCT00761475|Active Comparator|2|onlay mesh supported closure
33241112|NCT00761475|Active Comparator|3|sublay mesh supported closure
33241113|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
33241114|NCT04669574||Group 2|Participants who have previously had one progression.
33241115|NCT04669574||Group 3|Participants who have previously had a second recurrence.
33241116|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
33241117|NCT04477538||Participants with prepectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
33241118|NCT04477538||Participants with postpectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
33241119|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
33241120|NCT00761553|Experimental|1|Solid dietary supplements with exercise
33241121|NCT00761553|Experimental|2|Solid dietary supplements without exercise
33241122|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
33241123|NCT00761553|Experimental|4|Liquid supplements without exercise
33241124|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
33241125|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
33241126|NCT04176159|Experimental|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
33241127|NCT04176159|No Intervention|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
33241128|NCT01413399|Active Comparator|Intra-Arrest Therapeutic Hypothermia|
33241129|NCT01413399|Active Comparator|Post-Arrest Therapeutic Hypothermia|
32761417|NCT05006651|Active Comparator|Trachway|Intubation with video stylet
32761418|NCT05014685|Experimental|RA group|
32761419|NCT05014685|Experimental|RAM group|
32761420|NCT05014685|Experimental|RAB group|
32761421|NCT05014685|Active Comparator|RABM group|
32761422|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
32761423|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Programming of the VV interval to obtain the narrowest QRS-width"
32761424|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
32761425|NCT05014763|Active Comparator|CTG from deep palate|The connective tissue graft harvested from the deep palate during flap elevation for implant placement
32761426|NCT05014763|Experimental|CTG from tuberosity|The connective tissue graft harvested from the tuberosity
32761427|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
32761428|NCT05015309|Experimental|SH3765 tablet|Daily oral administration of SH3765 tablet
32761429|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
32761430|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
32761431|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
32761432|NCT05006495|Experimental|C3 laminectomy with C4-6 laminoplasty|Cervical myelopathy patients who underwent C3 laminectomy with laminoplasty.
32761433|NCT05006495|Active Comparator|C3-6 laminoplasty|Cervical myelopathy patients who underwent C3-6 laminoplasty.
32761434|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
32761435|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
32761436|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
32761437|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
32761438|NCT04816357||Endometriosis & Migraine|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)~For the cases migraine needs to be confirmed during the interview according to the IHS criteria."
32761439|NCT04816357||Endometriosis|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)"
32761440|NCT05014529||Control group|Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
32761441|NCT05014529||OSA without CPAP group|Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
32761442|NCT05014529||OSA with CPAP group|Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.
32761443|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
32761444|NCT05014373|Active Comparator|Experimental: Favipiravir + Best supportive Care|Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14
32761445|NCT05014373|Placebo Comparator|Comparator: Best Supportive Care|Best supportive care or Standard Treatment includes oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases
32761446|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
32761447|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
32761448|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
32761449|NCT04762459|Active Comparator|Almonertinib|Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.
32761450|NCT04762459|Experimental|Almonertinib/Pemetrexed/Cisplatin|"Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years."
32761451|NCT04762459|Active Comparator|Pemetrexed/Cisplatin|"Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years."
32761452|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
32761453|NCT03078569|No Intervention|Control group|without testosterone treatment
32761454|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
32761455|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
32761456|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v~GA101: 1000 mg iv~Ibrutinib: 420 mg po daily"
32761457|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
32761458|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
32761459|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
32761460|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
32761461|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
32761462|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
32761463|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
32761464|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
33398357|NCT04482946|Experimental|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
33398358|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
32761465|NCT05005715|Active Comparator|Dexmedetomidine group|After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
32761466|NCT05005715|Placebo Comparator|Control group|After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
32761467|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
32761468|NCT02341651|No Intervention|Usual Care|No active intervention
33398359|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
33398360|NCT04482478|Experimental|EDL(Extract of Dolichos lablab Linne)|The randomly assigned target was given a Extract of Dolichos lablab Linne (EDL) 715 mg/day for 12 weeks.
33398361|NCT04482478|Placebo Comparator|Placebo comparator|The randomly assigned target was given a placebo for 12 weeks.
33398362|NCT03683732||Frenchteenagers|
32910894|NCT05731089|Active Comparator|group A|Patients in group A were planned to defer the cataract surgery until receiving two injections of Aflibercept at monthly interval, the third injection was then given intra-operatively.
33398363|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
32761469|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
32761470|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
32761471|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
32761472|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
32761473|NCT05013593|Experimental|Symptomatic RCE|Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
32761474|NCT05013593|Experimental|Healthy RCE|Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
32761475|NCT05013593|Placebo Comparator|Symptomatic PL|Bladder symptomatic group receiving placebo
32761476|NCT05013593|Placebo Comparator|Healthy PL|Healthy group without bladder symptoms receiving placebo
33072170|NCT05415215|Other|Arm A: Pertuzumab IV and Trastuzumab IV Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with pertuzumab and trastuzumab intravenously (PH IV) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH IV will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH IV will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
33072171|NCT05415215|Other|Arm B: PH FDC SC Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with the fixed dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH FDC SC will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH FDC SC will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
33072172|NCT05415215|Experimental|Arm C: Adjuvant PH FDC SC in Hospital, Then at Home|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm C will receive 3 cycles of PH FDC SC in the hospital and then 3 cycles of PH FDC SC in the home setting. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
33072526|NCT05000216|Experimental|Cohort F, Arm F1: Ad26.COV2.S + Withhold IS (B cell depletion therapy)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
32761477|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
32761478|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
32761479|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
32761480|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
32761481|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
32761482|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
32761483|NCT05005637|Experimental|Anti Tuberculosis Therapy|"Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid.~Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets.~Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)"
32761484|NCT05005637|Active Comparator|Oral Steroid|Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
33241130|NCT04104555|Active Comparator|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
33241131|NCT04104555|Experimental|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
33241132|NCT04104555|Experimental|Signposting to multimedia|OSTRICH 'signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting information to the multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
33241133|NCT04104555|No Intervention|Standard written information only|OSTRICH signposting to multimedia' Study within a trial (SWAT) Participants will receive the standard written information sheet only. This will not include signposting to the multimedia trial information resources, in the OSTRICH recruitment pack.
33241134|NCT04104555|Experimental|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card on or shortly before their birthday from the OSTRICH study team to encourage completion of questionnaires.
33241135|NCT04104555|No Intervention|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
33241136|NCT04049487|Active Comparator|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
33241137|NCT04049487|Experimental|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
33241138|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
33241139|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
33241140|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
33241141|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
33398364|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
33398365|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
33398366|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
33398367|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
33398368|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
33398369|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
33398370|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
33398371|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
33398372|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
33398373|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
33398374|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
33398375|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
33398376|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
33398377|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
33398378|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
33398379|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
33398380|NCT02961582|Experimental|Sacral Neuromodulation|
33398381|NCT02961582|Other|Personalized Conservative Treatment|
33398382|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
33398383|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
33398384|NCT04039503|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
33398385|NCT04039503|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
33398386|NCT04039503|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
33398387|NCT04039503|Placebo Comparator|Placebo|Placebo administered SC once a week.
33398388|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
33398389|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
33398390|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
33398391|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
33398392|NCT05032066|Experimental|HZN-825 300 mg once daily (QD)|Two 150 mg oral tablets given in the morning with a meal and two matching placebo tablets given in the evening with a meal; total daily dose 300 mg HZN-825.
33398393|NCT05032066|Experimental|HZN-825-300 mg twice daily (BID)|Two 150 mg oral tablets given in the morning with a meal and two 150 mg oral tablets given in the evening with a meal; total daily dose 600 mg HZN-825.
33398394|NCT05032066|Placebo Comparator|Placebo BID|Matching placebo tablets (2) given in the morning with a meal and matching placebo tablets (2) given in the evening with a meal; total dose 4 placebo tablets.
33241142|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
33241143|NCT01283295||Normal Volunteers|
32761485|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
32761486|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
32761487|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
32761488|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
32761489|NCT05013515|Experimental|Salivary Gland Carcinomas|Patients with Salivary Gland Carcinomas were given Surufatinib .
32761490|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
32761491|NCT05013671|Active Comparator|residents with BPPV|
32761492|NCT05013671|Other|residents without BPPV|
32761493|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
32761494|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
32761495|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
32761496|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
32761497|NCT05013203||Aseptic (uninfected) Revision Spine Surgery|Aseptic revision for indications including but not limited to hardware failure, adjacent segment pathology, radiculopathy, instability, cord compression.
32761498|NCT05013203||Spine Surgery for Degenerative Disease|Primary degenerative pathology surgery where a disc sample is extracted to enable spinal decompression or fusion. The potential primary surgeries include but are not limited to microdiscectomy, laminectomy, and lumbar and cervical fusion
32761499|NCT05013203||Septic (infected) Revision Spine Surgery|Spine surgery for known infection specifically: epidural abscess or septic revision. Epidural abscess must be managed surgically for inclusion. Septic revision cases include any surgery to address infected hardware from a previous spinal surgery.
32761500|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
32761501|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
32761502|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
32761503|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
32761504|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
32761505|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
32761506|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
32761507|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
32761508|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
32761509|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
32761510|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
32761511|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
32761512|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
32761513|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
32761514|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
32761515|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
32761516|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
32761517|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
32761518|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
32761519|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
32761520|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
32761521|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
32761522|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
32761523|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
32761524|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
32761525|NCT02345239|Experimental|Pantoprazole|Pantoprazole
32761526|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
32761527|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
32761528|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
32761529|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
32761530|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
32761531|NCT03081065|No Intervention|Control|Usual care
32761532|NCT04688203|Active Comparator|Magnesium sulfate infudsion|patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
32761533|NCT04688203|Active Comparator|Labetalol infusion|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
32761534|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
32761535|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
32761536|NCT04679233|Experimental|Arm 1: Intervention Arm|Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.
32761537|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
32761538|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
32761539|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
32761540|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
32761541|NCT05254951|Experimental|Patients enrolled in the protocol|Patients will receive a tidal volume challenge to assess fluid responsiveness and then a volume expansion bolus to classify them into responders and not responders
32761542|NCT05254561|Active Comparator|purified protein derivative (PPD)|Group A
32761543|NCT05254561|Active Comparator|Candida antigen.|Group B
32761544|NCT05254561|Active Comparator|Measles, Mumps and Rubella vaccine (MMR).|Group C
32761545|NCT05254561|Active Comparator|Triple combination of PPD, Candida antigen and MMR|Group D
32761546|NCT05254405|Experimental|Open-Label Infusion of Brexanolone|This is a single arm pilot study of open label brexanolone delivered intravenously over a continuous 60-hour period. Infusions will be administered in a certified healthcare setting in accordance with the Zulresso™ dosing, administration and safety guidelines.
32761547|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
32761548|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
33241144|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
32744202|NCT04464993|Active Comparator|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day)."
32761549|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
32761550|NCT04509973|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
32761551|NCT04509973|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
32761552|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
32761553|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
32761554|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
32761555|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
32761556|NCT04496167|Experimental|EN3835|EN3835 up to 1.74mg.
33398395|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
33398396|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
33398397|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
32761557|NCT04496167|Placebo Comparator|Placebo|Placebo
32761558|NCT04491253|Experimental|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
32761559|NCT04491253|No Intervention|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
32761560|NCT04480645|Experimental|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
32761561|NCT05254249|Active Comparator|Treatment Group|In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.
32761562|NCT05254249|Placebo Comparator|Placebo Group|In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.
32761563|NCT05254249|No Intervention|Healty Control Group|Healthy control group was not given any treatment. Stool samples were taken to examine the gut microbiota profile.
32761564|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
32761565|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
32761566|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Standard management of pain and other symptoms in the terminal phase."
32761567|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Clinically-assisted hydration~Standard management of pain and other symptoms in the terminal phase"
32761568|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
32761569|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
32761570|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
32761571|NCT03145363|Experimental|Intervention|receive interactive text messages
32761572|NCT03145363|Active Comparator|Control|Receive informational text messages
32761573|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
32761574|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
32761575|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
32761576|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
32761577|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
32761578|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
32761579|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
32761580|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
33398398|NCT05418114|No Intervention|Group B|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine only.
33398399|NCT05418114|Active Comparator|Group A|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate
33398400|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
33398401|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
33398402|NCT05528952|Experimental|Experimental Arm (Arm A)|Atezolizumab + Bevacizumab + UCPVax
33398403|NCT05528952|Other|Control Arm (Arm B)|Atezoliumab + Bevacizumab
33398404|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
33398405|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
33398406|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
33398407|NCT01364025|No Intervention|hysterectomy alone|
33398408|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
33398409|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
33398410|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
33398411|NCT04875936|Experimental|Motor Imagery and Contingent Neurofeedback (NFB)|This group will receive real-time fMRI NFB on the bases of participant's own brain activity
33398412|NCT04875936|Sham Comparator|Motor Imagery and Non-contingent Neurofeedback (NFB)|This group will receive group will receive fMRI NFB based on another participant's brain activity
33398413|NCT05189769|Experimental|CP/No REACT|Traditional Coping Power for 7th graders, no school wide REACT training
33398414|NCT05189769|Experimental|CP/REACT|Traditional Coping Power for 7th graders and school wide REACT training
33398415|NCT05189769|Experimental|CP+/No REACT|New, adapted Coping Power for 7th graders intervention with no school wide REACT training
33398416|NCT05189769|Experimental|CP+/REACT|New, adapted Coping Power for 7th graders, school wide REACT training
33398417|NCT03672812|No Intervention|placebo|0,5ml
33398418|NCT03672812|Experimental|liraglutide|0,5ml
33398419|NCT05417880|Active Comparator|Group 1 (Control group)|Continue with current oral anti-hyperglycemic regime
33398420|NCT05417880|Active Comparator|Group 2 (Voreta group)|Empagliflozin 10 mg OD
33398421|NCT05417880|Experimental|Group 3 ( Voreta + SunnyD PRO group )|Empagliflozin 10 mg OD + Vitamin D3 (2000 IU) + Vitamin K2 (100 mcg)
33398422|NCT05029726|Experimental|Investigational|Patients will undergo regional ESPB with bupivacaine plus clonidine in the holding area of the OR immediately prior to surgery. 30mL of 0.25% bupivacaine/1:200,000 epinephrine/50mcg clonidine will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
33398423|NCT05029726|Placebo Comparator|Control|Patients will receive a placebo injection of normal saline via the same ESPB technique. 30ml of normal saline will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
33398424|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
33398425|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
33398426|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
33398427|NCT05186883|Experimental|Treatment with allogenic parathyroid cells|Patients with postoperative hypoparathyroidism receiving standard treatment and allogenic parathyroid cells
33398428|NCT05186883|Active Comparator|Control|Patients with postoperative hypoparathyroidism receiving standard treatment
33398429|NCT05522244|No Intervention|standard CTA|Standard CTA performed as standard of care for Stroke Workup
33398430|NCT05522244|Experimental|extended CTA|The standard CTA will be extended 3 cm below the carina with the aim of increase the LAA thrombus detection
33398431|NCT05007652|Experimental|multiple myeloma cohort (KRN125)|
33398432|NCT05007652|Active Comparator|multiple myeloma cohort (KRN8601)|
33398433|NCT05007652|Experimental|malignant lymphoma cohort|
33398434|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
33398435|NCT01367145|Active Comparator|Omacor|
33398436|NCT01367145|Placebo Comparator|Placebo|
33398437|NCT05521698|Experimental|ARM 1 (apalutamide,TURBT)|Patients receive apalutamide PO QD on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of treatment is permitted in the absence of unacceptable toxicity. Patients undergo blood specimen collection at baseline and at time of TURBT.
32910895|NCT05731089|Active Comparator|group B|Patients in group B were planned to undergo cataract surgery first and received the first injection intra-operatively, then received two post-operative injections with a monthly interval.
32910896|NCT05653713|Experimental|CSL324|Intravenous (IV) dose of CSL324
32761581|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
32761582|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
32761583|NCT02335879|Experimental|Recombinant Human Follitropin|
32761584|NCT05005325|Active Comparator|Experimental group(Male)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
32761585|NCT05005325|Experimental|Experimental group(Female)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
32761586|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
32910897|NCT05653713|Placebo Comparator|Placebo|IV dose of 0.9% saline
32910898|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
33398438|NCT05521698|Active Comparator|ARM 2 (TURBT)|Patients undergo TURBT on day 21. Patients undergo blood specimen collection at baseline and at time of TURBT.
33398439|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
33398440|NCT02405572|Active Comparator|Formula 1|infant formula
33398441|NCT02405572|Active Comparator|Formula 2|infant formula
33398442|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
33398443|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
33398444|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.~Intervention: Food: Low carbohydrate food"
33398445|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
33398446|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
33398447|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
33398448|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
33398449|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
33398450|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
33398451|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan~400 meter walk test for physical fitness"
33398452|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
33398453|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
32761587|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
32761588|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
32761589|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
32761590|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
32761591|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
32761592|NCT05013125|No Intervention|Conventional Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo usual colonoscopy as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
32761593|NCT05013125|Active Comparator|ENDO-AID assisted Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo ENDO-AID assisted colonoscopy with all polyps treated as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
32761594|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
32761595|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
33398454|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
32761596|NCT05012579|Experimental|TAPS delivered by Cala device|Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
32898182|NCT03932240|Experimental|Fibrinogen Concentrate (FC)|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and FC after separation from bypass. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
33398455|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
33398456|NCT03672656|Experimental|pattern scanning laser system Pascal|
33398457|NCT03672656|Active Comparator|conventional laser|
33398458|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
33398459|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
33398460|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
33398461|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
33398462|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
33398463|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
33398464|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
33398465|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
33398466|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
33398467|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
33398468|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
33398469|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
33398470|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
33398471|NCT03672578|Placebo Comparator|No label|Participant will not see a label
33398472|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
33398473|NCT02414074|Other|Parent Education|Everyday Parenting Program
33398474|NCT01367379||Physician of internal medicine in Taipei city hospital|
33398475|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
33398476|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
33398477|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
33398478|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
33398479|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
33398480|NCT02413840|No Intervention|control group|Psychological counseling only.
33398481|NCT01360827|Experimental|Arm 1 (Part 1)|
33398482|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
33398483|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
33398484|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
33398485|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
33398486|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
33398487|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RP2D will be determined in this part with escalating doses of oral etrumadenant in combination with a fixed dose of IV zimberelimab.
33398488|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RP2D + zimberelimab
33398489|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RP2D + zimberelimab
33398490|NCT05166837|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33398491|NCT05166837|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33398492|NCT05166837|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33398493|NCT05166837|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33398494|NCT05166837|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33398495|NCT02414230||Experimental F 18 T807|
33398496|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
33398497|NCT01367535|Experimental|Arm 1|
33398498|NCT01367535|Experimental|Arm 2|
33398499|NCT01367535|Active Comparator|Arm 3|
33398500|NCT01367535|Placebo Comparator|Arm 4|
33398501|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
33398502|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
33398503|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
33398504|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
33398505|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
33398506|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
33398507|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
33398508|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
33398509|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
33398510|NCT05187663|Active Comparator|Study group|In the test group, implant surface decontamination was performed with photodynamic therapy.
33398511|NCT05187663|Active Comparator|Control group|In the control group, implant surface decontamination was performed with 1% chlorhexidine gel.
33398512|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
33398513|NCT03672422||Chronic Pancreatitis|"Children with at least:~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.~*irreversible structural changes:~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
33398514|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
32910899|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
33398515|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
33398516|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
33398517|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
33398518|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
33398519|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
33398520|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
33398521|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
33398522|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
33398523|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
33398524|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
33398525|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
33398526|NCT03679286||All subjects|No intervention
33398527|NCT04482712|Placebo Comparator|Placebo|Administration of placebo daily during hospitalization
33398528|NCT04482712|Active Comparator|Rapamycin|Administration of rapamycin (sirolimus) 1mg daily during hospitalization
33398529|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
33398530|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
33398531|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
33398532|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
33241145|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
33241146|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
33241147|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
33241148|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
32744203|NCT04464993|Active Comparator|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio."
33241149|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
33241150|NCT00761787||1|Heart transplanted subjects.
32761597|NCT05254015|Experimental|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|"Compensatory Cognitive Training (CCT) Modules (7 sessions). Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illnesses. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive impairments and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Exposure to Discarding and Acquiring Modules (19 sessions). Symptoms of acquiring and saving are themselves avoidance behaviors to avoid internal distress related to negative thoughts and emotions. ET utilizes in vivo exposure exercises taking place in the home to enhance generalization of their new skills. Fear hierarchies typically start with a space that has low clutter volume or there is less of an urge to save a particular type of item in that environment."
32761598|NCT05254015|Active Comparator|Case Management (CM)|Case Management (CM). CM consists of a set of well-established strategies commonly used in community service settings to address serious and complex problems in particularly vulnerable and often marginalized populations such as those with HD.
32761599|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
32761600|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
32761601|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
32761602|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
32761603|NCT04426279||patient with chronic inflammatory rheumatism|
32761604|NCT05012501||PVT group|（1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2) In accordance with the diagnostic criteria of portal vein thrombosis in the 2015 European Society of Hepatology Clinical Practice Guidelines: Hepatic Vascular Diseases. Color ultrasound, CT, MRI, and other imaging studies confirmed the presence of portal vein thrombosis and the specific location of the thrombosis.
32761605|NCT05012501||without PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
32761606|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
32761607|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
32761608|NCT05005169|Experimental|intrapartum streptococcal B detection by PCR|The automatons will be installed by the laboratory in the delivery rooms and used delocalized by the obstetrical teams. Verification and validation of results will be ensured by the microbiology laboratory team, according to the recommendations and procedures already in use for off-site biology.
32761609|NCT05005169|Active Comparator|"intrapartum streptococcal B detection by SGB culture strategy"|
32761610|NCT05253781|Experimental|Intervention|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
32761611|NCT05253781|Placebo Comparator|Control|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
32761612|NCT05012423|Placebo Comparator|SAD Cohorts 1 to 7: Participants Receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
32761613|NCT05012423|Experimental|SAD Cohorts 1 to 7: Participants receiving ECC0509|Participants in each SAD cohort will be randomized to receive 1 of 7 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg).
32761614|NCT05012423|Placebo Comparator|MAD Cohorts 1 to 3: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
32761615|NCT05012423|Experimental|MAD Cohorts 1 to 3: Participants receiving ECC0509|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (8 mg, 20 mg, or 40 mg) for 14 days.
32761616|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
32761617|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
33241151|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
33241152|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
33241153|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
33241154|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
33241155|NCT00758433|Placebo Comparator|3|Placebo patch
33241156|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
32761618|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
32761619|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
32761620|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
32761621|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
32761622|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
32761623|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
32761624|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
32761625|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
32761626|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
32761627|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
32761628|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
32761629|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
32761630|NCT05229367|Experimental|Eccentric isokinetic group|In this group, eccentric isokinetic training of hamstring muscle was performed.
32761631|NCT05229367|Active Comparator|Concentric isokinetic group|In this group, concentric isokinetic training of hamstring muscle was performed.
32761632|NCT02340247|Experimental|Placebo|150mL water
32761633|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
32761634|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
33241157|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
32761636|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
32761637|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
32761638|NCT02339857||No-touch vein grafts to LAD|
32761639|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
32761640|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
32761641|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
32761642|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
32761643|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
32761644|NCT05178823|Active Comparator|Corsodyl|Chlorhexidine
32761645|NCT05178823|Experimental|Solumium Oral|Chlorine dioxide
32761646|NCT05178823|Experimental|Listerine Total Care|Essential oils, sodium fluoride, zinc chloride
32761647|NCT05178823|Experimental|BioGate Si*CLEAN|Microsilver
32761648|NCT03105583||Pregnant women visiting the obstetrics department|
32761649|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
32761650|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
32761651|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
32761652|NCT03080831|Active Comparator|Glucion 5%|
33241158|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
33241159|NCT00584012|Experimental|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
33241160|NCT05435846|Experimental|Phase 1: Dose Escalation|Patients receive either 300 or 400 mg capmatinib orally, twice a day and 1.5 or 2 mg trametinib orally once a day on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33241161|NCT05435846|Experimental|Phase 1b: Dose Expansion|Patients will receive the recommended phase 2 dose (RP2D) or capmatinib in combination with trametinib determined by the safety profile of the Phase 1 group. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33241162|NCT04457336|Experimental|Tildacerfont Group 1|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
32744204|NCT04464993|Active Comparator|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio). Simple adaptive content (by SST bout, time of day)."
33241163|NCT04457336|Experimental|Tildacerfont Group 2|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
32761653|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
33241164|NCT04457336|Experimental|Tildacerfont Group 3|Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
33241165|NCT04457336|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 12 weeks.
33241166|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
33241167|NCT03933878||Donor BAL samples|No intervention will be administered
33241168|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
33241169|NCT00920270|Experimental|colistin group|nebulized colistin
33241170|NCT04080674||Parkinson's disease|30 participants
33241171|NCT04080674||Essential Tremor|10 participants
32744205|NCT04425291|Experimental|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
32761654|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
32744206|NCT04425291|Experimental|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
32744207|NCT04425291|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
32744208|NCT04879719|Experimental|Ego-depletion group|Participants in this condition are asked to suppress their emotion while watching an emotional video of a surgery. Suppressing the natural emotional reaction to such a video demands cognitive resources and thus can induce a state of ego-depletion.
33241172|NCT04080674||Dystonia|20 participants
33241173|NCT04078724|Active Comparator|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
33241174|NCT04078724|Experimental|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
33241175|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
33241176|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
33241177|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
33241178|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
33241179|NCT04454450|Experimental|Imaged prior to primary debulking surgery|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
33241180|NCT04454450|Experimental|Imaged pre/postneoadjuvant chemotherapy (NACT)|In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).
33241181|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
33241182|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
33241183|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
33241184|NCT04080596|Experimental|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
33241185|NCT04522154|Other|MR-TTE|Patient receiving cardiac magnet resonance imaging and echocardiography
33241186|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738
33241187|NCT04521686|Experimental|LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab|Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab
33241188|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
33241189|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
33241190|NCT04441814||Lung cancer screening subjects|Subjects enrolled in SMILE lung cancer screening trial
33241191|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
33241192|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
33241193|NCT04431518|Experimental|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
33241194|NCT04431518|Active Comparator|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
33241195|NCT04430738|Experimental|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
33241196|NCT04430738|Experimental|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
33241197|NCT04430738|Experimental|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
33241198|NCT04430738|Experimental|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
32744209|NCT04879719|Active Comparator|Control group|Participants in the control group are asked to watch the same emotional video. However, they are required to simply watch the video without suppressing any emotions.
32744210|NCT04879485|No Intervention|Standard transfusion|Includes standard transfusion with a mixture of red blood cells and plasma
32910900|NCT05371431|Experimental|non-BFR groups|Traditional rehabilitation training is designed according to postoperative orthopaedic rehabilitation guidelines. Traditional rehabilitation trainings include grip and pinch, wrist flexion with forearm pronated, wrist extension with forearm pronated, wrist flexion with forearm supinated, wrist extension with forearm supinated, prayer sign (wrist flexion), prayer sign (wrist extension), forearm pronation, forearm supination. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
32910901|NCT05371431|Experimental|BFR groups|Patients in the BFR group underwent the same traditional rehabilitation training protocol with non-BFR utilizing a medical grade tourniquet system (ATS 4000 TS，Zimmer Surgical, Inc. Dover). The ATS 4000 tourniquet system tailors the individualized tourniquet pressure to each patient following determination of the limb occlusion pressure (LOP), and studies have shown that 50% LOP is safe and effective in the rehabilitation of DRF. When the tourniquet system was used, LOPs were reassessed for every session before training, and pressures were continually monitored. Participants were to perform the entirety of each training (including intra-set rest periods) under 50% LOP with the tourniquets released during the 2-minute rest periods between sets. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
32910902|NCT05653557|Experimental|Shen Que Moxibustion group|
32910903|NCT05653557|No Intervention|Control group|
32910904|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
32910905|NCT05644977|Experimental|Cohort 1: Emraclidine Dose 1|Participants will receive emraclidine dose 1 or emraclidine-matching placebo tablets, orally, once daily (QD) up to Day 14.
32910906|NCT05644977|Experimental|Cohort 2: Emraclidine Dose 2|Participants will receive emraclidine dose 2 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
32910907|NCT05644977|Experimental|Cohort 3: Emraclidine Dose 3|Participants will receive emraclidine dose 3 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
32910908|NCT05644977|Experimental|Cohort 4: Emraclidine Dose 4|Participants will receive emraclidine dose 4 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
32910909|NCT05644977|Experimental|Cohort 5: Emraclidine Dose 5|Participants will receive emraclidine dose 5 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
32910910|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
32910911|NCT05730933|Experimental|Intervention|
32910912|NCT05730933|No Intervention|Control|
32910913|NCT05371197|Experimental|PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab)
32761655|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
33398533|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
32761656|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
32761657|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
32761658|NCT05005091|Active Comparator|oral carbohydrate|the patients drunk oral carbohydrate two hours ago preoperatively
32761659|NCT05005091|No Intervention|no oral carbohydrate|the patients did not drink oral carbohydrate preoperatively
32761660|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
33398534|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
33398535|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
33241199|NCT04430738|Experimental|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
33241200|NCT04430738|Experimental|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
33241201|NCT04430738|Experimental|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
32744211|NCT04879485|Active Comparator|Plasma|Transfusion with plasma
32744212|NCT04879485|Active Comparator|Red Blood cells|Transfusion with red blood cells
32744213|NCT04879407||Warfarin|Reference group
32744214|NCT04879407||Rivaroxaban|Exposure group
32910914|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
32910915|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
32910916|NCT05730855||Oral Lichen Planus|
32910917|NCT05730855||Leukoplakia|
32761661|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
32761662|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
32761663|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
32761664|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
32761665|NCT03077321|No Intervention|Control|Wait list control
32761666|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
32761667|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
32761668|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
32761669|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
32761670|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
32761671|NCT05012345|Experimental|4 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 4 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
32761672|NCT05012345|Experimental|6 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 6 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
32761673|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
32761674|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
32761675|NCT05012033||Group A|Patients started acutely on high dose prednisolone (>30mg for any inflammatory condition)
32761676|NCT05012033||Group B|Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.
32761677|NCT05012033||Group C|Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.
32761678|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
32761679|NCT05011877||Acute Hypercapnic Respiratory Failure patients with Sleep Disorders|Acute Hypercapnic Respiratory Failure patients with Sleep Disorders
32761680|NCT05011877||Acute Hypercapnic Respiratory Failure patients without Sleep Disorders|Acute Hypercapnic Respiratory Failure patients without Sleep Disorders
32761681|NCT03895099|Experimental|A - Early follicular phase|Treatment by desogestrel at day 1 to day 3
32761682|NCT03895099|Experimental|B - Medium follicular phase|Treatment by desogestrel at day 4 to day 7
32761683|NCT03895099|Experimental|C - Late follicular phase|Treatment by desogestrel at day 7 to day 11
32761684|NCT03895099|Experimental|D - Ovulatory Phase|Treatment by desogestrel at day 12 to day 15
32761685|NCT03895099|Experimental|E - Luteal phase|Treatment by desogestrel at day 16 to day 30
32761686|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
32761687|NCT02344303|Experimental|Part A|Fixed sequence, open label
32761688|NCT02344303|Experimental|Part B|4 way cross over, double blind
32761689|NCT05011955|Experimental|Mindfulness, compassion and intercare based Intervention|Four week, one hour peer week, online group intervention plus home work based on mindfulness, compassion and intercare based programs.
32761690|NCT05011955|Active Comparator|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work based on psychoeducation about stress, anxiety, selfcare and effective communication.
32761691|NCT05011955|Other|General curricular intervention|All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
32761692|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
32761693|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
32761694|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
32761695|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
32761696|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
32761697|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
32761698|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
32910918|NCT05730855||Healthy control|
32761699|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
33241202|NCT04430738|Experimental|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
32761700|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
32742591|NCT04488107|Experimental|Dose expansion cohort of FCN-437c + letrozole|"The dose expansion stage will be initiated after escalating to MTD.~Six patients will be treated with FCN-437c combined with letrozole.~DLT assessment and PK blood collection will be completed in the first 28-day cycle.~If DLT does not occur in the first three patients, 15 additional patients were enrolled to complete the expansion study of MTD group.~If one DLT occurs in the first three patients, three additional patients will be enrolled onal patients were enrolled and completed the MTD group.~Patients will be evaluated every 8 weeks until disease progression, intolerable toxicity, death, investigator's decision or patient's voluntary withdrawal from the study."
32742592|NCT04974957|Experimental|SHR-1701+BP102|
33241203|NCT04430738|Experimental|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
33241204|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
33241205|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
33241206|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
33241207|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
33241208|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
33241209|NCT02585726|Experimental|VenaSeal Treatment Arm|
33241210|NCT04079270|Experimental|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
33241211|NCT04079270|Active Comparator|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
33241212|NCT04640480|Experimental|Cohort 1|Dosage 1
33241213|NCT04640480|Experimental|Cohort 2|Dosage 2
33241214|NCT04640480|Experimental|Cohort 3|Dosage 3
33241215|NCT04640480|Experimental|Cohort 4|Dosage 4
33241216|NCT04640480|Experimental|Cohort 5|Dosage 5
33241217|NCT04640480|Experimental|Cohort 6|Dosage 6
33241218|NCT04509674|Experimental|Empagliflozin|
33241219|NCT04509674|Placebo Comparator|Placebo|
33241220|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
33241221|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
33241222|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
33241223|NCT05674760|Active Comparator|Arterial Blood Gas (ABG) arm - Control arm|Patients in this arm will undergo arterial blood gas sampling to monitor CO2 as per the British Thoracic Society guidance which is standard practice.
33241224|NCT05674760|Experimental|transcutaneous CO2 arm|Patients in this arm will undergo transcutaneous monitoring to monitor CO2. This will be the experimental arm.
33241225|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
33241226|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
33241227|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
32910919|NCT01746095|Experimental|Vancomycin hydrochloride inhalation powder|32 or 64 mg twice daily (BID)
32910920|NCT01746095|Placebo Comparator|Placebo inhalation powder|Matching placebo inhalation powder BID
32910921|NCT05371119|Experimental|Blood Flow Restriction|Use of the BFR cuff during the training intervention
32910922|NCT05371119|Active Comparator|control|No use of inflated cuff
32910923|NCT05730777|Experimental|Bifidobacterium Bifidum Oral Capsule in addition to conventional treatment|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
32910924|NCT05730777|Active Comparator|conventional antitumor treatment|Patients in the control group will receive conventional antitumor treatment only.
32910925|NCT04425239|Active Comparator|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
32910926|NCT04425239|Experimental|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
32910927|NCT01309802|No Intervention|placebo|no intervention
32910928|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
33241228|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
32910931|NCT00366093|Experimental|1|eszopiclone 3 mg
32910932|NCT00366093|Placebo Comparator|2|Placebo tablet
32910933|NCT04379999|Active Comparator|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
32910934|NCT04379999|Active Comparator|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
32910935|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
32910936|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
32910937|NCT04332887|Experimental|Multidimensional Exercise Program|Patients in this group will receive a 12 week exercise program including: (1) one 20-30 minute individual exercise consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) telephone follow-up once per week for 12 weeks.
32910938|NCT04332887|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
32910939|NCT05370807|Experimental|Regorafenib|Patients take 2 oral tablets of 40mg of Regorafenib daily.
32910940|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
32742593|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
32742594|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
32910941|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
32910942|NCT05730621|Experimental|Sarpogrelate Sustained Release/Aspirin|Sarpogrelate Sustained Release/Aspirin Combination Therapy for 12 weeks
32910943|NCT05730621|Active Comparator|Aspirin|Aspirin Monotherapy qd for 12 weeks
32742595|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
32742596|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
32761701|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
32761702|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
33241229|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
33241230|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
33241231|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
32761703|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
33241232|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
33241233|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
33241234|NCT04080440|Active Comparator|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
33241235|NCT04080440|Experimental|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
33241236|NCT04078802|Experimental|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
33241237|NCT04078802|Experimental|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
33241238|NCT04078880|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
33241239|NCT04078880|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
33241240|NCT04503278|Experimental|Part 1 CLDN6 CAR-T/CLDN6 CAR-T(A)|Dose escalation in lymphodepleted patients until the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
33241241|NCT04503278|Experimental|Part 2 Vaccine-modulated|Dose escalation until the MTD and/or RP2D.
33241242|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
33241243|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
33241244|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
33241245|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
33241246|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
33241247|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
33241248|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
33241249|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
33241250|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
33241251|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
33241252|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
33241253|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
33241254|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
33241255|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
33241256|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
33241257|NCT04417946|Experimental|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
33241258|NCT04417946|Active Comparator|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
33241259|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
33241260|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
33241261|NCT05402384|Experimental|Main study arm - AVTX-801|subjects will wash out from food grade D-galactose then be put on medical grade D-galactose
33241262|NCT05402384|Placebo Comparator|Placebo|placebo crossover
33241263|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
33241264|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
33241265|NCT00764985||Syncope|
33241266|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
33241267|NCT00765141||No treatment|
33241268|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
33241269|NCT02583698|Placebo Comparator|placebo|
33241270|NCT04632992|Experimental|Arm A: Entrectinib|Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
33241271|NCT04632992|Experimental|Arm B: Inavolisib|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
33241272|NCT04632992|Experimental|Arm C: Alectinib|Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
33241273|NCT04632992|Experimental|Arm D: Ipatasertib|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
33241274|NCT04632992|Experimental|Arm E: Atezolizumab + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
32910944|NCT01346072|Other|Tolvaptan|Single arm study
32910945|NCT05730543|Experimental|Volbella or Juvederm Ultra XC filler|Injection will not exceed a total of 4 cc of hyaluronic acid filler for combined treatment sessions (initial treatment + possible touch up treatment session).
32910946|NCT04313231||MDS|"Female and male patients aged 18 years and older~MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
32910947|NCT04313231||control|age-matched healthy persons
32910948|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
32910949|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
32910950|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
32910951|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
32910952|NCT05363007|Experimental|Upfront SI|Upfront nanoliposomal irinotecan + 5-FU/leucovorin plus SI
32910953|NCT05363007|Experimental|Add-on SI|Add-on SI following limited progression to nanoliposomal irinotecan + 5-FU/leucovorin
32910954|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
32910955|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
32910956|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
32742597|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
32742598|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
32742599|NCT04974723||Patients Treated with Abaloparatide|Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
32910957|NCT05727501|Active Comparator|Post isometric relaxation|This Group will be treated with baseline treatment of heating for 15min and rehab protocol post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
32910958|NCT05727501|Active Comparator|Post facilitation stretching|This Group will be treated with baseline treatment of heating for 15min and rehab protocol post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
32910959|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
32910960|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
32910961|NCT05725005|Experimental|Group 1|Group 1 will receive 10 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
32910962|NCT05725005|Experimental|Group 2|Group 2 will receive 20 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
32910963|NCT05357235||Treatment intervention group|NA (TDF or TAF) combined with PEG-IFN was used. PEG-IFN was injected subcutaneously once a week and a personalized course of 24 weeks was used.
32910964|NCT05357235||Non therapeutic intervention observation group|patients do not receive treatment and are observed and followed up regularly.
32910965|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
32910966|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
32910967|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
32910968|NCT05343429|Active Comparator|Benzydamine hydrochloride (BN)|15 ml of 0.15 % Benzydamine hydrochloride (BN) to dissolved in 15 ml plain water in a sterile container
32910969|NCT05343429|Active Comparator|Aspirin (Ap)|600 mg Aspirin tablets dissolved in 30 ml of plain water
32910970|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
32910971|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
32910972|NCT05691387|Experimental|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
32910973|NCT05691387|Active Comparator|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
32910974|NCT05319873|Experimental|Phase Ib (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib PO BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32910975|NCT05319873|Experimental|Phase II, Arm C (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32910976|NCT05319873|Experimental|Phase II,Arm A(ribociclib,tucatinib, trastuzumab, fulvestrant)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32910977|NCT05319873|Active Comparator|Phase II,Arm B(docetaxel,carboplatin,trastuzumab,pertuzumab)|Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32910978|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
32910979|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
32910980|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
33398536|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
33398537|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
33398538|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
33398539|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.~Intervention with the Selfit system include a set of mobility task exercises."
33398540|NCT03671876|No Intervention|Therapy and no intervention|"Control group:~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
33398541|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
33398542|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
33398543|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
33398544|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
33398545|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
33398546|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
33398547|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
32742600|NCT04974723||Patients Treated with Teriparatide|Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.
32761704|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
32761705|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
33241275|NCT04632992|Experimental|Arm F: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
33241276|NCT04632992|Experimental|Arm G: PH FDC SC|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
33241277|NCT04632992|Experimental|Arm H: PH FDC SC + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
32744215|NCT04886193|Experimental|FLOT combined with PD-1|"The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery Q2W.~If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection, and will continue to receive 4 cycles of FLOT regimen + Teripril after surgery. Anti-treatment, the treatment plan is the same as before.~After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year."
32744216|NCT04878939|Experimental|Anterior segment retraction using sliding mechanics (friction)|Power chain
32744217|NCT04878939|Experimental|Anterior segment retraction using segmental mechanics (frictionless)|T-loop
32744218|NCT04879173||Hyperthyroidism caused by Graves' disease|
32744219|NCT04879173||Hyperthyroidism caused by painless/subacute thyroiditis|
32744220|NCT04878861|Experimental|Training in blind field|All participants undergo this intervention. Internal control is comparing sighted and non-sighted parts of the field.
32744221|NCT04337073|Placebo Comparator|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
32744222|NCT04337073|Active Comparator|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
32744223|NCT04275141|Other|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
32744224|NCT04275141|Other|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
32744225|NCT04885959|Placebo Comparator|Usual diet|Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.
32744226|NCT04885959|Experimental|PPBe Diet|Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.
32744227|NCT04886037||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
32744228|NCT04886037||control|It consists of healty women between the ages of 18-45
33241278|NCT04632992|Experimental|Arm I: Trastuzumab Emtansine + Tucatinib|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
33241279|NCT04632992|Experimental|Arm J: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
33241280|NCT04632992|Experimental|Arm K: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
33241281|NCT04632992|Experimental|Arm L: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
33241282|NCT04632992|Experimental|Arm M: Ipatasertib + Paclitaxel|Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
33241283|NCT04632992|Experimental|Arm N: Atezolizumab + Tiragolumab|Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
33241284|NCT04632992|Experimental|Arm O: Pralsetinib|Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
33241285|NCT00762099|Active Comparator|1|Pregabalin Group
33241286|NCT00762099|Placebo Comparator|2|Placebo group
33398548|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
33241287|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
33241288|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
33241289|NCT04078958|Experimental|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
33241290|NCT04078958|Active Comparator|Whey|5 g whey in capsules, single oral dose
33241291|NCT00762333||Myocardial Infarction|
33241292|NCT04080206|Experimental|188-0551 Spray|Investigational Topical Spray Product
33241293|NCT04080206|Active Comparator|Reference Listed Drug (RLD)|FDA Approved Topical Cream
33241294|NCT00765219|Experimental|1|CBT with ACS
33241295|NCT00765219|Experimental|2|CBT with Counselor
33241296|NCT00765219|Active Comparator|3|Usual Care
33241297|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
33241298|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
33241299|NCT00765297|Experimental|1|Healthy young 18-40years
33241300|NCT00765297|Experimental|2|Healthy elderly
33241301|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
33241302|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:~Triple-negative breast cancer (TNBC)~Squamous cell lung cancers~Non-squamous cell lung cancers with KRAS mutations~Non-squamous cell lung cancers with wild-type KRAS"
33241303|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
33241304|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
33241305|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
33241306|NCT04048785|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
33241307|NCT04048785|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
33241308|NCT05674682|Other|Venipuncture or digital puncture for HIV test|MSM and transgender women aged 18 years or older, willing and able to sign informed consent to accept venipuncture or digital puncture for HIV testing
33241309|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
33241310|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
33241311|NCT02583620|Other|Emmetropic volunteers|Blood sample
33241312|NCT02583620|Other|High myopic volunteers|Blood sample
33241313|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
33241314|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
33241315|NCT05332730|Experimental|BAT2506|BAT2506 injection, 50 mg, subcutaneous administration. Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
33241316|NCT05332730|Active Comparator|Simponi® (EU commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
33398549|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
33398550|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
33072173|NCT05415215|Experimental|Arm D: Adjuvant PH FDC SC at Home, Then in Hospital|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm D will receive 3 cycles of PH FDC SC in the home setting and then 3 cycles of PH FDC SC in the hospital. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
33072174|NCT05415215|Other|Arm E: Adjuvant Trastuzumab Emtansine|Participants with pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy and surgery will enter Arm E to receive trastuzumab emtansine for 14 cycles. Trastuzumab emtansine will be administered IV in the hospital as per prescribing information.
33072175|NCT05415033|Other|BREAST-Q|
33072176|NCT05413915|Active Comparator|Imatinib|Standard of care imatinib at 300 or 400 mg PO daily for 52 weeks
33072177|NCT05413915|Experimental|Imatinib and Asciminib|Asciminib (60 mg PO daily for 52 weeks) will be added to standard of care imatinib (300 or 400 mg PO daily for 52 weeks)
32761706|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
32761707|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
32761708|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
32761709|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
32761710|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
32761711|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
32761712|NCT02343835|No Intervention|Control|The patients without treatment
32761713|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
32761714|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
32761715|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
32761716|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
32761717|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
32761718|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
32761719|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
32761720|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
32761721|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
32761722|NCT02338765|Active Comparator|Control|Physical activity only
32761723|NCT02338687|Active Comparator|Education|Educational sessions
32761724|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
33241317|NCT05332730|Active Comparator|Simponi® (US commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
33072179|NCT05410145|Experimental|D3S-001|"Dose Escalation, D3S-001 administered orally.~Dose Expansion, D3S-001 administered orally in selected cancer type patients."
33241318|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
33241319|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
33241320|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
33241321|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
33241322|NCT00765609||2|Paediatric Analgesia Slide (the new device)
33241323|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
33072180|NCT05405114|Experimental|HU-non-eligible - NDec plus placebo|HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day
33072181|NCT05405114|Experimental|HU-non-eligible - NDec plus NDec|HU-non eligible patients randomised to treatment with NDec on both days
33072182|NCT05405114|Placebo Comparator|HU-non-eligible - Placebo plus placebo|HU-non eligible patients randomised to treatment with placebo on both days
33072183|NCT05405114|Experimental|HU-active - NDec plus placebo|HU-active patients randomised to treatment with NDec on one day and placebo on the other day
33072184|NCT05405114|Experimental|HU-active - NDec plus NDec|HU-active patients randomised to treatment with NDec on both days
33241324|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
33072185|NCT05405114|Active Comparator|HU-active - HU|HU-active patients randomised to continue on open-label HU treatment
33072186|NCT05404542|Experimental|Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of tavapadon, 0.25 milligrams (mg) tablet, on Day 1.
32761725|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
32761726|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
32761727|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
32761728|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
32761729|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
33241325|NCT00765687|No Intervention|Observation|
33241326|NCT04340882|Experimental|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33241327|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
32761730|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
32761731|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
33072187|NCT05404542|Experimental|Normal Renal Function|Participants with normal renal function will receive a single dose of tavapadon, 0.25 mg tablet, on Day 1.
33072188|NCT05401318||Primary resectable colon and rectal cancer|Patients with primary resectable, localized colon and rectal cancer eligible for blood and tissue sampling for organoid development.
33241328|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
33241329|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
33241330|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
33241331|NCT02582606|Experimental|Regular|Regular meal pattern
32761732|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
32761733|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
32761734|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
32761735|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
32761736|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
32761737|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
32761738|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
33072191|NCT05377749|Experimental|FACT intervention|Families Addressing Cancer Together (FACT) intervention plus questionnaires
33072192|NCT05377749|No Intervention|Wait-list control condition|Participants assigned to the waitlist control condition only complete questionnaires during the study period. After they have completed their 6-week study activities, they will receive access to the FACT intervention.
33241332|NCT02582606|Experimental|Irregular|Irregular meal pattern
33241333|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
33241334|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
33241335|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
33241336|NCT04080362|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
33241337|NCT02585336|No Intervention|Observation|
33241338|NCT02585336|Experimental|Brief intervention|
33398551|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
33398552|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
32761739|NCT03518359|Experimental|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
32761740|NCT03518359|Active Comparator|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
32761741|NCT05134675||Consumption|Patients consuming homemade beer
32761742|NCT05134675||Not consumption|Patients are not consuming homemade beer
32761743|NCT05038813|Experimental|Anlotinib combined with TQB2450|Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.
32761744|NCT04987177|Experimental|Workload conditions to be tested|The intervention is the external workload a participant propels against. Participants will propel against N=20 different external workloads.External workload will be controlled by the wheelchair ergometer.
32761745|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
32761746|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
32761747|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:~Oral lactulose~500 mg nitazoxanide tablets twice daily"
32761748|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:~Oral lactulose~250 mg metronidazole tablets every 8 hours"
32761749|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:~Oral lactulose~Two 200 mg rifaximine tablets every 8 hours"
32761750|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Dietary Supplement: Korean Red Ginseng"
32761751|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Other: Placebo"
32761752|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
32761753|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
32761754|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
32761755|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
32761756|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
32761757|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
32761758|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
32761759|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
32761760|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
32761761|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
32761762|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
32761763|NCT02334085||HOW study participants|
32761764|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
32761765|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
32761766|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
32761767|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
32761768|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
32761769|NCT02338063|Experimental|1|Virtual Reality
32761770|NCT02338063|Experimental|2|Health Promotion
32761771|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
33398553|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
32761772|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
32761773|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
32761774|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
32761775|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
32761776|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
32761777|NCT05011799|Experimental|Arm I (health education)|Participants attend 1-2 monthly peer educator-led education sessions about PCA genetic testing over 3 hours each for 18 months.
32761778|NCT05011799|Active Comparator|Arm II (cancer educational materials)|Participants receive mailed informational materials about PCA risk, family history, and genetic testing.
32761779|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
32761780|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
32761781|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
32761782|NCT05011643||Symptomatic statin users|Statin users with self-reported muscle symptoms
32761783|NCT05011643||Asymptomatic statin users|Statin users without muscle symptoms
32761784|NCT05011643||Non-statin using controls|Participants not using statins
32761785|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
32761786|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
32761787|NCT05004623|Other|Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.
32761788|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
32761789|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
32761790|NCT05004779|Experimental|human stem cell media apply lesion|human media apply after non ablative laser treatment
32761791|NCT05004779|Sham Comparator|control condition lesion|normal saline apply after non ablative laser treatment
32761792|NCT05011019|Experimental|AL2846 Capsules|"During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.~During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle."
32761793|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
32761794|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
32761795|NCT05011097|Experimental|Y150|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
32761796|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
32761797|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
32761798|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
32761799|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
32761800|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
32761801|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
32761802|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
32761803|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
32761804|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
32761805|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
32761806|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
32761807|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
32910981|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
32910982|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
32910983|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
33398554|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
33398555|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
33398556|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
32910984|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
32910985|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
32910986|NCT04741737|Experimental|reSLNB arm|repeat SLNB procedure is performed in when the patient is diagnosed with ipsilateral breast tumor recurrence, who had undergone partial mastectomy and sentinel lymph node biopsy for primary operation.
32910987|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
32910988|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
32910989|NCT05254275|Experimental|Peri-implant mucositis sites|Peri-implant mucositis sites will be randomly assigned to ozone treatment.
32910990|NCT05254275|Experimental|Contralateral peri-implant mucositis sites|Contralateral peri-implant mucositis sites with respect to those treated with ozone will be assigned to chlorhexidine treatment.
33398557|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
33398558|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
33398559|NCT02409160|No Intervention|Control Group|
33398560|NCT05171595||no myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
33398561|NCT05171595||Myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
33398562|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg|Modakafusp alfa 0.001 up to 14 milligram per kilogram (mg/kg), infusion, intravenously (IV), once every week (Q1W) on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.
33398563|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 2 weeks (Q2W) on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
33398564|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
33241339|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
32761808|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
32761809|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
32761810|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
32761811|NCT05011175||Individuals with Parkinson's Disease|Individuals that have been diagnosed with Parkinson's Disease will be enrolled to participant in the survey research.
32761812|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
32761813|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
32761814|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
32761815|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
32761816|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
32761817|NCT04477525|Experimental|ESP nerve block|
32761818|NCT04477525|No Intervention|Standard of Care|Standard of care includes IV opioids, NSAIDs (commonly ketorolac), +/- acetaminophen. No regional anesthesia will be given to control patients.
32761819|NCT03079973|Experimental|P-3073|
32761820|NCT03079973|Placebo Comparator|Vehicle|
32761821|NCT03861871|Experimental|Fenfluramine Hydrochloride|"Study medication will be administered as equal doses twice a day in the morning and in the evening approximately 12 hours apart.~Patients will first be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 30 mg/d).~After completion of the Titration Period, patients will continue to receive the ZX008 0.8 mg/kg/day dose and be treated for an additional 12 weeks (Maintenance Period). Study medication will continue to be administered twice a day in the morning and in the evening, approximately 12 hours apart.~After completion of the Maintenance Period, patients will enter the Taper Period, where they will decrease from 0.8 mg/kg twice a day to a dose of 0.4 mg/kg twice a day (maximum 30 mg/day). After 4 days at this dose level, patients will decrease their dose to 0.2 mg/kg/day. On day 9 of the Taper Period, all participants will stop taking study medication."
32761822|NCT03076853||Patients with Pharmaceutical Record|
32761823|NCT03737149|Experimental|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
32761824|NCT03737149|No Intervention|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
32761825|NCT05004545|Experimental|group 1 Profol Infusion to CABG patients to check lactate level|Propofol infusion according to bodyweight will be given to check lactate level on CPB
32761826|NCT05004545|Active Comparator|sevoflurane will be given to group 2 to check lacate level|Sevoflurane MAC % will be given to CABG patients to check lactate level
32761827|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
32761828|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
32761829|NCT05003999|Experimental|Intermittent catheterization starting with a hydrophilic catheter (HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter i.e. SpeediCath ® (Coloplast A/S, Humlebæk, Denmark)
32761830|NCT05003999|Active Comparator|Intermittent catheterization starting with a non-hydrophilic catheter (non-HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter i.e. Self-Cath ® (Coloplast A/S, Humlebæk, Denmark); Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
32761831|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
32761832|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
32761833|NCT04463615|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
32910991|NCT04741191|Experimental|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown)
32910992|NCT04741191|Active Comparator|Conventional therapy|Patient education and counseling, In bed activities, Ambulation
32910993|NCT05165901|Experimental|Nociceptive pain|patients with joint pain (knee and shoulder), myofascial pain syndrome
33072198|NCT05372419|Experimental|Lebrikizumab|Participants will receive Lebrikizumab subcutaneously (SC).
32910994|NCT05165901|Experimental|Neuropathic pain|patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)
32761838|NCT05003765|No Intervention|Saline injection (CTRL)|Arm 1- 50 Patients-Control Group (CTRL): No Block (Saline) Post-operatively patients will receive 20 mL of Saline (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
32761839|NCT05003765|Experimental|SPIP Block|Arm 2-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
32761840|NCT05003765|Experimental|SPIP Block + Magnesium|Arm 3-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine + 200mg of magnesium sulfate (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
32761841|NCT05003765|Experimental|SPIP Block + Magnesium + Buprenorphine|Arm 4-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine+ 200mg of magnesium sulfate + buprenorphine (300mcg) (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
32761842|NCT05010863||Patients with early gastric cancer|
32761843|NCT05010863||Patients with advanced gastric cancer|
32761844|NCT05010863||healthy person|
32761845|NCT05010863||Patients with colorectal cancer|
32761846|NCT05010863||Liver cancer patients|
32761847|NCT05010863||Breast cancer patient|
32761848|NCT05010863||Patients with atrophic gastritis|
32761849|NCT05003375||Multiple Sclerosis (MS)|People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS < 6.0, normal vision (if necessary corrected), Dutch speaking.
32761850|NCT05003375||Healthy Controls (HC)|Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
33398565|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
33398566|NCT03215030|Experimental|Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg|Dose(s) for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive modakafusp alfa TBD as a single agent. Participants in at least 1 cohort will receive modakafusp alfa TBD and modakafusp alfa TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.
33398567|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 120 mg|Participants will receive modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
33398568|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 240 mg|Participants will receive modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
33398569|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
33398570|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
33398571|NCT01367613|Experimental|Arm 1|
33398572|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
33398573|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
33398574|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
33398575|NCT01361061||patients with liver cirrhosis|
33398576|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
33398577|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
33398578|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
33398579|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
32910995|NCT05165901|Experimental|Mixed pain|patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain
33398580|NCT02405338|Experimental|WT1/PRAME vaccination|
33398581|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
32910996|NCT05154825||Spine Surgery Participants|Spine surgical candidates that will be receiving posterior only surgery for spinal deformity
33398582|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
33398583|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
33398584|NCT01364337|Active Comparator|DASH diet|
33398585|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
33398586|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
33398587|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
33398588|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
32910997|NCT05138835|Active Comparator|Group 1|Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.
33398589|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
32910998|NCT05138835|Experimental|Group 2|Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.
32910999|NCT05099055|Experimental|Test group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with dexmedetomidine 3 mcg (0.75 mL) previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
33398590|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
33072202|NCT05369403|Experimental|Lebrikizumab|Participants will receive Lebrikizumab by subcutaneous (SC) injection.
33398591|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
33398592|NCT03671720|Experimental|personalized vaccine|
33398593|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
33398594|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
33398595|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
33398596|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
33398597|NCT01364415|Experimental|Pasireotide LAR|
33398598|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48)~Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks.~Intervention Name: Bimekizumab"
33398599|NCT03598790|Experimental|Bimekizumab dose regimen 2|"Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label).~Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2.~Intervention Name: Bimekizumab"
32761851|NCT05010239|Active Comparator|Intervention group|Patients in the intervention group will receive a 30-minute MBST session by a palliative care physician trained in mindfulness practice. The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing. Outcomes will be measured at baseline and at minute 30.
32761852|NCT05010239|Placebo Comparator|Control group|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
32761853|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
32761854|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
32761855|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
32761856|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
32761857|NCT05003297||patients whom were hospitalized for 3 days or less|
32761858|NCT05003297||patients hospitalized for more than 3 days|
32761859|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
32761860|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
32761861|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
33398600|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
33398601|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
33398602|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
33398603|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
32761862|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
33398604|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
33398605|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
33398606|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
33398607|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
33398608|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
33072203|NCT05368558|Experimental|Cariprazine Dose A|Participants will receive cariprazine Dose A daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose A for 18 weeks.
33398609|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
32761863|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
32761864|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
32761865|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
32761866|NCT05010395|No Intervention|Control|Individuals in this arm did not receive a letter.
33398610|NCT05513586|Experimental|TAK-771|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.
33398611|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
32761867|NCT05010395|Experimental|Arm 1: Basic Letter|Individuals received a letter with information about the benefits of enrolling, the February 15th sign-up deadline, the HealthCare.gov website, and the call center phone number.
32761868|NCT05010395|Experimental|Arm 2: Action|"Individuals in this arm received a letter that emphasized only minimal marginal effort is required; and used adjectives and verbs connoting action (e.g., almost done, quick, act now, and fast)."
32911000|NCT05099055|Active Comparator|Control group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with morphine 100 mcg, fentanyl 15 mcg and normal saline 0.25 ml previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
32911001|NCT01311674|Active Comparator|Schedule 1- Standard dose primary vaccination series|Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
33072204|NCT05368558|Experimental|Cariprazine Dose B|Participants will receive cariprazine Dose B daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
33398612|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
33398613|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
32911002|NCT01311674|Experimental|Schedule 2 - High dose primary vaccination series|Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
32911003|NCT05084625|Experimental|Arm A- access to digitized support, an app|Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
33241340|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
33241341|NCT05319080|Experimental|Individualized magnetic resonance imaging (MRI) guided rTMS|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive a 20-min once-daily rTMS sessions over a period of 2 weeks (weekends off), and therefore accrue a total of 10 rTMS stimulation sessions. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
32761869|NCT05010395|Experimental|Arm 3: Action, Implementation|Individuals in this arm received a letter similar to Arm 2, but with the addition of a calendar that draws attention to the February 15th deadline; and provided fill-in blanks in which the recipient can write the planned month, day, and time when they intend to enroll.
32761870|NCT05010395|Experimental|Arm 4: Action, Implementation, Picture|Individuals in this arm received a letter similar to Arms 2 and 3, but with the addition of an image of then HealthCare.gov Chief Executive Officer Kevin Counihan
32761871|NCT05010395|Experimental|Arm 5: Norm|"Individuals in this arm received a letter that included the following social norm sentence: Americans are enrolling but you haven't joined them."
32911004|NCT05084625|No Intervention|Arm B-standard follow-up|Patients in Arm B-will continue with standard follow-up from baseline and onwards
32911005|NCT04742829|Experimental|GROUP 1|Patients treated with INTRAVIT® tablets
32911006|NCT04742829|No Intervention|GROUP 2|patients who will not take any medical therapy to overlap with the activity described for INTRAVIT® tablets.
32911007|NCT05578209|Experimental|Active|"Participants received the intervention of iTBS (The total pulse of every session is 1200 pulses) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).~*iTBS = intermittent theta burst stimulation"
32911008|NCT05578209|Sham Comparator|Sham|Participants received the sham intervention of iTBS (sham-coil) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).
32761872|NCT05010395|Experimental|Arm 6: Norm, Pledge|"Individuals in this arm received a letter that included a statement, to be checked in agreement, that I pledge to Get Covered at Healthcare.gov."
32911009|NCT05574309|Sham Comparator|Fallers|population of patients who have fallen from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort
32911010|NCT05574309|Other|non fallers|population of patients who did not fall from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort
32761873|NCT05010395|Experimental|Arm 7: Loss Aversion|"Individuals in this arm received a letter that warned You risk paying a fee of $325 or 2% of your income-whichever is higher."
32761874|NCT05010395|Experimental|Arm 8: Kitchen Sink|Individuals in this arm received a letter that includes all behavioral dynamics except for the pledge (due to space limitations).
33398614|NCT03213704|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO or via NG- or G-tube BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, an x-ray, bone scan, and/or MIBG scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.
33398615|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
33398616|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
33398617|NCT04035473|Active Comparator|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
33398618|NCT04035473|Active Comparator|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
33398619|NCT02405026||HIV infected patients|HIV infected patients with asthma
33398620|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
33398621|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
33398622|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor"
33398623|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence"
33398624|NCT04032977|Experimental|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
33398625|NCT04032977|Active Comparator|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
33398626|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
33398627|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
33398628|NCT04030247|Experimental|Plant Sterol|South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
33398629|NCT04481698||Mesoglycan|All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy)
33398630|NCT04481698||Control|standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners)
33398631|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
33398632|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
33398633|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
32761875|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
32761876|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
32761877|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
32761878|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
33241342|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33241343|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33241344|NCT05314868||Primary cohort|Pediatrics or adults who underwent cardiac repair surgery that nessecitated the use of a PhotoFix patch.
33241345|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
33241346|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
33241347|NCT02585258|Experimental|arm A|prednisolone 5 mg per day
33241348|NCT02585258|Placebo Comparator|arm B|placebo capsules once per day
33241349|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
33241350|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
33241351|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
33241352|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
33241353|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
33241354|NCT00762567|Experimental|1|phenylephrine
33241355|NCT04338620|Experimental|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
33398634|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
33072205|NCT05368558|Placebo Comparator|Placebo|Participants will receive placebo daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose C for 18 weeks.
33072206|NCT05366686|Experimental|Frailty and Quality of Life in Patients With Heart Failure|Patients in this group will receive a 12 week exercise program including: (1) one 40-60 minute individual consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) Nutritional consultation; (4) telephone follow-up once per week for 12 weeks
33072207|NCT05366686|No Intervention|Frailty and Quality of Life|Patients in this group maintain their daily life activities, and there is no intervention given.
33241356|NCT04338620|Active Comparator|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
33241357|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
33241358|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
33241359|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
33072208|NCT05364424|Experimental|R/R DLBCL|Participants will receive up to 3 21-day cycles of glofitamab, rituximab, ifosfamide, carboplatin, and etoposide (glofit-R-ICE).
33241360|NCT05520710|Experimental|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
33241361|NCT05520710|Active Comparator|Educational Group|The education group will receive information about self-management of cognitive symptoms at the time of randomization, a common intervention for adults with mild Traumatic Brain Injury.
33241362|NCT00766389||1|Defined glaucoma patients
33241363|NCT00766389||2|Glaucoma suspects and normal controls
33241364|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
33398635|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
33072215|NCT05360966|Experimental|AR-15512 Ophthalmic Solution (0.003%)|0.003% AR-15512 to be administered BID for 90 days. Both eyes will be treated.
33072216|NCT05360966|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
33072217|NCT05359445|Experimental|Dose-Finding Escalation/De-escalation (Phase Ia) and Extension Part (Phase Ib)|"Dose-Finding Escalation/De-escalation of IMA401 (Phase Ia)~IMA401 monotherapy extension cohort following the determination of the recommended dose for extension (RDE) (Phase Ib)"
33398636|NCT02408224||one arm|patients on Ticagrelor
33072218|NCT05358171|Experimental|HIgh UPF (Ultra-processed foods)|Participants will consume a diet containing 81% total energy from UPF for 6 weeks
33072219|NCT05358171|Active Comparator|No UPF|Participants will consume a diet containing 0% total energy from UPF for 6 weeks
33072220|NCT05357989|Experimental|10 mg Buntanetap,|Buntanetap 10 mg oral capsule with daily administration for a period of 6 months
33398637|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
33398638|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
33241365|NCT04335110|Other|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
33241366|NCT04628936|Experimental|KZR-616 45 mg + standard therapy (open-label)|All patients will receive a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration will end for all patients in Study KZR-616-003E when the last patient enrolled has completed 48 weeks of dosing.
33241367|NCT04323956|Experimental|Arm I (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33241368|NCT04323956|Active Comparator|Arm II (parsaclisib, R-CHOP, polatuzumab vedotin)|Patients receive parsaclisib PO once daily QD on days 1-10 or 1-14, polatuzumab vedotin IV, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33241369|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
33241370|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
33241371|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
33241372|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
33072221|NCT05357989|Experimental|20 mg Buntanetap|Buntanetap 20 mg oral capsule with daily administration for a period of 6 months
33072222|NCT05357989|Placebo Comparator|Placebo|Placebo oral capsule with daily administration for a period of 6 months
33072223|NCT05355935|Experimental|Part 1: Treatment Dose 1|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 1 or placebo, once on Day 1.
33072224|NCT05355935|Experimental|Part 1: Treatment Dose 2|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 2 or placebo, once on Day 1.
33072225|NCT05355935|Experimental|Part 2|Participants will be randomized to 1 of 4 treatment sequences (ABCD, BDAC, CADB, DCBA).
33072226|NCT05352815|Experimental|IcoSema|
33072227|NCT05352815|Active Comparator|Insulin icodec|
33241373|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
33241374|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
33241375|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
33241376|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
33241377|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
32745201|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
33241378|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
32745202|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
32745203|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
32745204|NCT03206957|Other|Study group|Down Syndrome children
32745205|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
32745206|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
32745207|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
32745208|NCT03206723|Active Comparator|Group 1|1. Standard care
32745209|NCT03206723|Active Comparator|Group 2|"Standard care~Bandage contact lens"
32745210|NCT04840407|Experimental|SHARP coach arm|The SHARP Peer Coach supports the direct care HHA and indirectly support the patient/family caregiver to enhance the patient's post-stroke recovery through two main pathways: 1) culturally sensitive, patient-centered reinforcement of rehabilitation regimens (prescribed physical/occupational exercises/training); and 2) early recognition and reporting of barriers to the rehabilitation therapist regarding adherence and recovery, including: a) environmental obstacles, b) family-related issues, c) psychological/clinical barriers (e.g., depression/anxiety).
32745211|NCT04840407|No Intervention|Usual care arm|
32745212|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
32745213|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
32745214|NCT04840563|Experimental|Kalifilcon A lenses|Commercially available kalifilcon A lenses (Bausch + Lomb)
32745215|NCT04840563|Active Comparator|Dailies Total1|Dailies Total1 (Alcon)
32745216|NCT04840563|Active Comparator|Precision1|Precision1 (Alcon)
32745217|NCT04840251|Experimental|Intervention|The treatment group will have a physiotherapy well-being review and be referred for rehabilitation. They will be seen after 6 months for follow-up
32745218|NCT04840251|No Intervention|Control|The control group will have initial assessments then receive brief advice on exercise. They will also be followed up after 6 months
32745219|NCT04840251|Other|Qualitative|to understand how it feels to take part in the well-being review, we will interview some participants who have already had this kind of treatment and ask questions about their experiences of it and how it was for them. We are also interested to know what differences they felt it made so that we can help to decide about the things we want to measure as outcomes in the interventional of the study.
32745220|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
32745221|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
32745222|NCT04856709|Other|study group|Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
32745223|NCT04857021|Active Comparator|GABA|Take GABA capsule once daily before sleep for 14 days.
32745224|NCT04857021|Placebo Comparator|Placebo|Take placebo capsule once daily before sleep for 14 days.
32745225|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
32745226|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
32745227|NCT04846023|Experimental|amplitude EEG (aEEG) via VEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes.
32745228|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
32745229|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
32745230|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
32745231|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
32745232|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
32745233|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
33241379|NCT04314128|Other|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.~Healthy controls will be recruited to match the patients."
33241380|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
33241381|NCT00759369|Experimental|1|Water prescription
32742601|NCT04488029|Experimental|Experimental Group|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
32911011|NCT05561751|Experimental|GPC-100 in combination with propranolol;|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol; or"
33241382|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
33241383|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
33241384|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
33241385|NCT00759447||3D Imaging with commercial Mammography Device|
33241386|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
33241387|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
33241388|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
33241389|NCT00766857|Experimental|1. Exenatide|
33241390|NCT00766857|Active Comparator|2. Insulin glargine|
33241391|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
33241392|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
33241393|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
33241394|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
33241395|NCT05394662|Experimental|Transcervical Gynecological Procedure + Juveena Hydrogel|Transcervical Gynecological Procedure + Juveena Hydrogel
33241396|NCT05394662|No Intervention|Transcervical Gynecological Procedure alone (standard of care)|Transcervical Gynecological Procedure alone (standard of care)
33241397|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
33241398|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
33241399|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
33241400|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
33398639|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
33398640|NCT04482790|Active Comparator|Conventional celluloid matrix|Conventional celluloid matrix technique in management of black triangle
33398641|NCT04482790|Experimental|Bioclear cervical matrix|Bioclear cervical matrix with injection molding technique in management of black triangle
32742602|NCT04488029|Active Comparator|Control Group 1 [Conventional Workbook Therapy]|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.
32742603|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
32742604|NCT03060681|No Intervention|C group|
33398642|NCT03738527|Experimental|TXA arm|
33398643|NCT03738527|Placebo Comparator|Placebo arm|
32911012|NCT05561751|Experimental|GPC-100 in combination with propranolol and G-CSF|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol and G-CSF."
32911013|NCT05556681||Treated with the investigational BD™ Sirolimus Drug Coated Catheter|Patients treated with the BD™ Sirolimus Drug Coated Catheter
32911014|NCT05081193|Experimental|Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy|Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
32911015|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
32911016|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
32911017|NCT04590963|Experimental|Arm A (monalizumab and cetuximab)|monalizumab in combination with cetuximab
32911018|NCT04590963|Active Comparator|Arm B (placebo and cetuximab)|placebo in combination with cetuximab
32911019|NCT01248104|Active Comparator|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
32911020|NCT01248104|Active Comparator|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
32911021|NCT01725815|Experimental|HARP Intervention|
32911022|NCT01725815|No Intervention|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
32911023|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
32911024|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
33398644|NCT03738449|Experimental|Group 1|"Period 1: D484~Period 2: CKD-387"
33398645|NCT03738449|Experimental|Group 2|"Period 1: CKD-387~Period 2: D484"
33398646|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
33398647|NCT03174262|No Intervention|Control Group|
33398648|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
33398649|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
33398650|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
33398651|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
33398652|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
33398653|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
33398654|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
33398655|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
33398656|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
33398657|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
33398658|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
33398659|NCT03671564|Experimental|Dose Escalation - Milademetan|All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
33398660|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
33398661|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
33398662|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
33398663|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
33398664|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
33398665|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
33398666|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
33398667|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
33398668|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
33398669|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
33398670|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
33398671|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
33398672|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
33398673|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
33398674|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
33398675|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
33398676|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
33398677|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
33398678|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
33398679|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
33398680|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
33398681|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
33398682|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
33398683|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
32911025|NCT05019651|Experimental|Single Arm- Apollo Wearable System|Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
33241401|NCT04624256|Experimental|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
33241402|NCT00762879||No treatment|
33241403|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
32911026|NCT01747343|Experimental|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
32911027|NCT04968249||Gold 0|Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted.
32911028|NCT04968249||Gold 1|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 >= 80% predicted.
32911029|NCT04968249||Gold 2|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-79% predicted.
32911030|NCT04968249||Preserved Ratio Impaired Spirometry (PRISm)|Participant shall be between ages 30-55 years and have: ≥10 year smoking history, post-bronchodilator of FEV1 50-79% predicted and a predicted FEV1/FVC ≥ 0.70.
32911031|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
32911032|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
32911033|NCT01748045|Experimental|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
32911034|NCT01748045|Placebo Comparator|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
32911035|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
32911036|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
32911037|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding or clinically relevant non-major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
33241404|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
32761879|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable. Once the high dose RP2D and schedule of ASP1951 in combination with pembrolizumab has been determined, expansion cohorts may be opened to enroll participants with NSCLC (all PD-L1 status), NSCLC PD-L1 high, SCCHN and cervical cancer (if any of these tumor specific expansion cohorts are not already opened). Also, low dose cohorts of ASP1951 in combination will be opened in NSCLC (all PD-L1 status), SCCHN and cervical cancer for further evaluation of response and safety and establishing a possible low dose RP2D based on clinical and biomarker activity.
32761880|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
32761881|NCT02331433|Experimental|Experimental: 1|
32761882|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
32761883|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
32761884|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
32761885|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
32761886|NCT02327221|Placebo Comparator|Placebo|
32761887|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
32761888|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
32761889|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
32761890|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
32761891|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
32761892|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
32761893|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
32761894|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
32761895|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
32761896|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
32761897|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
32761898|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
32761899|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
32761900|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
32761901|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
32761902|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
32761903|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
32761904|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
32761905|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
32761906|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
32761907|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
32761908|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
32761909|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
32761910|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
32761911|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
32761912|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
32761913|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
32761914|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
32761915|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
33241405|NCT00766935||1 - lymphoedema group|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
33241406|NCT00766935||2 - healthy individuals|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
33398684|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
33398685|NCT04481854|Experimental|Cricoid pressure group|Patients of this group will recieve cricoid pressure during direct laryngoscopy.
33398686|NCT04481854|Experimental|left paratracheal pressure group|Patients of this group will recieve left paratracheal pressure during direct laryngoscopy.
33398687|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
33398688|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
33277308|NCT00776321|Experimental|Eprotirome dose 2|
33241814|NCT04990232|Experimental|Immunotherapy|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation [(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.
33241815|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
33241816|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
33241817|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
33241818|NCT04076618|Experimental|Weight Loss plus Vest|
33241819|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
33241820|NCT04076618|Active Comparator|Weight Loss|
33241821|NCT00776451||1|Subjects diagnosed with Dry AMD
33241822|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
33241823|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
33241824|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
33241825|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
33241826|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
33241827|NCT00667875|Placebo Comparator|1|
32776443|NCT04792645|Placebo Comparator|Placebo|10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
33241828|NCT00667875|Active Comparator|2|Naltrexone
33241829|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
33241830|NCT05056610|Experimental|Patients with IBS or FI|Food antigens are added to duodenal mucosa during CLE
33241831|NCT05056610|Experimental|healthy controls|Food antigens are added to duodenal mucosa during CLE
33241832|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
33241833|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
32761983|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32761984|NCT05077813|Active Comparator|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32761985|NCT05077813|Placebo Comparator|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days 50- 50-
32761986|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
32761987|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
32761988|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
32761989|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
32761990|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
32761991|NCT00914251|Active Comparator|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
33241834|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
32761992|NCT00914251|Placebo Comparator|Placebo|
33241835|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
33241836|NCT00772395|Active Comparator|Risedronate|
32761993|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
32761994|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
32737115|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
33241837|NCT00772395|Placebo Comparator|Placebo|
33241838|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
33241839|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
32761995|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
32761996|NCT05076955|Experimental|Treatment of Diabetic Foot Ulcer|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
32761997|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
32761998|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
32761999|NCT05076721|Experimental|Simulation group|The simulation training group will receive a simulation training of a sepsis case which will see the participants implementing one-hour bundle sepsis with a high-fidelity manikin.
32762000|NCT05076721|Experimental|Conventional group|The conventional training group will receive a case-based discussion of a sepsis case which will see the participants implementing one-hour bundle sepsis.
32762001|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
32762002|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
32762003|NCT05077111|Experimental|Group A|sole Thoracic Epidural Anesthesia
32762004|NCT05077111|Active Comparator|Group B|General Anesthesia with One Lung Ventilation
32762005|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
32762006|NCT05075863|Experimental|Clomiphene Citrate|A total of 39 women were given clomiphene citrate, 100mg from 3 to 7 days of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
32762007|NCT05075863|Experimental|Letrozole|A total of 39 women were given letrozole, 5mg from day 3 to 7 of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
32762008|NCT05072119||Patients with PM|All patients underwent PM implantation
32762009|NCT05072119||Patients with ICD|All patients undeerwent ICD implantation
32762010|NCT05072119||Patients with ILR|All patients underwent ILR implantation
32762011|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
32762012|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
32762013|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
32762014|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
32762015|NCT05076331||Health and Aging Brain Study Cohort|Health and Aging Brain Study participants age 50 and older.
32762016|NCT05070325|Experimental|Cold application group (Group 1)|In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
32762017|NCT05070325|Experimental|Shotblocker group (Group 2)|The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
32762018|NCT05070325|Experimental|Control Group (Group 3)|The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
32762019|NCT05068141|Experimental|SG001 plus Nab-Paclitaxel|Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.
32762020|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
32762021|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
32762022|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
32762023|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
33241840|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
32762024|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
33241841|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
33241842|NCT05325398|Active Comparator|patients with NAFLD|17 patients will receive molecular hydrogen
33241843|NCT05325398|Placebo Comparator|probands in the control group|13 probands in the control group who will receive placebo.
33241844|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
33241845|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
33241846|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
33241847|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
33241848|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
33241849|NCT04060862|Experimental|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
33241850|NCT04060862|Placebo Comparator|Phase 3: Placebo + Palbociclib + Fulvestrant|
33241851|NCT05673746|Active Comparator|Arm A|"Treatment for peripheral neuropathy (including neuropathic pain), according to the standard of care (e.g. Cetirizine, Gabapentin). Patient will be followed-up as per protocol for a total of 9 weeks ."
33241852|NCT05673746|Experimental|Arm B|"In addition to the treatment for peripheral neuropathy and neuropathic pain, according to the standard of care (e.g. Cetirizine, Gabapentin), patient will receive acupuncture administration twice a week and for a 6-week treatment period. Patient will also be followed-up for 3 weeks after the end of treatment."
33241853|NCT00772473||1 group, usual acute triptan treatment|
33241854|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
33241855|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
32762025|NCT05050435||Early extubated (in operating room) patients after valvular cardiac surgery|
32762026|NCT05050435||Later extubated (in ICU) patients after valvular cardiac surgery|
32762027|NCT03142165|Experimental|BMS-986263|
32762028|NCT03142165|Placebo Comparator|Placebo|
32762029|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
32762030|NCT02330029|Active Comparator|Pinaverium|
32762031|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
32762032|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 minutes);~Social media (intensive reminders);~Regular personalized what's app interaction ( up to 2 months duration)"
32762033|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 mintues);~Social media ( less intensive reminders)"
32762034|NCT05076019|Experimental|Atorvastatin 80 mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
32762035|NCT05076019|Placebo Comparator|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
32762036|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
32762037|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
32762038|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
32762039|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
32762040|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
32762041|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
32776444|NCT04792645|Experimental|Memantine|10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
33241856|NCT04054544|Experimental|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
33241857|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
33241858|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
33241859|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
33241860|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
33241861|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
33241862|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
33241863|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
33241864|NCT03436550||Patients with Chronic Liver Disease|
33241865|NCT03436550||Control Group|
33241866|NCT00669903|Experimental|1|AZD0328 low dose
33241867|NCT00669903|Experimental|2|AZD0328 Optimal dose
33241868|NCT00669903|Experimental|3|AZD0328 High dose
33241869|NCT00669903|Placebo Comparator|4|Placebo Comparator
33241870|NCT00776763|Experimental|Avastin|
33241871|NCT00772551|Active Comparator|1|
33241872|NCT00772551|Active Comparator|2|
33241873|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
33241874|NCT00776841|Experimental|Dose 1|Dose 30 mg
33241875|NCT00776841|Experimental|Dose 2|Dose 100 mg
33241876|NCT00776841|Experimental|Dose 3|Dose 300 mg
33241877|NCT00776841|Experimental|Dose 4|Dose 900 mg
33241878|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
33241879|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
33241880|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
33241881|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
33241882|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
33241883|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
33241884|NCT04047615|Experimental|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
33241885|NCT03759392|Experimental|Omecamtiv Mecarbil|Omecamtiv mecarbil was administered as an oral modified-release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. The dose could be increased based on plasma concentrations at Weeks 2 and 6.
33241886|NCT03759392|Placebo Comparator|Placebo|Participants randomized this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.
33241887|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit~Serum bank : Additional samples for serum bank at each visit if possible~DNA banq : Additional sample for DNA banq at inclusion visit if possible~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
33241888|NCT00777075|Active Comparator|L-arginine|
33241889|NCT00777075|Placebo Comparator|placebo|
33241890|NCT04075760|Experimental|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
33241891|NCT04075760|Placebo Comparator|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
33241892|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
33241893|NCT04051346|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
33241894|NCT04051346|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
33241895|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
33241896|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
33241897|NCT00667719|Experimental|Aliskiren/Amlodipine/Hydrochlorothiazide|Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
33241898|NCT04032704|Experimental|Part A: Non-randomized LV monotherapy|Monotherapy dosing schedule 1.
33241899|NCT04032704|Experimental|Part B: Non-randomized LV monotherapy|Monotherapy dosing schedule 2.
33241900|NCT04032704|Experimental|Part C - Arm 1: Randomized LV monotherapy|Monotherapy dosing schedule 3.
33241901|NCT04032704|Experimental|Part C - Arm 2: Randomized LV combination therapy|Combination dosing schedule 1.
33241902|NCT04032704|Experimental|Part C - Arm 3: Randomized LV combination therapy|Combination dosing schedule 2.
33241903|NCT00777387|Active Comparator|1|slow-freeze
33241904|NCT00777387|Active Comparator|2|vitrification
33241905|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
33241906|NCT03433898|Experimental|Part 1|
33241907|NCT03433898|Experimental|Part 2|
33241908|NCT03433898|Experimental|Part 3|
33241909|NCT00780429||1|MMF+cyclosporine
33241910|NCT00780429||2|MMF+tacrolimus
33241911|NCT00780429||3|MMF+sirolimus
33241912|NCT00780507||1|Patients are in a state of remission
33241913|NCT00780507||2|Patients are in a flare
33241914|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
33241915|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
33241916|NCT00780585||1|Subjects who participated in previous Org 24448 trials
33241917|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
33241918|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
33241919|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
32762042|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
32762043|NCT03143647||Control|"Female~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1~Not pregnant"
32762044|NCT03143647||Case|"Female~Pregnant with possible pre-eclampsia~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1"
32762045|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
32762046|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
32762047|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
32762048|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
32762049|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
32762050|NCT04988971|Experimental|Group C|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsules, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
32762051|NCT04988971|Placebo Comparator|Group D|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsule simulated placebo, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
32906438|NCT00910208|Experimental|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
32762052|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
32762053|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
32762054|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
32762055|NCT05003219||ERAS group|patients received posterior cervical open-door laminoplasty under ERAS mode
32762056|NCT05003219||Conventional group|patients received posterior cervical open-door laminoplasty under routine perioperative management mode
32762057|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
32762058|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
32762059|NCT03076541||patients with restless legs syndrome|
32762060|NCT04931875||Total-body PET/CT (uExplorer)|The diagnostic value of dynamic parameters(K1、Ki etc) to evaluate the prognosis of lymphoma compared to the static ones(SUV、MTV、TLG etc).
32762061|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
32762062|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
32762063|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
32762064|NCT05002907||General adult population living along the Maroni River in French Guiana and Suriname|General adult population living along the Maroni River in French Guiana and Suriname, upstream from Apatou. All adults (men and women) 18 years or older of both sexes will be able to participate in the study, in French Guiana and Suriname. Participation will be based on volunteering and signing informed consent. The acceptability and diversity of recruitment will be improved by seeking community support through community leaders and local associations and through appropriate communication (radio spots, posters in health centers and public establishments) before the survey .
32762065|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
32762066|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
32762067|NCT05000879|Experimental|MMB for Moms|Subjects will receive digital delivery of Mindful Mood Balance for Moms for 12 weeks. Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
32762068|NCT05000879|No Intervention|Waitlist Control|Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
32762069|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
32762070|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
32762071|NCT05003063|Active Comparator|Donepezil|5mg Donepezil will be administered in pill form.
32762072|NCT05003063|Placebo Comparator|Placebo|5mg placebo will be administered in pill form.
32762073|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
32762074|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
32762075|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
32762076|NCT05002673|Experimental|SLEEPERONE|
32762077|NCT05002673|Experimental|COMFORTIN|
32762078|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
32762079|NCT05001035|Experimental|Zinc carbonated hydroxy apatite|Toothpaste to be added on white spot lesions in dental enamel
32762080|NCT05001035|Experimental|Bioactive glass|Toothpaste to be added on white spot lesions in dental enamel
32762081|NCT05001035|Experimental|Poly amido amine|Resinous material to be painted on white spot lesions in dental enamel
32762082|NCT05001035|No Intervention|Control|No material to be added
32762083|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
32762084|NCT05032651|Experimental|GROUP A-AI (model) Arm Description:|Artificial intelligence assisted platform supported system for the clinical physicians to prescribe ESA dose to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
32762085|NCT05032651|Experimental|GROUP B-AI (model) Arm Description:|ESA dose prescribed by clinical physicians as regular care to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
32762086|NCT05000723||PJI patients|"Patients (older than 18 years) with PJI of a total hip replacement treated at University Hospitals Leuven.~Diagnosis of PJI of the hip is made based on the EBJIS 2021 criteria. Patients will receive standard of care."
32762087|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
32762088|NCT05002517|Experimental|Tociliziumab group|Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
32762089|NCT05002517|Active Comparator|Metilprednisolone group|Patients in this arm will receive a daily intravenous dose of 250 mg methylprednisolone for 3 days.
32762090|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
32906439|NCT00910208|Active Comparator|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
32906440|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
33401940|NCT03298867|Placebo Comparator|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
32762091|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
33401941|NCT02906930|Experimental|3 mg oral semaglutide|
32762092|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
33401942|NCT02906930|Experimental|7 mg oral semaglutide|
33401943|NCT02906930|Experimental|14 mg oral semaglutide|
32762093|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
32762094|NCT05002205||COVID-19|exposed cohort with a diagnosis of COVID-19 in the last 6 months
32762095|NCT05002205||no history of COVID-19|non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.
32762096|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
32762097|NCT05002361|Active Comparator|Treatment A+B|24 mg dexamethasone i.v. perioperatively
32762098|NCT05002361|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively
32762099|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
32762100|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
32762101|NCT05002283|Experimental|Study group|the patients undergo free gingival graft harvest from the palate using a patient specific guide
32762102|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
32762103|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
32762104|NCT05001971|Experimental|Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
32762105|NCT04855123|Other|patient|
32762106|NCT05000801|Experimental|DC vaccine|Vaccination with autologous or HLA-matched donors' WT1/TERT/survivin loaded DCs plus follow-up care.
32762107|NCT02329093|Experimental|Bone Signal Changes|
32762108|NCT05000411|Experimental|Experimental group|
32762109|NCT05000411|Placebo Comparator|Control group|
32762110|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
32762111|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
32762112|NCT05001893||The use of a mixture of BonAlive® putty and autologous bone|A retrospective case-controlled study will be created to compare the use of a mixture of BonAlive® putty and autologous bone to autologous bone alone for clinical safety and efficacy.
32762113|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
32762114|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
32762115|NCT05001659|Other|computer simulator|training students ACLS by one computer simulator
32762116|NCT05001659|Other|mannequin simulator|training students ACLS by one mannequin simulator
32762117|NCT02328781|Experimental|Experimental|Drug-eluting stent
32762118|NCT05000099||phone calls|patients choosing phone calls as preferred communication technique
32762119|NCT05000099||video call|patients choosing video calls as preferred communication technique
32762120|NCT05000255|Experimental|Intervention 1: According to DGP|For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of post-COVID-19 patients (DGP, 2020). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients)
32762121|NCT05000255|Active Comparator|"Intervention 2: According to Cacioppo E.A.S.E."|The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients), too. The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions.
32762122|NCT05000255|No Intervention|Care as Usual; Standard psychological Support|The patients receive standard care from the psychologists, as is usual in this unit. No intervention is carried out.
32762123|NCT04498741|Experimental|EDP-938 and tacrolimus interaction (Part 1)|
32762124|NCT04498741|Experimental|EDP-938 and dabigatran interaction (Part 2)|
32762125|NCT04498741|Experimental|EDP-938 and rosuvastatin interaction (Part 3)|
32762126|NCT04498741|Experimental|EDP-938 and midazolam interaction (Part 4)|
32762127|NCT04999943|Active Comparator|Hypomemylating agent monotherapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle)
32762128|NCT04999943|Experimental|Combined cellular immunotherapy（eDC）with Hypomemylating agent therapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle) with Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin
32762129|NCT04938635|Experimental|VIT-2763 60 mg QD|VIT-2763 60 mg administered once daily
32762130|NCT04938635|Experimental|VIT-2763 60 mg BID|VIT-2763 60 mg administered twice daily
32762131|NCT04938635|Experimental|VIT-2763 120 mg BID|VIT-2763 120 mg administered twice daily
32762132|NCT04938635|Placebo Comparator|Placebo|Placebo capsule administered twice daily
32762133|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
32762134|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
32762135|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
32762136|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
32762137|NCT04932941|Experimental|MP1032|Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
32762138|NCT04932941|Placebo Comparator|Placebo|Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
32762139|NCT04932395|Experimental|Anshen Buxin Liuwei Pills|15 pills/time, 2 times/day, orally，for 8 weeks
32762140|NCT04932395|Placebo Comparator|Placebo|15 pills/time, 2 times/day, orally. for 8 weeks
32762141|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
32762142|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
32762143|NCT03538639||3|Healthy adult volunteers
32762144|NCT04932239|Experimental|Road traffic crashes first aid education module|It is an education module aiming to address the topics related to first aid: Recognizing emergency, Call for help, Scene safety, Airway and breathing, Haemorrhage control, First aid kit, Immobilization of fractures and transport of injured people.
32762145|NCT04932239|Placebo Comparator|Tuberculosis prevention education module|This education module covers the definition of the disease, types ways of prevention in working place, and its management
32762146|NCT04714879|Experimental|Slow oscillating transcranial direct current stimulation (so-tDCS)|7 experimental daytime naps with so-tDCS of different frequencies (fixed frequency of 0.75 Hz versus individually adapted frequency) and durations (5 min, 2 min, 30 sec) (Crossover assignment, applicable for each participant)
32762147|NCT04714879|Sham Comparator|Sham stimulation|sham so-tDCS during a daytime nap (Crossover assignment, applicable for each participant)
32762148|NCT04698811|Other|VIRTUAL ENEAGRAM: QUALITY OF LIFE, STRESS AND ANXIETY.|Training and testing battery.
33277309|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
33277310|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
32762149|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
33277311|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
33277312|NCT00989534|Experimental|Sleep loss and circadian misalignment|
32911093|NCT04486833|Experimental|Phase 1|"Dose Escalation: Up to 3 sequential dose escalation cohorts will be treated with quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.~Quaratusugene ozeplasmid doses will be evaluated (0.06 [starting dose], 0.09, and 0.12 mg/kg) until the RP2D is identified.~Expansion: Once the RP2D is identified, 2 expansion cohorts will be treated with the RP2D of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle until disease progression or unacceptable toxicity."
32911094|NCT04486833|Experimental|Phase 2 Combination|Patients will be treated with the RP2D of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.
32911095|NCT04486833|Active Comparator|Phase 2 Active Comparator|Patients will continue on monotherapy osimertinib 80 mg fixed dose oral daily tablet until disease progression.
32911096|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
32911097|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
32911098|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
32911099|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
32911100|NCT01751399|Experimental|LY2605541-Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541
32911101|NCT01751399|Experimental|LY2605541-Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
32911102|NCT01751399|Experimental|LY2605541-Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
32911103|NCT01751399|Experimental|LY2605541-Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
32911104|NCT05498727||Maternal Newborn and Child Health (MNCH) Clinics|Clients attending for routine service delivery at MNCH clinics.
33398768|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
32911105|NCT05498727||HIV Clinics|Patients attending for HIV clinic services
32911106|NCT05498727||Tuberculosis (TB) Clinics|Patients attending TB clinic services.
32911107|NCT04414215|Experimental|Cognitive training|Emotional working memory training
32911108|NCT04414215|Placebo Comparator|Placebo training|Placebo working memory training
33401944|NCT02906930|Placebo Comparator|Placebo|
32762150|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
32762151|NCT03076307|Experimental|Parkinson's disease|
32762152|NCT03076307|Active Comparator|Control group|
33277313|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
33401945|NCT05198596|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33401946|NCT05198596|Active Comparator|AZD1222|ChAdOx1 nCoV-19 vaccine
32762153|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
32762154|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
33277314|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
33277315|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
33277316|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
33277317|NCT04819022||Musculoskeletal disorder|
32762155|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
32762156|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
32762157|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
32762158|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
32762159|NCT04993937|Active Comparator|Control group|Control group will follow their daily routine activities.
32762160|NCT04993937|Experimental|Experimental group|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
32762161|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
32762162|NCT04993547|Experimental|Parents present, peers present|The children are accompanied by their parents during the COVID-19 testing, and a visible covid-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
32762163|NCT04993547|Active Comparator|Parent present, peers absent|The children are also accompanied by their parents, but a covered COVID-19 swab test waiting line is set-up whereby the children are unable to observe their peers being tested.
32762164|NCT04993547|Active Comparator|Parents absent, peers present|Parents are absent during the COVID-19 testing, and a visible COVID-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
32762165|NCT04993547|Active Comparator|Parents absent, peers absent|Parents are absent, and a covered COVID-19 swab test waiting line is set-up whereby the children are not able to observe their peers being tested.
32762166|NCT04654429|Placebo Comparator|Lower OT temperature with placebo (LP)|Lower OT temperature with placebo This group function as a main control arm. Incidence of PSS will be documented usual / standard OT temperature which is 17-19 degree celsius, and without giving any pharmacological intervention to prevent PSS.
32906441|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
33081999|NCT04626856|Experimental|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
32906442|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
32906443|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
33082000|NCT04626856|Placebo Comparator|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
33277318|NCT00074581|Experimental|1|Participants will begin ART in addition to receiving HIV primary care
32762167|NCT04654429|Active Comparator|Higher OT temperature with placebo (HP)|Higher OT temperature with placebo This group will receive one non-pharmacological intervention, which is higher OT temperature 19-22 degree celsius. The aim of this intervention is to reduce heat loss therefore incidence of PSS for obstetric population coming for lower segment cesarean section (LSCS) by reducing the temperature gradient between the body and environment.
32762168|NCT04654429|Active Comparator|Lower OT temperature with IV Ondansetron 4mg (LO)|Lower OT temperature with Ondansetron 4mg intravenous. This group also will receive one pharmacological intervention, which is IV ondansetron 4mg to prevent incidence of PSS under standard OT temperature 17-19 degrees.
32762169|NCT04654429|Active Comparator|higher OT temperature 19-22 and IV ondansetron 4mg (HO)|This group will receive 2 interventions - higher OT temperature 19-22 and IV ondansetron 4mg. This group is designed to see if when both intervention combined, will further reduce the incidence of PSS among obstetrics population.
32762170|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
32762171|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
32762172|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
32762173|NCT04639999||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
32762174|NCT04993079|Experimental|Clotild®|"Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 100 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study.~Sixty clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire."
32762175|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
32762176|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
32762177|NCT04993235||Sotos Syndrome|Children and adolescents with Sotos Syndrome
32762178|NCT04993235||Beckwith-Wiedemann Syndrome|Children and adolescents with Beckwith-Wiedemann Syndrome
32762179|NCT04993235||Control group|Adolescents with typical development
32762180|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
32762181|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
32762182|NCT03075605||Subjects with previous attack|Subjects with previous attack
32762183|NCT03075605||Controls|Controls
32762184|NCT04151485|Experimental|Mind/Body Group|All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
32762185|NCT04151485|Active Comparator|Support Group|All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
32762186|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
32762187|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
32762188|NCT04999007|No Intervention|Control|Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.
32762189|NCT04999007|Experimental|Intervention|Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.
32762190|NCT03979339|Experimental|blood sample collection|For all participants whatever the group Groups 0 and 4: Healthy volunteers Group1: Metastatic HER2-positive breast cancer Group 2: Advanced CA-125 positive ovarian cancer Group 3: Metastatic PSA-positive castrate-resistant prostate cancer Participants will receive the following interventions because they are enrolled in the study: blood sample collection of 32mL (4x8mL in EDTA tubes)
32762191|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
32762192|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
32762193|NCT03970993|Experimental|Group 1a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart and an optional booster vaccination 12 months after the third dose
32762194|NCT03970993|Experimental|Group 2a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
32762195|NCT03970993|Experimental|Group 3a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
32762196|NCT03970993|Experimental|Group 4a|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
33082001|NCT04626856|Placebo Comparator|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
32911109|NCT01752413|Experimental|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
32911110|NCT01752413|Active Comparator|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (>20 micrograms/L female, >30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
32911111|NCT05492253|Active Comparator|Infant cereal|Oatmeal cereal
32911112|NCT05492253|Experimental|Infant fruit|Pureed prunes
32911113|NCT05492253|Experimental|Infant vegetable|Pureed carrots
32911114|NCT05492253|Experimental|Infant meat|Pureed beef
32911115|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
32911116|NCT05490459|Experimental|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
32911117|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
32911118|NCT05481879|Experimental|Placebo-Controlled MAD Period: DYNE-101|Participants will be randomized to receive ascending doses of DYNE-101, once every 4 weeks (Q4W) or once every 8 weeks (Q8W) for up to 24 weeks.
33082002|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
32911119|NCT05481879|Placebo Comparator|Placebo-Controlled MAD Period: Placebo|Participants will be randomized to receive DYNE-101 matching placebo, Q4W or Q8W for up to 24 weeks.
32911120|NCT05481879|Experimental|Treatment Period: DYNE-101|"Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q4W or Q8W for up to 24 weeks.~Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q4W or Q8W for up to 24 weeks."
33082003|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
32911121|NCT05481879|Experimental|Long-Term Extension Period: DYNE-101|Participants will receive DYNE-101, Q4W or Q8W for up to 96 weeks.
33082004|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
33082005|NCT00219440|Experimental|A|ACTOS plus standard diet
33082006|NCT00219440|Experimental|B|Actos plus structured diet
33082007|NCT00219440|Experimental|C|Metformin plus standard diet
32906444|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
32911122|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
32762197|NCT03970993|Experimental|Group 5|Volunteers will receive 2 doses of 10μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 2μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
32762198|NCT03970993|No Intervention|Group 6|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
32762199|NCT03970993|No Intervention|Group 7|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
32762200|NCT03970993|Experimental|Group 1b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M, 4 weeks apart followed by an optional vaccination booster 12 months after the third dose.
32762201|NCT03970993|Experimental|Group 2b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks.
32762202|NCT03970993|Experimental|Group 3b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart.
32762203|NCT03970993|Experimental|Group 4b|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks.
32762204|NCT04998695|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
32762205|NCT04998695|Active Comparator|Sunflower oil|Intake of 45 g/d of sunflower oil as the only source of oil in the diet
32762206|NCT03935971|Experimental|Subjects with Allergic Contact Dermatitis|Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
32762207|NCT04998461||Obese patients with normal renal function|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
32762208|NCT04998461||Obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
32762209|NCT04998461||Non-obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
32762210|NCT04998461||Non-obese patients with normal renal function (control group)|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
32762211|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
32762212|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
32762213|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
32762214|NCT04998383|Experimental|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort
32762215|NCT04998383|Experimental|Noninvasive ventilation|Respiratory assistance is provided by a NIV either Puritan Bennet 840 (Covidien, U.S.A.), EngströmCarestation (GE Healthcare, Finland) or Hamilton-G5 (Hamilton Medical, Germany), will be used for conventional non-invasive ventilation via an oronasal mask that helps patients to cope with their Breathlessness. Settings will be adjusted based on the clinical assessment of the respiratory therapist as per standard practice.
32762216|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
32762217|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
32762218|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
32762219|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
32762220|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
32762221|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
32762222|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
32762223|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
32762224|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
32762225|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
32762226|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
32762227|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
32762228|NCT03075371|Active Comparator|intragastric glucose administration|
32762229|NCT03075371|Placebo Comparator|intragastric water administration|
32762230|NCT04998071|Active Comparator|ROUTINE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.25% bupivacaine 0.4 ml/kg. in each side.
32762231|NCT04998071|Active Comparator|ALTERNATIVE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.125% bupivacaine 0.4 ml/kg. in each side.
32762232|NCT03734263|Experimental|open label|sodium phenylbutyrate
32762233|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
32762234|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
33082008|NCT04626700|Experimental|iNAP|
33082009|NCT04626700|Active Comparator|CPAP|
32911123|NCT04750707|Other|single arm|Single arm, open label of hydroxyurea starting at 20mg/kg and increased to 30mg/kg depending on clinical need and according to standard guidelines
33082010|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
33082011|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
32762235|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
33072527|NCT05000216|Experimental|Cohort F, Arm F2: Alternative mRNA Vaccine + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
33072528|NCT05000216|Experimental|Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (B cell depletion therapy)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
33072529|NCT05000216|Experimental|Cohort D, Arm D4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
33072530|NCT05000216|Experimental|Cohort E, Arm E4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
33082012|NCT04626934|Active Comparator|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
33082013|NCT04626934|Experimental|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
33398769|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
33398770|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
32776445|NCT04832035|Experimental|"Standard psychotherapeutic care + coordinated and peer supported mental health care"|"Participants receive standard psychotherapeutic care in the public healthcare system. For participants and therapists in this group standard care and additional organisational support is available which is labeled coordinated and peer supported mental health care. This includes several additional organisational assistance components that are currently not part of the services of the public mental health care system, i.e. a coordination center, trained peers to support treatment utilisation, a support and training center for therapists, and an interpreter pool.This is Treatment as Usual plus coordination and peer support."
33082014|NCT04626778|Active Comparator|Peroxyl|1.5% Hydrogen Peroxide mouthwash
33082015|NCT04626778|Placebo Comparator|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
33082016|NCT04626973|Experimental|Intensive-targeting group|
33082017|NCT04626973|Active Comparator|Conventional-targeting group|
33082018|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
33082019|NCT00242463|Placebo Comparator|Placebo|
33082020|NCT00561808|Experimental|Observational|
33082021|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
33082022|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
33082023|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
33082024|NCT00561964|Experimental|1|
33082025|NCT00561964|Placebo Comparator|2|
33082026|NCT04626193|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
33082027|NCT04626193|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
33082037|NCT04626232|Experimental|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
33082038|NCT04626232|Other|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
33082039|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
33082040|NCT00242541|Experimental|Octreotide acetate|
33082041|NCT04625998|Experimental|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
33082042|NCT04625998|No Intervention|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
32911124|NCT04692519|Experimental|Intervention|The Duet 2.0 intervention is comprised of six training modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. Modules were translated into Spanish. Participants will watch one Duet intervention module a week and have up to 3 months to complete all 6 modules. As intervention families review the modules on their own time at home, they will receive remote coaching from an assigned interventionist and weekly module-specific fidelity/comprehension questions. Interventionists will check-in weekly via phone or video (~30-60 minutes), whichever is more convenient for the family. During the check-in, interventionists will do teach-back about the module, guide the family on how to incorporate the strategies into their daily lives, and provide feedback. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.
32911125|NCT04692519|No Intervention|Delayed Access|Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions.
32911126|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
32911127|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
32911128|NCT04387695|Experimental|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
32911129|NCT04387695|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
33082043|NCT04625842|Experimental|Patient focus group|Patients who received radiation treatment
33082044|NCT04625842|Experimental|Family focus group|Family of patients who received radiation treatment
33082045|NCT04625686||Inpatient Treatment|Inpatient psychiatric treatment
33082046|NCT04625686||OCIC Treatment|In-person outpatient crisis intervention
33241920|NCT04030910|Experimental|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
33241921|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
33241922|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
33241923|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
33398771|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
33082047|NCT04625686||Telehealth Therapy Treatment|Virtual outpatient therapy
33082048|NCT04625686||No Show Group|Participant who do not attend recommended treatment
32776446|NCT04832035|Other|"Standard psychotherapeutic care"|Participants receive standard psychotherapeutic care in the public healthcare system. For participants in this group no additional organisational support is available. This is Treatment as Usual.
32776447|NCT04792177|Experimental|Intervention group|Emotion regulation skills training group
32776448|NCT04792177|No Intervention|waitlist control group|The control group will not receive any intervention during the trial but will be offered the same treatment at the end of the six-months follow-up assessment.
32776449|NCT04832347|Experimental|Exercise group|Exercise group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
32776450|NCT04832347|Experimental|Vagus group|Vagus therapy will be applied to Group 2 for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
32776451|NCT04832347|No Intervention|Control group|Control group will be followed as a control group and no application will be made.
32906445|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
33082049|NCT04625920|Experimental|Virtual reality|women allocated to undergo hysteroscopy with Vr System
33082050|NCT04625920|Experimental|Standart care|women allocated to undergo hysteroscopy without VR
33082051|NCT00219674|Active Comparator|2|Group II
33082052|NCT00219674|Active Comparator|3|
33082053|NCT00219674|Active Comparator|4|
33082054|NCT00219674|Active Comparator|1|Group I
33398772|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
32906446|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
32906447|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
33082055|NCT04625959|Active Comparator|Base BT|16 weekly sessions of behavioral therapy.
33082056|NCT04625959|Experimental|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
33082057|NCT04625959|Experimental|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
33082058|NCT04625959|Experimental|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
33398773|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
33082059|NCT04625959|Experimental|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
33082060|NCT04625959|Experimental|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
33398774|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
33082061|NCT04625959|Experimental|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
33082062|NCT04625959|Experimental|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
33082063|NCT04625959|Experimental|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
33277655|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
32898473|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
32906448|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
33082064|NCT04625959|Experimental|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
33082065|NCT04625959|Experimental|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
33398775|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
33072531|NCT05000216|Experimental|Cohort F, Arm F4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction
33072532|NCT05000216|Experimental|Cohort A, Arm A1P: Moderna mRNA-1273, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33398776|NCT02407912|No Intervention|Control|No intervention was applied.
33398777|NCT02411500|Experimental|Formulation A|
33072533|NCT05000216|Experimental|Cohort A, Arm A2P: BNT162b2, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33072534|NCT05000216|Experimental|Cohort A, Arm A4P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
33072535|NCT05000216|Experimental|Cohort A, Arm A5P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
33082066|NCT04625959|Experimental|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
33398778|NCT02411500|Experimental|Formulation B|
32737116|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
32737117|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
33082067|NCT04625959|Experimental|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
32906449|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
32762236|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
32762237|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
32762238|NCT03671473|Experimental|Focused|fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
32762239|NCT03671473|Active Comparator|Radial|rESWT (2000shocks, 4 Bar, 5Hz)
32762240|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
32762241|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
32762242|NCT03623893|Other|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
33241924|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
32762243|NCT03623893|No Intervention|Control group|Unilateral inguinal hernia repair.
32898474|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
33241925|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
33241926|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
33241927|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
33241928|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
33241929|NCT04076306|Other|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
33241930|NCT04075214|Sham Comparator|delayed-active tAN|
33241931|NCT04075214|Experimental|active tAN|
33241932|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
33241933|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
33241934|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
33241935|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
33241936|NCT04076774|Experimental|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
33241937|NCT04076774|Active Comparator|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
32898475|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
33072536|NCT05000216|Experimental|Cohort B, Arm B1P: Moderna mRNA-1273, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33072537|NCT05000216|Experimental|Cohort B, Arm B2P: BNT162b2, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
32898476|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
32911130|NCT04638075|No Intervention|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
33398779|NCT02411500|Experimental|Formulation C|
33398780|NCT02411500|Experimental|Formulation D|
33398781|NCT02411500|Experimental|Formulation E|
33398782|NCT02411500|Experimental|Formulation F|
33398783|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
33398784|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
33398785|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
33398786|NCT03170128|Active Comparator|Outpatient Physical Therapy|
33398787|NCT03170128|Active Comparator|Home Exercises|
33398788|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
33398789|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
33398790|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
33398791|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
33398792|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
33398793|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
33398794|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
33398795|NCT02407678|No Intervention|Control|Untreated eye
33398796|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
33398797|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
33398798|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
33398799|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
33398800|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
33398801|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
33398802|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
33398803|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
32911131|NCT04638075|Experimental|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
32911132|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
32911133|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
32911134|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
32911135|NCT01753739|Experimental|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
32911136|NCT01753739|Active Comparator|Placebo|Placebo nasal spray BID for 14 days
32911137|NCT01753739|Experimental|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
32911138|NCT01753739|Experimental|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
32911139|NCT01753739|Experimental|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
32911140|NCT04348383|Experimental|Defibrotide + standard therapy|Defibrotide + standard therapy
32911141|NCT04348383|Placebo Comparator|Placebo|Placebo + standard therapy
32911142|NCT04498845|Active Comparator|Basic intervention group|Participants in the basic intervention group will have a 1-hour in-home assessment plan and family educational session.
32911143|NCT04498845|Experimental|Intermediate intervention group|Participants in the intermediate intervention group will have a 1-hour in-home assessment plan and educational session and refer worker to a 1-hr worker take home prevention educational session.
33082068|NCT04625959|Experimental|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
33082069|NCT04625959|Experimental|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
33072538|NCT05000216|Experimental|Cohort B, Arm B4P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
32898477|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
32898478|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
32898479|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
32898480|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
32898481|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
32898482|NCT00101036|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32898483|NCT04770818|Active Comparator|Modified Brostrum procedure|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL (anterior talo-fibular ligament), CFL (calcanealfibular ligament), lateral ankle capsule and extensor retinaculum.
32898484|NCT04770818|Active Comparator|Modified Brostrum procedure with InternalBrace ligament augmentation|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL, CFL, lateral ankle capsule and extensor retinaculum with InternalBrace fixation using a 4.75mm BioComposite SwiveLock.
32898485|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
32898486|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
32898487|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
32898488|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
32898489|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
32898490|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
32898491|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
32898492|NCT00030992|Experimental|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
32898493|NCT00032630|Other|Arm 1|Coronary artery bypass - on-pump
32898494|NCT00032630|Other|Arm 2|Coronary artery bypass - off-pump
32898495|NCT05447338|Experimental|Specific joint mobilization post muscle inhibition on C1 and C2|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. There will be 6 treatment sessions distributed over 2 weeks.
32898496|NCT05447338|Experimental|Specific joint mobilization post muscle inhibition on C1 and C2 + myofascial inductions|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. Myofascial inductions will also be applied to the cranial and cervical fascia, as well as to the suboccipital, pectoral, angular scapula, sternocleidomastoid, trapezius, internal and external pterygoid, masseter and temporal muscles. There will be 6 treatment sessions distributed over 2 weeks.
32898497|NCT05447338|Active Comparator|Maitland C2 + SNAG C1|The Maitland technique will be applied, central postero-anterior passive joint mobilization in the C2 vertebra. As well as the sustained apophyseal slip technique (SNAG) in rotation on C1. The dosage is from 1 to 5 mobilizations per technique. There will be 6 treatment sessions distributed over 2 weeks.
32898498|NCT00385450|Experimental|Nelfinavir/placebo|
32898499|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
32898500|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
32911144|NCT04498845|Experimental|Advanced intervention group|Participants in the advanced intervention group will have a 1-hour in-home assessment plan and educational session, refer worker to a 1-hr worker take home prevention educational session, and provision of D-LEAD all-purpose cleaner and laundry detergent.
32911145|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
32911146|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
32911147|NCT01754207|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
33241938|NCT03704480|Experimental|Amended ARM A|"One cycle equals 4 weeks (D1=D28);~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
33241939|NCT01029145||1|Bipolar patients that experience a new episode of any type
33398804|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
33072539|NCT05000216|Experimental|Cohort B, Arm B5P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
33072540|NCT05000216|Experimental|Cohort C, Arm C1P: Moderna mRNA-1273, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33072541|NCT05000216|Experimental|Cohort C, Arm C2P: BNT162b2, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
33072542|NCT05000216|Experimental|Cohort D, Arm D1P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
32762244|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
32762245|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
32762246|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
33072543|NCT05000216|Experimental|Cohort D, Arm D2P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
32762247|NCT03340051|Active Comparator|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
32762248|NCT03340051|Placebo Comparator|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
33072544|NCT05000216|Experimental|Cohort E, Arm E1P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
33072545|NCT05000216|Experimental|Cohort E, Arm E2P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
33072546|NCT05000216|Experimental|Cohort F, Arm F1P: BNT162b2, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
33082070|NCT04625959|Experimental|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
32762249|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
32762250|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
32762251|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
32762252|NCT04998227||suspect acute coronary syndrome|"Subjects with the diagnosis of suspected acute coronary syndrome (ACS), age between 20 to 80.~Exclusion criteria: pregnant women, patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2), cardiogenic shock."
32762253|NCT04438915|No Intervention|Average weight .control group|Average weight BMI (18.5_25)
32762254|NCT04438915|Active Comparator|Overweight|Overweight BMI ( 25_30 )
32762255|NCT04438915|Active Comparator|Mild obese|Mild obese BMI (30_35 )
33082071|NCT04625881|Active Comparator|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
33082072|NCT04625881|Placebo Comparator|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
32737118|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
32762256|NCT04433741|Other|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
32762257|NCT04433741|Other|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
32762258|NCT05387551|Experimental|CGM intervention|Continuous glucose monitoring with real-time glucose data using Dexcom G6.
32762259|NCT04997837|Experimental|PD-1 inhibitor and chemoradiotherapy|"PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.~PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.~Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy."
32762260|NCT04997837|Active Comparator|Chemotherapy|"Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~CapeOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.~SOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.~FOLFOX:~Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.~5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W."
32762261|NCT04299295|Experimental|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
32762262|NCT04299295|Active Comparator|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
33398805|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
33398806|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
32762263|NCT04271371||Prototype intervention|To be developed through Phase 1 and 2
32762264|NCT04997603|Other|Athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
32762265|NCT04997603|Other|Non-athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
32762266|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
32762267|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
32762268|NCT04997447|Experimental|Intervention group|Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)
32762269|NCT04997447|No Intervention|Control group|Continued monitoring of habitual daily step count without structured intervention. Classic control.
32762270|NCT04202263|Placebo Comparator|Placebo|Placebo cream without minocycline
32762271|NCT04202263|Active Comparator|Minocycline Arm|Minocycline cream (1%,2%,3%)
32762272|NCT04996979|Placebo Comparator|Control|Only standard care
32762273|NCT04996979|Experimental|Intervention group|The PENG block was performed for intervention group with local anaesthetic solution composed of 20 ml of ropivacaine 0.5%.
32762274|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
32898501|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
32898502|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
32898503|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
33082073|NCT04625608|Other|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
33398807|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
33082074|NCT04625608|Experimental|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
33082075|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
33398808|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
33398809|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
33398810|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
33398811|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
33082076|NCT04625335|Experimental|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
33082077|NCT04625335|Experimental|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
32762275|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
32762276|NCT04997291|Experimental|Dexrazoxane|
32762277|NCT02328079|Active Comparator|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
32762278|NCT02328079|Active Comparator|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
32762279|NCT04190641|Other|Flexible cystoscopy|Visualization of the urethra and bladder with the Ambu® aScope™ 4 Cysto and aView™ Urologia
32762280|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
32762281|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
32762282|NCT04992377|Experimental|R-EPOCH plus IBR for RT|
32762283|NCT02747329|Experimental|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
33082078|NCT04625452|Experimental|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
32911148|NCT05458167|Experimental|Device: Hedia Diabetes Assistant with physical activity module.|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use the Hedia Diabetes Assistant bolus calculator with the physical activity module (intervention) during a 24-hour period starting one hour before the bout of exercise.
33082079|NCT04625452|No Intervention|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
32911149|NCT05458167|Active Comparator|Usual treatment|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use their habitual diabetes management approach during a 24-hour period starting one hour before the bout of exercise (control).
32911150|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
32911151|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
33082080|NCT04625179|Experimental|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
33082081|NCT04625179|Active Comparator|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
33082082|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:~GM1-Gangliosidosis Morquio B Variant~Sialidosis~Galactosialidosis"
33082083|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:~Tay-Sachs Disease, incl. B1-Variante~Sandhoff Disease~GM2-Activator-Deficiency"
33082084|NCT04624867|Experimental|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
33082085|NCT04624516|Experimental|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
33082086|NCT04624516|No Intervention|Control Group|the group received usual care
33082087|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
32762284|NCT02747329|Active Comparator|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
32762285|NCT02747329|Experimental|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
32762286|NCT02747329|Active Comparator|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
32762287|NCT04992533|Active Comparator|Long-duration tourniquet|Tourniquets inflated before arthroscopic exploration and deflated after high tibial osteotomy
32762288|NCT04992533|Experimental|Short-duration tourniquet|Tourniquet should be inflated before arthroscopic exploration and deflated immediately after the exploration
32762289|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
32762290|NCT04997213|Experimental|Interventional group|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
32762291|NCT04997213|Active Comparator|Control group|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first were commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
32762292|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
32762293|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
32762294|NCT04996745|Experimental|Intervention Group|Patients randomized to the intervention group of the RCT will be given tablet-based education. The first clinic follow-up visit will consist of screening for consent, providing a QR code for Orthokids, and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will be provided with the tablet for repeat education, with Orthokids and the post-intervention questionnaire will be distributed. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care.
32762295|NCT04996745|No Intervention|Control Group|"Patients randomized to the control group of the RCT will receive the standard clinic experience. This group will not be exposed to any education enrichment about their child's fracture except for the physician's explanation within the exam room.~The first clinic follow-up visit will consist of screening for consent and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will consist of conducting the post-intervention questionnaire. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care."
32762296|NCT02578069|Experimental|Experimental|NOVA Intracranial sirolimus eluting stent system
32762297|NCT02578069|Active Comparator|Control|Apollo Intracranial stent system
32762298|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
32762299|NCT04996589||Lean subjects|BMI 18.5-22
32762300|NCT04996589||Obese subjects|BMI>30
32762301|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
32762302|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
32762303|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
32762304|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
32762305|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
32762306|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
32762307|NCT03072641|No Intervention|Control|
32762308|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
32762309|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
32762310|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
32762311|NCT05080543|Active Comparator|Group AT|will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
32762312|NCT05080543|Placebo Comparator|Controlled|will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
32762313|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
33398812|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
32762314|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
32762315|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
32762316|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
32762317|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
32762318|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
32762319|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
32762320|NCT05080309|Sham Comparator|Control|During labor the women will have free access to water only but not fruit juice or other calory source.
32762321|NCT05080309|Experimental|Carbohydrate|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
32762322|NCT04991675|Active Comparator|pelvic floor muscle exercises|Exercises were taught in the supine position, as described by Kegel (1948), and it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
32762323|NCT04991675|Active Comparator|diaphragmatic breathing exercises|Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
32762324|NCT04991909|Experimental|Treatment group A|
32762325|NCT04991909|Placebo Comparator|Treatment group B|
32762326|NCT04996433|Experimental|Cognitive Behavioral Analysis System of Psychotherapy (CBASP)|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
32762327|NCT04996433|Active Comparator|Behavioral Activation (BA)|Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
32762328|NCT04082377|Experimental|Recruitment maneuver with tidal volume (RM TV)|RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW ,RR at 7 breaths/min, PEEP at 5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM. The ventilation protocol could be changed at any time when concerned about patient safety.
32898333|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
33082088|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
32762329|NCT04082377|Active Comparator|Recruitment maneuver by PEEP (RM PEEP)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia 5 cmH2O PEEP.~RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver."
32762330|NCT04073875||Bioprosthetic aortic valve|Single 18F-GP1 PET-CT
32762331|NCT04073875||Bioprosthetic aortic valve thrombus - repeat imaging|18F-GP1 PET-CT at baseline and 3 months
32762332|NCT04996511|Experimental|Colorectal Surgery Patients|
32762333|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
32762334|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
32762335|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
32762336|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
32762337|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
32762338|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
32762339|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
32762340|NCT03144895|Other|Arterial catheter|by anatomical placement alone
32762341|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
32762342|NCT04920383|Experimental|Dose Escalation and Expansion|ALPN-202 + Pembrolizumab
32762343|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
32762344|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
32762345|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
32762346|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
32762347|NCT04991441|Experimental|Control|Participants will follow their usual or normal diet for 5 months (CON) followed by an Controlled Dietary Sodium Restriction (INT) diet for 2 months. During the sodium restricted diet, participants will be provided with 2 meals and snacks daily, for 30 days (Month 5 - days 1-30) and 1 meal and snacks daily, for 30 days (Month 6 - days 31-60). These meals should meet the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
32762348|NCT04991441|Experimental|Intervention|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
32762349|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
32762350|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
32762351|NCT04915313|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 4 weeks.
32762352|NCT04915313|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 4 weeks..
32898334|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
32898335|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
32898336|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
33082089|NCT04624711|Experimental|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
33082090|NCT04624594|Experimental|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
33277319|NCT00074581|Experimental|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
32762353|NCT03915613|Experimental|Insulin|"Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly]. Each mL contains: 100 units of insulin injection, human biosynthetic (rDNA Origin) REGULAR. Nonmedicinal ingredients contain: glycerol, hydrochloric acid, m-cresol, sodium hydroxide and water for injection.~Unopened vials should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials should be stored at room temperature <25°C (<77°F) and discarded after 28 days.~To obtain a dose Humulin R 160 U / placebo~16 sprays (0.1 mL/spray) are to be given per dose~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~The sprays will be administered between alternating nostrils"
32762354|NCT03915613|Placebo Comparator|Sterile Diluent|"Intranasal placebo will be prepared from Eli Lilly's sterile diluent used with Humulin® R (10 mL/vial, manufactured by Eli Lilly). Nonmedicinal ingredients contain: dibasic sodium phosphate, glycerin, liquefied phenol, metacresol, hydrochloric acid, sodium hydroxide and water for injection.~Unused sterile diluent should be kept at controlled room temperature until the expiration date. The USP defines controlled room temperature as (20° to 25°C [68° to 77°F]), with excursions permitted (15° to 30°C [59° to 86°F]). Once in-use, the sterile diluent vial should be used within 28 days.~Participants will follow the same dosage, frequency, and administration as Humulin:~16 sprays (0.1 mL/spray) are to be given per dose~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~The sprays will be administered between alternating nostrils"
32762355|NCT03143023|Experimental|arginine toothpaste|
32762356|NCT03143023|Active Comparator|fluoride toothpaste|
32762357|NCT04914455||Fluid responsiveness groups (responders and non-responders)|Fluid responsiveness is defined as an increase in stroke volume of 10% and more form baseline.
32762358|NCT05079529|Experimental|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|This group will receive capsule contains 180 mg of β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma lucidum which will be taken 3 times daily for 90 days
32762359|NCT05079529|Placebo Comparator|Placebo Group|This group will receive empty capsule which will be taken 3 times daily for 90 days
32762360|NCT03074435|No Intervention|Control|No intervention
32762361|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
32762362|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
32762363|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
32762364|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
32762365|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
32762366|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
32762367|NCT04996277|Experimental|Fractional Flow Reserve|Patients with FFR ≤ 0.8 will undergo PCI Patients with FFR > 0.8 will be treated with medication For study purposes, all patients will undergo OCT (subject's treatment strategy will be based on FFR results, e.g., stent-implanted OCT).
32762368|NCT04996277|Experimental|Optical CoherenceTomography|Patients with MLA < 4.5mm² will undergo PCI Other patients will be treated with medication For study purposes, all patients will undergo FFR (subject's treatment strategy is based on OCT results; reference to FFR results is not recommended)
32762369|NCT04996277|Experimental|angiography|Appropriate treatment (implantation of stents) will be given according to the evaluation of the physician.
32762370|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
32762371|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
32762372|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
32762373|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
32762374|NCT04991519||Stroke Survivors|Participants have had a left-hemisphere stroke with or without aphasia, or a stroke elsewhere in the brain causing aphasia. They are given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
32762375|NCT04991519||Controls|Participants are matched to aphasia cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
32762376|NCT03833089|No Intervention|Control|ICD recipients in optimal Medical treatment as per guidelines according to their comorbidity
32762377|NCT03833089|Experimental|Targeted serum potassium levels|ICD recipients recipients in optimal Medical treatment as per guidelines according to their comorbidity. In addition to guideline recommended treatment, this cohort will be treated to increase serum potassium levels to 4.5-5.0 mEq/L.
32762378|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
32898337|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
32737119|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
32737120|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
32737121|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
32737122|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
32737123|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
32737124|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
32737125|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
32737126|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
32737127|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
32737128|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
32737129|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
32737130|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
32737131|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
32737132|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
32737133|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
32737134|NCT03341819|Active Comparator|Retained Urinary Catheter|
32737135|NCT03341819|Experimental|Non-retained Urinary Catheter|
32737136|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
32737137|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
32737138|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
32737139|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
32737140|NCT04494581||Pregnant and postpartum women|Pregnant and postpartum women over 18, meeting inclusion and exclusion criteria.
32737141|NCT04494581||healthcare workers|Health professionals over 18, working in maternity wards included.
32737142|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
32737143|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
32737144|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
32737145|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
32898504|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
33072547|NCT05000216|Experimental|Cohort F, Arm F2P: Moderna mRNA-1273, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
32898505|NCT01217827|No Intervention|Control|This group does not receive an intervention.
33277320|NCT04728854||Adult bullous pemphigoid patients|Patients with diagnosis of bullous pemphigoid will participate in monitoring with face to face assessment and remote telehealth visits with store and forward images captured.
33277321|NCT00776477|Experimental|1|
33277322|NCT00776477|Active Comparator|2|
32737146|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
32906450|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
33277323|NCT04692116|Experimental|ExAblate Arm|ExAblate Model 4000 System for the treatment of Parkinson's disease
33072548|NCT04992013|Experimental|Niraparib|Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.
33072549|NCT04989816|Experimental|T-DXd arm|T-DXd monotherapy
33398813|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
33398814|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
32737147|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
32906451|NCT04967664|Experimental|Qutenza (capsaicin) 8% topical system|Qutenza (capsaicin 8% topical system, containing capsaicin 179 mg or capsaicin 640 µg/cm2 of topical system)
32906452|NCT04967664|Active Comparator|Low-dose capsaicin control|capsaicin 0.04% topical system
32906453|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
32906454|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
32906455|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
32906456|NCT05564819|Experimental|Treatment group|After recovering and returning to the ward, acetaminophen (10mg/kg) was taken orally immediately; once every 6 hours, a total of 4 times.
32906457|NCT05564819|Placebo Comparator|placebo group|The same amount of sterilized water was administered orally at the same time points.
32906458|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
32906459|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
32906460|NCT04967274|Experimental|Spinal cord injured subjects|
32906461|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
32906462|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
32906463|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
32906464|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
32906465|NCT04378322|Active Comparator|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
33241940|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
32911152|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
32911153|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
32911154|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
32911155|NCT04462107||Surveys|All participants will complete questionnaires at several time points, ranging from baseline to 3 months post partum.
33241941|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
33072550|NCT04989686||Cyclosporine A|"Males and females <18 years of age~Greater than 5 kg~Receiving cyclosporine A as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of cyclosporine A for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
33072551|NCT04989686||Tacrolimus|"Males and females <18 years of age~Greater than 5 kg~Receiving tacrolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of tacrolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
33241942|NCT00570687|Experimental|1|Technosphere Insulin
33241943|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
33241944|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
33241945|NCT04075058|Experimental|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
33241946|NCT04075058|Active Comparator|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
33241947|NCT04963166||12-17 years of age|12-17 years of age
33241948|NCT04963166||2-6 years of age|2-6 years of age
33241949|NCT04963166||7-11 years of age|7-11 years of age
33241950|NCT01029223|Experimental|ivabradine|
33241951|NCT01029223|Experimental|metoprolol|
33241952|NCT01029223|Placebo Comparator|placebo|
33241953|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
33241954|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
33241955|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
32762379|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
33241956|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
33241957|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
33241958|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
33241959|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
33241960|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
33241961|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
32762380|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
32906466|NCT04378322|Active Comparator|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
32906467|NCT04378322|Active Comparator|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
32906468|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
33072552|NCT04989686||Sirolimus|"Males and females <18 years of age~Greater than 5 kg~Receiving sirolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of sirolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
33241962|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
33241963|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
33241964|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
33241965|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
33241966|NCT04008758|Experimental|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
32906469|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
32906470|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
32906471|NCT01725932|No Intervention|Care As Usual|Control Group
32906472|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
32906473|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
32906474|NCT01467947|Experimental|Berinert|
32906475|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
32906476|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
32906477|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
32906478|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
32906479|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
32906480|NCT01720472||Community, Physical Performance|
32906481|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
32906482|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
32906483|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
32906484|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
32906485|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
32898338|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
32906486|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
33398815|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
33398816|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
32737148|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
32737149|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
33398817|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
33398818|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
33398819|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
33398820|NCT02403700||All study participants|One group observation study
33398821|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
32906487|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
32906488|NCT01726010|Experimental|22-G Procore Needle|
33398822|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
33398823|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
33398824|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
33398825|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
32911156|NCT01754519|Experimental|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
33241967|NCT04008758|No Intervention|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure > 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
32911157|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
32906489|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
32906490|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
33241968|NCT04006262|Experimental|Experimental arm|"Neo-adjuvant treatment (6 cycles - 12 weeks)~Surgery~Adjuvant treatment (9 cycles - 9 months)"
33241969|NCT01032499|Active Comparator|oxytetracycline|
33241970|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
33398826|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
33398827|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
33241971|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
32911158|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
32911159|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
32911160|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
32911161|NCT04308135||Controls|30 healthy controls.
33241972|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
32762381|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
32762382|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
32762383|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
32762384|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
32762385|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
32762386|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
32762387|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
32762388|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
32762389|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
32762390|NCT04991207|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
32762391|NCT04991207|Active Comparator|Bosentan|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily [b.i.d.]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
32762392|NCT04991207|Experimental|BIA 5-1058 and Bosentan|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple b.i.d. oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5 1058 400 mg (4 x 100 mg tablets) and bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
32762393|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
33241978|NCT01029301|Experimental|Experimental: Endymed study group|
33241979|NCT01029379||200 patients,ASA 1|
33241980|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
33241981|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
33241982|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
33241983|NCT01032655|Experimental|sequential, susceptibility guided|single arm
33241984|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
33241985|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
33241986|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
33241987|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
33241988|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
32911162|NCT01754909|Active Comparator|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
33398828|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
33398829|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
33398830|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
33072553|NCT04984876|Experimental|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
33398831|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
33398832|NCT03737279|Experimental|Meditation|"Intervention Group:~Routine care plus twice daily mindful meditation"
33398833|NCT03737279|Active Comparator|Routine care|"Control Group:~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
33398834|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
33398835|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
33398836|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
33241989|NCT03384836|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID and pembrolizumab IV over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33241990|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
32911163|NCT01754909|Placebo Comparator|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
32762394|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
32911164|NCT04375527|Experimental|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
33072554|NCT04984876|Experimental|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
32911165|NCT04297995|Experimental|Part 1: HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
33072555|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
33072556|NCT04984876|Experimental|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
32911166|NCT04297995|Experimental|Part 1: HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
32762395|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
32911167|NCT04297995|Experimental|Part 2: HLX10 Plus HLX07 Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
33401947|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
33241991|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
33241992|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in telehealth sessions with a community provider. The Siblings FORWARD program includes 6-7 sessions, depending upon whether the autistic adult participates. Siblings work with a program facilitator to develop a future plan of action. They learn communication and problem-solving skills, and about adult service systems.
33241993|NCT03374072|Active Comparator|Information Only Condition|We will create an online learning module for siblings in the control condition. Siblings in the control condition will be provided with access to the same information about resources for autistic adults provided to participants in the Siblings FORWARD program.
33241994|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
33241995|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
33241996|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
32762396|NCT03072095|Experimental|Text-only|Text-only outreach
32762397|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
32762398|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
32762399|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
32911168|NCT04297995|Placebo Comparator|Part 2: HLX10 Plus HLX07 Placebo Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 Placebo (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
32911169|NCT04340349|Experimental|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
32911170|NCT04340349|Placebo Comparator|Hydroxychloroquine plus Bromhexine|200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
32911171|NCT01755143|Experimental|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
32911172|NCT01755143|Sham Comparator|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
33072557|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
33241997|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
33241998|NCT05673980|Experimental|vitamin D2|Oral dose of Vitamin D2 every two weeks
33241999|NCT05673980|Placebo Comparator|Placebo|Without any intervention
33242000|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
33242001|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
33242002|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
33401948|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
32762400|NCT03826849|No Intervention|Waitlist Control|Assessment only condition for all 12 weeks of participation.
32762401|NCT03826849|Experimental|Insomnia Coach|Intervention condition that involves use of the Insomnia Coach app for 6 weeks.
33401949|NCT05274841|Other|Identified support needs|Identified need of either support from a psychologist, nurse, doctor, socialworker or a combination of theese.
32762402|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
32762403|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
33277656|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
32911173|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc…), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
32911174|NCT04272047|Experimental|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
33277657|NCT00781547|Placebo Comparator|Placebo|
32737150|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
33277658|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
33277659|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
33277660|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
33277661|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
32911175|NCT04272047|Experimental|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
33401950|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
33277662|NCT04000958|Experimental|PIFR group|
33277663|NCT04000958|Active Comparator|control group|
33277664|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
32911176|NCT04272047|Active Comparator|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
32911177|NCT04276311|Experimental|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
32911178|NCT04268771|Experimental|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
32911179|NCT04268771|Active Comparator|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab [Rituxan] or EU-approved rituximab [MabThera]) should be the same in the prior and the randomized treatment course, respectively."
32911180|NCT04267809|Experimental|Metformin group|22 subjects will receive Metformin 1000mg twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before metformin dosing.
32911181|NCT04267809|Placebo Comparator|Placebo group|22 subjects will receive placebo twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before placebo dosing.
32911182|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
32911183|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening, the Women's Cancer Early Detection Program (WCEDP).
32911184|NCT04227639|Active Comparator|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
33277665|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
33277666|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
33277667|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
33277668|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
33277669|NCT03190460|Experimental|Intervention|
33277670|NCT03190460|Other|Education|
32762404|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
32762405|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
32762406|NCT04991363|Experimental|Patients|
32762407|NCT03764371||sMPLC|Lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules).
32762408|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
32762409|NCT05078749|Active Comparator|Exercise training group|Continuous progressive exercise training will be applied to the treatment group. The exercises will be performed every day, twice a day, for an average of 10 minutes/session, for eight weeks. Exercise training will be updated regularly at two-week intervals. A different and progressive new exercise will be sent to the patients as a Youtube link. The patients will be interviewed by video every week.
33277671|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
33277672|NCT00993434|Active Comparator|Kid STRIDE Booklet|
32762410|NCT05078749|Sham Comparator|Control training group|The control group will be followed up as a home program by explaining the exercises and giving a brochure. They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
32762411|NCT04433663|Experimental|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
32762412|NCT04433663|Active Comparator|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
32762413|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
32762414|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
32762415|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
32762416|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
32762417|NCT04990973|Experimental|Mediterranean Diet and then AAD|Healthy participants that are randomized to the MedDiet followed by a 4-week washout and a crossover to the AAD.
32762418|NCT04990973|Experimental|Average American Diet (AAD) and then Mediterranean Diet|Healthy participants that are randomized to AAD followed by a 4-week washout and a crossover to the Mediterranean Diet.
32762419|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
32762420|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
32762421|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
32762422|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
32762423|NCT03071783|No Intervention|conventional|conventional handle
32762424|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
32762425|NCT02327377|Active Comparator|Online Education|Educational information about pain
32762426|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
32762427|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
32762428|NCT03144817|No Intervention|Control Group|
32762429|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
32762430|NCT04995575||all MINDACT patients who relapse|
32898339|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
33072563|NCT04975789|No Intervention|Usual Care Control|Standard of Care
33072564|NCT04975789|Experimental|InfoViz Intervention|Pain information visualization (InfoViz) tool, Trained interpreters will use the InfoViz tool twice, before and during the clinical encounter
33072565|NCT04975308|Experimental|Imlunestrant|Imlunestrant administered orally.
33072566|NCT04975308|Active Comparator|Investigator's Choice of Endocrine Therapy|Investigator's choice of exemestane administered orally or fulvestrant administered intramuscularly (IM). See local approved label for additional instructions.
33072567|NCT04975308|Experimental|Imlunestrant plus Abemaciclib|Imlunestrant plus abemaciclib administered orally.
33072568|NCT04969263|Experimental|mRNA-1273 vaccine (Pfizer/BioNTech)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
33072569|NCT04969263|Experimental|mRNA-1273 vaccine (Moderna)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
32911185|NCT04227639|Experimental|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
33277673|NCT00993434|Placebo Comparator|Safety Booklet|
32898340|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
32898341|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
33277674|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
33277675|NCT05347784||Patients without postoperative complications|
33277676|NCT05347784||Patients with postoperative complications|
33277677|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
32911186|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2014 European Thyroid Association Guideline.
32911187|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
32911188|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
32911189|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2014 European Thyroid Association Guideline.
32911190|NCT01755455|Active Comparator|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
33277678|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
32911191|NCT01755455|Placebo Comparator|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
32911192|NCT00366873|Active Comparator|1|cow-milk based infant formula
32911193|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
32911194|NCT05317325|Experimental|Experimental Group|Autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC) vaccine is administered in prime phase and personal neoantigen-sensitized DC(NeoDC) vaccine is administered in boost phase.
32911195|NCT05395923|Experimental|Palatal Pre-Suture (GPCS)|In the test group, GPCS (Silk, 4-0, 18 mm, 3/8 sharp needle) will be placed before the incision in the palatal region. GPCS will be taken one week after surgery.
32911196|NCT05395923|Active Comparator|No Palatal Suture (No GPCS) - Control|In the control group, no sutures will be applied before graft harvesting from the palate.
32911197|NCT04182399|Active Comparator|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
32911198|NCT04182399|Active Comparator|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
32911199|NCT04182399|Placebo Comparator|Patients Placebo|30 patients receive placebo
32911200|NCT05383365|Experimental|Suboccipital Myofascial Release|The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences
33277679|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
33277680|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
33072570|NCT04967885|Experimental|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
33242003|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
33242004|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
33072571|NCT04967885|Active Comparator|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
33072572|NCT04961996|Experimental|Arm A: Giredestrant|
33072573|NCT04961996|Active Comparator|Arm B: Endocrine Therapy of Physician's Choice|
33242005|NCT03610646|Experimental|MYL-1701P|MYL-1701P
33242006|NCT03610646|Active Comparator|Eylea|Eylea
33242007|NCT04075448|Experimental|Control - 50g Walnut|Control condition followed by experimental condition.
33242008|NCT04075448|Experimental|50 g Walnut - Control|Experimental condition followed by control condition.
33242009|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
33242010|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
33242011|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
33242012|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
33242013|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
33242014|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
33242015|NCT00441103|Placebo Comparator|Placebo/RNF|
33242016|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
33242017|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
32762431|NCT03739645|Experimental|1 group. patients with intracranial electrodes for epilepsy.|Exploratory study with 1 intervention.which is painful (laser) stimulation conditioned fear with patient as his/her own control. EEG activity will be recorded from the brain during this behavioral state, an opportunity afforded by implantation of electrodes in the brain for treatment of epilepsy. Electrical activation of parts of the brain will be measured by event related spectral perturbations (ERSP).
32762432|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
32762433|NCT03734965|Active Comparator|AWAKEN INTUBATION FIBEROPTIC|awaken intubation
32762434|NCT03734965|Experimental|AWAKEN INTUBATION VIDEOLARYNGOSCOPY|awaken intubation
32762435|NCT04994951|Experimental|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
32762436|NCT04994951|Active Comparator|control group|Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
32762437|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
32762438|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
32762439|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
33072574|NCT04957953||Pregnant Women Vaccinated against Covid-19|Woman over 18 years of age who has received at least one Covid-19 vaccine during her pregnancy, regardless of the trimester of pregnancy.
32762440|NCT03699709|Experimental|Intervention Arm|
32762441|NCT03699709|No Intervention|Control Arm|
32762442|NCT03645967|Other|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
32762443|NCT03570931|Experimental|RT001|RT001, oral, 3.84 g/day
32762444|NCT05078515||Patients with recurrence after TME|Patients who developed local recurrence after TME of rectal cancer
32762445|NCT05078515||Patients without recurrence after TME|Patients who did not develop local recurrence after TME of rectal cancer
33401951|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
33072575|NCT04957394|Experimental|Experimental (Family Partner)|The treatment group will receive six hours follow-up and support weekly. The service will be provided by a dedicated Family Partner.
33242018|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
33242019|NCT01029613||Rheumatoid arthritis|
33242020|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
33242021|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
33242022|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
33242023|NCT03538652|Placebo Comparator|EMA only|randomized control group undergoing mobile assessment without JITAI
33242024|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
33242025|NCT03538652|Active Comparator|JITAI|group receiving microrandomized active intervention: JITAI with both CBT and ACT
33242026|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
33242027|NCT03339128|Experimental|Eluxadoline 25mg|Eluxadoline 25mg, oral administration, twice daily
32911201|NCT05383365|Experimental|Deep Neck Flexor Exercise|After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg, the participant will increase the pressure to 12 mmHg by nodding action.
33242028|NCT03339128|Experimental|Eluxadoline 50mg|Eluxadoline 50mg, oral administration, twice daily
33072576|NCT04957394|No Intervention|Control group|"The control group will receive default support from the child welfare services. The service will be business as usual, provided by the local staff at the child welfare services."
32762446|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
33242029|NCT03339128|Experimental|Eluxadoline 100mg|Eluxadoline 100mg, oral administration, twice daily
32762447|NCT04477369|Other|Sequence A|7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.
32762448|NCT04477369|Other|Sequence B|7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.
32762449|NCT04477369|Other|Sequence C|7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.
33072577|NCT04947124|Experimental|1% QLS-101|dosed once a day for 14 days as either first or second dosing period per randomization
33072578|NCT04947124|Experimental|2% QLS-101|dosed once a day for 14 as either first or second dosing period per randomization
33072579|NCT04945330||Gastrointestinal (GI)|Participants with GI cancer.
33072580|NCT04945330||Head and neck (H&N)|Participants with H&N cancer.
33072581|NCT04945330||Lung|Participants with lung cancer.
33072582|NCT04945330||Soft tissue sarcoma (STS)|Participants with STS cancer.
33072583|NCT04945330||Primary central nervous system (CNS)|Participants with CNS cancer.
33072584|NCT04945330||Melanoma|Participants with Melanoma cancer.
33072585|NCT04945330||Pediatrics|
33072586|NCT04945330||Others|
32911202|NCT04246619|Experimental|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.~Investigator can choose on V2:~Total Pregabalin Krka daily dose: 25 mg/day~Total Pregabalin Krka daily dose: 50 mg/day~Total Pregabalin Krka daily dose: 75 mg/day~Total Pregabalin Krka daily dose: 150 mg/day~Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
32911203|NCT04246619|Experimental|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:~Investigator can choose on V2:~Total Dulsevia® daily dose: 30 mg/day~Total Dulsevia® daily dose: 60 mg/day~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
32911204|NCT04126005||Cohort 1 (Age < 18 Months)|"Motor function assessments (remote or in-clinic) every 2 months~Clinic assessments every 6 months"
33242030|NCT03339128|Experimental|Placebo|Dose-matched placebo, oral administration, twice daily
33242031|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
33072587|NCT04941287|Experimental|Arm A (cobimetinib, atezolizumab, varlilumab)|Patients receive cobimetinib PO QD on days 1-21 of each cycle, atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle, and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
33072588|NCT04941287|Experimental|Arm B (atezolizumab, varlilumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
33242032|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
33242033|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
32762450|NCT04477369|Other|Sequence D|7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.
32762451|NCT05080933||COVID-19|
33242034|NCT01033903|No Intervention|expectant managment|
33242035|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
32762452|NCT05080933||H1N1|
32762453|NCT02636699|Experimental|Viaskin Peanut 250mcg|
32762454|NCT02636699|Placebo Comparator|Placebo|
32762455|NCT05387161||Observational group|"A nutritional assessment will be held with the detection of anthropometric parameters. Each participant will be asked to fill in the SF36, the VAS scales, the KESS questionnaire, the SFFI questionnaire, the Questionnaire PUF and O'Leary/Santn, the BDI and the TAS for an assessment of the psychological component.~In addition, patients will be asked to fill in a FFQ of food consumption and a 7 days food diary. Finally, routine blood chemistry tests will also be performed, to which will be added those for measuring the inflammatory state and stool examination for the evaluation of fecal Calprotectin for the measurement of intestinal inflammatory markers.~The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative daily diet plan, which must be followed for 6 months.~At the end of the 6 months, all anthropometric assessments, blood chemistry and stool tests will be repeated, together with the questionnaires."
32762456|NCT05080855|Active Comparator|the cleft lip will be repaired by modified Millard technique|In the modified Millard technique, points (nasal and Vermilion border points) and lines (rotational and advancement flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created three flaps: advancement flap, rotational flap, and c flap. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. Using a vicryl 5-0, we sutured the anterior nasal floor; then, using vicryl 4-0, we sutured the alar base and muscle. Using vicryl 6-0, we sutured top of philtral column with point a, the peak of Cupid's bow, and tip of c flap with alar base. The suturing of mucosal lip was carried out using a vicryl 5-0.
32762457|NCT05080855|Active Comparator|the cleft lip will be repaired by Tennison-Randall technique.|In the Tennison-Randall technique, points (nasal and Vermilion border points) and lines (Skin triangle flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created equilateral triangle flap and releasing incision. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. The suturing of the anterior nasal floor, alar base, and muscle followed the same principles of the modified Millard technique. The cutaneous repair was done by suturing the top of philtral column, the peak of Cupid's bow, point a, the line between the top of philtral column and the peak of Cupid's bow with b-8 and 3-a with b-a.
32762458|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
32762459|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
32762460|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
32762461|NCT03071705|Experimental|Intervention|TKI plus Metformin
32762462|NCT03071705|Active Comparator|Control|TKI
32762463|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
32762464|NCT04995185|Experimental|PET/CT imaging|Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole
32762465|NCT03351439|Active Comparator|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
32762466|NCT03351439|Experimental|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
32762467|NCT03351439|Experimental|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
32911205|NCT04126005||Cohort 2 (Age ≥ 18 Months - 3 Years)|"Motor function assessments (remote or in-clinic) every 4 months~Clinic assessments every 6 months"
32911206|NCT04126005||Cohort 3 (Age > 3 - 5 Years)|"Motor function assessments (remote or in-clinic) every 6 months~Clinic assessments every 6 months"
32911207|NCT04126005||Cohort 4 (Age > 5 Years)|"Motor function assessments (remote or in-clinic) 12 months~Clinic assessments every 12 months"
32911208|NCT04126005||Cohort 5 (Deceased)|• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.
32911209|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
32737151|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
32911210|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
32911211|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
32762468|NCT03351439|Experimental|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
32762469|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
32762470|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
32762471|NCT05034601|Experimental|ESPB group|0.25% ropivacaine 0.5 ml/kg is injected at the fascial plane deep to the erector spinae muscle
32762472|NCT05034601|Active Comparator|TPVB group|0.25% ropivacaine 0.5 ml/kg is injected into the thoracic paravertebral space (T5) using TPVB approach.
32762473|NCT04990661|Experimental|Intervention group (massage group)|intradialytic massage for lower extremity was applied to the intervention group in three sessions a week and a total of six sessions for two weeks
32762474|NCT04990661|No Intervention|Control group|not administered except nursing interventions in the HD unit.
32762475|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
32762476|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
32762477|NCT04994639|Experimental|HPI group|Managing intraoperative hemodynamic condition under the HPI guidance
32762478|NCT04994639|No Intervention|Standard care group|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
33242036|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
32762479|NCT03139747|Experimental|Single Arm|
32762480|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
32762481|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
32762482|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
32762483|NCT04990583|Experimental|Carium Condition|Participants assigned to the Carium condition will receive a single session intervention and receive 12 months of access to the Carium adherence application.
32762484|NCT04990583|Active Comparator|Control Condition|Participants assigned to the Control condition will receive a single session intervention only.
32911212|NCT04740957|No Intervention|Observational cohort|"100 patients undergoing elective left colonic or rectal resection with a primary anastomosis will be recruited pre-operatively throughout the study period. This study will not affect or delay the intended treatment for study participants.~Patients will undergo serial endoscopic examination of the anastomosis post-operatively. Blood, urine, stool, and mucosal biopsies will be serially collected."
33242037|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
33242038|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
33242039|NCT03953300|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
33242040|NCT03953300|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
33242041|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
32911213|NCT04740957|Experimental|Distal limb feeding cohort|"This interventional arm will demonstrate the safety of re-introducing ileostomy effluent into the downstream (distal) limb of an ileostomy. The preliminary data will enable exploration of the association between microbiome and post-operative function and enable adequate powering of future interventional studies.~A subgroup of 20 patients undergoing a resection with a covering ileostomy will be recruited to the intervention arm. Complete healing of the colorectal anastomosis will first be confirmed by water-soluble contrast enema 8 weeks post-operatively (this is standard practice). Patients will be taught how to inject the output from the proximal ileostomy limb into the distal limb (this connects to the colon and thus the colorectal anastomosis) daily until the ileostomy closure date."
32911214|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
32911215|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
32911216|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
32911217|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
32911218|NCT05317091|Experimental|Laughter yoga practice|Laughter yoga for nurses The experimental group was divided into three groups as 18-17-16 people. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday Saturday between 20:00-21:00.laughter yoga for nurses-Deep breathing exercises Deep breathing exercises (5 minutes), Warm-up exercises (10 minutes) laughter yoga for nurses-Childish games Childish games (10 minutes), Laughter exercises (15 minutes).
32911219|NCT05317091|Experimental|Laughter yoga session parts-1|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
32911220|NCT05317091|Experimental|Laughter yoga session parts-2|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
32911221|NCT05317091|Experimental|Laughter yoga session parts-3|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
32911222|NCT05317091|Experimental|Laughter yoga session parts-4|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
32911223|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2<55%,using the TIVA technology with propofol,
32911224|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
32911225|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2<55%,using the VIMA technology with sevoflurane,
33242042|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
32762485|NCT05204719|Experimental|Prophylactic Delivery Room Continuous Positive Airway Pressure|If the infant is spontaneously breathing and allocated to the experimental arm, s/he will receive 20 min of 5 to 6 cm H2O of prophylactic continuous airway pressure using either a face mask or the appropriate size of nasal prong.
33242043|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
32911226|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
33072594|NCT04938908|Experimental|Ophthalmic probiotic|1 active drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
33072595|NCT04938908|Placebo Comparator|Placebo|1 placebo drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
33072596|NCT04938908|Experimental|Opthalmic Probiotic + Oral Probiotic|1 active drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
33072597|NCT04938908|Experimental|Oral Probiotic|1 placebo drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
33072598|NCT04923841|No Intervention|Control|Subjects in control will receive single vision spectacle lenses and a placebo desk lamp
32911227|NCT01757717|Experimental|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
32911228|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
32911229|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
32911230|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
32911231|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
32911232|NCT05316857|Other|Orelabrutinib + Rifampin|"Orelabrutinib is a white, round, uncoated table,Subjects take high dose orelabrutinib in the first day and the tenth day.~Rifampin is a capsule,Subjects take 600mg QD rifampin in the third day to the eleventh."
32911233|NCT05316857|Other|Orelabrutinib + Itraconazole|"Orelabrutinib is a white, round, uncoated table,Subjects take low dose orelabrutinib in the first day and the eighth day.~Itraconazole is a capsule,Subjects take 600mg QD rifampin in the third day to the tenth."
32911234|NCT01759277|Active Comparator|Control|Femoral perineural local anesthetic infusion
32911235|NCT01759277|Experimental|Experimental|Adductor canal perineural local anesthetic infusion
32911236|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
32911237|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
33242044|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
33242045|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
33242046|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
33242047|NCT03526250|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33242048|NCT05113316|Experimental|Messy Memories App Group|"Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days (affect rating sliders), their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.~The Messy Memories app will also collect data on how frequently and for how long each participant uses the app. Each response will trigger a prompt within the app, and will be recorded with a timestamp (date and time) to indicate when the participant provided a particular response. For all participants, self-report measures will be collected at weeks 4, 8, 12, and 16."
33242049|NCT05113316|No Intervention|Treatment as usual (TAU) Group|Subjects will not receive any study treatments or have access to the app but may seek standard treatment if they choose, in addition to completing self-report measures. For 8 weeks, TAU group will participate in the study under treatment as usual. For weeks 9-16, the TAU group will then switch and have full access to the Messy Memories App to review and use for a limited amount of time. Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days, their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.
33401952|NCT04580407|Experimental|TAK-672|TAK-672 will be administered at an initial dose of 200 U/kg with intravenous infusion at a rate of 1-2 mL/min. Subsequent doses will be determined based on the post-infusion factor VIII activity (FVIII:C) achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer (when available)
33401953|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
32911238|NCT04150991|Experimental|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
32911239|NCT04150991|Placebo Comparator|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
32911240|NCT05346939|Experimental|Senior high school athletes in Taiwan|"In the first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability at stage I (n=15). And the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer or basketball athletes (n=50) at stage II.~In the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue (n=50)."
32911241|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
32911242|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
32911243|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
32911244|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
32911245|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
32911246|NCT04040907|Active Comparator|XNW3009|
32911247|NCT04040907|Placebo Comparator|XNW3009 placebo|
32911248|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m^2) at term
32911249|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m^2) at term
32911250|NCT05341791|No Intervention|Standard administration of information notice|: During the standard study information administration, the participant will read though the written information notice which will be organized in sections. After each section, the study staff will explain to the participant the key information to understand. Throughout the process, participants will be allowed to ask study staff questions. We anticipate the time to administer consent by this standard approach will be approximately 45 to 60 minutes per participants.
33072599|NCT04923841|Experimental|BLT monotherapy|Subjects in BLT monotherapy group will receive a high intensity light box for bright light therapy and single vision spectacle lenses
33072600|NCT04923841|Experimental|BLT and DIMS|Subjects in BLT and DIMS group will receive a high intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
33072601|NCT04923841|Experimental|BLT and atropine|Subjects in BLT and atropine group will receive a high intensity light box for bright light therapy, single vision spectacle lens, and atropine 0.01% eye drop (twice a day)
32911251|NCT05341791|Experimental|video administration of information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
32911252|NCT05316389||A Retrospective|A = retrospective cohort including all patients treated at the ICO Angers between January 2017 and September 2021
32911253|NCT05316389||B Prospective|B = prospective including all patients treated at the ICO from February 2022 (2 years of recruitment)
32911254|NCT04094285|Experimental|1|
32911255|NCT04094285|Experimental|2|
32911256|NCT05325255|Experimental|Maitland mobilization with myofascial trigger point release group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Ischemic Compression technique: on subscapularis trigger points for 90 secs thrice a week for 2 weeks.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
32911257|NCT05325255|Active Comparator|Maitland mobilization alone group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
32911258|NCT01762631||Cohort 1|All participants enrolled between November 2012 and March 2013 under the original protocol.
32911259|NCT01762631||Cohort 2|After Cohort 1 was completed, the study investigators changed the protocol to eliminate the photograph/weight of the powdered formula alone in each bottle to reduce burden. All other protocol procedures remained the same. Cohort 2 participants enrolled between April 2013 and May 2014.
32911260|NCT05315427||Evaluation of the impact of music therapy on the pain of patients|One music therapy session
32911261|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
33072602|NCT04923841|Experimental|Atropine monotherapy|Subjects in atropine group will receive atropine 0.01% eye drop (twice a day) and single vision spectacle lenses
33072603|NCT04919538||Relapsing Polychondritis Cohort|
32762486|NCT05204719|No Intervention|No Prophylactic Delivery Room Continuous Positive Airway Pressure|"Alternatively, spontaneously breathing infants assigned to control group will receive the standard of care with no prophylactic delivery room continuous positive airway pressure (CPAP).~In both groups, CPAP can be used to help babies with persistent labored breathing or cyanosis after the initial steps as per the participating institution's neonatal resuscitation protocol. At any time, if the patient does not present spontaneous breathing, an escalation on the resuscitation measures will be performed and the study intervention will be terminated."
32762487|NCT04990271|Experimental|Conbercept intravitreal Injection|
32762488|NCT04990349|Experimental|Extracorporeal normoxemia|"After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.~The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
32762489|NCT04990349|Active Comparator|Extracorporeal hyperoxemia|"After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.~The objective is to maintain PO2 postoxygenator higher than 300 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
32762490|NCT05191459||Heart failure and preserved ejection fraction|42 patients 50-90 years with preserved ejection fraction (EF ≥50%)
32762491|NCT05191459||Heart failure and reduced ejection fraction|42 patients 50-90 years with reduced ejection fraction ((EF≤40%)
32762492|NCT04990193|Active Comparator|Control group|Children in the control group received the conventional physical therapy protocol which was designed to improve axial stability and trunk steadiness during standing and walking.
32762493|NCT04990193|Experimental|Study group|The children in the study group received the conventional protocol given to the control group. Moreover, they wore TheraTog orthotic undergarment with its strapping system eight hours every day for twelve consecutive weeks.
32762494|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
32762495|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
32762496|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
32762497|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
32762498|NCT02888821|Experimental|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
32762499|NCT02888821|Other|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
32762500|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
32762501|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
32762502|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
32762503|NCT04770805|Experimental|Fetoscopic repair|Sacral Myelomeningocele and Mye-LDM Fetoscopic repair
32762504|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
32762505|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
32762506|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
32762507|NCT02553967|Experimental|Immediate breast reconstruction|"Total mastectomy + immediate reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
32762508|NCT02553967|Experimental|Secondary breast reconstruction|"Within 2 months before surgery : Functional MRI~Reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
32762509|NCT04990115|Active Comparator|rotation|root canal preparation performed using rotating instruments
32762510|NCT04990115|Active Comparator|reciprocation|root canal preparation performed using reciprocating instruments
32762511|NCT04756375|Experimental|INTERVENTION|Use of virtual reality in the management of sickle cell patients with VOS
32762512|NCT04756375|Other|NO INTERVENTION|
32911262|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
32911263|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
33401954|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
32911264|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
33401955|NCT05256589|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participate in two arms of the study:~One arm is for obtaining performance data of the Sona Saliva C-19 Rapid self test and the comparator arm is to obtain data from the primary care route using approved RT-PCR testing."
32762513|NCT04987619|Experimental|BJR|70 mL of beetroot juice (BEET It Sport®; James White Drinks Ltd., Ipswich, UK)
32762514|NCT04987619|Placebo Comparator|PLA|70 mL of blackcurrant beverage Capri-Sun.
33072606|NCT04908202|Experimental|Deucravacitinib|
33072607|NCT04908202|Placebo Comparator|Placebo|
32911265|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
32911266|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
32911267|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
32911268|NCT01355588|Experimental|Ketorolac Tromethamine|
32911269|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
32911270|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
32911271|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
32911272|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
32911273|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
32911274|NCT04040049|Experimental|FLT190|FLT190 is a recombinant adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
32911275|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
32911276|NCT04022499|Experimental|Pre-NDPP|Presessions + usual care NDPP
33401956|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
32911277|NCT04022499|Active Comparator|Usual care NDPP|Usual care NDPP only
32911278|NCT04741113|Experimental|Intervention group -educational module|"The study intervention will include an online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion. The module will be sent to participants via secured link."
32911279|NCT04741113|No Intervention|Control group|No intervention
32911280|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
32911281|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
33242050|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33242051|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
33242052|NCT05673902|Experimental|RPH-104 80 mg|"RPH-104 80 mg SC once every 2 weeks for 24-60 weeks.~(If the patient develops a pericarditis recurrence during the safety follow-up period, at the discretion of the investigator treatment with the study drug might be re-initiated according to the following regimen: a single dose of 160 mg SC (first injection) followed by a dose of 80 mg SC 7 days and 14 days after the first injection and at doses of 80 mg SC every two weeks thereafter.)"
33242053|NCT03935282|Experimental|Intervention - AH-HA tool|With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
32762515|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
33242054|NCT03935282|No Intervention|Usual Care|Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.
33242055|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
33242056|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
33242057|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
33082091|NCT04624594|Active Comparator|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
33242058|NCT00570765|Experimental|DB OCA 10 mg|OCA 10 mg for 3 months during the DB phase.
32762516|NCT04989881|Experimental|Da Vinci Simulator|Participants will undergo a single session of training using the da Vinci Simulator
33242059|NCT00570765|Experimental|DB OCA 50 mg|OCA 50 mg for 3 months during the DB phase.
33242060|NCT00570765|Placebo Comparator|DB OCA Placebo|Matching placebo for 3 months during the DB phase.
32911282|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
32911283|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
32911284|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
32911285|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
32911286|NCT03921021|Experimental|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
32911287|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
32911288|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
32911289|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
33242061|NCT00570765|Experimental|LTSE OCA Total|After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
33242062|NCT00777621|Active Comparator|Calorie restriction|
33242063|NCT00777621|Active Comparator|Exercise|
33242064|NCT00777621|Experimental|Calorie restriction and exercise|
33242065|NCT00777699|Experimental|1|
33242066|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
33242067|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
33242068|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
33242069|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
32762517|NCT04989881|Active Comparator|Laparascopic training box|Participants will undergo a single session of training using a laparoscopic training box
32762518|NCT04469101|Experimental|Left Uterine Displacement|Supine with left tilt for uterine displacement
32762519|NCT04469101|Experimental|Left Lateral|Left lateral decubitus position
32762520|NCT04469101|Experimental|Right Lateral|Right lateral decubitus position
32762521|NCT04469101|Experimental|Upright|Upright seated position
32762522|NCT04987853||Acute COVID patients|Patients in the acute phase of the course of the disease
32762523|NCT04987853||Long Covid Patients|Patients with chronic symptoms after a previous Covid-19 (4-12 weeks)
32762524|NCT04987853||Postcovid patients|Patients with chronic symptoms after a previous Covid-19 (more than 12 weeks)
32762525|NCT05154565|Experimental|Immediate intervention (Group A)|Meditation intervention applied during Phase 1 of the study. During Phase 2, the formal meditation intervention is not completed, but participants are followed for outcome measurement. Participants may continue to use meditation in their daily routines or return to their usual routines.
32762526|NCT05154565|Other|Delayed intervention (Group B)|No intervention is applied in Phase 1 of the study. This group serves as the control group for Phase 1. The meditation intervention is applied in Phase 2 of the study.
32762527|NCT05138575|Active Comparator|Empagliflozin + Potassium Chloride (KCl)|"Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
32762528|NCT05138575|Active Comparator|Empagliflozin + Potassium Nitrate (KNO3)|"Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
32762529|NCT05138575|Placebo Comparator|Potassium Chloride (KCl) + Placebo for Empa|"Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin~Placebo arm will be 6 weeks in duration followed by a 2 week washout period."
32762530|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
32762531|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
32762532|NCT05115799|Experimental|Patients with Axilliary Web Syndrome and manual therapy and scar massage.|"These users will come from the first moment of the diagnosis of the thrombus in our unit, to receive manual therapy by the physical therapist. They will receive 15 sessions of manual therapy by the physiotherapist, 5 days a week, each session being approximately 40 minutes long. The session will begin with pendulum exercises of the shoulder to warm up the joint and give proprioceptive stimulation to the joint capsule. The physiotherapist will perform passive stretches looking to put tension on the cord lymphatic, never exceeding grade 6 VAS pain. Mainly the shoulder will be worked affected, and if the cord reaches the crease of the elbow or thumb, the extension-supination of the elbow, and ulnar deviation of the wrist.~Scar massage will be done in the area where the lymphatic cord originates at the proximal level while maintaining the tolerable tension of the lymphatic cord (during the massage also pain grade 6 VAS will be exceeded)."
32762533|NCT05115799|Other|Patients with Axilliary Web Syndrome and health education and kinesiotherapy.|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
32762534|NCT02405845|Other|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
32762535|NCT04037215|Other|COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|In order to explore the cognitive treatment of patients with early onset anorexia nervosa in front of images of silhouettes and food, it is currently used in the child psychiatry department of the Robert Debré Hospital, the eye-tracking method. Eye tracking is a non-invasive and painless method of recording the path of vision on images presented on a computer screen. In order to understand the specificities of the eye path in sick patients, we will compare the data with those of controls without eating disorders.
32762536|NCT04987151|Experimental|Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
32762537|NCT04987151|Experimental|Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking,
32762538|NCT04987151|Experimental|Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups
32762539|NCT04987151|No Intervention|Control Group|All the patients in the wait-list control group will receive one of the three trainings immediately after the intervention.
32762540|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
32762541|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
32762542|NCT04412291|Active Comparator|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:~Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep or Klexane or new oral anticoagulants incl. dabigatran, apixaban or rivaroxaban).~Steroids (Betapred)"
32762543|NCT04412291|Active Comparator|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.."
32762544|NCT04412291|Active Comparator|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.
32762545|NCT03141073|Experimental|HMS5552|75mg BID
32762546|NCT03141073|Placebo Comparator|Placebo|BID
33401957|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
32911290|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
32911291|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
32911292|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
32911293|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
32911294|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
32911295|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
32911296|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
32911297|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
32911298|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
32911299|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
32911300|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
32911301|NCT01256840||Calorie Restricting Group|
32911302|NCT01256840||Normal-eating controls|
32911303|NCT01256840||Obese comparison group|
32911304|NCT01763333|Experimental|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
32911305|NCT01763333|Experimental|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
32911306|NCT05315999|Experimental|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
32911307|NCT05315999|Placebo Comparator|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
32911308|NCT01763645|Experimental|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
32911309|NCT01763645|Active Comparator|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
32911310|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
32911311|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
32911312|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
32911313|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
32911314|NCT05315765||Phase 1|Qualitative interviews with patients to generate thematic framework and questionnaire
32911315|NCT05315765||Phase 2|Face validity assessment of questionnaire
32911316|NCT05315765||Phase 3|Completion of questionnaire to refine scale and item list
32911317|NCT03951779|Experimental|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
32911318|NCT03924791|Experimental|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
32911319|NCT03924791|No Intervention|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
32911320|NCT03908567|Placebo Comparator|Placebo|Nasal spray solution without active ingredient
32911321|NCT03908567|Experimental|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
32911322|NCT03908567|Experimental|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
32911323|NCT03908567|Experimental|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
32911324|NCT03908567|Experimental|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
33401958|NCT05255497|Experimental|Biodex Balance Group|This group performed exercises using the biodex balance system
32911325|NCT05315609|Experimental|Intervention: Virtual Reality Mindfulness Group|The intervention will be 4-weeks, twice per week, 15-minute/session VR-mindfulness intervention group.
32911326|NCT05315609|No Intervention|No intervention: Waitlist Control Group|These participants will be on a waitlist to receive the VR guided meditation program after data collection has been completed (after the 4 weeks)
32911327|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
32911328|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
32911329|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
32911330|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
32911331|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
32911332|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
32911333|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
32911334|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
32911335|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
32911336|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
32911337|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
32911338|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
32911339|NCT01361048|Active Comparator|oral metronidazole|control arm
32737152|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg~Study dosing of liraglutide:~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
33242070|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
33242071|NCT05118477|Experimental|AMS group|Patients randomised to the intervention group will receive the AMS; this will be connected to the dashboard and the alerting system. Clinical staff will have access to the dashboard and alerted accordingly for the assigned patients.
33242072|NCT05118477|Active Comparator|Standard Care group|"Patients in the control group will also receive the AMS however this will not be connected to the ward dashboard and clinical staff will not be able to access these patient's continuous vital signs:~Patient will not appear on the ward dashboard~No alerting system will be given to staff"
33242073|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
33242074|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
32762547|NCT04456361|Experimental|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
32762548|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
33242075|NCT00777933|Active Comparator|cyclosporine|
33242076|NCT00777933|Experimental|Tacrolimus|
33242077|NCT00773331|Experimental|1|
33242078|NCT00773331|Active Comparator|2|
33242079|NCT00778011|Active Comparator|1|
33242080|NCT00778011|Active Comparator|2|
33242081|NCT00778011|Active Comparator|3|
33242082|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
33242083|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
32762549|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
32762550|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
32762551|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
32762552|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
32911340|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
33242084|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
33242085|NCT00778089|Other|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
33242086|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
33242087|NCT00433381|Experimental|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
33242088|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
33242089|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
33242090|NCT00667017|Experimental|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
33242091|NCT00781131|Placebo Comparator|1|
33242092|NCT00781131|Experimental|2|Pregabalin 75 mg
33242093|NCT00781131|Experimental|3|Pregabalin 150 mg
33242094|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
32762553|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
32762554|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
32906493|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
32906494|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
32906495|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
32906496|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
32906497|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
32906498|NCT01469039|Experimental|ALKS 9072|
32906499|NCT01469039|Placebo Comparator|Placebo|
32906500|NCT01720784|Placebo Comparator|Placebo|
32906501|NCT01720784|Experimental|Low dose (1.5 g DF)|
32906502|NCT01720784|Experimental|High dose (2.25 gDF)|
32906503|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
32906504|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
32906505|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
32906506|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
32737153|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
32737154|NCT03342833|Active Comparator|Blood flow restriction|
32737155|NCT03342833|Sham Comparator|Usual training|
32911341|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
32911342|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
32911343|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
32911344|NCT01766219|Experimental|Arm 1: (6,8-bis[benzylthio]octanoic acid) 2,300 mg/m²|"Participants will not be treated with CPI-613 during pre-Cycle 1 and will only be treated with 3 weeks on/1 week off at 2,300 mg/m² as a starting dose. If none of these 3 participants develop a dose-limiting toxicity through Cycle 1, the dose for the 3-weeks-on-1-week-off treatment cycles will be 3,000 mg/m² in all subsequent participants in this trial.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
32911345|NCT01766219|Experimental|Arm 2: (6,8-bis[benzylthio]octanoic acid) 1,200/3,00 mg/m²|"Participants will received pre-cycle 1 week dose at 1200 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
33242095|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
33242096|NCT00778323|Experimental|A,2, II|
32911346|NCT01766219|Experimental|Arm 3 (6,8-bis[benzylthio]octanoic acid) 600/3,000 mg/m²|"Participants will received pre-cycle 1 week dose at 600 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
32911347|NCT05315531|Experimental|Water Intake|3-week intervention period during which articipants will be asked to increase their daily plain water consumption to at least 2.5 L/d of water for males and 2L/d for females.
32911348|NCT01767155|Experimental|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
32911349|NCT01767155|Active Comparator|doxorubicin/ standard chemotherapy|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
32911350|NCT01362686|Experimental|Donepezil|See intervention note.
32911351|NCT01362686|Experimental|Galantamine|See intervention note.
33242097|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
32911352|NCT01362686|Experimental|Rivastigmine|See intervention note.
32911353|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
32911354|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
32911355|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
32911356|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
32911357|NCT01322048|Placebo Comparator|Placebo|Placebo
32911358|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
32737156|NCT04494659|Experimental|Single arm|single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16
32911359|NCT05315375||Corpectomy|surgical procedure using expandable cage
32911360|NCT05315219|Experimental|Endoscopic Thyroidectomy Bilateral Areola Approach|
32911361|NCT05315219|No Intervention|Open Thyroidectomy|
33242098|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
33242099|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
33242100|NCT00773721|Experimental|1|Volunteers who are currently using CPAP treatment will trial a new mask system for up to five weeks
33401959|NCT05255497|No Intervention|Control Group|This group was informed about diabetes self-management.
33242101|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
33242102|NCT00778479|No Intervention|Control|no treatment
33242103|NCT00666705|Experimental|Maraviroc alone|
33242104|NCT00666705|Experimental|Maraviroc + Raltegravir|
33242105|NCT00666705|Experimental|Raltegravir alone|
33242106|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
33242107|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
32911362|NCT04351724|Experimental|(Hydroxy)Chloroquine (STOPPED)|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
32911363|NCT04351724|Experimental|Lopinavir/Ritonavir|Dosage: 200mg/50mg 4-0-4 on day 1 and 3-0-3 thereafter
32911364|NCT04351724|Other|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
32911365|NCT04351724|Experimental|Rivaroxaban|5mg 1-0-1
32911366|NCT04351724|Active Comparator|Thromboprophylaxis|according to local standard
32911367|NCT04351724|Experimental|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients > 120/80 mmHG are eligible
32911368|NCT04351724|Active Comparator|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
32911369|NCT04351724|Experimental|Asunercept 25mg|25mg 1x per week, maximum of four doses only patients with oxygen requirement
32911370|NCT04351724|Experimental|Asunercept 100mg|100mg 1x per week, maximum of four doses only patients with oxygen requirement
32911371|NCT04351724|Experimental|Asunercept 400mg|400mg 1x per week, maximum of four doses only patients with oxygen requirement
32911372|NCT04351724|Other|Best Standard of Care - Control Group for Asunercept|only patients with oxygen requirement
32911373|NCT04351724|Experimental|Remdesivir|200mg loading dose on day 1, 100mg for a total treatment duration of 5-10 days
32911374|NCT04351724|Experimental|Pentaglobin|Patients treated at the intensive care unit only, continuous infusion of 7ml/kg/day over 12h for 5 days
32911375|NCT04351724|Other|best standard of care|Patients treated at the intensive care unit only
32911376|NCT01767701|Experimental|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
32911377|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
32911378|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
32911379|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
32911380|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
32911381|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
32911382|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
32911383|NCT01767935|Experimental|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32911384|NCT01363388|Placebo Comparator|Placebo|
33242108|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
33242109|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
33242110|NCT00773799||rehabilitation center's hospitalized patients|
33242111|NCT04047849|Experimental|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
33242112|NCT04047849|No Intervention|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
32911385|NCT01363388|Experimental|CCX168|Active study medication
32911386|NCT01768013|Experimental|LEO 90105 Ointment|
32911387|NCT04351412|Active Comparator|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
33242113|NCT00773877||1|Primary open angle glaucoma
33242114|NCT00773877||2|Normal Controls
33242115|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
33242116|NCT04047927|Experimental|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
33242117|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
33242118|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
33242119|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
33242120|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
33242121|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
33242122|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
33242123|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
33242124|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
33242125|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
33242126|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
33242127|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
33242128|NCT00774111|Experimental|Sequence 1|
33242129|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
33242130|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
33242131|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
33242132|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
33242133|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
33242134|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
33242135|NCT00774423|Active Comparator|Riluzole|RILUTEK
33242136|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
33242137|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
33242138|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
33242139|NCT00778947|Active Comparator|1|
33242140|NCT00778947|Active Comparator|2|
33242141|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
33242142|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
33242143|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
33242144|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
33242145|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
33242146|NCT04046913|Active Comparator|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
33242147|NCT04046913|Placebo Comparator|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
33242148|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
33242149|NCT00781677||MDD|
33242150|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
33242151|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
33242152|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
33242153|NCT00774735|Experimental|Sequence 1|
33242154|NCT00774735|Experimental|Sequence 2|
33242155|NCT00666237|Experimental|Tube shunt surgery group|Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).
33242156|NCT00666237|Experimental|Trabeculectomy with Mitomycin C|Participants in this group will receive a Trabeculectomy surgery with Mitomycin C
33242157|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
33242158|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
33242159|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
33242160|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
33242161|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
33242162|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
33242163|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
33242164|NCT00785031|Active Comparator|internet based intervention|
33242165|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
33242166|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
33242167|NCT00789789||1|
33242168|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
33242169|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
33242170|NCT00662025|Experimental|1|
33242171|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
33242172|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
33242173|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
32911388|NCT04351412|Active Comparator|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
33242174|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
33242175|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
33242176|NCT05013645|Experimental|Sterilized probiotic (LfQi601)|Sterilized probiotic topically administered.
33242177|NCT05013645|Placebo Comparator|Gel control product|Inactive placebo.
33242178|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
33242179|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
33242180|NCT00782223||1|Hip X-rays DDH
33242181|NCT00782223||2|Hip X-rays, CP
33242182|NCT00782223||3|Long standing lower Limb X-rays
33242183|NCT00782223||4|Scoliosis, AP X-rays
33242184|NCT00782223||5|Scoliosis Lateral X-rays
33242185|NCT00790101|Experimental|1|Risedronate 35mg once a week
33242186|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
33242187|NCT00790101|Placebo Comparator|3|
33242188|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242189|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242190|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242191|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242192|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242193|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242194|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
33242195|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
33242196|NCT00782301|Active Comparator|Maraviroc|
33242197|NCT00782301|Active Comparator|Etravirine|
33242198|NCT00785343|Active Comparator|Conventional Treatment|
33242199|NCT00785343|Experimental|Robotic and Conventional Therapy|
33242200|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
33242201|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
33242202|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
33242203|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
33242204|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
33242205|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
33242206|NCT00785499|Experimental|skim milk|skim milk
33242207|NCT00785499|Experimental|whey|Whey milk drink
33242208|NCT00785499|Experimental|casein|casein milk drink
33242209|NCT00785499|Active Comparator|water|Danish mineral water
33242210|NCT00782457|Active Comparator|OPEN SURGERY|
33242211|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
33242212|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
33242213|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
33242214|NCT00790491|Experimental|Lifestyle counseling|
33242215|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
33242216|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
33242217|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
33242218|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
32911389|NCT04351412|Active Comparator|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
32911390|NCT01768325|Active Comparator|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
32911391|NCT01768325|Active Comparator|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
32911392|NCT05315141||Xiangya Hospital|
32911393|NCT05315141||The Second Xiangya Hospital|
32911394|NCT05315141||The Third Xiangya Hospital|
32911395|NCT05315141||Hunan Provincial People's Hospital|
32911396|NCT05315141||Xiangtan Central Hospital|
32911397|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
32911398|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
32911399|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
32911400|NCT05314907|Active Comparator|Training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush) and then she collects a self-sample at the health centre as a training.
32911401|NCT05314907|Placebo Comparator|No prior training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush).
32911402|NCT03684785|Experimental|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
32911403|NCT03684785|Experimental|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
32911404|NCT03684785|Experimental|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
32911405|NCT03684785|Experimental|Exploratory Phase 2, Merkel cell carinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
32911406|NCT03684785|Experimental|Exploratory Phase 2, Subcutaneous Dosing Cohort|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.
32911407|NCT03684785|Experimental|Exploratory Phase 2, Melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
33242219|NCT00785811|Placebo Comparator|2|Placebo
33242220|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
33242221|NCT00782613|Placebo Comparator|2|Placebo
33242222|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
33242223|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
33242224|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
33242225|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
33242226|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
33242227|NCT01029769|Active Comparator|initial olanzapin|
33242228|NCT01029769|Active Comparator|initial amisulpride|
33242229|NCT01029769|Active Comparator|early responders|
33242230|NCT01029769|Active Comparator|early non-responders switched|
33242231|NCT01029769|Active Comparator|ealy non-responders non-switched|
33242232|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
33242233|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
33242234|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
33242235|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
33242236|NCT05673668|Experimental|The endovascular denervation (EDN) group|Receive endovascular denervation (EDN) treatment
33242237|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
33242238|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
33242239|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
33242240|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
33242241|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
33242242|NCT03929666|Experimental|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
33242243|NCT03929666|Experimental|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
33242244|NCT03929666|Experimental|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
33242245|NCT03929666|Experimental|ZW25 + mFOLFOX6 with bevacizumab|ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
33242246|NCT03929666|Experimental|ZW25 + CisGem|ZW25 plus cisplatin and gemcitabine
33242247|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
33242248|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
33242249|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
33242250|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
33398837|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
33398838|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
33398839|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
32911408|NCT03684785|Experimental|Exploratory Phase 2, Liver Lesion|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.
32911409|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
32911410|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
32911411|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
32911412|NCT05297513|No Intervention|Standard treatment, no intervention|
32911413|NCT05297513|Experimental|Standard treatment, plus ActiveMatrix|
33242251|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
32911414|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
32911415|NCT04769999|Experimental|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
32911416|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
32911417|NCT03823287|Experimental|Faricimab|
33231564|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
33231565|NCT04105023|Experimental|genistein|Genistein capsules of 25 mg each, 50mg/day
33242252|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
33242253|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
33242254|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
33242255|NCT05254977||B.V. HOSPITAL|Local population in surrounding premises of site
33242256|NCT05254977||Baldia Hall Yazman|Local population in surrounding premises of site
33242257|NCT05254977||CIVIL HOSPITAL Bahahwalpur|Local population in surrounding premises of site
33242258|NCT05254977||DDHO KPT|Local population in surrounding premises of site
33242259|NCT05254977||Govt Girls Elementry School|Local population in surrounding premises of site
33242260|NCT05254977||Govt Higher Secondary School|Local population in surrounding premises of site
33242261|NCT05254977||Govt Sadiq Higher Secondary School|Local population in surrounding premises of site
33242262|NCT05254977||Govt TibIA College Bahawalpur|Local population in surrounding premises of site
33242263|NCT05254977||CEO Office DHA BWP|Local population in surrounding premises of site
33242264|NCT05254977||Papulation Welfare office APE|Local population in surrounding premises of site
33242265|NCT05254977||RHC Ballah Jhulan|Local population in surrounding premises of site
33242266|NCT05254977||RHC Channi Goth|Local population in surrounding premises of site
33242267|NCT05254977||RHC Choona wala|Local population in surrounding premises of site
33242268|NCT05254977||RHC Dera Bakha|Local population in surrounding premises of site
33242269|NCT05254977||RHC Headrajkan|Local population in surrounding premises of site
33242270|NCT05254977||RHC Khanqah sharif|Local population in surrounding premises of site
33242271|NCT05254977||RHC Khutri Banglow|Local population in surrounding premises of site
33242272|NCT05254977||RHC Kud Wala|Local population in surrounding premises of site
33242273|NCT05254977||RHC Lal Sohanra|Local population in surrounding premises of site
33242274|NCT05254977||RHC Mubarkpur|Local population in surrounding premises of site
33242275|NCT05254977||RHC Qaimpur|Local population in surrounding premises of site
33242276|NCT05254977||RHC Uch Sharif|Local population in surrounding premises of site
33242277|NCT05254977||Special Education Degree Colage|Local population in surrounding premises of site
33242278|NCT05254977||THQ HOSPITAL, AHMADPUR|Local population in surrounding premises of site
33242279|NCT05254977||THQ HOSPITAL, HASILPUR.|Local population in surrounding premises of site
33242280|NCT05254977||THQ KHAIR PUR TAMEWALI|Local population in surrounding premises of site
33242281|NCT05254977||THQ YAZMAN|Local population in surrounding premises of site
33242282|NCT05254977||TMA Office Hasilpur (NEW)|Local population in surrounding premises of site
33242283|NCT04074434||All Participants|
33242284|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
33242285|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
33242286|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).~."
33242287|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
33242288|NCT00790959|Experimental|SASA!|
33242289|NCT00790959|Active Comparator|Control|
33242290|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
33242291|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
33242292|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
33242293|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
33242294|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
33242295|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
33242296|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
33242297|NCT03923504|Active Comparator|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
33242298|NCT03923504|Active Comparator|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
33242299|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
32911418|NCT03823287|Active Comparator|Aflibercept|
33231566|NCT04105023|Placebo Comparator|placebo|Maltodextrin capsules, administered orally once every 12 hours
33231567|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
32911419|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
32911420|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
32911421|NCT01769573|Experimental|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
32911422|NCT01769573|Experimental|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
32911423|NCT01769573|Experimental|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
32911424|NCT01769573|Placebo Comparator|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
32911425|NCT01769573|Experimental|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
32911426|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
32911427|NCT05288543|Experimental|Single Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (25 mg), Cohort 2 (50 mg), Cohort 3 (100 mg), Cohort 4 (200 mg), Cohort 5 (300 mg), Cohort 6 (400 mg), Cohort 7 (500 mg) and Cohort 8 (600 mg)
32911428|NCT05288543|Experimental|Multiple Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (100 mg), Cohort 2 (300 mg) and Cohort 3 (500 mg)
32911429|NCT05288543|Placebo Comparator|Part A (Placebo)|Placebo tablets identical to IPG7236 tablets Dosage form: Tablet Route of Administration: Oral
32911430|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
33231568|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
32911431|NCT05282147|Other|Babies undergoing newborn eye screening|Babies having newborn eye screening with the intervention (Digital Imaging) technique in addition to the standard ophthalmoscopic technique.
32911432|NCT05224245|Experimental|Single arm: ACURATE Prime XL Transfemoral Aortic Valve System|Subjects who provide written informed consent, meet all eligibility criteria, and are approved by the Case Review Committee (CRC) will be implanted with ACURATE Prime XL Transfemoral Aortic Valve using iSLEEVE, ACURATE Prime XL Delivery System and ACURATE Prime XL Loading kit
32911433|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
32911434|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
32911435|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
32911436|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
32911437|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
32911438|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
32911439|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
33231569|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
33231570|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
32911440|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
32911441|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
33242300|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
33242301|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
33242302|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
33242303|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
33242304|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
32737157|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
32911442|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
32911443|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
32762555|NCT05090215|Active Comparator|Exercise intervention group|2 resistance training session per week using a home-based resistance training pack and 75 minutes of vigorous or 150 minutes of moderate aerobic exercise per week (as per UK government guidelines) for 12 weeks. They will have 4 assessment points, pre-op, prior to the start of the exercise programme postoperatively, at 6 weeks post commencement of exercise and at 12 weeks to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
32762556|NCT05090215|Placebo Comparator|Control group|This group will receive standard postoperative care. They will also have 4 assessment points, pre-op, prior to the start of their standard postoperative care, 6 and finally 12 weeks later to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
32762557|NCT04986995|Experimental|Opicapone|50 mg hard capsules
33242305|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
33242306|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
32762560|NCT04987073|Experimental|patients with CYP24A1 mutation|
32762561|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
32762562|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
32762563|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
32762564|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
32762565|NCT03971929|Experimental|SHR0532 tablet|up to 3 cohorts of subjects will receive multiple dose of oral tablets
32762566|NCT03971929|Placebo Comparator|SHR0532 placebo|up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
32762567|NCT03971929|Active Comparator|Hydrochlorothiazide|up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
32762568|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
32762569|NCT03626389||Patients receiving physiotherapy in primary care|Physiotherapy, without predetermined selection of specific modalities
32762570|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
32762571|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
32762572|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
32762573|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
32762574|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
32762575|NCT04986761|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
32762576|NCT04986761|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
32762577|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
32762578|NCT05067829|Active Comparator|Ideal Body weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR IDEAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR IDEAL BODY WEIGHT WILL BE GIVEN."
32762579|NCT05067829|Active Comparator|Total Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR TOTAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR TOTAL BODY WEIGHT WILL BE GIVEN."
32762580|NCT05067829|Active Comparator|Corrected Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR CORRECTED BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR CORRECTED BODY WEIGHT WILL BE GIVEN."
32762581|NCT05066971|Experimental|Participants in gradual self-adjustment rate control medication|Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.
32898342|NCT02399813|Experimental|Axalimogene filolisbac|Participants received intravenous (IV) infusion of axalimogene filolisbac administered over 60 minutes every 3 weeks at a dose of 1 x 10^9 colony forming units (cfu) for up to 2 years or until a discontinuation criterion was met (documented progression, unacceptable adverse events, withdrawn due to investigator's discretion, participant withdraws consent, pregnancy or noncompliance with study procedures or treatments). A treatment cycle was defined as 9 weeks in duration.
32898343|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
32898344|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.~Apart from that usual standard of care."
33242307|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
33242308|NCT02607722||Nintedanib|Patients with IPF
33242309|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
32737158|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
32911444|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
32911445|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
32911446|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
32911447|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
32911448|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
32911449|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
33398840|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
32911450|NCT02327117|Experimental|Tranexamic acid|
32911451|NCT02327117|Placebo Comparator|Normal Saline|
32911452|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
32911453|NCT03781089|Experimental|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L.
32911454|NCT03781089|No Intervention|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
32911455|NCT01365650|Experimental|Ketorolac Tromethamine|
32911456|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
32911457|NCT01365650|Experimental|Fluticasone Propionate|
33398841|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
33398842|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
33398843|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
33398844|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
33398845|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
33398846|NCT05233462|Active Comparator|control group|"intrathecal administration of a solution containing~bupivacaine 10 mg~morphine 100 micrograms~sufentanil 3 micrograms"
33398847|NCT05233462|Experimental|individualized group|"intrathecal administration of a solution containing~bupivacaine 0.05 mg per cm of patient's height~morphine 100 micrograms~sufentanil 3 micrograms"
33398848|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
33398849|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
33398850|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
32911458|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
32911459|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
32911460|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
32911461|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
32911462|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
32911463|NCT01770431|Experimental|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
32911464|NCT01770431|No Intervention|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
32911465|NCT03707925|Experimental|Diagnostic (bronchoscopic laser ablation, CBCT)|Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.
32911466|NCT01771055|Experimental|Galactose|Galactose
32911467|NCT01771055|Placebo Comparator|Standard resuscitation|Standard surgical methods of controlling bleeding
32911468|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
32911469|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
32911470|NCT01771991|Experimental|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
32911471|NCT01771991|Placebo Comparator|Placebo group|Cetaphil cream
32737159|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
33398851|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
32737160|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
32737161|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
32737162|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
32737163|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
32737164|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
32737165|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
32737166|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
32737167|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
32762582|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (80% limb occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
32762583|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
32762584|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (60% of the limb complete occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
32762585|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (max of 4/10 pain).
32762586|NCT05021965|Experimental|group 1: have two weeks of at-home tooth bleaching|Participants will receive two weeks of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) for the maxillary anterior teeth.
32762587|NCT05021965|Experimental|group 2 : have two sessions of in-office tooth bleaching|Participants will receive two sessions（with a 1- week interval ） of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
32762588|NCT05021965|Experimental|group 3 : one week of at-home and then have one session of in-office tooth bleaching|Participants will receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) and then receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
32762589|NCT05021965|Experimental|group 4 : one week of in-office and then have one session of at-home tooth bleaching|Participants will receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) and a week later receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%)for the maxillary anterior teeth.
32762590|NCT03069833|Experimental|Computer-aided diagnosis|
32762591|NCT03069833|No Intervention|traditional diagnosis|
32762592|NCT04986007|Experimental|digital Cognitive Behavioral Therapy for Insomnia|Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
32762593|NCT04986007|No Intervention|Waitlist Control|Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
32762594|NCT04988945|Experimental|Durvalumab + Tremelimumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD) and 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
32762595|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
32762596|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
33398852|NCT05172258|Experimental|Arm I (ipatasertib, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ipatasertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
32737168|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),~1 capsule 300 mg before each meal for a period of 90 days."
32737169|NCT05035719||Group 1|Cardiac patients
33242310|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
33242311|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
33242312|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
33242313|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
33231571|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
33398853|NCT05172258|Active Comparator|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
33242314|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
32762597|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
32762598|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
32762599|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
32762600|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
32762601|NCT04109521|Experimental|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor."
32762602|NCT04109521|No Intervention|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished).
32762603|NCT03539575|Other|Synthetic Psychoactive Cannabinoid Users|Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.
32762604|NCT04989257|Experimental|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
32762605|NCT04989257|Active Comparator|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
32762606|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
32762607|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
32762608|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
32762609|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
32762610|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
32762611|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
32762612|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
32762613|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
33242315|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
33242316|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
33242317|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
33242318|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
33242319|NCT05673590|Experimental|The treatment group-Utidelone monotherapy|Drug: Utidelone Injection Dose: 40 mg/m2/d intravenously Regimen: once daily on days 1-5 in a 21-day cycle
33242320|NCT05673590|Active Comparator|The control group-Docetaxel monotherapy|Drug: Docetaxel Injection Dose:75 mg/m2/d, administered intravenously Regimen: once on day 1 in a 21-day cycle
33242322|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
33242323|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
33242324|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
33242325|NCT01029847|Placebo Comparator|Placebo|
33398854|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
33242326|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
32911472|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
32911473|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
32911474|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
32911475|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
32911476|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
32911477|NCT03698487|Active Comparator|Intervention|"A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
32911478|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
32911479|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
32911480|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
32911481|NCT05175599|No Intervention|Land Birth|Women in the land birth group will labor and give birth according to standard of care procedures.
32911482|NCT05175599|Experimental|Water Birth|Women in the water birth group will give birth in the water. During the first stage of labor, women may enter or leave the water at any point.
32911483|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
32911484|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
33398855|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
32762614|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
32762615|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
32762616|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
32762617|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
32762618|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
32762619|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
32762620|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
32762621|NCT04988633|Experimental|Intervention CFG App|
32762622|NCT04988633|Experimental|Control Group|
32762623|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
32762624|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
32762625|NCT04106167||Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy|Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
32762626|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
32762627|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
32762628|NCT04025983|Experimental|GastimunHp Plus|1 sachet of GastimunHp Plus twice daily during or after meals.
32762629|NCT04025983|Placebo Comparator|Placebo|1 sachet of placebo twice daily during or after meals.
32762630|NCT04892069||Ryzodeg®|Participants are patients with Type 2 Diabetes (T2D) treated with Ryzodeg® (Insulin Degludec/Insulin Aspart) in a real-world adult population in Lebanon
32762631|NCT04986059|Experimental|Pre-event massage|
32762632|NCT04986059|No Intervention|Control|
32762633|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
32762634|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
32762635|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
32762636|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
32762637|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
32762638|NCT03137875||patient smear negative|patient with a negative TB microscopy result
32762639|NCT04986215||Benign pancreatic space occupying group|
32762640|NCT04986215||Malignant pancreatic space occupying group|
32762641|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
32762642|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
32762643|NCT04889105|Other|Performance evaluation|Preliminary performance evaluation to refine the Smart MOVE! intervention.
32762644|NCT04889105|Active Comparator|Smart MOVE!|Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.
32762645|NCT04889105|Placebo Comparator|Usual care|Participants will receive general walking advice for 12 weeks.
32762646|NCT02895451|Experimental|Extended behavioral intervention|Specific goal-setting, self-monitoring and feed-back
33242327|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.~Cycle length 28 days.~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.~Following identification of the MTD / RDE, dose expansion will follow."
33242328|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
33242329|NCT05673512|Active Comparator|IAH0968+ CAPEOX|IAH0968+ CAPEOX in HER2 positive metastatic colorectal cancer patient
33242330|NCT05673512|Active Comparator|CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
33242331|NCT03872492|Experimental|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).~At the end of phase 1 if the patient is considered as an responder he will make one more visit at week 12.~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
33242332|NCT02524249|Active Comparator|Early caffeine group|55 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
33242333|NCT02524249|Placebo Comparator|Late caffeine group|55 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
33242334|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
33242335|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
33242336|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD
33242337|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 100 mg BID + ritonavir 50 mg BID
33242338|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 100 mg QD + ritonavir 100 mg QD
33242339|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 150 mg QD + ritonavir 100 mg QD
33242340|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - V|lonafarnib 75 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
33242341|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 25 mg BID + ritonavir 100 mg BID
33242342|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID
33242343|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 50 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
33242344|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
33242345|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - X|lonafarnib 50 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
33242346|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of '20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
33242347|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
33398856|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
32911485|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
32911486|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
32911487|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
32911488|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
32911489|NCT04769297|Experimental|Sublingual Micro-Dose Ketamine|Ketamine micro-dose 37.5mg compounded sublingual daily administration
32911490|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
33398857|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
33398858|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
32743586|NCT04402437|Active Comparator|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
32911491|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
32743587|NCT04920591|Experimental|doll therapy (DT)|doll therapy (emathy dolls)
32743588|NCT04920591|No Intervention|Standard treatment (ST)|standard clinical practice
32911492|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
32911493|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
32911494|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
32911495|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
32911496|NCT03244475|Experimental|Neurofeedback|mTBI Veterans blindly assigned to a 6 week IASIS neurofeedback treatment with two sessions per week.
32743589|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
32911497|NCT03244475|Placebo Comparator|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with two sessions per week.
32911498|NCT03244475|No Intervention|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
32911499|NCT03244475|Experimental|Nexalin|After IASIS treatment is complete and participants in the mTBI group may have remaining PCS, additional Nexalin treatment will be offered.
32911500|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
32743590|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
32911501|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
32911502|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
32911503|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
32911504|NCT02631057||Non-Valvular Atrial Fibrillation|
32911505|NCT02631057||acute ischemic stroke|
32911506|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
32911507|NCT01325870|Experimental|S-CPR + ITPR|
32911508|NCT01325870|Active Comparator|S-CPR|
33398859|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
33398860|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
32911509|NCT01775735|Experimental|Treatment|The treatment is continuous stimulation with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
32911510|NCT01775735|Active Comparator|Control|The control is intermittent stimulation for 20 seconds every 90 minutes with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
33398861|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
33398862|NCT05152992|Experimental|Video and stimulation-based induction of emotion|Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
32911511|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
32911512|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
32911513|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
32911514|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
32911515|NCT05190315|Experimental|Chlorpromazine with standard of care chemoradiation|"Each patient will undergo 3 phases of treatment.~Concurrent Phase: includes concurrent radiation Monday - Friday (60 Gy total radiation dose in 2 Gy fractions), oral temozolomide (75 mg/m2/day) daily for a maximum 49 days starting Day 1 of radiation, and oral chlorpromazine (25 mg for first 3 patients, then escalate to 50 mg if no DLT) daily starting 7 days prior to radiation start.~Interim Phase: Continue oral chlorpromazine daily dose post-radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: 28 days after radiation fini (+/- 5 business days), Start oral temozolomide (starting dose 150 mg/m2/day and escalated to 200 mg/m2/day if no treatment related adverse events noted) once daily for 5 consecutive days of a 28 day cycle, and continue oral daily chlorpromazine seven days a week per cycle. The adjuvant phase treatment will continue for up to 6 cycles. Cycle length is 28 days."
33231572|NCT04104867|Placebo Comparator|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
33398863|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
33398864|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
32911516|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
32911517|NCT05167643|Experimental|Trastuzumab injection+Piperacillil tablets+Letrozole tablets|Trastuzumab injection:Once in 21 days IVD；Piperacillil tablets:125mg qd (d1-21) PO；Letrozole tablets:2.5mg POqd；According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
32762647|NCT02895451|No Intervention|Usual care|Hospital-based or home-based aerobic exercise 3 times a week with a duration of 30-60 minutes and an intensity of 40-80 % of Vo2max and resistance exercise 2 times a week of 1-3 sets of 10-15 repetitions. The exercise period is 16 weeks.
32911518|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.~Those are interventions that are not part of the standard care of the patients."
32911519|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
32911520|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
32911521|NCT05152199|Other|Cystoscopy with use of obturator sheath|This intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
32911522|NCT05152199|Active Comparator|Cystoscopy without use of obturator sheath|This intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
32911523|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
32911524|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
32911525|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
32911526|NCT03403257||Caregivers|Primary caregivers of subjects
32911527|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
32911528|NCT05184933|Experimental|Dipping vs non-dipping HTN|"Participants will wear an ambulatory blood pressure monitor (SpaceLabs, Inc.) which will take their blood pressure in 20-30-minute intervals for 24-48 hours to determine blood pressure dipping status.~All participants in this arm will complete the experiments in this order:~At-home polysomnography;~Constant Routine protocol;~Rested Wakefulness Trial AND Overnight Sleep Trial (Randomized crossover);~Sleep Regularization Trial"
32911529|NCT01366976|Placebo Comparator|Placebo|
32911530|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
33398865|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
33398866|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
33398867|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
33398868|NCT03175588|Experimental|virtual rehabilitation|video based exercise
33398869|NCT03175588|No Intervention|physical Activity|different type of physical Activity
32762648|NCT02659813|Experimental|Firewire|Experimental Group 1. Novel orthodontic archwire.
32911531|NCT01777217|Active Comparator|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
32911532|NCT01777217|Placebo Comparator|Placebo|Drug: Placebo oral
32911533|NCT03021707|Experimental|UV-FS laser|WaveLight® Ultraviolet Femtosecond Laser System during UV-Femto, single session (one treatment per eye per participant)
32911534|NCT05118893||Ablation-based rhythm-control|Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
32911535|NCT05118893||Rate-control|Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
33398872|NCT03175510||patients group|Patients with low back pain (18-65 years)
32743591|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
33398873|NCT02401984||Screening|A Screening tool will be administered to the participants.
32911536|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
32911537|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
32911538|NCT02948231|Experimental|Mistral|
33082092|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
32911539|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
32911540|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
32911541|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
32911542|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
32911543|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
32911544|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
32911545|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
32911546|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
32911547|NCT02255513|Experimental|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
33398874|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
33398875|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
33398876|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
33398877|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
32743592|NCT04926441||Students from 8 European Universities, regardless of field of study and academic year|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
32762649|NCT02659813|Experimental|CNiTi|Experimental Group 2. Current best available orthodontic archwire
32762650|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:~A ≥ 2-fold increase in serum creatinine OR~A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR~Urine output < 6.0 mL/kg over the preceding 12 hours OR~Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
32762651|NCT04917445|Experimental|SPIKES Protocol Compassionate Call|Nurses trained to contact IVF patients with negative pregnancy test results who were trained on the SPIKES-focused bad news delivery script.
32762652|NCT04917445|No Intervention|Control: Standard of Care Call|Nurses who will continue to deliver bad news as they have been in the past without a script.
32762653|NCT04904653|Experimental|Hemopatch Group:|Hemopatch + suction drainage
32762654|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
32762655|NCT03070691|Active Comparator|LDE225 0.75% cream|
32762656|NCT03070691|Placebo Comparator|Vehicle|
32762657|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
32762658|NCT04985591|Experimental|liposuction group|
32762659|NCT04985591|Placebo Comparator|Other plastic surgery group|
32762660|NCT02594683||Key Group of Interest|Exclusively formula fed subjects since 1 month of age
32762661|NCT02594683||Other-Fed Group|Mixed feeding of formula and breast milk
32762662|NCT02594683||Breastfeeding Group|Exclusively breastfeeding at least until 4 months of age
32762663|NCT04985747|Experimental|Polished palate|Participants will receive maxillary complete dentures with smooth palatal surfaces without modification.
32762664|NCT04985747|Experimental|Roughened palate|Participants will receive maxillary complete dentures with roughened palatal surfaces
32762665|NCT04985747|Experimental|Open palate|Participants will receive maxillary complete dentures with opened palatal surfaces
32762666|NCT02513173||Low back pain group|No intervention
32762667|NCT02513173||Control|No intervention
32762668|NCT04985435|Active Comparator|Choice group|50 patients will be randomized to the choice group, they will view a neutral information video on anti TNF and Filgotinib and will be given the opportunity to choose between these two treatments
33398878|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
32762669|NCT04985435|Active Comparator|Randomization group anti TNF|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with antiTNF
32762670|NCT04985435|Active Comparator|Randomization group Filgotinib|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with Filgotinib
32762671|NCT05084365|Experimental|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
32762672|NCT05084365|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
32762673|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
32762674|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
32762675|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
32762676|NCT03441139|Experimental|Cryotherapy + medical analgesics|Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
32762677|NCT03441139|Active Comparator|Medical analgesics|Medical analgesics alone according to the investigator's discretion
32762678|NCT04985279|Active Comparator|Standard clinical practice|"Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation using skin markers.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
32762679|NCT04985279|Experimental|Position and Angle Marking System (PAMS)|"PAMS will be attached to the ultrasound probe.~Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation by gentle pressing PAMS into the simulated patient's back to create skin indentations.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine, and the angle read off a graduated scale.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
32762680|NCT05084209|Experimental|Parkinson's medical decision making support intervention group|All participants will complete an online medical decision making intervention, lasting about 30 minutes, and complete pre and post surveys.
32762681|NCT04985669|Experimental|prucalopride group|prucalopride group will receive prucalopride 2 mg once daily
32762682|NCT04985669|Active Comparator|Lubiprostone group|lubiprostone group will receive lubiprostone 8 microgram twice daily
32762683|NCT05083897||30 patients in 1 group|measuring the effect of isometric hip adduction with knee extension on the peak torque of knee extensors
32762684|NCT04988711|Experimental|Hb Oxymeter|Hb mesurment
32762685|NCT04753957|Active Comparator|Vaginal progesterone|200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
32762686|NCT04753957|No Intervention|Control|No intervention, scheduled cesarean delivery
32762687|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
32762688|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
32762689|NCT03227263|Experimental|Bevacizumab|Intravenous infusion of Bevacizumab at a dose of 5 mg/kg
32762690|NCT03227263|Placebo Comparator|Placebo|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
32762691|NCT04985201|Experimental|Simvastatin + Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
32762692|NCT04985201|Active Comparator|Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles)
32762693|NCT03156595|Placebo Comparator|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
32762694|NCT03156595|Experimental|Hypnosis session|Hypnosis sessions with nurses or psychologists, with deepening sessions to facilitate self-hypnosis learning.
32762695|NCT04985123||Silicone Block patients|All subjects who received a successful penile implantation with the Silicone Block by the surgeons at the centers in this study.
33398879|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
32762696|NCT03092713|Active Comparator|Cognitive Intervention and Supported Employment (CCI-SE)|Combined cognitive and vocational rehabilitation in a mixed design.
32762697|NCT03092713|Active Comparator|Control group|Usual follow-up assessment and treatment provided by the multidisciplinary TBI rehabilitation team.
32762698|NCT04985045||Control group|Healthy women will be included
32762699|NCT04985045||Cerebral palsy group|Women with cerebral palsy will be included
32762700|NCT04988243|Other|Prospective and retrospective study of subjects undergoing aortic valve surgery|This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time
32762701|NCT02031601|Experimental|Combination therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
32762702|NCT02031601|Other|TKI alone therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
32762703|NCT04988165|Experimental|Treatment arm|
32762704|NCT02772679|Experimental|PolyTregs+IL-2|Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2
32762705|NCT04456127|No Intervention|Standard of Care|Scar section does not receive CO2 laser therapy.
32762706|NCT04456127|Experimental|Factional CO2|Scar section receives fractional CO2 laser therapy.
32762707|NCT04984577|Experimental|Compound Edaravone Injection-Low dose|
32762708|NCT04984577|Experimental|Compound Edaravone Injection-High dose|
32762709|NCT04984577|Active Comparator|Edaravone Injection|
32762710|NCT04984577|Placebo Comparator|Placebo Injection|
32762711|NCT05083429||Salmeterol inhaler|Reference group
32762712|NCT05083429||Tiotropium|Exposure group
32762713|NCT04984187|Other|Laser group|High Intensity Laser Therapy only , this group will receive laser for 4 weeks three times /week
32762714|NCT04984187|Other|Exercise group|Exercise , selected physiotherapy exercises will receive for 4 weeks ,3times/week
33072608|NCT04907656|Experimental|dCBT Condition|The dCBT used in this study (Daylight) was selected due to its noted efficacy in treating GAD. 25 interventions will be provided in four modules, with an average duration of 20 minutes. Sessions are unlocked weekly, and completion of an initial assessment drives an algorithm to personalize the program. Individuals may progress through treatment at a slower pace than weekly sessions; 10 weeks is allowed for treatment completion. Treatment is based on principles of applied relaxation, stimulus control, cognitive restructuring, and imaginal exposure. Participants schedule a time for each session and receive prompts if they miss the appointment. All interventions are aided by the use of an animated therapist.
33072609|NCT04907656|No Intervention|Waitlist (control) Condition|Participants allocated to the waitlist (control) condition will not receive an active intervention during the study. Participants will still complete all scheduled study assessments. They will receive access to the dCBT after completion of all study assessments.
33072610|NCT04907136|Experimental|Preferred ENDS|All participants will complete a lab visit where they will use their preferred ENDS ad libitum for up to 60 minutes
33072611|NCT04907136|Experimental|Preferred ENDS with HWL|All participants will complete a lab visit where they will use their preferred ENDS with a HWL on the device ad libitum for up to 60 minutes
33072612|NCT04906642|Active Comparator|Standard of Care|"Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):~Medication administration at surgery~Surgical irrigation and wound debridement~Surgical fracture preparation/fixation~Surgical closure"
33072613|NCT04906642|Experimental|Standard of Care plus Next Science|In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.
33072614|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
33072615|NCT04898127|Experimental|Rapid test and concert|Participants in this arm will be offered access to a concert, after a negative rapid test.
33242348|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
33242349|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
33242350|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
32762715|NCT04984187|Experimental|High intensity laser grouo|High intensity laser plus exercise will receive the selected exercises and laser 4 weeks, 3 times/week
32762716|NCT05088343|Experimental|Treatment|rosuvastatin alone and then in combination with hetrombopag
33072616|NCT04898127|No Intervention|Control|Participants in this are will not be offered access to a concert during the study period.
32762717|NCT04984265|Experimental|Stereotactic Body rRadiotherapy (SBRT)|SBRT targeting the area of the circuit of Ventricular Tachycardia
32762718|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training~150 minute moderate aerobic activities, such as brisk walking~Strength training 3 days /week~One on one sessions with exercise physiologist~Optional group sessions"
32762719|NCT03070145|No Intervention|Usual Care|Usual Care provided
32762720|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
32762721|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
32762722|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
32762723|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
32762724|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
32898345|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
33072617|NCT04896606|Experimental|SARS-CoV-2 CTLS + Standard of Care|Patients will get family donor derived SARS-CoV-2 cytotoxic t-lymphocytes up to 5 times every 2 weeks along with Standard of care of COVID-19.
33072618|NCT04896606|Active Comparator|Standard of Care Only|Patients will NOT received COVID CTLs but will get standard of care.
33242351|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
33242352|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
33242353|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
33242354|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
33242355|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
32911548|NCT02255513|Placebo Comparator|Placebo|"Placebo capsules (dose matched to HLD200 capsules)~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
32911549|NCT01778465|Experimental|Low salicylate diet, then Normal Diet|Patients followed a low salicylate diet for one week, then they followed a Normal diet for another week.
32911550|NCT01778465|Experimental|Normal diet, then Low Salicylate diet|Patients followed a Normal diet for one week, then they followed a Low Salicylate diet for another week.
32911551|NCT01779167|Experimental|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
33072619|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort A Monotherapy)|DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.
33072620|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort B Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.
33398880|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:~Abraxane (125 mg/m2) IV~Gemcitabine (1000 mg/m2) IV~Or~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)~Leucovorin 400 mg/m2 IV~5 FU 2400 mg/m2~Or~FOLFIRI: Irinotecan 180 mg/m2 IV~Leucovorin 400 mg/m² IV~5 FU 400 mg/m² IV bolus~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
32762725|NCT04983641|No Intervention|Control - No Pre-Visit Message|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were not sent any reminder e-mails or MyChart messages concerning PROMIS form completion at any timepoint prior to their scheduled clinic visit.
32762726|NCT04983641|Experimental|E-mail Arm|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were sent an initial reminder e-mail message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patient's did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder e-mail message.
32762727|NCT04983641|Experimental|"Digital Patient Portal MyChart Arm"|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patient's in this arm were sent an initial reminder MyChart message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patients did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder MyChart message.
32762728|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
32762729|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
32762730|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
32762731|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
32762732|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
32762733|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
32762734|NCT04983563|Experimental|Actigraphy|
32762735|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
32762736|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
32762737|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
32762738|NCT04584541|Other|case|Index cases (RA and SpA patients under immunosuppressive treatments)
32762739|NCT04584541|Other|controls|Members of index cases family cluster infected with the same viral strain
32762740|NCT04982861|Experimental|Cefixime trihydrate 100 mg/5 mL dry syrup|Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
32762741|NCT04982861|Active Comparator|Suprax® 100 mg/5 mL dry syrup|Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
32762742|NCT04456049|Experimental|Enzalutamide (Xtandi®)|Interventional treatment
32762743|NCT04456049|Active Comparator|Standard of care (SOC)|Supportive treatment
33072621|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort C Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.
33072622|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort D Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.
33398881|NCT03665441|Other|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
33072623|NCT04892017|Experimental|Expansion Cohort 1 (Part 2)|DCC-3116 tablets given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) (with a documented mutation in KRAS).
33398882|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
33072624|NCT04892017|Experimental|Expansion Cohort 2 (Part 2)|DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC) (with a documented mutation in KRAS, NRAS, NF1,or BRAF).
33072625|NCT04892017|Experimental|Expansion Cohort 3 (Part 2)|DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC) (with a documented mutation in KRAS, NRAS, NF1, or BRAF).
32906846|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
33072626|NCT04892017|Experimental|Expansion Cohort 4 (Part 2)|DCC-3116 tablets orally given in combination with binimetinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma (with a documented mutation in NRAS).
33072627|NCT04892017|Experimental|Expansion Cohort 5 (Part 2)|DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).
33242356|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
33242357|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
33242358|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
33242359|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
33072630|NCT04888832|No Intervention|Control Group|No change to work requirements or recertification period
33242360|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
33242361|NCT03066206|Experimental|Treatment (poziotinib)|Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33242362|NCT03025256|Experimental|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline, cycle 5 and then every 8 weeks. Patients undergo MRI at baseline, cycles 3, 5, and then every 8 weeks.
33242363|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
33242364|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
33242365|NCT03869372|Experimental|Study subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Based on responses to symptom surveys (IBS-SSS and PAGI-SYM), study subjects will be characterized as healthy or as having functional dyspepsia and/or IBS."
33242366|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
33242367|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
33242368|NCT03869216|Experimental|Intervention|Patients in the intervention will receive the educational intervention
33242369|NCT03869216|No Intervention|Usual Care|Patients in the control arm will receive usual care
33242370|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
33242371|NCT03925298||group 2|those with normal serum troponin level (<0.01μg/L)
33242372|NCT04073654|Active Comparator|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
33242373|NCT04073654|Experimental|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
33242374|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
33242375|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
33072631|NCT04888832|Active Comparator|Intervention Group 1|Standard 6-month recertification period, additional 6-month work requirement exemption
33072632|NCT04888832|Active Comparator|Intervention Group 2|Standard 6-month recertification period, additional 12-month work requirement exemption
33072633|NCT04888832|Active Comparator|Intervention Group 3|Standard 6-month recertification period, additional 12-month work requirement exemption
33072634|NCT04888832|Active Comparator|Intervention Group 4|12-month recertification period (6-month extension), additional 6-month work requirement exemption
32906847|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
33242376|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
33072635|NCT04881630|Active Comparator|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
33242377|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
33242378|NCT02580734|Experimental|melatonin|tablet with melatonin
33242379|NCT05673434|Experimental|Experimental: TM4SF1 positive CAR-T cells for digestive tumors|"The present study is proposed to study advanced malignant digestive tumors in adults, and the four escalating doses, namely, 0.5~1.0.,1.0~2.0,2.0~3.0 and 3.0~10.0 (×10 ^6/kg), will be given.~Intervention: Biological: TM4SF1-positive chimeric antigen receptor T-cell therapy"
33242382|NCT04073576|Experimental|AHCL|Advanced Hybrid Closed Loop
33242383|NCT04073576|Active Comparator|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
33072636|NCT04881630|Experimental|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
33072637|NCT04880863|Experimental|NAP in combination with docetaxel following obinutuzumab pretreatment|Subjects will receive obinutuzumab, 1,000 mg, administered by IV infusion on Days -13 and -12 of the first treatment cycle in order to reduce the titer of anti-drug antibodies to NAP. NAP will be administered in a daily dose of 10 μg/kg by IV bolus on Days 1 - 4 of treatment cycles 1-6, followed by docetaxel, 75 mg/m2 on Day 5. Treatment cycles with the combination NAP/docetaxel will be 21 days in duration. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1 and docetaxel on Day 2, in 21 days treatment cycles. Once NAP is given as monotherapy and not earlier than C7, cycles will be of 28 days of duration.
33072638|NCT04880629|Experimental|Sleep rectriction|Participants in METWI2 undergo both a baseline (unrestricted) sleep and sleep restriction condition. On the morning following each condition, participants complete an oral glucose tolerance test to measure changes in glucose and insulin following ingestion of a glucose load.
33242384|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
33242385|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
33072641|NCT04875338|Active Comparator|saline injection|2ml %0.9 NACI(Saline )injection to effected lateral epicondyle
33242386|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
33242387|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
33242388|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
33242389|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
33242390|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
33242391|NCT02881814|Experimental|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
33398883|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
32906848|NCT03405428|Other|All patients|
33072642|NCT04875338|Active Comparator|platet riched plasma injection|2 ml prp )injection to effected lateral epicondyle
33072643|NCT04875338|Active Comparator|betametazon injection|2 ml betametazon )injection to effected lateral epicondyle
33072644|NCT04869098|Experimental|Whey protein preload condition|Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
33072645|NCT04869098|Placebo Comparator|Placebo condition|Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
33072646|NCT04868526|Experimental|Control-Dietary Intervention|Control condition first, then the Dietary intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
32911552|NCT01780337|Active Comparator|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
32911553|NCT01780337|Placebo Comparator|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
32911554|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
32911555|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
33072647|NCT04868526|Experimental|Dietary intervention-Control|Dietary intervention first, then the Control condition. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
32906849|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
32906850|NCT01724294||Cohort|
32906851|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
32906852|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
32906853|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
32762744|NCT04572217|Experimental|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.~Patients will be followed every 2-12 weeks over one year.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
32762745|NCT04572217|No Intervention|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
32762746|NCT04455503|Experimental|Cohort A: Nivolumab and EVX-02A|EVX-02A administered IM.
32762747|NCT04455503|Experimental|Cohort B: Nivolumab and EVX-02B|EVX-02B administered IM.
32762748|NCT04455503|Experimental|Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B|The selected delivery methodology either EVX02A or EVX-02B.
32762749|NCT04553809|Active Comparator|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
32762750|NCT04553809|Experimental|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
32762751|NCT05376371|Experimental|CJC-TraC Intervention|Incarcerated individuals with HIV, hepatitis C, or substance use disorder readying for release will enroll in the CJC-TraC intervention intended to assist in transitioning their health care.
32762752|NCT05083195|Experimental|Telerehabilitation Group|This group will perform their exercises with pre-prepared personalized exercise videos over the telerehabilitation system 3 times a week for 8 weeks.
32762753|NCT05083195|Experimental|Control Group|This group will perform exercises with personalized exercise brochures defined over the telerehabilitation system 3 times a week for 8 weeks.
32762754|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
32762755|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
32762756|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
32762757|NCT05635955|Experimental|Remimazolam|Intravenous Remimazolam will be co-administrated with esketamine.
32762758|NCT05635955|Active Comparator|Propofol|Intravenous Propofol will be co-administrated with esketamine.
32762759|NCT05083117|Experimental|XW001|Treatment arm patients will receive inhaled XW001 1 mg, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
32762760|NCT05083117|Placebo Comparator|Placebo|Placebo arm patients will receive volume-matching placebo 1 mL, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
32762761|NCT04452461|Other|Single Arm Intervention|"Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.~Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.~Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.~5. Pancreatectomy 4 weeks following the last day of Chemotherapy as per standard of care.~6. Adjuvant chemotherapy: as per standard of care. 7. Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.~8. Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
33398884|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
33398885|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
33398886|NCT03663569||subjects with COPD|
32762764|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
32762765|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
33072650|NCT04861987|Experimental|PCS6422 + Capecitabine|Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles
33072651|NCT04861792|No Intervention|Usual Care|Patients seen before the intervention launch date.
33398887|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
33398888|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
33398889|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
33398890|NCT03596762|Experimental|160 mg Elinzanetant (BAY3427080)|Participants received 4x40 mg elinzanetant capsules.
32762766|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
32762767|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
32762768|NCT05635799|Experimental|Subjects with lower limb amputations|
32762769|NCT05635799|Active Comparator|Healthy volunteers|
33072652|NCT04861792|Experimental|Quality Improvement Intervention|Patients seen after the intervention launch date.
33398891|NCT03596762|Experimental|120 mg Elinzanetant (BAY3427080)|Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
33398892|NCT03596762|Experimental|80 mg Elinzanetant (BAY3427080)|Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
33398893|NCT03596762|Experimental|40 mg Elinzanetant (BAY3427080)|Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.
33398894|NCT03596762|Placebo Comparator|Placebo|Participants received four placebo capsules orally once daily in the evening before bedtime.
32762770|NCT05075941||Shelters Paris/93|
32762771|NCT05075941||Workers' hostels Paris/93|
32762772|NCT05075941||travelling community IDF(77/93/95)|
32762773|NCT05075941||Street/Camps Paris/93|
32762774|NCT05075941||Covid Homeless and migrants Marseille|
32762775|NCT05075941||Hostel Paris/93|
32762776|NCT04412681|Experimental|PE Enhanced Screening|"The PE screening program entails the following for all participants:~provision of additional demographic and risk factors~provision of mean arterial pressure~standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer~standard blood sample (as part of the FTS)~results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
32762777|NCT03019003|Experimental|Oral Decitabine and Durvalumab|Oral decitabine (ASTX 727) will be administered alone in Cycle 1 and the combination of oral decitabine and durvalumab therapy will be given in Cycles 2-12.
32762778|NCT05635565|Active Comparator|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
32762779|NCT05635565|Experimental|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
32762780|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32762781|NCT04437745|Experimental|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
32762782|NCT04437745|No Intervention|Control|No Intervention
32762783|NCT05214911|Experimental|Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)|ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL
32762784|NCT05214911|Active Comparator|Active Comparator: Leg® (Desloratadine 0.5 mg/mL)|Leg® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL
32762785|NCT04383925|Experimental|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
32762786|NCT04383925|Active Comparator|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
32762787|NCT05635253|Other|GROUP GSEM|In-office whitening treatment with 35% Hydrogen Peroxide
32762788|NCT05635253|Experimental|GROUP GP|In-office whitening treatment with 35% Hydrogen Peroxide + Polishing of whitened teeth
32762789|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
32762790|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
32762791|NCT03069599||10 resection only|patients undergoing surgical resection only
33072653|NCT04855006|Experimental|Vaginal Microbiome Transplant|Women are given the vaginal microbiome transplant at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
33398895|NCT04481386|Experimental|Active arm|Participants with a diagnosis of retinal detachment or vitreous haemorrhage, who are scheduled for vitrectomy surgery with a vitreous substitute
33398896|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
33398897|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
32906854|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
33242392|NCT02881814|Experimental|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
33242393|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
33398898|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
33398899|NCT02401360|Experimental|Experimental Group|Oral care regimen
32911556|NCT04769219|Experimental|secondary prevention training|Secondary prevention training will be given to 43 randomly selected patients between the fourth and sixth hours after AMI (in accordance with the patient's request). Secondary protection training will be carried out in two parts. First of all, the anatomical structure and functions of the heart, the definition of AMI, its causes, symptoms and risk factors will be explained, and then the issues to be considered after AMI will be explained. The content of the training will also be given to the participants in a written booklet.
32911557|NCT04769219|No Intervention|nursing care|43 randomly selected patients will form the control group and this group will be provided with routine care and follow-up in the clinic. No intervention will be made.
32911558|NCT02865473|No Intervention|primary open angle glaucoma patients|
32911559|NCT02865473|No Intervention|patients with primary angle closure|
32911560|NCT02865473|No Intervention|patients with neovascular glaucoma|
32911561|NCT02865473|No Intervention|PEX glaucoma patients|
32911562|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
33072654|NCT04855006|Placebo Comparator|Vaginal Microbiome Transplant Placebo|Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
33398900|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
33398901|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
32911563|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
32911564|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
32911565|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
32911566|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
32911567|NCT04769063|Experimental|Hip|
32911568|NCT04769063|Experimental|Knee|
32911569|NCT04769063|No Intervention|Control|
32911570|NCT01783847|Experimental|Recombinant human erythropoietin (EPO)|Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for >13 years/ day for 3 days
32911571|NCT01783847|Active Comparator|Methylprednisolone|Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
32911572|NCT01783847|Other|Observation|Observation
32911573|NCT05026385|Experimental|Intervention|"The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing.~After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase."
32911574|NCT05026385|No Intervention|Usual Care|The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
32911575|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
32911576|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
32911577|NCT02663531|Experimental|Healthy|Healthy volunteers
32911578|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
32911579|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
32911580|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
32911581|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
32911582|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
32911583|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
32911584|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
32911585|NCT02516813|Experimental|Ancillary cPoP: MSC2490484A+Fractionated RT|Ancillary Clinical proof-of-principle (cPOP) study, subjects will receive first dose of RT on Day 1, and will receive MSC2490484A capsule or Tablet formulation within 1.5 hour before the second dose of RT on Day 2.
32911586|NCT05009147|Experimental|experimental group|receive whole body manual massage
32911587|NCT05009147|No Intervention|control group|After experiment, receive whole body manual massage
32911588|NCT01785095|Experimental|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
32911589|NCT02990429|Experimental|Forced Air warmer (bair hugger)|".~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
32911590|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
32911591|NCT01786187|Active Comparator|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
32911592|NCT01786187|Experimental|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
32911593|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
32911594|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
32911595|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
32911596|NCT01786343|Experimental|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
32911597|NCT01786343|Experimental|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
32911598|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
32911599|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
32911600|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
32911601|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
32911602|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
32911603|NCT01786967|Experimental|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
32911606|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
33072655|NCT04855006|Experimental|Vaginal Microbiome Donors|Women allocated in the donor group will donate their vaginal secretion, which will be processed and analyzed throughy before it is used as a transplant. In total, the donors will each provide approximately 10 donations of vaginal secretion.
32911607|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
32911608|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
32911609|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
32911610|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
32911611|NCT01807637|Experimental|transcranial direct current stim|tDCS will be applied using a Soterix constant current stimulator with 5 x 5 cm (25cm2) carbon rubber electrodes (Covidien 664 REFX 2x2) applied to the scalp with 10-20 conductive paste. The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere [established during TMS motor threshold testing (Baseline Testing) and the functional MRI assessment]. The cathodal electrode will be placed over the contralateral motor cortex.
32911612|NCT01807637|Placebo Comparator|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
32911613|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
33072656|NCT04850105||TEGSEDI-exposed cohort|This cohort consist of patients diagnosed with hATTR-PN who are receiving any dose of commercial TEGSEDI and who have provided written informed consent to be included into the study.
33072657|NCT04850105||TEGSEDI-unexposed cohort|This cohort which will consist of patients diagnosed with hATTR-PN who have not taken any dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI treatment per applicable product label and who have provided written informed consent to be included into the study.
32762792|NCT04312867|Experimental|Project STRONG|Project STRONG is an active skill-based intervention designed to prevent adolescent dating violence among middle school boys. Boys and a parent will complete the web-based program together focusing on improving communication and emotion regulation.
32906855|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
32906856|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
32906857|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
32906858|NCT02465034|Active Comparator|Healthy Control|Healthy individuals will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
32906859|NCT03001037||Group A - Low Back Pain|"Group A:~Subject provides written authorization and/or consent per institution and geographical requirements~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100~Subjects in Group A are intended to be assessed with ViMove based on standard of care~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment~Observational study, no intervention"
32906860|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months~Subject is willing to follow up 3 months post initial assessment~Observational study, no intervention"
32906861|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
32906862|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
32906863|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
32906864|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
32906865|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
32906866|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
32906867|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
33072658|NCT04848961|Experimental|Women who have had a mammogram|Participants will consist of eligible women who have had a mammogram
33072659|NCT04848480|Experimental|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times
32906868|NCT01724372|Experimental|Antidepressant|Fluoxetine
32906869|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
32906870|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
32906871|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
32906872|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
32906873|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
32906874|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
32906875|NCT01584479||Low risk Control Group|"2 visits - Low Risk~~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
32906876|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
32911614|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
32911615|NCT01263314|Experimental|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
32911616|NCT01263314|Experimental|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
32911617|NCT01263314|Experimental|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
32911618|NCT01263314|Placebo Comparator|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
32911619|NCT01263314|Experimental|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
32911620|NCT01263314|Experimental|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
32911621|NCT01263314|Experimental|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
32911622|NCT01263314|Placebo Comparator|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
32911623|NCT01642901|Experimental|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
32911624|NCT01642901|Placebo Comparator|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
32743593|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
32737170|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 18 J"
33072660|NCT04848480|Active Comparator|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times
33072661|NCT04838808|Active Comparator|Rivaroxaban|Rivaroxaban 2.5mg oral twice daily for 90-days
32743594|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
33072662|NCT04838808|Placebo Comparator|Placebo|Oral placebo tablet twice daily for 90-days
33072663|NCT04836429|Experimental|Treatment (porfimer sodium, photodynamic therapy)|Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy
33072664|NCT04834726|Active Comparator|1: Usual Care|Patients will receive a phone call to schedule their appointment from an Access Center representative. Access Center representatives will make up to 3 attempts to schedule an appointment with the patient. Patients randomized to this arm will not receive any text messaging.
33072665|NCT04834726|Experimental|2A: Call Back + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
33072666|NCT04834726|Experimental|2B: Call Back + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
32743595|NCT04925973|Experimental|Treatment arm|Tofacitinib 10mg PO BID
32743596|NCT04400175|Experimental|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
32743597|NCT04400175|Sham Comparator|B-STD|B-STD will be fed with a standard feeding system.
33398902|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
32743598|NCT04431297|Other|Health Care Workers|Voluntary participation in the virtual presentations
32743599|NCT04926519||Aggressive periodontitis|Patients that got the diagnosis aggressive periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
32743600|NCT04926519||Chronic periodontitis|Patients that got the diagnosis chronic periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
32743601|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
32743602|NCT03056235|Placebo Comparator|Saline control|Saline
32743603|NCT04926207|Experimental|Physical Activity Breaks Intervention|Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
32743604|NCT04926207|Active Comparator|Talking Breaks Control|Participants will sit continuously for 3 hours. They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
32743605|NCT04912167|Experimental|ARNI-Sacubitril-Valsartan|patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.
32743606|NCT04912167|Active Comparator|ACEI-Enalapril|patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril
32743607|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
32743608|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
32743609|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
32743610|NCT04919967|Experimental|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course an also receive support through the Virtual Implementation Protocol.
32743611|NCT04919967|Active Comparator|E-learning/toolkit alone|Participants assigned to the e-learning/toolkit alone group will only complete the e-learning course/receive the e-learning toolkit.
32743612|NCT04919967|No Intervention|Treatment as usual|Participants assigned to this group will not be provided any additional training or implementation assistance. They will be able to take trainings outside of study protocol if they would otherwise plan or want to do so. They will be offered the study-specific training and implementation assistance after they have completed the final study assessments.
32743613|NCT04925661|Experimental|HEC53856|Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
32743614|NCT04925661|Active Comparator|Roxadustat|Drug: roxadustat TIW dosing There will be only one cohort: 70mg
32743615|NCT04925661|Placebo Comparator|Placebo|Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
32743616|NCT04925115|Experimental|Interventional group|"Interventional group:~Warm up and cool down (10 minutes before physical activity)~Brisk walking ( 30 minutes each session for 5 days in a week)~Week 1 to week 6 same protocol"
32743617|NCT04925115|No Intervention|Control group|Routine activity of daily life
32743618|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
32743619|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
33072667|NCT04834726|Experimental|2C: Call Back + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
33072668|NCT04834726|Experimental|2D: Call Back + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-outWill include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
32911625|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
32911626|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
32911627|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
32911628|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
32911629|NCT01612949||Test|A group of unlabeled subjects (mix of easy and difficult intubations) to test the reproducibility of the derived and validated model(s)
32911630|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
33072669|NCT04834726|Experimental|3A: In-Bound Call + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
33072670|NCT04834726|Experimental|3B: In-Bound Call + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
33242394|NCT04836494|Experimental|BBP-671 for SAD|The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
33242395|NCT04836494|Placebo Comparator|Placebo for SAD|The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
33072671|NCT04834726|Experimental|3C: In-Bound Call + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
33072672|NCT04834726|Experimental|3D: In-Bound Call + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-out. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
33242396|NCT04836494|Experimental|BBP-671 for MAD|The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
33242397|NCT04836494|Placebo Comparator|Placebo for MAD|The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
33242398|NCT04836494|Experimental|BBP-671 for SAD Food Effect|Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
33242399|NCT04836494|Experimental|BBP-671 for PA and MMA Patients|Up to sixteen (16) patients with either PA or MMA will receive BBP-671.
33242400|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
33072674|NCT04832750||Major Depressive Episode|At least one failed pharmaco trial in current episode
33072675|NCT04832750||Major Depressive Episode with comorbid Borderline Personality Disorder|At least one failed pharmaco trial in current episode
33242401|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
33242402|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
33072676|NCT04832750||Healthy Controls|No psychiatric disorders
32762793|NCT04312867|Active Comparator|Health Promotion|Health Promotion is an information-based program designed to mimic content areas provided during middle-school health education. The content is provided via a web-based interface to mirror the content delivery in the active intervention (Project STRONG).
33072677|NCT04829110|Experimental|A. ETOH|5 Males and 5 Females will receive deuterated water and drink 2.15 ounces of alcohol in the form of vodka and have de novo Lipogenesis measured at 11 time points during and after.
33072678|NCT04829110|Experimental|ETOH + Sucrose|5 Females will receive deuterated water and drink 1.72 ounces of alcohol in the form of vodka + 7 grams of sucrose and have de novo Lipogenesis measured at 11 time points during and after.
33072679|NCT04829110|Experimental|C. Sucrose|5 Females will receive deuterated water and drink a solution containing water and 35 grams of sucrose, and have de novo Lipogenesis measured at 11 time points during and after.
33072680|NCT04826640||Pregnant women who receive COVID-19 vaccine|Pregnant women who receive COVID-19 vaccine
33072681|NCT04819100|Experimental|Selpercatinib|Selpercatinib administered orally.
33072682|NCT04819100|Placebo Comparator|Placebo|Placebo administered orally.
33242403|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
33242404|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
33242405|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
33072686|NCT04813926||Patients diagnosed with PAH|
33072688|NCT04803877|Experimental|Regorafenib and Nivolumab|
33072689|NCT04797299||Single Arm Cohort|Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.
33072690|NCT04792502|Experimental|Planned Therapy|
32911631|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
32911632|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
32911633|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
33072691|NCT04790344|Experimental|Treatment Arm|All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.
33072692|NCT04784715|Experimental|Arm A|Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo
33072693|NCT04784715|Experimental|Arm B|Trastuzumab deruxtecan (T-DXd) plus pertuzumab
33072694|NCT04784715|Active Comparator|Arm C|Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)
33072695|NCT04781842|Experimental|Boxing Club Group|Participation in a weekly boxing program designed for people with Parkinson Disease
33072696|NCT04781842|No Intervention|Control group|No changes to regular physical activity during the study period
33072697|NCT04777422|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
33072698|NCT04775953|Experimental|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) <30 and not on dialysis. N=100
33072699|NCT04775953|Active Comparator|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
33242406|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
33072701|NCT04770363|Experimental|Bihemispheric Stimulation Group|The first group tDCS bihemispheric stimulation consisted of 20 minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex M1 (C3 and C4 of the international 10 -20 EEG electrode system).
33072702|NCT04770363|Experimental|Unihemispheric Stimulation Group|The second group unilateral stimulation, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone.
33072703|NCT04770363|Sham Comparator|Sham Group|The third sham group, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone, but delivering no current.
33072704|NCT04768920|Experimental|Teletx|The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc).
33072705|NCT04766892|Experimental|mavacamten (MYK-461)|
33072706|NCT04766021|Placebo Comparator|Placebo|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
33072707|NCT04766021|Experimental|100 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
33072708|NCT04766021|Experimental|150 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
33072709|NCT04766021|Experimental|200 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
33072710|NCT04762251|Experimental|Time-restricted eating (TRE)|The TRE group will be instructed to follow TRE (9 h/day) every day for 12 months with no other dietary instructions or advice provided. The TRE group will attend the same consult schedule as the CP group, but consultations will focus on timing of dietary intake and strategies to promote adherence. No dietary guidance regarding quantity or quality will be provided. Participants will be able to self-select the precise 9-h schedule that will best suit their lifestyles, with the caveat that the latest time of eating will be set at 7:00 pm. Outside of the elected eating window, participants will be allowed to consume water and black coffee and/or tea.
33242407|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
33242408|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
33242409|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
33242410|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
33242411|NCT04703192|Experimental|Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review.
33242412|NCT04703192|Experimental|Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody.
33242413|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
33242414|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
33242415|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
33242416|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
33242417|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
33242418|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
33242419|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
33242420|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
33242421|NCT03840902|Experimental|Arm 1: cCRT plus M7824 followed by M7824|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.
33072711|NCT04762251|Active Comparator|Current Best Practice (CP)|This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. No specific advice will be provided regarding time of day to start and finish eating and/or drinking (since this information is not outlined in current practice guidelines).
33072712|NCT04761198|Experimental|Squamous cell carcinoma of the head and neck|Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck
33072713|NCT04761198|Experimental|Cervical cancer on or after chemotherapy|Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
33072714|NCT04761198|Experimental|Gastric or gastroesophageal junction adenocarcinoma|Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
33072715|NCT04761198|Experimental|Endometrial carcinoma post-platinum <3L treatment|Advanced and/or metastatic endometrial carcinoma
33072716|NCT04761198|Experimental|Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors|Advanced or metastatic tumor mutational burden-high (TMB-H)
33072717|NCT04761198|Experimental|Rare disease with high prevalence of TIGIT expression|Select rare tumors
33072718|NCT04761198|Experimental|Ovarian cancer|Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy
33072719|NCT04761198|Experimental|Endometrial carcinoma post standard of care therapy|Advanced and/or metastatic endometrial carcinoma
33072720|NCT04759586|Active Comparator|Arm A (DA-EPOCH-R)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until ANC is >= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study,
33072721|NCT04759586|Experimental|Arm B (DA-EPOCH-R, nivolumab)|Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study,
33242422|NCT03840902|Active Comparator|Arm 2: cCRT plus placebo followed by durvalumab|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.
33242423|NCT04047225|Experimental|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
33242424|NCT04047225|No Intervention|No Analgesia Nociceptive Index (ANI)|Do not use ANI
33242425|NCT00782925|Experimental|1|"Study intervention:~A face/profile X-ray of their entire spine at baseline~Educational program~Exercise program~Self-led exercises~A follow-up at 12 and 24 months with their occupational therapist.~A follow-up at 18 months with a physical therapist.~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
33242426|NCT00782925|No Intervention|2|"Control intervention :~No intervention~A face/profile X-ray of their entire spine at baseline~A follow-up at 12 and 24 months with their occupational therapist,~A follow-up at 18 months with a physical therapist."
33242427|NCT00791115|Experimental|prostatectomy after radiotherapy|
33242428|NCT04073888|Other|Single arm|Men with Fabry Disease
33242429|NCT04072796||Case group|Case group reported urinary complaints
33242430|NCT04072796||Control group|Control group did not have any urinary complaints.
32911634|NCT01807871|Experimental|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
33242431|NCT03840668|Experimental|Dry eye|Participants who will be using the USB-powered eye mask.
32911635|NCT01807871|Active Comparator|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
32911636|NCT01091831|Active Comparator|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
33242432|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
33072722|NCT04759586|Active Comparator|Arm C (R-CHOP)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study,
33242433|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
33242434|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
33072723|NCT04759586|Experimental|Arm D (R-CHOP, nivolumab)|Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study,
33072724|NCT04759586|Active Comparator|Arm E (R-CHOP, radiation therapy)|Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients also undergo FDG-PET/CT on study,
33242435|NCT04072718|Other|Single arm|
33242436|NCT03838562|Experimental|Virtual Reality Arm|
33072725|NCT04759586|Experimental|Arm F (R-CHOP, nivolumab, radiation therapy)|Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients also undergo FDG-PET/CT on study,
33242437|NCT03838562|Active Comparator|Control Arm|
33242438|NCT04038086|Experimental|oral glucose tolerance test|
33072727|NCT04752332|Experimental|Abemaciclib Plus (+) Endocrine Therapy (ET)|Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
33072728|NCT04752332|Active Comparator|Placebo + ET|Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.
33072729|NCT04751370|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy, TME)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles. Starting least 2 weeks but no longer than 6 weeks after completion of cycle 2 of nivolumab and ipilimumab, patients undergo short-course radiation therapy of 5 fractions daily for 1 week. Patients then continue to receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. 8-12 weeks after completion of 4th cycle of nivolumab and ipilimumab, patients undergo TME. Patients also undergo MRI and CT prior to TME and during follow up, and undergo sigmoidoscopy prior to TME.
33242439|NCT04038086|Other|circadian rhythm|
33242440|NCT04038086|Experimental|effect of insulin on peptide transport|
33242443|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
33242444|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
33242445|NCT04072640|Experimental|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
33242446|NCT04072640|Active Comparator|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
33072730|NCT04748354|Active Comparator|Usual Care|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
33242447|NCT04072640|Experimental|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
33242448|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
33242449|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
33242450|NCT04819646|Experimental|Inflammation|Marine Lipid Oil concentrate softgel and dietary supplement capsule
33242451|NCT04073264|Experimental|monofilament|monofilament absorbable suture
33242452|NCT04073264|Active Comparator|polifilament|synthetic absorbable braided (polifilament) suture
33242453|NCT04019210|Experimental|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
33242454|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
33242455|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
33242456|NCT00427921|Experimental|1|Open Label
33242457|NCT02137850|Experimental|50 EDs (exposure days)|
33242458|NCT04794374|Experimental|Discharged COVID-19 survivors|"Telerehabilitation will be provided by physiotherapists including audio, video visits.~A brochure designed by physiotherapists for COVID-19 survivors will be used. Physiotherapists will call patients weekly and guide, design, modify the exercises accordingly to the patients."
33242459|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
32911637|NCT01091831|Active Comparator|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
32911638|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
32911639|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
33072731|NCT04748354|Experimental|Usual Care with Exercise|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
32911640|NCT00507299|Experimental|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
32911641|NCT00507299|Active Comparator|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
33072732|NCT04732949|Active Comparator|SNG001|SNG001 via inhalation using Ultra device, once a day for 14 days
33072733|NCT04732949|Placebo Comparator|Placebo|Placebo via inhalation using Ultra device, once a day for 14 days
33072734|NCT04720313|Experimental|CART BCMA|The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10^6, 450×10^6, 800×10^6 or 1200 ×10^6 The expansion phase (Part B) will include a dose between 450×10^6 to 800×10^6 CAR-positive (CAR+) T cells
33072735|NCT04715685|Experimental|40 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33242460|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
33242461|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
33242462|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
33242463|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
33242464|NCT04622683|Experimental|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
33242465|NCT04622683|Active Comparator|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
33072736|NCT04715685|Experimental|40 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33072737|NCT04715685|Experimental|40 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33072738|NCT04715685|Experimental|40 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33242466|NCT04786028|Experimental|Isatuximab with CyBorD and Lenalidomide Maintenance|This is a single arm study of Isatuximab administered intravenously in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), and Lenalidomide maintenance treatment
33242467|NCT01030081|Experimental|Amlodipine (Norvasc®)|
33072739|NCT04715685|Experimental|20 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33072740|NCT04715685|Experimental|20 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33072741|NCT04715685|Experimental|20 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33242468|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
33242469|NCT02108054|Experimental|1|People with alcohol use disorder
33242470|NCT02108054|Experimental|2|People without alcohol use disorder
33242471|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
33242472|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
33242473|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
33242474|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
33242475|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
32911642|NCT01263938|Other|Atorvastatin|
32911643|NCT01789775|Placebo Comparator|CD07805/47 gel Placebo|Placebo
33072742|NCT04715685|Experimental|20 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
33072743|NCT04686305|Experimental|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
33242476|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
33242477|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
33072744|NCT04686305|Experimental|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
33072745|NCT04686305|Experimental|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
33242478|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
33242479|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
33072746|NCT04686305|Experimental|Arm 1D: T-DXd|T-DXd
33072747|NCT04686305|Experimental|Arm 2A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
33072748|NCT04686305|Experimental|Arm 2B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
33242480|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
33398903|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
33072749|NCT04686305|Experimental|Arm 2C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
32762794|NCT05634941|Active Comparator|Active ON-tDCS|The active group will receive the active transcranial direct current stimulation via a saline-soaked pair of surface sponges. Patients received this treatment protocol for 5 consecutive days.
32762795|NCT05634941|Sham Comparator|Sham ON-tDCS|The sham group will also receive the transcranial direct current stimulation for 5 consecutive days on sham procedure. The rationale behind this sham procedure was to mimic the transient skin sensation at the beginning of active ON-tDCS without producing any conditioning effects on the brain.
32762796|NCT05634863|Experimental|KIDNEY TRANSPLANT PATIENTS WITH THE IMPLANTABLE CONTINUOUS VASCULAR MONITORING DEVICE|The intervention that is intended to be investigated is the implantable vascular monitoring device manufactured by COOK Medical Company. Its principle intended use is continuous monitoring of the graft perfusion (i.e. transplanted kidney) for the first 72 hours postoperatively. The kidney transplant patients in the intervention group will receive implantable continuous vascular monitoring device surveillance for the first 72 hours in addition to the standard care clinical observation as part of their postoperative care. The intervention will be removed after 72 hours postoperatively.
33072750|NCT04686305|Experimental|Arm 2D: T-DXd, Durvalumab|T-DXd, Durvalumab
33072751|NCT04685239|Active Comparator|Unipolar cup|Patients randomized to receive a conventional unipolar acetabular cup
33072752|NCT04685239|Active Comparator|dual mobility cup|Patients randomized to receive a double mobility acetabular cup
32762797|NCT05634863|No Intervention|KIDNEY TRANSPLANT PATIENTS WITH STANDARD CARE CLINICAL OBSERVATION|The kidney transplant patients in this group will receive the standard care clinical observation as part of their postoperative care. Their graft will be monitored postoperatively by the standard care clinical observation as per the NHS protocol.
32911644|NCT01789775|Experimental|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
33242481|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
33242482|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
33072755|NCT04684147|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
33072756|NCT04681144||Radium-223-dichloride (Xofigo, BAY88-8223)|Patients with metastatic castration-resistant prostate cancer (mCRPC)
33072757|NCT04673617|Experimental|Phase 1: Dose confirmation of AB-101 as monotherapy and in combination with rituximab|
33072758|NCT04673617|Experimental|Phase 2: AB-101 given with rituximab to patients with B-cell NHL at the R2PD|
33398904|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
33398905|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
33242483|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
33242484|NCT01030159||001|
33242485|NCT01030237|Experimental|FID 114657|FID 114657
33242486|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
33242487|NCT04046679|Experimental|Bleomycin|Bleomycin Infusion By Tattoo Machine
33242488|NCT04046679|Placebo Comparator|Saline Solution|Saline Infusion by Tattoo Machine
33398906|NCT02401282|Experimental|ABM|Attention bias modification
33398907|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
32911645|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
32911646|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
33398908|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
32743659|NCT04747054|Experimental|Radiotherapy added to systemic treatment|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~Loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) with 54 Gy/18 fractions in the head and neck region.~If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will start from cycle 3 or 4 of pembrolizumab (after radiotherapy administration) and will combine carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
32911647|NCT00498875||Questionnaire + Depression Intervention|
32911648|NCT01810289|Experimental|MJAP Clinics Intervention|START intervention. This is a stepped wedge design so each clinic will experience both conditions.
32911649|NCT01810289|No Intervention|MJAP Clinics Pre-Intervention|Standard of care. This is a stepped wedge design so each clinic will experience both conditions.
32911650|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
32911651|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
32911652|NCT01733069||No treatment|
32911653|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
32911654|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
32911655|NCT05168319|Experimental|pcTBS|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
32911656|NCT05168319|Active Comparator|10HZ rTMS|The rTMS protocol included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT), with the inter-train interval being set to 50 seconds (1500 pulses)
32911657|NCT05168319|Sham Comparator|Sham|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
32911658|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
32911659|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
33398909|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
32911660|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
32911661|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
32911662|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
32911663|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
33072761|NCT04659811|Experimental|Treatment for recurrent meningioma (pembrolizumab, stereotactic radiosurgery)|Participants with recurrent grade II or III meningioma will receive stereotactic radiosurgery. in conjunction with pembrolizumab 200mg IV infusion on day 1 (to -1) of radiation and then every 3 weeks
33398910|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
33398911|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
33398912|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
33072762|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
33072763|NCT04633252|Experimental|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
33072764|NCT04633252|Experimental|2/Safety Run-in (no longer applies; removed before enrollment)|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
33398913|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
33398914|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
33398915|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
33398916|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
33072765|NCT04633252|Experimental|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
32762798|NCT04286425|Placebo Comparator|Placebo|"500 µl of saline solution applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
32762799|NCT04286425|Active Comparator|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
32762800|NCT04262479|Experimental|GAD-vaccination with vitamin D suppletion|"Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart.~Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total)."
33398917|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
33072766|NCT04633252|Experimental|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
32762801|NCT04275323|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
32762802|NCT04275323|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
33072767|NCT04632498|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
33072768|NCT04632498|No Intervention|Wait-list Control (WL)|Patient Control receiving no treatment
33072769|NCT04632498|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
33072770|NCT04625504|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
33072771|NCT04625504|No Intervention|Wait-list Control (WL)|Patients Control receiving no treatment
33072772|NCT04625504|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
33398918|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
33398919|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
33398920|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
33398921|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
33398922|NCT04896580|Experimental|Active|Participants will be asked to complete a 12 week exercise program
33072773|NCT04610658|Experimental|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
33242489|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
33242490|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
33242491|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
33242492|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
33242493|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
33242494|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
33242495|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
33242496|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
32762803|NCT04133311|Active Comparator|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
32762804|NCT04133311|Active Comparator|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
32762805|NCT04237025|Experimental|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
32762806|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
32762807|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
32762808|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
32762809|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
32762810|NCT05183009|Experimental|Therapy|Neuromuscular electrical stimulation
32762811|NCT05183009|No Intervention|No Therapy|Under the care of the referring physician, with no therapy applied
32762812|NCT04035187|Experimental|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
32762813|NCT04035187|Experimental|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
32762814|NCT04035187|Experimental|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
32762815|NCT04035187|Experimental|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
32762816|NCT05161715|Experimental|10mg obicetrapib tablets|10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks
32762817|NCT05105789|Experimental|BinaxNOW Test + Lollipop PCR|"If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing.~If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later.~For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit."
32762818|NCT04014829||Control group for CPHP|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
32762819|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
32762820|NCT04014829||Control group for significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 24 and 48 hours.
32762821|NCT04014829||Significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 24 and 48 hours.
32911664|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
33072774|NCT04610658|Experimental|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
33072775|NCT04610658|Experimental|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
32762822|NCT05634629|Active Comparator|Anterior Lamellar Recession|
32762823|NCT05634629|Active Comparator|Bilamellar Tarsal Rotation|
33398923|NCT05668559|Experimental|Active rTMS Group|A stimulation set will be administered to each participant in the rTMS group with 15 sessions stimulation for total five days after surgery.
33242497|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
33242498|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
33242499|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
33242500|NCT00786357|Experimental|Intervention|
33242501|NCT00440401|Active Comparator|TachoSil®|
33242502|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
33398924|NCT05668559|Sham Comparator|Sham Stimulation Group|Patients randomly assigned to sham group will receive 15 sessions sham stimulation for total five days after surgery.
33398925|NCT04481932|Experimental|Trastuzumab combined with Pyrotinib and chemotherapy|The dosage of the above drugs can be adjusted according to the adverse reactions of the subjects. The subject continued to use the drug until the full cycle or the disease progressed or the toxicity was intolerable or withdrawn, or the researcher judged that the medication must be terminated.
33398926|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
33398927|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
33398928|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
33398929|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
33398930|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
33072776|NCT04610658|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Participants will be treated with nivolumab 1mg/kg, ipilimumab 3mg/kg plus maximum tolerated dose of lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at MTD every 3 weeks.
33398931|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
33398932|NCT02402374|Placebo Comparator|Placebo|Saline gel
33398933|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.~No more interventions were applied."
33398934|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.~It was not a intervention, it was the control group"
33398935|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
33398936|NCT03655691|Experimental|Dose 1|lower dose of ET-01
33398937|NCT03655691|Experimental|Dose 2|higher dose of ET-01
33398938|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
33072777|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
33242503|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
33242504|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
33242505|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
33242506|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
33398939|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
32762824|NCT05088031||1- Group ( A): 20 patients underwent shock wave therapy|1-Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head for 15 minutes on alternate days for four weeks for a total of 12 sessions14.
33072778|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
33242507|NCT04992507|Experimental|Arm I (surgical resection with TIVA)|Patients undergo surgical resection with TIVA.
33072779|NCT04599010|Active Comparator|FFM-indexed feeding|In FFM-indexed feeding, there will be a permissive feeding volume restriction to 150 ± 10 mL/kg (FFM)/day without increasing the milk calorie density or changing the type of formula milk for 2 weeks in the intervention group
32906877|NCT01584479||High Risk Control Group|"2 visits - High Risk~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
33072780|NCT04599010|Active Comparator|Standard feeding|The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period
33242508|NCT04992507|Active Comparator|Arm II (surgical resection with inhaled volatile anesthetics)|Patients undergo surgical resection with inhaled volatile anesthetics.
33398940|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
33242509|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
32743660|NCT04747054|Active Comparator|Systemic treatment|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
32743661|NCT04918563|Active Comparator|nitroglycerin|"NO donor (Nitropohl) vs pgysiological saline~1mg/ml nitorhlycerin"
33072781|NCT04597632|Experimental|brolucizumab 6 mg|Participants will receive brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals may be changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
33072782|NCT04597437|Experimental|Zanamivir|In the treatment group, participants weighing less than 50 kg will receive 12 mg/kg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.
33072783|NCT04597437|Placebo Comparator|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
33072784|NCT04596631|Experimental|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
33072785|NCT04596631|Placebo Comparator|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
33072786|NCT04595994|Experimental|Selinexor + Gemcitabine|"Dose escalation levels (Phase I):~All included patients will take both drugs:~Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).~Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).~Selinexor: tablet (20 mg tablets) Oral use.~Gemcitabine: Concentrate for solution for infusion. Intravenous use."
33072787|NCT04593264|Active Comparator|Traditional Supervised Prehabilitation with a Physical Therapist|
33072788|NCT04593264|Experimental|Self-guided Home-based Prehabilitation|
33072789|NCT04587791|Active Comparator|CBD 400mg|CBD 400 mg
33072790|NCT04587791|Active Comparator|CBD 800mg|CBD 800mg
33072791|NCT04587791|Active Comparator|CBD 1200mg|CBD 1200mg
33072792|NCT04587791|Placebo Comparator|Saline|saline
33072793|NCT04586478|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
33072794|NCT04586426|Experimental|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
33072795|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the RP2R(s) of the study treatment identified in Part 1.
33242510|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
32743662|NCT04918563|Active Comparator|acethylcholine|10 mg/ml acetylcholine vs physiological saline
33072796|NCT04579224|Active Comparator|Arm I (standard of care chemotherapy)|Patients receive 1 of the 3 standard of care chemotherapy regimens based on treating investigator's choice: Choice A: Patients receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice B: Patients receive gemcitabine IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Choice C: Patients receive paclitaxel IV on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33072797|NCT04579224|Experimental|Arm II (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33072798|NCT04579224|Experimental|Arm III (eribulin, gemcitabine)|Patients receive eribulin IV over 2-5 minutes and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33242511|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
32911665|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
32911666|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
32911667|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
32911668|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
32911669|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
32911670|NCT05155605|Experimental|Participants 50 years of age or older|The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
32911671|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
33242512|NCT00791427||AMD Patients|
33242513|NCT02669797|Experimental|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
32911672|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
32911673|NCT01267136|Experimental|Capital® with Codeine Suspension|
32911674|NCT01267136|Active Comparator|Tramadol suspension|
32911675|NCT05139771|Other|EndoArt® Artificial Endothelial Layer|EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema. One arm - all subjects will be implanted with EndoArt®.
32911676|NCT05134311|Experimental|3D-US|These subjects will have a 3D rendering of their vascular testing shown to them.
32911677|NCT05134311|No Intervention|Standard US|These subjects will be shown a hand drawn sketch of the results of the vascular testing.
32911678|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
33072800|NCT04561375|Active Comparator|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
33072801|NCT04561375|Placebo Comparator|Control Group|placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia
32911679|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
32911680|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
32911681|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
32911682|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
33398941|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
33398942|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
33398943|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
32911683|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
33398944|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
33398945|NCT03732521|Experimental|Intervention group|educational therapy
33398946|NCT03732521|No Intervention|Control group|usual clinical practice
33398947|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
33398948|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
33398949|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
33398950|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
32911684|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
33398951|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
33398952|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
33398953|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
32911685|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
32911686|NCT01790243|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
32911687|NCT01790243|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
32911688|NCT03235479|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
32911689|NCT03235479|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
32911690|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
32911691|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
33398954|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
33398955|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
33398956|NCT03571568|Experimental|BI-1206 IV|BI-1206 IV Standard 3+3 Dose-Escalation Design
32743663|NCT04918641||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.
32911692|NCT01791491|Experimental|Belatacept|
32911693|NCT01810991|Experimental|Nd:YAG Laser|Nd:YAG 1440nm Laser
33242514|NCT02669797|Experimental|EMI + HV + Video feedback, Virtual|"EMI + HV + Video Feedback (Arm 2) education visits will all be delivered virtually, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
33398957|NCT03571568|Experimental|BI-1206 SC|BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)
33242515|NCT02669797|Experimental|EMI + HV + Video feedback, Hybrid|"EMI + HV + Video Feedback (Arm 3) education visits will be delivered virtually and in-home, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
33242516|NCT00786435||1|Those with a cervical spinal cord injury
33242517|NCT00786435||2|Those with a thoracic spinal cord injury
33242518|NCT00786435||3|Healthy, control group
33242519|NCT00786513|Active Comparator|Control Arm|
33242520|NCT00786513|Experimental|Intervention Arm|
33242521|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
33242522|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
33242523|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
33242524|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
33242525|NCT02598960|Experimental|BMS-986156: Dose Escalation|
33242526|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
32743664|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
32911694|NCT05100381|Experimental|Experimental group|The experimental group will comprise 20 participants with chronic non-specific low back pain. The treatment will include dry needling of the lumbar multifidus muscle and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week.
32911695|NCT05100381|Placebo Comparator|Control group|"The control group will comprise 20 participants with chronic non-specific low back pain. The treatment will include sham dry needling of the lumbar multifidus muscle and routine physical therapy. The sham dry needling method consists of the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week."
32911696|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
32911697|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
32911698|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
32911699|NCT05098899|Experimental|MyGeneMyDiet® Recommendations for Weight Management|A set of nutrition and lifestyle advice for weight management derived from genetic information
32911700|NCT05098899|Active Comparator|Usual Standard of Care for Weight Management|A set of standard nutrition and lifestyle advice for weight management without genetic information
32911701|NCT01792817|Sham Comparator|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
32911702|NCT01792817|Experimental|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
33072802|NCT04553211|Experimental|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
32911703|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
32911704|NCT03179631|Experimental|Ataluren|10, 20 milligrams per kilogram (mg/kg)
32911705|NCT03179631|Placebo Comparator|Placebo|10, 20 mg/kg
32911706|NCT01811147|Experimental|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
32911707|NCT01811147|Experimental|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
32743665|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
32743666|NCT04918953|Experimental|group 1|oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days
32743667|NCT04918953|Experimental|group 2|oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days
32911708|NCT01811147|No Intervention|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
32911709|NCT01811147|No Intervention|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
32911710|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
32911711|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
32911712|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
32911713|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
33242527|NCT02598960|Experimental|BMS-986156: Dose Expansion|
32911714|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
32911715|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
32911716|NCT04749719|Experimental|DLPFC stimulation|F3-SO montage or OLE optimized with 2 mA stimulation for up to 30 min during memory and metamemory task.
32911717|NCT04749719|Sham Comparator|Sham tDCS|F3-SO montage or OLE optimized with sham stimulation for up to 30 min during memory and metamemory task.
32911718|NCT05069415|Active Comparator|Emmetropia|The target refraction for both eyes will be emmetropia (± 0.25 D).
32911719|NCT05069415|Experimental|Mini monovision|The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.
33242528|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
32911720|NCT01811303|Experimental|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
32911721|NCT01811303|Placebo Comparator|Control|Sucrose 50 g without d-fagomine, in 200 ml water
32911722|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
32911723|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
32911724|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
32911725|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
32911726|NCT05068869|Other|Dignio Digital Remote Care intervention group|Participants will receive the MyDignio app for individualized follow-up for 6 months.
32911727|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
33072803|NCT04553211|No Intervention|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
33072804|NCT04538066|Active Comparator|Bryostatin 1|20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
33072805|NCT04538066|Placebo Comparator|Placebo|Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
33242529|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
33242530|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
33072808|NCT04532918|Experimental|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
33072809|NCT04532918|Experimental|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
33072810|NCT04532918|Experimental|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
33072811|NCT04527146|Experimental|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
33072812|NCT04527146|Experimental|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
33072813|NCT04527146|Experimental|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
33072814|NCT04527146|Active Comparator|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
33072815|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
33072816|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
33072817|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
33072818|NCT04513925|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
33072819|NCT04513925|Active Comparator|Durvalumab|Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
33072820|NCT04511247|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
33242531|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
33242532|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
33242533|NCT00665847|Experimental|Etravirine (TMC125)|
33242534|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
33242535|NCT00783081|Experimental|low dose K-134|
33242536|NCT00783081|Experimental|mid dose K-134|
33242537|NCT00783081|Experimental|high dose K-134|
33242538|NCT00783081|Active Comparator|Comparator|
33242539|NCT00783081|Placebo Comparator|Placebo|
33398958|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
33398959|NCT05000957|Experimental|"Magic Max Laser Treatment + Colporrhaphy"|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~A/R colporrhaphy will be performed 1 month after last laser treatment."
33072821|NCT04511247|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
33072822|NCT04510428|Experimental|OSIG-Eye Drop|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
33072823|NCT04510428|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
33072824|NCT04487860|Experimental|AS012 dose regimen I|Oral
33072825|NCT04487860|Experimental|AS012 dose regimen II|Oral
33072826|NCT04487860|Experimental|AS012 dose regimen III|Oral
33072827|NCT04487860|Experimental|AS012 dose regimen IV|Oral
33072828|NCT04487860|Placebo Comparator|Placebo|Oral
33072829|NCT04483466|Experimental|Treatment with methotrexate|100 participants will be treated with methotrexate
33072830|NCT04483466|Placebo Comparator|Placebo methotrexate|50 will receive placebo
33072831|NCT04466475|Experimental|Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)|Patients receive 211At-OKT10-B10 IV continuously on day -10 to day - 4 (approximately day -7) and melphalan via infusion on day -2. Patients then undergo HCT on day 0.
33072832|NCT04456101||Control group|healthy individuals without COVID-19
33072833|NCT04456101||Severe/Critical COVID-19 rehabilitation group|①Individuals recovering from Severe/Critical COVID-19
33072834|NCT04456101||mild/moderate COVID-19 rehabilitation group|Individuals recovering from mild/moderate COVID-19
33072835|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 individuals with laboratory test for SRARS-COV2 turning negative
33072836|NCT04451408|Experimental|LY3372993 (Part A)|LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC).
33072837|NCT04451408|Experimental|LY3372993 (Part B)|LY3372993 administered as single dose IV or SC.
33072838|NCT04451408|Placebo Comparator|Placebo (Part A)|Placebo administered as multiple doses IV or SC.
33072839|NCT04451408|Placebo Comparator|Placebo (Part B)|Placebo administered as single dose IV or SC.
33072840|NCT04435366|Experimental|Zimura Treatment Group|Monthly Zimura 2mg Intravitreal Injections, followed by monthly injections or every other month injections from Month 12 to Month 23
33072841|NCT04435366|Sham Comparator|Sham Treatment Group|Monthly Sham Administration until Month 23
33072842|NCT04423913|Experimental|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
33072843|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
33072844|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
33072845|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
33072846|NCT04414163|Experimental|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
33398960|NCT05000957|Active Comparator|Colporrhaphy (control group 1)|A/R colporrhaphy only will be performed.
33072848|NCT04396899|Other|EHM Implantation|All patients will receive EHM implant
33072849|NCT04396574|Experimental|Lasmiditan Dose 1|Lasmiditan administered orally.
33072850|NCT04396574|Experimental|Lasmiditan Dose 2|Lasmiditan administered orally.
33072851|NCT04394585|Experimental|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
33072852|NCT04394585|Active Comparator|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
33072853|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label) from Parent Study|Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
33398961|NCT05000957|Other|No Treatment (control group 2)|Any surgery which do not affect condition of vagina, vulva and paraurethral region will be performed.
32911728|NCT04340271|Experimental|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
32911729|NCT04340271|Sham Comparator|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
32911730|NCT05049525|Active Comparator|Itraconazole and Terbinafine|During the first 4 weeks itraconazole will be administered alone at 200 mg twice daily, followed by itraconazole 200 mg twice daily and terbinafine 250 mg twice daily for the remaining 16 weeks. Both drugs will be administered orally.
32911731|NCT05049525|Placebo Comparator|Placebo|During the first 4 weeks a placebo will be administered alone at 200 mg twice daily, followed by placebo 200 mg twice daily and another placebo 250 mg twice daily for the remaining 16 weeks. Both placebos will be administered orally.
32911732|NCT01811693|Experimental|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
32911733|NCT01811693|Experimental|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
32911734|NCT01811693|Experimental|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
32911735|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
32911736|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
32911737|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
33072854|NCT04392154|Experimental|Lebrikizumab Q2W (Blinded) from Parent Study|Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
32911738|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
32911739|NCT01793909|Other|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
32911740|NCT01332188|Experimental|AC-170 0.05%|
32911741|NCT01332188|Experimental|AC-170 0.1%|
32911742|NCT01332188|Experimental|AC-170 0.24%|
32911743|NCT01332188|Placebo Comparator|AC-170 0%|
32911744|NCT01794455|Experimental|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
32911745|NCT01794455|Experimental|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
32911746|NCT01795079|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
32911747|NCT01795079|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
32911748|NCT04769141||Hypertension patients|a prospective 4-month, cohort feasibility study will evaluate blood pressure (n=20) using the CURATE.AI platform.
32911749|NCT04769141||Diabetic patients|a prospective 4-month, cohort feasibility study will evaluate glycaemic (n=20) control using the CURATE.AI platform.
32911750|NCT04749329|No Intervention|Control Group|no mesh was used for end colostomy fashions
32911751|NCT04749329|Experimental|Mesh Group|Mesh of Bio A was used for end colostomy fashions
32911752|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
32911753|NCT04749485|Experimental|HX008|
32911754|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
32911755|NCT01812005|Experimental|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32911756|NCT01812005|Experimental|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32911757|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
32911758|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
32911759|NCT01795859|Experimental|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
32911760|NCT01795859|Experimental|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
32911761|NCT01333592|Experimental|KAD-1229|
32911762|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
33398962|NCT04482166|Experimental|Candidates|Training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
32911763|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
32911764|NCT04749095|Active Comparator|Erector block|
32911765|NCT04749095|Active Comparator|sham block|
32911766|NCT01797029|Experimental|Vaccine|
32911767|NCT01797029|Placebo Comparator|Placebo|
32911768|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
32911769|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
32911770|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
32911771|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
32743668|NCT04918953|Experimental|group 3|budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks.
32911772|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
32911773|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
32911774|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
32911775|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
32911776|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
32911777|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
32911778|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
32911779|NCT04346576|Experimental|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, <0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
32911780|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
32911781|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
32911782|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
32911783|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
32911784|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
32911785|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
32911786|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
32911787|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
32911788|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
32911789|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
32911790|NCT01797575|Active Comparator|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
32911791|NCT01797575|Active Comparator|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
32911792|NCT01797575|Active Comparator|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
32911793|NCT01797575|Placebo Comparator|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
32911794|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
32911795|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
32911796|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
32911797|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
32911798|NCT03009032|Placebo Comparator|PLACEBO|Lactose
32911799|NCT02641353|Experimental|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
32911800|NCT02641353|Experimental|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
32911801|NCT02641353|Experimental|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
32911802|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
32911803|NCT01335542|Active Comparator|Peri-Articular Injection|
32911804|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
32911805|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
32911806|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
32911807|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
32911808|NCT05027139|Experimental|Zanidatamab plus evorpacept (ALX148)|
32911809|NCT01335620|Other|Tenofovir/Emtricitabine and Raltegravir|"Single arm study~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
32911810|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
32911811|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
32911812|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
32911813|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
33072855|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label Addendum)|Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
32911814|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
32911815|NCT01273766|No Intervention|control arm|blood tested on healthy patients
32911816|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
32911817|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
32911818|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
33072856|NCT04392154|Experimental|Lebrikizumab Q4W|"Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection.~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
33398963|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
33242540|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
33242541|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
33398964|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
33242542|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
33242543|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
32743669|NCT04923399||TN (Trigeminal Neuralgia) group|Trigeminal neuralgia patients undergoing trigeminal nerve microvascular decompression
33398965|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
33398966|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
33398967|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
32743670|NCT04923399||Non-TN group|patients without chronic pain or history of chronic pain
32911819|NCT01814813|Experimental|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
32911820|NCT01814813|Experimental|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
32911821|NCT01814813|Active Comparator|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
32911822|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
32743671|NCT04918485|Experimental|the experimental group received psychological intervention|
32911823|NCT01379924|Experimental|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
33398968|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
33398969|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
32743672|NCT04918485|No Intervention|the control group receive normal process before surgery|
32911824|NCT01379924|Active Comparator|Young Parents Program usual care|Patients receive regular standard of care without modules.
32911825|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
33398970|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
33398971|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
33398972|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
33398973|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
33242544|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
33242545|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
33242546|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
32911826|NCT04741269||Lack of knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
33242547|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
33242548|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
32743673|NCT04922931||Post-COVID-19 group|The Post-COVID-19 group or case group includes post-COVID patients (confirmed by PCR) >18 years undergoing scheduled surgery without pulmonary disease prior to SARS-CoV-2 infection that at the time of surgery present negative PCR and absence of clinic due to SARS-CoV-2.
32743674|NCT04922931||Control group|The control group includes patients over the age of 18 who did not have COVID-19 and without moderate-severe pulmonary pathology prior to surgery and in conditions of hemodynamic and respiratory stability at time of surgery.
33242549|NCT00783159|Experimental|A|Training I
33242550|NCT00783159|Experimental|B|Training II
33242551|NCT00783159|Active Comparator|C|Control
32911827|NCT04741269||Full knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
32911828|NCT01403090|Experimental|Angel Catheter|
32911829|NCT02642991|Experimental|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
32911830|NCT02642991|Active Comparator|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
32911831|NCT01403246|Experimental|Lenalidomide with Chlorambucil|
32911832|NCT01734551|Active Comparator|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
32911833|NCT01734551|Active Comparator|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
33242552|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
33242553|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
32911834|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
32911835|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
32911836|NCT01815515|Experimental|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography [CECT] and bone scintigraphy [BS]) undergo PET imaging with 18F-DCFBC radiotracer.
32911837|NCT05588895|Experimental|Notification|The notification arm will have its CT scans interpreted and reported according to standard clinical practice. Patients randomized to notification will receive a message sent by either the EHR patient portal or postal mail that will inform them of the CAC identified on their recent chest CT. It will provide an overview of CAC, an image of their chest CT, and current guideline recommendation that they discuss this finding with their clinician and consider statin therapy. A patient's primary care physician will be notified simultaneously via a secure EHR message. All communications will be signed by the Principal Investigator. Any treatment decisions will be made by the patient and their clinician.
33242554|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
33242555|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
33242556|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
33242557|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
33242558|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
33242559|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
33242560|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
33242561|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
33242562|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
32743675|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
33242563|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
33242564|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
33072857|NCT04387084|Experimental|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
33072858|NCT04378075|Experimental|Vatiquinone|15 milligrams/kilogram (mg/kg) if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
33242565|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
33242566|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
33398974|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
33242567|NCT02535078|Experimental|Arm 1|IV Tebentafusp (IMCgp100) with durvalumab (MEDI4736)
33242568|NCT02535078|Experimental|Arm 2|IV Tebentafusp (IMCgp100) with tremelimumab
33242569|NCT02535078|Experimental|Arm 3|IV Tebentafusp (IMCgp100) with durvalumab (MEDI4736) and tremelimumab
33242570|NCT02535078|Experimental|Arm 4|Tebentafusp (IMCgp100) (single agent)
33242571|NCT02535078|Experimental|Arm 5|Tebentafusp (IMCgp100) (single agent) subcutaneous injection
33242572|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
33242573|NCT04047069|Other|Control|Awareness Training
33242574|NCT04047069|Experimental|Intervention group|"Awareness Training~Person-Centered Occupational Therapy Intervention"
33072859|NCT04378075|Placebo Comparator|Placebo|Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
33277324|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
32743676|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32911838|NCT05588895|No Intervention|Usual Care|"The usual care arm will have its CT scans interpreted and reported according to standard clinical practice. This may mention the presence of CAC in the official radiology imaging report, per usual practice. The usual care arm will not receive any notification beyond this standard of care.~We intend to notify patients in the usual care arm at the end of 6 months if we determine that notification is effective at increasing statin rates."
32911839|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
33277325|NCT04299542|Active Comparator|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
33277326|NCT04299542|Active Comparator|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
32911840|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
33277327|NCT00780221||control|patients without coronary artery disease
33277328|NCT00780221||case|patients with coronary artery disease
33277329|NCT04272086|Placebo Comparator|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
33277330|NCT04272086|Experimental|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
33277331|NCT01086865|Active Comparator|Petivit BC|
33277332|NCT01086865|Experimental|Apetiviton BC|
33277333|NCT00780299|Active Comparator|2|control
33277334|NCT00780299|Experimental|1|HDHP
33277335|NCT03895034|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
33277336|NCT03960931|Experimental|Aquatic rehabilitation|
32911841|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
32911842|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
32911843|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - Low dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.
32911844|NCT02235909|Active Comparator|Double blind phase: Losartan|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.
32911845|NCT02235909|Active Comparator|WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.
32911846|NCT02235909|Placebo Comparator|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase
32911847|NCT02235909|Experimental|Open Label Phase: Azilsartan Medoxomil|Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
33277337|NCT03960931|Experimental|Land based physical activities|
33277338|NCT03960931|Other|Conventional rehabilitation|
33277339|NCT00776633|Experimental|Short triple|6 weeks triple therapy
33277340|NCT00776633|Active Comparator|Long triple|6 months triple therapy
33277341|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
33277342|NCT01093963|Placebo Comparator|Placebo|Drug
33277343|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
33277344|NCT03956563|Active Comparator|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
33072862|NCT04362072|Experimental|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
33072863|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
33242575|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
32911848|NCT02235909|Other|"Open Label Phase: Other"|If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.
32911849|NCT02235909|Active Comparator|Withdrawal Phase: Losartan 50 mg|Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
32911850|NCT02235909|Placebo Comparator|Withdrawal Phase: PLACEBO to Losartan|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
32911851|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - Medium dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.
32911852|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - High dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M
32911853|NCT02235909|Experimental|WITHDRAWAL Azilsartan Medoxomil - Medium dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.
32911854|NCT02235909|Experimental|WITHDRAWAL Azilsartan Medoxomil - High dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.
32911855|NCT02235909|Experimental|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
32911856|NCT02235909|Experimental|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
32911857|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
32911858|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
32911859|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
32743677|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
32911860|NCT01798589|Experimental|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
32911861|NCT05588817|Active Comparator|Group 1|Normal control
32911862|NCT05588817|Active Comparator|Group 2|Diagnosed Rhomatoid arthritis patients
33072864|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
33072865|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
33242576|NCT01030471|Experimental|Lifestyle counseling|
33242577|NCT01030471|No Intervention|Wait list control group|
33277345|NCT03956563|Sham Comparator|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
32743678|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
32911863|NCT05588739|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxation, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
32911864|NCT05588739|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
33072866|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
33072867|NCT04351334||Patients with ALK-positive NSCLC|
33277346|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
33277347|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
32743679|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
32743680|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
33072868|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
32911865|NCT01799135|Experimental|Experimental Arm|"Stereotactic Body Radiation Therapy: either 54 Gy in 3 fractions or 50-60 Gy in 5 fraction over a span of 15 days at most.~DCE-MRI was performed at four time points during therapy: at baseline prior to SBRT, 1-2 days after the first treatment fraction, 1-2 weeks after the end of the SBRT course, and 3 months after completing radiotherapy.~4D-CT scan 3 months after completing radiotherapy."
32911866|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
32911867|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
32911868|NCT05588661|Experimental|Perturbation Exercises|Perturbation Based Balance Training
33242578|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
33242579|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
33242580|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
32911869|NCT05588661|Experimental|Whole Body Vibration|Whole Body Vibration Therapy
32911870|NCT01736267|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
33242581|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
32911871|NCT05588427|Experimental|Ketone group|Ketone esters will be provided
32911872|NCT05588427|Placebo Comparator|Placebo group|Ketone placebo will be provided
33242582|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
33242583|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
33242584|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
32911876|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
33242585|NCT00791739|Experimental|one arm study|
33242586|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
32911877|NCT04949919|Experimental|ESRD patients with supervised training|The participants will receive in-hospital supervised exercise training prior to HD
32911878|NCT01799213|Experimental|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po per day (QD) vs placebo
32911879|NCT01799213|Placebo Comparator|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
32743681|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
32911880|NCT04928781|Experimental|Smoking Cessation Counseling - Intervention Arm|Intervention arm. All patients enrolled in the study will be provided with smoking cessation counseling.
32911881|NCT04928781|No Intervention|Retrospective Chart Review - Control Arm|Control arm. A retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm.
32911882|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
32911883|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
33242587|NCT00425269|No Intervention|Control|One lesson recieved after post-test
33277348|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
32743682|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
32743683|NCT04910997|Experimental|HRV Group|Heart rate variability training group
32743684|NCT04910997|Active Comparator|Traditional Exercise Group|Traditional (e.g. standard) exercise training
32743685|NCT04910997|No Intervention|Control Group|Usual care
33242588|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
32743686|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
32911884|NCT04919811|Experimental|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
32911885|NCT01815671|Other|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
32911886|NCT01815671|Other|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
32911887|NCT01382108||Normal participants|
32911888|NCT01382108||Meibomian Gland Dysfunction|
32911889|NCT01816451|Experimental|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
32911890|NCT01816451|Experimental|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of ~87% of maximal heart rate (HRmax)
32911891|NCT01816451|No Intervention|control|The control group did not do the running training program. Control did their normal physical activities.
32911892|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
32911893|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
32911894|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
32911895|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
32911896|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
32911897|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
33242589|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
33242590|NCT00791895|Experimental|A|
33242591|NCT01807728|Experimental|Group 1 Training Program|For Group 1, participants will aim to be recruited within the first week of their inpatient rehabilitation stay (admission time point).
32911898|NCT04893135|No Intervention|G1A|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, without the practice physical activity
32911899|NCT04893135|Experimental|G1B|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, with the practice physical activity
33242592|NCT01807728|Experimental|Group 2 Training Program|For Group 2, individuals may be enrolled in the study at any time over their inpatient rehabilitation stay. Data collection may occur at admission (Group 2 only), just prior to discharge and at 3, 6 and 12 months after discharge.
32911900|NCT04893135|No Intervention|G2|Controlled diabetes (HbA1c level <7%). This group will study the natural course of RANKL levels in balanced diabetic patients.
32911901|NCT04868877|Experimental|Part 2 NSCLC harboring EGFR exon 20 Insertion|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
32911902|NCT04868877|Experimental|Part 2 NSCLC harboring cMet exon 14 skipping mutation|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
32911903|NCT04868877|Experimental|Part 2 Select solid tumors harboring an EGFR or cMet driving mutation|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
32911904|NCT04868877|Experimental|Part 2 NSCLC First-line|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
33242593|NCT04074720|Other|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
33072869|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
32911905|NCT04868877|Experimental|Part 2 NSCLC Second-line or more|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
32911906|NCT01404650|Experimental|AUY922|
32911907|NCT04859673|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
32911908|NCT04859673|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy. Stimulation will not deliver as the transmitter head will be removed. The patients will receive the same frequency of air pressure and sound
32911909|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
32743687|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
32911910|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
32911911|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
32743688|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
32911912|NCT05588193|Experimental|Post Visit Outreach|Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.
32911913|NCT05588193|Experimental|Tele-Sexual Healthcare|Tele-sexual health visit with a specialist offered during the ED visit to patients.
32743689|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
32743690|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
32911914|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
33072870|NCT04345757|No Intervention|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
33072871|NCT04345757|Experimental|Study Group|Study group: Structured 10 week exercise protocol
32911915|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
32911916|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
32911917|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
32911918|NCT05588037|Experimental|RRD group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of rhegmatogenous retinal detachment complicated with cataract.
32911919|NCT05588037|Experimental|ERM group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of epiretinal membrane complicated with cataract.
33072873|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|ddEC x 4 + pembrolizumab→ PK x 4 + pembrolizumab, Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2). Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*
33231573|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
33231574|NCT04024605|Experimental|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
33231575|NCT04024605|Experimental|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
32762825|NCT05088031||2-Group (B): 20 patients would undergo intermittent mechanical traction|"2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest) 3 times weekly day after day for four weeks for a total of 12 sessions."
32762826|NCT05088031||Group (C): (Control group) 20 patients would underwent conventional physical therapy|"3-Group (C): (Control group) 20 patients would underwent conventional physical therapy consisted of hyperthermia using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the back, iliopsoas, and hamstring muscles and strengthening exercises for the abdominal muscles for 30 minutes."
32762827|NCT05087953||FAC group|Patients with familial amyloidotic cardiomyopathy.
32762828|NCT05087953||Non-FAC group|Patients with transthyretin gene mutations who do not have FAC.
32762829|NCT05087953||Control group|Healthy subjects.
32762830|NCT05087797|Experimental|nicorandil group|
32762831|NCT05087797|No Intervention|control group|
32906878|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
33231576|NCT04024605|Experimental|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
33231577|NCT04024605|Experimental|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
32743691|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
32911920|NCT05588037|Experimental|MH group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of macular hole complicated with cataract.
32911921|NCT05588037|Experimental|Vitreous cloudy group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of vitreous opacity complicated with cataract.
32911922|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
32911923|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
32911924|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
33072874|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|"CEX x 4→ PK x 4, Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*~*The addition of pembrolizumab is strongly recommended to all participating patients. However, patients with a documented contraindication, or unwilling to receive immunotherapy may be included in the study without the administration of pembrolizumab."
32911925|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
32911926|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
32911927|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
33072875|NCT04334759|Experimental|Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance|Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
33072876|NCT04334759|Active Comparator|Control Arm: Chemotherapy, then Observation|Standard Chemotherapy for 4 to 6 cycles, followed by Observation
32911928|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
33072877|NCT04334759|Active Comparator|Control Arm: Ipilimumab and Nivolumab|Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.
33072878|NCT04332939|Experimental|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
32911929|NCT01978431|Placebo Comparator|Placebo|methylphenidate
32911930|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
32911931|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg PO once weekly for 12 months
32911932|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
33401960|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
32743692|NCT04923009|Experimental|Simple-ICE group|Patients undergoing ablation using only ICE visualization and ablation catheter
32743693|NCT04923009|Active Comparator|Standard mapping catheter without ICE|Patients undergoing ablation using standard approach including diagnostic and mapping electrodes as well as ablation electrode
32743694|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
32743695|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
32743696|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
32762832|NCT05087719|Experimental|experimental group|The patients in the experimental group will get the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints, therapist repeatedly draw some letter, figures, digit, shapes ,alphabets on the palm of hand/digits of patient.For Stereognosis therapist command the patient to close his or her eyes, then on affected hand put some different kinds of objects and shapes then ask the patient to identify that object, the object might be of any kind like a key, rubber a block or a coin etc. Total time for stereognosis was 15 minutes. For motor training patients were guided by the therapist to use his or her affected hand more. Then patient practiced some task like drawing writing his or her name, folding the towel or a paper, eating something with different speed, picking small objects like nails and put them in to small boxes, organize the cards etc. This training session required 15 minutes.
33242594|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33072879|NCT04332939|Sham Comparator|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of sham tDCS."
33072880|NCT04332367|Experimental|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
33242595|NCT00786981|Other|Epidural steroid injection and physical therapy|
33242596|NCT00786981|Other|Epidural steroid injection|
33242597|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
33242598|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
33242599|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
33242600|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
33242601|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
33242602|NCT04073940|Experimental|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
33242603|NCT00783393|Experimental|Single arm|"The study consists of two steps:~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
33242604|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
33072881|NCT04332055|Experimental|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
32762833|NCT05087719|Active Comparator|conventional treatment|baseline treatment of hot pack for 15 minutes will be given.The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
32762834|NCT05087017||Intervention Group|Patients with COPD or Lung Fibrosis following rehabilitation program will be invited to participate and answer the questionnaires in the beginning and after eight weeks of rehabilitation.
32762835|NCT05087017||Control group|Patients with COPD or Lung Fibrosis who do not do any regular activity will be invited to participated and answer the questionnaires just once.
32762836|NCT05086861|Experimental|Oesophageal Pacing Arm|Patients undergoing atrial fibrillation ablation to isolate the left atrial posterior wall via catheter or staged hybrid ablation.
32762837|NCT05086783|Experimental|Video-based coaching|Participants in the intervention arm will receive the standard surgical teaching while in the operating room (master-apprentice model (MAM)), plus the intervention of reviewing the recorded video with the surgical coach after performing their first attempt at laparoscopic closure of the vaginal vault.
32762838|NCT05086783|Placebo Comparator|Standard surgical teaching|Participants in the control arm will receive the standard surgical teaching while in the operating room (master-apprentice model-(MAM)).
32762839|NCT05086705|Experimental|Arm A (EMBr Wave)|Patients utilize the EMBr Wave device for 4 weeks, then crossover to arm B for 4 weeks.
32762840|NCT05086705|Active Comparator|Arm B (crossover)|Patients receive no treatment for 4 weeks, then crossover to arm A for 4 weeks.
32762841|NCT05070949|Experimental|Mindful Self-Compassion|Participants will meet every 2 weeks via zoom application or equivalent online meeting platforms, for 12 weeks. The sessions will be led by a clinical psychologist. The curriculum will follow mindful compassion program by Neff KD
33072882|NCT04332055|No Intervention|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
33242605|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
33072884|NCT04310176|Active Comparator|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
33072885|NCT04310176|Experimental|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
33072886|NCT04300998||older lymphoma patients|This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
33242606|NCT02471352||1/ Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
33242607|NCT02471352||2/ Healthy Volunteers|Healthy Volunteers
33242608|NCT00792051|Active Comparator|1|Influenza vaccine
33242609|NCT00792051|Placebo Comparator|2|
33242610|NCT00787215||no treatment|observational: no treatment involved
33242611|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
33242612|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
32743697|NCT04923087||Patient hospitalized in geriatrics or EHPAD|Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents
32911933|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
32911934|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
32911935|NCT00366639||001|
32743698|NCT03055845|Experimental|STA363 dose 1|
32743699|NCT03055845|Experimental|STA363 dose 2|
32743700|NCT03055845|Experimental|STA363 dose 3|
32743701|NCT03055845|Placebo Comparator|Placebo|
32743702|NCT04922775|Other|conventional taping-Chinese medicine technique taping|Participants will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course.
32743703|NCT04922775|Other|Chinese medicine technique taping-conventional taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.
32743704|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
32743705|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
32743706|NCT04918251||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
32743707|NCT04918251||Amyotrophic lateral sclerosis patients|
32743708|NCT04918251||Multiple sclerosis patients|
32743709|NCT04918251||Frontotemporal dementia patients|
32743710|NCT03055455||Sepsis|Children with severe sepsis or septic shock
32743711|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
32743712|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
32743713|NCT04904055||Value-based Formulary Beneficiaries|enrolled in the value-based formulary
32743714|NCT04904055||Standard Formulary Beneficiaries|enrolled in a standard (i.e., non-value-based formulary)
32743715|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
32743716|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
32743717|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
32743718|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
32743719|NCT04917627|Active Comparator|vancomycin group (intervention arm)|We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
32743720|NCT04917627|No Intervention|control group|no vancomycin powder will be used
32743721|NCT04904133|Active Comparator|Saccharine Group|140 mg saccharin (Hermesetas) dissolved in 330 mL water for 4 weeks.
32743722|NCT04904133|Active Comparator|Sucralose Group|66 mg sucralose (Splenda) dissolved in 330 mL water for 4 weeks.
32743723|NCT04904133|Active Comparator|Aspartame+Acesulfame-K Group|88 mg aspartame+88 mg acesulfame-K (Takita) dissolved in 330 mL water for 4 weeks.
32743724|NCT04904133|Placebo Comparator|Control Group|330 mL water for 4 weeks.
32743725|NCT04904211|Experimental|Feasiblity and Safety|All eligible patients will be assigned to this arm
32743726|NCT04903743|Placebo Comparator|group B|28ml of 0.25% bupivacaine and 2ml normal saline
32743727|NCT04903743|Active Comparator|group BM|received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
32743728|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
32743729|NCT04917939||epilepsy with HS|
32743730|NCT04917939||epilepsy without HS|
32743731|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
32743732|NCT03055143|Active Comparator|Ref-08-038|
32743733|NCT04753840|Experimental|Experimental A: Drug group+lifestyle intervention|Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.
32743734|NCT04753840|Experimental|Experimental B: RIPC group+lifestyle intervention|The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.
32743735|NCT04753840|Other|Experimental c: lifestyle intervention|The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
32743736|NCT04903275|Experimental|Fluoride and Laser|In the split-mouth design, the left maxillary anterior teeth receive topical fluoride application and carbon dioxide (CO2) laser irradiation.
32743737|NCT04903275|Active Comparator|Fluoride|In the split-mouth design, this arm - the contralateral teeth (right maxillary incisors), will receive topical fluoride application.
32743738|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
32743739|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
32743740|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
32911936|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
32911937|NCT01385306|Experimental|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
33242613|NCT00792207|Experimental|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
33242614|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
33242615|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
33242616|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
33242617|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
33242618|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
32911938|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
32911939|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
32911940|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
33242619|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
33242620|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
33242621|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
33242622|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
33242623|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
33242624|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
33242625|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
33242626|NCT00783549|Experimental|Cohort 3|Optional cohort
33242627|NCT00783549|Experimental|Cohort 4|12 active
32911941|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
32911942|NCT04530123|Experimental|Cohort 1, Group A: Placebo + Placebo + TAK-101 2 mg/kg|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 milligram per kilogram (mg/kg) will be given 23 weeks after the second dose at approximately Week 24.
32911943|NCT04530123|Experimental|Cohort 1, Group B: TAK-101 2 mg/kg + Placebo + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.
32911944|NCT04530123|Experimental|Cohort 1, Group C: TAK-101 2 mg/kg + TAK-101 2 mg/kg + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.
33231578|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
33242628|NCT00783549|Experimental|Cohort 5|12 active
33242629|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
33242630|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
33242631|NCT00783627||1|Patient with sickle cell disease
33242632|NCT00783627||2|Healthy volunteers
33242633|NCT00430495|Experimental|Atacicept 25 mg|
33242634|NCT00430495|Experimental|Atacicept 75 mg|
33231579|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
33231580|NCT04044118|Experimental|Caloric Restriction|3-week low calorie diet
33231581|NCT04024839|Active Comparator|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
33242635|NCT00430495|Experimental|Atacicept 150 mg|
33242636|NCT00430495|Placebo Comparator|Placebo|
33242637|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
33242638|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
33242639|NCT02554695|No Intervention|young normal premenopausal women|no intervention
33242640|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
33242641|NCT00792285|No Intervention|Usual Care|Usual Care
32911945|NCT04530123|Experimental|Cohort 2, Group D: Placebo + Placebo + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
32911946|NCT04530123|Experimental|Cohort 2, Group E: TAK-101 4 mg/kg + Placebo + TAK-101 4 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
32911947|NCT04530123|Experimental|Cohort 2, Group F: TAK-101 4 mg/kg + TAK-101 4 mg/kg + TAK-101 4 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
32911948|NCT04530123|Experimental|Cohort 2, Group G: TAK-101 1 mg/kg + TAK-101 1 mg/kg + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24 (1 mg/kg may not be needed based on review of Cohort 1 data). Cohort 2 would start based on the results of Cohort 1.
32911949|NCT04530123|Experimental|Cohort 2, Group D: Placebo + Placebo + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.
32911950|NCT04530123|Experimental|Cohort 2, Group E: TAK-101 1 mg/kg + Placebo + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.
32911951|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
33231582|NCT04024839|Experimental|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
32911952|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
33072887|NCT04300998||older patients with lymphoma and other lymphoid malignancies|This is a prospective observational cohort where 80 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
32762842|NCT05070949|No Intervention|Wait List Control|Wait list control group will not participate in the MSC program during the first 12 weeks of the protocol but will be given an opportunity to participate after 12 weeks, using the same curriculum.
32762843|NCT04011787|Active Comparator|Intervention|bolus NGT feeding
32911953|NCT04524273|Experimental|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183."
32911954|NCT04524273|Placebo Comparator|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183."
32911955|NCT04524273|Experimental|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183"
32911956|NCT04524273|Placebo Comparator|Placebo, (MuSK-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183"
32911957|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
32911958|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
32911959|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
32911960|NCT05587803|Experimental|study group|This arm consists of all the patients that fulfill the inclusion and exclusion-criteria and are therefore suitable for the study. The Neurowave brain monitor is attached on the patients forehead and the study starts. At that moment the included patients are monitored by the Masimo/Sedline en the Neurosense/Neurowave monitor.
32911961|NCT01817855|Experimental|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
32911962|NCT01817855|Placebo Comparator|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
32911963|NCT05587647|Experimental|Experimental: YEGEP group/Intervention|Mothers will be informed about the program and invited to work. In the phone call, information will be given about the purpose, duration, requirements and volunteering of the study. The planned training schedule will be applied to these mothers.
32911964|NCT05587647|No Intervention|Control group|Annual care trainings are given to parents at the disabled center where the study will be conducted. There is no similar practice to these mothers on the same dates. place in the control group
32911965|NCT00368121|Experimental|Cetuximab + Dexamethasone|
32911966|NCT01801241|Active Comparator|Anatomic TSA using SOC Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will use the pre operative CT scan at least two weeks prior to surgery to define the glenoid pathology, select the implant of choice and plan the placement of that implant in the desired position. This information will be available to the surgeon at the time of surgery but the SmartBone models and the IRI will not be available. The surgeon will have pre operative x-rays and the pre operative CT scan provided by the radiology department for intra - use. The surgeon will perform the surgery using any of the instruments provided for guide pin placement operative the. These include a wide variety of free hand and adjustable guides that assist the surgeon for placement of the guide pin for location and trajectory.
32911967|NCT01801241|Experimental|Anatomic TSA Using IRI Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will have use of the SmartBone model of the patient's anatomy and glenoid guide-pin location, and the Intelligent Reuseable Instrument for placement of the glenoid implant.
32911968|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
32762844|NCT04011787|Other|Control|Continuous NGT feeding (standard care)
32762845|NCT03906877|Experimental|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
32762846|NCT03906877|Experimental|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
32762847|NCT03906877|Sham Comparator|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
32762848|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
32762849|NCT05086081||Prasugrel|Reference group
32762850|NCT05086081||Ticagrelor|Exposure group
32762851|NCT05085925|Experimental|Cognitive behavioral mindfulness intervention at entry|Cognitive behavioral mindfulness intervention at entry
32762852|NCT05085925|Active Comparator|Cognitive behavioral mindfulness intervention after 3 months|Cognitive behavioral mindfulness intervention after 3 months of wait list
32762853|NCT05085769||Study group|15 patients who had bariatric surgery
32762854|NCT05085769||Control group-1|8 morbidly obese participants who did not have bariatric surgery
32762855|NCT05085769||Control group-2|11 participants who were non-obese
32762856|NCT05085457|No Intervention|Control Group|On group I (T-ayre and standard protocol), SBT must begin with the pacient in T-ayre, oxygen support that is proprotional to the fraction of inspired oxygen in invasive mechanical ventilation (IMV), during 30 minutes. If the pacient does not show any sign of SBT failure, the rapid shallow beathing index (RSBI) will be calculated and pacients with RSBI lower than 105 L/min will be extubated, meanwhile pacients with RSBI higher than 105 L/min will return to MV for at least 24 hours until the perfomance of a new SBT.
32906507|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
32906508|NCT01569737||ella|
33072888|NCT04300998||older patients with myeloma and other plasma cell disorders|This is a prospective observational cohort where 40 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo
32898346|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
32898347|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
32898348|NCT02291055|Experimental|Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 3 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W) at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion every 4 weeks (Q4W) at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
32906509|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
32906510|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
33072889|NCT04298983|Experimental|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
33072890|NCT04290403|Experimental|Pull ups|Pull-up continence products
32906511|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
33072891|NCT04290403|Experimental|Styled briefs with tapes|Styled briefs with tapes
33398975|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
33072893|NCT04277546|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
33072894|NCT04277546|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
33072895|NCT04267939|Experimental|Dose escalation of elimusertib_Part A.1|Dose escalation will initiate with Part A.1 in which niraparib is used at a lower fixed dose.
33072896|NCT04267939|Experimental|Dose escalation of elimusertib_Part A.2|If the starting dose level in Part A.1 is tolerated, dose escalation in Part A.2 may be initiated on an optional basis. In Part A.2, niraparib is used at a higher fixed dose.
33398976|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
33398977|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
32906512|NCT05562089|Experimental|Prevail|
32906513|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
32906514|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
32906515|NCT04379492|Experimental|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
32906516|NCT04379492|Placebo Comparator|Arm B - placebo|Participants will receive placebo
32906517|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
32911969|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
32911970|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
33398978|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
33398979|NCT03629249|Experimental|QAW039 150 mg|QAW039 150 mg once daily orally
33398980|NCT03629249|Experimental|QAW039 450 mg|QAW039 450 mg once daily orally
33398981|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
33398982|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
33398983|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
33398984|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
33398985|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
33398986|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
33398987|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
33398988|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
33398989|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
33398990|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
33398991|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
33398992|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
33398993|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
33398994|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
33398995|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
33398996|NCT03670940||COPD patients|COPD patients without bronchiectasis
33398997|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
33398998|NCT02717078|Experimental|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
33398999|NCT02717078|Active Comparator|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
33399000|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
33399001|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
33399002|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
33399003|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
33399004|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
33399005|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
33399006|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
33399007|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
33399008|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
33399009|NCT03533582|Experimental|GROUP B2 ARM I|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles (4 pre-surgery, 2 post-surgery). After cycle 4, patients undergo surgery, then continue with 2 additional cycles of cisplatin.
33399010|NCT03533582|Experimental|GROUP B2 ARM II|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles.
33399011|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
33399012|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
32911971|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
32911972|NCT02687139|Experimental|18F-DCFPyL PET/CT|
32911973|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Abdomen)|Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
33242642|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
33242643|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
33242644|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
33242645|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
33072897|NCT04267939|Experimental|Dose expansion_sub-population 1_lower dose of niraparib|"MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.~MTD: Maximum tolerated dose. RP2D: Recommended phase 2 dose."
33072898|NCT04267939|Experimental|Dose expansion_sub-population 2_lower dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.
33072899|NCT04267939|Experimental|Dose expansion_sub-population 1_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
33072900|NCT04267939|Experimental|Dose expansion_sub-population 2_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
33399013|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
33242646|NCT04895280|Other|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
33242647|NCT04895280|Experimental|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
33242648|NCT04895280|Other|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
32911974|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Upper Arm)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
32911975|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Thigh)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
32911976|NCT01818245|Experimental|LY2605541: Cohort B (Injection site: Abdomen)|Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
32911977|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
32911978|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
33399014|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
33072904|NCT04255433|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
33072905|NCT04255433|Active Comparator|Dulaglutide|Dulaglutide administered SC once a week.
33072906|NCT04255043|Experimental|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
33072907|NCT04255043|Active Comparator|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
33072908|NCT04254419|Experimental|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
33072909|NCT04251416|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
32911979|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
32911980|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
32911981|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
32911982|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
33242649|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
33242650|NCT01034293|Experimental|low feeding frequency (3x)|
33242651|NCT01034293|Experimental|High feeding frequency (14x)|
33242652|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
33242653|NCT00792519|Active Comparator|HIV support group|group support
33242654|NCT03994783|Active Comparator|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
33242655|NCT03994783|Experimental|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
33242656|NCT04072536|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
33242657|NCT04072536|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
33242658|NCT00792597||spine or hip surgery|
33242659|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
33242660|NCT02423070||Cohort 1|Heart and Lung Transplant patients
33242661|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
32911983|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
32911984|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
32911985|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
33242662|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
32911986|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
32911987|NCT02687529||Low Risk|Tested with CST001
32911988|NCT02687529||Known Risk|Tested with CST001
32911989|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
32911990|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
32911991|NCT05587335|Experimental|In person|Couples will be assigned into in person relationship intervention.
33072910|NCT04246086|Experimental|Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
32911992|NCT05587335|Experimental|Online|Couples will be assigned into online relationship intervention.
32911993|NCT01819415|No Intervention|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
33242663|NCT00440011|Experimental|1|
33242664|NCT00440011|Active Comparator|2|
32911994|NCT01819415|Active Comparator|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
32911995|NCT01819415|Experimental|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
33399015|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
32911996|NCT01819415|No Intervention|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
32911997|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
32911998|NCT01819883||Healthy controls|
32911999|NCT01805297|Active Comparator|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
32912000|NCT01805297|Active Comparator|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
32912001|NCT04350749|Experimental|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
32912002|NCT04350749|Active Comparator|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
33231583|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33231584|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33231585|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33399016|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
33399017|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
33399018|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
33399019|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
33399020|NCT03370471|Experimental|Healthy Older Adults|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
33399021|NCT03370471|Experimental|Individuals with Aphasia|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
33399022|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
32912003|NCT01822301|Experimental|Repeat Facial fat grafting|
32912004|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
32912005|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
32912006|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
32912007|NCT01794143|Active Comparator|Sulfonylurea (glimepiride)|Sulfonylurea
32912008|NCT01794143|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
32912009|NCT01794143|Active Comparator|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
32912010|NCT01794143|Active Comparator|Insulin (glargine)|Insulin (glargine), Lantus
32912011|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
32912012|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
32912013|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
32912014|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
33072911|NCT04246086|Experimental|Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will have the option of receiving maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.
33072912|NCT04246086|Experimental|Arm A: IV Mosunetuzumab + Len (Randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
32912015|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
32912016|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
32912017|NCT01547741|Active Comparator|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
32912018|NCT01547741|Active Comparator|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
32912019|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
32912020|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
33242665|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
33242666|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
33242667|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
32912021|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
32912022|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
32912023|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
32912024|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
33072913|NCT04246086|Experimental|Arm B: SC Mosunetuzumab + Len (Randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
32762857|NCT05085457|Experimental|ExPreS Group|On group II (T-ayre and ExPreS protocol), the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, non invasive ventilation (NIV) should be scheduled or the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
32762858|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
32762859|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
32762860|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
32762861|NCT03726073|Sham Comparator|Non-intervention group|Usual care
32762862|NCT04873297|Experimental|Metoclopramide Group|One group will be given metoclopramide 10mg TDS
32762863|NCT04873297|Placebo Comparator|Placebo Group|This group will be given placebo (normal saline 10ml via NG TDS)
32762864|NCT02633501|Experimental|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
32762865|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
32762866|NCT02633501|Experimental|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
32762867|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
32762868|NCT05634473|Experimental|Patients with asthma/healthy subjects|
32762869|NCT05012813|Experimental|Supportive care (SFIT, biospecimen, interview)|Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.
32762870|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
32762871|NCT03138499|Experimental|Module B|Brentuximab alone
32762872|NCT05009381|Experimental|Treatment group|Treatment group will receive STYLAGE® XXL at enrollment with an optional touch up injection 30 days later
32762873|NCT05009381|Experimental|control group|Control group will not be treated at enrollment visit. Subjects will receive STYLAGE® XXL at visit 6 months after randomization, if they are still eligible for chin augmentation with an optional touch up injection 30 days later.
32762874|NCT05634317|Experimental|Behavioral activation|The SD-BA, consisting of 16 sessions (30 minutes each) twice a week over 8 weeks, will be delivered by the trained instructor through a videoconference mobile app. Participants will be asked to review their daily activity patterns and then choose activity goals and review their successes and areas of improvement. They will also be taught how to fill out the daily monitoring record, which will involve noting down their activities on the day of the session for each hour before the session, and rating the importance and degree of enjoyment associated with each activity.
32762875|NCT05634317|Active Comparator|Mindfulness|A mindfulness instructor will deliver the program through a videoconference mobile app, and include various mindfulness practices (e.g., mindful walking, body scanning) and sharing. To standardize the interventions in this study, the previous approach will be changed from 7 weekly 120-minute sessions to 16 sessions (30 minutes each) twice a week over 8 weeks. The participants will also be encouraged to perform 30 minutes of mindfulness practice every day. All participants will be given an audio (mp3) recording of guided mindfulness activities to enhance their daily practice, and a logbook via a mobile app or in hardcopy (according to their preference) to record the frequency of their self-practice at home and monitor their compliance rate. Our volunteers will provide support via smartphone to answer questions and address difficulties.
32762876|NCT05000021|Experimental|Treatment Group|Treatment group participants will receive a time-limited cognitive-behavioral intervention for 3 months plus CGM for 6 months to support participants in coping with diabetes distress and self-management of type 1 diabetes.
32762877|NCT05000021|No Intervention|Control Group|Control group participants will receive usual care, plus study supplied CGM for 6 months. They will also receive basic resources on diabetes distress and CGM, as would be delivered through usual care.
32762878|NCT05085145|Experimental|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
32762879|NCT05634239|Experimental|Health check|
32762880|NCT04858711|Active Comparator|ketamine-lidocaine-dexmedetomidine (KLD) group|combination of ketamine-lidocaine-dexmedetomidine in one syringe
32762881|NCT04858711|Active Comparator|fentanyl (control) group|syringe of fentanyl
32762882|NCT05634161||Cognitive Improvement software|Usability assessment of cognitive improvement software
32762883|NCT05084677|Experimental|PD-1 arm|PD-1 concurrent with and subsequent after concurrent chemoradiotherapy
32762884|NCT04794491|Experimental|Open-Label Conversion and Treatment Optimization|Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
33242668|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
32906518|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
32906519|NCT00912002|Experimental|MK-0941|MK-0941
32906520|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
32762887|NCT05633537|Experimental|group 1: zinc oxide-ozonated olive oil|"Group I: 30 primary molars were filled with fresh mix of zinc oxide powder with ozonated olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide-ozonated olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
33072914|NCT04243538|No Intervention|Control arm|Standard of care.
33399023|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
33399025|NCT05343325|Experimental|Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin|Neoadjuvant therapy will be performed for a total of 2 cycles, with 21 days as a cycle, which includes: ① Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles, and the total dose of radiation in the two cycles will be GTV 8 Gy/8 F and GTVnd 8 Gy/8 F; ② Teilizumab: 200 mg D1, Q3W for two cycles; ③ Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles; ④Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
33399026|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
33399027|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
33399028|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
33399029|NCT03349645|Experimental|AMPION™ 4 mL dose|4 mL intra-articular injection of AMPION™
33399030|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
33399031|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
33399032|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
33399033|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
33399034|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
33399035|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to bictegravir + tenofovir alafenamide + emtricitabine (B/FTC/TAF) for 48 weeks
33399036|NCT03348163|Active Comparator|Continue Current ART|Continue current antiretroviral therapy (ART) therapy (which is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks.
33399037|NCT03347695|Experimental|A new operation|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
33399038|NCT03347695|Other|A new operation (Selected pilot study)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
33399039|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
33399040|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
33399041|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
33399042|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
33399043|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
33399044|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
33399045|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
33399046|NCT03365791|Experimental|PDR001+LAG525|PDR001 300 mg and LAG525 400 mg administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
32912025|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
32912026|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
32912027|NCT01472822|Experimental|Omija extract.|
32912028|NCT01472822|Placebo Comparator|Placebo|
32912029|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
32912030|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
32912031|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
32912032|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
33242669|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
33242670|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
33072915|NCT04243538|Experimental|I-HoME intervention|Weekly televisits with a nurse practitioner that will implement the I-HoME intervention.
32912033|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
32912034|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
33072916|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
32743741|NCT04917003|Experimental|RIC group|"Patients who are allocated into RIC group will undergo the first EDAS surgery combined 3-month remote ischemic conditioning (RIC) treatment. The opposite operation will be performed at 3 months after the first operation.~RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used."
33242671|NCT03105102|Experimental|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
33242672|NCT03105102|Experimental|CTE: Open Label Continuous Treatment Extension|Participants who tolerate and derive benefit from receiving risankizumab and complete Sub-study 3 or Sub-study 4 will receive risankizumab dose 1 or dose 2 Q8W.
33242673|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
33242674|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
33242675|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
33242676|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
33242677|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
32906521|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
32906522|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
33242678|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
33242679|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
33242680|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
33242681|NCT01034371|Experimental|One-stop hybrid revasularization|
33242682|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
33242683|NCT04971213|Active Comparator|Non Invasive Ventilation|Bilevel non-invasive ventilation. Support pressure will be set to obtain a 6-8 mL/kg of predicted body weight PEEP will be set within 5-10 cmH2O and FiO2 for a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure) All settings will be adjusted according tolerance of the patient.
33242684|NCT04971213|Experimental|High-flow nasal cannula heated and humidified oxygen|"Flow will be set at 60 L/min and ajusted according the tolerance of the patient.~FiO2 will be set according a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure)"
32762888|NCT05633537|Experimental|group 2: zinc oxide- olive oil|"Group 2: 30 primary molars were filled with fresh mix of zinc oxide powder with olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
32762889|NCT05633537|Active Comparator|group 3:zinc oxide- eugenol|"Group 3: 30 primary molars were filled with zinc oxide- eugenol~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- eugenol) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
32762890|NCT03138187|No Intervention|control|without physical exercise sessions
32762891|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
32762892|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
32762893|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
32762894|NCT04771819|Experimental|SoftOx Wound Irrigation Solution (SWIS)|Blister wounds will be irrigated and soaked for 15 minutes.
32762895|NCT04771819|Active Comparator|Normal Saline|Blister wounds will be irrigated and soaked for 15 minutes.
32762896|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
32762897|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
32762898|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
32762899|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
32762900|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
32762901|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
32762902|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
32762903|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
32762904|NCT04166981|Active Comparator|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
32762905|NCT04166981|Experimental|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
32762906|NCT04756687||All Participants|RRMS participants treated with DMF will be identified in the EDMUS database for Observatoire Français de la Sclérose en Plaques (OFSEP) sites.
32898349|NCT02291055|Experimental|Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer and SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
32906523|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
32906524|NCT01726634|Experimental|Elastic Tapping|
33242685|NCT00774254|Experimental|A|
33242686|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
32912035|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
32912036|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
32912037|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
32912038|NCT01473368|No Intervention|control|
32912039|NCT04351490|Experimental|Group supplementation|
32912040|NCT04351490|No Intervention|Group usual treatment|
32912041|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
32912042|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
32912043|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
33242687|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
33242688|NCT00792675|Experimental|Exercise|
33242689|NCT04739930|Experimental|Bone Marrow Aspiration Group|A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.
33242690|NCT04739930|Sham Comparator|Control|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.
33242691|NCT00788229|Experimental|1. Study Drugs|
33242692|NCT00788229|Experimental|2. Study Drug|
33242693|NCT00788229|Experimental|3. Study Drug|
32912044|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
32912045|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
33242694|NCT00788229|Placebo Comparator|4. Placebo|
33242695|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
32912046|NCT01477229||Palliative treatment|Patients with systemic disease
33242696|NCT00788307|Experimental|Experimental Arm|
33242697|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
32912047|NCT01299935|Experimental|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
33072917|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
33072918|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
33242698|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
33242699|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
33242700|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
32906525|NCT01726712|No Intervention|Routine Care|
32906526|NCT01726712|Active Comparator|Supportive Contact|
32906527|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
32906528|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
32906529|NCT01720940|Experimental|continuous vancomycin infusion|
32906530|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
32906531|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
32906532|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).~MICT:~3 sessions per week~intensity at 65-75% HRmax~time-effort per session: 50 min"
32906533|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).~HIIT:~3 sessions per week~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax~time-effort per session: 25 min"
32906534|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
32906535|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
32912048|NCT01299935|Active Comparator|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
32912049|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
32912050|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
32912051|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
32912052|NCT05329181|Other|Integrated cognitive behavioral therapy adapted for homeless individuals|Four homeless individuals enrolled in the Treatment First program (a social services program where treatment is offered in conjunction with temporary transitional housing), who had access to stable and sober housing milieus, received the integrated cognitive behavioral treatment.
32912053|NCT05329025|Experimental|Treatment A|Participants with squamous cell carcinoma will receive QL1706, paclitaxel and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 until unacceptable toxicity or loss of clinical benefit.
33072919|NCT04241120|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
33242701|NCT04072328|Experimental|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
33242702|NCT04072328|Active Comparator|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
33242703|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
33072920|NCT04241120|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
33242704|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
33242705|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
33242706|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
33242707|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
33072921|NCT04240574|Other|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.~All subject will get the Debritom."
33242708|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
33072922|NCT04238689|Experimental|Group 1 - 0.1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
33242709|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
33242710|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
33242711|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
33242712|NCT04704830|Experimental|Standard Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 months olds
33242713|NCT04704830|Placebo Comparator|Standard Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 months olds
33242714|NCT04704830|Experimental|Seasonal Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 month olds
33242715|NCT04704830|Placebo Comparator|Seasonal Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 month olds
33242716|NCT00784017|Active Comparator|asparaginase medac|
33242717|NCT00784017|Experimental|recombinant asparaginase|
33242718|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
33242719|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
33242720|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
33242721|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
33242722|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
33242723|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
33242724|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
33242725|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
33242726|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
33242727|NCT00793143||Sleeve|
33242728|NCT00793143||Bypass|
32912054|NCT05329025|Experimental|Treatment B|Participants with non-squamous cell carcinoma will receive QL1706, bevacizumab, pemetrexed, and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706, bevacizumab and pemetrexed until unacceptable toxicity or loss of clinical benefit.
32912055|NCT01391468|Placebo Comparator|Placebo|cornstarch
32912056|NCT01391468|Experimental|Probiotics|probiotics
32912057|NCT05328869|Experimental|Relaxation group|Jacobson progressive relaxation training will be applied
32912058|NCT05328869|Other|Control group|No intervention will be applied
32912059|NCT01822457|Experimental|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
32912060|NCT01822457|No Intervention|control|Standard follow-up
32912061|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
33231586|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
32912062|NCT01391858|Placebo Comparator|placebo|placebo
32912063|NCT00103181|Active Comparator|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
32912064|NCT00103181|Experimental|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
32912065|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
33399047|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
32762907|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
32762908|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
32762909|NCT04776317|Experimental|Stage 1 (Naïve) Group 1|5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
32762910|NCT04776317|Experimental|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
32762911|NCT04776317|Experimental|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
32762912|NCT04776317|Experimental|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
32762913|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13|5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=7-10
32762914|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14|1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
32762915|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15|5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
32762916|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A,B|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
32762917|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
32762918|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=8-12
32762919|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
32762920|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
32762921|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
32762922|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=8-12
32762923|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=8-12
32762924|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
32762925|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
32762926|NCT04149821|Experimental|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
32762927|NCT04149821|Experimental|Cohort B Post BCL-2 Therapy|"Patients who progress after BCL-2 containing regimens~Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
32762928|NCT05077189||Study Group|Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
33399048|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
33399049|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
33399050|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
33399051|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
33399052|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
33399053|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
33399054|NCT03627065|Experimental|Parsaclisib|
33399055|NCT05665985|Experimental|Moringa Oliefera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
33399056|NCT05665985|Placebo Comparator|Placebo|Capsules similar to moringa oliefera, which contain powder, have no pharmacological effect.
32762929|NCT05077189||Control Group|Patients without CV-19 This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
32762930|NCT04766957|Experimental|Idracare|The treatment will be applied 2 times a week, preferably at night before going to bed.
32762931|NCT05393869|Experimental|Prevention (discussion, survey, interview, health education)|"PHASE 1: Participants attend focus groups over 90 minutes, complete an online survey and attend an interview over 60 minutes to aid in the refinement of anti-tobacco messages.~PHASE 2: Participants view anti-tobacco messages and rate them for perceived effectiveness and reactance."
32762932|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
32762933|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
32762934|NCT05632991|Active Comparator|External oblique intercostal plane block|Ultrasound-guided External oblique intercostal plane block before surgery
32762935|NCT05632991|Active Comparator|Subcostal Transversus Abdominis Plan Block Group|Ultrasound-guided Subcostal Transversus Abdominis Plan Block Group
32762936|NCT05073601||control group|group of subjects with healthy cornea
32762937|NCT05073601||keratoconus group|group of keratoconus patients with no history of thyroid dysfunction
32762938|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
32762939|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
32762940|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
32762941|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
32762942|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
32762943|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
32762944|NCT05631821|Active Comparator|Prospective Range Spinal System|Adolescent (between the ages of 10-18 years of age), with Idiopathic Scoliosis Range Spinal System: rod contour changes utilizing Differential Rod Bending and pre-operative templating in Adolescent Idiopathic Scoliosis: A pilot study. The prospective arm consented subjects will use the Rod Counour measurement system
33399057|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
33399058|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
33399059|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
33399060|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
33399061|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
33399062|NCT05665907||children with vestibular dysfunction with hearing loss|children with vestibular dysfunction with hearing loss
33399063|NCT05665907||children with vestibular dysfunction with normal inner ear function|children with vestibular dysfunction with normal inner ear function
33399064|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
33399065|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
33072923|NCT04238689|Experimental|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
33072924|NCT04238689|Experimental|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
33072925|NCT04238689|Experimental|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
33072926|NCT04238689|Experimental|Group 5 - 100mg TB31F|100mg of monoclonal antibody TB31F is administered subcutaneously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
33072927|NCT04236609|Active Comparator|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
33242729|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
33242730|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
33242731|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
33242732|NCT00788463|Experimental|Aerosol|
33072928|NCT04236609|Active Comparator|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
33072929|NCT04235504|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
33072930|NCT04235504|Experimental|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
33072931|NCT04232774|Experimental|Treated by the study device|
33072932|NCT04232657|Experimental|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
33072933|NCT04232657|Placebo Comparator|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
33072934|NCT04232657|Active Comparator|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
33072935|NCT04232566||Weight loss surgery|Gastric bypass surgery will be followed by weight loss as standard of care. Liver fibrosis by elastography will be determined before surgery.
33242733|NCT00788463|Active Comparator|Spray|
33072936|NCT04232553|Experimental|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
33072937|NCT04232553|Experimental|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
33242734|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
33242735|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
33242736|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
33242737|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
33242738|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
33242739|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
33242740|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
33242741|NCT04072562|Experimental|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
33242742|NCT04072562|Experimental|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
33242743|NCT04072562|Active Comparator|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
33242744|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
33242745|NCT04072484|No Intervention|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
33242746|NCT04072484|Experimental|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
33242747|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
33242748|NCT04941144||COVID-19 Vaccine Intramuscular Injection 0.5 milliliters (mL)|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
33072938|NCT04231266|Active Comparator|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
33072939|NCT04231266|Placebo Comparator|Placebo|Oral Placebo will be administered three times daily.
33072940|NCT04223856|Experimental|Arm A|Enfortumab vedotin + pembrolizumab
33072941|NCT04223856|Active Comparator|Arm B|Gemcitabine + cisplatin or carboplatin
33072942|NCT04223856|Experimental|Arm C (Not Recruiting)|Enfortumab vedotin + pembrolizumab + Cisplatin or carboplatin
32912066|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
32912067|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
32912068|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
33072943|NCT04221789|Experimental|intervention: TB treatment assistant|Patients receiving instructions to use phone application
33072944|NCT04221789|No Intervention|Control|Patients receiving instructions for usual care self administered treatment
32912069|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
32912070|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
32912071|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
32912072|NCT01823861|Experimental|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
32912073|NCT01823861|No Intervention|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
33072945|NCT04216277|Experimental|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
32762945|NCT05631821|No Intervention|Retrospective|Retrospective matched cohort of subjects from the investigating surgeon are subjects that have not used the Rod contour measurement system. There is no intervention because the second arm is retrospective chart review.
32762946|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered physical therapist (PT), and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
32912074|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
32912075|NCT05587257|Experimental|Group 1|six sessions of fractional carbon dioxide laser every 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
32912076|NCT05587257|Experimental|Group 2|six sessions of microneedling evry 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
32912077|NCT05587257|Experimental|Group 3|15 patient of alopecia areata that will be treated by topical nanominoxidil for 3 months.
32912078|NCT05587257|Active Comparator|Group 4|15 patient of alopecia areata that will be treated by topical minoxidil 5% for 3 months
32912079|NCT05585463||Oncology pediatric patients treated with acupuncture|"Patients in the oncology area of the Sant Joan de Déu Hospital treated at the UOPI (Integrative Pediatric Oncology Unit) from September 2019 to September 2021 have received treatment with acupuncture and intracutaneous Seirin New Pyonex Press Tack®.~Patients in active treatment and survivors are included. Acupuncture treatment can be received in a hospitalization ward, an intensive care unit, a day hospital or an outpatient clinic."
32912080|NCT01825655|Active Comparator|Cetirizine|zyrtec 10mg, oral, one time
32912081|NCT01825655|Placebo Comparator|Sugar pill|Placebo, one pill, one time
32912082|NCT04272489|Experimental|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
32912083|NCT04272489|Active Comparator|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
33399066|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
32912084|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
32912085|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
32912086|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
32912087|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
33399067|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
33399068|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
33399069|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
33399070|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
33242749|NCT04072406|Active Comparator|Arm I: Usual Care|"Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
33072946|NCT04216277|No Intervention|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
33242750|NCT04072406|Experimental|Arm II: Mindfulness Meditation|"Participants will listen to mindfulness meditations daily over the course of three weeks.~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
33242751|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
33242752|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
33242753|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
33242754|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
33242755|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
33072949|NCT04211831|Experimental|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
33242756|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
33242757|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
33242758|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
33242759|NCT03099174|Experimental|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
33242760|NCT03099174|Experimental|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
33242761|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
33242762|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
33242763|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
33242764|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
33242765|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
32737171|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 0 J"
33072950|NCT04211831|Experimental|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
33072951|NCT04211337|Experimental|Selpercatinib|Selpercatinib given orally.
33072952|NCT04211337|Active Comparator|Cabozantinib or Vandetanib|Cabozantinib or vandetanib given orally.
33072953|NCT04209595|Experimental|1/Arm 1|Escalating doses of PLX038 and rucaparib
33072954|NCT04209595|Experimental|2/Arm 2|MTD of PLX038 and rucaparib
33242766|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
33242767|NCT00788853||A|
33242768|NCT04071002|Active Comparator|surgical group|distal radius fractures that treated volar plate
33242769|NCT04071002|Active Comparator|conservative group|distal radius fractures that treated plaster of paris
32912088|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
32912089|NCT05328167|Experimental|Diagnostic (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo ultrasound at 1 month before TARE, 1-4 hours, 1 week, and 2 weeks post-TARE.
32912090|NCT04250727|Experimental|3mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.
33242770|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
33242771|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
33242772|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
33242773|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
33242774|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
33242775|NCT04458194|Active Comparator|Standard Care|Cancer survivors receive their standard care
32912091|NCT04250727|Experimental|6mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.
32912092|NCT04237623|Experimental|GM-CSF post-transplant|Sargramostim (GM-CSF) will start on Day +5 and continue until ANC >1000 x3 days or >1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
32912093|NCT05328011||overactive bladder syndrome|female patients with overactive bladder syndrome
32912094|NCT05328011||controls|women without overactive bladder syndrome
32912095|NCT05583279|Experimental|Phase 2|Cohort 1 and 2 youth will then complete baseline assessments (see 4.5) and Cohort 2 will continue receiving TAU while Cohort 1 begins receiving DBT-A (randomized by facility to either in-person or via telehealth delivery) for the next six months while Cohort 1 staff continue consultation with DBT-A. After six months, Phase 2 of this study will conclude with the youth of Cohorts 1 and 2 completing their first follow-up assessment. The implementation plan will be altered accordingly based on feedback from stakeholders prior to the start of Phase 2. The modified implementation plan will be used in the training of the staff in DBT-A at the second four facilities prior to the launch of Phase 3.
32912096|NCT05583279|Active Comparator|No intervention|Cohort 2 will not receive any treatment during Phase 2 of the study, which is the first part of the clinical trial. They will serve as a comparison group for Cohort 1.
33242776|NCT04458194|Experimental|YOCAS|Cancer survivors receive 8 virtual yoga sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
32912097|NCT05583279|Active Comparator|Phase 3|Phase 3 will begin with making any modifications to the treatment protocol based on a review of feedback from stakeholder interviews from Phase 2. Cohort 2 facilities will be randomized to delivering DBT-A in-person or via telehealth (one long-term and one short-term facility will be assigned to each condition). Staff in Cohort 2 will receive training and consultation in DBT-A and implement either telehealth or in-person delivered DBT-A in their facilities. Cohort 1 facilities will cross-over from in-person delivery of DBT-A to telehealth delivery, or vice-versa, thereby facilitating a within-facility comparison of DBT-A delivery methods. After six months, Phase 3 will conclude with the youth of Cohorts 1 and 2 completing their second follow-up assessment and all stakeholders of Cohorts 1 and 2 completing stakeholder interviews.
32912098|NCT01825889|Experimental|Evacetrapib (Participants With Renal Impairment)|Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment.
32912099|NCT01825889|Experimental|Evacetrapib (Healthy Participants)|Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.
32912100|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
32912101|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
32912102|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
33072955|NCT04199780|Experimental|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
33242777|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
33242778|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
33242779|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
32912103|NCT01826513|Experimental|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
32912104|NCT01826513|Active Comparator|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
32912105|NCT01826513|Experimental|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
32912106|NCT02692755|Experimental|Palbociclib + Letrozole or Fulvestrant|
33072956|NCT04199780|Experimental|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
33072957|NCT04199780|Experimental|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
32737172|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
32912107|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
32912108|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
32912109|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
32912110|NCT05580549||Essential Hypertension|A representative sample of adult patients, with hypertension (ICD-10 diagnose code I10.9) from 2-3 PHCC in Stockholm Region, Sweden. Age 30-85 years old.
32912111|NCT05327777|No Intervention|Control|Normal standard practices
32912112|NCT05327777|Experimental|Opioid Sparing|Providers required to prescribe 10 narcotic pills only
32912113|NCT05327777|Experimental|Zero Opioid|No narcotic prescription is provided to patient at discharge
33399071|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
33399072|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
33399073|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
33399074|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
32762947|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a physical therapist (PT). In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
32762948|NCT05630963||MDD subjects|Subjects diagnosed with Major Depression Disorder
32762949|NCT05630963||Remitted MDD subjects|Subjects with a history of major depressive disorder episode in the past
32762950|NCT05630963||Control subjects|Subjects with no history of known neurological and psychiatric illness.
32762951|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
32762952|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
32762953|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
32762954|NCT05047601|Experimental|PF-07321332/ritonavir (5 days)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10
32762955|NCT05047601|Experimental|PF-07321332/ritonavir (10-Day)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10.
32762956|NCT05047601|Placebo Comparator|Placebo|Participants will receive placebo every 12 hours from Day 1 through Day 10.
32762957|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
32762958|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
32762959|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
32762960|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
32762961|NCT05046197||Work Package 1 - patients and carers|"Qualitative interview of 48 Patients, or their carers where the patient lacks capacity, who have had a ReSPECT form completed in the previous 6 months. To include:~12 patients living in care homes 12 patients living at home (nearing the end of their life) 12 patients living at home (not nearing the end of their life)"
32762962|NCT05046197||Work Package 1 - GPs|Qualitative interview of 30 General Practitioners who are involved in the ReSPECT process
32762963|NCT05046197||Work Package 1 - Care home managers|Qualitative interview of 24 care home managers.
32762964|NCT05046197||Work Package 2 - Focus groups/interviews (Members of the Public)|Qualitative interview of 30 members of the public with an interest in healthcare regarding attitudes to the ReSPECT process.
32762965|NCT05046197||Work Package 2 - Focus groups/interviews (Health and Social Care Professionals)|Qualitative interview of 30 Non-GP Health and Social Care Professionals regarding attitudes to the ReSPECT process.
32762966|NCT05046197||Work Package 2 - Focus groups/interviews (Faith Leaders)|Qualitative interview of 8 faith leaders regarding attitudes to the ReSPECT process.
32762967|NCT05046197||Work Package 2 - Survey (Members of the Public)|Survey of 1000 members of the public to measure public awareness and acceptability of emergency care treatment plans
32762968|NCT05046197||Work Package 2 - Survey (GPs)|Survey of 1000 GPs to measure the views of GPs nationally regarding the use of emergency care treatment plans including ReSPECT, in primary care.
32762969|NCT05046197||Work Package 3 - Patient records|Patient records of 413 patients within 12 CCGs in England who have had a ReSPECT form completed in the previous 12 months
32762970|NCT05051059|Other|Soft tissue sarcoma of the thigh|Patients who underwent surgical resection of a deep intramuscular soft tissue sarcoma of the thigh
32762971|NCT05051059|No Intervention|Control group|A group of healthy age-matched individuals will be identified out of an available gait lab database to compare the gait pattern with tha of the patient group
32762972|NCT05051059|Other|Bone or soft tissue sarcoma of the lower extremity|Patients who underwent surgical resection of a bone or soft tissue sarcoma of the lower extremity
32762973|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
32762974|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
32762975|NCT05393011||Pregnant group|A female is considered pregnant when an explicit gestational sac inside the uterus is seen by ultrasound 4 weeks after embryo transfer.
32762976|NCT05393011||Non-pregnant group|A female is considered not pregnant when no explicit gestational sac is seen inside the uterus by ultrasound 4 weeks after embryo transfer.
32912114|NCT05441865||cognitive trajectory cohort|Th cognitive trajectory cohort, based on CLHLS dataset, will be used to evaluate the influence of cardiovascular risk factors on the cognitive trajectories among cognitively intact older adults
33072958|NCT04199780|Sham Comparator|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
32912115|NCT05441865||neuroiming sample|The neuroiming sample, including cognitively intact older adults with MRI data, will be used to explore the potential mechanism of the cardiovascular risk factors and cognitive function.
32912116|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
32912117|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
32912118|NCT05327621|Experimental|Pamiparib|Tablets 20mg per os : 40 mg / bid every day in continuous. Patients will be treated with Pamiparib. Cycles are defined in 28-day periods. Disease response will be assessed every 8 weeks (RECIST 1.1). Safety will be assessed continuously.
32912119|NCT05327387|Experimental|model-based electrical brain stimulation|
32912120|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
32912121|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
32912122|NCT05327309|Active Comparator|Propranolol|propranolol with a mean dose of 2mg/kg/day in 2 divided doses for a period of 6 months
32912123|NCT05327309|Experimental|Bleomycin|Bleomycin 15mg diluted in 15 ml of Normal Saline along with a dosage of 0.5 mg/kg for a period of 6 months.
32912124|NCT05326841|Experimental|Cholecalciferol group|Participants in this arm take a vitamin D3 dose 5000 international units (IU) daily by mouth for a duration of 12 weeks
32912125|NCT05326841|Placebo Comparator|placebo group|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks
32912126|NCT05576805||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV Treatment|Participants who had an SOT after January 1, 2016 and must have developed post-transplant CMV infection and were subsequently characterized as RRI to currently available anti-CMV treatment at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
32912127|NCT05576805||Cohort 2: Pre-emptive CMV Treatment|Participants who had an SOT after January 1, 2019, and who were preemptively treated for CMV at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
32912128|NCT05326763|Active Comparator|platelet rich plasma group|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle.
32912129|NCT05326763|Active Comparator|dextrose group|4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
32912130|NCT05326763|No Intervention|Placebo (the control group)|
32912131|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
32912132|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
33072959|NCT04195737|Experimental|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
32912133|NCT05748353||Patients with BRCA pathological variants with breast or ovarian cancers|Patient with pathogenetic mutation of BRCA 1 or 2 gene who have developed breast or ovarian neoplasm
33242780|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
33242781|NCT04072094|Experimental|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
33242782|NCT04072094|Active Comparator|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
33242783|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
33242784|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
33242785|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
33242786|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
33072960|NCT04195737|Active Comparator|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
33399075|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
33399076|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
33242787|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
32762979|NCT05034835|Experimental|With compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations) + wearing a compression garment for 3 months.
32762980|NCT05034835|Other|Without compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations).
32762981|NCT03138421|Experimental|ABX-1431 HCl|
32762982|NCT03138421|Placebo Comparator|Placebo|
32762983|NCT04705727|Experimental|budesonide/formoterol Turbuhaler®|After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
32762984|NCT04705727|Active Comparator|nebulisation of terbutaline|0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.
32762985|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
32762986|NCT05629637|Experimental|Mindfulness-Based Resilience Training (MBRT)|MBRT is an 2.5-day program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive-behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
32762987|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
32762988|NCT03110731|No Intervention|Control Group|no intervention
32762989|NCT05628155|Experimental|Oral diet including n-3 PUFA intake|Oral diet covering the nutritional requirements in macronutrients as recommended for people over 65 years of age (ANSES, 2019) and including intakes of n-3 PUFAs corresponding to the recommendations for people over 65 years of age
32762990|NCT05628155|No Intervention|Control|
32762991|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
32762992|NCT04677413|Experimental|Phase I Dose Cohorts|"DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)"
32762993|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
32762994|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
32762995|NCT05619965|Active Comparator|Awake Glidoscope Videolaryngoscope|Awake endotracheal intubation of cervical trauma patients by Glidoscope Videolaryngoscope
33242788|NCT02575898|Other|One|"Creative writing and questionnaires interventions:~First Session, Second Session, Third through Sixth Sessions"
33399079|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
33242789|NCT04019184|Experimental|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
33242790|NCT04019184|Placebo Comparator|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
33242791|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
33242792|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
33242793|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
33242794|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
33277349|NCT04256018|Experimental|LD TSEBT|"Mogamulizumab with low dose total skin electron beam therapy. •~LD (12 Gy) TSEBT will be initiated on Cycle 1 Day 2 (± 2 days) of mogamulizumab over 2 to 3 week period per standard of care (SOC), as tolerated. Mogamulizumab (1 mg/kg) will be administered over 60 minutes as follows (per SOC and FDA approved use in MF and SS):~Cycle 1 only: Days1; 8; 15; and 22 (± 2 days)~Cycle 2 and beyond: Day 1 and Day 15 (± 3 days)"
33399080|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
33399081|NCT04832022||Vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who accepted vaccination against SARS-CoV2
33399082|NCT04832022||Non vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who refused vaccination against SARS-CoV2
33399083|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
33399084|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
33399085|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
33399086|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
33399087|NCT05417334|Active Comparator|ON Radiofrequency treatment|Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with activated RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
33399088|NCT05417334|Sham Comparator|Sham Radiofrequency treatment|Application of the technique in the intervention group (inactive resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with inactive RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
33399089|NCT04652856|Experimental|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
33399090|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
33399091|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
33399092|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
33399093|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
33399094|NCT05417256|Active Comparator|Tappa Blocker Group|After orotracheal intubation, Tappa endobronchial blocker will be inserted using a broncoscope by an experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
33399095|NCT05417256|Active Comparator|Arndt Blocker Group|After orotracheal intubation, Arndt endobronchial blocker will be inserted using a broncoscope by the experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
33399096|NCT05665829|Active Comparator|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after intubation with microlaryngeal tube, a laryngoscope will be inserted transorally under direct vision and suspended. Laryngeal lesions are visualized with either microscope or endoscope, and removed with microsurgery instruments and sent for routine section
33399097|NCT05665829|Experimental|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, a transnasal channel flexible laryngoscope is used with prior trans-nasal, trans-oral and trans-laryngeal local anesthesia application. A 445nm blue laser is introduced via a working channel of laryngoscope, with a lesion-specific laser setting. Biopsy can be performed by devascularizing and thinning the lesion down to a pedicle, then removed with biopsy forcep. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. Patients are discharged on same day of procedure after close observation for 2 hours in day center.
33399098|NCT04609956|Experimental|virtual reality|Experimental arm is a virtual reality headphones
33399099|NCT04609956|Other|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
33399100|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
33399101|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
33399102|NCT02072148|Experimental|Low Risk Group I|"Group I:~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),~No LVI, no PNI, <3 positive nodes.~No ECS, No matted or Level >III,"
33399103|NCT02072148|Experimental|Intermediate Risk Group II|"Group II~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
33399104|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm~Contralateral or supraclavicular nodes"
33277350|NCT03961087|Active Comparator|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
32762996|NCT05619965|Active Comparator|Awake Fiberoptic bronchoscope|Awake endotracheal intubation of cervical trauma patients by Fiberoptic bronchoscope
32912134|NCT05748353||Patients with BRCA pathological variants without diagnosis of cancer|Patient with pathogenetic mutation of BRCA 1 or 2 gene without diagnosis of malignancy and without prophylactic surgery
32912135|NCT05748275||Argos|Biometry measurements first with the Argos device followed by the IOLMaster 700 device.
32912136|NCT05748275||IOLMaster 700|Biometry measurements first with the IOLMaster 700 device followed by the Argos device.
32912137|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
32912138|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
33399105|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins~≥ 1 mm ECS~Matted nodes"
32912139|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
32912140|NCT01414010|Active Comparator|Prebiotic|
32912141|NCT01414010|Active Comparator|Probiotic|
32912142|NCT01414010|Active Comparator|Antibiotic|
32912143|NCT01414010|No Intervention|Control|Control group, no intervention given.
32912144|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
32912145|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
32912146|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
33399106|NCT01735812|Experimental|symptomatic UF|
33399107|NCT04456608|Experimental|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
33399108|NCT05451030|Experimental|remote ischemic preconditioning|
33399109|NCT05451030|Sham Comparator|control group|
33399110|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
33399111|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
33399112|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
33399113|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
33399114|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
33399115|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
33399116|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
33399117|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
33399118|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
33399119|NCT04450212|Experimental|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
33399120|NCT04450212|Experimental|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2*1 (n=14) or CYP4F2*3 carriers (n=14) are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
32912147|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
32912148|NCT05313269|Experimental|ISAFE technique|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
32912149|NCT05313269|Active Comparator|Conventional technique|Adductor canal block catheter tip located in lateral to the femoral artery.
32912150|NCT05312723||Rhinitis allergy|Patients with rhinitis symptoms and positive skin pric test to one or more allergens.
32912151|NCT05312723||Non-rhinitis allergy|Patients with rhinitis symptoms and negative skin pric test to one or more allergens.
32912152|NCT05311397|Experimental|The first stage（Dose-escalation）|According to the initial dose, the highest dose and the modified Fibonacci method, the dose escalation of A166 for injection is designed as: 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg (the highest dose is tentatively set at 4.8 mg/kg).
32912153|NCT05311397|Experimental|The second stage（Dose-expansion）|The administered dose of A166 for injection is RS2D obtained in the first stage .
32912154|NCT05280041|Experimental|Fixed standardized - SOLENA-F|In the fixed standardized arm participants will be asked to complete the study modules of the intervention (CBT intervention itself) in a fixed standardized order from module 1 to module 10. Participants will only be able to start the following module once they complete the previous one. At the beginning and at the end of each module it is emphasized what participants will do in the following module.
32912155|NCT05280041|Experimental|Self-tailored - SOLENA-ST|In the self-tailored arm participants will be asked to complete most of the study modules of the intervention (CBT intervention itself) in a flexible format, according to their own needs at each moment. Participants will be asked to start the intervention by completing the preparatory modules (modules 1 and 2) following a fixed order. After completion of module 2, all the remaining modules become available at the same time. At the beginning and at the end of each module, participants are invited to reflect on their own needs and to complete the modules that better meet them.
32912156|NCT05280041|No Intervention|Waiting list control group|Participants in this group will start the intervention 10 weeks after the randomization. Participants in the waiting list control group will be randomly distributed by the fixed standardised and self-tailored arms. This arm will follow the exact same procedure of the active arms.
32912157|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
32912158|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
33399121|NCT05417022||Diamondback 360TM orbital atherectomy system|
33399122|NCT05430204|Active Comparator|one-hour Glucose tolerance test (GCT)|
33242795|NCT04070690|Other|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
33242796|NCT04070690|Other|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
33242797|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
33242798|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
33242799|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
32912159|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
32912160|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
33399123|NCT05430204|Experimental|CGM screening|
33399124|NCT05076552|Experimental|Phase 1a: Dose Escalation|In Phase 1a, participants will receive TACH101 in a 48 hour single-dose lead-in period followed by repeated dosing on a 3-day on/4-day off schedule in each 28 day cycle.
32912161|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
33399125|NCT05076552|Experimental|Phase 1b: Dose Expansion|"In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1 on a 3-day on/4-day off schedule. Two cohorts of participants will be enrolled:~Participants with gastrointestinal cancers.~Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC)."
33399126|NCT05074290|Experimental|Epidiferphane + taxane chemotherapy|
33399127|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
33399128|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
33399129|NCT05416866|Experimental|TR group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and retrolaminar block with 30-40 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
33399130|NCT05416866|Experimental|TQ group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and quadratus lumborum block with 30 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
33399131|NCT05052216||NORM|healthy children
33399132|NCT05052216||OSA|children with obstructive sleep apnea
33399133|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
33399134|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
33399135|NCT05416242|Active Comparator|Fixed appliance|Patients in this group will be treated using traditional brackets alone.
33399136|NCT05416242|Experimental|Self-ligaton appliance|Patients in this group will be treated using self-ligating brackets alone.
33399137|NCT05416242|Experimental|Self-ligaton appliance + piezocision|Patients in this group will be treated using self-ligating brackets associated with piezocision.
33399138|NCT05407194|Experimental|Supplement + progressive tendon loading therapy|The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
33399139|NCT05407194|Placebo Comparator|Placebo + progressive tendon loading therapy|The placebo consists of maltodextrin. In comparison the intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
33399140|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
33242800|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
33242801|NCT04074252|Active Comparator|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
33242802|NCT04074252|Active Comparator|Axillary Crutches|This group is given a set of axillary crutches.
33242803|NCT04072172|Experimental|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
33277351|NCT03961087|No Intervention|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
33242804|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
33242805|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~Adequate cardiac function by history and physical examination~bilirubin and hepatic transaminases < 2.5 x upper limit of normal~normal hematologic parameters Females should have a negative serum pregnancy test."
33242806|NCT00710216|Active Comparator|A|
33242807|NCT00710216|Experimental|B|
33242808|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
33242809|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
33242810|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
33242811|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
33242812|NCT00710372|Experimental|1|CYT006-AngQb
33242813|NCT00710372|Placebo Comparator|2|
33242814|NCT00710450||1|Allergic Asthma
33242815|NCT00710450||2|Allergic Rhinitis
33242816|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
33242817|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
33242818|NCT00710528|Experimental|one arm|
33242819|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
33242820|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
33242821|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
33242822|NCT00711074|Experimental|1|
33242823|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
33242824|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
33242825|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA~Dosage form: 1.6 mL DNA/PEIm nanomedicine~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
33242826|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
33242827|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
33242828|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
33242829|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA~Dosage form: 6.4 mL DNA/PEIm nanomedicine~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
33242830|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
33242831|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
33242832|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
33242833|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
33242834|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
33242835|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
33242836|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
33242837|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
33242838|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
33242839|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
33242840|NCT04101773|Other|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
33242841|NCT04101773|Other|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
33399141|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
33277352|NCT03960775|Experimental|Group A (dexmedetomidine)|dexmedetomidine infusion group
33399142|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
33399143|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
33399144|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
33399145|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
33399146|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
33072969|NCT04187833|Experimental|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
33072972|NCT04173585|Experimental|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:~Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3~Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4~Pegfilgrastim 6 mg sc on day 8 (optional)"
33072973|NCT04173273|Experimental|Etrasimod Dose A|
33072974|NCT04173273|Experimental|Etrasimod Dose B|
33072975|NCT04173273|Placebo Comparator|Placebo|
33242842|NCT04101773|Other|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
33242843|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
33242844|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
33242845|NCT04104347|Experimental|Metacognitive training (MCT)|
33242846|NCT04104347|Active Comparator|Support group|
33242847|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
32762997|NCT04659629|Experimental|Part 1: NL-201 Monotherapy Dose Escalation|NL-201 given as monotherapy by intravenous administration testing ascending doses and two different schedules.
32762998|NCT04659629|Experimental|Part 2: NL201 Monotherapy Expansion Cohorts|NL-201 given as monotherapy by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.
33242848|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
32762999|NCT04659629|Experimental|Part 3: NL-201 in Combination with Pembrolizumab Dose Escalation|NL-201, in combination with a set Pembrolizumab dose, testing ascending doses and two different schedules
32763000|NCT04659629|Experimental|Part 4: NL-201 in Combination with Pembrolizumab Expansion Cohorts|NL-201 in combination with Pembrolizumab in indication specific cohorts at a dose and schedule determined in Part 3
32763001|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
33072976|NCT04172987|Experimental|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day.
33072977|NCT04172987|Experimental|EE/NGM + Tirzepatide (Period 2)|Participants received a 28-day packet of a combination OC containing 21 days of tablets that consist of active ingredients (0.035 mg EE and 0.25 mg NGM) self-administered orally QD on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day and a single dose 5 mg tirzepatide administered subcutaneously (SC).
32763002|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
32763003|NCT04609787|Experimental|All participants|Quantitative sensory testing will be completed and current pain levels obtained. 20-minutes of immersive virtual reality will be completed, and then complete quantitative sensory testing again. We will compare pre-IVR quantitative sensory testing with post IVR levels.
32763004|NCT02985619|Active Comparator|IVB randomised group I|"Randomised patients [intravitreal bevacizumab (IVB) group I] with central foveal thickness >300µm on OCT will be submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus."
32898350|NCT02291055|Experimental|Part A Expansion (Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
33242849|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
33072978|NCT04171856|Experimental|Motor Skill Learning (CIRCUIT)|Intervention: training on the REAplan robot with a serious game based on motor skill learning (MSkL) serious game, the CIRCUIT.
33242850|NCT05529797|Experimental|Veovita-VR|Participants receive one VR session with positive emotional stimuli and positive behavioral activation.
33242851|NCT05529797|No Intervention|Care as Usual|Participants receive CAU.
33242852|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
33242853|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
32912162|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
32912163|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
33242854|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
32912164|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
32912165|NCT05748119|Placebo Comparator|A1a Placebo|Single Sentinel Placebo Comparator for 20 mg Dose of MEB-1170
32912166|NCT05748119|Experimental|A1a MEB-1170|Single MEB-1170 Sentinel 20 mg Dose
32912167|NCT05748119|Placebo Comparator|A1b Placebo|Single Placebo comparator for 20 mg dose cohort of MEB-1170
32912168|NCT05748119|Experimental|A1b MEB-1170|Single MEB-1170 20 mg dose cohort
32912169|NCT05748119|Placebo Comparator|A2a Placebo|Single Sentinel Placebo Comparator for 60 mg Dose of MEB-1170
32912170|NCT05748119|Experimental|A2a MEB-1170|Single MEB-1170 Sentinel 60 mg Dose
33242855|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
33242856|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
33242857|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
33399147|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
32912171|NCT05748119|Placebo Comparator|A2b Placebo|Single Placebo comparator for 60 mg dose cohort of MEB-1170
32912172|NCT05748119|Experimental|A2b MEB-1170|Single MEB-1170 60 mg dose cohort
32912173|NCT05748119|Placebo Comparator|A3a Placebo|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170
32912174|NCT05748119|Experimental|A3a MEB-1170|Single MEB-1170 Sentinel 120 mg Dose
32912175|NCT05748119|Placebo Comparator|A3b Placebo|Single Placebo comparator for 120 mg dose cohort of MEB-1170
32912176|NCT05748119|Experimental|A3b MEB-1170|Single MEB-1170 120 mg dose cohort
32912177|NCT05748119|Placebo Comparator|A4a Placebo|Single Sentinel Placebo Comparator for 200 mg Dose of MEB-1170
32912178|NCT05748119|Experimental|A4a MEB-1170|Single MEB-1170 Sentinel 200 mg Dose
32912179|NCT05748119|Placebo Comparator|A4b Placebo|Single Placebo comparator for 200 mg dose cohort of MEB-1170
32912180|NCT05748119|Placebo Comparator|A4b MEB-1170|Single MEB-1170 200 mg dose cohort
32912181|NCT05748119|Placebo Comparator|A5a Placebo|Single Sentinel Placebo Comparator for 400 mg Dose of MEB-1170
32912182|NCT05748119|Experimental|A5a MEB-1170|Single MEB-1170 Sentinel 400 mg Dose
32912183|NCT05748119|Placebo Comparator|A5b Placebo|Single Placebo comparator for 400 mg dose cohort of MEB-1170
32912184|NCT05748119|Experimental|A5b MEB-1170|Single MEB-1170 400 mg dose cohort
32912185|NCT05748119|Placebo Comparator|B1 Placebo|MAD Placebo 60 mg comparator cohort of MEB-1170
32912186|NCT05748119|Experimental|B1 MEB-1170|MAD 60 mg MEB-1170 cohort
32912187|NCT05748119|Placebo Comparator|B2 Placebo|MAD Placebo 100 mg comparator cohort of MEB-1170
32912188|NCT05748119|Experimental|B2 MEB-1170|MAD 100 mg MEB-1170 cohort
32912189|NCT05748119|Placebo Comparator|B3 Placebo|MAD Placebo 200 mg comparator cohort of MEB-1170
32912190|NCT05748119|Experimental|B3 MEB-1170|MAD 200 mg MEB-1170 cohort
32912191|NCT05748119|Placebo Comparator|B4 Placebo|MAD Placebo 400 mg comparator cohort of MEB-1170
32912192|NCT05748119|Experimental|B4 MEB-1170|MAD 400 mg MEB-1170 cohort
32912193|NCT05748119|Placebo Comparator|A3a Placebo Fed State|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170 in Fed State
32912194|NCT05748119|Experimental|A3a MEB-1170 Fed State|Single Sentinel 120 mg Dose of MEB-1170 in Fed State
32912195|NCT05748119|Placebo Comparator|A3b Placebo Fed State|Single Placebo comparator for 120 mg dose cohort of MEB-1170 in Fed State
32912196|NCT05748119|Experimental|A3b MEB-1170 Fed State|Single MEB-1170 120 mg dose cohort in Fed State
33277353|NCT03960775|Placebo Comparator|Group B (saline)|normal saline infusion group
33399148|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
33399149|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
33399150|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
33399151|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
33242858|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
32912197|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
32912198|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
32912199|NCT00557375||1|Brain tumor patients
32912200|NCT00557375||2|Caregivers of brain tumor patients
32912201|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
32912202|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
33072979|NCT04171856|Active Comparator|Motor control recovery (EASY)|Training on the REAplan robot with a serious game that requires similar type and amount of movements but does not rely on motor skill learning (EASY), a brick buster game.
32912203|NCT01416194||Bazedoxifene|
33242859|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
33242860|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
33242861|NCT04071938|Active Comparator|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
33399152|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
32912204|NCT01416194||Primary Comparator|
32912205|NCT01416194||Secondary Comparator|
33399153|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
33072980|NCT04171856|Active Comparator|Conventional|Training sessions with classical exercices focused on the upper limb administered by occupation therapist.
33242862|NCT04071938|No Intervention|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
33242863|NCT01572506|Active Comparator|Group 1|Age 70 and older with unexplained anemia
33242864|NCT01572506|Active Comparator|Group 2|Age 70 and older with iron deficient anemia
33242865|NCT01572506|Active Comparator|Group 3|Age 70 and older without anemia
33242866|NCT01572506|Active Comparator|Group 4|Age 18 - 50 without anemia
33242867|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
33242868|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
33242869|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
33242870|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
33242871|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
33242872|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
33399154|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
33399155|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
33399156|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
33399157|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
32912207|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
32912208|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
32912209|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
32912210|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
32912211|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
32912212|NCT05506605|Experimental|Switch from Etravirine to Doravirine|Switch from etravirine to Doravirine (Pifeltro) 100 mg each day
32912213|NCT04172961|Experimental|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
32912214|NCT04172961|Active Comparator|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
32912215|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
32912216|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
32912217|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
32912218|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
32912219|NCT04049799||Medically-supervised withdrawal (MSW)|
32912220|NCT04049799||Opioid agonist treatment (OAT)|
32912221|NCT02700165|Experimental|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
33242873|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
33242874|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
33242875|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
33242876|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
32912222|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
33242877|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
33242878|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
32912223|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
33242879|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
33242880|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
33242881|NCT03070392|Experimental|IMCgp100 (tebentafusp, Kimmtrak)|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
33399158|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
33399159|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
33399160|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
33399161|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
33399162|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
33399163|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
33242882|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
33242883|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
33242884|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
33242885|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
33242886|NCT00784043|Experimental|Unilateral|Unilaterally implanted
33242887|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
33242888|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
33242889|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
32737173|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
33072981|NCT04166643|Active Comparator|Education only|Education
33242890|NCT04071548|Experimental|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
33242891|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
33242892|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
33242893|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
32737174|NCT05035875||40 COPD patients|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
33399164|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
32737175|NCT05035875||40 healthy individuals|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
32737176|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
32737177|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
32737178|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
32737179|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
32737180|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
32737181|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
32737182|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
32737183|NCT05043909|Experimental|Experimental Group (EG)|The students in EG received VR-based training for elderly oral health care at 2-week (Time 2), 4-week (Time 3), and 6-week (Time 4) follow-ups. The learning module was divided into three sessions according to the physical condition (1) Mild disability, (2) Semi-disability, (3) Total disability and oral condition, (1) wearing dentures, (2) missing teeth of the elderly. Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
32912224|NCT05497635|Experimental|A low dose of group|All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.
32912225|NCT05497635|Experimental|A middle dose of group|All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.
33072982|NCT04166643|Experimental|WHHIP-PLUS and Function Focused Care|"Component I: Stakeholder Group Involvement:~Component II: Environment Assessment:~Component III: Organizational Changes To Reduce Job Stress:~Component IV- Worker Health Behavior Change including function focused care interventions"
32737184|NCT05043909|No Intervention|Control Group (CG)|The students in CG do not receive any of the interventions. However, the same VR-based curriculum of oral health care on dependency elderly were provided at the end of the study.
32737185|NCT05035563|No Intervention|Traditional communication management (Pre-intervention)|"Traditional communication practices are maintained, which consists of reporting the patient's medical conditions or specific requirements of the case, between the health team and the family.~According to the social and administrative conditions of each centers, medical telephone information is provided on the conditions of the patients."
32737186|NCT05035563|Experimental|Early and integral communication strategy (EICS) (Post-intervention)|"EICS that includes a bundle of various strategies that allow to favor communication and contact between family members, patients and health team.~That considers the delivery of: (1) Receive timely and understandable information; (2) Receive visits, companionship, and spiritual assistance"
33399165|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
33399166|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
33242894|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
33242895|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
33242896|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
32737187|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
33242897|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
33399167|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
33399168|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
33399169|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
33242898|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
33242899|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
33242900|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
33242901|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
33242902|NCT00711854|Active Comparator|2|Linezolid
33242903|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
33242904|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
33242905|NCT00795327|Experimental|1|single arm study
33242906|NCT04072068|Experimental|Edoxaban|edoxaban 60 mg daily
33242907|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
33242908|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
33242909|NCT05003882||Arm A|Commercially available, orally ingestible CBD product A
33242910|NCT05003882||Arm B|Commercially available, orally ingestible CBD product B
33242911|NCT05003882||Arm C|Commercially available, orally ingestible CBD product C
33242912|NCT05003882||Arm D|Commercially available, orally ingestible CBD product D
33242913|NCT05003882||Arm E|Commercially available, orally ingestible CBD product E
33242914|NCT05003882||Arm F|Commercially available, orally ingestible CBD product F
33242915|NCT05003882||Arm G|Commercially available, orally ingestible CBD product G
33242916|NCT05003882||Arm H|Commercially available, orally ingestible CBD product H
33242917|NCT05003882||Arm I|Commercially available, orally ingestible CBD product I
33242918|NCT05003882||Arm J|Commercially available, orally ingestible CBD product J
33242919|NCT05003882||Arm K|Commercially available, orally ingestible CBD product K
33242920|NCT05003882||Arm L|Commercially available, orally ingestible CBD product L
33399170|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
33399171|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
33399172|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
32912226|NCT05497635|Experimental|A high dose of group|All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.
33242921|NCT05003882||Arm M|Commercially available, orally ingestible CBD product M
33242922|NCT05003882||Control|Waitlist control
33242923|NCT00795405|Sham Comparator|1|No exposure to sporting events
33242924|NCT00795405|Experimental|2|Exposure to sporting events
33242925|NCT04046211|Experimental|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
33242926|NCT00712088|Experimental|1: Group Intervention|Group level intervention
33242927|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
33242928|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
33072987|NCT04145349|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
33072988|NCT04145349|Active Comparator|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
33242929|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
33242930|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
33072989|NCT04138381|Other|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:~Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity~Cohort B: single-agent, fixed selinexor dose in the same target population"
33072990|NCT04136171|Experimental|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks
33072991|NCT04136171|Placebo Comparator|Placebo|Eplontersen-matching placebo by subcutaneous injection once every 4 weeks
33072992|NCT04128501|Experimental|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
33072993|NCT04127786|Experimental|1:VRVg-2 Cohort 1-Primary Series Pediatric & adult participants -Booster Phase subset of 102 adults|VRVg-2, 3 injections at Day 0, Day 7, and Day 28 Booster dose of VRVg-2 for a subset of 102 adult participants at Month 12
33072994|NCT04127786|Active Comparator|2: Verorab Cohort 1-Primary Series Pediatric & adult participants -Booster Phase subset of 34 adults|Verorab, 3 injections at Day 0, Day 7, and Day 28 Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12
33242931|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
32912227|NCT05487651|Experimental|Cohort A, non-ALL relapsed/refractory|"These dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle) Other name: Fludara"
33072995|NCT04127786|Active Comparator|3:ImovaxRabies Cohort 1-Primary Series Pediatric & adult participants-Booster Phase subset 34 adults|Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28 Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12
33399173|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
33242932|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
33242933|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
33242934|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
33242935|NCT00766415|Experimental|AZD1981|
33399174|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
33242936|NCT00766415|Placebo Comparator|Placebo|
33242937|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
33242938|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
33242939|NCT00712478||A|
33399175|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
33399176|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
33399177|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
33399178|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
33399179|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
32912228|NCT05487651|Experimental|Cohort B, ALL releapsed/refractory|"This cohort is for patients with relapsed or refractory B-cell ALL afer 2 or more lines of therapy. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle)"
32912229|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
32912230|NCT01420016|No Intervention|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
32912231|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:~Risk Assessment (standard of care; Braden, Waterlow, or Norton)~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
32912232|NCT01398566|Experimental|SuperBetter Play|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
32912233|NCT05477979||Lung patients recieve first-line immunotherapy|For stage III-IV patients with lung cancer who have received immune checkpoint inhibitors as first-line therapy.
32912234|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
32912235|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
33072996|NCT04127786|Experimental|4: VRVg-2 Cohort 2 - Primary Series Adult participants - Booster Phase subset of 138 adults|VRVg-2, 2 injections at Day 0 and Day 7 Booster dose of VRVg-2 for a subset of 138 adult participants between Month 24 up to Month 36
33072997|NCT04127786|Active Comparator|5: Verorab Cohort 2 - Primary Series Adult participants - Booster Phase subset of 46 adults|Verorab, 2 injections at Day 0 and Day 7 Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36
33399180|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
33399181|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
33399182|NCT03735329|Experimental|Pulse oximetry monitoring|
33242940|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
33072998|NCT04127786|Active Comparator|6: Imovax Rabies Cohort 2 - Primary Series Adult participants - Booster Phase subset of 46 adults|Imovax Rabies, 2 injections at Day 0 and Day 7 Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36
33242941|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
33242942|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
33242943|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
33242944|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
33242945|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
32737188|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
32737189|NCT05035485|Active Comparator|Phenylephrine group|Rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred
33242946|NCT04659122|Experimental|AT-100 75 mg|Once daily AT-100 via intratracheal administration for up to 7 doses.
33242947|NCT04659122|Experimental|AT-100 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.
33242948|NCT04659122|Experimental|AT-100 75 mg or 150 mg (Optional Cohort)|Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
33242949|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
33242950|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
32737190|NCT05035485|Experimental|Norepinephrine group|Rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred
32737191|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
32737192|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
33242951|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
33242952|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
33242953|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
33242954|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
33242955|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
32912236|NCT05459493|Experimental|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
33399183|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
33399184|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
33242956|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
33242957|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
33242958|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
33073003|NCT04095260||high school athletes|High school athletes, ages 14 to 18, who are participating in an organized sports training program.
33073004|NCT04090957|Experimental|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for up to 53 weeks.
33242959|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
32737193|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
33242960|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
33242961|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
33242962|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
33242963|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
33242964|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
33242965|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
33242966|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
33242967|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
33242968|NCT04070222||Natural labour group|
33073005|NCT04090957|Experimental|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
33399185|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
33399186|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
33073006|NCT04090957|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for up to 53 weeks.
33073007|NCT04090957|Experimental|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
33073008|NCT04088396|Experimental|Baricitinib|Baricitinib given orally.
33242969|NCT04070222||Cesarean scar group|
33242970|NCT04070222||Cesarean with diverticulum (PCSD) group|
33242971|NCT03918876||Healty Dancers|Healthy adult dancers
33242972|NCT03918876||Injured Dancers|Injured adult dancers
33242973|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
33399187|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
33073009|NCT04088396|Placebo Comparator|Placebo|Placebo given orally.
33399188|NCT05665673||Study Group|Sociodemographic information about the stroke patients included in the study will be obtained and some physical tests will be performed.
33399189|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
33399190|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
33399191|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
33399192|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
33399193|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
33399194|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
33399195|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
33399196|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
33399197|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
33399198|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
33399199|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
33399200|NCT05039190|Active Comparator|Experimental: HBM9161 (680mg )|HBM9161 680mg; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
33399201|NCT05039190|Placebo Comparator|Placebo Comparator: Placebo|Placebo; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
33399202|NCT03095118|Experimental|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
33399203|NCT04228068|Experimental|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
33399204|NCT04228068|Active Comparator|Conventional care|Usual care
33399205|NCT04224480|Experimental|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
33399206|NCT04630158|Placebo Comparator|SAF312 Placebo|Randomized to a 1:1:1 topical eye drops, twice daily
33399207|NCT04630158|Experimental|SAF312 dose 1|Randomized to a 1:1:1 topical eye drops, twice daily
33399208|NCT04630158|Experimental|SAF312 dose 2|Randomized to a 1:1:1 topical eye drops, twice daily
33399209|NCT05389098|Experimental|Experimental|eat-hands type food mode
33399210|NCT05389098|Active Comparator|Control|Usual food administration
33399211|NCT02696902|Experimental|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
33399212|NCT02696902|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
33399213|NCT02696902|Experimental|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
33399214|NCT05386758|Experimental|Panel A - Severe Renal Impairment Group|Participants with severe renal impairment will receive a single oral 800 mg dose of molnupiravir.
33399215|NCT05386758|Experimental|Panel B - Healthy Control Group|Participants in the healthy mean matched control group will receive a single oral 800 mg dose of molnupiravir.
33399216|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
33399217|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
33399218|NCT05013216|Experimental|KRAS peptide vaccine|
33399219|NCT04606446|Experimental|1A Monotherapy Dose Escalation|PF-07248144 Monotherapy Escalation
33399220|NCT04606446|Experimental|1B Combination Dose Escalation|PF-07248144 with Fulvestrant Combination Dose Escalation
33399221|NCT04606446|Experimental|1C Combination Dose Escalation|PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation
33399222|NCT04606446|Experimental|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
33399223|NCT04606446|Experimental|2B Combination Dose Expansion Arm|PF-07248144 with Fulvestrant Dose Expansion
33399224|NCT04606446|Experimental|1D Combination Dose Escalation|PF-07248144 with PF-07220060 +Fulvestrant
33399225|NCT04606446|Experimental|2D Combination Dose Expansion Arm|PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion
33399226|NCT04606446|Experimental|China Monotherapy Dose Expansion|PF-07248144 Monotherapy Dose Expansion
33399227|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
33399228|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
33399229|NCT05011422|Experimental|ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)|"Patients will undergo standard of care conditioning regiment prior to HSCT~On Day 0, patients will undergo infusion of the ex vivo αβ-TCR/CD19 depleted haplo-HSCT from a stimulated peripheral stem cell source per institutional standard of care. Patients whose graft has a residual CD20+ count > 1.0 x 10^5 may receive a single infusion of rituximab on Day +1 at a dose of 375 mg/m^2 at provider's discretion."
33399230|NCT04064112|Experimental|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
33073010|NCT04088071||Patients with atrial fibrillation|Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
33399231|NCT04064112|Active Comparator|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
32763005|NCT02985619|Active Comparator|IVT randomised group II|Randomised patients [intravitreal triamcinolone (IVT) group II] with central foveal thickness >300µm on OCT will be submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Triamcinolone (1.20 mg/ 0.03 cc; Opthaac, Ophthalmos, São Paulo, Brazil) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
32763006|NCT02985619|Active Comparator|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm at week visit 24 will be allocated to group III (IVB, intravitreal bevacizumab). So, it won't get IVB injection at week visit 24 due OCT regular thickness (≤300µm) but will do regular monthly follow-up visits and prn-IVB therapy if central foveal thickness >300µm on OCT until last visit of study (48 week-visit). Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
32763007|NCT04977037|Experimental|Active tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
33399232|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
32763008|NCT04977037|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
32763009|NCT05587205|Experimental|Treatment at time of surgery|EO2002 intracameral injection
32763010|NCT05587205|Experimental|Treatment post surgery|EO2002 intracameral injection
32763011|NCT05587205|Active Comparator|Treatment at time of or post surgery|EO2002 intracameral injection
32763012|NCT05587205|Sham Comparator|Sham injection at time of or post surgery|Sham injection
32763013|NCT04958005||Children with early chilhood caries|Early chilhood caries group
32763014|NCT04958005||Without early chilhood caries|Control group
32763015|NCT05583929||Spastic Cerebral Palsy|Children with spastic cerebral palsy
32763016|NCT05583929||Healthy Developing Peers|Children with healthy developing peers
32763017|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
32763018|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
32763019|NCT04123613|Experimental|2.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
32763020|NCT04123613|Experimental|5.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
32763021|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
32763022|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
32763023|NCT04121897|Experimental|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
32763024|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
32763025|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
32763026|NCT04116593|Experimental|Intervention|
32763027|NCT04116593|No Intervention|Control|
32763028|NCT05392387||peg-IFN-alpha alone|Patients with chronic HBV infection only treated with peg-IFN-alpha
32763029|NCT05392387||nucleos(t)ide analogues alone|Patients with chronic HBV infection only treated with nucleos(t)ide analogues
32763030|NCT05392387||combination|Patients with chronic HBV infection treated with nucleos(t)ide analogues and peg-IFN-alpha
32763031|NCT04601051|Experimental|Polyneuropathy Part 1: NTLA-2001|Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001.
32763032|NCT04601051|Experimental|Polyneuropathy Part 2: NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
32763033|NCT04601051|Experimental|Cardiomyopathy Part 1 (UK only): NTLA-2001|Participants, assigned to one of 2 dose-escalation cohorts, will receive a single dose of NTLA-2001.
32763034|NCT04601051|Experimental|Cardiomyopathy Part 2 (UK only): NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
32763035|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32763036|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32763037|NCT04583579|Experimental|New Scleral Lens Wearers|All patients will be asked to wear scleral lenses for the duration of this study.
32763038|NCT04450199|Active Comparator|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
32763039|NCT04450199|Placebo Comparator|Placebo|12 over encapsulated placebo tablets
33242974|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
33399233|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
33242975|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
33242976|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
33242978|NCT02574104||Institution 1|"McGill University Health Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
33242979|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
33242980|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
33242981|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
33242982|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
33242983|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
32912237|NCT05437575|Experimental|Ketamine Hydrochloride|2 blinded doses 2.5mg/ml ketamine hydrochloride in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no adverse events
32912238|NCT05437575|Active Comparator|Fentanyl Citrate|2 blinded doses 10mcg/ml in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no adverse events
32912239|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
32912240|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
32912241|NCT05414487||Ofatumumab|17 RMS patients and 17 NMOSD patients prescribed with Ofatumumab will be enrolled after informed consent.
32912242|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
33399234|NCT04602936|Active Comparator|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
33399235|NCT04602936|Placebo Comparator|Placebo|Placebo (i.e., inactive compound for comparison)
33399236|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
33399237|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
33399238|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
33399239|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
33399240|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
33399241|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
33399242|NCT04984356|Experimental|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy. Cyclophosphamide 500 mg/m2/day x 3 (days -5 to -3) Fludarabine 30 mg/m2/day x 3 (days -5 to -3)"
33399243|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
33399244|NCT04597944||Participants with Hereditary or Acquired Angioedema|Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
33399245|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
33399246|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
33399247|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
33399248|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
33399249|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
33399250|NCT05745844|Experimental|NeuroMuscular Electro Stimulation group|Patients in the NeuroMuscular Electro Stimulation group will also have neurostimulation sessions using a CE marked medical device, in its destination, according to its instructions for use, therefore without expected clinical risk
33399251|NCT05745844|Active Comparator|Control Group|The control group (without NeuroMuscular Electro Stimulation) corresponds to the standard care routinely offered to patients in the investigating centre.
33399252|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
33399253|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
33242984|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
33242985|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
33242986|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Pending"
33242987|NCT02574104||Institution 10|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242988|NCT02574104||Institution 11|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242989|NCT02574104||Institution 12|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242990|NCT02574104||Institution 13|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242991|NCT02574104||Institution 14|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242992|NCT02574104||Institution 15|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
33242993|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
33242994|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
33242995|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
33242996|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
33242997|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
33242998|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
33242999|NCT00712946||2|Healthy age-matched volunteers
33243000|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
33243001|NCT00713024||1|Healthy control subjects
33243002|NCT00713024||2|Patients having neuropathic pain
33243003|NCT02577068|Active Comparator|nefopam group|
33243004|NCT02577068|Active Comparator|propacetamol group|
33243005|NCT02577068|Experimental|nefopam and propacetamol group|
33243006|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
33243007|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
33243008|NCT02576756||with difficult intubation|Control population
33243009|NCT02576756||without difficult intubation|Control population
33243010|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
33243011|NCT00582114|Active Comparator|1|Atenolol
33243012|NCT00582114|Experimental|2|Lisinopril
33243013|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
33243014|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
33243015|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
33243016|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
33243017|NCT04071080|Experimental|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
33243018|NCT04071080|Placebo Comparator|Placebo|500mL of Gatorade taken orally by the participant
33243019|NCT01719666|Other|isolated MPFL reconstruction|
33243020|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
33243021|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
33243022|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
33243023|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
33243024|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
33243025|NCT05673564||anatomical resection group|Anatomical resection was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
33243026|NCT05673564||nonanatomical resection group|Nonanatomical resection known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
33243027|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
33243028|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
33243029|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
33243030|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
33243031|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
33243032|NCT00713180|No Intervention|1|Pterygium free participants
33243033|NCT00713180|Experimental|2|Pterygium participants
33243034|NCT05673122|Experimental|Implant intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, the implant is in contact with the shield.
33243035|NCT05673122|Experimental|Implant not intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, there was a jumping gap more than 2mm between the shield and the implant, in which the gap was grafted with Xenograft.
32737194|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
32737195|NCT05054829|Experimental|PEERS|
33243038|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
33243039|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
33243040|NCT04070144|Experimental|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
33243041|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
33243042|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
33243043|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
33243044|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
33243045|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
33243046|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
33243047|NCT00713570||A,1,II|
33243048|NCT00789711||A|
33243049|NCT00789711||B|
33243050|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
33243051|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
33243052|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
33243053|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
33243054|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
33243055|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
33243056|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
33243057|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
33243058|NCT05325983|Experimental|lemonade ice cubes|10 ml lemonade ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
32763045|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
32763046|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
32763047|NCT04543877|Experimental|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
32763048|NCT04543877|Placebo Comparator|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
32763049|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Active comparator is 5-fluorouracil for first three cycles."
32763050|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Experimental: cetuximab for the first three cycles."
32763051|NCT04930549|Experimental|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg film-coated tablets
32763052|NCT04930549|Placebo Comparator|Placebo|Identical film-coated tablets without dapagliflozin
32763053|NCT04508621|Experimental|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
32763054|NCT04508621|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
32763055|NCT05392153|Experimental|Myofascial therapy group|The myofascial therapy group (n=26) will receive 12 sessions of 6-weekly lower extremity posterior muscle myofascial therapy.
32763056|NCT05392153|No Intervention|Control group|The control group (n=23) will not receive lower extremity posterior muscle myofascial therapy. They will continue the routine exercise program.
32763057|NCT05525585|Experimental|Early human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 4 to 7, after a total feeding volume greater than 120 ml/kg/day is achieved.
32763058|NCT05525585|Active Comparator|Delayed human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 10 to 14, after a total feeding volume greater than 120 ml/kg/day is achieved.
32763059|NCT04897945|Experimental|Shared decision-making with pharmacists|Participants randomized to the intervention arm will have an in-person visit to complete the baseline survey, record the participant's weight and receive a pharmacist-coordinated shared decision making intervention. Intervention participants will have follow-up research assessments visits at 6, 12 and 24 months.
32763060|NCT04897945|No Intervention|Usual Care|Participants randomized to the usual care control arm will have an in-person visit with the research study team to complete the baseline survey and record the participant's weight. These participants will then return to usual care with research assessments at 6, 12 and 24 months follow-up.
32763061|NCT03067727|Experimental|Dinoprostone vaginal insert|
32763062|NCT03067727|Placebo Comparator|Placebo|
32763063|NCT01794793|Experimental|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
32763064|NCT01794793|Experimental|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
32763065|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
32763066|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
32763067|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
32763068|NCT05492123|Active Comparator|Standard Chemoradiation|Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week or carboplatin AUC 2/week
32763069|NCT05492123|Experimental|Immunotherapy|4 cycles of induction therapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week (or carboplatin AUC 2/week) with concurrent nivolumab 240mg every 2 weeks.
32912243|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
33243059|NCT05325983|Placebo Comparator|water ice cubes|10 ml water ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
32737196|NCT05054829|Other|Controls|
32898351|NCT02291055|Experimental|Part B Expansion (Cervical): 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
33073011|NCT04084951|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-PBMC-HPV as a monotherapy is administered on Day 1 of every 3 week cycles for up to a year. In Cohort 3 (double-priming), SQZ-PBMC-HPV is also administered on Day 2 of Cycle 1. There are at least 3 groups (Cohorts) in this Phase as follows:~Cohort 1: specified dose SQZ-PBMC-HPV~Cohort 2: specified dose SQZ-PBMC-HPV~Cohort 3: specified dose SQZ-PBMC-HPV double-priming"
33073012|NCT04084951|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (Cohorts) in this Phase as follows:~Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab~Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab~Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab~Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab"
33243060|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
33243061|NCT00800553|Placebo Comparator|placebo|placebo
32912244|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
33243062|NCT04103801|Experimental|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
33243063|NCT04103801|Placebo Comparator|Water group|This group received the 2 ml of water
33243064|NCT00793767|Placebo Comparator|placebo|placebo
33243065|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
33243066|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
33243067|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
33399254|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
32912245|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
32912246|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
32912247|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
33243068|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
33073013|NCT04084951|Experimental|Part 3 Monotherapy Dose Expansion Phase|"In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (Cohorts) in this Phase as follows:~Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients~Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients~Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients~Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients"
33073014|NCT04082780|Experimental|Rifamycin|Rifamycin-SV MMX 600 mg PO two times a day (1200 mg) for 30 days
33243069|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
33073015|NCT04082780|Placebo Comparator|Placebo|Placebo PO two times a day for 30 days
33243070|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (total body irradiation, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
33243071|NCT04099745|Experimental|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
33243072|NCT04099745|Experimental|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
33243073|NCT00800709|Experimental|Memantine|
33243074|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
33243075|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
33243076|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
33243077|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
32763070|NCT01398319|Experimental|Group Brief Alcohol Booster Intervention|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
32763071|NCT01398319|Active Comparator|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence. While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
33243079|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
33243080|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
32763072|NCT01365169|Experimental|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
32763073|NCT01365169|Experimental|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
33243081|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
33243082|NCT00772577|Active Comparator|2|Ramipril
33243083|NCT02345850|Active Comparator|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
33399255|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
33399256|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
33399257|NCT03167632||dental patients|
33399258|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
32912248|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
33399259|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
33399260|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
33399261|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
33399262|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
33399263|NCT03168724|No Intervention|Control|Group not getting the intervention
33399264|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
33399265|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
33399266|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
33399267|NCT05745766||Canines assessed using 2D images|The 2D-based assessments of the impacted maxillary canine.
33399268|NCT05745766||Canines assessed using 3D images|The 3D-based assessments of the impacted maxillary canine.
33231587|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
33231588|NCT04024449||Control|"The adolescent with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.~Control group; with normal menstrual period, Non-chronic diseases"
33231589|NCT02550418|Experimental|Budesonide|
33231592|NCT00829114|Active Comparator|1|ART/COC group
33231593|NCT00829114|Active Comparator|2|COC group
33231594|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
33231595|NCT00790296|Placebo Comparator|Saline|Placebo
33231596|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
33231597|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
33231598|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
33231599|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
33231600|NCT00829270||mitochondrial diseases diagnosis|
33231601|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
33231602|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
33231603|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
33231604|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
33231605|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
33231606|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
33231607|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
33231608|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
33231609|NCT00829582|Sham Comparator|placebo|
33231610|NCT00831220||1|Patients with a COPD exacerbation
33231611|NCT00831220||2|Patients with stable COPD
33231612|NCT00831220||3|Smokers or former smokers
33231613|NCT00831220||4|Never smokers
33231614|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
33231615|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
33231616|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
33243084|NCT02345850|Experimental|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
33243085|NCT02345850|Experimental|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
33243086|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
33243087|NCT04099433|Experimental|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
33243088|NCT04099433|Placebo Comparator|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
33243089|NCT04045977|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
33243090|NCT04045977|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
33243091|NCT04021667|Experimental|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
33243092|NCT04021667|Experimental|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
33399269|NCT05745766||Canines assessed intra-operatively or post-operatively|The gold standard-based assessments are based on surgical exposure.
33399270|NCT04547712|Experimental|aDBS Single Threshold|Adaptive DBS Single Threshold Mode
32763074|NCT01365169|Experimental|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
32763075|NCT01365169|Experimental|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
32763076|NCT01365169|Experimental|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
32763077|NCT01365169|Experimental|TAPS (Technological Approach to Performance Status)|Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
32763078|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
32763079|NCT03068585|No Intervention|Control|Control therapy
32763080|NCT04463771|Experimental|Group A - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
32763081|NCT04463771|Experimental|Group B - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
32763082|NCT04463771|Experimental|Group C - retifanlimab + epacadostat|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
32763083|NCT04463771|Experimental|Group D - retifanlimab + pemigatinib|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
32763084|NCT04463771|Experimental|Group E - retifanlimab + epacadostat|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat
32763085|NCT04463771|Experimental|Group F - retifanlimab + INCAGN02385 and INCAGN02390|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab in combination with INCAGN02385 and INCAGN02390 intravenously
33399271|NCT04547712|Experimental|aDBS Dual Threshold|Adaptive DBS DualThreshold Mode
32763086|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
32763087|NCT01305889|Experimental|sertraline|12 weeks of sertraline
32763088|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
32763089|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
32763090|NCT05392075||COVID-19 diagnosis|The study will enroll all subjects who received care at Methodist Dallas Medical Center between August 1, 2021 and February 28, 2022, and were diagnosed with COVID-19. COVID-19 diagnosis for the purpose of this study is either a positive COVID-19 antigen or a positive COVID-19 PCR test.
32912249|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
33399272|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
33399273|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
33399274|NCT05418660||Cohort 1|The cohort includes patients who discontinue the treatment at 24 months and continue the follow-up at least for 3 months
33073016|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
33073017|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
33231617|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
33231618|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
33231619|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
33399275|NCT05418660||Cohort 2|The cohort includes patients who continue the treatment beyond 24 months until unacceptable toxicity or progression.
33399276|NCT03364309|Experimental|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
32763091|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
32912250|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
33231620|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
33231621|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
33231622|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
33231623|NCT02603406|No Intervention|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
33231624|NCT04106700|Experimental|Apixaban (single arm)|
33231625|NCT04107090|Experimental|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
33231626|NCT04107090|Other|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
33231627|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
33231628|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
33231629|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
33231630|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
33231631|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
33231632|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
33231633|NCT05567406|Experimental|Belumosudil|Participants will receive belumosudil orally, once daily (QD) or twice daily (BID) if they are taking strong CYP3A4 inducers or proton pump inhibitors.
33231634|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
33231635|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
33231636|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
33231637|NCT02603640|Experimental|epileptic patient|
32912251|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
33231638|NCT04043884|Experimental|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
33231639|NCT04043884|Active Comparator|Exercises|8-week exercise program, twice a week.
33243093|NCT04021667|No Intervention|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
33243094|NCT05485805|Experimental|Naproxen sodium/caffeine - Dose 1|Participants will receive a single dose of one tablet of naproxen sodium/caffeine plus one tablet of placebo after extraction of third molars.
33243095|NCT05485805|Experimental|Naproxen sodium/caffeine - Dose 2|Participants will receive a single dose of two tablets of naproxen sodium/caffeine after extraction of third molars.
33243096|NCT05485805|Experimental|Naproxen sodium|Participants will receive a single dose of one tablet of naproxen sodium plus one tablet of placebo after extraction of third molars.
33243097|NCT05485805|Experimental|Caffeine|Participants will receive a single dose of two tablets of caffeine after extraction of third molars.
33243098|NCT05485805|Placebo Comparator|Placebo|Participants will receive a single dose of two tablets of matching placebo after extraction of third molars.
33243099|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
33243100|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
33243101|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
33243102|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
33243103|NCT00001604||1|Subjects with a family history of stuttering
32763092|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
33243104|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
33243105|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
32763093|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
32763094|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
33243110|NCT04099043|Experimental|Continuous Monitoring|Single Arm, Randomized
33243111|NCT04073550|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
33243112|NCT04073550|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
33243113|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
33073018|NCT04077463|Experimental|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
33073019|NCT04077463|Experimental|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
33231640|NCT04103736|Experimental|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing ~12.6mmol naturally occurring dietary nitrates.
33231641|NCT04103736|Placebo Comparator|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
32763095|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
32763096|NCT05391997|Experimental|Modified Cervical and Shoulder Retraction exercises|Cervical extension traction protocol will be added as standard treatment. Then, patients either sit or stand in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range, then, in a seated or standing position, patients will maintain an upright posture and try to pull back their shoulders and extend their neck within the pain-free range.
33231642|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
32763097|NCT05391997|Active Comparator|Cervical Extension Traction exercises|Here, patients will receive Cervical Extension Traction exercises as standard treatment. Cervical extension traction includes a protocol in which traction will be applied within the extension range of the cervical region in full spine position.
32763098|NCT03136939||type 1 diabetes|
32763099|NCT03136939||type 2 diabetes|
32763100|NCT03136939||healthy people|
32763101|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
32763102|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
32763103|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
32763104|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
32763105|NCT04452305|Experimental|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
32763106|NCT04563481|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
32763107|NCT04563481|Experimental|Rehabilitation by Physiotherapist in the Clinic|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist in the clinic for 3 sessions per week.
33231643|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
33231644|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
33231645|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
33231646|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.~Morbid Obese women waiting for bariatric surgery.~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
33231647|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
33231648|NCT00829972||1|children undergoing adenotonsillectomy
33231649|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
33231650|NCT00830050|Experimental|Arm 1|
33231651|NCT00830050|Placebo Comparator|Arm 2|
33231652|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
33231653|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
33231654|NCT00831688|Active Comparator|1|Local overpressure treatment
32912252|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
33243114|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
33231655|NCT00831688|Placebo Comparator|2|Placebo treatment
33231656|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
33231657|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
33231658|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
33231659|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
33231660|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
32912253|NCT05209139|Experimental|Beetroot supplementation|Acute beetroot juice supplementation
32912254|NCT05209139|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
32912255|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
32912256|NCT03850899||Controls|Heavy drinkers without significant liver disease
32912257|NCT03850899||Donor|Healthy non-drinkers
33243115|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
32912258|NCT05114213|Experimental|Arm A: SBRT|mPDAC patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy). The primary tumor is treated with SBRT (6.6Gy x 5) on a MR-LINAC in breath-hold technique. For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney). Chemotherapy will be continued after SBRT.
32912259|NCT05114213|Active Comparator|Arm B: SOC|Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
32912260|NCT05747729|Experimental|Surufatinib/Serplulimab/Platinum/Etoposide|
32912261|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
32912262|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
32912263|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
33399277|NCT03364309|Experimental|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
33399278|NCT03364309|Placebo Comparator|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
33399279|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
32912264|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
33231661|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
33399280|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
33399281|NCT05166096|Experimental|Rho-11 administered in Period 1, oral aspirin administered in Period 2|
33399282|NCT05166096|Experimental|Oral aspirin administered in Period 1, Rho-11 administered in Period 2|
33399283|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
33399284|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
33399285|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
33399286|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
33399287|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
33399288|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
33399289|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
33399290|NCT05110638|Experimental|SKX-16 (Luliconazole 10% Solution)|
33399291|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
33399292|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
33399293|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
33399294|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
33399295|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
33399296|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
33399297|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
33399298|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
32737202|NCT05043753|No Intervention|Control group: Symphysis fundal height measurement|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNMs) using symphysis fundal height (SFH)
32737203|NCT05043753|Experimental|intervention group: Symphysis fundal height measurement and point of care ultrasound.|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNM) using symphysis fundal height (SFH) and point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
32737204|NCT05495711|Experimental|stem cell and collagen transplantation group|Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-UT)
32737205|NCT05495711|Active Comparator|control group|collagen transplantation
32737206|NCT05043597|Experimental|Thrombus aspiration|
32737207|NCT05043597|No Intervention|control group|
32737208|NCT03340571||Alzheimer's Patients|
32737209|NCT03340571||Healthy Volunteers|
32737210|NCT05043831|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Subjects will be treated with DSLT
32737211|NCT05043831|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects will be treated with SLT
32737212|NCT02494505|Experimental|mycophenolate mofetil|
32737213|NCT02494505|Placebo Comparator|placebo|placebo pills
32737214|NCT05054595|Active Comparator|Standard Pain Psychoeducation|
32737215|NCT05054595|Active Comparator|Audio-Recorded Mindfulness-Based Intervention|
32737216|NCT05054595|Experimental|Nurse-Led Mindfulness-Based Intervention|
32737217|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
32737218|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
32737219|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
32737220|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
32737221|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
32737222|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
33399299|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
32763108|NCT04497493|Experimental|tDCS group|participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
32763109|NCT04497493|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current turned off after 30s combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
32763110|NCT04445987|Experimental|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
33399300|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
33399301|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
32763111|NCT05391685|Experimental|therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only
32763112|NCT05391685|Experimental|therapeutic ultrasound+scar release techniques|Study group will be treated by various scar release techniques in addition to therapeutic ultrasound
32763113|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
32763114|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
32763115|NCT04808947|Experimental|Local infiltration analgesia|Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.
32763116|NCT04808947|Active Comparator|Local infiltration analgesia + ACB-iPACK block|"Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.~Patients in this group will also receive preoperative nerve blocks under ultrasound guidance. These will include:~Adductor canal block with 0.5% Ropivacaine w/epi 20 mL~iPack block with 0.25% Ropivacaine w/epi 10 mL"
32763117|NCT04439357|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32763118|NCT05391607|Experimental|Albumin 20%|3mL/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
32763119|NCT05391607|Experimental|Albumin 5%|12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
32763120|NCT05391607|Active Comparator|Ringer-lactate|Ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
32763121|NCT04433507|Active Comparator|Sleeve Gastrectomy group|This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
32763122|NCT04433507|Experimental|Sleeve Gastrectomy + Hiatal Hernia repair group|This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
32763123|NCT04363385|Other|Collection of blood sample|
32763124|NCT04800991|Experimental|Rhexium Onco Nutrition(HDT-202)|"subject mobile application and Investigator web portal with no invasive action on the human body"
32763125|NCT04795921||Patients with haemophilia|This investigation includes patients with haemophilia of all seventies (mild, moderate, severe), as well as female carriers and patients with Von-Willebrand-Disease (Typ III)
32763126|NCT04795921||Healthy controls|The control group consists of adult healthy female and male subjects.
32763127|NCT05431361|Experimental|Prehabilitation|PREHAB participants will receive a multimodal intervention comprising of exercise, nutrition, and psycho/behavioural/educational support provided by an interprofessional prehab team comprising kinesiologists, dietitians, psychologists, and a previous LLD study partner. To facilitate overall compliance and appropriate adaptation to the home-based intervention components, participants will receive printed material, and a study coordinator will communicate weekly with patients to provide encouragement, monitor adherence, and clarify any questions or concerns.
32763128|NCT05431361|No Intervention|Usual Care|Usual care participants will be instructed to resume typical lifestyle behaviours until the date of the surgery. To standardize exposure to publicly available resources, usual care participants will receive the 24-Hour Movement Guidelines for Adults,33 Canada's Food Guide,27 a list of stress management resources (website, apps, free reading material), and reference to the Smoker's Helpline.
32763129|NCT04790851|Experimental|Experimental group|Experimental Group (384 subjects) will receive: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
32763130|NCT04790851|Active Comparator|Control group A|Control Group A (384 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
32763131|NCT04790851|Active Comparator|Control group B|Control Group B (384 subjects) will receive: 1st dose: IIV4 only; 2nd dose: PPV23 only
32763132|NCT05391529||Colonoscopy|Patients awaiting colonoscopy
32737223|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
32737224|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
32737225|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
32912265|NCT05747651||Active SLE|"Patients will undergo regular follow-up where routine clinical examination and laboratory assessments will be conducted, and biological samples will be obtained. The patients will be instructed to contact their center whenever they develop a symptom suspicious of flare. In such cases, an unscheduled visit will be conducted for clinical examination, assessment and sampling similar to the last visit.~If a patient needs a major change in therapy at one of the scheduled visits or at an unscheduled visit, an early termination (ET) visit will be planned. Patients requiring a major change in therapy due to active disease (defined as BILAG A or B) from week 12 through week 52 will undergo two additional evaluations at week +26 and at week +52 from the time of early termination/new therapy initiation in order to determine biomarkers of secondary response after the change in therapy (herein termed secondary response) and persistent non- response (herein termed refractory disease)."
32912266|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscope under cervical collar application.
32912267|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
32912268|NCT05096975||Control group|"ADHD without emotion dysregulation (Control group) The group is composed of children with ADHD and with a score ≤ 180 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
32912269|NCT05096975||Deficit Emotion Self Regulation group|"ADHD without moderate emotion dysregulation (Deficit Emotion Self Regulation group) The group is composed of children with ADHD and with a score ≥180 and ≤ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
33073020|NCT04077463|Experimental|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
33243116|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
33243117|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
33243118|NCT00713804|No Intervention|WT|Waitlist (WT)
33243119|NCT02329470|Experimental|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
33243120|NCT02329470|No Intervention|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
33243121|NCT00713882||Observational|
33243122|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
33243123|NCT02848092|Experimental|FOCAL+Training|
33243124|NCT02848092|Sham Comparator|Rules of the Road Training|
33243125|NCT04070066|Experimental|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
33243126|NCT04070066|Active Comparator|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
32737226|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
33243127|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
33243128|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
32763133|NCT05391529||CCE|Patients awaiting colon capsule endoscopy
33243129|NCT02845518|Experimental|no arms|"All patients included will undergo a cardiac Magnetic Resonance Imaging (cMRI) at the baseline visit (V1), at 3- or 6-month follow up visit (V2 or V3), at 24-month follow up visit and in case of clinical worsening during the first 24-month of follow up.~All patients will complete a questionnaire on the acceptability and tolerability of cMRI and right heart catheterization at V1, V2 or V3 and V9, right heart catheterization being performed as a routine test in pulmonary arterial hypertension.~Depending on patient agreement, 22 ml of peripheral venous blood will be taken at visits V1, V2 or V3 and V9. On one of these 3 visits a blood sample of 5 ml will be taken from the pulmonary artery during the right cardiac catheterization."
33243130|NCT00714038||1|Patients with asthma in primary care
33243131|NCT04925388|Experimental|multiplex PCR|peritoneal samples will be analysed using Unyvero IAI test and using conventional method
33243132|NCT04925388|Other|conventional method|peritoneal samples will be analysed using only conventional method
33243133|NCT04046133|Experimental|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
32737227|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
32912270|NCT05096975||Dysregulation Profile Group|"ADHD with severe emotion dysregulation (Dysregulation Profile Group) The group is composed of children with ADHD and with a score ≥ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
32737228|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
32912271|NCT04740411|Experimental|Common Elements Toolbox (COMET)|
32912272|NCT04740411|No Intervention|Wait-list control condition|
32912273|NCT05394207|Experimental|GROUP 1 (Investigational product)|23 patients Investigational product: L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
33243134|NCT00794079|Experimental|A|omega-3 fatty acids
33243135|NCT00794079|Placebo Comparator|B|corn oil
33243136|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
33243137|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
33243138|NCT00794235|Other|Sorafenib and Dacarbacine|
33243139|NCT00800943|Experimental|Campath-1H|
33243140|NCT00714116|Experimental|SBI-087|
33243141|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
33243142|NCT00796341|Experimental|1|
33243143|NCT00796341|No Intervention|2|
33243144|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
33243145|NCT02575664|Placebo Comparator|Placebo|Placebo patch
33243146|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
33243147|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
32763134|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
32763135|NCT03644953|Experimental|Hydroxyurea and Transfusion (HAT)|Combination hydroxyurea and simple chronic transfusion therapy
32763136|NCT03630835|Experimental|99mTc-Annexin-V-128 uptake on scintigraphy|
32763137|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
32763138|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
32763139|NCT04764097|Experimental|Dapagliflozin|Dapagliflozin, Oral Tablet,10mg, od, 24 months.
32763140|NCT04764097|Placebo Comparator|Placebo|Placebo, Oral Tablet, od, 24 months.
32763141|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
32763142|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
32763143|NCT04761211|Experimental|smart bra|The patients who were going to take breast ultrasound in the breast surgery clinic were enrolled into the group. The patients were put on the device for about 3 minutes, and the breast was photographed at 5 sites. After that, the artificial intelligence learning was carried out on the photos of the training stage. For the photos of the verification stage, the algorithm obtained by the training stage was compared with the existing artificial intelligence algorithms of ultrasound and molybdenum target.
32763144|NCT03605017|Experimental|VREFT: Wonderkin Treatment|Administered by computer
32763145|NCT03605017|Active Comparator|VREFT: Attention Control|Administered by computer
32763146|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
32763147|NCT05391451|Experimental|Quadratus lumborum block (QLB) group|
32763148|NCT05391451|Active Comparator|Control group|
32763149|NCT03520309|Experimental|International Dental Federation|Dental Treatment: according to the decision based on the International Dental Federation (FDI) criteria
32763150|NCT03520309|Experimental|Caries Around Restorations System|Dental Treatment: according to the decision based on the Caries Around Restorations System (CARS) and treatment decision proposed by the International Caries Classification and Management System (ICCMS)
32763151|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
32763152|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
32763153|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
32763154|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
32763155|NCT04720729|Experimental|Single arm|Patients with HER2-negative metastatic breast cancer, starting a second line of chemotherapy
32763156|NCT03511417|Experimental|Middle-aged adults|Participants will use an over-the-counter hearing device in one ear until asymptotic speech perception performance is noted (maximum 12 weeks). The same individuals will use over-the-counter hearing devices in each ear until asymptotic performance is noted (the order of these two phases will be randomized across participants). They will be asked to use these devices at least 4 hours/day.
32763157|NCT03440437|Experimental|FS118 weekly|The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN.
32763158|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
32763159|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
32763160|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
32763161|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
32763162|NCT03273751|Experimental|Remote Ischemic Preconditioning (RIPC)|Four cycles of upper arm ischemia/reperfusion
32763163|NCT03273751|Sham Comparator|Sham control|Placement of a blood pressure cuff around upper arm without inflation.
32763164|NCT03136393|Active Comparator|Control|Community based antenatal counselling
32763165|NCT03136393|Experimental|Intervention|Community based dietary counselling
32763166|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
32763167|NCT03152539|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
32763168|NCT03152539|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
32763169|NCT03152539|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
32763170|NCT04648189|Experimental|Single dose cetuximab prior to surgery|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
33243148|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
33243149|NCT00796497|Experimental|ondansetron|
32912274|NCT05394207|Placebo Comparator|GROUP 2 (Comparator)|23 patients The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
32912275|NCT02703987|Experimental|Group I|Fermented infant milk formula
32912276|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
32912277|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
32912278|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
33231662|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
32737229|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
33231663|NCT00837304||UC|Patients with known ulcerative colitis
33231664|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
33231665|NCT00832156|Other|2|control wound site; application of mesh graft alone
33231666|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
33231667|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
33231668|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
33231669|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
33231670|NCT04043338|Experimental|XC130-A10H|XC130-A10H (single dose)
33231671|NCT04043338|Placebo Comparator|Placebo|placebo (single dose)
33231672|NCT00832234|Experimental|BDR|
33231673|NCT05036980|Experimental|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
33231674|NCT05036980|Experimental|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
33231675|NCT05036980|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
33231676|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
33231677|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
33231678|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
33231679|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
32912279|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
32912280|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
32912281|NCT05073341|Experimental|experimental and control group and intervention is given in the experimental group|Nurse-led family intervention is given in the experimental group having three components i.e infarmation about the patient condition , guidance, and emotional support
32912282|NCT05073341|Other|control group|No intervention will be given in the control group
32912283|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
32912284|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
32912285|NCT05371587|Active Comparator|A - Standard resistance training prescription|"Standard resistance training prescription: participants will perform three sessions per week comprised of six resistance training exercises - horizontal leg press, lat-pulldown, knee extension, chest press, leg curls and shoulder press. They will perform 3 sets of 10 repetitions using 65% percent of the maximal load that can be lifted once according to a one repetition maximum (1RM) test. Their progression model will be as follows:~Weeks 1-3 65%1RM; Weeks 4-6 70%1RM; 1RM reassessment at week 6; Weeks 7-9 70% of the updated 1RM; Weeks 10-12 75%1RM.~Prior to beginning of the program four visits will take place:~Laboratory visit for measuring physiological and anthropometric outcomes (see outcomes section)~1RM testing~Endurance and maximal voluntary contraction testing + introduction with the exercise program~A second introduction session with the exercise program"
33231680|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
33243150|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
32763172|NCT04551313|Experimental|social skill training group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
32763173|NCT04551313|Active Comparator|control group|Regular therapy
33243151|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
33243152|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
33243153|NCT00796575|Placebo Comparator|placebo|placebo
33243154|NCT04330820|Experimental|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
33243155|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
33243156|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
33073021|NCT04077463|Experimental|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
33073022|NCT04077463|Experimental|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing [NGS] and Immunohistochemical [IHC]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
33243157|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
32763174|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
32763175|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
33073023|NCT04077463|Experimental|Phase 1b (expansion) Cohort E: Lazertinib and Amivantamab|Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter. Cohort E will seek to validate the immunohistochemical (IHC)-based biomarker strategy, by characterizing the activity of Amivantamab and Lazertinib combination in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC. In addition, Cohort E will seek to collect prospective data to confirm that prophylactic anticoagulation safely and effectively decreases the incidence of VTE events for patients treated with the combination of Amivantamab and Lazertinib, using Cohort F as reference.
33073024|NCT04077463|Experimental|Phase 1b (expansion) Cohort F: Amivantamab Monotherapy|Participants will receive Amivantamab monotherapy once weekly (QW) for 4 weeks, then every 2 weeks thereafter. Cohort F will seek to validate the IHC-based biomarker strategy, previously identified in Cohort D, by characterizing the activity of JNJ-61186372 monotherapy (Cohort F) in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC.
33243158|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
33243159|NCT02554461||female players|national team players
33243160|NCT02554461||male players|national team players
33243161|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
33243162|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
33243163|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
33243164|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
33243165|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
33243166|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
33243167|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
33243168|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
33243169|NCT00801255|Experimental|Cohort A|
33243170|NCT00801255|Experimental|Cohort B|
33243171|NCT00801255|Experimental|Cohort C|
33243172|NCT00801255|Experimental|Cohort D|
33243173|NCT00801255|Experimental|Cohort E|
33243174|NCT00801255|Experimental|Cohort F|
33243175|NCT00801255|Experimental|Cohort G|
33243176|NCT04893590|Experimental|Fatigue self-management SMS intervention|The participants will receive a 12-week fatigue self-management SMS text intervention using mobile phones to target patient activation levels in people with disabilities.
33243177|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
33243178|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
33243179|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
33243180|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
33073025|NCT04074044|Experimental|BHmApp users|Participants using BHmApp tor bladder education and training
33243181|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
33243182|NCT04069988|No Intervention|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
33243183|NCT04069988|Experimental|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
33243184|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
33243185|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
33243186|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
33243187|NCT05673408||Subject Group 1|Neonates, Infant, Children <3 years of age
32763176|NCT05377801|Experimental|The intervention group|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
32763177|NCT05377801|No Intervention|The control group|The control group would receive the same amount of health education.
33243188|NCT05673408||Subject Group 2|Children 3-12 years of age
33073029|NCT04050982|Experimental|AF CARE|Patients will interface with digital application.
33243189|NCT05673408||Subject Group 3|Adolescent/Adult >12 years of age
33243190|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
33243191|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
33243192|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
33243193|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
33243194|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
33243195|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
33243196|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
33243197|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
33243198|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
33243199|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
33243200|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
33243201|NCT00794703|Experimental|1. Micafungin|
33243202|NCT00794703|Active Comparator|2. Itraconazole|
33243203|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
33243204|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
33243205|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
33243206|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
32763178|NCT04537897|Experimental|BI 474121|
32763179|NCT04537897|Experimental|BI 474121 + Midazolam|
33073030|NCT04050982|Active Comparator|Usual Care|Usual care wait list
33073031|NCT04049331|Experimental|Testosterone|Testosterone undecanoate injection 750 MG/3 ML
33073032|NCT04049331|Placebo Comparator|Placebo|clinical grade saline 0.9% sodium chloride injection
33399302|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
33243207|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
33243208|NCT02576262||HPV-positive women，30-65 years of age|
33243209|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
33243210|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
33243211|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
33243212|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
32763180|NCT04537897|Placebo Comparator|Placebo group|
32763181|NCT04528771|Experimental|SNO|12 patients in the S-nitrosylation arm will receive SNO (six-hour treatment with a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr).
32763182|NCT04528771|Placebo Comparator|Placebo|12 patients in the placebo arm will receive nitrogen gas (six-hour treatment).
32763183|NCT04543513|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
33243213|NCT04577066|Experimental|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
33243214|NCT04577066|Active Comparator|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
33243215|NCT04577066|Placebo Comparator|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
33243216|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
33243217|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
33243218|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
33243219|NCT00580866|No Intervention|PT Only Group|No brace is used
33243220|NCT04940013|Other|Study participants|Study participants will be persons who have late period of up to 14 days
33399303|NCT03167008||fertile male group|"total of 30 fertile male (as control)~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
33399304|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
33399305|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
33399306|NCT05414851|Experimental|Whole-Food, Plant-Based Start|This group starts with the whole-food, plant-based diet, then gets the low-carbohydrate diet after the washout period.
33399307|NCT05414851|Experimental|Low-Carbohydrate Start|This group starts with the low-carbohydrate diet, then gets the whole-food, plant-based diet after the washout period.
32935780|NCT04322162|Experimental|Active implementation - Wave 2 (Third and Fourth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 2 corresponds to Wave 2."
33231681|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
33231682|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
33231683|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
33231684|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
33231685|NCT00837850|Active Comparator|1|
33231686|NCT00837850|Active Comparator|2|
33231687|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
33231688|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
33231689|NCT00832468|Placebo Comparator|sham ear acupressure|
33231690|NCT00832468|Experimental|ear acupressure|
33231691|NCT00832546|Placebo Comparator|1|Placebo
33231692|NCT00832546|Experimental|2|Powder in solution
33231693|NCT00832546|Experimental|3|
33231694|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
33231695|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
33231696|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
33231697|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
33231698|NCT04043572||Healthy Controls|Healthy volunteers
33231699|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:~- Invasively: if the patient is subjected to (EPS)~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
33231700|NCT05565378|Active Comparator|Pembrolizumab Monotherapy|Participants will be administered an intravenous (IV) infusion of pembrolizumab as monotherapy in a fixed dose.
33231701|NCT05565378|Experimental|Dostarlimab Monotherapy|Participants will be administered an IV infusion of dostarlimab as monotherapy in a fixed dose.
33231702|NCT05565378|Experimental|Substudy 1A|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of GSK4428859A (EOS884448) in a fixed dose (Dose A).
33231703|NCT05565378|Experimental|Substudy 1B|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of GSK4428859A (EOS884448) in a fixed dose (Dose B).
33231704|NCT05565378|Experimental|Substudy 1C|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of GSK4428859A (EOS884448) in a fixed dose (Dose C).
33243221|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
33243222|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
33243223|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
33243224|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
33243225|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
32737230|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
32737231|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
32737232|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
33399308|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
33243226|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
33399309|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
32737233|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
33073041|NCT04033055|Experimental|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
33073042|NCT04033055|Active Comparator|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
33243227|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
33243228|NCT00621244|Experimental|Arm 1, Group X|
33243229|NCT00621244|Experimental|Arm 1, Group Y|
33243230|NCT00621244|Experimental|Arm 2, Group X|
33243231|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
33243232|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
33243233|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
33243234|NCT04021901||F21|balloon diameter F21
33243235|NCT04021901||F24|balloon diameter F24
33073046|NCT04015596|Experimental|Intervention|Participants receive Naproxen Sodium.
33073047|NCT04015596|Placebo Comparator|Placebo|Participants receive placebo.
33073048|NCT04010461|Experimental|TMS to dlPFC, without a concurrent task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are in a resting state
33073049|NCT04010461|Experimental|TMS to vertex, without concurrent task|TMS (intermittent theta burst stimulation) will be applied to the cerebral vertex, when subjects are in a resting state
33073050|NCT04010461|Experimental|TMS to dlPFC, during task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are engaged in the n-back working memory task
33073051|NCT03990571|Experimental|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33073052|NCT03985722|Experimental|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
33073053|NCT03969212|Experimental|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
33073054|NCT03969212|Placebo Comparator|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
33243236|NCT01087346|Active Comparator|Control|Information about child health
33243237|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
33243238|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
33243239|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
32737234|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
32737235|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
32737236|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
32737237|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
32737238|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
32737239|NCT05034705|Active Comparator|Active comparator: Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
32737240|NCT05034705|Experimental|Experimental: Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
32737241|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
32737242|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
32737243|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
32737244|NCT05034237|Experimental|ND;YAG 1064 NM LASER|monthly sessions of laser hair removal
32737245|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
32737246|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
32737247|NCT05043519|Experimental|FAM-NP41 Fluorescence Imaging|The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.
33243240|NCT00801645|Experimental|Obese exercise|
33073055|NCT03966105||Patients with LSS surgery indication|
33073056|NCT03964727|Experimental|Sacituzumab Govitecan-hziy|Participants with non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer, or metastatic small cell lung cancer (mSCLC) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.
33073057|NCT03961815|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
33243241|NCT00801645|No Intervention|Obese Control|
32737248|NCT05440019||HEALTHY WOMEN IVI VALENCIA|"Participants will be exposed to four sessions of image captures using FERTIGO® device.~Prior to the session, a vaginal ultrasound (US) will be performed, for measuring the endometrial thickness as in the usual practice."
33243242|NCT00801645|Experimental|Lean Exercise|
33243243|NCT00801645|No Intervention|Lean Control|
33073058|NCT03961815|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
32737249|NCT05034315|Experimental|Whole egg consumption|
32737250|NCT05034315|No Intervention|No egg control|
33073059|NCT03954327|Experimental|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
33073060|NCT03954327|Placebo Comparator|Placebo|Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
33073061|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients are taking MBG453 plus hypomethylating agents
33073062|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients are taking placebo plus hypomethylating agents
33073063|NCT03943446|Experimental|TAK-018 0.30 g Low Dose|TAK-018 3*0.10 gram (g), tablets, orally, twice daily (BID) for up to 26 weeks.
33243244|NCT04652570|Experimental|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
33073064|NCT03943446|Experimental|TAK-018 1.5 g High Dose|TAK-018 3*0.50 g, tablets, orally, BID for up to 26 weeks.
33073065|NCT03943446|Placebo Comparator|Placebo|TAK-018 placebo-matching 3*0 g tablets, orally, BID for up to 26 weeks.
33243245|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
33243246|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
33243247|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
33243248|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33243249|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
33243250|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
33243251|NCT04045899|Active Comparator|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
33243252|NCT04045899|Experimental|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
33243253|NCT04045899|Experimental|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
33243254|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
33243255|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
33243256|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
33243257|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
33243258|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
32912286|NCT05371587|Experimental|B- Autonomy and perceptions approach to resistance training (APART)|"Participants will perform 3 sessions/week of the same exercises. They will perform 3 sets of each exercise, self-select the load they lift in each set and perform repetitions aiming to reach a level of effort of 7-8 on a 0-10 rating of perceived effort scale (RPE) at the end of the set. Their progression model will be as follows: Weeks 1-3 RPE 7/10; Weeks 4-12 RPE 8/10. The selected RPE score of 7 and then 8 out of 10 has been shown to lead to increases in maximal strength in previous research. Prior to beginning of the program four visits will take place:~Laboratory visit (similar to standard).~1RM testing where the principles of perceived effort will be introduced.~Endurance and maximal voluntary contraction testing + introduction with the exercise program. Participants will practice how to self-select the load they prefer and then perform repetitions leading to the target RPE score.~A second introduction session with the exercise program and the RPE construct."
33243259|NCT00714818|No Intervention|WT|Waitlist
33399310|NCT04970082|Experimental|FFR followed by FFR-DWP (investigation)|The FFR measurement is performed with the standard method first followed by the FFR measurement with the DWP method.
32737251|NCT05430347|Experimental|TCbHPy*6|"Pyrotinib combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) Py (pyrotinib 400mg, qD, D1-21)"
32912287|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
33073068|NCT03939416|Experimental|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
33073069|NCT03939416|Active Comparator|CONTROL|Patients treated with the standart treatment
33073070|NCT03929523|Experimental|HOPE group|hypothermic oxygenated perfusion
33073071|NCT03929523|Active Comparator|Control group|classic static cold storage
33073072|NCT03927833|Active Comparator|Continuous Phototherapy|Continuous phototherapy
33073073|NCT03927833|Experimental|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
33073074|NCT03922724|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
33073075|NCT03922724|Experimental|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
33073076|NCT03922724|No Intervention|3/Donor Arm|Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5
33073077|NCT03922724|Experimental|4/mRIC Arm|modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
33399311|NCT04970082|Experimental|FFR-DWP (investigation) followed by FFR|The FFR measurement is performed with the DWP method first followed by the FFR measurement with the standard method.
33243260|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
32763184|NCT04421053||women with GDM|After participants enrollment, we conducted follow-up visit every two weeks. Blood glucose values, body weight, life style record and clinical information are collected. Blood samples and stool samples are collected from participants in Beijing.
32763185|NCT04405063|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
32763186|NCT04405063|Active Comparator|SeQuent® Please|Paclitaxel Coated PTCA Balloon Catheter
33243261|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
33243262|NCT00796887|Experimental|Niaspan® 500mg|
33243263|NCT00796887|Experimental|Niaspan® 1000mg|
32763187|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
32763188|NCT05090527|Active Comparator|Directly delabeled trough risk stratification tool|"Patients who are stratified as  no penicillin allergy undergo a one dose full dose provocation test with 500 mg amoxicillin."
32763189|NCT05090527|Active Comparator|Low risk patients|Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin
33073078|NCT03922724|Experimental|5/ATL-RIC Arm|modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis
33243264|NCT00796887|Placebo Comparator|Placebo|
33243265|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
33243266|NCT00835822|Experimental|A|Arm treated with Investigational product.
33243267|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
32763190|NCT05090527|Active Comparator|High risk|Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.
33243268|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
33243269|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
33243270|NCT02553213|Other|Control group|Caloric restriction
33399312|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
33399313|NCT04952766|Other|immunocompromised and healthy subjects|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
33399314|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
33399315|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
32763191|NCT04400305|No Intervention|Control|No Intervention: Control Group This group will complete baseline and final questionnaires (online). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 6 week period following the study.
32763192|NCT04400305|Other|Intervention|Participants will complete a baseline questionnaire, and receive access to the our online platform for 6 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 3 weeks, a check-in session will occur over the phone. At 6 weeks the participant will be contacted to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
33399316|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
32763195|NCT04381039|Experimental|customized insole group|
32763196|NCT01672853|Experimental|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
32763197|NCT01672853|Experimental|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
32763198|NCT01672853|Placebo Comparator|Treatment Arm C|Placebo for 96 weeks
32763199|NCT04317937|Experimental|Jaw Movement Group|"A: Jaw opening-closing movements~Active jaw movements~Active neck exercises~Head-Neck extension on jaw opening (Mandible moves vertically downward);~B: Isometric strengthening exercises (Same as control group) C: Postural Advice and Home Exercise Program with Dairy (Same as control group)"
32763200|NCT04317937|Active Comparator|Exercise therapy|"A: Active neck exercises Active neck exercises Active jaw movements (Active Jaw movement will not be perform in this group) B: Isometric strengthening exercises C: Postural Advice and Home Exercise Program with Dairy i: Postural Advise ii: Home Exercise Program (unsupervised) iii: Home Dairy~Frequency and Duration of Treatment Non-specific Chronic Neck Pain (more than 3 months history of pain)~Initial Assessment (week 1) 60 minutes First treatment session (week1) 40 minutes~3 treatment sessions per week (week- 2) 40 minutes~3 treatment sessions per week (week- 3) 40 minutes~3 treatment sessions per week (week- 4) 40 minutes~3 treatment sessions per week (week- 5) 40 minutes~Last treatment session (week 6) 40 minutes~Final Assessment (week 6) 60 minutes"
32763201|NCT05090449|Active Comparator|A1: Individual formulation of chlorthalidone|(Higroton 50, product of Sandoz, S.A. de C.V.)
32763202|NCT05090449|Active Comparator|A2:Individual formulation Losartan|(COZAAR, product of Schering Plough, S.A. de C.V., S.A. de C.V.)
32763203|NCT05090449|Active Comparator|A3: Co-administration of individual formulations|Co-administration of individual formulations of chlorthalidone and losartan potassium
32763204|NCT05090449|Experimental|B: Fixed combination of chlorthalidone and losartan potassium|B: Fixed combination of chlorthalidone and losartan potassium (product of Laboratorios Silanes S.A. de C.V.)
32763205|NCT05090137|Other|Diuretic cessation|Participants will be asked to withhold their diuretic therapy (loop diuretics and mineralocorticoid receptor antagonists) 48 hours prior to visit
32763206|NCT05090137|Other|Usual diuretic regimen|Participants will take their usual diuretic regimen prior to study visit. At least one week is required between cross-over visits
32763207|NCT03067025||30 youth with MS|
32763208|NCT03067025||30 healthy control participants|
32763209|NCT05431049||combined spino-epidural anesthesia (CSEA)|Percutaneous nephrolithotomy under combined spino-epidural anesthesia
32763210|NCT05431049||general anesthesia (GA)|Percutaneous nephrolithotomy under general anesthesia
32763211|NCT02782715|Experimental|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~Dose level I: 6 Gy x 5 fractions~Dose level II: 8 Gy x 5 fractions~Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
32763212|NCT05090059|Experimental|Lower limb myofascial trigger points f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ (millijoule)/mm2 administered on 3 or 4 myofascial points (identified based on Fascial Manipulation principles), 1500 shocks per point.
32763213|NCT05090059|Active Comparator|Plantar fascia insertion f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment, with a frequency of 5 Hz, an energy flux density of 0.32 mJ(millijoule)/mm2, for a total of 2000 shocks administered on the area of the painful heel on the medial calcaneal tubercle.
32763214|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
32763215|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
32763216|NCT05089981|Active Comparator|NAC group|IV N acetyl cysteine 300mg will be administered in doses as described in protocol
32763217|NCT05089981|Placebo Comparator|NAC Placebo group|IV Placebo of N acetyl cysteine will be administered in doses as described in protocol (Placebo will be normal saline in a look alike preparation with same volume as active NAC arm)
32763218|NCT04271189|Experimental|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
32763219|NCT04271189|Active Comparator|STANDARD CARE|Standard of care according to the local health service.
32763220|NCT05089747||Adult with solid cancer. No intervention.|
32763221|NCT05730491|Experimental|Social Learning and Cognitive Behavioral Therapy (SLCBT)|
32763222|NCT05730491|Placebo Comparator|Attention Education Control|
32763223|NCT03349801||no AMD|No interventions
32763224|NCT03349801||early AMD|No interventions.
32763225|NCT03349801||intermediate AMD|No interventions.
32763226|NCT03349801||late AMD|No interventions.
32763227|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
33073081|NCT03914625|Active Comparator|Arm A (SR-Avg control)|Arm A: See detailed description.
33073082|NCT03914625|Experimental|Arm B (SR-Avg experimental)|Arm B: See detailed description.
33399317|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
32763228|NCT05089591|Active Comparator|Study eyes|Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations).
32763229|NCT05089591|Sham Comparator|Control eyes|The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
32763230|NCT05730413|Active Comparator|Once Daily Regimen|Patients who take bisoprolol 5 mg per day.
32763231|NCT05730413|Experimental|Twice Daily Regimen|Patients who take bisoprolol 2.5 mg twice per day.
32763232|NCT04223557|Experimental|HIFU treatment|Transcutaneous non-invasive ultrasound will be administered to the peri-renal fat for one time via a high-intensity focused ultrasound system(HIFU) device.
32763233|NCT04223557|Sham Comparator|Sham treatment|Partcipates will receive the same procedure as those in experimental arm except that the device will not be activated.
32763234|NCT04206059|Experimental|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
32763235|NCT04166929|Experimental|Haplo-stem cell transplant followed by NK infusion|"Haplo stem cell transplant (from bone marrow or apheresis) is followed by a haplo-NK cell infusion (target dose ≥1*106/kg b.w.) at day 7.~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused"
32763236|NCT04166929|Active Comparator|Haplo-stem cell transplant|Patients in this arm receive standard haplo stem cell transplant (from bone marrow or apheresis) transplant without subsequent NK cell infusion.
32763237|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
32763238|NCT01071577||Patients|Patients donating BMSC for autologous use
32763239|NCT05730335|Experimental|Rapid Acoustic Pulse (RAP)|Participants will receive 2 separate RAP cellulite treatments sessions.
32763240|NCT01038193||aSAH patients|Cognitive assessment
32763241|NCT05730257|Experimental|Robot-assisted Kidney Transplantation (RAKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality. The anaestethic protocol will be tailored to suit robot-assisted surgery"
32763242|NCT05730257|Active Comparator|Open Kidney Transplantation (OKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for anaesthesia and renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality."
32763243|NCT05377645|Experimental|Cervical mobilization|Mobilization Cyriax's cervical mobilization technique and traditional physiotherapy were applied to the intervention group. For Cyriax Mobilization technique, the patient was asked to lying supine position. Cervical ROM applied all directions. Also AP and ML glides applied to the cervical region. The treatment was done 3 times a week for 2 weeks. Also traditional physiotherapy techniques were applied to the experimental group. Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Continuous ultrasound type was applied with full contact technique.. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
32763244|NCT05377645|Active Comparator|Traditional physiotherapy|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the suboccipital area with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
32763245|NCT05430737|Experimental|stereotactic body radiotherapy|Long-term ADT of 2-3years were administered. Neoadjuvant ADT within 6 months was allowed.Then patients with high-risk prostate cancer recieve stereotactic body radiotherapy with pelvic radiation and GTV boost based on multiparameter magnetic resonance image.
32763246|NCT04148573|Active Comparator|Arm NFX88 - 1|1.05 g/day NFX88
32763247|NCT04148573|Active Comparator|Arm NFX88 - 2|2.10 g/day NFX88
32763248|NCT04148573|Active Comparator|Arm NFX88 - 3|4.20 g/day NFX88
32763249|NCT04148573|Placebo Comparator|Arm PLACEBO - 4|Placebo
32763250|NCT03136783|Other|Patient with stage IV melanoma|
32763251|NCT05430503||Long COVID|Caucasian subjects with a history of SARS CoV-2 infection confirmed by nasopharyngeal swab with real-time polymerase-chain reaction were included in the study. They were referred to investigators' pulmonary function laboratory after being tested negative for SARS-CoV-2, because of dyspnea, fatigue, and exercise intolerance persisting or occurring at least 3 months after the COVID-19 acute phase and lasting ≥2 months.
32763252|NCT05430503||Healthy controls|Anthropometrically-matched healthy subjects, without history of COVID-19 and vaccinated against SARS-CoV-2 infection.
32763253|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
32763254|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
32763255|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
33073083|NCT03914625|Active Comparator|Arm C (SR-High Control)|Arm C: See detailed description.
33073084|NCT03914625|Experimental|Arm D (SR-High experimental)|Arm D See detailed description.
33073085|NCT03914625|Experimental|B-LLy|See detailed description.
33073086|NCT03914625|Experimental|DS B-ALL|See detailed description.
33073087|NCT03914625|Experimental|NCI SR or HR DS B-ALL|See detailed description.
33399318|NCT04905186||healthy adults|This is a cross-over study with no intervention.
33399319|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
32912288|NCT04740021|Experimental|Experimental: LP002+EP|Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on day 1 PLUS etoposide 100 mg/m^2 IV on days 1, 2 and 3 of each 21-day cycle
32912289|NCT03724695|No Intervention|Control|Usual Care
32912290|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
32912291|NCT05747417|Experimental|prism glasses|prisms glasses are advised with ranging of 4prism diopters to 10 prism diopters
32912292|NCT05747417|No Intervention|presbyopic glasses|simple presbyopia glasses according to age are advised
32912293|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
32912294|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
32912295|NCT03663387||Normal subjects|70
32912296|NCT01837901|Sham Comparator|Sham|OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.
32912297|NCT01837901|Experimental|150%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.
32912298|NCT01837901|Experimental|200%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.
33243271|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
33243272|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
33243273|NCT00843934|Experimental|anti-cancer agent|
33243274|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
33243275|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
33243276|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
33243277|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
33243278|NCT04042948|Experimental|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
33243279|NCT04042948|No Intervention|Control Group|without any intervention when remove the drainage tube
33243280|NCT00796965|Experimental|1|
33243281|NCT00796965|Placebo Comparator|2|
32912299|NCT05058287|Experimental|Group 1: Topical Steroid|
32737252|NCT05430347|Active Comparator|TCbHP*6|"Pertuzumab combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) P (Pertuzumab, 840mg for the first dose, 420mg for the rest, D1))"
32912300|NCT05058287|Placebo Comparator|Group 2: Topical Normal Saline|
33243282|NCT04566302|Experimental|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
33243283|NCT00765245|Experimental|Arm I: Lenalidomide|
33243284|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
33243285|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
33243286|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
33243287|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
32737253|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
32737254|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
32737255|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
32737256|NCT05034549|No Intervention|Control|
32737257|NCT05034549|Experimental|Noninvasive ventilation|
32912301|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
33243288|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
32912302|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
32912303|NCT05038085|Experimental|experimental group application|progressive muscle relaxation exercise health education
33243289|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
33243290|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
33243291|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
33243292|NCT00841126|Active Comparator|Lanthanum carbonate|
33243293|NCT00841126|Placebo Comparator|Placebo|
33243294|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
33243295|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
33243296|NCT00718562|Experimental|Nilotinib|
33243297|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
33243298|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
33243299|NCT00801957|Other|3|Control group vaccination and challenge dose only
33243300|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
33243301|NCT00916565||Experimental milk-based infant formula|
33243302|NCT00916565||Control milk-based infant formula|
33243303|NCT00916565||Breastfed Reference Group|
33243304|NCT02547688|Other|Nasal High Flow|All subjects are in this group
33243305|NCT00714974|No Intervention|1|Standard of care
33243306|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
33243307|NCT00836134|Experimental|1|rectus sheath block
33243308|NCT00836134|Active Comparator|2|local anesthetic infiltration
33243309|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
33243310|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
33243311|NCT00715052|No Intervention|2|
33243312|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
33243313|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
32763256|NCT05730023|Experimental|Active tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training
32763257|NCT05730023|Active Comparator|Placebo tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training
32763258|NCT05089045|Experimental|Population Ⅰ|
32763259|NCT04132817|Experimental|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
32763260|NCT04132817|Experimental|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
32763261|NCT04132817|Experimental|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
32763262|NCT05088811||Liver cirrhosis|Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
32763263|NCT05088811||Hepatocellular Carcinoma|Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination
33243314|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
33243315|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
33243316|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
33243317|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
33243318|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
33243319|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
33243320|NCT02573558||DEX|patients who received dexmedetomidine during the operation
33243321|NCT02573558||PPF|patients who received propofol during the operation
33243322|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
33243323|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
33243324|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
33243325|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
33399320|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
33243326|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
33243327|NCT00844012|Experimental|Experimental group|
33243328|NCT00844012|Active Comparator|Control|
33243329|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
33243330|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
33243331|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
33243332|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
33243333|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
33399321|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
33399322|NCT05745610|Experimental|Shen Hai Long Group|
33399323|NCT05745610|Active Comparator|Sheng Jing Group|
33399324|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.~Phone call 48 hours after discharge. Discharge instructions will be reinforced.~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
33399325|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
33399326|NCT02395354|Other|A balloon dilatation|A balloon dilatation
33399327|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
32763264|NCT05088811||Control|Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
32763265|NCT03288493|Experimental|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
32763266|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
32912304|NCT05038085|No Intervention|control group application|No intervention will be made in the control group.
32912305|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
32912306|NCT05035043|Experimental|NAFLD patients|Non-Alcoholic Fatty Liver Disease patients
32912307|NCT04339569||History of patellar tendinopathy|
32912308|NCT04339569||Healthy controls|
32912309|NCT01839695|Experimental|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
32912310|NCT04339647|Experimental|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
33243334|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
33243335|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
32912311|NCT04339647|No Intervention|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
32912312|NCT04986683|Experimental|Patients with drug-resistant epilepsy|All patients who undergo two-stage epilepsy surgery will receive two longitudinal evaluations of brain MRI and neuropsychology test: a month before surgery and 1.5 years after surgery.
33243336|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
33243337|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
33243338|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
33243339|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
33243340|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
33243341|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
33243342|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
32912313|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
32912314|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
32912315|NCT05280093|Experimental|Hybrid sinus node sparing ablation procedure|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
32912316|NCT05251779|Experimental|Cang-Ai Group|The test group inhaled the volatile oil of Cang-Ai at a concentration of 1% by inhalation once a day for 30 minutes
33243343|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
33243344|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
33243345|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
33243346|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
33243347|NCT00802191||Control Group|Participants with no movement disorders.
33243348|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
33243349|NCT02572466||ESRD group|"Aged 18 years or older.~was diagnosed as End-stage renal disease for more than one year.~Attend hemodialysis 3 times a week consistently for more than 6 months.~Hemodialysis with Kt/V > 1.2~No urine output or is less than 500 ml per day.~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
33243350|NCT02572466||Control group|"Aged 18 years or older.~without kidney disease (eGFR > 60 ml/min/1.73m2)"
33243351|NCT00797121|Experimental|Preoperative biliary drainage|
33243352|NCT00797121|No Intervention|Controlled group|
33243353|NCT00715364|Experimental|1|
33243354|NCT00715364|Placebo Comparator|2|
33243355|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
33243356|NCT02601677|Active Comparator|Standard Control|Fluoxetine
33243357|NCT04558112|Experimental|100 mg L-DOPA|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
33243358|NCT04558112|Placebo Comparator|Placebo|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
32912317|NCT05251779|Active Comparator|Bergamot group|The control group inhaled the bergamot essential oils at a concentration of 1% by inhalation once a day for 30 minutes
33243359|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
33243360|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
33243361|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
32912318|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
33243362|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
33243363|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
33243364|NCT00797199||4- Controls|Women not on HRT or healthy controls.
33243365|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
33243366|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
33243367|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
33243368|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
33243369|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
33243370|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
33243371|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
33243372|NCT05478239|Experimental|Prostate cancer patients|Men with biochemical recurrence of prostate cancer after initial local therapy.
32763267|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
33073092|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
33073093|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
33073094|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
33073095|NCT03885908|Active Comparator|In-person geriatric co-management group|"In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
33243373|NCT04282226|Active Comparator|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
32763268|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
33073096|NCT03885908|Experimental|Automated geriatric co-management program group|
33243374|NCT04282226|Placebo Comparator|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
32763269|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
32763270|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
33399328|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
33399329|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
33243375|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
33243376|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
33243377|NCT04046367|Experimental|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
33243378|NCT04046367|Active Comparator|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
33243379|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
33243380|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
33243381|NCT04798521|Experimental|Tele-HCV Treatment|Participants allocated to telemedicine intervention arm are scheduled for treatment assessment by a study clinician. For a majority of participants, this will also be the treatment initiation visit. If additional studies are necessary for routine treatment decision making, peers will assist participants in navigating health system barriers and arrangement of second telemedicine visit.
32763271|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
33243382|NCT04798521|Active Comparator|Community Linkage to Care|Participants allocated to the community linkage-to-care arm will complete screening, be offered enrollment, and undergo informed consent as in the telemedicine arm. Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment.
33243383|NCT05505227|Active Comparator|Intervention|
33243384|NCT05505227|Placebo Comparator|Control|
33243385|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
32763272|NCT03288493|Experimental|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
32763273|NCT04118387|Active Comparator|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
32763274|NCT04118387|Active Comparator|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
32763275|NCT04118387|Active Comparator|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
32763276|NCT05729945|Experimental|Home Visiting Group|The home visiting group receives the program interventions which comprises home visits.
32763277|NCT05729945|No Intervention|Business as Usual Group|The control group is business as usual and does not receive the program intervention.
32763278|NCT05080231||COVID-19 Vaccinated Individuals|Males and females, 13years old and above, vaccinated for COVID-19
32763279|NCT05080231||Previously positive for COVID-19 and unvaccinated individuals|Males and females, 13years old and above, unvaccinated for COVID-19 and previously tested positive for COVID-19.
32763280|NCT05080231||No previous COVID infection or vaccination|Males and females, 13years old and above, unvaccinated for COVID-19 and previously not tested positive for COVID-19.
32763281|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
33243386|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
33243387|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
33243388|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
33243389|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
33243390|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
33399330|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
33399331|NCT04480996||Road traffic accidents with medicines|Road traffic accidents cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Drugs Responsible for Cognitive and Psychomotor Side Effects
33073100|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
33073101|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
33073102|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
33243391|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
33243392|NCT02601443|No Intervention|Routine care (watch and wait)|
33243393|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
33243394|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
33243395|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
33243396|NCT04069832|Other|Intervention|SINGLE-SESSION CONSULTATION
33243397|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
33243398|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
33243399|NCT04068974|Experimental|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
33243400|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
33243401|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
33243402|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
33243403|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
33243404|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
32912319|NCT03349281|Experimental|Dose Level 1: Pevonedistat 15 + VXLD|"Pevonedistat: 15 mg/m2 intravenously (IV)~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For central nervous system (CNS) negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
32912320|NCT03349281|Active Comparator|Dose Level -1: Pevonedistat 10 + VXLD|"Pevonedistat: 10 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For CNS negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
32912321|NCT03349281|Active Comparator|Dose Level 2: Pevonedistat 20 + VXLD|"Pevonedistat: 20 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For CNS negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
32912322|NCT03287817|Experimental|AUTO3|Patient with relapsed or refractory DLBCL
33399332|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
32912323|NCT05747339|Experimental|Tumor treatment vaccine for patients with advanced solid tumors|Tumor treatment vaccine(TTV) would be given deep subcutaneously in the arm or near the tumor.The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32912324|NCT00367809|Experimental|1|
32912325|NCT00367809|Active Comparator|2|
32912326|NCT00367809|No Intervention|3|
32912327|NCT05747261|Experimental|Cohort 1|Subjects in Cohort 1 will receive ANB-004 at a dose 1. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
32912328|NCT05747261|Experimental|Cohort 2|Subjeсts in Cohort 2 will receive ANB-004 at a dose 2. The dose for Cohort 2 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
32912329|NCT05747261|Experimental|Cohort 3|Subjects of Cohort 3, if included, will receive the drug at a dose 3. The dose for Cohort 3 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
32912330|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
32763282|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
33243405|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
33243406|NCT02572700||Patients with skin psoriasis without arthrits|20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
33243407|NCT02572700||Healthy controls|20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
33243408|NCT00836368|Experimental|MaxiGamma|
32763283|NCT05077267|Experimental|ABNCoV2 100ug single dose|ABNCoV2 100ug single dose. Intervention type: Biological/Vaccine
32763284|NCT05077267|Experimental|ABNCoV2 50ug single dose|ABNCoV2 50ug single dose. Intervention type: Biological/Vaccine
32912331|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
32912332|NCT03206151|Experimental|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m^2 and 250mg/m^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
32912333|NCT03206151|Active Comparator|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
32912334|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
32912335|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
32912336|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
32912337|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
32912338|NCT01842815|Experimental|755nm Alexandrite Laser Single Pass (Right Side).|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
32912339|NCT01842815|Experimental|755nm Alexandrite Laser Double Pass (Left Side)|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.
32912340|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
32912341|NCT04831697|Experimental|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health-educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15minutes); and Structured Diabetes Education and Skills Training (15 minutes). The final 5min will be used for debriefing/reviewing goals.
32912342|NCT04831697|Active Comparator|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
32912343|NCT04814927|Active Comparator|Copper IUD|The copper IUD contains approximately 176 mg of copper wire wrapped around a vertical stem. It is FDA approved for pregnancy prevention for 10 years.
32912344|NCT04814927|Active Comparator|Etonogestrel Implant|The ETG implant is a single, radiopaque, rod shaped implant containing 68 mg of etonogestrel. It is FDA approved for pregnancy prevention for 3 years.
32912345|NCT04814927|Active Comparator|Levonorgestrel IUS|The LNG IUS contains approximately 52 mg. of LNG. It is FDA approved for pregnancy prevention for 5 - 6 years.
33243409|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
33243410|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
33243411|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32912346|NCT04814927|Active Comparator|DMPA Sub-cutaneous|DMPA contains 104 mg of medroxyprogesterone acetate in 0.65 mL of fluid, administered by subcutaneous injection in the abdominal fat, thigh or skin over the deltoid muscle. It is FDA approved for pregnancy prevention for 14 weeks.
32912347|NCT04810949|Experimental|serum vitamin D levels >20ng/ml (Group 1)|Patients with serum vitamin D levels >20ng/ml that will receive Vitamin D supplementation
33399333|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
32763285|NCT05077267|Experimental|ABNCoV2 100ug two doses|ABNCoV2 100ug two doses 4 weeks apart. Intervention type: Biological/Vaccine
32763286|NCT05075083|Experimental|Experimental Group|A total 400 subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days
32763287|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
32763288|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
32763289|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
32763290|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
32763291|NCT05430425||body weight|(grup VA; igel=n:40 clasic lma n=40),
32763292|NCT05430425||thyromental distance|grup T; igel=n:40 clasic lma n=40)
32763293|NCT05430425||resize with 3 fingers|grup p; igel=n:40 clasic lma n=40
32763294|NCT04001309|Experimental|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
32763295|NCT04001309|Experimental|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
32763296|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
32763297|NCT03135925|Other|Intervention|Exercise program
32763298|NCT05729789|Experimental|Group Written Exposure Therapy|"Patients will be invited to participate in group Written Exposure Therapy (described in the Interventions section)."
32763299|NCT04021381|Experimental|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate
32763300|NCT04021381|Placebo Comparator|Placebo|Patients are treated with placebo
32763301|NCT03930797|Experimental|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
32763302|NCT03930797|Active Comparator|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
32763303|NCT04020523|Experimental|Patient with an injected breast MR exam|
32763304|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
32763305|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
32763306|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
32763307|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
32763308|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
32763309|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
32763310|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
32763311|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
32763312|NCT03066869|Experimental|H.P. ACTHAR GEL|
32763313|NCT04200131|Experimental|Moray micro-forceps|
32763314|NCT05729633|Experimental|Robot mediated Impairment-oriented training(RMIT)|Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen
32763315|NCT05729633|Experimental|Robot mediated impairment-orientyed and task-specific training (RMIT+RMTT)|Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT
32912348|NCT04810949|Experimental|serum vitamin D levels >20ng/ml ( Group 2)|Patients with vitamin D levels >20ng/ml that will receive diet and hygiene measures
32912349|NCT04810949|Other|serum vitamin D3 levels < 20ng/ml (Group3)|Patients with Vitamin D levels<20ng/ml will receive vitamin D3 supplementation according to primary care discresion
32912350|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
32912351|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
32912352|NCT04795583|Experimental|Prednisone|"Treatment adjusted by weight. Prednisone 25 mg capsules:~≤ 50kg = 2 capsules QD x 7 days (maximum dose = 50mg/day)~50 - 80kg = 3 capsules QD x 7 days (maximum dose = 75mg/day)~> 80kg = 4 capsules QD x 7 days (maximum dose = 100mg/day)"
32912353|NCT04795583|Placebo Comparator|Placebo|Capsules with the same appearance as Prednisone
32912354|NCT05139147|Experimental|DAISe Thrombectomy System|Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
32912355|NCT05747027|Experimental|laparoscopic abdominal ventral rectopexy|
32912356|NCT05747027|Experimental|transvaginal sacrospinous rectopexy|
32912357|NCT05137665||Amyotrophic Lateral Sclerosis ALS|Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
32912358|NCT05137665||Healthy|Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
32912359|NCT05746949|No Intervention|jet ventilation group|Jet ventilation
32912360|NCT05746949|Experimental|Optiflow group|High flow nasal oxygen
33073103|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: - All participants who eat baked milk less than once per month. - Participants who never eat baked milk or straight milk. On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
32912361|NCT02902107|Experimental|surgical resection and intraoperative radiation therapy (IORT)|Brachytherapy will be administered using the CivaSheet, a novel permanent LDR palladium-103 (Pd-103) planar brachytherapy device that is applied directly to the surgical resection bed.
32912362|NCT05746871|Experimental|GroupA_Agilik first|This arm will be assessed at T0, then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and will perform T1 evaluations, and then it will repeat the evaluations after other 5 weeks (T2) during which they performed they standard care
32912363|NCT05746871|Experimental|GroupB_standard care first|This arm will be assessed at T0, then it will continue with their standard care and will perform T1 evaluation after 5 weeks, and then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and the final evaluation (T2)
32912364|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
33073104|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
33243412|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
33243413|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
33243414|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
33243415|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
33243416|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
33243417|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
33243418|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
33243419|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
33243420|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
32763316|NCT05729555|Experimental|Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
32763317|NCT05729555|Active Comparator|Motrin® IB (ibuprofen tablets USP) 200mg and BENADRYL® (diphenhydramine hydrochloride tablet) 25 mg|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading~Distributed by: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division Usage and dosage：Once a day, two tablets at a time"
32763318|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
32763319|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
32763320|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
32763321|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
32763322|NCT05424185||type 1 scapular dyskinesis|type 1 scapular dyskinesis classified by dyskinesis classification test
32763323|NCT05424185||type 2 scapular dyskinesis|type 2 scapular dyskinesis classified by dyskinesis classification test
32763324|NCT05424185||type 3 scapular dyskinesis|type 3 scapular dyskinesis classified by dyskinesis classification test
32763325|NCT05424185||type 4 scapular dyskinesis|type 4 scapular dyskinesis classified by dyskinesis classification test
32763326|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
32763327|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
32763328|NCT05037305|Other|Intervention arm|All individuals in the Intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Upon completion of the testing, they will be provided a link to an educational video about pharmacogenetic testing and results. Surveys will be performed before and after the pharmacogenetic testing.
32763329|NCT05037305|Other|Delayed intervention arm|All individuals in the Delayed intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Surveys will be performed before and after the pharmacogenetic testing. Upon completion of the first follow up survey, they will be provided a link to an educational video about pharmacogenetic testing and results. A second follow up survey will then be completed.
32763330|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
32763331|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
32763332|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
32763333|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
32763334|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
32763335|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
32763336|NCT04962685|Experimental|Unilateral Posterior Crossbite|
32763337|NCT04962685|No Intervention|Normal occlusion|
32763338|NCT03777215|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
32763339|NCT03777215|Placebo Comparator|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
32763340|NCT04945213|Experimental|Biperiden|Drug: Biperiden 5mg of biperiden diluted in 10 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
32763341|NCT04945213|Placebo Comparator|Placebo|"Placebo~1ml of 0.9% saline diluted in 10 ml 0.9% saline - every 6 hours for 10 consecutive days - IV"
32763342|NCT05410847|Experimental|Experimental|"Camrelizumab: 200mg，iv，30min, q3w, 4 cycles. Nab-Paclitaxel: intraperitoneal nab-paclitaxel 80 mg/m2 and intravenous nab-paclitaxel 180 mg/m2 on days 1, q3w, 4 cycles.~S-1：According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week, q3w, 4 cycles.~For patients who were operable, the original regimen was continued for 4 cycles of adjuvant treatment after operation, followed by maintenance of carrelizumab monotherapy to 1 year.~Inoperable patients were selected for follow-up treatment according to guidelines recommended by the investigator."
32763343|NCT05407571|Other|Echogenic Amniotic Fluid|estimation the nature of echogenic amniotic fluid.to overcome unnecessary intervention due to turbid amniotic fluid, assessing the neonatal outcome and estimation the gestational age at time of delivery in patients with echogenic amniotic fluid.
32912365|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
32912366|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
32912367|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
33243421|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
33243422|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
32912372|NCT02658669|Experimental|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
32912373|NCT02658669|Active Comparator|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
32912374|NCT04791215||Prospective Sample Collection|Prospective sample collection from participants treated with pembrolizumab monotherapy at Columbia University Irving Medical Center under standard of care treatment. Prospective cohort subjects must consent to provide available archived tumor and blood for whole exome sequencing (WES) (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.
32912375|NCT04791215||Retrospective Sample Collection|Retrospective sample collection from participants that consent to provide genetic data from previous whole exome sequencing (WES) in the form of files for creation of plasma ctDNA panels.
33243423|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
33243424|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
33243425|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
33243426|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
33243427|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
33243428|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
32763344|NCT04540939|Experimental|Mindfulness-Based Cognitive Therapy|
32763345|NCT04540939|Experimental|Muscle Relaxation Therapy|
33399334|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
33399335|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
33243429|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
33243430|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
33243431|NCT05525117|Experimental|online intervention in addition to treatment-as-usual|online intervention: covivio in addition to treatment as usual
33243432|NCT05525117|Other|treatment-as-usual|Other: treatment as usual
33243433|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
33243434|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
33399336|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
33243435|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
33243436|NCT00655863|Placebo Comparator|Placebo QD|
33243437|NCT00655863|Experimental|Alogliptin 25 mg QD|
33243438|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
33243439|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
33243440|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
33243441|NCT04263922|Experimental|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
33243442|NCT04263922|Active Comparator|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
33243443|NCT05672030||Aspirin-exacerbated respiratory disease (AERD)|Aspirin-exacerbated respiratory disease (AERD)
33243444|NCT05672030||Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)|Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)
33243445|NCT05672030||Healthy controls|Individuals who do not have AERD or CRSwNP
33243446|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
33243447|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
33243448|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
33243449|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
33243450|NCT00841984||1|patients with complex neurological disease of unknown cause
33243451|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
33243452|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
33243453|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
33243454|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
33243455|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
33243456|NCT00719030|Experimental|1|Pomegranate pill
33243457|NCT00719030|Placebo Comparator|2|
33243458|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
33243459|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
33243460|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
33243461|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
32912376|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
32912377|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
32912378|NCT04775147|Experimental|Intervention group|Achieving SBP level of <120mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
33399337|NCT05745532|Experimental|Experimental|Ten transfusion-dependent β-thalassaemia subjects aged 8-16 years will be reinfused with β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q.
33399338|NCT05745454|Experimental|HER2-E-CART cells|HER2-E-CART cells were intravenously transfused and followed up to 2 years after the last cell transfusion
33399339|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
33399340|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
32912379|NCT04775147|No Intervention|Control group|Maintaining SBP level of <140mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
32912380|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
32912381|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
33399341|NCT05745298|Experimental|AFES and RMT Paraplegia Group|Patients with a diagnosis of paraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 2 weeks.
32737258|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
32912382|NCT01845155|Active Comparator|Counselling|Counselling
33073105|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: - All participants who eat peanut less than once per month - Participants who never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
33399342|NCT05745298|Experimental|AFES and RMT Tetraplegia Group|Patients with a diagnosis of tetraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 4 weeks.
33399343|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
33399344|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
33073106|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
33243462|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
32763346|NCT05729477|Active Comparator|Group 1 Phaco Subject Cohort|The Group 1 Phaco subject cohort will begin enrolling subjects sequentially in the first initial arm of the study with up to 250 eyes total.
32763347|NCT05729477|Active Comparator|Group 2 miCOR System Subject Cohort|The Group 2 MICOR System subject cohort, non-use of miLOOP will enroll subsequently with up to 250 eyes total.
32763348|NCT05729477|Active Comparator|Group 3 miCOR System Subject Cohort|The Group 3 MICOR System subject cohort, use of miLOOP optional will enroll subsequently with up to 250 eyes total.
32763349|NCT04750291|Experimental|Botulinum toxin|Infiltration with botulinum toxin
32763350|NCT04750291|Placebo Comparator|Placebo|Infiltration with placebo or sterile saline
32763351|NCT05729399|Experimental|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
32763352|NCT04708951|Active Comparator|ECV colonoscopy|EndoCuff Vision® device (ECV)
32763353|NCT04708951|Experimental|G-EYE® colonoscopy|G-EYE® colonoscope (G-EYE)
32763354|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
32763355|NCT04611217|Experimental|High Fiber diet|Group receiving a high fiber diet
32763356|NCT04611217|Other|Low Fiber diet|Control group receiving a low fiber diet
32763357|NCT04593745|Other|ALL AIEOP-BFM induction|Intraocular pressure messured in children treated with steroids
32763358|NCT03812575||Active eosinophilic esophagitis|
32763359|NCT03812575||Eosinophilic esophagitis in remission|
32763360|NCT03812575||No eosinophilic esophagitis|
32763361|NCT05404217|Active Comparator|LN-OS-22|2 capsules orally once a day for 56 days
32763362|NCT05404217|Placebo Comparator|Maltodextrin|2 capsules orally once a day for 56 days
32763363|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
32763364|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
32763365|NCT03756337|Experimental|Neuro 2 Upgrade|Participant wears Neuro 1 sound processor and is tested, then is upgraded with the new sound processor Neuro 2 and tested.
32763366|NCT03756337|Experimental|Neuro 1 Downgrade|Participant wears Neuro 2 sound processor and is tested, then is downgraded with the sound processor Neuro 1 and tested.
32763367|NCT05729243|Experimental|Cytisine|"Cytisine will be given as 1.5 mg tablet formulations for 25 days.~The following treatment schedule will be followed:~Days 1 to 3: 1.5 mg taken every 2 hours (6 pills (9 mg)/day)~Days 4 to 12: 1.5 mg taken every 2.5 hours (5 pills (7.5 mg)/day)~Days 13 to 16: 1.5 mg taken every 3 hours (4 pills (6 mg)/day)~Days 17 to 20: Taper down to 1 tablet every 5 hours (3 pills (4.5 mg)/day)~Days 21 to 25: Taper down to 1-2 tablets daily (1.5-3 mg/day)"
32763368|NCT05729243|Placebo Comparator|Placebo|Placebo will be given following the same schedule as the Cytisine Arm.
32763369|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
32912383|NCT02578641|Experimental|Arm A|"4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.~*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
32912384|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
32912385|NCT05746715||genetic Creutzfeldt-Jakob Disease (CJD) patients|A group of patients diagnosed with CJD, who are carriers of E200K mutation in the PRNP gene (gCJD)
33243463|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
32912386|NCT05746715||Healthy first degree relatives|A group of first-degree healthy relatives (HR) (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD.
32912387|NCT05088525|Active Comparator|Two-tunnel meniscal root repair without a peripheral stabilization suture|Standard root repair surgery.
32912388|NCT05088525|Experimental|Meniscal root repair with an additional transtibial peripheral stabilization suture|Meniscus root repair with an added stabilization suture
32912389|NCT05084859|Experimental|CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.~Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled."
32912390|NCT05084859|Experimental|NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.~Subjects will receive increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled."
32912391|NCT05084859|Experimental|CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.~Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15)."
33243464|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
33243465|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
33243466|NCT00806091||COPD subjects|healthy subjects
33243467|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
32912392|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
32912393|NCT05746637||Study population|The entire study population
33243468|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
32912394|NCT02431260|Experimental|INCB054329 Monotherapy|
33243469|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
32912395|NCT05745545|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|
33243470|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
33243471|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
33243472|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
33243473|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
33243474|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
33243475|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
33243476|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
32763370|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
32763371|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
32763372|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
32763373|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
32763374|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
32763375|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
32763376|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
32763377|NCT03066557|Active Comparator|study group|TACE and Apatinib
32763378|NCT03066557|Experimental|control group|TACE alone
32763379|NCT04574401|Experimental|Dose escalation|Dose-cohort escalation of a single intravenous injection of IS-002 at four different dose levels
32763380|NCT05596409|Experimental|Elacestrant|Subjects will take a starting dose of 400 mg of elacestrant dihydrochloride in tablet form once daily for up to 6 months.
32763381|NCT05376241||Women with negative reactions to mammography evidence|Recruit up to 40 women from the Ipsos survey who agreed to be contact for a follow-up phone interview. The Investigator will specifically recruit women who expressed negative reactions to mammography evidence, so the team may assess how to improve the mammography decision aid using insights from those who were negatively affected.
32763382|NCT05729087|Experimental|Blended Intervention Group|A 10-week lifestyle intervention will be provided, addressing physical activity (PA) and healthy diet simultaneously. The program mode is a web- and center-based blended intervention. The web-based lifestyle behavior intervention will be developed based on the Health Action Process Approach.
32763383|NCT05729087|No Intervention|Control Group|No treatment will be provided during the intervention period. Relevant intervention materials are accessible and available for all participants in the control group after the completion of data collection.
32763384|NCT05308667|Experimental|iTBS + mCIMT group|
32763385|NCT05308667|Sham Comparator|Sham iTBS+ mCIMT group|
32763386|NCT05308667|Active Comparator|mCIMT group|
32763387|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
32763388|NCT05738161|Experimental|Magrolimab in combination with Cisplatin and Gemcitabine|Magrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma.
32763389|NCT05595317|Experimental|Study group|Traditional physiotherapy + A non-immersive virtual reality game will be played to provide treatment for lower limbs.
32763390|NCT05595317|Sham Comparator|Sham-controlled group|Traditional physiotherapy + A sham non-immersive virtual reality game will be played but not provides treatment for lower limbs.
32763392|NCT05594225|Experimental|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
32763393|NCT05594225|No Intervention|Standard-of-care|Participants will be provided routine instructions related to physical activity and rehabilitation exercises
32763394|NCT05738005|Other|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|MyFitnessPal smartphone application is used to track daily dietary intake and herbal/alternative supplements.
32763395|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 1 (T1)|Oral coated beads 8 g glucose (content glucose/bead 47% w/w)
32763396|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
32763397|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 3 (T3)|Oral coated beads 16 g glucose (content glucose/bead 47% w/w)
32763398|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 4 (T4)|Oral uncoated beads 12 g glucose
32763399|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 5 (T5)|Oral coated beads 12 g glucose (content glucose/bead 60% w/w)
32763400|NCT05737927|Active Comparator|MULTIPLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
32912396|NCT05745545|Placebo Comparator|Placebo|
32912397|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15|
32912398|NCT04630769|Experimental|Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15|
32912399|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15|
32912400|NCT04630769|Experimental|Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6|
32912401|NCT04630769|Experimental|Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6|
32912402|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
32912403|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
32912404|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
32912405|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
32912406|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
32912407|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
32912408|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
32912409|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
32912410|NCT02724033|Active Comparator|Group B|Group B - antiemetic
32912411|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
32912412|NCT05011539||Ovarian cancer|The patients with ovarian cancer
32912413|NCT05011539||Control group|
32912414|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
32912415|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
32912416|NCT02724423|Experimental|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
32912417|NCT02724423|Experimental|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
32912418|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
32912419|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
32912420|NCT05745311|Experimental|low-dose group （The KPCXM18 injection）|Intravenous infusion of 20 mg twice daily at intervals of 12±2 hours for 10 days.
32912421|NCT05745311|Experimental|middle-dose group （The KPCXM18 injection）|Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 10 days.
32912422|NCT05745311|Experimental|high-dose group （The KPCXM18 injection）|Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 10 days.
32912423|NCT05745311|Placebo Comparator|Placebo|Intravenous infusion twice a day with an interval of 12±2 hours for 10 days.
32912424|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
32912425|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
32912426|NCT05743673||Validation Cohort|Older subjects (>60 years old) presenting for moderate to high-risk surgical procedure with reported subjective metabolic equivalents of >4 METS and with a score of <2 on the revised cardiac risk index (RCRI) undergoing submaximal exercise testing.
32912427|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
32912428|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
32912429|NCT05743205|Experimental|Educational Intervention|Educational intervention
32912430|NCT04985253||Operable breast neoplasm cohort|Operable breast cancer (OBC) ER +/Her2 neg or triple negative breast cancer patients diagnosed and treated at Tata Memorial Centre, Mumbai from 01 Jan 2010 to 31 Dec 2013 with a five-year follow up or events within the 5 years.
32912431|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
32912432|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
32912433|NCT04950621|Experimental|Remimazolam|In remimazolam group, a 0.1 mg/kg dose of intravenous remimazolam was administered for induction, and 0.3-0.7 mg/kg/h infusion for maintenance after intubation.
32912434|NCT04950621|Active Comparator|Propofol|In propofol group, a 2 mg/kg dose of intravenous propofol was administered for induction, and 4-12 mg/kg/h infusion for maintenance after intubation.
32912435|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
32912436|NCT01578135||Phase I|
32912437|NCT01578135||Phase II|
32912438|NCT04575155|Experimental|TEAM Strategy|Patients randomized to the TEAM intervention arm will receive at least one call from a Walgreens pharmacist to help them with their complex Rx regimens. Pharmacists will have read/write EHR access with established Epic security points. Through shared access to patients' medical records, pharmacists can perform comprehensive medication therapy management services, document and communicate patients' Rx challenges for review and action by primary care providers. After the pharmacist calls the patient for a Comprehensive Medication Review, they will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
32912439|NCT04575155|No Intervention|Enhanced Usual Care|Patients randomized to enhanced usual care will have the medical record available to a Walgreens pharmacist with 'read only' access. All patients at the five targeted health centers already have read-only access in place. This means the Walgreens pharmacist will have the capability to review a patient's record as necessary. The pharmacist may refer to the EHR as needed and in a reactive manner; such as if a patient were to request a medication requiring review for billing purposes (i.e. verify insurance, prior authorizations), or if a patient safety concern was raised (e.g. potential drug-drug or drug- disease interaction, therapeutic duplication, etc.). Similarly, read only EHR access means pharmacists must continue to use existing communication channels (e.g. phone, fax) to contact prescribers.
32912440|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
32912441|NCT05737121|Experimental|VNX001|VNX001 (lidocaine HCl [200 mg] and heparin sodium [50,000 USPU] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)
32912442|NCT05737121|Placebo Comparator|Placebo|Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
32912443|NCT05737121|Experimental|Lidocaine|Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)
32912444|NCT05737121|Experimental|Heparin|Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
32912445|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
32912446|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~Dolutegravir(DTG) 50 mg orally once daily"
32912447|NCT01848899|Experimental|Ioxaglate Arm|
32912448|NCT01848899|Experimental|Iodixanol arm|
32912449|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
32912450|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
33243477|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
33243478|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
32912451|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
32912452|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
32912453|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
32912454|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
32912455|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
32912456|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
32912457|NCT00422487|Experimental|MBX-2044 1.5 mg|
32912458|NCT00422487|Experimental|MBX-2044 4.5 mg|
32912459|NCT00422487|Experimental|MBX-2044 15 mg|
32912460|NCT00422487|Experimental|MBX-2044 30 mg|
32912461|NCT00422487|Experimental|MBX-2044 60 mg|
33243479|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
33243480|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
33243481|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
32912462|NCT00422487|Experimental|MBX-2044 90 mg|
32912463|NCT00422487|Placebo Comparator|Placebo|
32912464|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
32912465|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
33243482|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
33243483|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
33243484|NCT00802815|Experimental|Etanercept|
33243485|NCT04100759|Experimental|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
33243486|NCT04100759|Experimental|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
32912466|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
32912467|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
32912468|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
32912469|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
32912470|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
32912471|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
32912472|NCT04930965|Experimental|Intervention|
32912473|NCT04930965|No Intervention|Usual care|
32912474|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
32912475|NCT05731505|Experimental|THE EFFECT OF A SUPPORTIVE APPROACH STRUCTURED ACCORDING TO KOLCABA'S COMFORT THEORY|The study group consisted of parents who were given a supportive approach structured according to Kolcaba's Comfort Theory by the researcher.
32912476|NCT05731505|Experimental|KOLCABA COMFORT THEORY APPLİED TO PARENTS OF CHİLDREN WİTH CEREBRAL PALSY|During the training given by the researcher, the children continued their routine education in the rehabilitation center. Although the education to be done is for the child and their parents, the education was given directly to the parents, since the mental perception levels of the children may not be sufficient and mostly children with CP live dependent on their parents. The parent who will be involved in the research is the primary caregiver who is most interested in the child.
32912477|NCT04457219|Active Comparator|Conventional dressing with 120 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
32912478|NCT04457219|Experimental|Conventional dressing with 60 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
32912479|NCT04457219|Experimental|Haemostatic dressing with 60 minutes external compression|A haemostatic absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. This consists of a mineral-based dressing that accelerates local haemostasis. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
33243487|NCT04100759|Experimental|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
33243488|NCT00836914|Active Comparator|CAL-101|
33243489|NCT00836914|Placebo Comparator|Placebo|
33243490|NCT04124042|Experimental|Stage A: 0.15 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|Low dose active in Stage A and Stage B
33243491|NCT04124042|Experimental|Stage A: 0.15 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|Low dose active in Stage A, high dose active in Stage B
33243492|NCT04124042|Experimental|Stage A: 0.45 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|High dose active in Stage A, low dose active in Stage B
33243493|NCT04124042|Experimental|Stage A: 0.45 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|High dose active in Stage A and Stage B
33243494|NCT04124042|Placebo Comparator|Stage A: Placebo, Stage B: 0.15 mg/mL XT-150|Inactive comparator in Stage A, low dose active in Stage B
33243495|NCT04124042|Placebo Comparator|Stage A: Placebo, Stage B: 0.45 mg/mL XT-150|Inactive comparator in Stage A, high dose active in Stage B
33243496|NCT05180175|Experimental|Access to protein profile|
33243497|NCT05180175|No Intervention|No access to protein profile|
33243498|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
32763403|NCT05728853||Trans gender males|Trans gender males in hormonal therapy
32763404|NCT04152967|Experimental|new-designed PTFE valved conduit|In this group, new-designed PTFE valved conduits will be applied for patients.
33243499|NCT04117412|Other|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
33243500|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
33243501|NCT00802971|No Intervention|2: Control|
33243502|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
33243503|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
33243504|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
33243505|NCT04115852||CON|Healthy Controls
33243506|NCT04115852||BED|Patients with Binge-Eating-Disorder
33243507|NCT00716222||1|Obese adolescent and young adult with sleep disorder
33243508|NCT00716222||2|Obese adolescent and young adult without sleep disorder
33243509|NCT00716222||3|Lean adolescent and young adult with sleep disorder
33243510|NCT00803127||no treament|
33243511|NCT00001160||thyroid cancer|Patients with thyroid cancer
33243512|NCT00001160||thyroid nodules|Patients with thyroid nodules
33243513|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
33243514|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
33243515|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
32912480|NCT04450979|Active Comparator|Bioactive hydrolysate|20 g of hydrolysed rice protein
32737259|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
32912481|NCT04450979|Placebo Comparator|Placebo|20 g micro crystalline cellulose
32737260|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
32737261|NCT05054673|Experimental|intervention|PALFIQUE universal adhesive (Tokuyama self-cure universal adhesive)
32737262|NCT05054673|Active Comparator|control|3M™ ESPE™ single bond Universal Adhesive
32737263|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
32737264|NCT05054205|Experimental|Experimental group|To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes.The data were collected in three stages as pre-test, post-test and follow-up (after 30 day).
32737265|NCT05054205|No Intervention|Control group|Normal care was continued in the control group.
32737266|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
32737267|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
32737268|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
32737269|NCT05043363||Observational cohort|"Patients with an established diagnosis of inflammatory bowel disease who have been identified as being 'at risk' by either their secondary care doctor or GP and now require endoscopic assessment for ongoing disease symptoms but are unable to access endoscopy services urgently.~Patients presenting directly to their GP practice with symptoms of anorectal disease (e.g. rectal bleeding or pain) or symptoms that would warrant referral to a hospital under a 2WW appointment according to NICE criteria~Recruited patients will undergo rectal examination in primary care with the LumenEye X1 with either contemporaneous or retrospective image review by a secondary care clinician. This will require a glycerine suppository to be administered. Patient feedback will be sought with a post-procedural questionnaire."
32737270|NCT05043129||HIV infenction/AIDS|experimental group
32737271|NCT05043129||Healthy population|Control group
32737272|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
32737273|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
32737274|NCT03340103|Experimental|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
32737275|NCT03340103|Placebo Comparator|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
32737276|NCT05054283||Length of hospital Stay (normal)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
32737277|NCT05054283||Length of hospital Stay (prolonged)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
32737278|NCT04473183||General Healthy Population|Participants in this group are part of the general healthy population of adults 18 years-of-age and older, not known to be exposed to the virus as reported by potential participants and who have not sought medical help in the previous 4 months.
32737279|NCT04473183||Medical School Residents|Participants in this group are medical school residents.
32737280|NCT04473183||Individuals who are HIV positive|Participants in this group are HIV positive.
32737281|NCT05034003|Experimental|zirconia crowns|Zirconia crowns placed on primary incisor teeth
32737282|NCT05034003|Experimental|composite strip crowns|composite strip crowns placed on primary incisor teeth
32737283|NCT05034003|No Intervention|Control tooth|Caries-free primary incisor tooth
32737284|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
32737285|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
32737286|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
32737287|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
32737288|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
32737289|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
32737290|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
32737291|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
32737292|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
32737293|NCT05033691|Experimental|Early SRS treatment with SoC|Stereotactic surgery (SRS) to the brain metastases and continuation of Osimertinib, at 2 month (8 weeks) post Osimertinib start
33399345|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
32737294|NCT05033691|Active Comparator|SoC Tagrisso treatment only|continuation of osimertinib alone
32737295|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
32912482|NCT04433273|No Intervention|Group A: Healthy control group|Neither placebo nor vestibular stimulation is administered
32912483|NCT04433273|Placebo Comparator|Group B: Placebo control group|Placebo stimulation along with regular treatment
32912484|NCT04433273|Active Comparator|Group C: Intervention group|Electrical vestibular nerve stimulation along with regular treatment
32912485|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
32912486|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
32912487|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
32912488|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
32912489|NCT04372979|Experimental|SARS-CoV-2 patients treated with convalescent plasma|Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
32912490|NCT04372979|Active Comparator|SARS-CoV-2 patients treated with standard plasma|Subjects will receive an intravenous injection of standard Plasma.
33243516|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
32912493|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
32912494|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
32912495|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
32912496|NCT02429934|Active Comparator|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
32912497|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
32912498|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
32912499|NCT04262141|Experimental|IMG-7289 in ET and PV Patients|"Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered:~The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity.~The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity."
32912500|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
32912501|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
32912502|NCT04261361|Experimental|CBT-AD intervention|"Adherence counseling~Psycho-education package~The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls."
32912503|NCT04261361|Active Comparator|enhanced treatments usual (ETAU)|"Adherence counseling;~Psycho-education package;~To maintain some control over the contact time, we will give them 4 bi-weekly individual phone calls of about 10 minutes each while the CBT-AD intervention group is having their 8 weeks of face-to-face group sessions."
32912504|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
32912505|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
32912506|NCT05722847||Low risk|Subjects will be considered low risk if they have non-small cell histology, a length of hospital stay <= 8 days, no or low comorbidity, no emergency department use or hospitalization in the 6 months prior, no wheelchair requirement when hospital discharge, or other than Black and/or Hispanic race.
32912507|NCT05722847||High risk|Subjects will be considered high risk if they have small cell histology, a length of hospital stay > 8 days, high comorbidity, emergency department use or hospitalization in the 6 months prior, prescription of a wheelchair when hospital discharge, or Black and/or Hispanic race.
32912508|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
32912509|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
32912510|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
32912511|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
32912512|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
32912513|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
32912514|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
32912515|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
32912516|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
32912517|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
32912518|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
33243517|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
32912519|NCT05716763|Experimental|Tramadol hydrochloride 5mg/mL oral solution (IMP 08P1902F0)|
32912520|NCT05716763|Active Comparator|Tramadol hydrochloride 100mg/mL oral solution (Contramal(r))|
32912521|NCT00558467|Other|Pramipexole|
32912522|NCT00558467|Placebo Comparator|Placebo|
32912523|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
32912524|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
32912525|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
32912526|NCT04226495|Active Comparator|Sufentanil Bolus|
32912527|NCT04226495|Experimental|Sufentanil Infusion|
32912528|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
33243518|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
33243519|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
33243520|NCT00842374||Non-STEMI ACS|
33243521|NCT04070846|Experimental|[14C] LC350189|Single oral dose
33243522|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
33243523|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
33243524|NCT00716300||1|obese and insulin resistant subjects
32912529|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
33243525|NCT00716300||2|lean and normolipidaemic subjects
33243526|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
32912530|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
32912531|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
32912532|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
32912533|NCT01854359|Other|Active treatment|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
33243527|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
33243528|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
32912534|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
33243529|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
33243530|NCT00842452|Experimental|Oral Topotecan|
33243531|NCT02552745||study group|parecoxib sodium was administered postoperatively
33243532|NCT02552745||control group|parecoxib sodium was not administered postoperatively
33243533|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
32912535|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
33243534|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
33243535|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
33243536|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
33243537|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
33243538|NCT04045821|Placebo Comparator|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D&C procedure will be completed.
33243539|NCT04045821|Experimental|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D&C procedure will be completed.
33243540|NCT04068584|Experimental|Complete Smart Angel|Smat Angel application with artificial intelligence
32912536|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
33243541|NCT04068584|Experimental|Basic Smart Angel|Smat Angel application without artificial intelligence
33399346|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
33243542|NCT04068584|No Intervention|Control|
33399347|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.~Intervention: Survey"
33243543|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
33243544|NCT00842842|Experimental|2: glue|mesh fixation with glue
33243545|NCT00803439||Cohort Group 1|Subjects number 1 to 20
33243546|NCT00803439||Cohort Group 2|Subjects number 21 to 40
32737296|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
32763405|NCT04152967|Active Comparator|Bovine jugular valved conduit|In this group, bovine jugular vein valved conduits will be applied for patients.
33243547|NCT00803439||Cohort Group 3|Subjects number 41 to 60
33243548|NCT00803439||Cohort Group 4|Subjects number 61 to 80
33243549|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
33243550|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
33243551|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
33243552|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
33243553|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
33243554|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
33243555|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
33243556|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
33243557|NCT00803673|Experimental|Active|100mcg 719
33243558|NCT00803673|Experimental|Active 2|500mcg '719
33243559|NCT00803673|Experimental|Active 3|1000mcg '719
33243560|NCT00803673|Placebo Comparator|Placebo|Placebo '719
33399348|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
32737297|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
32737298|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
33399349|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
33399350|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
33399351|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
32912537|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
32912538|NCT04017143|Experimental|HPV App group|Participants will be assigned to receive an HPV app.
32912539|NCT04017143|No Intervention|Usual Care|This is a usual care group that receives a brochure that is usually distributed by a clinic.
32912540|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
32912541|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
32912542|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
32912543|NCT04899141||Coronary Artery Disease|
32912544|NCT04795635|Experimental|CMM + Axon Therapy|"Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days). Participants randomized to the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows:~Month 1: 6 treatments~WEEK 1: 3 treatments (consecutive treatments are best)~WEEK 2-4: Weekly treatments~Month 2: Bi-monthly treatment~Months 3-12: Treatments every 2-4 weeks~In addition to in-clinic assessments and treatments, all participants will a receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the participant is not in clinic for treatment."
32912545|NCT04795635|No Intervention|CMM Only|Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days)
32912546|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
32912547|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
32912548|NCT00555711||Modulated Imaging|Modulated Imaging
32912549|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
32912550|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
32912551|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
32912552|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
32912553|NCT05446545||ND-EOC|Newly diagnosed patients with advanced EOC who are eligible for radical surgery.
32912554|NCT05446545||platinum-sensitive rEOC|Patients relapsed from platinum-based therapy who are eligible for secondary cytoreductive surgery.
32912555|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
32912556|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
32912557|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
32912558|NCT02427984||Controls|Patients free from hip devices
33243561|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
32912559|NCT02643225||pregnant women with gestational diabetes|case group
32912560|NCT02643225||non diabetic pregnant women|control group
32912561|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
32912562|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
32912563|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
32912564|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
32912565|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
32912566|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
32912567|NCT05690009||Patients with albuminuria|Patients aged 40 or older without preexisting diagnoses of chronic kidney disease, type 1 diabetes, and type 2 diabetes with positive albuminuria by dipsticks and/or microalbuminuria test or albumin-to-creatinine ratio in a single urine sample.
32912568|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
33243562|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
32912569|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
32912570|NCT05687279|Experimental|RSVt Vaccine Group|2 intranasal administrations (56 days apart) of the RSVt vaccine at D01 and D57
32912571|NCT05687279|Placebo Comparator|Control Group|2 intranasal administrations (56 days apart) of the placebo at D01 and D57
32912572|NCT02643849|Experimental|Spanner|
32912573|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32912574|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
32912575|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
32912576|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
32912577|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
32912578|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
32912579|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
32912580|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
32912581|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
32912582|NCT05679479|Experimental|Meplzaumb|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
32912583|NCT05679479|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
32912584|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
32912585|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
32912586|NCT05675969|Experimental|Pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. The sample will be collected as close as possible to the diagnosis of pre-eclampsia during a routine care assessment
32912587|NCT05675969|Active Comparator|Non pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. sampling will be performed during routine care according to the matching.
32912588|NCT03697967|Experimental|Supine|Infant placed supine for 120 seconds before cord clamping
32912589|NCT03697967|Experimental|Prone|Infant placed prone for 120 seconds before cord clamping
32737299|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
32763406|NCT05728775|Experimental|Remimazolam TIVA|Remimazolam is administered at 6-12 mg/kg/h intravenously for anesthesia induction and at 1.0-2.0 mg/kg/h for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
32763407|NCT05728775|Active Comparator|Propofol TIVA|Propofol 1.5-2.5mg/kg is administered intravenously for anesthesia induction and propofol at 4-12mg/kg/h is used for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
32763408|NCT05737771|Other|Group A|administrate DWP16001 + DWC202213 at first period, and administrate DWJ1563 at second period
32763409|NCT05737771|Other|Group B|administrate DWJ1563 at first period, and administrate DWP16001 + DWC202213 at second period
32763410|NCT05728697||Patients with nonalcoholic fatty liver disease and elevated body mass index|Patients who have BMI >=25 and suspected nonalcoholic fatty liver disease based on imaging, laboratory workup, or clinical history. Patients are included in the study if they have been selected for routine clinical endoscopic ultrasound (can be for any indication) with liver biopsy either during the same session or within 6 months.
32763411|NCT04477135|Other|perinatologists|perinatologists working actively and performing ultrasonography every day
32763412|NCT04446377|Experimental|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
32763413|NCT04446377|Placebo Comparator|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
32763414|NCT05737693|Experimental|0.2mg/kg ketamine with psychotherapy|Two infusions of low dose Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.2 mg/kg for 40 minutes.
32763415|NCT05737693|Experimental|0.5mg/kg ketamine with psychotherapy|2. Two infusions of Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.5 mg/kg for 40 minutes.
32763416|NCT05737693|Active Comparator|Midazolam with psychotherapy|Midazolam combined with trauma-focused psychotherapy. Midazolam infusion procedure will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusion at a rate 0.045 mg/kg for 40 minutes.
32763417|NCT05728619|Experimental|Phase 1b|Escalating doses of HTMC0435 and Temozolomide
32763418|NCT05728619|Experimental|Phase 2|Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide
32763419|NCT05737615||Participants with Pancreatic Cancer|Participants have histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma
32763420|NCT05737537|Other|infected pediatric cancer patients|
32763421|NCT05238779||End Stage Liver Disease (ESLD)|Patients with ESLD
32763422|NCT05737459||Group K|Those who have been administered ketamine for perioperative sedation
32763423|NCT05737459||Group D|Those who have been administered dexmedetomidine for perioperative sedation.
32763424|NCT05576831|No Intervention|HPV-A VSCC|Patients with HPV-A VSCC and margins that are negative for cancer but <8mm (regardless of in-situ (HSIL) margin status) will be eligible for the de-escalation prospective study.
32763425|NCT05576831|Experimental|HPV-I VSCC|If the margins are negative for cancer but <8mm, or positive for Differentiated vulvar intraepithelial neoplasia (dVIN), and/or positive for p53 abnormality on IHC, these patients will be randomized (2:1) to further re-excision vs observation only.
32763426|NCT05737303|Experimental|Nab-Paclitaxel/carboplatin for systemic therapy after surgery|Nab-Paclitaxel/carboplatin q3 weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles
32763427|NCT05737303|Active Comparator|Paclitaxel/carboplatin for systemic therapy|"Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve） 2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
32763428|NCT04824547|Active Comparator|Stabilization exercise group|"Spinal stabilization exercise will be applied all patients accompanied by physiotherapist.~Sessions will be included selected exercises according to motor learning phases."
32763429|NCT04824547|Active Comparator|yoga group|Yoga program will be applied all patients in this group accompanied by physiotherapist. Sessions will be included selected breathing exercises, warm up, asana and relaxation.
32763430|NCT05207813||Basivertebral nerve ablation treatment|Patient-reported outcomes at three (3) follow-up visits for previously treated participants from the CLBP Single-Arm study.
32763431|NCT04710199|Experimental|Maraviroc experimental group|Maraviroc tablet combined with standard treatment
32763432|NCT04710199|Other|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
32763433|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
32763434|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
32912590|NCT03695081|Experimental|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
32737300|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
32737301|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
32763435|NCT04648501|Experimental|Dual-task group|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
32763436|NCT04648501|Active Comparator|Single-task group|Single-task (conventional balance, coordination and cognitive training- active control) group participants will receive 10 minutes of warm-up, 20 minutes of conventional balance and coordination exercises that are in accordance to previously published literature, 20 minutes of cognitive training as single-task (same 4 tasks provided for the CIBT) and 10 minutes of cool down. In addition, falls prevention strategies will also be taught.
32763437|NCT05558501|Experimental|Mild Intermittent Hypoxia (MIH)|This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory.
32763438|NCT05558501|Sham Comparator|Sham Mild Intermittent Hypoxia (Sham MIH)|This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory.
32763439|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
32763440|NCT03066167||Controls|Healthy Controls with no known dysphagia
32763441|NCT04599049|Other|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
32763442|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
33399352|NCT05745220|Other|Daily contact lens wear|Participant wear silicone hydrogel contact lenses daily for 6 weeks ±2 days for a minimum wearing time of 5 days per week and 8 hours per day - corneal sensitivity will be measured and compared at baseline versus after 7±2 days and 5 weeks ±2 days daily contact lens wear.
33399353|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
33399354|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
33399355|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
33399356|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
33399357|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
33399358|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
33399359|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
32763443|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
33399360|NCT05745142||metastatic Renal Cell Carcinoma patients|metastatic Renal Cell Carcinoma patients with clear cell histology.
33399361|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
33399362|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
33399363|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
33399364|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
33399365|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
33399366|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
33399367|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
33399368|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
32912591|NCT03695081|No Intervention|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
32912592|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
32912593|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
32912594|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
32912595|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
32912596|NCT03636347|Placebo Comparator|Placebo oral tablet|
33243563|NCT04017195|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
33243564|NCT04017195|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
33243565|NCT04017195|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
33243566|NCT04017195|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
33243567|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
33243568|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
33243569|NCT00837226||Study group-Bariatric procedure performed|
33243570|NCT00837226||Control group: No bariatric procedures|
33243571|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
33243572|NCT00844870|Active Comparator|1|stabilization training group
32912597|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
32912598|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
32912599|NCT01484288|Experimental|Device group|Barostim Neo system
32912600|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
32912601|NCT01860287|Experimental|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
32912602|NCT01860287|Experimental|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
32912603|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
32912604|NCT01421498|Placebo Comparator|Placebo|Placebo
33243573|NCT00844870|Experimental|2|auditory response training group
33243574|NCT00716612|Placebo Comparator|2|PO Placebo QD
33243575|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
33243576|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
33243577|NCT00842920|Experimental|Simvastatin 60 mg|Simvastatin 60 mg once daily
33243578|NCT00842920|Experimental|Simvastatin 20 mg|Simvastatin 20 mg once daily
33243579|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
33243580|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
33243581|NCT00716690|Experimental|treatment|
33243582|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
33243583|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
33243584|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
33243585|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
33243586|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
33243587|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
33243588|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
33243589|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
33243590|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
33243591|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
33399369|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
33399370|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
33243592|NCT00716846|Active Comparator|statin-1|simvastatin
32737302|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
32737303|NCT03095157|Placebo Comparator|Placebo|
33243593|NCT00716846|Active Comparator|statin-2|atorvastatin
33243594|NCT00716846|Active Comparator|statin-3|pitavastatin
32912605|NCT04701723|Experimental|Cardiac Coherence Training|"The cardiac coherence training will consist in the realization during 3 months by the patient, at home :~of 6 respiratory cycles by minute (inspiration : 4,5 seconds/expiration : 5,5 seconds),~during 5 minutes,~3 times a day (morning, late morning and late afternoon)"
33399371|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
32912608|NCT04677621|Experimental|Nurse Telehealth Intervention|Allocated to tele-intervention
32912609|NCT04677621|Active Comparator|Standard Deep Brain Stimulation (DBS)|Allocated to conventional approach
32912610|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
32912611|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
32912612|NCT05446311||DS group|Subjects going to receive dinalbuphine sebacate for post-cesarean section pain.
32912613|NCT04739085||Defocus curve group|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to the distances of 30 cm, 40 cm, 60 cm, and 80 cm, respectively.
32912614|NCT04739085||wDDART group|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
32912615|NCT01422200|Experimental|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
32912616|NCT01422200|Active Comparator|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
32912617|NCT05445765|Experimental|anti-CD33 CAR T cells|Dose escalation phase: anti-CD33 CAR T cells will be transduced with a lentiviral vector to express anti-CD33 CARs
32912618|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
33243595|NCT00797979|Experimental|1|Skull Grip bone fixation
32912619|NCT01860521|Active Comparator|Continuous Epidural Infusion|
32912620|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
32912621|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules with breakfast, 4 capsules with lunch and 4 capsules with dinner)
32912622|NCT05445687|Experimental|Hearing Impairment cases|"Hearing impaired children who will receive the proposed narrative intervention program.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months."
32912623|NCT05445687|Active Comparator|Hearing Impairment control|The Hearing impairment control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
33243596|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
33243597|NCT00620854|Experimental|rsCTA|Oral Tablet
33243598|NCT00620854|Experimental|rsCTB|Oral Tablet
33243599|NCT00620854|Active Comparator|Fortical|Nasal Spray
33243600|NCT05672966|Experimental|1-BV601DP(Low dose HPV vaccine with adjuvant)|Subjects received low dose of BV601DP
32912624|NCT05445687|Experimental|Developmental language disorder cases|Developmental language disorder children who will receive the proposed narrative intervention program. The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months.
32912625|NCT05445687|Active Comparator|Developmental language disorder control|The developmental language disorder control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
32912626|NCT04566861|Experimental|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
32912627|NCT04566861|No Intervention|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
32912628|NCT04566861|No Intervention|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
33243601|NCT05672966|Experimental|1-BV601DPP(Low dose HPV vaccine without adjuvant)|Subjects received low dose of BV601DPP
32737304|NCT03095157|Experimental|Treatment|
32737305|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
33243602|NCT05672966|Placebo Comparator|1-Placebo|Subjects received placebo
33243603|NCT05672966|Experimental|2-BV601DP(High dose HPV vaccine with adjuvant)|Subjects received high dose of BV601DP
33243604|NCT05672966|Experimental|2-BV601DPP(High dose HPV vaccine without adjuvant)|Subjects received high dose of BV601DPP
33243605|NCT05672966|Placebo Comparator|2-Placebo|Subjects received placebo
33243606|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
33243607|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
33243608|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
32737306|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
32912629|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
32912630|NCT00367653|Experimental|1|
32912631|NCT00367653|Experimental|2|
32912632|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
33399372|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
33243609|NCT00798057||Proton Radiation|
32912633|NCT05445531|Active Comparator|Control|Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
32912634|NCT05445531|Active Comparator|Recovered|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
32912635|NCT05445531|Experimental|Long Covid|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
32912636|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
32912637|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
32912638|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
32912639|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
32912640|NCT05445453|Experimental|Intervention|"Physicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research.~If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study.~After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit."
32912641|NCT05445297|Other|Amiodarone group|
32912642|NCT05445297|Other|Refralon group|
32912643|NCT01539980|Experimental|Sericin scaffold|
32912644|NCT05445063|Experimental|Participants receiving intervention|Participants will receive autologous transplantation of induced pluripotent stem cell-derived retinal pigment epitheliums.
32912645|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
32912646|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
32912647|NCT05437029|Experimental|Q-Griffithsin Group 1: 3.0 mg daily spray|In Group 1, up to 12 participants will receive a dose of 3.0 mg intranasal Q-GRFT administered once daily, as 2 sprays (100 µL/ spray) in each nostril, for 7 days.
32737307|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
32912648|NCT05437029|Experimental|Q-Griffithsin Group 2: two 3.0 mg sprays per day|In Group 2, up to 12 participants will be enrolled to receive a total of 6.0 mg intranasal Q-GRFT administered as 3.0 mg twice daily (3.0 mg BID), with 2 sprays (100 µL/ spray) in each nostril approximately every 12 hours, for 7 days.
32912649|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
32912650|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
32737308|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
32912651|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
32912652|NCT05434065|Experimental|Celebrex treatment arm|Celecoxib 200 mg/dose, started within 6 h after onset, then one dose per day for 21 days.
32912653|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
32912654|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
32912655|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
33243610|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
33243611|NCT04043182|No Intervention|group control|You will not receive any type of intervention
33243612|NCT04043182|Experimental|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
32737309|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
33243613|NCT04043182|Placebo Comparator|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
33243614|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
33243615|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
33243616|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
33243617|NCT04797585|Active Comparator|Laparoscopic supracervical hysterectomy|Minimally invasive procedure to remove a woman's uterus
33243618|NCT04797585|Experimental|Vaginal hysterectomy|Surgical procedure to remove the uterus
33243619|NCT04043260|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
33243620|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
33243621|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
33243622|NCT04766229|Experimental|Single Arm|All participants in single arm study
33243623|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
33243624|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
33399373|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
33399374|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
33399375|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
33399376|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
33399377|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
33399378|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
33399379|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
33399380|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
33399381|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
33399382|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
32737310|NCT04135677|Active Comparator|DAPT group|asprin 100mg qd together clopidogrel 75mg for 24 weeks
33399383|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
33399384|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
33399385|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
33399386|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
33399387|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
33399388|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
33399389|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
33399390|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
33399391|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
33399392|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
33399393|NCT04480606|Experimental|Home exercise group|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group.
33399394|NCT04480606|No Intervention|Control Group|The control group will be asked to remain isolated as they are and the exercise program will not be implemented.
33399395|NCT05408923|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
33399396|NCT05408923|Active Comparator|Irrisept|Patients in this group will be given the study drug (Irrisept).
33399397|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
32737311|NCT04135677|Experimental|Anticoagulation group|rivaroxaban 20mg qd for for 12 weeks and continued DAPT(asprin 100mg qd together clopidogrel 75mg) for 24 weeks
32737312|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
32737313|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
32737314|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
32737315|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
32737316|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
32737317|NCT05033925|Placebo Comparator|Placebo|receive a plasebo capsule 2 doses per day
32737318|NCT05033925|Experimental|FADA 800 mg/day|receive FADA capsules twice a day (each 400 mg)
32737319|NCT05033925|Experimental|FADA 2000 mg/day|receive FADA capsules twice a day (each 1000 mg)
32737320|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
32737321|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
32737322|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
32737323|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
32737324|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
32737325|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
32737326|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
32737327|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
32737328|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
32737329|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
32737330|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
32737331|NCT05033457||unilateral biportal endoscopy technique group|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group
32737332|NCT05033457||percutaneous endoscopic transforaminal discectomy group|Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group
32737333|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
32737334|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
32737335|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
33399398|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
33399399|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
33399400|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
33399401|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
33399402|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
32737336|NCT05033535|Experimental|S086|
32737337|NCT05033535|Placebo Comparator|Olmesartan medoxomil|S086 PLCEBO
32737338|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
32737339|NCT04434495|Experimental|PRP group|mock embryo transfer and PRP injection
32737340|NCT04434495|No Intervention|control group|only mock embryo transfer
32737341|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
32737342|NCT03339011|No Intervention|No intervention|No attention from the study
32737343|NCT05053893|Experimental|New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)|Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.
32737344|NCT05053893|Experimental|Traditional treatment group(EPO combined with ACEI or ARB )|Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.
32737345|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
32737346|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
32737347|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
32737348|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
32737349|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
32737350|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
32737351|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
32737352|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
32737353|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
32737354|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
32737355|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
32912656|NCT05662319|Experimental|All participants|"In standard of care (SOC) period, participants will receive on-demand or prophylactic treatment with clotting factor concentrates (CFCs) or bypassing agents (BPAs) for 6 months (from Day -168 to Day -1). In fitusiran treatment period, participants will receive subcutaneous fitusiran prophylaxis once every other month (Q2M) or once monthly (QM) for 36 months (from Day 1 to Day 1009). In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive Antithrombin concentrate (ATIIIC) as rescue medicine.~."
32912657|NCT05444907||DBS-induced Mania Cohort|Patients diagnosed with Parkinson's Disease (PD) who were submitted to deep brain stimulation (DBS) surgery irrespective of its target and who developed a manic episode or mixed affective state diagnosed after surgery and associated to DBS modulation, i.e., after switching on the device or changing modulation parameters.
32912658|NCT05444907||DBS Control Cohort|Patients diagnosed with PD who were submitted to DBS surgery irrespective of its target and who did not develop DBS-induced mania.
32912659|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
32912660|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
32912661|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
32912662|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
32912663|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
32912664|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
32912665|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
32912666|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
32912667|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
32912668|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
32912669|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
32912670|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
32912671|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
33399403|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
33399404|NCT03621007||POMC deficiency obesity|
33399405|NCT03621007||LEPR deficiency obesity|
32912672|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
33399406|NCT03621007||PCSK1 deficiency obesity|
32912673|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
32912674|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
32912675|NCT05442411|Experimental|post operative pain score|post operative pain score at 1hour, 2 hour, 4 hour, 6 hour, and 12 hour
32912676|NCT05442411|Experimental|morphine requirement|post operative PCA morphine requirement
32912677|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
32912678|NCT05444829|Experimental|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
32912679|NCT05444829|Other|classical reduction and fixation|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
32912680|NCT05654363||Intrathecal morphine|Adult women American Society of Anaesthesiologists (ASA) physical status <= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who consented to the execution of a preoperative spinal analgesia with intrathecal morphine (as part of our standard practice) and who did not present any contraindications to lumbar puncture.
32912681|NCT05654363||Intravenous morphine|Adult women American Society of Anaesthesiologists (ASA) physical status <= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who did not consent to the execution of a preoperative spinal analgesia or presented contraindications to lumbar puncture (coagulopathy or incorrect discontinuation of anticoagulant drugs, increased intracranial pressure, infection at the site of injection, major spinal deformities).
32912682|NCT05652725|Placebo Comparator|Placebo Control 1|Clarity Product Form 1 - control
32912683|NCT05652725|Placebo Comparator|Placebo Control 2|Clarity Product Form 2 - control
32912684|NCT05652725|Placebo Comparator|Placebo Control 3|Clarity Product Form 3 - control
32912685|NCT05652725|Placebo Comparator|Placebo Control 4|Clarity Product Form 4 - control
32912686|NCT05652725|Experimental|Active Product 1.1|Clarity Product Form 1 - active product 1
32912687|NCT05652725|Experimental|Active Product 2.1|Clarity Product Form 2 - active product 1
32912688|NCT05652725|Experimental|Active Product 3.1|Clarity Product Form 3 - active product 1
32912689|NCT05652725|Experimental|Active Product 4.1|Clarity Product Form 4 - active product 1
32912690|NCT05652725|Experimental|Active Product 4.2|Clarity Product Form 4 - active product 2
32912691|NCT05652725|Experimental|Active Product 4.3|Clarity Product Form 4 - active product 3
32912692|NCT01423760|Experimental|Tecemotide (L-BLP25)|
33399407|NCT04889950|Experimental|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
32912693|NCT01423760|Other|Observational|
32912694|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
32912695|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
32912696|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
32763444|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
32763445|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
32763446|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
32763447|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
32763448|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
32763449|NCT05199545|Experimental|Dietary supplement group|2 tablets / day for 6 weeks of the dietary supplement (Rhodiola rosea L. and Crocus sativus L.), to be taken every day in the morning with a large glass of water, from D1 to D42.
32763450|NCT05199545|Placebo Comparator|Placebo group|2 tablets / day for 6 weeks of the placebo, to be taken every day in the morning with a large glass of water, from D1 to D42.
32763451|NCT05737225||Popliteal sciatic nerve block group|regional anesthesia applied patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
32763452|NCT05737225||Control group|patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
32763453|NCT05188313|Active Comparator|Chemoradiation according to the CROSS regimen|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy."
32763454|NCT05188313|Experimental|Chemoradiation according to the CROSS regimen combined with trastuzumab and pertuzumab|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.~Pertuzumab will be administered intravenously first, on Day 1, 22, 43, 64, and 85 using a fixed dose of 840 mg.~Trastuzumab will be administered intravenously on Day 1 of each treatment cycle, using an initial dose of 4 mg/kg on day 1, followed by doses of 2 mg/kg weekly up to week 6. From week 7 onwards trastuzumab will be administered at a dose of 6 mg/kg, every three weeks."
32763455|NCT04540315|Experimental|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
32763456|NCT04540315|No Intervention|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will receive reported outcome survey by email.
32763457|NCT05551793|Experimental|Dupilumab|Dupilumab: weekly 300mg SC injections Manufacturer: Regeneron
32763458|NCT05551793|Placebo Comparator|Placebo|Placebo: weekly SC injections of equivalent volume Manufacturer: Regeneron
32763459|NCT05737069|Experimental|Ibuprofen arginine granules 400 mg|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
32763460|NCT05737069|Active Comparator|Ibuprofen arginine granules 400 mg (Spedifen)|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
32763461|NCT03065777|Experimental|ONE ENDO|Single file rotary system
32763462|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
32763463|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
32763464|NCT04310137|Experimental|Therapist-Directed Re-loading|Participants in this arm will be instructed to increase their activity by walking 10% more steps per day than the steps recorded in the most recent activity monitoring (i.e. StepWatch) measurement (e.g. 10% more than the initial monitoring values and 10% more than the second monitoring values once they are completed).
32763465|NCT04310137|No Intervention|Self-Directed Re-loading|Participants in this arm will be instructed to slowly increase their walking.
32763466|NCT05172557|Experimental|Healthy Living Program|In addition to usual clinical Inflammatory Bowel Disease medical care, subjects will participate in a Wellness Program.
32763467|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
32763468|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
32763469|NCT05542277|Experimental|ClearPlasma|Investigational Group (A): one-time infusion (up to 12 hours after surgery) of unlimited plasminogen depleted plasma PDP units generated by ClearPlasma™ device.
32763470|NCT05542277|Placebo Comparator|Control|Control Group (B): one-time infusion (up to 12 hours) of unlimited regular plasma, Fresh frozen plasma (FFP) with mock ClearPlasma™ device.
32763471|NCT03188731||Pregnant Women|
32763472|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
32763473|NCT03066011||Voriconazole Group|Oral and Intravenous
32763474|NCT03066011||Posaconazole Group|Oral and Intravenous
32763475|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
32763476|NCT03781297|Active Comparator|Intervention: NET+G|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks plus the option to receive genealogical services.
32763477|NCT03781297|Active Comparator|Intervention: NET|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks.
33399408|NCT04889950|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
33399409|NCT04881760|Experimental|LY3437943 Dose 1|LY3437943 administered subcutaneously (SC)
33399410|NCT04881760|Experimental|LY3437943 Dose 2|LY3437943 administered SC
32737356|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
33399411|NCT04881760|Experimental|LY3437943 Dose 3|LY3437943 administered SC
33399412|NCT04881760|Experimental|LY3437943 Dose 4|LY3437943 administered SC
33399413|NCT04881760|Placebo Comparator|Placebo|Placebo administered SC
32912697|NCT05444751|Experimental|SA + ESP Block|Spinal Anesthesia: Patients will be provided with iv sedation, if desired, to facilitate placement of spinal anesthetic. Midazolam (2-5mg, iv), ketamine (up to 20 mg, lv) and/or propofol (0.1-0.2 mg/kg) will be permitted.
32912698|NCT05444751|Active Comparator|GA + ESP Block|General anesthesia: induction of general anesthesia to facilitate endotracheal intubation: fentanyl (up to 2μg.kg.min-1), propofol (1-2 mg.kg-1), vecuronium (1-2 mg.kg-1).
32912699|NCT01485770|Experimental|Placebo, Then ADX-N05|Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
32912700|NCT01485770|Placebo Comparator|ADX-N05, Then Placebo|Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).
32912701|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
32912702|NCT05444673|Experimental|Paprizumab combined with cisplatin and 5-FU|Patients received four cycles of paprizumab (200mg iv, 21-day cycle) in combination with 5-fu (500mg/m2 iv) plus cisplatin (80mg/m2 iv, 21-day cycle). Reassessment after completion of neoadjuvant chemotherapy was performed in operable patients.
32912703|NCT05444439|Other|One group of naive H.Pylori infection will submitted for upper endoscopy.|"Upper endoscopy will be done under complete septic condition and multiple gastric biopsies from corpus and antrum will be taken for :~Histopathological examination.~Culture and sensitivity of endoscopic biopsies.~detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent Helicobacter Pylori genotypes by polymerase chain reaction amplification(PCR).~Then start empirical antibiotics regimens."
32912704|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
33399414|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
33399415|NCT03093870|Experimental|Varlitinib and Capecitabine|
32912705|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
32912706|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
32912707|NCT04738929|Experimental|Normal weight|Normal weight subjects (BMI=18.5-25)
33399416|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
33399417|NCT02394184||patients with bicuspid aortic valve stenosis|
33399418|NCT05744908|Active Comparator|With Hunner's ulcer|Pentosan Polysulfate 100 mg
33399419|NCT05744908|Active Comparator|Without Hunner's ulcer|Pentosan Polysulfate 100 mg
32912708|NCT04738929|Experimental|Obese|Obese subjects (BMI=30-34.99)
33243625|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
33243626|NCT04068506|Experimental|Group A|Gabapentin 600 mg Tab
33243627|NCT04068506|Active Comparator|Group B|Paracetamol 1000 mg Tab
33243628|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
33243629|NCT00851188|Experimental|CBT self-help booklet|
33243630|NCT00851188|Active Comparator|Waiting list|
33243631|NCT04068740||Mitral valve disease|
33243632|NCT04068740||Aortic valve disease|
33243633|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
33243634|NCT00843154|Experimental|Candesartan QD|
33243635|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
33243636|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
33243637|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
33243638|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
33243639|NCT00803985|Active Comparator|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
33243640|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33243641|NCT00851266|Experimental|1|V512
33243642|NCT00851266|Placebo Comparator|2|Placebo to V512
33243643|NCT04067570|Experimental|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed~/ - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes~/ - 6-24 months of androgen deprivation therapy (ADT)"
32737357|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
33243644|NCT00806871|Active Comparator|A|
32737358|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
32763478|NCT05728463|Experimental|Single-incision laparoscopic cholecystectomy|SILC was defined as laparoscopic surgery done through a single trans-umbilical incision
32763479|NCT05728463|Active Comparator|Conventional laparoscopic cholecystectomy|CLC was defined as three or four port surgery carried out with either French or American position.
32763480|NCT05527457|Placebo Comparator|Placebo|Placebo (saline) nasal spray, taken before bedtime. Dosage is taken on one instance for one night only.
32763481|NCT05527457|Experimental|BAY2586116 (oro-nasal breathing night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the oro-nasal breathing night.
32763482|NCT05527457|Experimental|BAY2586116 (nasal breathing only night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the nasal only breathing night.
32763483|NCT05520749||Luspatercept treated patients|Adult patients (i.e. aged >=18 years) with diagnosis of MDS according to WHO 2016 classification that met IPSS-R criteria for very low, low, or intermediate-risk MDS treated with Luspatercept
32763484|NCT05092243|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
32763485|NCT05092243|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
32763486|NCT05728385|Experimental|Modified SPD as adjunct to asthma medications in children|Explore if the modified specific carbohydrate diet has an effect on asthma control in children and if it will affect the frequency, severity, and duration of asthma and thus provide it as a potential complementary treatment option for them.
32763487|NCT05728385|No Intervention|Usual asthma medications only in children with moderate asthma|Assess control based on the usual asthma medications only
32763488|NCT03609697|Experimental|Community-based lifestyle intervention|Participants will attend 7 community-based group intervention sessions plus 2 individual face-to-face dietician consultation sessions during the first 6 months, followed by a 6-month maintenance phase which they will receive monthly phone support from the research team.
32763489|NCT03609697|Other|Minimal intervention (SMS intervention)|Participants will receive one SMS per month during the first 6 months, followed by a 6-month maintenance phase which participants will receive one SMS every 2 months.
32763490|NCT04943861|Active Comparator|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
32763491|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
32763492|NCT03073525|Other|Part 1: Vigil + Atezo|Part 1 is a safety run-in cohort. Vigil immunotherapy will be administered at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. The initial dose is to be administered over one hour and if well tolerated, subsequent infusions may be administered over 30 minutes. Vigil should be administered first, followed 30 minutes later by atezolizumab.
32763493|NCT03073525|Experimental|Part 2: Vigil then Vigil + Atezo|"Part 2 is a randomized, open label intra-patient crossover study of Vigil, the checkpoint inhibitor Atezolizumab and the combination of the two agents.~Vigil immunotherapy will be administered at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses for 2 cycles (1 cycle = 21 days)."
32763494|NCT03073525|Active Comparator|Part 2: Atezo then Vigil + Atezo|"Part 2 is a randomized, open label intra-patient crossover study of Vigil, the checkpoint inhibitor Atezolizumab and the combination of the two agents~Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks for 2 cycles (1 cycle = 21 days). The initial dose is to be administered over one hour and if well tolerated, subsequent infusions may be administered over 30 minutes."
32763495|NCT03073525|Other|Part 3: Atezo Only|Part 3 is an expansion cohort. Once all Vigil doses have been exhausted, patients whose disease is stable or responding may continue Atezolizumab, only if pre-approved by Sponsor. Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks until disease progression.
32763496|NCT05728307||Intervention Group|The intervention group consists of patients admitted to the 4 neonatal subunits where neoGuard was installed: the preterm units (category A and category B), and the high dependence units (HDU-1 and HDU-2).
32763497|NCT05728307||Comparison Group|The comparison group consists patients admitted 4 subunits where neoGuard was not installed: the neonatal intensive care unit (NICU), the KMC/category C room, the isolation room and the stable full-term room. These subunits will receive the standard-of-care/current practice, which consists of either a bedside cardiac monitor or intermittent monitoring every 3 hours using manual equipment such as hand-held pulse oximeters for pulse rate and oxygen saturation, digital axillary thermometers for temperature, and manual counting of breaths for respiratory rate.
32763498|NCT05517863|Experimental|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
32763499|NCT05517863|Experimental|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
32763500|NCT05517863|Active Comparator|traditional wound care|"(II) Traditional wound care inform of~Wound care treatment~Debridement to remove necrotic tissue~Irrigation of the wound by normal saline~Change dressing daily to protect wound from infection~Foot care~Wash feet daily, dry carefully especially between toe~Avoid extreme temperatures~Inspection daily of foot blisters~Foot wear~Avoid walking bare foot~Properly fitted shoes~Avoid wearing open-toed shoes"
32763501|NCT02563015|Experimental|Cholecalciferol 400|400 IU orally per day
32763502|NCT02563015|Experimental|Cholecalciferol 1000|1000 IU orally per day
32763503|NCT02563015|Active Comparator|Reference 400|400 IU orally per day
32763504|NCT05510687|Experimental|Glasses to correct presbyopia and digital financial training|The intervention is the provision of glasses to correct presbyopia plus digital financial training to use bKash, a popular mobile banking application that is becoming the preferred mode of transferring payments to the bank accounts of OAA and WA beneficiaries in Bangladesh.
32763505|NCT05510687|No Intervention|Control-No treatment|"Mobile phone with preloaded bank transaction tracking app: Participants will be provided a basic mobile phone handset. The bank transaction tracking application that is being developed to measure the primary outcomes for this trial will be installed on these phones before giving them to the participants. A mobile data pack will also be remotely loaded on the mobile phone to facilitate internet access for mobile banking.~Eyeglasses: These participants will receive a free pair of eyeglasses at the conclusion of the study to correct refractive errors, unless they have obtained such glasses on their own during the study."
32763506|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
32763507|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
32763508|NCT05094973|Experimental|Canine and molar distalization and molar derotation|Evaluating the canine and molar distalization and molar derotation in dental Class II patients who where submitted to Carriere Motion Appliance® for a mean of 4 months.
32763509|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
32763510|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
32763511|NCT05736835|Experimental|CVXGA1|CVXGA1 single intranasal dose 10e7 PFU
32763512|NCT05736835|Placebo Comparator|Placebo|0.9% sterile saline
32763513|NCT05487911|Experimental|rTMS|20 sessions of rTMS
32763514|NCT05736757|No Intervention|Control group|Control group (no tissue fibrinogen activator)
32763515|NCT05736757|Experimental|Drug group|Drug group (injection of 50 ug tissue fibrinogen activator into the suprachoroidal cavity or subretinal space )
32912709|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
32912710|NCT04338633|Active Comparator|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
32912711|NCT04338633|Experimental|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
32763516|NCT04483817|Experimental|A: Transcutaneous tibial nerve stimulation|The transcutaneous electrostimulation of the posterior tibial nerve (ETNTP) will be applied to group A: place two surface electrodes, one 32 mm in diameter, 5 cm cephalad of the internal malleolus and 1 cm medial posterior of the tibia; and another 50x50 mm electrode in the calcaneous. The flexion of the first toe will indicate the correct placement of the electrodes. Stimulation is performed according to the Stoller method with a stimulator programmed at 20Hz and 200 µs, with a continuous current, 12 sessions, 2 weekly are completed. The intensity of the current will be tolerance by the subject.
32912712|NCT04338633|Experimental|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
32912713|NCT01866839|Experimental|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
32912714|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
32912715|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
32912716|NCT00368511|No Intervention|1|Listening to music and posture changes
32912717|NCT03283085|Experimental|25 mg Ontamalimab|Participants will be receiving 25 milligram (mg) of ontamalimab solution for injection subcutaneously (SC) every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
32912718|NCT03283085|Experimental|75 mg Ontamalimab|Participants will be receiving 75 mg of ontamalimab solution for injection SC every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
32912719|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
32912720|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
32912721|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
32912722|NCT05444205|Experimental|Higher resources/lower challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they did not posses any measured risk factors. Participants are provided with a choice of the following preventive interventions: Text4Baby/Bright by Text (depending on child age), Nurture Program, and/or Family Centers.
33243645|NCT00806871|Active Comparator|B|
33243646|NCT00806871|Placebo Comparator|C|
33243647|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
33243648|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
33243649|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
33243650|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
33243651|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
33243652|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
33243653|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
33243654|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
33243655|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
33243656|NCT04069208|Experimental|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
33243657|NCT04042246|No Intervention|Control|No intervention is implemented among Control
33243658|NCT04042246|Experimental|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
33243659|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
33243660|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
33243661|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
33243662|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
33243663|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
33243664|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
33243665|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
33243666|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
33243667|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
33243668|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
33243669|NCT00845104|Experimental|Arm I|See Detailed Description
33243670|NCT00804063||1|glaucoma patients
33243671|NCT00804063||2|non-glaucoma controls
32912723|NCT05444205|Experimental|Lower Resources/Lower Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they were low-income, a teen parent, their newborn had health challenges (more than five weeks premature or a neonatal intensive care unit stay of longer than 4 weeks, or they reported mild parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
32912724|NCT05444205|Experimental|Moderate Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a history of mental health problems, low social support, or moderate parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
32912725|NCT05444205|Experimental|Serious Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a histories of involvement with child welfare, incarceration, opioid use disorder, recent homelessness, or that their child is displaying serious behavior problems. Participants are provided with a choice of the following preventive interventions: Smart Beginnings, Family Check-Up or if the child was less than two weeks old, Healthy Families America.
32912726|NCT05413395|Experimental|Protocol|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO) applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
32912727|NCT05413395|Active Comparator|Control|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation amended with deionized water to match the colloidal oatmeal concentration of the Protocol arm applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
32912728|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
32912729|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
32912730|NCT05406609||General|Shoulder surgery under general anesthesia
32912731|NCT05406609||Regional|Shoulder surgery under regional anesthesia
32912732|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
32912733|NCT04738851|Experimental|healthy volunteers|Virtual mirror therapy task : TMV Classic mirror therapy task : TMC Control task :TC
32912734|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
32912735|NCT01542398|No Intervention|Waiting List Control|
32912736|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
32912737|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
33243672|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
33399420|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~Who provides: registered nurse~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline~Tailoring: 1500 mg/1.73m2~How well: expert nurse would assist administration"
33399421|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
33399422|NCT01568346|Active Comparator|MRI|MRI
33399423|NCT01568346|No Intervention|No MRI|No MRI
33399424|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
33399425|NCT02393872|Experimental|All-families component|School-based intervention.
32906572|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
32912738|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
32912739|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
32912740|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
32912741|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
33243673|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
33243674|NCT01034605|Experimental|inulin|oligofructose
33243675|NCT03994939|Experimental|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
32912742|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year period. Electronic devices to trace activity.
32912743|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
32912744|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
32912745|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
33243676|NCT03994939|No Intervention|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
33243677|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
33243678|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
33243679|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
33399426|NCT02393872|No Intervention|Control|Control group.
33399427|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
33399428|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
33399429|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
33399430|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
33399431|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
33399432|NCT04530552|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO on study. Patients also undergo collection of blood samples throughout the study.
33399433|NCT05744830|Experimental|Overdenture|Each patient in this group will receive a single implant overdenture.
33399434|NCT05744830|Experimental|Complete Denture|Each patient in this group will receive a removable complete denture without implants.
33399435|NCT04793646|Active Comparator|N-acetylcysteine syrup|Thirty pSS patients
33399436|NCT04793646|Placebo Comparator|Placebo syrup|Thirty pSS patients
33399437|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
33399438|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
33399439|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
33399440|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
33399441|NCT05336214|Experimental|Refer|Practice referral of patients to a virtual CGM initiation service
33399442|NCT05336214|Experimental|Learn|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care
33399443|NCT05336214|Experimental|Learn + Practice Facilitation|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care plus practice facilitation
33399444|NCT05232292|Active Comparator|Vaccinated|vaccinated ACS & CHF patients over 65 years
33399445|NCT05232292|No Intervention|Not vaccinated|not vaccinated ACS & CHF patients over 65 years
33399446|NCT03607890|Experimental|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
33399447|NCT03607890|Experimental|Cohort 2: Nivolumab and Relatlimab|480mg/960mg or 480mg/160mg (sequential administration)
33399448|NCT03607890|Experimental|Cohort 3: Nivolumab and Relatlimab|480mg/480mg (sequential administration)
33399449|NCT02393638|Experimental|study group|Simulation and lecture
33399450|NCT02393638|Active Comparator|control group|Lecture only
33399451|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
33399452|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
33399453|NCT03596736|Experimental|Elbow Hemiarthroplasty|
33399454|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
33399455|NCT05744752|Other|Group A|Control; Placebo 1ml NaCl 0.9% daily for 12 weeks
32912746|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
32912747|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
32912748|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
32912749|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
32912750|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
32912751|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
32912752|NCT03003299|Experimental|TAVR - Failing surgical or transcatheter valve|Patients with a failing surgical or transcatheter bioprosthetic valve will undergo transcatheter aortic valve replacement (TAVR).
32912753|NCT03000257|Experimental|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
32912754|NCT03000257|Experimental|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
32912755|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
32912756|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
32912757|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
32912758|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
32912759|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
32912760|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
32912761|NCT05443893||Normal subjects|Gait analysis with artificial intelligence and traditional methods
32912762|NCT05443893||Subjects with abnormal gait|Gait analysis with artificial intelligence and traditional methods
32912763|NCT05443581|Experimental|Intervention group|"Participations in this group are required to follow a healthy vegetarian diet （avoid meat, poultry, fish, dairy） during the 24-weeks trail.~Daily energy intake = BMR(basal metabolic rate) × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
32912764|NCT05443581|Active Comparator|Control group|"Participations in this group are required to follow a healthy omnivorous diet (No restriction on food sources) during the 24-weeks trail.~Daily energy intake = BMR × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
32912765|NCT02891447|Experimental|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
32912766|NCT05443503|Other|Intervention|"Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH).~Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track."
32912767|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
32912768|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
32912769|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
32912770|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
32912771|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
32912772|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
32912773|NCT05392413||reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
32912774|NCT05392413||non-reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
32912775|NCT05391711|Experimental|Culturally Smart Relationships|The mentors assigned to this group will receive additional trainings and support related to Justice, Equity, Diversity and Inclusion (JEDI).
32912776|NCT05391711|No Intervention|Control Group|The mentors assigned to this group will NOT receive an intervention. They will receive the regular training activities that the agency provides.
32912777|NCT05443269|Experimental|Jump Start Program|The intervention consists of following the Jump Start plan for 7 days
33243680|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
32912778|NCT05443113||Children (<11 years) with pectus excavatum|All pediatric PE patients aged younger than 11 years upon first visit of our outpatient clinic
32912779|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
32912780|NCT05442801|Active Comparator|Cyclopentolate arm|"To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled.~Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes."
32912781|NCT05442801|Active Comparator|Tropicamide arm|"To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes."
33243681|NCT00762762|Active Comparator|Total toothpaste|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste.
33243682|NCT00762762|Placebo Comparator|Fluoride mouthrinse|Swish whole mouth 2x/day for 12 months with fluoride mouthrinse.
33243683|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
33243684|NCT00578864|Experimental|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
33243685|NCT00578864|Active Comparator|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
33243686|NCT01034683|Experimental|Esophageal Carcinoma|
32912782|NCT05442723|Other|Case|Patients with extensive LAD disease treated with off-pump CABG
32912783|NCT05442723|Other|Control|Patients with extensive LAD disease treated with on-pump CABG
32912784|NCT05442333|Active Comparator|preoperative radiotherapy|The patients which will receive preoperative radiotherapy
32912785|NCT05442333|Active Comparator|postoperative radiotherapy|The patients which will receive postoperative radiotherapy
33243687|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
33399456|NCT05744752|Active Comparator|Group B|Pb Group; Lead acetate 19.5mg/kg b.w daily for 12 weeks
32912786|NCT04739631|Experimental|acupuncture group|The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
32912787|NCT04739631|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
32912788|NCT04739631|No Intervention|waitlist-control group|As an waitlist-control group, no acupuncture will be performed.
32912789|NCT05339373|Other|Sequence TR|18 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32912790|NCT05339373|Other|Sequence RT|18 subjects assigned to the sequence RT will receive a single 100 mg dose of the test product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of thetest product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33243688|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
33243689|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
33243690|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
33243691|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
33243692|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
32912791|NCT05331729|Experimental|Patients with idiopathic pulmonary fibrosis|
32912792|NCT05331729|Active Comparator|Healthy volunteers|
32912793|NCT05439993|Experimental|Tepotinib plus paclitaxel arm|
32912794|NCT04739553|Experimental|His Pacing|Implant of a supplementary His pacing lead in addition to a traditional RV pacing lead.
32912795|NCT05439135|Experimental|midgut|A soft TET tube is inserted into the colon via the paraffin-lubricated gastroscope channel. If patients cannot tolerate endoscopy or anesthesia, or it is difficult to confirm the bypass intestine under endoscopy, a nasojejunal tube will be inserted under digital fluoroscopy.
32912796|NCT05439135|Experimental|colonic|A soft TET tube is inserted into the colon via the paraffin-lubricated colonoscope channel.
32912797|NCT05300997||Haemorrhagic Stroke [N=100]|Haemorrhagic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
32912798|NCT05300997||Acute Ischaemic Stroke [N=300]|Acute Ischaemic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
33243693|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
33243694|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
33243695|NCT00631566|Experimental|1|
33243696|NCT00631566|Placebo Comparator|2|
33243697|NCT00631566|No Intervention|No MRSA colonization|
33243698|NCT04067414|Experimental|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
33243699|NCT00717548|Experimental|A|
33243700|NCT00722852|Experimental|1|
33243701|NCT00722852|Placebo Comparator|2|
33243702|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
33243703|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
33243704|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
33243705|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
33243706|NCT04071600|Placebo Comparator|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
33243707|NCT04071600|Active Comparator|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
33243708|NCT04071600|No Intervention|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
33243709|NCT05657444|Experimental|TNK group|
33243710|NCT05657444|No Intervention|control group|
33243711|NCT04072302|Experimental|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
33243712|NCT04072302|Placebo Comparator|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
33243713|NCT04072302|Experimental|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243714|NCT04072302|Placebo Comparator|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243715|NCT04072302|Experimental|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243716|NCT04072302|Placebo Comparator|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243717|NCT04072302|Experimental|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243718|NCT04072302|Placebo Comparator|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243719|NCT04072302|Experimental|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243720|NCT04072302|Placebo Comparator|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243721|NCT04072302|Experimental|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243722|NCT04072302|Placebo Comparator|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
33243723|NCT04103411|Experimental|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
33243724|NCT04103411|Active Comparator|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
33243725|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
33243726|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
33243727|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
33243728|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
33243729|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
33243730|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
32912799|NCT05300997||Stroke of uncertain origin [N=45]|Stroke of uncertain origin subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
32912800|NCT05300997||Transient Ischemic Attack (TIA) [N=75]|TIA subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
32912801|NCT05300997||Stroke Mimics [N=30]|Stroke Mimics subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
32912802|NCT05300997||Control Subjects [N=100]|Control group subjects, if they agree, will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital on day 1; b) 18 hours +/- 6 hours after sample 1 (if available); and c) 30 hours+/- 6 hours after sample 1 (if available).
32912803|NCT05438355||The infertility women with PCOS|Infertile women undergoing assisted reproduction were consecutively recruited at Ji Ai G-IVF institute from March 2021 to December 2021. Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved . Patients were divided in PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
32912804|NCT05438355||The infertility women without PCOS|Infertility women with fallopian tubal factor infertility and with normal menstrual cycles were undergoing IVF/ICSI cycles at Shanghai Ji Ai G-IVF institute from March 2021 to December 2021.Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved.
32912805|NCT05295225|Active Comparator|Green Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a green light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
32912806|NCT05295225|Placebo Comparator|White Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a white light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
32912807|NCT04133493|Placebo Comparator|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
32912808|NCT04133493|Active Comparator|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
32912809|NCT05268315|Experimental|Brief Psychoeducational Intervention|Parents of children with cancer who complete the study participate in a brief, 1-session psychoeducational intervention.
32912810|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
32912811|NCT02662023|Experimental|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
32912812|NCT02662023|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
32912813|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
32912814|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
32912815|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
33399457|NCT05744752|Experimental|Group C|Pb + Allium sativum extract; Lead acetate 19.5mg/kg b.w followed by Allium sativum(AS) extract 500 mg/kg b.w daily for 12 weeks
33399458|NCT05744752|Other|Group D|CPb + Moringa oleifera extract; Lead acetate 19.5mg/kg b.w followed by Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
33399459|NCT05744752|Active Comparator|Group E|Allium sativum extract; Allium sativum extract 500mg/kg b.w daily for 12 weeks
33399460|NCT05744752|Experimental|Group F|Moringa oleifera extract; Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
33399461|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
33399462|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
33243731|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
32763517|NCT04483817|Active Comparator|B: Percutaneous tibial nerve stimulation|The percutaneous electrostimulation of the posterior tibial nerve (EPNTP) will be applied to group B: inserting a 0.25x30mm surgical steel needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia , and a surface electrode of 50x50 mm in the calcaneous. The flexion of the first finger will indicate its correct placement. The stimulation parameters will also follow the Stoller method.
32763518|NCT05733481|Other|Patients with the presence of coronary arterial de novo or restenotic chronic total occlusion.|Successful crossing of the targeted chronic total occlusion, defined as angiography confirmed guidewire placement in the true lumen without utilization of a re-entry device.
32763519|NCT04483739|Experimental|Krd Induction|4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
33243732|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
33243733|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
33243734|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
32763520|NCT04483739|Experimental|Isa-KRd induction|"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.~Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22"
32763521|NCT04483739|Experimental|KRd post ASCT consolidation|4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
33243735|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
33243736|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
32763522|NCT04483739|Experimental|Isa-KRd post ASCT consolidation:|4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
32763523|NCT04483739|Experimental|KRd light consolidation|12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
32763524|NCT04483739|Experimental|Isa-KRd light consolidation|Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
33243737|NCT04833426|Active Comparator|Testosterone therapy|Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
33399463|NCT02393404|Experimental|FMT alone|Functional movement training group
33399464|NCT02393404|No Intervention|Control|No intervention control group
32763525|NCT05732935|Experimental|Time Restricted Eating intervention|In the time restricted eating condition, participants will be instructed to fast for a target of 16 hours per day for a 24 week period.
32763526|NCT05732935|Active Comparator|Successful Aging Comparison Group (LEARN)|In the LEARN group, participants will be educated on health related topics similar to that of the TRE intervention for 24 weeks.
32763527|NCT05728229|Experimental|Experimental Group (GS)|GS patients, in addition to the pharmacological therapy foreseen by the clinical conditions, will take 1 sachet a day of SiderAl® Med, a food for special purposes, for 28 days. GS patients will take the food for special purposes during hospitalization (between T0 and T1) and during the 1 month of returning home (between T1 and T2). During the second month of returning home (between T2 and T3), GS patients will no longer take the food for special purposes.
32763528|NCT05728229|No Intervention|Control Group (GC)|The patients of the GC, on the other hand, will continue to take the drug as required by their clinical conditions and will not take the SiderAL® Med food for special purposes, but will only be observed and evaluated at the various time-points foreseen by the study.
32763529|NCT05483855||Objective 1: Telehealth Visit|Any rheumatology patient, seen and treated by a participating physician, who is 19 years and older, with the target condition(s) of interest, and is already scheduled for a telehealth visit.
32763530|NCT05483855||Objective 2: ArthritisPower App|Patients diagnosed with Rheumatoid Arthritis who already have a pre-scheduled in-office visit.
32763531|NCT05732233|Experimental|Ultivision AI colonoscopy (CADe Arm)|Ultivision AI is used to aid in real-time detection of adenomas.
32763532|NCT05732233|Active Comparator|Standard colonoscopy (Control Arm)|Patients will undergo standard colonoscopy without AI.
32763533|NCT04157231|No Intervention|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
32763534|NCT04157231|Other|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.~Refresher training will be given monthly during the intervention."
32763535|NCT05092087||Control group/ non-regularity group|those who completed 8 consultations by average interval time more than 3 weeks were in the non-regularity group
32763536|NCT05092087||test group/ regularity group|those who completed the consultations and interval time within in 3 weeks were in the higher regularity
33243738|NCT04833426|Placebo Comparator|Placebo therapy|Daily application of two pump auctions of placebo gel.
32763537|NCT04413643|Experimental|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
32763538|NCT05473715|Experimental|Customized treatment interval|After the initial study injection at baseline, participants will receive their next study injection at Week 16. Participants in this study arm will also be issued a home monitoring device, which will allow for regular OCT monitoring (at least 5 times a week) at home.
32763539|NCT05473715|Active Comparator|Treat and extend (T&E) 2 week adjustment|Participants will receive treatment in intervals maintained (8 weeks) or adjusted in 2 weeks increments each time (up to a maximum of 16 weeks and minimum of 4 weeks), as long as all extension/shortening criteria are met.
32763540|NCT05727475|Active Comparator|Study group|In this group, a composite facing will be placed on the anterior incisors to mask the opacity. Minimal invasive treatment will be done without drilling or removal of enamel. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.
32763541|NCT05727475|Active Comparator|Control group|"In this group, fluoride gel application will be done for all teeth using 1.23% APF gel delivered through a foam tray. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.~After filling the C-OHIP-SF19 questionnaire 1 month post treatment, if the child is not happy with the appearance after fluoride gel application, a composite facing will be offered."
32763542|NCT05725655|Experimental|Hot water immersion|Patients allocated to hot water immersion will enter a bath and submerge down to the neck in warm water (40 degrees celsius) for 15 min.
32763543|NCT05725655|No Intervention|Control|Patients allocated to control group will sit down for a 15 min rest.
32763544|NCT05094583||Intervention Arm|Patients who expressed wish to quit smoking and accept use of the SmokeFree app
32763545|NCT05094583||Control Arm|Patients who expressed wish to quit smoking but declines all support or use of SmokeFree app
32763546|NCT05724875|Experimental|Arm A: FLASH RT|
32763547|NCT05724875|Active Comparator|Arm B: Conventional RT|
32763548|NCT05091775|Placebo Comparator|Standard management of acute fissure(Diltiazem Jelly,supportive care,placebo suppository, sitz bath)|Patients in the first group underwent for 14 consecutive days treatment with diltiazem gel 2 times a day, a basin of warm water 2 times a day and drink daily 8-12 a glass of water will be placed with a placebo suppository.
32763549|NCT05091775|Experimental|Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)|Patients in the second group or treatment group will be treated with diltiazem gel topically 3 times a day for 14 consecutive days, pelvis of warm water 2 times a day and drink daily 8-12 glasses of water plus Asacol anal suppository (mesalazine) are taken 1 piece every night.
32763550|NCT05724719||Unprovoked First Seizure (UFS)|Participants will undergo cognitive screening assessment, MRI imaging and EEG (if not already done) within 2-4 weeks of the initial First seizure clinic visit. Seizure recurrence will be monitored by a diary provided to each participant with details of the research team to contact in the event of a seizure. A researcher via perform telephone reminders at 3, 6, 9 and 12 months following the seizure. The primary outcome will be seizure recurrence at 12 months.
32763551|NCT05724719||Healthy Controls|Healthy control participants will complete the same neuropsychological battery, MRI scans and EEG protocols to evaluate baseline level of impairment in a healthy population and for the group comparisons of UFS to healthy controls to establish the changes already present at initial presentation with UFS.
32763552|NCT05091541|Experimental|CT120 in relapsed/refractory B-cell non-Hodgkin's lymphoma patients|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection（CT120）will be infused at 1.0 x 10^6 CAR+ T cells/kg、3.0 x 10^6 CAR+ T cells/kg、6.0 x 10^6 CAR+ T cells/kg in relapsed/refractory B-cell non-Hodgkin's lymphoma patients
32763553|NCT05376085|Experimental|RT|"T: DA-5215 R: DA-5215-R"
32763554|NCT05376085|Experimental|TR|"T: DA-5215 R: DA-5215-R"
32763555|NCT05091463|Experimental|Transcutaneous spinal stimulation|Participants with chronic SCI will receive 60 sessions of activity based-locomotor training (AB-LT) combined with transcutaneous stimulation (scTS).
32763556|NCT05091385||Severe asthma patients treated with mepolizumab|Patients having received mepolizumab 100 mg SC every 4 weeks for at least 12 months in six severe-asthma clinics in Poland between December 2017 and December 2019
32763557|NCT02631551|Experimental|GSP 301 NS|
32763558|NCT02631551|Active Comparator|Olopatadine HCl NS|
32763559|NCT02631551|Active Comparator|Mometasone furoate NS|
32763560|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
32763561|NCT05706961|Experimental|Power Walking|
32763562|NCT05706961|Active Comparator|Standardized Outpatient Cardiac Rehabilitation|
32763563|NCT04445597|Other|COVID-19 positive or negative patients|Hospitalised patients with or without COVID-19 (with or without olfactory dysfunctions)
33243739|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
33243740|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
33243741|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
33243742|NCT04074408|Experimental|Cohort 1|low dose hUMSCs or high dose hUMSCs
33243743|NCT04074408|Experimental|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
33399465|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
33399466|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
33399467|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
32912816|NCT04052685|Experimental|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
32912817|NCT04052685|Active Comparator|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
32912818|NCT04048161|Experimental|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
32912819|NCT04048161|Experimental|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
33399468|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
32763564|NCT05094193|Experimental|Trocar-site infiltration|Trocar-site infiltration with 20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 5 mm trocar site) associated with bilateral TAP block with 20 mL of normal saline in each side
32763565|NCT05094193|Active Comparator|TAP block|Trocar-site infiltration with 20 mL of normal saline associated with bilateral TAP block with 20 mL of ropivacaine 0.375% in each side
32763566|NCT05723393|Active Comparator|10 ml T2 ESPB group|T2 ESPB group where ESPB is performed at T2 with local anesthetics 10ml
32737359|NCT05042271||Meropenem: Patients who underwent TPE (Phase 1)|In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
33243744|NCT01366092|Experimental|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
33243745|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
33243746|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
33243747|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
33243748|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
33243749|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
33243750|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
33243751|NCT01344252|Experimental|Topical|
33243752|NCT01344252|Active Comparator|subtenon|
33243753|NCT04101383|Experimental|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
32737360|NCT05042271||Meropenem: after TPE (Phase 2)|was similar to phase 1 except that the meropenem administration and PK studies were conducted >6 hours apart from the next TPE
33243754|NCT04101383|Active Comparator|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
33243755|NCT02576808|Experimental|Ginger extract|Drug
33243756|NCT02576808|Active Comparator|Loratadine|Drug
33243757|NCT04100681|Active Comparator|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
33243758|NCT04100681|Sham Comparator|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
33243759|NCT04098965|Experimental|Experimental|Physical Therapy Techniques
32737361|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
33243760|NCT04098965|Other|Control|physician treatment
33243761|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
33243762|NCT02576730||healthy subjects|patients without foot and ankle fracture s
33243763|NCT04098887|Experimental|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
32737362|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
32763567|NCT05723393|Active Comparator|20 ml ESPB group|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
33243764|NCT04100603||Patients with CDI|Patients who are infected with C. diff
32737363|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
33243765|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
33243766|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
33243767|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
33243768|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
33243769|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
33243770|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
33243771|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
33399469|NCT03528642|Experimental|Treatment (telaglenastat, temozolomide, RT)|Patients receive telaglenastat PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
33399470|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
33243772|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
32763568|NCT03010657|Experimental|Experimental intervention|Subjects will add certain foods to what they normally eat.
33243773|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
33243774|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
33243775|NCT04073160|Experimental|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
33243776|NCT04073160|Experimental|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
33243777|NCT01294332|Experimental|Exercise|Aerobic exercise performed for 12 weeks
33243778|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
33243779|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
33243780|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
32763569|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
32763570|NCT03010657|No Intervention|Observational|Subjects will continue eating normally.
32763571|NCT04165811|Experimental|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
32763572|NCT04165811|Experimental|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
32763573|NCT05091151|Active Comparator|Intranasal dexmedetomidine at dose of 2 mcg/kg|Subjects in IND 2 group received Intranasal dexmedetomidine at dose of 2 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
32763574|NCT05091151|Active Comparator|Intranasal dexmedetomidine at dose of 4 mcg/kg.|Subjects in IND 4 group received Intranasal dexmedetomidine at dose of 4 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
32763575|NCT04752917|Experimental|Intervention|Headphones
32763576|NCT04752917|No Intervention|Control|Standard of care
32763577|NCT05377021|Active Comparator|"Diet group"|
32763578|NCT05377021|Experimental|"Diet and exercise combination group"|
32763579|NCT05466539|Experimental|Treatment Group|AbobotulinumtoxinA
32763580|NCT05466539|Placebo Comparator|Control Group|Normal Saline
32763581|NCT05093647||patient|"The women who followed up for HrP (high-risk pregnancy ) were invited to participate and women with HrP in the second trimester (14th to 28th gestational weeks), between 20 to 40 years old, and followed up at our perinatology department with a diagnosis of IUGR (intrauterine growth retardation~), cholestasis, diabetes, preeclampsia, or hypertension were included."
32763582|NCT05093647||control|The pregnant women admitted for routine second-trimester ultrasonography assessment but with no risk for pregnancy formed the control group.
32763585|NCT05093257||Group I|age and sex matched healthy control individuals.
32763586|NCT05093257||Group II|available number of ITP patients.
32737364|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
32737365|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
32912820|NCT05625191||Control Group- Without Phonotrauma|Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for participants without voice disorders, acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in three voice conditions (breathy, typical, and pressed). For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition.
32912821|NCT05625191||Patients Diagnosed with Phonotrauma|"Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for Participants who have a diagnosis of phonotrauma will be instructed to produce five repetitions of the same three vowels but in only two conditions: typical voice and resonant voice following stimulability assessment and with cues. They will be instructed to maintain relatively consistent volume and pitch across conditions. For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition."
32912823|NCT03995979|Experimental|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
32912824|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
32912825|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
32912826|NCT03974217|Experimental|Talazoparib|"Talazoparib is administered orally on a daily basis~Hydroxyurea is allowed for up to two cycles per institutional guidelines"
32912827|NCT02664987||Patients receiving cancer pain treatment|
32912831|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
32912832|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
32912833|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
32912834|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
32912835|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
32912836|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
32912837|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
32912838|NCT03928041|Other|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
32912839|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
32912840|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
32912841|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
32912842|NCT00553631|Active Comparator|imiglucerase|
32912843|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
32912844|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
32912845|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
32912846|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
32912847|NCT05608343|Active Comparator|Difamilast Ointment|1% Difamilast Ointment
32912848|NCT05608343|Placebo Comparator|Vehicle Controlled|Matching placebo
32912849|NCT05210985||premature babies|Fifty infants between 4-18 months with a history of premature birth and with the consent of their parents will be included in the study. Babies with the chromosomal anomalies, serious congenital problems, and whose parents are not willing to work will not be included in the study.
32912850|NCT00553319|Placebo Comparator|Placebo|Placebo
32912851|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
32912852|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
32912853|NCT04768673|Experimental|Group 1|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
33243781|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
33243782|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
33243783|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
33399471|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
32912854|NCT04768673|Experimental|Group 2|Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
32912855|NCT04768673|Experimental|Group 3|Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
32912856|NCT04768673|Experimental|Group 4|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
32912857|NCT04768673|Experimental|Group 5|Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
32912858|NCT04768673|Experimental|Group 6|Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
32912859|NCT05197179|Other|Single-dose A|A single dose A of FB2001 or placebo will be administered by intravenous (IV) infusion
32912860|NCT05197179|Other|Single-dose B|A single dose B of FB2001 or placebo will be administered by intravenous (IV) infusion
32912861|NCT05197179|Other|Multiple-dose A|Dose A of FB2001 or placebo will be administered by intravenous (IV) infusion once daily for 5 consecutive days
32912862|NCT05197179|Other|Multiple-dose B|Dose B of FB2001 or placebo will be administered by intravenous (IV) infusion twice daily for 5.5 consecutive days
32912863|NCT05197179|Other|Single-dose C|A single dose C of FB2001 or placebo will be administered by intravenous (IV) infusion
32912864|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
32912865|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
33243784|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
32912866|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
32912867|NCT04738773|Active Comparator|Patients receiving Naltrexone|
32912868|NCT04738773|Placebo Comparator|Patients receiving Placebo|
32912869|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
32912870|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
32912871|NCT04739397||Cataract|Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular
32912872|NCT04739397||Non-Cataract|patients with bilateral clear lenses (no cataracts)
33243785|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
33243786|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
32912873|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
32912874|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
32912875|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
32912876|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
32912877|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
32912878|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
32912879|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
32912880|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
33243787|NCT01034761|No Intervention|Usual care|
33243788|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
33243789|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
33243790|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
33243791|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
33243792|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
33243793|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
33243794|NCT01231932||Individuals with cancer|Individuals with cancer
33243795|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
32912881|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
32912882|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
32912883|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
32912884|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
32912885|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
32912886|NCT05134935|Active Comparator|OKL|
32912887|NCT05134935|Experimental|DIMS|
32912888|NCT04338711|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
32912889|NCT04338711|Experimental|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
32912890|NCT04338711|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
32912891|NCT04338711|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
32912892|NCT04338711|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
32912893|NCT04338711|Active Comparator|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
32912894|NCT03609177|Experimental|Advance Care Planning|"-Survey:~A group of older patients with advanced cancer (N=450) will have a survey over the course of the 36 months of recruitment.~Participants will be provided written copies of the questions to follow along during the interviews"
32912895|NCT03609177|Experimental|Advance Care Planning-Video Declaration|"Video Declaration:~From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.~For those participants that agree to the video declaration, they will proceed with recording of their video declarations~The RA will begin by reading a standardized introduction to aid the subject do the video"
33243796|NCT02108028||Cohort 1A / Initial Young Adults with Children|Young adults who have a child(ren) and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
32912896|NCT03609177|Other|Comprehensive Record Review of ACP|"A review of Medical orders for resuscitation preferences in the electronic health record~A review of Medical orders for Palliative care consultations preferences in the electronic health record~A review of Medical orders for Hospice use preferences in the electronic health record"
33399472|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
33243797|NCT02108028||Cohort 1B / Comparison Young Adults with Children|Young adults who have children and are 18- 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
32912897|NCT03609177|Experimental|Main Study Arm|Patients with cancer being seen at the 30 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
32912898|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
32912899|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
33243798|NCT02108028||Cohort 2A / Initial Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
33243799|NCT02108028||Cohort 2B / Comparison Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
33399473|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
32763587|NCT05093179|Experimental|Deep tissue massage group|"The one session of deep tissue massage was performed. The patient's positions were changed depending on the specificity of used techniques.~The following techniques were used:~Shifting the rectus abdominis m.,~Stretching of the fascia within the costal arches,~trigger points compression (30-60 s).~Stretching of the chest fascia, superficially with forearm or fingertips on intercostal muscles,~filleting the pectoral muscles,~hook and stretch with the proximal phalanges of the fingers 2-4 and the forearm~filleting between the pectoral muscles and the deltoids,~Releasing the lateral edge of the scapula using the fingers and stretching the tissues, Releasing the medial edge of the scapula using the fingers and the weight of the patient,~hook and stretch of the trapezius muscle,~Subsequently, the patient took a prone position.~Stretching of the levator scapulae and supraspinatus muscles using the fist, forearm and elbow were performed."
32763588|NCT05093179|Active Comparator|Classic massage group|The one session of classic massage was performed. The massage was performed with moderate force. The entire procedure took about 15-20 min. The sequence of standard classic massage techniques was used in standard way and patterns.
32763589|NCT04626167|Experimental|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
32763590|NCT04538989|Experimental|RZ358 Cohort 1|
32763591|NCT04538989|Experimental|RZ358 Cohort 2|
32763592|NCT04538989|Experimental|RZ358 Cohort 3|
32763593|NCT04538989|Experimental|RZ358 Cohort 4|
32763594|NCT05704907|Other|gallblader ultrasound|
32763595|NCT05092945|Active Comparator|Subject with Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
32763596|NCT05092945|Experimental|Subject with type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
32763597|NCT05092945|Active Comparator|Subject without Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
32763598|NCT05092945|Experimental|Subject without type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
32763599|NCT04413175|Experimental|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
32763600|NCT04413175|No Intervention|control group|control group
32763601|NCT05439551||Pediatric and adults suspected of acute bacterial or viral infection|ED, Hospital admitted, and urgent care center patients over the age of 90 days, with clinical suspicion of acute bacterial or viral infection.
32763602|NCT05421689|Experimental|Experimental: 150 x 10⁶ AMDC-GIR dosage|31 subjects will be receiving two doses of 150 x 10⁶ AMDC-GIR spaced 4-6 weeks apart.
32763603|NCT05421689|Sham Comparator|Experimental: Identical Placebo composed of the same cryopreservation medium used for AMDC-GIR|31 subjects will be receiving two doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Doses will be spaced 4-6 weeks apart.
32763604|NCT05377957||Brachytherapy|Uveal melanoma patients treated with Ruthenium-106 plaque brachytherapy
32763605|NCT05377957||Proton therapy|Uveal melanoma patients treated with proton therapy
32763606|NCT05377957||Enucleation|Uveal melanoma patients treated with enucleation
32763607|NCT05689073|Experimental|Interactive Q&A chatbot|
32763608|NCT05689073|Active Comparator|Educational booklet|
32763609|NCT05684939||cancer patients and cancer survivors|answer to an online questionnaire
32763610|NCT05675735|Experimental|Cohort 1|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in group 1. Group 1 will start the six-month intervention at Baseline and end at Month 6.
32763611|NCT05675735|Experimental|Cohort 2|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 2. Cohort 2 will start the six-month intervention at Month 6 and end at Month 12.
32763612|NCT05675735|Experimental|Cohort 3|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 3. Cohort 3 will start the six-month intervention at Month 12 and end at Month 18.
32763613|NCT05675735|Experimental|Cohort 4|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 4. Cohort 4 will start the six-month intervention at Month 18 and end at Month 24.
32763614|NCT05675735|Experimental|Cohort 5|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 24 and end at Month 30.
32763615|NCT05675735|Experimental|Cohort 6|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 30 and end at Month 36.
32763616|NCT05411315|Experimental|Restricted-use of arterial catheters|
32763617|NCT05411315|Active Comparator|Standard-use of arterial catheters|
32763618|NCT05667623|Experimental|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
32763619|NCT05667623|Placebo Comparator|0% OPA-15406 Vehicle|The vehicle of OPA-15406 vehicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
32763620|NCT05663333||DOCTA cohort|Patients > 50 years of age with suspected giant cell arteritis requiring temporal artery biopsy in the dermatology department
32763621|NCT05635409|Experimental|Dose 1|The starting dose of this trial is selected as a dose of cells that is likely to be the minimal therapeutic dose, i.e. 100,000 surviving DA neurons per putamen, obtained by transplanting 3.54 million STEM-PD cells per putamen.
32763622|NCT05635409|Experimental|Dose 2|"To ensure that the investigators are not using a potentially suboptimal cell dose, the investigators also plan to test a higher dose, which is double the dose of dose 1, i.e., 200,000 surviving DA neurons (= 7.08 million transplanted STEM-PD cells) per putamen.~The Data and Safety Monitoring Board (DSMB) for the trial will make a recommendation for the dosing once participants 1-4 have been dosed and data is available for imaging and clinical measurements, as well as safety reports, 6 months after the last patient has been grafted. The DSMB can recommend either to: i) remain at dose 1; ii) proceed to dose 2; or, iii) wait longer to collect more data. The final decision will be made by the clinical sub-group of the Trial Management Group, after receiving confirmation of the DSMB's recommendation."
33399474|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
33399475|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
32763623|NCT05634707|Experimental|Fluoxetine pre-surgery|Patients randomized to the experimental arm will receive fluoxetine at 20 mg/day for 5 days (initiation dose) followed by a maintenance dose of 40 mg/day starting on Day 6 (dose level 1) or 60 mg/day starting on Day 6 (dose level 2).
32763624|NCT05634707|Active Comparator|Temozolomide pre-surgery|Temozolomide pre-surgery (control) arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
32763625|NCT05623865|Experimental|Experimental group|"After the initial evaluation, the patients will be randomly divided into two groups as the Experimental group and the control group.Experimental group will receive kinesiotape treatment in addition to those applied in the control group.~Kinesiotape to the kinesio tape group will be done by a PM&R spesialist doctor who has a certificate of kinesiotaping, in accordance with the literature, using the lymphedema method."
33399476|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
33399477|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
32763626|NCT05623865|Other|Control group|Elevation and cold application, which is applied in the prevention and treatment of classical edema, will be recommended to the control group. In addition, wrist, elbow, finger range of motion and stretching exercises will be taught as a home exercise program.
32763627|NCT05620433|Experimental|Joint Effort mobile application|The Joint Effort mobile application aims to support young adults in taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude, and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation, and activation of intention). The objectives include: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, and to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
32763628|NCT05620433|Active Comparator|Brief normative feedback and standard information|The comparator is composed of a brief normative feedback regarding last month's frequency of cannabis use and basic reliable non-personalized information on lower-risk cannabis use (official public websites).
32763629|NCT04447469|Active Comparator|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
32763630|NCT04447469|Active Comparator|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
32763631|NCT04447469|Placebo Comparator|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
32763632|NCT04447469|Active Comparator|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
32763633|NCT04447469|Active Comparator|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
32763634|NCT04447469|Placebo Comparator|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
32763635|NCT04447235|Placebo Comparator|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
32763636|NCT04447235|Experimental|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
32763637|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
32763638|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
32763639|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
32763640|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
32763641|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
32763642|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
32763643|NCT04443023|Active Comparator|Sapien|Patients randomized to treatment
32763644|NCT04443023|Active Comparator|Myval|Patients randomized to treatment
32763645|NCT04442867|Experimental|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
32763646|NCT04442867|Other|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
32912900|NCT05111691|Experimental|Dry needling|"Two needles will be inserted on or near the most tender point of the low back. Two additional needles will be inserted on the opposite side at the level of the most tender point regardless of unilateral or bilateral low back pain (LBP). After piercing the skin, the needle will be directed toward the spinous process in a slight inferior-medial angle (approximately 20-30°). Once the needle is inserted, the treating investigator will use a ultrasound scanner to visualize the needle placement and to confirm that needle has reached the deeper layer of the lumbar multifidus (LM) muscle.~Once the needle placement is confirmed, it will be pulled slightly in and out within the muscle and redirected in small angles for 10 seconds after insertion. The needles will stay (in situ) in the LM for approximately 10 minutes after the insertion and then will be withdrawn."
32912901|NCT05590403|Experimental|Adults HA-RSV Group|Healthy adults (HA) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
32912902|NCT05590403|Placebo Comparator|Adults HA-Placebo Group|HA 50-59 YOA, who receive 1 dose of placebo at Day 1.
32912903|NCT05590403|Experimental|Adults AIR-RSV Group|Adults at increased risk (AIR) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
32912904|NCT05590403|Placebo Comparator|Adults AIR-Placebo Group|Adults AIR 50-59 YOA, who receive 1 dose of placebo at Day 1.
32912905|NCT05590403|Experimental|OA-RSV Group|Older adults (OA) ≥60 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
33243800|NCT02108028||Cohort 3A / Initial Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
33243801|NCT02108028||Cohort 3B / Comparison Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
32912906|NCT05108337|Experimental|Scpb group|Superficial cervical plexus block group
32912907|NCT05108337|Sham Comparator|Control group|Saline group
32912908|NCT04739241|Experimental|Group A (experimental arm)|Premixed insulin therapy
32912909|NCT04739241|Active Comparator|Group B (active comparator)|Basal bolus insulin therapy
32912910|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
32912911|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
32912912|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
32912913|NCT04707807||Nightshift workers|
32912914|NCT04707807||Non-nightshift workers|
32912915|NCT03549273|Experimental|Treatment|Glizigen® spray + Ocoxin-Visuid® oral solution
32912916|NCT04707963|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
33243802|NCT02108028||Cohort 4 / Non-patient participants|Family members, friends, or health care providers of patient participant. COMPLETE
33243803|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
32912917|NCT04707963|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
32912918|NCT05089227|Experimental|"intervention group"|
32912919|NCT05089227|Active Comparator|"standard group"|
32912920|NCT03475173|Experimental|Laser Speckle Blood Flow Group|
33243804|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
33243805|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
33243806|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
33243807|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
33243808|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
33243809|NCT04745832|Experimental|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
33243810|NCT04745832|Experimental|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
33243811|NCT01933620||Patient|Patients who might become colonized or infected with a multi drug-resistant organism
33243812|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
33243813|NCT04619004|Experimental|Study Group 1: Patritumab deruxtecan 5.6 mg/kg|Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)
33243814|NCT04619004|Experimental|Study Group 2: Patritumab deruxtecan Up-Titration|Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)
33243815|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
33243816|NCT02576340|Active Comparator|study|drug was administered
33243817|NCT02576340|No Intervention|control|no drug administered
33243818|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
33243819|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
33243820|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.~Intervention: application of a contralateral drainage in surgical wound closure."
33243821|NCT04071444|Experimental|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
33243822|NCT04071444|No Intervention|Control group|The control group (CG) received routine care.
33243823|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
33243824|NCT00128778|Experimental|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
33243825|NCT00128778|No Intervention|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
33243826|NCT05673252||Cervical cancer patients|The population is represented by women being admitted to the Gynecology Ward who are affected by cervical cancer.
33243827|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
33243828|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
33243829|NCT04901910|Experimental|Physical Activity (PA) Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
33243830|NCT04901910|Experimental|Verdi plus PA Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
33243831|NCT04901910|No Intervention|Attention-Control condition Social Media Group|This will be an 8 week Social Media Group available to the participant with social media topics.
33243832|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
33243833|NCT00709488|Experimental|Litx™ BPH Therapy|
33243834|NCT00714246|Experimental|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
33243835|NCT00714246|Experimental|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
33243836|NCT00714246|Experimental|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
33243837|NCT00714246|Experimental|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
33243838|NCT00714246|Experimental|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
33243839|NCT00714246|Experimental|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
33243840|NCT00714246|Experimental|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
33243841|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
33243842|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
33243843|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
33243844|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
33243845|NCT04071210|Experimental|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1*10(9) CFU) 2 times/day for 12 weeks
33243846|NCT04071210|Placebo Comparator|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
33243847|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
33243848|NCT00026754||Cohort 1|Patients
33243849|NCT00026754||Cohort 2|Healthy Volunteers
33243850|NCT00714324||1|Paper screening
33243851|NCT00714324||2|Electronic screening
33243852|NCT00714402||a|children with proven of probable invasive bacterial infections
33243853|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
33243854|NCT00709566|No Intervention|Control|Waiting List control.
33243855|NCT00709566|Active Comparator|Exercise therapy|
33243856|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
33243857|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
33243858|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
33243859|NCT04454658|Experimental|Segment A: ABBV-744 Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
33243860|NCT04454658|Experimental|Segment A: ABBV-744 Monotherapy|Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
33243861|NCT04454658|Experimental|"Segment B: Ruxolitinib + ABBV-744 Add on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as add-on therapy."
33243862|NCT04454658|Experimental|Segment C: ABBV-744 + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
33243863|NCT04454658|Experimental|Segment D: ABBV-744 + Ruxolitinib|Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
33243864|NCT04071054||Hemodialysis patients|
33243865|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
33243866|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
33243867|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
33243868|NCT00709800|Experimental|2|
33243869|NCT00709800|Experimental|3|
32763647|NCT05090761|Active Comparator|SAPB|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
33243870|NCT00709800|Experimental|4|
32763648|NCT05090761|Active Comparator|SAPB with Mg|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
32763649|NCT05090761|Active Comparator|SAPB with Mg and Buprenorphine|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg and 300 mcg of buprenorphine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
32763650|NCT05084443|Placebo Comparator|Placebo/Control|Placebo drink-- Orally (200 ml/day)
32763651|NCT05084443|Experimental|Roselle Based drink (Test)|Roselle-Based Drink--- Orally (200 ml/day)
32763652|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
32763653|NCT05082649|Experimental|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
32763654|NCT05082649|Active Comparator|Face to Face Exercises|Face to face (in clinic) progressive spinal stabilization exercises.
32763655|NCT05608109|Experimental|Alcohol personalized normative feedback (APNF)|"Participants will receive feedback about their consumption, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
32763656|NCT05608109|Experimental|Social media personalized normative feedback (SMPNF)|"Participants will receive feedback about their consumption and alcohol related consumption posts, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
32763657|NCT05608109|Experimental|Alcohol and social media personalized normative feedback (APNF + SMPNF)|"Participants will go through the alcohol personalized normative feedback process and the social media personalized normative feedback.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
32763658|NCT05608109|No Intervention|Attention control|"Participants will receive feedback about their consumption of desserts, what they think their peers consume, and actual dessert consumption statistics are for individuals in their age group in the United States.~Participants in this condition will participate in a baseline survey/feedback intervention. They will then complete follow-up surveys and feedback interventions at 3-months and 6-months."
32763659|NCT05607095|Experimental|Participants with Metastatic Uveal Melanoma|Participants have metastatic uveal melanoma who will undergo surgical excision to generate LN-144
32763660|NCT04139057|Experimental|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
32763661|NCT04127903|Experimental|the Length of Right Main Stem Bronchus >=15mm|
32763662|NCT04127903|Experimental|the Length of Right Main Stem Bronchus <15mm|
32763663|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
32763664|NCT04089059|Other|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
32763665|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
32763666|NCT05095285|No Intervention|The control group|• In addition to incubator cover and nesting, no other non-pharmacological intervention was applied to the control group.
32763667|NCT05095285|Experimental|The swaddling group|•Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.
32763668|NCT05095285|Experimental|The oropharyngeal colostrum group|• In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue.
32763669|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
32763670|NCT05376943||Patients diagnosed with HCC after receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who underwent direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will be assessed and also the composition of therapy and the response to treatment will be evaluated.
32912921|NCT05071287|Placebo Comparator|Control Group (mHealth+low-fat diet group)|The low-fat group will be asked to restrict total calorie and total fat consumption according to the Look AHEAD intervention and MyPlate guidelines, with 26-44% carbs, 10-30% protein, and less than 30% fat.
33243871|NCT00709800|Placebo Comparator|5|
33243872|NCT00709800|Experimental|1|
33243873|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
33243874|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
33243875|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
33243876|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
33243877|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
33243878|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
33243879|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
33243880|NCT04070976|Active Comparator|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
33243881|NCT04070976|Experimental|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
33243882|NCT00710190|Experimental|Rheos Implant|
33243883|NCT00715182|Experimental|TKI258|
33243884|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
33243885|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
33243886|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
33243887|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
33243888|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
33243889|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
33243890|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
33243891|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
33243892|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
33243893|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
33243894|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
33399478|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
33399479|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
33399480|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
32763671|NCT05376943||Patients diagnosed with HCC who were not receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who were not receiving direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will also be assessed.
32763672|NCT04074785|Experimental|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
32763673|NCT04074785|Experimental|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
32763674|NCT04533841|Active Comparator|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
32763675|NCT04533841|Placebo Comparator|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
32763676|NCT04537663|Experimental|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI [Statens Serum Institut]) - Danish strain 1331.
32763677|NCT04537663|Placebo Comparator|Placebo|Intradermal injection of sterile 0.9% NaCl.
32763678|NCT04536805|Experimental|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
32763679|NCT04536805|Experimental|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
32763680|NCT04536805|Experimental|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
32763681|NCT05376865|Experimental|Intervention|Vitamin D3 supplement every week
32763682|NCT05376865|Placebo Comparator|Control|Placebo every week
32763683|NCT05062447||Adaptive emotions, non-metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a non-metastatic disease
32763684|NCT05062447||Adaptive emotions, metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a metastatic disease
32763685|NCT05062447||maladaptive emotions, non-metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a non-metastatic disease
32763686|NCT05062447||maladaptive emotions, metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a metastatic disease
32763687|NCT05058157|Active Comparator|Ketone Precursor Formula 1|Formula 1 (in each cycle, up to 4 formula will be tested) Ketone precursors formula (powder to reconstitute in drinking water, or in a ready-to-drink format).
32763688|NCT05058157|Active Comparator|Ketone Precursor Formula 2|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format).
32763689|NCT05058157|Active Comparator|Ketone Precursor Formula 3|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format)
32763690|NCT05058157|Active Comparator|Ketone Precursor Formula 4|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format), or placebo
32763691|NCT04064411|Active Comparator|abaloparatide-SC|Participants self-administered daily doses of abaloparatide 80 mcg SC for 12 months using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
32763692|NCT04064411|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS 300 mcg applied to the thigh for 5 minutes once daily for 12 months.
32763693|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
32763694|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
32763695|NCT04058795|Experimental|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
32763696|NCT04058795|Experimental|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
32763697|NCT04058795|Experimental|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
32763698|NCT04058795|No Intervention|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
32763699|NCT05086159|Active Comparator|Traditional Education|"Traditional biomedical education for back pain and standard stress education. Education was developed from Back School, National PTSD Center, and PTSD Coach."
32763700|NCT05086159|Experimental|Pain Neuroscience Education|Pain neuroscience education (PNE) was developed for this research comparing pain and stress symptoms to a radar that can become hypervigilant to threat.
32763701|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
32763702|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
32763703|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
32763704|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
32763705|NCT05083663|Experimental|Group I|received bupivacaine 0.375 % 15 mL + normal saline 4ml +hyaluronidase 800 IU in 1 ml.
32763706|NCT05083663|No Intervention|Group II|received bupivacaine 0.375% 15 mL + normal saline5 ml.
33243895|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
32763707|NCT05082415||Brolucizumab|Participants received brolucizumab injection during the index period
32763708|NCT05050825|Experimental|CDSA strategy|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers trained on the CDSA strategy
32763709|NCT05050825|No Intervention|Routine practice|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers according to routine practice at the health facility
32763710|NCT04012931|Experimental|Rilpivirine (RPV) (25 mg or adjusted weight-based dose)|Participants will receive rilpivirine (RPV 25 milligram [mg], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals [ARVs] such as nucleoside/nucleotide reverse transcriptase inhibitor [N{t}RTIs] and integrase inhibitors) for 48 weeks.
32763711|NCT05333393|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
32763712|NCT05333393|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
32763713|NCT05331287|Experimental|snifing Position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The snifing position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
32763714|NCT05331287|Experimental|neutral position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The Head Extension was obtained by the occiput of the patient close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
32763715|NCT05331287|Experimental|Head Extension|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The extension position with a 7-cm pillow underneath the shoulder and the occiput close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
32763716|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
32763717|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
32763718|NCT05304611|Experimental|Adult Dose-escalation study: Arm 1: 300 mg of L9LS|Participants will receive 300 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 2.
32763719|NCT05304611|Experimental|Adult Dose-escalation study: Arm 2: 600 mg of L9LS|Participants will receive 600 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 3.
32763720|NCT05304611|Experimental|Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS|Participants will receive highest dose of 20 mg/kg IV of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for subjects aged 6 -10 years.
32763721|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 1: 150 mg of L9LS|Subjects age 6-10 years will receive 150 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin arm 2.
32763722|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 2: 300 mg of L9LS|Subjects age 6-10 years will receive 300 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin weight de-escalation.
32763723|NCT05304611|Placebo Comparator|Subject 6-10 years Dose-escalation study: Arm 3: Placebo|Half of subjects age 6-10 will receive placebo of Normal Saline for comparison.
32763724|NCT05304611|Experimental|Efficacy study: Arm 1: 150 mg of L9LS|75 children age 6-10 will receive 150 mg of L9LS.
32763725|NCT05304611|Experimental|Efficacy study: Arm 2: 300 mg of L9LS|75 children age 6-10 will receive 300 mg of L9LS.
32763726|NCT05304611|Placebo Comparator|Efficacy study: Arm 3: Placebo|75 children age 6-10 will receive normal saline placebo.
32763727|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
32763728|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
32763729|NCT02660359|Experimental|600 U Dysport® Group|
32763730|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
32763731|NCT02660359|Experimental|800 U Dysport® Group|
32763732|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
32763733|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
33243896|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
33243897|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
33243898|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
33243899|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
33243900|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
32763734|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
33082093|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
32737366|NCT05054049|Experimental|Abbott i-stat Allinity|Randomised patients to this arm receive the application of the point of care testing device to provide further diagnostic information to assist clinical decision making.
32737367|NCT05054049|Placebo Comparator|Usual Care|Randomised patients to this arm receive usual care.
32737368|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
33082094|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
33082095|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
33082096|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
33082097|NCT04624360|Experimental|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
33243901|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
33243902|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
33243903|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
33243904|NCT00710658|No Intervention|2|The control group receiving usual care
33243905|NCT00710736|Experimental|ARRY-334543 + capecitabine|
33243906|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
33243907|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
33243908|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
33243909|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
33243910|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
33243911|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
33243912|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
33243913|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
33243914|NCT03912792||XLHED Patients|
33243915|NCT03912792||Healthy Controls|
33243916|NCT00711048|Experimental|1|30 mg, oral, single dose
33243917|NCT00711048|Experimental|2|95 mg, oral, single dose
33243918|NCT00711048|Placebo Comparator|3|Oral solution, single dose
33243919|NCT04070742|Experimental|FMX-101|
33243920|NCT04269876|Experimental|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
33082098|NCT04624360|Placebo Comparator|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
33082099|NCT04624438|Experimental|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
33243921|NCT04269876|Placebo Comparator|Placebo|Placebo softgels with Placebo capsules
33243922|NCT04069806|Experimental|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
33243923|NCT04069806|No Intervention|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
33243924|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
33243925|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
33243926|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
33243927|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
33243928|NCT00851344|Placebo Comparator|placebo|placebo tablet
33243929|NCT00855478|Experimental|1|Cypher drug-eluting stent
33243930|NCT04523922|Experimental|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
33243931|NCT04523922|Active Comparator|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
33243932|NCT00711126|Experimental|Arm 1|HVTs
33243933|NCT00711126|Experimental|Arm 2|HVTs
32737369|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
32737370|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
33243934|NCT00711126|Experimental|Arm 3|HVTs
33243935|NCT00711126|Experimental|Arm 4|HVTs
33243936|NCT00711126|Experimental|Arm 5|HVTs
33243937|NCT00711126|Experimental|Arm 6|HVTs
32763735|NCT05287373|Active Comparator|PNS Therapy plus Conventional Medical Management|peripheral nerve stimulator plus conventional medical management
32763736|NCT05287373|Other|Conventional Medical Management|Control arm conventional medical management only
32763737|NCT03987581|Experimental|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
32763738|NCT03987581|Experimental|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
32763739|NCT03987581|Experimental|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
32763740|NCT03987581|Active Comparator|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
32763741|NCT03982511|Experimental|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
32763742|NCT03982511|No Intervention|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
32763743|NCT04990141||Cases group|Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy
33082100|NCT04624438|Experimental|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
33082101|NCT04624438|Experimental|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
33082102|NCT04624438|No Intervention|Control group - CONTROL|Group of healthy young adults who received no intervention.
33082103|NCT04624048||University population|Survey to analyze the impact of COVID-19.
32763744|NCT04990141||Control group|Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy
32763745|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
32763746|NCT04901299|Experimental|NERATINIB + FULVESTRANT|"After the screening procedures confirm participation in the research study.~- Each Cycle = 28 days~Neratinib (oral, once daily)~Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter"
32763747|NCT01290055|Experimental|Group 1 - Yellow fever vaccine and deuterated water for two weeks|In group 1, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 2 weeks (Days 14 to 28 post-vaccination). They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
32763748|NCT01290055|Experimental|Group 2a - Yellow fever vaccine and deuterated water for three weeks|"In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.~In group 2a, phlebotomies will occur at weekly at 8, 9, 10, 11,12, 14 and 20 weeks post vaccination~Participants in Group 2a will begin drinking deuterated water at month 2~Participants will drink 2H2O 50ml TID for the first week, then 50ml BID for 3 weeks.~In group 2b, phlebotomies will occur weekly at 24, 25, 26, 27, and 28 post vaccination."
32763749|NCT01290055|Experimental|Group 2b - Yellow fever vaccine and deuterated water for three weeks|"In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.~Participants in Group 2b will begin drinking deuterated water at month 6~Participants will drink 2H2O 50ml TID for the first week, then 50ml BID for 3 weeks."
32763750|NCT05376397|Experimental|THRIVE 365|
32763751|NCT04955899|Experimental|Active Stimulation|Active stimulation for 12 weeks
32763752|NCT04757311||Metastatic Colorectal Cancer Patients|All RAS wild type metastatic colorectal cancer patients
32763753|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
32763754|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
32763755|NCT04626505|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for 12 weeks.
32763756|NCT04626505|Experimental|Ziltivekimab 30 mg|Participants will receive ziltivekimab 30 mg for 12 weeks.
32763757|NCT04626505|Placebo Comparator|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for 12 weeks.
32763758|NCT05276609|Experimental|HS-20093 (Phase Ia: Dose escalation)|There are seven escalating dose cohorts.
32763759|NCT05276609|Experimental|HS-20093 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
32763760|NCT04909099||Knee Ostearthritis/ Low Bakc Pain|Patients referred for physical therapy rehabilitation
32763761|NCT05068297|Experimental|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
32763762|NCT05068297|Active Comparator|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
33243938|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
33243939|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
33243940|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
33082104|NCT01580605||Users of somatropin|
32737371|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
32737372|NCT05032911||Asymptomatic participants|Asymptomatic subjects should not present any pain in the cervical region during the last 3 months and no previous treatment for neck pain in order to be included in the study.
32737373|NCT05032911||Neck pain patients|Patients with neck pain should have an intensity of pain of at least 3 points out of 10 on a Visual Analog Scale and a neck pain duration of at least 3 months of evolution. Neck pain could be from nonspecific mechanical origin, associated with whiplash or with a previous medical diagnosis of degenerative or inflammatory alterations of the cervical spine, associated or not with headache and pain in the shoulder region or the upper limb.
32737374|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
32737375|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
32737376|NCT05032989|Experimental|Extraction of distoangular and vertically positioned 3rd molar using cowhorn forcep|Extraction with new technique
32737377|NCT05032989|Active Comparator|Extraction of distoangular and vertically positioned 3rd molar via conventional method|Extraction with the conventional technique
32737378|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
32737379|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
32737380|NCT05032287|Active Comparator|tamsulosin|tamsulosin 0.4 mg once daily
32737381|NCT05032287|Placebo Comparator|Placeb|Placebo once daily
32737382|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
32737383|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
32737384|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
32737385|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
32737386|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
32737387|NCT03094689|No Intervention|Control group|
32737388|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
32737389|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
32737390|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
32737391|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
32737392|NCT03096015|Experimental|Intensive Treatment for Aphasia|
32737393|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
32737394|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
32737395|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
32737396|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
32737397|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
32737398|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
32737399|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
32737400|NCT04467957|Experimental|CF Cohort|16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.
32737401|NCT04467957|Experimental|Control Cohort|10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.
33243941|NCT00715572|Active Comparator|A|
33243942|NCT00715572|Active Comparator|B|
32763763|NCT05067985||SARS-CoV-2 pregnant women|After receiving approval from the local ethics committee and permission to use the hospital archives, we included records of spinal anesthesia performed on confirmed SARS- CoV-2 patients in the Ankara City Hospital between April 2020 and February 2021, as well as related data, in our study. Patients who did not have their data gathered, or whose operation took more than 3 hours due to any reason, were excluded from the study
32763764|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
32763765|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
32763766|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
32763767|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
32763770|NCT04449913|Experimental|Active group|10 days intensive meditation retreat
32763771|NCT04449913|Other|Control group|Waiting for a 10 days intensive meditation retreat
32763772|NCT05374759||Group 1|Patients with sepsis who develop AKI
32763773|NCT05374759||Group 2|Patients with sepsis who do not develop AKI
32763774|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
32763775|NCT04262869|Experimental|Arm I (squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, paclitaxel IV over 3 hours and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV every 4 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
32763776|NCT04262869|Experimental|Arm II (non-squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, pemetrexed IV over 10 minutes and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV and pemetrexed IV every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
32763777|NCT04041583||Arm 1|Patients undergoing posterior cervical arthrodesis procedures for spondylosis supplemented with CIS involving three or more segmental levels in the subaxial cervicothoracic spine (between C2-upper thoracic)
32763778|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
32763779|NCT04437823|Experimental|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
32763780|NCT04437823|No Intervention|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
32763781|NCT04822753|Experimental|Platelet Rich Plasma injection to lumbar facet joint|Platelet Rich Plasma injection to lumbar facet joint
32763782|NCT04822753|Placebo Comparator|Placebo injection to lumbar facet joint|Placebo injection to lumbar facet joint
32763783|NCT05254613|Experimental|Cohort 1|Participants will receive a single SC dose of ALXN1830 or placebo (750 mg).
32763784|NCT05254613|Experimental|Cohort 2|Participants will receive a single SC dose of ALXN1830 or placebo (1500 mg).
33082105|NCT04624126|Experimental|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
32763785|NCT05254613|Experimental|Cohort 3|Participants will receive a single SC dose of ALXN1830 or placebo (2250 mg).
32763786|NCT05254613|Experimental|Cohort 4|Participants will receive multiple SC doses of ALXN1830 or placebo (300 mg twice weekly; 8 doses total).
32763787|NCT05254613|Experimental|Cohort 5|Participants will receive multiple SC doses of ALXN1830 or placebo (750 mg once weekly; 12 doses total).
32763788|NCT05254613|Experimental|Cohort 6|Participants will receive multiple SC doses of ALXN1830 or placebo (1500 mg once weekly; 4 doses total).
32763789|NCT05254613|Experimental|Cohort 7|Participants will receive multiple SC doses of ALXN1830 or placebo (2250 mg once weekly; 4 doses total).
32763790|NCT05092165|Active Comparator|Methylene Blue|Methylene blue will be infused during renal replacement therapy
32763791|NCT05092165|Other|Control|
32763792|NCT04682821|Experimental|with Artificial intelligence assistant system|The experiment group would receive the training with the help of artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
33243943|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
33243944|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
33243945|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
32912922|NCT05071287|Experimental|Intervention Group (mHealth + low-carbohydrate/ketogenic diet group)|Total calories will be set according to Look AHEAD intervention, and carbohydrate consumption restriction will be set based on recommendations from American Diabetic Association, National Kidney Foundation, and other evidence-based resources. Participants in this group will be asked to consume a low-carb/ketogenic diet. Specially, participants will receive a carbohydrate, protein, and fat intake goal based on 1.5 : 1 ratio (1.5 grams of fat to 1 gram of carbohydrate and protein combined). Daily macronutrient and calorie consumption will be individualized for each participant using ideal body weight as inferred from wrist circumference and activity level. Carbohydrate consumption will be less than 10% (20~50 g), protein 10-20% (1.0~1.2g/kg ideal body weight), and fat 70-80% of total daily energy, respectively. Nutritional ketosis will be reached by consuming such diet (0.5 mmol/L).
32912923|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912924|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912925|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912926|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912927|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912928|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912929|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912930|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912931|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
32912932|NCT05070975||Twins|Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection
32912933|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral~Dose: 200 mg PO with small sip of water~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
32912934|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous~Dose: 25 mg~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
32912935|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy~Dose: 300cc during cystoscopy to visualize the ureters~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~Contraindications when used as a genitourinary irrigation solution: anuria"
32912936|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy~Dose: 300cc~Known adverse events: no known significant adverse events~Contraindications: none"
32912937|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
32737402|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
32912938|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
32912939|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
32737403|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
33243946|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
32763793|NCT04682821|No Intervention|without Artificial intelligence assistant system|The control group would receive the training without the help of artificial intelligence assistant system. That is, they would receive the common training process.
32763794|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
32763795|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
32763796|NCT04643431|Experimental|Carotid SHAPE estimation|The ultrasound contrast agent is infused (4-10 mL/min). An area within the plaque demonstrating internal flow is selected and a software based calibration algorithm is executed. After selecting the optimal acoustic output power 3D SHAPE volumes of the entire plaque (including the carotid artery) are acquired. Infusion is stopped and after microbubble clearance a second set of 3D SHAPE volumes (without contrast) are obtained.
32763799|NCT05088577|Experimental|Whole egg|Two whole eggs (50g each) to be eaten daily during 8 weeks
32763800|NCT05088577|Experimental|Annatto-enriched egg|Two whole eggs (50g each) enriched with annatto (Bixa orellana L.) to be eaten daily during 8 weeks. Dose of annatto: 1,2 mg bixin/kg of body weight.
32763801|NCT05088577|Placebo Comparator|Egg whites - Control|Two egg whites to be eaten daily during 8 weeks
32763802|NCT03964259|Active Comparator|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
32763803|NCT03964259|Experimental|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
32763804|NCT04942327|Other|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
32763805|NCT04893161|Other|belimumab|All patients with SLE receive belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48. The patients who had SRI-4 response at week 48 were divided into response group and the patients without SRI-4 response at week 48 were divided into no response group.
32763806|NCT04601311|Experimental|Guided self-determination|3 to 5 one-hour digital or analogue guided self-determination sessions
32763807|NCT04601311|Active Comparator|Personal support in goal-pursuing|Up to five personal goal pursuing support sessions
32763808|NCT04884035|Experimental|Administration of CC-220 with R-CHOP-21|CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
32763809|NCT04884035|Experimental|Administration of CC-99282 with R-CHOP-21|CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
32763810|NCT04884035|Experimental|Administration of CC-220 with polatuzumab-R-CHP|CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
32763811|NCT04884035|Experimental|Administration of CC-99282 with polatuzumab-R-CHP|CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
33399481|NCT03465696|No Intervention|Group #1 (Control)|"Group #1 (Control)~Oral survey 1 will be administered and patients will be asked:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
32763812|NCT04582981|Experimental|Arm A|Combination treatment of Fruquintinib and Raltitrexed
32763813|NCT04582981|Experimental|Arm B|Monotherapy of Fruquintinib
32763814|NCT03760627|Experimental|Refugees Mindfulness Resiliency Training|The Collateral Repair Project (CRP) will conduct a Mindfulness Resiliency Training Program (MRTP) for refugees residing in Amman, Jordan. A small support group will demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
32763815|NCT03760627|Placebo Comparator|Control arm|The control group will receive the training after the study group at 2 months and the control group will then become the study group for the new session. A new group of 20 participants will be recruited who will act as a control for that session. The surveys from the control group will be compared with the study group at 0 and 2 months. Each session will last for two months. The control group will receive the training at the end of the two months. This process will be repeated for a total of nine sessions over a total period of 12 months.
32763816|NCT03579667|Experimental|Diet intervention|
32763817|NCT03579667|No Intervention|Control|
32763818|NCT04433351|Experimental|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
32763819|NCT04433351|Experimental|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
32763820|NCT03278821|Experimental|Self Match|The patient must choose between the five possible treatment options.
32763821|NCT03278821|Active Comparator|Expert Match|The Patient is referred to treatment by standard procedure which is Expert Match based on patient data.
32763822|NCT04873427||early metastatic prostate cancer patients|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
33082106|NCT04623970|Experimental|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
33082107|NCT04623970|Experimental|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
33243947|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
33243948|NCT00715806|Experimental|1|
33243949|NCT00715806|Active Comparator|2|
33082108|NCT04623970|Experimental|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
32737404|NCT04467879|Experimental|"Zona Plus - Active - Normal Grip"|Using the Zona Plus Device, the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment (the session calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
33243950|NCT00851500|Experimental|low dose K-604|
33082109|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
33243951|NCT00851500|Experimental|high dose K-604|
33243952|NCT00851500|Placebo Comparator|placebo|
33243953|NCT00711204|Placebo Comparator|1|
33243954|NCT00711204|Active Comparator|2|
33243955|NCT04042870|Experimental|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
33243956|NCT00845338|Experimental|Arm 1|
33243957|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
33243958|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
33082110|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
33082111|NCT04623892|Experimental|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
32912940|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
32912941|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
33243959|NCT00923962|Active Comparator|Type 2 Diabetes patients|
33243960|NCT00923962|Active Comparator|Healthy|
33243961|NCT00923962|Active Comparator|Artherosclerosis|
33243962|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
33243963|NCT00711438|Active Comparator|WL|Best supportive care
33243964|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
33243965|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
33243966|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
33243967|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
33243968|NCT04097470|Active Comparator|Arm A: Decitabine|"Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.~Dosage for Decitabine 20 mg/m2 i.v."
33243969|NCT04097470|Experimental|Arm B: Decitabine and Midostaurin|"Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.~Dosage for Decitabine 20 mg/m2 i.v.~Dosage for Midostaurin 50 mg b.i.d."
33243970|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
33243971|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
33243972|NCT04041934|Experimental|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
33243973|NCT04041934|Experimental|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
33243974|NCT04041934|Experimental|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
33243975|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
33243976|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
33243977|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
33243978|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
33243979|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
33243980|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
33243981|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
33243982|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
33243983|NCT04197336|Sham Comparator|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine & a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed & their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
33243984|NCT04197336|Active Comparator|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
32912942|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
33243985|NCT04042090|Experimental|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
33243986|NCT04042090|No Intervention|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
33243987|NCT04069650||None-malnutrition|normal nutritionnal status
33243988|NCT04069650||Malnutrition|"weight loss was superior to 5% in the past month;~a weight loss was superior to 10% in the past 6 months;~a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old)."
32763823|NCT04873427||non-relapsing/non-metastatic patients with indolent malignant disease|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
33243989|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
33243990|NCT00851734|Experimental|LX214 0.2%|
33243991|NCT00851734|Placebo Comparator|placebo|placebo
32763824|NCT04518787||Control|Healthy child
33243992|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
33243993|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
33243994|NCT04019028|Experimental|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
32763825|NCT04518787||Experimental|Patients with language disorder
32763826|NCT04862741|Experimental|NX-13 250mg IR|Oral
32763827|NCT04862741|Experimental|NX-13 500mg IR|Oral
32763828|NCT04862741|Experimental|NX-13 500mg MR|Oral
32763829|NCT04862741|Placebo Comparator|Placebo|Oral
32763830|NCT04683055|Active Comparator|Phacoemulsification combined with trabeculectomy|Patients will undergo Two site phacoemulsification combined with trabeculectomy with Mitomycin C
32763831|NCT04683055|Active Comparator|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients will undergo two phacoemulsification combined with deep sclerectomy and ab-externo trabeculotomy
32763832|NCT04474249||COVID-19|Patients with PCR-confirmed COVID-19 who were treated in the intensive care unit.
32763833|NCT02508493||Major Depressive Disorder Population|100 Individuals with DSM-5-defined MDD, aged 18-65
32763834|NCT02508493||Healthy Control Population|100 healthy controls matched on age, sex and years of education
32763835|NCT04613089||CLN1 Disease, Haltia-Santavuori Disease|Patients with genetic mutations in the CLN1/PPT1 gene, causing a lysosomal enzyme deficiency of PPT1.
32763836|NCT04613089||CLN2 Disease, Jansky-Bielschowsky Disease|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1.
33082112|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
33243995|NCT04019028|Experimental|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.~TMS coil is fixed on the target area based on MEP hotspot."
33243996|NCT04019028|Sham Comparator|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
33243997|NCT00845572|Experimental|Consta Club|
32763837|NCT04613089||CLN2 Disease - ERT (Brineura) treated|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1, previously and/or currently receiving enzyme-replacement therapy (ERT) with Cerliponase alpha (Brineura).
32763838|NCT04613089||CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease|Patients with genetic mutations in the CLN3 gene.
32763839|NCT04613089||CLN4 disease, Parry disease|Patients with genetic mutations in the CLN4/DNAJC5 gene.
32763840|NCT04613089||CLN5 Disease|Patients with genetic mutations in the CLN5 gene.
32763841|NCT04613089||CLN6 Disease, Kufs Disease Type A|Patients with genetic mutations in the CLN6 gene.
32763842|NCT04613089||CLN7 Disease|Patients with genetic mutations in the CLN7/MFSD8 gene.
32763843|NCT04613089||CLN8 Disease|Patients with genetic mutations in the CLN8 gene.
32763844|NCT04613089||CLN10 Disease|Patients with genetic mutations in the CLN10/CTSD gene, causing a lysosomal enzyme deficiency of Cathepsin D.
32763845|NCT04613089||CLN11 Disease|Patients with genetic mutations in the CLN11/GRN gene.
32763846|NCT04613089||CLN12 Disease|Patients with genetic mutations in the CLN12/ATP13A2 gene.
32763847|NCT04613089||CLN13 Disease, Kufs Disease Type B|Patients with genetic mutations in the CLN13/CTSF gene, causing a lysosomal enzyme deficiency of Cathepsin F.
33243998|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
33243999|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
33244000|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
33244001|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
33244002|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
33244003|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
33244004|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
33244005|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
33244006|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
32763848|NCT04613089||CLN14 Disease|Patients with genetic mutations in the CLN14/KCTD7 gene.
32912943|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
32912944|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
32912945|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
32912946|NCT02679807|Placebo Comparator|Placebo|sucrose
32763849|NCT03924167|Experimental|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (5-7); (c) children (8-11); and (d) adolescent (12-17) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
32763850|NCT03924167|No Intervention|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
32763851|NCT05098639|Active Comparator|BASICS|Participants in the active control will receive a modified single session BASICS. BASICS is a well-documented and empirically supported prevention/intervention program for college student drinkers. BASICS targets heavy drinking students that have experienced or are at an increased risk for a variety of alcohol-related problems linked to college student life. The program is designed to help students make better alcohol-use decisions based on a broader understanding of the risks associated with problem drinking. It enhances motivation to change and promotes the development of skills to moderate drinking. The overall style of the program uses motivational interviewing and emphasizes empathy and non-judgmental interaction. The aims of BASICS are to (1) reduce alcohol consumption and consequences, (2) promote healthier and more responsible choices, and (3) provide information and coping skills.
32763852|NCT05098639|Experimental|Deviance Regulation Theory|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on the injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
32763853|NCT05098639|Experimental|Deviance Regulation Theory+BASICS|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs but also follows the framework of BASICS. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on both descriptive and injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
32763854|NCT04469179|Experimental|Cohort 1|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
32763855|NCT04469179|Experimental|Cohort 2|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
32763856|NCT04469179|Experimental|Cohort 3|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
32912947|NCT05052957|Experimental|stem cell mobilization after radiation therapy|Participants at University Hospitals-Seidman Cancer Center (UH-SCC) will receive stem cell mobilization after 6 weeks of standard of care (SOC) radiotherapy. Followed by SOC chemotherapy.
32912948|NCT05052957|Active Comparator|stem cell mobilization after surgery|Participants at the NIH Cancer Center (NIH-CC) will receive stem cell mobilization following SOC surgery prior to SOC radiotherapy. Followed by SOC chemotherapy.
32912949|NCT05051631|Experimental|Intervention plus 12 months maintenance|Clinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
32912950|NCT05051631|Experimental|Intervention plus 10 months maintenance|Clinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
32912951|NCT05051631|Experimental|Intervention plus 8 months maintenance|Clinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
32912952|NCT05051631|Experimental|Intervention plus 6 months maintenance|Clinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
32912953|NCT05051631|Experimental|Intervention plus 4 months maintenance|Clinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
32912954|NCT05037357||nasopharyngeal carcinoma patients|Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
32912955|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
32912956|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
32912957|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
32912958|NCT01649856|Experimental|A: Rituximab SC|
32912959|NCT01649856|Active Comparator|B: Rituximab IV|
32912960|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
32912961|NCT05031663|Experimental|Almonds|The almond group will receive 15% of their daily energy intake in the form of almonds
32912962|NCT05031663|Placebo Comparator|Pretzel|The placebo group will receive an isocaloric carbohydrate based pretzel snack
32912963|NCT05009199|Experimental|[18F]MNI-444|After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of [18F]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
33399482|NCT03465696|Experimental|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
33399483|NCT03465696|Experimental|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
32912964|NCT05007483|Experimental|Group 1 (Modified paleolithic elimination diet).|Modified paleolithic elimination diet.
32912965|NCT05007483|Experimental|Group 2 (TROO)|Time Restricted Olive Oil Based (TROO) Ketogenic Diet
33082113|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
33399484|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
33399485|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
33399486|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
33399487|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
33399488|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
33399489|NCT02398630|Other|Open Label|"This is a single arm open label study.~Its procedures involve:~Transvaginal Echography~Conventional Virtual Histerosalpingography~Virtual Histerosalpingography by MRI~Blood draw for Antimullerian Hormone Dosing"
33399490|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
33399491|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
33399492|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
33399493|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
32912966|NCT05007483|Active Comparator|Group 3 Control|Usual diet with Dietary Guidelines for Americans Diet information
33399494|NCT03402906|Experimental|Family-Clinician Collaboration|"Experimental group which will be performing the Family-Clinician Collaboration Program. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the patient.~Intervention: Behavioral - Family-Clinician Collaboration Program; Behavioral - Standard Care at KIR"
33399495|NCT03402906|Sham Comparator|Control|"Control group in which patient will receive the standard treatment provided at Kessler Institute for Rehabilitation (KIR).~Intervention: Behavioral - Standard Care at KIR"
33399496|NCT03345979|Experimental|Treatment Group 1|Regular injections
33399497|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
33399498|NCT04680468|Experimental|Belantamab mafodotin|Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.
32763857|NCT04469179|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
33399499|NCT04654338|Experimental|Intervention Arm|
33399500|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
33399501|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
33399502|NCT04615416|Experimental|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
33399503|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
33399504|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
33399505|NCT04572750|Experimental|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
33399506|NCT04572750|No Intervention|Control|Individuals will be provided care as usual
32763858|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
33399507|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
32763859|NCT04531579|Experimental|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
32763860|NCT04531579|Placebo Comparator|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
32763861|NCT04362085|Experimental|Therapeutic Anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
32763862|NCT04362085|No Intervention|Standard Care|Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
32763863|NCT04354597|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive weekly HCQ 400mg X 1 Day PO and AZ 500mg PO X 3 Days; weekly for 16 weeks.
32763864|NCT04354597|No Intervention|Study Arm B (No treatment)|Subjects will receive no treatment in this group and will be serving as control.
32763865|NCT03839459|Experimental|Denosumab|
32763866|NCT04413409|Experimental|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
33399508|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
32763867|NCT04413409|No Intervention|systemic group|After confirmation of puncture, receive systemic treatment
32763868|NCT05375461|Experimental|TQB3616 capsules plus fulvestrant|"The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
33399509|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
33399510|NCT04254198|Placebo Comparator|Control|Modified Attention Placebo Control
33399511|NCT04254198|Experimental|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
33399512|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
33399513|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
33399514|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
33399515|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
33399516|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
33399517|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
33399518|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
32763869|NCT05375461|Placebo Comparator|TQB3616-matching placebo plus fulvestrant|"The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
33399519|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg"
33399520|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
33399521|NCT02392858|Other|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
33399522|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
33399523|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
33399524|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.~Wounds of patients will be managed by closed dressing to be changed on every third day."
33399525|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
32763870|NCT05098093|Active Comparator|Standardized botanical extract|
32763871|NCT05098093|Active Comparator|Dry botanical extract|
32763872|NCT05098093|Active Comparator|Botanical powder|
33399526|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
33399527|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
33399528|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
32763873|NCT05097781|Experimental|Treatment arm|Local irradiation + immunotherapy
32763874|NCT04524481||Patients with mild haemophilia A or B|(FVIII or IX >5 %, ≥ 18 years' old)
32763875|NCT04524481||Patients with moderate haemophilia A or B|(FVIII or IX 1-5 %, ≥ 18 years' old)
33399529|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
33399530|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
33399531|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
33399532|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
33399533|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
33399534|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
32763876|NCT04524481||Patients with severe haemophilia A or B|(FVIII or IX <1 %, ≥ 18 years' old)
32763877|NCT05374213|Experimental|Mindfulness-based intervention|Participants will take part in an adapted and abbreviated version of the traditional eight-week MBCT protocol, conducted virtually via Zoom. Participants will meet for five, weekly, two-hour sessions. The group size will be larger than traditional MBCT groups (i.e. 16-20 participants rather than 12 participants).
32763878|NCT05374213|No Intervention|Waitlist|Participants will be placed in a group with no treatment interventions for the duration of five weeks. Once these five weeks are complete, these participants will be placed in the next mindfulness clinic session to receive treatment. This does not the typical wait-list time for clinical services, which currently exceeds eight weeks
32763879|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
33399535|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
33399536|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
33399537|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
33399538|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
33399539|NCT05744596||Incisura biopsy +|this arm has the incisura biopsy scored and added in the OLGA final stage
33399540|NCT05744596||Incisura biopsy -|this arm only has corpus and antrum biopsies scored for OLGA staging
33399541|NCT05379985|Experimental|Experimental: RMC-6236|"Enrollment into dose exploration may be from any advanced solid tumor type with specific KRAS p.G12 mutations.~Dose Expansion may proceed with one or more groups consisting of subjects with a single histotype/genotype (for example, KRAS p.G12 mutant NSCLC, PDAC, or CRC)."
33399542|NCT02392780|Experimental|Cannabidiol|
33399543|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
33399544|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
33399545|NCT02393014|Experimental|Low fall risk|low fall risk patients
33399546|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
33399547|NCT02393014|Experimental|High fall risk|high fall risk patients
33399548|NCT04487886|Experimental|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
33399549|NCT04487886|Placebo Comparator|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
33399550|NCT04053478|Experimental|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
33399551|NCT04053478|Experimental|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
33399552|NCT04053478|Experimental|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
33399553|NCT04053478|Experimental|Myometrium + Vasopressin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
32763880|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
32763881|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
32763882|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
32912967|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
33399554|NCT04053478|Experimental|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
33399555|NCT04053478|Experimental|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
33399556|NCT04053478|Experimental|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
33244007|NCT04502550||Parkinson's Disease patients with DBS, no stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
33399557|NCT04053478|Experimental|Umbilical artery + Vasopressin|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
32763883|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
32763884|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
32763885|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
32763886|NCT04245475|No Intervention|Control Group|No treatment, side study to test the assumptions of our quantitative sensory testing pain paradigm
32763887|NCT04245475|Active Comparator|Low Tech/passive Virtual Reality first|Low Tech VR first brief test phase thermal stimulus + High Tech VR during a second test phase pain stimulus
32763888|NCT04245475|Experimental|High Tech/interactive Virtual Reality first|High Tech/Interactive VR during first brief test phase thermal stimulus + Low Tech VR during a second brief thermal stimulus.
32763889|NCT05098405|Experimental|Dose-escalation Cohorts (q3w)|"The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
32763890|NCT05098405|Experimental|Dose-escalation Cohorts (q1w)|"The starting dose is 0,5mg/kg every week (q1w) and up to 3 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
32763891|NCT05097547|Experimental|Contingency management|This arm will include data from participants who received CM
32763892|NCT05096221|Experimental|SRP-9001 followed by Placebo|Participants will receive single intravenous (IV) infusion of SRP-9001 on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.
32763893|NCT05096221|Placebo Comparator|Placebo followed by SRP-9001|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of SRP-9001 at Year 2.
32763894|NCT04110613|Active Comparator|noFast: Start tube feeds within 1 hour of procedure|The noFAST group will have post-PEG tube feeds initiated <1 hour after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
32763895|NCT04110613|No Intervention|FAST: Start tube feeds 4 hours after procedure|The FAST group will have post-PEG tube feeds initiated 4 hours after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
32763896|NCT03987139|Other|All patients|Patients included in the study.
32763897|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
32763898|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
32763899|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
32763900|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
32763901|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
32763902|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
32763903|NCT04829123|Experimental|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763904|NCT04829123|Experimental|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763905|NCT04829123|Experimental|Single dose of 5.1 mg HEC88473|Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763906|NCT04829123|Experimental|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763907|NCT04829123|Experimental|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763908|NCT04829123|Experimental|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763909|NCT04829123|Experimental|Single dose of 34.0 mg HEC88473|Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763910|NCT04829123|Experimental|Single dose of 44.2 mg HEC88473|Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
32763911|NCT04829123|Experimental|Multiple doses of 1.7 mg HEC88473|Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
32763912|NCT04829123|Experimental|Multiple doses of 5.1 mg HEC88473|Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
32763913|NCT04829123|Experimental|Multiple doses of 10.2 mg HEC88473|Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
32763914|NCT05177159||Postoperative delirium|
32763915|NCT05177159||Non postoperative delirium|
32763916|NCT03939949|Experimental|High Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about pain) twice daily for six days.
32763917|NCT03939949|Experimental|Low Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to pain) twice daily for six days.
32763918|NCT03939949|Active Comparator|Active control|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about pain) twice daily for six days.
32763919|NCT05163665|Experimental|Through-the-Scope clip group|Through the scope Dual Action Tissue Clip (DAT) clipping equipment and technique performed in closure of GI defect area after polyp removal.
32912968|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
32912969|NCT03294135|Experimental|Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 28 (+10) and 300 (+21), booster vaccination of 55 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
32912970|NCT03294135|Experimental|Accelerated/Rapid Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 7 (+3) and 21 (+7), booster vaccination of 9 subjects in study V48P7E1 (NCT00387634) 40 subjects received their booster vaccination before enrolment in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
32912971|NCT03294135|Experimental|Accelerated Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 133 subjects in study V48P7 on Days 0, 14 (+3) and 300 (+21), booster vaccination of 109 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
32912972|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
32912973|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
32912974|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
32912975|NCT02398188|Experimental|LIPO-202|Experimental arm
32912976|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
32912977|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
32912978|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
32912979|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
32912980|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
32912981|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
32912982|NCT05448066|Active Comparator|Standard diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
32912983|NCT05448066|Experimental|CRD diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.
32912984|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
32912985|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
32912986|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
32912987|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
32912988|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
32912989|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
32912990|NCT02397096|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
32912991|NCT02397096|Active Comparator|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
32912992|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
32912993|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
33244008|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
33244009|NCT04502550||Parkinson's Disease patients with DBS, Gpi stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads during propofol induced loss of consciousness."
33244010|NCT04502550||Parkinson's Disease patients with DBS, Gpe stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads during propofol induced loss of consciousness."
33399558|NCT04053478|Experimental|Umbilical vein + Ephedrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
32763920|NCT05163665|Active Comparator|X-Tack suturing group|Use of Endoscopic Helix Tacking System (X-Tack) by Apollo Endosurgery for the closure of GI defect after polyp removal.
32763921|NCT04434599|Active Comparator|Fluoroscopically guided ablation|These patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
32763922|NCT04434599|Active Comparator|Contact force guided ablation|These patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
32763923|NCT04434599|Active Comparator|Local impedance guided ablation|These patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
32763924|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
32763925|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32763926|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
32763927|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
32763928|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
32763929|NCT04773665|Experimental|Phase 1a, Group G1|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
32763930|NCT04773665|Experimental|Phase 1a, Group G2|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
32763931|NCT04773665|Placebo Comparator|Phase 1a, Group G3|20 participants age 18-54 will receive placebo at Days 1 and 28
32763932|NCT04773665|Experimental|Phase 1b, Group G4|27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
32763933|NCT04773665|Placebo Comparator|Phase 1b, Group G5|27 participants age 18-54 will receive placebo at Day 1
32763934|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
32763935|NCT04759703|Experimental|Pramipexole|Medication arm; 0.25 or 0.5 mg of pramipexole
32763936|NCT04759703|Placebo Comparator|Placebo|Placebo arm; 0.25 or 0.5 mg of placebo
32763937|NCT03597581|Experimental|Single agent RGX-202-01 Dose Escalation|RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
32763938|NCT03597581|Experimental|RGX-202-01 in combination with FOLFIRI Dose Escalation|"RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle."
32763939|NCT03597581|Experimental|Expansion: 2nd Line Colorectal Cancer (CRC) KRAS (+)|"2nd Line CRC RAS (+)~RGX-201-01 is administered orally twice on days 1-28 of each 28-day cycle.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle.~Bevacizumab is administered as follows: 5 mg/kg on Days 1 and 15 of each 28-day cycle."
32763940|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
32912994|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
33399559|NCT04053478|Experimental|Umbilical vein + Phenylephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
33399560|NCT04053478|Experimental|Umbilical vein + Norepinephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
33399561|NCT04053478|Experimental|Umbilical vein + Vasopressin|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
33244011|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpe stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
32912995|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
32912996|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
32912997|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
32912998|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
32912999|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
32913000|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
32913001|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
32913002|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
32913003|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
32913004|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
32913005|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
32913006|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
32913007|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
32913008|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
32913009|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
33244012|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpi stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
33244013|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, no stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will not receive any stimulation via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
33244014|NCT04227184|Experimental|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
33244015|NCT04227184|Experimental|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
33244016|NCT04190446|Experimental|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks.
33244017|NCT04190446|Experimental|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks.
33244018|NCT04018950|Experimental|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
33244019|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
33244020|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
33244021|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
33244022|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
33244023|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
33244024|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
32763941|NCT03573089|Active Comparator|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
33244025|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
33244026|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
33244027|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
33244028|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
33244029|NCT00923806|Experimental|Gene Therapy Treatment|
33244030|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
33244031|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
33244032|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
32763942|NCT03573089|Experimental|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
33244033|NCT00711984|Active Comparator|2|Best medical treatment alone
33244034|NCT00856102|Experimental|Exercise|
33244035|NCT00856102|No Intervention|Control|
33244036|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
33244037|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
33244038|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
33244039|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
33244040|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
33244041|NCT00716118||1|IVF patients.
33244042|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
33244043|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
32763943|NCT05087407|Experimental|decomprssion and drainage seton|
32763944|NCT05087407|Active Comparator|Cutting seton|
32763945|NCT05086003|Experimental|Kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation after preparation with thymoglobuline and total lymphoid irradiation
32763946|NCT05090501|Experimental|Green|Green exercise participants will exercise in the nature-based condition.
32763947|NCT05090501|Experimental|Indoor|Indoor participants will exercise in the indoor condition.
33244044|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
33244045|NCT04103970|No Intervention|Control group|"Usual care:~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
33244046|NCT04103970|Experimental|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
33073114|NCT03773965|Experimental|Baricitinib|Baricitinib given orally.
33244047|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
33244048|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
33073117|NCT03762096|Experimental|Resveratrol|
33244049|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
33244050|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
33244051|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
33244052|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
33244053|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
33244054|NCT00712218|Active Comparator|A|
33244055|NCT00712218|Experimental|B|
33073118|NCT03762096|Placebo Comparator|Placebo|
33073119|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
33073120|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
33073121|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
33244056|NCT00848224|Experimental|2|
33244057|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
33244058|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
33244059|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
33244060|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
33244061|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
33244062|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
33244063|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
33244064|NCT00718614|Other|4|healthy volunteers, matched for age and sex
33244065|NCT04069728|Other|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
33244066|NCT04069728|Experimental|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
33244067|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
33244068|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33244069|NCT00712452|Other|1|systemic lupus erythematosus
33244070|NCT00712452|Other|2|breast cancer
33244071|NCT00712452|Other|3|Hodgkin disease
33244072|NCT04070274|Experimental|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
33244073|NCT04070274|Experimental|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
33244074|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
33244075|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
33244076|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
33244077|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
33244078|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
33244079|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
33244080|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
32763948|NCT05026801|Active Comparator|Azithromycin plus hydroxychloroquine|Azithromycin 500 mg plus hydroxychloroquine 600 mg by mouth daily for six consecutive days
32763949|NCT05026801|Placebo Comparator|Placebo|Placebo
32763950|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
32763951|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
33073122|NCT03745339||Controls|Men and women with no history of a substance-use disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
33073123|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
32763952|NCT05020795|Experimental|Balloon inflation|Endovascular thrombectomy with simultaneous balloon inflation using a balloon guide catheter
32763953|NCT05020795|Active Comparator|No balloon inflation|Endovascular thrombectomy without simultaneous balloon inflation using a balloon guide catheter
32763954|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
33073124|NCT03739814|Experimental|Cohort 1 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description
33073125|NCT03739814|Experimental|Cohort 2 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description.
32763955|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
32763956|NCT04718675|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of KB-0742.
32763957|NCT04718675|Experimental|Part 2: Cohort Expansion|"Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) in Part 1, the following expansion cohorts will be enrolled:~Cohort A: Relapsed or refractory (R/R) solid tumors with evidence of MYC amplication/overexpression.~Cohort B: Relapsed or refractory (R/R) small cell lung cancer (SCLC) and soft tissue sarcomas with evidence of transcription factor dysregulation."
32913010|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
32913011|NCT04915950|Experimental|Temanogrel (Stage A Dose 1)|
32913012|NCT04915950|Experimental|Temanogrel (Stage A Dose 2)|
33244081|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
33244082|NCT02544880|Experimental|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
33244083|NCT02544880|Experimental|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
33244084|NCT02544880|Other|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
33244085|NCT00718926||Sjogren|Sjogren syndrome with dry eye
33244086|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
33244087|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
33244088|NCT00718926||control|normal patients
33244089|NCT04068870|Experimental|Contraceptive management program|
33244090|NCT04068870|No Intervention|Usual care|
33244091|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
33244092|NCT00856648||Group 1|SCI
33244093|NCT00856648||Group 2|Able-bodied
33244094|NCT00719082||AARP Community|Members of AARP Geriatric Community
33244095|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
33244096|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
33244097|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
33244098|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
33244099|NCT00856882|Experimental|soy protein and isoflavones|
33244100|NCT00856882|Experimental|milk protein and isoflavones|
33244101|NCT00856882|Placebo Comparator|milk protein only|
33244102|NCT00712686|Active Comparator|A1|
33244103|NCT00712686|Active Comparator|B1|
33244104|NCT04041856|Active Comparator|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
33244105|NCT04041856|No Intervention|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
33244106|NCT04371666|Experimental|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
33244107|NCT04371666|Experimental|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
33244108|NCT00856960|Active Comparator|1|Aliskiren 600 mg
33244109|NCT00856960|Active Comparator|2|Aliskiren 150 mg
33244110|NCT00856960|Active Comparator|3|Losartan 100 mg
33244111|NCT00856960|Placebo Comparator|4|Placebo
33244112|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
33244113|NCT00712764|Active Comparator|1|
33244114|NCT00712764|Placebo Comparator|2|
33244115|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
33244116|NCT00848458|Active Comparator|Azelaic acid topical|
33244117|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
33244118|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
33244119|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
33244120|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
33244121|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
33244122|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
33244123|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
33244124|NCT00848692|Experimental|1|Rituximab
33244125|NCT00848692|Placebo Comparator|2|Placebo (saline)
33244126|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
33244127|NCT00712842||2|Healthy control subjects
33244128|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
32737405|NCT04467879|Sham Comparator|"Control Device - Sham - Weaker Grip"|Using the Zona Sham Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment (the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
32737406|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
32737407|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
32737408|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
32737409|NCT05052879|Experimental|TORONTO 20 + 30/60|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of Toronto association, oral;~1 tablet of tadalafil placebo, oral."
32737410|NCT05052879|Active Comparator|TADALAFIL|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of tadalafil , oral;~1 tablet of Toronto association placebo, oral."
32913013|NCT04915950|Placebo Comparator|Placebo (Stage A)|
32913014|NCT04915950|Experimental|Temanogrel (Stage B Dose 1)|
33244129|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
33244130|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
33244131|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
33244132|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
33244133|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
33244134|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
33244135|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
33244136|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
33244137|NCT00713154|Placebo Comparator|1|Placebo group
33244138|NCT00713154|Active Comparator|2|Control Group
33244139|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
33244140|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
33244141|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
33244142|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
33244143|NCT04069130|Experimental|BIA 5|single oral dose of 400 mg as an oral capsule
33244144|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
33244145|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
33244146|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
33244147|NCT04042012|Experimental|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
33244148|NCT04042012|Experimental|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
33073126|NCT03737955|Experimental|Treatment (gemtuzumab ozogamicin)|Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
33073127|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
32913015|NCT04915950|Experimental|Temanogrel (Stage B Dose 2)|
32913016|NCT04915950|Placebo Comparator|Placebo (Stage B)|
32913017|NCT04976595|Experimental|Natesto|Participants will administer Natesto, gel, intranasally, three times daily up to Day 120. A multiple-dose dispenser will be used for gel deposition into the nasal cavity.
32913018|NCT03074643|Placebo Comparator|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
32913019|NCT03074643|Active Comparator|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
33244149|NCT04042012|Experimental|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
33244150|NCT00719238|Experimental|1|
33244151|NCT00719238|Active Comparator|2|
33244152|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
33244153|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
33244154|NCT00857038|Experimental|1|Doxycycline 100mg daily
33244155|NCT00857038|Placebo Comparator|2|Placebo
33244156|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
33244157|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
33244158|NCT00720200|Experimental|1|
33244159|NCT00720200|Active Comparator|2|
33244160|NCT03926988|Other|Intervention|NeVa Stent Retriever
33244161|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
33244162|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
33244163|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
33244164|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
33244165|NCT00719394|Experimental|GSI 136|
33244166|NCT00719394|Placebo Comparator|placebo|
33244167|NCT00857194||Group 2|Chronic, stable spinal cord injury
33244168|NCT04011410|Experimental|Hydroxychloroquine|"Hydroxychloroquine (HCQ)~DOSAGE FORM: 200 mg tablet, oral route~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg~FREQUENCY: HCQ is taken twice daily (morning and night) with food.~DURACTION OF HCQ: 90-days"
33244169|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
33244170|NCT00857350||HIV+, opiod dependent|
33244171|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
33244172|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
33244173|NCT04068558|Experimental|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
33244174|NCT04068558|Experimental|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
33244175|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
33244176|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
33244177|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
33244178|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
33244179|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
32913020|NCT03074643|Active Comparator|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
32913021|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
32913022|NCT00367965|Experimental|1|eszopiclone 3 mg
32913023|NCT00367965|Placebo Comparator|2|placebo tablet
33244180|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
33244181|NCT04018768||Ibuprofen + Percocet|
33244182|NCT04018768||Percocet|
33244183|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
33244184|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
33244185|NCT00848848|Active Comparator|1|
33244186|NCT00848848|Active Comparator|2|
33244187|NCT00848848|Active Comparator|3|
33244188|NCT00848848|Active Comparator|4|
33244189|NCT00848848|Active Comparator|5|
33244190|NCT00848848|Active Comparator|6|
33244191|NCT00848848|Active Comparator|7|
33244192|NCT00848848|Active Comparator|8|
33244193|NCT00848848|Active Comparator|9|
33244194|NCT00848848|Active Comparator|10|
33244195|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
33244196|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
33244197|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
32913024|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
32737411|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
32913025|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
32763958|NCT03818659|Active Comparator|Self-Guided|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
33244198|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
33244199|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
33244200|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
33244201|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
33244202|NCT00857662|Experimental|Onyx|
33244203|NCT00857662|Active Comparator|TRUFILL|
33244204|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
33244205|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
33244206|NCT04067180|Experimental|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
33244207|NCT04067180|Active Comparator|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
32763959|NCT03818659|Experimental|Full Support|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
32763960|NCT03818659|No Intervention|Usual Care|"The investigators will also conduct non-randomized comparisons of BP control in the Full Support and Self-Guided intervention arms to BP control in non-participating Usual Care institutions in PCORnet."
32763961|NCT05073575|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
32763962|NCT05073575|Active Comparator|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
32763963|NCT03789877|Experimental|Group I (home-based walking program, rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
32763964|NCT03789877|Active Comparator|Group II (home-based exercise program, sham rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo sham repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
32763965|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
32763966|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
32763967|NCT03786991||Organ donors|Organ donors after neurologic death (NDD) of 18 years old and older for whom consent to organ donation has been obtained.
32763968|NCT03786991||Liver and kidney Recipients|Liver and kidney recipients of 18 years old and older.
32763969|NCT04965727|Experimental|Deep brain stimulation|"Participants will undergo a surgery for Deep Brain Stimulation (DBS). The neurostimulation system will be used for neuro-rehabilitation of the motor function.~Participants will follow a 3-month neuro-rehabilitation using DBS at a frequency of 3 times per week with physiotherapist."
32763970|NCT05066009|Experimental|Prescribed medication followed by drug holiday|Participants will complete the study assessments on a day when they take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they do not take the medication.
33244208|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
33244209|NCT02545894|Experimental|Treatment|"Intervention given:~visual tracking pressing a button every time a picture is seen on the screen~playing dominoes and snap~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
33244210|NCT02545894|No Intervention|Post intervention|Repeated testing
33244211|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
33244212|NCT00424177|Experimental|eltrombopag|
33244213|NCT04068116|Experimental|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion & re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
33244214|NCT04068116|Active Comparator|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
33244215|NCT00716430|Active Comparator|QI|Quality Improvement Centres
33244216|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
33244217|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32763971|NCT05066009|Experimental|Drug holiday followed by prescribed medication|Participants will complete the study assessments on a day when they do not take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they take their medication as prescribed.
33244218|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33244219|NCT04069286|Experimental|Treated Group|in which dry Aroeira extract (Schinus terebinthifolius raddi, 640mg / tablet) will be administered + amoxicillin 500mg 2 tablets + clarithromycin, 500mg 1 tablet given twice daily (12/12 hours).
33244220|NCT04069286|Active Comparator|Control Group|in which 1 tablet of 20mg of omeprazole will be administered + amoxicillin 2 tablets of 500mg + clarithromycin, 1 tablet of 500mg administered twice daily (12/12 hours).
33244221|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
33244222|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
33244223|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
33244224|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
33244225|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
32763972|NCT03943693|Active Comparator|Single Shock Group|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only.
32763973|NCT03943693|Active Comparator|Double Shock Group|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.
32763974|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
32763975|NCT05375617||Acute lymphoblastic leukemia cohort|
32763976|NCT05375617||Brain tumor cohort|
32763977|NCT03809533|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Kidney recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
32763978|NCT03809533|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Starting post-operative day 1, kidney recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
32763979|NCT03410017||Normally-hearing|Children with normal hearing
32763980|NCT03654547|Experimental|Dose Escalation|Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
33244226|NCT03992846|Experimental|Linzagolix 75 mg|
33244227|NCT03992846|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
33244228|NCT03992846|Placebo Comparator|Placebo|
33244229|NCT00713622|Active Comparator|1|
33244230|NCT00713622|Active Comparator|2|
33244231|NCT00719940|Experimental|1|Cognitive behavioral therapy
33244232|NCT00719940|Placebo Comparator|2|Waiting group
33244233|NCT00720018|Experimental|Period 1|NP101 Patch
33244234|NCT00720018|Experimental|Period 2|NP101 Patch
33244235|NCT00720018|Experimental|Period 3|NP101 Patch
33244236|NCT00720018|Experimental|Period 4|NP101 Patch
33244237|NCT00720018|Experimental|Period 5|NP101 Patch
33244238|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
33244239|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
33244240|NCT03992456|Experimental|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
32913026|NCT02975505|Experimental|Strict SBP Target|Target Systolic Blood Pressure <120 mm Hg
33244241|NCT03992456|Active Comparator|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
33073131|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
33073132|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
33073133|NCT03706365|Experimental|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
33073134|NCT03706365|Experimental|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
33244242|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
33244243|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
33244244|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
32763981|NCT03654547|Experimental|Dose Expansion|A Dose Expansion cohort will be opened to enroll patients with selected advanced solid tumors and evaluate the safety, PK and preliminary efficacy of TT-00420 to determine the recommended phase 2 dose in patients with advanced solid tumors.
32763982|NCT03516877|Experimental|ESRT|"Volunteer surgery and anesthesia faculty from UCSF working at Parnassus Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Zuckerberg San Francisco General Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Mission Bay Hospital site and interested in training."
32763983|NCT04800523|Experimental|Arm 1 - Non-functional Device|a non-functional UroMonitor will be inserted by urologist.
32763984|NCT04654897|Experimental|Elinzanetant (NT-814, BAY3427080)|Subjects received a single dose of 120 mg radioactive labeled elinzanetant ([14C]-NT-814) orally.
32763985|NCT03236077|No Intervention|Control|
32763986|NCT03236077|Experimental|Intervention|
32763987|NCT05358925|Experimental|BPD Videos and Feedback|Ten daily 12-minute psychoeducational videos about BPD and personalized feedback about performance on neuropsychological tasks.
32763988|NCT05358925|Experimental|BPD Videos and No Feedback|Ten daily 12-minute psychoeducational videos about BPD.
32763989|NCT05358925|Sham Comparator|Non-BPD Videos and No Feedback|Ten daily 12-minute educational videos about health-related topics other than BPD.
32763990|NCT04554043|Experimental|SHR7280 dose 1(male)|oral administration for 14 days,Phase I(PART 1)
32763991|NCT04554043|Experimental|SHR7280 dose 2(male)|oral administration for 14 days,Phase I(PART 1)
32763992|NCT04554043|Experimental|SHR7280 dose 3(male)|oral administration for 14 days,Phase I(PART 1)
32763993|NCT04554043|Experimental|SHR7280 dose 4(male)|oral administration for 14 days,Phase I(PART 1)
32763994|NCT04554043|Experimental|SHR7280 dose 5(male)|oral administration for 14 days,Phase I(PART 1)
32763995|NCT04554043|Experimental|SHR7280 dose 1(female)|oral administration for 21 days,Phase I(PART 2)
32763996|NCT04554043|Experimental|SHR7280 dose 2(female)|oral administration for 21 days,Phase I(PART 2)
32763997|NCT04554043|Experimental|SHR7280 dose 3(female)|oral administration for 21 days,Phase I(PART 2)
32763998|NCT04554043|Experimental|SHR7280 dose 4(female)|oral administration for 21 days,Phase I(PART 2)
32763999|NCT04554043|Experimental|SHR7280 dose 6(male)|oral administration for 14 days,Phase I(PART 1)
32764000|NCT04554043|Experimental|SHR7280 dose 7(male)|oral administration for 14 days,Phase I(PART 1)
32764001|NCT04523935|Placebo Comparator|Placebo-Sequence 1|The placebo contained fructose powder in packets identical to the medicines.
32764002|NCT04523935|Active Comparator|Drug-Sequence 2|GABA-B agonists, muscarinic acetylcholine receptor antagonists, inhibitors of the vesicular monoamine transporter, benzodiazepines, antiepileptics, and tricyclic antidepressants were used.
33244245|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
33244246|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
33244247|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
33244248|NCT04041544|Active Comparator|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
33244249|NCT04041544|Placebo Comparator|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
33244250|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
33244251|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
33244252|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
33244253|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
33244254|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
33244255|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
33244256|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
33244257|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
32764003|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
32764004|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
33244258|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
32764005|NCT05059301|Experimental|RSV OA_Lot 1|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and were followed up until the study end (Month 6).
32764006|NCT05059301|Experimental|RSV OA_Lot 2|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and were followed up until the study end (Month 6).
32764007|NCT05059301|Experimental|RSV OA_Lot 3|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and were followed up until the study end (Month 6).
32764008|NCT03450473|Other|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
32764009|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
32764010|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
32764011|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
32764012|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
32764013|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
32764014|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
32764015|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
32764016|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
32764017|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
32764018|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
32764019|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
32764020|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
32764021|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
32764022|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
32764023|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
32764024|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
32764025|NCT04625530|Experimental|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
32764026|NCT04625530|Experimental|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
32913027|NCT02975505|No Intervention|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
32764027|NCT04625530|Experimental|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
32913028|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
33073135|NCT03706365|Active Comparator|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
33244259|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
33244260|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
33073136|NCT03706365|Active Comparator|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
33073137|NCT03706365|Experimental|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
33399562|NCT04474392||At-Risk (N=180)|"No evidence of inflammatory arthritis on clinical examination AND~At elevated risk for RA based on familial or serologic risk~Familial risk includes having a first degree relatives (FDRs) with RA~Serologic risk includes asymptomatic serum ACPA positivity~There will be 1 study visit per year for 3 years; for a subset of 30 of these participants, there will be an additional 3 quarterly visits in one year.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
33073138|NCT03706365|Active Comparator|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
32737412|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
32737413|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
32913029|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
32913030|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
32913031|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
32913032|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
32913033|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
32913034|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
32913035|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
32913036|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
32913037|NCT04922463|No Intervention|Control group|
32913038|NCT04922463|Experimental|1x PLASOMA|
32913039|NCT04922463|Experimental|2x PLASOMA|
32913040|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
32913041|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
33073139|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
33073140|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
32737414|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
33244261|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
32764028|NCT04625530|No Intervention|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
32764029|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
33244262|NCT00713856|Active Comparator|1|
33244263|NCT00713856|Active Comparator|2|
32764030|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
32764031|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
32764032|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
32764033|NCT04635436||Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
32764034|NCT04634968|Experimental|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
32764035|NCT04634968|Placebo Comparator|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
32764036|NCT04634266|Experimental|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
32764037|NCT04634266|No Intervention|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
32764038|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
32764039|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
32764040|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
32764041|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
32764042|NCT01936870||Fesoterodine (Toviaz)|
32764043|NCT04632940|Experimental|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
32764044|NCT04632940|Placebo Comparator|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
32764045|NCT01618864|Other|Luxe|
32764046|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
32764047|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
32764048|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
32764049|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
33244264|NCT03472040|Experimental|BCX7353 150 mg once daily|
33244265|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
33244266|NCT00713934|Experimental|1|
33244267|NCT00713934|Experimental|2|
33244268|NCT00849160|Experimental|Darunavir/r|
33244269|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
33244270|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
33244271|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
33244272|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
33244273|NCT00857974|Active Comparator|Physical Activity|
33244274|NCT00720252|Experimental|A|
33244275|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
33244276|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
32913042|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
33244277|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
33244278|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
33244279|NCT00718406|Active Comparator|A|A=metoprolol
33244280|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
33244281|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.~30 minute structural MRI will be obtained to permit co-registration of PET images."
33244282|NCT05374070|Active Comparator|Streptococcus salivarius K12|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
33244283|NCT05374070|Active Comparator|Streptococcus salivarius K12 with a prebiotic included|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
33244284|NCT05374070|Active Comparator|Streptococcus salivarius M18|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
33244285|NCT05374070|Active Comparator|Streptococcus salivarius M18 with a prebiotic included|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
33244286|NCT00720408|Experimental|Prograf-XL + MMF|
33244287|NCT00720408|Active Comparator|Prograf + MMF|
33244288|NCT00849316||A|
33244289|NCT05373836||brain tumor surgery|adult patients undergoing brain tumor surgery
33244290|NCT00852670|Experimental|A|
33244291|NCT00852670|Placebo Comparator|B|
33244292|NCT00717210|Active Comparator|A|Conventional Radiotherapy
33244293|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
33399563|NCT04474392||Healthy Controls (N=120)|"No history of RA~No FDRs with RA~No systemic use of immunosuppressants for autoimmune disease~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
33244294|NCT05373758|Experimental|Maintenance on TLD|Participants will undergo routine enhanced adherence counseling (EAC) at the enrollment visit (Week 0) and will be maintained on TLD. At Week 24, participants will undergo phlebotomy for repeat plasma HIV-1 RNA viral load testing. If the HIV-1 RNA viral load is >1,000 copies/mL, the participant will be switched to protease inhibitor (PI)-based second-line ART. Otherwise, the participant will be continued on TLD. Participants will continue to have routine care visits, EAC, and viral load monitoring at intervals determined by the clinic as per national guidelines. At study completion, participants will undergo plasma HIV-1 RNA viral load testing at Week 48. For pregnant participants randomized to the Maintenance on TLD arm, the second visit will be completed at Week 4, rather than Week 24.
33244295|NCT05373758|Experimental|Individualized Care|Participants will undergo routine EAC, point-of-care urine tenofovir (TFV) testing, and genotypic resistance testing (GRT) at enrollment. Participants will return when GRT results are available for a treatment decision. Side effects and tolerance will also be assessed. All information will be used to make an optimal treatment recommendation with participant input. Participants will have an additional study visit at Week 24 and will continue to have routine care visits, adherence counseling by the clinic, and viral load monitoring at intervals determined by the clinic per national guidelines. Participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
33244296|NCT05373758|Experimental|Immediate Switch|Participants will undergo routine EAC and a switch from TLD to PI-based second-line ART at the enrollment visit (Week 0). Participants will have an additional study visit at Week 24. Participants will continue to have routine care visits and viral load monitoring at intervals determined by the clinic per national guidelines. At study completion, participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
33244297|NCT00849394||1|Shortened infusions of bevacizumab
33244298|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
33244299|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
33244300|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
33244301|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
32764050|NCT03315455|Experimental|Arm A: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
32764051|NCT03315455|Experimental|Arm B: Emicizumab Prophylaxis at 6 mg/kg Q4W|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm B will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
32764052|NCT03315455|Other|Arm C: No Prophylaxis (Control Arm)|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm C will not receive any prophylactic treatment for at least 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
32764053|NCT03315455|Experimental|Arm D: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants <12 years old with hemophilia A and FVIII inhibitors who are enrolled to Arm D will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
32764054|NCT04615078|Experimental|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
32764055|NCT04615078|No Intervention|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
32764056|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
32764057|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
32764058|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
32764059|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
32764060|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
32764061|NCT04642469|Experimental|Durvalumab|Intravenous administration of Durvalumab
32764062|NCT04642469|Placebo Comparator|Placebo|Intravenous administration of placebo
32764063|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
32764064|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
32764065|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
32764066|NCT03259295|Experimental|Skin tag removal initial visit plus follow-up|Removal of skin tags 1 cm or less using Digiclamp and follow-up 2-3 months after skin tag removal to assess functionality and effectiveness of the device.
32764067|NCT04871399|Active Comparator|Conventional Right hemicolectomy (Non-CME)|Patients will undergo conventional non-CME procedure.
32764068|NCT04871399|Experimental|Right hemicolectomy with CME+CVL|Patients will undergo Right hemicolectomy CME+CVL procedure.
32764069|NCT04869761|Experimental|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.
32764070|NCT04869761|Experimental|Dose Arm 2|Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0.
32913043|NCT04914507|Other|Anterior Vertebral Body Tethering|The subject is will receive anterior vertebral body tethering surgery, as clinically indicated, after all pre-operative assessments are complete.
32764071|NCT04432025|Active Comparator|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
33244302|NCT05373680|Experimental|Metformin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive metformin 1000 mg PO daily added to their usual therapy.
33244303|NCT05373680|Experimental|Empagliflozin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive empagliflozin 10 mg daily PO added to their usual therapy.
33244304|NCT05373680|Other|Control group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive their usual therapy.
33244305|NCT04018378|Experimental|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
32913044|NCT04910373|Experimental|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period
33244306|NCT04018378|Experimental|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
33244307|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
33244308|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
33244309|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
33244310|NCT05373524|Active Comparator|the rheopheresis group|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
33244311|NCT05373524|Placebo Comparator|the shamapheresis group|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
33244312|NCT00849550|Experimental|XELOX-A-Ev|
33244313|NCT04018976|Experimental|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
33244314|NCT04018976|Active Comparator|Heat Only|AVACEN 100 applies heat only
33244315|NCT04018976|Sham Comparator|Sham|AVACEN 100 applies neither heat nor vacuum
33244316|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
33244317|NCT05373368|Experimental|home residents|multi purpose activities were performed for home residents
33244318|NCT05373368|Experimental|nursing home residents|multi purpose activities were performed for nursing home residents
33244319|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
33244320|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
33244321|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
33244322|NCT00858676|Active Comparator|Acarbose|
33244323|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
32913045|NCT04910373|Placebo Comparator|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
32913046|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
33244324|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
33244325|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
32913047|NCT04885179||Individuals with SPLIS|Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
33244326|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
33244327|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
33244328|NCT00849628||1|Constipation
33244329|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
33244330|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
33244331|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
33244332|NCT00858910|Placebo Comparator|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
33244333|NCT03436238||MINSS cohort|"Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
33244334|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
33244335|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
33244336|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
33244337|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
33244338|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
33244339|NCT00720824|Placebo Comparator|2|Office routine
33244340|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
33244341|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
33244342|NCT05373134|Experimental|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
33244343|NCT05373134|Placebo Comparator|Placebo|Placebo will be given in a same manner as experimental drug
33244344|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
33244345|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
33244346|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
33244347|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
33244348|NCT00578448|Active Comparator|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
33244349|NCT00578448|Active Comparator|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
32913048|NCT04885179||Parents of individuals with SPLIS|Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
33244350|NCT05373056|Active Comparator|Group 1- Control group|They will performer the conventional exercise program por epicondylar muscles.
33244351|NCT05373056|Experimental|Group 2 - Experimental group|The experimental group will perform the conventional exercise program and also a scapular exercise program.
33244352|NCT05372978|Experimental|Cash|Participants will receive a one-time unconditional cash transfer of $8,500 CAD.
33244353|NCT05372978|No Intervention|Control|Participants will not receive a cash transfer.
33244354|NCT02571764|Experimental|Nutritional Oats Cookie|
33244355|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
33244356|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
33244357|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
32913049|NCT04885179||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
32746113|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~A urine sample is taken if possible."
33244358|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
33244359|NCT04070430|Active Comparator|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
33244360|NCT04070430|Active Comparator|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
32764072|NCT04432025|Experimental|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
32764073|NCT04867889|Active Comparator|Active Treatment iTBS|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 20 sessions on 20 week days, one session per day.
32764074|NCT04867889|Sham Comparator|Sham treatment|Sham treatment given either with a sham stimulation coil or by flipping an active coil 90 degrees.
32764075|NCT04440371|Active Comparator|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
32764076|NCT04440371|Active Comparator|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol & betamethasone containing cream will be applied once a day
32764077|NCT04431401|Experimental|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
32764078|NCT04431401|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
32764079|NCT04430543|Experimental|CBM Group|This group will receive Cognitive Bias Modification training
32764080|NCT04430543|Sham Comparator|Control Group|This group will receive Sham (control) training
32764081|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
32764082|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
32764083|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
32764084|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
32764085|NCT04432649|Experimental|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
32764086|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
32764087|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
32764088|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
32764089|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
32764090|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
32764091|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
32764092|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
32764093|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
32764094|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
32764095|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
32764096|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
32764097|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
32764098|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
32764099|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
32764100|NCT04618757|Experimental|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
32764101|NCT04618757|Experimental|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
32764102|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
32764103|NCT04602923|Experimental|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
32764104|NCT04602923|Experimental|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
32764105|NCT04602923|Experimental|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
32764106|NCT01484093|Experimental|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
32764107|NCT00694655|Other|Yellow Fever Virus Vaccine|Participants receiving the yellow fever virus vaccine
32764108|NCT04433975|Experimental|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
32764109|NCT04433975|Active Comparator|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
32913050|NCT05448027|Experimental|Low intensity laser therapy group|• Group (A): lt will include 26 participants suffering from primary dysmenorrhea who will receive low intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
32913051|NCT05448027|Experimental|High intensity laser therapy group|Group (B): It will include 26 participants suffering from primary dysmenorrhea who will receive high intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
32913052|NCT04338867|Active Comparator|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
32913053|NCT04338867|Active Comparator|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
32913054|NCT05447949|Experimental|Group 1 (ESPB + Dexmedetomidine)|Patients received Ultrasound guided ESPB with addition of dexmedetomidine 1 Mcg/kg to 30 ml levobupivacaine 0.25%, N=30 (16)
32913055|NCT05447949|Experimental|Group 2 (ESPB+ dexamethasone)|Patients received Ultrasound guided ESPB with addition of dexamethasone 10 mg to 30 ml levobupivacaine 0.25%, N=30 (16)
32913056|NCT05447949|Active Comparator|Group 3 (ESPB)|Patients received Ultrasound guided ESPB with 30 ml levobupivacaine 0.25%, N=30
33244361|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
33244362|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
33244363|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
33244364|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
32746114|NCT04786665|Experimental|Strawberry powder|Participants consume 1 package of standard strawberry powder (26 g) daily for 8 weeks
32913060|NCT04850625||Pyrotinib Plus Vinorelbine|lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)
32913061|NCT04850625||Lapatinib Plus Capecitabine|pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)
32913062|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
32913063|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
32913064|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
32913065|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
33244365|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
33244366|NCT04067024|Active Comparator|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
33244367|NCT04067024|Experimental|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
33244368|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
33244369|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
33244370|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
33244371|NCT05364710|Experimental|Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where he/she will consume the active intervention.
33244372|NCT05364710|Experimental|Group B|Crossover study: Participants will be consuming the active intervention on a clinic day at least 1 week prior to a clinic day where he/she will consume placebo.
32913066|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
32913067|NCT05447871|Experimental|Ultrasound guided single injection modified 4 in 1 block technique|Patients in this group will receive ultrasound guided single injection modified 4 in 1 block with 25 ml bupivacaine 0.25%
32913068|NCT05447871|Active Comparator|Ultrasound guided adductor canal block technique|Patients in this group will receive ultrasound guided aduuctor canal block with 20 ml bupivacaine 0.25%
32913069|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
32913070|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
32913071|NCT05447793||Fitostimoline Plus|Formulation in gauzes and cream based on a particular Triticum Vulgare Extract (Rigenase®) and polyhexanide, an antiseptic which does not give any bacterial resistance.
32913072|NCT05447793||Connettivina Bio Plus|Formulation in gauzes and cream based on hyaluronic acid and silver sulphadiazine.
32913073|NCT00369447|Experimental|1|200 mg dose
32746115|NCT04786665|Placebo Comparator|Placebo group|Participants consume 1 package of placebo powder (26 g) daily for 8 weeks
32913074|NCT00369447|Placebo Comparator|2|
32913075|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
32913076|NCT05447715|Other|Fruquintinib sequential BEV+FOLFIRI|
32746116|NCT03233087||Top third of subjects based levels of selected biomarker.|
32746117|NCT03233087||Middle third of subjects based levels of selected biomarker.|
32913077|NCT05447715|Other|BEV+FOLFIRI sequential fruquintinib|
32913078|NCT05447637||Individuals who meet NCCN Testing Criteria|
32913079|NCT05447637||Individuals who do not meet NCCN Testing Criteria|
32913080|NCT00914823|Experimental|kisspeptin, GnRH|intravenous or subcutaneous administration of kisspeptin 112-121 and/or administration of GnRH
32913081|NCT05447481|Experimental|Chicory inulin-type fructan - placebo|Dietary supplement: chicory inulin-type fructan Placebo: maltodextrin
33244373|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
33244374|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
33244375|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
33244376|NCT04067544|Other|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
33244377|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
33244378|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
33244379|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
32746118|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
32746119|NCT04786821|Placebo Comparator|Standard Exercise Training Programme|Participants will receive interventions by an exercise specialist based on the participant's tolerance. These sessions will be delivered by a exercise specialist.
33399564|NCT04474392||RA Diagnosis (N=40)|"Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR~Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
33399565|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.~Intervention: Topical Dynamic Phototherapy (TDP)"
32746120|NCT04786821|Active Comparator|Exoskeleton Exercise Programme|The Phoenix Exoskeleton suit will be used in this study. It is a powered Exoskeleton, with a modular design. Participants will receive interventions by an research physiotherapist based on the participant's tolerance.
32764110|NCT04433585|Experimental|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
32764111|NCT04433585|Experimental|LY3471851 Mid Dose|LY3471851 administered SC.
33399566|NCT04468776|Active Comparator|Medication (zolpidem or trazodone)|Zolpidem or trazodone, as prescribed by physician
33399567|NCT04468776|Active Comparator|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|Internet-based CBT-I program
33399568|NCT04468776|Experimental|Combination|Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program
32764112|NCT04433585|Experimental|LY3471851 Low Dose|LY3471851 administered SC
32764113|NCT04433585|Placebo Comparator|Placebo|Placebo administered SC.
32764114|NCT04432805|Experimental|Pregnant women|Pregnant women suspected of COVID-19
32764115|NCT04432493|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
32764116|NCT04432493|Placebo Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
32764117|NCT04982939|Experimental|Experimental Group-Sintilimab in combination with SOX|Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.
32764118|NCT04982939|Active Comparator|Active Comparator-SOX|Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
32764119|NCT04982549|Experimental|Durvalumab + platinum-based chemotherapy and radiation|"All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
32764120|NCT02875223|Experimental|CC-90011 and Rifampicin|
32764121|NCT02875223|Experimental|CC-90011 and Itraconazole|
32764122|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and biopsy on study. Patients also undergo blood sample collection on study.
32764123|NCT04982627|Experimental|Brief Negotiation Interview Chatbot (BNI Chatbot)|Participants will receive a link to register for the chatbot. Following registration, they will complete the initial chat, which includes instructions for the entire study. The chatbot will then guide the participant through multiple BNIs focused on the goal of bup engagement, with the following steps: 1) Raise the Subject/Establish Rapport; 2) Enhance Motivation; 3) Provide & Elicit Feedback; and 4) Negotiate a Plan. The chatbot then reminds the participant of their reasons why they might engage in OUD treatment based on their responses to Steps 2 & 3, and their negotiated plan. The chatbot will electronically connect participants to a treatment provider of their choice, based on available options.
32764124|NCT04982627|Active Comparator|Standard Care (OUD Education & Referral Resources)|• SC: The RA will provide participants with an electronic link, which provides OUD and bup education, and lists OUD treatment options and descriptions and locations, including bup prescribers. After reviewing, participants will be asked to choose from among the list of and a referral will be made based on the receiving treatment providers' procedures. These participants will not have access to the BNI chatbot. However, the referral facilitation, the electronic link will direct participants to a short Feasibility, Acceptability and Satisfaction (FAS) Assessment to obtain feedback on the process.
32764125|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
32764126|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
32764127|NCT04981691|Experimental|anti-MESO CAR-T cells|"The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.~Interventions:~Drug: anti-MESO CAR-T cells~Drug: Fludarabine~Drug: Cyclophosphamide"
32764128|NCT02621021|Experimental|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
32913082|NCT05447481|Experimental|Placebo - chicory inulin-type fructan|Placebo: maltodextrin Dietary Supplement: chicory inulin-type fructan
32913083|NCT04772235|Experimental|Advanced and/or metastatic EGFR mutant NSCLC|Eligible advanced and/or metastatic EGFR mutant NSCLC patients will receive the combination of osimertinib and repotrectinib.
32913084|NCT04766463|Experimental|Treatment group A|
32913085|NCT04766463|Experimental|Treatment group B|
32913086|NCT04766463|Placebo Comparator|Treatment group C|
32913087|NCT04766463|Active Comparator|Treatment group D|
32764129|NCT02621021|Experimental|2/ACT TIL + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
32913088|NCT05452707||Patients|"Patients will be observed during their active training sessions.~Patients will be asked questions about:~fatigue~physical fatigue~pain~the difficulty of the session~motivation"
33244380|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
33244381|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
33244382|NCT00717600|Experimental|1|Oral probiotics
33244383|NCT00721058|Other|1|
33244384|NCT00720720|Active Comparator|1|plant sterol enriched margarine
33244385|NCT00720720|Placebo Comparator|2|placebo margarine
33244386|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
33244387|NCT00850018|Active Comparator|2|Participants will receive usual care.
33244388|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
33073147|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
33073148|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
33073149|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
33244389|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
33244390|NCT04067102|Experimental|Nab-paclitaxel Based Regimens|
32764130|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
32764131|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
32764132|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
32764133|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
32764134|NCT00790933|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
32764135|NCT04981457|Active Comparator|patients who recieve misoprostol alone|Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.
32764136|NCT04981457|Active Comparator|patients who recieve misoprostol and iso sorbide mononitrate|Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.
32764137|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
32764138|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
32764139|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
32764140|NCT04558931|Experimental|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~CellProtect will be given IV infusion at the dose of 3x10^7 cells/kg day 29 , 43 and 3-10x10^7 on day 57.~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
32764141|NCT04558931|Active Comparator|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
32764142|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
32764143|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
32764144|NCT04981379|Active Comparator|Hydroxychloroquine + Favipiravir|Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
32764145|NCT04981379|Active Comparator|Favipiravir + Placebo (Hydroxychloroquine)|Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)
32764146|NCT04981379|Active Comparator|Hydroxychloroquine + Placebo (Favipiravir)|Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
32764147|NCT04981379|Placebo Comparator|Placebo (Favipiravir) + Placebo (Hydroxychloroquine)|Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)
32764148|NCT04389775|Experimental|Cohort A|Subcutaneously administer a single dose of XW003, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
32764149|NCT04389775|Placebo Comparator|Placebo A|Subcutaneously administer a single dose of volume-matching placebo, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
32764150|NCT04389775|Experimental|Cohort B|Subcutaneously administer multiple SC doses of XW003, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
33244391|NCT04067102|Active Comparator|Paclitaxel Based Regimens|
33244392|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
33244393|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
33244394|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
33244395|NCT04067154|Experimental|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
33244396|NCT05311202|Experimental|low-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 30 minutes
32764151|NCT04389775|Placebo Comparator|Placebo B|Subcutaneously administer multiple SC doses of volume-matching placebo, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
32764152|NCT04352569|Active Comparator|transcranial direct current stimulation|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the LTP, le cathode over L DLPFG.
32764153|NCT04352569|Sham Comparator|transcranial direct current stimulation sham|tDCS device allows sham stimulation. This technic give the same impression that active stimulation and allows optimum placebo stimulation.
32764154|NCT05375383|Active Comparator|Streptococcus salivarius K12 lozenge|Streptococcus salivarius K12 lozenge
32764155|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic A|Streptococcus salivarius K12 lozenge with prebiotic
32764156|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic B|Streptococcus salivarius K12 lozenge with prebiotic
32764157|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic A and B|Streptococcus salivarius K12
32764158|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder|Streptococcus salivarius K12 powder
32764159|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic A|Streptococcus salivarius K12 powder with prebiotic
32764160|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic B|Streptococcus salivarius K12 powder with prebiotic
32764161|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic A and B|Streptococcus salivarius K12 powder with prebiotic
32764162|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges|Streptococcus salivarius M18 lozenge
32764163|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges containing prebiotic A|Streptococcus salivarius M18 lozenge with prebiotic
32764164|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges der containing prebiotic B|Streptococcus salivarius M18 lozenge with prebiotic
32764165|NCT05375383|Active Comparator|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|Streptococcus salivarius M18 lozenge with prebiotic
32764166|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
32764167|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
32764168|NCT02987803|No Intervention|Control Group|Participants in the control group will receive educational articles about obstetric hospitals. The articles will prompt the participant to look up hospitals in their geographic location. Participants will not know they are participating in a trial.
32764169|NCT02987803|Experimental|Data Group|"Participants in the intervention group will receive an educational module designed to support them in selecting a delivering hospital, which will include an educational video, articles, and a data tool with cesarean delivery rate data for hospitals in their geographic location.~Participants will not know they are participating in a trial."
32764170|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
32764171|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
32764172|NCT02998879|Experimental|Velmanase Alfa|velmanase alfa 1mg/kg body weight infusion
32764173|NCT02926651|Active Comparator|Conventional Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
32764174|NCT02926651|Active Comparator|Conventional Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
33073150|NCT03610802||Biological relatives|Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.
33073151|NCT03610802||Patients|Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.
32764175|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
32764176|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
32764177|NCT02697487||No Treatment|This is a longitudinal observational study involving individuals who are depressed, depressed with other comorbidities and non-depressed individuals. The primary aim of this study is to describe the longitudinal course of illness and real world treatment outcomes for depressed patients receiving routine care from their providers. Health outcomes and biospecimens along with the functional and economic burden of depression will be characterized and compared amongst three groups: (1) depressed patients, (2) depressed patients with comorbid illnesses, and (3) non-depressed patients.
32764178|NCT04305145|Experimental|Infliximab|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Infliximab: Predetermined intravenous single dose, up to 3 doses over 7 weeks.~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
32913089|NCT05452707||Therapists|"Therapists will be asked questions about the observed training sessions of the patients. The questions will be about:~Estimation of active training time~Estimation of patient's fatigue~Estimation of the patient's perceived difficulty of the session~Estimation of the patient's perceived physical fatigue of the session~Estimation of the patient's perceived motivation for the session"
32913090|NCT04763889|Experimental|CBT workshop|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. In the intervention group participants will attend a day workshop or two half day workshops focused on using CBT to manage their anxiety and stress.
32913091|NCT04763889|No Intervention|Self-help control treatment as usual group|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. Participants in the treatment as usual group will receive the workshop materials after the active treatment group have completed their final follow-up at 3 months
32913092|NCT04743921|Experimental|Reparel Sleeve Group|Patients receiving reparel knee sleeve for treatment of knee osteoarthritis.
32913093|NCT04724499|Experimental|High-Intensity Intervals Training|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the exercise group (HIIT), will receive an exercise bike and have 3 weekly supervised exercise training sessions for four (4) months/16weeks.~Participants can choose to participate in the exercise sessions at home via zoom or in clinic.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post High-Intensity Intervals Training (HIIT) tests and four (4) month follow up test and receive 3 MRIs over the span of 9 months."
33073152|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
33073153|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
33244397|NCT05311202|Experimental|moderate-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 40 minutes
33244398|NCT05311202|Experimental|high-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 50 minutes
33244399|NCT05311202|Experimental|moderate-volume low-intensity group|Participants will attend the trainer-supervised resistance exercise program for 45 minutes
33244400|NCT05311202|Experimental|Control group|Reading for 40 minutes
33244401|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
33244402|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
33244403|NCT05659290|Experimental|Arm A|Efficacy of Fruquintinib alternating Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
33244404|NCT05659290|Active Comparator|Arm B|Efficacy of Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
33244405|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
33244406|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
33244407|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
33244408|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
33244409|NCT05304494||Severe Breathlessness|Breathlessness requiring admission or supplementary oxygen
33244410|NCT05304494||Moderate Breathlessness|Breathlessness requiring medical intervention < 24 hours without meeting the criteria for severe breathlessness
33244411|NCT05304494||Mild Breathlessness|Breathlessness not requiring any medical intervention within 24 hours other than a dose change in the individuals pre-established pharmacological treatment plan
33244412|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
33244413|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
33244414|NCT05277272||Patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis|Multi-institutional cohort registry of patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis
33244415|NCT00717678|Experimental|Prograf-XL + MMF|
33244416|NCT00717678|Active Comparator|Prograf + MMF|
33244417|NCT05145296|Other|Patients with cPRA ≥99%|This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
33244418|NCT04078152|Experimental|Treatment|Durvalumab Monotherapy
33244419|NCT04078152|No Intervention|Off Treatment|Follow up Only
33244420|NCT05050682|Experimental|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
32764179|NCT04305145|Experimental|Inpatient|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~methylprednisone-Predetermined intravenous dose, 2x daily up to 7 weeks~prednisone Oral daily predetermined dose~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
32764180|NCT04305145|Experimental|Outpatient|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits~Prednisone Predetermined oral dose, 2x daily up to 7 weeks~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
33244421|NCT04230304|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33244422|NCT05036408|Experimental|Supportive care (cancer pain rehabilitation program)|Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan. Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
33244423|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
33244424|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
33244425|NCT04067466|Experimental|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
33244426|NCT04067466|Placebo Comparator|Control product|Maltodextrin, plum powder
33244427|NCT02571842|Experimental|Rituximab|"Drug: Rituximab~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4~Other Name: Mabthera"
33244428|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily~Other Name: Enalapril, Lorsartan, Prednisolone"
33244429|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
33244430|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
33244431|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
33244432|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
33244433|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
33244434|NCT00720954|Other|A|CT guided pleural needle biopsy
33244435|NCT00720954|Other|B|Thoracoscopy
32764181|NCT04271059||TBI without polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.
32764182|NCT04271059||TBI with polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.
32764183|NCT04271059||Healthy Control|Subjects who have not experienced any TBIs within the last six months.
32764184|NCT04248673|Placebo Comparator|carbohydrate rich bread|
32764185|NCT04248673|Experimental|carbohydrate reduced bread|
32764186|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
32764187|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
32764188|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
32764189|NCT01670279|Placebo Comparator|Placebo|Placebo
32764190|NCT04226677|Experimental|aerobic exercise group|Aerobic exercise group is received treadmill training.
32764191|NCT04226677|Experimental|Video based exercise group|Video based exercise group is received exergame training.
33244436|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
33244437|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
33244438|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
32764192|NCT04226677|Experimental|Control group|Control group
32764193|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
33244439|NCT02571062|Experimental|experimental formulation|crossover design
33244440|NCT02571062|Experimental|final formulation|crossover design
33244441|NCT04069338|Active Comparator|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
33244442|NCT04069338|Active Comparator|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
33244443|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
33399569|NCT03593915|Experimental|Ph 1b and 2: MDS|"Patients with previously untreated MDS~Patients with MDS who have received <6 cycles of HMAs (during dose escalation only)~Patients with de novo (cause unknown) or secondary MDS (treatment-related) who are not eligible for intensive induction chemotherapy or stem cell transplant~All French-American-British (FAB) subtypes~Intermediate and above per IPSS-R groups"
32764194|NCT04188145|Active Comparator|Fluoropyrimidine|
33399570|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
33399571|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
32764195|NCT04188145|Active Comparator|Fluoropyrimidine + Bevacizumab|
33244444|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
33244445|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
33399572|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
33399573|NCT02392546|Placebo Comparator|Placebo|placebo
32764196|NCT04981769||Patients|Patients presenting to clinical sites for Covid-19 testing who are 2 years of age or older.
33244446|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
33399574|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
33399575|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
33073157|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
33399576|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
33399577|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
33399578|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
33399579|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
33399580|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
33244447|NCT04961528|Experimental|Terlipressin|"Dosage: 1 mg /5 ml Pharmaceutical form: solution for infusion Posology: 1 mg /8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers"
33399581|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
32764197|NCT04532125|Experimental|ARGX-117 IV|Subjects receiving ARGX-117 IV
32764198|NCT04532125|Placebo Comparator|Placebo IV|Subjects receiving placebo IV
32764199|NCT04532125|Experimental|ARGX-117 PH20 SC|Subjects receiving ARGX-117 PH20 SC
32764200|NCT04532125|Placebo Comparator|Placebo PH20 SC|Subjects receiving placebo PH20 SC
32764201|NCT04532125|Experimental|ARGX-117 + rHuPH20|Subjects receiving ARGX-117 + rHuPH20
33244448|NCT04961528|Experimental|Tranexamic Acid|"Dosage : 500 mg /5 ml Pharmaceutical form: solution for infusion Posology (and adjustments based on toxicity) : 500 mg/ 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
33244449|NCT04961528|Placebo Comparator|Normal Saline Placebo|"Dose : normal saline solution (NaCl 0.9%) Pharmaceutical form : solution for infusion Posology : 5ml / 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
33244450|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
33244451|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
33244452|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
33244453|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
33244454|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
33244455|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
33244456|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
33244457|NCT04069182|Other|Behavioral Activation Therapy|Psychological intervention
33244458|NCT00850252|Experimental|Lifeline blood vessel|
33244459|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
33244460|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
32764202|NCT04532125|Placebo Comparator|Placebo + rHuPH20|Subjects receiving placebo + rHuPH20
33073158|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
33244461|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
33244462|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
33244463|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
33244464|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
33244465|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
33244466|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
33073159|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
33244467|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
33244468|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
33399582|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
32764203|NCT04980989|Experimental|Mobile software|Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.
32764204|NCT04980989|Active Comparator|Telephone calls|Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.
32764205|NCT04532047|Experimental|Experimental: in utero enzyme replacement therapy|ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.
33244469|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
33244470|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
32764206|NCT04117321||Pregnant women|Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.
32764207|NCT04117321||New Born Baby|new born baby of an enrolled pregnant woman.
32764208|NCT04117321||Father of new born baby|Biological father of an enrolled new born baby.
32764209|NCT04102813|Experimental|Functional Therapy (FT)|The FT includes a variety of functional techniques such as diaphragmatic breathing, and thoracic and abdominal manipulation, designed to stimulate the neurofunctional interconnection between body, mind and immune system. The FT session will last 30 minutes.
32764210|NCT04102813|No Intervention|Attention Control (AC)|The AC group will listen an audiobook lasting for 30 minutes, which will be used as attention control activity
33244471|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
32764211|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
32764212|NCT03063983|No Intervention|Control|31 weeks of MAP
32764213|NCT03945721|Experimental|Niraparib|"Niraparib will be administered orally on a daily basis~Radiation Therapy will be administered concurrently with Niraparib"
32764214|NCT01876355|Experimental|Clonidine|
32764215|NCT01876355|Placebo Comparator|Sodium chloride|
32764216|NCT03943303|Experimental|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.
32764217|NCT03943303|Placebo Comparator|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.
32764218|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
32764219|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
32764220|NCT02747407||Basic Science Group II (vaccination at 9 months)|Patients undergo standard of care treatment and collection of blood samples as in Group I. Patients then receive hepatitis A and tetanus toxoid vaccinations at month 9.
32764221|NCT02747407||Basic Science Groups I (vaccination pre-treatment)|Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.
32764222|NCT01870193|Active Comparator|Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
32764223|NCT01870193|Active Comparator|Elderly active|Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months
32764224|NCT01870193|Placebo Comparator|Elderly placebo|Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
32764225|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
32764226|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
32764227|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
33073160|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
33244472|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
32764228|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
33244473|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
33244474|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
32764229|NCT05096455||severe acute pancreatitis|Patients 18 years of age or older admitted to intensive care or resuscitation for severe acute pancreatitis (AP) with hypertriglyceridemia (HTG)
32764230|NCT04432415|Experimental|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
33244475|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
33244476|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
33244477|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
33244478|NCT00860002||3|LAM versus UMLT-M
33244479|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
33244480|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
33244481|NCT00860002||6|LUVO+LAM versus LUAO+LAM
33244482|NCT00860002||7|LUVO+LM versus LUAO+LM
33244483|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
32764231|NCT04432415|Experimental|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
33244484|NCT00860002||9|LUVO versus UMLT-UVO
32764232|NCT04432415|Placebo Comparator|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
32764233|NCT05331937|Experimental|real rTMS|verum rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
32764234|NCT05331937|Sham Comparator|sham rTMS|sham rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
32764235|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
32764236|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
33244485|NCT00860002||10|UMLT-UVO versus UMLT-UAO
33244486|NCT00860002||11|LUAO versus UMLT-UAO
33244487|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
33244488|NCT00860002||13|LUVO versus LM
33244489|NCT00860002||14|LUVO versus LAM
33244490|NCT00860002||15|LUVO versus LUAO+LM
33244491|NCT00860002||16|LUVO versus LUAO+UMLT-M
33244492|NCT00860002||17|LUVO versus LUAO+LAM
33244493|NCT04939454|Experimental|sarcopenic COPD patient|
33244494|NCT04939454|Other|non-sarcopenic COPD patient|
33244495|NCT00721266|Experimental|1|
33244496|NCT00853450|Experimental|1|AZD6482 on top of ASA
33244497|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
33244498|NCT04066790|Experimental|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
33244499|NCT04066790|Active Comparator|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
33244500|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
33244501|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
33244502|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
33244503|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
33244504|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
32764237|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
32764238|NCT04980755|Experimental|Phase one|"Participants will be asked to attend four weekly sessions of Body Reprogramming via group video call.~Each session will include up to 8 patients and will consist of a 25-30 minute live presentation"
32764239|NCT04980755|Experimental|Phase two|We anticipate that participant sin phase two will complete the same intervention, but it may be somewhat modified following participant feedback in phase one.
32764240|NCT03485053|Experimental|IOP Injection / MPB-1514|Administered IV infusion
32764241|NCT02356939|Experimental|Intraductal stent (IST)|"For intervention : intraductal removable stent In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation."
32764242|NCT02356939|Experimental|Without intraductal stent (no IST)|For intervention : stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP) Each center will perform its habitual postoperative follow up.
32764243|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
32764244|NCT05102461|Placebo Comparator|Placebo|Subjects randomized in the Placebo Arm will take one placebo capsule daily. Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
33244505|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
33244506|NCT00722904||2|Healthy volunteers
33073161|NCT03579901|Other|Primary Breast Reconstruction|Subjects age 18 and over, Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
33073162|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
32764245|NCT05102461|Active Comparator|Treatment|Subjects randomized in the Treatment Arm will take one placebo capsule daily. One Florajen Digestion capsule contains 15 billion live cultures of Lactobacillus acidophilus (7.5 billion), Bifodobacterium lactis (6.0 billion), and Bifidobacterium longum (1.5 billion). Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
33244507|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
32764246|NCT05375227|Experimental|Electric Toothbrush|Electric toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
32764247|NCT05375227|Active Comparator|Manual toothbrush|Manual toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
32764248|NCT04980131|Experimental|Group C|Group C were received PPSF with pointed lotus-style regulator
32764249|NCT04980131|Experimental|Group B|Group B were received PPSF with Flat ended lotus root regulator
32764250|NCT04980131|No Intervention|Group A|Group A were received traditional PPSF
32764251|NCT04974203|Experimental|CT Value <25|Patients with CT value <25
32764252|NCT04974203|Experimental|CT Value 25+|Patients with CT value of 25 or higher
32764253|NCT04974203|Experimental|Negative|Patients with negative PCR test result
32764254|NCT05102227||LBBAP|Patients implanted with a dual-chamber DF-1 cardioverter-defibrillator. Ventricular tachy sensing is performed via an IS-1 pacing lead placed in the interventricular septum.
32764255|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
32764256|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
32764257|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
32764258|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
32764259|NCT05375149||LTx rejection|Lung transplanted patients with acute or chronic rejection
32764260|NCT05375149||LTx non-rejection|Lung transplanted patients without any form of rejection
32764261|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
32764262|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
32764263|NCT05101837|Experimental|MIND-GROUP|Daily mindfulness sessions on android
32764264|NCT04980209||Ultrasonic and c-arm combination group|Ultrasound and c-arm were combined to evaluate intraoperatively conditions
32764265|NCT04980209||c-arm group|c-arm group was used to evaluate intraoperatively conditions
32764266|NCT03334201|Other|Western diet first|To receive Western diet controlled feeding first, followed by non-Western diet controlled feeding
32764267|NCT03334201|Other|Non-Western diet first|To receive non-Western diet controlled feeding first, followed by Western diet controlled feeding
33073163|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
33244508|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
33244509|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
33244510|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
33244511|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
32764269|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
32764270|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
32764271|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
32764272|NCT03283033|Experimental|Experimental 3|Introduction of a new salad bar and marketing conditions during second semester of school year
32764273|NCT03283033|Experimental|Experimental 2|Introduction of marketing conditions during second semester of school year
32764274|NCT03283033|Experimental|Experimental 1|Introduction of a new salad bar during second semester of school year
32764275|NCT03283033|No Intervention|Control|No introduction of a new salad bar and no introduction of marketing conditions
32764276|NCT03210571|Experimental|eyeWatch device|
32764277|NCT05104021|Experimental|game group|"Children who accepted to participate in the game were taken to the playground with minimum two and maximum four people. After the children were introduced to each other, the rules of the game were explained. Between the children playing, dice were rolled to determine the starting order of the game. The player who scored the highest number had the right to start the game first. With the help of the stopwatch, the playing time was started, and the children played the game in accordance with the rules.~For the child who first reached the square of the world, the time was stopped and recorded in the Child Follow-up Form. The game was played with a maximum game duration of 15 minutes. In the same way, the times of the children who reached the world square in the second, third and fourth places were recorded on the Follow-up Form."
33073164|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
33244512|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
33244513|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
33244514|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
33244515|NCT00721344|Experimental|1|
33244516|NCT00721344|Experimental|2|
33244517|NCT00721344|Experimental|3|
33073165|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
33244518|NCT00721344|Experimental|4|
33399583|NCT05744440|Experimental|allogenic NK cells|Enrolled patients will receive prespecified dose of allogenic NK cells
33399584|NCT03734627||Upper Gastrointestinal Surgery - Transit|
33399585|NCT03734627||Control - Transit|
33399586|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
33399587|NCT03734627||Control - Gut Function|
33399588|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
32737415|NCT04974645|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
33244519|NCT04076020|Experimental|Intervention arm|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
33244520|NCT04076020|Active Comparator|Usual care arm|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.~Participants are directed to use the WebMD application as often as they would like."
33244521|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
33244522|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
33244523|NCT00717990|Experimental|1|XELIRI/Avastin
33244524|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
33244525|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
33244526|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
33244527|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
33244528|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
33244529|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
33244530|NCT04902872|Experimental|Phase 1 Dose Escalation (Daily Dosing x 3)|CBX-12 administered on a daily x 3, 3 week schedule
33244531|NCT04902872|Experimental|Phase 1 Dose Escalation (Once Weekly Dosing )|CBX-12 administered once weekly, 4 week schedule
32764278|NCT05104021|No Intervention|control group|"Children in the control group were allowed to walk for 15 minutes on a flat surface in the clinic accompanied by the researcher and their parents. As soon as the child came out of his room, the time was started with the help of a stopwatch. The time was stopped when the child went back to bed.~The pain and fear scores of each child who completed the game and mobilization were evaluated separately and simultaneously by the child, parent and researcher with the help of the Visual Analog Scale and the Child Fear Scale, and then the physiological parameter measurements were made by the researcher and the Child Follow-up Form was evaluated after the procedure. and data collection was terminated."
32764279|NCT05103865|Experimental|Experimental group (EG)|
33244532|NCT04902872|Experimental|Phase 2 Ovarian Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
32764280|NCT05103865|Active Comparator|Control group|
32764281|NCT05323123|Experimental|Intervention|Participants will receive PrEP
32764282|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
32764283|NCT05103787|Active Comparator|deep parasternal plane block|Subjects will receive bilateral deep parasternal intercostal plane block after induction of anesthesia.
32764284|NCT05103787|Placebo Comparator|control|subjects will receive skin puncture with needle on the same location as the treatment group without administration of local anesthetics after induction of anesthesia,
32764285|NCT03115021|Experimental|Active tPCS / Sham tDCS|All subject will receive active tPCS and sham tDCS for 20 minutes simultaneously.
32764286|NCT03115021|Experimental|Sham tPCS / Active tDCS|All subject will receive sham tPCS and active tDCS for 20 minutes simultaneously.
32764287|NCT03115021|Experimental|Sham tPCS / Sham tDCS|All subject will receive sham tPCS and sham tDCS for 20 minutes simultaneously.
32764288|NCT03079999|Experimental|Aspirin|Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.
32764289|NCT03079999|Placebo Comparator|Placebo|Patients on the placebo arm will receive blinded placebo and take it twice a day.
33244533|NCT04902872|Experimental|Phase 2 Small Cell Lung Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
33244534|NCT00721422|Experimental|Group 1-Normal|
33244535|NCT00721422|Experimental|Group 2-Mild|
33244536|NCT00721422|Experimental|Group 3-Moderate|
33244537|NCT00721422|Experimental|Group 4-Severe|
33244538|NCT04878302|Experimental|Experimental: Taming Tics Together Protocol|"Families will participate in the 5-day telehealth-based intensive intervention and will receive three treatment formats which will provide CBIT and co-occurring diagnosis treatment:~Child/teen-only groups~Individual one-to-one sessions~Parent/caregiver-only groups"
33244539|NCT04878302|No Intervention|1-Month Waitlist Control|Families in the 1-month waitlist control group will participate in the initial intake assessment, then receive no treatment for a 1-month period. Following the 1-month period, families will participate in an assessment, then will be offered a place in a Taming Tics Together group
33244540|NCT00722982||1|
33244541|NCT00722982||2|
32764290|NCT04980053|Experimental|Back Massage|"Back massage will be initiated in the first 2 hours after birth and it will be performed every 6 hours for 15 minutes until the mother is discharged from the hospital. After the mother's outfits are removed and the mother is situated in a suitable position, the back of the mother will be massaged by euphlorage, petrissage, friction methods. Then, the participants breast will be milked by hand every 3 hours and will be measured in the breast milk storage bag and delivered to the baby nurses until the 5th-7th day."
32913094|NCT04724499|Active Comparator|Attention Control|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the Attention Control group, will receive instruction on a 16 week home-based stretching program.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post home-based stretching program tests and receive 3 MRIs over the span of 9 months.~At the end of the 16-week home-based stretching program, participants will be provided the option to participate in the High-Intensity Intervals Training (HIIT) program."
33399589|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
33244542|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
33244543|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
33244544|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
32764291|NCT04980053|Experimental|Breast Massage|Breast massage will be initiated in the first 2 hours after delivery and it will be practised every 6 hours until being discharged. After the researcher washes her hands, the participant's outfits are removed and she is situated in a sitting position, the massage will be practised on both breasts for 10 minutes by the researcher herself. After the mother's breast will be milked by hand every 3 hours and the milk obtained from the breast will be measured in the breast milk storage bag and delivered to the baby nurses.
32764292|NCT04980053|No Intervention|Control Group|No intervention will be made to the control group, standard hospital procedures will be applied and the relevant forms will be filled out. Until the mother is discharged from the hospital, the amount of milk obtained from the mother will be measured every 3 hours by the researcher.
32764293|NCT04973969|Other|study group|The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
32764294|NCT02961205|Experimental|Oral Nutritional Supplementation|Patients randomized to the interventional arm will receive Ensure Enlive (Abbott Nutrition), a high energy, high protein oral supplement.
32764295|NCT02961205|No Intervention|Standard of care|Patients randomized to the control arm will continue their usual diet.
32764296|NCT04979975|Experimental|Placebo|placebo matching UB-621
32764297|NCT04979975|Experimental|UB-621 low-dose|low-dose of UB-621
32764298|NCT04979975|Experimental|UB-621 high-dose|high-dose of UB-621
33399590|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
33399591|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
33399592|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
33399593|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
33399594|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
33399595|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
33399596|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
33399597|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
33399598|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
33399599|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
33399600|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
33399601|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
33399602|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
33399603|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
33399604|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
33399605|NCT03592277|Experimental|TREATMENT with Vitamins C and B1|Patients in the Vitamins C and B1 arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
33399606|NCT03592277|No Intervention|PLACEBO with saline only|Patients in the placebo (control group) arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
33399607|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
33399608|NCT03167710|Experimental|dry needling, manipulation stretching|
33399609|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
32764299|NCT02958709|Experimental|high dose RIF, INH, PZA, EMB|Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.
32764300|NCT02958709|Experimental|high dose RIF, INH, PZA, LEVO|Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
32764301|NCT02958709|Active Comparator|standard dose RIF, INH, PZA, EMB|Arm 3 participants will receive standard of care dose rifampicin plus ethambutol for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
32913095|NCT05447325|Experimental|Message exposure (sequence: regular PSAs then flavor PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the first 6 months of the study, and will then receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the second 6 months of the study.
32913096|NCT05447325|Experimental|Message exposure (sequence: flavor PSAs then regular PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the first 6 months of the study, and will then receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the second 6 months of the study.
32913097|NCT05447325|Experimental|No message exposure (control condition)|Participants will not be receiving any PSA exposure over the 12 months.
32913098|NCT05452629|Experimental|Mindfulness Induction|A brief and single session of mindfulness practice for 30-minute.
32913099|NCT05452629|Experimental|Relaxation Induction|A brief and single session of self-directed relaxation for 30-minute.
32913100|NCT05452629|No Intervention|Control Condition|Open thinking.
32913101|NCT05452395|Experimental|Post-acute care|comprehensive geriatric assessment, and either home-based or hospital-based post-acute care
32913102|NCT05452395|No Intervention|control group|comprehensive geriatric assessment only
32913103|NCT05447247|Experimental|Acupuncturing Ba Liao point under ultrasound guidance|
32913104|NCT05447247|Experimental|Conventional acupuncture|
32764302|NCT04979663|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
32764303|NCT05307367|Experimental|WP1-3|WP1+2: no intervention WP3: exercise training as intervention
32764304|NCT04979819|Experimental|Multiple Sclerosis|Patients with multiple sclerosis will perform the UULEX and fill in the other mentioned parameters. Validity and reliability of the UULEX will be measured.
33073166|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
33073167|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
32913105|NCT05447169||High risk population of nasopharyngeal carcinoma|first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
32913106|NCT04704453|Experimental|Experimental arm (A): capsaicin patch|
32913107|NCT04704453|Other|Standard arm (B): amitriptyline|
32913108|NCT04687137|Experimental|TAK-743|
33244545|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
33244546|NCT00853918|Experimental|$20 Cash|
32913109|NCT05451537||Sepsis associated encephalopathy group|Patients were diagnosed with sepsis related encephalopathy
32913110|NCT05451537||None sepsis associated encephalopathy group|Patients were not diagnosed with sepsis related encephalopathy
32913111|NCT04656561|Experimental|ANX007 Group 1|ANX007 administered every month
32913112|NCT04656561|Experimental|ANX007 Group 2|ANX007 administered every other month
32913113|NCT04656561|Sham Comparator|Sham Group 3|Sham injection administered every month
32913114|NCT04656561|Sham Comparator|Sham Group 4|Sham injection administered every other month
32913115|NCT05446701||60 case|Sixty patients diagnosed as NMOSD based on the recently revised 2015 international consensus diagnostic criteria for NMOSD (9) ,attending Neurology clinic, Asyut University hospitals, Asyut university and Kasr Al-Ainy multiple sclerosis/neuroimmunology clinic, Cairo University hospitals, Cairo University, Egypt, through one and half year from study onset
32913116|NCT05446701||60 control|Sixty healthy volunteers, without any neurological or systemic medical diseases, age and sex matched , will be enrolled as healthy controls(HCs).
33244547|NCT00853918|Experimental|$50 Cash|
33244548|NCT00853918|Experimental|$50 Check|
32913117|NCT05451459|Experimental|Intervention Group|Participants in the intervention group will be offered four one-day group workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports. The workshops will be offered online via Zoom and will be video recorded. The intervention group will also receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment, which will be mailed to them. At the end of the workshop parents will be instructed to practice the skills they learned with their child for the next 3 weeks (for at least 3 hrs per week).
33073168|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
33244549|NCT00853918|Experimental|$100 Check|
33399610|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
33073171|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
33073172|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
33073173|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adult-onset Still's disease and related conditions.
33073174|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
33244550|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
33073175|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by the presence of episodic fever and/ or arthritis.
33244551|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
33244552|NCT00723060|Active Comparator|1|escitalopram high dose group
33244553|NCT00723060|Active Comparator|2|escitalopram conventional group
33244554|NCT00860236|Active Comparator|Psycoeducation/counseling|
33244555|NCT00860236|Active Comparator|Cognitive behavioural therapy|
33244556|NCT04069416||Group I|175 patients who fall within the Milan criteria.
33244557|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
33244558|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
33244559|NCT00860392|Experimental|1|Biomarker evaluation
33244560|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
33244561|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
33244562|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
33073176|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
33244564|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
33244565|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
33244566|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
33244567|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
33244568|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
33244569|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
33244570|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
33244571|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
33244572|NCT00854074|Experimental|1|Spinal neurostimulation
33244573|NCT04068324|No Intervention|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
33244574|NCT04068324|Experimental|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
33244575|NCT04068324|Experimental|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
33244576|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
33244577|NCT00721656|Placebo Comparator|Placebo|
33244578|NCT00721656|Experimental|KLS-0611|
33244579|NCT04066712|Experimental|A: Normal (control) renal function|
33244580|NCT04066712|Experimental|B: Mild impairment renal function|
33244581|NCT04066712|Experimental|C: Moderate impairment renal function|
33244582|NCT04066712|Experimental|D: Severe impairment renal function|
33244583|NCT00723216|Active Comparator|1|Enoxaparin
33244584|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
33244585|NCT00619918|Experimental|1|3% saline
33244586|NCT00619918|Placebo Comparator|2|Normal saline
33244587|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
33244588|NCT00724178|Placebo Comparator|B|Double placebo
33244589|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
33244590|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
33244591|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
33244592|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
33244593|NCT04800536|Experimental|Cardiovascular effects of rapidly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with a rapidly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
33244594|NCT04800536|Experimental|Cardiovascular effects of slowly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with slowly declining plasma glucose (<0.085 mmol/l/min). A combined hyperglycaemic and euglycaemic clamp with a slowly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
33244595|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
33244596|NCT00721812|Other|Part A|Single dose escalation
33244597|NCT00721812|Other|Part B|14 day repeat dose escalation
33244598|NCT00721812|Other|Part C|Fixed dose food effect
33244599|NCT04800224|Placebo Comparator|Placebo|Patients in the Placebo group will receive an identical number of capsules containing 900 mg / day of placebo (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
33244600|NCT04800224|Active Comparator|Propolis|Participants in the Propolis group will receive propolis EPP-AF at a dose of 900 mg / day (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
33244601|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
33244602|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
33244603|NCT00718146|Experimental|Group 1|Age 16 to 60 years
33244604|NCT00718146|Experimental|Group 2|Age over 60 years
33244605|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
33244606|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
33244607|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
33244608|NCT00724256|Experimental|1|
33244609|NCT00724256|Active Comparator|2|
33244610|NCT04041466|Experimental|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
33244611|NCT04041466|Experimental|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
32737416|NCT04974645|Other|Education|"Education digitally delivers weekly fact sheets that include information on:~Alcohol-specific topics;~Drug-specific topics;~General addiction topics;~Statistics relating to alcohol and substance use."
33244612|NCT04041466|Experimental|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
33244613|NCT04067934|Experimental|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
33244614|NCT04752722|Experimental|Phase 1|Dose escalation phase
33399611|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
32737417|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
33244615|NCT04752722|Experimental|Phase 2|"Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients, up to 4 cycles of treatment with EG-70~Cohort 2: RP2D with eligible high-risk NMIBC patients who have been incompletely treated with BCG or are BCG-naïve"
33244616|NCT00860704|Active Comparator|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
33244617|NCT00860704|Active Comparator|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
33244618|NCT00860704|Active Comparator|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
33244619|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
33399612|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
33244620|NCT04742660|Placebo Comparator|group R|Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.
32737418|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
33399613|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
33399614|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
33399615|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
33399616|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
33399617|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
33399618|NCT03734471|Active Comparator|Traditional|
33399619|NCT03734471|Experimental|Reactor Device|
33399620|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
33399621|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
33399622|NCT03106246||T2DM|Patients with established type II diabetes.
33399623|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
33399624|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
32764307|NCT04429217|Experimental|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
32764308|NCT04429217|Active Comparator|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
33399625|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
32913118|NCT05451459|Other|Wait-list home-based group|The wait-list home-based group will serve as the control group (during intervention). This group will be instructed to continue their typical routines and activities for the duration of the 12-week intervention. At the end of the 12 weeks, they will be asked to complete the post-test surveys (same as questionnaires completed prior to randomization). Their participation in the research will be complete at this time. However, because the intervention has been shown to potentially benefit families, immediately following the post-test, participants in the wait-list home-based group will be offered the chance to complete the home-based intervention program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) as described for the intervention group). No data will be collected for research from them during this time.
32913119|NCT05451147|Experimental|Group A|DRUG: Chhinnavahni Kashaya Vati FORM: Tablet DOSE: 1 g TDS (2 Tab. of 500 mg each), Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN: 20 ml of Agnimantha Kwatha DURATION: 3 Months
32913120|NCT05451147|Active Comparator|GROUP B|DRUG: Metformin FORM: Tablet DOSE: 500mg BID/TDS, Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN:: Plain Water DURATION 3 Months
32913121|NCT05446389|Experimental|Intervention Group|Infants randomized in to the experimental group will receive the PAL intervention 2 times a week until the infant transitions to room air or < 2L high flow nasal cannula and is able to begin attempting feeds by mouth. The PAL is an FDA cleared medical device that has a sensor that will connect to the infant's pacifier and can read the infant's suck. Then, the device plays music as positive reinforcement to help improve sucking skills. This intervention typically lasts about 15 minutes and is implemented while the infant is receiving gavage feeds.
32913122|NCT05446389|No Intervention|Control Group|Infants randomized in to the control group will not receive music therapy intervention throughout NICU admission.
32913123|NCT05450991||Hirschsprung's Disease|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with histologically confirmed Hirschsprung's disease.
33399626|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
32913124|NCT05450991||Anorectal Malformations|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with an anorectal malformation.
32913125|NCT05445375|No Intervention|Current education regimen|Participants will be given a PAD pamphlet and ad hoc verbal teaching by vascular providers.
32913126|NCT05445375|Active Comparator|Intervention|Participants will be given the current education regimen and watch a 20 minute online PAD education video.
32913127|NCT01429064|Experimental|ODM-201|
32913128|NCT04555551|Experimental|Targeted MCARH109 CAR Modified T cells|Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
32913129|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
32913130|NCT04553367|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
32913131|NCT04553367|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
32913132|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
32913133|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
32913134|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
32913135|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
32913136|NCT05450445|Experimental|Intervention: myHealthHub|
32913137|NCT05450445|Active Comparator|Active control: TV-only|
32913138|NCT05450367||patients with a haematological malignancy treated with immunotherapy|
32913139|NCT05450289|Active Comparator|Control Group|Control group will receive allergen specific immunotherapy and standard pharmacotherapy
32913140|NCT05450289|Experimental|Experimental Group|Experimental group will receive allergen specific immunotherapy, standard pharmacotherapy, and nigella sativa oil
33244621|NCT04742660|Active Comparator|group G|participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.
33244622|NCT00860782|Experimental|Annual Parent Intervention (API) Group|Participants in this group will receive the parent educational support intervention once a year for 2 years.
33244623|NCT00860782|Experimental|Quarterly Parent Intervention (QPI) Group|Participants in this group will receive the parent educational support intervention quarterly (4 times a year) for 2 years.
33244624|NCT04069260|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
33244625|NCT04734938|No Intervention|Habitual Diet|All volunteers will participate in this arm, continuing this habitual diet for 1 week
33244626|NCT04734938|Experimental|100% Huel|All volunteers will participate in this arm of the study and consumer 100% Huel as their food for 4 weeks
33244627|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
33244628|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
32737419|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
32764309|NCT05094271|Active Comparator|Supplemental Oxygen during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
32764310|NCT05094271|Placebo Comparator|Room Air during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min of pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
32764311|NCT05094271|Experimental|Supplemental Oxygen for 3 Months|Over a 12-week period, participants randomized to receive supplemental Oxygen for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
32764312|NCT05094271|Experimental|PAP Therapy for 3 Months|Over a 12-week period, participants randomized to receive supplemental PAP therapy for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
32764313|NCT04979585|Experimental|Experimental|Patients with untreated advanced mucosal melanoma
32764314|NCT05101603|Active Comparator|Control|Only non surgical periodontal treatment
32764315|NCT05101603|Experimental|Test|Nd:YAG Laser and air abrasive combined application addition to non surgical periodontal treatment
32764316|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
32764317|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
32764318|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
32764319|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
32764320|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
32764321|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
32764322|NCT02481817||iSGS patients|Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.
32764323|NCT05103709|Experimental|MULTI-FORTIFIED|The product to be evaluated is bread made from wheat flour fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)] and a previtamin mix [Vitamin A (240 ug), Vitamin b12 (0.72 ug), zinc (5.25 mg) per daily serving]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
32764324|NCT05103709|Active Comparator|FORTIFIED|The active comparator is bread fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
32764325|NCT05103709|No Intervention|CONTROL|The control group will be followed for 120 days. No product will be provided.
32764326|NCT04979897||Intensive care unit stay during high bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a high bed occupancy in the pandemic
32764327|NCT04979897||Intensive care unit stay during low bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a low bed occupancy in the pandemic
32764328|NCT05103553|Experimental|Annual screening at outpatient clinic|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) wil be randomized into the intervention group (annual assessment at the outpatient clinic). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
32764329|NCT05103553|No Intervention|Annual screening at Care Pathway Systemic Sclerosis|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) will be randomized into the control group (annual assessment at the care pathway). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
32764330|NCT04979195||Group 1|patients with stable renal function.
32764331|NCT04979195||Group 2|Patients who developed AKI.
32764332|NCT05101525|Experimental|Patient with effective tendon healing|
32764333|NCT05101525|Active Comparator|Patient without tendon healing|
32764334|NCT05103397|Active Comparator|low dose group|low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).
32764335|NCT05103397|Active Comparator|high dose group|high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).
32764336|NCT05103397|Placebo Comparator|Placebo group|placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
32764337|NCT05101447|Experimental|MMF PK|
32764338|NCT05101447|Active Comparator|MMF BSA|
32764339|NCT05100745|Experimental|Activated Therapy|Therapy: these subjects will undergo 30 treatments with an activated Vibratosleeve TUS device.
32764340|NCT05100745|Sham Comparator|Sham Therapy|An inactive (sham) device will be used in these subjects for the first 30 treatments followed by a 30-treatment regimen with an activated VibratoSleeve TUS device after crossover.
32898352|NCT02291055|Experimental|Part B Expansion (Cervical): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
32898353|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
32898354|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
32898355|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
33244629|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
33244630|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
33244631|NCT04041388|Other|Tooth tipping|
33244632|NCT00854152|Experimental|1|
33244633|NCT00721890|Experimental|1|
33244634|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
33244635|NCT00854230|Experimental|1|Naltrexone
33244636|NCT00854230|Placebo Comparator|2|
33244637|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
32898356|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
33244638|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
33244639|NCT02571582||Patients died|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
33244640|NCT02571582||living patients|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
33244641|NCT04018144||Group-1|Healthy individuals
33244642|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
33244643|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
33244644|NCT04697966|Experimental|Mindfulness (Headspace app)|
33244645|NCT04697966|Active Comparator|Active Control Condition|
33244646|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
33244647|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
33244648|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
33244649|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
33244650|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
33244651|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
33244652|NCT04683068|Active Comparator|First-person gain-framed self-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 1 receives a self-referred narrative message in which the protagonist explains that he has decided to have a genetic test to discover BRCA germline mutation. He then explains the reasons why this decision is important to himself (e.g., implementing preventive behaviors) and what are the possible benefits for the individual."
32764341|NCT05101291|Experimental|Fractional spinal anaesthesia|"After FIC block or femoral nerve block with ropivacaine 3.5mg/ml 20-40ml. The LiDCOplus was calibrated with 0.3-0.45 mmol lithium based on body weight. After calibration and baseline parameter registration, the LiDCOplus system provided cardiac output variables A dural puncture by a 18G Tuohy needle was performed either between the L2 - L3 or the L3 - L4 interspaces, preferably using a mid-line approach. A catheter 20G was then inserted 4-5 cm into the intrathecal space. A solution (10 ml) of 1.5 mg/ml bupivacaine and 10 µg/ml fentanyl was prepared. Intrathecal anaesthesia was induced by giving 1,5 ml (2.25 mg of bupivacaine and 15 µg of fentanyl) of the solution, followed by a second 1.5 ml injection after 25 min.~MAP was maintained with a norepinephrine to target a MAP >65mmHg or to avoid a > 30% decline in MAP from baseline. Invasive haemodynamic parameters were recorded every 5 min for 45 min after initial intrathecal dose was given."
32764342|NCT04342169|Experimental|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
33244653|NCT04683068|Experimental|First-person gain-framed family-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 2 receives a family-referred narrative message in which the frame is similar to the previous message, but the character this time explains what are that the benefits for his family and why his decision to have a genetic test is important to them."
33244654|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
33244655|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
32764343|NCT04342169|Placebo Comparator|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
33244656|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
33244657|NCT05632250|Other|ConvaFoam dressings|All participants wounds will be assessed and allocated a dressing based upon the investigator's clinical judgement. They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 12 weeks as part of their standard of care
33244658|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
33244659|NCT00854386|Active Comparator|1|liberal fluid administration group
33244660|NCT00854386|Experimental|2|Restrictive fluid administration group
33244661|NCT00804219|Experimental|TBE low responder|
33244662|NCT00804219|Experimental|FSME responder|
33244663|NCT00804219|Experimental|hepatitis B non-responder|
33244664|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
32764344|NCT05103163|Experimental|Foot reflexology group|Before the reflexology application, a personal information form was applied to the patients who had abdominal surgery. As a pre-test, satisfaction levels in terms of pain and nursing were evaluated. Then, vital signs (systolic blood pressure, diastolic blood pressure, pulse, respiration and saturation) were measured. Foot warming movements were started and then the warming movements were terminated by applying pressure to the solar plexus area of the left foot. Then in order; Reflexology was applied to the brain, lymphatic system, blood pressure area, lung, adrenal gland, thyroid, diaphragm, stomach and joint areas. Afterwards, relaxation movements were made for the foot, pressure was applied to the solar plexus and the reflexology application was completed within 30 minutes. Immediately after the application, vital signs were re-measured as a post-test, and the numerical pain scale and care satisfaction scale were applied again.
32764345|NCT05103163|No Intervention|No treatment group|To the patients in the control group; Personal Information Form, Numerical Pain Scale (NPS) and Newcastle Nursing Care Satisfaction Scale (NNCSS) were applied as pre-test. After the questions were answered, NNCSS with NPS was applied again 40 minutes later as a final test, without any intervention other than the clinical protocol.
33244665|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
33244666|NCT00721838||1|Surgery group
33244667|NCT00721838||2|Control - Lifestyle modification program
32764346|NCT04979273|Active Comparator|Control Group|Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
33244668|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
32764347|NCT04979273|Experimental|Dextrose group|Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
33244669|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
33244670|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
33244671|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
33244672|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
33244673|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
33244674|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
33244675|NCT02552901|Experimental|LFT Dye Detection Monitor|
33244676|NCT02552901|Active Comparator|Serial Blood Draws|
33244677|NCT00861172|Experimental|1|
33244678|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
33244679|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
32913141|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
32913142|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
32913143|NCT05443815||HaemoCer-PLUS|Patients who had receive HaemoCer-PLUS
32913144|NCT05449899|Experimental|G-CSF+DAC+BF|For patients with sAML undergoing allo-HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
32913145|NCT05449899|Active Comparator|G-CSF+DAC+BUCY|For patients with sAML undergoing allo-HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
33399627|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
33244680|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
33244681|NCT00861250|Experimental|Vel/Dex|
33244682|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
33244683|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
33244684|NCT00807183|Experimental|Tx3|Active air filter
33244685|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
33244686|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
33244687|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
33244688|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
33244689|NCT02571738|Placebo Comparator|Control|Standard of Care
33244690|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
33244691|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
33244692|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
33244693|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
33244694|NCT04019106|Experimental|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
33244695|NCT04019106|Experimental|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
33244696|NCT04019106|Experimental|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
33244697|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
33244698|NCT02571608|Placebo Comparator|Placebo|Placebo
33244699|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
33244700|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
33244701|NCT00798447|Experimental|lipid emulsion with n-3 FA|
33244702|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
33244703|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
33244704|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
33244705|NCT00722306|Experimental|A425|A425 Treated
33244706|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
33244707|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
33244708|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
33244709|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
33244710|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
33244711|NCT00804375|Experimental|2PX|Pain medication
33244712|NCT00804375|Placebo Comparator|placebo|placebo
33244713|NCT04067700|Other|Coronary perfusion PET/CT patients|
33244714|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
33244715|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
33244716|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
33244717|NCT00865228|Placebo Comparator|Placebo BID|
33244718|NCT00724412|Active Comparator|Systane|Systane
33244719|NCT00724412|Active Comparator|Optive|Optive
33244720|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
33244721|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
33244722|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
33244723|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
33244724|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
33244725|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
33244726|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
33244727|NCT00722462|Experimental|1|Active acupuncture
33244728|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
33244729|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
33244730|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
33244731|NCT00724646||1|Habilitation assistants
33244732|NCT00724646||2|Parents/ legal guardians
33244733|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
33244734|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
33244735|NCT05374044||rectal cancer with NAT|The patients are planned to receive neoadjvant therapy, and then receive radical surgery.
33244736|NCT04067804|No Intervention|Usual Care|Standard school disciplinary practices.
33244737|NCT04067804|Experimental|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
33244738|NCT00854542|Active Comparator|TCSCT|
33244739|NCT00854542|Placebo Comparator|Usual Care|
33244740|NCT00722540|Experimental|A|
33244741|NCT00722540|Experimental|B|
33244742|NCT00722540|Experimental|C|
33244743|NCT00722540|Experimental|D|
33244744|NCT00722540|Experimental|E|
33244745|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
33244746|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
33244747|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
33244748|NCT04261790|Other|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
33244749|NCT00861484|Experimental|GSK958108 3 mg|Experimental
33244750|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
33244751|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
33244752|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
33244753|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
33244754|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
33244755|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
33244756|NCT00724724|Active Comparator|2|Aspirin
33244757|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
33244758|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
33244759|NCT05373966||Delphi Panel|A team of experts in the field of robotic RNU will be invited to participate in the current survey. These experts are identified according to surgical experience, research and academic interest, expertise in running training courses, and participation in live-surgery cases.
33244760|NCT04042558|Experimental|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route~Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
33244761|NCT04042558|Experimental|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
32913146|NCT05449665|Experimental|Control - High Fibre - Low Fibre (CTRL - HF - LF)|"Phase 1 - CTRL: Control diet with moderate fibre consumption for 13days.~Phase 2 - HF: ad libitum consumption of HF meals for 13days.~Phase 3 - LF: ad libitum consumption of LF meals for 13days."
32913147|NCT04506411|Experimental|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
32913148|NCT04506411|Active Comparator|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
32913149|NCT04506411|Placebo Comparator|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
32913150|NCT04338789|Experimental|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
32913151|NCT04338789|Experimental|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
32913152|NCT04338789|No Intervention|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
32913153|NCT05441163|Experimental|APA and nutrition program|
32913154|NCT05441163|No Intervention|control group|
32913155|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
32913156|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
32913157|NCT05441631|Active Comparator|Intensive insulin therapy|
32913158|NCT05441631|Active Comparator|Conventional insulin therapy|
32913159|NCT05449353|Experimental|Trauma-infomed Cognitive Behavioural Therapy|Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
32913160|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
33244762|NCT04130204|Experimental|Active|DYV700, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
32737420|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
33244763|NCT04130204|Placebo Comparator|Placebo|Placebo, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
33244764|NCT00723918|Active Comparator|1|methadone plus SAB placebo
33244765|NCT00723918|Experimental|2|methadone plus active SAB
33244766|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
33244767|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
33244768|NCT00722618|Other|Comparison|Written materials
33244769|NCT05373888||Main|Enterostomy patients, including colostomates, ileostomates or jejunostomates.
33244770|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
33244771|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
33244772|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
33244773|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
33244774|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
33244775|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
33244776|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
33244777|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
33244778|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
33244779|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
33244780|NCT02570594|Other|healthy volunteers|
33244781|NCT00722280|Experimental|Hand Transplantation|Described above
33244782|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
33244783|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
33244784|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
33244785|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
33244786|NCT05373732|Experimental|Transcendental Meditation|The Transcendental Meditation (TM) technique is described as a simple, natural technique that is practiced twice a day for 20 minutes while sitting comfortably with eyes closed. There are no required changes in lifestyle, beliefs or philosophy. Instruction in the TM technique involves a seven-step course over five sessions (90-minute meetings).
33244787|NCT05373732|Active Comparator|Health Education|The health education (HE) intervention provided behavioral instructions for CVD risk factor prevention . This group received written materials, structured presentations, didactic instructions and group support for modifying the major cardiovascular risk factors including salt restriction, weight reduction, aerobic exercise, alcohol and smoking cessation.
33244788|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
33244789|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
33244790|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
33244791|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
33244792|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
32913161|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
32913162|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
32913163|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32737421|NCT05041881|Active Comparator|Trifocal IOL group|Patients implanted during cataract or refractive surgery with trifocal lens, which allowed to see for far, intermediate and near distance, but due to optic design having unwanted effect like optical phenomena and lower contrast sensitivity
32737422|NCT05041881|Active Comparator|Accommodating IOL group|Patients implanted during cataract or refractive surgery with accommodating lens, which allowed to see for far and should improve intermediate distance better than monofocal lens do.
32737423|NCT05041881|Active Comparator|Monofocal IOL group|Patients implanted during cataract or refractive surgery with standard monofocal lens, which allowed to see for far but patients do not experiences optical phenomena or low contrast sensitivity.
32737424|NCT04494191|Experimental|T test|Test drug (AphroFemine) 1 tablet contains 100 mg Flibanserin
32737425|NCT04494191|Active Comparator|B reference|Reference drug (Addyi) 1 tablet contains 100 mg Flibanserin
32737426|NCT05041725|Experimental|remimazolam infusion|Intraoperative remimazolam infusion for postoperative sedation
32737427|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
32737428|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
32737429|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
32737430|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine ± Oxaliplatin chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine ± Oxaliplatin adjuvant chemotherapy. The use of Oxaliplatin depends on the doctor's decision.
32737431|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
32737432|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
32737433|NCT05030883|Experimental|unreliable source|In this condition participants receive a news message from an unreliable source
32737434|NCT05030883|Experimental|reliable source|In this condition participants receive a news message from an reliable source
32737435|NCT05030883|Experimental|no source|In this condition participants receive a news message without a source
32737436|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
32737437|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
32737438|NCT05052177||Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk|"inclusion criteria:~> 18-years-old~Right systemic ventricle~Severe tricuspid regurgitation~Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy~High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation~exclusion criteria - pregnant ou breastfeeding women"
32737439|NCT03094845|Placebo Comparator|Placebo|
32737440|NCT03094845|Experimental|hdmASIT+TM|
32737441|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
32737442|NCT05041413|Experimental|Moms Quit Intervention|12 weeks of the Moms Quit text message intervention
32737443|NCT05041413|Active Comparator|Text4Baby|12 weeks of Text4Baby messages
32737444|NCT05031039||Female Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians females that have unilateral or bilateral cleft lip and palate deformity
32737445|NCT05031039||Male Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians males that have unilateral or bilateral cleft lip and palate deformity
32737446|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
32737447|NCT03336749|Active Comparator|Control group|Traditional task-specific training
32737448|NCT05052021||Perioperative or Recent Covid19 Infection|"Patients will be classified as having Perioperative Covid19 Infection if they test positive for SARS-CoV-2 within 7 days before and 30 days after surgery.~Patients will be classified as having Recent Covid19 infection if they tested positive for Covid19 within 1-6 weeks before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
32737449|NCT05052021||No or Previous Covid19 Infection|"Patients will be classified as having No Covid19 Infection if they have never tested positive for Covid19.~Patients will be classified as having Previous Covid19 Infection when they tested positive for Covid19 infection 7 weeks or more before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
32737450|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
32737451|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
32737452|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
32737453|NCT05040945|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy
32913164|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32737454|NCT05040945|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy
32737455|NCT04494269|Active Comparator|Subjects with normal hepatic function|Single dose of Tegoprazan 50mg
32737456|NCT04494269|Experimental|Subjects with mild hepatic impairment|Single dose of Tegoprazan 50mg
32913165|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
32913166|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
32913167|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
32737457|NCT04494269|Experimental|Subjects with moderate hepatic impairment|Single dose of Tegoprazan 50mg
32913168|NCT05449041||Glaucoma patients|Patients diagnosed with Glaucoma of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
32913169|NCT05449041||Glaucoma controlls|Gender- and age-matched controls to the Glaucoma patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
32913170|NCT05449041||Cateract patients|Patients diagnosed with Cataract of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
32913171|NCT05449041||Cataract controlls|Gender- and age-matched controls to the Cataract patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
32913172|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
32913173|NCT05430867|Experimental|Memantine monotherapy group|Memantine 20mg once-daily
32737458|NCT04494269|Experimental|Subjects with severe hepatic impairment|Single dose of Tegoprazan 50mg
32737459|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
32913174|NCT05430867|Experimental|GV-971 monotherapy group|GV-971 450mg twice a day
32913175|NCT05430867|Experimental|Memantine combined with GV-971 group|Memantine 20mg once-daily plus GV-971 450mg twice a day
32913176|NCT05448885|Experimental|Experimental: GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
32913177|NCT01547000|Placebo Comparator|Inactive placebo|
32913178|NCT01547000|Experimental|Extended-release Guanfacine|
32913179|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
32913180|NCT00369603|Experimental|Aricept|Aricept Treatment Group
32913181|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
32913182|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
32913183|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
32913184|NCT05448417|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of noninvasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the noninvasive bi-level positive pressure mode, and the highfrequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
32913185|NCT05448417|Active Comparator|Bilevel positive pressure ventilation|Bilevel positive pressure ventilation Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
32913186|NCT05420649|No Intervention|Intubated general anesthesia LMS|Patients received LMS with intubated general anesthesia
32913187|NCT05420649|Experimental|Non-intubated LMS with apnea|Patients received non-intubated LMS with administration of muscle relaxant and optiflow(HFNO) device.
32913188|NCT05420649|Experimental|Non-intubated LMS with spontaneous breathing|Patients received non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
32913189|NCT05419947|Experimental|Fixed dose 3 hours|Fixed dose 2.5 mg with IV administration at a time greater than 3 hours before surgery.
32913190|NCT05419947|Experimental|Fixed dose 30 min|Fixed dose 2.5 mg with IV administration during the immediate preoperative period (15-30 minutes before surgery).
32737460|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
32913191|NCT05419947|Experimental|Weight-adjusted dose 3 hour|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration greater than 3 hours before surgery.
32913192|NCT05419947|Experimental|Weight-adjusted dose 30 min|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration during the immediate preoperative period (15-30 minutes before surgery).
32913193|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
32913194|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
32913195|NCT05416905|Experimental|STN-DBS|The patients in this group will be treated with STN-DBS.
32913196|NCT05416905|Active Comparator|GPi-DBS|The patients in this group will be treated with GPi-DBS.
32913197|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
32737461|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
32737462|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
32913198|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
32913199|NCT05405283|Active Comparator|Comirnaty® (Pfizer-BioNTech)|
32913200|NCT05405283|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|
32913201|NCT04375605|Active Comparator|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
32737463|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
33399628|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
33073177|NCT03509571|Experimental|Ketogenic Diet Group|Ketogenic diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that included ≈72% total energy as fat, ≈25% as protein, and ≈3% as carbohydrate during enteral feeding and ≈65% total energy as fat, ≈27% as protein, and ≈8% as carbohydrate and fiber during solid feeding. Patients will start receiving ketogenic diet within the 72 hours injury, after completing their baseline measurements.
33399629|NCT03115138|Other|Patients with glial tumor|
33399630|NCT05665517|Experimental|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q&A) corpora were formed."
32913202|NCT04375605|Experimental|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
32913203|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
32913204|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
32913205|NCT05448183|Experimental|Toripalimab combined withTACE|
32913206|NCT04732455|Placebo Comparator|Group Control (C)|20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
33399631|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
32737464|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
33399632|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
33399633|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
33399634|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
33399635|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
33399636|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
33399637|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
33399638|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
33399639|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
33399640|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
33399641|NCT04869826||Outpatients Complicated Hypertension Clinic|This study population consists of approximately 200 adult male and female participants (≥ 19 years of age; minimum 30% male/female). Participants will be recruited from eligible patients who are referred to the Complicated Hypertension Clinic at the Saint John Regional Hospital (SJRH) as well as non-patient participants who are willing to volunteer to consent to participate in the study.
33073178|NCT03509571|Other|Standard Diet Group|Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
33073179|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=48 group
33073180|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=48 group
32737465|NCT05030727|Other|Evaluation of intraoperative NGAL levels in terms of acute kidney injury in geriatric patients|only one group
33399642|NCT03401112|Experimental|IMR-687 50 mg/100 mg|A starting dose of IMR-687 50 mg with dose escalation after 4 or 12 weeks, up to 100 mg was administered to participants. Duration of administration was 16 (Week 17) or 24 weeks (Week 25).
32737466|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
32737467|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
32737468|NCT05040789|Experimental|Group 1|CoVLP Lot 1
32737469|NCT05040789|Experimental|Group 2|CoVLP Lot 2
33399643|NCT03401112|Experimental|IMR-687 100 mg/200 mg|A starting dose of IMR-687 100 mg with dose escalation after 4 or 12 weeks, up to 200 mg was administered to participants. Duration of administration was 24 weeks (Week 25).
33399644|NCT03401112|Placebo Comparator|Placebo|Matching placebo was administered for 16 (Week 17) or 24 weeks (Week 25).
33399645|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
33399646|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
32913207|NCT04732455|Experimental|Group lidocaine infusion (L)|20 adult breast cancer patients on Taxane chemo protocol will receive lidocaine i.v infusion (2 mg/kg) in 200ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy lidocaine (2 mg/kg) re-infused after each session. If lidocaine side effects such as circumoral numbness, twitches, metal test, tachy or bradycardia recorded at any time, lidocaine infusion will be reduced to 1mg/kg, if side effects persist, the patients will be managed accordingly as well as lidocaine infusion will be stopped and patient will be excluded from the study.
33399647|NCT04866316||GSH Participants|"Qualitative - Semi-structured focus group discussions with care recipients~Quantitative - Pre-test post-test design using survey-based data collection~Quantitative - Retrospective cohort design with propensity score matched comparators"
32737470|NCT05040789|Experimental|Group 3|CoVLP Lot 3
33073181|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=48 group
32764348|NCT05103007|Active Comparator|Drug-eluting bead transarterial chemoembolization（DEB-TACE)|Percutaneous drug-eluting bead transarterial chemoembolization, followed by conventional transarterial chemoembolization（cTACE) every 2 months. A total of 3 times of chemoembolization will be performed.
32764349|NCT05103007|Experimental|PVL/PVE+DEB-TACE|PVL and PVE will be performed randomly assigned according to 1:1 according to the random number table.
32764350|NCT04155749|Experimental|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
32764351|NCT04155749|Experimental|Arm 2|Phase 1 Study of Bivalent BCMA-Specific Adapter (SPRX001) and Universal CAR-Modified T cell (ARC-T Cells) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
32764352|NCT05093881|Experimental|Cellgram-LC|Patients with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
32764353|NCT04973423|No Intervention|CALM|Tight control of inflammatory activity by calprotectin.
32764354|NCT04973423|Other|CALM + IRM|Tight control of inflammatory activity by calprotectin associated with transmural evaluation.
32764355|NCT05073991||Lung surgery|Patients underwent lung surgery.
32764356|NCT05073991||Open aortic suregry|Patients underwent open aortic surgery.
32764357|NCT05073991||Thoracic endovascular aortic repair (TEVAR)|Patients underwent TEVAR.
32764358|NCT05073991||Endovascular aneurysm repair (EVAR)|Patients underwent EVAR.
32764359|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
32764360|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
32764361|NCT05100433|Experimental|Microbiological analysis of root canals after endodontic procedures|Bacterial levels and activity in root canal samples after chemomechanical procedures and ultrasonic irrigation.
32764362|NCT05099887|Other|wound application|Application of Procenta as wound cover
32764363|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
32764364|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
32764365|NCT05036473|Experimental|25/100mg treatment group|25/100mg WD-1603
32764366|NCT05036473|Experimental|25/150mg treatment group|25/150mg WD-1603
32764367|NCT05036473|Experimental|2x25/100mg treatment group|2x25/100mg WD-1603
32764368|NCT05036473|Placebo Comparator|placebo group|placebo are tablets-matching with the same active groups.
32764369|NCT04979351|Experimental|Abdominal Massage Group|Abdominal massage for 15 minutes twice a day application.
32764370|NCT04979351|No Intervention|Placebo Group|Abdominal massage was not applied.
32764371|NCT04985851|Experimental|maintenance treatment durvalumab + anlotinib|"Durvalumab 1500 mg monotherapy will be continued q4w. Anlotinib will be administered according to prescribing information in general use. The dose is 12mg, QD, PO, 14 days-on and 7 days-off.~N.B. If a patient's weight falls to 30 kg or below (≤30 kg) the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg.~Anlotinib is available at three dose levels, 12 mg, 10 mg, and 8 mg. Dose reduction may take place whenever toxicity that is not controlled with optimal supportive care is noted during the study. If a subject subsequently tolerates treatment well at that level in the judgment of the investigator, the dose may be increased to the next dose level. If a subject cannot tolerate treatment after dose reduction to 8 mg, treatment will be discontinued"
32764372|NCT04985851|Active Comparator|maintenance treatment durvalumab|Durvalumab 1500 mg monotherapy will be continued q4w.
32764373|NCT04929769|Experimental|1|the group of LRH
32764374|NCT04929769|Active Comparator|2|the group of ARH
32764375|NCT04838249||Female Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
33244793|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
33244794|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
33244795|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
33244796|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
33244797|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
33244798|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
33244799|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
33244800|NCT00854698|Experimental|Group with MVA|
32898358|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
32898359|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
33244801|NCT00854698|Other|group without MVA|
33244802|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
33244803|NCT00804453|Active Comparator|1|Standard blood line
33244804|NCT00804453|Experimental|2|Cartridge blood line
33244805|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
33244806|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
33244807|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
33244808|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
33399648|NCT04866316||Policy owners, implementers & care partners, health and social care professionals|"Qualitative - Semi-structured in-depth interview with key policy and programme decision-makers~Qualitative - Semi-structured focus group discussions with health and social care professionals~Qualitative - Participant observations~Quantitative - Longitudinal monitoring of process indicators"
33399649|NCT04762680|Experimental|Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1|2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
33399650|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2|2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
33399651|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3|2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
33244815|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
33244816|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
33244817|NCT02571374|Experimental|symbiotic group|Symbiotic group
33244818|NCT02571374|Placebo Comparator|placebo group|placebo group
33244819|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
33244820|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
33244821|NCT00724230||Arm 1|Overall study population.
33244822|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
33244823|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
33244824|NCT00861718|Experimental|AZD7268|
33244825|NCT00861718|Placebo Comparator|Placebo|
33244826|NCT05373108|Experimental|Intervention Arm|A consecutive subset of eligible patients based on inclusion/exclusion criteria will receive a 1-week course of Macitentan (10 mg po daily) prior to their routine 1-year coronary angiogram (7th and final dose of Macitentan will occur on the day of the angiogram).
33244827|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
33244828|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
33244829|NCT03952520|Active Comparator|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
33244830|NCT03952520|Experimental|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
33244831|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
33244832|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
33244833|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
33244834|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
33244835|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
32764376|NCT04838249||Male Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
32764377|NCT04838249||Female cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
32764378|NCT04838249||Male cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
32764379|NCT04930861|Experimental|Covidir|Patient (adults aged ≥18 years) with mild or moderate COVID-19 and flu-symptoms onset within 72 hours prior to inclusion. Treatment begins at the hospital. On the 4th day, participants who are well will be discharged and continue treatment up to Day 10 at home. All participants will receive Codivir 20 mg SC 2 x daily.
32764380|NCT04274153|Experimental|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
32764381|NCT04868305|Active Comparator|Intramedullary nail|Intramedullary nail with proximal lagscrew and distal locking screw(s)
32764382|NCT04868305|Active Comparator|Hip arthroplasty|Hemiarthroplasty (HA) or Total hip arthroplasty (THA). A cemented dual-mobility cup will be utilized in THA. Addition of cerclage/trochanter claw plate to fixate trochanter major will be used when suitable.
32764383|NCT04979507|Experimental|Experimental Group|
32764384|NCT04979507|Active Comparator|Control group|
32764385|NCT05099575||Pregnant women who receive oxytocin|
32764386|NCT05099575||Pregnant Women who receive carbetocin|
32764387|NCT05099575||Pregnant women who receive misoprostol|
32764388|NCT05099575||Pregnant women who receive ergometrine|
32764389|NCT05099341|Experimental|Patients with recurrent depression with a number of depressive episodes ≥ 3|
32764390|NCT05099341|Experimental|Patients with a first depressive episode|
32764391|NCT05099341|Active Comparator|Healthy, non-depressed subjects|
32764392|NCT04979039||normal pregnancy|Adult pregnant women scheduled for cesarean section under spinal anesthesia
32764393|NCT04919551|Experimental|KGD|Oral administration after fasting/high-fat meal/low-fat meal
32764394|NCT04919551|Experimental|GDK|Oral administration after high-fat meal/low-fat meal/fasting
32764395|NCT04919551|Experimental|DKG|Oral administration after low-fat meal/fasting/high-fat meal
32764396|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
32764397|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
32764398|NCT04907773|Other|Potassium measurement|
32764399|NCT04973813|Experimental|Guideline + Active Choice + action&coping planning (GA+)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning.
33244836|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
33244837|NCT00725114|Active Comparator|Tetrodotoxin|
33244838|NCT00725114|Placebo Comparator|Sugar injection|
33244839|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
32764400|NCT04973813|Experimental|Guideline + Active Choice (GA)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
32764401|NCT04973813|Experimental|Guideline + Information (GI)|Participants received the national physical activity guideline, and information about pros and cons of physical activity, and possible barriers to physical activity.
32764402|NCT04973813|Other|Guideline (G)|Comparison arm. Participants received the national physical activity guideline.
32764403|NCT04894981|Experimental|Immersive condition|Performance driving wheelchair in immersive condition (in Cave automatic environment or with HMD)
32764404|NCT04894981|Experimental|Non Immersive condition|Performance driving wheelchair in non immersive condition (with screen and physical simulator or screen only)
32898360|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
33244840|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
33244841|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
33244842|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
33244843|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
33244844|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
33244845|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
33244846|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
32764405|NCT04973501|Experimental|Manual physiotherapeutic correction (MFK) Method|The MFK was chosen for our clinical experience- it was developed in Czech Republic.The MFK Method consists of five established steps: anamnesis, assessment, diagnoses, treatment and checkup. In the course of all those steps, the computer MFK System software is used. This software allows us to display and visualize the patient´s functional muscle imbalance at the day of the assesment based on the assessment of muscle strength by manual muscle tests. Hereafter the physiotherapist performs muscle test and records results in the software. Then, the software visually describes the patient´s imbalance at the day of the assessment. Based on these diagnostic maps and the software suggestions the therapist chooses the body areas where the therapeutic techniques may be applied.
32764406|NCT04973501|Experimental|Dynamic Neuromuscular Stabilization (DNS) Method|Dynamic Neuromuscular Stabilization (DNS) is a neurophysiological rehabilitative approach encompassing a set of functional tests assessing the quality of postural stabilization patterns and a treatment approach based on developmental kinesiology models. DNS diagnosis is based on comparison of the individual's postural stabilization pattern to the developmental stabilization pattern of healthy infants. The assessor uses DNS evaluation sheet to screen client's posture in 11 developmental positions if the patient can perform them all. If not, only the tests that the patient can perform sufficiently and safely serve for functional assessment. The strategy of DNS manual treatment is to utilize only those functional exercises in developmental positions that are the most suitable for the specific client. The goal is to improve spinal and joint stability by focusing on the global stabilization system consequently improving quality of movement and mobility.
33244847|NCT04066166||Subjects|Healthy
33244848|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
33244849|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
32898361|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
33244850|NCT00722514|Experimental|IG|Patient education
33244851|NCT00722514|Other|CG|without patient education
33244852|NCT05653388||Enrolled Subjects|Once enrolled subjects will provide Archival Tissue, Optional Fresh tumor from a biopsy and blood collections at baseline, day 8 of cycle 1, day 1 of cycles 2-6, and at progression.
33244853|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
33244854|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
33244855|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
33244856|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
33244857|NCT00861796|Experimental|1|
33244858|NCT00861796|Placebo Comparator|2|
33244859|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
33244860|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
33244861|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
33244862|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times~and chemotherapy schedule"
33244863|NCT05373030|Experimental|Recombinant adenovirus type-5-vectored COVID-19 vaccine|
33244864|NCT05373030|Active Comparator|Inactivated COVID-19 vaccine|
33244865|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
33244866|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
33244869|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
33244870|NCT00861874|Experimental|Treatment|
33244871|NCT03765242||Patient initiating warfarin|
33244872|NCT03765242||Patient initiating apixaban|
33244873|NCT05372874||Healthy voluntaries control group (Group 1)|
33244874|NCT05372874||sofosbuvir/daclatasvir treated group (group 2)|
33244875|NCT05372874||sofosbuvir /daclatasvir/ ribavirin treated group (group 3)|
33244876|NCT02544646|Other|trabeculectomy|
33244877|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
33244878|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
33244879|NCT04067856|Active Comparator|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
33244880|NCT04067856|Active Comparator|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
33244881|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
33244882|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
33244883|NCT05372796|Experimental|Control Group|participants were given home exercise (once a day for 5 weeks)
33244884|NCT05372796|Experimental|IASTM (instrument-assisted soft tissue mobilization)|IASTM was applied to the patients (M. Sternocleidomastoideus, M. Trapezius, M. Paraspinales and M. Levator Scapula) in the IASTM group twice a week for 5 weeks.
33244885|NCT05372796|Experimental|OTES (Occipital Transcutenous Electric Stimulation)|Participants in the OTES group were treated with a Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom) 3 times a week for 5 weeks. Four self-adhesive 40*40 mm sized electrodes were attached to the occipital region of the patients bilaterally, covering the occipital nerves. The current intensity was adjusted according to the patient. The current intensity started from 0 mA and the current intensity was increased one by one every 30 seconds, the patient was allowed to tolerate the current by giving current without muscle twitching or harmful stimulation. The current frequency was determined as 2/100 Hz. Square waves at 2 Hz were applied for 3 seconds followed by an automatic shift to 100 Hz for another 3 seconds.
33244886|NCT04042714|Experimental|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
33244887|NCT03401918|Experimental|Patients with recurrent pregnancy loss or unexplained infertility|"Patients with recurrent pregnancy loss or unexplained infertility will have an assessment of the uterine environment at the time of implantation, followed by testing of uterine endometrial gene expression using the ERA test and the uterine micro biome.~Those who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome."
33244888|NCT03401918|Experimental|Healthy Control Patients|Patients who have had a normal delivery and no history of infertility or recurrent pregnancy loss will have assessment of the uterine environment at the time of implantation.
33244889|NCT03613116|Experimental|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
33244890|NCT03613116|Active Comparator|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
33244891|NCT05227378|Experimental|neoantigen tumor vaccine|neoantigen tumor vaccine with or without PD-1/L1
33244892|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
33244893|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
33244894|NCT00866398||1 DES|Patients receiving drug-eluting stent
33244895|NCT00866398||2 BMS|Patients receiving bare metal stent
33244896|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
33244897|NCT00725348|Experimental|A|R115866
33244898|NCT05371548|Experimental|Intervention (SAM app)|"Patients will receive training in and access to the SAM app at discharge. SAM uses prescribed and dispensed medication data to display a continuously updated drug list and provides patients and caregivers with tools to address barriers to adherence.~Drug information: Provides patient-friendly drug monographs. Interaction checker: Generates drug-drug interactions between the patient's medications and other OTC drugs.~Adherence alerts: Uses decision algorithms to alert users to adherence problems with the new regimen.~Side effect checker: Displays possible side effects for each medication and frequency of occurrence.~PIMs alerts: Alerts patients to potentially inappropriate medications in their list.~Pharmacist connect: Connects users with pharmacists through a secured messaging service.~Social connect: Allows users to share medication experiences. Caregiver connect: Allows patients to enroll caregivers who can use the app. Weekly medication schedule & pill reminders"
33244899|NCT05371548|No Intervention|Control (usual care)|Patients will receive usual care at discharge. On study units, medication reconciliation is conducted for all patients. Patients have their community medication list obtained via fax from their community pharmacy. The list is validated by the unit pharmacist who then reconciles it with admission orders, and recommends changes as needed to the attending physician. At discharge, the community drug list is reconciled with medications administered in hospital and the discharge prescription is generated by the attending physician or resident, classifying each medication as new medication, dose modification, discontinued therapy, or continued community medication. The discharge prescription is provided to the patient. Patients fill their discharge prescription at their community pharmacy. If there are questions about changes to the community drug list, the pharmacist will ask the patient, and if not clear will contact the discharging physician.
33244900|NCT03083288|Experimental|Single Arm|
33244901|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
33244902|NCT05325216|Experimental|POPRC group|pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
32913208|NCT04732455|Experimental|Group duloxetine (D)|20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once per day starting from the night pre chemotherapy session until the end of cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy the duloxetine dose will be adjusted to 60 mg daily till the end of the cycle. They also will receive 200 ml normal saline over forty minutes before each chemotherapy session until end of the cycle.
32913209|NCT05393193|Other|HIV-exposed neonates|Point-of-care HIV testing at birth
32913210|NCT05393193|Other|HIV-positive infants identified through birth HIV screening|Early antiretroviral treatment per standard of care, including dolutegravir-based regimen beginning at 4 weeks of age for infants weighing at least 3.0kg.
32913211|NCT04721145|Experimental|Dexcom G6 Continuous Glucose Monitor|Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
33244903|NCT05325216|Active Comparator|SRC group|standard radical cystectomy with orthotopic ileal neobladder
32710822|NCT04520607|Experimental|Arm 1|Subjects assigned to this arm will receive one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study); performed on Day 1, at Week 48 and every 52 weeks thereafter.
32710823|NCT04520607|Experimental|Arm 2|Subjects assigned to this arm will receive one intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study) on Day 1, followed by one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle at Week 48 and every 52 weeks thereafter.
32710824|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
32710825|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
32737471|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
32737472|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
32737473|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
32737474|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
32737475|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
32737476|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
32913212|NCT04309227|Experimental|Traditional High-Intensity Training|Participants will perform their training at ~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
32913213|NCT04309227|Experimental|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at ~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
32913214|NCT04309227|No Intervention|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
32913215|NCT04306965|Experimental|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
32913216|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
33244904|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
33244905|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
33244906|NCT00866632|No Intervention|Group Education|
33244907|NCT00866632|No Intervention|Telephone Education|
32764407|NCT04858945|Experimental|Teach-back group|The first education session will be arranged at the day or the following day of admission before delivery, with a group meeting involving three women and one educator. The main purpose of the first session is to help women understand and prepare for the labor. On the day of discharge after delivery, women will receive the second group education session hosted by an educator. The main purpose of the second session is to help women understand postpartum health issues, get to know the practice of postpartum recovery and learn newborn care skills. At two-week postpartum, a short online meeting will be arranged. During the meeting, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
32764408|NCT04858945|Active Comparator|Control group|Teach-back group and control group share some education content and communication methods, e.g. power-point presentation, educational video clips, live demonstration, information booklet, group discussion, and Q&A, expect that before the end of each education session.
32764409|NCT04973735|Experimental|30mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764410|NCT04973735|Experimental|150mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764411|NCT04973735|Experimental|600mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764412|NCT04973735|Experimental|1200mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764413|NCT04973735|Experimental|2400mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764414|NCT04973735|Placebo Comparator|Placebo|Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
32764415|NCT04860973|Experimental|Weighted blankets|Provided with weighted blanket suitable for participant's weight
32764416|NCT04860973|No Intervention|Standard linen|Use of standard hospital linen
32764417|NCT04973579||Simultaneous cardiac surgery and carotid stenting|Patients with Heart Team and NeuroVascular Team recommendation to perform simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) including proximal or distal neuroembolic protection and cardiac surgery (CABG or surgical valve replacement / repair procedure)
32764418|NCT04834063||NAFLD Cases|Non- alcoholic fatty liver disease
32764419|NCT04834063||control|healthy individual with normal liver on abdominal ultrasound
32764420|NCT04978805|Experimental|Progressive Relaxation Exercise|A total of 56 sessions of progressive relaxation were performed, 7 days a week for 8 weeks. Each session is set as fifty minutes
32764421|NCT04978805|No Intervention|Control group|Routine maintenance will be applied
32764422|NCT04978961|Experimental|Focused Acceptance and Commitment Therapy (FACT)|"Focused Acceptance & Commitment Therapy (FACT): FACT is a brief type of cognitive behavioral therapy that helps patients reduce disability through increased acceptance, reconnection with values, and reduced unhelpful control/coping strategies. Patients randomized to the intervention group received FACT per the study manual, delivered by an integrated Behavioral Health Consultant (BHC). Patients had one individual visit (30 minutes) and three consecutive weekly group visits (one hour) followed by a booster visit two months later. These classes (group visits) were rolling, not cohort-driven, meaning new and returning patients will be attending together. After the individual BHC visit and each class, patients had behavioral homework to complete."
32764423|NCT04978961|Active Comparator|Enhanced Treatment as Usual (ETAU)|"Patients randomized to the Enhanced-Treatment As Usual (ETAU) group received enhancement of usual primary care via 1-page (2-sided) educational handouts on four topic areas: Sleep, Pacing, Relaxation and Goal Setting. All topics have an evidence base in standard Cognitive Behavioral Therapy treatment of pain. One handout per assessment visit was given to each patient. Patients will continue to see their primary care clinicians and have access to all routine clinical services throughout the study."
32764424|NCT04794205|Experimental|Low Dose BCP|Subjects will receive low dose of BCP.
32764425|NCT04794205|Experimental|Medium Dose BCP|Subjects will receive a medium dose of BCP
32764426|NCT04794205|Experimental|High Dose BCP|Subjects will receive high dose of BCP.
32764427|NCT04794205|Experimental|Placebo|Subjects will receive placebo drug.
32764428|NCT04973033|Experimental|Tofactitinib|Tofacitinib 5mg twice a day
32764429|NCT04436653|Experimental|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
32764430|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
32764431|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
32764432|NCT02660281|Other|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
32764433|NCT02660281|Other|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
32764434|NCT02660281|Other|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
33244908|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
32913217|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
32913218|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
32913219|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
32913220|NCT01431794|Active Comparator|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
32913221|NCT01431794|Active Comparator|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
32913222|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
32913223|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
32913224|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
32913225|NCT04254237|Active Comparator|Intervention group|Infraumbilical Hasson trocar incision.
32913226|NCT04254237|Sham Comparator|Control group|Supraumbilical Hasson trocar incision.
32913227|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
32913228|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
32913229|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
32913230|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
32913231|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
32913232|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
32913233|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
32913234|NCT04204005|Active Comparator|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
32913235|NCT04204005|Placebo Comparator|Placebo|Composition: maltodextrin (2 grams)
32913236|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
32913237|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
32913238|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
32913239|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
32913240|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
32913241|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
33399652|NCT04762680|Experimental|Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were previously vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
33399653|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
33399654|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
32913242|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
32913243|NCT05365893|Experimental|PHL (Paricalcitol, Hydroxychloroquine, Losartan)|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
32913244|NCT05365893|Active Comparator|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
32913245|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
32913246|NCT05358873|Experimental|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Subjects will receive the Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
33244909|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
32764435|NCT02660281|Other|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
33244910|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
33244911|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
33244912|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
32764436|NCT02660281|Other|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
32764437|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
32764438|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
32764439|NCT02438995|Experimental|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
32764440|NCT02438995|Experimental|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
32764441|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
32764442|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
32764443|NCT05108389||Pregnant women with kidney disease|Pregnant women with kidney disease. No intervention.
32764444|NCT04978883||pSS-ILD|diagnosis of pSS-ILD was based on abnormal HRCT and PFTs
32764445|NCT04978883||pSS non-ILD|pSS patients after exclusion of pSS-ILD and concomitant pulmonary diseases were considered as pSS non-ILD
32764446|NCT05108311|Experimental|Treatment|The Treatment sequence including joint Manual therapy techniques and soft tissue release techniques is proposed.
32764447|NCT04155125|Experimental|efepoetin alfa|"Route of administration: Subcutaneous Injection.~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
32764448|NCT04155125|Placebo Comparator|Mircera|"Route of administration: Subcutaneous Injection.~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
32764449|NCT04662307|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The intelligent cardiopulmonary rehabilitation system is designed to improve the user's adherence to pre-determined training intensity. The training intensity is pre-determined using the 60%-80% heart rate reserve which is obtained from the cardiopulmonary exercise test at prestest. The system allows dynamically auto-adjust the paddling resistance in accordance to the patient's current hear rate and paddling rate, with the goal to maintain the patient's heart rate at the pre-determined heart rate zone through the training period.
32764450|NCT05107921|Experimental|Bromfenac sodium hydrate eye drops|The patients will receive bromfenac sodium hydrate eye drops twice daily for 14 days.
32764451|NCT04526041|Other|Professional beatboxer singer|1 professional beatboxer singer will be asked to produced different sounds while undergoing the different procedures. Researchers wil then select the most interesting sounds to be studied.
32764452|NCT04526041|Other|Experimented beatboxer singer|10 experimented beatboxer singer will be asked to reproduced the sounds record by the first subject (professional singer) while undergoing the different procedures.
32764453|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
32764454|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
33244913|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
33244914|NCT04065698|Experimental|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
33244915|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
33244916|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
32710826|NCT04416451|Experimental|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
32710827|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
32710828|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
32710829|NCT04348747|Experimental|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 22, and 43. Patients will also receive pembrolizumab IV on the same days.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, every 3 months in the opinion of principal investigator."
32710830|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
33244917|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
32710831|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
32710832|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
32710833|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
32710834|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
32710835|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
32710836|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
32710837|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
32710838|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
32710839|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
32710840|NCT04468555|Experimental|Global postural reeducation|Patients completed 3 sessions of global postural reeducation for 3 weeks.
32710841|NCT04468555|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
32710842|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
32710843|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
32710844|NCT04468711|Active Comparator|treatment group|vitamin D plus topical 1% hydrocortisone cream twice daily
32710845|NCT04468711|Placebo Comparator|placebo group|placebo plus plus topical 1% hydrocortisone cream twice daily
32710846|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
32710847|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
32710848|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
32710849|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
32710850|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
32710851|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
32710852|NCT04059939|Experimental|Reading Plus Attention Control|
32710853|NCT04059939|Experimental|Reading Plus Anxiety|
32710854|NCT04059939|Active Comparator|BAU|
32710855|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
32710856|NCT05494255|Active Comparator|Group RM|One single recruitment maneuver will be applied in this group at the end of the surgery and before the extubation
33244918|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
33244919|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
33399655|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
33244920|NCT00725426|Experimental|1|Bosutinib
33244921|NCT00730106||1|Patients with pre-defined alarm symptoms
33244922|NCT00730106||2|Patients without pre-defined alarm symptoms
33244923|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
33244924|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
33244925|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
33244926|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
33244927|NCT03334500|Experimental|Cohort 1|Gleason 6 (n=10)
33244928|NCT03334500|Experimental|Cohort 2|Gleason 7-8 (n=10)
33244929|NCT03334500|Experimental|Cohort 3|Gleason 9 or oligometastic disease (n=10)
33244930|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
33244931|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
33244932|NCT00807339|Experimental|1|Phase I dose escalation
33244933|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
33244934|NCT00730262|Experimental|Single-Arm|
33244935|NCT00862030||1|Study Cohort
33244936|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
33244937|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
33244938|NCT00725088|Experimental|1|exercise training group
33244939|NCT00725088|No Intervention|2|control group
33244940|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
33244941|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
33244942|NCT00866866|Experimental|N-Acetyl Cysteine|
33244943|NCT00866866|Placebo Comparator|Placebo|
33244944|NCT00804765|Experimental|1|Therapeutic education
33399656|NCT04762680|Active Comparator|Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
33399657|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 1|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
33244945|NCT00804765|Placebo Comparator|2|
33244946|NCT00855244|Other|BMT survivors|Diagnostic exams
33244947|NCT00312728|Experimental|bevacizumab|
33244948|NCT00866944|Experimental|1|Adecatumumab alone
33244949|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
33244950|NCT00866944|Active Comparator|3|FOLFOX 4 alone
33244951|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
33244952|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
33244953|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
33244954|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
33244955|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
33244956|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
33244957|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
33244958|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
33244959|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
33244960|NCT04040686|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection
33244961|NCT00577824|Experimental|1|
33244962|NCT00577824|Experimental|2|
33244963|NCT00577824|Placebo Comparator|3|
33244964|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
33244965|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
33244966|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
33244967|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244968|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
32913247|NCT05358873|Placebo Comparator|Placebo|Subjects will receive the Normal saline solution (0.9% NaCl) nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
33244969|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244970|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244971|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244972|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244973|NCT02632448|Experimental|Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
33244974|NCT00867022||1|Women with gestational diabetes
32913248|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
33244975|NCT00867022||2|Pregnant women without gestational daibetes
33244976|NCT00867022||3|Women with gestational diabetes and hypertension
33244977|NCT00867022||4|Non pregnant women
33244978|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
33244979|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
33244980|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
33244981|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
33244982|NCT04040764|Experimental|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
33244983|NCT04040764|Active Comparator|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
33244984|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
33244985|NCT00855322|Experimental|1|Gym group exercise intervention
33244986|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
33244987|NCT00855322|No Intervention|3|Control group
33244988|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
33244989|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
33244990|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
33244991|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
33244992|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
33244993|NCT05333406|Experimental|Dose group A (Low dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
33244994|NCT05333406|Experimental|Dose group B (High dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
33244995|NCT00867256|Experimental|Large Diameter Metal on Metal|
33244996|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
33244997|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
33244998|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
32710857|NCT05494255|No Intervention|Group NoRM|Usual care will be applied in this group
33244999|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
32913249|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
33245000|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
33245001|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
33245002|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
33245003|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
33245004|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
33245005|NCT00805155||Cohort Group 1|Subjects number 1 to 20
32710858|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
32710859|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
32710860|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
33245006|NCT00805155||Cohort Group 2|Subjects number 21 to 50
33245007|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
33245008|NCT04016350|Experimental|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
32710861|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
32710862|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
32710863|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
32710864|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
32710865|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
32710866|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
32710867|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
32710868|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
32710869|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
32710870|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
32710871|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
32710872|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
32710873|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
32710874|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
32710875|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
32710876|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
32710877|NCT02207699|Experimental|Benzonatate 200 mg|
32710878|NCT02207699|Experimental|Benzonatate 800 mg|
32710879|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
32710880|NCT02207699|Placebo Comparator|Placebo|
32710881|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
32710882|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
32710883|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
32710884|NCT02203487|Placebo Comparator|Placebo|
32710885|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
32710886|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
32710887|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
32710888|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
32710889|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
32710890|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
32710891|NCT04334941|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
32737477|NCT05030181|Active Comparator|kinesiotaping and exercise|'I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
33245009|NCT04016350|Experimental|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
33245010|NCT00725166||Young|Young men 19-25 years old
33245011|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
33245012|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
33245013|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
33245014|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
33245015|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
33245016|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
33245017|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
33245018|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
32913250|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
32913251|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
33245019|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
33245020|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
33245021|NCT05227066|Experimental|traditional physical therapy group|received traditional physical therapy protocol
33245022|NCT05227066|Experimental|lower extremity weights group|received the same traditional physical therapy in addition to lower extremity weights
33245023|NCT05210634|Placebo Comparator|Group 1: Placebo|Single oral administration of 4 ml of Placebo MCT oil
33245024|NCT05210634|Active Comparator|Group 2: 12.5 mg THCv (CHI-915)|Single oral administration of 12.5 mg THCv in MCT oil
33245025|NCT05210634|Active Comparator|Group 3: 25 mg THCv (CHI-915)|Single oral administration of 25 mg THCv in MCT oil
33245026|NCT05210634|Active Comparator|Group 4: 50 mg THCv (CHI-915)|Single oral administration of 50 mg THCv in MCT oil
33245027|NCT05210634|Active Comparator|Group 5: 100 mg THCv (CHI-915)|Single oral administration of 100 mg THCv in MCT oil
33245028|NCT05210634|Active Comparator|Group 6: 200 mg THCv (CHI-915)|Single oral administration of 200 mg THCv in MCT oil
33245029|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
33245030|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
33245031|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
33245032|NCT00805233|Active Comparator|2|ranibizumab injection alone.
33245033|NCT03842566||20-29 Years Old|
33245034|NCT03842566||30-39 Years Old|
33245035|NCT03842566||40-49 Years Old|
33245036|NCT03842566||50-59 Years Old|
33245037|NCT03842566||60-69 Years Old|
33245038|NCT03842566||70-79 Years Old|
33245039|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
33245040|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
33245041|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
33245042|NCT00798837|Other|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions.~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
33245043|NCT03906136|Experimental|TREAT-TO-TARGET (T2T)|"Participants will receive secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders will continue to receive 4-weekly doses until Week 32 if they maintain the response. In case these patients experience a loss of response from week 24 they will be escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.~Patients who are non-responders at Week 12 will receive 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders will continue to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 will receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
33245044|NCT03906136|Active Comparator|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
33245045|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
33245046|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
33245047|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
33245048|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
33245049|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
33245050|NCT00730496|Experimental|1|the study group, 45 women
33245051|NCT00730496|No Intervention|2|the control group, 45 women
33245052|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
33245053|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
33245054|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
33245055|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
33245056|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
33245057|NCT00725582|Experimental|A|
33245058|NCT00725582|Placebo Comparator|B|
33245059|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
33245060|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
33245061|NCT00862108|Experimental|Methylphenidate|
33245062|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
33245063|NCT04041154|Experimental|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
33245064|NCT04041154|Experimental|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
33245065|NCT04041154|Experimental|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
33245066|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
33245067|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
33245068|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
33245069|NCT00870376||urodynamic studies|
33245070|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
33245071|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
33245072|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
33245073|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
33245074|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
33245075|NCT05152134|Experimental|Empowered Relief On Demand|Empowered Relief On-Demand will include roughly 60 minutes of interactive and multimedia pain educational content that targets pain and stress self-regulation, pain medication misuse, a personalized plan for relief and a 'relaxation medicine' resource.
33245076|NCT05152134|Placebo Comparator|"Health Education (HE; Living Better)"|"The HE arm is an interactive digital general health education intervention called Living Better that is devoid of specific content on pain, psychological skills, and has no active strategies or worksheets."
33245077|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
33245078|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
33245079|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
33245080|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
33245081|NCT05121402|Experimental|Low dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
33245082|NCT05121402|Experimental|Middle dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
33245083|NCT05121402|Experimental|High dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
33245084|NCT05121402|Placebo Comparator|Placebo|Placebo twice daily for 8 weeks.
33245085|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
33245086|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
33245087|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
33245088|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
33245089|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
33245090|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
33245091|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
33245092|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
33245093|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
33245094|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
33245095|NCT00725556|Other|1|Speech therapy
33245096|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
33399658|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 2|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
33399659|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 3|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
33399660|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 4|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
33399661|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
33399662|NCT02392312||ATF-Fresenius S|intravenous
33399663|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
33399664|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
32710892|NCT04334941|Experimental|Arm II (atezolizumab, talazoparib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and talazoparib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
32710893|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
32710894|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
32710895|NCT02207933|Experimental|AP shifting group|
32710896|NCT02207933|Active Comparator|gait training group|
32710897|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
32710898|NCT02199587|No Intervention|Endocrine test without medical clown|
32710899|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
32710900|NCT02208167|Other|Chronic HIV infection|HXTC infusion
32710901|NCT02208167|Other|Acute HIV infection|HXTC infusion
32710902|NCT03532763|Experimental|Tocotrienol-rich fraction|
32710903|NCT03532763|Placebo Comparator|Placebo|
32710904|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
32710905|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
32710906|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
32710907|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
32710908|NCT03532685|No Intervention|Severe Obese Patients|usual care
32710909|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
32710910|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
32710911|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
32710912|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
32710913|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
32710914|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
32710915|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
32710916|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
32710917|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
32710918|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
32710919|NCT04254133||Case Ascertainment|Men with metastatic prostate cancer
32710920|NCT04254133||Family Recruitment|Male relatives of men with metastatic prostate cancer found to have a germline DNA Repair Gene mutation
32710921|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
32710922|NCT05263661|Experimental|LIFT|ligation of interesphincteric fistula tract
32710923|NCT05263661|Active Comparator|FLAP|Rectal advancement flap
32710924|NCT04468477|Active Comparator|Patients attending cardiac outpatient clinic|
32710925|NCT04881448|Experimental|patients with chronic kidney disease|
32710926|NCT05058313|Experimental|Postmenopausal patients|
32710927|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
32710928|NCT02199899|Placebo Comparator|Placebo|
32710929|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
32710930|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
33245097|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
33245098|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
33245099|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
33245100|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
32764455|NCT05184361|Experimental|Intermittent energy restriction (IER)|"Initially participants will undergo 2-weeks of neutral energy balance (EB). After this, the IER will consist of: 2-weeks of energy restriction interspersed with 1-week in neutral EB (total of 23-week period).~At the end, 8-weeks in neutral EB will be required."
33245101|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
32764456|NCT05184361|Active Comparator|Continuous energy restriction (CER)|Similarly to IER, CER participants will undergo 2-weeks of neutral EB. After this, the CER will consist of: 16-weeks of continuous energy restriction. At the end, 8-weeks in neutral EB will be required.
32764457|NCT05173285|Experimental|Brief Online ACT Intervention|Intervention Condition: Participants in this arm will take part in a brief ACT intervention delivered online via Qualtrics across 4-weeks; one session per week. The first two weeks will focus on mindfulness, with participants being invited to practice formal (i.e. 3-minute breathing exercise) and informal mindfulness practices (e.g. mindful walking, mindful drink etc.) during the week. The final two weeks will focus on values, specifically supporting participants to identify their personal values and set goals relating to these values. Participants have up to 6 weeks to complete the 4-week intervention.
32764458|NCT05173285|Other|Waitlist Control|Control Condition: Participants in this arm will not receive an intervention. They will however, been given access to the brief online ACT intervention at the end of study.
32764459|NCT04972877|Active Comparator|Treatment group|Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
32764460|NCT04972877|Sham Comparator|Control group|Control group protocol：participants will receive sham electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
32764461|NCT05164081|Experimental|Dual antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using dual antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
32764462|NCT05164081|Active Comparator|Single antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using single antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
32764463|NCT03061877||Anxiety or depression|
32764464|NCT03061877||Non-anxiety or depression|
32764465|NCT04602325||Inherited Hyperammonemias|"A clinical diagnosis of 1 of 7 diagnosed urea cycle disorders:~N-acetylglutamate Synthetase Deficiency (NAGS)~Carbamyl Phosphate Synthetase Deficiency (CPSD)~Ornithine Transcarbamylase Deficiency (OTCD)~Argininosuccinate Synthetase Deficiency (ASD)~Argininosuccinate Lyase Deficiency (ALD)~Arginase Deficiency (AD)~Hyperammonemia-Hyperornithinemia-Homocitrullinuria (HHH)~A clinical diagnosis of 1 of 2 organic acidemias:~Propionic Acidemia (PA)~Methylmalonic Acidemia (MMA)"
32764466|NCT04602325||Acute Metabolic Disorder + Neurological Sequelae|"Acute metabolic disorder without hyperammonemia but with neurological sequelae:~Maple Syrup Urine Disease (MSUD)~Glutaric Acidemia (GA1)"
32764467|NCT04602325||Fatty Acid Oxidation Disorders|"Acute metabolic disorder without hyperammonemia and without neurological sequelae:~Medium Chain-Acyl CoA Dehydrogenase Deficiency~Very Long Chain-Acyl CoA Dehydrogenase Deficiency~Trifunctional Protein Deficiency~Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency~Carnitine Palmitoyltransferase I or II Deficiency~Carnitine/Acylcarnitine Translocase Deficiency~Primary Carnitine Transport Deficiency"
32764468|NCT04602325||Hypoxic-Ischemic Encephalopathy|Patients with hypoxic-ischemic encephalopathy
32764469|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in healthy young adults.|
32764470|NCT04973189|Placebo Comparator|placebo in healthy young adults.|
32764471|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in elderly subjects.|
32764472|NCT04973189|Placebo Comparator|placebo in elderly subject|
32764473|NCT04601935|Experimental|LCAR-BCX cells product|Each subject will be given a single-dose infusion in each dose levelThe dose-finding phase of this study is designed primarily using the Bayesian optimal interval (BOIN) method, which is combined with accelerated titration at the beginning of the study to assess incidence of DLT (dose-limiting toxicity) and estimate MTD (maximum tolerated dose).
32764474|NCT04220723||End-Stage Liver Disease|End-stage liver disease patients who are being followed up at the Department of Gastroentereology of Hacettepe University Faculty of Medicine will be included in the study. When the participants come to the gastroenterology department for control, they will be directed to us and the assessment will begin after written and verbal approval is obtained. The Liver Frailty Index will be used to assess the frailty of the participants. Accordingly, hand grip test, 5 repeat sit-up test and side, semi-tandem and tandem balance measurements will be made and a total frailty score will be obtained. Submaximal aerobic capacities and functional capacities will be evaluated by 6 Minute Walk Test. Then, maximal inspiratory muscle pressure and maximal expiratory muscle pressure of the participants will be measured and respiratory muscle strength will be evaluated. Finally, maximal aerobic capacity will be measured by Shuttle Walk Test.
32764475|NCT04592887|Experimental|FLASH radiotherapy for painful bone metastasis(-es)|
32764476|NCT04978025|Experimental|Silver Group|"Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
32764477|NCT04978025|Placebo Comparator|Placebo Group|"Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days~By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days."
33245102|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
33245103|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
33245104|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
32710931|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
32710932|NCT02208479||cardiac surgery|
32710933|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
32710934|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
32710935|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
32710936|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
32710937|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
32710938|NCT04440709|Experimental|Brain/neural hand exoskeleton (B/NHE)|
32710939|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
32710940|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
32710941|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
32710942|NCT04235023|Other|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
32710943|NCT04235023|Other|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index < 15 per hour
32710944|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
32710945|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
32710946|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
32710947|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
32710948|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
32710949|NCT04467385|Experimental|Experimental Group|Virtual Reality training(VR) + Sensory Integration therapy + conventional therapy
32710950|NCT04467385|Experimental|Control Group|VR training + conventional therapy
32710951|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
32710952|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
32710953|NCT05263505|Experimental|Baricitinib|4mg daily
32710954|NCT05263505|Active Comparator|Antiproliferative|methotrexate, azathioprine, or mycophenolate
32710955|NCT04467307|Active Comparator|Foreign body aspiration.|Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group.
32710956|NCT04467307|Active Comparator|Group with no foreign body aspiration|Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy.
32710957|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
32710958|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
32710959|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
32710960|NCT04881214|No Intervention|Control|Patients in this arm will receive standard of care
32710961|NCT04881214|Experimental|Pulmonary Rehabilitation|Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
32710962|NCT04467151|Experimental|anti-SARS-CoV-2 plasma|Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma
32710963|NCT04467151|Placebo Comparator|Placebo|Patients receive one dose (250-300ml) of placebo (albumin 5%)
32710964|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
32710965|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
32710966|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
32710967|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
32710968|NCT03526705|Experimental|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
32913252|NCT04709601|Experimental|Group 1 - Patients with negative and positive urine culture|
32913253|NCT05289297|Active Comparator|Karydakis Flap Procedure|Vertical eccentric elliptical incision down to the post-sacral fascia, complete removal of unhealthy tissue, and normal tissue around the cyst and sinus tracts. Mobilization of the medial wound edge and advancement of the skin. Flap along the midline to the post-sacral fascia and suturing its margin to the lateral wound margin.
32737478|NCT05030181|Active Comparator|exercise|1-month home exercise program.
32737479|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
32737480|NCT02493179|Placebo Comparator|Placebo|Placebo
32737481|NCT05030259||patients with fasciotomy|
32737482|NCT05030259||patients without fasciotomy|
32737483|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
32737484|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
32737485|NCT05040867|No Intervention|Control group (CG)|Participants will continue with their daily life and usual care.
32737486|NCT05040867|Experimental|Traditional periodization exercise group (TEG)|Participants will participate in a physical exercise program with a preplanned intensity progression.
32737487|NCT05040867|Experimental|Heart Rate Variability exercise group (HRVG)|Participants will participate in a physical exercise program guide by participants' daily heart rate variability to plan the intensity progression.
32737488|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
32737489|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
32737490|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
32737491|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
32737492|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan~Physical activity~Cognitive behavioral program"
32737493|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan~Physical activity~Cognitive Behavioral Program~Protein Shakes~Phytosterols supplement~Berberine supplement~Anti-oxidant supplement~Probiotic supplement~Fish Oil supplement~Multiple Vitamin/Multiple Mineral supplement"
32737494|NCT05041179|Active Comparator|7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)|"First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning~Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening"
32737495|NCT05041179|Active Comparator|4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)|"First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning~Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening"
32737496|NCT05041179|Active Comparator|2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)|"First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning~Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening"
32737497|NCT05041179|Placebo Comparator|Placebo control (7.2 g isomaltulose)(arm D)|"First dose (3.6 g isomaltulose) consumed in the morning~Second dose (3.6 g isomaltulose) taken in the evening"
32737498|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
32737499|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
32737500|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
32737501|NCT05040399|Other|Locking Compression Plates|Patients in whom we used Locking compression plates for sternal fixation
32737502|NCT05040399|Other|Wires|Patients in whom we used Sternal Wires for sternal fixation
32737503|NCT05051709|Active Comparator|Foot with no fusion|
32737504|NCT05051709|Active Comparator|Foot with fusion|
32737505|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
32737506|NCT05040555|Experimental|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1~5.
32737507|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
32710969|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.~."
32710970|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
32710971|NCT05488795|Other|Suite TB-HBPM pre intervention|Each suite/cluster throughout the institution will begin in the baseline usual care phase in the first year.
32710972|NCT05488795|Other|Suite TB-HBPM throughout intervention implementation|Each suite will be randomized to implement the TB-HBPM program during one of three wedges separated by six months between each, 1.5 years later.
32710973|NCT05488795|Other|Suite TB-HBPM post intervention implementation|Post implementation phase of the suites 2 years after introduction of intervention.
32710974|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
32710975|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
32710976|NCT05488405|Experimental|Mesalamine treatment|Treatment of patient with mesalamine oral suspension
33245105|NCT00617344|Experimental|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
33245106|NCT00617344|Experimental|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
33245107|NCT00617344|Experimental|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
32710977|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
32710978|NCT04189159|Experimental|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
32710979|NCT04189159|No Intervention|Control|Usual treatment
33245108|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
33245109|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
33245110|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
33245111|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
33245112|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
33245113|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
33245114|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
33245115|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
32710980|NCT02204111||Control Cluster|Care as usual
32710981|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
32710982|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
32710983|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
32710984|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
32710985|NCT05263271|Experimental|Experimental cohort|Gentulizumab administered IV once a week and a dosing cycle is 4 weeks
32710986|NCT02204423|Experimental|Trans-Radial PCI|
32764478|NCT05269225|Experimental|Organic diet|Consuming organic food from the start of 2nd trimester and until gestational week 37.
33245116|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
33245117|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
33245118|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
33245119|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
33245120|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
33245121|NCT03256266||healthy controls|healthy controls
33245122|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
33245123|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
32710987|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
33245124|NCT00867880|Experimental|1|
33245125|NCT00867880|Active Comparator|2|
33245126|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
33245127|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
32710988|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
32710989|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
32710990|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
32710991|NCT05471089|Experimental|Experimental|Application of radiofrequency diathermy in addition to the exercises protocol same Exercise protocol than control group. Ten sessions of treatment were applied: daily the first week (Monday to Friday), three the second week (Monday, Wednesday, Friday) and two the last week (Monday and Thursday)
32710992|NCT05471089|Active Comparator|Control|Exercise protocol consisting of: eccentric and concentric strengthening of quadriceps (three squat series of 20 repetitions), hamstrings (three series of 20 seconds performing the bridge exercise), gluteus medius (three series of 20 seconds performing the clam exercise), gastrocnemius and soleus (three series of stretching exercises for 1 minute each). These exercises will be performed along 20 minutes approximately with a minute of rest between each exercise series, never exceeding 3mm in VAS. Participants have to assist to a local facility center to be supervised at doing the exercises daily (from Monday two Friday) along three weeks.
32710993|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
32710994|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
32710995|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
32710996|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
32710997|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
32710998|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
32710999|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
32711000|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
32711001|NCT03581383|Experimental|Telemedicine Arm|The telemedicine Model will track outcomes and record patient experiences with HCV management and treatment with telemedicine.
32711002|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
32711003|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
32711004|NCT04154917|Experimental|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
32711005|NCT04154917|No Intervention|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
32764479|NCT05269225|Placebo Comparator|Conventional diet|Consuming conventional food throughout the whole pregnancy.
32913254|NCT05289297|Active Comparator|Burow's Triangle Advancement Flap Procedure|The flap is incised along the base of the wedge-shaped defect, and a small Burow's triangle is excised on the opposite side. The skin is mobilized and shifted in the direction of the arrow to close the defect. Excising the small Burow's triangle eliminates a dog ear at the base of the flap.
32711006|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
32913255|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
32913256|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
32913257|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
33245128|NCT04040374|Experimental|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
32711007|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
32711008|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
32711009|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
32711012|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
32711013|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
32711014|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
32711015|NCT02200601|Experimental|Seipher Wellness|
32711016|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
32711017|NCT04172623|Experimental|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
32711018|NCT04172623|Active Comparator|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
32711019|NCT02200757|Experimental|Aldoxorubicin|
32711020|NCT02200757|Active Comparator|Topotecan|
32711021|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
32711022|NCT04161391|Experimental|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.~The food-effect sub-study determines the effect of food on a dose of TPX-0046 at the RP2D dose level.~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Phase 2 Cohorts:~Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)~Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)~Cohort III (MTC + RET mutation, RET TKI Therapy Naive)~Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)~Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)~Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
32711023|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
32711024|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
32711025|NCT05374057|Experimental|Chiropractic Spinal Manipulative Therapy (CSMT)|A specific contact, high-velocity, low-amplitude, spinal thrust manipulation directed to spinal biomechanical dysfunction in the cervical and/or thoracic spinal column, as diagnosed by standard chiropractic tests, in accordance with their clinical judgment.
32711026|NCT05374057|Sham Comparator|CSMT sham manipulation|A broad non-specific contact, low-velocity, low-amplitude sham push manoeuvre in a non-therapeutic directional line.
32711027|NCT05374057|Active Comparator|Ibuprofen|Ibuprofen 600mg, 3 times daily for 12 days.
32711028|NCT05374057|Sham Comparator|Placebo medication|Placebo medication, x 3 times daily for 12 days.
32711029|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
32711030|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
33245129|NCT04040374|Active Comparator|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
33245130|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
33245131|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
33245132|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
33245133|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
32711031|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
32711032|NCT05223101|Experimental|Sequence A|TRTR
32711033|NCT05223101|Experimental|Sequence B|RTRT
32711034|NCT05448391|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
32711035|NCT05010109|Experimental|Standard Treatment Plan (Cohort One)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
32711036|NCT05010109|Experimental|Model Based Personalized Treatment Plan (Cohort Two)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
32711037|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
32711038|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
32711039|NCT03528187||Patient Cohort 1|"Age 18 or over~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care~Informed written consent~Able to tolerate MRI"
32711040|NCT03528187||Patient Cohort 2|"Age 18 or over~Attending weight management service at UCLH~Informed written consent~Able to tolerate MRI"
32711041|NCT03528187||Controls|"Age 18 or over~BMI less than 25~Informed written consent~Able to tolerate MRI"
32764480|NCT05127811|Experimental|100mg(on empty)|
32764481|NCT05127811|Experimental|200mg(on empty)|
32764482|NCT05127811|Experimental|400mg(on empty)|
32764483|NCT05127811|Experimental|600mg(on empty)|
32764484|NCT05127811|Experimental|600mg（with a meal）|
32764485|NCT05127811|Experimental|800mg(with a meal)|
32764486|NCT04978103|Experimental|Single Arm|Hundred postmenopausal women were enrolled and received therapeutic dose of Gum Arabic (0.5 gm/kg/day) and followed for 12 weeks then the intended outcomes will be compared before and after completion of the study
32764487|NCT04437173|Experimental|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
32764488|NCT04437173|No Intervention|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
32764489|NCT05259085|Experimental|Cohort 1: Mild IHF|Participants will receive ALXN2050.
32764490|NCT05259085|Experimental|Cohort 2: Moderate IHF|Participants will receive ALXN2050.
32764491|NCT05259085|Experimental|Cohort 3: Severe IHF|Participants will receive ALXN2050.
32764492|NCT05259085|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
32764493|NCT04154579|Experimental|HeRe We Arts|This is an 8 week, arts-based session that includes educational & experiential components. Topics include: Introduction to Arts & Health; Music, Well-Being, & Resilience; Movement & Physical Activity; Art & Well-Being; Writing & Communication/Self-Expression; Theater & Socialization; Art Appreciation & a Healthy Brain; & Summary/Integration of the Arts into Daily Lives.
32764494|NCT04154579|Active Comparator|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational & some experiential components. Topics include: Introduction to Health, Resilience, & Well-Being; Nutrition & Healthy Eating; Exercise, Chair Yoga, & Sleep; Mental Health, Stress Management, & Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, & Complementary & Alternative Medicine; Chronic Illnesses & Chronic Pain; Health & Behaviors; Summary & Navigating the Healthcare System.
32764495|NCT04508179|Experimental|7HP349 Capsules|Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (3-period cross-over)
32711042|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
32711043|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
32711044|NCT05438953|Experimental|PEP Vaccinated|
32764496|NCT04508179|Placebo Comparator|Placebo Capsules|Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)
33399665|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
32711045|NCT05438953|Experimental|PrEP Vaccinated|
32711046|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
32711047|NCT04132999|Active Comparator|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
32711048|NCT04132999|Active Comparator|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
32711049|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
32711050|NCT04027699|Experimental|Mini-bolus|"First injection of 2ml/kg (saline solution)~Second injection of 18ml/kg (saline solution)"
32711051|NCT05203523|Experimental|Group 1 (G1)|Participants will receive active tACS simultaneously with cognitive exercises.
32711052|NCT05203523|Sham Comparator|Group 2 (G2)|Participants will receive sham tACS simultaneously with cognitive exercises.
32711053|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
32711054|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
32711055|NCT02220647|Experimental|Treatment A (FDC)|
32711056|NCT02220647|Active Comparator|Treatment B (single agents)|
32711057|NCT05426395|Active Comparator|Dose 1 (2.6 µg)|Adding Vitamin B12 at a dose of 2.6 µg
32711058|NCT05426395|Active Comparator|Dose 2 (10 µg)|Adding Vitamin B12 at a dose of 10 µg
32711059|NCT05426395|Active Comparator|Dose 3 (50 µg)|Adding Vitamin B12 at a dose of 50 µg
32711060|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
32711061|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
32711062|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
32711063|NCT04155385|Active Comparator|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
32711064|NCT04155385|Experimental|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
32711065|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
32711066|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
32711067|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
32711068|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
32711069|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
32711070|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
32711071|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
32711072|NCT03524755|No Intervention|Control Group|The control group received usual care.
33245134|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
33245135|NCT05226052|Experimental|S. boulardii|treatment arm group (3 capsules of Floratil 200mg®/day)
33245136|NCT05226052|Placebo Comparator|Placebo|control group (3 capsules of placebo/day)
33245137|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
32711073|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
32711074|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
32711075|NCT02209103|Placebo Comparator|Placebo|Placebo
32711076|NCT03956095||Ensure Surgery Immunonutrition Shake supplements|Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
32711077|NCT02205281|No Intervention|Standard Care|
32711078|NCT02205281|Experimental|Lifestyle Intervention|
32711079|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
32711080|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
32711081|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
32711082|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
32711083|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
32711084|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
32711089|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
32711090|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
32711091|NCT02258399|Active Comparator|Breakfast Rest|
32711092|NCT02258399|Active Comparator|Breakfast Exercise|
32711093|NCT02258399|Experimental|Fasted Exercise|
32711094|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
32711095|NCT04972123|Experimental|CPC Adminstration|Single dose of CPC will be given during tilt table test
32711096|NCT04972123|Placebo Comparator|Placebo Adminstration|Single dose of Placebo will be given during tilt table test
32711097|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
32711098|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
32711099|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
32711100|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
32711101|NCT03274375|Experimental|IA session|"4 Rituximab injections~10 IA sessions"
33245138|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
32711102|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
32711103|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
32711104|NCT04466839||parkinsonian patients|Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.
32711105|NCT04467073|Experimental|Stepped-Care Online Reciprocal Imitation Training (Online RIT)|"Participants completed four telehealth modules over a period of 5 weeks (~1 per week, 1 week to practice). Two variables were selected as tailoring variables for this stepped-care model. Fidelity (RIT-PFF) and self-efficacy (EIPSES) at 5 weeks were used to determine which participants were in need of a step up in care, in the form of remote parent coaching.~Parents who demonstrated ≥80% on the RIT-PFF, and who reported gains on the EIPSES continued to have access to Online RIT and practiced on their own for the next 5 weeks, but did not receive any remote coaching. Parents who demonstrated <80% fidelity on the RIT-PFF and/or who didn't report increases in the EIPSES were directed into coaching. Coaching involved videoconferences once per week (wks. 6-10) with a parent coach (PI), and followed the occupational performance coaching model. Sessions included review of successes and challenges, parent practice with feedback, problem solving, and planning."
32711106|NCT04467073|No Intervention|Wait List Control|Participants provided with information about available community resources after randomization. These participants were given the opportunity to engage in the stepped-care format of Online RIT after the post-intervention data collection time point; however their data was included exclusively in control group analyses.
32711107|NCT04466605|Experimental|Tele-Yoga Therapy|All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
33245139|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
33245140|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
32711108|NCT04466605|Active Comparator|Usual Care|Patients randomized to usual care continued to receive care for their chronic musculoskeletal pain from their primary care physician. There was no attempt by to influence clinical management unless an emergency arose
32711109|NCT03916081|Active Comparator|Roflumilast Cream 0.05%|Participants apply roflumilast cream 0.05% QD for 28 days.
32711110|NCT03916081|Active Comparator|Roflumilast Cream 0.15%|Participants apply roflumilast cream 0.15% QD for 28 days.
32711111|NCT03916081|Placebo Comparator|Vehicle Cream|Participants apply vehicle cream QD for 28 days.
32711112|NCT04961827|Experimental|Intervention: Self-efficacy based images|Intervention group with self-efficacy based images sent through instant messaging biweekly for 6 times.
32711113|NCT04961827|Active Comparator|Active control: knowledge based images|Active control group with knowledge based images sent through instant messaging biweekly for 6 times.
32711114|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
32711115|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
32711116|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
32711117|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
32711118|NCT04942405|Experimental|TURKOVAC SARS-COV-2 Vaccine|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
32711119|NCT04942405|Active Comparator|CoronaVac|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
32711120|NCT04933513||preoperative Parkinson' disease|pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively
32711121|NCT04141501|Placebo Comparator|Control: Placebo|30 Patients will receive placebo
32711122|NCT04141501|Active Comparator|Intervention: Psilocybin|30 Patients will receive psilocybin
32711123|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
32711124|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
32711125|NCT03821233|Experimental|ZW49|
32711126|NCT04467229|Experimental|Focus group with chronically painful adolescents|Adolescents with chronic pain
32711127|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
32711128|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
32711131|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
32711132|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
32711133|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
32711134|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
32711135|NCT03116113|Experimental|Part 1: BIIB112 Dose 1|Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
32711136|NCT03116113|Experimental|Part 1: BIIB112 Dose 2|Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
33245141|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
33245142|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
33245143|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
32711137|NCT03116113|Experimental|Part 1: BIIB112 Dose 3|Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
33245144|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
33245145|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
33245146|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
33245147|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
33245148|NCT04066998|Experimental|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
33245149|NCT04066998|Other|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
33245150|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
33245151|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
33245152|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
33245153|NCT00725790|Experimental|A|Vardenafil treatment group
32711138|NCT03116113|Experimental|Part 1: BIIB112 Dose 4|Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
32711139|NCT03116113|Experimental|Part 1: BIIB112 Dose 5|Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
33245154|NCT00725790|Placebo Comparator|B|Placebo treatment group
32711140|NCT03116113|Experimental|Part 1: BIIB112 Dose 6|Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
33245155|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
33245156|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
33245157|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
33245158|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
33245159|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
33245160|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
33245161|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
33245162|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
33245163|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
33245164|NCT00725946|Experimental|Iodine-124 PET-CT scan|
33245165|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
32711141|NCT03116113|Experimental|Part 2: BIIB112 High Dose|Participants will receive a single high dose of BIIB112 by sub-retinal injection.
32711142|NCT03116113|Experimental|Part 2: BIIB112 Low Dose|Participants will receive a single low dose of BIIB112 by sub-retinal injection.
32711143|NCT03116113|No Intervention|Part 2: Untreated Group|Participants will receive no intervention to allow for a controlled comparison.
32711144|NCT04468009|No Intervention|Standard of care|Standard of care for Covid-19
32711145|NCT04468009|Experimental|PCC-19|Treatment with convalescent plasma
32711146|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
32711147|NCT03088813|Active Comparator|Control Arm|Topotecan
32711148|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
32711149|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
32711150|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
32711151|NCT04467931||1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
32711152|NCT04467931||1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB|Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
32711153|NCT04467931||2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
32711154|NCT04467931||2.2 COVID-19 Hospitalized, ACEI vs. ARB|Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
32711155|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
32711156|NCT04744129|Active Comparator|NN414|To investigate the role of NN414 compared with placebo in migraine patients.
32711157|NCT04744129|Placebo Comparator|Saline|To investigate the role of NN414 compared with placebo in migraine patients.
33245166|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
33245167|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
32711158|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
32711159|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
32711160|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
32711161|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
32711162|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
32711163|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
32711164|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
32711165|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
32711166|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
32711167|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
32711168|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…~**Drop down menu**~Learning a new skill..."
32906602|NCT01574807|Experimental|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
33245168|NCT04066842||1 - Controls|Control Healthy controls
33245169|NCT04066842||2 - SSc|SSc Systemic Sclerosis
32711169|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…~**Drop down menu**~Learning a new skill..."
32711170|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
32711171|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
32711172|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
32711173|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
32711174|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
32711175|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
32711176|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
32711177|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
32711178|NCT02373891|Experimental|T1|
32711179|NCT02373891|Experimental|T0|
32711180|NCT05353231|Experimental|Intervention 1 - Attention Feedback Awareness and Control Training|
32711181|NCT05353231|Experimental|Intervention 2 - Mindful Disengagement from Thoughts Training|
32711182|NCT05353231|Placebo Comparator|Placebo|
32711183|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
32711184|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
32711185|NCT05321173||Extubation ≤ 8 hour|Patients who mechanically ventilated less than 8 hours postoperatively
32711186|NCT05321173||Extubation > 8 hour|Patients who mechanically ventilated more than 8 hours postoperatively
32711187|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
32711188|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy~infuse colloid (Volulyte) 200 ml if SVV is > 20%~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
32711189|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
32711190|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
32711191|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
32711192|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
32711193|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
32711194|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
32711195|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
32711196|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
32711197|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
32711198|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
32711199|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
32711200|NCT04466917|Experimental|ABP 215|"Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles."
32711201|NCT04466917|Active Comparator|Bevacizumab|"Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles."
32711202|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
32711203|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
32711204|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
32711205|NCT04466683|Experimental|Low radiation arm|A single dose of 35 cGY delivered to the whole thorax
33245170|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
33245171|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
33245172|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
33245173|NCT00731432|Placebo Comparator|B|Placebo Patch
33245174|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
33245175|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
33245176|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
33245177|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
33245178|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
33245179|NCT00726804|Other|2|
32711206|NCT04466683|Experimental|High radiation arm|A single dose of 100 cGY delivered to the whole thorax
32711207|NCT04466683|No Intervention|Control arm|Patients will receive no radiation therapy but will have research samples collected and best supportive care
33245180|NCT00726960|Experimental|1|Aprepitant
33245181|NCT00726960|Placebo Comparator|2|Placebo
33245182|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
33245183|NCT02570958|Experimental|Indocyanine green|
33245184|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
33245185|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
33245186|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
33245187|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
33245188|NCT00727038|No Intervention|2|Conventional treatment
33245189|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
33245190|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
33245191|NCT04018586|Experimental|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
32711208|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
33245192|NCT04018586|Active Comparator|Heat Only|AVACEN 100 device with heat only
33245193|NCT04018586|Sham Comparator|Sham|AVACEN 100 device with neither heat nor vacuum
33245194|NCT00726258|Placebo Comparator|1|Drip of physiological serum
33245195|NCT00726258|Active Comparator|2|Drip of ketamine
32711209|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
32711210|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
32711211|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
32711212|NCT05373433|Experimental|Experimental group|SSD8432 750mg and Ritonavir 100mg
32711213|NCT05373433|Placebo Comparator|Control group|SSD8432 placebo and Ritonavir placebo
33245196|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
33245197|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
33245198|NCT04822584|Experimental|Phototherapy associated with active treatment|"Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of baricitinib)"
33245199|NCT04822584|Placebo Comparator|Phototherapy associated with placebo|"Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib)."
33245200|NCT00727142|Active Comparator|open shunt|functioning shunt
33245201|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
32711214|NCT04671433|Experimental|Experimental - Immediate Treatment|RPGR4e11
32711215|NCT04671433|Other|Deferred Treatment|Deferred Treatment
32711216|NCT04671433|Active Comparator|Experimental Immediate Treatment|RPGR2e11
32711217|NCT02362971||Included|Patients included into the randomized controlled trial
32711218|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
32711219|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
32711220|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
32711221|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
32711222|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
32711223|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
32711224|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
32711225|NCT02362737|No Intervention|Control|Usual care.
32711226|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).~Patients will not be pre-screened prior to hospital visit."
33245202|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION + NONINVASIVE VENTILATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session with non-invasive ventilation.
33245203|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session without non-invasive ventilation.
33245204|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
33245205|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
33245206|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
33245207|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
33245208|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
32711227|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
32711228|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
33245209|NCT00726492|No Intervention|Control|No treatment
33245210|NCT02915198|Experimental|Metformin|Participants receive initial treatment with metformin XR 500 mg 1 tablet daily, with stepwise titration to a maximum dose of 2000 mg (4 tablets) daily.
33245211|NCT02915198|Placebo Comparator|Placebo|Participants receive initial treatment with 1 tablet daily of placebo (for metformin XR), with stepwise titration to a maximum of 4 tablets daily.
33245212|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
33245213|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
33245214|NCT00726726|Other|A|
32711229|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
32711230|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
32711231|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
32711232|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
32711233|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
32711234|NCT02362815|No Intervention|Control|Patient are not allowed to drink
32711235|NCT04467541|Experimental|Inactivated enterovirus type 71 vaccine|Inactivated enterovirus type 71 vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
32711236|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
32711237|NCT02373423|No Intervention|Control|No intervention program
32711238|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
33245215|NCT00726726|Experimental|B|
33245216|NCT00726726|Experimental|C|+ Other
33245217|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
33245218|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
33399666|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
33245219|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
33245220|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
33245221|NCT02914938|Experimental|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
33399667|NCT04462536|Placebo Comparator|Placebo|Vehicle only
33399668|NCT04462536|Experimental|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
32711239|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
32711240|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
32711241|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
32711242|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
32711243|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
32711244|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
32711245|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
32711246|NCT04645693||HIV Subjects with Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with no diagnosis of non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
32711247|NCT04645693||HIV Subjects without Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with a diagnosis of one or more systemic non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
32711248|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
32711249|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
32711250|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:~7.5 mg/kg gentamicin once daily for 14 days.~Topical Arm:~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
32711251|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
32711252|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
32711253|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
32711254|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
32711255|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
32711256|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
32711257|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
32711258|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
32711259|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
32711260|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
32711261|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
32711262|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
32711263|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
32711264|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
32711265|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
32711266|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
32711267|NCT02362113||Isfahani adults|GI/GL
32711268|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32913258|NCT04689009|Active Comparator|SOC Group|SOC Group (or control group) will follow the standard therapy with visits twice a week. More specifically, the treatment consists of: dressing change, cleansing and eventual debridement of the lesion, the topic treatment and compression bandage.
32913259|NCT04689009|Experimental|EmoLED Group|EmoLED Group will be visited once a week. Therapy in this case includes, in addition to the standard therapy, a treatment with EmoLED device; it consists in irradiating each 5 cm diameter area of the lesion for 60 seconds, with the blue light emitted by the device. For lesions larger than 5 cm, several applications will be applied on adjacent areas, until the whole lesion is covered.
32913260|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
32913261|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
32913262|NCT04685499|Experimental|Telomelysin (OBP-301)|All patients will receive intratumoral injection(s) with OBP-301. If tolerated and no progression is observed, up to twelve injections may be given in each patient.
32913263|NCT04678869|Experimental|Cirprofloxacin prophylaxis|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
32913264|NCT04678869|Active Comparator|Standard of care|standard of care
32913265|NCT04668339|Experimental|Study Group 1, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32913266|NCT04668339|Experimental|Study Group 2, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32913267|NCT04668339|Experimental|Study Group 3, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32711269|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
32711270|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
32711271|NCT02732275|Experimental|DS-3201b|
32711272|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
32711273|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
32711274|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
32711275|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
32711276|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
32711277|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
32711278|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
33245222|NCT02914938|Experimental|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
33245223|NCT02914938|Experimental|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
32913268|NCT04668339|Placebo Comparator|Study Group 4, Younger Adult Participants|Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
32913269|NCT04668339|Experimental|Study Group 1, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32913270|NCT04668339|Experimental|Study Group 2, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32913271|NCT04668339|Experimental|Study Group 3, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
32913272|NCT04668339|Placebo Comparator|Study Group 4, Older Adult Participants|Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
33245224|NCT00732056|Experimental|1|3+3 cohort dose escalation
32711279|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
32711280|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
32711281|NCT04640155|Other|Regular Diet|
32711282|NCT04640155|Experimental|Low FODMAP|
32711283|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
32711284|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
32711285|NCT02205437||Controls|Healthy subjects without psychotic disorder.
32913273|NCT01432886|Experimental|1|
33245225|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
33245226|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
33245227|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
33399669|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
33399670|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
33399671|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
33245228|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
33245229|NCT00727428|Experimental|Group A|
33245230|NCT02089880|Experimental|C-brace then stance control orthosis|
33245231|NCT02089880|Experimental|Stance control orthosis then C-brace|
33245232|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
33245233|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
32711286|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
32711287|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
32711288|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
32711289|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
32711290|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
32711291|NCT04479423|Experimental|Soda water|400ml soda water was drunk to obtain good vision before undergoing MCE examination.
32711292|NCT04479423|No Intervention|water|900ml clear water(100 ml water of simethicone solution was not included) was drunk to obtain good vision before undergoing MCE examination.
32711293|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
32711294|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
32711295|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
32913274|NCT05242887||Older adults hospitalized in acute geriatric units|Response to a questionnaire
33245234|NCT00727376||Observation|Esophageal cancer patients
33245235|NCT04018482|Experimental|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
33245236|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
33245237|NCT00727454|Placebo Comparator|1 Control|No treatment
33245238|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
33245239|NCT00727662|Experimental|1|Yoga
33245240|NCT00727662|Active Comparator|2|A Wellness Seminar series
33245241|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
33245242|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
33245243|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
33399672|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
32711296|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
32711297|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
32711298|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
32711299|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
32711300|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
32711301|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
32711302|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
32711303|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
32711304|NCT03974061|Experimental|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
32711305|NCT03974061|Active Comparator|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
32711306|NCT02221193|Experimental|site specific vs panoral disinfection|
32711307|NCT03927261|Experimental|Dose Escalation and Dose Expansion of PRGN-3006|Participants will be treated in dose escalation phase to identify the safety and maximum tolerated dose (MTD) of PRGN-3006.
32711308|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
32711309|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
32711310|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
32711311|NCT02221271|Experimental|NPB-01|
32711312|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
32711313|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
32711314|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
32711315|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
32711316|NCT03912207|Experimental|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
32711317|NCT03912207|Experimental|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
32711318|NCT03912207|Experimental|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG (Arm A) and 3 volunteers will receive aerosol inhaled normal saline placebo (Arm B). All Group 3 volunteers will have a bronchoscopy 14 days post challenge Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted. For group 3 volunteers this will be offered after unblinding.
32711319|NCT03912207|Experimental|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
32711320|NCT03912207|Experimental|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
32711321|NCT03912207|Experimental|Group 6, Intradermal injection, 14 Day Bronchoscopy|Group 6: 6 volunteers will receive 1 x 10^6 cfu intradermal injection BCG + aerosol saline and will have a bronchoscopy 14 days post challenge All volunteers in group 6 will be offered an optional follow up at 12 months
32711322|NCT03912207|Experimental|Group 7, 14 Day Bronchoscopy|"Group 7: 10 volunteers will receive 1 x 10^7cfu aerosol inhaled BCG. All Group 7 volunteers will have a bronchoscopy 14 days post challenge.~Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted"
32711323|NCT03912207|Experimental|Group 8, Bronchoscopy Day 14|Group 8: 10 historically BCG vaccinated volunteers will receive aerosol inhaled BCG at a dose to be confirmed from emerging study data TB044 (Clinicaltrials.gov NCT04777721). All Group 8 volunteers will have a bronchoscopy 14 days post challenge.
32711324|NCT05262413|Experimental|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
32711325|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 weeks follow-up; Part B: Open-label PRN1008, 24 weeks; 4 weeks follow-up
32711326|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
32711327|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
32711328|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
32711329|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
32711330|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
32711331|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
32711332|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
32711333|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
32711334|NCT02205827|No Intervention|Single-arm|healthy volunteers
32711335|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
32711336|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
32711337|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
32711338|NCT05262335|Experimental|Experimental: Experimental group 1|Initial treatment: Anlotinib + Oxaliplatin + Capecitabine. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
32711339|NCT05262335|Experimental|Experimental: Experimental group 2|Initial treatment: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
32711340|NCT05262335|Experimental|Experimental: Experimental group 3|Initial treatment: Anlotinib + Standard first-line chemotherapy Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
32711341|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
32711342|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
32711343|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
32711344|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
32711345|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
32711346|NCT03525769||Type 2 Diabetes Mellitus|
32711347|NCT02373189|Experimental|Bright light|
32711348|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
32711349|NCT03522181|Placebo Comparator|control group|saline
32711350|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
32711351|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
32711352|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
32711353|NCT03695783|Experimental|Online decision aid called IBD&me|IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
32711354|NCT03695783|Active Comparator|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
32711355|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
32711356|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
32711357|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
32711358|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
32711359|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
32711360|NCT05186129|Experimental|Clopid® 75 mg(Clopidogrel)Tablet of Ferozsons Laboratories Ltd. Pakistan|Single dose of Clopid® 75 mg Tablet administered under fasting condition
32711361|NCT05186129|Active Comparator|Plavix® 75mg Tablet of Sanofi Winthrop Industrie France for Sanofi Pakistan.|Single dose of Plavix® 75 mg Tablet administered under fasting condition
32711362|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
32711363|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
32711364|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
32711365|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
32737508|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
32711366|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
33399673|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
32711367|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
33399674|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
32711368|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711369|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711370|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711371|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711372|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711373|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711374|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32913275|NCT05239455||Healthy adult participants|Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 1-6°C.
32913276|NCT01433042|Experimental|capsule endoscopy|
32913277|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
32913278|NCT04642755||Group 2|LTBI+ and uncontrolled DM
32711375|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
32711376|NCT02361723|Experimental|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
32711377|NCT02361723|Experimental|Breast Cancer|60mg BID Ora
32711378|NCT02361723|Experimental|Prostate Cancer|60mg BID Oral
32711379|NCT02361723|Experimental|Small Cell Lung Cancer|60mg BID Oral
32711380|NCT02361723|Experimental|Gastric Cancer|60mg BID Oral
32913279|NCT04642755||Group 3|LTBI+ and helminth infection
32913280|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
32913281|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
32913282|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
32711381|NCT03596281|Experimental|Cohort A|
32711382|NCT03596281|Experimental|Cohort B|
32711383|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
32711384|NCT02221505|Experimental|LOP628 - AML|With LOP628
32711385|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
32711386|NCT02038803||Adults- Cystic Fibrosis|Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.
32711387|NCT05172167||Early vaccinated against COVID-19|80 subjects with less than 4 months after being fully vaccinated against COVID-19
32711388|NCT05172167||Late vaccinated against COVID-19|80 subjects with more than 4 months after being fully vaccinated against COVID-19
32711389|NCT05172167||COVID-19 infection|40 patients diagnostic of COVID-19
32913283|NCT04635189|Active Comparator|Experimental Arm: Cycle 1-4 All subjects|"Subjects will be treated with the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
32913284|NCT04635189|Experimental|Experimental Arm: Cycle 5+ Partial Response or Better|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle"
32913285|NCT04635189|Active Comparator|Experimental Arm: Cycle 5+ Less than Partial Response|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
32913286|NCT01551056|Experimental|AC-170 0.24%|
32711390|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
32711391|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
32711392|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
32711393|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
32711394|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
32711395|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
32711396|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
32913287|NCT01551056|Placebo Comparator|AC-170 0%|
32913288|NCT04614753|Active Comparator|Dealcoholized Muscadine Wine|Participants in this arm will receive 300ml of dealcoholized muscadine wine daily for six weeks. After a 7- day run-in period, participants will receive dealcoholized muscadine wine daily for six weeks
32913289|NCT04614753|Active Comparator|Control Beverage|Participants in this arm will receive 300 ml of sugar water and acid content for six weeks. After a 7-day run in period, participants will receive sugar water for six weeks.
32913290|NCT04585503|Experimental|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
32913291|NCT05227131|Experimental|Margetuximab + Tucatinib + Capecitabine|All eligible patients will receive the combination of margetuximab 15 mg/kg by intravenous infusion on Day 1 of each cycle (no loading dose is required), capecitabine at 1000 mg per square meter of body-surface area orally twice daily on days 1 to 14 of each 21-day cycle, and tucatinib 300 mg orally twice daily (every 12 hours) continuously in 21-day cycles.
32711397|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
32913292|NCT05218239|Active Comparator|Routine education group|Routine education, including postpartum lifestyle, Kegel exercise and Knack method.
33245244|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~HbA1c>=7.5%~1 severe hypoglycaemia or more~More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~step 1: 3 sensors per month~step 2: 4 sensors per month~step 3: 5 sensors per month~step 4: continuous use"
33245245|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
33245246|NCT04474314|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
32711398|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
32711399|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
32711400|NCT05168891|Experimental|Test group (TG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. Finally, the patients will be enrolled in a peri-implant maintenance therapy (PIMT) program every 3 months.
32711401|NCT05168891|Experimental|Control group (CG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. After one month, the regenerative surgical therapy will be performed as it follows: the intrabony component of the defect will be filled with a xenograft and covered with a collagen membrane allowing a non-submerged healing. Finally, the patients will be enrolled in a PIMT program every 3 months.
32711402|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
32711403|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
32711404|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
32711405|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
32711406|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
32711407|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
32711408|NCT02209805|Experimental|BIRB 796 BS, low dose|
32711409|NCT02209805|Experimental|BIRB 796 BS, high dose|
32711410|NCT02209805|Placebo Comparator|Placebo|
32711411|NCT02209805|Experimental|BIRB 796 BS, medium dose|
32711412|NCT02290093|Active Comparator|Standard full-volume PEG|
33245247|NCT04474314|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
33245248|NCT04474314|Placebo Comparator|Placebo|Oral administration of once daily Placebo
33245249|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
32913293|NCT05218239|Experimental|Global training group|Global training was added on the basis of routine education.
32913294|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
32913295|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
32913296|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
32913297|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
33245250|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
33245251|NCT02569788|Experimental|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
33245252|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
33245253|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
33245254|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
33245255|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
33245256|NCT04460664||Subjects admitted to floor|COVID-19 patients admitted to the floor as initial place of hospitalization
33245257|NCT04460664||Subjects admitted or transferred to ICU|COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
32711413|NCT02290093|Experimental|Split-dose full-volume PEG|
32711414|NCT02290093|Experimental|Split-dose low-volume PEG|
32711415|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
33245258|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
33245259|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
32711416|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
32711417|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
32711418|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
32913298|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
32913299|NCT04564911|Experimental|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
33245260|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
33245261|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
32711419|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
32711420|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
33245262|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
33245263|NCT04065672|Experimental|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
33245264|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
33245265|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
32711421|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
33245266|NCT00657267|Experimental|Single-Arm Study|
33245267|NCT05612100||Observational (alopecia questionnaires and surveys)|Patients complete alopecia questionnaires and surveys on study.
33245268|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
33245269|NCT00733850|Active Comparator|2|Gemcitabine
32711422|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
33245270|NCT04016961|Experimental|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
33245271|NCT04016961|Active Comparator|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
33245272|NCT03146442|Active Comparator|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
32913300|NCT04564911|Active Comparator|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
32913301|NCT01436006||CT scan|patient with cancer
32913302|NCT04551729|Active Comparator|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
32913303|NCT04551729|Experimental|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
32913304|NCT05201391|Experimental|"Eat Right Now (ERN) mobile application"|Participants in this single-arm trial will receive the ERN app as the intervention.
32913305|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
32913306|NCT04532151|Other|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
32913307|NCT04532151|Other|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
32913308|NCT04532151|Other|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
32913309|NCT04505085|Experimental|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
32913310|NCT04505085|Experimental|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
32913311|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
32913312|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
32913313|NCT04707729|No Intervention|Standard of care|Patients will be intubated according to both the standard of care
32913314|NCT04707729|Experimental|Standard of care + ROX algorithm|In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is <0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
32913315|NCT02838069|Experimental|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
32913316|NCT02838069|Experimental|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
32913317|NCT02838069|Placebo Comparator|Placebo|0.5% glucose in saline with 4.5% albumin
33399675|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
33399676|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
33399677|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
32711423|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
32913318|NCT04487613|Active Comparator|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
32913319|NCT04487613|Placebo Comparator|Placebo|Participants received placebo capsule orally twice daily for 3 days.
32913320|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
32913321|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
32913322|NCT05161377|Active Comparator|Surgical management|
32913323|NCT05161377|Active Comparator|Endovascular management|
32711424|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
32913324|NCT04479969|Other|Intervention|This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
32913325|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
32913326|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
32913327|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
32913328|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
32913329|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
32913330|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
32913331|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
32913332|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
32913333|NCT02688309||Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
32913334|NCT02688309||OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
32913335|NCT00370851|Experimental|1|Intravitreal injection of Avastin
32913336|NCT00370851|Sham Comparator|2|
32913337|NCT05126355|Experimental|On the Move|On the Move group exercise program to improve walking. Delivered twice per week for 12 weeks.
32913338|NCT05126355|Other|On the Move - Delayed|Individuals in this arm will be placed on a wait-list for 12 weeks and will receive no intervention during this time. At the end of the 12 weeks they will receive the On the Move group exercise program. This is a wait-list control group.
32913339|NCT05124171|Experimental|Comirnaty® (Pfizer-BioNTech)|Length of use : 1 day
32913340|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|Length of use : 1 day
32913341|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|Length of use : 1 day
32913342|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
33399678|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
33399679|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
32913343|NCT05124093|Placebo Comparator|Apnoea without apnoeic oxygenation|High-flow nasal oxygen administration ceases at the onset of apnoea.
32913344|NCT05124093|Active Comparator|Apnoeic oxygenation with high-flow nasal oxygen at 70 L/min (HFNO)|100% oxygen is administered via high-flow nasal cannulae at 70L/min from the onset of apnoea until four minutes of apnoea has completed.
32913345|NCT05124093|Active Comparator|Apnoeic oxygenation with high-flow nasal oxygen at 120 L/min (uHFNO)|100% oxygen is administered via high-flow nasal cannulae at 120L/min from the onset of apnoea until four minutes of apnoea has completed.
32913346|NCT05119803||Parkinson's patients|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'.~The 'Unified Parkinson's Disease Assessment Scale Part 3' will be used to evaluate the motor function of Parkinson's patients.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes.~The upper extremity functions of Parkinson's patients will be evaluated with the '9-Hole Peg Test'.~A short version of PDQ-39, called the 8-item Parkinson's Disease Questionnaire (PDQ-8), will be applied to determine the quality of life of Parkinson's patients. The PDQ-8 consists of eight items that belong to each of the eight dimensions in the original PDQ-39."
32913347|NCT05119803||Healthy control group|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'. This scale is frequently used for the general determination of the cognitive status of individuals rather than for the purpose of diagnosis.~The upper extremity functions of healty control group will be evaluated with the '9-Hole Peg Test'.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes."
32913348|NCT00370929|Experimental|Meditation|
32913349|NCT04390737|Experimental|HH2853 administered on a BID schedule in continuous 28-day treatment cycles|"HH2853 is supplied as tables with dosage strength of 25mg and 200mg. HH2853 Tablet will be administered orally on a continuous twice daily (BID) schedule, on a flat scale of mg and not individually adjusted by weight or body surface area. A treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations.~All patients will be treated with HH2853 orally on a continuous BID schedule, beginning on Cycle 1 Day 1. But patients in accelerated titration (ATD) part should be administered a single dose on the first day in order to evaluate the PK of a single dose administration. Dosing is twice daily from the second day thereafter."
32913350|NCT05099289|Experimental|AtaCor EV-ICD Lead System|Subjects inserted with the AtaCor EV-ICD Lead Model AC-7000
32913351|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
32913352|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
33399680|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
32711425|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
32711426|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
32711427|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
32711428|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
32711429|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
32711430|NCT04465825|Active Comparator|Interspersing HITT in exercise|We will test whether introducing HITT into an acute exercise bout will increase overall energy expenditure or time to fatigue.
32711431|NCT04465825|No Intervention|Acute exercise bout with no HITT|Exercise will occur at 50% peak without introducing HITT.
32711432|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
32711433|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
32711434|NCT05262179|Experimental|CTO0101|
32711435|NCT05262179|Placebo Comparator|Placebo (Vehicle)|
32711436|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
32711437|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
32711438|NCT05262101|Experimental|TQB2858 injection|TQB2858 injection (1800mg intravenous(iv), on day 1 of every 3 weeks)
33399681|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
33399682|NCT04831060||Case (patients with stage 3 or 4 periodontitis)|
32711439|NCT04059445|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
32711440|NCT04059445|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
32711441|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
32711442|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
32711443|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
32711444|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
32711445|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
32711446|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
32711447|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
32711448|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
32711449|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
32711450|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
32711451|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
32711452|NCT03160677|Experimental|Intensive blood pressure management|
32711453|NCT03160677|Active Comparator|Standard blood pressure management|
32711454|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
32711455|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
32711456|NCT03395197|Experimental|Combination arm|Talazoparib plus enzalutamide
32711457|NCT03395197|Active Comparator|Monotherapy arm|Ezalutamide plus placebo
32711458|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
32711459|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
32711460|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
32711461|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
32711462|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
32711463|NCT02359071||handovers with higher durations|Higher than 20 minutes
32711464|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
32711465|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
32711466|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
32711467|NCT05092841|Experimental|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
32711468|NCT05092841|Placebo Comparator|PXT3003 Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
32711469|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
32711470|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
32711471|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
32711472|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
32711473|NCT03160131|Active Comparator|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
32711474|NCT03160131|No Intervention|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
32711475|NCT02210429|Active Comparator|IV Opioids|
32711476|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
32711477|NCT02210429|Active Comparator|Supraclavicular Catheter|
32711478|NCT02210429|Active Comparator|Supraclavicular Angiocath|
32711479|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
32711480|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
32711481|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
32711482|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
32711483|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
32711484|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
32711485|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
32711486|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
32711487|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
32711488|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
32711489|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
32711490|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
32711491|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
32711492|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
32711493|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
32711494|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
32711495|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
32711496|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
32711497|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
32711498|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
32711499|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
32711500|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
32711501|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
32711502|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
32711503|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
32711504|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
32711505|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
32711506|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
32711507|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
32711508|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
32711509|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32711510|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
32711511|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
32711512|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
32711513|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
32711514|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
32711515|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
32711516|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
32711517|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
32913353|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
32913354|NCT05099133|Experimental|LEO 138559 Dose 1|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
33399683|NCT04831060||Control (healthy periodontium)|Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries or aesthetic surgeries
32711518|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
32711519|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
32711520|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
32711521|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
32711522|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
32711523|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
32711524|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
32711525|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
32711526|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
32711527|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
32711528|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
32711529|NCT04478799|Experimental|Group A (Transcutanous Posterior Tibial Nerve Stimulation)|Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
32711530|NCT04478799|Sham Comparator|Group B (Sham Control)|Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
32711531|NCT05057195|Experimental|Interstitial radiation therapy|Duration: 11 days
32711532|NCT05057195|Active Comparator|Postoperative external beam therapy, on the bed of the removed tumor|Duration: 4 weeks
32711535|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
32711536|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
32711537|NCT05055713|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
32711538|NCT05055713|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
32711539|NCT05055713|Experimental|Primary prevention-1|Endoscopic therapy
32711540|NCT05055713|Experimental|Primary prevention-2|Endoscopic therapy+ PSE
32711541|NCT05055713|Experimental|Acute bleeding-1|Endoscopic therapy+somatostatin
32711542|NCT05055713|Experimental|Acute bleeding-2|Endoscopic therapy+PSE+somatostatin
32711543|NCT02360865|Experimental|COPD|Acute exercise bouts
32711544|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
32711545|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
32711546|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
32711547|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
32711548|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
32711549|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
32711550|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
32711551|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
32711552|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
32711553|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
32711554|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
32711555|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
33399684|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
32711556|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
32711557|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
32711558|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
32711559|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
32711560|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
32711561|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
32711562|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
32711563|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
32711564|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
32711565|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
32711566|NCT04439097|Experimental|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
32711567|NCT04439097|Active Comparator|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
32711568|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
32711569|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
32711570|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
32711571|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add~Control lens : Lotrafilcon B and Etafilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
33399685|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
33399686|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
33399687|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
32711572|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
32711573|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
32711574|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
32711575|NCT02225639|Active Comparator|PRC-063|
32711576|NCT02225639|Placebo Comparator|Placebo|
32711577|NCT05231109|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The exercise program was arranged 3 times a day for 6 months, and each exercise was 10 repetitions. The patients were called for physiotherapist control once every 2 weeks.
32711578|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
32711579|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
32711580|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
32711581|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
32711582|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
32913355|NCT05099133|Experimental|LEO 138559 Dose 2|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
32913356|NCT05099133|Experimental|LEO 138559 Dose 3|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
33245273|NCT03146442|Experimental|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
33245274|NCT03146442|Placebo Comparator|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
33245275|NCT00732602|Active Comparator|B|GLP-2 infusion
33245276|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
32711583|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
32711584|NCT02215421|No Intervention|No game play|No intervention control.
32711585|NCT04624113|Experimental|Phase I: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
32711586|NCT04624113|Experimental|Phase 2: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
32711587|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
32711588|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
32711589|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
32711590|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
32711591|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
32711592|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
33245277|NCT00732602|Active Comparator|A|GIP-infusion
33245278|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
33245279|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
33245280|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
33245281|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
33245282|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
33245283|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
32711593|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
33245284|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
33245285|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
33245286|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
33245287|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
33245288|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
33245289|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
33245290|NCT02569268||exposure population|No special intervention(s) .
33245291|NCT04066920|Experimental|IBER treatment arm|This is the only arm in a single-arm phase II study.
33245292|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
33245293|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
33245294|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
33245295|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
33399688|NCT05742334|Experimental|Robot Assisted Radical Prostatectomy with MLG-COMPLETE Allograft|Implantation of the MLG-COMPLETE allograft during your robot-assisted radical prostatectomy surgery.
32913357|NCT05099133|Placebo Comparator|Placebo|LEO 138559 placebo will be administered subcutaneously up to 3 injections per dosing
32913358|NCT00552617|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
32711594|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
32913359|NCT00552617|Experimental|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
32711595|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
32711596|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
32711597|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
32711598|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
32913360|NCT00552617|Experimental|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
32711599|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
32711600|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
32711601|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
32711602|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
32711603|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
32711604|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
32711605|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
32711606|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
32711607|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage~Preop smoking and alcohol~Preop parenteral nutrition~Oral bowel preparation (mechanical bowel preparation )~Preoperative fasting > 12 hours~Pre-anesthetic medication~Anti-thrombotic prophylaxis~Antimicrobial prophylaxis and skin preparation~Intravenous analgesia : PCA~Prevention of postoperative nausea and vomiting (PONV) (X)~Incision : surgeon direction~Avoiding hypothermia~Nasogastric intubation (O)~Postop glycemic control~Positive fluid balance~Perianastomotic drain removal over POD #5~Somatostatin analogues~Transurethral catheter removal~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)~Postop routine artificial nutrition (O), soft diet at POD #5~Early and scheduled mobilization"
32711608|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)~dietary supplement~procedure (preoperative and postoperative)~drug"
32711609|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
32711610|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
32711611|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
32711612|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
32711613|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
32711614|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
32711615|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
32711616|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
32711617|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
32711618|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
32711619|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
32711620|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
32711621|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
33245296|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
33245297|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
32764497|NCT04400149||1|amniotic fluid progesterone (this group will be evaluated by the amniotic fluid which was received via amniocentesis). This group consisted of pregnant women who had high risk in the antenal test and give consent to perform amniocentesis. Notwithstanding, amniocentesis detects chromosome abnormalities, neural tube defects, and genetic disorders for the fetuses. İn a routine amniocentesis, 1-2 ml amniotic fluid which was taken in the first place was discarded in order to prevent maternal contamination. Then 15-20 ml amniotic fluid was taken from all of the patients to diagnose genetic disorders of the fetuses. İn this study we evaluate the amniotic fluid progesterone in this 1-2 ml amniotic fluid which was discarded and throw away. Therefore, we are not performing an extra invasive procedure for pregnant women
32764498|NCT04400149||2|serum progesterone (this group consisted of the pregnant women who have amniocentesis procedure and blood samples were taken in the same procedure )
32764499|NCT04437017|Experimental|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
32764500|NCT04437017|Active Comparator|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
32764501|NCT05107375|Experimental|Population Ⅰ|One dose of influenza virus split vaccine and one dose of recombinant Novel coronavirus vaccine (CHO cells) were given in the contralateral arm on day 0, the second dose of recombinant Novel coronavirus vaccine (CHO cells) on day 30 and the third dose of recombinant Novel coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
33245298|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
33245299|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
33245300|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
33245301|NCT00805623|No Intervention|AW|no pacifier , no sucrose
33245302|NCT00805623|Active Comparator|AS|sucrose without pacifier
33245303|NCT00805623|No Intervention|PW|
33245304|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
33245305|NCT04280172|Experimental|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
33245306|NCT04280172|Active Comparator|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
33245307|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
33245308|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
33245309|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
32764502|NCT05107375|Experimental|Population Ⅱ|The first dose of recombinant Novel Coronavirus vaccine (CHO cells) was given on day 0, the second dose of recombinant Coronavirus vaccine (CHO cells) on day 30, the first dose of influenza virus lysate vaccine on day 44, and the third dose of recombinant Coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
32764503|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
32764504|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
32764505|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
33245310|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
33245311|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
33245312|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
33245313|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
33245314|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
33245315|NCT00727922|Experimental|1|
33245316|NCT00809289|Experimental|One|
33245317|NCT00809289|Placebo Comparator|Two|
33245318|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
33245319|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
33245320|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
32764506|NCT04972643|Experimental|EPA and DHA intervention|EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
32764507|NCT04972643|Experimental|EPA intervention|EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
32764508|NCT04972643|Experimental|DHA intervention|DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
32764509|NCT04972643|Placebo Comparator|Placebo|Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
32764510|NCT05107141|Active Comparator|xenograft and a collagen membrane|
32764511|NCT05107141|Active Comparator|allograft and a collagen membrane|
32764512|NCT05107063||Dyslipidemic participants with Type 2 diabetes|Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.
32764513|NCT04977713|Experimental|Acupressure group|In the acupressure uterine contractions were checked before the care application began. Acupressure was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
32764514|NCT04977713|Experimental|Shower Group|The shower group, uterine contractions were checked before the care application began. A shower was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
32764515|NCT04977713|No Intervention|Control group|The women in the control group underwent routine hospital care. They were administered neither pharmacological nor nonpharmacological methods to reduce labour pain.
32764516|NCT05106907|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
32764517|NCT04977401|Sham Comparator|Group Glycerol|Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
32764518|NCT04977401|Active Comparator|Group Gel ORISE|Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
32764519|NCT05106829|Active Comparator|Physical therapy program with treadmill training without using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill for 30 min./ session.
32764520|NCT05106829|Experimental|Physical therapy program with treadmill training with using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill with ankle weights for 30 min./ session.
32764521|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
32764522|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
32764523|NCT04422613|Experimental|characterization of pulmonary damage|This clinical trial will be characterized the pulmonary damage after COVID-19 pneumonia
32764524|NCT04971317|Experimental|Sugar-Sweetened Beverage (SSB) Video|
32764525|NCT04971317|Experimental|Water Video|
32764526|NCT04971317|Active Comparator|Control|
32764527|NCT04249609|Experimental|High Carbohydrate Meals Around Exercise|On day 1, high CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will consist of pasta, meat ball and orange juice. On the day 2, participants will exercise for 60 minutes and then in 60 minutes will consume morning meal, providing 30% of their total daily energy requirements. Morning meal will consist of oats, skimmed-milk, banana and seedless raisins.
32764528|NCT04249609|Experimental|Low Carbohydrate Meals Around Exercise|On day 1, low CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will based on burger, cheese, mushroom, nuts, and butter.On the day 2, participants will exercise fro 60 minutes and then in 60 will consume morning meal, providing 30% of their total daily energy requirements. Meal will consist of white bread, egg, cheese, olive oil, nuts, and olives.
32764529|NCT04971707|Active Comparator|standard exercise training|The physical exercises intervention will include a standardized aerobic exercises training, three sessions per week for 3 months.
32764530|NCT04971707|Experimental|HRV-guided exercise training|The physical exercises intervention will include an individualized aerobic exercises training, three sessions per week for 3 months.
32764531|NCT05106751|Experimental|YVOIRE Classic plus|
32764532|NCT05106751|Active Comparator|Restylane Lidocaine|
32764533|NCT04383379|Experimental|Intervention group|6 NICUs in the intervention group . The participating units of the intervention group determine the improvement items (one or more) in each quarter from the list of best practices of breast feeding quality improvement of Jiangsu Province, and report the improvement plan to the supervision unit, and recommend the application of PDSA (plan-do-study-act) for the implementation of quality improvement loop. Report the implementation of quality improvement to the supervision unit on a quarterly basis.
32764534|NCT04383379|No Intervention|control group|Continue current practices
32764535|NCT05106673|Experimental|clinical centers that receive implementation support|These clinical centers receive support during the implementation of the CHIMPS-intervention. There are three different implementation interventions.
32711622|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
33245321|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
33245322|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
33245323|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
32711623|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
32711624|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
32711625|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
32711626|NCT02217449||HD|Prediction of histology
32711627|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
32711628|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
32711629|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
33245324|NCT05623722|No Intervention|Control Group|Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent.
32711630|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
32711631|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
32711632|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
32711633|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
32711634|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
32711635|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
32711636|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
32711637|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
32711638|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
32711639|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
32711640|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
32711641|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
32711642|NCT03133039|Active Comparator|bioabsorbable screw|
32711643|NCT03133039|Active Comparator|titanium screw|
32711644|NCT05013983|Experimental|Low-dose vaccine (6-11 years)|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
32711645|NCT05013983|Experimental|Medium-dose vaccine (6-11 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
32913361|NCT00552617|Experimental|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
33399689|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
32711646|NCT05013983|Experimental|Medium-dose vaccine (12-17 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
32711647|NCT05013983|Experimental|High-dose vaccine (12-17 years)|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
32711648|NCT05013983|Placebo Comparator|Low-dose placebo (6-11 years)|three doses of low-dose placebo at the schedule of day 0, 21，42.
32711649|NCT05013983|Placebo Comparator|Medium-dose placebo (6-11 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
32711650|NCT05013983|Placebo Comparator|Medium-dose placebo (12-17 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
32711651|NCT05013983|Placebo Comparator|High-dose placebo (12-17 years)|three doses of high-dose placebo at the schedule of day 0, 21，42.
32711652|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
32711653|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
32711654|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
32711655|NCT02357433|No Intervention|Control Group|Standard practice
32711656|NCT01672255|Active Comparator|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
32711657|NCT01672255|Placebo Comparator|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
32711658|NCT02222519||Statin use group|patients taking statins for at least 3 months
32711659|NCT02222519||non statin use|no history of taking statin
32711660|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
32711661|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
32711662|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
32711663|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
32711664|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
32711665|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
32711666|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
32711667|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
32711668|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
32711669|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
32711670|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
32711671|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
32711672|NCT02222597||positive infrascanner finding|
32711673|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
32711674|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
32711675|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
32711676|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
32711677|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
32711678|NCT04478955||normal|no make up
32711679|NCT04478955||eyeliner only|three days a week at least for 6 months
32711680|NCT04478955||mascara only|three days a week at least for 6 months
32711681|NCT04478955||eyeliner and mascara|three days a week at least for 6 months
32711682|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
32711683|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.~Low dose cytarabine.~Standard Intensive Chemotherapy."
32711684|NCT02294383||Pre/post surgery pelvic floor assessment|
32711685|NCT02294383||Conservative treatmen monitoring|
32711686|NCT02294383||Pelvic floor muscle contrictions|
32711687|NCT02294383||Imaging reproducibility|
32711688|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
32711689|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
32711690|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
32711691|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
32711692|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
32711693|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
33399690|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
32711694|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
32711695|NCT01457443||Observation|Patients with Pompe disease
32711696|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
32711697|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
32711698|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
32711699|NCT02359539|Experimental|PRF|Platelets rich fibrin,
32711700|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
32711701|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
32711702|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
32711703|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
32711704|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
32711705|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
32711706|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
32711707|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
32711708|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
32711709|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
32711710|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
32711711|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
32711712|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
32711713|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
32711714|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
32711715|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
32711716|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
32711717|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
32711718|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
32711719|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2-3 years
32711720|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
32711721|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
32711722|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
32711723|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
32711724|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
32711725|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
32711726|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
32711727|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
32711728|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
32764536|NCT05106673|Experimental|No Intervention: Treatment as usual|These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
32764537|NCT04977557|Other|single arm|"its a quasi experimental study where single group is used (self controlled clinical trial).~clinical features were compared before iand after intervention"
32764538|NCT04316143|Experimental|50 mg zamicastat|50 mg zamicastat once daily (half a tablet of 100 mg)
32764539|NCT04316143|Experimental|100 mg zamicastat once daily|100 mg zamicastat once daily (one tablet of 100 mg)
32764540|NCT04316143|Experimental|150 mg zamicastat once daily|150 mg zamicastat once daily (one and a half tablet of 100 mg)
32764541|NCT04316143|Experimental|200 mg zamicastat once daily|200 mg zamicastat once daily (two tablets of 100 mg)
32764542|NCT04977323|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive the pictures they want. They will be asked to trace and color the pictures that need coloring. The nurse will color with children during the procedure. And after the procedure, the child will take his or her picture which he colored during the procedure.
32764543|NCT04977323|Experimental|Watching cartoons|Watching cartoons: In this group, children will watch cartoons as they like. Watching will continue until the procedure is complete.
32764544|NCT04977323|Experimental|Group listening to music|Listening to music: In this group, children will listen to cartoon music as they like. Listen will continue until the procedure is complete.
32764545|NCT04977323|No Intervention|Standard care provided group as control group|Control group. The kids in this group will be allowed to keep their family near. The routine blood taking
32764546|NCT04977089||Ischemic heart disease patients .|Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
32764547|NCT05104801|Experimental|Arm A: tislelizumab+sitravatinib|Patients will receive sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
32764548|NCT05104801|Experimental|Arm B: sitravatinib|Patients will receive sitravatinib 100 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
32764549|NCT04977011|Experimental|experimental group|30 minutes music intervention for 3 days on bedside
32764550|NCT04977011|No Intervention|control group|usually care
32764551|NCT04530877|Experimental|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
32764552|NCT04530877|Active Comparator|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
32764553|NCT04971083|No Intervention|Usual Care|"Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
32764554|NCT04971083|Active Comparator|Intervention Group|"Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care.~Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
32764555|NCT04274023|Experimental|TSR-042 arm|TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
32764556|NCT04971239|Active Comparator|topical methotrexate microemulsion|Group(A): topical methotrexate micro emulsion formulation, each patient will be instructed to apply a very thin film of 0.5 ml of it over the three psoriatic plaques three times weekly .
32764557|NCT04971239|Experimental|combination of topical methotrexate microemulsion and excimer light|Group(B) : excimer laser will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks.
32764558|NCT04971239|Experimental|combination of topical methotrexate microemulsion and narrow band-ultraviolet B|Group(C) : Narrow band ultraviolet B will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks
32764559|NCT05121649||Before|Injured patients included in the study from health trusts where video streaming not yet has been implemented in the EMCC
32764560|NCT05121649||After|Injured patients included in the study from health trusts where video streaming has been implemented in the EMCC
32764561|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
32764562|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
32764563|NCT04903093|Experimental|Part A: Abrocitinib Tablet|
32764564|NCT04903093|Experimental|Part A: Abrocitinib Suspension F1|
32764565|NCT04903093|Experimental|Part A: Abrocitinib Tablet + Famotidine|
32764566|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1|
32764567|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2|
32764568|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3|
32764569|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4|
33245325|NCT05623722|Experimental|Erector Spinae Plane Block Group|"Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU.~Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent."
33245326|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
33245327|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
33245328|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
33245329|NCT04066530|Experimental|AD-203|
33245330|NCT04066530|Active Comparator|Mucosta tab.|
33245331|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
33245332|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
33245333|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
33245334|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
32711729|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
33245335|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
33245336|NCT00728208|Experimental|GSK372475|Drug
33245337|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
32711730|NCT02220179|No Intervention|control|service as usual
33245338|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
33245339|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
32711731|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
32711732|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
33245340|NCT00799305||COPD patients|
33245341|NCT00730314|Experimental|1|Unrelated donor
33245342|NCT00730314|Experimental|2|Cord Blood
32711733|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
32711734|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
32711735|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
32764570|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5|
33245343|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
33245344|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
33245345|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
32764571|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6|
32764572|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1 + Famotidine|
32764573|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2 + Famotidine|
33245346|NCT04065230||TAF antiviral therapy group|
33245347|NCT04213794|Experimental|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours.
33245348|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
33245349|NCT00728078|No Intervention|2|control group
33245350|NCT00653991|Experimental|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
33245351|NCT00653991|Active Comparator|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
33245352|NCT04786106|Active Comparator|CCH+PTT|Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
33245353|NCT04786106|Active Comparator|Surgery+PTT|Men will undergo either penile plication or I&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
33245354|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
33245355|NCT04066088|Sham Comparator|Placebo|
32711736|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
32711737|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
32711738|NCT04439019|Experimental|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
32711739|NCT03521947||One group of children below 18 years old|
32711740|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
32711741|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
32711742|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
32711743|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
32711744|NCT04465903||Dysphagia patients|The first group consists of 85 dysphagia patients who have at least six months of dysphagia complaints. The participants will given the Turkish version of Sydney Swallow questionnaire (SSQ-T), consisted of 17 questions, eating assessment tool-10 and two scales evaluated with FEES. After the two weeks, 30 participants will given the SSQ-T for sampling.
32711745|NCT04465903||Healthy adults|The second group consists of 85 healty participants will given the SSQ-T consists of 17 questions, eating assessment tool-10.
32711746|NCT02222987|Active Comparator|Terbogrel|
32711747|NCT02222987|Experimental|Terbogrel with Clopidogrel|
32711748|NCT02222987|Active Comparator|Clopidogrel|
32711749|NCT03147573|Experimental|Blood pressure monitoring|
32711750|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
32711751|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
32711752|NCT02220257||Newly diagnosed type 1 diabetes|
32711753|NCT04479033|No Intervention|Control|Participants assigned to the control group had screened positive for cognitive impairment but refused the intervention. They were provided with a GP referral letter and information on helplines and caregiver support. Follow-up interviews were scheduled at week 24.
32711754|NCT04479033|Experimental|Intervention|Weekly meeting/communication sessions with members of intervention team for a total of 24 weeks.
32711755|NCT03521869|Active Comparator|Compression bandage group|
32711756|NCT03521869|Active Comparator|Standard gauze group|
32711757|NCT02481245|Experimental|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
32711758|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
32711759|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
32711760|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
33245356|NCT04066088|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
32711761|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
32711762|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
32711763|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
32711764|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
32711765|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
32764574|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3 + Famotidine|
32711766|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
32711767|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
32711768|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
32711769|NCT03521167|No Intervention|T|traditional opioid based regimen
32711770|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
32711771|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
32711772|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
32711773|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
32711774|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
32711775|NCT02226575|No Intervention|Control|Controls only dilivery standard care
32711776|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
32711777|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
32711778|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
32711779|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
32711780|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
32711781|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
32711782|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
32711783|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
32711784|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
32711785|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
32711786|NCT03147339|No Intervention|control|Low calorie diet
32711787|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
32711788|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
32711789|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
32711790|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
32711791|NCT02356341||NovaTears®|
32711792|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
32711793|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
32711794|NCT05256121|No Intervention|control|At 6 months and 12months the study team will communicate with the participants by phone to inquire about risk factors data, propose alternative activities, and provide positive reinforcement and feedback
32711795|NCT05256121|Experimental|intervention|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants' every 3-4 weeks by phone. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
32711796|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
32711797|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
33245357|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
33245358|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
33245359|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
33245360|NCT02570178|No Intervention|standard practice advice|standard practice advice
32711798|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
32711799|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
32711800|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
32711801|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
32711802|NCT02226731|Other|Late Belfort-Dildy balloon device|
32711803|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
32711804|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
33245361|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
33245362|NCT00733148||1|Routine Care
33245363|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
33245364|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept~Placebo"
33245365|NCT00809601|Experimental|1|
33245366|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
33245367|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
33245368|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
33245369|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
33245370|NCT00730470|Experimental|1|
33245371|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
33245372|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
33245373|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
33245374|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
33399691|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
33399692|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
32764575|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4 + Famotidine|
32764576|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5 + Famotidine|
32764577|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6 + Famotidine|
32764578|NCT04970849||one group that is IBD endoscopist who perform the endoscopy for IBD patients|Complete the questionnaire online
32764579|NCT04529785|Active Comparator|SVC only|Patients in Group 1 will receive an SVC isolation only
32764580|NCT04529785|Active Comparator|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
32764581|NCT04976465||combined with aPL(+)|the antiphospholipid antibodies appear in blood at least once
32764582|NCT04976465||combined with aPL(-)|the antiphospholipid antibodies never appear in blood
32764583|NCT04970615||Two-dimensional images|Patients who receive pre-operativeinformation while the two-dimensional MR images are being shown to them by the neurosurgeon.
32764584|NCT04970615||Three-dimensional printed model|Patients who receive pre-operative information while the three-dimensional printed models are being shown to them by the neurosurgeon.
32764585|NCT04271293||Patients with PEG and oral anticoagulan treatment|Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.
32764586|NCT04208659|Experimental|Self-administration of Auricular Acupuncture Group|There is only one arm in this pilot project, whose purpose is to determine safety of self-administration of Battlefield Acupuncture over a six month period and how well a prosthesis facilitates needle insertion. Five ASP (Aiguille D'acupuncture semi-permanente) needles will be self-inserted into each participant's ear every two weeks according to the standardized acupuncture points in Battlefield Acupuncture.
32764587|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
32764588|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
32764589|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
32764590|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
32764591|NCT04848025|Experimental|3D customized airway stents|
32764592|NCT03059849|Active Comparator|Temporary increase in adalimumab|
32764593|NCT03059849|No Intervention|Continued monitoring as per standard of care|
32764594|NCT04822441||Patients who contracted dengue fever before 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy before 34 weeks outside the peri-partum period (more than 12 days before childbirth)
32764595|NCT04822441||Patients who contracted dengue fever after 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy after 34 weeks outside the peri-partum period (more than 12 days before childbirth)
32764596|NCT04822441||Patients who have contracted dengue during the peripartum period|Patients who have contracted dengue during the peripartum period or who have a suspicion of dengue (in the 12 days preceding childbirth)
32764597|NCT04976075||Adults|Patients of 18 or more years old
32764598|NCT04976075||Pediatrics|Patients less than 18 years old
32764599|NCT04796701|Experimental|Follow Home Intervention|If possible, all included participants are physically followed home by a hospital-based project worker on the day of discharge. During the visit, the focus is on: basic human needs, medication review reconciliation, and a comprehensive geriatric assessment. Problems, challenges and concerns are discussed. Finally, a conference for the following working day is arranged either as a physical visit or a video conference. The patient, relatives, community-based nurse and project worker are invited to participate and health status and challenges are discussed They are recommended to contact the project worker about health and practical issues up to 7 days after discharge where the intervention ends. Subsequently, the responsibility for treatment and care is assigned to the GP and home healthcare provider.
32764600|NCT04796701|No Intervention|Control|On the day of discharge, the hospital-based nurse digitally sends a summary of the hospital stay and a treatment and care plan to the community-based nurse. If needed, the hospital-based nurse contacts the community-based nurse by phone as a supplement to the plan. Finally, a discharge letter conducted by the hospital-based doctor is digitally sent to the GP
32764601|NCT04156165|Active Comparator|VLCD-Control|Very low calorie diet, 600 kcal pr day for eight weeks.
32764602|NCT04156165|Experimental|VLCD-Active|Very low calorie diet plus additional 25 g protein powder, 700 kcal pr day for eight weeks.
32764603|NCT04156165|Active Comparator|Maintenance-Control|"12-week weight maintenance diets: Moderate protein weight maintenance diet (MP-WMD): Recommended healthy diet including 25 g beef daily.~The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar)."
32764604|NCT04156165|Experimental|Maintenance-Active|12-week weight maintenance diets: High protein weight maintenance diet (HP-WMD): The macronutrient distribution will be 25 energy percentage (E%) from protein, 45 E% from carbohydrate and 30 E% from fat. The diet will include 150 g beef as a daily source of protein, The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar).
32764605|NCT04970693|Experimental|Furmonertinib 80mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after first/second generation EGFR-TKI therapy. These patients will receive furmonertinib 80mg combined with radiotherapy as following therapy.
32764606|NCT04970693|Experimental|Furmonertinib 160mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after third generation EGFR-TKI therapy. These patients will receive furmonertinib 160mg combined with radiotherapy as following therapy.
32764607|NCT04970069|Active Comparator|Analgesic education|
32764608|NCT04970069|Placebo Comparator|General perioperative education|
32764609|NCT04918537|Experimental|Intervention walnuts|During the 3 last weeks of the study, the participants will eat a 30g daily walnut serving
33245375|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
33399693|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
33399694|NCT04806100|No Intervention|No Brace|Participants will be tested while wearing no brace.
32711805|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
32711806|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
32711807|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
32711808|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
32711809|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
32711810|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
32711811|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.~The Brain contour will be generated using the segmentation wizard and edits as required.~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
32711812|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
32711813|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
32711814|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
32711815|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
32711816|NCT02226887|Experimental|MESH|
32711817|NCT02226887|Active Comparator|NO MESH|
32711818|NCT04465513|Active Comparator|Best Standard of Care + CARDIO|Combination of CARDIO and Best Standard of Care
32711819|NCT04465513|Placebo Comparator|Best Standard of Care|Placebo and Best Standard of Care
32711820|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
32711821|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
32711822|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
32711823|NCT03517501|Active Comparator|ART-123|
32711824|NCT03517501|Placebo Comparator|Placebo|
32711825|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
32711826|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
32711827|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
32711828|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
32711829|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
32711830|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
32711831|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
32711832|NCT04465123|Experimental|Furosemide with spironolactone or hydrochlorothiazide|"IV furosemide dosage will be adjusted according to the protocol as follows. Level 1: previous oral furosemide dose ≤80 mg/day; furosemide 80 mg IV bolus every 6 hours Level 2: previous oral furosemide dose 81-160 mg/day; furosemide 160 mg IV bolus every 6 hours Level 3: previous oral furosemide dose >160 mg/day; furosemide 250 mg IV bolus every 6 hours Furosemide dosage will be adjusted to keep urine output between 3,000 and 5,000 ml/day and >600 ml during 6 hours after furosemide administration.~If the urine output <3,000 ml/day or <600 ml per 6 hours, furosemide dosage will be increase 1-level up per protocol above.~If the urine output >5,000 ml/day, furosemide dosage will be reduced 1-level down per protocol above.~Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels."
32913362|NCT00552617|Experimental|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
32913363|NCT00552617|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
32913364|NCT00552617|Experimental|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
32913365|NCT00552617|Experimental|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
32913366|NCT00552617|Experimental|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
32913367|NCT00552617|Experimental|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
32913368|NCT04387305|Experimental|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
32913369|NCT04387305|Experimental|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
32711833|NCT04465123|Active Comparator|Furosemide with placebo|"IV furosemide dosage will be adjusted according to the pre-defined protocol as shown in the experimental group.~Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels."
32711834|NCT04658303||Pimonidazole|Single dose of 0.5 gm/m^2 of pimonidazole (approximately 13 mg/kg)
32711835|NCT04465279|Experimental|Trifocal Diffractive Intraocular Lens (FineVision)|36 eyes having implantation of trifocal diffractive IOL (FineVision)
32913370|NCT04387305|Experimental|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
32913371|NCT04387305|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
32913372|NCT04356963|Experimental|Virtual Reality Sessions|All participants will participate in virtual reality sessions.
32913373|NCT04356963|Active Comparator|Comparator Sessions|All participants will participate in tablet-based sessions to content-less sessions wearing the virtual reality headset
32913374|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
32913375|NCT05585021|Experimental|Wonderlab Kids instant probiotics|Wonderlab Kids instant probiotics (hawthorn flavor) (4 strains, 20 billion CFU/bottle) 2g/bottle
32913376|NCT05585021|Placebo Comparator|Instant probiotic placebo|Instant probiotic placebo (ET) 2g/bottle
32913377|NCT05056077|Experimental|Condition I (text, health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32711836|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
32711837|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
32711838|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
32711839|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
32913378|NCT05056077|Experimental|Condition II (text, health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
32913379|NCT05056077|Experimental|Condition III (text, health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913380|NCT05056077|Experimental|Condition IV (text, health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks.
33073189|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
32711840|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.~Participants receive talazoparib 1 mg by mouth daily."
32711841|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.~Participants receive talazoparib 1 mg by mouth daily."
32913381|NCT05056077|Experimental|Condition IX (health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913382|NCT05056077|Experimental|Condition V (text, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913383|NCT05056077|Experimental|Condition VI (text, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
32913384|NCT05056077|Experimental|Condition VII (text, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913385|NCT05056077|Experimental|Condition VIII (text)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks.
33073190|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
32711842|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
32711843|NCT02295319|No Intervention|Control|Usual discharge procedures
32711844|NCT02231255||Idiopathic Parkinson's disease patients|
32711845|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
32711846|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
32711847|NCT04465981||Patients with lab-confirmed COVID-19|Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
32711848|NCT04465981||Patients who are suspected to have or are confirmed to not have COVID-19|Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
32711849|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
33073191|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
33245376|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
33245377|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
32711850|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
32711851|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
32711852|NCT03147183||candidates for renal transplant|
32711853|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
32711854|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
32711855|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
32711856|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
32711857|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
32711858|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)<1.25 m2, 50mg; bid when 1.25 m2≤BSA<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.~3 weeks/4cycles"
32711859|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.~3 weeks/4cycles"
32711860|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
32711861|NCT03147027||VT ablation group|
32711862|NCT03147027||medication group|
32711863|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
32711864|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
32711865|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
32711866|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
32913386|NCT05056077|Experimental|Condition X (health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
32711867|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711868|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711869|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711870|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711871|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711872|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32711873|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
32711874|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
32711875|NCT02348229|Experimental|ERAS group|ERAS protocols
32711876|NCT02348229|Other|conventional pathway group|using conventional pathway
32711877|NCT02227433|Experimental|brentuximab vedotin (BV)|
32711878|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
32711879|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
32711880|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
32711881|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
32711882|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
32711883|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
32711884|NCT04831619|Experimental|PET scanner in addition to MRI|
32711885|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
32711886|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
32711887|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
32711888|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
32711889|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
32711890|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
32711891|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
32711892|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
32711893|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
32711894|NCT04026295|Experimental|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
32711895|NCT04026295|Active Comparator|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
32711896|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
32711897|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
32711898|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
32711899|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
32711900|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
33245378|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245379|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245380|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
33245381|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245382|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245383|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245384|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245385|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245386|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245387|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245388|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
33245389|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
33245390|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
33245391|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
33245392|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
33245393|NCT00808587||No Treatment|
33245394|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.~Once included in the study:~A series of clinical, analytical and echocardiographic parameters will be collected and measured~Will be performed:~Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)~Analytical to rule out monoclonal protein:~Proteinogram and serum immunoglobulins.~Light chains free in serum -Freelite-~Immunofixation in serum and urine.~The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.~The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).~No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
33245395|NCT00733382|Experimental|1|
33245396|NCT00733382|Active Comparator|2|
33245397|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
33245398|NCT00728442|No Intervention|2|
33245399|NCT00733460|Experimental|BF-PET|
33245400|NCT04065308|Experimental|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
33245401|NCT00728598||1|Proliferative diabetic retinopathy, active.
33245402|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
33245403|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
33245404|NCT00733538|Active Comparator|1|patients receiving zometa treatment
33245405|NCT00733538|No Intervention|2|No treatment, just follow-up
33245406|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
33245407|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
33245408|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
33245409|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
33245410|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
33245411|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
33245412|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
33245413|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
33245414|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
33245415|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
33245416|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
33399695|NCT04806100|Experimental|CDO-A|The first brace tested will be labeled CDO-A, this will be either the stiff or the compliant device.
32913387|NCT05056077|Experimental|Condition XI (health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
33245417|NCT04052412|Experimental|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
32711901|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
32711902|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
32711903|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
32711904|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
32711905|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
32711906|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
32711907|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
32711908|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
32711909|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
32711910|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
32711911|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
32711912|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
32711913|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
32711914|NCT02223767|Experimental|Verum TMS|10 Hz TMS over medial prefrontal cortex
32711915|NCT02223767|Experimental|Sham TMS|10 Hz sham TMS over medial prefrontal cortex
32711916|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
32711917|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
32711918|NCT02355327|Experimental|Laselle Kegel Exerciser|
32711919|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
32711920|NCT02223845|Experimental|Music|Played music during embryo transfer
32711921|NCT02223845|No Intervention|Control|No music played during embryo transfer
32711922|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
32711923|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
32711924|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
32711925|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
32711926|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
32711927|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
32711928|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
32711929|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
32711930|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
32711931|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
33399696|NCT04806100|Experimental|CDO-B|The second brace tested will be labeled CDO-B, this will be either the stiff or the compliant device.
32711932|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
32711933|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
32711934|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
33399697|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
32711935|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
32711936|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
32711937|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
32711938|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
32711939|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
32711940|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
32711941|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
32711942|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
32711943|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
32711944|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
32711945|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
32711946|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
32711947|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
32711948|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
32711949|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
32711950|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
32711951|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
32711952|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
32711953|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
32711954|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
32711955|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
32711956|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
32711957|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
33245418|NCT04052412|Experimental|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
32764610|NCT04970303||Case group|investigator will recruit 60 patients with ADHD (aged between 6 and 16). Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD.
33245419|NCT00733616|Experimental|1|
33245420|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
33245421|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
33245422|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
33399698|NCT04800484|Experimental|Arm 1:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO
32764611|NCT04970303||Control group|investigator will recruit 60 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed.
32764612|NCT03942835|Experimental|Healthy participants aged from 6 to 90 year-old|
32764613|NCT03942835|Experimental|patients with ADHD with no treatment|patients with ADHD aged from 6 to 90 year-old with no treatment
32764614|NCT03942835|Experimental|patients with ADHD with treatment|patients with ADHD aged from 6 to 90 year-old with psychostimulant treatment (Methylphenidate)
32764615|NCT04975529|Experimental|Intervention Arm|Participants in intervention schools received access to daily, online after school programming, including live sessions with sports providers (via Zoom; rotating to provide exposure to multiple sports over the course of the intervention), weekly team meetings with a health coach (via Zoom), text-messages via the Remind app, and monthly delivery of Activity Kits with sports equipment, activity books, fresh produce, and incentives directly to their homes over 6-months.
32764616|NCT04975529|Experimental|Comparison Arm|Participants in comparison schools received access to the Game on Philly app with workout and sports content that could be used asynchronously, and received one activity kit delivery with sports equipment and a self-guided activity book at the start of the program.
32764617|NCT04902547|Experimental|Multidisciplinary Tapering Program Only|Patients in this arm will take part in the clinical multidisciplinary opioid tapering program (MTP).
33245423|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
33245424|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
33245425|NCT03924804|Experimental|Group A: 2 ml/kg group|
33245426|NCT03924804|Experimental|Group B: 8 ml/kg group|
33245427|NCT03924804|Experimental|Group C: 16 ml/kg group|
33245428|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
33245429|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
33245430|NCT00733772|Sham Comparator|B|TLC diet
33245431|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
33245432|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
33245433|NCT00728390|Experimental|1|
33245434|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
33245435|NCT00734552|Other|2|Normal protein diet
33245436|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
33245437|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
33245438|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
33245439|NCT00738608||1|33 pat. with verum
33245440|NCT00738608||2|33 Pat. with placebo
33245441|NCT01081262|Experimental|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
33245442|NCT01081262|Experimental|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
33245443|NCT01081262|Experimental|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
33245444|NCT01081262|Experimental|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
33245445|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
33245446|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
33245447|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
33245448|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
33245449|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
32711958|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
32711959|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
32711960|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
33245450|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
33245451|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
33245452|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
33399699|NCT04800484|Experimental|Arm 2:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO
33399700|NCT04800484|Experimental|Arm 3:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO
32711961|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
32711962|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
32711963|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
32711964|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
32711965|NCT02224079|Experimental|BIIB 722 CL|
32711966|NCT02224079|Placebo Comparator|Placebo|
32711967|NCT03159741|Experimental|Inhibitor + GLP-2|
32711968|NCT03159741|Experimental|Placebo + GLP-2|
32711969|NCT03159741|Active Comparator|Placebo + GIP|
32711970|NCT03159741|Placebo Comparator|Placebo + Saline|
32711971|NCT03516721|Other|Obese adolescents|
32711972|NCT03516721|Other|Lean adolescents|
32711973|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
32711974|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
32711975|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
32711976|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
32711977|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
32711978|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
32711979|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
32711980|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
32711981|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
32711982|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
32711983|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
32711984|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
32711985|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
32711986|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
32711987|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
32711988|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
33245453|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
33245454|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
33245455|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
33245456|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
33245457|NCT04066010|No Intervention|Control|
33245458|NCT04066010|Other|Intervention|Mobile application intervention
33245459|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
33245460|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
33245461|NCT00730626|Placebo Comparator|3|Placebo
33245462|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
33245463|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
33245464|NCT00728780|Experimental|A|ABT-143 15/135mg
33245465|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
33245466|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
33245467|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
33245468|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
33245469|NCT00870844|Placebo Comparator|Placebo|
33245470|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
33245471|NCT00734708|Placebo Comparator|P|control
33245472|NCT04066296|Active Comparator|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
33245473|NCT04066296|Active Comparator|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
32711989|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
32711990|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
32711991|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
32711992|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
33245474|NCT00862576||1|Burning Mouth Syndrome Group
32711993|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
32711994|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
32711995|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
32711996|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
32711997|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
33245475|NCT00862576||2|Control Group
33245476|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
33245477|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
33245478|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
33245479|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
33245480|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
33245481|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
33245482|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
33245483|NCT00868270||Children with UTIs|
33245484|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
33245485|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
33245486|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
33245487|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
33245488|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
33245489|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
33245490|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
33245491|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
33245492|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
33245493|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
33245494|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
33245495|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
33245496|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
33245497|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
33245498|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
32764618|NCT04902547|Experimental|Patient Education Workshop & Multidisciplinary Tapering Program|As above, though patients in this group will also take part in an opioid education workshop
32764619|NCT04975685|Experimental|TAU + SMART|Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
32764620|NCT04975685|Sham Comparator|TAU + Sham training|Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
32764621|NCT04975685|No Intervention|TAU (treatment-as-usual)|Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
32764622|NCT04880161|Experimental|Active|Ampion
32764623|NCT04880161|Placebo Comparator|Control|Placebo
32764624|NCT04969679|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Active group will receive E. coli Nissle 1917 (Mutaflor®).
32764625|NCT04969679|Placebo Comparator|Placebo|Placebo group will receive placebo drug.
32764626|NCT04969757|Experimental|Predigraft|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
32764627|NCT04757155|Experimental|iCALM Intervention Group|iCALM is a brief, online psychotherapeutic intervention for patients with advanced and metastatic cancer. It consists of one introductory module and four therapeutic modules composed of written psychoeducational material, videos, and exercises. The intervention is designed to be completed in 9 weeks.
32764628|NCT04757155|No Intervention|Care as usual|Participants in the usual care group (UC) will receive routine care. At Princess Margaret Cancer Centre, routine care includes a referral to Psychiatry, Psychology, or Social Work, based on patients' needs.
32764629|NCT04432259|Experimental|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
32764630|NCT04432259|Placebo Comparator|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
32764631|NCT03933085|Experimental|MCI Group|A within-subject, multiple baseline design, with each subject serving as their own control,4 will be implemented to get the maximum number of participants trained in the use of the MSS during the proposed funding period. This 2-year study will involve four phases: a 4-month translation and cultural adaptation development phase, a 12-month recruitment and treatment implementation phase, a 6-month post data collection only phase, and a 2-month data analysis and result writing phase. Data analyses will be conducted using the Statistical Package for the Social Sciences (SPSS) program.
32764632|NCT04969523|Experimental|es-ketamine|es-ketamine 0.5mg/kg iv
32764633|NCT04969523|Placebo Comparator|saline|iv saline with the same volume of es-ketamine
32764634|NCT03578107|Other|Improvement intervention1|receive the following improvement intervention for 18 months：
32764635|NCT03578107|Other|Improvement intervention2|receive the following improvement intervention for 12 months：
32764636|NCT03578107|Other|Improvement intervention3|receive the following improvement intervention for 6 months：
32764637|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
32764638|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
32764639|NCT03918031|Active Comparator|PFI for Smoking & Distress Tolerance|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.
32764640|NCT03918031|Active Comparator|PFI for Smoking Only|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).
32764641|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
32764642|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
32764643|NCT05090683|Experimental|Mind-body mobile application|Participants are asked to engage with a user-guided mobile application (app) that employs mind-based techniques that include: expressive writing, meditation, cognitive behavioural therapy, and pain education. The app also includes access to podcasts that focus on pain counselling and pain education.
32764644|NCT05090683|No Intervention|Control|Participants are asked to continue with usual care for pain treatments. They are asked not to start any new forms of treatment.
33245499|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
33245500|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
33245501|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
33245502|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
33245503|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
32764645|NCT04964219|Experimental|S-ketamine group|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
32764646|NCT04964219|Placebo Comparator|Control group|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
32764647|NCT04529395|Experimental|Aromatherapy group|
32764648|NCT04529395|Active Comparator|Control group|
32764649|NCT04975451|Experimental|ADCb|Anlotinib (anlotinib 12mg qd p.o. d1-14/21day/cycle)and Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
32764650|NCT04437043|Other|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
32764651|NCT04437043|Other|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
32764652|NCT04437043|Other|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
32764653|NCT04432337|Experimental|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
32764654|NCT04432337|Active Comparator|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
32764655|NCT04975373|Other|study group|study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
32764656|NCT04975373|No Intervention|control group|women will not receive hyaluronic acid after operative hysteroscopy
32764657|NCT04974983||A|Treatment without bevacizumab
32764658|NCT04974983||B|Treatment with bevacizumab
32764661|NCT04968977||UPLM-ISR|
32764662|NCT04968665||healthy volunteers|gait testing and MRI at baseline for healthy volunteers
32764663|NCT04968665||ACL-deficient patients|gait testing and MRI at pre-operation, 6 months post-operation, 1 year post-operation, 2 years post-operation
32764664|NCT04963829|Active Comparator|Study Group (SG)|Participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.
32764665|NCT04963829|Active Comparator|Control Group 1 (CG1)|Participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment),
32764666|NCT04963829|Active Comparator|Control Group 2 (CG2)|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum)
32764667|NCT04963985|Experimental|Tafamidis group|During the treatment period, each participant will receive 20 mg tafamidis meglumine once daily for 24 weeks.
32764668|NCT04974905|Other|patients with infrainguinal arterial occlusive disease after failed antegrade approach|
32764669|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
32764670|NCT04974827|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
32764671|NCT04963595|Experimental|Pyrotinib and Vinorelbine with Inetetamab|
32764672|NCT04963595|Experimental|Pyrotinib and Vinorelbine without Inetetamab|
32764673|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
33399701|NCT04800484|Experimental|Arm 4:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO
32711998|NCT02231879|Active Comparator|Year 1 crossover|G-CSF or plerixafor, blinded
32764674|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
32764675|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
32764676|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
32711999|NCT02231879|Active Comparator|Year 2 crossover|G-CSF or plerixafor, blinded
32712000|NCT03152331|Experimental|Receptive Awareness Training|
32712001|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
32712002|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
32712003|NCT02228291|Placebo Comparator|Placebo|Cellulose
32712004|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
32712005|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
32712006|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
32712007|NCT04530383|Experimental|Metformin dose regimen A|Participants with CFRD on elexacaftor/tezacaftor/ivacaftor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures through week 14. They will then undergo a two week washout period. For the second half of the study metformin will be resumed and, if tolerated, dose will be increased by 500mg on weeks 17 and 18 to a final dose of 1000 mg twice daily through end of study (week 30).
32764677|NCT04963907|Active Comparator|Active CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
32764678|NCT04963907|Sham Comparator|Sham CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
32764679|NCT04963127||Prospective Cohort|400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.
32764680|NCT04963127||Retrospective Cohort|400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.
32764681|NCT04963361||fear of movement group|The score of fear of movement scale was more than 37
32764682|NCT04963361||non-fear of movement group|The score of fear of movement scale was no more than 37
32764683|NCT04968431||Mitral Stenosis patient|
32764684|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
32764685|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
32764686|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
32764687|NCT04968509|Experimental|treatment with PCSK9 inhibitor and statin|Patients in experimental group were treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab subcutaneously every two weeks ) and conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
32764688|NCT04968509|Other|statin-only treatment|Patients in control group were only treated with conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
32764689|NCT04955015||patients|patients with caotid atherosclerosis refering to carotid endarterectomy
32764690|NCT04963049|Experimental|With Mask|
32764691|NCT04968041|Experimental|MI-CBT KNA Program|6-week group intervention using MI and CBT strategies to promote adherence to a ketogenic nutrition program.
32764692|NCT04954235||Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia who received treatment with 2 infusions of 4 mg / Kg each of hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) separated by 48 hours
32764693|NCT04954235||Not Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia not exposed to hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) during hospitalization corresponding to the period prior to the approval of the hyperimmune anti-SARS-CoV-2 serum for its use.
32764694|NCT03060941|Experimental|Group 1|Physical activity education
32764695|NCT03060941|Experimental|Group 2|Physical activity education and facility access
32764696|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
32764697|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
32764698|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
32764699|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
32764700|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
33245504|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
32712008|NCT04530383|Experimental|Metformin dose regimen B|Participants with CFRD on elexacaftor/tezacaftor/ivafactor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures. If tolerated, dose will be increased by 500mg on weeks 1 and 2 to a final dose of 1000 mg twice daily through week 14.They will then undergo a two week washout period. For the second half of the study metformin will be resumed at a dose of 500 mg twice daily through the end of study (week 30).
32712009|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
32712010|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
32712011|NCT04464967|Experimental|Phase 1, Cohort 1|SNK01 (low dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
32712012|NCT04464967|Experimental|Phase 1, Cohort 2|SNK01 (high dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
32712013|NCT04464967|Experimental|Phase 1, Cohort 3|SNK01 (low dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
32712014|NCT04464967|Experimental|Phase 1, Cohort 4|SNK01 (high dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
32712015|NCT04464967|Experimental|Phase 2, Expansion Cohort 1|SNK01 (TBD RP2D) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
32712016|NCT04464967|Experimental|Phase 2, Expansion Cohort 2|SNK01 (TBD RP2D) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
32712017|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
32712018|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
32712019|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33399702|NCT04800484|Experimental|Arm 5:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO
33399703|NCT04800484|Experimental|Arm 6:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO
32712020|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg
32712021|NCT02289235|Placebo Comparator|Placebo|Placebo powder capsule
32712022|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
32712023|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
32712024|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
32712025|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
32712026|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
32712027|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
32712028|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
32712029|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
32712030|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
32712031|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
32712032|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
32712033|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
32712034|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
33399704|NCT04800484|Experimental|Arm 7:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO
32712035|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
32712036|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
32712037|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
32712038|NCT03519763||Control group|Fifteen patients without isthmocele
32712039|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
32712040|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
32712041|NCT04478253|Experimental|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
32712042|NCT04478253|No Intervention|Usual care|Insertion of the drain according to the usual management protocol
32712043|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
32712044|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
32712045|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
32712046|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
32712047|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
32712048|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
32712049|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
32712050|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
32712051|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
32712052|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
32712053|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
32712054|NCT04777175||KRAS mutation|patients carry with KRAS mutation
32712055|NCT04777175||ALK fusion|patients carry with ALK fusion
32712056|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
32712057|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
32712058|NCT04777175||RET fusion|patients carry with RET fusion
32712059|NCT04777175||BRAF mutation|patients carry with BRAF mutation
32712060|NCT04478643|Placebo Comparator|PLACEBO|"Collection of microbiological samples from the two deepest sites in two different quadrants.~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
32712061|NCT04478643|Experimental|PROBIOTIC (L. Reuteri)|"Collection of microbiological samples from the two deepest sites in two different quadrants.~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
32712062|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
32712063|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
32712064|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
32712065|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
32712066|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
32712067|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
32764701|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
32764702|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
32913388|NCT05056077|Experimental|Condition XII (health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks.
32913389|NCT05056077|Experimental|Condition XIII (health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913390|NCT05056077|Experimental|Condition XIV (health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
32913391|NCT05056077|Experimental|Condition XV (support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
32913392|NCT05056077|Experimental|Condition XVI (study booklet)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer.
32913393|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
32913394|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
32913395|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
32913396|NCT04897542|Experimental|Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT|"Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.~All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan."
32712068|NCT02289391|Placebo Comparator|Control group|"With a history of asthma~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
32712069|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
32712070|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
32712071|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
32712072|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
32712073|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
32712074|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
32712075|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
32913397|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
32913398|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
32913399|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
32913400|NCT05053581||Patient|
32913401|NCT02572323|Active Comparator|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
32913402|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
32913403|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
32913404|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
33399705|NCT04800484|Experimental|Arm 8:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO
33399706|NCT04800484|Experimental|Arm 9:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO
32913405|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
32913406|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
32913407|NCT04279587|Experimental|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
32913408|NCT02420262|Experimental|IDegLira|
32913409|NCT02420262|Active Comparator|IGlar plus IAsp|
32913410|NCT02520141|Experimental|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32913411|NCT04276701|Experimental|Systemic lupus erythematosus (SLE)|
32913412|NCT05037747|Experimental|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
32913413|NCT05037747|No Intervention|Control|The control group was asked to continue their usual low-protein diet eating schedule and pattern.
32712076|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
32712077|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
32712078|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
32712079|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
32913414|NCT04267887|Experimental|Treatment (apalutamide, abiraterone acetate, prednisone, ADT)|Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care.
32712080|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
32712081|NCT04478331|No Intervention|CONTROL|The Control group will receive the usual care. In the physical activity (PA) field, this includes two individual motivational interviews with a PA professional, and a group workshop during the first year after BS. PA recommendations will be explained to each participant, and their achievement will be encouraged and supported during these sessions. No face-to-face PA sessions will be offered as part of the usual care.
32712082|NCT04478331|Experimental|ACTI-VISIO|The two PA sessions per week will be delivered via videoconferencing (developed by Mooven™). The PA program consists in tailored adapted PA sessions led by a professional specialized in adapted PA. These sessions were specifically designed to be appropriate for the population and were developed in collaboration with the authors to ensure standardization of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, the professional and the participants will interact simultaneously, and the execution of the exercises will be monitored and adapted live by the professional. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the RPE exceed 7, the professional specialized in adapted PA will adjust the training load. In addition to the exercises, the sessions will also include advice and tips for reaching the recommended PA level.
32712083|NCT04478331|Experimental|ACTI-MOBIL|The PA sessions will be delivered by an eHealth platform (developed by BePatient™) associated with an activity bracelet. The researchers enrich PA content on the platform and ensure standardization of the recommended volume of PA. The platform consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet, and a video demonstration of PA sessions performed by a peer. The PA sessions are automatically broadcasted twice a week for 12 weeks. To ensure the safety of the PA, the sessions were designed to be appropriate for this population and the RPE will be measured after each session on a 10-point scale. If the RPE exceeds 7 for 3 consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery, and frequently asked questions.
32913415|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
32913416|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
32913417|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
32913418|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
32913419|NCT04264455||ICD Implantation|Patients receive an ICD only
32913420|NCT04237077|Experimental|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
32913421|NCT04237077|Active Comparator|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
32913422|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
32913423|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
32913424|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
32913425|NCT04174755|Experimental|Semaglutide 0.25/0.5/1 mg plus standard of care|
32913426|NCT04174755|Other|Standard of care alone|
32913427|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
33399707|NCT04800484|Experimental|Arm 10:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO
32764703|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
32764704|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
32764705|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
32764706|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
32764707|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
32764708|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
32764709|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
32764710|NCT04967729|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
32764711|NCT04962425||The case group|Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
32764712|NCT04962425||The control group|Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
32764713|NCT04962269||prostate cancer|The patient was pathologically diagnosed with prostate cancer
32764714|NCT04962269||benign prostatic hyperplasia|The patient was pathologically diagnosed with benign prostatic hyperplasia
32764715|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
32764716|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
32764717|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
32764718|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
32764719|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
32764720|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
32764721|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
32764722|NCT04953533||patients with gout|"age:year of 25~60;~consistent with the 2015 ACR gout diagnostic criteria ,and serum uric acid >420umol/L;~The patient are willing to take part in our study."
32764723|NCT04953533||patients with hyperuricemia|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid >420umol/L without gout flares."
32764724|NCT04953533||healthy controls|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid ≤420umol/L."
32764725|NCT04967417|Experimental|Non-squamous cell carcinoma|"4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks~Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles"
32764726|NCT04967417|Experimental|Squamous cell carcinoma|"4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks~Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"
32764727|NCT04953611||Group A in GOLD|CAT<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year<2；
32764728|NCT04953611||Group B in GOLD|CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year<2
32764729|NCT04953611||Group C in GOLD|CAT<10、mMRC 0-1、 FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
32764730|NCT04953611||Group D in GOLD|CAT≥10、mMRC≥2、FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
32764731|NCT04953611||Control Group|not COPD
32764732|NCT04966949|Experimental|lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
32764733|NCT04966949|Active Comparator|nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
32764734|NCT04432103|Experimental|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
32764735|NCT04432103|Experimental|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
33399708|NCT04800484|Experimental|Arm 11:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO
33399709|NCT04800484|Experimental|Arm 12:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO
32764736|NCT02658175|Experimental|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 [NCT02211209] and ISIS 304801-CS16 [NCT02300233]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
32712084|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
32712085|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
33399710|NCT04800484|Experimental|Arm 13:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO
33399711|NCT04800484|Experimental|Arm 14:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO
32712086|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
32712087|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
32712088|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
32712089|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
32712090|NCT04486313|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
32712091|NCT04486313|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
32712092|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
32712093|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
32712094|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
32712095|NCT03516253|No Intervention|Control group|Dietary Supplement: Mineral oil (5 gel capsules, each 1g mineral oil), 3 months with lunch.
32712096|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
32712097|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
32712098|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
32712099|NCT02289547|No Intervention|Group A|observational arm
32712100|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
32712101|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
32712102|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
32712103|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
32712104|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
32712105|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of CCH (4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
32712106|NCT04466345|Experimental|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
32712107|NCT04466345|Placebo Comparator|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
32712108|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
32712109|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
32712110|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
32712111|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
32712112|NCT04461275|Experimental|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
32712113|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
32712114|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
32764737|NCT02658175|Experimental|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
32764738|NCT02658175|Experimental|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
32764739|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
32764740|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
32764741|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
32764742|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
32764743|NCT04966715|Experimental|Patients planned for complete cytoreductive surgery|Only one arm in the study. All patients operated for complete cytoreductive surgery and who signed informed consent form
32764744|NCT02774785|Experimental|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
32764745|NCT02774785|No Intervention|Control Arm|Randomized for surgical procedure to happen as per standard care
32764746|NCT04953455||pre-operation|Within one month before operation of diagnoses with a ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
32764747|NCT04953455||early after operation|Within three months after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
32764748|NCT04953455||lately after operation|within three months to one year after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement
32764749|NCT04953455||healthy volunteers|Healthy people without abnormalities
32764750|NCT03234361|Experimental|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
32764751|NCT03234361|Placebo Comparator|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
32764752|NCT04953299|Experimental|Functional Imagery training|The FIT sessions will occur weekly for four weeks and last an hour per session. The sessions will be conducted over Zoom. Sessions will be facilitated by the PI who is trained in FIT, and attended by 4 participants.
32764753|NCT04953299|Active Comparator|Control|The control condition will ask participants to complete the 12 week NHS weight loss plan.
32764754|NCT04210141|Active Comparator|Standard of care|Patients will receive an initial antivenom dose of 80mL lyophilized BPI viper antivenom, as per current national guidelines
32764755|NCT04210141|Experimental|Adaptive arm|Patients will receive an initial dose of lyophilized BPI viper antivenom determined by the adaptive model.
32764756|NCT04966793||Bronchiectasis patients group|Bronchiectasis patients group: Sputum specimens from bronchiectasis patients aged 18 to 79 years old .
32764757|NCT04966793||Healthy control group|Healthy control group: Sputum specimens from healthy people.
32764758|NCT04962191||Lung Cancer|The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
32764759|NCT04186117|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected at before any treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
32764760|NCT04953221||M1 Test group|YJ001 for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32764761|NCT04953221||M1 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32764762|NCT04953221||M2 Test group:|YJ001 for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32764763|NCT04953221||M2 control group:|YJ001 simulant for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32764764|NCT04953221||M3 Test group|YJ001 for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32913428|NCT04738305|Other|Dignity Therapy Intervention|All the patients that accepted to participate in the study were provided with Dignity Therapy Intervention. A short-term intervention aimed at reducing existential distress of patients facing with advanced illness.
33399712|NCT04800484|Experimental|Arm 15:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO
32913429|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~1st point at patient's inclusion visit~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
32913430|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
32913431|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
32913432|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
32913433|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
32913434|NCT04843319|Experimental|VERU-100 at various doses|2 ml, 2.5 ml, 3 ml, 3.5 ml of VERU-100
32913435|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
32913436|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
32712115|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
32712116|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
32913437|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
32913438|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
32913439|NCT04168671|Other|Asthma|Asthma and symptomatic during exercise
32913440|NCT04168671|Other|Severe asthma|Severe asthma and symptomatic during exercise
32913441|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
32913442|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
32913443|NCT04168203|Experimental|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
32712117|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
32712118|NCT02228993||Awake Craniotomy|
32712119|NCT02228993||General Anesthesia Craniotomy|
32712120|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7~with~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
32712121|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
32913444|NCT04168203|Placebo Comparator|Control|oral placebo for a duration of 12 months
32913445|NCT04152993|Experimental|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
32913446|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
32913447|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
32913448|NCT05020821|Active Comparator|Single-shot interscalene block with intravenous dexmedetomidine|participants receiving single-shot interscalene block with intravenous dexmedetomidine
33399713|NCT04800484|Experimental|Arm 16:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO
32913449|NCT05020821|Experimental|Continuous interscalene brachial plexus block|participants receiving continuous interscalene brachial plexus block
32913450|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
32913451|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
33399714|NCT04800484|Experimental|Arm 17:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO
32712122|NCT04437563|No Intervention|Control|('Standard' care). No intervention offered.
32913452|NCT04135989|Other|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
32913453|NCT04135989|Other|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
33245505|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
33245506|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
33245507|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
33245508|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
33245509|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
33245510|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
33245511|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
32712123|NCT04437563|Experimental|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
32712124|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
33245512|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
33245513|NCT00868894|Experimental|1|
32712125|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
32712126|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
32712127|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
32712128|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
32712129|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
32712130|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
32712131|NCT02353845||normal control|
32712132|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
32712133|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
32712134|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
32712135|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
32712136|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
32712137|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
32712138|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
33245514|NCT00868894|Experimental|2|
33245515|NCT00868894|Placebo Comparator|3|
33245516|NCT00868894|Active Comparator|4|
33245517|NCT00730938|Active Comparator|1|
33245518|NCT00730938|Placebo Comparator|2|Saline placebo
33245519|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
33245520|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
33245521|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
33245522|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
33245523|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
33245524|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
33245525|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
33245526|NCT00731016|Other|1|Zoledronic acid, pravastatin
33245527|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
32712139|NCT03516097|Experimental|Experimental Group B|mobile app usage
32712140|NCT03516097|Active Comparator|Control Group|Structured school based intervention
33245528|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
32712141|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
32712142|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
32712143|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
32712144|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
32712145|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
32712146|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
32712147|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
32712148|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
32712149|NCT03146637|Experimental|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
32712150|NCT03146637|Active Comparator|Traditional CIK treatment group|CIK cells were not activated
32712151|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
32712152|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
32712153|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
32712154|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
32712155|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
32712156|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
32712157|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
32712158|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
32712159|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
32712160|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
32712161|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
32712162|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
32712163|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
32712164|NCT03542669|Experimental|6B11-OCIK injection|
32712165|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
32712166|NCT03146481|Placebo Comparator|placebo|Placebo
32712167|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
32712168|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
32712169|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
32712170|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
32712171|NCT02353767||Controls|"age ± 7 years from cases~duration of HIV-1 infection ± 3 years from cases~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
32712172|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
32712173|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
32712174|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
32712175|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
32712176|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
32712177|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
32712178|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
32712179|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
32712180|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
32764765|NCT04953221||M3 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
32712181|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
32712182|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
32764766|NCT04006951|Experimental|Biological collection|"For all the patients include in the study :~Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy~Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
32712183|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
32712184|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
32712185|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
32712186|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
32712187|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
32712188|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
32712189|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
32712190|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
32712191|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
32712192|NCT04581473|Experimental|CT041 autologous CAR T-cell injection|Two stages: Phase 1b: dose escalation and dose expansion; Phase 2: verify CT041 efficacy and safety
32712193|NCT04581473|Active Comparator|Physician's Choice|Participants will receive physician's choice of treatment in Phase II
32712194|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
32712195|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
32712196|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
32712197|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
32712198|NCT04345211|Active Comparator|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
32712199|NCT04345211|Active Comparator|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
32712200|NCT04345211|Active Comparator|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
32712201|NCT04345211|No Intervention|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
32712202|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
32712203|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
32712204|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
32712205|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
32712206|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
32712207|NCT02296489||Healthy volunteers|
32712208|NCT02296489||Asthma patients|
32712209|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
32712210|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
32712211|NCT02258867|Placebo Comparator|Placebo|
32712212|NCT02258867|Experimental|Gevokizumab|
32712213|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
32764767|NCT05106439|Experimental|Competition arm|"Programs with at least five interns were grouped into program-based teams. Interns within the same residency institution in programs that did not meet this criterion were grouped into institution-based teams, with a minimum of five participants per team.~For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance. For those randomized to competition arm, teams were assigned an opponent team according to a weekly equally randomly selected rule from three options: 1. total randomization, by which the opponent team was assigned regardless of institution and specialty; 2. within-institution randomization, by which two competing teams were from the same institution; 3. within-specialty randomization, by which two paired teams were from the same specialty. For each pair of competing teams, there was a 50/50 chance that they would compete on average daily step counts or average daily sleep minutes."
33245529|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
33245530|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
33245531|NCT00738842|Experimental|1|
32712214|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
32712215|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
33245532|NCT00738842|Placebo Comparator|2|
33245533|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
33245534|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
33245535|NCT00729222|Placebo Comparator|1|Placebo
33245536|NCT00729222|Experimental|2|rolofylline
33245537|NCT03896386|Other|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
33245538|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
33245539|NCT00729300|Placebo Comparator|1|Placebo
33245540|NCT00729300|Experimental|2|disulfiram
33245541|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
32764768|NCT05106439|Experimental|Non-competition group|For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance.
33245542|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
33245543|NCT00869596|Placebo Comparator|1|Placebo
33245544|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
33245545|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
33245546|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
33245547|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
33245548|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
33245549|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
33245550|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
33245551|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
33245552|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
33245553|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
32712216|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
32712217|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
33245554|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
33245555|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
33245556|NCT00653523|Experimental|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
33245557|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
33245558|NCT00739076|Experimental|1|Virtual Reality Hypnosis
33245559|NCT00739076|Experimental|2|Virtual Reality Distraction
33245560|NCT00739076|Experimental|3|Standard treatment.
33245561|NCT00869830|Experimental|biofeedback|
32712218|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
32712219|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
32712220|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
32712221|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
32712222|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
32712223|NCT02351193||Group I|poor responder females with age less than 35
32712224|NCT02351193||Group II|poor responder females with age more than 35
32712225|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
32712226|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
32712227|NCT02353533|Other|EMR|Standard EMR technique
32712228|NCT02353533|Experimental|FTRD|
32712229|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
32712230|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
32712231|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
32712232|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
32712233|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
32712234|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
32712235|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
32712236|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
32712237|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
32712238|NCT04330391|No Intervention|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
32712239|NCT04330391|Experimental|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
32712240|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
32712241|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
32712242|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
32712243|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
32712244|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
32712245|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
32712246|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
32712247|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
32764769|NCT04418531|Experimental|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
32764770|NCT05037019|Experimental|Single fraction radiotherapy|Single fraction of 21 Gy stereotactic radiation therapy delivered to a single malignant lesion of the breast prior to any other treatment for breast cancer.
32764771|NCT03773575|Experimental|Prevena|PREVENA™ PEEL & PLACE™ Dressing Kit
32764772|NCT03773575|No Intervention|Standard Care|sterile gauze dressing supplemented with an Ace wrap
32764773|NCT02615119|Experimental|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
33245562|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
32712248|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
33245563|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
32712249|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
32712250|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
32712251|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
33245564|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
33245565|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
33245566|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
33245567|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
32913454|NCT04135989|Other|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
33245568|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
33245569|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
33245570|NCT02717442|Placebo Comparator|Placebo|
33245571|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
33245572|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
33245573|NCT00734942|Experimental|1|intervention group
33245574|NCT00734942|No Intervention|2|waiting group
33245575|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
32913455|NCT04135989|Other|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
32913456|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
33245576|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
33245577|NCT00808977|Experimental|Dersalazine|
32913457|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
33245578|NCT00808977|Active Comparator|Mesalazine|
33245579|NCT00808977|Placebo Comparator|Placebo|
32913458|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
33245580|NCT04065854|No Intervention|Control|The control group will receive standard brief falls assessment and advice.
33245581|NCT04065854|Active Comparator|Intervention|Therapy intervention.
33245582|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
33245583|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
33399715|NCT04800484|Experimental|Arm 18:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO
32712252|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
32712253|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
32712254|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
32712255|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
32712256|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
32712257|NCT02229773|Experimental|BIBB 1464 MS low dose|
32712258|NCT02229773|Placebo Comparator|Placebo|
32712259|NCT02229773|Active Comparator|Pravastatin|
32712260|NCT02229773|Experimental|BIBB 1464 MS medium dose|
32712261|NCT02229773|Experimental|BIBB 1464 MS high dose|
32712262|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
32712263|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
32712264|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
32712265|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
32712266|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
32712267|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
32712268|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
32712269|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
32712270|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
32712271|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
32712272|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
32712273|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
32712274|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
32712275|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
32712276|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
32712277|NCT04305275|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 60 mg dose (tablets) orally in the morning for 28 days.
32712278|NCT04305275|Placebo Comparator|SAGE-324 Matched Placebo|Participants will receive SAGE-324 matched placebo, oral tablets for 28 days.
32913459|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
32913460|NCT01815983|Experimental|Videolaryngoscopy review.|Video review.
32913461|NCT04987749|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 600) over the right inferior frontal gyrus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
32913462|NCT04987749|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the right inferior frontal gyrus for 8 weeks (2 days/week).
32913463|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
32913464|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
32913465|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
32913466|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
32913467|NCT04690439|Experimental|Group A|Group A will receive first PBM + manual lymphatic drainage for 9 weeks (2 sessions/week), followed by 9 weeks only manual lymphatic drainage.
32913468|NCT04690439|Active Comparator|Group B|Group B will first receive only manual lymphatic drainage for 9 weeks, followed by the combination of PBM and manual lymphatic drainage for 9 weeks (2x/week).
32913469|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
32913470|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
32712279|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
32913471|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
32913472|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
32913473|NCT04945629|Active Comparator|Simple suture|Atraumatic exodontia followed by simple suture
32712280|NCT05231031|Active Comparator|Aerobic exercise|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks
32712281|NCT05231031|Experimental|Aerobic, Breathing exercises , and relaxation training|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks in addition to breathing exercises and relaxation training for the same period
32712282|NCT03337451|Experimental|OPN-305|
32712283|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
32712284|NCT04214639|Experimental|IDP-126 Gel|
32712285|NCT04214639|Placebo Comparator|IDP-126 Vehicle Gel|
32712286|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)~Subgroup A3: Consist of bilateral ceramic on metal THAs"
32712287|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
32712288|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
33399716|NCT04800484|Experimental|Arm 19:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO
33399717|NCT04800484|Experimental|Arm 20:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO
32712289|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
32712290|NCT02296957|No Intervention|Control|Usual Care
32712291|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
32712292|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
32913474|NCT04945629|Experimental|PRGF-Endoret|Atraumatic exodontia followed by simple suture
32913475|NCT04938765|Experimental|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
32913476|NCT04938765|Placebo Comparator|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
32913477|NCT04932369|Experimental|ER GROUP|The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologist. The training includes group gathering, homework and telephone consultation as needed.
32913478|NCT04932369|No Intervention|Control group|They completed two assessments, 3-months apart
33399718|NCT04800484|Experimental|Arm 21:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO
32712293|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
32913479|NCT03996057|Experimental|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
32913480|NCT03996057|Active Comparator|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
32913481|NCT04338243|Experimental|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
32712294|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
32712295|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
32712296|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
32712297|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
32712298|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
32712299|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
32712300|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
32712301|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
32712302|NCT01639937||1|Subjects with palliated congenital heart disease including, but not limited to, d TGA, ccTGA, single ventricles, hypoplastic left heart syndrome and tricuspid atresia will be recruited
32712303|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
32712304|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
32712305|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
32913482|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
32913483|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
32913484|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
32913485|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
32913486|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
32913487|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF < 40%.~LVEF = Left ventricular ejection fraction"
33245584|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
33399719|NCT04800484|Experimental|Arm 22:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO
33399720|NCT04800484|Experimental|Arm 23:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO
32712306|NCT04208087|Experimental|SI-722|
32712307|NCT04208087|Placebo Comparator|Placebo|
32712308|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
32712309|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
32712310|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
32712311|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
32712312|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
32712313|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
32712314|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
32712315|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
32913488|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.~LVEF = Left ventricular ejection fraction"
32913489|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF > 50%.~LVEF = Left ventricular ejection fraction"
32712316|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
32913490|NCT04910919|Active Comparator|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
32712317|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
32712318|NCT04189133|Experimental|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
32712319|NCT04189133|Active Comparator|Control group|"The control group will receive the administration im of Gonasi HP as follows:~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
32913491|NCT04910919|Experimental|Honey Intervention|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
32913492|NCT04905225||Ascending aortic replacement|Ascending aortic replacement in ascending aortic aneurysm in men and women
32913493|NCT03961347|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
33399721|NCT04800484|Experimental|Arm 24:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO
32712320|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
32712321|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
32712322|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
32712323|NCT02346123||Single group|Group which contains all the patients of the study.
32712324|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
32712325|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
32712326|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
32712327|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
32712328|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
32712329|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
32712330|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
32712331|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
32712332|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
32712333|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
32712334|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
32712335|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
32712336|NCT04088357|Active Comparator|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
32712337|NCT04088357|Placebo Comparator|Topical Vehicle Gel|Vehicle Gel
32712338|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
32712339|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
32712340|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
32712341|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
32712342|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
32712343|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
32712344|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
32712345|NCT03518593|No Intervention|Control|Existing cash transfer only
32712346|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
32712347|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
32712348|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
32712349|NCT03192995|Active Comparator|Experimental|lorcaserin, extended release
32712350|NCT03192995|Placebo Comparator|Control|Placebo
32712351|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
32712352|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
32712353|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
32712354|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
32712355|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
32712356|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
32712357|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
32712358|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
32712359|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
32712360|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
32712361|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
32712362|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
32712363|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
32712364|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
32712365|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
32712366|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
32712367|NCT03149601||Obese|Participants with BMI > or = 95th percentile
32712368|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
32712369|NCT04464811||Heart failure with diuretic resistance|This group includes acute heart failure patients who has diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have received oral furosemide before. Diuretic resistance was defined as urine output <250 hr at 2 hours after furosemide administration.
32712370|NCT04464811||Heart failure without diuretic resistance|This group includes acute heart failure patients who do not have diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide before. Patients will be defined not to have diuretic resistance if their urine output ≥250 hr at 2 hours after furosemide administration.
32712371|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
32712372|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
32712373|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
32712374|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
32712375|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
32712376|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
32764774|NCT02615119|Experimental|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
32764775|NCT02615119|Experimental|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
33245585|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
32712377|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
32712378|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
32712379|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
32712380|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
32712381|NCT02345421||At risk population|
32712382|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
32712383|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
32712384|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
32712385|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
32712386|NCT03137381|Experimental|Cohort 1: CTP-543 4 mg BID|Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
32712387|NCT03137381|Experimental|Cohort 2: CTP-543 8 mg BID|Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
32712388|NCT03137381|Experimental|Cohort 3: CTP-543 12 mg BID|Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
32712389|NCT03137381|Placebo Comparator|Combined Placebo|Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.
32712390|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
32712391|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
32712392|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
32712393|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
32712394|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
32712395|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
32712396|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
32712397|NCT04047563|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
32712398|NCT04047563|Experimental|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
32712399|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
32712400|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
32712401|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
32712402|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
32712403|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
32712404|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
32712405|NCT01541345|Active Comparator|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
32712406|NCT01541345|Experimental|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
32712407|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
32712408|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
32712409|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
32712410|NCT03949673|Other|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
32712411|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
32712412|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
32712413|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
32712414|NCT03515473||CI532|Patients with CI532 cochlear implant
32712415|NCT03515473||CI522|Patients with CI522 cochlear implant
32712416|NCT03515473||CI512|Patients with CI512 cochlear implant
32712417|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
32712418|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
32712419|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
32712420|NCT02350491||healthy group|Healthy pregnant woman.
32712421|NCT02298751|Experimental|CET via smartphone|Cue Exposure Treatment
32712422|NCT02298751|Experimental|CET via group sessions|Cue Exposure Treatment
32712423|NCT02298751|No Intervention|Aftercare as usual|
32712424|NCT05634005|Experimental|Ordering Providers Assigned to Visible Clinical Decision Support Alerts|Clinical decision support alert will fire and become visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
32712425|NCT05634005|No Intervention|Ordering Providers Assigned to No Visible Clinical Decision Support Alerts|Clinical decision support alert will not be visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
32712426|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
32712427|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
32712428|NCT05633693|Experimental|Counterpressure Maneuvers|"Counterpressure maneuver (CPM) trials will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect movement.~CPM:~Leg crossing and muscle tensing: Legs are crossed while upright and lower body musculature is isometrically contracted (clinical)~Crouching: Participant crouches down resting weight on the balls of their feet, pressing calves against the back surface of the thighs (clinical)~Exaggerated anterior-posterior sway: Participant sways back and forth with feet planted on ground at a pace/amplitude that is comfortable (discrete)~Gluteal clenching: Participant rhythmically tenses and relaxes the gluteal muscles at a pace/duration that is comfortable (discrete)~Participants serve as their own controls and complete both testing arms."
32712429|NCT05633693|Sham Comparator|Baseline Stand|"Participants will perform a sit-stand test, followed by 5-minutes of baseline (quiet) standing trial on a force platform while cardiorespiratory responses are recorded.~Sit-stand test: following 5-minutes of supine rest, the participant will be passively moved into the seated position. They will then be asked to actively move into the standing position.~Baseline stand: immediately following the sit-stand test, the baseline trial will begin. Participants will stand quietly on the force platform for 5-minutes. This trial will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect their movement.~Participants serve as their own controls and complete both testing arms."
32712430|NCT05196295|Experimental|Hydrogen capsules|Participants will be allocated by doctors and receive either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
32712431|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
32712432|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
32712433|NCT05629715|Active Comparator|ROSA|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the ROSA Knee System.
32712434|NCT05629715|Active Comparator|KneeAlign|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the KneeAlign navigation system.
32712435|NCT05629715|No Intervention|Conventional|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using conventional instrumentation.
32712436|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
32712437|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
33245586|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
32712438|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
32712439|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
32712440|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
32712441|NCT04464889|Experimental|MDG1021|Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
32712442|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
32712443|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
32712444|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
32712445|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center~A GFC is defined as follows:~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)~Local medical guidelines, consented by orthopedic surgeons and geriatrician~Pre-defined order set for assessing laboratory values~Pre-defined patient pathway to guarantee a fast track in the emergency room~Daily communication among involved specialists~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~Daily patient visit by geriatrician~Daily patient visit by orthopedic surgeon in combination with nurse~Daily therapy by physiotherapists, except for weekends~Access to social workers, if required"
32712446|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center~A UCC is defined as follows:~No geriatrician available in trauma/orthopaedic department~No pre-operative visit by a geriatrician as a standard~No pre-defined medical guidelines for geriatric fracture patients~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~No daily patient visits by a geriatrician as a standard"
32712447|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
32712448|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
32712449|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
32712450|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
32712451|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
32712452|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
32712453|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
32712454|NCT05255523|Experimental|Arm 1|Pyrotinib：400mg qd po continuous medication Capecitabine: 1000 mg/m2 bid po for 14 consecutive days with 7 days off, every 21 days as a cycle.
32712455|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
32712456|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
32712457|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
33399722|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
32712458|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
32712459|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
32712460|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
32712461|NCT03926117|Placebo Comparator|Placebo|Matching placebo
32712462|NCT03926117|Experimental|Ziltivekimab 7.5 mg|
32712463|NCT03926117|Experimental|Ziltivekimab 15 mg|
32712464|NCT03926117|Experimental|Ziltivekimab 30 mg|
32712465|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
32712466|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
32712467|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
32712468|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
32712469|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
32712470|NCT05255289|Experimental|Before TOT|Data obtained before the operation
32712471|NCT05255289|Experimental|After TOT|Data obtained after the operation
32712472|NCT03912233|Experimental|Part 1: F/MF genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive multiple dose levels of VX-121 in TC with TEZ/VX-561.
32712473|NCT03912233|Placebo Comparator|Part 1: Placebo|
32712474|NCT03912233|Experimental|Part 2: F/F genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive VX-121 in TC with TEZ/VX-561
32712475|NCT03912233|Active Comparator|Part 2: Placebo + TEZ/IVA|
32712476|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
32712477|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
32712478|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
32712479|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
32712480|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
32712481|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
32712482|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
32712483|NCT05624801|Active Comparator|Weekly|weekly administration of one capsule, corresponding to approximately 3'500 IU cholecalciferol daily.
32712484|NCT05624801|Active Comparator|Monthly|monthly administration of one capsule, corresponding to approximately 800 IU cholecalciferol daily.
32712485|NCT05624801|No Intervention|Control|no treatment
32712486|NCT04478097|Experimental|Reference-Reference-Test|
32712487|NCT04478097|Experimental|Reference-Test-Reference|
32712488|NCT04478097|Experimental|Test-Reference-Reference|
32712489|NCT01161641|Experimental|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
32712490|NCT01161641|Experimental|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
32712491|NCT01161641|Experimental|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
32712492|NCT03518281|Placebo Comparator|Placebo|
32712493|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
32712494|NCT03897257|Experimental|UHE-103A1 cream|Topical cream applied twice daily for 2 weeks.
32712495|NCT03897257|Experimental|UHE-103A2 cream|Topical cream applied twice daily for 2 weeks.
32712496|NCT03897257|Experimental|UHE-103B cream|Topical cream applied twice daily for 2 weeks.
32712497|NCT03897257|Experimental|UHE-103A1B cream|Topical cream applied twice daily for 2 weeks.
32712498|NCT03897257|Experimental|UHE-103A2B cream|Topical cream applied twice daily for 2 weeks.
32712499|NCT05255211|Experimental|Remimazolam|IV Remimazolam tosilate 0.3mg/kg
32712500|NCT05255211|Active Comparator|propofol|IV propofol 1.2~2.5mg/kg
32712501|NCT05255211|Placebo Comparator|saline|IV saline solution 10ml
32712502|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
32712503|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
32712504|NCT03149367|Experimental|Fixed suture|
32712505|NCT03149367|Experimental|Adjustable suture|
32712506|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
32712507|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
32764776|NCT02615119|Experimental|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
32764777|NCT02615119|Experimental|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
32764778|NCT02615119|Active Comparator|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
32764779|NCT02598349|Experimental|Proton Radiation with capecitabine|The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.
32764780|NCT05089201|Experimental|Animal-assisted interaction (AAI)|Dogs and handlers will visit with patients for 20 minutes and discuss semi-scripted topics.
32764781|NCT05089201|Active Comparator|Conversational interaction|Handlers will have a 20 minute semi-scripted conversation with patients.
32764782|NCT05089201|No Intervention|Treatment as usual|Patients will receive treatment as usual.
32764783|NCT02555293|Experimental|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
32764784|NCT02555293|No Intervention|standard therapy|Patients directed to the control group will not receive Rifaximin.
32764785|NCT05104255||Twin neonates|The demographic data and characteristics of the twins were evaluated.
32764786|NCT05087251|Experimental|Intervention: Five Psycho-educational Sessions|Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, ~50 minutes each) with a trained interventionist focused on psychoeducational topics. This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach. Sessions will be based on an intervention manual.
32764787|NCT05087251|Experimental|Enhanced Usual Care: One Psycho-educational Session|At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (~50 minutes) with a study clinician. This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work.
32764788|NCT05084911|Experimental|Test|Pyramax tablet
32764789|NCT05084911|Placebo Comparator|Control|Placebo tablet
32764790|NCT03293017|Experimental|Baclofen 30 mg/day|baclofen 30 mg/day
32764791|NCT03293017|Experimental|Baclofen 60 mg/day|
32764792|NCT03293017|Placebo Comparator|Placebo|
32764793|NCT04436809|Other|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
32764794|NCT04436809|Other|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
32764795|NCT04658251||Patients with an intronic variant unknown in a gene implicated in cone disorders.|
32764796|NCT03198559|Experimental|Experimental|"Participants current ART regimen:~2 grams disulfiram by mouth per day for a total of 28 days~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
32764797|NCT04859491|Active Comparator|Carbohydrate|Carbohydrate in the amount of 1.2 g/kg of body weight (bw). Gatorade®, Chicago, IL, USA.
32764798|NCT04859491|Active Comparator|Carbohydrate-Protein|Carbohydrate in the amount of 0.8 g/kg bw (Gatorade®, Chicago, IL, USA) plus protein in the amount of 0.4 g/kg bw (biPro Elite, Agropur Inc., Appleton, WI, USA).
32764799|NCT04859491|Placebo Comparator|Placebo|Flavored water (G Zero, Gatorade®, Chicago, IL, USA).
32764800|NCT05106049||cases|non-alcoholic fatty liver patients
32764801|NCT05106049||control|healthy persons
32764802|NCT05081791|Experimental|Exercise Training|This group will engage in a 12-week exercise training program
32764803|NCT05081791|No Intervention|Control group|Usual care. Patients in this group will be offered the same program at the end of the study
32764804|NCT04523545|Experimental|Treatment|
32764805|NCT05105893|Other|Dates group|The experimental group of women was given several dates orally and instructed to take seven a day and record their consumption until the beginning of the active phase of labor. Seven pieces of dates are about 80g of daily consumption
32764806|NCT05105893|Other|No dates|This group wasnt provided dates.
32764807|NCT05105815|Experimental|IPM001|A neoantigen/tumor-specific antigen sensitized autoimmune cell injection
32764808|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
32764809|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
32764810|NCT02749513|Experimental|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
33399723|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
32712508|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
32712509|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
32712510|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
32712511|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
32712512|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
32712513|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
32712514|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
32712515|NCT05613985|Active Comparator|Arm A: Usual Care alone|
32712516|NCT05613985|Experimental|Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|
32712517|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
32712518|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
32712519|NCT03896009|Experimental|AXS-07|Taken once upon a qualifying migraine
32712520|NCT03896009|Active Comparator|Meloxicam|Taken once upon a qualifying migraine
32712521|NCT03896009|Active Comparator|Rizatriptan|Taken once upon a qualifying migraine
32712522|NCT03896009|Placebo Comparator|Placebo|Taken once upon a qualifying migraine
32712523|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
32712524|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
32712525|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
32712526|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
32712527|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
33245587|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
33245588|NCT00800007|Active Comparator|ANZ-521|
32712528|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
32712529|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
32712530|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
32712531|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
32712532|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
32712533|NCT02344875|Experimental|Male elder subjects|Male 65- Years
32712534|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
33245589|NCT00800007|Placebo Comparator|Placebo|
33245590|NCT00739232|Active Comparator|Active|Active
32712535|NCT02344875|Experimental|Female elder subjects|Female 65- Years
32712536|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
32712537|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
33245591|NCT00739232|Placebo Comparator|Placebo|Placebo
32712538|NCT02293915|Placebo Comparator|Placebo|
32712539|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
32712540|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
32712541|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
32712542|NCT02298049|Other|Scanning|"Repeated measures:~Satiation scan + Pre-meal scan~All participants undertook both scans"
32712543|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
32712544|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
33245592|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
33245593|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
32712545|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
32712546|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
32712547|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
32712548|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
32712549|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
32712550|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
32712551|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
33245594|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
32712552|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
32712553|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
32712554|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
32712555|NCT02344797|No Intervention|Control|
32712556|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
32712557|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
32712558|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
32712559|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
32712560|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
32712561|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
32712562|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
32712563|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
32712564|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
32712565|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
32712566|NCT02342925|Experimental|RG1662 plus metformin|
32712567|NCT02342925|Experimental|metformin alone|
32712568|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
32712569|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
32712570|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
32712571|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
32712572|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
32712573|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
32712574|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
32712575|NCT02344641|No Intervention|control group|control group do not receive exenatide
32712576|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
32712577|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
32712578|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
32712579|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
32712580|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
32712581|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
32712582|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
32712583|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
32712584|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
32712585|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
32712586|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
32913494|NCT03961347|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
33245595|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
33245596|NCT00735020|Experimental|1|
32712587|NCT04083183|Experimental|Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)|Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.
32712588|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
32712589|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
32712590|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
32712591|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, will be dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
32712592|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
32712593|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
32712594|NCT03766685|Experimental|Bimekizumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
32712595|NCT03766685|Experimental|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
32712596|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
32712597|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
32712598|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
32712599|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.~The follow-up of patients will be performed according to standard clinical practice of each site"
32712600|NCT03514849|Experimental|PCI group|
32712601|NCT03514849|Placebo Comparator|Control group|
32712602|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
32712603|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
32712604|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
32712605|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
32712606|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
32712607|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
32712608|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
32712609|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
32712610|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
32712611|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
32712612|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
32712613|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
32712614|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
32712615|NCT03513835||Mitochondrial myopathy|
32913495|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
32712616|NCT03513835||Healthy controls|
32712617|NCT02299219|Experimental|Taking Charge Experimental Group|
32712618|NCT02299219|Active Comparator|Control Group|
32712619|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
32712620|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
32712621|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
32712622|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
32712623|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
32712624|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
32712625|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
32712626|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
32712627|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
32712628|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
32712629|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
32712630|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
32712631|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
32712632|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
32712633|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
32712634|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
32712635|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
32712636|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
32712637|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
32712638|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
32712639|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
32712640|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
32712641|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
32712642|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
32712643|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
32913496|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
32913497|NCT03902067|Experimental|UC-MSC|UC-MSC transplantation
32913498|NCT03902067|Placebo Comparator|Control Group|Routine treatment
32913499|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
32913500|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
33245597|NCT00735020|Active Comparator|2|
33245598|NCT04065906|Experimental|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
33245599|NCT04065906|Other|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
32712644|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
32712645|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
32712646|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
32712647|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
32712648|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
32712649|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
32712650|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
33245600|NCT04065906|Other|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
32712651|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
32712652|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
32712653|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
32712654|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
32712655|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
32712656|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
33399724|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
33399725|NCT03359395|Active Comparator|Alfentanil|
32712657|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
32712658|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
32712659|NCT00157339|Experimental|1|
32712660|NCT00157339|Active Comparator|2|
32712661|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
32712662|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
32712663|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
32712664|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
32712665|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
32712666|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
32712667|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
32712668|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
32712669|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
32712670|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
32712673|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
32712674|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
32712675|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
32712676|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
32712677|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
32712678|NCT02343705|Experimental|Latella Knee Implant System|
32712679|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
33073192|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
33245601|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
33245602|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
33245603|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
33245604|NCT00809211|Experimental|Nilotinib|
33245605|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
33245606|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
33245607|NCT00729456|No Intervention|1|
33245608|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
33245609|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
33245610|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
33245611|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
33245612|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
32712680|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
32712681|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
32712682|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
32712683|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
32712684|NCT03513523|Experimental|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
32712685|NCT03513523|Experimental|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
32712686|NCT03513523|Placebo Comparator|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
32712687|NCT03647111||Cohorts 1|
32712688|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
32712689|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
32712690|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
32712691|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
32712692|NCT02232581|Experimental|Alovudine - low|
32712693|NCT02232581|Experimental|Alovudine - medium|
32712694|NCT02232581|Experimental|Alovudine - high|
32712695|NCT02232581|Placebo Comparator|Placebo|
32712696|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
32712697|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
32712698|NCT04464499||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
32712699|NCT04464499||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
32712700|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
32712701|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
32712702|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
32712703|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
32712704|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
32712705|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
33245613|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
33245614|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
33245615|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
33245616|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
33245617|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
33245618|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
33073193|NCT03448042|Experimental|Dose Escalation|Participants will be assigned sequentially to escalating doses of runimotamab up to the maximum tolerated dose (MTD).
32764811|NCT02684227|Experimental|Treatment (enzalutamide, paclitaxel, carboplatin)|Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
32764812|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
32764813|NCT03058523||Pregnant|30 pregnant women
32764814|NCT05110339|Experimental|Ropivacaine plus Dexmedetomidine|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg corrected in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
32764815|NCT05110339|Active Comparator|Control group|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
32764816|NCT05111665|Experimental|Mindfulness-based Cognitive Therapy (MBCT)|Remitted depressed participants received eight-weekly, two-hour MBCT sessions (Segal et al., 2013). This program combines MBSR meditation practices (e.g., body scan, mindful stretching, mindfulness of breath/body/sounds/thoughts) with traditional CT techniques (e.g., psychoeducation about depression symptoms and automatic thoughts, exercises designed to demonstrate how the nature of one's thoughts change with one's mood, questioning of automatic thoughts and creating a relapse prevention plan). Finally, participants engaged in a daily meditation practice and homework exercises directed at integrating the application of awareness skills into daily life. Each MBCT group was led by a masters-level clinician who was an active MBCT/Mindfulness-Based Stress Reduction (MBSR) instructor.
32764817|NCT05111665|Active Comparator|Relaxation Group Therapy (RGT)|The revised edition of the Changeways Relaxation Programme (Paterson, 1997) served as the active control condition to control for non-specific group factors including group participation, expectation of change or therapeutic contact and attention. The rationale was that relaxation can be used to better manage life stressors which precipitate depressive episodes. Participants received eight-weekly, two-hour relaxation training sessions. This group program combines psychoeducation regarding the effects of stress, diaphragmatic breathing, progressive muscle relaxation, passive relaxation and imagery. It also incorporates time for participants to discuss the events of the week to facilitate the supportive aspect of group participation. Finally, participants were asked to engage in daily exercises to practice the various relaxation strategies. Each RGT group was led by a doctoral-level therapist.
32764818|NCT05111665|Placebo Comparator|Treatment as usual (TAU)|Participants randomized to the TAU group were instructed that participants would receive MBCT at the end of the follow-up period and to seek help from their family doctors or other sources as the normally would, should the participants encounter symptomatic deterioration or other difficulties over the course of the study. At the end of the follow-up phase, participants in the TAU and RGT group were offered the opportunity to receive MBCT.
32764819|NCT04966403|Experimental|standard physical therapy|Participants in the standard physical therapy received the standard physical therapy (sPT) program, which was conducted according to the needs of each participant and was generally concerned with building strength, enhancing developmental skills, boosting balance, coordination, and postural control, improving physical fitness, and minimizing the development of the compensatory movement patterns that children with DS are likely to develop.
32764820|NCT04966403|Experimental|trampoline-based stretch-shortening cycle exercises|In addition to the sPT, the SSC group received 15-minute SSC exercise sessions, twice weekly, with a total of 24 sessions over 12 successive weeks.
32764821|NCT04952831||Patients with mild CSM|mJOA score ≥15
32764822|NCT04952831||Patients with moderate CSM|mJOA score 13~14
32764823|NCT04952831||Patients with severe CSM|mJOA score ≤ 12
32764824|NCT04952831||Controls|health volunteers
32764825|NCT04814407||Lung cancer patients|Patients age over 20, with suspected or confirmed diagnosis of lung cancer.
32764826|NCT04814407||Indeterminate subjects|Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
32764827|NCT04814407||Control subjects|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
32764828|NCT04965545||Wilson's disease cohort|Patients were clinically diagnosed according to the Leipzig Score and included in the study when they were confirmed to carry ATP7B pathogenic variants in 2 different alleles.
32764829|NCT04965467||Screening population|Screening for Fabry disease with early symptoms
32764830|NCT04795375|Experimental|Intervention|The intervention group will receive Physical activity counseling and guidance by a certified Nurse during the six months after the surgery, additional to the routine follow-up after bariatric surgery at Hadassah-Ein Kerem Hospital.
32764831|NCT04795375|No Intervention|Control|"The control group will receive the routine follow-up followed at Hadassah-Ein Kerem Hospital after bariatric surgery, which includes long term follow-up with the surgeon and a dietitian.~Participants at the Control group will receive Physical activity counseling by a certified nurse at the end of trial."
32764832|NCT04961411||published cases of patients with gallstone ileus|We will observe clinical signs, diagnostic procedures and therapeutic procedures and options
32764833|NCT05110105|Experimental|Intervention|Participants will receive interactive board game health education.
32764834|NCT05110105|Active Comparator|Control|Participants will receive conventional health education.
32764835|NCT04425785|Experimental|Physical Exercise Group|A structured exercise program for 12 weeks
32764836|NCT04425785|Experimental|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
32764837|NCT04425785|No Intervention|Standard Clinical Care|Standard Clinical Care
32764838|NCT05105659||B thalassemia Major patients|
32764839|NCT05105659||B thalassemia Intermedia patients|
32764840|NCT05105659||Healthy Controls|
33073194|NCT03448042|Experimental|Dose Expansion|Participants will receive runimotamab based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
32764841|NCT05105581||Group 1 (Patients)|"Patients: 37 patients with OCD diagnosed according to DSM-5~Inclusion criteria:~both sex~age groups : 18 : 60 are included~accept to participate in the study~Exclusion criteria~presence of major neurological disease as head trauma and sensory or motor defect as blindness or deafness~Active psychiatric disordes~patients refuse to participate in the study"
32764842|NCT05105581||Group 2 (Controlled)|37 healthy populations matched with PT group in age , sex , socioeconomic state
33245619|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
33245620|NCT00735098|Experimental|1|KBA exercise protocol
33245621|NCT00735098|Experimental|2|strength training exercise protocol
32764843|NCT04425629|Experimental|casirivimab+imdevimab low dose|Low dose or body-weight equivalent for those under 18 years of age.
32764844|NCT05111275|Experimental|Group MEMO|Patients will perform cognitive exercises on the MEMO site at least 4 times per week for a month. During this month, patients will be contacted by phone on a weekly basis in order to maintain their motivation and ensure their treatment compliance. The time spent on the site during the month of evaluation will be quantified by the study investigator, via the professional profile created on the MEMO site, allowing to see the patient's activity on this same site.
32764845|NCT05111275|No Intervention|Control Group|Patients will not change their habits or perform cognitive exercises during the same assessment period.
32764846|NCT05105347|Experimental|Medium dose group (Adalimumab plus medium dose oral glucocorticosteroid)|Patients will be given adalimumab with 30mg daily prednisone or equivalent with a fixed slow tapering plan.
32764847|NCT05105347|Active Comparator|High dose group (Adalimumab plus high dose oral glucocorticosteroid)|Patients will be given adalimumab with 60mg daily prednisone or equivalent with a fixed slow tapering plan.
32764848|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
32764849|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
32764850|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
32764851|NCT04952675||low-risk group|Risk Index∈[0,0.5)
32764852|NCT04952675||high-risk group|Risk Index∈[0.5,1)
32764853|NCT05110963|Placebo Comparator|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence.
32764854|NCT05110963|Active Comparator|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
32764855|NCT05110963|Experimental|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
32764856|NCT04424537|Placebo Comparator|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
32764857|NCT04424537|Active Comparator|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
32898362|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
33245622|NCT00735098|Experimental|3|KBA and strength training protocol
33245623|NCT00735098|Sham Comparator|4|
33245624|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
33245625|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
33245626|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
33245627|NCT00871078||C|HIV-negative patients (control group)
33245628|NCT04065594|Experimental|PRP dressing|
33245629|NCT04065594|Experimental|conventional ordinary dressing|
33245630|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
33245631|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
33245632|NCT00862966|Experimental|citrate|
33245633|NCT00862966|Active Comparator|heparin|
33399726|NCT03359395|Placebo Comparator|placebo|
32712706|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
33073195|NCT03447743|Other|XR-NTX services as usual|Participants will receive on-going XR-NTX injections in a local community clinic
33073196|NCT03446001|Experimental|TRx0237 16 mg/day|
32712707|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
32712708|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
32712709|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
32712710|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
32712711|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
32712712|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
33073197|NCT03446001|Placebo Comparator|Placebo|
32712713|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
32712714|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
32712715|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
32712716|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
32712717|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
32712718|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
32712719|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
32712720|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
32712721|NCT05039177|Experimental|Dose Escalation (Parts A1a, A2a, or A3a): ERAS-007 in combination with encorafenib and cetuximab|ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
32712722|NCT05039177|Experimental|Dose Escalation (Parts B1a, B2a, B3a or B4a): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC and KRASm PDAC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
32712723|NCT05039177|Experimental|Dose Expan (Parts A1b, A1c, A2b, A2c, A3b, or A3c): ERAS-007 in combo with encorafenib & cetuximab|ERAS-007 will be orally administered at the recommended dose (as determined from Parts A1a, A2a or A3a) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.
32712724|NCT05039177|Experimental|Dose Expansion (Parts B1b, B2b, B3b, and B4b): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered at the recommended dose (as determined from Parts B1a, B2a, B3a or B4a) in combination with palbociclib to study participants with KRASm or NRASm CRC.
32712725|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
32712726|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
32712727|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
32712728|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
32712729|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
32712730|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
32712731|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
32712732|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
32712733|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
32712734|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
32712735|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
32712736|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;~T3 or T4 stage;~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
32712737|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
33245634|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32764858|NCT04424537|Experimental|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
32764859|NCT04952441|Experimental|Intervention Group|Intervention group will attend the RISE program which consists of eight 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor
32764860|NCT04952441|Active Comparator|Wait-list Control Group|The control group will attend the RISE program after the 3 month wait-list period (study months 6-7)
32764861|NCT05110651|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 200mg once daily
32764862|NCT05110651|No Intervention|No treatment|No treatment
32764863|NCT05105113|Experimental|Zirconia dental implant|Patients treated with zirconia dental implant (Tav-dental) to replace missing tooth
32764864|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
32764865|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
32764866|NCT05104879|Experimental|Biosketch Card|Patients within the experimental group received a biosketch card during rooming, pre-clinician encounter, and were not informed about their involvement. To blind the outcome measure, the research assistant did not explain the reason for the card upon rooming the patient nor did they inform the midlevel provider.
32764867|NCT05104879|No Intervention|No Card|No bio sketch card was provided to these participants.
32764868|NCT04952363|Experimental|HFCWO+WBVT|Subjects received HFCWO+WBVT intervention twice a week for a period of 8 weeks
32764869|NCT04952363|Active Comparator|HFCWO only|Subjects received HFCWO intervention twice a week for a period of 8 weeks
32764870|NCT05104645|Experimental|Patients after a Stroke|
32764871|NCT05104645|Active Comparator|Healthy Volunteering|
32764872|NCT04961333|Experimental|Rehabilitation group|Rehabilitation group will be provided multidisciplinary interventions online and individually by ExorLive app. The screening with self-scored questionnaires and physical tests will be performed before and after 8 weeks rehabilitation.
32764873|NCT04961333|No Intervention|Waiting list controls|Passive waiting list or control group, which will be offered to participate in rehabilitation after at least 8 weeks of waiting time. The group will fulfil screening twice, following the time schedule of intervention group. When invited to rehabilitation a new screening will be asked to be completed if the waiting time after the last screening will be longer than 2 weeks.
32764874|NCT05110573||Laparoscopic pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a laparoscopic approach.
32764875|NCT05110573||Open pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a traditional open approach.
32764876|NCT04952207||DAA Group|Chronic hepatitis C patients treated with DAA
32764877|NCT04632589|Experimental|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
32764878|NCT04632589|Placebo Comparator|Placebo|6 weeks of daily oral placebo tablet
32764879|NCT04952285||Normal saline（I）|Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery
32764880|NCT04952285||Tranexamic acid（II）|Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour
32764881|NCT04961099|Experimental|low-dose group|low-dose group: HY01 10mg（20mg/ml）
32764882|NCT04961099|Experimental|high-dose group|high-dose group: HY01 20mg（40mg/ml）
32764883|NCT04976881|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote medication reconciliation, reproductive planning, or patient education on diabetes self-management within the context of preconception care, 2) variable physician preconception counseling without any EHR notifications or counseling support; and 3) no specific patient support or prompts to promote healthy behaviors post-visits.
32764884|NCT04976881|Active Comparator|PREPARED Strategy|Our PREPARED strategy will utilize health information and consumer technologies to 'hardwire' preconception care and promote diabetes self-management among reproductive-aged, adult women with T2DM in primary care. PREPARED will leverage electronic health record technology at clinic visits to: [1] promote medication reconciliation and safety, [2] prompt provider preconception counseling, and [3] deliver low literacy print tools to reinforce counseling and promote diabetes self-care. Post-visit, text messaging will be used to: [4] encourage healthy lifestyle behaviors.
32764885|NCT04965233||Participants recruited in Denmark|Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
32764886|NCT04965233||Participant recruited in the United States of America|Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
32764887|NCT04975009|Experimental|PTSD group|Participants will be screened and diagnosed using typical screening procedures and diagnostic criteria (e.g., the clinically administered PTSD scale). Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
33245635|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
33245636|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
33245637|NCT00739466|Placebo Comparator|placebo|IV saline infusion
33245638|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
32712738|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
32712739|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
32712740|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
32764888|NCT04975009|Experimental|Healthy control group|Participants will be healthy adults without a history of psychiatric illness. Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
32764889|NCT04964999|Experimental|Exercise|Participants will perform aerobic and strength exercises for 2 weeks.
32764890|NCT04964999|No Intervention|No exercise|Participants will not perform any exercises.
32764891|NCT05108701|Experimental|I-MBCT|"Participants randomized to I-MBCT (Mindfulness-Based Cognitive Therapy) receive 12 weekly 60- minute sessions of I-MBCT according to the protocol of Segal et al. (2002), integrated with the theme, rationale, intention and practice skills (TRIP) protocol (Woods et al. 2016, 2019). The original MBCT protocol, created for eight group sessions lasting two hours, is adapted to twelve individual sessions."
32712741|NCT05230797|Experimental|zinc-oxide propolis|Propolis is a natural resinous mixture produced by honeybees from substances collected from parts of plants, buds, and exudates. The essential principle compounds responsible for biological activities are polyphenols, aromatic acids, and diterpenic acids. Numerous biological properties of propolis have been reported including cytotoxic, antiherpes, free radical scavenging, antimicrobial, and anti-HIV activities The antibacterial effect of propolis is bactericidal by inhibiting their mobility. Propolis kills the fungi and also inhibits the growth of the viruses.
32764892|NCT05108701|Active Comparator|CBT|Participants randomized to Individual Cognitive Behavioural Therapy (CBT) receive 12 weekly 60-minute individual sessions of standard CBT strategies following Beck et al. (1979). Participants receive a copy of Greenberger and Padesky's Mind over Mood (The Guilford Press, 1995) for use during the intervention.
32764893|NCT05108545|Experimental|Amphotericin B liposomes|Patients with suspected fungal neutropenia and fever will receive amphotericin B liposome 3 mg/kg intravenously. Treatment will be continued until the ANC≥500 /mm^3 (0.5×10^9 /L) for more than 72 hrs in terms of patients without evidence of baseline fungal infection and breakthrough fungal infection; or treatment will be continued according to investigator's judgement with a duration ranging from 14 days to 12 weeks in terms of patients with evidence of baseline fungal infection and breakthrough fungal infection.
32764894|NCT04952129|Experimental|Selenomethionine|50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
32764895|NCT04952129|Experimental|Methylselenocysteine|50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
32764896|NCT05100043||Cases|Patients having multiple recurrent and recalcitrant cutaneous and genital warts
32764897|NCT05100043||Controls|Healthy volunteers matched for age and sex
32764898|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
32764899|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
32764900|NCT05081323|Experimental|Self-applied treatment with THERA|Participants in this group will use the Self-applied treatment with THERA for a maximum period of one month.
32764901|NCT05081323|No Intervention|Control without treatment|Participants in this group keep on a waiting list, after one month, they will receive the self-applied treatment
32764902|NCT04431791||Regorafenib|
32764903|NCT04431791||Fruquintinib|
32764904|NCT05007769|Experimental|Ramucirumab + Atezolizumab + N-803|-Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.
32764905|NCT04952051|Experimental|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
32764906|NCT04952051|Active Comparator|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
32764907|NCT04979143|Other|HoLVP with the use of Moses 2.0 technology|HoLVP with the use of Moses 2.0 technology
32764908|NCT04979143|Other|HoLVP without the use of Moses 2.0 technology|HoLVP without the use of Moses 2.0 technology
32764909|NCT04960943|Experimental|Pyrotinib|Pyrotinib with or without paclitaxel/trastuzumab treatment
32764910|NCT05077033|Experimental|Intratumoral phIL12 gene electrotransfer|
32764911|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
32764912|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
32764913|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
32764914|NCT04890067||Localized Osteosarcoma|This cohort include patients affected by localized Osteosarcoma, referred to participating Institutions.
33245639|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
33245640|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
32712742|NCT05230797|Active Comparator|zinc-oxide eugenol|Zinc oxide-eugenol cement (ZOE) has been used as a root canal filling material for primary teeth and has long been the material of choice of pediatric dentists worldwide, although it fails to meet the ideal requirements of root canal filling material for primary teeth due to limited antimicrobial action, and a slower rate of resorption than the roots of the primary teeth. Studies report that the success rate of ZOE ranges from 65% to 86% so it's materials of choice if primary teeth are not nearing exfoliation.
33245641|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
33245642|NCT00735332|Experimental|Single-Arm|
32712743|NCT05001269|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
32712744|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
32712745|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
32712746|NCT04837001|Experimental|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
32712747|NCT04837001|Placebo Comparator|Placebo|Placebo (normal saline) will be administered as a single IV bolus injection.
32712748|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
32712749|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
32712750|NCT04899999|Experimental|Financial reward graphic message|
32712751|NCT04899999|Experimental|Health reward graphic message|
32712752|NCT04899999|Experimental|Self-efficacy graphic message|
32712753|NCT04899999|Experimental|Social norms graphic message|
32712754|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
32712755|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
32712756|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
32712757|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
32764915|NCT03060317||Validation group DOC|Examination with neurological scales.
32712758|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
32712759|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
32712760|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
32712761|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
32712762|NCT02341131|No Intervention|Healthy Controls|No intervention
33245643|NCT00869908||A|
32712763|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
32712764|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
32712765|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
32712766|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
32712767|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
32712768|NCT03507439|Experimental|Heart failure patients|Patients with worsening heart failure (HF) and recent hospitalization for the treatment of HF or patients with chronic stable HF with either preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)
33245644|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
32712769|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
32712770|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
32712771|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
32712772|NCT03111849||hospitalized chronic obstructive patients|
32712773|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
32712774|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
32712775|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
32712776|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
32712777|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
32712778|NCT02306785|Experimental|Formulation D|TP05 Coating D
32712779|NCT02306785|Experimental|Formulation E|TP05 Coating E
32712780|NCT02306785|Experimental|Formulation H|TP05 Coating H
33245645|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
32712781|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
32712782|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
33245646|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
32913501|NCT04900623|Experimental|LOW RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
32913502|NCT04900623|Experimental|INTERMEDIATE RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
32913503|NCT04893837||Standard care plus infrascans|"All participants will receive regular clinical neurological assessments as ordered by the clinical care team. In addition, a research team member will perform an infrascan. This process will be repeated hourly at the same timepoint as the clinical neurological assessments. If a patient's neurological status deteriorates at any time point, and the medical team orders an early (unplanned) CT scan, the neurological data collection will cease once the patient is sent to CT.~Infrascan results will not be shared with the clinical care team, and will not guide the participants' care in any way."
32913504|NCT00552071|Experimental|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
32913505|NCT00552071|Active Comparator|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
32913506|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
32913507|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
32913508|NCT02988557|Experimental|Treadmill|
32913509|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
32913510|NCT05530889|Experimental|TEST/CONTROL|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (12-16 days).
32913511|NCT05530889|Experimental|CONTROL/TEST|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (12-16 days).
32913512|NCT00107289|Experimental|Radiation|
33245647|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
33245648|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
32712783|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
32712784|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
32712785|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
32712786|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
32712787|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
32712788|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
32712789|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
32712790|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
32712791|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
32712792|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
32712793|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
32712794|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
32712795|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
32764916|NCT04964531||Adults|group of adults includes all patients aging 19 years or more
32764917|NCT04964531||children|group of children includes all patients aging less than 19 years
32764918|NCT04525885|Experimental|Gefapixant 45 mg twice daily (BID)|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
32712796|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
32764919|NCT04525885|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks). This arm is not included in protocol amendment 5 or later.
32764920|NCT04525885|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
32764921|NCT04964687||Transplanted patients seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
32764922|NCT04964687||Transplanted patients not seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
32764923|NCT05081167|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day
32764924|NCT05081167|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day
32764925|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
32764926|NCT04431713|Experimental|Exenatide|
32764927|NCT04431713|No Intervention|Standard of care|
32764928|NCT04773925|Experimental|Mindfulness group|As this is a pilot feasibility trial, there is only one arm. All subjects will receive the mindfulness intervention if they consent to participate in the study.
32764929|NCT05104333|Experimental|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
32764930|NCT05104333|Experimental|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
32764931|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
32764932|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
32764933|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
32764934|NCT04436419|Placebo Comparator|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
32764935|NCT04436419|Active Comparator|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
32764936|NCT04951895||control group|patients with normal TMJ
32764937|NCT04951895||Study group|Patients with TMJ internal deragement
32764938|NCT05094895|Active Comparator|Stretta Treatment|Patients will receive the Stretta treatment
32764939|NCT05094895|Sham Comparator|Sham treatment|Patients will receive the sham treatment
32764940|NCT04819763|Experimental|Physical training of the lateral pterygoid muscle|Static stretching and isometric contraction exercises of the lateral pterygoid muscle are used to strengthen and restore a physiological lateral movement of the mandible.
32764941|NCT04819763|Active Comparator|Stabilization appliance therapy|Hard acrylic splint with anterior canine guidance for the lower jaw.
32764942|NCT04960631||Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy|
32764943|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
32764944|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
32764945|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
32764946|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
32712797|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
32913513|NCT05523323|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
33073198|NCT03446001|Experimental|TRx0237 8 mg/day|
33245649|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
33245650|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
33245651|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
33245652|NCT04695392|Experimental|Intervention|R2 Bundle
32712798|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
32712799|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
33245653|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
33245654|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
32712800|NCT04003311||Comprehensive Anatomic Versa-Dial Titanium Humeral Heads|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads to repair shoulder malfunction/disease.
32743284|NCT04930575|Experimental|Muscle Energy Technique group|"Patients in the group (B) will receive muscle energy technique on tonic muscles in the neck (sternocleidomastoid, scalenes, levator scapulae, and upper trapezius) in addition to strengthening exercise for deep cervical flexors and advice to correct positions three times per week for 4 weeks.~The aim of the Muscle Energy Technique in the context of NP is to decrease pain, improve movement, motor control, and function and thereby reduce disability.~A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body thus alleviating the patient's signs and symptoms."
33245655|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
33245656|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
33245657|NCT00731796||3|Stroke victims that do not have a visual field deficit
33245658|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
33245659|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
33245660|NCT00735410|Experimental|1|
33245661|NCT00729768|Experimental|1|
33245662|NCT00729768|Active Comparator|2|
33245663|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
33245664|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
33245665|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
33245666|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
33245667|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
33245669|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
33245670|NCT00735488||A|Thalassemia Minor carriers
33245671|NCT00735488||B|Sickle cell carriers
33245672|NCT00738504||1|
33245673|NCT00738504||2|
33245674|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
33245675|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
33245676|NCT04039906|No Intervention|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
33245677|NCT04039906|Experimental|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
33245678|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
33245679|NCT04064372|Experimental|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
33399727|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.~Common warts, plantar warts, and condyloma acuminata"
33399728|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
32712801|NCT04702997|Experimental|Bardoxolone methyl|"Patients randomized to receive bardoxolone methyl capsules orally once daily for 12 weeks at a starting dose of 5 mg and titrated up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g)~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
32712802|NCT04702997|Placebo Comparator|Placebo|"Patients who received placebo, once-daily, orally, remained on placebo throughout the study duration of 12 weeks and followed the same titration to maintain the blind,~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
32712803|NCT03938701|Experimental|Fluorescence imaging with OTL38|"Fluorescence imaging with OTL38 in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients. A non-randomised, non-blinded, prospective, feasibility study.~- Administration of 0.0125 mg/kg OTL38 to a total of 30 patients: 10 with Crohn's disease, 10 with ulcerative colitis and 10 with rheumatoid arthritis."
32712804|NCT04771923|Experimental|Tranexamic acid|
32712805|NCT04771923|Experimental|Adrenaline|
32712806|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
32712807|NCT04718415|Experimental|sintilimab + carboplatin + nab-paclitaxel|"Treatment with sintilimab, nab-paclitaxel and carboplatin for up to 2 - 4 cycles:~Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
32712808|NCT04631549|Experimental|Healthy participants|Intervention: Drug: SHR3680 single dose
32712809|NCT04631549|Experimental|Mild liver impairment|Intervention: Drug: SHR3680 single dose
32712810|NCT04631549|Experimental|Moderate liver impairment|Intervention: Drug: SHR3680 single dose
32712811|NCT02303275|Other|Lifestyle Change|Lifestyle Change
32712812|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
32712813|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
32712814|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
32712815|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System
32712816|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|Ab-interno transluminal viscoelastic delivery using OMNI surgical System
32712817|NCT04616573|Active Comparator|iStent Inject implantation|iStent Inject implantation using the iStent device
32712818|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
32712819|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
32712820|NCT04598321|Experimental|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
32712821|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
32712822|NCT04718025|Experimental|Low-dose ticagrelor with aspirin (LDTA)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS."
32712823|NCT04718025|Experimental|Low-dose ticagrelor with placebo (LDTP)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;~ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS."
32764947|NCT04951505|Experimental|cefepime-taniborbactam|
32764948|NCT04951349|Experimental|Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
32913514|NCT05523323|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib-matching placebo will be administered until progressive disease or unacceptable toxicity.
32913515|NCT03863457|Experimental|UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER|Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-Gln in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-Gln will also be evaluated in all subjects.
32913516|NCT04880889|Experimental|BL 3000 (active) and Pantogar matching Placebo|One capsule, once a day for 180 days for BL3000 and one capsule three times a day for Pantogar-Placebo.
32913517|NCT04880889|Active Comparator|Pantogar and BL3000 matching placebo|One capsule, three times a day for 180 days
32913518|NCT04738383|Experimental|Version 1: Paramedic|Physician is replaced by a paramedic, but the physician still acts as a supervisor.
32913519|NCT04738383|Experimental|Version 2: Physician-on-call|Physician is not present, but is on call.
32913520|NCT04738383|Experimental|Version 3: Trained instructor|Physician acts as a supervisor, but is not constantly present. The instructor received a special training preparing for emergency cases.
32712824|NCT04718025|Active Comparator|Standard-dose ticagrelor with aspirin (SDTA)|Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.
32712825|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
32913521|NCT04738383|No Intervention|Control group|The sessions take place in the usual way, meaning that a physician is present in every session.
32913522|NCT03844347|Experimental|C-Bien|
32913523|NCT03844347|No Intervention|Control|
32913524|NCT04866771|Experimental|Transcranial Direct Current Stimulation (tDCS)|Facilitatory transcranial direct current stimulation (tDCS)
32913525|NCT04866771|Sham Comparator|Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group|Sham tDCS followed by a switch to anodal tDCS.
32913526|NCT03833427|Experimental|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks [Q3W]) in combination with selumetinib at dose level 1 (dosed orally; twice daily [BID]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913527|NCT03833427|Experimental|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913528|NCT03833427|Experimental|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913529|NCT03833427|Experimental|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913530|NCT03833427|Experimental|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913531|NCT03833427|Experimental|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913532|NCT03833427|Experimental|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
32913533|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
32913534|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
32913535|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
32913536|NCT04856241|Experimental|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support & networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
33245680|NCT04064372|Active Comparator|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
32764949|NCT04951349|Placebo Comparator|Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
32764950|NCT04951349|Experimental|Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
32764951|NCT04951349|Placebo Comparator|Placebo Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
32764952|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
32764953|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
32764954|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
32764955|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
32764956|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
32764957|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
32764958|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764959|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764960|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764961|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764962|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764963|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764964|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764965|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
32764966|NCT04586413||Non-hospitalised post-COVID-19 patients|This cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
32764967|NCT04586413||Hospitalised post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
32764968|NCT04586413||Intensive care post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
32764969|NCT04593199|Sham Comparator|Physical Activity Tracking App Only|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity.
33073199|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
33245681|NCT05555342|Experimental|IRE ablation and radiation therapy|Patients will be treated with IRE ablation directed at the target lesion on day 1. Moderate-dose, single-fraction radiation therapy will be delivered to the target lesion on day 8 to day 15.
32764970|NCT04593199|Active Comparator|Physical Activity Tracking + Gamified Smartphone App|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity. Additionally, they were asked to use the gamified smartphone app, Draco, during the intervention period.
32712826|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
32712827|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
32712828|NCT05254899|Experimental|Inductive and concurrent anti-PD-1 antibody combined with chemo-radiotherapy|All the enrolled patients receive 3 cycles of anti-PD-1 antibody (Tislelizumab 200mg d1) + P-GEMOX (Pegaspargase 3000u d2, Gemcitabine 1g/m2 d2, Oxaliplatin 85mg/m2 d2) systemic treatment every 14 days, followed by involved-site radiotherapy with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
32712829|NCT02307097|Experimental|CBB|
32712830|NCT02307097|Experimental|CBT|
32712831|NCT02307097|Active Comparator|WAIT|
32712832|NCT03148509|Experimental|bupropion|receive bupropion
32764971|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
32764972|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
32712833|NCT03148509|Experimental|risperidone|receive risperidone
32712834|NCT03148509|Experimental|aripiprazole|receive aripiprazole
32712835|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
32712836|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
32712837|NCT04464343||Posterior cruciate ligament injury group|According to the previous clinical diagnosis, volunteers who has never suffered the Posterior cruciate ligament injury.
32712838|NCT04464343||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
32712839|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
32712840|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
32712841|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
32712842|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
32712843|NCT05254665|Experimental|Docetaxel Polymeric Micelles for Injection|Docetaxel Polymeric Micelles for Injection
32712844|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
32712845|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
32712846|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
32712847|NCT05254587||Retrospective|
32712848|NCT05254587||Prospective|
32712849|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
32712850|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
32712851|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
32712852|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
32712853|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
32712854|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
32712855|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
32712856|NCT03512899|Active Comparator|Axillary vein access|Axillary vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
32712857|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
32712858|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
32712859|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
32712860|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
32712861|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
32913537|NCT04856241|Active Comparator|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
32913538|NCT04849377|Experimental|Group I - 50 Gy/200 mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1,T2 N0 RT 5 days per week for 6 weeks and Cisplatin weekly for 5 weeks
32913539|NCT04849377|Experimental|Group II - 54 Gy/200mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
32913540|NCT04849377|Experimental|Group III - 60 Gy/240 mg/m2|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
32913541|NCT04849377|Experimental|Group IV - TPF Induction followed by 60 Gy and Carboplatin AUC 1.5|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T4, N2c, >3 nodes, ENE, or Matted Nodes Induction Therapy: Cisplatin, Docetaxel, Fluorouracil followed by RT 60 GY + Carboplatin AUC 9.0 Docetaxel every 21 days for 3 cycles, Cisplatin every 21 days for 3 cycles, Fluorouracil continuous infusion over 4 days (every 21 days for 3 cycles). Followed by RT 5 days per week for 6 weeks and Carboplatin weekly for 6 weeks.
32913542|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
32913543|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
32913544|NCT04738227|Experimental|Low level Laser Therapy Group|"Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.~6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).~Following are the parameters which will be employed for the laser:~Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.~A sum total of 22 points will receive LLLT per session involving all three major salivary glands."
32913545|NCT04614389|Other|CEUS and SWE|CEUS & SWE
32913546|NCT05441553|Experimental|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
32913547|NCT04768595|Placebo Comparator|Placebo|1g corn oil capsules
32913548|NCT04768595|Experimental|Ceto 10|1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.
32913549|NCT04768595|Active Comparator|Omega-3|1 g capsules containing traditional, commericially available omega-3 marine oil.
32913550|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
32913551|NCT00371163||Psoriasis|Males or females with psoriasis
33245682|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
33245683|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
33245684|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
33245685|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
33245686|NCT00729404|Experimental|Arm 1|
33245687|NCT00729404|Experimental|Arm 2|
33245688|NCT00876304|Experimental|PF-04802540|
33245689|NCT00876304|Placebo Comparator|Placebo|
32913552|NCT00371163||No skin disease|Males or females with no skin diseases
32913553|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
32913554|NCT02874443|Experimental|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.~Intervention centers will receive knowledge translation of labor management guidelines"
32913555|NCT02874443|No Intervention|Control centers|No intervention at control centers
32913556|NCT04738539||Patients with or being evaluated for neurogenic bladder|Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.
32913557|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
33245690|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
33073200|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
33245691|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
33245692|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
33245693|NCT04065932|Experimental|BMS-985165-01 prototype formulation 1|
33245694|NCT04065932|Experimental|BMS-986165 Tablet|
33245695|NCT04065932|Experimental|BMS-985165-01 prototype formulation 2|
33245696|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3|
33245697|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3 or 4|
33245698|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3, 4 or 5|
33245699|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
33245700|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
32913559|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
32913560|NCT03770403|Experimental|ARGX-113|
32913561|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
32913562|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
32913563|NCT05511779|Experimental|Dose Escalation Phase: Cohort 1: BCV 0.3 mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
32913564|NCT05511779|Experimental|Dose Escalation Phase: Cohort 2: BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
32913565|NCT05511779|Experimental|Expansion Phase: BCV Recommended dosage regimen in the Dose Escalation Phase|BCV: Recommended dosage administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
32913566|NCT04832139|Experimental|Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)|Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
32913567|NCT04832139|Experimental|Marstacimab PFS, then marstacimab PFP|Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
32913568|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
33245701|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
32913569|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
32913570|NCT05510921|No Intervention|Control group|The control group will not receive any intervention
32913571|NCT05510921|Experimental|Minimalist music group|a live session of minimalist music piano piece
32913572|NCT05510921|Experimental|Minimalist music plus birdsongs group|a live session of minimalist music piano piece with the superposition of bird song sounds
32913573|NCT04817475||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
32913574|NCT05454501|Active Comparator|Exercise Training|8-week real-time online exercise training will be provided. The content of the training will be aerobic based exercises, strength and flexibility exercises with warm up and cool down phases.
32913575|NCT05454501|Active Comparator|Patient Education|Patients will be given face-to-face education about their disease, the importance of physical activity and how to do it safely. They will be followed up with information leaflets and weekly phone calls.
32913576|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
33073201|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
33245702|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
33245703|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
33245704|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
33245705|NCT04064268|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
33245706|NCT04064268|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
33245707|NCT04064268|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
32712862|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
32712863|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
32712864|NCT05254197||Retrospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 1998, and who have had MR re-examination after first MR exam because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. It is practically impossible to obtain informed consent from patients of this retrospective cohort, and consent was waived by the Institutional Review Board. Target population of this retrospective cohort is 1,500 tumors.
32712865|NCT05254197||Prospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since February 2022, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. The cohort will consists of patients who agree to participate with written consent. Target population of this prospective cohort is 1,500 tumors.
32712866|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
32712867|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
32712868|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
32712869|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
32712870|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
32712871|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
32712872|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
32712873|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
32712874|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
32712875|NCT03507127|Active Comparator|Varenicline|
32712876|NCT03507127|Placebo Comparator|Placebo|
32712877|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
32712878|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
32712879|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
32712880|NCT02307409||Healthy Controls|Healthy Controls will be enrol
32712881|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
32712882|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
32712883|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
32712884|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
32712885|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
32712886|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
32712887|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
32712888|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
32712889|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
32712890|NCT04658433|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.
32712891|NCT04658433|No Intervention|Control group|
32712892|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
32764973|NCT03059225|Experimental|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
32764974|NCT04522843||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
32764975|NCT04522843||Colitis|Patients with active colitis
32764976|NCT04522843||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
32764977|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
32764978|NCT04416685|Other|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
32764979|NCT04416685|Other|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
32764980|NCT04416685|Other|Level III|those tumors located inferior to the portal confluence
32764981|NCT04944407|Experimental|LHP GROUP|patients recieved minimal invasive LHP procedure with diode laser
32764982|NCT04944407|Active Comparator|MM GROUP|patients received conventional MM hemorroidectomy
32764983|NCT04428775|Experimental|Group I (Low Dose)|Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)
32764984|NCT04428775|Experimental|Group II (High Dose)|Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)
32764985|NCT04944329||COLCOVID|adults undergoing hip fracture surgery
32764986|NCT04436263|Experimental|Supplement|Ethanol-water extract of winery by-products
32764987|NCT04436263|Placebo Comparator|Placebo|Maltodextrin-based placebo
32764988|NCT04951271|Experimental|Intervention (SFA) group|solution-focused approach intervention was applied for 7 weeks
32764989|NCT04951271|No Intervention|Control (no intervention) group|No intervention was made.
32764990|NCT04272619|Experimental|Liver Cancer Education|
32764991|NCT04950569|Experimental|Levosimendan|Receive standard heart failure treatment, plus levosimendan treatment.
32764992|NCT04950569|No Intervention|Control|Receive standard heart failure treatment, without levosimendan treatment.
32764993|NCT04944251|Experimental|aerobic exercise group|the patients in the aerobic group started to exercise at a heart rate corresponding to 60% of the maximal VO2, by adjusting the pedal resistance of the exercise bike, consistent with the Karvonen formula. This was followed by exercise cycling at a heart rate corresponding to 70% of maximal VO2 in the second month, and 80% of maximal VO2 in the third month, for 30 minutes, 3 days a week
32764994|NCT04944251|Experimental|strength exercise group|The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
32764995|NCT04944251|No Intervention|control group|The patients who didn't want to exercise were included in the control group.
33245708|NCT04039672|Experimental|Biopsy|Skin biopsy before BRAFi/MEKi treatment
33245709|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
33245710|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
32764999|NCT04944641|Experimental|A: Routine AED group|Routine and proper antiepileptic drugs group
32765000|NCT04944641|Experimental|B: AED and education group|Routine, proper antiepileptic drugs and education group
32765001|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
32765002|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
32765003|NCT04943705|Experimental|Yin and Yang Regulating Moxibustion|1.The acupoints will be selected as Shenque and Mingmen.The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Each treatment was 60min, once a week, Wenyang Yishen moxibustion and Peiyuan Guben moxibustion were performed alternately. Each patient received WenYang Yishen moxibustion and then Peiyuan Guben moxibustion for a total of 12 weeks of treatment and 12 weeks of follow-up at the end of the treatment. 2.The diet and exercise control implementation plan is as follows:Participants weighed ≤113.6 kg (250 lbs) and had a prescription diet of 1200-1499 kcal/day, including traditional foods, of which protein was about 15-20 kcal, fat was about 20-35%, and the rest came from carbohydrates. People weighing ≥113.6 kg are prescribed 1500-1800 kcal per day. They were also instructed to continue moderate-intensity physical activities (such as jogging, brisk walking) at least 5 days a week, at least 210 minutes a week, preferably ≥270 minutes a week。
32765004|NCT04943705|Active Comparator|Mild Moxibustion|1.The acupoints will be selected as Zhongwan, Guanyuan, Sanyinjiao (double).The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Light one end of the moxa stick and hang it about 2-3cm above the skin, taking the patient's local skin redness and conscious warmth as the degree. Moxa-box moxibustion will be used for 20 minutes each treatment, once every other day, 3 times a week, for a total of 12 weeks of treatment, and 12 weeks of follow-up after the treatment. 2.Lifestyle modification:It will be performed as the same as the Yin and Yang Regulating Moxibustion group.
32765005|NCT04950491|Experimental|Test group (s-CAIS)|The test group workflow used a fully computer-guided implant surgical protocol.
32765006|NCT04950491|Other|Control group (CIS)|The control group workflow used a conventional implant surgical protocol.
32765007|NCT04950335||AOPT|patients underwent AOPT to treat large cystic OLTs (>10mm)
32765008|NCT04950335||AOCT|patients underwent AOCT to treat large cystic OLTs (>10mm)
32765009|NCT04944173|Experimental|MRD Negative|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have no detectable ctDNA at MRD landmark and will receive no further therapy.
32765010|NCT04944173|Experimental|MRD Positive, no further therapy|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to no further therapy.
33245711|NCT05225974|Experimental|Liraglutide injection|
32712893|NCT04636437|Experimental|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|By mouth daily with or without food
32712894|NCT04636437|Experimental|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|By mouth daily with or without food
32712895|NCT04636437|Experimental|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
32712896|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
33245712|NCT05225974|Active Comparator|Liraglutide injection(Victoza®)|
32712897|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
32712898|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
32712899|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
32712900|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
32712901|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
32712902|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
32712903|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
32712904|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
32712905|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
32712906|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
32712907|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
32712908|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
32712909|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
32712910|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
32712911|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
32712912|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
32712913|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
32712914|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
32712915|NCT05253885||Smartphone addiction group|
32712916|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
32712917|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
32712918|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
32712919|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
32712920|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
32712921|NCT04477551|Experimental|Diode laser (device) with scaling and root planing|Diode laser (device) with conventional scaling and root planing
32712922|NCT04477551|Active Comparator|Conventional scaling and root planing|Conventional scaling and root planing
32712923|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
32712924|NCT05253729|Experimental|Focused Extracorporeal Shock Wave Therapy (F-ESWT)|Participants in the intervention group received low-intensity F-ESWT once a week for three sessions plus conservative treatment.
32712925|NCT05253729|Active Comparator|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
32712926|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
33245713|NCT01139970|Experimental|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
33245714|NCT00729638|Experimental|Single arm|Single arm phase I study
33245715|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
32712927|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
32712928|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
32712929|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
32712930|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
32712931|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
33245716|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
32712932|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
32712933|NCT02348541|Other|CollaGUARD|
32712934|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
32712935|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
32712936|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:~In the first 6 to 12 hours of admission to ICU~Second US after 12-24 hours of inclusion.~Third US after 24-48 hours of inclusion.~Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
32712937|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
32712938|NCT05227677|Experimental|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals and the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
33245717|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
33245718|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
33245719|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
33245720|NCT00735800|Active Comparator|Supportive Counseling|
33245721|NCT00735800|Experimental|Problem-Solving|
33245722|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
33245723|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
33245724|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
33245725|NCT00729716|Experimental|A|BioCart™II treatment
33245726|NCT00729716|Active Comparator|B|Microfracture procedure
33245727|NCT00863200||Telephone Intervention Group|
33245728|NCT00863200||Standard Care Group|
33245729|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
33245730|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
33245731|NCT00740324|Active Comparator|N|
33245732|NCT00740324|Active Comparator|B|
33245733|NCT00740324|Active Comparator|G|
33245734|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
33245735|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
33245736|NCT04040998|Experimental|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
33245737|NCT04040998|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
33245738|NCT05575440||Observational (18F-TFB PET/CT)|Patients receive fluorine F18 tetrafluoroborate IV and undergo PET/CT scan on study.
33245739|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
33245740|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
33245741|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
33245742|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
33245743|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
32712939|NCT05227677|Active Comparator|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals，but investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
32712940|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
33245744|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin (21-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
33245745|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin(28-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
33245746|NCT02099058|Experimental|Monotherapy Expansion Cohort|Telisotuzumab vedotin will be administered every 14 days on a 28-day dosing cycle.
33245747|NCT02099058|Experimental|Arm A (Telisotuzumab vedotin plus Erlotinib)|Telisotuzumab vedotin to be evaluated with Erlotinib.
33245748|NCT02099058|Experimental|Arm D (Telisotuzumab vedotin plus Nivolumab)|Telisotuzumab vedotin to be evaluated with Nivolumab.
32712941|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
32712942|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
32712943|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
32712944|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
32712945|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
32712946|NCT02442973||Control group (CG):|Standard practice group
32712947|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
32712948|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
32712949|NCT03512509|Experimental|A|Low glycaemic potato
32712950|NCT03512509|Experimental|B|High glycaemic potato
32712951|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
32712952|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
32712953|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
32712954|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
33245749|NCT02099058|Experimental|Arm E (Telisotuzumab vedotin plus Osimertinib)|Telisotuzumab vedotin to be evaluated with Osimertinib.
32712955|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
32712956|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
32712957|NCT04463953|Experimental|ZID regimen|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.
32712958|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
32712959|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
33245750|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
33245751|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
32712960|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
32712961|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
32712962|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
32712963|NCT02307955|Experimental|firefly|participants treated with firefly device
32712964|NCT02307955|Other|Control|Standard of care
32712965|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
32712966|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
32712967|NCT03512431||Study group|Only one arm in the present study
32712968|NCT02348307|Active Comparator|FYU-981|
32712969|NCT02348307|Placebo Comparator|Placebo|
32712970|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
32712971|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
32712972|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
32712973|NCT02300701|Experimental|Xolair/Omalizumab|
32712974|NCT02300701|Placebo Comparator|Placebo|
32712975|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
32712976|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
32712977|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
32712978|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
32712979|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
32712980|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with moderate renal impairment"
32712981|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with mild renal impairment"
32712982|NCT02300857|Active Comparator|Low carbohydrate diet|
32712983|NCT02300857|Active Comparator|Moderate carbohydrate diet|
32712984|NCT02300857|Active Comparator|High carbohydrate diet|
32712985|NCT04464733|Experimental|Treatment group A|
32712986|NCT04464733|Experimental|Treatment group B|
32712987|NCT04464733|Experimental|Treatment group C|
32712988|NCT04464733|Experimental|Treatment group D|
32712989|NCT04464733|Experimental|Treatment group E|
32712990|NCT04464733|Experimental|Treatment group F|
32712991|NCT04464733|Experimental|Treatment group C-|
32712992|NCT04464733|Experimental|Treatment group G|
32712993|NCT04464733|Experimental|Treatment group H|
32712994|NCT04464733|Experimental|Treatment group I|
32712995|NCT04464733|Experimental|Treatment group J|
32712996|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
32712997|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
32712998|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
32712999|NCT04465045||Unique cohort|All women, 18 to 43 years, operated from laparoscopy-hysteroscopy for unexplained infertility in montpellier university hospital
32713000|NCT04421703|Experimental|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
32713001|NCT04421703|Experimental|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
32713002|NCT04464655||Healthy Volunteers|Age: >18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
32713003|NCT04464655||Patients|Age: > 18y, Clinically indicated CMR exam
32713004|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
32713005|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
32713006|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
32713007|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
32713008|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
32713009|NCT03511885||high cardiovascular risk patients|"Coronary patients~Elective coronary artery bypass surgery (CABG).~Elective percutaneous coronary intervention (PCI) .~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
32713010|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
32713011|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
32713012|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
32713013|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
32713014|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
32713015|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
32913577|NCT03716349|Experimental|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
33073202|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
33073203|NCT03433755|Placebo Comparator|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
33073204|NCT03433755|Placebo Comparator|Placebo QM|Placebo SC QM for 12 weeks
33073205|NCT03433755|Experimental|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
32713016|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
32713017|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
32713018|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
32713019|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
32713020|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
32713021|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
32713022|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU~Duration of ICU stay must be a minimum of 24 hours.~Mini-Mental State Examination (MMSE) Score of 25 or above~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
32713023|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
32713024|NCT03511495||Keratoconic Patients|
32713025|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
32713026|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
32713027|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32713028|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32713029|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
32713030|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
32713031|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
32713032|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
32713033|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
32713034|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
32713035|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
32713036|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
32713037|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
32713038|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
32713039|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
32713040|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
33245752|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
32713041|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
33245753|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
33245754|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
33245755|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
33245756|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
32713042|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
32713043|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
32713044|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
32713045|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
32713046|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
32713047|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
32713048|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
32713049|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
32713050|NCT02339103|Experimental|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
32713051|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
32713052|NCT02335437||Acute EBV infection|
32713053|NCT02335437||Healthy controls|
32713054|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
32713055|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
32713056|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
32713057|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
32713058|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
32713059|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
32713060|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
32713061|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
32713062|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
32713063|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
32713064|NCT02338947|Active Comparator|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
32713065|NCT02338947|Active Comparator|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
32713066|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
32713067|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
32713068|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
32713069|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
32713070|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
32713071|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
32713072|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
33245757|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
32713073|NCT02339025||Tricare Participants|From WRNMC
32713074|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
32713075|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
32713076|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
32713077|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
32713078|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
32713079|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
32713080|NCT02335359|Placebo Comparator|Placebo|Saline
32713081|NCT03511339|No Intervention|Control|Brain rest
32713082|NCT03511339|Experimental|TecTraum Device|Treatment with study device
32713083|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
32713084|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
32713085|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
32713086|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel~Group 1 patients:~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
32713087|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
32713088|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
32713089|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
32713090|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
32713091|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
32713092|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
32713093|NCT03933735|Experimental|Arm A: Dose Escalation|Up to 15 cohorts of participants receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
32713094|NCT03933735|Experimental|Arm B: Dose Expansion Dose A|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
32713095|NCT03933735|Experimental|Arm B: Dose Expansion Dose B|An expansion cohort will be enrolled at the recommended phase 2 Dose B.
32713096|NCT03933735|Experimental|Arm E: Monotherapy Once Every 4 Weeks (Q4W)|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
32713097|NCT03933735|Experimental|Arm F: Monotherapy Dose C|An expansion cohort will be enrolled at the recommended phase 2 Dose C.
32713098|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.~The second stage: continue to apply another plan until there is progress or intolerance."
32713099|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
32713100|NCT03922035|Experimental|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
32713101|NCT03922035|Active Comparator|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
32713102|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
32713103|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
32713104|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months."
32713105|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.
32713106|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
32713107|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
32713108|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
32713109|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
32713110|NCT02303665|No Intervention|The control group|No Intervention
32713111|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
32713112|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
32713113|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
32713114|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
32713115|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
32713116|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
32713117|NCT03901053|Experimental|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
32713118|NCT03901053|Experimental|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
32713119|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
32713120|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
32713121|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
32713122|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
32713123|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
32713124|NCT03506035||Healthy controls|From health blood donors
32713125|NCT02309749||Naive cohort|
32713126|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
32713127|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
32713128|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
32713129|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
32713130|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
32713131|NCT04464109|Active Comparator|Retro-scleral placement of the implant|"Surgical steps;~Two anterior scleral relaxing incisions~A 360° scleral incision around the optic nerve to disinsert it~Two posterior scleral relaxing incisions~The implant is inserted posterior to posterior scleral edges~The posterior sclera is closed then the anterior sclera is overlapped and closed.~The implant is completely seated in the intraconal space"
32713132|NCT04464109|Active Comparator|Intrascleral placement of the implant|"Anterior and posterior sclerotomies with the implant partly in the scleral shell and partly in the intraconal space.~Anterior relaxing sclerotomies not reaching the optic nerve~A 360° scleral incision around the optic nerve.~The anterior sclera flaps are overlapped and closed~Part of the implant remains in the scleral shell, while the remaining part is sitting in the intraconal space."
32713133|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713134|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713135|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713136|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713137|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713138|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713139|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713140|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713141|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
32713142|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
32713143|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
32913578|NCT03716349|Active Comparator|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
32913579|NCT05454423|Experimental|aquatic exercise + Traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received aquatic exercise and Traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
32913580|NCT05454423|Placebo Comparator|traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
33073206|NCT03433755|Experimental|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
33245758|NCT03778294|Experimental|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning cycles 2, patients receive standard of care temozolomide on days 1-5. Cycles with temozolomide repeat every 28 days for up to 7 cycles in the in the absence of disease progression or unacceptable toxicity.
33245759|NCT00732186|Experimental|Group 1 and Group 2|
33245760|NCT04064996|Active Comparator|Group A|Routine rehabilitation program patient education
33245761|NCT04064996|Experimental|Group B|Routine rehabilitation program + foot exercise training
33245762|NCT00729872|Experimental|1|AG011: low dose
33245763|NCT00729872|Placebo Comparator|2|Placebo: low dose
33245764|NCT00729872|Experimental|3|AG011: mid dose
33245765|NCT00729872|Placebo Comparator|4|Placebo: mid dose
33245766|NCT00729872|Experimental|5|AG011: high dose
33245767|NCT00729872|Placebo Comparator|6|Placebo: high dose
32713144|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
33245768|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
33245769|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
33245770|NCT04039828|Experimental|Stratum|"Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175~In total, 350 participants will be enrolled"
33245771|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
32713145|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
33245772|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
33245773|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
33245774|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
33245775|NCT04063826|Other|PET MRI Scan|Imaging scan of the liver
33245776|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
33245777|NCT04064970||PASS Cohort|
33245778|NCT00740948|Experimental|1|Rituximab
33245779|NCT00740948|Placebo Comparator|2|Placebo
33245780|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
33245781|NCT04735068|Experimental|Binimetinib and Hydroxychloroquine|"Hydroxychloroquine (HCQ)in combination with Binimetinib (B). The starting dose for HCQ will be 400mg. Tablets of HCQ are available in 200 mg strength. HCQ will be administered in divided doses (every 12 hours) with or without food.~The starting dose of B is 45mg. B will be administered in divided doses (every 12 hours) with or without food"
33245782|NCT00732342|No Intervention|1|Standard Treatment
33245783|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
33245784|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
33245785|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
33245786|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
32713146|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
32713147|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
32713148|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
32713149|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
32713150|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
32713151|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
32713152|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
32713153|NCT02301949|Placebo Comparator|Placebo Group|
32713154|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
32713155|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
32713156|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
32713157|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
32713158|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
32713159|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
32713160|NCT05159401|Experimental|"the first group: the method of vibroacoustic lung massage using the BARK VibroLUNG device"|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
32713161|NCT05159401|Experimental|the second group:the method of oscillating REР therapy using Acapella DH Green|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
32713162|NCT05159401|Experimental|the third group:the method of hardware stimulation of cough (Comfortable cough Plus)|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
32713163|NCT05159401|Experimental|the fourth group:classical manual chest massage with percussion|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
32713164|NCT02335047|Other|lower back pain|
32713165|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
32713166|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
32713167|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
32713168|NCT03510871|Experimental|nivolumab plus ipilimumab|nivolumab plus ipilimumab
32713169|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
32713170|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
32713171|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
32713172|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
32713173|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
32713174|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
32713175|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
32713176|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
32713177|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
32713178|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
32713179|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
32713180|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
32713181|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
33073207|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
32713182|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
32713183|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
32713184|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
32713185|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
32713186|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
32713187|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
32713188|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
32713189|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
32713190|NCT05230953|Experimental|4th dose mRNA1273 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (50microgram) of the mRNA1273 vaccine
32713191|NCT05230953|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
32713192|NCT05230953|Experimental|4th dose BNT162b2 vaccine|The outcomes will be compared to those participating in study IRB-8980-21, with a similar protocol, initiated 1 week earlier.
32713193|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
32713194|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
32713195|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
32713196|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
32713197|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
32713198|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
32713199|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
32713200|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
32713201|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
32713202|NCT04888000|Other|single|Educational intervention.
32713203|NCT05159349||Exposed group|
32713204|NCT05159349||Non-exposed group|
32713205|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
32713206|NCT05157321|Active Comparator|Study Group|The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.
32713207|NCT05157321|Sham Comparator|control group|The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.
32713208|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
32713209|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
32713210|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
32713211|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
32713212|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
32713213|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
32713214|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
32713215|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
32713216|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
32713217|NCT02310295|Active Comparator|Laser|focal laser therapy
32713218|NCT05012865||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
32713219|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
32713220|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
32713221|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
32713222|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
32713223|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
32713224|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
32713225|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
32713226|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
32713227|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
32713228|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
32713229|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
32713230|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
32713231|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
32713232|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
32713233|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
32713234|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
32713235|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
32713236|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
32713237|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
32713238|NCT03790683|Experimental|EnsoETM|Participants receive esophageal warming. Original study design anticipated esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU. After 7 patients, protocol was adjusted to specify only esophageal warming unless addition of surface warming was warranted.
32713239|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
32713240|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
32713241|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
32713242|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
32713243|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
33245787|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
33245788|NCT00734916|Active Comparator|1|Omegaven 10%
33245789|NCT00734916|Active Comparator|2|Intralipid 10%
33245790|NCT00734916|Placebo Comparator|3|Placebo
33245791|NCT00872092||Breath test|Subjects with suspected SBBO
33245792|NCT00738816|Other|Intervention|Systematic medication review
33245793|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
33245794|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
33245795|NCT00735150||1|25 female and 5 male BRCA carriers
33245796|NCT05157412|Experimental|Steroids + Doxycycline|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily one hour before meal as a maintenance dose) for 3 weeks.
33245797|NCT05157412|Active Comparator|Steroids Only|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.
33245798|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
32713244|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
32713245|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
32713246|NCT02304133|Placebo Comparator|Control|no training
32713247|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
33245799|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
33245800|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
33245801|NCT00877240|Other|Lifestyle counseling|
32713248|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
32713249|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
32713250|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
32713251|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
32713252|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
32713253|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
32713254|NCT02310841|Experimental|unilateral transfemoral amputees|
32713255|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
32713256|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
32713257|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
32713258|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
32713259|NCT04197934|Experimental|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32713260|NCT04197934|Experimental|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33399729|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
32713261|NCT04197934|Experimental|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32713262|NCT04197934|Experimental|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC LM receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32713263|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
32713264|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
32713265|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
32713266|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
32713267|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
32713268|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
32713269|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
32713270|NCT02331693|Experimental|anti-EGFR CAR T|
32713271|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
32713272|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
32713273|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
32713274|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
32713275|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
32713276|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
32713277|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
32713278|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
32713279|NCT02304289|Experimental|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
32713280|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
32713281|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
32713282|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
32713283|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
32713284|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
32713285|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
32713286|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
32713287|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
32713288|NCT04463407|No Intervention|Control group|Participants keep their normal routine without intervention.
33245802|NCT04719156|Other|ICG use followed by SPY-PHI imaging.|Participants will be injected with 2.0mg/kg of ICG dye to access tumor margin using Stryker SPY imaging technology.
33073208|NCT03412877|Experimental|1/iTCR|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin
33245803|NCT00863590|Experimental|A|Panel A
33245804|NCT00863590|Experimental|B|Panel B
33245805|NCT00863590|Experimental|C|Panel C
33245806|NCT00863590|Experimental|D|Panel D
32713289|NCT04463407|Experimental|Experimental group|Participants receive a single nutritional intervention previous to a critical period.
32713290|NCT04463485|Experimental|Delayed Clamping|The intervention group was waited 60 seconds for umbilical cord clamping in the second stage of labor.
32713291|NCT04463485|No Intervention|Early Clamping|No interventions have been assigned.
32713292|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
32713293|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
32713294|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
32713295|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
32713296|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
32713297|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
32713298|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
32713299|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
32713300|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
32713301|NCT04463329|Active Comparator|Group C|conventional two-operator axillary brachial plexus blockage
32713302|NCT04463329|Active Comparator|Group J|axillary brachial plexus block with single operator using Jedi grip
32713303|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
32713304|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
32713305|NCT02333955|Experimental|3 mg IV push|GCS-100
32713306|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
32713307|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
32713308|NCT03509233|Experimental|FMD|Full mouth disinfection
32713309|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
32713310|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
32713311|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
32713312|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
32713313|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
32713314|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
32713315|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
32713316|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
32713317|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
32713318|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
32713319|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
32713320|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
32713321|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
32713322|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
32713323|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
32713324|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
32713325|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
32713326|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
33245807|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
32913581|NCT04806321|Experimental|Project SOLVE|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents solve, rather than be overwhelmed by, everyday problems. The program includes: (1) An introduction to problem solving; (2) Testimonials from valued others (older adolescents; celebrities) describing their use of problem solving skills; (3) Evidence from studies that our brains are capable of problem solving and that problem solving can be helpful; and (4) Activities designed to enable adolescents to practice sequential problem solving using a few steps (SOLVE Steps)."
33073209|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
33245808|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
33245809|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
33245810|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
33245811|NCT00863668|Active Comparator|Efavirenz|
33245812|NCT00863668|Experimental|Raltegravir|
33245813|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
33245814|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
33245815|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
33245816|NCT00735540||A|Acute organic diseases
33245817|NCT00735540||B|Patients with chronic diseases
33245818|NCT00735540||C|Patients with psychiatric diagnosis
33245819|NCT00872248|Experimental|1|Parturients received spinal anesthesia
33245820|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
33245821|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
33245822|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
33245823|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
33245824|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
33245825|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
33245826|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
33245827|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
33245828|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
33245829|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
33245830|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
33245831|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
33245832|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
33245833|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
33245834|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
33245835|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
33245839|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
33245840|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
33245841|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
33245842|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
33245843|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
33245844|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
33245845|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
33245846|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
33245847|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
33245848|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
33245849|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
33245850|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
33245851|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
33245852|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
33245853|NCT00735774|Experimental|11C-ORM-13070|
32913582|NCT04806321|Active Comparator|Project SUCCESS|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from valued others describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives."
32913583|NCT04802031|Experimental|Treatment (isatuximab)|Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a >=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
32913584|NCT04794075|Experimental|Experimental group with the therapeutic education and nursing support program|In addition to the conventional oncology follow-up, patients will participate in an initial educational assessments day.
32913585|NCT04794075|No Intervention|Control group|Patients will have the conventional oncology follow-up.
32913586|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
32713327|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
32713328|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
32713329|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
32713330|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
32913595|NCT05454345|Experimental|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin-containing regimen|Thirteen weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin.
32913596|NCT05454345|Experimental|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin&SMZ/TMP-containing regimen|Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin.
32713331|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
32913597|NCT05454345|Active Comparator|The six-month standard Rifampin&Isoniazid&Pyrazinamide&Ethambutol-containing regimen|Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid.
32713332|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
32713333|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
32713334|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
32713335|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
32713336|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
32713337|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
32713338|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
32713339|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
32713340|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
32713341|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
32913598|NCT05454345|Active Comparator|The four-month Rifapentine&Isoniazid&Pyrazinamide&Moxifloxacin -containing regimen|Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin.
32913599|NCT05454111|Active Comparator|CARTO-Finder-guided ablation plus PVI|Pulmonary vein circumferential isolation + + ablation of sites recognized by CARTO-Finder module as the core of rotors.
32913600|NCT05454111|Experimental|Multiscale entropy-guided ablation plus PVI|Pulmonary vein circumferential isolation + ablation of sites recognized by multiscale entropy analysis as the core of rotors.
32713342|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + LAM561 (during Concurrent phase - duration 6 weeks)*:~LAM561 will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.~* One extra week may be allowed."
33245854|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
32913601|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
32913602|NCT04459611|Experimental|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
32913603|NCT04459611|Experimental|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
32913604|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
32713343|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + LAM561 (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):~LAM561 will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. LAM561 will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.~Both arms will be followed by a 4-week safety follow-up"
32713344|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
32713345|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
32913605|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
32913606|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
33245855|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
32913607|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).~They use the HeartMan system in addition to receiving standard care."
32913608|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
32913609|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
33245856|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
32713346|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
32713347|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
32713348|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
33245857|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
32713349|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
32713350|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
33245858|NCT00736008||A|Patients with thromboembolic events
33245859|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
32713351|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
33245860|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
33245861|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
33245862|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
33245863|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
33245864|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
33245865|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
33245866|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
33245867|NCT00733200|No Intervention|Control group|
33245868|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
33245869|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
33245870|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
33245871|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
33245872|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
33245873|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
33245874|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
32713352|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
32713353|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
32913610|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
33245875|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
32713354|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
33245876|NCT00877552||Control|Typically developing
33245877|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
33245878|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
33245879|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
33245880|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
33245881|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
33245882|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
33245883|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
33245884|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
33245885|NCT00415519|Experimental|1|
33245886|NCT00415519|Placebo Comparator|2|
32713355|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
33245887|NCT05741294|Experimental|Tirbanibulin 2.5 milligrams (mg) ointment|Participants will apply tirbanibulin ointment- topically at a dose of 2.5 mg once daily for 5 consecutive days- on the face or scalp.
32713356|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
32713357|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
32713358|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
32713359|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
32913611|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
32913612|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
32913613|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
32913614|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
32913615|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
33245888|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
32913616|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
33245889|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
33245890|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
33245891|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
33245892|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
33245893|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
33245894|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
33245895|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
33245896|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
33245897|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
33245898|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
33245899|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
33245900|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
33245901|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
33245902|NCT00423943|Experimental|D|modafinil
33245903|NCT00423943|Placebo Comparator|Placebo|placebo
33245904|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
33245905|NCT00877630||2:conventional group|patients underwent open thyroidectomy
33245906|NCT00736346|Active Comparator|1|
33245907|NCT00736346|Active Comparator|2|
33245908|NCT00736346|Active Comparator|3|
33245909|NCT00736346|No Intervention|4|
33245910|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
33245911|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
33245912|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
33245913|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
33245914|NCT00864136||Group 1|
33245915|NCT00864136||Group 2|
33245916|NCT00864136||Group 3|
33245917|NCT05742308|Experimental|Experimental: Laughter yoga|The intervention group received laughter yoga twice a week for three weeks.
33245918|NCT05742308|No Intervention|No Intervention: Control group|The control group did not take part in the laughter yoga program.
33245919|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
33245920|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
33245921|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
33245922|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
32913617|NCT04293393|Active Comparator|Arm A: Doxorubicin plus cyclophosphamide and taxane|"Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.~Approximately duration of 24 weeks (6 months)."
32913618|NCT04293393|Experimental|Arm B: Letrozole plus abemaciclib +/- LHRH|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- luteinizing hormone-releasing hormone (LHRH) analogs in premenopausal women, up to 12 months, in 28-day cycles.
32913619|NCT05453331||Awake MER-guided surgical procedure under local anesthesia with intraoperative testing|Awake micro-electrode recording-guided surgical procedure under local anesthesia with intraoperative testing
32913620|NCT05453331||Asleep MRI-guided and CT-verified surgical procedure|Asleep MRI-guided and CT-verified surgical procedure
32913621|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
32713360|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
32713361|NCT02333565|Experimental|Combinaison everolimus and octreotide|
32713362|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
32913622|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
32913623|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
32913624|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
32913625|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
32913626|NCT05453019|Experimental|tinnitus group|Patients who have tinnitus got cochlear implant
32713363|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
32713364|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
32713365|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
32913627|NCT05453019|Active Comparator|without tinnitus group|Patients who have no tinnitus got cochlear implant
33073210|NCT03406507|Experimental|Ravulizumab|Complement inhibitor treatment-naïve and eculizumab-experienced participants received ravulizumab.
32713366|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
32713367|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
33245923|NCT05742230|Experimental|Henagliflozin 10 mg|Single 10 mg tablet, administered orally once daily for 12 weeks
33245924|NCT05742230|Other|blank control|standard treatment
32713368|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
32713369|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
32713370|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
32713371|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
32713372|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
32713373|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
32713374|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
32713375|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
33073211|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
33073212|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
33073213|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
33245925|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
32913628|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
32913629|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
32913630|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
32713376|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
32913631|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
32913632|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
32913633|NCT04337463|Experimental|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
32913634|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
32913635|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
32913636|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
32913637|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
32913638|NCT05451381|Experimental|Propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group (PR):~continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h"
32913639|NCT05451381|Experimental|Dexmedetomidine group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group Dexmedetomidine (DEX):~continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h"
32913640|NCT05451381|Experimental|Dexmedetomidine and propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h"
32913641|NCT05450913|Other|patients with unilateral hip and leg pain|"Musculoskeletal system examination, neurological examination, visual analog scale (VAS) score and DN4 (Douleur Neuropathique 4 Questions) of patients presenting with unilateral hip and/or leg pain, 3 tests frequently used in the diagnosis of priformis (Freiberg test, Pace sign, FADIR) ) will be applied.~Patients with suspected priformis syndrome will be given an intramuscular injection If the pain intensity decreases by 50% or more after the intramuscular injection, the diagnosis of piriformis will be made."
32713377|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
32713378|NCT02312323|Experimental|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
32713379|NCT02312323|Active Comparator|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
32713380|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
32713381|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
32713382|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
32913642|NCT05446779||Sudden death|Unexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
32913643|NCT05446779||Control|Death because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
33245926|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
32913644|NCT05423301|Experimental|experimental|
33245927|NCT05741138|Experimental|Core strengthening group|Group A would be given the Standard Physical Therapy Treatment along with core strengthening exercises Core strengthening exercises will be carried out in their respective standard positions (can be modified according to patient's comfortability)
33245928|NCT05741138|Sham Comparator|Conventional treatment group|Group B would be given only Standard Physical Therapy treatment.
33245929|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
33245930|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
33245931|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
33245932|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
33245933|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
33245934|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
33245935|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
33245936|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
33245937|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
33245938|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
32913645|NCT05423301|Active Comparator|control|
32913646|NCT05404425|Experimental|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
32913647|NCT05404425|Other|Standard Procedure|Usual management of patients
32913648|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
32913649|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
33245939|NCT03994549|Active Comparator|ZP7570|Single subcutaneous injection
33245940|NCT03994549|Placebo Comparator|Placebo|Single subcutaneous injection
33245941|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
33245942|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
33245943|NCT05225896||DNER ataxia|Patients with well-characterized DNER antibodies.
33245944|NCT02366221||All subjects|Subjects with a history of complex arm trauma
33245945|NCT04645394|Placebo Comparator|Placebo|The participants are receiving 1 dose of each in the stated order.
33245946|NCT04645394|Active Comparator|Fermented aronia high dose|The participants are receiving 1 dose of each in the stated order.
33245947|NCT04645394|Active Comparator|Fermented aronia low dose|The participants are receiving 1 dose of each in the stated order.
33245948|NCT04645394|Active Comparator|Aronia|The participants are receiving 1 dose of each in the stated order.
33245949|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
33245950|NCT00877786|Active Comparator|Face-to-face group therapy|
33245951|NCT00877786|Active Comparator|Online chat group therapy|
33245952|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 20 HIV seropositive individuals"
33245953|NCT01033669||Dry Powder Inhalers|
33245954|NCT00872638|Active Comparator|1|
33245955|NCT00872638|Active Comparator|2|
33245956|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
33245957|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
33245958|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
33245959|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
33245960|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
33245961|NCT00877864|Placebo Comparator|Control|
32713383|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
32713384|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
32713385|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Not Refractory)|
32713386|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Refractory)|
32713387|NCT03801525|Experimental|Phase 2: Treatment Naïve CLL|
32713388|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
32713389|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib (U2)|
32713390|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
32713391|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib (U2)|
32713392|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
32713393|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
32713394|NCT02304601||Comorbid symptoms|
32713395|NCT02304601||No comorbid symptoms|
32713396|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
32713397|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
32713398|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
32713399|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
32713400|NCT03501745|Other|Management Group|
32713401|NCT03501745|Other|control group|
32713402|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
32713403|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
32713404|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
32713405|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
32713406|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
32713407|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
32713408|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
32713409|NCT02039661|Active Comparator|Lidocaine Spray|
32713410|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
32713411|NCT02312479|Experimental|Nyxoah SAT therapy|
32713412|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
32913650|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
32913651|NCT04338477|Experimental|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
32913652|NCT04000737|Experimental|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
32913653|NCT04000737|Active Comparator|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
32913654|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
32913655|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
32913656|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
32913657|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
32913658|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
32913659|NCT03910413|Other|Dual Energy CT|
32913660|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
32913661|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
32913662|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
32913663|NCT04895592|Experimental|Arm A (SRS, low dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
32913664|NCT04895592|Experimental|Arm B (SRS, high dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
32913665|NCT03702777|Experimental|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
32913666|NCT03702777|Placebo Comparator|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
32913667|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
32913668|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
32713413|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
32713414|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
32713415|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
32713416|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection~Other Names:~ADSC, mesenchymal cells, stromal cells"
32713417|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
32913669|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
32913670|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
32913671|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
32743285|NCT04930575|Experimental|Mulligan Technique group|Patient in group A will receive specialized SNAGs technique adapted from Mulligan (2005), in addition to strengthening exercise for DNF muscles and advice to correct position three times per week for 4 weeks.
33245962|NCT00877942||1|Typically developing children drawn from the general population
32713418|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
33245963|NCT00877942||2|Children with Turner Syndrome
33245964|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
33245965|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
33245966|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
32713419|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
32713420|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
33245967|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
32713421|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
32713422|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
33245968|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
33245969|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
32913672|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
33245970|NCT05740904|Experimental|New defocus spectacle lens|The children in the experimental group will wear new defocus spectacle lens and receive follow-up examinations every half year.
33245971|NCT05740904|Active Comparator|Conventional aspheric single-vision spectacle lenses|The children in the control group will wear conventional aspheric single-vision spectacles and receive follow-up examinations every half year.
33245972|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
33245973|NCT00872716|Placebo Comparator|Placebo|
33245974|NCT05740826||Study group|People with temporomandibular disorder which was determined based on one of the following factors observed during the examination: acoustic symptoms, present temporomandibular joint pain, problems with opening the mouth, deviation of the jaw during abduction, or reported locking of the jaw.
33245975|NCT05740826||Control group|People without temporomandibular disorder.
33245976|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
33245977|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
33245978|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
33245979|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
33245980|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
32713423|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
32765011|NCT04944173|Experimental|MRD Positive, consolidation durvalumab|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to eight additional cycles of durvalumab
33245981|NCT04064138|Active Comparator|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
33245982|NCT04064138|Active Comparator|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
33245983|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
33245984|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
33245985|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
33245986|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
33245987|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
33245988|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
33245989|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
33245990|NCT05741996|Experimental|Effetcs of Taping type and Orthosis on Pain,|The order of the elastic taping, rigid taping, and braces was randomized using a computer-generated random sequence created before the research (Random.org). Both knees of each participant were taped and braced. The participants were allowed to become accustomed to the applied elastic taping, rigid taping, and braces before the gait analysis and evaluations. All the taping techniques and braces were similar for all the participants. The participants performed four evaluation condition trials at baseline and with the elastic taping, rigid taping, and braces after 45 minutes.
33245991|NCT05741996|Experimental|Effetcs of Taping type and Orthosis on Gait and functionality|"The Western Ontario and McMaster Universities Turkish Version 3.1 (WOMAC) index is a self-administered questionnaire that assesses three aspects of a patient's health status -pain, stiffness, and physical function - in those with lower limb Osteoarthritis.~Gait analysis was conducted using a 3-dimensional VICON gait analysis system (Workstation Version 4.0, Oxford, UK). Each participant was assessed four times before and after the applications."
33245992|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
33245993|NCT00878176|Experimental|1|(Crossover study)
33245994|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
33245995|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
33245996|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
33245997|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
33245998|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
33245999|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
32713424|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
32713425|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
32713426|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
32913673|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
32913674|NCT05374473|Experimental|Intervention|Intervention-tailored program with information regarding modifiable lifestyle related risk factors implicated in disease progression.
32913675|NCT05374473|Other|Standard-care|containing general health information sourced from standard MS websites.
32913676|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
33246000|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
33246001|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
33246002|NCT03743662|Experimental|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
33246003|NCT03743662|Experimental|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
33246004|NCT00710762|Experimental|BIBF1120|
33246005|NCT00710762|Placebo Comparator|Placebo|
33246006|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
33246007|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
33246008|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
33246009|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
33246010|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
33246011|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
33246012|NCT00573430|Experimental|1|Candesartan Cilexetil
33246013|NCT00573430|Experimental|2|Candesartan Cilexetil
32913677|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
32913678|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
33246014|NCT00573430|Experimental|3|Candesartan Cilexetil
33246015|NCT00711516|Experimental|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
32913679|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
33246016|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
32913680|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
33246017|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
33246018|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
33246019|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
33246020|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
33246021|NCT05740748|Experimental|Tezepelumab|tezepelumab 210 mg sc q4wks 20 weeks treatment
33246022|NCT05740748|Placebo Comparator|Placebo|placebo sc q4wks 20 weeks treatment
33246023|NCT00873028|Experimental|1|
33246024|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
33246025|NCT03900338||PWV>10|Patients with PWV > 10 (SSphygmoCor) in two different measurements
32913681|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
32713427|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
32713428|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
32713429|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
32713430|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
32713431|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
32713432|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
32713433|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
32713434|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
32713435|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
32713436|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
32713437|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
32713438|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
32713439|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
32713440|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
32713441|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
32713442|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
32713443|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
32713444|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
32713445|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
32713446|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
32713447|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
32713448|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
32713449|NCT02333175|No Intervention|Care as usual|Care as usual
32713450|NCT04463173|Experimental|High fat food oral administration|Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
32713451|NCT04463173|Experimental|Fasting oral administration|Anaprazole 40mg, single dose, oral administration before breakfast.
32713452|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
32713453|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
32713454|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
32713455|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
32713456|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
32713457|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
32713458|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
33246026|NCT03900338||PWV<10|Patients with PWV < 10 (SphygmoCor) in two different measurements
32713459|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
32713460|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
32713461|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
32713462|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
32713463|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
32713464|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
32713465|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
32713466|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
32713467|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
32713468|NCT03144531|Experimental|SKIP Intervention|
32713469|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
32713470|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
32713471|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
32713472|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
32713473|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
32713474|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
32713475|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
32713476|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
32713477|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
32713478|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
32713479|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
32713480|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
32713481|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
32713482|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
32713483|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~every 28 days until progression of disease or toxicity"
32713484|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
32713485|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
32713486|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
32713487|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
32713488|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
32713489|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
32713490|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
32713491|NCT02305147||Controls|Healthy controls: N=50
32713492|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
32713493|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
32713494|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
32713495|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
32713496|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
32713497|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
32913682|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
33246027|NCT04039516|Experimental|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
32713498|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
33246028|NCT04039516|No Intervention|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
33399730|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
32713499|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
32713500|NCT02313259||Age-matched controls|15 drivers without ocular disease.
32713501|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
32713502|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
32713503|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
32713504|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
32713505|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
32713506|NCT02317471|Other|control group|Oxaliplatin+S-1
32713507|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
32713508|NCT02332551|No Intervention|Control|
32713509|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
32713510|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
32713511|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
32713512|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
32713513|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
32713514|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
32713515|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
32713516|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
32713517|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
32713518|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
32713519|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
32713520|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
32713521|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
32713522|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
32713523|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
32713524|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
32713525|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
32713526|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
32713527|NCT02305303|Experimental|Diary|Use of diary
32713528|NCT02305303|No Intervention|Without Diary|
33399731|NCT05683015|Experimental|Standard of care - tildrakizumab|Patients will continue to receive tildrakizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (100mg)
32713529|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
32713530|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
32713531|NCT04463563|Active Comparator|NIRS group. Brain oxygen saturations group.|A monitor by means of non-invasive stickers will display cerebral oximetry (brain oxygen saturations) throughout the heart surgery.This gives a direct reading of brain frontal lobe oxygen levels. The baseline is recorded before the patient goes to sleep (anaesthetised) and throughout the surgery and time on cardiopulmonary bypass if the brain oxygen levels fall below baseline then various physiological changes are made to restore oxygen to baseline.
32713532|NCT04463563|No Intervention|Standard Patient Monitoring|No cerebral monitoring. Standard patient monitoring according to normal practice at Castle Hill Hospital apply.
32713533|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
32713534|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
32713535|NCT04463017|Active Comparator|Active Treatment: HU6|Planned doses of HU6; N = 74
32713536|NCT04463017|Placebo Comparator|Placebo Comparator|Non-active study drug N = 14
32713537|NCT05078073|Experimental|aGVHD-HBOT|Patients after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
32713538|NCT05078073|No Intervention|aGVHD-HBOT free|Patients after allo-HSCT will NOT receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
32713539|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
32713540|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
32713541|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
32713542|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
32713543|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
32713544|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
32713545|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
32713546|NCT03502993||MOFICHE|This is an observational study assessing the management and outcome of children presenting to Emergency Departments (ED) with fever across Europe. This study will use large departmental datasets to collect information on at least 50,000 febrile episodes . This study will use large-scale, pseudo-anonymized departmental data, and will not involve consented patient recruitment; nor will it use patient samples. Data included in MOFICHE will be based on that collected as part of routine clinical care. Antibiotic prescription, hospitalisation and number/type of investigations, re-attendance at ED within 5 days of the first hospital presentation will be recorded.
32713547|NCT03502993||BIVA studies|A minimum of 3,000 children will be recruited to the BIVA-ED study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
32713548|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
32713549|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
32713550|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
32713551|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
32713552|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
32713553|NCT03332797|Experimental|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
32913683|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
32913684|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
32913685|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
32913686|NCT04337853|Experimental|Intervention group|N=6
32913687|NCT04337853|Active Comparator|Control group|N=7
32713554|NCT03332797|Experimental|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
32713555|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
32713556|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
32713557|NCT03332797|Experimental|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
32713558|NCT03332797|Experimental|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
32713559|NCT03332797|Experimental|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
32713560|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
32713561|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
32713562|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
32713563|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
32713564|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
32713565|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
32713566|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
32713567|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
32713568|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
32713569|NCT02313493|No Intervention|Care as usual control group|
32713570|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
32713571|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
32713572|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
32913688|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
33399732|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
33246029|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
33246030|NCT05741684|Experimental|iCBT and ABM|A combined internet-delivered Cognitive Behavioral Therapy (iCBT) and Attention Bias Modification (ABM) intervention to reduce depressive symptoms in firefighters.
33246031|NCT05741684|No Intervention|Control|No intervention
33246032|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 200 mg|Capsules containing sodium pentaborate pentahydrate 200 mg
33246033|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 400 mg|Capsules containing sodium pentaborate pentahydrate 400 mg
33246034|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 600 mg|Capsules containing sodium pentaborate pentahydrate 600 mg
33246035|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 800 mg|Capsules containing sodium pentaborate pentahydrate 800 mg
33246036|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 1000 mg|Capsules containing sodium pentaborate pentahydrate 1000 mg
33246037|NCT05741606|Placebo Comparator|Placebo capsules|
32713573|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
33246038|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
33246039|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
33246040|NCT00186888|Other|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
32713574|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
32713575|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
32713576|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
32713577|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
32713578|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
32713579|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
32713580|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Electroencephalography~MRI"
32713581|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
32713582|NCT02318017|Placebo Comparator|Placebo|Placebo - once
32713583|NCT02313727|Active Comparator|pamidronate|pamidronate
32713584|NCT02313727|Placebo Comparator|placebo|placebo
32713585|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
32713586|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
32713587|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
32713588|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
32713589|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
32713590|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
32713591|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
32713592|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
32713593|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
32713594|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
32713595|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
32713596|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
32713597|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
32713598|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
32713599|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
32713600|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
32713601|NCT02305927|Placebo Comparator|Placebo|
32713602|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
32713603|NCT02318407|Placebo Comparator|Placebo|No active drug
32713604|NCT03500575|Experimental|photopheresis|
32713605|NCT03500575|No Intervention|control|
33399733|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
33399734|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
32713606|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
32713607|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
32713608|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
33399735|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
32713609|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
32713610|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
32713611|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
32713612|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
32713613|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
32713614|NCT02314273|No Intervention|control group|control group
32713615|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
32713616|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
32713617|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
32713618|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
32713619|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
32713620|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
32713621|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
32713622|NCT04464031|Experimental|Alert group|
32713623|NCT04464031|No Intervention|Control group|
32713624|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
32713625|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
32713626|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
32713627|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
32713628|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
32713629|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
32713630|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
32713631|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
32713632|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
32713633|NCT03508375|Experimental|SSc without ILD|
32713634|NCT03508375|Experimental|SSc with ILD|
32713635|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
32713636|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
32713637|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
32713638|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
32713639|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
32713640|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
32713641|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
32713642|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
32713643|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
32913689|NCT03465111|Experimental|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
33246041|NCT00186888|Other|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular carboplatin is also given three times, depending on whether they respond to window. External Beam Radiation 44-46 Gy administered using standard practices."
33399736|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
33399737|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
32713644|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
32713645|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
32713646|NCT04462939|Experimental|Healthy lactating women - Supplement|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
32713647|NCT04462939|Placebo Comparator|Healthy lactating women - Placebo|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
32713648|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
32713649|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
32713650|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
32713651|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
32713652|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
32713653|NCT02306239|Experimental|terlipressin|patients received terlipressin
32713654|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
32713655|NCT02319187|Active Comparator|Arm A|S1
32713656|NCT02319187|Experimental|Arm B|S1 and irinotecan
32713657|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
32713658|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
32713659|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
32713660|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
32713661|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
32713662|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
32713663|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
32713664|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
32713665|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
32713666|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
32713667|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
32713668|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
32713669|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
32713670|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
32713671|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
32713672|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
32713673|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
32713674|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
32713675|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
32713676|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
32713677|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
32713678|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
32713679|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
33399738|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
32713680|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
32713681|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
32713682|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
32713683|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
32713684|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
32713685|NCT02320747|No Intervention|Control Group|
32713686|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
32713687|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
32713688|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
32713689|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):~Gefitinib 250 mg daily from day 1 to day 21"
32713690|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
32713691|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
32713692|NCT04462783|Experimental|Patient's symptom data without pulse oximeter|Some patients may not be given a pulse oximeter to enter heart rate and O2 saturation into the CovidX application.
32713693|NCT04462783|Experimental|Patient's symptom data with a pulse oximeter|Some patients will be given (or may have) a pulse oximeter in order to enter heart rate and O2 saturation data into the CovidX application.
32713694|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
32713695|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
32713696|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
32713697|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
32713698|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
32713699|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
32713700|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
32713701|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
32713702|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
32713703|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
32713704|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
32713705|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
32713706|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
32713707|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
32713708|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
32765012|NCT04960319|Experimental|Intravascular Lithotripsy|Study Device Treatment: IVL balloon catheter size is chosen in a 1:1 ratio to the distal reference vessel diameter. If the IVL balloon cannot be delivered into the target lesion a Guide catheter extension is recommended. The balloon catheter is then inflated to 4 ATM and 10 impulses are delivered. The balloon is then inflated to 6 ATM and deflated to reestablish blood flow. Up to 80 impulses can subsequently be delivered and the balloon can be repositioned within the lesion. In multiple lesions with different reference vessel diameters different sizes of IVL balloon can be used.
32713709|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
32713710|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
32713711|NCT03499171|Experimental|Citalopram|20mg, once a day
32713712|NCT03499171|Placebo Comparator|Placebo|Once a day
32713713|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
32713714|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32713715|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
32713716|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
32713717|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
32713718|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
32713719|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
32713720|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
32713721|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
32713722|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
32713723|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
32713724|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
32713725|NCT04461613|Experimental|Group 1|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 1 will receive an original International Physical Activity Questionnaire short form (IPAQ-sf). Group 1 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 1 will be asked to fill a revised version of IPAQ-sf to describe physical activities in the last 7 days."
32713726|NCT04461613|Experimental|Group 2|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 2 will receive a revised version of International Physical Activity Questionnaire short form (IPAQ-sf). Group 2 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 2 will be asked to fill an original IPAQ-sf to describe physical activities in the last 7 days."
32713727|NCT04461769|Experimental|Slow Oscillation Synchronization with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
32713728|NCT04461769|Sham Comparator|Sham Control|No current delivered.
32713729|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
32713730|NCT02324413|Placebo Comparator|Placebo|
32713731|NCT03498703|Experimental|Azathioprine|
32713732|NCT03498703|Placebo Comparator|Control|
32713733|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
32743286|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~ABG or CBG to be obtained at 4 hrs. post extubation~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
32713734|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
32713735|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
32713736|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
32713737|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
32713738|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
32713739|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
32713740|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
32713741|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
33399739|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
32713742|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
32713743|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
32713744|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
32713745|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
32713746|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
32713747|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
32713748|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
32713749|NCT02320357|Experimental|Clopidogrel|
32713750|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
32713751|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
32713752|NCT03498235|Experimental|Team Sevoflurane|
32713753|NCT03498235|Experimental|Team Propofol|
32713754|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
32713755|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
32713756|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
32713757|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
32713758|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
32713759|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
32713760|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
32713761|NCT03498157|No Intervention|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
32713762|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
32713763|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
32713764|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
33399740|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
32713765|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
32713766|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
32713767|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
32713768|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
32713769|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
32713770|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
32713771|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
32713772|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
32713773|NCT02320669|Placebo Comparator|Placebo|Placebo Control
32713774|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
32713775|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
32713776|NCT02325271||Control group|Subjects with normal glucose tolerance
32713777|NCT02325271||Diabetes group|Patients with type 2 diabetes
32713778|NCT05129917|Placebo Comparator|Placebo|consume 1 sachet per day for 14 day
32713779|NCT05129917|Experimental|Gojinsen® drinks|consume 1 sachet per day for 14 day
32713780|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
32713781|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
32713782|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
32713783|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
32713784|NCT05043805|Active Comparator|Dextromethorphan|add on therapy
32713785|NCT05043805|Placebo Comparator|placebo|add on therapy
32713786|NCT04789213||Patients with Living Donor Liver Transplantation|
32713787|NCT04789213||Patients with Deceased Donor Liver Transplantation|
32713788|NCT04774003|Experimental|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
32713789|NCT04774003|Experimental|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
32713790|NCT04774003|Placebo Comparator|Placebo|Placebo x 1 dose (n=10) at Day 1
32713791|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
32713792|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
32713793|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
32713794|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
32713795|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
32713796|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
32713797|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
32713798|NCT04706221|Experimental|Blood Volume Monitoring|
32713799|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
32713800|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
32713801|NCT04635943|Active Comparator|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
32713802|NCT04635943|Placebo Comparator|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
33246042|NCT00186888|Other|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
33246043|NCT04039594||ECMO|
33246044|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
32713803|NCT04398355|No Intervention|control|basic treatment+Swallowing rehabilitation training
32713804|NCT04398355|Experimental|Combination treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
33246045|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
33246046|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
33246047|NCT05127538|Active Comparator|Individuals diagnosed with neuropathic pain due to type 2 diabetes|"Individuals between the ages of 40-65~Individuals who take 4 points or more from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points or more from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
33246048|NCT05127538|Active Comparator|Individuals with type 2 diabetes but no neuropathic pain|"Individuals between the ages of 40-65~Individuals who take 4 points from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
32913690|NCT03465111|Experimental|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
32913691|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
32913692|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
32913693|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
32913694|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
33246049|NCT05127538|Active Comparator|Healthy control group|"Individuals between the ages of 40-65~Individuals who have no pain (Taking 1 point or less according to the Visual Pain Scale)"
32713805|NCT04398355|Experimental|Liu-Zi-Jue treatment|basic treatment+Swallowing rehabilitation training+Liu-Zi-Jue
32713806|NCT04398355|Experimental|acupuncture treatment|basic treatment+Swallowing rehabilitation training+acupuncture
32713807|NCT04344535|Active Comparator|Convalescent Donor Plasma|
32713808|NCT04344535|Placebo Comparator|Standard Donor Plasma|
32713809|NCT04292275|Experimental|Digital Health Tools + Standard of Care|
32713810|NCT04292275|Other|Standard of Care|
32713811|NCT04461847|Experimental|patients underwent ESM|
32913695|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
32913696|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
33246050|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
33246051|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
33246052|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
33246053|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
33246054|NCT05111782|Experimental|Treatment Group|The treatment group will consist of persons with low back pain. This group will be further divided into groups for each decade.
33246055|NCT05111782|No Intervention|Healthy Control Group|The control group will consist of healthy controls. This group will be further divided into groups for each decade.
33399741|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
32713812|NCT04461847|Active Comparator|patients underwent SM|
32713813|NCT04461925|Experimental|Experimental group|"On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day 1, Day 4, Day 7."
32713814|NCT04461925|Active Comparator|Control Group|Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies
32713815|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
32713816|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
32713817|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
32713818|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
32713819|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
32713820|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)~Tyrosine Kinase Inhibitors:~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
33399742|NCT05666453|Experimental|Treatment group|LIV-GAMMA SN Inj. administration after ABO-incompatible liver transplantation
32713821|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
32713822|NCT04462549|Experimental|Resource Facilitation|This group is receiving Resource Facilitation
32713823|NCT04462549|No Intervention|Control|Not receiving Resource Facilitation
32713824|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
32713825|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
32713826|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
32713827|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
32713828|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
32713829|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
32713830|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
32713831|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
32713832|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
32713833|NCT02321371|Active Comparator|Lactulose therapy|
32713834|NCT04002037|Active Comparator|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
32713835|NCT04002037|Active Comparator|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
32713836|NCT04002037|Active Comparator|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
32713837|NCT03931681|Experimental|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
32713838|NCT05144425|Active Comparator|group A|underwent TKA with using pneumatic tourniquet
32713839|NCT05144425|Placebo Comparator|group B|underwent TKA without using pneumatic tourniquet
32713840|NCT05143879|Placebo Comparator|Placebo|8 subjects took 3 g/kg/day of placebo during 9 weeks
32713841|NCT05143879|Active Comparator|Nitrate|8 subjects took 3 g/kg/day of nitrate during 9 weeks
32713842|NCT05143879|Active Comparator|Citrulline|8 subjects took 3 g/kg/day of citrulline during 9 weeks
32713843|NCT05143879|Active Comparator|Nitrate plus Citrulline|8 subjects took 3 g/kg/day of nitrate plus citrulline during 9 weeks
32713844|NCT05143411|Experimental|Use of mobile application|Single arm: At the first time, the researcher will collect all glycemic levels before using the mobile application. Then, all the participants will receive the mobile application to select their main meals, breakfast, lunch, and dinner. Then, the application must calculate the insulin bolus according to their initial profile and the food before being eaten.
32713845|NCT04462237|Experimental|collagen matrix + platelet-derived growth factor|Root coverage procedure using collagen matrix + platelet-derived growth factor for the treatment of multiple adjacent gingival recessions
32713846|NCT04462237|Active Comparator|collagen matrix alone|Root coverage procedure using collagen matrix alone (without the use of the platelet-derived growth factor) for the treatment of multiple adjacent gingival recessions
32713847|NCT05129839|Experimental|Lightened and Musical Baby Mobile Group|The children in the study group were applied a lightened and musical baby mobile before sleeping at night.
32713848|NCT05129839|No Intervention|Control Group|The children in the control group were not given lightened and musical baby mobile, and their routine sleep patterns were continued.
33399743|NCT05666453|Other|Comparator group|No administration after ABO-incompatible liver transplantation
32713849|NCT05129761||• Patient with a clinical history of cough|Syrup Hydryllin ( Syrup Hydryllin & Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan & Diphenhydramine) in the symptomatic management of cough in routine practice by physicians. Subjects will be observed for overall safety and effectiveness of study drug from visit 1 (baseline visit, screening, and start of treatment), to visit 2 (Week 1-2, end of treatment) in the routine practice.
32713850|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
32713851|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
32713852|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
32713853|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
32713854|NCT03493399|Experimental|Problem Gamblers|Interference
32713855|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
32713856|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
32713857|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
32713858|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
32713859|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
32713860|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
32713861|NCT03546829|Experimental|Arm 1 - Experimental|
32713862|NCT03546829|Active Comparator|Arm 2 - Control Arm|
32713863|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
32713864|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
32713865|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
32713866|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
32713867|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
32713868|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
32713869|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
32713870|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
32713871|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
32713872|NCT03493243||Adolescents exposed|Only clinical questionnaires
32713873|NCT05118685|Active Comparator|the first group estrogen group|they will receive estrogen conjugate vaginal cream one tube every night for 14 nights; then, one tube 2 nights in 1 week (two tubes every week) for 10 weeks.
32713874|NCT05118685|Experimental|the second group PRP group|they will receive a Platelet-rich plasma injection every 3 weeks for 4 times. PRP will be administered to the anterior vaginal wall using 27-G needles o and it is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
32713875|NCT05046847|Experimental|TQB3811|The initial dose is 2.5mg, once a day (QD), and the medication stage is divided into single administration and continuous administration. The single administration is given once a day, and the continuous administration is entered 4 days after drug withdrawal. The drug is administered continuously until the disease progresses.
32713876|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
32713877|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
32713878|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
32713879|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
32713880|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
32713881|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
32713882|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
32713883|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
32713884|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
32713885|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
32713886|NCT03173521|Experimental|open label|"Adeno-associated viral vector serotype 8 with liver-specific thyroxine-binding globulin (TBG) promoter driving the expression of the human ARSB gene diluted in its final formulation medium [Drug product (DP) diluted in 0.9% saline solution and 0.25% of human serum albumin].~Four dose levels are available:~'Starting dose' is 6x1011 gc of vector per kg of body weight.~'High dose' is 2x1012 gc of vector per kg of body weight.~'Very high dose' is 6x1012 gc of vector per kg of body weight.~'Low dose' is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein (e.g. median cubital vein) over 2-4 hours using an infusion pump. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
32713887|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
32713888|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
32713889|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
32713890|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
32713891|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
32713892|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
32713893|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
32713894|NCT04881955|Experimental|[14C]-Ecopipam|Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl
32713895|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
32713896|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
32713897|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
32713898|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
32713899|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
32713900|NCT02740231|Active Comparator|Reference product|Hylan G-F 20
32713901|NCT02740231|Experimental|JTA-004 50 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
32713902|NCT02740231|Experimental|JTA-004 50 (4 ml)|Sodium hyaluronate, plasma proteins and clonidine
32713903|NCT02740231|Experimental|JTA-004 100 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
32713904|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
32713905|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
32713906|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
32713907|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
32713908|NCT04715191|Experimental|CARE T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 plus IL21 (CARE T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
32713909|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
32913697|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
32913698|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
32913699|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
32913700|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
32713910|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg~days 57-70 no drug will be given"
32913701|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
32913702|NCT03418389||Pediatric-onset Hypophosphatasia|
32713911|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
32913703|NCT01557452|Experimental|Givinostat|Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
32913704|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
32913705|NCT05298657||Poor IVF Treatment Responders|
32913706|NCT05298657||Hyper IVF Treatment Responders|
32913707|NCT05298657||Normal responders/ Control group|
32913708|NCT05283837|Experimental|Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)|Pertuzumab (ZRC-3277) will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
32913709|NCT05283837|Active Comparator|Pertuzumab (Perjeta®, a product of Genentech, Inc.,)|Perjeta® will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
32913710|NCT05276739|Experimental|Bright light|Participants will receive a 6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake). Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
32913711|NCT05276739|Experimental|Time-restricted eating|Participants will consume 4 identical meals, as in the other groups, except that the meal window will be restricted to 6.5 hours instead of 12 hours (meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
32913712|NCT05276739|Sham Comparator|Control|Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
32913713|NCT01440920|Experimental|Cohort 1|0.3 mg
32913714|NCT01440920|Experimental|Cohort 2|1 mg
32913715|NCT01440920|Experimental|Cohort 3|3 mg
32913716|NCT05261685|Experimental|Hyperopic patients planned to undergo single-step transepithelial PRK|Patients with moderate hyperopia or hyperopic astigmatism were planned to undergo transepithelial PRK using the new single-step StreamLight PRK Technology.
32913717|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
33246056|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
32713912|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
32713913|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
32713914|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
32713915|NCT04674241|Active Comparator|DEX group|The DEX group will receives dexmedetomidine intraoperative.
32713916|NCT04674241|Placebo Comparator|Placebo group|The placebo group will receives 0.9% saline intraoperative.
32713917|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
32713918|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
32713919|NCT04650295|Experimental|Household Remedy|
32713920|NCT04650295|Placebo Comparator|Tap Water|
32713921|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
32713922|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
32713923|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
32713924|NCT04495127|Experimental|Selumetinib|
32713925|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
32713926|NCT03889561|No Intervention|Control|SSB taxes
32713927|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
32713928|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
32713929|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
32713930|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713931|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713932|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713933|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713934|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713935|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
32713936|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
32713937|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
32713938|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
32713939|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
32713940|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
32713941|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
32743287|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~ABG or CBG to be obtained at 4 hrs. post extubation~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
32743288|NCT04957251|Experimental|Anterior approach|Patient's undergoing an anterior approach to the hip
32743289|NCT04957251|Active Comparator|Posterior Approach|Patient's undergoing an posterior approach to the hip
32913718|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
33246057|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
32713942|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
32713943|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
32713944|NCT04392869|Experimental|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
32713945|NCT04392869|Experimental|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
32713946|NCT04392869|No Intervention|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
32713947|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
32713948|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
32713949|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
32713950|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
32713951|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
32713952|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
32713953|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
32713954|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
32713955|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
32713956|NCT02235467|No Intervention|ABA parent training control|
32713957|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
32713958|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
32713959|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
32713960|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
32713961|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
32713962|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
32713963|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
32713964|NCT02235779|Other|Cryobiopsy|
32713965|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
32713966|NCT01388491|Experimental|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel [DSG]/20 mcg ethinyl estradiol [EE]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
32713967|NCT01388491|Active Comparator|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
32713968|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
32713969|NCT02236091||Inpatients|
32713970|NCT02236169|Experimental|Ipratropium bromide|
32713971|NCT02236169|Active Comparator|ATROVENT|
33246058|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
32713972|NCT01352533|Active Comparator|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
32713973|NCT01352533|Experimental|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
32713974|NCT01352533|Experimental|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
32713975|NCT03961061|Active Comparator|Brenner FIT (Standard Care)|Adolescents will participate in Brenner Families in Training along with their caregiver. They will receive all components of standard Brenner FIT treatments.
32713976|NCT03961061|Experimental|Brenner mFIT (standard care plus mobile health components)|"Adolescents will participate in Brenner Families in Training along with their caregiver.~Brenner mFIT (Families in Training + mobile health) includes all components of the standard Brenner FIT"
32713977|NCT05101057||Treated|Patients who underwent ACDF surgery and who received post surgical therapy with the SpinalogicTM Non-Invasive Bone Graft Stimulation Device.
32713978|NCT05101057||Control|Patients who underwent ACDF surgery and did not receive post surgical Bone Graft Stimulation.
32713979|NCT05099029|Experimental|EV71 Vaccine|
32713980|NCT05099029|Placebo Comparator|Placebo|
32713981|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
32713982|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
32713983|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
32713984|NCT03492697|Experimental|PF-06882961|
32713985|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
32713986|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
32713987|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
32713988|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
32713989|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
32713990|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
32713991|NCT03755219||StdPPM|"Standard pure polypropylene mesh.~Standard is defined in SHR by weight ≥ 50 g/square meter."
32713992|NCT03755219||LWM|"Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh.~The study uses SHR's classification of light-weight = <50 g/square meter."
32713993|NCT03755219||Tacks, metal|Metal staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
32713994|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
32713995|NCT03755219||Tacks, uncategorized|"Staples or tacks were in SHR 2005-2011 not further categorized.~This category also includes staples/tacks registered from 2012 and forth, not being specified as either metal or absorbable."
32713996|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
32713997|NCT03755219||Non-fixation|Mesh is deployed without fixation
32713998|NCT03755219||3D Mesh|Mesh categorized by anatomical shaped, rather than material or weight. Therefore, this category will be excluded in the original study. Depending on the volume of casess found, the 3D mesh category may eventually be analyzed separately in another study..
32713999|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
32714000|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
32714001|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
32714002|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
32714003|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
32714004|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
32714005|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
32714006|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
32714007|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
32714008|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
32714009|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
32714010|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
32714011|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
32714012|NCT04939363|Experimental|combination of Ibrutinib, Venetoclax and Obinutuzumab|"Obinutuzumab intravenous infusion:~Cycles 1: Day 1: Obinutuzumab 100 mg Day 1 (or 2): Obinutuzumab 900 mg Day 8: Obinutuzumab 1000 mg Day 15: Obinutuzumab 1000 mg Cycles 2-6: Day 1: Obinutuzumab 1000 mg The first infusion of Obinutuzumab may be administered at the full dose (1000 mg) on day 1 of cycle 1, if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100 mg infusion on day 1 is not well tolerated, the remaining 900 mg of the first dose should be administered on day 2.~Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~Venetoclax with an accelerated ramp-up and close inpatient TLS monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:~Cycle 1: Day 15: Venetoclax 20 mg Days 16-17: Venetoclax 50 mg Days 18-21: Venetoclax 100 mg Days: 22-28: Venetoclax 200 mg Cycles 2-12: Days 1-28: Venetoclax 400 mg"
32714013|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
32714014|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
32714015|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
32714016|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
32714017|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
32714018|NCT02236325|Experimental|DBT Brief Suicide Intervention|
32714019|NCT02236325|Active Comparator|Relaxation Training|
32714020|NCT03489733|Experimental|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
32714021|NCT03489733|Experimental|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
32714022|NCT03489733|No Intervention|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
32714023|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
32714024|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
32714025|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
32714026|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
32714027|NCT03253393|Experimental|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging
32714028|NCT03253393|Experimental|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging
32714029|NCT03253393|Experimental|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch
32714030|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
32714031|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
32714032|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
32714033|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
32714034|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
32714035|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
32714036|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
32714037|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
32913719|NCT05251389|Experimental|A: FMT from an ICI non-responding donor|Patients will receive FMT from an ICI non-responding donor (defined as ≥20% increase according to RECIST 1.1 criteria within the past 3 months). Patients will continue their anti-PD-1 treatment.
32913720|NCT05251389|Experimental|B: FMT from an ICI responding donor|Patients will receive FMT from an ICI responding donor (defined as ≥30% decrease or disappearance of all lesions according to RECIST 1.1 criteria within the past 24 months). Patients will continue their anti-PD-1 treatment.
32913721|NCT00371709|Experimental|Arm 1|
32913722|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
32913723|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
32913724|NCT05244993|Experimental|AK105+Anlotinib Hydrochloride+Albumin Paclitaxel|AK105 200mg IV Day 1 Anlotinib Hydrochloride 12mg PO once daily on Days 1-14 Albumin paclitaxel 125mg/m2 IV Days 1, 8 Cycled every 21 days until disease progression, death or toxicity is intolerable (for subjects who can continue to tolerate the treatment, albumin paclitaxel lasts for at least 6 cycles)
32913725|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
32913726|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
32913727|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
32913728|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
32913729|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
32913730|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
32913731|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
32913732|NCT03181971|Experimental|Water Access and Promotion|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
32913733|NCT03181971|No Intervention|Control|Usual care.
32913734|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
33246059|NCT04039282|Other|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
33246060|NCT04039282|Other|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
33246061|NCT05740670|Experimental|Dr. Kellyann's Bone Broth|During the bone broth phases, each week will be separated into 'fasting days' and 'feeding days'. There will be 2 non-consecutive fasting days and 5 feeding days per week. On fasting days, participants will be instructed to consume 1 packet of bone broth every 2 hours, for a total of 7 packets/day. On feeding days, participants will consume 3 meals/day, made up of 'Yes' foods portioned according to instructions provided in the Bone Broth Diet Quick Reference Guide and 1 packet of bone broth, twice a day, as snacks between meals. If a bone broth serving is missed participants are instructed to consume the serving as soon as they remember. Participants will be advised not to exceed 7servings of bone broth on fasting days and 2 servings on feeding days. During the maintenance phase, participants will not consume any bone broth.
33246062|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
32714038|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every 2 weeks for a maximum of 12 cycles~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
32913735|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
33246063|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
32913736|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
32913737|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
32913738|NCT05132439|Experimental|Metformin ER 1000mg|daily by mouth
32913739|NCT05132439|Placebo Comparator|Matching placebo|daily by mouth
32913740|NCT05107167|Experimental|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve.
33246064|NCT00878566|Active Comparator|Usual Care|
33246065|NCT00878566|Experimental|Enhanced pharmacist care|
33246066|NCT04065282|Experimental|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
33246067|NCT00873262|Active Comparator|Hormones|
33246068|NCT00873262|Placebo Comparator|Solvent|
33246069|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
33246070|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
33246071|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
33246072|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
32714039|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.~Folinic acid, 5-FU, Bevacizumab~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
32714040|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice~Administration until progression occurs in the third line or unacceptable toxicity"
32913741|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
32913742|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
32913743|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
32913744|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
32913745|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
32913746|NCT01559948|Experimental|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
32913747|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
32913748|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
32913749|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
32913750|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
32714041|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity~or depending on the patient's general condition and the study physician's decision~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
32714042|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
32714043|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
32714044|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
32714045|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
32714046|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
32714047|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
32714048|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
32714049|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
32714050|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
32714051|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
32714052|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
32714053|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
32714054|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
32714055|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
32714056|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
32714057|NCT02262065||Controls|Patients with well tolerated arthroplasties
32714058|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
33246073|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
32714059|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
32913751|NCT05085171|Experimental|intervention(Enhanced package of care) Arm|The patients with advanced HIV disease that receive HIV care at the intervention clinics will receive the enhanced intervention package which will include: point of care CD4 testing with visitect, screening for TB and cryptococcal meningitis using Fujifilm LAM and semiquantitative crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for one month. Those with a high crAg titers will receive treatment for CNS cryptococcal disease.
32913752|NCT05085171|No Intervention|Standard of care Arm|The patients with advanced HIV disease that receive HIV care at the standard of care clinics will receive the usual routine HIV care as per the Uganda national guidelines. That is CD4 testing with flowcytometry or other CD4 testing modalities available, screening for TB and cryptococcal meningitis using Alere LAM and crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for 3-6 month. Treatment of all asymptomatic crAG positives with fluconazole as per guidelines.
32913753|NCT05083845|Active Comparator|Erector Spinae Plane Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area.
32913754|NCT05083845|Active Comparator|Erector Spinae Plane Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine was injected into the area.
32913755|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
32913756|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
32913757|NCT05071833|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
32913758|NCT05071833|Experimental|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
32913759|NCT04337385|Experimental|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
32913760|NCT04337385|Experimental|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
32913761|NCT05040321|Experimental|MIB-626|Subjects will either take MIB-626 or placebo tablet twice a day for 90 days. For those who receive MIB-626, we plan on giving subjects 1000mg of the drug, twice a day for 90 days. MIB-626 will be in two 500mg tablets.
32913762|NCT05040321|Placebo Comparator|Placebo Tablet|Subjects will be randomized to receive either the placebo or MIB-626 tablets twice a day orally.
32913763|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32913764|NCT04337541|No Intervention|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
32913765|NCT04337541|Experimental|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
32913766|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
32913767|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
32913768|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
32913769|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
32714060|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
32714061|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
32714062|NCT02612129|Experimental|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
32714063|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
32714064|NCT04588727|Experimental|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
32714065|NCT04588727|Experimental|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
32714066|NCT04588727|Experimental|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
32714067|NCT04588727|Experimental|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
32714068|NCT04588727|Experimental|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
32913770|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
33082114|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
32714069|NCT04588727|Experimental|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
32714070|NCT04588727|Experimental|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
32714071|NCT04588727|Placebo Comparator|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
32714072|NCT04588727|Experimental|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
32714073|NCT04588727|Placebo Comparator|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
32714074|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
32714075|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
32714076|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
32714077|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
32714078|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
32714079|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
32714080|NCT02262455|Experimental|STM 434|
32714081|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
32714082|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
32714083|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
32714084|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
32714085|NCT02262611||Hypertension patients - Pneumology|
32714086|NCT02262611||Hypertension patients - Cardiology|
32714087|NCT02262611||Hypertension patients - Nephrology|
32714088|NCT02262611||Hypertension patients - Diabetology|
32714089|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
32714090|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
32714091|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
32714092|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
32714093|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
32714094|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
32714095|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
33082115|NCT04623619|Experimental|Acetyl L-Carnitine|Acetyl L-Carnitine
32714096|NCT04476875|Active Comparator|Open outpatient clinic programme (OOCP)|OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist, and had access to nurse-led consultations and telephone helpline.
32714097|NCT04476875|No Intervention|Traditional scheduled routine follow up (TSRF)|Appointments for the TSRF group were scheduled according to routine procedures.
32714098|NCT04476719|Experimental|Atafenovir 200 mg Kapsül|Capsules containing 207.009 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride (Atabay-Turkey).
32714099|NCT04476719|Active Comparator|Arbidol 100 mg Kapsül|Capsules containing 103.504 umifenovir hydrochloride monohydrate equivalent to 100 mg umifenovir hydrochloride (OTC-Pharma Russia).
32714100|NCT04476563||ChILI|Patients who are already on CPI therapy and have developed liver injury
32714101|NCT04476563||Control|Patients with cancer who are starting on checkpoint inhibitors
32714102|NCT04476485||experimental group|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy.
32714103|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
32714104|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
32714105|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
32714106|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
32714107|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
32714108|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
32714109|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
32714110|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
32714111|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
33082116|NCT04623619|No Intervention|Standard of care|Standard of care
32913771|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
32913772|NCT04337229|Experimental|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
32913773|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
32913774|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
32913775|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
32913776|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
32913777|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
32913778|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
32913779|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
32913780|NCT02703597|Experimental|ASPIRE Group|Participants engage in up to five 70-minute sessions of ASPIRE spread over a period of 5 weeks. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Baseline survey again completed. About one month after assessment 4, this group receives a 5th assessment followed by a hybrid version of the GSA-ASPIRE-Network program (moderated by Kahoot!). The group receives additional assessments after 3 sessions, following the last session of the program, and about one month after the program has ended (assessment 8).
32935781|NCT04322162|Experimental|Active implementation - Wave 3 (Fifth and Sixth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 3 corresponds to Wave 3."
32714112|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
32714113|NCT02262845||Group E: Other|In subjects with other indications
32714114|NCT04476641|Experimental|DC-CIK|
32714115|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
32714116|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
32714117|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
32714118|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
32714119|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
32714120|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
32714121|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
32714122|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
32714123|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
32714124|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
32714125|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
32714126|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
32714127|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
32714128|NCT02513303|Experimental|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
32714129|NCT02513303|Other|Control Group|AV fistula surgery
32714130|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
32714131|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
32714132|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
32714133|NCT01620515|Experimental|NX-1207 2.5 mg|
32714134|NCT01620515|Experimental|NX-1207 15 mg|
32714135|NCT01616303|Active Comparator|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
32714136|NCT01616303|Experimental|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
32714137|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
32714138|NCT01597349|Experimental|FP01 High dose|
32714139|NCT01597349|Experimental|FP01 Low dose|
32714140|NCT01597349|Placebo Comparator|Placebo|
32714141|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
32714142|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
32714143|NCT02263469|Experimental|Replenine®-VF|
32714144|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
32714145|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
32714146|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
32714147|NCT01571297|Active Comparator|RM-131|
32714148|NCT01571297|Placebo Comparator|Placebo|
32714149|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
32714150|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
32714151|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
32714152|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
32714153|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
32714154|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
32714155|NCT01543919|Experimental|PH-787904 (arm1)|
32714156|NCT01543919|Experimental|PH-787904 (arm2)|
32714157|NCT01543919|Experimental|PH-787904 (arm3)|
32714158|NCT01543919|Experimental|PH-787904 (arm4)|
32714159|NCT01543919|Experimental|PH-787904 (arm5)|
32714160|NCT01543919|Experimental|Placebo|
32714161|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
32714162|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
32714163|NCT01543451|Experimental|Elsiglutide|
32714164|NCT01543451|Placebo Comparator|Placebo|
32714165|NCT01536041|Experimental|Experimental 200 mg dose|
32935782|NCT05442320|Active Comparator|500 ppm|Toothpaste with 500 ppm fluoride (Biodent, Ilirija d.d)
32714166|NCT01536041|Experimental|Experimental 20 mg dose|
32714167|NCT01536041|Active Comparator|Active Comparator Montelukast|
32714168|NCT01536041|Placebo Comparator|Placebo Comparator|
32714169|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
32714170|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
32714171|NCT01522469|Experimental|Crenolanib Besylate|
32714172|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
32714173|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
32714174|NCT02264015|Experimental|Cilobradine low|
32714175|NCT02264015|Placebo Comparator|Placebo|
32714176|NCT02264015|Active Comparator|Moxifloxacin|
32714177|NCT02264015|Experimental|Cilobradine high|
32714178|NCT02264093|Experimental|Talsaclidine with Propranol|
32714179|NCT02264093|Active Comparator|Propranolol|
32714180|NCT02264093|Active Comparator|Talsaclidine|
32714181|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
32714182|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
32714183|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
32714184|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
32714185|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
32714186|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
32714187|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
32913781|NCT02703597|Experimental|GSA-ASPIRE-Network Group|Participants engage in five 70-minute sessions of ASPIRE conducted over a period of 5 weeks, with 2 booster sessions. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. ASPIRE use is coupled with game-based social activities (GSAs). ASPIRE use, participants watch videos and engage in activities on the same computer. Each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute GSAs. Participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended (assessment 4), participants complete psychosocial surveys and social network surveys.
32714188|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
32913782|NCT01507688|Experimental|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
32913783|NCT01507688|No Intervention|Arm 2 Usual Care|Usual care
32913784|NCT02366403|Experimental|SKY|a standardized meditation program
33399744|NCT05666453|Other|Reference group|No administration after ABO-compatible liver transplantation
32913785|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
32714189|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
32913786|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
32913787|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
32913788|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
32913789|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
32913790|NCT04987593|Experimental|Intervention|Four probiotic strains to be consumed once daily
32913791|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
32913792|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
32913793|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
32913794|NCT04849923|No Intervention|controll group|This group has no additional strength training
32913795|NCT04849923|Experimental|1 training per week|This group performs one strength training session per week
32913796|NCT04849923|Experimental|3 trainings per week|This group performs two strength training sessions per week
32913797|NCT04837989|Experimental|Diabetes Body Project|Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
32714190|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
32913798|NCT04837989|Active Comparator|Educational|Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.
32714191|NCT01495247|Experimental|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
32714192|NCT01495247|Experimental|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
32714193|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
32714194|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
32913799|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
32913800|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
33399745|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
32913801|NCT00717795||1|Arm 1 - Physical Activity intervention
33399746|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
32765013|NCT04960319|Active Comparator|Rotational Atherectomy|Control group treatment: Rotablation should be performed as described in the ESC-Consensus document. Burr/vessel-ratio is 0.5 - 0.75. The use of different burr sizes as well as the use of a temporary pacemaker is left to the operator's discretion.
33399747|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
33399748|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
33399749|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
33399750|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
32765014|NCT04950647|Experimental|Test group 1|Nitroketazine tablet 600 mg group
32765015|NCT04950647|Experimental|Test group 2|Nitroketazine tablets 1200 mg group
33399751|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
32765016|NCT04950647|Placebo Comparator|Control group|placebo group
32765017|NCT01675765|Experimental|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
32765018|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
32765019|NCT04522453|Active Comparator|paper mental health Gap Action Program-Intervention Guide|This arm will be training and supervision as usual employing the standard paper version of the mental health Gap Action Program-Intervention Guide. Primary care workers will be trained to use the paper version of this tool and will use the paper version when evaluating patients.
32765020|NCT04522453|Experimental|digital mental health Gap Action Program-Intervention Guide|This arm will be training and supervision in an experimental approach using a digital version of version of the mental health Gap Action Program-Intervention Guide. The digital version allows for interactive decision making on diagnoses and care, and it allows for entering of patient data. Primary care workers in this arm will be trained to use the digital version of this tool and will use the digital version when evaluating patients.
32765021|NCT05011435||Users|users of the web-application
32765022|NCT04950413|Active Comparator|Traditional Treatment Arm|conventional physical therapy program (infrared, stretching exercise, isometric strengthening exercise)
32765023|NCT04950413|Experimental|IASTM treatment arm|Instrument-assisted soft tissue mobilization (IASTM) is a therapeutic technique that is based on the soft tissue mobilization rationale introduced by James Cyriax.
32765024|NCT04950413|Experimental|Phonophoresis treatment arm|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2.
32765025|NCT04950413|Experimental|Combined IASTM and phonophoresis treatment arm|Combined phonophoresis and M2t Blade
32765026|NCT04285255|Active Comparator|Opioids anesthesia|received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
32765027|NCT04285255|Active Comparator|OFA|received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
32765028|NCT04943003|Experimental|Active tDCS|"SimNIBS will be used for modeling. It is a free and open source software package for the simulation of electric field induced by tDCS in the individual brain.~Modeling will be done using T1-weighted anatomical images of each subject to reconstruct a high-resolution head model of each individual. For electrode placement, we will simulate areas F5 and F6, according to the EEG 10-20 system, for the anode and cathode, respectively, targeting the left and right Dorsolateral Prefrontal Cortex (DLPFC). This group will receive active tDCS, for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area."
32765029|NCT04943003|Sham Comparator|Sham tDCS|The electrodes will be placed in the same way as in the Active tDCS group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Afterwards, the device will be turned off, no longer emitting current.
32765030|NCT04963543|Experimental|FID123238|FID123238 applied to the ocular surface, 1 application per day, for five consecutive days
32765031|NCT04943081|Experimental|Case group|Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.
32913802|NCT00717795||2|Arm 2 - Wait-list control
32913803|NCT02973867||Cohort called Elodie|Obese patients
33399752|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
33399753|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
33399754|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
33399755|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
33246074|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
33246075|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
33246076|NCT00873340||Group 1|
32714195|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
32714196|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
32714197|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
32714198|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
32714199|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
33246077|NCT00736398||Observation|Spinal fusion
33246078|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
33246079|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
33246080|NCT04065360|Experimental|Cognitive behavioural family intervention|
33246081|NCT04065360|Active Comparator|Usual group psychoeducation|
33399756|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
32714200|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
32714201|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
32714202|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
32714203|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
32714204|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
32714205|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
32714206|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
32714207|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
32714208|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
32714209|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
32714210|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
32714211|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
32714212|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
32714213|NCT02264483||COPD exacerbation|"No intervention.~The subjects will be divided in 2 subgroups according to the image study:~COPD exacerbation with pneumonia~COPD exacerbation without pneumonia"
32714214|NCT02264483||COPD stable patients|
32714215|NCT04476407|Experimental|G1|subjects with nomal renal function
32714216|NCT04476407|Experimental|G2|subjects with mild renal impairment
32714217|NCT04476407|Experimental|G3|subjects with moderate renal impairment
32714218|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
32714219|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
32714220|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
32714221|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
32714222|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
32714223|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
32714224|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
32714225|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
32714226|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
32714227|NCT01470131|Experimental|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
32714228|NCT01470131|Placebo Comparator|Placebo|Placebo in combination with Bortezomib and Dexamethasone
32714229|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
32714230|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
32714231|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
32714232|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
32714233|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
32714234|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
32913804|NCT04338087||Fertility treatments|Men participating in fertility treatments.
32913805|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
32913806|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
32913807|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
32913808|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
32913809|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
33246082|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
32913810|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
32913811|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
32913812|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
32913813|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
32913814|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
32913815|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
32913816|NCT04725903|Experimental|Treatment (proton beam therapy)|Patients undergo conventionally fractionated proton beam therapy daily on Monday-Friday directed to the prostate, pelvic lymph nodes, and para-aortic lymph nodes. Patients may receive an optional high-dose rate brachytherapy boost. Androgen deprivation therapy is required.
32913817|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
32913818|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
32913819|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
32913820|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
32913821|NCT04699539|Experimental|Arm A|GTV uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
33246083|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
33399757|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
33399758|NCT05741632|Experimental|Moxifloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Moxifloxacin during cataract surgery.
33399759|NCT05741632|Active Comparator|Levofloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Levofloxacin during cataract surgery.
33399760|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
33399761|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
33399762|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
33399763|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
33399764|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
33399765|NCT02397070|Experimental|Jaw exercise program|
33399766|NCT02397070|Active Comparator|Occlusal splint and counseling|
33399767|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
33399768|NCT05741320||public|Subjects older than 16 years of age and not working in any health sector will be included in the study.
33399769|NCT03584789|No Intervention|Standard Practice|The patients in this arm were part of usual care with their dental provider.
33399770|NCT03584789|Experimental|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
32714235|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
32714236|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
32714237|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
32714238|NCT02925338||Patients treated with Inflectra|
32714239|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
32714240|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
32714241|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
32714242|NCT01449071|Placebo Comparator|Placebo Group|
32714243|NCT01449071|Experimental|Epratuzumab 600 mg Group|
32714244|NCT01449071|Experimental|Epratuzumab 100 mg Group|
32714245|NCT01449071|Experimental|Epratuzumab 400 mg Group|
32714246|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
32714247|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
32714248|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
32714249|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
32913822|NCT04699539|Experimental|Arm B|GTV non-uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
32714250|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
32714251|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
32714252|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
32714253|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
32714254|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
32714255|NCT04423328|Experimental|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
32714256|NCT04423328|Sham Comparator|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
32714257|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
32714258|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
32714259|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
32714260|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
32714261|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
32714262|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
32714263|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
32714264|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
32714265|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
32714266|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
32714267|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
32714268|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
32714269|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
32714270|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
32714271|NCT04458974|Experimental|Experimental group (Exp)|Active tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation)
32714272|NCT04458974|Sham Comparator|Sham-tDCS (Sham)|Sham tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation
32714273|NCT04458974|Other|Control group (Control)|Conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation) without tDCS.
32714274|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
32714275|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
33082117|NCT00562198|Experimental|1|Investigational drug Stalevo 200
33082118|NCT00220025|Experimental|NBUVB|
32765032|NCT04930081|Experimental|Parent Management Training|The well-researched Postivie Parenting Program (Triple P) is selected as the intervention program for the parent management training arm. It is an 8-week program that aims at equipping parents with effective parenting strategies.
32765033|NCT04930081|Experimental|Mindful Parenting Program|The Mindful Parenting program, developed by Prof Susan Bogel is selected as the intervention program for the mindful parenting arm. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in the parenting context.
32765034|NCT04930081|No Intervention|Waitlist Control Group|The waitlist control group will not receive any service until two months after the intervention arms complete their training. Depending of the availability of the program instructor, either the Parent Management Training or the Mindful Parenting program will be offered to this group.
32765035|NCT04942691|No Intervention|non-exercise group (control group)|The control group not performed physical activity for a total of 20-weeks.
32765036|NCT04942691|Experimental|exercise group|The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
32765037|NCT04160221|Active Comparator|12 hours interval|Mifepristone followed by Misoprostol treatment
32765038|NCT04160221|Active Comparator|24 hours interval|Mifepristone followed by Misoprostol treatment
32765039|NCT04942847|No Intervention|The control group|The control group received routine nursing, including diet nursing, life nursing, direct and indirect training, health education and so on. Patients were followed up regularly by telephone after discharge
32765040|NCT04942847|Experimental|Dual task training group|On the basis of routine swallowing function training, the use of sucking training rehabilitation device is mainly used for tongue muscle training and lip muscle training to improve the control and delivery ability of tongue muscle to food.At the same time,adopt Troup's playing and comprehensive analysis ability training.Disrupt the three sets of cards, instruct the patient to read words or say colors, and measure the patient's reaction time with an electronic timer.Comprehensive analysis ability training: including digital training or item classification training.
32765041|NCT04121299|Experimental|Carvedilol 40mg Extended Release Once Daily|participants will be randomized to carvedilol 40 mg extended release once daily for the 1st or 2nd 4 week treatment period
32765042|NCT04121299|Active Comparator|Amlodipine 10mg Once Daily|participants will be randomized to amlodipine 10 mg once daily for the 1st or 2nd 4 week treatment period
32765043|NCT04942769|Experimental|selenium|selenium was administered to patients with autoimmune thyroiditis
32765044|NCT04253665|No Intervention|Usual care|Discharge teaching is usually not delivered in a systematic or consistenly way, nor by relying on a particular intervention model.
32765045|NCT04253665|Experimental|Discharge teaching|Receiving tailored discharge teaching by nurses during hospital stay.
32765046|NCT04942301|Experimental|Endostar pump for three days|Group A: The first cycle, Endostar 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump for 72 hours;
32765047|NCT04942301|Experimental|Endostar pump for seven days|Group B: Cycle 1, Endo 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump injection for 168 hours;
32765048|NCT04960007||Group A|Sarcopenia patients.
32765049|NCT04960007||Group B|Dynapenia patients.
32765050|NCT04960007||Group C|Age and gender matched non-sarcopenia and non-dynapenia patients.
32765051|NCT04959539|Active Comparator|endoscopic transcanal tympanoplasty with attico-antrostomy|
32765052|NCT04959539|Active Comparator|endoscopic assisted canal wall up mastoidectomy|
32765053|NCT04184479|Active Comparator|A-LEVAmetoden by Bertz et al|Individual dietary advices for weight loss, based on the participants' food record of 4 consecutive days aimed to achieve an energy intake reduction of 500 kcal/d with a nutrient composition according to the Nordic Nutrition Recommendations. Follow up visits after 3 months, 1 year and 2 years after baseline. Follow up by electronic platform every other week until 3 months after baseline and each month after 3 months until 1 year after baseline.
32765054|NCT04184479|Placebo Comparator|B-Ordinary treatment|Dietary advices for weight loss aimed to achieve calorie restriction. Follow up visits after 3 months, 1 year and 2 years after baseline. Additional visits, up to 4 times in the first year after baseline.
32765055|NCT04959227||whirling dervish group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
32765056|NCT04959227||control group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
32765057|NCT04145011|Experimental|COOLIEF Cooled Radiofrequency Probe|Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
32765058|NCT04145011|Active Comparator|Conventional (Standard) Radiofrequency Probe|Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
32765059|NCT04959461|Experimental|webCHAT|Single session 20-40minute self-guided web program that discusses promotes healthy decision making around driving and discusses the risks of alcohol and cannabis-influenced driving.
33082119|NCT03454594|Experimental|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
33082120|NCT03454594|No Intervention|control|all the participants in this group did not receive low level laser irradiation during the study period
33082121|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
33082122|NCT04623463|Other|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
33082123|NCT04623814|Experimental|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
33082124|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
32765060|NCT04959461|Active Comparator|Usual Care|Existing driving school education
32765061|NCT04725175|Experimental|PIPE-307|
32765062|NCT04725175|Placebo Comparator|Placebo|
32765063|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
32765064|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
32765065|NCT04704349|Experimental|Scintigraphy acquisitions|All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.
33246084|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
33246085|NCT04849312||Training|A subset of patients that are used to train the machine learning algorithm.
32765068|NCT03059069|Experimental|Glitamin|800mg/day
32765069|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
32765070|NCT04942223|Other|Subjects undergoing virtually planned GBR for extended and complex alveolar defects.|"Subjects undergoing virtually planned GBR for extended and complex alveolar defects.~The subjects were selected from the population of patients referring to the Oral & Maxillofacial Surgery Unit of S.Orsola-Malpighi University Hospital for oral function rehabilitation. Eligibility criteria were: the presence of horizontal and vertical alveolar defects in both jaws, inadequate for the placement of at least two fixtures, even ≤6 mm long ones; ≥ 18 years; informed consent signed."
32765071|NCT04000555|Experimental|Study drug|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
32765072|NCT04000555|Placebo Comparator|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
32765073|NCT04950023||early COPD|1) <60 years old; 2) smoking ≥ 10 pack years. 3) with any of the following anomalies: a. Post-bronchodilator FEV1/FVC< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (>60 ml/yr).
32765074|NCT04950023||Control|1) <60 years old; 2) Pre-bronchodilator FEV1/FVC≥70% and FEV1 ≥ 80% predicted; 3) no exposure to harmful factors such as cigarettes and dust pollution.
32765075|NCT03710785|Experimental|forward neck posture syndrome patients|Patients diagnosed with forward neck posture syndrome in cervical plain X-ray have a cervical spine extension exercise for 4 weeks
32765076|NCT04941911|Active Comparator|Intervention group|Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.
32765077|NCT04941911|Placebo Comparator|Placebo group|Sodium chloride 0.9% w/v
32765078|NCT04949945|Experimental|CHF patients who will receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients)(experimental group) will receive guided self help culturally adapted cognitive behavioral therapy.
32765079|NCT04949945|No Intervention|CHF patients will not receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients) (control group) will not receive Self Help Culturally Cognitive Behavior Therapy.
32765080|NCT04563715|Active Comparator|Standard of Care|HIV counseling and testing
32765081|NCT04563715|Experimental|Standard of Care plus Network Intervention|Network intervention
32765082|NCT04941677||schizophrenia group|No intervention age between 20-65, diagnosed schizophrenia by DSM-5.
32765083|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
32765084|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
32765085|NCT03284827|Experimental|NOAC|60 mg once daily
32765086|NCT03284827|Active Comparator|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)
32765087|NCT04959071|Experimental|Group A|Group A included participants who underwent VAC therapy for diabetic Foot ulcers
32765088|NCT04959071|Active Comparator|Group B|Group B included participants who underwent conventional dressings for diabetic foot ulcers
32765089|NCT04949321|Experimental|Gadovist (gadobutrol) / two MRI|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)
32765090|NCT04434001|Experimental|ZEPLAST|"In case of bleeding and:~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;~MCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;~CT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg."
32765091|NCT04434001|Active Comparator|Control|"In case of bleeding and:~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;~fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg."
32765092|NCT04958993|Experimental|Anlotinib combined with concurrent chemoradiotherapy|"Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.~Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)"
32765093|NCT04683913|Experimental|Immediate Intervention: Telerehabilitation|Immediate entry into the gait modification intervention delivered using teleconferencing methods
32765094|NCT04683913|Experimental|Delayed Intervention: Telerehabilitation|Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods
32765095|NCT04959383|Experimental|Low complexity Exergame balance training group|Wobble board based exergame balance training, the game complexity will be low for this group.
32765096|NCT04959383|Experimental|Moderate complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be moderate for this group.
32765097|NCT04959383|Experimental|High complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be high for this group.
32765098|NCT04959383|Active Comparator|Control group|Wii fit based Exergame training on a stable surface
32765099|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
32765100|NCT04958603||Traditional surgery group|Traditionally loosen the lateral support belt proximally
32765101|NCT04958603||New surgery group|"Laterally loosen the outer support belt, that is, L-shaped loosen"
33246086|NCT04849312||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
32765102|NCT03540901|Active Comparator|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
32765103|NCT03540901|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
32765104|NCT04958759|Experimental|Functional Inspiratory Muscle Training Group|Functional inspiratory muscle training in patients with chronic kidney disease
32765105|NCT04958759|Experimental|Inspiratory Muscle Training Group|Inspiratory muscle training in patients with chronic kidney disease
32765106|NCT04958759|Experimental|Control Group|Breathing exercises in patients with chronic kidney disease
32765107|NCT03517735|Experimental|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
32765108|NCT03517735|Active Comparator|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
32765109|NCT04958915||30 ° flexion position|Scan the knee at 30° flexion
32765110|NCT04958915||conventional flexion position|Routine body scan of the knee joint
32765111|NCT03489811|Experimental|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
32765112|NCT03489811|Active Comparator|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
32765113|NCT03489811|Placebo Comparator|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
32765114|NCT04941131|Experimental|chlorhexidine digluconate mouthwash|
32765115|NCT04941131|Experimental|chlorhexidine digluconate lozenges|
32765116|NCT04941131|Experimental|povidone iodine mouthwash|
32765117|NCT04941131|No Intervention|tap water|
32765118|NCT03400501|Experimental|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
32765119|NCT03400501|Active Comparator|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
32765120|NCT04940975|Experimental|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
32765121|NCT04940975|Active Comparator|Insomnia educational program (Treatment as Usual Group)|A program composed of four educational talks on sleep hygiene and relaxation training, plus two individual sessions for the reviewing of sleep patterns.
32765122|NCT04426591|Experimental|Biotin labeled Red Blood Cells|Participants receiving a transfusion with biotin labeled RBCs. Samples will be taken for 12 weeks after the biotinylated transfusion. During this time participants will continue to receive regular monthly transfusions (non-biotinylated) as part of CTT.
32765123|NCT04940741|Experimental|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
32765124|NCT04940741|Placebo Comparator|Placebo|The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
32765125|NCT03312751|Experimental|Emapalumab|
32765126|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
32765127|NCT04423679||< CIN2|Non-cases will include those with <CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
32765128|NCT04383847|Experimental|Main study|There is only 1 arm because this is a feasibility and acceptability pilot.
32913823|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
33399771|NCT03584789|Experimental|Clinical Decision Support + Education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
32765129|NCT03231475|Experimental|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
32765130|NCT04419467|Experimental|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
32765131|NCT04419467|Experimental|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
32765132|NCT04419467|Placebo Comparator|Placebo|Administered as a single IV loading dose followed by SC infusions
32765133|NCT04415957|Experimental|Elastic Tape Group (ETG)|The ET placement was previously described by Pinto et al. (2020). Briefly, the subject's trunk was passively extended for ET placement. The ET was placed considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. ET has shown six days of durability on average, so the participants were asked to return to change the ET after seven days.
32765134|NCT04415957|No Intervention|Control Group (CG)|CG received instructions about the importance of becoming physical activity. Furthermore, the participants included in CG were invited to place the ETs at the end of the protocol.
32765135|NCT04958681||Covid-19 history positive|
32765136|NCT04958681||Covid-19 history negative|
32765137|NCT04949009||Patients with primary immune thrombocytopenia (ITP)|"Ever been diagnosed as ITP patients. The diagnostic criteria comply with the Chinese Guidelines for the Diagnosis and Treatment of Adult Primary Immune Thrombocytopenia (2020 Edition)"
32765138|NCT04948541|Experimental|treatment|
32765139|NCT04948541|Experimental|no treatment|
32765140|NCT04948229||Control Group|This group will be included subjects who had no history or diagnosis of any disease, no infection history within last two weeks, no history of any particular medication, who were admitted to emergency department (ED) with complaints other than infectious issues, and who gave their written consent to participate in the study.
32913824|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
33246087|NCT04040140|Experimental|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
33246088|NCT00879892|Active Comparator|Hypothermia and xenon|
33246089|NCT00879892|Active Comparator|Hypothermia|
33246090|NCT00095784|Experimental|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
32714276|NCT05461118|Experimental|Treatment group|Consented subjects will undergo osteotomies for their resective and reconstructive procedures using mixed reality adjuncts (Magic Leap ®, Microsoft Hololens ®) to commercially available navigation platforms (BrainLAB ®).
32714277|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
32714278|NCT05434910|Experimental|Intervention|"Changes in mean arterial pressure (MAP).~In all subjects MAP is temporally adjusted using noradrenaline to the following three levels:~MAP 65 mmHg.~MAP 80 mmHg.~MAP 95 mmHg. When MAP has been stable at the given level for 20 min, measurements are conducted over 5 min. When the measurements are done, the study is finished. The study will last approximately 2 hours.~Measurements include internal carotid and vertebral artery blood flow, mean arterial pressure, heart rate, peripheral O2 saturation, cardiac output, left ventricle ejection fraction, frontal lobe and muscle oxygenation, blood velocity in the middle cerebral artery, pupillometry, and arterial, central venous, and internal jugular venous gas variables and blood samples for analysis of metabolomics."
32714279|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
32714280|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
32714281|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
33246091|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
33246092|NCT00873574||2|1 control for each family
33246093|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
33246094|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
33246095|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
33246096|NCT00740142|Placebo Comparator|2|Oral lactulose
33246097|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
32714282|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
32714283|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
32714284|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
32714285|NCT05379296|Active Comparator|Diabetes Prevention Program (DPP)|CDC-approved 12-month DPP virtual lifestyle program
32714286|NCT05379296|Experimental|Diabetes Prevention Program Plus (DPP+)|CDC-approved 12-month DPP virtual lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
32714287|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
32714288|NCT05378828|Other|Use of an electric wheelchair with or without sensors|During 3 weeks, the electric weehlchair will not have sensors, then sensors will be put on the wheelchair for the next 3 weeks then removed for 3 other weeks.
32714289|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
32913825|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
32913826|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
32913827|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
32913828|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
32913829|NCT04336917|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
32913830|NCT04336917|No Intervention|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
32913831|NCT04574583|Experimental|1/Sequential Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN M7824 + CV301
32913832|NCT04574583|Experimental|2/Combination Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN Escalating doses of SX-682 + M7824 + CV301
32913833|NCT04574583|Experimental|3/Disease-Specific Expansion|RP2D of SX-682 + M7824 + CV301
32913834|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
32913835|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
32913836|NCT00371475|Experimental|Arm 1|
32913837|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
32913838|NCT01562678|Experimental|Liraglutide|
32913839|NCT01562678|Placebo Comparator|Placebo|
32913840|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
32913841|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
32913842|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
32913843|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
32913844|NCT04496349|Experimental|APG-115 monotherapy|APG-115 will be given alone
33246098|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
32913845|NCT04496349|Experimental|APG-115 + APG-2575 combination|APG-115 is given in combination with APG-2575
32913846|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
32714290|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
32714291|NCT01417091|Experimental|Treatment group|
32714292|NCT01417091|No Intervention|Untreated reference group|
32714293|NCT01412177|Experimental|OTO-104|
32913847|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
32913848|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
32913849|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
32913850|NCT04461171|Experimental|ERAS|Administration of a perioperative non-narcotic, multimodal pain management pathway.
32913851|NCT04461171|No Intervention|Non-ERAS (Conventional)|Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
32913852|NCT04336683|Other|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
32714294|NCT01412177|Placebo Comparator|Placebo|
32714295|NCT01411163|Experimental|Creatine|
32714296|NCT00156533|Placebo Comparator|Placebo|QHS dosing with placebo (i.e. nightly dose)
32714297|NCT00156533|Active Comparator|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
32714298|NCT00156533|Experimental|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
32714299|NCT00156533|No Intervention|Control|Monitor only condition (no placebo, no drug).
32714300|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
32714301|NCT01410695|Experimental|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
32714302|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
32714303|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
32714304|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
32913853|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
32913854|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
33246099|NCT04039048|Experimental|ctDCS during Balance training|
33246100|NCT04039048|Sham Comparator|ctDCS sham during Balance training|
32714305|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
33246101|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
32913855|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
32913856|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
32913857|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
32913858|NCT02770365|Experimental|Test Product|estradiol cream
32913859|NCT02770365|Active Comparator|Reference Product|estradiol cream
32913860|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
32913861|NCT04336449|Experimental|Cohort 1 100 mg eptinezumab|
32913862|NCT04336449|Experimental|Cohort 2 300 mg eptinezumab|
32913863|NCT04336449|Placebo Comparator|Placebo|
32913864|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
32913865|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
32913866|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
32714306|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
32714307|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
32714308|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
32714309|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
32714310|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
32714311|NCT01660022|Placebo Comparator|Placebo|Placebo
32913867|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
32913868|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
32913869|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
32913870|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
32913871|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
32913872|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
32714312|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
32714313|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
32714314|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
32714315|NCT02265653|Experimental|BIIL 284 BS tablet C|
32913873|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
32913874|NCT04336527|Experimental|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
33246102|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
33246103|NCT05224492|Experimental|Sulforaphane Group|
32714316|NCT02265653|Experimental|BIIL 284 BS tablet D|
32714317|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
32714318|NCT01396811|Experimental|Active|Product 33525
32714319|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
33246104|NCT05224492|Placebo Comparator|Placebo Group|
32714320|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
32714321|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
32714322|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
32714323|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
32714324|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
32714325|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
32714326|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
32714327|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
33246105|NCT00879112|Experimental|1|MB07811 Cohort 1
33246106|NCT00879112|Experimental|2|MB07811 Cohort 2
33246107|NCT00879112|Experimental|3|MB07811 Cohort 3
33246108|NCT00879112|Placebo Comparator|4|Cohort 4
33246109|NCT00736710|Experimental|1|
33246110|NCT00736710|Sham Comparator|2|
32714328|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
32714329|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
32714330|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
32714331|NCT04453631|Experimental|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
33246111|NCT04039126|Experimental|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
33246112|NCT04039126|Active Comparator|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
32714332|NCT04453631|Active Comparator|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
32714333|NCT04453631|Active Comparator|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
32714334|NCT04453631|Placebo Comparator|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
33246113|NCT05582850|Experimental|DT-9081|Capsule, 25 mg, 50 mg and 100 mg
33246114|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
33246115|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
33246116|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
33246117|NCT00740298|Active Comparator|1|Sweet Taste
33246118|NCT00740298|Active Comparator|2|warmth
33246119|NCT04064190|Experimental|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
33246120|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
33246121|NCT00873886|Other|Esterase|
33246122|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
33246123|NCT00736788|Placebo Comparator|2|oral suspension
33246124|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
33246125|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
33246126|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
33246127|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
33246128|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
33246129|NCT05741346|Experimental|BCX9930|All subjects receive BCX9930 for 96 weeks
33246130|NCT05741268|Experimental|Dialectical behavior therapy|Dialectical behavior therapy will be applied through psychoeducation, discussion, rehearsal, and homework assignments. Four modules were administered in Mindfulness, Emotion Regulation, Emotion Regulation, and Emotion Regulation.
33246131|NCT05741268|Active Comparator|Routine psychological care|they will receive psychological care such as stress management and social skills training.
33246132|NCT00879346|Experimental|1|160mg oral dose of AZD8931
33246133|NCT05741190||myope|Patients with myopia
33246134|NCT05741190||Hypermetrope|Patients with hypermetropia
33246135|NCT05741190||Astigmatic|Patients with Astigmatism
33246136|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
33246137|NCT00736866|Experimental|Acetylcysteine|
33246138|NCT00736866|Placebo Comparator|Control|
33246139|NCT00879424|Experimental|1|
33246140|NCT00879424|Placebo Comparator|2|
33399772|NCT05740228|Experimental|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
33246141|NCT05741112|Other|Control: study provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be prompted to order their device and receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
33246142|NCT05741112|Other|Treatment: study provided wearables|Following consent and the completion of the baseline assessments the treatment group will be prompted to order their device and receive basic education on symptom management along with the enhanced education on wearable devices.
32935783|NCT05442320|Experimental|1000 ppm|Toothpaste with 1000 ppm fluoride (Biodent, Ilirija d.d)
33246143|NCT05741112|Other|Control: self provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
33246144|NCT05741112|Other|Treatment: self provided wearables|Following consent and the completion of the baseline assessments the treatment group will receive basic education on symptom management along with the enhanced education on wearable devices.
33246145|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
33246146|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
33246147|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
33246148|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
33246149|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
33246150|NCT00879502||1|Men with the fragile X premutation
33246151|NCT00879502||2|Healthy men
33246152|NCT00879502||3|Brothers of men with the fragile X premutation
33246153|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
33246154|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
33246155|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
33246156|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
33246157|NCT00713544|Active Comparator|1|
33246158|NCT00713544|Experimental|2|20mg
33246159|NCT00713544|Experimental|3|50mg
33246160|NCT00713544|Experimental|4|100mg
33246161|NCT00713544|Experimental|5|150mg
33246162|NCT00713544|Placebo Comparator|6|
33246163|NCT05741450|Active Comparator|Monthly Replacement Spherical Silicone Hydrogel Contact Lens 1|Subjects will wear Monthly Replacement Silicone Hydrogel Contact Lens 1 for the first period of 15 minutes and Daily Disposable Spherical Silicone Hydrogel Contact Lens 2 for the second period of 15 minutes.
33246164|NCT05741450|Experimental|Daily Disposable Silicone Hydrogel Contact Lens 2|Subjects will wear Daily Disposable Spherical Silicone Hydrogel Contact Lens 2 for the second period of 15 minutes.
33246165|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
33246166|NCT00737126|Experimental|2|Administration of oral folic acid
33246167|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
33246168|NCT00740766|Experimental|Monitored|
33246169|NCT00740766|No Intervention|Unmonitored|
33246170|NCT00415363|Experimental|A|
33246171|NCT00415363|Placebo Comparator|B|
33246172|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
33246173|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
33246174|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
33246175|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
33246176|NCT05529056|Experimental|Test Arm 1|LPTAT01
33246177|NCT05529056|Experimental|Test Arm 2|LPTAT02
33246178|NCT05529056|Experimental|Test Arm 3|LPTAT03
33246179|NCT05529056|Placebo Comparator|Reference Arm|LPTAT04
33246180|NCT00740922||1|
33246181|NCT05523440|Active Comparator|Arm 1: Niraparib|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily.
33246182|NCT05523440|Experimental|Arm 2: Niraparib and Bevacizumab|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily. Bevacizumab (15 mg/kg, IV on day 1 of each cycle).
33246183|NCT05740514|Experimental|Twelve-week Exercise|Study participants will participate in an exercise program consisting of aerobic and resistance exercise. This arm will last twelve weeks.
33246184|NCT05740514|Experimental|One-week Detraining|Study participants will undergo unilateral knee immobilization for a one-week period.
33246185|NCT05740514|Experimental|Four-week Re-training|Study participants will once again participate in an exercise program consisting of aerobic and resistance exercise. This arm will last four weeks.
33246186|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
33246187|NCT05740436||Frail elderly subjects|Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
33246188|NCT05740436||Pre-Frail elderly subjects|Pre-Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
32714335|NCT01369589|Experimental|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
33246189|NCT05740436||Non-frail elderly Frail subjects|Non-frail Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
32714336|NCT01369589|Experimental|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
33246190|NCT00741078|Experimental|atorvastatin, amlodipine|
32714337|NCT00156065|Active Comparator|Haloperidol/Haloperidol|Haloperidol in original study (NCT00156104) and in current long-term extension.
32714338|NCT00156065|Experimental|Asenapine/Asenapine|Asenapine in original study and asenapine in current long-term extension.
32714339|NCT00156065|Experimental|Placebo/Asenapine|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041023 asenapine trial, were randomized (double-blind) into the long-term 041513 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52-week trial.
33246191|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
33246192|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
33246193|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
33246194|NCT00741234|Experimental|A|Advanced solid tumors
33246195|NCT00741234|Experimental|B|Advanced hematologic malignancies
33246196|NCT00741234|Experimental|C|Myelodysplastic Syndrome
33246197|NCT00741312|Experimental|I|
33246198|NCT00741312|Active Comparator|II|
33246199|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
33246200|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
33246201|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
33246202|NCT02568306|Experimental|NNC0165-1562|
33246203|NCT02568306|Placebo Comparator|Placebo|
33246204|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
33246205|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
33246206|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
33246207|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
33246208|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
33246209|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
33246210|NCT05740280|Experimental|iCP-NI|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
33246211|NCT05740280|Placebo Comparator|Placebo|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
33246212|NCT05741034|Experimental|JUVÉDERM® VOLITE™|"Participants will receive VOLITE for initial treatment and exit the study at month 12 after last treatment.~Participants may have the opportunity to receive optional touch-up treatment of VOLITE during the follow-up duration period."
33246213|NCT05741034|Other|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive VOLITE treatment and exit the study at month 9 after last treatment.
33246214|NCT05740722|Experimental|Placebo|Placebo vs study drug
33246215|NCT05740722|Experimental|Nicotinamid Riboside|Placebo vs study drug
33246216|NCT00414973|Experimental|A|
33246217|NCT00414973|Active Comparator|B|
33246218|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
33246219|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
33246220|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
33246221|NCT00414661||Study group|All enrolled subjects
32714340|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
32714341|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
32714342|NCT05591573|Experimental|Low glycemic index drink|Fruit drink containing low glycemic index sugar.
32714343|NCT05591573|Experimental|High glycemic index drink|Fruit drink containing high glycemic index sugar.
32714344|NCT04476173|Experimental|Methoxyflurane|Patients treated with inhaled methoxyflurane (3 mg)
32714345|NCT04476173|Active Comparator|Morphine|Patients treated with intravenous morphine (5 mg)
32714346|NCT05570981||Chronic Refractory Cough (CRC)|Individuals with a diagnosis of chronic refractory cough
32714347|NCT05570981||Healthy controls|Healthy control subjects matched to the CRC group by age and gender
32714348|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
32714349|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
32714350|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
32714351|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
32714352|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
32714353|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
32714354|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
32714355|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
32714356|NCT05377970|Experimental|Prehabilitation Intervention Program|Patients enrolled in this arm will receive the preabilitation intervention program prior to their surgery to complete
32714357|NCT05377580|Placebo Comparator|Placebo|Participants will receive placebo in intravenously (IV) in Induction period. Subsequent study treatment will be determined by the participant's clinical response status at Week 12
32714358|NCT05377580|Experimental|IBI112 dose 1|Participants will receive IBI112 dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
32714359|NCT05377580|Experimental|IBI112 dose 2|Participants will receive IBI112 dose 2 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
32714360|NCT01355393|Experimental|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
32714361|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
32714362|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
32714363|NCT01355393|Experimental|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
32714364|NCT01355393|Experimental|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
32714365|NCT01355393|Experimental|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
32714366|NCT01355393|Experimental|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
32714367|NCT05425472|Experimental|HR070803|HR070803 monotherapy will be administered by intravenous infusion
32714368|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
32714369|NCT01348919|Experimental|CEP-18770 in Combination With Lenalidomide and Dexamethasone|
32714370|NCT05542901|Other|Diabetic Group (DG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to diabetic polyneuropathy.
32714371|NCT05542901|Other|Traumatic Group (TG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to traumatic causes.
32714372|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
32714373|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
32714374|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
32714375|NCT02266589|No Intervention|Placebo|Placebo
32714376|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
32714377|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
32714378|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
32913875|NCT04336527|Active Comparator|Home Treatment without Peer Support|Patients receive conventional home treatment by a homehome treatment/crisis resolution team without contacts to a peer support worker.
32913876|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
32913877|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
32913878|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
32913879|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
32714379|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
32714380|NCT01321463|Experimental|PH-797804|
32913880|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
32913881|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
32913882|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
32913883|NCT05349045||an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group|
32913884|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
32913885|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
32913886|NCT04737915|Experimental|Virtual Reality Exposure|Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
32913887|NCT04737915|Experimental|In Vivo Exposure|Participants completed a single session of exposure administered in vivo. The exposure exercise involved looking over actual railings into an atrium at various floor levels. Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
32913888|NCT04737915|No Intervention|Waitlist Control|Participants watched a neutral video during the time participants in other conditions were completing the exposure exercise. Participants received no exposure-based intervention.
32913889|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
32913890|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
32913891|NCT05350137|Active Comparator|Group A: 100% oxygen|After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen.
32913892|NCT05350137|Experimental|Group B: Carbon dioxide|After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide.
32913893|NCT04335357|Placebo Comparator|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
33246222|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
33246223|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
33246224|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
32714381|NCT01321463|Placebo Comparator|Placebo|
33246225|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
33246226|NCT00708708||A|Patients with moderate to severe plaque psoriasis
33246227|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
32913894|NCT04335357|Active Comparator|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
32714382|NCT05437289|Experimental|300 mg AZD7442 IM|Administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) sequentially by intramuscular (IM) injection.
32714383|NCT05437289|Placebo Comparator|300mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
32714384|NCT05437289|Experimental|600 mg AZD7442 IM|Administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) sequentially by intramuscular (IM) injection.
32714385|NCT05437289|Placebo Comparator|600mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
32714386|NCT05437289|Experimental|300 mg AZD7442 IV|co-administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) by intravenous (IV) infusion.
32714387|NCT05437289|Placebo Comparator|300mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
32714388|NCT05437289|Experimental|600 mg AZD7442 IV|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
32714389|NCT05437289|Placebo Comparator|600mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
32714390|NCT01311713|Experimental|(Part 1): CEP-9722|
32714391|NCT01311713|Experimental|(Part 2): CEP-9722|
32714392|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
32714393|NCT01300013|Experimental|Omecamtiv mecarbil|
32714394|NCT01300013|Placebo Comparator|Placebo|
32714395|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
32714396|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
32714397|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
32714398|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
32714399|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
32714400|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
32714401|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
32714402|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
32714403|NCT04476095|Experimental|Active PBMT|Active PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
32913895|NCT05350059|Experimental|High Intensity Focused Ultrasound (HIFU) treatment to breast cancer|High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection
32913896|NCT05349903|Experimental|Rice flour|Rapidly digestible control
32714404|NCT04476095|Placebo Comparator|Placebo PBMT|Placebo PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
32714405|NCT04475861|Experimental|L-arginine supplements|The enrolled subjects will then be randomized into two groups. Study Group: will take a supplementation pill containing 5 g L-arginine (0.5g/ pill, GNC, USA) All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
32714406|NCT04475861|No Intervention|nutritional supports|"The enrolled subjects will then be randomized into two groups. Control group: will take a supplementation pill containing 5 g whey protein (5g/ pack, Santosa,Taiwan).~All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians."
32714407|NCT05328557|Experimental|CUG252|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
32714408|NCT05328557|Placebo Comparator|Placebo|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
32714409|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
32714410|NCT05309135|Active Comparator|Low dose Rho kinase inhibitor Y-27632|Low dose Rho kinase inhibitor Y-27632
32714411|NCT05309135|Active Comparator|Mid dose Rho kinase inhibitor Y-27632|Mid dose Rho kinase inhibitor Y-27632
32714412|NCT05309135|Active Comparator|High dose Rho kinase inhibitor Y-27632|High dose Rho kinase inhibitor Y-27632
32714413|NCT05307809|Experimental|Psoriasis|
32714414|NCT05307809|Experimental|Psoriatic arthritis|
32714415|NCT05307809|Active Comparator|Controls|
32714416|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
32714417|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
32913897|NCT05349903|Experimental|Alternanoligosaccharide 15|
32913898|NCT05349903|Experimental|Waxy potato starch|
32913899|NCT05349903|Experimental|Combination of waxy potato starch and epigallocatechin gallate (EGCG)|
33246228|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
33246229|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
33246230|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
33246231|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in phakic eyes|
32765141|NCT04948229||Moderate Disease Group|This group will be consisted of the patients whose diagnoses of moderate COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
32765142|NCT04948229||Severe/Critical Disease Group|This group will be consisted of the patients whose diagnoses of severe/critical COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
32765143|NCT04940819|Experimental|Mobile Application Intervention|Participants in this arm will receive mobile application dietary intervention as well as usual CKD dietary care.
32765144|NCT04940819|No Intervention|Care as Usual|Participants in this arm will receive usual CKD dietary care.
32765145|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
32765146|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
32765147|NCT04940429||Roux n Y Gastric Bypass (RYGB)|"Participants in this arm will include patients who will be having a RYGB after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit.~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
32765148|NCT04940429||Sleeve gastrectomy (SG)|"Participants in this arm will include patients who will be having a SG after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit:~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
32765149|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
32765150|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
32765151|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
32765152|NCT04940507|Experimental|Tumor cohort|"Intervention 1:~Participants will undergo a partial tumor ablation with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel). Blood and CSF samples will be drawn on several timepoints before and after the procedure.~Intervention 2:~Participants will undergo a standard of care tumor biopsy/excision one day after the Intervention 1. Blood samples will be drawn on several timepoints before and after the procedure."
32765153|NCT04940507|Other|Essential tremor cohort|To identify the levels of circulating free DNA release after MRgFUS procedure in non-tumoral patients and to check whether the MRgFUS procedure induce tumoral mutations itself, we will draw blood samples from essential tremor patients before and after standard of care MRgFUS thalamotomy procedure.
32765154|NCT04940273|Experimental|remifentanil|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
32765155|NCT04958525||Endoscopic Surgery Group|After a full evaluation of the patient's condition, the informed consent was signed to perform keyhole neuroendoscopic ultrasound-guided hematoma removal for the patient.
32765156|NCT04958525||Microsurgery group|After a full evaluation of the patient's condition, the informed consent was signed to perform small bone window craniotomy for hematoma removal under microscope for the patient.
32765157|NCT02642107|Experimental|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
32765158|NCT02642107|Active Comparator|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
32765159|NCT04948385|Active Comparator|Patients|Deep sedation for digestive endoscopy.
32765160|NCT04948385|Other|Escorts|Accompanying persons are the adults who accompany the patients home. They do not receive any medication or intervention.
32765161|NCT04940117|Experimental|blood test data before and after taking|Checking eGRF value before and after taking Eefooton oral solution
32765162|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
32765163|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
33246232|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in pseudophakic eyes|
33246233|NCT03904381|Active Comparator|XEN implantation combined with cataract extraction|
33246234|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
32765164|NCT04947761|Experimental|modified Cheonwangbosimdan Hydrogel patch|Group receiving modified Cheonwangbosimdan Hydrogel patch
32765165|NCT04947761|Placebo Comparator|Placebo patch|Group receiving placebo patch
32765166|NCT04958213|Other|Conventional physical therapy|Conventional physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises) will be applied to this group for 4 weeks (20 sessions).
32765167|NCT04958213|Active Comparator|Dextrose prolotherapy treatment|This group will be treated with 15% dextrose prolotherapy around and inside the knee, 2 times with a two-week interval, and home exercise program (isometric and isotonic exercises).
32765168|NCT04958135|Experimental|Sequence 1: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fasted conditions.~Period 2: Acoramidis as an immediate-release tablet under fed conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
32765169|NCT04958135|Experimental|Sequence 2: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fed conditions.~Period 2: Acoramidis as an immediate-release tablet under fasted conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
32765170|NCT04948151|Experimental|Sildenafil Cream, 3.6%|
32765171|NCT04948151|Placebo Comparator|Placebo Cream|
32765172|NCT04939493|Experimental|Rhythmic Auditory Cueing|Group (B): Patients in this group will receive the same designed physical therapy program given to the control group in addition to auditory cueing during bilateral arm training using the metronome.
32765173|NCT04939493|Active Comparator|Bilateral arm training|Patients in this group will receive a standard physical therapy program in addition to Bilateral arm training.
32765174|NCT04947995||Gastric cancer group|
32765175|NCT04947995||Precancerous lesion group|
32765176|NCT04947995||Healthy group|
32765177|NCT04939337|Experimental|TH-SC01|TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
32765178|NCT04939025|No Intervention|Historic cohort|
32765179|NCT04939025|Other|Multi-interventional program cohort|
32765180|NCT04947371|Experimental|Anlotinib Hydrochloride|Oral anlotinib 12 mg/d
32765182|NCT04957121||on-hours|"Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as on-hours."
32765183|NCT04957121||off-hours|"Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as off-hours. Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as off-hours."
32765184|NCT02633293|Experimental|Inhaled Treprostinil|Open-label access
32765185|NCT04938713|Active Comparator|AB group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
32765186|NCT04938713|Other|BA group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
32765187|NCT04938401||epistaxis|Postoperative pituitary tumor group with epistaxis
32765188|NCT04938401||no epistaxis|Postoperative pituitary tumor group without epistaxis
32765189|NCT04938011|Experimental|Progesterone + 7|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
32765190|NCT04938011|Active Comparator|Progesterone + 6|the transfer of day 6 blastocysts on the 6th day of progesterone supplementation
32765191|NCT04296019|Experimental|Fruquintinib|Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
32765192|NCT04296019|No Intervention|Observation|Patients who achieved SD or PR or CR following palliative first-line treatment will receive treatment-free observation.
32765193|NCT04947215||Cases group|It includes 100 neonates who are admitted in the neonatal intensive care unit in Assiut University children hospital suffering from RDS. The cases will be subdivided into subgroups according to1. Full term or preterm, 2. Type of pregnancy (normal or complicated), 3. Mode of delivery, and 4. LPCAT1 genetic polymorphism.
32765194|NCT04947215||control group|include 60 neonates without RDS.
32898363|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.
32898364|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
32913900|NCT05349903|Experimental|Combination of chickpea flour and epigallocatechin gallate (EGCG)|
32714418|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
32714419|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
32714420|NCT01293461|Experimental|CBX129801|
33246235|NCT05740566|Experimental|Tarlatamab|Participants will receive tarlatamab as an intravenous (IV) infusion.
33246236|NCT05740566|Active Comparator|Standard of Care|Participants will receive treatment per local standard of care (SOC).
33246237|NCT00737256|Experimental|1|
33246238|NCT00737256|Active Comparator|2|
33246239|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
33246240|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
32714421|NCT01293461|Placebo Comparator|Placebo|
32714422|NCT05260541|Experimental|Double-blind PRAX-114|Double-blind period - 40 or 60 mg PRAX-114 once daily in the evening
32714423|NCT05260541|Placebo Comparator|Double-blind Placebo|Double-blind period - placebo once daily in the evening
32913901|NCT05349903|Experimental|Inulin|
33246241|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
33246242|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
33246243|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
33246244|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
33246245|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
33246246|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
33246247|NCT05740488|Experimental|apalutamide combined with 89Sr and ADT|Neoadjuvant therapy with apalutamide in combination with 89Sr and ADT
33246248|NCT04806724|Experimental|Program #1|Participants attend 5 sessions (1.5 hours each) consisting of education and skills training to address cancer-related reproductive and sexual health concerns. Sessions occur via videoconference.
33246249|NCT04806724|Active Comparator|Program #2|Participants attend 4 sessions (1.5 hours each) consisting of education and skills training to address cancer-related concerns. Sessions occur via videoconference.
33246250|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
33246251|NCT05742126|Experimental|HSK36273|Multiple continuous IV infusion ascending doses in cohort 1-5
33246252|NCT05742126|Placebo Comparator|Placebo|5 cohorts with matching placebo to HSK36273
33246253|NCT05742126|Active Comparator|Heparin sodium injection|Cohort 1-2 with matching positive control to HSK36273
33246254|NCT00880516||control|Adults with normal sinuses
33246255|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
33246256|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
33246257|NCT00737412|Placebo Comparator|2|Placebo
33246258|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
33246259|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
33246260|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
33246261|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
33246262|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
33246263|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
33246264|NCT00874588|Experimental|Phase I study|
33246265|NCT04064658|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
33399773|NCT05740228|Experimental|Anodal High-Definition (HD) tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
33246266|NCT04064658|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
33246267|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
33246268|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
33246269|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
33246270|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
32714424|NCT05260541|Experimental|Open-label Extension PRAX-114|Open-label extension period - 40 mg PRAX-114 once daily in the evening
32714425|NCT05255237|Experimental|Jaktinib|Patients will administer the study product twice per day for 24 weeks, for the safty assessment.
32714426|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
32714427|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
33246271|NCT00883324||1|fetal fibronectin specimens collected with a speculum
33246272|NCT00883324||2|fetal fibronectin specimens collected without a speculum
33246273|NCT00737646|Other|1|Usual care
32714428|NCT04475627||Participants randomised to 1.5T then 3T|Participants randomized to be scanned at 1.5T first followed by 3T
33246274|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
33246275|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
33246276|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
33246277|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
33246278|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
33246279|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
33246280|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
32714429|NCT04475627||Participants randomised to 3T then 1.5T|Participants randomized to be scanned at 3T first followed by 1.5T
32714430|NCT05252663|Experimental|Study group|Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds.
32714431|NCT05252663|Active Comparator|Control group|Percussion, vibration and shaking were used accompanied with postural drainage.
32714432|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
32714433|NCT05231525|Experimental|WiTOF|
32714434|NCT05231525|Active Comparator|TOFscan|
32714435|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
32714436|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
32935784|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
33246281|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
33246282|NCT00874666|Experimental|2|garlic powder tablet
33246283|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
33246284|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
33246285|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
33246286|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
33246287|NCT00880828|Placebo Comparator|C|Acetaminophen only
33246288|NCT04440202|Active Comparator|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
33246289|NCT04440202|Experimental|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
33246290|NCT05741970|Active Comparator|IL-6 and CRP levels of the hypertensive and periodontitis group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
32913902|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
32913903|NCT05348655||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic"
32714437|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
32913904|NCT05348655||Per Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, and 2023-2024 epidemic. The need for continuation of the study will be reassessed after each season"
32913905|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
32913906|NCT05349825||Patients with Hypertensive episode|50 individuals presenting with a hypertensive episode (patients under 60, >140/90 mmHg, patients over 60, >150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment
32913907|NCT05349825||Patients with controlled hypertension|50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.
32913908|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
32913909|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
32913910|NCT04335825|Active Comparator|phacotrabeculectomy|patients undergoing phacotrabeculectomy
32913911|NCT04335825|Active Comparator|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
32913912|NCT04903860|Active Comparator|Single use reamers|Total hip replacement with the use of disposable reamers
32913913|NCT04903860|Active Comparator|conventional ancillary|Total hip replacement with the use of conventional reamers
32913914|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
32913915|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
32714438|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
32714439|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
32714440|NCT02138786|Experimental|selinexor|"oral tablets~10 mg & 25 mg (bottled); or~20 mg (blister pack)"
32714441|NCT05177939|Experimental|NPB-01|Intravenous immunoglobulin
32714442|NCT05177939|Active Comparator|NPB-01-ME|methylprednisolone sodium succinate
32913916|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
32913917|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
32913918|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
32913919|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
32913920|NCT04336059|Other|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
32913921|NCT04336059|Experimental|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
32913922|NCT05348187|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC) tissue. The therascreen KRAS RGQ PCR Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
32714443|NCT05174507|Other|Group 1 (anakinra; placebo; empagliflozin)|"Group 1:~study day 1: anakinra; study day2: placebo; study day 3: empagliflozin"
32714444|NCT05174507|Other|Group 2 (placebo; anakinra; empagliflozin)|study day 1: placebo; study day2: anakinra; study day 3: empagliflozin
32714445|NCT05174507|Other|Group 3 (empagliflozin; placebo; anakinra)|study day 1: empagliflozin; study day2: placebo; study day 3: anakinra
32714446|NCT05174507|Other|Group 4 (empagliflozin; anakinra; placebo)|study day 1: empagliflozin; study day2: anakinra; study day 3: placebo
32714447|NCT05174507|Other|Group 5 (placebo; empagliflozin; anakinra)|study day 1: placebo; study day2: empagliflozin; study day 3: anakinra
32714448|NCT05174507|Other|Group 6 (anakinra; empagliflozin; placebo)|study day 1:anakinra; study day2: empagliflozin; study day 3: placebo
32913923|NCT01512446|Active Comparator|Alendronate|
32913924|NCT01512446|Placebo Comparator|Placebo|
32913925|NCT04334967|Experimental|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
32714449|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32714450|NCT05172869|Active Comparator|Group S: Suprainguinal Performed FICB|Suprainguinal Performed FICB
32714451|NCT05172869|Active Comparator|Group I: Infrainguinal Performed FICB|Infrainguinal Performed FICB
32714452|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
32714453|NCT05408468|Experimental|FAMCOPE-ICU|A digital eHealth emotion regulation and coping intervention.
32913926|NCT04334967|Active Comparator|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
32714454|NCT05408468|No Intervention|Usual Care|The care and support routinely provided to SDMs of critically ill patients.
32714455|NCT04456478|Active Comparator|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
32714456|NCT04456478|Experimental|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
32714457|NCT02233595||Adjuvant chemotherapy|
32714458|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
32714459|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
32714460|NCT04258592|Experimental|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Adult patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
32714461|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
32714462|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
32714463|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
32714464|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
32714465|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
32714466|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
32714467|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
32714468|NCT02268149|Placebo Comparator|Placebo|
32714469|NCT01258907|Experimental|A|
32714470|NCT01258907|Experimental|B|
32714471|NCT01258907|Placebo Comparator|C|
32714472|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
32714473|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
32714474|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
32714475|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
32714476|NCT02233907||Chronic obstructive pulmonary disease patients|
32714477|NCT05407454||Study Group|Patients with diabetes (all types)
32714478|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
32714479|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
32714480|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
32714481|NCT01254773|Placebo Comparator|Placebo|
32714482|NCT05424224||patients with depression|patients with depression
32714483|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
32714484|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
32714485|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
32714486|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
32714487|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
32714488|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
32714489|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
32714490|NCT01235585|Experimental|Bitopertin oral dose level 1|
32714491|NCT01235585|Experimental|Bitopertin oral dose level 2|
32714492|NCT01235585|Placebo Comparator|Placebo|
32714493|NCT01329341|Experimental|Arm 1|Service Dogs
32714494|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
32714495|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
32714496|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
32714497|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
32714498|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
32714499|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
32714500|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
32714501|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
32714502|NCT05129501|Experimental|Treatment: Tiwahe Wicaghwicayapi|Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Complete the program over 7 weeks, fidelity checking during program Part 3: Takes survey immediately after program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey
32714503|NCT05129501|No Intervention|Wait List Control: Tiwahe Wicaghwicayapi|"Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Waitlist with access to resources while treatment group completes program Part 3: Takes survey immediately after experimental group completes program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey~*Complete program"
32913927|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
32913928|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
32913929|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
32913930|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
32913931|NCT04335123|Experimental|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
32913932|NCT05454579||- 150 HIV-positive participants, both who were diagnosed with HIV infection and new cases.|Newly diagnosed HIV-infected participants will be linked to care to start ART. Known HIV-positive participants will be linked to care if they are not in care already. All HIV-positive participants will undergo viral load and CD4 testing at screening/baseline, and be invited back every 6 months for assessment of adherence, viral load testing, STI testing, FBS and lipid profile. A CD4 count will be repeated at Month 12 and Month 24.
32913933|NCT05454579||- 150 HIV-negative participants who are already receiving PrEP or who will accept PrEP.|HIV-negative participants will be offered PrEP. Those who accept PrEP will enroll in the PrEP program in each country, undergo creatinine testing at screening/baseline and be invited back at Month 1, Month 3, and every three months thereafter for HIV testing and assessment of adherence. STI testing, FBS, creatinine and lipid profile will be repeated every 6 months.
32913934|NCT05454579||- 150 HIV-negative participants who will refuse PrEP.|HIV-negative participants who do not wish to start PrEP will be invited back at every three months for HIV-testing. STI-testing, FBS and lipid profile will be repeated every 6 months.
32913935|NCT05347953||Single arm|Patients with self-reported symptoms of positional dependent palpitations
32913936|NCT05453565||Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
32913937|NCT05453565||Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
32913938|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
32913939|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
32913940|NCT05452473|Experimental|CDSS-assisted screening endoscopy|Participants will be tested for CDSS-assisted screening upper gastrointestinal endoscopy
32913941|NCT05452473|Placebo Comparator|Conventional routine screening endoscopy|Participants will be tested for Conventional routine screening upper gastrointestinal endoscopy
33246291|NCT05741970|No Intervention|IL-6 and CRP levels of the hypertensive and healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
33246292|NCT05741970|Active Comparator|IL-6 and CRP levels of the periodontitis and healthy group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
33246293|NCT05741970|No Intervention|IL-6 and CRP levels of the systemically and periodontally healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
33246294|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
32714504|NCT01234025|Experimental|Part 1 Cohort 1|
32714505|NCT01234025|Experimental|Part 1 Cohort 2|
33246295|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
32714506|NCT01234025|Experimental|Part 2 Arm A|
32714507|NCT01234025|Experimental|Part 2 Arm B|
32714508|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
32714509|NCT05103839|Experimental|Yoga for Caregivers and Persons With Dementia|Persons With Dementia and their caregivers will participate in up to 20 group yoga classes.
32714510|NCT01221077|Experimental|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
32714511|NCT01221077|Placebo Comparator|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
32714512|NCT02234297|Experimental|BLZ-100|
32714513|NCT04475159|Experimental|PIPAC arm|Together with neoadjuvant systemic therpay PIPAC will be performed twice and regional chemotherpay will be administered before planned CRS/HIPEC
33246296|NCT00422461|Placebo Comparator|Placebo|
33246297|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
33246298|NCT00422461|Experimental|PF-00489791 4 mg|
33246299|NCT00422461|Experimental|PF-00489791 10 mg|
32714514|NCT01208129|Experimental|Active drug|
32714515|NCT01208129|Placebo Comparator|Vehicle alone|
32714516|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
32714517|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
32714518|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
32714519|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
32913942|NCT04737993|Active Comparator|prf shoulder joint|pulsed rf stimulation of joint capsel and prf stimlation of subscapular nerve
32913943|NCT04737993|Active Comparator|prf subscapular nerve|pulsed RF stimulation of subscapular nerve
32913944|NCT04737993|Active Comparator|subscapular nerve block|lidocain injection of subscapular nerve
32913945|NCT05450055|Experimental|intraperitoneal analgesic group|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump. At the same time, patients in both groups were connected with intravenous controlled intravenous controlled analgesia (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
32913946|NCT05450055|Placebo Comparator|control group|Before the end of surgery, patients in the control group (C group) were extensively sprayed with 20mL normal saline intraperitoneally before the peritoneum was sutured. The surgeon placed an intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. In the control group, 0.9% normal saline was injected intraperitoneally with 10mL/h, and the total volume in the pump was 720mL. At the same time, patients in both groups were connected with intravenous controlled analgesia pump (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
32714520|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
32913947|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
32913948|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
32913949|NCT05437965||isolated coronary arteritis|
32913950|NCT05437965||coronary artery disease|
32913951|NCT01512758|Experimental|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
32913952|NCT01512758|Experimental|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
32913953|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
32913954|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
32913955|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
32913956|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
32913957|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
32913958|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
32913959|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
32913960|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
32913961|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
32913962|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
32913963|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
32913964|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
32714521|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
32913965|NCT05303571||Monodof|monofocal and EDOF lens
32913966|NCT05303571||Bidof|Bifocal and EDOF lens
32913967|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
32913968|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
32935785|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
32935786|NCT05451056|Experimental|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity .
32714522|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
32714523|NCT05626985||Hepatocellular Carcinoma patients|Blood samples are collected before liver resection.
32714524|NCT05626985||Liver cirrhosis|The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
32935787|NCT04304690|Other|caregiver|caregivers from emergency, ICU, virology and infectious disease services
32714525|NCT05626985||Hepatitis|Patients with various hapatitis.
32714526|NCT05626985||Benign tumor-like lesions|Benign hepatic tumors were diagnosed based on imaging findings and histological examinations after hepatic resection.
32714527|NCT05626985||Healthy control|The healthy control group consist of people undergoing routine medical examination. Blood samples are collected.
32714528|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
32714529|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
32714530|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
32714531|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
32714532|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
32714533|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
32714534|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
32714535|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
32714536|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
32714537|NCT01096979|Experimental|Placebo|Pbo
32714538|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
32714539|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
32714540|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
32714541|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
33082125|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
32714542|NCT01173731|Experimental|AFQ056|
32714543|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
32714544|NCT01092065|Placebo Comparator|Placebo|
32714545|NCT05626829|Experimental|Tranilast|concurrent Tranilast 100mg 3 times per day
32714546|NCT01173497|Experimental|INIPARIB, irinotecan|
32714547|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
32714548|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
32714549|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
32714550|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
32714551|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
32714552|NCT05373992|Experimental|Screen Time Restricted|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
32714553|NCT05373992|Experimental|Aerobic Exercise|Participants will be asked to engage in 30-minutes of aerobic exercise (AE) daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
32714554|NCT05373992|Experimental|Screen Time Restricted & Aerobic Exercise|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) as well as engage in 30-minutes of AE in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
32714555|NCT05373992|Active Comparator|Stretching|Participants will be asked to follow a daily stretching program for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
32714556|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
32714557|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
33246300|NCT04346134|Experimental|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
33246301|NCT04346134|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
33246302|NCT00712920|Placebo Comparator|1|Placebo
33246303|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
33246304|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
33246305|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
33246306|NCT01037647||Healthy men|Healthy men
33246307|NCT00874744|Experimental|bevacizumab|
33246308|NCT00874744|Experimental|Triamcinolone|
32714558|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
32714559|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
32714560|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
32714561|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
32898365|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
32898366|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
32898367|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
32898368|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
32898369|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
32898370|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
32898371|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
32898372|NCT01970865|Experimental|PF-06463922|
32898373|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
32898374|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
32898375|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
32898376|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
32898377|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
32898378|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
32898379|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
32898380|NCT01237457|Experimental|Treatment|Patients with somatostatin receptor-expressing neuroendocrine neoplasms will receive up to 200 mCi of 177Lu-DOTATATE every 6-11 weeks, preferably 6-9 weeks to a cumulative dose of 800 mCi.
32898381|NCT00756353||Wave 1|
32898382|NCT00756353||Wave 2|
32898383|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
32898384|NCT00694850|Experimental|Arm 1|
32898385|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
32898386|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
32898387|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
32898388|NCT00199030|Experimental|Arm A|In Arm A, patients with refractory relapse receive a 2 week treatment with MabCampath followed by remission evaluation. In case of insufficient response, treatment with cladribine is added.
32898389|NCT00199030|Experimental|Arm B|In Arm B, patients with molecular relapse (minimal residual disease) receive a 4 week treatment with MabCampath followed by remission evaluation.
32898390|NCT00198978|Experimental|Interventional arm|
32898391|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
32898392|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
32898393|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
32898394|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
32898395|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
32714562|NCT05624489|Experimental|Intervention|"Each participant-time point will be randomized between a prompt containing an engagement strategy vs. no prompt. A Bayesian algorithm will iteratively adjust the probability of receiving a prompt or no prompt at any time point, using brushing behavior data. Patterns suggesting positive effects of the prompts on brushing adherence will result in higher subsequent probabilities of receiving the prompts, whereas patterns suggesting null or negative effects will result in lower probabilities of receiving the prompts. A participant is assigned to an engagement prompt will be randomized equally between the three types of engagement strategies: (1) Standard reciprocity prompt: delivering non-contingent reward points as a gift to support goals; (2) Reciprocity by proxy prompt: delivering a message indicating a donation to the person's selected charity; (3) Curiosity prompt: delivering oral health information in a manner that motivates the participant to seek new knowledge and information."
32714563|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
32913969|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
32913970|NCT04334733|Experimental|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
33246309|NCT03993769|Experimental|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33246310|NCT03993769|Experimental|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33246311|NCT04038658|Experimental|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
33246312|NCT04038658|No Intervention|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
33246313|NCT05736744|Active Comparator|Rocuronium/MgSO4|"The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval"
33246314|NCT05736744|Active Comparator|Cis-Atracurium/MgSO4|"The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals."
33246315|NCT04270084|Other|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
33246316|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
33246317|NCT05735106||Group A (predicted easy intubation)|Group A labelled as predicted easy intubation on the basis of NC/TM distance ratio <5
33246318|NCT05735106||Group B (predicted difficult intubation)|Group B labelled as predicted Difficult intubation on the basis of NC/TM distance ratio ≥ 5
33246319|NCT00874900|Experimental|Game|
33246320|NCT00874900|Experimental|Game + Activation|
33246321|NCT00874900|No Intervention|Booklet|
32913971|NCT04334733|Experimental|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
32913972|NCT04334733|Experimental|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
32913973|NCT04334733|Experimental|Control group|No intervention was made to children in the control group
32913974|NCT05382897|Experimental|Fasting-Mimicking Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based fasting-mimicking diet for 5 days once a month for 3 months.
32913975|NCT05382897|Experimental|Caloric-Sufficient Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based caloric-sufficient diet for 5 days once a month for 3 months.
33246322|NCT00874900|Experimental|Booklet + Activation|
32913976|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
33246323|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
33246324|NCT05741814|Active Comparator|Propofol|Patients receive gynaecologist guided individualised propofol sedation
33246325|NCT05741814|Active Comparator|Anaesthetic guided anaesthesia|Patients receive anaesthetist guided full anaesthesia
33246326|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
33246327|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
33246328|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
33246329|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
33246330|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
33246331|NCT05741736|Other|Group|A structured 5-day lifestyle modification program led by endocrinologists-diabetologists together with a nutritionist, a psychologist, and a kinesiologist is aiming to educate on lifestyle modification necessary to lose weight.
33246332|NCT00883636||Focal Segmental Glomerulosclerosis|
33246333|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
33246334|NCT05733702||Single arm study:|Patients with IBD requiring a treatment change at the time of inclusion
33246335|NCT00883714|Experimental|Supervised exercise|
33246336|NCT00883714|Active Comparator|Control group|
33246337|NCT05733078|Placebo Comparator|Control / Crossover|"The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks.~Crossover: After first 12 weeks, the control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores."
33246338|NCT05733078|Experimental|Intervention|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
33246339|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
33246340|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
33246341|NCT05732142|Experimental|PIVoT|Gender-transformative family planning counseling and contraception provision at the time of infant vaccination
33246342|NCT05732142|No Intervention|Standard of care|Standard infant vaccination and family planning referrals
33246343|NCT00874978|Experimental|lenalidomide|
33246344|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
33246345|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
32913977|NCT05244135|Experimental|Pulmonary rehabilitation in VR (VR group)|"The VR group will perform the endurance exercise training using the Virtual Park, developed by CNR-STIIMA. The system includes a COSMED cycle-ergometer, a virtual environment and a physiological sensor-either a HR band or a pulse-oximeter depending on the target patient's needs. The virtual environment represents a ride in a park, enriched with realistic elements and sound effects, in order to simulate a daily life situation.~In the VR group, the VR Tier One device (Stolgraf®) will be used as a VR source. Thanks to using a head mounted display and the phenomenon of total immersion, VR therapy provides an intense visual, auditory and kinaesthetic stimulation. The aim of the software was to calm and improve the mood, while motivating and cognitively activating the patient."
33246346|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
33246347|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
33246348|NCT05728632|Experimental|Nebivolol|nebivolol, capsule, 5 mg once daily, for 12 months
33246349|NCT05728632|Placebo Comparator|Placebo|placebo, capsule, once daily, for 12 months
33246350|NCT04180540|Experimental|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
33246351|NCT04180540|Active Comparator|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
32714564|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
33246352|NCT05741658|Other|Dapagliflozin|4-week, Daily Oral Use of Dapagliflozin 10mg Tablet in Adults with Fontan Circulation
33246353|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
33246354|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
33246355|NCT05741580||peri-urethral bulk agent injection of Bulkamid® for urinary incontinence|patients who received a first injection of Bulkamid® in the context of urinary incontinence
33246356|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
33246357|NCT05741502|Experimental|Clozapine Arm|Patients will be placed on Clozapine and titrated as clinically needed and followed for 4 months.
33246358|NCT05741502|Active Comparator|Non-Clozapine arm|Patients will be continued on non-Clozapine antipsychotic and followed for 4 months.
33246359|NCT05727072|Experimental|LY3848575 IV|Single ascending doses of LY3848575 administered intravenously (IV).
33246360|NCT05727072|Placebo Comparator|Placebo IV|Placebo administered IV.
33246361|NCT05727072|Experimental|LY3848575 SC|Multiple doses of LY3848575 administered subcutaneously (SC).
33246362|NCT05727072|Placebo Comparator|Placebo SC|Placebo administered SC.
32714565|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
32714566|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
32714567|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
32714568|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
32913978|NCT05244135|Active Comparator|Traditional Pulmonary Rehabilitation (TPR)|"In the TPR group, exercise training will be performed on the bicycle. The training will be conducted on cycle ergometers with the use of the Peloton™ system, which ensures the monitoring of performance parameters.~In the TPR group, Schultz Autogenous Training will be performed. Schultz Autogenic Training has been shown to be effective in treating these pathologies. In both groups the relaxation training will be carried out once a day and will last about 20 minutes."
32913979|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
32913980|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
32913981|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
32913982|NCT04335513|Experimental|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
32913983|NCT04335513|Active Comparator|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
32913984|NCT05219019||PD patients who have elected DBS|Ten individuals with moderate to advanced Parkinson's disease who have elected to undergo deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi) as standard of care for management of Parkinson's disease tremor and/or motor complications
32913985|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
32913986|NCT01514396|Experimental|Surgical Glue|Surgiseal
32913987|NCT05265039|Experimental|Cognitive Processing Therapy (CPT)|
32913988|NCT05265039|Active Comparator|Relaxation Training (RT)|
32913989|NCT05263557|Experimental|DHEA|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
32913990|NCT05263557|Experimental|11KA4|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
32913991|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
32714569|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
32714570|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
33246363|NCT05577936|Experimental|Xperience no rinse antimicrobial solution group|XPERIENCE Advanced Surgical Irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure
32913992|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
32913993|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
32913994|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
32913995|NCT01568528|Other|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
32913996|NCT05199207|Experimental|Sarcopenic patient|Patient with sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
32913997|NCT05199207|Active Comparator|Non sarcopenic patient|Patient without sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
32913998|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Japanese subjects|
33246364|NCT05577936|Active Comparator|Normal saline solution group|Standard of care irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure.
33246365|NCT00710424|Experimental|Sativex|
32714571|NCT01037231|Experimental|Oxabact (tm)|
32714572|NCT01037231|Placebo Comparator|Placebo|
32714573|NCT03135197||Migalastat|Migalastat administered according to SmPC
32714574|NCT05624255|Experimental|ophthalmology consultation|Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography [OCT]
32913999|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects|
33246366|NCT00710424|Placebo Comparator|Placebo|
32714575|NCT02291614|Experimental|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32914000|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Caucasian subjects|
32714576|NCT02291614|Experimental|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714577|NCT02291614|Experimental|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714578|NCT02291614|Experimental|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714579|NCT02291614|Experimental|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714580|NCT02291614|Experimental|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
32714581|NCT02291614|Experimental|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714582|NCT02291614|Experimental|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
32714583|NCT02291614|Experimental|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
32714584|NCT02291614|Experimental|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
32714585|NCT02291614|Experimental|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
32714586|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
32714587|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
32714588|NCT05372900|Experimental|Test - Control product|Subject will start with consuming the test product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the control product daily for total 14 days (during intervention period 2).
32714589|NCT05372900|Experimental|Control - Test product|Subject will start with consuming the control product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the test product daily for total 14 days (during intervention period 2).
32714590|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
32714591|NCT01027013|Placebo Comparator|Placebo eye drops|
32714592|NCT05570630|Experimental|VAX-MOM COVID-19 Intervention|
32714593|NCT05570630|Active Comparator|Standard of Care|
32714594|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
32714595|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
32714596|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
32714597|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
32714598|NCT04197076||Neoadjuvant targeted therapy|TKIs
32714599|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
32714600|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
32714601|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
32714602|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
32714603|NCT04887454|Experimental|Once-Weekly HIIT|Once-weekly HIIT for 16 weeks, led by certified athletic coaches
32714604|NCT04887454|Experimental|Thrice-Weekly HIIT|Thrice-weekly HIIT for 16 weeks, led by certified athletic coaches
32714605|NCT04887454|Other|Usual Care|Bi-weekly health education, led by research personnel
32714606|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
32714607|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
32714608|NCT04475237||Healthy mandibles|Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities
32714609|NCT05622383|Experimental|aromatherapy|aromatherapy will be applied
32714610|NCT05622383|Experimental|music concert|music concert will be applied
32714611|NCT05622383|Experimental|aromatherapy,music concert|aromatherapy, music concert will be applied
32714612|NCT05622383|No Intervention|control|Routine maintenance will be applied.
32714613|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
32714614|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
32714615|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
32714616|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
32714617|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
32714618|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
32714619|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
32914001|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects|
32914002|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Japanese subjects|
33246367|NCT00612586|Experimental|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
32914003|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects|
32914004|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Caucasian subjects|
32914005|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects|
32914006|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
32914007|NCT05254431|Experimental|Exercise|The Experimental Design is a randomized trial of Moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls
32914008|NCT05254431|No Intervention|Usual Care|Participants in the control group will be instructed to maintain their routine activity level for 12 weeks
32914009|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
33246368|NCT00612586|Placebo Comparator|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
32914010|NCT05223231|Experimental|LBL-019|singal -arm
33246369|NCT05576922|Active Comparator|Connective tissue graft|Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
33246370|NCT05576922|Experimental|Collagen matrix + rhPDGF-BB|Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB
33246371|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
33246372|NCT00738036||Group C|Control, not exposed to acute pain
33246373|NCT05741424||Before innovative diagnostic technologies|
33246374|NCT05741424||After innovative diagnostic technologies|
33246375|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
33246376|NCT00883870|Experimental|Placebo|Intramuscular injection
33246377|NCT04038892|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
33246378|NCT04038892|Experimental|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
33246379|NCT04038892|Experimental|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
33246380|NCT05544552|Experimental|Phase 1 Part A - dose escalation|TYRA-300 taken once daily by mouth in 28-day cycles starting at 10 mg daily.
33246381|NCT05544552|Experimental|Phase 1 Part B - dose expansion|TYRA-300 taken once daily by mouth in 28-day cycles.
33246382|NCT05544552|Experimental|Phase 2|TYRA-300 taken once daily by mouth in 28-day cycles at doses determined during Phase 1.
33246383|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
33246384|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
33246385|NCT05536440|Experimental|Cohort 1 active|Dose A
33246386|NCT05536440|Placebo Comparator|Cohort 1 placebo|Dose A
33246387|NCT05536440|Experimental|Cohort 2 active|Dose B
33246388|NCT05536440|Placebo Comparator|Cohort 2 placebo|Dose B
33246389|NCT05536440|Experimental|Cohort 3 active|Dose C
33246390|NCT05536440|Placebo Comparator|Cohort 3 placebo|Dose C
33246391|NCT05536440|Experimental|Cohort 4 active|Dose D
33246392|NCT05536440|Placebo Comparator|Cohort 4 placebo|Dose D
33246393|NCT05536440|Experimental|Cohort 5 active|Dose E
33246394|NCT05536440|Placebo Comparator|Cohort 5 placebo|Dose E
33246395|NCT05536440|Experimental|Cohort 6 active|Dose F
33246396|NCT05536440|Placebo Comparator|Cohort 6 placebo|Dose F
33246397|NCT05536440|Experimental|Cohort 7 active|Dose G
33246398|NCT05536440|Placebo Comparator|Cohort 7 placebo|Dose G
32914011|NCT05013255|Active Comparator|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
32914012|NCT05013255|Active Comparator|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
32914013|NCT05013255|No Intervention|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
32914014|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
32914015|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
32914016|NCT04088643|Experimental|tACS group|NEXALIN ADI transcranial alternating current stimulator
32914017|NCT04088643|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
33082126|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
33082127|NCT04623814|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
33246399|NCT05536440|Experimental|Cohort 8 active|Dose H
33246400|NCT05536440|Placebo Comparator|Cohort 8 placebo|Dose H
33246401|NCT05525130|Experimental|Food supplement|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
33246402|NCT05525130|Placebo Comparator|Placebo|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
33246403|NCT05507190|Experimental|One arm|Self-management group. This pilot-study uses a one-group before-after design.
33246404|NCT02567994|Experimental|Teneligliptin|20mg qd
32714620|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
32714621|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
33246405|NCT02567994|Active Comparator|Sitagliptin|100mg qd
33246406|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
33246407|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
32714622|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
32714623|NCT01022801|Experimental|Entecavir (0.01 mg)|
32714624|NCT01022801|Experimental|Entecavir (0.1 mg)|
33246408|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
32714625|NCT01022801|Experimental|Entecavir (0.5 mg)|
32714626|NCT05628389|Other|Ask-Advice-Assist (AAA)|All patients will be screened for tobacco use, and offer brief cessation advice and counseling.
32714627|NCT05628389|Experimental|Ask-Advise-Connect (AAC)|Patients in will be connected to phone counseling and will receive six sessions of telephone counseling.
32714628|NCT05628389|Experimental|Ask-Advise-Connect + Nicotine Replacement Therapy (AAC+NRT)|In addition to AAC, patients will be offered NRT.
32714629|NCT05628311|Experimental|IBI362 4.0 mg|"①2mg, subcutaneously (SC), once a week* 4weeks;~②4mg, SC, once a week* 44weeks."
32714630|NCT05628311|Experimental|IBI362 6.0 mg|"①2mg, SC, once a week* 4weeks;~②4mg, SC, once a week* 4weeks；~③6mg, SC, once a week* 40weeks."
32714631|NCT05628311|Placebo Comparator|placebo|"placebo, SC, once a week* 24weeks;~2mg, SC, once a week* 4weeks;~4mg, SC, once a week* 4weeks；~6mg, SC, once a week* 16weeks."
32714632|NCT05422274|Experimental|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
32714633|NCT05422274|Sham Comparator|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
32714634|NCT05598515|Experimental|Time-Restricted Feeding|
32714635|NCT05422118|Active Comparator|case|people who have spontaneous bacterial peritonitis
32714636|NCT05422118|Active Comparator|control|people who donot have spontaneous bacterial peritonitis
33246409|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
32714637|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
32714638|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
32714639|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
32714640|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
32714641|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
32714642|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
32714643|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
32714644|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
32714645|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
32714646|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
32714647|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
32714648|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
32714649|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
32714650|NCT05405582|Experimental|community-based differentiated biosocial HIV prevention (incl. PrEP) with SRH|The intervention is available to all 15-30 year olds residing in the intervention cluster. Area based peer navigators mobilise all young people living in their cluster. They provide sexual health promotion, condoms, HIV self-tests, pregnancy test, and conduct structured psychosocial and health needs assessment with the young people they support. Based on the needs assessment they develop a tailored plan which includes, varying degrees of peer-mentorship and psychosocial support, lay-counselling and ART/PrEP adherence support. The peer navigators refer young people to mobile SRH services. The mobile SRH services provide gender and HIV status neutral nurse-led HIV testing, Individualised risk assessments for HIV care and PrEP, contraception and wider SRH services. The nurses liaise with the peer navigators to provide ongoing support for 3-monthly follow-ups with repeat HIV testing, adherence support and PrEP/ART/contraception refills.
32714651|NCT05405582|Active Comparator|Standard of Care|SOC is available to all young people in the delayed clusters. Care is provided in a nurse led Primary Health Clinics (PHC) to young people who attend the clinic. This includes HIV counselling and point of care testing, immediate initiation of ART if positive and PrEP if negative and eligible according to South African National PrEP guidelines. This is followed by a 3-monthly follow-up with repeat HIV testing, safety bloods, clinic-based counselling and adherence support and PrEP/ART refills. Clinic attendees are offered family planning support and syndromic management for STIs (as per South African National Department of Health Guideline).
32714652|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
32714653|NCT01009775|Experimental|YM155 plus docetaxel|
32714654|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
32714655|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
32714656|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
32914018|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
32914019|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
32914020|NCT04998825|Experimental|Proteoglycan F group|"Taking Proteoglycan F~Dosage of Proteoglycan F: 50mg/day~Used time: 24 weeks"
32914021|NCT04998825|Placebo Comparator|Control group|"Taking Placebo (Dextrin)~Dosage of Placebo: 50mg/day~Used time: 24 weeks"
32914022|NCT00372177|Active Comparator|EP1645|Single-Dose
32914023|NCT04980339||ASO group|All participants with TGA/TBA after ASO
32914024|NCT04902417|No Intervention|Low Dairy Habitual Diet|Participants will follow their usual diet for 6-weeks, which includes low dairy consumption as screened for with the inclusion criteria.
32914025|NCT04902417|Experimental|High Dairy Diet|Participants will be provided with 3 servings of dairy per day to replace other foods within their diet (preventing weight gain over the intervention period) for 6-weeks
32914026|NCT05177991|Active Comparator|Liposomal Bupivacaine (Exparel)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
32914027|NCT05177991|Active Comparator|Bupivacaine (Marcaine)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
32914028|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
32914029|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
32914030|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
32914031|NCT04080843|Experimental|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
32914032|NCT04076397|Other|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire~Patients in the lipofilling group will also have:~the repair of the last dressing during the consultation at J15~Ablation of any threads~Control of the digital and abdominal scar~Making a photo of their finger at V1 and M6"
32914033|NCT04076397|Other|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire"
32914034|NCT04869189|Experimental|High Sphere-Game/Video/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively.
32914035|NCT04869189|Experimental|High Sphere-VA/Video/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
32914036|NCT04869189|Experimental|High Sphere-VA/Game/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
32914037|NCT04869189|Experimental|High Sphere-Game/VA/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
33246410|NCT05697978|Other|Monofocal lens|Eyes of patients with implanted monofocal aspheric lens Clareon (Alcon LLC)
33246413|NCT05500170|Experimental|Intervention|Participants in the intervention group will receive 500mg of NR twice daily
32914038|NCT04869189|Experimental|High Sphere-Video/VA/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
33082128|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
33246414|NCT05500170|Placebo Comparator|Placebo|Participants in the intervention group will receive 500mg of sham placebo twice daily
33246415|NCT04681534|Active Comparator|conventional DBS|
33246416|NCT04681534|Experimental|adaptive DBS|
33246417|NCT05484804|No Intervention|Standard Care|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management.
33399774|NCT05740228|Sham Comparator|Sham stimulation|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
33246418|NCT05484804|Active Comparator|Data Accountability and Transparency|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) support from a Practice Facilitator to help implement the interventions and build workflows and quality improvement cycles; 2) use of a Maternal Warning System for missed visits/parameters and abnormal values with real-time feedback; 3) use of a Perinatal Equity Dashboard that displays outcome data stratified by race; and 2) Racial Equity Training.
32765195|NCT05115565|No Intervention|Control group|When the patients are admitted to the clinic, the patient identification form and the SF-36 Quality of Life Scale will be filled by face-to-face interview method. On the morning of the operation, before the operation, the GCS, EHA and WOMAC index will be filled. After the operation, the pain during rest and movement (24., 48., 72., 96. hours and 15. days) will be evaluated with VAS. The total amount of analgesics used by the patients will be recorded by looking at the nurse observation form records where the nurses recorded the drugs they administered at the 24th, 48th, 72nd, and 96th hours after the surgery, and by asking the patients on the 15th day after discharge. The WOMAC Index will be re-administered at discharge and on the 15th day, and the VCS, ROM, and the SF-36 Quality of Life Scale on the 15th day.
32765196|NCT05115565|Experimental|Intervention group|Unlike the control group, the patients in the intervention group will be informed about TENS and the application will be made. The electrodes of TENS will be placed 2 cm below and 2 cm above the incision site. TENS settings Frequency: 100 Hz; Pulse width (duration): 150 μs; Flow Intensity (Amplitude): By adjusting it to be 30 mA, TENS will be applied 3 times a day (09.00, 13.00, 17.00) for 20 minutes during the time the patients stay in the clinic (3 days).It is planned to start the TENS application the day after the surgery.
32765197|NCT04003675||Adolescent elite athletes|Adolescent boys and girls elite athletes over 16 years of age studying at elite sport high schools in Norway.
32765198|NCT04003675||Adolescent controls|Adolescent boys and girls over 16 years of age studying at regular high schools in Norway.
32765199|NCT04003675||Trainers and leaders|Trainers (with more than 20 percent employment status) at elite sport high schools, and leaders/principals at elite sport high schools and regular high schools.
32765200|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
32765201|NCT04677907|Active Comparator|Cemented knee replacement|total knee replacement with cemented modular knee replacement as per current standard for total knee replacements.
32765202|NCT04677907|Experimental|Uncemented knee replacement|total knee replacement with uncemented modular knee replacement, which is CE certified and accepted in the field.
32765203|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~Standard LAR Octreotide will be administered.~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
32765204|NCT04957355|Experimental|Experimental|"All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session.~Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz."
32765205|NCT05115487||Sjögren's syndrome|Subjects diagnosed with primary sjögren's syndrome according to the 2016 ACR/EULAR primary sjögren classification criteria will be included in the study.
32765206|NCT05115487||Healthy controls|
32765207|NCT04957199||Community|Individuals with or without COVID-19 in society
32765208|NCT04436887|No Intervention|Primary closure|Primary closure of midline laparotomy
32765209|NCT04436887|Experimental|Mesh closure|Sub-lay permanent mesh supported the closure
32765210|NCT05115175|Experimental|Intervention immediately|The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
32765211|NCT05115175|Experimental|Intervention in ten weeks following waitlist|This group received the same intervention as the first arm, however, the participants in arm 2 received the intervention after a 10-week waitlist period. The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
32765212|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with nicotine replacement therapy and text support|Participants in this arm will be instructed to quit tobacco cigarettes with nicotine replacement therapy (patches and lozenges) and text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
32765213|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with nicotine replacement therapy and text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with nicotine replacement therapy (patches and lozenges) and text message support.
32765214|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with text support.|Participants in this arm will be instructed to quit tobacco cigarettes with text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
33082129|NCT01580644|Experimental|Period 2: formulation 2 capsule|
33082130|NCT01580644|Experimental|Period 3: Selected formulation + food|
33082131|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
33082132|NCT04623151|Experimental|Online leaflet in narrative format|
33399775|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
32714657|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
32714658|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
32714659|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
32714660|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
32714661|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
32714662|NCT05627921|Experimental|botulinum toxin group|
32714663|NCT05627921|Experimental|botilinum toxin and ESWT group|
32714664|NCT04423172|Experimental|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
32714665|NCT04423172|No Intervention|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
32714666|NCT05573165|Experimental|3h Group|the patient's parents are instructed to stop feeding 3 hours for scheduled anesthesia. (3 hours of preoperative fasting for breast milk)
32714667|NCT05573165|Active Comparator|4h Group|the patient's parents are instructed to stop feeding 4 hours for scheduled anesthesia (4 hours of preoperative fasting for breast milk)
32714668|NCT04880044|Experimental|EC/EG & EGD|"Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay~If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)~If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent"
33082133|NCT04623151|Active Comparator|Online leaflet in non-narrative format|
33082134|NCT04623151|No Intervention|No leaflet (control)|
32714669|NCT05404256|Experimental|The experimental group|Radical gastrectomy of gastric cancer +TissePatchTM to cover pancreatic capsule wound
32714670|NCT05404256|Other|The control group|Radical gastrectomy for gastric cancer
32714671|NCT05371106||breastfeeding mothers|pregnant women after week 37 intending to nurse or nursing mothers of infants aged 1-12 months
32714672|NCT05572697|Experimental|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|"In addition to the standard rehabilitation program, participants will receive the sleep intervention delivered via a smartphone app. We will use a Norwegian a program named Assistert Selvhjelp (In English: Assisted Self-Help). The app is fully automated and requires no contact with healthcare personnel. It can also be assessed on computers, but in the present project we will use the app-delivered version. It is based on the principles from face-to-face CBT-I including several modules consisting of sleep hygiene, stimulus control sleep restriction, cognitive therapy, and relaxation training. The modules also consist of learning material (e.g., quizzes and materials explaining and educating the patients about important sleep dimensions)."
32765215|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with text message support.
32765216|NCT03800329|Active Comparator|Snap40 Monitor|Patients randomly assigned to wear the Snap40 monitor will wear the device for 48 hours following discharge from the hospital.
32765217|NCT03800329|Placebo Comparator|No Monitor|Patients randomly assigned to not wear the Snap40 monitor will continue with their follow-up surgical care in the ordinary fashion.
32765218|NCT04946513||Group 1|Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。
32765219|NCT05112133|Placebo Comparator|Control|Water administrated just before a meal
32765220|NCT05112133|Experimental|Mulberry leaf extract before|250 mg of Mulberry leaf extract was administered before a standard meal
32765221|NCT05112133|Experimental|Mulberry leaf extract during|250 mg of Mulberry leaf extract was administered during a standard meal
32765222|NCT03058133|Other|fMRI study|
32765223|NCT04798495|Experimental|HAPPY|Single arm longitudinal design.
32765224|NCT05114707|Experimental|camrelizumab group|
32765225|NCT04937621||SARS-CoV-2 infection|This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
32765226|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
32765227|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) </= 10 years, Expanded Disability Status Scale (EDSS) </=3.5~EDSS:~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
33246419|NCT05484804|Active Comparator|Community-Based Doula (CBD) Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) shared care of high-risk patients with Community-Based Doulas; and 2) Racial Equity Training.
32714673|NCT05572697|Active Comparator|Usual care|Participants randomized to usual care will receive the standard inpatient rehabilitation program. This is a traditional rehabilitation program consisting of physical activity, mindfulness excises, psychoeducation and acceptance and commitment therapy. One of the educational sessions is about sleep. Although this educational session overlaps with some of the content included in the intervention (e.g., sleep hygiene, stimulus control), it does not include any of the interactive features of the app.
32714674|NCT05627843|Experimental|Trial group|Children on regular hemodialysis whose weight 30 kg or above
32714675|NCT05627843|Placebo Comparator|Placebo group|Children on regular hemodialysis whose weight 30 kg or above
32714676|NCT05370014|Experimental|iCINGS Fam Intervention|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM) is 14-week, nurse coordinated, Community Health Worker (CHW) supported telehealth intervention structure. After baseline assessment, dyads randomized to the intervention group (n= 125 dyads) will have two planning sessions (over 2 weeks) followed by eight topic-guided sessions delivered by a member of the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly), Follow up assessments will occur at month 4 and month 7.
32714677|NCT05370014|No Intervention|Attention Control|After baseline assessment, dyads randomized to the attention control group (n= 125 dyads) will receive monthly (3 in total; 7-10 min each) scripted phone calls on focused on general health risks and health promotion. Monthly telephone calls will cover readily accessible evidence-based public health messaging from the Centers for Disease Control and Prevention (CDC) Your Health, NIH and other public health community facing websites related to COVID-19 mitigation such as risk reduction and prevention strategies including flu vaccines, asymptomatic spread, and contact tracing. Follow up assessments will occur at month 4 and month 7.
32714678|NCT05564117|Experimental|Oral semaglutide 25 mg|Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 64 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), and 25 mg (weeks 13 to 64).
32714679|NCT05564117|Placebo Comparator|Oral semaglutide placebo|Participants will receive placebo tablets matched to semaglutide orally once daily for 64 weeks.
32714680|NCT05403242|Experimental|RC48-ADC Combined With S-1|
32714681|NCT05627765|Experimental|Standard treatment (ST) arm|Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
32714682|NCT05627765|Experimental|Integrated Intervention (II) arm|Participants in the II arm will receive brief advice on alcohol use based on the FRAMES model in addition to the brief smoking cessation intervention at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
32714683|NCT05627765|No Intervention|Control arm|Participants will be provided with two leaflets designed by Department of health: one for smoking cessation and another for alcohol abstinence.
32714684|NCT05402540|Experimental|STRAIN COUNTER STRAIN GROUP|Strain Counter Strain Technique in combination with conventional physiotherapy
32714685|NCT05402540|Experimental|ACTIVE RELEASE TECHNIQUE GROUP|Active Release Technique in combination with conventional physiotherapy
32714686|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
32714687|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
32714688|NCT05402150|Experimental|Behavioral Activation|14 days of daily excercises
32714689|NCT05402150|Experimental|Mindfulness and Gratitude|14 days of daily excercises
32714690|NCT05402150|Experimental|Combination: Behavioral Activation and Mindfulness and Gratitude|14 days of daily excercises
32714691|NCT05402150|No Intervention|Waitlist control group|Will receive the intervention (combination) after two weeks of intervention time of the other groups.
32714692|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
32714693|NCT01003379|Placebo Comparator|Placebo|
32714694|NCT05401916|Active Comparator|Intravenous paracetamol|Intravenous paracetamol 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
32714695|NCT05401916|Active Comparator|Intravenous ibuprofen|"800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery.~All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min."
32714696|NCT01119833|Experimental|GMI-1070|
32714697|NCT01119833|Placebo Comparator|Placebo|
32714698|NCT01113593|Experimental|1|
32714699|NCT01113593|Experimental|2|
32714700|NCT01113593|Experimental|3|
32714701|NCT01113593|Experimental|4|
32714702|NCT01113593|Experimental|5|
32714703|NCT05401838|Experimental|G-BCBT|68 active duty service member participants assigned to G-BCBT will undergo 12 group therapy sessions scheduled on a weekly basis.
32714704|NCT05401838|Active Comparator|DBT|68 active duty service member participants in the DBT condition will receive 24 weekly group therapy sessions each lasting 90 minutes.
32714705|NCT01001351|Placebo Comparator|Placebo|
32714706|NCT01001351|Experimental|PRT-201|
33399776|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
33082135|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
33246420|NCT05484804|Active Comparator|Data Accountability and Transparency + Community-Based Doula Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management, and practices receive all the Data Accountability and Doula Interventions described in Arms 2 and 3.
33246421|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
33246422|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
33246423|NCT05695326|Experimental|Effects of a 3D Printing Technology Learning Program|
33246424|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
33246425|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
32714707|NCT04137224|Experimental|IgPro20|20% liquid formulation of human immunoglobulin for subcutaneous use
32714708|NCT04137224|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
32714709|NCT04137068|Other|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks. Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
32898396|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
32898397|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
32898398|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
32898399|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
32898400|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
32898401|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
32898402|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
32898403|NCT01262131|Active Comparator|Resonator Protocol A|
32898404|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
32898405|NCT01262131|Placebo Comparator|Inactive Resonator|
32898406|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32898407|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32898408|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32898409|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32898410|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32714710|NCT05401760|Active Comparator|Group A: includes eyes for whom combined phacoaspiration & angle surgery will be done.|"Group A: for whom combined phacoaspiration & angle surgery trabeculotomy will be done.~continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture.~Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~Suturing of scleral flap with 10-0 Nylon suture."
32714711|NCT05401760|Active Comparator|Group B : includes eyes with only phacoaspiration will be done|"Group B: for whom phacoaspiration only will be done.~2 side ports will be fashioned.~Trypan blue will be injected to aid visualization of the anterior capsule & continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture."
32714712|NCT05367752|Experimental|Group 1: Myofascial release with TENS conductive glove|Participants allocated to this group received six sessions of a myofascial release protocol with a TENS conductive glove applying a TENS current of 120Hz frequency through an electrotherapy device.
32714713|NCT05367752|Experimental|Group 2: Myofascial release without TENS conductive glove|Participants allocated to this group received the same myofascial release protocol with group 1 without the TENS conductive glove.
32714714|NCT05367752|Experimental|Group 3: Conventional TENS|Participants allocated to this group received the application of a conventional TENS current.
32714715|NCT05367752|Active Comparator|Control: Sham TENS|Participants allocated to this group received the same TENS treatment with group 3, but with the current intensity set to zero to ensure that they received no current.
32714716|NCT05418764|Experimental|Intervention group|Participants will receive standardized training by performing five hysterectomies on the Miya Model with a trainer who is a sub-PI at each Institution, with each of these training sessions filmed and then scored by blinded experts - Residents in the simulation arm will train until they reach a score of 27 on the modified Vagina Surgical Skills Index (VSSI)
32714717|NCT05418764|No Intervention|Control group|The training will be whatever is standard at their Institution
32914039|NCT04869189|Experimental|High Sphere-Video/Game/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
32714718|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
32714719|NCT05399186|No Intervention|Control group|Usual care group - receiving traditional preoperative preparation and assessment (1 week) prior to total joint arthroplastic surgery
32914040|NCT04869189|Experimental|Low Sphere-Game/Video/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video, or continuous VA test).
32914041|NCT04869189|Experimental|Low Sphere-VA/Video/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game).
32914042|NCT04869189|Experimental|Low Sphere-VA/Game/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video).
32914043|NCT04869189|Experimental|Low Sphere-Game/VA/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video).
32914044|NCT04869189|Experimental|Low Sphere-Video/VA/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game).
32914045|NCT04869189|Experimental|Low Sphere-Video/Game/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test).
32914046|NCT05141253|Experimental|RD133 treatment group|"Administration of RD133 Three dose groups of 1.0×10^6 CAR-T/kg, 3.0×10^6 CAR-T/kg, and 6.0×10^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
32714720|NCT05399186|Experimental|Early preoperative assessment and optimization|Interventional group - receiving early preoperative assessment and optimization (6-12 months) in wait of total joint arthroplastic surgery
32714721|NCT05418296|Experimental|Persons residing in long-term care homes|Subjects' ADLs are studied with intervention compared to baseline (without intervention).
32714722|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
32714723|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
33246426|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
33246427|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
33246428|NCT05678946||Integrated face-to-face rehabilitation and telerehabilitation|Participation in integrated face-to-face rehabilitation and telerehabilitation services for family caregivers organized by the Social Insurance Institution of Finland (Kela)
32714724|NCT05367128|Experimental|Posture-focus group|Participants will be instructed to pay most attention to practice the posture task during training
32714725|NCT05367128|Experimental|Supraposture-focus group|Participants will be instructed to pay most attention to practice the cognitive task during training
32714726|NCT05367128|Active Comparator|Control group|Participants will not be receive any instruction to prioritize either task
32714727|NCT05366738|Experimental|Treatment Sequence 1|Participants assigned to Treatment Sequence 1 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 3.
32714728|NCT05366738|Experimental|Treatment Sequence 2|Participants assigned to Treatment Sequence 2 will receive vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 3.
32914047|NCT05457309|Experimental|malignant fungating wounds care regimen|malignant fungating wounds care regimen based on the evidences, expert consultation, pre-experiment and final determination
33246429|NCT05678946||Social Holidays|Participation in face-to-face Social Holidays for family caregivers organized by Maaseudun Terveys- ja Lomahuolto (MTLH), a non-profit organization
33246430|NCT05678946||Face-to-face rehabilitation|Participation in face-to-face rehabilitation services for family caregivers and the care recipients organized by Kela
33246431|NCT00875290|No Intervention|Control|Observational arm
33246432|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
33246433|NCT00923416||Prostate Cancer|
33246434|NCT00884104|Experimental|1.tamsulosin + solifenacin|
33246435|NCT04140214|Experimental|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
33246436|NCT04140214|Experimental|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
33246437|NCT04140214|Experimental|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
33246438|NCT04140214|No Intervention|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
33246439|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
33246440|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
33246441|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
33246442|NCT00613834|Experimental|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
33246443|NCT00613834|Placebo Comparator|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
33246444|NCT00875368|Active Comparator|Maraviroc|
33246445|NCT00875368|Placebo Comparator|Placebo|Placebo drug
33246446|NCT04012138|Experimental|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
33246447|NCT04012138|Active Comparator|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
32714729|NCT05366738|Experimental|Treatment Sequence 3|Participants assigned to Treatment Sequence 3 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 1, vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 3.
32714730|NCT05399108|Experimental|The Novel Lateral Approach|In this arm, the catheterization of the internal jugular vein is done with ultrasound guidance displaying the vein on its short axis using a lateral approach and in-plane technique. The catheterization is done according to the newest international recommendations for good clinical practice.
32714731|NCT05399108|Active Comparator|The Conventional Approach|In this group catheterization of the jugular internal vein is done by conventional approach with ultrasound guidance using displaying on its short axis and using the out-of-plane technique.
32714732|NCT05364788||All participants|Appendiceal Cancer Patients
32714733|NCT05399030|Experimental|ICP-332|Single ascending doses of ICP-332 tablet; Multiple ascending doses of ICP-332 tablet
32714734|NCT05399030|Placebo Comparator|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo
32714735|NCT05417828||Participant with Chronic stroke|"Participants over 18 years of age~Participants should be able to understand the verbal cues during the training"
32714736|NCT05398874|Active Comparator|Ginkgo + standard|the patients received Ginkgo biloba extract in addition to standard treatment
32714737|NCT05398874|Placebo Comparator|placebo + standard|the patients received a placebo in addition to the standard treatment
32914048|NCT04334265|Experimental|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
32914049|NCT04334265|No Intervention|regular treatment group|
32914050|NCT05457231|Experimental|CST-SF group|The feedback process was as follows. Feedback was given after each interview, including brief feedback and SF. Brief feedback was provided by the clinical instructor based on the Gap-Kalamazoo Communication Skills Assessment Form immediately after each interview. Within two weeks after the first and second interviews, the interns received SF from experts and clinical instructors based on the Communication Skills Measure for Therapist. The SF of the third interview could not be completed because the internship had ended.
32914051|NCT04866849||STUDY GROUP|"patient diagnosed with bruxism The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
32914052|NCT04866849||CONTROL GROUP|healthy volunteers
32914053|NCT05457153|Experimental|Technology-Based Well-Being Process Program|"WEBEPROP will be conducted for 8 weeks. The program for the intervention group is included the modüls. In the program, the modules of Self-Knowledge, Inner Communication and Awareness of Perceptions, Emotion and Thought Management will be completed in 8 weeks (each model two weeks) . The other module will not be accessible and cannot be switched before the prevous module is completed."
32914054|NCT05457153|Active Comparator|Control Group|After the first follow-ups have been made to the control group, they will continue to receive standard care. After the monitoring of the initiative group within the scope of the program is completed, the website of the well-being process program will be made available to the control group. Children and adolescents will benefit from the modules by promoting the website.
32914055|NCT04737837||children|Children aged 4~16 years with focal onset seizures
32914056|NCT04737837||Adult|Adults aged >16 years with focal onset seizures
32914057|NCT04826133|Active Comparator|Acute Pretreatment with Calcitriol|To explore the effects of acute pre-treatment with Calcitriol on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
32914058|NCT04826133|Placebo Comparator|Acute Pretreatment with Placebo|To explore the effects of acute pre-treatment with placebo on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
32914059|NCT05456919||BRCA Mutated and no RRS|
32714738|NCT01281176|Experimental|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
32714739|NCT01281176|Experimental|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
32714740|NCT01281176|Experimental|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
32914060|NCT05456919||BRCA Mutated and RRS|
32914061|NCT05456919||BRCA Mutated and oncological diagnosis|
32914062|NCT05456919||BRCA Wildtype without oncological diagnosis|
32914063|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
33246448|NCT04012138|Experimental|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
32914064|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
32914065|NCT04737447|Active Comparator|Group A (Control Group)|20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.
32914066|NCT04737447|Active Comparator|Group B (Study Group)|20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (> ten years old) are allowed to higher frequency standards than younger participants (< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.
32914067|NCT04774809|Active Comparator|SHR0302 Low Dose|Drug: SHR0302 SHR0302 Ointment BID Low Dose
32914068|NCT04774809|Active Comparator|SHR0302 High Dose|Drug: SHR0302 SHR0302 Ointment BID High Dose
32914069|NCT04774809|Placebo Comparator|Placebo Comparator: Vehicle|Drug: vehicle Vehicle BID Placebo
32914070|NCT04750239|Experimental|Nivatrotamab|Subcutaneous administration of nivatrotamab up to 13 cycles
32914071|NCT03848715|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
33246449|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
32714741|NCT01281176|Experimental|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
32714742|NCT01281176|Experimental|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
32914072|NCT03848715|Placebo Comparator|Placebo|same volume of 0.9% saline
32714743|NCT01281176|Experimental|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
32714744|NCT05417516|Active Comparator|Whole Breast Irradiation (WBI)|26 Gy in 5 fractions to the whole breast
32714745|NCT05417516|Experimental|Partial Breast Irradiation (PBI)|26 Gy in 5 fractions to the tumour bed with a margin of normal tissue
32914073|NCT05456763|Experimental|group A|150 mg sodium butyrate twice a day for 12 weeks
32914074|NCT05456763|Placebo Comparator|group B|placebo capsules twice a day for 12 weeks
32914075|NCT05456607|Active Comparator|Control|Online Mood Monitoring for 12 weeks
32914076|NCT05456607|Experimental|Single Insomnia Treatment|Cognitive-behavioral therapy for insomnia delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
32914077|NCT05456607|Experimental|Single Depression Treatment|Cognitive-behavioral therapy for depression delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
32914078|NCT05456607|Experimental|Sequenced Depression and Insomnia Treatment|Cognitive-behavioral therapy for depression followed by cognitive-behavioral therapy for insomnia each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the depression treatment only for 4 weeks after which the access to the insomnia treatment is also made available. Total duration of access for 12 weeks.
32914079|NCT05456607|Experimental|Sequenced Insomnia and Depression Treatment|Cognitive-behavioral therapy for insomnia followed by cognitive-behavioral therapy for depression each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the insomnia treatment only for 4 weeks after which the access to the depression treatment is also made available. Total duration of access for 12 weeks.
32914080|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
32914081|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
32914082|NCT05456451|Experimental|Parkinson group(pre and post treatment)|5 participants will be evaluated for tremor and autonomic dysfunction at pre and post treatment
32914083|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
33246450|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
33246451|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
32714746|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
33246452|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
33246453|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
32714747|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
32714748|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
32714749|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
32714750|NCT05417360|Experimental|Akkermansia muciniphila (A. muciniphila)|After an 8-week low caloric diet (LCD, ~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the intervention group, will receive pasteurized A. muciniphila.
32714751|NCT05417360|Placebo Comparator|Placebo|After an 8-week low caloric diet (LCD, ~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the control group, will receive a placebo.
32714752|NCT05417204|Experimental|Correction of abnormal somatic response to a meal|Biofeedback in patients with functional dyspepsia and abnormal somatic response to a probe meal
32914084|NCT04556175|Experimental|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
32914085|NCT04556175|Active Comparator|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
32914086|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
32914087|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
32914088|NCT04550715|Experimental|Brief intervention (BI) then Portal|The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.
32914089|NCT04550715|Experimental|Brief intervention (BI) then Enhanced Usual Care (EUC)|The BI will be delivered at intake and EUC will be added 4 weeks later.
33246454|NCT03920098||Mother-infant dyads|Mother-infant dyads
32714753|NCT05417204|Active Comparator|Sham intervention in patients with normal somatic response to a meal|Biofeedback in patients with functional dyspepsia and normal somatic response to a probe meal
32714754|NCT05361902|Experimental|Intervention Arm|All included patients will be treated according to the treatment protocol: Adaptive radiotherapy according to UPRATE
32714755|NCT05361746|Experimental|SBU+ Treatment Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive .
32714756|NCT05361746|Active Comparator|SBU Control Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using the predicate device, Scotchbond Universal (SBU) Adhesive.
32714757|NCT05360810|Active Comparator|Wei Nasal Jet Tube Group (Group W)|After induction of anesthesia, the Wei Nasal Jet Tube was placed in the patients.
32714758|NCT05360810|Active Comparator|Gastro-Laryngeal Tube Group (Group G)|After the induction of anesthesia, the Gastro Laryngeal Tube was placed in the patients.
32914090|NCT04550715|Experimental|Enhanced Usual Care (EUC) then Portal|EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.
32914091|NCT04550715|Active Comparator|Enhanced Usual Care (EUC) then EUC|EUC will be delivered at intake and delivered again 4 weeks later.
32914092|NCT05456061|No Intervention|Group 1|No intervention
32914093|NCT05456061|Active Comparator|Group 2|3% diquafosol eye drops 6 times / day
32914094|NCT05456061|Active Comparator|Group 3|Punctal plug insertion, lower eyelid
32914095|NCT05456061|Active Comparator|Group 4|3% diquafosol eye drops 6 times / day + Punctal plug insertion, lower eyelid
32914096|NCT04300413|Experimental|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
32914097|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
32914098|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
32914099|NCT02369874|Active Comparator|Standard of Care|Standard of Care
32914100|NCT04335045|Active Comparator|100mg Dose|1 x 100 mg PH100 capsule (n=6)
32714759|NCT05360732|Experimental|Experimental: FOLFIRINOX|FOLFIRINOX: Oxaliplatin, Leucovorin and 5-Fluorouracl, Irinotecan,
32714760|NCT00152477|Experimental|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
32714761|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
32714762|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
32714763|NCT01112423|Experimental|BMS-823778 (2 mg)|
32714764|NCT01112423|Experimental|BMS-823778 (10 mg)|
32714765|NCT01112423|Experimental|BMS-823778 (20 mg)|
32714766|NCT01112423|Placebo Comparator|Placebo|
32714767|NCT05558891|Experimental|Experimental: THRIVE + Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
32714768|NCT05558891|Active Comparator|Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
32714769|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
32914101|NCT04335045|Placebo Comparator|Control for 100mg Dose|1 placebo capsule (n=2)
32914102|NCT04335045|Active Comparator|200mg Dose|1 x 200 mg PH100 capsule (n=6)
32914103|NCT04335045|Placebo Comparator|Control for 200mg Dose|1 placebo capsule (n=2)
32714770|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
32714771|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
32714772|NCT01111955|Placebo Comparator|Placebo|+ metformin
32714773|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
32714774|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
32914104|NCT04335045|Active Comparator|400mg Dose|2 x 200 mg PH100 capsules (n=6)
32914105|NCT04335045|Placebo Comparator|Control for 400mg Dose|2 placebo capsules (n=2)
32914106|NCT04335045|Active Comparator|800mg Dose|4 x 200 mg PH100 capsules (n=6)
32914107|NCT04335045|Placebo Comparator|Control for 800mg Dose|4 placebo capsules (n=2)
32914108|NCT04335045|Active Comparator|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
32914109|NCT04335045|Placebo Comparator|Control for 1200mg Dose|6 placebo capsules (n=2)
32914110|NCT04335045|Active Comparator|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
32914111|NCT04335045|Placebo Comparator|Control for 1600mg Dose|8 placebo capsules (n=2)
32914112|NCT03696225|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
32914113|NCT03696225|Active Comparator|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
32914114|NCT03671889|Experimental|Blood Brain Barrier (BBB) Disruption|ExAblate Model 4000 Type 2.0 System
32914115|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
32914116|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
32914117|NCT03628989|No Intervention|Procedure-Only Patients|
32914118|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
32914119|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
32914120|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
32914121|NCT00372645|Placebo Comparator|Placebo|Placebo
32914122|NCT05455827|Experimental|Intervention A|Enhancing condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
32914123|NCT05455827|Active Comparator|Intervention B|Minimising condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
32914124|NCT04335435|Experimental|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
32914125|NCT04279431||SIC Negative|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC negative group are those patients who obtain a 'Negative' result on the BrainScope One Structural Injury Classifier (SIC) algorithm.
32914126|NCT04279431||SIC Positive/Equivocal|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC positive group are those patients who obtain a 'Positive' or 'Equivocal' result on the BrainScope One SIC algorithm.
32914127|NCT04275843|Active Comparator|Traditional Diet|Unprocessed/minimally processed whole foods.
32914128|NCT04275843|Active Comparator|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
33399777|NCT05736484|No Intervention|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
32714775|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
32714776|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
32714777|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
32714778|NCT04256174|Experimental|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
32714779|NCT04256174|Experimental|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
32714780|NCT04256174|Experimental|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
32714781|NCT04256174|Experimental|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
32714782|NCT04256174|Experimental|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
32714783|NCT04256174|Experimental|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
32714784|NCT04256174|Experimental|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
32714785|NCT04256174|Experimental|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
32714786|NCT04256174|Experimental|Part 2: Loading dose cohort|A loading dose followed by multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
32714787|NCT05533229||Pregnant patients scheduled for C section|Spinal anesthesia
32714788|NCT05360498|Experimental|Intervention Arm|Adaptive Need-based Sequence
32914129|NCT04797429|Experimental|intervention group|The intervention group will receive antidiabetic therapy according to the current guidelines but with the additional opportunity to use the peer support IMS tool. Peer support and moderation of the intervention group will be provided by moderators. Moderators will be supervised by a dietitian.
32914130|NCT04797429|Active Comparator|control group|The control group receives the antidiabetic therapy according to the current guidelines, but without having access to the IMS tool. This means that participants receive medical treatment by their practitioner according to the Austrian recommendations.
32914131|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
32914132|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
32914133|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
32914134|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
32914135|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
32914136|NCT03473535|Active Comparator|PST Alone|Participants will receive six sessions of face-to-face PST.
32914137|NCT03473535|Experimental|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
32914138|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
32914139|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
32914140|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
32914141|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
32914142|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
32914143|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
32914144|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
32914145|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
32914146|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
33246455|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
32714789|NCT05360498|Active Comparator|Attention control|"This group will be participants that were randomized to the Attention control arm and will not receive the SMSH + TIP-C adaptive intervention."
32714790|NCT00153179|Active Comparator|1|Acipimox treatment for 7 days
32714791|NCT00153179|Placebo Comparator|2|placebo treatment for 7 days
32714792|NCT05358158|Experimental|Drain-free group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
32714793|NCT05358158|Active Comparator|Chest drain group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard postoperative chest tube.
32714794|NCT05627531|No Intervention|Blank composition book with encouragement to write|The comparison group will receive a blank composition book with encouragement to write.
32714795|NCT05627531|Experimental|Narrative Medicine|The intervention group will receive a blank composition book with daily writing prompts developed during at least one in-person session with the Narrative Medicine Coordinator to discuss their writing and their writing process.
33246456|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
32714796|NCT05357144|Experimental|Drug shops, also known as Accredited Drug Dispensing Outlets (ADDOs), owners or staff|All drug shopkeepers in intervention areas (within Shinyanga or Mwanza) will be invited to participate in Malkia Klabu, a loyalty card program. Consenting drug shops in intervention areas should be willing and able to keep records of referrals and sexual and reproductive health (SRH) product distribution given to AGYW through the use of Maisha Meds during the one month run-in period.
33246457|NCT00884260|Experimental|Arm 1|
32714797|NCT05357144|Placebo Comparator|Shopkeepers in control arm for comparison area|Drug shopkeepers, staff and/or owners as part of the control arm will receive standard HIV training, guidance on referring AGYW to proximal HIV care, and HIVST for free distribution to AGYW.
32714798|NCT05532839|Experimental|High intensity interval training|High-intensity interval training is a training that cycles between high bursts of activity and predetermined times of less intensive exercise or rest period.
32714799|NCT05532839|Experimental|Moderate intensity continuous interval training|Moderate-intensity continuous training consists of periods followed by 50 minutes of exercise - bicycling, running, jogging, marching, paddling, etc. - at a recorded frequency of 70-75 percent maximal heart rate.
32714800|NCT05526989|Experimental|Dostarlimab and Niraparib treatment|Participants will be given 500 mg Dostarlimab IV every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks, along with 200 mg Niraparib by mouth once daily days 1-21 of all cycles.
32714801|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.~nicotine"
32914147|NCT05455749|Experimental|holoBLG|
32914148|NCT05455593|Active Comparator|Water aerobics|Aerobic exercises performed in a swimming pool.
32914149|NCT05455593|Active Comparator|Metacognitive Training (MCT)|Treatment program for psychosis based on Cognitive-behavioral therapy (CBT), cognitive remediation (CRT) and psychoeducation.
32914150|NCT05455593|Experimental|Combined intervention (water aerobics + MCT)|Combination of water aerobics and MCT sessions.
33246458|NCT04038814||VAP1 - historical group|Routine prevention of VAP
33246459|NCT04038814||VAP2 - study group|Modified prevention of VAP
33246460|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
33246461|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
33246462|NCT05201872||laparoscopic surgery|Different surgical methods for rectal cancer resection
33246463|NCT05201872||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
33246464|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
33246465|NCT02543788|Other|Controls|healthy volunteers
33246466|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
33246467|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
33246468|NCT00884338|Experimental|Exercise|
32714802|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
32714803|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
32714804|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
32714805|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
32714806|NCT05415176|Experimental|Taurine and Exercise (Tau+Exe)|Individuals who will receive 3g of taurine supplementation combined with physical training in the period of 16 weeks
32714807|NCT05415176|Experimental|Taurine (Tau)|Individuals who will receive 3g of taurine supplementation
32714808|NCT05415176|Experimental|Exercise (Exe)|Individuals who will perform a physical training and receive a placebo supplementation in the period of 16 weeks
32714809|NCT05415176|Placebo Comparator|Placebo (Cont)|Individuals who will receive a placebo supplementation in the period of 16 weeks
32714810|NCT05627297||SR|
32714811|NCT05627297||RFA|
32714812|NCT05627141|Experimental|Photobiomodulation|10 participants will receive active photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
32714813|NCT05627141|Sham Comparator|Sham Photobiomodulation|10 participants will receive sham photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
32714814|NCT05627141|Experimental|Active Cryotherapy|10 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression on the lower limbs, or sham (25°C for 20 min) damage and fatigue induction protocol. muscle.
32714815|NCT05627141|Sham Comparator|Sham Cryotherapy|10 participants will receive sham cryotherapy (25°C for 20 min) combined with light compression on the lower limbs immediately after the damage and fatigue induction protocol. muscle.
32714816|NCT05627141|Experimental|Massage|10 participants will receive the effective massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
32714817|NCT05627141|Sham Comparator|Sham Massage|10 participants will receive the sham massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
32714818|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
32714819|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
32714820|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
32714821|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
32714822|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
32714823|NCT05355974|Experimental|Norepinephrine plus Isotonic Fluids|The treatment group will receive a continuous infusion of norepinephrine at 0.10 mcg/kg/min started 2-5 minutes prior to Rapid Sequence Intubation (assuming normal systolic blood pressure 90-140mmHg) in addition to a standard fluid bolus of Lactated Ringers or Normal Saline or Plasmalyte at 999 mL/hr.
32714824|NCT05355974|Active Comparator|Isotonic Fluids|The control group will receive an infusion of Lactated Ringers or Normal Saline or Plasma-Lyte with at least 500 mL at 999 ml/hr 2-5 minutes prior to Rapid Sequence Intubation.
32714825|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
32714826|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
32714827|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
32714828|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
32714829|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
32714830|NCT05355350|Experimental|piperacillin tazobactam|
32714831|NCT05355350|Active Comparator|meropenem|
32714832|NCT05415020|Active Comparator|Virtual Therapy Group|
32714833|NCT05415020|Sham Comparator|Attention Placebo Group|
33246469|NCT00884338|Active Comparator|Control group|
32914151|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
32914152|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
32914153|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
32914154|NCT04771299|Active Comparator|Cariprazine|1.5mg of Cariprazine added to their current treatment for 6 week period
32914155|NCT04771299|Placebo Comparator|Placebo|Matching placebo added to their current treatment for 6 week period.
32914156|NCT05455359|Experimental|Arm 1|Patients will be undergo 1 week observation period followed by 4 weeks of prucalopride followed by 1 weeks of a wash out followed by 4 weeks of famotidine
32914157|NCT05455359|Experimental|Arm 2|Patients will be undergo 1 week observation period followed by 4 weeks of famotidine followed by 1 weeks of a wash out followed by 4 weeks of prucalopride
32914158|NCT04716309|Active Comparator|VLP|Open reduction and volar locking plate
32914159|NCT04716309|Active Comparator|CRPP|Closed reduction and percutaenous K-wires/pins
32914160|NCT05441007|Experimental|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
32914161|NCT05441007|Experimental|Hypercapnic|Participants inhale ambient air, the hypercapnic gas mixture, and ambient air.
32914162|NCT05441007|Experimental|Hypoxic and Hypercapnic|Participants inhale ambient air, the hypoxic and hypercapnic gas mixture, and ambient air.
32914163|NCT04333641||small AAA patients|all patients with small AAA
32914164|NCT04694001|Other|Hemiplegia due to Cerebrovascular Accident (CVA)|
32914165|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
32914166|NCT04680585|Other|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
32914167|NCT04680585|Experimental|MOVIN|Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
32914168|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
32914169|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
32914170|NCT04333797|Other|Transitional age youth|Assessed group.
32914171|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
32914172|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
32914173|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
32914174|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
32914175|NCT04737525|Experimental|Test group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and porcine-derived membrane.
32914176|NCT04737525|Experimental|Control group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and connective tissue grafting (CTG).
32914177|NCT02633397|Experimental|Riociguat|Treatment Arm
32914178|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
33246470|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
32914179|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
32914180|NCT02581527|Active Comparator|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
32914181|NCT02581527|Experimental|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
32914182|NCT02581527|Experimental|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
32914183|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
32914184|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
33246471|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
33246472|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
32714834|NCT05355116|Experimental|Group A: Physiolab S1|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 25-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 8℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
32914185|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
32914186|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
32914187|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
32914188|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
32914189|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
32914190|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
32914191|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
32914192|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
33246473|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
33246474|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
33246475|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
32714835|NCT05355116|Experimental|Group B: Breg Vpulse|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a dynamic peak pressure of 50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will not be lower than 5.5℃. The selected pressure and temperature represents the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
32914193|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
32914194|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
32914195|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
32914196|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
32914197|NCT00708045|Experimental|All patients|All participants enrolled.
32914198|NCT00571389||Cancer Cohort|The first cohort of patients to be enrolled for this study will be adults (males and females) with histological proven solid tumors of any stage, seen for routine cancer care at participating community cancer clinic sites. Patients on clinical trials with experimental study drugs will be allowed to participate in this observational prospective study.
32914199|NCT00571389||Healthy Volunteer Cohort|Healthy volunteers make up the second, smaller study population for this observational biospecimen laboratory study. Healthy volunteers serve primarily to aid in the proficiency, quality control and/or optimization of study procedures, experimental design assay development, and for device/equipment validation.
32914200|NCT00571389||COVID-19 Disease Cohort|Due to the COVID-19 pandemic and the consequent amendment to aid in the research response, study subjects with COVID-19 disease may participate in all aspects of this protocol, but depending on their disease state, infection timeline, and age, participation may be limited to only one component, procedure, and/or type of biospecimen collection. Age is a very important criteria, as pediatric subjects (5-17 years old) will only be eligible to participate in minimally invasive biospecimen collection procedures.
33246476|NCT00875680|Experimental|autoPPC|
33246477|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
33246478|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
33246479|NCT00884416|Experimental|Sorafenib dose titration|
32914201|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
32914202|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
32914203|NCT01515956|Experimental|BMN 110 Weekly|
32914204|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
32914205|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
32914206|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
32914207|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
32914208|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
32914209|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
32914210|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
32914211|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
33246480|NCT04675996|Experimental|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
32745660|NCT04821765|Experimental|Chemoradiotherapy Combined With PD-1 Antibody|The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy（Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles). After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
32914212|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
32914213|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
32914214|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
32914215|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
32914216|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
32914217|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
32914218|NCT05440968|Other|A - Intervention|A - After randomization, participants will be offered information on healthy lifestyles according to their score on the FINDRISC questionnaire and subsequently a POC-A1c measurement + a confirmatory test order (Oral Glucose Tolerance Test)
32914219|NCT05440968|Other|B - Control|B - After randomization, will be offered the same information on healthy lifestyles according to their FINDRISC score, and will receive an order to an Oral Glucose Tolerance Test.
32914220|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
32914221|NCT01516424|Experimental|Blonanserin|Antipsychotics
32914222|NCT01516424|Active Comparator|Risperidone|Antipsychotics
32914223|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
32914224|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
32914225|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
32914226|NCT04492839|Experimental|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
32914227|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
32914228|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
33246481|NCT00875758|Active Comparator|Standard threshold|
33246482|NCT00875758|Experimental|Low-threshold|
32914229|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
32914230|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
32914231|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
32714836|NCT05355116|Experimental|Group C: Cryo/Cuff|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
32914232|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
32914233|NCT01649232|Experimental|active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
32914234|NCT01649232|No Intervention|controls|Healthy people that not receive tDCS
32914235|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
32914236|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
32914237|NCT02785185|Experimental|IDP-122 Lotion|Lotion
32914238|NCT02785185|Active Comparator|Ultravate Cream|Cream
32914239|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
32914240|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
32914241|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
32914242|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
32914243|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
32714837|NCT05355116|Experimental|Group D: GameReady|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 5-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 1℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
32714838|NCT05355116|Experimental|Group E: Physiolab Gel Therapy Wrap|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
32714839|NCT05393648|Experimental|Active iTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
32714840|NCT05393648|Placebo Comparator|Sham iTBS|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
32914244|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
32914245|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
32914246|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
32914247|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
32914248|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
32914249|NCT04486755|Experimental|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
32914250|NCT04486755|Experimental|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
32914251|NCT04486755|Experimental|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
32914252|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
32914253|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
32914254|NCT04440501|No Intervention|Standard education (Control)|Standard education regarding the gluten free diet by the nutritionist will be provided.
32914255|NCT04440501|Experimental|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
32914256|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
32914257|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
32914258|NCT04420845|Other|Intervention|
32914259|NCT05106309|Experimental|Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions|Oral Dose
32914260|NCT05106309|Experimental|Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions|Oral Dose
32914261|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
32914262|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
32914263|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
32914264|NCT04372563||healthy|Healthy patients with normal aortic dimensions
32914265|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
32914266|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
32914267|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32714841|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
32714842|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
32914268|NCT04356261|Placebo Comparator|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
32914269|NCT04356261|Active Comparator|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
32914270|NCT04356261|Active Comparator|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
32914271|NCT05062317|Experimental|ctDNA (Low Risk)|Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.
32914272|NCT05062317|Experimental|ctDNA (High Risk)|Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX [5-fluorouracil, leucovorin and oxaliplatin] or FOLFIRI [5-fluorouracil, leucovorin and irinotecan] with or without bevacizumab)
32914273|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
32914274|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
32914275|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
32914276|NCT04349319|Other|Digital preoperative planning|To use digital preoperative planning software
32714843|NCT05354102|Experimental|BMC128 in combination with Nivolumab|"Four 28-day treatment cycles of the standard Nivolumab treatment protocol (480 mg on Day 1 of each cycle) together with a QD regimen of BMC128, followed by a Iong-term Nivolumab monotherapy.~Prior to starting this combination treatment, patients will undergo:~I. Native microbiota depletion stage - patients will be treated with oral vancomycin 500mg and neomycin 1000mg q6h for 72 hours.~II. BMC128 monotherapy induction stage - One BMC128 capsule will be administered once daily QD for a period of 14 days."
32714844|NCT05414084|Experimental|(Poly)phenol tablets|Single ingestion of 3 tablets containing different amounts of the most representative dietary (poly)phenols (i.e. flavonoid subclasses, phenolic acids, lignans, ellagitannins, stilbenes, flavonols, procyanidins and phenylethanoids)
32914277|NCT05045937||COVID-19 patients treated with Ivermectin|This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
32914278|NCT05045937||COVID-19 patients declining Ivermectin and wanting traditional treatment|This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
32914279|NCT01521026|Experimental|Cognitive Training|Cognitive training group
32914280|NCT01521026|No Intervention|Standard Pharmacotherapy|
32914281|NCT00373581|Experimental|Vigabatrin, cocaine|
32914282|NCT00373581|Placebo Comparator|placebo, cocaine|
32914283|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
32914284|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
32714845|NCT05392712|Other|healthy volunteers|
32914285|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
32914286|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
32914287|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
32914288|NCT04311567|Experimental|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
32914289|NCT04311567|Active Comparator|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
32914290|NCT04259775|Active Comparator|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
32914291|NCT04259775|Active Comparator|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
32914292|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
32914293|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
32914294|NCT01573052|Active Comparator|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
32914295|NCT01573052|Experimental|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
32914296|NCT04993599|Experimental|Pediatric patients|<Intervention> The participants(Pediatric patients) mainly interact with the social robot which is controlled by the researcher behind the scene
32714846|NCT05392712|Experimental|Chest pain patients who will undergo CAG or CTA|
32914297|NCT04993599|Experimental|Carers|<Intervention> The participants(Carers) interact with the social robot and watch how their child interact with the robot which is controlled by the researcher behind the scene
32914298|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
32914299|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
32714847|NCT05392712|Experimental|AMI patients|
32714848|NCT05413148|Active Comparator|Wharton jelly-derived mesenchymal stem cell|Single subtenon injection of Wharton jelly-derived mesenchymal stem cells will be performed on a single eye after randomization
32914300|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
32914301|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
32714849|NCT05413148|Active Comparator|Mesenchymal stem cell exosome (Wharton jelly-derived)|Single subtenon injection of mesenchymal stem cell exosomes (Wharton jelly-derived)will be performed on a single eye after randomization.
32914302|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
32914303|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
32914304|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
32914305|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
32914306|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
32914307|NCT05566028|Experimental|Expermental group 1|Pateints assigned to this group are treated with D150, D759 and D745 formulation I
32914308|NCT05566028|Experimental|Experimental group 2|Pateints assigned to this group are treated with D150, D759 and D745 formulation II
32914309|NCT05566028|Placebo Comparator|Placebo group|Pateints assigned to this group are treated with D150, D759 and D745 placebo
32914310|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
33082136|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
32714850|NCT05413148|Placebo Comparator|Placebo|A single subtenon injection of saline will be performed on a single eye after randomization.
32714851|NCT05412992|Active Comparator|DMTS Patch|DMTS applied to upper outer arm
32714852|NCT05412992|Placebo Comparator|Placebo Patch|Placebo system (with no drug) to match DMTS applied to the upper arm
32914311|NCT04251117|Experimental|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
32914312|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
32914313|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
32914314|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
32914315|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
32914316|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
32914317|NCT04958811|Experimental|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
32914318|NCT01525862|Experimental|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
32914319|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
32914320|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
32914321|NCT05565794|Experimental|Pemigatinib|Intake of 13.5 mg pemigatinib once daily per oral
32914322|NCT04164069|Experimental|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
32914323|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
32914324|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
32914325|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
32914326|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
32914327|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
32914328|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
32914329|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
32914330|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
32914331|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
32914332|NCT01577966|Experimental|Sulfasalazine|
32714857|NCT05392322|Active Comparator|Self-help skills|Effect of self-help skills on fine motor skills in children with down's syndrome
32714858|NCT05392322|Experimental|Virtual video reality gaming|Effects of virtual video reality gaming on fine motor skills in children with down's syndrome
32714859|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
32714860|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
32714861|NCT05352932||patient group|Patients with chronic pancreatitis or idiopathic recurrent acute pancreatitis are considered as study subjects.
32714862|NCT05006378|Placebo Comparator|Placebo Capsule|
32714863|NCT05006378|Experimental|Chamomile Tea|Subjects will consume three servings of chamomile tea throughout the day for the one-week treatment period. Each tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
32714864|NCT05006378|Experimental|Chamomile Extract Capsule|Subjects will consume three chamomile capsules throughout the day for the one-week treatment period. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
32914333|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
32914334|NCT01578044|Placebo Comparator|Control|Usual care
33082137|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
33082138|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
33082139|NCT00562237|Placebo Comparator|1|
33082140|NCT00562237|Experimental|2|
33082141|NCT00562237|Experimental|3|
33082142|NCT00562237|Experimental|4|
33082143|NCT00562237|Experimental|5|
33082144|NCT00562237|Experimental|6|
33082145|NCT00562237|Experimental|7|
33082146|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
32914335|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
32914336|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
32914337|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
32914338|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
32914339|NCT05565170|Active Comparator|Structured ICT-assisted multimodal lifestyle intervention|Participants assigned to this study arm follow an intensive structured, digitally supported multimodal lifestyle intervention programme (combination of individual and group-based in-person consultations/sessions and digital activities in the LETHE mobile phone App). Intervention duration is 2 years.
32714865|NCT04973072|No Intervention|Control|Participants in this arm will not receive any intervention.
32914340|NCT05565170|Sham Comparator|Self-guided multimodal lifestyle intervention|Participants assigned to this study arm receive regular health advice in connection with the study visits (and through a simplified version of the LETHE mobile phone App), and are recommended and encouraged to independently implement healthy lifestyle changes that are suitable and fit in with their daily routine. Intervention duration is 2 years.
32914341|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
32914342|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
32914343|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
32914344|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
32914345|NCT01578902|Experimental|Hypofractionated radiotherapy using SABR|Stereotactic radiation: 35Gy in 5 fractions over 29 days
32914346|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
32914347|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
32914348|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
32914349|NCT04918875||Patients 12 years of age or older with suspected or confirmed COVID-19, deemed to require oxygen.|
32914350|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
32714866|NCT04973072|Experimental|One large reward|Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
32714867|NCT04973072|Experimental|Small wins|Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
32714868|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
32714869|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
32714870|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
32714871|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
32714872|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
32714873|NCT05392088||Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and at least one value of high-sensitivity cardiac troponin I (hs-cTnI) >99th percentile upper reference limit measured during the index hospitalization.
32714874|NCT05392088||No Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and value of high-sensitivity cardiac troponin I (hs-cTnI) <99th percentile upper reference limit.
32714875|NCT05076825|Experimental|Neurodynamic Sliding|participents receive routine physical therapy along with TENS, Hot pack and Neurodynamic Stretching. (For 30 seconds, 3 times per session for 3 alternative days a week & duration of 4 weeks).
32914351|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
32914352|NCT03985761|Experimental|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
32935788|NCT05451979|Experimental|MedBIKE HIIT|Participants will complete the baseline assessments and begin the MedBIKE HIIT Exercise Program intervention within 2-weeks. After the completion of the 12-week program, participants will return for follow-up assessments which will be repeated at 6- and 12-months post intervention.
32935789|NCT05451979|No Intervention|Standard of Care|Participants will complete the baseline assessments and continue with standard of care (no intervention) for 12-weeks then return for a repeat assessment. Participants will then crossover into the MedBIKE HIIT Exercise Program intervention group for 12-weeks. A post-intervention assessment will be completed and follow-up assessments at 6- and 12-months post intervention.
32935790|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
33246483|NCT04018300|Experimental|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
33246484|NCT04018300|Experimental|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
33246485|NCT04018300|Placebo Comparator|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
33246486|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
33246487|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
33246488|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
32714876|NCT05076825|Active Comparator|Static Streching|Participent receive the routine physical therapy treatment that will include TENS, Hot pack and static stretching for 30 seconds and 3 times per session for 3 alternative days a week (duration of 4 weeks).
32714877|NCT04968938|Experimental|MDMA-assisted therapy|Two sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 mg initial dose and optional supplemental dose half that of initial dose 1.5 to 2 hours later
32714878|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
33246489|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
32935791|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
32935792|NCT05442242|Active Comparator|Unicompartmental knee osteoarthritis|
32935793|NCT05442242|Active Comparator|High tibial osteotomy|
33246490|NCT00884494|Experimental|Roux-en-Y gastric bypass|
33246491|NCT00884494|Experimental|Lean|
33246492|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
33246493|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
33246494|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
33246495|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
33246496|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
33246497|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
33246498|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
33246499|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
33246500|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
33246501|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
33246502|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
33246503|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
33246504|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
33246505|NCT00704730|Experimental|1|
33246506|NCT00704730|Placebo Comparator|2|
33246507|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
33246508|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
33246509|NCT04038034|Placebo Comparator|group A|35 patients treated with pressure lowering drugs and placebo
32914353|NCT03985761|Active Comparator|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
32914354|NCT05565014|Experimental|Virus Activated Killer immune Cells（VAK）|The VAK should be given once a week, three times a circle. The VAK could given 1 or 2 circle for each subject. The dosage of Pleural Effusion（more than 10^5/kg cells in 30-50mL solvent） differs from Peritoneal Effusion（more than 10^4/kg cells in 30-50mL solvent）
32914355|NCT05565014|Placebo Comparator|saline|50ml of saline was injected once a week,three times a circle.The saline could given 1 or 2 circle for each subject.
32914356|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
32914357|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
32914358|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
32914359|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
32914360|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
32914361|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
32914362|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
32914363|NCT02809911|Other|Active Provant|Active Provant Treatment
32914364|NCT03910101|Active Comparator|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
32914365|NCT03910101|Active Comparator|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
32914366|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
32914367|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
32914368|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
32914369|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
32914370|NCT01580072|Experimental|Self monitoring for patients with COPD|
32914371|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
32914372|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
33246510|NCT04038034|Experimental|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
32914373|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
32914374|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
32914375|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
32914376|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
33082147|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
33082148|NCT01580683|Experimental|Ascorbic acid|
32745731|NCT04826679|Experimental|Experimental|"Camrelizumab + Cisplatin + Nab-paclitaxel~Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
33246511|NCT04037878|Experimental|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
33246512|NCT04037878|Experimental|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
33246513|NCT04037878|Other|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
32914377|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
32914378|NCT05564858|Experimental|FDA022-BB05|"phase Ia: Participants with locally advanced or metastatic tumor will be administered FDA022-BB05 intravenously once at escalated doses in each cycle (of 21 days) during Phase Ia part of the study until disease progression or intolerable toxicity.~phase Ib: Cohort expansion, Recommended doses from phase Ia."
32914379|NCT05564780|Experimental|Treatment|"Antihypertensive drugs will be provided to the participants in the arm, including RASI and/or a single pill combination based on RASI.~If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided."
32914380|NCT05564780|No Intervention|Control|If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided.
32914381|NCT05564234|Active Comparator|Neoadjuvant chemotherapy|cases with predictive index value score 8 or greater in which primary cytoreductive surgery was not feasible were were referred for neoadjuvant chemotherapy then interval cytoreductive surgery was done
33246514|NCT00881842|Experimental|1|
33246515|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
32914382|NCT05564234|Active Comparator|primary cytoreductive surgery|cases with predictive index value score less than 8 were offered primary cytoreductive surgery.
32914383|NCT05564000|Experimental|Experimental group|"Experimental group: accept three weeks Dating Violence Prevention Program online; every week 20-30 minutes.~The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up design to analyze the immediate and continued educational effects."
32914384|NCT05564000|No Intervention|Control group|Control group: no intervention. The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up.
32914385|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
33082149|NCT01580683|Placebo Comparator|Placebo|
33082150|NCT04623229|Experimental|MCS|
33246516|NCT05668416|Experimental|experiment|The intervention group will include parents who were trained in the preoperative period. The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital.
33246517|NCT05668416|No Intervention|control|The control group will be the oral information group that is in the hospital routine. Parents in this group will be informed verbally when they come to the hospital for anesthesia and file procedures the day before the surgery.
33246518|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
33246519|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
33246520|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
33246521|NCT00885820|Active Comparator|2|No protocol biopsies
33246522|NCT05481216||PLWHIV with COVID-19 cases|Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
33246523|NCT05481216||PLWHIV without COVID-19 controls|Patients at least 18 years of age with documented HIV-1 infection.
33246524|NCT05481216||HIV seronegative patients with COVID-19 controls|Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
32914386|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
32914387|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
32914388|NCT03786003|Active Comparator|Thoracotomy|Open surgery
32914389|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
32914390|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
32914391|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
32914392|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
32914393|NCT05563064|Experimental|Karika Syrup|Karika syrup has been used to treat thrombocytopenia
32914394|NCT05562440|Experimental|Focus Group Discussion on breast cancer risk prediction report|Woman population with no breast cancer who received the dummy report result
32914395|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
32914396|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
32914397|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
32914398|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
32914399|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
32914400|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
32914401|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
32914402|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
32914403|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
32914404|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
32914405|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
32914406|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
33246525|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
33246526|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
32914409|NCT01581710|Active Comparator|montelukast to placebo|14 days
32914410|NCT01581710|No Intervention|Washout|14 days
32914411|NCT01581710|Active Comparator|Placebo to montelukast|14 days
32914412|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
32914413|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
32914414|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
32914415|NCT02889393|Experimental|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
33246527|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
33082151|NCT04623229|Experimental|ReLACS Early|
33082152|NCT04623229|Experimental|ReLACS Standard|
32914416|NCT02889393|Experimental|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
32914417|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
32714879|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
32914418|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
32914419|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
32914420|NCT02819973|Experimental|Educational Video 2|Caucasian Video
32914421|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
32914422|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
32914423|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
32914424|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
32914425|NCT03566667|Other|Standard care|Usual standard care
32914426|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
32914427|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
32914428|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
32914429|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
32914430|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
32914431|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
32914432|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
32914433|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
32914434|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
32914435|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
32914436|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
32914437|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
32914438|NCT01533974|Active Comparator|CBT|
32914439|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
32914440|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
32914441|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
32914442|NCT05556980|Experimental|totally laparoscopic distal gastrectomy|patients in this arm will receive totally laparoscopic distal gastrectomy
33246528|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
33246529|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
32914443|NCT05556980|No Intervention|laparoscopy-assisted distal gastrectomy|patients in this group will receive laparoscopy-assisted distal gastrectomy
32914444|NCT05556044|Other|Empagliflozin 10 MG|
32914445|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
32914446|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
32914447|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
32914448|NCT01583894||Chronic pain patients|
32914449|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
32914450|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
32914451|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
32914452|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
32914453|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
32914454|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
32914455|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
32914456|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
32914457|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
32914458|NCT03138369|Experimental|Vestibular nerve stimulation|Usage of wearable vestibular nerve stimulator that non-invasively stimulates the vestibular nerves by administering a small electrical current through the skin behind the ears. Should be worn up to one hour a day and at least 5 hours a week.
32914459|NCT03138369|Sham Comparator|Sham vestibular nerve stimulation|Usage of wearable control device that appears identical to active device. Instead of stimulating the vestibular nerves this device will discharge its battery into an internal resistor. Should be worn up to one hour a day and at least 5 hours a week.
32914460|NCT01534910|Placebo Comparator|Sugar pill|placebo
32914461|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
32914462|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
32914463|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
32914464|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
32914465|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
33246530|NCT00885898|Active Comparator|2|"Conventional"
32714880|NCT05412758|Experimental|Oesophageal/GOJ cancer|"AROMA 1: 216 treatment naive patients with oesophageal/GOJ cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with oesophageal/GOJ cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
32714881|NCT05412758|Experimental|Gastric cancer|"AROMA 1: 216 treatment naive patients with gastric cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with gastric cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
32714882|NCT05412758|Experimental|Control/ normal patients with upper gastrointestinal symptoms|"AROMA 1: 216 control subjects will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 control subjects will be recruited for biosample collection at the time of their routine endoscopy procedure."
32714883|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
32714887|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
32714888|NCT05352464|Experimental|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
32714889|NCT05352464|Active Comparator|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.
32914466|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
32914467|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
32914468|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
32914469|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
33246531|NCT05462574||Participants with Pulmonary Arterial Hypertension (PAH)|Participants with heritable, idiopathic, and scleroderma associated PAH.
33246532|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
33246533|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
32914470|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
33246534|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
33246535|NCT05093322|Experimental|Part 1- Dose escalation|Dose escalation study with sequential dose escalation of surufatinib in combination with gemcitabine. Patients with any recurrent or refractory solid tumors or lymphoma, who have a known or expected dysfunction of VEGFR-1, -2, and -3; FGFR-1; or CSF-1R pathways may be enrolled.
33246536|NCT05093322|Experimental|Part 2 - Dose expansion|Once the MTD/RP2D has been determined in the part 1 portion of the study, the part 2 disease specific cohorts for patients with refractory or recurrent osteosarcoma, Ewing Sarcoma, and RMS and non- RMS will open for enrollment.
33246537|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
33246538|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
33246539|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
32745732|NCT04813341|Experimental|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles
33246540|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
33246541|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
32914471|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
33246542|NCT00810381|Placebo Comparator|4|Physiologic saline solution
33246543|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
33246544|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
32914472|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
33246545|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
33246546|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
33246547|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
33246548|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
33246549|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
33246550|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
33246551|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
33246552|NCT00699972|Experimental|1|
33246553|NCT00699972|Experimental|2|
33246554|NCT00699972|Placebo Comparator|3|
32914473|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
32914474|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
32935794|NCT05451823|Experimental|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
32935795|NCT05441150|Active Comparator|Ketamine Group|Patients who received low-dose ketamine infusion
33246555|NCT00800475|Active Comparator|Test Drug|
33246556|NCT00800475|Active Comparator|Reference Drug|
33246557|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
33246558|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
33246559|NCT00922311|Experimental|Aliskiren|
33246560|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
33246561|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
33246562|NCT00810927|Placebo Comparator|3|Physiologic saline solution
33246563|NCT00813657|Experimental|Lifestyle counseling|
32914475|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
32914476|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
32914477|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
32914478|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
32914479|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
32914480|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
32914481|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
32914482|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
32914483|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
32914484|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
33246564|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
32914485|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
32914486|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
32914487|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
32914488|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
33246565|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
32914489|NCT04737291|Experimental|Angioplasty by DCB|angioplasty of stenotic , ocluded or recoil segment using drug coated ballon
32914490|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
32914491|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
32914492|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
32914493|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
32914494|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32914495|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
32914496|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
32914497|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
32914498|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
32914499|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
32914500|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
32914501|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
32765228|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive~EDSS:~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
32765229|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive~EDSS:~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
32765230|NCT04937855||Control group|25 gender and age matching healthy controls
32765231|NCT04937855||ARDS group 1|100 ARDS patients at the time of check in hospital
32765232|NCT04937855||ARDS group 2|100 ARDS patients at the time of 24h after check in hospital
32765233|NCT04937855||ARDS group 3|100 ARDS patients at the time of 48h after check in hospital
32765234|NCT04937855||ARDS group 4|100 ARDS patients at the time of 72h after check in hospital
32765235|NCT03572413|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
32765236|NCT03572413|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
32765237|NCT04946747|Active Comparator|Trained|"Both groups will be shown how to use the Virtual Reality goggles. The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.~Both groups will also wear our smart head-impact sensor system to measure their response to training."
32765238|NCT04946747|Active Comparator|Control|Both groups will be shown how to use the Virtual Reality goggles. The Control group will also receive the same CS and the same US, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge. Both groups will also wear our smart head-impact sensor system to measure their response to training.
32765239|NCT04522375|Experimental|FP-045|The study will enroll a total of 6 young adult/adolescent patients progressing through three dose levels, followed by a minimum of 8 and up to 12 pediatric patients progressing through up to three dose levels.
32765240|NCT04937933|Active Comparator|Coolant spray group|Coolant spray (Cryos ®Spray, Phyto Performance, Italy) was applied as suggested by the manufacturer (at a distance of 20 cm from the injured area for 5-10 s). Saline solution was sprayed for the same duration and at the same distance from the injured area as well. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
32765241|NCT04937933|Placebo Comparator|Placebo group|A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
32765242|NCT04956419|Experimental|Treatment group A|SHR8008 capsule
32765243|NCT04956419|Active Comparator|Treatment group B|Fluconazole capsule
32765244|NCT04956653||Patients diagnosed with Cervical Degenerative Disease|Patients who suffered from Cervical Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to CDD group.
32765245|NCT04956653||Patients diagnosed with Thoracic Degenerative Disease|Patients who suffered from Thoracic Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to TDD group.
32765246|NCT04956653||Patients diagnosed with Lumbar Degenerative Disease|Patients who suffered from Lumbar Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to LDD group.
32765247|NCT04615429|Experimental|Mesenchymal Stromal cells|Approximately 1x10E6 MSC/kg
32765248|NCT04615429|Placebo Comparator|Control group|Solution identical to experimental treatment, without the MSC
32765249|NCT04956965|Active Comparator|Patient free cardiac amyloidosis|Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
32765250|NCT04956965|Experimental|Patient with Transthyretin cardiac amyloidosis|Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
32905413|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
32914502|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
32914503|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
32914504|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
32914505|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
32914506|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
32914507|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
32914508|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
32914509|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
32914510|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
32914511|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
32914512|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
32914513|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
32914514|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
32914515|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
32914516|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
32914517|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
32914518|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
32914519|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
32914520|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
32914521|NCT03004911|Experimental|Mobile application|
32914522|NCT03004911|Active Comparator|Paper booklet|
32914523|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
32914524|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site~Total 1.0mL (For both hands total 2.0 mL)"
32914525|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
32914526|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
32914527|NCT02914509|Experimental|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
32914528|NCT02914509|Placebo Comparator|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
32914529|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
32914530|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
32914531|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
32914532|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
32914533|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
32914534|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
32914535|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
32914537|NCT02738489|Experimental|Injection SHR-1210 60mg Cohort|
32914538|NCT02738489|Experimental|Injection SHR-1210 200mg Cohort|
32914539|NCT02738489|Experimental|Injection SHR-1210 400mg Cohort|
32914540|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
32935796|NCT05441150|Sham Comparator|Control group|Patients who received 0.9% Sodium Chloride Solution, Intravenous, (NaCl) infusion
33246566|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
33246567|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
32765251|NCT05114395|Experimental|Telerehabilitation Group|"The intervention group includes a hybrid program of face-to-face sessions and video sessions. In the first consultation, a face-to-face one, patients will be instructed with behavioral and lifestyle measures and it will be prescribed a 12-week exercise program, including exercises to be performed three times a day and two weekly exercise sessions - three face-to-face sessions (2 initial and one at 8 weeks) and video sessions of 30 minutes, divided into 3 phases with gradual addition of exercises of increasing difficulty in terms of duration, number of repetitions and positions.~In the middle of the treatment (at 6 weeks) a medical teleconsultation is performed for reassessment. In the end of the 12-week program there will also be a face-to-face consultation."
32765252|NCT05114395|Active Comparator|Face-to-Face Group|The control group develops the entire program in face-to-face consultations and exercise sessions.
32765253|NCT04946669|Experimental|Refractory Dermatomyositis|Patients who have been receiving glucocorticoids in combination with at least one immunosuppressive therapy for at least 3 months and who have failed therapy or are intolerant to therapy
32765254|NCT03437941|Experimental|Dose Determination Segment 1|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
32765255|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
32765256|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
32765257|NCT03437941|Experimental|Dose Expansion - ARant-Resistant Cohort|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
32765258|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm A|Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
32765259|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm B|Patients randomized to this cohort will receive enzalutamide, placebo, and CORT125281.
32765260|NCT04946357|Experimental|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))
32765261|NCT04946357|Experimental|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))
32765262|NCT03219775|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
32765263|NCT05114317||Women with Lipoedema|No interventions administered.
32765264|NCT04946045|Experimental|İntervention (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking) Group|"Tactile/Kinesthetic Stimulation (15 min): It was applied 3 times a day, once every 3 hours for 10 days.~Nonnutritive Sucking: It was applied 8 times a day for 10 days with Orogastric (OG) feeding throughout the feeding."
32765265|NCT04946045|No Intervention|Control (Nonnutritive Sucking) Group|1) Nonnutritive Sucking: Administered during feeding with Orogastric (OG) 8 times a day for 10 days.
32765266|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
32765267|NCT03100045|Experimental|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
32765268|NCT03100045|Experimental|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
32765269|NCT03100045|Experimental|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
32765270|NCT03100045|Experimental|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
32765271|NCT03100045|Experimental|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
32765272|NCT03100045|Experimental|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
32765273|NCT04956107||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
32765274|NCT04956107||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
32765275|NCT02986087|Experimental|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
32765276|NCT04946123|No Intervention|methimazole (control)|Patients with hyperthyroidism under methimazole treatment
32765277|NCT04946123|Experimental|methimazole+L-carnitine+selenium (intervention)|Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
32765278|NCT04945889||Geriatric inpatients at risk for sepsis|"Consecutive patients admitted to an Acute Geriatric Unit for any reason presenting at least one National Institute for Health and Care Excellence (NICE) risk factor for sepsis (age ≥75 years, impaired immune function, long-term corticosteroid therapy, immunosuppressive or antineoplastic drug treatment, surgery or other invasive procedures within 6 weeks, any breach of skin integrity, intravenous drug misuse, indwelling lines or catheters).~In those with suspected infection (i.e. antibiotic prescription and a culture test within 24 hours before-72 hours after), clinical parameters (respiratory rate, blood pressure, heart rate, body temperature, peripheral oxygen saturation, mental status) were assessed at least twice daily throughout hospital stay and used by study investigators to determine the qSOFA, NEWS and MEWS."
32765279|NCT04945811|Experimental|Interlukein 6 and procalcitonin|Interlukein 6 and procalcitonin levels in COVID 19 patients
32765280|NCT04945265||Women aged <30|
32765281|NCT04945265||Women aged 30-36|
32765282|NCT04945265||Women aged 37-40|
32765283|NCT04945265||Women aged >40|
33246568|NCT05066217|Placebo Comparator|Placebo|Placebo Comparator: Matching Placebo - Cohort 2 Matching placebo will be administered twice a day (BID) in equally divided doses with food.
33082153|NCT04623112|Other|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
33082154|NCT04623112|Experimental|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
33246569|NCT05066217|Experimental|Active|"Drug: EPX-100 drug product is an oral aqueous solution of clemizole hydrochloride and provided in a concentration of 5 mg/mL.~Other Name: Cohort 1"
33246570|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
33246571|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
33246572|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
33246573|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
33246574|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
33246575|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
33246576|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
33246577|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
33246578|NCT00811161|Experimental|needle free injector of HA|
33246579|NCT00611026|Active Comparator|1|
33246580|NCT00611026|Placebo Comparator|2|
32765284|NCT04945265||Women undergoing egg freezing/male factor infertility/genetic testing|
32765285|NCT04945265||unidentified cause of infertility|
32765286|NCT04945265||PCOS|
32765287|NCT04945265||endometriosis|
32765288|NCT04945265||tubal disorders|
32765289|NCT04945265||ovulatory disorders|
32765290|NCT04945265||other causes of infertility e.g., fibroids.|
32765291|NCT04955561|Experimental|Randomised to begin with oxygen-supplementation at 10L/min during ESWT|Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
32765292|NCT04955561|Experimental|Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
32935797|NCT05439980||CKD aged 8-<13 years|8-<13 years n = 25
32935798|NCT05439980||CKD aged 13-18 years|13-18 years n = 25
32935799|NCT05439980||Parents/caregivers|Parent/caregivers of children and young people with CKD 4-5D n=50
32935800|NCT04270214|Other|Dysport|Single arm study, all participants will receive Dysport injections
32935801|NCT05018689|Active Comparator|Aevidum curriculum|Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
32935802|NCT05018689|Active Comparator|Aevidum curriculum + club|Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.
32935803|NCT04238624|Experimental|BRAF-mutant ATC|Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
32935804|NCT04217707|Other|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
32935805|NCT05450744|Experimental|131I-TLX101 + standard of care|
32935806|NCT04747405|No Intervention|A standard|standard of care
32935807|NCT04747405|Experimental|B therapy group|standard of care and therapy group
32935808|NCT05144022|Experimental|Interventions group: High stress condition (bungee jump)|25-30 healthy male volunteers participating in a bungee jump
32935809|NCT05144022|Placebo Comparator|Control group: No stress condition|10-15 healthy males serving as a control group without undergoing a stress event/intervention
32935810|NCT05450588||Sedentary|It will be obtained by open call for both students and administrative staff at the CES University.
32935811|NCT05450588||Physically active|Under the collaboration framework bet ween DBSS international SAS and Smart Fit Colombia, a sample of personal trainers who reside and work in Medellín, or its metropolitan area will be invited to participate.
32935812|NCT05450588||Athletes|Under the collaboration framework between DBSS international SAS and ARTHROS Physiotherapy and Exercise Center, a sample of professional athletes from different sports disciplines will be invited to participate.
32935813|NCT04746859|Experimental|Intervention|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training), complete the baseline survey then be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer. Patients will be administered additional surveys at 3 and 6 months and a final survey at 12 months.
32935814|NCT04746859|Other|Wait-list Control|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training) and complete a baseline survey, after which they will receive usual care from their healthcare providers. Patients will be administered another survey at 3 months and a final survey at 6 months. After study completion (about 6-months after the initial prevention visit), patients will be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer.
32914541|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
32914542|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
32914543|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
32914544|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
32914545|NCT02430233|No Intervention|No treatment|No treatment
32914546|NCT05489705||Mavacamten|Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM
32914547|NCT05489705||Beta-blocker (BB) / non-dihydropyridine (non-DHP) calcium channel blocker (CCB) / disopyramide|Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM
32914548|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
32914549|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
32914550|NCT05484011|Experimental|Part A|Patients will have regularly scheduled study visits on days 1, 8, and 15 of each cycle. On Day 1 patients will receive odetiglucan and CDX-1140. On Days 8 & 15 only odetiflucan. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
32914551|NCT05484011|Experimental|Part B|Patients will have regularly scheduled study visits on day 1 of each cycle. On Day 1 patients will receive odetiglucan and CDA-1140. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
32714890|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
32714891|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
32914552|NCT05474807|Experimental|Intervention group|The experimental arm will receive the online strengths use intervention program over a period of 6 weeks, through an LMS software solution.
32914553|NCT02417285|Experimental|CC-122 in combination with Obinutuzumab|CC-122 will be administered orally QD starting on Day 1 for 5 consecutive days followed by 2 days off study drug every 7 days (5/7-day schedule) in each 28-day cycle in combination with Obinutuzumab administered as an intravenous (IV) infusion at a dose of 1000 mg on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8.
32914554|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
32914555|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
32914556|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
32914557|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
33246581|NCT00611026|Experimental|3|
33246582|NCT00813969|Experimental|Autologous MSC transplantation|
32714892|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
32914558|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
32914559|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
32914560|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
32914561|NCT02981420|Experimental|Safety Planning|Intervention group
32914562|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
32914563|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
32914564|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
32914565|NCT03001622|Other|IFX-1|
32914566|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
32914567|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
32714893|NCT05077371|Experimental|Experimental group 1|newly diagnosed breast cancer patients receiving the peer support program at the beginning of their medical treatment.
32714894|NCT05077371|Experimental|Experimental group 2|newly diagnosed breast cancer patients receiving the social peer support program at the end of their medical treatment.
32914568|NCT05470985|Experimental|Ozanimod Dose Level 1|
32914569|NCT05470985|Experimental|Ozanimod Dose Level 2|
32714895|NCT05352152||Patients with ascites infection|Patients who is confirmed with ascites infection or clinically diagnosed as ascites infection will be enrolled in this cohort.
32914570|NCT05465525|Placebo Comparator|Control group|Patients will be operated under general anesthesia.
32914571|NCT05465525|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
32914572|NCT05465525|Active Comparator|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
32914573|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
32914574|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
32914575|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
32914576|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
32914577|NCT01594424|Experimental|IVIG + Tocilizumab|
32914578|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
32914579|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
32914580|NCT01595516|Active Comparator|Nebivolol|
32914581|NCT01595516|Active Comparator|Metoprolol|
32914582|NCT01595516|Placebo Comparator|Placebo|
32914583|NCT01595516|Other|Bradykinin|
32914584|NCT01595516|Other|Saline|
32914585|NCT01595516|Other|Vitamin C|
32714896|NCT05077215|Experimental|Arm 1: EG-007+ Len+Pem Regimen|
32714897|NCT05077215|Active Comparator|Arm 2: Len+Pem Regimen|
32914586|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
32914587|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
32914588|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
32914589|NCT01596842|Active Comparator|Omega-3 fatty acid|
32914590|NCT01596842|Placebo Comparator|Olive oil|
32914591|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
32914592|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
32914593|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
33082155|NCT04623112|Experimental|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
33246583|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
33246584|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
33246585|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
32714898|NCT05391542|Experimental|Coaxial tubular superelastic nickel-titanium Group (TuNT)|0.016-inch coaxial tubular superelastic nickel-titanium archwire (TuNT) (Speed tubular supercable, Speed System™ Orthodontics, Ontario, Canada) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks
32714899|NCT05391542|Experimental|Copper-nickel-titanium Group (CuNT)|0.014-inch Copper-nickel-titanium archwire (CuNT) (Damon Optimal-Force Copper Ni-Ti®, Ormco, Glendora, Calif) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks.
32714900|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
32714901|NCT05412134|Experimental|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed at Visit 1 and Visit 2 to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
32765293|NCT04955561|Experimental|Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
32765294|NCT04955639|Active Comparator|Control|A commercially available mobile phone app and program
32765295|NCT04955639|Active Comparator|Pivot|Pivot mobile phone app and program
32765296|NCT04945577||Experimental: Mild Clinical Group|patients showing mild clinical symptoms without pneumonia.
32765297|NCT04945577||Experimental: Moderate Clinical Group|patients with fever, other respiratory symptoms, and pneumonia findings based on radiological imaging
32765298|NCT04945577||Experimental: severe/critical clinical group|severe one of these as follows; patients with hypoxia (≤93% oxygen saturation), respiratory distress (RR >30 times per minute), partial pressure of arterial blood oxygen (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) ≤ 300 mmHg, patients whose chest imaging shows that lung damage develops significantly within 24 to 48 hours, or critical one of these as follows; respiratory failure requiring mechanical ventilation, signs of septic shock with multiple organ failure requiring intensive care unit admission.
32765299|NCT04936841|Experimental|NKTR-214, anti-PD therapy plus Palliative Radiation|"Cycle 1 consists of anti-PD-1 therapy (200mg) and NKTR-214 (0.006 mg/kg3 administered intravenously), followed by palliative radiation (8 Gy x 3 or 4 Gy x 5 fractions) combined with anti-PD-1 therapy and NKTR-214 in cycle 2.~In subsequent cycles participants will receive NKTR-214 and anti-PD-1."
32765300|NCT04945343|Other|Children who had growing rods instrumentation for correction of Early Onset Scoliosis|Growing spine profiler instrumentation
32765301|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
32765302|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
32765303|NCT04945499|Other|D-glucose|During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
32765304|NCT04944875|Active Comparator|Group I; group headphone|In the first group of the patients in the isolation group wear the headphones but do not listen to music during the procedure. Then patients were sedated by midazolam and propofol.
32765305|NCT04944875|Active Comparator|Group II; group music|"In the second group of the patients wear the headphones and listen to Vivaldi's The Four Seasons violin concertos by sound isolating headphones during the procedure.~Then patients were sedated by midazolam and propofol."
32765306|NCT04944875|Active Comparator|Group III; group maternal voice|In the third group of the patients wear the headphones and listen the maternal voice during the procedure.Then patients were sedated by midazolam and propofol.
32765307|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
32765308|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
32765309|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
32765310|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
32765311|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
32765312|NCT04936295|Experimental|Fulvestrant plus Anlotinib|Each participant receives fulvestrant combined with anlotinib.
32765313|NCT04955873|Experimental|Test - Group A - Dentsply biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Dentsply Sirona Symbios Xenograft Granules and the resorbable collagen membrane Dentsply Sirona Symbios Collagen Membrane SR."
32714902|NCT05412134|Active Comparator|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
32714903|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~Clinician's diagnosis based on his/her assessment~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
32914594|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
32914595|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
32914596|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
32914597|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
32914598|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
32914599|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
32914600|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
32914601|NCT02980952|Placebo Comparator|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
32914602|NCT02980952|Experimental|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
32914603|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
32914604|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
32914605|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
32914606|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
32914607|NCT05566808|Other|Autologous Costal Cartilage Graft|Patients undergoing rhinoplasty will receive autologous rib graft.
32914608|NCT05566808|Other|Costal Cartilage Allograft|Patients undergoing rhinoplasty will receive costal cartilage allograft.
32914609|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
32714904|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
32714905|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
32914610|NCT03001232|No Intervention|Care as usual|The control group received care as usual
32914611|NCT05566418|No Intervention|Group A|Group A will get standard therapy and the Mulligan mobilization technique for 12 sessions. A Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide. The patient will be instructed to constantly extend their wrists while the therapist applies manual resistance to their attempts, and the therapist will continue to work on the patient. When the user can fully extend their wrist without discomfort, the lateral glide will be abolished. Three repeats will be performed, each separated by a fifteen-to twenty-second interval.
32914612|NCT05566418|Experimental|Group B|In addition to the standard treatment, Group B participants will receive 12 sessions of myofascial release technique and Mulligan mobilization. Participants will be instructed to lie supine on the plinth with the afflicted arm internally rotated, elbow slightly flexed and pronated, and palm of hand on the plinth. While standing on the side of the body affected by the ailment being treated, the therapist turned their body to face the affected hand. Myofascial release will be performed on the patient The therapeutic session will last five minutes and will be repeated twice.
32914613|NCT05566340||isolated aortic valve replacement group|Isolated aortic valve replacement surgery.
32914614|NCT05566340||aortic valve replacement with mitral valve repair group|Aortic valve replacement with mitral valve repair
32914615|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
32914616|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
32914617|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
32914618|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
32914619|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
32914620|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
32914621|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
32914622|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
32914623|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
32914624|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
32914625|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
32914626|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
32914627|NCT04769882|Active Comparator|Er:YAG laser therapy group|The removal of caries was performed with Er:YAG laser (Doctor Smile, Lambda SRL,Italy) with BOOST handpiece to cut the enamel and open the cavity, and 90° handpiece to remove the carious dentin with tips of 800 µ in diameter and 8 mm or 12 mm in length, in relation to the depth and distance of the lesion.
32714906|NCT05559008|Experimental|T1 subtypes based on next generation sequencing results|T1 subtypes based on next generation sequencing results
32714907|NCT05559008|Experimental|T2 subtypes based on next generation sequencing results|T2 subtypes based on next generation sequencing results
32714908|NCT05559008|Experimental|T3.1 subtypes based on next generation sequencing results|T3.1 subtypes based on next generation sequencing results
32714909|NCT05559008|Experimental|T3.2 subtypes based on next generation sequencing results|T3.2 subtypes based on next generation sequencing results
32714910|NCT05076669|Active Comparator|Control|The control group will receive the routine care prescribed by the sites and will be provided with ostomy equipment by FSK.
32714911|NCT05076669|Experimental|interventional group|The interventional group will benefit from delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites.
32714912|NCT05389904|Active Comparator|Patients colonized with toxigenic C. difficile who do not receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive standard of care
32714913|NCT05389904|Active Comparator|Patients colonized with toxigenic C. difficile who receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive a preemptive prevention bundle for C. difficile including enhanced room cleaning, C. difficile precautions, pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
32714914|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
32714915|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
32714916|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
32914628|NCT04769882|No Intervention|Traditional therapy group|The removal of caries was performed with manual and rotating instruments, such as dentin spoon (ASA Dental S.p.a.), turbine (NSK Dental Italy S.r.l.) with diamond burs (Kerr Dental Italia S.r.l.) to cut the enamel and open the cavity and drill handpiece (KaVo Dental Italia S.r.l.) with tungsten carbide burs (Kerr Dental Italia S.r.l.) to remove the infected dentin.
32914629|NCT05462717|Experimental|RMC-6291|Dose Escalation and Dose Expansion
32914630|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
32914631|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
32914632|NCT05460299|Experimental|Telko plus conventional physical therapy (CPT)|All patients received 15-minute CPT, three times a week, for four weeks. The patients in the experimental group received 15-minute Telko at the end of each CPT session.
32914633|NCT05460299|Active Comparator|Conventional physiotherapy|All patients received 15-minute CPT, three times a week, for four weeks.
32914634|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
33246586|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
32714917|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
32714918|NCT05351840|Experimental|Period I|Subject will receive Drug(LivaloV), then take it by oral, once-daily form Day 1 to Day 7
32714919|NCT05351840|Experimental|Period II|Subject will receive Drug(A), then take it by oral, once-daily form Day 14 to Day 23
32914635|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
32914636|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
32914637|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
32914638|NCT05451017|Experimental|AEF0117 1.0 mg in fasted condition|16 participants receive 1 dose of AEF0117 1 mg in fasted condition
32914639|NCT05451017|Experimental|AEF0117 1.0 mg once daily (QD) in fed condition|16 participants receive 1 dose of AEF0117 1 mg fed condition
32914640|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
32914641|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
32914642|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
32914643|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
32914644|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
32914645|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
32914646|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
32914647|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
32914648|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
32914650|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
32914651|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
32914652|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
32914653|NCT05044052|Experimental|Intervention Group - Viral prescription pad + emphasis|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. As part of the intervention, these physicians will also receive additional emphasis on the viral prescription pad by 1) encouraging it in the dissemination email of the MyPractice feedback report, and (2) mailing a paper version of the viral prescription pad with instructions on embedding the viral prescription pad into the recipient's EMR.
32914654|NCT05044052|No Intervention|Control group|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. This group will not receive any additional emphasis on the viral prescription pad and will not receive a paper copy in the mail.
32914655|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
32914656|NCT02988947|No Intervention|Control Group|No intervention / Standard care
32914657|NCT05042726|Experimental|cTBS First|The first stage, participants received cTBS treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with pseudo-stimulation for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
32714920|NCT05351840|Experimental|Period III|Subject will receive Drug(LivaloVA), then take it by oral, once-daily form Day 24 to Day 30
32714921|NCT05076201|Experimental|Patients with completed rehab|The aim of this research is to follow-up a cohort of patients at the end of their detoxification cure (cocaïne).
32714922|NCT05557526|No Intervention|Standard Medical Care Control Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation without additional intervention.
32714923|NCT05557526|Experimental|Optimize Expectation Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation and an additional verbal intervention to optimize the expectation of the patient towards the procedure.
32714924|NCT05063175|Active Comparator|Control Group|Children in the control group received the conventional physical therapy protocol which was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking.
33246587|NCT00646113|Experimental|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
32714925|NCT05063175|Experimental|Experimental Group|The children in the experimental group received the conventional protocol applied to the control group. Further, they wore TheraTog orthotic undergarment with its strapping system for 8 hours daily for 12 successive weeks.
32714926|NCT05350826|Experimental|Ambulatory medical assistance|Patient benefiting from the ambulatory medical assistance nurse program in addition to conventional care for patients chronic lymphoid leukemia under targeted therapy
32914658|NCT05042726|Experimental|Pseudo-stimulation First|The first stage, participants received pseudo-stimulation treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with cTBS for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
32914659|NCT04431479||Observational (questionnaire, biospecimen, chart review)|Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.
32914660|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
32914661|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
32914662|NCT01735955|Experimental|Nilotinib|All participants who were on nilotinib treatment in a Novartis-sponsored study and were benefiting from the treatment as judged by the investigator, will receive nilotinib at the starting dose of the parent study. After this, the dose of nilotinib is based on the investigator's judgment.
32914663|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.~3400 pregnant women in early pregnancy will be studied in this cohort."
32914664|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.~4000 pregnant women in early pregnancy will be studied in this cohort."
32914665|NCT03000764|Experimental|Biomarkers|
32914666|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
32914667|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
32914668|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
32914669|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
32914670|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
32914671|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
32914672|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
32914673|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
32914674|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
32914675|NCT04980482|Experimental|Cohort A, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
32914676|NCT04980482|Experimental|Cohort A, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
32914677|NCT04980482|Experimental|Cohort B, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
32914678|NCT04980482|Experimental|Cohort B, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
32914679|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
32914680|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
32914681|NCT04349189||Group 3|50 Men and Women with sickle cell trait
33246588|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
33246589|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
33246590|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
32714927|NCT05350826|No Intervention|Conventional care|Patient benefiting from conventional care for patients chronic lymphoid leukemia under targeted therapy
32914682|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait, or VTE
32914683|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
32914684|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
32914685|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
32914686|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
33246591|NCT04016883|Sham Comparator|Conventional web platform|Participants asked to review the web platform for 4 weeks.
33246592|NCT04016883|Experimental|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
33246593|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
32914687|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
32914688|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
32714928|NCT05053425|Experimental|Venetoclax group|"Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc.~Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients. In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7 days for MRD negative.~regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the patient's ECOG performance status ≥2,the reduction of regimen IA(cytarabine+idarubicin)was 5+2.~Maintenance therapy: azacytidine 75mg/m2, d1-7, sc."
32914689|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
32914690|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
32914691|NCT03010683|Active Comparator|liraglutide|
32914692|NCT03010683|Active Comparator|Metformin|
32914693|NCT05467046||AD-patients|
32714929|NCT02318134|Experimental|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
32914694|NCT04877678|Active Comparator|Treatment group|Participants will be treated with bepotastine.
32714930|NCT02318134|Placebo Comparator|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
32714931|NCT05541380||Cohort A|patients who were pathologically (histologically) diagnosed as papillary carcinoma (PTC). They are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
32714932|NCT05541380||Cohort B|patients who were pathologically diagnosed as DTC other than PTC, which includes follicular carcinoma, Hurthle cell carcinoma, and poorly differentiated carcinoma. The patients are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
32714933|NCT05541380||Cohort C|patients who were pathologically diagnosed as medullary thyroid cancer (MTC) with persistent disease.
32914695|NCT04877678|Placebo Comparator|Placebo group|Participants will be treated with identical looking placebo.
32914696|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
32914697|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
32914698|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
32914699|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
32914700|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
32914701|NCT05420207||MSM patients|
32914702|NCT05420207||Physician treating MSM patients|
32914703|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
33246594|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
32714934|NCT05541380||Cohort D|patients who were pathologically diagnosed as anaplastic thyroid cancer (ATC).
32714935|NCT05541380||Cohort E|"the patients who had performed large scale NGS oncopanel test previously and fulfil with the criteria in cohort A, B, C, or D.~The patients must meet all the inclusion criteria and none of the exclusion criteria in each cohort."
32714936|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
32714937|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
32714938|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
32714939|NCT05350436|Experimental|Young adult non singers|
32714940|NCT05350436|Experimental|Young adult singers|
32914704|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
32914705|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
32714941|NCT05350436|Experimental|Older adult non singers|
32714942|NCT05350436|Experimental|Older adult singers|
32714943|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
32714944|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
32714945|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
32714946|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
32714947|NCT05350124|Experimental|Group 1|Vitamin C (200 mg) capsule, and vitamin E (400 IU) capsule every day for 12 weeks.
32714948|NCT05350124|Experimental|Group 2|Vitamin C (200 mg) capsule, and placebo every day for 12 weeks.
32714949|NCT05350124|Experimental|Group 3|Vitamin E (400 IU) capsule, and placebo every day for 12 weeks.
32714950|NCT05350124|Experimental|Group 4|Placebo capsule (2 pills) every day for 12 weeks.
32714951|NCT02329899||Possible MBD|"Defined by:~a bleeding score >= 4 in adults;~a bleeding score >= 2 in children (for girls, up to menses);~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.~In this group, the second step of investigations will be performed."
32714952|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
32714953|NCT05389826|Experimental|mHealth App group|Patients will be followed with the developed mobile web app,
32714954|NCT05389826|No Intervention|Control|Patients will be treated according to the current clinical practice.
32714955|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
32714956|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
32714957|NCT05389436|Experimental|Experimental|The patient is discharged from the ER following X-ray, casting, charts. The patient is contacted when surgery is scheduled, and this is performed in a ambulatory setting
32714958|NCT05389436|Active Comparator|Standard|The patient is admitted from the ER, surgery is performed when possible in regards to surgical capacity and swelling. Discharged when mobilised with cast.
32714959|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
32714960|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
32714961|NCT05075655|Experimental|EBUS-MFB and EBUS-TBNA|patient will have both TBNA and MFB in the same operating time
32714962|NCT05345054||Phase 1|Study Population and Enrollment. To ensure survey feasibility and acceptability for our target population we will purposively recruit older African American patients at each of the three participating sites. Using conservative estimates of clinical volume as well as US county level census data we estimate enrolling 3 elderly (>65 years of age) African American participants per site per week with a target enrollment of 12 patients per site.
32714963|NCT05345054||Phase 2|To gain a broad understanding of barriers to surgical access and care in the Deep South, each study site will conduct key informant interviews. Participants will be recruited from five socioecological levels: patient, caregivers/provider, organizational, community, and policy-levels. At each site, two key informant interviews will be performed at each socioecological level (2 patients, 2 caregivers, 2 providers, 2 organizational leaders, 2 community leaders, and 2 policy leaders = 12 per site). We will purposively sample 100% of the participants at the patient and caregiver level (n=12) to be African American and >65 years old.
32714964|NCT05345054||Phase 3|"Enrollment Process. Eligibility criteria for this phase of study enrollment will be broadened to include all English-speaking patients >18 years of age undergoing or having recently undergone (<7 days) an ACS-NSQIP defined surgical procedure. At each site, eligible participants will be approached by a trained research associate pre-operatively in clinic (for elective cases) or post-operatively in the hospital (for emergency cases <7 days). Because each enrollment site has a unique schedule, site representatives will coordinate the most efficient weekly schedule.~We expect to reach our target enrollment (100 participants total, 33 at each site) in 1 year based on conservative estimates of clinical case volume. We expect to enroll at least 20% elderly participants (>65 years of age) and between 30-50% African American participants based on county level (Greenville - Butler County, Demopolis - Marengo County, Alexander City - Tallapoosa County) census data."
32714965|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
32714968|NCT05018871|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
32914706|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
32914707|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
32914708|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
32935815|NCT05450510|Active Comparator|Accelerated (ACCEL) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
32914709|NCT05408585|Active Comparator|"SIFIB with concentration A"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles. Suprainguinal fascia iliaca block will be performed with concentration A."
32914710|NCT05408585|Active Comparator|"SIFIB with concentration B"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles.Suprainguinal fascia iliaca block performed with concentration B"
32914711|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
32914712|NCT03005132||GBM tissues|GBM tissues from GBM patients
32914713|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
32914714|NCT04749407||chemoradiotherapy|
32914715|NCT05460182|Experimental|CAF+CTG|"After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed.~A 1-2-mm-thick CTG was harvested using a single incision approach from the palate in the area between the second pre-molar and the second molar. The wound on the donor site of the palate was then sutured. The graft was positioned on the instrumented root surface immediately apical or at the level of the CEJ and then stabilized using a compressive crossing suture, anchored to the periosteum apical to the graft and closed with a palatal knot. The flap was coronally displaced 1-2 mm above the CEJ and sutured"
32914716|NCT05460182|Active Comparator|CAF|After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed. The flap was coronally displaced 1-2 mm above the CEJ and sutured
32914717|NCT05373017|Experimental|EGS Delirium Model|The delivery of the model will occur in five phases that correspond to the known stages of recovery after surgery. During the acute stage (0 - 1 month after surgery), participants will undergo the initial case review and two initial virtual visits, and the development of the recovery care plan. During the recovery (2 - 6 months after surgery) and maintenance (7-12 months after surgery) stages, the participants will undergo the interaction phase of the EGS Delirium Recovery Model.
32914718|NCT05373017|Other|Usual Care|Participants will receive the usual rehabilitation and post-operative care.
32914719|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
32914720|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
32914721|NCT03012477|Experimental|cisplatin + AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.~AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
32914722|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
32714969|NCT05388578||Primary cohort|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps.
32714970|NCT05388578||Patients with indication for AF|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps. Patients with an indication for atrial fibrillation (AF) will additionally receive a wrist-worn single-lead ECG device.
32714971|NCT05018793|Experimental|Treatment Group|Single intrathecal injection of 100 million cells
32714972|NCT05344586|Experimental|Intervention group|Hamstring stretching program with neural load
32714973|NCT05344586|Experimental|Control group|Hamstring stretching program without neural load
32935816|NCT05450510|Active Comparator|Slow (SLOW) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
33246595|NCT00814203||Chronic obstructive lung disease|those with a condition
33246596|NCT00422383|Experimental|1|
33246597|NCT00422383|Experimental|2|
33246598|NCT00422383|Experimental|3|
33246599|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
33246600|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
33246601|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
33246602|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
33246603|NCT00817791|Experimental|HBO|
32714974|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
32714975|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
33246604|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
33246605|NCT02542540|No Intervention|Children with OI without training|No training
33246606|NCT00811629||control group|
32714976|NCT05348174|Active Comparator|Virtual Reality Assisted Guided Imagery (VRAGI )|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR guided imagery on VR Head Mounted Displays (Meta Quest 2). They will experience video content and the accompanying guided imagery and nature soundscapes.
32714977|NCT05348174|Sham Comparator|Virtual Reality No Guided Imagery or other audio ( VR No GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR visual content on VR Head Mounted Displays (Meta Quest 2) but will not experience the accompanying guided imagery narration or nature soundscapes.
32714978|NCT05348174|Active Comparator|Laptop Assisted Guided Imagery (Laptop AGI)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience video content and the accompanying guided imagery and nature soundscapes on a laptop.
32714979|NCT05348174|Sham Comparator|Laptop no Guided Imagery or other audio (Laptop no GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience only the video content on a laptop and will no experience the accompanying guided imagery or nature soundscapes.
32714980|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
32714981|NCT03143751|No Intervention|Control|Standard cares alone.
32714982|NCT04940637|Experimental|Niraparib and Dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
32714983|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
32714984|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
32714985|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
32714986|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
32714987|NCT04925427|Experimental|Case Management and Peer Recovery|Participants in the CM/PRC + OEND arm will receive one year of service delivery. During the initial intake interview the CM will identify primary, secondary, and tertiary barriers to treatment initiation and completion, then create an action plan tailored to each client. PRCs with lived SUD or incarceration experience will address recovery barriers, while CMs will focus on service barriers. Where beneficial and desired by the clients, PRCs will accompany clients to provider and select service appointments to promote engagement and retention. CM/PRC teams will provide OEND upon community re-entry. The teams will provide follow-up phone calls and home visits to facilitate service linkages. Contact frequency will depend on clients' individual barriers (e.g., transportation, homelessness), but will include at least weekly in-person or telephone check-ins for first six months, reduced to monthly check-ins after that.
32714988|NCT04925427|Placebo Comparator|Naloxone-Only|Participants randomized to the Usual care + OEND condition will be trained on naloxone administration by research staff at the time of randomization. Upon community re-entry,they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
32714989|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
32714990|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
32714991|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
32714992|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
32714993|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
32714994|NCT02329821||HCC group|patients with hepatocellular carcinoma
32714995|NCT02329821||donor group|patient for liver transplantation donation
32714996|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
32714997|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
32714998|NCT00494234|Experimental|KU-0059436 (AZD2281) 100 mg BID|
32714999|NCT00494234|Experimental|KU-0059436 (AZD2281) 400 mg BID|
32715000|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
32715001|NCT04861623|Active Comparator|Orange Juice then Placebo juice (Fanta)|Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
32715002|NCT04861623|Active Comparator|Placebo (Fanta) then Orange juice|Participants will be provided Fanta for 84 days in this arm. After 28 days wash-out period, participants will receive Orange juice for 84 days.
32715003|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
33246607|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
33246608|NCT00814359|Active Comparator|Benzydamine HCl|
33246609|NCT00814437||Donors|Oocyte donor
33246610|NCT00811707||1: volunteers|non-pregnant female
33246611|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
33246612|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
32914723|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
32914724|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
32914725|NCT04827914|Experimental|Enhanced Care Condition|
32914726|NCT04827914|Active Comparator|Basic Care Condition|
32914727|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
32914728|NCT02999282|Experimental|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
32914729|NCT02999282|Sham Comparator|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
32914730|NCT02999282|Experimental|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
32914731|NCT02999282|Sham Comparator|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
32914732|NCT04813172|Experimental|Head and neck cancer patients|Patients from the Eye and Ear Institute Survivorship Clinic who are diagnosed with head and neck cancer.
32914733|NCT03019107|Experimental|VentFree Stimulation|Breath synchronized abdominal NMES
32914734|NCT03019107|Sham Comparator|Sham Stimulation|Sham breath synchronized abdominal NMES
32914735|NCT04784780|Experimental|Elobixibat|AJG533 (elobixibat) 10 mg orally once a day before meals for 12 weeks
32914736|NCT04784780|Placebo Comparator|Placebo|AJG533 placebo orally once a day before meals for 12 weeks
32914737|NCT04770584|Other|PTSD group|After the initial screening / baseline assessment visit, Post Traumatic Stress Disorder participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
32914738|NCT04770584|Other|Trauma-Exposed Healthy Controls (TEHC)|After the initial screening / baseline assessment visit, trauma-exposed healthy participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
32914739|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
32914740|NCT04725188|Experimental|Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.
32914741|NCT04725188|Experimental|Arm 2: Pembrolizumab/Vibostolimab coformulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years.
32914742|NCT04725188|Active Comparator|Arm 3: Placebo + Docetaxel|Participants receive normal saline IV infusion, Q3W for up to 35 cycles up to approximately 2 years plus Docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.
32914743|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
32914744|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
32914745|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
32914746|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
32914747|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
32914748|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
32914749|NCT03004742|Placebo Comparator|Placebo|Placebo
33246613|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
32715004|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
32914750|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
32914751|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
32914752|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
33246614|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
33246615|NCT00612040|Experimental|SIBA (D)|
33246616|NCT00612040|Experimental|SIBA (E)|
33246617|NCT00612040|Experimental|IGlar|
32914753|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
32914754|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
32914755|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
32914756|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
32914757|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
32914758|NCT05422742|Active Comparator|SRP|Scaling and rooting planning
32914759|NCT05422742|Experimental|SRP + MM|Scaling and rooting planning in combination with minocycline microspheres
32914760|NCT05422742|No Intervention|Periodontally-Healthy Subjects|No Intervention
32914761|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
32914762|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
32914763|NCT05406752|Experimental|paracetamol Uniflash (125 mg/ 1.25 mL)|1 sachet of paracetamol Uniflash 125mg / 1.25 mL
32914764|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
32914765|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
32914766|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
32914767|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
32914768|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
32914769|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
32914770|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
32914771|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
32914772|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
32715005|NCT05556746|Experimental|BCZD|Bedaquiline 200 mg for 8 weeks + pyrazinamide 1000 - 2000 mg (according to weight) for 8 weeks + clofazimine 300 mg for 2 weeks, followed by 100 mg for 6 weeks + delamanid 200 mg for 8 weeks, all given once daily.
32914773|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
32914774|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
32914775|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
32914776|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
32914777|NCT02248142||RLS patients|
32914778|NCT05331482|Experimental|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
32914779|NCT05331482|Active Comparator|Conventional training protocol-|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
32914780|NCT05331482|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
32914781|NCT04667780|Experimental|Colchicine|"This arm will receive Standard COVID-19 care + Colchicine~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half."
32914782|NCT04667780|Other|Control - Standard COVID-19 care|This arm will receive standard COVID-19 care as per the hospital guidelines.
32914783|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
32914784|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
32914785|NCT02248220||Parkinson's disease patients|
32914786|NCT03004508|Experimental|Gingko biloba Extract|
32914787|NCT03004508|Placebo Comparator|Placebo|
32914788|NCT03021759|No Intervention|Control|No intervention
32914789|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
32914790|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
33246618|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
32914791|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
32914792|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
32914793|NCT03004430|Experimental|MAM|Mantra Meditation Group
32914794|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
32914795|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
32715006|NCT05556746|Active Comparator|Standard TB Treatment|Rifampin, isoniazid, ethambutol and pyrazinamide for 8 weeks, followed by rifampin and isoniazid for 18 weeks; given daily in fixed dose combinations at standard weight-based doses.
32715007|NCT04898595|No Intervention|Usual Process of Care|No intervention
32914796|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
32914797|NCT03004352|No Intervention|control subjects-control|
32914798|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
33246619|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
33246620|NCT02551497|Experimental|Other drug|Other drug BID
33246621|NCT02551497|Experimental|placebo|Placebo to match BID
33246622|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
33246623|NCT00814515|Placebo Comparator|2|Vehicle
33246624|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
32715008|NCT04898595|Experimental|Standardized approach to discontinuation of CRRT|Criteria-driven approach
32715009|NCT05346770||Individual Patient|Each case will represent one individual patient and patient case. The cases may not be related and may cover different clinical practice areas.
32715010|NCT04815993|Experimental|SYN-020, 5 mg|6 subjects to receive a single 5 mg dose of SYN-020
32715011|NCT04815993|Experimental|SYN-020, 15 mg|6 subjects to receive a single 15 mg dose of SYN-020
32715012|NCT04815993|Experimental|SYN-020, 45 mg|6 subjects to receive a single 45 mg dose of SYN-020
32715013|NCT04815993|Experimental|SYN-020, 150 mg|6 subjects to receive a single 150 mg dose of SYN-020
32914799|NCT03004352|No Intervention|hypoxemic COPD-control|
32914800|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
32914801|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
32914802|NCT05310422|Experimental|Tivanisiran sodium ophthalmic solution|
32914803|NCT05310422|Placebo Comparator|Vehicle ophthalmic solution|
32914804|NCT04575896|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
32914805|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
32914806|NCT05289674|Experimental|Interventional study with a pre-, post-test design|"After the subject are diagnosed with infection (tuberculosis/TB or urinary tract infection/ UTI), they will receive 400 kcal/day (96 g/day divided 4 times consumption) of high calorie formula prescribed by the researcher (A pediatrician) for 90 days consumption ( 8640 g). the subject will be monitored every 30 days for acceptance, tolerance, weight increment, length increment evaluation.~The blood are withdrawn at day 0 (before invention) and day 90 (after intervention) to measure the IL-6 and IL-10 levels"
32914807|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
32914808|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
32914809|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
32914810|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
32914811|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
32914812|NCT04534556|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
33246625|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
33246626|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
32914813|NCT04534556|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
32914814|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
32914815|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
32914816|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
32715014|NCT05554406|Active Comparator|Arm I (cytarabine, daunorubicin)|Patients receive cytarabine IV and daunorubicin IV per standard approach on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
32914817|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
32914818|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
32914819|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
32914820|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
32914821|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
32914822|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
32914823|NCT02281409|Experimental|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
32914824|NCT02281409|Experimental|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
32914825|NCT04523480|Experimental|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
32914826|NCT04523480|Active Comparator|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
32914827|NCT04523480|Active Comparator|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
32914828|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
32914829|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
33399778|NCT05736484|Experimental|Social Support Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 26-week intervention period. Participants will also work with a virtual health coach throughout the intervention period to increase their physical activity.~At the end of the 26 week intervention period, participants will enter a 26 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study."
32715015|NCT05554406|Experimental|Arm II (cytarabine, daunorubicin, venetoclax)|Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
32715016|NCT05554406|Experimental|Arm III (azacitidine, venetoclax)|Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
32715017|NCT05554406|Experimental|Arm IV (daunorubicin and cytarabine liposome)|Patients receive daunorubicin and cytarabine liposome IV on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
32715018|NCT04834869||Pfizer-BioNTech COVID-19 Vaccine|Recently vaccinated individuals by Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
32715019|NCT04834869||Moderna COVID-19 Vaccine|Recently vaccinated individuals by Moderna COVID-19 Vaccine
32715020|NCT04834869||AstraZeneca-Oxford University COVID-19 Vaccine|Recently vaccinated individuals by AstraZeneca-Oxford University COVID-19 Vaccine (Vaxzevria)
32715021|NCT04834869||CoronaVac|Recently vaccinated individuals by CoronaVac (Sinovac COVID-19 Vaccine)
32715022|NCT04834869||Sinopharm|Recently vaccinated individuals by Vero Cells (Sinopharm COVID-19 Vaccine)
32715023|NCT04834869||Sputnik V|Recently vaccinated individuals by Sputnik V COVID-19 Vaccine
32715024|NCT04834869||Janssen|Recently vaccinated individuals by Janssen COVID-19 Vaccine
32914830|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
32914831|NCT05250908|Experimental|INTIBIA Therapeutic|Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
32914832|NCT05250908|Experimental|INTIBIA Non-Therapeutic|Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
32914833|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
32914834|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
32914835|NCT05215184||Chronic Pain Patients|
32914836|NCT05215184||Healthy Controls|
32914837|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
32715025|NCT04834869||CureVac|Recently vaccinated individuals by CureVac COVID-19 Vaccine
32715026|NCT04834869||Novavax|Recently vaccinated individuals by Novavax COVID-19 Vaccine
32914838|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
32914839|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 (Starting Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Group 1/ Dose Level 1:~Participants in group 0 will receive the starting dose of study drugs (below):~VS-6766 (2.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
32914840|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 2- Dose Level 2 (Second Highest Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Participants in group 2 will receive the second highest dose of study drugs (below):~VS-6766 (3.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
32914841|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 3 - Lower Dose Level 1|"Participants in this group will received a lower dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (400mg) via intravenous (IV) needle in vein every 2 weeks"
32914842|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 4 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (300mg) via intravenous (IV) needle in vein every 2 weeks"
32914843|NCT05200442|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|"Participants in this arm will help test the efficacy of the VS-6766 and cetuximab dose established in phase 1 of the study. Participants will take the same two drugs ( VS-6766 and cetuximab) at the best tolerated dose that was found during the first phase of the study.~Participants in this group will also keep a pill diary. This helps you keep track of when you take your pills. The study team at your doctor's office will show you how to use this diary. Each time you visit the clinic, you must bring the pill diary, any remaining pills, and the pill bottle."
32914844|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
32914845|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
32914846|NCT03004040||Control|matched control subjects (non-LCII)
32914847|NCT05198882|Experimental|LITT technology|Laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
32914848|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
32914849|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
32914850|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
32914851|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
32914852|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
32914853|NCT05183204|Experimental|Arm 1: Newly diagnosed MGMT unmethylated glioblastoma|
32914854|NCT05183204|Experimental|Arm 2: Recurrent glioblastoma, regardless of methylation status|
32715027|NCT04834869||Covaxin|Recently vaccinated individuals by Covaxin COVID-19 Vaccine
32715028|NCT04834869||CanSino|Recently vaccinated individuals by CanSino COVID-19 Vaccine
32715029|NCT05341544|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 10 days.
32715030|NCT05341544|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 10 days.
32715031|NCT04803591|Experimental|A: Tranexamic Acid group|Patients in the Tranexamic Acid (TXA) group (arm-A) will be administered with 2 doses of intravenous tranexamic acid (cumulative dose 10ml=1g) as follows: the first dose 10 minutes before the surgical incision (1 vial of 5 ml = 0,5g by slow intravenous injection(=1ml/minute)), and the second 3 hours after the start of surgery (1 vial of 5 ml = 0,5g, by slow intravenous injection).
32715032|NCT04803591|No Intervention|B : No treatment group|In the control group, will not be administered TXA or any other drugs.
32715033|NCT05341232|Experimental|Problem-Solving Training|Participants will learn to program LEGO robots and will be encouraged to actively solve problems.
32914855|NCT04287803|Experimental|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
32914856|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
32914857|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
32914858|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
32914859|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
32914860|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
32914861|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
32914862|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
32715034|NCT05341232|Active Comparator|Step-By-Step Training|Participants will learn to program LEGO robots and will be instructed step by step.
32914863|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
32914864|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
33246627|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
33246628|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
32914867|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
32914868|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
32914869|NCT04466618|Placebo Comparator|Saline|Saline infusion
32715035|NCT05341232|Placebo Comparator|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
32914870|NCT04466618|Active Comparator|Exendin-9,39|Exendin-9,39 infusion
32914871|NCT04466618|Active Comparator|Saline + Intralipid/Heparin|Induction of acute insulin resistance during Saline infusion
32914872|NCT04466618|Active Comparator|Exendin-9,39 + Intralipid/Heparin|Induction of acute insulin resistance during Exendin-9,39 infusion
32715036|NCT04555863|Experimental|haMSter app|Patients receiving the app for personal use for 6 months
32715037|NCT04750785||All Participants|Participants who have been diagnosed with CHM will be enrolled.
32715038|NCT05536856|Experimental|Control group|30 patients will apply the 5-Fluorouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder.
32715039|NCT05536856|Experimental|Study group|30 patients will apply a new effervescent mixture formula of 5-Fluorouracil prepared at faculty of pharmacy (Girls) - Al-Azhar university
32914873|NCT01881113|Experimental|AC-170 0.24%|
32914874|NCT01881113|Placebo Comparator|AC-170 0%|
32914875|NCT05155280|Experimental|Anorexia Nervosa patients|"30 patients with anorexia nervosa = 15 with moderate to high anxiety (STAI YB anxiety (STAI YB > 51) and 15 with low anxiety (STAI YB<51).~A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2."
32914876|NCT05155280|Placebo Comparator|Controls|15 healthy volunteers (control group) and a low level of anxiety trait (< 51) A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2.
32914877|NCT05140694|Experimental|Empagliflozin|Empagliflozin 10mg p.o. once daily (available to control over ~25mg)
32914878|NCT05140694|Experimental|Dulaglutide|Dulaglutide 0.75mg s.c. once weekly (available to control over ~1.5mg)
32914879|NCT05140694|Experimental|Empagliflozin and Dulagludie|Empagliflozin 10mg p.o. once daily and dulaglutide 0.75mg s.c. once weekly
32914880|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
32914881|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
32914882|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
32914883|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
32914884|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
32914885|NCT05673044|Experimental|modified Studer ileal neobladder|the segment of the iso-peristaltic segment is 8 cm and the total length of the ileum used is 40 cm instead of 60 cm.
32914886|NCT05673044|Experimental|modified spiral ileal neobladder|the chimney of the spiral neobladder will be an angled one instead of straight.
32914887|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
32914888|NCT01883141|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
32914889|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
32914890|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
32914891|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
32914892|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
32914893|NCT00558311|Experimental|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
32914894|NCT00558311|Placebo Comparator|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
32914895|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
32914896|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
32914897|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
32914898|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
32914899|NCT05672654|Active Comparator|Control group|
32914900|NCT05672654|Active Comparator|HIV positive CD4<350 cells/mm^3|
32914901|NCT05672654|Active Comparator|Immune-compromised patients- department rheumatology|
32914902|NCT05672654|Active Comparator|Immune-compromised patients- department nephrology|
32914903|NCT05672654|Active Comparator|Immune-compromised patients- department neurology|
32914904|NCT05672654|Active Comparator|Primary immune deficiency en common variable immunodeficiency|
32914905|NCT05351723|Experimental|Exercise + cognitive training + education|Intervention group: each session comprises (1) 50 min of physical exercise, (2) 20 min of break time or education on dementia and lifestyle habits, and (3) 50 min of cognitive training.
32914906|NCT05351723|Other|Education|Control group: education on dementia and lifestyle habits.
32914907|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
33399779|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
32914908|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
33399780|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
33399781|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
33399782|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
32914909|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
32914910|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
32914911|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
33399783|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
33399784|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
33399785|NCT05659732|Experimental|PEP07 Monotherapy (Arm A)|"The dose finding of PEP07 monotherapy consists of an accelerated dose escalation followed by a standard 3+3 dose escalation. Accelerated titration will continue until 1 patient experiences a DLT, or ≥ grade 2 AE related to PEP07 (except for hematologic toxicities) at any dose level, after which, additional 2 patients will be enrolled in the same cohort, and the study will be switched to a 3+3 scheme.~Expansion cohorts with 12 patients will be opened for Arm A at the RP2D once efficacy signal is observed at this level."
33399786|NCT05733676|Active Comparator|Resin Infiltration|Resin infiltration of early intervention of caries lesion as a consequences of orthodontic treatment
33399787|NCT05733676|Active Comparator|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride early intervention of caries lesion as a consequences of orthodontic treatment
33399788|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
33399789|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
33399790|NCT04479748|Other|Dextenza insert|Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).
33399791|NCT04479748|Other|Fellow-eye|The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.
33399792|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
33399793|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
32914912|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
32914913|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
33246629|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
33246630|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
33246631|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
33246632|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
33246633|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
33399794|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
33399795|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
33399796|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
33399797|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
32715040|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
32715041|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
32715042|NCT04468893|Experimental|Positive Psychology Intervention with chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression with the support of a chat service provided by therapists.
32914914|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
32914915|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
32914916|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
32914917|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
32914918|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
32914919|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
33399798|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
33399799|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
33399800|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
33399801|NCT05731180|No Intervention|Not trained group (CNT)|Control Group (CNT): 70 Students. The CNT group will only receive an introductory lecture about the SAITI-T study and how to use the website. The CNT subjects will not receive training on lung sounds.
33399802|NCT05731180|Experimental|Trained group for 3 days to identify pathological lung sounds (EXP)|Exposed group (EXP): 70 students. EXP group - subjects will be trained for 3 days to identify pathological lung sounds before assessment/assessments. The EXP subjects additionally have an introductory lecture about the SAITI-T study and how to use the website.
33399803|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
33399804|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
33399805|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
33399806|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
33399807|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
33399808|NCT03355573|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
33399809|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
33399810|NCT03584009|Active Comparator|Fulvestrant|Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
33399811|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
33399812|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
32715043|NCT04468893|Active Comparator|Positive Psychology Intervention without chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression without the support of the chat service.
32715044|NCT04735263|Other|Intermediate Age-Related macular degeneration patients|"Subjects can have either:~Bilateral high-risk iAMD~High-risk iAMD in one eye with GA and/or CNV in the fellow eye No control arm"
32715045|NCT00493298||Tysabri|According to the local prescribing information
32715046|NCT04730115||Group 1. The treatment group (T)|The treatment group comprised of 30 cases treated with functional appliance for one year in puberty.
32715047|NCT04730115||Group 2. The control group (C)|The control group consists of 12 patients who had insufficient oral hygiene; didn't take any orthodontic treatment for one year.
32715048|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
32715049|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
32715050|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
32715051|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
32715052|NCT04343469|Active Comparator|Bariatric surgery|The effect of bariatric surgery (RYGB or LSG) on central inflammation
32715053|NCT04343469|No Intervention|No intervention|Healthy lean volunteers
32715054|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
32715055|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
32715056|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
32715057|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
33246634|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
32715058|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
32715059|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
32715060|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
32715061|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
32715062|NCT04662723|Experimental|Corticosteroids combined with RASBs|Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5 mg/kg/bw) on alternate days until the end of month. This treatment will be repeated for three consecutive months. In addition, patients will receive RASBs that will be titrated to their maximum anti-proteinuric effect. The dose of methylprednisolone succinate will be individualized (15 mg/kg) based on the ideal body weight. In overweight and obese IgAN patients the ideal body weight will be considered. The drug will be administered in a single daily dose intravenously for 30-60 min. To avoid obesity and diabetes corticosteroids will be administered only in the morning.
32715063|NCT04662723|Active Comparator|RASBs|Patients will receive RASBs alone that will be titrated to their maximum anti-proteinuric effect.
32715064|NCT04662723|Experimental|SGLT2i combined with Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive SGLT2i combined with RASBs.
32715065|NCT04662723|Active Comparator|Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive RASBs alone.
32715066|NCT00326690|Experimental|treatment|
32715067|NCT00326690|No Intervention|Control|
32715068|NCT04050501|Active Comparator|non-invasive Vagus Nerve Stimulation|non-invasive Vagus Nerve Stimulation on top of best medical practice
32715069|NCT04050501|No Intervention|Standard Care|Best medical practice alone
32715070|NCT05340764|Active Comparator|2-hour infusion of infliximab|2 hour infusion of infliximab
32715071|NCT05340764|Experimental|1-hour infusion of infliximab|1 hour infusion of infliximab
32715072|NCT05307926||PD-1 based therapy cohort|Patients who received PD-1 inhibitors or PD-1 inhibitors plus Lenvatinib therapy 2-4 weeks after the operation were included in the PD-1-based therapy cohort.
32715073|NCT05307926||TACE cohort|Patients who received 1 TACE about a month after the operation were included in the control cohort.
32715074|NCT05610800|Active Comparator|Exenatide, NRT, and Smoking Cessation Counseling|Participants will receive once weekly exenatide injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
32715075|NCT05610800|Placebo Comparator|Placebo, NRT, and Smoking Cessation Counseling|Participants will receive once weekly saline injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
32715076|NCT02329275||Azoospermic men|
32715077|NCT02329275||Men with proven fertility|
32914920|NCT04249973||IgE-mediated cow's milk allergy|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
32914921|NCT04249973||Suspected of cow's milk allergy, but with negative diagnosis|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
32914922|NCT04249973||IgE-mediated food allergy, other than cow's milk|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
32914923|NCT04249973||Healthy brothers and sisters|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
32914924|NCT04327310|Experimental|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
32914925|NCT04327310|Placebo Comparator|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
32914926|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
32914927|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
32914928|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
32914929|NCT04203797|Experimental|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
32914930|NCT04203797|Experimental|Matching placebo|Matching dupilumab
32914931|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
32914932|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
32914933|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
32914934|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
32914935|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
32914936|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
32914937|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
32914938|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
32914939|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
32914940|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
32914941|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
32914942|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
32914943|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
32914944|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
32914945|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
33073215|NCT03335228|Experimental|Eclipse Easy Spin for PRP Treatment|Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.
33246635|NCT00421993|Active Comparator|2|Adapalene Topical Gel
33246636|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
32914946|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
32914947|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22~Dexamethasone- 10 mg/m2 orally or IV on days 1-14~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.~For patients without central nervous system (CNS) involvement:~Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)~Methotrexate 12 mg administered intrathecally on day 8~For patients with CNS involvement:~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
32914948|NCT05672420|Experimental|umbilical cord derived mesenchymal stem cells (UC-MSCs)|In the Phase Ib study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia, UC-MSCs will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, frequency of infusion will be preset with 3 escalation levels: frequency 1, frequency 2, frequency 3, total course of treatment: 2 weeks; In the Phase II study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia/primary hematological maligancies who are going to receive hematopoietic stem cell transplantation, UC-MSCs will be preset according to the recommended phase II dose (RP2D) from the Phase Ib study, total course of treatment: 2 weeks.
32914949|NCT05333471|Experimental|Interventional|As this is a single arm study, this arm includes all participants. Participants will receive fecal microbiota transplantation (FMT) delivered by colonoscopy as a treatment for chronic granulomatous disease (CGD)-associated colitis (AC).
32914950|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
32914951|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
32914952|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
32914953|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
32914954|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
32914955|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
32914956|NCT05322941|Experimental|AEF0117|The current study tests 3 doses of AEF0117 (1.0, 0.3, and 0.1 mg).AEF0117 capsules ; dose range 0.1 to 1.0mg by mouth, once a day for 12 weeks.
32715078|NCT04248452|Experimental|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32715079|NCT04248452|Experimental|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32715080|NCT04248452|Experimental|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
32914957|NCT05322941|Placebo Comparator|Placebo|corn oil capsules once a day for 12 weeks.
32914958|NCT03003182||in clinical trials|
32914959|NCT03003182||out of clinical trials|
32715081|NCT04248452|Active Comparator|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
32715082|NCT04248452|Experimental|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
32715083|NCT04248452|Active Comparator|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
32715084|NCT04026945|Other|Active Treatment (ST-CP) Group|"This study uses a dose-escalating approach in the active treatment arm. There is no comparator product. All qualifying patients receive the active treatment ST-CP as an injection in the region around the spermatic cord. The following dosing cohorts will be used:~I: 1 x 2 mL of 140 mg/mL ST-CP (= 280 mg lidocaine) II: 1 x 3 mL of 140 mg/mL ST-CP (= 420 mg lidocaine) III: 1 x 4 mL of 140 mg/mL ST-CP (= 560 mg lidocaine)"
32715085|NCT03895047|Active Comparator|dACC,I,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
32745760|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
32715086|NCT03895047|Active Comparator|dACC,AC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week.12 sessions of Neurofeedback Training, 1-2 times per week."
32745761|NCT04813029|Experimental|Straight Leg Raise|Patients perform straight leg raise maneuver at the end of High-resolution Manometry test
33246637|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
32914960|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
32745762|NCT04427631|Experimental|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
32745763|NCT04817865||Standard Pre-Procedural Urine Culture|This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C&S) methods performed before injection.
32745764|NCT04817865||Pre-Procedural M-PCR/P-AST|This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST.
32745765|NCT04428255|Experimental|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
32745766|NCT04428255|Experimental|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
32745767|NCT04428255|Placebo Comparator|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
32745768|NCT04818099|Experimental|routine supportive psychotherapy and votioxetine|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given votioxetine 10mg/tablet, one tablet each time, once a day, for 2 months.
32745769|NCT04818099|Placebo Comparator|routine supportive psychotherapy and control|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given placebo, one tablet each time, once a day, for 2 months.
32745770|NCT04817709||Arm 1|Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment. Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
32745771|NCT04817709||Arm 2|Patents receive an educational booklet about breast reconstruction surgery during appointment. Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
32745772|NCT05618847|Experimental|active cycle of breathing technique with acapella|"Sit up with good posture to use the Acapella. Take in a fairly deep breath and hold it for about 3 seconds. Place the Acapella mouthpiece in your mouth. Seal your lips tightly around the mouthpiece.~Exhale as much as possible (but not to forcefully) through the mouthpiece. Keep your cheeks as firm as possible when you exhale. Try not to inhale through the device.~Repeat this maneuver for 10 breaths. Try to resist coughing during this phase. After these 10 blows, perform 3 huffs, then a big cough to bring the sputum up and out. Try not to swallow the mucus"
32745773|NCT05618847|Active Comparator|active cycle of breathing technique|Ask patient to breathe in and out gently through nose if he/she can. If patient breathe out through their mouth. Ask patient to let go of any tension in body with each breath out. Gradually try to make the breaths slower. Ask patient to take a long, slow, deep breath in, through nose. Try to keep chest and shoulders relaxed. Repeat 3-5 times. Huff is exhaling through an open mouth and throat instead of coughing. It helps move sputum up in airways so that patient can clear it in a controlled way. To 'huff' ask patient to squeeze air quickly from lungs, out through open mouth and throat, as if trying to mist up a mirror or glasses. Ask to use abdominal muscles to help squeeze the air out, but do not force it so much that cause wheezing or tightness in chest. Huffing should always be followed by breathing control.
32745774|NCT05618769|Experimental|Intervention (LONG LOVE Framework)|"Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to current standard of care) follow-up in accordance with our newly developed framework to identify modi able influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography.~In case of any modi able influencing factors, appropriate lifestyle and/or medical interventions will be undertaken."
32745775|NCT05618769|No Intervention|Control|"Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.~Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias."
32914961|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
32914962|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
32914963|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
33246638|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
33246639|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
33246640|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
33246641|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
33246642|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
33246643|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
32765314|NCT04955873|Active Comparator|Active comparator - Group B - Geistlich biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Geistlich Bio-oss Collagen and the resorbable collagen membrane Geistlich BioGide."
32765315|NCT04955873|No Intervention|Control - Group C - Spontaneous healing|Spontaneous postextraction alveolar healing
32765316|NCT05114239|Experimental|Timolol|Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
32765317|NCT05114239|Placebo Comparator|Standard Wound Care|Petrolatum ointment
32765318|NCT04945031||cannabis-induced psychosis|
32765319|NCT05113849|Experimental|Cohort A (Low-dose group)|IN-B009 (Low-dose)
32765320|NCT05113849|Experimental|Cohort B (High-dose group)|IN-B009 (High-dose)
32765321|NCT04935827||Patients initiating dialysis for end-stage kidney disease|"Patients whose start of dialysis is from 12/1/2007-11/30/2017. We use the following inclusion criteria:~Adult (>= 18 years old)~Did not die or have a transplant prior to the 90th day of dialysis~Valid medical evidence form~Medicare Part A/B as primary payer in the 30 days prior to initiating dialysis~Initiating dialysis in the USA"
32765322|NCT04944719||chronically ill adult patients colonized by streptococcus pneumoniae|At baseline, adult patients with chronic disease who are colonized with Streptococcus pneumoniae will be identified. Then, after determining the colonized subjects, monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be taken to determine colonization by other serotypes or resolution of colonization status in these patients.
32765323|NCT04944719||chronically ill adult patients not colonized by streptococcus pneumoniae|Subjects who are not colonized with S. pneumoniae will be followed by monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be collected every six months to determine colonization during the follow-up time in the study.
32765324|NCT04472611|Experimental|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
32765325|NCT04472611|No Intervention|Standard of care (SOC)|Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
32765326|NCT04469725|Experimental|Thymic carcinoma|enrolled subjects will receive KN046 every 2 weeks.
32765327|NCT04418999|Experimental|Dexamethasone insert|Per participant, one eye will be randomized to receive the intracanalicular dexamethasone insert at the baseline visit (study eye). DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus at the day 1 visit by pulling the lower lid taught and using a forceps to insert the medication into the lower canaliculus through the lower punctum.
32765328|NCT04418999|Active Comparator|Loteprednol etabonate ophthalmic gel 0.38%|Per participant, one eye will be randomized to receive the standard of care topical lotemax etabonate ophthalmic gel 0.38% (control eye). Patients will be prescribed a loteprednol etabonate ophthalmic gel 0.38% and will instill one drop into the eye following a 4x/day,3x/day,2x/day,1/xday weekly taper
32765329|NCT04427527|Experimental|Multi-level Intervention|Receives the project intervention first
32765330|NCT04427527|No Intervention|Delayed Multi-level Intervention|Offered the intervention later in the project
32765331|NCT02623361|Placebo Comparator|Sham|
32765332|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
32765333|NCT05113693|Experimental|1|"Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.~Period 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition."
32765334|NCT05113693|Experimental|2|"Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition.~Period 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition."
32765335|NCT05113459|Experimental|disitamab vedotin + PD-1+Capecitabine|disitamab vedotin：2.5mg/kg,iv,d1,q2w ,6cycle PD-1: 200mg,iv,d1,q2w，6cycle Capecitabine：1000mg/m2 ,po, bid,d1-14,q3w, 4cycle
32765336|NCT04944485|Active Comparator|class V cavities treated with putty nanohybrid resin composite|Selective enamel etching will be done and a universal adhesive (Prime&Bond universal™ ,Dentsply)will be applied to both enamel and dentin. After gentle dryness and solvent evaporation the bonding agent will be cured for 20 seconds. Composite (Neo Spectra™ST, Dentsply, Sirona, USA) will be placed incrementally and light cured for 20 seconds
32765337|NCT04944485|Experimental|class V cavities treated with Self adhesive giomer containing nanohybrid flowable composite|Cleaning and gentle air blowing of the preparation. Then applying FIT SA F03 (Low Flow), SHOFU, USA. Spread in a thin layer (≤0.5mm) on the prepared surface with needle tip, microbrush and gently air-blow leave for 20 seconds then light cure for 5 seconds. Then,apply additional increments (≤2mm) of FIT SA and light cure each increment for 10 seconds then finish and polish
32765338|NCT04526197|Experimental|Treatment Sequence A-B|"Participants received 1 treatment during each study period in the following sequence:~Treatment A: Celecoxib.~Treatment B: Celecoxib plus ALXN1840."
32765339|NCT04526197|Experimental|Treatment Sequence B-A|"Participants received 1 treatment during each study period in the following sequence:~Treatment B: Celecoxib plus ALXN1840.~Treatment A: Celecoxib."
32765340|NCT04935983|Active Comparator|High CHO|High CHO diet for 36 h
32765341|NCT04935983|Experimental|Low CHO|Low CHO diet for 36 h
32765342|NCT04955483||Virtual single-energy imaging reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev)
32765343|NCT04955483||Virtual single energy (70-140Kev, interval 10Kev) combined with MAR reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev) combined with MAR reconstruction group
32905476|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
32715087|NCT03895047|Active Comparator|I,dACC,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
32914966|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
32914967|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
32715088|NCT03895047|Active Comparator|I,AC,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
32914968|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
32914969|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
32914970|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
32914971|NCT05672342|Experimental|Arm I (CBD)|Patients receive CBD PO on study.
32914972|NCT05672342|Experimental|Arm II (CBD + THC)|Patients receive CBD PO + THC PO on study.
32914973|NCT05672342|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO on study.
32914974|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
32914975|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
32914976|NCT04064762|Experimental|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
32715089|NCT03895047|Active Comparator|AC,dACC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
32914977|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~Low resolution transrectal ultrasound examination (LR-TRUS)~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
32914978|NCT05672264|Experimental|WB-EMS group|WB-EMS application
32914979|NCT05672264|Active Comparator|Control|Standardised physiotherapy (six sessions)
32914980|NCT04015700|Experimental|Vaccine (GNOS-PV01 + INO-9012)|"Standard radiation therapy will be administered per standard of care and is outside the scope of this study.~GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2."
32914981|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
32914982|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
32914983|NCT05430464|Experimental|1726nm Laser Treatment|
32914984|NCT05430464|Sham Comparator|Sham Laser Treatment|
32914985|NCT02926677|Experimental|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
32914986|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
32914987|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
32914988|NCT04177511|Experimental|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.~Standard treatment will be continued by the patients of this arm."
32914989|NCT04177511|No Intervention|Standard treatment|Patients of this arm will continue their standard treatment.
32914990|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
32914991|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
32914992|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
32914993|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
32914994|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
32914995|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
32715090|NCT03895047|Active Comparator|AC,I,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
32715091|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
32715092|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
32715093|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
32715094|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
32715095|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
32715096|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
32715097|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 1)|Soft capsule for oral administration
32715098|NCT04608513|Placebo Comparator|Placebo single dose (dose level 1)|Soft capsule for oral administration
32715099|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 2)|Soft capsule for oral administration
32715100|NCT04608513|Placebo Comparator|Placebo single dose (dose level 2)|Soft capsule for oral administration
32715101|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 1)|Soft capsule for oral administration
32715102|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 1)|Soft capsule for oral administration
32715103|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 2)|Soft capsule for oral administration
32715104|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 2)|Soft capsule for oral administration
32914996|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
32914997|NCT04133675|Active Comparator|Emsella Chair Active Treatment|Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
32914998|NCT04133675|Sham Comparator|Emsella Sham Treatment|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
32914999|NCT03830060||Group I:|Fifty AP patients on admission
32915000|NCT03830060||Group II:|The previous AP patients after 72 hours
32915001|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
32915002|NCT04769804||Patients with recurrent pityriasis versicolor|
32915003|NCT04769804||Healthy age and sex-matched controls|
32915004|NCT04350437|Other|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
32915005|NCT03002792||general anesthesia|caries treatment under general anesthesia
32915006|NCT03002792||caries treatment only|caries treatment without general anesthesia
32915007|NCT05672108|Experimental|Lung chemoembolization|Patients receive lipiodol intra-arterially (IA), mitomycin IA, and embospheres IA and undergo TACE on study. Patients also undergo angiography and computed tomography (CT) at baseline and follow up.
32915008|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
32915009|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
32915010|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
32915011|NCT03970070|Experimental|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
32915012|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
32915013|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
32915014|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
32915015|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
32915016|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
33246644|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
33246645|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
33246646|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
33246647|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
32715105|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 3)|Soft capsule for oral administration
33246648|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
32715106|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 3)|Soft capsule for oral administration
33246649|NCT00884962|Experimental|PLVR|
33246650|NCT00814749|Active Comparator|surgical therapy|
32915017|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
32915018|NCT01891331|Experimental|VT-1161 300mg QD|
32915019|NCT01891331|Experimental|VT-1161 600mg QD|
32915020|NCT01891331|Experimental|VT-1161 600mg BID|
32915021|NCT01891331|Active Comparator|Fluconazole 150mg|
32915022|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
32715107|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 4)|Soft capsule for oral administration
33246651|NCT00814749|Active Comparator|individual management|
33246652|NCT01037725|Experimental|AZD5847 oral suspension|Active
32915023|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
32915024|NCT05671952|Experimental|intervention group|Application of integrated intervention system programs
33246653|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
33246654|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
33246655|NCT02551029|Placebo Comparator|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
33246656|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
33246657|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
33246658|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
33246659|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
33246660|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
33246661|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
33246662|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
33246663|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
33246664|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
33399813|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
32715108|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 4)|Soft capsule for oral administration
32715109|NCT04577313|Active Comparator|Continuous Counseling|Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.
32915025|NCT05671952|No Intervention|Control group|No intervention
32915026|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
32915027|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
32915028|NCT03835754|Experimental|OCS Preservation|
32915029|NCT04067609|Experimental|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
32915030|NCT04067609|Placebo Comparator|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
32915031|NCT05671718|Experimental|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
32715110|NCT04577313|Active Comparator|Fixed Counseling|Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.
32715111|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
32715112|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
32715113|NCT03520647|Experimental|Treatment Arm|G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide
32715114|NCT04536207|Experimental|the study group|Group (A) the study group received cryotherapy
32715115|NCT04536207|No Intervention|the control group|Group (B) the control group not received cryotherapy
32915032|NCT05671718|No Intervention|Physician-Led Treatment Hospital Based|Representing standard of care, primary care clinics will refer to hospital-based, physician-led care who will provide outpatient treatment. The typical clinical operations involve initiation of new patients once or twice weekly and PCCs are required to schedule a clinic day/time for the patient prior to referral (generally < 72 hours from the time of referral). All individuals receiving care at this site will receive care at the district RR-TB treatment program for the catchment area. For HIV co-infected persons, their HIV treatment is also transferred to the RR-TB physician with details about the HIV treatment communicated in the transfer of care letter. Physicians often cover multiple clinics and routinely take on call sessions on the weekend, due to staffing limitations, thus preventing their sole focus on the RR-TB program and limiting the number of days the RR-TB clinic offers new patient visits and, in most cases, days for follow-up visits.
32915033|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
32915034|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
32915035|NCT03037203|Placebo Comparator|Arm C|Placebo
32915036|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
32915037|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
32915038|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
32915039|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
32915040|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
32915041|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
32915042|NCT03705104|Active Comparator|Experimental without introduction group and follow up phone calls|One extra arm (non randomized) has been included to examine whether participants who receive the EPIO intervention without receiving an introduction session and follow up phone calls will still describe benefiting from the receiving the intervention
32915043|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
32915044|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
32915045|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
32915046|NCT03022097|Placebo Comparator|Placebo|Placebo
32915047|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
32915048|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
32915049|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
32915050|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
32915051|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
32915052|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
32915053|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
32915054|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
32915055|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
32915056|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
32915057|NCT03002558||control (non-OSA)|Patients without sleep apnoea
32915058|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
32915059|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
32915060|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
32915061|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
33246665|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
32765344|NCT04447963|Experimental|Non-invasive treatment of wrinkles and rhytids|"The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete three (3) treatment visits and two follow-up visits.~At the baseline visit health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.~The treatment administration phase consists of three (3) treatment visits, delivered 1 week apart.~At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device."
33246666|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
33246667|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
33246668|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
33246669|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
32765345|NCT04933019|Other|Clindamycin Resistance Genes among Staphylococcus Isolates by Using Real Time PCR|
32765346|NCT04933019|Other|Clindamycin sensetive Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|
32765347|NCT05068531||Observational|We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
32765348|NCT04955093|Experimental|Intervention|
32765349|NCT04955093|No Intervention|Control|
32765350|NCT05060965|Experimental|Cessation intervention|"All participants will receive nicotine replacement therapy and a referral to both Maryland Quitline and Johns Hopkins Tobacco Treatment Clinic for continued cessation care.~Nicotine replacement therapy: Nicoderm patches, gum, lozenges~Low nicotine dependence: Lozenge (2 mg) or Gum (2 mg) or Patch (7 mg)~Moderate nicotine dependence: Patch (14 mg) and Lozenge (2 mg) or Gum (2 mg)~High nicotine dependence: Patch (21 mg) and Lozenge (4 mg) or Gum (4 mg)~Regardless of the level of nicotine addiction and subsequent dose of nicotine replacement therapy (NRT), participants of this trials are described as recipients of NRT products."
32765351|NCT04935281||percutaneous repair with an intraoperative assissted ultrasound|a radiologist did an intraoperative ultrasound before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon.
32765352|NCT04935281||percutaneous repair without an intraoperative assissted ultrasound|the course of the sural nerve was determined according to the technique described by Blackmon et al .This technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon
32765353|NCT04935515|Experimental|Mild|Patients with mild symptoms and normal CRP.
32765354|NCT04935515|Experimental|Moderate|Patients with mild symptoms and less than 10 fold increase in CRP.
32765355|NCT04935515|Experimental|Severe|Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
32765356|NCT04447729|Experimental|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
32765357|NCT04090645|Other|TheraShere in treatment of primary & secondary liver carcinoma|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
32765358|NCT04935203|No Intervention|Control message group|Participants will not receive the priming manipulation.
32765359|NCT04935203|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
32765360|NCT04935203|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
32765361|NCT04935203|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
32765362|NCT04029025|Active Comparator|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
32765363|NCT04029025|Active Comparator|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
32765364|NCT04029025|Active Comparator|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C).
32765365|NCT04932551||Physician|
32765366|NCT05110885||Individuals living in Turkey|Individuals from different regions of Turkey who meet inclusion criteria
32765367|NCT04935125|Active Comparator|Standard Program|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.
32765368|NCT04935125|Experimental|Strength training|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions
32765369|NCT04955171|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
32765370|NCT04955171|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
33399814|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
33246670|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
32715116|NCT03610737|Active Comparator|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
32715117|NCT03610737|Active Comparator|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
32715118|NCT03353259|No Intervention|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
33246671|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
33246672|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
32715119|NCT03353259|Active Comparator|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
32715120|NCT03353259|Active Comparator|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
32715121|NCT04527627|Experimental|Experimental Group (EG)|The nursing empowerment intervention will be administered in the experimental group
32715122|NCT04527627|No Intervention|Control Group (CG)|The nursing empowerment intervention will not be administered in the control group
32715123|NCT04477239|Placebo Comparator|Placebo|Oral administration of one capsule of Placebo
32715124|NCT04477239|Active Comparator|Purified gluten (10 mg)|Oral administration of capsules containing 10 mg of purified gluten.
32715125|NCT04477239|Active Comparator|Purified gluten (50 mg)|Oral administration of capsules containing 50 mg of purified gluten.
32715126|NCT04477239|Active Comparator|Purified gluten (100 mg)|Oral administration of capsules containing 100 mg of purified gluten.
32715127|NCT04477239|Active Comparator|Purified gluten (500 mg)|Oral administration of capsules containing 500 mg of purified gluten.
32715128|NCT04477239|Active Comparator|Purified gluten (1000 mg)|Oral administration of capsules containing 1000 mg of purified gluten.
32715129|NCT04513743|Experimental|Healthy adults|UNEEG™ medical 24/7 EEG™ SubQ
32715130|NCT04478721|Experimental|Temocillin|Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.
32715131|NCT04478721|Active Comparator|Meropenem|Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.
32715132|NCT04248218|No Intervention|Normal/Control|Control Group/Standard Care
32715133|NCT04248218|Active Comparator|Active Rehabilitation Group/Case|Active Rehabilitation Cohort/Intervention
32715134|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
32715135|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
32715136|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
32715137|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
32715138|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
32715139|NCT04437537||Pilot Group|Ten subjects with a DFU non-responsive to standard of care for a minimum of treatment period of 28 days.
32715140|NCT04247594|Experimental|Cohort A open label|Participants will receive progressively higher doses of voxelotor administration starting from 1500 mg
32715141|NCT04425915|Experimental|Convalescent Plasma with Standard of Care|Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
32715142|NCT04425915|Active Comparator|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
32715143|NCT04350723|Experimental|Intervention - Awake Proning|"The oxygen mask or NIPPV or HFNC will be initiated at the treating team's discretion. The patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating oxygen mask or NIPPV or HFNC treatment.~Once the patient achieves the above parameters within 15 minutes of initiating oxygen therapy through any modality, the healthcare team will start awake proning."
32715144|NCT04350723|No Intervention|Control - Standard of Care|"The patient will receive usual care without proning at the discretion of the treating team.~The oxygen mask or NIPPV or HFNC will be initiated, the choice of starting oxygen mask versus NIPPV versus HFNC will be up to the treating team, the patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating NIPPV or HFNC treatment."
32745776|NCT04428099|Experimental|Intervention|Lifestyle change promotion program
32745777|NCT04428099|Active Comparator|Control 1|MBCT program
32745778|NCT04428099|Placebo Comparator|Control 2|Usual care
32715145|NCT05307536|Experimental|Autologous BMMNCs infusion combined with educational intervention|"Bone marrows are harvested from the patient's iliac depending on the patient's body weight as follows: 8 ml/kg for patients under 10 kg; [80 ml + (body weight in kg - 10) × 7 ml] for patients above 10 kg. Mononuclear cells from collected bone marrow are infused intrathecally through a space between number vertebrae 4th and 5th. Two transplantations will be conducted at an interval of 6 months. The educational intervention will be developed based on the Early Start Denver Model for 6 months after the first infusion.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
32765371|NCT03951883|Active Comparator|Typical Diet (TD)|Participants will be instructed to continue habitual dietary intake.
32765372|NCT03951883|Experimental|Increased Egg Consumption (IE)|Participants will be prescribed an additional 2 eggs per day to their diet.
32765373|NCT04376281|Experimental|Noradrenaline group|
32765374|NCT04932629|Experimental|Experimental Group|The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
32765375|NCT04332445|Experimental|Experimental|subjects, 18-70 y, healthy
32765376|NCT04954703|Experimental|Muscle energy technique of gluteus maximus and tensor fascia lata|INTERVENTIONAL GROUP (muscle energy technique of gluteus maximus and tensor fascia lata)
32765377|NCT04954703|Active Comparator|Myofascial release of iliotibial band|CONTROL GROUP(Myofascial release of iliotibial band)
32765378|NCT04299373|Experimental|Alcohol: Oral administration|Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
32765379|NCT04299373|Experimental|Alcohol: Intravenous administration|Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.
32765380|NCT04932863||Subjects with cancer of any type and stage under active or prior medical treatment|BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.
32765381|NCT04278313|Experimental|PRP group|Platelet RICH Plasma prepared using RegenLab FDA approved device.
32765382|NCT04278313|Placebo Comparator|PPP group|Platelet POOR Plasma prepared using RegenLab FDA approved device.
32765383|NCT04934735|Active Comparator|The intervention group: received a complex case-management rehabilitation program|The intervention group was followed at 6, 12, 18, 24 months after entering the study. The follow-up was conducted by the case manager for patients in the intervention group, and by a research assistant for patients in the control group. Medical data were retrieved from the computerized medical records in the relevant hospitals.
32765384|NCT04934735|No Intervention|The control: group received the standard care|The control group received regular care.
32765385|NCT04232839|Experimental|T1 (Test 1)|
32765386|NCT04232839|Experimental|T2 (Test 2)|
32765387|NCT04232839|Experimental|T3 (Test 3)|
32765388|NCT04232839|Experimental|T4 (Test 4)|
32765389|NCT04232839|Experimental|T5 (Test 5)|
32765390|NCT04232839|Experimental|T6 (Test 6)|
32765391|NCT04232839|Experimental|R1 (Reference 1)|
32765392|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with collagen sponge.|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with collagen sponge (CS).
32765393|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
32765394|NCT04934813|Experimental|Alveolar ridge preservation with particulated xenograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Demineralized bovine bone mineral xenograft (DBBM) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
32765395|NCT04934813|Experimental|Alveolar ridge preservation without bone grafting covered with socket sealing mean|Alveolar ridge preservation after tooth extraction. No bone graft was applied and the socket was covered with free gingival graft (FGG).
32765396|NCT04934423|Experimental|active tDCS|tDCS active, for 30 minutes for 5 consecutive days, with an anode positioned in the left dorsolateral prefrontal cortex and cathode electrode placed over the right supraorbital area. The EEG International 10-20 system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (MRI) to estimate and individualize a dose to be administered.
32765397|NCT04934423|Sham Comparator|Sham tDCS|The electrodes will be positioned in the same way as in the intervention group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Subsequently, the device is switched off, no longer emitting current.
32765398|NCT03890887|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1291583 alone. Test - BI 1291583 + Itraconazole
32765399|NCT05098951|Experimental|Patients with stiffness of joint receive acupuncture therapy|This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.
32765400|NCT04934501||PAD patients|The entire cohort exists of patients recently treated with an endovascular stent placement in the superficial femoral artery (SFA).
32765401|NCT04111861|Experimental|Intevention|To see if singing can be used as a detractive method from patients experiencing ongoing pain.
32765402|NCT04932161|Experimental|Titanium Granules as a bone graft in intrabony defects|In test group, after reflection of flap and degranulation, bone graft i.e., titanium particles will be placed in the void created by the defect and sutures will be placed.
32915062|NCT01893983|No Intervention|Referral alone|This is the current standard of care
32915063|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
33399815|NCT05193019||Patients undergoing PCI|
32715146|NCT05307536|Active Comparator|Educational intervention (controlled group)|"The educational intervention will be developed based on the Early Start Denver Model for six months after enrollment.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
32915064|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
32915065|NCT03691610|Experimental|Group 1|MenACYW conjugate vaccine + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
32915066|NCT03691610|Active Comparator|Group 2|MENVEO® + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
32915067|NCT03691610|Experimental|Group 3|MenACYW conjugate vaccine at 17 to 19 months of age and 20 to 23 months of age
32915068|NCT03691610|Active Comparator|Group 4|Menactra® at 17 to 19 months of age and 20 to 23 months of age
32915069|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
32915070|NCT02988791|Placebo Comparator|Placebo|Placebo
32915071|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
32915072|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
32915073|NCT04047875|Experimental|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
32915074|NCT04047875|Placebo Comparator|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
32915075|NCT03610568|Experimental|Growing up GREAT! Intervention|
32915076|NCT03610568|No Intervention|Control|
32915077|NCT05225675|Experimental|ARGX-117|Intravenous administration of ARGX-117
32715147|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
32715148|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
32915078|NCT05225675|Placebo Comparator|Placebo|Intravenous administration of placebo
32715149|NCT04310787||HBV-ACLF|To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
32715150|NCT05307302||Adolescent basketball players|Adolescent basketball players between the ages of 13-18 playing in basketball teams
32715151|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
32715152|NCT02328651|Active Comparator|Ribavirin treatment|
32715153|NCT05306522|Experimental|Telerehabitation Group|Patients will undergo telerehabilitation based spinal stabilization exercise 3 days per week for 6 weeks.
32715154|NCT05306522|Experimental|Face to face Group|Patients will undergo spinal stabilization exercise 3 days per week for 6 weeks.
32715155|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
32915079|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
33246673|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
33246674|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
32715158|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
32715159|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
32715160|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
32715161|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
32715162|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
32745779|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
32915080|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
32915081|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
32915082|NCT05662280|Experimental|Active intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, we will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
32715163|NCT05509712||Focus Groups to Refine MobileMen App Content|Focus groups are conducted virtually to refine content in the mobile app for African American men. African American men are recruited in Louisiana and Washington, DC and surrounding areas, using via listservs, ResearchMatch, social media, community events, local networking, and word of mouth.
32715164|NCT05509712||Beta testing of MobileMen App Prototype|The prototype MobileMen app is evaluated for feasibility, acceptability, and usability in semi-structured interviews with African American men recruited in Louisiana who meet eligibility criteria similar to those used for the focus groups
32715165|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
32915083|NCT05662280|Experimental|Sham intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, we will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
32915084|NCT02870205|Experimental|GSP 301 NS|
32915085|NCT02870205|Active Comparator|GOM-NS|
32915086|NCT02870205|Active Comparator|GMM-2 NS|
32715166|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
32715167|NCT05306444|Experimental|HBM 7008 - Part 1|"Experimental Part 1: Dose escalation~Intravenous IV administrations of HBM7008 on Days 1 of each 21 day treatment cycle~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
32715168|NCT05306444|Experimental|HBM 7008 - Part 2|"Experimental Part 2 - Dose Expansion~Treatment administered at Maximum Tolerated Dose (MTD) and / or Recommended Phase 2 Dose (RP2D) established in Part 1."
32715169|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
32715170|NCT05338034|Experimental|HPG1860 3 mg|20 subjects will be treated with HPG1860 3 mg once daily at a similar time with or without food.
32715171|NCT05338034|Experimental|HPG1860 5 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
32715172|NCT05338034|Experimental|HPG1860 8 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
32715173|NCT05338034|Placebo Comparator|Placebo|20 subjects will be treated with Placebo once daily at a similar time with or without food.
32715174|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
32715175|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
32715176|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
32715177|NCT05337566|Experimental|Azithromycin + Cefuroxime|These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision.
32715178|NCT05337566|Active Comparator|Placebo + Cefuroxime|These patients will receive placebo (2 tablets) per orally in the evening before the operation ans single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision.
32715179|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
32715180|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
32715181|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
32745780|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
32915087|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
32915088|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
32715182|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
32915089|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
32915090|NCT03002090|Experimental|Iron trained|
32915091|NCT03002090|Experimental|Iron Untrained|
32915092|NCT03002090|Experimental|BZKL Trained|
32915093|NCT03002090|Experimental|BZKL Untrained|
33246675|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
32915094|NCT03002090|Experimental|Placebo Trained|
32915095|NCT03002090|Placebo Comparator|Placebo Untrained|
32915096|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
32915097|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 3rd step.~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
32915098|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
32915099|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
32915100|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
32915101|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
32715183|NCT04197453||Consented Arm|Subjects with a recent (within 18 months) hospitalization for myocardial infarction, unstable angina, ischemic stroke, or critical limb ischemia, and subjects undergoing coronary, peripheral, or carotid revascularization, including surgical and percutaneous revascularization, with an LDL-C greater than or equal to 70 mg/dL who may be eligible for PCSK9 inhibitor therapy.
32715184|NCT04197453||Electronic Health Record (EHR) arm|Subjects with an inpatient or outpatient diagnosis of clinical ASCVD within the prior 12 months including coronary heart disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease, or prior coronary or peripheral or carotid revascularization.
33246676|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
32915102|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
32915103|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
32915104|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
33246677|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
32915106|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
33246678|NCT00611884|Experimental|SIBA (D)|
33073221|NCT03288545|Experimental|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
33073222|NCT03288545|Experimental|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
33246679|NCT00611884|Experimental|SIBA (E)|
33246680|NCT00611884|Experimental|SIBA (D) M, W, F|
33073223|NCT03288545|Experimental|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
32915107|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
32915108|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
32915109|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
32915110|NCT03598166|No Intervention|Control|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Patients who call will speak to a research assistant who is trained in patient navigation and can facilitate referrals for colonoscopy or FIT. Patients will receive a follow-up telephone call that reiterates information in the letter.~Patients will also be asked to complete a questionnaire about their beliefs and attitudes regarding CRC screening. The questionnaire will be mailed with the invitation letter and will also be administered over the telephone by the research assistant."
32915111|NCT03598166|Experimental|Septin9|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Letters will also include an option to participate in the blood test, with instructions to call the study number to schedule the blood draw. This option will not appear in the letters sent to the control group. Patients will also receive a follow-up telephone call and a questionnaire.~Participants who choose to the blood test (Septin9) will undergo phlebotomy. The blood sample will be run by an off-site commercial laboratory. The study team will notify patients and their primary care physicians of blood test results and will facilitate a colonoscopy referral for those with positive tests."
32915112|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
32915113|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
32915114|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
32915115|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
32915116|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
32915117|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU
32915118|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
32915119|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
32715185|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
32715186|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
32715187|NCT04886986|Experimental|All Subjects|Patients enrolled in the study will receive the study drugs 225Ac-J591 and 177Lu-PSMA-I&T, along with 68Ga-PSMA-11.
32715188|NCT03077841|Experimental|Arm I (hypofractionated partial breast irradiation)|Patients undergo hypofractionated partial breast irradiation daily for 10 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
32715189|NCT03077841|Active Comparator|Arm II (hypofractionated partial breast irradiation)|Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
32715190|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
32715191|NCT05335616|Experimental|"Intervention Guideline"|Participants are given written information (a hypothetical new guideline).
32715192|NCT05335616|Experimental|"Intervention Treatment fee item"|Participants are given written information about a hypothetical new treatment fee item.
32715193|NCT05530148|Experimental|Martial Arts Group|Participants will be trained in the martial arts exercises using both in-person group sessions and asynchronous remote learning via video content distributed to them each week. Participants will be asked to attend as many of the 24 in-person sessions as they can. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
32715194|NCT05530148|Active Comparator|Flexing, Toning and Balance|Flexibility, Toning and Balance or FTB will be used to refer to our resistive exercise comparison. As in the experimental group, participants will be asked to attend as many of the 24 in-person intervention sessions as they can, whilst also practicing the exercises remotely via video content distributed to them. The remote portion of this intervention will be asynchronous. Heart-rate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the martial arts experimental group.
32715195|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
32715196|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
32915120|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
32915121|NCT05207423||Participants With Advanced NSCLC With EGFR Exon-20 Mutations|Participants diagnosed with advanced NSCLC with EGFR exon 20 insertions (ex20ins) mutations who were treated according to routine clinical practice will be observed retrospectively up to 6 months or until the end of follow-up.
33246681|NCT00611884|Active Comparator|IGlar|
32915122|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
32915123|NCT02872857|Placebo Comparator|Placebo|
32915124|NCT02872857|Experimental|8mg galantamine twice daily|
32915125|NCT02872857|Experimental|12mg galantamine twice daily|
32715197|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
32915126|NCT03958409|Experimental|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
32915127|NCT03958409|Active Comparator|Standard care|The participants will be evaluated for the standard of care received.
32915128|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
32915129|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
32915130|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
32915131|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
32915132|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
32915133|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
32915134|NCT03945461|Experimental|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
32915135|NCT03945461|No Intervention|Standard Care|Standard hospital management with no deviations from usual care
33246682|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
33246683|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
33246684|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
33246685|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
33246686|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
32715198|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
32715199|NCT05384756|Experimental|Treatment (TMLI, alemtuzumab)|Patients receive alemtuzumab IV over 4 hours QD on days -7 to -3. Patients undergo TMLI BID on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.
32715200|NCT02913495|Experimental|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
32715201|NCT02913495|Active Comparator|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
32715202|NCT05335226|Experimental|Haplo-HSCT group|58 patients will be involved in this group
32715203|NCT05335226|Experimental|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group|58 patients will be involved in this group
32715204|NCT02314780|Experimental|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
32715205|NCT02314780|Experimental|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
32715206|NCT02314780|Placebo Comparator|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
32715207|NCT05305664|Experimental|Pelacarsen (TQJ230)|
32715208|NCT05305664|Placebo Comparator|Placebo|
32715209|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
32715210|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
32915136|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
32915137|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
32915138|NCT05197751|Experimental|3 µg dose cohort|3 µg MSP3-CRM-Vac4All/Alhydrogel®
32915139|NCT05197751|Experimental|10 µg dose cohort|10 µg MSP3-CRM-Vac4All/Alhydrogel®
32915140|NCT05197751|Experimental|30 µg dose cohort|30 µg MSP3-CRM-Vac4All/Alhydrogel®
32915141|NCT03921281|Experimental|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
32915142|NCT03921281|Other|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
32915143|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
33073224|NCT03288545|Experimental|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
33246687|NCT00413413|Active Comparator|Valsartan 80 mg|
33246688|NCT00413413|Active Comparator|Valsartan 160 mg|
33246689|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
32915144|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
33246690|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
33246691|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
32915145|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
32915146|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
32915147|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
32915148|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
32915149|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
32915150|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
32915151|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
32915152|NCT04350671|Experimental|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
32915153|NCT04350671|Active Comparator|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
32915154|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
32915155|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
32915156|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
32915157|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
32915158|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
32915159|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
32915160|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
32915161|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
32915162|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
32915163|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
33246692|NCT01040533||Failed / complicated jejunoileal bypass|
33246693|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
33246694|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
33246695|NCT01040767|Active Comparator|Class|
33246696|NCT01040767|Active Comparator|Web|
33246697|NCT01040767|No Intervention|Control|
33246698|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
32715211|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
32715212|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
32715213|NCT05304104|Experimental|Telehealth Cognitive Behavioral Therapy (teleCBT)|About one-half of participants will be randomly assigned to Telehealth Cognitive Behavioral Therapy (teleCBT), a virtual Cognitive Behavioral Therapy (CBT) for binge eating disorders delivered via an Office of Information and Technology (OI&T)-approved video platform, by a master's-level research clinician. TeleCBT will be administered in 8 to 10 hourly individual sessions over a three-month treatment period.
32715214|NCT05304104|Active Comparator|Self-Help Cognitive Behavioral Therapy (shCBT)|About one-half of participants will be randomly assigned to Self-Help Cognitive Behavioral Therapy (shCBT), a Self-Help CBT for binge eating disorders initiated by a research assistant via telephone and then continued by the participant at home. These materials are the same exact ones provided to participants in TeleCBT (i.e., treatments are matched for materials), and will be mailed to participants. They will be instructed to work independently through one chapter per week for the following 12 weeks (i.e., treatment length is matched to TeleCBT).
32715215|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
32715216|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
32715217|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
32715218|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
32715219|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
32715220|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
32715221|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
32715222|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
32715223|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
32715224|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
32715225|NCT03110757|Active Comparator|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
32715226|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
32715227|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
32715228|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
32715229|NCT05303870|Experimental|IAPT|
32715230|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
32715231|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
32715232|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
32715233|NCT05303792|Experimental|Arm A (inotuzumab ozogamicin, chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive inotuzumab ozogamicin IV and IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
32915164|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
32915165|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
32915166|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
32915167|NCT00374751|Experimental|Samarium (153SM)|Injection of Samarium (153SM)
32915168|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
32915169|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
32915170|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
32915171|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant & nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
32915172|NCT02876757||5ARI Users|
32915173|NCT02876757||Non 5ARI users|
32915174|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
32915175|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
32915176|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
32915177|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
32915178|NCT04850846|Experimental|Metformin|"Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months.~Metformin Extension:~Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose )"
32915179|NCT04850846|Experimental|Placebo|Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.
32915180|NCT05166083||Trans man|"Trans man is assigned female at birth and identify as man"
32915181|NCT04826354|Experimental|Rosuvastatin|Rosuvastatin 20mg
32915182|NCT04826354|Active Comparator|Rosuvamibe|Rosuvastatin plus ezetimibe 10/5
32915183|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
32915184|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
32915185|NCT05589350|Experimental|High-fat yogurt|Daily consumption of 1-2 servings (based on daily calorie requirement) of high-fat yogurt
32915186|NCT05589350|Active Comparator|Low-fat yogurt and butter|Daily consumption of 1-2 servings of low-fat yogurt along with daily consumption of about 10 grams of animal butter
32915187|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
32915188|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
32915189|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
32915190|NCT02987933||Healthy Normals|Age and gender matched controls
32915191|NCT04743440||Physicians|We will include specialists in anaesthesiology who work at the Anaesthesiology Department, Hillerød hospital, during the trial period. It is an inclusion criterion that they take part in the Anaesthesiology Department's specialist in-house on-call rotation (i.e., attending physician). Each of the included physician participants will be responsible for conducting the airway management in four patient participants; two who have been randomised to the i-gelTM LMA, and two to the Ambu® AuraGainTM LMA, respectively.
32915192|NCT04707794||Elderly|Patients > 65 years age undergoing non-cardiac surgery will be administered general anesthesia maintained with sevoflurane or desflurane titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
32915193|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
32915194|NCT04701866|Experimental|Music|Music will be provided for participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks).
32915195|NCT04701866|No Intervention|Usual Care|Participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks) will be administered as per usual care. That is, without music provided or permitted. Contact time with clinicians before, during, and after ketamine treatments will be matched.
32915196|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
32915197|NCT01900067|No Intervention|Control|no active warming, standard of care
32915198|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
32915199|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
32915200|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
32915201|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
32915202|NCT02902250|Active Comparator|Conservative Treatment|Conservative Treatment for compression fracture
32915203|NCT02759588|Experimental|GL-ONC1|
32915204|NCT02219438|Experimental|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
32915205|NCT02219438|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
32915206|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
32915207|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
32915208|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
32915209|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
32915210|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
32715234|NCT05303792|Active Comparator|Arm B (chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, doxorubicin IV on day 4, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
32745781|NCT04812561|Experimental|Bronch™ group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day, 800 mg/day as Bronch™)
32915211|NCT01903187|Active Comparator|Sham procedure|Sham procedure
32915212|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
32915213|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
32915214|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
32915215|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
32915216|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
32915217|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
32915218|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
32915219|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
32915220|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
32915221|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
32915222|NCT04594616|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
32915223|NCT04594616|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
32745782|NCT04812561|Placebo Comparator|Placebo group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day)
32915224|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
32915225|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
32915226|NCT03688139|Experimental|Engage Therapy|Participants receive Engage therapy for 9 weeks.
32915227|NCT03688139|Active Comparator|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
32915228|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
32915229|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
32915230|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
32915231|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
32915232|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
32745783|NCT04812405|Other|Teeth|Occlusal examination
32915233|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
32915234|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
32915235|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
32915236|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
32915237|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
32915238|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
32915239|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
32915240|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
32915241|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
32915242|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
32915243|NCT04976777|Experimental|Updated Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) 0.7 mg|DEX PS DDS 0.7 mg implant was administered intravitreally into the study eye using updated applicator at Day 1 and followed until Day 7.
32915244|NCT04976777|Active Comparator|Approved DEX PS DDS 0.7 mg|DEX PS DDS 0.7 mg implant was administered into the study eye using currently approved applicator at Day 1 and followed until Day 7.
32915245|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
32915246|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
32915247|NCT04522232|Placebo Comparator|group A|women that underwent conventional Total laparoscopic hysterectomy
32915248|NCT04522232|Experimental|group B|women that underwent Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
32915249|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
32915250|NCT03686657|Active Comparator|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
32915251|NCT03686657|Experimental|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
32915252|NCT03686657|Experimental|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
32915253|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
32715235|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
32915254|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
33246699|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
33246700|NCT01041001|Active Comparator|Microfracture treatment|
33246701|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
33246702|NCT01041157|Experimental|1|resistance training
33246703|NCT01041235|Experimental|ATI-1123|
32715236|NCT05610566|Experimental|A single set of test|The HighLife Trans-Septal TMVR System comprises a 28mm Transcatheter Mitral Valve, a loop placement catheter, a sub-annular implant and its delivery systems.
32915255|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
32915256|NCT03587987|Active Comparator|Neopuff|neopuff
32915257|NCT03587987|Experimental|r PAP|rPap device
32915258|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
32915259|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
32915260|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
32915261|NCT03049917|No Intervention|No incentive|No incentive
32915262|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
32915263|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
32915264|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
32915265|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
32915266|NCT05473208|No Intervention|Control Group|Participants randomly assigned to control group will not wear an exoskeleton during working hours.
32915267|NCT05473208|Experimental|Exoskeleton Group|Participants randomly assigned to exoskeleton group will be given instructions and explanations on how to use/adjust/loosen the exoskeleton, and after a period of familiarisation, they will be wearing an exoskeleton during their working hours for a period of one year.
33246704|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
32715237|NCT05080569|Experimental|MOH/IUI treatment with LPS|(Mild) Ovarian stimulating treatment and insemination are according to regular treatment protocol. Females assigned to the treatment group start LPS, applying 3dd200mg Utrogestan in vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation
33246705|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
33246706|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
32715238|NCT05080569|Placebo Comparator|MOH/IUI treatment with placebo|"Females will receive regular MOH/IUI treatment. The female cycle is mildly stimulated and monitored until the desired amount of ripe follicles is achieved. In the absence of other reasons to cancel the treatment, ovulation is triggered and subsequently pre-washed semen is inseminated into the uterus.~Females assigned to the placebo group start placebo, applying 3dd1 vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation"
32715239|NCT05383508|Active Comparator|Product Sequence 1|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; Cig on Day 2; CM35 on Day 3"
33246707|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
33246708|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
33246709|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
33246710|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
33246711|NCT03760939|Experimental|Ambulatory care|Colorectal surgery in ambulatory care
32715240|NCT05383508|Active Comparator|Product Sequence 2|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; CM35 on Day 2; Cig on Day 3"
32715241|NCT05383508|Active Comparator|Product Sequence 3|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CA35 on Day 2; CM35 on Day 3"
32715242|NCT05383508|Active Comparator|Product Sequence 4|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CM35 on Day 2; CA35 on Day 3"
32715243|NCT05383508|Active Comparator|Product Sequence 5|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; Cig on Day 2; CA35 on Day 3"
32765403|NCT04932161|Active Comparator|Hydroxyapatite as a bone graft in intrabony defects|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
33246712|NCT03760939|Other|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
33246713|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
32765404|NCT05073523|Other|Meal A|Diet: meal proportion 1
32765405|NCT05073523|Other|Meal B|Diet: meal proportion 2
33246714|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
33246715|NCT04038112|Other|Method of Levels (MOL)|all participants will be offered intervention
33246716|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
32765406|NCT05073523|Other|Meal C|Diet: meal proportion 3
32765407|NCT04934345||FC administration|"All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.~After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked.~PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')~PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion."
32765408|NCT04516993|Experimental|Tenecteplase arm|
32765409|NCT04516993|Other|Best treatment arm (e.g. Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|The best treatment selected by local doctors
32765410|NCT04922177|Experimental|CAD/CAM Group|For the CAD/CAM group, an indirect ceramic restoration will be made using an optical impression.
32765411|NCT04922177|Active Comparator|Direct method Group|For the direct method group, a restoration using a Glass Ionomer Cement will be performed.
32765412|NCT03817957|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
32765413|NCT03817957|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
32765414|NCT03817957|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
32905477|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
33246717|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
32715244|NCT05383508|Active Comparator|Product Sequence 6|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; CA35 on Day 2; Cig on Day 3"
32715245|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
32715246|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
32715247|NCT05302856|Experimental|Presumably fertile male patients going through ART treatment|
32715248|NCT05302856|Experimental|Subfertile/infertile male patients with abnormal semen analysis|
32715249|NCT05302856|Experimental|Male patients suffering from unexplained infertility|
32715250|NCT02030925|Experimental|IW-3718|Twice a day
32715251|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
32715254|NCT05080413|Experimental|Parkinson disease group|A total of 10 patients in this group will walk under the same conditions (off- state of antiparkinson drugs). Participants will be instructed to walk three laps on a 10-meter track under each of the following three conditions : 1) without stimulation, 2) with visual cues using a laser shoe, 3) with auditory cues using a metronome.
32715255|NCT05506826|Experimental|fine motor activities group|Patients in this group will receive conventional therapy for 1 month sixty minutes/day, 5 days/week in addition to performing fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes
32715256|NCT05506826|Active Comparator|control group|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
32715257|NCT04039893|Other|Node-positive breast cancer patients|All patients with positive lymph nodes for who an axillary node clearance is proposed as part of the surgical treatment
32715258|NCT05301764|Experimental|LVGN6051 combined with Anlotinib|LVGN6051 Dose Escalation in the combination treatment with Anlotinib
32715259|NCT04022967|Experimental|Arm 1 : Dual maintenance therapy DTG+3TC|
32715260|NCT04022967|Experimental|Arm 2 : Dual maintenance therapy ATV/r+3TC|
32715261|NCT04022967|Active Comparator|Arm 3 : Reference triple therapy TDF+3TC+EFV|
32715262|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
32715263|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
32715264|NCT05332574|Experimental|GB263T|Experimental: GB263T
32715265|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
32715266|NCT05610488|Experimental|Vabysmo (Faricimab) 6 mg|Vabysmo (Faricimab) 6 mg solution for intravitreal injection All consenting, enrolled patients will receive an intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits up to month 12.
32715267|NCT01646398|Experimental|>= 65-year age group-13vPnC|
32715268|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
32745784|NCT04816929|Experimental|Bobath Method Group|The Bobath based exercises for 60 minutes will be formed according to the needs of the individual and will involve trunk exercises such as placing, stretching, functional reach, rotations, functional strengthening and, balance and walking exercises etc. It will be performed 3 days a week for 8 weeks.
32905478|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
32905479|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
32905480|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
32905481|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
32905482|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
32905483|NCT04983966|Experimental|Desflurane group|General anesthesia with volatile agent of desflurane
32905484|NCT04983966|Active Comparator|Remimazolam group|Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
32905485|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
32905486|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
32905487|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
32905488|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
32715269|NCT05080101|Active Comparator|Conventional Physiotherapy Group|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
32715270|NCT05080101|Experimental|Basic Body Awareness Therapy Group|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
32715271|NCT05527886|Experimental|Group 1|Randomized AAROM, Slow Load, or Plyometric intervention
32715272|NCT05527886|Experimental|Group 2|Randomized AAROM, Slow Load, or Plyometric intervention
32715273|NCT05527886|Experimental|Group 3|Randomized AAROM, Slow Load, or Plyometric intervention
32715274|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
32715275|NCT05527652|Experimental|Self-Supporting Nasopharyngeal Airway (ssNPA)|
32715276|NCT05527652|No Intervention|Standard of Care|Waitlist control group: While waiting, participants will continue to receive the treatment they would have had before which will likely include being placed on the waiting list for positive airway pressure (PAP). After a period of being on the waitlist (8 weeks) there is an option to cross-over to the device arm.
32715277|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
32715278|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
32915268|NCT03526835|Experimental|MCLA-158|In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.
32915269|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
32915270|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
32915271|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
32915272|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
32915273|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
32915274|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
32915275|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
32915276|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
32915277|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
32915279|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
32915280|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
32915281|NCT03050619||New users of Empagliflozin|New users of empagliflozin
32915282|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
32915283|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
33073225|NCT03288545|Experimental|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
33246718|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
32715279|NCT05301452|Placebo Comparator|Control Group|This group will receive an application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
32715280|NCT05301452|Active Comparator|ILIB Group|This group will receive an application of ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
32915284|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
32915285|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
32915286|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
33246719|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
32915287|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
33246720|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
33246721|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
32915288|NCT04430348|Experimental|PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.01 mg/kg
32915289|NCT04430348|Experimental|PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.03 mg/kg
32915290|NCT04430348|Experimental|PTX-35 Dose Level 3|Dose Level 3: PTX-35 0.10 mg/kg
32915291|NCT04430348|Experimental|PTX-35 Dose Level 4|Dose Level 4: PTX-35 0.30 mg/kg
32915292|NCT04430348|Experimental|PTX-35 Dose Level 5|Dose Level 5: PTX-35 1.0 mg/kg
32915293|NCT04430348|Experimental|PTX-35 Dose Level 6|Dose Level 6: PTX-35 3.0 mg/kg
32915294|NCT04430348|Experimental|PTX-35 Dose Level 7|Dose Level 7: PTX-35 10.0 mg/kg
32915295|NCT04420130|Experimental|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
32915296|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
32915297|NCT04348604|Experimental|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
32915298|NCT04348604|Active Comparator|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
32915299|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
32915300|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
33246722|NCT04037644|Experimental|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
33246723|NCT04037644|Active Comparator|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
33246724|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
33246725|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
33246726|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
33246727|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time >6 months reported by the patient and/or by the responsible physician since HIV transmission.
33246728|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
33246729|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
33246730|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
33246731|NCT04038190|Experimental|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
33246732|NCT04038190|No Intervention|Standard Orientation Course|Standard freshman orientation seminar course condition
32765415|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
32765416|NCT04922489||Patients with Astra Tech EV|Patients who has receive Astra Tech dental implant system placement.
32765417|NCT05015335|Experimental|Adalimumab|Adalimumab administered subcutaneously at 40mg every 2 weeks
32765418|NCT05015335|Active Comparator|Methotrexate|Methotrexate given 10mg orally once a week.
32765419|NCT03805243|Experimental|test of sensors for somnonaute device|monitoring with sensors
32765420|NCT03805243|Experimental|test of sensors for uronaute device|monitoring with sensors
32765421|NCT03805243|Experimental|test of sensors for toconaute device|monitoring with sensors
32765422|NCT03805243|Experimental|test of sensors for cardioskin device|monitoring with sensors
32765423|NCT03805243|Experimental|test of sensors for neuronaute device|monitoring with sensors
32765424|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
32765425|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
32765426|NCT03667027||Patients undergoing LTx with respiratory failure (cases)|Patients are receiving a respiratory support modality (mechanical ventilation and/or extracorporeal life support) as a bridge to lung transplantation (LTx).
32765427|NCT03667027||Patients undergoing LTx without prior respiratory support|Patients undergoing lung transplantation but do not require prior bridging respiratory support.
32765428|NCT03667027||Elective thoracic surgical patients|Patients undergoing elective thoracic surgery for planned lung or esophageal resection.
32765429|NCT03534817|Experimental|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
32765430|NCT03534817|No Intervention|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
32765431|NCT04933799|Active Comparator|PF-06650833 + Standard of Care treatment|Subjects randomized to the PF-06650833 arm of the study will receive 400 mg PF-06650833 (2 x 200 mg tablets) of the MR formulation orally QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). Subjects who cannot take tablets PO will receive PF-06650833 200 mg IR suspension formulation every 6 hours (NG tube or OG tube, or equivalent). Subjects for whom concomitant administration of a strong inhibitor of CYP3A4 (eg, ritonavir) will have the dose reduced to either 200 mg MR or IR QD. All dosing of study drug will be in addition to current hospital SOC treatment that must include treatment targeting SARS-CoV-2.
32765432|NCT04933799|Placebo Comparator|Placebo + Standard of Care treatment|Placebo will match the Active comparator in dosage form, dosage, frequency and duration.
32765433|NCT03921619|No Intervention|No Sling|Participants will perform the balance tests without any added equipment.
32765434|NCT03921619|Experimental|Sling (Dominant)|Participants will perform the balance tests with a sling on the dominant arm.
32765435|NCT04931147|Experimental|Part A SAD - Cohort 1|This is the first treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive 2 mg of RXC007 on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765436|NCT04931147|Experimental|Part A SAD - Cohort 2|This is the second treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Cohort 1 Dose Escalation Data Review) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765437|NCT04931147|Experimental|Part A SAD - Cohort 3|This is the third treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765438|NCT04931147|Experimental|Part A SAD - Cohort 4|This is the fourth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765439|NCT04931147|Experimental|Part A SAD - Cohort 5|This is the fifth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765440|NCT04931147|Experimental|Part A SAD - Cohort 6|This is the sixth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765441|NCT04931147|Experimental|Part A SAD - Optional Cohort 7|This is an optional seventh treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765442|NCT04931147|Experimental|Part A SAD - Optional Cohort 8|This is an optional eighth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
32765443|NCT04931147|Experimental|Part B MAD - Cohort 1|This is the first treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
33246733|NCT00885430|Experimental|Pico-Salax|
32715281|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32715282|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32715283|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32915301|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
32915302|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
32915303|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
32915304|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
32915305|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
32915306|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
32915307|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
32915308|NCT04280822|Experimental|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
32915309|NCT04280822|Active Comparator|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
32915310|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
32915311|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
32915312|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
32915313|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
32915314|NCT05437640|Active Comparator|Protein Redistribution Diet|PD participants may first be randomized to follow the Protein Redistribution Diet followed by the Protein Consistent Diet.
32915315|NCT05437640|Active Comparator|Protein Consistent Diet|PD participants may first be randomized to follow the Protein Consistent Diet followed by the Protein Redistribution Diet.
32915316|NCT04895579|Experimental|Copanlisib (30-60mg iv)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days or 1500mg day 1 q28d). They will also receive Copanlisib ranging from 30mg to 60mg (IV infusion on days 1 and 15, q 28 days).
32915317|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
32915318|NCT03051633|No Intervention|Control|Assessment only
32915319|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
32915320|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
32915321|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
32915322|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
32915323|NCT00555971|Placebo Comparator|Placebo Group|Subjects randomized to placebo
32915324|NCT00555971|Active Comparator|Omalizumab Group|Subjects randomized to omalizumab
32915325|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
32915326|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
33246734|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
33246735|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
33246736|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
33246737|NCT00886444|Experimental|Ferucarbotran|
33246738|NCT00888550|Experimental|1. Splinting|
32715284|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32715285|NCT05301374|Experimental|Cartoon Group|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended. Parent was with their children during the procedure in both groups.
32715286|NCT05301374|No Intervention|Control Group|No intervention was performed to reduce anxiety and pain for children in the control group. Parent was with their children during the procedure in both groups.
32715287|NCT05079867||Perimodiolar (PM)|Patients to be implanted with: Mid Scala or CI532 / 632 (Slim modiolar) electrode
32715288|NCT05079867||Lateral wall (PL)|Patients to be implanted with: Slim J or CI522 / 622 (Slim Lateral) electrode
32715289|NCT05382104|Experimental|Sequence 1: Treatment A + Treatment B + Treatment C|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 under fasting condition as Treatment A, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a low fat/low calorie meal as Treatment B, and further followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a high fat/high calorie meal as Treatment C. There will be a washout period of minimum of 72 hours between each ID dosing.
32715290|NCT05382104|Experimental|Sequence 2: Treatment B + Treatment C + Treatment A|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a low fat/low calorie meal as Treatment B, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a high fat/high calorie meal as Treatment C, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 under fasting condition as Treatment A. There will be a washout period of minimum of 72 hours between each ID dosing.
32915327|NCT01850108|Experimental|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
32915328|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
32915329|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
32915330|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
32915331|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
32915332|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
32915333|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
32915334|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
32915335|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
32915336|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
32915337|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
32915338|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
32915339|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
32915340|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
32915341|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
32915342|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
32915343|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
32915344|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
33246739|NCT00888550|Active Comparator|2. No Splinting|
33246740|NCT00888706|Active Comparator|1|
33246741|NCT00888706|Active Comparator|2|
33246742|NCT00888706|Active Comparator|3|
33246743|NCT00888706|Experimental|4|
33246744|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
33246745|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
33246746|NCT04037722|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
33246747|NCT04037722|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
32715291|NCT05382104|Experimental|Sequence 3: Treatment C + Treatment A + Treatment B|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a high fat/high calorie meal as Treatment C, followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 2 under fasting condition as Treatment A, and followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 3 administered with a low fat/low calorie meal as Treatment B. There will be a washout period of minimum of 72 hours between each ID dosing.
32715292|NCT05382104|Experimental|Sequence 4: Treatment C + Treatment B + Treatment A|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a high fat/high calorie meal as Treatment C, followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 2 administered with a low fat/low calorie meal as Treatment B, and followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 3 under fasting condition as Treatment A. There will be a washout period of minimum of 72 hours between each ID dosing.
32915345|NCT05410106|Experimental|PneuX endotracheal tube|Patients will be intubated using the PneuX endotracheal tube system
32715293|NCT05382104|Experimental|Sequence 5: Treatment A + Treatment C + Treatment B|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 under fasting condition as Treatment A, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a high fat/high calorie meal as Treatment C, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a low fat/low calorie meal as Treatment B. There will be a washout period of minimum of 72 hours between each ID dosing.
32715294|NCT05382104|Experimental|Sequence 6: Treatment B + Treatment A + Treatment C|Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a low fat/low calorie meal as Treatment B, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 under fasting condition as Treatment A, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a high fat/high calorie meal as Treatment C. There will be a washout period of minimum of 72 hours between each ID dosing.
32715295|NCT03916809|Experimental|Active EMST + Standard Care|Patients randomized to the Active EMST + Standard Care arm (ACTIVE) will use the EMST150 device as packaged, i.e. following package instructions with a device that has its valve spring maintained.
32715296|NCT03916809|Sham Comparator|Sham EMST + Standard Care|Those randomized to the Sham EMST + Standard Care arm (SHAM) will use an EMST150 device that has been modified by removing the internal spring, which allows the valve to open in response to airflow through the device regardless of the amount of pressure generated.
32715297|NCT03892239|Experimental|Intervention|Monitoring and suggestion of training progress. Behaviour change strategy based on increasing knowledge.
32715298|NCT03892239|Active Comparator|Control|Monitoring and suggestion of training progress.
32715299|NCT04246814|Placebo Comparator|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
32715300|NCT04246814|Active Comparator|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
32715301|NCT04246814|Active Comparator|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
32715302|NCT04246814|Active Comparator|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
32715303|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
32715304|NCT03141879|No Intervention|Regular care|(Wait-list control)
32715305|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.~Other Name: ESD"
32715306|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
32715307|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
32715308|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
32715309|NCT05079711||Symptomatic for vaginal yeast|Women presenting to the clinic with symptoms of vulvovaginal candidiasis.
32715310|NCT05079711||Asymptomatic for vaginal yeast|Women presenting to the clinic with no symptoms of vulvovaginal candidiasis.
32915346|NCT05410106|Active Comparator|Standard care|Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
32915347|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
32715311|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
32715312|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
32715313|NCT05331950||Office workers|The office workers will do their routine job tasks and will be observed through injury predictor (functional movement screen) at baseline and after actual injuries happened 6 months
32915348|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
32915349|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
32915350|NCT04226768|Experimental|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
32915351|NCT04226768|Active Comparator|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
32915352|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
32915353|NCT04737213|Experimental|SGM-101|Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
32915354|NCT04169282|Experimental|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
32915355|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
32915356|NCT02945553|Active Comparator|Microstimulation|Microstimulation
32715314|NCT05079555|No Intervention|Control group|The control group consisted of patients who followed conventional therapy.
32715315|NCT05079555|Experimental|Intervention group|The intervention group consisted of patients rehabilitated using the robotic platform.
32715316|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
32715317|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
32715318|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
32715319|NCT05610410||Patients with angina and no obstructive coronary arteries|
32915357|NCT05376722|Experimental|pamiparib|Subjects received pamiparib 40 mg orally, twice a day; abiraterone acetate 1000 mg orally, once a day; prednisone acetate tablets (prednisone) 5 mg, once a day; every 30 days Treatment cycle, treatment for 4-6 cycles, that is, 4-6 months. Robot-assisted laparoscopic radical prostatectomy and extended lymph node dissection within 30 days of the end of 4 months of neoadjuvant therapy. If the subjects have intolerable toxic reactions during the treatment period, the dose adjustment can be carried out. Day 1 of cycle 1, day 15 and day 1±3 days of each cycle thereafter, and 1 follow-up within 30 days after the end of treatment and before surgery; 1 prostate MRI during the screening period and within 30 days after the end of treatment and before surgery Scan, PSMA PET/CT scan or CT scan
32915358|NCT05349500|Experimental|OA CARE|Participants assigned to the OA CARE intervention will receive a 12-month Medical Membership to a local YMCA and participate in a 12-week weight loss program. Participants will also work with an OA CARE Navigator, who, in partnership with their primary care provider (PCP), will identify any additional programs or resources that may help them manage their osteoarthritis (OA) symptoms.
32915359|NCT05349500|Placebo Comparator|Usual Care|Participants assigned to this group will receive no additional treatment from the study for about 12 months.
32915360|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
32915361|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
32915362|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
32915363|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
32915364|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
32915365|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
32915366|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
32915367|NCT04737057|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding injections and drilling. It is one of a number of biologically orientated strategies for managing dental decay
33073226|NCT03288545|Experimental|Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
32715320|NCT05610410||Patients with HFpEF|
32715321|NCT05330858|Experimental|ESK-001 Liquid|ESK-001 administered as an oral liquid
32715322|NCT05330858|Experimental|ESK-001 Tablet Fasted|ESK-001 administered as an oral tablet in the fasted state
32715323|NCT05330858|Experimental|ESK-001 Tablet Fed|ESK-001 administered as an oral tablet in the fed state
32715324|NCT05330858|Experimental|ESK-001 and Rabeprazole|ESK-001 administered as an oral tablet with rabeprazole
32715325|NCT05330546|Experimental|Osseodensification technique group|10 patients will be randomly assigned to the osseodensification group so the implant osteotomy will be prepared using densah burs
32715326|NCT05330546|Active Comparator|Ridge expansion screw group|10 patients will be randomly assigned to the ridge expansion screw group so the implant osteotomy will be prepared using ridge expansion screws
32715327|NCT05330234|Other|Therapists|Single arm study. Participants are members of the therapy team at Imperial College Healthcare NHS Trust's stroke wards.
32715328|NCT05300204|Experimental|Intervention Group 1 - Self-help Strategies for depression|Exposure to information about self-help strategies for depression
32715329|NCT05300204|Experimental|Intervention Group 2 - General information about depression|Exposure to general information about depression
32715330|NCT05299502|Experimental|Nutritional Intervention|Intervention promoting healthy eating by a Registered Dietitian.
32715331|NCT05299502|No Intervention|Standard Care|Women will have their usual medical pregnancy follow-ups by their MDs without access to nutritional care.
32715332|NCT05381090|Active Comparator|Healthy control|Venous blood collection
32715333|NCT05381090|Experimental|Parkinson's disease|Venous blood collection
32715334|NCT05381090|Experimental|Parkinson's disease dementia|Venous blood collection
32715335|NCT05381090|Experimental|Dementia with Lewy Bodies|Venous blood collection
32715336|NCT05381090|Experimental|Alzheimer's disease|Venous blood collection
32715337|NCT05610332|Experimental|Immune activated experimental group|Albumin paclitaxel 260mg/m2, ivgtt, d1, d8 Carrelizumab: 200mg, ivgtt, d1, q3w
32915368|NCT04737057|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a promising therapeutic agent for managing caries lesions in young children and those with special care needs
32915369|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
32915370|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
32915371|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
32915372|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
32915373|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
32915374|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
32915375|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
32915376|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
33246748|NCT04037722|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
33246749|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
33246750|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
33246751|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
33246752|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
33246753|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
32915377|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
32915378|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
32915379|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
32915380|NCT03112473|No Intervention|Control group|No Active intervention
32915381|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
32915382|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
32915383|NCT03112863|Experimental|Bakuchiol|Bakuchiol 0.5% applied to face twice daily
32915384|NCT03112863|Active Comparator|Retinol|0.5% retinol applied to face nightly
32915385|NCT05257460|Active Comparator|Closed-loop using standard rapid-acting insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
32915386|NCT05257460|Experimental|Closed-loop using ultra-rapid insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using ultra-rapid insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
32915387|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
33246754|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
32915388|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
32915389|NCT02280317|Experimental|Cohort 1: 0.5 mg/kg|VAL201-001 Sub-cutaneous injection. 0.5 mg/kg
32915390|NCT02280317|Experimental|Cohort 2: 1 mg/kg|VAL201-001 Sub-cutaneous injection. 1.0 mg/kg
32915391|NCT02280317|Experimental|Cohort 3: 2 mg/kg|VAL201-001 Sub-cutaneous injection. 2.0 mg/kg
32915392|NCT02280317|Experimental|Cohort 4: 4 mg/kg|VAL201-001 Sub-cutaneous injection. 4.0 mg/kg
32915393|NCT02280317|Experimental|Cohort 5: up to 8 mg/kg|VAL201-001 Sub-cutaneous injection. 8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
32915394|NCT02249312|Experimental|BIIIL|
32915395|NCT02249312|Placebo Comparator|Placebo|
32915396|NCT05095454|Experimental|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
32915397|NCT05095454|Experimental|Transcutaneous Epidural Stimulation|Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
32915398|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
32915399|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
32915400|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
32915401|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
32915402|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
32915403|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
32915404|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
32915405|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
32915406|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
32915407|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
32715338|NCT05610332|Active Comparator|Immune activated control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
32915408|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
32915409|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
32915410|NCT05249114|Experimental|Cohort 1|Cabozantinib 20 mg daily with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 20 mg qd.
32915411|NCT05249114|Experimental|Cohort 2|Cabozantinib 40 mg qod alternating with 20 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
32915412|NCT05249114|Experimental|Cohort 3|Cabozantinib 40 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
32915413|NCT05249114|Experimental|Cohort 4|Cabozantinib 60 mg qod alternating with 40 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd.
32915414|NCT05249114|Experimental|Cohort 5|Cabozantinib 60 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd until disease progression.
32915415|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
32715339|NCT05610332|Experimental|Immune silence experimental group|Carrelizumab: 200mg, ivgtt, d1, q3w Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
32715340|NCT05610332|Active Comparator|Immunosilent control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
32915416|NCT05245292|Experimental|3BNC117-LS + 10-1074-LS + N-803|3BNC117-LS dosed at 30 mg/kg IV, day 0 10-1074-LS dosed at 10 mg/kg IV, day 0 N-803 dosed at 6 mcg/kg, SC, 8 doses every 3 weeks (week 1 through week 22)
32915417|NCT05236790|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|Colonoscopies will be performed according to the standard of care. Patients will undergo colonoscopies using CAD-eye (CADe and CADx) and Scale-eye. All optically diagnosed (CADx) polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. CADx will be combined with human input for final diagnosis.
33073227|NCT03288545|Experimental|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
33073228|NCT03288545|Experimental|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
33073229|NCT03288545|Experimental|Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
33073230|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
33073231|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
33073232|NCT03288545|Experimental|Cohort L: Enfortumab vedotin in MIBC in perioperative setting|Enfortumab vedotin on days 1 and 8 and every 21 days
32745785|NCT04816929|Active Comparator|Task-Oriented Approach Group|The task-oriented approach for 60 minutes will be formed according to the needs of the individual and involve exercises targeting functional tasks determined. It will be performed 3 days a week for 8 weeks.
32745786|NCT04825899||NGS Panel|patients who had NGS 481 gene mutation detected
32745787|NCT04816851||Ozaki group|Patients undergoing aortic valve reconstruction using autologous pericardium (OZAKI technique) at Assiut University Hospitals in conjunction with Al-Nas hospital in cairo.
32745788|NCT05618691|Experimental|GFH312 40mg|Participant will receive GFH312 40mg once daily approximately at same time each day for 12 weeks.
32745789|NCT05618691|Experimental|GFH312 80mg|Participant will receive GFH312 80mg once daily approximately at same time each day for 12 weeks.
32745790|NCT05618691|Experimental|GFH312 120mg|Participant will receive GFH312 120mg once daily approximately at same time each day for 12 weeks.
32745791|NCT05618691|Experimental|Placebo|Participant will receive placebo once daily approximately at same time each day for 12 weeks.
32745792|NCT04807959||20Lighter Program Participants|All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.
32745793|NCT04807569|Experimental|Experimental group|"10 sessions of non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation."
32745794|NCT04807569|Experimental|Control group|one-month course of drug therapy with alpha-1-adrenoblocker according to the standard scheme
32745795|NCT04807491|Active Comparator|Kabat Technique's|Kabat exercises on Upper fulcrum, Intermediate fulcrum and lower fulcrum
32745796|NCT04807491|Experimental|Neuromuscular Re-Education:|For initiation, Facilitation, Movement control and movement control
32745797|NCT04807413|Experimental|Study Arm: The balloon will be opened to deliver nitric oxide at 40 ppm.|Nitric oxide balloon will be connected to the CPB machine. Participants randomized to this group will receive 40 ppm nitric oxide through the pump.
32745798|NCT04807413|Active Comparator|Control Arm: The balloon will be closed and no nitric oxide will be delivered.|Participants in this group will receive standard of care treatment. Participation in the trial will not affect surgery management in any way.
32745799|NCT05617053||DAART|Popliteal artery lesion treated by directional atherectomy with anti-restenotic therapy for the treatment of popliteal atherosclerotic lesions.
32745800|NCT05617053||ATP/Supera stenting|Angioplasty and Supera stent implantation for the treatment of popliteal atherosclerotic lesions.
32745801|NCT04356729|Experimental|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.~Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks~Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
32745802|NCT04825665|Experimental|Continuous force|A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar on one side
32745803|NCT04825665|Experimental|Intermittent force|A buccally directed tipping force of 150 g removed every 21 days for a 7-day rest period applied to the maxillary first premolar on one side
32745804|NCT05618535|Sham Comparator|Zero position|All monitoring was done from 9 to 11 a.m., and the whole monitoring process was carried out in a specific and quiet environment at 20-24℃ to avoid other auditory and visual stimuli. After 10min of the relaxed supine position, the blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured in the 0° position for 5min.
32745805|NCT05618535|Experimental|30 degrees position|Within 30 seconds after the 0° position measurement completion, the subjects were transferred to the 30° position and rested for 15 minutes under the 30° position. In other words, a washout period of 15 minutes was established between two measurements to ensure the stability of vital signs and avoid confounding effects. The blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured again for 5 minutes after the vital signs were stable.
33073233|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
33073234|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
32745806|NCT04825587|Experimental|Concomitant ACL and ALL reconstruction|The participant will undergo both the ACL and ALL reconstruction surgery.
32745807|NCT04825587|Experimental|ACL reconstruction alone|The participant will undergo only ACL reconstruction surgery.
32745808|NCT04427319|Experimental|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
32745809|NCT04427319|Placebo Comparator|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
32745810|NCT05616975||reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests
33073235|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
32745811|NCT05616975||validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests
32745812|NCT05616975||normative|Collection of normative SWAY Balance, Functional, and Cognitive data
32745813|NCT04807335|Experimental|Investigational medicinal product CT001|intranasal dosage of CT001
33246755|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
33246756|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
33246757|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
32765444|NCT04931147|Experimental|Part B MAD - Cohort 2|This is the second treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD and previous MAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
32765445|NCT04931147|Experimental|Part B MAD - Optional Cohort 3|This is an optional third treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
32765446|NCT04931147|Experimental|Part B MAD - Optional Cohort 4|This is an optional fourth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
32765447|NCT04985383|Experimental|AKST1210 b2M apheresis device|AKST1210 column will be connected in series for the duration of each hemodialysis session.
32765448|NCT03533257|Active Comparator|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
32765449|NCT03533257|Placebo Comparator|Placebo|Taste-matched Placebo
32765450|NCT04933409|Experimental|3D printed replica of Donor tooth|3D printed replica of Donor tooth
32765451|NCT04933409|Active Comparator|Conventional|Conventional method of autotransplantation.
32765452|NCT04574479|Placebo Comparator|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
32765453|NCT04574479|Experimental|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
32765454|NCT04933487|Experimental|Ankoris IOL Implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris
32765455|NCT03338257|Experimental|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
32765456|NCT03338257|No Intervention|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
32765457|NCT04933955|Active Comparator|biodentine|pulptomy with biodentine
32765458|NCT04933955|Active Comparator|Theracal PT|pulpotomy with Theracal PT
32765459|NCT04933955|Active Comparator|Neo Putty|pulpotomy with Neo putty
32765460|NCT02925013|Experimental|Study group|Pregnant women at delivery
32765461|NCT02925013|Other|Control group|Women in fertility age not pregnant
32765462|NCT04933175|Experimental|fluzopali combined with anlotinib|Patients 18 years of age or older, 75 years of age or younger with histologically proven small cell carcinoma of the lung were assessed by radiography as having an extensive stage (according to the American Veteran Lung Cancer Association). Patients received first-line two-drug chemotherapy with standard cisplatin, carboplatin, or lobaplatin, combined with or without immunotherapy, and developed radiologically evaluated disease progression during treatment or within 6 months of completion of treatment.
32765463|NCT02370901|Experimental|Helmet|Patients will be referred to a cranial orthotist who will create a custom cranial orthotic device. They will undergo adjustments monthly. At these appointments anthropometric measurements will be done by the cranial orthotist. The orthotist will be blinded and will not be informed of which patient is involved in the study.
32765464|NCT02370901|Experimental|home therapies|Patients will be referred to a physical therapist. They will be offered education, neck stretching exercises, and repositioning techniques, and reassurance.
32765465|NCT04431167|Experimental|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
32765466|NCT04431167|No Intervention|Usual Care Group|This group will receive all regular medical care and advice healthy
32765467|NCT04931225|Experimental|Landiolol injection|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
32765468|NCT04931225|No Intervention|Usual tachycardia management|No treatment, usual tachycardia management.
32765469|NCT04516057|Experimental|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
32765470|NCT04516057|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
32765471|NCT04921709||IBD Patients with Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
33246758|NCT00886756|Experimental|1|
32745814|NCT04807335|Active Comparator|Comparator 1|Ketamine 10mg iv
32745815|NCT04807335|Active Comparator|Comparator 2|Sufentanil 10mcg iv
33246759|NCT00886756|Placebo Comparator|2|
32745816|NCT05616507|Experimental|Arm A|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
32745817|NCT05616507|No Intervention|Arm B|observation
32745818|NCT04806945|Experimental|HLX10|HLX10 + chemotherapy
32745819|NCT04806945|Placebo Comparator|Placebo|Placebo + chemotherapy
32745820|NCT04806711|Experimental|Menicon Z Night|The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers
32745821|NCT04806711|Active Comparator|Control|The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers
32745822|NCT04806789||Children with suspected acute appendicitis|"Cohort: Children with suspected acute appendicitis. Clinical examination (including history of nausea, vomiting, temperature, information of rebound tenderness, right iliac fossa pain, duration of symptoms, gender and weight) and blood samples will be obtained at the emergency department (blood gas, C-reactive protein, neutrophiles and white blood cell count). Radiology (ultrasound and/or computed tomography) will be performed thereafter.~Outcome measures~Primary outcome measure: Plasma sodium. To investigate if plasma sodium is an independent predictor of perforation in children with acute appendicitis. In advance, five variables (Plasma sodium, C-reactive protein, symptom duration, age and temperature) will be included in the final multivariable analysis"
32745823|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
32745824|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
32745825|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
32745826|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
32745827|NCT04806633|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI
32745828|NCT04806633|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following cardiac catheterization and PCI
32745829|NCT04806399|No Intervention|Usual Care Control Group|
32745830|NCT04806399|Active Comparator|Outreach Contact with Decision Counseling Group|
32745831|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
32745832|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
32745833|NCT04353297|Experimental|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
32745834|NCT04353297|Active Comparator|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
32745835|NCT05616897|Other|Medicine students|students with normal expected fitness
32745836|NCT05616897|Other|Physical education students|students with better expected fitness
32745837|NCT04427475|Other|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
32745838|NCT04427475|Other|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
32745839|NCT04797975|Experimental|KDS-1000|NK cells expanded ex vivo using PM21 membrane particles:
32745840|NCT04797975|Placebo Comparator|Control|0.9% Normal Saline
32745841|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - telemedicine before face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone telemedicine consultation before face-to-face evaluation
32745842|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - only face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone only face-to-face evaluation
32745843|NCT05616819|Active Comparator|Treatment Order A|Blue light treatment for 2 weeks, a 4-week washout period, and 2 weeks of placebo (amber) light treatment.
32745844|NCT05616819|Placebo Comparator|Treatment Order B|Placebo light treatment for 2 weeks, a 4-week washout period, and 2 weeks of blue light treatment.
32745845|NCT04797819||Serum sST2 level < 14.5 ng/mL|
32745846|NCT04797819||14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL|
32745847|NCT04797819||20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL|
32745848|NCT04797819||Serum sST2 level ≥ 25.9 ng/mL|
32745849|NCT04806009|Experimental|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program. The MLWI Intervention was developed and presented by the Principle Investigator (PI) who is a psychiatrist and have completed the Training of Mindfulness Facilitation (TMF) program at the Mindful Awareness Research Center of University of California, Los Angeles.
32745850|NCT04806009|Active Comparator|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|Participants in the Control Group will receive CBT-I after follow the WeChat mini-program. The CBT-I was developed and presented by a researcher who is a psychiatrist/psychologist and have many years' experiences in CBT.
32745851|NCT04806243|Experimental|Carelizumab Combined With Regorafenib arm|
32915418|NCT05236790|No Intervention|Real time polyp detection using a standard colonoscopy without CAD eye|Real time polyp detection using a standard colonoscopy without CAD eye and without CADe. Patients will undergo a standard colonoscopy. Polyp size measurement will be assessed visually (phase 1 and 2) or with instruments such as snare or forceps (phase 3 or later) and polyp classification will be done by CADx without further input by the endoscopist. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
32915419|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
32915420|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
32915421|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
32915422|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
32915423|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
32915424|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
32915425|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
32915426|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
32915427|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
32915428|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
32915429|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
32915430|NCT05199194|Experimental|Mechanical Thrombectomy preceded by TNK|Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.
32915431|NCT05199194|Placebo Comparator|Mechanical Thrombectomy preceded by Placebo|Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.
32915432|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
32915433|NCT05014880|Placebo Comparator|ICR (Intensive Cardiac Rehabilitation)|"20 patients will be randomly assigned to the standard of care group, which will receive the standard health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR group."
32915434|NCT05014880|Experimental|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|"20 patients will be randomly assigned to the Time-Restricted Eating (TRE) group which will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR x TRE group."
32915435|NCT04978454|Experimental|Cohort 1A|10^4 TCID50of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 80% of subjects meet the case definition for influenza in Cohort 1A, the dose will escalate to include Cohort 2A. N = 13
32915436|NCT04978454|Experimental|Cohort 1B|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A and 1B meet the case definition for influenza, proceed to Cohort 1C. Cumulatively, if fewer than 80% of subjects in Cohorts 1A and 1B meet the case definition for influenza, the dose will escalate to include Cohort 2A. N = 13
32915437|NCT04978454|Experimental|Cohort 1C|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and sham sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more of the subjects in Cohorts 1A, 1B, and 1C combined meet the case definition for influenza then the optimal dose of 104 TCID50 will be selected. Cumulatively, if fewer than 80% of subjects in Cohorts 1A, 1B, and 1C meet the case definition for influenza the dose will escalate to include Cohort 2A. N = 13
32915438|NCT04978454|Experimental|Cohort 2A|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more subjects in Cohort 2A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 70% of subjects meet the case definition for influenza in Cohort 2A, the dose will escalate to include Cohort 3A. N = 13
32915439|NCT04978454|Experimental|Cohort 2B|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1.If 70% or more subjects in Cohort 2A and 2B meet the case definition for influenza, proceed to Cohort 2C. Cumulatively, if fewer than 70% of subjects in Cohorts 2A and 2B meet the case definition for influenza, the dose will escalate to include Cohort 3A N = 13
32915440|NCT04978454|Experimental|Cohort 2C|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more of the subjects in Cohorts 2A, 2B, and 2C combined meet the case definition for influenza then the optimal dose of 10^4 TCID50 will be selected. Cumulatively, if fewer than 70% of subjects in Cohorts 2A, 2B, and 2C meet the case definition for influenza the dose will escalate to include Cohort 3A. N = 13
33246760|NCT00402337|Active Comparator|72 ug linaclotide acetate|
33246761|NCT00402337|Active Comparator|145 ug linaclotide acetate|
33246762|NCT00402337|Active Comparator|290 ug linaclotide acetate|
33246763|NCT00402337|Active Comparator|579 ug linaclotide acetate|
32915441|NCT04978454|Experimental|Cohort 3A|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If no safety threshold is met (halting conditions) proceed to Cohort 3B. N = 18
32915442|NCT04978454|Experimental|Cohort 3B|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. N = 18
32915443|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
32915444|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
32915445|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
32915446|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
32915447|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
32915448|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
32915449|NCT00374361||African-American Adolescents|African-American Adolescents
32915450|NCT05735951|Experimental|Mild renally impaired patients|Mild renally impaired patients
32915451|NCT05735951|Experimental|Moderate renally impaired patients|Moderate renally impaired patients
32915452|NCT05735951|Experimental|Severe renally impaired patients|Severe renally impaired patients
32915453|NCT05735951|Experimental|Matching controls|Matching volunteer without renal impairement
32915454|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
32915455|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
32915456|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
33082156|NCT04623385|Active Comparator|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
33246764|NCT00402337|Placebo Comparator|Matching Placebo|
33246765|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
33246766|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
32715341|NCT05298410|Experimental|Limitless|Participants will be instructed to take Limitless capsules for 30 days starting with the first dose to be administered in clinic on Visit 2 (Day 1, Baseline). The last dose will occur in clinic on Visit 3 (Day 30). Participants will be instructed to take two capsules two hours with water after breakfast, and two capsules two hours after dinner. Do not take food after evening dose before bed. (i.e. no snacking or desserts.). If a dose is missed participants are instructed to skip that dose. Participants will be advised not to exceed four capsules daily.
33246767|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
32715342|NCT05329142||Stage 1: Usual Care clinical data:|The patient will firstly be identified as having attended the ED due to acute illicit drug toxicity and must fit the inclusion and exclusion criteria. The research team will complete the electronic Case Report Form (eCRF), which will include defined data.
32715343|NCT05329142||Stage 2: Surplus sampling Mass Spectrometry|"The research team will select patients with acute moderate / severe toxicity, which will be defined as those requiring at least one of:~Patient admitted to hospital due to acute illicit drug toxicity~Pre-hospital cardio/pulmonary resuscitation~Any part of patient's ED care was in the Resuscitation area of the ED~Patient died in the ED or within 72 hours~A surplus sample of the standard of care SST sample from this group will be analysed by way of Mass Spectrometry."
32715344|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
32915457|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of gelofusine without a cooling vest."
32915458|NCT01935791|Experimental|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min without a cooling vest.
32915459|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~No brown adipose tissue (BAT) identified on visit 1, therefore no visit 2."
33082157|NCT04623385|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
33082158|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
33246768|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
33246769|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
32765472|NCT04921709||IBD Patients without Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
32765473|NCT04930835|Active Comparator|Conventional Loading|implants are loaded at least after two months of healing
32765474|NCT04930835|Experimental|Immediate Loading|implants are loaded the same day of surgery
32765475|NCT04976725|Experimental|Ostepathic manipulative treatment|The effects of osteopathy treatment method on the migraine
32765476|NCT04976725|Experimental|Myofascial relaxation Treatment|The effects of myofascial treatment method on the migraine
32765477|NCT04976725|Experimental|Control treatment|Control group will have just medication treatment
32765478|NCT02195947|Experimental|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
32765479|NCT02195947|No Intervention|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
32765480|NCT02109367||Pelvic mass|Women who present to the Gynecologic Oncology clinic with a pelvic mass who are scheduled to undergo surgical excision.
32765481|NCT04913207|Sham Comparator|Traditional echo-fluoroscopy guided group|LAA angiography is performed with a 6F pigtail catheter in LAA at the view of RAO 30°, CAU 20° and RAO 30°, CRA 20°. Next, the outline of the LAA will be drawn on the screen according to the LAA angiography. LAmbre device size selection is based on diameters of LAA ostium and landing zone measured on LAA angiography. The process of device implantation, assessment, releasing will be carried out at RAO 30°, CAU 20°. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
32765482|NCT04913207|Experimental|3D-CTA guided group|Patients in 3D-CTA based perimeter group will undergo CCTA examination before LAAO and a 3D model of the left atrium is reconstructed by a workstation. LAmbre device size selection is based on perimeters of LAA ostium and landing zone which are obtained by the measurement method shown previously in this protocol. After transseptal puncture, LAA angiography is performed with a 6F pigtail catheter in LAA at the tangent angle view which is obtained preoperatively by 3D-CCTA. Then, the outline of the LAA will be drawn on the screen according to the LAA angiography. The process of device implantation, assessment, releasing will be carried out at this tangent angle view. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
32765483|NCT01698307|Active Comparator|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
32765484|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI).
32765485|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
32765486|NCT04111757|Experimental|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
32765487|NCT05119153|Placebo Comparator|Placebo Comparator|Placebo composed of water and caramel color.
32765488|NCT05119153|Experimental|Light Roasted Coffee|12 oz light roast coffee beverage prepared at 55 g ground coffee/L water
32765489|NCT05119153|Experimental|Medium Roasted Coffee|12 oz medium roast coffee beverage prepared at 55 g ground coffee/L water
32765490|NCT05119153|Experimental|Dark Roasted Coffee|12 oz dark roast coffee beverage prepared at 55 g ground coffee/L water
32765491|NCT04930757||Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.|Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.
32765492|NCT04955587||Patients with longstanding complicated fatigue|The participants receive no intervention as part of this study.
32765493|NCT04955587||Healthy controls|The participants receive no intervention as part of this study.
32765494|NCT04955587||Controls with rheumatic disease|The participants receive no intervention as part of this study.
32765495|NCT04520113|Active Comparator|Standard Tracing|"Households of tuberculosis index patients receive standard household contact tracing during regular weekday business hours."
32765496|NCT04520113|Experimental|Holiday Tracing|Households of tuberculosis index patients in rural South Africa receive household contact tracing during holidays (Christmas and Easter).
32765497|NCT04520113|Experimental|Evening / Weekend Tracing|Households of tuberculosis index patients in urban South Africa receive household contact tracing during evenings and weekends.
32765498|NCT04954339|Experimental|Atezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
32765499|NCT04930523|Active Comparator|Decompression|It include the pre- Physiotherapy treatment than decompression and post physiotherapy treatment.
32765500|NCT04930523|Experimental|Experimental|It includes the Pre physiotherapy treatment than ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precaution and Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) then Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes and at last Post physiotherapy treatment
32715345|NCT05297786|Experimental|Lanadelumab|Subjects will receive lanadelumab (300 mg) subcutaneously at the beginning of the study and 14 days later
32715346|NCT05297786|Placebo Comparator|Placebo|Subjects will receive placebo subcutaneously at the beginning of the study and 14 days later
32915460|NCT01935791|Experimental|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius. Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
32715347|NCT05609396|No Intervention|Usual care|Standard reminder letter only
32715348|NCT05609396|Experimental|Enhanced reminder letter only|Behaviorally enhanced reminder letter
32715349|NCT05609396|Experimental|Usual care plus test kit|Standard reminder letter plus test kit
32715350|NCT05609396|Experimental|Enhanced reminder plus test kit|Behaviorally enhanced reminder letter plus test kit
32715351|NCT05297630||Jet Echo group|Biological markers from heart failure patients who underwent therapeutic adjustment according to a daily ultrasound scan
32715352|NCT05297630||Conventional management group|Biological markers from heart failure patients who had conventional management.
33246770|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
32915461|NCT01935791|Experimental|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius."
32915462|NCT01935791|Experimental|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius."
32915463|NCT01935791|Experimental|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius."
33246771|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
32915464|NCT01935791|Experimental|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
32915465|NCT01935791|Experimental|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|"Visit 1 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius"
33246772|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
33246773|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
32715353|NCT05327504|Experimental|Written Exposure Therapy|Written Exposure Therapy (WET) plus Treatment As Usual (TAU). WET is a 5 session, evidence-based trauma-focused written narrative exposure treatment. At each session, patients are instructed to write about the same trauma event and therapists provide feedback about adherence and offer suggestions. The first session includes psychoeducation about PTSD and a treatment rationale prior to general trauma narrative writing instructions, and specific instructions for completing the first writing session, before completing the first writing (30 minutes) session. Participants are instructed to write about the same trauma event at each following session, with an emphasis on delving into their deepest emotions and thoughts, in as much detail as possible, about the event. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
32715354|NCT05327504|Active Comparator|Neutral Topic Writing|Treatment As Usual (TAU) augmented by a neutral topic writing condition. The neutral topic writing condition involves writing about an assigned topic during each of the five writing sessions. As opposed to writing about trauma, the specific focus of this condition is on writing for 30 minutes about topics related to their life without writing about emotions or opinions. Rather, they are asked to write about specific objects or events in detail, as accurately as possible, and with as much description as possible. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
32745852|NCT04805931|No Intervention|Control|Will receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
33082159|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
32715356|NCT05327426|Experimental|fIPV-dmLT|Intradermal administration of fIPV with the addition of 0.47ug dmLT
32715357|NCT05327426|Active Comparator|fIPV|Intradermal administration of fIPV alone.
32715358|NCT05327270|Experimental|Nivolumab|Nivolumab will be given as an injection directly into an oral lesion.
32715359|NCT05526092|Experimental|Oat-rich and low-gluten diet|Participants will consume oats and oat products and follow low-gluten diet for 6 weeks.
32715360|NCT05526092|Placebo Comparator|Rice-rich and low-gluten diet|Participants will consume rice and rice products and follow low-gluten diet for 6 weeks.
32715361|NCT05297396|Experimental|Slow Tapering of Chronic Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will have their opioid medication doses slowly and gradually reduced every 4 weeks.
32715362|NCT05297396|No Intervention|Continued Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will stay on the same dose of opioids they are currently using at the beginning of the study for the entire 12-month duration of the study.
32715363|NCT05598398|Active Comparator|Control (Wet-to-dry dressings)|Subjects randomized to the control group with receive standard of care (wet-to-dry dressings) for treatment of their pressure sore.
32715364|NCT05598398|Experimental|Treatment (NPWT with Instillation)|Subjects who are randomized into the treatment arm (NPWT with Instillation) will receive the V.A.C. VeraFlo™ Cleanse Choice Dressing Systems for treatment of their pressure sore.
32715365|NCT05296382|Experimental|Crushed Tebipenem Tablet with Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through. Subjects will also receive concurrent enteral tube feeds (feeds run for 2h before dose and 4h post-dose).
32715366|NCT05296382|Experimental|Whole Tebipenem Tablet|Tebipenem tablet will be swallowed whole without crushing.
32715367|NCT05296382|Experimental|Crushed Tebipenem Tablet without Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through.
32715368|NCT05296304|Experimental|Bexarotene Combined With Radiotherapy|Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
32715369|NCT05525780|Experimental|GB-5001|GB-5001 Suspension for intramuscular (IM) injection at three doses
32715370|NCT05525780|Placebo Comparator|Placebo|Placebo Suspension for intramuscular (IM) injection, Volume to be matched with the active drug in the respective cohort
32715371|NCT05525780|Active Comparator|Oral cohort|Aricept® tablet
32715372|NCT05326256|Experimental|PSSE Group|Physiotherapy Scoliosis Specific Exercises (PSSE), 45-minute exercise session with the supervisor, twice a week for 12 weeks
33082160|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
32715373|NCT05326256|Experimental|Vestibular Exercise Group|Vestibular exercises to be added to PSSE exercises, 45-minute exercise session with the supervisor, twice a week for 12 weeks
32715374|NCT05269082||Cohort 1|Pediatric and adult participants who are on Gammagard S/D prescribed for any approved indication will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
32715375|NCT05269082||Cohort 2|Pediatric and adult participants who were previously treated with Gammagard S/D prescribed for any approved indication and are on another human immunoglobulin treatment will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
32715376|NCT05269082||Cohort 3|Pediatric and adult primary immunodeficiency (PID) participants with immunoglobin A (IgA) deficiency who have a serum IgA level of less than (<) 7 milligrams per deciliter (mg/dL) (0.07 grams/liter [g/L]) or below the detectable limit and have received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D) will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
32715377|NCT05324696|Placebo Comparator|Treatment with placebo device|Device similar to the one developed, but which does not generate pressure
32715378|NCT05324696|Experimental|Treatment with a working device|Treatment with a functioning device, which generates the necessary pressure to open the Eustachian tube
32715379|NCT05324696|Active Comparator|Surgical treatment|Surgical treatment (myringotomy with placement of ventilation tubes) which is the treatment currently applied in children with otitis media with effusion that do not resolve with medical treatment and/or autoinflation
32715380|NCT05497856|Experimental|Integrated neuromuscular inhibition technique|ischemic compression, strain counter strain, muscle energy techniques
32715381|NCT05497856|Active Comparator|Myofascial Release|Deep sustained pressure on the trigger points
32715382|NCT01658150|Experimental|isradipine|open label
32715383|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
32715384|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
33082161|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
32915466|NCT01936259|Active Comparator|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
32915467|NCT01936259|Experimental|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
32915468|NCT05735873|Experimental|Low-energy diet arm|Subjects who receive low-energy premade meals for three meals each day for 12 weeks.
32915469|NCT05735795|Other|Carbon Black Tattoo arm|In patients with breast cancer diagnosed with positive axillary lymph node involvement by fine needle aspiration cytology, 0.1-0.5 ml Carbon Black Tattoo dye will be applied simultaneously to the lymph node capsule and surrounding tissue, while clips are placed on the axilla before starting neoadjuvant chemotherapy. After the neoadjuvant treatment is completed, the patient who is taken into surgery will be injected with periareolar blue dye as in the standard practice, and blue stained node, clipped node and carbon stained node will be searched as sentinal lymph node. The removed lymph nodes will be evaluated histopathologically in terms of metastasis with a frozen study during the operation, and if metastasis is detected, axillary lymph node dissection will be performed
32915470|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
32915471|NCT03068949|Active Comparator|FluBlok|FluBlok 0.5 mL given IM X1
32915472|NCT03068949|Active Comparator|Fluzone|Fluzone 0.5 mL given IM X1
32915473|NCT03068949|Active Comparator|FluCelVax|FluCelVax 0.5 mL given IM X 1
32915474|NCT03068949|Active Comparator|Fluzone HD|Fluzone HD 0.5 mL given IM X1
32915475|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
32915476|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
32915477|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
32915478|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
32915479|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
32915480|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
32915481|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
32915482|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
32915483|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
32915484|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
32915485|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
32915486|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
33246774|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
33246775|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
33246776|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
33246777|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
33246778|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
33246779|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
33246780|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
33246781|NCT00887302||1|Gastric Band
32715385|NCT05295524|Experimental|Patients with Cystic Fibrosis, with KAFTRIO® treatment prescription|Patients with Cystic Fibrosis, for whom treatment with KAFTRIO® is prescribed, regardless of previously prescribed CFTR modulator treatments.
32745853|NCT04805931|Experimental|Scarcity|Will receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
32915487|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
33246782|NCT00887302||2|Gastric Sleeve
33246783|NCT00887302||3|Gastric Bypass with PEG tube
32715386|NCT05295368|Experimental|multicomponent intervention|1) 1. Training Nurses/service coordinators as Health Coaches and Hybrid Follow-up Approach of in-person, Telephone and Secure Video Sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
32715387|NCT05295368|No Intervention|Usual care|treated by physicians and nurses who are not trained in SKOPE treatment algorithms.
32715388|NCT05294510|No Intervention|Control|Children who present to a village health worker during a control period are evaluated and managed using the current standard of care per Uganda National Guidelines for Integrated Community Case Management (ICCM). Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
32715389|NCT05294510|Experimental|Intervention|Children who present to a village health worker during an intervention period are evaluated and managed using a modified ICCM algorithm that includes point-of-care C-reactive protein testing. Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
32715390|NCT05323916|Active Comparator|"Neuroproprioceptive facilitation, inhibition"|"According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, participants undergoes one hour a day of individual physiotherapy on a neurophysiological basis - neuroproprioceptive facilitation, inhibition, which, by combining appropriate stimuli in a suitable time sequence, maintains optimal motor pathway function and optimal irritability of control or regulation structures."
32715391|NCT05323916|Active Comparator|Technology based physical therapy|According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, they will undergo physiotherapy for an hour a day using the implementation of modern technologies based on the principles of sensorimotor learning, i.e. repeating specific and targeted functions in different environments / conditions in order to strengthen the memory footprint and initiate structural changes in the central nervous system. According to the indication, participants will be offered one of the robotic systems using an exoskeleton (Gloreha, Erigo and Meditutor, Lokomat and Ekso) or a therapy using virtual environment.
32715392|NCT05323916|Experimental|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|The concept of therapy implementing the ICF model is based on a comprehensive, so-called biopsychosocial approach to the patient and his/her disease (four hours). The key is to set individual goals of the therapy together with the rehabilitator and with the use of so-called ICF core sets, which individually take into account the given situation of the rehabilitated person. This approach includes interdisciplinary diagnosis of the current condition, i.e. not only based on the diagnosis, but also on the functional status and activities performed, it also takes into account the socio-psychological background of the patient.
32715393|NCT05323916|Placebo Comparator|Control group|Participants will undergo standard care.
32715399|NCT01658072|Experimental|Peri-Articular Injection|
32715400|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
33246784|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
32715401|NCT05293184||Individuals with Angelman Syndrome|Individuals from birth to adulthood with Angelman Syndrome
32715402|NCT05293106|Active Comparator|Pathogen-reduced (PR) platelet transfusions|FDA approved and already used in this patient population
32715403|NCT05293106|Active Comparator|Large volume delayed sampling - LVDS|FDA approved and already used in this patient population
32715404|NCT05322668|Experimental|Condition 1|"All the subjects will receive all the treatment in the same order.~The following prototypes will be applied on hands areas:~Application of the prototype (812A-v1) at Day 0, Application of the prototype (812C-v1) at Day 0, Application of the prototype (812D-v1) at Day 0, Application of the prototype (812F-v1) at Day 0,"
32715407|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
32715408|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
32715409|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
32715410|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
32715411|NCT05519540|Experimental|Group 1: Japanese: Xevinapant (Debio 1143)|
32715412|NCT05519540|Experimental|Group 2: Non-Japanese East Asian: Xevinapant (Debio 1143)|
32715413|NCT05292872||OCA Treatment Group|PBC patients with a history of inadequate response or intolerance to UDCA who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
33246785|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
33246786|NCT04037098|Experimental|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
32915488|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
32915489|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
32915490|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
32915491|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
32915492|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
32915493|NCT04967066||children with febrile convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Seizures.~Fever (≥38°C).~Exclusion criteria~Central nervous system infection.~Epilepsy.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
32915494|NCT04967066||Febrile children without convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Fever (≥38°C) due to acute infection.~Exclusion criteria~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
32915495|NCT04967066||Healthy control children|"Inclusion criteria~Age from 6 months to 6 years.~Presented for routine check-up.~Exclusion criteria~Fever.~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea).~Any illness in the last month."
32915496|NCT04959344|Experimental|Kleb4V target dose|Study participants receive 2 target doses of the non-adjuvanted investigational product 2 months apart.
32915497|NCT04959344|Experimental|Kleb4V target dose + AS03|Study participants receive 2 target doses of the adjuvanted investigational product 2 months apart.
32915498|NCT04959344|Experimental|Kleb4V low dose|Study participants receive 2 low doses of the non-adjuvanted investigational product 2 months apart.
32915499|NCT04959344|Experimental|Kleb4V low dose + AS03|Study participants receive 2 low doses of the adjuvanted investigational product 2 months apart.
32915500|NCT04959344|Placebo Comparator|Placebo (Diluent)|Study participants receive 2 doses of the Placebo 2 months apart.
32915501|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
32915502|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
32915503|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
32915504|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
32915505|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
32915506|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
32915507|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
32915508|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
33246787|NCT04037098|Placebo Comparator|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
33246788|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
33246789|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
32915509|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
32915510|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
32915511|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
32915512|NCT01694186|Sham Comparator|sham injection|sham injection
32915513|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
32915514|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
32915515|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
32915516|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
32915517|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
32915518|NCT05735717|Experimental|Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
32915519|NCT05735717|Experimental|Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
32915520|NCT05735717|Experimental|Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients Only|Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.
32915521|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
32915522|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
32915523|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
32915524|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
32915525|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
32915526|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
32915527|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
32915528|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
32915529|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
32915530|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
32915531|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
32915532|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
32915533|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
32915534|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
32915535|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
32915536|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
32915537|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
32915538|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
32915539|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
32915540|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
32915541|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
32915542|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
32915543|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
33246790|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
32915544|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
32915545|NCT00374985|Experimental|one arm|
32915546|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
32915547|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
32915548|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
32915549|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
32915550|NCT01695668|Active Comparator|Restasis|Cyclosporine
32915551|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
32915552|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
32915553|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
32915554|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
32915555|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
32915556|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
32915557|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
33246791|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
33246792|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
33246793|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
33246794|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
33246795|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
33246796|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
33246797|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
33246798|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
33246799|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
33246800|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
33246801|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
33246802|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
32715414|NCT05292872||Control Group|PBC patients with a history of inadequate response or intolerance to UDCA who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
32745854|NCT04805931|Experimental|Social good|Will receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
32915558|NCT03256760|Placebo Comparator|Placebo|Placebo
32915559|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
32915560|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
32915561|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
32915562|NCT04333329|Experimental|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
33082162|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
32715416|NCT04422548|Active Comparator|AI-assisted Group|
32915563|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
32915564|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
32915565|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
32915566|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
32915567|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
32915568|NCT05735561||Proximal Humerus Fracture Anterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is anterior to the glenoid.
32915569|NCT05735561||Proximal Humerus Fracture Posterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is posterior to the glenoid.
32915570|NCT05735561||Proximal Humerus Fracture Varus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in varus compared to the glenoid.
32915571|NCT05735561||Proximal Humerus Fracture Valgus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in valgus compared to the gelnoid.
32915572|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
32915573|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
32915574|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
32915575|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
32915576|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
32915577|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
32915578|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
32915579|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
32715417|NCT04422548|Active Comparator|Standard|
32715418|NCT05265728|Experimental|Natalizumab 300 mg|Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.
32715419|NCT05322044|No Intervention|Control (no financial incentive)|No incentive. Usual care (plus EMD with reminders) for 12-weeks.
32715420|NCT05322044|Experimental|Intervention (financial incentive)|Financial incentive dependent upon daily medication adherence (plus EMD with reminders) for 12-weeks.
32715421|NCT05321888|Active Comparator|Mechanical Ventilation|Mechanical Ventilation
32715422|NCT05321888|Experimental|Mechanical Ventilation with Postural drainage|Mechanical Ventilation with Postural drainage
32715423|NCT02035137|Active Comparator|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
32915580|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
32915581|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
32915582|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
32915583|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
32915584|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
32915585|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
32915586|NCT03137108|Experimental|Incomplete Spinal cord injury|
32915587|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
32915588|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
32915589|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
33246803|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
32715424|NCT02035137|Active Comparator|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
32715425|NCT02035137|Active Comparator|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
32915590|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
32915591|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
32915592|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
32915593|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
32915594|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
32915595|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
33246804|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
33246805|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
32915596|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
32915597|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).~Self-weighing (weekly).~Self-checking of blood pressure (weekly).~Checking fetal heart rate (weekly).~Visits with caregivers."
32915598|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
32915599|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
32915600|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
32915601|NCT01939301|Placebo Comparator|Placebo|Oxygen
33246806|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
32915603|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
32915604|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
32715426|NCT05321810||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
32715427|NCT05321810||Apixaban cohort|Patients with NVAF treated with apixaban
32915605|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
32915606|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
32915607|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
32915608|NCT05735405|Experimental|Experimental Group|The experimental group will first perform 30 minutes of pedaling as a moderate intensity aerobic activity. Subsequently it will carry out a daily cognitive training of 60 minutes to improve attentional, working memory and executive functions.
33246807|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
32715428|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
32915609|NCT05735405|Experimental|Control Group|The control group will first carry out a daily 60-minute cognitive training to improve attentional, working memory and executive functions. It will then perform 30 minutes of pedaling as a moderate intensity aerobic activity.
32915610|NCT05735249|Experimental|ARN-75039|Escalating single or multiple doses of ARN-75039 oral capsules
32915611|NCT05735249|Placebo Comparator|Placebo|Matching placebo capsules in a same SAD and MAD dosing regimen as ARN-75039
32915612|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
32915613|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
32915614|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
32915615|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
32915616|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
32915617|NCT01631552|Experimental|Sacituzumab Govitecan-hziy (SG) 8 mg/kg|Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
32915618|NCT01631552|Experimental|SG 10 mg/kg|Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
33246808|NCT01038115|Active Comparator|Cryoballoon|
33246809|NCT01038115|Active Comparator|Radiofrequency|
32915619|NCT01631552|Experimental|SG 12 mg/kg|Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
32915620|NCT01631552|Experimental|SG 18 mg/kg|Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
32915621|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
32915622|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
32915623|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
32915624|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
32915625|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
32915626|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
32915627|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
32915628|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
32915629|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
32915630|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
32915631|NCT02343120|Experimental|Zanubrutinib|Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up
32915632|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
32915633|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
32915634|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
32915635|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
32715429|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
32915636|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
32915637|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
32915638|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
33246810|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
32715430|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
32715431|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
32915639|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
33246811|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
32915640|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
32915641|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
32915642|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
32915643|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
32915644|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
32915645|NCT04333251|Experimental|convalescent plasma|This arm will receive convalescent plasma
32915646|NCT04333251|Placebo Comparator|best supportive care|Oxygen therapy
32915647|NCT03837860|Active Comparator|Oxycodone/Placebo|Each study participant will receive all three study interventions in random order.In this arm, the participant receives oxycodone or placebo
32915648|NCT03837860|Active Comparator|Oxycodone/Risperidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or risperidone
33246812|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
33246813|NCT04401982||Glaucoma Suspect|Individuals with a diagnosis of glaucoma suspect
33246814|NCT01038271|Active Comparator|Standard Palliative Care Group|
33246815|NCT01038271|Active Comparator|Integrated Palliative Care Group|
33246816|NCT00889876|Experimental|Metformin|
33246817|NCT00889876|Experimental|Exercise|
32915649|NCT03837860|Active Comparator|Oxycodone/Ziprasidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or ziprasidone
32915650|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
32915651|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
32915652|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
32915653|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
32915654|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
32915655|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
32915656|NCT05734937|Experimental|gastric assessment of gastric volume|ultrasound assessment of gastric volume in Preoperative and postoperative period in right lateral decubitus position in pediatric patients
32915657|NCT05734859|Experimental|EHARW Treatment group|The experimental group will drink a total amount of 20 mL/ kg body weight/day of EHARW for 4 weeks on an empty stomach according to the researcher's instruction.
32915658|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
32715432|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
32715433|NCT05321498|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
32715434|NCT05321498|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.
32915659|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
33246818|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10^4 cells/m^2~Dose Level 2: 3 x 10^4 cells/m^2~Dose Level 5: 1 x 10^6 cells/m^2~Dose Level 6: 3 x 10^6 cells/m^2~Dose Level 7: 1 x 10^7 cells/m^2~Dose Level 8: 3 x 10^7 cells/m^2~Dose Level 9:1 x 10^8 cells/m^2"
32715435|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
32715436|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
32715437|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
32915660|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
32915661|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
32915662|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
32915663|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
32915664|NCT04768205|Active Comparator|Study group|The therapy and Kinesio tex gold tape that was affixed to stretched and neck localised were applied
32915665|NCT04768205|Placebo Comparator|Sham control group|The therapy and Kinesio tex gold tape that was affixed to different neck localised as no-stretched were applied
32915666|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32915667|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
32915668|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
32915669|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
32915670|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
32915671|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
32915672|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
32915673|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
33246819|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
33246820|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
33246821|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
33246822|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
33246823|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
32915674|NCT05734703|Experimental|Standard Topical Daily Dose|Only one arm in the study. Subjects treated with the topical daily for 90 days. The comparison will be 'before' and 'after' treatment skin biopsy results.
32915675|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
32915676|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
32915677|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
32915678|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
32915679|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
32915680|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
32915681|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
32915682|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
32915683|NCT05491655|Experimental|High intensity His bundle pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 3.5V/1msec.~After one month these patients will continue to receive active pacing treatment with 3.5V/1msec."
32915684|NCT05491655|Sham Comparator|Back up only pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 2V/1msec.~After one month these patients will receive back up only pacing (pacemaker programmed to VVI 30 bpm) for 6 months."
32915685|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
32915686|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
33082163|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
33246824|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
33246825|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
32715438|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
32915687|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
33246826|NCT01038583||Aspirin|100 mg enteric-coated aspirin
33246827|NCT01038583||Placebo|Placebo
33246828|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
33246829|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
32915688|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
32915689|NCT05489471||Adult Chest Radiographs|All chest X-rays for patients over 16 years from either a GP referral or performed in the Emergency department (ED) of the acute hospital, which includes Accident and Emergency attendances and in-patient studies.
32915690|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
32915691|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
32915692|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
33082164|NCT04623034|Experimental|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
33082165|NCT04623034|Experimental|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
33082166|NCT04623034|Experimental|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
32915693|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
32715439|NCT05292248|Experimental|CONFIDENCE Education Intervention|Participants will attend the 5-week CONFIDENCEProgram. This program will include attending 5 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, balancing employment and caregiving, and more.
32715440|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
32715441|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
32715442|NCT05291624||Patients with preoperative suspicion of endometriosis|Consecutive patients undergoing ultrasonographic preoperative assessment and subsequent surgical approach for deep endometriosis
32715443|NCT03757299|Experimental|Self HPV|
32715444|NCT05264870|Active Comparator|Group A|combined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil
32715445|NCT05264870|Active Comparator|Group B|combined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil
32715446|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
32715447|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
32715448|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
32915694|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
32915695|NCT05482451|Experimental|Nivolumab + all-trans retinoic acid|"Nivolumab: 3mg/kg intravenously on day 1.~All-trans retinoic acid (Vesanoid) 45 mg/m2 on days 1-14. The dose of Vesanoid can be increased with addition of 15 mg/m2 in next course of treatment if there is no severe adverse effects. Therefore, the dose of Vesanoid could be 60 mg/m2 from the second course, 75 mg/m2 from the third course, till the maximal dose of 150 mg/m2 if patients tolerated the treatment. The decision of dose escalation is left to in-charge physician.~The treatment cycle will repeat every 2 weeks."
32915696|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
32915697|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
32915698|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
32915699|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
32915700|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
32915701|NCT05463263|Experimental|Phase 1 (Part 1, Dose Escalation)|Up to 5 dose levels with STP938 administered as oral monotherapy
32915702|NCT05463263|Experimental|Phase 2 (Part 2; expansion)|At defined dose level(s) with STP938 administered as oral monotherapy
32915703|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
32915704|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
32715449|NCT05264714|Experimental|Cluster Headache Subjects|Subjects with cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.
32715450|NCT04249232|Active Comparator|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
32915705|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
32915706|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
33082167|NCT04623034|Experimental|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
33082168|NCT04623034|Experimental|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
32915707|NCT01951391|Other|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
32915708|NCT01951391|Other|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
32915709|NCT01953575|Experimental|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
32915710|NCT01953575|Experimental|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
32915711|NCT01953575|Placebo Comparator|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
32915712|NCT05734469|Other|Popliteal sciatic nerve block|A local anesthetic solution of 30ml of ROPIVACAINE 0,5% (4mg/kg maximum) will be used for the popliteal sciatic nerve block (popliteal sciatic, saphenous) by real-time ultrasound guidance (associated with a standardized general anesthesia)
32915713|NCT05734469|Other|Ankle block|A maximum solution of 15ml of ROPIVACAINE 0. 5%( 4mg/kg maximum) for the ankle block (saphenous, superficial peroneal, deep peroneal and tibial nerves) by real-time ultrasound guidance (associated with a standardized general anesthesia)
32915714|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
32915715|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
32915716|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
32915717|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
32915718|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
32915719|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
32915720|NCT04350281|Active Comparator|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
32915721|NCT04350281|Active Comparator|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
32915722|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
32915723|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
32915724|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
32915725|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
32915726|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
32915727|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
32915728|NCT04891692|Experimental|Phasic Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
32915729|NCT04891692|Experimental|Combined Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's combined (tonic and phasic) setting. Treatment at 3 kHz, modulation 4 Hz and 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
33082169|NCT04623034|Experimental|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
33082170|NCT04622800|Other|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
33082171|NCT04622878|Other|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
33082172|NCT04622722|Active Comparator|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
32715451|NCT04249232|Placebo Comparator|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
32715452|NCT05079087|Experimental|PENG BLOCK arm|The first arm will consist of patients that undergo PENG block administering a mixture of Ropivacaine 0.5% + Dexamethasone 4 mg in a volume of 20 ml before performing the spinal anaesthesia.
32915730|NCT05732987||Biobank- samples from NMID patients|600 samples from NMID patients from the Biobank Dermatology Unispital Basel (USB) (Biobank USB) and from the biobank of the Dermatology Department of the University Hospital Zürich (USZ) (Biobank USZ) will be included.
32915731|NCT05732987||Formalin-fixed and paraffin-embedded (FFPE) samples|About 50 of formalin-fixed and paraffin-embedded (FFPE) samples from the Dermatology USB collected before 2014 for RNA and protein expression analyses will be reused. The patients in questions are informed about the study and the coded use of their samples.
32915732|NCT05732987||Biobank- samples from controls|2'700 anonymized control genomes as well as 150 anonymized control samples for the proteomics approach can be used as control samples from the biobank of the Dermatology Department of the University Hospital Zürich (Biobank Dermatology USZ).
32915733|NCT05732987||Fresh skin samples from healthy donors|A maximum of 20 fresh skin samples from healthy donors are required per skin location. They will be requested from healthy volunteers after information about the study and receiving the informed consent.
32915734|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
32915735|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
32915736|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
32915737|NCT03097653|Experimental|Decision-aid|
32915738|NCT03097653|Active Comparator|Standard information|
32915739|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
32915740|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
32915741|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
32915742|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
32915743|NCT02128958|Experimental|CF102|orally q12h
32915744|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
32915745|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
32915746|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
32915747|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
32915748|NCT04903470|Experimental|Effect of atropine on the defecation|Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine.
32915749|NCT04903470|Experimental|Effect of bisacodyl on the defecation|Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl.
32915750|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
32915751|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
32915752|NCT04903002|Other|Crossover sequence 1: Oxytocin first|Patients receive 2-weeks courses of 24-IU oxytocin, placebo, 48-IU oxytocin.
32915753|NCT04903002|Other|Crossover sequence 2: placebo first|Patients receive 2-weeks courses of placebo, 24-IU oxytocin, 48-IU oxytocin.
32915754|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
32915755|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
32915756|NCT04902846||Control (no kidney injury)|Patients who receive ICI but no develop kidney injury
32915757|NCT04902846||Case (kidney injury)|Patients who receive ICI and develop kidney injury
32915758|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
32915759|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
32915760|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
32915761|NCT01633892|Experimental|Fat Grafting|
32915762|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
32915763|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
32915764|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
32915765|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
32915766|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
32915767|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~Week 1: walk at least 3,000 steps every day.~Week 2: walk at least 3,500 steps every day.~Week 3: walk at least 4,000 steps every day.~Week 4: walk at least 4,500 steps every day.~Weeks 5-12: walk at least 5,000 steps every day."
32915768|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~Walk on a flat surface at a constant speed until there is mild to moderate pain~Rest until the pain has completely ceased~Resume walking at the same speed~Increase the speed when you can walk 8 minutes without stopping for leg symptoms~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
32915769|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
32915770|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
32915771|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
32915772|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
32915773|NCT04891380|Other|Cardiac arrest patients|Cardiac arrest patients receiving cardiopulmonary resuscitation with LUCAS 2 Active Decompression 2.
32915774|NCT04891380|Other|Hypotension|Patients developed or may develope hypotension of non traumatic origin.
32915775|NCT04891380|Other|Intensive care patient transport|Patients who are transported from one intensive department to another.
32915776|NCT04891380|Other|LUCAS 2 Active Decompression|The hemodynamic measurements of the cardiac arrest patients in the present study will be compared with the hemodynamic measurements achieved in the previous study NCT02479152.
32915777|NCT01955837|Experimental|TAS-102|
32915778|NCT01955837|Placebo Comparator|Placebo|
32915779|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
32915780|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
32915781|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
32915782|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
32915783|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
32915784|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
32915785|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
32915786|NCT01956071|Experimental|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
32915787|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
32915788|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
32915789|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
32915790|NCT04902378|Experimental|Tandem t:slim X2 insulin pump with Control IQ technology plus CGM|Participants randomized to the intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology and Dexcom G6 Continuous Glucose Monitor.
32915791|NCT04902378|No Intervention|Standard insulin delivery (multiple daily injections (MDI) or pump) and CGM|Participants randomized to the control group will be fitted with the Dexcom G6 Continuous Glucose Monitor. They will continue to use standard insulin delivery (MDI or pump) and CGM.
32915792|NCT05727449||General Anesthesia for Cesarean Delivery|
32915793|NCT05727449||Spinal Anesthesia for Cesarean Delivery|
32915794|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
32915795|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
32915796|NCT05740241||Healthy participants aged more than 65 years old|Participation in 8 physical activity sessions, lasting 45 minutes, at the rate of 2 sessions per week
32915797|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
32915798|NCT05740085||Rheumatoid Arthritis Patients|Patients that are diagnosed with rheumatoid arthritis
32915799|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
32915800|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
32915801|NCT05439317||knee osteoarthritis group|individuals being diagnosed with osteoarthritis and classified by K-L grading
33246830|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
32915802|NCT05439317||healthy group|individuals without knee pain or diagnosis of knee osteoarthritis
33082173|NCT04622722|Placebo Comparator|Group B|Group B: Having Isocaloric diet provide 360 kcal.
33246831|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
33246832|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
33246833|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
33246834|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
33246835|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
33246836|NCT00887848|Experimental|Lokomat training|Lokomat training
33246837|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
33246838|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
33246839|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
33246840|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
33246841|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
33246842|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
33246843|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
33246844|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
33246845|NCT01038817|No Intervention|control|no application on the other side
33246846|NCT01324219|Active Comparator|Staff|
33246847|NCT01324219|Experimental|Resident|
33246848|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
33246849|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
33246850|NCT01038895|Active Comparator|Ramipril|10 mg/daily
33246851|NCT01038895|Experimental|Aliskiren|300 mg/ daily
33246852|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
33246853|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
33246854|NCT04598269|Experimental|ATI-1777 topical solution 2.0% w/w|ATI-1777 topical solution 2.0% w/w, twice daily
33246855|NCT04598269|Placebo Comparator|Vehicle|Vehicle topical solution, twice daily
33246856|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
33246857|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
32715453|NCT05079087|Active Comparator|Ketamine- Midazolam arm|The second arm consist in Patients that will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
32715454|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
32715455|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
32715456|NCT03144999|Experimental|High Dose|AAVCAGsCD59
33246858|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
33246859|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
33246860|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
32715457|NCT05263622|Experimental|Group A|Half of patients will be included in this group according to the split-mouth design.
33246861|NCT00402103|Experimental|Aliskiren/Amlodipine|
32915803|NCT02365506|Experimental|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
32915804|NCT02365506|Experimental|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
32915805|NCT02365506|Placebo Comparator|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
32915806|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
32915807|NCT01639664|No Intervention|Control group|standard practice
33246862|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
33246863|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
33246864|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
33246865|NCT00812175||Group 1|
33246866|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
33246867|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
32915808|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
32915809|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~- 365-405nm, power 1-2mW, exposure 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min"
32915810|NCT04707105||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
32915811|NCT04707105||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
32915812|NCT04707105||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
32915813|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
32915814|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
32915815|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
33246868|NCT00641667|Experimental|Fentanyl|
32715458|NCT05263622|Experimental|Group B|Half of patients will be included in this group according to the split-mouth design.
32715459|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
32715460|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
32715461|NCT05486156|Experimental|Intervention A Time with e-Nature Group|After signing the Free and Informed Consent Term, participants will be directed to a multicomponent intervention based on the experience of aesthetic, emotional and multisensory appreciation, knowledge, environmental education/interpretation and active involvement. At the end of the activity, the participants will fill in the post-intervention questionnaires, which will be applied immediately and 30 days after the intervention.
32715462|NCT05486156|No Intervention|Control Group|The group will do an activity made up of contact with nature during a light walk with attention directed to the senses. The trail will be accompanied by a guide who will not make any type of intervention other than offering the questionnaires to be filled in at the end of the activity and driving in the section foreseen for the activity.
32715463|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
32715464|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
32715465|NCT05262842|Experimental|JS001+IMP4297|
32715466|NCT03394053||Affected Patient|Person with a clinical diagnosis of a PID; either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity
32715467|NCT03394053||Normal Volunteer|Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight >110lbs, no history of viral hepatitis B or C, have a negative HIV screening test
32715468|NCT03394053||Relative of Patient|Biological relatives (age 0-75 years) of a subject who meets affected patient criteria, but who do not have a PID themselves
32715469|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
32715470|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
32715471|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
32715472|NCT03618225|Active Comparator|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
32715473|NCT03618225|Placebo Comparator|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
32715474|NCT05516576|Experimental|endoscopic gastroplasty with endomina®|
32715475|NCT05516576|No Intervention|control|
32715476|NCT05319860|Active Comparator|Standard of Care With No Study Intervention|Participants will receive standard medical care, consisting of antiemetic medicine at the first sign of Chemotherapy-Induced Nausea and Vomiting (CINV) on a schedule as prescribed by the healthcare provider.
32915816|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
32915817|NCT04707027|Sham Comparator|complete polypoidal regression arm|follow up monthly with color fundus photography and OCT at each visit
32915818|NCT04707027|Active Comparator|incomplete polypoidal regression arm|continue treatment with aflibercept injection (treat and extend regimen)
32915819|NCT05418491||Partially hydrolyzed protein Infant formula|Originating from A.R.T. cohort.
32915820|NCT05418491||Standard infant formula|Originating from A.R.T. cohort.
32915821|NCT05418491||Exclusively breastfed infants|Originating from A.R.T. cohort.
32915822|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
32915823|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
32915824|NCT05726669|Experimental|Intervention group|Self-help intervention based on cognitive behavioural therapy for depression in pulmonary hypertension. There will be four booklets which will take four weeks for participants to work through in their own time at home.
32715477|NCT05319860|Experimental|Standard of Care With Study Intervention|Participants will receive an aromatherapy inhaler for complementary in addition to their standard of care antiemetic medication for Chemotherapy-Induced Nausea and Vomiting (CINV).
32715478|NCT03566199|Experimental|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
32715479|NCT05290688|Other|Untreated RRMS patients|Untreated RRMS patients with a 50 ml blood sample during their routine care
32715480|NCT03561831|Active Comparator|propofol group|patients who anesthesized by propofol
32915825|NCT05726669|No Intervention|Wait list control group|The wait list control group will not receive the self-help intervention, and will be compared to the intervention group on the outcome measures. The wait-list control group will receive the intervention after study completion if it is found to be helpful (June 2024).
32915826|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
32915827|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
32915828|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
32915829|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
32915830|NCT05415137|Experimental|Efzofitimod 3 mg/kg|
32915831|NCT05415137|Experimental|Efzofitimod 5 mg/kg|
32915832|NCT05415137|Placebo Comparator|Placebo|
32915833|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
32715481|NCT03561831|Active Comparator|sevoflurane group|patients who anesthesized by sevoflurane
32715482|NCT05262374||Laparoscopic Arm|This cohort of participants will have their procedure completed by a human surgeon
32715483|NCT05262374||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
32715484|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
32715485|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
32715486|NCT05289830|Experimental|Participants receiving Escitalopram|
32715487|NCT05289830|Placebo Comparator|Participants receiving Placebo|
32915834|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
32915835|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
32915836|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
32915837|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
32915838|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
32915839|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
32915840|NCT04420260|Experimental|Treatment oropharyngeal spray + immunostimulant emulsion|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
32715488|NCT05262296||Laparoscopic Surgeon|This cohort of participants will have their procedure completed by a human surgeon.
32715489|NCT05262296||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System
32915841|NCT04420260|Placebo Comparator|Placebo|Placebo oropharyngeal spray + Placebo emulsion was taken PO.
33399816|NCT05666375|Active Comparator|Percutaneous translumbar permcath|"Local anesthesia in adults and general anesthesia in pediatrics.~The patient under fasting condition is placed prone on angiography table.~Skin preparation and a sterile draping of the operating field.~Puncture site is chosen 1.5 cm above right iliac crest 10 cm lateral to the posterior median line.~Puncture into inferior vena cava is made using 21 gauge 15 cm long needle, inserted at 45 degree angle from the horizontal and advanced medially and superiorly under us then fluoroscopic guidance.~Entry into the IVC is made below the level of the renal veins, immediately anterior to the 3rd lumber vertebra.~Intravascular position of the needle is confirmed by free aspiration of blood and injection of contrast media under fluoroscopy.~A guide wire is introduced through the needle and advanced well into the IVC.~The needle is replaced with a dilator. A catheter of appropriate length is tunneled subcutaneously from the right flank and advanced to the IVC"
32715490|NCT05230485|Experimental|Higher CPAP|CPAP level will be 2 cmH2O higher than pre-extubation measured mean airway pressure
32715491|NCT05230485|Active Comparator|Equivalent CPAP|CPAP level will be equal to the pre-extubation measured mean airway pressure
33399817|NCT05666375|Active Comparator|Percutaneous transhepatic permcath|"The patient lies in supine position.~The procedure is done under local anesthesia.~Under ultrasound guidance; access by a 21 gauge angiocatheter (15cm) to right or middle hepatic vein through intercostal or subcostal approach.~Entrance of the hepatic veins is confirmed by injection of diluted contrast media (iopromide) under fluoroscopy.~A 0.018-inch guidewire is advanced through the needle and into the right atrium.~Intravascular catheter length is measured and selected in standard fashion.~The initial access needle is exchanged over the guidewire for a coaxial transitional sheath, which permits replacement of the 0.018-inch guidewire with a 0.035-inch guidewire.~The tunneled catheter is inserted over the wire through a peel-away sheath"
32915844|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
33399818|NCT03707275|Experimental|Alexa+ Arm|
32915846|NCT05724563|Experimental|Zimberelimab and Domvanalimab|Individual will be given Zimberelimab (AB122) 360 mg IV in a 1 hour infusion + 30 minute rest + Domvanalimab (AB154) 1200 mg IV in a 1 hour infusion every three weeks. Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason
32915847|NCT00375453|Experimental|Arm 1|
32915848|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
32915849|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
32915850|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
32915851|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
32915852|NCT01706588|Placebo Comparator|Placebo 1 mL|
32915853|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
32915854|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
32915855|NCT05405439|Experimental|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets，28 days as a treatment cycle.
32915856|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
32915857|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
32915858|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
32715492|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
32915859|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
33399819|NCT03707275|Other|Standard of Care Arm|
32915862|NCT05397353|Experimental|Sleepio|Participants will receive the SleepioTM app
32915863|NCT05405205|Experimental|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
32915864|NCT05405205|Experimental|probiotic|probiotic consisting of the identical three different strains of Lactobacillus fermentum
32915865|NCT05405205|Placebo Comparator|placebo|microcrystalline cellulose
32915866|NCT05739851|Experimental|Sequence A(Before→ After)|
32915867|NCT05739851|Experimental|Sequence B(After→ Before)|
32715493|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
32915868|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
32915869|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
32715494|NCT05261984|Experimental|Former ICU patients|Research subjects with a prior history of ICU treatment within six months.
32915870|NCT05739773|Experimental|Study|the five-element music group
32915871|NCT05739773|Placebo Comparator|Control|binaural beats group
32915872|NCT05710445|Experimental|Augmented Reality|Subjects in this group will have their intravenous catheter placed while the physician uses a mixed reality headset to view the ultrasound images being used to guide the catheter placement.
32915873|NCT05710445|No Intervention|Control|Subjects in this group will have their intravenous catheter placed using standard of care. The physician will use the monitor on the ultrasound machine only to view the ultrasound images being used to guide the catheter placement.
32915874|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
32915875|NCT05739695|Experimental|VBN|Virtual bronchoscopy
32915876|NCT05739695|Experimental|VBN+rEBUS|Combination of VBN and radial EBUS
32915877|NCT05739695|Active Comparator|rEBUS|Radial EBUS as a gold standard
32915878|NCT05739539|Active Comparator|pars plana vitrectomy with ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy and ILM peeling
32915879|NCT05739539|Active Comparator|pars plana vitrectomy without ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy without ILM peeling
32915880|NCT05396105|Experimental|Part A: Low dose|Single low dose of PHA-022121 soft capsules for oral use (PHVS416)
32915881|NCT05396105|Experimental|Part A: Medium dose|Single medium dose of PHA-022121 soft capsules for oral use (PHVS416)
32915882|NCT05396105|Experimental|Part A: High dose|Single high dose of PHA-022121 soft capsules for oral use (PHVS416)
32915883|NCT05396105|Experimental|Part B: Selected dose|Single dose of PHA-022121 soft capsules for oral use (PHVS416)
32715495|NCT05261984|Active Comparator|Age- and sex-matched control group|Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.
32715496|NCT05078697||early pregnancy women|According to the 2020 high-risk population score model, participants with high risks for GDM and normal health participants will be enrolled into the study.
32715497|NCT05261750|Experimental|Auto-Dendritic Adjuvant Therapy|Patients will be given standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
33246869|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
32715498|NCT05261750|Experimental|Allo-Dendritic-secretome and Auto-Dendritic Adjuvant Therapy|Patients will be given standrad medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
32743290|NCT04957017|Active Comparator|Intervention group|"The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training."
32915884|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
32915885|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
32915886|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
32915887|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
32915888|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
32915889|NCT05708807||Observational - all|All included stroke patients.
32915890|NCT05739461||triangular cross-section neck implant|
32915891|NCT05739461||round cross-section neck implant|
32915892|NCT05704439|Active Comparator|Model 1-Neurologist Initiation of Treatment for Hypertension or Hyperlipidemia|Neurologist Initiation of antihypertensive or treatment for hyperlipidemia
32915893|NCT05704439|Placebo Comparator|Model 2-Usual Care|Usual care
32915894|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
33246870|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
32915897|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
32915898|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
32915899|NCT05380427|Experimental|Single Dose 1|0.0025%(0.025 mg/mL)
32915900|NCT05380427|Experimental|Single Dose 2|0.005%（于0.05 mg/mL）
33246871|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
33246872|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
33246873|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
33246874|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
32715499|NCT05078385|Experimental|AGLE-102|The study is designed to examine the safety of administering EVs derived from allogeneic MSCs to 2nd degree burn wounds of less than 20% TBSA. The study will consist of a single dose level which will evaluate the safety of administering allogeneic Extracellular Vesicles-with a total of 10 patients. The chosen dosage will correlate to a dose of MSCs administered under another protocol (IND 14810). The dose level delivered will be EVs derived from approximately 1 X 104 MSCs for each cm2 treated area not to exceed 20% TBSA in total (cumulative, if more than one area is treated). The limitation in wound sizes to be treated will not change throughout the study. Up to 2 additional administrations of EVs will be given over a period of no more than 8 weeks. The first treatment will be administered within 48 hours of the burn injury. The subsequent treatments will be administered no less than 7 days and no more than 6 weeks apart.
32715500|NCT05260658|Experimental|Part A: CFTX-1554 Single Ascending Dose (SAD)|Up to 7 dose levels with CFTX-1554 administered as oral liquid formulation under fasted conditions (at 1 single dose level only, drug intake under fed conditions, and as capsule under fasted conditions and under fed conditions, will be assessed)
32715501|NCT05260658|Placebo Comparator|Part A placebo|Single placebo administration in study Part A
32715502|NCT05260658|Experimental|Part B: CFTX-1554 Multiple Ascending Dose (MAD)|Up to 4 dose levels with CFTX-1554 in Part B. Doses and dosing frequency will be decided based on the results of study Part A.
32715503|NCT05260658|Placebo Comparator|Part B placebo|Multiple placebo administration in study Part B
32715504|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
32715505|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
32915901|NCT05380427|Experimental|Single Dose 3|0.01%（0.1 mg/mL）
32915902|NCT05380427|Experimental|Single Dose 4|0.02%（0.2 mg/mL）
32915903|NCT05380427|Experimental|Multiple Dose 1|0.05%（0.05 mg/mL）
32915904|NCT05380427|Experimental|Multiple Dose 2|0.01%（0.01 mg/mL）
32915905|NCT05380427|Experimental|Multiple Dose 3|0.02%（0.02 mg/mL）
32915906|NCT05380427|Placebo Comparator|Placebo|Liniment containing anhydrous ethanol, propylene glycol and polyethylene glycol 400
32915907|NCT05405127|Active Comparator|Traditional physical therapy|breathing exercises
32915908|NCT05405127|Experimental|Core stability exercise|core stability exercise along with breathing exercises and pain pressure algometer is used
32915909|NCT05699525|Experimental|Personalized|Participants receive the personalized Maya app intervention for 6 weeks
32915910|NCT05699525|Active Comparator|General Non-Personalized|Participants receive the general MAYA app intervention for 6 weeks
32915911|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
32915912|NCT05739305||Cancer|Death certificates of patients died by cancer or with cancer.
32915913|NCT05739305||Cardiovascular|Death certificates of patients died by cardiovascular conditions or complications.
32915914|NCT05739305||Tuberculosis|Death certificates of patients died by or with tuberculosis, including patients with HIV.
32915915|NCT05739305||Infants|Death certificates of pediatric patients with more than a month of birth, and less than 18 years old.
32915916|NCT05739305||Congenital malformations|Death certificates of patients died by congenital malformations, independently of age.
32915917|NCT05739305||Maternal|Death certificates of patients died by obstetrical conditions during pregnancy or delivery.
32915918|NCT05739305||Contagious|Death certificates of patients died by contagious/infectious diseases.
32915919|NCT05404347||Gallbladder Cancer|Patients with confirmed diagnosis of gallbladder cancer
32915920|NCT05400993|Experimental|treatment group|Chidamide combined with EC -- T regimen was treated with 1 cycle every 21 days, followed by 4 cycles of EC followed by 4 cycles of T, a total of 8 cycles
32915921|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
32915922|NCT05121285|Experimental|Contrast fluid by lower GI endoscopy and enema with and without positioning|There is a washout period of at least four weeks between the two interventions (delivery by lower GI endoscopy and enema)
32915923|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
32915924|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
32915925|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
32915926|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
32915927|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
32915928|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
32715506|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
33246875|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
33246876|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
33246877|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
33246878|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
32715507|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
32715508|NCT05260034|Active Comparator|Otago Group|The control group will receive balance exercises adapted from the evidenced-based Otago Exercise program. Briefly, all eight sessions (~30 min) will involve balance exercises and strength exercises using ankle weights, and will progressively increase as performance improves by increasing resistance or the difficulty of the balance exercises (e.g., reducing base of support).
32715509|NCT05260034|Experimental|FAST Group|Participants randomized to the intervention arm will undergo the FAST program, a progressive safe-falling training based on the tuck and roll strategy. As part of the FAST program, participants will train 30 minutes twice a week for a period of four weeks under the supervision of a trained researcher. Participants will wear protective gear (knee, hip, head) and they will complete a 10-minute stretching exercise routine to minimize the risk of injury.
32715510|NCT05078307|Active Comparator|OHR System|Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.
32715511|NCT05078307|Experimental|OHV System|Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.
32715512|NCT05288348|Experimental|DSUVIA (sufentanil)|Subjects will receive a single dose of 30 micrograms DSUVIA (sufentanil) tablet utilizing a sublingual applicator
32715513|NCT05288348|Active Comparator|Standard Care|Subjects will receive standard care pain management
32715514|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
32715515|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
32715516|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
32915929|NCT05739227|Experimental|allogenic CD19-CAR-NK|Enrolled patients will receive prespecified dose of allogenic CD19-CAR-NK cells.
32915930|NCT05739149|Experimental|Microvessel Ultrasound Imaging for Chronic Ulcers|Subjects with chronic diabetic ulcers and venous ulcers will undergo wound debridement and treatment as standard of care and receive research microvessel ultrasound examination and two skin biopsies
32915931|NCT05739071|Experimental|Experimental (group 1)|This group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening).
32915932|NCT05739071|Placebo Comparator|Control (group 2)|This group will receive two sachets of placebo a day (same way as group 1).
32915933|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
32915934|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
32915935|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
32915936|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
32915937|NCT05738993|Experimental|BCD-178 group|single IV infusion of BCD-178 at a dose of 420 mg
32915938|NCT05738993|Active Comparator|Perjeta Group|single IV infusion of Perjeta at a dose of 420 mg
32915939|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
32915940|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
33246879|NCT02567058|Experimental|3 groups of subjects|"3 groups:~group I : healthy volunters~group II : patient with an immobilisation (between 1 and 2 months)~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
32915941|NCT02992808|Active Comparator|Recombinant preparations|
32915942|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
32915943|NCT05356013|Placebo Comparator|Placebo|All subjects who are randomized to Placebo will receive an identical placebo pill to the experimental drug starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. After study conclusion (week 8), the dose will be discontinued.
33246880|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
33246881|NCT00815451|Experimental|polyphenol-rich dark chocolate|
33246882|NCT05665530|Experimental|PRT2527|PRT2527 will be administered by intravenous infusion once weekly on a 21-day treatment cycle at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication-specific cohorts during the dose confirmation phase.
33246883|NCT02552199||with hyperhidrosis|Patients with primary hyperhidrosis
33246884|NCT02552199||healthy|Healthy adult patients
33246885|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
33246886|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
33246887|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
33246888|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
32915944|NCT05356013|Experimental|Caplyta|All subjects who are randomized to Caplyta will receive 42mg/day starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. Dosage changes and reductions will not be permitted. After study conclusion (week 8), the dose will be discontinued.
32915945|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
32915946|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
32915947|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
32915948|NCT01640834|Experimental|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.~Placebo: 2 capsules, administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
32915949|NCT01640834|Experimental|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
32915950|NCT01640834|Placebo Comparator|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
32915951|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
32915952|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
32915953|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
32915954|NCT05658731|Experimental|Stratum A (new diagnosis, substructure informed radiation therapy)|Patients will undergo radiation therapy which has been planned according to dose constraints to specific brain substructures.
32915955|NCT05658731|Other|Stratum B (patients ≥ 2 years after standard radiation therapy)|Patients who completed radiation therapy under standard planning procedures ≥ 2 years ago.
32915956|NCT05658731|Other|Stratum C (healthy controls matched to Stratum A)|Healthy patients who are matched to Stratum A patients
32915957|NCT05327855|Experimental|OPL-0301 Dose 1|Participants are randomized to OPL-0301 Dose 1 administered once daily for 90 days
32915958|NCT05327855|Experimental|OPL-0301 Dose 2|Participants are randomized to OPL-0301 Dose 2 administered once daily for 90 days
32915959|NCT05327855|Placebo Comparator|Placebo|Participants are randomized to matching placebo administered once daily for 90 days
32915960|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
32915961|NCT05321147|Experimental|PTCL that express KIR3DL2|lacutamab will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
32915962|NCT05316935|Experimental|Non-obese group|Patients will be stratified into EEC group with 40 cases and EAH group with 40 cases. Each group will be randomized to GnRHa + Letrozole group and Diane-35 + metformin group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
32915963|NCT05316935|Experimental|Obese group|"Patients will be stratified into EEC group with 19 cases and EAH group with 19 cases. Interventional Study Model was Simon two-stage optimal design.~Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded."
32915964|NCT05711186|Other|Structured SDM|Structured shared decision making for the choice between SAVR and TAVR
32915965|NCT05711186|Other|Usual Care|Usual care for the choice between SAVR and TAVR
32915966|NCT05738759|Experimental|Epidural Anesthetic Cocktail|Patients which received epidural anesthetic cocktail following endoscopic discectomy
32915967|NCT05738759|Placebo Comparator|Placebo|Patients which received placebo following endoscopic discectomy
32915968|NCT05738681|Experimental|NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C using NAC-long 1,200 mg/day for 8 weeks (NAC long group). Genetic test (acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
32915969|NCT05738681|No Intervention|Non-NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C were using anti-TB alone (non-NAC group). Genetic test (Acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
32915970|NCT05647733|Active Comparator|Intervention group: Low splanchnic blood volume Restrictive fluid management strategy|The intervention group is targeted at lowering splanchnic blood volume using a phlebotomy and restricting fluid infusion, individualized to the physiological needs of this population and the distinct LT surgical phases. The strategy will first consist of performing a phlebotomy without fluid replacement at the start of surgery.We will combine it with fluid restriction to prevent excessive fluid administration and its effect on splanchnic blood volume and blood loss, combined with the effect of the phlebotomy, as well as to limit fluid overload, as previously reported. Fluid will be administered to compensate blood loss and treat severe hemodynamic instability.The phlebotomy will be transfused back at the beginning of the reperfusion phase where fluid management will be based on a goal-directed therapy (GDT) using either PPV or SV, as in the control group.
32915971|NCT05647733|Sham Comparator|Control group: Optimized cardiac output liberal fluid management strategy|The control group will receive a liberal intraoperative fluid management strategy optimizing cardiac output throughout the surgery. It will consist of administering 250 mL fluid boluses until SV stops to increase by more than 10% or until PPV is below 12%, a dynamic indicator of fluid responsiveness validated in many surgical populations, including ESLD patients undergoing a LT.This strategy is informed by data from recent clinical trials on benefits of GDT in major surgery, data on strategies used in major surgery, liver resection or LT and our survey on current practice.
32915972|NCT05738603|No Intervention|Standard Therapy Group|The standard therapy group patients will have invasive blood pressure monitoring + standard medical therapy. The therapeutic decision regarding treatment of hypotension, the use of fluids and vasopressors will be determined by the anaesthesia team. The decisions will be based on the information from the standard invasive blood pressure monitoring.
32915973|NCT05738603|Experimental|Hypotension Prediction Index Group|The HPI-group will have the HPI based monitoring with the Acumen IQ sensor (Edwards Lifesciences) and the HPI algorithm connected also to the HemoSphere platform (Edwards Lifesciences). The hemodynamic management will be based on the HPI indications and the specific algorithm, which considers hypovolemia, impaired contractility and vasodilatation. An alert pops up on the monitor screen when the HPI values exceeds 85 and then the clinician needs to make therapeutic decision in order to avoid the hypotensive episode.
32915974|NCT05738447|Experimental|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
32915975|NCT05644925|Experimental|PICSO+PCI|
32915976|NCT05644925|Active Comparator|Standard PCI|
32915977|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32915978|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
33246889|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
33246890|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
32715517|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
32715518|NCT05259800|Experimental|Peppermint Oil|Subjects will be exposed to vapor of peppermint oil
32715519|NCT05259800|Placebo Comparator|Placebo|Subjects will be exposed to vapor of placebo (mineral oil)
32715520|NCT05078151|Other|Metastatic prostate cancer|Patients will receive whole-body MRI with diffusion-weighted imaging at baseline and after 4 and 8 weeks of treatment.
32715521|NCT05257382|Active Comparator|Endoscopy suite|In this arm, ENB procedure will be performed in a classical endoscopy suite equipped by a fluoroscopy.
32715522|NCT05257382|Experimental|CBCT suite|In this arm, ENB procedure will be performed in a n hybrid room equipped by a cone beam CT (CBCT). This will allow to perform a real time visualisation of the lesion, enhanced fluoroscopy and to use the CrossCountry technique if required.
32715523|NCT05387187|Experimental|Pu Yang Wan Wu Tang plus Pentoxifylline|
32915979|NCT05280509|Experimental|Phase 1b - Dose Level 1|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
32715524|NCT05387187|Active Comparator|Pentoxifylline|
32915980|NCT05280509|Experimental|Phase 1b - Dose Level 2|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
32915981|NCT05280509|Experimental|Phase 1b - Dose Level 3|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
33246891|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
33246892|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
32715525|NCT05287490|Experimental|treatment|
32715526|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
32715527|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
32715528|NCT05287334|Experimental|Voluntary blood donors|Voluntary blood donors undergoing standard blood donation while measuring electrical impedance of the chest .
32715529|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
32715530|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
32715531|NCT05318534|Experimental|GL-0719|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects"
32715532|NCT05318534|Placebo Comparator|Placebo|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects"
32715533|NCT03199755|Active Comparator|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.~Tablets per dose, are given BID for 3 days as shown below:~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days~Body weight (kg) and Tablets: 5 to <15 kg, 1 tab; 15 to <25 kg, 2 tabs; 25 to <35 kg, 3 tabs; 35 kg and over, 4 tabs."
32715534|NCT03199755|Experimental|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA1x: 5 to < 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2>30 kg, 1 tab."
32715535|NCT03199755|Experimental|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA2x: 5 to < 15 kg, 1/2 tab; 15-30 kg, 1 tab; >30 kg, 2 tabs."
32715536|NCT05318066|Active Comparator|Arm Fluids (FL)|500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.
32715537|NCT05318066|Active Comparator|Arm Vasopressor (VP)|Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
32715538|NCT03161535|Experimental|exercise group|The rehabilitation program was composed of two parts: an exercise program and a diet-teaching program. The exercise program was a 12-week home-based program that comprised moderate-intensity brisk walking for 40 min per session, with 3 sessions per week; in addition, weekly exercise counseling was provided through telephone. The diet teaching program was provided to the patients by using a diet booklet at baseline (same timing as the exercise program), and its contents were used to instruct the patients regarding dietary principles to be followed.
32715539|NCT03161535|No Intervention|usual-care group|The control group (CG) received usual care, whereas a nurse, the manager for esophageal cancer treatment, provided routine care, conducted follow-ups, and offered information on esophageal cancer to the experimental group (EG).
32715540|NCT05317910|Experimental|Music intervention|Music intervention (duration 20 minutes) every day for 30 days
32715541|NCT05317754|Experimental|Mindful breathing|
32715542|NCT05317754|Experimental|Prostrations, according to Tibetan Buddhist tradition|
32715543|NCT05317754|Experimental|The Koan Mu, according to Zen Buddhist tradition|
32715544|NCT05317754|Experimental|The mirror exercise, according to Toltec tradition|
32715545|NCT05387109|Experimental|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
32715546|NCT04422704|Experimental|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
32715547|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
32715548|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
32915982|NCT05280509|Experimental|Phase 2 - Cohort 1 JAKi treatment-naïve MF|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose of ruxolitinib will be based on the subject's baseline platelet count."
32915983|NCT05280509|Experimental|Phase 2 - Cohort 2 suboptimal response to Ruxolitinib|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose schedule will be the stable ruxolitinib dose schedule as the subject is currently taking prior to entry into the study."
32915984|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
32715549|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
32915985|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
32915986|NCT05638607|Experimental|Intensified occupational therapy|Two hours occupational therapy each weekday with specific focus on basic ADL
32915987|NCT05638607|Active Comparator|Usual care|Occupational therapist instruct nursing staff on how to assist patients with basic ADL
32715550|NCT05081661|Experimental|Motor Imagery Group A|This group will follow a program of motor imagery.
32715551|NCT05081661|Placebo Comparator|Motor Imagery Group B|This group will follow a placebo program inspired from Bodyscan
32715552|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
32715553|NCT05255588||Cohort|Subjects who are at high-risk (Asia Pacific Colorectal Screening Score ≥4.0) of developing CRC aged ≥40
32715554|NCT02966379|Experimental|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
32715555|NCT05314946|Active Comparator|Percutaneous enteral access|Feeding tube, either gastrostomy (G-) tube or gastrojejunostomy (GJ-) tube (placed by Interventional Radiology) or J-tube (surgically placed)
32715556|NCT05314946|Experimental|No percutaneous enteral access|No feeding tube placed.
32715557|NCT02957799|Experimental|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
32715558|NCT02957799|Experimental|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
32715559|NCT05285306|Experimental|PEACE Program|3 sessions of tailored coping skills related to pelvic examinations
32715560|NCT02951013|Experimental|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
32715561|NCT02951013|Active Comparator|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
32715562|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
32715563|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
32715564|NCT04243226|Experimental|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life. This will be a randomized-controlled clinical trial, by using a mixed method to explore the feasibility and validity of such a safety exercise prescription. In the next stage, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
32715565|NCT04243226|No Intervention|No exercise prescription in TBI patients|Routine Care of TBI Patients
32715566|NCT05081505|Experimental|Community-based physical fitness exercise course|Included 12-week structural exercise course (0-12 weeks) and 12-week autonomous group class (12-24 weeks).
32715567|NCT05283122|Experimental|The Mostafa Maged technique to prevent and control post-partum bleeding in placenta previa cases|primigravida patients with placenta previa conditions and their ages between ( 18 - 30 ) years old
32715568|NCT05080803||Early DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
32715569|NCT05080803||Advanced DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
32715570|NCT05080803||Severe DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
32715571|NCT05080803||Atrophic diabetic maculopathy|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
32915988|NCT05711108||Long Term Care Residents Using Glucose Lowering Medication|
32915989|NCT05738369|Experimental|Probiotic|Participants received treatment with Biogaia L. reuteri Prodentis® lozenges
32915990|NCT05738369|Placebo Comparator|Sugar free lozenges|Participants received Hersheyland Ice Breakers Mints sugar free lozenges
32915991|NCT05738369|No Intervention|Negative control|Participants received no lozenges or supplements
33246893|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
33246894|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
32715572|NCT05493254|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
32715573|NCT05493254|Active Comparator|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
32715574|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
32715575|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
32715576|NCT02431767|Experimental|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715577|NCT02431767|Placebo Comparator|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715578|NCT02431767|Experimental|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715579|NCT02431767|Placebo Comparator|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715580|NCT02431767|Experimental|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715581|NCT02431767|Placebo Comparator|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
32715582|NCT02431767|Experimental|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
32715583|NCT02431767|Placebo Comparator|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
32715584|NCT04422782|Other|Single Arm|Single Arm
32915992|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
32915993|NCT05710874|Experimental|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
33246895|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
32715585|NCT05082363||systemic lupus wth renal affection|pt diagnosed with lupus nephritis
32715586|NCT05082363||systemic lupus without renal affection|pt diagnosed as systemic lupus without renal affection
32715587|NCT05512598|Experimental|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
32715588|NCT04422860|Experimental|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
32715589|NCT04422860|Active Comparator|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
32715590|NCT04422860|Active Comparator|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
32715591|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
32715592|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
32715593|NCT05314010|Experimental|MIL62|
32715594|NCT05314010|Placebo Comparator|Placebo|
32715595|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~Receive recommendation for bedrest (standard of care).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
32745885|NCT04796571|No Intervention|passive control arn|To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.
32915994|NCT05710874|Experimental|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoride) paste (MI Paste Plus®) in addition to twice daily use of conventional toothpaste..
32915995|NCT05710874|Experimental|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
32715596|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
32715597|NCT05230563|No Intervention|Control Group|Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images
32715598|NCT05230563|Experimental|"Experimental Group - with the aid of Taihao lung CT decision support system"|"Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images with the aid of Taihao lung CT decision support system"
32715599|NCT05313620|Experimental|Ulcerative colitis patients treated with tofacitinib|Tofacitinib 5 mg/day oral per clinical practice
32915996|NCT05710874|Placebo Comparator|Conventional|Twice daily use of conventional toothpaste.
32915997|NCT05737745|No Intervention|Usual care|Endometrial cancer survivors will receive standard survivorship care including a one-time educational newsletter about survivorship physical activity and nutrition recommendations. Fitbits will be given to track physical activity.
32715600|NCT05313620|Active Comparator|Ulcerative colitis patients treated with an anti-TNFα drug|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice
32915998|NCT05737745|Experimental|FitEx-ECS|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS intervention program, with a focus on walking. Fitbits will be given to track physical activity.
32915999|NCT05737745|Experimental|FitEx-ECS+ Yoga|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS+yoga intervention program, with a focus on postures, breathwork, and mindfulness. Fitbits will be given to track physical activity.
32916000|NCT05737667|Experimental|YRI+Mobile Supervision|Youth Readiness Intervention delivered by teachers receiving mobile-based supervision
32715601|NCT05313620|No Intervention|healthy controls|
32715602|NCT05063019|Experimental|Magnetic resonance imaging and enterography following computed tomography|Magnetic resonance imaging and enterography will be performed after computed tomography but before surgery.
32715603|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
32715604|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
32715605|NCT04243148|Experimental|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
32715606|NCT04243148|Experimental|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
32715607|NCT04571697||Participants Initiating Therapy with Methotrexate or Anti-TNF|Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.
32715608|NCT05482334|Experimental|Sargramostim|Sargramostim 250 μg/m2/day subcutaneously (5 days per week)
32715609|NCT05482334|Placebo Comparator|Placebo Control - Saline|Placebo equivalent volume subcutaneously (5 days per week)
32715610|NCT05082129|Experimental|Intervention|The intervention will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). Their results will be shared with the patients after both MRI scans are preformed and results calculated. Their treatment selection will therefore be informed by the TransiCap results.
32715611|NCT05082129|Experimental|Control|The control arm will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). The patients will undergo 2 MRI scans but their results will be shared with the patients after 12 months has elapsed. They will receive standard care treatment not informed by the TransiCap results.
32715612|NCT05253794|Experimental|Colchicine|Colchicine 0.6mg PO daily for 6 months
32715613|NCT05253794|Placebo Comparator|Placebo|Placebo tablet daily for 6 months
32715614|NCT05081973||Intubated preterm infants|Infants with a birth weight < 1250 grams who have required endotracheal tube and mechanical ventilation within the first 7 days of life, and have been on an invasive mechanical ventilator for at least 48 hours, and have not completed 60 days after birth, and have met the traditional extubation criteria of the institution, and have been considered for elective extubation for the first time.
32715615|NCT05313152|Experimental|TAVO103A Low Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
32715616|NCT05313152|Experimental|TAVO10A Medium Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
32916001|NCT05737667|Active Comparator|YRI+Standard Supervision|Youth Readiness Intervention delivered by teachers receiving standard supervision
32916002|NCT05737667|No Intervention|Control|Wait listed control
32916003|NCT05259995|Experimental|Sustained Acoustic Medicine Device Group 1|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
32916004|NCT05259995|Active Comparator|Sustained Acoustic Medicine Device Group 2|Patients receive treatment from the SAM Ultrasonic Diathermy Device 2 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
32715617|NCT05313152|Experimental|TAVO103A High Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
32715618|NCT05313152|Placebo Comparator|Placebo|Placebo single ascending dose IV infusion.
32715619|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
33246896|NCT04045275|Experimental|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
32916005|NCT05256563||Right brain stroke survivors|People with right brain stroke who are recruited to the study.
32916006|NCT05626751|Experimental|HZN-825|HZN-825 will be administered by mouth (PO) twice daily (BID) for 52 weeks
32916007|NCT05737433|Experimental|[14C]-RCF 225mg|[14C]-rencofilstat, 225mg oral dose, self-micro-emulsifying drug delivery system, single dose
32916008|NCT05737199|Experimental|MK-3475 (Pembrolizumab)|Treatment with MK-3475 (pembrolizumab) 200 mg.
32916009|NCT05625269|Experimental|Education and follow-up group|Patients in the intervention group will be given training on the procedure and home care process on the first day of hospitalization and the day before discharge. Afterwards, patients will be followed up by phone at intervals of two weeks. The purpose of telephone monitoring is to question adherence to treatment, to identify and change barriers, to apply counseling and to control symptoms.
32916010|NCT05625269|No Intervention|Control group|The control group will be given the standard care applied in the clinic, and the patients of this group will be given training after the research is completed.
32916011|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
32916012|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
32916013|NCT05616767|Experimental|Training on self-screening and HPV vaccination administration|teaching SMM in Tanzania to conduct self-exams for oropharyngeal hrHPV-associated cancers using cellphone-mediated oral selfies, and administering the HPV vaccination series (with 2 and 6-8 month follow-up) to those who request it
32916014|NCT05238467||A|Group A will consist of 50 participants with a diagnosis of one of the following cancers: breast, colorectal, or prostate cancers who received myelosuppressive cytotoxic chemotherapy at the time of COVID vaccination, or who received chemotherapy within 30 days prior to the initial or booster vaccination, or who started on chemotherapy within 30 days after the initial or booster COVID vaccination. Cytotoxic chemotherapy can be given either in the neoadjuvant/adjuvant setting or metastatic setting.
32916015|NCT05238467||B|Group B will consist of 25 participants with a diagnosis of breast, colorectal, or prostate cancers who are on non-myelosuppressive treatment including endocrine therapy, tyrosine kinase inhibitor or anti-HER 2 therapy.
32916016|NCT05238467||C|Group C will consist of 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent, without evidence of disease recurrence, and >12 months from completion of chemotherapy or radiation.
32715620|NCT05312138|Experimental|Transcutaneous Posterior Tibial Nerve Stimulation Group|The treatment will be carried out by the physiotherapist using the TenStem Eco Basic device.
32715621|NCT05312138|Active Comparator|Repetitive Transcranial Magnetic Stimulation Group|The treatment will be applied with a Power Mag device.
32916017|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
32916018|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
32916019|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
32916020|NCT05736575||Chronic Pain Patient|A blood draw is to be performed to analyze peripheral BDNF.
32916021|NCT05736575||Asymptomatic subject|A blood draw is to be performed to analyze peripheral BDNF.
32916022|NCT05611697|Experimental|Single anastomosis sleeve ileal bypass|A Single anastomosis sleeve ileal bypass procedure is performed.
32916023|NCT05611697|Active Comparator|Sleeve gastrectomy|A sleeve gastrectomy procedure is performed.
32916024|NCT05736419|Experimental|Participants with Sickle Cell Disease or β-Thalassemia|Participants will have severe sickle cell disease or transfusion-dependent β-thalassemia.
32916025|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
32916026|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
32916027|NCT05604209|Experimental|C62|C62 administered at Day 0 and M4 on Day 28
32715622|NCT04257279|Experimental|Robotic|Patients receiving spine surgery with posterior stabilization placed by ExcelsiusGPS
32715623|NCT04128423|Experimental|AMV564|
32715624|NCT05282966||Prospective Cohort with QSant Testing|2,000 participants will be enrolled across sites within 90-days post-kidney transplant and followed for 24-months
32715625|NCT05282966||Retrospective Control Cohort without QSant Testing|2,000 site-matched controls from UNOS database who underwent a kidney transplant no more than 5 years prior to the study completion date
32916028|NCT05604209|Experimental|C1C62|C1C62 administered at Day 0 and M3M4 on Day 28
32916029|NCT05604209|Placebo Comparator|Placebo|Placebo administered on Day 0 and Day 28
32916030|NCT05227001|Experimental|PF-07852352 Influenza saRNA, low dose|
32916031|NCT05227001|Experimental|PF-07852352 Influenza saRNA, mid dose|
32916032|NCT05227001|Experimental|PF-07852352 Influenza saRNA, high dose|
32916033|NCT05227001|Experimental|PF-07836391 Influenza saRNA, low dose|
32916034|NCT05227001|Experimental|PF-07836391 Influenza saRNA, mid dose|
32916035|NCT05227001|Experimental|PF-07836391 Influenza saRNA, high dose|
32916036|NCT05227001|Experimental|PF-07836394 Influenza saRNA, low dose|
32916037|NCT05227001|Experimental|PF-07836394 Influenza saRNA, mid dose|
32916038|NCT05227001|Experimental|PF-07836394 Influenza saRNA, high dose|
32916039|NCT05227001|Experimental|PF-07836395 Influenza saRNA, low dose|
32916040|NCT05227001|Experimental|PF-07836395 Influenza saRNA, mid dose|
32916041|NCT05227001|Experimental|PF-07836395 Influenza saRNA, high dose|
32916042|NCT05227001|Experimental|PF-07836396 Influenza saRNA, low dose|
32916043|NCT05227001|Experimental|PF-07836396 Influenza saRNA, mid dose|
32916044|NCT05227001|Experimental|PF-07836396 Influenza saRNA, high dose|
32916045|NCT05227001|Experimental|PF-07867246 Influenza saRNA, mid dose|
32916046|NCT05227001|Experimental|PF-07867246 Influenza saRNA, low dose|
32916047|NCT05227001|Experimental|PF-07867246 Influenza saRNA, high dose|
32916048|NCT05227001|Placebo Comparator|Placebo|
32916049|NCT05227001|Active Comparator|Quadrivalent influenza vaccine (QIV)|
32916050|NCT05227001|Experimental|PF-07871987 Influenza saRNA, low dose|
32715626|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
32715627|NCT05281016|Experimental|Delayed Intervention Control Group|Participants randomised to the Control Group will be offered standard care and will be introduced to 6 month delayed intervention which consists of the online community LITE programme.
32715628|NCT05281016|Experimental|Intervention Group|Participants randomised to the Intervention Group will receive standard care plus invitation to participate in the online community LITE programme for 4-5 months.
32715629|NCT02035917|Experimental|Locking plate|
32916051|NCT05227001|Experimental|PF-07871987 Influenza saRNA, mid dose|
32916052|NCT05227001|Experimental|PF-07871987 Influenza saRNA, high dose|
32916053|NCT05227001|Experimental|PF-07914705 Influenza saRNA mid dose|
32715630|NCT02035917|Active Comparator|Non-Locking plate|
32715631|NCT05253716|Experimental|immune nutrition support|In the immune nutrition support group, in addition to diet, and patients will also consume two bottles per day of a high-calorie, high-protein ONS and three capsules of fish oil after discharge lasted for 6 months.
32715632|NCT05253716|No Intervention|control|In the control group, patients will receive nutrition counseling in addition to diet.
32916054|NCT05227001|Experimental|PF-07914705 Influenza saRNA, high dose|
32916055|NCT05227001|Experimental|PF-07915048 Influenza saRNA, high dose|
32916056|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
32916057|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
32916058|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
32916059|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
32916060|NCT05736341|Experimental|Remimazolam|Patient group who receives remimazolam for sedation after delivery
32916061|NCT05736341|Active Comparator|Midazolam|Patient group who receives midazolam for sedation after delivery
32916062|NCT05598749|Placebo Comparator|Placebo|
32916063|NCT05598749|Experimental|Verum|
32916064|NCT05736263|Experimental|Moderate intensity exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform moderate-intensity aerobic exercise
32916065|NCT05736263|Experimental|High intensity interval exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform High intensity interval exercise
32916066|NCT05736263|Experimental|Combined exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform combined exercise
32916067|NCT05736263|Experimental|Resistance exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform resistance exercise
32916068|NCT05215223|Experimental|whole body vibration|the patient will be received whole body vibration for three times/ week in addition to aerobic exercise for 3 times per week, 45 minutes per session for eight weeks
32916069|NCT05215223|Active Comparator|Aerboic exercise|Moderate intensity aerobic exercise in form of walking on treadmill for 3 times per week, 45 minutes per session for eight weeks
32916070|NCT05213273|Experimental|Group A: Fresh/frozen fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish), excluding the consumption of canned fish.
32916071|NCT05213273|Experimental|Group B: Canned fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
32916072|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
32916073|NCT05589467|Experimental|DASH Diet and Fried Potatoes|DASH-FP (fried potatoes) group
32916074|NCT05589467|Experimental|DASH Diet and Non-Fried Potatoes|DASH-NFP (non-fried potatoes) group
32916075|NCT05589467|Experimental|DASh Diet and No Potatoes|DASH-NP (no potatoes) group
32916076|NCT05736185|Experimental|EIT-PEEP strategy|PEEP selected by EIT which remained at 15 min
32916077|NCT05736185|Experimental|Low FiO2-PEEP strategy|PEEP selected by low FiO2-PEEP table which remained at 15 min
32916078|NCT05736185|Experimental|High FiO2-PEEP strategy|PEEP selected by high FiO2-PEEP table which remained at 15 min
32916079|NCT05200481|Other|Brigatinib monotherapy Arm A|Brigatinib 180mg QD (1 x 180mg tablet) until progression
32916080|NCT05200481|Experimental|Brigatinib Carboplatin-Pemetrexed combination therapy Arm B|Brigatinib 180mg QD (1 x 180mg tablet) until progression + Carboplatin AUC of 5 mg/mL/min IV infusion every 3 weeks for 4 infusions + pemetrexed 500 mg/m² IV infusion every 3 weeks for 4 infusions
32715633|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
32715634|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
32715635|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
32715636|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
32916081|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
32916082|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
32916083|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
32916084|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
32916085|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
32916086|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
32916087|NCT05587517|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
32916088|NCT05587517|Placebo Comparator|Supportive Conversation arm|"The Supportive Conversation (SC) arm includes a supportive, empathic encounter without specific skill-building for approximately the same amount of time as EMPOWER.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after SC within 3 months conducted in person and by phone."
32916089|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32916090|NCT01614392|Experimental|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
32916091|NCT01614392|Experimental|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
32916092|NCT05176691|Experimental|Treatment|All patients to receive HMPL-760 daily.
32916093|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
32916094|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
33082174|NCT04622956|Experimental|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
32715637|NCT05311436|Experimental|Experimental|"Pregnant women will receive monthly intensive dietary counseling, daily iron-folate, calcium supplementation, and at least four antenatal visits to local ANC service providers from enrollment before 16 weeks of gestation to delivery of the baby will be ensured.~Adolescent girls will receive twice-monthly nutrition education sessions to improve dietary diversity scores from enrolment to 6 months of enrollment.~Under 2y children will receive monthly growth monitoring and promotion, IYCF counseling~Severely stunted children: Daily 1 egg for 3 consecutive months and 1 sachet of multiple micronutrient powder supplementation for 6 months."
32715638|NCT05311436|No Intervention|Control|Participants will receive the standard of care in the area
33246897|NCT04045275|No Intervention|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
33246898|NCT05325138||Parents|Parents of girls aged 9-14 years old
33246899|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
32916095|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
32916096|NCT05736107|Experimental|CBL-514 Injection|Participant will receive CBL-514 2 mg/cm² administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
32916097|NCT05736107|Placebo Comparator|0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
32916098|NCT05736029||Non-operable NSCLC patients receiving ICI therapy|Patients with non-operable stage IIIB-IV NSCLC treated with immune check inhibitor anti cancer treatment as a standard of care
32916099|NCT05736029||Operable NSCLC Patients Receiving ICI as Neoadjuvant or Adjuvant Therapy|Patients with operable stage II-IIIA NSCLC, treated with immune check inhibitor in the neoadjuvant or adjuvant setting
32916100|NCT05736029||Healthy volunteers|Sex and aged matched non-diseased volunteers
32916101|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
32916102|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
32916103|NCT02992184||HCV patients|228 HCV patients
32916104|NCT02992184||control|189 controls
32916105|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
32916106|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
32916107|NCT05161169|Experimental|Sequencing cohort|Infants receive genome sequencing with analysis of approximately 1000 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
32916108|NCT05161169|No Intervention|Control cohort|Infants receive a detailed family history report plus standard well-child care.
32916109|NCT05710718|Experimental|PureWick™ System|The PureWick™ System includes the PureWick™ Female External Catheter and the PureWick™ Urine Collection System. The PureWick™ Female External Catheter (PureWick™ FEC) is marketed in both the United States and Europe. In the U.S. PureWick™ FEC is a Class I, 510(k) exempt device. In Europe, the PureWick™ FEC is a Class I, Conformitè Europëenne (CE) marked, non-sterile device.
32916110|NCT05710718|Active Comparator|Hollister® Female Urinary Pouch External Collection Device|The urinary collection pouch with a skin barrier is suitable for non-ambulatory females with urinary incontinence.
32916111|NCT05146661|Experimental|Treatment|The NEURESCUE device will be used as an adjunct to ALS.
32916112|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
33246900|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
32715639|NCT05210205|Experimental|EAA-enhanced food products|Consume approximately 1500 calories of EAA-enhanced food products plus ad libitum consumption of 3 combat rations each day during training.
32715640|NCT05210205|Experimental|Energy dense food products|Consume approximately 1500 calories of energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
32715641|NCT05210205|Active Comparator|Control food products|Consume approximately 1500 calories of low energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
32916113|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
32916114|NCT05139563|Sham Comparator|Placebo injection|This group will first receive 3 mL intramuscular injections of a 20% fat emulsion (Intralipid 20%) every 2 months for 6 months.
32916115|NCT05139563|Experimental|Placebo implant|This group will first receive a single-use subdermal implant in the inner side of the upper arm for a duration of 6 months before removal.
33082175|NCT04622956|No Intervention|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
32916116|NCT05034185||Patients with one or more polyps detected|"During colonoscopy, the Clinician inspect for the presence of polyps as per routine clinical practice with the CAD EYE function turned off. When a polyp is encountered, the Clinician will make a prediction on the histology based on the white light and BLI features of the polyp with and without optical magnification, as per routine clinical practice. Following this, the CAD EYE function will be switched on and the Clinician will take note of the CADx prediction for the same polyp, which will be either neoplastic or hyperplastic.~In addition, other polyp features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The polyp will be resected and sent for pathological examination, which will form the gold standard for the diagnosis of polyp histology."
32916117|NCT05546801|Experimental|questionnaire|Questionnaire on postnatal development
32916120|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32916121|NCT05136131|Experimental|True cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. The unblinded non-MRP cardiologist will call out as per usual All clear, following which a shock is delivered as per the Ottawa Cardioversion Protocol in the 'shock' arm."
32916122|NCT05136131|Sham Comparator|Sham cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. No shock is delivered in the sham shock arm."
33246901|NCT05426382|Experimental|Digital solution group|"Participants will be instructed to download a lifestyle-changing mobile application to which they will have access for 9 months. The program aims to provide remote symptom monitoring by a health coach and by having participants enter data (on diet, exercise, weight, stress and energy levels, etc) and patient reported outcomes (PROs) via the SidekickHealth platform to empower positive lifestyle changes.~The intervention consists of a 12-week digital behavioral change program with an additional 6-month maintenance program, during which time the patient still has access to the application but with limited features compared to the first 12 weeks. During the total 9-month study period all participants will also receive standard of care."
33246902|NCT04045509|Other|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
32916123|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
32916124|NCT05536973|Experimental|Dose 1|A single intravitreal injection of ADVM-022 2E11 vg/eye
32916125|NCT05536973|Experimental|Dose 2|A single intravitreal injection of ADVM-022 6E10 vg/eye
32916126|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
33246903|NCT04045509|Other|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
33246904|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
32745886|NCT04804683|Other|Cohort of patients with Fibromuscular Dysplasia|Intervention consists in blood/urine sampling
32916127|NCT05001737|Experimental|Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)|MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
32916128|NCT04997525|Active Comparator|Natural cycle|These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
32916129|NCT04997525|Active Comparator|Estradiol and progesterone|These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
32916130|NCT04997525|Active Comparator|Gonadotropin|These women will receive daily gonadotropin injection before embryo tranfer. Ovulation will be stimulated using hCG injection.
32916131|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
32916132|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
32916133|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
32916134|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
32916135|NCT04432571|Active Comparator|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
32916136|NCT04432571|Experimental|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
32916137|NCT04432571|Experimental|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
32916138|NCT04432571|Experimental|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
32916139|NCT04432571|Experimental|E-NAV/CCT|E-Nav/Conditional cash transfer
32916140|NCT04432571|Experimental|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
32916141|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
32916144|NCT04429607|Active Comparator|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
32916145|NCT04429607|Active Comparator|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
32916146|NCT04429607|Active Comparator|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
32916147|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss, MHL= mixed hearing loss
32916148|NCT04427033||CHL & MHL (5 to 17 years)|
32916149|NCT04427033||SSD (5 years and older)|SSD= single sided deafness
32916150|NCT04408313|Experimental|XR-B|Extended-release buprenorphine
32916151|NCT04408313|Active Comparator|XR-NTX|Extended-release naltrexone
32916152|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
33246905|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
33246906|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
33246907|NCT00812721|Placebo Comparator|1|Preservative Free Saline
33246908|NCT00812721|Active Comparator|2|Optive (TM)
32916153|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
32916154|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
32916155|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
32916156|NCT01651442|Active Comparator|Sleep Medication 1|
32916157|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
32916158|NCT01651442|Active Comparator|Sleep Medication 2 Following Sleep Medication 1|
32916159|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
32916160|NCT01651442|Active Comparator|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
32916161|NCT05710406|Experimental|Arm I (encorafenib, cetuximab)|Patients receive encorafenib PO and cetuximab IV on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
32916162|NCT05710406|Active Comparator|Arm II (patient observation)|Patients undergo observation per usual care on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
32916163|NCT04960553|Experimental|Device : Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up investigation : Up to 102 subjects with exuding chronic wounds deemed adequate by the Principle Investigator and Clinical Team for assigned treatment
32916164|NCT04959929|Experimental|Focal vibration therapy|Myovolt delivers vibration with a frequency between 50-80 Hz. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold. If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
32916165|NCT05710328|Experimental|Diagnostic (FDG-PET/CT scan)|Patients receive FDG IV, undergo PET/CT, receive standard of care chemotherapy, and undergo standard of care surgery on study.
32916166|NCT04941599|Active Comparator|2-Hydroxybenzylamine (2-HOBA)|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
32916167|NCT04941599|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for 6 weeks.
32916168|NCT05438420|Experimental|Dose escalation of Q702 in combination with fixed dose of pembrolizumab|Give one week on/one week off at selected dose level
32916169|NCT05438420|Experimental|Dose expansion of Q702 in combination with fixed dose of pembrolizumab|Give intravenously once every three week at 200 mg
32916170|NCT04901975|Experimental|Spironolactone|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation.~Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every ~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg.~Spironolactone administration will begin after the Fontan procedure in the hospital prior to discharge or at the first outpatient visit ~ 2 weeks after discharge."
32916171|NCT04901975|No Intervention|Observational|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
32916172|NCT04901975|No Intervention|Control|"The purpose of this study is to non-invasively characterize the fibrotic consequences of SV physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion (figure 1) along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.~Control subjects who are non-SV patients but who have normal heart function who are undergoing CMR for evaluation (eg patients undergoing CMR for vascular ring evaluation, family history of congenital heart disease but found to be normal, etc) will have study related MRI and CMR sequences performed."
33082176|NCT00242892|Experimental|1|Intra coronary measures of pressure
33246909|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
33246910|NCT00812721|Active Comparator|4|Systane (TM)
33246911|NCT00812721|Active Comparator|5|Systane Ultra (TM)
33246912|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
33246913|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
32916173|NCT04901975|No Intervention|Observational - 1A|"Subjects who were enrolled in this study in Spironolactone arm and patient's family would like to continue participation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
32916174|NCT05428592|Experimental|LVRNA009 study group|
32916175|NCT05428592|Active Comparator|CoronaVac® control group|
32916176|NCT04901741|Experimental|Arm 1: olaptesed pegol + pembrolizumab + nanoliposomal irinotecan + 5-FU + LV|
32916177|NCT04901741|Experimental|Arm 2: olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel|
33246914|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
33246915|NCT03994393|Active Comparator|Cohort 1|Participants with no evidence of T790M
33246916|NCT03994393|Active Comparator|Cohort 2|Participants with evidence of T790M
33246917|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
33246918|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
33246919|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
33246920|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
33246921|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
33246922|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
33246923|NCT04045119|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
33246924|NCT00818415|Experimental|Arm 1|
33246925|NCT00818415|Active Comparator|Arm 2|
33246926|NCT04045197|Experimental|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
33246927|NCT04045197|No Intervention|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
32916178|NCT05421416|Experimental|Loratadine Arm|Loratadine 10mg, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
32916179|NCT05421416|Placebo Comparator|Placebo Arm|Placebo capsule, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
32916180|NCT05078489|Experimental|Action-observation arm|Participants will be asked to watch videos of neck exercises without performing any exercise. The intervention will take approximately 15 minutes.
32916181|NCT05078489|Placebo Comparator|Placebo intervention|Participants will be asked to watch videos of landscapes. The intervention will take approximately 15 minutes.
32916182|NCT05710250|Experimental|Mindfulness based stress reduction (MBSR) program|15 students will follow a 6-week MBSR program with 2h30 sessions per week in group and daily exercises lasting 30-40 minutes per day.
32916183|NCT05710250|Active Comparator|Muscular relaxation program|15 students will follow a 6-week muscular relaxation program with 2h30 group sessions per week in group and daily exercises lasting 30-40 minutes per day.
32916184|NCT05074277|No Intervention|Control (8 hours nocturnal sleep)|Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
32916185|NCT05074277|Experimental|Simulated Night Shift Work|Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
32916186|NCT05710172|Experimental|Auditory Mirror Therapy Device|Modified 3M Peltor Tactical 300 Electronic Hearing Protector. The modification consists of connecting the left microphone to the right microphone tab on the circuit board, and vice versa.
32916187|NCT05710172|Sham Comparator|Sham Headphone Device|Non-Modified 3M Peltor Tactical 300 Electronic Hearing Protector
32916188|NCT05069597|Experimental|Run-in Period: Creon|Participants will receive Creon daily for 112 days.
32916189|NCT05069597|Experimental|Treatment Period: Creon|Participants will receive Creon daily for 112 days.
32916190|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; Unesbulin PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
32916191|NCT04876235|Experimental|LAMS group|place LAMS under endoscopic ultrasound. Direct endoscopic necrosectomy(DEN) was performed through the LAMS with a forward viewing gastroscope if necessary
32916192|NCT04876235|Active Comparator|DPPS group|Place DPPS under endoscopic ultrasound. When required, DEN was performed once the cystogastrostomy/duodenostomy tract had matured. This was done by first removing the stents followed by dilation of the tract with a radial expansion balloon and insertion of a forward viewing gastroscope through the tract for DEN
32916193|NCT04868045|Experimental|Patients with a history of thyroid hormone suppression (TSH<0.5 mU/L) for at least 5 years|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
33246928|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
33246929|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
32765501|NCT04304833|Active Comparator|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
32765502|NCT04304833|Experimental|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
32765503|NCT04912661|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
32765504|NCT04912661|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
32765508|NCT04391959|Experimental|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
32765509|NCT04391959|Experimental|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
32765510|NCT03429985|Experimental|FRRM Intervention|The experimental arm will receive the FRRM intervention.
32765511|NCT03429985|No Intervention|Control|The control arm will not receive the FRRM intervention.
32765512|NCT04921319|Experimental|VExUS-Guided Arm|Will receive 24 hour fluid balance target based on daily VExUS score.
32765513|NCT04921319|No Intervention|Usual Care Control Arm|Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.
32765514|NCT04939831|Experimental|1|the group of LRH
32765515|NCT04939831|Active Comparator|2|the group of ARH
32765516|NCT04921085||adult inpatients|adult inpatients with 7 categories of diseases (including digestive system, respiratory system, cardiovascular and endocrine system, tumor, nervous system, and urinary system)
32765517|NCT03357523|Experimental|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
32765518|NCT03357523|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
32765519|NCT04921475||Renal regional oxygen saturation|Renal regional oxygen saturation is measured by using near infrared spectroscopy during transcatheter aortic valve implantation
32765520|NCT04912349|Experimental|Test Group|Patients received the transurethral split of the prostate(TUSP) treatment.
32765521|NCT04912349|Active Comparator|Control Group|Patients received the transurethral resection of the prostate(TURP) treatment.
32765522|NCT04939753||Sevoflurane group|Patients that received sevoflurane while in ICU care.
32765523|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
32765524|NCT04402541|Experimental|CB-5339|Orally administered CB-5339
32765525|NCT04405037|Experimental|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
32765526|NCT04405037|No Intervention|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
32765527|NCT04509739|Experimental|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
32765528|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
32916194|NCT04868045|Experimental|Patients with no history of TSH suppression|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
32916195|NCT04311983|Active Comparator|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
32916196|NCT04311983|Experimental|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
32916197|NCT04841135|Other|Alzheimer disease group|
32715642|NCT05253404|No Intervention|Anesthesia remove endotracheal tube|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at MAC 2-3%, at the same time we perform suction secretions in endotracheal tube and oral cavity and give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
32715643|NCT05253404|Experimental|Switching endotracheal tube to laryngeal mask|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at 2.63%-2.97%, we perform suction secretions in endotracheal tube and oral cavity, then switching endotracheal tube to laryngeal mask. Then we discontinue inhalation anesthestic sevoflurane and support oxygen at the rate of 6L/min. At the same time, give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when sevofulrane at MAC 0.4, spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
32916198|NCT04841135|Other|Control|
32715644|NCT05204355||Scleroderma|Patients with Scleroderma will be imaged with UTE MRI to compare MRI with CT for identifying Interstitial Lung Disease
33246930|NCT04044963|Experimental|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
32715645|NCT05204355||Scleroderma ILD|Patients with Scleroderma ILD who are initiating treatment will be imaged using hyperpolarized 129Xe MRI to assess treatment efficacy.
32715646|NCT05310890|Experimental|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
32715647|NCT05310890|Other|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
33246931|NCT04044963|No Intervention|Control Group|This will consist of regular care, which is standard procedure.
33246932|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
32715648|NCT05199753|Experimental|LM-108 Dose Escalation|
33246933|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
32715649|NCT05199753|Experimental|LM-108 Dose Expansion|
32715650|NCT05199753|Experimental|LM-108 combination dose escalation|
32715651|NCT05199753|Experimental|LM-108 combination dose expansion|
32916200|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
33246934|NCT00813033|Other|patient decision aid|
33246935|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
32916201|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
33246936|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
33246937|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
33246938|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled~1 time per day 21 days"
33246939|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled~1 time per day 21 days"
32715652|NCT05253092|Other|Virtual mindfulness meditation|
32715653|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
32745887|NCT04811157|Experimental|Test group|Healthy adults consuming test product
32916202|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
32916203|NCT04803539|Active Comparator|Capecitabine|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
33082177|NCT04622566|Experimental|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
32916204|NCT04803539|Experimental|Capecitabine + Apatinib + Camrelizumab|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
32916205|NCT04799015|Experimental|Dexamethasone|Dexamethasone 10mg IV + metoclopramide 10mg IV
32916206|NCT04799015|Placebo Comparator|Placebo|Placebo IV + metoclopramide 10mg IV
32916207|NCT05710094|Experimental|Group 1|Single dose of 500ppm HOCl + 1 % HAc, or placebo
32916208|NCT05710094|Experimental|Group 2|Single dose of 500ppm HOCl + 2 % HAc, or placebo
32916209|NCT05710094|Experimental|Group 3|Single dose of 500ppm HOCl + 3 % HAc, or placebo
32916210|NCT05710094|Experimental|Group 4|Single dose of 1000ppm HOCl + 3 % HAc, or placebo
32916211|NCT05710094|Experimental|Group 5|Multiple doses (OD for 5 days) of xppm HOCl + x% HAc#
32715654|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
32916212|NCT05710094|Experimental|Group 6|Multiple doses (BID for 5 days) of xppm HOCl + x% HAc#
32916213|NCT05710094|Experimental|Group 7|Multiple doses (TID for 5 days) of xppm HOCl + x% HAc#
32916214|NCT05376176|Experimental|STN1010904 ophthalmic suspension 0.03% BID|
32916215|NCT05376176|Experimental|STN1010904 ophthalmic suspension 0.1% BID|
32916216|NCT05376176|Placebo Comparator|Placebo Vehicle BID|
32916217|NCT04792775|Experimental|Prolonged Exposure + Emotion Regulation Skills Training|Twelve, 90-minute sessions of Prolonged Exposure (PE) with Dialectical Behavior Therapy (DBT) Emotion Regulation Skills Training.
32916218|NCT04788251|Experimental|Exercise-based fall prevention intervention|To receive 7 weeks of exercise-based programme
32916219|NCT04788251|Other|Wait-list controls|To receive fall prevention resources while waiting for programme
32916220|NCT04349345||sperm count over time|observation
32916221|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
32916222|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
32916223|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
32916224|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
32715655|NCT05279768|Experimental|WJ-MSCs|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
32715656|NCT05279768|Experimental|Secretomes|Patients will be given tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
32715657|NCT05279768|Experimental|WJ-MSCs and Secretomes|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
32715658|NCT05279768|Placebo Comparator|Control|Patients will be given Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
32916225|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
32916226|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
32916227|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
32916228|NCT01602120|Experimental|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
32916229|NCT01602120|Experimental|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
32916230|NCT01602120|Experimental|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
32916231|NCT01602120|Experimental|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
33246940|NCT04044885|Experimental|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
33246941|NCT04044885|No Intervention|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
33246942|NCT00888004|Experimental|Active|
33246943|NCT00888004|Placebo Comparator|Placebo|
32715659|NCT05176431|Active Comparator|Focused extracorporeal shock wave therapy|
32916232|NCT04277117|Other|Waitlisted control|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~No meal delivery~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 4X a week"
32916233|NCT04277117|Experimental|"Daily Warm MTM in-person delivery"|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~10 medically-tailored meals (MTM) per week, delivered daily Mon-Fri~Each day, 1 hot and 1 frozen + snack delivered to the participant's home by trained volunteers and/or paid delivery drivers who provide human interaction.~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 4X a week"
32916234|NCT04277117|Experimental|"Weekly Frozen MTM drop shipment"|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~10 medically-tailored meals (MTM) delivered once a week~Each week all meals are frozen.~Meals are shipped to the participant's home with no human interaction~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 4X a week."
32916235|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
32715660|NCT05176431|Active Comparator|Radial extracorporeal shock wave therapy|
32715661|NCT05176431|Sham Comparator|Sham extracorporeal shock wave therapy|
32916236|NCT03094715|Other|Best medical care|Best medical treatment
32916237|NCT04777331|Experimental|Prasinezumab|"Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).~Participants will enter into the optional Open Label Extension (OLE) once the double-blind treatment period has completed."
32916238|NCT04777331|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion Q4W.
32916239|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
32916240|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
32916241|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
32916242|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
32916243|NCT05709938|Experimental|Glargine|Glargine-regular insulin regimen
32916244|NCT05709938|Active Comparator|NPH|NPH- regular insulin regimen
32916245|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
32916246|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
32916247|NCT03029039||blood donor voluntary|Blood samples will be collected.
32916248|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
32916249|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~ceftriaxone 500 mg intramuscularly 2 hours before the procedure~gentamicin 2mg/kg intramuscularly 2 hours before the procedure~amikacin 5 mg/kg intramuscularly 2 hours before the procedure~aztreonam 500 mg intramuscularly 2 hours before the procedure~imipenem 500 mg intramuscularly 2 hours before the procedure~ceftriaxone 2000 mg intravenously 1 hour before the procedure~gentamicin 2 mg/kg intravenously 1 hour before the procedure~amikacin 5mg/kg intravenously 1 hour before the procedure~aztreonam 2000 mg intravenously 1 hour before the procedure~imipenem 1000 mg intravenously 1 hour before the procedure"
32916250|NCT04755335|Other|Early detection of PAD, assessment of the disease progression and treatment response|"The objective of this arm of the study is to evaluate the potentials of Ultrasound Perfusion imaging technique for early detection of peripheral arterial disease in patients and assess the disease progression and monitor the treatment response.~The investigators anticipate that our new cost-effective and non-invasive ultrasound perfusion technique offers a quantitative imaging of perfusion and microvessels of cuff muscle that would separate PAD from non-PAD and help early detection of PAD and would help monitoring the disease progression and treatment response."
32916251|NCT05709782|Experimental|Group 1 (Therapeutic Cohort)|Participants in Group 1 will receive spine radiosurgery on the MR LINAC machine, along with imaging scans using the same machine.
32916252|NCT05709782|Experimental|Group 2 (Imaging-only Cohort)|Participants in Group 2 will receive spine radiosurgery using a standard radiation therapy machine and have the opportunity to get imaging on the MR LINAC.
33246944|NCT05537922||Retrospective Cohort|This cohort includes the analysis of a multicentric retrospective cohort of more than 2,000 patients. This cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model). All available clinical data will be collected. Also, CT and PET scans will be collected and a first radiomic signature.
33246945|NCT05537922||Prospective Cohort|The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients.
33246946|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
33246947|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
32742832|NCT04951869|No Intervention|Control group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, No Protescal gel was applied at the uterine suture site in this Control group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). No application of Protescal gel (0.5 mL) over the subcutaneous tissue prior to skin closure in this Control group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
32715662|NCT04422392|Experimental|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Thirteen cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
32715663|NCT04422392|Active Comparator|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
32715664|NCT04458987|Experimental|Expert patient in addictology|before/ after comparison, each patients being its own control
32715665|NCT04399863|Experimental|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
32715666|NCT05310266|Active Comparator|Group TAP|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
32715667|NCT05310266|Active Comparator|Group QLB|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
32715668|NCT05310032|Experimental|HSG4112 800 mg Single Dose|Single oral dosing of HSG4112 800 mg
32715669|NCT05310032|Experimental|HSG4112 1200 mg Single Dose|Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing
32715670|NCT05310032|Experimental|HSG4112 800 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
32715671|NCT05310032|Placebo Comparator|Placebo 800 mg Multiple Dose|Multiple oral dosing of placebo 800 mg for 14 days
32715672|NCT05310032|Experimental|HSG4112 1200 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
32715673|NCT05310032|Placebo Comparator|Placebo 1200mg Multiple Dose|Multiple oral dosing of placebo 1200 mg for 14 days
32715674|NCT05251532|Experimental|Kinesio Taping Group (KTG)|Distortion taping with Kinesio Tex will be applied to the patients in addition to conventional rehabilitation through a pediatric physiotherapist.
32715675|NCT05251532|Active Comparator|Conventional Rehabilitation Group (CRG)|Conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
32715676|NCT05627063|Experimental|ABSK121-NX|"Dose escalation of oral ABSK121-NX will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. Patients will receive a single dose of ABSK121-NX on Day -7 followed by a 7-day washout, as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD).~The dose escalation will start at 3 mg QD followed by dose escalation of a total of 8 potential dose levels. Once RDE is determined, an RDE-confirmation group of up to 24 more patients may be enrolled at the selected dose levels to further evaluate safety and efficacy (up to 12 per dose level/regimen), if approved by the sponsor. In addition, a preliminary food-effect (FE) may be evaluated in at least 6 patients from the RDE- confirmation part.~After the RDE is confirmed in the dose Escalation part, the dose Expansion phase will be conducted."
32715677|NCT03863067|Experimental|Lumbar spinal stenosis patients|Epiduroscopy in patients with lumbar spinal stenosis
32715678|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
32715679|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
32715680|NCT05219006|Experimental|ketogenic dieting + conventional treatment|Nutrition team will help patients implement an Atkins-type ketogenic diet. The diet should be continued for at least 6 weeks. They will be able to continue with the pharmacological-based treatment but without any changes having been made in the last 6 weeks or during the time they are in the study. To ensure adherence to the diet, urine ketones will be determined twice a week.
32715681|NCT05219006|Active Comparator|Healthy dieting + conventional treatment|In addition to their basic (pharmacological) treatment, the nutrition team will help them implement a low-calorie, non-ketogenic diet. The presence of ketones will also be determined in urine to avoid bias
32715682|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
32715683|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
32715684|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
32715685|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
32715686|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
32715687|NCT04257201|Active Comparator|Control -- no mushrooms|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
32715688|NCT04257201|Experimental|Yellow Oyster -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
32742833|NCT03251261||Specimen collection|
32715689|NCT04257201|Experimental|Yellow Oyster -- 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
32715690|NCT04257201|Experimental|White button -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
32715691|NCT04257201|Experimental|White button 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
32715692|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
32715693|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
32715694|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
32715695|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
32715696|NCT04167033|Experimental|Premature ovarian insufficiency|60 patients with POI followed in the endocrinology department
32715697|NCT04167033|Other|healthy volunteers|60 healthy volunteers matched with POI's patients
32715698|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
32715699|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
32715700|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
32715701|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
32715702|NCT05279456|Experimental|Spikogen vaccine - accelerated arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 2
32715703|NCT05279456|Experimental|Spikogen vaccine - standard arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 4
32715704|NCT05278988|Active Comparator|Group A|Treatment according to WHO MDR-TB treatment guidelines (2019).
32715705|NCT05278988|Experimental|Group B(PRS Regimen V)|bedaquiline, delamanid, clofazimine, pyrazinamide
32715706|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
32715707|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
32715708|NCT05277896|Active Comparator|Ketamine Group|Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
32715709|NCT05277896|Active Comparator|Etomidate Group|Patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
32715710|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
32715711|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
32715712|NCT03847701|Active Comparator|High in SDS|Balanced diet high in Slowly Digestible Starch
32715713|NCT03847701|Placebo Comparator|Low in SDS|Balanced diet low in Slowly Digestible Starch
32715714|NCT05249972|Experimental|AKP02|cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
32715715|NCT05249972|Active Comparator|Enstilar|cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
32715716|NCT05249972|Placebo Comparator|Placebo|cutaneous spray
32715717|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
32715718|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
32715719|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
32715720|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
32715721|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
32715722|NCT05277740||CIS|Diagnosis of Clinically Isolated Syndrome (CIS) with abnormal MRI.
32715723|NCT05277740||RRMS|Diagnosis of Relapsing-Remitting MS (RRMS).
32715724|NCT05277740||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
32715725|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
32715726|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
32715727|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
32715728|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
32715729|NCT05276726|Experimental|Phase 1 ,Dose Exploration ,monotherapy|Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D
32715730|NCT05276726|Experimental|Phase 2, Dose Expansion, Part1 monotherapy|Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)
32715731|NCT05276726|Experimental|Phase 2 Dose Expansion, Part 2 monotherapy|Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC
32715732|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
32742834|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
32916253|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: at consultations after inclusion in the study~faeces: day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
32715733|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
32715734|NCT05218460|Experimental|All subjects will have an MRI examination|
32715735|NCT05152251||Study Group|Down Syndrome
32715736|NCT05152251||Control Group|Typically Developing Children
32715737|NCT05378009|Experimental|group A|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
32715738|NCT05378009|Active Comparator|Group B|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
32715739|NCT05217680|Experimental|PRO-169|Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
32715740|NCT05217680|Active Comparator|Lucentis ®|Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
32715741|NCT03637023|Experimental|Virtual Reality|Virtual Reality will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
32715742|NCT03637023|Active Comparator|Exercise Therapy|Exercise Therapy will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
32715743|NCT05197673|Experimental|Intervention group|This arm will receive TPB intervention to build positive attitudes towards COVID-19 related preventive behaviour (e.g., good compliance with infection control measures, encouraging uptake of testing and vaccination), subjective norms (tackling strategies for perceived social pressure from others or normative beliefs), and improve perceived behavioural control towards risks of outbreaks in workplace.
32715744|NCT05197673|No Intervention|Control group|Control group will receive only general health information.
32715745|NCT05275790|Experimental|Vestal active device|10 subjects to receive an active device plus a diet plan for 12 weeks.
32715746|NCT02281552|Experimental|tofacitinib modified release tablet|
32715747|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
32715748|NCT03832647|Experimental|Salicylic acid & Epiduo 0.1%-2.5% Topical Gel|"Salicylic acid: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
32715749|NCT03832647|Placebo Comparator|Hydréane légère & Epiduo 0.1%-2.5% Topical Gel|"Hydréane légère: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
32715750|NCT00901979|Experimental|LCQ908 Dose 1|
32715751|NCT00901979|Experimental|LCQ908 Dose 2|
32715752|NCT00901979|Experimental|LCQ908 Dose 3|
32715753|NCT00901979|Experimental|LCQ908 Dose 4|
32715754|NCT00901979|Experimental|LCQ908 Dose 5|
32715755|NCT00901979|Placebo Comparator|Placebo|
32715756|NCT00901979|Active Comparator|Sitagliptin|
32715757|NCT05249582|Experimental|Virtual Reality Condition|Participants will be using a virtual reality headset to engage with a mountain climbing game.
32715758|NCT05249582|Active Comparator|Control Condition|Participants will be mimicking hand movements displayed on a television screen.
32715759|NCT03806361|Experimental|With ADRC|Supplementation of fat grafts with ADRC
32715760|NCT03806361|Active Comparator|Structural|Structural fat grafting
32715761|NCT05274074|No Intervention|Aim 1|
32715762|NCT05274074|Experimental|Aim 2|We will be utilizing the Life Enhancing Activities or Caregivers (LEAF) intervention to display that social networks' can be used as a means of reinforcing the positive life skills of the intervention; and that these same skills will enhance social networks, increase mutual satisfaction in social interactions, and boost motivation to reach out to others, thus combatting social isolation.
32715763|NCT03778671|Experimental|Group B|Patients will receive Levobupivacaine 5%
32715764|NCT03778671|Active Comparator|Group D|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine .
32715765|NCT03778671|Active Comparator|Group F|Patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
32715766|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
32715767|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
32715768|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
32715769|NCT05478434|Experimental|Robot and stimulation PPC-M1|Combined paired pulse stimulation (PAS) with robot-assisted therapy
32715770|NCT05478434|Sham Comparator|Robot and sham stimulation PPC-M1|Combined sham PAS with robot-assisted therapy
32715771|NCT03692715|Experimental|ciprofloxacin|Single dose oral or intravenous ciprofloxacin prior to shockwave lithotripsy
32715772|NCT03692715|Placebo Comparator|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
32742835|NCT04964661||SpA women MRI|Women affected by spondyloarthritis and performed a sacroiliac MRI
32916254|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
32916255|NCT05334368|Experimental|Depemokimab|All participants in this arm will receive depemokimab.
32916256|NCT05334368|Placebo Comparator|Placebo|All participants in this arm will receive placebo.
32916257|NCT04184375|Experimental|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
32715773|NCT05216120|Experimental|Pemigatinib|Participants will be provided with a bottle of pemigatinib tablets on Day 1 of each cycle (one cycle = 21 days). A bottle contains 4.5 mg X 42 tablets total. Each pemigatinib bottle is sufficient for one cycle. Resupply will be provided as necessary on Day 1 of each cycle.
32916258|NCT04184375|No Intervention|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
32916259|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
32916260|NCT05304728||Primary Objective: Severe Sepsis|The primary endpoint for this study is defined as the presence of sufficient data for SOWS training and algorithm development to proceed with subsequent validation. To provide sufficient data subsets (severe sepsis EHR encounters) for training and validation of the Sepsis Onset Warning System algorithm. There will not be any interventions administered.
32916262|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
32916263|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
32715774|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
32715775|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
32715776|NCT03558789||MT|patients complaining about metallic taste before, during or after treatment of head and neck cancer.
32916264|NCT02947529|Placebo Comparator|Hemiarthroplasty - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
32916265|NCT02947529|Experimental|Intramedullary nail - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
32916266|NCT02947529|Experimental|Hemiarthroplasty - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
32916267|NCT02947529|Placebo Comparator|Intramedullary nail - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
32916268|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
32916269|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
32916270|NCT04725305|Experimental|BiZact|A bipolar electrosurgical device that employs radiofrequency(RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger
32916271|NCT04725305|Active Comparator|Standard of care|In electrocautery tonsillectomy (or diathermy) electric current from a radiofrequency generator is passed through the tissue between two electrodes. The resulting high temperature (400º-600ºC) cuts the tissue and simultaneously seals the blood vessels
32916272|NCT04173221|Experimental|Intervention|
32715777|NCT03558789||No-MT|patients not complaining about metallic taste before, during or after treatment of head and neck cancer.
32745888|NCT04811157|Placebo Comparator|Control group|Healthy adults consuming control product
32916273|NCT04173221|Other|Control|
32916274|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
32916275|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
32916276|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
32916277|NCT02986529|Placebo Comparator|Placebo|Oral
32916278|NCT02296853|Experimental|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
32916279|NCT02296853|Active Comparator|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
32916280|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
32916281|NCT02683265|Experimental|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
32916282|NCT02683265|Placebo Comparator|Placebo comparator|Placebo capsules
32916283|NCT02987829|Experimental|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
32916284|NCT02987829|Experimental|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
32916285|NCT02987829|Experimental|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
32916286|NCT02987829|Experimental|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
32715778|NCT05215496|Experimental|[18F]fluoro-PEG-folate PET/CT scan|Patients with FIGO stage IIIB/IIIC epithelial ovarian cancer, 185 MBq of [18F]fluoro-PEG-folate.
32715779|NCT05161091|Experimental|Radio-induced oral mucositis / Medical Device|Patient with radio-induced oral mucositis at least grade 2 treated with experimental medical device
32916287|NCT02987829|Experimental|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
32916288|NCT02987829|Experimental|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
32916289|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
32916290|NCT02989545|No Intervention|Off treatment|2 week period without intervention
32916291|NCT02989545|Experimental|Treatment period|2 week period with intervention
32916292|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
32916293|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
32916294|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
32715780|NCT05161091|Placebo Comparator|Radio-induced oral mucositis / Placebo comparator|Patient with radio-induced oral mucositis at least grade 2 treated with placebo
32715781|NCT05161091|Experimental|Chemo-induced oral mucositis / Medical Device|Patient with chemo-induced oral mucositis at least grade 2 treated with experimental medical device
32715782|NCT05161091|Placebo Comparator|Chemo-induced oral mucositis / placebo comparator|Patient with chemo-induced oral mucositis at least grade 2 treated with placebo
32916295|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
32916296|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
32916297|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
32916298|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
32715783|NCT03495921|Experimental|Vigil + Irinotecan and Temozolomide|"Group A Schedule:~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days Vigil 1.0 x 10e6 cells/injection, intradermal, Day 15, every 21 days for a minimum of 4 administrations to a maximum of 12 administrations depending on quantity of Vigil manufactured from surgical specimens and so long as the patient is clinically stable and without disease progression.~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
32745889|NCT04811391||Vaccinated participants|Participants who have received 2 doses of the pfizer Covid-19 vaccine or 1 or dose of the Astra Zeneca Covid-19 Vaccine
33082178|NCT04622488|Active Comparator|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
33246948|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
33246949|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
32916299|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
32916300|NCT05108571|Experimental|Sequence A|
32916301|NCT05108571|Experimental|Sequence B|
32916302|NCT05098275|Experimental|Sequence A|
32916303|NCT05098275|Experimental|Sequence B|
32916304|NCT05031351|Experimental|High dosage Withania somnifera|544mg oral twice a day
32916305|NCT05031351|Experimental|Medium dosage Withania somnifera|272mg oral twice a day
32916306|NCT05031351|Placebo Comparator|Placebo|Matched capsules twice a day
32916307|NCT05709704||Postpartum Women WITH DRA|Participants who have the diagnosis of diastasis rectus abdominis
32916308|NCT05709704||Postpartum Women WITHOUT DRA|Participants who do not have a diagnosis of diastasis rectus abdominis
32916309|NCT05709548|No Intervention|control group|patients who undergo urgent laparoscopic cholecystectomy according to the usual technique without the administration of indocyanine green
32715784|NCT03495921|Active Comparator|Irinotecan and Temozolomide|"Group B Schedule:~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study.~Within 6 weeks of second relapse or progression, subjects randomized to Group B, will be allowed to cross-over to receive single agent Vigil every 21 days following End of Treatment assessments. Subjects who cross-over may receive up to 12 doses of Vigil depending upon the quantity of Vigil manufactured. Cross-over must occur within 2 years of End of Treatment assessments of Group B enrollment."
32715785|NCT00890591|Experimental|Treatment|
32715786|NCT05248334|Experimental|Ranibizumab group|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
32715787|NCT05248334|Active Comparator|PPV group|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
32715788|NCT05214560||All participants|Participants who require a BD Spinal needle
32715789|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
32715790|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
32715791|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
32715792|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
32916310|NCT05709548|Active Comparator|intervention group|Patients who undergo urgent laparoscopic cholecystectomy for acute cholecystitis with the administration of indocyanine green preoperatively.
32916311|NCT04993209|Experimental|NDV-HXP-S 1μg|NDV-HXP-S 1μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
32916312|NCT04993209|Experimental|NDV-HXP-S 3μg|NDV-HXP-S 3μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
33082179|NCT04622488|Experimental|Calcium Hydroxide|
33082180|NCT00220298|Experimental|Arm 1|
32715793|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
32715794|NCT05214404||Ulcerative colitis group|Patients with ulcerative colitis as observation group
32715795|NCT05214404||Non-ulcerative colitis group|Non-ulcerative colitis as control group
32715796|NCT03317223|Experimental|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
32715797|NCT03317223|Active Comparator|Lansoprazole/Clarithromycin/Amoxicillin|Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
32715798|NCT00889889|Experimental|1|
32715799|NCT00889889|Placebo Comparator|2|
32715800|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
32715801|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
32715802|NCT05273138||Systemic sclerosis patients|Patients fulfilling the ACR/EULAR criteria for systemic sclerosis
32715803|NCT05273138||Healthy subjects|
32715804|NCT02566863|Experimental|Dexmedetomidine|Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure
32715805|NCT05137847||Remitoro|Participants with recurrent or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) will be administered with Remitoro 9 microgram per kilogram (mcg/kg), intravenous (IV) infusion, over 1 hour once daily for 5 consecutive days followed by 16 days withdrawal period in a 21 day cycle (up to maximum of 8 cycles). The dosage will be adjusted depending on the condition of the participant. All the participants will be observed for up to 24 weeks prospectively.
33082181|NCT04622761|No Intervention|control|Immediate surgery (radical prostatectomy) (standard care)
32916313|NCT04993209|Experimental|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscularly, with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
32916314|NCT04993209|Active Comparator|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU dose (0.5 mL) with an interval of 28 days apart Intramuscular (deltoid). In the original version of protocol, the control arm consisted in placebo use. There was a changing post hoc to Adsorbed inactivated COVID-19 vaccine (CoronaVac) due to decision of Data and Safety Monitoring Board, when 219 (50% of original sample) subjects have already included in the study. Therefore, those who received a placebo at the first vaccine visit started to receive active control vaccine and those who were included from that moment forward received two doses of active control vaccine. The original study protocol provided for the inclusion of the placebo arm (10% of population of study), in order to serve as a control for safety evaluations and to assess the attack rate of natural infection to which participants will be exposed during the study.
33246950|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
33246951|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
33246952|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
33246953|NCT00890188|Experimental|THALIDOMIDE and UFUR|
33246954|NCT05388942|Experimental|Virtual reality hypnosis (VRH)|
33246955|NCT05388942|Active Comparator|Nitrous oxide (NO)|
33246956|NCT04037566|Experimental|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
33246957|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
33246958|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
33246959|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
33246960|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
33246961|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
33246962|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
32715806|NCT02434263|Experimental|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
32745890|NCT04811391||Unvaccinated participants|Have not received any doses of any form of COVID-19 vaccine
32916315|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
32916316|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
32916317|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
32916318|NCT05274230|Experimental|MDMA-Assisted Psychotherapy Participants|Participants who have completed the MDMA-Assisted Psychotherapy and consented to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
32916319|NCT04905459||Retinal Imaging and Mydriatic Agents|Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.
33246963|NCT04062162|Active Comparator|Interventional group|Walking football training
33246964|NCT04062162|No Intervention|Control group|Usual care
33246965|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
33246966|NCT05630352|Experimental|Dose level 1|Injection in the muscle at 0-, 8-, and 16-weeks.
33246967|NCT05630352|Experimental|Dose level 2|Injection in the muscle at 0-, 8-, and 16-weeks
33246968|NCT05630352|Experimental|Dose level 3|Infection in the muscle at 0-, 8- and 16- weeks
33246969|NCT05630352|Experimental|Dose level 4|Injection in the muscle at 0-, 8- and 16- weeks
33246970|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
33073236|NCT03277924|Experimental|Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS|C1-6: Adults, IP d1-14 sunitinib 37.5mg/d then MP sunitinib 25mg/d+nivolumab 240mg ev 2 weeks. Pediatrics, IP d1-14 sunitinib 25mg/d, if BSA>1.7 sunitinib 37.5mg/d and MP sunitinib 25mg/d+nivolumab (dose weight dependent). C7a level 0: Epirubicin 60mg/m2/d, d1,2, ifosfamide 3g/m2/d d1-3 and nivolumab 360mg. 3 or more DLTs level -1 same treatment than in level 0, but nivolumab 240mg. C7b level 0: Doxorubicin 75mg/m2/d, d1, dacarbazine 400mg/m2/d (also on d2) and nivolumab 360mg. 3 or more DLTs level -1 same tratment than in level 0, but nivolumab 240mg. GCSF support is mandatory. 1-year maintenance of nivolumab. C8 level 0: In the IP, CDDP 120mg/m2 (d1-2), doxorubicin 75mg/m2 in (d3-4 and d36-39), nivolumab 240mg (d5), and on d18,39,53 and methotrexate 12g/m2 on d22,29,57,64, surgery and MP with nivolumab on d210, every 2 weeks up to d364. 3 or more DLTs level -1, with nivolumab 360mg on d4,36, surgery and MP with nivolumab on d210, ev 3 weeks up to d364.
33073237|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
33073238|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
33246971|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
33246972|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
33246973|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
33246974|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
33246975|NCT05617014||Cognitively Normal (CN)|700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.
33246976|NCT05617014||Mild Cognitive Impairment (MCI)|450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.
33246977|NCT05617014||Dementia (DEM)|350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.
33246978|NCT05045820|Active Comparator|Treatment|
33246979|NCT05045820|Sham Comparator|Sham|
33246980|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
33246981|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
33246982|NCT05486286|Experimental|video assisted NG placement|This is a single-arm study. A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes.
33246983|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
33246984|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
33246985|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
33246986|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
33246987|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
33246988|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
33246989|NCT00890578||2-breast|half breast surgeries (20 out of 40)
33246990|NCT00890734|Experimental|1|
33246991|NCT00890734|Placebo Comparator|2|
33246992|NCT00890812||Factors VIII, IX and XI levels measured|Case group
33246993|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
33246994|NCT04061772|Experimental|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
33246995|NCT05333874|Active Comparator|Neoadjuvant chemotherapy|"If Circulating tumor DNA (ctDNA) blood test is positive, change in treatment can be made. Participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery.~The participant's core biopsy specimens will be sent to NateraTM to sequence the primary tumor. The baseline blood work for ctDNA will be collected prior to the initiation of systemic therapy. Subsequently, ctDNA will be collected prior to each cycle of neoadjuvant chemotherapy. Participants will undergo surgery and ctDNA needs to be collected fourteen days post-surgery The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months, 12months and 24 months post-operatively."
33246996|NCT05333874|Other|Observational|Observation for triple negative breast cancer (TNBC): No adjuvant chemotherapy. Patients may complete checkpoint inhibitor from neoadjuvant setting. human epidermal growth factor receptor 2 (HER2) positive breast cancer: complete twelve months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for Circulating tumor DNA (ct-DNA) re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
32916320|NCT05263934|Experimental|Participants receiving depemokimab+placebo matching mepolizumab|
32916321|NCT05263934|Active Comparator|Participants receiving mepolizumab+placebo matching depemokimab|
32916322|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
32916323|NCT05249192|Experimental|Immediate UC removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
32916324|NCT05249192|Active Comparator|Early UC removal|Urinary catheter removal on first postoperative day (6 a.m.) as per standard protocol
32916325|NCT05231798|Experimental|Down Syndrome|Adults between 18-55 with Down Syndrome.
32916326|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
32916327|NCT05226104|Other|Healthy Participants|Subjects who are interested in treatment for facial fine lines and wrinkles will be recruited for the study.
32916328|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
32916329|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
32916330|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
32916331|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
32916332|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
32916333|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
33399820|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
32916335|NCT03167541|Experimental|1|Treatment Order: Test, Reference
32916336|NCT03167541|Experimental|2|Treatment Order: Reference, Test
32916337|NCT03168321|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
32916338|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
32916339|NCT04817085|Experimental|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
32916340|NCT04817085|Active Comparator|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
32916341|NCT04786587||Pregnant woman|
32916342|NCT04531293|Other|Total-breath method followed by standard method|Total Lung Capacity (TLC) measurement performed on device EasyOne Pro (TM) according to total-breath method followed by TLC measurement performed on device MasterScreen (TM) according to standard method.
32916343|NCT04531293|Other|Standard method followed by total breath method|Total Lung Capacity (TLC) measurement performed on device Masterscreen (TM) according to standard method followed by TLC measurement performed on device EasyOne Pro (TM) according to total-breath method.
33246997|NCT04061928|Experimental|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
32916344|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
32916345|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
32916346|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
32916347|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
32916348|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
32916349|NCT01662908|Experimental|edoxaban tosylate|
32916350|NCT01662908|Active Comparator|heparin/warfarin|
32916353|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
32916354|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
32916355|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
32916356|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
32916357|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
32916358|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
32916359|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
32916360|NCT03717207||type 2 diabetes mellitus (T2DM) patients under SGLT2-I therapy (SGLT2-I users)|"T2DM patients affected by vaso vagal syncope, and under SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.~."
32916361|NCT03717207||type 2 diabetes mellitus (T2DM) patients without SGLT2-I therapy (Non-SGLT2-I users)|T2DM patients affected by vaso vagal syncope, and without SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.
32916362|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
32916363|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
32916364|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
32916365|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
32916366|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
32916367|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
32916368|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
32916369|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
32916370|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
32916371|NCT05709314|Experimental|AMDX-2011P 50 mg|AMDX2011P 50mg (2ml) single bolus injection intravenous for diagnostic review
32916372|NCT05709314|Experimental|AMDX-2011P 100 mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
32916373|NCT05709314|Experimental|AMDX-2011P 150 mg or 200 mg|AMDX2011P 200mg (6-8ml) single bolus injection intravenous for diagnostic review
32916374|NCT05709314|Experimental|AMDX-2011P TBD|AMDX2011P (dose TBD) single bolus injection intravenous for diagnostic review
32916375|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
32916376|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
32916377|NCT04525599|Experimental|Group 1, ASP3772 Low Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a low-dose level.
32916378|NCT04525599|Active Comparator|Group 1, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
32916379|NCT04525599|Experimental|Group 2, ASP3772 Medium Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a medium-dose level.
32916380|NCT04525599|Active Comparator|Group 2, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
32916381|NCT04525599|Experimental|Group 3, ASP3772 High Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a high-dose level.
32916382|NCT04525599|Active Comparator|Group 3, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
32916383|NCT04479735|Experimental|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
32916384|NCT04479735|No Intervention|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
32916385|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
32745891|NCT04811313|Active Comparator|T group|each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.
32916386|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
32916387|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
32916388|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
32916389|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
32916390|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
33399821|NCT04167462|Experimental|Arm A:BMS-986165 oral administration|
32916391|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
33246998|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
33246999|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
33247000|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
33247001|NCT00699582|Experimental|1|
33247002|NCT00699582|Experimental|2|
32916392|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
32916393|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
32916394|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
32916395|NCT03543111|No Intervention|Control|No intervention - Control participants are provided intervention materials at the end of the study.
32916396|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
32916397|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
32916398|NCT03525951|Other|Typically Developing Children Study 2 (TD2)|No-intervention comparison group measured over time.
32916399|NCT03525951|Experimental|Children with Dev Language Disorder Study 2 (DLD2)|Enhanced Milieu Teaching
32916400|NCT03525951|Experimental|Children with Autism Spectrum Disorders Study 2 (ASD+DLD 2)|Enhanced Milieu Teaching
32916401|NCT03525951|Other|Typically Developing Children Study 1 (TD1)|No-intervention group for observational data comparison.
32916402|NCT03525951|Other|Children with Dev Language Disorder Study 1 (DLD1)|No-intervention group for observational data comparison.
32916403|NCT05183828|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD for 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of saliva samples. If tumor resection occurs before or after day 22, letrozole administration must occur for a minimum of 14 days and a maximum of 70 days of total treatment.
32916404|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
32916405|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
32916406|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
32916407|NCT05709236|Experimental|Completely edentulous maxillary arch digital impression|treated with Maxillary screw-retained prosthesis with digital full-arch impression
32916408|NCT05709236|Active Comparator|Completely edentulous maxillary arch conventional impression|treated with Maxillary screw-retained prosthesis with conventional full-arch impression
32916409|NCT03471663|Experimental|D-0502|D-0502
32916410|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
33247003|NCT00699582|Placebo Comparator|3|
33247004|NCT05593770|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
33247005|NCT05593770|Placebo Comparator|Placebo|"Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
33247006|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
32916411|NCT04360239|Experimental|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
32916412|NCT04360239|No Intervention|Control|No fish oil supplementation
32916413|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
32916414|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
32916415|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
32916416|NCT01665092|Placebo Comparator|Control|Normal saline
32916417|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
33247007|NCT04645173||TYRX Envelope|Participants who received a TYRX envelope during CIED implantation
33247008|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
32916418|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
32916419|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
32916420|NCT04348695|Experimental|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days."
32916421|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
32916422|NCT04344561|Experimental|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
32916423|NCT04344561|No Intervention|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
33247009|NCT04062084|Experimental|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
32916424|NCT05709158||Case: G4 neutropenia occurs after palbociclib initiation|Grade 4 neutropenia occurs after initiation of palbociclib Note that: Case patients are categorized as control before incurring grade 4 neutropenia
32916425|NCT05709158||Control: G4 neutropenia does not occur after palbociclib initiation|Grade 4 neutropenia does not occur after initiation of palbociclib
32916426|NCT04316871|Placebo Comparator|Group D|where patients will receive epidural 15 ml of Marcaine 25% and and epinephrine 1:200,000.
32916427|NCT04316871|Active Comparator|Group A|where patients will receive epidural 15 ml volume of 1.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
32916428|NCT04316871|Active Comparator|Group B|where patients will receive epidural 15 ml volume of 3 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
32916429|NCT04316871|Active Comparator|Group C|where patients will receive epidural 15 ml volume of 4.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
32916430|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
32916431|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
32916432|NCT01665170|Placebo Comparator|Placebo|Placebo arm
32916433|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
32916434|NCT04292145|Experimental|Relaxation Application|Participants will follow the relaxation application.
32916435|NCT04292145|Active Comparator|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
32916436|NCT04704869|Experimental|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
33247010|NCT04062084|Experimental|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
33247011|NCT05592366|No Intervention|Standard of Care|Participants in this arm will only receive standard of care.
33247012|NCT05592366|Experimental|Adjusted CHAT-AD|Using CHAT, participants will be asked questions about their needs to fully support and care for their loved one after the loved one is released from the hospital.
33247013|NCT00640341|Experimental|PureVision|PureVision Contact Lens
33247014|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
33247015|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
33247016|NCT00816153|Experimental|PVI|PVI guided fluid management
33247017|NCT00816153|No Intervention|Control|
32916437|NCT04704869|Active Comparator|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
33247018|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
32916439|NCT04142385||Observational (health information collection)|Participants receive a questionnaire, undergo a targeted physical and anal clinical exam, undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for cytology and HPV DNA at months 0, 6, and 12. Participants also undergo HRA and penile clinical exam at month 12.
32916440|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
32916441|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
33247019|NCT00699348|Experimental|C.E.R.A.|
33247020|NCT05480670|Experimental|Berberine arm|Participants in this group will receive an oral 550 mg Berberine supplement tablet BDS for 3-months as an add-on to the changes in the diet/life-style for 3-months. The changes in the diet/life-style include limiting fat and carbohydrate intake and improve dietary behavior without the application of a calorie-restricted diet program. Exercise will also be recommended to include 30 min/day of moderate to intense activity.
33247021|NCT05480670|No Intervention|Control arm|Participants in this group will undergo changes in their diet/life-style.
33247022|NCT05327634||Deprescribing|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
33247023|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
33247024|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
33247025|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
33247026|NCT05317026|Experimental|V-SBRT|Vertebroplasty followed by Stereotactic Body Radiation Therapy (SBRT)
33247027|NCT05317026|Other|SBRT|SBRT is the actual standard of care.
32765529|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
33247028|NCT05316324|Experimental|Prepectoral Breast Reconstruction with ADM|
33247029|NCT05316324|Experimental|Prepectoral Breast Reconstruction without ADM|
33247030|NCT05575830|Experimental|RZV or Shingrix®)|Recombinant Zoster Vaccine
33247031|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
33247032|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
32765530|NCT04930679|Experimental|Group I|1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
33247033|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
33247034|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
33247035|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
33247036|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
33247037|NCT04987788|Experimental|Motívate group|Participants will engage with an app on an iPad, smartphone or computer.
33247038|NCT04987788|Active Comparator|Control Group|Participant receive a link to watch a general health information video.
33247039|NCT03667690|Experimental|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
33247040|NCT03667690|Active Comparator|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
33247041|NCT00821535|Other|Active group|maraviroc dosing group
33247042|NCT04062006|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
33247043|NCT04872582|Experimental|PD-1 immune checkpoint inhibitor combined with bevacizumab|
33247044|NCT04061538|Experimental|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
33247045|NCT04061538|Placebo Comparator|Placebo|Placebo tablet, once a day for 10 days
33247046|NCT04388748|Experimental|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
33247047|NCT04388748|No Intervention|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
33247048|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
33247049|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
33247050|NCT04351620|Experimental|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
33247051|NCT00888394|Experimental|1|
33247052|NCT00888394|Experimental|2|
33247053|NCT00888394|Experimental|3|
33247054|NCT00888394|Experimental|4|
33247055|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
33247056|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
33247057|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
33247058|NCT02541760|No Intervention|Control|No intervention
33247059|NCT00888472|Experimental|1|
33247060|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
32765531|NCT04930679|Experimental|Group II|2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
32765532|NCT04436185|No Intervention|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
32765533|NCT04436185|Experimental|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
32765534|NCT04436185|Experimental|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
33247061|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
33247062|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
33247063|NCT04534959|No Intervention|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
33247064|NCT04534959|Experimental|Post-Implementation Targeting Normoxemia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxemia intervention period of the stepped-wedge implementation process (up to 25 months).
33247065|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
33247066|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
32765535|NCT04400201|Experimental|Remimazolam Tosilate|
33073239|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
33399822|NCT04167462|Placebo Comparator|Arm B: Placebo oral administration|
32765536|NCT04400201|Active Comparator|Propofol|
32765537|NCT05434845|No Intervention|UA and PC ratio on original sample|Original urine sample
32765538|NCT05434845|Active Comparator|UA and PC ratio with 1 mL of whole blood added|1 mL of whole blood added to 20 mLs of urine
32765539|NCT05434845|Active Comparator|UA and PC ratio with 2 mL of whole blood added|2 mL of whole blood added to 20 mLs of urine
32765540|NCT05434845|Active Comparator|UA and PC ratio with 5 mL of whole blood added|5 mL of whole blood added to 20 mLs of urine
32765541|NCT04920773|Experimental|Ayurveda Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
32765542|NCT04920773|Active Comparator|Usual Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
32765543|NCT04423107|Active Comparator|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
32765544|NCT04423107|Active Comparator|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
32765545|NCT01675531|Experimental|Targin|Targin
32765546|NCT04920851||Covid with sepsis|Covid patient with sepsis
32765547|NCT04920851||covid without sepsis|Covid patient without sepsis
32765548|NCT05406999|Active Comparator|ADT alone + prostatectomy|A total of 100 subjects receive ADT for 6 cycles (28 days per cycle) before prostatectomy. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765549|NCT05406999|Experimental|ADT plus Abiraterone|A total of 150 subjects in this group received abiraterone acetate + prednisolone acetate daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765550|NCT05406999|Experimental|ADT plus Enzalutamide|A total of 50 subjects in this group received enzalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765551|NCT05406999|Experimental|ADT plus Apalutamide|A total of 150 subjects in this group received apalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765552|NCT05406999|Experimental|ADT plus Darotamide|A total of 150 subjects in this group received darotamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765553|NCT05406999|Experimental|ADT plus Rizvilutamide|A total of 150 subjects in this group received rizvilutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765554|NCT05406999|Experimental|PARP inhibitor + abiraterone + ADT|A total of 100 subjects in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor plus abiraterone along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765555|NCT05406999|Experimental|PARP inhibitor + ADT|A total of 50 subjects in this group in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor along with ADT mentioned above. Enrolled patients carry homologous recombination repair (HRR) gene mutation verified by molecular testing. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
32765556|NCT05118607|Other|Intervention (IG1)|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency
32765557|NCT04930211|Active Comparator|Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
32765558|NCT04930211|Active Comparator|Degenerative disc disease without Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
32765559|NCT03177265|Experimental|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
32765560|NCT03177265|Other|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
32765561|NCT03177265|Experimental|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
32765562|NCT03177265|Active Comparator|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
32765563|NCT03054311|Experimental|Lifestyle Matters intervention|
32765564|NCT04851145|Experimental|Experimental|
32765565|NCT04912271|Experimental|Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone|Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
32765566|NCT04912271|Active Comparator|Palonosetron, aprepitant or fosaprepitant, dexamethasone|Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
32765567|NCT02807779|Experimental|Dexamethasone|Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
32765568|NCT02807779|Active Comparator|Drug Coated Balloon|Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
32765569|NCT02807779|Active Comparator|Plain Balloon Angioplasty|Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.
32765570|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
32765571|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
32765572|NCT05406531|Experimental|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT-Ca uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
32765573|NCT05406531|Experimental|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
32765574|NCT05406531|Experimental|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
32765575|NCT05406531|No Intervention|Waiting list|No intervention.
32765576|NCT02769091|Experimental|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
32765577|NCT02769091|Placebo Comparator|Placebo|Matching placebo
32765578|NCT04912193||antithrombin III < 50 %|preoperative antithrombin III levels <50%
32765579|NCT04912193||Antithrombin III ≥ 50 %|preoperative antithrombin III levels ≥ 50 %
32765580|NCT02680561|Experimental|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
32765581|NCT02680561|Experimental|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
32765582|NCT02680561|Active Comparator|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
32765583|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
32765584|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
32765585|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
32765586|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
32765587|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
32765588|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
32765589|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
32765590|NCT05118373|Other|Exposure|The campaign targets 3 TV stations, 8 radio stations, 2 billboard companies and social media platforms including YouTube, Twitter, Facebook, Instagram and LinkedIn with an anticipated reach of 1,433,201 people in Lusaka and Copperbelt provinces. Of the targeted TV and radio media houses, two each are national stations and will reach beyond these two intervention provinces including to Central and Southern province with an estimated 8% and 11% mass-media penetration compared to 21% and 38% for Copperbelt and Lusaka respectively.
32765591|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
32765592|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
32765593|NCT05116111|Experimental|SYHA1402 1000 mg plus placebo 500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1000 mg and placebo 500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
32765594|NCT05116111|Experimental|SYHA1402 1500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
32765595|NCT05116111|Placebo Comparator|Placebo 1500 mg|Eligible patients will be randomly assigned to receive placebo 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
32765596|NCT04929977|Other|Wearable device with smart mobile phone|20 mother/care provider-infant pairs practicing Kangaroo Mother Care, from a tertiary super-specialty hospital selected to wear the device ( few days in the hospital and for a week at home when discharged)
32765597|NCT05095051|Experimental|Healthy subjects|To assess safety and tolerability of limb cryocompression, as well as to determine the optimal temperature and pressure to be used. The occurrence or lack of core hypothermia will be studied.
32765598|NCT05095051|Experimental|Cancer patients|Once the optimal temperature and pressure of limb cryocompression is established in healthy subjects, a group of cancer patients will undergo limb cryocompression over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
32765599|NCT05597631|No Intervention|Control|Control
32765600|NCT05597631|Experimental|G-IVF PLUS|G-IVF PLUS
32765601|NCT04912037|Experimental|with AI-assisted system|The novice doctors are trained in colonoscopy with an artificial intelligence assisted system that can indicate abnormal lesions and the speed of withdrawal in real time, as well as feedback on the percentage of overspeed.
32765602|NCT04912037|No Intervention|without AI-assisted system|The novice doctors receive routine colonoscopy training without artificial intelligence assistance system and no special tips
32765603|NCT04824469|Experimental|web based training|"Patients on the first day; Patient Information Form (1st and 2nd part), Memorial Symptom Assessment Scale, Covid-19 Symptom Assessment Inventory, Morisky Compliance Scale, World Health Organization Quality of Life Scale Short Form Turkish Version, E-Health literacy scale on website or mobile devices Google via the form or by sending a phone link.~Morisky Compliance Scale will be applied on the 7th day by sending a link to the website or mobile devices via google form.~Patients in the intervention group will be asked to fill out the Covid-19 Symptom Assessment Inventory on the website when they experience changes in their symptoms.~Patients in the intervention group will be provided with web-based training and telephone (SMS) reminder service for 4 weeks.~All questionnaires and web site evaluation form will be filled in the pre-test after 4 weeks."
32765604|NCT04824469|No Intervention|standard care|The scales applied to the intervention group on the first day, by sending the E-Health literacy scale form or phone link via Google on mobile devices. The symptoms of the patients in the control group will be evaluated at the end of the 1st day, 7th day, 14th day and 4th day. No intervention was planned for the patients in the control group during the follow-up. In the standard practice protocol, after patients are informed for follow-up and treatment at home, they are called by the Ministry of Health and family physicians for symptom follow-up. The standard hospital protocol does not include a scheduled training program, telephone monitoring, or web-based training. After collecting the data in the intervention group, the website will be opened to the use of the control group.
32765605|NCT04258059|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
32765606|NCT04258059|Sham Comparator|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
32765607|NCT05071183|Experimental|TPX-0005 + Trametinib|"TPX-0005 + Trametinib Dose Escalation and Dose Expansion~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC"
32765608|NCT05406063|Experimental|SBRT with 9 Gy x 3 fractions to the treatment site.|Patients will be treated with SBRT delivering 9 Gy x 3 fractions (BED10: 51.3 Gy) to the treatment site.
32765609|NCT05406063|Active Comparator|SBRT with 7 Gy x 5 fractions to the treatment site|Patients will be treated with SBRT delivering 7 Gy x 5 fractions (BED10: 59.5 Gy) to the treatment site.
32765610|NCT05037097|Experimental|Study Group 1, Adult Participants Not Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29
32765611|NCT05037097|Experimental|Study Group 2, Adult Participants Not Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
32765612|NCT05037097|Experimental|Study Group 3, Adult Participants Not Previously Vaccinated to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
32765613|NCT05037097|Experimental|Study Group 4, Adult Participants Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1
32765614|NCT05037097|Experimental|Study Group 5, Adult Participants Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1
32765615|NCT05037097|Experimental|Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1
32765616|NCT05025163|No Intervention|control group|no intervention in the control group
32765617|NCT05025163|Experimental|fluoride foam group|intervention; fluoride foam application (with 1.23% fluoride foam application on teeth )
32765618|NCT05025163|Experimental|fluoride varnish group|intervention; fluoride varnish application (with 2.26% fluoride varnish application on teeth)
32765619|NCT02674321|Experimental|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
32765620|NCT05070637|Experimental|No-touch laparoscopic radical nephrectomy|Group A patients will undergo a no-touch laparoscopic radical nephrectomy, with the dissection being done through the Gerota's fascia plane until exposure of the corresponding great vessel (vena cava on the right side, and aorta on the left side) is obtained. The renal pedicle will be directly isolated, and ligated using Weck® clips with no kidney manipulation.
32765621|NCT05070637|Active Comparator|Conventional laparoscopic radical nephrectomy|Group B patients will undergo a conventional laparoscopic radical nephrectomy approach, starting with opening of the Gerota's fascia, identification of the ureter, traction on the peri-renal fat below the ureter while dissecting cephalad until the renal pedicle is reached. The renal pedicle will then be isolated while maintaining traction on the kidney, and peri-renal fat, and ligated using Weck® clips.
32765622|NCT05070637|Other|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in patients with hypo-functioning kidneys, and no renal cell carcinoma.
32765623|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
32765624|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
32765625|NCT02665507|Active Comparator|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
32765626|NCT02665507|Sham Comparator|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
32765627|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
32765628|NCT02919241|Experimental|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
32765629|NCT02919241|Experimental|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
32765630|NCT02592031|Experimental|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
32765631|NCT02592031|Experimental|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
32765632|NCT02592031|Active Comparator|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
32765633|NCT05404113|Experimental|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG + Conventional PT
32765634|NCT05404113|Experimental|deep friction massage|Cyriax deep friction massage+ Conventional PT
32905489|NCT04983888|Experimental|Primary Focal Segmental Glomerulosclerosis (FSGS)|Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.
33247067|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
33247068|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
33247069|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
32765635|NCT05002231|Experimental|Losmapimod 15 mg oral tablet in healthy subjects (Treatment Regimen A)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
32765636|NCT05002231|Experimental|Losmapimod two 7.5 mg oral tablets in healthy subjects (Treatment Regimen B)|Subjects will be randomized to 1 of 6 treatment sequences to receive two 7.5 mg tablets of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
33247070|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
32765637|NCT05002231|Experimental|Losmapimod one 15 mg oral tablet in healthy subjects (Treatment Regimen C)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fed conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before breakfast and will receive a high-fat breakfast approximately 30 minutes before dose administration. Subjects must consume the meal within 25 minutes or less. Washout period of 48 hours between dosing.
32765638|NCT04423263|Experimental|Intervention|Receives bilateral internal iliac artery occlusion
32765639|NCT04423263|Active Comparator|Control|Does not receive bilateral internal iliac artery occlusion
32765640|NCT02857543|Active Comparator|plant-based diet|Plant-based diet with as few added oils and fats as possible
32765641|NCT02857543|Active Comparator|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
32765642|NCT02857543|Active Comparator|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
32765643|NCT05377671|Experimental|Cognitive deficit group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
32765644|NCT05377671|Experimental|Without cognitive group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
32765645|NCT04784299|Experimental|YVOIRE volume plus|Hyaluronic acid dermal filler
32765646|NCT04784299|Active Comparator|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
32765647|NCT02765659|Other|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
32765648|NCT02765659|Other|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
32765649|NCT02765659|Other|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
32765650|NCT02333149|Experimental|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
32765651|NCT02333149|Placebo Comparator|Placebo|Drug: Placebo
32765652|NCT02315131|Experimental|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
32765653|NCT02315131|Placebo Comparator|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
32765654|NCT02315131|Experimental|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
32765655|NCT02315131|Experimental|TV46017 60 μg- COPD|Stage 2
32765656|NCT02315131|Experimental|TV46017 120 μg- COPD|Stage 2
32765657|NCT02315131|Experimental|TV46017 240 μg- COPD|Stage 2
32765658|NCT02144857|Active Comparator|Anti-TNFa regimen|Etanercept 50 mg
32765659|NCT02144857|Active Comparator|Anti IL12/23 regimen|ustekinumab 45 mg
32765660|NCT02144857|Active Comparator|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
32765661|NCT02144857|Active Comparator|anti-interleukin 17 A regimen|secukinumab 300 mg
32765662|NCT02144857|Active Comparator|inhibitor of phosphodiesterase-4|apremilast 30mg
32765663|NCT02029963|Experimental|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
32765664|NCT02029963|Experimental|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
32765665|NCT02029963|Experimental|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
32765666|NCT04514965||PBC patients offered bezafibrate treatment|"All patients started on bezafibrate treatment are offered inclusion in the study.~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus."
32765667|NCT05122429|Experimental|myCompass Only|Self-guided e-health treatment
32916442|NCT05364567|Experimental|Study group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). They had vitamin D supplementation through the injection of cholecalciferol additionally. The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline. Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
32916443|NCT05364567|Active Comparator|Control group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
32916444|NCT02298491|Experimental|H.P. Acthar Gel|
32916445|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
32916446|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
32916447|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
32916448|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
32916449|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
32715807|NCT04127318|Experimental|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
32916450|NCT04707339||Acute Appendicitis pre-COVID management|Audit of Acute appendicitis management in 2017-18
32916451|NCT04707339||Acute Appendicitis during COVID management|Audit of Acute appendicitis management in 2020
32916452|NCT05698706|Experimental|De-novo BCC with thickness not more than 2.0 mm|Areas with de-novo BCC of thickness not more than 2.0 mm (as confirmed by ultrasound imaging or histopathological examination) will be treated by high intensity focused ultrasound
32916453|NCT04086615|Experimental|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
32916454|NCT04086615|Sham Comparator|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
32916455|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
32916456|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
32916457|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
32916458|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
32916459|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
32916460|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
33247071|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
33247072|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
33247073|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
33247074|NCT00816465|Experimental|1|Patients receiving Hoodia
33247075|NCT00816465|Placebo Comparator|2|Patients receiving placebo
33247076|NCT00822003|Active Comparator|1|Human GLP-1
32715808|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
32715809|NCT00968825|Active Comparator|Dose D|RT001
32715810|NCT00968825|Placebo Comparator|Dose E|Placebo
33073240|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
33073241|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
33073242|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
32715811|NCT05248100|Experimental|Conditional Cash Transfer|Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
33073243|NCT03239340|Experimental|Osimertinib|An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
33247077|NCT00822003|Placebo Comparator|2|Placebo tablet
33247078|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
33247079|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
33247080|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
33247081|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
33247082|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
33247083|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
33247084|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
33247085|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
32715812|NCT05248100|No Intervention|Control|Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.
32715813|NCT02346435||Active Surveillance|
32715814|NCT02346435||Immediate Intervention|May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
32715815|NCT02346435||Crossover (Delayed Intervention)|Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
32715816|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
32715817|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
32715818|NCT05214014|Experimental|Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells|Group 1: Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells
32715819|NCT05214014|Active Comparator|Patients with multiple sclerosis receiving standard treatment|Group 2: Patients with multiple sclerosis receiving standard treatment
32715820|NCT05074563|Active Comparator|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
32715821|NCT05074563|Other|Control|The control arm will have no access to the online training.
32715822|NCT05271344|Placebo Comparator|Placebo Group|Placebo products for probiotics, prebiotics, omega 3 and vitamin D
32715823|NCT05271344|Experimental|Treated Group|Omega 3 fatty acids for 7 days (before starting conventional oral immunonutrition supplement), Probiotics for 14 days before and after the operation, Prebiotics for 14 days before and after the operation, Vitamin D for 6 days before the operation.
32715824|NCT04474457||COVID-19/Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
32715825|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
32715826|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
32715827|NCT05084469||Episodic Cluster Headache patients|Patients will perform two PET-MRI scans: (1) during cluster period and (2) during pain-free remission period. Scans during cluster periods will aim to acquire data before, during and after crisis. Sumatriptan 6mg will be injected subcutaneously under PET-MRI camera to relieve patient pain.
32715828|NCT05247398|Experimental|Dynamic Stability Exercise Program|Involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults. The intervention focuses on enhancing mobility and strength of the thumb for use during daily activities.
32715829|NCT00884507|Placebo Comparator|Placebo|
33247086|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
33247087|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
33247088|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
33247089|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
33247090|NCT02566746|Active Comparator|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
33247091|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
33247092|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
33247093|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
33247094|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
33247095|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
33247096|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
33247097|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
33247098|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
33247099|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
33247100|NCT04625907|Experimental|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
33247101|NCT04625907|Active Comparator|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
33247102|NCT04625907|Experimental|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
33247103|NCT04625907|Active Comparator|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
32715830|NCT00884507|Experimental|RO5313534 15mg|
32715831|NCT00884507|Experimental|RO5313534 1mg|
33247104|NCT04625907|Experimental|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
33247105|NCT04625907|Experimental|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
33247106|NCT04625907|Active Comparator|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
33247107|NCT04625907|Experimental|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
33247108|NCT04625907|Active Comparator|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
33247109|NCT04625907|Experimental|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
33247110|NCT04625907|Active Comparator|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
33247111|NCT04625907|Experimental|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
33247112|NCT04625907|Experimental|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
33247113|NCT04625907|Experimental|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
33247114|NCT04625907|No Intervention|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
33247115|NCT04625907|Experimental|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
33247116|NCT04625907|No Intervention|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
32715832|NCT00884507|Experimental|RO5313534 5mg|
32715833|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
32715834|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
32715835|NCT05270408|Experimental|Active stimulation at 1mA|Participants will receive 1 mA active HD-tDCS for 20 minutes.
32916461|NCT05136170|Experimental|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF). in this arm one drop of cenegermin 20 mcg/mL will be instilled in both eyes TID for 28 consecutive days.
32916462|NCT05136170|Placebo Comparator|Vehicle|In this arm one drop of vehicle will be instilled in both eyes TID for 28 consecutive days.
32916463|NCT05364177|Experimental|68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT scan|Participants with multiple myeloma will perform 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT within 7-day interval
32916464|NCT05363943|Active Comparator|Fixation|open reduction and internal fixation by using lateral and medial plates.
32916465|NCT05363943|Experimental|Replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
32916466|NCT01668602|Experimental|Cohort 1 - FastFES Training|Participants with chronic stroke in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
32916467|NCT01668602|Experimental|Cohort 2 - FastFES and Fast Walking|Participants with chronic stroke in Cohort 2 who complete 3 sessions of FastFES and 3 sessions of fast walking.
32916468|NCT05363865|Experimental|Virtual Community Intervention|Participants will participate in a community with structured sessions as well as the ability to communicate freely with others.
32916469|NCT05363865|Active Comparator|Standard of Care|Participants will be exposed to what's disseminated within their communities
32916470|NCT05698628|Experimental|Preemptive distal perfusion group|Distal perfusion catheterization will be done within 1 hour after VA-ECMO application.
32916471|NCT05698628|Active Comparator|Conventional distal perfusion group|The conventional group will undergo distal perfusion catheterization at the time of limb ischemia sign.
32916472|NCT03247569||Edoxaban|Patients treated with Edoxaban
32916473|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
32916474|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
32916475|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
32715836|NCT05270408|Experimental|Active stimulation at 2mA|Participants will receive 2 mA active HD-tDCS for 20 minutes.
32715837|NCT05270408|Sham Comparator|Sham group|Participants will receive sham HD-tDCS for 20 minutes, meaning no stimulation.
32916476|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
32916477|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
32916478|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
32916479|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
32916480|NCT03008733|Placebo Comparator|healthy|healthy patient
32916481|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 1|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
32916482|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 2|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
32916483|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 3|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
32916484|NCT05117060|Placebo Comparator|LEO 152020 placebo tablet|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
32916485|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
32715838|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
32715839|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
32715840|NCT05084235|Active Comparator|Empaglifloxin|
32715841|NCT05084235|Placebo Comparator|Placebo|
32715842|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
32916486|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
32916487|NCT05690828|Experimental|Group 1 (Cognitive remediation)|
32916488|NCT05690828|No Intervention|Group 2 (No cognitive remediation)|
32916489|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
32916490|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
32916491|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
32916492|NCT05092022|Experimental|Requested self-sampled HPV test|This group will receive the self-sampled HPV test. Included with the test are the test instructions, a lab requisition form, and a pre-paid mailer so that it can be sent back to the lab for testing. Results of the test will be shared with the participant.
32916493|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
32916494|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
32916495|NCT05086952|Experimental|B-A-D-C|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
32765668|NCT05122429|Experimental|myCompass + Delayed Text Therapy Support|Self-guided e-health treatment with delayed (44min) text support from a therapist.
32765669|NCT05122429|Experimental|myCompass + Delayed Video Therapy Support|Self-guided e-health treatment with delayed (44min) video support from a therapist.
32765670|NCT05122273||Children and adults with confirmed neuromuscular disease|Children and adults with confirmed genetic Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), limb-girdle dystrophy, spinal muscular atrophy (SMA), myopathy or neuropathy.
32765671|NCT01794715|Experimental|Ultrasound performed by nurses|Examinations including ultrasound examinations
32765672|NCT01794715|Active Comparator|Ultrasound not performed|Examinations not including ultrasound examinations, otherwise active
32765673|NCT01519141||HIV-negative controls|HIV-negative individuals
32765674|NCT01519141||HIV-infected patients|HIV-infected patients who are on a stable antiretroviral drug regimen for at least a year; all plasma HIV RNA levels within the past year must be below conventional levels of detection (< 50 copies RNA/mL).
32765675|NCT05118217||Clinical DPN without pain|"Score above 2.5 on the Michigan Neuropathy Screening Instrument~Score below 4 on the DN4"
32765676|NCT05118217||Painful DPN|"Score above 2.5 on the MNSI~Score above 4 on the DN4"
32765677|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
32765678|NCT05117983|Active Comparator|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
32765679|NCT05117983|Active Comparator|BD patient with HRSD score of at least 18|BD patients who meet the DSM-5 diagnostic criteria of BD and their current depression episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
32765680|NCT05117671||revision total hip or knee arthroplasties|THA/TKA patients that underwent revision surgery between 01.01.2013 until 31.12.2018
32765681|NCT05117437||Athletic group|Healthy male athletes who have been doing regular anaerobic sports (such as basketball, volleyball and handball) for at least 3 months
32765682|NCT05117437||Control group|Healthy sedentary (not doing regular sports for at least 3 months) men with age and physical characteristics similar to the athlete group
32765683|NCT03807817|Experimental|Moderate Alcohol|
32765684|NCT03807817|Experimental|Low Alcohol|
32765685|NCT03807817|Active Comparator|Placebo Alcohol|
32765686|NCT03807817|Active Comparator|No Alcohol|
32765687|NCT02871115|Experimental|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will~Perform detailed medication reconciliation~Obtain allergy and vaccination history~Evaluate and document polypharmacy (number of medications)~Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
32765688|NCT02871115|Active Comparator|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care~Study staff will obtain all patient-reported measures from the patient.~Remind participant to complete self-report measures"
32765689|NCT04288375|Experimental|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
32765690|NCT02078947|Experimental|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
32765691|NCT02078947|Active Comparator|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
32765692|NCT02078947|Sham Comparator|Usual Care|Patients receive advice on being physically active as well as usual care
32765693|NCT04212247|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
32765694|NCT04212247|Placebo Comparator|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
32765695|NCT05122117|Experimental|Methylene blue mediated photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
32765696|NCT05122117|Placebo Comparator|Scaling and root planing|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
32765697|NCT05117125||VAP|Enrolled participants that fully meet the criteria of VAP.
32765698|NCT05117125||Suspect VAP|Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.
32765699|NCT05117125||No VAP|Enrolled participants that do not develop VAP.
32765700|NCT05117047||robot-assisted liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 71 HCC patients were included in robotic liver resection cohort.
32765701|NCT05117047||laparoscopic liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 141 HCC patients were included in laparoscopic liver resection cohort.
32765702|NCT05117047||open liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 157 HCC patients were included in open liver resection cohort.
32765703|NCT05121961|Experimental|Platelet-rich Plasma|Patients will receive an intra-articular injection 3 mL of autologous platelet-rich plasma in the sacroiliac joint.
32765704|NCT05121961|Active Comparator|Steroid/Anesthetic|Patients will receive an intra-articular injection 40 mg Depo-medrol mixed with 2 mL 0.25% bupivicaine in the sacroiliac joint.
32765705|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.1 mg/kg
32765706|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.3 mg/kg
32765707|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 3|Dose Level 3: PTX-35 1.0 mg/kg
32765708|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 4|Dose Level 4: PTX-35 3.0 mg/kg
32765709|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 5|Dose Level 5: PTX-35 10.0 mg/kg
32765710|NCT05116969|Experimental|Stage 2 Multiple Ascending Dose Regimen 6|4 doses of PTX-35 with each dose separated by 7 days
32765711|NCT05116969|Experimental|Stage 2 Multiple Ascending Dose Regimen 7|3 doses of PTX-35 with each dose separated by 14 days
32765712|NCT05121883||Edaravone dexborneol group|Patients with edaravone dexborneol initiating within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days will be classified into this group.
32765713|NCT05121883||Standard medication group|Patients who do not recieve edaravone dexborneol will be classified into this group.
32765714|NCT05116657||SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
32765715|NCT05116657||Non-SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
32765716|NCT05116501|Experimental|low VWF|In patients with low VWF levels, whole-exome sequencing will be performed to identity possible variants in the VWF gene or other genes that are associated with reduced VWF plasma levels. Furthermore, a correlation study between variants identified and the bleeding symptoms of patients will be performed.
32765717|NCT05116501|Other|Healthy controls|In healthy controls, the investigators will analyze the whole-exome sequencing to include the variants that are either not present in healthy controls or are present but with a significantly lower frequency than the patients.
32765718|NCT05116423||ITP inpatients|The study population included nonsplenectomized primary ITP inpatients 18 years of age or older. Patients who had a diagnosis of connective tissue disease, cancer (solid tumor or leukemia), or primary immune deficiency were excluded.
32765719|NCT05116345|Experimental|DEXTENZA|a single intracanalicular dexamethasone (0.4 mg) insert
32765720|NCT05116345|Active Comparator|Topical Dexamethasone Treatment|"Standard of care topical dexamethasone treatment through Month 2 dosing and tapering following:~6x/day week 1 4x/day weeks 2-4 2x/day weeks 5-8 Day of surgery dexamethasone ointment and patch will be applied post-surgically for overnight treatment and removed at post-operative day 1 visit in Group B eyes."
32765721|NCT05109013||NT group - normotensive children|
32765722|NCT05109013||HT group - hypertensive children|
32765723|NCT05120401||dry eye with presbyopia|dry eye with presbyopia , Intervention : glasses prescrubed
32765724|NCT05120401||dry eye with presbyopia without glasses use|no glasses use
32765725|NCT05112211|Experimental|doxycycline|patients administrated with doxycycline tablets 100mg orally per day
32765726|NCT05120167|Active Comparator|Endocervical cytology performed by liquid-based cytology|Endocervical sample collected by brushing and preserved in a liquid base, and evaluated as cytology.
32765727|NCT05120167|Active Comparator|Endocervical cell block from a canal sample preserved in a buffered formalin base|"Endocervical sample collected by brushing and preserved in a buffered formalin base for obtaining a cell block, and evaluated similarly as histology."
32765728|NCT05120167|Active Comparator|Endocervical curettage|Endocervical curettage sample preserved in buffered formalin and evaluated by histology.
32765729|NCT05096689|Experimental|Non-operative|Non-operative treatment of lateral humeral condyle fractures
32765730|NCT05076097|Experimental|Orelabtutinib in combination of rituximab and lenalidomide(OLR) Arm|Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
32765731|NCT05059717|Experimental|Diagnostic (standard of care MRI, MR DENSE MRI)|Patients undergo standard of care MRI and then undergo an MRI of the liver using MR DENSE imaging sequences over 60-90 minutes. Healthy volunteers undergo MRI of the liver using DENSE imaging sequences.
32765732|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
32765733|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal & fetal wellbeing & finally the neonatal outcome
33247117|NCT04625907|Active Comparator|CT3: Relpased Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 (Escalate to 150mg/m2/day in Cycle 2 if no toxicity > grade 3) as an oral tablets prior to vincristine and irinotecan on days 1-5
32715843|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
32715844|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
32715845|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
32715846|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
32715847|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
32715848|NCT05213390|Experimental|Dora follow-up phone call|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards. The entire conversation will be supervised by a clinician. This clinician will be able to interrupt the call at any point if the system fails, the patient struggles to interact with it, or DORA does not collect sufficient information from the patient. The clinician will record a clinical assessment which will be compared to the DORA assessment.
32715851|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
32715852|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
32715853|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
32715854|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
32715855|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
32715856|NCT00966953|Active Comparator|Total/Whitening|positive control
32715857|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
32715858|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
32715859|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~The MG collects relevant clinical information~The MG takes 2 photographs of the lesion with his smartphone.~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~The dermatologist proposes an appointment to the patient."
32715860|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
32715861|NCT05247320||Prospective|
32715862|NCT05247320||Retrospective|
32715863|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
32715864|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
32715865|NCT05084079|Experimental|Formula-based|Initial insulin regimen was decided according to the formula developed by the investigators previously.
32715866|NCT05084079|Placebo Comparator|Weight-based|Initial insulin regimen was decided according to current guidelines.
32715867|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
32715868|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
32715869|NCT05247242|Experimental|Tarrant Community Fitness Program: LOF-VR|LOF-VR
32715870|NCT05247242|Experimental|Tarrant Community Fitness Program: VR-LOF|VR-LOF
32715871|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
32715872|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
32715873|NCT00963053|Experimental|VA111913 100mg twice daily|
32715874|NCT00963053|Placebo Comparator|Starch pill|
32715875|NCT05246852|Experimental|intervention group|
32715876|NCT05246852|No Intervention|control group|
33247118|NCT04625907|Experimental|CT3: Relapsed Chemotherapy - VIRR|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Regorafenib: Children between 6 and 24 months = 65 mg/m2, children less than 12 and/or less than 40kg dose = 82 mg/m2 Maximum 120 mg, Fixed dose of 120 mg for patients over 12 years of age AND ≥ 40 kg, as an oral tablets on days 8 to 21.
33247119|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
33247120|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
33247121|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
33247122|NCT04061616|Experimental|Participants|All the participants volunteer to participate to the study that were included.
33247123|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
32765734|NCT05119933|Experimental|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
33247124|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
33247125|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
33247126|NCT00822315|Active Comparator|1|efavirenz
33247127|NCT00822315|Experimental|2|raltegravir 400 mg
33247128|NCT00822315|Experimental|3|raltegravir 800 mg
33247129|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
33247130|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
32765735|NCT05085847|Experimental|Mindfulness-based intervention (MBI)|Participants received mindfulness training for 8 weeks (two-hour meetings; 16 hours total)
33247131|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
33247132|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
33247133|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
33247134|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
33247135|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
33247136|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
33247137|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
33247138|NCT00822393|Active Comparator|1|Busulfan
33247139|NCT00822393|Experimental|2|Treosulfan
33247140|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
33247141|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
33247142|NCT02541058||Suspected 22q.11.2 deletion/duplication|
33247143|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
33247144|NCT00819195||HC|Healthy control volunteers
33247145|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
33247146|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
32765736|NCT05085847|Active Comparator|Active control group|Participants received lectures for 8 weeks (two-hour meetings; 16 hours total)
32765737|NCT04932577|Experimental|Faecal microbiota transplantation|The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.
32765738|NCT04932577|Placebo Comparator|Placebo|The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
32765739|NCT04882111|Experimental|Discharged Cancer Patients|25 patients, adults ≥ 18, with stage II - IV solid tumor malignancy discharging from an acute care hospital to a SNF in the metro Denver area who have decisional capacity to consent and are English speaking.
32765740|NCT05078281||Cases|Patients with severe eosinophilic asthma receiving benralizumab.
32765741|NCT04842019|Experimental|KRN23|KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks for 48 weeks. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
32765742|NCT05230069||Patients post emergency evaluation|Interview of patients post notification of emergency system
32765743|NCT04513639|Experimental|Arm A|Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.
32765744|NCT04513639|Active Comparator|Arm B|Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.
32765745|NCT04765735|Experimental|Open-loop testing, then Closed-loop testing|Subjects receive Open-loop testing, then Closed-loop testing (Spinal Cord Stimulation - SCS Therapy)
32765746|NCT04765735|Experimental|Closed-loop testing, then Open-loop testing|Subjects receive Closed-loop testing, then Open-loop testing (Spinal Cord Stimulation - SCS Therapy)
32765747|NCT04746001||Infection|
32916496|NCT05086952|Experimental|C-D-A-B|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
33073244|NCT03223753|Active Comparator|Arm I (tracking device, limited version of device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the limited version of device app/website to get basic information related to their physical activity for 6 months.
33247147|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
33247148|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
33247149|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
32765748|NCT04746001||Tumours|
32765749|NCT04696549|Experimental|virtual visual art experience for individuals with dementia and their family care-partners|Individuals with dementia and their family care-partners will participate in three monthly one-hour virtual art sessions in which the facilitator uses Visual Thinking Strategies technique to facilitate participants' viewing and discussion about virtual art images.
32765750|NCT04675801||Bridging therapy with LMWH (n=475)|Bridging therapy with LMWH was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
32765751|NCT04675801||Bridging therapy with tirofiban (n=475)|Bridging therapy with tirofiban was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
32765752|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
32765753|NCT04675333|Experimental|Evorpacept (ALX148) + Pembrolizumab + Chemotherapy|Evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.
32765754|NCT04675333|Active Comparator|Pembrolizumab + Chemotherapy|Pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.
32765755|NCT05229991|Experimental|Intervention Group|Lonafarnib 50mg co-administered with ritonavir 200 mg
32765756|NCT05119543||Grade|The changes in myopia rate in 3 years were compared by generalized estimation equation in different grades
32765757|NCT05229913|Placebo Comparator|The control group （Esketamine is not added）|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
32765758|NCT05229913|Experimental|Esketamine experimental group(E0.2)|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
32765759|NCT05229913|Experimental|Esketamine experimental group (E0.4)|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
32765760|NCT05229913|Experimental|Esketamine experimental group (E0.6)|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
32765761|NCT05229913|Experimental|Esketamine experimental group (E0.8)|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
32765762|NCT05229835|Experimental|Time restricted eating|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period
32765763|NCT05229835|Experimental|Time restricted eating combined with exercise|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period combined with aerobic exercise 3 times a week.
32765764|NCT05229835|Experimental|Exercise|Tasks for participants are to perform aerobic exercise 3 times a week.
32765765|NCT05229835|No Intervention|Control|Tasks for participants are keeping their daily habits
32765766|NCT05119465||Group|Hospitalized Patients with Corona virus disease
32765767|NCT04594681|Placebo Comparator|Placebo|
32765768|NCT04594681|Experimental|KHK4951|
32765769|NCT05229757|Experimental|Study Group|Children with cerebral palsy in the patient group received treatment in a special education and rehabilitation center two days a week for 8 weeks.
32765770|NCT05229757|Active Comparator|Control Group|Individuals in the control group were followed with a home program for 8 weeks.
32765771|NCT05229289|Experimental|FMT along with SMT|"FMT + Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
32765772|NCT05229289|Active Comparator|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
32765773|NCT01362517|Experimental|Quinvaxem|
32765774|NCT05229133|Experimental|Refractive correction using CLEAR|Subjects 18+ years old with myopic (-0.50 to -10.00 D) astigmatism (up to -5.00 D) treated bilaterally with FEMTO LDV Z8 using CLEAR application.
32765775|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
32765776|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
32765777|NCT05108155||THA|Patient with primary total hip arthroplasty
32765778|NCT05228821|Experimental|Active Drug|Generic Name: Voxelotor Dosage Form: tablet Dosage: 1500mg Frequency: QD Duration: 12 weeks
32765779|NCT05228821|Placebo Comparator|Placebo|Generic Name: Placebo Dosage Form: Tablet Dosage: N/A Frequency: QD Duration: 12 weeks
32765780|NCT04418479|Active Comparator|Aspirin monotherapy arm|Patients will receive 100 mg of aspirin once daily.
32765781|NCT04418479|Experimental|Clopidogrel monotherapy arm|Patients will receive 75 mg of clopidogrel once daily.
32765782|NCT04375735|Experimental|BLES treatment|For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation. BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
32765783|NCT04375735|No Intervention|Control|Patients will receive standard treatment and will not receive surfactant.
32765784|NCT01362439|Experimental|Paliperidone ER|
32765785|NCT05228743|Experimental|HIPEC plus Paclitaxel IP/IV, S-1|After laparoscopic exploration, HIPEC was started immediately, at least 4 HIPEC was completed.Three to six weeks after HIPEC was completed, chemotherapy was started.The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
32765786|NCT05228743|No Intervention|Paclitaxel IP/IV, S-1|Within one week after laparoscopic exploration, chemotherapy was started. The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
32765787|NCT05228665|Experimental|Prospective cohort|Participants will be shown a paced breathing programme and instructed to implement this for 10 minutes twice daily for 4 weeks. During the 10-minute breathing exercises, the participant will need to wear the Polar H10 chest strap and can remove this when finished. The breathing will ideally be a breathing pattern of a 4-second nasal inhale, and 6-second nasal exhale using the 'resonance' programme in the 'biofeedback' section of EliteHRV app. They will be advised to monitor the graph of HRV on EliteHRV which allows real-time assessment of HRV and to aim to breathe in and out deeply to raise the HRV graph reading as much as possible each time. They will be advised to perform the breathing programme lying down with minimal distractions on waking in the morning and just before bed in the evening, preferably in the same location each time.
32765788|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
32765789|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
32765790|NCT05228587|Experimental|Liver Transplants|"Indocyanine Green will be injected in liver donors for measuring plasma disappearance rate with a non invasive measurement device.~Liver recipients will receive indocyanine green injection for measuring plasma disappearance rate at different time-points."
32765791|NCT03307915|Experimental|Group 1: Ad26.Mos4.HIV + MVA-Mosaic/Placebo|Participants will receive adenovirus serotype 26-Mosaic 4 -Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5*10^10 virus particles (vp) as intramuscular (IM) injection at Weeks 0 and 12 (1 injection) followed by modified Vaccinia Ankara-Mosaic (MVA-Mosaic) 10^8 Plaque-forming unit (pfu) and placebo as IM injection at Weeks 24 and 36 (2 injections).
32765792|NCT03307915|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV, 5*10^10 vp as IM injection at Weeks 0 and 12 (1 injection) followed by both Ad26.Mos4.HIV 5*10^10 vp plus Clade C gp140 (125 microgram [mcg]) plus Mosaic gp140 (125 mcg) with aluminum phosphate adjuvant or an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36 (2 injections).
32765793|NCT03307915|Placebo Comparator|Group 3: Placebo|Participants will receive 0.9 percent (%) saline as IM injection at Weeks 0, 12 (one injection) and at Week 24, 36 (two injections).
32765794|NCT04164901|Experimental|Vorasidenib|Vorasidenib 40 mg, continuous daily dosing.
32765795|NCT04164901|Placebo Comparator|Matching Placebo|Matching placebo 40 mg, continuous daily dosing. Participants who experience centrally-confirmed radiographic disease progression and who were receiving placebo will have the option to cross-over to vorasidenib, provided certain criteria are met.
32765796|NCT04154059|Experimental|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
32765797|NCT04154059|No Intervention|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
32765798|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
32765799|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
32765800|NCT05227963|Experimental|Experimental Group(Group A)|Experimental Group received soft tissue mobilization with neck isometric strengthening exercises.
33247150|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
32765801|NCT05227963|Other|Control group (Group B)|Control group received neck isometric strengthening exercises alone.
33247151|NCT04739280||Single center registry for WACE|We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.
33247152|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
32765802|NCT05010343|Active Comparator|carbon ion irradation group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
32765803|NCT05010343|Active Comparator|Carbon Ion Irradiation With SIB group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
32765804|NCT04990921|Experimental|Palliative Radiation in Combination with Pembrolizumab|"Stereotactic radiation therapy will be delivered using either linac-based SBRT using 10x flattening filter-free (FFF) photons or Cyberknife Pencil Beam Technology utilizing 6X photons. Treatment will be delivered in 1-5 fractions. Fractionation and total dose (1500 - 3000 cGy) will depend on the site of disease, previous radiation treatment, and patient symptomatology.~Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for intravenous infusion. Pembrolizumab at a dose of 200 mg will be administered intravenously every 3 weeks (± 3 days)."
32765805|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
32765806|NCT04037059||Spinal Deformity Patients|For patients with disabling spinal deformities, long segment fusions have been shown to improve the health related quality of life (HRQOL). A consequence of spine fusion however is elimination of range of motion especially in the lumbar spine. Even in patients who report overall improvement in pain related domains, difficulty with some ADL's in this patient group has been well documented in previous studies. Complaints such as inability to dress independently, bathing of lower halves of their body, driving a motor vehicle, getting in and out of a chair/bed and performing perineal hygiene care following toileting have been reported.
32765807|NCT02673385||Brazelton scale|Procurement across Brazelton scale
32765808|NCT02673385||No test|usual care
32765809|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
32765810|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
32765811|NCT04853407|Experimental|LY03005 extended-release tablets 80 mg group|orally once a day
32765812|NCT04853407|Experimental|LY03005 extended-release tablets 160 mg group|orally once a day
32765813|NCT04853407|Placebo Comparator|Placebo group|orally once a day
32765814|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
32765815|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
32765816|NCT02495311||Women with uterine myoma|Women with uterine myoma
32765817|NCT02495311||Women with adenomyosis|Women with adenomyosis
32765818|NCT02495311||Women without uterine myoma or adenomyosis|Control group
32765819|NCT04218487|Experimental|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
32765820|NCT04218487|Placebo Comparator|Control group|2.4g (6 capsules) three times daily for 12 weeks
32765821|NCT04507477|Experimental|Rituximab + Ex-vivo lung perfusion|Donor lungs deemed suitable for such patients will undergo ex vivo lung perfusion (EVLP) as per standard practice. In clinical practice almost all adult donor lungs are EBV seropositive. If in the rare case the donor lung is EBV seronegative, then the lung transplant candidate/recipient will no longer need to be part of the study. Therefore, for EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours. Lungs will then be transplanted as per standard procedure.
32765822|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
32765823|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
32765824|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
32765825|NCT01391143|Experimental|MGA271|Fc-optimized, humanized monoclonal antibody
32765826|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
32765827|NCT04825561|Active Comparator|Active Comparator|AD-208 and Placebo of AD-2081
32765828|NCT04825561|Placebo Comparator|Placebo Comparator|Placebo of AD-208 and Placebo of AD-2081
32765829|NCT04825561|Experimental|Experimental Comparator|Placebo of AD-208 and AD-2081
32765830|NCT05122897|Experimental|Pagalinor®2 (PA) test arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
32765831|NCT05122897|Active Comparator|Titanium-6Aluminum- 7Niobium alloy (TAN) control arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
32765832|NCT04505293|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2000™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
32765833|NCT03915223|Experimental|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
32765834|NCT03915223|Placebo Comparator|"Arm  injection physiological serum"|Single dose of physilogical serum
32765835|NCT05102149|Experimental|Test arm|PB-201: 100 mg each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
32765836|NCT05102149|Active Comparator|Vildagliptin arm|Vildagliptin: 50 mg each time, orally in the morning and evening respectively; PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
32765837|NCT05102149|Placebo Comparator|Placebo arm|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
32765838|NCT04019431|Experimental|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
32765839|NCT04019431|Active Comparator|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
32765840|NCT04019431|Active Comparator|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
32765841|NCT04922749|No Intervention|TAU|Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.
32765842|NCT04922749|Experimental|MULTI+|Lifestyle treatment
32765843|NCT04870099|Experimental|Guided self-help|"Participants are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
32765844|NCT04412395|Active Comparator|Arm 01 (SOC + Lactoferrin 1200 mg QID)|Patients randomized to this group will receive two 600 mg Lactoferrin tablets QID plus the Standard of Care (SOC) treatment(s).
32765845|NCT04412395|Placebo Comparator|Arm 02 (SOC + Placebo QID)|Patients randomized to this group will receive two placebo tablets QID plus the SOC treatment(s).
32765846|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
32765847|NCT05048173||Sentinel lymph node group|woman who had sentinel lymph node mapping and biopsy
32765848|NCT05048173||Lymphadenectomy group|woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping
32765849|NCT04754269|Experimental|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children. Parents will receive that reinforce and expand on the messages in the video.
32765850|NCT04754269|Experimental|Reading Intervention|Parents will watch a video that promotes reading to children. Parents will receive text messages that reinforce and expand on the messages in the video.
32765851|NCT04987099|Experimental|Experimental Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 550 mg of choline once daily for the duration of their pregnancy.
32765852|NCT04987099|Placebo Comparator|Control Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 25 mg of choline once daily for the duration of their pregnancy.
32765853|NCT03906721|Experimental|Conditioning & Open-Label Placebo (COLP)|Days 1 to 3 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 4 to 6 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
32765854|NCT03906721|Other|Treatment-as-usual|For the duration of the study, days 1 to 6, oxycodone will be prescribed on a schedule of 3-4 times per day.
32765855|NCT04668001|Experimental|Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
32765856|NCT04668001|Placebo Comparator|Sham Transcranial Photobiomodulation (tPBM-Sham)|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
32715877|NCT04240808|Experimental|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes
32715878|NCT05084001|Experimental|38% SDF (Saforide, Toyo Seiyaku Kasei Co. Ltd., Japan)|application of silver diamine fluoride solution on occlusal surface of primary molars
32715879|NCT05084001|Active Comparator|5% NaF varnish (Duraphat, Colgate Palmolive, USA)|application of sodium fluoride varnish on occlusal surface of primary molars
33247153|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
33247154|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
32765857|NCT03994081|Experimental|alpha Transcranial alternating current stimulation (tACS).|10 Hz tACS with a zero-to-peak amplitude of 1 mA for 40 minutes.
32765858|NCT03994081|Sham Comparator|Sham stimulation|20 seconds of ramp-up, 40 seconds of 10 Hz tACS with zero-to-peak amplitude of 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation.
33247155|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
33247156|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
33247157|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
33247158|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
33247159|NCT02551341|No Intervention|control|normal ventilation
33247160|NCT02551341|Experimental|intervention|higher PEEP ventilation
32715880|NCT05084001|Placebo Comparator|Tonic water|application of tonic water on occlusal surface of primary molars
32715881|NCT00961805|Experimental|Dance Group|Belly dance
32715882|NCT00961805|No Intervention|Control Group|Waiting list
32715883|NCT04878952|No Intervention|Arm I: Usual Care|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
32715884|NCT04878952|Experimental|Arm II: Usual Care + Continuous physical activity monitoring via a wearable device|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
32715885|NCT05245916|Experimental|IBI397 single-agent dose escalation|
32715886|NCT05245916|Experimental|IBI397+ Rituximab|
32715887|NCT05245916|Experimental|IBI397 + Sintilimab|
32715888|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
32715889|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
32715890|NCT04878484|Experimental|Cohort 1: TCRT-ESO-A2: 0.3 × 1010 TCRT-ESO-A2 cells * ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
32765859|NCT04096573|Experimental|LC51-0255 low dose|Oral, daily, low dose for induction period, high dose for OLE period
32765860|NCT04096573|Experimental|LC51-0255 middle dose|Oral, daily, middle dose for induction period, high dose for OLE period
32765861|NCT04096573|Experimental|LC51-0255 high dose|Oral, daily, high dose for induction period, high dose for OLE period
32765862|NCT04096573|Placebo Comparator|placebo|Oral, daily, placebo for induction period, high dose for OLE period
32765863|NCT04919083||Non-exposed cohort (protective factor)|Group of patients operated on during the year 2021 in San Juan de Dios Hospital for hip fracture and to which the new programme implementing functional recovery and therapeutic exercise will be applied with follow-up for one year. The implementation of a functional recovery plan and subsequent follow-up is considered a protective factor in relation to the loss of functionality.
32765864|NCT04919083||Exposed cohort (retrospective)|Complete cohort of patients operated on during the year 2020 in San Juan de Dios Hospital for hip fracture and to whom no specific functional recovery plan was applied.
32765865|NCT04781257||Household contacts with co-prevalent/incipient TB|Household contacts diagnosed with active TB at baseline/during the study period
32765866|NCT04781257||Household contacts staying healthy|Household contacts without active TB who remain healthy throughout the study
32765867|NCT04529863||Tocilizumab|Reference group
32765868|NCT04529863||Abatacept|Exposure group
32765869|NCT04772209|Active Comparator|Sodium bicarbonate Arm|In this arm, the catheter lock solution is sodium bicarbonate
32765870|NCT04772209|Active Comparator|Heparin arm|In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)
32765871|NCT04441957||Group A, MOCA-group|Procedure/Surgery: MOCA Mechano-Chemical Ablation plus Elastic Compression
32765872|NCT04441957||Group B, Elastic Compression only group|Treatment: Elastic Compression only
32765873|NCT04594603||Group(1): Cataract with no diabetic retinopathy|
32765874|NCT04594603||Group (2): Cataract associated with diabetic retinopathy|
32765875|NCT04432441|Active Comparator|Therapeutic physical exercise program for scapulo-humeral stabilitation|Therapeutic physical exercise program for scapulo-humeral stabilitation
32765876|NCT04432441|Active Comparator|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation
32765877|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
32765878|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
32765879|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
32715891|NCT04878484|Experimental|Cohort 2: TCRT-ESO-A2: 1.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor.
32765880|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
32765881|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
33247161|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
32765882|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
32765883|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
32765884|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
32765885|NCT04582591|Experimental|Cannabidiol|Patients will receive cannabidiol in conjunction with their standard chemotherapy treatment
32765886|NCT04217239|Experimental|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
32765887|NCT04217239|Active Comparator|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
32765888|NCT04212481|Experimental|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
32765889|NCT04212481|Active Comparator|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
32765890|NCT04212481|Active Comparator|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
32765891|NCT03997669||experimental group|patients with malignant pleural effusion
32765892|NCT03997669||control group|patients with benign pleural effusion
32765893|NCT04497883|Experimental|Cohort A: Non-Hispanic, Caucasian|Non-Hispanic, Caucasian group participants will receive 400 milligram (mg) maribavir tablets orally once on Day 1 during treatment period 1.
32765894|NCT04497883|Experimental|Cohort B: Japanese Descent|Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1 followed by 200 mg or 800 mg maribavir tablets orally once on Day 1 during treatment period 2 followed by 800 mg or 200 mg maribavir tablets orally once on Day 1 during treatment period 3 in cross-over fashion. A washout period of 72 hours will be maintained between treatment period 1, 2, and 3.
32765895|NCT03756103|Experimental|SPH3127 tablet Dose 1|Low-dose group
32765896|NCT03756103|Experimental|SPH3127 tablet Dose 2|Mid-dose group
32765897|NCT03756103|Experimental|SPH3127 tablet Dose 3|High-dose group
32765898|NCT03756103|Placebo Comparator|SPH3127 tablet Placebo|Placebo Control group
32765899|NCT04347655|Experimental|HFrEF|patients with heart failure with reduced ejection fraction
32765900|NCT04347655|Experimental|HFpEF|heart failure with preserved ejection fraction
32765901|NCT04347655|Active Comparator|Control|healthy (no heart failure) control participants
32765902|NCT03688633|Experimental|Candesartan|
32765903|NCT03688633|Active Comparator|Usual care|
32765904|NCT04436029|Experimental|Descartes 11|
32765905|NCT03743935|Experimental|Early cardiac MRI post-STEMI|Early stages post-STEMI (within the first 5 days)
32765906|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 1|Participants will receive a single dose of 1.5 mcg/kg E-WE thrombin.
32765907|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 2|Participants will receive a single dose of 3.0 mcg/kg E-WE thrombin.
32765908|NCT03963895|Placebo Comparator|Placebo|Participants will receive a single dose of placebo
32765909|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
32765910|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
32765911|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
32765912|NCT03662815|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.~GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01."
32765913|NCT03509467|Experimental|Intervention Group A|"Intervention Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
32765914|NCT03509467|Experimental|Intervention Group B|"Intervention Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
32905515|NCT03438032||SSc-ILD|SSc-ILD subjects will be defined by those who fulfill 2013 American College of Rheumatology SSc criteria and have forearm modified Rodnan skin scores (mRSS) ≥1 (a validated, semi-quantitative scoring system for dermal fibrosis) and clinically relevant SSc-interstitial lung disease (ILD). A subject will be defined as having ILD if they have radiographic evidence for ILD and a forced vital capacity <70% on pulmonary function test (PFT).
32916497|NCT05086952|Experimental|D-B-C-A|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
32916498|NCT05086952|Experimental|A-C-B-D|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
32916499|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
32916500|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
32916501|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
32916502|NCT05363475|Experimental|Prospective|Participants will be monitored by the ForeSite Intelligent Surface system for 2-3 weeks.
32916503|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
32916504|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
32916505|NCT05690750||Case|Cirrhosis with GAVE
32916506|NCT05690750||Control|Cirrhosis without GAVE
32916507|NCT05667662|Experimental|PUR1900 40 mg|4 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
32916508|NCT05667662|Experimental|PUR1900 20 mg|2 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) and 2 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
32916509|NCT05667662|Placebo Comparator|Placebo|4 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
32916510|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
32916511|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
32715892|NCT04878484|Experimental|Cohort 3: TCRT-ESO-A2 : 3.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
32715893|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
32715894|NCT00875459|Experimental|VIAject™|Single injection
32715895|NCT05244746|Active Comparator|Rectus sheath block|
32715896|NCT05244746|Placebo Comparator|Control|
32916512|NCT02781285||3group three|patients take no Chinese Medicine
32916513|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
32715897|NCT03837353|Experimental|Cohort 1A|In dose-escalation Cohort 1A, the dose of docetaxel 75 mg/m2 will remain fixed. The DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until Prostate Cancer Working Group 3 (PCWG3) progression or unacceptable toxicity.
33247162|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
33247163|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
33247164|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
33247165|NCT00893230|Placebo Comparator|microcrystalline cellulose|
32715898|NCT03837353|Experimental|Cohort 1B|In dose-expansion Cohort 1B, either the maximum tolerated dose (MTD) or highest dose tested of DKN-01 in combination with docetaxel in Cohort 1A will be the dose used. The dose of docetaxel 75 mg/m2 will remain fixed. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until PCWG3 progression or unacceptable toxicity.
32742836|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
33247166|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
32916514|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
32916515|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
32916516|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
32916517|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
32916518|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
32916519|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
32916520|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
32916521|NCT03505281||Patients|
32916522|NCT03505281||Healthy volunteers|
32916523|NCT05067140|Experimental|ARV-766 Part A|Part A: Oral tablet(s), once or twice daily in 28 day cycles
32916524|NCT05067140|Experimental|ARV-766 Part B|Part B: Oral tablet(s) once daily in 28 days
32916525|NCT04333095|Active Comparator|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
32916526|NCT04333095|Placebo Comparator|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
32916527|NCT05045144|Experimental|RSV1 Group|Participants randomized to the RSV1 Group receive one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
32916528|NCT05045144|Experimental|RSV2 Group|Participants randomized to the RSV2 Group receive one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
32916529|NCT05045144|Experimental|RSV3 Group|Participants randomized to the RSV3 Group receive one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
32916530|NCT05045144|Experimental|RSV1+Flu Group|Participants randomized to the RSV1+Flu Group receive one dose of RSV MAT Lot 1 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
32916531|NCT05045144|Experimental|RSV2+Flu Group|Participants randomized to the RSV2+Flu Group receive one dose of RSV MAT Lot 2 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
32916532|NCT05045144|Experimental|RSV3+Flu Group|Participants randomized to the RSV3+Flu Group receive one dose of RSV MAT Lot 3 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
32916533|NCT05045144|Active Comparator|Flu+P Group|Participants randomized to the Flu+P Group receive one dose of Flu D-QIV vaccine co-administered with one dose of Placebo, intramuscularly, at Day 1.
32916534|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
32916535|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
32916536|NCT05357079|Experimental|Topical TXA Treatment|2 gm TXA/100 ml of normal saline
32715899|NCT03837353|Experimental|Cohort 2A|In dose-escalation Cohort 2A, DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
32715900|NCT03837353|Experimental|Cohort 2B|In dose-expansion Cohort 2B, the MTD or highest dose tested of DKN-01 monotherapy in Cohort 2A will be the dose used. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
32916537|NCT05357079|Placebo Comparator|No Topical Treatment|Normal saline
33247167|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
32916539|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan|Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
32916540|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost|Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
32916541|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan|Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
32916542|NCT05039684||Ocular hypertension - No treatment|Patients ocular hypertension untreated
32715901|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
32715902|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
32715903|NCT05168150|No Intervention|Control Group No-expert mediated post hoc benchmark group|"30 participants. Individuals receive identical introductory information,same time, to perform, same scenarios as other groups.~Students receive their scores on 5 performance metrics compared to expert performance benchmarks. Scores are presented in the 5 minute breaks between tasks. Student goal is to be within the benchmark in all five metrics."
32715904|NCT05168150|Experimental|Experimental Group - Intelligent Continuous Expertise Monitoring System group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task, participants receive no feedback. For the subsequent 4 practice tasks participants will receive real-time auditory feedback instruction by the intelligent system. After each of the 5 attempts, a student takes a 5-minute break. During each of the 5 breaks the participants will be shown the errors they made during the task by the intelligent system regarding five performance metrics monitored. After seeing each error outline, the participant will be shown a video demonstration to learn how to expertly perform on each performance metric. On their 6th attempt they will perform on the realistic scenario without any feedback given."
32742837|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
32742838|NCT04961853|Experimental|Cases|
32742839|NCT04964583|Experimental|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
33247168|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
33247169|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
32916546|NCT05661968|Experimental|Online educational program|A 6-week educational program delivered online based on information and recommendations from international clinical practice guidelines for the management of back pain.
32916547|NCT05661968|No Intervention|Control group|The control group will receive no intervention and will be instructed to follow their clinical practice normally.
32916548|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
32916549|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
32916550|NCT02249468||Mild and Moderate Alzheimer's Disease|
32916551|NCT02249468||Cognitively intact healthy people|
32916552|NCT02442297|Experimental|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
32916553|NCT02442297|Experimental|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
32916554|NCT03281031|Other|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
32916555|NCT02092155||Indwelling tunneled pleural catheter|
32916556|NCT01658241|Experimental|Single Arm Main population|
32916557|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
32916558|NCT05352945|No Intervention|control arm|"conventional anaesthesia~The botulinum toxin injection procedure will be carried out in the standard way, according to the recommendations applicable in France, and after local anaesthesia."
32916559|NCT05352945|Experimental|interventional arm|"conventional anaethesia and use of the self-hypnosis mask~The mask and the helmet are positioned and activated 10 minutes before the procedure, with the travel to india programme chosen because it was developed for pain management and its duration is compatible with the procedure (25 minutes)."
33247170|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
33247171|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
32916560|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
32916561|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
32916562|NCT05344053|Experimental|Community-based precise management|
32916563|NCT05344053|Active Comparator|Standard community-based management|
32916564|NCT04974086|Experimental|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
32916565|NCT05343585|Experimental|Experimental|"Training and use of Openfit~Using the app to estimate food intake from simulated meals in a laboratory at PBRC or LSU (participants will not eat food during the meals)~Rating the usability and satisfaction of the app"
32916566|NCT05335239|Experimental|Intervention group|Every third month, a dental nurse will visit at home and deliver professional dental cleaning and delivery of one new toothbrush and fluoride toothpaste (>4000ppm) (n:3) for the next three months. The visit is expected to take at the most 30 minutes.
32916567|NCT05335239|No Intervention|Controll group|Continuous with oral care as usual, either by themselves or nursing assisted (help with oral hygiene procedure) during the whole study period. Home care aides working with the control study participants deliver a toothbrush and fluoride toothpaste (> 4000 ppm) (n:3) every third month during the study period.
32916568|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
32916569|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
32916570|NCT05325099|Experimental|AKI patient with azacitidine treatment|azacitidine (subcutaneous injection)
32916571|NCT05325099|Placebo Comparator|AKI patient with placebo treatment|Placebo drug (subcutaneous injection)
32715905|NCT05168150|Experimental|Experimental Group In-person expert-mediated instruction group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task participants receive no feedback. For the subsequent 4 practice tasks participants receive real-time auditory feedback instruction by in-person expert during the task. After each of the 5 tasks, students takes a 5-minute break. During each of the 5 breaks the in-person expert provides feedback to the participant based on their OSATS score assessment during the previous trial. If the expert feels it is appropriate the expert will demonstrate how to do the specific procedure which has been found to be a concern on the simulator themselves so the participant can understand how to improve their performance. On their 6th attempt they will perform on the realistic scenario without any feedback given."
32715906|NCT05083767|Experimental|Whole Body Vibration|
32916572|NCT04974008|Experimental|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
32916573|NCT05293509|Experimental|Phase I: Sequential Pharmacological PTIS|
32916574|NCT05293509|Experimental|Phase II: RTC Regimen and GVHD Prophylaxis Based on Post-Cy|
32916575|NCT04736433||ACE Inhibitors|Reference group
33247172|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
33247173|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
33247174|NCT00891826|Placebo Comparator|Corn oil|
33247175|NCT00891826|Experimental|Omega-3 fatty acids|
33247176|NCT04060992|Experimental|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
33247177|NCT04060992|Active Comparator|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
32715907|NCT05083767|Placebo Comparator|Control Group|
32715908|NCT05166590|No Intervention|Normal Sleep|Participants will sleep in the laboratory for 8 hours and then undergo the same social-rejection paradigm as the experimental group to serve as a control comparison.
32715909|NCT05166590|Experimental|Total Sleep Restriction|Participants will experience a night of total sleep restriction and then undergo a social-rejection task in the morning.
32916576|NCT04736433||Sacubitril/Valsartan|Exposure group
32916577|NCT02296775|Experimental|DRL_RI|
32916578|NCT02296775|Active Comparator|Rituxan|
32916579|NCT02296775|Active Comparator|MabThera|
32916580|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
32916581|NCT05240469|No Intervention|Standard sperm selection|In the control group the oocytes will be injected with sperm that is selected by embryologists using conventional methods in the IVF lab.
32916582|NCT05240469|Experimental|Automated sperm selection|The only intervention is the additional sperm selection step using software immediately prior to ICSI.
32916583|NCT04736589|Experimental|Inetetamab plus Rapamycin plus Chemotherapy|"Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;~Drug: Rapamycin Oral 2mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
32916584|NCT04736589|Active Comparator|Pyrotinib plus chemotherapy|"Drug:Pyrotinib Oral 400mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
33247178|NCT04060992|Active Comparator|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
33247179|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
33247180|NCT04161066|Experimental|Open-label|Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
33247181|NCT04061304|Experimental|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
32916585|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
32916586|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
32916587|NCT02970747||Car/Dex/Dara (KdD)|Patients treated with carfilzomib, dexamethasone and daratumumab dosage form, dosage, frequency and duration of treatment according to current SmPC
32916588|NCT05201859|Experimental|Adjuvant Sintilimab Plus Capecitabine|Lead-in Phase: Sintilimab (200mg, D1, D14 for 2 cycles); Adjuvant Phase: Sintilimab ( 200mg D1, every three weeks, a total of 24 weeks, 8 cycles) + Capecitabine ( 1000 mg/m2, BID, D1-14 every three weeks, a total of 24 weeks, 8 cycles).
32916589|NCT05201859|Active Comparator|Adjuvant Capecitabine|Capecitabine 1000 mg/m2, BID, D1-14, every three weeks, a total of 24 weeks, 8 cycles.
32916590|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
32916591|NCT02594111|Placebo Comparator|Placebo|Matching placebo
32916592|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
32916593|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
32916594|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
32916595|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
32916596|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
32916597|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
32916598|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
32916599|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
32916600|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
33247182|NCT04061304|Experimental|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
33247183|NCT04061304|Sham Comparator|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
32916609|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
32916610|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle."
32916611|NCT04876742|Experimental|0.5 liters of alcoholic beer|
32916612|NCT04876742|Placebo Comparator|0.5 liters of water|
32916613|NCT04876742|No Intervention|non-interventional cohort control group|
32916614|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
32916615|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
32916616|NCT04870112|Experimental|Patients with NSCLC|Patients with Non-Small Cell Lung Cancer
32916617|NCT04870112|Experimental|Patients with SCLC|Patients with Small Cell Lung Cancer
32916618|NCT03029117||corrected and uncorrected rheumatic valve lesions|
32916619|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
32916620|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
32715910|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32916621|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
32916622|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
32916623|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
32916624|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
32916625|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
32916626|NCT04115345|Experimental|Renal Autologous Cell Therapy (REACT)|The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula. The participant will receive a second injection 6 months after the first injection into the same kidney.
32715911|NCT00872885|Experimental|A|Dose 1
32715912|NCT00872885|Experimental|B|Dose 2
32715913|NCT00872885|Experimental|C|Dose 3
32715914|NCT00872885|Active Comparator|D|Morphine
32916627|NCT05611892||18F-FDS PET/CT|a single intravenous dose of 18F-FDS followed by PET/CT scan.
32916628|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected only RI~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
32916629|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected RI +ICG~prepare fluorescence camera when the surgery begin~surgeon uses the camera to decect fluorescence flow on SLN~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
32916630|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
32916631|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
32916632|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
32916633|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
32916634|NCT04115033|Experimental|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
32916635|NCT04115033|Sham Comparator|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
32916636|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
32916637|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
32916638|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
32916639|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
32916640|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
32916641|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
32916642|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
32715915|NCT00872885|Placebo Comparator|E|Placebo
32715916|NCT05212688|Active Comparator|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 & GV24 midline; A window of 2 weeks will be allowed, the study questionnaires will be administered at the prespecified timepoints; Extra points will be used if multiple symptoms; A max. of two upper sternal indwelling studs may be used after the second treatment if dyspnoea is present; Instructions will be given to massage the studs for 1 minute prior to exercise, if dyspnoeic or if very anxious, as often as necessary up to 12 times/day; Studs can electively remain in place for 4 weeks; Studs at SP6 may be used from second treatment if fatigue is still prevalent with self-massage 3 times daily; Patients will be asked to rest for 15 mins after each treatment; Clear instructions about self-needling will be given to each patient
32715917|NCT05212688|Active Comparator|Active Control|Patients randomised to the Active Control will be contacted once per week for 6 weeks for a semi-structured telephone consultation. Delays of up to 2 weeks in delivery of the Active Control session are allowed within the protocol. Patients will be asked during the telephone call to complete the study questionnaires at week 0, 2, 6. Participants will also be asked after the telephone call to rest for 15 minutes if they are able. The patients will also be telephoned on week 12 to complete the study assessments. Patients in Arm B will be required to attend RM in person for the baseline visit and at week 6 to perform the 1 Minute Sit to Stand Test (1-MSTS). Other visits will be telephone calls and completion of questionnaires (paper or via patient portal).
32715918|NCT05088213|Experimental|Patients in Group 1 undergo suction mini percutaneous nephrolithotomy|
32715919|NCT05088213|Experimental|Patients in Group 2 undergo standard percutaneous nephrolithotomy|
32916643|NCT01588665||Pregnant women and pregnant adolescents|
32715920|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
32715921|NCT05166122|Active Comparator|AI workflow|In AI work flow, patients will be screened by taking normal retinal images and all images will be assessed for the severity of diabetic retinopathy by a computerized artificial intelligence system immediately after the photograph is taken via the Internet and retinal images will be sent to the retinal ophthalmologist for overreading.
32715922|NCT05166122|No Intervention|Manual workflow|Volunteers who have been screened by manual workflow will be screened by imaging the retina and image that are not normal will be sent to assess the severity of diabetic retinopathy by specialist staff.
32715923|NCT05088135|Experimental|Bilateral Auricular Vagus Nerve Stimulation|
32715924|NCT05088135|Experimental|Unilateral - Right Auricular Vagus Nerve Stimulation|
32715925|NCT05088135|Experimental|Unilateral - Left Auricular Vagus Nerve Stimulation|
32715926|NCT05456165|Experimental|GRT-C901/GRT-R902 Vaccine arm|After surgical resection, patients who are circulating tumor DNA (ctDNA) positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction, randomization, and vaccine manufacturing. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will receive a total of 6 doses of GRT-C901/ GRT-R902, 2 doses of ipilimumab, and 13 doses of atezolizumab. Study visits occur every 28 days.
32715927|NCT05456165|Active Comparator|Observation arm|After surgical resection, patients who are ctDNA positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction and randomization. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will be observed via study visits occur every 12 weeks.
32715928|NCT05083689|Active Comparator|Injections of 1.25 mg of intravitreal bevacizumab with topical drops of Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
32715929|NCT05083689|Placebo Comparator|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
32715930|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
32715931|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
32715932|NCT00871325|Placebo Comparator|Placebo|Placebo TID
32715933|NCT05243264|Experimental|Internet-Based Program|Participants will be provided with access to a 10-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
32715934|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
32715935|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
32715936|NCT05165966|Experimental|Experimental Group-High-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with high-dosage of COVID-19 vaccine (Vero cell), Inactivated.
32715937|NCT05165966|Experimental|Experimental Group-Medium-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with medium-dosage of COVID-19 vaccine (Vero cell), Inactivated.
32715938|NCT00870155|Experimental|Dirucotide|
32715939|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
32715940|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
32715941|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
32715942|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
32715943|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
32715944|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
32715945|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
32715946|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
32715947|NCT05165732|Experimental|Experimental Group 1|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
32715948|NCT05165732|Experimental|Experimental Group 2|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
32715949|NCT05165732|Experimental|Experimental Group 3|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd.
32742840|NCT04964583|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.
32715950|NCT05165732|Experimental|Experimental Group 4|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
32916644|NCT04100135|Experimental|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
32916645|NCT04100135|Sham Comparator|Control Arm|Sham device PFO closure (PFO not closed)
32715951|NCT05165732|Experimental|Experimental Group 5|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.
32715952|NCT04474769|Experimental|Educational intervention|Intervention group's preceptors is given an eight-hour education entity about orientation and preceptorship. The objective is to enhance preceptors' knowledge and skills about the orientation and to give preceptors means to precept new graduate nurses better.
32715953|NCT04474769|No Intervention|No intervention|Nursing units at the control group continue to precept as before.
32715954|NCT04477083|Active Comparator|inhalable hydroxychloroquine (HCQ).|supportive and symptomatic treatment and inhalable hydroxychloroquine (HCQ).
32715955|NCT04477083|Placebo Comparator|Placebo|supportive and symptomatic treatment
32715956|NCT05165108|Experimental|Non-Invasive VNS|Non-Invasive VNS will decrease inflammation in people with Crohn's disease leading to decrease in inflammatory markers and symptoms of disease.
33247184|NCT04061304|Sham Comparator|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
33247185|NCT03605368|Active Comparator|Video Modeling|
32715959|NCT04674397||Test group|Living kidney donors
32715960|NCT04422158|Experimental|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
32715961|NCT04422158|Experimental|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
32715962|NCT04422158|Placebo Comparator|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
32715963|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
32715964|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
32715965|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
32715966|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
32715967|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
32715968|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
32715969|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
32715970|NCT04474067||• Asymptomatic or Pre-symptomatic Infection|Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.
32715971|NCT04474067||Mild COVID-19|"Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.~According to NIH classification"
32715972|NCT04474067||Moderate COVID-19|COVID-19 patients who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.
32715973|NCT04474067||Severe COVID-19|COVID-19 patients who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, or lung infiltrates >50%
32715974|NCT04474067||Critical COVID-19|COVID-19 patients who have respiratory failure, septic shock, and/or multiple organ dysfunction.
32715975|NCT04474067||Sepsis|A control group of patients with sepsis-related cytokine storm
32715976|NCT04474067||CAR-T CRS|A control group of patients with cytokine release syndrome due to CAR-T therapy
32715977|NCT05478122|Experimental|Interventional|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
32715978|NCT04568395|Experimental|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
32715979|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
32916646|NCT05595122|Experimental|Intervention|EUS-CDS using FCSEMS through LAMS
32916647|NCT03190005||group 1|placebo control without medication.
32916648|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
32916649|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
32916650|NCT03190005||group 4|normo-reactive responser after clopidogrel.
33247186|NCT03605368|Experimental|Virtual Reality Intervention|
33247187|NCT00921336|Experimental|KW-2450|
32715980|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
32715981|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
32715982|NCT05242562|Experimental|Pleinvue|a 1L poly ethylene glycol PEG solution with added ascorbate (Pleinvue, Norgine, active ingredients PEG 3350, Sodium ascorbate, Sodium sulfate, Ascorbic acid, Sodium chloride, Potassium chlorid)
32715983|NCT05242562|Active Comparator|Moviprep|a 2L PEG solution with added ascorbate (Moviprep, Norgine, active ingredients Macrogol 3350, Sodium Sulphate Anhydrous, Sodium chloride, Potassium chloride, Ascorbic acid, Sodium ascorbate)
32916651|NCT03190005||group 5|reaction after OPC-13013
32916652|NCT03190005||group 6|reaction after AR-C
32916653|NCT03190005||group 7|reaction after simastatin
32916654|NCT04637009|Experimental|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
32916655|NCT04637009|Experimental|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
32916656|NCT05579366|Experimental|PRO1184|PRO1184 monotherapy in escalating doses in Part A and at the recommended dose in Part B.
32916657|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
32916658|NCT04627103|Experimental|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
32916659|NCT04816214|Experimental|Combination of capmatinib + osimertinib (run-in part)|For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required, a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)
32916660|NCT04816214|Experimental|Combination of capmatinib + osimertinib (randomized part)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).
32916661|NCT04816214|Active Comparator|Platinum + pemetrexed based doublet chemotherapy (randomized part)|For randomized part: following local guidelines as per standard of care and products labels Participants randomized to platinum-pemetrexed based doublet chemotherapy arm will be allowed to crossover to receive capmatinib in combination with osimertinib
32916662|NCT04046003|Experimental|Tai Chi intervention|24-form Yang style Tai Chi
32916663|NCT04814654|Experimental|CHALO! 2.0|MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment and a a link to a study-specific webpage listing MSM specific testing, prevention, and care resources. Participants will also be able to interact with online outreach workers.
33247188|NCT04036786|Experimental|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
33247189|NCT04036786|Other|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
32916664|NCT04814654|Active Comparator|Attention-matched control (AMC)|MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health and a link to a study-specific webpage listing testing resources and MSM-specific services. Participants will also be able to interact with online outreach workers.
32916665|NCT04814654|Active Comparator|Digital coupon only control (DCO)|MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a study specific webpage link listing testing and MSM specific services.
32916666|NCT04798118|Experimental|group treated with toilet bronchoscope|"Toilet bronchoscopy will be done as supportive care to sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~Copious secretion~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
33247190|NCT05195112|Experimental|MT921|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 3mg/cm2"
33247191|NCT05195112|Placebo Comparator|Placebo|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 0mg/cm2"
33247192|NCT05190978|Experimental|Acellular Dermal Matrix|Patients will receive ADM during their initial tissue expander placement.
33247193|NCT05190978|Active Comparator|Control|Patients will not receive ADM during their initial tissue expander placement.
33247194|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
32715984|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
32916667|NCT04798118|Active Comparator|group treated with standered care|"sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~Copious secretion~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
32916668|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo~Single Saline Injection into the Pectoralis Muscle"
32916669|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
32916670|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
33247195|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
33247196|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
33247197|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
33247198|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
33247199|NCT00892138|Experimental|Mindfulness training|Mindfulness training
33247200|NCT00892138|No Intervention|Control|Study program as usual
33247201|NCT02567370|Placebo Comparator|Placebo|
33247202|NCT02567370|Active Comparator|AMG 581|
33247203|NCT04668144|Active Comparator|Prasugrel|Prasugrel only administered at the start of PCI
32765915|NCT03509467|Placebo Comparator|Control Group A|"Control Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
32765916|NCT03509467|Placebo Comparator|Control Group B|"Control Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
32765917|NCT03490903|Experimental|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
32765918|NCT03490903|Active Comparator|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
32765919|NCT03438721|Experimental|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
32765920|NCT03438721|Experimental|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
32765921|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
32765922|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
32765923|NCT04276909|Experimental|Lum Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection at the beginning of the surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
32765924|NCT04253509||Lung cancer|
32765925|NCT04253509||Benign pulmonary disease|
32765926|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
32765927|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
32765928|NCT04248985||Pre-Intervention|Baseline measurement of timing and behavior in OOH cardiac arrest patients presenting with ongoing CPR.
32765929|NCT04248985||Post-Intervention|Timing and behavior in OOH cardiac arrest patents presenting with ongoing CPR
32765930|NCT04169191|Experimental|Sildenafil|
32765931|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
32765932|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
32765933|NCT03225547|Experimental|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
32765934|NCT03225547|Experimental|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
32765935|NCT03954613|Experimental|Group A|Donepezil/Memantin Combination
32765936|NCT03954613|Experimental|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
32765937|NCT03954613|Active Comparator|Group C|Donepezil Mono
32765938|NCT03954613|Active Comparator|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
32765939|NCT03954613|Active Comparator|Group E|Memantine Mono
32765940|NCT03954613|Active Comparator|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
32765941|NCT04504201||Early Breast Cancer Patients|Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.
32765942|NCT04504201||Medical Oncology Clinicians|Oncology providers associated with community-based practices
32765943|NCT04103359|Experimental|MDS patients|MDS patients receiving blood transfusion
32765944|NCT04052893|Experimental|Study group|100 patients will be assigned into a study group.
32765945|NCT04052893|Active Comparator|Control group|100 patients will be assigned into a control group.
32765946|NCT03367819|Experimental|Phase 1: mCRPC/NSCLC|Isatuximab dose 1 and REGN2810 predefined dose
32916671|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
32916672|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
32916673|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
32916674|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
32916675|NCT05559866|Active Comparator|Control Group: ESG|Subjects will undergo ESG utilizing approved device alone
32916676|NCT05559866|Experimental|Treatment Group: ESG + HAPC|Subjects will undergo ESG as approved and on-label while also utilizing Hybrid APC approved and on-label.
32916677|NCT05106777|Experimental|Surufatinib|Drug: Surufatinib Surufatinib will be given orally.
32916678|NCT04795934|Active Comparator|Laparoscopic Nissen Fundoplication (LNF)|Control
32916679|NCT04795934|Active Comparator|Combo Transoral Incisionless Fundoplication (CTIF)|Treatment
32916680|NCT01461915|Experimental|Run-in|"During the Run-In Period, patients will receive gemcitabine + nab-paclitaxel + dociparstat to assess the compatibility of the combination.~• Nab-paclitaxel + gemcitabine + dociparstat:~Nab-paclitaxel 125 mg/m2 will be administered intravenously (IV) over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
32916681|NCT01461915|Experimental|Arm A|"Patients randomized to Arm A will receive gemcitabine + nab-paclitaxel + dociparstat.~• Nab-paclitaxel + gemcitabine + dociparstat:~Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
32916682|NCT01461915|Active Comparator|Arm B|"Patients randomized to Arm B will receive gemcitabine + nab-paclitaxel. • Nab-paclitaxel + gemcitabine:~o Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle)."
32916683|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
32916684|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
32916685|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
32916686|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
32916687|NCT01683422|Experimental|Proton Radiation|"Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles"
32916688|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
32916689|NCT02240654||Dabigatran etexilate|
32916690|NCT00027183||1|Healthy Volunteers
32916691|NCT00027183||2|Cystic Fibrosis subjects
32916692|NCT05066061|Active Comparator|standard|Only use local anesthetic cream
32916693|NCT05066061|Experimental|anxiolytic gas|Use local anesthetic cream and anesthetic and anxiolytic gas
32916694|NCT05066061|Experimental|virtual reality|Use local anesthetic cream and virtual reality mask
32916695|NCT04781673|Active Comparator|Ketamine|"Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
32916696|NCT04781673|Active Comparator|Lidocaine|"Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
32916697|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
32916698|NCT01683812|Experimental|Cranial Cup Arm|Single arm
32916699|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
32916700|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
32916701|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
32916702|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
32715985|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
32916703|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
32916704|NCT04663737|Experimental|Group A|Group A will receive the best supportive care and/or recommended standard of care (at this point no standard of care drugs are recommended by CDC for patients with moderate COVID-19) in combination with the study drug Silmitasertib
32916705|NCT04663737|Active Comparator|Group B|Group B (control) that will receive the same care as the Group A but without Silmitasertib
32916706|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
32916707|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
32916708|NCT02303093||Panzyga|Patient receiving panzyga
32916709|NCT04606173|Experimental|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
32916710|NCT04606173|No Intervention|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
32916711|NCT04960215|Active Comparator|Coenzyme Q10|
32916712|NCT04960215|Placebo Comparator|Placebo|
32916713|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
32916714|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
32916715|NCT04555317|No Intervention|Standard of Care|No intervention. Standard of care cancer pathway followed.
32916716|NCT04555317|Active Comparator|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
32916717|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
32916718|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
32916719|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
32916720|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
32916721|NCT03200535|No Intervention|Usual care|Usual care
32916722|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
32916723|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
32916724|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
32715986|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
32916725|NCT04028063|Experimental|doxorubicin with AGEN1884 and AGEN2034|Doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. Doxorubicin dosing is standard at 75 mg/m2 via Bolus with prior Dexrazoxane. AGEN2034 - 300 mg IV over 60min with infusion pump. AGEN1884 - 1 mg/kg IV over 90 min (-10 /+20 min) with infusion pump, within 30 minutes (0 / +20) of completion of AGEN2034.
32916726|NCT03998735|Experimental|Group 1 (N=15)|160 µg/g herbal snuff, median level found in commercial moist snuff
32916727|NCT03998735|Experimental|Group 2 (N=15)|70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded)
32916728|NCT03998735|Experimental|Group 3 (N=15)|3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff
32916729|NCT03998735|Active Comparator|Group 4(N=10)|0 µg/g herbal snuff, control group will use unmodified herbal snuff
32916730|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:~their intention to practice skin to skin at the time of delivery~if they participated in skin to skin in a previous pregnancy~if they had any formal education about skin to skin~if they did have formal education was it either~a.) Provided at a prenatal appointment,~b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
33247204|NCT04668144|Experimental|Prasugrel + Cangrelor|Cangrelor plus prasugrel concomitantly administered at the start of PCI
32742841|NCT04964583|Placebo Comparator|Placebo|Placebo one tablet every 12 hours for ten days.
32742842|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
32916731|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
32916732|NCT02314169|Experimental|Part A (nivolumab)|Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
32916733|NCT02314169|Experimental|Part B Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
32916734|NCT02314169|Experimental|Part B Arm II (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
32916735|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
33247205|NCT04668144|Active Comparator|Cangrelor followed by Prasugrel|Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion
32715987|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
32715988|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
32715989|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
32715990|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
32715991|NCT04473989|Placebo Comparator|Placebo|Injection product without active teriparatide
32715992|NCT04473989|Experimental|PTH 40ug/w|Injection product with active teriparatide
32715993|NCT05209490|Other|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|
32715994|NCT05209490|Other|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|
32715995|NCT05083455||Enoxaparin|Reference group
32715996|NCT05083455||Rivaroxaban|Exposure group
32715997|NCT04414423|Experimental|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
32715998|NCT04414423|Active Comparator|autogenous bone graft|grafting with autogenous bone graft
32715999|NCT00861185|Experimental|Senicapoc|
32716000|NCT00861185|Placebo Comparator|Placebo|
32716001|NCT05163080|Active Comparator|Arm A|Peptide Vaccine (SurVaxM) in emulsion with Montanide given together with locally administered Sargramostim plus adjuvant oral Temozolomide
32716002|NCT05163080|Placebo Comparator|Arm B|Saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide
32716003|NCT05083377||Patients who have been prescribed clozapine during 2018|Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.
32716004|NCT04473911|Experimental|Regimen 1: Fludarabine, Cyclophosphamide, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~Pre- stem cell transplant:~Fludarabine predetermined dose, intravenously, 4 times per cycle~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Total body irradiation (TBI) once during treatment cycle~Post stem cell transplant:~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
32742843|NCT04426773|Experimental|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
32742844|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
32745892|NCT04811313|Active Comparator|TC group|each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
32745893|NCT04811313|Active Comparator|C group|each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
32745894|NCT04811313|Placebo Comparator|P group|participants will receive the regular standard care without adding tranexamic acid or caudal epidural block
32916736|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
32916737|NCT01685684|Experimental|Oxycodone DETERx|
32916738|NCT01685684|Placebo Comparator|Placebo|
32916739|NCT04511871|Experimental|CCT303-406|"To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors.~Dose cohorts:~Dose 1: 3x10^5 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~Dose 2: 1x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~Dose 3: 3x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~Dose 4: 1x10^7 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion"
32916740|NCT02305433|Experimental|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
32916741|NCT02305433|Experimental|Physiotherapy (physical exercise) for operated hip fracture patients|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
32916742|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
32916743|NCT02305433|No Intervention|Usual care for operated hip fracture patients|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
32916744|NCT04505319|Experimental|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.~The filler will inject in the face."
33247206|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
33247207|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
32716005|NCT04473911|Experimental|Regimen 2: Fludarabine, Melphalan, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~Pre- stem cell transplant:~Fludarabine predetermined dose, intravenously 3 times per cycle~Melphalan, infusion, determined dosage, once per cycle~Total body irradiation (TBI) once per cycle.~Post stem cell transplant~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
32716006|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
32716007|NCT02322073||Obese|Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status
32716008|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
32716009|NCT05162222|Experimental|Danicamtiv, followed by itraconazole + danicamtiv|
32716010|NCT05162222|Experimental|Danicamtiv, followed by diltiazem + danicamtiv|
32916745|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
32916746|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
32916747|NCT04472091|Experimental|Genicular artery embolization|"Participants will undergo the genicular artery embolization (GAE) procedure for the treatment of moderate to severe knee osteoarthritis. A total of 30 patients will be enrolled in the single treatment arm of the study.~The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, patients will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ). Following treatment, patients will undergo follow-up at 1, 6, 12, and 24 months post GAE."
32916748|NCT04579679|Experimental|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1~Cohort D:~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
32916749|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
32916750|NCT04568213|Experimental|Hypochlorous Gel Application|
32916751|NCT05440851|Other|ULTIMATE domain: ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal|
32916752|NCT05440851|Other|Invasive mechanical ventilation domain|
32916753|NCT03978767|Experimental|NSAID Analgesic bundle|Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
32916754|NCT03978767|Active Comparator|NSAID free analgesic bundle|Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
32916755|NCT04436133|Experimental|vaccine group|
32916756|NCT04436133|Active Comparator|Positive control group|
32916757|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
32916758|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
32916759|NCT04550429|Active Comparator|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
32916760|NCT04550429|Sham Comparator|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
32916761|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
32916762|NCT03931655||Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
32916763|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
32916764|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
32916765|NCT04852809||Questionnaire|Observational
32916766|NCT04852809||Focus Group|Observational
32916767|NCT04549103|Experimental|Intervention Group|Intervention group will receive the 16-week Baduanjin exercise intervention.
32916768|NCT04549103|No Intervention|Control Group|Control group will not receive the exercise intervention, but they will attend four education classes about managing their health status.
32916769|NCT04651790|Active Comparator|Vaccine 0-14|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
32916770|NCT04651790|Experimental|Vaccine 0-28|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
32916771|NCT04543955|Experimental|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
32716011|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
32716012|NCT05241158|Active Comparator|Group A|Group A: Counselling group Patients were given a briefing about the procedure; the use of local anesthetic along with potential benefits and side effects of the drug. The steps of the endoscopy procedure (gastroscopy or colonoscopy) were explained in detail including the position, intubation, biopsy or intervention wherever applicable, extubation and post-procedure observation period in the recovery room. Detailed instructions were provided regarding post-procedural care, introduction of diet & follow-up.
32716013|NCT05241158|Active Comparator|Group B|Group B: Video group Patients in the visual aid group (video group) were provided with the same information mentioned in intervention group A. In addition to that, patients watched a 5 minutes video of the respective procedure. Video showed the animation of a gastroscopy or colonoscopy procedure with a voice over explaining all the steps of the procedure in addition to the pre and post-procedure precautions to be observed.
32716014|NCT05088057|Experimental|Camrelizumab+Chemotherapy|"PD-1+AC-T: Participants receive Camrelizumab Q3W + doxorubicin Q3W + cyclophosphamide Q3W for 4 cycles, followed by Camrelizumab Q3W + docetaxel Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery.~PD-1+TA: Participants receive Camrelizumab Q3W for 8 cycles , docetaxel Q3W + doxorubicin Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery."
32716015|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
32716016|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
32916772|NCT04543955|Experimental|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
32916773|NCT04633148|Experimental|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
32916774|NCT04847037|Experimental|Connected Tools|For the experimental group, the postoperative procedure requires the use of personal connected tools: a smartphone, a digital tablet or a computer with internet connection. A scale and a connected watch will also be loaned to patients so that they can take the necessary measures. Before returning home, patients must be trained to take correct measures and inform them on the dedicated platform.
32916775|NCT04847037|No Intervention|No Connected Tools|Patients randomized to the control group will be operated according to the same protocol as the experimental group. For them, there will be no home follow-up, so no special procedure to follow.
32916776|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
32916777|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
32716017|NCT00857285|Experimental|1|olmesartan medoxomil
32716018|NCT00857285|Active Comparator|2|losartan potassium
32716019|NCT05238896|Experimental|Baricitinib|Patients receiving baricitinib 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
32716020|NCT05238896|Placebo Comparator|Placebo|Patients receiving placebo 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
32716021|NCT05087901||Silicone-filled eyes|
32716022|NCT04461457|Experimental|Intraperitoneal Radioimmunotherapy boost|Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.
32716023|NCT04473833|Experimental|Participants in the Kentucky Ovarian Cancer Screening Program|Participants from the Kentucky Ovarian Cancer Screening Program who choose to participate in this trial will undergo further serial transvaginal ultrasonography (TVS) screening.
32716024|NCT05087511||only preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
32716025|NCT05087511||riskly preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
32716026|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
32716027|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
32716028|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
32716029|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
32916778|NCT04623554|Active Comparator|Intervention arm|Prehabilitation program
32916779|NCT04623554|No Intervention|Control arm|Usual care
32716030|NCT05206604|Experimental|PF-07295324|Ointment
32716031|NCT05206604|Experimental|PF-07259955|Cream
32716032|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
32716033|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
32716034|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
32716035|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
32716036|NCT04461379|Experimental|BCG Vaccine|A single dose BCG vaccine intradermally 0.1 ml.
32716037|NCT04461379|Placebo Comparator|Placebo|A single dose intradermally 0.1 ml of NaCl 0.9% solution
32716038|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
32716039|NCT05238350|Experimental|Acupressure (intervention group)|The intervention group was performed with 45 patients. Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
32716040|NCT05238350|No Intervention|Control group|Thecontrol group was performed with 45 patients. Any application was not performed for the control group.
32716041|NCT04461145|Other|ACL group|
32716042|NCT05650138|Experimental|jacobson's progressive muscular relaxation technique|Questionnaire will be used as subjective measurements of activity of daily living and Bp will be monitored for initial readings. They will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis twice a week for four weeks. At the end of 4 weeks of treatment session blood pressure will be recorded questionnaire will be filled
32716043|NCT05650138|Active Comparator|30 min walk|4 weeks, twice a week, 30 minutes walk
32716044|NCT05205746|Experimental|Intramuscular|10 8.0 EID 50/dose intramuscular
32716045|NCT05205746|Experimental|Intranasal|10 8.0 EID 50/dose intranasal
32716046|NCT05205746|Other|Intramuscular Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intramuscular After mask opening ChAdOx-1-S[recombinant]) Intramuscular
32716047|NCT05205746|Other|Intranasal Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intranasal After mask opening ChAdOx-1-S[recombinant]) Intramuscular
32716048|NCT05083221|Experimental|Hear-Talk-Activity audiological rehabilitation program|Audiological intervention program
32716049|NCT05083221|No Intervention|Control group|Waitlist control program
32716050|NCT00852839|Experimental|552-02|
32716051|NCT00852839|Placebo Comparator|Placebo|
32716052|NCT01517659|Experimental|Fat Reduction|The Zeltiq CoolSculpting System will be used to treat subcutaneous fat on each inner thigh.
32716053|NCT04876612|Placebo Comparator|Patients who received placebo after transforminal epidural steroid injection|Patients who took placebo for 12 weeks after TFESI
32716054|NCT04876612|Experimental|Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection|Patients who took limaprost (Opalmon®) for 12 weeks after TFESI
32716055|NCT05087433|Experimental|İntervention Group|"Practicing Progressive Relaxation Exercises The training of the Zoom application progressive relaxation exercise for the nurses was done in two sessions for a total of 60 minutes. During the first interview, the definition, purpose, benefits, and application techniques of PRE were explained to the nurses in the intervention group. In the second session, the steps of progressive relaxation exercises were demonstrated by the trainer.~The trainer performed the PRE exercise online with the nurses. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month."
32716056|NCT05087433|No Intervention|Control Group|No intervention was applied to the control group during the study. However, after the research was completed, the video of the application of the progressive relaxation exercises to the control group was shared on the WhatsApp group.
32716057|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
32716058|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
32716059|NCT05238116|Experimental|PC945|PC945 dose, administered via nebulizer, twice daily
32716060|NCT05238116|Placebo Comparator|Placebo|PC945-placebo administered via nebulizer, twice daily
32916780|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
32916781|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
32916782|NCT05481086||1|Individuals with fibromyalgia syndrome
32916783|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
32916784|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
32916785|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
32916786|NCT02175173||E2080|Children ages >= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing >= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
32916787|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
32916788|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
32916789|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
32916790|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
32916791|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
32916792|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
32916793|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
32916794|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
32916795|NCT04736043||Patients with resected pancreatic cancer who require adjuvant chemotherapy|
32716061|NCT04876534|Experimental|Tocilizumab|32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
32916796|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
32916797|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
32916798|NCT03215901|No Intervention|Pure Control|Participants view no video.
32916799|NCT04121403|Active Comparator|Rituximab|Biosimilar rituximab concentrate for solution for infusion
32916800|NCT04121403|Active Comparator|Cladribine|Mavenclad oral cladribine tablets
32916801|NCT04115085|Experimental|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
32916802|NCT04115085|Experimental|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
33247208|NCT00401245|Active Comparator|A|
32716062|NCT04876534|Active Comparator|Methylprednisolone|32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks
32716063|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
32716064|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
32716065|NCT05087043|Experimental|Oral Stimulation and Supplemental Nursing System group|Oral motor Stimulation (OMS) and an Supplemental Nursing System (SNS) were applied to preterm infants in the experimental group.
32716066|NCT05087043|No Intervention|control group|The clinic's routine feeding protocol was applied to the babies in the control group.
32716067|NCT05082753|Experimental|Ivermectin tablets (3 mg Ivermectin)|
32716068|NCT05082753|Active Comparator|Stromectol ® tablets (3 mg Ivermectin)|
32716069|NCT05650060||Secukinumab|all patients with psoriasis who received secukinumab
32716070|NCT02443831|Experimental|CD19/22 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19/22CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19/22CAR T-cells.
32716071|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
32916803|NCT04115085|Experimental|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
32916804|NCT05406141|Experimental|children with food protein allergy|
32916805|NCT04047537|Other|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
32916806|NCT04047537|Other|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
33247209|NCT00401245|Active Comparator|B|
32916807|NCT04047537|Other|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
32916808|NCT03984201|Active Comparator|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
32916809|NCT03984201|Active Comparator|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
32916810|NCT03984201|Sham Comparator|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
32916811|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
32916812|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
32916813|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
32916814|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
32916815|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
32916816|NCT02049515|Experimental|IPI-145|IPI-145 was administered orally and supplied as 5 mg and 25 mg formulated capsules.
32916817|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab was administered as an intravenous (IV) infusion and was supplied in single-use vials at two strengths, 100 mg/5 milliliters (mL) and 1000 mg/50 mL.
32916818|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
32916819|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
32916820|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
32916821|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
32916822|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
32916823|NCT03224403|Placebo Comparator|Placebo|Placebo
32916824|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
32916825|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
32916826|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
32916827|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
33247210|NCT00401245|Active Comparator|C|
32916828|NCT04501523|Experimental|A|ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine
32916829|NCT04501523|Active Comparator|B|ctDNA positive, non-pCR Intervention: capecitabine(standard care)
32916830|NCT04501523|Experimental|C|ctDNA positive, pCR Intervention: capecitabine
32916831|NCT04501523|No Intervention|D|Follow up(standard care)
32916832|NCT04499573|Experimental|intervention/treatment|"Intervention:~Patient (cohort 1 and 2) or donor (cohort 3) leukapheresis~Drug therapy:~Fludarabine 120 mg/m2~Cyclophosphamide 750 mg/m2~Etoposide 450 mg/m2~Cytarabine 900 mg/m2~Dexamethasone 30 mg/m2~Tocilizumab 8 mg/kg BW~Biological:~Cohort 1 and 2: autologous CD19/CD22 CAR-T lymphocytes, dose 0.15 - 1.5х106/kg~Cohort 3: allogeneic CD19/CD22 CAR-T lymphocytes, dose 0.1х106/kg + allogeneic HSCT from a haploidentical or matched related donor"
33247211|NCT00401245|Active Comparator|D|
33247212|NCT00401245|Active Comparator|E|
33247213|NCT00401245|Active Comparator|F|
33247214|NCT00401245|Active Comparator|G|
33247215|NCT00401245|Placebo Comparator|H|
33247216|NCT04661280|No Intervention|Cognitive remediation|Non-drug treatment, cognitive remediation, cognitive stimulation
33247217|NCT04661280|Experimental|Cognitive remediation + Donepezil|Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
32916833|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
32916834|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
32916835|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
32916836|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
32916837|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
32916838|NCT03895697|Experimental|Dasiglucagon batch A crossover to dasiglucagon batch B|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch A then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch B
32916839|NCT03895697|Experimental|Dasiglucagon batch B crossover to dasiglucagon batch A|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch B then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch A
32916840|NCT04706871|Experimental|taVNS group|
32916841|NCT04706871|Placebo Comparator|tnVNS group|
32916842|NCT01926041|Experimental|Intervention|A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.
32916843|NCT01926041|No Intervention|Control|Usual care
32916844|NCT05440773|Experimental|Treatment group 1 (TG 1)|Group of 8 persons receiving A. afra infusions of 5g/1liter of water, 3drinks a day, daily for 1week (7 days) (current recommendation)
32916845|NCT05440773|Experimental|Treatment group 2 (TG 2)|Group of 8 persons receiving A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
32916846|NCT05440773|Experimental|Treatment group 3 (TG 3)|Group of 8 persons receiving A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
32716072|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
32716073|NCT05086887||Migrants from malaria endemic countries arriving to or living in Sweden|The study population consists of participants born in a malaria endemic country living in Sweden, irrespective of time of residency in Sweden (e.g newly arrived migrants as well as individuals with longer residency in Sweden or another non-endemic country). Participants of all ages can be included in the study.
32716074|NCT04876378||Diagnostic (questionnaires, MRI)|Patients complete a series of questionnaires over 15 minutes about knee function and pain, as well as physical activity. Patients also undergo an MRI over 60 minutes.
32716075|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
32716076|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
32716077|NCT04919733|Experimental|Non fluoroscopy CIED implant|Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
32716078|NCT04876222|Active Comparator|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
32716079|NCT04876222|No Intervention|Subacute CAG|The patient is triaged to the coronary care unit (CCU) for rhythm surveillance, and additional diagnostics, and in case there is found indication for CAG, it is planned for the coming day in daytime (12-24 hours after cardiac arrest). Revascularization is performed if indicated according to guidelines.
32716080|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32716081|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32916847|NCT05440773|Experimental|Treatment group 4 (TG 4)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
32916848|NCT05440773|Experimental|Treatment group 5 (TG 5)|Group of 8 persons flavored A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
32916849|NCT05440773|Experimental|Treatment group 6 (TG 6)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
32916850|NCT05440773|Placebo Comparator|Treatment group 7|Group of 4 persons receiving flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
32716082|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32916851|NCT05440773|Placebo Comparator|Treatment group 8|Group of 4 participants receiving regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
32916852|NCT04736277||Noncardiac surgery|Documentation of HbA1c in patients undergoing noncardiac surgery under general anesthesia
32916853|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
32916854|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
32916855|NCT04706637|Experimental|evogliptin|evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
32916856|NCT04706637|Active Comparator|dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
32916857|NCT03832985|Experimental|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
32916858|NCT03832985|Experimental|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
32916859|NCT03832985|Active Comparator|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
32916860|NCT04735809|Placebo Comparator|Placebo|Microcystalline Cellulose
32916861|NCT04735809|Experimental|Treatment|Whole Cell Algae Fermentate
32916862|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
33073245|NCT03223753|Experimental|Arm II (tracking device, interactive-reward based device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the full version of the interactive-reward based device app/website to see their activity, earn activity points, see other's activity, and interact with other patients for 6 months.
33073246|NCT03219268|Experimental|Dose level 1|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33073247|NCT03219268|Experimental|Dose level 2|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33247218|NCT05278702||hemodialysis|
33247219|NCT05278702||peritoneal dialysis|
33247220|NCT04036474|Experimental|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
33247221|NCT04036474|No Intervention|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
33247222|NCT05278312|Experimental|Otago Exercise Program|Older adults will receive the Otago Exercise Program for 8 weeks plus health awareness videos.
33247223|NCT05278312|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
32716083|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32716084|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32716085|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
32716086|NCT00838981|Active Comparator|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
32716087|NCT00838981|Placebo Comparator|Sugar Pill Plus Contingency Management|Placebo: sugar pill
32716088|NCT00838981|Active Comparator|Modafinil Plus Voucher Control|
32716089|NCT00838981|Placebo Comparator|Sugar Pill Plus Voucher Control|
32716090|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
32916863|NCT04706949|Experimental|Pyrotinib combined with pemetrexed plus carboplatin|
32716091|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
32716092|NCT05082441|Experimental|experimental|Exparel group
32716093|NCT05082441|Active Comparator|control|plain bupivacaine
32716094|NCT05204576|No Intervention|Standard care treatment as usual (TAU)|Individuals will receive buprenorphine or methadone in addition to regular individual or group sessions as offered by the clinic
32716095|NCT05204576|Experimental|CBT4CBT-Copes|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily texts with a link to a survey.
32916864|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
33073248|NCT03219268|Experimental|Dose level 3|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33073249|NCT03219268|Experimental|Dose level 4|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33073250|NCT03219268|Experimental|Dose level 5|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33247224|NCT04036240|Experimental|Finger feeder|HMF supplementation will be given by finger feeder
33247225|NCT04036240|No Intervention|Control|HMF supplementation will be given by mother preference such as cup, bottle.
33247226|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
33247227|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
33247228|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
33247229|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
32916865|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar >2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
32916866|NCT03434457||Prenatal and 3 to 72 months|
32916867|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
32916868|NCT01582763||NC|Normal controls (NC)
32716096|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
32916869|NCT01582763||IC|Infectious controls (IC)
32916870|NCT01582763||OND|Other neurological diseases (OND)
32916871|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
32916872|NCT04469231|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
32716097|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
32716098|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
32716099|NCT05159414|Experimental|Glaucoma patients|Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
32716100|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
32716101|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
32716102|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
32716103|NCT05237258|Experimental|Specialty Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
32716104|NCT05237258|Experimental|Primary Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
32716105|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
32716106|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
32716107|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
32716108|NCT05235854|Active Comparator|Meniscal wall infiltration group|Administration of Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe under ultrasound control.
32716109|NCT05235854|Active Comparator|Intra-articular infiltration group|"The procedure is identical in all respects to the experimental group, except that the ultrasound procedure is mimicked and the infiltration of dexamethasone 2 mg (Diprostene®) is performed intra-articularly.~Administration Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe."
32716110|NCT05074251|Experimental|HIV self testing|HIV+ women will receive HIV self-tests (2) to bring home to her partner to offer for testing
32716111|NCT05074251|Active Comparator|Standard of care|In the standard of care arm, women will receive standard of care partner referrals for HIV testing, including counselling about disclosure and referral for her partner(s) to return to the facility for testing.
32716112|NCT05086445|Experimental|LY3502970 (Part A)|Single doses of LY3502970 administered orally.
32716113|NCT05086445|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally.
32716114|NCT05086445|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
32716115|NCT05086445|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
32716116|NCT05158478|Experimental|Subject glucometer measurement|
32716117|NCT05086185||Orange Juice (control)|Orange juice providing a 0.35 mEq/kg dose of potassium
32716118|NCT05086185||Orange Juice plus Fiber|Same amount of orange juice as Orange Juice treatment with 0.15 g/kg of psyllium-based fiber added
32716119|NCT05047445|Experimental|COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis)|
32716120|NCT05047445|Experimental|COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis)|
32745895|NCT04810845|Experimental|Patients undergoing coronary angiography with planned PCI|Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled
32745896|NCT04810923|Experimental|i-PRF group|arthrocentesis procedure plus four consecutive intra-articular injection of i-PRF.
32916873|NCT04454723|Experimental|Tranfusions and blood collection|"Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections.~Data on patient demographics, disease, and length of hospice stay will also be collected."
32916874|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
32916875|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
32916876|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
32916877|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
32916878|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
32916879|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
32916880|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
32716121|NCT05203484|Experimental|Multielectrode mapping|Participants assigned to the Multielectrode Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with either a Pentaray or Octaray catheter (Biosense Webster; each 45 catheters, randomly allocated). Catheter ablation of potential diastolic pathways and Scar homogenisation will be performed with a irrigated 3.5mm tip catheter (QDot; Biosense Webster).
32716122|NCT05203484|Active Comparator|Point-by-Point Mapping|Participants assigned to the Point-by-Point Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with a QDot catheter (Biosense Webster). Catheter ablation of potential diastolic pathways and scar homogenisation will also be performed with the QDot catheter.
32716123|NCT04854291|Experimental|Donor FMT|FMT from a healthy donor
33247230|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
33247231|NCT00569127|Experimental|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
32716124|NCT04854291|Placebo Comparator|Placebo|NaCl + glycerol mixture (carrier solution of FMT arm)
32716125|NCT04851405|Active Comparator|Otago Exercise Programme+ Intervention Group (OEP+)|"Physiotherapists receive OEP training, a 2 hour workshop on the coaching protocol using the OEP app, and online training on the Brief Action Plan Approach with 2 telephone practice sessions with an experienced Brief Action Plan counsellor.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up OEP app and Fitbit. PT will return bi-weekly over the course of two months (four visits total) for follow-up. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit. Between Months 7-12, PTs will continue to a phone call follow-up once a month to review the exercise routine.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also have access to the OEP app which allows the PT to prescribe exercises and record the participant's exercise goal."
32716126|NCT04851405|Placebo Comparator|Otago Exercise Programme Group (OEP)|"Physiotherapists receive OEP Training and a 2 hour workshop on just the counselling protocol.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up the Fitbit. For the first two months, PTs will provide bi-weekly home visits. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also receive a Fitbit. Between Months 7-12, older adults will receive follow-up phone calls from the research staff."
32716127|NCT05235542|Experimental|Phase Ib#Dosage regimen 1#|Subjects receive AK104 plus AK117 every 3- week cycle (Q3W) until progression
32716128|NCT05235542|Experimental|Phase Ib#Dosage regimen 2#|Subjects receive AK104 plus AK117 every 6- week cycle (Q6W) until progression
32716129|NCT05235542|Experimental|Phase II#Cohort 1#|Gastric Cancer or Gastroesophageal Junction Cancer: AK104 + XELOX (Oxaliplatin + Capecitabine)+AK117 every 3- week cycle (Q3W) until progression
32716130|NCT05235542|Experimental|Phase II#Cohort 2#|Esophageal squamous cell cancer: AK104 + 5-FU/Paclitaxel+Cisplatin± AK117 every 3- week cycle (Q3W) until progression
32716131|NCT05235542|Experimental|Phase II#Cohort 3#|Gastric Cancer or Gastroesophageal Junction Cancer or Esophageal squamous cell cancer: AK117 +Paclitaxel/Docetaxel/Irinotecan every 3- or 4- week cycle (Q3W or Q4W) until progression
32716132|NCT00840281|Experimental|1|
32716133|NCT00840281|Active Comparator|2|
32716134|NCT05086029||Psoriatic arthritis patients|
32716135|NCT05086029||healthy volunteers|
32716136|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
32716137|NCT05073705|No Intervention|Control Group|Control condition. The control condition will be standard of care. At the MRRH HIV clinic, ALHIV are identified for the transition to adult HIV care after careful consideration of factors that are individual specific. Under current standard of care, clinic visits are guided by a number of factors including the patient's age, clinical status, availability of school programs, distance from the clinic, and ability to afford transport fare to the clinic
32716138|NCT05073705|Experimental|Intervention group|The exact content to be delivered in this intervention will emerge from the Aim 2 study but is expected to consist of 6 group-based, weekly 90-minute sessions and involve elements of cognitive behavioral strategies, self-efficacy training, problem solving, psychoeducation, and resilience strengthening. This is in line with previous research among adults living with HIV suggesting that multicomponent self-management interventions are more effective in improving different health outcomes. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic. A closed group format of at least 6 participants will be used to maximize confidentiality and group cohesion.
32716139|NCT05202938||Septic shock with SIMD: SIMD+|8 patients in septic shock (Sepsis-3-) with SIMD: ejection fraction (LVEF) < 45% in the first 48 hours of admission into the intensive care unit. No prior cardiac ultrasound or normal cardiac ultrasound values less than 2 years ago , or an ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine) required to obtain a LVEF ≥ 45%, or a drop of ≥ 20% compared to the LVEF value record ed less than 2 years ago.
32716140|NCT05202938||Septic shock without SIMD: SIMD-|8 patients in septic shock (Sepsis-3) without SIMD. Ejection fraction (LVEF) ≥ 45% with or without ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine), or similar to the LVEF recorded less than 2 years ago.
32716141|NCT05202938||Acute Heart Failure with reduced Ejection Fraction: HFrEF|8 patients with acutely reduced ejection fraction (LVEF) < 50%. with or without ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine) No prior cardiac ultrasound, or normal cardiac ultrasound values less than 2 years ago, or a drop of ≥ 20% compared to the LVEF recorded less than 2 years ago. No evidence of sepsis or septic shock.
32716142|NCT05202938||Acute Heart Failure with preserved Ejection Fraction: HFpEF|8 patients with acute heart failure and a preserved ejection fraction (ejection fraction (LVEF ≥ 50% or similar to normal cardiac ultrasound values recorded less than 2 years ago). No evidence of septic shock.
32916881|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
32716143|NCT05085951|Experimental|Prophylactic pyloric balloon dilatation|OGD and dilatation
32716144|NCT05085951|Placebo Comparator|No endoscopic intervention|OGD but no dilatation
32716145|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
32716146|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
32716147|NCT05155982|Experimental|Group A (18-54 yrs)|COVAC-1 25 ug
32716148|NCT05155982|Placebo Comparator|Group B (18-54 yrs)|Placebo Control
32716149|NCT05155982|Experimental|Group C (18-54 yrs)|COVAC-1 50 ug
32716150|NCT05155982|Placebo Comparator|Group D (18-54 yrs)|Placebo Control
32716151|NCT05155982|Experimental|Group E (55+ yrs)|COVAC-1 25 ug
32716152|NCT05155982|Placebo Comparator|Group F (55+ yrs)|Placebo Control
32716153|NCT05155982|Experimental|Group G (55+ yrs)|COVAC-1 50 ug
32716154|NCT05155982|Placebo Comparator|Group H (55+ yrs)|Placebo Control
32716155|NCT04820283|Experimental|Care manager intervention (nurse)|
32716156|NCT04820283|Active Comparator|Internet-based CBT|
32716157|NCT00838799|Experimental|1|
32716158|NCT00838799|Experimental|2|
32716159|NCT00838799|Experimental|3|
32716160|NCT00838799|Active Comparator|4|
32716161|NCT00838799|Placebo Comparator|5|
32716162|NCT05234216|Experimental|Comfort Group|Centers evaluating patients after surgery requiring postoperative opioid treatment with an ICU comfort scale.
32716163|NCT05234216|Other|Pain Group|Centers evaluating patients, after surgery requiring postoperative opioid treatment, with a pain numerical verbal scale in the postoperative care service.
32745897|NCT04810923|Experimental|Control group|arthrocentesis procedure alone.
32905516|NCT03438032||Control|Healthy control subjects recruited from the Northwestern community will complete demographic and basic medical forms to ensure health
32905517|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
32905518|NCT04209348|Experimental|Physical Activity Intervention|The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
32905519|NCT04209348|Active Comparator|Wellness Education|The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats & safety checks).
32905520|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32905521|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
32905522|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
32905523|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
32905524|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
32905525|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
32905526|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
32905527|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
32905528|NCT04382300|Experimental|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
32905529|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
32905530|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
32905531|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
32916882|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
32916883|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
32916884|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
32916885|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
32916886|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
32916887|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
32916888|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
32916889|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
32916890|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
32916891|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
32916892|NCT03435783|Experimental|Intervention|
32916893|NCT03435783|Active Comparator|Attention-matched control|
32916894|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
32916895|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
32916896|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
32916897|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
32916898|NCT01989221|Other|Placebo followed by Sancuso|Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks
32916899|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI
32916900|NCT03226899|Placebo Comparator|Placebo + XOI|placebo tablet QD plus a stable, medically appropriate dose of an XOI
32916901|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
32916902|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
33247232|NCT00569127|Experimental|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33247233|NCT04036162|Experimental|Young group|Young Right-handed healthy volunteers
32916903|NCT01958645|Experimental|A|MEDI8111
33247234|NCT04036162|Experimental|Aged group|Aged Right-handed healthy volunteers
32745898|NCT04803981|Experimental|Standard diet with daily SpoonfulONE|Participants will receive one serving of SO (one of three possible forms of SO: mix-ins, puffs, or crackers) daily in addition to a standard diet. The SO form fed on a given day will be at the discretion of the parent/guardian.
32916904|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
32916905|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
32916906|NCT03437031|Experimental|Latent-Virtual Reality (VR)|Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.
32916907|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
32916908|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
32916909|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
32916910|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
33073251|NCT03219268|Experimental|Dose level 6|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33073252|NCT03219268|Experimental|Dose level 7|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33247235|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
33247236|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
33247237|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
33247238|NCT00893620|Other|1|Treatment
32916911|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
32916912|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
32916913|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
32916914|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
32916915|NCT03665285|Experimental|NC318|NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.
32916916|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
32916917|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
32716164|NCT05025735|Experimental|Phase 2 study of Fulvestrant, alpelisib and dapagliflozin|"A cycle length is defined as 28 days.~Fulvestrant 500 mg intramuscular, Cycle 1, Day 1 and Day 15; Cycle 2 and beyond 500 mg Intramuscular Day 1.~Alpelisib 300 mg by mouth, daily, continuously beginning on Cycle 1, Day 1.~Dapagliflozin 10 mg by mouth, daily, continuously beginning Cycle 1, Day 3."
32916918|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
32916919|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
32916920|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
32916921|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
32916922|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
32916923|NCT04332627|Active Comparator|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
32916924|NCT04332627|Placebo Comparator|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
32916925|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
32916926|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
32916927|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
32916928|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
32916929|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
32716165|NCT05085639|Experimental|GLS-5310 1.2 mg (Group 1)|GLS-5310 1.2 mg (ID + Gene-Derm) at Day 0 and Week 8
32716166|NCT05085639|Experimental|GLS-5310 2.4 mg (Group 2)|GLS-5310 1.2 mg (ID + Gene-Derm) + 1.2 mg (IN) at Day 0 and Week 8
32716167|NCT05085639|Experimental|GLS-5310 1.2 mg (Group 3)|GLS-5310 1.2 mg ID at Day 0 and Week 8
32916930|NCT01963091|Experimental|oxytocin|
32916931|NCT01963091|Placebo Comparator|placebo|
33073253|NCT03219268|Experimental|Dose level 8|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
33073254|NCT03219268|Experimental|Dose level 9|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles
32716168|NCT05085639|Placebo Comparator|Placebo (Group 4)|Placebo (ID + Gene-Derm) at Day 0 and Week 8
32716169|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
32716170|NCT00836069|Experimental|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
32716171|NCT00836069|Experimental|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
32716172|NCT00836069|Active Comparator|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
32716173|NCT00836069|Placebo Comparator|Placebo|Inactive Substance (placebo) for 10 weeks.
32745899|NCT04803981|No Intervention|Standard diet|Participants will feed on a standard diet only, with no intervention, and complete questionnaires
32745900|NCT04352439|Experimental|Aspirin|Patients with a Khorana risk score of 1 receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.
33247239|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
32916932|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
32916933|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
32916934|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
32916935|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
32916936|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
32916937|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
32916938|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
32916939|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
32916940|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
32916941|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
33073255|NCT03219268|Experimental|Dose level 10|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles
33247240|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
33247241|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
33247242|NCT00892450|Experimental|Arm 1|crossover design
33247243|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
33247244|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
33247245|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
33247246|NCT01566565|Active Comparator|Theophylline|
32916942|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
32916943|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
32916944|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
32916945|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
32916946|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
32916947|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
32916948|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
32916949|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
32916950|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
32916951|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
32916952|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
32916953|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
32916954|NCT01687790|Experimental|molecular breast imaging|
32916955|NCT05473598|Active Comparator|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
32916956|NCT05473598|Experimental|UC + Stand Down app (app only)|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
32916957|NCT05473598|Experimental|UC + Peer-Supported Stand Down (PS-Stand Down)|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approximately 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
32916958|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
32916959|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
32916960|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
32916961|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
32916962|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
32916963|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
32916964|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
32916965|NCT04735887|Experimental|SADL-eM & conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive a copy of the SADL-eM in addition to conventional therapy.
32916966|NCT04735887|No Intervention|Conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive conventional therapy.
32916967|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
32916968|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
32916969|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
32916970|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
32916971|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
32916972|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
32916973|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
32916974|NCT03302091|Experimental|BI 1467335 Normal (R)|Participants with normal renal function.
32916975|NCT03302091|Experimental|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
32916976|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
32916977|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
32916978|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
32916979|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
32916980|NCT04436744|Experimental|Giredestrant + Palbociclib|
32916981|NCT04436744|Active Comparator|Anastrozole + Palbociclib|
33247247|NCT01566565|Active Comparator|Bambuterol|
32916982|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
32916983|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
32916984|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
32916985|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
32716174|NCT05023395|Experimental|Investigational Medicinal Product|Patients will be assigned to receive oral MEE-HU Medicus with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
32716175|NCT05023395|Placebo Comparator|Placebo|Patients will be assigned to receive oral matching placebo with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
32916986|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
32916987|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
32916988|NCT04385888|Experimental|Low-calorie sweetener restriction|Participants will be instructed to avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners, and to instead consume unsweetened alternatives, such as plain or sparkling water for 12 weeks.
32916989|NCT04385888|No Intervention|Usual consumption/control|Participants will continue low-calorie sweetener consumption, as usual.
32916990|NCT04359758|Experimental|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
32916991|NCT04359758|Active Comparator|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
32916992|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
32916993|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
32916994|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
32916995|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
32916996|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
33247248|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
33247249|NCT00655993|Placebo Comparator|1|placebo drug
32916999|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
32917000|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
32917001|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
32917002|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
32917003|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
32917004|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
32917005|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
32917006|NCT04352270|Active Comparator|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
32917007|NCT04352270|Experimental|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
32917008|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
32917009|NCT04327154|Experimental|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
32917010|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
32917011|NCT03304119||Control group control|Group that has not been checked for patellar instability.
32917012|NCT04313504|Experimental|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
32917013|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
32917014|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
32917015|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
32917016|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
33247250|NCT00655993|Active Comparator|2|simvastatin
33247251|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
32917017|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
32917018|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
32917019|NCT04812626|Experimental|Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;|Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
32917020|NCT04812626|Experimental|Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination|"Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.~Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks."
32917021|NCT04265222|Other|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
32917022|NCT04265222|Experimental|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
32917023|NCT04249700|Experimental|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
32716176|NCT05155670|Experimental|Robotic therapy|All participants will receive a program of robot-assisted rehabilitation exercises., including passive, active-assisive and active MCP Range-of-Motion Exercises, and active bidigital pinching movements in the transparent mode.
32716177|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
32917024|NCT04793516|Experimental|VR-based spatial retraining|Game-like therapy activities will be taken place in a virtual environment, provided through an immersive head-mounted display.
32917025|NCT04218812|Active Comparator|No electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data without ESI
32917026|NCT04218812|Experimental|Automated Electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data with ESI
32917027|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
32917028|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
32917029|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
32917030|NCT04755140||Endoprosthesis|Patients with a endoprosthesis
32917031|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
32917032|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
32917033|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
32917034|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
32917035|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
32917036|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
32917037|NCT01998269||Adult patients with diabetes and hypertension|
32917038|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
32917039|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
32716178|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
32745901|NCT04351815|Experimental|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
32917040|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
32917041|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
33247252|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
32917042|NCT01999517|Placebo Comparator|Placebo|IV Fluids
32917043|NCT04670198|Experimental|Intervention|The intervention arm will receive the Youth Empowerment Skills (YES) programme.
32917044|NCT04670198|Other|Waiting-list control|The waiting-list control arm will receive usual care for six months before receiving the Youth Empowerment Skills (YES) programme.
32917045|NCT04170062|Experimental|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
32917046|NCT04170062|Experimental|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
32917047|NCT04170062|Experimental|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
32917048|NCT04170062|Experimental|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
32917049|NCT04170062|Experimental|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
32917050|NCT04170062|Experimental|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
32917051|NCT04170062|Experimental|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
33073256|NCT03218917|Experimental|Brensocatib 10 mg|Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
33073257|NCT03218917|Experimental|Brensocatib 25 mg|Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
33073258|NCT03218917|Placebo Comparator|Placebo|Participants received the matching placebo QD before breakfast, for 24 weeks.
33073259|NCT03212274|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and/or MRI, as well as a tumor biopsy and blood sample collection on study.
33073260|NCT03207841|Experimental|LC/HP group|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
33073261|NCT03207841|No Intervention|Control|Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
33247253|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
33247254|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
33247255|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
33247256|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
33247257|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
33247258|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
33247259|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
32716179|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
32745902|NCT04351815|Other|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
32716180|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
32716181|NCT05202860|Experimental|HPV vaccine|Commercially available nonavalent HPV vaccine (Gardasil(R) 9) given intramuscularly at baseline, month 2 and month 6
32716182|NCT05202860|Placebo Comparator|Isotonic Saltwater Vaccine|0.9% NaCl given intramuscularly at baseline, month 2 and month 6
32716183|NCT05020847|Active Comparator|Standard F75|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
32716184|NCT05020847|Experimental|Alternative F75 with CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
32917052|NCT04170062|Experimental|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
32917053|NCT04170062|Experimental|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
32917054|NCT04170062|Experimental|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
32917055|NCT04170062|Experimental|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
32917056|NCT04170062|Experimental|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
32917057|NCT04153760|Active Comparator|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
32917058|NCT04153760|Placebo Comparator|Placebo|Placebo daily for six weeks post-randomization (postpartum)
32917059|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
32917060|NCT02566772|Experimental|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
32917061|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
33247260|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
33247261|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
33247262|NCT00816699|Active Comparator|2|Preprint preoperative risk information
33247263|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
32716185|NCT05020847|Experimental|Alternative F75 without CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
32716186|NCT05202782|Experimental|Treatment (zanubrutinib and CAR T-cell therapy)|"LEAD- IN PHASE: Patients receive zanubrutinib PO BID for 7-14 days in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive standard of care CAR T-cell therapy IV at 4 weeks.~MAINTENANCE PHASE: Patients receive zanubrutinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity."
32917062|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
32917063|NCT01999985|Experimental|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
33247264|NCT00822627|Experimental|Vaccination group|Vaccination group
32716187|NCT05430659||EBL equal or more than 500 ml|The intraoperative estimated blood loss equal or more than 500 ml
32917064|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
32917065|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
32917066|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
32917067|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~50 mg, twice-a-day, for 12 months"
32917068|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
32917069|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
32917070|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
32917071|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
32917072|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
32917073|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
32917074|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
32917075|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
32917076|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
32917077|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
32917078|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
32917079|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
32917080|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
32917081|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
32917082|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
32917083|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
32917084|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
32917085|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
32917086|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
32917087|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
32917088|NCT01974089||Pneumonia|Patients with community aquired pneumonia
32917089|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
32917090|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
32716188|NCT05430659||EBL less than 500 ml|The intraoperative estimated blood loss less than 500 ml
32917091|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
32917092|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
32917093|NCT03307005|Experimental|Intervention|
32917094|NCT03307005|Placebo Comparator|Control|
32917095|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
32917096|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
33247265|NCT00822627|Experimental|Education/referral|Education/referral
32917097|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
32917098|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
32917099|NCT03214679|Active Comparator|Usual Care|Usual care represents the current process after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
32917100|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
32917101|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
32917102|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
32917103|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
32917104|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
32917105|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
32716189|NCT05202080|Experimental|Opioid Counseling and PCS Video Group|This arm of the study will receive the opioid counseling and pain coping skills video 2 weeks prior to their surgery in addition to the conventional information provided to all patients undergoing total joint arthroplasty.
32917106|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
32917107|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
32917108|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
32917109|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917110|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917111|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917112|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917113|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917114|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
32917115|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
32917116|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
32716190|NCT05202080|No Intervention|Standard of Care Group|This arm of the study will the conventional information provided to all patients undergoing total joint arthroplasty.
32716191|NCT00935987|Experimental|CYT387|
32716192|NCT05155124|Experimental|Cetuximab and trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
32716193|NCT04473677||Fecal Occult Blood Test|People in this group will detect hemoglobin in stool before colonoscopy by the new qFIT.
32716194|NCT05232578|Experimental|Arm A- early salvage radiotherapy (eSRT)|Early salvage radiotherapy (eSRT) will be administered immediately after the confirmation of the biochemical relapse (prostate-specific antigen PSA level increase to ≈ 0,2 ng/ml) after radical prostatectomy with defined risk factors and no clinical recurrence signs on prostate specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT).
32716195|NCT05232578|Experimental|Arm B- delayed salvage radiotherapy (dSRT)|The patient is by the biochemical relapse analysis (PSA level 0,2 ng/ml) referred for further follow-up of PSA values. dSRT is initiated, if PSA further increase to values of ≥ 0.4 ng/ml is confirmed and the presence of a potential clinical relapse is excluded with repeated PSMA-PET-CT in line with standard procedures
32716196|NCT04438343|Experimental|experimental group|
32716197|NCT04438343|Active Comparator|control group|
32716198|NCT05200832||COVID+|Participants who have experienced COVID-19
32917117|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
32917118|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
32917119|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
32917120|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
32917121|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
32917122|NCT03463941|Experimental|African American church members|
32917123|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
32917124|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
32917125|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
32917126|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
32917127|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
32917128|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
32917129|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
32917130|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
32917131|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
32917132|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
32917133|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
32917134|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
32917135|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
32917136|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
32917137|NCT03470493|Experimental|Participants|ApneaLink Air
32917138|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
32716199|NCT05200832||COVID-|Participants who have not experienced COVID-19
32716200|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
32917139|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
32917140|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
32917141|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
32917142|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
32917143|NCT02219984||patients anticoagulated|
32917144|NCT04735029|Experimental|Thermal Gun group|"The thermal gun applied on acupressure points in TCM. The thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
32917145|NCT04735029|Active Comparator|Heat Pack group|A hydrocollator heat pack used to simulate traditional thermal therapy. The application of the heat pack was wrapped with six layers of terry towels to bring the temperature down to around 43°C.
32917146|NCT04604444|Experimental|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
32917147|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
32917148|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
32917149|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
32917150|NCT01817192|Active Comparator|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
32917151|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
32917152|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
32917153|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
32716201|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
33073262|NCT03204240|Experimental|Intervention|This group will receive electrical stimulation induced exercises in addition to their standard care during in-patient rehabilitation (IPR). Standard care will include respiration therapy, bed mobility, transfers, wheelchair mobility skills, bowel and bladder management, tone and spasticity management, and skills for performing other activities of daily living. Exercises will include neuromuscular electrical stimulation (NMES) induced-resistance exercise (RE) (1x/day) and NMES-aerobic exercise (1x/day) for 3 days/week.
33073263|NCT03204240|No Intervention|Control|This group will receive standard care plus passive dynamic exercise of the lower legs (sham treatment for NMES-RE, 1x/day) and transcutaneous electrical nerve stimulation (TENS, sham treatment for NMES-aerobic exercise, 1x/day) during IPR.
33073264|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
33073265|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
33073266|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
33073267|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
33073268|NCT03157128|Experimental|LOXO-292|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
33073269|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
33073270|NCT03149770|Placebo Comparator|2|Placebo
33073271|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
33073272|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
33247266|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
33247267|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
33247268|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
33247269|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
33247270|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
32716202|NCT05200364|Experimental|Experimental :STRO-002 treatment in combination with Bevacizumab|"Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg~Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg"
32716203|NCT05389085|Other|Prospective non-blinded clinical study|All patients enrolled with with suspicious pigmented skin tumours will be scanned with reflectance confocal microscopy and photoacoustic imaging by an experienced examiner in a 30 minutes to 1-hour session. Subsequently, material for RNA and lipid analysis is obtained from tape-stripped lesional skin at the bedside. The skin tumors in patients enrolled will subsequently be treated according to hospital and national guidelines.
33073273|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
33073274|NCT03122925||Control|Healthy subjects
33247271|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
33247272|NCT00696072|Active Comparator|A1|
33247273|NCT00696072|Active Comparator|A2|
33247274|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
33247275|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
33247276|NCT00822705|Active Comparator|Oral PYY3-36|
33247277|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
33247278|NCT00822705|Placebo Comparator|4|
33247279|NCT00822783|Active Comparator|Omalizumab|
33247280|NCT00822783|Placebo Comparator|Placebo|
32745903|NCT04796025|Experimental|T-Double|TACE Combined With Sintilimab Plus Bevacizumab Biosimilar
32745904|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
32917154|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
32917155|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
32917156|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
32917157|NCT04735497||Failed Weaning|Patients who failed to be liberated from mechanical ventillation
32917158|NCT04735497||Successful Weaning|Patients who were liberated from mechanical ventillation and needed no respiratory support
32917159|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
32917160|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
32716204|NCT05231954|No Intervention|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
32917161|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
32917162|NCT04577456|Experimental|Active|Reinfusion of chyme using the Insides System for subjects with Type II intestinal failure dependent on PN
32917163|NCT04577456|No Intervention|Control|Standard of care therapies in accordance with ASPEN and ESPEN treatment guidelines
32917164|NCT01606826||Asthmatics|Subjects with active asthma.
32917165|NCT01606826||Healthy Controls|Subjects without any known pulmonary disease.
32917166|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
32917167|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
32917168|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
32917169|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
32917170|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
32917171|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
32917172|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
32917173|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
32917174|NCT03323307|Experimental|OCT imaging|OCT device images retina
32917175|NCT03323853|Experimental|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
32917176|NCT03323853|Other|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
32917177|NCT03260595|Experimental|Crisaborole ointment 2%|
32917178|NCT03260595|Placebo Comparator|Vehicle|
32917179|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
32917180|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
32917181|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
32917182|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
32917183|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
32917184|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
32917185|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
32716205|NCT05231954|Experimental|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
32917186|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
32917187|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
32917188|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
32917189|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
32917190|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
32716206|NCT05231954|Active Comparator|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
32917191|NCT01242800|Active Comparator|Arm I|Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
32917192|NCT01242800|Experimental|Arm II|Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
32917193|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
32917194|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
32917195|NCT02057081|Experimental|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
32917196|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
32917197|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
32917198|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
32917199|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
32917200|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
32917201|NCT01979159|Experimental|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
32917202|NCT03273543|Experimental|Nasal Tip Projection|
32716207|NCT05200208|Experimental|Citicoline Supplement|Participants with AD will receive dietary citicoline supplements in addition to their standard of care donepezil.
32716208|NCT05200208|Placebo Comparator|Placebo|Participants with AD will receive a placebo supplement in addition to their standard of care donepezil.
32716209|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
32716210|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
32716211|NCT05200052|Active Comparator|Colchicine 0.5 mg oral tablet|100 patients presented with anterior Myocardial infarction undergoing primary Percutaneous coronary intervention will receive colchicine tablet 1mg loading dose and colchicine 0.5 mg maintance dose for 6 months and will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
32917203|NCT03273543|Experimental|Upper Lip Position|
32917204|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
33073275|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
33073276|NCT03110744|Experimental|Palbociclib|application on 21 consecutive days of a 28 days cycle
33073277|NCT03071120|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
32917205|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
32917206|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
32917207|NCT04555226|Active Comparator|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
32917208|NCT04555226|Experimental|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
32917209|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
32917210|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
32917211|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
32716212|NCT05200052|No Intervention|Standard anti ischemic treatment|100 patients presented with anterior myocardial infarction undergoing primary percutaneous coronary intervention will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
32716213|NCT05399693||Patients with Platelet Transfusion Refractoriness|
32716214|NCT05399693||Patients without Platelet Transfusion Refractoriness|
32716215|NCT05230082|Experimental|Immediate Start|Patients will receive acupuncture treatment two times per week for 12 weeks.
32716216|NCT05230082|Active Comparator|Delayed start|Patients will act as control group for the first 12 weeks then will receive acupuncture treatment two times per week for 12 weeks.
32716217|NCT00925535|Active Comparator|Treatment A|Lersivirine
32716218|NCT00925535|Active Comparator|Treatment B|Rifabutin
32716219|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
32716220|NCT04969835|Experimental|AVA6000 Phase 1a|Patients in Phase Ia will receive escalating doses of AVA6000 following a 3+3 design, commencing with a starting dose of 80mg/m2, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
32716221|NCT04969835|Experimental|AVA6000 Phase 1b|Patients in Phase Ib will receive the RP2D dose of AVA6000, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first. One to three tumour types will be selected based on the assessment of Phase 1a data.
32716222|NCT05148494|Active Comparator|Fleet Enema|Patient is to administer one sodium bisphosphate (Fleet) enema at home 2 hours prior to arrival for surgery and a second enema one hour prior to arrival for surgery. Each 120 mL application of rectally administered enema contains 19g of monobasic sodium phosphate and 9 g of dibasic sodium phosphate. Patient is to follow standard packaging instructions from the manufacturer.
32716223|NCT05148494|Active Comparator|Pico Salax|Patient is to take Pico Salax oral bowel preparation which is a combination product consisting of 10 mg picosulfate sodium, 3.5 g magnesium oxide, and 12 g citric acid per sachet the day prior to surgery. Patient is to take 2 doses of this product, as per standard packaging instructions from the manufacturer. Specifically patient is to take the first packet contents dissolved in 150 mL water at 3pm the day before surgery. Patient is to take the second packet dissolved in 150 mL water at 8pm the day before surgery. Patient should drink 2-3L of clear liquids after each dose, for a total of 4-6L.
32917212|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
32917213|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
32917214|NCT04553822|Experimental|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
32917215|NCT04553822|Experimental|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
32917216|NCT04553822|Active Comparator|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
32917217|NCT03919994||ABILIFY MAINTENA®|Subjects newly initiated
32917218|NCT03919994||ARISTADA®|Subjects newly initiated
32917219|NCT03919994||INVEGA SUSTENNA®|Subjects newly initiated
32917220|NCT03919994||RISPERDAL CONSTA®|Subjects newly initiated
32917221|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
32917222|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
32716224|NCT04964609|Experimental|Single Arm|Comparison of EmbracePlus SpO2 readings with arterial blood saturation laboratory analysis in the same subject
32917223|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
32716225|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
32716226|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
32917224|NCT00482690|Experimental|NRT|open label NRT self comparator design
32917225|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
32917226|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
32917227|NCT04513964||Control|Patient not suffering from COVID-19
32716227|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
32917228|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
32917229|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
32917230|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
32917231|NCT04768283|No Intervention|Control group|Cardiac rehabilitation physical training program included: respiratory muscle training (7 days/week, for 15 minutes) and aerobic exercises on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax).
32917232|NCT04768283|Experimental|Intervention group 1|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training and strength exercises with weights, elastic resistance rubbers."
32716228|NCT05346653|Active Comparator|SGLT2i|Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
32716229|NCT05346653|Active Comparator|No SGLT2i|Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
32716230|NCT05147480|Active Comparator|yoga group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers intervention: 6-week, once a week internet-based mother and baby yoga
32716231|NCT05147480|No Intervention|control group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers the standardized follow-up without intervention
32716232|NCT05146388|No Intervention|Pre-Implementation - Usual Care|In pre-implementation phase, patient e-Rxs will be generated by the EHR in the usual fashion.
32716233|NCT05146388|Experimental|Post-Implementation - EHR-Based Approach|
32716234|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
32917233|NCT04768283|Experimental|Intervention group 2|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training with static and dynamic balance training device Biodex Balance System TM SD and strength exercises with HUR strength training machines."
32917234|NCT03496545|Active Comparator|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
32716235|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
32716236|NCT04236518|Experimental|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/animal protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly animal protein sources
32716237|NCT04236518|Experimental|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/plant protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly plant protein sources
32716238|NCT04236440|Experimental|Part A: A1A2+Part B+Part C|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
32716239|NCT04236440|Experimental|Part A: A2A1+Part B+Part C|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
32716240|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
32716241|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
32917235|NCT03496545|Experimental|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
32917236|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
32917237|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
32716242|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
32716243|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
32917238|NCT02309489|Experimental|Intervention|"Receive standard maternity care~Woman and partner attend one extra couple counselling session during pregnancy (A)~Partner attends one group education session for men (B)~Partner participates in pre-discharge consultation (C)"
32917239|NCT02309489|No Intervention|Control|"Receive standard maternity care~No active encouragement of partner involvement, no extra sessions offered"
32917240|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
32917241|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
32917242|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
32917243|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
32917244|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
32917245|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
32917246|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
32917247|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
32917248|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
32917249|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
32917250|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
32917251|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
32917252|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
32917253|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
32917254|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
32917255|NCT01982123|Experimental|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
32917256|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
33247281|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
32716244|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
32716245|NCT05199896|Experimental|All protocols (behavioral and EEG and fMRI)|If participants accepts (non-sighted participants and Healthy volunteers), they will carry out the behavioral protocol and the EEG protocol and fMRI protocol.
32716246|NCT05199896|Experimental|Behavioral protocol and EEG protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
32716247|NCT05199896|Experimental|Behavioral protocol and fMRI protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
32716248|NCT05198414||Healthcare workers|Healthcare workers at the first line and healthcare directives.
32716249|NCT04954859|Experimental|Nucleos(t)ide analogue (NA) naïve participants|Participants who have not received NA therapy during the parent study. No study treatment will be administered in this study.
32716250|NCT04954859|Experimental|NA controlled participants|Participants who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods. NA cessation at 3 months. No study treatment will be administered in this study.
32917257|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
32917258|NCT01711658|Placebo Comparator|IMRT + cisplatin + placebo|Intensity Modulated Radiation Therapy (IMRT) with cisplatin and placebo
32917259|NCT01711658|Active Comparator|IMRT + cisplatin + lapatinib|IMRT with cisplatin and lapatinib
32917260|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
32917261|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
32917262|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
32917263|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
32917264|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
32917265|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
32917266|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
32917267|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
32917268|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
32917269|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
32917270|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
32917271|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
32917272|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
32917273|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
32917274|NCT04417166|Experimental|Pembrolizumab and Radiotherapy|"Induction Phase:~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.~Maintenance Phase:~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
32917275|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
32917276|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
32917277|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
32917278|NCT03476330|Experimental|Quercetin|All patients will be treated with oral quercetin.
32917279|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
32917280|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
32917281|NCT04413344|Active Comparator|Active|
32917282|NCT04413344|Placebo Comparator|Placebo|
32917283|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
32917284|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
32917285|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
32917286|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
32917287|NCT03441152|Active Comparator|CT|application of CT
32917288|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
33247282|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
32917289|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
32917290|NCT03435146|Experimental|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~IPT plus DTG +2NRTIs~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs"
32917291|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
33073278|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
33247283|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
32917292|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
32917293|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
32917294|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever >38°C, C reactive Protein (CRP) >100mg/L, no infection focus expected in ≥ 24h.
32917295|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
32917296|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
32917297|NCT01717742|Active Comparator|tPA and placebo|
32917298|NCT01717742|Experimental|tPA and DNase|
32917299|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
32917300|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
32917301|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
32917302|NCT02064959|Active Comparator|Normothermia|standard care - normothermia (37°C)
32917303|NCT01736930|Active Comparator|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
32917304|NCT01736930|No Intervention|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
32917305|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
32917306|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
33247284|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
33247285|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
33247286|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
33247287|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
32917307|NCT01737944|Experimental|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
32917308|NCT01737944|Experimental|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
32917309|NCT01737944|Experimental|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
32917310|NCT01737944|Experimental|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
32917311|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
32917312|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
32917313|NCT01740206|Active Comparator|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
32917314|NCT01740206|Experimental|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
32917315|NCT01740362|Other|Healthy volunteers|Healthy volunteers
32917316|NCT01740362|Experimental|Mild renal impairment|patients with mild (>50 and ≤80 mL/min) renal impairment
32917317|NCT01740362|Experimental|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
32917318|NCT01740362|Experimental|severe renal impairment|patients with severe (<30 mL/min) renal impairment
33247288|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
33247289|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
33247290|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
33247291|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
33247292|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
33247293|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
33247294|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
32917319|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
32917320|NCT04232852|Active Comparator|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
32917321|NCT04232852|Placebo Comparator|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
32917322|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
32917323|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
32917324|NCT01741454|Active Comparator|Tamsulosin plus placebo 7-day treatment|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
32917325|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 7-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
32745905|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
32917326|NCT01741454|Active Comparator|Tamsulosin plus placebo 21-day treamtnet|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
32917327|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 21-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
32917328|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
32917329|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
32917330|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
32917331|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
32917332|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
32917333|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
32917334|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
32917335|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
32917336|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
32917337|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
32917338|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
32917339|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
32917340|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
32917341|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
32917342|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fed Washout Period (7days) Period 2: Fasted"
32917343|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fasted Washout Period (7days) Period 2: Fed"
32917344|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
32917345|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
32917346|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
32917347|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
32917348|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
32917349|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
32917350|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
32917351|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
32917352|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
32917353|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
32917354|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
32917355|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
32917356|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
32716251|NCT05197946||Subjects with CP survey|Subjects in this group are age 8 and older with a diagnosis of cerebral palsy. Participants are either able to affirmatively consent or assent with LAR consent. This sample will have a CFCS score ranging between 1 and 3 and should be able to unambiguously respond to a 65 item multiple choice survey.
32716252|NCT05197946||Control Subjects survey|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are either able to affirmatively consent or assent with LAR consent.
32716253|NCT05197946||Subjects with CP MRI|Subjects are 8 years or older with a diagnosis of cerebral palsy and clinical imaging demonstrating isolated periventricular white matter injury. Clinical assessment states that neurologic symptoms are attributed to this isolated injury. Subjects in this group must be able to lie still in a scanner for 1.5 hours in at most 2 sessions and be able to have an MRI. Participants must be able to affirmatively consent or assent with LAR consent.
32716254|NCT05197946||Control Subjects MRI|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are able to affirmatively consent and are able to have an MRI. Subjects also should be able to lie still in a scanner for 1.5 hours.
32716255|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
32716256|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
32716257|NCT05197166||Nursing students|Nursing students exposed to standing environments (prolonged walking and prolonged standing) during acute clinical settings (e.g., hospitals).
32716258|NCT05196932||COVID Card|Enrolled patients will receive antibody testing using both: 1) point-of-care, semi-quantitative SARS-CoV-2 antibodies test, 2) SARS-CoV-2 central laboratory antibodies test
32917357|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
32917358|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
32917359|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
32917360|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
32917361|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
32716259|NCT05649670|Experimental|Intervention (MSU)|Deployment of MSU + conventional ambulance
32917362|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
32917363|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
32917364|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
32917365|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
32917366|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
32917367|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
32917368|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
32917369|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
32917370|NCT01742936|Experimental|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
32917371|NCT01742936|Experimental|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
32917372|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
32917373|NCT02312765|No Intervention|Control|Standard care
32917374|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
32917375|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
32917376|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
32917377|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
32716260|NCT05649670|No Intervention|Control (usual care)|Deployment of conventional ambulance
32917378|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
32917379|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
32917380|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
32917381|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
32917382|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
32917383|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
32917384|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
32716261|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
32716262|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
32716263|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
32745923|NCT04803279||Ponto 3 SuperPower users|"Patients who are fitted either unilaterlaly or bilatterally on abutment since the device came to the market in 2016, and who have follwoed the clinics normal routine fitting and follow up visits.~They must also have undergone the normal procedures performed as part of the clinics routine for fitting and following up. Data will be collected from these routine visits."
32917385|NCT02343575|Experimental|Valproic Acid|"Start:~VPA PO/NGT 500 mg BID~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
32917386|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
32917387|NCT01744340|Experimental|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
32917388|NCT01744340|Experimental|Colon- closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
32917389|NCT04130906|Active Comparator|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
32917390|NCT04130906|Sham Comparator|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
32917391|NCT01744574|Placebo Comparator|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
32917392|NCT01744574|Experimental|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
32716264|NCT05229770|Experimental|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
32917393|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
32917394|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
32917395|NCT01744730|Active Comparator|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
33247295|NCT05180370||Outpatient or inpatient diagnosed with Heart Failure at least 6 months ago|ADAPTATION HF is a prospective, observational, cross-sectional, multicenter, survey-based study. Patients who applied to the cardiology outpatient clinic with a preliminary diagnosis of HF or were hospitalized for HF and had a diagnosis of HF for at least 6 months will be included in the study.
33247296|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
32716265|NCT05229770|No Intervention|Standard|Participants randomised to standard treatment will receive regular OAT clinic follow-up without added supplementation.
32716266|NCT05228756|Other|Resistance Band exercise for Sickle Cell Disease|Participants will complete 16 exercise session at home wearing an accelerometer
32716267|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
32716268|NCT05142254|Experimental|Tadalafil and Hydroxyurea|Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day
32716269|NCT05142254|Placebo Comparator|Placebo and Hydroxyurea|Placebo and Hydroxyurea 20 mg/kg/day
32716270|NCT00835211|Experimental|1|
32716271|NCT00835211|Active Comparator|2|
32716272|NCT05227820|Experimental|Experimental Arm: NE3107|All participants will take 200mg BID (12 hours apart) of NE3107 for 3 months.
32716273|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
32716274|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
32716275|NCT05141708||Talazoparib-treated adults with HER2- gBRCAm mBC|Adult patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib treatment in first-line or later line of therapy between January 1, 2018 and September 30, 2020.
32716276|NCT05304377|Experimental|phase 1b expansion arm at recommended dose level 1|ELVN-001 administered orally once daily at RDE-1 in CML without T315I mutations
32716277|NCT05304377|Experimental|Phase 1b expansion arm at recommended dose level 2|ELVN-001 administered orally once daily at RDE-2 in CML without T315I mutations
32716278|NCT05304377|Experimental|Phase 1b expansion arm in T315I mutated CML|ELVN-001 administered orally once daily at RDE-3
32716279|NCT05304377|Experimental|Phase 1a dose escalation in CML|ELVN-001 administered orally once daily in 3+3 dose escalation
32716280|NCT05227664|Experimental|cohort1(AK117 +AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 and AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
32716281|NCT05227664|Experimental|cohort2(AK117 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
32765947|NCT03367819|Experimental|Cohort A-1: mCRPC, isatuximab and REGN2810 combination|Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
32765948|NCT03367819|Experimental|Cohort A-2: mCRPC, isatuximab monotherapy|Participants with mCRPC will be given isatuximab dose 2
32765949|NCT03367819|Experimental|Phase 2 Cohort B: NSCLC|Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
32765950|NCT03367819|Experimental|Possibly Phase 2 Cohort C: mCRPC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC
32765951|NCT03367819|Experimental|Possibly Phase 2 Cohort D: NSCLC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
32765952|NCT04023253|Experimental|mirabegron|Receive mirabegron 2 mg treatment per day
32765953|NCT04023253|Experimental|solifenacin|Receive solifenacin 5 mg treatment per day
32765954|NCT03947515|Experimental|cancer group|
32765955|NCT03947515|Experimental|control group|
32765956|NCT03044509||TB exposure|
32765957|NCT03044509||TB infection (latent TB)|
32765958|NCT03044509||TB disease (active TB)|
32765959|NCT04506463|Experimental|Arm A|MM-II 1 ml
32765960|NCT04506463|Experimental|Arm B|MM-II 3 ml
32765961|NCT04506463|Experimental|Arm C|MM-II 6 ml
32765962|NCT04506463|Placebo Comparator|Arm 4|Placebo 1ml
32765963|NCT04506463|Placebo Comparator|Arm 5|Placebo 3ml
32765964|NCT04506463|Placebo Comparator|Arm 6|Placebo 6ml
32765965|NCT03969199|Experimental|MANNA Food Delivery Service|MANNA will deliver meals to patients randomized to the intervention arm of the study every week on the same day for 90 days. Each delivery will include: 7 breakfast meals, 7 lunch meals, 7 dinner entrees, health desserts, and fresh fruit. Meals will be delivered frozen and can be stored in a freezer until ready to eat. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
32765966|NCT03969199|No Intervention|Standard of Care Counseling|Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
32765967|NCT03066739|Active Comparator|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
32765968|NCT03066739|Active Comparator|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
32765969|NCT03066739|Active Comparator|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
32765970|NCT04875871|Experimental|High-dose group|3 fractions of 12 Gy Relative Biological Effectiveness (RBE)
32765971|NCT04875871|Experimental|Reduced-dose group|3 fractions of 8-10 Gy RBE
32765972|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
32765973|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
32765974|NCT04781725|Experimental|INT230-6 Treated Arm|"Part I: Patients will receive up to 3 doses of INT230-6 injected weekly prior to breast surgery~Part II: Patients will receive up to 2 intratumoral doses of INT230-6 (over a 15-day period) prior to breast surgery"
32765975|NCT04781725|Placebo Comparator|Control Arm|"Part I: No intervention while awaiting surgery~Part II: Placebo saline injection"
32765976|NCT04761835|Active Comparator|Dietary Peanut|Participants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.
32765977|NCT04761835|No Intervention|Strict avoidance|Participants in this group will be asked to strictly avoid any peanut in their diet for 1 year. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine whether they will transition to daily dietary peanut or continue with clinical care.
32765978|NCT02753335|Experimental|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
32765979|NCT02753335|Experimental|Desensitization|Tactile stimulation of the affected limb with different materials.
32765980|NCT02550769|Experimental|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
32765981|NCT02550769|Active Comparator|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
32765982|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
32765983|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
32765984|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
32765985|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
32765986|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
32765987|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
32905532|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
32905533|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
32905534|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
32917396|NCT01744730|Active Comparator|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
32917397|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
32917398|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
32917399|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
32917400|NCT04129970|Experimental|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
32917401|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
32917402|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
32917403|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
32917404|NCT02413151|Active Comparator|Control|Regular lifestyle
32917405|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
32917406|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
33247297|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
33247298|NCT04061460|Other|non smokers|patient who never smoked
33247299|NCT04061460|Other|former smoker|patient who smoked in the past
33247300|NCT04061460|Other|smoker|patient who still smoke
33247301|NCT00823017|Experimental|1|Patient-preferred music
32917407|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
32917408|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
32917409|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
32917410|NCT00354965|Experimental|ARM 1|
32917411|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
32917412|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
32917413|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
32917414|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
32917415|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
32917416|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
32917417|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
32917418|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
32917419|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
32917420|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
32917421|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
33247302|NCT00823017|Experimental|2|Relaxation Music
33247303|NCT00823017|Placebo Comparator|3|Standard of Care
33247304|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
33247305|NCT00819429|Experimental|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
33247306|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
32716282|NCT05227664|Experimental|cohort3(AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
32716283|NCT05226650|Experimental|Regular meal pattern|Participants will follow a regular meal pattern for a week
32917422|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
32917423|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
32917424|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
32917425|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
32716284|NCT05226650|Experimental|Irregular meal pattern|Participants will follow an irregular meal pattern for a week
32716285|NCT05304143|Experimental|Virtual Reality intervention group|The exploration in the intervention group will be carried out with virtual reality glasses compatible with the magnetic resonance imaging equipment.
32716286|NCT05304143|Active Comparator|Conventional nurse support|The exploration in the control group will be carried out with the standard procedure for claustrophobic patients that includes close nursing support.
32716287|NCT05226494|Experimental|Treatment (fb-PMT)|Daily subcutaneous injection of fb-PMT in three escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.
32716288|NCT05291819|Other|Conventional treat-to-target|Conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity
32917426|NCT04349033|Experimental|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
32917427|NCT04349033|Active Comparator|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
32917428|NCT04349033|Placebo Comparator|Pain Information Control|Patients are interviewed about their pain history and experience.
32917429|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
32917430|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
32917431|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
32917432|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
32917433|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
32917434|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
32917435|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
32917436|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
32917437|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
32716289|NCT05291819|Experimental|Imaging informed treat-to-target|Imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity.
32716290|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
32917438|NCT01723514|Experimental|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
32917439|NCT01723514|Placebo Comparator|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
32917440|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
32917441|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
33073279|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
32716291|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
32917442|NCT02044367|Experimental|Reference|multiple dose of dabigatran
32917443|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
32917444|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
33247307|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
32917445|NCT05719259||Specific patient group developing Ventilator Associated Pneumonia in ICU|"Participants will be followed up to 28 days after VAP onset or until ICU discharge, whichever comes latest.~Visit 0: Screening Screening of every eligible subject for inclusion/exclusion criteria, from the moment of initiation of IMV.~Visit 1: Enrolment Takes place within the 48h after meeting eligibility criteria.~Daily:~Screening for the FDA criteria for VAP diagnosis up to the occurrence of VAP or until ICU discharge."
32917446|NCT01745822|Experimental|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
32917447|NCT01745822|Placebo Comparator|Placebo|matching placebo (of tenofovir disoproxil fumarate)
32917448|NCT05719181|Experimental|control group|group consist of 16 patients with no protein application
32917449|NCT05719103|Active Comparator|HFNC SP|HFNC flow at 60 L/min or maximum tolerable flow at supine position
32917450|NCT05719103|Active Comparator|HFNC PP|HFNC flow at 60 L/min or maximum tolerable flow at prone position
32917451|NCT05719103|Active Comparator|NIV SP|CPAP with full face mask at 10 cmH2O at supine position
32917452|NCT05719103|Active Comparator|NIV PP|CPAP with full face mask at 10 cmH2O at prone position
32917453|NCT05719103|Placebo Comparator|MC SP|Mask oxygen at supine position
32917454|NCT05719103|Placebo Comparator|MC PP|Mask oxygen at prone position
32917455|NCT04122950|Experimental|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
32917456|NCT04122950|No Intervention|Control|Continue with normal daily routine.
32917457|NCT05719025||HIV + COVID+|
32917458|NCT05719025||HIV + COVID -|
32917459|NCT05719025||HIV - COVID +|
32917460|NCT05719025||HIV- COVID-|
32917461|NCT04002050|Active Comparator|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
32917462|NCT04002050|No Intervention|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
32917463|NCT05718947||MS scan cohort|10 patients with a known clinical diagnosis of relapsing remitting MS according to the 2017 McDonald criteria between ages of 18-65 years, who had a new lesion on their clinical brain MRI in the prior 15 months. We intend to include patients on low-efficacy medication (interferon β, peginterferon, glatiramer acetate, teriflunomide) as well as patients on high-efficacy medication (natalizumab, ocrelizumab, alemtuzumab, fingolimod) to have a varied and representative study population.
32917464|NCT04769024|Active Comparator|LUMEEN activities|Participants will benefit from LUMEEN activities for 8 weeks (2 session/week)
32716292|NCT05472662|Experimental|Test Treatment|"Placebo HFA-152a propellant via pMDI:~Administration: Single-dose administration."
32716293|NCT05472662|Placebo Comparator|Reference treatment|"Placebo HFA-134a propellant via pMDI:~Administration: Single-dose administration."
32716294|NCT05226338|Experimental|Sequence 1|3 period, 3 dose level
32716295|NCT05226338|Experimental|Sequence 2|3 period, 3 dose level
32716296|NCT05226338|Experimental|Sequence 3|3 period, 3 dose level
32716297|NCT05226338|Experimental|Sequence 4|3 period, 3 dose level
32716298|NCT05226338|Experimental|Sequence 5|3 period, 3 dose level
32716299|NCT05226338|Experimental|Sequence 6|3 period, 3 dose level
32716300|NCT00834743|Experimental|1|
32716301|NCT00834743|Active Comparator|2|
32716302|NCT04896502|Experimental|Telemedicine Arm|For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
32917465|NCT04769024|Sham Comparator|USUAL activities|Participants will benefit from the thematic group workshops for 8 weeks (2 sessions/week)
32917466|NCT05718869|Experimental|Treatment (tafasitamab and zanubrutinib)|Patients receive tafasitamab IV and zanubrutinib PO on study. Patients also undergo collection of blood samples on study and undergo CT scan and bone marrow biopsy throughout the trial.
32917467|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
32917468|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
32917469|NCT01747850|Experimental|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
32917470|NCT01747850|Placebo Comparator|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
32917471|NCT01747850|Experimental|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
32917473|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
32917474|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
32917475|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
32917476|NCT01747928|Experimental|Group 1|
32917477|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
32917478|NCT02046317|Active Comparator|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
32917479|NCT02355275|Experimental|Home Exercise Program|
32917480|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
32917481|NCT01724060||Gastric banding|Patients due for gastric banding
32917482|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
32917483|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
32917484|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
32917485|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
32917486|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
32917487|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
32917488|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
32917489|NCT01727180||Chronic kidney disease|
32917490|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
32917491|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
32917492|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
32917493|NCT02047643|Experimental|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
32716303|NCT04896502|Active Comparator|Standard of Care Education|For subjects randomized to receive standard of care asthma education, written and verbal information will be provided regarding identification and removal of potential asthma triggers in the home but no formal assessment of the home will be performed, nor will participants in this arm receive trigger reduction materials.
32716304|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
32716305|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
32716306|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
32716307|NCT05649592||Lumbar disc herniation patients|
32716308|NCT05649592||healthy volunteers|
32917494|NCT02047643|Experimental|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
32917495|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
32917496|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
32917497|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
32917498|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
32917499|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
32917500|NCT05718479|Experimental|Trauma Informed Prenatal Intervention (TPI)|The experimental arm consists of four weekly, individual (45-60 minute) sessions via Zoom with a research staff member facilitating motivational interviewing focused on behavior change and mindfulness awareness practice.
32917501|NCT05718479|Active Comparator|Prenatal Education Topics|The active comparator arm consists of four weekly, individual (30-minute) sessions via Zoom with a research staff member delivering prenatal education topics consisting of lecture (power point slides) and video.
32917502|NCT05718401||Intervention group|Patients With Multiple Myeloma Myocardial Amyloidosis
32917503|NCT05718401||Control group|Patients With Multiple Myeloma but without Myocardial Amyloidosis.
32917504|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
32917505|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
32917506|NCT00354575|Experimental|A|Chinese Herb (CCH1)
32917507|NCT00354575|Placebo Comparator|B|Starch powder as placebo
33247308|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
32917508|NCT05718323|Experimental|Treatment Arm|
32917509|NCT01748240|Experimental|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
32917510|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
32917511|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
32917512|NCT04769180||Patients affected with NCWS|100 patients with a definitive diagnosis of NCWS, based on DBPC gluten/wheat challenge.
32917513|NCT04769180||Patients affected with CD|50 patients affected with CD, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
32917514|NCT04769180||Patients affected with IBS not related to NCWS or other food allergies/intolerances|50 patients affected with IBS, according to the Rome IV criteria, not related to NCWS or other food allergies/intolerances, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
32917515|NCT01748942|Experimental|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
32917516|NCT01748942|Active Comparator|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
32917517|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
32917518|NCT05718245|Experimental|HEPA first and sham|This group of participants will be assigned an intervention of HEPA filters with the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to sham filters for 6 months.
32917519|NCT05718245|Sham Comparator|Sham first and HEPA|This group of participants will be assigned an intervention of sham filters without the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to HEPA filters for 6 months.
32917520|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
32917521|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
32917522|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
32917523|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
32917524|NCT04769336||Patient|Each patient will undergo simultaneous testing with two different CBC analyzers.
32917525|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
32917526|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
32917527|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
32917528|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
32917529|NCT05718089|Experimental|Continuous aerobic exercise|The participants will complete a 10-min warm up, followed by 40 min of continuous aerobic exercise at an individualized intensity at 64-76% of the maximal heart rate HRmax on a bicycle ergometer/walking.
32917530|NCT05718089|Experimental|High intensity interval training|The training consists of 10 minutes of warm up followed by 25 minutes of high intensity interval training (5 bouts of 4 min at >85% HRmax interspaced by 4 minutes of low intensity training) and finally a 4 min cool-down.
32917531|NCT05718089|Experimental|Resistance training|The participants will complete moderate intensity whole-body resistance training. This will consist of 4 sets with 4 exercises (leg press, chest press, back row, leg extension in appropriate machines) with a brief warm-up prior to each exercise. Each set will be interspersed by 2-min breaks. Each set (including breaks) will thus equate to 2.5 min. Intensity will be set a 12-repetition max (RM, i.e., can repeated no more than 12 times) or 10 repetitions with 1-2 repetitions in reserve (i.e., 10 repetitions where failure would occur within 1-2 more repetitions).
32917532|NCT05718011|Experimental|dexmedetomidine|0.5 micrograms/kg
32917533|NCT05718011|Active Comparator|ketamine|0.5 milligram/kg
32917534|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
32917535|NCT01730846|Placebo Comparator|Placebo|placebo control
32917536|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
33247309|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
33247310|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
32716309|NCT05226260|Experimental|Intervention|Intervention clinics receiving fully functional Epic order panel with set default [short] duration by diagnosis: for cellulitis and drained abscess, 5 days. For impetigo and undrained abscess, 7 days.
32716310|NCT05226260|No Intervention|Control|Control clinics receiving basic Epic order panel with antibiotic doses by diagnosis but duration free text (must be entered manually by clinician prescriber).
32716311|NCT04875754|Experimental|Group 1: ICM-203 (Low dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1
32716312|NCT04875754|Experimental|Group 2: ICM-203 (Medium dose) vs Placebo|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
32917537|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
32917538|NCT04348799||control group|premature infants without BPD after postnatal day 28
32917539|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
32917540|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
32917541|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
32917542|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
32917543|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
32917544|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
32917545|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
32917546|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
32917547|NCT03870230|Experimental|OHT|patients with ocular hypertension
32716313|NCT04875754|Experimental|Group 3: ICM-203 (High dose) vs Placebo|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
32716314|NCT00918983|Experimental|NX-1207|
32716315|NCT00918983|Placebo Comparator|Placebo|
32716316|NCT05225558|Experimental|Combination therapy - Vancomycin IV plus Delpazolid 800 mg, PO, BID|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
32716317|NCT05225558|Placebo Comparator|Monotherapy - Vancomycin IV plus Placebo of Delpazolid|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
32716318|NCT05649514|Experimental|Single arm|Prodromal Alzheimer's patients
32917548|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
32917549|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
32917550|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
32917551|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
32917552|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
32917553|NCT01732718|Experimental|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
32917554|NCT01732718|Placebo Comparator|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
32917555|NCT02053259|Experimental|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
32917556|NCT02053259|Experimental|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
32917557|NCT02053259|Experimental|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
32716319|NCT00834431|Experimental|1|
32716320|NCT00834431|Active Comparator|2|
32716321|NCT05138900|Experimental|Stereotactic Body Radiation Therapy (SBRT)|A single fraction of targeted SBRT
32743291|NCT04957017|No Intervention|Control group|The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled face-to-face at their homes with the ones volunteering to participate in the study, complying with the social distance rules. The same survey was re-filled after three months. No training was given to the women with chronic disease during the three-month period. After the research was completed, a 45 minute-training which is the same with the one provided to the intervention group was given individually to the control group, complying the social distance rules.
32917558|NCT02053259|Active Comparator|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
32917559|NCT05317520|Experimental|Intervention group|Cold vapor was applied 3 times in total at 0th,2nd and 6th hours.
32917560|NCT05317520|No Intervention|Control group|No cold vapor was applied at 0th,2nd and 6th hours.
32917561|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
32917562|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
32917563|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
32917564|NCT01749956|Experimental|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)~5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;~Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;~Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):~Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.~Modified FOLFOX6:~Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
32917565|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
32917566|NCT05537051|Experimental|PM1021 150 mg, 450 mg, 900 mg or 1200 mg monotherapy or in combination with PM8001 (20 mg/kg)|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
32917567|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
32917568|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
32917569|NCT03868904||OCS Lung INSPIRE Trial|
32716322|NCT05225480|Experimental|intervention arm|"The illness perception conversation will be delivered in one session during around 15 minutes. The conversation will be based on responses to the eight item Brief illness perception questionnaire and a rating of the most relevant item made by the patient on the same day.~The aim of the conversation will be to get an overview of the patient's illness perceptions concerning their knee OA and what is deemed the most maladaptive perceptions by the participant. Participants will be invited to elaborate on their thoughts concerning these perceptions.Although any maladaptive perceptions will be corrected if natural during the conversation, the conversation will not lead to any active attempts of changing illness perceptions. Rather, the conversation focusses on giving patients time and opportunity to express knee pain related perceptions and worries concerning their knee pain."
32716323|NCT05225480|Active Comparator|control arm|"The control conversation will be delivered in one session during around 15 minutes. In order to create two similar conversational settings where the only difference is the actual content of the conversations. The conversation will be based on responses to an eight item questionnaire concerning motivation for research participation and - similar to the illnes perception conversation - a rating of the most relevant item made by the patient.~The aim of the conversation will be to get an overview of the patient's motivation for research participation and let them elaborate on their thoughts concerning their motivation."
32716324|NCT00917111|Experimental|CO2 Gas|
32716325|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
32716326|NCT05224622|Experimental|Drive In|Drive In attendees will undergo one breath sampling.
32716327|NCT05224622|Experimental|Healthy|Healthy attendees will undergo two successive breath sampling.
32716328|NCT05224622|Experimental|Corona Department|Healthy attendees will undergo five successive breath sampling.
32716329|NCT04875767|Experimental|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.
32716330|NCT04875767|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
32716331|NCT05191940|Other|Particle radiotherapy|According to the radiation plan using protons or carbon ions (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
32716332|NCT05653115||Bariatric surgery|Individuals with morbid obesity and clinically relevant portal hypertension undergoing bariatric surgery
32716333|NCT00834275|Experimental|1|
32917570|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
32917571|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
32917572|NCT05532059|Experimental|GPLET|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day (<60kg) or 12 mg/ d（≥60kg）from days 1 to 21; intravenous tislelizumab 200 mg on day 15
32917573|NCT05532059|Active Comparator|GP|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8
32917574|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
32917575|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
32917576|NCT05525039|Placebo Comparator|Control Group|Subjects assigned to Contro Group will not receive VT or HMB. They will receive daily protein supplement for 6 months.
32917577|NCT05525039|Active Comparator|HMB only Group|Subjects assigned to HMB only Group will receive HMB supplement at 3g/day and daily protein supplement for 6 months.
32917578|NCT05525039|Active Comparator|VT only Group|Subjects assigned to VT only Group will receive VT (0.3g, 35Hz, at least 3 times/week) and daily protein supplement for 6 months
32917579|NCT05525039|Experimental|HMB + VT Group|Subjects assigned to HMB + VT Group will receive HMB supplement at 3g/day, VT at least 3 times/week and daily protein supplement for 6 months.
32917580|NCT05317130||This is an observational study.|The cohort will consist of elite Para athletes (athletes with an impairment).
32917581|NCT03754244|Experimental|TQB3456|p.o. qd
32917582|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
32917583|NCT05316818|Experimental|Triplet regimen (FOLFOXIRI)|The treatment planned consisted of irinotecan 160 mg/m² in 250 ml of NaCl 0.9% over 1 hr, followed by 85 mg/m² oxaliplatin in 250 ml dextrose 5% given concurrently with a 400 mg/m² leucovorin intra venous infusion in 250 ml dextrose 5% for 120 min, followed by 2400 mg/m² for 44-hr continuous infusion
32917584|NCT05316818|Active Comparator|standard duplet regimen (FOLFOX or FOLFIRI)|Regimen consisted of 180 mg/m² intravenous infusion of irinotecan for 60 min OR 85 mg/m² oxaliplatin day 1 only followed by a 200 mg/m² intra venous infusion of leucovorin for 120 min, a 400 mg/m² intravenous bolus of fluorouracil, and a 600 mg/m² continuous infusion of fluorouracil for 22 hr to be repeated on day 2
32917585|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
32917586|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
32917587|NCT01754480|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
32917588|NCT01754480|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
32917589|NCT05524961|Experimental|Timed-Bright light therapy (BLT group)|10,000lux bright light
32917590|NCT05524961|Active Comparator|Timed-inactivated negative ion generator (Active-control group)|Inactivated negative ion generator
32917591|NCT05524961|Placebo Comparator|Random-time inactivated negative ion generator (placebo group)|Inactivated negative ion generator
32917592|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
32917593|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
32917594|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
32917595|NCT02368457|No Intervention|CONTROL|No drug treatment
33247311|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
32917596|NCT01754714|Experimental|1000 mg SAMe (S-adenosyl-L-methionine)|
32917597|NCT01754714|Experimental|1500 mg SAMe|
32917598|NCT01754714|Experimental|2000 mg SAMe|
32917599|NCT01754714|No Intervention|No treatment|
32917600|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
32917601|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
32917602|NCT05503355|Experimental|Treatment|BSR-236 + venetoclax
32917603|NCT03649958|Active Comparator|HIRREM-SOP or Cereset|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.
33073281|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg twice daily (BID)
33247312|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
33247313|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
33247314|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
33247315|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
33073282|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
33073285|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
32716334|NCT00834275|Active Comparator|2|
32716335|NCT05191472|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32716336|NCT05191004|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with fulvestrant until the recommended Phase 2 combination dose (RP2cD) is determined.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
32716337|NCT05191004|Experimental|Phase 2 NUV-422 + fulvestrant|"NUV-422 will be administered orally at the RP2cD in combination with fulvestrant.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
32716338|NCT05191004|Experimental|Phase 2 NUV-422 monotherapy|NUV-422 will be administered orally at the RP2cD.
32716339|NCT05191004|Experimental|Phase 2 fulvestrant monotherapy|500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter.
32716340|NCT00834197|Experimental|1|
32716341|NCT00834197|Active Comparator|2|
32716342|NCT05224310|Active Comparator|Pectoral nerve block|Starting from the lateral third of the clavicle and moving distally and laterally to the midaxillary line. The pectoral major and minor muscles will be identified and 10 mL of bupivacaine 0.25% will be injected between the 2 muscles, and then move the ultrasound probe towards the axilla until the serratus anterior is identified above the second, third, and fourth ribs then injection of 20 mL of bupivacaine 0.25% after negative aspiration into the fascial plane between pectoralis minor and serratus anterior muscles.
32905535|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
32905536|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
32905537|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
32905538|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
32905539|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
32905540|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
32905541|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
32905542|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
32905543|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
32905544|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
32905545|NCT01394705|No Intervention|Standard of Care|standard of care (office provider exercise counseling)
32905546|NCT01394705|Experimental|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
32905547|NCT01395329|Active Comparator|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
32905548|NCT01395329|Active Comparator|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
32905549|NCT01395329|Placebo Comparator|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
32905550|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
32905551|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
32905552|NCT00831272|Placebo Comparator|Placebo|Placebo
32905553|NCT00831428||Scottish swimming team|
32905554|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
32905555|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
32716343|NCT05224310|Active Comparator|Serratus anterior plane block|"Aiming to find the serratus anterior muscle the investigator will identify the fifth rib in the midaxillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) will be detected using ultrasound.~The investigator will penetrate the serratus anterior muscle by a 23 GA, 35 mm needle in-plane to ultrasound probe from supero-anterior to postero-inferior to inject deep to it."
32917604|NCT03649958|Active Comparator|Cereset 2x|Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,
32917605|NCT05500391|Experimental|Experimental|Telesurveillance by a nurse
32917606|NCT05500391|Other|Control|On-site surveillance by a hospital physician
32917607|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
32917608|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
32917609|NCT03527108|Experimental|Patients with prior IO therapy|
32917610|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
32716344|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
32716345|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
32716346|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
32716347|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
32917611|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
32917612|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
32917613|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
32917614|NCT01757678|Other|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
32917615|NCT05491031|Experimental|Multiple sclerosis|
32917616|NCT05316272|Experimental|Exercise and placebo|supervised bone-loading exercise 3 days per week and one placebo pill per day for 36 weeks
32917617|NCT05316272|Experimental|Exercise and DHEA|supervised bone-loading exercise 3 days per week and one dose of DHEA (50 milligrams) per day for 36 weeks
32917618|NCT05316272|Experimental|no exercise and DHEA|no supervised bone exercise and one dose of DHEA (50 milligrams) per day for 36 weeks
32917619|NCT05316272|Experimental|no exercise and placebo|no supervised bone-loading exercise and one placebo pill per day for 36 weeks
32917620|NCT05488067|Experimental|Atorvastatin+ALGS-Xanthoma|"Drug: atorvastatin Dosage form: tablet Route of administration: oral Duration: 6 months （After 6 months of medication, according to the actual situation of the patient, choose to maintain the original dosage, gradually reduce the dosage or stop the medication）~Administration method:~Initial dose: ① < 1 year old: 1.25mg/d, qd; ② 1-5 years old: 2.5mg/d, qd; ③ 6-9 years old: 5mg/d, qd; ④ ≥ 10 years old: 10mg/d, qd. The maximum dose is 40mg/d and not more than 1mg/kg/d. During the follow-up, the medication was adjusted according to the laboratory results until non-HDL-C≤4.2mmol/L（162 mg/dL）, xanthoma disappear, or the patient had moderate or more serious adverse reactions."
32917621|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
32917622|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
32917623|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
32716348|NCT05223998|Experimental|Full-thickness skin microcolumns Implantation|implantation of FTSM on open wound
32917624|NCT05316038||Belatacept cohort|Kidney transplanted patients for whom a conversion from Tacrolimus to belatacept has been decided will be included in this cohort.
32917625|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
32917626|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
32917627|NCT01759160|Active Comparator|Marsh|Marsh Plasma TCI with high initial target
32917628|NCT01759160|Active Comparator|Schnider|Schnider Plasma TCI with high initial target
32917629|NCT05458739||Treatment Group|The removed specimen (as part of BCS) is scanned with the ClearCoast MR System.
32716349|NCT00830219|Experimental|1|
32716350|NCT00830219|Active Comparator|2|
32716351|NCT05223062||Psoriatic arthritis|Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
32716352|NCT05135468|Experimental|CU-40102 Spray|0.25% (2.275mg/mL) Finasteride
32716353|NCT05135468|Placebo Comparator|Placebo for CU-40102 Spray|Placebo Spray
32917630|NCT05458739||Historical Group|Historical data of patients undergone BCS, under the same eligibility criteria and performed by the same study surgeons, thus minimizing inter-groups and inter-surgeon variability and bias, will serve as a control group for the comparison of the complete resection rate.
32917631|NCT05315882||Allogeneic stem cell transplantation|Observational, no interventional
32917632|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
32716354|NCT04765865||Wave 1|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, blood sample collection for fatty acid estimation, and four (4) 24-hour dietary recalls (n=450).
32917633|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
32917634|NCT03461978|Other|10 patients with meibomian gland dysfunction|
32917635|NCT03461978|Other|10 patients with cataract|
32917636|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
32716355|NCT04765865||Wave 2|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey and 24-hour and spot urine assessments (n=450).
32716356|NCT04765865||Wave 3|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, and four (4) 24-hour dietary recalls (n=450).
32917637|NCT03461978|Other|10 patients after partial corneal transplantation|
32917638|NCT03461978|Other|5 patients with demodicosis|
32917639|NCT03461978|Other|5 patients with conjunctival pathologies|
32917640|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
32917641|NCT03461978|Other|5 patients with aniridia|
32917642|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
32917643|NCT04769492|Other|Pilot Intervention|Tailored violence prevention intervention (#ChopViolence/#ChopHIV) for B-YGBMSM and B-TW in the Chicago HBC.
32917644|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
32917645|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
32917646|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
32917647|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
32917648|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
32917649|NCT05435339|Experimental|GEN1053 Monotherapy|
32716358|NCT05386979|Other|Opioid anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, sufentanil 0.3μg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and remifentanil 0.2-0.5 μg/kg·min to maintain anesthesia. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and sufentanil 10 μg will be given after surgery. For PCA, sufentanil 2μg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
32716359|NCT05386979|Experimental|Opioid free anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, naborphine 0.2mg/kg，esketamine 0.3mg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and esketamine 0.3～0.5mg/kg·h. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and naborphine 0.2mg/kg will be given after surgery. For PCA, naborphine 2mg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
32716360|NCT05221970|Other|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
32716361|NCT05221970|Other|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
32716362|NCT05221970|Other|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
32716363|NCT05221970|No Intervention|Waiting list|No intervention.
32917650|NCT04769258||Patients with IBD treated with immunomodulatory drugs|
32917651|NCT04769258||Patients with IBD not treated with the immunomodulatory drugs|
32917652|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
32917653|NCT01762904|Experimental|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.~Interventions:~Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls~Other: Preparing skin's areas to be tested with two antiseptics and two controls"
32917654|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
32917655|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
32917656|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
32917657|NCT01762982|Experimental|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
32917658|NCT01762982|Active Comparator|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight [w/w]) water solution
32917659|NCT01762982|Placebo Comparator|Negative Control 1|Normal saline water (0.9% weight by volume [w/v])
33247316|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
32716364|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
33247317|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
33247318|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
33247319|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
33247320|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
33247321|NCT05511818|Placebo Comparator|Placebo Control 1|Rest Product Form 1 - control
33247322|NCT05511818|Placebo Comparator|Placebo Control 2|Rest Product Form 2 - control
32716365|NCT02274766|Placebo Comparator|Placebo|Placebo
32716366|NCT04757363|Experimental|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
32716367|NCT05134532|Experimental|intervention|"Potential subjects will be screened to determine if they meet the eligibility criteria. The screening period is 21 days.~Subjects who meet all the eligibility criteria will be commenced regorafenib 160mg once daily for the first 3 weeks of each 4-week cycle."
32716368|NCT00829673|Experimental|1|
32716369|NCT00829673|Active Comparator|2|Focalin®
32716370|NCT05221658|Experimental|Arm A|As first-line therapy
32716371|NCT05221658|Experimental|Arm B1|EGFR H score ≥ 200, as third-line or above therapy
32716372|NCT05221658|Experimental|Arm B2|EGFR H score <200, as third-line or above therapy
32716373|NCT05432284|Placebo Comparator|Placebo|Placebo (ambient air)
32716374|NCT05432284|Experimental|Vaporized high THC alone|30mg of vaporized pure THC
32716375|NCT05432284|Experimental|Vaporized low THC alone|15mg of vaporized pure THC
32716376|NCT05432284|Experimental|Vaporized low beta-myrcene|2mg of vaporized beta-myrcene
32716377|NCT05432284|Experimental|Vaporized high beta-myrcene|9mg of vaporized beta-myrcene
32716378|NCT05432284|Experimental|Vaporized low THC and low beta-myrcene|15mg vaporized THC with 2mg vaporized beta-myrcene
32716379|NCT05432284|Experimental|Vaporized low THC and high beta-myrcene|15mg vaporized THC with 9mg vaporized beta-myrcene
32716380|NCT05432284|Experimental|Vaporized high THC and low beta-myrcene|30mg vaporized THC with 2mg vaporized beta-myrcene
32716381|NCT05432284|Experimental|Vaporized high THC and high beta-myrcene|30mg vaporized THC with 9mg vaporized beta-myrcene
32716382|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
32716383|NCT03134495||non-exposed children|all children with no prescription of PPI
32716384|NCT04875676|Active Comparator|Cohort 1 (4-week boost vaccination)|(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
32716385|NCT04875676|Active Comparator|Cohort 2 (8-week boost vaccination)|(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
32716386|NCT04875676|Active Comparator|Cohort 3 (12-week boost vaccination)|(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
32716387|NCT05133596|Experimental|Study population|Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.
32917660|NCT01762982|Placebo Comparator|Negative Control 2|Empty Finn Chamber
32917661|NCT05315492|Experimental|Intervention communes|CCC intervention
32917662|NCT05315492|No Intervention|Control communes|Standard care
32917663|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
32917664|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
32917665|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
32917666|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
32917667|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
32917668|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
32917669|NCT01763606|Experimental|Enoxaparin|Patients assigned to enoxaparin.
33247323|NCT05511818|Placebo Comparator|Placebo Control 3|Rest Product Form 3 - control
33247324|NCT05511818|Experimental|Active Product 1.1|Rest Product Form 1 - active product 1
33247325|NCT05511818|Experimental|Active Product 1.2|Rest Product Form 1 - active product 2
33247326|NCT05511818|Experimental|Active Product 1.3|Rest Product Form 1 - active product 3
33247327|NCT05511818|Experimental|Active Product 1.4|Rest Product Form 1 - active product 4
32765988|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
32765989|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
33247328|NCT05511818|Experimental|Active Product 2.1|Rest Product Form 2 - active product 1
33247329|NCT05511818|Experimental|Active Product 2.2|Rest Product Form 2 - active product 2
33247330|NCT05511818|Experimental|Active Product 3.1|Rest Product Form 3 - active product 1
32765990|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
32765991|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
32765992|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
32765993|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
32765994|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
32765995|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
32765996|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
32765997|NCT04349605|Experimental|Meditation|This is a daily 15 minute meditation with guided breathing. Accessible through an app.
32765998|NCT04349605|Experimental|Kundalini Yoga|This is a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
32765999|NCT04349605|No Intervention|Treatment as Usual|This group will serve as the comparison to assess the efficacy of the active treatments in that no study treatment will be provided. The participants will be asked to not start new treatments during the 8 weeks of the study.
32766000|NCT00790543||Observation|Children newly diagnosed with Crohn's disease.
32766001|NCT04324567||APR-open|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparotomy.
32766002|NCT04324567||APR-robot|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparoscopic robot assisted technique.
32766003|NCT04299451|Experimental|Open dialogue about CAM (ODC-COC)|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
32766004|NCT04299451|No Intervention|Standard care|Standard care including referral to a homepage about complementary alternative medicine
32766005|NCT04503265|Experimental|AMXI-5001 Treatment|Single Arm Study, all participants will receive AMXI-5001.
32766006|NCT04264663|Experimental|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and furazolidone 100mg po bid for 14d
32766007|NCT04264663|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
32766008|NCT04264585|Experimental|Standard ICBT|Clients assigned to the Standard ICBT condition will receive the standard version of the ICBT course, which consists of four lessons spread across the span of five weeks. Clients will receive five weeks of therapist support.
32766009|NCT04264585|Experimental|ICBT with Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive the Planning for Change lesson before Lesson 1 of the UniWellbeing Course.
32766010|NCT04264585|Experimental|ICBT with Booster|Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course.
32766011|NCT04264585|Experimental|ICBT with Motivational Interviewing and Booster|Clients assigned to the ICBT with Motivational Interviewing and Booster condition will receive access to both the Motivational Interviewing content (before Lesson 1 of the UniWellbeing Course) and the booster session (one month after ICBT course).
32766012|NCT05403307||Two doses or more of BNT162b2|Defined as ≥ 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
32917670|NCT01763606|Experimental|Aspirin|Patients assigned to Aspirin.
32917671|NCT05315180|Experimental|dose exploration|Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 1-6 subjects treated at the lowest planned dose level. If no DLT is observed, dose escalation will continue to the next planned dose cohort
33247331|NCT05511818|Experimental|Active Product 3.2|Rest Product Form 3 - active product 2
32917672|NCT05315180|Experimental|dose expansion|dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 2 groups may be done concurrently
32917673|NCT05309564|Experimental|Intervention|Intervention with single botulinum neurotoxin injection into masseter.
32917674|NCT05309564|No Intervention|Control|No intervention
32917675|NCT03161756|Experimental|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
32917676|NCT03161756|Experimental|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
32917677|NCT01765712|Placebo Comparator|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
32917678|NCT01765712|Experimental|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
32917679|NCT03099434|Active Comparator|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
32917680|NCT03099434|Active Comparator|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
32917681|NCT03099434|No Intervention|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
32917682|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
32917683|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
32917684|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
32917685|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
32917686|NCT01766024|Experimental|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
32917687|NCT01766024|Experimental|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
32917688|NCT05404295|Active Comparator|Umbilical cord blood platelel lysate group|A Umbilical cord blood platelel lysate gel will be applied in diabetic foot ulcer every three days for one month.
32917689|NCT05404295|Placebo Comparator|Control group|The control group will receive the clinical standard of care; removable of any necrotic, hyperkeratotic and infected tissue, cleansing of the wound with normal saline and covering of the ulcer with dressing with normal saline and then with a few layers of sterile gauze, and non-compressible bandage.
32917690|NCT01766102|Active Comparator|Intra-operative Mammography|Intra-operative Specimen Mammography
32917691|NCT01766102|Active Comparator|Standard Mammography|Standard Specimen Mammography
32917692|NCT05301920|Experimental|Experimental Group|N=20 60Hz pulse electrical stimulation The clinical trial device performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
32917693|NCT05297708||All Participants|he population would be pediatric patients 6 years to <19 years of age who were referred for elevated blood pressure. At the initial clinic visit, the participant will be consented and a thorough history will be taken. An ECHO and non-invasive vascular measurements will be taken (central BP, augmentation index, pulse wave velocity). Patients will have an ambulatory blood pressure monitor (ABPM) placed and be trained to use a home blood pressure monitor (HBP) which will be sent home with them. The monitors in this study are FDA-approved and are being used as indicated. After one day at home, patients will return the ABPM via mail and continue to take measurements with the HBP for 20 days.
32917694|NCT05297084||Aggressive periodontitis|25 young medically free patients with deep periodontal pockets >5mm
32917695|NCT05297084||Periodontally healthy individuals|25 young medically free individuals with no periodontal inflammation signs
33247332|NCT05511818|Placebo Comparator|Placebo Control 4|Rest Product Form 4 - control
33247333|NCT05511818|Experimental|Active Product 4|Rest Product Form 4 - active product 1
33247334|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
33247335|NCT00817245|No Intervention|2|No medical treatment
33247336|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
32766013|NCT05403307||One dose of BNT162b2|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
32766014|NCT05403307||One dose or more of BNT162b2|Defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
32766015|NCT05403307||Two doses of BNT162b2|Defined as 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset.
32766016|NCT05403307||Three doses of BNT162b2|Defined as 3 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 3rd dose and acute respiratory illness (ARI) symptom onset.
32766017|NCT05403307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines according to Brazil National Immunization Program recommendations.
32766018|NCT05403307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
32766019|NCT02827045||Depressive phase|Vestibular test
32766020|NCT02827045||Maniac phase|Vestibular test
32766021|NCT02827045||Euthimic phase|Vestibular test
32766022|NCT02827045||Healthy subject|Vestibular test
32766023|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
32766024|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
32766025|NCT04599751|Experimental|Hair removal treatment|Trio laser module (Alma Lasers)
32766026|NCT04563559|Other|DEXTENZA vs prednisolone acetate 1%)|Subjects will randomly receive Dextenza or prednisolone acetate 1% in the first eye after surgery. At the time of the second eye surgery, the other eye will receive the drug that the first eye did not receive. Subjects will receive both drugs during the course of the study and therefore there is only 1 ARM for this study.
32766027|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
32766028|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
32766029|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
32766030|NCT05403073|No Intervention|No Nerve Blocking|Pain management at ER Department will be as usually with iv drugs and 3 kilogram soft traction.
32766031|NCT05403073|Active Comparator|Ultrasound Nerve blocking|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
32766032|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
32766033|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
32766034|NCT05399017|Experimental|EZVent|"Subjects who are involved in the clinical trial are already mechanically ventilated on traditional standard commercial ventilator. Baseline measurements (T0) will be taken from each patient before being transferred to EZVent ventilator. The following measurements will be taken: Vital Signs and hemodynamics (heart rate, blood pressure, temperature, Respiratory rate), Chest X-ray, Arterial blood gases as well as the ventilator mode parameters (dependent on each mode) and lung mechanics parameters (Peak, Plateau, Mean Airway Pressure, Tidal Volume, Airway Resistance and Static Compliance).~After taking the baseline measurements, subjects will be disconnected from their traditional standard ventilator and immediately connected to EZVent using the same previous original setting.~After 60 & 120 minutes of ventilation on EZVent (T1&T2) respectively, the same measurement will be taken (Vital signs and Hemodynamics will be continuously monitored and recorded every five minutes)."
32766035|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
32766036|NCT05123833|Active Comparator|Dartos Fascia|Dartos flap is used as a covering layer for urethra during repair of hypospadias
32766037|NCT05123833|Active Comparator|Tunica Vaginalis|Tunica Vaginalis Flap is used as a covering layer for urethra during repair of hypospadias
32766038|NCT05123677||Low Risk|These patients are screened to be low-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians & Gynaecologists, respectively.
32766039|NCT05123677||High Risk|These patients are screened to be high-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians & Gynaecologists, respectively.
32766040|NCT05123443||1 - Cross sectional genetics study|International, multicentre study assessing genetic predictors of chronic inflammation in 1000 MS patients with both susceptibility-based brain MRI scan and DNA from peripheral blood samples.The cross-sectional group will include 100 NUH participants who were previously scanned with iron sensitive sequences. These patients will be contacted by their clinical team and invited to participate. Blood samples will be stored in a -80° freezer until all 100 samples have been acquired. At this point, the samples will be shipped to the US for analysis, along with previously acquired MRI scans.
32917696|NCT05296850|Experimental|Manual release group|Manual release will perform with plantar fascia and flexor hallucis longus stretching and tissue mobilization. Stretching/mobilization will applied for approximately 3 minutes.
32917697|NCT05296850|Experimental|Kinesio taping group|Two techniques will be used in kinesio taping application; first technique is the gastrocnemius muscle inhibition technique and the plantar fascia ligament correction technique and other technique is the transverse arch ligament correction technique.
32917698|NCT04351022|Experimental|CD38 positive relapsed or refractory acute myeloid leukemia|
32917699|NCT05252936|Experimental|Spanish language content|Social media campaign content with Spanish language voiceover
32917700|NCT05252936|Experimental|K'iche' language content|Social media campaign content with K'iche' language voiceover
32917701|NCT05252936|Experimental|Kaqchikel language content|Social media campaign content with Kaqchikel language voiceover
33247337|NCT05457686|Experimental|kinesiology group|In the group receiving kinesiology treatment, kinesiotaping is applied to the sub-knee region in accordance with the lymphatic correction technique from the first postoperative day to reduce edema and pain. Accordingly, the proximal part of the tape is placed close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate bands are applied so that the strips cross each other (from the medial and lateral of the knee). On the first postoperative day, on the third day, the patients will be taped with kinesio tape and discharged on the fourth day. After discharge, they will be asked to remove the tapes after 3 days as they were taught.
33247338|NCT05457686|Sham Comparator|sham taping group|Sham application will be taped with a plaster from the same area on the same days as the kinesio application. No tension will be applied while taping. The difference of the plaster from the kinesiotape is that it does not contain tension and does not allow stretching.
32716388|NCT05375591||Benign Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be benign and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
32716389|NCT05375591||Metastatic Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be metastatic in nature and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
32716390|NCT05375591||Second Primary Lung Cancers|CT scans of patients with a new lung nodule(s) subsequently confirmed to be a new second primary lung cancer and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
32716391|NCT05189366|Experimental|Experimental arm : Speech therapy + Sophrology|"In the experimental arm, patients will receive 6 sessions of sophrology. The sessions are individual and last approximately 50 minutes.~In addition to the sophrology sessions, patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition."
32716392|NCT05189366|Active Comparator|Control arm : Speech therapy|Patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
32716393|NCT05189288|Experimental|Reference-Test|D418 Tab. - CKD-388 Tab.
32716394|NCT05189288|Experimental|Test-Reference|CKD-388 Tab. - D418 Tab.
32716395|NCT05220254|Experimental|MindCotine mobile app program|
32716396|NCT05188196|Active Comparator|Collagen Membrane|ridge preservation with collagen membrane + collagenated bovine bone mineral
32716397|NCT05188196|Experimental|Collagen Sponge|ridge preservation with collagen sponge + collagenated bovine bone mineral
32716398|NCT05133362|Active Comparator|Standard Care with Ekso Group|Participants in the SCG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. For each participant, an individualized plan of care consistent with evidence-based practice standards will be provided based on rehabilitation goals. The interventions during each treatment session will include forward gait training with EksoNR, neuromuscular movement-related tasks, mobility tasks, and interventions using products and technology, and education for caregivers, family, and friends.
32917702|NCT05252936|Active Comparator|Control|A control group that is not exposed to any of the social media campaign content will serve as control to allow for comparison of outcomes with treatment arms.
32917703|NCT05229068|Experimental|Prior_RSV MAT Group|Maternal participants who received a single 120 µg dose of RSV MAT vaccine at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery).
32917704|NCT05229068|Experimental|Prior_Placebo Group|Maternal participants who received a single dose of placebo at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies or who did not participate in the parent studies and did not receive any RSV vaccine in the past*, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery). *The unvaccinated participants are enrolled if the study cannot enroll sufficient numbers of the maternal participants who received placebo in the parent studies.
32917705|NCT05210114|Experimental|Skin Hydration Sensor|
32917706|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
32917707|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
32917708|NCT05176808|Active Comparator|Telehealth Parent Coaching (TC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting the child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is 12 weeks with 2 sessions per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Trained study coaches will join families in their homes remotely via Kennedy Krieger Institute's secure Zoom password-protected account to provide coaching."
32917709|NCT05176808|Active Comparator|In-person Coaching(IPC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is12 weeks with sessions 2 times per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Coaching will be delivered in families' homes by trained study coaches to support parent implementation of NDBI strategies during daily life activities with their toddler with ASD."
32917710|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
32917711|NCT01767506|Experimental|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
32917712|NCT01767506|Active Comparator|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
32716399|NCT05133362|Experimental|Standard Care with Ekso and Backward Walking Group|Participants in the SCBWG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. Once a week, each participant will receive standard care as described in the standard care with Ekso group.Once a week, each participant will receive backward walking training with EksoNR during their treatment session.
32716400|NCT05132114|No Intervention|Control Group|LLETZ (without intraoperative Lugol's iodine)
32716401|NCT05132114|Experimental|Iodine group|LLETZ after the intraoperative application of Lugol's iodine
32917713|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
32716402|NCT05219474|Experimental|Cochlear implant subjects|Participates in 7 visits over a six-month duration. Subjects will be given several tests that require them to listen to sounds presented to their cochlear implant and answer questions about those sounds.
32716403|NCT05219474|No Intervention|Normal hearing subjects|Participates in 1 visit lasting 3 hours. Will be given several tests that require you to listen to sounds and answer questions about those sounds. The sounds will be distorted in ways that approximate how a cochlear implant sounds.
32917714|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
32917715|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
32917716|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
32917717|NCT05370209|Experimental|Otinova® Ear Spray|Otinova® Ear Spray 1-2 sprays, twice daily for 7 days
32716404|NCT05131100||Participants receiving Somavert|
32716405|NCT05187182|Experimental|Dose Escalation (CA4948 + FOLFOX + Nivolumab)|"CA4948 (dose will depend on dose level assigned) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~Each cycle is 14 days."
32716406|NCT05187182|Experimental|Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab)|"CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~Each cycle is 14 days."
32917718|NCT05365997|No Intervention|Control|Clinicians will receive no further interventions beyond usual practice.
32917719|NCT05365997|Experimental|Intervention|Clinicians receive a nudge consisting of an electronic health record in-basket message indicating a patient has a default pended order for palliative care.
32917720|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
32716407|NCT05187182|Experimental|Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab)|"CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth Standard of care mFOLFOX7 every 14 days. Pembrolizumab every 21 days. Trastuzumab every 21 days.~Each cycle is 42 days."
32917721|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
32917722|NCT01768520|Experimental|Entelon tab. 150mg|
32917723|NCT01768520|Active Comparator|Celebrex cap.|
32917724|NCT01768520|Placebo Comparator|Placebo|
32917725|NCT05346965|Experimental|Musical training programme|Participants in the experimental group received a weekly 1-hour musical training lesson for 6 months delivered by professionally qualified musicians. The participants will be assigned a particular musical instrument to learn, and this is based on their interests as well as their capabilities (i.e., fine motor skills), The training will begin at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song).
32917726|NCT05346965|Active Comparator|Wait-list control group|To ensure equity of access to potentially effective intervention (i.e. musical training programme), participants in the wait-list control group will receive the same musical training programme as participants in the intervention group after the completion of all assessments.
32917727|NCT01768832|Experimental|Treadmill|Individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
32917728|NCT01768832|Experimental|Tango|Individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
32917729|NCT01768832|Active Comparator|Stretching|Individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
32917730|NCT01769222|Experimental|Ipilimumab 25 mg|Participants receive ipilimumab intratumorally on Day 1
32917731|NCT01769222|Experimental|Ipilimumab 25 mg and radiation therapy|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
32917732|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
32716408|NCT05187104|Experimental|Patients with age-related macular degeneration receiving standard treatment and retinal stem cells|Patients with age-related macular degeneration receiving standard treatment and autologous retinal stem and progenitor cells
32716409|NCT05187104|Active Comparator|Patients with age-related macular degeneration receiving standard treatment|Patients with age-related macular degeneration receiving standard treatment
32716410|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
32716411|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
32716412|NCT05186090|Experimental|24-week resistance exercise program|Participants will engage in supervised 24-week resistance exercise program with goal of maintaining 180 minutes of exercise per week.
32716413|NCT05186090|No Intervention|Wait-list control group|Control group will be asked to maintain their usual lifestyle.
32716416|NCT05186012|Experimental|Arm A (Single agent)|
32716417|NCT05186012|Experimental|Arm B (combo)|
32716418|NCT05185934|Active Comparator|Food supplement Endocalyx|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months.
32716419|NCT05185934|Placebo Comparator|Placebo|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the placebo for 4 months.
32716420|NCT05130164||Single group|Single group will be selected for age estimation using CBCT Scans
32716421|NCT05129696|No Intervention|Control (C): Status quo health and nutrition program|
32716422|NCT05129696|Experimental|Treatment (T): adaption of Reach Up and Learn home visiting program to a group setting|
32716423|NCT05129696|Experimental|Treatment + (T+): Enhanced play materials/activities package|
32716424|NCT05129384|Active Comparator|Treatment|B. infantis EVC001 infant probiotic
32716425|NCT05129384|Placebo Comparator|Placebo|Lactose
32716426|NCT05109104|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32716427|NCT05109104|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32716428|NCT05109104|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32716429|NCT05109104|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32716430|NCT05184998||Hypokalemia group|defined as sK range (0, 3.5] mmo/L
32716431|NCT05184998||Normokalemia group|defined as sK range (3.5, 5.0] mmo/L
32716432|NCT05184998||Hyperkalemia group|defined as sK range (5.0, ~) mmo/L
32716433|NCT05108870|Experimental|Phase 1: Dose-Finding Group 1 - Drug Combination 1|"All participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel.~- HB-201 will be administered on cycle 1 day 15, cycle 2 day 15, and cycle 3 day 15 with three 21-day cycles of carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15"
32716434|NCT05108870|Experimental|Phase 1: Dose-Finding Group 2 - Drug Combination 2|"All participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel.~Participants will be given 3 doses of HB-201 & HB-202 alternating two vector therapy. Patients will receive 2 doses of HB-202 and 1 dose of HB-201. HB-202 will be administered on cycle 1 day 15 and cycle 3 day 15, and HB-201 will be administered on cycle 2 day 15 with three 21-day cycles of chemotherapy with carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15."
32716435|NCT05108870|Experimental|Phase 2: Efficacy Arm 1 - HB-201 + Chemotherapy|"Participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
32716436|NCT05108870|Experimental|Phase 2: Efficacy Arm 2 - HB-201 and HB-202 + Chemotherapy|"Participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
32716437|NCT05108636|Experimental|Therapeutic Touch|"TD process:~After the procedure was explained, the focus was on the child to be treated,~Intended to help the child's treatment and sleep,~The patient's energy field was scanned with the hands at a distance of 8-12 cm from the patient's skin (2 times)~To remove the blockages determined regarding the energy flow and to facilitate the energy flow, manual cleaning was performed (2 times),~Imbalances in the energy fields were tried to be treated by using mental visualization techniques such as dreaming, positive thinking and visualization, by directing the universal life energy to sick individuals with calm and rhythmic hand movements (2 times),~Reassessed to determine whether success has been achieved in treating imbalances in the energy field."
32917733|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
32917734|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
32917735|NCT05164562||type 1 diabetes|"type 1 diabetes group: patients with type 1 diabetes"
32917736|NCT02585414||85 healthy subjects with no history of DES|
32917737|NCT02585414||255 subjects with DES|
32917738|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
32917739|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
32917740|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
32917741|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
32917742|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
32917743|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
32716438|NCT05108636|Experimental|Music Rest|"Parents and children will be informed about the Music Rest before the procedure.~One day before the Music Rest practice, the child's sleep will be evaluated with Actigraphy. Starting the day after the first measurement, the Music Rest will be held for three days as a 20-minute practice period per day. In order to help the child sleep, the child will be listened to music (such as lullaby, classical music) preferred by the patient or his family.~Before the Music Rest application, the patient's room will be ventilated and a spacious and quiet environment will be provided during the application.~The sound level of the music played will be kept between 45-65 dB.~Nursing interventions will be written in more detail after the data of the research is collected."
32716439|NCT04421612|Experimental|Intensive|This group recieve access to a new module every 3rd day.
32716440|NCT04421612|Experimental|Ordinary|This group recieve access to a new module every 5th day.
32716441|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
32716442|NCT05126342|Experimental|Cohort A|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.
32716443|NCT05126342|Experimental|Cohort B|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi maintenance therapy.
32917744|NCT05129306||Patients|Patients with moderate to severe Allergic Rhinitis who have been prescribed RYALTRIS® nasal spray by their healthcare professional. Observational.
32917745|NCT05128994|Experimental|Non-invasive FES|Wearable FES sleeve with non-invasive user controls
32917746|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
32917747|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
32917748|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
32917749|NCT01770314|Experimental|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
32716444|NCT05649358|Experimental|Evaluation of non-invasive lactate sensor|To determine the efficacy and accuracy of the non-invasive lactate sensor
32716445|NCT05183516|Experimental|Tdap|Open label study, no placebo comparator
32917750|NCT01770314|No Intervention|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
32917751|NCT05295953|Active Comparator|TBS (Theta burst stimulation)|Four sessions of TBS in one day
32917752|NCT05295953|Placebo Comparator|Sham TMS|Four sessions of sham TMS
32917753|NCT05289791|Experimental|ultrasonic activation of bioceramic sealer|ultrasonic activation of bioceramic sealer for 20 seconds
32917754|NCT05289791|Active Comparator|bioceramic sealer|bioceramic sealer
32917755|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
32716446|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
32716447|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
32716448|NCT05181722|Active Comparator|Intervention group|The study participants in this group will receive support from the patient navigator as part of this study.
32716449|NCT05181722|No Intervention|Usual care group|The study participants in this group will receive the usual care per the institutional protocol.
32716450|NCT05473910|Experimental|TSC-100 Treatment Arm|HA-1 positive patients
32716451|NCT05473910|Experimental|TSC 101 Treatment Arm|HA-1 negative and HA-2 positive patients
32917756|NCT05284097|Experimental|Study Intervention|"Subjects will receive the following study vaccines as a 0.5 mL IM injection into the deltoid:~Ad26.ZEBOV at a dose of 5x10^10 vp on Day 1~MVA-BN-Filo at a dose of 1x10^8 Inf U on Day 57"
32917757|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
32917758|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
32917759|NCT02548676||Healthy controls|age- and sex matched controls
32917760|NCT05283629|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
32917761|NCT05283629|Active Comparator|Education Comparison Control|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
32917762|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
32917763|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
32917764|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
32917765|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
32917766|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
32917767|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
32917768|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
32917769|NCT05277233||Early-onset preeclampsia|Defined as preeclampsia that develops before 34 weeks of gestation
32917770|NCT05277233||Late-onset preeclampsia|Defined as preeclampsia that develops after 34 weeks of gestation
32917771|NCT05277233||Control|Healthy pregnancies, matched to early and late-onset cases
32917772|NCT05274269|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
32917773|NCT05274269|Placebo Comparator|Placebo|Participants will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
32917774|NCT01771952|Experimental|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
32917775|NCT01771952|Sham Comparator|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
32716452|NCT05473910|Active Comparator|Standard of Care or Control arm|
32716453|NCT05180708|Active Comparator|Active|
32917776|NCT01772654|Experimental|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
32716454|NCT05180708|Placebo Comparator|Vehicle|
32917777|NCT01772654|Active Comparator|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
32917778|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
32917779|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
32917780|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
32917781|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
32917782|NCT05266001|Active Comparator|GM-CSF|Intravenous GM-CSF 125 mcg/m2/day x 7 days
32917783|NCT05266001|Placebo Comparator|Placebo|Intravenous placebo x 7 days
32917784|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
32917785|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
32917786|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
32917787|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
32917788|NCT00421655|Experimental|1|
32743292|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
32917789|NCT00421655|Placebo Comparator|2|
32917790|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
32917791|NCT02391701|No Intervention|Control|No intervention
32917792|NCT05257499|Experimental|On line debfriefing|Participants in this group will practice the skills taught as above but in the presence of the same certified instructor who will guide them throughout all the steps of HBB using a virtual platform (Webex® or Zoom®).
32917793|NCT05257499|No Intervention|In person debriefing|Participants in this group will practice the skills taught in the virtual class on the neonatal mannequin. They are expected to work as a small group of 3 to 4 at a time. They will receive coaching, debriefing and feedback from a certified instructor who will conduct the traditional in-person training with face-to-face feedback and debriefing.
32917794|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
32917795|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
32917796|NCT05240573|Experimental|SKI App|
32917797|NCT05240573|Active Comparator|CMUH Dialysis Care App|
32917798|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
32917799|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
32716455|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
32917800|NCT05093660||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological specimen confirmation.
33247339|NCT05457686|Other|only physical therapy group(control group)|"Conservative will be explained on the second day after the operation. Go for a visit with a local cold application 20 times once a day. Ankle pumping exercises, deep breathing exercises, isometric and hip exercises will be planned with a load that can be applied to students who are being applied for bed training.~Increased the number and allowance of exercises; isotonic knee and exercises that make you feel It will be added. You will be discharged on the 4th day after the surgery on the 2nd or 3rd day. You will do home exercises after discharge. On the 10th day, you will be called for control."
32716456|NCT05180630|Experimental|Study Group|Group will be fit using three different hearing aid couplings. Each participant will be supplying a rating of sound quality for each condition.
32716457|NCT05180474|Experimental|Treatment|Open Label, single arm where GEN1047 will be administered.
32716458|NCT05180084|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
32716459|NCT05180084|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
33247340|NCT05132634|Experimental|Arms|"Experimental Group:~Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~Since the care hours were between 08:00_10:00 in the morning and 20:00-22:00 at night, classical hand massage was applied to the patient by the researcher between the time zones specified daily.~It was followed up with the Pressure Wound Staging Form.~Control Group:~The Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~It was followed up with the Pressure Wound Staging Form."
33247341|NCT05440448|Experimental|Patch-free occlusion therapy|
33247342|NCT05440448|Active Comparator|Standard-of-care patching with an adhesive patch|
32716460|NCT05179538|Experimental|Single Arm Treatment|Cued picture naming therapy will be delivered to all participants. There will be four cohorts of participants based on BDNF and ApoE genotypes.
32716461|NCT05179460||Clean Cohort|Clean cohort refers to cohort of participants who had their first documented exposure to pentosan polysulfate sodium (PPS; Elmiron) on or after 22 May 2018 and who are assumed to have had shorter exposure (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
32716462|NCT05179460||Overall Cohort|Overall cohort refers to cohort of participants who had their first documented exposure to PPS (Elmiron) any time beginning 01 January 2015 and who are assumed to have relatively longer exposure (the earliest available data based on the linked database between the intelligent research in sight (IRIS) registry and Komodo database in this study).
32716463|NCT05179460||Interstitial Cystitis (IC) Cohort|IC cohort refers to cohort of participants who had at least one IC diagnosis beginning 01 January 2015 and had no documented exposure to PPS based on the records from the Komodo database (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
32716464|NCT05124470|Experimental|musical training sessions|24 musical training sessions over the 6 months + 3 months of follow-up post cognitive remediation.
32716465|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
32917801|NCT05093660||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance.
32917802|NCT05235191|Experimental|methadone|In this arm patients will take methadone 5mg
32917803|NCT05235191|Placebo Comparator|placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
32917804|NCT05072990||Observational group|
32716466|NCT05124236|Experimental|Preoperative radiosurgery|The interventional arm is single fraction preoperative radiosurgery to a brain metastasis identified for neurosurgical resection.
32716467|NCT05124236|Active Comparator|Postoperative hypofractionated stereotactic radiotherapy|The active comparator arm is the standard of care of postoperative hypofractionated stereotactic radiotherapy to the surgical cavity in 5 fractions following resection of the brain metastasis.
32917805|NCT05066204|Other|Sequence: self-study, then teaching video|Participants first do self-study, then right afterwards watch a teaching video, then become tested on a simulator and are videorecorded for evaluation
32917806|NCT05066204|Other|Sequence: teaching video, then self study|Participants first watch a teaching video, then do self-study, then become tested on a simulator and are videorecorded for evaluation
32917807|NCT01774604|Experimental|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
32917808|NCT01774604|Placebo Comparator|Placebo|Placebo suppositories (#2)
32917809|NCT01774760|Experimental|Patients with stage III-IV head and neck cancer|18F-EF5 PET/CT scan
33247343|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
33247344|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
33247345|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
33247346|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
33247347|NCT05439200|Experimental|Asynchronous movies|Asynchronous 3D movies
33247348|NCT05439200|Active Comparator|Standard-of-care patching with an adhesive patch|Standard-of-care patching with an adhesive patch
33247349|NCT04646382|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
32917810|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
33247350|NCT04646382|Experimental|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
33247351|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
33247352|NCT05739188|Experimental|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--GPRC5D CAR-T Cells after lymphodepleting therapy.
33247353|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
33247354|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
33247355|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
33247356|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
33247357|NCT05115474||Participants with TNBC (triple negative breast cancer)|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
32716468|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
33247358|NCT05115474||Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
33247359|NCT05115474||Participants with Hormone Receptor (HR) +Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
33247360|NCT04608318|Experimental|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
33247361|NCT04608318|Experimental|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
32716469|NCT05102552|Active Comparator|Cohort 1|BIS-001: Treatment A and SPN-817: Treatment B
32716470|NCT05102552|Active Comparator|Cohort 2|BIS-001: Treatment A and SPN-817: Treatment C
33247362|NCT04608318|Experimental|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
33247363|NCT05733806||Gynecologic rare tumors|The study will include patients with rare gynecologic malignancies
33247364|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
33247365|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
32716471|NCT05101616|Experimental|camrelizumab+chemotherapy|neoadjuvant treatment with camrelizumab+chemotherapy
32716472|NCT05101616|Active Comparator|chemotherapy|neoadjuvant treatment with chemotherapy
32917811|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
32917812|NCT01775774|Experimental|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
33247366|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
33247367|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
33247368|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
32917813|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
32917814|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
32917815|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
32917816|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
32917817|NCT01775852|Active Comparator|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
32917818|NCT01775852|No Intervention|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
32917819|NCT01776632|Experimental|Physical activity|Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
32917820|NCT01776632|Active Comparator|Cancer screening|Latinas exposed to Faith in Action intervention on cancer screening and prevention.
32917821|NCT05209061||Colo-rectal cancer patients|Patients receiving right colectomy or ileo-ceacal resection for colorectal cancer
32716473|NCT05096390|Experimental|axitinib + pembrolizumab|"Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.~Pembrolizumab will be administrated intravenously (IV) over 30 minutes at the dose of 200 mg every 3 weeks according to recent summary of product characteristics (SPC) together with axitinib."
32716474|NCT05096390|Active Comparator|axitinib alone (control)|Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.
32716475|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
32716476|NCT05119556|No Intervention|Standard of Care|Participants will receive standard of care for COPD management per local guidance. In addition, they will receive 4-weekly phone calls for 13 weeks post discharge to inquire about health status and exacerbations.
32716477|NCT05119556|Active Comparator|Video Telehealth Pulmonary Rehabilitation|In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.
32716478|NCT05649202||All inmates entering the CPPLS|Patients with positive HCV serology
32716479|NCT05116982|Experimental|ORGONO Living Silica Acacia Gum-MMST Powder|ORGONO Living Silica Acacia gum-MMST Power. In capsules. One capsule a day for 7 days.
32716480|NCT05116982|Experimental|ORGONO Living Silica Malto-OSA Powder|ORGONO Living Silica Malto-OSA Powder. In capsules. One capsule a day for 7 days.
32716481|NCT05116982|Experimental|ORGONO Living Silica Collagen Booster|ORGONO Living Silica Collagen Booster. Liquid. One bottle a day for 7 days.
32716482|NCT05116982|Placebo Comparator|Placebo|Placebo. In capsules and liquid. One capsule and one bottle a day for 7 days.
32716483|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
32716484|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
32716485|NCT05114798|Experimental|Time Restricted Eating (TRE)|During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
32716486|NCT05114798|Active Comparator|Calorie Restriction (Cal-R)|Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed. Subjects will be instructed to consume 100% of energy needs split between 3 meals every day.
32716487|NCT05114798|No Intervention|Control|Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center monthly for outcome measurements.
32716488|NCT05114564|Experimental|Lens A (Test)|Subjects will be randomized to wear test lenses for one month and then cross over to wear control lenses for one month.
32716489|NCT05114564|Active Comparator|Lens B (Control)|Subjects will be randomized to wear control lenses for one month and then cross over to wear test lenses for one month.
32716490|NCT05114096|Experimental|Single-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection."
32716491|NCT05114096|Active Comparator|Double-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the Double-Dose arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen)."
32716492|NCT05114018|Experimental|Experimental group receiving pasteurized Akkermansia muciniphila|Experimental group receiving pasteurized Akkermansia muciniphila.
32716493|NCT05114018|Placebo Comparator|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
32716494|NCT05178524|Experimental|Bifico Group|Continued administration during perioperative period
32917822|NCT05208047|Experimental|Part 1a|CGT9486 plus sunitinib 37.5 mg QD
32716495|NCT05178524|No Intervention|Control Group|No intervention
32716496|NCT05177978|Experimental|Phosphatidylserine|100 mg elemental phosphatidylserine
32716497|NCT05177978|Placebo Comparator|Placebo|Placebo comparator
32716498|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
32716499|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
32716500|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
32716501|NCT05177822|Experimental|anakinra|
32716502|NCT05177822|Placebo Comparator|placebo|
32716503|NCT05175248|Experimental|Plant-based Intervention Group|Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
32716504|NCT05175248|No Intervention|Control Group|Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.
32716505|NCT05174468||Screen-eligible Subjects|High-risk for lung cancer population who meet the USPSTF eligibility. One 10-L breath sample will be collected from each subject. During breath collection, subjects will be asked to exhale into a portable breath sampling device through a single use filter. Subjects will not be contacted to donate additional/serial breath specimens after the initial breath samples. Subjects will fill out a medical questionnaire and medical records will also be reviewed to extract low-dose CT scan (LDCT) screening results and any additional tumour-related information including histologic subtype, tumor stage, and sites of disease.
32716506|NCT05173922|Experimental|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan.
32716507|NCT05173922|Active Comparator|Web control|The control group will view National Institute on Aging Home Safety Checklist.
32716508|NCT02272816|Experimental|Carboplatin AUC-10|
32716509|NCT05173610|Experimental|SBRT arm|Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma
32716510|NCT05113238|Active Comparator|AGT-Initial|Oocytes will be injected with spermatozoa and will be incubated in 10 mM calcium ionophore (Sigma-Aldrich) for two rounds of 10 minutes at 37 C, 30 minutes after ICSI injection, and then will be rinsed and transferred into culture medium.
32716511|NCT05113238|Experimental|AGT-revised|"ejaculated spermatozoa will be exposed to calcium ionophore in a drop on the ICSI dish before injection. During the ICSI procedure, spermatozoa will be aspirated individually from the drop containing calcium ionophore and immobilized in a separate PVP drop. Next, approximately 0.4 pL of calcium ionophore will be aspirated into the micropipette and injected into the oocyte with the spermatozoa.~Post-ICSI oocytes will be then exposed to 50 mM calcium ionophore for 10 minutes at 37C, and then will be washed and placed in culture medium."
32716512|NCT04869436|Experimental|Dupilumab group|Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
32716513|NCT04421846|Other|Group 1 : Status epilepticus|
32716514|NCT04421846|Other|Group 2 : Dysimmune encephalitis|
32716515|NCT04421846|Other|Group 3 : Control patients|
32716516|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
32716517|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
32716518|NCT05171894|Experimental|Hemoporfin+81.6 J/cm2 PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32716519|NCT05171894|Experimental|Hemoporfin+102 J/cm2PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32716520|NCT05171894|Experimental|Hemoporfin+122 J/cm2 PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32716521|NCT05171894|Placebo Comparator|Placebo+81.6 J/cm2 PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32917823|NCT05208047|Experimental|Part 2 - Experimental Group|CGT9486 plus sunitinib 37.5 mg QD
32917824|NCT05208047|Active Comparator|Part 2 - Control Group|sunitinib 37.5 mg QD
32917825|NCT05208047|Experimental|Part 1b - DDI Cohort 1|CGT9486 plus sunitinib 37.5 mg QD
32917826|NCT05208047|Experimental|Part 1b - DDI Cohort 2|sunitinib 37.5 mg QD plus CGT9486
32917827|NCT01777412|Experimental|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
32917828|NCT04912895|Experimental|SARS-CoV-2 Positive|Participants who test positive for SARS-CoV-2 with the Polymerase Chain Reaction (PCR) test.
32917829|NCT04912895|Active Comparator|Non-COVID-19 Acute Respiratory Illness|Participants who have an acute respiratory illness other than SARS-CoV-2 infection.
33247369|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
33247370|NCT04596150|Experimental|ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative|CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer
33247371|NCT04596150|Experimental|ARM B - CX-2009 Monotherapy, TNBC|CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)
33247372|NCT04596150|Experimental|ARM C - CX-2009 Combination therapy, TNBC|CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC
32917830|NCT04912895|Other|Healthy Controls|Participants without any acute respiratory illness.
32716522|NCT05171894|Placebo Comparator|Placebo+102 J/cm2PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32716523|NCT05171894|Placebo Comparator|Placebo+122 J/cm2 PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion within 20 minnutes. The fixed laser irradiation will begin 10 minutes after the start of intravenous study drug infusion. The total irradiation time is 20 minutes.
32716524|NCT05092100|Experimental|Behavioral|This arm will use behavioral procedures to test memory for different visual stimulus conditions.
32716525|NCT05092100|Experimental|fMRI pattern similarity|This arm will use fMRI and behavioral methods to test memory for different visual stimulus conditions.
32716526|NCT05092100|Experimental|eye tracking|This arm will use eye tracking and behavioral methods to test memory for different visual stimulus conditions.
32716527|NCT05170256|Experimental|Treatment arm|
32716528|NCT05470556||Overweight adolescents|This group will consist of 20 overweight adolescents (Body mass index (BMI) percentile value is 85.-95)
32716529|NCT05470556||Obese adolescents|This group will consist of 20 obese adolescents (BMI percentile value is above the 95th)
32716530|NCT05470556||normal weight|This group will consist of 20 normal-weight adolescents (BMI percentile value is 5th-85th.)
32716531|NCT05111600|Experimental|Treatment|After confirmation of eligibility criteria and ICF signature, subject undergoes to skin biopsy for collection of autologous epidermal cells to be used to produce IMP under GMP process. Approximately 2 months later, IMP is transplanted on selected area.
32716532|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
32716533|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
32716534|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
32716535|NCT05091476|Experimental|Eyes treated with the OPTiC System|Eyes that OPTiC System treatment has been completed
32716536|NCT05091476|No Intervention|Fellow Eye|Contralateral comparator
32716537|NCT05648890||Group 1|Patients above 65 years old undergoing surgery in general or regional anesthesia.
32716538|NCT05468216|Experimental|MovIn-Lessons group|The schools which will implement the movement integration in the learning activities of primary education subjects (maths, natural science and English).
32716539|NCT05468216|No Intervention|Control group|Schools which will continues applying the same methodology in the realization of the learning activities.
32716540|NCT05169008|Experimental|Vaccine Group|1000 participants，500 children aged 6-12 years and 500 adolescents aged 13-17 years, Ad5-nCoV or Ad5-nCoV-IH, ≥90 days after two doses of CoronaVac. Intramuscular injection or nebulized inhalation.
32716541|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
32716542|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
32716543|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
32716544|NCT05168774|Experimental|Low Dose (20-30mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (20-30 mg) for 52 weeks
32716545|NCT05168774|Experimental|High Dose (40-60 mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (40-60 mg) for 52 weeks
32716546|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
32716547|NCT05053256||HFpEF|Heart failure with preserved ejection fraction
32716548|NCT05053256||HFrEF|Heart failure with reduced ejection fraction
32716549|NCT04998266|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
32716550|NCT04998266|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
32716551|NCT04875520|Active Comparator|Weekly Screening testing plus symptomatic testing|Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.
32716552|NCT04875520|Active Comparator|Symptomatic testing|All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.
32716553|NCT04998188|Experimental|Collagen Injection|This group of patients will be treated with single intra-articular injection of collagen.
32716554|NCT04998188|Placebo Comparator|Placebo (saline solution)|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
32716555|NCT04997486|No Intervention|Control|Subjects will consume all meals/snacks during a ~15-h daily eating period (~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
32716556|NCT04997486|Experimental|TRE isocaloric|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
32716557|NCT04997486|Experimental|TRE ad libitum|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting) without any other dietary advice.
32716558|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
32716559|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
32716560|NCT04997018|Experimental|Prostate cancer patients|"Intermediate-risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate-risk patients will be defined as:~PSA 10-20 ng/ml or~Gleason score = 7~Clinical stage T2b/T2c"
32716561|NCT05051774|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the 12 weeks intervention consists of three monthly group education and center-based group exercise followed by 20 minutes of individualized telephone follow-up at weeks 3, 7, and 11.
32716562|NCT05051774|No Intervention|Control Group|The control group will receive the usual care provided in the study hospital included an unstructured health education conducted by a nurse on healthy lifestyle and health assessment and brief unstructured health education on their conditions, focusing on the risk factors management and stress management by the cardiologist.
32716563|NCT05648734||Group A|Patients received Corticosteroids only
32716564|NCT05648734||Group B|Patients received Corticosteroids in combination with Colchicine
32716565|NCT05648734||Group C|Patients received Corticosteroids in combination with Pirfenidone
32716566|NCT05648734||Group D|Patients received Corticosteroids in combination with Colchicine and Pirfenidone
32716567|NCT05085704||Adolescents and adults with Glut1 deficiency|"Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.~Ages 16 to 65~Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included."
32716568|NCT05085704||Normal healthy adolescents and adults|"Adolescents or adults in good general health.~Ages 16 to 65.~Persons with dental fillings, dental crowns, and short (max. 4 cm) dental retainer wires can be included."
32716569|NCT05051462|Experimental|Intervention group|Study participants participating in family constellation therapy between assessment 1 and 2.
32716570|NCT05051462|No Intervention|Wait-list control group|Study participants participating in family constellation therapy only after all 3 assessment points.
32716571|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
32716572|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
32716573|NCT05085548|Experimental|Dose Escalation|Participants will receive ProAgio in escalating doses.
32716574|NCT05085548|Experimental|Biopsy Arm|Participants will receive ProAgio at the RP2D and undergo tumor biopsy.
32716575|NCT05085548|Experimental|Standard Arm|Participants will receive ProAgio at the RP2D.
32716576|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
32716577|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
32716578|NCT05051072|Other|MRI in morphological sequence, diffusion tensor and resting functional|"standard anatomical sequences T1, FLAIR (Fluid Attenuated Inversion Recovery), TOF(Time-of-flight MR angiography) , DRIVE, sequence centered on the V after injection of gadolinated contrast product as part of routine care,~diffusion tensor sequence (DTI)"
32716579|NCT05050526|Experimental|Exercise program|Participants in the experimental group will take part in a 12-week exercise program.
32716580|NCT05050526|No Intervention|Control|Participants in the control group will not receive any intervention.
32716581|NCT05648656|Active Comparator|TXA|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days.
32716582|NCT05648656|Placebo Comparator|Control|Nebulization with 0.9%normal saline 5mL 8 hourly for 2 days
32716583|NCT05050214|Experimental|Experimental: GAZYVA, GAZYVARO(Obinutuzumab)|Participants will receive Obinutuzumab 1000 mg solution for infusion (total dose of 3000 mg in 30 days).
32716584|NCT05083364|Experimental|ARO-C3 (Healthy Volunteers)|1 or 2 doses of ARO-C3 by subcutaneous (sc) injection
32716585|NCT05083364|Placebo Comparator|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
32716586|NCT05083364|Experimental|ARO-C3 (Adult Patients with C3G or IgAN)|2 doses of ARO-C3 by sc injection
32716587|NCT05083364|Experimental|ARO-C3 (Adult Patients with PNH)|2 doses of ARO-C3 by sc injection
32716588|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
32716589|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
33247373|NCT00823407|Other|MDA|
32716590|NCT05049746|Other|Intervention Arm|"Participants in the intervention arm only will then be asked to look at the decision tool that includes educational materials about the diagnosis and treatment of breast cancer.~These could be written information, graphics, videos, animations, or questionnaires.~This decision tool will personalize the decision to you specifically and support your decision-making process"
32716591|NCT05049746|No Intervention|Non-Intervention Arm|Participants undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes.
32716592|NCT04875364|Experimental|Early PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
32716593|NCT04875364|Experimental|Usual PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
32716594|NCT04875286||Observational (medical record review, questionnaires))|Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
32716595|NCT05082584|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
32716596|NCT04869124|Active Comparator|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
32716597|NCT04869124|Placebo Comparator|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
32716598|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
32716599|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
32716600|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
32716601|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
32716602|NCT04995224||Study 1A|Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
32716603|NCT04995224||Study 1B|Prospective cohort study with 450 newly diagnosed patients with IBD
32716604|NCT04995224||Study 2|Cross-sectional study with 10,000 patients in IBD Boost study
32716605|NCT04995224||Study 3|Cross-sectional study with 15,000 patients in IBD BioResource
32716606|NCT05648578|Experimental|Experimental|Participants received reiki application for 4 weeks.
32716607|NCT05648578|No Intervention|Control|No intervention was applied to the participants in the control group
32716608|NCT05049356||Children referred to outpatient clinic|Diagnostic interview (Schedule for Affective Disorders and Schizophrenia (K-SADS) cf. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) with parents. Diagnostic groups/cohorts (e.g., DMDD, ADHD, Oppositional Defiant Disorder) will be based on the diagnoses given cf. K-SADS.
32716609|NCT05049356||Typical developing children and their parent(s)|Norm values on hair cortisol data will be obtained from typical developing children and their parent(s) by the same procedure as described under Outcome measure(s), 21. Stress Response by Cortisol levels.
32716610|NCT05648266|Active Comparator|Continuous SAPB|postoperative serratus-anterior-plane-block 20ml Ropivacain 0,75%, pain catheter with continous administered Ropivacain (5ml/h 0,2% for 48h)
32716611|NCT05648266|Placebo Comparator|Placebo|standard of care
32716612|NCT05049122|Experimental|Dupilumab|Dupilumab every 2 weeks (q2w). Dosing interval may be changed from q2w to q4w at week 24
32716613|NCT05082038|Other|Group IF|Two Tapered IF implants will be installed in one side of the mandible
32716614|NCT05082038|Other|Group CF|Two Tapered IF implants will be installed in the other side of the mandible
32716615|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
32716616|NCT05079776||Children aged 0-18 months of age|Children aged 0-18 months of age with no structural abnormalities of the lower limbs or orthopedic conditions
32716617|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
32716618|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
32716619|NCT04221230|Experimental|BTRX-335140|BTRX-335140
32716620|NCT04221230|Placebo Comparator|Placebo|Placebo
32716621|NCT05047094|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds in Combination with Standard Treatment of Pembrolizumab
32716622|NCT04993742|Experimental|MOMS Intervention|"Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.~Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups~No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines"
32716623|NCT04993352|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody.
32716624|NCT04992026|Experimental|ADT plus abiraterone + surgery|After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
32716625|NCT04992026|Active Comparator|ADT plus abiraterone|Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.
32716626|NCT05077826|Experimental|Full Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of up to 4 milliamps, delivered for up to 40 minutes.
32716627|NCT05077826|Placebo Comparator|Partial Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of 0.1 milliamp, delivered for up to 40 minutes.
32716628|NCT04991402||Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)|Pregnant women living with HIV not on antiretroviral therapy (ART) at their 1st antenatal care visit and initiating DTG-based ART in pregnancy.
32716629|NCT04991402||Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)|Pregnant women living with HIV already on DTG-based ART prior to pregnancy and continuing DTG use through pregnancy.
32917831|NCT01777568|Experimental|30% oxygen|Inspired oxygen will be maintained at 30%.
33247374|NCT04514523|Experimental|Implementation Arm|
32716630|NCT04991402||HIV uninfected pregnant women|Pregnant women not living with HIV
32716631|NCT04420832|Active Comparator|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
32716632|NCT04420832|Other|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
32716633|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
32716634|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
32716635|NCT04990544|Experimental|Adult Group 2a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
32716636|NCT04990544|Experimental|Adult Group 2b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
32716637|NCT04990544|Experimental|Adult Group 2c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28.
32716638|NCT04990544|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
32716639|NCT04990544|Experimental|Elderly Group 2d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
32716640|NCT04990544|Experimental|Elderly Group 2e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
32716641|NCT04990544|Experimental|Elderly Group 2f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
32716642|NCT04990544|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
32716643|NCT04989998|Experimental|Hip7 Software on Kick/ CORI platforms|Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.
32716644|NCT04989998|Active Comparator|Conventional procedures with standard, manual instrumentation and digital templating techniques|Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.
32716645|NCT05046938|Experimental|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
32716646|NCT05046938|No Intervention|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
32716647|NCT05077436|Experimental|Sequence 1|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fasted state receive Vamifeport Formulation 1~Day 5: Participants in fed state receive Vamifeport Formulation 1~Day 9: Participants in fed state receive Vamifeport Formulation 2~Day 13: Participants in fasted state receive Vamifeport Formulation 2"
32716648|NCT05077436|Experimental|Sequence 2|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fed state receive Vamifeport Formulation 1~Day 5: Participants in fasted state receive Vamifeport Formulation 2~Day 9: Participants in fasted state receive Vamifeport Formulation 1~Day 13: Participants in fed state receive Vamifeport Formulation 2"
32716649|NCT05077436|Experimental|Sequence 3|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fasted state receive Vamifeport Formulation 2~Day 5: Participants in fed state receive Vamifeport Formulation 2~Day 9: Participants in fed state receive Vamifeport Formulation 1~Day 13: Participants in fasted state receive Vamifeport Formulation 1"
32716650|NCT05077436|Experimental|Sequence 4|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fed state receive Vamifeport Formulation 2~Day 5: Participants in fasted state receive Vamifeport Formulation 1~Day 9: Participants in fasted state receive Vamifeport Formulation 2~Day 13: Participants in fed state receive Vamifeport Formulation 1"
32716651|NCT05042102|Experimental|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
32716652|NCT05042102|Experimental|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
32716653|NCT05042102|Experimental|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
32716654|NCT05042102|Experimental|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
32716655|NCT05076890|Experimental|15 mg/g Full Spectrum Hemp Extract|A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
32716656|NCT05076890|Experimental|50 mg/g Full Spectrum Hemp Extract|A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.
32716657|NCT05041712||Case cohort|Observational study of children between the ages of 2 days to < 18 years who are cannulated onto ECMO at participating sites
32716658|NCT05041712||Control cohort|Observational study of children between the ages of 2 days to < 18 years admitted to the Johns Hopkins Pediatric Intensive Care Unit (PICU) or Pediatric Cardiac Intensive Care Unit (PCICU) for any reason.
33247375|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
33247376|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
32766041|NCT05123443||2 - Longitudinal cohort MRI study|"The repeat MRI cohort group will be split into two phases. Phase 1: 30 participants who have consented to provide blood samples in the cross sectional genetics study will also be invited to participate by having an additional 7T MRI (funding already secured).~Phase 2: Following completion of phase 1 and securing additional funds we aim to perform more scans to complete our analysis. Exact number of phase 2 participants will be determined from analysis of pilot data."
32766042|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
32766043|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
32766044|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
32766045|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
32766046|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
32766047|NCT04920461|Experimental|Additional MRI sequences|
32766048|NCT04920305|Experimental|Phosphatidylserine group|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
32766049|NCT04920305|Placebo Comparator|Bean powder group|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
32766050|NCT04930133||Cohort A|T790M+ patients sequentially treated with osimertinib in cohort A
32766051|NCT04930133||Cohort B|T790M- patients treated with chemotherapy or other treatments in cohort B
32766052|NCT04930133||Cohort C|patients with unknown mutation status in cohort C
32766053|NCT04930133||Cohort D|Cohort D included patients who were still ongoing with afatinib.
32766054|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
32766055|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
32766057|NCT04911647|Active Comparator|The Plastic stent|Patient group with plastic stent inserted in biliary obstruction through endoscope
32766058|NCT04911647|Experimental|The metal stent|Patient group with metal stent inserted in biliary obstruction through endoscope
32766059|NCT03057041|Experimental|Fentanyl|
32766060|NCT03057041|Placebo Comparator|Placebo|
32766061|NCT04911569|Experimental|Cryoneurolysis|All 25 patients will receive cryoneurolysis
32766062|NCT05123209|Experimental|IM83 CAR-T cells|
32766063|NCT05123209|Experimental|IM83 CAR-T cells +The second-line treatment|
32766064|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
32766065|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
32766066|NCT04377685||COVID19 patients|Patient tested positive for SARS-CoV-2 who had a CT scan
32766067|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
32766068|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
32766069|NCT04321291|Experimental|Nurse information|The patient will receive a generic information leaflet plus an Individual information by nurse on biosimilars
32766070|NCT04321291|Other|Information Leaflet|The patient will receive a generic information leaflet only
32766071|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
32766072|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
32766073|NCT03949777|Experimental|Study Cohort|61 subjects will undergo colonoscopy
32766074|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
32766075|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
32766076|NCT04184323|Active Comparator|EX-527|The drug will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
32766077|NCT04184323|Placebo Comparator|Placebo|The placebo will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
32766078|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
32766079|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
32766080|NCT04165993|Experimental|Concurrent chemotherapy and KN026|KN026 combined with docetaxol
32917832|NCT01777568|Experimental|80% oxygen|Inspired oxygen will be maintained at 80%.
32917833|NCT05200013|Experimental|Cohort 1|Dose 0.3mg/kg
33247377|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
32917834|NCT05200013|Experimental|Cohort 2|Dose 1mg/kg
32917835|NCT05200013|Experimental|Cohort 3|Dose: 3 mg/kg
33247378|NCT05421806||Treatment naive|
32716659|NCT05076266||Women Who Decline TMIST|Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.
32716660|NCT05041010|Experimental|Neu2000KWL|
33247379|NCT05421806||Treatment switched|Virologically suppressed (VL < 50 copies for more than 6 months)
32716661|NCT05041010|Placebo Comparator|Placebo|
32716662|NCT04210076|Experimental|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
32716663|NCT04210076|Active Comparator|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
32716664|NCT04210076|No Intervention|No-training|Teams will not engage in any mindfulness training
32716665|NCT05075798||group patients|Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI.
32716666|NCT05074940|Experimental|Amivantamab|Amivantamab weekly for the first cycle and biweekly thereafter.
32716667|NCT04986566|Experimental|Arm I (telemonitoring)|Patients wear a Vivofit 4 daily for 30 days after hospital discharge for steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients assessments are monitored by the surgical team in real-time to identify outcome trends, including onset, worsening/improving measures, and sporadic versus consistent measures.
32716668|NCT04986566|Active Comparator|Arm II (enhanced usual care)|Patients wear a Vivofit 4 for daily steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients use standard procedures for reporting problems.
32716669|NCT05038982|Experimental|Prurigo Nodularis|Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
32716670|NCT05038982|Experimental|Chronic Pruritus of Unknown Origin|Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
32766081|NCT04165993|Experimental|KN026 monotherapy|KN026 monotherapy
32766082|NCT04165993|Experimental|A combination treatment of KN026 and KN046|KN026 combined with KN046
32766083|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
32766084|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
32766085|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
32766086|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
32766087|NCT04911413|Experimental|low-dose group,|A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery
32766088|NCT04911413|Experimental|middle-dose group,|A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery
32766089|NCT04911413|Experimental|high-dose group|A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery
32766090|NCT05123053|Experimental|Treatment Arm|subjects will be given active drug and titrated up in 10mg increments (with max single dose being 30mg) until a change or drug side effect is noticed.
32766091|NCT04911725|Experimental|With device use|Volunteers included will use IMD during one of the two periods of the study.
32766092|NCT04911725|No Intervention|Without device use|Volunteers included will not use IMD during the other period of the study (reverse of experimental)
32766093|NCT04929665|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
32766094|NCT04929665|Active Comparator|Erector spinae block|Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
32917836|NCT05200013|Experimental|Cohort 4|Dose: 10 mg/kg
32917837|NCT05200013|Experimental|Cohort 5|Dose: 20 mg/kg
32917838|NCT05200013|Experimental|Cohort 6|Dose: 40 mg/kg
32917839|NCT05184023|Experimental|Treatment group|
32917840|NCT05184023|Sham Comparator|Sham group|
32917841|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
32917842|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
32917843|NCT05173883|Experimental|A cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 6 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
32917844|NCT05173883|Experimental|B cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 12 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
32917845|NCT05173883|Experimental|C cohort and D cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 24 injections，0.075mg/ml（C1)，0.10mg/ml(C2)，0.12mg/ml(D2),
32917846|NCT05173883|Placebo Comparator|A cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
32917847|NCT05173883|Placebo Comparator|B cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
32917848|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
32716671|NCT05074472|Experimental|Active Treatment: ZB131|During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
32716672|NCT05074238|Experimental|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
32917849|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
32917850|NCT05166707|Experimental|BIXINK OC Free|A 6 week ERP-based intervention
32716673|NCT05074238|Experimental|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
32917851|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
33247380|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
32716674|NCT05074160||OLP Registry primary analysis population|Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
32716675|NCT05037656|No Intervention|Control|Students in the control group will receive the standard health education curriculum.
32716676|NCT05037656|Experimental|Experimental|Students in the treatment group will receive the school-based classroom curriculum.
32716677|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
32716678|NCT05037500|Experimental|Treatment (decitabine and cedazuridine, enzalutamide)|Patients receive decitabine and cedazuridine PO QD on either days 1-3, 1-4, or 1-5 and enzalutamide PO QD on days 1-28. Treatments repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32716679|NCT05036798|Experimental|Tislelizumab combined with Lenvatinib and GEMOX|"Chemotherapy regimen(GEMOX):~Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD~Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.~If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated"
32716680|NCT04984850|Experimental|Intervention plus usual care|
32716681|NCT04984850|No Intervention|Usual care only|
32716682|NCT05073224|Experimental|Postpartum|Participants who are six months postpartum will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless Electromyography (EMG) sensors will be used to record EMG and limb steadiness (via Inertial Measurement Units (IMU). Physical activity will be measured by questionnaire and accelerometer.
32743293|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
32743294|NCT03241433|Active Comparator|No exercise|No excercise training will be done
33073286|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
33247381|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
32743295|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
32743296|NCT03058731||Control|Other biological mesh
32743297|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
32766095|NCT04929665|Active Comparator|Thoracic Paravertebral block and Erector spinae Block|In patients who are planned to have combined erector spinae block and thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 10 ml of 0.25% bupivacaine will be given to this area. Then, with the same needle, return 1-2 cm from the paravertebral area and inject 10 ml of 0.25% bupivacaine into the interfacial area under the erector spinae muscle.
32766096|NCT04120285|No Intervention|Primary Care Treatment|The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
32766097|NCT04120285|Active Comparator|Primary care treatment with eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
32766098|NCT04120285|Active Comparator|Primary care treatment with guided eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
32766099|NCT04911179|Experimental|Combined multicomponent physical exercise and cognitive stimulation (Vivfrail-Cog)|"The supervised multicomponent exercise training program (resistance, endurance, balance and flexibility) will be comprised of upper and lower body exercises tailored to the individual's functional capacity. Subjects will be encouraged at performing strength and endurance exercise at a moderate intensity. Exercise will progress in terms of intensity and difficulty upon individual adaptation.~The cognitive intervention will include the performance of different exercises with pencil and paper in order to train different cognitive areas, especially the executive functions."
32766100|NCT04911179|No Intervention|Usual care|The usual care group will receive normal outpatient care (including the evidence-based Otago exercise program).
32766101|NCT04919915|Other|Intervention group|Households are randomly assigned to the intervention group with asthma education and received two HEPA air cleaners designed to reduce PM and NH3.
32766102|NCT04919915|No Intervention|Control group|Households are randomly assigned to the control group. They only received the asthma education during the study period. These households receive a HEPA air cleaner at the end of the study.
32766103|NCT03830203|Experimental|BAT1806|BAT1806 injection: 8 mg/kg, intravenous infusion by 60 min
32766104|NCT03830203|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 8 mg/kg, intravenous infusion by 60 min
32766105|NCT03889795|Experimental|Dose Escalation|C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin in the Morning.
32766106|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
32766107|NCT03872791|Experimental|KN046|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
32766108|NCT03872791|Experimental|KN046 plus nab-paclitaxel|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity
32766109|NCT04920227|Experimental|CLASS+PHACO|CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification
32766110|NCT04920227|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery
32766111|NCT03860155|Experimental|allo-APZ2-ACLF|Application of IMP into peripheral vein (arm) by use of a perfusor.
32766112|NCT04430777|Placebo Comparator|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
32766113|NCT04430777|Experimental|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
32917852|NCT05153837|Experimental|oral water|Experimental group: oral administration of 500 ml of water.
33073287|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
33247382|NCT05417048||Breat cancer|Histologically confirmed breast cancer patients(Stage I-III)
33247383|NCT05417048||Benign breast disease|Histologically confirmed breast fibroma, intraductal papilloma,mammary hyperplasia, breast cyst etc
33247384|NCT05417048||Healthy control|No breast lesions detected by clinical examination/mammography/ultrasound/breast magnetic resonance imaging (MRI)
33247385|NCT03922620|Experimental|Liposomal Bupivacaine Group|No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
33247386|NCT03922620|Active Comparator|Peripheral Nerve Block Group|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration
33247387|NCT03898908|Experimental|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
33247388|NCT00419263|Experimental|Peramivir 150 mg|
33247389|NCT00419263|Experimental|Peramivir 300 mg|
33247390|NCT00419263|Placebo Comparator|Placebo|
33247391|NCT03893370|Active Comparator|Treatment|RJA MCS
33247392|NCT03893370|Sham Comparator|Sham Control|Sham
33247393|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
33247394|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
33247395|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
33247396|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
33247397|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
33247398|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
33247399|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
33247400|NCT04060914|Experimental|Ticagrelor(90mg)|
32766114|NCT04430777|Experimental|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
32766115|NCT04910789|Experimental|Thoracoabdominal approach|Radical surgery should be finished via Thoracoabdominal approach.
33247401|NCT04060914|Experimental|Ticagrelor(90/60mg)|
33247402|NCT04060914|Active Comparator|Clopidogrel(75mg)|
33247403|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
33247404|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
33247405|NCT05461950||Self-breathing infants|Vigorous infants with spontaneous onset of respiration within one minute after delivery by cesarean section, receiving extra-uterine placental transfusion and physiology-based cord clamping
33247406|NCT05461950||Infants with respiratory support|Infants with no or poor spontaneous onset of respiration after delivery by cesarean section, receiving extra-uterine placental transfusion, intact-cord stabilisation (any respiratory support) and physiology-based cord clamping after transfer to resuscitation table
33247407|NCT05461950||Historical control group|Infants delivered by cesarean section in a time period when delayed cord clamping after 1-3 minutes was default procedure. Less-than-vigorous infants needing respiratory support or full resuscitation had their umbilical cords cut early (within 30 seconds)
33247408|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
33247409|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
33247410|NCT05324904|Active Comparator|group 1|this group will be intralesionaly injected with vitamin D3
33247411|NCT05324904|Active Comparator|group 2|this group will be intralesionally injected with acyclovir
33247412|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
33247413|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
33247414|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
33247415|NCT01589107|No Intervention|control group|usual care
33247416|NCT01589107|Experimental|Video Arm|
33247417|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
33247418|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
33247419|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
33247420|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
33247421|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
33247422|NCT04580160|Experimental|Duo Venous Stent System Implantation|
32917853|NCT05153837|Active Comparator|intravenous|Active comparator: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
32917854|NCT04911335|Experimental|phase 2 open intervention|All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
32917855|NCT04899167|Experimental|4 years after kidney transplantation|Patients 4 years after KT (N=10); 5 with estimated (e) glomerular filtration rate (GFR) ≤35 mL/min/1.73m2, and 5 with estimated (e) glomerular filtration rate (GFR)>35 mL/min/1.73m2.
32917856|NCT04899167|Experimental|7 years after kidney transplantation|Patients 7 years after KT (N=10); 5 patients with eGFR ≤35 mL/min/1.73m2, and 5 with eGFR>35 mL/min/1.73m2.
32917857|NCT05136755|Experimental|NMDAE|An NMDA enhancer
32917858|NCT05136755|Placebo Comparator|Placebo|Placebo
33247423|NCT05403086|Experimental|Psilocybin|A single moderate-to-high dose of oral psilocybin, plus 4-5 sessions of a brief, existential psychotherapy.
32917859|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
32917860|NCT05132075|Experimental|JDQ443|Participants will be treated with JDQ443
32917861|NCT05132075|Active Comparator|Docetaxel|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels
32917862|NCT01809548|Experimental|Early complementary feeding group|"Early intervention group:~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
32917863|NCT01809548|Experimental|Late complementary feeding group:|"Late intervention group:~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
32917864|NCT04873349|Active Comparator|Olive leaf capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
32917865|NCT04873349|Placebo Comparator|Starch capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a placebo starch capsules (750 mg) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the placebo comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
32917866|NCT01780454|Experimental|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
32917867|NCT04869449|Experimental|Ketoconazole|Participants will be taking 400 mg of the study drug (two 200 mg tablets) by mouth twice a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation) and in the evening after their biopsy or surgery (after the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
32917868|NCT01420874|Experimental|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
32917869|NCT04867187|Experimental|rTMS active and active mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.
32917870|NCT04867187|Sham Comparator|rTMS active and sham mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.
32917871|NCT05116709|Experimental|BAT6005 single drug dose escalation study|"The whole is divided into two phases.The first stage: 10mg group, 30mg group, 100mg group using accelerated titration method to increase the dose.The second stage: 300mg group, 600mg group, 900mg group according to the standard 3+3 rule dose increase study."
33247424|NCT05403086|Active Comparator|Ketamine|A single low-to-moderate dose of oral liquid ketamine, plus 4-5 sessions of a brief, existential psychotherapy.
33247425|NCT01035307||Genomic and Proteomic Profiling|
33247426|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
33247427|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
32917872|NCT01780922|Active Comparator|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
33247428|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
33247429|NCT00712712|Experimental|Patient who has undergone radiofrequency ablation of bone metastases|Patient who has undergone radiofrequency ablation of bone metastases, localized, causing pain refractory to radiotherapy or not accessible to new irradiation, biphosphonates and well-conducted morphine analgesic treatment.
32766116|NCT04910789|Active Comparator|Transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach.
32766117|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
32766118|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
32766119|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
32766120|NCT04910477|Experimental|Dexmedetomidine|Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
32766121|NCT04910477|Experimental|Neostigmine/atropine|Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
32766122|NCT04910477|Placebo Comparator|Saline placebo|Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
32766123|NCT03487705|Other|child essential tremor|electromyogram with accelerometer
32766124|NCT04431089|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
32766125|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
32766126|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
32766127|NCT04910555||women over 65 years old with OAB|Community-dwelling women over 65 years old, with non-neurogenic OAB, with or without UI
32766128|NCT03104569|Experimental|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
32766129|NCT03104569|No Intervention|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
32766130|NCT04910633||Solid Tumor and COVID-19|Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
32766131|NCT05099419|Experimental|High Frequency rTMS Protocol|High frequency with 10 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered in 10-second trains with a 50-second pause between the trains.
32766132|NCT05099419|Experimental|Low Frequency rTMS Protocol|Low frequency 1 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered continuously.
32766133|NCT04919603|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
32766134|NCT04919603|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)>.
32766135|NCT05092633|Experimental|Control|Will have miniscrew only without laser application
32766136|NCT05092633|Experimental|Experimental|Will have miniscrew and laser application
32766137|NCT04929275|Other|Enhanced recovery program|
32766138|NCT05079685||Cases-Control|Women aged 18-39 years, with BMI <30 and good ovarian reserve, undergoing study for primary sterility, subsidiary of conducting tubal patency studies to rule out pathology of the same and thus be able to perform Spousal or Donor IA.
32766139|NCT04929353|Other|ARM A|Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)
32766140|NCT04929353|Other|Arm B|Standard symptom reporting following the conventional modalities of clinical oncology practice
32766141|NCT03843151|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1358894 alone. Test - BI 1358894 + Itraconazole
32766142|NCT04919759|Active Comparator|Rashakaty Basic (R-Basic)|Participants in the R-Basic intervention arm had access to a website that contained the study questionnaires and nutrition education materials
32766143|NCT04919759|Experimental|Rashakaty Enhanced (R-Enhanced)|Participants in the R-Enhanced intervention were given access to smart phones applications for monitoring diet and physical activity levels as well as an online access to a nutritionist
32766144|NCT03711019|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
33247430|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
32766145|NCT03711019|Active Comparator|RUL-UB ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
32766146|NCT03711019|Active Comparator|Bitemporal ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
33247431|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
33247432|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
33247433|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
33247434|NCT04035850|Experimental|Participants|Vortioxetine PO tablets, 5-20mg Daily
33247435|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
32766147|NCT04919837|Experimental|Algorithm assisted group|Patients receive assisting devices fitting services from human doctors assisted by the machine learning model
33247436|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
33247437|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
32766148|NCT04919837|Experimental|Human doctor group|Patients receive assisting devices fitting services from humanr doctors
32766149|NCT02918305|Sham Comparator|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
32766150|NCT02918305|Sham Comparator|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
32766151|NCT04929509|Experimental|self-assembling peptide (P11-4)|"Curodont Repair; Credentis will be applied to the~white spot lesion at baseline."
32766152|NCT04929509|Active Comparator|nanosilver fluoride varnish|"(Study group) Nano-silver fluoride varnish will be applied to the~white spot lesion at baseline."
32766153|NCT04929509|Placebo Comparator|sodium fluoride varnish|"(Control group) Fluoride varnish (Duraflor) will be applied to the~white spot lesion at baseline and 6 months follow up."
32766154|NCT04929119||Before wearing the Orthokeratology|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
32766155|NCT04929119||Wear Orthokeratology for a week|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
32766156|NCT04929119||Wear Orthokeratology for a month|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
32766157|NCT04929119||Wear Orthokeratology for three months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
32766158|NCT04929119||Wear Orthokeratology for six months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
32766159|NCT02798107||All patients treated with idarucizumab|
32766160|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
32766161|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
32766162|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
32766163|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
32766164|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
32766165|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
32766166|NCT05009485|Experimental|Intervention|Participants will be remotely monitored with the Current Health platform, respond to daily respiratory surveys, receive daily medication reminders and an action plan. Daily dashboard rounds and vital sign alarms from the continuously collected vital signs will be used to identify changes in health and escalated accordingly.
32766167|NCT04910165|Experimental|Exparel|Liposomal Bupivacaine use as active ingredient in the block
33247438|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
33247439|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
33247440|NCT00895648|Experimental|Alimta plus Cisplatin|
33247441|NCT05361512||Patients having an epidural placed for labour analgesia or anesthesia for cesarean delivery|Patients with BMI>=50 who are having an epidural placed may take part in this study.
33247442|NCT00893854|Experimental|Diclophenac|
32716683|NCT05073224|Active Comparator|Nulligravid|Participants who have never been pregnant will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless EMG sensors will be used to record EMG and limb steadiness (via IMUs). Physical activity will be measured by questionnaire and accelerometer.
33247443|NCT00893854|Experimental|Triamcinolone|
32716684|NCT04983602|No Intervention|Usual care Control group|The usual care control group receives conventional care in the Emergency Department (ED) or Acute Medical Assessment Unit (AMAU)The comparison group will receive routine care as would be usual in the ED or AMAU. Currently there is no dedicated team to perform CGA in the ED and AMAU at UHL with ad hoc allied health assessment available only at the discretion of the referring ED doctor or medical team. This process will be continued during the study and will be documented. The participants in this group will under baseline data collection prior to randomisation and follow up.
32716685|NCT04983602|Experimental|Comprehensive Geriatric assessment arm|The intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team (consisting of a geriatric specialist registrar, specialist geriatric nurse, senior pharmacist, senior physiotherapist, senior occupational therapist, and senior medical social worker) in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED.
32716686|NCT04983602|Experimental|EDPLUS arm|The ED PLUS intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED. Additionally the participants in this arm will undergo a 6 week physiotherapy led intervention in the community involving 3 home visits and weekly telephone support. The intervention will involved assessment of the patients function in terms of strength, balance and mobility. Following assessment the intervention will be aimed at addressing deficits in the function of the participants, review of their medical management by a geriatrician trainee and focusing on self management of their own program.
32716687|NCT04982744||Patients affected by Li Fraumeni and Li Fraumeni Like syndromes|The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
32716688|NCT05036330||Observational (evaluation, examination, questionnaire)|Patients undergo speech and swallow evaluation by speech pathologist or study staff member and examination of TEP and laryngectomy stoma. Patients also complete questionnaires over 30 minutes about use the ProvoxLife HME system, symptoms, ability to communicate, exercise and physical activity levels, and quality of life at baseline and 3 months post-ProvoxLife.
32716689|NCT05036252||Participants with HER2-positive breast cancer|Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF > 10% to < 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.
32716690|NCT04422002||Surgical treatment|
32716691|NCT04422002||Palliative treatment|
32716692|NCT05071898|Experimental|Open label administration of semaglutide|Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
32716693|NCT05034458|Experimental|Diet|Patients will do biologic treatment according to international guidelines and will do Crohns Disease Exclusion Diet( modulen- phase one ant two CDED) for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.
32716694|NCT05034458|No Intervention|Control|Patients with normal treatment( biologic treatment indicated for CD)
32716695|NCT04982354|Experimental|Investigational Treatment|Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.
32716696|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
32716697|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
32716698|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
32716699|NCT04209218|Placebo Comparator|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
32716700|NCT04209218|Experimental|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
32716701|NCT04209218|Experimental|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
32716702|NCT04209218|Experimental|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
32917873|NCT01780922|Active Comparator|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
32917874|NCT01780922|Placebo Comparator|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
32917875|NCT04847063|Experimental|1/ HIPEC: Oxaliplatin Randomized treatment assignment|HIPEC with intraperitoneal oxaliplatin and IV 5-FU, randomly assigned
32917876|NCT04847063|Experimental|2/ HIPEC: Mitomycin C Randomized treatment assignment|HIPEC with intraperitoneal mitomycin C, randomly assigned
32917877|NCT04847063|Experimental|3/ HIPEC: Cisplatin, Doxorubicin Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and doxorubicin, in addition to IV sodium thiosulfate, randomly assigned
32917878|NCT04847063|Experimental|4/ HIPEC: Cisplatin, Mitomycin C Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and mitomycin C, in addition to IV sodium thiosulfate, randomly assigned
32917879|NCT05112497||Crohn's Disease|"Pregnant CD patients~Newborn of pregnant CD patients~Father of the newborn~Non-pregnant CD women"
32917880|NCT05112497||Healthy Control|"Pregnant women without CD~Newborn of pregnant women without CD~Father of the newborn"
32917881|NCT04838951|Experimental|Intervention arm|CADe system will be used during withdrawal phase of colonoscopy.
32917882|NCT04838951|No Intervention|Control arm|Colonoscopy will be performed according to hospital protocol.
32917883|NCT05104619||tumor samples|(SCC of the tongue)
32917884|NCT05104619||healthy tissues|
32917885|NCT04835519|Experimental|chimeric antigen receptor T cell treatment|
32917886|NCT05099315||Dupilumab treated Patients (observational)|Patients with atopic dermatitis with indication for dupilumab treatment will be observed.
32917887|NCT05099315||Cyclosporine treated Patients (observational)|Patients with atopic dermatitis with indication for cyclosporine treatment will be observed.
32917888|NCT05099315||Baricitinib treated Patients (observational)|Patients with atopic dermatitis with indication for baricitinib treatment will be observed.
32917889|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
32917890|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
32917891|NCT05067725|No Intervention|Control|Standard of practice
32917892|NCT05067725|Experimental|CarePath Intervention|Clinician decision support computer tool that consists of a best practice alert (BPA) embedded with a headache questionnaire, Medication Express Lane (for medication ordering), and Ask-a-doc button (for prompt virtual consultation with a neurologist)
32917893|NCT05066165|Experimental|Arm 1: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count <5%, administered by IV infusion following lymphodepleting chemotherapy.
32917894|NCT05066165|Experimental|Arm 2: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.
32917895|NCT05063591|Experimental|Intervention arm|Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.
32917896|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses [40 milligrams (mg) - 200 mg] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
32917897|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
32716703|NCT04209062|Experimental|Study device|
32716704|NCT04209062|Active Comparator|Control device|
32716705|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
32716706|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
32716707|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
32716708|NCT04981262|Experimental|Stimulance|4 weeks intervention with Stimulance for all participants
32716709|NCT04981262|Experimental|Stimulance 6 months|6 months intervention
32716710|NCT04981262|No Intervention|No intervention|6 months control group
32716711|NCT04981184|Other|Gait and balance measurement|"Gait analysis with surface electromyography measurement: surface electromyography signals (of affected and non-affected legs), gait and stance parameters are collected while the patient walks for 30 seconds on the treadmill with integrated sensor equipment (for measuring the force distribution).~Balance analysis with Biodex balance system SD: measurements of postural stability, fall risk, limits of stability, sensory integration are collected."
32716712|NCT05033366||Proov test strip users that record results with the Proov app|Participants using Proov test strips along with the Proov app who have logged at least one complete cycle will be asked to complete an online survey about fertility test results and current/previous pregnancy status. They will also be asked cycle history (irregular vs regular, cycle length), fertility testing (partners semen analysis results, AMH level, HSG results), possible fertility medications taken or prescribed, age, race, smoking status, and BMI.
32716713|NCT05033132|Experimental|Balstilimab|Balstilimab monotherapy: approximately 147 patients.
32716714|NCT05033132|Experimental|Balstilimab + Zalifrelimab|Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.
32743298|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
32917898|NCT04765241|Experimental|mHealth Physical Activity Intervention|The intervention arm will receive a 12 month mobile health (mHealth) physical activity intervention with a goal of increasing their moderate-vigorous intensity physical activity levels by 90 minutes per week above baseline
32917899|NCT04765241|No Intervention|Control|Controls will receive general health education materials
32716715|NCT05031650|Active Comparator|openCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:~If the HR > 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
32917900|NCT05055089||new-generation bioprostheses|Patients undergoing surgical aortic valve replacement with new-generation bioprostheses
32917901|NCT05055089||traditional bioprosthesis|patients who received a traditional bioprosthesis
32917902|NCT05051969|Experimental|8 Week Remote Mindfulness-Based Stress Reduction Program|8 Week Remote MBSR Course for MNPS Employees.
32716716|NCT05031650|Active Comparator|standardCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:~If the HR > 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
32917903|NCT05051969|No Intervention|8 week waitlist control|8 week waitlist control. They will complete the same assessments at baseline, 8 and 12 weeks
32917904|NCT05043623|Experimental|Arm 1 - Clinician Collected/supervised Rhinoswab first, then CTDN swab|Rhinoswab test administered and immediately followed by CTDN. Rhinoswab swab tested on respiratory panel vs CTDN swab tested on respiratory panel (standard of care).
32917905|NCT05043623|Experimental|Arm 2 - Clinician Collected/supervised CTDN swab first, then Rhinoswab|CTDN test administered and immediately followed by Rhinoswab. CTDN swab tested on respiratory panel (standard of care) vs Rhinoswab swab tested on respiratory panel.
32716717|NCT05031338||SX-One MicroKnife with ultrasound guidance|Carpal Tunnel Release using the SX-One MicroKnife with ultrasound guidance
32917906|NCT05043623|Experimental|Arm 3 - Self-collected Rhinoswab, saliva swab, CTDN|In children 5-18 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. All samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc)
32917907|NCT05043623|Experimental|Arm 4 - Self-collected RAT, saliva, CTDN|In children 1 month -5 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. Saliva and CTDN samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc), RAT test kit will be Abbott PanBio
32917908|NCT04886622|Experimental|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
32917909|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
32917910|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
32917911|NCT05028881||HIV positive|No interventions
32917912|NCT05028881||HIV uninfected|No interventions
32917913|NCT04994795||Pembrolizumab monotherapy|
32716718|NCT05031338||Traditional mini-open technique without ultrasound guidance|Carpal Tunnel Release using the traditional mini-open technique without ultrasound guidance
32716719|NCT05070026|Experimental|uni-portal VATS group|
32716720|NCT05070026|Experimental|three port VATS group|
32716721|NCT04980326|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2) in addition to Psychological First Aid (PFA) and care-as-usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.~Participants allocated to the experimental arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria."
32716722|NCT04980326|Active Comparator|Psychological First Aid (PFA)|Participants allocated to the control arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.
32716723|NCT04979702|Active Comparator|Active Control|Patients will have access to our online exercise resources throughout the 12-week intervention.
33247444|NCT05351294|Experimental|Arm 1|All enrolled patients will receive standard oncologic care at the discretion of the treating physicians, but will also complete the EORTC QLQ-C30, EQ-5D-5L, PTPQ, FAMCARE-P16 at baseline before randomization. Follow-up assessment using EORTC QLQ-C30, PTPQ, FAMCARE-P16 will occur every 3 months, and using EQ-5D-5L will occur every 1 month, for a total of 12 months. These will be administered during standard-of-care clinic or infusion center visits.
32716724|NCT04979702|Experimental|Experimental: mHealth technology assisted exercise counselling (mHealth)|Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
32716725|NCT05068466|Experimental|INCB054707 (Dose A)|Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
32716726|NCT05068466|Experimental|INCB054707 (Dose B)|Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.
32716727|NCT05068466|Placebo Comparator|Placebo (Dose A)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
32766168|NCT04910165|Active Comparator|Control|Ropivacaine use as active ingredient in the block
32716728|NCT05068466|Placebo Comparator|Placebo (Dose B)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
32716729|NCT04979000||Cases|Patients with a confirmed diagnosis of sinonasal cancer.
32716730|NCT04979000||Controls|Patients being seen for benign conditions at Johns Hopkins.
32716731|NCT04218968|Experimental|carvedilol therapy|
32716732|NCT04218032||blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
32716733|NCT05067764|Experimental|Aponeurectomy with grafting|The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
32716734|NCT05067764|Active Comparator|Aponeurectomy alone|The control group evaluates the aponeurectomy alone.
32716735|NCT04978142|Experimental|Active|Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies. The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2). The anode will be placed over the right dlPFC and cathode over the left dlPFC).
32716736|NCT04978142|Sham Comparator|Sham|Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods. The electrode configuration and placement will be identical to the active stimulation.
32716737|NCT05066750|Experimental|Mindful breathing video|Participants watch a 10 minute mindful breathing video
32716738|NCT05066750|Active Comparator|Control video|Participants watch a 10 minute control video
32716739|NCT04977362|Experimental|ERAS protocol (intervention group)|The innovative care process in the intervention group is characterized by an interdisciplinary approach according to the previously established enhanced recovery after surgery protocol. This process aims at improving the clinical outcome after cardiac surgery, increasing patient satisfaction and quality of life, enabling early professional reentry and participation, and optimizing the cost-effectiveness of service provision. In addition, intersectoral barriers are being broken down in order to establish an interdisciplinary and cross-sectoral overall care process for patients with heart valve surgery as a new form of care in the future.
32766169|NCT02730325|Active Comparator|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
32766170|NCT02730325|Placebo Comparator|Placebo BID|Placebo
32766171|NCT04500847|Active Comparator|Group 1|25 MCI and mild to moderate AD subjects
32766172|NCT04500847|Placebo Comparator|Group 2|10 MCI and mild to moderate AD subjects
32766173|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
32766174|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
32766175|NCT04500769|Experimental|Acute Resistance Exercise|Participants will perform four exercises: squat, knee extension, leg press, and lat pulldown at 80% of 1-RM determined during a previous visit.
32766176|NCT04928495|Placebo Comparator|Treatment group 1|Control placebo (Vitamin C - 500mg / day, for 10 days)
32766177|NCT04928495|Active Comparator|Treatment group 2|N-acetylcysteine (NAC; 1800 mg / day, for 10 days)
32766178|NCT04928495|Active Comparator|Treatment group 3|NAC (1800 mg / day) + bromhexine-BMX (32 mg / day for 10 days)
32766179|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
32766180|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
32766181|NCT05015413|Experimental|shock wave group|Group A will receive shockwave therapy 2 session per week for 6 weeks
32766182|NCT05015413|Experimental|low level laser group|Group B will receive low level laser therapy 2 session per week for 6 weeks
32766183|NCT04919135|Experimental|Treatment (UC-MSC trasnplatation)|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
32766184|NCT04919135|Other|control arm|standard frailty treatment and supplementary medication
32766185|NCT01636375||Direct Anterior Approach|
32766186|NCT01636375||Posterior Approach|
32917914|NCT04994795||Chemotherapy and pembrolizumab combination therapy|
32917915|NCT04994795||Chemotherapy doublet|
32716740|NCT04977362|Active Comparator|Treatment as usual (control group)|The control group undergoes standard heart valve surgery. In this case, no preoperative interventions take place, the patient is operated on the affected heart valve in a minimally invasive procedure without prehabilitation. After surgery, the patient is transfered to an intensive care unit (not a specialized postanesthesia care unit) depending on the individual condition and then transfered to the general ward. Patients receive medical, nursing, and physiotherapeutic care in accordance with current hospital standards.
32716741|NCT04977050|Experimental|Intervention Site|All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.
32716742|NCT04977050|No Intervention|Controled site|All miners in the Wyoming Control mine site who will be administered serological testing 3 months.
32716743|NCT05028374|Other|"A single booster dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly"|The dose of Moderna mRNA vaccine to be administered is the same for all patients in all enrollment cohorts: 0.5 mL administered intramuscularly as a single dose, according to the manufacturer's package insert.
32716744|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
32716745|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
32716746|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
32716747|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
32716748|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
32716749|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
32716750|NCT05064722|Experimental|SNAP-S|Creation of a D-I diversion in participants undergoing primary sleeve gastrectomy (SNAP-S cohort)
32716751|NCT05064722|Experimental|SNAP-PS|Creation of a D-I diversion in participants who have experienced inadequate weight loss following sleeve gastrectomy (SNAP-PS cohort)
32716752|NCT04421300|Experimental|smile exercise|smile exercise, 4 times a day，8 weeks
32716753|NCT04421300|Active Comparator|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
32716754|NCT05026736|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
32716755|NCT04868812|Experimental|Patient|All participants will be screened to ensure inclusion/exclusion criteria are met. A biopsy will be taken from each patient one month before the first laser treatment and one month after the last laser treatment. The MonaLisa treatment will be performed monthly for 3 months. A clinical evaluation will be recorded for each patient using validated questionnaires at baseline and one month after the last procedure.
32716756|NCT05026502||Participants Being Treated With Elagolix + E2/NETA|Participants will receive Elagolix with Estradiol/Norethindrone Acetate per Standard of Care, as prescribed by their physicians.
32716757|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
32716758|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
32716759|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
32716760|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
32716761|NCT05025878||[U-13C]glucose|All participants consented to the study will receive the [U-13C]glucose infusion and collection of ascites for research.
32716762|NCT05025800|Experimental|Treatment (ALX148, rituximab, lenalidomide)|Patients receive ALX148 IV over 1 hour once on days 1, 8, 15 and 22, or days 1 and 15, or day 1 depending on dose level. Patients also receive rituximab IV over 4-6 hours on days 1, 8, 15 and 22 of cycle 1, then on day 1 of cycles 2-6, and lenalidomide PO QD on days 1-21 of cycles 1-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32716763|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
32716764|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
32716765|NCT05025722||Confirmed PXE participants|Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.
32716766|NCT05025722||PXE carrier participants|Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.
32716767|NCT05025722||Non-PXE normal participants|Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.
32716768|NCT05648188||NSCLC patients|Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).
32716769|NCT04974164||Clinic cases group|Those with a positive RT-PCR test will be the test-positive cases or clinic cases (approximate N=700)
32716770|NCT04974164||Clinic controls group|Those with a negative RT-PCR test will be the test-negative cases or clinic controls (N=700)
32743299|NCT04936737|Experimental|Beta-alanine supplementation and high intensity exercise|Individuals will participate in a high-intensity exercise and will be supplemented with beta-alanine. This protocol will be conducted for six non-consecutive days.
32766187|NCT04919213||Individuals with Intellectual Disabilities|Individuals will be invited to take part in an online survey (paper version will also be available). The participants will be recruited through advertisements on relevant platforms (e.g., Facebook, Twitter) and through relevant social care organisations. The study hopes to recruit 100 individuals from all over England (UK). A subgroup will be asked if they would like to take part in a one-to-one open-ended interview (n=20) and/or in direct observations (n=30).
32766188|NCT04919213||Family carers|Family carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of family carers (n=7) will be asked if they would like to take part in a focus group.
32766189|NCT04919213||Paid carers|Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
32766190|NCT04919213||Professionals with safeguarding responsibilities|Professionals with safeguarding duties (e.g., social workers, learning disability nurses, police and safeguarding adults board members) supporting people with ID in England who use the internet will also be invited to take part in an online survey (n=50). A subgroup (n=7) from London and Kent (England, UK) will be asked if they would like to take part in a focus group.
32766191|NCT04922593|Experimental|LY03010 treatment group|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4oxo-4Hpyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89 g/mol.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 141."
32766192|NCT04922593|Active Comparator|INVEGA SUSTENNA treatment group|"INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available. INVEGA SUSTENNA is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber).~In SUSTENNA treatment group, all subjects will receive the first dose of 234 mg IM injection in the deltoid muscle on Day 1, and a second dose of 156 mg of IM injection in the deltoid muscle on Day 8, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 148."
32766193|NCT04928885|Experimental|WW Treatment Group|Individuals will receive the 12-week Wits Workout Program. Individuals will take the baseline, 3 mos and 6 mos follow-up surveys. They will also take the Wits Workout satisfaction survey and participate in the 6 mos focus-groups.
32766194|NCT04928885|Other|WW Control Group|Individuals will be on a waitlist and will take the baseline, 3 mos and 6 mos. assessments. They will receive the Wits Workout workshop after the 6 month study period is completed.
32766195|NCT01573429|Other|Dermal Carboxymethylcellulose arm|d-BPA administered dermally using a carboxymethylcellulose suspension
32766196|NCT01573429|Other|Dermal ethanol arm|d-BPA is administered dermally using an ethanol solution
32766197|NCT01573429|Other|Oral arm|d-BPA administered orally
32766198|NCT04928027||Persons with PD|Adults with PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Self-Assessment
32766199|NCT04928027||Significant Others of those with PD|Adults whose significant other has a diagnosis of PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Observer report
32766200|NCT02632123||Development cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
32766201|NCT02632123||Validation cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
32766202|NCT03055559||Globifer Forte|
32766203|NCT04910009|No Intervention|Theoretical training group|Students participating in only theoretical training of the privacy education for two 40-minute sessions.
32766204|NCT04910009|Experimental|Digital story and ethical case analysis group|Students participating in 2 sessions of 40-minute theoretical training and then participating in 4 sessions of 60-minute digital story and ethical case analysis preparation and presentation.
32766205|NCT04910009|Experimental|Only ethical case analysis group|Students participating in 2 sessions of 40 minutes of theoretical training and then participating in 4 sessions of 60-minute ethical case analysis preparation and presentation only.
32766206|NCT01518673||X-rays|
32766207|NCT04909931|Experimental|vitamin D supplementation group|First arm ; add on vitamin D 40,000 IU/week for 12 weeks
32766208|NCT04909931|Experimental|second arm|add on placebo
32766209|NCT05129995|Experimental|Passive heat treatment|Infrared sauna bathing
32766210|NCT04928807|Experimental|Short course radiotherapy sequential camrelizumab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.~The patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.~Postoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles"
32766211|NCT04928807|Active Comparator|Long term concurrent chemoradiotherapy and sequential chemotherapy|"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).~The patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles"
32766212|NCT02360839|No Intervention|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
32766213|NCT02360839|Other|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
33247445|NCT05351294|Experimental|Arm 2|Patients enrolled in Arm 2 will also be seen be a radiation oncologist during the course of the study. The RO will review the patient's most recently completed EQ 5D-5L questionnaires and perform a complete History and Physical evaluation to determine if there is any immediate role for PRT. Based on the patient's type of cancer and areas of spread, the RO will also discuss types of symptoms that could develop in the future, and give instructions and educational materials to the patient so he/she can better identify those symptoms early on.
33073288|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
33247446|NCT00893932||SIRS|
33247447|NCT00895726|Experimental|APD209|
33247448|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
33247449|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
33247450|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
32766214|NCT04919291|Active Comparator|Topoguided LASIK|Topoguided ablation profile on dominant eye
32766215|NCT04919291|Active Comparator|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
32766216|NCT05129293|Experimental|Prospective Memory Intervention|Participants randomized to the PM intervention (active group) will meet with an interventionist twice a week for four weeks. The first four sessions will focus on visual imagery, while the last four sessions will focus on implementation intentions. Participants will be led through a manualized treatment.
32766217|NCT05129293|Active Comparator|Educational|The control group (Education) will meet with a research assistant for the same frequency of sessions and will receive psychoeducation on MS and cognitive functioning. The interventionists will be following a manual and accompanying PowerPoint slides.
32766218|NCT04918589|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
32766219|NCT04918589|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
32766220|NCT04496401|Experimental|Tacrolimus then Envarsus|Tacrolimus will be started on the day of surgery. After a stable trough level is achieved (on postoperative day 7-17) the first PK profile will be measured. Subsequently, the switch to ENVARSUS® will be performed
32766221|NCT04928651||Clonidine|Preterm infants (< gw 37+0) who are in need for analgesic or sedative medication will receive treatment with clonidine according to an algorithm based on pain and sedative scoring results
32766222|NCT05128981|Other|MI-CBT via the Internet|The MI-specific CBT will consist of 8 modules delivered via the Internet with home assignments that can be reviewed and reported in the research groups secure platform.
32766223|NCT04101643|Experimental|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
32766224|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
32766225|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
32766226|NCT04082455|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
32766227|NCT04062799||Study cohort|
32766228|NCT04909619|Experimental|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|Patients randomized to this arm will receive an ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg of 0.2% ropivacaine per side, for a total of 0.3 ml/kg immediately after induction of general anesthesia and prior to incision. Participants will also receive local infiltration of the palate with an equivalent injection volume of 0.9% saline with 1:400,000 epinephrine at 2 ml/kg. Pediatric anesthesiologists with fellowship training in regional anesthesia will perform the nerve block. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
32917916|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
33073289|NCT02968810|Experimental|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
33247451|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
33247452|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
33247453|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
33247454|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
33247455|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
33247456|NCT03823404|Experimental|COR388 80 mg twice daily (BID)|COR388 hydrochloric acid (HCl), 80 mg orally administered capsule, BID (twice daily) with water approximately 12 hours apart and no less than 6 hours apart
33247457|NCT03823404|Experimental|COR388 40 mg BID|COR388 HCl, 40 mg orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
32716771|NCT04874974|Experimental|Metacognitive and Defusion Training|All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.
32917917|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
33247458|NCT03823404|Placebo Comparator|Placebo BID|Placebo orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
32917918|NCT04976933||Primary Caregivers|Primary caregivers of children receiving Tacrolimus or cyclosporine immunosuppression for an allogeneic transplant will be introduced to the mHealth adherence app and allowed the opportunity to interact with the app alongside research staff. Following this session primary caregivers are asked to use the app at home until Day 100 or weaning of immunosuppressant, whichever is first.
32917919|NCT04419948|Experimental|Control|100g white bread plus 40ml butter
32917920|NCT04419948|Experimental|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
32917921|NCT04419948|Experimental|Refined olive oil|100g white bread plus 40ml refined olive oil
33247459|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
33247460|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
33247461|NCT05731544|Experimental|Phase 1 (SAD Cohorts)|Phase 1 comprises of randomized healthy adult subjects in 4 cohorts. 10 subjects will be randomized at 7:3 (active and placebo) in sequential order in 4 dose escalating cohorts. Each cohort is composed of 2 sentinel subjects randomized at 1:1 (active and placebo), followed by 8 additional subjects randomized at 3:1 (active and placebo).
33247462|NCT05731544|Experimental|Phase 1 single dose, 3-period crossover, food effect substudy in 2 cohorts.|Each cohort comprises of 12 healthy adult subjects randomized at 1:1:1:1:1:1 in a 3-period crossover study with 6 treatment sequences.
33247463|NCT05731544|Experimental|Phase 2 (MAD Cohorts)|Phase 2 comprises of 1 cohort of 16 healthy adult subjects randomized at 3:1 (active and placebo) and 7 cohorts of T2DM adult subjects randomized at 5:1 (active and placebo) to obtain further safety and efficacy data to identify the potential optimal biological dose (OBD)/recommended Phase 2 dose (RP2D).
33247464|NCT00410761|No Intervention|1|Placebo vandetanib
33247465|NCT00410761|Experimental|2|Vandetanib
33247466|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
33247467|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
33247468|NCT03818178|Experimental|Intralipid|
32716772|NCT05062460|Other|1-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 1 hour after eating.
32716773|NCT05062460|Other|2-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 2 hours after eating.
33247469|NCT03818178|Experimental|Palm Oil|
33247470|NCT03818178|Placebo Comparator|Saline|
32716774|NCT04972760|Experimental|baricitinib arm|Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
32716775|NCT04972760|Placebo Comparator|placebo arm|Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
32716776|NCT04972526||Out-of-hospital Cardiac Arrest|Patients receiving TEE as part of their clinical evaluation during cardiac arrest that occurred outside the hospital (e.g. in/at a home or residence, in a public area, during transport to the emergency department, etc.)
32716777|NCT04972526||In-hospital Cardiac Arrest|Patients receiving TEE as part of the clinical evaluation during cardiac arrest that occurred within a hospital (e.g in the emergency department, an Intensive Care Unit, a hospital ward, the operating room, etc.)
32716778|NCT04972526||Undifferentiated Shock or Acute Hemodynamic Decompensation|Patients receiving TEE as part of the initial evaluation of undifferentiated shock or acute hemodynamic decompensation
32716779|NCT04972526||Hemodynamic Monitoring in a Critically Ill Patient|Critically ill patients receiving TEE as part of hemodynamic monitoring
32716780|NCT04972526||Procedural Guidance|Patients receiving TEE as a means to assist providers performing procedures (e.g. intravenous pacemaker placement, veno-arterial or veno-venous extracorporeal membrane oxygenation [ECMO], impella heart pump placement, intra-aortic balloon pump placement, etc.)
32917922|NCT04419948|Experimental|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
32917923|NCT04419948|Experimental|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
32917924|NCT01781078|Experimental|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
32917925|NCT01781078|Experimental|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
32917926|NCT04665713||Normal|children whose BMI are in the normal range(From P5 to P85)
32917927|NCT04665713||Overweight|children whose BMI are above the normal range(over P85)
32917928|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
33247471|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
33247472|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
33247473|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
32917929|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
32917930|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
32917931|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
32917932|NCT04657367||Diabetes|Patients with diagnosed diabetes
32917933|NCT04657367||Prediabetes|Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
32716781|NCT05023772|Experimental|Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery|Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
32716782|NCT05062382|Experimental|Complementary feeding program|Promotion of eggs.
32917934|NCT04657367||Normoglycemia|Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
32917935|NCT01312922|Experimental|PNB01|oral, once daily administration
32917936|NCT01312922|Active Comparator|citalopram|oral, once daily administration
32917937|NCT01312922|Sham Comparator|pipamperone|oral, once daily administration
32917938|NCT03785405|Experimental|sacubitril/valsartan|single arm, open label sacubitril/valsartan
32716783|NCT05062382|No Intervention|Comparison|Comparison arm with no program
32716784|NCT05022524|Experimental|Transition-Age Adults|16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.
32716785|NCT05061758|Experimental|Four injections of 250µg LY3056480|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~Group 2 - Regimen 2. Weekly~Group 3 - Regimen 3. Every two weeks"
32716786|NCT05061758|Placebo Comparator|Four injections of placebo|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~Group 2 - Regimen 2. Weekly~Group 3 - Regimen 3. Every two weeks"
32716787|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
32716788|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
32716789|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
32716790|NCT05021822|Active Comparator|Block Group|
32716791|NCT05021822|No Intervention|Control Group|
32716792|NCT05021666|Experimental|Group A1|PB-718 vs placebo
32716793|NCT05021666|Experimental|Group A2|PB-718 vs placebo
32716794|NCT05021666|Experimental|Group A3|PB-718 vs placebo
32716795|NCT05021666|Experimental|Group A4|PB-718 vs placebo
32716796|NCT05021666|Experimental|Group A5|PB-718 vs placebo
32716797|NCT05021666|Experimental|Group A6|PB-718 vs placebo
32716798|NCT05021666|Experimental|Group B1|PB-718 vs placebo
32716799|NCT05021666|Experimental|Group B2|PB-718 vs placebo
32716800|NCT05021666|Experimental|Group B3|PB-718 vs placebo
32716801|NCT05021666|Experimental|Group B4|PB-718 vs placebo
32716802|NCT04971824|Experimental|Physiotherapeutic arm|"There will be the physiotherapeutic intervention, total duration for each participant is three months.~The participants will be asked to fill three validated questionnaires in the beginning and in the end of study and keep records of their exercises, period and ovulation in their diaries."
32716803|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
32716804|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
32716805|NCT04970108|Experimental|Egito|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Egito, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan placebo, oral."
32716806|NCT04970108|Active Comparator|Empagliflozin + telmisartan|"The patient must take 3 tablets once a day, as follows:~1 tablet Egito placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan, oral."
32716807|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
32716808|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
32716809|NCT04969952|Experimental|Group A|Group A had watching educational module plus ACP brochure
32716810|NCT04969952|Active Comparator|Group B|Group B ACP brochure only
32716811|NCT05061290|Experimental|Control Porridge|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
32716812|NCT05061290|Experimental|Reference Porride A|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Ascorbic acid, Corn starch
32917939|NCT04648709||asymptomatic patients|asymptomatic patients with PCR-positive PCR
32917940|NCT04648709||mild symptoms patients|patients with mild symptoms and PCR positive
32917941|NCT04648709||seriously symptomatic patients|seriously symptomatic patients with PCR positive
32917942|NCT04648709||patients in resuscitation|patients in resuscitation with positive PCR
32917943|NCT04648709||heathly volunteer|heathly volunteer as control
32917944|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
32917945|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
32917946|NCT03763643|Experimental|Rituximab + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
32917947|NCT03763643|Placebo Comparator|Placebo + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
32716813|NCT05061290|Experimental|Test Porridge B|Wholegrain maize flour, Moringa leaf powder, Mango powder, Carrot powder, Corn starch
32716814|NCT05061290|Experimental|Test Porridge C|Wholegrain maize flour, Baobab fruit powder, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
32716815|NCT05061290|Experimental|Test Porridge D|Wholegrain maize flour, Baobab fruit powder, Moringa leaf powder, Mango powder, Carrot powder
32917948|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
32917949|NCT01783574|Active Comparator|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
32917950|NCT01783574|Placebo Comparator|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
32917951|NCT04371653|Experimental|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
32917952|NCT04371653|Placebo Comparator|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
32716816|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
32716817|NCT02361580|No Intervention|No Diary|Control Group
32716818|NCT04421534|Experimental|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
32716819|NCT04421534|Experimental|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
32716820|NCT04421534|Active Comparator|Standard of care only|Standard of care treatment; as per MOHP protocol
32716821|NCT05060744|Active Comparator|Intervention (Antacid)|"An Antacid, a CE marked medical device under normal conditions of use.~Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet)~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
32716822|NCT05060744|Placebo Comparator|Control|"The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers.~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
32716823|NCT05059028|Active Comparator|Oxytocin massage|
32716824|NCT05059028|Active Comparator|music therapy|
32716825|NCT05059028|No Intervention|control group|
32716826|NCT05058638|Experimental|Aquamin®|
32716827|NCT05018000|Active Comparator|Arm 1: Enhanced usual care|Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.
32716828|NCT05018000|Experimental|Arm 2: Brief financial navigation intervention|Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.
32716829|NCT05018000|Experimental|Arm 3: Extended financial navigation intervention|Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).
32716830|NCT05058170||Renal transplant patients|
32716831|NCT05017064|Experimental|Cryotherapy group|An intraoral ice pack will be placed on the mucosal groove during root canal treatment.
32716832|NCT05017064|Placebo Comparator|Control group|No ice pack will be used.
32716833|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
32716834|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
32716835|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
32716836|NCT05057234|Experimental|Simultaneous - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress or reported within 4 weeks of enrollment
32716837|NCT05057234|Experimental|Simultaneous - no additional testing|Patients undergoing no additional testing while tissue-based NGS panel is in progress or reported within 4 weeks of enrolment
32743300|NCT04936737|Experimental|Beta-alanine supplementation only|In this protocol, the individuals will be supplemented with beta-alanine without the exercise protocol for six non-consecutive days.
33247474|NCT04061070|Sham Comparator|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
32917953|NCT00119912|Active Comparator|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
32917954|NCT00119912|No Intervention|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
32716838|NCT05057234|Experimental|Sequential - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx if standard tissue based NGS oncopanel testing identifies no somatic tier 1 variant of strong clinical significance
32917955|NCT00119912|Active Comparator|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
32917956|NCT00356837|Experimental|A|Those with extremity fractures.
32917957|NCT03656783|Other|HIV patients on stable therapy|HIV patients on stable therapy switching from Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
33247475|NCT04061070|Active Comparator|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
32716839|NCT04205552|Experimental|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)~o Nivolumab 240 mg i.v. over 30 min"
32716840|NCT04205552|Experimental|Nivolumab/Relatlimab (80 mg)|"Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)~Nivolumab 240 mg i.v. over 30 min~Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
32716841|NCT04205552|Experimental|Nivolumab/Relatlimab (240 mg)|"Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)~Nivolumab 240 mg i.v. over 30 min~Relatlimab 240 mg i.v. over 30 min (within 30 min of nivolumab)"
32716842|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
32716843|NCT04966520|Experimental|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham|"Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months.~Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered)."
32716844|NCT05055440||Mechanically ventilated patients with COVID-19 in the ICU|Mechanically ventilated patients with COVID-19 admitted to the intensive care unit using sedation and neuromuscular blocker
32716845|NCT04965740||North American First Responders|Spread directly to union representatives for email and messaging to those interested in taking the survey
32716846|NCT04965740||Oceana and European first responders|First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.
32716847|NCT04964726|Experimental|Real-time fMRI dyadic neurofeedback|
32716848|NCT05054738|Experimental|Combined Recovery Program (CRP)+Treatment-as-usual (TAU)|Combined Recovery Program (CRP) is a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit. Attendance of CRP will be in addition to Treatment as Usual (TAU), that is, standard inpatient programming.
32716849|NCT05054738|Active Comparator|CRP+ Stable & Able (S&A)+TAU|Combined Recovery Program (CRP) a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit, plus a home telehealth program (Stable & Able) which begins on day 1 of hospital discharge. Attendance of CRP and S&A will be in addition to TAU, that is, standard inpatient programming.
32716850|NCT05054738|No Intervention|Treatment-as-usual only (TAU):|TAU will only receive the usual care on the inpatient unit including medical and medication management.
32716851|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
32716852|NCT04215848|Experimental|As-needed Budesonide/Formoterol|As-needed Budesonide/Formoterol (160/4.5 ug)
32716853|NCT04215848|Active Comparator|Budesonide|Budesonide (200 ug) twice daily
32716855|NCT04215146|Active Comparator|Cohort 1|Patients receive paclitaxel alone.
32716856|NCT04215146|Experimental|Cohort 2|Patients receive pelareorep + paclitaxel.
32716857|NCT04215146|Experimental|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
32716858|NCT04949750|Experimental|Paper based cognitive training|Patients with Alzheimer's disease in the early stage receive 12 weeks paper based cognitive training and standard care (medication)
32716859|NCT04949750|No Intervention|Control group|Patients with Alzheimer's disease in the early stage only receive standard care (medication)
32716860|NCT04214678|Experimental|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
32716861|NCT04214678|Active Comparator|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
32716862|NCT05010200|Experimental|Cohort 1 - Primary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC.
33247476|NCT04035460|Active Comparator|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
32716863|NCT05010200|Experimental|Cohort 2 - Secondary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC, and CDX-301
32716864|NCT05010200|Experimental|Cohort 3 - Expansion treatment cohort|An expansion cohort if the treatment of all 3 together has not triggered a safety stopping event.
32917958|NCT01784588|Active Comparator|Solyx Single Incision Sling System|Solyx Single Incision Sling System
32917959|NCT01784588|Active Comparator|Obtryx II Sling System|Obtryx II Sling System
32917960|NCT03632135|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
32917961|NCT03632135|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
32917962|NCT01784666|Experimental|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
32917963|NCT01784666|Experimental|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
32917964|NCT01784666|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
32917965|NCT01733186|Experimental|CARTISTEM®|Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
32917966|NCT01734746|Experimental|Tracerinjection|The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
32917967|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
32716867|NCT05463770|Experimental|SEP-363856|
32716868|NCT04960592||SCS Responders|Patients who receive Spinal Cord Stimulation treatment and experience greater than 50% reduction in pain score following treatment.
32716869|NCT04960592||SCS Non Responders|Patients who receive Spinal Cord Stimulation treatment and do not experience greater than 50% reduction in pain score following treatment.
32716870|NCT04949360|Active Comparator|Standard CBTi (CBTi-S):|This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
32716871|NCT04949360|Placebo Comparator|Minimal intervention - Sleep hygiene (MI-SH):|This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
32716872|NCT04949360|Experimental|Online CBTI (CBTI-O)|This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
32716873|NCT04949360|Experimental|Online CBTi + additional features (CBTi-O+)|This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
32716874|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
32716875|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
32917968|NCT01785134|Sham Comparator|Control|Gastric bypass operation without omentectomy.
32917969|NCT01785134|Active Comparator|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
32917970|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
32716876|NCT04947800|Experimental|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
32716877|NCT04947800|Experimental|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
32716878|NCT04947800|Experimental|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
32716879|NCT04959266|Experimental|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
32716880|NCT04959266|Experimental|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
32716881|NCT04959266|Experimental|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
32917971|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
32716882|NCT04957862|Active Comparator|robotic assisted evacuation|In the intervention arm, patients will receive stereotactic robotic assisted HICH evacuation according to the protocol under general anesthesia.
32716883|NCT04957862|No Intervention|Concomitant care|All enrolled HICH patients in this study will receive standard medical treatment in the first 3-4 weeks according to the ASA/AHA guideline . Continued medical treatment is applied to patients in the control arm. Both arms will receive identical rehabilitation therapy three times per week for 180 days at one facility. Rehabilitation therapy includes identical physical therapy, occupational therapy, speech therapy, functional training, acupuncture and massage.
32917972|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
32917973|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
32917974|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
32917975|NCT01785680|Active Comparator|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
32917976|NCT01785680|Experimental|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
32917977|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
32917978|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
32917979|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
32917980|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
32716884|NCT04957628||Control group|2500 participants will be recruited before the intervention procedures are implemented at the respective hospitals. Baseline data on alcohol, psychoactive medicinal and illicit drug use (AUDIT-4 and DUDIT), stages-of-change questionnaire on alcohol, medicinal drugs and illicit drug use, and mental distress will be recorded. Left-over full blood from routine diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the control group will receive acute medical treatment according to hospital procedures. After 12 months, the data from baseline will be coupled to data from patient journals and data from relevant registries.
32917981|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until January 1st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
32917982|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2009 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres
32917983|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2020 until January 1st 2030 who have been or are to be treated with coagulation proteins in one of the participating centres
32917984|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
32917985|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
32917986|NCT04362293|Experimental|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
32716885|NCT04957628||Case group|2500 participants will be recruited after the intervention procedures are implemented. Baseline data on alcohol, psychoactive medicinal and illicit drug use, stages-of-change questionnaires, and mental distress will be recorded. Left-over blood from diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the case group will receive treatment according to new hospital procedures, including screening for harmful alcohol use and non-prescribed use of psychoactive medicinal drugs and intervention. If feasible, a new blood sample will be collected 2 months after inclusion, which will be analyzed for PEth. After 12 months, the data from baseline will be coupled to patient journals and relevant registries.
32917987|NCT04362293|Experimental|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
32917988|NCT04336397|Active Comparator|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
32917989|NCT04336397|Active Comparator|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
32917990|NCT04336397|No Intervention|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
32917991|NCT04296695|Experimental|B/F/TAF|50mg/600mg/300mg
32917992|NCT04296695|Active Comparator|TDF/3TC/EFV|300mg/300mg/400mg
32917993|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
32917994|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
32917995|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
32917996|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
32917997|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
33247477|NCT04035460|Active Comparator|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
33247478|NCT05508776|Experimental|LEO 152020 Dose A|A single oral dose of LEO 152020 Dose A according to the randomization schedule.
33247479|NCT05508776|Experimental|LEO 152020 Dose B|A single dose of LEO 152020 Dose B according to the randomization schedule.
33247480|NCT05508776|Active Comparator|Moxifloxacin|A single oral dose of moxifloxacin 400 mg according to the randomization schedule.
33247481|NCT05508776|Placebo Comparator|Placebo|A single dose of placebo according to the randomization schedule.
33247482|NCT02565342|Experimental|Interscalene brachial plexus block|
33247483|NCT00896350|Experimental|BOLD MRI|Determine the amount of oxygen supply to tumors.
33247484|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
32716888|NCT04956458|Experimental|Lumbar motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
32716889|NCT04956458|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
32716890|NCT05009030||Study group|Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
32716891|NCT05008484|Experimental|NMES Plus Vitamin D|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach and 2000IU oral vitamin D supplementation daily for 9 months.
32716892|NCT05008484|Experimental|Passive movement plus vitamin D|Subjects will undergo 9 months of simple passive movement exercise at home and 2000IU oral vitamin D supplementation daily for 9 months.
32743301|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
32917998|NCT04281251|Experimental|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
32917999|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
32918000|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
32918001|NCT04259645|Active Comparator|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
32918002|NCT04259645|Experimental|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
32918003|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
32918004|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
32918005|NCT04219709|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
32918006|NCT04219709|Active Comparator|Standard diet|Dietary Intervention, food delivery
32918007|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
32918008|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33247485|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
33247486|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
32918009|NCT01787006|Experimental|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
32918010|NCT01787006|Active Comparator|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
32918011|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
32918012|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
32918013|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
32716893|NCT04212416|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
32918014|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
32918015|NCT04219085|Active Comparator|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
32918016|NCT04219085|Experimental|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
32918017|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
32918018|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
32918019|NCT03186209|Experimental|Benralizumab|Benralizumab administered subcutaneously
32918020|NCT03186209|Placebo Comparator|Placebo|Placebo administered subcutaneously
32918021|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
32716894|NCT05007314|Experimental|Human Science|Arm 1 will include university graduates that hold at least a science undergraduate degree (or equivalent) in human science, including psychology, neuroscience, human biology, or medicine.
32716895|NCT05007314|Active Comparator|Natural or non-science|Arm 2 will include university graduates from non-human or non-scientific fields such as engineering, history, language studies, or law.
32716896|NCT04947722|Experimental|PREVENT Program|
32716897|NCT04947722|No Intervention|Control Group|Residents in homes allocated to the control group will receive usual care as provided within their home.
32716898|NCT04947254|Active Comparator|Group A (Apa, ADT, XRT)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
32716899|NCT04947254|Experimental|Group B (Apa, ADT, XRT, AAP, niraparib)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive abiraterone acetate PO QD, prednisone PO BID, physician's choice ADT, and niraparib PO QD. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
32716900|NCT05005910|Experimental|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
32716901|NCT05005910|Active Comparator|PPIs|PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days
32716902|NCT04954664|Experimental|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
32716903|NCT04954664|Active Comparator|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
32716904|NCT04946864|Experimental|single arm|APG2575
32716905|NCT04946864|Experimental|combination arm|APG2575+palbociclib i
32716906|NCT04945148|Experimental|Metformin|Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.
32716907|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
32716908|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
32716909|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
32716910|NCT04953806|Experimental|Step-CBT|Participants will complete Step-CBT, an integrative 12-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
32716911|NCT04953806|No Intervention|Wait-list control|Participants are assigned to wait-list control
32716912|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn & Yahr Stage 1-3
32716913|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
32766229|NCT04909619|Active Comparator|Local anesthetic infiltration of the palate|Patients randomized to this arm will receive local infiltration of the palate using 0.125% bupivacaine + 1:400,000 epinephrine at a dose of 2 ml/kg intraoperatively. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
32766230|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
32766231|NCT04928573||Group I|"All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.~The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive."
32766232|NCT05128747|Active Comparator|group of intervention will receive nutritional program|group of type 2 diabetes on diabetic diet undergo nutritional program (low fat contents) to control the lipid profile (lowering cholesterol profile) in duration of 3 months.
32716914|NCT05003570|Experimental|Remifentanil|Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
32766233|NCT05128747|No Intervention|group of control will not receive nutritional program|group of type 2 diabetes on diabetic drugs without nutritional program to compare their lipid profile with the diabetic patients on nutritional program.
32766234|NCT03056729|Experimental|Cohort HV1|
32716915|NCT05003570|Active Comparator|Fentanyl|Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
32766235|NCT03056729|Experimental|Cohort HV2|
32716916|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
32716917|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
32766236|NCT03056729|Experimental|Cohort HV3|
32766237|NCT03056729|Experimental|Cohort HV4|
32766238|NCT03056729|Experimental|Cohort HV5|
32766239|NCT03056729|Experimental|Cohort AD1|
32766240|NCT05128669|Experimental|CPIP+ECS|"CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy (PaCT), elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.~ECS (Enhanced Caregiving Support) is described in other arm."
33073290|NCT02968810|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
32716918|NCT05002478|Experimental|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
32716919|NCT05002478|No Intervention|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
32716920|NCT04944680|No Intervention|Control group|Stroke patients accept the traditional rehabilitation alone.
32918022|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
32918023|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
32918024|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
32918025|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
32716921|NCT04944680|Active Comparator|Transcranial Direct Current Stimulation group|Stroke patients accept the Transcranial Direct Current Stimulation alone.
32918026|NCT04141709|Experimental|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
32918027|NCT04141709|No Intervention|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).~There is a 2:1 randomization between intervention and observation group."
32918028|NCT01787240|Placebo Comparator|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
32918029|NCT01787240|Experimental|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
32918030|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
32918031|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
32918032|NCT04926116|Experimental|AK3280 Cohort 1|Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.
32918033|NCT04926116|Experimental|AK3280 Cohort 2|The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.
32918034|NCT04926116|Experimental|AK3280 Optional Cohort|This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
32918035|NCT04926116|Placebo Comparator|Control Arm|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
32716922|NCT04944680|Active Comparator|Motor imagery group|Stroke patients do the motor imagery alone.
32716923|NCT04944680|Experimental|Transcranial Direct Current Stimulation and motor imagery group|Stroke patients accept the Transcranial Direct Current Stimulation and do the motor imagery at the same time.
32716924|NCT05001698|Experimental|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
32716925|NCT04421144|Experimental|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
32716926|NCT02514824|Experimental|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
32716927|NCT02514824|Experimental|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
32716928|NCT02514824|Experimental|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
32716929|NCT02514824|Experimental|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
32716930|NCT04999592|Active Comparator|No prophylaxis (placebo)|"Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.~Administer antibiotics in response to infection."
32716931|NCT04999592|Experimental|Prophylaxis|Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
33247487|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
33247488|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
32918036|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
32918037|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
32918038|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
32918039|NCT04903652|Experimental|Pyrotinib plus Vinorelbine|
32918040|NCT04769102|Experimental|Spastic Cerebral Palsy|spastic Cerebral palsy children will be adapted in adaptive seat with flat and then Contoured cushions while kinematic changes of upper limb reaching movement are monitored through video capture with kinovea 2D software motion analysis system.
32918041|NCT04071821|Experimental|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
33247489|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32918042|NCT04071821|Active Comparator|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
32918043|NCT04071821|Experimental|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
32918044|NCT04071821|Experimental|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
32918045|NCT04071821|Experimental|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
33247490|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
33247491|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
33247492|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
32716932|NCT04999358|Experimental|Protein group|Participants in the protein group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the protein group will be provided with an additional targeted protein education session, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten. The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD
32716933|NCT04999358|Placebo Comparator|Control group|Participants in the control group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the control group will receive an additional dietary education session that is similar to the standard practice sessions, containing only information that is usually provided in the cardiac rehabilitation programme.The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD.
32716934|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
32716935|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
32716936|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
32716937|NCT02452190|Experimental|Reslizumab|Reslizumab
32716938|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
32716939|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
32918046|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
33247493|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
32766241|NCT05128669|Active Comparator|ECS only|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
32766242|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
32766243|NCT03843073|Experimental|Connected Catheter Users|
32766244|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
32766245|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
32766246|NCT05128435||Positive Children|Children under 15 years old tested positive for SARS-CoV-2 by PCR on nasopharyngeal swab
32766247|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
32766248|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
32766249|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
32766250|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
32766251|NCT04918901||Severe COVID-19|Comparative Analysis of Clinical Parameters and Radiographic Changes
32766252|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
32766253|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
32766254|NCT04927481|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.
32766255|NCT05117749|Experimental|Mild UC-Saffron 100|Mild UC patients, receiving 100 milligram (mg)/day saffron for 8 weeks (50 mg two times (BID)), n=10
32766256|NCT05117749|Experimental|Moderate UC-Saffron 100|Moderate UC patients, receiving100 mg/day saffron for 8 weeks (50 mg BID), n=10
32766257|NCT05117749|Experimental|Mild UC-Saffron 50|Mild UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
32766258|NCT05117749|Experimental|Moderate UC-Saffron 50|Moderate UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
32766259|NCT05117749|Placebo Comparator|Mild UC-placebo|Mild UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
32766260|NCT05117749|Placebo Comparator|Moderate UC-placebo|Moderate UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
32766261|NCT04918667|Experimental|Berberine MetX™ Ultra Absorption|16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.
32766262|NCT04918667|Active Comparator|Berberine MetX™|16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).
32766263|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
32766264|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
32766265|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
32766266|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
33247494|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
32766268|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
32918047|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
33247495|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
32716940|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
32716941|NCT00730639|Experimental|Melanoma - BMS-936558 (MDX-1106)|
32918048|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
32716942|NCT00730639|Experimental|RCC - BMS-936558 (MDX-1106)|
32716943|NCT00730639|Experimental|mCRPC - BMS-936558 (MDX-1106)|
32716944|NCT00730639|Experimental|NSCLC - BMS-936558 (MDX-1106)|
32716945|NCT00730639|Experimental|CRC - BMS-936558 (MDX-1106)|
32716946|NCT02407405|Experimental|1|Selumetinib 50 mg BID daily
32716947|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.
32716948|NCT04017871|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
32716949|NCT04017871|Placebo Comparator|Control|10 days of care and classic activities
33247496|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
32918049|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
32918050|NCT02977403|Sham Comparator|AB Control|Control condition - the probe is equally likely to replace the food picture and the neutral picture. There is no correlation between picture type and probe location, and no training of attention should occur.
32918051|NCT02977403|Experimental|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
32918052|NCT02977403|Other|Booster Training|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
32918053|NCT02977403|Active Comparator|Booster Training - active comparator|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
33247497|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
33247498|NCT00418561|Experimental|Cohort 1|Metazym (Recombinant human arylsulfatase A (rhASA)): 25 U/kg as a single dose - hereafter 50 U/kg
33247499|NCT00418561|Experimental|Cohort 2|100 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
33247500|NCT00418561|Experimental|Cohort 3|200 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
33247501|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
33247502|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
33247503|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
33247504|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
32716950|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
32716951|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
32716952|NCT03964207|Experimental|T1 followed by T2|
32716953|NCT03964207|Experimental|T2 followed by T1|
32716954|NCT03489421||HIV Infected|
32716955|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
33247505|NCT04016584|Experimental|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -~hemoglobin A1c > 8% at or prior to enrollment, or~hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):~Fasting plasma glucose > 130 mg/dL~2-hour post-prandial or random blood glucose > 180 mg/dL~> 1 hypoglycemic event (blood glucose < 70 mg/dL) , or~adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
33247506|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
32716956|NCT04461535|Experimental|AVS with ACTH stimulation|Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.
32716957|NCT04461535|No Intervention|AVS without ACTH stimulation|Patients divided into AVS without ACTH stimulation group take the same procedure of AVS with a continuous saline infusion.
32716958|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
32716959|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
32716960|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
32716961|NCT04462003|Active Comparator|Apixaban|50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily
32716962|NCT04462003|Active Comparator|Enoxaparin|50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)
32716963|NCT04460989||standard implant|arthroplasty with a standard implant
32716964|NCT04460989||personalized implant|arthroplasty with a customized implant
33247507|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
33247508|NCT00409747|Experimental|Minocycline|
32716965|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
32716966|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
32716967|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
32716968|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
32716969|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for from a minimum of 4 weeks up to 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
32716970|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks.
32716971|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
32716972|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
32716973|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
32716974|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
32716975|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
32716976|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
32716977|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
32716978|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
32716979|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
32716980|NCT01578967|Other|ABVD followed by Brentuximab vedotin|Single arm trial
32716981|NCT01186003|No Intervention|Standard insulin drip therapy|
32716982|NCT01186003|Active Comparator|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
32716983|NCT03496909|Active Comparator|Standard OT|
32716984|NCT03496909|Experimental|PhysioTouch|
32716985|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
32716986|NCT02322697|No Intervention|control group|No intervention
32716987|NCT05149963|Experimental|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of CBT aiming to reduce their loneliness. The intervention is modular and has been developed for this study. In total there are 10 treatment modules, 1) Assessment, 2) Formulation and Psychoeducation, 3) Challenging Negative Interpersonal Appraisals and Counterproductive Behaviours, 4) Challenging Negative Thoughts and Cognitive Biases, 5) Challenging Self-focussed Attention, Hypervigilance and Camouflaging, 6) Values-based Social-skills Training, 7) Problem Solving, 8) Findings Friends, 9) Managing Emotions and 10) Relapse Prevention. All participants will complete module 1) Assessment and module 2) Formulation and Psychoeducation. They will then work with the clinician to collaboratively develop a treatment plan based on their formulation. The treatment will be comprised of one or more of the intervention modules. All participants will then complete module 10) Relapse Prevention at the end of their treatment.
32716988|NCT05149963|No Intervention|Baseline Phase 1 (12 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
32716989|NCT05149963|No Intervention|Baseline Phase 2 (19 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
32716990|NCT05149963|No Intervention|Baseline Phase 3 (26 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
32716991|NCT05149963|No Intervention|Baseline Phase 4 (33 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
32716992|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
32716993|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
32716994|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
32716995|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
32716996|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
32716997|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care~Re-assessment 24 weeks (6 month) after enrolment.~Afterwards crossover into experimental group"
32716998|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally~Patients will receive study medication until disease progression or unacceptable toxicity"
32716999|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally~Patients will receive study medication until disease progression or unacceptable toxicity"
32717000|NCT03488719|Experimental|Cohort 1|Tesofensine 0.25mg
32717001|NCT03488719|Experimental|Cohort 2|Tesofensine 0.50mg
32717002|NCT03488719|Experimental|Cohort 3|Tesofensine 0.75mg
32717003|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
32717004|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
32717005|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
32717006|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
32717007|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
32717008|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
32717009|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
32717010|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
32717011|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
32717012|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
32717013|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
32717014|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
32717015|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
32717016|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
32717017|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
32717018|NCT03485755||Children|Children 8-10 years of age
32918054|NCT01789814|Active Comparator|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
32717019|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
32717020|NCT05150665|Experimental|En-Masse Retraction|Six anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
32717021|NCT05150665|Experimental|two step retraction|Six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to the upper lateral incisor and a power chain
32717022|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
32717023|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
32717024|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
32717025|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks~Cirrhotics:~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
32717026|NCT00821249|Experimental|ARRY-520|
32717027|NCT00821249|Experimental|ARRY-520 + G-CSF support|
32717028|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
32717029|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
32717030|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
32717031|NCT00825539|Placebo Comparator|Placebo|
32717032|NCT00825539|Experimental|AQW051|
32717033|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
32717034|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: CPA, GX-I7 and pembrolizumab"
32717035|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
32717036|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
32717037|NCT04472585|Active Comparator|Ivermectin alone|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
33399823|NCT05131165|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
32717038|NCT04472585|Active Comparator|Ivermectin with Zinc|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
32717039|NCT04472585|Placebo Comparator|Placebo|Placebo drug plus standard care
32717040|NCT04472585|Active Comparator|Ivermectin (oral) alone|Oral ivermectin 0.2mg/kg/day
32717041|NCT04472585|Active Comparator|Ivermectin (oral) with Zinc|Oral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
32717042|NCT04472585|Active Comparator|Zinc Alone|20mg Zinc Sulphate 8 hourly plus standard care
32717043|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
32717044|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
32717045|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
32717046|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
32717047|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
32717048|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
32717049|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
32717050|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
32717051|NCT00814073|Experimental|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
32717052|NCT00814073|Placebo Comparator|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
32717053|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
32717054|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
32717055|NCT05150353|Experimental|Patients with cardiac amyloidosis|
32717056|NCT05150353|Placebo Comparator|Healthy volunteers|
32717057|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
32717058|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
32717059|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
32717060|NCT05134285||control|pregnancy without preeclampsia
32717061|NCT05134285||preeclampsia|pregnancy complicated with preeclampsia at the first delivery or at the second delivery
32717062|NCT05134285||recurrent preeclampsia|pregnancy complicated with preeclampsia at two deliveries
32717063|NCT05130853|Experimental|SoCIAL Group|Subjects will conduct SoCIAL programme once a week, for a total of 10 weeks. Every session consists of two different modules: 1) a training programme that helps patients recognize emotions and important social signals (such as facial expressions and prosody) and develop strategy focused on the Theory of Mind; 2) a training in narrative enhancement. Time of administration for both modules is 30 minutes; the operator, however, can choose to focus the session on one module rather than the other, based on the subject's specific needs.
32717064|NCT05130853|Active Comparator|Control Group - Treatment-as-usual (TAU)|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study (10 weeks). TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
32717065|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
32717066|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
32717067|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
32717068|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
32717069|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
32717070|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
32717071|NCT00811889|Placebo Comparator|Placebo|
32717072|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
32717073|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
32717074|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
32717075|NCT03488329|Experimental|Intervention|"Intervention group~Individual nutritional therapy"
32717076|NCT03488329|No Intervention|Control|"Control group~Standard treatment"
32717077|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
32717078|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
32717079|NCT00811499|Placebo Comparator|Placebo|
32717080|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
32717081|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
32717082|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
32717083|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
32717084|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
32717085|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
32717086|NCT03675815|Experimental|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
32717087|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
32717088|NCT05091697|Experimental|Multicomponent treatment VIRTUAL FIBROWALK + TAU|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
32717089|NCT05091697|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
32717090|NCT05068219|Active Comparator|Usual technique|Standard rehabilitation
32717091|NCT05068219|Experimental|CR technique|Standard rehabilitation + 3 CR
32717092|NCT03560609|Active Comparator|Subjects With Keratoconus|
32717093|NCT03560609|Active Comparator|Subjects with Glaucoma|
32717094|NCT04896619|Experimental|Daily dose of Kori-tofu mixed in 3 slices of bread|Kori tofu as part of bread
32717095|NCT04896619|Active Comparator|Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread|Whey protein, soy oil and maltodextrin as part of bread
32717096|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
32717097|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
32717098|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
32717099|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
32717100|NCT03471065|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
32717101|NCT05057221|Experimental|Uproleselan|Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
32717102|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
32717103|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
32717104|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
32717105|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
32717106|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
32717107|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
32717108|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
32717109|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
32717110|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
32717111|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
32717112|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
32717113|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
32717114|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
32918055|NCT01789814|Active Comparator|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
32918056|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
32918057|NCT00356447|Active Comparator|Arm 1|
32918058|NCT00356447|Placebo Comparator|Arm 2|
32717115|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
32717116|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
32717117|NCT04750759|Active Comparator|Niclosamide + Camostat|Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
32717118|NCT04750759|Placebo Comparator|Placebo|Patients will receive placebo orally over a period of 7 days.
32717119|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
32717120|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
32717121|NCT03496363||CHD with Hypothyroidism|
32918059|NCT01736852|Experimental|CRB plus Pitocin|
32918060|NCT01736852|Active Comparator|Pitocin|
32918061|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part II:~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
32918062|NCT01790750|Other|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
32918063|NCT04068623||Triple negative breast cancer|
32918064|NCT01809938|Active Comparator|Black Tea|
32918065|NCT01809938|Active Comparator|Tea with Milk|
32918066|NCT02922413|Experimental|Hemin for injection|Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
32918067|NCT02922413|Placebo Comparator|Placebo|A double blind dose of saline.
32918068|NCT01810952|Experimental|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is >200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
32918069|NCT01810952|Experimental|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
32918070|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
32918071|NCT04059887|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
32717122|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
32717123|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
32717124|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
32918072|NCT04025411|Experimental|Experimental group|Patient with stroke ischemic or hemorrhagic will be included. They will have visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device and electroencephalography (EEG).
33399824|NCT05131165|Experimental|Intervention group receiving messages (Messages Group)|"Participants will receive the same information as those in the Control Group, but in addition, receive the Daily Text Message Intervention."
33399825|NCT05131165|Experimental|Intervention group receiving messages and incentives (Incentives Group)|"Participants will receive the same information as the Control group. Additionally, they will receive the Daily Text Message Intervention and will be eligible for prize drawings."
33399826|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
33399827|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
32717125|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
32717126|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
32717127|NCT03496129|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
32717128|NCT03496129|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
33399828|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
33399829|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
32717129|NCT03496129|Active Comparator|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
32717130|NCT05210543||Anaphylactic reaction (observational)|Patients who experienced an anaphylactic reaction will be observed
32717131|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
32717132|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
32717133|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
32717134|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
32717135|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
32717136|NCT04460443|Experimental|Sofosbuvir and ledipsavir|Sofosbuvir and ledipsavir plus standard of care treatment.
32717137|NCT04460443|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir plus standard of card treatment..
32717138|NCT04460443|No Intervention|Standard treatment|Standard treatment alone
32717139|NCT04460287|Placebo Comparator|Milk Drink Unfortified (Negative Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days.
32717140|NCT04460287|Active Comparator|Milk Drink Unfortified Plus Fish Oil (Positive Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
32717141|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Wet Mixing Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
32717142|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Dry Blending Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
32717143|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
32717144|NCT04460521|Experimental|NAC Group|Participants in this group will given an N-acetylcysteine 500mg oral tablet daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
32717145|NCT04460521|Placebo Comparator|Placebo Group|Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
32717146|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
32717147|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
32717148|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
32717149|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
32717150|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
32717151|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
32717152|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
32717153|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
32717154|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
32717155|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
32717156|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
32717157|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
32717158|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
32717159|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
32717160|NCT00790127|Placebo Comparator|Placebo|Placebo
32717161|NCT00790127|Experimental|HQK-1001|HQK-1001
32717162|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
32717163|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.~RP2D in dose expansion."
32717164|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
32717165|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
32717166|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
32717167|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
32717168|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
32717169|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
32717170|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
32717171|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
32717172|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
32717173|NCT04188769|Sham Comparator|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
33073291|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumab interval to 4 weeks after 1 year
32717174|NCT04188769|Sham Comparator|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
32717175|NCT04188769|Active Comparator|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
32717176|NCT04188769|Active Comparator|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
32717177|NCT04188769|Experimental|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
32717178|NCT04188769|Experimental|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
32717179|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
32717180|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
32717181|NCT00686933|Experimental|1|
32717182|NCT04071613|Active Comparator|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
32717183|NCT04071613|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
32717184|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
33073292|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo prostatectomy on week 9.
33073293|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
33073294|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
33073295|NCT02927236|Experimental|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
32717185|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.~Participation in this study has no effect on the interventional procedure, or the chosen approach."
32717186|NCT04035499|Experimental|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©® is a progressive walking and resistance exercise program
32717187|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
32717188|NCT00683423|Experimental|A|
32717189|NCT00683423|Placebo Comparator|B|
32717190|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
32717191|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
32717192|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
33073296|NCT02927236|Sham Comparator|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
32717193|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
32717194|NCT05149807|Experimental|SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
32717195|NCT05149807|Placebo Comparator|Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
32717196|NCT00679991|Active Comparator|PRT-201|
32717197|NCT00679991|Placebo Comparator|2|
32717198|NCT04459897||diagnosed or treated for granulomatous hepatitis fol|The cohort is composed by patient diagnosed or treated for granulomatous hepatitis followed in the internal medicine and / or Hepato-gastroenterology departments (Croix-Rousse Hospital, Edouard-Herriot Hospital, Lyon Sud Hospital Center).
32717199|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
32717200|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
32717201|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
32717202|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
32717203|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
32717204|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
32717205|NCT02799095|Experimental|ALKS 4230|
32717206|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
32717207|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
32717208|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
32717209|NCT04609319||Cohort 1|
32717210|NCT03965377|Experimental|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
32717211|NCT03916627|Experimental|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
32717212|NCT03916627|Experimental|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
32717213|NCT03916627|Experimental|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) No longer enrolling
32717214|NCT03916627|Experimental|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
32717215|NCT03916627|Experimental|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) No longer enrolling
32717216|NCT03916627|Experimental|Cohort B2|SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)
32717217|NCT01352585||JAK2 Positive Participants|
32717218|NCT01352585||JAK2 Negative Participants|
32717219|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
32717220|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
32717221|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
32717222|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
32717223|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
32717224|NCT02773355||Saxenda®|
32717225|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
32717226|NCT04582487|Other|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
32717227|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
32717228|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
32717229|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
32717230|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
32717231|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
32717232|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
32717233|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
32717234|NCT04526821|Experimental|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
32717235|NCT04526821|Placebo Comparator|Maltodextrin|Maltodextrin plus standard measures of personal protection.
33073297|NCT02927236|Other|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
33073298|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
33247509|NCT04016740|Experimental|Multimodal General Anesthesia|"Intraoperative~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.~Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision~Ketamine (0.06 to 0.12 mg.kg/hr)~Remifentanil (0.05-0.2 mcg/kg/min)~Dexmedetomidine (0.2-1.0 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion ± Sevoflurane titrated based on EEG monitoring~Postoperative~Standard pain management protocol~Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)~Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion"
33247510|NCT04016740|Other|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
33247511|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
33247512|NCT01035541||C group|Conventional fluid management
33247513|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
32717236|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
32717237|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
33247514|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
33399830|NCT05680441||Healty group|The controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10.
32717238|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
32717239|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
32717240|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
32717241|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
32717242|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
32717243|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
32717244|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
32717245|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
32717246|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
32717247|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
32717248|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
32717249|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
32717250|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
32717251|NCT03504553|No Intervention|Control|Normal operating room environment.
32717252|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
32717253|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
32717254|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
32717255|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
32717256|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
32717257|NCT04472741|Other|FUSE|wide angle colonoscope
32717258|NCT04472741|Other|HD Pentax i10 colonoscopes|SFV instrument
32717259|NCT04472741|Other|Endocuff|Cuff on SFV
32717260|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
32717261|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
32717262|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
32717263|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
32717264|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
32717265|NCT04472819|Experimental|SHR2285 Part 1A|Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
32717266|NCT04472819|Placebo Comparator|Placebo Part 1A|Single ascending doses of placebo orally
32717267|NCT04472819|Experimental|SHR2285 Part 1B|Participant received one dose of SHR2285 tablet as single-dose oral administration
32717268|NCT04472819|Placebo Comparator|Placebo Part 1B|Single doses of placebo orally
32717269|NCT04472819|Experimental|SHR2285 Part 2|Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
32717270|NCT04472819|Placebo Comparator|Placebo Part 2|Multiple ascending doses of placebo orally
32717271|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
32717272|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
32717273|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
32717274|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
32717275|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
32717276|NCT04473521|No Intervention|No Adhesive|No adhesive will be applied.
32717277|NCT04473521|Active Comparator|Super Poligrip Free (SPF)|The denture adhesive of 1.00grams (g) +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilised using this adhesive up to 2 times (maximum [max] 3 adhesive applications per day) at examiner's discretion.
32717278|NCT04473521|Experimental|Investigational Adhesive|The denture adhesive of 1.00g +/- 0.05g will be applied only to the maxillary denture only in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
32717279|NCT04473521|Experimental|Investigational Adhesive + Hot drink|The denture adhesive of 1.00g +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Hot drinks will be provided within 1 hour of completing lunch and dinner and must be consumed within 30 minutes. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
32717280|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
32717281|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
32717282|NCT04473287|Experimental|intervention group|Reflexology was applied to the intervention group during the procedure for 45 minutes.
32717283|NCT04473287|No Intervention|control group|Reflexology was not applied to the control group during the procedure. The control group received standard care and treatment.
32717284|NCT04473365||Without parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 1 will constitute those without parasite co-infection
32717285|NCT04473365||With parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 2 will constitute those with parasite co-infection
32717286|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
32717287|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
32717288|NCT04497779||Screening (biospecimen collection, medical record review, CCP)|"PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.~CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.~CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed."
32717289|NCT00672191|Experimental|1|
32717290|NCT02361346|Experimental|Part 1: Cohort 1 - 5 Micrograms/Kilogram/Dose (mcg/kg/Dose)|Part 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
32918073|NCT04025411|Active Comparator|Control group|Patient with stroke ischemic or hemorrhagic will be included. They will have simulation with the traditional Mirror Therapy (TM) and electroencephalography (EEG).
32717291|NCT02361346|Experimental|Part 1: Cohort 2- 10 mcg/kg/Dose|Part 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part) until recommended phase 2 dose of MT-3724 is determined
33247515|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
33247516|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
33247517|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
33247518|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
33247519|NCT00825903|Experimental|1|Aquatic based exercise
33247520|NCT03742375|Experimental|HPV genotyping|
33247521|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
33247522|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
33247523|NCT00894478||3|Control Group- Healthy Volunteers
33247524|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
33247525|NCT04017676|No Intervention|Control group|The first group will be under the usual treatment conditions (TAU)
32717292|NCT02361346|Experimental|Part 1: Cohort 3- 20 mcg/kg/Dose|Part 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
32717293|NCT02361346|Experimental|Part 1: Cohort 4- 50 mcg/kg/Dose|Part 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
32717294|NCT02361346|Experimental|Part 1: Cohort 5- 100 mcg/kg/Dose|Part 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
32717295|NCT02361346|Experimental|Part 1: Cohort 6- 75 mcg/kg/Dose|Part 1b: MT-3724 75 mcg/kg/dose IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Part 1 portion of the study)
32717296|NCT02361346|Experimental|Part 2: Cohort 7- MTD Expansion Cohort|Part 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
33247526|NCT04017676|Experimental|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
33399831|NCT05680441||Periodontitis stage 3 grade B|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00).
32918074|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
32918075|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918076|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918077|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918078|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918079|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918080|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
32918081|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
32918082|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
33247527|NCT04035772|Experimental|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
32918083|NCT01811030|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
32918084|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations."
32918085|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
32918086|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
32918087|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
32717297|NCT02361346|Experimental|Part 3: All MT-3724 Treated Participants|Part 3: MT-3724 IV 50 µg/kg/dose administered on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Treatment will continue until death, disease progression, unacceptable toxicity, withdrawal of consent, or another reason for withdrawal, or until study discontinuation
32717298|NCT02361346|Experimental|Part 4: All MT-3724 Treated Participants|Part 4: In this arm, subjects were planned to receive all doses of MT-3724 as IV infusion as confirmed in Part 3.
32717299|NCT04460963|Other|Biological evaluation|Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up
32918088|NCT01811654|No Intervention|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
32918089|NCT01811654|Active Comparator|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
32918090|NCT04012697|Experimental|Peer Support|Peer support services from a peer support worker in the emergency department.
32918091|NCT04012697|No Intervention|Usual care|Usual care in the emergency department.
32918092|NCT01794806|Experimental|Tooth extraction and grafting|Tooth extraction and grafting with allograft
32717300|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32717301|NCT04403243|Experimental|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
32717302|NCT04403243|Experimental|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
32717303|NCT04403243|Experimental|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy singly. Patients will be follow-up during 45 days after randomization
32918093|NCT01794806|Sham Comparator|Tooth extraction|Tooth extraction
32918094|NCT04010357|Experimental|Abemaciclib|"Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.~Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
32918095|NCT03983603|Experimental|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
32918096|NCT03983603|Placebo Comparator|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
32918097|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
32918098|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
32918099|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
33247528|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
32717304|NCT04403243|Active Comparator|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
32717305|NCT00779519|Placebo Comparator|Placebo|
32717306|NCT00779519|Experimental|TTP435|
32717307|NCT05648032|Experimental|PLT (lyophilized platelet) with steroid|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
32918100|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
32918101|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
32918102|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
32918103|NCT03500289|Experimental|Ketamine|
32918104|NCT03500289|Placebo Comparator|Midazolam|
32918105|NCT03981575||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months
32918106|NCT01812044|Other|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
32717308|NCT05648032|Experimental|PLT (lyophilized platelet)|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline, once
32918107|NCT01812044|Other|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
32918108|NCT01812044|Other|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
32918109|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
32918110|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
32717309|NCT05648032|Active Comparator|Steroid|1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
32918111|NCT03974789||Suspected Cushing Disease|
32918112|NCT01812668|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
32918113|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
32918114|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
32918115|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
32918116|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
32918117|NCT04344821|Placebo Comparator|Control|No diet or exercise intervention
32918118|NCT04344821|Experimental|No Diet plus Exercise|No diet, exercise only intervention
32717310|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
32717311|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
32717312|NCT00774761|Experimental|1|
32717313|NCT00774761|Experimental|2|
32717314|NCT00774761|Active Comparator|3|
32717315|NCT00774761|Active Comparator|4|
32717316|NCT00774761|Active Comparator|5|
32717317|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
32717318|NCT04383509|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
32717319|NCT04383509|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
32717320|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
32717321|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
32918119|NCT04344821|Experimental|High Protein Diet plus Exercise|High protein diet and exercise intervention
32717322|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
32918120|NCT04344821|Experimental|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
32918121|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
32918122|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
32918123|NCT03949283|Active Comparator|Physician Choice Treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
32918124|NCT03949283|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
32918125|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
32717323|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
32717324|NCT05647954|Experimental|HX008 Plus Transcatheter Arterial Chemoembolization(TACE)|
32717325|NCT05647954|Active Comparator|Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE)|
32717326|NCT05647954|Active Comparator|Pembrolizumab|
32717327|NCT04874116|Experimental|Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging|Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
32918126|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
32918127|NCT03932279||CD30+ lymphoproliferative disorders|
32918128|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
32918129|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
32918130|NCT03932279||Healthy controls|
32918131|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
32918132|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
32918133|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
33247529|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
32717328|NCT04874116|Active Comparator|Mobile phone text messaging|Participants receive mobile phone text messaging alone for 12 months.
32717329|NCT00770081|Experimental|1|50mg qd vildagliptin
32717330|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
32717331|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
32717332|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
32717333|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
32717334|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
32717335|NCT00666497|Experimental|A|Azacitidine
32717336|NCT00666497|Experimental|B|MGCD0103
32717337|NCT00666497|Experimental|C|Azacitidine + MGCD0103
32717338|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
32717339|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
32717340|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
32717341|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
32717342|NCT04367675|Experimental|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
32717343|NCT04367675|Experimental|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
32717344|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
32717345|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
32717346|NCT04346459|Active Comparator|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
32717347|NCT04346459|Active Comparator|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
32717348|NCT04346459|Active Comparator|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
32717349|NCT00760955|Experimental|TAK-583 5 mg QD|
32918134|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
32918135|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
33247530|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
33247531|NCT00630747|Experimental|Idursulfase|
33247532|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
32918136|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
32918137|NCT01796912|Active Comparator|First Lipoprotein Apheresis, then sham apheresis|Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
32717350|NCT00760955|Experimental|TAK-583 50 mg QD|
32717351|NCT00760955|Experimental|TAK-583 100 mg QD|
32717352|NCT00760955|Placebo Comparator|Placebo QD|
32717353|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
32717354|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
32717355|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
32717356|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
32717357|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
32918138|NCT01796912|Sham Comparator|First Sham Apheresis, then Lipoprotein Apheresis|Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis
32918139|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
32918140|NCT04345133|Active Comparator|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
32918141|NCT04345133|Other|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
32918142|NCT05328674|Active Comparator|Microfracture method|
32918143|NCT05328674|Experimental|Method of autogenous PRP (Auto Cart-Arthrex) cartilage transplant|
33247533|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
33247534|NCT05278078|Other|psychological support|Psychological support will be given to the experimental group.
32918146|NCT01798316|Active Comparator|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
32918147|NCT01798316|Active Comparator|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
32918148|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
32918149|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
32918150|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
32717358|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
32717359|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period."
32717360|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
32743302|NCT04956861|No Intervention|Phase 1|Phase 1 is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 7 hours/night (short sleep).
32743303|NCT04956861|Experimental|Phase 2|Phase 2 is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep less than 7 hours/night.
32743304|NCT04935957||Single-group|Male and female adult subjects with controlled diabetes 1 and 2.
32918151|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
32918152|NCT05723237|Experimental|Experiment|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
32918153|NCT05723237|No Intervention|Control Group|No application will be made to the control group (n=60).
32918154|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
32918155|NCT01798394|Active Comparator|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
32918156|NCT01798394|Placebo Comparator|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
32918157|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
32918158|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
32918159|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
32918160|NCT01798550|Experimental|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
32918161|NCT01798550|Active Comparator|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
32918162|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32918163|NCT03833414||(Group1)|Triceps lifting approach .
33247535|NCT05278078|Other|nutritional education|Nutrition education will be given to the experimental group.
32717361|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:~Communication regarding child's high weight status~Counseling regarding cardiovascular risk factor screening and assessment~Behavioral counseling~Interval follow-up to readdress weight, and~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
32918164|NCT03833414||(Group 2)|olecranon osteotomy approach
32918165|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
32918166|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
33247536|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the experimental group.
33247537|NCT05278078|Other|no intervation|No intervention will be applied to the control group
32918169|NCT01800890|Other|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:~Coloplast A~Coloplast B~SenSura Click~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
32918170|NCT01800890|Experimental|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:~Coloplast C (C)~Coloplast B (B)~SenSura Click (S)~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
32918171|NCT01800890|Experimental|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:~Coloplast A (A)~Coloplast C (C)~SenSura Click (S)~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
32918172|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
32918173|NCT01813214|Experimental|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
32918174|NCT01813214|Experimental|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
32918175|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
32918176|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
32918177|NCT01815008|Experimental|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
32918178|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
32918179|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
32918180|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
33247538|NCT00823485|Active Comparator|2|drainage of hemorraghia
33247539|NCT00823485|Experimental|1|Actylise
32918183|NCT01801124|Experimental|EXPAREL|undiluted EXPAREL 266 mg
32918184|NCT05328596|Experimental|CBT treatment|The CBT-treatment arm includes a review of the patient´s social conditions and overall health. It also includes manual based Cognitive Behavioural Treatment (CBT) in 10 individual sessions.
32918185|NCT05328596|Active Comparator|Wait list control|The control treatment includes a review of the patient´s social conditions, overall health and psychoeducation.
32918186|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
33247540|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
33247541|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
33247542|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
33247543|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
33247544|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
33247545|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
33247546|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
33247547|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
32918187|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
32918188|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
32717362|NCT04320407|Experimental|Osia 2 System|Osia 2 Active Osseointegrated Implant System for Bone Conduction
32717363|NCT00758303|Active Comparator|1|Low Dose TRIA-662
32717364|NCT00758303|Active Comparator|2|High Dose TRIA-662
32918189|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
32918190|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
32918191|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
32918192|NCT01819844|Experimental|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg.
32918193|NCT05723081||Native Americans|Native Americans / American Indians
32918194|NCT01819922|Experimental|PF-05175157|
32918195|NCT01819922|Placebo Comparator|Placebo|
32918196|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
32918197|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
32918198|NCT05328362|Active Comparator|CanCope mindfulness|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
32918199|NCT05328362|Active Comparator|CanCope distraction|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
33247548|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
33247549|NCT04017598|Active Comparator|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
33247550|NCT04017598|Experimental|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
33247551|NCT04017598|Placebo Comparator|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
33247552|NCT00823875|Experimental|1|
33247553|NCT00823875|Experimental|2|
33247554|NCT00823875|Experimental|3|
33247555|NCT00823875|Other|4|Control Group
33247556|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
32717365|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
32717366|NCT00664625|Experimental|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
32717367|NCT00664625|Experimental|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
32717368|NCT00664625|Experimental|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
32717369|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
32717370|NCT00663767|Placebo Comparator|Placebo|
32717371|NCT00663767|Experimental|Placebo, ARRY-371797|
32717372|NCT00663767|Experimental|ARRY-371797, Placebo|
33247557|NCT04035928|Experimental|3D digital scanning for maxillofacial prosthetics|
32918200|NCT05328362|Placebo Comparator|CanCope attention control|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
32918201|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
32918202|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
32717373|NCT00663767|Experimental|ARRY-371797|
32717374|NCT00663767|Active Comparator|Celecoxib, Placebo|
32717375|NCT00663767|Experimental|Celecoxib, ARRY-371797|
32717376|NCT00662597|Experimental|ASA404|
32918203|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~Oxaliplatin is administered intravenously~Leucovorin is administered intravenously~Irinotecan is administered intravenously~5-Fluorouracil is administered intravenously~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
32918204|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
32918205|NCT03501693||FFDM alone|FFDM alone images
32918206|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
32918207|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
32918208|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
32918209|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
32918210|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
32918211|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
32918212|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
32918213|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
32918214|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
33247558|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
32717377|NCT00662597|Placebo Comparator|ASA40 Placebo|
32918215|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
32918216|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
32918217|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
32918218|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
32918219|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
32918220|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
32918221|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
32717378|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
32717379|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
32918222|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
32717380|NCT04314089|Experimental|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
32717381|NCT00660959|Experimental|Active Comparator|lixivaptan
32918223|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
32918224|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
32918225|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
32918226|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
32918227|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
32918228|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
32918229|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
32918230|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
32918231|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
32918232|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
32918233|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
32918234|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
32717382|NCT00660959|Placebo Comparator|Placebo|placebo
32717383|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
32918235|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
32918236|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
32918237|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
32918238|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
32918239|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
32918240|NCT03522441|Placebo Comparator|Placebo|
32918241|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
32918242|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
32918243|NCT03585543|Experimental|Single group intervention arm|
33247559|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
33247560|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
32717384|NCT00757757|Experimental|MCS110|
32717385|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
32717386|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
32717387|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
32717388|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
32918244|NCT04332549|Active Comparator|Reconstitution Method 1|
32918245|NCT04332549|Active Comparator|Reconstitution Method 2|
32918246|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
33247561|NCT04036084||Control|
32918247|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
32918248|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
32918249|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
32918250|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
32918251|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
32918252|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
32918253|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
32918254|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
32918255|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
32918256|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
32918257|NCT04735107|Experimental|Reinforcement|Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage
32918258|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
32918259|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
32918260|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
32918261|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
32918262|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
32918263|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
32918264|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
32918265|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
32918266|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
32918267|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
32918268|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
32918269|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
32918270|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
32918271|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
32918272|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
32918273|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
32918274|NCT03352323|Experimental|oxymetazoline cream|
32918275|NCT04734639|Experimental|Obese adolescents|20 adolescents with obesity are involved and will perform the three conditions.
32918276|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
33247562|NCT00397189|Experimental|Circadin|
33247563|NCT00397189|Placebo Comparator|placebo|
33247564|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
33247565|NCT00898300||Patients with confirmed or suspected head and neck cancer|
33247566|NCT01035619|Experimental|Moxidectin|
33073299|NCT02924038|Experimental|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
33073300|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
33247567|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
33247568|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
33247569|NCT04044651|Experimental|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
33247570|NCT04044651|Active Comparator|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
33247571|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
32717389|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
33247572|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
33247573|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
33247574|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
33247575|NCT00819975|Active Comparator|Casein|
33247576|NCT00819975|Active Comparator|Whey Isolate|
32717390|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
32717391|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
32717392|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
32717393|NCT05647720|Experimental|Third molar extraction group|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
32717394|NCT05647720|Experimental|Third molar presence group|Without extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
32717395|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
32717396|NCT04249115|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
32717397|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
32717398|NCT02280083|Placebo Comparator|placebo|excipient
32717399|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
32717400|NCT00752297|Placebo Comparator|2|Preservative-free Saline
32717401|NCT04472273||high-flow nasal cannula group|Group 1
32717402|NCT04472273||classic nasal cannula group|Group 2
32717403|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
32717404|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
32717405|NCT02280395|Experimental|RUT058-60|
32717406|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
32717407|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
32717408|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
32717409|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
32717410|NCT02280551||Adolescents|1927 Grade 7 high school students
32717411|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
32717412|NCT00744731|Experimental|001|placebo placebo for 1 week
32717413|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
32717414|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
32717415|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
32717416|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
32717417|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
32717418|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
32717419|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
32717420|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
32717421|NCT04232033|Active Comparator|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
32717422|NCT04232033|Placebo Comparator|Placebo infusion (saline)|Saline infusion
32717423|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
32918277|NCT03598647|Active Comparator|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
32918278|NCT03598647|Experimental|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
32918279|NCT03598647|No Intervention|Exercisers|Engaging in >=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
32918280|NCT03598647|No Intervention|Non-exercisers|Engaging in <30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
32918281|NCT03599271|Experimental|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
32918282|NCT03599271|Active Comparator|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
32918283|NCT03599271|Experimental|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
32717424|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
32717425|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
32717426|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
32717427|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
32918284|NCT04734561|Experimental|Inspiratory muscle training group|Participants will perform an inspiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
32918285|NCT04734561|Sham Comparator|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
32918286|NCT04734561|Experimental|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
32918287|NCT04734561|Sham Comparator|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
32717428|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
32717429|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
32918288|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
32918289|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
32918290|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
32717430|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
32717431|NCT00649025|Experimental|1|FlutiForm 250/10ug
32717432|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
32717433|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
32717434|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and~Normal and stable allograft function at screening visit defined as-~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
32717435|NCT04219163|Experimental|CLL-1.CAR|Group A
32717436|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
32717437|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
32717438|NCT00739739|Experimental|PD 0299685 15mg|
32717439|NCT00739739|Experimental|PD 0299685 30mg|
32717440|NCT00739739|Placebo Comparator|Placebo|
32717441|NCT00739349|Experimental|1|Cyclosporine 0.05%
32717442|NCT00739349|Experimental|2|Cyclosporine 0.1%
32717443|NCT00739349|Placebo Comparator|3|vehicle/placebo
32717444|NCT00627419|Experimental|1|IPI-504
32717445|NCT00152009|Experimental|SPD503 (Guanfacine HCl) (2 mg)|
32717446|NCT00152009|Experimental|SPD503 (3 mg)|
32717447|NCT00152009|Experimental|SPD503 (4 mg)|
32717448|NCT00152009|Placebo Comparator|Placebo|
32717449|NCT04182035|Experimental|Patient-tailored treatment group|Objectives & approach: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
32717450|NCT04182035|Active Comparator|Non patient-tailored treatment group|Objectives & approach: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
33247577|NCT00819975|Active Comparator|Whey Hydrolysate|
33247578|NCT00819975|Active Comparator|Alphalact-Albumin|
33247579|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
32766269|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
33247580|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
33247581|NCT04044417|Placebo Comparator|open flap debridement only|surgical treatment of periodontal defects
32766270|NCT05117593|Experimental|FBL-MTX|"A single dose of FBL-MTX will be administered by slow intravenous injection in the morning, under fasted conditions.~A maximum of 4 dose levels (0.1 mg, 0.33 mg, 1 mg and 2.5 mg) are pre-planned."
32766271|NCT05117593|Placebo Comparator|Placebo|A single dose of placebo will be administered by slow injection in the morning, under fasted conditions.
32766272|NCT04927013|Experimental|Message-based Outreach Intervention (MBI) for Survivors|Cancer survivors randomized to receive a targeted letter with a unique website log in, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
32766273|NCT04927013|Active Comparator|Standard Outreach for Survivors|Cancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
32766274|NCT04927013|Experimental|Message-based Outreach Intervention for Close Relatives|Close relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
32766275|NCT04927013|Active Comparator|Standard Outreach for Close Relatives|Close relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
32766276|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
32766277|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
32766278|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
32766279|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
32766280|NCT03053375|Experimental|Chronic; active device|MDCure active device
32766281|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
32766282|NCT05405023|Experimental|Concentric exercises with wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements
32766283|NCT05405023|Active Comparator|Concentric exercises without wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation
32766284|NCT04918433|Active Comparator|TRANSEVERSUS THORACIS MUSCLE PLANE BLOCK (TTPB)|After induction of anaesthesia, ultrasound guided transverses thoracis muscle plane block will be done using 0.25% bupivacaine
32766285|NCT04918433|Active Comparator|PECTO-INTERCOSTAL FACIAL PLANE BLOCK (PIFB)|After induction of anaesthesia, ultrasound guided pectointercostal facial plane block will be done using 0.25% bupivacaine
32766286|NCT05093803|Active Comparator|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity.
32766287|NCT05093803|Experimental|APP GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through the use of an app based on machine learning, so they have constant stimuli for the improvement of the parameters.
32766288|NCT04926467|Experimental|Anakinra plus Chemotherapy|Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
32766289|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
32766290|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
32766291|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
32766292|NCT04866043||NostraData Database|All prescriptions for lisdexamfetamine dimesylate available in the NostraData database at any time in the last 12 months will be collected in Australia.
32766293|NCT04866043||Physician Survey|Physician will provide de-identified data of participants who have been prescribed lisdexamfetamine dimesylate at least once during the study period for indications other than attention deficit hyperactivity disorder (ADHD) in Australia.
32766294|NCT05128045|Experimental|Experimental: NEW-R Intervention|NEW-R Intervention plus services as usual
32766295|NCT05128045|No Intervention|Control|Services as usual
32766296|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
32766297|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
32918291|NCT04734717|Experimental|COVID19|
32918292|NCT04734717|Experimental|Controll|
32918293|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
32918294|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
32766298|NCT05127889|Experimental|Self-assembling peptide P11-4 varnish (study group)|"Test lesions will be wiped with NaOCl to remove pellicle,~Etched for 20 s with 35% H3PO4 Etching Gel to remove mineral deposits on the tooth surface and rinsed with water in accordance with the manufacturer's instructions.~The lesions will be dried and isolated with cotton rolls.~The varnish will be applied and left undisturbed for 5minutes (till disappearance) to allow diffusion of self-assembly."
32766299|NCT05127889|Experimental|Arginine-enriched Sodium Fluoride varnish (study group)|"The Arginine powder will be suspended at 2%.~A 10 mL of 5% sodium fluoride varnish tube dispensed in a sterile container.~200 mg of Arginine will be vigorously mixed with the varnish matrix for 60 sec using a sterile microbrush.~After dryness of the white spot lesion, the prepared varnish will be applied evenly using the micro brush.~After application the patient will be instructed to avoid rinsing, eating soft diet and avoid hot drinks for 2 hrs."
32766300|NCT05127889|Active Comparator|Tri Calcium Phosphate Fluoride varnish (positive control group)|"To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~The varnish will be mixed with the brush to avoid separation of the material during storage~However, to guarantee the best results suction will be used during application of the varnish.~A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.~All patients will be encouraged to maintain good oral hygiene through regular brushing."
32766301|NCT04778449||Observational (questionnaire, medical chart review)|Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
32766302|NCT04926935||Patients hospitalized in the ICU during the study period.|Patients hospitalized in the ICU during the study period with clinically suspected infection.
32766303|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
32766304|NCT04764019|Experimental|Patients|Patients with chronic digestive symptoms in whom intestinal dysmotility is suspected
32766305|NCT04583761||cases|Healthcare workers with mild symptoms of COVID-19 and a positive RT-PCR test for SARS-CoV-2
32766306|NCT04583761||controls|Healthcare workers with mild symptoms of COVID-19 and a negative RT-PCR test for SARS-CoV-2
32766307|NCT04531891|Experimental|All-out, high-intensity, intermittent exercise protocol|
32766308|NCT04531891|Experimental|5 min, high-intensity, intermittent exercise protocol|
32766309|NCT04926389|Experimental|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|
32766310|NCT04926389|Active Comparator|low-level laser therapy applied every 3 weeks|
32766311|NCT04926155|Experimental|Metformin+ADT+abiraterone|Patients in this arm will be treatet with metformin plus ADT and abiraterone
32766312|NCT04926155|No Intervention|ADT+abiraterone|Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.
32766313|NCT05133583|Experimental|intervatonal|
32766314|NCT05133583|No Intervention|control|
32766315|NCT05301517|Experimental|Roxadustat|Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be based on the participant's weight group. The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.
32766316|NCT05301517|Active Comparator|SEPO®|Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be 150 international units (IU)/kg subcutaneously TIW.
32766317|NCT04918043||HUCS, NKL|Newborns and their mothers at the Helsinki University Central Hospital maternity ward.
32766318|NCT04917965||Healthy Term Neonates|Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
32766319|NCT04917965||Term infants of diabetic mothers|Infants born at 37 weeks gestational age or greater to mothers of any age with gestational diabetes or Type 1 or Type 2 diabetes, managed with either diet or insulin. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
32766320|NCT04909775|Experimental|Arm 1|Patients will receive 4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before cystectomy discussion. The patients reach clinical complete remission will receive tislelizumab maintenance therapy for a year or 13 cycles.
32766321|NCT05133349|Experimental|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
33247582|NCT04044417|Active Comparator|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
33247583|NCT04044417|Active Comparator|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
32766324|NCT04925141|Experimental|Dasatinib tablets|Dasatinib tablets 100 mg orally once daily
32766325|NCT04908917|Experimental|PAC with HEPA|Intervention group (N=100) to use a portable air cleaner (with a HEPA filter in PAC)
32766326|NCT04908917|Sham Comparator|PAC without HEPA|control group (N=100) with a sham portable air cleaner (no HEPA filter in PAC)
32766327|NCT04908995|Experimental|EC5026|Single 8 mg oral dose of EC5026
32766328|NCT04908995|Placebo Comparator|Placebo|Single dose of matching oral placebo
32766329|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
32766330|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
32766331|NCT04925063|Experimental|Metformin+ADT+abiraterone|Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
32766332|NCT04925063|No Intervention|ADT+abiraterone|Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
32766333|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.5km/h|
32766334|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.8km/h|
32766335|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 1.1km/h|
32766336|NCT05127343|Active Comparator|Resin based sealant (Ultraseal XT Hydro)|
32766337|NCT05127343|Active Comparator|Glass ionomer based sealant (Fugi Triage)|
32766338|NCT05133037||Adolescent girls between 13-15 years old|Parental history of eating pathology or no parental history of eating pathology
32766339|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
32766340|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
32766341|NCT05132959||Patient Group|Patients with supraspinatus tendinosis
32766342|NCT05132959||Control Group|Patients without shoulder pain
32766343|NCT04925297||Non-NS ( Non-neurological sequelae) group|Patients who do not develop neurological dysfunction after acute carbon monoxide poisoning
32766344|NCT04925297||NS (Neurological sequelae) group|Patients who develop neurological dysfunction after acute carbon monoxide poisoning
32766345|NCT04495777||students|students were assessed in order to have a risk for TMD in order to their status of having parafunctional habits and neck pain
32766346|NCT03055169||intensive care patients|patients with a least one organ dysfunction
32766347|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
32766348|NCT05132725|Experimental|Dietary intervention CHO counting combined with GFD|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants' recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' weight. The carbohydrate counts will be distributed into three main meals and 3 snacks, with the general dietary advice and diet that will be prescribed by hospital for participants
32766349|NCT05132725|Experimental|Dietary intervention CHO Counting with GFD & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet, with the general dietary advice and diet that will be prescribed by hospital for participants
32766350|NCT05132725|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
32766351|NCT04908527|Experimental|Walk group|Patients walked to operating room (OR)
32766352|NCT04908527|No Intervention|Bed group|Patients go to OR while in bed
32766353|NCT05132647||Cerebellar ataxia and Healthy adults|We will not administer any intervention to the patients in this study
32766354|NCT04924829||Tocilizumab|Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
32766355|NCT04924829||Non-tocilizumab|Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.
32766356|NCT04165759||patients|Patients with lung cancer who are candidates for surgery.
32766357|NCT05132413|Experimental|treatment group|
32766358|NCT05132413|Placebo Comparator|Placebo group 1|
32766359|NCT05132413|Placebo Comparator|Placebo group 2|
32766360|NCT04924751|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
33247584|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
33247585|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
32918295|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
32918296|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
32918297|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
32918298|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
32918299|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
32717451|NCT04182035|No Intervention|Control group|The subjects randomized to the control group will not receive any intervention, if necessary medication use is permitted and will be monitored using the iMTAQ. Patients will be asked not to seek other treatment options (if possible). If this is not possible, patients will be considered lost to follow-up.
32918300|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
32918301|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
32918302|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
32918303|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
32918304|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
32918305|NCT04734483|Active Comparator|functional findings|Participants with laryngeal stenosis
32918306|NCT04734483|Active Comparator|to find anatomic feathers of larynx|Participants with laryngeal stenosis
32918307|NCT04734483|Active Comparator|to determine the type of stenosis of larynx and method of surgical treatment|Participants with laryngeal stenosis
32918308|NCT04734483|Active Comparator|determining the motor abilities of the muscles of the larynx|Participants with laryngeal stenosis
32918309|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
32918310|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
32918311|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
32918312|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
32717452|NCT02280707|Experimental|Intervention|
32918313|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 cigarettes~Smokes cigarettes daily > 1/day~Uses IQOS less than daily~Uses less than 30 HeatSticks/month~Cigarette is > 95% of tobacco/nicotine product (all product use)"
32717453|NCT02280707|No Intervention|Control|
32918314|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
32918315|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
32918316|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
33247586|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
33247587|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
33247588|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
32717454|NCT04473131||COVID-19 positive|"Inclusion criteria:~Male or female aged over 18 years~Admitted patients to ICU with a suspicious COVID19 infection~Tested positive for SARS-CoV-2~Exclusion criteria:~Burn and trauma~Any immunological diseases, or immunosuppressive medications~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
32717455|NCT04473131||COVID-19 negative|"Inclusion criteria:~Male or female aged over 18 years~Admitted patients to ICU~Tested negative for SARS-CoV-2~Exclusion criteria:~Burn and trauma~Any immunological diseases, or immunosuppressive medications~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
32743305|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
32717456|NCT04473131||Heathy volunteers|"Inclusion criteria:~Male or female aged over 18 years~Normal clinical examination~Exclusion criteria:~Person with an infectious syndrome during the last 90 days~Extreme physical stress within the last week~Person receiving within the last 90 days, a treatment based on: antivirals; antibiotics; antiparasitics; antifungals; non-steroidal anti-inflammatory drugs; immunosuppressive therapy; corticosteroids; therapeutic antibodies; chemotherapy~Person with history of: innate or acquired immune deficiency; hematological disease; solid tumor; severe chronic disease; surgery or hospitalization within the last 2 years; pregnancy within the last year; participation to a phase I clinical assay during the last year; participation to a phase I clinical assay during the last year; pregnant or breastfeeding women; a person with restricted liberty or under legal protection~Sample collection time points: 1 (day of blood sample donation)"
32717457|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
32717458|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 1-9|"Patients receive bosentan PO BID on days 8-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32918317|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
32918318|NCT03359889||patients administered with PraxbindTM|
32717459|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 10-12|"Patients receive bosentan PO BID on days -7 to 21 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32717460|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 13-21|"Patients receive bosentan PO BID on days 1-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32717461|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
32918319|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
32918320|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
32918321|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
32918322|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
32918323|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
32918324|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
32717462|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
32918325|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
32918326|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
32717463|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
32918327|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
32918328|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
32918329|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
32717464|NCT04473209|Active Comparator|diabetic group|diabetic patients with chronic periodontitis
32717465|NCT04473209|Active Comparator|non-diabetic group|non diabetic patients with chronic periodontitis
32717466|NCT02281019||Indeterminate strictures or undefined filling defects|
32717467|NCT02281019||Biliary stone cases|
32717468|NCT02281019||Other indications|
32743306|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
32743307|NCT03057405||intra-operative CBCT|
32743308|NCT03057405||3D virtual planning + intra-operative navigation|
32743309|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
32918330|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
32918331|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
32918332|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
32918333|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
32743310|NCT04486703|Experimental|Exercise with music group|physical therapy program combined with music therapy
32743311|NCT04486703|Experimental|Exercise group|physical therapy program without music
32918334|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
32918335|NCT02310750|Experimental|PF-06700841 Tablet|
32743312|NCT04930497|Experimental|vestibular socket technique with bone grafting|
32743313|NCT04930497|Active Comparator|vestibular socket technique without bone grafting|
32743314|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
32743315|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
32743316|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
32743317|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
32743318|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
32743319|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
32743320|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
32743321|NCT03241355|Placebo Comparator|placebo maltodextrin|
32743322|NCT04930419|Other|Videolaryngoscopy group|
32743323|NCT04930419|Other|Direct laryngoscopy group|
32743324|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
32743325|NCT04935333||Leiomyoma samples|Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
32743326|NCT04935333||Leiomyosarcoma samples|Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
32743327|NCT04935333||Control samples|Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour
32743328|NCT03241043|Experimental|Envarsus - Advagraf|
32743329|NCT03241043|Active Comparator|Advagraf - Envarsus|
32743330|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
32743331|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
32743332|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
32743333|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
32743334|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
32743335|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
32743336|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
32743337|NCT03057171||health individuals|patients who will undergo screening EGD
32743338|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
32743339|NCT02453945|No Intervention|Control|Usual Care
32743340|NCT04956315||Examiner effect group|Two examiners performed the test on one healthy subject with both devices for ten consecutive days. We measured the AD of both knees and calculated the ADD of every test. We evaluated the contralateral-side effect by comparing the AD standard deviations of each knee with both devices, and compared the average ADD tested by different examiners with the same device, to estimate examiner effect.
32743341|NCT04956315||Method effect group|The experienced examiner performed tests on 20 healthy subjects using both devices. The means and standard deviations of both knees were calculated. We examined the difference in measurements using each device to determine the method effect.
32743342|NCT04956315||Equipment effectiveness group|The experienced examiner performed tests on 200 ACL ruptureand 200 healthy subjects using each device. Effectiveness was analyzed using 1.5 mm and 3 mm threshold values in ACL tears.
32743343|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
32743344|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
32743345|NCT04956471||hospitalized patients with swallowing disorder after stroke,.|
32743346|NCT04935645|Experimental|Experimental Group|The experimental group was informed about progressive muscle relaxation (PMR) before colonoscopy. PMR audio recordings were given to the patients. Abdominal pain and distention scores were determined after colonoscopy. PMR was applied to the patients for 30 minutes. These scores were determined again after exercise and at the 2nd, 4th, 8th, 12th, 16th, and 24th hours.
32743347|NCT04935645|No Intervention|Control Group|VAS pain and VAS distension scores of the control group were determined after colonoscopy and 30 minutes later. VAS form was given to all patients to determine VAS abdominal pain and VAS distension scores at the 2nd, 4th, 8th, 12th, 16th and 24th hours after the procedure. The day after the colonoscopy, post test data were collected.
32743348|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
32743349|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
32717469|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
32717470|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
33247589|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
33247590|NCT00820131|Experimental|1|
32717471|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
32717472|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
32717473|NCT04040231|Experimental|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
33247591|NCT00820131|Active Comparator|2|
32717474|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
32717475|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
33247592|NCT00699374|Experimental|Arm A|sunitinib arm
33247593|NCT00699374|Active Comparator|Arm B|sorafenib arm
33247594|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
33247595|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
33247596|NCT00824187|Experimental|Arm 1|
33247597|NCT00824187|Placebo Comparator|Arm 2|
33247598|NCT00826137|Experimental|A|Treated with prebiotics.
33247599|NCT00826137|Placebo Comparator|B|Placebo treated.
32717476|NCT00624845|Experimental|Drug|
32717477|NCT00624845|Placebo Comparator|Vehicle|
32717478|NCT00728351|Experimental|vildagliptin + metformin|
32717479|NCT00728351|Active Comparator|metformin|
32717480|NCT00622193|Experimental|1 Active 50 mg|
32717481|NCT00622193|Experimental|2 Active 100 mg|
32717482|NCT00622193|Placebo Comparator|3 Placebo|
32717483|NCT00616811|Experimental|Vildagliptin|
33247600|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
33247601|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
33247602|NCT00826215|Experimental|1|Electroacupuncture treatment
32717484|NCT00616811|Active Comparator|Sitagliptin|
33247603|NCT00826215|Sham Comparator|2|Sham laser acupuncture
33247604|NCT03680053|Experimental|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
33247605|NCT03680053|Active Comparator|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
33247606|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
33247607|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
33247608|NCT04667078|Experimental|Cangrelor group|treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.
33247609|NCT04667078|Active Comparator|Best medical management group|treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.
33247610|NCT04035538|Experimental|A group|
33247611|NCT04035538|Experimental|B group|
33247612|NCT00894946|Experimental|Recurrent IVF implantation failure|
32766361|NCT04924751|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
32766362|NCT05126953|Experimental|samfilcon A Lenses with EPG01 Packaging Solution|
32766363|NCT05126953|Active Comparator|B+L Ultra Lenses|
32766364|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
32766365|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
32766366|NCT04140175||Women with suspected or confirmed endometriosis|Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions.
32766367|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
32766368|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
32766369|NCT05132257||PM No-ROP|Premature without retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
33247613|NCT00894946|Experimental|Endometriosis|
33247614|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
33247615|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
33247616|NCT01042561|Experimental|Vitamin d|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
33247617|NCT05312996|Experimental|Hypertension|Hypertension test group.
33247618|NCT05312996|Other|Active Comparator|Non Hypertension compare group.
33247619|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
33247620|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
32766370|NCT05132257||Mild ROP|Prematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at < 37 weeks gestation.
32766371|NCT05132257||Severe ROP|Prematurity with type 1 retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
32766372|NCT05132257||Fullterm|Heathal fullterm.
32766373|NCT04924595|No Intervention|Regular treatment|
32766374|NCT04924595|Experimental|Exercise Intervention|
33247621|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
33247622|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
33247623|NCT04035616|Placebo Comparator|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
33247624|NCT04035616|Active Comparator|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
33247625|NCT05289362|Experimental|Treating pancreatic duct stones by using baskets|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the basket will be used to remove the stones first, and the balloon will replace the basket after 15 minutes to remove any remaining stones. Finally, the effect of the basket will be evaluated.
33247626|NCT05289362|Active Comparator|Treating pancreatic duct stones by using balloons|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the balloon will be used to remove the stones first, and the basket will replace the balloon after 15 minutes to remove any remaining stones. Finally, the effect of the balloon will be evaluated.
33247627|NCT01042639|Active Comparator|physical activity once a day|
33247628|NCT01042639|Experimental|physical activity twice a day|
33247629|NCT01042639|No Intervention|control|
32905556|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
32918336|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
32918337|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
32918338|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
32918339|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
32918340|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
32918341|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
32918342|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
32918343|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
32918344|NCT03568539|Experimental|IBI308|
32918345|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
32918346|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
32918347|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
32918348|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
33247630|NCT04035304|Experimental|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
32717485|NCT02265952|Experimental|Open-label|Open-label REGN1500
32717486|NCT00615251|Experimental|1|
32717487|NCT00615251|Active Comparator|2|
32717488|NCT03946397|Experimental|Multisensory massage|
32717489|NCT03946397|No Intervention|Control|
32717490|NCT00614705|Experimental|1|
32717491|NCT00614705|Placebo Comparator|2|
32717492|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
33247631|NCT04035304|No Intervention|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
33247632|NCT05274542|Experimental|high intensity with blood flow restriction group|
33247633|NCT05274542|Active Comparator|high intensity without blood flow restriction group|
32717493|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
32717494|NCT05647642||low dose midazolam|0,025 mg/kg Midazolam
32717495|NCT05647642||high dose midazolam|0,05 mg/kg Midazolam
32717496|NCT05647642||low dose dexmedetothymidine|0.5 mg/kg dexmedetothymidine 10 minute infusion
32717497|NCT05647642||high dose dexmedetothymidine|1mg/kg dexmedetothymidine 10 minute infusion
32717498|NCT04873726|No Intervention|Pre: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
32717499|NCT04873726|No Intervention|Pre: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
32717500|NCT04873726|No Intervention|Pre: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
32717501|NCT04873726|Experimental|Post Exp: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
32918349|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
32918350|NCT03377127|Active Comparator|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
32918351|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
32918352|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
32918353|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
32918354|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
33247634|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
33247635|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
32717502|NCT04873726|Experimental|Post Exp: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
32717503|NCT04873726|Experimental|Post Exp: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
32717504|NCT04873726|Placebo Comparator|Post Pla: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
32717505|NCT04873726|Placebo Comparator|Post Pla: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
32717506|NCT04873726|Placebo Comparator|Post Pla: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
32717507|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
32717508|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
32717509|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
32717510|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
32717511|NCT05647486||EVAR|Patients with AAA, treated electively by EVAR. The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed.
32717512|NCT04873570|Experimental|Test Group|Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
32717513|NCT04873570|Active Comparator|Reference Group|Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
32717514|NCT05647408|Active Comparator|Intravenously DMX|Male and female volunteers received one dose of DXM. Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 subjects intravenously (treatment A) according to a randomization list generated prior to the start of the clinical phase.
32717515|NCT05647408|Active Comparator|Intranasally DMX|Male and female volunteers received one dose of either DXM Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 healthy subjects intranasally (treatment B). According to a randomization list generated prior to the start of the clinical phase.
32717516|NCT03287245|Experimental|Idasanutlin|Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
32717517|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
32717518|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
32717519|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
32717520|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
32717521|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
32717522|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
32717523|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
32717524|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
32717525|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
32717526|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
32717527|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
32717528|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
32717529|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
32717530|NCT03486925|Experimental|oxytocin group|
32717531|NCT03486925|Placebo Comparator|placebo group|
32717532|NCT03486847|Experimental|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
33247636|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
33247637|NCT01036243|Active Comparator|reference product|standard infant formula
33247638|NCT00895024||Caregivers|
33247639|NCT05268614|Experimental|Chemo-radiotherapy|Participants will receive chemo-radiotherapy.
33247640|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
32717533|NCT03486847|Active Comparator|One recruitment with PEEP|One alveolar recruitment at before surgery
33247641|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
32717534|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
32717535|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
32717536|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:~Patient's undergoing hemodialysis.~Male and female of any race~18 years/ older.~Those with dysphagia were excluded.~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
32717537|NCT03495271||Healthy Controls|"Inclusion Criteria~No tongue, lip, or cheek piercings~Over 18 years of age~Normal taste and smell function~No known issues with salivation or dry mouth~Willing to comply with study protocol (taste samples and provide saliva)~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
32717538|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
32717539|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
32717540|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
32717541|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
32717542|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
32717543|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
32717544|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
32717545|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
32717546|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
32717547|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
32717548|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
32717549|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
32717550|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
32717551|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
32717552|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
32717553|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
32717554|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717555|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717556|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717557|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717558|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717559|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
32717560|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
32717561|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33247642|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
32717562|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
32717563|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
32717564|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
32717565|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
32717566|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
32717567|NCT04445389|Experimental|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
32717568|NCT04445389|Experimental|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
32717569|NCT04445389|Placebo Comparator|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
32717570|NCT04445389|Placebo Comparator|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
32717571|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
32717572|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
32717573|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
32717574|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
32717575|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
32717576|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
32717577|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
32717578|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
32717579|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
32717580|NCT01595503|Experimental|fMRI-based targeting|
32717581|NCT01595503|Active Comparator|landmark-based targeting|
32717582|NCT05647330|Experimental|Hydroxychloroquine combined with gemcitabine|"Hydroxychloroquine sulfate tablets: twice a day, each time (600mg). Continuous oral administration. Until the disease progresses or becomes intolerable.~gemcitabine was administered intravenously at a dose of 1000mg/m2 for 30min,d1, 8, and every 3 weeks (21 days) until disease progression or intolerable toxicity, with a maximum duration of 2 years."
32717583|NCT04460755|Active Comparator|Control group|A group of participants that will be using toothpaste without tooth whitening ingredients.
32717584|NCT04460755|Experimental|Whitening toothpaste 1|A group of participants that will be using urea peroxide whitening toothpastes.
32717585|NCT04460755|Experimental|Whitening toothpaste 2|A group of participants that will be using hydrogen peroxide whitening toothpastes.
32717586|NCT04460755|Experimental|Whitening toothpaste 3|A group of participants that will be using whitening toothpastes that contain abrasive ingredients.
32717587|NCT04460755|Experimental|Whitening toothpaste 4|A group of participants that will be using whitening toothpastes that contain enzymes as whitening ingredients.
32717588|NCT04460755|Experimental|Whitening toothpaste 5|A group of participants that will be using toothpastes that contain an activated charcoal.
32717589|NCT05388409||CASE|Kidney transplanted patients with PSVD
32717590|NCT05388409||Control 1|Kidney transplanted patients without PSVD
32717591|NCT05388409||Control 2|patient with PVSD without transplantation
32717592|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
32717593|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
32717594|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
32717595|NCT05647174|Active Comparator|MGPOCUS-assisted bronchoscope-guided intubation|
32717596|NCT05647174|Experimental|Bronchoscope-guided Intubation|
32717597|NCT05388331||RIS/1-2 criteria|
33073301|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
33247643|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
33247644|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
32766375|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
32766376|NCT04133935|Experimental|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment
32766377|NCT04133935|Active Comparator|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
32766378|NCT04924049|Experimental|Experimental|The video-assisted education group also received routine treatment and care per protocol. Additionally, this patient group watched patient education through video in the patient room before TKR. The contents of the VE were developed by the researchers and included early postoperative care for TKR (knee positioning, early mobilization, pain control, and cold application), ADLs at home (bathing and toileting, eating, sleeping, vehicle driving, housekeeping, sexual life, praying, and maintaining home safety), and gradual exercise at home (for the first 90 days after discharge).
32766379|NCT04924049|No Intervention|Control|The control group received routine treatment and care per protocol.
32766380|NCT04435717|Experimental|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
32766381|NCT04435717|Experimental|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
32766382|NCT04435717|No Intervention|standard care treatment|Usual / standard care treatment
32766383|NCT04907981||Novel coronavirus infection|All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
32766384|NCT04907981||Not infected by novel coronavirus|Healthy controls and patients with liver disease
32766385|NCT04907981||Recovered patients with nucleic acid negative after infection with novel coronavirus|Novel coronavirus nucleic acid changed from positive to negative.
32766386|NCT05124223||Post-COVID-19|From May 2020 to May 2021, we retrospectively examined 104 clinical cardiac magnetic resonance (CMR) examinations performed in patients with suspected cardiac involvement post COVID-19. The mean time from first positive PCR to CMR was 112 +- 76 days. During their COVID-19 disease, 21% of patients required hospitalization, 17% supplemental oxygen and 7% mechanical ventilation.
32766387|NCT05124223||Post-COVID-19-Vaccination|Between May 2021 and August 2021, we examined 27 patients with suspected cardiac disease after COVID-19 vaccination.
33247645|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
32766388|NCT04075981|Experimental|Botulinum toxin|"All patients from the experimental group will receive botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 200 U dissolved in 4 mL of 0.9% normal saline and 50 U/1 mL will be injected at each fat pad).~Botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.~The whole estimated dosage would be therefore 200 units of incobotulinumtoxin A,"
32766389|NCT04075981|Placebo Comparator|Placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo dissolved in 4 mL of 0.9% normal saline will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
32766390|NCT05122195||Group A, compression therapy group|Elastic compression therapy with a thigh length stockings of 23-32 mmHg, at least 8 hours a day.
32766391|NCT05122195||Group B, control group|No compression therapy prescribed in the follow-up period.
32766392|NCT04917497||Levosimendan Treated Group|All patients consecutively admitted to the medical ICU of the University Hospital Zurich aged over 18 years, with an underlying cardiogenic shock, receiving Levosimendan.
32766393|NCT03933007|Other|Pharmacokinetic study|all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)
32766394|NCT04924439|Experimental|experimental group (foot reflexology group)|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other.~Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks."
32918355|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
32918356|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
32918357|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
32918358|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
32918359|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
32717598|NCT05388331||RIS/3-4 criteria|
32717599|NCT05388331||NON RIS/0 criteria|
32717600|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
32717601|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
32717602|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
32717603|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
32717604|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
32717605|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
32717606|NCT00625417|Experimental|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
32717607|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
32717608|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
32717609|NCT04312789|Experimental|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
32717610|NCT05152225||Infective endocarditis|Infective endocarditis with systematic brain MRI and digital subtraction angiography (DSA) performed routinely.
32717611|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
32717612|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
32717613|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
32717614|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
32717615|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
32918360|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
32918361|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
32717616|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
32918362|NCT03382509|Experimental|Single Dose Group|
32717617|NCT05647096|Experimental|NucleoCapture Treatment|Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.
32717618|NCT05647096|No Intervention|Standard of Care|Participants in the Standard of Care arm will receive standard medical care alone.
32717619|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
32717620|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
32717621|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
33247646|NCT05704478|Active Comparator|Intervention|Participants will be administered the drug vericiguat
33247647|NCT05704478|Placebo Comparator|Control|Participants will be administered a placebo
33247648|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
32717625|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
32717626|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
32918363|NCT03382509|Experimental|Multiple Dose Group|
33247649|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
32717627|NCT04460365|Active Comparator|Active|Softgel capsules: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin once a day with a meal for 18 months
32717628|NCT04460365|Placebo Comparator|Placebo|Identical capsule containing no active ingredients
32717629|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
32717630|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
32717631|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
32717632|NCT05151913||Previous ICP, recurrence|Pregnant women with at least one previously completed parturition with ICP and ICP during the present study
32717633|NCT05151913||Previous ICP, non-recurrence|Pregnant women with at least one previously completed parturition with ICP and no ICP during the present study
32717634|NCT05151913||No previous ICP|Pregnant women with at least one previously completed parturition with no previous ICP and no ICP during the present study
32717635|NCT04179019|Experimental|Amlodipine|Amlodipine (dose 10 mg, once daily)
32717636|NCT02324179||HIV positive|people with HIV diagnosis
32717637|NCT02324179||Control (HIV negative)|people without HIV
32717638|NCT04157101|Experimental|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
32717639|NCT04157101|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
32717640|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
32717641|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
32717642|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
32717643|NCT04135417|Experimental|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
33247650|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
33247651|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
33247652|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
33247653|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
32717644|NCT05151757|Experimental|To test the effectiveness of a training course to improve graders ability to detect glaucoma|"Study design: This is an uncontrolled interventional experimental before and after study in which a minimum of 42 non-physician graders shall be trained to screen for glaucoma using optic nerve photos obtained for diabetic retinopathy (DR) screening in Vietnam.~The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma, obtained from the on-going ORBIS CAFÉ DR screening programme (in which the graders are working), population-based eye studies in the UK (NICOLA) and the standard Glaucomatous Optic Neuropathy Evaluation (GONE) set of images. (https://gone-project.com/newgone/). The test set contains 60 normal and glaucomatous optic disc images."
32717645|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
32717646|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
32717647|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
32717648|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
32717649|NCT05151289|Experimental|Patients consulting in one of the participating centers for intra uterine growth restriction.|All included patients
32717650|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
32717651|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
32717652|NCT05151055|Experimental|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
32717653|NCT05151055|Placebo Comparator|Placebo|
32717654|NCT03911089|Other|Open label|UCD Anamix Infant
32717655|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
32717656|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
32717657|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
33247654|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
32717658|NCT03799393|Active Comparator|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
32717659|NCT03799393|Experimental|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
32717660|NCT03796819|Experimental|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
33247655|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
33247656|NCT00625443|Experimental|Placebo (double-blind)|
33247657|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
33247658|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
33247659|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
33247660|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
33247661|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
33247662|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
33247663|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
33247664|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
33247665|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
33247666|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
33247667|NCT00826371|Experimental|1|
33247668|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
32717661|NCT03796819|No Intervention|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
32717662|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
32717663|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
32717664|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
32717665|NCT04865146||TRIGEN™ INTERTAN™|Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail
32717666|NCT04459741|Experimental|HIV+ Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
32717667|NCT04459741|Other|HIV+ Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
32717668|NCT04459741|Experimental|HIV- Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
32717669|NCT04459741|Other|HIV- Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
32717670|NCT04459663|Experimental|JS001 combined with Axitinib|JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
32717671|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
32717672|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
33247669|NCT00824499|No Intervention|VR|
33247670|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
33247671|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
33247672|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
33247673|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
33247674|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
33247675|NCT02549703||Secondary Progressive Multiple Sclerosis|
33247676|NCT02549703||Primary Progressive Multiple Sclerosis|
33247677|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
33247678|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
33247679|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
33247680|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
33247681|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
33247682|NCT05278156|Experimental|CPL500036 low dose|Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.
33247683|NCT05278156|Experimental|CPL500036 high dose|Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.
33247684|NCT05278156|Placebo Comparator|Placebo|Patients are to receive placebo administered once dail for 28-days treatment period.
33247685|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
33247686|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
32918364|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
32918365|NCT04332315|Active Comparator|VALS|Vaginally asissted laparoscopic sacrocolpopexy
32918366|NCT04332315|Active Comparator|AS|Abdominal Sacrocolpopexy
32918367|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
32918368|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
32918369|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
32918370|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
32918371|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
32918372|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
32918373|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
32918374|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
32918375|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
32918376|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
32918377|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
32918378|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
32918379|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
32918380|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
32717673|NCT04459975||AKI (-)|patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine > 1,5x baseline according with KDIGO guidelines)
32717674|NCT04459975||AKI (+)|"patient treated in ICU for COVID-19 infection and with occurrence of AKI among which:~• Severe AKI patients (define as creatinine > 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death)."
32717675|NCT04460053|Experimental|Neurofilament light protein measurement|Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
32717676|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
32717677|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
32918381|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
32918382|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
32918383|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
32717678|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
32918384|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
32918385|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
32918386|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
32918387|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
32918388|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMapp 50mg/kg IV administered every third day for 3 infusions."
32918389|NCT02361762|Experimental|Training|Computerized executive control training
32918390|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
32918391|NCT02337738|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
32918392|NCT02337738|Experimental|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
32918393|NCT02337738|Placebo Comparator|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
33247687|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
32717679|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
32717680|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
33247688|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
32717681|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
32717682|NCT05150899||Tamsulosin 0.4mg|group A receive Tamsulosin 0.4mg in combination of NSAI drug if patient present with colic, if not in renal colic at bed time Tamsulosin 0.4mg with analgesic on demand.
32717683|NCT05150899||fexofenadine 180 mg in combination of Tamsulosin 0.4mg|group B receive pheniramine maleate 50mg injection every 12hr for 24 hr in combination of Tamsulosin 0.4mg and NSAI drug then fexofenadine 180 mg in combination of Tamsulosin 0.4mg and NSAI drug on demand if patient present with colic. if not in renal colic at bed time fexofenadine 180 mg in combination of Tamsulosin with NSAI on demand.
32717684|NCT01530997|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
32717685|NCT00593905||Group 1|"GROUP 1~Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.~WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
33247689|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
33247690|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
33247691|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
33247692|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
33247693|NCT00824889|Other|1|Healthy volunteer
33247694|NCT00824889|Other|2|atopic dermatitis patient
33247695|NCT00824889|Other|3|contact dermatitis patient
33247696|NCT00824889|Other|4|psoriasis patient
33247697|NCT00824889|Other|5|lichen planus patient
33247698|NCT00824889|Other|6|GVH patient
33247699|NCT00824889|Other|7|melanoma patient
33247700|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
33247701|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
33247702|NCT00820521|Experimental|active|
33247703|NCT00820521|Placebo Comparator|placebo|
33247704|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
33247705|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
33247706|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
33247707|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
33247708|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
33247709|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
33247710|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
33247711|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
33247712|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.~The patient will complete a total of 6 cycles of chemotherapy."
33247713|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
33247714|NCT00881998|Active Comparator|2|
33247715|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
33247716|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
33247717|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
33247718|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
33247719|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
33247720|NCT00826761|Active Comparator|1|High dose Lb. casei
33247721|NCT00826761|Active Comparator|2|Low dose Lb. Casei
33247722|NCT00826761|Placebo Comparator|3|
33247723|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
32918394|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
33247724|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
33247725|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
33247726|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
33247727|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
33247728|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
33247729|NCT00825123|Experimental|Ivabradine|
33247730|NCT00825123|Active Comparator|Metoprolol|
33247731|NCT00825123|Placebo Comparator|Placebo|
33247732|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
32717686|NCT00593905||Group 2|"Group 2~Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.~WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
32717687|NCT03477253|Active Comparator|LC within 72 hours of disease onset|Immediate laparoscopic cholecystectomy within 72 hours of the onset of symptoms was performed in these patients
32717688|NCT03477253|Active Comparator|LC after 72 hours of disease onset|Late laparoscopic cholecystectomy after 72 hours of the onset of symptoms was performed in these patients
32717689|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
32717690|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
32717691|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
32717692|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
32717693|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
32717694|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
32717695|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
32717696|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
32717697|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
32717698|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
32717699|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
32717700|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
32717701|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
32717702|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
32717703|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
32717704|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
32717705|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
32717706|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
32717707|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
33073302|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
32717708|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
33247733|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
33247734|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
33247735|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
33073303|NCT02873962|Experimental|Cohort 1: Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
33247736|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
33247737|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
33247738|NCT04017988|Experimental|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
33247739|NCT04017988|Placebo Comparator|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
33247740|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
33247741|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
32717709|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
33247742|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
32717710|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
32717711|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
32717712|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
32717713|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
32717714|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
32717715|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
32717716|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
32717717|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
32717718|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
32717719|NCT03481387|Other|PERCEVAL S valve|patients to be treated with PERCEVAL S valve
32717720|NCT05647018|Active Comparator|Deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
32717721|NCT05647018|Active Comparator|Non-deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
32717722|NCT05154019|Experimental|Intervention|Line Managers from organisations in the intervention arm will complete a self-led online training course consisting of 5 modules, over a period of 5-6 weeks
32717723|NCT05154019|No Intervention|Waitlist Control|Line Managers from organisations in the intervention arm will receive no training. They will be given access to the online intervention at the end of a 3-month period.
32717724|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
32717725|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
32717726|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
32717727|NCT05153785|Experimental|Lidocaine arm|The experimental arm will receive a bolus of 1,5mg/kg Lidocaine before induction of anesthesia, immediately followed by an infusion of 1,5mg/kg/h until 1 hour post surgery.
32717728|NCT05153785|Placebo Comparator|Placebo arm|The placebo arm will receive the same amount of normal Saline.
32717729|NCT00151775|Experimental|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
32717730|NCT00151775|Experimental|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
32717731|NCT00151775|Experimental|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
33247743|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
33073304|NCT02873962|Experimental|Cohort 2: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
33247744|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33247745|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
33247746|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
33247747|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
33247748|NCT00820833|Placebo Comparator|1|Standard infant formula
33247749|NCT00820833|Experimental|2|Test formula
33247750|NCT00820833|No Intervention|3|Breastfeeding reference group
33247751|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
33247752|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
33247753|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
33247754|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
33247755|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
33247756|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
33247757|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
33247758|NCT00882076|Experimental|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
33247759|NCT00882076|Experimental|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
33247760|NCT00882076|Experimental|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
33247761|NCT00882076|Experimental|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
33247762|NCT00882076|Experimental|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
33247763|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
33247764|NCT00825435|No Intervention|2|Standard of Care (SOC)
33247765|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
33247766|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
33247767|NCT00827151|Active Comparator|Estrogen and lifestyle|
33247768|NCT00827151|No Intervention|Lifestyle|
33247769|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
33247770|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
33247771|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
33247772|NCT00825591|Placebo Comparator|2|
33247773|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
33247774|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
33247775|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
33247776|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
33247777|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
33247778|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
33247779|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
33247780|NCT00899860||patients with renal cell cancer|
33247781|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
33247782|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
33247783|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
33247784|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
33247785|NCT04038424|Experimental|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
33247786|NCT04038424|No Intervention|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
33247787|NCT03417154|Experimental|Stage 1 Arms 1&2: Nivolumab and Cyclophosphamide|
33247788|NCT03417154|Experimental|Stage 2: Nivolumab and Cyclophosphamide|
33247789|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
33247790|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
33247791|NCT04549324||Sleep Apnea (AHI ≥ 15 per hour)|Patients with moderate/severe sleep apnea (Apnea/hypopnea-index ≥ 15 per hour).
32918395|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
32918396|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
32918397|NCT02308488|Experimental|Radiation Therapy|
32918398|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
32918399|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
32918400|NCT05438394|Experimental|melphalan hydrochloride for injection|Drug Name: melphalan hydrochloride The dosage of different dosage groups were: 9 mg/m2; 18 mg/m2; 27 mg/m2; 40 mg/m2 Administration frequency: once for each subject
32918401|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
32918402|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
32918403|NCT01803074|Experimental|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918404|NCT01803074|Experimental|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918405|NCT01803074|Experimental|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918406|NCT01803074|Experimental|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918407|NCT01803074|Experimental|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
32918408|NCT01803074|Experimental|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
32918409|NCT01803074|Experimental|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
32918410|NCT01803074|Experimental|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918411|NCT01803074|Experimental|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918412|NCT01803074|Experimental|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918413|NCT01803074|Experimental|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
33247792|NCT04549324||Non-Sleep Apnea (AHI < 5 per hour)|Patients without sleep apnea (Apnea/hypopnea-index < 5 per hour).
33247793|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
33247794|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
33247795|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
33247796|NCT00882388|Active Comparator|ASA|aspirin only
33247797|NCT00882388|Active Comparator|Cele|
33247798|NCT00882388|Experimental|ASA + Cele|
33247799|NCT00882388|Active Comparator|ASA + Clo|
33247800|NCT00882388|Experimental|ASA + Clo + Cele|
33247801|NCT00901420||Prostatectomy|
33247802|NCT00901420||Prostatectomy After Radiation Therapy|
33247803|NCT00900406||Recipients of stem cells with graft versus host disease|
33247804|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
33247805|NCT00900406||Donator of stem cells|
33247806|NCT00396877|Placebo Comparator|Placebo|
33247807|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
32918414|NCT01803074|Experimental|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
32918415|NCT01803074|Experimental|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
32918416|NCT05328284||PASCAL|patients treated with PASCAL leaflet repair system in the treatment of TR in a commercial use setting
32918417|NCT05328206||Standard of care for intubated children with a cuffed endotracheal tube (c-ETT)|
32918418|NCT01805024|Experimental|Omigapil|Omigapil treatment oral administration once per day after breakfast Cohort 1 Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
32918419|NCT05328128|Experimental|Study Group|Children and families included in the study group were directed to the child development unit to receive toilet training.
32918420|NCT05328128|No Intervention|Control Group|The control group consisted of families who wanted to manage toilet training process themselves.
32918421|NCT05327894|Other|Medium Risk (MR)|Subject is defined as MR if > 6months of age at diagnosis, OR < 6 months of age with White Blood cell Count (WBC) < 300 at diagnosis and good prednisone response. Subject gets 1st cycle of blinatumomab. If MRD is >0.01%, after 1st cycle of blinatumomab, subject will be allocated to HR treatment from that phase, and will be eligible for HSCT. If MRD is undetectable or < 0.01% after the 1st cycle of blinatumomab (TP2) patient will be eligible for replacement of MARMA by 2nd cycle of blinatumomab after receipt of lymphoid style consolidation (Protocol IB) or of myeloid style consolidation (ADE/MAE).
33073305|NCT02873962|Experimental|Cohort 3: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
33247808|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
33073306|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
33073307|NCT02830724|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
33247809|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
33247810|NCT03633253||MCR syndroms|
33247811|NCT03633253||Non MCR syndroms|
33073308|NCT02830724|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
33247812|NCT00882466|No Intervention|PCI only|primary PCI only
33247813|NCT00882466|Experimental|EPO|
33247814|NCT00901498|Experimental|Treatment A (Reference)|
33247815|NCT00901498|Active Comparator|Treatment B|
33247816|NCT00901498|Active Comparator|Treatment C|
33247817|NCT00901498|Active Comparator|Treatment D|
33247818|NCT00901498|Active Comparator|Treatment E|
33247819|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
33247820|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
33247821|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
33247822|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
33247826|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
33247827|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
33247828|NCT00901654|Experimental|ACE527|
33247829|NCT00901654|Placebo Comparator|Placebo comparator|
33247830|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
33247831|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
33247832|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
33247833|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
33247834|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
33247835|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
33247836|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
33247837|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
33247838|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
33247839|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
33247840|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
32766395|NCT04924439|No Intervention|control group|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
32766396|NCT05126875|Experimental|Treatment arm|Treatment with stereotactic radiosurgery
32766397|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
32766398|NCT04917263||Retrospective|
32766399|NCT04917263||Prospective|
32766400|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients < 18 years old~Suspected or confirmed cerebral infarction~With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy~Patients treated between January 2015, 1st and May 2018, 31st"
32766401|NCT04907435||patient with simultaneous laparoscopic operations|
32766402|NCT04907435||patient with simultaneous open operations|
32766403|NCT05404399|Experimental|Free From Pain Exercise Book|"Participants in Group 1 will be asked to engage in the 3 sets of exercises within the exercise book for the following 12 weeks. They will be advised to engage in the exercises at least five times a week. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Reading the weekly reading material. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day.~Furthermore, it will be recommended that participants in Group 1 read one motivation/reason chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information.~Participants in Group 1 will also be asked to fill in the exercise diary, found at the back of the exercise book, each time they exercise as part of the Free From Pain programme."
32766404|NCT05404399|Active Comparator|Usual Care (physiotherapy)|"Those in Group 2 (control group) will not be provided with the Free From Pain Exercise Book, and will instead be referred to physiotherapy as part of standard / usual care. They will be asked to report when their physiotherapy commenced."
32766405|NCT04923503|Experimental|lean ramadan fasting|conduct ramadan fasting for 30 days
32766406|NCT04923503|Experimental|obese ramadan fasting|conduct ramadan fasting for 30 days
32766407|NCT04923503|Experimental|diabetics ramadan fasting|conduct ramadan fasting for 30 days
32766408|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
32766409|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
32766410|NCT04907747|Experimental|Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days
32766411|NCT04907747|Experimental|Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
32766412|NCT04907747|Active Comparator|Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days|Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
32766413|NCT03812263|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
32766414|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
32766415|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
32766416|NCT05049421||Patients following CABG|Recruitment amongst patients enrolled in SWEDEGRAFT RCT at Aarhus University Hospital scheduled for follow-up
32766417|NCT04907123|Experimental|UNa+ Driven Intensive Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: Spot Urinary Sodium > 70 mEq/L AND mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
32766418|NCT04907123|Active Comparator|Standard Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
32766419|NCT05030857|Experimental|GLPG4716 and Midazolam|
32918422|NCT05327894|Other|High risk (HR)|"Subject is defined as HR if < 6 months of age with WBC > 300 at diagnosis OR poor prednisone response. Also MR patients with end of induction MRD ≥ 1%, or MRD > 0.01% after the 1st cycle of blinatumomab, will be allocated to HR treatment. Subject gets 1 cycle of blinatumomab.~Thereafter patient is eligible for hematopoietic stem cell transplantation (HSCT) with or without experimental therapy in an investigational window."
32918423|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
32918424|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
32918425|NCT05327660|Active Comparator|Quitline treatment as usual (TAU)|Quitline services provided by participating state quitlines
32918426|NCT05327660|Experimental|Quitline TAU plus remote CO monitoring|Quitline service plus daily CO monitoring via a smartphone app
32918427|NCT05327660|Experimental|Quitline TAU plus incentivized remote CO monitoring|Quitline TAU plus remote CO monitoring with small monetary incentives
32918428|NCT01822574|Active Comparator|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
32918429|NCT01822574|Active Comparator|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
32918430|NCT01822574|Active Comparator|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
32918431|NCT01822886|Experimental|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
32918432|NCT01823510|Experimental|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
32918433|NCT01823510|Active Comparator|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
32918434|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
32918435|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
32918436|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
32918437|NCT05327582|Experimental|PLENA regimen|Subject received PLENA regimen every 3 weeks until achieving a second assessable complete response or up to a maximum of 8 cycles. Treatment continued until progressive disease or intolerable toxicity, or withdrawal of consent.
32918438|NCT00681200|Active Comparator|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that this comparison group does not have a stress management component.
32918439|NCT00681200|Experimental|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic American Heart Association (AHA) recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
32918440|NCT05327036||pregnant women with Single Umbilical Artery|pregnant women with Single Umbilical Artery
32918441|NCT05327036||pregnant women with Umbilical Artery Embolism|pregnant women with Umbilical Artery Embolism
32918442|NCT05327036||Normal pregnant women|Normal pregnant women without pregnancy complications
32918443|NCT01824446|Experimental|Radiolabeled SPD602|
32918444|NCT05299970|Experimental|fermented porridge|this study arm participant will consume fermented millet porridge, daily
32918445|NCT05299970|Active Comparator|Non-fermented porridge|this study arm participants will consume non-fermented millet porridge, daily
32918446|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
32918447|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
32918448|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
32918449|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
32918450|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
33247841|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
32918451|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
32918452|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
32918453|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
32918454|NCT05748392|Other|Veraflo™ Cleanse Choice Complete™ Dressing Use with Assessments|Subject will have Veraflo™ Cleanse Choice Complete™ dressing applied and used per instructions for use. 3D imaging and wound / peri-wound skin characteristics will be taken during the treatment.
32918455|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
32918456|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
32918457|NCT05748236|Active Comparator|Lamotrigine|Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day)
32918458|NCT05748236|Active Comparator|Carbamazepine|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day)
32918459|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
32918460|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
32918461|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.~NOTE: This is a cross-over design and subjects will participate in both arms."
32918462|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
32918463|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
32918464|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
32918465|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
32918466|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
32918467|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
33247842|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
32717732|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
32717733|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
32717734|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
32717735|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
33247843|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
32766420|NCT04917341||preoperative endometrial sampling result (secondary hospital)/1|Endometrial biopsy samples taken at the stage 2 state hospital
32766421|NCT04917341||preoperative endometrial sampling result (tertiary hospital)/2|Endometrial biopsy samples taken at the stage (tertiary hospital)
32766422|NCT04917341||final postoperative pathology/3|final postoperative pathology results with grade (endometrium cancer)
32766423|NCT03810859|Experimental|All patients|Blood sample
33247844|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
33247845|NCT00837291|Experimental|CF101 1 mg BID|
32766424|NCT04917185|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
32766425|NCT04917185|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
32766426|NCT03319459|Experimental|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
32766427|NCT03319459|Experimental|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
32766428|NCT03319459|Experimental|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
32766429|NCT04923425||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
32766430|NCT04923425||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
32766431|NCT04923425||Non exposure|Non-pharmacological treatment (psychotherapy)
32766432|NCT04916951|No Intervention|Amoxicillin - standard-of-care dose|Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin
32766433|NCT04916951|No Intervention|Cephalexin - standard-of-care dose|Obtain cephalexin plasma concentrations in patients already receiving cephalexin
32766434|NCT04916951|Experimental|Amoxicillin - study dose|Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin
32766435|NCT04916951|Experimental|Cephalexin - study dose|Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin
33247846|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
33247847|NCT00882622|Active Comparator|RIPC|
32766438|NCT04430933|Experimental|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
32766439|NCT04430933|Experimental|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
32766440|NCT04430933|Experimental|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
32766441|NCT04839133|Other|Feasibility study group|
32766442|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
32766443|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
32766444|NCT04815343|Experimental|Bilateral users|two implant systemswith two sound processors
32766445|NCT04815343|Experimental|Bimodal user|with one sound processor and one hearing aid
32766446|NCT04906733||Cancer patient|RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.
32766447|NCT03176095|Active Comparator|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.~The probiotic product consisted of two different bacterial strains."
32766448|NCT03176095|Placebo Comparator|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
32766449|NCT04906655|Experimental|Cohort A glycopyrronium 30 minutes cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time in cotton gloves~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put cotton gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
33247848|NCT00882622|Sham Comparator|CONTROL|
33247849|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
33247850|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
33247851|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
33247852|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
33247853|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
33247854|NCT00900874|Active Comparator|1|Salbutamol + steroid
33247855|NCT00900874|Active Comparator|2|Formoterol + steroid
32918468|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
32918469|NCT04544787|Experimental|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
32717736|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
32918470|NCT04544787|Experimental|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
32918471|NCT04544787|Experimental|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
33247856|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
32717737|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
32717738|NCT03473119||Control|Healthy individuals
32717739|NCT03473119||Asthma|Asthma acute exacerbations
32717740|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
32717741|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
32717742|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
32717743|NCT03473119||CAP|Community-acquired pneumonia
32717744|NCT05646940||PI-OMM|25 PI fed with OMM and their mothers
32717745|NCT05646940||PI-DHM|25 PI fed with DHM and their mothers
32717746|NCT05646940||TI-OMM|25 TI fed with OMM and their mothers as control group
32717747|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
32717748|NCT03476863|Active Comparator|Conventional mechanical ventilation|
32717749|NCT00609323|Experimental|1|
32717750|NCT00609323|Placebo Comparator|2|
32717751|NCT05139277|Experimental|CONVIVO system|During tumor resection, study investigators trained in the use of the system will determine when the CONVIVO imaging system will be used for in vivo¬ imaging. At this point 5 mg/kg of fluorescein will be administered intravenously by an anesthesia provider over one minute.Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique.
32717752|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
32717753|NCT00605735|Experimental|A1|
32717754|NCT00605735|Placebo Comparator|P1|
32717755|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
32717756|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
32717757|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
32717758|NCT04472039||Studygroup|Retrospective analysis of OCT, IOP and distance corrected visual acuity from the patients history.
32717759|NCT04459195|Experimental|2 Minute Static stretching|Stretching applications will be applied to the first group for 2 minutes .
32717760|NCT04459195|Experimental|5 Minute Static stretching|Stretching applications will be applied to the first group for 5 minutes.
32717761|NCT04471961|Experimental|Children with cancer (Proband) with theirs parents|
32717762|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
32717763|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
32918472|NCT04544787|Experimental|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
33247857|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
33247858|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
32918473|NCT04544787|Experimental|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
32918474|NCT04544787|Experimental|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
32918475|NCT04544787|Placebo Comparator|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
32918476|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
32918477|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
32918478|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32918479|NCT04470375|Experimental|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
32918480|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
32918481|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
32918482|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
32918483|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
32918484|NCT05233592||T1D Patients Using CGM|Type 1 Diabetes patients using CGM who have received COVID-19 vaccine booster shot (first or second)
32918485|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
32918486|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
32918487|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
32918488|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
32918489|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
32918490|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
32918491|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
32918492|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
32918493|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
32918494|NCT05748158|Other|Weight loss|A 37 week behavioral intervention aimed at decreasing energy intake and increasing physical activity.
32918495|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
32918496|NCT05748080|Experimental|Apple intervention|the eating of 2 apples a day for a period of 6 weeks
33247859|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
33247860|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
33247861|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
33399832|NCT05680441||Periodontitis stage 3 grade C|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were >1.0, all periodontitis patients were considered grade C.
33073309|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
33073310|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
32766450|NCT04906655|Experimental|Cohort B glycopyrronium 30 minutes under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time under occlusion~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
32766451|NCT04906655|Experimental|Cohort C glycopyrronium overnight in cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight in cotton gloves~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the cotton gloves on both hands and go to bed.~In the morning, after at least 4 hours of wearing the gloves , remove the cotton gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
32766452|NCT04906655|Experimental|Cohort D glycopyrronium overnight under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight under occlusion~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the occlusive gloves and go to bed.~In the morning, after at least 4 hours of wearing the gloves, remove the occlusive gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
32766453|NCT03130699|Experimental|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
32766454|NCT03130699|Experimental|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
32766455|NCT03130699|Experimental|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
32766456|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
32766457|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
32766458|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
32766459|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
32766460|NCT02648581|Experimental|Subcutaneous Ustekinumab|
32766461|NCT04916717|Other|Counseling|Quasi-experimental design. Face-to-face and telephone counseling were applied to individuals in the intervention group.
32766462|NCT02609815|Experimental|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
32766463|NCT02609815|Active Comparator|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
32766464|NCT04923581|Experimental|Condition 1|Participants will receive the constant component only.
32766465|NCT04923581|Experimental|Condition 2|Participants will receive the constant component and storytelling videos .
32766466|NCT04923581|Experimental|Condition 3|Participants will receive the constant component and oral health promotion messages.
32766467|NCT04923581|Experimental|Condition 4|Participants will receive the constant component and a motivational interview session.
32766468|NCT04923581|Experimental|Condition 5|Participants will receive the constant component, oral health promotion messages and storytelling videos.
32766469|NCT04923581|Experimental|Condition 6|Participants will receive the constant component, oral health promotion messages, storytelling videos, and a motivational interview session.
32766470|NCT04923581|Experimental|Condition 7|Participants will receive the constant component, oral health promotion messages and a motivational interview session.
32717764|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
32766471|NCT04923581|Experimental|Condition 8|Participants will receive the constant component, storytelling videos, and a motivational interview session.
32717765|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
32717766|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
32717767|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
32717768|NCT04471571|Active Comparator|Resin infiltration group|Enamel lesions for this group will be treated only by resin infiltration.
32717769|NCT04471571|Experimental|Microabrasion + resin infiltration group|Enamel lesions for this group will be treated first by microabrasion followed by resin infiltration.
32717770|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
32717771|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
32717772|NCT04472975||Multiple sclerosis (MS) cohort|Individuals with multiple sclerosis without any exposure to disease-mofidying drugs (DMDs) and with exposure to one or more DMDs.
32717773|NCT02257684|Experimental|Pegcrisantaspase|
32717774|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
32717775|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
32717776|NCT04473053|Experimental|Nafamostat|It is intended that the licensed dose (0.2mg/kg/hr) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/hr for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped.
32717777|NCT04473053|Experimental|TD139|"Patients will inhale 5mg x 2 (10 mg) twice daily for the first 48 hrs and then subsequently 5mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler - in which case treatment will be stopped at such time.~CE marked inhalers will be provided by the Manufacturer. All patients will receive guidance on how to use the inhaler by an appropriately trained member of the research team. Two individual inhalers will be used by each patient over the course of the 14 day study period (each inhaler will be used by one patient for 7 days) and will be thoroughly cleaned with an antiseptic wipe before and after each use."
32717778|NCT04473053|Active Comparator|Standard of Care|All treatment arms will be compared to the Standard of Care arm.
32717779|NCT05646784|Experimental|Cerebiome for Depressive patient|Patients in a current episode of MDD admitted at Hotel-Dieu de France University Hospital, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-IV criteria, and not currently taking any antidepressant medication
32717780|NCT05646784|Placebo Comparator|Placebo for Control group|Second group of patients in a current episode of MDD admitted at Hotel-Dieu de France University Hospital, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-IV criteria, and not currently taking any antidepressant medication
32717781|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
32717782|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
32717783|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
32717784|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
32717785|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
32717786|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
32717787|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
32717788|NCT02283437|Active Comparator|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
32717789|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
32717790|NCT04872712|Active Comparator|Press Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
32717791|NCT04872712|Active Comparator|Filiform Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with filiform needles treatment will be treated with 20-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The needles are inserted approximately 12 mm deep at the acupuncture points HT7 Shenmen and PC6 Neiguan and 25 mm deep at the ST36 Zusanli and SP6 Sanyinjiao.
32717792|NCT04892524|Experimental|Virtual multidisciplinary review|Participants in this arm will be reviewed in a virtual clinic by a multidisciplinary team
32717793|NCT04892524|No Intervention|Face-to-face review|Participants in this group will be reviewed in a face-to-face clinic
32717794|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
32717795|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.~Standard Rehabilitation Protocol"
32717796|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
32717797|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
32717798|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
32717799|NCT00600275|Experimental|BGT226|
32717800|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
32717801|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
32717802|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
32717803|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
32717804|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
32717805|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
32717806|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
32717807|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
32717808|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
32766472|NCT01315639|Other|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
32717809|NCT00581477|Experimental|Droxidopa|Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.
32717810|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
32717811|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
32717812|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
32717813|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
32717814|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
32717815|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
32717816|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
32717817|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
32717818|NCT05152771|Other|Ketogenic Diet|This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.
32766473|NCT04916639|Experimental|Active group|Physiomer®, undiluted seawater nasal spray
32766474|NCT04916639|No Intervention|control group|
32766475|NCT04662463|Experimental|CBM-I assignment|Patients will receive CBM-I assignments
32766476|NCT04662463|Placebo Comparator|Placebo assignment|Patients will receive placebo assignments
32766477|NCT04655521||COVID-19 patients|
32766478|NCT04655521||Healthy controls|
32766479|NCT04655521||Non-COVID-19 patients with respiratory tract infection|
32766480|NCT04906967|Active Comparator|modified sural flap|modified sural flap used to cover soft tissue defect around ankle
32766481|NCT04906967|Active Comparator|anterolateral thigh flap|anterolateral thigh flap used to cover soft tissue defect around ankle
33073313|NCT02726581|Experimental|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
32766482|NCT04585399|Experimental|Contingency Management|Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
32766483|NCT04585399|No Intervention|Standard Care|Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
32766484|NCT04906811|Active Comparator|Fat grafting with the AuraGen 1-2-3 with AuraClens System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
32766485|NCT04906811|Active Comparator|Fat grafting with the Revolve System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.
32766486|NCT01118767|Experimental|Cell phone intervention|Participant receives short text messages
32766487|NCT01118767|No Intervention|Standard of care|Participant receives standard of care support but not short text messages
32766488|NCT04922879|Experimental|Individualized lung rehabilitation programme|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
32766489|NCT04906343|No Intervention|Group 1 (2 years)|Group 1, surveillance colonoscopy in two years after the last complete colonoscopy in SPS patient.
32766490|NCT04906343|Active Comparator|Group 2 (3 years)|Group 2, surveillance colonoscopy in three years after the last complete colonoscopy in SPS patient.
32766491|NCT05132023|Experimental|Empagliform|Test drug
32766492|NCT05132023|Active Comparator|Synjardy|Reference drug
32766493|NCT05404087||Pre-operative staging of breast cancer with CEBCT|Women who have been diagnosed with breast cancer and need to have a pre-operative staging and this will be done with contrast-enhanced breast CT.
32766494|NCT05404087||Follow-up of women with breast cancer treated with neo-adjuvant chemotherapy|Women who are selected for neo-adjuvant chemotherapy to reduce the size of the tumor need to be followed-up in order to evaluate the treatment response.
32766495|NCT04904159||Benign|Patients who have benign pathologies after thyroidectomy
32766496|NCT04904159||Malign|Patients who have malign pathologies after thyroidectomy
32766497|NCT04498663|Experimental|Therapeutic Interview Condition|The therapeutic interview for chronic pain will be a one-session interview lasting approximately 90 minutes. The goals of the therapeutic interview are to promote awareness of the role of trauma and interpersonal stress in pain, to encourage experience of emotions associated with interpersonal stressors and conflicts, and to encourage more adaptive interpersonal communication in current relationships.
33399833|NCT05680441||Gingivitis|Only generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis.
33399834|NCT04160520|Experimental|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
33399835|NCT04160520|Active Comparator|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
33399836|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
32766498|NCT04498663|No Intervention|Waitlist Control Condition|Participants in the waitlist control condition will receive a delayed interview (after 6-week follow-up assessment), if they choose to do so.
32766499|NCT04916483|Experimental|Exploring the effectiveness of GCST in people with schizophrenia.|The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
32766500|NCT04916483|No Intervention|Control group|The control group maintains the usual care.
32766501|NCT05003167|Experimental|Expiratory Muscle Strength Training|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
32766502|NCT05131711|Experimental|rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy|Patients with rGBMs will receive combined stereotactic radiosurgery and enhanced immunal adjuvants (GM-CSF, Sapylin, MnCl2). The safety and efficacy will be analyzed.
32766503|NCT05131711|No Intervention|rGBM Group with|After biopsy or tumor resection, this rGBM group was treated with FDA-approved strategies proposed by the MDT group.
32766504|NCT04122079||Clinical (outpatients)|Patients receiving mental health treatment at the three psychotherapeutic centers; two university clinics and a family mental health clinic
32766505|NCT04122079||Clinical (self-reported)|Students and community nonstudent participants who were receiving psychological or psychiatric treatment
33073314|NCT02726581|Active Comparator|Control Arm|"Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
33073315|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
33399837|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
33399838|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
33399839|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (compact)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (compact) throughout the entire course of the study.
33399840|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (strong defocus)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (strong defocus) throughout the entire course of the study.
32717819|NCT04771975|Experimental|MatchQEP group|"All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the MatchQEP group will receive exercise information and program sessions tailored by a qualified exercise professional (QEP) specifically for each BCS in the dyad. Dyads will meet with the QEP via Zoom once per week for 10 weeks for up to 60 minutes. For four weeks following the 10-week intervention period, the QEP will be available for consultation (i.e., a post-intervention tapering period) as needed by the MatchQEP group participants."
32717820|NCT04771975|Active Comparator|Match group|"All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the Match (control) group will independently communicate and support each other around exercise for 10 weeks. They will not have any contact with a QEP during this time."
32717821|NCT04471025|Active Comparator|Group I|USG guided infraclavicular block with single operator jedi grip technique
32717822|NCT04471025|Active Comparator|Group 2|USG guided infraclavicular block with conventional double operator technique
32717823|NCT05152693|Experimental|Low Variety Small Portion Without Beverage|Test meal with food components mixed together (low variety) with a small portion of food served without water
32717824|NCT05152693|Experimental|High Variety Small Portion Without Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food served without water
32717825|NCT05152693|Experimental|Low Variety Small Portion With Beverage|Test meal with food components mixed together (low variety) with a small portion of food and water
32717826|NCT05152693|Experimental|High Variety Small Portion With Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food and water
32717827|NCT05152693|Experimental|Low Variety Large Portion With Beverage|Test meal with food components mixed together (low variety) with a large portion of food and water
32766506|NCT04122079||Non-clinical (Community)|Members of the community
32766507|NCT04122079||Non-clinical (Students)|University undergraduate students
32766508|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
32766509|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
32766510|NCT04012957|Experimental|Darbepoetin Alfa Injection|Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.
32766511|NCT04012957|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
32766512|NCT05125705|Experimental|Platelet rich plasma injection|Patients will be treated with a single PRP injection, where 8 mL of whole blood will be collected and 2.5 mL of PRP will be given to the patient. Routine physiotherapy regimens will be implemented, similar to placebo arm.
32766513|NCT05125705|Placebo Comparator|Saline injection|Patients will be treated with 2.5 mL saline 0.9%. Routine physiotherapy regimens will be implemented, similar to intervention arm.
32766514|NCT04906031|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
32766515|NCT04906265|Active Comparator|High Intensity Functional Exercise|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient.
32766516|NCT04906265|Experimental|High Intensity Functional Exercise and wearable sensor|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient. In addition, follow-up and feedback during the rehabilitation period will be given via a wearable inertial measurement unit (IMU).
32766517|NCT04906265|Active Comparator|Standard rehabilitation|The intervention comprises the standard rehabilitation services: walking training and adaptions to the walking pattern of the patient prior to surgery together with func-tional exercises. The intervention is tailored to each patient, based on the type of fracture, type of surgery, and assessment by the PT as well as treatment goals.
32766518|NCT05131243|Experimental|ctDNA positive patients|Postoperative ctDNA-positive patients will receive chemotherapy for 6 months.The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
32766519|NCT05131243|Active Comparator|ctDNA negative patients|Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
32766520|NCT05125627|Experimental|Treatment A|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
33073316|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
33073317|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
33399841|NCT05288335|Experimental|single vision frame glasses|Subjects that were randomized to receive the single vision frame glasses throughout the entire course of the study.
32717828|NCT05152693|Experimental|High Variety Large Portion With Beverage|Test meal with food components separated on the plate (high variety) with a large portion of food and water
33399842|NCT05282953|Experimental|Patients with Retinitis Pigmentosa|
32717829|NCT04471181||All patients with ruptured abdominal aortic aneurysms|"All patients will undergo CTA to confirm the diagnosis. The use of balloon for aortic clamp in case of haemodynamic instability can be used.~All patients included in the research study must undergo standard EVAR with a bifurcated graft or an aorto-uni-iliac and a femoral to femoral crossover. In aneurysms with short proximal neck down to 4mm, or in cases where completion angiography indicates type Ia endoleak, the Heli-FX EndoAnchor system is recommended to be used, as indicated. All patients will have plain abdominal x-rays on discharge. Participants will undergo CTA in 3months and annually post-op.. In case of an adverse event before the 3 months follow up CTA, a more urgent imaging might be requested and proceed to appropriate action according to the findings."
32717830|NCT00497159|Placebo Comparator|1|Placebo
32717831|NCT00497159|Experimental|2|Dimebon
32717832|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for exclusion of PE or DVT are:~low or intermediate clinical probability and D-dimer <0,50 µg/mL~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)~high clinical probability and negative CT and US.~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
32717833|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for confirmation of PE or DVT are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasonography (US).~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
32717834|NCT04470947||Next generation functional drug screening|
32717835|NCT04470947||Comprehensive genomic profiling|
32717836|NCT04470947||Physician's choice|
32717837|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
32717838|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
32717839|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
32717840|NCT00572585|Experimental|AEB071|
32717841|NCT00572585|Placebo Comparator|Placebo|
32717842|NCT04471259||Patients' injured side|The Biodex, AOFAS, VAS were tested on the patients' injured side
32717843|NCT04471259||Patients' uninjured side|The Biodex, AOFAS, VAS were tested on the patients' uninjured side
32717844|NCT05154877|Active Comparator|DMI5R|The subject will undergo two PET/CT scans, one on the DMI5R scanner and one on the OMNI scanner
32717845|NCT05154877|Active Comparator|DIQ5R|The subject will undergo two PET/CT scans, one on the DIQ5R scanner and one on the OMNI scanner
32717846|NCT00570635|Experimental|A|
32717847|NCT00570635|Experimental|B|
32717848|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
32717849|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
32717850|NCT00569387|Experimental|Vaccine group|
32717851|NCT04468087|Experimental|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
32717852|NCT04468087|Experimental|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
32717853|NCT04468087|Experimental|Sofusbuvir + Daclatasvir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofosbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
32717854|NCT04468087|Placebo Comparator|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
32717855|NCT04468087|Placebo Comparator|Placebo Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
32717856|NCT04468087|Placebo Comparator|Placebo Sofusbuvir + Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
32717857|NCT00569153|Experimental|Arm 1 (TAK-700)|
32717858|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
32717859|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
32717860|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
32717861|NCT05153005||Talaromycosis|Participants: AIDS patients complicated with Talaromycosis. Intervention(s): To use the specific antigen of taloromyces marneffei which is mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and qPCR, dd-PCR and mass spectrometry identification in the diagnosis and efficacy evaluation of AIDS patients complicated with Talaromycosis.
32717862|NCT05153005||Pneumocystis pneumonia|Participants: AIDS patients complicated with Pneumocystis pneumonia Intervention(s)：To use (1,3)- β- D-glucan (G antigen) , qPCR, dd-PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies.
33073318|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
33073319|NCT02678429|Active Comparator|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response first then change to settings from Atlas
33073320|NCT02678429|Experimental|DBS progamming from Atlas|DBS settings determined from the a functional atlas first then change to settings determined by standard of care
33073321|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
33247862|NCT04044183|Experimental|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
33399843|NCT04350372|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
32717863|NCT05153005||Cryptococcus|Participants: AIDS patients complicated with Cryptococcus Intervention(s)：To use (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen(CrAg) serological detection, qPCR, DD PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies of disease.
32717864|NCT05646628||Participants|Older adults (aged 65 years and over) enrolled in the BASIL+ trial randomized to receive the intervention (collaborative care focusing on behavioral activation) and confirmed as having chronic pain
32717865|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
32717866|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
32766521|NCT05125627|Active Comparator|Treatment B|"Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
32766522|NCT04399265|Experimental|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
32766523|NCT04399265|Placebo Comparator|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
32766524|NCT05125549|Experimental|Treatment A|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
32766525|NCT05125549|Active Comparator|Treatment B|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
32766526|NCT04398719|Active Comparator|CBD|
32766527|NCT04398719|Placebo Comparator|Placebo|
32766528|NCT05131087|Experimental|Cadence|Cadence procedure
32766529|NCT04906577|Experimental|VIZOLF|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to the body odour emitted by the child during the first 5 days of life
32766530|NCT04906577|Experimental|VIZ|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to a neutral odour during the first 5 days of life
32766531|NCT03810079|Active Comparator|Anodal tDCS High Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined high level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
32766532|NCT03810079|Active Comparator|Anodal tDCS Low Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined low level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
32766533|NCT03810079|Sham Comparator|Anodal tDCS Random Vigilance|Patients will undergo continuous 20 channels EEG and receive tDCS (bilateral prefrontal stimulation) at a random level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
32766534|NCT04903847|No Intervention|Dolutegravir/tenofovir disproxil/lamivudine|Continue dolutegravir 50 mg, tenofovir disproxil 245 mg, ,and lamivudine 300 mg once daily for 48 weeks.
32766535|NCT04903847|Experimental|dolutegravir/lamivudine|dolutegravir 50 mg/lamivudine 300 mg once daily for 48 weeks
32766536|NCT04903847|Experimental|doravirine/tenofovir disproxil/lamivudine|100 mg doravirin, 245 mg tenofovirdisoproxil and 300 mg lamivudine once daily for 48 weeks.
32766537|NCT05131009||Patients with pulmonary complications following abdominal surgery|
32766538|NCT05131009||Patients without pulmonary complications following abdominal surgery|
32918497|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
32918498|NCT05153252|Experimental|Morning Exercise (AM)|Participants in this group will be prescribed morning aerobic exercise.
32918499|NCT05153252|Experimental|Evening Exercise (PM)|Participants in this group will be prescribed evening aerobic exercise.
32918500|NCT05748002||stable group|
32918501|NCT05748002||subclinical keratoconus|
32918502|NCT05748002||normal group|
32918503|NCT05748002||follow up group|
32717867|NCT05137327|Experimental|Classroom Behavior Support (CBS) Condition|"Consultants follow the problem-solving process used in the comparison condition and attempt to address barriers to integrity using the knowledge, skills, beliefs, or stress components in the CBS manual. Consultants conduct a Values Interview, so teacher values can be used in the individual goal setting and decision making process. Consultants are trained to (a) incorporate the teacher's values into the problem-solving process, (b) elicit change talk from teachers using techniques borrowed from Motivational Interviewing, and (c) engage in Socratic questioning and cognitive restructuring for beliefs that may be barriers to integrity (e.g., should statements). Enhanced performance feedback involves highlighting connections between teacher integrity and child outcomes and using this as a catalyst for a knowledge, skills, beliefs, or stress component. Consultants use change rulers to elicit motivation to achieve the stated goals."
32717868|NCT05137327|Active Comparator|Standard Problem Solving Comparison Condition|Consultation in the comparison condition follows a 5-step problem solving approach and provide brief performance feedback procedures that mirror (in duration, content, and process) best practice procedures (Gilbertson et al., 2007; Noell et al., 1997). The guiding principles for this condition are that the performance feedback portion of the session should be limited to 5 to 10 minutes and unless the teacher initiates discussion of other content, the problem solving should remain student-focused, rather than teacher-focused. Discussion on teacher values and beliefs, and attempts to facilitate change talk, are contra-indicated. If the teacher initiates discussion of knowledge, beliefs, or skills, the consultant may answer questions, but may not use strategies associated with Motivational Interview or Cognitive-Behavioral Therapy (CBT) or strategies in CBS condition. We have separate scripts and checklists for each condition.
32717869|NCT05103241|Experimental|[14C]GP681|Subject will receive single dose of orally [14C] GP681 .
32717870|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
32918504|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
33247863|NCT04044183|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
33247864|NCT00900952||1|Infected elderly patients
32717871|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
32717872|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
32717873|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
32717874|NCT05059015|Active Comparator|CERVICAL HPV|Routine screening procedure based on HPV tests with cervical sampling by a health personnel
32717875|NCT05059015|Experimental|SELF SAMPLING HPV ARM 2|Screening based on HPV self-testing and colposcopic evaluation
32717876|NCT05059015|Experimental|SELF SAMPLING HPV ARM 3|Arm 3: screening based only on HPV self-testing
32717877|NCT05050747||Arm 1|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger
32717878|NCT05050747||Arm 2|Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
32717879|NCT05050747||Arm 3|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger
32717880|NCT00566345|Experimental|1|Vero-cell derived influenza vaccine
32918509|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
32918510|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
32918511|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
32918512|NCT05314881|Experimental|SLE patients|
32918513|NCT05011994|Experimental|Maintenance intervention|Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
32918514|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
32918515|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
32918516|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
32918517|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
32918518|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
32918519|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
32918520|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
32918521|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
32918522|NCT05747846|Active Comparator|wide-awake local anesthesia no tourniquet|Patients will be operated under local anesthesia without a tourniquet (WALANT technique)
32918523|NCT05747846|Active Comparator|Tourniquet|Patients will be operated under local anesthesia with the use of a tourniquet
32717881|NCT00566345|Placebo Comparator|2|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
32918524|NCT05747768|Experimental|Healthy Volunteers|Healthy volunteer received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
32918525|NCT05747768|Experimental|Patients with mild-to-moderate renal impairment|Patients with mild-to-moderate renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
32918526|NCT05747768|Experimental|Patients with moderate to severe renal impairment|Patients with moderate to severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
32918527|NCT05747768|Experimental|Patients with severe renal impairment|Patients with severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
32918528|NCT05747768|Experimental|Patients with end-stage renal disease|Patients with end-stage renal disease received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
32717882|NCT02256982|Experimental|Resectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to surgery~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
32717883|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to radiation therapy with protons or photons, determined by available resources~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
32717884|NCT05014867||Arm 1|Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5
32918529|NCT01837550|Active Comparator|Control group|no professional support
32918530|NCT01837550|Experimental|Intervention group|Professional support via Internet
32918531|NCT05005052|Experimental|Sulodexide arm|Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks
32918532|NCT05005052|Placebo Comparator|Placebo arm|Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks
32918533|NCT04452435|Experimental|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
32918534|NCT04452435|Placebo Comparator|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
32918535|NCT05747690|Experimental|KIO015 - Cohort 1|One injection of KIO015 on the hemi-face. The untreated hemi-face is used as a comparator.
32918536|NCT05747690|Experimental|KIO015 - Cohort 2|3 injections at one month interval on the hemi-face. The untreated hemi-face is used as a comparator.
32717885|NCT05014867||Arm 2|Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5
32717886|NCT05014867||Arm 3|Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS
32717887|NCT05014867||Arm 4|Poor responders women undergoing conventional frozen embryo transfer on Day 5
32717888|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
32918537|NCT04994210|Experimental|Sintilimab+Chidamide|Sintilimab：200mg(fixed dosage), ivd, qd, q21d Chidamide: 30mg,biw,continued oral
33247865|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
32717889|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
32717890|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
32717891|NCT04860154|Experimental|PDT with stent|Before photodynamic therapy, candidate patients undergoing biliary biopsy and biliary duct drainage. If pathology shows a bile duct malignancy, PDT therapy will carry out until total bilirubin drops below 100 μmol/L.Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or metal stent will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
32918538|NCT04923776|Experimental|Experimental: Chemotherapy+SBRT|"Addition of SBRT, directed at liver metastases, to standard of care (SOC) treatment atezolizumab+chemotherapy in SCLC. All patients must undergo a mandatory biopsy of a liver lesion prior to chemotherapy initiation.~Cycle 1 of chemoimmunotherapy will be administered as per standard of care, with radiation planning to be done subsequently in anticipation of liver-directed SBRT."
32918539|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
32918540|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
32918541|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
32918542|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
32918543|NCT05314803|Experimental|Yoga|Participants receive online, group-based yoga classes 2 times/week for 60 minutes/class over 12 weeks.
32717892|NCT04860154|No Intervention|ERCP stent|After obtaining bile duct biopsy, the candidates were placed with biliary plastic stents or metal stents directly.
32717893|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
32717894|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
32717895|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
32717896|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
32717897|NCT05646472||≥ 65 Community-dwelling older adults|
32717898|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
32717899|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
32717900|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
32717901|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
32717902|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
32717903|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
32717904|NCT04947631|Experimental|DKF-313|Dutasteride 0.5mg + Tadalafil 5mg
32717905|NCT04947631|Active Comparator|Dutasteride|Dutasteride 0.5mg
32717906|NCT04947631|Active Comparator|Tadalafil|Tadalafil 5mg
32717907|NCT05068921|Experimental|TQB2858|TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
32717908|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
32918544|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
32918545|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~ERI/EOS~Special Implant Status~Implant in Backup Mode (ROM)~VT/ VF Detection Inactive~Emergency Pacing~250 Ω > RV Pacing Impedance > 1500 Ω~Symptomatic VT/VF therapies including both ATP and shock~VT/VF storm~HM transmission failure >3 days"
32717909|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
32717910|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
32717911|NCT00560183|Experimental|1|
32717912|NCT00560183|Placebo Comparator|2|
32717913|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
32717914|NCT00542633|Experimental|A|VIAject™
32717915|NCT00542633|Active Comparator|B|Regular Human Insulin
32717916|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
32717917|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
32717918|NCT05005897|Experimental|Screening - treatment|From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
32717919|NCT05005897|No Intervention|Control|The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.
32918546|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
32918547|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
32918550|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
32717920|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
32717921|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
32717922|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
32717923|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
32717924|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
32717925|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
32918551|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
32717926|NCT00483977|Active Comparator|Oxycodone|
32717927|NCT00483977|Placebo Comparator|Placebo|
32717928|NCT00483977|Experimental|PF-00592379|
32717929|NCT04891549|Active Comparator|Tension band fixation|Surgical fixation of the patella fracture utilizing the AO principles using K-wires, screws, cerclage and sutures by surgeons choice.
32717930|NCT04891549|Experimental|Plate fixation|Surgical fixation of the patella fracture utilizing the AO principles and a locking plate with the number of screws by surgeons choice. Additional fixation by surgeons choice.
32717931|NCT00481325|Experimental|A1|
32717932|NCT00481325|Active Comparator|A2|
32717933|NCT00481325|Placebo Comparator|A3|
32717934|NCT04809025||the pathology of endoscopic biopsy|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies
32717935|NCT04809025||the pathology of surgical resection specimen|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens
32717936|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
32717937|NCT04803409|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
32717938|NCT04803409|No Intervention|Control Group|Control Group
32717939|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
32717940|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
32717941|NCT00542009|Experimental|CE-326,597 100 mg QD|
32717942|NCT00542009|Experimental|CE-326,597 50 mg QD|
32918552|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
32918553|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
32918554|NCT04917068||Bulimia Nervosa|Participants with diagnosed bulimia nervosa (BN) who will complete all tasks during Visits 1 and 2 in addition to ecological momentary assessment (EMA) procedures following Visit 2.
32918555|NCT04917068||Healthy Control|Participants without diagnosed BN or other current or past eating disorders who will complete all tasks during Visits 1 and 2 and will not complete EMA procedures following Visit 2.
32918556|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
32717943|NCT00542009|Experimental|CE-326,597 25 mg QD|
32717944|NCT00542009|Placebo Comparator|Placebo|
32717945|NCT00542009|Experimental|CE-326,597 5mg QD|
32717946|NCT03480451|Other|Single Arm|"This project is being withdrawn. No revisions to ARM is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
32717947|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
32717948|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
32717949|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
32717950|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
32918557|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
32918558|NCT04885712|Active Comparator|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
32918559|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
32918560|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
33247866|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
33247867|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
32918561|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
32918562|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
33247868|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
33247869|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
33247870|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
33247871|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
33247872|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
33247873|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
33247874|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
33247875|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
33247876|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
33247877|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
33247878|NCT00837603|Active Comparator|Training|Ergometer Training
33247879|NCT00837603|No Intervention|2|Counseling
33247880|NCT00905944|No Intervention|Control|
33247881|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
33247882|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
33247883|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
33247884|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
33247885|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
32918563|NCT00559754|Experimental|1|
33247886|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
33247887|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
33247888|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
32918564|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
32918565|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
33247889|NCT02549391|Experimental|KHK7580|
33247890|NCT02549391|Active Comparator|KRN1493|
33247891|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
33247892|NCT00902122|Active Comparator|2|surgery
33247893|NCT00902122|Experimental|3|p53 gene therapy
33247894|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
33247895|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
33247896|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
33247897|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
33247898|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
33247899|NCT00908674||Group 1|
33247900|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
33247901|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
33247902|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
33247903|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
32717951|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
32717952|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
32717953|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
32717954|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
32717955|NCT04454905|Experimental|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
32717956|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
32717957|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
32717958|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
32717959|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
32717960|NCT00538343|Experimental|RTA 744|
32717961|NCT04458025|Active Comparator|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
32918566|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
32918567|NCT04714125||Patients with COVID-19|Patients hospitalized with COVID-19 from the General Hospital of the University of Sao Paulo, Brazil.
32918568|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
32918569|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
32918570|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
32918571|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
32918572|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
32918573|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
32918574|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
32918575|NCT04838054|Experimental|Test - stabilized chlorine dioxide rinse|Subjects will receive CloSYS Ultra Sensitive Rinse
32918576|NCT04838054|Placebo Comparator|Placebo - oral rinse, no active ingredients|Subjects will receive oral rinse - no active ingredients
32918577|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
32918578|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
32918579|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
32918580|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
32918581|NCT05747300|Active Comparator|MTA pulpotomy|Vital pulpotomy primary Molars using MTA
32918582|NCT05747300|Experimental|Wellroot PT pulpotomy|Vital pulpotomy primary Molars using premixed bioceramic paste wellroot PT
32918583|NCT04739462|Experimental|Intervention|Participants in this arm will receive the study intervention.
32918584|NCT04739462|No Intervention|Routine Antenatal Care|Participants in this arm will receive no intervention.
32918585|NCT05747222|Experimental|Group Action Observation Therapy (G-AOT)|"G-AOT patients will carry out AOT therapy in addition to conventional rehabilitation therapies. In case of bilateral clinical engagement, treatment with AOT will have been conducted on the limb that on motor outcome measures appears less involved.~G-AOT patients will undergo rehabilitation treatment with AOT once a day, 5 days a week. 15 sessions will then be given, for a total duration of 3 weeks of experimental treatment with AOT."
32918586|NCT05747222|Active Comparator|Group Conventional (G-CONV)|G-CONV patients will only carry out rehabilitation treatments as per clinical practice.
32918587|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
32918588|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
33247904|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
32766539|NCT03647917|Experimental|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
32766540|NCT03647917|Experimental|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
32766541|NCT04905875||Critically ill patients with COVID-19|n centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing PP - that are homogeneous in terms of both clinical and treatment characteristics - will be prospectively observed.
32766542|NCT03637309|Experimental|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
32766543|NCT04905719||Patients with dyspnea|Patients who visit a general practitioner for dyspnea will undergo a Point-of-Care ultrasound examination of the lungs to identify the presence or the absence of A-profile, B-profile and pleural effusion.
32766544|NCT04905719||Patients with abdominal pain|Patients who visit a general practitioner for abdominal pain in the right upper quadrant will undergo abdominal Point-of-Care ultrasound examination to identify cholecystolithiasis.
32766545|NCT04905719||Patients with suspected deep vein thrombosis|Patients who visit a general practitioner for pain and / or swelling of the lower extremity will undergo compression ultrasound testing to identify proximal deep vein thrombosis.
32766546|NCT03619681|Experimental|KN026|
32766547|NCT03609073|Experimental|Intervention|
32766548|NCT04916093|Experimental|Sitagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
32766549|NCT04916093|Experimental|Vildagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.
32766550|NCT04916093|Active Comparator|Metformin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily
32766551|NCT05130619|Experimental|Treatment order A-.B-C-D|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
32766552|NCT05130619|Experimental|Treatment order B-D-A-C|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
32766553|NCT05130619|Experimental|Treatment order C-A-D-B|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
32766554|NCT05130619|Experimental|Treatment order D-C-B-A|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
32766555|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
32766556|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
32766557|NCT04903769|Other|Parkinson's Patients and Caregivers|Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease
32766558|NCT05130541|Placebo Comparator|Control|Usual Care
32766559|NCT05130541|Experimental|Proning|Proning, rotating 90 degrees on long axis every 30 minutes - 2 hours
32766560|NCT04905485|Other|Intervention|All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
32766561|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
32766562|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
32766563|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
32766564|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
32766565|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
32766566|NCT04905329||"Patients with high and gray zone risk reccurrence early breast cancer"|
32766567|NCT04905329||Patients with gastointestinal cancers|
32918589|NCT01846988|Active Comparator|APAP pressurized comparison|randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.
32918590|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
32918591|NCT04622930|Experimental|Experimental: Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
32918592|NCT04622930|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
32918593|NCT05746832|Active Comparator|One session application of (ERCP) in the management of common bile duct stones.|One session application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
32918594|NCT05746832|Active Comparator|Two sessions application of (ERCP) in the management of common bile duct stones.|Two sessions application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones.and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
32918595|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
32918596|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
32918597|NCT00559364|Experimental|Viokase® 16|
32918598|NCT00559364|Placebo Comparator|Placebo|
32918599|NCT05746676|Active Comparator|group 1|
32918600|NCT05746676|Active Comparator|group 2|
32918601|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
32918602|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
32918603|NCT04574336|Experimental|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
32918604|NCT04574336|Active Comparator|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
32918605|NCT01849172|Experimental|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
32918606|NCT01849172|Sham Comparator|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
32918607|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
33399844|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
32918608|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:~Severe patients~Non-severe patients"
32918609|NCT05746598||1|NSCLC patients Who developed Toxicity to Chemotherapeutic agents
33399845|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
33399846|NCT04792801||Patients with HCC and whose liver transplant plan has been validated|"Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.~The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation."
33399847|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
33399848|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
33399849|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
33247905|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
33247906|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
32717962|NCT04458025|Experimental|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
32717963|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
32717964|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
32717965|NCT00473525|Placebo Comparator|Placebo|
32717966|NCT00473525|Experimental|PF-00734200 10 mg QD|
32717967|NCT00473525|Experimental|PF-00734200 20 mg QD|
32717968|NCT00473525|Experimental|PF-00734200 5 mg QD|
32717969|NCT00473525|Experimental|PF-00734200 2 mg QD|
32717970|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
32717971|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
32766568|NCT04905329||Patients with gynecological malignancies|
32766569|NCT02767921|Experimental|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
32766570|NCT04903379|Other|Pain science education and self management strategies|The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
32766571|NCT02642809|Experimental|Arm 1: Pembrolizumab and Brachytherapy|"Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.~Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.~Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.~Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.~Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
32766572|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
32766573|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
32766574|NCT05125393|Experimental|Linear stapler group|In the experimental group, indocyanine green was injected for development during the operation after ileocolic vessel and the middle colonic vessel were dissected. The tributary vessels of the Henle trunk were disconnected with a linear stapler if there was no obvious lymph node development, which means ligated not in the root. Otherwise, they were transferred to the experimental group.
32766575|NCT05125393|No Intervention|Conventional group|The branches of Henle trunk were dissected according to the conventional method and clamped at the root.
32766576|NCT04905095|Experimental|EWS|Early Warning Score will be implemented in the computer system of the nursing station
32766577|NCT04905095|No Intervention|Control|Nursing supervision will be carried out in the usual way.
32766578|NCT05125315||low-hemosynamics|
32766579|NCT05125315||high-hemodynamics|
32766580|NCT05125159|Experimental|angioplasty guidewire-assisted transseptal group|Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.
32766581|NCT05125159|Sham Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
32766582|NCT04902833||Cohort I|"Approximately 75 anemic (Hgb <11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.~- Single Blood Draw"
32766583|NCT04902833||Cohort 2|"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia~-Single Blood Draw"
32766584|NCT02532127|Experimental|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
32766585|NCT04915547|Experimental|Group-Based Exercise|The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
32766586|NCT04915547|No Intervention|Control Group|Participants randomly allocated to the control group will remain on a waiting list. In addition, weekly contact will be made to ensure that they do not start treatment during the study protocol. After the end of the study, participants randomly allocated to the control group will receive the same intervention as the Group-Based Exercise.
32766587|NCT05079607|Experimental|Mitopure Topical Formula|
32766588|NCT02370589|Experimental|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
32766589|NCT02370589|Experimental|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
32766590|NCT02370589|Experimental|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
32918610|NCT05746598||2|NSCLC patients Who did not developToxicity to Chemotherapeutic agents
32717972|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
32717973|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
32717974|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
32766591|NCT02370589|Experimental|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
32766592|NCT02370589|Experimental|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
32766593|NCT02370589|Experimental|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
32766594|NCT02370589|Experimental|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
32766595|NCT02370589|Experimental|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
32766596|NCT02370589|Experimental|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
32766597|NCT02370589|Experimental|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
32766598|NCT02370589|Experimental|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
32766599|NCT02370589|Experimental|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
32766600|NCT02370589|Placebo Comparator|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
32766601|NCT04915625||Death group|Retrospective observational studies
32766602|NCT04915625||Survival group|Retrospective observational studies
32766603|NCT01752049|Active Comparator|Topical timolol maleate|"Drug: • Topical timolol maleate 0.5% drops~Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient)."
32766604|NCT01752049|Placebo Comparator|Placebo|"placebo saline drops~-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient."
32766605|NCT05067673|Placebo Comparator|Control group|Placebo dry needling
32766606|NCT05067673|Experimental|Experimental group|Dry needling
32766607|NCT04966507|Active Comparator|Listerine Cool Mint Antiseptic Mouthwash|Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.
32766608|NCT04966507|Placebo Comparator|Biotene Oral Rinse|Daily use of a placebo mouthwash with no known antibacterial qualities (Biotene Oral Rinse) during the 12-week follow-up period.
32766609|NCT04904627||Polyehtylene vs Poliìycarbonate|super rigid vs rigid material
32766610|NCT04904627||Free pelvis vs classic pelvis|fixed pelvis versus free pelvis, allowing adjustment in the sagittal plane.
32766611|NCT05049265|Experimental|JS007|
32766612|NCT05013619||adolescent cerebral palsy|Demographical data, the subtypes of CP, Gross Motor Functional Classification System level, circumstances of pain, pain questionnaire will be analyzed.
32766613|NCT05013619||adolescent cerebral palsy's mother|pain questionnaire will be analyzed.
32766614|NCT04904783|Active Comparator|Study arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
32766615|NCT04904783|No Intervention|Control Arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.
32766616|NCT05136079|Experimental|Prophylactic lymphaticovenous anastomosis|Intervention participants will undergo prophylactic lymphaticovenous anastomosis as an addendum to axillary or ilioinguinal lymphadenectomy for treatment of cutaneous malignancy.
32766617|NCT05136079|No Intervention|Lymphadenectomy without lymphaticovenous anastomosis|Control participants will undergo axillary or ilioinguinal lymphadenectomy without lymphaticovenous anastomosis for treatment of cutaneous malignancy .
32766618|NCT04915469|No Intervention|Pre-standardization group|Pre intervention- patient level data are abstracted retrospectively from the charts of patients with VL >1000 copies/ml on demographic characteristics and clinical outcomes and facility level data from summary forms for up to 24 months prior to the implementation of the standardized EAC package.
32766619|NCT04915469|Other|Post-standardization group|This group of participants will receive the standardized enhanced adherence package. After implementation of the standardized EAC package, data will be prospectively collected from participants with high viral load (>1000 copies).
32766620|NCT04959877||1|Patients diagnosed with oropharyngeal dysphagia who require speech therapy treatment for this reason and who have voluntarily opted for the blended treatment modality.
32766621|NCT05124145||surveillance network|The surveillance network is made of 200 health professionals from 85 practices
32766622|NCT05136625|Active Comparator|Control|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine)
32918611|NCT04488536||Frail patients|Clinical Frailty Scale level 5-9
32918612|NCT04488536||Nonfrail patients|Clinical Frailty Scale level 1-4
32918613|NCT04476212|Experimental|Intervention|In the experimental arm, the surgical wound will be irrigated using an antibiotic solution (amoxicillin-clavulanate) for topical prophylaxis
32918614|NCT04476212|No Intervention|Control|In the control arm, the surgical wound will be irrigated with saline, which is our routine at present.
32918615|NCT05745038|Experimental|Arm 1 - SONATA Intervention|
32918616|NCT04297436|Other|Bexsero|Each participant is compared to baseline (before vaccination)
32918617|NCT05744492|Experimental|Supervised Vivifrail (S-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Once-per-week, subjects assigned to this group will attend the primary care center to execute one of the three exercise sessions per week under the supervision of the physical therapist.
32918618|NCT05744492|Experimental|Non-supervised Vivifrail Group (NS-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Subjects assigned to this group will follow a domiciliary-based program and they will not attend the primary care center to execute the exercises.
32918619|NCT05744492|No Intervention|Control group (UCG)|Subjects will receive usual care following prevention protocols of Primary Care Services in Madrid. Concisely, the benefits of physical activity are individually explained and subjects are advised to walk as much as possible with the aim of reaching at least 30 minutes a day, 5 days a week, following the recommendations of the World Health Organization. No structured exercise-based interventions are programmed in this group.
32918620|NCT05742386|Experimental|HPV vaccine communication training|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
32918621|NCT05742386|Experimental|HPV vaccine communication training and standing orders optimization|Staff in clinics randomized to this arm will receive the AAT and conduct a set of activities to optimize use of HPV vaccine standing orders.
32918622|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
32918623|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
32918624|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
32918625|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
32918626|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
32918627|NCT04275752|No Intervention|Usual Care Group|Subjects will receive no formal exercise recommendations
32918628|NCT04275752|Experimental|Exercise Intervention Group|Subjects will complete an exercise program
32918629|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
32918630|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
32918631|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
32918632|NCT05735054||endoscopic group|the patients who underwent endoscopic transaxillary thyroidectomy
32918633|NCT05735054||open group|the patients who underwent open thyroidectomy
32918634|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32918635|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).~Participants may continue to receive treatment until discontinuation criteria are met."
32918636|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32918637|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32918638|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32918639|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
33247907|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
33247908|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
33247909|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
33247910|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
33247911|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
33247912|NCT04018599|Experimental|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
33247913|NCT04018599|Experimental|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
33247914|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
33247915|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
33247916|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
33247917|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
33247918|NCT04034914|Experimental|Yoga Therapy|
33247919|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
33247920|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
33247921|NCT04034602|Experimental|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
33247922|NCT04034602|Active Comparator|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
33247923|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
33247924|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
33247925|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
32717975|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
33247926|NCT00827385||hypertensive|
33247927|NCT00827385||normotensive|
33247928|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
33247929|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
33247930|NCT00909142||Group1|
33247931|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
33247932|NCT00906256|Active Comparator|AZD7295|AZD7295
33247933|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
33247934|NCT00838071|Experimental|IGIV-HB Grifols|
33247935|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
33247936|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
33247937|NCT04044573|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
33247938|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
33247939|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
33247940|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
33247941|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
33247942|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
33247943|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
33247944|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
33247945|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
33399850|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
33399851|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
33399852|NCT05682859|Active Comparator|Roflumilast|20 of the participating patients are randomized to the active arm where systemic roflumilast 500 microgram tablets are received.
32766623|NCT05136625|Experimental|Treatment|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine) Transnasal sphenopalatine ganglion block (Levobupivacaine 7,5%)
32766624|NCT04402697|No Intervention|Normal-weight (NW)|Individuals with BMI<25 kg/m2
32766625|NCT04402697|Experimental|Overweight-Obese (OW-OB)|Individuals with BMI>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
32766626|NCT04402697|Experimental|Metabolically obese normal-weight (MONW)|Individuals with BMI<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
32766627|NCT04902521|Experimental|Transcranial magnetic stimulation with constraint induced movement therapy|CIMT/TMS: Five participants will receive a one-hour weekly occupational therapy session of CIMT with 2-hours of daily home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of TMS 1HZ.
32766628|NCT04902521|Sham Comparator|constraint induced movement therapy Sham transcrianial magnetic stimulation|(CIMT/sham TMS): Five participants will receive a one-hour weekly session of CIMT with 2-hours daily of home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of sham TMS 1HZ.
32766629|NCT05124847|Experimental|TRE-Control|
32766630|NCT05124847|Experimental|Control-TRE|
32766631|NCT04402619|Experimental|Online CBT|Ten modules with minimum therapist guidance
32766632|NCT04902001|Experimental|Adolescents with obesity|Adolescents with obesity aged 12-16 years old
32766633|NCT05124613||Patients waitlisted for Knee Surgery|Adults identified by a consultant orthopaedic surgeon at the study site as being on a waiting list for surgery on their knee and as experiencing a delay to their knee surgery as a result of the COVID-19 pandemic will be eligible to participate in this survey. The survey will include one validated questionnaire and a series of bespoke questions.
32766634|NCT05124535||Persons aged 18-29|
32766635|NCT05124535||Persons aged 30-39|
32766636|NCT05124535||Persons aged 40-65|
32766637|NCT04904237|Experimental|aza-ven +MBF|treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
32766638|NCT05136469|Experimental|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
32766639|NCT05136469|Active Comparator|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
32766640|NCT04894487|No Intervention|Control Group|The babies have got sternum incision after the pediatric cardiac surgery. Experiment is about the dressing of the sternum incision. There is no extra intervention during sternum dressing at control group like routine of pediatric cardiovascular surgery intensive care clinic. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
32766641|NCT04894487|Experimental|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABIES GROUP|Baby mobile and Brahms Lullaby started before the 10 minutes of sternum dressing process and controlled permanence of the baby mobile and Brahms Lullaby during sternum dressing. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
32766642|NCT05136235|Other|Extremely preterm newborns|All extremely preterm newborns in Flanders will be included, it is a single arm study
32766643|NCT04902209||1- study group- patients after surgical treatment of acetabular fracture|1- study group- patients after surgical treatment of hip acetabular fracture
32766644|NCT04902209||2- control group- healthy subjects|2- control group- healthy subjects age, BMI matched
32766645|NCT04957537|Other|6 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 weeks (i.e. 18 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
32766646|NCT04957537|Other|8 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 8 weeks (i.e. 24 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
32766647|NCT04894409|Experimental|Experimental group|The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution.
32766648|NCT04894409|Active Comparator|Control group|"The control group was instructed to do mouthwashes and nose rinse in a conventional way."
32766649|NCT04949113|Experimental|A: Neoadjuvant|"2 cycles of neoadjuvant ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by a total lymph node dissection (TLND) and if applicable, resection of in-transit metastases.~Patients with a pathologic partial or non-response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks 11 cycles. In case of BRAF V600E/K mutation-positivity, patients will be treated with adjuvant dabrafenib plus trametinib for 46 weeks instead."
33247946|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
33247947|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
33247948|NCT00902902||1|
33247949|NCT00902902||2|
33247950|NCT04318587|Experimental|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
32766650|NCT04949113|Active Comparator|B: Adjuvant|Standard upfront total lymph node dissection (TLND) and if applicable, resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks
32766651|NCT05115955|Experimental|DS group|Combination of routine analgesic regimen and preoperative administration of 2 ml NALDEBAIN® ER Injection (150 mg Dinalbuphine Sebacate, 75 mg/ml, 2 ml/vial).
32766652|NCT05115955|Placebo Comparator|Control group|Combination of routine analgesic regimen and preoperative administration of 2 ml sesame oil (2 ml/vial).
32766653|NCT04901897|Experimental|kalifilcon A|kalifilcon A daily disposable contact lens
32766654|NCT04901897|Active Comparator|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
32766655|NCT04901897|Active Comparator|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
32766656|NCT04895371|Experimental|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
32766657|NCT04895371|Active Comparator|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
32766658|NCT04914923|Experimental|Cognitive Behaviour Therapy|This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
32766659|NCT04914923|Experimental|Mindfulness-based Cognitive Therapy|This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
32766660|NCT04914923|No Intervention|Waitlist|This study arm will not receive an intervention for 12 weeks.
32766661|NCT05135065|Experimental|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
32766662|NCT05135065|No Intervention|Enhanced Supervision as Usual (ESAU) Condition|ESAU therapists will be given standard, paper-based facilitation resources for STAND and will receive 4 hours of training on how to navigate these materials and self-assess fidelity. ESAU therapists will also be trained how to upload recordings into Care4 and complete self-assessments for each session. Supervisors will be given access to these data and recordings once uploaded (but not Lyssn scores or electronic facilitation resources).
32766663|NCT04894331||SNAS patients|Patients with (a) history of SNAS (coexistence of typical cutaneous and gastrointestinal symptoms); (b) positive Ni-patch test; (c) clinical improvement of at least 70% from baseline after 4 weeks of low-Ni diet; (d) positivity of a double-blind placebo-controlled oral Ni challenge (DBPCO). Exclusion criteria include (a) age < 18 years and >65 years; (b) other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth; (c) diabetes mellitus; (d) hepatic, renal or cardiac dysfunction; (e) thyroid disease or tumour; (f) concomitant treatment with steroids and/or antihistamines in the previous 4 weeks; (g) pregnancy and lactation; (h) smoking, abuse of alcohol, coffee, tea, and cola intake, and (i) inability to give written informed consent.
32766664|NCT05134909|Experimental|Study: Keratoconus|Customized contact lenses will be fitted to each study subject based on their own optical defects.
32766665|NCT04893941|Experimental|CM310 75mg arm|75mg for 3 doses, every 2 weeks, SC
32766666|NCT04893941|Experimental|CM310 150mg arm|150mg for 3 doses, every 2 weeks, SC
32766667|NCT04893941|Experimental|CM310 300mg arm|300mg for 3 doses, every 2 weeks, SC
32766668|NCT04893941|Experimental|CM310 600(1st)+300mg(2nd,3rd) arm|600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
32766669|NCT04893941|Placebo Comparator|placebo arm|placebo for 3 doses, every 2 weeks, SC
32766670|NCT05057845|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|
32766671|NCT04901585||Totally intracorporeal distal gastrectomy|All patients who underwent minimally invasive distal gastrectomy with intracorporeal anastomosis for gastric cancer
32766672|NCT05109949|Experimental|Dapagliflozin 10 mg|Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.
32766673|NCT05109949|Experimental|Empagliflozin 25 mg|Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.
32766674|NCT05109949|Placebo Comparator|Placebo|Calcinated magnesium is a white powdery compound, MgO, used in pharmaceuticals as binder.
32766675|NCT04893473||Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
33247951|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
33247952|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
33399853|NCT05682859|Placebo Comparator|Placebo|20 of the participating patients are randomized to the active arm where systemic placebo tablets are received.
33399854|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
33247953|NCT04035070|Experimental|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
33247954|NCT04035070|Experimental|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
32918640|NCT05732870||Participant undergoing orthopaedic surgery|"Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, elbow, ankle).~Patients with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.~Patients undergoing acute low-velocity or fragility fracture fixation surgery."
32918641|NCT04420494|Experimental|Patients treated with umbilical cord blood|
32918642|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
32918643|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
32918644|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
32918645|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
32918646|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
32918647|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
32918648|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
32918649|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
32918650|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
32918651|NCT05369910|Experimental|Flash first|"Light exposure (Flash) first, light deprivation (Dark) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
32918652|NCT05369910|Experimental|Dark first|"Light deprivation (Dark) first, Light exposure (Flash) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
33247955|NCT04035070|Active Comparator|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
32918653|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
32918654|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
32918655|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
32918656|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
32918657|NCT04883892|Experimental|BMAC injection|Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint
32918658|NCT04883892|Active Comparator|HA injections|"two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.~After 12 months patients are allowed to cross-over in the BMAC arm."
32918659|NCT05437770|Experimental|BFR (Blood-Flow Restricted exercise)|The BFR training intervention group will perform low load blood-flow restricted exercise. Training twice a week for 12 weeks. The group will also attend a two hours education lecture with osteoarthritis information.
32918660|NCT05437770|Active Comparator|Standard rehabilitation|The standard rehabilitation group will be offered participation in the Good Life with osteoArthritis in Denmark programme (GLA:D). The programme includes supervised team group training twice a week for 8 weeks and an education lecture. The GLA:D programme will be followed by 4 weeks of team group training continuing the exercises from the GLA:D programme.
32918661|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
32918662|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
32918663|NCT04893486|Experimental|Active|
32918664|NCT04893486|Placebo Comparator|Vehicle|
32918665|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
32918666|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
32918667|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 1|In year 1, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
33247956|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
33247957|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
33399855|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
32766676|NCT04893473||Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
32766677|NCT04901429|Experimental|Truncal Vagotomy|Truncal vagotomy will be performed during other routine procedure.
32766678|NCT04901429|No Intervention|No Truncal Vagotomy|No truncal vagotomy will be performed during other routine procedure.
32766679|NCT04926259|Experimental|18F-T807, PET/CT|PET/CT perform after injecting 18F-T807
32766680|NCT04901663|Active Comparator|Omeprazole Group|Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD
32766681|NCT04901663|Experimental|Vonoprazan Group|Vonoprazan 20 mg BD Amoxicillin 1000 mg BD
32766682|NCT05134597||Group 1 - Patients with Chronic Venous Disease (CVD)|Patients with CVD at different stages, according to CEAP Classification of Chronic Venous Disorders, will be recruited.
32766683|NCT05134597||Group 2 - Healthy subjects without Chronic Venous Disease (CVD)|Voluntary healthy subjects without Chronic Venous Disease (CVD) will be recruited.
32766684|NCT05134519|Experimental|RC48 for neadjuvant chemotherapy|RC48-ADC: 2.0 mg/kg, IV drip, Q2W
32766685|NCT04394663|Experimental|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
32766686|NCT04394663|Active Comparator|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
32766687|NCT05133193|Experimental|14d concomitant therapy|The eligible patients received 14-day concomitant therapy, including vonoprazan and three kinds of antibiotics according to the previous eradication regimens and antibiotic use. Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.
32766688|NCT04901117|Experimental|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
32766689|NCT04901117|Active Comparator|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
32766690|NCT05121571|Experimental|HAIC of FOLFOX|Retreatment With hepatic arterial infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin
32766691|NCT05121571|Active Comparator|Sorafenib|
32766692|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
32766693|NCT05088733|Experimental|Yang Yin Fu Zheng Jie Du therapy|
32766694|NCT05088733|Placebo Comparator|Routine medical care|
32766695|NCT04924777|Experimental|Brisk walk|
32766696|NCT04924777|Experimental|Aerobic Training|
32766697|NCT04924777|Experimental|Strength Training|
32766698|NCT04861285|Experimental|RACESTYPTINE Solution with cord|The participant will receive RACESTYPTINE Solution into the sulcus. The solution is used in combination with a non-medicated gingival retraction cord.
32766699|NCT04861285|Experimental|RACEGEL with cord|The participant will receive RACEGEL into the sulcus. The gel is used in combination with a non-medicated gingival retraction cord.
32766700|NCT04861285|Experimental|RACEGEL without cord|The participant will receive RACEGEL into the sulcus. No cord will be added.
32766701|NCT05115331|Active Comparator|Conventional Radiation Dose|8 Gy in a single fraction
32766702|NCT05115331|Experimental|Experimental Radiation Dose|16 Gy in 2 fractions
32766703|NCT04832815|Experimental|Equine Therapy|
32766704|NCT04832815|No Intervention|Treatment as Usual (TAU)|
32766705|NCT04832815|Experimental|Therapeutic Horsemanship Program|
32766706|NCT04725955|Placebo Comparator|Glucose Solution|
32766707|NCT04725955|Active Comparator|Wheat bread enriched with a-cyclodextrin|
32766708|NCT04725955|Experimental|Wheat bread enriched with hydroxytyrosol encapsulated in a-cyclodextrin|
32766709|NCT04725955|Placebo Comparator|White wheat bread|
32766710|NCT04674007||Healthy basketball, volleyball and handball players|Healthy basketball, volleyball and handball players
32766711|NCT05005585|Experimental|vestibuler socket therapy|immediate implant placement in esthatic zone with final crown placement after 2 months with VST technique
32766712|NCT05005585|Experimental|contour augmentation|Early implant placement in esthatic zone with contour augmentation and final crown after 3 months of implant placement
32918668|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 2|In year 2, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
33399856|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
33399857|NCT05175937||APP group|Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
33399858|NCT05175937||Bedside transmitter group|Patient wearing ICD monitored remotely through a bedside transmitter
33399859|NCT04152252||Baseline|No CPR feedback during CPR
32717976|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
32717977|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
32717978|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
32717979|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
32717980|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
32717981|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
32717982|NCT05259553|Experimental|Patients with multiple myeloma|Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.
32766713|NCT04646239||Participants in the CROWN CORONATION trial|The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.
32766714|NCT04934527|Experimental|Experimental|Patients with positive CMV serology at transplantation will receive 6 infusions of Cytotect every 15 days with the first injection on the day of transplantation. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
32766715|NCT05288647|Experimental|Group A|Patients treated with four computer-guided sodium hyaluronate injections in superior TMJ space.
32766716|NCT05288647|Active Comparator|Group B|Patients treated with four conventional sodium hyaluronate injections in superior TMJ space.
32766717|NCT05287009|Experimental|ILM nonpeeling|
32766718|NCT05287009|Other|ILM peeling|
32766719|NCT04576663|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
32766720|NCT04576663|Experimental|0.3125 μg/kg/min group|A maintenance dose of phenylephrine (0.3125 μg/kg/ min) infusion simultaneous with subarachnoid block
32766721|NCT04576663|Experimental|0.625 μg/kg/min group|A maintenance dose of phenylephrine (0.625 μg/kg/ min) infusion simultaneous with subarachnoid block
32766722|NCT04576663|Experimental|0.9375 μg/kg/min group|A maintenance dose of phenylephrine (0.9375 μg/kg/ min) infusion simultaneous with subarachnoid block
32766723|NCT04560517||Anorexia Nervosa|
32766724|NCT04560517||Healthy Control Subjects|
32766725|NCT05284123|Experimental|Self-compassion intervention|Brief (20-minute) workshop with a self-compassion writing exercise and information about mental health resources available to students.
32766726|NCT05284123|Experimental|Mental health literacy intervention|Brief (20-minute) workshop with information and a written reflection about common mental disorders, and information about mental health resources available to students.
32766727|NCT05284123|Active Comparator|Control|Brief (7-minute) workshop with information about mental health resources available to students.
32766728|NCT04491409||Observational (standard of care, medical chart review)|Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.
32766729|NCT04905199||Non-floating catheter|When using non-floating catheter.
32766730|NCT04905199||Floating catheter|When using floating catheter.
32766731|NCT04763005|No Intervention|Healthy controls|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry.
32766732|NCT04763005|Experimental|Hypertensive Patients|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry. In addition, randomization to an eight-week high-intensity interval intervention or control condition with physical activity recommendations.
32766733|NCT05281549|Active Comparator|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
32766734|NCT05281549|Experimental|Tenecteplase 0.25mg/kg|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5~10 seconds
32766735|NCT05281549|Experimental|Tenecteplase 0.4mg/kg|Patients will receive intravenous Tenecteplase, 0.4mg/kg, maximum 40mg, administered as a bolus over 5~10 seconds
32766736|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
32766737|NCT05276479||Healthy subjects|Healthy subjects aged 18-30 years
33399860|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
33399861|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
33399862|NCT04394676|Experimental|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
33399863|NCT04394676|Active Comparator|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
33399864|NCT04384146|Experimental|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
33399865|NCT05420922||Systemic therapy|ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib)
33399866|NCT05420922||Local treatment|local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
33399867|NCT05420922||Triple therapy|"Systemic therapy plus Local treatment:~ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib) plus local treatment (TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc)"
33399868|NCT05283096||Patients with chronic inflammatory rheumatic disease|
33399869|NCT04381650|Experimental|Dose Escalation: TAK-981 + Pembrolizumab (Fixed Dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
33399870|NCT04381650|Experimental|Dose Expansion Phase: Cohort A: Non-squamous NSCLC|TAK-981 as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399871|NCT04381650|Experimental|Dose Expansion Phase: Cohort B: Cervical Cancer|TAK-981 as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399872|NCT04381650|Experimental|Dose Expansion Phase: Cohort C: MSS-CRC|TAK-981 as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399873|NCT04381650|Experimental|Dose Expansion Phase: Cohort D: Cutaneous Melanoma|TAK-981 as IV infusion in participants with Cutaneous melanoma on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399874|NCT04381650|Experimental|Dose Expansion Phase: Cohort E: Squamous NSCLC|TAK-981 as IV infusion in participants with Squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399875|NCT04381650|Experimental|Dose Expansion Phase: Cohort F: Small Cell Lung Cancer|TAK-981 as IV infusion in participants with Small cell lung cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399876|NCT04381650|Experimental|Dose Expansion Phase: Cohort G: HNSCC|TAK-981 as IV infusion in participants with head and neck squamous cell carcinoma (HNSCC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399877|NCT04381650|Experimental|Dose Expansion Phase: Cohort H: MSI-H/dMMR CRC|TAK-981 as IV infusion in participants with microsatellite instability, high levels/ mismatch-repair-deficient colorectal cancer (MSI-H/dMMR CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
33399878|NCT02948959|Placebo Comparator|Placebo|Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist [LABA], long acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
33399879|NCT02948959|Experimental|Dupilumab|Dupilumab 200 milligrams (mg) (in 1.14 milliliters [mL] for >30 kilograms [kg] bodyweight [BW]) or 100 mg (in 0.67 mL for less than or equal to (<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
33399880|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
32918669|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
32918670|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
32918671|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
32918672|NCT04392219|Experimental|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
32918673|NCT04392219|Placebo Comparator|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
32918674|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
32918675|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
32918676|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
32918677|NCT04365153|Placebo Comparator|Control|Placebo
32918678|NCT03654417|Active Comparator|EMLA|
32918679|NCT03654417|Active Comparator|Lidocaine|
32918680|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
32918681|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
32918682|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
32918683|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
32918684|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
32918685|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
32918686|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
32918687|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
32918688|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
32918689|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
32918690|NCT02354976|Placebo Comparator|Placebo|
32918691|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
32918692|NCT02354976|Active Comparator|Fenofibrate 200mg|
32918693|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
32918694|NCT04889664|Experimental|Ketamine and Written Exposure Therapy|Intravenous Ketamine 0.5 mg/kg and Written Exposure Therapy
32918695|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918696|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918697|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918698|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32717983|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
32717984|NCT00465959|Experimental|400 mg TrIP|
32717985|NCT00465959|Experimental|800 mg TrIP|
32717986|NCT00465959|Placebo Comparator|Placebo|
32717987|NCT04458727||Patients who used supportive measures during home training|
32717988|NCT04458727||patients who did not use supp. measures during home training|
32918699|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918700|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918701|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
32918702|NCT04125914|Experimental|Prevention (weight management, health behavior intervention)|Participants undergo weight management and health behavior intervention with a combination of 4 components for 16 weeks. TELEPHONE COACHING: Participants receive 1 phone call each week from a coach over 30-45 minutes to discuss diet, physical activity and goal setting. EMAIL COACHING: Participants receive 1 phone call to discuss the process over 10-15 minutes and then receive 1 email each week for 16 weeks. NO COACHING: Participants receive 1 phone call the first week over 10-15 minutes to discuss the process. TEXT MESSAGING: Participants receive 7-12 text messages comprising information about diet and physical activity each week for 16 weeks. SELF-MONITORING: Participants record their food intake and weight directly into the Fitbit website or application 4-7 days each week or 1 day each week for 16 weeks. FAMILY TEAM INTERVENTION: Participants receive 2 group phone calls and join a Facebook group that is monitored by research staff where they can interact with each other and coaches.
32918703|NCT05725772||Parkinson's disease|People with Parkinson's disease living in medically underserved areas
32918704|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
32918705|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
32918706|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); PTG-300 (Part 2); Open label extension PTG-300 (Part 3)|
32918707|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); Placebo (Part 2); Open label extension PTG-300 (Part 3)|
32918708|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
32918709|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
32918710|NCT02265224|Experimental|Test - Reference|N-acetylcysteine (NAC) 600 mg uncoated tablet (single dose) followed by NAC 600 mg film-coated tablet (single dose)
32918711|NCT02265224|Active Comparator|Reference - Test|N-acetylcysteine (NAC) 600 mg film-coated tablet (single dose) followed by NAC 600 mg uncoated tablet (single dose)
32918712|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
32918713|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
32918714|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
32918715|NCT04045652||Kenyan women|Kenyan women, some HIV-infected and some HIV-uninfected, VIA negative at enrollment.
32918716|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
32918717|NCT04332081|No Intervention|Standard of Care|
32918718|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
32918719|NCT03922334|Experimental|Navigation Group|Women who are randomized into NNM2 will be assigned to a patient navigator. The patient navigator will meet with the patient after delivery occurs for introductions and education. The patient navigator will offer support and resources (transportation, community referrals, support for your mental health, connection to your doctors, etc.). The navigator will also help to schedule postpartum medical appointments, and will remind the patients of these appointments via text, email, or phone calls. The navigator will continue to provide psychosocial support and continued linkage to resources through one-year postpartum.
33399881|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
33399882|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
33399883|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
33399884|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
33399885|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
32717989|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
32717990|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
32717991|NCT04176445|Other|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
32918720|NCT03922334|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
32918721|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
32918722|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
32918723|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
32918724|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
32918725|NCT05314725|Experimental|SGLT-2 inhibitor|
32918726|NCT05314725|Placebo Comparator|placebo|
32918727|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
32918728|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
32918729|NCT03867500|Experimental|Niacin|Intravenous niacin infusion
32918730|NCT03867500|Placebo Comparator|Saline|Intravenous saline infusion
32918731|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:~Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion.~Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion."
32918732|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
32918733|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
32918734|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
32918735|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
32918736|NCT03407313|Experimental|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
32918737|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
33247958|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
33247959|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
33247960|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
33247961|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
33247962|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
33247963|NCT00906412||ET Group|Total of 25 participants with ET
33247964|NCT00906412||Controls|25 controls without ET
33247965|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
33247966|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
33247967|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
33247968|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
33247969|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
33247970|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
33247971|NCT04034758|Placebo Comparator|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
33247972|NCT04034758|Active Comparator|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2*10^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
33247973|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
33247974|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
33247975|NCT01042951|Placebo Comparator|Placebo|
33247976|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
33247977|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
33247978|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
33247979|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
32918738|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
32918739|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
32918740|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
32918741|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
32918742|NCT03803540|Experimental|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
32918743|NCT01860950|Active Comparator|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
32918744|NCT01860950|Active Comparator|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
32717992|NCT04176445|Other|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
32918745|NCT01860950|Experimental|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
32918746|NCT01860950|Experimental|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
32918747|NCT01860950|Sham Comparator|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
32918748|NCT01860950|Sham Comparator|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
32918749|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
32918750|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
32918751|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
32918752|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
32918753|NCT05692154|Experimental|Arm A (active-active)|Two days of pre-treatment with Fexofenadine, then Fexofenadine180 mg during the test pollen challenge.
32918754|NCT05692154|Experimental|Arm B (placebo-active)|Two days of pre-treatment with Placebo, then Fexofenadine180 during the test pollen challenge.
32918755|NCT03670017|Other|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
32918756|NCT03747146|Active Comparator|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
32918757|NCT03747146|Sham Comparator|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
32918758|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
32918759|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
32918760|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
32717993|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
32918761|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
32918762|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
32918763|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
33247980|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
33247981|NCT01043107||Compuer radiaton group|
32717994|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
32717995|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
32918764|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
32918765|NCT04290039|Active Comparator|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
32918766|NCT04290039|Active Comparator|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
32918767|NCT04290039|Active Comparator|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.~Each vial will only be used to administer a single dose, to a single subject."
33247982|NCT01043107||control group|
33247983|NCT00909688|Experimental|1|BLI-489
33247984|NCT00909688|Placebo Comparator|2|placebo
33247985|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
32718000|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
32718001|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
32718002|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
32718003|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
32718004|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
32718005|NCT04471649||Experimental|Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.
32718006|NCT04471649||Active Comparator|Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen
32718007|NCT03479749|Experimental|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
33247986|NCT04034836|Experimental|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
33247987|NCT04034836|Active Comparator|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
33247988|NCT04034836|Active Comparator|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
32718008|NCT03479749|Experimental|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
32718009|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
33399886|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
33399887|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
32718010|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
32718011|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
32718012|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
32718013|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
32718014|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
32718015|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
32718016|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
32718017|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
32718018|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
32918768|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
32918769|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
32918770|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
32718019|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
32718020|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
32718021|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
32718022|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
32718023|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
32718024|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
32718025|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
32718026|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
32718027|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
32718028|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
32918771|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
32918772|NCT04735419||Cases|Cases are defined as infants who develop invasive GBS disease (iGBS disease= isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life.
32918773|NCT04735419||Controls|Controls are defined as infants who are exposed to the same serotype of GBS at birth as the case - but who do not develop iGBS disease in the first 90 days of life.
32918774|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
32918775|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
32918776|NCT05679596|Experimental|Exogenous ketone monoester (KET)|KET will be provided at a dose of 360 mg kg-1 body mass per serving at 2 servings per day between each main meal (ΔG®; TΔS Ltd, UK, Oxford, UK).
32918777|NCT05679596|Active Comparator|Energy matched control (CON)|CON will be provided at a dose energy matched to the KET supplement and consist of both carbohydrate (i.e., fructose) and fat (i.e., corn and canola oil 50:50 ratio). 1/3 of the supplemental energy will come from carbohydrate while 2/3 will come from fat. We have excluded protein from the CON supplement since it is well established to influence our primary outcome measure (MPS rates). A non-caloric sweetener will also be added to the CON supplement.
32918778|NCT03415581|Placebo Comparator|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
32918779|NCT03415581|Active Comparator|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
32718029|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
32718030|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
32718031|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
32718032|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
32718033|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
32718034|NCT00519389|Placebo Comparator|Placebo|
32918780|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
32918781|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
32918782|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
32918783|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
32918784|NCT05672186|Sham Comparator|Waitlist control|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the control group will be placed on a waitlist to receive market service after follow- up data collection is complete.
32918785|NCT05672186|Experimental|Experimental group|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the intervention group will receive the full-service market intervention following randomization.
32918786|NCT03467906||Weight loss < median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
32918787|NCT03467906||Weight loss > median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
32918788|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
32918789|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
32918790|NCT05671874|Experimental|Web-based Decision Aid + Communication (DA+C) tool|Surrogate(s) will read/click through the DA+C tool prior to the clinician-family meeting and complete the integrated worksheet. Surrogate(s) will have unlimited access to the DA+C tool and may return to the tool and edit the worksheet at any time.
32718035|NCT04459429|Experimental|NHF by smaller cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the smaller cannula
32718036|NCT04459429|Experimental|NHF by larger cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the larger cannula
32718037|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
32918791|NCT05671874|No Intervention|Usual Care|No decision aid
33247989|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
33247990|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
33247991|NCT00407797|Experimental|Pregabalin|
33247992|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
33247993|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
32718038|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
32718039|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
33247994|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
32718040|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
32718041|NCT04459039|Experimental|Fluid restriction|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
32718042|NCT04459039|Placebo Comparator|Non-fluid restriction|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously
32718043|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
32718044|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
32718045|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
32718046|NCT03476005|No Intervention|Historical controls|no extra training provided
32718047|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
32718048|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
32718049|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
32918800|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
32918801|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
32918802|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
32918803|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
32918804|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
32918805|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
32918806|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
32918807|NCT03949335|Experimental|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
32918808|NCT03949335|Active Comparator|Control|Bilateral implantation with control IOL Model ZCB00
32918809|NCT05314257|Active Comparator|Group G|IV granisetron 1mg
32718050|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
32718051|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
32718052|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
32718053|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
32718054|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32718055|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32718056|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32718057|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32718058|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32718059|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32918810|NCT05314257|Placebo Comparator|Group C|IV 5ml of 0.9% normal saline
32918811|NCT03690375|Experimental|BBL Left|Left arm selected to be treated with BBL, right arm not treated
32918812|NCT03690375|Experimental|BBL Right|Right arm selected to be treated with BBL, left arm not treated
32918813|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
32918814|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
32718060|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
32918815|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.~Phase II (part 2) - low carb diet:~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
32918816|NCT04234425|Experimental|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
32918817|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
32918818|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
32918819|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
32918820|NCT02354586|Experimental|Niraparib|
32918821|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
32918822|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33399888|NCT05420766|Experimental|Shortened Sleep|In this 4-week sleep protocol, children in this experimental condition follow a Stabilized Sleep schedule (i.e., their usual bed time) during weeks 1, 3 and 4. During week 2, they follow a Shortened Sleep schedule, during which they go to bed 90 later than is typical.
33399889|NCT05420766|Active Comparator|Usual Sleep Schedule|In this control arm of the 4-week sleep protocol, children follow the Stabilized Sleep schedule for all 4 weeks.
32918823|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
32918824|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
32918825|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
32918826|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
32918827|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32918828|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32918829|NCT03440450|Experimental|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32918830|NCT03440450|Experimental|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32918831|NCT03440450|Experimental|Expansion Cohort: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with biliary tract cancer: FF-10832 Gemcitabine Liposome Injection, RP2D administered intravenously (IV) on Day 1 of each 21-day cycle
32918832|NCT04196907|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
32918833|NCT05668754|Experimental|Experimental: SDX|SDX capsules at the optimized daily dose, once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
32918834|NCT05668754|Placebo Comparator|Active Comparator|Placebo capsules once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
32918835|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
32918836|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
33399890|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
33399891|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
33399892|NCT05420610||Patients with major burn.|Adult patients (age > 18 years) suffered from major burn which defined as total burned surface area (TBSA) > 20% with at least second degree burn depth were admitted to the intensive care unit (ICU) of the Burn Center at a tertiary medical center were retrospectively reviewed.
32918837|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
32918838|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
32918839|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
32918840|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
32918841|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
32918842|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
32918843|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
32918844|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
32918845|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
32918846|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
32918847|NCT03708393|Active Comparator|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
32918848|NCT03708393|Experimental|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
32918849|NCT03946059|Experimental|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
32918850|NCT03946059|Experimental|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
32918851|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
32918852|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
32918853|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
32918854|NCT03937791|Experimental|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
32918855|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
32918856|NCT04173429|Experimental|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
32918857|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
32918858|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
32918859|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
32918860|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
32918861|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
32918862|NCT04167189|Other|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
32918863|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
32918864|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
32918865|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
32918866|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
32918867|NCT04149405|Active Comparator|Group A|"Subjects with chronic periodontitis and osteoporosis.~Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
32918868|NCT04149405|Active Comparator|Group B|"Subjects with chronic periodontitis and systemically healthy.~Phase 1 periodontal theraphy was administered to the subjects."
33247995|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
33247996|NCT00903526||candidemia|
32918869|NCT04149405|Active Comparator|Group C|"Subjects with periodontally healthy and osteoporosis.~Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
32918870|NCT04149405|No Intervention|Group D|"Systemically and periodontally healthy controls~No intervention has been made."
32918871|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
32918872|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
32918873|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
32918874|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
32918875|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
32918876|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
32918877|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
32918878|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
33399893|NCT05420532|Experimental|Exergaming Group|A video game-based physical activity training will be applied under a physiotherapist supervision for 1 days/week for 8 weeks.
32918879|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
32918880|NCT04350320|Experimental|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.~+ standard therapy for COVID-19 according to the stablished hospital protocols."
32918881|NCT04350320|Placebo Comparator|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
32918882|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
32918883|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
32918884|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
32918885|NCT05314491||Multigen Plus CCK|
32918886|NCT05314491||Multigen Plus CCK in combination with AMF TT cones|
32918887|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
32918888|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
32918889|NCT00556322|Experimental|1|
32918890|NCT00556322|Active Comparator|2|
32918891|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
32918892|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
32918893|NCT05664386|Active Comparator|propofol group|According to grouping，patients were premeditated with injection of Propofol 2-2.5mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is >60, propofol 1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.Then propofol was maintained in group P at 4-12 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min .BIS was kept at 40 ~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
32918894|NCT05664386|Experimental|ciprofol group|Group C was given ciprofol 0.4 ~ 0.5mg/kg, if bispectral index(BIS) value ≤60 during anesthesia induction, cisatracurium 0.2mg/kg and sufentanil 0.5μg/kg were injected intravenously, endotracheal intubation was performed after the improvement of muscle relaxation. If the BIS value was greater than 60, ciprofol 0.2mg/kg each time, and the interval of administration was greater than 1min, until BIS≤60. Cisatracurium and sufentanil were injected intravenously, followed by endotrachealintubation.Ciprofol was maintained in Group C at 0.8-2.5 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min . Intermittent addition of cisatracurium,Sufentanil was added as required, and total dosage of Sufentanil was 0.7ug ~ 1ug/kg. BIS was kept at 40 ~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
32918895|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
32918896|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
32918897|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
32918898|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
33399894|NCT01568580|Experimental|test drug|GreenGene
33399895|NCT05175859||Early tracheostomy|Tracheostomy time before day 10 following endotracheal airway management and invasive ventilation.
33399896|NCT05175859||Late tracheostomy|Tracheostomy time after day 11 following endotracheal airway management and invasive ventilation.
33399897|NCT04107870|Experimental|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
32918899|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
32918900|NCT01869686|Experimental|Denosumab|single subcutaneous injection
32918901|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
32918902|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
32918903|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
32918904|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
32918905|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
32918906|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
32918907|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
32918908|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
32918909|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
32918910|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
32918911|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
32918912|NCT03739983|Experimental|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
32918913|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
32918914|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
32918915|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
33399898|NCT04107870|Active Comparator|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
33399899|NCT05175703|Other|the infrainguinal arteries disease group|Actual patient group with any atherosclerotic change in the infrainguinal arteries
33399900|NCT04102800|Other|Treatment|Benralizumab 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150
32718061|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
32718062|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
32718063|NCT05204849|Active Comparator|Active irrigation and aspiration|Patients randomized to IRRAflow will receive a ventricular catheter with active irrigation and aspiration.
32718064|NCT05204849|Active Comparator|Standard passive external ventricular drainage|Patients randomized to passive external ventricular drainage will receive a standard EVD.
32718065|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
32718066|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
33399901|NCT05175547|Active Comparator|Intensive blood pressure management group|Target blood pressure of 90-120mmHg (Intensive BP management group)
33399902|NCT05175547|Active Comparator|Standard blood pressure management group|Target blood pressure of 90-160mmHg (Standard BP management group)
32718067|NCT00517049|Experimental|1|
32718068|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
32718069|NCT00514865|Experimental|E1|1-2 mg of ONO-2333
32918916|NCT03764007|Experimental|18F-Fluorocholine PET|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
32918917|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
32918918|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
32918919|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
32918920|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
32918921|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
33399903|NCT03632226||1|Healthy Volunteers
33399904|NCT05682703||EBV virus infector|QPCR/EBV antibody, diagnosed as EBV infection patient
32918922|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
32918923|NCT03360890|Experimental|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
32918924|NCT03360890|Experimental|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
32918925|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
32918926|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
32918927|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
32918928|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
33247997|NCT03991234|Experimental|Coordinated Reading and Math Intervention|Coordinated intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction addressing similar skills as those addressed in the reading intervention arm & similar skills as the math intervention arm.
33247998|NCT03991234|Active Comparator|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction designed to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
33073322|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
33247999|NCT03991234|Active Comparator|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge, counting strategies, and arithmetic skill.
33248000|NCT03991234|No Intervention|Business-as-usual Control|Participation in the school's typical reading and math classroom instruction and, if designated by the school, its supplemental program.
33248001|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
33248002|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
33248003|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
33248004|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
33248005|NCT00924274|Experimental|Lifestyle counseling|
33248006|NCT00924274|Active Comparator|sunflower oil|
33248007|NCT00903838|Experimental|1|
33248008|NCT00903838|Active Comparator|2|
33248009|NCT00924430|Other|1|
32918929|NCT01874132|Experimental|Aerobic exercise training|Dose response
32918930|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
32918931|NCT01874132|No Intervention|Control|Non-exercising control group
32918932|NCT02332590|Active Comparator|Adalimumab 40 mg/Sarilumab 200 mg|Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than [<] 20% improvement from baseline in tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
33073325|NCT02639273|Experimental|Drug|single dose nalmefene
33073326|NCT02639273|Placebo Comparator|Placebo|single dose placebo
33248010|NCT00924430|Other|2|
33248011|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
33248012|NCT00924586|Placebo Comparator|P|
33248013|NCT00924586|Experimental|E|
33248014|NCT00568126|Experimental|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
33248015|NCT00568126|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
33248016|NCT00903994|Other|Single Arm|Single Arm
33248017|NCT00924742|Experimental|Test drug|
33248018|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
33248019|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
33248020|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
33248021|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
33399905|NCT05682703||nasopharyngeal carcinoma patients|Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)
33399906|NCT05682703||Healthy people|healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism
32918933|NCT02332590|Experimental|Sarilumab 200 mg/Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during the DB period. The dosing frequency of placebo for adalimumab was adjusted to 40 mg qw dosing in case of participants with inadequate response (<20% improvement from baseline in TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in OLE period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
32918934|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
32918935|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
32918936|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
32918937|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
32918938|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
32918939|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
32918940|NCT01874756|Experimental|LY500307 25mg|LY500307 25mg
32918941|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
32918942|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
32918943|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
32918944|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
32918945|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
32918946|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
32918947|NCT05656586||Participants|"Inclusion criteria for all aims/experiments~Receiving DBS therapy in GP for treatment of PD~Implanted with Medtronic Percept DBS system~At least 3 months since initial activation of the neurostimulator"
32918948|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
32718070|NCT00514865|Experimental|E2|5-10 mg of ONO-2333
32718071|NCT00514865|Placebo Comparator|P|placebo comparator
32718072|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
32718073|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
32718074|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
32718075|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
32718076|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
32918949|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
32918950|NCT00554840|Active Comparator|varenicline|
32718077|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
32718078|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
32718079|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
32918951|NCT00554840|Placebo Comparator|placebo|
32918952|NCT05652140||High-Risk with increased CRF|ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
32918953|NCT05652140||High-Risk with decreased CRF|ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
32918954|NCT05652140||Low-Risk with increased CRF|Non-ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
32918955|NCT05652140||Low-Risk with decreased CRF|Non-ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
32918956|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
33073327|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
33073328|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
33399908|NCT05664919|Experimental|Drug group|3500 participants will use SA58 Nasal Spray in drug group.
33399909|NCT05664919|No Intervention|Blank control group|3500 participants won't be given medication in blank control group.
33399910|NCT05646901||Premenopausal women with obesity|
33399911|NCT05646901||Postmenopausal women with obesity|
32766738|NCT04400695|Experimental|RC48-ADC|RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
32766739|NCT04400695|Active Comparator|Physician's Choice|"Physician's Choice:~HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.~Physician's choice from the following options:~Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets"
32766740|NCT05255809|Experimental|Alexander Technique + Routine Physical Therapy|Routine Physical Therapy+Alexander Technique Verbal Instructions in Trunk stabilising exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
32766741|NCT05255809|Placebo Comparator|Control Group|Routine Physical Therapy duration: two days a week for 16 weeks. Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes.
32766742|NCT05239351|Experimental|Jalucomplex 1|Sixteen patients will be administered Jalucomplex® 1 for the treatment of minor-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
32766743|NCT05239351|Experimental|Jalucomplex 2|Sixteen patients will be administered Jalucomplex® 2 for the treatment of medium-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
32766744|NCT05239351|Experimental|Jalucomplex 3|Sixteen patients will be administered Jalucomplex® 3 for the treatment of major-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
32766745|NCT04182061|Experimental|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
32766746|NCT04182061|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
32766747|NCT05230147|Experimental|Spinal cord stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define the stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. Stimulation is initiated within 2 min before tilting the table. Then verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
32766748|NCT05230147|Sham Comparator|Sham stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. No stimulation is initiated. Two minutes after, verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
32766749|NCT05229055|Active Comparator|Intranasal ketamine|Ketamine solution 250 mg/5ml was used. It was applied intranasally using a nasal spray pump whereeach spray delivered approximately 0.4 ml of solution corresponding to 20 mg of ketamine. After initial evaluation, each patient having the inclusion criteria receives one pulverisation (0.4 ml) per nostril of ketamine corresponding to a total dose of 20 mg of ketamine. Ketamine dosing was based on previous reports of intranasal ketamine use in ED patients, doses ranged from 0.45mg/kg to 1.25mg/kg (9).
32766750|NCT05229055|Active Comparator|subcutanous ketamine|Ketamine dosing by subcutanous route was based on previous reports use for post operative pain management. . The results of these reports revealed that low-dose ketamine 20-60 mg (0.5mg/kg for patients weighing 40-120 kg) showed an over all decrease in either the amount of opioid used or the amount of pain experienced (10, 11).For our study, we decided to chose a dose of 20mg of ketamine for all patients administered via 1ml insulin syringe once subcutaneously.
32766751|NCT04227301||Hyponatremic patients|Patients hospitalized at the University Hospital of Basel and presenting with hyponatremia will be screened for the study
32766752|NCT05214547|Experimental|Experimental Group|The patients received shock-wave exposure (energy flux density= 0.12 mJ/mm2, at 8 Hz), twice a week, for six weeks. Standard physiotherapy care was applied.
32766753|NCT05214547|Placebo Comparator|PlaceboGroup|In the placebo group, the device applicator was positioned in the same way as the experimental shock-wave group. The previously recorded 8 Hz pulsed shock wave sounds were played, as if the actual application was being performed, however the device itself was off during the session, and its pedal was not pressed. Standard physiotherapy care was applied.
32766754|NCT05207059|Experimental|Study Arm|The intervention will comprise four modules, namely the HELMS Journey, HELMS Model, HELMS Lifestyle and HELMS Community. The HELMS Journey will provide anticipatory guidance for both HELMS and routine clinic visits. The HELMS Model will deliver the 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management') care plan, detailed below. The HELMS Lifestyle will provide lifestyle support in terms of healthy eating through the 6P tool ('Portion', 'Proportion', 'Pleasure', 'Phase', Physicality', 'Psychology'), physical activity, sleep and mental well-being. Finally, the HELMS Connection will provide community support and improve engagement with the program.
32766755|NCT05205499|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
32918957|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
32918958|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
32918959|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
32718080|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
32718081|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
32918960|NCT05646836|Experimental|Arm A: Dose-Escalation and Expansion: XmAb24306+Cevostamab|Participants will receive escalating doses of XmAb24306 with a fixed dose regimen for cevostamab up to the maximum tolerated dose (MTD). After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled.
32918961|NCT05646836|Experimental|Arm B: Single-Agent Cevostamab Expansion|Participants will receive cevostamab alone.
32918962|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32918963|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
32918964|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
32918965|NCT03881007|Experimental|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
32918966|NCT03881007|Experimental|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
32918967|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
32918968|NCT00554606|Experimental|Canakinumab|Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.
32918969|NCT04332159|Experimental|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
32918970|NCT04332159|Placebo Comparator|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
32918971|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
32918972|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
32918973|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
32718082|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
32718083|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
33399912|NCT05646901||Men with obesity|
33399913|NCT05646901||Premenopausal women without obesity|
33399914|NCT05646901||Postmenopausal women without obesity|
33399915|NCT05646901||Men without obesity|
32718084|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
32918974|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
32918975|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
32918976|NCT04350476|Other|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:~VitalConnect Vital Sign Patch (FDA approved for this indication)"
32918977|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
32918978|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
32718085|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
32918979|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
32918980|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
32918981|NCT00554216|Placebo Comparator|Placebo|Placebo to match
32918982|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
32918983|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
32918984|NCT03040856|Experimental|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
32918985|NCT03040856|Experimental|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
32918986|NCT03040856|Placebo Comparator|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
32918987|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
32918988|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
32918989|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
32918990|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
32718086|NCT04471103|Experimental|Real-Time Delphi Method|The Real-Time Delphi Method involves a single-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant once they have rated an outcome. They can then modify how they rated the outcome based on this feedback if they wish. Participants can also re-visit and re-rate outcomes as many times as they wish when the survey is live. Duration will span approximately 5 weeks.
32718087|NCT04471103|Active Comparator|Multi-round Delphi Method|The Multi-Round Delphi Method involves a three-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant at the end of Round 1 and the end of Round 2. Participants can then modify how they rated the outcome based on feedback, in Rounds 2 and 3, if they wish. Each survey Round will run for 3 weeks approximately. In between survey Rounds, there will be a downtime of approximately 10 days before providing feedback and a further 7 days before starting the next round. Duration will span approximately 14 weeks.
32718088|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
32718089|NCT02284295||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to aromatic hydrocarbons"
32718090|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
32718091|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
32718092|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
32718093|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
32718094|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
32918991|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
33399916|NCT03328650||Proximal Humerus Fracture Patients|As part of their routine care, patients who have experienced a proximal humerus fracture that requires operative fixation will receive the A.L.P.S® Proximal Humerus Plating System. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
32718095|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
32718096|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
32718097|NCT00513617|Placebo Comparator|Placebo|No Arginine
32718098|NCT00511043|Experimental|All pts|PTK787
32718099|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
32718100|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
32718101|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
32718102|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
32718103|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
32718104|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
32718105|NCT02482298|Experimental|Dose A|
32718106|NCT02482298|Experimental|Dose B|
32718107|NCT02482298|Placebo Comparator|Placebo|
32718108|NCT02284607|Experimental|MHAA4549A higher dose|
32718109|NCT02284607|Experimental|MHAA4549A lower dose|
32718110|NCT02284607|Placebo Comparator|Placebo|
32718111|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
32718112|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
32718113|NCT04470479|Experimental|Pilocarpine Hydrochloride|Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
32718114|NCT04470479|Placebo Comparator|placebo|Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks
32718115|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
32718116|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
32718117|NCT00385697|Experimental|1|
32718118|NCT00385697|Experimental|2|
32718119|NCT00385697|Experimental|3|
32718120|NCT00385697|Placebo Comparator|4|
32718121|NCT00383513|Experimental|Epratuzumab|
32718122|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
32718123|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
32718124|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
32718125|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
32718126|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
32718127|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
32718128|NCT00440531|Active Comparator|3|ENGERIX-B™
32718129|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
32718130|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
32718131|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
32718132|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
32918992|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
33248022|NCT05014282|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with their state's tobacco quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
33248023|NCT05014282|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
33248024|NCT00904228|Experimental|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
33248025|NCT00904228|Active Comparator|Stockinet Cap|Usual practice
33248026|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
33248027|NCT00924976|No Intervention|2|Representative payeeship as usual
33248028|NCT03824860|Experimental|Yoga Program|Eight-weeks, therapist and self-guided yoga
33248029|NCT03824860|No Intervention|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
33248030|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
32718133|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
32718134|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
32718135|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
32718136|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
32718137|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
32718138|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
32718139|NCT00375401|Experimental|CP-945,598 Treatment A|
32718140|NCT00375401|Experimental|CP-945,598 Treatment B|
32718141|NCT00375401|Placebo Comparator|Placebo|
32718142|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
32718143|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
32918993|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
32918994|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
32918995|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
32918996|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
32918997|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
32918998|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
32918999|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
32919000|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
32919001|NCT02352090|Active Comparator|Progestin-Only|Dienogest
32919002|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
32919003|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
32919004|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
33248031|NCT01037101|Active Comparator|IVET+DCS|
33248032|NCT01037101|Experimental|VRET+DCS|
33248033|NCT01037101|Experimental|VRET+Placebo|
33248034|NCT01037101|Active Comparator|IVET+Placebo|
33248035|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
33248036|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
33248037|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
33248038|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
32718144|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
32718145|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
32718146|NCT00432185|Active Comparator|1|One day treatment
32718147|NCT00432185|Active Comparator|2|Two day treatment
32718148|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
32718149|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
32718150|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
32718151|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
32718152|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
32718153|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
32718154|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
32718155|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
32718156|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
32718157|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
32718158|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
32718159|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
32718160|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
32718161|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
32718162|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
32718163|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
32718164|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
32919005|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
33248039|NCT01788553||patients with generalized anxiety disorder|
32919006|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
32919007|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
32919008|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
32919009|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
32718165|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
32919010|NCT03847233|Experimental|Jetstream Atherectomy System|
32919011|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
32919012|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
32919013|NCT05566964||ME&MGopen|Use of ME&MGopen mobile app, at home for 12 months
32919014|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
32919015|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
32919016|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
32919017|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
32718166|NCT04470557||Patients with COVID-19|The patients will be subjected to to laboratory analyses, a number of hematological, immunological and biochemical parameters like total leucocytic count and differential count of CBC, ESR, D- dimer levels in plasma, CRP, serum urea and creatinine levels, serum levels of AST, ALT liver enzymes, serum ferritin levels Also, CT scan of chest, clinical assessment and the severity and course of the disease.
32718167|NCT00372437|Experimental|1|
32718168|NCT00369473|Experimental|1|350
32718169|NCT00369473|Experimental|2|350
32718170|NCT04470791|Experimental|F(ab')2 antivenom plus local cryotherapy.|Group A: patients with a Crotalus snakebite, and grade II envenomation received F(ab')2 antivenom therapy and application of local cryotherapy.
32718171|NCT04470791|Active Comparator|F(ab')2 antivenom.|Group B: patients who received only F(ab')2 antivenom therapy.
32718172|NCT00425321|Experimental|RWJ-445380 100 mg|
32718173|NCT00425321|Experimental|RWJ-445380 200 mg|
32718174|NCT00425321|Experimental|RWJ-445380 300 mg|
32718175|NCT00425321|Placebo Comparator|Placebo|
32718176|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
32718177|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
32718178|NCT00422981|Placebo Comparator|Placebo|Placebo
32718179|NCT00360035|Experimental|GX15-070MS|Obatoclax mesylate 60mg
32718180|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
32718181|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
32718182|NCT00417287|Active Comparator|High dose|128 mg/m2
32718183|NCT00417287|Active Comparator|Low dose|54 mg/m2
32718184|NCT00356681|Placebo Comparator|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
32718185|NCT00356681|Experimental|Arm B Experimental|Blinded AMG 706 plus paclitaxel
32718186|NCT00356681|Active Comparator|Arm C Comparator|Open-label bevacizumab plus paclitaxel
32718187|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
32919018|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
32919019|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
32919020|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
32919021|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
32919022|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
32919023|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
32919024|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
32919025|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
32919026|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
32919027|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
32919028|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
32919029|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
32919030|NCT04714203||cohort|Sarcopenia assessment
32919031|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
32919032|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
33248040|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
32919033|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
32919034|NCT05602766||NGENLA (Somatrogon)|Patients with GHD without epiphyseal closure who received NGENLA (Somatrogon)
32919035|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
32919036|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
32919037|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
32919038|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
32919039|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
32919040|NCT02989142|No Intervention|Control arm|No intervention
32919041|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
32919042|NCT04016259|Experimental|Self-CES|
32919043|NCT04016259|Placebo Comparator|Sham-CES|
32919044|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
32919045|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
32919046|NCT00552188|Placebo Comparator|Placebo|Matching placebo
32919047|NCT05546294|Experimental|RA patients receiving aerobic and home exercise|A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients. Then the patients were showed a daily home exercise program to apply once a day at their home.
32919048|NCT05546294|Active Comparator|RA patients receiving only home exercise|The patients were showed only a daily home exercise program to apply once a day at their home.
32919049|NCT05546294|Other|Healthy control group|There is no intervention to this group.
32919050|NCT00377793|Experimental|Arm 1|
32919051|NCT00377793|Placebo Comparator|Arm 2|
32919052|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
32919053|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
32919054|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
32919055|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
32919056|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
32919057|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
32919058|NCT00552110|Active Comparator|Mometasone|MFNS once daily
32718188|NCT00417209|Experimental|Larotaxel (XRP9881)|
32718189|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
32919059|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
32919060|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
32919061|NCT05594888||PART 1- Group A|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability of maximum isometric grip strength assessed with:~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [kPa]"
32919062|NCT05594888||PART 1 - Group B|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability and assessment of intersession reliability of maximum isometric grip strength assessed with:~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [kPa]"
32919063|NCT05594888||PART 2|"Male and female volunteers (age ≥ 10 years).~Maximum isometric grip strength is assessed (no intervention):~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [KPa]"
33073329|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
32919064|NCT05313789||Intensive Care Patients (Cardiovascular)|Intensive care unit patients, mechanically ventilated and lacking communication. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
32919065|NCT05313789||Intensive Care Patients (Internal diseases)|Intensive care unit patients, both mechanically ventilated and lacking communication and mechanically ventilated and conscious. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
32919066|NCT05313789||Intensive Care Patients (Obese)|Intensive care unit patients. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
32919067|NCT02051972||Indicated for a VVI(R) pacemaker|
32919068|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
32919069|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
32919070|NCT05524610|No Intervention|Pre-Implementation of Routine Sexual Function Screening (Baseline)|This arm will include patients with and surviving cancer who are seen during the Pre-Implementation study period. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The pre-implementation survey will assess sexual function communication and patient satisfaction. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
32919071|NCT05524610|Experimental|Post-Implementation of Routine Sexual Function Screening|This arm will include patients with and surviving cancer who are seen during the Post-Implementation study period, once the routine sexual function screening intervention has been implemented. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The post-implementation survey will assess sexual function communication and patient satisfaction, as well as measures of acceptability, feasibility, and appropriateness of the intervention. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
32919072|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
32919073|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
32919074|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
32919075|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
32919076|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
32919077|NCT03860181|Active Comparator|Metal staples - Surgeon 2|Metal staples
32919078|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
32919079|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
32919080|NCT03250520|Experimental|glioma brain stem|
32718190|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
32718191|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
32718192|NCT03789773|Experimental|Diagnostic (holographic mm-wave imaging)|Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.
32718193|NCT04470635||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
32718194|NCT04470635||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
32718195|NCT04470635||Healthy children with gingivitis|Systemically healthy children with gingivitis
32718196|NCT04470635||Healthy children and healthy gingiva|Systemically healthy children with healthy gingiva
32718197|NCT04470167|Experimental|TPX-115|Subjects receive ultrasound-guided intratendinous injection of TPX-115
32718198|NCT04470167|Placebo Comparator|Placebo|Subjects receive ultrasound-guided intratendinous placebo injection
32718199|NCT04470401|Placebo Comparator|Placebo|Abobotulinumtoxina 400 IU in 2cc of saline solution
32718200|NCT04470401|Experimental|Abobotulinumtoxina - 400IU|placebo (2cc of saline solution)
32718201|NCT00355355|Experimental|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
32718202|NCT00355355|Active Comparator|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
32718203|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
32718204|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
32718205|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
32718206|NCT00351767|Experimental|1|
32718207|NCT00351767|Experimental|2|
32718208|NCT00351767|Experimental|3|
32718209|NCT00351767|Placebo Comparator|4|
32718210|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
33248041|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
33248042|NCT01040377||Inadequate initial weight loss after gastric bypass|
33248043|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
33248044|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
33248045|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
33248046|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
33248047|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
33248048|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
33248049|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
33248050|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
33248051|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
33248052|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
33248053|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
32718211|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
32718212|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
32718213|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
32718214|NCT02287649|Other|patients with rituximab treatment|blood sample intake
32718215|NCT00344045|Active Comparator|A|
32718216|NCT00344045|Placebo Comparator|B|
32718217|NCT02256436|Active Comparator|Control|Participants receive paclitaxel 175 mg/m^2 intravenously (IV) or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
32718218|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
32718219|NCT00343109|Experimental|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
32718220|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32718221|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
32718222|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
32718223|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
32718224|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
32718225|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
32718226|NCT00336713|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
32718227|NCT00336713|Placebo Comparator|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
32718228|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
32718229|NCT00332657|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
32718230|NCT00332657|Experimental|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
32718231|NCT00332657|Sham Comparator|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
32718232|NCT03133949||Patients with idiopathic inflammatory aortitis|
32718233|NCT03133949||a group of witnesses|
32718234|NCT00330473|Experimental|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
32718235|NCT00330473|Active Comparator|2|Treatment Options available on the market.
32718236|NCT00327743|Experimental|larotaxel + Capecitabine|
32718237|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
32718238|NCT02284997|No Intervention|Control|No treatment
32718239|NCT00326183|Active Comparator|1|Arm 1: vaccine
32718240|NCT00326183|Active Comparator|2|Arm 2: Active comparator
32919081|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
32919082|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
32919083|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
32919084|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
32919085|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
32919086|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
32919087|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
32919088|NCT03223610|Experimental|Arm 1: Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
32919089|NCT03223610|Experimental|Arm 2: Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
32919090|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
32919091|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
32919092|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
32919093|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
32919094|NCT03193190|Active Comparator|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
33248054|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
33248055|NCT00925210|Experimental|Sequential pEBUS - ENB|
32718241|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
32718242|NCT00322517|Experimental|SU014813|
32718243|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
32718244|NCT02285231|Experimental|Placebo|Placebo Supplementation
32718245|NCT00321815|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
32718246|NCT00321815|Active Comparator|B|Standard of Care chemotherapy
32718247|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
32718248|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery~12 patients aged over 15 years, operated more than 10 years before"
32718249|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery~100 parents of patients, 5 years after the operation~100 patients aged over 15 years and operated over 10 years ago"
32718250|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
32718251|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
32718252|NCT00309179|Experimental|1|
32718253|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
32718254|NCT00394199|Experimental|1|FlutiForm 100/10ug
32718255|NCT00394199|Experimental|2|Fluticasone 100
32718256|NCT00394199|Active Comparator|3|Formoterol 10
32718257|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
32718258|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
32718259|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
32718260|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
32718261|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
33248056|NCT04604821|Experimental|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
32718262|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
32718263|NCT00309023|Experimental|dose escalation|
32718264|NCT05202041|Experimental|AccuFFRangio Group|NSTE-ACS patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
32718265|NCT05202041|Active Comparator|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.
32718266|NCT00303251|Experimental|TKI258|
32718267|NCT00299507|Experimental|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
32718268|NCT00299507|Experimental|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
32718269|NCT00299507|Experimental|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
32718270|NCT00299507|Sham Comparator|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
32718271|NCT02285309||Cardiac surgery|
32718272|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
32718273|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
32718274|NCT00297401|Experimental|1|
32718275|NCT00297401|Placebo Comparator|2|
32718276|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
32718277|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
32718278|NCT00297089|Active Comparator|A|Pemetrexed + ABT-751
32718279|NCT00297089|Placebo Comparator|B|Pemetrexed + placebo
32718280|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
32718281|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
32718282|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
32718283|NCT00286793|Experimental|SIngle Arm Study of AT-101 in combination with Docetaxel|
32718284|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
32718285|NCT02285465|Placebo Comparator|Placebo cohort|
32718286|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
32718287|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
32718288|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
32718289|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
32718290|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
32718291|NCT03133637||Ceftriaxone Arm|
32718292|NCT00267371|Active Comparator|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
32718293|NCT00267371|Active Comparator|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
32718294|NCT00254891|Experimental|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
32718295|NCT00254891|Active Comparator|B|Standard of care chemotherapy
32919095|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
32919096|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
32919097|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + AB928|Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
32919098|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
32919099|NCT03193190|Experimental|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
32919100|NCT03193190|Experimental|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
32919101|NCT03193190|Experimental|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
32919102|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
33399917|NCT05175079|Experimental|Accupressure group|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
32718296|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
32718297|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
32718298|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
32718299|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
32718300|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
32718301|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
32718302|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
32718303|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
32718304|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
32718305|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
32718306|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
32718307|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
32718308|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
32718309|NCT00254579|Experimental|15 mg/kg CP-675,206|
32718310|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
32718311|NCT02288585|Active Comparator|Plant sterols|Plant sterols
32718312|NCT02288585|Placebo Comparator|Placebo product|Placebo product
32718313|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
32919103|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
32919104|NCT03193190|Active Comparator|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
32919105|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab|Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
32919106|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + LSTA1|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Day 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV on Days 1, 8, and 15 of each 28 day cycle; LSTA1 3.2 mg/kg slow IV push on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV on Days 1, 8, and 15 of each 28 day cycle.
32919107|NCT03193190|Experimental|Cohort 1: Chemotherapy + LSTA1|Cohort 1: Participants will receive Nab-paclitaxel 125 mg/m^2 IV on Days 1, 8, and 15 of each 28 day cycle; LSTA1 3.2 mg/kg slow IV push on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV on Days 1, 8, and 15 of each 28 day cycle.
32919108|NCT00377481|Experimental|1|
32919109|NCT00377481|Active Comparator|2|
32919110|NCT00377559|Experimental|1.|Myocet+docetaxel
32919111|NCT04834778|Experimental|Cohort 1 - 25 mg|25 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919112|NCT04834778|Experimental|Cohort 2 - 50 mg|50 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919113|NCT04834778|Experimental|Cohort 3 - 100 mg|100 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919114|NCT04834778|Experimental|Cohort 4 - 200 mg|200 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919115|NCT04834778|Experimental|Cohort 5 - 400 mg|400 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919116|NCT04834778|Experimental|Cohort 6 - 600 mg|600 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919117|NCT04834778|Experimental|Cohort 7 - 900 mg|900 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919118|NCT04834778|Experimental|Cohort 8 - 300 mg|300 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
32919119|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
32919120|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
32919121|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
32919122|NCT04811924|Active Comparator|CXL with MMC|Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
32919123|NCT04811924|Placebo Comparator|CXL without MMC|Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).
32919124|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
32718314|NCT00231257|Experimental|1|Cypher Bx Velocity
32919125|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
32919126|NCT04786262|Experimental|VX-880|
32919127|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
32919128|NCT04773080||esophageal cancer surgery|patients undergoing elective esophageal surgery for cancer
32919129|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
32919130|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
32919131|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
32919132|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
32718315|NCT00231257|Active Comparator|2|Brachytherapy
32919133|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
32718316|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
32718317|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
32718318|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
32718319|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
32718320|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
33248057|NCT04604821|Other|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
33399918|NCT05175079|Placebo Comparator|Control group|
32718321|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
32718322|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
32718323|NCT00206687|Experimental|Arm 1|
32718324|NCT00206687|Sham Comparator|Arm 2|
32718325|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
32718326|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
32718327|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
32718328|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
32718329|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
32718330|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
32718331|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
32718332|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
32718333|NCT05726357|Active Comparator|standard root canal treatment|standard root canal treatment
32718334|NCT05726357|Active Comparator|Pulpotomy|vital pulp therapy
32718335|NCT04470323||COVID19 patients|Patients admitted to Assiut university Hospitals diagnosed as COVID19 positive patients by PCR.
32718336|NCT04470323||healthy volunteer|as negative control for each sample
32718337|NCT04470245|Active Comparator|Healthy volunteers|
32718338|NCT04470245|Active Comparator|Patients undergoing surgery|We will include adults (over 18 years of age) undergoing surgical decompression of the ulnar nerve at the elbow for cubital tunnel syndrome.
32718339|NCT05726045|Active Comparator|HIIT morning|High-intensity interval training (HIIT) in the morning
32718340|NCT05726045|Experimental|HIIT evening|High-intensity interval training (HIIT) in the evening
32718341|NCT05726045|Active Comparator|HIIT morning + CRT|High-intensity interval training (HIIT) in the morning + cognitive remediation treatment (CRT)
32718342|NCT05726045|Experimental|HIIT evening + CRT|High-intensity interval training (HIIT) in the evening+ cognitive remediation treatment (CRT)
32718343|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
32718344|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
32718345|NCT02450552|Placebo Comparator|Placebo|
32718346|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
32718347|NCT02508428|Active Comparator|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
32718348|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
32718349|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
32718350|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
32919134|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
32919135|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
32919136|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
32718351|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
32919137|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
32919138|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
32919139|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
32718352|NCT02447744|Experimental|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
32718353|NCT02447744|Other|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
32718354|NCT04923386||Diabetics who receive mRNA COVID-19 vaccine|Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines
32718355|NCT04200560|Experimental|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
32718356|NCT04200560|Experimental|Healthy Older Adult Subjects|Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
32718357|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
32718358|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
32718359|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
32718360|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
32718361|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
32718362|NCT04940000|Experimental|Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.|
32718363|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
32718364|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
32718365|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
32718366|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
32718367|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
32718368|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
32718369|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
32718370|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
32919140|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
32919141|NCT00377871|Active Comparator|1|Valve design 1
32919142|NCT00377871|Active Comparator|2|Valve design 2
32919143|NCT00377871|No Intervention|Control|Healthy control
32919144|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
32919145|NCT04763408||Lenvatinib|Participants with advanced or unresectable HCC will initiate treatment with lenvatinib capsules based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
32919146|NCT04763408||Sorafenib|Participants with advanced or unresectable HCC will initiate treatment with sorafenib tablets based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
32919147|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
32919148|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
32919149|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
32919150|NCT02351856|Experimental|ARRY-371797|
32919151|NCT03850275|Experimental|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
32919152|NCT03850275|Experimental|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
32718371|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
32718372|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
32718373|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
32718374|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
32718375|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
32718376|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
32766756|NCT03965611||Patients with isolated severe traumatic brain injury (TBI)|TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
32766757|NCT03965611||Patients with severe trauma without TBI|Patients with severe trauma without TBI (AISextrahead score > 3). Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
32766758|NCT03965611||Healthy Controls|"Persons who have not had the conditions being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements.~Oropharyngeal and rectal swabs will be taken only once, at inclusion, after that the participation of the control individual in the trial will be completed."
32766759|NCT05191225|Experimental|Rapid infusion group|After the administration of intravenous premedication (usually dexchlorpheniramine 5 mg IV and paracetamol 1 g IV), rituximab will be administered at standard dose (375 mg/m2 diluted in 250 ml of saline) administered in one hour, divided into: 10 first minutes at 450 mg/hour, and 50 minutes later at 720 mg/hour.
32766760|NCT05191225|Experimental|Ultrarapid infusion group|After the administration of intravenous premedication, the dose of rituximab will be administered at standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
32766761|NCT05191225|Experimental|Ultrarapid plus infusion group|After the administration of oral premedication, the dose of rituximab will be administered at the standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
32766762|NCT05189275|Experimental|Cannabidiol 40 mg (CBD40)|Subjects consume beverages with 40mg of CBD.
32766763|NCT05189275|Experimental|Cannabidiol 20 mg (CBD20)|Subjects consume beverages with 20mg of CBD.
32766764|NCT05189275|Experimental|Cannabidiol 0 mg (CBD0)|Subjects consume beverages with 0mg of CBD.
32766765|NCT05189275|Placebo Comparator|Placebo Beverage (PLAC)|Subjects consume calorie matched beverages with 0 CBD.
32766766|NCT05187325||myofascial trigger point and disc displacement with reduction|the participants have myofascial trigger points in master muscle and also temporomandibular joint disc displacement with reduction.
32766767|NCT05187325||disc displacement with reduction|the participants have only temporomandibular joint disc displacement with reduction.
32766768|NCT05185921|Experimental|Cognitive-behavioral therapy virtual|The intervention will be provided by 2 psychotherapists. The total of sessions will be eight carried out weekly, for 2 to 3 months. They will also receive standard treatment, i.e. psychiatric management with or without drugs.
32766769|NCT05185921|No Intervention|Control|They will only receive standard treatment, i.e. psychiatric management with or without drugs.
32766770|NCT03914833||Patients|Patients aged 13 to 25 years old with a concussion in sports practice less than 72 hours previously
32766771|NCT03914833||Control - High-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
32766772|NCT03914833||Control - Non-high-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
32766773|NCT05173051|Experimental|Ability of Swallowing solid placebos vs. a crushed placebo|During routine FEES examination, patients are sequentially being given 3 different solid placebos pills and one crushed placebo mixed with semisolid texture.
32766776|NCT03909217|Experimental|TECAS|Patients will receive transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) daily.
32766777|NCT03909217|Active Comparator|Anti-depressants|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by a clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
32766778|NCT05154331||Women of reproductive age|Women 15-49 years of age
32766779|NCT04769947||Cohort 1|Cohort 1 retrospective/prospective study: 293 patients enrolled and reported in Fava et al 2019 (1) with at least 1 year of follow up at the end of the study (February 2017) and 107 patients enrolled but not reported in Fava et al 2019 since their follow-up was shorter than 1 year. The data for these patients will be collected since the end of previous study.
32766780|NCT04769947||Cohort 2|Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study.
32766781|NCT04769947||Cohort 3|Cohort 3 prospective study: patients who have discontinued TKI therapy after the study approval in each center. These patients will also participate in the validation process of Phase 2 of a questionnaire developed by an expert panel of eight CML patients with the purpose of capturing the experiences of people along all phases of the TFR.
32766782|NCT04914533|Experimental|Intervention Arm|Luminance Red Treatment Arm
32766783|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
32766784|NCT02650921|No Intervention|No Intervention|
32766785|NCT04914143|Experimental|Experimental group|
32766786|NCT04914143|Placebo Comparator|placebo comparator group|
32718377|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
32718378|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
32718379|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
32718380|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
32718381|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
32718382|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
32718383|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
32718384|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
32718385|NCT00687505|Experimental|1|Single ascending doses
32718386|NCT03472417|Active Comparator|Active partial rebreathing device|
32718387|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
32766787|NCT04913987|Experimental|Total knee|Standard care
32766788|NCT04913987|Experimental|Partial knee|Intervention using relatively new partial knee.
32766789|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
32766790|NCT05139589||Infective endocarditis, surgical arm|Patients with infective endocardits requiring valve surgery
32766791|NCT05139589||Infective endocarditis, conservative arm|Patients with infective endocardits, not requiring valve surgery
32766792|NCT05139589||Valve disease, heart, surgically repaired|Patients requiring valve surgery
32766793|NCT04914299|Experimental|A novel mobile-App based intervention|"An App-based positive intelligence intervention consisting of 6 weeks of weekly videos and support group sessions, and 6 weeks of daily App-guided practices."
32766794|NCT04914299|Active Comparator|Standard of Care|Standard prenatal care and follow up
32766795|NCT03801109|Experimental|Hyperbaric group|
32766796|NCT03801109|Experimental|Magnetic group|
32766797|NCT03801109|Active Comparator|Physical group|
32766798|NCT03801109|No Intervention|Baseline group|
32766799|NCT04914221|Experimental|Group I|Period I- comparator / Period II- comparator / Period III-JLP-2002
32766800|NCT04914221|Experimental|Group II|Period I- comparator / Period II- -JLP-2002 / Period III- comparator
32766801|NCT04914221|Experimental|Group III|Period I- JLP-2002/ Period II- comparator / Period III- comparator
32766802|NCT04739449|No Intervention|Control|Two facilities will follow their local protocols for infection prevention, including COVID-19 precautions. We will swab environmental surfaces at these sites to compare outcomes.
32766803|NCT04739449|Experimental|Intervention|"Using a cluster-randomized design, we will test a multimodal aging-friendly intervention including four components (4Cs):~Coaching staff~Cleaning protocols, standardized~Communication with staff and leadership~Collaboration with local expertise~We hypothesize that the implementation of this organizational QI educational program will be associated with lower odds of SARS-CoV-2 transmission to the environment."
32766804|NCT03711877|Experimental|scalp cooling system|'Scalp cooling device' will be used to prevent alopecia during chemotherapy regimen infusion.
32766805|NCT03711877|Active Comparator|cold cap|'Cold cap' will be used to prevent alopecia during chemotherapy regimen infusion.
32766806|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
32766807|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
32766808|NCT05124379|Other|Hemoclin Gel|
32766809|NCT03344263|Experimental|tests of attentional performance|
32718388|NCT05259319|Experimental|Atezolizumab + Tiragolumab + SBRT|"Atezolizumab + Tiragolumab (every 21 days during 24 months or until progression) + SBRT (treatment will be delivered on 5 days).~The combination of SBRT and Immunotherapies will be performed using to different schemes. For the 6 first inclusions the combination will use a sequential scheme. If the safety criteria are respected the following patients will be able to be treated by concomitant scheme."
32718389|NCT05259007|Experimental|Group 1|Group 1 propolis with lactic acid extract on top of the treatment given by doctor
32718390|NCT05259007|Other|Group 2|Grorup 2 Lactic acid extract on top of the treatment by the doctor
32718391|NCT05259007|Placebo Comparator|Group 3|Group 3 the treatment given by the doctor and placebo treatment
32718392|NCT02255656|Experimental|Alemtuzumab|All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
32718393|NCT00380653|Experimental|sapacitabine low dose|sapacitabine administered every 12 hours for 7 days followed by 14 days of rest or every 12 hours for 3 consecutive days per week for 2 weeks followed by 7 days of rest in patients with advanced leukemias or myelodysplastic syndromes The starting dose is (A) 75 mg twice daily x 7 days followed by 14 days of rest; Evaluated doses: 75mg, 100mg, 125mg, 175mg, 225mg, 275mg, 325mg and 375mg
32718394|NCT00380653|Experimental|sapacitabine high dose|"The starting dose is 375 mg twice daily x 3 consecutive days per week for 2 weeks followed by 7days of rest.~Evaluated doses: 375mg, 425mg and 475mg"
32718395|NCT04099537|Experimental|Approach cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to pull the joystick toward (approach) them when seeing skin stimuli on a computer screen.
32718396|NCT04099537|Experimental|Avoidance cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push the joystick away (avoidance) from them when seeing skin stimuli on a computer screen.
32766810|NCT04892615||Cohort A|The drainage tube was removed on the 5th day after surgery.
32766811|NCT04892615||Cohort B|The drainage tube was removed on the 7th day after surgery.
32766812|NCT05109325|No Intervention|Enhanced usual care + assessment|Daily assessments (without delivery of intervention components) will be conducted with EUC participants and they will receive a brochure with violence, substance use, and mental health resources.
32766813|NCT05109325|Experimental|IntERact|Participants will receive three remotely delivered behavioral therapy sessions (combining motivational interviewing, cognitive behavioral skills training, and care management), with an smartphone APP supporting the therapy and delivering therapeutic content in-between therapy sessions.
32766814|NCT04892381||Lichen Planus group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin
32766815|NCT04892381||Control group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA
32766816|NCT05100121|Experimental|Intervention|The intervention consists of standard care and an app for routine symptom reporting, weekly the first month and thereafter as mutually agreed, at minimum once a month in one year, with instant self-care advice in combination with supportive care with a district nurse. At coaching sessions with the district nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and to plan eventual additional actions needed. The intervention will last for 12 months.
32766817|NCT05100121|No Intervention|Control|The participants in the control group will only receive standard care. Usually after ended curative treatment the follow-up is a blood sample (PSA) every three or six months the first year, this can be handled either by a nurse or a physician in secondary care. Most hospitals also have one physical meeting with a physician three months after ended treatment (Regional Cancer Centers, 2020). All patients are allocated a contact nurse with a telephone number to contact when needed.
32766818|NCT03054779|Experimental|Canola oil|regular canola oil
32766819|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
32766820|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
32766821|NCT04900961|Active Comparator|Intervention|A personalised, resistance-based exercise intervention for patients during the convalescence phase in-hospital through to 3-months post-discharge, a duration reflecting chronic, maintenance treatment studies. To maximise enrolment of eligible patients, the intervention may be initiated in-hospital or in the community post-discharge. Resistance bands may be used according to the exercise guideline.
32766822|NCT04900961|No Intervention|Control|Standard of care treatment
32766823|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
32766824|NCT04892225|Experimental|Intervention group|Individuals in this group will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks.
32766825|NCT04892225|No Intervention|Control group|Randomly assigned Control group will not receive any text message.
32766826|NCT04900649|Experimental|study group|the study group has conducted chest resisted exercise combined with chest expansion exercise in addition to a usual chest physiotherapy. For chest resistance exercise, the children in the study group underwent sequential 12-week chest resistance exercise and chest expansion exercise, three sessions a week. Chest resistance exercises have been consisted of manual resistance exercise and resistance exercise via POWER breath KH2.
32766827|NCT04900649|Experimental|control group|12-week usual chest physiotherapy in form of bilateral vibration and gentle percussion for 3-5 minutes with distal finger phalanges to the upper apical lobes in modified drainage positions, placing the patient in a side-lying position or a prone position to increase oxygenation, at least 2-3 times a week
32766828|NCT04913909|Active Comparator|Dentoblis™ group|In Probiotic group; Dentoblis™, as a test lozenge, contains 4 billion CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota, has been utilized one lozenge a day for 30 days.
32919153|NCT03850275|Experimental|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
32919154|NCT03850275|Experimental|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
32919155|NCT03850275|Experimental|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
32919156|NCT03850275|Experimental|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
32919157|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
32919158|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
32919159|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
32919160|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
32919161|NCT03825939|Active Comparator|Intravenous Tranexamic Acid followed by Intravenous Placebo|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery~IV 0.9% sterile saline"
32919162|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
32718397|NCT04099537|Placebo Comparator|Placebo cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push and pull the joystick towards or away from them (no rule) when seeing skin stimuli on a computer screen.
32718398|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
32919163|NCT00551642|Active Comparator|Inhaled Nitric Oxide (INO)|INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days
32919164|NCT00551642|Placebo Comparator|Placebo|Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.
32919165|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
32919166|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
32919167|NCT05471414|Experimental|Whole-food, Plant-based Diet (WFPBD)|Home-delivered WFPBD meals will be provided to participants, along with nutritional coaching and education. 12 meals a week will be delivered for the first 4 weeks, followed by 6 meals a week for the next 4 weeks. Finally, for the last 18 weeks they will not receive pre-packed meals, but will continue to receive WFPBD coaching. 30 participants are anticipated to be accrued in this arm.
32919168|NCT05471414|Active Comparator|General Nutrition Counseling|Participants will receive general nutritional counseling weekly for the first 4 weeks, followed by monthly nutritional counseling for the following 18 weeks. 30 participants are anticipated to be accrued in this arm.
32919169|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
32919170|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
32919171|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
32919172|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
32718399|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
33248058|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
33248059|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
32718400|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
32718401|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
32919173|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
32919174|NCT04690322|Active Comparator|Extended half-life factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
32919175|NCT04690322|Active Comparator|Non-Factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
32919176|NCT05313399|Active Comparator|control group|the group have open bite caused by non-nutritive sucking habits and treat them with palatal crib.
32919177|NCT05313399|Experimental|experimental group|the group have open bite caused by by non-nutritive sucking habit and treat them with bonded spur.
32919178|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
32919179|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRT|
32919180|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
32919181|NCT05453162|Experimental|Early morning PE|26 participants randomized to 10 weekly PE sessions in early morning (between 07:00-10:00) with homework exposures occurring occur at this same time of day.
32919182|NCT05453162|Experimental|Late afternoon PE|26 participants randomized to 10 weekly PE sessions in late afternoon (16:00 or later) with homework exposures occurring occur at this same time of day.
32718402|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
32718403|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
32919183|NCT04678856|Experimental|Part A and B: Dupilumab|Dupilumab administered every 2 weeks.
32919184|NCT04678856|Placebo Comparator|Part A and B: Matching placebo|Placebo administered every 2 weeks
32919185|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
32919186|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
32919187|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
32919188|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
32718404|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
32718405|NCT05369728|Other|First line coronary scanner group|The patient will benefit from a coronary CT scan in 1st line (evaluation of the coronary anatomy), then according to the result it will be managed according to the CAD-RADS decision algorithm.
32718406|NCT05369728|Other|First line functional test strategy group|The patient benefits from a functional test in 1st line (search for myocardial ischemia by myocardial scintigraphy: SPECT, stress echography, or MRI), then according to the result he will be managed in accordance with the European recommendations.
32718407|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
32718408|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
32718409|NCT03951025|Active Comparator|Melatonin oral administration|Consumption of one tablet with 1 mg of melatonin orally
32718410|NCT03951025|Experimental|Melatonin sublingual administration|Consumption of one tablet with 1 mg of melatonin sublingually
32919189|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
32919190|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
32919191|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
32919192|NCT04671212||Orthopedic Surgery Patients|Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
32919193|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
32919194|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
32919195|NCT04629248|Experimental|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
32919196|NCT04629248|Active Comparator|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
32919197|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
32718411|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
32718412|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
32718413|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
32718414|NCT05646082|Experimental|Open Label|
32718415|NCT05258461|Experimental|The intervention group|The intervention group will receive conventional adverse event management and have access to the smartphone app during chemotherapy.
32718416|NCT05258461|Active Comparator|The control group|The control group will receive conventional adverse event management during chemotherapy. Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience.
32718417|NCT05156749|Experimental|short-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with fiberglass long-arm casts. The investigators were able to demonstrate that in distal metaphyseal forearm fracture, treatment with a short-arm cast is not inferior to a long-arm cast.~Patients are going to receive a short-arm cast for fracture treatment."
32718418|NCT05156749|Active Comparator|long-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with a fiberglass long-arm cast.~Patients are going to receive a long-arm cast for fracture treatment."
32718419|NCT03475615|Experimental|SOXP|
32718420|NCT03475615|Active Comparator|SOX|
32718422|NCT05258383||Lung Neoplasm patients|Lung Neoplasm patients (adults)
32718423|NCT05258383||Pelvic Neoplasm patients|Pelvic Neoplasm patients (adults)
32718424|NCT05258383||Breast Cancer patients|Breast Cancer patients(adults)
32718425|NCT05258383||Ear Nose and Throat (ENT) Cancer patients|Ear Nose and Throat (ENT) Cancer patients (adults)
32718426|NCT05258383||Pediatric Cancer patients|Pediatric cancer patients (under 18 years-old) : neurologic cancer , abdomen cancer, Thorax cancer, Ear Nose and Throat (ENT) Cancer
32718427|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
32718428|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
32718429|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
32718430|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
32766829|NCT04913909|Placebo Comparator|Placebo group|The placebo was indistinguishable in form, size, color, smell and taste from the probiotic lozenge, but contained no bacteria and utilized one lozenge a day for 30 days . Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code.
32766830|NCT04891601|Active Comparator|Group II MA Mesh alone repair|patient use mesh alone as treatment of inguinal hernia
32766831|NCT04891601|Active Comparator|Group I CMD Combined Mesh & darn|patients utilize both mesh and darn repair
32766832|NCT01596335|Experimental|TA-650|
32766833|NCT01596335|Active Comparator|VGIH|
32766834|NCT04891679|Active Comparator|Group A (Titrated OMS)|Titrated oral misoprostol solution
32766835|NCT04891679|Active Comparator|Group B (Static OMS)|Static oral misoprostol solution
32766836|NCT04913831|Experimental|Cerebrolysin|
32766837|NCT04913831|Placebo Comparator|Placebo|
32766838|NCT04900415|Experimental|Vitamin A and smell training|14-day course of daily oral vitamin A 7500µg RAE in combination with smell training three times per day for 4 weeks
32766839|NCT04900415|Active Comparator|Smell training|Smell training three times per day for 4 weeks
32766840|NCT04900415|No Intervention|Control|Observation
32766841|NCT03051035|Experimental|KO-947|
32766842|NCT04900571|Experimental|Nitrofurantoin|Measuring pain score using numerical pain scale post-operatively at different time intervals.
32766843|NCT04900571|Experimental|Calcium Hydroxide|Measuring pain score using numerical pain scale post-operatively at different time intervals.
32766844|NCT04900571|Experimental|Control|Measuring pain score using numerical pain scale post-operatively at different time intervals.
32766845|NCT04900337|Experimental|AMOR 18 Powder & Inhalation|"AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.~AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually)."
32766846|NCT04900337|Placebo Comparator|Placebo|"Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.~Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product."
32766847|NCT04913753|Experimental|No systematic CBEU|Patients will not have bacterial culture performed before double J removal.
32766848|NCT04913753|Active Comparator|Systematic CBEU|Patients will have a systematic urine culture performed before double J removal.
32766849|NCT04900727||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
32766850|NCT04900727||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
32766851|NCT04900727||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
32766852|NCT04900181|Experimental|the same-day discharge surgery|Patients in the the same-day discharge surgery group were admitted to hospital, operated and discharged within 24 hour
32766853|NCT04900181|No Intervention|inpatient surgery|Patients in inpatient surgery follow routine procedures and do not need to be discharged on the same day.
32766854|NCT04913597||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment. After initial treatment, maintenance therapy were performance. At initial therapy, rhTPO will be suspended when platelet counts ≥100×10^9 / L. During maintenance therapy, patients with platelet counts >150×10^9 / L will suspend treatment until platelet counts drop to ≤150×10^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10^9 / L to ≤150×10^9 / L. Dose modification is not required when platelet count is ≥30×10^9 / L to <100×10^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
32766855|NCT04913597||Avatrombopag group|Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled. The reason for switch will be recorded. Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets. The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10^9/L. Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10^9/L and 150×10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
32766856|NCT04891211|Active Comparator|Pediatric endocrinologist|Patient selection by pediatric endocrinologist on the basis of vitamin D
32766857|NCT04891211|No Intervention|Ophthalmologist|"Evaluation of the results by 2 different retina specialists during the examination of patients~Interpretation of the results without knowing the vitamin D level of patients"
32766858|NCT04817189|Experimental|NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg|"Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Dexamethasone (8 mg) will be administered on Day 1 of each cycle."
32718431|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
32718432|NCT03478345|Experimental|THRIVE Study|
32919198|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
32718433|NCT03475537|Experimental|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
32718434|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
32718435|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
32718436|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
32718437|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
32718438|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
32718439|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
32718440|NCT05155969|Experimental|Eskatamine group|Low-dose esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction
32718441|NCT05155969|Placebo Comparator|Placebo group|Placebo (40 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction.
32718442|NCT03784417|Experimental|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
32718443|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
32718444|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
32718445|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
32718446|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
32718447|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
32718448|NCT02523157|Experimental|Intervention|Wellbeing Plan
32718449|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
32718450|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2 according to 0,28-day immunization schedule.
32718451|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2 according to 0,28-day immunization schedule.
32718452|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2 according to 0,28-day immunization schedule.
32718453|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3 according to 0,28-day immunization schedule.
32718454|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3 according to 0,28-day immunization schedule.
32718455|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3 according to 0,28-day immunization schedule.
33399919|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
32919199|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
32718456|NCT05112913|Active Comparator|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1 according to 0,28-day immunization schedule.
32718457|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
32718458|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
32718459|NCT04458961|Active Comparator|One-stage|
32919200|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
33073330|NCT02567435|Experimental|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
33248060|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
32718460|NCT04458961|Active Comparator|Two-stage|
33248061|NCT04015492|Experimental|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
32718461|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
32718462|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
32718463|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
32718464|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
32718465|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
32718466|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
32718467|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
32718468|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
32718469|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
32718470|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
32718471|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
32718472|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
32718473|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
32718474|NCT03477721||Group without cancer cachexia (TB)|
32718475|NCT05231551||Single-group study|Patients having first trimester voluntary termination of pregnancy in Montpellier university hospital.
32718476|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
32919201|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
32919202|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
32919203|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
32919204|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
33399920|NCT05628571|Placebo Comparator|Fluoride toothpaste|Participants will brush their teeth with a commercially available Fluoride toothpaste (1450 ppm F) and a commercially available adult soft bristle toothbrush
32718477|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
32718478|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
32718479|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
32718480|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
32919205|NCT02988440|Other|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
32919206|NCT05405192|Experimental|Dostarlimab Group|Participants will receive a total of up to 20 cycles of Dostarlimab: 4 cycles of Dostarlimab at a dose of 500 mg on day 1 of each of the 21-day cycle and 16 cycles of Dostarlimab at a dose of 1000 mg on day 1 of each of the 42-day cycle.
32919207|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
32919208|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
32919209|NCT02971839|Experimental|VX-561 20 mg|
32919210|NCT02971839|Experimental|VX-561 100 mg|
32919211|NCT02971839|Experimental|VX-561 150 mg|
32919212|NCT02971839|Active Comparator|Ivacaftor|
32919213|NCT02971839|Placebo Comparator|Placebo|
33399921|NCT05628571|Experimental|Zinc toothpaste|Participants will brush their teeth with a toothpaste containing amine base, zinc lactate and fluoride (1400 ppm F) and a commercially available adult soft bristle toothbrush
32718481|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
32718482|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
32718483|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
32718484|NCT05189197|Experimental|Experimental: Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg bis in die（BID） administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved complete response （CR）will continue to receive zanubrutinib 160mg BID for 1 year."
32718485|NCT05084599|Placebo Comparator|left-tilt group|After spinal anesthesia, the patient was placed in a 15° left position until the fetus was delivered, and metaraminol was given at an initial rate of 2.00μg/kg/min throughout the process.
32718486|NCT05084599|Experimental|supine group|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
32718487|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
32718488|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
32919214|NCT05378282||Diabetic patients without diabetic nephropathy|i. Patients with ≥ 20 years of T2D evolution with normoalbuminuria ii. Patients without a personal or family history of kidney disease in 1st degree relatives iii. Age ≥ 18 years
32919215|NCT05378282||Diabetic patients with diabetic nephropathy|"i. T2D diagnosed at least 5 years before initiating renal replacement therapy ii. Background or diabetic retinopathy by self-report to ensure that albuminuria was the consequence of diabetic nephropathy rather than a non-diabetic glomerulopathy iii. albuminuria ≥ 300 mg/24 h in at least two out of three sterile urine samples iv. no hematuria or signs (including cellular casts), history or predisposition to other kidney or urinary tract disease.~v. Age ≥ 18 years"
32919216|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
32919217|NCT05376488|Active Comparator|Meal type A|Meal type A: equicaloric meal as meal type B and C with differing constituents
32919218|NCT05376488|Active Comparator|Meal type B|Meal type B: equicaloric meal as meal type A and C with differing constituents
32919219|NCT05376488|Experimental|Meal type C|Meal type C: equicaloric meal as meal type B and A with differing constituents
32919220|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
33399922|NCT05255016|Sham Comparator|Standard of care + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
32718489|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
32718490|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
32718491|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
32718492|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
32718493|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
32718494|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
32718495|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
32919221|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
32919222|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
32919223|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
32919224|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
32919225|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
32919226|NCT04567706||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
32718496|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
32718497|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
32718498|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
32718499|NCT00701623|Experimental|1|patients treated with heparin
32718500|NCT00701623|Experimental|2|Patients treated with heparin
32718501|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
32718502|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
32718503|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
32718504|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
32718505|NCT04456153|Experimental|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
32718506|NCT04456153|Placebo Comparator|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
32718507|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
32718508|NCT04403971|Experimental|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
32718509|NCT04403971|Sham Comparator|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
32718510|NCT04403971|Placebo Comparator|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
32718511|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
32718512|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
32742845|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
32919227|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
32919228|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
32919229|NCT02301156|Experimental|Ublituximab + Ibrutinib|Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.
32919230|NCT02301156|Active Comparator|Ibrutinib|Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.
33248062|NCT04015492|Experimental|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
32718513|NCT04923230|Experimental|CAP Intervention|CAP is a parent-focused intervention being developed to help parents in states with legalized medical marijuana to address adolescent marijuana use. The proposed intervention will address the effects of marijuana on adolescent behavioral health, brain development, and social functioning and enhance parent motivation to use CAP concepts. Guided by formative research, CAP will build skills and provide strategies to: (1) restrict adolescent exposure to cannabis products and parent cannabis use in the home, (2) improve parent communication about their own cannabis use and expectations about youth marijuana use, (3) improve monitoring, (4) increase positive reinforcement for youth abstinence, and (5) address parent negative emotions. Parents will meet in groups with an interventionist for two 75-minute sessions. Presentations, discussion, and roleplay will be used to help parents gain mastery of preventive parenting behaviors and related strategies to reduce adolescent marijuana use.
32718514|NCT04923230|No Intervention|Wait List|Parents randomly assigned to Wait List Delayed CAP (WL) will receive no intervention for the baseline to 3-month follow-up period. Thus, the WL condition will serve as a comparison group from baseline to the 3-month assessment point. After the 3-month follow-up assessment, WL parents will be offered the CAP intervention. The final assessment for the WL participants will function as a 3-month follow-up assessment, allowing us to aggregate data all 60 parent-adolescent dyads to conduct within group analyses of pre- to post-intervention change on key variables of interest.
32718515|NCT02446886|Active Comparator|One Time Treatment|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
32718516|NCT02446886|Experimental|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
32718517|NCT04351243|Experimental|Gimsilumab|Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8
32718518|NCT04351243|Placebo Comparator|Placebo|Normal saline on Day 1 Normal saline on Day 8
32718519|NCT04164121|Experimental|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
32718520|NCT04164121|Placebo Comparator|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
32718521|NCT04164121|Experimental|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
32718522|NCT04164121|Placebo Comparator|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
32718523|NCT04164121|Experimental|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
32718524|NCT04164121|Placebo Comparator|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
32718525|NCT04132141|Other|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
33248063|NCT04015570|Experimental|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.~Standard Medical Treatment (Albumin + High Caloric Diet)"
33248064|NCT04015570|Active Comparator|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
32718526|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
32718527|NCT05008003|Active Comparator|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
32718528|NCT05008003|Experimental|Investigational treatment|This arm will receive vitamin D3 supplement as add-on to the standard of care.
32742846|NCT04961931|Other|diabetes group|After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.
32919231|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
32919232|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
32919233|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
32919234|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
32919235|NCT04768712|Experimental|Weight bearing aerobic exercise|
32919236|NCT04768712|No Intervention|Lifestyle counseling|
32919237|NCT04768556|Experimental|ADHD group|ADHD group: 20 participants having received a positive diagnosis of ADHD
33248065|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
32919238|NCT04768556|Other|Control group 1|Control group 1: 20 participants having received a negative diagnosis of ADHD
32919239|NCT04768556|Other|Control group 2|Control group 2: 20 participants as healthy volunteers
32919240|NCT04514276|Experimental|consecutive fetoneonatal healthcare|inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
32919241|NCT04514276|No Intervention|standard fetoneonatal healthcare|inclusion criteria: due to health insurance data by AOK PPLUS & ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.
32919242|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
33248066|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
33248067|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
33248068|NCT00396565|Placebo Comparator|Placebo|
32919243|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
32919244|NCT02278484|Other|Balloon Sinus Dilation|
32919245|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
32919246|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
32919247|NCT03971721|Experimental|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
33399923|NCT05255016|Experimental|Standard of care + CXL + Riboflavin 0.25% TE Solution|Standard of care treatment and the experimental combination product. The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. The riboflavin solution is an isotonic (0.9%) sodium chloride solution containing 0.25% riboflavin, 1% hydroxypropylmethylcellulose, and 0.007% benzalkonium chloride, adjusted to a pH of 7.0, and packaged in 2 mL sterile syringes for topical ophthalmic use.
32919250|NCT03979677|Experimental|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
32919251|NCT00558038|Active Comparator|1|
33248069|NCT00396565|Active Comparator|Olanzapine|
33248070|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
33248071|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
32919252|NCT00558038|Experimental|2|
33248072|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
33248073|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
33248074|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
33248075|NCT00925444|Experimental|FOREseal|
33248076|NCT00925444|Active Comparator|Stapling|
33248077|NCT00904774||premature neonates|gestational age less than 28 weeks
33248078|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
33248079|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
32919253|NCT05348330|Experimental|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
32919254|NCT05348330|Active Comparator|Costo-transverse ligament block|Under ultrasound guidance the continuous costo-transverse ligament block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
32919255|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
32919256|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
32919257|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
32919258|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
32919259|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
32919260|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
33399924|NCT05610397||1 level STALIF® C Ti|25 patients who have a 1 level implant with STALIF® C Ti
33399925|NCT05610397||1 level STALIF® C FLX|25 patients who have a 1 level implant with STALIF® C FLX
33399926|NCT05610397||1 level STALIF® M Ti|25 patients who have a 1 level implant with STALIF® M Ti
32919261|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
32919262|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
32919263|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
32919264|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
32919265|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
32919266|NCT01487499|No Intervention|Historical Controls|No intervention
32919267|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
32919268|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
32919269|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
32919270|NCT00378729|Active Comparator|A|
32919271|NCT00378729|Active Comparator|B|
32919272|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
32919273|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
32919274|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
32919275|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
32919276|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
32919277|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
32919278|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
33399927|NCT05610397||1 level STALIF® M FLX|25 patients who have a 1 level implant with STALIF® M FLX
33399928|NCT05610397||2 level STALIF® C Ti|25 patients who have a 2 level implant with STALIF® C Ti
33399929|NCT05610397||2 level STALIF® C FLX|25 patients who have a 2 level implant with STALIF® C FLX
33399930|NCT05610397||2 level STALIF® M Ti|25 patients who have a 2 level implant with STALIF® M Ti
33399931|NCT05610397||2 level STALIF® M FLX|25 patients who have a 2 level implant with STALIF® M FLX
33399932|NCT05598528||EGFR-positive lung patients recieving 3rd generation EGFR-TKIs as first-line therapy|Stage III-IV EGFR-positive lung patients receiving 3rd generation EGFR-TKIs (Osimertinib 80mg/Qd or Almonertinib 110mg/Qd or Furmonertinib 80mg/Qd) as first-line therapy.
32919279|NCT04368728|Experimental|10 µg dose, 18-55 years of age (2 doses)|
33399933|NCT05243719|Experimental|Treatment Options 1, 2, 3, 4, 5|Participants will fall into 1 of 5 treatment options dependent on the treatment received (ADP101 or placebo) during the parent study and their tolerance of the treatment regimen during the parent study.
33399934|NCT05598450|Experimental|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, rTMS+MEG for implementation intervention
33399935|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
33399936|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
32919280|NCT04368728|Experimental|20 µg dose, 18-55 years of age (2 doses)|
32919281|NCT04368728|Experimental|30 µg dose, 18-55 years of age (2 doses)|
32919282|NCT04368728|Experimental|10 µg dose, 65-85 years of age (2 doses)|
32919283|NCT04368728|Experimental|20 µg dose, 65-85 years of age (2 doses)|
32919284|NCT04368728|Experimental|30 µg dose, 65-85 years of age (2 doses)|
32919285|NCT04368728|Experimental|30 µg dose, ≥12 years of age (2 doses)|
32919286|NCT04368728|Placebo Comparator|Placebo, 18-55 years of age|
32919287|NCT04368728|Placebo Comparator|Placebo, 65-85 years of age|
32919288|NCT04368728|Placebo Comparator|Placebo, ≥12 years of age|
32919289|NCT04368728|Experimental|100 µg dose, 18-55 years of age (2 doses)|
32919290|NCT04368728|Other|Vaccination of Placebo recipients with BNT162b2 - Stage 1|Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.
32919291|NCT04368728|Other|Vaccination of placebo recipients with BNT162b2 - Stage 2|Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
32718529|NCT04978129|Experimental|Online and Text Message Intervention|Participants randomized to the intervention will receive a link to the online intervention following baseline completion. The online and Text Message intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS. Intervention participants will receive personalized PBS Text Messages 3x per week (based on self-selections from the interactive online intervention) for 8 consecutive weeks timed to occur on a random weekday as well as Friday and Saturday.
32919292|NCT04368728|Experimental|Booster vaccination of Phase 1 participants with BNT162b2 at a dose of 30 µg|
32919293|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 30 µg|
32919294|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
32919295|NCT04368728|Experimental|Vaccination of BNT162b2-naive participants with BNT162b2SA at a dose of 30 µg|
32919296|NCT04368728|Experimental|Booster and further vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
32919297|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 5 µg|
32919298|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 10 µg|
32718530|NCT04978129|No Intervention|Wait List Control|The wait-list control condition will not receive any intervention content during the 8-week period of data collection, but will complete baseline, 2-month, and daily surveys according to the same schedule as the intervention group in order to assess event-level PBS use, PBS non-use, alcohol and marijuana use, CAM and SAM use, and related consequences for up to 24 days over an 8-week period. All wait-list control participants will receive the intervention at the end of the 8-week period of data collection for the pilot study.
32718531|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
32718532|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
32718533|NCT03448939|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
32718534|NCT03448939|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
32919299|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
32919300|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
32919301|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
32919302|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
32919305|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
32919306|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
32919307|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
32919308|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
32919309|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
32919310|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
32919311|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
32919312|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
32919313|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
32919314|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
32919315|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
32718535|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
32919316|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
32919317|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
32919318|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32919319|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
32919320|NCT04332003|Active Comparator|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
32718536|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
32919321|NCT04332003|No Intervention|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
32919322|NCT04749056|Experimental|EPAS screening (intervention)|"Patients undergo EPAS (electronic psycho-oncological adaptive screening), a tablet-based screening application consisting of three adaptive tests and one supportive care checklist. EPAS provides immediate feedback via a printed results page, which presents and interprets the level of distress and contains individualized recommendations for psychosocial services.~The results pages are printed by research assistants immediately after the screening on a mobile printer and given to the participants together with a brochure containing information about all psychosocial services available at the health care institution.~The treating physicians also receive a slightly modified results page, but are not expected to discuss these with the patient unless they are highly distressed.~Before and during the screening, patients are explained how to use the program by the research assistance and supported if needed.~The whole screening process takes about 30 minutes."
32919323|NCT04749056|No Intervention|Care as usual (control)|"Patients complete the assessment paper pencil. The same instruments as in the intervention condition are used except for the 3 adaptive tests (i.e., the supportive care checklist and the outcomes).~Neither patients nor physicians receive any feedback of the results. Psychosocial services are recommended by the physicians on their own discretion only, and patients are not handed out the information brochure."
32718537|NCT03851107|Experimental|Community-based activity program|Engagement in 6-week community-based activity program
32718538|NCT03691207|Experimental|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
32718539|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
32718540|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
32919324|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
32919325|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
32919326|NCT04748978|Experimental|symptomatic uterine fibroids|patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis
32919327|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
32919328|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
32718541|NCT02504294|Other|Standard of Care|Standard of care arm
32718542|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
32718543|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
32718544|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
32718545|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
32718546|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
32718547|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
32718548|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
32718549|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
32718550|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
32718551|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
32718552|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
32718553|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
33248080|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
33248081|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
33248082|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
33248083|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
33248084|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
33248085|NCT02924376|Experimental|Cohort A Pemigatinib|Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
33248086|NCT02924376|Experimental|Cohort B Pemigatinib|Pemigatinibin subjects with other FGF/FGFR alterations
33248087|NCT02924376|Experimental|Cohort C Pemigatinib|Pemigatinib in subjects negative for FGF/FGFR alteration
33248088|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
32919329|NCT04198818|Experimental|Dose escalaltion study of HH2710|to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
33248089|NCT00921492|Experimental|Low-frequency electro-acupuncture|
33248090|NCT00921492|Active Comparator|Meeting a therapist - attention|
33248091|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
33248092|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
32718554|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
32718555|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
32919330|NCT05291234|Experimental|Stage A: ABBV-916|Participants will receive the same dose of ABBV-916 for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32718556|NCT05651230|Experimental|Rhamnan sulfate|The subjects will take rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
32718557|NCT05651230|Placebo Comparator|Placebo|The subjects will take placebo (Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
32718558|NCT05556538||Those who had TFESI and whose subcutaneous fat index was above the cut-off value|Those who are above the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
32919331|NCT05291234|Placebo Comparator|Stage A: Placebo for ABBV-916|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32919332|NCT05291234|Experimental|Stage B: ABBV-916 Dose A|Participants will receive ABBV-916 Dose A for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32718559|NCT05556538||Those who had TFESI and whose subcutaneous fat index was below the cut-off value|Those who are below the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
32718560|NCT04859062|Placebo Comparator|control|no lidocaine gel 2% is applied
32718561|NCT04859062|Experimental|lidocaine group|the lidocaine gel 2% is applied to the operative eye preoperatively
32718562|NCT05645926||Patients with MI who underwent revascularization during study period|Patients newly diagnosed with MI and underwent revascularization (PCI or CABG) during study period
32718563|NCT05538598|Experimental|Intramuscular Dry Needling|IMDN will be performed at the sacral multifidus and fibularis longus muscles.
32718564|NCT04872166|Experimental|BTX-A51 Dose Cohort 1|Starting dose (SD) of BTX-A51 administered orally 5 times per week in a 28-day cycle
33399937|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
32718565|NCT04872166|Experimental|BTX-A51 Dose Cohort 2|Up to 2-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
32718566|NCT04872166|Experimental|BTX-A51 Dose Cohort 3|Up to 3.5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
32718567|NCT04872166|Experimental|BTX-A51 Dose Cohort 4|Up to 5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
32718568|NCT04872166|Experimental|BTX-A51 Dose Cohort 5|Up to 7-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
32718569|NCT04872166|Experimental|BTX-A51 Dose Cohort 6|Up to 10-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
32718570|NCT04864210|Experimental|Liposomal bupivacaine|The patient will receive an intercostal nerve block by the surgeon in the operating room after anesthetic has been administered. The surgeon will use thoracoscopic guidance to administer the intercostal nerve block. The medication used in this block will liposomal bupivacaine (Exparel).
32718571|NCT04864210|Active Comparator|Bupivacaine|The patient will receive a paravertebral block by the anesthesiologist staffing the pain service area within the hospital prior to surgery. This regional anesthesia will be done using ultrasound guidance. The medication used in this block will be plain bupivacaine with epinephrine.
32718572|NCT05525494|Active Comparator|Text Fixed R/R Messages with Direct Appointment Schedule Link + Text Pre-Appointment Reminders|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
33248093|NCT03687762|Active Comparator|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
33248094|NCT03687762|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
33248095|NCT03687762|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
33248096|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
32766859|NCT04817189|Active Comparator|Standard of care + Dexamethasone 8 mg|"Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy and one of the 5-HT3-RAs recommended by European Society for Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC) guidelines (standard of care), i.e. either:~Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)"
32766860|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
32766861|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
32766862|NCT04885049|Experimental|Group A|Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
32766863|NCT04885049|Experimental|Group B|Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
32766864|NCT04884581|Experimental|GI Genius CADx device|
32766865|NCT04056533|Experimental|CMV CTLs|1x10^5 CMV-CTLs/kg
32766866|NCT04392011|Experimental|Arm 1|"Six non-naive* subjects (3 men, 3 women) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
32766867|NCT04392011|Experimental|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 men and 6 women) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
32766868|NCT04890587|Experimental|AL8326|"Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles.~Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.~Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles."
32766869|NCT04891055||patients treated with nivolumab|Patients candidates for II line therapy with Nivolumab from clinical practice
32766870|NCT04891055||patients treated with TKI|Patients candidates for II line therapy with TKI from clinical practice
32766871|NCT04890665|Experimental|Experimental: Self-applied psychological intervention for healthcare workers|Participants in this group will receive 9 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, stress, burnout, fatigue compassion, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life. The participants will have the option to do 3 extra modules that are complimentary for the intervention.
32919333|NCT05291234|Placebo Comparator|Stage B: Placebo for ABBV-916 Dose A|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32919334|NCT05291234|Experimental|Stage B: ABBV-916 Dose B|Participants will receive ABBV-916 Dose B for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32919335|NCT05291234|Placebo Comparator|Stage B: Placebo for ABBV-916 Dose B|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
32919336|NCT04889118|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
32919337|NCT04889118|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
32919338|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
32718573|NCT05525494|Active Comparator|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
32919339|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
32919340|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
32919341|NCT02665221|Placebo Comparator|Control group|
32919342|NCT02665221|Experimental|Treatment group|
32919343|NCT05289050|Placebo Comparator|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient. The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
32919344|NCT05289050|Experimental|S-ketamine|For patients in the s-ketamine group, anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h) ,analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
32919345|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
32919346|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
32718574|NCT05525494|Active Comparator|Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment Reminders|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
32919347|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
32919348|NCT03782181|No Intervention|Control group|No intervention arm
32919349|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
32919350|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
32919351|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
32718575|NCT05525494|Active Comparator|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
32919352|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
32919353|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
32742847|NCT04961931|Other|non-diabetes group|After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.
32742848|NCT04961931|Other|control|After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.
32742849|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
32742850|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
32742851|NCT04952181|Experimental|optical biometry|
32742852|NCT04952181|Experimental|ultrasonic biometry|
32742853|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
32718576|NCT05525494|Active Comparator|Portal Fixed R/R Messages with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
32718577|NCT05525494|Active Comparator|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
32718578|NCT05525494|No Intervention|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
32718579|NCT05519878|Experimental|Arm I (BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses.
32718580|NCT05519878|Experimental|Arm II (OT)|Patients undergo 6 occupational therapist-led sessions over 60 minutes each.
32718581|NCT05519878|Experimental|Arm III (OT, BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses and to complete the occupational therapist-led session over 60 minutes.
32718582|NCT05519878|Active Comparator|Arm IV (Control)|Patients undergo routine treatment and usual follow up care with their medical oncologist.
32718583|NCT05645770||coronary artery disease|
32718584|NCT05645770||control|
32718585|NCT04871542||Observational (biospecimen collection, questionnaire)|Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
32718586|NCT05650918|Experimental|MesoPher and mitazalimab combination therapy|"MesoPher. 25 million lysate loaded DCs administered in the form of 3 biweekly and 2 additional vaccinations (3 and 6 months after the third vaccination). 1/3 intradermal injection in the forearm and 2/3 via the intravenous route.~mitazalimab, 75µg/kg-150µg/kg-300µg/kg-600µg/kg or 1200µg/kg via intravenous route in the form of 3 biweekly and 2 additional infusions (3 and 6 months after the third vaccination)."
32718587|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
32718588|NCT05644678|Active Comparator|Conventional treatment|Patients will be treated using the fixed appliances to track the impacted canines after opening the appropriate distance
32718589|NCT05644678|Experimental|Surgically-assisted treatment|Patients will be treated using fixed appliances assisted by minimally-invasive corticotomy (alveolar perforations and piezocision) to accelerate impacted canines' traction after opening the appropriate distance.
32919354|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
32919355|NCT05280704|Other|V1 Lidocaine, D2 Saline|Will undergo volar technique 1st with 4 mL of 1% lidocaine and then dorsal technique 2nd with 4 mL of 0.9% sterile saline. This is a 1-time dose.
32718590|NCT05650762|Experimental|Cinnamon|
32718591|NCT05650606|Experimental|High Intensity Gait Training|"HIGT will be performed 4-6 times per week in place of conventional physical therapy. The patient's heart rate(HR)and blood pressure(BP) will be measured throughout each session. If the HR or BP is out of the acceptable range, patients will undergo standard physical therapy for that session, and the medical team will be contacted.~Target HR zones will be calculated with the Karvonen formula. The first session goal is to reach a target HR range that is 50-60% of heart rate reserve. The goal for subsequent sessions is to reach 70-80% of heart rate reserve. Rate of perceived exertion (RPE) will also be utilized.~The primary therapist will design an individualized HIGT treatment program with a combination of speed dependent treadmill activities, activity-based treadmill activities, stair training, and over ground activities.~The patient will be reminded during each session to ask for a rest as needed. Standing rests are preferred over sitting rests, but either may be utilized."
32742854|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
32742855|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
32742856|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
32742857|NCT04431687|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
32742858|NCT04431687|Experimental|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
32742859|NCT04431687|Experimental|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
32742860|NCT04431687|Experimental|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
32742861|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
32742862|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
32742863|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
32742864|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
32742865|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
32919356|NCT05280704|Other|V1 Saline, D2 Lidocaine|Will undergo volar technique 1st with 4 mL of 0.9% sterile saline and then dorsal technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
32919357|NCT05280704|Other|D1 Lidocaine, V2 Saline|Will undergo dorsal technique first with 4 mL of 1% lidocaine and then volar technique second with 0.9% sterile saline. This is a 1-time dose.
32919358|NCT05280704|Other|D1 Saline, V2 Lidocaine|Will undergo dorsal technique 1st with 4 mL of 0.9% sterile saline and then volar technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
33399938|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
32718592|NCT05650606|Active Comparator|Conventional|The conventional physical therapy sessions are what a patient would normally receive during their rehabilitation. Physical therapy sessions are usually 60-90 minutes per day for 5 days each week, and possibly one 30-minute session on a 6th day. Physical therapy sessions are focused on gait, balance, and strengthening activities to address goals related to functional mobility. Clinicians administering therapy to patients in this arm will not be given instructions on the types of therapies they administer; however, they will not be permitted to do HIGT with patients. Therapists will be permitted to use other devices such as Ekso exoskeleton, Lite Gait, Rifton Tram Body Weight Support Devices, and Electrical Stimulation devices including the XCITE and RT300.
32919361|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
32919362|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
32919363|NCT05242952|Experimental|Immediate Intervention Group|Participants will enter an online game and learn about how to prevent cardiovascular and metabolic conditions.
32919364|NCT05242952|Other|Waitlist Control Group|Participants will enter an online game at a later date after the immediate intervention group and learn about how to prevent cardiovascular and metabolic conditions.
32919365|NCT05239208|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
32919366|NCT05239208|Active Comparator|Control Group|Dietary counseling
32919367|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
32919368|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
32919369|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
32919370|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
32919371|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
32919372|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
32919373|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
32919374|NCT04892862|Active Comparator|dorsal surgical approach|dorsal surgical approach
32919375|NCT04892862|Active Comparator|volar surgical approach|volar surgical approach
32919376|NCT04263818|Experimental|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
32919377|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
32919378|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
32919379|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
32718595|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
32718596|NCT05650450||Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)|
32718597|NCT05650216|Experimental|Immunotherapy combined with Chemoradiotherapy|"A:Chemotherapy: nab-paclitaxel (80mg/m2), carboplatin (AUC=2)，on day 1,8,15,22,29;~B:Immunotherapy: camrelizumab (200mg)，IV on days 5 and 26;~C:Radiotherapy: Primary lesion and adjacent lymph nodes: 41.4Gy, 1.8Gy/23f; Abscopal lymph node 2Gy, 0.5Gy/4f.~D:Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
33399939|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
32718599|NCT05092672|Experimental|High traffic-related air pollution first|Participants will exercise in an environment with high levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with low levels of traffic-related air pollution.
32718600|NCT05092672|Experimental|Low traffic-related air pollution|Participants will exercise in an environment with low levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with high levels of traffic-related air pollution.
32718601|NCT04419610|Experimental|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
32718602|NCT04419610|Placebo Comparator|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
32718603|NCT04848688|Experimental|Moxidectin|8 mg Moxidectin at day 0 administered orally
32718604|NCT04848688|Experimental|Ivermectin|200 ug/kg Ivermectin at day 0 administered orally
32718605|NCT05079568|Experimental|Active VR Group|"Subjects will be provided an Oculus Go VR headset pre-loaded with a menu of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes."
32718606|NCT05079568|Sham Comparator|Sham VR Group|Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
32718607|NCT05471908|Experimental|As-needed (PRN) post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
32718608|NCT05471908|Active Comparator|Automatic post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
32718609|NCT05466526|Experimental|The participants who received HFDS|All participants in the arm were suffering from primary open-angle glaucoma and were indicated for surgery due to either progression of field defect and raised intraocular pressure above 21 mmHg in spite of maximum medical treatment or for patients who were not compliant patient to their medical treatment.
32718610|NCT05369650|Experimental|Lidocaine 1 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
32718611|NCT05369650|Experimental|Lidocaine 1.5 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1.5mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
32718612|NCT05369650|Experimental|Lidocaine 2 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 2mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
32718613|NCT05458960|Experimental|Arm 1: Social needs navigator program|Participants will be paired with a community health worker who will provide tailored support to address unmet social needs. The number and frequency of calls will be limited only by participants' needs, interest, and willingness to interact. The type of contact could include phone calls, or home/community visits. The community health worker will: (1) identify and assess patients' unmet social needs; (2) jointly generate solutions; (3) help prioritize among multiple needs; (4) identify community resources that could help resolve the problem(s); (5) determine eligibility for services; (6) help patients access available resources by scheduling appointments and providing appointment reminders; (7) prepare patients to interact with service agencies and/or act as an advocate; (8) provide support such as arranging transportation; (9) oversee follow-up problem-solving actions; and (10) review progress made towards resolving unmet social needs and adapt solutions.
32718614|NCT05458960|Active Comparator|Arm 2: Enhanced usual care|Participants will receive verbal referral to a federally funded, free, 24-hr assistance hotline, United Way 2-1-1, which connects callers with community services to help address unmet social needs.
32718615|NCT05458960|No Intervention|Arm 3: Clinic provider|4 WUSM colposcopy providers, 4 staff members, and 1 community health worker will be surveyed to assess potential for dissemination.
32718616|NCT05643742|Experimental|CTX112|Administered by IV infusion following lymphodepleting chemotherapy.
33399940|NCT04074018|Experimental|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
32919380|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
32919381|NCT02325414|Experimental|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
32919382|NCT02325414|Experimental|Placebo|Intravenous infusion of placebo at baseline.
32919383|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
32919384|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
32919385|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
32919386|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
32919387|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
32919388|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
32919389|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
32919390|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
32919391|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
32919392|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
32919393|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
32919394|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
33399941|NCT04074018|Active Comparator|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
33399942|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
33399943|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
33399944|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
33399945|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
33399946|NCT05598372|Experimental|shotblocker|infant pain during vaccination and mother anxiety
32919395|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
32919396|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
32919397|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
32919398|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
32919399|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
33399947|NCT05598372|Experimental|lullaby|infant pain during vaccination and mother anxiety
33399948|NCT05598372|No Intervention|CONTROL|not infant pain during vaccination and mother anxiety
33399949|NCT05178888|Experimental|Dose Escalation|Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.
33399950|NCT05178888|Experimental|Dose Expansion|Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.
33399951|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
33399952|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
33248097|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
33399953|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
32919402|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
32919403|NCT02298192|Experimental|Once weekly titration|
32919404|NCT02298192|Experimental|Twice weekly titration|
32919405|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
32919406|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
32919407|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
32919408|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
32919409|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
33248098|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
33248099|NCT00567580|Active Comparator|PBRT Alone|Prostate bed radiotherapy (PBRT) begins within 6 weeks (+/- 2 weeks) after registration.
32919410|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
32919411|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
32919412|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
33248100|NCT00567580|Experimental|PBRT + STAD|Prostate bed radiotherapy (PBRT) and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before radiotherapy (RT), and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
33248101|NCT00567580|Experimental|PLNRT + PBRT + STADT|Pelvic lymph node radiotherapy (PLNRT), prostate bed radiotherapy (PBRT), and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before RT, and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
33248102|NCT04060836|Experimental|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
33248103|NCT04060836|Experimental|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
33248104|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
33248105|NCT00693420|Placebo Comparator|2|Vehicle solution
33248106|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
33248107|NCT04034524||New users of GLP1 receptor agonists (exposure)|
33248108|NCT04034524||New users of basal insulin (reference)|
33248109|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
32919413|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
32718617|NCT04855396||Patients with Severe Traumatic Brain Injury|Participants will be enrolled in the HOBIT trial
32718618|NCT05071612|Experimental|AD109 Dose 1|
32919414|NCT02624739|Experimental|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
32919415|NCT02624739|Active Comparator|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
33248110|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
33248111|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
32919418|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
32919419|NCT03781479|Experimental|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
32919420|NCT03781479|Experimental|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
32919421|NCT05110196|Experimental|Capmatinib|Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.
32919422|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
32919423|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
32919424|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
32919425|NCT03779997|Experimental|Video-based DOT Application|
32919426|NCT03779997|No Intervention|Treatment as Usual (TAU)|
32919427|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
32919428|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
32919429|NCT03998462|Active Comparator|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
32919430|NCT03998462|Placebo Comparator|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
33248112|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
33399954|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA >1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
33399955|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
33399956|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
33399957|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
33399958|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
33399959|NCT03987282|Active Comparator|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
33399960|NCT03987282|Experimental|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
33399961|NCT03985020|No Intervention|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
33399962|NCT03985020|Active Comparator|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
32919431|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
32919432|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
32919433|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
32919434|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
32919435|NCT01897766||Somatropin|Patients administered Somatropin.
32919436|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
32919437|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
32919438|NCT02520297|Experimental|TRV130|Drug: TRV130
32919439|NCT03964532|Experimental|Phase I/Phase II|Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
32919440|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
32919441|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
32919442|NCT03024320|Active Comparator|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
32919443|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
32919444|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
32919445|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
33399963|NCT03985020|Experimental|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
32718619|NCT05071612|Experimental|AD109 Dose 2|
32718620|NCT05071612|Experimental|AD504 Dose 1|
32919446|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
32919447|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
32718621|NCT05071612|Experimental|AD504 Dose 2|
32718622|NCT05071612|Active Comparator|Atomoxetine 1|
32718623|NCT05071612|Active Comparator|Atomoxetine 2|
32718624|NCT05071612|Placebo Comparator|Placebo 1|
32718625|NCT05071612|Placebo Comparator|Placebo 2|
32718626|NCT05069740|Experimental|Salsalate|3000 mg/day salsalate (1500 mg twice daily) for 5 days
32718627|NCT05069740|Placebo Comparator|Placebo|1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days
32718628|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
32718629|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
32718630|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
32718631|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
32742866|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
32919448|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
32919449|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
32919450|NCT05065346|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
32919451|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
32919452|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
32919453|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
32919454|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
32919455|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
32919456|NCT05313165|Experimental|Treated with LimFlow|Treatment with the LimFlow Stent Graft System
32919457|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
32718632|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
32718633|NCT05428150|Active Comparator|Regimen A|Esbriet® 801 mg (267 mg oral capsule x 3), three times daily (TID) with meals (6 hours apart) for 3 days, total daily dose of 2403 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
32718634|NCT05428150|Experimental|Regimen B|EXCL-100, 1200 mg (600 mg oral tablet x 2), twice daily with meals (BID, every 12 hours) for 3 days, total daily dose of 2400 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
32718635|NCT05643508|Experimental|(D) DWC202206 + DWC202207|
32718636|NCT05643508|Active Comparator|(P+D) DWC202206 + DWC202207|
32718637|NCT05643508|Active Comparator|(D+P) DWC202206 + DWC202207|
32718638|NCT05642728|Experimental|Case management group|
32718639|NCT05642728|No Intervention|Control group|
32718640|NCT05179408|Experimental|Telerehabilitation|Telerehabilitation intervention consisting of exercise training, education, and behavioral support
32718641|NCT05179408|No Intervention|Control|No intervention arm, with assessment of functional and patient-reported outcomes only
32718642|NCT02737501|Experimental|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
32718643|NCT02737501|Active Comparator|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
32718644|NCT02737501|Experimental|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
32718645|NCT04848220|Experimental|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
32718646|NCT04848220|Experimental|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
32718647|NCT04848220|Placebo Comparator|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
32718648|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
32718649|NCT05642182|Experimental|Drug (SFA002) Vitamin D, Magnesium|Drug (SFA002) 1000 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 IU once daily
32718650|NCT05642182|Experimental|Drug (SFA002) Vitamin D, Magnesium and Propionate|Drug (SFA002) 1000 mg, Propionate 150 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 mg once daily
32718651|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
32718652|NCT05425030|Experimental|Free LSSS Arm|Participants will receive 6 months of free low-sodium salt by delivery from a community health worker. In addition, the same educational information as provided in Arm 2 (Information Only Arm, below) will be provided.
32718653|NCT05425030|Active Comparator|Information Only Arm|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
32718654|NCT05425030|No Intervention|No Intervention|Participants will not receive any intervention of any sort.
32718655|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
32718656|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
32718657|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
32718658|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
32718659|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
32718660|NCT03526549|Experimental|EN3835 Active|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
32718661|NCT05052034||BAROQUE MUSIC|This group would listen to baroque music to control their anxiety level during their oral surgeries.
32919458|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
32718662|NCT05052034||CLASSICISM MUSIC|this group would listen to classical music to control their anxiety level during their oral surgeries.
32718663|NCT05052034||CONTROL GROUP|This group would not listen to music during their oral intervention, acting as a control group.
32742867|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
32742868|NCT03058575|Other|Control|No Intervention
32919459|NCT05042882|Experimental|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
32919460|NCT05042882|No Intervention|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks >2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
32919461|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
32919462|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
32919463|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
32919464|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites~no Intervention provided"
32919465|NCT02280122||periodontally healthy|"PPD ≤ 3 mm~PAL-V ≤ 2 mm at < 30% of sites~BOP < 20%~No radiographically detectable bone loss: distance cemento-enamel junction to provided~no Intervention but aMMP-8 test"
32919466|NCT02296476|Experimental|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
32919467|NCT02296476|Experimental|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
32919468|NCT02296476|Experimental|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
32919469|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
32919470|NCT04979078|Experimental|Experimental group|The experimental group receives 9 sessions of photobiomodulation therapy (3x/week for 3 weeks).
32919471|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
32919472|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
33399964|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
33399965|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
32919475|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
32919476|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
32718664|NCT05641480|Experimental|Subjective cognitive decline group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
32742869|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
32919477|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.~The entire duration of the experience will be kept at 10 minutes."
33399966|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
32919478|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
32919479|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
32919480|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
32919481|NCT00552032|Experimental|Mometasone Furoate nasal spray|
32742870|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~induction: attention of the patient fixed on an object or a part of the body,~the dissociation where the patient cuts off auditory, visual and tactile perceptions,~and finally the opening towards a hypnotic experience thanks to the imaginary."
32919482|NCT00552032|Placebo Comparator|Placebo|
32919483|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
32919484|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
32919485|NCT04935632||Before implementation|Prior to the implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
32919486|NCT04935632||After implementation|After implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
32919487|NCT04935632||at a distance from the implementation|Approximately 8 months after implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia.
32919488|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
32919489|NCT02277548|Experimental|Lyrica at 300 mg per day|
32919490|NCT02277548|Placebo Comparator|Placebo|
32919491|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
33073331|NCT02567435|Experimental|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
33248113|NCT04034680|Experimental|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
33248114|NCT04034680|Active Comparator|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
32742871|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
32742872|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
32742873|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
32742874|NCT04961463|Experimental|İnterventions group|İnterventions group:The 7-session psychoeducation program prepared on the basis of the Roy Adaptation Model was applied to the intervention group once a week for 90-120 minutes
32742875|NCT04961463|No Intervention|Control group|Except for the routine hospital controls, no intervention was made to the control group
32742876|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
33248115|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
33399967|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
32919492|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
32919493|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
32919494|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
32919495|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
32919496|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
32718665|NCT05641480|Experimental|Mild cognitive impairment group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
32718666|NCT05641480|Experimental|Mild dementia group|On the basis of the above two treatment options, oral donepezil hydrochloride tablets or carpalatine heavy tartrate tablets should be added.
32718667|NCT05047198|Active Comparator|Control|Catheter Ablation using invasive mapping
32718668|NCT05047198|Experimental|Treatment|Radio-ablation using non-invasive mapping
32718669|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
32919497|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
32919498|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
32919499|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
32919500|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
32919501|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
32919502|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
32919503|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
32718670|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
32919504|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
32919505|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
33073332|NCT02567435|Experimental|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32718671|NCT05640934|Active Comparator|Melatonin group|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
32718672|NCT05640934|Placebo Comparator|Control group|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
32919506|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
32919507|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
32919508|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
32919509|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
32919510|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
32919511|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
32919512|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
32919513|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL. Closed to Enrollment.
32919514|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
32919515|NCT01071993|Active Comparator|atorvastatin|
32919516|NCT01071993|Placebo Comparator|placebo|
32919517|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
33073333|NCT02543996||Affected or unaffected cohorts (including genetic carriers or non-carriers as|Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)
33248116|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
33248117|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
33248118|NCT04060602|Experimental|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
33248119|NCT04060602|Active Comparator|Education|This arm is provided educational materials about risky cannabis use.
33248120|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
32718673|NCT05037370|Experimental|LASIK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
32718674|NCT05037370|Experimental|PRK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
32742877|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
32742878|NCT04961385||ChAd0x1 nCoV-19 vaccinees|Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old
33248121|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
33248122|NCT05277844|Active Comparator|Arm 1: Continuation of TKI therapy alone|Patients in this arm will continue to receive standard treatment of TKI alone
32919518|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
32919519|NCT03756818|Experimental|Treatment (mivavotinib and paclitaxel)|Patients receive mivavotinib PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32919520|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
32919521|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
32919522|NCT03029936||Obesity Group|
32919523|NCT03029936||Asthma Group|
32718675|NCT05634304|Experimental|The mobile app self-management (mSM) program focusing on patients' needs in OA patients|An individualized mobile app self-management (mSM) program for managing OA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their OA situations.
32718676|NCT05634304|No Intervention|Control group for mSM program|The control group will receive with the usual care only and follow-up 6 months.
32919524|NCT03029936||Obesity-Asthma Group|
32919525|NCT03029936||Control|
32919526|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
32919527|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
32919528|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
32919529|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
32919530|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
32718677|NCT03377803|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
32919531|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
32919532|NCT03673124|Other|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
32919533|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
32919534|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
32919535|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
32919536|NCT03539744|Active Comparator|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
32919537|NCT03539744|Experimental|US Cohort|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
32919538|NCT05296785|Other|Participants|patients undergoes intramedullary nail with Limb Reconstruction System
32919539|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
32919540|NCT02973555|Experimental|PRP injection|
32919541|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
32919542|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
32919543|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
32919544|NCT01020903|Active Comparator|Aprepitant|
33399968|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
32742879|NCT04944459|Experimental|Muse-S|multi-sensor neurofeedback-assisted mindfulness training device (Muse-S)
32742880|NCT04952025||ALS patients|
32919545|NCT01020903|Placebo Comparator|Placebo|
32919546|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
32919547|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
32919548|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
32919549|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
32919550|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
32919551|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
32919552|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
32919553|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
32919554|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
33248123|NCT05277844|Experimental|Arm 2: Continuation of TKI therapy + Local Consolidative Radiation therapy to 1-5 sites|Patients will receive local consolidate radiation therapy to all oligo-metastatic sites plus radiation therapy to primary disease in addition to TKI
33248124|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
33248125|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
33248126|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
33248127|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
33248128|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
33248129|NCT00921570|Experimental|Amlodipine|
33248130|NCT00921570|Experimental|Valsartan|
33248131|NCT00921570|Experimental|Valsartan+Amlodipine|
33248132|NCT00926068|Experimental|HO/03/03 10µg|
33248133|NCT00926068|Placebo Comparator|Placebo|
32766872|NCT04890665|Active Comparator|Control: Self-applied psychological intervention for healthcare workers|The participants in this group will receive exactly the same intervention but delivered through a therapist in a weekly session through an online video call. The participants will be informed also about the 3 extra modules and briefly what it is the contents of these modules so they can accept or not receive these extra contents.
32766873|NCT04890353|Experimental|standard management plus Dimethyl Fumarate|
32766874|NCT04890353|Placebo Comparator|standard management plus placebo|
32766875|NCT04899713||Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)|Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
32766876|NCT04899713||Control group (neo-adjuvant chemotherapy alone)|Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
32766877|NCT04899479|Experimental|SGLT-2 inhibitor|The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
32766878|NCT04899479|Placebo Comparator|Control|The control group will not receive any additional drugs.
32766879|NCT04430621|Experimental|FSH|FSH, 300 IU s.c.
32766880|NCT04430621|Placebo Comparator|Control|Placebo, s.c.
32766881|NCT04394351|Experimental|Part A - High Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
32766882|NCT04394351|Experimental|Part A - Low Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
32766883|NCT04394351|Experimental|Part B - High Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
32766884|NCT04394351|Experimental|Part B - Low Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
32766885|NCT04394351|Experimental|Part C - High Dose|Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.
32766886|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:~Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria~Living and staying at home because of physical and social distancing~Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)~Agree to participate in the study~The exclusion criteria are:~A concomitant participation to another medical trial~Living in semi-autonomous residence or CHSLD"
32766887|NCT04900259||COVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the COVID-19 period
32766888|NCT04900259||PreCOVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the preCOVID-19 period
32766889|NCT04884503|Experimental|Patients diagnosed with BMS traeting with Clonazepam|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
32766890|NCT04884503|Active Comparator|Patients diagnosed with BMS treating with tongue pads|patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions
32766891|NCT04884425|Active Comparator|PEMF Device Group|This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
32766892|NCT04884425|No Intervention|Waiting List Control Group|These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
33248134|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
33248135|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
33248136|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
33248137|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
33248138|NCT05322642|Experimental|Experimental: (UP-A)|The UP-A (Ehrenreich et al., 2008) is an emotion-focused, transdiagnostic CBT for adolescents A 10-session youth-focused programmed by adapting the core modules of UP-A, for indicated prevention and school settings.
33248139|NCT05322642|Active Comparator|Active control condition|"The active control condition will be based on the 10 session of Progressive Relaxation Training programme of Bernstein and Borkovec.~It follows a similar structure as the UP-A. A group format will be used."
33248140|NCT00605176|Active Comparator|3.75% imiquimod cream|
33248141|NCT00605176|Active Comparator|2.5% imiquimod cream|
33248142|NCT00605176|Placebo Comparator|Placebo cream|
32718678|NCT03377803|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
32718679|NCT04845958||Pediatric Patients with Unexplained Enlarged Spleen|
32718680|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
32718681|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
32718682|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
32718683|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
32718684|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
32718685|NCT03471403||FAP|FAP patients with duodenal adenomas
32718686|NCT05013580|Experimental|Open Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with a type of tissue (the amnion-chorion membrane) taken from a placenta and will be left partially open to heal.
32718687|NCT05013580|Active Comparator|Closed Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with collagen tissue and stitched closed while it heals.
32718688|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
32718689|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
32718690|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
32718691|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
32718692|NCT04844164|Experimental|Cushing's Disease|
32718693|NCT04844164|Experimental|Acromegaly|
32718694|NCT04844164|Experimental|Diabetes Mellitus Type 1|
32718695|NCT04844164|Experimental|Primary Hyperparathyroidism|
32718696|NCT04844164|Experimental|Control group|
32718697|NCT03469921||15-17 years old|15-17 years old
32718698|NCT03469921||18-25 years old|18-25 years old
32718699|NCT03469921||26-30 years old|26-30 years old
32718700|NCT03469921||acute leukemia|acute leukemia
32718701|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
32718702|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
32718703|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
32718704|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
32718705|NCT03469921||patients included in clinical trials|patients included in clinical trials
32718706|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
32718707|NCT04975867|Experimental|Hypothermia group|Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
32718708|NCT04975867|Active Comparator|Normothermia group|For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
32718709|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
32718710|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
32718711|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
32718712|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
32718713|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
32718714|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
32718715|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
32718716|NCT05372770|Experimental|Group 1: Transgender women using Flourish|"After gender-confirming surgery, this group will use the Flourish Vaginal Care System for six months, ramping up usage with healing. They will use Balance external wash beginning day 6 after surgery; Restore® vaginal moisturizing gel on dilators beginning day 6 after surgery; Restore every other day at bedtime with BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime beginning week 6 after surgery through end of study at 6 months."
32718717|NCT05372770|No Intervention|Group 2: Transgender women not using Flourish|After gender-confirming surgery, this group will use only KY jelly on dilators beginning day 6 after surgery according to routine care; they will use any standard hygiene product (soap, body wash, etc) of their choice except products used by Group 1 through the end of the study at 6 months.
32718718|NCT05372770|Other|Group 3: Cisgender women|This group will use the Flourish Vaginal Care system for 6 months: Balance external wash daily; Restore intravaginal gel every other day at bedtime; BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime through the end of study.
32718719|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
32718720|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
33399969|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
32718721|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
32718722|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
32718723|NCT05368714|Experimental|Economic Empowerment (EE)|EE consists of a child development account (CDA) held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda).
32718724|NCT05368714|Experimental|Multiple Family Group (MFG) - based Family Strengthening (FS) Intervention:|MFG-based consists of 16 sessions focused on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. Core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
32718725|NCT05368714|Experimental|Combined EE plus MFG-based FS|EE+ MFG-based FS combines both the child development account and 16 sessions of MFG.
32718726|NCT03000829|Experimental|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
32718727|NCT03000829|Placebo Comparator|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
32718728|NCT05626582|Experimental|Pain Stimulus - Learning Only|Capsaicin combined with heat applied to intact skin
33399970|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
32919557|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
32919558|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
32919559|NCT00965055|Placebo Comparator|Atorvastatin|
32919560|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
32919561|NCT04331925|Other|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
32919562|NCT04331925|Experimental|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
32919563|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
33248143|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
33248144|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
33248145|NCT00743028|Experimental|1|
33248146|NCT00743028|Experimental|2|
33248147|NCT00743028|Experimental|3|
33248148|NCT00743028|Experimental|4|
32718729|NCT05626582|Experimental|Pain Stimulus - Learning and Retention|Capsaicin combined with heat applied to intact skin
33248149|NCT00743028|Experimental|5|
33248150|NCT00743028|Experimental|6|
33248151|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
32718730|NCT05626582|No Intervention|No Stimulus|Nothing applied to skin
32718731|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
32718732|NCT04419844|Active Comparator|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
32718733|NCT04419844|Active Comparator|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
32742881|NCT04952025||normal controls|
32919564|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
32919565|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
32919566|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
32919567|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
32919568|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
32919569|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
32919570|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
32919571|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
32919572|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
32919573|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
32919574|NCT00935649|No Intervention|Untreated Toe|
32919575|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
32919576|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
32919577|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
32919578|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
32919579|NCT00896025|Active Comparator|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
32919580|NCT00896025|No Intervention|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
32919581|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
32919582|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
32919583|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
32919584|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
32919585|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
32919586|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
32919587|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
32919588|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
32919589|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
32919590|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
32919591|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
32919592|NCT05292261|Experimental|Team handball group|The team handball group participants were encouraged to performed at least two out of three weekly supervised team handball training sessions of 60 min each, for 36 weeks.
32919593|NCT05292261|No Intervention|Control group|The control group participants were instructed to keep their regular daily physical activity for 36 weeks.
32919594|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
32919595|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
32919596|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
33248152|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
32742882|NCT04951791|Experimental|treatment|patients will receive intravenous infusion of SMOFlipid 20%
32919597|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
32742883|NCT04951791|Placebo Comparator|control|patients will receive intravenous infusion of normal saline 0.9%
32742884|NCT04951713|Experimental|XZP-3287 combined with clarithromycin|XZP-3287 combined with clarithromycin
32742885|NCT04951713|Experimental|XZP-3287 combined with rifampicin|XZP-3287 combined with rifampicin
32919598|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
32919599|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
32919600|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
32919601|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
32742886|NCT04944225|No Intervention|Control group: Pain management during the standard of care phase|In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.
32743350|NCT04956393|Experimental|Immediate SOAR Program|Participants with a past sport-related knee injury randomized to the 'immediate intervention' group will complete an 8-week (weeks 1-8) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) followed by an additional 8 weeks (weeks 10-17) of home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and optional weekly group-based exercise classes. Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more immediate SOAR group knee injury participants.
32919602|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
32766893|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
32766894|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
32766895|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
32766896|NCT04890197|Active Comparator|tahini|48 gr per day
32766897|NCT04890197|Placebo Comparator|control|no intervention
32766898|NCT04889963|Placebo Comparator|control group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)
32766899|NCT04889963|Active Comparator|conditioned medium group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium
32766900|NCT04889963|Active Comparator|stem cells group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition
32766901|NCT04889963|Experimental|composite group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium
32766902|NCT04412213||children of possitive family history of stuttering|
32766903|NCT04412213||children of negative family history of stuttering|
32766904|NCT04889885|Experimental|High-intensity laser therapy (HILT)|The participants in the intervention group were treated by HILT which was applied to the knee joint (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
32766905|NCT04889885|Sham Comparator|Sham laser|The control group received a sham laser by the same laser machine (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
32766906|NCT04899401|Experimental|Standard of care +PediaFlù®|
32766907|NCT04899401|Active Comparator|Standard of care|
32766908|NCT04889651|Experimental|A(TRTR)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence A: T-R-T-R~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
32766909|NCT04889651|Experimental|B(RTRT)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence B: R-T-R-T~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
32766910|NCT04898777|Active Comparator|ERCP-BD|ERCP Biliary Drainage by papillary approach with stent placement.
32766911|NCT04898777|Active Comparator|EUS-BD|Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
32766912|NCT04889339|Experimental|Test group: Braces designed with growth modulation simulation|The braces will be designed using a growth modulation method.
32766913|NCT04889339|Active Comparator|Control group: Conventional method|The braces will be designed by an orthotist without growth modulation simulation.
32766914|NCT04884347|Experimental|Alline proMEN|The qualitative and quantitative formula is as follows: 500 mg Keratin, 225 mg Inactive dried yeast rich in vitamin (containing 200 mg Saccharomyces cerevisiae 100% inactivated, 11.218.4 mg Vitamin B3, 6.8-7.2 mg Vitamin B5, 1.6-1.8 mg Vitamin B6, 1.6-1.8 mg Vitamin B2, 1.6 -1.8 mg Vitamin B1, 0.2-0.4 mg Vitamin B9, 0.2 mg Vitamin B8, 5.6 μg Vitamin B12), 150 mg Venus hair fern extract, 117.6 mg Iron gluconate (containing 14.7 mg Iron), 84.2 mg Sodium ascorbate coated, 76.8 mg Zinc gluconate (11 mg Zinc) 24 mg Beta carotene 20%, 14.8 mg Vitamin E, 256.3 mg Acacia gum, 100 mg Microcrystalline cellulose, 11.3 mg Magnesium stearate, 78 mg White coating (containing: 23.4-39 mg Hydroxypropylmethylcellulose (E464), 15.6-23.4 mg Calcium sulfate anhydrous (E516), 15.6-23.4 mg Magnesium carbonate, light (E504), 7.8-15.6 mg Hydroxypropylcellulose (E463), 3.9-11.7 mg Stearic acid (E570)).
32766915|NCT04884347|Placebo Comparator|Placebo|1095 mg Microcrystalline cellulose, 5 mg Magnesium stearate, 55 mg White coating (containing: 16.5-27.5 mg Hydroxypropylmethylcellulose (E464), 11.0-16.5 mg Calcium sulfate anhydrous (E516), 11.0-16.5 mg Magnesium carbonate, light (E504), 5.5-11.0 mg Hydroxypropylcellulose (E463), 2.8-8.2 mg Stearic acid (E570).
32766916|NCT04883723|Experimental|Experiment I (Shotblocker) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
32766917|NCT04883723|Experimental|Experiment II (Manual Pressure) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
32919603|NCT00836355|Experimental|Enoxaparin|
32919604|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
32919605|NCT00836355|Experimental|Enoxaparin and minocycline|
32919606|NCT00836355|No Intervention|Control|
32919607|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
32919608|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
32919609|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
32919610|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
32919611|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
32919612|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
32919613|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
32919614|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32919615|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
32919616|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
32919617|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
32919618|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
32919619|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
32919620|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
32919621|NCT00760461|Other|Domperidone|
32919622|NCT00750555|Other|1|
32919623|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
32919624|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
32919625|NCT00751335|Experimental|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
32919626|NCT00751335|Experimental|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
32919627|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
32919628|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
32919629|NCT00706329|Experimental|Deflux|Treatment with Deflux.
32919630|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
32919631|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
32919632|NCT00688935|Experimental|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
32919633|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
32919634|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
32919635|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
32919636|NCT00668265|Experimental|Seroquel|
32919637|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
32919638|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
32919639|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
32919640|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
32919641|NCT05313087||Controls - who are NOT in any of the groups listed below|Adults and children age 5 and over.
32919642|NCT05313087||Previous COVID infection|Adults and children age 5 and over.
32919643|NCT05313087||Asthma receiving immunomodulator medications|Adults and children age 5 and over.
32919644|NCT05313087||Asthma receiving chronic oral steroids|Adults and children age 5 and over.
32919645|NCT05313087||Asthma - NOT receiving immunomodulator medications or chronic oral steroids|Adults and children age 5 and over.
32919646|NCT05313087||Chronic Obstructive Pulmonary Disease (COPD|Adults
32919647|NCT05313087||Rheumatoid Arthritis receiving immunomodulator medications|Adults and children age 5 and over.
32919648|NCT05313087||Rheumatoid Arthritis NOT receiving immunomodulator medications|Adults and children age 5 and over.
32919649|NCT05313087||Interstitial lung disease|Adults and children age 5 and over.
32919650|NCT05313087||Cancer patients receiving chemotherapy|Adults and children age 5 and over.
32919651|NCT05313087||Bronchiectasis|Adults and children age 5 and over.
32919652|NCT05313087||Cystic fibrosis|Adults and children age 5 and over.
33248153|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
33248154|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
33248155|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
33248156|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
33248157|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
33248158|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
33248159|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
32718734|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
32718735|NCT05361538|Experimental|MTA Group|Use true circular microwave needle for ultrasound-guided thermal ablation in MSA （microwave spherical ablation） group.
32718736|NCT05361538|No Intervention|MWA Group|Use normal microwave needle for ultrasound-guided thermal ablation in MTA （microwave ablation） group.
32718737|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
32718738|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
32718739|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
33248160|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
33248161|NCT00905398|Experimental|nilotinib|single arm study
33248162|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
33248163|NCT00905710|No Intervention|1|Conventional colonoscopy
33248164|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
33248165|NCT00926302|Experimental|Test drug|Levetiracetam one period
32919653|NCT00633087|Experimental|2-deoxyglucose|
32919654|NCT00610467|Experimental|Disease Group|Patients with suspicious breast diseases
32919655|NCT00610467|Experimental|Control Group|Healthy volunteers for system testing
33248166|NCT00926302|Active Comparator|Reference drug|Keppra one period
33248167|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
33248168|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
32718740|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
32718741|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
32919656|NCT05312931||Group A|students who underwent original concept of First Aid
32919657|NCT05312931||Group B|student who underwent new concept of First Aid
32919658|NCT04713891|Experimental|Phase 1a: Cohort 1|KF-0210 tablet will be administered at 120 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
32919659|NCT04713891|Experimental|Phase 1a: Cohort 2|KF-0210 tablet will be administered at 240 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
32919660|NCT04713891|Experimental|Phase 1a: Cohort 3|KF-0210 tablet will be administered at 450 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
32919661|NCT04713891|Experimental|Phase 1a: Cohort 4|KF-0210 tablet will be administered at 600 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
32919662|NCT04713891|Experimental|Phase Ib, Cohort 1|KF-0210 (dose RP2D-2, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
33248169|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
33248170|NCT00905788|Experimental|Embryo Expulsion|
33248171|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
33248172|NCT00927238|Other|Outcomes from lumbar fusion study|
33248173|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
33248174|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
33248175|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
33248176|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
33248177|NCT00926692||Healthy Subjects|All subjects are considered healthy
33248178|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
33248179|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
33248180|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
33248181|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
33248182|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
32919663|NCT04713891|Experimental|Phase Ib, Cohort 2|KF-0210 (dose RP2D-1, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
32919664|NCT04713891|Experimental|Phase Ib, Cohort 3|KF-0210 (dose RP2D, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
32919665|NCT00379509|Experimental|GW572016|
32919666|NCT00597909|Experimental|Arm 1|
32718742|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
32919667|NCT00597909|Experimental|Arm 2|
32919668|NCT00597909|Placebo Comparator|Arm 3|
32919669|NCT00422955|Experimental|Arm 1|
32919670|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
32919671|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
32919672|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
32919673|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
32919674|NCT05600673|Experimental|Bimatoprost + CO2|Each patient received three CO2 fractional laser sessions 3 weeks apart with immediate and subsequent daily Bimatoprost 0.03%,1 drop for each 1cm².
32919675|NCT05600673|Active Comparator|CO2|Each patient received only three CO2 fractional laser sessions 3 weeks apart
32919676|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
32718743|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
32919677|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
32919678|NCT01760889|Experimental|SPD489 Low Dose Range|
32919679|NCT01760889|Experimental|SPD489 High Dose Range|
33248183|NCT00926770||Pretem infants (GG < 37+0)|
33248184|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
33248185|NCT03415464|No Intervention|Regular army training|Regular military training.
33248186|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
32718744|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
32718745|NCT05623072|Active Comparator|Experimental group|Participants will take active tDCS stimulation
32718746|NCT05623072|Sham Comparator|Control group|Participants will take sham tDCS stimulation
33248187|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
33248188|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, & Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
33248189|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
33248190|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
33248191|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
33248192|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
32919680|NCT01760889|Placebo Comparator|Placebo|
32919681|NCT05600517|No Intervention|Standard prevention fluoride P4+|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
32919682|NCT05600517|Experimental|Intensive prevention P4+|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
32919683|NCT05600517|No Intervention|Standard prevention fluoride P4-|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
32919684|NCT05600517|Experimental|Intensive prevention P4-|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
32919685|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
32919686|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
32919687|NCT05600439|Experimental|Experimental GP|CareME Program. Group attachment-based intervention program developed for improving relational abilities in professional caregivers working in Youth Residential Care (YRC) settings.
32919688|NCT05600439|No Intervention|Control GP|The control group had no intervention assigned.
32919689|NCT05600361|Other|Patients having 13C Pyruvate DNP for lymphoma early treatment response evaluate|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
32919690|NCT05600127|Experimental|Avelumab|3 cycles of avelumab (Bavencio), 800mg intravenous instillation in 60 min, every 2 weeks.
32919691|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
32919692|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
32919693|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
32919694|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
32919695|NCT05599737|Experimental|Radiotherapy|"Stereotactic radiotherapy in 5 fractions (on alternate day)~Whole prostate: 36.25 Gy - 7.25Gy/fraction~GTV-RT (boost): target 50 Gy - 10 Gy/fraction"
32919696|NCT05599659|Experimental|Palliative care|Participants will receive palliative care.
32919697|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
32718747|NCT04854772|Experimental|Mind Body Syndrome Therapy for Long Covid|"The participants will receive an initial one-on-one interview, followed by 1 to 2 hour biweekly group interactive, educational sessions for 12 weeks. This program also includes a day-long retreat at the end of the required course period. Participants will also be provided reading materials to study during the intervention period"
32718748|NCT05357248|Experimental|Intervention- BT-NCBT-00x|"The treatment, BT-NCBT-00x, consists of a software as a medical device developed by the study Sponsor, Better Therapeutics. It delivers treatment to participants with cardiometabolic disease, using behavioral therapy that targets individual behaviors related to improving dietary quality and physical activity. BT-NCBT-00x is accessed via the participants' smartphone after downloading from the phone's corresponding app store.~Participants will receive behavioral support by the Better Therapeutics patient services team in the form of phone calls as necessary or requested by the patient"
32718749|NCT05008432||HFpEF Patients Diagnosed with Obstructive Sleep Apnea|Right heart cath patients who are diagnosed with HFpEF will undergo a home sleep apnea test (for patients hospitalized with HFpEF, the initial home sleep test will be performed in hospital overnight)
32718750|NCT05617300|Experimental|MBDC course|8 week MBDC Course including 8 weekly 2 hour classes and a retreat (4 hours). Individual classes will be held virtually via web-based video calls.
32718751|NCT05005078|Placebo Comparator|Placebo|WST-057 Matching placebo
32718752|NCT05005078|Experimental|WST-057 active|WST-057 topical solution
32718753|NCT05352880|Experimental|transplant recipients|They will be recruited from the Renal Transplantation Clinic at Alexandria Main University hospital
32718754|NCT05616676|Experimental|Brief digital imagery-competing task|Access to a brief digital imagery-competing task for 24 weeks (first 4 weeks with optional researcher support).
32718755|NCT05616676|Experimental|Brief digital music-listening task|Access to a brief digital music-listening task for 24 weeks (first 4 weeks with optional researcher support).
32919698|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
32919699|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
32718756|NCT05616676|Experimental|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events for 24 weeks.
32718757|NCT04999462|Experimental|Full-fat fermented dairy|1 serving per day of full-fat yogurt and full-fat fermented cheese
32919700|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
32919701|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
32919702|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
32919703|NCT05599425|Active Comparator|Healthy Living Education|The basic healthy living education intervention is a 24-session program (two sessions/week for 12 weeks) designed to educate participants about major modifiable risk factors for Alzheimer's disease. The first session each week is didactic, intended to increase knowledge about each Alzheimer's disease risk factor. The second session involves repetition and practice of didactic material as well as strategizing cues to action
32919704|NCT05599425|Experimental|Enhanced Healthy Living Education|The enhanced healthy living education intervention will include the same didactic content as the basic HLE course for the first session each week. The second session will focus on personal health beliefs and how they affect specific health behaviors. This may include discussing perceived benefits, troubleshooting barriers to action, making specific action plans, and implementing natural reward systems to bolster self-efficacy.
32919705|NCT05599347|Experimental|Azithromycin|5-day consecutive treatment with oral azithromycin 500 mg once daily
32919706|NCT05599347|Placebo Comparator|Control|5-day consecutive oral placebo once daily
32919707|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
32919708|NCT05599269|Other|Examination of dentures with SR Phonares II teeth|
32919709|NCT05599113|Experimental|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and muscle pain treatments, is non-invasive, is well tolerated by patients, and has few side effects.
32919710|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
32919711|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
32919712|NCT01621737|Placebo Comparator|Placebo|
32919713|NCT05598801||VersaWrap|All enrolled patients will received VersaWrap applied prior to surgical closure on the affected tendon.
32919714|NCT05597241|Experimental|Cohort 1, Apimostinel|Apimostinel, 25 mg IV single dose
32718758|NCT04999462|Active Comparator|Low-fat fermented dairy|1 serving per day of low-fat yogurt and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
32919715|NCT05597241|Placebo Comparator|Cohort 1, Placebo|Placebo, IV single Dose
32919716|NCT05597241|Experimental|Cohort 2, Apimostinel, 1 mg IV 8 consecutive daily doses|Apimostinel, 1 mg IV 8 consecutive daily doses
32718759|NCT04999462|Placebo Comparator|Non-dairy, non-fermented foods|2 servings per day of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
32718760|NCT04992832|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.
32718761|NCT04992832|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
32718762|NCT05344066|Active Comparator|Best NHS Care|Best National Health Service (NHS) Care
32718763|NCT05344066|Experimental|Intermittent Low Energy Diet|Intermittent Low Energy Diet
32919717|NCT05597241|Placebo Comparator|Cohort 2, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
32919718|NCT05597241|Experimental|Cohort 3, Apimostinel, 5 mg IV 8 consecutive daily doses|Apimostinel, 5 mg IV 8 consecutive daily doses
32919719|NCT05597241|Placebo Comparator|Cohort 3, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
32919720|NCT05597241|Experimental|Cohort 4, Apimostinel, 10 mg IV 8 consecutive daily doses|Apimostinel, 10 mg IV 8 consecutive daily doses
32718764|NCT04853992|Experimental|Active - Placebo|Patients will receive active treatment for 7 days, followed by a washout period of 7 days and then placebo for 7 days
32718765|NCT04853992|Experimental|Placebo - Active|Patients will receive placebo for 7 days, followed by a washout period of 7 days and then active treatment for 7 days
32718766|NCT05608954||Physical Therapy Modalities|Children diagnosed with cerebral palsy will be followed longitudinally in their therapies within the physiotherapeutic treatment.
32718767|NCT05603338|Active Comparator|LSG|just laparoscopic sleeve gastrectomy without banding
32718768|NCT05603338|Experimental|LSG with omental band|laparoscopic sleeve gastrectomy with omental banding
32718769|NCT04988308|Placebo Comparator|Part 1 (Group 1): Placebo|Participants will receive placebo subcutaneously (SC) at Week 0 through Week 15. At Week 16, participants will cross over to receive bermekimab dose 1 SC every week thereafter through Week 31.
32718770|NCT04988308|Active Comparator|Part 1 (Group 2): Adalimumab|Participants will receive adalimumab 160 milligrams (mg) SC at Week 0, placebo SC at Week 1, followed by adalimumab 80 mg SC and placebo SC at Weeks 2 and 3. Participants will then receive adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
32718771|NCT04988308|Experimental|Part 1 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC and placebo SC at Week 0, followed by bermekimab dose 1 SC at Week 1 and every week thereafter through Week 31.
32718772|NCT04988308|Placebo Comparator|Part 2 (Group 1): Placebo|Participants will receive placebo SC from Week 0 through Week 11. At Week 12, participants will cross over to receive bermekimab dose 1 SC weekly through Week 31.
32718773|NCT04988308|Experimental|Part 2 (Group 2): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 31.
32919721|NCT05597241|Placebo Comparator|Cohort 4, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
32919722|NCT05597241|Experimental|Cohort 5, Apimostinel, 25 mg IV, 8 consecutive daily doses|Apimostinel, 25 mg IV 8 consecutive daily doses
32919723|NCT05597241|Placebo Comparator|Cohort 5, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
32919724|NCT04706169||Older adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Older adult group: over 65 years.
32919725|NCT04706169||Adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Adult groups: 20 to 64 years.
32718774|NCT04988308|Experimental|Part 2 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 1 SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
32718775|NCT04988308|Experimental|Part 2 (Group 4): Bermekimab Dose 2|Participants will receive bermekimab dose 2 SC and placebo SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 2 SC and placebo SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
32718776|NCT05586490|Experimental|In-lab and in home feasibility testing of research device in people with Parkinson's disease (PwP)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). This arm will use the experimental device in home feasibility testing (aim 3).
32718777|NCT05586490|Active Comparator|In-home feasibility testing (alternate device)|"Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2).~This arm will use another device to compare to the experimental device for in home feasibility of using the device at home (aim 3)."
32718778|NCT05586490|Other|In-home feasibility testing (no device in at home portion)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). For the at home portion, this arm will not use any device but have the same outcomes measured. (aim 3)
32718779|NCT04984798|Experimental|Vitamin E Dose-Escalation|Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks. The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily). Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
32718780|NCT04974658|Active Comparator|The block group (ISP)|After aseptic preparation of the injection area, the needle will be introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of 0.25% bupivacaine on each side will be injected for each block.
32718781|NCT04974658|Placebo Comparator|control group (C)|No block will be performed
32919726|NCT05594277||surgical elderly patients|Patients ≥ 70 years old, undergoing a major surgery in general and vascular surgery, urology, orthopedics at Maggiore della Carità University Hospital, Novara, Italy, having a General Practitioner listed in the Local Health Authority of Novara.
32919727|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
32919728|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
32919729|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.|COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
32919730|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
32919731|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
32919732|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
32919733|NCT05562687||Control group|subjects who do not have any heart disease, hypertension, or other chronic &inflammatory diseases, and their coronary arteries are normal
32919734|NCT05562687||CAD group with essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have high blood pressure
32919735|NCT05562687||CAD group without essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have normal blood pressure
33073334|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
32718782|NCT04843306|Experimental|ABC technique plus biofeedback|Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
32718783|NCT04843306|Active Comparator|Standard of care ABC technique.|Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.
32718784|NCT04843228|Experimental|Active Cognitive Bias Modification Group|This group of participants will receive 4 sessions of CBM targeting their interpretation biases for perfectionism and intolerance to uncertainty.
32718785|NCT04843228|Placebo Comparator|Placebo-Control Cognitive Bias Modification Group|This group of participants will receive 4 sessions of inactive CBM.
32718786|NCT04843072|Experimental|Evolut R/Pro bioprosthesis|Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)
32718787|NCT04843072|Active Comparator|Edwards Sapien S3/Ultra bioprosthesis|Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)
32919736|NCT05562687||Hypertension group without CAD|the subjects were characterized by the normal coronary artery and high blood pressure
32919737|NCT02010983|Experimental|longstanding achalasia|
32919738|NCT05722925|Experimental|Fluciclovine PET/CT|Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.
32919739|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
33248193|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
33248194|NCT00746148|Experimental|1|Reflexology
33248195|NCT00746148|No Intervention|2|No intervention
32919740|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
32919741|NCT01912313|Experimental|Rectal biopsy|
32919742|NCT05722769|Experimental|CSTOP Now! Child Sex Trafficking Stops with You|For this RCT, our research team has created CSTOP Now! online, interactive learning management system training. This CSTOP Now! online training will be offer to middle school staff in Kentucky counties randomized to this experimental intervention arm. This training seeks to provide middle school staff with information and resources to identify, intervene in, and prevent child sex trafficking (CST). This training will provide middle school staff with the knowledge, skills, and efficacy to intervene with children at risk of or experiencing CST. This training will also provide staff with skills to disrupt harmful attitudes or misinformation about CST.
32919743|NCT05722769|Active Comparator|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed training videos designed to identify child sex trafficking. For middle school staff in counties randomized to the active comparator, we offer these video as online training. Prevent Child Abuse Kentucky has consented to this use of their child sex trafficking identification training videos.
32919744|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
32718788|NCT05576662|Experimental|Nirmatrelvir plus ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days, and attend follow-up visits through week 15.
32919745|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
32919746|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
32919747|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
32919748|NCT05550519|Experimental|Discontinuation of Nucleos(t)ide (NA) Treatment|Participants will receive standard of care NA treatment (Entecavir [ETV], Tenofovir Disoproxil Fumarate [TDF], Tenofovir Alafenamide [TAF]) in screening phase (up to 6 weeks) and in baseline visit (Day -1). NA treatment will be discontinued on Day 1 up to 96 weeks (Post-NA discontinuation off-treatment phase). Off-treatment refers to the phase after baseline, in which NA treatment will be discontinued.
32919749|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
32919750|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
32919753|NCT05722691|Experimental|Double-stranded RNA sodium salt|Arm 1 (n=400) received the study drug RADAMIN®VIRO once intramuscularly, 5 mg (1 vial).
32919754|NCT05722691|Placebo Comparator|Placebo|Arm 2 (n = 400) received 1 vial of placebo once intramuscularly
32919755|NCT05722613||(Group A) periodontally healthy as a control|BOP <10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).
32919756|NCT05722613||(Group B) periodontitis currently unstable|Generalized periodontitis, currently unstable (PPD ≥ 5mm or PPD at ≥ 4mm with BOP).
32919757|NCT05722613||(Group C)periodontitis currently stable .|Generalized periodontitis, currently stable (BOP < 10 % PPD ≤4 mm and no BOP at 4mm sites)
32919758|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
32919759|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
32919760|NCT05722535|No Intervention|Delayed MDPT|Families assigned to the control condition will receive the MDPT after study completion.
32919761|NCT05722535|Experimental|MDPT|Families randomized to the intervention condition will receive the MDPT after they complete the baseline survey.
32919762|NCT05523843||Treatment seeking individuals|Individuals seeking treatment in the Laureate Psychiatric Clinic and Hospital (LPCH).
32919763|NCT05523843||Healthcare professionals|Healthcare professionals (HCPS) include nurses, psychologists, therapists, medical doctors, dieticians, etc who work at LPCH and are engaged in direct patient care.
32919764|NCT05494125|Experimental|ESP Catheters with Ropivacaine 0.2%|
32919765|NCT05494125|Placebo Comparator|ESP Catheters with Saline Solution|
33248196|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
32718789|NCT05576662|Placebo Comparator|Placebo plus ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days, and attend follow-up visits through week 15.
32718790|NCT05319028|Experimental|Continuous Dosing Schedule|Mivavotinib 100 mg once daily (QD)
32919766|NCT01548651|Placebo Comparator|Placebo|Placebo 5 mg orally daily for 6 months
32919767|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
32919768|NCT05722457|Other|Investigation of the Effects of External Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
32919769|NCT05722457|Other|Investigation of the Effects of İnternal Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of internal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of İnternal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
32919770|NCT05478525|Experimental|0.5 g GLY-200|
32919771|NCT05478525|Experimental|1.0 g GLY-200|
32919772|NCT05478525|Experimental|2.0 g GLY-200|
32919773|NCT05478525|Placebo Comparator|Placebo for 0.5 g GLY-200 arm|
32919774|NCT05478525|Placebo Comparator|Placebo for 1.0 g GLY-200 arm|
32919775|NCT05478525|Placebo Comparator|Placebo for 2.0 GLY-200 arm|
32919776|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
32919777|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
32718791|NCT05319028|Experimental|Induction Dosing Schedule|Mivavotinib 120 mg QD for 14 days, then 80 mg QD starting Day 15
32718792|NCT03751007|Experimental|AG019 Cohort 1 - Low Dose/Adults|
32718793|NCT03751007|Experimental|AG019 Cohort 2 - High Dose/Adults|
32718794|NCT03751007|Experimental|AG019 Cohort 3 - Low Dose/Adolescents|
32718795|NCT03751007|Experimental|AG019 Cohort 4 - High Dose/Adolescents|
32718796|NCT03751007|Experimental|Combination Cohort 1 - Adults|
32718797|NCT03751007|Experimental|Combination Cohort 2 - Adolescents|
32718798|NCT05725967||Primary Obesity Endoscopic Procedures|Primary endoscopic procedures for treatment of obesity.
32718799|NCT05725967||Endoscopic Revision of Bariatric Surgical Procedures|Endoscopic revision of post-bariatric surgical complications.
32919778|NCT05453877||subjects from Kailuan community|"1. Age from 18 to 90 years old; 2. Comes from the Kailuan Cohort, completed ≥1 visits which the medical history, physiological indicators were measured; 3. Without contraindications of CT and MR scan; 4. Can cooperate with the measurement of the medical history, physiological indicators and brain imaging.~Subjects with the following conditions should be excluded:~1. Known clinical history with congenital or acquired organic diseases (such as aortic stenosis); 2. Known history of drug abuse; 3. Pregnant and lactating women; 4. With clinical history of psychiatric diseases (such as schizophrenia)."
33248197|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
33248198|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
33248199|NCT00567502||2|Xagrid + Other cytoreductive
33248200|NCT00567502||3|Other cytoreductive
32718800|NCT05725967||Bariatric Surgery Procedures|Bariatric surgical procedures.
32718801|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
33248201|NCT00746304||1|infantile esotropia
33248202|NCT00746304||2|acquired esotropia
33248203|NCT00396331|Experimental|G-CSF plus Plerixafor|
33248204|NCT00927550|Experimental|lithium plus usual care|
33248205|NCT00927550|Active Comparator|usual care without lithium therapy|
33248206|NCT00926926|Experimental|Active OTG|
33248207|NCT00926926|Placebo Comparator|Placebo|
32718802|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
33248208|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
33248209|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
33248210|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
33248211|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
33248212|NCT00927004|Experimental|Etoricoxib 60 mg|
33248213|NCT00927004|Placebo Comparator|Sugar pill|
32718803|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
32718804|NCT05726279|No Intervention|Observational Cohort|Participants treated with standard guideline-based care for 24 hours. Blood pressure treatment thresholds will be used according to standard practice parameters
32718805|NCT05726279|Experimental|Interventional|Autoregulation-guided blood pressure management for 24 hours. Blood pressure will be measured every four hours by arm cuff; however, in lieu of predetermined blood pressure treatment thresholds, an optimal mean arterial pressure (MAP) range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
32919779|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
32919780|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
32919781|NCT05414565||Vivity IOL|Subjects previously implanted with Vivity or Vivity toric IOL
33248214|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
33248215|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
33248216|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
32919782|NCT05414565||Aspheric Monofocal IOL|Subjects previously implanted with an aspheric monofocal or monofocal toric IOL
33248217|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
33248218|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
33248219|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
33248220|NCT04014946|Other|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
33248221|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
32919783|NCT05722379||high-grade AVB patients undergoing permanent pacemaker implantations|
32919784|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
32919785|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
32919786|NCT05722301|Experimental|Testosterone Therapy|
32919787|NCT05722301|Placebo Comparator|No Testosterone Therapy|
32919788|NCT05413005|Experimental|Group A (ECP regular-intensity arm)|ECP in a regular-intensity arm plus T1DM standard of care
32919789|NCT05413005|Experimental|Group B (ECP accelerated-intensity arm)|ECP in an accelerated-intensity arm plus T1DM standard of care
32919792|NCT04344509||COVID19-positive patients|
32919793|NCT04344509||COVID19-negative patients|
32919794|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
32919795|NCT02978729|Active Comparator|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
32919796|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
32919797|NCT05722223|Experimental|Training group|Pancreatic patients will participate in the trimodal prehabilitation: nutrition, psychological and exercise support.
32919798|NCT05381961||Stable hemodialysis regimen|Up to 50 patients on hemodialysis >6 months, with stable target/dry weight, and have not been hospitalized recently
32919799|NCT05381961||Unstable hemodialysis regimen|Up to 20 patients who have been on hemodialysis <6 months, or have unintended weight loss/gain, or have recently been hospitalized
32919800|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
32919801|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
32919802|NCT05722067|Experimental|oocytes treated with calcium ionophore|Oocytes treated with a ready-to-use ionophore compound (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF). After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes subjected to AOA will transfer to the same time-lapse culture dish with the controlled sibling group.
32718806|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
32919803|NCT05722067|No Intervention|oocytes undergo routine IVF/ICSI protocol|Untreated control oocytes will immediately place into the time-lapse imaging system, and the culture protocol was routine.
32919804|NCT05290077|Active Comparator|Cases|group of vitiligo patients
32919805|NCT05290077|Active Comparator|control group|healthy group
32919806|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
32919807|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
32919808|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
32919809|NCT05723471|Experimental|Adaptative Physical Activity|
32919810|NCT05723471|No Intervention|Standard Exercise|
32919811|NCT05723315|Experimental|Experimental Group 1|The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).
32919812|NCT05723315|No Intervention|Control Gruop|The experimental group was given an intravenous infusion of the same amount of normal saline
32919813|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
32919814|NCT05721833|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
32919815|NCT05721833|Active Comparator|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
32919816|NCT05263401|Experimental|Ketone salt|Na-D/L-3-hydroxybutyrate dissolved in tap water.
32919817|NCT05263401|Experimental|Ketone ester|(R)-3-Hydroxybutyl (R)-3-hydroxybutyrate
32919818|NCT05263401|Placebo Comparator|Placebo|Tap water
32919819|NCT05715749|Experimental|In-home body weight support harness system|All participants will be entered into treatment arm and receive an in-home body weight support harness system
32919820|NCT05715671|Experimental|Esketamine for induction 0.2mg/kg and maintenance 0.2mg/kg/h|
32919821|NCT05715671|Experimental|Esketamine for induction 0.3mg/kg and maintenance 0.3mg/kg/h|
32919822|NCT05715671|No Intervention|No esketamine|
32919823|NCT05721755|Experimental|Arm A (pembrolizumab and radiation)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV with radiation therapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
32919824|NCT05721755|Active Comparator|Arm B (pembrolizumab monotherapy)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV monotherapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
32919825|NCT05721755|No Intervention|Arm S (no intervention)|Patients proceed directly to Step II.
32718807|NCT04580537|Experimental|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
32919826|NCT05721755|Experimental|Arm T (pembrolizumab, chemotherapy)|Patients receive pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV and fluorouracil IV on study.
32919827|NCT05715593|Experimental|Education|
32919828|NCT05715593|No Intervention|Control|
32919829|NCT00570531|Experimental|Bevacizumab|
32919830|NCT05721599|Experimental|Intervention group|Structured integrated care model
32919831|NCT05721599|No Intervention|Control group|General outpatient care
32919832|NCT05258565|Active Comparator|acute ischemic stroke without covid -19 infection|Administration of IV tPA: the dose of activase is ,9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
32919833|NCT05258565|Active Comparator|acute ischemic stroke associated with covid -19 infection|Administration of IV tPA: the dose of activase is, 9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
32919834|NCT04344743|Experimental|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
32919835|NCT05715515|Experimental|Nasal sampling/Testing (Self-Test) + Nasopharyngeal sampling/Testing (Professional Use)|"Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit.~The first NP swab sample will be used to conduct a Panbio™ COVID- 19/FluA&B Rapid Panel Professional Use test.~The second NP swab sample will be eluted in Universal Transport Medium (UTM) provided by Abbott/the Core Laboratory, labelled and stored, according to the laboratory manual. UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, according to the laboratory manual."
32919836|NCT05216991||TetraGraph monitoring on dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
32919837|NCT05216991||TetraGraph monitoring on non-dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
32919838|NCT05715437|Experimental|Bupivacaine plus Normal Saline|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml Normal saline postoperative TKA.
32718808|NCT04580537|Active Comparator|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
32718809|NCT04546841|Experimental|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.~Part I: Age 18-55 at the time of screening, n=12~Part II: Age 56-74 years at the time of screening, n=12~Part III: Age ≥ 75 years at the time of screening, n=12"
32718810|NCT00112073|Experimental|0.15 mg/kg active bapineuzumab|
32718811|NCT00112073|Placebo Comparator|0.15 mg/kg placebo|
32718812|NCT00112073|Experimental|0.5 mg/kg active bapineuzumab|
32718813|NCT00112073|Placebo Comparator|0.5 mg/kg placebo|
32919839|NCT05715437|Experimental|Bupivacaine and Ketamine|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml ketamine (50mg) postoperative TKA.
32919840|NCT05216367|Experimental|Cohort 1 (healthy subjects)|8 healthy subjects with normal hepatic function will receive a single dose of 5 mg (1x5 mg) fruquintinib
32919841|NCT05216367|Experimental|Cohort 2 (moderate hepatic impairment)|8 subjects with moderate hepatic impairment will receive a single dose of 2 mg (2 x 1 mg) fruquintinib
32919842|NCT05216367|Experimental|Cohort 3 (mild hepatic impairment)|8 subjects with mild hepatic impairment will receive a single dose of 5 mg (1 x 5 mg) fruquintinib
32718814|NCT00112073|Experimental|1.0 mg/kg active bapineuzumab|
32718815|NCT00112073|Placebo Comparator|1.0 mg/kg placebo|
32718816|NCT00112073|Experimental|2.0 mg/kg active bapineuzumab|
32718817|NCT00112073|Placebo Comparator|2.0 mg/kg placebo|
32718818|NCT00141323|Experimental|lasofoxifene 0.5 mg/day|
32718819|NCT00141323|Placebo Comparator|placebo|
32718820|NCT00141323|Experimental|lasofoxifene 0.25 mg/day|
32718821|NCT00135395|Active Comparator|A|
32718822|NCT00135395|Active Comparator|B|
32718823|NCT05725889||DIABETES|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels, and the duration of their diabetes were recorded.
32718824|NCT05725889||CONTROL|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels were recorded.
32718825|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
32919843|NCT05721521|Experimental|High intensity|
32919844|NCT05721521|Experimental|Moderate intensity|
32919845|NCT05721521|Experimental|Low intensity|
32919846|NCT05721521|Placebo Comparator|No exercise (control)|
32919847|NCT05105451||Patients in the control group were followed up without dNCR postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
32718826|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
32718827|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
32718828|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
32718829|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
32718830|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
32718831|NCT02230631||Part 2 (prospective observational evaluation)|
32718832|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
32919848|NCT05105451||Patients in the case group were followed up with dNCR postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time), it is defined as the occurrence of dNCR.
32919849|NCT05721443|Experimental|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
32919850|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
32919851|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
32919852|NCT05715281|Experimental|Treatment (atezolizumab, tiragolumab)|Patients receive atezolizumab and tiragolumab IV on day 1 of a 21-day cycle on study. Patients also undergo ECHO during screening, and CT scans, tumor biopsy, and blood sample collection on study.
32919853|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
32919854|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
32919855|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
32919856|NCT05721365||Pre-Infusion|Participants prior to commencing Adoptive Cell Therapy (ACT).
32919857|NCT05721365||Acute|Participants either receiving ACT or up to 30 days post treatment.
32919858|NCT05721365||Sub-acute|Up to 12 months post ACT.
32919859|NCT05721365||Long term follow up|From 12 months post ACT onwards
32919860|NCT05097807|Experimental|The impact of word-picture-based shallow reading in social media|Use Microblog on their smartphone, a word-picture-based social media service similar to twitter.
32919861|NCT05097807|Experimental|The impact of short video-based shallow reading in social media|Use Tiktok on their smartphone, a short video-based social media service.
32919862|NCT05097807|Active Comparator|The impact of full-length sci-fi novel reading|Read a full-length sci-fi novel (Three body) on their own smartphone.
32919863|NCT05097807|Active Comparator|The impact of film/TV series|Watch a film on their own smartphone.
32919864|NCT02988817|Experimental|Enapotamab vedotin (HuMax-AXL-ADC)|Participants in all cohorts of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC) intravenously (IV).
32919865|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
32919866|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
32919867|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
32718833|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
33248222|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
33248223|NCT00928330|Experimental|A|
32919870|NCT05065281|Experimental|Education|Participants that have undergone the educational intervention
32919871|NCT05065281|No Intervention|Waitlist|Participants still waiting to cross over to intervention arm
32919872|NCT00511329|Experimental|Somatropin|
32919873|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
32919874|NCT05714501|Experimental|Single Arm|Millipede System
32718834|NCT02230787|Active Comparator|Recession coverage without Emdogain|
32718835|NCT02230787|Experimental|Recession coverage with Emdogain|
32718836|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
32742922|NCT04415853|Active Comparator|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
32919875|NCT00501345|Experimental|Aspirin|
32919876|NCT05721287|Active Comparator|SBS-1000|Investigational Product
33248224|NCT00928330|Experimental|B|
33248225|NCT00928330|Experimental|C|
33248226|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
32718837|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
32718838|NCT05723549|Experimental|group1|Period1 : HCP1803-3
32718839|NCT05723549|Active Comparator|group2|Period1 : RLD2002, HCP1904-1
32919877|NCT05721287|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride [NaCl])
32919878|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
32919879|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
32919880|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
32919881|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
32919882|NCT02978651|Placebo Comparator|Placebo|Placebo
32919883|NCT05712629|Active Comparator|Responden Intervention|Arm 1 (Interventional) : Respondent has given bread with composit flour and vla with dadiah. pregnant women received 1 pieces bread containing 50 gram provide total fat 4 gram, protein 5 gram, carbohydrate 23.8 gram, Fe 2 mg, 2150 kcal and vla dadiah containing 30 gram provide 308 kcal.
32919884|NCT05712629|Placebo Comparator|Responden Placebo|Arm 2 (Placebo) : Respondent has given bread with original flour (wheat flour) and vla original without dadiah. pregnant women received 1 pieces bread containing 50 gram and vla containing 30 gram.
32919885|NCT04972383|Experimental|Platelet Rich Plasma group|single injection platelet rich plasma
32919886|NCT04972383|Experimental|Hyaluronic Acid group|single injection of hyaluronic acid
32919887|NCT04962321|Experimental|PsychoEd|These participants are enrolled to participate in the 8-session education sessions.
32919888|NCT05721131||Temperature measurement|Each subject will have their temperature measured by both the NC° Thermometer (Gen 3) and the reference clinical thermometer.
32919889|NCT05243485||Cohort 1 (reference group)|500 patients will be included as an observatory control group and as a reference group to the second cohort. The PreHEART score is calculated without further consequences for triage in the ambulance and are transferred to the ED of the nearest hospital for standard care.
32919890|NCT05243485||Cohort 2 (intervention group)|500 patients will be included in the interventional cohort. The calculated PreHEART score has consequences for triage in the ambulance. If the PreHEART score is ≥ 5, the patient is classified as a high-risk patient for having NSTE-ACS. These patients are immediately transferred to the ED of the nearest PCI center for further diagnostic examination and to rule out other life-threatening pathologies. When the PreHEART score is ≤ 4, the patient is classified as a low-risk patient for having NSTE-ACS and is transferred to the ED of the nearest hospital without PCI facilities (non-PCI center) for further diagnostic work-up
32919891|NCT04954443|Experimental|Removing urinary catheter at 24 hours after surgery|The participants will removing urinary catheters at 24 hour after vaginal surgery of pelvic organ prolapse.
32718840|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
32718841|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
32919892|NCT04954443|Placebo Comparator|Removing urinary catheter at 48 hours after surgery|The participants will removing urinary catheters at 48 hour after vaginal surgery of pelvic organ prolapse.
32718842|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
32718843|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
32718844|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
32919893|NCT05721053||Older Adults in Radiation Therapy|Older Adults who are receiving Radiation Therapy.
32919894|NCT05207761|Experimental|Sequence 1|"Period 1: D565 7days~Period 2: D565+D930 91days"
32919895|NCT05207761|Experimental|Sequence 2|"Period 1: D930 91days~Period 2: D565+D930 7days"
32919896|NCT05720975||Experimental: iNstroke|Study device
32919897|NCT04912869|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
32919898|NCT04912869|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching Placebo.
32919899|NCT05459935|Experimental|PBM Tonsil Arm|Photobiomodulation exposure of hypertrophic tonsils
32919900|NCT05459935|Sham Comparator|Tonsil Control Arm|Sham (non-powered) exposure of hypertrophic tonsils
32919901|NCT05720897|Experimental|Auditory Alone Brief Relaxation|Participants randomized to this arm will receive earphones to listen to a guided brief relaxation recording, focusing on breathing and a body scan, prior to their dental procedure.
32919902|NCT05720897|Experimental|Relaxation Virtual Reality|Participants will receive virtual reality goggles and choose a scene of their liking to experience, prior to their dental procedure.
32919903|NCT05178979|Experimental|Intervention|The intervention arm will receive up to 4 sessions of training. Trained intervention facilitator experienced in health professional trainings will lead the training. The intervention content delivered is aimed to increase HIV providers' knowledge, motivation, skills, and empathy to: 1) equitably deliver ART program guidelines (i.e., quality of care) and 2) provide gender sensitive counseling to address ART patients' gendered barriers to HIV care engagement, increasing patient satisfaction, retention, and ART adherence, and reducing gender disparities in HIV outcomes.
32919904|NCT05178979|No Intervention|Control|The control arm will receive no training.
32919905|NCT00370695|Experimental|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
32919906|NCT05720819|Experimental|Intervention Group (Biofeedback-VR intervention plus standard clinical care)|This arm includes individuals with chronic migraine receiving the home-based biofeedback-VR intervention plus standard medical care as treatment for chronic migraine
32919907|NCT05720819|No Intervention|Control Group (standard clinical care alone)|This arm, a wait-list control group, includes individuals with chronic migraine receiving standard medical care alone as treatment for chronic migraine.
32919908|NCT00356187|Experimental|Propranol Treatment|
32919909|NCT00356187|No Intervention|Standard of Care|
32919910|NCT05709899|Other|Group I : Bilateral erector spinae plane block.|"Ultrasound (US) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. A high frequency linear-array US transducer covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. 2-3 ml of 2% lidocaine depocaine HCL will be infiltrated.16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the US beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle. 20 ml of bupivacaine 0.5% sunnypivacaine will be injected in this potential space over five minutes. The injectate will be observed spreading underneath the ES muscle lifting the muscle of the transverse process. This will be repeated on the opposite side."
32919911|NCT05709899|Other|Group II : Transmuscular quadratus lumborum block|"Patient will be positioned in left lateral to obtain appropriate view of QL. Aseptic precautions will be taken by wearing sterile gown and sterile drapes. By using Ultrasound MacroMaxx™ with linear probe (HFL38_10-5 MHz) covered with sterile plastic sheath SiteRite placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this juncture the layers of abdominal layers will start to taper. When the probe will be placed in the posterior axillary line as per the posterior approach, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL noticed. At the junction of the tapered ends of abdominal muscles and QL, a 21 g 100 mm SonoPlexStimu cannula needle will be inserted in plane. Under ultrasound guidance, in that space 20 mL of 0.5% bupivacaine sunnypivacainewill be injected separating the fascia."
32919912|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
32919913|NCT05708963||U.K. Embryologists|U.K. embryologists of all ages, career levels, and other sociodemographic groups will be asked questions about their physical and mental health related to their occupational characteristics using the nationally validated surveys and questionnaires, and also about their working conditions in the ART/IVF laboratories using a custom occupational questionnaire and the single-item work unit grade (A-F).
32919914|NCT04879563|Experimental|ASCAPE-based follow-up strategy|Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
32919915|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function healthy adults|Testing of manometric, impedance and biomechanical measurements during swallowing in healthy volunteer adult subjects.
32919916|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function in patients with ineffective esophageal motility|Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with ineffective esophageal motility.
32919917|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function patients with symptoms but normal esophageal manometry|"Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with symptoms of dysphagia but normal esophageal manometry by the Chicago Classification criteria."
32919918|NCT04680117|Other|Cases with SA, classified by age group|Patient hospitalized for assessment of severe asthma
32919919|NCT04680117|Other|Controls among children w/ SA: frequent&infrequent exacerbators|Frequent exacerbators have 2 or more asthma severe exacerbations in the past years
32919920|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
32919921|NCT00320931|Experimental|Hybrid PET/CT|
32919922|NCT05704205|Experimental|NB-UVB+OTT|8-16 weeks of NB-UVB phototherapy combined with (a minimum of) 3 months of optimal topical therapy
32919923|NCT05704205|Active Comparator|Optimal topical therapy (OTT)|(a minimum of) 3 months of optimal topical therapy
32919924|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
32919925|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
32919926|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
32919927|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
32919928|NCT05720585|Experimental|Intervention group|
32919929|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
32919930|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
32919931|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
32919932|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
32919933|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
33248227|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
33248228|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
33248229|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
33248230|NCT04014712|Experimental|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
33248231|NCT04014712|Placebo Comparator|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
32718845|NCT05721209|Experimental|VRTT With Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
33248232|NCT00932074|Experimental|3% KP-413 Ointment|
33248233|NCT00932074|Experimental|1% KP-413 Ointment|
33248234|NCT00932074|Placebo Comparator|Placebo|
32766918|NCT04883723|No Intervention|Control Group|The patients in the Manual Pressure group were given detailed information about the procedure and the research, and the patients who agreed to participate in the study were signed by an informed consent form. Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Injection was given using the normal intramuscular injection procedure. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
32919934|NCT05702801|Experimental|Exposure to stochastic vibratory stimulation|All participants will be exposed to vibratory stimulations at different levels of 0Hz, 40Hz, and 80Hz.
33248235|NCT04034368|Experimental|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
33248236|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
32718846|NCT05721209|Experimental|VRTT With Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
32919935|NCT04874623|Experimental|CDI|
33248237|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
33248238|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
33248239|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
33248240|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
33248241|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
33248242|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
33248243|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
33248244|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
33248245|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
33248246|NCT00929032||Liver transplant recipient|Liver transplant recipient
33248247|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
33248248|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
33248249|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
33248250|NCT00932386|Placebo Comparator|normal saline|
33248251|NCT00932464|Experimental|1|Neratinib Fasted
33248252|NCT00932464|Experimental|2|Neratinib Fed
33248253|NCT00932542|Experimental|Eutectic mixture|
33248254|NCT00932542|Placebo Comparator|placebo|
33248255|NCT00932542|Active Comparator|Medicaina|
33248256|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
33248257|NCT05277454|Experimental|HMPL-653 open-label treatment arm|"Dose-escalation Stage:~Participants will be treated with escalating doses of HMPL-653 to determine the MTD and RP2D.~Dose-expansion Stage:~Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of HMPL-653 in TGCT and specific advanced solid tumors."
33248258|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
33248259|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
33248260|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
33399971|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
32919936|NCT05702255|Experimental|Active acupoints group|All participants in the active group will be treated with basic acupoints Zhongwan (CV 12), Tianshu (ST25) in alternation with Sanyinjiao (SP 6), Zusanli (ST 36). Moreover according to traditional Chinese medicine diagnosis, additional acupoints will be added. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
32919937|NCT05702255|Sham Comparator|Sham acupoints group|All participants on the sham acupoints group will recieive sham Zhongwan (CV 12), sham Tianshu (ST25), sham Sanyinjiao (SP 6), and sham Zusanli (ST 36) acupressure. All the sham points are 2 cm outside and parallel to the actual points which do not match any recognized acupuncture points and are thought to have no therapeutic effect. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
32919938|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
32919939|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
32919940|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
32919941|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
32919942|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
32919943|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
32919944|NCT05720429|Experimental|Primary care workers|"Primary care health personnel who will voluntarily join the psychoeducational program of their center.~All professional profiles working in primary care centers are eligible (ie primary care nurses, physiotherapists, family doctors, pediatricians, dentists, administrative staff, etc.). Groups of 10-15 people. Several groups can be established in the same center if the demand is high enough."
32919945|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
32718847|NCT05721209|Active Comparator|VRTT Without Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
32718848|NCT05721209|Active Comparator|VRTT Without Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
32718849|NCT04261049|Experimental|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
33248261|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
33399972|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
32718852|NCT05715359||Reconstruction of jaws.|Patients treated with free tissue transfer reconstruction of the jaws.
32718853|NCT05725811|Active Comparator|Intervention group 1|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~For the IG 1, the technique will be applied to the hamstrings muscles. In this group, participants will sit on the floor on a mat with the roller under their thighs. Their hands will be placed on the floor with their fingers pointing downwards. The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers. The limb that will not be tested will function as a lever, it will remain bent to the side, which will allow the simple realization of the glide.~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome & Tuner v.11.8 IOS)."
32919946|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
33073335|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
32919947|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
32919948|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
32919949|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
32919950|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
32919951|NCT05720351|Active Comparator|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
33248262|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
33399973|NCT03732911|Experimental|Intervention|Intervention arm
32919952|NCT05720351|Active Comparator|Staircase maneuver|Patients undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
32919953|NCT05697965|Experimental|Vancomycin loaded group|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty operations
32919954|NCT05697965|Experimental|Non vancomycin loaded group|Total knee & hip arthroplasty done without applying local vancomycin powder comparing the results with vancomycin loaded group
32919955|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
32919956|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
32919957|NCT05720273|Experimental|Palicalcitol|Maintenance hemodialysis patients with secondary hyperparathyroidism (SHPT) treat with palicalcitol
32919958|NCT05696249|Experimental|Group with an OhmTrak device|The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
32919959|NCT05696249|Other|Group without an OhmTrak device|The control group will receive identical outpatient therapy and instruction in self-therapy, except they will not have access to the OhmTrak device.
32919960|NCT00183963|No Intervention|1|
32919961|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
32919962|NCT00183963|Active Comparator|3|Fulvestrant 250mg
32919963|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
33248263|NCT04014634|Placebo Comparator|Placebo|Injection of NaCl
33248264|NCT04014634|Experimental|Verum|
33248265|NCT01043575|Experimental|1|Rifapentine
33248266|NCT01043575|Active Comparator|2|Rifampin
33248267|NCT00932776|Experimental|TBA|
33248268|NCT00932776|Active Comparator|Control|
33248269|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
33399974|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
33399975|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
32919964|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
32919965|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
32919966|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
32919967|NCT05691647|Experimental|Chronotherapy + treatment as usual|
32919968|NCT05691647|Active Comparator|Treatment as usual|medication, cognitive behavioral therapy, and other psychotherapies.
32919969|NCT04659213|Experimental|Interventional Group|Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor. In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
32919970|NCT04659213|No Intervention|Control Group|Placement of a luminal esophageal temperature probe (LET) during RF ablation
32919971|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
32919972|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
33073336|NCT02531880|Experimental|1|Patients will be given the study drug
33399976|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
33399977|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
33399978|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
32919973|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
32919974|NCT00176631|Experimental|licorice root extract and docetaxel|
32919975|NCT05684081|Experimental|INTERVENTION|Refers to the intervention arm i.e. ECASH payment of health workers
32919976|NCT05684081|No Intervention|CONTROL|Refers to status Quo or no intervention i.e. payment using cash
32919977|NCT05719961|Experimental|INS062|
32919978|NCT05719961|Active Comparator|NovoRapid ®|
32919979|NCT05719961|Experimental|HR20014|
32919980|NCT05719961|Active Comparator|BIAsp 30|
32919981|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
32919982|NCT04317807|Active Comparator|Study Drug group|Participants in this group will receive 500 mg of levetiracetam twice daily for 12 weeks. After 12 weeks, levetiracetam will be gradually decreased and stopped over the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
32919983|NCT04317807|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo that looks like the levetiracetam pill twice daily for 12 weeks. After 12 weeks, the levetiracetam dose will be tapered for the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
32919984|NCT05719883|Experimental|Maurora® Sirolimus Eluting Stent System|Device: Maurora® Sirolimus Eluting Stent System A sirolimus eluting intracranial stent system with platform is made of L605 CoCr alloys.
32919985|NCT05719883|Active Comparator|APOLLO™ Intracranial Stent System|Device: Apollo Intracranial Stent System A 316L stainless steel balloon-expandable intracranial stent system.
32919986|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
33399979|NCT03898596|Other|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
32919988|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
32919990|NCT04266717|Experimental|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
32919991|NCT04266717|Active Comparator|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
32919992|NCT05719805|Experimental|Mavacamten Dose 1|
32919993|NCT05719805|Experimental|Mavacamten Dose 2|
32919994|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E7 Inf.U.
32919995|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E8 Inf.U.
32919996|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E9 Inf.U.
33399980|NCT02688088|Active Comparator|Drug Cocktail - Period 1|Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.
32919997|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E10 Inf.U.
32919998|NCT04246671|Experimental|Stage 2: Chordoma Cancer Cohort|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level defined in stage 1.
32919999|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab, every three weeks with three administrations in total at the dose defined in stage 1.
32920000|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + Pertuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab and pertuzumab. TAEK-VAC-HerBy will be administered every three weeks with three administrations in total at the dose defined in stage 1.
32920001|NCT04246671|Experimental|Stage 2: HER2-positive Gastric/GEJ cancer cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to HER2-positive gastric/GEJ cancer patients who are on stable dose of trastuzumab. TAEK-VAC-HerBy will be administered every three weeks with
32718854|NCT05725811|Active Comparator|Intervention group 2|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~The IG 2 will perform the same technique on a different muscle group: the quadriceps. In this way, the positioning will be different, the participants will be in the prone position, in a plank position, leaning on the forearms, the body well aligned and the studied lower limb well stretched. However, the participant will also perform a self-massage in the direction of the muscle fibers until they feel slight pain. The duration of the procedure will be set at 4 minutes in this study; 3 rounds of 1 minute (30 s rest).~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome & Tuner v.11.8 IOS)."
32718855|NCT05725811|No Intervention|Control group|The participants will remain at rest in a chair for 4 minutes.
32920002|NCT05678309||patient library|Patient with pruritus sine materia
32920003|NCT04225611|Experimental|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
32920005|NCT05677061|Experimental|HA-coated|Hydroxyapatite coating on Screw thread of DHS
32920006|NCT05677061|Active Comparator|NON-coated|No coating on Screw thread of DHS
32920007|NCT04007601|Active Comparator|Active tDCS|Remotely delivered active tDCS + cognitive training
32718856|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
32718857|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
32718858|NCT00057473|Experimental|Arm A|
32718859|NCT00057473|Active Comparator|Arm B|
32718860|NCT05725577|Other|Care via the telemedicine system|Intervention
32718861|NCT05725577|Other|Standard care|Control
32718862|NCT05726123|Placebo Comparator|Control group (G1)|Control group (G1): in which the suit shall be switched on, but with the current of all electrodes at 0 mA.
32718863|NCT05726123|Experimental|Suit group (G2)|Suit group (G2): will only receive treatment with the neuromodulation suit at the intensity preset by the manufacturer and according to the assessment criteria. The duration of the treatment will be 1 hour. Exopulse Molly Suit with all 58 electrodes active with an intensity of 2 milliamperes (mA) and pulse width of 30 milliseconds (ms)
32920008|NCT04007601|Placebo Comparator|Sham tDCS|Remotely delivered sham tDCS + cognitive training
32920009|NCT05676827||Study group|Participants with masticatory muscle pain lasting for over 3 months.
32920010|NCT05676827||Control group|Participants without masticatory muscle pain in last 6 months.
32920011|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
32920012|NCT05717855|Other|Screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia
33399981|NCT02688088|Experimental|200 mg Abemaciclib + Drug Cocktail - Period 2|200 mg Abemaciclib administered orally every 12 hours (Q12H) on Days 1 - 12 in Period 2 with a single dose of drug cocktail: 100 mgcaffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 8 in Period 2.
32920013|NCT01996371|Other|Group 1|Unilateral pedicle screws
32920014|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
32920015|NCT01996371|Other|Group 3|Bilateral pedicle screws
32920016|NCT05719493|No Intervention|multicomponent-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
32920017|NCT05719493|Experimental|munticomponent-treatment benefiting group|Partcipants in the intervention group will receive the care from the usual practice plus the studied intervention.
32920018|NCT05669885|Experimental|Sildenafil|Oral administration of 100 mg sildenafil.
32920019|NCT05669885|Placebo Comparator|Placebo|
32920020|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
32920021|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
32920022|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
32920023|NCT05719415|Experimental|Pre and post BPA|
32920024|NCT03987789|Active Comparator|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
32920025|NCT03987789|Experimental|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
32920026|NCT05664659|Active Comparator|Oxytocin+Misoprostol|Patients in this group will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.
32920027|NCT05664659|Experimental|Carbetocin|Patients in this group will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.
32920028|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
32718864|NCT05726123|Experimental|Suit + VR group (G3):|Suit + VR group (G3): the intervention on this group was carried out in the same way as the suit group. However, the session was different as the participant wore VR glasses besides wearing the suit for an hour. The patient sees the same room he is in and a person performing a series of exercises he must follow as indicated by the video by video and voice commands. As exercise are performed in a laying position the patient must stay in this position for the whole session.
32718865|NCT05726123|Experimental|Exercise group (G4):|Exercise group: The procedure carried out is the same as in the suit group, but the session performed was a 1-hour session of strength exercise carried out by a certified professional.
32920029|NCT05719337||Hypertensive heart disease group|Systolic blood pressure exceeded 140 mmHg and/or diastolic blood pressure exceeded 90 mmHg, or a history of systemic hypertension in the absence of other cardiac or systemic disease was described as hypertension.
32920030|NCT05719337||Hypertrophic cardiomyopathy group|Wall thickness≥15 mm in the absence of other causes of hypertrophy in a non-dilated left ventricle (LV) defines HCM. End diastolic wall thickness≥13 mm can be diagnostic if there is a family history of HCM or a known disease-causing genetic mutation.
32920031|NCT05719337||Cardiac amyloidosis group|Clinical diagnosis of cardiac amyloidosis confirmed by blood tests or tissue biopsy.
32920032|NCT05719337||Fabry disease group|Clinical diagnosis of Fabray disease confirmed by blood biomarkers or genetic testing.
32920033|NCT03985839||MICRORAPTOR™ REGENESORB™ Suture Anchor|MICRORAPTOR™ REGENESORB™ Suture Anchor
32920034|NCT03985839||MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
32920035|NCT03985839||MICRORAPTOR™ Knotless PEEK Suture Anchor|MICRORAPTOR™ Knotless PEEK Suture Anchor
32920036|NCT00358319|Experimental|Phase I|Dose escalation phase
33399982|NCT02688088|Experimental|200 mg Abemaciclib - Period 3|200 mg Abemaciclib administered orally Q12H on Days 13 to 28 in Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
33399983|NCT02688088|Experimental|200 mg Abemaciclib - Period 4|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 in Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
33399984|NCT02688088|Experimental|Safety Extension Period|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 onwards in extension period. Participants may continue to receive abemaciclib until discontinuation criteria are met.
33399985|NCT05598216||Fasting state|based on the sampling time and the serum's aspect
33399986|NCT05598216||non-fasting state|based on the sampling time and the serum's aspect
33399987|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
33399988|NCT04728204|Experimental|Intervention group|8 module, 8 week long internet-based intervention for reducing burden of depression
33399989|NCT04728204|No Intervention|Control group|Participants randomized to the control group will be instructed to wait until the intervention group finishes the treatment and that they will be able to use the same intervention afterwards.
32920037|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
33399990|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
33399991|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
33399992|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
32920038|NCT03981783|Active Comparator|Best available care (BAC)|
33399993|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
33399994|NCT05653960||Subjects who undergo EMR or ESD|Subjects who undergo EMR or ESD for colorectal lesions
33399995|NCT05666219|Experimental|Treatment group|Patients receiving Injection Aminophylline
32920039|NCT03981783|Experimental|Telerehabilitation (TH)|
32920040|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
32920041|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
32920042|NCT05717699|Experimental|Experimental Group|Single intratumoral injection of Ad-TD-nsIL12. Total dose will be 3x10^9vp, 1x10^10vp or 3x10^10 vp suspended in 1 ml according to cohort design.
32920043|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
32920044|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
32920045|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
32920046|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
32920047|NCT05717543|Experimental|Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma|"Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma will be included.~Imaging by retroillumination will be realized. In case of bilateral disease, both eyes will be photographed"
32920048|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
32920049|NCT05663801|Active Comparator|Group A (control group )|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride in pectoral nerve block .
32718866|NCT05376917|Experimental|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50 Diopters (D) on the dominated eye
32920050|NCT05663801|Active Comparator|Group B ( Ketamine group)|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) in pectoral nerve block .
32920051|NCT05663801|Active Comparator|Group C (Magnesium sulfate group)|Patients will be given 30 mL 0.25% bupivacaine hydrochloride plus magnesium sulfate ( 28 ml bupivacaine 0.25% plus 2ml magnesium sulfate (50%) in pectoral nerve block
32920052|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
32920053|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
32920054|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
32920055|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
32920056|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
32920057|NCT05717465|Active Comparator|Standard informed consent|Video with audio narration containing information provided in the standard informed consent process for a lumbar puncture
32920058|NCT05717465|Experimental|Visual aid group|Video with identical audio narration (to the control) containing information provided in the standard informed consent process for a lumbar puncture. The video also received statistical information in the form of visual aids; anatomy diagrams, Paling diagrams and Paling scales
32920059|NCT05653193|Active Comparator|Antifungal|Any oral triazole antifungal as per routine care
32920060|NCT05653193|Experimental|Antifungal plus inteferon gamma|Any oral triazole antifungal as per routine care plus interferon-gamma three times weekly subcutaneously 50 micrograms/m2 for 3 months
32920061|NCT05717231|Experimental|laughter yoga|Laughter yoga was performed face-to-face with the intervention group for 35-40 minutes twice a week and in 6 sessions in total.
32718867|NCT05376917|Experimental|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
32718868|NCT05376917|Experimental|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
32718869|NCT05376917|Experimental|Zeiss AT Lara / Zeiss AT Lara|Micro-monovision with refractive target of -0.75 Diopters (D) on the non-dominant eye
32718870|NCT04469777|Experimental|Systemic erythropoietin injections|20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
32718871|NCT05372783|Experimental|STI-9199|4 mg, 10 mg or 20 mg STI-9199 administered intranasally
32920062|NCT05717231|No Intervention|Control group|No intervention was performed for the control group
32920063|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
32920064|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
32920065|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
32920066|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
32920067|NCT05646017||Type 1 diabetes patients|Type 1 diabetes patients using intermittently continuous glucose monitoring during the Spanish greatest heatwave in Castilla-La Mancha (Spain).
32920068|NCT05714345|Experimental|Lymphodepletion with ALLO-647, fludarabine, and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
32920069|NCT05714345|Experimental|Lymphodepletion with fludarabine and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
32920070|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
32920071|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
32920072|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
32920073|NCT05711303|Active Comparator|Superba Boost|One 1000 mg capsule per day Superba Boost for 12 weeks
32920074|NCT05711303|Placebo Comparator|Placebo|One 1000 mg capsule per day placebo for 12 weeks
32920075|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
32920076|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
32920077|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
32920078|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
32920079|NCT05716919|Experimental|Cohort 1 - 4|Cohort 1 : 50 mg/day Cohort 2 : 100 mg/day Cohort 3: 200mg/day [Cohort 4: 300mg/day: based on the result of Safety Review Meeting (SRM)]
32920080|NCT05716919|Placebo Comparator|Placebo|
32920081|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
32920082|NCT05716841|No Intervention|Control Group|It will be treated with stretching and simple baseline strengthening of the upper limb through any regular mean (like TheraBand) in a moderate manner with 10 to 20 repetitions for 3 days per week for six weeks.
32920083|NCT05716841|Experimental|Experimental group|This experimental group will be treated with stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
32920084|NCT05642351||Alzheimer's Disease|recruited according to criteria by National Institute on Aging (McKhann et al., 2011).
32920085|NCT05642351||Behavioral variant of frontotemporal dementia|recruited following criteria by Rascovsky et al. (2011)
32920086|NCT03306615|Experimental|Treatment Arm|Hyaluronidase plus saline
32920087|NCT03306615|Placebo Comparator|Control Arm|Normal Saline
32920088|NCT05641805||Duchenne Muscular Dystrophy|
32920089|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
32920090|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
32920091|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
32920092|NCT02953665|Active Comparator|Liraglutide|Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
32920093|NCT02953665|Placebo Comparator|Placebo|Placebo will be self-administered subcutaneously once daily according to the same schedule.
32920094|NCT05707013|Experimental|HP Arize 3D-Printed Orthotics|Patients will receive the HP Arize 3D-printed orthotics for treatment of plantar fasciitis.
32920095|NCT05707013|Active Comparator|Traditional Orthotics|Patients will receive traditionally fabricated orthotics for treatment of plantar fasciitis.
32920096|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
32920097|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
32920098|NCT05638373|Experimental|One shade universal composite|shade matching composite
32920099|NCT05638373|Active Comparator|Nanohybrid resin composite|Conventional Nanohybrid resin composite
32920100|NCT05635097|Other|One group intervention|One group without comparator
32920101|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
32920102|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
32718872|NCT05372783|Placebo Comparator|Placebo|Placebo administered intranasally
32718873|NCT03527849|Experimental|In-Person MBSR Course|
32718874|NCT03527849|Experimental|Online MBSR Course|
32920103|NCT05689541|Other|Single group|
32920104|NCT02276157|Experimental|MB group|Direct POC performed with third-generation prototype multibending ultra-slim endoscope (CHF-Y0010; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
32920105|NCT02276157|Active Comparator|Conventional group|Direct POC performed with conventional ultra-slim endoscope (GIF-XP290N; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
32920106|NCT05716607|Experimental|Once-daily dual-release hydrocortisone|
32920107|NCT05716607|Active Comparator|Thrice-daily conventional immediate-release hydrocortisone|
32920108|NCT05688371|Active Comparator|standard dose morphine|children will receive 0.05 mg morphine /kg.as a bolus dose followed by 0.05 mg/kg/hr morphine continous infusion dissolved in 100 ml normal saline with lockout interval of 15 min.PCA bolus dose 1 ml (0.5 mg morphine).
32920109|NCT05688371|Active Comparator|low dose morphine plus dexmedetomidine|children will receive 0.05 mg morphine /kg bolus dose followed by 0.02mg/kg/hr plus 0.2 µg/kg dexmedetomidine in 100 ml normal saline with lockout interval of 15 min.PCA bolus dose 1 ml (0.2 mg + 2 mic dexmedetomidine)
32920110|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
32920111|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
32718875|NCT03527849|Active Comparator|In-Person HEP|
32718876|NCT05708573|Experimental|Cohort 1|Participants will receive a single dose of rosuvastatin in the morning of Day 1 in Treatment Period 1. Following a washout period of 5 days, participants will receive ALXN2040 three times daily on Days 1 through 7 in treatment period 2.
32718877|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
32718878|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
32920112|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
32920113|NCT05683769||erosive hand osteoarthritis|EHOA was diagnosed according to the American College of Rheumatology (ACR) criteria and to the presence of the classical central erosion in at least two IP joints. Further inclusion criteria were the availability of plain radiography of both hands performed in the previous 6 months. Plain radiographs of both hands were collected and scored by two readers according to Kallman's classification in a blind observation.
32920114|NCT05683769||psoriatic arthritis|PsA was diagnosed following the CASPAR classification guidelines and only patients with the peripheral arthritis pattern were considered; all PsA group had also the diagnosis of psoriasis confirmed by an expert dermatologist. These patients had also to be naive to conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) or have withdrawn any DMARDs for at least three months, because of inadequate response or intolerance.
32920115|NCT05683769||Control Group|The control group was represented by healthy volunteers age-and sex-matched to study patients and were recruited among the hospital staff; HC did not exhibit symptoms or signs attributable to OA, psoriasis, as well as to autoimmune disorders and systemic inflammatory arthropathies.
32920116|NCT05634083|Experimental|Uremic Pateints group|Patients with end-stage renal failure with itching
32920117|NCT05716529|Experimental|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
32920118|NCT05716529|Active Comparator|conventional physical therapy program|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises
32920119|NCT05440695||CNAP Group|The CNAP finger cuff and NIBP cuff were on the same arm of the patient while the intravenous catheter was on the contralateral side. After intrathecal injection, systolic, diastolic, and mean blood pressures were measured and were recorded manually at every minute on the CNAP monitor.
32920120|NCT05440695||NIBP Group|In the control group, only oscillometric NIBP measurements were done in pregnant women similar to the study group without a CNAP. After intrathecal injection, systolic, diastolic, and mean blood pressures with oscillometric method were set at the frequency of 3 minutes for the first 15 minutes, and at 5-minute intervals thereafter, and were recorded manually.
32920121|NCT05716451|Experimental|Intervention Group|Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.
32920122|NCT05716451|No Intervention|Control Group|Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.
32920123|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
32920124|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
32920125|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
32920126|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen~Pelvic RT (by IMRT or IGRT protocol):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
32920127|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles~Prostate-only RT (IMRT or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
32920128|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles~Pelvic RT (IMRT or IGRT):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
32718879|NCT04468295|Experimental|0.018-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.018-inch slot orthodontic bracket system.
32718880|NCT04468295|Active Comparator|0.022-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.022-inch slot orthodontic bracket system.
32718881|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
32718882|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
32718883|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
32718884|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
32718885|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
32718886|NCT05674955|Experimental|Circuit weight group|
32718887|NCT05674955|Experimental|Aerobic group|
32920129|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen~Prostate-only RT (IMRt or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
32920130|NCT05677607||Intracranial atherosclerosis and small vessel disease|Patients diagnosed with intracranial large artery atherosclerosis and cerebral small vessel disease based on imaging screening.
32920131|NCT02296242|Experimental|BVD-523|
32920132|NCT05716373|Experimental|Experimental:|reiki will be aplicated
32920133|NCT05716373|No Intervention|control|Routine maintenance will be applied.
32920134|NCT05716217|Experimental|Training group|
32920135|NCT05716217|No Intervention|Normal care|
32920136|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
32920137|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
32920138|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
32920139|NCT05661695|Other|RT's in ICU|We will collect ventilator pressure, flow, volume, oxygen and breathing pattern data, etc, as well as arterial blood-gas exchange and hemodynamic data of adults attached to ventilators. the RRT's will treat patients as normal without the assistance of the RT Assistant for the pre-intervention phase and will be observed collecting the same data and performing patient care with the assistance of the RT Assistant during the intervention phase. The RRTs will then be given a likert scale questionnaire on the use of the RT Assistant.
32920140|NCT05653583|Active Comparator|Wrist Device|Twice daily stimulation sessions during the 4-week treatment period
32920141|NCT05653583|Active Comparator|Ear Device|Twice daily stimulation sessions during the 4-week treatment period
32920142|NCT05653583|Sham Comparator|Sham Device|"Twice daily stimulation sessions during the 4-week treatment period"
32920143|NCT05622461|Experimental|Road-to-recovery group (R2R)|Usual medical care plus the R2R-TBI intervention (self-guided web-program)
32920144|NCT05622461|Active Comparator|Internet resources comparison group (IRC)|Usual medical care plus internet resources
32920145|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
32920146|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
32920147|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
32920148|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
32920149|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
32920150|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
32920151|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
32920152|NCT05640869|Experimental|Modified DPP|Participants in this arm will participate in the modified Diabetes Prevention Program curriculum.
32920153|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
32920154|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
32920155|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
32718888|NCT05674955|Experimental|Control Group|
32718889|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
32920157|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
32920158|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
32920159|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
32920160|NCT05615207|Active Comparator|Standard of Care (physical practice)|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on physical practice. The Standard of Care / Physical practice will include physically performing movements that closely or entirely mimic elements of the BBS. For example, if a subject struggles with the sit to stand portion of the BBS, they will physically practice sit to stand based on the treating physical therapist's clinical decision of appropriate task parameters and dosage. The individual subject's MS fatigue and their performance of the task will be taken into account when deciding dosage.
32920161|NCT05615207|Experimental|Motor Imagery|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on using motor imagery to imagine themselves performing the balance task with which they struggled on the BBS. Motor imagery practice involves having the participant imagine themselves performing elements of the BBS without physically moving. The participants in this group will be guided through 1 session of motor imagery that will be recorded on their person phone for them to use as a home exercise program.
32920162|NCT04888416|Experimental|Acute care|Acute care practitioners who will receive the I-STROM intervention
32920163|NCT04888416|Experimental|Inpatient|Inpatient practitioners who will receive the I-STROM intervention
32920164|NCT04888416|Experimental|Outpatient|Outpatient practitioners who will receive the I-STROM intervention
32920165|NCT05715983|Active Comparator|Bascom II procedure|Pilonidal sinus is excised, subcutaneous fat and skin are closed in the lateralization with interrupted suture.
32920166|NCT05715983|Active Comparator|Sinus Laser Closer (SiLaC)|Pilonidal sinus is locally excised by dermopunch or scalpel, curettage of the sinus tract with laser destruction
32920167|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
32920168|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
33399996|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
32718890|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
32718891|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
32718892|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
32718893|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
32718894|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
32718895|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
32718896|NCT04441541|Experimental|Treadmill with auditory feedback group|
32718897|NCT04441541|Experimental|Treadmill with visual feedback group|
32718898|NCT04441541|Experimental|Treadmill with auditory and visual feedback group|
32718899|NCT04441541|Active Comparator|Treadmill training group|
32718900|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
32718901|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
32718902|NCT05725499|Experimental|Participants with a chronic SCI (≥ 6 months after injury)|Participants will complete three days of baseline assessments (including a baseline orthostatic test and a day of neurophysiological mapping), five days of stimulation mapping to locate the optimal spinal sites for a blood pressure response, a day of testing with stimulation applied during an orthostatic provocation and a two-week (total of six days) training period with repeated exposure to stimulation, followed by two days of additional orthostatic tests (with and without stimulation)
32718903|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
32718904|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
32920169|NCT04197960|Experimental|microwave ablation|ablate all tumors including at least 2mm safe margin except for tumors adjacent to thyroid capsule.
32920170|NCT04197960|Active Comparator|surgical resection|lobectomy + central lymph node dissection
32920171|NCT05637671|Active Comparator|oxybutynin|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks
32920172|NCT05637671|Active Comparator|paroxetine|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks
32920173|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
32920174|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
32920175|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
32920176|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
32920177|NCT05631899|Experimental|KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks.~Anti-PD-1 antibody is administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 4 weeks afterwards, until:~Unacceptable toxicity occurred or disease progression; or~Reactive T cells are undetected repeatedly after the last vaccine dose; or~Vaccine exhaustion."
32920178|NCT05610215|Experimental|hybrid ablation|Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation
32920179|NCT05610215|Active Comparator|catheter ablation|Participants in this group will receive catheter endocardial ablation only
32920180|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
32920181|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
32920182|NCT05576285||Accelerating head growth in infancy|Infants <=18 months of age referred to head ultrasound because of accelerating head growth
32920183|NCT05576285||Children at ICU with neurological symptoms that require brain MRI or CT|Children < 15 years of age who are cared for at ICU becaus of neurological symptoms that require brain MRI or CT scans
32920184|NCT05576285||Children entering the emergency department with the need of acute brain CT|Children < 2 years of age that enter the emergency department because of brainthreatening conditions that require acute brain CT scans
32920185|NCT03363633|No Intervention|Observation|
32920186|NCT03363633|Experimental|Injection + Compression|
32920187|NCT03363633|Active Comparator|Compression|
32920188|NCT05602025|Experimental|Participants receiving depemokimab via a SSD|
32920189|NCT05602025|Experimental|Participants receiving depemokimab via an autoinjector|
32920190|NCT05614193||Imaging group|Participants with suspecting brain stroke or vascular lesion conducted conventional CT or MR imaging and deep enhanced imaging.
32920191|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
32920192|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
32920193|NCT05607563|Experimental|PM1009 120 mg monotherapy|PM1009 120 mg
32920194|NCT05607563|Experimental|PM1009 300 mg monotherapy|PM1009 300 mg
32920195|NCT05607563|Experimental|PM1009 600 mg monotherapy|PM1009 600 mg
32920196|NCT05607563|Experimental|PM1009 1200 mg monotherapy|PM1009 1200 mg
32920197|NCT05601635|Active Comparator|High dose|Dietary supplement containing 400 mg of active ingredient tributyrin
32920198|NCT05601635|Active Comparator|Low dose|Dietary supplement containing 200 mg of active ingredient tributyrin
32920199|NCT05564429|Other|Only one arm|All subjects receive the same tests
32920200|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
32920201|NCT05594927|Experimental|Icaritin soft capsule|
32920202|NCT05594927|Active Comparator|Huachansu tablet|
32920203|NCT05584085|Experimental|Acceptance and commitment therapy integrated in diabetes education (ACT-DE)|"The proposed intervention is a six-week acceptance-based diabetes education programme (ACT-DE) comprising acceptance and commitment therapy and diabetes education.~Session 1: Diabetes education and introduction of ACT-DE programme Session 2: Mindfulness cultivation Session 3: Value clarification Session 4: Integrating ACT into diabetes self-management Session 5: Booster session Session length: 120 minutes Group-based (6-8 participants) and face-to-face mode of delivery"
32920204|NCT05584085|Placebo Comparator|Diabetes education|One session of diabetes education, group-based (6-8 participants) and 120 minutes via face-to-face delivery.
32920207|NCT05582369|Experimental|Affective Rewards Messages|Throughout the study, each week participants will be asked to plan two exercise sessions for the upcoming week, and will be asked to report on how they did with those plans at the end of the day when they planned to exercise. At the very beginning of the time window when they planned to exercise participants will be randomized with 40% probability to receive no message, 20% probability to receive a reminder to fill out the study questionnaire at the end of the day, and 40% probability to receive one of two types of affective rewards messages (active intervention). The two types are: 1) low-reflection messages written by participants at the beginning of the study, about the affective rewards of exercise they have previously experienced; and 2) high-reflection messages that prompt participants to reflect on the affective rewards of exercise and text back a response.
32920208|NCT05575505|No Intervention|Control Group|Mesalamine group, who will receive 1 g mesalamine three times daily for 6 months.
32920209|NCT05575505|Active Comparator|Pentoxifylline group|The pentoxifylline group will receive 1 g mesalamine three times daily plus pentoxifylline 400 mg two times daily for 6 months.
32920210|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
32920211|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
32920212|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
32920213|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
32920214|NCT05573555|Experimental|ARV-471 in combination with Ribociclib|ARV-471 administered orally QD continuously and Ribociclib administered orally QD consecutively for 21 days followed by 7 days off treatment on 28-day cycles
32920215|NCT00000261|Experimental|Moderate drinking adults|
32920216|NCT05592587|Experimental|Distraction using eye massage device producing both vibrations and nature sounds.|
32920217|NCT05592587|Experimental|Distraction using eye massage device producing vibratory stimulations only.|
32920218|NCT05592587|Other|Using basic behavior guidance techniques and without using any type of distraction aids.|
32920219|NCT00000783||1|Sexually active HIV-infected concordant couples
32920220|NCT00000783||2|Sexually active HIV-infected discordant couples
32920221|NCT05592353|Active Comparator|Brace|
32920222|NCT05592353|No Intervention|No Brace|
32920223|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
32920224|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
32920225|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
32920226|NCT00358397|Experimental|Treatment arm|
32920227|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
32920228|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
32920229|NCT05189691|Experimental|behavior change and walking exercise|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale, Short Form 36 (SF-36) scales and continuously recorded step counts will be evaluated at week 0, 4 and at the end of week 12.
32920230|NCT05189691|No Intervention|behavior change|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated at week 0, 4 and at the end of week 12.
32920231|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
32920232|NCT05550233|Experimental|DCB treatment|drug-coated balloon in PCI
32920233|NCT05550233|Other|DES treatment|drug-eluted stent in PCI
32920234|NCT05371847|Active Comparator|breast cancer patients|Women and men in the prospective cohort study will be invited to participate in this additional validity and/or reliability testing
32920235|NCT05371847|Active Comparator|healthy volunteers|age- and gender-matched
32920236|NCT05548205|Experimental|Continuous Glucose Monitoring (CGM)|Patients in the CGM group will be instructed to wear a CGM uninterruptedly for 2 weeks duration.
32920237|NCT05548205|Active Comparator|Blood Glucose Monitoring (BGM)|Patients in the BGM group will be instructed to check their blood glucose utilizing fingerstick glucose monitoring multiple times daily depending on their insulin regimen for 2 weeks duration.
32920239|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
32920240|NCT05362487||Swiss COPD patients|
32920241|NCT05362331|Experimental|Companion for CAR-T Web Application (CC)|Enrolled participants and caregivers will receive access to the CC web application during the participants Chimeric Antigen Receptor T-cell (CAR-T) therapy. Key components include (1) educational videos and materials, (2) appointment calendars and 'Appointment Companion' features to prepare for clinical appointments, and (3) tools to assist with vital sign and neurological monitoring at home.
32920242|NCT05139797||Artificial Intelligence Screening for Cardiac Amyloidosis|An artificial intelligence algorithm will produce a probability of cardiac amyloidosis that will trigger referral to specialty clinic for further evaluation.
32920243|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
32920244|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
32920245|NCT05545007|Experimental|HSRS pre-operative|"Patients undergo HSRS (hypofractionated Radiosurgery) on day 1, consisting in 27 Gray (gy) administered in 3 daily fractions.~Within 1 weeks, patients undergo surgical resection."
32920246|NCT05545007|Active Comparator|HSRS post-operative|Patients undergo surgical resection on day 1. Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.
32920247|NCT05543681|Active Comparator|Active Comparator: IGC-AD1Active|IGC-AD1 Active Treatment THC plus another API plus excipients.
32920248|NCT05543681|Placebo Comparator|Placebo Comparator: IGC-AD1 Placebo|IGC-AD1 Placebo, similar to Active in color, taste, and texture, with excipients but without APIs.
32920249|NCT04331613|Experimental|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
32920250|NCT05355077|Experimental|Group 1|JT001 (VV116):200 mg, oral, Twice a day
32920251|NCT05355077|Experimental|Group 2|JT001 (VV116):400 mg, oral, Twice a day
32920252|NCT05355077|Experimental|Group 3|JT001 (VV116):600 mg, oral, Twice a day
32920253|NCT01647516|Experimental|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
32920254|NCT01647516|Experimental|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
32920255|NCT01647516|Placebo Comparator|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
32920256|NCT05133323|Experimental|Lu AG09222 High Dose|Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
32920257|NCT05133323|Experimental|Lu AG09222 Low Dose|Participants will receive a single low dose of Lu AG09222 by IV infusion.
32920258|NCT05133323|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.
32920259|NCT05536349|Experimental|Pirtobrutinib plus Venetoclax plus Obinutuzumab (combination)|Participants will receive the study drugs in cycles. Each cycle is 28 days.
32920260|NCT05127551|Active Comparator|iStent Infinite|Subjects implanted with iStent Infinite system
32920261|NCT05127551|Active Comparator|Competitor Device|Subject implanted with competitor device
32920262|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
32920263|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
32920264|NCT05174403||SPG5 patients|Adult SPG5 patients with diagnostic confirmed by the identification of two mutations in the CYP7B1 gene
32920265|NCT05124821||Certofix Paed|Paediatric patients in need for short-term (≤ 30 days) catheterisation of the superior vena cava using the Seldinger technique for infusion and volume therapy or parenteral nutrition, for administration of highly osmolar or very vein-irritating solutions/drugs, for continuous or intermittent monitoring of the central venous pressure, for blood sampling, or when peripheral venous puncture is not possible in state of shock, in patients with injured extremities or no detectable peripheral veins.
32920266|NCT05347979|Experimental|Dabigatran Etexilate (NIMP) and Relacorilant (IMP)|Following an overnight fast, participants will receive 75 mg dabigatran etexilate on Day 1, 400 mg dose of relacorilant QD on Days 3 to 13, and 75 mg dabigatran etexilate on Day 12. On Day 12, dabigatran etexilate will be dosed at approximately the same time as the relacorilant dose.
32920267|NCT05533697|Experimental|Arm 1a (Dose Escalation): mRNA-4359 Alone|Participants will be administered mRNA-4359 at an applicable dose as monotherapy.
32920268|NCT05533697|Experimental|Arm 1b (Dose Confirmation): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
32920269|NCT05533697|Experimental|Arm 2 (Dose Expansion): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
32920270|NCT05444699|Experimental|Prednisolone|"Prednisolone Sodium Phosphate (25 mg/5 mL) oral suspension administered 1 mg/kg* (up to 20 mg = 4 mL) once a day for 3 days.~*(0-5 kg: 5 mg; 5.01-7.5 kg: 7.5 mg; 7.51-10 kg: 10 mg; 10.01-12.5 kg: 12.5 mg; 12.51-15 kg: 15 mg; 15.01-17.5 kg: 17.5 mg; ≥ 17.51 kg: 20 mg)"
32920271|NCT05444699|Placebo Comparator|Placebo|Sugar syrup oral suspension containing saccharum 630-640 mg/g and aqua purificata 360-370 mg/g administered the same amount in milliliters as experimental product (up to 4 mL) once a day for 3 days.
32920272|NCT02321514|Experimental|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
32920273|NCT05120531||Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
32920274|NCT05120531||Non-Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
32920275|NCT05530655|No Intervention|Control group|Patients who receive radiation but no intervention
32920276|NCT05530655|Experimental|Intervention group|
32920277|NCT05118035|Experimental|Intervention|"Patients randomized to intervention will have access to the screening tool. Once the AI-ECG indicates high risk of mortality, a warning message would be immediately triggered and sent to the corresponding attending physicians. Notifications appear in the recipient's smartphone message system for the prompt attention. The message notified the physician that, An ECG was received for patient X. An ECG indicates high risk of mortality. Please intensively attend to patient's conditions. If the physicians need to further identify the ECG, click on the following link to connect the ECG and the result of AI-ECG prediction. Of note, although we will actively send a warning message for high risk cases, the AI-ECG report for low risk cases still presented the degree of risk. Physicians can check the relative severity by access EHR for patients in the intervention group."
32920278|NCT05118035|No Intervention|Control|Patients will continue routine practice.
32920279|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
32920280|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
32920281|NCT05325515|Active Comparator|Fosamax (conventional alendronate)|Conventional alendronate 70mg weekly for 16 weeks
32718905|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
32718906|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
32920282|NCT05325515|Experimental|Binosto (effervescent and buffered alendronate)|Effervescent and buffered alendronate70mg weekly for 16 weeks
32920283|NCT05527691|Experimental|SupportGroove|"8-week intervention that is remotely delivered through a mobile app, consisting of daily quests (positive psychology-based activities) completed individually and as a couple."
32920284|NCT05527691|No Intervention|Waitlist control|Participants will be waitlisted for 8 weeks.
32920285|NCT04344041|Experimental|Intervention group|High dose of vitamin D3
32920286|NCT04344041|Active Comparator|Comparator group|Standard dose of vitamin D3
32920287|NCT05322707|Experimental|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
32920288|NCT05322707|Active Comparator|Symbicort®|Inhalation Aerosol, 2 actuations orally inhaled twice daily
32920289|NCT05322707|Placebo Comparator|Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
32920290|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
32920291|NCT05110937||Sepsis|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
32920292|NCT05110937||Healthy Controls|"Blood Collection.~The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable."
32920293|NCT05110937||Trauma|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
32920294|NCT02977793||Non-pathologic young adults|18-28 years old
32920295|NCT02977793||Non-pathologic adults|29-80 years old
32920296|NCT02977793||Pathologic adults|29-80 years old
32920297|NCT05107115|Experimental|Rilzabrutinib dose A|dose A
32920298|NCT05107115|Experimental|Rilzabrutinib dose B|dose B
32920299|NCT05107115|Experimental|Rilzabrutinib dose C|dose C
32920300|NCT05107115|Placebo Comparator|Placebo|Matching placebo
33073343|NCT02504853||Affected Genetic|Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs).
32718907|NCT05725343|Experimental|Canakinumab|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
32718908|NCT05725343|Placebo Comparator|Placebo|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
33073344|NCT02504853||Affected Non-Syndromic Food|Individuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
33248270|NCT04437238|Experimental|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
33248271|NCT04437238|Placebo Comparator|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
33248272|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
33248273|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
33248274|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
33248275|NCT00929422||spinal cord injury 1|
33248276|NCT00929422||spinal cord injury 2|
33248277|NCT00929422||spinal cord injury 3|
32718909|NCT04469309|Experimental|Group I|Group I will receive Brandoff Exercises
32718910|NCT04469309|Active Comparator|Group II|Group II will receive Somersault exercises
32718911|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
32718912|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
32718913|NCT05330351||Pediatric Trauma Patients|Pediatric patients (<18 years old) who have suffered a traumatic event requiring surgical fixation within 48 hours prior to time to arrival in the operating room.
32718914|NCT04469387|Active Comparator|NS Group|NS Group includes patients who simply receive responsible segments fused (L4-S1).
32718915|NCT04469387|Experimental|LD Group|LD Group includes patients who receive responsible segments fused (L4-S1) plus limited decompression at adjacent segment (L3/4).
32718916|NCT05725265|Experimental|Large-area low-level laser therapy|Large-area low-level laser therapy(Venusure) was administered at proximal forearm, upper arm and axillary region of affected side. The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
33073345|NCT02504853||Allergic GI Disease|Individuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
33248278|NCT00929422||normal control|
33248279|NCT00932932||PWS not receiving Growth Hormone|
33248280|NCT00932932||Control subjects healthy or obese|
33248281|NCT00932932||PWS subjects starting Growth Hormone|
33248282|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
33248283|NCT00907816||control|
33248284|NCT00567268||Gabapentin|Patients taking Gabapentin
33248285|NCT00907894|Experimental|Stratum 1|
33248286|NCT00907894|Experimental|Stratum 2|
33248287|NCT00907894|Experimental|Stratum 3|
33248288|NCT03976648|Experimental|GLPG1690 600 mg|Participants who received GLPG1690 600 milligrams (mg) in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
33248289|NCT03976648|Experimental|Placebo|Participants who received placebo matched to GLPG1690 in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
33248290|NCT04014556|Active Comparator|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
33248291|NCT04014556|Active Comparator|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
33248292|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
33248293|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
33248294|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
33248295|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
33248296|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
32920301|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
32920302|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
32920303|NCT05320289|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
32920304|NCT04877574|Experimental|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI index.
32920305|NCT04877574|Active Comparator|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
32920306|NCT05519423|Experimental|Morbid obesity individuals|"All subjects participating in the study will be given physical activity incentive program (PAI) individually. After evaluating it is aimed to provide information transfer and motivation support to increase physical activity levels before bariatric surgery within the scope of PAI.~For this purpose, individual face-to-face interviews will conduct with all cases; verbal information will be given about the importance of physical activity, its effects and different levels of severity. The progress of the program will be made with the whats app application.~8-week follow-up chart will be given to the individuals, about the completion of the physical activity follow-up chart prepared in order to raise awareness about the activity levels of individuals in daily life and to increase their physical activity levels.~All subjects will record daily step counts, low, moderate, and vigorous activities on the chart at the end of the day, every day for 8 weeks."
32920307|NCT05096429|Experimental|Intervention|Within these cities/towns, the health department will work with stakeholders to prioritize overdose prevention interventions to neighborhoods with the highest probability of future overdose deaths, as predicted by the PROVIDENT model.
32920308|NCT05096429|No Intervention|Control|Cities/towns assigned to the control arm will continue to work with the health department and distribute these interventions at existing resource levels, but without receiving information on predicted probability of overdose risk for specific neighborhoods.
32920309|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
32920310|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
32920311|NCT00359255|Active Comparator|1|
32718917|NCT05725265|Placebo Comparator|Conventional low-level laser therapy|Conventional low-level laser therapy was administrated on antecubital fossa and the axilla of affected side. The wavelength was 808nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
32718918|NCT04468373|Experimental|WA-NG (NG-IMT) Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
32718919|NCT05725187||Low risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the low-risk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
32920312|NCT00359255|Experimental|2|
32920313|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
32920314|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
32920315|NCT05513027|Experimental|Augmented Whole-body Scanning via Magnifying PET (AWSM-PET)|All enrolled subjects will undergo SOC FDG-PET/CT scan with an AWSM PET device positioned at the far end of the Biograph Vision PET/CT scanner. The patient will receive 10-20 mCi FDG injection according to the SOC FDG-PET/CT protocol dosing schedule. The entire study will require approximately 2 ½ - 3 hours (from the time patient arrives to the completion of the scan).
32920316|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
32920317|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
32718920|NCT05725187||High risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the highrisk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
32920318|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
32920319|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
32920320|NCT05503901|Experimental|Group 1: STN1012600 0.002%|
32920321|NCT05503901|Experimental|Group 2: STN1012600 0.002%|
32920322|NCT05503901|Experimental|Group 3: STN1012600 0.002% + Timolol 0.5%|
32920323|NCT05083091|Active Comparator|Monitor & Accept (MA-MBI)|14-day smartphone based mindfulness meditation attention monitoring and acceptance skills training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
32920324|NCT05083091|Active Comparator|Monitor Only (MO-MBI)|14-day smartphone based mindfulness meditation training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
32920325|NCT05083091|Active Comparator|Coping Condition (CC)|14-day smartphone based training intervention focused on coping strategies consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
32920326|NCT05079425|Experimental|Part A: Fasting|Single ascending dose (SAD).
32920327|NCT05079425|Experimental|Part A: Fed|Single ascending dose (SAD).
32920328|NCT05079425|Experimental|Part B: Fasting|Multiple Ascending Dose (MAD)
32920329|NCT05310461|Experimental|Early transcatheter or surgical aortic valve replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
32920330|NCT05310461|Other|Control Intervention|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention.
32920331|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
32920332|NCT05501483|Active Comparator|Pioglitazone|Pioglitazone is known to affect fat cells and is used as an active comparator. It reduces HbA1c but increase fat mass slightly. We hypothesize that pioglitazone may have particular benefits in individuals with a specific adipose cellularity.
32920333|NCT05501483|Experimental|Empagliflozin|Empagliflozin reduces HbA1c and increase lipolysis possibly due to increased glucagon secretion. It also reduces fat mass weight to a minor degree.
32920334|NCT05501483|Experimental|Semaglutide|Semaglutide reduces body weight, including fat mass, to a more significant degree than empagliflozin but has no known direct effects on adipose tissue.
32920335|NCT05501093||Diabetic patients|Diabetic patients who plan to undergo bariatric surgery
32920336|NCT05501093||Normo-glycemic (non-diabetic) patients|Non-diabetic patients who plan to undergo bariatric surgery
32920337|NCT05292131|Experimental|Test|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-2mL presentation (test).
32920338|NCT05292131|Other|Reference|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-1x2mL presentation (reference).
32920339|NCT05069441||Patients with extubation after a weaning trial|Patients who sucessfully complete a spontaneous breathing trial are enrolled in this group.
32718921|NCT05725109||Before Period (1/9/2022 to 10/9/2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients with active hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
32718922|NCT05725109||After Period (1/9/2023 to 10/9/2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients with active hepatitis C infection will be disseminated to healthcare providers and clinic staff.
32718923|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
32920340|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
32718924|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
32718925|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
32718926|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
32718927|NCT05614349|Experimental|Paxlovid|Nirmatrelvir/ritonavir (Paxlovid™) BD x 5 days
32718928|NCT05614349|No Intervention|Control group|Usual care (i.e., supportive care and symptom relief)
32920341|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
32920342|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
32920343|NCT05493215|Experimental|Imatinib TDM|Patients with diagnosed gastrointestinal stromal tumor (GIST) who are currently being treated with imatinib.
32920344|NCT05491499||Youth with Chronic pain|We will recruit 38 youth with primary and secondary chronic pain syndromes[29; 31] ages 10-17 years who are admitted to the Mayo Family Pediatric Pain Rehabilitation Center at Boston Children's Hospital. This longitudinal cohort study will examine responses to the OA and Fitkids Treadmill tests at 2 timepoints: 1) within 5 days of IIPT admission and 2) within 1 week of IIPT discharge. Twelve participants will complete a 3rd visit within 5 days of the first study visit to examine OA test-retest reliability.
32920345|NCT00359333|Experimental|Single Group|
32920346|NCT04344275|Experimental|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
32920347|NCT04344275|Placebo Comparator|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
32920348|NCT05065619|Experimental|MT-2766 High dose|
32920349|NCT05065619|Placebo Comparator|Placebo|
32920350|NCT05065619|Experimental|MT-2766 Low dose|
32920351|NCT05477381||Asymptomatic women with a history of preterm birth|Pregnant women >18 years of age, with a history of spontaneous PTB before 34 weeks. All women have biweekly visits for routine transvaginal cervical length measurement between 14-24 weeks of gestation. During these visits data on cervical softening will be collected as additional marker.
32920352|NCT05477381||Symptomatic women with symptoms of threatened preterm birth|Pregnant women >18 years of age, between 24 and 34 weeks of gestation, presenting with symptoms of threatened Preterm birth (e.g. abdominal pain, blood loss, contractions, or other complaints suggestive for threatened Preterm birth).
32920353|NCT05060237|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single photodynamic therapy (PDT)."
32920354|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
32920355|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
32920356|NCT05280587|Experimental|Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
32920357|NCT05280587|No Intervention|Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
32920358|NCT05474651||Questionnaires assessed expectant fathers who quit smoking|"Participants who met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~Males ≥18 years old;~The wife has given birth, the newborn is live, and the number of days of birth is less than or equal to 28 days;~Self-reported smoking at least 1 cigarette per day on average for at least 1 month in the past 1 year;~Self-reported that they had quit smoking during their wife's pregnancy on purpose, and maintained it for at least 24 hours;"
32920359|NCT04714983|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
32920360|NCT04714983|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
32920361|NCT04714983|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
32920362|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.075 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
32920363|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.12 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
33073346|NCT02504853||Unaffected Relative / Healthy Volunteer|Unaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.
33073347|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
33399997|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
32920364|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.15 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
32920365|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation Maximum Tolerated Dose|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD. This dose will be added to this record when it is determined.
32920366|NCT05270057|Experimental|Dose Expansion Phase|Subjects will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase. This dose will be added to this record when it is determined.
32920367|NCT05044715|Experimental|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) as an intervention.
32920368|NCT05044715|Experimental|Compassion-Focused Therapy|Participants in this arm will be enrolled in a CFT group intervention.
32920369|NCT05044637|Experimental|Primaquine (3.5mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
32920370|NCT05044637|Active Comparator|Primaquine (7.0mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
32920371|NCT05044637|Active Comparator|Primaquine (7.0mg x 14d)|Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).
32920372|NCT05043077|Experimental|Study Group|Mydriasis with microdrops
32920373|NCT05043077|Active Comparator|Control Group|Mydriasis with standard drops
32920374|NCT05465369|Experimental|injectable flowable composite with giomer technology (beatifil flow plus x)|Injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
32920375|NCT05465369|Active Comparator|high viscosity glass ionomer (Equia Fil ) in ART|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
32920376|NCT05031455|Experimental|Aspirin Challenge|All subjects will undergo a standardized aspirin challenge
32920377|NCT00380601|Experimental|1|
32920378|NCT05029973|Experimental|Treatment Group|HAIC Combined With Sintilimab and Bevacizumab Biosimilar
32920379|NCT05443451|Experimental|Transperineal Microwave needle ablation for symptomatic BPH|
32920380|NCT05442983|Experimental|PanCytoVir™ 500 mg twice daily|
32920381|NCT05442983|Experimental|PanCytoVir™ 1000 mg twice daily|
32920382|NCT05442983|Placebo Comparator|Placebo twice daily|
32920383|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
32920384|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
32920385|NCT05020535|Experimental|Experimental|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
32920386|NCT05020535|Placebo Comparator|Control|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
32920387|NCT05017571|No Intervention|Adults no obesity, insulin resistance, or inflammation|Adults without obesity, insulin resistance or inflammation
32920388|NCT05017571|No Intervention|Adults with obesity, but no insulin resistance/inflammation|Adults with obesity, but without insulin resistance or inflammation
32920389|NCT05017571|Experimental|Colchicine - Adolescents|Adolescents given Colchicine 0.6 mg per day (1 capsule per day)
32920390|NCT05017571|Experimental|Colchicine - Adults|Adults given Colchicine 0.6 mg per day (1 capsule per day)
32920391|NCT05017571|Placebo Comparator|Placebo - Adolescents|Adolescents given Placebo (1 capsule per day)
32920392|NCT05017571|Placebo Comparator|Placebo - Adults|Adults given Placebo (1 capsule per day)
32920393|NCT05016713|Active Comparator|Intervention group 1|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
32920394|NCT05016713|Active Comparator|Intervention group 2|Chlorhexidine mouthwash is added to the previous oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.
32920395|NCT05016713|Placebo Comparator|Control group|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
32920396|NCT05004311|Experimental|Group A (severe renal function impairment)|Eight (8) participants with severe renal impairment.
33248297|NCT00933400|Active Comparator|Traditional Strategy (Group A)|In the traditional-care arm (Group A), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
33248298|NCT00933400|Experimental|CT Coronary Angiography (Group B)|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
33248299|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
33248300|NCT00907972|Placebo Comparator|Placebo|Placebo
32718929|NCT05614349|Experimental|Other Emerging Interventions (arm 3)|Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence
33248301|NCT03799744|Experimental|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
33248302|NCT03799744|Experimental|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
33248303|NCT00908050|Placebo Comparator|Placebo|Placebo arm
33248304|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
33248305|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
33248306|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
33248307|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
33248308|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
33248309|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
33248310|NCT04015258|Experimental|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
33248311|NCT04015258|Experimental|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
33248312|NCT04015258|Placebo Comparator|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
33248313|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
33248314|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
33248315|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
33248316|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
33248317|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
33248318|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
33248319|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
33248320|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
33248321|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
32718930|NCT05614349|Experimental|Other Emerging Interventions (arm 4)|Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence
32718931|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
32718932|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
32718933|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
32718934|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
32718935|NCT03531749|No Intervention|HIV- Control|Unsupplemented
32920397|NCT05004311|Experimental|Group B (healthy)|Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.
32920398|NCT05443529||Adaptive sports group|Individuals with stroke who regularly, and on a long-term basis, participate in adaptive sports
32920399|NCT05443529||Non adaptive sports group|Individuals with stroke who do not engage in adaptive sports
32920400|NCT05253521||South Asian Origin|Individuals who identify as having Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origin
32920401|NCT05253521||White Individuals of European Origin|Individuals who identify as having western European, other northern European, southern European, eastern European or other European origin
32920402|NCT05240339||PD participants with minor phenomena|
32920403|NCT05236751||Elective intracranial intervention patients|Adult patients (18-89 years at the time of surgery) scheduled for elective intracranial (open surgical or endoscopic) intervention and require general anesthesia and a hospital stay of at least one day post-procedure.
32920404|NCT05233397|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
32920405|NCT04979247|Experimental|Oliceridine|Patients receive Oliceridine for pain control.
32920406|NCT05430269|Experimental|Intervention group|ICU patients who developed diarhea after a course of antibiotic therapy treated with Faecal bacteriotherapy (FBT) delivered as enema
32920407|NCT05430269|Active Comparator|Control group|ICU patients who developed diarhea after a course of antibiotic therapy treated standard-of-care protocolised treatment of postantibiotic diarhea
32920408|NCT05231369|Experimental|group 1: 25 ug of ChulaCov19 BNA159 mRNA vaccine|The participants will receive 25 ug of the vaccine.
32920409|NCT05231369|Experimental|group 2: 50 ug of ChulaCov19 BNA159 mRNA vaccine|If 25 ug is safe, then will proceed to enroll 12 more participants to receive 50 ug.
32920410|NCT04997681|Experimental|Exercise Intervention Training and Cognitive Intervention Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Cognitive Training (NeuropeakTM)
32920411|NCT04997681|Active Comparator|Exercise Intervention Training and Control Cognitive Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
32920412|NCT04997681|Active Comparator|Control Exercise Training and Cognitive Intervention Training|Control Balance and Toning Exercise Training (BAT) + Cognitive Training (NeuropeakTM)
32920413|NCT04997681|Placebo Comparator|Control Exercise Training and Control Cognitive Training|Control Balance and Toning Exercise Training (BAT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
32920414|NCT04993781|Experimental|eSTEPS Clinical Decision Support|Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
32920415|NCT04993781|No Intervention|Usual Care|Usual primary care practices regarding exercise-related fall prevention planning
32920416|NCT04989803|Experimental|KITE-363|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable."
32920417|NCT05428007|Experimental|Study Group|Participants receive sarilumab at 150 mg flat dose is administered subcutaneously every 2 weeks for 12 doses from day 1, cycle 1 in combination with a regimen of ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg and relatlimab at 160 mg flat dose every 4 weeks two times during the 8-week induction period, then the same regimen again up to week 16, and up to week 24 in maintenance. After week 24 the regimen will be ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg with relatlimab at 160 mg flat dose every 4 weeks for 8 week cycles for up to a total of 2 years in patients with unresectable Stage III/Stage IV melanoma.
32920418|NCT05229341|Experimental|Diagnostic (needle biopsy, DDMS-2)|Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.
32920419|NCT05422625|Active Comparator|Active PTNS|Once a week induction consisting of active PTNS treatments for 30 minutes for 12 consecutive weeks.
32920420|NCT05422625|Placebo Comparator|Sham PTNS|Once a week induction consisting of Sham PTNS treatments for 30 minutes for 12 consecutive weeks.
32920421|NCT05226533|Experimental|Niclosamide 432mg|Niclosamide 432mg (intramuscular injection) + Remdesivir
32920422|NCT05226533|Experimental|Niclosamide 960mg|Niclosamide 960mg (intramuscular injection) + Remdesivir
32920423|NCT05226533|Placebo Comparator|Placebo|Placebo (intramuscular injection) + Remdesivir
32920424|NCT00359567|Experimental|1|palonosetron
32920425|NCT00359567|Active Comparator|2|granisetron hydrochloride
32920426|NCT05217641|Experimental|Part A, Group 1: Low dose BG505 MD39.3 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 mRNA formulated administered at months 0, 2, and 6
32920427|NCT05217641|Experimental|Part A, Group 2: Low dose BG505 MD39.3 gp151 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
32920428|NCT05217641|Experimental|Part A, Group 3: Low dose BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
32920429|NCT05217641|Experimental|Part B, Group 1: BG505 MD39.3 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 mRNA administered at months 0, 2, and 6
32920430|NCT05217641|Experimental|Part B, Group 2: BG505 MD39.3 gp151 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
32920431|NCT05217641|Experimental|Part B, Group 3: BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
32920432|NCT05210465||patients with stable angina pectoris and prior MI|
33399998|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
32920435|NCT05199857|Experimental|Wellness education and Home exercise programs|
32920436|NCT04983407|Experimental|Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine|Up to three dose levels of bactiraxcept plus nab-paclitaxel and gemcitabine
32920437|NCT04983407|Experimental|Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine|
32718936|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
32718937|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
32718938|NCT05265689|Experimental|Bike Club|Participants will receive a 12-hour bicycle safety education program
32718939|NCT05265689|Experimental|Bike Club Plus|Participants will receive an enhanced version of the 12-hour bicycle safety education program which will include a parent training session on bicycling safety best practices, child development as it relates to bicycling, strategies for practice at home, and feedback on their adolescent's bicycling performance.
33248322|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
32718940|NCT05265689|No Intervention|Control Group|The control group will not receive any bicycle safety education programming.
32718941|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
32718942|NCT05583305||Patients diagnosed with APS|"Investigators shall recruit patients with the following criteria:~Diagnosed with APS who fulfilled the modified Sapporo criteria:~at least one clinical criterion (vascular thrombosis or pregnancy morbidity); and~laboratory criteria (aPL positivity twice, 12 weeks apart):~i. Lupus anticoagulant positivity requires screening, mixing, and confirmation test as per International Society of Thrombosis and Hemostasis guidelines (11).~ii. Anticardiolipin antibodies positivity requires a medium to high titer IgG and/or IgM level by ELISA assays.~iii. Anti-β2 glycoprotein antibodies positivity requires a >99th titer IgG and/or IgM level by ELISA assays.~Patients age ≥18 years~Patients who are able to provide an informed consent to study procedures"
32718943|NCT05583305||Controls|From the ongoing prospective Brain Health Longitudinal study which contained stroke- and dementia free participants (CREC Ref. No: 2018.148), investigators shall identify age- and gender-matched individuals without aPLs as controls
32920438|NCT04983407|Active Comparator|Phase 2: nab-paclitaxel and gemcitabine alone|
32920439|NCT04978571|Experimental|Active Neurostim Device|Patients in this group will receive the active devices for the initial 4 study weeks.
32920440|NCT04978571|Sham Comparator|Sham Neurostim Device|Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
32920441|NCT05421923|Experimental|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
32920442|NCT05421923|Placebo Comparator|Placebo|Ascending single and multiple doses of SR1375 placebo orally
32920443|NCT05418413|Active Comparator|Conventional Twin-block appliance|The patients in this control group will be treated using the conventional Twin-block appliance (CTB).
32718944|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
32718945|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
32718946|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
32920444|NCT05418413|Experimental|Esthetic Twin-block appliance|the patients in this experimental group will be treated using the esthetic Twin-block appliance (ETB).
32920445|NCT05194631|Experimental|Regeneration Capacity of Satellite Cells|In vitro Regeneration Capacity of Satellite Cells from the Quadriceps Compared to That of the Diaphragm isolated From one patient
32920446|NCT05418023||Autism Spectrum Disorder (ASD)|
32718947|NCT05258747|Experimental|Olaparib tablets, 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
32920447|NCT05418023||Non-ASD|
32920448|NCT05417555|Active Comparator|LIFUP Dose Group 1|Administration of low intensity focused ultrasound (LIFUP) dose level 1 to the entorhinal cortex.
32920449|NCT05417555|Active Comparator|LIFUP Dose Group 2|Administration of low intensity focused ultrasound (LIFUP) dose level 2 to the entorhinal cortex.
32920450|NCT05417555|Active Comparator|LIFUP Dose Group 3|Administration of low intensity focused ultrasound (LIFUP) dose level 3 to the entorhinal cortex.
32920451|NCT05417555|Sham Comparator|Sham LIFUP|"No administration of LIFUP. The device will be affixed to the user's head but not turned on.~Additionally, if at the end of the study, the treatment has been shown to be effective, placebo subjects will be offered a free session using the optimally effective dose, if they consented to being contacted for this purpose."
32920452|NCT05416541||pregnant patients|
32920453|NCT05414201|Experimental|Adalimumab|Participants will receive a loading dose of Adalimumab 80mg SC at Baseline followed a week later by a dose of Adalimumab 40mg SC every other week.
33248323|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
32718948|NCT05258747|Active Comparator|Lynparza® (olaparib) tablets 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
32718949|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
32718950|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
32718951|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
32920455|NCT05188235|Experimental|Infants with developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
32920456|NCT05188235|Active Comparator|Infants without developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
32920457|NCT04685421|Experimental|Liposomal Bupivacaine PK|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
32920458|NCT05183633||One single trial|
32920459|NCT05406947||Low risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
32920460|NCT05406947||Middle risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
32920461|NCT05406947||High risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
32920462|NCT05440539|Experimental|Written Group|Participants received only written handouts with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive these handouts at the time of recruitment during pregnancy and again after delivery.
32920463|NCT05440539|Experimental|Workshop Group|Participants received written handouts and attend a virtual interactive workshop with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive the handouts at the time of recruitment during pregnancy and again after delivery. The workshop is conducted prior to completion of pregnancy.
32920464|NCT05180591|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
32920465|NCT05180591|Placebo Comparator|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
32920466|NCT04745429|Experimental|Intervention|19 people suffering from psoriasis were performing excersises for 10 weeks
32920467|NCT04745429|No Intervention|Control|19 people suffeing from psoriasis that didn't train the exercises
32920468|NCT05172479||Positive qSOFA|Adult patients with suspected infection and a qSOFA score ≥ 2 at the triage in the ED who are planned for hospitalization
32920469|NCT05172479||Negative qSOFA|Adult patients with suspected infection and a qSOFA score < 2 at the triage in the ED who are planned for hospitalization
32920470|NCT05172479||Positive SIRS|Adult patients with suspected infection and a SIRS criteria ≥ 2 at the triage in the ED who are planned for hospitalization
32920471|NCT05172479||Negative SIRS|Adult patients with suspected infection and a SIRS criteria < 2 at the triage in the ED who are planned for hospitalization
32920472|NCT05172479||Positive NEWS|Adult patients with suspected infection and a NEWS ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
32920473|NCT05172479||Negative NEWS|Adult patients with suspected infection and a NEWS < 5 at the triage in the ED who are planned for hospitalization
32920474|NCT05172479||Positive NEWS2|Adult patients with suspected infection and a NEWS2 ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
32920475|NCT05172479||Negative NEWS2|Adult patients with suspected infection and a NEWS2 < 5 at the triage in the ED who are planned for hospitalization
32920476|NCT05172479||Positive MEWS|Adult patients with suspected infection and a MEWS ≥ 5 at the triage in the ED who are planned for hospitalization
32920477|NCT05172479||Negative MEWS|Adult patients with suspected infection and a MEWS < 5 at the triage in the ED who are planned for hospitalization
32920478|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
32920479|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
33248324|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
33248325|NCT00930202|No Intervention|Standard Care|No intervention
33248326|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
32718952|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
32920480|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
32920481|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
32920482|NCT05400629|Experimental|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
32920483|NCT05168735|Experimental|Intravenous Ketamine + Mindfulness Exercises|
32920484|NCT05168735|Active Comparator|Intravenous Ketamine + Academic Exercises|
32920485|NCT04706013|Experimental|Single Arm Active|Pyridoxal 5'-Phosphate
32920486|NCT04745195||Complement-mediated thrombotic microangiopathy|
32920487|NCT04745195||Thrombotic microangiopathty with normal complement regulation|
32920488|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
32920489|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
32920491|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
32920492|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
32920493|NCT04880772|No Intervention|Standard care|Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)
32920494|NCT04880772|Experimental|Prehabilitation|Surgery School plus Moderate intensity exercise & Forceval (multivitamin)
32920495|NCT04880382|Other|Standard Arm A: treatment by ICI will be continued|After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization
32920496|NCT04880382|Experimental|Experimental Arm B: treatment by ICI will be discontinued|After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.
32920497|NCT00359645|No Intervention|Control|Annual auto questionnaire
32920498|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
32920499|NCT00359723|Experimental|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
32920500|NCT00359723|Experimental|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
32920501|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
32718953|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
32920502|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
32920503|NCT05392751|Experimental|EA-2353|EA-2353 Ophthalmic Suspension will be administered via unilateral intravitreal injection into the Study Eye weekly for one month (4 injections)
32920504|NCT04973267|Experimental|Game Plan for PrEP|Participants will be asked to use Game Plan for PrEP for however long they wish. Game Plan for PrEP is a web-based intervention that provides users with feedback about how much their risk for HIV is reduced on PrEP, their risk for bacterial STIs, and helps them make a plan to take their medication regularly and reduce their risk for STIs. Game Plan for PrEP also providers users with feedback about their alcohol use compared to others in their age group and encourages them to make a plan to reduce it.
32920505|NCT04973267|Sham Comparator|Lifestyle Habits Videos|Participants in this condition will view several videos that encourage them to adopt sleep hygiene and healthy diet behaviors. The videos were selected to last as long as the average time users engage with Game Plan for PrEP in its initial modules.
32920506|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
32920507|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
32920508|NCT05152823|Experimental|Single Intrathecal Delivery|
32920509|NCT05151185|No Intervention|Control group|The dementia case manager in the control group undergo existing training. The family caregiver in the control group receive routine service.
32920510|NCT05151185|Experimental|training program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program.
32920511|NCT04744805||mask wear|
32920512|NCT04744805||dry eye|
32920513|NCT05148533|Experimental|TJ1133 Injection|
32920514|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
32920515|NCT05145491|Active Comparator|Immediate Vitrectomy|
32920516|NCT05145491|Other|Deferred Vitrectomy|
32920517|NCT05142605|Experimental|Cohort 1: Meaning-Centered Grief Therapy/MCGT|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
32920518|NCT05142605|Active Comparator|Group 2: Supportive Psychotherapy /SP|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
32920519|NCT05142605|Active Comparator|Group 3: Enhanced usual care/EUC|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
32920520|NCT04969913||19 + years|Healthy adults over the age of 19 years
32920521|NCT04969913||Ages 11 - 18 years|Healthy children between the ages of 11 and 18 years
32920522|NCT04969913||Ages 5 - 10 years|Healthy children between the ages of 5 and 10 years
32920523|NCT04969913||Ages 6 months - 4 years|Healthy infants between the ages of 6 months and four years
32920524|NCT04967339|Experimental|Foot deformity correcting insole arm|"Patients allocated to the foot deformity correcting insole arm will receive insoles to correct their foot deformities (plano-valgus foot deformity)."
32920525|NCT04967339|Active Comparator|Lateral wedge insole arm|"Patient allocated to the Lateral wedge insole arm will receive conventional lateral wedge insole."
32920526|NCT04963673||DFG> 40 ml / min|Kidney transplant population followed at CHU Amiens (group 1 ⇾ DFG> 40 ml / min).
32920527|NCT04963673||DFG < 40 ml / min|Kidney transplant population followed at CHU Amiens (group 2 ⇾ DFG < 40 ml / min).
32920528|NCT05381909|Experimental|Phase 1a: Dose Escalation Part A|Participants will receive escalating doses of BGB-24714 as monotherapy
32920529|NCT05381909|Experimental|Phase 1a: Dose Escalation Part B|Participants will receive increasing dose levels of BGB-24714 in combination with chemotherapy
32920530|NCT05381909|Experimental|Phase 1b: (Dose Expansion)|Participants will receive the recommended phase 2 dose (RP2D) of BGB-24714 monotherapy or in combination with chemotherapy as determined from Phase 1a
32920531|NCT04959695|Experimental|Prolonged exposure with PE Coach|The mobile application will be incorporated into each PE psychotherapy session and used to support homework between sessions.
32920532|NCT04959695|Active Comparator|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
32920533|NCT04957277|Experimental|load modulation|Participants will experience different body weight loading conditions - with body weight added by a weighted vest or removed using the ZeroG overhead harness.
33248327|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
33248328|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
33248329|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
33248330|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
33248331|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
33248332|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
33248333|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
33248334|NCT03993067|Active Comparator|Standard Treatment|Fibrin glue and Tabotamp on cut surface
33248335|NCT03993067|Experimental|Hemopatch|Hemopatch on cut surface
32920534|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
32920535|NCT04500899|Experimental|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
32920536|NCT04950803|Active Comparator|Active arm|Subjects will take microbiome immunity formula (SIM01) daily for 3 months
32920537|NCT04950803|Placebo Comparator|Placebo arm|Subjects will take active vitamin daily for 3 months
32920538|NCT04873661|Experimental|Hypnosis|In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
32920539|NCT04873661|Experimental|Cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
32920540|NCT04873661|Experimental|Meditation|The meditation-based intervention will consist of 8 weekly sessions (2h45 each) in groups of approximately 10 participants, as well as half a day of intensive practice between the fifth and the sixth session. Participants will learn how to implement self-compassion meditation, through practical exercises proposed during the sessions. At-home practice is encouraged between sessions.
32920541|NCT04873661|No Intervention|Control group|Participants in the control group will not receive any intervention during the whole duration of the study. They will be assessed at the same times and in the same ways than the 3 experimental groups. After the study, they will have the opportunity to participe in one of the 3 interventions if they want to.
32920542|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
32920543|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
32920544|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
32920545|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
32920546|NCT04476797|Experimental|GC4711 + SBRT|
32920547|NCT04476797|Placebo Comparator|Placebo + SBRT|
32920548|NCT04862585|Active Comparator|Arm I (paclitaxel, pre-medications)|Patients continue on pre-medications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel.
32920549|NCT04862585|Experimental|Arm II (paclitaxel)|Patients discontinue premedications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel, unless patient develops a subsequent infusion HSR.
32920550|NCT04860947||MS patients|
32920551|NCT04858607||Immunocompromised individuals|Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
32920552|NCT04858607||Healthy individuals|Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
32920554|NCT04933331||Curodont Repair Fluoride Plus (Curodont) cohort|The effectiveness of Curodont treatment in this group will be compared to other treatment options and cohorts. Curodont will be professionally applied in the dental clinic. The treatment time takes about 5 minutes. Patients receive one professional dose application and be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.
32920555|NCT04933331||Other tooth-specific initial lesion interventional treatments cohort(s)|"Silver Diamine Fluoride (SDF). The treatment time is about 2 minutes.~Glass Ionomer Sealants: The treatment time takes about 5 minutes per sealant. Typically four sealants are completed in one visit.~All patients will be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months."
32920556|NCT04933331||Control cohort, no tooth-specific treatment or whole mouth treatment.|If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.
32920557|NCT04933331||Orthodontic cohort|Patients in active orthodontic care will be analyzed separately from other patients to account for the impact of orthodontic appliances on treatment outcomes. Orthodontic appliances are recognized by the American Dental Association Caries Risk Assessment as a risk factor for caries because they create dental plaque stagnation areas that are difficult to clean. Initial caries lesions are very frequently seen immediately surrounding orthodontic brackets (braces), yet continued plaque stagnation over the treated areas may heavily influence the success of any treatment. All groups/cohorts above will be represented in the orthodontic cohort in parallel.
32920558|NCT04933097|Experimental|Sarcopenia|Only one arm with the sarcopenia assessment.
32920559|NCT04931459|Experimental|ACU193 Administration|Participants will receive 1 to 3 doses of ACU193 by intravenous (IV) infusion.
32920560|NCT04931459|Placebo Comparator|Placebo Administration|"Participants receive 1 to 3 doses of matching ACU193 placebo by intravenous (IV) infusion.~2 participants per cohort will receive placebo."
32920561|NCT04673409||Suspected myocarditis of undefined aetiology|Patients with signs and symptoms of acute myocarditis (as defined by the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases).
32920562|NCT04673409||Suspected myocarditis with autoimmune rheumatic disease|Patients with suspected myocarditis due to an underlying AIRD.
32920563|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
32920564|NCT02977091||short stature|healthy short children
32920565|NCT04469075|Experimental|topical clindamycin and triamcinolone|Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
32920566|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
32920567|NCT02977325||water cure exclusively|This group followed exclusively the water cure
32920568|NCT04916015||children (0-14 years)|
32920569|NCT04916015||AYAs (15-25 years)|
32920570|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
32920571|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
32920572|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
32920573|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
32920574|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
32920575|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
32920576|NCT04832087||Cohort A|Participants with SBS who started Teduglutide after FDA approval (May 2019)
32920577|NCT04832087||Cohort B|Subjects who participated in any of the teduglutide pediatric clinical trial studies (TED-C13-003, TED-C14-006, SHP633-303, or SHP633-304) and subsequently started therapy with teduglutide
32920578|NCT04826237|Experimental|Statin|"Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day;~Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone:~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
32718954|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
32718955|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
32920579|NCT04826237|Placebo Comparator|Placebo|"Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
32920580|NCT04913285|Experimental|Dose Escalation Monotherapy (Part A1)|Dose escalation of KIN-2787
32920581|NCT04913285|Experimental|Dose Escalation Combination therapy (Part A2)|Dose escalation of KIN-2787 and binimetinib
32920582|NCT04913285|Experimental|Dose Expansion (Part B)|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
32718956|NCT05724797|Experimental|NRS-033: Cohorts 1-3|Cohorts 1-3: 6 participants in each cohort will receive active drug (NRS-033)
32718957|NCT05724797|Placebo Comparator|Placebo: Cohorts 1-3|Cohorts 1-3: 2 participants in each cohort will receive the matching placebo dose
32920583|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
32920584|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
32920585|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
32920586|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
32920587|NCT04907201||Patients|A group pf 30 patients with lower limb spasticity who are already candidate for cryoneurotomy will be invited to have an extra electrophysiological test for participation in this study. The test will be done for both limbs for a better comparison.
32920588|NCT04907201||Healthy participants|A group of 30 healthy participants will be invited as a control group, and they will have a single session of electrodiagnostic test for their lower limb in dominant side.
32920589|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
32920590|NCT04897217|Active Comparator|Megestrol Acetate Arm - Control Arm|Megestrol Acetate 160 mg by mouth daily
32920591|NCT04897217|Experimental|Levonorgestrel IUD - Comparison Arm|Levonorgestrel intrauterine device with 52 mg progestin (Releases 20mcg/daily)
32920592|NCT04896515||Standard Nutrition Arm|"In INTENT (the parent study) participants will be randomised to the i) Standard Nutrition or ii) Intensive Nutrition arm. A brief description of each is below.~In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~Parenteral Nutrition (PN) will only be used if the above methods have been attempted, or an absolute contraindication to enteral nutrition (EN) develops.~After ICU:~1. Nutrition management will be as per usual site management at that hospital."
32920593|NCT04896515||Intensive Nutrition Arm|"In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision and assessed daily until ICU discharge~If there is an interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~1. An intensive nutrition intervention will be provided on the ward.~The goal of nutrition care across the hospital stay will be to ensure 80-100% of participant's estimated energy requirements are met."
32718958|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
32718959|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
32718960|NCT05246189||Patient with PXE working aged|Patient diagnosed with PXE on working age and followed up by the French Reference Center.
32718961|NCT04441151|Experimental|Experimental group|Pulmonary rehabilitation therapy
32718962|NCT04441151|No Intervention|Control group|Routine medical treatment
32920594|NCT04417907|Placebo Comparator|Placebo|Participants will take 2mg placebo PO QD for six weeks.
32920595|NCT04417907|Experimental|PER 1 Week Titration|Participants will take 2mg perampanel PO QD for one week, followed by 4mg perampanel PO QD for five weeks.
32718963|NCT05724641|Experimental|Healthy Volunteers|N = 10, who do not use contact lenses or eye glasses and have a recent evaluation of vision 10/10 ta participate in the repeatability study.
32718964|NCT05724641|Experimental|Chronic|N = 30 (10 patients with thyroid associated orbitopathy (TAO), 10 patients with inflammatory optic neuropathy (ION), 10 patients with ischemic neuropathy), all chronic patients followed in ophthalmology consultation, enlightened volunteers ta participate in the study, and presenting a decrease in residual visual acuity entering the TAO, inflammatory or ischemic frameworks.
32718965|NCT05724641|Experimental|Acute|N = 30 (10 patients with TAO, 10 patients with ION, 10 patients with ischemic neuropathy) all patients seen in the acute phase in ophthalmology consultation who will accept participation in the study, knowing the constraint of repeating the examination in the chronic phase.
32718966|NCT05239793|Other|NJOY e-cigarette|NJOY e-cigarette containing 5% nicotine strength pods
32718967|NCT05223179|Experimental|CODA-VAX H1N1|Live Attenuated Vaccine administered by Intramuscular Injection
32920596|NCT04417907|Experimental|PER 2 Week Titration|Participants will take 2mg perampanel PO QD for two weeks, followed by 4mg perampanel PO QD for four weeks.
32920597|NCT04417907|Experimental|PER 4 mg|Participants will take 4mg perampanel PO QD for six weeks
32920598|NCT04798547|Placebo Comparator|Standard Length Myotomy|Patients randomized to received 8 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
32920599|NCT04798547|Experimental|Short Length Myotomy|Patients randomized to received 4 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
32920600|NCT04797767|Experimental|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
32920601|NCT04797143||control group|patients in control group receive standard care
32920602|NCT04797143||intervention group|intervention group after implementation of a MCP
32920605|NCT05752461|Experimental|Treatment group A: SHR-2004 injection|
32920606|NCT05752461|Experimental|Treatment group B: SHR-2004 injection|
32920607|NCT05752461|Experimental|Treatment group C: SHR-2004 injection|
32920608|NCT05752461|Active Comparator|Treatment group D: Enoxaparin sodium injection|
32920609|NCT00002583|No Intervention|Observation|Observation only
32920610|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
32920611|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
32718968|NCT05223179|Active Comparator|Flucelvax Quad|Licensed Injectable Seasonal Influenza Vaccine
32920612|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
32920613|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
32920614|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
32920615|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
32920616|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
32920617|NCT04889417|Experimental|Intervention|Computerized brain game training and online interactive physical exercise training
32920618|NCT04889417|Active Comparator|Control|Control computer games and online interactive stretching exercises.
32920619|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
32920620|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
32920621|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
32920622|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
32718969|NCT05223179|Placebo Comparator|Saline|Normal Sterile Saline for Intramuscular Injection
32718970|NCT05540405|Experimental|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
32718971|NCT05540405|Experimental|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
32718972|NCT05540405|Placebo Comparator|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
32718973|NCT05540327|Experimental|M5049 low dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received low dose of M5049 in WILLOW study will continue to receive M5049 low dose and matching placebo.
32920623|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
32920624|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
32920625|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
32920626|NCT00360737|Active Comparator|NP-018|Subjects received one or two vials of NP-018 administered intravenously.
32920627|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
32920628|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
32920629|NCT05752305|Experimental|Methylprednisolone group|Preoperative administration of 40mg of methylprednisolone via submucosa
32718974|NCT05540327|Experimental|M5049 medium dose+ Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received medium dose of M5049 in WILLOW study will continue to receive M5049 medium dose and matching placebo.
32920630|NCT05752305|Experimental|Dexamethasone group|Preoperative administration of 8mg of dexamethasone via submucosa
32920631|NCT04343729|Active Comparator|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
32920632|NCT04343729|Placebo Comparator|Placebo|Saline solution, twice daily, for 5 days. Injectable.
32920633|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
32920634|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
32920635|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
32920636|NCT04887857|Experimental|CC-486 in combination with Venetoclax|
32920637|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
32920638|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
32920639|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
32920640|NCT04823611|Placebo Comparator|Part A:Placebo|Placebo solution for subcutaneous injection.
32920641|NCT04823611|Experimental|Part A:AZD8233|AZD8233 for subcutaneous injection.
32920642|NCT04823611|Placebo Comparator|Part B:Placebo|Placebo solution for subcutaneous injection.
32920643|NCT04823611|Experimental|Part B:AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
32920644|NCT04823611|Experimental|Part B:AZD8233 low dose|AZD8233 low dose for subcutaneous injection.
32718975|NCT05540327|Experimental|M5049 high dose|Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or high dose of M5049 in WILLOW study will receive M5049 high dose .
32718976|NCT05724485|Active Comparator|BCAA group|12.45 grams of branched-chain amino acids orally per day before bedtime for 12 weeks.
32718977|NCT05724485|Placebo Comparator|Placebo group|12.45 grams of placebo (Maltodextrin) orally per day before bedtime for 12 weeks.
32718978|NCT05724407||Standard of care|Female patient diagnosed for breast cancer
32718979|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
32718980|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
32718981|NCT04468997|Experimental|601 dose level 1 treatment|
32718982|NCT04468997|Experimental|601 dose level 2 treatment|
32718983|NCT04468997|Experimental|601 dose level 3 treatment|
32718984|NCT04468997|Experimental|601 dose level 4 treatment|
32718985|NCT04468997|Experimental|601 dose level 5 treatment|
32718986|NCT04468997|Experimental|601 dose level 6 treatment|
32718987|NCT04469153||SARS-COV 2 positive patient|57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital. For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
32718988|NCT04468217||Subjects with positive test to SARS-COV2|Employees of critical services companies and healthcare workers with a positive test to SARS-COV2.
32920645|NCT04823611|Placebo Comparator|Part C: Placebo|Placebo solution for subcutaneous injection.
32920646|NCT04823611|Experimental|Part C: AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
32920647|NCT05752227||benign lung lesions|Patient who were diagnosed with peripheral lung lesions including consolidation, atelectasis, or cavitation
32920648|NCT05752227||malignant lung lesions|patients diagnosed with malignant lung lesions
32718989|NCT04468217||Subjects with negative test to SARS-COV2|Employees of critical services companies and healthcare workers with a negative test to SARS-COV2.
32718990|NCT04441385|Experimental|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
32718991|NCT04441385|Other|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
32920649|NCT04416737|Experimental|Upper Peritoneal, then Lower Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.
33248336|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
33248337|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
33248338|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
33248339|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
33248340|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
33248341|NCT01043731||Ginven indication for laparoscopic anterior resection|
33248342|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
33248343|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
33248344|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
32718992|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
32718993|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
32718994|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
33248345|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
33248346|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
33248347|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
33248348|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
33248349|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
33248350|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
32742923|NCT04415151|Experimental|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
32742924|NCT04415151|Placebo Comparator|Placebo|Matching placebo will be administered.
33248351|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
33248352|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
33248353|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
33248354|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
33248355|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
33248356|NCT01044121|Experimental|Mattress Firmness|
33248357|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
33248358|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
33248359|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
33248360|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
33248361|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
32718995|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
32718996|NCT05724329|Experimental|Tislelizumab + Dasatinib + Quercetin|"Treatment with Tislelizumab, dasatinib and quercetin for up to 3 cycles (cycle length: 21 days):~Tislelizumab (IV), dose= 200mg, day=1. Dasatinib (PO), dose=100mg/day, day= 1,2,3. Quercetin (PO), dose=1250mg/day, day= 1,2,3."
32718997|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
32718998|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
32920650|NCT04416737|Experimental|Lower Peritoneal, then Upper Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.
32920651|NCT04665999||Free-cycling females|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
32920652|NCT04665999||Females taking Monophasic contraception|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
32920653|NCT04802473|Experimental|Gingival recession treatment|Gingival recession treatment by means of tunnel technique and OrACell dermal matrix.
32920654|NCT04401995|Experimental|Nivolumab and Vidutolimod (CMP-001) Combination with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with Vidutolimod 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 2.~Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks."
32920655|NCT04401995|Experimental|Nivolumab with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 3.~Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks."
32920656|NCT00002643|Experimental|Arm I|See detailed description.
32920657|NCT04771897|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with newly diagnosed DIPG or DMG will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level is reached and radiation therapy.
32920658|NCT04771897|Experimental|Part 2 BXQ-350 Tumor and Plasma Concentrations|Newly diagnosed DIPG or DMG patients undergoing neurosurgical biopsy prior to receiving radiation therapy will receive BXQ-350 at the MTD established in Part 1, or the highest planned dose level, and radiation therapy. Excised tumor tissue and plasma samples will be evaluated for SapC levels and pharmacodynamic effects.
32920659|NCT04342559|Experimental|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
32920660|NCT04342559|Experimental|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
32920661|NCT04770571||Vuepoint II OCT|
32920662|NCT04770571||Reline-C|
32920663|NCT04779437|Experimental|Imagery Cognitive Bias Modification First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of imagery cognitive bias modification followed by two weeks of cognitive control training. Daily QIDS will be completed throughout the intervention phases.
32920664|NCT04779437|Experimental|Cognitive Control Training First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of cognitive control training followed by two weeks of imagery cognitive bias modification. Daily QIDS will be completed throughout the intervention phases.
33073348|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
33248362|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
32718999|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
32719000|NCT03528473|Experimental|Exercise|Patients involved in the 6 months-physical training group.
32719001|NCT03528473|No Intervention|Control|Patients in control group carry on their usual follow-up programme.
32719002|NCT05179499|Active Comparator|Intervention Arm|Participants will receive peripheral vasopressor infusion of norepinephrine (16 micrograms/ml) during the initial 48 hour study period. All other care will be as per local protocol.
32920665|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
32920666|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
32920667|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
32719003|NCT05179499|Placebo Comparator|Standard care|Participants allocated to the control arm will receive standard care as defined by the UK NICE guidelines and the Surviving Sepsis Campaign guidelines during the 48 hour study period post randomisation. All other care will be as per local protocol.
32719004|NCT05724251||Healthy|participants without periodontitis
32920668|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
32920669|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
32920670|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
32920671|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
32920672|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
32920673|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
32920674|NCT05752149|Experimental|WP-I dose 1|n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
32920675|NCT05752149|Experimental|WP-I dose 2|n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
32920676|NCT05752149|Experimental|WP-I dose 3|n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.
32719005|NCT05724251||periodontitis|participants with stage-3 periodontitis
32719006|NCT05724095|Sham Comparator|control|
32920677|NCT05752149|Experimental|WP-II|n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.
32920678|NCT01151605|Experimental|obese|20 obese subjects
32920679|NCT01151605|Active Comparator|lean|20 lean subjects
32920680|NCT01151605|Experimental|type 2 diabetes|20 type 2 diabetes
32920681|NCT04398485|Experimental|ION251|In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.
32920682|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
33248363|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
33248364|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
32719007|NCT05724095|Experimental|low frequency stimulation|
32719008|NCT05724095|Experimental|high frequency stimulation|
32719009|NCT05724017|Experimental|Street Games Intervention Group|Street Games Intervention Group
32742925|NCT04942743||control group|patients with normal TMJ
32742926|NCT04942743||Study group|patients with TMJ internal derangement
32742927|NCT04949997||control|patients without heart failure
32742928|NCT04949997||HF|patients with heart failure
32920683|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
32920684|NCT04768127|Experimental|Early aftercare (intervention group 1)|Patients in this group will begin the ACHT program immediately after their bariatric metabolic operation. 3 weeks post surgery, they will attend the initial examination and meet their case manager. The obesity guide will then set up an electronic case file for the patient and introduce the patient to the obesity app. Through the next 18 months the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 2 patients visit a sports physician who assesses their mobility and physical capacity to compile a personal training plan, which will be uploaded onto the patient's case file and thus be available to the patient via the app. In months 3,6,9.12 and 18, patients will attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined by a physician and receive tailored dietary advice from a nutritional advisor. In month 18 patients revisit the surgical centre for the follow-up examination
32920685|NCT04768127|Experimental|Mid-term to long-term aftercare (intervention group 2)|Patients in this group first visit the study center 18 months after their bariatric surgery for the initial examination and start the program in month 19 post-op. At the center, they will meet their obesity guide who will set up an electronic case file for the patient and introduce the patient to the obesity app. Throughout the next 18 months, the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 19 post-surgery, patients visit a sports physician who assesses their mobility and devises a personal training plan. This plan will be uploaded onto the patient's case file and made available to the patient via the app. In months 19,21,24, 30 and 36, patients attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined and receive tailored dietary advice. In month 36, patients will be reexamined at the study center.
32920686|NCT04768127|No Intervention|control group 1 (early aftercare)|"Analogous to intervention group I, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination (18 months after the operation) at the obesity centre.~If interested, patients in this group can be included in intervention group II until the required number of cases (140 patients) has been reached."
32920687|NCT04768127|No Intervention|control group 2 (mid-term to long-term aftercare)|Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
32920688|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~Objective salivary normo-function~Objective salivary dysfunction"
32920689|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
32920690|NCT05752071|Experimental|Treatment group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is set to the following settings: 10,5 Volt, 14 hz, 330 Micro sec, Cycling 5 seconds off 0,1 sec on. The pacemaker is turned on.
32920691|NCT05752071|Sham Comparator|Control group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is turned off.
32920692|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
32920693|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
32920694|NCT04759157|Active Comparator|Couples-based treatment|Participants will attend 3, sessions (75, 50, 50 min) over video with a study therapist to discuss education about OSA and CPAP, strategies adjust to CPAP as a couple and techniques to improve sleep health.
32920695|NCT04759157|Other|Standard Information Control|Participants will receive treatment as usual and also standardized information about OSA and CPAP.
33399999|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
32920696|NCT05751993|Experimental|ADAPT intervention|Participants will receive a smart scale and a physical activity tracker and will have three daily goals: weigh daily, a daily personalized active minutes goal, and a daily calorie goal. For 12 weeks, participants will receive 0-3 text messages per day about their behaviors and progress towards their goals which they will be able to rate (like/dislike), along with weekly personalized feedback, progress graphs, and lessons and resources available on the website.
32920697|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
32920698|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
32920699|NCT05751915||PET CAV 0|Normal perfusion with normal global stress (> 1.7 mL/min/g)
32920700|NCT05751915||PET CAV 1|Normal perfusion with abnormal global stress MBF (<1.7 mL/min/g and ejection fraction >45%) OR Single vessel perfusion defect with normal global stress MBF.
32920701|NCT05751915||PET CAV 2/3|Normal perfusion with abnormal global stress MBF (<1.7 mL/min/g) and ejection fraction < 45% OR Single vessel perfusion defect with abnormal global stress MBF (<1.7 mL/min/g) OR Multivessel perfusion defects v
32920702|NCT04627441|Experimental|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
32920703|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
32920704|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
32719010|NCT05508191|Experimental|Secretome + Fractional CO₂ Laser|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for fractional CO₂ laser, AMIⓇ device is used with this following settings: 15 mJ energy, 900 µs pulse duration, density level 15, and depth level 2.
32719011|NCT05508191|Experimental|Secretome + Microneedle|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for microneedle, DrPenⓇ dermapen is used in this following direction and order: vertical, horizontal, and diagonal, with the depth of 150 µm.
32719012|NCT04468685|Experimental|Ondansetron|Ondansetron intraperitoneal in the gall bladder bed
32719013|NCT04468685|Placebo Comparator|Saline|Normal saline intraperitoneal in the gall bladder bed
32719014|NCT05099861||healthy volunteers|Healthy volunteers with no sign of internal disease. Age 18-50, both women and men.
33248365|NCT00624819|Experimental|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
33248366|NCT00624819|Active Comparator|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
33248367|NCT00624819|Experimental|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
33248368|NCT00624819|Experimental|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).~The Unprimed Group was added only in Year 4 of the study."
33248369|NCT01049347|Active Comparator|amitriptyline|
33248370|NCT01049347|Active Comparator|paroxetine|
33248371|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
33248372|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
33248373|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
33248374|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
33248375|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
33248376|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
33248377|NCT00838227|Experimental|One arm|Study withdrawn due to lack of funds.
33248378|NCT00827619|Other|1|single arm non-randomized post-market study
32719015|NCT05099861||patients with internal disease|Patients with internal disease, both women and men.
33248379|NCT04043559||patients with an acute symptomatic infarction|
33248380|NCT04043559||controls with cryptogenic stroke|
33248381|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
33248382|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
33248383|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
33248384|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
33248385|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
33248386|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
33248387|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
33248388|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
33248389|NCT00831285|Experimental|tortilla with high amylose flour|
32719016|NCT05079035|Experimental|Experimental: TTAX03|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.
33248390|NCT00831285|Experimental|barley tortilla with low amylose flour|
33248391|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
33248392|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
33248393|NCT00831285|Active Comparator|glucose|
32920705|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
32920706|NCT04054115|Experimental|Treatment Arm|"Baseline cardiac catheterization under GA. (Standard of Care, SOC)~Transfer patient to MRI unit~Baseline MRI~Obtain ABG for pCO2 from existing femoral arterial access.~Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.~MRI phase contrast imaging for flow measurements(SOC).~During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.~Post alprostadil infusion~1ml blood sample taken from existing femoral venous access for prostaglandin level.~Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.~Repeat MRI flow measurements~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC)."
32920707|NCT04051151|Experimental|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
32920708|NCT04051151|No Intervention|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
32920709|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
32920710|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
32920711|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
32920712|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
32920713|NCT04488601|Experimental|Rapamycin 5|Rapamycin 5 mg/week
32920714|NCT04488601|Experimental|Rapamycin 10|Rapamycin 10 mg/week
32920715|NCT04488601|Placebo Comparator|Placebo 1|Placebo once per week
32920716|NCT04044365||1/Project 1 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
32920717|NCT04044365||2/Project 1 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=20 child/parent pairs
32920718|NCT04044365||3/Project 1 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=35 child/parent pairs
32920719|NCT04044365||4/Project 2 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
32920720|NCT04044365||5/Project 2 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
32920721|NCT04044365||6/Project 2 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
32920722|NCT05073133|Experimental|OAV101|A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes
32920723|NCT05751759|Experimental|Cohort 1|8 participants with mild hepatic impairment (Child-Pugh A) will be given Dose A of mitiperstat.
32920724|NCT05751759|Experimental|Cohort 2|8 participants with moderate hepatic impairment (Child-Pugh B) will be given Dose A of mitiperstat.
32920725|NCT05751759|Experimental|Cohort 3|8 participants with severe hepatic impairment (Child-Pugh C) will be given Dose A of mitiperstat.
32920726|NCT05751759|Experimental|Cohort 4|8-12 participants with normal hepatic function will be given Dose A of mitiperstat.
32920727|NCT05032807|Experimental|Novel lipid formulation cannabidiol|
32920728|NCT05032807|Active Comparator|Standard formulation cannabidiol|
32920729|NCT04040387|Experimental|Treatment Arm|Intervention with NightWare Therapeutic System
32920730|NCT04040387|Sham Comparator|Sham Arm|NightWare system set to not provide any interventions
32920731|NCT00002715|Experimental|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
32920732|NCT04972513||Prevention (survey, breathe tests, biospecimen collection)|Participants undergo computer-based spirometry testing, nitric oxide breath testing, airwave oscillometry, and an assessment of endothelial function. Participants will undergo collection of blood. Current e-cigarette users also vape their own e-cigarette device for 30 minutes.
32920733|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
32920734|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
32920735|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
32920736|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
32920737|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
32920738|NCT04739345|Active Comparator|Group 1|Non-severe patients should meet all following conditions: (1) Epidemiology history, (2) Fever or other respiratory symptoms, (3) Typical CT image abnormities of viral pneumonia, and (4) Positive result of RT-PCR for SARS-CoV-2 RNA.
32920739|NCT04739345|Placebo Comparator|Group 2|Severe patients should meet at least one of the following conditions: (1) Shortness of breath, RR ≥ 30 times/min, (2) Oxygen saturation (Resting state) ≤ 93%, (3) PaO2/FiO2 ≤ 300 mmHg.
32920740|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
32920741|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
32920742|NCT01623739|Active Comparator|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
32920743|NCT01623739|Active Comparator|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
32920744|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
32920745|NCT04354103|Experimental|patients with Tourette's syndrome|Atomoxetine in Patients With Tourette's Syndrome
32920746|NCT04039529|No Intervention|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
32920747|NCT04039529|Experimental|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
33400000|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
33400001|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
33400002|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
32920748|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
32920749|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
32920750|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
32920751|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
32920752|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
32920753|NCT05751681|Experimental|Group (A)|will be subjected to progestin primed ovarian stimulation protocol Women in group (A), will be prescribed 20 mg oral dose of dydrogesterone (Duphaston, Abbott) from the 2nd day of the cycle and continued until the trigger day. Transvaginal follicular monitoring will be done for all patients starting the 6th day of cycle.
32920754|NCT05751681|Active Comparator|group (B)|Gonadotropin Releasing Hormone Antagonist Protocol when the size of dominant follicles reaches 12-13 mm, 0.25 mg of cetrotide (Merck-Serono Germany) will be injected subcutaneously daily and continued until the day of trigger shot.
32920755|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
32920756|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
32920757|NCT04311671|Experimental|Moxidectin|In onchocerciasis endemic areas: Moxidectin 8 mg per oral on Day 0
32920758|NCT04311671|Active Comparator|Ivermectin|In onchocerciasis endemic areas: Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
32920759|NCT04311671|Experimental|Moxidectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Moxidectin 8 mg per oral with concomitant albendazole 400 mg per oral on Day 0
32920760|NCT04311671|Active Comparator|Ivermectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Ivermectin treatment with approximately 150 microgram/kilogram (μg/kg) per oral determined based on height with concomitant albendazole 400 mg per oral on Day 0
32920761|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
32719017|NCT05079035|Placebo Comparator|Control: Saline|2.0mL of sterile, preservative free 0.9% NaCl alone
32920762|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
32920763|NCT04722185|Experimental|Evaluation of the Veriton SPECT/CT system|To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
32920764|NCT04721639|Experimental|The experimental intervention (Sphinx Yoga Therapy)|In this group, participants will be intervened with Sphinx Yoga therapy which will take place in a conserved therapy center of Koohi Goth Hospital. This stretching exercise session will take place in the afternoon and for a duration of 10 minutes followed by 30 minutes therapy session five times per week (total 12 weeks).
32719018|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
32719019|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
32920765|NCT04721639|No Intervention|The control intervention (Usual Care)|In this Group, participants won't be receiving any intervention and provided with the usual care.
32920766|NCT05751603|No Intervention|Control group|Routine anesthetic process; sugammadex is administered when spontaneous respiration is returned (before extubation)
32920767|NCT05751603|Experimental|Experimental group|sugammadex is administered just after extubation.
32920768|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
32719020|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
32719021|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
32719022|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
33073349|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
33400003|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
32920769|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
33248394|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
33248395|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
33248396|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
33248397|NCT00365989|Experimental|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
33248398|NCT00702169||1|Premature and term newborn infants (male/female)
33248399|NCT00838461|Active Comparator|1|HSD-016
33248400|NCT00838461|Placebo Comparator|2|placebo
33400004|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
33248401|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
33248402|NCT00831363||1|minimal invasive approach
33248403|NCT00831363||2|traditional transgluteal approach
33248404|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
33248405|NCT03488953|Other|Transplantation Arm|
33248406|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
33248407|NCT04044339|Experimental|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
33248408|NCT04044339|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
33248409|NCT04044339|Experimental|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
33248410|NCT04044339|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
33248411|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
33248412|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
33248413|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
33248414|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
33248415|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
33248416|NCT00831519||Macrosomial, GD|
33248417|NCT00831519||Macrosomial, control|
33248418|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
33248419|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
33248420|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
33248421|NCT04044261|Experimental|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
33248422|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
33248423|NCT00838773|Experimental|YHA|Young Heterosexual Adults
33248424|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
33248425|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
33248426|NCT00838851|Experimental|CCRE|
33248427|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
33248428|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33400005|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
33400006|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
33400007|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
32920770|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
32719023|NCT05070299|Experimental|Psychosexual Educational Partners Program (PEPP)|Women and their partners will work through a three module workbook together, completing each module over a 2-week period (6 weeks total).
32719024|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
32920771|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
32920772|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
32920773|NCT04713449|Experimental|Empowered Survivor online|The online intervention, called Empowered Survivor (ES) is a self-management intervention for patients with head and neck cancer. The intervention contains the following modules: Introduction; Difficulty Swallowing and Muscle Strength; Oral Care; Long-term Follow-Up Care/Oral exams; Calm and Connect; and Maintaining.
32920774|NCT04713449|Active Comparator|Springboard Beyond Cancer|Springboard Beyond Cancer is a general resource for survivors of all cancer. It is a free self-management program for cancer survivors developed by trusted sources, the ACS and the NCI.
32920775|NCT05751525||Early SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea therapy in the first six months of life.
32920776|NCT05751525||Late SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea older than the age of 6 months.
32920777|NCT04709705|Experimental|Cryopreserved platelets|Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
32920778|NCT04709705|Active Comparator|Liquid stored platelets|Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
32920779|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
32920780|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
32920781|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
32920782|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
32920783|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
32920784|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
32920785|NCT04032587|Experimental|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
32719025|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
32719026|NCT04440917|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib
32920786|NCT04032587|Active Comparator|Healthy Controls|
32920787|NCT04343183|Active Comparator|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
32920788|NCT04343183|No Intervention|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
32719027|NCT04192019|Experimental|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
32719028|NCT04192019|Experimental|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
32719029|NCT04192019|No Intervention|No treatment|No treatment before the start of exercise
32719030|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
32719031|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
32719032|NCT05469815|Experimental|Lost Children Society Game|Online therapeutic role-playing session
32920789|NCT04707053||Intraaxial lesion group|Patients with intraaxial brainstem lesions (lesions located in the brainstem) + experienced brainstem surgery in our department during the study period
33400008|NCT05239195|Active Comparator|Video Laryngoscope Group|For patients assigned to the video laryngoscope group, the operator will use a video laryngoscope on the first laryngoscopy attempt. A video laryngoscope will be defined as a laryngoscope with a camera and a video screen. Trial protocol will not dictate the brand of video laryngoscope.
32719033|NCT05464823|Other|Molecular Testing|Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
32719034|NCT05459129|Active Comparator|Atezo + Tira|Participants in the atezolizumab plus tiragolumab arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
32719035|NCT05459129|Experimental|Atezo + Tira + CP|Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
32920790|NCT04707053||Extraaxial lesion group|Patients with extraaxial brainstem lesions (lesions close to the brainstem) + experienced brainstem surgery in our department during the study period
32920791|NCT01631071|Experimental|Elderly subjects aged over 60 years|
32920792|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
32719036|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
32719037|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
32920793|NCT04023227|Experimental|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
32920794|NCT04023227|Active Comparator|Enalapril|"Enalapril 10 mg b.i.d.~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
32920795|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
32920796|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
32920797|NCT05751447|Experimental|Immune cells|Lymph node puncture and/ or bronchoscopy.
32920798|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
32920799|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
32920800|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
32920801|NCT05751369|Active Comparator|Education Only|Treatment as usual with brief videos and weblink
32920802|NCT05751369|Experimental|TECW+|Education plus motivational enhancement
32920803|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
32920804|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
32920805|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
32920806|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
32719038|NCT05455931||Patients with MF/SS|Adult patients with diagnosed MF/SS receiving Poteligeo treatment.
32719039|NCT05062031|Experimental|DIMS®|Defocus Incorporated Multiple Segments® lenses
32920807|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
32920808|NCT04701671||Normal Weight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are not randomly assigned to undergo MRI scans at baseline and 18-months.
32920809|NCT04701671||Normal Weight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are randomly assigned to undergo MRI scans at baseline and 18-months.
32920810|NCT04701671||Overweight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are not randomly assigned to undergo MRI scans at baseline and 18-months.
32920811|NCT04701671||Overweight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are randomly assigned to undergo MRI scans at baseline and 18-months.
32920812|NCT04701671||Overweight/Obese Experimental, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are not randomly assigned to undergo MRI scans at baseline and 18-months.
32920813|NCT04701671||Overweight/Obese Experimental with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are randomly assigned to undergo MRI scans at baseline and 18-months.
32920814|NCT05729217||Group 1 aged 7-12 years|Group 1 will mainly be primary school students from grade 1 to 6.
32920815|NCT05729217||Group 2 aged 13-15 years|Group 2 will mainly be middle school students from grade 13 to 15.
32920816|NCT05729217||Group 2 aged 16-18 years|Group 3 will mainly be high school students from grade 16 to 18.
33400009|NCT05239195|Active Comparator|Direct Laryngoscope Group|For patients assigned to the direct laryngoscope group, the operator will use a direct laryngoscope on the first laryngoscopy attempt. A direct laryngoscope will be defined as a laryngoscope without a camera or a video screen. Trial protocol will not dictate the brand of direct laryngoscope or the blade shape.
32920817|NCT04299425|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
32920818|NCT04299425|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).
32719040|NCT05062031|Active Comparator|Low-concentration atropine + monofocal lenses|
32719041|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
32719042|NCT05017415|Experimental|Standard toilet chair (hip angle 90°)|uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.
32719043|NCT05017415|Experimental|Toilet chair with decreased hip angle|uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.
32719044|NCT05446571|Experimental|Letermovir|Maternal daily administration of letermovir + placebo of valaciclovir
32719045|NCT05446571|Active Comparator|Valaciclovir|Maternal daily administration of valaciclovir + placebo of letermovir
32719046|NCT05439005|Experimental|OFA group|OFA (Opioid Free Anaesthesia) group:
32920819|NCT05751291|Active Comparator|Group A|Group A (PENG block) patients will receive PENG block under ultrasound-guided (USG) guidance using curvilinear low-frequency ultrasound probe (2-5 MHz) will initially be placed in a transverse plane over the Anterior inferior iliac spine ( AIIS ) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees to visualize the Iliopubic Eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle. A 22 Gauge needle will be inserted in-plane and the needle tip will be positioned in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane.
32920820|NCT05751291|Active Comparator|Group B|"Group B (FIC) patients will receive FIC block under USG guidance using high-frequency linear transducer (6-13 MHz) will be used to identify the femoral artery at the level of the inguinal crease. Immediately lateral and deep to the femoral artery and vein the iliopsoas muscle is overlaid by a hyperechoic fascia iliaca. The femoral nerve is seen lateral to the femoral artery wedged between the iliopsoas muscle and the fascia iliaca.~Maneuvering the transducer laterally helps to visualize the Sartorius muscle covered by its own fascia alongside the fascia iliaca. A line is drawn connecting the anterior superior iliac spine to the pubic tubercle; the needle tip is positioned at lateral third of the line under the fascia iliaca. 20 mL of 0.25% bupivacaine will be injected until it spreads laterally toward the iliac spine and medially toward the femoral nerve."
32920821|NCT04691843|Active Comparator|Standard iron dose|Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
32920822|NCT04691843|Experimental|Early, high-dose iron|Iron supplementation will start at 3mg/kg/day when infant is on enteral feeds of 60mL/kg/day and at least one week old, then increased to 6mg/kg/day when enteral feeds are at 100mL/kg/day. Iron dosing will be adjusted to maintain ferritin level of 70-400ng/mL. At 36 weeks corrected age, iron supplementation will be adjusted to the dose routinely used for preterm infants.
32920823|NCT05727189|Experimental|Part 1 Single Dose|Parallel group comparison, single dose level of 5 forms of the investigational study drug.
32920824|NCT05727189|Experimental|Part 2: Single escalating doses|Parallel group comparison, single p.o. dose escalation (3 dose levels) of 4 forms investigational study drug and placebo. Dose levels separated by 7-day washout periods. Doses to be determined by review of data from Part 1.
32920825|NCT05727189|Experimental|Part 3: Multiple Dose|Parallel group comparison of 4 active treatments dosed p.o. x 4 days. Each active is dosed in a 2-period placebo-controlled crossover separated by a 5-day washout. Doses to be determined by review of data from Part 2.
32920826|NCT05727189|Experimental|Part 4: Food Effects|Two-period single p.o. dose fasted/fed crossover separated by 5-day washout period. Dose to be determined by review of data from Part 2.
32920827|NCT04684901|No Intervention|Standard of Care Group|Standard of Care - No AlloWrap used during surgery
32920828|NCT04684901|Experimental|AlloWrap Group|AlloWrap used in surgery
32920829|NCT04291859|Experimental|Lu AF28996|"Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14) in all OD Cohorts 1-4 (5). On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.~For the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days (Day 1 to Day 24), followed by down-titration as per Investigator's judgement.~For the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days (Day 1 to Day 39), followed by down-titration as per Investigator's judgement."
32920830|NCT05720949|No Intervention|Group 1 - Control|Patients randomized to this group will receive an adductor canal block (ACB) and Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block.
32920831|NCT05720949|Experimental|Group 2 - Intervention|"Patients randomized to this group will receive an adductor canal block (ACB), Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block, and the genicular nerve block (intervention).~The genicular nerve block is a total of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius."
32920832|NCT01634191|Experimental|Elderly: Apremilast 30 mg|Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
32920833|NCT01634191|Experimental|Younger: Apremilast 30 mg|Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
32920834|NCT04005443|Other|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
32920835|NCT05751213|Experimental|knack technique.|pelvic floor muscle exercises with knack technique.
32920836|NCT05751213|Active Comparator|pelvic floor muscle exercises|pelvic floor muscle exercises
32719047|NCT05439005|No Intervention|CGA control group|CGA (Conventional General Anaesthesia) control group:
32719048|NCT05434481|Active Comparator|Aneurysm group|Patients operated for aneurysm of the ascending aorta according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
33073350|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
33073351|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
33073352|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
32719049|NCT05434481|Active Comparator|Type A aortic dissection group|Patients operated for type A aortic dissection according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
32719050|NCT05434481|Sham Comparator|Control group|Patients without aortic aneurysm or aortic dissection operated for aortic valve replacement (AVR) and/or coronary artery bypass with a saphenous vein graft for proximal aortic anastomosis to collect the aortic sample. For patients operated for AVR, an aortic sample will be collected before closing the aorta.
32920837|NCT04003649|Experimental|Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)|Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
32920838|NCT04003649|Experimental|Arm II (nivolumab, IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
32920839|NCT04003649|Experimental|Arm III (IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.
32920840|NCT05713851|Experimental|Dapaglifozin group|Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days.
32920841|NCT05713851|Placebo Comparator|Standard of care|Without receiving any of the interventional drugs.
32920842|NCT05751057|Experimental|NSTEMI patients|Patients will undergo CMR before ICA
32920843|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
32920844|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
32920845|NCT05710185|Experimental|Subjects with Palmoplantar pustulosis|All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
32920846|NCT04680377||Participants receiving standard of care durvalumab|Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment
32920847|NCT05710107|Active Comparator|PENG + LFC Block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule [5,6]. In the PENG block, a low-frequency, curvilinear probe is used to visualize the anterior inferior iliac spine, iliopsoas tendon, and iliopubic eminence. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. The needle is advanced until the tip lies on the lateral and inferior margin of the iliopsoas tendon between the anterior inferior iliac spine (lateral) and iliopubic eminence (deep).
32920848|NCT05710107|Active Comparator|QL Block|The lateral QL block is performed by injecting local anesthetic deep to the transversus abdominis aponeurosis and superficial to the fascia transversalis with direct ultrasound guidance. After completing consent, placing monitors and providing mild sedation, the patient is positioned laterally and the muscular anatomy (external oblique, internal oblique, transverse abdominis, quadratus lumborum and latissimus dorsi muscles) identified. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. Local anesthetic is deposited incrementally with frequent aspiration in the anterolateral border of the quadratus lumborum muscle at the junction of the transversalis fascia, outside the anterior layer of the thoracolumbar fascia and superficial to the fascia transversalis.
32920849|NCT05700981|Experimental|Colon capsule endoscopy|Patients randomized to colon capsule endoscopy
32920850|NCT05700981|No Intervention|Colonoscopy|Patients randomized to colonoscopy
32920851|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
32920852|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
32920853|NCT05750901|Other|Treatment Arm|Patients will receive fractional ablative treatment for laxity.
32920854|NCT03995069|Experimental|3D|The participant's voluntary grip forces in all 3 dimensions will be shown to the participant via computer screen.
32920855|NCT03995069|Active Comparator|1D|The participant's voluntary grip force in 1 dimension will be shown to the participant via computer screen.
32920856|NCT05698875|Other|Test meal 1|High glycaemic load breakfast meal
32920857|NCT05698875|Other|Test meal 2|High glycaemic lead with additional 10g protein breakfast meal
32920858|NCT05698875|Other|Test meal 3|Medium glycaemic load breakfast meal
32920859|NCT05698485|Experimental|3 Step Skin Care Regimen|3 different skin care products will be applied to the face
32920860|NCT04287647|Active Comparator|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
32920861|NCT04287647|Sham Comparator|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
32920862|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
32920863|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
33400010|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
33400011|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
32719051|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
32719052|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
32920864|NCT05693025|Active Comparator|Standard Implementation (SI)|Participants the Standard Implementation (SI) model complete a 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete standard exercises recommended in the base program.
32920865|NCT05693025|Experimental|Enhanced Implementation (EI)|Participants the Enhanced Implementation (SI) model complete the 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete personalized exercises prescribed by a licensed Physical Therapist to help reduce potential risks of falling.
32920866|NCT05693025|Active Comparator|Standard Training (ST)|Participants the Standard Training (ST) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide standard knowledge-based training about how to become more physically active.
32920867|NCT05693025|Experimental|Enhanced Training (ET)|Participants the Enhanced Training (ET) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide habit-formation training about how to form regular habits for physical activity. Participants are paired with a student 'coach' trained in motivational interviewing skills to provide virtual assistance in maintaining motivation during the programming.
32920868|NCT04668521||COHORT A|Women with a pelvic mass, symptomatic or asymptomatic.
32920869|NCT04668521||COHORT B|Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
32920870|NCT04668521||COHORT C|Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
32920871|NCT05750823|Experimental|Ruxolitinib Cream|Participants with non-segmental vitiligo with genital involvement will receive ruxolitinib 1.5% cream BID for up to 48 weeks
32920872|NCT04281875|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
32920873|NCT04281875|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
32920874|NCT05688735|Active Comparator|Experimental Topical Product|Topical moisturizer With Colloidal Oatmeal and Isosorbide Diesters + Topical Steroids
32920875|NCT05688735|Placebo Comparator|Control Topical Product|Topical moisturizer With Colloidal Oatmeal WITHOUT Isosorbide Diesters + Topical Steroids
32920876|NCT04276493|Experimental|Cohort 1- ZW25 + Docetaxel|ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
33073353|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
33248429|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33248430|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33400012|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
33400013|NCT05238883|Experimental|Dose Escalation - HFB200301 monotherapy|Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
32719053|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
32719054|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
32719055|NCT05387837|Experimental|Neovascular Age-related Macular Degeneration|"Cohort A1 - 0.25 mg/kg of D-4517.2~Cohort B1 - 0.5 mg/kg of D-4517.2~Cohort C1 - 1.0 mg/kg of D-4517.2~Cohort D1 - 2.0 mg/kg of D-4517.2"
32920877|NCT04276493|Experimental|Cohort 2- ZW25 + Tiselizumab + Chemotherapy|ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
32920878|NCT05687721|Experimental|Therapeutic arm|Copanlisib will be administered through intravenous infusion (IV) at 60 mg on Day 1, 8 and 15, and avelumab will be administered 800 mg IV on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
32920879|NCT05750667|Experimental|Penn Medicine (health system)-mediated|Probands receive automated text messages and/or emails through the Way to Health (WTH) platform containing information about FH and cascade screening from Penn Medicine, and a request to identify first-degree biological relatives. Probands choose whether to contact relatives themselves or share contact information so that automated text messages and/or emails can be sent by Penn Medicine to relatives directly via WTH. If probands opt to contact relatives themselves (self-contact), they receive tips on how to do this effectively. If probands opt for Penn Medicine to contact their relatives (direct contact), relatives receive information via WTH about FH and instructions for screening. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
32920880|NCT05750667|Experimental|Family Heart Foundation-mediated|After using WTH to conduct an identity screen and giving probands an option to opt-out of having their information shared with Family Heart Foundation (FHF), FHF reaches out directly to probands via an FHF-employed navigator. During an initial call, the navigator introduces the proband to navigation services, conducts a social history, and initiates a plan for contacting relatives. Probands choose whether to contact relatives themselves (self-contact) or have FHF contact relatives directly (direct contact). Those who choose self-contact receive personalized coaching to address barriers and concerns. For direct contact relatives, FHF will call these relatives directly. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
32920881|NCT05750667|No Intervention|Usual Care|Probands randomized to this arm will not receive any contact from the research team or Family Heart Foundation regarding cascade screening (i.e., no intervention).
32920882|NCT05440175|Experimental|Group A|The participants will be given Mirror therapy along with the electrical muscle stimulation and exercises.
32920883|NCT05440175|Experimental|Group B|The participants will be given constraint induced movement therapy (CIMT) along with exercises.
32920884|NCT05440175|Experimental|Group C|The participants will be given mirror therapy and exercises.
32920885|NCT05670795|Experimental|recombinant follicle stimulating hormone|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany)
32920886|NCT05670795|Active Comparator|recombinant follicle stimulating hormone and clomiphene citrate|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany) Klomen® (50 mg, Koçak Farma, Tekirdag, Turkey)
32920887|NCT04266197|Experimental|RT234 0.5 mg Cohort 1|RT234 at a capsule dose strength of 0.5 mg.
32920888|NCT04266197|Experimental|RT234 1.0 mg Cohort 2|RT234 at a capsule dose strength of 1.0 mg.
32920889|NCT05750511||metastatic melanoma|1,000 subjects with metastatic melanoma stage III or IV suitable for systemic treatment from centers of the German Dermatologic Cooperative Oncology Group (DeCOG)
32920890|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
32920891|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
32920892|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
32920893|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
32920894|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
32920895|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
32920896|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
32920897|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
32719056|NCT05387837|Experimental|Diabetic Macular Edema|"Cohort B2 - 0.5 mg/kg of D-4517.2~Cohort C2 - 1.0 mg/kg of D-4517.2~Cohort D2 - 2.0 mg/kg of D-4517.2"
32719057|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
32719058|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
32719059|NCT04468139|Experimental|Quercetin|Quercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
32719060|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
32719061|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
32719062|NCT04939649|Experimental|Ketamine|Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
32719063|NCT04939649|Active Comparator|Midazolam|Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
32920898|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
32920899|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
32920900|NCT05669313||Adult patients planned for treatment with rivaroxaban|
32920901|NCT05750355|Experimental|TPN171H|Subjects will receive TPN171H orally for single dose
32920902|NCT05750355|Placebo Comparator|Placebo|Subjects will receive Placebo orally for single dose
32920903|NCT04665635|Active Comparator|Rectosigmoid resection|
32920904|NCT04665635|Active Comparator|Rectosigmoid seromuscular tumor shaving|
32920905|NCT05669157|Experimental|Current practice: radiography request by physician|No interventions will be performed. There is no change in current practice.
32920906|NCT05669157|Experimental|Radiography request by the nurse|the intake and referral nurse will request a radiography if required according to the local cooperation protocol
32920907|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
32920908|NCT05750277|Experimental|Early Time-Restricted Eating|This group will self-select their eating window as long as it is between 8am-6pm, and will aim to fast within this window as many occasions as possible between Monday-Friday for 4 weeks.
32920909|NCT05750277|No Intervention|Control|This group will maintain their habitual lifestyle for 4 weeks.
32920910|NCT04343963|Active Comparator|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
32920911|NCT04343963|Placebo Comparator|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
32920912|NCT05750199|Experimental|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
32920913|NCT05750199|Experimental|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course.
32920914|NCT04248179|Active Comparator|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 * 10ml * 5mg/ml Ropivacaine = 150mg Ropivacaine.
32920915|NCT04248179|Placebo Comparator|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 * 10ml * 9mg/ml Sodium chloride = 189mg Sodium chloride.
32920916|NCT05750121|Experimental|Treatment group|The intervention group will receive home-based motor-cognitive training and usual emergency care.
32920917|NCT05750121|No Intervention|Usual care group|Usual care includes wound care, community nurse service, medications and on-site physiotherapy, occupational therapy, community nurse service, medical social work service, and geriatric nurse follow-up service will be referred when necessary.
32920918|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
32920919|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
32920920|NCT05662371|Placebo Comparator|Standard Clinical Care Group|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
32920921|NCT05662371|Experimental|Nociception Level-guided Analgesia Group|In the nociception level-guided group, sufentanil will be administered to maintain a nociception level value between 10 and 25. In case the nociception level values rise greater than 25 for more than 60 s, additional 2.5 microgram sufentanil (if nociception level increase remained less than 45) or 5 micrograms (if nociception level increase greater than 45). Atropine will be administered when heart rate decreases less than 30 min-1. Because the nociception level may be sensitive to such medication, nociception level values will then not used for at least 5 min to guide analgesia, with the exception of norepinephrine as this drug will be given as continuous infusion
32920922|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
32920923|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
32920924|NCT02976545|Other|Healthy controls|Healthy controls
32920925|NCT05657691|Experimental|10 mg Xanamem™|10 mg Xanamem™ capsule, to be administered orally once every morning with or without food
32920926|NCT05657691|Placebo Comparator|Placebo|Placebo capsule, to be administered orally once every morning with or without food
32719064|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
32920927|NCT02976233||Acute Respiratory Failure in NIV|
32920928|NCT05653479|Experimental|Treatment Group 1|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
32920929|NCT05653479|Experimental|Treatment Group 2|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
32920930|NCT05653479|Experimental|Treatment Group 3|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
32920931|NCT05653479|Experimental|Treatment Group 4|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Non-Japanese Non-East Asian participants
32920932|NCT03920267|Experimental|BMS-986165 Dose 1|
32920933|NCT03920267|Experimental|BMS-986165 Dose 2|
32920934|NCT03920267|Experimental|BMS-986165 Dose 3|
32920935|NCT05749965||Limit indications|Obèse (BMI>30), ACL déficiency, HKA > 10°, flessum >10° [HKA : hop knee angle]
32920936|NCT05749965||Historical indications|Patient with a BMI between 18,5 and 30, HKA <10°, functionnal ACL, no flessum or <5°
32920937|NCT05648253|Experimental|Hyivy Device|Participants will receive a Hyivy device with both verbal and written instructions. Recommended use is three times per week for 12 weeks and consists of: 10 minutes of heat (37-42ºC) per session and 10 minutes of dilation per session
32920938|NCT05447507|Active Comparator|Remimazolam|
32920939|NCT05447507|Active Comparator|Dexmedetomidine|
32920940|NCT05749887|Other|salvage sugery|Salvage surgery for patients diagnosed locally advanced cervical cancr with residual tumor after standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+ brachytherapy)
32920941|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
32920942|NCT05644821|Experimental|Intervention group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the intervention group, when the respective questionnaire thresholds are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center, as well as subsequent actions, if necessary.
32920943|NCT05644821|No Intervention|Control group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the control group, ePROMs will be collected 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group will therefore receive treatment according to the current clinical routine.
32920944|NCT05644821|Other|Comparison group|In patients who are fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours), ePROMs are collected at 24 and 52 weeks, but no alarms or further actions are derived from them. Thus, treatment is provided according to routine clinical practice. Patients are not randomized.
32920945|NCT05643105||Colon cancer patients with intestinal anastomosis|There is a single cohort of patients, the one operated on for colon cancer with intestinal continuity construction through an anastomosis without derivative stoma construction of any kind.
32920946|NCT05638737|Experimental|AZD4831|AZD4831
32920947|NCT05638737|Placebo Comparator|Placebo|Placebo
32719065|NCT04927949|Sham Comparator|patients without HPR|standard primary PCI
32920948|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
32920949|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
32920950|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
32719066|NCT04927949|Experimental|patients with HPR randomized to cangrelor|Cangrelor perfusion started before PCI
32719067|NCT04927949|Placebo Comparator|patients with HPR randomized to standard of care|standard primary PCI
32719068|NCT04589819|Active Comparator|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide [rDNA origin] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
32719069|NCT04589819|Placebo Comparator|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
32719070|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.~Intervention: Use of MAGHD App/MAGHD Framework"
32719071|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).~Intervention: Use of MAGHD App/MAGHD Framework"
32719072|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).~Intervention: Use of MAGHD App/MAGHD Framework"
32719073|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
32719074|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
32719075|NCT04845035|Experimental|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
32719076|NCT04467983|Active Comparator|Denosumab alone|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
32920951|NCT05749731||post-COVID-19 patients in geriatric rehabilitation|Patients in European geriatric rehabilitation departments as the result of COVID-19 disease.
32920952|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
32920953|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
33073354|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
33073355|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
33073356|NCT02428985||Riociguat|Riociguat treatment group
33400014|NCT05238883|Experimental|Dose Escalation - HFB200301 in combination with tislelizumab|Participants will be administered HFB200301 at dose levels 1-4 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Dose for Expansion (RDE).
32920954|NCT05635305|Experimental|BE study|"Cohort 1 (BE) is a four-period, four-sequence, four-treatment crossover BE and food effect study of zoliflodacin granules for oral suspension manufactured by Dr. Reddy's (test product, ZoliDr) and those manufactured by Patheon (reference product, ZoliPa) as a 3 g oral dose under fasting and a [specific] fed condition. This cohort will comprise of approximately 32 subjects (8 healthy subjects per treatment sequence) in 4 x 4 BE treatment arms in fasted and [specific] fed conditions. Healthy subjects will be randomized into 4 parallel treatment sequences to receive sequential Treatments A, B, C, and D in William's Square design pattern where:~Treatment A is ZoliPa fasted~Treatment B is ZoliDr fasted~Treatment C is ZoliPa [specific] fed condition~Treatment D is ZoliDr [specific] fed condition~Based on William's Square design, below treatment sequences will be followed:~A-B-C-D B-A-D-C C-D-A-B D-C-B-A"
32920955|NCT05635305|Experimental|DDI study|This is an open-label, 2-period, 2-treatment, fixed sequence crossover DDI study in healthy subjects. It will investigate PK of zoliflodacin (ZoliPa) in the absence and presence of itraconazole. Approximately 18 subjects will receive ZoliPa on Day 1 under fasting condition. After a washout of 72 hours after dosing of ZoliPa, on Day 4, subjects will receive a 400 mg loading dose of itraconazole followed by 200 mg of itraconazole once daily from Day 5-8. From Day 4 to Day 8, itraconazole will be administered immediately after a full meal. On Day 9, both itraconazole and zoliflodacin (ZoliPa) will be administered under fasting conditions at -1 hours and 0 hours, respectively. Itraconazole will then be administered with food at 24 hours (Day 10) and 48 hours (Day 11) after administration of zoliflodacin (ZoliPa).
32920956|NCT01636297|Experimental|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
32920957|NCT01636297|Experimental|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
32920958|NCT01636297|No Intervention|No Exercise|Participants received no exercise intervention and served as the control group
32920959|NCT05749653|Other|bi-annual CDTI|bi-annual CDTI with high coverage
32920960|NCT05634213|Experimental|saline injection|After the patient is placed on cardiopulmonary bypass, the surgeon will inject a saline into the atria.
32920961|NCT05634213|No Intervention|standard of care|The patient will be placed on cardiopulmonary bypass as usual and the surgery will proceed without an attempt to inject saline into the atrial tissue.
32920962|NCT05630703|Experimental|Mindfulness Training|Behavioral: Mindfulness-based Eating Awareness Training in IBS - The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
32920963|NCT05630703|Active Comparator|fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet|Dietary: Low FODMAP Diet - Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format.
32920964|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
32920965|NCT05749575|Experimental|Chidamide Plus Toripalimab Plus Paclitaxel|Cedaramine: 20mg, twice a week.Toripalimab: 240mg, once in 3 weeks,intravenous.Paclitaxel: 175mg / m2, once in 3 weeks, routine preventive anti-allergy treatment, surgery after 4 cycles of IV infusion.
32920966|NCT05628987||Azoospermia|After an abstinence period of 2-7 days, two basic semen analysis, the absence of spermatozoa
32920967|NCT05628987||Oligozoospermia|After an abstinence period of 2-7 days, the total sperm number <39*10^6 per ejaculate or the sperm concentration < 15 * 10^6 per ml
32920968|NCT05628987||Asthenozoospermia|After an abstinence period of 2-7 days, the progressive motility (PR) < 32%
32920969|NCT05628987||Teratozoospermia|After an abstinence period of 2-7 days, the percentage of morphologically normal spermatozoa <4%
32719077|NCT04467983|Active Comparator|Combination therapy|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
32719078|NCT04839731|Placebo Comparator|Placebo group|10 patients will be divided into 7 and 14 day treatment groups with 5 patients each. They will apply Nourivan base cream from Pure Science Rx, twice per day for their designated time.
32719079|NCT04839731|Experimental|7 day medication group|The 7 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days.
32719080|NCT04839731|Experimental|14 day medication group|The 14 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days.
32719081|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
32719082|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
32719083|NCT04836923|Experimental|LIFT subgroup|PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
32719084|NCT04836923|Experimental|LIFT + REAP subgroup|"PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. We will also employ Realistic Effort Action Planning (REAP), a form of personality-informed motivational interviewing in a subset of patients to potentially enhance patient engagement and adherence to the home-exercise prescription."
32719085|NCT04808453|Experimental|CPI-300|Dose Escalation Group: CPI-300 will be administered via intravenous infusion once every 2 weeks for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
32719086|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 4e11|Deferred treatment
32719087|NCT04794101|Active Comparator|Already treated in MGT-RPGR-021|Already treated
32719088|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 2e11|Deferred treatment
32719089|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
32719090|NCT04770779|Experimental|Mitapivat|"Double-Blind Period: Participants will receive mitapivat 100 milligrams (mg) orally, twice daily (BID) for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
32920970|NCT05628987||Control|After an abstinence period of 2-7 days, the basic semen analysis is normal.
33248431|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33248432|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33248433|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33248434|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
33248435|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
33248436|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
33248437|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
33248438|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
33248439|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
33248440|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
33248441|NCT04018365|Experimental|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of <7.0%, 10 mg will be continued: in case of >=7.0%, it will be increased to 25 mg.
33248442|NCT00839007|Experimental|A|Dose 1 of CD-NP
33248443|NCT00839007|Experimental|B|Dose 2 of CD-NP
33248444|NCT00839007|Experimental|C|Dose 3 of CD-NP
32766919|NCT04898699|Experimental|PrEP+|PrEP+ is an experimental pre-exposure prophylaxis (PrEP)-focused prevention strategy providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with two adherence self-management interventions: (1) real-time feedback from point-of-care urine drug-level assay, (2) HIV self-testing and (3) 2-way text message reminders in addition to standard of care HIV risk-reduction counseling among male clients (MC) of female sex workers in Kisumu, Kenya.
32766920|NCT04883801||COVID-19 case group|Newborns born to pregnant women diagnosed with COVID-19 during hospitalization for delivery
32766921|NCT04883801||Control group|Newborns born to pregnant women who were not diagnosed with COVID-19 in their medical history and hospitalization for delivery
32766922|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
32766923|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
32766924|NCT04899011||Middle ear surgery|
32766925|NCT04888715|Experimental|DWN12088 and Pirfenidone|T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily
32766926|NCT04888715|Experimental|DWN12088 and Nintedanib|T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily
32766927|NCT04898387|Experimental|T4030 Group|
32766928|NCT04898387|Active Comparator|Ganfort Group|
32766929|NCT04888871||Only Fundal Pressure (Kristeller Maneuver)|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Only Fundal Pressure (Kristeller Maneuver) and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
32766930|NCT04888871||Only Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying only vacuum extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
32766931|NCT04888871||Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
32766932|NCT04888559|Active Comparator|Whole grain breakfast product|
32766933|NCT04888559|Placebo Comparator|Reference|
32766934|NCT04897997||non smokers|never having smoked patients
32766935|NCT04897997||smokers|actively smoking patients
33248445|NCT00839007|Experimental|D|Dose 4 of CD-NP
33248446|NCT00839007|Experimental|E|Dose 5 of CD-NP
33248447|NCT00839007|Experimental|F|Dose 6 of CD-NP
33248448|NCT00839007|Placebo Comparator|G|Placebo
33248449|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
33248450|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
33248451|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
33248452|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
33248453|NCT00828165|Experimental|ARRY-300|
33248454|NCT00828165|Placebo Comparator|Placebo|Placebo
33248455|NCT00839085|No Intervention|1|normal procedure of CABG
33248456|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
33400015|NCT05238883|Experimental|Dose Expansion - HFB200301 monotherapy|Participants will be administered HFB200301 at monotherapy RDE as an intravenous infusion.
32766936|NCT04897997||acute coronary syndrome|patients with the coronary indication of ACS
32766937|NCT04897997||stable|patients with the coronary indication of stable or silent ischemia
32766938|NCT04888325|Experimental|Oral glucose|ORal glucose consumption 1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours
32766939|NCT04888325|Experimental|Intravenous glucose|0% intravenous glucose infusion at a rate of 3.6 ml/kg/h
32766940|NCT04888091|Active Comparator|Cervical mucus removal with cotton swab|Cervical mucus will be removed with cotton swab before embryo transfer
32766941|NCT04888091|Active Comparator|Cervical mucus removal with cannula|Cervical mucus will be removed with cannula before embryo transfer
32766942|NCT04888091|No Intervention|No cervical mucus removal|Cervical mucus will not be removed prior to embryo transfer
32766943|NCT03050723|Other|Princess® FILLER|
32766944|NCT04888403|Experimental|Toripalimab combined with neoadjuvant radiotherapy and chemotherapy Single arm study|"Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy."
32766945|NCT04883567||AI arm|AI would be used to assist the trainee endoscopist
32766946|NCT04883567||Non-AI arm|Trainee endoscopist would perform OGD as usual.
32766947|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
32766948|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
32766949|NCT04882787|Experimental|BTE hearing aid model|BTE or SP-BTE (super power) hearing aid fitting
32766950|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
32766951|NCT04882865||"healthy volunteers as patients"|"use of the device (AMMP) and the process on 5 healthy volunteers undergoing proning, as well as general care (movement up or down the bed, rotated laterally). As well, repositioning sheets will be used for general care. Surveys of the impressions of team members of the value (ease of use, efficiency, safety, physical demands) of using the AMMP and the repositioning sheets with these patients will be completed.~The impressions of the volunteers as patients will be surveyed, with particular reference to comfort and security during movement"
32766952|NCT04882865||ICU patients severe respiratory failure|patients with severe respiratory failure eligible for prone ventilation will be recruited with surveys provided to team members to gauge their impressions of the value of using the AMMP with the proning process for these patients. Surveys for 40 proning processes will be obtained. Movement from back to stomach or from stomach to back is considered a single process. A single patient may undergo multiple proning processes as prone ventilation is delivered for several days, with multiple healthcare team members participating in their care. We anticipate this will involve 10 patients, and 3 team members to be involved with each proning process.
32766953|NCT04882865||Patients admitted to the ICU|40 patients will have the AMMP used for general care. An additional 40 will have repositioning sheets used for general care. Healthcare team members involved with the care of these patients will be surveyed re their impressions of the value of using the AMMP or the repositioning sheets. We cannot predict the number of healthcare team members involved with the care of each patient s because of clinical conditions and length of stay
32766954|NCT04883021|Experimental|Dual Target Theta Burst Stimulation|The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
32766955|NCT04897685|Experimental|Nature-based treatment group|The participants in the treatment group were offered 12 nature-based group therapy sessions in addition to standard care.
32766956|NCT04897685|No Intervention|Control group|The participants in the control group continued treatment as usual in the health care services.
32766957|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
32766958|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
32766959|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
32766960|NCT03050645||previous GDM|Women with previous GDM
33248457|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
33400016|NCT05238883|Experimental|Dose Expansion - HFB200301 in combination with tislelizumab|Participations will be administered HFB200301 in combination with tislelizumab at combination RDE as an intravenous infusion.
33400017|NCT05174923||Age Range 45 to </= 60|
33400018|NCT05174923||Age Range 61 to </= 75|
32766961|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
32766962|NCT04882943||patients with unexplained or refractory chronic cough|Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
32766964|NCT04887545||Thoracentesis|Patients who need removal of excess pleural effusion and assessed for the possibility of lung cancer.
32766965|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
32766966|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
32766967|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
32766968|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
32766969|NCT04896905||Isolation group with active Covid19|Patients assigned to rehab which had to be treated in isolation wards dur to active disease
32766970|NCT04896905||Post-Covid-group|Patients assigned to rehab after active disease, still having restrictions in activity and particiaption
32766971|NCT04896905||Control group|Pateints assigned to rehabilitation in the same time period without any signs of Sars-coV-2 infection
32766972|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
32766973|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
32766974|NCT04887233|Experimental|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
32766975|NCT04887233|Placebo Comparator|Placebo nasal spray|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
32766976|NCT04887311|Experimental|Cohort 1|"Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day.~Group 2 - Group 4~Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg:~Group 2~Patients aged 4-12 years weighing 15kg to <25 kg will take 340 mg/day. Group 3~Patients aged 4-12 years weighing 25kg to <35 kg will take 510 mg/day. Group 4~Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day."
32766977|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)"
32766978|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)"
32766979|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Medical air (MA)~Oxygen (4 Liter/min)"
32766980|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)~Medical air (MA)"
32766981|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Medical air (MA)~Oxygen (2 Liter/min)"
32766982|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)~Medical air (MA)"
32766983|NCT04897139|Experimental|treatment arm|treatment arm
32766984|NCT04886921|Experimental|TRAM abdominal muscle training group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~All subjects will receive 1-hr training sessions consisting of core stability exercises for 12 weeks for the TRAM group."
32766985|NCT04886921|No Intervention|TRAM control group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~The control group was not received any exercise program."
32766986|NCT04886921|No Intervention|Healthy women group|A control group comprising female volunteers who were apparently healthy and had comparable socioeconomic backgrounds and physical conditions was recruited by convenience sampling from communities.
32766987|NCT04886843|Active Comparator|Cold Therapy|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week. In addition to this application, a cold pack was applied on the affected side dorsiflexor muscle skin. The cold pack was applied on a moist towel for five minutes. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES.
32766988|NCT04886843|Placebo Comparator|Control|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week.
32766989|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
32766990|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
32905557|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
33248458|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
33400019|NCT05174923||Age >/= 76|
33248459|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
33248460|NCT00828243||Genetic association|Infants with and without neonatal respiratory distress syndrome undergo surfactant gene sequencing to identify genomic variants associated with neonatal respiratory distress syndrome
33248461|NCT00828243||Nutrient|To newborn infants with respiratory distress syndrome, we administer stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based comparison of surfactant phospholipid and protein turnover.
33248462|NCT00839163|Experimental|Arm 1|
33248463|NCT00839163|Experimental|Arm 2|
33248464|NCT00839163|Experimental|Arm 3|
33248465|NCT00839163|Experimental|Arm 4|
33248466|NCT00839163|Active Comparator|Arm 5|
33248467|NCT02549001|Experimental|P-3058 10%|P-3058 10%
33248468|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
33248469|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
33248470|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
33248471|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
33248472|NCT00832143|No Intervention|1|Usual Care
33248473|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
33248474|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
33248475|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
33248476|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
33248477|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
33248478|NCT04043871||Patients with renal insufficiency|
33248479|NCT00832221|Active Comparator|1|
33248480|NCT00832221|Active Comparator|2|
33248481|NCT00828399|Experimental|Glutamine|
33248482|NCT00828399|Placebo Comparator|Whole protein|
33248483|NCT04044027|No Intervention|Control Group|
33248484|NCT04044027|Experimental|Intervention Group|
32920971|NCT04387201|Placebo Comparator|Cyanocobalamin|Placebo comparator
33248485|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
33248486|NCT04043715|Other|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
33248487|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
33248488|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
33248489|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
33248490|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
33248491|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
33248492|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
33248493|NCT04018521|Active Comparator|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
33248494|NCT04018521|Active Comparator|Usual Care|Coordinated Specialty Care (CSC)
33248495|NCT00832689|Experimental|1|
33248496|NCT00567190|Experimental|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
33400020|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
32920972|NCT04387201|Experimental|Dulaglutide|Experimental arm
32920973|NCT05625399|Experimental|Nivolumab + Relatlimab FDC SC|
32920974|NCT05625399|Active Comparator|Nivolumab + Relatlimab FDC IV|
32920975|NCT04370587|Experimental|Phase 1|T3011 single agent dose escalation in participants with solid tumors
32920976|NCT04370587|Experimental|Phase 2a Part 1 Arm A|RP2D T3011 single agent in participants with melanoma
32920977|NCT04370587|Experimental|Phase 2a Part 1 Arm B|RP2D T3011 single agent in participants with other solid tumors
32920978|NCT04370587|Experimental|Phase 2a Part 2 Arm C|RP2D T3011 + pembrolizumab in participants with NSCLC
32920979|NCT04370587|Experimental|Rollover Arm|RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent
32920980|NCT04178005|Other|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.~Each treatment course is divided into 2 treatment cycles:~Administration of first treatment course (year 1 treatment):~First cycle: Starts on Day 1 of the study~Second cycle: Administered 23 to 27 days after the last dose of first cycle.~Administration of second treatment course (year 2 treatment):~First cycle: Administered at least 43 weeks after the last dose of year 1 treatment~Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
32920981|NCT05749497||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
32920982|NCT05623761|Active Comparator|Group 1 - toothpaste containing thermal water of Castera-Verduzan and 1450 ppm Sodium fluoride|Subjects will receive thermal water/sodium fluoride toothpaste (BUCCOTHERM® Sensitive Gums with Fluoride)
32920983|NCT05623761|Active Comparator|Group 2 - toothpaste containing thermal water of Castera-Verduzan|Subjects will receive thermal water toothpaste (BUCCOTHERM® Sensitive Gums Fluoride-Free)
32920984|NCT05621109|Experimental|Intervention|Rapid moderate weight loss (at least 10% of body weight at baseline over 8-10 weeks or BMI 23 kg/m^2 is achieved) by very low-calorie diet (VLCD), reintroduction (4 weeks), weight loss maintenance until pregnancy (up to 12 months), and a high protein, high fiber diet during pregnancy (n=120 couples).
32920985|NCT05621109|No Intervention|Standard of care|The control group will not receive any dietary advice prior to pregnancy. During pregnancy control subjects will receive dietary advice similar to the intervention group, i.e. a high protein, high fiber diet (n=120 couples).
33248497|NCT00567190|Placebo Comparator|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
32920986|NCT05749419||study group and control group|"Study group - children with chronic diseases, disabilities, or congenital anomalies.~Control group - their siblings."
32920987|NCT05614089|Experimental|Glargine|Insulin glargine (long-acting insulin analogue)
32920988|NCT05614089|Active Comparator|NPH or premixed 70/30 (human insulin)|NPH or premixed 70/30 (human insulin)
33248498|NCT00922389|Experimental|G-CSF + Stem cells|
33248499|NCT00922389|Other|No stem cell group|
32920991|NCT05598021||Ultrasound assessment|Quantitative comparison between ultrasound images performed in active self-correction and in a spontaneous position
32920992|NCT05598021||RX assessment|Quantitative comparison between radiological images performed in active self-correction and in a spontaneous position
32920993|NCT05749185|Active Comparator|Group H ( high voltage) radiofrequency|
32920994|NCT05749185|Active Comparator|Group S ( standard) radiofrequency|
32920995|NCT05749107||Atrial secondary tricuspid regurgitation|Patients with persistent/permanent atrial fibrillation and any degree of isolated tricuspid regurgitation
32920996|NCT05585541||Ataxic multiple sclerosis|In the study, those aged between 18-50 years, diagnosed with MS by a neurologist, Expanded Disability Status Scale (EDSS) score between 3-5, EDSS pyramidal system score ≤ 3 and cerebellar functional system score ≥ 1, patients who have been clinically stable for the last 3 months and have agreed to participate in the study will be included.
32920997|NCT04650815||0.5 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
32920998|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
32920999|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
32921000|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
32921001|NCT05749029|Experimental|Intervention|
32921002|NCT05749029|No Intervention|Waitlist Control|Control participants will receive no intervention during the study but will be given the option of accessing the online self-compassion intervention after the study is complete.
32921003|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
32921004|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
32921005|NCT05748951|Experimental|Tear Duct Plug|A device inserted into the tear duct to block tear drainage
32921006|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
32921007|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
32921008|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
32921009|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
32921010|NCT04231331|Placebo Comparator|Placebo|All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
32921011|NCT04231331|Active Comparator|Ertugliflozin|All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
32921012|NCT05748873|Experimental|Step 1 : SPVN06 dose 1|Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.
32921013|NCT05748873|Experimental|Step 1 : SPVN06 dose 2|Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0
32921014|NCT05748873|Experimental|Step 1 : SPVN06 dose 3|Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0
33248500|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
33248501|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
32719091|NCT04770779|Placebo Comparator|Placebo|"Double-Blind Period: Participants will receive placebo matching mitapivat orally, BID for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
33248502|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
32719092|NCT04758611|Experimental|Treatment Arm|The Treatment Arm receives the eShunt implant
32719093|NCT04750889||RFID tags localization|
32719094|NCT04750889||Wire localization|
32719095|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
32719096|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
32719097|NCT04702451|Experimental|Tailored|Tailored ablation strategy
32719098|NCT04702451|Active Comparator|Anatomical|Anatomical ablation strategy
32719099|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
32719100|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
33248503|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
32719101|NCT04699721|Experimental|Arm 1|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
32719102|NCT04398407|Experimental|Coaching and Achievement of Peer Providers (CAPP)|"CAPP will consist of 16 individualized, one-on-one sessions using Zoom or other videoconferencing software and occurring over a 4-month period. Coaching meetings will take approximately one hour per week. The coach will tailor and individualize the modules and time spent on modules to meet the goals of each peer provider.~Modules:~Module 1: Establishing and solidifying the working alliance, understanding the work setting and role Module 2: Understand Generic drivers of burnout and role stress Module 3: Discuss specific sources of role stressors and burnout Module 4: Set SMART Goals Module 5: Overcome challenges for workplace success Module 6: Develop Skills for Workplace Success Module 7: Managing co-worker and supervisory relations in the workplace Module 8: Wrap-up sessions~During the first stage of research, the CAPP intervention will be further developed and refined, prior to the Randomized clinical trial."
32719103|NCT04398407|Active Comparator|Enhanced control|"The enhanced control condition will include 1 generic informational session conducted by a CAPP coach.During that session, the coach will introduce the key concepts under study and provide information about the drivers of burnout and role stress. The CAPP coach will discuss the need to set goals to overcome these challenges and will provide one article via email describing burnout and role stressors that is suitable for a lay person."
32719104|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
32719105|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
32719106|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
32719107|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
32719108|NCT03526211|Experimental|Experimental|Patients with FES Cycling
32719109|NCT04284293|Experimental|Group 1A|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 300,000 CNS10-NPC (n=3)"
32719110|NCT04284293|Experimental|Group 1B|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=3)"
32719111|NCT04284293|Experimental|Group 2|"Visual acuity between 20/80 and 20/200~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=10)"
32719112|NCT04257383|Experimental|Treatment|Families in the treatment cells will receive the Sugira Muryango treatment immediately after household identification and enrollment.
32719113|NCT04257383|Experimental|Waitlist Control|Families in the control cells will receive the Sugira Muryango treatment following the completion of the 12-month follow up on the original treatment group.
32719114|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
32921015|NCT05748873|Experimental|Step 2 : SPVN06 Dose Recommended 1|Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0
32921016|NCT05748873|Experimental|Step 2 : SPVN06 Dose Recommended 2|Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0
33248504|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
32719115|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
32719116|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
32719117|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
32719118|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
32719119|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
32719120|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
32719121|NCT04467047|Experimental|Intervention|Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
32719122|NCT04467203|Experimental|Fadanafil fast to fat meal|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-> At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal"
32719123|NCT04467203|Experimental|Fadanfil fat meal to fat|"Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
32719124|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
32719125|NCT04221035|Experimental|phase induction-R-I|R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.
32719126|NCT04221035|Experimental|Phase high dose chemotherapy consolidation|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
32719127|NCT04221035|Experimental|Phase of radiotherapy|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
32719128|NCT01601704|Experimental|NB32|
32719129|NCT01601704|Placebo Comparator|PBO|
32719130|NCT04842682|Experimental|Active intervention|"Solo groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)~Combi groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml) and combined with DNA-HIV-PT123 HIV-1 vaccine (solution at 4.0 mg/ml)"
32719131|NCT04842682|Placebo Comparator|Placebo|Commercial Sodium Chloride at 0.9% (NaCl 0.9%)
32719132|NCT04842214||Oncologic disorders|"All patients assigned for oncological rehabilitation with the diagnosis Cancer are included to this cohort."
32719133|NCT04969276|Experimental|Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine|Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.
32719134|NCT04969276|Active Comparator|Group 2: Fluzone HD Quadrivalent Influenza Vaccine|Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.
32719135|NCT04969276|Active Comparator|Group 3: COVID-19 Vaccine|Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.
32719136|NCT04969198|Experimental|Nicotine Patch + Nicotine Mini Lozenge|"No medication for 1 Week after Target Quit Day (TQD). Medication started 1 Week after TQD.~Patches (Nicotine): 14 mg Patches for 4 weeks postquit (Week 1-5), then 7 mg patches for 4 weeks (Week 6-9)~Mini Lozenge (Nicotine): 2 mg Mini Lozenges 5x per day (up to 20x day max) for 8 weeks post quit (Week 1-9)"
32719137|NCT05304676|Experimental|KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation. Children will be treated for 3 days a week over 4 weeks.
32719138|NCT05304676|Active Comparator|Conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
32719139|NCT04666636|Placebo Comparator|Placebo|Participants in the group will receive placebo.
32719140|NCT04666636|Experimental|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
32719141|NCT05298748|Other|Ambient noise followed by Womb sound|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of ambient noise followed by commercially available womb sounds over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
32719142|NCT05298748|Other|Womb sound recordings followed by ambient noise|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of commercially available womb sounds followed by ambient noise over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
32719143|NCT05288920|Active Comparator|Radiofrequency group|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
32719144|NCT05288920|Placebo Comparator|Steroids group|Transforaminal injection of Steroids alone
32719145|NCT05374330|Experimental|Electroacupuncture|Acupuncture needles will be inserted into the body at standardized acupuncture points. Electrical current will then be applied using 2 channels of electrical current for a total of 4 points receiving electroacupuncture
32719146|NCT05374330|Sham Comparator|Sham acupuncture|Sham Acupuncture needles will be placed at standardized acupuncture points. Sham electrical current will then be applied using 2 channels / 4 points as in the electroacupuncture group. The electrical current will not be turned on.
32719147|NCT05374330|No Intervention|Waitlist|The wait list group will be required to complete questionnaires at 4 separate time points over the 12 week study period.
32719148|NCT05265520|Active Comparator|His-CRT implantation|His-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an endocardial His-bundle pacing leads directly pacing the intrinsic conduction system.
32719149|NCT05265520|Active Comparator|BIV-CRT implantation|BIV-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
32719150|NCT04943380||patients with hematuria undergoing investigation for UC|Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as > 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
32719151|NCT04925284|Experimental|XB002 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
32719152|NCT04925284|Experimental|XB002 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), urothelial cancer (Cohort C), ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J) and hormone-receptor positive breast cancer (Cohort K).
32719153|NCT04925284|Experimental|XB002 + Nivolumab Dose Escalation Cohorts|Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
32719154|NCT04925284|Experimental|XB002 + Nivolumab Dose Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).
32719155|NCT04925284|Experimental|XB002 + Bevacizumab Dose Escalation Cohorts|Subjects (Cohort AB) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
32719156|NCT04925284|Experimental|XB002 + Bevacizumab Dose Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with epithelial ovarian cancer [EOC] (Cohort DB)
32719157|NCT04923958|Experimental|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 1500 patients, including 300 people living with HIV and 300 people with diabetes, for evaluation of various novel TB triage and diagnostic tests.
32719158|NCT04923958|Experimental|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 200 patients for evaluation of novel rDST assays.
32719159|NCT04922632|Experimental|Transcendental Medication (TM)|Transcendental Meditation (TM): a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
33248505|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
33248506|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
33248507|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
33248508|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~docetaxel (T) + bevacizumab for 4 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
32719160|NCT04922632|Experimental|Experience Resolution Methodology (ERM)|Experience Resolution Methodology (ERM): is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
32719161|NCT04922632|Experimental|TM+ERM|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM): an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
32719162|NCT04922632|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU): is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
32719163|NCT05373940|Experimental|Heart failure optimal therapy alone (HFOT)|Heart failure Optimal therapy without implantable cardioverter defibrillator. This group will not undergo an ICD implantation. They will be treated according to the HFOT recommended in the latest guidelines.
32719164|NCT05373940|Active Comparator|Heart failure optimal therapy (HFOT) + Implantable cardioverter defibrillator (ICD)|Optimal medical therapy + implantable cardioverter defibrillator (HFOT+ICD). This group will undergo an ICD implantation (standard of care), any brand, CE marked, implantable (lifelong), available and reimbursed in the French market (the type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.
32719165|NCT04909138|Active Comparator|DRG stimulation therapy at 20 Hz and 30 seconds ON, 90 seconds OFF|
32719166|NCT04909138|Active Comparator|DRG stimulation therapy at 5 Hz and 30 seconds ON, 90 seconds OFF|
32921017|NCT05748873|No Intervention|Step 2 : Control group|
32921018|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
32719167|NCT04419142|Experimental|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
32719168|NCT04419142|Experimental|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
32921019|NCT05583981||Observational (interview)|Participants participate in interview over 30-60 minutes.
32921020|NCT00361985|Experimental|1|Nexium group
33400021|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
33400022|NCT05174689|Other|EIA wih house dust mite|Patients with EIA and house-dust mite allergy and an eNO > 30 ppb
32719169|NCT04908046|Experimental|HMPL-295S1 open-label treatment arm|"During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
32719170|NCT05371834|Experimental|Microwave Treatment (Swift System)|5-10 Watts of microwave energy applied locally on each wart for a 2-3 second burst with 3-5 repetitions per lesion.
32719171|NCT05371834|Active Comparator|Cryotherapy Treatment|For each wart, two cycles of cryotherapy treatment is administered.
32719172|NCT05256940|Experimental|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, and is delivered in three sessions in person, virtually, or by telephone.
32719173|NCT05256940|Active Comparator|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
32719174|NCT04899544|Experimental|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|A 16-week center-based PRT intervention (PRT-C) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
32719175|NCT04899544|Experimental|Home-Based Pivotal Response Treatment (PRT) Intervention (PRT-H)|A 16-week home-based PRT intervention (PRT-H) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
32719176|NCT04899544|No Intervention|Treatment As Usual (TAU)|This is a control group that consists of children who are receiving treatment as usual (TAU) for a 16-week period. These families will be invited to participate in PRT after completing the 16-week TAU phase.
32719177|NCT05371444|Experimental|Controlled DoF|The treatment that this gruop will receive consist in a training with the exoskeleton that will restrict the DoF of the arm and trunk
32719178|NCT05371444|Active Comparator|Non controlled DoF|The treatment that this gruop will receive consist in a training with out the exoskeleton and without restriction of the DoF
32719179|NCT05371444|No Intervention|Conventional|This group will only recieve the conventional therapy that is given by the medical center
32719180|NCT05370976|Experimental|Experimental group|
32719181|NCT04890106|Experimental|Bimatoprost 0.01% Ophthalmic Solution|"Bimatoprost Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Mankind Pharma Limited, India.~Intervention Drug: Test - Bimatoprost 0.01% Ophthalmic Solution"
32719182|NCT04890106|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|"LUMIGAN® ( Contains Bimatoprost) Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Allergan, Inc.,~Intervention Drug: Reference - Bimatoprost 0.01% Ophthalmic Solution"
32719183|NCT04833556||Postpartum haemorrhage|Patients undergoing cesarean delivery with postpartum haemorrhage (blood loss more than or equal to 1,000 ml.)
32719184|NCT04645732|Experimental|Personalized exercise therapy and self-management program in addition to usual care|"Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour).~Furthermore, this group will receive the treatment described under usual care below."
32719185|NCT04645732|Active Comparator|Usual care alone|Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
32719186|NCT04840654|Active Comparator|Caudal block|This group will receive the Caudal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
32719187|NCT04840654|Active Comparator|Pudendal Block|This group will receive the Pudendal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
32719188|NCT04840498||Magic Camp Session #1|Children ages 9-18
32719189|NCT04840498||Magic Camp Session #2|Children ages 9-18
32719190|NCT05247190|Experimental|Treating self-criticism|8-session group intervention targeting self-criticism given 2-hrs/week with booster session after 3-months.
32719191|NCT05238922|Experimental|Phase 1a Dose Escalation|"INCB123667 will be administered at a protocol defined starting regimen once daily (QD) orally in 28-day cycles.~Subsequent dose regimens will be determined during study conduct."
32719192|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 1 Gynecological Tumors|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma or clear cell ovarian cancer, or endometrial adenocarcinoma, uterine carcinosarcoma, or uterine papillary serous carcinoma).
32921021|NCT05577351|Experimental|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove thrombus in the neuro-vasculature using the RapidPulseTM (feasibility) device.
32921022|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
32921023|NCT00362063|No Intervention|healthy controls|No growth hormone is given
32921024|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
32921025|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
32921026|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
32921027|NCT00382239|Placebo Comparator|Placebo/placebo|
32921028|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
32921029|NCT04634201|Experimental|Experimental group|
32719193|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 2 GI Tumors|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have gastrointestinal tumors (gastric, GEJ, and esophageal adenocarcinomas).
32719194|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 3 Breast Cancer|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have breast cancer (participants with HR-positive/HER2-negative breast cancer who have had disease progression on or been intolerant of therapies known to confer clinical benefit, including a CDK4/6 inhibitor).
32719195|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 4 Tumor Agnostic|at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. This group will include participants who have had disease progression on prior standard treatment or are intolerant to or ineligible for standard treatment or there is no available treatment to improve the participant's disease outcome.
32921030|NCT04634201|Sham Comparator|control group|
32921031|NCT05748717||Paediatric patients with sickle cell disease with normal TCD velocity without clinical stroke|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with no prior history of stroke or previous Transcranial Doppler study showing a maximum time-averaged mean velocity of greater than 169 cm/sec, and who have not received a red cell transfusion in the past two months and are considered to be at steady state.
32921032|NCT05748717||Paediatric patients with sickle cell disease with an abnormal TCD velocity (with or without stroke)|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with an abnormal TCD velocity, who have not received a red cell transfusion in the past two months and are considered to be at steady state.
32921033|NCT03968419|Experimental|canakinumab monotherapy|All patients will receive canakinumab (ACZ885) prior to surgery
32921034|NCT03968419|Experimental|canakinumab + pembrolizumab|All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
32921035|NCT03968419|Experimental|pembrolizumab monotherapy|All patients will receive 2 doses of pembrolizumab prior to surgery
32921036|NCT05571735||TB cohort|"TB cohort - Bacteriologically confirmed TB patients (18 years and above)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
32921037|NCT05571735||Healthy comparator|"Comparator- Clinically healthy individuals (54 in healthy comparator)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
32921038|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
32921039|NCT05570955|Other|Intervention|50% of subjects will be randomized to a reporting tool designed to promote better adherence to treatment by having subjects report their progress on a weekly basis (the goal is not to test this tool but to help assure there is a broad range of adherence behavior including some positive adherence outliers)
32921040|NCT05570955|No Intervention|No Intervention|50% of subjects will not receive additional outreach to improve adherence
32921041|NCT05556603||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
32921042|NCT05556603||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
32921043|NCT05556603||Healthy arm|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
32921044|NCT05556603||High risk for pancreatic cancer arm|Participants with high risk for pancreatic cancer, from whom a blood sample will be collected.
32921045|NCT04218851|Experimental|Posaconazole|On Day 1 participants receive 2 administrations of posaconazole (POS) 6 mg/kg body weight by intravenous (IV) infusion. On Days 2 through 7, participants receive POS 6 mg/kg body weight once daily by IV infusion. Beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on the IV formulation.
32921046|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
32921047|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
33248509|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
32719196|NCT04640194|Other|Control group|Standard of care alone
33248510|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
33248511|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
33248512|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
32719197|NCT04640194|Experimental|Treatment group A|Alteplase (low dose) on top of standard of care
32719198|NCT04640194|Experimental|Treatment group B|Alteplase (high dose) on top of standard of care
32905558|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
32719199|NCT05228158||Tazemetostat|Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation will receive Tazemetostat 800 milligram (mg), tablet, orally, twice daily or as per physicians discretion in routine clinical practice. All the participants will be observed for up to Week 52 prospectively.
32719200|NCT05214664|Experimental|Guiding device for inferior alveolar nerve block|"The system consists of a reusable angulator with a tube, a reusable plunger, and a single-use syringe body.~These three components are combined with a single-use needle and an anesthetic cartridge to create the ready-to-use EZ-Block® device."
32719201|NCT05214664|Active Comparator|Conventional freehand technique for providing anesthesia|"The injection site is located in the middle of the triangle with an upper base formed, during maximum mouth opening, outside by the mandibular ramus, inside by the mesial pterygoid muscle and above by the lateral pterygoid muscle.~The needle is inserted up to the bone contact (about 20mm) while the body of the syringe is directed towards the contralateral premolars or molars.~Use of a disposable carpule syringe with aspiration. Use of a 35mm long needle with a 0.5mm diameter. Use of an articaine anesthesia carpule with adrenaline 1/200000."
32719202|NCT05206084|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
32719203|NCT05206084|Active Comparator|XIENCE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
32719204|NCT04833166|Experimental|Full glottic view on CMAC- D blade|Deliberately obtaining a full glottis view is deﬁned as negotiation and advancement of CMAC D blade tip positioned at the vallecula. Occasionally, external laryngeal pressure may be needed to assist in obtaining a full glottic view. The full glottic view is defined as a percentage of glottic opening (POGO) approximate 100%.
32719205|NCT04833166|Active Comparator|Partial glottic view on CMAC- D blade|The partial glottis view is deﬁned as a percentage of glottic opening <50%. This is achieved by deliberately position the CMAC D-blade tip proximally away from the vallecular.
32719206|NCT05356390|Experimental|Stabilization exercises|Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.
32719207|NCT05356390|Active Comparator|Muscle energy techniques|Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.
32719208|NCT04852042|Experimental|mHealth Group|12 month text messaging program about diet and physical activity behavioral goals
32719209|NCT04852042|Experimental|mHealth+Community Health Worker (CHW) support|same as mHealth group + monthly behavioral phone counseling by a CHW
32719210|NCT04852042|No Intervention|Control group|Assessments only
32719211|NCT04851886|Active Comparator|Individual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 sessions of robot-assisted upper-limb rehabilitation. During the sessions, a therapist will administer one-on-one therapy (i.e. each study volunteer will work with a single therapist).
32905559|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
32905560|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
32719212|NCT04851886|Experimental|Group robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will also undergo 18 sessions of robot-assisted upper-limb rehabilitation. However, a therapist will administer the intervention as group therapy with up to three subjects participating in the session at the same time. To facilitate the deliver of the therapeutic intervention, the robot will be equipped with a camera system (called PostureCheck) designed to track the quality of the exercises.
32719213|NCT04832698||Observational (survey administration)|Participants complete a survey over 10 minutes before and after completing training and using the Mentice endovascular simulator device.
32719214|NCT05199298|Experimental|"Mandala Activity-Based Breastfeeding Program"|The group receiving Mandala Activity-Based Breastfeeding Program
32719215|NCT05199298|No Intervention|Control group|the group that did not receive any training/initiative
32719216|NCT05198362|Placebo Comparator|Placebo|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated Tesomet dose from the double-blind period
32719217|NCT05198362|Experimental|Tesomet Low Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
32719218|NCT05198362|Experimental|Tesomet Medium Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
32719219|NCT05198362|Experimental|Tesomet High Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
32719220|NCT05197348|Experimental|Meaning-Centered Group Psychotherapy (MCP).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis. The investigators will follow the manualized MCP for patients with advanced cancer.
32719221|NCT05197348|Active Comparator|Cognitive Behavioral Psychotherapy (CBT).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis, with the following sessions. The investigators will follow the manualized CBT or patients with advanced cancer.
32719222|NCT05196100|Experimental|Confidence socket|Participants to receive a confidence socket system
32719223|NCT05355220|Experimental|silver spike point Therapy Group|One group will receive electrotherapy (silver spike point) for 10 mints along with conservative managment
32719224|NCT05355220|Active Comparator|Conservative treatment group|2nd group will receive strengthening, stretching and stabilization exercises for prlvic girlde
32719225|NCT05188222|Experimental|Intervention Group|Patients in the intervention group will receive an oral preparation of 50 grams of Maltodextrin solution mixed in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
32719226|NCT05188222|Placebo Comparator|Placebo Group|Patients in the intervention group will receive a placebo in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
32719227|NCT05184712|Experimental|AK112 in combination with Pemetrexed and Carboplatin|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
32719228|NCT05184712|Placebo Comparator|Placebo in combination with Pemetrexed and Carboplatin|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
32719229|NCT05354206|Experimental|Evaluation of motor evoked potentials during non-invasive spinal cord stimulation and leg movements|This arm will receive the transcranial magnetic stimulation to evaluate the excitability of the corticospinal tract first then the arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal track second.
32719230|NCT05354206|Experimental|Reaction time evaluation during non-invasive spinal cord stimulation and leg movements|This arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal tract first then the arm will receive the transcranial magnetic stimulation to excite the corticospinal tract second
32719231|NCT04839484|Experimental|Lumina|Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
32719232|NCT04839484|Active Comparator|Restylane Defyne|Restylane Defyne Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
32719233|NCT04411264|No Intervention|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
32921048|NCT05748639|Experimental|Quit Genius - Alcohol|QG-A is a smart phone application targeting alcohol use disorder. QG-A includes standardized cognitive-behavioral therapy in the form of videos, in-app text, audio recordings, and quizzes. The application provides users with information on how to reduce or abstain from alcohol use. Once successfully enrolled in QG-A, a medical provider will evaluate each QG-A participant for appropriateness for pharmacotherapy during an initial 60-minute assessment to confirm an alcohol use disorder diagnosis and collect relevant medical and psychiatric history of the patient. The medical provider will subsequently prescribe oral naltrexone via the QG-A telemedicine platform. A study counselor will provide manualized CBT-based support to QG-A participants via the video telemedicine function, as well as asynchronously via the in-app chat function.
33248513|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
33248514|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
33248515|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
33248516|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
33248517|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
33248518|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
33248519|NCT01046539|Placebo Comparator|Placebo|
33248520|NCT04015024|Experimental|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
33248521|NCT04015024|Experimental|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
33248522|NCT04015024|Experimental|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
33248523|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
33248524|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
33248525|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
33248526|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
33248527|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
33248528|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
33248529|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
33248530|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
33248531|NCT00839709||depletion immunosuppression|
33248532|NCT00839709||no depletion immunosuppression|
33248533|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
33248534|NCT00930358|Active Comparator|General anesthesia|Gold standard
33400023|NCT05174689|Other|EIA without sensitization|Patients with EIA without allergic sensitization and an eNO < 20 ppb
33400024|NCT05174689|Other|Healthy controls|Healthy controls without allergic sensitization or known asthma
33248535|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
33248536|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
32719234|NCT04411264|Experimental|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
32719235|NCT04818112|Experimental|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
32719236|NCT04818112|Active Comparator|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
32719237|NCT04810156|Active Comparator|Cohort A: Steroids and MMF in grade 3-4 ir-hepatitis|Patients with ≥ 3 grade ir-hepatitis will be treated with high-dose steroids 2 mg/kg/day intravenously. A diagnostic liver biopsy will be taken. Patients with mixed or cholestatic liver injury patterns will be added UDCA. Treatment evaluation will be performed after 72 hours, patients in UDCA will be evaluated will be on day 7. Patients with sufficient steroid response defined as ≥ 20% reduction in ALT, AST, ALP or bilirubin at day 4 or day 7 will undergo steroid tapering with a transition to peroral steroids. Patients with initial insufficient treatment response, defined as less than < 20% reduction in ALT, AST, ALP, or bilirubin, are considered as having a steroid-refractory condition and will be added MMF. In case of no response or increase of ALT, AST, ALP, or bilirubin during treatment with steroids plus MMF a third-line treatment may be introduced according to the individual treating hepatologist.
32719238|NCT04810156|Active Comparator|Cohort B: Prednisolone versus MMF in steroiddependent ≥2 ir-hepatitis (randomized)|Patients who experienced relapse of ir-hepatitis of grade ≥2 during prednisolone tapering or within one months after ended tapering will be randomized to either 100% dose of current steroid dose or restart of steroid 0.5-1 mg/kg versus adding MMF (if the patient received prednisolone the tapering plan hereof is continued, prednisolone up to 25 mg can be added if clinical indicated). Treatment efficacy is evaluated after seven days, if sufficient response the patients continued treatment, in case of insufficient response a cross-over will be performed.
32719239|NCT04805554|Experimental|Joint Insights Decision Aid|Participants view the entire Joint Insights decision aid for knee osteoarthritis including: Education Module with information about knee osteoarthritis and risks and benefits of various treatment options, Preferences and Values elicitation questions, and Personalized Risk/Benefit Report.
32719240|NCT04805554|Active Comparator|Education Module Only|Participants view the Joint Insights Education Module only
32719241|NCT04851028|Experimental|One2One|1) Weekly individual (one2one) Music Therapy intervention lasting 5 months (n=20 sessions)
32719242|NCT04851028|Experimental|Small-group|2) Weekly small group (max 8 people per group) Music Therapy intervention lasting 5 months (n=20 sessions)
32719243|NCT04851028|No Intervention|Control|Standard weekly music social listening in large group available in all care-homes. Lasting 5 months (n=20 sessions)
32719244|NCT05183230|Experimental|Proof-of-Concept WellPATH-PREVENT (R61)|
32719245|NCT05183230|Experimental|Optimized WellPATH-PREVENT (R33)|
32905561|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
32905562|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
32905563|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
32905564|NCT05620940|Active Comparator|Vivitrol Injection|Vivitrol, Single Dose, IM injection
32905565|NCT05620940|Experimental|IVL3004 (A mg)|IM, Single Dose
32905566|NCT05620940|Experimental|IVL3004 (B mg)|SC, Single Dose
32905567|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
32905568|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
32905569|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
32905570|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
32905571|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
32905572|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
32905573|NCT05124704|Experimental|Combined epidural with general anesthesia|Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery.
32905574|NCT05124704|Sham Comparator|General anesthesia|In this group, same dose of normal saline was administered before induction and during surgery.
32905575|NCT00834236|Experimental|gastric cancer|gastric cancer patients
32905576|NCT00834236|Active Comparator|normal subject|healthy subject
32905577|NCT01431131|Active Comparator|Intrasocket graft|Positive control
32905578|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
32905579|NCT05102318|Experimental|Direct Pulp Capping with Biodentine|Direct Pulp Capping with Biodentine
32905580|NCT05102318|Experimental|Partial Pulpotomy with Biodentine|Partial Pulpotomy with Biodentine
32905581|NCT05102318|Experimental|Pulpotomy with Biodentine|Pulpotomy with Biodentine
32905582|NCT05102318|Experimental|Direct Pulp Capping with MTA|Direct Pulp Capping with MTA
32905583|NCT05102318|Experimental|Partial Pulpotomy with MTA|Partial Pulpotomy with MTA
32905584|NCT05102318|Experimental|Pulpotomy with MTA|Pulpotomy with MTA
32745948|NCT04802967|Active Comparator|KLS (part A and B)|"KLS 80 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules will be administered with 240 mL of water.~In the part B KLS (40 mg, 80 mg or 160 mg) are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water. To maintain the blind, subjects assigned to receive 160 mg KLS alone are administered two KLS 80 mg capsules and subjects assigned to receive either 40 mg KLS alone or 80 mg KLS alone also receive a placebo capsule (dummy placebo)."
32921049|NCT05748639|Active Comparator|Medical Management|Medical management comprises standard care for alcohol use disorder. A medical provider, upon evaluation of each participant for appropriateness for pharmacotherapy, will subsequently prescribe naltrexone via a non-QG-A telemedicine platform, according to standard clinical practice. Participants will meet with the medical provider monthly over the 6-month course of treatment. In MM, participants receive dose adjustments and brief medical management as normally provided to patients in office-based settings (session duration is 15-20 minutes). The medical provider will deliver education about the study medication and answer any participant questions. Subsequent 15-20 minute sessions will review drinking patterns, overall functioning, medication adherence, and adverse effects. Participants who discontinue medication because of intolerance can continue to attend monthly medical management sessions to support abstinence.
32921050|NCT04218617|Experimental|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
32921051|NCT04218617|Active Comparator|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
32921052|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
32921053|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
32921054|NCT05551377|Experimental|Intervention group|At T0, in-clinic inclusion, we will record basic characteristics and several questionnaires, we will also perform a short tilt-table-test and standing blood pressure (BP) test. Intake is followed by one week of horizontal sleeping for baseline home-based BP measurements. Participants in the intervention group will then sleep in a head-up tilt position for two weeks each in angles 6°, 12° and 18°. At the second and final in-clinic meeting, at T1, measurements done at T0 will be repeated, complemented with an assessment of barriers and facilitators of HUTS. During HUTS daily BP measurements will be done, and data will be collected on orthostatic tolerance, nighttime urine production, subjective comfort of HUTS, falls.
32921055|NCT05551377|Other|Delayed intervention group|Follows the same structure as the intervention group, but starts with a HUTS placebo angle of 1° for two weeks, followed by two intervention angles of 6° and 12° for two weeks each. The 1°-angle serves as the control intervention.
32921056|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
32921057|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
32921058|NCT04214561||SB group|Patients diagnosed with SB.
32921059|NCT04214561||Healthy controls|Patients without diagnosed SB.
32921060|NCT05746533||Participants Undergoing Hip Preservation/Surgical Interventions|Data will be prospectively collected on participants undergoing hip preservation at Yale-New Haven Hospital.
32921061|NCT03875729|Experimental|teplizumab|Sterile solution for injection.
32921062|NCT03875729|Placebo Comparator|Placebo|Sterile solution for injection
32921063|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
32921064|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
32921065|NCT04207151|No Intervention|Standard of Care|Participants will receive HIV and STI testing, clinical monitoring, client centered counseling and PrEP prescriptions as standard of care, this includes scheduled visits every three months.
32921066|NCT04207151|Experimental|Pre- and Post- SNAPS intervention|In addition to the standard of care treatment, approximately twenty subjects will be selected for interview pre- and post-SNAPS intervention to assess PrEP facilitators and barriers for uptake. Participants of interest include cis- and trans-women, for which there is limited data regarding PrEP and HIV prevention.
32921067|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
32921068|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
32921069|NCT05523765|Experimental|Brepocitinib Dose Level 1 PO QD|
32921070|NCT05523765|Experimental|Brepocitinib Dose Level 2 PO QD|
32921071|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
32921072|NCT04610411|Experimental|surgical navigation|standard surgical method except for navigated instrumentation of pedicle screws and rod implants
33248537|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
32745949|NCT04802967|Active Comparator|Gabapentin (part B)|Gabapentin 300 mg are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.To maintain the blind, subjects assigned to receive 300 mg gabapentin also receive a placebo capsule (dummy placebo).
32745950|NCT04802967|Placebo Comparator|Placebo (part B)|To maintain the blind subjects assigned to receive placebo receive 2 placebo capsules. Capsules will be administered with 240 mL of water.
32921073|NCT04610411|Active Comparator|standard surgical method|standard surgical method established at the institution
32719246|NCT05183230|No Intervention|Attention Control Usual Care (R33)|The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.
32719247|NCT04850092||Non-hypotensive|Mean blood pressure is maintained after positional change from supine to prone.
32719248|NCT04850092||Hypotensive|Mean blood pressure decrease < 20% after positional change from supine to prone.
32921074|NCT05742399|Active Comparator|Hyaluronic acid nanoparticles (2%)|patients with tear trough will receive hyaluronic acid nano-gel (2%) 2 applications / day (morning and evening) on tear troughs for 1 month
32921075|NCT05742399|Placebo Comparator|Placebo|patients with tear trough will receive placebo conventional gel having the same color, form and packaging for 1 month
32921076|NCT04607915|Experimental|Intervention for TECC Model|
32921077|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally daily
32921078|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken orally daily"
32921081|NCT05741151|Experimental|PET-Neck Parkinsonian patients|Brain and neck PET-CT with 68Ga-PSMA scan would be administered
32921082|NCT01641835||Normals|No eye disease.
32921083|NCT04200209|Experimental|Hospital|Twelve wards of the hospital will be evaluated at the same time.
32921084|NCT04185311|Experimental|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
32921085|NCT05513937|Active Comparator|Nebivolol|Single dose Phase (4 weeks): patients will be treated with Nebivolol 5mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
32921086|NCT05513937|Active Comparator|Amlodipine|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
32921087|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
32921088|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
32921089|NCT04584749|Experimental|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
32921090|NCT04584749|Placebo Comparator|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
33400025|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
32719249|NCT05176054|Experimental|Experimental group|Researchers will conduct the health service program for the experimental group.
32719250|NCT05176054|No Intervention|Contrast group|The contrast group will be receiving the routine care only.
32719251|NCT05175664||MCI|Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
32719252|NCT05175664||AD|Patients diagnosed with mild to moderate Alzheimer's disease (AD)
32719253|NCT05175664||NDD|Patients under investigation of a neurodegenerative disease (NDD)
32719254|NCT05175664||DLB|Patients diagnosed with Dementia with Lewy Bodies (DLB)
32719255|NCT05175664||VaD|Patients with vascular dementia (VaD)
32719256|NCT05175664||FTD|Frontotemporal dementia (FTD)
32719257|NCT05175664||NPH|Normal pressure hydrocephalus (NPH)
32719258|NCT05175664||Healthy Controls|Healthy Controls without brain disease
32921091|NCT05736861|Experimental|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
32921092|NCT05736861|Placebo Comparator|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
32719259|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
32921093|NCT01643707||Phase I|Control
32921094|NCT01643707||Phase II|Treatment
32921095|NCT04581629|Experimental|CLTX-305|CLTX-305 (encaleret) dose finding study to determine safety, tolerability and dose response during three (3) periods and a long term extension of this study with dose levels at QD and BID; up to 41 months of active treatment per participant
32921096|NCT04579991|Active Comparator|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
32921097|NCT04579991|Placebo Comparator|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
32921098|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
32921099|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
32921100|NCT05502315|Experimental|Experimental Group|"40 mg of cabozantinib taken orally every day (days 1-28) of a 28 day cycle~480 mg of nivolumab given intravenously on the first day (day 1) of each 28 day cycle"
32921101|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
32921102|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
32921103|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
32921104|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
32921105|NCT05734755|Experimental|The COMB group|Participants in The COMB group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
32921106|NCT05734755|Experimental|The EXER-only group|Participants in The EXER-only group will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
32921107|NCT05734755|Experimental|The IDBC-only group|Participants in The IDBC-only group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity.
32921108|NCT05734755|No Intervention|The Control Group|Participants in The Control Group will attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity. As the purpose of the health talk is to control the group interactive effect in exercise training, the group size, and the frequency and the time of the health talks will be similar to those offered in the exercise programme for the COMB and EXER-only groups.
32921109|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
32921110|NCT05449457|No Intervention|Layered Closure|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
32719260|NCT04837924|Experimental|B (FICB)|Participants receiving fascia iliaca compartment block (FICB)
33248538|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
33248539|NCT00372775|Experimental|Sunitinib|
32719261|NCT04837924|Sham Comparator|A (PLACEBO)|Participants receiving sham injection matching fascia iliaca compartment block (FICB)
32719262|NCT05169346|Active Comparator|Active Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of active neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
32719263|NCT05169346|Sham Comparator|Sham Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of sham (placebo) neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
32921111|NCT05449457|Experimental|Layered Closure with 2-Octyl Cyanoacrylate|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
32921112|NCT05493501|Experimental|Aumolertinib monotherapy|
33400026|NCT05666141|Experimental|PES stimulation in volunteers|10 volunteers will receive PES stimulation. For healthy volunteers, the study protocol includes 1 stimulation trial. Each stimulation trial consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
32745951|NCT04426617|Experimental|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & fentanyl).
32745952|NCT04426617|Experimental|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & midazolam).
32745953|NCT04426617|Placebo Comparator|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
32905585|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
32905586|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
32905587|NCT05015504|Experimental|Time restricted feeding|The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase
32905588|NCT05000450|Experimental|ALLO-605, ALLO-647|
32905589|NCT00886262|Experimental|Vasopressin|
32905590|NCT00886262|Placebo Comparator|Normal saline placebo|
32905591|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
32905592|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
32905593|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
32905594|NCT00836342||Previous history of SCC|Participants had previous history of SCC
32905595|NCT00836342||Previous history of BCC|Participants had previous history of BCC
32905596|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
32905597|NCT03313778|Experimental|Part A: Dose Escalation|Participants will receive a fixed applicable dose of mRNA-4157 administered via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.
32905598|NCT03313778|Experimental|Part B: Dose Escalation|Participants will receive a fixed applicable dose of mRNA-4157 administered via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
32905599|NCT03313778|Experimental|Part A: Dose Expansion|Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles.
32905600|NCT03313778|Experimental|Part B, C, and D: Dose Expansion|Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles. Participants will also receive a fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
32905601|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32905602|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
32905603|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
32905604|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
32905605|NCT03247088|Experimental|Treatment (sorafenib, busulfan, fludarabine, HSCT)|"PRE-STEM CELL INFUSION: Patients receive sorafenib orally PO QD or BID on days -24 to -5, busulfan IV over 3 hours on days -20 and -13 and -6 and -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~STEM CELL INFUSION: Patients receive allogeneic HSCT IV in the absence of disease progression or unacceptable toxicity.~POST-STEM CELL INFUSION: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus PO BID beginning day 5 for about 50 days, filgrastim SC on day 7 and sorafenib PO BID beginning between days +30 and +120 for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with matched unrelated donor receive mycophenolate mofetil PO TID or IV over 2 hours TID beginning on day 5 for up to 90 days for longer."
32905606|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
32905607|NCT04970966|Experimental|PuraSinus|Placement of PuraSinus in ethmoid cavity following ESS
32905608|NCT04970966|Active Comparator|Bioresorbable Nasal Dressing|Placement of bioresorbable nasal dressing (PosiSep X) in ethmoid cavity following ESS
32905609|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
32921113|NCT05493501|Experimental|Aumolertinib + platinum-based doublet chemotherapy|"For adenocarcinoma, either:~Aumolertinib + cisplatin with pemetrexed, or~Aumolertinib + carboplatin with pemetrexed~For squamous cell carcinoma, one of the following:~Aumolertinib + cisplatin or carboplatin with paclitaxel;~Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or~Aumolertinib + cisplatin or carboplatin with gemcitabine"
32921114|NCT05493501|Active Comparator|Osimertinib monotherapy|
32921115|NCT04558151|Experimental|Training arm|Patients perform inspiratory muscle training containing of 30 breaths twice a day for 14-18 days before surgery.
32921116|NCT04558151|No Intervention|Control arm|No preoperative inspiratory muscle training
33248540|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
33248541|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
33248542|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
33248543|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
33248544|NCT00839787|Placebo Comparator|Placebo|Normal saline
33248545|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
33248546|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
33248547|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
33248548|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
33248549|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
33248550|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
33248551|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
33248552|NCT04014478|Experimental|Endovascular Denervation|
33248553|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
33248554|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
33248555|NCT00934414|Experimental|Smokers|
32921117|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
32745954|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
32921118|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
32921119|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
32921120|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
32921121|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
32921122|NCT05731713|Experimental|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
33248556|NCT00934414|Experimental|Non-Smokers|
33248557|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
33248558|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
33248559|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
33248560|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
33248561|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
33248562|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
33248563|NCT00936988|Experimental|cinacalcet|
33248564|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
33248565|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
32719264|NCT05406544||FD qualitative study on quality of life.|FD patients (FD monostotic, FD polyostotic, with or without craniofacial damages) will be invited to attend a focus group on the following themes: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The focus-groups will be conducted in a semi-directive manner by a moderator and will be recorded; after a verbatim transcription of the focus group recordings, the data will be analyzed manually and with the help of a semantic analysis software. It will allow common notions about quality of life in FD to emerge. A demographic questionnaire will also be completed by the participants.
32745955|NCT04263441|Experimental|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
32921123|NCT05731713|Experimental|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
32921124|NCT05448339||PVHA|Patients undergo tumor feeding vessels deprivation combined with tyrosine kinase inhibitor before liver transplantation
32921125|NCT05448339||TACE|Patients undergo TACE therapy combined with tyrosine kinase inhibitor before liver transplantation
32921126|NCT04556201|Experimental|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
32921127|NCT03561259|Experimental|131I-MIBG|131I-MIBG
32921128|NCT03561259|Experimental|131I-MIBG + Vorinostat|131I-MIBG + Vorinostat
32921129|NCT05492409|Experimental|GNR-069|Weekly subcutaneous injections of GNR-069 in the individually titrated dose.
32921130|NCT04449393|Experimental|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
32921131|NCT04449393|Placebo Comparator|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
32921132|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
32921133|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
32921134|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
32921135|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
32921136|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
32921137|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
32921138|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
32921139|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
32921140|NCT05490225|Experimental|Ark Implantation|Single arm study. Depending on the clinical needs of the patient, the physician will decide if a single return Ark is needed (ex. easily cannulatable arterial pull site but the venous return access site is poorly accessible for cannulation) or two Arks (both arterial pull and venous return are poorly accessible for cannulation).
32921141|NCT03002779|Experimental|JNJ-53718678|
32921142|NCT03788291|Experimental|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.~Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.~Patients not in a MRD negative CR, will continue acalabrutinib.~Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
32921143|NCT05488977|Experimental|Exercise training|8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (~60 % HRmax) in between intervals, twice a week) on treadmills. In addition, the participants will perform exercise once a week on their own following the correct exercise intensity.
32921144|NCT05488977|No Intervention|Control|No intervention. Carry on their normal life.
32921145|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
33248566|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
32921146|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
32719265|NCT05406544||FD quantitative sudy on quality of life and olfaction.|Participants will receive two questionnaires to complete: the SF36 questionnaire (quality of life) and the SELF-MOQ questionnaire (olfaction impairment evaluation). Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. A demographic questionnaire will also be completed.
32921147|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
32921148|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
32921149|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
32719266|NCT05406544||FD qualitative and quantitative study on quality of life and olfaction.|Patients will be invited to attend a focus group on quality of life (qualitative study) as described for group 1 and to complete questionnaires on quality of life and olfaction (quantitative study) as described for group 2
32719267|NCT04831996|Experimental|Treat Group 1 : Normal Renal Function|eGFR: ≥ 90 mL/min/1.73 m^2
32719268|NCT04831996|Experimental|Treat Group 2 : Mild Renal Impairment|eGFR: 60-89 mL/min/1.73 m^2
32719269|NCT04831996|Experimental|Treat Group 3 : Moderate Renal Impairment|eGFR: 30-59 mL/min/1.73 m^2
32719270|NCT04831996|Experimental|Treat Group 4 : Severe Renal Impairment|eGFR: 15-29 mL/min/1.73 m^2 and not on Hemo Dialysis
32719271|NCT04831996|Experimental|Treat Group 5 : Kidney Failure|eGFR: < 15 mL/min/1.73 m^2 on Hemo Dialysis
32921150|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
32921151|NCT04593459|Experimental|Probiotic|"Probiotic product consisting of these 7 bacterial strains:~Lactobacillus salivarius W57~Lactobacillus casei W56~Lactobacillus rhamnosus W71~Lactococcus lactis W58~Enterococcus faecium W54~Lactobacillus plantarum W62~Lactobacillus acidophilus W22~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
32921152|NCT04593459|Placebo Comparator|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
32921153|NCT04593459|Active Comparator|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
32921154|NCT04120883|Experimental|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
33248567|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
33248568|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
33248569|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
32719273|NCT04796272|Active Comparator|Traditional exercise|fatigued multiple sclerosis patients with a traditional training program
33248570|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
32719274|NCT04796272|Experimental|Individual exercise|tired multiple sclerosis patients with an adapted and individualized training program
32905610|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
32905611|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
32905612|NCT04067726|Experimental|Denosumab|"Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
33248571|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
33248572|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
33248573|NCT03702634|No Intervention|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
33248574|NCT03702634|Experimental|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
33248575|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
33248576|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
33248577|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
33248578|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
33248579|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
33248580|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
32921155|NCT04120883|Experimental|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
32921156|NCT01651195|Active Comparator|Probiotic tablet (military recruits)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
32921157|NCT01651195|Placebo Comparator|Placebo tablet (military recruits)|Crystalline cellulose 2 x 2, 3 weeks
32921158|NCT01651195|Active Comparator|Probiotic tablet (reserve officer candidates)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
32921159|NCT01651195|Placebo Comparator|Placebo tablet (reserve officer candidates)|Crystalline cellulose 2 x 2, 3 weeks
32921160|NCT05242965|Experimental|Arm I (STEMVAC, sargramostim)|Patients receive STEMVAC ID and sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
32921161|NCT05242965|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
32921162|NCT04744961||Surgical site infections|
32921163|NCT04744961||Normal would healing|
32921164|NCT04593303|Active Comparator|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
32921165|NCT04593303|Other|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
32921166|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
32921167|NCT03775109|Placebo Comparator|Dextrose|
32921168|NCT03251924|Experimental|BMS-986226|administered intravenously
32921169|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
32921170|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
32921171|NCT04591119|Active Comparator|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
32921172|NCT04591119|Active Comparator|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
32921173|NCT04591119|No Intervention|Control Group|At the control group, no intervention for pain management will be done.
32921174|NCT01651351|Experimental|Cohort 1|"Day 1:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min~Day 15:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min"
32921175|NCT01651351|Experimental|Cohort 2|"Day 1:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min~Day 15:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min"
32921176|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
33248581|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
33248582|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
33248583|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
32921177|NCT03774329|Other|Usual care|
32921178|NCT03767075|Experimental|Module 1 Arm 1 - atezolizumab|"Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)~Arm 1A: BRCA1 or BRCA2 mutations~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations~Arm 1C: tumors with POLE mutation, POLD1 mutation.~Arm 1D: hypermutated tumors~Arm 1E: tumors with other mutations in DNA-repair genes.~Arm 1F: tumors with amplified PDL1~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1."
32921179|NCT03172195|Experimental|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
32921180|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
32921181|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
32921182|NCT05466123|Experimental|Virtual reality intervention in palliative care patients|Palliative care patients with a limited life expectancy will participate in a virtual reality experience for 10-30 minutes
32921183|NCT03122197|Experimental|Letrozole|"The treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with < 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
32921184|NCT04383639|Active Comparator|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
33248584|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
32921185|NCT04383639|Experimental|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
32921186|NCT04383639|Experimental|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
32921187|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg/d in 3-4 divided dosages) given for a maximum of 10 weeks (depending on postmenstrual gestational age at birth)
33248585|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development~Describe the levels longitudinally~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
32921188|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
32921189|NCT04535999|Experimental|Open Label|Secukinumab
32921190|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
32921191|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
32921192|NCT04330911|Experimental|The HIIT Group (High Intensity Interval Training Group)|
32921193|NCT04330911|Experimental|The MICT Group (Moderate Intensity Continous Training Group)|
32921194|NCT03038269|Sham Comparator|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
32921195|NCT03038269|Active Comparator|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
32921196|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
32921197|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
32921198|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
32719275|NCT05406466|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
32921199|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
32921200|NCT05452785|Experimental|DFD-29 under fasting condition|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
32921201|NCT05452785|Experimental|DFD-29 after high-fat meal|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
32921202|NCT05452785|Active Comparator|Solodyn under fasting condition|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast
32921203|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
32921204|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
32921205|NCT04531709||Recently diagnosed TGCT|
32921206|NCT04531709||Long-term survivors of TGCT|
32921207|NCT05217849|Experimental|Tai Chi|Participants will engage in 60-minute Tai Chi classes twice a week for 12 weeks. The classes will be live-streamed over the internet. Tai Chi is an ancient Chinese system of gentle physical exercise and stretching. It involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
32719276|NCT05152420|Experimental|Part 1 - Cohort 1|Single dose cohort
32719277|NCT05152420|Experimental|Part 1 - Cohort 2|Single dose cohort
32719278|NCT05152420|Experimental|Part 1 - Cohort 3|Single dose cohort
32719279|NCT05152420|Experimental|Part 1 - Cohort 4|Single dose cohort
32921208|NCT05217849|Experimental|Gentle, Mindful Movement|Participants will engage in a gentle, mindful movement class twice a week for 12 weeks. The classes will be one hour long and will be live-streamed over the internet. The mindful movement classes will combine elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
32719280|NCT05152420|Experimental|Part 1 - Cohort 5|Single dose cohort
32719281|NCT05152420|Experimental|Part 1 - Cohort 6|Single dose cohort
32719282|NCT05152420|Experimental|Part 2 - Cohort 1|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32719283|NCT05152420|Experimental|Part 2 - Cohort 2|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32921209|NCT05217849|Active Comparator|Health and Wellness Education|Participants will engage in bi-weekly 60 minute sessions of Health and Wellness Education classes. The classes will be held on-line for 12 weeks.
32921210|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
32921211|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
32719284|NCT05152420|Experimental|Part 2 - Cohort 3|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32921212|NCT04527185|Experimental|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
32921213|NCT04527185|Placebo Comparator|Placebo|Administered one time during the laboratory session.
32921214|NCT01932242|Experimental|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
32921215|NCT01932242|Experimental|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
32921216|NCT05215509|Experimental|RA patients TNFi Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
32921217|NCT05215509|Active Comparator|RA patients TNFi Control|"This group will be allocated to control and therefore no supervised exercise regimen"
32921218|NCT05215509|Experimental|RA patients IL-6Rb Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
32921219|NCT05215509|Active Comparator|RA patients IL-6Rb Control|"This group will be allocated to control and therefore no supervised exercise regimen"
32921220|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
32921221|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
32921222|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
32921223|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
33248586|NCT00934882|Experimental|Arm 1|
33248587|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
33248588|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
33400027|NCT05666141|Sham Comparator|Sham treatment in volunteers|10 volunteers will receive Sham treatment. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
33400028|NCT05666141|Experimental|PES stimulation + PES stimulation in patients|20 patients will receive PES stimulation twice. For patients, the protocol thus includes 2 stimulation trails. Each stimulation trial consists of 3 PES sessions, so they receive 6 PES sessions in total. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
32921224|NCT04518215|Experimental|ESPB group|Erector Spinae Plain Block
33400029|NCT05666141|Other|PES stimulation + Sham treatment in patients|20 patients will receive PES stimulation and afterwards Sham treatment. During the first stimulation trial, they will receive 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003). During the second stimulation trial, the same method and same device will be used. However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
33400030|NCT05666141|Sham Comparator|Sham treatment + Sham treatment in patients|20 patients will receive Sham twice. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
32719285|NCT05152420|Experimental|Part 2 - Cohort 4|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32719286|NCT05152420|Experimental|Part 2 - Cohort 5|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32719287|NCT05152420|Experimental|Part 2 - Cohort 6|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32719288|NCT05152420|Experimental|Part 2 - Cohort 7|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
32921225|NCT04518215|Active Comparator|IV Analgesia group|Intra-Venous Analgesia
32921226|NCT05213559|Experimental|wheat-based biscuit enriched with plant proteins|Subjects follow a hypocaloric dietary intervention supplemented with certain amount of wheat-based biscuits enriched with plant proteins daily.
32921227|NCT05213559|Active Comparator|wheat biscuit|Subjects follow a hypocaloric dietary intervention supplemented with certain isocaloric amount of common wheat biscuits daily.
32921228|NCT04517747|Experimental|Ramucirumab plus TAS-102|Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
32921229|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
32921230|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
32921231|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
32921232|NCT05212077|Experimental|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
32921233|NCT05212077|Active Comparator|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
32921234|NCT04516109|Active Comparator|Arthrosocpic labral repair|Patients undergoing arthroscopic labral repair with the use of the modified hip capsule slotted cannula.
32921235|NCT04516109|Active Comparator|Arthroscopic bone grafting|Patients undergoing arthroscopic bone grafting of subchrondral cyst with the use of the modified bone graft delivery tool set and modified hip capsule slotted cannula.
32921236|NCT05442957|Experimental|BRIGHT|BRIGHT is a manualized theory-based video tele-cognitive behavioral therapy (CBT) intervention delivered one-on-one by a licensed clinical psychologist.
32921237|NCT05442957|Active Comparator|Attention Control|The attention control arm is a manualized video tele-supportive care intervention that addresses non-body image aspects of HNC survivorship.
32921238|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
32921239|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
32921240|NCT03740165|Experimental|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
33400031|NCT05583721|Experimental|Stratum A|Sickle Cell patients with diastolic dysfunction
32921241|NCT03740165|Experimental|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
32921242|NCT03740165|Active Comparator|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
32921243|NCT05200923|Experimental|Pelvic health Electrically Evoked Recording (PEER) 2 Study|Collect physiological signals
32921244|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
32921245|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
33400032|NCT05583721|Experimental|Stratum B|Sickle cell patients without diastolic dysfunction
33400033|NCT05583721|Experimental|Stratum C|Healthy controls
33400034|NCT05682547|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 8 weeks.
33400035|NCT05682547|Active Comparator|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 8 weeks
33400036|NCT05581693|Experimental|A (L04RD1 -> L04TD2)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD2
33400037|NCT05581693|Experimental|B (L04TD2 -> L04RD1)|Administration of 1 tablet of L04TD2, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
32921246|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
32921247|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
32921248|NCT05439681|Experimental|MCO - low flux - high flux - HDF|"Patients who are on hemodialysis will be treated with four different hemodialysis sessions:~Treatment 1: MCO membrane~Treatment 2: low flux membrane~Treatment 3: high flux membrane~Treatment 4: HDF treatment with high flux membrane The order of the treatment regimens with the different membranes will be randomized."
32921249|NCT05439681|Experimental|low flux - high flux - MCO - HDF|
32921250|NCT05439681|Experimental|high flux - HDF - low flux - MCO|
32921251|NCT05439681|Experimental|HDF - MCO - high flux - low flux|
32921252|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
32921253|NCT05437263|Experimental|Brepocitinib Dose Level 1 PO QD|
32921254|NCT05437263|Experimental|Brepocitinib Dose Level 2 PO QD|
32921255|NCT05437263|Placebo Comparator|Placebo PO QD|
32921256|NCT01934582|Experimental|Open label extension|
32921257|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
32921258|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
32921259|NCT05436717|Experimental|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies, such as the promotion of wellbeing through the practice of mindfulness, compassion, acceptance, and spirituality and the estimated time for completing the whole program is 8 weeks
32921260|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
32921261|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
32921262|NCT04565691|Experimental|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
32719289|NCT05142202|Experimental|Doubly Accelerated Partial Breast Irradiation after Breast-Conserving Surgery|"All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.~The control group consists of standard adjuvant APBI with multicatheter interstitial brachytherapy technique 8 x 4 Gy in 5 consecutive days or 7 x 4,3 Gy in 4 consecutive days (6 hours minimum gap between the fractions)."
32719290|NCT05121766|Experimental|Study arm - Omega 3 supplement|Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
32719291|NCT05121766|Placebo Comparator|Control arm - placebo|3 Soybean Oil Placebo capsules 2x/day (a total of 6 mini-capsules per day).
32921263|NCT05735834|Experimental|Arm A - Rituximab + Zanubrutinib|"Zanubrutinib (160 mg BID orally continuous dosing) is administered for 12 cycles of 28 days each. After cycle 12:~Patients in Complete Response (CR) will stop treatment and enter the follow-up phase.~Patients in partial response (PR) will continue zanubrutinib treatment (160 mg BID orally continuous dosing) for 12 additional cycles of 28 days each for a total of 24 cycles.~Patients in stable disease (SD) or progressive disease (PD) will stop treatment and will enter the follow-up phase.~Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~Patients in CR will stop treatment and enter the follow-up phase.~Patients in PR will go on with rituximab 375 mg/m2 IV on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~Patients in SD or PD will discontinue treatment and will enter the follow-up phase."
32921264|NCT05735834|Active Comparator|Arm B - Rituximab|"Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~Patients in CR will stop treatment and enter the follow-up phase.~Patients in PR will go on with rituximab 375 mg/m2 iv on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~Patients in SD or PD will discontinue treatment and will enter the follow-up phase"
33400038|NCT05568121|Experimental|A (L04RD1 -> L04TD1)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD1
33400039|NCT05568121|Experimental|B (L04TD1 -> L04RD1)|Administration of 1 tablet of L04TD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
33400040|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
32719292|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
32719293|NCT04556656|Experimental|Pridopidine|45 mg pridopidine twice daily (BID)
32719294|NCT04556656|Placebo Comparator|Placebo|Matching placebo
32921265|NCT05184777|Experimental|Patients undergoing ovarian stimulation for IVF/ICSI|90 patients undergoing ovarian stimulation for IVF/ICSI; Low, average and high responders will be included in equal proportions, in order to cover the widest range of hormonal values (30 blood and saliva samples per ovarian stimulation point will be taken for determination of progesterone and oestradiol).
32921266|NCT05184777|Experimental|Patients for embryo transfer (ET) undergoing hormonal replacement therapy|30 patients for embryo transfer (ET) undergoing hormonal replacement therapy. These patients will only have a progesterone determination in their blood and saliva samples on the day of ET.
32921267|NCT03721367||Urea Cycle Disorders|
32921268|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
32921269|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
32921270|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
32921271|NCT01655563|Experimental|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
32921272|NCT05180019||Patient COS IVI Bilbao|Patients will come to the IVIRMA Bilbao clinic to start their respective ART cycles (vitrification, IVF/ICSI, donors) following usual clinical practice.
32921274|NCT05172141|Experimental|IBI314|Low/medium/high dose, intravenously, once, on Day 1
32921275|NCT05172141|Placebo Comparator|Placebo|Placebo, intravenously, once, on Day 1
32921276|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
32921277|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
32921278|NCT05735756|Active Comparator|Citalopram 20mg|
32921279|NCT05735756|Placebo Comparator|Placebo|
32921280|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
32921281|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
32921282|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
32921283|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
32921284|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
32921285|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
32921286|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
32921287|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
32921288|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
32921289|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
32921290|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
32719295|NCT05403346||SARS COv-2 RT-PCR AND Self collected CoviDx Covid-19 Antigen Self-Test|Sequentially enrolled symptomatic patients will have a nasal swab collected for high-sensitive SARS-CoV-2 RT-PCR testing as comparator and self collect a nasal swab for CoviDx™ Covid-19 Antigen self-testing. Order of tests will be performed following a randomization scheme.
32719296|NCT05400616|Experimental|Intervention|For each nostril, the donated nasal wash sample is quiesced to 15 mls with saline Nasal Microbiota Transplant therapy.
32719297|NCT05400616|Placebo Comparator|Control|For each nostril, 15 mls of saline will be used as the placebo therapy.
32935817|NCT04746703|Experimental|MRI before and 6 months after bariatric surgery|"Recruitment of patient with planned bariatric surgery in Louis Mourier Hospital by the nutritionist, during the preoperative day hospitalisation (performed during the multidisciplinary preparation for bariatric surgery) when patients are deemed eligible for bariatric surgery according to HAS (High Authority of Health) criteria.~Programming of MRI in the month between preoperative visit and surgery. During this exam without injection of contrast agents in the radiology department of Louis Mourier Hospital, additional sequences with specific acquisitions as previously validated in humans will be performed for the study.~Bariatric surgery will be performed as in usual care in Louis Mourier hospital. The same MRI will be performed in day hospitalization scheduled 6 months after surgery."
32719298|NCT05108506|Experimental|No strict need to void following surgery before discharge|Participants randomized to this arm will have no strict need to void following surgery before they are discharged.
32935818|NCT05438810|Experimental|FCN-437c+Fulvestrant ± Goserelin acetate|
32921291|NCT05735522|Active Comparator|Active group|"We are using an extracorporeal magnetic stimulation chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. Each step has a defined duration and a defined frequency of magnetic field pulsations. In each step, it is also defined, which of the magnetic field generators are working. The pulsations last for 6 seconds followed by 6 seconds of rest.~Step 1: 10Hz, 7 minutes, 6 seconds on, 6 seconds off, both stimulators generate the magnetic field. Step 2: 10Hz, 4 minutes, the stimulator under the seat generates the magnetic field. Step 3: 10Hz, 7 minutes, the stimulator in the backrest generates the magnetic field. Step 4: 30Hz, 10 minutes, both stimulators generate the magnetic field. Step 5: After 5 minutes, both stimulators generate the magnetic field.~During the treatment, we adjusted the magnetic field density. It varied from 2-100%. The maximum was 3 Teslas."
32921292|NCT05735522|Sham Comparator|Sham group|We are using extracorporeal magnetic stimulation, a chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. We used the same program as in the active group with the difference that the magnetic field density was always at 2% so the effects of the pulsating are negligible.
32921293|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
32921294|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
32921295|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
32921296|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
32921297|NCT05735444||Observation group|
32921298|NCT01656187|Experimental|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
32921299|NCT01656187|Experimental|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
32921300|NCT01658059|Experimental|group 1|homeopathic remedy first , placebo second
32921301|NCT01658059|Experimental|group 2|placebo first, homeopathic remedy second
32921302|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
32921303|NCT01658995|Active Comparator|Post ESI implant - Doxycycline|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
32921304|NCT01658995|Placebo Comparator|Post ESI implant - Placebo|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received placebo 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
32921305|NCT01350141|Placebo Comparator|Treatment A|
32921306|NCT01350141|Experimental|Treatment B|
32921307|NCT01350141|Experimental|Treatment C|
32921308|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
32921309|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
32935819|NCT05438810|Placebo Comparator|Placebo+ Fulvestrant ± Goserelin acetate|
33400041|NCT05173441|Experimental|High Dose Group|Standard of care (SOC)+high dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
33400042|NCT05173441|Experimental|Low Dose Group|Standard of care (SOC)+low dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
33400043|NCT05173441|Placebo Comparator|Control Group|Standard of care (SOC)+placebo (0.9% sodium chloride). Placebo will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
33400044|NCT05682469|Experimental|VR group|VR cognitive training receives eight gardening activities. The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.
33400045|NCT05682469|Active Comparator|control group|The control group is performing traditional cognitive training program.
32921310|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
32921311|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
32921312|NCT05164107|Experimental|Globe Mapping and Ablation System|
32921313|NCT05414409|No Intervention|Comparison of microbiome by BMI Category|The gut microbiome and metabolites of 42 lean and 42 obese youth with type 1 diabetes will be evaluated cross-sectionally.
32921314|NCT05414409|Experimental|Metformin|This is a group of 30 youth with type 1 diabetes and obesity who will receive metformin for 6 months.
32921315|NCT01597687|Experimental|Malaysia Group|Malaysian adults aged >19 years with prolonged cough of 2 weeks or more.
32921316|NCT01597687|Experimental|Taiwan Group|Taiwanese adults aged >19 years with prolonged cough of 2 weeks or more.
32921317|NCT01597687|Experimental|Thailand Group|Thailandese adults aged >19 years with prolonged cough of 2 weeks or more.
32719299|NCT05108506|Placebo Comparator|Strict need to void following surgery before discharge|Participants randomized to this arm will have a strict need to void following surgery before they are discharged.
32921318|NCT05405361|Experimental|Dose regimen 1|ARGX-117/Placebo IV
32921319|NCT05405361|Experimental|Dose regimen 2|ARGX-117/Placebo IV
32921320|NCT05154513||Cohort 1|Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.
32921321|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
32921322|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
32921323|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
33248589|NCT04014400|Experimental|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
32921325|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
33248590|NCT04014400|Active Comparator|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
33248591|NCT00566098|Experimental|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
33248592|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
33248593|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
32719300|NCT04548154|Experimental|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
32921326|NCT05388669|Experimental|Arm A: Lazertinib with Amivantamab SC-CF|Lazertinib 240 mg will be administered orally once daily. Participants will receive Amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 milligrams (mg)/ 2240 mg depending on the body weight by manual injection.
32921327|NCT05388669|Experimental|Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion|Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion.
32921328|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
32921329|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
32921330|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
32921331|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
32921332|NCT01662583|Experimental|Plain Text Message|plain text message reminder
32921333|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
32921334|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
32921335|NCT05141721|Experimental|Vaccine Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and after completing vaccine production screening, patients will receive a total of 6 administrations of GRT-C901/GRT-R902 plus ipilimumab co-administered only with the first dose of GRT-C901 and GRT-R902. All patients will receive atezolizumab in addition to maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
32921336|NCT05141721|Active Comparator|Control Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and undergoing vaccine production screening, patients will receive maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
32921337|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
32921338|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
33248594|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
33248595|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
33400046|NCT05226949||Cases|"54 newborns with neonatal HSV infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
33400047|NCT05226949||Controls|"108 newborns without infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Controls will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
32921339|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
32921340|NCT05139303|Experimental|MAD therapy|
32921341|NCT01694563|Other|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
32921342|NCT05373381|Experimental|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles.
32921343|NCT05125029|No Intervention|Placebo|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
32921344|NCT05125029|Active Comparator|10 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
32921345|NCT05125029|Active Comparator|20 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
32921346|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
32921347|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
32921348|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
32921349|NCT00382395|Experimental|1|SOLX Gold Shunt
32921350|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
32921351|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
32935820|NCT04732351||Active sentry|Cataract procedures conducted with the active Sentry handpiece
32921352|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
32921353|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
32921354|NCT04527237|Experimental|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
32921355|NCT04527237|Placebo Comparator|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
32921356|NCT02993185|Experimental|Your Move|Sex education intervention
32921357|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
32921358|NCT05367609|Other|Children undergoing Spine Fusion Surgery|"This arm will include approximately 300 children undergoing spine fusion surgery~Pharmacokinetic (PK): collection of 10-13 serial blood samples to determine serum levels of methadone/oxycodone and its metabolites~Pharmacogenetic (PG): Preoperative CYP2D6 genotyping (for preferential recruitment of CYP2D6 PMs and UMs). This will be collected in the pre-operative clinic via blood if there are clinical labs needed for standard of care. If no blood is needed in the pre-op clinic, the investigators will collect this via saliva.~Postoperative Analgesia Dose and PK Sampling Schedule:~Clinical care providers are blinded to CYP2D6/CYP2B6 when prescribing oxycodone/methadone; and genetic analysis of proposed targeted genes. Results of these samples will be used to determine personalized analgesia plan."
32921359|NCT01940510|Experimental|Healthy subjects|
32921360|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
32921361|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
32921362|NCT05735366|Experimental|Part1: Dose Escalation part|Patients will receive SAIL66 as a IV infusion at escalated doses.
32921363|NCT05735366|Experimental|Part2: Expansion part|Patients will receive SAIL66 as a IV infusion at the recommended dose.
32921364|NCT01601977|Experimental|Intervention|AVAPS-AE
32921365|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
32921366|NCT05364645|Experimental|Arm A (carboplatin, pemetrexed, selpercatinib)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also selpercatinib PO BID in the absence of disease progression or unacceptable toxicity.
32921367|NCT05364645|Active Comparator|Arm B (carboplatin, pemetrexed)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32921368|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
32921369|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
32719301|NCT04418986|Sham Comparator|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
32719302|NCT04418986|Active Comparator|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
32719303|NCT04418908|Active Comparator|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
32719304|NCT04418908|Placebo Comparator|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
32719305|NCT05399992||Inclisiran cohort|Participants prescribed inclisiran in combination with Standard of Care (SoC)
32719306|NCT05399992||SoC cohort|Participants prescribed standard of Care (SoC) only. Patients can be treated with maximum tolerated dose of statins and/or with add-on therapy with ezetimibe, PCSK9 inhibitors (alirocumab or evolocumab), fibrates, bempedoic acid or bile acid sequestrants, but not inclisiran.
32719307|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
32719308|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
32921370|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
32921371|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
32921372|NCT01602679|Experimental|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
32921373|NCT01602679|Placebo Comparator|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
32921374|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
32921375|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
32921376|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
32921377|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
32921378|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
32921379|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
32921380|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
32921381|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
32921382|NCT05735210|Experimental|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|Mean difference between the Polso™ Watch and reference measurement, and the associated standard deviation using data from the rest and induced change measurements following initialization
32921383|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
32921384|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
32921385|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
32921386|NCT05735132|Active Comparator|Line arm|Conventional line blocking is used in radial artery cannulation for local infiltration.
32921387|NCT05735132|Experimental|Bar arm|Bar-blocking is used in radial artery cannulation for local infiltration.
32921388|NCT05735132|Experimental|V arm|V-blocking is used in radial artery cannulation for local infiltration.
32921389|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
32921390|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
32921391|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
32921392|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
32921393|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
32921394|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
32921395|NCT05118633|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
32921396|NCT05118633|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull, as well as being asked to journal about their daily activities in an app.
33400048|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
33400049|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
32921397|NCT05362305|Experimental|Essential Coaching for Every Mother|Mothers in the intervention group will receive in-hospital education by a non-study nurse midwife while on the postnatal ward prior to discharge as per standard protocol on the unit. On the third day after birth, mothers will receive daily text messages to 6 weeks postpartum. The messages will be sent automatically each day based on the date of birth of the infant.
32921398|NCT05362305|No Intervention|Standard Care|Mothers will receive in-person education provided by a non-study nurse midwife while on the postnatal ward prior to discharge as per current standard protocol on the unit. Mothers in this group will not receive any further text messages from the program.
32921399|NCT02992093||obese with PCOS|all the indicators
32921400|NCT02992093||nonobese with PCOS|all the indicators
32921401|NCT02992093||PCOS with IGT|all the indicators
32921402|NCT02992093||PCOS with T2DM|all the indicators
32921403|NCT02992093||Healthy volunteers|all the indicators
32921404|NCT05358951|Active Comparator|NON-COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaires then be randomized to not receive additional coaching support sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
32935821|NCT04732351||Non-active sentry|Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
33400050|NCT05682313|Experimental|Elastography arm|single arm that includes all patient who have consented for ultrasound elastography
32921405|NCT05358951|Experimental|COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaire then be randomized to receive 2 individualized remote coaching sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
32921406|NCT05328297|Experimental|JNJ-55308942|Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.
32921407|NCT05328297|Placebo Comparator|Placebo|Participants will receive a matching placebo capsule once daily for 6 weeks.
32921408|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
32921409|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
32921410|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YXZ|Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
32921411|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZYX|Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
32921412|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XZY|Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
32921413|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YZX|Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
32921414|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZXY|Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days.
32921415|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XYZ|Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
32921416|NCT05106153|Experimental|Treatment Phase: Treatment Sequence ABFCED|Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
32921417|NCT05106153|Experimental|Treatment Phase: Treatment Sequence BCADFE|Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
32921418|NCT05106153|Experimental|Treatment Phase: Treatment Sequence CDBEAF|Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
32935822|NCT04738513|Active Comparator|Conventional preparation technique|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
33248596|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
33248597|NCT03743272||Liver condition|Participants who have a history of of liver disease
33248598|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
33248599|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
33248600|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
33248601|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
33248602|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
33248603|NCT04014088|Active Comparator|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
33248604|NCT04014088|Active Comparator|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
33248605|NCT00935194|Experimental|blank|do not take antiviral therapy
32719309|NCT04546126|Experimental|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
33248606|NCT00935194|Experimental|Oseltamivir|antiviral therapy
33248607|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
33248608|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
33248609|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
33248610|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
33248611|NCT00690378|Experimental|1|NXL/104 ceftazidime
33248612|NCT00690378|Active Comparator|2|comparator 4 x daily
32921419|NCT05106153|Experimental|Treatment Phase: Treatment Sequence DECFBA|Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
32921420|NCT05106153|Experimental|Treatment Phase: Treatment Sequence: EFDACB|Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
32921421|NCT05106153|Experimental|Treatment Phase: Treatment Sequence FAEBDC|Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
33248613|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
32921422|NCT01606735|Experimental|Dose 1|
32921423|NCT01606735|Experimental|Dose 2|
32921424|NCT01606735|Experimental|Dose 3|
32921425|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
32921426|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
32921427|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
32921428|NCT05100459|Experimental|Pasture-raised whey protein|whey protein from strictly grass fed cows
32921429|NCT05100459|Experimental|Conventional whey protein|whey protein from conventional animal feeding operation
32921430|NCT05100459|Placebo Comparator|Placebo|Maltodextrin given in iso-caloric amounts to protein
32921431|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
32921432|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
32921433|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
32921434|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
32921435|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
32921436|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
32921437|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
32921438|NCT00000387|Active Comparator|A,2,III|Regular treatment
32921439|NCT05095311|Experimental|Experimental group|This subset of 8 individuals will complete all 3 experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents, 2) a placebo pill and nedocromil sodium (4 mg), or 3) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion. This group will be composed of individuals who have a high histamine response to intense exercise.
32921440|NCT05095311|Placebo Comparator|Control-only group|This subset of 4 individuals will complete one of the experimental study visits, and will ingest either a placebo pill and placebo inhaler contents. This group will be composed of individuals who have a low histamine response to intense exercise.
32921441|NCT05095311|No Intervention|Selection pool|Twenty-six total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (8 experimental, 4 control-only) will be a subset of the initial 26. The other 14 participants will not take part in further study.
33248614|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
32719310|NCT04762498|Experimental|Pegloticase 16mg cohort|16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
32719311|NCT04762498|Experimental|Pegloticase 24/32mg cohort|24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
32719312|NCT04527328|Experimental|AKST1210|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
32719313|NCT04527328|Sham Comparator|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
32719314|NCT05397808|Experimental|pilates group|Pilates training will be held for eight weeks, two days a week for 1 hour. The investigators divided the individuals in the pilates exercise group into groups of 12 or 13 to verify whether they did the exercises correctly. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises, and 15 minutes of cooling and stretching exercises was arranged for the pilates group. The activities were performed in ten repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during postpartum will be used in the training.
32921442|NCT01922336|Experimental|SB2|SB2 (Study drug)
32921443|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
32921444|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
32921445|NCT01608061|Experimental|DBS-f on|DBS-f on
32921446|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
32935823|NCT04738513|Experimental|Vertical preprartion|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using Vertical preparation technique.
32935824|NCT04338854|Experimental|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
33248615|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
33400051|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Test treatment~Reference treatment"
32921447|NCT05092269|Experimental|Ustekinumab|Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.
32921448|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
32921449|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
32921450|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
32921451|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
32921452|NCT04330755|Placebo Comparator|Group C|Control group will received saline
32921453|NCT04330755|Active Comparator|Group L|Levosimendan group will received levosimendan infusion
32921454|NCT04330755|Active Comparator|Group M|Levosimendan and Magnesium sulphate group will received both drugs
32921455|NCT04366323|Experimental|Experimental|
32921456|NCT04366323|No Intervention|Control|
32921457|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
32921458|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
32921459|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
32921460|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
32921461|NCT04713111|Other|Lifestyle Intervention Group (Exercisers)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace, 2 or more times a week for a duration of 4 weeks."
32921462|NCT04713111|Other|Lifestyle Intervention Group (Meditators)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks."
32921463|NCT04713111|No Intervention|Garmin wearable arm|Existing stress and recovery participants were invited to participate in a Garmin wearable arm where they were provided a Garmin Vivoactive 4 smartwatch to wear continuously, and in particular, while they were on shift at work for a total of 4 consecutive weeks.
32921464|NCT04713111|No Intervention|Hair cortisol arm|Interested existing stress and recovery participants were invited to participate in a one time hair sample collection for cortisol analysis.
32921465|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
32921466|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
32935825|NCT04338854|Experimental|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
33248616|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
33248617|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
33248618|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
33248619|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
32766991|NCT04886765|Experimental|ALMB-0168|"Dose Escalation Cohort ：The accelerated titration and traditional 3+3 design will be used in the dose-escalation phase. Seven dose cohorts will be evaluated. ALMB-0168 will be administered intravenously once every 3 weeks until either the disease progresses or intolerable toxicity occurs.~Dose Expansion Cohort: Based on the results of Part I, 1-3 dose expansion cohorts will be started to further evaluate the safety and efficacy of ALMB-0168."
32766992|NCT04896671|Experimental|Intervention group|Each participant joins a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes.
33248620|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
33248621|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
33248622|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
33248623|NCT00935350|Placebo Comparator|2|White bread and milk control
33248624|NCT00935350|Placebo Comparator|3|Granola control
33248625|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
33248626|NCT00935350|Placebo Comparator|5|White rice control
33248627|NCT00935350|Placebo Comparator|6|Fruit yogurt control
32766993|NCT04896671|No Intervention|Waitlist control group|They receive no treatments.
33248628|NCT00935350|Placebo Comparator|7|Turkey dinner control
33248629|NCT00935350|Experimental|8|Granola
32766994|NCT04396847|Experimental|Lorcaserin first, then placebo|Participants first receive lorcaserin (10 mg BID) for 7 days. After a washout period of 7 days, they then receive placebo tablets (BID) for 7 days.
32766995|NCT04396847|Placebo Comparator|Placebo first, then lorcaserin|Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
32766996|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
32766997|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
32766998|NCT04886375|Active Comparator|esp group|The investigators performed erector spina plane block to that patient group for postoperative analgesia
32766999|NCT04886375|Active Comparator|pecs group|The investigators performed modified pectoral nerve block to that patient group for postoperative analgesia
32767000|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 1 default|Receiver-in-canal hearing aid with current default compression strategy
32767001|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 2|Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
32767002|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 1|Receiver-in-canal hearing aid with modified compression strategy 1
32767003|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 2|Receiver-in-canal hearing aid with modified compression strategy 2
32767004|NCT04882709|No Intervention|No device|Stimuli recordings without hearing aid
32767005|NCT04896359|Experimental|Vitamin C|i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery
32767006|NCT04896359|Placebo Comparator|Control|i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery
32767008|NCT04896047|Experimental|CKD patients|Patients with CKD, non-diabetic, without a history of renal transplantation, without digestive pathology, aged 18 to 70 and an estimate of the glomerular filtration rate (eGFR) <60 ml / min / 1.73m2 according to the formula of CKD-EPI.
32767009|NCT04896047|Active Comparator|Haemodialysis patients|Patients on hemodialysis, for more than 3 months, with no history of kidney transplantation, without digestive pathology, aged 18 to 70 with a BMI between 18 and 30 kg / m2
32767010|NCT04896047|Active Comparator|Healthy volunteers|Healthy volunteers (controls) recruited from the population of living kidney donors
32767011|NCT04896203||Group 1|Ulcerative Colitis or Crohn's Disease patients, in remission according to inclusion criteria
32767012|NCT04896203||Group 2|Ulcerative Colitis or Crohn's Disease patients, with activity defined by the inclusion criteria
32767013|NCT04895891|Experimental|EOS imaging|For each patient, EOS images are compared with computed tomography [CT] images
32767014|NCT04896125||Lumigan PF|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
32767015|NCT04896125||Xalatan|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.005% latanoprost (containing 0.02% BAK as a preservative) (Xalatan, Pfizer, NY, USA).
32767016|NCT04896125||Control|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
32767017|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
33248630|NCT00935350|Experimental|9|Cornflakes and milk
33248631|NCT00935350|Experimental|10|White Rice
33248632|NCT00935350|Experimental|11|Fruit yogurt
33248633|NCT00935350|Experimental|12|Turkey dinner
33248634|NCT00935350|Placebo Comparator|13|White Bread
33248635|NCT00935350|Placebo Comparator|14|White bread
33248636|NCT00935350|Experimental|15|Granola
33248637|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
33248638|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
33248639|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
33248640|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
33248641|NCT00839943|Active Comparator|ozone|obese vs non-obese women
32921467|NCT04713189|Experimental|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
32921468|NCT04713189|Experimental|Placebo|Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
32921469|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
32921470|NCT04712955|Active Comparator|Bloodflow restricted exercise|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRRE) conducted as 4 sets of bilateral knee extensions at 30% of 1RM until voluntary fatigue. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
32921471|NCT04712955|No Intervention|Non-exercise control|No intervention.
32921472|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
32921473|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
32921474|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
32921475|NCT00382473|Experimental|exercise|
32921476|NCT05326893|Experimental|Study Group|"Femoral nerve neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
32921477|NCT05326893|Placebo Comparator|Placebo Group|"Femoral nerve placebo neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
32921478|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
32921479|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
32921480|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
32921481|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
32921482|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
32921483|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
32921484|NCT02992561|Active Comparator|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
32921485|NCT02992561|No Intervention|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
32921486|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
32921487|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
33248642|NCT00839943|Active Comparator|air|obese vs non obese women
33248643|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
33248644|NCT00746382|Placebo Comparator|2|Placebo cream
32921488|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
32921489|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
32921490|NCT05322135|Experimental|PET scan|PET scans: an 11C-Glutamine PET scan and an 18F-FSPG PET scan. A small tube (called an IV) will be placed in a vein in your arm through which you will receive the radioactive material for the PET scan(s).
32921491|NCT01924988|Experimental|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
32921492|NCT05320263|Experimental|contact aspiration first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by contact aspiration
33248645|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
33400052|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Reference treatment~Test treatment"
32921493|NCT05320263|Sham Comparator|Stent retriever first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by Stent retriever
33400053|NCT05075161|Experimental|Pirfenidone|Patients randomized to Pirfernidone Group will receive tables of 267 mg
33400054|NCT05075161|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive 5 ml of Water
32719315|NCT05397808|Active Comparator|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
32719316|NCT04747288||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG). Exclusion Criteria: NA.
32719317|NCT04747288||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 and 1997 revised Systemic lupus erythematosus criteria. Exclusion Criteria: NA.
32719318|NCT04747288||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min. Exclusion Criteria: NA.
32767018|NCT04895657|Other|Piperacillin/Tazobactam Intermittent infusion|4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.
32767019|NCT04895657|Other|Piperacillin/Tazobactam Continuous infusion|4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.
32767020|NCT04885673|Active Comparator|Group A (High flow nasal cannula group)|(Vapotherm) will be used during the bronchoscopy time flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
32767021|NCT04885673|Active Comparator|Group B (Apeieoc oxygenation group)|The standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
32767022|NCT04895423|Experimental|Group №1: Methotrexate therapy|
32767023|NCT04895423|Experimental|Group №2: Mycophenolate mofetil therapy|
32767024|NCT04895423|Experimental|Group №3: Cyclosporine therapy|
32767025|NCT04895423|Experimental|Group №4: Dupilumab therapy|
32767026|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
32767027|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
32767028|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
32767029|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
32767030|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
32767031|NCT04882163|Experimental|CC-220 + Polatuzumab vedotin + rituximab- Cohort A|Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
32767032|NCT04882163|Experimental|CC-220 + Tafasitamab- Cohort B|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
32767033|NCT04882163|Experimental|CC-220 + Rituximab + Chemo (Cohort C)|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
32767034|NCT04882163|Experimental|CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)|Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
32767035|NCT04882163|Experimental|CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E|Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
32767036|NCT04882163|Experimental|CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)|Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
32767037|NCT04882007|Experimental|OSE-127 High dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
32767038|NCT04882007|Experimental|OSE-127 Low dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
32767039|NCT04882007|Placebo Comparator|Placebo induction phase|Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
32767040|NCT04882007|Experimental|OSE-127 High dose optional extension phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
32767041|NCT04885751|Experimental|eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
32767042|NCT04885751|Active Comparator|rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
32767043|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
32767044|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
32921494|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
32719319|NCT04747288||non AIDDES Healthy Controls|Non AIDDES Healthy Controls were enrolled with inclusion criteria: (1) aged between 20 and 75 years; (2) without any Chronic disease. Exclusion Criteria: any Sjögren's syndrome, Systemic lupus erythematosus, or Dry eye syndrome.
32719320|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
32719321|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
32719322|NCT05394844|Active Comparator|CGM with DM education|if you are in the intervention group you will received culturally tailored diabetes education and use a Real Time CGM device to see your glucose over 12 weeks. Both group will completed blinded CGM at the beginning of the study and at 24 weeks
32719323|NCT05394844|No Intervention|Education only|If you are in the control group your will receive culturally tailored diabetes education and wear a blinded prior to education and after education sessions complete and 24 weeks
32921495|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
32921496|NCT05734742|Experimental|Video|
32921497|NCT04502433|No Intervention|Control cohort|"Approximately 28 patients will be included in this main control cohort.~The above-mentioned control cohort population will continue receiving the SoC"
32921498|NCT04502433|Experimental|Poractant alfa treated cohort|42 patients will be treated with CUROSURF® (poractant alfa).
32921499|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
32921500|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
32921501|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~1st Group/Cohort - ST elevation myocardial infarction"
32921502|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
32921503|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
32921504|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
32921505|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
32921506|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
32921507|NCT05069961|Active Comparator|ESPB Group|20ml Ropivacaine is injected near the nerves in the back and then continued using an infusion pump.
32921508|NCT05069961|Active Comparator|TEA Group|5ml Bupivacaine is injected into the space around the spinal cord and then continued using an infusion pump.
32921509|NCT05734664|Experimental|Scan with Pulsify sensor|A trained operator will perform on each volunteer two scans with the Pulsify sensor. Both scans will have a different orientation of the sensor.
33400055|NCT05073055|Active Comparator|Group SA|Group 1 (SE) (n = 35): patients undergoing spinal anesthesia of patients in our hospital to do unilateral inguinal hernia operation. Block application and the times when the sensory block reaches the T10 level are recorded. Surgery is allowed in patients who develop sensory block at the T10 level. During our study, no changes will be made to the procedure described above, which is standardized during our study, only patient data will be recorded observationally. Patients who do not have sufficient sensory block to start the procedure despite waiting 10 minutes will be registered and excluded from the study and additional anesthesia will be applied.
32719324|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
32921510|NCT05734664|Experimental|Scan with state-of-the-art ultrasound equipment|Immediately after acquisition with the Pulsify sensor, an echocardiographist will record a complete 2D and 3D ultrasound data set using a state-of-the-art equipment.
32921511|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
32921512|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
32935826|NCT04338854|Experimental|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
32921513|NCT05734586|Other|DYSPHAGING Interventional group|"Step 1: delivery of the EAT-10 questionnaire for swallowing disorders screening;~Step 2: in case of EAT≥2 score, immediate implementation of upper airway protection measures in 3 areas:~1: Postural adjustments; 2 : Hygienic and dietary rules ; 3: Food textures The hypothesis is that allied health professionals in acute geriatric wards, rehabilitation units, and Long Term Care Units are able to implement the current recommendations for screening for sarcopenic dysphagia and to implement preventive measures but in a systematic way.~Patient characteristics will be collected at each site at the end of the study by a clinical research assistant based on their medical records.~At the end of the study, each allied health professionals who has been involved in the care of at least one patient will fill out a satisfaction questionnaire."
32921514|NCT05066607|Experimental|Single-stage|"Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and Dexamethasone 10-20 mg weekly on days 1, 8, 15 and 22.~Each cycle will be of 28 days duration. During cycle 1, Isatuximab will be administered weekly on days 1, 8, 15, and 22 then days 1 and 15 in subsequent cycles from cycle 2 to 9 or 12.~For each individual patient, the treatment period will be 12 months, unless CR at the completion of 9 cycles, disease progression or unacceptable toxicity occurs. The duration of follow-up for overall survival will be 1 year after the last patient enters overall survival follow-up."
32921515|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
32921516|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
32921517|NCT04499547|Experimental|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
32921518|NCT04499547|No Intervention|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
32921519|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
32921520|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
32921521|NCT05045625|Experimental|Study Group|Twelve patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
32921522|NCT05297409||Hyperkalemia patient with Chronic kidney disease|
32921523|NCT05297409||hyperkalemia patient with heart failure|
32921524|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
32921525|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
32921526|NCT01675297|Active Comparator|Risedronate|Sedron tablet: one tablet once a week for 12months
32921527|NCT05295537|Active Comparator|PERCUTANEOUS LIVER BIOPSY (PLB)|Patients randomized to percutaneous liver biopsy.
32921528|NCT05295537|Experimental|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS - LB)|Patients randomized to EUS-guided liver biopsy
32921529|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
32921530|NCT05294289||PROS patients treated with alpelisib|Patients with PROS who receive treatment with alpelisb
32921531|NCT05294289||PROS patients not treated with alpelisib|Patients with PROS who don't receive treatment with apelisib
33248646|NCT04060368|Experimental|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
33248647|NCT04060368|Active Comparator|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
33248648|NCT00828867|Experimental|Cohort 1|100mg
33248649|NCT00828867|Experimental|Cohort 2|200mg
33248650|NCT00828867|Experimental|Cohort 3|400mg
32719325|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
33248651|NCT00828867|Experimental|Cohort 4|800mg
33248652|NCT00828867|Experimental|Cohort 5|1500mg
33248653|NCT00828867|Experimental|Cohort 6|2000mg
33248654|NCT00828867|Experimental|Cohort 7|800mg with food
33248655|NCT00828867|Experimental|Cohort 8|3000mg
33248656|NCT00828867|Experimental|Cohort 9|4000mg
33248657|NCT00746460|Experimental|A|Behavioral
33248658|NCT00567112|Experimental|DFC (fasted)|
33248659|NCT00567112|Experimental|OCT (fasted)|
33248660|NCT00567112|Experimental|OCT (after meal)|
33248661|NCT00567112|Active Comparator|OCT (before meal)|
33248662|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
33248663|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
32767045|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
32767046|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
32767047|NCT04885517|Experimental|Spontaneous breathing, Venturi Mask FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 0.5 (Venturi Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767048|NCT04885517|Experimental|Spontaneous breathing, Non Rebreathing Mask, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767049|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767050|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, supine decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during supine decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767051|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, prone decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during prone decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767052|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767053|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (12 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767054|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
32767055|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
32767056|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
32767057|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
32767058|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
32767059|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
32767060|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
32767061|NCT04400981|Experimental|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.~Patients randomized to remote ischemic conditioning will also receive standard medical therapy"
32767062|NCT04400981|Active Comparator|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
32767063|NCT04895345|Experimental|TQB2450+Intensity modulated radiotherapy|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.
32767064|NCT04885361|Experimental|Arm 1 injection|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
32767065|NCT04885361|Experimental|Arm 2 injections separated by 21 days|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
32767066|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
32767067|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
32767068|NCT04894955|Experimental|Main study group|
32767069|NCT04881695||Patients|Women aged 18-26 years with congenital (Turner syndrome or other determined or undetermined genetic cause) or acquired (post-therapeutic)
32767070|NCT04881695||Controls|Women aged 18-26 years who do not have a condition that compromises their fertility
32767071|NCT04885439|Experimental|NextSteps Intervention|Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.
32767072|NCT04885439|No Intervention|Usual Medical Care|UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.
32719326|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
32719327|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
32719328|NCT04822636|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
32719329|NCT05304910|Experimental|Lu AG09222 Low Dose|Participants will receive a single dose of Lu AG09222 by subcutaneous (SC) injection on Day 1.
32719330|NCT05304910|Experimental|Lu AG09222 High Dose|Participants will receive a single dose of Lu AG09222 by SC injection on Day 1.
32719331|NCT05304910|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching LU AG0922 by SC injection on Day 1.
32719332|NCT04821934|Experimental|Telerehabilitation (TR) at home + Telesurveillance program (TSu)|These COVID-19 patients will enter the usual telesurveillance program together with a specific remote rehabilitation program on exercise activity.
32719333|NCT04821934|Active Comparator|Telesurveillance (TSu) alone|These COVID-19 patients will enter the usual remote telesurveillance program
32719334|NCT04466501|Experimental|ACR LAB for Professional User|
32719335|NCT04821778|Placebo Comparator|Definitive Chemoradiation|This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
32719336|NCT04821778|Experimental|Chemoradiation Combined With Immunotherapy/targeting agents|This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
32719337|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
32719338|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
32719339|NCT04831450|Experimental|Cemiplimab After CRT in HNSCC|Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.
32719340|NCT04831216|Experimental|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
32719341|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
32719342|NCT04830982|Experimental|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
32719343|NCT04830982|Placebo Comparator|Placebo|Placebo as additive to hypothermic hyperkalemic cardioplegia.
32719344|NCT04821544|No Intervention|Control|Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.
32719345|NCT04821544|Experimental|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
32719346|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
32719347|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
32719348|NCT04821466|Experimental|Virtual Reality Headset|VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
32719349|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
32719350|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
32719351|NCT05341882||Mindfulness|The seven weekly sessions teach veterans how to use mindfulness techniques in everyday life and when dealing with stress and negative emotions related to moral injury.
32719352|NCT05341882||Educational Support|As an active control condition, we developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
32719353|NCT04466423|Experimental|Small group intervention|Those randomized to the immediate intervention arm will be asked to meet approximately every other week for 6 months, covering 12 sessions. We will ask each group to meet in a relatively private setting (e.g., a restaurant near campus or a reserved meeting room), rather than more public spaces (e.g. river room, cafeteria) where interruptions are more likely.
32719354|NCT04466423|Placebo Comparator|Control|"Participants randomized to Arm 2 (delayed intervention) will be wait listed to begin sessions 6 months after the start of the study. This participation will be optional."
32719355|NCT04466033|Experimental|Magneto Microcatheter|
32767073|NCT04410809|Placebo Comparator|Placebo|The same composition as the active medication but without the active substance TA-46
32719356|NCT05302804|Experimental|Menthol gel application|Menthol gel will be applied to the skin prior to exercise in the heat
32719357|NCT05302804|Placebo Comparator|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
32719358|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
33400056|NCT05073055|Active Comparator|Group ESP+TA|Group 2 (Errector spina block + TA) (n = 35): 2% lidocaine hydrochloride (10 mg / ml) 15 ml, 0.5% bupivacaine hydrochloride (20 mg / ml) 15 ml, serum 8.4% Sodium Bicarbonate 5 ml to be used for each patient before the operation in order to apply the erectile spina block block with tumescent anesthesia. Adding adrenaline tartrate (5 μg / mL) to 5 ml with saline, a total of 40 ml of mixture was prepared. Hydrodissection was achieved using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle on the Transverse Process of L1. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
33400057|NCT05518903|Experimental|Diagnostic (gallium GA 68 FAPi-46, PET/CT)|Patients receive 68Ga-FAP-46 IV, then allow 60 minutes for 68Ga-FAPI-46 uptake. Patients then undergo PET/CT scans over 30 minutes at baseline (before SOC therapy), up to 2 scans approximately 8 weeks apart (at SOC re-staging visits), and a then a scan within 4 weeks of SOC surgical resection, if applicable.
33400058|NCT05065957|Experimental|Phase IIa:Dose-Finding Stage|"Level -5: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -4: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -3: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -2: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level 1: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg TS-1).~Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg TS-1)."
33400059|NCT05065957|Active Comparator|Phase IIb/III: Dose Expansion Stage|"ASC+ D07001-softgel capsules plus Xeloda (or TS-1)~ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)"
33400060|NCT05141227|Experimental|two stage ORIF|Two-stage Open reduction and internal fixation
32767074|NCT04410809|Experimental|TA-46|Decoy protein of the fibroblast growth factor receptor 3
32767075|NCT04894565|Experimental|intervention|effect of rehabilitation program in the intervention arm
32767076|NCT04881851|Experimental|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
32767077|NCT04881851|Experimental|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
33400061|NCT05141227|Experimental|single stage Ex. Fix|Single-stage external fixation with minimal internal fixation if needed
33400062|NCT05518357|Experimental|LILRB4 STAR-T|LILRB4 STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 25-30mg/m2/day and cyclophosphamide treatment at dose 250-300mg/m2 for 3 days and take a rest for 2 days before infusion. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg
33400063|NCT05140837||cross-sectional study|
33400064|NCT05140837||real-world cohort study|
33400065|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
32767078|NCT04881851|Placebo Comparator|Folic acid|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
32767079|NCT04872335|Experimental|Gong's Mobilization|Subjects received gong's mobilization three times in a week for 4 weeks.
32767080|NCT04872335|Experimental|Gradually Graded Exercise Therapy|Subjects received gradually graded exercise therapy three times in a week for 4 weeks.
32767081|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
32767082|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
32767083|NCT04871789||Patients with severe COVID-19 pneumonia|
32767084|NCT04871789||Patients who had an asymptomatic COVID-19 3 months ago|
32767085|NCT04871789||People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick|
32767086|NCT04881305||Cases|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, with cognitive/emotional complaints.
32767087|NCT04881305||Controls|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, reporting no cognitive/emotional complaints.
32767088|NCT04871633|Active Comparator|Remdesivir|patients having drug Remdesivir in addition to conventional treatment according to disease grade (steroids, anticoagulants, antibiotics if needed, oxygen therapy, paracetamol, antihistamine)
32767089|NCT04871633|Other|Conventional|patients having Standard Conventional therapy only.
32767090|NCT04881071|Experimental|Scarf|
32767091|NCT04881071|No Intervention|Usual clinical practice|
32767092|NCT04880915|Experimental|SMOKE PROTECTION|Pre- and post-operative blood and urine samples of the surgical team (surgeon, surgical resident, anaesthesiologist, scrub nurse, circulating nurse, support staff and researcher), who worked in the standard practice, and the use of four different preventive measures that may affect the surgical smoke exposure during total mastectomy surgery in the operating room of the General Surgery Department of a University HospitaL. The surgical resident, anaesthesiologist, anaesthesia technician and support staff included in the study did not consist of the same people due to the change in the work schedules. Blood and urine samples were collected from a team of seven people before and after surgery [7 volunteers × 2 (blood and urine before and after surgery) = 14 (14 blood analysis + 14 urine analysis) 14 × 5 surgery = 70 (70 blood analysis + 70 urine analysis)].
32767093|NCT04880993|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
32767094|NCT04880993|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
32719359|NCT04145440|Experimental|MOR202 - Cohort 1|Patients with newly diagnosed or relapsed membranous nephropathy
32719360|NCT04145440|Experimental|MOR202 - Cohort 2|Patients with membranous nephropathy refractory to immunosuppressive treatment
32719361|NCT04062305|Experimental|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
32719362|NCT04722250|Experimental|Medtronic Self-Expanding TAV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
32719363|NCT04722250|Experimental|Edwards Balloon-Expandable THV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
32719364|NCT04514848|Experimental|Individuals accessing screening for syphilis and HIV|Individuals at risk for syphilis and HIV (e.g. gay and bisexual men, indigenous communities experiencing a resurgence of syphilis, persons who inject drugs, etc) will undergo testing with both POCT and standard laboratory testing. Individuals testing positive for syphilis or HIV on the POCT will be informed that this is a preliminary positive and standard testing will be done. Individuals testing positive for syphilis on POCT may be offered treatment at the time of testing.
32719365|NCT04508764|No Intervention|Usual Care|"For approximately the first 6 months of the study, or until 75 patient with cancer who is initially approached in clinic (probands) are enrolled, the investigators will be enrolling probands into the Usual Care group. During this time, the investigators will clarify usual care regarding cascade genetic testing for each participating clinic and proband participant. The investigators will do this by proband participant surveys, as well as initial provider semi-structured interviews.~Proband: Complete Cascade Genetic Testing survey. The survey will also contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. At 6 months, there will be a follow-up survey~Family Member: Complete survey at study entry and at 6 month follow-up"
32719366|NCT04508764|Experimental|FACT Toolkit (FACTT)|"Proband: Introduced to FACTT and will complete Cascade Genetic Testing survey. The survey will contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. The probands will also fill out assessments of each FACTT component. At 6 months, there will be a follow-up survey.~Family Member: Introduced to FACTT and will complete surveys at study entry and 6 month follow-up. They will also fill out assessments of each FACTT component"
32719367|NCT04508140|Experimental|Single Arm|The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
32719368|NCT04829188|Active Comparator|Structured Telephone Support (STS)|Post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care provider (PCP) within seven days post-discharge.
32719369|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Standard Response Team (RPM-Low, Standard Team)|Questions are pushed to members patients times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
32719370|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Standard Team (RPM-High, Standard Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
32719371|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Enhanced Team (RPM-Low, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
32719372|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Enhanced Team (RPM-High, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans.Team members (e.g., CRNP, social workers, nurses) address RPM triggers, meet with the patient three times, pharmacy review, develop care plans, and discuss advance directives).
32719373|NCT03323944|Experimental|Cohort 1: huCART-meso cells via intravenous infusion (IV).|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells on day 0 via intravenous infusion.
32767095|NCT05183243|Experimental|Monotherapy Dose Escalation.|Treatment with GH21 alone, conducted until disease progression, intolerance or end of study.
32767096|NCT04871555||mesio-temporal epilepsy|patients suffering from mesiotemporal epilepsy type
32719374|NCT03323944|Experimental|Cohort -1: low dose huCART-meso cells via intravenous infusion|In the event that 2 DLTs occur among subjects enrolled in Cohort 1, then enrollment in Cohort 1 will be stopped and the dose will be de-escalated by 10-fold to 1-3x10^6 cells/m2. Subjects will receive a single dose of 1-3x10^6 cells/m^2 lentiviral transduced huCART-meso cells on day 0.
32719375|NCT03323944|Experimental|Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)|Permanently closed
32921532|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
32921533|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
32921534|NCT05041803|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
32921535|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
32921536|NCT05041257|Experimental|Mirvetuximab Soravtansine|Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
32921537|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
32921538|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
32719376|NCT03323944|Experimental|Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Permanently closed
32719377|NCT03323944|Experimental|Cohort 4 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Cohort inclusion will allow for the administration of lentiviral transduced huCART meso cells during first line standard of care chemotherapy. Subjects will receive a single dose of of 1-3x10^7 cells/m^2 lentiviral transduced huCART-meso cells on day 0 following a minimum 1 week washout from standard care chemotherapy
32719378|NCT04820452|Experimental|cohort 1 IBI302 treated with high dose level of IBI302|Drug: IBI302 4mg/eye;Intraocular injection
32921539|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
32921540|NCT05505890||SFIPB|"suprainguinal fascia iliaca plane block with 50ml of %0.25 bupivacaine will be used for postoperative analgesia~."
32921541|NCT05505890||control|Fascia iliac block will not be applied to this group. Postoperative analgesia will be provided with other analgesia modalities.
32921542|NCT04748744||Patients undergoing colorectal surgery|
32921543|NCT05734430||GAP Social|Individuals ages 18+ years with an appendix cancer diagnosis in the United States.
32921544|NCT05734430||GAP Vanderbilt|Individuals ages 18+ years with an appendix cancer diagnosis seen at Vanderbilt.
32921545|NCT05734430||GAP Parent|Biological parents of active GAP (Social and Vanderbilt) Study participants.
32921546|NCT05733884|Experimental|Daily Disposable Multifocal Soft Contact lenses, PEGAVISION, Taiwan|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
32921547|NCT05733884|Active Comparator|Omafilcon A, dual-focus optical design, USA|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
32921548|NCT05733572|Experimental|active treatment group|active drug treatment group
32921549|NCT05733572|Placebo Comparator|placebo group|pacebo group
33400066|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
32719379|NCT04820452|Active Comparator|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
33400067|NCT05095831||Suspicion of solid neoplastic lesion|Patients with high suspicion of solid pancreas neoplasia: carcinoma, intrapapillary mucinous neoplasia (IPMN), neuroendocrine tumor, lymphoma, or intrapancreatic metastasis; based on CT/MR.
32921552|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
32935827|NCT04338854|Experimental|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
33400068|NCT05095831||Suspicion of a solid inflammatory lesion|Patients with high suspicion of solid inflammatory lesions: acute, chronic, or autoimmune pancreatitis; based on CT/MR.
32719380|NCT04820452|Experimental|cohort 1 IBI302 treated with low dose level of IBI302|Drug: IBI302 2mg/eye;Intraocular injection
32719381|NCT05298202|Experimental|Capsaicin gel application|Capsaicin gel will be applied to the skin prior to exercise in the heat
32719382|NCT05298202|Placebo Comparator|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
32719383|NCT05327920||Participants Receiving Upadacitinib|Participants receiving upadacitinib for Rheumatoid Arthritis
32719384|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
32719385|NCT05224726|Experimental|PRP Treatment|PRP preparation will be applied on uterine incision after its closure.
32719386|NCT05224726|No Intervention|Control|Normal Cesarean delivery stages.
32719387|NCT04458922|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on ay 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and undergo biopsy and collection of blood samples on study.
32719388|NCT04809064|Experimental|Arthroscopic Bankart repair with remplissage of Hill-Sachs lesion/rehabilitation|Arthroscopic Bankart repair surgery with remplissage of Hill-Sachs lesion and post-operative rehabilitation.
32719389|NCT04809064|Experimental|Open Bankart/rehabilitation|Open Bankart surgery and post-operative rehabilitation.
32921553|NCT05276973|Experimental|Treatment (paclitaxel, carboplatin, ipatasertib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ipatasertib PO QD until 24 hours before surgery in the absence of disease progression or unacceptable toxicity.
32921554|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
32719390|NCT04809064|Experimental|Latarjet/rehabilitation|Latarjet surgical procedure and post-operative rehabilitation.
32719391|NCT03262558||Patients with ECC|No intervention
32921555|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
32921556|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
32921557|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
32921558|NCT05039307|Experimental|Intervention group (Educational and motivational strategy)|The intervention group will be provided with a multi-component intervention entailing the following components distributed over the 24-months study: 4 individualized education sessions at the household, 4 group activities (2 group education sessions and 2 physical activity sessions) at the healthcare center, and 4 focus groups at the healthcare center as well. The motivational components of goal setting and the use of a pedometer will be incorporated in the individualized education sessions. Moreover, community activities will be incorporated in the second year of the study after exploring whether the activities are feasible and acceptable by the community. The topics covered by the intervention are healthy diet, physical activity, weight control strategies and knowledge and awareness of T2DM and GDM. Additionally, at baseline participants will be provided with a healthy lifestyle brochure with general recommendations.
32921559|NCT05039307|No Intervention|Comparison group (Basic educational strategy)|The comparison group will be limited to receive the healthy lifestyle brochure with general recommendations at baseline only.
32719392|NCT05327452|Experimental|Supervised aerobic and resistance exercise (SUP)|"Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
33400069|NCT05095831||Control group|Patients without a history of any type of solid or hematologic malignancy, hepato-pancreato-biliary disease (including fatty liver and pancreas disease), tobacco/alcohol habits, or morbid obesity with bariatric surgery criteria; who require EUS evaluation (e.g., suspicious of a subepithelial lesion in the context of chronic dyspepsia).
33400070|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
33400071|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
32719393|NCT05327452|Experimental|Unsupervised aerobic and resistance exercise (UNSUP)|"Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
32719394|NCT05327452|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
32719395|NCT05325034|Active Comparator|Early intervention|Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.
32719396|NCT05325034|Other|Late intervention|Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.
32719397|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
32719398|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
32719399|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
32719400|NCT04827238||Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement|Patients who have an echocardiographic transaortic mean gradient ≥ 20mmHg OR VARC-3 criteria for ≥ moderate hemodynamic valve deterioration post TAVR on any TTE > 1 month post-TAVR
32719401|NCT05323552||Hernia repair with laparoscopic TEP approach without curare and without orotracheal intubation.|Patients will undergo laparsocopic TEP hernia repair without curare and without orotracheal intubation.
32719402|NCT04036708|Experimental|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
32719403|NCT04036708|Active Comparator|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
32742929|NCT04960761|Experimental|Intervention Group|Pre-operative training will be given by the clinic nurse with audio and picture book. Training content with audio and picture book; Before the operation, the procedures performed during the admission of the patient to the service (introducing the clinic and staff to the patient), what are the preoperative preparations (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown), wearing a patient tag on the wrist, taking him to the operating room on a stretcher), which will be used during the operation anesthesia techniques and how to provide sedation (the anesthetic agent can be given by mask or IV catheter, the reasons are the clothes worn by doctors and nurses in the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.).
32719404|NCT04194970|Experimental|Group I (monitoring with live-feedback system)|WBM smart insole system is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the WBM smart insole system in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with WBM smart insole system. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with WBM smart insole system during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
32767097|NCT04871555||basal temporal epilepsy|patients suffering from basal temporal epilepsy type
32767098|NCT04871555||temporal lateral epilepsy|patients suffering from temporal lateral epilepsy type
32767099|NCT04871555||operculo insular epilepsy|patients suffering from operculo insular epilepsy type
32767100|NCT04871555||temporo-insular epilepsy|patients suffering from temporo- insular epilepsy type
32767101|NCT04871555||healthy subjects|non epileptic patients
32767102|NCT05139251|Experimental|Recovering from Intimate partner violence through Strengths and Empowerment (RISE) +ePALS|
32767103|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
32767104|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
32767105|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
32767106|NCT04430231||Wait list time > 6 weeks|Wait list time > 6 weeks
32767107|NCT04936997|Experimental|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
32767108|NCT04880525|Experimental|Study Group|The study group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). In addition to pilates, the women in the SG followed a personalized weight loss diet. In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
32767109|NCT04880525|No Intervention|Control Group|The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.
32767110|NCT04880369|Experimental|Lignan capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
32767111|NCT04880369|Experimental|Isoflavones capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
32767112|NCT04880369|Placebo Comparator|Placebo capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
32767113|NCT04870931||TEM-Group|All patients that underwent TEM
32767114|NCT04870931||TEM-ESD-Group|All patients that underwent TEM-ESD
32767115|NCT04879901|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
32767116|NCT04738175|Experimental|COVI-AMG|40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
32767117|NCT04738175|Placebo Comparator|Placebo|Placebo will be administered
32767118|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
32767119|NCT04711187|Experimental|AT-527 Formulation 1 Dose 1|
32767120|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1|
32767121|NCT04711187|Experimental|AT-527 Formulation 2 Dose 2|
32767122|NCT04711187|Experimental|AT-527 Formulation 1 Dose 3|
32767123|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3|
32767124|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1 Fast/Fed|
32767125|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3 Fast/Fed|
32767126|NCT04676399|Experimental|Hydrochlorothiazide Pill (12.5 mg twice a day)|"Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Chronic pain~Dose(s): 12.5 mg twice per day for 14 days.~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
32767127|NCT04676399|Placebo Comparator|Placebo|"Has no active ingredients but is made to look like the study drug.~2 pills/day for 14 days."
32767128|NCT04880213|Experimental|Japanese: M5049 Dose A (low dose)|
32767129|NCT04880213|Experimental|Japanese: M5049 Dose B (medium dose)|
32767130|NCT04880213|Experimental|Japanese: M5049 Dose C (high dose)|
32767131|NCT04880213|Experimental|Caucasian: M5049 Dose A (low dose)|
32767132|NCT04880213|Experimental|Caucasian: M5049 Dose B (medium dose)|
32767133|NCT04880213|Experimental|Caucasian: M5049 Dose C (high dose)|
32767134|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
32767135|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
32767136|NCT04630847|Experimental|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
32767137|NCT04430309|Experimental|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
32767138|NCT04430309|Active Comparator|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
32767139|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
32767140|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
32767141|NCT04880135|Experimental|Supervised stretching and strengthening exercise|Stretching and strengthening exercises will be performed under the supervision of Physical therapist for a period of one month
32921560|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
32921561|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
32921562|NCT05036187|Experimental|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
32921563|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss.
32921564|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
32921565|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
32921566|NCT05036187|Experimental|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
32921567|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
32921568|NCT05036187|Experimental|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
32921569|NCT05036187|Experimental|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
32921570|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
32921571|NCT05265351|Experimental|Patients with confirmed or suspected diaphragm dysfunction|"Diaphragm function will be assess. Surface electromyography of the diaphragm will be performed in parallel. The abdominals displacement will be recorded using strain gauge. The intra-thoracic and intra-abdominal pressure will be measured using esophageal and gastric catheter-balloon.~Ultrafast ultrasound imaging will be performed during Cervical and bi-lateral anterior magnetic stimulation, and during phrenic electrical stimulation."
32921572|NCT01698463|Other|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
32921573|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
32921574|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
32921575|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
32921576|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
32921577|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
32921578|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
32921579|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
33073357|NCT02428712|Experimental|FORE8394|"Group A: Phase 1-Dose Escalation: Adult patients.~Group B: Phase 1-Dose Escalation: Pediatric patients.~Phase 2a-Dose Extension: Adult patients with advanced unresectable solid tumors will be enrolled among two cohorts.~Cohort 1: Activating BRAF V600 mutations (glioma patients only)~Cohort 2: Activating BRAF non-V600 mutations~Phase 2a-RP2D Confirmation: Adult patients.~Phase 2a-RP2D Redefinition and Extension:~Cohort 3: Activating BRAF V600 or activating non-V600 mutation~Cohort 4: Activating BRAF non-V600 mutations~Phase 2a-RP2D Redefinition:~Cohort 6A: Advanced activating BRAF-mutated solid tumors~Cohort 7A: Advanced activating BRAF-mutated solid tumors~Cohort 8A: Advanced activating BRAF-mutated solid tumors"
32921580|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
32719405|NCT04194970|Active Comparator|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the WBM smart insole system in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
32719406|NCT05216224|Experimental|ATI-450|ATI-450 50mg oral tablet BID
32921581|NCT01952444|Experimental|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
32921582|NCT01952444|Other|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
32921583|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
32921584|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
33248664|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
33248665|NCT01742832|Active Comparator|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
33248666|NCT01742832|Placebo Comparator|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
33248667|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
33248668|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
33248669|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
32719407|NCT05216224|Experimental|Placebo|Placebo oral tablet BID
33248670|NCT00935506|Experimental|Clopidogrel + Aspirin|
33248671|NCT00833157|Experimental|Glucosamine|
33248672|NCT00833157|Experimental|Ibuprofen|
33248673|NCT00833157|Placebo Comparator|Placebo|
32921585|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
33248674|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
33248675|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
32921586|NCT01679197|Experimental|Treatment|Metreleptin
32921587|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
32921588|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
32921589|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
32921590|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
32921591|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
33248676|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
33248677|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
32921594|NCT05495984|Experimental|Primary Objective: Event-Related Potentials (ERPs)|Use ERPs elicited by unknown infant face and cry stimuli to determine whether neural markers translate to maternal mentalization in mothers with opioid use disorder (OUD) at 4-12 months postpartum
33248678|NCT04285671|Experimental|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33248679|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
33248680|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
33248681|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
33248682|NCT00935740||Heart Failure|Subjects with LVEF < 40%
33248683|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
33248684|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
33248685|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
33248686|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
32921595|NCT05495984|Experimental|Secondary Objective: ERPs + Mothering from the Inside Out (MIO)|Use Event-Related Potentials (ERPs) elicited by unknown infant face and cry stimuli to determine whether neural response changes with participation in an evidence-based parenting intervention designed specifically for mothers with OUD: Mothering from the Inside Out (MIO).
32921596|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
32921597|NCT05732324||IVUS PCI optimization group|"PCI will be optimized according to the IVUS. IVUS will be performed before PCI and will be used to select PCI strategy.~Operators will try to reach an optimal anatomical PCI result as assessed by IVUS aiming for the following criteria:~good stent apposition;~good stent expansion (minimal stent area (MSA) >90% of distal reference lumen area and/or MSA ≥5.5mm2);~plaque burden 5mm proximal and distal to the stent <50%);~no stent edge dissection.~After stent optimization an IVUS run will be performed. The IVUS run will be considered as final when further anatomical optimization will not be thought to be possible."
32921598|NCT05732324||Historical FFR PCI optimization group|The goal will be to achieve the optimal functional result, defined as an FFR post PCI ≥ 0.95. Further stented segment post-dilatation will be mandatory if FFR post PCI < 0.95. In case of a clear evidence of significant atheroma proximal or distal to the stented segment, the operators will be encouraged to optimize the functional result further by implanting additional stents.
32719408|NCT05316298||PRESERVE protocol|"Treatment according to the PRESERVE protocol consists of 2 study phases. Phase 1 consists of standard-of-care non-surgical treatment, performed in accordance with current treatment guidelines, during which the research team performs observations.~After failed standard-of care non surgical treatment, subjects will be included in study phase 2 and undergo treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by postoperative treatment regimen including woundcare, 10 days of antibiotics and offloading."
32719409|NCT03061786||AKI|
32921599|NCT05014347||Health Care Professionals|Health Care Professionals (HCP) working in PancreatoBiliary Endoscopy and EUS Division of IRCCS San Raffaele (both endoscopists and nurses)
32921600|NCT05014347||"Expert patients"|a set of at least 30 outpatients undergoing EUS, who already underwent this procedure at least once
32921601|NCT05014347||Patients|100 consecutive patients undergoing EUS
32921602|NCT01614847|Experimental|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
32921603|NCT01614847|Placebo Comparator|Normal saline|
32921604|NCT01617421|Experimental|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
32921605|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
32921606|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
32935828|NCT04338854|Experimental|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
32719410|NCT03061786||non-AKI|
32719411|NCT04808362|Experimental|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
32719412|NCT04193176|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
32719413|NCT04193176|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
32719414|NCT03054142||AKI|
32719415|NCT03054142||non-AKI|
32719416|NCT04020484|Experimental|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
32719417|NCT04020484|Other|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
32719418|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
32719419|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
32921607|NCT05258175|Experimental|Kinesio taping muscle facilitation technique along with standardized physiotherapy protocol|"On the diaphragmatic muscle, muscle facilitation technique will be applied from proximal to distal with 10-15% tension when the participant is standing and exhaled out and the body is in extension. The base of the tape will be about 1 inch below the xiphoid area.~Then the one tail of tape applied with 10% tension on the rib cage with maximum deep inspiration followed by expiration and the other tail of tape will be applied to the subcostal area in forward bending position while taking deep breath with arms adduct and being crossed.~The tape will be changed on every fifth day and assessment will be done at baseline and 2nd week of intervention Total number of sessions: 3"
32921608|NCT05258175|Active Comparator|Standardized physiotherapy protocol|"Pursed lip breathing exercise: Patient instructed to breathe through nose and inspiration should be slowly and expiration is done through mouth by pursing the lips slowly such that if flame is held in front, then the flame should be bended but not blow off. 3 sets a day for 15 days.~Diaphragmatic breathing exercise: Patient sitting comfortably, with knees bent and shoulders, head and neck relaxed. Patient will be instructed to place one hand on upper chest and the other just below your rib cage. Breathe in slowly through nose so that stomach moves out against your hand. 3 sets a day for 15 days.~Deep breathing exercise: Patient instructed to take slow and deep breaths, inhaling through the nose and exhaling through the mouth. Participant is asked to place their hand on their abdomen and expand their abdomen to lift their hand during inhalation. 3 sets a day for 15 days."
32921609|NCT05257941|Active Comparator|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
32921610|NCT05257941|Active Comparator|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.
32921611|NCT02235493||Retrospective Case Only|
32921612|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
32921613|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
32921614|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
32921615|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
32921616|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
32921617|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
32921618|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
32921619|NCT04996797|Experimental|Cohort 1 PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
32921620|NCT04996797|Placebo Comparator|Cohort 1 Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
32921621|NCT04996797|Experimental|CDx+ Expansion Cohort PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
32921622|NCT04996797|Placebo Comparator|CDx+ Expansion Cohort Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
32921623|NCT05249205|No Intervention|Control|Participants in the control group will be asked to maintain their regular lifestyle for the duration of the study. They will not receive an intervention.
33248687|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
33248688|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
32921624|NCT05249205|Experimental|REHIT1|Participants in the REHIT1 group will perform a single REHIT session per week for 6 weeks.
32921625|NCT05249205|Experimental|REHIT2|Participants in the REHIT2 group will perform 2 REHIT sessions per week for 6 weeks.
32921626|NCT04988295|Experimental|Arm A: LACP/ACP-L|LACP dosing (from study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.
32921627|NCT04988295|Active Comparator|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
32921628|NCT04988295|Experimental|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
33248689|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
33248690|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
33248691|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
33248692|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
33248693|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
33248694|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
33248695|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
33248696|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
33248697|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
32921629|NCT04988295|Experimental|Arm A2 (Extension Cohort): ACP-L|Participants will receive Amivantamab and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.
32921630|NCT04988295|Experimental|Arm C2 (Extension Cohort): ACP|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
32921631|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
32921632|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
32921633|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
32921634|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
32921635|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
32921636|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
32921637|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
32921638|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
32921639|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
32921640|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
32921641|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
32921642|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
32921643|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
32719420|NCT04381624|Experimental|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
32719421|NCT04381624|Placebo Comparator|Sham Transcutaneous Vagal Stimulation|The device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
32921644|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
32719422|NCT04808206||Obese patients eligible for laparoscopic bariatric surgery|
32719423|NCT04009876|Experimental|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
32719424|NCT04009876|Experimental|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
32719425|NCT05287516|Experimental|Breakfast meal with 460 kcal|
32719426|NCT05287516|Active Comparator|Breakfast meal with 230 kcal|
32719427|NCT04826302|Experimental|Myofascial treatment|4 sessions of myofascial intervention, 40 minutes per session, 1 session per week
32719428|NCT04826302|Sham Comparator|Sham myofascial treatment|4 sessions of sham myofascial intervention, 40 minutes per session, 1 session per week
32745956|NCT04263441|No Intervention|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review. Subjects will be asked to share thoughts on the satisfaction survey.
32921645|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
32921646|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
32921647|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
33400072|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
32921648|NCT05730530|Experimental|Intervention|Classroom assigned to receive the 6-week long nutrition education curriculum
32921649|NCT05730530|No Intervention|Control|Classroom assigned to receive no intervention
32921650|NCT04830969|Experimental|A: Diabetic + SRP + SPT|The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
32921651|NCT04830969|Experimental|B: Non-Diabetic + SRP + SPT|The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
32921652|NCT04830969|Active Comparator|C: Diabetic + SRP|The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
32921653|NCT04830969|Active Comparator|D: Non-Diabetic + SRP|The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
32921654|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG > 240, NPH initiation: 14, dose increases by 4; For pts. with CPG > 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG > 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG > 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG <60 mg/dl, NPH initiation: 0, ½ of previous dose.
32921655|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
32921656|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
32921657|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
32921658|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
32719429|NCT05309902|Experimental|Sequence 1: (Regimen A + Regimen B + Regimen C + Regimen D)|Regimen A (soticlestat 300 milligram [mg] tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
32921659|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
32921660|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
32921661|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
32921662|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
32921663|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
32921664|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
32921665|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
32921666|NCT05727644|Active Comparator|Participants with normal renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
32921667|NCT05727644|Experimental|Participants with impaired renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
32921668|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
32921669|NCT05726786|Experimental|Immunonutrition|Seven days of preoperative oral supplementation with an immune-enhanced oral nutrition
32921670|NCT05726786|No Intervention|No immunonutrition (control)|Standard of care
32921671|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
32745957|NCT04802889|Experimental|cadaver eyes|The Central region of the retina and preretinal structures of cadaver eyes are examined
32921672|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
32921673|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
32921674|NCT04818957|Experimental|Vitamin D Oral Thin Film (OTF)|Study subjects will receive vitamin D OTF for a maximum of 12 weeks.
32921675|NCT01621477|Experimental|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
32921676|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
32921677|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
32921678|NCT05486078|Experimental|MD-Tissue Medical Device|
32921679|NCT04816149|Active Comparator|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
32935829|NCT04338854|Experimental|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
32935830|NCT04338854|Experimental|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
33400073|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
32921680|NCT04816149|Experimental|Treatment for Relationships and Safety Together (TR&ST)|TR&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
32921681|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
32921682|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
32921683|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
32921684|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
32921685|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
32921686|NCT04804761|Experimental|Real EA group|
32921687|NCT04804761|Sham Comparator|Sham EA group|
32921688|NCT04971993||Heart Failure NYHA Class II|Participants are diagnosed with NYHA Class II heart failure.
32921689|NCT04971993||Heart Failure NYHA Class III|Participants are diagnosed with NYHA Class III heart failure.
32921690|NCT04971993||At risk for arrythmias|Participants are indicated for an insertable cardiac monitor with no history of heart failure.
32921691|NCT05479214|Experimental|Metformin Group|will include 75 patients who will be treated with metformin ( 1gm with the 2 main meals ) combined with insulin therapy
32921692|NCT05479214|Experimental|Insulin alone group|will include 75 patients who will be treated with insulin alone
32921693|NCT04798053|Experimental|Patient affected by a chronic inflammatory rheumatism|patient affected by a chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Systemic lupus, Still disease, scleroderma…),
32921694|NCT04798053|Active Comparator|Controls|patient affected by a non-inflammatory or degenerative musculo-skeletal disease during the containment period
32921695|NCT05740202|Experimental|SHR-7367|
32921696|NCT04778397|Experimental|Magrolimab + Azacitidine|Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.
32921697|NCT04778397|Active Comparator|Control Arm: Venetoclax + Azacitidine|Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
32921698|NCT04778397|Active Comparator|Control Arm: 7+3 Chemotherapy|Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
32921699|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
33248698|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
33400074|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
32921700|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
32921701|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
33400075|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
33400076|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
33400077|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
33400078|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
33400079|NCT03338569|Active Comparator|Intervention|6000 mg per day Vitamin C supplement
33400080|NCT03338023|Experimental|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
33400081|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
33400082|NCT05053633||Combined spinal epidural anesthesia|Apply combined spinal epidural anesthesia
33400083|NCT05094115|No Intervention|Training as usual|Training as Usual for the 3rd SFAB is the U.S. Army Master Resilience Trainer (MRT). It focuses on teaching resilience skills and is one of the foundational pillars of the Comprehensive Soldier Fitness program. MRT course is intended to impart training resilience skills, designed to introduce other resilience concepts that soldiers will likely encounter through their careers. Key focus of course are (1) resilience, (2) building mental toughness, (3) identifying character strengths, and (5) strengthening relationships. The 3rd SFAB uses a a team training grounded in strengths-based leadership. The Small Team Development Consultant and Brigade Behavioral Health Provider serves as a consultant to units conducting their own resiliency training as usual. No booster sessions will be offered to Training as Usual.
32719430|NCT05309902|Experimental|Sequence 2: (Regimen B + Regimen D + Regimen A + Regimen C)|Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen C (soticlestat -matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 4.
32921702|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
32921703|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
32921704|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
32921705|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
32921706|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
32921707|NCT05723822|Experimental|Single Arm|Participants who meet all eligibility criteria will don a pair of Walkasins and the PhySens-IMM System. They will perform some brief balance exercises (i.e., sensory integration exercises) and then complete the outcome assessments first with their Walkasins turned off and without the use of an assistive device. After a brief rest period, they will repeat the outcome assessments with their Walkasins turned on.
32921708|NCT05723432|Experimental|KD6001+Toripalimab|KD6001 combined with toripalimab in patients with advanced melanoma
32921709|NCT05720780|Experimental|Usual training with the support of music (MS)|This is the group performing training with the support of the music; it will be the intervention study group (MS)
32921710|NCT05720780|Active Comparator|Usual training without music (C)|This is the usual training group without the support of the music, it will be the control group (C)
32921711|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
32921712|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
32921713|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
32921714|NCT04958031|Experimental|CVL-871 1.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.
32921715|NCT04958031|Experimental|CVL-871 3.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.
32921716|NCT04958031|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.
32921717|NCT05740124|Experimental|Slip recovery training|Once weekly sessions of slip recovery training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve volitional and reactive stepping movements that mimic the movements necessary to recover balance after slipping while walking.
32921718|NCT05740124|Active Comparator|Alternative balance training|Once weekly sessions of balance training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve standing balance under varied sensory conditions, and tandem walking forward and backward under varied sensory conditions.
32921719|NCT05740046|Experimental|experimental group|Group that will receive the intervention sessions using the Intorus tool
32921720|NCT05740046|No Intervention|control group|Group that will receive the intervention sessions without using the Intorus tool
32921721|NCT04950543||Meditation|
32719431|NCT05309902|Experimental|Sequence 3: (Regimen C + Regimen A + Regimen D + Regimen B)|Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
32719432|NCT05309902|Experimental|Sequence 4: (Regimen D + Regimen C + Regimen B + Regimen A)|Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
32719433|NCT05281744|Experimental|Dementia Care Consultation program|The Dementia Care Consultation program provides an in-depth, personalized service for individuals and families facing ADRD.
32921722|NCT05739968|Active Comparator|control group|Control Group: Usual care + oncology case manager (OCM) care, UC group or Control group
32935831|NCT04338854|Experimental|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
32935832|NCT04338854|Experimental|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
32935833|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
32719434|NCT05281744|No Intervention|Routine Care|Members randomized into the control group will receive routine care.
32719435|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
32719436|NCT02993068|Experimental|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
32921723|NCT05739968|Experimental|experimental group|The experimental group is Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care. Main contents of MAP are to (a) cope multi-domain of distress, and (b) develop an active life style to handle their life after cancer, including effective coping, relaxation, regular physical activities, and balance nutrition. Four face-to face interventions will be delivered, including: day before hospital discharge post-operation, before the last weekly instillations of induction therapy (around 6±2 weeks post operation), 2nd-time cystoscopy and before 1st maintenance therapy (around 3- month post operation) and 3rd-time cystoscopy which before the second cycle of maintenance therapy (around 6- month post operation) [section 1-4], respectively.
32719437|NCT02993068|Experimental|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
32921724|NCT04770207|Experimental|Tumor diameter|Comparison of tumor diameter 1-2 month before and after injection of drug-eluting microspheres.
32921725|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
32921726|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
32921727|NCT05739890||30-40|The study will compare 50 embryos from infertile women <30 years old and fathers 40 and above.
32921728|NCT05739890||30-30|50 embryos from infertile women <30 years old and fathers <30
32921729|NCT04752033|Experimental|Morphine|Subjected to sequential up and down dose titration using biased coin method in parallel with the hydromorphone arm
32921730|NCT04752033|Experimental|Hydromorphone|Subjected to sequential up and down dose titration using biased coin method in parallel with the morphine arm
32921731|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
32921732|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
32921733|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
32921734|NCT04931979|Experimental|Treatment|Pembrolizumab 200mg i.v. three-weekly in combination with salvage radiation therapy (SRT) according to standard of care
32921735|NCT05739812|Experimental|Urological disease group|Patients with urological diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor, renal pelvis carcinoma, ureteral tumor, bladder cancer, prostate cancer, pelvic tumor) will be treated by telesurgery.
32921736|NCT04929795|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of music beat serving as a type of rhythmic auditory stimulation (RAS).
32921737|NCT04929795|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
32719438|NCT02993068|Active Comparator|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
32719439|NCT02993068|Experimental|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
32719440|NCT02987686|Experimental|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
32719441|NCT02987686|No Intervention|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
32719442|NCT05369026|Experimental|Fortetropin|Foretetropin, which is non-thermal pasteurized, freeze-dried fertilized egg yolk, per day
32921738|NCT04929795|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of RAS.
32719443|NCT05369026|Placebo Comparator|Placebo|Cheese powder, which is isonitrogenous, isoenergetic, and macronutrient-matched with Fortetropin
32719444|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
32745958|NCT05616117||High-dose intrauterine D3-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy from 12 weeks to delivery.
32745959|NCT05616117||Low-dose intrauterine D3-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy from 12 weeks to delivery
32921739|NCT04929795|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
32921740|NCT05739734|Experimental|CRIS100 treatment|Administration of a single dose of CRIS100
32921741|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent : Rocuronium 1mg/kg~After endotracheal intubation : normal saline(0.025 ml/kg)~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
32921742|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent :Succinylcholine 1mg/kg~After endotracheal intubation : Cisatracurium 0.08mg/kg~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
32921743|NCT04750395|Experimental|Haloperidol|Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
32921744|NCT04750395|Experimental|Olanzapine|Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
32719445|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
32719446|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
33400084|NCT05094115|Active Comparator|Training as usual with psychological flexibility training|"Training as usual, with psychological flexibility training delivered during a 2-day workshop.~Day 1 provides an overview of the training and describes the posture or stance to prepare for response to challenging situations in a psychologically flexible manner.~Day 2 provides common coping strategies."
32921747|NCT03706079|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
32921748|NCT03706079|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
32921749|NCT05707598||Laparoscopic multivisceral resection group|Patients who underwent laparoscopic multivisceral resection for clinical T4b colorectal cancer
32921750|NCT05707598||Open multivisceral resection group|Patients who underwent open multivisceral resection for clinical T4b colorectal cancer
32719447|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
32921751|NCT04365855|Other|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
32921752|NCT04364217|Other|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
32921753|NCT04920201|Experimental|Over-ground walking without GEMS-H|
32921754|NCT04920201|Experimental|Over-ground walking with GEMS-H with resist mode|
32921755|NCT04920201|Experimental|Stair ascent with GEMS-H with assist mode|
32921756|NCT04920201|Experimental|Incline walking with GEMS-H with assist mode|
32719448|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
32719449|NCT04817176|Experimental|MI-CBT KNA Program|The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
32719450|NCT04817176|Active Comparator|KN Information-Only Program|6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
32719451|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
32921757|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
32921758|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
32921759|NCT04366245|Experimental|Experimental|
32921760|NCT04366245|Active Comparator|Comparator|
32921761|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
32921762|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
32935834|NCT04730401|Experimental|High-titre CP|200mL high-titre CP on admittance
32935835|NCT04730401|Active Comparator|low-titre CP|200ml low-titre CP on admittance
32935836|NCT04730401|Placebo Comparator|Placebo|200mL saline as placebo on admittance
32935837|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
32921763|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
32921764|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
32921765|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
32921766|NCT04699773|Experimental|LITT with Hypofractionated RT|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.
32921767|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
32921768|NCT02975063|No Intervention|Control|No intervention.
32921769|NCT02288156|Active Comparator|0.1mM|
32921770|NCT02288156|Experimental|0.01mM|
32921771|NCT02288156|Experimental|0.001mM|
32921772|NCT02288156|Placebo Comparator|Placebo|
32921773|NCT04350177|Active Comparator|Single Ascending Dose (SAD)|In Part A, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
32921774|NCT04350177|Active Comparator|Multiple Ascending Dose (MAD)|In Part B, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
32921775|NCT04350177|Active Comparator|Multiple Ascending Dose (MAD) Parkinson's patients|In Part C, cohorts will consist of eight (8) patients; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
32921776|NCT01623037|Experimental|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
32921777|NCT04087343|Experimental|Meals plus exercise|
32921778|NCT04087343|Active Comparator|Meals only|
32921779|NCT05700266|Experimental|Rivaroxaban and Aspirin|Rivaroxaban (2.5mg orally twice a day for 90 days) and Aspirin (100mg once a day for 1 year)
32921780|NCT05700266|Active Comparator|Clopidogrel and Aspirin|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days) and Aspirin (100mg once a day for 1 year)
32921781|NCT04340193|Experimental|Nivolumab + Ipilimumab + TACE|TACE (Trans-arterial ChemoEmbolization)
32921782|NCT04340193|Experimental|Nivolumab + TACE|
32921783|NCT04340193|Active Comparator|TACE|
32921784|NCT05416333|Experimental|azelaic acid treatment|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
32921785|NCT05416333|Sham Comparator|control (no additional treatment)|Subjects will continue to use their current primary provider prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
32921786|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
32921787|NCT02249689|Experimental|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
32921788|NCT02249689|Active Comparator|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
32935838|NCT05451121|Experimental|propofol|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol (hypnotic agent) using a syringe pump at the dose of 1-1.5 mg / kg / h
33400087|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
33400088|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
33400089|NCT05682079||children with cerebral palsy|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
33400090|NCT05682079||typical kids|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
33400091|NCT02687542|Placebo Comparator|Placebo|Placebo
33400092|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
33400093|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
32719452|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
32719453|NCT04370704|Experimental|Phase 2 Cohort A|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
32719454|NCT04370704|Experimental|Phase 2 Cohort B|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
32719455|NCT04370704|Experimental|Phase 1 Part 3|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 when used in combination.
32719456|NCT04370704|Experimental|Phase 1 Part 4|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 in combination.
32719457|NCT04355650|Experimental|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
32719458|NCT05277922|Experimental|C21|15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
32767142|NCT04880135|Experimental|Home-based stretching and strengthening exercises|Stretching and strengthening exercises will be performed at home by individuals having musculoskeletal pain due to quarantine for a period of one month.
33248699|NCT04044105|No Intervention|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
33248700|NCT04044105|Experimental|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
33248701|NCT04044105|Experimental|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
33400094|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
32719459|NCT05277922|Experimental|Control group|4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
32719460|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
32719461|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
32719462|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
32719463|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
32719464|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
32719465|NCT04323202|Experimental|Permbrolizumab|Participants will undergo fine cut CT imaging (head and neck) followed by at least 4 doses of pembrolizumab q 3 weeks. After the 4th dose of pembrolizumab as appropriate, patients will undergo standard surgical resection, with all non-marginal tissue as well as the pre-op biopsy to be stored for collateral research. 2 weeks after initial flap or graft insert (which would be equivalent to stage 1 of a forehead flap) patients would continue for a total of approximately 1 year of pembrolizumab q 3 weeks (another 13 doses, thus 17 doses total).
32719466|NCT02917096|Experimental|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
32719467|NCT04816552|Experimental|CHoBI7 mHealth program Arm|The first arm will receive the CHoBI7 mHealth program and a general message on oral rehydration solution (ORS) (CHoBI7 mHealth program Arm) .
32719468|NCT04816552|Active Comparator|Standard Recommendation Arm|The second arm will serve as a Control Arm and only receive a general message on oral rehydration solution (ORS).
32719469|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
32719470|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.~Lenalidomide 25 mg is taken orally on days 1 to 21.~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
32719471|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
32719472|NCT05276050|Experimental|Study group|Participants in this group will receive active F8-coil delivered rTMS.
32719473|NCT05276050|Active Comparator|Active control group|Participants in this group will receive active H-coil delivered rTMS.
32767143|NCT04879667|No Intervention|group (1)|surgical management of gastrocutaneous fistula after laparoscopic sleeve gatrectomy by surgical exploration
33400095|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
32921789|NCT05423132|Active Comparator|Physiological serum Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The physiological serum (NaCl 0.9%) will be injected, on each side, into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
33248702|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
33248703|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
32921790|NCT05423132|Experimental|Ropivacaine Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The local anaesthetic (Ropivacaine) will be injected into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
32921791|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
32921792|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
32921793|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
32921794|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
32921795|NCT05688956|Experimental|(i) ONS + Exercise group|This group will consume whey protein ONS enriched with leucine and vitamin D, twice a day for 12 weeks. The optimal time to consume the ONS on non-exercise days will be based on each participants 24-hour dietary recall. On exercise days, participants will be asked to consume the ONS after breakfast and after the exercise class. Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist.
32921796|NCT05688956|Active Comparator|(ii) Exercise-alone group|Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist. The participants will not be provided with a placebo ONS.
32921797|NCT04683939|Experimental|Part 1A - BNT141 monotherapy escalation|Administration once every three weeks (Q3W)
32921798|NCT04683939|Experimental|Part 1B - BNT141 in combination with nab-paclitaxel and gemcitabine|BNT141 will be administered once every three weeks (Q3W). Nab-paclitaxel and gemcitabine will be administered on three days of each 28-day cycle.
32921799|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
32921800|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
32921801|NCT04086953|Experimental|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
33073358|NCT02425904|Experimental|Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine|"Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
33248704|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
33248705|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
32921802|NCT04086953|Experimental|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
32921803|NCT05413616|No Intervention|Standard care|
32921804|NCT05413616|Experimental|FITFOOD lifestyle intervention|Lifestyle intervention consisting of both a nutritional and exercise intervention.
32921805|NCT04901403|Other|Education intervention|Parents in the treatment group will receive information about Earned Income Tax Credit, including how to sign up for free. They will also receive help with budgeting and finances from their home visitor.
32921806|NCT04901403|Other|Control group|Control group families will receive home visiting services as usual.
32921807|NCT05682638|Experimental|Vaccine group|Phase 3(Base the result of Phase 1 and Phase 2, intervent 100μg): initial vaccination stage- LVRNA009; crossover vaccination stage- placebo
32921808|NCT05682638|Placebo Comparator|Control group|Phase 3: initial vaccination stage- placebo; crossover vaccination stage- LVRNA009
32921809|NCT04899297||Quality of life|
32719474|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
32719475|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
32719476|NCT04194424|Experimental|Multidisciplinary program|Multidisciplinary weight loss program
32719477|NCT04194424|Other|Control|Standard care
32719478|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
32719479|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
32921810|NCT02438969||AUD/ELS-|Treatment seeking or non-treatment seeking individuals with AUD without ELS exposure
32921811|NCT02438969||AUD/ELS+|Treatment-seeking or non-treatment seeking individuals with AUD and early life stress (ELS) exposure
32921812|NCT02438969||non-AUD/ELS-|non-AUD controls without ELS exposure
32719480|NCT04311502|Experimental|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
32719481|NCT04311502|Active Comparator|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
32921813|NCT02438969||non-AUD/ELS+|Non-AUD controls with ELS exposure
32921814|NCT05681702|Active Comparator|DAPT de-escalation|Aspirin 81-mg od and clopidogrel 75-mg qd.
32719482|NCT04311502|Experimental|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
32719483|NCT03895996|Experimental|AVT001 (Treatment)|Infusion of AVT001 (treatment)
32719484|NCT03895996|Placebo Comparator|Matched placebo|Infusion of AVT001-matched placebo
32719485|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
32921815|NCT05681702|Experimental|Potent P2Y12 monotherapy|Potent P2Y12 inhibitor with prasugrel 10 mg od or ticagrelor 90 mg BID.
32921816|NCT04675983|Experimental|Sintilimab + Ramucirumab|Ramucirumab on days 1 and 8 in combination with Sintilimab on day 1 of each 21-day cycle until disease progression, intolerable toxicity or other criteria for treatment discontinuation
32921817|NCT04675983|Active Comparator|Cisplatin+ 5-fluorouracil/Oxaliplatin+capecitabine|Cisplatin on day 1 in combination with 5-fluorouracil, continuous pumping for 24 hours a day on days 1 to 5 of each 21-day cycle. (FP regimen) or Oxaliplatin on day 1 in combination with capecitabine on days 1 to 14 of each 21-day cycle. (XELOX regimen)
32921818|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
32921819|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
32921820|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
32921821|NCT05739344|Experimental|Experimental Group|Cognitive behavioral approach based resilience development program
32921822|NCT04890327|No Intervention|Standard of Care|Patient presents to new Gynecologic Oncology appointment, family health history is collected by the physician during the clinic visit. Both the subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
33248706|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
32719486|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
32719487|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
32921823|NCT04890327|Experimental|Office|Patient presents to new Gynecologic Oncology appointment, subject is given access to a desk top computer in office and instructed to complete web-based family health history tool. Physician reviews results of patients web-based family health history tool.Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
32921824|NCT04890327|Experimental|Home|Patient is emailed a link containing web-based family health history tool prior to presenting for new Gynecologic Oncology appointment. Physician reviews results of patients web-based family health history tool. Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
32719488|NCT03875092|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
32719489|NCT03875092|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
32719490|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
32719491|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
32921825|NCT05400356||Complication group|"Postoperative complications are defined as postoperative death, vital organ dysfunction, and mechanical ventilation duration greater than 24 hours.The vital organ dysfunction includes new developed acute kidney injury, long-term low cardiac output, severe liver function injury and neurological function injury.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
32921826|NCT05400356||Non-complication group|"Patients with none of postoperative complications which showed in Complication group.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
32921827|NCT04889703|Experimental|15% Trichloroacetic acid (TCA) chemical peel|15% trichloroacetic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
32921828|NCT04889703|Experimental|30% Salicylic acid chemical peel|30% salicylic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
32921829|NCT05739266||Before step test|"Before step test.~-Participants record their before-step-test voice."
32921830|NCT05739266||After step test|"After step test.~-Participants record their after-step-test voice."
32921831|NCT04884477||COVID-19 with previous anti-CD20 therapy and Convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy and who received Convalescent plasma in addition to standard treatment for COVID-19
32921832|NCT04884477||COVID-19 with previous anti-CD20 therapy and no convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy treated with standard COVID-19 treatment and who did not receive Convalescent plasma treatment for COVID-19
32921833|NCT05679362|Experimental|immediate individual treatment (A)|5 online individual sessions
32719492|NCT05274958|Experimental|Initial PROM plus monthly PROM plus educational video|These patients receive usual care plus monthly PROMs and educational video(s) while on the waitlist
32719493|NCT05274958|No Intervention|Usual Care|Patients will complete the initial bundle of PROMs, then no further PROMs while they remain on the waitlist
32719494|NCT04816396|Experimental|experimental|For 8 weeks, Reminiscence Therapy based on Roy Adaptation Model will be applied
32719495|NCT04816396|No Intervention|No İntervention|No intervention will be applied to this group.
32719496|NCT05207488|Experimental|Exercise + Prebiotic|The Exercise + Prebiotic intervention group will consume 10 g/d of fructo-oligosaccharides (FOS). Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
32719497|NCT05207488|Placebo Comparator|Exercise + Placebo|The Exercise + Placebo group will consume 10 g/d of a placebo (maltodextrin) powder every day. Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
32921834|NCT05679362|Experimental|immediate group treatment (B)|5 online group sessions with other women with PCOS
32921835|NCT05679362|No Intervention|wait-list-control group|The wait-list control group receives no treatment for the first three months, at which point they will cross over to one of the intervention arms (individual treatment A or group treatment B) and start with the intervention.
33400096|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
32921837|NCT05676476|Experimental|Intervention|Antihypertensive treatment for a BP goal of less than 140/90 mmHg
32921838|NCT05676476|No Intervention|Usual Care|Antihypertensive treatment only if BP ≥ 160/110 mmHg
32921839|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
32921840|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
32921841|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
32921842|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
32767144|NCT04879667|Active Comparator|group (2)|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
32767145|NCT04550195|Experimental|Part A Single Ascending Dose (SAD) Cohort A1|
32767146|NCT04550195|Experimental|Part A SAD Cohort A2|
32767147|NCT04550195|Experimental|Part A SAD Cohort A3|
32767148|NCT04550195|Experimental|Part A SAD Cohort A4|
32767149|NCT04550195|Experimental|Part A SAD Cohort A5|
32767150|NCT04550195|Experimental|Part A SAD Cohort A6|
32767151|NCT04550195|Experimental|Part B Multiple Ascending Dose (MAD) Cohort B1|
32767152|NCT04550195|Experimental|Part B MAD Cohort B2|
32767153|NCT04550195|Experimental|Part B MAD Cohort B3|
32767154|NCT04550195|Experimental|Part B MAD Cohort B4|
32767155|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C1|
32767156|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C2|
32767157|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C3|
32767158|NCT04525391|Experimental|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects > 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
32767159|NCT04870697|Experimental|ACT group|In addition to usual care, participants in the ACT group will receive ACT intervention. ACT intervention will be conducted in an individual-based format with four weekly sessions. The first session is a face-to-face format and the other three sessions are online live format.
32767160|NCT04870697|Other|Control group|Participants in the control group will receive usual care in the study setting delivered by clinical staff. The rationale for adopting usual care as a control group is not only because it is more commonly used but also for practical and ethical considerations, as usual care is what is already being delivered clinically, therefore the results of the study can support any necessity of changes to clinical practice or not.
32767161|NCT04879511|Active Comparator|Receiving metformin|Active group receiving metformin with basal /bolus insulin
32767162|NCT04879511|Placebo Comparator|Placebo|Control group receiving Placebo with basal/bolus insulin
32767163|NCT04361825|Experimental|Durvalumab(MEDI4736) and AZD6738 combination|
32767164|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
32767165|NCT03048695|No Intervention|Waiting list|
32767166|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
32767167|NCT04423055|Experimental|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
32767168|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
32767169|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
32767170|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
32767171|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
32767172|NCT04879277|Other|Healthy subject|"The intervention, specific to the study, is to take blood samples on patients healthy volunteers.~Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex."
32767173|NCT04879277|Other|Patient with phenylketonuria|The intervention, specific to the study, is to take blood samples on patients with phenylketonuria
32767174|NCT04878887|Other|IP-DRA|In plane distal radial artery catherterization
32767175|NCT04878887|Other|IP-PRA|In plane proximal radial artery catherterization
32767176|NCT04879199|Experimental|Typically Developing (TD) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) who are typically developing, 3) able to stand and walk alone without using assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
32767177|NCT04879199|Experimental|Spastic Cerebral Palsy (sCP) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) with the diagnosis of spastic CP or CP similar (both unilateral and bilateral), functionally classified level I or II according to the Gross Motor Function Classification System (GMFCS) [98], 3) being able to stand and walk alone without assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
32767178|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
32767179|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
32767180|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
32767181|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
32767182|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
32767183|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
32767184|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
32767185|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
32767186|NCT04037813|Active Comparator|Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
32767187|NCT04037813|Active Comparator|Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
32767188|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
32921843|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
32719498|NCT04806958|Experimental|Conventional Emergency Dispatch PLUS PulsePoint notification|Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.
32719499|NCT04806958|No Intervention|Conventional Emergency Dispatch|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.
32719500|NCT04806646|Experimental|Single Arm Treatment|"One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.~TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.~TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.~If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study."
32719501|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
32719502|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
32719503|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
32719504|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
32719505|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
32719506|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
32719507|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
32719508|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
32719509|NCT04939610|Experimental|Phase 1: Dose Escalation|Up to 30 patients with solid tumors.
32719510|NCT04939610|Experimental|Phase 1: RP2D Expansion Cohort|Up to 20 patients with solid tumors.
32719511|NCT04939610|Experimental|Phase 2: Specific Solid Tumors|Cohorts of up to 40 patients each with Advanced or Solid Tumors
32719512|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
32719513|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
32719514|NCT04193878|Placebo Comparator|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
32719515|NCT04193878|Active Comparator|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
32719516|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
32719517|NCT04253626|Experimental|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
32719518|NCT04253626|Active Comparator|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
32719519|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
32719520|NCT02501642|Other|Treatment as usual|Treatment as usual
32719521|NCT04816006|Experimental|Aerobic Exercise Training|Breast cancer survivors randomized to the intervention group will participate in a moderate-intensity aerobic exercise program for 24 weeks.
32719522|NCT04816006|Active Comparator|Health Education (Control)|Individuals randomized to Health Education will receive individual education and counseling related to general cancer-related health and support across 24 weeks.
32719523|NCT03840148|Experimental|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
32719524|NCT03840148|Active Comparator|Meropenem|Meropenem will be administered q8h IV over 30 minutes.
32719525|NCT04253548|Experimental|iPeer2Peer Program|Participates in the iPeer2Peer Program
32921844|NCT04670523|Other|Test group|Test group: The patients of the study group are getting their chest tube removed according to the investigators' current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room immediately following wound closure (Postoperative day 0 (POD0)). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
32921845|NCT04670523|Other|Control group|In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day 1 (POD1).
32921846|NCT05396534|Experimental|byLAWT arm|Personalized protocol that uses a contact-force catheter, a multichannel radiofrequency generator, and integrated MDCT-derived Left Atrial Wall Thickness (LAWT) information to adapt the ablation index target to the subjacent LAWT.
32921847|NCT05396534|Active Comparator|CLOSE arm|In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. We uses a contact-force catheter. Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of 400 at the posterior wall/roof an 550 at the anterior wall are reached.
32921848|NCT03363893|Experimental|Module 1 Part A|Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.
32921849|NCT03363893|Experimental|Module 1 Part B|"Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 (samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.~To date Module 1 Part B Arm has recruited a cohort of CRPC participants."
32921850|NCT03363893|Experimental|Module 1 Part B-1 TNBC Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
32921851|NCT03363893|Experimental|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
32921852|NCT03363893|Experimental|Module 4|Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
32921853|NCT04660539|Experimental|Satralizumab Treatment|Participants will receive satralizumab subcutaneously (SC) every 4 weeks (Q4W)
32921854|NCT05663840|Experimental|Progressive resistance exercise (exercise group)|Subjects will receive physical therapy that will predominantly include progressive resistance exercise training program along with continuation of standard of care (exercise group)
32921855|NCT05663840|Active Comparator|Standard of care (non-exercise group).|Subjects will receive continuation of standard of care (non-exercise group).
32921856|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
32935839|NCT05451121|Experimental|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. continuous infusion of Dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
32935840|NCT05451121|Experimental|propofol and dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h
32719526|NCT04251130||Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
32719527|NCT04251130||Mild Cognitively Impaired Older Adults or Older Adults with Alzheimer's Disease|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
32719528|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
32719529|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
32719530|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
32719531|NCT04806334|Experimental|4D MRI of pelvis/bladder with genomic analysis of bladder tumor|Patients with sessile appearing bladder masses who are destined to undergo transurethral resection of the bladder tumor (TURBT) and are felt by the treating physician to harbor MIBC will be enrolled. Prior to TURBT, ALL subjects will undergo axial imaging for clinical staging in the form of contrast enhanced MRI of the abdomen and pelvis (standard of care). The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI). Both the abdominal and pelvic MRI will have an official interpretation by a radiologist, thus both can be used in the care of the subject. Next, ALL subjects will undergo TURBT at which time, voided urine, blood and fresh frozen bladder tumor will be collected. Follow-up pathology will be collected.
32719532|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
32719533|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
32746085|NCT04808037|Experimental|Group A, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose Modification Guidelines for Corneal-Related Adverse Events Associated with belantamab mafodotin"
32921857|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
32921858|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
32921859|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
32719534|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
32921860|NCT05374538|Experimental|Dose Escalation Phase, Cohort 1a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
32921861|NCT05374538|Experimental|Dose Escalation Phase, Cohort 1b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy or are naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
33248707|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
32719535|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
32921862|NCT05374538|Experimental|Expansion Phase, Cohort 2a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
32921863|NCT05374538|Experimental|Expansion Phase, Cohort 2b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
32719536|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
32719537|NCT04825210|Experimental|Integrated Behavioral Health - Prevention (IBH-P)|The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
32921864|NCT05374538|Experimental|Expansion Phase, Cohort 2c: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
32921865|NCT04659603|Experimental|Cohort A metastatic breast cancer (mBC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
32921866|NCT04659603|Experimental|Cohort B metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
32921867|NCT04659603|Experimental|Cohort C Metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks combined with gemcitabine on Day 1, Day 8 and Day 15 every 4 weeks administered via intravenous infusion (IV)
33400097|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
33400098|NCT05054569|Experimental|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
33400099|NCT05682001||DC group|Anterior lens capsule tissues from DC patients
33400100|NCT05682001||ARC group|Anterior lens capsule tissues from ARC patients
33400101|NCT05682001||NC group|anterior lens capsules collected from three age-matched transparent crystals of cadaveric eyes
32746086|NCT04808037|Experimental|Group B, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose modification guidance based on visual acuity"
32719538|NCT04825210|Active Comparator|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents [pocket guide]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
32719539|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
33400102|NCT05490511|Active Comparator|CYP3A5 expressers without chronic kidney disease|
33400103|NCT05490511|Active Comparator|CYP3A5 non-expressers without chronic kidney disease|
33400104|NCT05490511|Active Comparator|CYP3A5 expressers with chronic kidney disease|
33400105|NCT05490511|Active Comparator|CYP3A5 non-expressers with chronic kidney disease|
33400106|NCT05721976|Experimental|"With Love, Grandma (Con Cariño, Abuelita) Group"|"Cancer survivor-Daughter dyads randomized to the With Love, Grandma (Con Cariño, Abuelita) group will access a digital lifestyle program that includes 8 modules of didactic, behavioral, and family communication/parenting/grandparenting content from smartphones over the course of 10-12 weeks."
33400107|NCT05721976|No Intervention|Control Group|This group is intended to reflect typical services cancer survivors and family members receive from healthcare providers.
33400108|NCT03217266|Experimental|Step 1 (tumor tissue testing, navtemadlin)|Patients undergo tumor tissue testing for p53 gene status and receive navtemadlin PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks 1 to 5 in the absence of disease progression or unacceptable toxicity.
33400109|NCT03217266|Experimental|Step 2, Group I (navtemadlin, radiation therapy)|Patients receive navtemadlin as in Step 1 and undergo radiation therapy daily on weeks 1-5 in the absence of disease progression or unacceptable toxicity.
33400110|NCT03217266|Experimental|Step 2, Group II (radiation therapy)|Patients undergo radiation therapy daily on weeks 1-5 in the absence of disease progression or unacceptable toxicity.
32921880|NCT04872387|Experimental|BAY2586116 Dose step 1 and Placebo|"Each participant of Dose step 1 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
32921881|NCT04872387|Experimental|BAY2586116 Dose step 2 and Placebo|"Each participant of Dose step 2 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
32921882|NCT04872387|Experimental|BAY2586116 Dose step 3 and Placebo|"Each participant of Dose step 3 will receive single and multiple doses of BAY2586116 or placebo administered once daily (OD) for 5 consecutive days.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
32935841|NCT04967443|Active Comparator|Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site|One 2 mg capsule manufactured at the current site, Barceloneta
32719540|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
32719541|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
32719542|NCT02622100||Bioresorbable Vascular Scaffold|
32719543|NCT02611024|Experimental|Lurbinectedin Escalation Group|Irinotecan 75 mg/m^2 as a 90-min (-5-min/+30-min) intravenous (i.v.) infusion, followed by Lurbinectedin with starting dose of 1.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion)
32719544|NCT02611024|Experimental|Irinotecan Escalation Group|Starting dose of Irinotecan 15 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 3.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion).
32719545|NCT02611024|Experimental|Intermediate Escalation Group|Starting dose of Irinotecan 50 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 2.6 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion. No Irinotecan dose will be administered on Day 8 in this group.
32719546|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
32719547|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
32719548|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
32719549|NCT03812614|Experimental|FAM-ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
32719550|NCT03812614|Active Comparator|I-DSMES|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
32719551|NCT04814992|Active Comparator|Computer-Assisted Preoperative CBT Intervention|"Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained coach across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience."
32935842|NCT04967443|Experimental|Prazosin HCL 2 mg capsule Ascoli site|One 2 mg capsule manufactured at the proposed site (Ascoli)
32719552|NCT04814992|No Intervention|Treatment-as-usual (control)|Patients scheduled to undergo total joint arthroplasty at the study site are automatically enrolled in a mandatory 4-hour education class delivered by a nurse educator or physical therapist. Utilizing an in-person Powerpoint presentation format, patients are informed about pre-habilitation exercises to do prior to surgery; what to expect the day of surgery; the multimodal analgesia protocol used in the perioperative period; options for anesthesia and analgesia; and the expectation of physical therapy after surgery.
32719553|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) ([FIO2 × mean airway pressure × 100]/PaO2) above 4
32719554|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
32719555|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
32719556|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
32719557|NCT04222504|Experimental|Intervention Salons|Intervention: Behavioral: Provision of sexual health preventative services in the salon setting
32719558|NCT04222504|No Intervention|Control Salons|No Intervention
32719559|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
32719560|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
32719561|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
32719562|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
32719563|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
32719564|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
33248708|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
33248709|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
33248710|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
33248711|NCT00840645|Experimental|1. YM178|
33248712|NCT00566722|Experimental|Open Label|
33248713|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
33248714|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
33248715|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
33248716|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
32746087|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
33248717|NCT00935896|No Intervention|high VT group|
33248718|NCT00935896|Experimental|Low tidal volume|
33248719|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
33248720|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
33248721|NCT00746538|Experimental|1|metallic stent group
33248722|NCT00746538|Active Comparator|2|plastic stent group
33248723|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
33248724|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
33248725|NCT02563314|Experimental|intervention|
33248726|NCT02563314|Other|control|
33248727|NCT00840723||Current smokers|Current cigarette smokers with no other illness
33248728|NCT00840723||Healthy controls|Healthy non smokers
33248729|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
32719565|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
32719566|NCT04922762|Experimental|Moderate Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, normal volume exercise training
32719567|NCT04922762|Experimental|High Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of high intensity, normal volume exercise training
32921883|NCT04312659||Infliximab|Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
32921884|NCT05650892||Sample collection aortic tissue|Sample collection thoracic aorta tissue
32719568|NCT04922762|Experimental|Moderate Intensity, High Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, high volume exercise training
32719569|NCT04201496|Experimental|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
32719570|NCT04201496|Experimental|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
32719571|NCT04201496|Active Comparator|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
32719572|NCT04201496|Active Comparator|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
32719573|NCT02500550|Experimental|ATIR101|
32719574|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
32719575|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
32719576|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
32719577|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
32719578|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
32719579|NCT04824040||Study group|Patients with a genetically confirmed dysferlinopathy.
32719580|NCT04824040||Control group|Healthy Volunteers
32719581|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
32719582|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
32719583|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
32719584|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
32719585|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
32719586|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
32719587|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
32719588|NCT02446366|Experimental|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
32719589|NCT04814446|Experimental|Gardasil 9®|Nonavalent HPV vaccine
32719590|NCT04814446|Placebo Comparator|Placebo|NaCl 0.9 % solution for injection
32719591|NCT04797286|Experimental|Sildenafil|Sildenafil 20 mg by mouth three(3) times each day
32719592|NCT04797286|Placebo Comparator|Placebo|Placebo by mouth three(3) times each day
32719593|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
32719594|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
32719595|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
32746088|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
32746089|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
33248730|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
33248731|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
33248732|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
33248733|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
33248734|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
33248735|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
33248736|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
33248737|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
33248738|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
33248739|NCT04014166|Experimental|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
33248740|NCT03881046||lung cancer|
33248741|NCT03881046||healthy control group|
33248742|NCT04016727|Experimental|PRP group|patients in which 60 units of prp was injected
33248743|NCT04016727|No Intervention|Control group|patients not given any intervention
32746090|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
32921885|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
33248744|NCT04014244|Experimental|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
33248745|NCT04014244|Experimental|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
33248746|NCT00834015|Other|Experimental|combined strength and aerobic training
33248747|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
33248748|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
32921886|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
32921887|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
32921888|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
32921889|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
32921890|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
33248749|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
33248750|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
33248751|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
33248752|NCT00937924|Placebo Comparator|1|Control. Normal Saline Injections.
33248753|NCT00937924|Experimental|2|Diphenhydramine injections given as adjunct sedative.
33248754|NCT00937924|Experimental|3|Promethazine given as an adjunct sedative.
33248755|NCT00743886|Placebo Comparator|2|saline
33248756|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
33248757|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
33248758|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
33248759|NCT00746772|Active Comparator|1|Patients with oral lichen planus
33248760|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
33248761|NCT00938080|Experimental|AG013: one mouth rinse/day|
33248762|NCT00938080|Experimental|AG013: three mouth rinses/day|
33248763|NCT00938080|Experimental|AG013: six mouth rinses/day|
33248764|NCT00938080|Placebo Comparator|one mouth rinse/day|
33248765|NCT00938080|Placebo Comparator|three mouth rinses/day|
33248766|NCT00938080|Placebo Comparator|six mouth rinses/day|
33248767|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
33248768|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
33248769|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
33248770|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
33248771|NCT00834327|Placebo Comparator|5|Placebo
33248772|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
33248773|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
33248774|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
33248775|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
32767189|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
32767190|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
32767191|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
32767192|NCT04878809|Experimental|Experimental group|People attending L'Horitzó School (students, teachers, administrative and service staff)
32767193|NCT04878809|Other|Control Group|Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
32767194|NCT04430465|Experimental|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
32767195|NCT04430465|Experimental|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
32767196|NCT04870541|Active Comparator|Patients receiving Ondansetron|
32767197|NCT04870541|Active Comparator|Patients receiving Nefopam|
32767198|NCT04870385|Experimental|Treatment|5-week online prevention program
32767199|NCT04870385|Other|Control|Waitlist control
32767200|NCT04870073|Experimental|Retrograde autologous priming + mannitol|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
32767201|NCT04870073|Experimental|Retrograde autologous priming alone|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
32767202|NCT04870073|Experimental|Conventional priming + mannitol|Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
32767203|NCT04870073|Active Comparator|Conventional priming alone|Participants will receive conventional priming alone.
32767204|NCT04878731|Experimental|single arm|PF-06741086 300mg subcutaneous(SC)
32767205|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
32767206|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
32767207|NCT04878341|Experimental|Erector Spinae plane Block|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and the transverse process of T5-T7 vertebrae and Erector Spinae (ES) fascia will be located with a linear ultrasound probe. A 19G or 20G epidural needle (according to age) will be positioned under the ES muscle and a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered; after hydrodissection, the catheter will be threaded, followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
32767208|NCT04878341|Active Comparator|Thoracic Epidural Anesthesia|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and a 19G or 20G epidural needle (according to age) will be positioned at T5-T7 level with cathether placement; a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered and followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
32767209|NCT04878497||Warfarin|New users of warfarin
32767210|NCT04878497||Dabigatran|New users of dabigatran
32767211|NCT04878497||Rivaroxaban|New users of rivaroxaban
32767212|NCT04878497||Apixaban|New users of apixaban
32767213|NCT04878497||Edoxaban|New users of edoxaban
32767214|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
32767215|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
32767216|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
32767217|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
32767218|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
32921891|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
32921892|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
32921893|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
32921894|NCT05739110||micronecrosis(+) group|Hepatocellular patients with tumor micronecrosis.
32921895|NCT05739110||micronecrosis(-) group|Hepatocellular patients without tumor micronecrosis.
32719596|NCT04797130|No Intervention|Control group|All subjects eligible for inclusion in this study receive usual care physiotherapy as prescribed by the physician. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Patients in the control group will receive an accelerometer, measuring PA, which is applied by the physiotherapist during the first treatment. They receive no other additional intervention. Usual care physiotherapy sessions will take approximately 20-30 minutes per session.
32719597|NCT04797130|Experimental|Intervention group|Patients in the intervention group will receive usual care physiotherapy and use Hospital Fit 2.0 (HF) additionally. After the last treatment session (max. 7 days), the therapist will remove the accelerometer and participation in the study will end.
32719598|NCT05653024|Experimental|Inhaled salbutamol|8 puffs of 100 mcg of inhaled salbutamol once
32719599|NCT05653024|Placebo Comparator|Placebo|8 puffs of inhaled placebo once
32719600|NCT04814134|Experimental|CPNS Therapy|Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
32719601|NCT04814134|Other|Standard of Care|Available standard treatment
32719602|NCT04796974|Experimental|Cention|Alcasite restorative material
32921896|NCT05739032|Experimental|Exercise group|Exercise group received aerobic exercise (30-min walking) and upper and lower extremity strength training for 12 weeks for 3 days/week.
32921897|NCT05739032|No Intervention|Control group|Control group continued only routine follow-up.
32719603|NCT04796584||MS subjects who are being treated with ocrelizumab|Ocrelizumab's immunomodulating mechanisms of action is B-cell lytic. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
32719604|NCT04796584||MS subjects who are being treated with fingolimod|Fingolimod's immunomodulating mechanisms of action is to prevent mobilization of B and T cells from peripheral lymphoid organs. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
32719605|NCT04796584||MS subjects who are being treated with natalizumab|Natalizumab's immunomodulating mechanisms of action is to block transmigration of monocytes, and lymphocytes into the central nervous system. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
32719606|NCT04796584||MS subjects who are being treated with dimethyl fumarate/diroximel fumarate|Dimethyl Fumarate's immunomodulating mechanisms of action is to reduce inflammation-induced oxidative stress. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
33248776|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
32921898|NCT04638699|No Intervention|Phase 1 Survey of the actual state|
32921899|NCT04638699|Other|Phase 2 Survey after the OptiScreen training|
32719607|NCT04813276|Experimental|Serious game intervention|Participants receive the Strong Together serious game program on a tablet computer.
32719608|NCT04813276|Active Comparator|Enhanced care as usual|Participants receive a paper-based self-advocacy guide.
32719609|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
32719610|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
32746091|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
32746092|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
32921900|NCT05738954||Second trimester|Second trimester fetal morphology Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.
32921901|NCT02403323|Experimental|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
32921902|NCT02403323|No Intervention|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 [NCT02394028]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
32921903|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
33248777|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
33248778|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
32719611|NCT05195866|Active Comparator|Group A - CRP POCT|Participants assigned to Group A will take C-reactive protein (CRP) point of care test (POCT) during a check-up with their healthcare worker (HCW). The assistant investigator will attend the child's consultation with the local HCW and complete the case report form (CRF). Consequently, the CRP result will be recorded in the CRF, which will be the basis for choosing a treatment, depending on its result.
33248779|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
33248780|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
33248781|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
33248782|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
33248783|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
33248784|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
33248785|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
33248786|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
33248787|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
33248788|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
33248789|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
33248790|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
33248791|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
33248792|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
33400111|NCT05648500|Experimental|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
32719612|NCT05195866|No Intervention|Group B - Usual care|HCWs will also consult children who have been randomised to Group B. The assistant investigator will complete the CRF for these children, but the CRP POCT will not test them. They will receive the treatment prescribed by the HCW as usual care
33248793|NCT00830427|Experimental|PF-00610355|
33248794|NCT00830427|Experimental|PF - 00610355|
32746093|NCT03203915|Experimental|Group 1|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
32746094|NCT03203915|Experimental|Group 2|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
32767219|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
33400112|NCT05648500|Placebo Comparator|Matching placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
33400113|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
32767220|NCT02614859|Active Comparator|Observation and Bicalutamide|Cycles 1-2: Observation without treatment Cycles 3-8: Bicalutamide 50 mg daily continuously to end of study
32767221|NCT02614859|Experimental|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
32767222|NCT04384445|Experimental|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
32767223|NCT04384445|Placebo Comparator|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
32767224|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
32767225|NCT04877795||Cardiac Surgery|Adult Patients undergoing elective on-pump cardiac surgery (i.e. Coronary artery bypass graft surgery (CABG) and/or valvular surgery)
32767226|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
32767227|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
32767228|NCT04877717|Experimental|SHR-A1904|
32767229|NCT04877951|Other|Effect of LSVT BIG therapy on Postural Control and Gait Parameters|LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
32767230|NCT03046199|No Intervention|Control|
32767231|NCT03046199|Experimental|Questionnaire|
32767232|NCT03046199|Experimental|Coordination|
32767233|NCT03046199|Experimental|Questionnaire + coordination|
32767234|NCT04877171|Experimental|telemedicine neurology consultation|Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.
32767235|NCT04877171|Active Comparator|in-person neurology consultation|Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.
32767236|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
32767237|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
32767238|NCT04876859|Active Comparator|Conventional Radiofrequency Group|Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
32719613|NCT04813198|Active Comparator|TIPSTART|Following baseline testing, the study orientation and randomization, the TIPSTART group will engage in 5.5 hours (30 minutes, on 11 separate occasions, over 10 weeks) of training delivered through Zoom and supported by instructional and communication apps, and that is further supervised by our TIPSTART study navigators who will provide motivational support and detailed lifestyle behavioral prescriptions (150 to 300 minutes per week of aerobic and strength training, with mental practice of material discussed each week). Participants will also be asked to complete approximately 3 total hours of repeated testing that occurs online via surveys and face-to-face interviews for the 12-week study.
32719614|NCT04813198|No Intervention|Wait-list Control|Following baseline testing, the study orientation and randomization, the wait-list control group will be asked to continue living life as usual until their delayed TIPSTART program is initiated. Participants will be asked to complete repeated online surveys and face-to-face interviews during the first 12 weeks, concurrently, with participants assigned to the TIPSTART intervention.
32719615|NCT05652946|Experimental|Inpatient Rehabilitation with ART|Inpatient rehabilitation with advanced rehabilitation technology
32719616|NCT05652946|Active Comparator|Inpatient Rehabilitation without ART|Inpatient rehabilitation without advanced rehabilitation technology
32719617|NCT04418752|Other|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
32719618|NCT04813042|Experimental|Working Out Dads|Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child & Family Health Service).
32746095|NCT03203915|Experimental|Group 3|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
33248795|NCT00830427|Placebo Comparator|Placebo|
33248796|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
32935843|NCT04967443|Experimental|Prazosin HCL 1 mg capsule Ascoli site|Two 1 mg capsule manufactured at the proposed site, Ascoli
33248797|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
33248798|NCT00841113|Experimental|1 Abarelix|Investigative drug
33248799|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
33248800|NCT00741546||A|Patients referred for cardiac surgery intervention
33248801|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
33248802|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
33248803|NCT00566020|Experimental|Lamotrigine|study drug
33248804|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
33248805|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
33248806|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
33248807|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
33248808|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
33248809|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
33248810|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
33248811|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
33248812|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
33248813|NCT00741624|Experimental|1|bilateral post refractive surgery subject
33248814|NCT00830583|Other|1|pompe's disease suspected patient
33248815|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
33248816|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
33248817|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
33248818|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
33248819|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
33248820|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
33248821|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
33248822|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
33248823|NCT00744198|Active Comparator|1|Autologous sling
33248824|NCT00744198|Active Comparator|2|Synthetic sling
33248825|NCT00744198|Active Comparator|3|Biological sling
33248826|NCT04013776|Active Comparator|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
33248827|NCT04013776|No Intervention|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
33248828|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
33248829|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
33248830|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
33248831|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
33248832|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
33248833|NCT00936286|Experimental|Respiratory Muscle Training|
33400114|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
32719619|NCT04813042|Active Comparator|Usual Care|Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
32719620|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
32719621|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
32719622|NCT05652712||Immunotherapy Regimen|Patients receiving different treatment regimens of Toripalimab in each center were consecutively enrolled from January 1, 2019 to December 31, 2022
32719623|NCT04418674|Experimental|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
32719624|NCT04418674|Active Comparator|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
33248834|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
33248835|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
32719625|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
32719626|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
32719627|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
32719628|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
33248836|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
32719629|NCT04795882|Experimental|Cohort 1: BCMA CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells
32719630|NCT04795882|Experimental|Cohort 2: BCMA/CD19 CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells
32719631|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
33248837|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
33248838|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
33248839|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
32719632|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
32719633|NCT05184790||Brain cancer|Patients having radiation therapy for treatment of brain cancer.
33248840|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
33073359|NCT02425904|Experimental|LCH-related disorders + Clofarabine|"Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
32719634|NCT05184790||Breast cancer|Patients having radiation therapy for treatment of breast cancer.
32719635|NCT05184790||Head and neck cancer|Patients having radiation therapy for treatment of head and neck cancer.
32719636|NCT05184790||Kidney cancer|Patients having radiation therapy for treatment of kidney cancer.
32719637|NCT05184790||Liver cancer|Patients having radiation therapy for treatment of liver cancer.
32935844|NCT04967443|Active Comparator|Prazosin HCL 5 mg capsule Barceloneta site|One 5 mg capsule manufactured at the current site, Barceloneta
33248841|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
33248842|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
33248843|NCT00841425||Swimmers|
33248844|NCT05311566|Experimental|Patients with primary IB2-IIIB cervical cancer|Patients with primary IB2-IIIB cervical cancer, including squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma.
33248845|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
33248846|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
33248847|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
33248848|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
33248849|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
33248850|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
32921904|NCT04283409|Experimental|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
32921905|NCT04283409|Experimental|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
32921906|NCT05738798|Experimental|oral immunotherapy|oral immunotherapy, maintenance phase with daily 300 mg allergenic protein during 1 year
32921907|NCT05738798|No Intervention|routine care|strictly avoidance of the specific allergenic food
33248851|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
33248852|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
33248853|NCT00744510|Experimental|1|Reflexology
33248854|NCT00744510|No Intervention|2|
33248855|NCT00940186||pikamilone|
32719638|NCT05184790||Pancreatic cancer|Patients having radiation therapy for treatment of pancreatic cancer.
32719639|NCT05184790||Prostatic cancer|Patients having radiation therapy for treatment of prostate cancer.
32719640|NCT05184790||Spinal neoplasm|Patients having radiation therapy for treatment of spinal cancer.
32719641|NCT05184790||Cardiac arrhythmia|Patients having radiation therapy for treatment of cardiac arrhythmia
32719642|NCT05182450|Experimental|Active capsule|Colored capsule containing 300 mg mango leaf extract (Zynamite®) standardized to contain ≥ 60% mangiferin. Supplied by PLT Health Solutions, Inc.
32719643|NCT05182450|Placebo Comparator|Placebo capsule|Colored capsule, appearance-matched to the active experimental capsule
32719644|NCT04794868||Culprit vessel of acute coronary syndrome|Culprit vessel of acute coronary syndrome
32719645|NCT04794868||Non-culprit vessel of acute coronary syndrome|Non-culprit vessel of acute coronary syndrome
32719646|NCT05178550|Experimental|Group 1 (low dose-high dose)|Participants receive 25 IU/kg heparin on days 1 and 2, and 50 IU/kg Heparin on days 4 and 5
32719647|NCT05178550|Experimental|Group 2 (high dose-low dose)|Participants receive 50 IU/kg heparin on days 1 and 2, and 25 IU/kg Heparin on days 4 and 5
32719648|NCT05254678|Active Comparator|Standard exercise program|Participants in this group will take part the general exercise program delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent exercise workouts within the application, and (3) exercise specific education within the Education Module of the HEAL-ME application.
32719649|NCT05254678|Experimental|Integrated physiotherapy and exercise|Participants in this group will take part in an integrated physiotherapy and exercise intervention delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group physiotherapeutic exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent physiotherapeutic exercise workouts, and (3) breast cancer specific physiotherapy education delivered through weekly modules.
32719650|NCT05652244|Experimental|Retraction with mini-implants|Mini-implants will be used as an anchor unit.
32719651|NCT05652244|Active Comparator|Retraction with transpalatal arches|Transpalatal arches will be used as an anchor unit.
32719652|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
32719653|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
32719654|NCT03542344|Experimental|BI 1015550|
32719655|NCT03542344|Placebo Comparator|Placebo|
32719656|NCT04199468|Experimental|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
32719657|NCT04199468|Experimental|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
32719658|NCT04199468|Experimental|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
32719659|NCT04199468|Experimental|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
32719660|NCT04938596|Experimental|Respiratory Bundle Group|The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
32719661|NCT04938596|No Intervention|Standard of care|Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
32719662|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
32719663|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
32719664|NCT05173792|Experimental|AK119|Subjects will receive escalating doses of AK119 every 2 or 3 weeks.
32719665|NCT03542188|Active Comparator|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
32921908|NCT04858737|Experimental|e-predicD-Work intervention|In this arm, worker participants will receive an online personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS).
32921909|NCT04858737|Active Comparator|m-Health control|In this arm, worker participants will continue receiving the usual care from their health providers. In addition, they will use an App with the same appearance as the e-predictD-Work App but it will only send weekly short messages about stress and general health that will be extracted from brochures and websites of official agencies.
32921910|NCT05643482|Experimental|HBOT Arm|Pressurized at 2.0 atmospheres absolute of pressure (ATA) Breathe 100% oxygen 90 minute session, 5 days per week, for 20 sessions
32921911|NCT05643482|Sham Comparator|Control Arm|Placebo Gas Pressurized at 2.0 ATA Breathe placebo gas system of 10.5% oxygen and 89.5% nitrogen to mimic the partial pressure of oxygen breathed in regular air at sea level pressure 90 minute session, 5 days per week, for 20 sessions
32921912|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
32921913|NCT01690117|No Intervention|control group|usual care
32921914|NCT04286607|Experimental|ARQ-151 Cream 0.3%|
32921915|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
32921916|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
32921917|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
32921918|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
32921919|NCT04632303|Experimental|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
32921920|NCT04632303|No Intervention|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
32921921|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
33248856|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
32719666|NCT03542188|Experimental|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-trombolysis and early EVT.
32719667|NCT05651776|Experimental|Intervention of golf and rehab|2x/week x 6 weeks participation in a golf and PD rehab program
32719668|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
32719669|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + GA adjunct total: 1-2 mcg/kg~Sedation: 0-0.25 mcg/kg~Post-op: 0.5-1 mcg/kg~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)~Fluid repletion based on maintenance and losses"
32719670|NCT04811794||Group A (largest part of the cohort)|Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
32719671|NCT04811794||Group B (very small part of the cohort)|Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
32719672|NCT05168332|Experimental|Experimental(Group A): EMG-BF guided patellar taping|The experimental group (Group A): EMG-BF guided patellar taping Maximum voluntary isometric contraction exercise at 60, and 90 degrees angle for six weeks.
32719673|NCT05168332|Sham Comparator|Control group (Group B): sham patellar taping without EMG-BF guided stimulation.|Control group (Group B): sham patellar taping without EMG-BF guided stimulation; maximum voluntary isometric contraction exercise at angles of 60, and 90 degrees for six weeks.
32719674|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
32719675|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
32719676|NCT05651698|Experimental|HeartMan Intervention group|80 patients are in the intervention group (40 in Belgium and 40 in Italy).
32719677|NCT05651698|No Intervention|Control group|40 patients are in the intervention group (20 in Belgium and 20 in Italy). Standard care consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year.
32719678|NCT04943432|Experimental|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
32719679|NCT05651464|Active Comparator|Intervention: Prophylactic antibiotic treatment|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
32719680|NCT05651464|No Intervention|Control Arm: No prophylactic antibiotic treatment|Control group - no intervention.
32921922|NCT01690273|No Intervention|ankylosing spondylitis control|control group
32921923|NCT01690273|Experimental|mobility exercise|mobility exercises
32921924|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
32921925|NCT04278417|Experimental|Brolucizumab Arm|Intra-vitreal injection
32921926|NCT04278417|Active Comparator|Panretinal photocoagulation laser Arm|laser
32921927|NCT05362370||Cohort 1|Participants will receive a Stryker PEEK Customized Implant
32935845|NCT04967443|Active Comparator|Prazosin HCL 1 x 5 mg capsule Ascoli site|One 5 mg capsule manufactured at the proposed site, Ascoli
32935846|NCT04724317|Sham Comparator|Steroid Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% added to triamcinolone 40 mg under the ultrasound guidance
33248857|NCT00940186||tablet|
32921928|NCT05738720|Experimental|Homespirometer Group (HsGr)|"Patients will be taught to use the homespirometer device, download the phone application, use the application, use the video call feature, measure saturation and heart rate with the same device, and daily symptom scoring in the device's system.~Patients will be asked to perform pulmonary function tests with a spirometer device, measure saturation and heart rate, score symptoms, and write down any problems related to their illness twice a week on days without exercise. The evaluations made after 2 tests. They will be sent to the researchers via the device.andthe video containing the exercises after the first training will be sent to them via whatsapp for the exercise compliance of the patients. In the first exercise week, the first 2 exercise sessions will be done one-on-one via video call, and the exercises will be done correctly."
32921929|NCT05738720|Active Comparator|Control Group (CGr)|The same exercise training will be taught to the study group and the same exercise video will be sent to the patients via WhatsApp. The first 2 exercise sessions will be done one-on-one via video call (via whatsapp), and the exercises will be done correctly. Patients will be given an exercise diary and asked to take notes on their weekly exercises.
32921930|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
32921931|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
32921932|NCT05641298|Active Comparator|ARV-1801(ACG-701) Active Group|ARV-1801(ACG-701) tablets by mouth twice a day for 14 days
32921933|NCT05641298|Placebo Comparator|Placebo Group|Placebo tablets by mouth twice a day for 14 days
32921934|NCT04342247||androgen deficient|
32921935|NCT04342247||healthy|
32921936|NCT04620369|Experimental|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
32921937|NCT04620369|Placebo Comparator|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
32921938|NCT05637476|Active Comparator|Group A (Active control group)|Group A (number=20): which is the control group with medial tibial stress syndrome, they will receive a selected physical therapy exercise program.
32921939|NCT05637476|Experimental|Group B (Experimental group)|Group B (number=20): which is the experimental group with Medial tibial stress syndrome, they will receive the same physical therapy exercise program as group A in addition to, functional strength training of hip abductors.
32921940|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
32921941|NCT04852887|Active Comparator|Arm 1: Breast Radiation Therapy + Endocrine Therapy|Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
32921942|NCT04852887|Active Comparator|Arm 2: No Breast Radiation Therapy + Endocrine Therapy|No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
32921943|NCT05738642|Experimental|4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function. 2. 4 F- PCC by intravenous infusion of cluster
32921944|NCT05738642|No Intervention|non 4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function.
32921945|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
32719681|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
32719682|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
32719683|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
32719684|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
32719685|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
32746096|NCT03203915|Experimental|Group 4|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
32746097|NCT03203915|Experimental|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
33400115|NCT03114904|Other|"Usual weaning management"|
33400116|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
32719686|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
32921946|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
32921947|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
32719687|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
32719688|NCT04793698|Experimental|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
32719689|NCT04793698|Active Comparator|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
32921948|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
32719690|NCT03427996||Coronary disease|
32921949|NCT05360186|Experimental|Intervention group (Group A): NCH gel after USG-MVA|In the intervention group (Group A), a 15 cm sterile delivery cannula will be inserted through the internal os and a syringe of NCH gel (5ml) will be applied to the uterine cavity after cleansing the cervix with an antiseptic solution.
32719691|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
32719692|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
32921950|NCT05360186|No Intervention|Controlled group (Group B): No NCH gel after USG-MVA|In the control group (Group B), as the patient is conscious during the procedure, an empty 5ml syringe will be inserted into the internal os and held for 1 minute as a sham procedure.
32719693|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
32921951|NCT05370157|Experimental|TeamTRACS (Team Training in Roles, Awareness, Communication, and Support)|CACs randomized to the intervention condition (n = 4) will participate in TeamTRACS. CACs will receive an implementation guide to assist in preparing for and maximizing the impact of training.
32921952|NCT05370157|No Intervention|Waitlist Comparison|CACs randomized to the waitlist comparison (n = 2) will participate in TeamTRACS approximately 4 months after CACs in the intervention condition.
32921953|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
32921954|NCT05738564|Active Comparator|Group (EL) Epinepherine and Lidocaone group|Group (EL) (63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.(63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.
32719694|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
32921955|NCT05738564|Active Comparator|Group( OL) Oxymetazoline and lidocaine group|Group OL (63 patients): These patients received five drops of lidocaine hydrochloride (Xylocaine 2%, 20 mg/ml; AstraZeneca, London, UK) using a prefilled dropper, followed by six drops of hydrochloride Oxymetazoline (Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
32921956|NCT05629364|Experimental|0.15% KIO-101|.15% KIO-101 eyedrops
32921957|NCT05629364|Experimental|0.3% KIO-101|0.3% KIO-101 eyedrops
32921958|NCT05629364|Placebo Comparator|Vehicle|Vehicle eyedrops
32935847|NCT04724317|Active Comparator|Ozone Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by injection of 10 ml of Oxygen-Ozone mixture (15 µg/ml) under the ultrasound guidance
33073360|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
33400117|NCT05598138|Other|Intervention|A blood sample (10 ml) will be taken for each patient included in the study
32719695|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
32719696|NCT03424018|Experimental|BMN 111|
32719697|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
32719698|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
33400118|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
33400119|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
32921959|NCT05343572|Experimental|Endometrial Disorders|"Three groups of patients, with 10 subjects per group:~Asherman's syndrome, as classified by the American Society of Reproductive Medicine (ASRM) by extent of uterine cavity involvement and adhesion type. Specifically, refractory Asherman's syndrome: patients who have had at least one operative hysteroscopy which was unsuccessful.~Atrophic endometrium, as defined by maximal endometrial lining thickness ≤6mm documented in at least 2 cycles on either:~Day of luteinizing hormone (LH) surge in natural cycle~Day of human chorionic gonadotropin (hCG) trigger in the setting of fresh IVF cycle~Day 14 of estradiol in the setting of frozen embryo transfer things (FET) cycles~Recurrent implantation failure, defined as failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen transfer cycles in a woman under 40 years"
32921960|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
32921961|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
32921962|NCT04350086|Experimental|Experimental arm|
32921963|NCT05738408|No Intervention|Control: Usual Care|will receive standard treatment which entails referral to Vermont Quit Network. This network offers a wide range of free cessation services, including NRT and web-based modules on preparing to quit and developing a plan
32921964|NCT05738408|Experimental|Intervention: Financial incentives and nicotine replacement therapy intervention|an intervention where patients are assigned to financial incentives and NRT of their choice; use of CO monitor to assess abstinence
32921965|NCT05738330|Active Comparator|SMaRRT-HD (Symptom Monitoring on Renal Replacement Therapy - Hemodialysis)|Dialysis clinics randomized to SMaRRT-HD will implement the SMaRRT-HD symptom monitoring system. SMaRRT-HD consists of 1) tablet-based symptom reporting using a patient reported outcome measure (PROM) and 2) supported clinician follow-up consisting of symptom alerts, guidances for symptom management, and symptom tracking reports that are shared with patients. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
32921966|NCT05738330|Active Comparator|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
32921967|NCT03837392|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) - participants in this arm will take part in an online ACT + psychoeducation intervention. The intervention will provide psychoeducation surrounding perinatal anxiety and depression as well as on engaging social support and coping strategies. The ACT portion of the intervention will focus on developing psychological flexibility, which is defined as behaviorally pursuing one's values even in the presence of barriers (e.g., thoughts, emotions). Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
32921968|NCT03837392|Active Comparator|Supportive Psychoeducation|Control group - participants in this arm will take part in an online psychoeducation and support intervention. This intervention will focus on psychoeducation surrounding perinatal anxiety and depression, as well as on engaging social support and coping strategies. Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
32921969|NCT03417739|Experimental|BVD-523|BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
32921970|NCT05322356|Experimental|Intervention|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D system
32921971|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
32921972|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
32921973|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
32921974|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
32921975|NCT05738252||Neo-adjuvant Chemotherapy|Patients who will be receiving neo-adjuvant chemotherapy prior to surgery.
32921976|NCT05738252||No Chemotherapy|Patients who do not have planned chemotherapy.
32719699|NCT04792372|Other|Periodontitis patients|Single-group receiving periodontal treatment. The data will be evaluated according to the healing potential of individuals in the group and also site-specifically.
32719700|NCT05235256|Active Comparator|SPGB Group|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
32719701|NCT05235256|Active Comparator|GONB Group|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
32719702|NCT04792216|Experimental|Wild Salmon|Wild salmon fillets in a raw form
32719703|NCT04792216|Experimental|Farmed Salmon|Farmed salmon fillets in a raw form
32719704|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
32719705|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
32719706|NCT05651386|Other|Six food elimination diet|The six food elimination diet will be performed in all subjects.
32719707|NCT05651308|Experimental|Intervention|The intervention group will assign care coordinators to PLWD based on perceived need for assistance with care coordination. Perceived need will be measured through a proxy's responses to a previously validated telephone survey on perceptions of care coordination.
32719708|NCT05651308|Active Comparator|Control|Usual care assigns patients to care coordinators in response to a discharge from a hospital or a direct referral from a physician.
32921977|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
32921978|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
32921979|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
32921980|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
32921981|NCT05319548|Active Comparator|Starting with Purple-Red Carrot Juice|Participants are randomized to consume purple-red carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple carrot juice.
32921982|NCT05319548|Active Comparator|Starting with Purple Carrot Juice|Participants are randomized to consume purple carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple-red carrot juice.
32719709|NCT03347188|Experimental|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters [mL] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
32921983|NCT05319548|Active Comparator|Starting with Red Carrot Juice|Participants are randomized to consume red carrot juice first (250 mL) in under 2 minutes. They will crossover to purple-red carrot juice and to purple carrot juice.
32921984|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
32921985|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
32921986|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
32921987|NCT03369223|Experimental|Part 1A: BMS-986249|
32921988|NCT03369223|Experimental|Part 1B: BMS-986249 + nivolumab (nivo)|
32921989|NCT03369223|Experimental|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
32921990|NCT03369223|Experimental|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
32921991|NCT03369223|Experimental|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
32921992|NCT03369223|Experimental|Part 2B Cohort 1: BMS-986249 + nivo|Advanced or intermediate hepatocellular carcinoma (HCC)
32719710|NCT03347188|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
32719711|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
32921993|NCT03369223|Experimental|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
32921994|NCT03369223|Experimental|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
32921995|NCT03369223|Experimental|Part 2A Arm A: BMS-986249 + nivo then nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
32921996|NCT03369223|Experimental|Part 2A Arm B: BMS-986249 + nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
32921997|NCT03369223|Experimental|Part 2A Arm E: Nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
32921998|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
32921999|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
32922000|NCT05309018||Patients|
32922001|NCT05309018||medical staff|
32922002|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
32922003|NCT05736692|Experimental|Brief Sleep Intervention|1-session intervention designed to improve adolescent sleep quality and/or quantity.
33073361|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
33248858|NCT00835107|Experimental|Ziprasidone|
33248859|NCT00835107|Placebo Comparator|Sugar pill|
33248860|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
33248861|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
32719712|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
33248862|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
33248863|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
32719713|NCT04791514|Experimental|Treprostinil Palmitil Inhalation Powder|"Participants will be administered a single dose of trepreostinil palmitil inhalation powder (TPIP). The first participant will be administered TPIP 112.5 μg. Dose levels for subsequent participants will be determined based on information collected for the previous participant(s) by a Safety Review Committee.~An optional extended-use period for 16 weeks will be available to participants who have completed the core, single-dose period."
33248864|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
32719714|NCT04810546|Experimental|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
32719715|NCT04810546|No Intervention|Usual care|Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
32719716|NCT04596826|Experimental|healthy subjects|
32719717|NCT04596826|Experimental|glaucoma patients|
32719718|NCT04596826|Placebo Comparator|healthy volunteers|
33248865|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
33248866|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
32719719|NCT04596826|Placebo Comparator|Glaucoma patients|
32746098|NCT03203915|Experimental|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
32746099|NCT04807803|Experimental|Patients with compensated cirrhosis and portal hypertension|
33248867|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
33248868|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
33248869|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
33248870|NCT00742014|Experimental|1|
33248871|NCT00742092|Experimental|1|miglustat
33248872|NCT00742092|Placebo Comparator|2|placebo
33248873|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
33248874|NCT00742248|Active Comparator|A|Formoterol pMDI
33248875|NCT00742248|Active Comparator|B|Formoterol dry powder
33248876|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
33248877|NCT04249167|Experimental|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33248878|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
33248879|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
33248880|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
33248881|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
33248882|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
33248883|NCT05447910|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD for 2-8 weeks prior to surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo collection of blood and tissue samples.
33248884|NCT03883854||1 group|"Complete iron profile~serum iron~serum ferritin~total iron binding capacity~transferrin saturation (TSAT)"
33248885|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each~Step 2: Treat boost volume to prostate and seminal vesicles~Acceptable treatment modalities:~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT~Permanent prostate implant (PPI):~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
32922004|NCT05736692|No Intervention|Control|Care as Usual. Those in this condition will be asked to continue their scheduled/prescribed care until the next study assessment. Note that, to ensure that all participants (control and sleep intervention) are offered the current standard of care, all will get a simple handout on sleep hygiene and any who is not receiving follow-up care will be referred to the Brain Health and Wellness Center (the multidisciplinary program to which all PCSS care at Cincinnati Children's is routed).
32922005|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
32922006|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
32922007|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
32922008|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
32922009|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
32922010|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
32922011|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
32922012|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
32922013|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
32922014|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
32922015|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
32922016|NCT05736614|No Intervention|Stage 1 Standard of Care (SOC) Control Condition|SOC participants will receive an informational pamphlet about the PrEP as a form of HIV prevention and referrals to local PrEP Prescribers.
32922017|NCT05736614|Experimental|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
32719720|NCT02440568|Experimental|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
32922018|NCT05736614|No Intervention|Stage 2 SOC Control Condition|Research staff will show a brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission. Participants will continue to see their PrEP prescriber for routine clinical care.
32922019|NCT05736614|Experimental|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
32719721|NCT02440568|Experimental|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
32719722|NCT02440568|Experimental|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
32746100|NCT04801017|Experimental|OT-101 + Artemisinin + Standard of Care|"OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.~Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral"
33400120|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
32922020|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
32922021|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
32922022|NCT05586152|Experimental|INV-102 0.1% BID|Part 1, Cohort 1: INV-102 ophthalmic solution 0.1% administered twice daily for 2 weeks
32746101|NCT04801017|Placebo Comparator|Placebo + Artemisinin + Standard of Care|Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
32922023|NCT05586152|Experimental|INV-102 0.25% BID|Part 1, Cohort 2: INV-102 ophthalmic solution 0.25% administered twice daily for 2 weeks
32922024|NCT05586152|Experimental|INV-102 0.7% BID|Part 1, Cohort 3: INV-102 ophthalmic solution 0.7% administered twice daily for 2 weeks
32719723|NCT02440568|Experimental|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
32719724|NCT04921436|Experimental|cardiac surgery patients with preventive treatment|"In addition to standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery), the following antibiotic regimens will be used perioperatively:~Doxycycline (the day before surgery 200 mg and 100 mg on days 1 and 2 after surgery) or Rimfampicin (150 mg 2 times a day before and after surgery) + Gentamicin (240 mg 3 times a day before and 2 days after surgery) or Clarithromycin (500 mg once daily for up to 2 days after surgery).~The route of administration (oral / intravenous) will depend on the condition of the patient."
32719725|NCT04921436|No Intervention|cardiac surgery patients without preventive treatment|standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery)
32719726|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
32922025|NCT05586152|Experimental|INV-102 0.7% TID|Part 1, Cohort 4: INV-102 ophthalmic solution 0.7% administered three times daily for 2 weeks
32922026|NCT05586152|Experimental|INV-102 TBD% BID|Part 2, Cohort 5: INV-102 ophthalmic solution administered for 2 weeks using a dose based on the results from Part 1, Cohorts 1 to 4
32922027|NCT05586152|Placebo Comparator|Vehicle|Part 1 (Cohorts 1-4) and Part 2 (Cohort 5): Vehicle ophthalmic solution administered two or three times daily (dependent on the cohort and the frequency of dosing of INV-102) for 2 weeks
32922028|NCT05585372|No Intervention|control group|The control group will receive general stability exercises and neurodynamic mobilization only
32922029|NCT05585372|Experimental|CT guided opening mobilization of cervical intervertebral foreman|"Grade four manual therapy mobilization of cervical intervertebral foreman guided by 3 dimensions computed tomography (CT) as following :~Determining the poper direction of cervical IVF by 3D CT.~the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
32922030|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
32922031|NCT05578820|Experimental|Dose escalation phase|"Stimotimagene copolymerplasmid will be administered intratumoral once in a dose of 20 mkg of DNA per 1 cm3 of tumor (for cohort 1) and 40 mkg of DNA per 1 cm3 of tumor (for cohort 2).~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
32922032|NCT05578820|Experimental|Two times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally twice with 5-day interval in the optimal dose selected at previous stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
32922033|NCT05578820|Experimental|Tree times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally three times with 5-day interval in the optimal dose selected at first stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
32922034|NCT05269004|Experimental|Ocrelizumab|Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046). Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
32922035|NCT05736458|Experimental|High regional controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of high regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
32719727|NCT00931606|Experimental|1|ACE-011 Treatment Group (Dose Level 1)
32922036|NCT05736458|Active Comparator|Low controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of low regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
32922037|NCT05736458|Experimental|High regional controllability TMS target in ADHD participants|We will administer TMS to an individualized target of high regional controllability while patient completes a working memory task inside the MRI scanner.
32719728|NCT00931606|Experimental|2|ACE-011 Treatment Group (Dose Level 2)
32719729|NCT00931606|Experimental|3|ACE-011 Treatment Group (Dose Level 3)
32719730|NCT00931606|Placebo Comparator|4|Placebo
32719731|NCT05643976|Active Comparator|Standard-of-care cardiac rehabilitation (SOC CR)|
32719732|NCT05643976|Experimental|Cardiac Rehabilitation + KardioPAC (CR+KardioPAC)|
32719733|NCT04783168|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.
32746102|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
32922038|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
32922039|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
32922040|NCT05736380|Active Comparator|Unilateral cerebellar rTMS|
32922041|NCT05736380|Sham Comparator|Sham cerebellar rTMS|
32922042|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
32922043|NCT04609137|Experimental|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
32922044|NCT04609137|Active Comparator|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
32922045|NCT05736302||Individuals without movement limitations|Individuals who are not classified as impaired or functionally limited per results of physical function testing.
32922046|NCT05736302||Individuals with impaired movement|Individuals who are classified as impaired, but not functionally limited per results of physical function testing.
32922047|NCT05736302||Individuals with impaired movement who are functionally impaired|Individuals who are classified as impaired and functionally limited per results of physical function testing.
32922048|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
32719734|NCT04783168|Active Comparator|Arm II (usual care, Fitbit)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count
32719735|NCT04783168|Experimental|Arm III (usual care, Fitbit, Fitbit app)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.
32719736|NCT05643664|Active Comparator|Standart technology|the zone of aortic and main artery clamping is determined by the surgeon intraoperatively.
32719737|NCT05643664|Experimental|Artificial intellect|"The multispiral computed tomography data is evaluated using artificial intelligence and the definition of safe zones of aortic and main artery clamping is performed. Intraoperatively, clamping is performed in the settlement zones."
32719738|NCT04783090|Experimental|1st cohort|MT1013 injection at 2.5 mg.
32922049|NCT04599855|Experimental|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale [MADRS] assessment).
32922050|NCT04599855|Experimental|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
32719739|NCT04783090|Experimental|2nd cohort|MT1013 injection at 5 mg.
32719740|NCT04783090|Experimental|3rd cohort|MT1013 injection at 10 mg.
32719741|NCT04783090|Experimental|4th cohort|MT1013 injection at 15 mg.
32922051|NCT04599855|Experimental|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
32922052|NCT04768088|Experimental|One-week training of falling techniques on landing biomechanics associated with ACL loading|Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment.
32922053|NCT03288103|Experimental|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for a 3 year period.
32922054|NCT05254340|Experimental|Healthy volunteers|Adults ages 18-75 years with no prior history of gastrointestinal diseases or symptoms.
32922055|NCT05314855||Obese individuals with normal insulin sensitivity|
32719742|NCT04783090|Experimental|5th cohort|MT1013 injection at 20 mg.
32719743|NCT04790734|Experimental|Remimazolam|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
32719744|NCT04790734|Active Comparator|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 2.0 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
32719745|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
32719746|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
32922056|NCT05314855||Obese individuals with impaired insulin sensitivity|
32719747|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
32922057|NCT05314855||Obese patients with type 2 diabetes|
32719748|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
32719749|NCT04540900|Active Comparator|KB301|non-integrating HSV-1 vector expressing human type III collagen injection
32922058|NCT04265625|No Intervention|blind tracheotomy|no endoscopic guidance tracheotomy
32719750|NCT04540900|Placebo Comparator|Placebo|sterile isotonic saline injection
32922059|NCT04265625|Experimental|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
32922060|NCT05559164|Experimental|Anti-HER2 targeted therapy + Lipitor 40mg daily|Participants will receive Lipitor 40 mg PO daily while receiving anti-HER2 therapy.
32719751|NCT04789954|Experimental|AryoSeven 10 μg/kg|Single dose, intravenously
32719752|NCT04789954|Experimental|AryoSeven 30 μg/kg|Single dose, intravenously
32719753|NCT04789954|Experimental|AryoSeven 90 μg/kg|Single dose, intravenously
32719754|NCT04789954|Experimental|AryoSeven 270 μg/kg|Single dose, intravenously
33400121|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
32719755|NCT04789954|Active Comparator|NovoSeven 30 μg/kg|Single dose, intravenously
32922061|NCT04258839|Experimental|Arm 1|Brexpiprazole
32922062|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
32922063|NCT05244512|Experimental|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
32922064|NCT05244512|Active Comparator|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
32922065|NCT04258137|Experimental|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
32922066|NCT04258137|No Intervention|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
32922067|NCT04258137|Experimental|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
32922068|NCT04258137|No Intervention|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
32922069|NCT04257747|Sham Comparator|Healthy volunteers|
32922070|NCT04257747|Active Comparator|patients requiring radial forearm flap reconstruction|
32922071|NCT04257747|Experimental|patients having received hand allotransplantation|
32922072|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
32719756|NCT04420624|Experimental|Colchicine|colchicine and standard therapy
32719757|NCT04420624|No Intervention|Comparator|standard therapy
32922073|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
32719758|NCT04341064|Experimental|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
32719759|NCT04341064|No Intervention|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
33400122|NCT03739476|Experimental|Interventional|Quetiapine 25 milligrams 1 hour after surgery and each 12 hours for 3 days
33400123|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
32719760|NCT03090191|Experimental|Clostridium difficile vaccine|
32719761|NCT03090191|Placebo Comparator|Placebo|
32719762|NCT04782778|Active Comparator|Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
32719763|NCT04782778|Active Comparator|Ultrasound Guided Supraclavicular Block|US-guided supraclavicular block with 1 mg/kg Bupivacaine (%0,25)
32719764|NCT04782544|Active Comparator|Treatment|5 grams of buttermilk powder daily for 10 weeks, oral.
32719765|NCT04782544|Placebo Comparator|Placebo|5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
32719766|NCT04798534|Experimental|Intervention group|CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support. MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
32719767|NCT04798534|No Intervention|Control group|The control group CHW will perform business as usual. Both control group CHW and MMT patients do not have access to the online platform.
32719768|NCT00646204|Experimental|1-Active study drug|memantine 10 mg bid
32922074|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium~oral use~3 times / day (morning, noon, evening)~666 mg per capsule~14 - 19 days"
32922075|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate~oral use~3 times / day (morning, noon, evening)~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)~14 - 19 days"
32922076|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,~oral use~3 times / day (morning, noon, evening)~14 - 19 days"
32922077|NCT05058872|Experimental|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg - once a day for 21 days
32922078|NCT05058872|Placebo Comparator|Placebo|Placebo once a day for 21 days
32922079|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
32922080|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
32719769|NCT00646204|Placebo Comparator|2-placebo comparator|2 tabs bid
32719770|NCT00543712|Experimental|PRO95780|
32719771|NCT00474604|Active Comparator|Participants without breast cancer|
32719772|NCT00474604|Experimental|Participants with breast cancer|
32719773|NCT00434434|Experimental|1|
32719774|NCT00434434|Experimental|2|
32719775|NCT00434434|Placebo Comparator|3|
32719776|NCT04047797|Experimental|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
32719777|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
32719778|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
32719779|NCT04020107|Active Comparator|Compressive garment associated with physical therapy|
32719780|NCT04020107|Placebo Comparator|Low compressive garment associated with physical therapy|
32719781|NCT04002401|Experimental|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional rituximab.
32719782|NCT03995225|Experimental|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app.
32719783|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
32719784|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
32719785|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
32719786|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
32719787|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
32719788|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
32719789|NCT03522857||Curtin University|Physiotherapy
32719790|NCT03522857||Notre Dame University|Physiotherapy
32719791|NCT03522857||University College Dublin|Physiotherapists
32719792|NCT03522857||Leeds Beckett University|Physiotherapists
32719793|NCT03522857||University College Cork|Physiotherapists
32719794|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
32719795|NCT03522857||University of Ulster|Physiotherapy
32719796|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
32719797|NCT03956537||Pedicle screw system alone|
32719798|NCT03956537||Pedicle screw system with cages|
32719799|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
32719800|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
32719801|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
32719802|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
32922081|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
32922082|NCT05056922|Experimental|Tele-PCIT (Parent-Child Interaction Therapy)|
32922083|NCT05056922|Active Comparator|Treatment as Usual|
32922084|NCT03618771|Experimental|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
32922085|NCT03618771|Experimental|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
32922086|NCT05054036|Experimental|MoviPrep|"For MoviPrep, the dose, schedule, and route of administration are as follows:~On the evening prior to the colonoscopy, mix the powder with lukewarm water to a total volume of 32 oz. Drink 8 oz. every 15 minutes until the solution is finished. Drink 16 oz. of clear liquids before bed.~On the morning of the procedure, repeat the above steps and make sure all fluids are consumed at least 2 hours prior to colonoscopy.~Limit food intake to a regular breakfast, light lunch and clear soup or plain yogurt for dinner on the day prior to the colonoscopy (completed at least 1 hour prior to the first MoviPrep dose.~Consume only clear liquids from the start of MoviPrep until after the colonoscopy."
32922087|NCT05054036|Active Comparator|GoLYTELY|"For GoLYTELY, the dose, schedule, and route of administrate are as follows:~On the evening prior to the colonoscopy, mix powder with lukewarm water to a total volume of 4 liters. Drink 2 liters of the solution and store the rest in the refrigerator.~Drink the remaining 2 liters on the morning of the procedure.~Limit food intake to a light breakfast on the day prior to the colonoscopy, followed by only clear liquids until the procedure is complete.~Avoid red and purple liquids."
32922088|NCT04595565|Experimental|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
32922089|NCT04595565|Other|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
32922090|NCT05049824|Experimental|SFM Treatment Arm|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion
32922091|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
32922092|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
32719803|NCT03522623||IBD|Children and families with IBD will be surveyed
32922095|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
32922096|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
32719804|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
32719805|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
32719806|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
32719807|NCT04936256||Bilateral implantation of the Clareon monofocal IOL|Clareon monofocal intraocular lens (IOL)
32719808|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
32719809|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
32719810|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
32719811|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
32719812|NCT02466386|Experimental|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
32719815|NCT04936100|Experimental|"Visual acuity assessment using Vision Screening module of Easy Vision application"|
32719816|NCT04936100|Experimental|"Visual acuity assessment using Test Yourself module of Easy Vision application"|
32719817|NCT04936100|Experimental|"Visual acuity assessment using Peek Acuity application"|
32719818|NCT04936100|Other|Visual acuity assessment using the conventional methods|
32719819|NCT04936022|Other|Control|To receive standard care lifestyle advice only
32922097|NCT04560621|Experimental|MAPS+|
32922098|NCT04560621|No Intervention|Standard of Care|
32922099|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
32922100|NCT03538899|Experimental|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
32922101|NCT04238715|Experimental|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
32922102|NCT04230681|Active Comparator|Fentanyl|
32922103|NCT04230681|Active Comparator|Hydromorphone|
32922104|NCT04538625|Placebo Comparator|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
32719820|NCT04936022|Experimental|Isometric Exercise|To receive standard care lifestyle advice plus 3 sessions of isometric exercise per week
32719821|NCT01633060|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
32719822|NCT01633060|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
32719823|NCT05645549|Experimental|Centering Pregnancy with Care Navigation for pregnant Marshallese women|Forty pregnant Marshallese women will be enrolled in the group prenatal intervention, Centering Pregnancy, with care navigation to determine the feasibility of the intervention and the preliminary effectiveness to improve maternal and infant health care outcomes.
32922105|NCT04538625|Experimental|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
32922106|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/twice daily (BID)~Cisplatin - 15 mg/m^2~Irinotecan - 20 mg/m^2"
32922107|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 40 mg/m^2"
32922108|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 60 mg/m^2"
32922109|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
32922110|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 40 mg/m^2"
32922111|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
32922112|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
32922113|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
32922114|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
32922115|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
32922116|NCT04187391|Experimental|Active tDCS plus individual language training|Active tDCS plus individual language training
32922117|NCT04187391|Active Comparator|placebo tDCS plus individual language training|placebo tDCS plus individual language training
32922118|NCT04187391|Active Comparator|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
32719824|NCT05645549|No Intervention|Pregnant Marshallese women enrolled in standard prenatal care|We will use a 1:1 propensity score matching with pregnant Marshallese women who completed standard prenatal care to compare their maternal and infant health care outcomes with those participants enrolled in the intervention.
32922119|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
32922120|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
32719825|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
32719826|NCT03914495|Placebo Comparator|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
32922121|NCT04532541||Patients with childhood onset SLE|Participants in this group were derived from patients diagnosed with SLE at an age of less than 18 years old, and these patients were hospitalized in our center. Peripheral blood was collected from the patient and their biological parents for gene analysis to obtain the overall incidence of monogenic lupus in the cohort.
32922122|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
32922123|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the participants reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, participants will be treated with selexipag as long as the treatment is beneficial to the participants, as per investigator's decision.
32922124|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
32719827|NCT03914495|Active Comparator|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
32719828|NCT03906695|Experimental|10-Day Schedule|"10-Day Schedule~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
32719829|NCT03906695|Experimental|5-Day Schedule A|"5-Day Schedule A~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
32719830|NCT03906695|Experimental|5-Day Schedule B|"5-Day Schedule B~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
32719831|NCT03906695|Experimental|5-Day Schedule C|"5-Day Schedule C~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
32719832|NCT03906695|Experimental|7-Day Schedule|"7-Day Schedule~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
32719833|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
32719834|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
32719835|NCT03878459|Experimental|Intervention|pioglitazone treatment
32719836|NCT03878459|Placebo Comparator|control|subjects will receive placebo
32719837|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
32719838|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
32719839|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
32719840|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
32719841|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
32719842|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
32719843|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
32719844|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.
32719845|NCT02775851|Active Comparator|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.
32719846|NCT05473000|Experimental|Ozone (O3)|Participants of the experimental group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.
32719847|NCT05473000|Sham Comparator|Room air|Participants of the sham group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling room air during each exercise session.
32719850|NCT04240756|Experimental|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
32719851|NCT04240756|Active Comparator|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
32719852|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
32719853|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
32719854|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
32719855|NCT03522389|Active Comparator|Gait training group|Gait training
32719856|NCT03522389|Other|Control group|Education
32719857|NCT04467125|Experimental|EMLA|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
32719858|NCT04467125|Active Comparator|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.
32719859|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 6 months and treatment is ongoing at the time of enrollment.
32719860|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
32719861|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
32719862|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
32719863|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
32719864|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
32922125|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
32922126|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
32922127|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
32922128|NCT05711251|Experimental|Physical Activity in Health Promotion Group|"Students who chose the Physical Activity in Health Promotion course were included in the experimental group. The participants in this group took the courses shown in the weekly schedule below during the semester.~Historical Development of Physical Activity~Physical Activity Definition and Types~Physical Activity Measurement~Physical Fitness and Inactivity~Physical Activity in Healthy Adults~Physical Activity in Children~Physical Activity in the Elderly~Physical Activity for the Disabled~Physical Activity at Work-I~Physical Activity at Work-II"
32922129|NCT05711251|No Intervention|Control Group|"Students who chose the Posture Disorders and Waist and Neck Health courses given by different instructors at the same time and day were included in the control group. the participants in this group took 2 different courses, shown in the weekly schedule below, at the same time, from different physiotherapists during the semester.~Waist and Neck Health~Functional anatomy, biomechanics and pathomechanics of the spine~Risk factors for low back and neck pain~Back and neck pain related disorders~Outcome measures in low back and neck pain~Treatment approaches~Cervical and Lumbar disc lesions and physiotherapy~Exercise principles for low back and neck pain~Core stabilization, strengthening and stretching exercises~Neck school: Organization, methods and principles~Ergonomics"
33400124|NCT05000268|Active Comparator|Painful Healthcare Workers with COVID-19|Healthcare workers who have had COVID-19 infection in the past and are now in pain without COVID-19 infection
33400125|NCT05000268|Active Comparator|Painful Health Care Workers without COVID-19|Healthcare workers with past and present pain without COVID-19 infection
32719865|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
32719866|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
32719867|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
32719868|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32719869|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32719870|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
32719871|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
32719872|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
32719873|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
32719874|NCT04920656||Breast cancer patients|All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.
32719875|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
32719876|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
32719877|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
32719878|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
32719879|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
32719880|NCT04943354|Active Comparator|Study of single-nucleotide polymorphisms in women diagnosed with premature ovarian failure|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), proinflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in the study group of women diagnosed with premature ovarian failure.
32719881|NCT04943354|Active Comparator|Study of single-nucleotide polymorphisms in a control group of healthy women|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in a control group of healthy women .
32719882|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
32719883|NCT02545205|Active Comparator|Conventional gait training|
32719884|NCT02532257|Experimental|Treatment (lenalidomide, rituximab, ibrutinib)|Patients receive lenalidomide PO on days 1-21, rituximab IV over 4-6 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of all subsequent cycles, and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
32719885|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
32719886|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
32719887|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
32746103|NCT04801251|Other|Resident|Full history.complete systemic and cardiac physical examination
33400126|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|Haloperidol + Promethazine + Chlorpromazine are all psychiatric drugs that have been well tested. The combination of these 3 drugs, however, have never been randomised.
32922130|NCT04526535||No B-lines|Patients with no significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (any field with 3 or more B-lines)
32922131|NCT04526535||B lines|Patients with significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (3 or more B-lines in at least one lung field)
33400127|NCT03639558|Experimental|Haloperidol + Promethazine|Haloperidol + Promethazine are both psychiatric drugs with antipsychotic and calming properties.
32719888|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32719889|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
32719890|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
32719891|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
32719892|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
32719893|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
32719894|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
32719895|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
32719896|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
32719897|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
32719898|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
32719899|NCT02153957|Experimental|1|enhanced PA home intervention group for the first 12 weeks; followed by 12 weeks of PA maintenance on their own.
32719900|NCT02153957|Active Comparator|2|usual physical activity (no intervention) for 12 weeks; followed by the enhanced PA home intervention for 12 weeks.
32719901|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
32719902|NCT04466813|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
32719903|NCT04466813|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
32719904|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
32719905|NCT03386721|Experimental|Cohort A (Part I)|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
32719906|NCT03386721|Experimental|Cohort B (Part I)|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
32719907|NCT03386721|Experimental|Cohort C (Part I)|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
32719908|NCT03386721|Experimental|Cohort D Arm I (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
32719909|NCT03386721|Experimental|Cohort D Arm 2 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
33400128|NCT05477485|No Intervention|Usual care|Providers will be cluster-randomized by provider characteristics (HIV patient volume) and patient characteristics (distribution of providers' patients by age, gender, race/ethnicity, and urbanicity). Participants who are patients of providers assigned to the usual care arm will receive standard state-level care for missing or late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
32719910|NCT03386721|Experimental|Cohort D Arm 3 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
32719911|NCT03386721|Experimental|Cohort E Arm I (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
32719912|NCT03386721|Experimental|Cohort E Arm 2 (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
32719913|NCT03386721|Experimental|Cohort F (Part I)|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional."
32719914|NCT03386721|Experimental|Cohort G (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
32719915|NCT03386721|Experimental|Cohort H (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
32719916|NCT03386721|Experimental|Cohort I (Part III)|Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
32719917|NCT03386721|Experimental|Cohort J (Part III)|Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
32719918|NCT03386721|Experimental|Cohort K (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
32719919|NCT03386721|Experimental|Cohort L (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
32719920|NCT03386721|Experimental|Cohort M (Part III)|Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
32746104|NCT04801251|Other|Assistant Lecturer|Echocardiographic examination
33073362|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
33400129|NCT05477485|Experimental|AIMS program - patient|Providers will be cluster-randomized by provider characteristics (HIV patient volume) and patient characteristics (distribution of providers' patients by age, gender, race/ethnicity, and urbanicity). Participants who are patients of providers assigned to the AIMS program arm will receive patient-level support.
33400130|NCT05477485|Experimental|AIMS program - provider|Providers will be cluster-randomized by provider characteristics (HIV patient volume) and patient characteristics (distribution of providers' patients by age, gender, race/ethnicity, and urbanicity). Participants assigned to the AIMS program arm will receive provider-level support.
33400131|NCT03506646|Experimental|Beetroot juice-Placebo|Subjects will be tested on two different days. The first day will be beetroot juice and the second day will be a placebo. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
33400132|NCT03506646|Experimental|Placebo-Beetroot juice|Subjects will be tested on two different days. The first day will be a placebo and the second day will be beetroot juice. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
33400133|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
33400134|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
33400135|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
33400136|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
33400137|NCT05470855|Experimental|Experimental Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will receive one dose of varicella vaccine.
33400138|NCT05470855|No Intervention|Control Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine.
33400139|NCT05470855|Experimental|Safety group|30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected.
33400140|NCT05470855|Experimental|Etiological study group|Herpes fluid collected from varicella cases in study 1 will be used to conduct etiological study on the pathogenic strains of varicella cases.
33400141|NCT05681923||High-Risk Cohort|"High family risk cohort for recurrence of autism and other developmental disorders in siblings (have at least one child with a confirmed diagnosis of autism)~Specific to the High Risk cohort:~Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken"
33400142|NCT05681923||Low Risk Cohort|Low family risk cohort for recurrence of autism and occurrence of other developmental disorders in siblings. The risk is comparable to the risk observed in the general population (do not have a child with autism, nor with other developmental disorders).
33400143|NCT01568268|Experimental|Palonsetron|
33400144|NCT01568268|Placebo Comparator|Placebo|
33400145|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
33400146|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
33400147|NCT04978519|Experimental|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
33400148|NCT05598060|Experimental|neoadjuvant stereotactic body radiation therapy followed by hepatectomy|Experimental: Phase1(Cohort 1): neoadjuvant stereotactic body radiation therapy (24Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 2): neoadjuvant stereotactic body radiation therapy (30Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 3): neoadjuvant stereotactic body radiation therapy (36Gy/3Fr) followed by hepatectomy
33400149|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
33400150|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
33400151|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
33400152|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
33400153|NCT03210714|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
33400154|NCT04919707|Experimental|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
32719921|NCT03386721|Experimental|Cohort N (Part III)|Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
32922132|NCT03584165|Experimental|BIIB111|Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
32719922|NCT04466735|Experimental|Active group|Participants will be on the active intervention for 6 months
32719923|NCT04466735|Placebo Comparator|Placebo Group|Participants will be on the placebo intervention for 6 months
32719924|NCT04466735|Active Comparator|Open phase on active product|At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months.
32719925|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
32922133|NCT03584165|Experimental|BIIB112|Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
32922134|NCT03584165|No Intervention|Untreated|Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
32922135|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
32922136|NCT04330365|Active Comparator|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
32922137|NCT04330365|Active Comparator|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
32922138|NCT04330365|Placebo Comparator|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
32935848|NCT04724317|Active Comparator|PRF Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by pulsed radiofrequency application under the ultrasound guidance
32719926|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
33073363|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
33248886|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
32719927|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
32719928|NCT03524105|Active Comparator|Thrive Professional Learning track|
32719929|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
32719930|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
32719931|NCT01468883|Active Comparator|M|Modified radical mastectomy
32719932|NCT01468883|Experimental|X|Excisional biopsy plus radiation
32719933|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
32719934|NCT05393661||Patients undergoing inpatient rehabilitation poststroke|Inpatient rehabilitation poststroke
33400155|NCT04919707|Experimental|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
32922139|NCT03467373|Experimental|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
32922140|NCT03467373|Experimental|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by G/R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
32922141|NCT03467373|Experimental|Part 2: DLBCL Pola-R-CHP|Participants with untreated DLBCL will receive Pola-R-CHP + glofitamab on Day 1 of each 21-day cycle for a maximum of 6 cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
32922142|NCT03578237|Experimental|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
32922143|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
32922144|NCT00362765|Experimental|1|
32922145|NCT00362765|Active Comparator|2|
32922146|NCT00362765|Active Comparator|3|
32922147|NCT00362765|Placebo Comparator|4|
32922148|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
32922149|NCT03430011|Experimental|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
32922150|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
32922151|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
32719935|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
32719936|NCT05085093||Study Group|HPV vaccine group
32719937|NCT05085093||Control group|non HPV vaccine group
32719938|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
32719939|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
32719940|NCT05084781|Experimental|Coblation Debridement|FLOW 90 / WEREWOLF debridement of rotator cuff footprint.
32719941|NCT05084781|Active Comparator|Mechanical Debridement|Standard mechanical debridement of rotator cuff footprint.
32719942|NCT05084703|Experimental|Patients operated for previous shoulder instability|Different functionnal test to be done
32719943|NCT05084703|Active Comparator|Healthy volunteer|Different functionnal test to be done
32719944|NCT05081739|Active Comparator|Prospera Surveillance|Subjects will undergo Prospera testing in accordance with the institution's Control Group EMB surveillance standard of care schedule, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Prospera test results will be provided to investigators. Prospera cfDNA level < 0.15 % will be interpreted as negative, and screening EMB will be omitted. EMB will be performed for cfDNA level ≥ 0.15 %. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion. Additional research blood samples will be collected for research purposes; the results of testing performed on research samples will not be provided to investigators.
32746105|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
32746106|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
32922152|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
32922153|NCT04174365|Experimental|Brexpiprazole|
32922154|NCT04174365|Placebo Comparator|Placebo|No Intervention
32922155|NCT03301883|Experimental|Tocilizumab|Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
32922156|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
32922157|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
32922158|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
32922159|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
32922160|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
32922161|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
32922162|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
32719945|NCT05081739|No Intervention|EMB Surveillance|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Research blood samples will be obtained at the time of each EMB. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion. Research blood samples will be collected for research purposes; the results of testing performed on research samples will not be provided to investigators.
32719946|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
32719947|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
32719948|NCT05073939|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
32719949|NCT05073939|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
33248887|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
33248888|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
33248889|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
33248890|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
33248891|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
32719954|NCT04789018||Observational (survey, virtual genetic board, interview)|Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
32719955|NCT05065125||LDLT cohort|Living-donor liver transplatation (LDLT) patients with anastomotic biliary stricture
32719956|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
32719957|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
32719958|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
32719959|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
32719960|NCT03523481||NHF use|
32719961|NCT04206982|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
32719962|NCT04206982|Active Comparator|Pulmonary vein isolation arm|
32719963|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
32719964|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
32719965|NCT05254301|Experimental|Personalized multimodal treatment|A combination of biometric parameter oriented nutritional counseling and a tailored physical training program.
32719966|NCT05254301|Active Comparator|Standard care|Physiotherapy with standard care advice for gradual cardiorespiratory and resistance training. (In this standard care setting, nutritional screening nor counseling is included.)
32719967|NCT05433610|Experimental|Constant Treadmill Load Test (CTLT) using non-invasive ventilation (NIV)|Exercise capacity testing using PS in HF patients
32719968|NCT05433610|Experimental|Constant Treadmill Load Test (CTLT) using NIV|Exercise capacity testing using CPAP in HF patients
32719969|NCT05433610|Active Comparator|Constant Treadmill Load Test (CTLT) without NIV|Exercise capacity testing without NIV in HF patients
32719970|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
32719971|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
32746107|NCT04800705||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
32746108|NCT04800705||Control group|The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
32719972|NCT04192630|Experimental|CVisc50 Ophthalmic Viscosurgical Device (OVD)|CVisc50 OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to Intraocular Lens (IOL) implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
32719973|NCT04192630|Active Comparator|ProVisc OVD|ProVisc OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
32719974|NCT00159783|Experimental|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
32719975|NCT00159783|Active Comparator|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
32719976|NCT04158154|Experimental|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
32746109|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
32922163|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
32922164|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
33248892|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
32922165|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
32922166|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
32922167|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
33248893|NCT00841737|Active Comparator|Control group|Individual conventional care
33248894|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
33248895|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
33248896|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
32922168|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
33248897|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
32922169|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
32922170|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
32922171|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
32922172|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
32922173|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
32935849|NCT04697017|Other|Multiple births (twins and triplets)|Twins and triplets who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study
33248898|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
33248899|NCT00835653||1|patients with a carpal tunnel syndrome
33248900|NCT00835653||2|patients without a carpal tunnel syndrome
33248901|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
33248902|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
33248903|NCT05670938||Non-seminomatous germ cell tumours, stage I low risk|No lymphadenopathy or metastases on the postoperative scan. Three consecutive blood drawings with normal tumour markers. Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases.
33248904|NCT05670938||Non-seminomatous germ cell tumours, stage I high risk|"After completion of one cycle of Bleomycin, etoposide and platinum (BEP). Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
32719977|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities. Patients undergo blood sample collection on study.
32719978|NCT04682067|Experimental|Contingency Management|Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
32719979|NCT04682067|Placebo Comparator|Usual Care|Participants in the usual care (UC) group will receive the standard smoking cessation treatment offered at the Health Promotion Research Center's Tobacco Treatment Research Program (TTRP) at the University of Oklahoma. This includes at least 4 treatment sessions of counseling and the opportunity to use nicotine replacement therapy or medications.
32719980|NCT01023737|Experimental|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
32719981|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
32719982|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
32719983|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
32719984|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
32719985|NCT04136314|Experimental|Gain-Frame Survey [A]|
32719986|NCT04136314|Experimental|Loss-Frame Survey [B]|
32719987|NCT04465955|Experimental|NGM621 Treatment Group A (every 4 weeks)|NGM621 single IVT injection
32719988|NCT04465955|Experimental|NGM621 Treatment Group C (every 8 weeks)|NGM621 single IVT injection
32719989|NCT04465955|Sham Comparator|Sham Group B (every 4 wks) & D (every 8 wks)|Sham
32719990|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
32719991|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
32719992|NCT04128904|Active Comparator|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
32719993|NCT04128904|Active Comparator|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
32719994|NCT02936323|Experimental|Phase 1: Dose Escalation|"Cohort 1 will consist of two (2) participants who will receive PEN-221 at the starting dose of 1.0 mg. The first participant will be followed for at least 7 days for safety and dose limiting toxicity (DLT). If PEN-221 is tolerated, the second participant will be enrolled into the cohort. The two (2) participants will be followed for safety and DLTs for at least a 4-week observation period. The Safety Review Committee (SRC) will determine the initiation of cohort 2.~Cohort 2 and each subsequent dose escalation cohort will consist of 3 to 6 participants who will be treated at each dose level of PEN-221 as determined by the SRC and will be followed for safety and DLTs for at least a 3-week observation period. Each dose escalation level and cohort initiation will be determined by the SRC.~Dose escalation will continue until the Maximum Tolerated Dose (MTD) of PEN-221 is determined and the Recommended Phase 2a Dose (RP2D) is established by the SRC."
32719995|NCT02936323|Experimental|Phase 2a: Dose Expansion (GI mid-gut NET)|Gastrointestinal mid-gut NET Cohort
32719996|NCT02936323|Experimental|Phase 2a: Dose Expansion (PNET)|Pancreatic NET Cohort
32719997|NCT02936323|Experimental|Phase 2a: Dose Expansion (SCLC)|Small Cell Lung Cancer Cohort
32719998|NCT04625751||T2DM +CAN|
32719999|NCT04625751||T2DM -CAN|
32720000|NCT04625751||Healthy control|
32720001|NCT04105270|Experimental|Arm A (RMT)|
32720002|NCT04105270|Experimental|Arm B (Placebo)|
32720003|NCT04105270|Experimental|Safety Run-in|10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization
32720004|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
32720005|NCT04596891|Experimental|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
33248905|NCT05670938||Seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
33248906|NCT05670938||Non-seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
32720006|NCT04067596|Experimental|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
32720007|NCT05634785|Experimental|ATLCAR.CD30|Single Group Assignment: Subjects with Nonseminomatous Germ Cell Tumors who meet eligibility criteria for cellular therapy.
32720008|NCT04590573|Experimental|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
32720009|NCT04590573|Experimental|EFCT|Emotion focused couple therapy (EFCT), 5-session
32720010|NCT04590573|Active Comparator|Control|Social activity wait-list groups (Control), 5-session
32720011|NCT03985930|Experimental|Distraction Group|Children between the ages of 3 and 6 years will be distracted using virtual reality content delivered through goggles.
32720012|NCT03985930|Active Comparator|Treatment as Usual|Children randomized to this group will receive the usual medical care.
32720013|NCT05044221||Interviews: Past ICU patients and caregivers|Former ICU patients and their families that meet the following criteria: Adults > 18 years and above who required at least 48 hours of invasive mechanical ventilation and were in the ICU at least 4 days with an ICU admission in the past five years; and able to participate in a workshop in English.
32720014|NCT05044221||Interviews: Health care professionals|Active working health professionals with prior experience working directly in the ICU setting and/or care for ICU patients in their own clinical rea (acute, subacute and/or community settings).
32720015|NCT00887939||1|Affected physical urticaria
32720016|NCT00887939||2|Healthy volunteer
32720017|NCT00887939||3|Unaffected relative
32720018|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
32720019|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
32720020|NCT04770064|Experimental|High-dose/short-duration Fisetin (FIS-hi)|
32720021|NCT04770064|Experimental|Low-dose/sustained duration Fisetin (FIS-lo)|
32720022|NCT04770064|Placebo Comparator|Placebo|
32720023|NCT05393349|Experimental|Intervention Group|
32720024|NCT05393349|No Intervention|Standard Group|
32720025|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
32720026|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
32720027|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
32720028|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
32720029|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
32720030|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
32720031|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
32720032|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
32720033|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
32720034|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
32720035|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
32720036|NCT04551261|Experimental|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
32720037|NCT04551261|Experimental|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
32720038|NCT04690387|Experimental|0.1 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen
32720039|NCT04690387|Experimental|0.33 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen
32720040|NCT04690387|Experimental|1.0 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen
32922174|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
32922175|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
32922176|NCT05736068|Experimental|Non-surgical|No reduction. Application of a cast.
32922177|NCT05736068|Active Comparator|Surgical|Closed reduction under general anesthesia with or without additional pin fixation of surgeons' choice followed by cast immobilization.
32922178|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
32922179|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
32922180|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
32922181|NCT04173507|Experimental|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32922182|NCT05735990||640PM implanted|Patients implanted binocularly with Medicontur's intraocular lens model 640PM.
32922183|NCT05228522|Experimental|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
32922184|NCT05228522|No Intervention|Comparison control|Comparison control families meet with the Study Physician and a Registered Dietitian as a family to review laboratory results and receive lifestyle counseling. Control families will be contacted on a monthly basis for a total of 12 months.
32922185|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
32922186|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
32922187|NCT05033756|Experimental|Pembrolizumab / Olaparib|All eligible participants according to the definition of cohorts 1-3 will receive pembrolizumab i.v. 200 mg q3w in combination with olaparib tablets 300 mg twice daily (total dose 600 mg per day).
32922188|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
32922189|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
32922190|NCT03532295|Experimental|Regimen A: Retifanlimab+RT+bevacizumab|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Treatment may continue for up to two years."
32720041|NCT04690387|Experimental|0.1 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
32720042|NCT04690387|Experimental|0.33 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
32922191|NCT03532295|Experimental|Regimen B: Retifanlimab+RT+bevacizumab+epacadostat|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Epacadostat will be administered orally at 400 mg BID.~Treatment may continue for up to two years."
33248907|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
32720043|NCT04690387|Experimental|1.0 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
32720044|NCT04690387|Experimental|0.1 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
32720045|NCT04690387|Experimental|0.33 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
32720046|NCT04690387|Experimental|1.0 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF
32720047|NCT03534401|No Intervention|Standard Contraceptive Counseling|Providers at control clinics receive no additional training; clients receive standard contraceptive counseling services.
32720048|NCT03534401|Experimental|ARCHES Kenya Intervention in Contraceptive Counseling|Providers at intervention clinics receive training on ARCHES strategies integrated into contraceptive counseling; clients receive the ARCHES Kenya intervention integrated within standard contraceptive counseling services.
32720049|NCT05392725||Normal renal function group|Observe survival time
32720050|NCT05392725||Renal dysfunction group|Observe survival time
32743351|NCT04956393|Other|Delayed SOAR Program|Participants with a past sport-related knee injury randomized to the 'delayed intervention' group will have a 9-week unstandardized delay before completing an 8-week SOAR program (weeks 10-17). During the delay (weeks 1-9) the delay comparison intervention will be unstandardized to reflect usual care in Canada. After the 9-week delay, these participants will complete an 8-week (weeks 10-17) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and an optional weekly group-based exercise classes). Consented trained physiotherapists will deliver the SOAR program from week 10 to week 17 to one or more delayed SOAR group knee injury participants.
32720051|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
32922192|NCT05216042|Experimental|Experimental: Low NP Genotype Group|150 Healthy self-identified African-American and Caucasian adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
32720052|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
32720053|NCT04769830||AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
32720054|NCT04769830||non-AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
32720055|NCT04534257|Experimental|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
32720056|NCT04528953|Experimental|interval group|
32922193|NCT05216042|Experimental|Active Comparator: High NP Genotype Group|50 Healthy self-identified African-American and Caucasian adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
32922194|NCT05030714|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.
32922195|NCT05028452|Other|Internet based support|Internet based support for informal caregivers to individuals who are undergoing treatment for head and neck cancer.
32922196|NCT03522077|Experimental|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
32720057|NCT04528953|Experimental|Qigong exercise|
32720058|NCT04528953|Active Comparator|continuous walking|
32922197|NCT03522077|Active Comparator|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
32935850|NCT04697017|Other|Singletons|Singletons who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study.
32935851|NCT04943419||Colorectal cancer|Patients with colorectal cancer qualified for elective operations.
33400156|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
33400157|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
32720059|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
32720060|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
32720061|NCT04946955|Experimental|Application and website with promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
32720062|NCT04946955|Other|Application and website without promotion|
32720063|NCT05392647|Experimental|Single arm|Hetrombopag
32720064|NCT04064723|Active Comparator|Stem components|Randomization between two stem components. LCU or Corail stem.
32720065|NCT04064723|Active Comparator|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
32922198|NCT03522077|Experimental|SoftSeal®-STF hemostatic|Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
32922199|NCT03522077|Active Comparator|VascBand™ Hemostat|Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
32922200|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
32922201|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
32922202|NCT04499079|No Intervention|Probation Referral Practice as Usual|Data are collected regarding standard probation practice and outcomes before implementation of the Learning Health System.
32922203|NCT04499079|Experimental|Learning Health System|Participating counties receive a system-level intervention, a Learning Health System, designed to improve youth connection to substance use treatment.
33248908|NCT05669924|Experimental|Methylphenidate|
33248909|NCT05669924|Placebo Comparator|Placebo|
33248910|NCT00844233|Experimental|1|Irinotecan Bead
32922204|NCT04476693|Experimental|Breakfast Consumption (BC)|"The consumption of a standardised breakfast followed by a standardised lunch 3-h after the last mouthful of breakfast meal. All the ingredients of the breakfast and lunch provided will be weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period will be provided to avoid carry-over effects between conditions.~The standardised lunch will consist of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
32922205|NCT04476693|Experimental|Breakfast omission (BO)|"Participant will consume water, the individual volume of which was calculated based on the liquid content of the breakfast. A standardised lunch will be consumed 3-h after the last mouthful of water. All the ingredients of the breakfast and lunch provided were weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period was provided to avoid carry-over effects between conditions.~The standardised lunch consists of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
32922206|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
32922207|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
32922208|NCT04349618|Active Comparator|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
33248911|NCT00841893|Experimental|1|Mustard
33248912|NCT00841893|Experimental|2|Placebo
32922209|NCT04349618|Experimental|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
32922210|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
33248913|NCT05245682|Experimental|Treatment (tolinapant, radiation therapy)|Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
33248914|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
33248915|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
33248916|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
33248917|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
33248918|NCT05233436|Experimental|Part 1A Dose Escalation Monotherapy|Participants will receive PF-07265028 at escalating dose levels.
33248919|NCT05233436|Experimental|Part 1B Dose Escalation Combination|Participants will receive PF-07265028 at escalating dose levels in combination with sasanlimab fixed dose
33248920|NCT05233436|Experimental|Part 2A Dose Expansion Combination (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
33248921|NCT05233436|Experimental|Part 2A Dose Expansion Combination (UC)|Participants with urothelial cancer (UC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
33248922|NCT05233436|Experimental|Part 2A Dose Expansion Combination (Gastric/GEJ)|Participants with gastric/gastroesophageal junction cancer (Gastric/GEJ) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
33248923|NCT05233436|Experimental|Part 2A Dose Expansion Combination (NSCLC)|Participants with non small cell lung cancer (NSCLC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
32922211|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
32922212|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
32720066|NCT04922619|Active Comparator|Cochlear Implant (CI) with default fitting then tonotopy based fitting|Cochlear Implant with default fitting first during 6 weeks then with tonotopy based fitting during 6 weeks
32922213|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
32922214|NCT04474509|Experimental|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
32720067|NCT04922619|Active Comparator|Cochlear Implant (CI) with tonotopy based fitting then default fitting|Cochlear Implant with tonotopy based fitting during 6 weeks then with default fitting during 6 weeks
32922215|NCT04474509|Experimental|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
32922216|NCT04474509|Experimental|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
32922217|NCT02986568|Experimental|Cervical cancer|"Primary cervical cancer patients, FIGO stage IB1-IIB~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
32922218|NCT02986568|Experimental|Uterine cancer|"Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA~Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
32922219|NCT02986568|Experimental|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion~Primary cervical cancer~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
32922220|NCT02986568|Experimental|Non-cervical cancer, pelvic sidewall invasion|"Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis~Patients showing uncontrolled pelvic pain due to the tumor invasion"
32922221|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
32922222|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
32922223|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
32922224|NCT05209880|Experimental|Intervention Arm|The intervention will take place in the emergency department or days after an emergency department visit at home/hospital virtually using zoom or phone by our trained clinicians. At the time of follow-up assessments, participants may also receive additional counseling by our trained clinicians as needed.
32922225|NCT05209880|No Intervention|Control Arm|No intervention will be conducted (standard of care).
32922226|NCT00421967|Experimental|1|
32922227|NCT00421967|Active Comparator|2|
32922228|NCT04744337|Other|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliance for skeletal class II, Angle's class II division 2 malocclusion.
32935852|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
32720068|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
32720069|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
32720070|NCT04476927|Experimental|DiaNose procedure|all subjects will be required to undergo the DiaNose exhalation test.
32720071|NCT00033137||Family Members|A relative of a patient with a confirmed or suspected diagnosis of BHD (related by blood)
32720072|NCT00033137||Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis(Spouses have been removed from the inclusion criteria for this study. This closed cohort has been created for spouses previously enrolled on study.)
32922229|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
32922230|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
32922231|NCT04451187|Experimental|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
32922232|NCT04451187|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
33400158|NCT04911361|Active Comparator|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
32922233|NCT04451187|Experimental|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
32922234|NCT04451187|Experimental|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
32922235|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
32922236|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
32720073|NCT00033137||Patients|Patients with phenotype or genotype suggestive of Birt Hogg Dub(SqrRoot)(Copyright) and/or Renal tumor histology consistent with BHD
32922237|NCT04997798|Experimental|Dalpiciclib in combination with exemestane and trastuzumab plus pyrotinib|Patients are treated with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) for six cycles plus oral Dalpiciclib (125 mg QD x 21，Q4W) and Exemestane (25 mg po QD ）and oral pyrotinib (320 mg po QD) for 20 weeks.
32922238|NCT03199469|Experimental|Lower Dose|"1.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~1.3 x10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time."
32922239|NCT03199469|Experimental|Higher Dose|"3.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~3.5 x 10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time"
32922240|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
32922241|NCT04997096|Experimental|Exercise|"Participants randomized to one of two groups with 2:1 ratio: exercise (n=20)~- Aerobic and Resistance Exercise for 16 weeks"
32922242|NCT04997096|Active Comparator|Attention Control|"Participants randomized to one of two groups with attention control (n=10).~-Attention Control for 16 weeks home-based stretching"
32922243|NCT04089969|Experimental|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
32922244|NCT05209646|Experimental|Trial (Intervention) group|Patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation
33400159|NCT04911361|Experimental|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
32922245|NCT05209646|No Intervention|Control (Non-intervention) group|No honey will be given to this group
32720074|NCT04444323|Experimental|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
32720075|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
32720076|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
32720077|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
32720078|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
32720079|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
32720080|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
32720081|NCT03110445|Experimental|rVV-740CTA vaccine|
32720082|NCT04408599|Experimental|NC410|NC410 for IV infusion of various dose strengths administered in 14 day dosing cycles
32720083|NCT03382457|Experimental|Treatment|Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System
33248924|NCT05233436|Experimental|Part 2A Dose Expansion Combination (selected tumor types)|Participants with selected tumor types will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
33248925|NCT05233436|Experimental|Part 2B Dose Expansion Monotherapy (selected tumor types)|Participants with selected tumor types will receive PF-07265028 single agent at the recommended dose from Part 1A.
33248926|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
33248927|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
32720084|NCT03138681|Placebo Comparator|Placebo|
32720085|NCT03138681|Experimental|ATP|
32720086|NCT03138681|Experimental|phosphocreatine|
32720087|NCT04839861|Active Comparator|Mightier Online Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration.
32720088|NCT04839861|Experimental|Mightier Online Plus Offline Family Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration. Parents will be encouraged to play Mightier offline Family Games at least once a week for the 6 week duration.
32720089|NCT04796103|Active Comparator|Dextrose Prolotherapy Group|Patients diagnosed with chondromalacia patella
33248928|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
32720090|NCT04796103|Placebo Comparator|Serum Physiological Group|Patients diagnosed with chondromalacia patella
32720091|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
33248929|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
32720092|NCT05392491||Control group (without coronary lesions)|Cohort control group. No interventions.
32720093|NCT05392491||Coronary Lesion < 30%|Participants with coronary lesion under 30%. No interventions.
32720094|NCT05392491||Coronary Lesion > 30% and < 50%|Participants with coronary lesions greater than 30% and under 50%. No interventions.
32720095|NCT05392257|Experimental|Arms|
32720096|NCT00002663|Experimental|EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) following hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel (tab-cel) at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720097|NCT00002663|Experimental|EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)|Patients with EBV+ PTLD following solid organ transplant (SOT) who were R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720098|NCT00002663|Experimental|EBV+ AID-LPD (Tab-cel Only)|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720099|NCT00002663|Experimental|EBV+ LMS (Tab-cel Only)|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720100|NCT00002663|Experimental|EBV+ NPC (Tab-cel Only)|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32743352|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
33248930|NCT02567474|No Intervention|control|no intervention
33248931|NCT02567474|Experimental|intervention|self management intervention based on 5A model
33248932|NCT00835887|Experimental|1|Treatment with low dose flavanoids
33248933|NCT00835887|Experimental|2|Treatment with high dose flavanoids
33248934|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
33248935|NCT00842049|Experimental|Study|Insertion of lumbar drain
33248936|NCT00842049|Other|Control|Normal clinical management without lumbar drain
33248937|NCT05220878|Experimental|GNR-069|Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069, doses are calculated individually.
33248938|NCT05220878|Active Comparator|Nplate|Control group (80 patients) - multiple weekly subcutaneous injections of Nplate, doses are calculated individually.
33248939|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
33248940|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
33248941|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
33248942|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
33248943|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
33248944|NCT05667740|Experimental|Gamma-PN3|"Inactivated whole-cell pneumococcal vaccine at 50, 250 or 1000 mcg of protein content.~One dose on Day 1 and second dose Day 29"
33248945|NCT05667740|Placebo Comparator|Placebo|Saline on Day 1 and second dose Day 29
33248946|NCT05667740|Active Comparator|Prevenar-13|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
33248947|NCT05667740|Active Comparator|Pneumovax-23|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
33400160|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
33400161|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
33073366|NCT02356159|Experimental|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
33073367|NCT02356159|Experimental|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
33073368|NCT02339012||Frail|frail individuals ages 50-64 years; 65-79 years; 80+ years
33400162|NCT04906993|Experimental|camrelizumab combined with famitinib malate|
32720101|NCT00002663|Experimental|EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)|Patients with EBV+ following PTLD HCT who were R/R to rituximab or rituximab naive will receive IV infusion of transplant donor-derived EBV-cytotoxic T lymphocytes (CTLs) at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720102|NCT00002663|Experimental|EBV+ PTLD-SOT R/R Rituximab + Chemo (EBV-CTLs Only)|Patients with EBV+ PTLD following SOT who were R/R to rituximab and chemotherapy will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720103|NCT00002663|Experimental|EBV+ Viremia (EBV-CTLs Only)|Patients with EBV+ viremia will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720104|NCT00002663|Experimental|EBV+ PID-LPD (Tab-cel or EBV-CTLs)|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel or transplant donor-derived EBV- CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720105|NCT00002663|Experimental|EBV+ Lymphoma (Tab-cel or EBV-CTLs)|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel or transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32720106|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
32720107|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
32720108|NCT05391867|Experimental|Lenvatinib group (Group-A)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Lenvatinib. Cap. Lenvatinib will be given at doses of 4 mg 12 hourly.
32720109|NCT05391867|Experimental|Sorafenib group (Group-B)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.
32720110|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
32720111|NCT02288975||Control|Patients with septic shock will get routine ICU care.
32720112|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
32720113|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
32720114|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
32720115|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
32720116|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
32720117|NCT04710615|Experimental|Assistance device|"With prescription assistance device:~During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline)."
32720118|NCT04710615|No Intervention|No device|During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, …
32720119|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
32720120|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
32720121|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
32720122|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
32720123|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
32743353|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
32743354|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
33073369|NCT02339012||Healthy|healthy individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
33073370|NCT02339012||Non-Healthy/Non-Frail|non-healthy/non-frail individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
33073371|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
33400163|NCT04906993|Active Comparator|platinum-based chemotherapy|
33400164|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
33400165|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
32720124|NCT05391789|Experimental|normal dose|Patients would be given 400000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
32720125|NCT05391789|Experimental|high dose|Patients would be given 800000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
32720126|NCT05391789|Placebo Comparator|placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
32720127|NCT02240368||Group 1|Children age between 1 month to 12 months
32720128|NCT02240368||Group 2|Children age between 13 months and 36 months
32720129|NCT02240368||Group 3|Children age between 37 months to 144 months
33248948|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
32922246|NCT04432311|Experimental|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
33248949|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
33248950|NCT00738296|Active Comparator|A|Group A: Comparator
33248951|NCT00738296|Active Comparator|B|Group B: Comparator
33248952|NCT00738296|Experimental|C|Group C: Drug
33248953|NCT00844701||Non-smoker|Non-smoking control
33248954|NCT00844701||Nicotine Dependent Smoking Group|current smokers
33248955|NCT05216354|Experimental|Cohort 1 (healthy subjects)|8 subject with normal renal function will be administered 5mg (1 x 5 mg capsule) fruquintinib
33248956|NCT05216354|Experimental|Cohort 2 (severe renal impairment)|8 subjects with severe renal impairment will be administered 2 mg (2 x 1 mg capsules) fruquintinib
33248957|NCT05216354|Experimental|Cohort 3 (moderate renal impairment)|8 subjects with moderate renal impairment will be administered 5 mg (a x 5 mg capsule) fruquintinib
33248958|NCT00836043||Group 1|
33248959|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33248960|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
33248961|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
33248962|NCT00836121||tumor|
33248963|NCT05667428|Experimental|Leprorelin group|Leprorelin was given subcutaneously before each cycle of chemotherapy.
33248964|NCT05667428|Placebo Comparator|Control group|Normal salinewas given subcutaneously before each cycle of chemotherapy.
33248965|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
33248966|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
33248967|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
33248968|NCT05664542|Experimental|ESPB group|this group will receive ESPB using ropivacaine and dexmedetomidine
33248969|NCT05664542|No Intervention|Control group|this group will not receive any block
33248970|NCT04344795|Experimental|TPST-1495 monotherapy dose escalation|Subjects will receive escalating doses of TPST-1495 administered orally twice daily until maximum tolerated dose is reached or until disease progression
33248971|NCT04344795|Experimental|TPST-1495 monotherapy dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules until RP2D for the selected schedule is determined or until disease progression.
33248972|NCT04344795|Experimental|TPST-1495 monotherapy dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
33248973|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules in combination with pembrolizumab until RP2D for the selected schedule is determined or until disease progression.
33248974|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
33248975|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
33400166|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
32922247|NCT04432311|Active Comparator|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
32922248|NCT05194202|Experimental|ED-HEART (Intervention Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED HEART) by a trained health educator, complete an exit survey while in the ED, complete a 6-week check-in to confirm contact information and aid retention, and complete a 12-week follow up survey.
32922249|NCT05194202|No Intervention|Enhanced Standard Care (Control Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive enhanced standard care (i.e., standard care + teen resource list), complete a 6-week check in to confirm contact information and aid retention, and complete a 12-week follow up survey.
32922250|NCT04081701||Meningioma|Cohort of 30 subjects with meningioma.
33400167|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).~Patients will receive the study drug until disease relapse or progression."
32922251|NCT04081701||Non-Meningioma|"Cohort of 60 subjects with non-meningioma:~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
32922252|NCT04990388|Experimental|UX053 Dose Level 1S ->OL-1R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922253|NCT04990388|Experimental|UX053 Dose Level 2S->OL-2R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922254|NCT04990388|Experimental|UX053 Dose Level 3S->OL-3R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922255|NCT04990388|Experimental|UX053 or Placebo Dose Level DB-1R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922256|NCT04990388|Experimental|UX053 Dose Level DB-2R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922257|NCT04990388|Experimental|UX053 Dose Level DB-3R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
32922261|NCT04330443|Experimental|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than >8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
32922262|NCT04330443|No Intervention|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
32922263|NCT04986332|Experimental|"GROUP COPD"|100 participants, 50 males and 50 females with COPD and multiple chronic conditions
32922264|NCT04986332|Active Comparator|"GROUP HF"|100 participants, 50 males and 50 females with HF and multiple chronic conditions
32922265|NCT04986332|Active Comparator|"GROUP HEALTHY PARTICIPANTS"|"100 healthy participants or control group which will be compared to Group A and Group B by age and sex"
32922266|NCT04330677|Experimental|1. Oxytocin spray, 2. Estrogen gel|
32922267|NCT04330677|Experimental|1. Oxytocin spray, 2. Placebo gel|
32922268|NCT04330677|Experimental|1. Placebo spray, 2. Estrogen gel|
33400168|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
32720130|NCT02290301||Type 2 Diabetes Mellitus|
32922269|NCT04330677|Placebo Comparator|1. Placebo spray, 2. Placebo gel|
32922270|NCT04978766|Experimental|Interactive Book Reading Group|Participants in this arm will take baseline measures, will receive the intervention and will take posttest measures.
32922271|NCT04978766|No Intervention|Control Group|Participants in this arm will take baseline and posttest measures. For ethical purposes, they will receive the intervention after posttest measures are taken.
32720131|NCT04699071|Experimental|patients with recurrent clear cell carcinoma of gynecological origin (CCGC)|Recurrent clear cell carcinoma of gynecological origin (ovarian and endometrial primary) after progression on chemotherapy.
32720132|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
32922272|NCT04965116|Experimental|Early Initiation d-POPs|Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.
32922273|NCT04965116|Experimental|Early Initiation n-POPs|Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.
32922274|NCT04965116|Placebo Comparator|Interval Initiation of d-POPs|Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.
33400169|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
33400170|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
33400173|NCT05241067|Placebo Comparator|Normal saline|Placebo (Dose: equal volume saline) + Standard of care
33400174|NCT05241067|Active Comparator|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
33400175|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
33400176|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
33400177|NCT05597982|Experimental|KTFT|
33400178|NCT05597982|Experimental|PN|
33400179|NCT05681767|Experimental|Intervention group|Motivational multicomponent lifestyle intervention + treatment as usual
33400180|NCT05681767|Other|Control group|Treatment as usual
32922275|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
32922276|NCT02422615|Experimental|Ribociclib + fulvestrant|Ribociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
32922277|NCT02422615|Placebo Comparator|Ribociclib placebo + fulvestrant|Ribociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
32922278|NCT04389632|Experimental|SGN-B6A|SGN-B6A monotherapy
32922279|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
32922280|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography and digital dermoscopy.
32922281|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
32922282|NCT04964960|Experimental|Pembrolizumab with standard of care chemotherapy treatment|Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
32922283|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
32922284|NCT05114486|Experimental|Pilocarpine 2% Ophthalmic Spray|2% pilocarpine ophthalmic spray administered with the Optejet dispenser
32922285|NCT05114486|Placebo Comparator|Placebo Spray|Placebo ophthalmic spray administered with the Optejet dispenser
32922286|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
32922287|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
32922288|NCT04946942|Experimental|Caregiver Checklist (CHEC)|CHEC is composed of two elements: 1) a checklist to identify the needs and concerns of unpaid/family caregivers who accompany older adults (aged 65+) to their primary care visits and 2) Tip Sheet for clinicians.
32922289|NCT04946942|Active Comparator|Usual care|Attendance at primary care appointments as usual.
32922290|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide in separate syringes|Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
32935853|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
32935854|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
32720133|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
32922291|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide combined in DV3384 device|Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
32922292|NCT04940078|Experimental|Part B: Cagrilintide and semaglutide combined in DV3384 device|Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.
32922293|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
32922294|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
32922295|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
32720134|NCT05391633|Placebo Comparator|Placebo|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the non-intervention arm will be played a blank recording of approximately 60 minutes duration, once every 24 hours for a 2-week (14 day) period.
32720135|NCT05391633|Experimental|Recorded Voice Exposure|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the intervention arm will be played a recording of their mother's voice with approximately 60 minutes of scripted content, once per 24 hours for a 2-week (14 day) intervention period. (Mothers will be recorded reading a children's book and the recording will be looped to create the 60 minutes of content).
32922296|NCT05711095|Experimental|Fortified plant protein blend|20g of plant-based protein blend fortified with 2 g leucine
32922297|NCT05711095|Experimental|Normal plant protein blend|20g of plant-based protein blend
32720136|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
32720137|NCT02239978||Control|Age-matched healthy adults
32720138|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
32922298|NCT05711095|Active Comparator|Whey protein|20g of whey protein
32922299|NCT04887116|Experimental|Virtual Reality Exposure Therapy|Virtual Reality Exposure Therapy
32922300|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
32720139|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
32720140|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
32720141|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
32720142|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
32720143|NCT04688307|Experimental|Lifestyle modification and smoking reduction failure|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is not more than 50% of the baseline
32720144|NCT04688307|Experimental|Lifestyle modification and smoking reduction|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is 50% of the baseline or more
32720145|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
32922301|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
32922302|NCT04388163|Experimental|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
32922303|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
32922304|NCT04351958|Experimental|"Augmented Reality (No Time Wasted)"|
32922305|NCT05203627|Experimental|Arm I (telehealth session, guidebook)|Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.
32720146|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
32922306|NCT05203627|Active Comparator|Arm II (standard nutritional support)|Patients receive standard nutritional support.
32922307|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
32743355|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
32922308|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
32922309|NCT04323176|Experimental|Village Model|Participate as a member of the Village using a website for 12 months.
32922310|NCT03157635|Experimental|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg) intravenous (IV) infusion. Doses are planned to be escalated up to Cohort 5.
32922311|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
32935855|NCT05448014|Experimental|CFT group intervention|
32935856|NCT05448014|No Intervention|Control group|Waiting list
32922312|NCT03157635|Experimental|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg IV of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
32922313|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg weekly (QW) starting on Day 8 for a maximum treatment duration of 5 months.
32922314|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg every 2 weeks (Q2W) for a maximum treatment duration of 5 months.
32922315|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg every 4 weeks (Q4W) starting on Day 8 for a maximum treatment duration of 5 months.
32922316|NCT03157635|Experimental|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:~Participants >/= 100 kg: loading dose of 1500 mg IV on Day 1; Participants < 100 kg: loading dose of 1000 mg IV on Day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
32922317|NCT03157635|Experimental|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
32922318|NCT03157635|Experimental|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of ten years from entry into OLE.
32922319|NCT05176093|Active Comparator|Engensis|Active Comparator: Engensis 64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
32922320|NCT05176093|Placebo Comparator|Placebo|Placebo Comparator: Placebo 32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
32935857|NCT05450887|Experimental|OCA 5 mg titrated to 10 mg ± UDCA|"OCA 5 mg once daily for 3 months and then titrating up to 10 mg based on tolerability and response.~Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA."
32935858|NCT05450887|Placebo Comparator|Placebo ± UDCA|Placebo once daily. Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA.
32935859|NCT05450042|Experimental|SELUTION SLR DCB|Sustained Limus Release drug eluting balloon
33400181|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
33400182|NCT01353274||Patients with hypertension|
32720147|NCT04788862|Experimental|Group 1: High prior P. falciparum exposure|6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
32720148|NCT04788862|Experimental|Group 2: Low prior P. falciparum exposure|6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
32720149|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:~cyclophosphamide (50 mg/day, daily, per os)~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
32720150|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
32720151|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
32720152|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
32720153|NCT03967288|Experimental|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
32720154|NCT03967288|Active Comparator|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
32720155|NCT04636281|Experimental|Passive static stretching exercise|Group 1 will receive passive static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
32720156|NCT04636281|Experimental|Active static stretching|Group 2 will receive active static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
32720157|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
32922321|NCT04259762|Experimental|Breast, Colorectal, and Cervical Cancer Screening|The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.
32922322|NCT04259762|No Intervention|Control|Historical control
32922323|NCT05172661|Experimental|Integrated training model|"Participants in this group will accept postural and cognitive training at the same time, e.g. naming animals while standing on the foam.~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
32922324|NCT05172661|Experimental|Consecutive training model|"Participants in this group will accept postural and cognitive training separately and for identical durations (both 30 minutes).~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
33400183|NCT05005507|Experimental|Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.
32720158|NCT05399368|Experimental|RPT193 400 mg|RPT193 400 mg oral tablet administered daily for 16 weeks
32720159|NCT05399368|Experimental|RPT193 200 mg|RPT193 200 mg oral tablet administered daily for 16 weeks
32720160|NCT05399368|Experimental|RPT193 50 mg|RPT193 50 mg oral tablet administered daily for 16 weeks
32720161|NCT05399368|Placebo Comparator|Placebo|Matching placebo oral tablet administered daily for 16 weeks
32720162|NCT04629417|Experimental|Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
32720163|NCT04629417|Active Comparator|OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
32720164|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
32720165|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
32922325|NCT05711017|Experimental|Huashibaidu|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
32922326|NCT05711017|Placebo Comparator|Placebo|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
32922327|NCT04377555|Experimental|All Participants|Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
32922328|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
32922329|NCT04220294|Active Comparator|Interrupted sutures|Subcutaneous tissue closure by interrupted sutures.
32922330|NCT04220294|Active Comparator|Continuous sutures|Subcutaneous tissue closure by continuous sutures.
32922331|NCT05710939|Active Comparator|scapular stabilization exercises|scapular stabilization exercises applied to 1st group for 5 days/week for 6 weeks
32922332|NCT05710939|Active Comparator|classic shoulder exercises|classic shoulder exercises applied to 1st group for 5 days/week for 6 weeks
32922333|NCT04213196|Experimental|HSK21542 0.2 μg/kg（15 min)|Healthy volunteers 0.2 μg/kg HSK21542
32922334|NCT04213196|Experimental|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
32922335|NCT04213196|Experimental|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
32922336|NCT04213196|Experimental|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
32922337|NCT04213196|Experimental|HSK21542 0.75 μg/kg|Healthy volunteers 0.75 μg/kg HSK21542 or Placebo
32922338|NCT04213196|Experimental|HSK21542 1.5 μg/kg|Healthy volunteers 1.5 μg/kg HSK21542 or Placebo
32922339|NCT04213196|Experimental|HSK21542 2.25 μg/kg|Healthy volunteers 2.25 μg/kg HSK21542 or Placebo
32922340|NCT04213196|Experimental|HSK21542 3.375 μg/kg|Healthy volunteers 3.375 μg/kg HSK21542 or Placebo
32922341|NCT04213196|Experimental|HSK21542 0.2 μg/kg（2min)|Healthy volunteers 0.2 μg/kg HSK21542 or Placebo
32922342|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
32922343|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
32922344|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
32922345|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
32767239|NCT04876859|Sham Comparator|Anesthetic plus steroid group|The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
32922346|NCT04029363|Other|Single arm|Single arm, non-randomized
32935860|NCT05450042|Active Comparator|Paclitaxel eluting balloon|Conventional: Medtronic INpact
33248976|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
33248977|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
33248978|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
33248979|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
33248980|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
33248981|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
33248982|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
33400184|NCT05005507|Experimental|Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.
32767240|NCT03049241||knee extensors|
32767241|NCT03049241||ankle plantar|
32767242|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
32767243|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
32767244|NCT05257889||neonatal seizures cases|Cases of neonatal seizures
32767245|NCT05257889||seizure-free neonates|cases that are seizure free
32767246|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
32767247|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
32767248|NCT04360265||ABO-102|Participants from prior interventional trials involving the administration of ABO-102.
32767249|NCT04876313|Experimental|Combined Drugs|Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles
32767250|NCT04876469|Active Comparator|Radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level) in both groups.~In patients in the Radiocontrast media group, contrast material will be given before the application, and primarily the localization of the DRG will be determined. After this stage, the needle will be directed towards the detected localization. Finally, the localization of the dorsal root ganglion will be confirmed by sensory and motor stimuli."
32767251|NCT04876469|Active Comparator|Non-radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level).~In patients in the Non-radiocontrast media group, the localization of the dorsal root ganglion will be determined just by sensory and motor stimuli."
32767252|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
32767253|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
32922347|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
32922348|NCT04198454|Active Comparator|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
32922349|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
32922350|NCT04198454|Experimental|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
32922351|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
32922352|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
32922353|NCT05152459|Experimental|Treatment (tazemetostat, umbralisib, ublituximab)|Patients receive ublituximab IV on days 1, 8, and 15 of cycle 1, day 1 of cycle 2-6, and day 1 of every 3 cycles thereafter. Patients also receive tazemetostat PO BID umbralisib by PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
32922354|NCT04195256|Experimental|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
33400185|NCT05005507|Experimental|Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.
32720166|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
32720167|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
32922355|NCT04195256|Experimental|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
32922356|NCT04195256|Experimental|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
32935861|NCT04633057|Experimental|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
33400186|NCT04739358|Experimental|Monotherapy|"Dose Escalation Phase for participants with MET-driven NSCLC.~Dose Expansion Phase: CNS Efficacy Dose Expansion Cohort for participants with MET-driven NSCLC and measurable CNS disease."
33400187|NCT04739358|Experimental|Combination Therapy|"Dose Escalation Phase for participants with evidence of MET-driven acquired -resistance.~Dose Expansion Phase for participants with evidence of MET-driven acquired -resistance with or without measurable CNS disease."
32720168|NCT04167111|Active Comparator|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
32720169|NCT04167111|Active Comparator|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
32720170|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
32720171|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
32720172|NCT03304665||Healthy Volunteers|Healthy Volunteers
32720173|NCT03962062|Experimental|Cohort 1: 12-17 years|Moxidectin 8mg per oral, single dose
32720174|NCT03962062|Experimental|Cohort 2: 8-11 years|Moxidectin 8mg (or lower dose) per oral, single dose
32720175|NCT03962062|Experimental|Cohort 3: 4-7 years|Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
32720176|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
32720177|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
32720178|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
32720179|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
32720180|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
32720181|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
32720182|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
33400188|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
33400189|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
32720183|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
32720184|NCT03289923|Experimental|Active TMS+ Cognitive Therapy|active
32720185|NCT03289923|Sham Comparator|Sham TMS + Cognitive Therapy|inactive
32720186|NCT03942952||CNS demyelinating diagnosis|"Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody, Optic Neuritis.~3T and 7T MRI~Neuropsychological testing~Optical Coherence Tomography~Questionnaires: Quality of Life and Behavior scales~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one to year and a half year later"
32720187|NCT03942952||Healthy Control|"3T and 7T MRI~Neuropsychological testing~Optical Coherence Tomography~Questionnaires: Quality of Life and Behavior scales~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year to a year and a half later"
32767254|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
32767255|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
32767256|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
32767257|NCT04876547||In pregnancy|Appendectomy in pregnancy (n=12)
32767258|NCT04876547||In postpartum|Appendectomy in postpartum first six week (n=20)
32767259|NCT04876001|Experimental|Face-to-face BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call."
32767260|NCT04876001|Experimental|Web-based BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call. All treatments will be delivered using pre-established web and telephone."
32767261|NCT04876001|No Intervention|Waiting-list|The participant in this arm will be asked to filled the online questionnaires at weeks 0 (baseline), 1 (mid-treatment), 2 (post-treatment), 4 and 12 (follow up). After the final follow up, all participants will be allowed to join the web-based BBTI treatment.
32767262|NCT04875845||6-hours fasting gastric volume|gastric volume measured after 6-hours fasting
32767263|NCT04875845||8-hours fasting gastric volume|gastric volume measured after 8-hours fasting
32767264|NCT04869293|Experimental|3D virtual reality|Use of Hypnosis 3D virtual reality headset
32767265|NCT04869293|No Intervention|Control|Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
32767266|NCT04875611|Experimental|Experimental therapy:OPDIVO (Nivolumab)|
32767267|NCT04875689|Experimental|Group A (Experimental)|Patient receive laser therapy along with conventional therapy
32767268|NCT04875689|Other|Group B: Conventional treatment|patient will receive conventional therapy
32767269|NCT04386317|Experimental|terazosin therapy|
32767270|NCT04369625|Experimental|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
32767271|NCT04369625|Experimental|CHIMPS-P|"CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
32767272|NCT04369625|Experimental|The CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
32767273|NCT04369625|Experimental|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
32767274|NCT04369625|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
32767275|NCT04366895|Experimental|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
32767276|NCT04366895|Experimental|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
32720188|NCT03140085|Active Comparator|Anbiotica|
32922357|NCT04195256|Active Comparator|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
32922358|NCT04194944|Experimental|Selpercatinib|Selpercatinib administered orally.
32922359|NCT04194944|Active Comparator|Pemetrexed with or without Pembrolizumab|Pemetrexed administered intravenously (IV) plus the investigator's discretion of carboplatin IV or cisplatin IV with or without pembrolizumab IV.
32922360|NCT04194944|Active Comparator|Pemetrexed with Pembrolizumab|Pemetrexed administered IV plus the investigator's discretion of carboplatin IV or cisplatin IV with pembrolizumab IV.
32922361|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
32922362|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
32922363|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
32922364|NCT05710861|Experimental|F-HIFU Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA <20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
32922365|NCT05710861|Active Comparator|Prostatectomy Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA <20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
32922366|NCT05102864|Active Comparator|Active intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of active iTBS to the left dorsolateral prefrontal cortex
32922367|NCT05102864|Sham Comparator|Sham intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of sham iTBS to the left dorsolateral prefrontal cortex
32922368|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
32922369|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
32922370|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
32922371|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
32922372|NCT04874870|Active Comparator|No Splint Group|This group will receive Xiaflex injection only
32720189|NCT03140085|Active Comparator|Bacteriophages|
32720190|NCT03140085|Placebo Comparator|Placebo|
32720191|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
32720192|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
32922373|NCT04874870|Active Comparator|Splint Group|This group will receive Xiaflex injection and hand-based custom orthosis to maintain finger extension
32922374|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
32922375|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
32720193|NCT05391399|Experimental|group A Interlocking detachable coils system|The coil is designed with mechanical release, which can be recovered and repositioned at any time when the release process meets certain conditions.
32720194|NCT05391399|Active Comparator|group B Interlock Fibered IDC Occlusion System|The coil adopts the design of mechanical release, and can be recovered, repositioned and released at any time when the release process meets certain conditions.
32720195|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
32922376|NCT01715233|Experimental|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
32922377|NCT04868630||Outpatients; Atlantic Sleep Centre & SJRH Respiratory Clinic|The study population consists of approximately 80 adult, outpatient participants recruited from the Atlantic Sleep Centre and the Respiratory Clinic at the Horizon Health Network, Saint John Regional Hospital.
32935862|NCT04633057|Active Comparator|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
33073372|NCT02313428|Experimental|Standard of Care with Topical Oxygen Treatment|patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
33248983|NCT05661188|Experimental|atezolizumab and tiragolumab in concomitancy with standard chemoradiotherapy|"TIRANUS is a Phase II, single-arm, open-label, non-randomized, multicenter clinical trial of atezolizumab and tiragolumab in concomitance with standard chemoradiotherapy as first-line in treatment-naïve, localized squamous cell carcinoma of the anal canal who are candidates for radical chemoradiotherapy. Patients with well differentiated stage I anal margin cancer or previously treated with immunotherapy are not eligible.~All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase)."
33248984|NCT00940264||Given indication for cholecystectomy|
33248985|NCT04013230|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic.
33248986|NCT04013230|Active Comparator|Web-COP|Usual care plus group sessions and a web-based treatment program
33248987|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
33248988|NCT05195138|Experimental|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education (MBDE) will be delivered in-person in a group of 10-14 participants during 8 weekly sessions followed by 2 bimonthly individual sessions. Sessions integrate Mindfulness-Based Stress Reduction and Diabetes Self-Management Education. MBDE will introduce breath awareness meditation, body scan, walking meditation, mindful yoga, and applying mindfulness to daily activities, as well as core areas from DSME. MBDE will include incremental goal setting to build participants' self-efficacy for diabetes self-management behaviors, mindful attention to diabetes self-management, and on development of social support in the group. Participants will complete daily home mindfulness exercises and self-monitoring of diabetes self-management behaviors.
33248989|NCT05195138|Active Comparator|Standard Diabetes Self-Management Education|Standard DSME will be delivered in-person, in a group setting with 10-14 participants per group. Standard DSME will be delivered by a certified diabetes educator in eight weekly sessions of 2 hours duration. Sessions will cover seven core content areas - healthy eating, physical activity, medication usage, self-monitoring, preventing and treating acute and chronic complications, healthy coping, and problem solving.
33248990|NCT04013698|Experimental|PEEP level 5 cmH2O to 15 cmH2O|
33248991|NCT04013698|Experimental|PEEP level 15 cmH2O to 5 cmH2O|
33248992|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
33248993|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
33248994|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
33248995|NCT05193344|Experimental|Digital solution group|Participants will be instructed to download a remote symptom monitoring and lifestyle-changing mobile application to which they will have access for 12 months. The program aims to provide remote symptom monitoring by having participants enter data (on diet, exercise, weight, etc) and answer questionnaires via the SidekickHealth platform, and to empower positive lifestyle changes. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
33248996|NCT05193344|Active Comparator|Standard of care - control group|All participants in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF. After the baseline measurements and data collection, there will be scheduled visits to a health care provider at 3, 6, and 12 months.
33248997|NCT00842673|Experimental|1|30 mg ST101
33248998|NCT00842673|Experimental|2|90 mg ST101
33248999|NCT00842673|Experimental|3|180 mg ST101
33249000|NCT00842673|Placebo Comparator|4|Placebo
33249001|NCT04013308|Experimental|10 iontophoresis treatments with potassium iodide|
33249002|NCT04013308|No Intervention|10 iontophoresis treatments with placebo|
33249003|NCT00836199|Placebo Comparator|Placebo vaccine|
33249004|NCT00836199|Experimental|NicVAX vaccine|
32720196|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
33249005|NCT05280262|Other|Group 1 Asymptomatic|"Group 1 - Prospective cohort of children and young adults enrolled at diagnosis and followed longitudinally~Patients will be evaluated at 5 time-points (Baseline - Follow Up 1-4 [FU1-4]) during therapy using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. In addition one saliva sample (or stored DNA from a remission bone marrow sample extracted during routine trial procedures) will be collected as a source of germline DNA and a clinical report form will be completed at study entry and at completion of the study. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
33249006|NCT05280262|Other|Group 2 Symptomatic|"Group 2 - Children and young adults with Stroke-like syndrome/PRES and /or seizures (SPS)~Following a diagnosis of SPS, patients and their families can be approached for informed consent to enter this study within 4 weeks following SPS event. If consent is obtained, patients will be evaluated at up to 7 timepoints, or until end of treatment, using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. Follow up visit 2 will take place at 12 months, with Follow up 3-7 [FU3-7] scheduled at 6 monthly timepoints. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
33249007|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
33249008|NCT02547753||Control group|healthy patients who need tooth extraction
33249009|NCT04013386|Active Comparator|Aprepitant/Dexamethasone Group|
33249010|NCT04013386|Active Comparator|Mertazepine /Dexamethasone Group|
32767277|NCT05257187|Active Comparator|6 hour foley catheter retention|Patients will have the foley catheter in place for up to 6 hours starting from insertion time to removal. If the catheter falls out earlier than the 6 hour mark, the patient will still be included for analysis.
32767278|NCT05257187|Placebo Comparator|12 hour foley balloon retention|Patients will have the foley catheter in place for up to 12 hours starting from insertion time to removal. If the catheter falls out earlier than the 12 hour mark, the patient will still be included for analysis.
32767279|NCT04429763|Experimental|Experimental|Usual tratment for COVID-19 plus MSC
32767280|NCT04429763|Placebo Comparator|Control|Usual treatment for COVID-19
32767281|NCT05257031|Experimental|SmofKabiven extra Nitrogen|"The investigational product will be administered in a volume that provides the target caloric intake of 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2 to 5.~If calories are provided from other sources (e.g., enteral/oral nutrition/oral nutritional supplements or non-nutritional sources including glucose solution for drug dilution or propofol), the dose of the investigational product will be reduced accordingly to avoid calorie overload above the respective daily caloric targets."
32767282|NCT05256953|Active Comparator|Group ESP|bilateral ESPB (total of 40 ml, %0.25 bupivacaine) + IV morphine PCA
32767283|NCT05256953|Active Comparator|Group GA|only IV morphine PCA
32767284|NCT04875299||adalimumab TDM|Patients with active ankylosing spondylitis receiving adalimumab treatment.
32767285|NCT04875143|Placebo Comparator|PLACEBO|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
32767286|NCT04875143|Experimental|Citrus aurantium L.|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
32767287|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
32767288|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg single dose usage
32767289|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg single dose usage
32767290|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg single dose usage
32767291|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg single dose usage
32767292|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg single dose usage
32767293|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
32767294|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, i.v. single dose usage.
32767295|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
32767296|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
32767297|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
32767298|NCT04868903|Active Comparator|Low Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
32767299|NCT04868903|Active Comparator|Medium Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
32767300|NCT04868903|Active Comparator|High Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
32767301|NCT05256485|Active Comparator|cognitive behavioral therapy|Standard CBT comprises an array of approaches directed toward modifying dysfunctional thinking and behavior. The two critical components are analysis of thoughts, feelings, and behaviors, as well as skills training for achieving active behavior and thought modification.
32767302|NCT05256485|Active Comparator|mindfulness based relapse prevention|"MBRP training is based on a two-component process:~Attention to present moment experience, even if it includes craving or negative emotion.~An accepting attitude towards this experience letting it be exactly as it is, without judging it or reacting to it."
32767303|NCT05256485|Active Comparator|twelve-step therapy|12-step therapy was based on strengthening conscious contact with God and awakening spirituality through prayer and meditation
32767304|NCT04874675|Active Comparator|Diclofenac /Acetaminophen/Codeine|routine pain medication used in post extraction pain management
32767305|NCT04874675|Active Comparator|Ibuprofen/Acetaminophen/codeine|routine pain medication used in post extraction pain management
32767306|NCT04874363||smoker|active smokers
32767307|NCT04874363||non-smoker|Patients who have never smoked
33249011|NCT04013386|Active Comparator|Dexamethasone Group|
33249012|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
33249013|NCT00940420|Experimental|A|
33249014|NCT00940420|Experimental|B|
32922378|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
32720197|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
32922379|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
32922380|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
32720198|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
32720199|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
32720200|NCT04788004||Cohort 1|Participants in this group started their recovery process < 1 year ago
32720201|NCT04788004||Cohort 2|Participants in this group started their recovery process 1 to <2 years ago
32720202|NCT04788004||Cohort 3|Participants in this group started their recovery process 2 to <3 years ago
32720203|NCT04788004||Cohort 4|Participants in this group started their recovery process 3 to <4 years ago
32922381|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
32922382|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
32922383|NCT05145283|Active Comparator|Conestat alfa (Ruconest®) intervention group|The intervention group will receive conestat alfa (Ruconest®) as a 10-minute slow intravenous injection (up to 56 ml) once during the TAVI procedure followed by a second administration (up to 28 ml) again three hours later. The first administration will include a dosage of 100 U/kg (maximum 8400 U) conestat alfa. The dosing of the second administration will be 50 U/kg (maximum 4200 U).
32922384|NCT05145283|Placebo Comparator|saline injection placebo group|Subjects randomized into the placebo group will receive an intravenous normal saline injection with corresponding volume over 10 minutes during the TAVI procedure and three hours later after the first administration.
32922385|NCT04865744|Active Comparator|Oral semaglutide 7 mg|The semaglutide 7 mg tablet taken orally with upto120 ml of water.
32922386|NCT04865744|Placebo Comparator|Placebo|The placebo tablet taken orally with 120 ml of water.
32922387|NCT04865744|Active Comparator|Oral semaglutide 14 mg|The semaglutide 14 mg tablet taken with upto 120 ml of water.
32922388|NCT05076487||African American Women with Food Security|30 African American women with obesity who are food secure
32922389|NCT05076487||African American Women with Food Insecurity|30 African American women with obesity who are food insecure
32922390|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
32922391|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
32922392|NCT05071508||Preterm Infants|Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
33249015|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
32922393|NCT05056909|Active Comparator|Standard of care|CKD care, as routinely provided in the respective nephrology outpatient clinic.
32922394|NCT05056909|Experimental|Intervention|standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.
32720204|NCT04788004||Cohort 5|Participants in this group started their recovery process 4 to <5 years ago
32720205|NCT04788004||Cohort 6|Participants in this group started their recovery process 5 to <6 years ago
32922395|NCT04880226|Other|Healthy Volunteers|Imaging of healthy volunteers would performed to optimize image parameters (contrast, SNR) prior to clinical imaging of actual patients receiving treatment.
32720206|NCT04788004||Cohort 7|Participants in this group started their recovery process 6 to <7 years ago
32720207|NCT04788004||Cohort 8|Participants in this group started their recovery process 7 to <8 years ago
32720208|NCT04788004||Cohort 9|Participants in this group started their recovery process 8 to <9 years ago
32720209|NCT04788004||Cohort 10|Participants in this group started their recovery process 9 to <10 years ago
32720210|NCT05386563|Experimental|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|
32720211|NCT05386563|Sham Comparator|Sham|
32922396|NCT04880226|Experimental|Patients receiving MRI-guided procedures|As described in the study protocol this imaging would be performed to evaluate a given sequence for potential benefit during MR-guided interventions.
32922397|NCT04826588|Active Comparator|Methylprednisolone sodium succinate 10 mg/kg|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
32922398|NCT04826588|Active Comparator|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
32922399|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
32922400|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
32922401|NCT05064956|Experimental|Ad26.ZEBOV|Ad26.ZEBOV will be given as a booster dose to all participants approximately 4 years after administration of the 2-dose Ebola regimen, Ad26.ZEBOV/MVA-BN-Filo, as part of the parent trial VAC52150EBL2002.
32922402|NCT05710627|No Intervention|Control|Standard of care
32922403|NCT05710627|Experimental|Treatment|TENEX device will be used
33249016|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
33249017|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
33249018|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
32922404|NCT04824872|Experimental|Sequence 1|Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose
32922405|NCT04824872|Experimental|Sequence 2|Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo
32922406|NCT04824872|Experimental|Sequence 3|Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose
32922407|NCT04824872|Experimental|Sequence 4|Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo
32922408|NCT04824872|Experimental|Sequence 5|Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose
33249019|NCT05181488|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
32922409|NCT04824872|Experimental|Sequence 6|Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose
32922410|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
32720212|NCT05386563|No Intervention|No Intervention (Control)|
32922411|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
32922412|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
32922413|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
32922414|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
32922415|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
32922416|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
32922417|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
32922418|NCT05062772||Glioblastoma|
32922419|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
32922420|NCT04083794|Other|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
32922421|NCT04785950||Women with IUS|Women aged 18 to 35 years from Spain who chose to use any low-dose LNG-IUS marketed in Spain for the first time during routine clinical practice
32922422|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
32922423|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
33249020|NCT05180396||Cases with the diagnosis of Heart Failure (Acute and Chronic)|Application of a questionnaire consisting of different questions to patients.
33249021|NCT04013074|Experimental|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
33249022|NCT04013074|Active Comparator|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
33249023|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
32720213|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
32720214|NCT04426929|Experimental|Conventional Group|Electrotherapy program will be applied to all individuals. conventional exercise therapy will be applied to this group.
32720215|NCT04426929|Experimental|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
32720216|NCT04426929|Experimental|Video Based Exercise Group|Video based exercise program will be applied to the this group.
32720217|NCT03521453||Before|Conventionnel written information
32922424|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
32720218|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
32720219|NCT04057677|Experimental|Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with pre-diabetes and type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
32720220|NCT04057677|Experimental|Non-Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
32720221|NCT03521297|Placebo Comparator|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
32720222|NCT03521297|Experimental|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
32720223|NCT04393701|Experimental|neonates tested in Normandie, France|All neonates will be tested in Normandie
32720224|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
32720225|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
32720226|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
32720227|NCT02289911|Active Comparator|Class|Traditional learning form
32922425|NCT04781348|Experimental|Platelet Rich Plasma and fat grafting|Group will receive Platelet Rich Plasma plus fat grafting
32922426|NCT04781348|Experimental|Fat grafting|Group will receive only fat grafting
32922427|NCT04777916||Standard intensive 3+7 YOUNG OR ELDERLY|Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
32922428|NCT04777916||GO, Mylotarg®) with 3+7|Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
32922429|NCT04777916||CPX-351, Vyxeos®)|Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
32922430|NCT04777916||Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)|Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
32935863|NCT02230410|Experimental|focal cryo ablation|Subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
33249024|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
33400190|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
32720228|NCT02289911|Active Comparator|Web|Didactic training using internet
32720229|NCT04381299||Intervention|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
32720230|NCT04381299||Control|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
32720231|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
32720232|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
32720235|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
32720236|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
32720237|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
32922431|NCT04777916||Refractory or relapsed AML|"Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).~In the real life, because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients."
32922432|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
32720238|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
32720239|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
32922433|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
32922434|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
32922435|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
32922436|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
32922437|NCT01721473||non-smokers|not a regular cigarette user
32922438|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
32922439|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
32922440|NCT03075254|Active Comparator|Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
32922441|NCT03075254|Experimental|Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
32922442|NCT03075254|Experimental|Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
32922443|NCT04773782|Experimental|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
32922444|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
32922445|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
33249025|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
33249026|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
32720240|NCT03984539|Active Comparator|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
32922448|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
32922449|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
32922450|NCT03072602|Active Comparator|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
33073373|NCT02313428|No Intervention|Standard of Care only|patients that have a chronic wound will receive only their standard of care treatment.
33249027|NCT00940654||Patients with fever|
33249028|NCT00940654||Patients without any fever|
33249029|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
33249030|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
33249031|NCT05081882|Experimental|Kava Intervention|
33249032|NCT05081882|Placebo Comparator|Placebo Control|
32720241|NCT03984539|Experimental|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
32720242|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
32720243|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
32720244|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
32720245|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
32720246|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
32720247|NCT02291471|Experimental|T0001|
32720248|NCT03899961|Active Comparator|Oxytocin|Oxytocin 2.5 U i.v.
32720249|NCT03899961|Experimental|Carbetocin|Carbetocin 100 µg i.v.
32720250|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
32720251|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
32720252|NCT04079673|Active Comparator|Patient controlled epidural analgesia|Use of patient controlled epidural analgesia (PCEA) for postoperative pain control
32922451|NCT03070184|Experimental|African-American|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
33249033|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
33249034|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
32922452|NCT03070184|Active Comparator|Caucasians (White)|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
32922453|NCT04021082|Experimental|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
32720253|NCT04079673|Sham Comparator|Intravenous patient controlled analgesia|Use of intravenous patient controlled analgesia(IVPCA) for postoperative pain control
32922454|NCT04021082|Experimental|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
32922455|NCT04021082|Experimental|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive [ALK+] and negative [ALK-]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
33249035|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
33249036|NCT00940732|Experimental|Help-seeking list|
32922456|NCT04021082|Experimental|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
32922457|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
33249037|NCT00940732|Experimental|Feedback|
33249038|NCT00940732|No Intervention|Control|
32720254|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
32720255|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
32720256|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
32720257|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
32720258|NCT05370963|Active Comparator|hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
32720259|NCT05370963|Active Comparator|dexmedtemodine group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Dexmedetomidine 0.5 mic/kg
32720260|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
32720261|NCT05318157|Experimental|Sublingual Immunotherapy group|
32720262|NCT05318157|Experimental|Drugs treatment group|
32720263|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
32720264|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
32720265|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
32922458|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
33249039|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
33249040|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
32720266|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
32720267|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
32743356|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
33249041|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
33249042|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
33249043|NCT04013464|Experimental|MDD and Health Control|MDD in open label
33249044|NCT04043247|Sham Comparator|Control Group|Same as TEAS group but without electrical stimulation
33249045|NCT04043247|Experimental|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
32767308|NCT04868669|Experimental|Intervention|In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
32767309|NCT04868669|No Intervention|Control|Pregnant women in this arm will receive standard antenatal care.
32767310|NCT04874285|No Intervention|control group|Women with risk factors for abortion, treated with progesterone
32767311|NCT04874285|Experimental|study group|Women with risk factors for abortion, treated with progesterone and a dietary supplement containing hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
32767312|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
32767313|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
32767314|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
32767315|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
32767316|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
32767317|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
32767318|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
32767319|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
32767320|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
32767321|NCT05256407|Experimental|Intervention, digital support|Parents are offered participation in a digital channel consisting of video consultations, parental support gruops and parental education.
32767322|NCT05256407|No Intervention|Control, usual care|Usual child health care.
32767323|NCT04873973|No Intervention|Control|Participants in this group are routinely treated.
32767324|NCT04873973|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
32767325|NCT04874129|Other|A Group|Two-way Crossover
32767326|NCT04874129|Other|B Group|Two-way Crossover
32767327|NCT05256329||Oncology patients|Patients suffering from specific solid cancers or hematological malignancies
32767328|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
32767329|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
32767330|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
32767331|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
32767332|NCT05256173|Experimental|Melatonin Tablets|
32767333|NCT05256173|Placebo Comparator|Lactasin Tablets|
32767334|NCT05256173|Experimental|transcutaneous vagus nerve stimulation|
32767335|NCT05256173|Sham Comparator|sham transcutaneous vagus nerve stimulation|
32767336|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
32767337|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
32767338|NCT04868825|Experimental|Experimental (Intervention)|
32767339|NCT04868825|Active Comparator|Active Comparator|
32767340|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
32767341|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
32767342|NCT04868201|Experimental|0-anxiety|0-anxiety is based on the principles of VRT and CBT, which currently is the most researched and used treatment for anxiety disorders. The 0-anxiety intervention is an app-based intervention consisting of six modules that can be followed according to a user's own timing and without the intervention of a therapist.
32767343|NCT04868201|No Intervention|wait-list condition|
32767344|NCT04429997|Experimental|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
32767345|NCT04429997|Experimental|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
32767346|NCT05255939|Experimental|dTRA group|Investigators perform percutaneous coronary intervention by dTRA
32767347|NCT05255939|Other|TRA group|Investigators perform percutaneous coronary intervention by conventional TRA
32767348|NCT02648347|Experimental|Vadadustat|
32767349|NCT02648347|Active Comparator|Darbepoetin alfa|
32720268|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
32720269|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
32720270|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
32720271|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
32720272|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
33249046|NCT04012918|Experimental|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
33249047|NCT04012918|Active Comparator|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
32720273|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
32720274|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
32720275|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
32720276|NCT02291705|Experimental|rectus sheath block|rectus sheath block
32720277|NCT02291705|Active Comparator|tramadol|tramadol control group
32720278|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
32720279|NCT03518021|Experimental|Naloxone, intranasal|
32720280|NCT03518021|Active Comparator|Naloxone, intramuscular|
32720281|NCT03518021|Placebo Comparator|placebo, intranasal|
32720282|NCT03518021|Placebo Comparator|placebo, intramuscular|
32720283|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
33249048|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
33249049|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
32720284|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
32720285|NCT05314335|Experimental|Reflexology socks+Walking|In the first interview; patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Afterwards, the reflexology socks designed by the researcher for the patients; will be told to wear and walk 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday). Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale, and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 30th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
32720286|NCT05314335|Other|Just walking|In the first interview, patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Subsequently, patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 130th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
33249050|NCT05131490|Experimental|Experimental|Experimental group intervention consists two months a mobile application intervention developed for gynecological cancer patients receiving chemotherapy
33249051|NCT05131490|No Intervention|No intervention|Control group receive routine care.
33249052|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
33249053|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
33249054|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
33249055|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
32720287|NCT03734289|Active Comparator|Immediate Coaching|Immediately following randomization, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
32720288|NCT03734289|Active Comparator|Delayed Coaching|6 weeks following the initial visit, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
32720289|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
32720290|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
32720291|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
33249056|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
33249057|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
33249058|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
33249059|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
33249060|NCT00843219||PET/CT Scan|
33249061|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
33249062|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
33249063|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
33249064|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
33249065|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
33249066|NCT00836667|Experimental|1|
33249067|NCT00836667|Active Comparator|2|
33249068|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
33249069|NCT00940030|Active Comparator|enema|
33249070|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
33249071|NCT00845559|No Intervention|No Treatment|
33249072|NCT05123612|Experimental|Fiber|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.
33249073|NCT05123612|Experimental|Fermented Foods|Participants will be asked to consume 6 servings of fermented foods per day.
33249074|NCT05123612|Experimental|Fiber + Fermented Foods|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.
33249075|NCT05123612|No Intervention|Comparator|Participants will receive usual care for pregnancy and postpartum.
33249076|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
33249077|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
33249078|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
33249079|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
33249080|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
33249081|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
33249082|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
33249083|NCT00940810|Experimental|PDD procedure|
33249084|NCT00940810|Active Comparator|Conservative Care|
33249085|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
33249086|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
33249087|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
33249088|NCT05107778|Experimental|Queue ASC42 10mg|ASC42 10mg, ih PEG-IFN α-2a and ETV for 12 weeks.
33249089|NCT05107778|Experimental|Queue ASC42 15mg|ASC42 15mg , ih PEG-IFN α-2a and ETV for 12 weeks.
33249090|NCT05107778|Placebo Comparator|Queue Placebo|Placebo, ih PEG-IFN α-2a and ETV for 12 weeks.
33400191|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
32720292|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
32720293|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
33400192|NCT05221255|Sham Comparator|Sham Therapy|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation plus non-real magnetic stimulation.
32720294|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
32720295|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
32720296|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
32720297|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
32720298|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
32720299|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
33249091|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33249092|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33249093|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
32743357|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
33249094|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33249095|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33400193|NCT05221255|Experimental|Spinal magnetic stimulation|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation followed by real spinal magnetic stimulation.
33400194|NCT05419999|Experimental|tDCS plus WET|Subjects will receive transcranial direct current stimulation (tDCS) plus written exposure therapy (WET)
32743358|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
33249096|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33249097|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
33249098|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
33249099|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
33249100|NCT04477616|Experimental|Experimental: Experimental/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
33249101|NCT04477616|Active Comparator|Comparator: Comparator/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
33249102|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
33249103|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
33249104|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
33249105|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
33400195|NCT05419999|Sham Comparator|Sham plus WET|Subjects will receive sham transcranial direct current stimulation (tDCS) treatment plus written exposure therapy (WET)
32720300|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
32743359|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
32743360|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
33249106|NCT04445792|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
33249107|NCT04445792|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
33249108|NCT04445792|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
33249109|NCT04445792|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
33249110|NCT04445792|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
33249111|NCT04445792|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
33249112|NCT04043013|Active Comparator|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
33249113|NCT04043013|Active Comparator|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
33249114|NCT04043013|Active Comparator|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
33249115|NCT04043013|Active Comparator|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
33249116|NCT04400474|Experimental|Cabozantinib 40 mg + Atezolizumab 1200 mg|"Cabozantinib 40 mg tablets, oral administration, once daily, continuously.~Atezolizumab 1200 mg administered intravenously, every three weeks (cycle)."
33249117|NCT00845637|Active Comparator|Eggplant extract|
33249118|NCT00845637|Placebo Comparator|Placebo|
32922459|NCT04010786|Experimental|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
32922460|NCT04010786|Placebo Comparator|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
32922461|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
32922462|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
32922463|NCT03981926|No Intervention|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
32922464|NCT03981926|Experimental|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
32922466|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
33400196|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
32922467|NCT04734626||Mitochondrial Disease|Individuals with suspected (based on clinical presentation) or definite genetic mitochondrial disease
32922468|NCT04734626||Healthy Controls/Volunteers|Individuals with no history of suspected (based on clinical presentation) or definite genetic mitochondrial disease
32922469|NCT04711148|Placebo Comparator|placebo|"The Core Part：Participants receive placebo~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
32922470|NCT04711148|Experimental|orelabrutinib(low dose)|"The Core Part：Participants receive low dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
32922471|NCT04711148|Experimental|orelabrutinib(medium dose)|"The Core Part ：Participants receive medium dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
32922472|NCT04711148|Experimental|orelabrutinib (high dose)|"The Core Part：Participants receive high dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
32922473|NCT02294630|Active Comparator|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
32922474|NCT02294630|Active Comparator|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
32922475|NCT02294630|Active Comparator|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
32922476|NCT02294630|Active Comparator|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
32922477|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
32922478|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kits, and personalized one-on-one education and coaching.
32922479|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
33400197|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
33400198|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
33400199|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
33400200|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
33400201|NCT04831021|Experimental|Patients issued from dialysis units (clinic)|
32922480|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
32922481|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
32922482|NCT02806388||tumor tissue for molecular profiling|
32922483|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
32922484|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
32922485|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
32922486|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
32922487|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
32922488|NCT05006989|Experimental|Intervention Group|Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
32922489|NCT05006989|Placebo Comparator|Placebo Group|Participants will be provided placebo powder to be consumed.
32922490|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
32922491|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
32922492|NCT04983823|Experimental|Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|"Optimization of pharmacotherapy:~This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.~Exercise intervention: Individualized training program will be provided by an exercise physiologist"
32922493|NCT04983823|Active Comparator|Usual care|All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
32922494|NCT05710549|Experimental|neurophysiological measurements|40 cognitively-unimpaired healthy young adults (age 18-35 years old), 40 cognitively-unimpaired healthy older adults (age 55+ years old), and 40 age-matched patients with mild cognitive impairment (MCI) (age 55+ years old) will be assessed using high-density electroencephalography (hdEEG) to characterize the spatiotemporal dynamics of brain oscillations during personalized, autobiographical memory (ABM) tasks.
32922495|NCT05710549|Experimental|neuropsychological examination|40 MCI patients (age 55+ years old) will undergo 20min multi-channel protocols of transcranial alternating current stimulation; tACS (either gamma, beta, or ActiSham stimulation randomized across the three laboratory sessions) to modify cognitive functioning (MoCA score), and oscillatory brain activity during performing personalized, autobiographical memory (ABM) tasks and resting-state EEG.
32922496|NCT03871556|Experimental|Experimental Group|
32922497|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
32922498|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
32743361|NCT04935567|Experimental|Predicted responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (≥50% seizure reduction).
32922499|NCT05710393||Affected|(Affected) persons with a medical history of symptoms related to Hidradenitis Suppurativa.
32743362|NCT04935567|Active Comparator|Predicted non-responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (<50% seizure reduction).
32922500|NCT05710393||Unaffected-control|(Unaffected) family of participants, having no history of symptoms related to Hidradenitis Suppurativa.
32922501|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
32922502|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
32922503|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
33073374|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
32767350|NCT05255783|Other|Critically ill adults requiring insulin|Patients admitted to the intensive care unit requiring insulin infusion to maintain blood glucose within target range
32767351|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
32767352|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
32767353|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
32767354|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
32767355|NCT04867967|Experimental|Iyengar Yoga Intervention|"8-week yoga class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
32767356|NCT04867967|Active Comparator|Mindfulness-based stress reduction|"8-week MBSR class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
32767357|NCT04867967|No Intervention|Waitlist control|Waitlist control, ususal care
32767358|NCT01669343|Other|Post-menopausal Women Using Adjuvant Letrozole|Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
32767359|NCT04873505|Experimental|Troches|25 persons take one probiotic troche after each meal.
32767360|NCT04873505|Placebo Comparator|Troches do not contain probiotics|25 persons take one troche that does not contain probiotics after each meal.
32767361|NCT04867811|Experimental|group A|received conventional therapy
32767362|NCT04867811|Experimental|group B|received TENS in addition to conventional therapy
32767363|NCT04867811|Experimental|group C|received cupping therapy with conventional therapy
32767364|NCT04867811|Experimental|group D|TENS and cupping therapy plus conventional therapy
32767365|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 / Starting Dose|"Phase 1/the dose-finding arm of this study will use three dose levels (a starting dose, second dose and highest dose) of the venetoclax, CC-486 and obinutuzumab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to groups 2 and 3 to take higher doses until the safest/ most tolerable dose is found.~Group 1/ Dose Level 1:~Participants in group 1 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at a starting dose used in previous human studies. Participants in this group will receive:~Venetoclax:~400 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
32767366|NCT04722601|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|Participants in this arm will help test the efficacy of the three-drug regimen and dose established in the phase 1 of the study. Participants will take two drugs (venetoclax and CC-48) used in the same three-drug regimen during the first phase of this study. These two drugs will be paired together by themselves and given to participants in the expansion cohort before obinutuzumab (a third drug) is added during cycle 4 of treatment.
32767367|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 2 - Dose Level 2 /Second Dose|"Participants in group 2 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the second highest dose (dose level 2) set by doctors leading the study. Participants in this group will receive:~Venetoclax:~600 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
32767368|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 3 - Dose Level 3/ Highest Dose|"Participants in group 3 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the highest dose (dose level 3) set by doctors leading the study. Participants in this group will receive:~Venetoclax:~800 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
32767369|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 4 - Lower Dose Level 1|"Participants in this group will received a lower dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~Venetoclax:~400 mg on days 1-28~CC-486:~150 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
32767370|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 5 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~Venetoclax:~400 mg on days 1-10 only~CC-486:~150 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
32767371|NCT04389281|Experimental|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
32767372|NCT05403619||Patients|Patients hospitalized for shortness of breath with realization of an enhanced FoCUS
32720301|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
32720302|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
32922504|NCT02711852|Experimental|Duvelisib|Participants received the same dose from their previous duvelisib study. All doses were taken twice daily. Two dose reductions were allowed per participant, but doses were not less than 10 milligrams (mg). Participants received duvelisib until disease progression or unacceptable toxicity.
32922505|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
32922506|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
32922507|NCT04687046||Cohort 1 JUVÉDERM VOLUX® with 3D Imaging|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
32922508|NCT04687046||Cohort 2 JUVÉDERM VOLUX®|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.
32922509|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
32720303|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
32922510|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
32922511|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
32922512|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
32922513|NCT03836066|Experimental|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
32922514|NCT02501330||Bosutinib|
32922515|NCT02427698|Active Comparator|cyrolipolysis|
32922516|NCT02427698|Active Comparator|cryolipolysis plus subcision|
32922517|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
32720304|NCT03588975|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
32720305|NCT03588975|Active Comparator|microfracture|surgical procedure
32922520|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
32922521|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
32922522|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
32922523|NCT02318654|Active Comparator|Ice Pack|
32922524|NCT02318654|Active Comparator|Topical EMLA cream|
32922525|NCT04349930|Experimental|Cannabidiol|CBD vaginal suppository
32922526|NCT04349930|Placebo Comparator|Placebo|Placebo vaginal suppository
32922527|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
32720306|NCT02294669|Experimental|Turris Facet Fuser|
32720307|NCT04056273|Experimental|Guide sheath group|Transbronchial biopsy with a guide sheath
32720308|NCT04056273|Active Comparator|Conventional group|Transbronchial biopsy without a guide sheath
32720309|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
32720310|NCT04010721|Other|Experimental : experiment 1,2 and 3|"One user included participates all experiments:~Visit 1 : experiment 1~Visit 2 : experiment 2~Visit 3 : experiment 3"
32720311|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
32922528|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.~Patient will be monitored for 24h to rule out potential adverse events."
32935864|NCT05447936|Active Comparator|Female arm|Ten healthy active female XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
32720312|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
32720313|NCT04005495|Experimental|Teaching kitchen program|The teaching kitchen model is an innovative, multidisciplinary approach for motivating and establishing healthful habits and behaviors. The program combines didactic information with experiential learning in nutrition, culinary arts, exercise, yoga, and mindfulness.
32720314|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
32720315|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
32720316|NCT03541005|Experimental|Obex|a nutritional supplement Obex® 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
32720317|NCT03541005|Placebo Comparator|Placebo|Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
32720318|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
32720319|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
32720320|NCT03445923|No Intervention|Morphology|Embryos for transfer will be selected based on standard morphological evaluation.
32720321|NCT03445923|Active Comparator|TLM|Embryos for transfer will be selected base on standard morphological evaluation and information from time-lapse monitoring.
32720322|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
32720323|NCT03138993|Active Comparator|Patient decision aid|
32720324|NCT03138993|Sham Comparator|General sleep education|
32720325|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
32720326|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
32720327|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
32720328|NCT03383211||HIV+|Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.
32720329|NCT03383211||LTBI|Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.
32720330|NCT03383211||HV+/LTBI|Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.
32720331|NCT03383211||Healthy Control|Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.
32720332|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
32720333|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
32720334|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
32720335|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
32720336|NCT03823521|Experimental|Cardioplexol™- Cardioplegia Solution|Cardioplexol™ will be used as cardioplegic solution in cardiac surgery
32720337|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
32767373|NCT04678765|Active Comparator|Ultrasound-guided distal peripheral nerve block|Patients will receive the ultrasound-guided distal peripheral nerve block (locoregional anesthesia)
32720338|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
32720339|NCT03136341|Active Comparator|Abobotulinum toxin A|
32720340|NCT03136341|Placebo Comparator|Placebo|
32720341|NCT04465175|Active Comparator|Second dose magnesium sulphate|Second dose magnesium sulphate 50 mg/kg infused over one hour
32720342|NCT04465175|Placebo Comparator|Placebo|Normal saline (2.5 ml/kg) infused over one hour
32720343|NCT03158883|Experimental|Non-responders|"Patients who initially progress at first response assessment on a PD-1 inhibitor will be enrolled to the non-responder arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
32720344|NCT03158883|Experimental|Progressors|"Patients who initially present with PR, CR, or SD to a PD-1 inhibitor but subsequently progress will be enrolled to the progressor arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
32720345|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
32720346|NCT03041649|Active Comparator|GT button change - Mic-Key|Subjects randomized to the Mic-Key arm will have the Mic-Key button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mini One button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
32720347|NCT03041649|Active Comparator|GT button change - Mini One|Subjects randomized to the Mini One arm will have the Mini One button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mic-Key button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
32720348|NCT03520829||Patient treated for Gamma Knife|
32720349|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
32767374|NCT04678765|Experimental|Ultrasound-guided quadruple-injection axillary nerve block|Patients will receive the ultrasound-guided quadruple-injection axillary nerve block (locoregional anesthesia)
32767375|NCT04383743|Experimental|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
32767376|NCT03201523|Experimental|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
32767377|NCT02675179|Experimental|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
32767378|NCT04617067|Experimental|All Patients|Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
32767379|NCT04600531|Experimental|Group 1a - Conventional tDCS - Anodal first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
32767380|NCT04600531|Sham Comparator|Group 1b - Conventional tDCS - Sham first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
32767381|NCT04600531|Experimental|Group 2a - HD tDCS - Anodal first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
32767382|NCT04600531|Sham Comparator|Group 2b - HD tDCS - Sham first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
32767383|NCT05064865|Experimental|Freeze-dried table grape powder|The intervention group will consume 46 g/day of a freeze-dried table grape powder.
32767384|NCT05064865|Placebo Comparator|Placebo grape powder|The control group will consume the same amount of a placebo with a similar taste to the table grape powder.
32767385|NCT05062057||Palpitations|n=20 peri- and postmenopausal women with self-reported palpitations within 2 weeks prior to enrollment
32767386|NCT05062057||No palpitations|n=20 peri- and postmenopausal women with no self-reported palpitations within 6 months prior to enrollment
32767387|NCT05023057|Experimental|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training and social activity; (3) physical exercise; (4) nutritional guidance; and (5) motivational training.
32767388|NCT05023057|No Intervention|Control|At baseline, the participants in the control group will meet a study doctor, be prescribed medication when necessary, and receive educational booklets corresponding to their risk factors and a booklet on lifestyle guidelines to prevent dementia. They will receive usual care during the study period and be informed that they could participate in the multidomain intervention program after this study end.
32767389|NCT04669015|Experimental|Active plus SOC|Inhaled Novaferon, given 20 ug BID, daily for 10 days, plus Standard of Care
32767390|NCT04669015|Placebo Comparator|Placebo plus SOC|Inhaled vehicle formulation (placebo), given BID, daily for 10 days, plus Standard of Care
32767391|NCT02590783|Experimental|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
32767392|NCT02590783|Active Comparator|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
32767393|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
32767394|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
32767395|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
32767396|NCT04981171|Experimental|Electro-thumbtack Needle Therapy (ETN) group|Electro-thumbtack needles (0.25×2 mm) will be inserted into acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, turn on the device to produce a proper electric stimulation that the participant can tolerate.
32767397|NCT04981171|Sham Comparator|Sham Electro-thumbtack Needle Therapy (ETN) group|Sham electro-thumbtack needles (0.25×0.2 mm) which are specially produced have blunt tips instead of sharp needle tip. They will be taped on acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, produce a minimal level of electric stimulation for 30 seconds before turning off the device.
32767398|NCT04978831|Experimental|Respiratory exercise device group|
32767399|NCT04978831|Experimental|Reading aloud group|
32767400|NCT04978831|No Intervention|Control group|
32767401|NCT04978363|No Intervention|Arm 1. NONE|Participants will be tested while wearing no boot and no assistive device.
32767402|NCT04978363|Experimental|Arm 2. BOOT|The first intervention condition tested is a walking boot only on the subject's right lower extremity.
32767403|NCT04978363|Experimental|Arm 3. HFC+BOOT|The second intervention condition tested is a Hands Free Crutch (HFC) with the walking boot, both worn on the subject's right lower extremity.
32767404|NCT04978363|Experimental|Arm 4. SAC+BOOT|The third intervention condition tested is standard axillary crutches (SAC) with the walking boot worn in non-weight bearing on the subject's right lower extremity.
32767405|NCT04978363|Experimental|Arm 5. HFC|The fourth intervention condition tested is the Hands Free Crutch worn on the subject's right lower extremity without the walking boot.
32767406|NCT04978363|Experimental|Arm 6. SAC|The fifth and last intervention condition tested is standard axillary crutches with the subject non-weight bearing on the right lower extremity without the walking boot.
32767407|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
32767408|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
32767409|NCT01687153||Traumatic Brain Injury (TBI)|65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
32767410|NCT01687153||Post Traumatic Stress Disorder (PTSD)|65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
32767411|NCT01687153||Controls|65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
32767412|NCT01687153||TBI w/ MCI|65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
32767413|NCT01687153||PTSD w/ MCI|65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
32767414|NCT01687153||Controls w/ MCI|65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
32767415|NCT03047759|Active Comparator|Intervention A|water flosser
32767416|NCT03047759|Active Comparator|Intervention B|air floss
32767417|NCT04435639|Experimental|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
32767418|NCT04435639|Active Comparator|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
32767419|NCT04145531|Experimental|JZP-458|"Part A (IM JZP-458) of the study will have 2 IM cohorts:~Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit."
32767420|NCT04969237||healthy subjects 2019|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
32767421|NCT04969237||healthy subjects 2020|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
32767422|NCT04969237||healthy subjects 2021|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
32767423|NCT04969237||post-COVID subjects 2021|subjects with diseases not influencing vitamine D values without substitution with diagnosed post-COVID syndrome
32767424|NCT01669915|Active Comparator|Vitamin D + fish oil|
32767425|NCT01669915|Active Comparator|Vitamin D + fish oil placebo|
32767426|NCT01669915|Active Comparator|Vitamin D placebo + fish oil|
32767427|NCT01669915|Placebo Comparator|Vitamin D placebo + fish oil placebo|
32767428|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
33400202|NCT05681689|Experimental|Indication for H. pylori testing|Patients who have been treated for H. pylori and need to undergo eradication confirmation testing. Patients will be enrolled for this study if all acceptance criteria are met. Patients will undergo 13C Urea Breath Test in addition to non-invasive diagnostic comparators (H. pylori Stool Testing and Comparator Breath Test) OR invasive diagnostic comparator (Endoscopy for Rapid Urease Testing and Histology).
32767429|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
32767430|NCT05048251|Experimental|cTBS|continuous TBS to right MFG
32767431|NCT05048251|Experimental|iTBS|intermittent TBS to right MFG
32767432|NCT05048251|Sham Comparator|sham|sham stimulation to right MFG
32767433|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
32767434|NCT05137639|Experimental|PRF group|Participants received platelet-rich fibrin (PRF) prior to free skin grafting
32767435|NCT05137639|No Intervention|non-PRF group|Standard surgical procedure (free skin grafting to reconstruct donor sites without PRF).
32767436|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
32767437|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
32767438|NCT05137561|Active Comparator|PSMA PET/CT guided biopsy arm|PSMA PET/CT guided biopsy will be done from PSMA avid lesion of the prostate after reviewing the whole body PSMA PET/CT scan.
32767439|NCT05137561|Active Comparator|MRI directed TRUS guided biopsy|The MRI-directed transrectal ultrasound-guided per-rectal prostate biopsy will be done by cognitive fusion.
32767440|NCT04341467|Experimental|Amisulpride group|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
32767441|NCT04341467|Active Comparator|Olanzapine group|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
32767442|NCT04933591|Active Comparator|study group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months
32922529|NCT04585958|Experimental|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21 or days 8-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients taking olaparib BID on days 1-21 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, and 15 of cycle 1, day 1 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after cycle 4 and then at treatment end. Patients taking olaparib BID on days 8-14 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, 9, and 15 of cycle 1, days 1 and 8 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after that, and at treatment end. Patients undergo biopsy at baseline, and then on day 3 or day 10 of cycle 1.
32922530|NCT04579250|Experimental|Group 1: H10ssF-6473 (20 mcg), ages 18-50 years|H10ssF-6473 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
32922531|NCT04579250|Experimental|Group 2A: H10ssF-6473 (60 mcg), ages 18-50 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
32922532|NCT04579250|Experimental|Group 2B: H10ssF-6473 (60 mcg), ages 55-70 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
32922533|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
32922534|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
32922535|NCT03699020|Experimental|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
32922536|NCT03699020|Experimental|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
32922537|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32922538|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32922539|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
32922540|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
32922541|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
32922542|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
32922543|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
32922544|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
32922545|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
32922546|NCT01727791|Experimental|open label|
32922547|NCT01728337|Active Comparator|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
32922548|NCT01728337|Active Comparator|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
32922549|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
32922550|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
32720350|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
33400203|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PLACEBO THERAPY SESSION~Post-Placebo therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
32720351|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
32720352|NCT03138447|Experimental|Prospective Cohort|
32720353|NCT03138447|No Intervention|Retrospective Cohort|
32720354|NCT03517709|Other|Conventional|
32922551|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
32922552|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
32922553|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
32922554|NCT02991703|Active Comparator|SphygmoCor®|
32922555|NCT02991703|Experimental|pOpmètre®|
32922556|NCT04726969|Experimental|Arm A: moxidectin and albendazole|Combination therapy of moxidectin (8 mg, i.e. 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
32922557|NCT04726969|Placebo Comparator|Arm B: albendazole|Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
32922558|NCT04726969|Experimental|Arm C: ivermectin and albendazole|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
32922559|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
32922560|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
32922561|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
32922562|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
32922563|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebos weekly for 8 weeks
32720355|NCT03517709|Other|Blood Pressure Monitor|
32922564|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
32720356|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
32922565|NCT05317429|Experimental|Treatment|Carbohydrate-rich meal
32922566|NCT05317429|Active Comparator|Control|Carbohydrate-rich meal
32922567|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
32922568|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
32922569|NCT05317351|Active Comparator|"Standard Colonoscopy (SC)"|"Subjects enrolled to arm 1 (SC) will undergo colonoscopy using a standard colonoscope."
32922570|NCT05317351|Active Comparator|"Artificial Intelligence Aided Colonoscopy (GI Genius™) (AI)"|"Subjects enrolled to arm 2 (AI) will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)"
32922571|NCT05317351|Experimental|Combined Artificial Intelligence (GI Genius™) and G-EYE® Colonoscopy (AG)|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
32922572|NCT04342013|Experimental|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
32922573|NCT04342013|No Intervention|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
32922574|NCT03478553||People with IPF|
32922575|NCT03478553||Family members without IPF|
32922576|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
32922577|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
32922578|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
32922579|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
32720357|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
32720358|NCT02429791|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
32720359|NCT02429791|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
32922580|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
32922581|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
32922582|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
32922583|NCT03452891|Experimental|Simvastatin Methylcellulose|simvastatin in methylcellulose gel
32922584|NCT03452891|Placebo Comparator|Methylcellulose Gel|Methylcellulose gel
32922585|NCT04341935|Experimental|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
32720360|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
32720361|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
32720362|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
32720363|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
32720364|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
32720365|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
32720366|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
32720367|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
32720368|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
32720369|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
32720370|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
32720371|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
32720372|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
32720373|NCT02295137|Experimental|pre-procedure image guidance|
32720374|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
32720375|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
32720376|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
32720377|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
32720378|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
32720379|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
32720380|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
32720381|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
32720382|NCT04542993|Active Comparator|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
32720383|NCT04542993|Placebo Comparator|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
32720384|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
32720385|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
32720386|NCT03517397|Experimental|Mobile Contingency Management|
32720387|NCT03002415|Experimental|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.~Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days."
32720388|NCT03002415|Placebo Comparator|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
32720389|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
32720390|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.~Sorafenib: Twice daily, according to dose level upon entry.~Each cycle is repeated every 28 days."
32720391|NCT02000869||wait-listed kidney transplant candidates|
32720392|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
32720393|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
32720394|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
32720395|NCT03520205|Active Comparator|Continuous Epidural|Patient will receive epidural anesthesia
32720396|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
32720397|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
33249119|NCT03992833|Experimental|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
33249120|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
33249121|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
33249122|NCT00837057|Other|early crrt, late crrt|
33249123|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
33249124|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
33249125|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
33249126|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
32720398|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
32720399|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
32720400|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
32720401|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
32720402|NCT03133169||No chelation|"group 2: cases without chelation~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
32720403|NCT03133169||splenectomy|"group 3: cases with splenectomy~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
32720404|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
32720405|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
32720406|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
32720407|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
32720408|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
33249127|NCT03896048||Successful extubation|
33249128|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
33249129|NCT04263038|Active Comparator|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
33249130|NCT04263038|Placebo Comparator|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
33249131|NCT00845715|Other|Early motion|
33249132|NCT00845715|Other|Standard motion|
33249133|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
33249134|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
33249135|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
33249136|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
33249137|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
33249138|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
32720409|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
32720410|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
32720411|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
32720412|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
32720413|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
32720414|NCT02295449|Experimental|1|
32720415|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
33249139|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
33249140|NCT04042857|Experimental|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
32922586|NCT04341935|Active Comparator|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
32922587|NCT04723303|Experimental|Treatment Arm|A single IV infusion of ULSC's in patients with DM or PM
32922588|NCT04693351|Experimental|Troriluzole|Troriluzole- 2 100mg capsules once daily for the first two weeks. Troriluzole- 2 140mg capsules once daily from week two through week ten.
32922589|NCT04693351|Placebo Comparator|Placebo|Placebo- 2 100mg capsules once daily for the first two weeks. Placebo- 2 140mg capsules once daily from week two through week ten.
32922590|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
32922591|NCT05317039|Experimental|Group A|Group A will be treated with the buccal plate repositioning technique and grafted with SCPC.
32922592|NCT05317039|Active Comparator|Group B|Group B will be similarly managed and grafted using DFDBA
32922593|NCT05316961|Experimental|PEMF group|"Participants will receive active pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 1.5 mT, 10Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
33249141|NCT04235907|Active Comparator|Traditional Physical Therapy|Patients will be given a prescription to see a physical therapist and a paper-based rehabilitation protocol. Patients will be allowed to receive physical therapy at a location of patients' choosing. This arm represents the current standard of care.
32720416|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
32720417|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
32720418|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
32720419|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
32720420|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
32720421|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
32720422|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
32720423|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
32720424|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
32720425|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
32720426|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
32720427|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
32720428|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
32720429|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
32720430|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
32922594|NCT05316961|Sham Comparator|Sham group|"Participants will receive sham pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 0 mT, 0Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
32922595|NCT05316883|Other|clozapine treatment|Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect
32720431|NCT03516773|Experimental|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
32720432|NCT03516773|Experimental|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
32720433|NCT03516773|Active Comparator|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
32922596|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
33249142|NCT04235907|Active Comparator|Telerehabilitation|Patients will be given access to a website containing instructions with pictures and videos for the exercises patients are to complete as part of patients' rehabilitation. Patients will not be given a prescription to physical therapy. Patients in this group will receive weekly calls from a physical therapist during weeks 6-12 post-operatively.
32922597|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
32922598|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
32922599|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
32922600|NCT05316649||HPB group|Adult patients undergoing for elective liver or pancreas surgery at Department of Surgery, University Hospital Hradec Kralove, Czech Republic.
32922601|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
32922602|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
32720434|NCT03516773|Experimental|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
32922603|NCT03990363|Experimental|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
32922604|NCT03990363|Experimental|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
32922605|NCT03990363|Experimental|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
32922606|NCT03990363|Experimental|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
32922607|NCT03990363|Placebo Comparator|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
32922608|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
32922609|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
32922610|NCT02444663|Experimental|Device Valgus - 0 Newton force|Device performed fluoroscopic valgus stress X-rays - 0 Newton force
32922611|NCT02444663|Experimental|Device Valgus - 10 Newton force|Device performed fluoroscopic valgus stress X-rays - 10 Newton force
33249143|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
33249144|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
33249145|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
33249146|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
33249147|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
33249148|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
33249149|NCT03830281|Active Comparator|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
32720435|NCT03516773|Experimental|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
32720436|NCT05187455|Experimental|Renal transplantation(S group)|n=17,CLCR≤30ml/min
32720437|NCT05187455|Experimental|the control group|n=17, CLCR≥80ml/min
32720438|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
32720439|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
32922612|NCT02444663|Experimental|Device Valgus - 20 Newton force|Device performed fluoroscopic valgus stress X-rays - 20 Newton force
32922613|NCT02444663|Experimental|Device Valgus - 30 Newton force|Device performed fluoroscopic valgus stress X-rays - 30 Newton force
32922614|NCT02444663|Experimental|Device Varus - 0 Newton force|Device performed fluoroscopic varus stress X-rays - 0 Newton force
32922615|NCT02444663|Experimental|Device Varus - 10 Newton force|Device performed fluoroscopic varus stress X-rays - 10 Newton force
33249150|NCT03830281|Experimental|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
33249151|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
33249152|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
33249153|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
33249154|NCT00563368|Active Comparator|TPM 92|high dose topiramate
32767443|NCT04933591|No Intervention|control group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/
32767444|NCT04872881|Active Comparator|ETT Group|"ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
32767445|NCT04872881|Active Comparator|LMA Group|"After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
32767446|NCT04606459|Active Comparator|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
32767447|NCT04606459|Experimental|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
32767448|NCT05137483||With cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
32767449|NCT05137483||without cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
32767450|NCT04872647|No Intervention|Usual Diabetic Care|Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
32767451|NCT04872647|Experimental|Usual Diabetic Care Plus Virtual Health Coaching|"For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as lose weight, or improve my blood sugar numbers, etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text."
32767452|NCT04591249|Other|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
32767453|NCT04591249|Experimental|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
32767454|NCT04922281|Active Comparator|ICM-guided Management|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
32767455|NCT04922281|Placebo Comparator|Conventional Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
32767456|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
32767457|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
32767458|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
32767459|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
32767460|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
32767461|NCT04587583|Active Comparator|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
32767462|NCT04587583|Active Comparator|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
32767463|NCT04341155|Active Comparator|Dexamethasone|"Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
32767464|NCT04341155|Placebo Comparator|Placebo|"Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
32922616|NCT02444663|Experimental|Device Varus - 20 Newton force|Device performed fluoroscopic varus stress X-rays - 20 Newton force
33249155|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
33249156|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
33249157|NCT00563368|Placebo Comparator|Placebo|
32767465|NCT04581811|Experimental|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
32767466|NCT04581811|Active Comparator|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
32767467|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
32767468|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
32767469|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
32767470|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
32767471|NCT05137249||patients with COVID 19 disease|Patients diagnosed with and hospitalized due to COVID-19. Subgroups: ICU admitted COVID-19 + patients vs COVID 19 pts. at normal ward-
32767472|NCT05137249||Healthy volunteers|healthy volnuteers
32767473|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
32767474|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
32767475|NCT04430153||Mismatch|A group with good observed but low perceived function.
32767476|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
32767477|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
32767478|NCT04487899||Instructors group|Group of flight instructors at the reactor school.
32767479|NCT04487899||Students group|Group of students at the reactor school.
32767480|NCT04865705|Experimental|Tilelizumab+Albumin Paclitaxel + Carboplatin/Cisplatin|Tilelizumab 200mg d1 Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1IV,Q3W *2cycles
32767481|NCT04375111|Active Comparator|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
32767482|NCT04375111|Active Comparator|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
32767483|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
32767484|NCT04898179||Telecare group|"When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.~At the start and end of the program, patients were administered the SF-12 quality of life questionnaire."
32767485|NCT04898179||Control group|The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.
32767486|NCT04867577||vertebral osteoporotic compression fracture|Patients with osteoporotic vertebral compression receiving vertebroplasty or cemented screws reconstruction
32767487|NCT05137171|Experimental|AK105 and anlortinib|AK105 200mg iv q3w;anlotinib 12mg 2w on/1w off po qd;21 days as a cycle until PD,intolerable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
32767488|NCT04384679|Experimental|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
32767489|NCT04384679|No Intervention|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
32767490|NCT05137015|Experimental|Intervention|The intervention group will use the new injury prevention program at least twice per week in their training sessions.
32767491|NCT05137015|No Intervention|Control|The control group will continue their usual training routine.
32767492|NCT04866875|Active Comparator|Rapid weight loss|Participants in this group will be deprived in 1000 kcal/day (calculated based on their individual energy requirements) for 10 weeks
32767493|NCT04866875|Experimental|Slow weight loss|Participants in this group will be deprived in 500 kcal/day (calculated based on their individual energy requirements) for 20 weeks
32767494|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:~At the time of consent~3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)~3 months after second swab~6 months after second swab~12 months after second swab"
32767495|NCT04858997|Experimental|Palbociclib-AI|ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
33249158|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
33249159|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
33249160|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
33249161|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
32922617|NCT02444663|Experimental|Device Varus - 30 Newton force|Device performed fluoroscopic varus stress X-rays - 30 Newton force
32922618|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
32922619|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
32922620|NCT04341857|Experimental|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
33249162|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
32922621|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
32922622|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
32922623|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
32922624|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
32922625|NCT04661839|Experimental|COVID-HIGIV Dose Level 1 (100 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 1 (100 mg/kg).
32922626|NCT04661839|Experimental|COVID-HIGIV Dose Level 2 (200 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 2 (200 mg/kg).
32922627|NCT04661839|Experimental|COVID-HIGIV Dose Level 3 (400 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 3 (400 mg/kg).
32922628|NCT04661839|Placebo Comparator|Dose Placebo (saline)|Eligible subjects randomized to receive a single IV infusion of saline placebo.
32922629|NCT04745039|Experimental|Endopatch System|Participants will be treated with Endopatch System
33400204|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~BUDDHIFY THERAPY SESSION~Post-Buddhify therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
33400205|NCT02690194|No Intervention|Control Group|"Pre-Procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
32922630|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
32922631|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
32922632|NCT03083405||Healthy controls|Patients without diagnosed SB.
32922633|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
32922634|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
32922635|NCT04635241|Experimental|Inhaled heparin|Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
32922636|NCT04635241|No Intervention|Standard care|Standard care
32922637|NCT04616677|Active Comparator|Parts 1 and 2: Cohort 1 (JNJ-42847922)|Healthy participants with normal renal function [estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter (mL)/minute (min)] will receive single oral dose of JNJ-42847922 on Day 1.
32922638|NCT04616677|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with severe renal impairment (eGFR 15 to 29 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
32922639|NCT04616677|Experimental|Part 2 (Optional): Cohort 3 (JNJ-42847922)|Participants with moderate renal impairment (eGFR 30 to 59 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
32922640|NCT03966651|Experimental|PRRT with 177Lu-DOTATATE|
32922641|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
32922642|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
32922643|NCT03963453||Interventional|Regular physical exercise group
32922644|NCT03963453||Control|Standards of care treatment
32922645|NCT04606927|Active Comparator|Natriuresis guided treatment|
32922646|NCT04606927|No Intervention|Standard of care|
32922647|NCT03954483|Experimental|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
33249163|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
33249164|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
32922648|NCT03954483|Experimental|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
32922649|NCT03954483|Placebo Comparator|Placebo|Participants will receive a placebo prior to experiments.
33249165|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
32922650|NCT05709925|Other|Group A|Group A will be receiving moist heat for 10 minutes followed by myofascial release through stripping technique to the lumbar region. After that post-treatment stretching would be performed. Total treatment plan would be of 30 minutes, comprising of total 9 sessions (3 weeks), 3 sessions on alternate days
32922651|NCT05709925|Experimental|Group B|Group B will be receiving moist heat for 10 minutes followed by Instrument Assisted Soft Tissue Mobilization using long bar tool for 5-7 minutes with gentle horizontal stroking at an angle of 45 degrees. After that, post treatment stretching consisting of 2-3 sets of 10 repetitions of the targeted muscle group will be performed.Total treatment plan will be of 3 weeks comprising of total 9 sessions, 3 sessions on alternate days.
33249166|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
33249167|NCT00562120|Placebo Comparator|Placebo|
32922652|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
32922653|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
33249168|NCT00562120|Active Comparator|Allegra|
33249169|NCT00562120|Active Comparator|Allegra-D|
32922654|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
32922655|NCT04545541|Experimental|Nebulised heparin|"Participants assigned to nebulised UFH will receive nebulised UFH in addition to the standard care required as determined by the treating team. Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days."
32922656|NCT04545541|No Intervention|Control group|"Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin (Australia, Ireland).~Participants assigned to placebo will receive Nebulised 0.9% Sodium Chloride (5 mL) administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days (USA)."
32922657|NCT00002925|Active Comparator|ADE|
32922658|NCT00002925|Experimental|ADEP|
32922659|NCT05316415|Experimental|Acemaşiran Music Group|Listening to Acemaşiran music for 40 minutes in successive three days and two times a day (noon and evening) Routine clinical care
32922660|NCT05316415|No Intervention|Control Group|Routine clinical care
32922661|NCT05709847|Active Comparator|Conventional coffee|Participants will be provided with a conventional, low CGA coffee to brew and consume which contains less CGA than the experimental arm.
32922662|NCT05709847|Experimental|CGA-rich coffee (Speciality coffee)|Participants will be provided with a single origin, CGA-rich specialty coffee as graded by the Specialty Coffee Association of America's Q-grading system to brew and consume
33249170|NCT00562120|Experimental|PF-03654746|
33249171|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
33249172|NCT00939172|Experimental|TTP607|
33249173|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
32922663|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
32922664|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
32922665|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
32922666|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
32922667|NCT04526899|Experimental|BNT111 + cemiplimab|
32922668|NCT04526899|Experimental|BNT111 monotherapy|
32922669|NCT04526899|Experimental|Cemiplimab monotherapy|
32922670|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
32922671|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
32922672|NCT02446223|Experimental|Active|
32922673|NCT03949647||1|Healthy males and females aged 18 years and older
32922674|NCT05709769||Training Group|A primary cohort of eligible patients from the cancer center of Zhejiang Provincial People's Hospital is used for developing the radiomics-based nomogram prediction model. In the training cohort, a sample size of 88 was required to accept the hypothesis that the prediction accuracy of the radiomics-based nomogram model was greater than 45% with 90% power and to reject the hypothesis that the prediction accuracy rate was less than 30% with an α error of 5%. Initially, we planned to enroll 77 patients in the first stage. If 27 or more prediction accuracy rates were observed, we planned to continue to the second stage for a total of 88 patients for the analysis. Considering some deviant cases, the preplanned accrual number was set to 100 patients in the training cohort.
32720440|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
32720441|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
32720442|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
32922675|NCT05709769||Validation Group|An independent cohort of eligible patients is used for external validation. we are planning to enroll an additional 50 patients to further validate this radiomics-based nomogram prediction model.
32922676|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
32922677|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
32922678|NCT04483297|Experimental|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation
32922679|NCT04483297|Other|Control|Local Autologous Bone + Posterior Fixation
32922680|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
32922681|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
32922682|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
32922683|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
32922684|NCT05315869||Retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix located in the retrocaecal position.
32922685|NCT05315869||Non-retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix not located in the retrocaecal position.
32922686|NCT05315791|Experimental|a: ground into pieces|0~3mm
32922687|NCT05315791|Experimental|b: replace the bone|0~3mm
32922688|NCT05315791|Experimental|c: turn inward|0~3mm
32922689|NCT05315791|Experimental|d: ground into pieces|3~5mm
32922690|NCT05315791|Experimental|e: replace the bone|3~5mm
32922691|NCT05315791|Experimental|f: turn inward|3~5mm
32922692|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
32922693|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
32720443|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
32720444|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
32720445|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
32720446|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
32720447|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
33249174|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
33249175|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
33249176|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
32922694|NCT04350853|Experimental|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
32720448|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
32922695|NCT05709691|Experimental|Experimental|Oculomotor therapy and adapted yoga.
32922696|NCT05709691|Active Comparator|Active Comparator|Adapted yoga.
32922697|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
32922698|NCT05315557|Experimental|Terlipressin|Terlipressin 1mg/24 hours
33073375|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
32720449|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
32720450|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
32720451|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
32720452|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
32720453|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
32720454|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
32720455|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
32720456|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
32720457|NCT02295839|No Intervention|Usual care|
32720458|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
32720459|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
32720460|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
32720461|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
32720462|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
32720463|NCT02292641|Other|Patients with advanced or recurrent rectal cancer|Provide these patients with a compartmentalized radiology report which will provide surgeons with data on optimal exenterative surgery
32720464|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
32922699|NCT05315557|Active Comparator|Vasopressin|Vasopressin 0.03 U/hour
32922700|NCT05315401|Experimental|Probiotic 9 log CFU/day|The intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
32922701|NCT05315401|Placebo Comparator|Placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as a light-yellow powder.
32922702|NCT05315401|Experimental|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week
32922703|NCT02877303|Experimental|Treatment (blinatumomab, inotuzumab, combination chemotherapy)|See detailed description.
32922704|NCT05709613|No Intervention|No feedback device|This group will have no access to the feedback device
32922705|NCT05709613|Experimental|Feedback device|This group will have access to the feedback device
32922706|NCT04322851||B-line positive|
32922707|NCT04322851||B-line negative|
32922708|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
32922709|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
32922710|NCT04320199|Experimental|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
32922711|NCT04320199|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
32922712|NCT05312125|Active Comparator|control group|Children in this group will take routine physiotherapy (stretching, strengthening) program during 6 weeks. 3 days/week.
32922713|NCT05312125|Active Comparator|intervention group|Children in this group will take routine physiotherapy (stretching, strengthening) program + backward downhill walking (10 minutes in a day) during 6 weeks. 3 days/week.
33249177|NCT00561730||Pantoprazole|All patients enrolled
33249178|NCT00697112||A|
33249179|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
33400206|NCT05399641|Experimental|Group A|Single day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day.
33400207|NCT05399641|Experimental|Group B (3 Day dosing)|Three day dosing, 300 mg Ibrexafungerp BID for a total of 600mg a day.
33400208|NCT05399641|Experimental|Group b (7 Day dosing)|Seven day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day
33400209|NCT05593666|Experimental|LXE408 short regimen|LXE408 once daily for seven days (followed by 7 days of placebo).
33400210|NCT05593666|Experimental|LXE408 long regimen|LXE408 once daily for 14 days
32767496|NCT05135143|Active Comparator|Infertility male patients|Infertile male patients will receive the antioxidant formula for more than 172 days. Divided in two groups. One will take the active substance, to the other group placebo treatment will be given.
32767497|NCT05135143|Placebo Comparator|Control group|Placebo treatment and control and comparative variables will be measured.
32767498|NCT04865549|Experimental|TAD arm|Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
32767500|NCT04867265|Active Comparator|Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
32767501|NCT04867265|Active Comparator|Resusci Anne QCPR AED (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
32767502|NCT04867265|Active Comparator|Resusci Baby QCPR (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
32767503|NCT04865653|Experimental|Oral drinking solution of LSD base|Oral drinking solution of 0.1 mg LSD base in 96% ethanol
32767504|NCT04865653|Experimental|Solid orodispersible film containing LSD base|Solid orodispersible film containing 0.1 mg LSD base
32767505|NCT04865653|Experimental|Oral drinking solution of LSD tartrate|Oral drinking solution of 0.146 mg LSD tartrate in water
32767506|NCT04865653|Experimental|Intravenous administration of LSD tartrate|Intravenous administration of 0.146 mg LSD tartrate in water
32767507|NCT04865653|Placebo Comparator|Placebo|Placebo for all formulations
32767508|NCT04858763||2020 Cohort|This is the 2020 MS cohort who experienced a clinician confirmed relapse during April - June 2020, during the first wave of the COVID-19 pandemic.
32767509|NCT04858763||2019 Cohort|2019 MS cohort who experienced a clinician confirmed relapse during April - June 2019.
32767510|NCT04863469|Experimental|B-POC high load Intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
32767511|NCT04863469|Sham Comparator|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
32767512|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
32767513|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
32767514|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
32767515|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
32767516|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
32767517|NCT04351711||convalescent patients|Additional 1-year follow-up visit
32767518|NCT05306119|Active Comparator|Main group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment with an individual program of medical rehabilitation with the use of means, affecting both diseases lasting up to 21 days
32767519|NCT05306119|No Intervention|Comparison group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment lasting up to 21 days
32767520|NCT05306119|No Intervention|Control group|Healthy people aged 40-60 y.o.
32767521|NCT05305729||Subjects with a genetic disease|
32767522|NCT04488679|Experimental|PRF along with MTA|5 ml of the participant blood will be drawn into 10 ml test tubes without an anticoagulant and centrifuged immediately .centrifugation will be done using a tabletop centrifuge for 12 min at 2700 rounds per minute. The resultant product will exhibit three layers. platelet-poor plasma at the surface, PRF clot in the middle, and red blood cells at the bottom. Sterile tweezers inserted into a test tube to retrieve the PRF clot. The prepared fibrin membrane will be gently packed over the pulp
32767523|NCT04488679|Active Comparator|MTA direct pulp capping|MTA is primarily calcium oxide in the form of tricalcium silicate, dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity, MTA is considered a silicate cement rather than an oxide mixture, a so its biocompatibility is due to its reaction products. MTA elevates the expression of transcription factors, induces dentin bridge formation, possesses biocompatibility9, and sustains a high pH for a longer duration and a close physiochemical seal with dentin that forms an insoluble barrier to prevent microleakag
32767524|NCT05305417|Experimental|Regenerative Endodontic Treatment|This treatment consists of obturated the root canal preparations under an biological-based protocol using autologous biological elements and bioactive materials that allows restore the connective pulp-like tissue within the canals.
32767525|NCT05305417|Active Comparator|Conventional root canal treatment|This treatment consist on obturated the root canal preparations under the conventional protocol with an inert biomaterials like guttapercha and endodontics cements to seal the root canals.
32767526|NCT05305339||Group A (Control group)|Singleton pregnancies undergoing elective pre-labour CS at gestational age (34+0 to 40+0) that are otherwise healthy.
32720465|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
32720466|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
33249180|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
32720467|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
32720468|NCT03516461|Experimental|Selective Microbiota Transplant (SMT)|Patients undergo once SMT a day for three consecutive days.
32720469|NCT03516461|Experimental|Fecal Microbiota Transplantation (FMT)|Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
32720470|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD~50 - 90 years of age~In-patients or out-patients~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
32720471|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2~50 - 90 years of age~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
32720472|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
32720473|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
32720474|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
32720475|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
32720476|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
32720477|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
32720478|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
32720479|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
32720480|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
32720481|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
32720482|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
32720483|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
32720484|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
32720485|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:~A digital chest x-ray using the study MinXray unit.~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
32720486|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
32720487|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
32720488|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
32720489|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
32720490|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
32720491|NCT02296385|Experimental|Supplementation|Supplementation
32720492|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
32720493|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
32720494|NCT03519113|Active Comparator|Control group|I.V HBIG
32720495|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
32922714|NCT05709535||Experimental: [18F]PSMA-1007 Injection|A single intravenous dose of 3 - 4 MBq/kg (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging.
33249181|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
33249182|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
33249183|NCT00621855|Placebo Comparator|placebo|matched placebo
33249184|NCT04012762|Active Comparator|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
33249185|NCT04012762|Active Comparator|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
33249186|NCT04258280|Active Comparator|Usual Care|
33249187|NCT04258280|Experimental|Enhanced Care|
33249188|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
33249189|NCT00940966|Active Comparator|ADA diet|standard ADA diet
33249190|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
33249191|NCT04230356|Experimental|VSTs to Prevent|VSTs are given through an IV infusion 21 days after transplant to see if the VSTs will help prevent a viral infection.
33249192|NCT04230356|Experimental|VSTs to Treat|VSTs will be given only if a viral infection develops.
32720496|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
32720497|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
32720498|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
33249193|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
33249194|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
33249195|NCT04222088||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
33249196|NCT04222088||Patients detected with Plasmodium vivax (Chloroquine)|Patients with mono-infection of Plasmodium falciparum with ≥ 250 per µl
33249197|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
33249198|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
33249199|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
33249200|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
33249201|NCT05633732||Standardized View Group|The echocardiography view images of patients in this group are standardized.
33249202|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
33249203|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
33249204|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
33249205|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
33249206|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
33249207|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
33249208|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
33249209|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
33249210|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
32720499|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
32720500|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
32720501|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
33249211|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
33249212|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
33249213|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
33249214|NCT05545202|Other|A: Pentaisomaltose 16 %|Pentaisomaltose 40 % sterile solution; 40 mL will be transferred to a total volume of 100 mL, so the final concentration is 16 %.
33249215|NCT05545202|Other|B: A combination of Pentaisomaltose 10 % and DMSO 2 %|"Combination of IMP and comparator:~Pentaisomaltose 40 % sterile solution; 25 mL will be transferred to a total volume of 100 mL, so the final concentration is 10 %.~DMSO 99.9 % sterile solution; 2 mL will be transferred to a total volume of 100 mL, so the final concentration is 2 %."
33249216|NCT05545202|Active Comparator|C: DMSO 10 %|"Comparator:~DMSO 99.9 % sterile solution; 10 mL will be transferred to a total volume of 100 mL, so the final concentration is 10 %."
33249217|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
33400211|NCT05593666|Active Comparator|Standard of care|AmBisome® 10 mg/kg IV single dose (SDA)
32922715|NCT03912519|Active Comparator|Parallel placement of 16 gauge electrodes|Parallel Group will undergo radiofrequency ablation via the approach described in Spine Intervention Practice Guidelines via 16 gauge electrodes. Specifically, the target nerve will be targeted with a parallel approach so as the electrode lay parallel to the nerves location within the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
32922716|NCT03912519|Active Comparator|Perpendicular placement with 22 gauge electrodes|Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
32922717|NCT05308927||Incident patients|Children initiated Norditropin® upon their inclusion in the study but independently from the decision to participate in this study
32922718|NCT05308927||Prevalent patients - finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and finished their growth upon their inclusion. Data collected retrospectively from medical records
32922719|NCT05308927||Prevalent patients - not finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and did not finish their growth upon inclusion. Data collected both retrospectively and prospectively
32922720|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
32922721|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
32922722|NCT05303077|Experimental|Study Infant Formula|Infant formula supplemented with omega 3 fatty acids and inactive Bifidobacteria
32922723|NCT05303077|Active Comparator|Infant Formula|Infant formula
32922724|NCT05303077|Active Comparator|Breastfeed Active comparator|Infants who are breastfed
32720502|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
32720503|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
32720504|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
32720505|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
32720506|NCT02293343||control group|healthy subjects
32720507|NCT02293343||IgE positive|patients with high IgE level in serum
32720508|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
32720509|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
32720510|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
32922725|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
32922726|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
32922727|NCT02448641|Sham Comparator|Sham Control|Sham surgery
32922728|NCT04246177|Experimental|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
32922729|NCT04246177|Active Comparator|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
32720511|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
32720512|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
32720513|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
32720514|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
32720515|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
32720516|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
32720517|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
32922730|NCT03898479|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
32922731|NCT04744259|Experimental|Behavioural activation|The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with an intellectual disability and depressive symptoms.
32922732|NCT04744259|No Intervention|Treatment as usual|This will include the existing treatments available in NHS and social care for adults with intellectual disability with depression, including anti-depressants, mood stabilizers, and any available psychological interventions. Additionally, for all those in the study, we will provide their General Practitioner with a summary of the NICE guidelines on treatment of depression for adults with intellectual disabilities.
32922733|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
32922734|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
32922735|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
32720518|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
32922736|NCT04227379|Experimental|DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
32720519|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
32720520|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
32720521|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
32922737|NCT04227379|Active Comparator|DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message. There will be no customizable or interactive content for the DSE arm."
32922738|NCT03057431|Placebo Comparator|Placebo|Once daily for 3 years
32922739|NCT03057431|Experimental|12.5 mg hydrochlorothiazide|Once daily for 3 years
32922740|NCT03057431|Experimental|25.0 mg hydrochlorothiazide|Once daily for 3 years
32922741|NCT03057431|Experimental|50.0 mg hydrochlorothiazide|Once daily for 3 years
33400212|NCT05390359|Experimental|High-intensity and short-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
32922742|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
32922743|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
32922744|NCT05709457|Experimental|RCT Participants|Women and children who participated in the earlier study.
32922745|NCT05709457|No Intervention|Non-RCT participants|Women and children in the same communities included in the earlier study who did not participate in that study.
33400213|NCT05390359|Experimental|Low-intensity and long-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
32720522|NCT04934072|Experimental|FKS518|
32720523|NCT04934072|Active Comparator|US-licensed Prolia|
32720524|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
32720525|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
32720526|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
32720527|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
32720528|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
33400214|NCT05390359|Experimental|High-intensity, short-duration and 20 Hz|The technique consists of the percutaneous electrical stimulation of the tendon applying a alternating current through a ultrasound-guided needle.
33400215|NCT05390359|Sham Comparator|Sham electrolysis|The technique consists of an introduction ultrasound-guided needle without electrical stimulation.
33400216|NCT05593510|Experimental|No prep ready-to-eat meals|
32720529|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
32720530|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
33400217|NCT05593510|Active Comparator|Ingredient bundles (e.g. meal kits)|
32922748|NCT04210843|Experimental|Ligelizumab Dose 1 and 3|Liquid in vial 72 mg/mL followed by 120 mg/mL PFS
32922749|NCT04210843|Experimental|Ligelizumab Dose 2 and 3|Liquid in vial 120 mg/mL followed by 120 mg/mL PFS
33400218|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor: the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
32922750|NCT04330053|Experimental|Experimental|Information - Education about falls and Exercise for Fall Prevention
32922751|NCT04330053|Active Comparator|Control|Information - Education about falls without Exercise for Fall Prevention
32922752|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
32922753|NCT00383253|Experimental|10%|
32720531|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
32922754|NCT00383253|Experimental|25%|
32922755|NCT00383253|Experimental|50%|
32922756|NCT00383253|Placebo Comparator|Control|
32922757|NCT04204837|Experimental|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
32922758|NCT04204837|Experimental|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
32922759|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
32922760|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
32922761|NCT05709379|Experimental|Control trial|Sitting from 8 am until 3pm.
32922762|NCT05709379|Experimental|High intensity sedentary breaks|Physical activity on 80-85% of individual VO2max every hour. Modality: Hill walking/jogging on treadmill.
32922763|NCT05709379|Experimental|Low intensity sedentary breaks|Physical activity on 25-30% of individual VO2max every hour. Modality: Hill walking on treadmill.
32922764|NCT02240485|Experimental|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"Couple therapy: The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Treatment for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
32922765|NCT02240485|Active Comparator|Usual individual/group treatment|Usual individual/group treatment: The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
32922766|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
32922767|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
32922768|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
32922769|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 1_Cohort 1|
32922770|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 2_Cohort 2|
32922771|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 3_Cohort 3|
32922772|NCT02637687|Experimental|Phase 2 expansion: Patients with tumors bearing NTRK fusions (IFS)_Cohort 1|
32922773|NCT02637687|Experimental|Phase 2 expansion: Other extra-cranial solid tumors_Cohort 2|
32720532|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
32922774|NCT02637687|Experimental|Phase 2 expansion: Primary CNS tumors_Cohort 3|
32922775|NCT02637687|Experimental|Phase 2 expansion: bone health assessment_sub-cohort|
32922776|NCT02637687|Experimental|Phase 1 dose escalation: Dose expansion|
32922777|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
32922778|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
32922779|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
32922780|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
32922781|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
32922782|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
32922783|NCT00003075|Experimental|Fenretinide|
32922784|NCT00003075|Placebo Comparator|Placebo|
32922785|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
32922786|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
32922787|NCT00003093|Experimental|Treatment|See detailed description.
32922788|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
32922789|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
32922790|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
32922791|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
32922792|NCT04137445|Experimental|Study Provided Diet|A group of complementary foods provided to participants by researchers.
32922793|NCT04137445|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
32922794|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
32922795|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
32720533|NCT04465019||TBI Group|Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
32720534|NCT04465019||CVA Group|Subjects in the CVA group included all patients in the hospital that used the EKSO® during their rehabilitation process during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
32720535|NCT04464941|Experimental|oral health promotion program|"The oral health promotion program was a composite intervention with both group and individual components. The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method 2. Individual behavioral modification method"
32720536|NCT04464941|No Intervention|Usual care group|
32720537|NCT04933838|Placebo Comparator|Control Group|1% licocaine 3 mL + Normal saline 3 mL mixture
32720538|NCT04933838|Experimental|Atelocollagen group|1% lidocaine 3 mL + atelocollagen 3 mL mixture
32720539|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
32720540|NCT04933526|Active Comparator|Flumatinib|600mg QD orally form 1 to 12 months
32720541|NCT04933526|Placebo Comparator|Dasatinib|100mg QD orally form 1 to 12 months
32720542|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
32922798|NCT05237401|Active Comparator|Non-Surgical Periodontal treatment (NSPT)|Half of the study participants (controls) will be randomised to receive continued non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist in each centre, including oral hygiene.
32922799|NCT05237401|Experimental|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|"The other half of the study participants (test) will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD). The aim of the surgery will be to achieve thorough debridement of the furcation area and (if possible) improve accessibility for patient-performed hygiene in the furcation area.~Some of the included maxillary molars may have additional FI on the same tooth (for example, grade III FI buccal to mesial and grade I, II or III distal). In this occurrence, the other furcation will be treated according to judgment by the treating clinician. We anticipate that, based on inclusion criteria, the majority of cases will have multiple grade III FI."
32922800|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
32720543|NCT04933448|Experimental|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
32720544|NCT04933448|No Intervention|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (<8 or 8-12), and pre-injury school program (regular or special education).
32720545|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~healthy patients;~patients with colonic Crohn disease in acute phase;~patients with colonic Crohn disease in chronic phase;~patients with ulcerative colitis in acute phase;~patients with ulcerative colitis in chronic phase;~patients with colon cancer"
32720546|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
32922801|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
32922802|NCT05228197||Calibration Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion criteria but in addition, purposive identification of cases with a variety and representative sample of different pathology features are needed for this stage (e.g. normal glands, cancer glands, high-grade PIN, inflammation)."
32922803|NCT05228197||Validation Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion."
32922804|NCT05223439||Individuals diagnosed with neuropathic pain due to lumbar disc degeneration|Individuals with neuropathic pain due to lumbar disc degeneration were included in this group.
32922805|NCT05223439||Individuals with lumbar disc degeneration but no neuropathic pain|Individuals without neuropathic pain due to lumbar disc degeneration were included in this group.
32922806|NCT05223439||Healthy Controls|Healthy individuals who did not have any problems that would affect gait were included.
32720547|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
32720548|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
32720549|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
32720550|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
32720551|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
32720552|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
32922807|NCT05709301|Experimental|Donepezil|
32922808|NCT05709301|Placebo Comparator|Placebo|
32922809|NCT04329897|Experimental|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
32922810|NCT04329897|No Intervention|Control|Subjects randomizing into this arm did not receive the text message study intervention.
32922811|NCT04047433|Experimental|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
32720553|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
32720554|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
32720555|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
32720556|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
32720557|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
32720558|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
32720559|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
32720560|NCT03518099|Experimental|witness|
32720561|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
32720562|NCT02297165|Experimental|Program|olfactory stimulation program
32720563|NCT02297165|No Intervention|Control|normal follow-up
32720564|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
32720565|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
32720566|NCT03515603|Active Comparator|microsurgical technique|
32720567|NCT03515603|Active Comparator|endoscopic technique|
32720568|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
32720569|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
32720570|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
32720571|NCT04465097|Experimental|Tucidinostat and Exemestane|Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.
32720572|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
32720573|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
32720574|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
32720575|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
32720576|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
32720577|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
32720578|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
32720579|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
32720580|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
32720581|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
32922812|NCT04047433|Experimental|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
32922813|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
32922814|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
32922815|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
32922816|NCT04329741|Experimental|Intervention|6-week basic dog obedience training course
32720582|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
32720583|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
32720584|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
32720585|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
32720586|NCT02298881||Dry eye group|People with dry eye symptoms
32720587|NCT02298881||Non-dry eye group|People with no dry eye symptoms
32720588|NCT03515447||Before period|During this period no patient received Romiplostim.
32720589|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
32720590|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
32720591|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
32720592|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
32720593|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
32720594|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
32720595|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
32720596|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
32720597|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
32720598|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
32720599|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
32720600|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
32720601|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
32720602|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
32720603|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
32720604|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
32720605|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
32720606|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
32720607|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
32720608|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
32720609|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
32720610|NCT04932356|Other|Therapeutic Education by phone|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit and then reinforcement each 15 days over the weak points of this visit.
32922817|NCT04329741|No Intervention|Control|Waitlist control
32720611|NCT04932356|Other|Traditional Therapeutic Education|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit.
32720612|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
32720613|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
32720614|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
32720615|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
32720616|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
32922818|NCT05155267||Chronic Kidney disease participants (CKD)|CKD submitted to hemodialysis
32922819|NCT05155267||Controls|Healthy participants
32922820|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
32922821|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
32922822|NCT05709223|Experimental|Participants receiving both Categorical Loudness Scaling Based Fitting and behavioural fitting.|Participants will receive a categorical loudness scaling based fitting (Interventional) and behavioural fitting with 4 weeks experience of both MAPS
32922823|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
32922824|NCT05115409|Experimental|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL
32720617|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
32720618|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
32720619|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
32720620|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
32720621|NCT03515213|Active Comparator|Active|
32720622|NCT03515213|Placebo Comparator|Placebo|
32720623|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
32720624|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
32922825|NCT03981523|Experimental|BZN-60|150 mg twice a day for 60 days.
32720625|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
32922826|NCT03981523|Experimental|BZN-30|150 mg once a day for 30 days.
32720626|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
32922827|NCT03981523|Experimental|BZN-90|150 mg once a day for 90 days.
32922828|NCT03981523|Experimental|NFX-60|240 mg twice a day for 60 days.
32922829|NCT03981523|Experimental|NFX-30|240 mg twice a day for 30 days.
32922830|NCT03981523|Experimental|NFX-90|240 mg once a day for 90 days.
33400219|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|non invasive analgesia monitoring with ANSPEC-PRO and MEDSTORM the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
32720627|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
32720628|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
32720629|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
32720630|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
32922831|NCT03965923|Experimental|Cohort 1: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
32922832|NCT03965923|Experimental|Cohort 1: Truvada Tablet|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
32720631|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
32720632|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
32720633|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
32720634|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
32720635|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
32720636|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
32720637|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
32720638|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
32720639|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
32720640|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
32720641|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
32720642|NCT01680159|Experimental|TA-650|
32720643|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
32720644|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
32720645|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
32720646|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
32720647|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
32720648|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
32720649|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
32720650|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
32720651|NCT03514823|Experimental|IMT Group|
32720652|NCT03514823|Sham Comparator|No IMT Group|
32720653|NCT02972853|Experimental|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study. For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, we acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional pilot fMRI study."
32720654|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
32720655|NCT04931888|Experimental|Intervention|The intervention arm will receive the EMPOWER curriculum between the pre- and post-evaluations.
32720656|NCT04931888|Other|Waitlist|"The waitlist control arm will receive the EMPOWER curriculum after the evaluations. They will receive a second set of evaluations at the same time as the post evaluations of the control arm."
32720657|NCT05178797|Experimental|K-tapping and exercise (Group A)|Group A will be given kinesiology taping technique and exercise therapy
32720658|NCT05178797|Active Comparator|Compression decongestive therapy (Group B )|Group B will be given compression decongestive therapy (manual lymphatic drainage, short stretch bandage and exercise therapy)
32720659|NCT04931810|Experimental|All Nations Breath of Life|ANBL is a culturally tailored smoking cessation program that incorporates group-based and individual counseling. Participants may elect to take pharmacotherapy, but are not required to do so.
32720660|NCT02834403|Experimental|Experimental|"Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 5, 7.5 (starting dose), 10, 12.5, 15, 17.5, and 20 mg/kg will be administered IV on Days 1-5. For 5-15 mg/kg L-NMMA doses, docetaxel will be administered at 75 mg/m2. For 17.5 and 20 mg/kg L-NMMA doses, docetaxel will be administered at 100 mg/m2. Docetaxel will be administered IV 15 min after the Day 1 L-NMMA infusion. Amlodipine (10 mg) will be orally administered daily for 6 days, starting 24 hours before the Day 1 L-NMMA infusion. Enteric-coated aspirin (81 mg) will be orally administered once daily during the 6 21-day cycles. Pegfilgrastim (6 mg) will be administered subcutaneously 24 h after docetaxel.~Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study."
32720661|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
32720662|NCT03435315|Active Comparator|Treadmill exercise|
32720663|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
32720664|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
32720665|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
32720666|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
32720667|NCT03405753|Active Comparator|Aroia|
32720668|NCT03405753|Placebo Comparator|Placebo|
32720669|NCT02302469|Other|revlimid|a dose-escalation of revlimid
32720670|NCT02664597|Sham Comparator|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
32720671|NCT02664597|Experimental|ADNEXMR SCORING|In the intervention group, patients will undergo a pelvic MR imaging as routinely performed, including morphological sequences and functional sequences. Prospectively, the radiologist will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score.
32720672|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
32720673|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
32720674|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
32720675|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
32720676|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
32720677|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
32720678|NCT02634411|Experimental|8 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 8 days.
32720679|NCT02634411|Sham Comparator|15 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 15 days.
32720680|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
32720681|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
32743363|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
32743364|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
32720682|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
32720683|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
32720684|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
32720685|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
32720686|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
32720687|NCT03334461|Experimental|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
32720688|NCT03334461|Experimental|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
32720689|NCT03334461|No Intervention|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
32720690|NCT02302703|Active Comparator|the low FODMAP diet|
32720691|NCT02302703|Active Comparator|Gluten free diet|
32720692|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
32720693|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
32720694|NCT04542525|Experimental|PanOptix Toric Trifocal IOL|ACRYSOF IQ PanOptix Toric Trifocal IOL Model TFNT20 implanted in the capsular bag in the posterior chamber following cataract surgery. At least one eye will be implanted.
32720695|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
32720696|NCT02582619||Rehabilitation Professionals|Focus group consisting of rehabilitation professionals that will inform the study on vocational rehabilitation interventions rendered during acute to in-patient rehabilitation in KwaZulu-Natal.
32720697|NCT02582619||People living with Spinal Cord Injuries (PLWSCI)|"Focus group consisting of PLWSCI that will inform the study on the perspective of the patient on vocational rehabilitation needs or desires during acute care and in-patient rehabilitation.~This group will inform the study on the employment rate amongst people living with spinal cord injuries as well as factors that influence employment.~This group will also inform the study on the perceived barriers and facilitators of employment"
32720698|NCT02582619||Stakeholders|"Representatives from the following departments or organisations will be invited to participate in the interviews and focus groups:~Government Departments:~Education Social Development Health Labour Transport~Private Companies:~Insurance Companies and Health Risk Management companies Non-profit Organisations QASA DPSA"
32720699|NCT02582619||Experts|A delphi technique will be used to get an expert opinion and consensus on the aspects of the model to be developed.
33400220|NCT04986163|Active Comparator|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
32720700|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
32720701|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
32720702|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
32720703|NCT04464551|Experimental|[14C]D-0316|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (75mg, 50µCi) of [14C]D-0316 to healthy Chinese male subjects
32720704|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
32720705|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
32720706|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
32720707|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
32720708|NCT04931498||GMPR sub-study|Study population will be split into five haplotypes based on a combination of rare and common variants at the GMPR locus. A total of 26 volunteers per genotypic group in a comparison between heterozygous and homozygous individuals will be tested.
32720709|NCT04931498||SWAP70 sub-study|To assess genotype-specific effects on SWAP70 protein levels as well as coronary artery disease-related immune processes, we will recruit 50 volunteers stratified by variant genotype, i.e. major and minor homozygotes only (25 participants will be recruited to each group).
32720710|NCT05089929||Endoflip 2.0|The investigators will perform FLIP topography (Endoflip 2.0) analysis on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
32720711|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
32720712|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
32720713|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
32720714|NCT03510767|Experimental|TQ-B3525|
32720715|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
32720716|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
32720717|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
32720718|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
32720719|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
32720720|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
32720721|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
32720722|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
32720723|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
32720724|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
32720725|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
32720726|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
32720727|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
32720728|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
32720729|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
32720732|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
32720733|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
32720734|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
32720735|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
32720736|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
32720737|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
32720738|NCT05089773||group 1|The only group in this retrospective study includes patients diagnosed with transposition of the great arteries receiving arterial switch operation in children's hospital of fudan university and shanghai children's medical center.
32720739|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
32720740|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
32720741|NCT02435966|No Intervention|Untreated control|Natural history of the condition
32720742|NCT00590265|Experimental|1|
32720743|NCT00590265|Placebo Comparator|2|
32720744|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
32720745|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
32720746|NCT05089539|Experimental|HFpEF with ARNI treatment|Sacubitril/valsartan (ARNI, 100mg bid)
32720747|NCT05089539|Placebo Comparator|Control group|placebo (100mg bid)
32720748|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
32720749|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
32720750|NCT05089383||combined progesterone group|patients will receive vaginal plus subcutaneous or per os progesterone
32720751|NCT05089383||Vaginal progesterone group|patients will receive vaginal progesterone
32720752|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
32720753|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
32720754|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
32720755|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
32720756|NCT02303249|No Intervention|Control|Standard health care services
32720757|NCT05088993|Experimental|Antigravity Treadmill Group|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
32720758|NCT05088993|Active Comparator|Conventional Exercise Group|This group received the conventional exercise program only.
32720759|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
32720760|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
32720761|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
32720762|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
32720763|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease
32720764|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
32720765|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should be without any autoimmune disease.
32720766|NCT04464395|Experimental|CPI-006 Dose Escalation|CPI-006 + Standard of Care
32720767|NCT04464395|Other|Control Arm|Standard of Care Only
32720768|NCT01679301|Active Comparator|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
32720769|NCT01679301|Experimental|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
32720770|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
32720771|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
32720772|NCT03513029|Experimental|Study Device|VytronUS Ablation System
32720773|NCT05088837|Experimental|muscle energy technique|muscle energy technique was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles, it was done 3 times per session for 12 sessions.
32720774|NCT05088837|Experimental|ice and heat packs|Alternating ice and heat (20 min , 10 heat,10 cold),3times per week for 12sessions.
32720775|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
32720776|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
32743365|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
32743366|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
32922833|NCT03965923|Experimental|Cohort 2: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
33249218|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
32922834|NCT03965923|Experimental|Cohort 2: Truvada Tablet|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
32720777|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
33249219|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
33249220|NCT00848133|Active Comparator|mini-midvastus|
33249221|NCT00848133|Active Comparator|mini-subvastus|
33249222|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
33249223|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
33249224|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
33249225|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
33249226|NCT05632406||Adults without obesity|body mass index below 30 kg/m^2
33249227|NCT05632406||Adults with obesity|body mass index above 30 kg/m^2
32720778|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
32720779|NCT04464239|Experimental|Part A: Cohort 1: TS-142 10 mg|Single dose of TS-142 10 mg or placebo in a fasted condition
33249228|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
33400221|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~education about signs and symptoms of urinary retention"
32720780|NCT04464239|Experimental|Part A: Cohort 2: TS-142 30 mg|Single dose of TS-142 30 mg or placebo in a fasted condition.
32720781|NCT04464239|Experimental|Part B: Cohort 4: TS-142 20 mg|Daily doses of 20 mg TS-142 or placebo for 7 days before bedtime.
33400222|NCT02684344|Active Comparator|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
32720782|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
32743367|NCT03239951|Experimental|Device|Temporary implant (iTind)
32743368|NCT04935099|Experimental|Blueberry/Placebo|In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.
32922835|NCT03965923|Experimental|Cohort 3: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
32922836|NCT03965923|Experimental|Cohort 3: Truvada Tablet|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
32922837|NCT03962725|Active Comparator|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
32922838|NCT03962725|Experimental|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
32922839|NCT05707117|Experimental|Group A: Tendon neuroplastic training (TNT)|the strength training of the wrist extensors are being done with the help of an externally pace device
32922840|NCT05707117|Active Comparator|Group B: Conventional treatment|static stretching and myofascial release on wrist extensors
32922841|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
32922842|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
32922843|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
32922844|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
32922845|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
32922846|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
32922847|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
32922848|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
32743369|NCT04935099|Experimental|Placebo/Blueberry|In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.
32922849|NCT05699473|Experimental|5-MTHF glucosamine|1 single dose (400µg)
32922850|NCT05699473|Experimental|5-MTHF calcium salt 1|1 single dose (400µg)
32922851|NCT05699473|Experimental|5-MTHF calcium salt 2|1 single dose (400µg)
32922852|NCT05087095|Experimental|Proof-of-concept trial|Inform CALM adaptations for SMs, Veterans, their beneficiaries, and civilians with cancer metastasis to the brain (bMET)
32922853|NCT05087095|Experimental|Primary Brain Tumor (PBT) CALM Intervention|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone.
32922854|NCT05087095|Active Comparator|Primary Brain Tumor (PBT) Treatment as Usual (TUC) Control|Survey Administration. Participants will be asked to complete self-report surveys of behavioral and psychological variables.
32922855|NCT05087095|Experimental|Cancer Metastasis to the Brain (bMET) CALM Intervention|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone.
32922856|NCT05087095|Active Comparator|bMET TUC Control|Survey Administration. Participants will be asked to complete self-report surveys of behavioral and psychological variables.
32922857|NCT05077345||1/Venous blood sampling|The vessel was determined for cannulation and an anatomical tourniquet was applied. Skin antiseptic was prepared. The plastic wings of the winged angioket were held open. The skin over the vein to be accessed was stretched with the fingers of the free hand. The needle was inserted into the skin a few millimeters distal to the point to be inserted, and the blood was vascularized until the education. The cannula was advanced by retracting the stylet. The tourniquet was removed and the cannula was fixed.
32922858|NCT05077345||2/Heel puncture|The skin was prepared with an antiseptic. The baby's heel was placed at an angle between the thumb and forefinger, with the other fingers grasping the ankle from behind. Pressure was applied to the back of the ankle with the other fingers by taking support against the thumb. The first drop of blood was wiped with sterile gauze by inserting the needle, and the next drops of blood were absorbed into the paper by touching the middle of the ring on the filter paper. An adhesive bandage was applied by applying pressure to the puncture site.
33249229|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
33400223|NCT05574400|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water at multiple postoperative time points over a 30-minute infusion period.
32720783|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
32720784|NCT05088447||Stable Disease|"15 control stable disease participants"
32720785|NCT05088447||Frequent Exacerbation Cohort|"15 experimental frequent exacerbation cohort"
32720786|NCT03512873|Experimental|Tranilast|
32720787|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
32720788|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
32720789|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
32720790|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
32720791|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
32720792|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
32720793|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
32720794|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
32720795|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
32720796|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
32720797|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
32720798|NCT05081349|Experimental|Hydra+L-Carnitine|Hydroxycarbamide+ L-Carnitine+supportive treatment
32720799|NCT05081349|Active Comparator|Hydra only|Hydroxycarbamide+ supportive treatment
32720800|NCT05081349|Active Comparator|L-Carnitine only|L-Carnitine+ supportive treatment
32720801|NCT05081349|No Intervention|Supportive measures|Supportive only
32720802|NCT03512717|Experimental|Potenfill|
32720803|NCT03512717|Active Comparator|Powerfill|
32720804|NCT03132545||PCOS|
32720805|NCT03132545||controls|
32720806|NCT05071599|Experimental|Twin arch brackets|the malocclusion for this group will be treated using fixed appliance which utilize twin arch brackets system.
32720807|NCT05071599|Experimental|Conventional brackets|"the malocclusion for this group will be treated using fixed appliance which utilize conventional pre-adjusted edgewise brackets system."
32720808|NCT04464005|Experimental|Pads with cold magnesium sulfate 33% solution|
32720809|NCT04464005|Placebo Comparator|Pads with cold water|
32720810|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
32720811|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
32720812|NCT05377593|Active Comparator|eminoplasty with patient specific Titanium onlay implant|
32720813|NCT05377593|Active Comparator|eminoplasty with patient specific zirconium dioxide onlay implant|
32720814|NCT03510299|Placebo Comparator|Control group|
32720815|NCT03510299|Experimental|McGrath group|
32720816|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
32720817|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
32720818|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
32720819|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
32720820|NCT05068089||Nissen fundoplication surgery and Enteral nutrition|The cohort population retrospectively enrolled in the study is represented by pediatric patients with severe motor and intellectual disabilities (with progressive e non- progressive neurological disease) followed-up at Nutrition Unit of Ospedale Pediatrico Bambino Gesù between January 2009 to January 2020.
32720821|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
32720822|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
32720823|NCT04541511|Experimental|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
32720824|NCT04541511|Experimental|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
32720825|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
32720826|NCT03509831|Other|INT2150-A|
32720827|NCT03509831|Other|INT2150-B|
32720828|NCT05065827||Normal oxygenation|Normal oxygenation based on the BERLIN criteria for ARDS
32720829|NCT05065827||Mild deficit in oxygenation|Mild deficit in oxygenation based on the BERLIN criteria for ARDS
32720830|NCT05065827||Moderate deficit in oxygenation|Moderate deficit in oxygenation based on the BERLIN criteria for ARDS
32720831|NCT05065827||Severe deficit in oxygenation|Severe deficit in oxygenation based on the BERLIN criteria for ARDS
32720832|NCT02303483|Placebo Comparator|Placebo|lime tablets
32922859|NCT05077345||3:Orogastric Catheter insertion|The head of the bed was raised and the newborn was placed on his back. The midpoint distance from the tip of the nose to the ear, xiphoid and umbilicus was measured to determine the insertion length. With one hand, the infant's mouth was opened while his head was stabilized. With the other hand, the MV probe was advanced to the specified depth. The position of the OG probe was confirmed and fixed.
32922860|NCT05077345||4:Umbilical Catheter insertion|The system was filled with liquid by connecting the tap to the UK. The faucet was turned off, sterile gauze was placed around the umbilical clamp and lifted out of the sterile area. The other assistant held the cord with a clamp and lifted it vertically up and away from the sterile field. The cord and its surroundings were prepared with an antiseptic solution and covered. The umbilicus was tied with a single knot and the cord was cut horizontally with a scalpel. Bleeding on the surface of the cord was wiped with sterile gauze. The cord stump was grasped with toothed forceps close to the vessel to be catheterized. The catheter was placed in the lumen of the vessel and advanced in the vessel. When the catheter exceeded 5 cm, it was aspirated to confirm the intraluminal position. The blood that came with an average of 0.5 ml bolus solution was cleaned and the catheter was fixed.
32922861|NCT05077345||5:Tracheal Intubation|The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
32922862|NCT05062369|Experimental|Participants receiving active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
32935865|NCT05447936|Active Comparator|Male arm|Ten healthy active male XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
32935866|NCT04739384|Experimental|Standard dose of ticagrelor (90 mg twice daily).|Standard dose of ticagrelor (90 mg twice daily) followed by lower dose of ticagrelor (60 mg twice daily).
32720833|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
32720834|NCT05046327|Experimental|20 mg Avatrombopag daily|Avatrombopag
32720835|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
32720836|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
32720837|NCT05378061|Experimental|PACAP-38|A time- and volume-controlled infusion pump is used to administer PACAP-38 by intravenous infusion over 20 minutes.
32720838|NCT05378061|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
32720839|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
32720840|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
32720841|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
32720842|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
32720843|NCT04535583||EMA plus passive sensing|Participants will be responding to up to 3 ecological momentary assessments per day plus carrying a smartphone and wearing a smartwatch. Both the smartphone and smartwatch will passively collect sensor data continuously.
32720844|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
32720845|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
32720846|NCT04487847|Experimental|PIRADS 1-2|25 patients with PIRADS 1-2 (probably benign) on mpMRI
32720847|NCT04487847|Experimental|PIRADS 3|25 patients with PIRADS 3 (equivocal scan) on mpMRI
32720848|NCT04487847|Experimental|PIRADS 4-5|25 patients with PIRADS 4-5 (probably malignant) on mpMRI
32720849|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
32720850|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
32720851|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
32720852|NCT04820127|No Intervention|Control (usual care)|Patients in the control group will benefit from the usual care with a half-yearly visit by the specialist physician (geriatrician, neurologist or psychiatrist) according to AD French national management guidelines (HAS 2011 and HAS 2018).
32720853|NCT04820127|Experimental|Intervention (personalized care program)|Patients in the intervention group will benefit from personalized care preceded by a standardized assessment
32720854|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
32720855|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
32720856|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
32720857|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
32720858|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
32720859|NCT04506099|Active Comparator|TINS Active|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
32720860|NCT04506099|Sham Comparator|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
32720861|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
32720862|NCT02739269|Sham Comparator|AFC group|AFC measurement
32720863|NCT04757493|Active Comparator|Prucalopride group (A)|"Prucalopride 2 mg tablet, once daily in morning before breakfast will use as intervention in arm A."
32720864|NCT04757493|Placebo Comparator|Placebo group (B)|"Placebo will be given at the same time and same dose in arm B . Both active drug and placebo have packed in the same type of strip."
32720865|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
32720866|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
32720867|NCT02303951|Experimental|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):~Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally~Day 22-28: vemurafenib 720 mg bid orally~Triple-Treatment (week 5 ongoing):~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
32720868|NCT04406415|Experimental|10 mg|10 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
32720869|NCT04406415|Experimental|50 mg|50 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
32720870|NCT04406415|Experimental|100 mg|100 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
32720871|NCT04406415|Experimental|200 mg|200 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
32720872|NCT04406415|Placebo Comparator|Placebo|Placebo administered three times a day (t.i.d., approximately q8h) for up to 5 days
32922863|NCT05062369|Sham Comparator|Participants receiving active and sham active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
32922864|NCT02210559|Experimental|FG-3019 + Gemcitabine + Nab-paclitaxel|Participants will receive FG-3019 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion on Days 1 and 15 of each treatment cycle and on Day 8 of the first cycle, gemcitabine 1000 mg/square meter (m^2) and nab-paclitaxel 125 mg/m^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
32922865|NCT02210559|Active Comparator|Gemcitabine + Nab-paclitaxel|Participants will receive gemcitabine 1000 mg/ meter squared (m^2) and nab-paclitaxel 125 mg/m^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
32922866|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
32922867|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
32922868|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
32922869|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
32720873|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
32720874|NCT05738187|Experimental|local cryotherapy treatment|
32720875|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
32720876|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
32720877|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
32720878|NCT02304185|Experimental|gp140, 50 mcg|
32720879|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
32922870|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
32922871|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
32922872|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
32922873|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
32922874|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
32922875|NCT03699631|Experimental|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
32922876|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
32922877|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
32922878|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
32922879|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
32922880|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
32922881|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
32720880|NCT02304185|Placebo Comparator|Placebo 1|
32720881|NCT02304185|Experimental|gp140, 250 mcg|
32720882|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
32720883|NCT02304185|Placebo Comparator|Placebo 2|
32720884|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
32922882|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
32935867|NCT04739384|Experimental|Low dose of ticagrelor (60 mg twice daily).|Low dose of ticagrelor (60 mg twice daily) followed by standard dose of ticagrelor (90 mg twice daily).
32922883|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
32922884|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
32922885|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
32922886|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
32922887|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
32922888|NCT03507673||Progynova/Dydrogesterone|
32922889|NCT03507673||Spontaneous cycle|
32922890|NCT03507673||Progynova/Crinone|
32922891|NCT03507673||Others Medication|
33249230|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
33249231|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
33249232|NCT05616416||All ED Patient|All patients visited the emergency department during the period.
33249233|NCT05604170|Experimental|Ganaxolone (GNX) oral suspension, 3 times a day (TID)|
33249234|NCT05279950|Active Comparator|Piezoelectric|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a piezoelectric device
33249235|NCT05279950|Experimental|Magnetostrictive|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a magnetostrictive device.
32922892|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
32922893|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
32922894|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
32922895|NCT03439891|Experimental|Part 1: Dose Escalation (CLOSED TO ENROLLMENT)|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
32922896|NCT03439891|Experimental|Part 2: Child Pugh B Expansion (sorafenib, nivolumab)|Participants receive sorafenib on days 1-28, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32922897|NCT04943575|Active Comparator|Intervention 1|EZC Pak
32922898|NCT04943575|Active Comparator|Intervention 2|EZC Pak+D
32922899|NCT04943575|Placebo Comparator|Placebo|
32935868|NCT05450575||single arm, single group(No interventional)|Observational
33249236|NCT05602064|Experimental|Group I (Ibuprofen)|"Participants will receive ibuprofen 100 mg/5 ml (BRUFEN®, Kahira Pharmaceuticals & Chemical Industries Co.) The solution will be administered Once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages range from 10 mg/kg/day to a maximum of 40 mg/kg/day"
32935869|NCT04704596|Active Comparator|dynamic lung compliance for detection of optimum PEEP|detection of optimum PEEP by measurement of the dynamic lung compliance (by the ventilator machine) after lung recruitment
33249237|NCT05602064|Experimental|Group II (Paracetamol)|"Participants will receive paracetamol 250 mg/5 ml (CETAL®, EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.) The solution will be administered once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages are between 15-20mg/kg/day to a maximum of 60 mg/kg/day"
33249238|NCT05602064|Placebo Comparator|Group III (Placebo)|The placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
33249239|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
33249240|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
33400224|NCT05574400|Experimental|Low-dose Caffeine|Prepared intravenous low-dose caffeine citrate (1.5 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
32935870|NCT04704596|Active Comparator|Lung ultrasound for detection of the optimum PEEP|Lung ultrasound will be used to detect the optimum PEEP after lung recruitment
32935871|NCT05450497|Experimental|Propofol Group|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h
32720885|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
32720886|NCT02304263||Younger (18-35 years old)|iohexol
32720887|NCT02304263||Older (>60 years old)|iohexol
32720888|NCT04376619|Experimental|KDIGO guidelines|Part 1 of study, those identified as high risk for AKI then will have Kidney Disease Global Improving outcomes guideline implemented to see if this reduces incidence of AKI
33249241|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
33249242|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
32720889|NCT04376619|Experimental|RIPC|part 2 of study, those identified as high risk of AKI will have Kidney Disease Improving Global Outcomes guidelines and RIPC implemented to see if this reduces incidence of AKI compared to part 2 of study
32720890|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
33249243|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
33249244|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
33249245|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
33249246|NCT04013620|Experimental|transient belatacept|
33249247|NCT05589038|Experimental|Baby Wash/Shampoo|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, up to 4 weeks.
33249248|NCT05589038|Experimental|Baby Wash/Shampoo + Baby Lotion|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, and apply lotion at least once daily after bathing, for 4 weeks.
33249249|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
33249250|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
33249251|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
33249252|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
33249253|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
33249254|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
33249255|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
33249256|NCT04220229|Experimental|Treatment (cabozantinib S-malate, radiation therapy)|Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients also undergo standard of care radiation therapy for 5-6 weeks.
33249257|NCT04012684|Experimental|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
32720891|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
32720892|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
32935872|NCT05450497|Experimental|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
32720893|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
32935873|NCT05450497|Experimental|Dexmedetomidine and propofol|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h"
33249258|NCT04012684|Experimental|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
33249259|NCT04012684|Sham Comparator|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
33249260|NCT04012684|Sham Comparator|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
33249261|NCT05051228||GEAR cohort|This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
33249262|NCT00944788|Experimental|qi-gong|
33249263|NCT00944788|No Intervention|Usual care|
33249264|NCT00749112|Experimental|A|
33249265|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
33249266|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
33249267|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
32767527|NCT05305339||Group B (Chronic hypertension)|It means systolic blood pressure of 140 mm Hg or more, a diastolic blood pressure of 90 mm Hg or more, or both, that is diagnosed or present before pregnancy or before 20 weeks of gestation on two occasions at least 4 hours apart. Hypertension that is diagnosed for the first-time during pregnancy and that does not resolve in the typical postpartum period also is classified as chronic hypertension
32767528|NCT05305339||Group C (Gestational hypertension)|It is usually diagnosed when systolic blood pressure is 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation, in a woman with a previously normal blood pressure. Gestational hypertension is considered severe when the systolic level reaches 160 mm Hg or the diastolic level reaches 110 mm Hg or both.
32767529|NCT05305339||Group D (Preeclampsia)|Women with PE fulfilled the criteria if they had hypertension (> 140/90 mmHg) and proteinuria (> 0.3 gm/day or ≥ +1 by dipstick urine analysis at ≥ 20 weeks of gestation or protein-to-creatinine ratio of 0.30 or more). If no proteinuria, hypertension associated with thrombocytopenia, renal or liver impairment, or pulmonary edema was sufficient to diagnose PE as per ACOG Practice Bulletin No .202
32767530|NCT04794283||Hand milking with Diabetes|93 women with DM1, DM2 and medically treated GDM who are patients in specialist maternity care at Soderhospital in Stockholm and who plan to hand milk are part of this group.
32767531|NCT04794283||Not hand milking with diabetes|A group of 93 women are then selected from 1 April 2021and back in the same number as the group1 (n=93) this group only gave milk substitute the first 24h.
32767532|NCT05305183|Active Comparator|Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|subjects received 70 mg alendronate sodium tablet weekly and a minodronate tablet matching placebo monthly for 48 weeks.
32767533|NCT05305183|Experimental|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo|subjects received 50mg minodronate tablets monthly and an alendronate sodium tablets -matching placebo weekly for 48 weeks.
32767534|NCT04782271|Experimental|Single administration Low Dose once daily|1 treatment day
32767535|NCT04782271|Experimental|Single administration Middle Dose once daily|1 treatment day
32767536|NCT04782271|Experimental|Single administration High Dose once daily|1 treatment day
32767537|NCT04782271|Experimental|Single administration High Dose twice daily|1 treatment day
32767538|NCT04782271|Experimental|Multiple administrations Low Dose once daily|7 treatment days
32767539|NCT04782271|Experimental|Multiple administrations Middle Dose once daily|7 treatment days
32767540|NCT04782271|Experimental|Multiple administrations High Dose once daily|7 treatment days
32767541|NCT04782271|Experimental|Multiple administrations High Dose twice daily|7 treatment days
32767542|NCT04781179|Experimental|CM-II Technique|
32767543|NCT04781179|Placebo Comparator|Psychoeducation|
32767544|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
32767545|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
32767546|NCT04570891|Experimental|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
32767547|NCT04570891|Placebo Comparator|Control|No regional block is provided at the end of surgery.
32767548|NCT05305027||IVF patients: first serum βHCG|IVF patients who undergo βHCG after fresh or frozen embryo transfer
32767549|NCT04767607||Breast cancer plus chemotherapy|Patients of the group will receive chemotherapy treatment.
32767550|NCT04767607||Breast cancer without chemotherapy|Patients of the group will not receive chemotherapy treatment.
32767551|NCT04763317||AFFECTED|"Affected with PrCa < 70 years~Affected with metastatic castration resistant PrCa (mCRPC) at any age~Affected with PrCa and a family history defined as~two or more cases in family with one case < 70~three or more cases any age (FDR or SDR)"
32767552|NCT04763317||UNAFFECTED|"- Aged >30 and with a family history defined as::~FDR diagnosed < 70~2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed < 70 years~3 or more cases at any age (on same side of family)"
32767553|NCT05304793|Experimental|Arm I (TAB)|Patients participate in 4 weekly TAB in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. Patients also receive treatment handouts, a CD with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. Patients may receive additional support calls over 10-15 minutes from the TAB provider within 1 week following each session.
32767554|NCT05304793|Active Comparator|Arm II (usual care)|Patients receive usual management of dyspnea from the treating physician.
32767555|NCT04759027||X-ray|Measurements of subacromial distance on standardized direct radiography
32767556|NCT04759027||ultrasound|Measurements of subacromial distance on ultrasound
32767557|NCT05304637|Experimental|Therapy Arm|Patient receive iTEAR100 treatment
32767558|NCT04226755|Experimental|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
32767559|NCT04226755|Active Comparator|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
32767560|NCT04511767||ASD group|the autism spectrum disorder group
32767561|NCT04511767||GDD group|the global developmental disorder group
32767562|NCT04511767||LD group|the language disorder group
32767563|NCT05304559|Experimental|Drug group|S-ketamine 0.1mg/kg was injected intravenously during anesthesia induction and esmolamine 0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
32935874|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
32935875|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
33249268|NCT02567864|Active Comparator|control|The control group maintains daily activities.
33073376|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
33249269|NCT04012606|Experimental|TORIPALIMAB|
33249270|NCT04012606|Active Comparator|Chemotherapy|
33249271|NCT00744744||Survey|
33249272|NCT05565560|Experimental|Apremilast|Participants with a weight between ≥ 15 kg to < 50 kg will receive apremilast 20 mg twice daily (BID) tablet. Participants weighing ≥ 50 kg will receive apremilast 30 mg BID tablet.
33249273|NCT04043091|Experimental|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis >70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
33249274|NCT04043091|No Intervention|standard of care|stable obstructive coronary artery disease (coronary artery stenosis >70%) - no intervention (revascularization), just standard medical therapy
33249275|NCT00944866||RA with drug|
33249276|NCT00944866||RA without drug|
33249277|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
33249278|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
33249279|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
32720894|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
32720895|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
33249280|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
32720896|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
33249281|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
33249282|NCT04062110|Active Comparator|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
33249283|NCT04062110|Active Comparator|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
33249284|NCT00747630|Experimental|Intervention|The group selected to watch the video.
33249285|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
33249286|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
33249287|NCT00744900|Experimental|A|
33249288|NCT00727090|Experimental|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
33249289|NCT00727090|No Intervention|2|Usual care by the attending physician staff
33249290|NCT00852033|No Intervention|1|Assessment Group (no intervention)
33249291|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
33249292|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
33249293|NCT00852033|Active Comparator|4|BMI and TBI
33249294|NCT05048654||Group A: Retrospective|Retrospectively, there will be an abstract of AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.
33249295|NCT05048654||Group B: Prospective|Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. Per standard of care AMH and FSH will be drawn at each time point.
33249296|NCT05003726|Experimental|Non-pharmacological group including KM|Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
33249297|NCT05003726|Active Comparator|Pharmacological group|Pharmacological treatment will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
33249298|NCT00944944||Gyn Pts with lymphedema|
33249299|NCT00944944||Gyn Pts without Lymphedema|
33249300|NCT00848835||control|all patients in the control group
33249301|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
33249302|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
33249303|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
33249304|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
33249305|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
33249306|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
33249307|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
33249308|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
33249309|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
33249310|NCT04012450|Active Comparator|Epidural Anesthesia|Women in labor receiving epidural anesthesia
33249311|NCT04012450|Active Comparator|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
32720897|NCT05738109|Experimental|Self-guided journaling Intervention|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they will also complete a follow-up survey and exit interview
32720898|NCT05738109|No Intervention|Waitlist Control|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they receive access to the 91-day Self-Talk Journal for their own personal use.
32720899|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
32720900|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
32720901|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
32720902|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
32720903|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
32720904|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
32720905|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
32720906|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
32720907|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
32720908|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
32720909|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle after TC administration"
32720910|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
32720911|NCT05738031||Group A|"Aim 1 (Part A). To utilize natural language processing (NLP) to identify all ED patients with incidentally detected lung nodules found on chest radiographs or chest or abdominal CT scans, and to develop a standardized referral and notification process~Aim 1.1) Utilization of NLP to screen radiologic reports and identify nodules meeting criteria for follow-up per Fleischner Society Guidelines~Aim 1.2) Creation of an electronic medical record-based notification system to alert patients and providers of the identification of an IPN that requires follow-up, tracked by a dedicated patient navigator~Aim 1.3) Establishment of a multidisciplinary lung nodule management team, hereafter referred to as the lung nodule clinic, to ensure guideline-directed management of nodules with emphasis on high risk nodules as identified in subsequent aims"
32720912|NCT05738031||Group B|"Aim 2 (Part B). To clinically risk stratify patients with IPNs utilizing artificial intelligence (AI) processing of known clinical risks factors for pulmonary malignancy, such as age, smoking history, and history of malignancy, along with radiographic risk classifiers including nodule location, size, and imaging features.~Aim 2.1) Development of an integrated classifier based on automated scanning and data retrieval from the electronic medical record (EMR) to stratify patients with IPNs as low, intermediate or high risk for malignancy, with factor analysis to assess contributions of individual factors to the model~Aim 2.2) Prospective evaluation of the integrated classifier and comparison of automated integrated classifier to established manual risk calculators"
32720913|NCT05738031||Group C|"Aim 3 (Part C). To investigate biologic risk classifiers that may aid in the risk stratification of pulmonary nodules~Aim 3.1) Evaluation of a blood-based gene expression assay for risk stratification of pulmonary nodules using biobanked specimens~Aim 3.2) Prospective collection of plasma from patients enrolled in lung nodule clinic and evaluation of gene expression to assess malignancy risk"
32720914|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
32720915|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
32720916|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
32720917|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
32720918|NCT04120701|Experimental|Chemotherapy|
32720919|NCT04120701|No Intervention|Follow-up within the study|
32720920|NCT04120701|No Intervention|Follow-up outside the study|
32720921|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
32720922|NCT04997733|Experimental|Fecal microbiota|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation (endoscopic and oral)
33400225|NCT05574400|Experimental|High-dose Caffeine|Prepared intravenous high-dose caffeine citrate (3 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
32720923|NCT04997733|Sham Comparator|Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation (endoscopic and oral)
32720924|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
32720925|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
32720926|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
32720927|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
32720928|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
32720929|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
32720930|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
32720931|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
32720932|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
32720933|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
32720934|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
32720935|NCT04958967|Experimental|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 240mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
32720936|NCT04958967|Experimental|treated subjects will receive Furmonertinib 160mg/day|treated subjects will receive Furmonertinib 160 mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
32720937|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
32720938|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
32720939|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
32720940|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
32720941|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
32720942|NCT05737953||Mucinous tumour group|
32720943|NCT05737953||Non-mucinous tumour group|
32720944|NCT05737719||Prehab|Patients awaiting a knee surgical procedure, and after the surgery
32720945|NCT05737719||Control|Patients after the surgery
32720946|NCT03512483|No Intervention|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
32720947|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
32720948|NCT05737641|Placebo Comparator|water ingestion|Ingestion of 102 mL of fresh water
32720949|NCT05737641|Active Comparator|jelly ingestion|ingestion of 100 gr strawberry jelly
32720950|NCT05159011|No Intervention|Usual Care|Virtual Genetic Counseling
32720951|NCT05159011|Other|Chatbot|computer program that that uses machine learning to provide tailored counseling to patients
32720952|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
32720953|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
32720954|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
32743370|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
32743371|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
32720955|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
32720956|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
33400226|NCT05199571|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections at Week 0, 1, 2 and monthly thereafter starting at Week 4
32720957|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
32720958|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
32720959|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
32720960|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
32720961|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
32720962|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
32720963|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
32720964|NCT05158777|Experimental|Experimental Group with the immunization course of 0,28 days or 0,56 days|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.
32720965|NCT05158777|Active Comparator|Control Group|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.
32720966|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
32720967|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
32720968|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
32720969|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
32720970|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
32720971|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
32720972|NCT03474211||vaccinated|
32720973|NCT03474211||non vaccinated|
32720974|NCT04259047|Experimental|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
32720975|NCT04259047|Active Comparator|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
32720976|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
32720977|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
32720978|NCT04091893|Active Comparator|Usual care/wait list|
32720979|NCT04091893|Experimental|Art Rx|
32922900|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
32922901|NCT04937959||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32922902|NCT04937959||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32922903|NCT04937959||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32922904|NCT04937959||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32922905|NCT04905745||Facial palsy|Adulthood facial palsy patients group who receive Korean integrative medicine.
32922906|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
32922907|NCT04867135||No Sepsis / Sepsis|To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.
32922908|NCT04860661|Placebo Comparator|N group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
32922909|NCT04860661|Experimental|Es group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
32922910|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
32922911|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
32922912|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
32922913|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
32922914|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
32922915|NCT01740817|Experimental|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
32922916|NCT01740817|Experimental|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
32922917|NCT01742065|No Intervention|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
32922918|NCT01742065|Active Comparator|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
32922919|NCT04728217|Experimental|Patients receiving Efmoroctocog alfa|For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
32922920|NCT04721665||NAFLD patients|No intervention
32922921|NCT05656807|Active Comparator|Go NAPSACC|Centers randomized to Go NAPSACC will receive the traditional Go NAPSACC program. This will include the center director leading the Go NAPSACC effort with support from a Go NAPSACC Implementation advisor. The advisor will orient each center to Go NAPSACC and its online tools and check in monthly with directors as they work through 2 cycles of Go NAPSACC over 6 months. Centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals.
32922922|NCT05656807|Experimental|Go NAPSACC Enhanced|Centers randomized to Go NAPSACC Enhanced will receive the traditional Go NAPSACC program as described in the Active Comparator arm. Additionally, child care providers will simultaneously receive a weight management program, Go NAPSACC Cares over 6 months. The health educator will orient providers with the website and its tools and resources. Providers will take a self-assessment and choose a goal of weight maintenance or weight loss. They will go through 18 lessons with accompanying resources. Within the website they will self-monitor their weight, physical activity, and red foods (diet quality). Providers will receive daily tips, weekly reminders via text message or email, and tailored weekly feedback based on their weight management goals and progress.
32922923|NCT04702711||Patients with symptoms of generalized anxiety in primary health care|Patients (18 years or older) with symptoms of generalized anxiety at a primary health care center.
32922924|NCT04702711||Health care professionals|Health care professionals working with patients with symptoms of generalized anxiety in a primary health care center.
32720980|NCT04091893|Experimental|Artful Meditation|
32922925|NCT05642065|Experimental|Arm 1|Participants will undergo lower extremity movement assessment on the Forward Step Down Test before and after a home exercise program (HEP) consisting of five hip activation exercises. These exercises will be performed 2x/week for 8 weeks. Surface EMG of the gluteus maximus and medius, in addition to tracking of participant compliance on the HEP program will also be assessed pre- and post-intervention.
32922926|NCT04655365|Experimental|Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging Subjects|Enrolled subjects will receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL Injection followed by a single PET/CT scan acquired at 1-2 hours post-dosing. After initial 18F-DCFPyL PET/CT, the patients with positive 18F-DCFPyL PET/CT imaging will be treated with enzalutamide (160 mg po id) for M0CRPC disease within less than two weeks. 18F-DCFPyL PET/CT scan will then be repeated 90 days after the start of enzalutamide treatment.
32922927|NCT04633993|Experimental|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
32922928|NCT04633993|No Intervention|Usual Care|Routine care.
32720981|NCT04091893|Experimental|Art Rx + Artful Meditation|
32720982|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
32922929|NCT04581343|Experimental|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
32922930|NCT04565743|Active Comparator|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
32922931|NCT04565743|No Intervention|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
32720983|NCT04013269|Active Comparator|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
32720984|NCT04013269|No Intervention|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
32720985|NCT04464863||Cases|Acute stroke patients during the first week of evolution
32720986|NCT04464863||Control|Age and sex 1:1 healthy participants
32720987|NCT05158699|Active Comparator|topical bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week.
32720988|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide|one subconjunctival injection of 10 mg triamcinolone acetonide during cataract surgery (TA, Triesence/Vistrec) in the inferotemporal quadrant, 6mm from the limbus.
32720989|NCT05158699|Active Comparator|intracameral ketorolac|intracameral injection of ketorolac tromethamine solution during cataract surgery (Omidria). A 4ml vial of Omidria (ketorolac concentration 2.88mg/ml) is added to 500ml of the irrigation solution used during cataract surgery, resulting in a ketorolac concentration of 0.023mg/ml. At the end of the surgery, the anterior chamber will be filled with the ketorolac solution.
32720990|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide & intracameral ketorolac|one subconjunctival injection of 10 mg triamcinolone acetonide & intracameral injection of ketorolac tromethamine solution (Omidria; 0.023mg/mL) during cataract surgery.
32720991|NCT05158465|Experimental|Motivational Interviewing and Assessments|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo. Three one-on-one, half hour educational and skill-building MI sessions will address: proper oral hygiene technique, bacteria and dental caries process, and nutrition. Intervention group adolescents will also receive three calls over one month reinforcing their hygiene behavior goals.
32720992|NCT05158465|No Intervention|Assessments Only|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo.
32720993|NCT04464629|Experimental|Intracanalicular Sustained Release Dexamethasone, 0.4 mg|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
32720994|NCT04464629|Active Comparator|topical prednisolone acetate 1%.|
32720995|NCT02304887||Bisphosphonate|
32720996|NCT02304887||Selective estrogen receptor modulator|
32720997|NCT02304887||Teriparatide|
32720998|NCT02304887||Senosumab|
32720999|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
32721000|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
32721001|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
32721002|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
32721003|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
32922932|NCT01743859|Experimental|Azacitidine + Lenalidomide + Off Therapy|Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.
32922933|NCT01746043|Experimental|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
32922934|NCT01746043|Experimental|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
32922935|NCT01746043|Experimental|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
32922936|NCT01746043|Placebo Comparator|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
32922937|NCT05635903|Experimental|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h continuous infusion using a syringe pump)
32922938|NCT05635903|Experimental|Intermittent nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Intermittent nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls 0.9% normal saline nebulised every 6 hours)
32922939|NCT05635903|Active Comparator|Intermittent standard nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|Intermittent standard nebulization of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser ((5mls 0.9% normal saline nebulised every 6 hours)
32922940|NCT01746511|Active Comparator|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
32922941|NCT01746511|Experimental|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
32922942|NCT01746745|Experimental|[^14C]-LY2940680|Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)
32922943|NCT01746979|Active Comparator|Gemcitabine plus TH-302|
32922944|NCT01746979|Placebo Comparator|Gemcitabine plus placebo|
32922945|NCT04552171|Experimental|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
32922946|NCT04552171|No Intervention|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
32922947|NCT04534387|Experimental|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
32922948|NCT04534387|Active Comparator|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
32922949|NCT04514653|Active Comparator|Ranibizumab control|Control treatment arm
32922950|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
32922951|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
32922952|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3)|RGX-314 Dose 3
32922953|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3) and Local Steroid|RGX-314 Dose 3 and Local Steroid
32922954|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
32922955|NCT05631535|Experimental|Intervention with a very low-energy diet|
32922956|NCT05631535|Active Comparator|Control group|
32922957|NCT01748227|Other|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
32922958|NCT05619913|Experimental|Arm 1 - Single agent eribulin arm|"Eribulin until progression of disease (PD) as defined by RECIST v1.1, unacceptable toxicity or physician/patient discretion or choice to cease treatment.~Patients who progress on the single agent eribulin arm may receive combination eribulin and pembrolizumab."
32767564|NCT05304559|Experimental|Device group|The hip fracture was diagnosed clinically on admission and ultrasound-guided iliofascial space block was performed after evaluation, and the analgesia lasted until 2 days after operation.
32767565|NCT05304559|Placebo Comparator|Normal saline group|normal saline 0.1ml/kg was injected intravenously during anesthesia induction and normal saline 0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
32767566|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
32767567|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
32767568|NCT04478851|Experimental|Intervention|All participants will be involved in group exercise classes, twice a week for 12 weeks.
32767569|NCT04866797|Active Comparator|cyclic merocyanine long-UVA absorber|
32767570|NCT04866797|Placebo Comparator|placebo|
32767571|NCT04476355|No Intervention|control group|In the same ICU, the former(2019-12~2020-12) patients were the control group, data collected through case system.
32767572|NCT04476355|Experimental|experimental group|In the same ICU, the patients in the study period were the experimental group
32767573|NCT04865471|Experimental|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
32767574|NCT04117711|Experimental|AT-007|
32767575|NCT04117711|Placebo Comparator|Placebo Comparator|
32767576|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
32767577|NCT05304325||Obese with type 2 diabetes|
32767578|NCT05304325||Obese insulin-sensitive|
32767579|NCT05304325||Obese insulin-resistant|
32767580|NCT05304169|Experimental|Leuprorelin Acetate (Eligard® 45 mg)|Patients received two subcutaneous injections of Eligard® 45 mg (leuprorelin acetate), with the first injection given at baseline (Visit 1) and the second after 168 ± 3 days at Visit 4.
32767581|NCT04867031|Experimental|White fish (cod)|Participants will consume 1 portion (~130g) of white fish (Bird's Eye Inspirations Cod Fillets with Tomato & Rosemary), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
32767582|NCT04867031|Experimental|Semi-skimmed milk|Participants will consume 1 portion (~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
32767583|NCT04867031|Experimental|Dried seaweed sheets|Participants will consume 1 portion (~6g) of dried seaweed sheets (Itsu Crispy Seaweed Thins), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
32767584|NCT04732195|Experimental|Pilocarpine microneedle patch|Participants will receive in their left forearm the microneedle patch. Upon application to skin, the MNs penetrate into the skin's upper layers and dissolve in the interstitial fluid to release the loaded drugs. MN patches are painless and can be administered with little or no training.
32767585|NCT04732195|Active Comparator|Pilocarpine Iontophoresis|Participants will receive in their right forearm the pilocarpine iontophoresis. Uses a gel disc containing Pilocarpine that drives the medication into the skin with a small electric current (iontophoresis) followed a 30-minute period of sweat collection.
32767586|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
32767587|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
32767588|NCT05304091||Patients with bradykinin-mediated angioedema|Patients with bradykinin-mediated angioedema, aged 18 years or older, followed in the internal medicine department of the Lille University Hospital
32767589|NCT04865081|Experimental|VACCIN box group|The anesthesiologist will intubate the participants in the VACCIN box group while using the VACCIN box that will be placed over the participants' head.
32767590|NCT04865081|No Intervention|Control group|Enrolled participants in the control group will be intubated without the use of the VACCIN intubation box (standard anesthesia).
32767591|NCT04865003||DNI group|patients with infection of two or more deep neck spaces (DNI group)
32767592|NCT04865003||DNI + DNM group|patients with infection of two or more deep neck spaces with secondary descending necrotizing mediastinitis (DNI + DNM group)
32767593|NCT04730011|Experimental|Treatment Group|Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.
32767594|NCT04864769|Experimental|Krill Protein Hydrolysate|Krill Protein Hydrolysate
32767595|NCT04864769|Active Comparator|Soy protein isolate|Soy Protein isolate
32767596|NCT04864769|Active Comparator|Whey protein isolate|Whey protein isolate
32767597|NCT04864769|Sham Comparator|Control|Water
32767598|NCT04728451|Active Comparator|Full-Time Spectacle Wear|Parents are asked to encourage their child to wear the spectacles full-time (all waking hours). A study staff member works closely with families throughout the child's participation to provide support and encouragement and to make suggestions on methods parents can use to maximize spectacle wear.
32767599|NCT04728451|Active Comparator|Ad-Lib Spectacle Wear|Parents are asked to encourage their child to wear the spectacles as much as possible for the initial 30 days after dispensing, and thereafter to continue to offer the spectacles to the child but not force the child to wear them if they resist or refuse. Limited support for parents is provided with regard to maximizing spectacle wear.
32922959|NCT05619913|Experimental|Arm 2 - Combination eribulin and pembrolizumab arm|Eribulin for a maximum of 6 cycles. Pembrolizumab until PD or a maximum of 35 cycles (including the 6 cycles where it is administered in combination with eribulin) or until unacceptable toxicity or physician/patient discretion or choice to cease treatment.
32721004|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
32721005|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
32922960|NCT01748695|Experimental|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
32922961|NCT01748695|Experimental|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
32922962|NCT05617495|Active Comparator|15-Minute mbNF|Participants receiving 15-minute session of mbNF
32922963|NCT05617495|Active Comparator|30-Minute mbNF|Participants receiving 30-minute session of mbNF
32922964|NCT05614453|Experimental|Treatment|Tislelizumab 200mg (IV) every 21 days for up to 35 cycles Sitravatinib 100mg (oral) given daily until disease progression or unacceptable toxicity
32721006|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
32721007|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
32721008|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
32721009|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
32721010|NCT05158075|Experimental|Neurocognitive training|The experimental group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group neurocognitive intervention sessions, that will last about 60-90 minutes each. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
32721011|NCT05158075|Sham Comparator|Sham cognitive training|The active control group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group sessions of sham intervention that mimic the neurocognitive sessions of the experimental group. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
32721012|NCT05158075|Other|Control|Participants in the control group will receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise) and will receive an individualized diet and physical exercise planning for 6 weeks.
32721013|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
32721014|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
32922965|NCT05609461||Chronic stroke patients with knee hyperextension|
32922966|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
32721015|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
32721016|NCT05157763|Experimental|EscharEx 5%|The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
32922967|NCT01750255|Placebo Comparator|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
32721017|NCT04457869|Experimental|Single arm|
32721018|NCT03739099|Active Comparator|Closed-loop insulin delivery 24/7, day and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
32721019|NCT03739099|Other|Closed-loop insulin delivery 7/7, dinner and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
32721020|NCT03512093||Retrospective chart review|
32721021|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
32721022|NCT03512093||Interviews of mothers|
32721023|NCT03690427|Experimental|Endothelial function|Brachial artery flow-mediated dilation will be used to measure endothelial function
32721024|NCT03690427|Experimental|Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness
32922968|NCT01750255|Active Comparator|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
32922969|NCT04339933||BC|Patients who were diagnosed with bladder cancer
32922970|NCT05605015|Experimental|ACTIVE-CR INTERVENTION|Participants will complete a 6-week remote, technology-based physical activity intervention named ACTIVE-CR, in which they will be required to wear a wrist worn monitor to measure daily physical activity. Participants will be able to view their physical activity feedback on a web-based platform and will receive three online trainer sessions across the 6 weeks to help them to understand and interpret their data.
32922971|NCT05605015|No Intervention|CONTROL|Participants in the control group will receive usual care from their healthcare team (if relevant) and will be invited to have an assessment at baseline and 6-weeks. Control participants will not receive any form of intervention. At the end of the study, control participants will receive a summary of their physical activity data measured at baseline and 6-weeks (in a booklet format with guidance on how to interpret and use the information).
32922972|NCT01751971|Active Comparator|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
32922973|NCT01751971|Sham Comparator|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
32922974|NCT05585125|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Participants in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, participants will restart beta-blockers, gradually up-titrating until reaching their home dose and finally during period 4, the investigators will again conduct a dose reduction until they are off of beta-blockers. If the subject chooses to continue into Period 5 the investigators will repeat the same up-titration process until the participant reaches their home dose, and finally during Period 6, the dose will be reduced until the participant is off of their beta-blocker."
32922975|NCT05585125|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF beta blockers. Participants in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where up-titration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, the investigators will again conduct a dose reduction, until the participant is off of beta blockers and finally during Period 4, the investigators will up-titrate them back to their home dose of beta blockers. If the participant chooses to continue into Period 5 the investigators will repeat the same down-titration process until the participant is off their beta-blocker, and finally during Period 6, the dose will be increased until the participant is back to their home dose."
32922976|NCT01754389|Active Comparator|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
32922977|NCT01754389|Experimental|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
32922978|NCT01754389|Experimental|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
33249312|NCT04118595|Experimental|Full Intervention (Video + Telecare + PCP communication)|Patients in this arm will watch an interactive pain management video; receive a pain assessment phone call and be given medication and behavioral pain management strategy recommendations; and an index visit and telecare summary will be shared with patient's primary care provider.
33249313|NCT04118595|Experimental|Video-only Intervention|Patients in this arm will watch an interactive pain management video.
32922981|NCT04288453|Experimental|Community-based activity program|Engagement in 8-week community-based activity program
33073377|NCT02284308||Patients with any subtype of NSCLC, primary UICC Stage III, age ≥ 75 years|All registered patients will undergo a geriatric assessment to assess vulnerability. Based on this assessment, patients are offered treatment according to the discretion of the physician and patient.
33249314|NCT04118595|No Intervention|Usual Care|Patients will receive the typical care provided by medical personnel for their acute pain.
33249315|NCT00945022|Experimental|Lipsus|
33249316|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
33249317|NCT02565212|Active Comparator|Group 2|montelukast
33249318|NCT02565212|Active Comparator|Group 3|mometasone furoate
33249319|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
33249320|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
32721025|NCT03690427|Experimental|Biomarkers of|Prooxidant and inflammatory plasma biomarkers will be used to assess oxidative stress and inflammatory status
32743372|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
32743373|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
32743374|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
32743375|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
33073378|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
33249321|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
33249322|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
33249323|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
33249324|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
33249325|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
33249326|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head & Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 & Modified xerostomia questionnaires will be used.
33249327|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination & Generalised activites of daily living scale (G-ADL) questionnaires will be used.
33249328|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG & LENT SOM(A) questionnaires will be used.
33249329|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
33249330|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
32721026|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
32721027|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
32721028|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
32721029|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
32743376|NCT04930185|Experimental|Pamphlet|Participants will received pamphlet about COVID-19 vaccination
32743377|NCT04930185|Experimental|Webinar|Participants will received webinar about COVID-19 vaccination
32743378|NCT04930185|Experimental|SMS|Participants will received SMS about COVID-19 vaccination
32743379|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
33073379|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
33249331|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
33073380|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
33249332|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
33249333|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
33249334|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
33249335|NCT00560950|Experimental|1st Revaccination Group|
33073381|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
33249336|NCT00560950|Experimental|2nd Revaccination Group|
33249337|NCT02562144|Experimental|Xylocaine spray|
33249338|NCT02562144|Placebo Comparator|Placebo|
33249339|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
33249340|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
33249341|NCT00945178|Experimental|Part A: A|AZD1386
33249342|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
33249343|NCT00945178|Experimental|Part B: A|Naproxen
33249344|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
33249345|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
33073382|NCT02233868|Experimental|Phase I|PET scan with [11C]PBR28 followed by PET scan with FDG and MRI.
33073383|NCT02233868|Experimental|Phase II|After 3 weeks of abstinence or non-abstinence, PET scan with [11C]PBR28 followed by PET scan with FDG and MRI are repeated.
32721030|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
32721031|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care and will be offered research exome sequencing."
32721032|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care."
32721033|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care and will be offered research exome sequencing."
32721034|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care."
32721035|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
32721036|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
32721037|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
32721038|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
32721039|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
32721040|NCT05302570|Experimental|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
32721041|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
32721042|NCT02305355|Active Comparator|any statin|
32721043|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
32721044|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
32721045|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
32721046|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
32721047|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
32721048|NCT03511859||Cancer Group|The biopsy result is breast cancer.
32721049|NCT03511703|Experimental|Apatinib|
32721050|NCT03511703|Other|TACE|
32721051|NCT03777436|Experimental|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
32721052|NCT03777436|Experimental|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
32721053|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
32721054|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
32721055|NCT05157373||Group 1|Patients with any type of endometrial cancer
32721056|NCT05157373||Group 2|Patients with hyperplastic endometrial lesion (all type of endometrial hyperplasia and endometrial polyps). In this group will be included the breast cancer survivors under tamoxifen.
32721057|NCT05157373||Control group|A random sample of women without any endometrial pathology.
32721058|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
32721059|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
32721060|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
32721061|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
32721062|NCT05157295|Experimental|Experimental Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 4 different detrusor muscle sites along the posterior bladder wall and dome.
33249346|NCT05301478|Experimental|Diabetic with elevated plantar pressure|Diabetic with elevated plantar pressure
33249347|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
33249348|NCT00945412|Active Comparator|Electrocautery|
33249349|NCT00749424|Experimental|1|crushing technique
32922982|NCT01754623|Experimental|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery."
33249350|NCT00749424|Active Comparator|2|provisional T stenting technique
32922985|NCT01755169|Experimental|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
32922986|NCT01755169|Experimental|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
32922987|NCT01755169|Experimental|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
32922988|NCT01755169|Placebo Comparator|Placebo|
32922989|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
32922990|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
32922991|NCT01755949|Active Comparator|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
32922992|NCT01755949|Placebo Comparator|Chronic atrial fibrillation, placebo|Matching placebo. Subjects not undergoing ablation.
32922993|NCT01755949|Active Comparator|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
32922994|NCT01755949|Placebo Comparator|Pre-ablation, sinus rhythm, placebo|Matching placebo. Subjects undergoing ablation.
32922995|NCT01755949|Active Comparator|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
32922996|NCT01755949|Placebo Comparator|Pre-ablation, AF, placebo|Matching placebo. Subjects undergoing ablation.
32922997|NCT04769245||Single donor convalescent plasma|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
32922998|NCT04769245||ACB- IP 1.0|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
32922999|NCT01756885|Active Comparator|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Days 85-168: Placebo - 1.0mg twice daily orally"
32923000|NCT01756885|Experimental|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
32923001|NCT04209907|Active Comparator|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
32923002|NCT04209907|No Intervention|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
32923003|NCT04172701||LAMA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.
32923004|NCT04172701||ICS/LABA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.
32923005|NCT05554939|Experimental|Patients with refractory or relapsed B-cell NHL|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, allogenic targeting CD19 chimeric antigen receptor γδT cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
32923006|NCT04151875|Experimental|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
32923007|NCT04151875|Active Comparator|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
32923008|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
32923009|NCT01760239|Experimental|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP <90% and <120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
32923010|NCT01760239|No Intervention|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
32923011|NCT01760473|Experimental|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
32923012|NCT01760473|Experimental|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
32923013|NCT01760473|Experimental|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
32923014|NCT01760473|Experimental|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
32923015|NCT01760473|Experimental|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
32923016|NCT01760473|Experimental|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
32923017|NCT01760473|Active Comparator|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
32923018|NCT01760473|Sham Comparator|Placebo|Intranasal challenge drug: Intranasal lactose powder.
32923019|NCT01760473|Active Comparator|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
32923020|NCT01760785|Active Comparator|divalproex sodium|
32923021|NCT01760785|Placebo Comparator|sugar pill|
32923022|NCT01761019|Other|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
32923023|NCT01761175|Active Comparator|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
32923024|NCT01761175|Active Comparator|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
32721063|NCT05157295|Active Comparator|Control Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 20 different detrusor muscle sites along the posterior bladder wall and dome.
32721064|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 106 weeks.
32721065|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
32721066|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32721067|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
32721068|NCT03339141|Placebo Comparator|supine position|Patients are placed in the supine position at 0° from arrival in the room until intubation
32721069|NCT03339141|Active Comparator|25° head-up position|Patients are placed in the 25° head-up position (half-seat or whole body proclive) from arrival in the room until intubation.
32721070|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
32721071|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
32923025|NCT04769089|Experimental|Pulse Dye Laser|Treatment with PDL alone.
32923026|NCT04769089|Experimental|CO2 Laser|Treatment with CO2 alone.
32923027|NCT04769089|Experimental|Combination|Treatment with both PDL and CO2 laser.
32923028|NCT04769089|Active Comparator|No treatment|No laser treatment.
32923029|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
32923030|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
32923031|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
32923032|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
32923033|NCT04005079|Experimental|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
32923034|NCT04005079|Active Comparator|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
32923035|NCT01761643|No Intervention|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
32923036|NCT01761643|Active Comparator|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.~Subjects will have visits with the study coordinator to introduce the iTAB texting system.~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
32923037|NCT01762501|Experimental|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
32923038|NCT01762501|Active Comparator|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
32923039|NCT05539963|Experimental|Stimulan-VG|Participants will receive Stimulan-VG on Day 1 following surgical debridement. Systemic antibiotics for 3 days ± 2 days following the debridement surgery.
32923040|NCT05539963|Active Comparator|Standard of Care|Participants will receive Systemic antibiotics for 4-6 weeks following the debridement surgery.
32923041|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
32721072|NCT03288363|Experimental|tDCS|20 sessions tDCS (DC-Stimulator Plus -Neuroconn) during 2 Weeks on temporal cortex - each session : 30 minutes - 2 mA - 2 sessions per day - evaluation at 12 weeks post-treatment
32721073|NCT03288363|Sham Comparator|sham stimulation|the same parameters of stimulation as with real current stimulation (time, parameters to be seen on the apparatus screen) 20 sessions during 2 Weeks on temporal cortex - each session : 30 minutes - 2 sessions per day.
32923042|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
32923043|NCT01764607|Experimental|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
32923044|NCT01764685|Experimental|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
32923045|NCT01764685|Placebo Comparator|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
32923046|NCT01764919|Experimental|[124I]FIAU|Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
32923047|NCT01765465|Experimental|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
32923048|NCT01765465|Placebo Comparator|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
32721074|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
32721075|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
32923049|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
32923050|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
32923051|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
32923052|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
32923053|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
32923054|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
32923055|NCT01766713|Experimental|Ezetimibe|10 mg/day of Ezetimibe
32923056|NCT01766713|Placebo Comparator|Placebo|one tablet per day (identical to ezetimibe)
32923057|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
32923058|NCT01767103|Experimental|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
32923059|NCT01767103|Experimental|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
32923060|NCT01767103|Experimental|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
32923061|NCT05516485|Experimental|Diagnostic (MRE, tumor grading)|Patients undergo MRE scan over 25 minutes before surgery at the time of standard of care pre-operative MRI scan. On the day of surgery, the surgeon grades and records tumor consistency/stiffness during the operation and afterwards.
32923062|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
32721076|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
32743380|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
32923063|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
32923064|NCT01767415|Experimental|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
32923065|NCT01769209|Experimental|Bortezomib + Chemotherapy|Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
32923066|NCT01769365|Experimental|7-day quadruple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days,~metronidazole 500 mg twice daily for 7 days"
32923067|NCT01769365|Experimental|10-day sequential therapy|"pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
32923068|NCT01769365|Active Comparator|7-day standard triple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days."
32923069|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
32923070|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
32923071|NCT01770691|Experimental|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
32923072|NCT01771627|Experimental|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
32923073|NCT01771627|Active Comparator|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
32923074|NCT01773187|Experimental|Pacritinib|Pacritinib 400 mg QD
32923075|NCT01773187|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
32923076|NCT01774045|Experimental|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
32923077|NCT01774045|Placebo Comparator|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
32923078|NCT01775371|Experimental|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
32923079|NCT01775371|Active Comparator|Usual Care|Usual opioid analgesia determined by the provider
33400227|NCT05569018|Experimental|Blended group transversal protocol (BLGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in blended (face-to-face + online) and group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
33400228|NCT05569018|Active Comparator|Face-to-face group transversal protocol (FFGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in traditional (face-to-face) group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
32721077|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
32721078|NCT03511547|No Intervention|Control|
32721079|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
32721080|NCT03122431|Active Comparator|Inactive SLE with standard dose of HCQ|This subproject includes one arm of lupus patients with inactive disease, in which will be maintained on standard dose of Hydroxychloroquine (400mg/day).
32721081|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes one arm of lupus patients with inactive disease: in which the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced).
32721082|NCT03263637|Experimental|Arm A: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory haematological malignancies excluding AML/ALL/high-risk MDS/CMML/CLL.
32721083|NCT03263637|Experimental|Arm B: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory AML, ALL, high-risk MDS, CMML, CLL and Richter's syndrome.
32721084|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
32721085|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
32721086|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
32721087|NCT03511469|Experimental|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
32721088|NCT05297656|Experimental|Experimental Group|"A total of 8 sessions of graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~All patients will also receive home exercise therapy including stretching of the trapezius muscle and posture exercises"
32743381|NCT04930341|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
32923080|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
32923081|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
32923082|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
32721089|NCT05297656|Sham Comparator|Sham Comparator Group|"A total of 8 sessions of sham graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~Sham graston massage is not a deep tissue massage, but will be performed with the device superficially, without applying pressure and mobilization.~All patients will also receive home exercises."
33249351|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
32923083|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
32923084|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
32923085|NCT03723811|Experimental|1|SJP002 BID
32721090|NCT05297656|Other|Control group|The volunteers in the control group will be only given home exercise therapy including stretching of the trapezius muscle and posture exercises
32721091|NCT02990481|Experimental|Arm 1 - TRK-950|"Solid tumor~TRK-950 (Three dose levels will be explored during Arm 1)"
32721092|NCT02990481|Experimental|Arm 2 - TRK-950|"Colon cancer~TRK-950 (Low dose and High dose)"
32721093|NCT02990481|Experimental|Arm 3 -TRK-950|"Cholangiocarcinomas~TRK-950 (Low dose)"
33249352|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
33249353|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
33249354|NCT00950092|Other|Treatment|
33249355|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
33249356|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
33249357|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
33249358|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
32721094|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.~Tool: Toi Même mobile app"
33249359|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
32721095|NCT05248360|Experimental|Experimental group|Hydrogen-oxygen mixed gas(H2-O2, 66.6% hydrogen, 33.3% oxygen) inhalation, 900ml/min, 2h/d
33249360|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
33249361|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
33249362|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
33249363|NCT00745446|Experimental|1|1 hour exposure to filtered air
33249364|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
32721096|NCT05248360|Placebo Comparator|Control group|Air inhalation, 900ml/min, 2h/d
33249365|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
33249366|NCT05425446|Experimental|SAD Cohort 1|All randomized patients will receive one dose of either DONQ52 Dose A or placebo
33249367|NCT05425446|Experimental|SAD Cohort 2|All randomized patients will receive one dose of either DONQ52 Dose B or placebo
32721097|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
33249368|NCT05425446|Experimental|SAD Cohort 3|All randomized patients will receive one dose of either DONQ52 Dose C or placebo
33249369|NCT05425446|Experimental|SAD Cohort 4|All randomized patients will receive one dose of either DONQ52 Dose D or placebo
33249370|NCT05425446|Experimental|MAD Cohort 1|All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo
33249371|NCT05425446|Experimental|MAD Cohort 2|All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo
33249372|NCT05425446|Experimental|MAD Cohort 3|All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo
32923086|NCT03723811|Experimental|2|SJP002 QID
33249373|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
33249374|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
33249375|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
33249376|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
33249377|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
33249378|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
33249379|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
33249380|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
32721098|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
32721099|NCT05092503|Experimental|JINZHEN low dose arm|Patients will take 0.375 gram of JINZHEN Granules twice a day for 14 days.
32721100|NCT05092503|Experimental|JINZHEN middle dose arm|Patients will take 0.75 gram of JINZHEN Granules twice a day for 14 days.
32721101|NCT05092503|Experimental|JINZHEN high dose arm|Patients will take 1.5 gram of JINZHEN Granules twice a day for 14 days.
32721102|NCT05092503|Placebo Comparator|Placebo arm|Patients will take placebo granules twice a day for 14 days.
32721103|NCT02506465|Experimental|iTind arm|iTind implant is implant during the study for 5-7 days.
32721104|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
32721105|NCT05092425||with CPPV|Group 1 is childrens with contralateral patent processus vaginalis.
32721106|NCT05092425||without CPPV|Group 2 is childrens without contralateral patent processus vaginalis.
32721107|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
32721108|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
32721109|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
32721110|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
32721111|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
32721112|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
32721113|NCT05376189|Active Comparator|Control Group|This group will be given standardized tuberculosis drug with 400 IU of oral Vitamin D3
32721114|NCT05376189|Experimental|Moderate Dose|This group will be given standardized tuberculosis drug with 5000 IU of oral Vitamin D3
32721115|NCT05376189|Experimental|High Dose|This group will be given standardized tuberculosis drug with 10000 IU of oral Vitamin D3
32721116|NCT02235298|Experimental|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
32721117|NCT02235298|Active Comparator|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
32721118|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
32721119|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
32721120|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
32721121|NCT04657263||Person at risk of infection according to French 2019 immunization|Person at risk of infection according to French 2019 immunization
32721122|NCT03942887|Active Comparator|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
32721123|NCT03942887|Active Comparator|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
32721124|NCT05136391|Experimental|XTR003|Administration and investigation of myocardial fatty acid radiotracer
32721125|NCT04619199|Experimental|Idiopathic Pulmonary Fibrosis|Blood sample were performed during the study for all patients.
32721126|NCT02234596|Experimental|Nintedanib|
32721127|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
32721128|NCT04499937|Experimental|Streak incentive|Subjects start with no money in an account, but they earn a fixed amount with each response. In this arm, each adult report is worth $3.17 so an adult subject can earn up to $200 if he/she responds to all surveys. If an adult completes at least 75% of the reports, he/she will receive an $100 bonus for a total maximum of $300. In this arm, each child report is worth 0.52 cents so a child subject can earn up to $33 if he/she responds to all surveys. If a child completes at least 75% of the reports, he/she will receive a $17 bonus for a total maximum of $50.
32721129|NCT04499937|Experimental|Loss-based incentive|Subjects start with the maximum possible compensation, but money is deducted for each missed response. Adult subjects will lose $4.76 for each missed survey. Child subjects will lose $0.79 for each missed survey.
32721130|NCT04499937|Active Comparator|Flat-fee control status quo condition|Subjects will receive the maximum possible compensation at the end of the study regardless of response rate.
32721131|NCT04499937|Active Comparator|Flat-Fitbit control status quo condition|Subjects will be compensated by keeping the Fitbit at the end of the study regardless of response rate.
32721132|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
32721133|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
32721134|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
32721135|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
32721136|NCT03704350|Active Comparator|20-24.9 BMI|Participants with a BMI that falls between 20 and 24.9 who will receive the controlled diet
32721137|NCT03704350|Active Comparator|25-29.9 BMI|Participants with a BMI that falls between 25 and 29.9 who will receive the controlled diet
32721138|NCT03704350|Active Comparator|30-34.9 BMI|Participants with a BMI that falls between 30 and 34.9 who will receive the controlled diet
32721139|NCT03704350|Active Comparator|35-39.9 BMI|Participants with a BMI that falls between 35 and 39.9 who will receive the controlled diet
32721140|NCT03704350|Active Comparator|40-44.9 BMI|Participants with a BMI that falls between 40 and 44.9 who will receive the controlled diet
32923087|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
32923088|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
32721141|NCT03704350|Active Comparator|45-50 BMI|Participants with a BMI that falls between 45 and 50 who will receive the controlled diet.
32721142|NCT04463849|Experimental|COVID-19 positive patients|Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
32721143|NCT04463849|Other|Healthy volunteers|Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
32721144|NCT04463849|Other|Type 2 diabetes patients|Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
32721145|NCT05737407|Experimental|LUS-guided Peep|"After induction of anesthesia and intubation, patients will be briefly turned onto their side and LUS will be performed in the posterior areas of the lung; PEEP will be adjusted in increments of 1 cmH20/minute starting from zero while maintaining visual inspection of LUS up to the point where signs of eventual subpleural consolidations and/or multiple B lines are not present anymore.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
32721146|NCT05737407|Active Comparator|Standard setting of Peep|"After induction, patients will be similarly scanned with LUS on their side but PEEP will be set at 4 cmH2O independently from results of LUS.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
32721147|NCT05219812|Experimental|Group 1 (BAY2395840 - placebo)|Participants will be randomly assigned to treatment regimen of double-blind BAY2395840, and after an interim single blind period for washout will switch to double-blind placebo.
32721148|NCT05219812|Experimental|Group 2 (Placebo - BAY2395840)|Participants will start with a treatment regimen of double-blind placebo, and after an interim single blind period for washout will switch to double-blind BAY2395840.
32721149|NCT04539951|Active Comparator|serotonin treatment|In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
32721150|NCT04539951|Active Comparator|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.
32721151|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
32721152|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
32721153|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
32721154|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
32721155|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
32743382|NCT04930341|No Intervention|Control group|Routine maintenance will be applied
33249381|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
32767600|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
32767601|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
32767602|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
32767603|NCT04451785|Active Comparator|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
32767604|NCT04451785|Experimental|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
32767605|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
32767606|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
32767607|NCT05303857|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given semaglutide 1.34 mg/ml (SC, administered by personal injector, once weekly)
32767608|NCT05303857|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given placebo (SC, administered by personal injector, once weekly)
32767609|NCT04709107||Elective|Patients undergoing elective revascularisation (endovascular or surgical) for PAD.
32767610|NCT04709107||Emergent|Patients undergoing emergent revascularisation (endovascular or surgical) for PAD.
32767611|NCT04858919|Other|study group|virgins with genital tract lesion
32767612|NCT05303389|Experimental|Posterior plating group|Fix the posterior fragment using a buttress plate through a posterolateral approach by an interval between flexor hallucis longus and peroneii.
32767613|NCT05303389|Active Comparator|Anterior to posterior group|Fix the posterior fragment using anterior to posterior 4.0 mm cannulated screws under xray guidance.
32767614|NCT04858841|Experimental|Levetiracetam|The group receives oral levetiracetam.
32767615|NCT04858841|Experimental|Perampanel|The group receives oral perampanel.
32767616|NCT04858841|Placebo Comparator|Placebo|The group receives oral placebo.
32767617|NCT04702243||Affected Participants|Subjects who have suppurative lung disease without a known genetic diagnosis
32767618|NCT04702243||Unaffected Family Members|Unaffected family members may be enrolled in the study for collection of DNA only
32767619|NCT04858529|Experimental|THP|
32767620|NCT04858529|Active Comparator|TCHP|
32767621|NCT04866407|Experimental|Mentha x piperita|A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.
32767622|NCT04866407|Experimental|Eucalyptus globulus|A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.
32767623|NCT04866407|No Intervention|No intervention|Each participant will have one extremity that receives no essential oil intervention.
33249382|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
33249383|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
32767624|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
32767625|NCT03970915|Experimental|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
32767626|NCT03970915|Sham Comparator|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
32767627|NCT05303155||Patient with COVID 19|Pediatric patient infected by COVID 19
32767628|NCT05303155||Pediatric patient without infection of COVID 19|Pediatric patient without infection of COVID 19
32767629|NCT05302999|Experimental|Low dose|600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
32767630|NCT05302999|Experimental|Medium dose|1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
32767631|NCT05302999|Placebo Comparator|Control|The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.
32767632|NCT03919435|Experimental|On Drug|
32767633|NCT04379089||Children <18|"Infants, children, and young adults age < 18 years~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
32767634|NCT04363177|Experimental|Web-based psychosocial peer-to-peer support|"Web-based psychosocial peer-to-peer support, using Thinking Healthy two times during pregnancy"
32767635|NCT04363177|Active Comparator|Standard perinatal care|Perinatal standard care in Hong Kong, Shanghai
32767636|NCT05302921|Experimental|All patients|"Patients less than 40 years old with relapsed/refractory solid tumors and at least 2 sites of measurable disease will receive the current pediatric RP2D of nivolumab and ipilimumab for one cycle and undergo cryoablation therapy of one tumor site. Patients will continue to receive cycles of checkpoint inhibition as long as there is no disease progression of unacceptable toxicity (maximum of 13 cycles [12 months]).~There are 4 patient cohorts:~Osteosarcoma~Ewing sarcoma~Rhabdomyosarcoma~All other solid tumors (non-statistical)"
33249384|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
33249385|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
33249386|NCT00749736|Placebo Comparator|3|placebo for six months
33249387|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
32923089|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
32923090|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
32923091|NCT03717103|Experimental|IBI188|Part A : Initial dose escalation, Part B : Maintenance dose escalation
32923092|NCT03694015|Active Comparator|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.~Minimum of kV image matching on unit daily."
32923093|NCT03694015|Active Comparator|VMAT rapid (Arm 2)|"Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows:~If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion~If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion~If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ"
32923094|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
32923095|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
32923096|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
33249388|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
32721156|NCT04434807|Experimental|Minimally invasive hematoma evacuation|Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
32721157|NCT04434807|No Intervention|Standard care (medical therapy)|Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
32721158|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
32721159|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
32721160|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
32721161|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
32721162|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
32721163|NCT04415541|Experimental|Psychodynamic Psychotheray|Following Coordinated Specialty Care, we will offer weekly psychodynamic psychotherapy and medication management sessions which will be conducted solely by the PI, Keith Gallagher, in the initial pilot period. Consent will be obtained to record audio and video of the sessions
32721164|NCT04415541|Active Comparator|Treatment as Usual|Following Coordinated Specialty Care, patients will be referred to general mental health providers in the community, which would typically include less intensive and frequent psychotherapy by a social worker or psychologist as well as medication management by a psychiatrist who may not be a specialist in psychotic disorders.
32923097|NCT04350931|Active Comparator|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
32923098|NCT04350931|Placebo Comparator|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
32923099|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
32923100|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
32923101|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
32923102|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
32923103|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
32923104|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
32923105|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
32923106|NCT05490979|Experimental|Contemplative dyad meditation|
32923107|NCT05490979|Active Comparator|Fast friends|
32923108|NCT05490979|No Intervention|No intervention|
32923109|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
33249389|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
33249390|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
33249391|NCT00749814|Experimental|A|Study group will receive melatonin.
33249392|NCT00749814|Placebo Comparator|B|Placebo
33249393|NCT00749814|No Intervention|C|No intervention control group.
33249394|NCT00950482|Active Comparator|TA|Active TA
33249395|NCT00950482|Active Comparator|AA|Alternative Acupuncture
33249396|NCT00950482|Active Comparator|WC|Waiting Group
33249397|NCT00748176||A|
33249398|NCT02041936|Experimental|NanoKnife IRE System|
33249399|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
33249400|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
33249401|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
33249402|NCT00950560||inpatient|
33249403|NCT00950560||outpatient|
33249404|NCT00950560||emergency patient|
33249405|NCT04159922||Type 2 diabetic patients with foot wounds|
33249406|NCT00941200||Blood collection|
33249407|NCT00945880|Experimental|Experimental Group|clemizole hydrochloride, 100mg, BID
33249408|NCT04061174|Experimental|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
33400229|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
32721165|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
32721166|NCT05092113|Experimental|Group A|a compound glutamine capsule was taken orally in the first cycle of chemotherapy, and a compound glutamine capsule simulated placebo was taken in the second cycle of chemotherapy. All patients take drugs orally on the first day of each cycle of chemotherapy, 3 tablets 3 times a day, and the course of the treatment was 3 weeks.
32721167|NCT05092113|Experimental|Group B|in the first cycle of chemotherapy, a compound glutamine capsule simulated placebo was given ,and in the second cycle, a compound glutamine capsule was taken at the same time of chemotherapy. All patients take orally from the first day of chemotherapy, 3 times a day after meals, 3 tablets each time, and the course of treatment was 3 weeks.
32721168|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
32721169|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
32721170|NCT05737251|Experimental|PoET Group|Participants received two sessions of PoET and filled out the questionnaires.
32721171|NCT05737251|No Intervention|Control Group|Participants only filled out the questionnaires.
32721172|NCT02301689||Heart Failure patients|
32721173|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
32721174|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
32721175|NCT05091489||Men who have sex with men (MSM) non-using PrEP|Focus group (10 persons)
32721176|NCT05091489||Male entertainment workers|Focus group (10 persons)
32721177|NCT05091489||Free-lance based entertainment female workers non-using PrEP|Focus group (10 persons)
32721178|NCT05091489||Venue-based entertainment female workers non-using PrEP|Focus group (10 persons)
32721179|NCT05091489||Transgender women (TGW) non-using PrEP|Focus group (10 persons)
32721180|NCT05091489||Healthcare workers in charge of key-populations|Focus group (10 persons)
32721181|NCT05091489||Community workers in charge of key-populations|Focus group (10 persons)
32721182|NCT05091489||PrEP users|Focus group (10 persons)
32721183|NCT05091489||NCHADS|Individual semi-directive interview (1 person) (NCHADS: operational unit of the Ministry of Health in charge of health sector policy development for HIV/AIDS)
32721184|NCT05091489||National Aids Authority|Individual semi-directive interview (1 person) (National Aids Authority: in charge to lead, manage, coordinate and facilitate the comprehensive and multi-sectoral response to HIV and AIDS in Cambodia)
32721185|NCT05091489||Ministry of Health|Individual semi-directive interview (1 person)
32721186|NCT05091489||Key influencer in the MSM and/or TGW community|Individual semi-directive interview (1 person)
32721187|NCT05091489||Key influencer in the EW community|Individual semi-directive interview (1 person)
32721188|NCT05091489||Khana|"Individual semi-directive interview (1 person)~Khana : an umbrella organization belonging to the HIV/AIDS international Alliance"
32721189|NCT05091489||High class and hidden MSM|Individual semi-directive interview (1 person)
32721190|NCT05091489||Discontinued PrEP user|Individual semi-directive interview (1 person)
32721191|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
32721192|NCT05091411|Experimental|Population Ⅰ|3 doses of experimental vaccine (pilot scale batch) were given at day 0, 30 and 60.
32721193|NCT05091411|Experimental|Population Ⅱ|3 doses of experimental vaccine (process validation lot 1) at day 0, 30 and 60;
32721194|NCT05091411|Experimental|Population Ⅲ|3 doses of experimental vaccine (process validation lot 2) at day 0, 30 and 60;
32721195|NCT05091411|Experimental|Population Ⅳ|3 doses of experimental vaccine (process validation lot 3) were given at day 0, 30 and 60.
32721196|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
32721197|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
32721198|NCT04309305|Experimental|Stroke RE|After discharge from the acute rehabilitation facility, participants in the stroke RE group will participate 3 days a week for 10 weeks in robotic exoskeleton gait training provided by a trained, licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
32721199|NCT04309305|Active Comparator|Stroke SOC|After discharge from the acute rehabilitation facility, participants in the stroke SOC group will participate 3 days a week for 10 weeks in standard of care gait training provided by a licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
32721200|NCT04309305|Other|Healthy Control|Participants in the healthy control group will not participate in any gait training. Healthy control participants will only be asked to complete 3 testing sessions.
32721201|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
32721202|NCT05737173|Experimental|Leukocyte-rich platelet-rich plasma|Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
32721203|NCT05737173|Experimental|Leukocyte-poor platelet-rich plasma|Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
32721204|NCT05737173|Experimental|Corticosteroid|Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
32721205|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
32721206|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
32721207|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
32721208|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
32721209|NCT05091177||the patience group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and color ultrasound.
32721210|NCT05091177||the normal group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and ultrasound.
32721211|NCT02302001|Experimental|Primary Breast Augmentation|
32721212|NCT05737095||Premature infants|premature infants born between 32 and 36 weeks of amenorrhea + 6 days hospitalized for respiratory distress
32721213|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
32721214|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
32721215|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
32721216|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
32721217|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
32721218|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
32721219|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
32721220|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
32721221|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
32743383|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
33400230|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
33400231|NCT05694832|Experimental|Expressive writing weekly session|Weekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.
33400232|NCT03974100|Experimental|GP2411|60 mg /mL subcutaneous injection every 6 months
33400233|NCT03974100|Active Comparator|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
32721222|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
32721223|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
32721224|NCT04217577|Experimental|Dried Plums|Consume dried plums daily.
32721225|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
32721226|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
32721227|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
32721228|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
32721229|NCT04122261|Experimental|experimental group|MicroHand S robotic surgery group
32721230|NCT04122261|Experimental|control group|da Vinci robotic surgery group
32721231|NCT05158439|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
32721232|NCT05091099|Active Comparator|On time Zoledronate|Zoledronate would be given (one dose for one year) after the completiong of denosumab on time
32721233|NCT05091099|Experimental|Alendronate and Zoledronate|Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
32721234|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
32721235|NCT05197426|Experimental|Oral Azacitidine|
32721236|NCT05197426|Placebo Comparator|Placebo|
32721237|NCT03505151|Experimental|All subjects|
32721238|NCT02306681||SAQ-Self-Assessment Questionnaire|
32721239|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
32721240|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
32721241|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
32721242|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
32721243|NCT05090943||Quality of life questionnaires|
32721244|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
32721245|NCT05736939||Men with long COVID-19 syndrome|Patients were male adults (>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
32721246|NCT05736939||Women with long COVID-19 syndrome|Patients were women adults (>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
32767637|NCT05302843|Experimental|dose exploration and dose expansion|Patients receive BPI-28592 PO. Cycles repeat every 28 days.
32767638|NCT04700917|Experimental|Intervention Group|This group will receive the iCBT for IBD online intervention once enrolled.
32767639|NCT04700917|No Intervention|Treatment as Usual|This group will be offered the iCBT for IBD intervention 24 weeks after enrollment.
32767640|NCT05302219|Experimental|Measurement of plethysmography curve|Calm measurement of plethysmography curve using pulse oximetry with simultaneous monitoring of the breath cycle. In this experimental arm, participants will vary their breath cycle (different respiratory rates and different tidal volumes).
32767641|NCT04690465|Experimental|Resistance training|In the 16 week resistance training, there will be 3 sessions per week, the duration of each session will be 60 minutes, which include 10min of warm-up, 40min of main exercise, and 10min of cool-down. The intensity will be light to somewhat hard (Rating of Perceived Exertion (RPE) 11 to 13; using the Cantonese version of RPE). In resistance training, the weights (resistance) will be from participants' own bodies, dumbbells, and adjustable ankle weights.
32767642|NCT04690465|Active Comparator|Eight-form Yang-style Tai Chi program|In Tai Chi, the 16-week program will be divided into cognitive, associated, and automatic stages. The coach will apply a group teaching with individual instruction on specific movements based on participant's needs in skills learning and acquisition. The same training principles of individuality and progression as well as training log-book used in resistance training will also be applied to Tai Chi training program.
33249409|NCT04061174|Experimental|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
32721247|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
32721248|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
32721249|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
32721250|NCT05377437|Experimental|Participants|Participants of the study
32721251|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
32721252|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
32721253|NCT04463459|No Intervention|Chemotherapy + Placebo|Patients receiving chemotherapy This group will be received chemotherapy and placebo
33249410|NCT00950638|Active Comparator|dose comparison|
33249411|NCT00950638|Active Comparator|Dose comparison|
33249412|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
33249413|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
33249414|NCT00941278|Experimental|PH-10 Treatment|
33249415|NCT00619359|Experimental|1|Arm 1: study medication
33249416|NCT00619359|Active Comparator|2|Arm 2: Active comparator
33249417|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
33249418|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
33249419|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
33249420|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
33249421|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
33249422|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
33249423|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
33249424|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
33249425|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
33249426|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
33249427|NCT00849069|Experimental|Group A|
33249428|NCT00849069|Active Comparator|Group B|
33249429|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
33249430|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
32721254|NCT04463459|Active Comparator|Chemotherapy + Vitamin C + Vitamin E|Patients receiving vitamin C and E with Chemotherapy This group will be received vitamin C (500 mg) twice daily and vitamin E (400 mg) once daily with chemotherapy for 6 weeks
33249431|NCT00941590||Patients with tick borne encephalitis.|
33249432|NCT04042545|Experimental|inhaled THC/CBD (PPP001)|PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device
33249433|NCT04042545|Placebo Comparator|Placebo|Placebo inhalation with a device
33249434|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
33249435|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
33249436|NCT00852267|Experimental|Low CHO, High SatFat Diet|
33249437|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
33249438|NCT00372229|Experimental|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
33249439|NCT00372229|Active Comparator|Pre-emptive CMV Therapy|
33249440|NCT05301010|Experimental|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
32721255|NCT04018677|Experimental|TOGETHER app users|TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
32923110|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
32923111|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
32721256|NCT00821587|Active Comparator|Tacrolimus|Tacrolimus
32721257|NCT00821587|Active Comparator|Cyclosporine|Cyclosporine
32721258|NCT04463381||Group 1|sharp choledochotomy by a scalpel or scissor
32721259|NCT04463381||Group 2|choledochotomy by a diathermy hook
32923112|NCT03003169||ambulatory surgery description|
32923113|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
32923114|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
32923115|NCT01778179|Active Comparator|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
32721260|NCT04463381||Group 3|choledochotomy by an ultrasonic device
32721261|NCT05736783|Experimental|plyometric exercises|performing plyometric exercises for 6 weeks
32923116|NCT01778179|Placebo Comparator|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
32923117|NCT01538303||measurement absolute flow and resistance|
32721262|NCT05736783|Experimental|strenghtening of quadriceps and hamstring|performing strengthening of quadriceps and hamstring for 6 weeks
32721263|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
32721264|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
32721265|NCT03534375||Female Early Adolescents|
32721266|NCT03534375||Male Early Adolescents|
32721267|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
32721268|NCT03507335||Sinus|Patients with sinus rhythm during measurements
32721269|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
32721270|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
32721271|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
32721272|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
32721273|NCT03419195|Experimental|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C <9%).
32721274|NCT03419195|Experimental|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
32721275|NCT05090709|Experimental|Experimental A - Mobilisation Intervention|Participants receive 4 separate treatment sessions of the 30 minute spinal mobilisation intervention.
32721276|NCT05090709|Active Comparator|Experimental B - General Massage|Participants receive 4 separate treatment sessions of the 30 minute general massage.
32721277|NCT04457011|Experimental|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
32721278|NCT04457011|Experimental|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
32721279|NCT04457011|Placebo Comparator|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
32721280|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
32721281|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
32721282|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
32721283|NCT05735223|Experimental|Stretched flaccid penile length (SFPL) following RALP.|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery).
32721284|NCT04456855||Locoregional surgery|
32721285|NCT04456855||No surgery|
32721286|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
32721287|NCT04778644|Experimental|Patients with psychosis|People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
32721288|NCT04778644|Experimental|Healthy controls|People who do not have a diagnosis of schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
32721289|NCT03276351|Active Comparator|Long-Stemmed with Hybrid Fixation|Participants will receive the Long-Stemmed revision implant with Hybrid Fixation during their surgery.
32721290|NCT03276351|Experimental|Short-Stemmed with Augmented Fixation|Participants will receive the Short-Stemmed primary implant with Augmented Fixation during their surgery.
32721291|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
32721292|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
32721293|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
32721294|NCT04785274||SpHb|
32721295|NCT04785274||Control|
32721296|NCT04457791|Experimental|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
32721297|NCT04457791|No Intervention|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
32721298|NCT04539093||End-stage heart failure patients requiring lvad support|Patients with end-stage heart failure with reduced ejection fraction, requiring mechanical circulatory support.
32721299|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
32767643|NCT04690465|No Intervention|Non-treatment Concurrent Control|Participants in this group will not participate in any specific intervention during the whole study (the 16-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, medicine used, illness, diet, sleep quality and other health and physical activity related information (e.g., attending healthy eating workshops).
32767644|NCT04689997|Experimental|computerized Substance Brief Intervention cSBI|Enhanced care PCPs will address the serious morbidity of teen substance use during routine check-up visits using cSBI and follow up care using a new Module of CHADIS that facilitates guideline-based care. The CHADIS c-SBI Module will include pre-visit screening tools and embedded education that cover substance use and strengths and goals. It will also include reminders to the patient about their goals and commitments for change and teleprompted interview hints for the PCP. These hints will be aimed at enhancing a patient focused discussion of individual strengths and barriers related to the teens' goals in a motivational interviewing style.
32767645|NCT04689997|No Intervention|Standard care|Standard care PCPs will screen using a standard SU tool and carry out their usual health supervision visits without additional decision support.
32767646|NCT04682743|Sham Comparator|saline group|
32767647|NCT04682743|Active Comparator|ondansetron group|
32767648|NCT04682743|Active Comparator|paracetamol group|
32767649|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32767650|NCT05301985|No Intervention|Fasting group|conventional preoperative fasting protocol The participants in the Fasting group stopped oral intake at 12:00 pm, the night before surgery. After surgery the participants fasted until the recovery of function of the bowel.
32767651|NCT05301985|Experimental|Carbohydrate group|preoperative nutrition The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
32767652|NCT04331509||Symptom tracker users|No Intervention
33400234|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
32767655|NCT04275037|Experimental|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
32767656|NCT04275037|Active Comparator|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
32721300|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
32923118|NCT05490043|Experimental|ATG-101|"Dose Escalation Phase:~Will be conducted with an enhanced PDx cohort.~Dose Expansion Phase:~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
32923119|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
32721301|NCT04778176|Experimental|DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate|Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).
32923120|NCT05475925|Experimental|Part A Dose Escalation 1 mg/kg of DR-01|Subjects in this arm will initially receive 1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 6 mg/kg) thereafter for up to 25 cycles total.
32721302|NCT04457635|Experimental|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
32721303|NCT04457635|Active Comparator|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
32721304|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
32721305|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
32721306|NCT04785196|Experimental|APG-115+Toripalimab|
32721307|NCT05733819|Active Comparator|Walking without personalized rhythmic auditory stimulation|Subjects will complete a 6MWT without any auditory cues
32721308|NCT05733819|Experimental|Walking with personalized rhythmic auditory stimulation|Subjects will complete a 6MWT with personalized rhythmic auditory cues
32721309|NCT05110027|Experimental|Period 1: Enpatoran + [14C]enpatoran microtracer|
32721310|NCT05110027|Experimental|Period 2: Enpatoran + [14C]enpatoran microdose|
32721311|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
32721312|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
32721313|NCT05174026|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minute, and then undergo PET-MRI over 1 hour, 30 days before radiation therapy, and 3 and 6 months after radiation therapy.
32721314|NCT05089513|Experimental|Robotic surgery|Robotic surgery in both live donor and recipient
32721315|NCT05376813|Experimental|Experimental arm|All participants are healthy volunteers
32721316|NCT05076253|Active Comparator|Ivermectin|Ivermectin 12 mg per day for 5 plus standard care
32721317|NCT05076253|Placebo Comparator|Placebo|Placebo plus standard care
32721318|NCT04776928|Experimental|Provider-level push report notifications|Push reports will be sent via using a secure email client. The email will be sent to the email address provided to the study team by the surgeon or site.
32721319|NCT04776928|No Intervention|No intervention|Sites who did not sign Exhibit B-1.
32721320|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
32721321|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
32721322|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
32721323|NCT05723523|Experimental|CI-CDS|In clinics randomized to the CI-CDS, the providers will be given the option to use the CI-CDS tool during eligible patient encounters.
32721324|NCT05723523|No Intervention|Usual Care (UC)|In clinics randomized to UC, patients will receive usual care at their primary care visits over the accrual period (no intervention will be given).
32721325|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
32721326|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
32923121|NCT05475925|Experimental|Part A Dose Escalation 3 mg/kg of DR-01|Subjects in this arm will initially receive 3 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
33249441|NCT05301010|Active Comparator|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
33249442|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
33249443|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
33249444|NCT04012294|Experimental|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
33249445|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
32721327|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
32721328|NCT05077839|Experimental|experimental group|In the experimental group, the treatment regimen is trifluridine/tipiracil 35mg/m2 orally taken on d1-5 and d8-12, oxaliplatin 85mg/m2 and bevacizumab 5mg/kg intravenously infused on d1 and d15 every 4 weeks, up to 6 cycles. Then patients will be given trifluridine/tipiracil and bevacizumab maintenance treatment.
32721329|NCT05077839|No Intervention|control group|The control group was XELOX plus bevacizumab regimen, bevacizumab 7.5mg/kg, d1 oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 3 weeks, up to 8 cycles. Then patients will be given capecitabine and bevacizumab maintenance treatment.
33249446|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
33249447|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
33249448|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
33249449|NCT05301400|Active Comparator|Overcast implant single restauration|
33249450|NCT05301400|Active Comparator|Cad/cam direct implant restauration|
33249451|NCT05301400|Active Comparator|Cad/cam implant restauration with transepithelial pilar|
32721330|NCT05077683|Active Comparator|DAPT|aspirin (≤100mg per day) and P2Y12 inhibitors (i.e. clopidogrel 75mg per day or ticagrelor 90mg twice a day), as per current guidelines
32721331|NCT05077683|Experimental|DAPT + Direct Oral AntiCoagulants (DOAC)|aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily) and rivaroxaban 2.5mg twice daily.
32721332|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
32721333|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
32721334|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
32721335|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
32721336|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
32721337|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
32721338|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
33249452|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
33249453|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
33249454|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
32721339|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
32721340|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
32721341|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
33249455|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
33249456|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
33249457|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
33249458|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
33249459|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
33249460|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
33249461|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
33249462|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
33249463|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
32743384|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33249464|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
33249465|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
33249466|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
33249467|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
33249468|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
33249469|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
33249470|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the immediate intervention arm will have access to the MyPEEPS Mobile from the baseline visit to 3-month follow-up visit. They will continue with follow-up visits at 6 months and 9 months, but will no longer have access to the MyPEEPS Mobile past the 3-month follow-up visit.
33249471|NCT03167606|Experimental|Delayed Intervention|Study participants randomized to the delayed intervention arm will complete visits at baseline, 3 months, 6 months, 9 months, and 12 months. They will have access to the MyPEEPS Mobile from the 9-month follow-up visit until the 12-month follow-up visit.
33249472|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
32721342|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
32721343|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
32721344|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
32721345|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
32721346|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
32721347|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
32923122|NCT05475925|Experimental|Part A Dose Escalation 6 mg/kg of DR-01|Subjects in this arm will initially receive 6 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
32923123|NCT05475925|Experimental|Part A Dose Escalation 10 mg/kg of DR-01|Subjects in this arm will initially receive 10 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
32923124|NCT05475925|Experimental|Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01|This cohort would only be triggered should a DLT occur at Dose Level 1 or if recommended by the Safety Review Committee. Subjects in this arm would initially receive 0.3 to <1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 3 mg/kg) thereafter for up to 25 cycles total.
32923125|NCT05475925|Experimental|Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for LGL leukemia subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
32923126|NCT05475925|Experimental|Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for cytotoxic lymphoma subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
32923127|NCT02994017|Other|cystic fibrosis patients|
32923128|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
33249473|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
33249474|NCT01049815|Experimental|Sevelamer hydrochloride|
32721348|NCT05118451|Experimental|3d reconstruction visualization model to guide preoperative planning and surgery|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
33249475|NCT01049815|Active Comparator|Calcium carbonate|
33249476|NCT00849615|Experimental|FLOT|
33249477|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
33249478|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
33249479|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
33249480|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
33249481|NCT00849771||2|Non-operative/Conservative Care
32721349|NCT05118451|No Intervention|Based on high-quality thin slice CT images to guide preoperative planning and surgery.|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
32721350|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
33249482|NCT00941902||Patients scheduled to bariatric surgery|
33249483|NCT04088942|Experimental|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
32721351|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
32721352|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
32721353|NCT04719247|Experimental|Turmeric|Turmeric extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
32721354|NCT04719247|Experimental|Thymus Vulgaris|Thymus Vulgaris extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
32721355|NCT04719247|Experimental|Nigella Sativa|Nigella Sativa extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
32721356|NCT04719247|Experimental|Aloe Vera|Aloe Vera extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
32721357|NCT04719247|Active Comparator|Formocresol|Formocresol will be used as a dental pulp dressing material after pulpotomy to be compared with other materials.
33249484|NCT04088942|Active Comparator|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
32721358|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
32721359|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
32721360|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
32721361|NCT05094921|Experimental|Group A (Halliwick method group)|Under water exercise program according to halliwick concept which will be applied as three sessions per week for three successive months. Underwater exercises will be performed under the supervision of a certified aquatic therapist. This practitioner will instruct the child in proper techniques for performing exercises while ensuring child's safety by using flotation devices, body boards or float belts when necessary. Also the pool where the children will perform underwater exercises will be equipped with ramps, chair lifts, stairs, and handrails to facilitate a child's ability to access the pool.
32721362|NCT05094921|Active Comparator|Group B (conventional physical therapy group)|Conventional selected exercise program for 60 minutes , three sessions per week for three successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises, (3) improving postural responses, (4) Flexibility exercises, (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles) and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
32721363|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
33249485|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
32721364|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
32721365|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
32721366|NCT04457323|Experimental|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
32721367|NCT04457323|Active Comparator|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
32721368|NCT05718297|Experimental|Experimental arm|Brigatinib 180 mg once daily p.o., with seven day lead-in at 90 mg once daily, for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent
32767657|NCT04275037|No Intervention|Control Group|The control group will receive usual medical care
32767658|NCT04649593|No Intervention|according to clinical guidlines|Dystocic progress and an observed low AFL value (< 12.0 mmol/l).
32767659|NCT04649593|Experimental|intevention|"At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups.~Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started."
32923129|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
32923130|NCT05473273||Natural Cycle Protocol|"Ultrasound monitoring to monitor follicular and endometrial growth. Serial measurements of serum Lutenizing Hormone (LH), estradiol (E2), and progesterone (P4) to identify ovulation.~Minimal endometrial thickness of 7 mm is required. No progesterone supplementation. Embryo transfer (ET) will be scheduled 5 days after the day of ovulation (120 hours of P4 exposure).~Blood samples will be drawn to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 on day of ovulation (P4 rise), on the day before ET, on the day of ET and 3 and 10 days later, between 9 and 12 am.~A blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days in case of pregnancy, between 9 and 12 am.~In case of pregnancy, a blood test to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 will be performed at 5 weeks +/- 3 days between 9 and 12 am.."
32923131|NCT05473273||Hormone Replacement Therapy Protocol|"Ultrasound monitoring of endometrial growth and exclude growing follicle~Oral Estradiol Valerate (Progyluton) 4 mg on cycle day 2 at 7 pm for 2 days. On 3rd day, increase dose to 6 mg. The dose may be increased based on endometrial thickness.~Once endometrial thickness is at least 7 mm and trilaminar, after 10-15 days of Estradiol Valerate administration, start Endometrin 100 mg at 1 pm and 9 pm. From 2nd day onwards increase to 3 times daily. Continue Progyluton & Endometrin until 12 weeks of pregnancy~ET on the 5th full day of Endometrin administration~Blood test to measure PIBF, IL-17, IFγ, IL-4, IL-10 and TGF-ß1 on the 1st day of Endometrin supplementation (before 1st administration), on the 4th day of Endometrin administration, on the day of ET and 3 and10 days after, 4 to 7 hours after the morning administration.~Blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days if pregnancy."
32923132|NCT05451043|Experimental|Pancreatic Cancer|Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
32923133|NCT05451043|Experimental|Hepatocellular Cancer|Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
32721369|NCT05718297|Active Comparator|Control arm|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
32721370|NCT04768036|No Intervention|Usual Medical Care|As per standard of care
32721371|NCT04768036|Experimental|"SMART on FHIR application of the IMPROVE DD VTE CPR"|"This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients.~Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records.~2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm."
32721372|NCT04448431|Experimental|Vortioxetine|8 weeks treatment
32721373|NCT04448431|Active Comparator|Desvenlafaxine|8 weeks treatment
32721374|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
32721375|NCT04784962|Sham Comparator|Control Arm|Sham device
32721376|NCT04784962|Experimental|Intervention Arm|Standard rehabilitation care including physiotherapy + Adjunctive Neuromuscular Stimulation Device Usage
32721377|NCT05094765|Experimental|FMT|60 capsules per day for 2 day
32721378|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
32721379|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
32721380|NCT05713149||Subjects with osteomyelitis-associated pressure ulcers|Subjects with neuromotor disability and admitted for the treatment of osteomyelitis-associated pressure ulcers
32721381|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
32721382|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
32721383|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
32721384|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
32721385|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
32721386|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
32721387|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
32721388|NCT05161975|Placebo Comparator|Placebo|Food supplement tablets do not contain vitamin K2
32721389|NCT05161975|Experimental|Vitamin K2|Food supplement tablets contain vitamin K2
32721390|NCT05712291|Other|total knee arthroplasty using the active robotic system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
32923134|NCT05451043|Experimental|Biliary Tract Cancer|Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
32923135|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
32721391|NCT05712291|Other|total knee arthroplasty using the standard manual technic|Primary total knee arthroplasty using the standard recommended set of instruments
32721392|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
32721393|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
32923136|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
32923137|NCT02700295||Orthokeratology contact lens group|
32923138|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
32721394|NCT05707377|Experimental|Part 1 and Part 2: Zanubrutinib High dose|Participants will receive Zanubrutinib twice daily
32923139|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
32923140|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
32923141|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
32923142|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
32721395|NCT05707377|Experimental|Part 2: Zanubrutinib Low Dose|Participants will receive Zanubrutinib once daily
32721396|NCT05707377|Active Comparator|Tacrolimus|Participants will receive tacrolimus capsules for 64 weeks
32923143|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
32923144|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
32923145|NCT02478775|Experimental|Frequent Blood Sampling, Degarelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period. This arm was terminated due to Adverse Events and the study was continued with the Cetrorelix product.
32923146|NCT02478775|Experimental|Frequent Blood Sampling, Cetrorelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Cetrorelix blockade over a 2-day period.
32923147|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
32923148|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
32721397|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
32721398|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
32721399|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
32721400|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
32721401|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
32746110|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
32923149|NCT02414347||Experimental F 18 T807|
32923150|NCT01783561|Active Comparator|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
32923151|NCT01783561|Placebo Comparator|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
32923152|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
32923153|NCT01783639|Experimental|Arm 1|"Device: WIRION™ Embolic Protection System~Interventions: Carotid Artery Stent"
32923154|NCT04744727|Active Comparator|paracetamol group|Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
32923155|NCT04744727|Active Comparator|pethidine group|Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
32923156|NCT02243527|Experimental|Inspiratory Muscle Training|
32721402|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
32721403|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
32923157|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
32721404|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
32923158|NCT02454179|Experimental|Arm 1|pembrolizumab
32923159|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
32923160|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
32923161|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
32721405|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
32923162|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
32721406|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
32721407|NCT04608955|Experimental|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
32923163|NCT02907203|Experimental|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
32721408|NCT04608955|Experimental|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
32721409|NCT04608955|Experimental|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
32721410|NCT04608955|Active Comparator|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
32923164|NCT01386437||Fungal infections|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
32721411|NCT04608955|Experimental|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
32721412|NCT04608955|Active Comparator|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
32923165|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
32721413|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
32721414|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
32721415|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
32721416|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
32721417|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
32721418|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
32721419|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
32746111|NCT04794777|Experimental|Experimental arm|Individualised therapy based on results of the PSMA PET/CT.
32923166|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
32923167|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
32923168|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~Ocular and systemic health data will be extracted from the study participant's medical record."
32923169|NCT04743869|Active Comparator|KYPHON® ActivOs™10 Bone Cement with hydroxyapatite|As a reference device KYPHON® ActivOs™10 Bone Cement with hydroxyapatite (Medtronic) for treatment of vertebral compression fractures will be used. It is a polymethylmethacrylate (PMMA) bone cement containing hydroxyapatite (HA) for use in the treatment of patients with vertebral compression fractures (VCFs) who are undergoing minimally invasive surgery with KYPHON® Balloon Kyphoplasty. This bone substitute has already been approved and is in use in the patients at the age of 50 or older.
32923170|NCT04743869|Experimental|KyphOs FS™|The test device KyphOs FS™ will be used in patients at the age of 50 and older in order to prove its superiority over the currently used PMMA bone cement.
32923171|NCT02260531|Experimental|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive~Cabozantinib- orally administered daily per treatment cycle, 60 mg per day~Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
32923172|NCT02260531|Experimental|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
32923173|NCT02260531|Experimental|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
32923174|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
32923175|NCT04744103|Experimental|TCA peal|Patients will have their actinic cheilitis treated with a TCA peal.
32923176|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
32923177|NCT02115997|Experimental|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
32923178|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
32923179|NCT02848001|Experimental|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
32923180|NCT02848001|Experimental|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
32923181|NCT01647763|Experimental|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
32923182|NCT01647763|Active Comparator|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)~Resection using a circular stapler"
32923183|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
32923184|NCT02839733||Healthy Volunteer|Children and young adults healthy volunteer
32923185|NCT01641055|Experimental|Salmon protein hydrolysate|
32923186|NCT01641055|Experimental|Herring protein hydrolysate|
32923187|NCT01641055|Sham Comparator|Cod protein|
32923188|NCT01641055|Placebo Comparator|Milk protein|
32923189|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
32923190|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
32923191|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
32923192|NCT01247207|Experimental|Ataluren|Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day and 20 mg/kg in the evening).
32923193|NCT01787383|Active Comparator|Ingenol mebutate gel 0.05 %|
32923194|NCT01787383|Active Comparator|Ingenol mebutate gel 0.015 %|
32923195|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
32923196|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
32923197|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
32923198|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
32923199|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
32923200|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
32923201|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
32923202|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
32923203|NCT00937001|Experimental|Biopsy/Ultrasound|
32923204|NCT01788631|Active Comparator|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
32923205|NCT01788631|Placebo Comparator|Placebo Arm|Placebo infused over 48 hours
32923206|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
32923207|NCT01789255|Experimental|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
32923208|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32923209|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32923210|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32923211|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32923212|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
32923213|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
32923214|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
32923215|NCT01807585|Experimental|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
32923216|NCT01807585|Active Comparator|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
32923217|NCT01807585|Experimental|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
32923218|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
32923219|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
32923220|NCT01808755|Experimental|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
32923221|NCT01808755|Active Comparator|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
32923222|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
32923223|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
32923224|NCT01790581|Active Comparator|Balance Training|
32923225|NCT01790581|Experimental|Balance Training w/ STARS|
32923226|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
32923227|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane
32923228|NCT00568139||Control|Patients with adrenocortical carcinoma not treated with mitotane
32923229|NCT02648165|Experimental|ABM +|Attention Bias Modification
32923230|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
32721420|NCT04579783|Active Comparator|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
32923231|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
32923232|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
32923233|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
32923234|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
32721421|NCT04579783|Active Comparator|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
32721422|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
32923235|NCT02469389|Experimental|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
32923236|NCT02469389|Active Comparator|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
32923237|NCT01790659|Experimental|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
32923238|NCT01790659|Experimental|Paromomycin|Paromomycin alone
32721423|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
32721424|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
32923239|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
32923240|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
32923241|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
32923242|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
32923243|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
32721425|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
32721426|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
32721427|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
32721428|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
32721429|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
32721430|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
33249486|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
32721433|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
32923244|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
32923245|NCT00681655|Experimental|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
32721434|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
32923246|NCT00338065|Experimental|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
32923247|NCT00338065|Experimental|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
32923248|NCT00338065|Experimental|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
32923249|NCT00338065|Active Comparator|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
32923250|NCT01811875|Experimental|Optivate 500IU|Optivate 500IU
32923251|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
32923252|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
32923253|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
32721435|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
32721436|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
32923261|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
32923262|NCT00422045|Experimental|1|Low Level Laser Therapy
32923263|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
32923264|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
32923265|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
32923266|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
32923267|NCT01734889|Experimental|Orfadin suspension|Drug: nitisinone, oral suspension
32923268|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
32923269|NCT01735981|Other|control|hand-held video game control
32923270|NCT01736527|Experimental|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
32721437|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
32721438|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
32721439|NCT04930328||Retrospective Data Collection|Retrospective Data Collection
32721440|NCT05108974|Experimental|3 months choline bitartrate|Over the 9-month study, participants will receive a total of 3 months of choline bitartrate (19 mg/kg) and a total of 6 months of placebo
32923271|NCT01795105||Aripiprazole (Abilify® Tablets/Abilify® ODT)|
32923272|NCT01796665|Experimental|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
32923273|NCT01796665|Active Comparator|Reference product|Acanya Gel applied to the affected areas of the face once daily.
32923274|NCT01796665|Placebo Comparator|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
32923275|NCT01796977|Active Comparator|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
32721441|NCT05108974|Experimental|6 months choline bitartrate|Over the 9-month study, participants will receive a total of 6 months of choline bitartrate (19 mg/kg) and a total of 3 months of placebo
32721442|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
32721443|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
32721444|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
32721445|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
32721446|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
32721447|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
32721448|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
32743385|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
32743386|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32743387|NCT04956237||Tenonian surgery|Hospital recruitment with outpatient surgery without the presence of an anesthesiologist, without loco-regional anesthesia and without intravenous route
32743388|NCT04956237||Peribulbar surgery|Gold standard: City recruitment with outpatient surgery with the presence of an anesthesiologist and with loco-regional anesthesia
32743389|NCT02314559|Experimental|Propofol (manual titration)|
32743390|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
32743391|NCT04934709|Experimental|PBMT-sMF|Volunteers underwent intervention (active PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
32743392|NCT04934709|Placebo Comparator|Placebo|Volunteers underwent intervention (placebo PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
32743393|NCT04934631||CBT-ED trainees and therapists.|Qualified clinicians delivering CBT-ED throughout a variety of treatment settings, working with adult eating disorder patients. Clinicians will audio-record CBT-ED therapy sessions with their eating disorder patients.
32743394|NCT04934631||Eating Disorder patients.|Adult (18+ years) eating disorder patients currently accessing CBT-ED from one of the CBT-ED therapists/trainees stated above. Patients will have one of their therapy sessions audio-recorded.
32743395|NCT04934631||Raters/Judges.|Either experts or non-experts in the field of CBT-ED. Raters will use the CBTS-ED to assess clinician competence when listening to the therapy session audio-recordings.
32743396|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
32743397|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
32743398|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
32743399|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
32743400|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
32743401|NCT04929873|Placebo Comparator|routine treatment|routine nursing
32743402|NCT04929873|Experimental|Experimental group|Immediately after the establishment of the side branch cycle, the closed transdone is connected for real-time monitoring of pressure, and clinical nursing practice is guided by transdictor pressure.
32743403|NCT04486547|No Intervention|Follow up Posttest and HbA1c|56.0% of the adolescents with type 1 diabetes were aged 12-14 years and 52.0% were male in the control group (n=25)
32743404|NCT04486547|Experimental|Information Motivation Behavioral Skills Based Intervention|52.0% of the adolescents with type 1 diabetes were aged 15-18 years and 52.0% were female(n=25)
32743405|NCT03239405||SCS|Treated via suction callibrated system
32743406|NCT03239405||Bougie|Treated with multiple tubes & bougie
32743407|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
32743408|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
32743409|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
32743410|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
32743411|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
32743412|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
32721449|NCT05161585|Experimental|ctDNA dynamic monitoring + routine postoperative follow-up|"ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total. At the same time, routine postoperative follow-up is given.~To be pointed out, after the completion of the adjuvant chemotherapy, if the ctDNA test indicates positive, patients will immediately perform chest, abdominal and pelvic CT and other imaging tests to determine whether there is recurrence /metastasis. If it is not confirmed, repeat the imaging review every two months, and continue to perform ctDNA test every three months. If the following ctDNA test is negative for two consecutive times, the above imaging reexamination will return to the routine follow-up frequency. In addition, during the follow-up, the following situations may occur: the imaging examination has found recurrence/metastasis, but the ctDNA test is still negative. At this time, the patient will be informed and treated in time of the recurrence/metastasis."
32721450|NCT05161585|No Intervention|routine postoperative follow-up|Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
32721451|NCT04930250|Experimental|Oat bran fibre processed with method A|Beverage powder with 12% oat bran processed with method A
32721452|NCT04930250|Experimental|Oat bran fibre processed with method B|Beverage powder with 12% oat bran processed with method B
32721453|NCT04930250|Experimental|Oat bran fibre processed with method C|Beverage powder with 12% oat bran processed with method C
32721454|NCT04930250|Active Comparator|Minimally-processed oat bran (positive control)|Beverage powder with minimally-processed oat bran (Positive Control)
32721455|NCT04930250|Placebo Comparator|Readily-digestible carbohydrate (negative control)|Beverage powder with readily digestible carbohydrate (Negative Control)
32721456|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
32721457|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
32721458|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
32721459|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
32721460|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
32721461|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
32721462|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
32721463|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
32721464|NCT04286113|Active Comparator|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
32721465|NCT04286113|Experimental|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
32721466|NCT05094375|Experimental|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
32721467|NCT05094375|Active Comparator|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
32721468|NCT04458181|Experimental|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
32721469|NCT04458181|No Intervention|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
32721470|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
32721471|NCT02738801|Placebo Comparator|Placebo QD|
32721472|NCT04345861|Active Comparator|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
32721473|NCT04345861|Experimental|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
32721474|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
32721475|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
32746112|NCT04794777|Active Comparator|Control arm|Standard salvage therapy. Results of PSMA PET/CT blinded.
32721476|NCT04305067|Experimental|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
32721477|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
33249487|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
33249488|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
33249489|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
33249490|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
33249491|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
32721478|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
32923276|NCT01796977|Placebo Comparator|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
32923277|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
33249492|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
33249493|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
33249494|NCT05323058|Experimental|tulsi extract|4% tulsi extract as intervention
32923278|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
32923279|NCT02586857|Experimental|Cohort 1|ACP-196 200 mg administered orally (PO) twice per day (BID)
32923280|NCT02586857|Experimental|Cohort 2|ACP-196 400mg administered orally (PO) once per day (QD).
32923281|NCT01798225|Placebo Comparator|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
32923282|NCT01798225|Experimental|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
32923283|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
32923284|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
32923285|NCT01800877|Other|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
32923286|NCT01800877|Other|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
32923287|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
32923288|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
33073384|NCT02233829|Active Comparator|Evening MRI/PET/Raclopride/IV Methylphenidate Session|The PET [11C] raclopride scan will be done between 5-7 PM. After iv catheters are inserted blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plus-infusion method for [11C]raclopride and the administration of intravenous MP (0.5 mg/kg) forty-five minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
33249495|NCT05323058|Active Comparator|benzydamine hydrochloride|0.15% benzydamine hydrochloride
33249496|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
33249497|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
33249498|NCT00552760|Experimental|Ramelteon|8 mg
33249499|NCT00552760|Placebo Comparator|Placebo|
33249500|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
33249501|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
33249502|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
33249503|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
33249504|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
33249505|NCT04012372|Experimental|ROSA water|Ad libitum hydration with ROSA oligomineral water
33249506|NCT04012372|Active Comparator|Control water|Ad libitum hydration with other waters
33249507|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
33249508|NCT02562534|Other|Patients with conductive troubles|Patients with conductive troubles
33249509|NCT02562534|Other|Patients with rhythm troubles|Patients with rhythm troubles
33249510|NCT02562534|Other|Volunteers|Volunteers with normal ECG
33249511|NCT00852579|Experimental|1|Active treatment.
33249512|NCT00852579|Placebo Comparator|2|Placebo control group.
33249513|NCT00942058||CA9 level|Serum and urinary CA9 level
33249514|NCT02562456|Active Comparator|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
33249515|NCT02562456|Experimental|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
33249516|NCT00850083||Children in the ED|
32923289|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
32923290|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
32923291|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
32721479|NCT05094297|Experimental|Investigate the effects of an exercise intervention on U.S. Veterans.|A total of 25 U.S. Veterans (≥ 18 years of age), who suffer from pain, fatigue, low energy levels or are unable to physically do things they were once able to do, will be enrolled.
32721480|NCT03504059|No Intervention|Control|The usual educational program is applied
32721481|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
32721482|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
32721483|NCT04438473|Experimental|Pectin|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
32721484|NCT04438473|Placebo Comparator|Control|standard formula enteral nutrition feeding without pectin for 7 days
32721485|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
32721486|NCT04266379|Experimental|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
32721487|NCT04266379|Active Comparator|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
32721488|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
32721489|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
32721490|NCT05095545|Experimental|Group 1|"AV5080 80 mg/day (80 mg in the morning + placebo in the evening)"
32721491|NCT05095545|Experimental|Group 2|"AV5080 160 mg/day (80 mg in the morning + 80 mg in the evening)"
32721492|NCT05095545|Placebo Comparator|Group 3|"Placebo (placebo in the morning + placebo in the evening)"
32721493|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
32721494|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
32721495|NCT05062174||mifepristone + surgery|Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery
32721496|NCT05095467|Experimental|Group A|"patients with locally resectable GC (cT4aNxM0, P0)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
32721497|NCT05095467|Experimental|Group B|"patients with peritoneal metastasis stage P1a or P1b (cTxNxM1, P1a or P1b)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
32721498|NCT05095467|Experimental|Group C|"group C is patients with peritoneal metastasis stage P1c (cTxNxM1, P1c)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
32721499|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
32721500|NCT03270982||Comprehensive SRS Replacement|Comprehensive SRS Device
32721501|NCT05095077|Experimental|Tadalafil|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
32721502|NCT05095077|Placebo Comparator|Placebo|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
32721503|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
32721504|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
32721505|NCT04234477|Experimental|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
32721506|NCT04234477|Experimental|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
32721507|NCT04234477|Active Comparator|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
32721508|NCT04533711|Experimental|OA-PCP|Participants assigned to the OA-PCP intervention will receive an initial physical activity (PA) coaching call then, 5 more calls over the course of 12 months. Participants, if they agree, will also receive monthly check-in emails between phone calls.
32721509|NCT04533711|Placebo Comparator|Attention Control|Participants assigned to the Attention Control group will receive the same number of phone calls over the course of 12 months, focused on understanding osteoarthritis (OA) and current information on treatment options. Participants, if they agree, will also receive monthly check-in emails between phone calls.
32721510|NCT02449031||TOBI® PODHALER® cohort|
32721511|NCT02449031||non-TOBI® PODHALER® cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
32721512|NCT04232449|Active Comparator|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
32721513|NCT04232449|Placebo Comparator|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
32721514|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
32721515|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
32721516|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
32743413|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
32743414|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
32743415|NCT04486469|Experimental|Subjects with Irritable bowel syndrome|Experimental group is formed with 24 patients diagnosed with IBS treated in the digestive system service of the Virgen de la Arrixaca and Reina Sofía General University Hospitals.
32743416|NCT04486079|Experimental|Carbohyrate loading|Group A will receive 400ml of the carbohydrate rich drink, Nutricia preOp 2 hours before operation. This is the intervention group.
32743417|NCT04486079|No Intervention|Fasting|Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
32743418|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
32743419|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
32743420|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
32743421|NCT05387681|Experimental|Envafolimab, Endostatin and SOX regimen|Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen
32743422|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
32743423|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
32743424|NCT04485845|Active Comparator|metformin treated group|A group of patients treated with a daily dose of metformin
32743425|NCT04485845|Experimental|vildagliptin treated group|A group of patients treated with a daily dose of vildagliptin
32743426|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
32743427|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
32721517|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
32721518|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
32721519|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
32923292|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
32923293|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
32923294|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
32923295|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
32923296|NCT02479763|No Intervention|Conventional loss-of-resistance|
32923297|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
32721520|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
32721521|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
32721522|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
32721523|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
32721524|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
32721525|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
32923298|NCT04744493|Experimental|treatment arm of Exablate 4000 as a single arm|Only one arm of treatment by Exablate 4000 was established.
32923299|NCT04744571|Experimental|DCB group|Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions
32721526|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
32923300|NCT04744571|Active Comparator|DES group|Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions
32923301|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
32923302|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
32923303|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
32923304|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
32721527|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
32721528|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
32923305|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
32923306|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
32721529|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
32721530|NCT04458415|Experimental|TPR Arm|Surgeon will use the Traxi Panniculus Retractor to retract the panniculus during cesarean section.
32721531|NCT04458415|Active Comparator|Silk Tape Arm|Surgeon will use silk tape to retract the panniculus during cesarean section.
32721532|NCT05094063|Experimental|experimental group|Training will be given to the patients in the experimental group.
32721533|NCT05094063|No Intervention|control group|untrained patient group
32721534|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
32767660|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
32767661|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
32767662|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
32767663|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
32767664|NCT04636333|Experimental|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
32923307|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
32923308|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
32923309|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
32923310|NCT02521259||normal BIS group|BIS range from 40 to 60
32923311|NCT02257177|Active Comparator|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32923312|NCT02257177|Active Comparator|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32923313|NCT02257177|Active Comparator|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32923314|NCT02257177|Active Comparator|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32923315|NCT02257177|Active Comparator|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32923316|NCT02257177|Active Comparator|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32721535|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
32923317|NCT02257177|Placebo Comparator|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
32721536|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
32721537|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
32721538|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
32721539|NCT04458493|Experimental|control|no supplement will be provided on the day of the experiment
32721540|NCT04458493|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 400ml, 20% solution)
32923318|NCT02257177|Active Comparator|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
32923319|NCT02257177|Active Comparator|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
33249517|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
33249518|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
33249519|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
33249520|NCT00745680||A|A: AMI patient
33249521|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
33249522|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
33249523|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
33249524|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
32721541|NCT05094999|Experimental|Intervention group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
32721542|NCT05094999|Sham Comparator|Control group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
32721543|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
32923320|NCT02257177|Active Comparator|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
32923321|NCT02257177|Placebo Comparator|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
32721544|NCT05093985|Experimental|Neuromuscular electrical stimulation with blood flow restriction|This is the intervention condition
32923322|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
32923323|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
32923324|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
33249525|NCT05300932|Experimental|Baricitinib 4mg|4mg of oral Baricitinib everyday for 48 weeks.
32721545|NCT05093985|No Intervention|No intervention|This is the control condition
32721546|NCT03523663||Control|healthy children without ADHD or other mental health issues
32923325|NCT01815229|Experimental|tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
32923326|NCT01815229|Placebo Comparator|Healthy Control|To replicate activation, neutrophils were isolated from 30mL blood of healthy volunteers and cocultured with TLF from subjects with or without sore throat pain.
32923327|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
32923328|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
32923329|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
32923330|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
32923331|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
32923332|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
32923333|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
32923334|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
32923335|NCT00001595||Patients with pituitary tumors or hypothalmic defects|Patients with pituitary tumors or hypothalmic defects
32923336|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
32923337|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
32923338|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
32923339|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
32923340|NCT01879345|Placebo Comparator|Placebo|placebo tablets
32923341|NCT04341389|Active Comparator|Arm 1|1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
32923342|NCT04341389|Active Comparator|Arm 2|5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
32923343|NCT04341389|Placebo Comparator|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
32721547|NCT03523663||ADHD|children diagnosed with ADHD
33249526|NCT05300932|Active Comparator|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
33249527|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
33249528|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
32721548|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
32721549|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
32923344|NCT05329207|Experimental|(Intervention group) Hearing impaired adolescent experimental group|Hearing Impaired Adolescent Group implemented Web-Based Adolescent Health Promotion Education Program
32923345|NCT05329207|No Intervention|(Control group) Hearing impaired adolescent control Group|Hearing Impaired Adolescent Group that did not apply Web-Based Adolescent Health Promotion Education Program
32923346|NCT05329051|Experimental|SCTV01E Group|Participants will receive one dose of SCTV01E on Day 0
32923347|NCT05329051|Active Comparator|Comirnaty Group|Participants will receive one dose of Comirnaty on Day 0
32923348|NCT01804075|Active Comparator|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Methadone 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
33249529|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
33249530|NCT00850161|Active Comparator|aspart|Subcutaneous administration
32923349|NCT01804075|Active Comparator|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Morphine 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
32923350|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
32923351|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
32923352|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
32923353|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
32923354|NCT02530541|Experimental|CHG 1 min|1 min application time
32923355|NCT02530541|Experimental|CHG 2 min|2 min application time
32721550|NCT05374785|Experimental|Arm 1|60 mg BID of CPL409116
32721551|NCT05374785|Experimental|Arm 2|120 mg BID of CPL409116
32923356|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
32923357|NCT02416973|Other|Sham of Provant|Sham of Provant
32923358|NCT02416973|Other|Active Treatment|Active Provant Treatment
32923359|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
32923360|NCT01804465|Experimental|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
32923361|NCT01804465|Experimental|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
32923362|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
32923363|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
32923364|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
32721552|NCT05374785|Experimental|Arm 3|240 mg BID of CPL409116
32721553|NCT05374785|Placebo Comparator|Arm 4|Placebo
32721554|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
32721555|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
32721556|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
32721557|NCT05093907|Experimental|BEY1107 + Capecitabine|Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.
32923365|NCT01805089|Active Comparator|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
32923366|NCT01805089|Placebo Comparator|Placebo|Taken orally, once per day, at/around 9:00pm
32923367|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
32923368|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
32923369|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
32721558|NCT03793543|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
32721559|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
32721560|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
32721561|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
32721562|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
32721563|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
32721564|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
32721565|NCT05093751||Meningioma patients|
32721566|NCT03783091|Experimental|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
32923370|NCT01816711||Hip fracture, Frail elderly, Non-supplemented|Frail elderly with a hip fracture who did not received vitamin D supplementation
32923371|NCT01816711||Hip fracture, Frail elderly, Supplemented|Frail elderly with a hip fracture who received vitamin D supplementation
32923372|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
32923373|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
32923374|NCT02417831|Active Comparator|tamsulosin capsules|
32923375|NCT02417831|Active Comparator|tamsulosin HCl capsules|
32923376|NCT02271451|Experimental|Q collar|subjects wearing the q collar
32923377|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
32923378|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
32923379|NCT02273323|Experimental|Tea|Black tea
32767665|NCT04636333|Experimental|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
32767666|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
32767667|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
32767668|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
32767669|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
32767670|NCT04636333|Placebo Comparator|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
32767671|NCT04636333|Placebo Comparator|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
32767672|NCT04636177|Active Comparator|Standard Physiotherapy Rehabilitation (SPR)|Sessions are individually-tailored and based on the Guide to Physical Therapy Practice 3.0 consisting of 1) therapeutic exercise, 2) balance and proprioception, 3) strength training, and 4) use of modalities (e.g., heat/cold pack). Patients will be given a structured Home Exercise Program (HEP) with prescribed exercises for home. SPR participants will be allocated a VR headset for recreational use.
32767673|NCT04636177|Experimental|Pain Rehabilitation Virtual Reality (PRVR)|Sessions will follow the same guidelines as SPR, with half of the physiotherapy (PT) sessions delivered in virtual reality (VR). VR in PT will engage participants in a series of immersive games customized to align with individual PT needs. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP.
32767674|NCT04084561|Experimental|HRHA|High Risk, High Ancestry
32767675|NCT04084561|Experimental|LRLA|Low Risk, Low Ancestry
32767676|NCT04084561|Experimental|HRLA|High Risk, Low Ancestry
32767677|NCT04084561|Experimental|LRHA|Low Risk, High Ancestry
32767678|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
32767679|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
32767680|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
32767681|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
32767682|NCT04435561|Experimental|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).~The muscles that will receive dry needling are the following ones:~Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.~Lower limb: gastrocnemius, soleus and anterior tibial muscles."
32767683|NCT04435561|Other|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
32767684|NCT04288687|Other|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
32767685|NCT04481737|Experimental|PDTA-IIMR|
32767686|NCT04481737|Active Comparator|Peer support|
32767687|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
32767688|NCT04481581|Experimental|Intervention arm- Oxygen titration with electronic alerts|Oxygen titration will be done based on electronic alerts and decisions support tool by Respiratory Therapists, if FiO2=> 0.4 and SpO2 =>94% for more than 45 minutes
32767689|NCT04481581|No Intervention|Control Arm- Oxygen titration by one time physician orders|Oxygen titration will be done ventilator management guidelines for the medical intensive care unit. Titration is done by one-time orders.
32767690|NCT01477957||Surgery|bariatric surgery
32767691|NCT04481113|Experimental|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
32767692|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
32767693|NCT04485481|Experimental|Experimental: Cohort 1:1 - 1:6 ADX-914|ADX-914 single SC dose
32767694|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 1:1 - 1:6 placebo|Placebo single SC dose
32767695|NCT04485481|Experimental|Experimental: Cohort 2:1- 2:3|ADX-914 multiple SC dose once every 2 weeks for 6 weeks
32767696|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 2:1- 2:3|Placebo multiple SC dose once every 2 weeks for 6 weeks
32923380|NCT02273323|Placebo Comparator|Placebo|Placebo
32721567|NCT03783091|Placebo Comparator|Saline Placebo|Single IV saline administered over a 10-15 minute period.
32721568|NCT05057481|Active Comparator|MMF arm|
32721569|NCT05057481|Active Comparator|Rituximab arm|
32721570|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
32721571|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
32721572|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
32721573|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
32923381|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
32923382|NCT02274649|Active Comparator|Control|Control group receiving general peer support
32923383|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
32923384|NCT05328817|Experimental|Erythromycin|Receive 1) erythromycin 250 mg iv every 6 hours for 48 hours followed by 333 mg orally (pills) every 8 hours for 5 days
32923385|NCT05328817|Experimental|Azithromycin|Receive azithromycin 500 mg iv daily for 48 hours followed by 500 mg orally (pills) for 5 days.
32721574|NCT05374707|Experimental|The motivational interviewing group|"The data of the study were collected through online questionnaires. An motivational interviewing lasting 30 minutes on average, both online and face-to-face, was carried out with the experimental group. Four reminder text messages were sent to the experimental group in a one-month period.~One month after the interview was carried out and Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale were completed as a pretest for the experimental group, the scales were completed again as a post-test."
32721575|NCT05374707|No Intervention|The group in which no motivational interviews were conducted|The control group, on the other hand, were asked to fill in Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale as a pretest, and again a month later as a post-test.
32721576|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
32721577|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
32721578|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
32721579|NCT04616365|Experimental|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
32721580|NCT04993911|Experimental|Balance training + conventional exercises|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~Walking forward Walking backward Side stepping Walk heel to toe Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
32923386|NCT05328739|Experimental|Home care group|"The home care program included education, counseling and nursing care to determine and meet the self-care/dependant care needs of patients and caregivers at home after brain surgery.~At preoperative period (PRP) an average of 90-120 minutes of training was given to both the patient and the caregiver until the patient was discharged. At this stage, the training was carried out in order to prepare the patient and caregiver for the transition to home. At postoperative period (POP) two home visits were made within the first month following the discharge, planned for education, counseling and nursing care. The first home visit was made in the first week after discharge (10-18 days after surgery), and the second home visit was made 30-40 days after surgery. Then, in the home visits made once in the 2nd, 3rd and 4th months.No home visits were made between the 4th-month attempt and the 6th month, but telephone counseling was provided when necessary. Home visits ranged from 60 to 120 minutes."
32923387|NCT05328739|No Intervention|Control group|The patient received routine care in the hospital until discharge. Three home visits were made to collect the data of patients and caregivers in the 1st and 3rd and 6th months of POP after discharge, but no intervention was made. The visits took about 30-45 minutes.
32923388|NCT05328583|Experimental|Treatment group A（Part A）|Drug1: HRS5685, dose 1; Drug2: Placebo
32923389|NCT05328583|Experimental|Treatment group B（Part A）|Drug1: HRS5685, dose 2; Drug2: Placebo
32923390|NCT05328583|Experimental|Treatment group C（Part A）|Drug1: HRS5685, dose 3; Drug2: Placebo
32923391|NCT05328583|Experimental|Treatment group D（Part A）|Drug1: HRS5685, dose 4; Drug2: Placebo
32743428|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
32743429|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
32743430|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
32743431|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
32743432|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
32923392|NCT05328583|Experimental|Treatment group E（Part A）|Drug1: HRS5685, dose 5; Drug2: Placebo
32923393|NCT05328583|Experimental|Treatment group F（Part A）|Drug1: HRS5685, dose 6; Drug2: Placebo
32923394|NCT05328583|Experimental|Treatment group G（Part B）|Drug1: HRS5685, dose 3; Drug2: Placebo
32923395|NCT05328583|Experimental|Treatment group H（Part B）|Drug1: HRS5685, dose 4; Drug2: Placebo
32721581|NCT04993911|Active Comparator|Only conventional|"CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
32923396|NCT05328427|Active Comparator|Stopping|Discontinuation of nucleoside analogue treatment
32721582|NCT02228590|Other|APL-130277|open label baseline comparison
32721583|NCT03503279|No Intervention|Macintosh Laryngoscope|
32923397|NCT05328427|No Intervention|Continue|Treatment with nucleoside analogue continued
32923398|NCT05748535|Experimental|Unilateral Right Ear|Auricular vagus nerve stimulation performed through the unilateral right ear.
32923399|NCT05748535|Experimental|Unilateral Left Ear|Auricular vagus nerve stimulation performed through the unilateral left ear.
32923400|NCT05748535|Experimental|Bilateral Ear|Auricular vagus nerve stimulation performed through the bilateral ear.
32923401|NCT01816945|Experimental|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
32923402|NCT01816945|No Intervention|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
32923403|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
32923404|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
32721584|NCT03503279|Active Comparator|McGrath MAC® Video Laryngoscope|
32721585|NCT04489537|Experimental|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
32923405|NCT01817491|Active Comparator|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
32923406|NCT01817491|Active Comparator|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
32721586|NCT04489537|Active Comparator|Standard of Care|Standard of care administered on-demand during bleeding episodes
32721587|NCT05374629|Experimental|The Intervention group had Shared Decision Making of smoking cessation.|The intervention group had the shared decision-making of smoking cessation which was guided by the smoking cessation health educator, and it containing the nicotine addiction, the impact of smoking on health, the methods and difficulties about smoking cessation, and the way of decision.
32721588|NCT05374629|No Intervention|The control group received routine smoking cessation health education|The control group received routine smoking cessation health education by another smoking cessation health educator, and it containing the harm of smoking, the benefits of quitting smoking, smoking cessation methods, and second-generation smoking cessation .
32923407|NCT04341545|Experimental|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
32923408|NCT04341545|Placebo Comparator|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
32923409|NCT05328271|Placebo Comparator|Placebo|Maltodextrin
32923410|NCT05328271|Active Comparator|1500 mg L-Valine|1500 mg L-Valine
32923411|NCT05328271|Experimental|250 mg Beta-Aminoisobutryic Acid|250 mg Beta-Aminoisobutryic Acid
32923412|NCT05328271|Experimental|500 mg Beta-Aminoisobutryic Acid|500 mg Beta-Aminoisobutryic Acid
32923413|NCT05328271|Experimental|1500 mg Beta-Aminoisobutryic Acid|1500 mg Beta-Aminoisobutryic Acid
32721589|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
32923414|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
32721590|NCT04932057|Experimental|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
32721591|NCT04932057|Experimental|Action Observation (AO Group)|Participants will watch a person while performing an upper extremity functionality test.
32721592|NCT04932057|Active Comparator|Action Practice|Participants will perform an upper extremity task 4 more times.
32721593|NCT04932057|Placebo Comparator|Observation|Participants will watch a slide show which will only contain landscapes.
32721594|NCT04932057|No Intervention|Control|Participants will wait without any performance till the second assesment.
32721595|NCT04784182|Experimental|Synbiotic supplement group|Daily consumption of pills containing prebiotics and probiotics
32923415|NCT02481557|No Intervention|No Treatment|No Treatment
32923416|NCT01818427|Experimental|plasma|infusion of 2 units of plasma
32923417|NCT01818427|No Intervention|standard air medical care|control group
32923418|NCT05328193|Active Comparator|Teaching Kitchen Outreach|All participants (both the intervention and control condition) will receive to 11 weekly short (about 2-3 minutes) Teaching Kitchen Outreach (TKO) videos. Recipe specific groceries will be delivered to participants' homes by a third party grocery delivery company, or will be available for pickup at a central location(s). These recipes reflect foods that can be purchased with SNAP and WIC and include tested meals and snacks that were developed and evaluated in person in Parks and Recreation after-school programming.
32923419|NCT05328193|Experimental|Healthier Families, COVID Edition|Those randomized to the intervention condition will also receive a 12-weekly health coach via a virtual platform (such as Zoom, FaceTime, or What's App) to provide an adapted version of the previously tested Healthier Families program. Adaptations include: shortening each session to 30 minutes and delivering the programming via a virtual platform. The health coach will provide the Healthier Families modules either to individual child-parent pairs.
33249531|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
33249532|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
33249533|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
32923420|NCT05327881||Septic shock patients|"Adult patients on vasopressors for greater than 6 hours to maintain a mean arterial pressure greater than or equal to 65 mm Hg. Inclusion criteria: age over 18, urinary catheter in situ, anticipated stay >24 hours, and signed informed consent by patient or next-of-kin.~Septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level > 18 mg/dL [2 mmol/L] despite adequate volume resuscitation"
32923421|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
32923422|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
32923423|NCT05748457||2015-2017|Patients treated for anorexia nervosa in the years 2015-2017 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
32923424|NCT05748457||2018-2020|Patients treated for anorexia nervosa in the years 2018-2020 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
32923425|NCT05748379|Other|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper after tooth extraction with bone augmentation by using allogeneic bone.
32923426|NCT05748379|Other|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment after tooth extraction with bone augmentation by using allogeneic bone.
32923427|NCT05748301||ICU Clinicians|ICU doctors at the senior registrar, ICU fellow or consultant level will evaluate the AI Clinician system.
32923428|NCT05748301||Septic patients|Septic patients meeting the inclusion criteria will be included on the system.
32923429|NCT02481713|Experimental|MI condition|motivational interview condition
32721596|NCT04784182|Placebo Comparator|Placebo group|Daily consumption of pills containing maltodextrin
32721597|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
32721598|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
32923430|NCT02481713|Sham Comparator|CI condition|learning style interview condition
32923431|NCT01819597|Other|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
32923432|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
32721599|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
33400235|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
32721600|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
32721601|NCT04912479|No Intervention|control|Patients will be given a plan to reduce progressively their dosage of Benzodiazepin every 2 weeks. Over a 6-month period they will receive a phone call from the hospital twice a month to reinforce their motivation.
32721602|NCT04912479|Experimental|intervention group|In addition to the progressive withdrawal of BZD, patients will be given a connected watch that provide them with information on their sleep quality and their performed activities. They will also receive a check-up phone call twice a month over a 6-month period.
32721603|NCT05030038||Aromatase inhibitor for breast cancer treatment|Participants will receive their standard of care for breast cancer treatment which includes an aromatase inhibitor. Pre-study assessments will be done at baseline as well as stool and blood samples at baseline, then again at 4 weeks and at 12 weeks during the course of the trial.
32721604|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
32721605|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
32721606|NCT05163379||INTENSIVE CARE PATIENTS|EARLY MOBILIZATION OF INTUBE PATIENTS
32721607|NCT04831827|Experimental|IVR Reminder|Participants will receive an interactive voice reminder
32721608|NCT04831827|Active Comparator|Personalized Phone Call Reminder|Participants will receive a personalized phone call
32721609|NCT04831827|Active Comparator|Portal Message Only|Participants will receive a online patient portal message reminder
32721610|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
32923433|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
33400236|NCT02946931||Prizbind® for Intravenous Solution|Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
32923434|NCT05748223|Experimental|Mindfulness Group|The patients in this group received mindfulness meditation before dental implant surgery.
32923435|NCT05748223|No Intervention|Conventional Group|The patients in this group did not receive mindfulness meditation before dental implant surgery.
32923436|NCT05327179|Experimental|Group 1|Action Observation Treatment
32923437|NCT05327179|Experimental|Group 2|Virtual Rehabilitation
32923438|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
32923439|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
32923440|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
32923441|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
32923442|NCT05326867|Active Comparator|Infiltration of 2% Lidocaine with Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
32721611|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
32721612|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
32721613|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
32721614|NCT05093283|Experimental|Workgroup|The probes will be fixed by giving the left lateral position for NST to the pregnant women in the intervention group by the researcher. After providing internet connection with a smart phone for the image, by clicking on youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video watching virtual reality glasses will be provided. The name and surname of the pregnant woman will be written on the NST trace and the trace will be photographed. After the NST process is completed, the NST traces will be evaluated by the researchers.
32721615|NCT05093283|No Intervention|Control|Unlike the study group, only video monitoring will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
32721616|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
32721617|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
33249534|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
32721618|NCT05376033|Experimental|Premixed Sealer + Single cone|Premixed flowable hydraulic calcium silicate sealer was applied with a a K File #15 that was inserted into the canal to reach the WL - 3mm and gently moved around the root canal walls. Then, gutta-percha points were gently inserted at the WL -0.5mm and compacted with lateral condensation/vertical condensation.
32721619|NCT05376033|Experimental|Premixed Sealer + Thermafil|Premixed bioceramic sealer was applied and previously described. Pre-heated carrier was inserted in the canal at WL-0.5mm. The carrier excess was removed with a Thermacut bur.
32721620|NCT05376033|Other|Sealer + Thermafil|Epoxy-resin-based sealer was mixed and immediately inserted into the root canal using a K File #15. Pre-heated carrier was inserted in the canal at WL -0.5mm. The carriers excess was removed with a bur.
32721621|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
32721622|NCT02312921||Control|Usual care
32721623|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
32721624|NCT05087355||Influenza|
33249535|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
33249536|NCT00850239|Experimental|1|dutogliptin/PHX1149T
33249537|NCT00850239|Placebo Comparator|2|Plabeco
32923443|NCT05326867|Active Comparator|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
32923444|NCT05326789|Experimental|interventional|20 patients with inclusion criteria and without exclusion criteria will be entered in the interventional arm attempting to use REBOA during non-traumatic cardiac arrest.
32923445|NCT05324995|Experimental|Multimodal injection|The first group was treated using a preemptive periarticular injection of multimodal drugs. Therefore, a combination of drugs consisted of 50 mg bupivacaine hydrochloride 0.5% (AstraZeneca, Cenexi, France), 1 ml morphine sulfate 10 mg/ml (DarouPakhsh, Tehran, Iran), 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) and 30 mg ketorolac (Caspian Tamin, Rasht, Iran) diluted by 0.9% sodium chloride solution to make a total 100 ml of injection drug was injected in periarticular area. The injections were done within 15 minutes before the incision in seven areas of the joint as followed: 15 ml in posterolateral soft tissue and lateral femoral periosteum, 15 ml posteromedial soft tissue and medial femoral periosteum, 20 ml inferomedial capsule, 20 ml superomedial capsule, 10 ml lateral capsule, 10 ml medial subcutaneous tissues and 10 ml lateral subcutaneous tissue.
32923446|NCT05324995|Experimental|epinephrine group (placebo group)|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary, similar to the first group.
32923447|NCT05324995|Experimental|celecoxib group (control group)|The third group administered celecoxib (200 mg) orally immediately before the surgery initiation.
32923448|NCT05318521|Active Comparator|Ibuprofen Modified-Release Tablets 800 mg (IBUMR)|Ibuprofen Modified-Release Tablets 800 mg (IBUMR), twice daily with 12h interval, for 12-week treatment period.
32923449|NCT05318521|Placebo Comparator|placebo|placebo 800mg, twice daily with 12h interval, for 12-week treatment period.
32923450|NCT05312905|Active Comparator|Mirror Therapy|Exercises including mirror therapy will be applied to the participants in the Mirror Therapy group. The mirror will be placed in such a way that the affected extremity of the patient could not be seen behind the mirror and the healthy extremity would be in front of his eyes, the patient will perform the exercises indicated by the physiotherapist with his intact extremity, looking into the mirror. The exercises will be performed in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
33249538|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
32923451|NCT05312905|Experimental|Mirror+Cognitive Therapy|The participants in the Mirror+Cognitive Therapy will be given a cognitive task with the application of mirror therapy. Cognitive tasks with mirror therapy will be applied in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
32923452|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
32923453|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
32923454|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
32923455|NCT05274061|Experimental|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy (AIM-CBCT for PTSD)|This is a single-arm study in which each couple will receive AIM-CBCT. The intervention is described in the section below.
32923456|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
32923457|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
32923458|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
32923459|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
32923460|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
32923461|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
32923462|NCT05748145|Experimental|Metronidazole treated arm|Administration of Metronidazole for 10 days prior to surgery in CRC patients
32923463|NCT05747989|Active Comparator|skin stitched with two-component skin adhesive|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
33249539|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
33249540|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
33249541|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
33249542|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
33249543|NCT00856089|Experimental|Retapamulin|
33249544|NCT00942370||accelerometric device|
33400237|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
33400238|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
32721625|NCT05087355||Covid 19|
32721626|NCT05087355||Control group|hospitalisation due to other disease (not influenza or Covid 19)
32721627|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
32721628|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
32743433|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
32923464|NCT05747989|Placebo Comparator|skin stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0. (Optilene® DSMP 19, 3/8 needle, thread size 4/0
32923465|NCT05747911||Migraine|
32923466|NCT05747911||Without Migraine|
32923467|NCT02422511|Active Comparator|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
32923468|NCT02422511|Experimental|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
32923469|NCT02422511|Active Comparator|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
32923470|NCT02422511|Experimental|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
32923471|NCT05747833|Experimental|Toy IV Catheter Before Peripheral Cannula application|Intervention Group: Child Fear Scale will be applied to the children who will meet the inclusion criteria. The data collection form will be filled in by the researcher according to the information received from the patient file and parents. Children in the intervention group will be shown the procedure on the doll with the IV Catheter developed by the researchers, and then it will be applied to it.
32923472|NCT05747833|No Intervention|Standard of care|Control group will not be aplied other than the normal procedure of the hospital. In both groups, at the end of the procedure, the child's reactions will be observed during the procedure and the Wong-Baker Faces Pain Scale, the Child Anxiety Scale and the Child Emotional Indicators Scale will be filled independently by the researcher and the parent in line with the child's reactions.
32923473|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
32923474|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
32923475|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
32721629|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
32721630|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
32721631|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
32721632|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
32721633|NCT05060835||Breast Cancer|patients diagnosed with breast cancer at any stage.
32721634|NCT05060835||Prostate cancer|patients diagnosed with prostate cancer at any stage
32721635|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
32721636|NCT03564145|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 40 weeks.
32721637|NCT04965909|Experimental|Educational and therapeutic exercise program|Participants will receive a 3-month online physiotherapy program comprised of 'pain neuroscience education' (month 1) and 'gradual exposure to movement' (month 2 and 3). They will receive an informative booklet online.
32721638|NCT04965909|No Intervention|Passive control group (usual care)|Participants will receive the 'usual care'. They will receive an informative booklet online and the possibility of receiving the therapeutic program, once the study is completed.
32721639|NCT02309255||coronary heart disease patients|
32721640|NCT05388253|Experimental|Static Stretching Among Plantar Fasciitis Patients|Using Static Stretching exercises
32721641|NCT05388253|Experimental|Deep Kneading Massage Among Plantar Fasciitis Patients|Using Deep Kneading Massage technique
32923476|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
32923477|NCT05747677|Experimental|HH-120 Nasal Spray|
32923478|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
32923479|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
32923480|NCT01823497|Active Comparator|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
32721642|NCT04964895|Other|patients with cystectomy|
32743434|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
32721643|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
33249545|NCT04041999|Experimental|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment."
33249546|NCT04041999|Active Comparator|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are performed to work various cognitive functions."
33249547|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
33249548|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
33249549|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
33249550|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
33249551|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
33249552|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
33249553|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
33249554|NCT04042779|Active Comparator|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
33249555|NCT04042779|Active Comparator|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
32721644|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
33249556|NCT04042779|Active Comparator|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
33249557|NCT04042779|Sham Comparator|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
32721645|NCT05163067|Experimental|Combined aerobic exercise and cognitive training program|
33249558|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
32721646|NCT05163067|No Intervention|Standard health counseling at baseline|
32743435|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
32767697|NCT03996109|Experimental|Aim2Be|Youth-parent dyads randomized to Aim2Be
33249559|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
33249560|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
33249561|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
33249562|NCT00853203||Part 2, Standard Care Control Group|Written Materials
33249563|NCT00748800|Experimental|1|
33249564|NCT00748800|Active Comparator|2|
33249565|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
33249566|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
33249567|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
33249568|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
33249569|NCT00560404|Experimental|1|
33249570|NCT00560404|Active Comparator|2|
33249571|NCT00751920|Experimental|1|
33249572|NCT00850551|Active Comparator|Usual Care|Usual Care
33249573|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
33249574|NCT00850629|Placebo Comparator|placebo|Placebo
33249575|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
33249576|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
33249577|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
33249578|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
32721647|NCT04863261|Active Comparator|Intervention|Clinics randomized to the intervention. A notification will be sent to the provider when a patient on CAB+RPV LA needs to be scheduled for their injections or when an appointment needs to be confirmed. Alerts are sent out to the provider when a patient is due or overdue for their injections.
32721648|NCT04863261|No Intervention|Control|Clinics randomized to the control group. No alerts or notification will be sent. The providers will manage their CAB+RPV LA patients using standard of care in their clinic.
32721649|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
32721650|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
32721651|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
32721652|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
32721653|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
32721654|NCT03423355|Active Comparator|Dapagliflozin (Forxiga®)|Treatment with the SGLT2 inhibitor dapagliflozin 10 mg once daily for 28 days.
32721655|NCT03423355|Placebo Comparator|Placebo matching Dapagliflozin|Treatment with the Dapagliflozin matching placebo once daily for 28 days.
32721656|NCT03423355|Other|Hydrochlorothiazide|Treatment with the Hydrochlorothiazide 25 mg once daily for 28 days
32721657|NCT04481997||Diabetic patients with CAD submitted to PCI|Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI
32721658|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
32721659|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
32721660|NCT04430985|Experimental|FOLFOX + Immunotherapy|"8 cycles of FOLFOX every 2 weeks with intrahepatic administration of oxaliplatin in cycles 1-4, thereafter (cycles 5-8) oxaliplatin i given i.v.; starting from cycle 3 this is combined with i.v. administration of nivolumab (cycle 3-8) and ipilimumab (cycle 3 + 6)~Immunotherapy:~Starting from cycle 3: Nivolumab 3 mg/kg i.v. on day 3 (every 2nd week, total of 6 administrations), Ipilimumab 1 mg/kg i.v. on day 3 (every 6th week, total of 2 administrations)"
32721661|NCT03506243|Experimental|Test group|Follitrope PFS
32721662|NCT03506243|Active Comparator|Control group|Gonal-F pen
32721663|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
32721664|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
32721665|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
32721666|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
32721667|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
32721668|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
32721669|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
32721670|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the standard care alone
32721671|NCT04774497|Experimental|Oxygen inhalation treatment group|"Patients receive chemotherapy for breast cancer.~Patients are randomly divided into inhalation treatment group. Oxygen inhalation is started on the first day of chemotherapy, and the oxygen inhalation volume is 2 L / min, 8 hours / day for 3 consecutive days.（d1，d2，d3）.~Blood samples are collected before and after chemotherapy（d0，d3）.~CIS and BFI are measured before chemotherapy（d0, d3 chemotherapy regimen/ d0, d3， chemotherapy regimen）."
32721672|NCT04774497|Placebo Comparator|Oxygen non-inhalation treatment group|"Patients receive chemotherapy for breast cancer.~Patients are randomly divided into non-inhalation treatment group.~Blood samples are collected before and after chemotherapy（d0，d3）.~CIS and BFI are measured before chemotherapy（d0, d3，chemotherapy regimen/ d0, d3， chemotherapy regimen）."
32721673|NCT04413357|Active Comparator|Balanced Nutritional Drink|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.
32721674|NCT04413357|Active Comparator|Balanced Nutritional Drink - DMA|The study interventions contain protein, carbohydrate and fat and are intended for use as retail Supplemental Nutrition for people living with diabetes.
32721675|NCT04413357|Active Comparator|Balanced Nutritional Drink - DMB|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition for people living with diabetes.
32721676|NCT04030585|Experimental|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
32721677|NCT04030585|Active Comparator|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
32721678|NCT04410549|Experimental|COVID-19 patient with pulmonary thrombosis|"patients with COVID-19, high D-dimer levels and contrast CT scan negative for pulmonary thrombosis~patients with contrast CT scan positive for pulmonary embolism in areas where contrast CT scan was negative."
32767698|NCT03996109|Active Comparator|BnLt|Youth-parent dyads randomized to BnLt
32767699|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
32923481|NCT01823497|Active Comparator|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
32923482|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
32923483|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
33400239|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
33400240|NCT04769323|Experimental|Group 1|Group 1 use virtual reality.
33249579|NCT00850707||4|60 healthy subjects as controls
32721679|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
32721680|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
32721681|NCT04658277|Active Comparator|Treatment|Patients will be given one tab of Clarithromycin 250mg daily.
32721682|NCT04658277|Placebo Comparator|usual care|Patients will receive usual medical care
32721683|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
32721684|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
32721685|NCT04456777|Experimental|1group|patients with vortioxetine
32721686|NCT04456777|Placebo Comparator|2 group|patients without vortioxetine
32721687|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
32721688|NCT04336371||Anxiety level|patient's psychological experience the anxiety level
32721689|NCT05390983|Experimental|carotid endarterectomy|carotid endarterectomy with stent removal
32721690|NCT05390983|Active Comparator|repeated angioplasty and stenting|percutaneous transluminal angioplasty with or without stenting
32721691|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
32721692|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
32721693|NCT04650633|Experimental|SHR-1701|R/M SCCHN subjects failure after 1 lines of platinum based chemotherapy or after anti PD-1/PD-L1 antibody therapy.
32721694|NCT04775368|Experimental|Diagnosis orientation group|For this study, there is only one arm. Each patient complete diagnosis questionnaires.
32721695|NCT04456621|Experimental|PBT arm|
32721696|NCT04055103|Active Comparator|Intervention Group|Half of the participating hospitals will be in the intervention group for the first 6 months. The intervention will switch to the control group after the 6 months.
32721697|NCT04055103|No Intervention|Control Group|Half of the participating hospitals will be in the control group for the first 6 months. The control group will undergo the intervention in the second 6 months.
32721698|NCT05162989|Experimental|iCare HOME2 vs iCare IC200|Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).
32923486|NCT05747521|Experimental|Anrotinib hydrochloride combined with adriamycin|Anrotinib hydrochloride combined with adriamycin neoadjuvant therapy for patients with high-grade soft tissue sarcoma
32923487|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
32923488|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
32923489|NCT05234047||CKD-5D patients receiving denosumab|
32923490|NCT05226559|Active Comparator|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
32923491|NCT05226559|No Intervention|Usual care|Standard pharmacological treatment alone
32923492|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
32923493|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
32923494|NCT01823653|Experimental|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
32923495|NCT05118763|Experimental|INNA-051 arm 1|INNA-051 intranasal spray low dose administered once on each of Days 1, 4, 7 and 10
32923496|NCT05118763|Experimental|INNA-051 arm 2|INNA-051 intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
32923497|NCT05118763|Placebo Comparator|Placebo|Placebo intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
32923498|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
32923499|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
32923500|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
32721699|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
32721700|NCT04621071|Experimental|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
32721701|NCT04621071|Placebo Comparator|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
32721702|NCT05160727|Experimental|Treatment group|"Concurrent Chemoradiotherapy:~Radiation: The dose is determined according to the treatment site and the purpose of treatment.~Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Tislelizumab: 200mg ivgtt d1 q3w~Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w. Tislelizumab: 200mg ivgtt d1 q3w. Efficacy assessment every 3 cycles."
32923501|NCT01824589|Active Comparator|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
32923502|NCT01824589|Active Comparator|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
32721703|NCT03506009|Experimental|Argatroban combined with rt-PA|
32721704|NCT03506009|Active Comparator|rt-PA|
32721705|NCT04538157|Experimental|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
32721706|NCT04538157|No Intervention|Usual Care|Usual Care
32721707|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
32721708|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
32721709|NCT04463927|Experimental|Intervention Group|The non-nutritive sucking is applied to the group during the examination for retinopathy of prematurity
32721710|NCT04463927|No Intervention|Control Group|The non-nutritive sucking is not applied to the control group.
32721711|NCT04456543|Experimental|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
32721712|NCT04456543|Active Comparator|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
32721713|NCT05374551|Other|All participants|All participants will complete all experimental conditions, which include transcranial magnetic stimulation (continuous theta-burst stimulation) to a brain region of experimental interest and to a control brain region.
32721714|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
32721715|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
32721716|NCT04860349|Experimental|High Intensity Interval Training|20 minutes of High Intensity Interval Training for experimental group.
32721717|NCT04860349|No Intervention|Control|No intervention for the control group.
32721718|NCT04537845||with cancer pain|
32721719|NCT04537845||without cancer pain|
32721720|NCT03505931||Eluvia|Patients treated with Eluvia stent
32721721|NCT04456387|Experimental|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
32721722|NCT04456387|Experimental|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
32721723|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
32721724|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
32721725|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
32721726|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
32721727|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
32923503|NCT01824589|Active Comparator|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
32923504|NCT01824589|Active Comparator|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
32923505|NCT05747287|Experimental|Experimental group|
32923506|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
32923507|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
33249580|NCT00951730||Down syndrome|Adult and children with Down syndrome.
33249581|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
32923508|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
32721728|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
32721729|NCT05388019|Experimental|Prospective interventional cohort of newly-implanted patients|This cohort will consist of patients who recently underwent LVAD implantation at Massachusetts General Hospital, and their caregivers. These patients will receive only multidisciplinary team care from the time of their implant.
32923509|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
32923510|NCT02487563|Experimental|Experimental Group 2|Decitabine
32923511|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
32721730|NCT05388019|Experimental|Prospective interventional cohort of previously-implanted patients|This cohort will consist of patients who have previously undergone LVAD implantation at Massachusetts General Hospital who are being followed-up with standard-of-care VAD clinic visits, and their caregivers. These patients will receive a hybrid of multidisciplinary team care and standard-of-care visits.
32721731|NCT05388019|No Intervention|Retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past and no longer have an LVAD implanted (due to transplant, death, explant, etc.).
32923512|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
32923513|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
32923514|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
32923515|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
32923516|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
32923517|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
32923518|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
32923519|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
32923520|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
32923521|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
32923522|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.~All participants will receive CPAP in addition to this intervention."
32923523|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.~All participants will receive CPAP in addition to this intervention."
32923524|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
32923525|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
32923526|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
32923527|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
32923528|NCT02428595|Experimental|Treatment|Eclipse™ System
32721732|NCT05388019|Experimental|Primary caregiver cohort|This cohort will consist of primary caregivers of VAD patients from the two interventional cohorts. They will be administered a questionnaire at two timepoints. Each VAD patient will be associated with only one primary caregiver for the duration of the study.
32721733|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
32923529|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
32923530|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
32923531|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
32923532|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
32923533|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
32721734|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
32721735|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
32721736|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
32721737|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
32721738|NCT03874351|Experimental|Active tDCS|Twenty minutes of direct current at intensity of 1.5 milliamperes (mA).
32721739|NCT03874351|Sham Comparator|Sham tDCS|Thirty seconds of direct current at 1.5 mA, followed by 0 mA for the remaining time of the 20-minute stimulation period.
32923534|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
33249582|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
33249583|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
32721740|NCT05015998||Non-dialysis dependent patients with CKD stage 3-5|A cohort of patients will be created from the Stockholm CREAtinine Measurement (SCREAM) cohort based on the eligibility criteria.
32721741|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
32721742|NCT05081115||ABCDE-Stress Echo in Coronary Artery Disease (SECAD project)|All patients with known or suspected CAD will be evaluated with ABCDE-SE. Patients will be referred according to existing 2020 guidelines indication; status post heart transplant; pediatric patients and congenital heart disease ; peri-partum cardiomyopathy. Information on demographics, lifestyle and other risk factors and ongoing therapy will be collected. Data related to carotid disease and cardiac calcification will be collected. All patients will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints, such as cancer or neurodegenerative disease, characterized by endothelial dysfunction (step D positivity) and autonomic dysfunction (step E positivity). A sample size of about 2 430 patients with a 5-year follow-up is required to provide 90% power with an alpha error of 5% to detect a difference for the primary endpoint of all-cause mortality among those with positive versus negative SE also considering a 20% drop-out.
32721743|NCT05081115||ABCDE-Stress Echo in Diastolic Heart failure (SEDIA project)|Patients with dyspnea and known or suspected heart failure with preserved ejection fraction by 2019 European Society of Cardiology criteria will be enrolled and studied with cycle-ergometer in semi-supine SE (or treadmill). A score of at least 1 according to the criteria proposed by Pieske et al. is required for inclusion. In patients unable to exercise or did not allow sampling of CFVR, pharmacological test (vasodilator or dobutamine) is recommended. Assuming that the hypothesis of proportionality of hazard holds, as required for Cox proportional hazards regression, with a power of 90%, an attrition rate of 10% and a 5-year follow-up period of a sample size of 181 patients is required.
32721744|NCT05081115||ABCDE-Stress Echo in Hypertrophic Cardiomyopathy (SEHCA project)|The primary aim is to evaluate the feasibility of comprehensive ABCDEFG-SE in the evaluation of HCM. The secondary aim is to assess the value of each of obtaained parameters in predicting response to specific therapy and other interventions. The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium-long-term. HCM diagnosis will be based on existing guidelines. All patients will be followed-up. In patients and first-degree relatives with genetic characterization different phenotypes will be correlated with specific genotypes. Non-imaging or routine imaging non-ultrasound exams will be collected and analyzed with neural network analysis developed in project 5. We assume that a sample size of 338 patients is required.
32742930|NCT04960761|No Intervention|Control Group|Routine training will be given by a nurse working in the clinic during the preoperative period. The content of the routine training: What are the procedures performed during the admission of the patient to the service before the operation (introducing the clinic and the staff to the patient), what the preoperative preparation is (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown, wearing a patient tag on the wrist, with a stretcher. being taken to the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.), there may be some medical materials that were applied to the patient during the surgery (nasogastric tube, IV catheter, types of drains placed in the wound site) includes information such as
33249584|NCT00942526|Sham Comparator|2|perioperative gargling with water
33249585|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
33249586|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
32721745|NCT05081115||ABCDE-Stress Echo post-Radiotherapy (SERA project)|Radiation-induced heart disease is associated with a significantly higher morbidity and mortality in cancer patients. The most frequent forms treated with chest radiation therapy are breast, lung, and esophageal cancers or lymphoma. The chances of developing radiation-induced heart disease increase with higher cumulative doses (>30 Gray) in anterior or left sided irradiation, concomitant chemotherapy, presence of cardiovascular risk factors, and increased distance from time of irradiation. The estimated incidence of major cardiac events related to ischemic heart disease is 30% at 10 years post-treatment in female patients with radiotherapy post-breast cancer. The resulting epicardial artery stenosis, low grade inflammation , myocardial fibrosis, microvascular injury , alterations in autonomic balance, valve leaflets, and accelerated calcification can lead to significant alteration of all SE steps. A sample size of 507 patients is required and will be enrolled.
32721746|NCT05081115||ABCDE- Artificial Intelligence Stress echo (AI-SEE)|The project have 2 separate aims: AI-SEE images: To make SE reading operator-independent for each of the essential reading steps (from A to E). AI-SEE data: To identify the links between clinical imaging and stress variables and develop a tailored personalized model for risk prediction. For each parameter assessment (positivity versus negativity), the area under the receiver-operating characteristic curve produced by the deep learning algorithm will be compared to that produced by the experienced cardiologist (cross-sectional analysis). AI-SEE images: a set of images from 1 250 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently prospectively tested on a different set of 1250 patients (validation set). AI-SEE data: a set of data from 2 500 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently tested on a different set of 2 500 patients (validation set).
33249587|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
33249588|NCT04042389|Experimental|WhatsApp|WhatsApp reminders
33249589|NCT04042389|Experimental|Email|Email reminders
33249590|NCT04042389|Other|Control|No reminder
32721747|NCT05081115||ABCDE- Environmental Stress Echocardiography, air pollution and medical radiation (ESTER project)|The primary aim is to assess the inter-patient correlation between SE results and outdoor air pollution levels in patients matched for clinical, coronary anatomy (if available) and resting functional features. Secondary aim is to assess the effects of air quality and cumulative medical radiation exposure in prognostic modeling using traditional risk factors and SE results. All patients enrolled in projects 1 to 4 have information on house residency and work place in the data bank. The air epidemiology unit will obtain same day local air quality data from publicly available data sets from regional authority of environmental protection. For each patient and each test of the same patient, the values of 2 particulate and 4 gaseous pollutants will be collected when available. Data on medical radiation exposure will also be systematically collected. Of the 2 430 tests recruited in protocol 1, at least 600 will have access to geo-referenced air quality data.
32742931|NCT04960605|Other|Test group|Patients with Primary Sjögren Syndrom
32742932|NCT04960605|Other|Control group|Patients with Primary Sjögren Syndrom, matched to the test group
32742933|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
33249591|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
33249592|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
32742934|NCT04942509|Experimental|Coloring|This group did mindful coloring for at least 5 days or at least 100 minutes in total during a 10-day period
32742935|NCT04942509|No Intervention|Wait-list control|This group did not do mindful coloring at all during a 10-day period.
32742936|NCT04942587|Experimental|mother's voices|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
32742937|NCT04942587|Experimental|father's voices group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of father's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
32742938|NCT04942587|No Intervention|control group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes.Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
32742939|NCT04942431|Experimental|Interventiongroup|60 min per day school based Physical activity program (for one year)
32742940|NCT04942431|No Intervention|Waitinggroup|Intervention starts after one year.
32742941|NCT04942119|No Intervention|Routine standard care group|This group will continue to receive the usual recommended care provided in the clinic and usual follow-up appointment as well as clinical assessment. Any required nutrition education by the dietitian or medication counseling will be provided at any visit or when requested.
33249593|NCT05300854|Active Comparator|Standard anesthesia in addition to serratus plane block|general anesthesia was given then ultrasound-guided serratus plane block
32742942|NCT04942119|Experimental|Multifactorial intervention group|"Correction of magnesium and/or potassium levels, and correction of the underlying disease, if possible by a endocrinologist.~Education at each follow-up visit by a specialized dietitian, reinforcing optimal diet and exercise, with pre-& post-nutrition and physical activity assessment using the validated revised summary of diabetes self-care activities (SDSCA) scale.~Medication reconciliation and counseling, online post adherence questionnaire and confirm adherence by fixed medication possession ratio (FMPR) approach."
33249594|NCT05300854|Active Comparator|Standard anesthesia in addition to para-vertebral block|general anesthesia was given then ultrasound-guided para-vertebral block
32742943|NCT04949451|Placebo Comparator|TRF-C|Follows time restricted feeding protocol.
32923535|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
32923536|NCT02543723|Active Comparator|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
32721748|NCT05081115||SETOF Stress Echo in operated Tetralogy of Fallot.|The primary aim is to evaluate the feasibility of right ventricular SE in patients with repaired Tetralogy of Fallot. The secondary aim is to assess the presence and amount of right ventricular contractile reserve and its correlation with indices of functional severity (NYHA class, cardiac natriuretic peptides, peak VO2, 6-min walking test, etc.). The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium and long-term. Patients with repaired Tetralogy of Fallot or Fallot-like pathology evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age>10 years, height>140 cm, NYHA class I or II. Data on medical radiation exposure will also be systematically collected. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
32923537|NCT02543723|No Intervention|Control|Patients received standard of care.
33249595|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
33249596|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
32721749|NCT05081115||Stress Echo for surveillance post-COVID-19 (SECOV).|Cardiovascular abnormalities are observed in half of all COVID-19 patients and may range from RWMA to interstitial lung disease with alveolar capillary distress, global contractile dysfunction, coronary microvascular abnormalities and cardiac autonomic dysfunction. In addition, pulmonary hypertension and valves abnormalities are a possible consequence. The primary aim is to assess the feasibility of an integrated ABCDEFG approach in post-COVID 19 patients. Secondary aim is to prevalence of abnormalities of different SE parameters in populations stratified according to severity of COVID-19. Tertiary aim is to assess the prognostic value of individually considered or combined SE indices in prognostic modeling using traditional risk factors and COVID-19 variables. The relevant parameters related to COVID-19 infection will be collected .SE will be performed from 3 months to 3 years after infection. A sample size of 406 patients is required.
33249597|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
32721750|NCT05081115||RESURGE: Recovery by stress echo of conventionally unfit donor good hearts.|The primary aim is to recruit hearts from donation which are currently excluded by conventional criteria as aged hearts in patients > 55 years and ≤ 55 years with multiple risk factors. Secondary aim is to assess outcome in SE-driven transplantation compared to hearts transplanted in the same cardiac surgery centers on the basis of conventional criteria. Tertiary aim is to assess the additional prognostic value of other signs not used for decision-making. These aspects may include diastolic function, preload reserve, coronary microvascular function, and residual innervation of the intrinsic cardiac autonomic system through assessment of HRR in donor heart. In case of donor with age >55 years o ≤ 55 years but with concomitant ≥ 3 risk factors (diabetes, hypertension, smoking, obesity, hypercholesterolemia) or history of cardiac arrest, the protocol will be applied.
33400241|NCT04769323|Experimental|Group 2|Group 2 do traditional home exercises.
32721751|NCT05081115||SEMIR- Stress echo in ischemic mitral regurgitation|The value of SE testing as an indicator of outcome will be assessed in patients with resting moderate mitral regurgitation (effective regurgitant orifice 0.2-0.39 cm2, and regurgitant volume 30-59 ml) of ischemic origin and angiographically documented CAD, and will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints. Patients undergoing CABG with or without mitral repair or PCI with or without mitral valve intervention will be separately analyzed. A sample size of 173 patients per arm (CABG or PCI) is required. The primary hypothesis is that patients with moderate mitral regurgitation worsening of ≥ 1 grade during exercise have worse outcome on medical therapy and greater benefit from valve correction. The secondary hypothesis is that patients with worse SE pre-surgery parameters will have worse prognosis independent of regurgitation severity and treatment (medical therapy or valve repair).
32721752|NCT05081115||SEVA: Stress Echocardiography in Valvular Heart Disease|SE is recommended in valvular heart disease in patients characterized by a mismatch between resting transthoracic echocardiography findings and symptoms during exercise or activities of daily living: 1. Severe valve disease without symptoms; 2. Non-severe single- or multi-valve disease with symptoms; and 3. Symptomatic valve disease of indeterminate severity in context of low flow. The primary aim is to evaluate the feasibility of ABCDEFG-SE plus L (left atrium), P (pulmonary vascular reserve) and R (right ventricular function) in these patients. The secondary aim is to assess the correlation of each SE parameter with indices of functional severity (NYHA, cardiac natriuretic peptides, peak oxygen consumption, etc.). The tertiary aim is to assess the prognostic value of SE for prognostic stratification in the long-term. A sample size of about 217 patients per sub-group is required to evaluate the tertiary endpoint with 90% power and an alpha error of 5% .
32721753|NCT05081115||SESPASM - SE for coronary vasospasm|The primary aim is to evaluate the feasibility and safety of hyperventilation and exercise ABCDE-SE in patients with angiographically normal coronary arteries and an intermediate-to-high pre-test probability of coronary vasospasm of epicardial arteries or microvasculature. The secondary aim is to assess the positivity rate of A and D criteria in these patients, compared to standard ECG criteria. The tertiary aim is to assess the prognostic value of the different responses of SE leading to SE-driven therapies. Only patients with strong (Class 1) indication to vasospasm testing according to the recent guidelines will be initially considered. Patients prepared for exercise testing will undergo vasospasm testing in the morning with hyperventilation. If negative or equivocal at 5 minutes after the end of hyperventilation, the patient will start exercise with the usual protocol. A sample size of 513 patients is required with a 5-year follow-up for the composite endpoint.
32721754|NCT02603146|Experimental|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
32923538|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~Level -1 - 27mg/m2~Level 0 - 36mg/m2~Level 1 - 45mg/m2~Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
32923539|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
32923540|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
32923541|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
32923542|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
32923543|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
32923544|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
32923545|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
32923546|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
32923547|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
32923548|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
32923549|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
32923550|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
32923551|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
32721755|NCT02603146|Placebo Comparator|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
32721756|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
32721757|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
32923552|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
32923553|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
32923554|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
32923555|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
32721758|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
32721759|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
32721760|NCT04954690|Placebo Comparator|Usual Care|Patients randomized to usual care will receive recommendations for exercise based on the Surgeon General's recommendations for physical activity among adults as well as the American Heart Association and American College of Sports Medicine recommendations for older individuals or individuals with chronic conditions. These guidelines are applicable to this patient population. Patients will not receive coaching but will receive accelerometers to obtain data for comparison to the intervention groups at each time point (baseline, 8 weeks, and 3 months post-KT).
32721761|NCT04954690|Active Comparator|Weekly Coaching|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise
32923556|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
32923557|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
33400242|NCT04769323|Experimental|Group 3|Group 3 do traditional home exercises and virtual reality.
32721762|NCT04954690|Active Comparator|Weekly Coaching + Caregiver Participation|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise with the addition of caregiver participation to promote adherence and engagement
32721763|NCT03942627|Experimental|Mindfulness Program|The intervention consists of an introductory video in which a mindfulness expert explains the program's approach and models practices to increase women's comfort with the material, four audio-recorded mindfulness practices for mothers' use when the baby is in the NICU, each available in 5- and 10-minute versions, and a brief video and four additional audio mindfulness practices (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
33249598|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
33249599|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
33249600|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
33249601|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
33249602|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
32721764|NCT03942627|Placebo Comparator|Infant Health Education Program|The intervention consists of an introductory video explaining the program's approach, four audio recordings providing education about infant health and development, each available in 5- and 10-minute versions, and a brief video and four additional educational recordings (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
32742944|NCT04949451|Experimental|TRF-P|Follows time restricted feeding protocol, consumes protein supplement
32742945|NCT04949451|Experimental|TRF-S|Follows time restricted feeding protocol, consumes ketogenic supplement
32742946|NCT04942197|Experimental|Arm 1|Participants who received three dimensional ultrasound with pregnancy application
33249603|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
33249604|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
33249605|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
33249606|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
33249607|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
33249608|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
33249609|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
32742947|NCT04942197|Placebo Comparator|Arm 2|Participants who received three dimensional ultrasound without pregnancy management application
33249610|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~Participants will remain on this research study as long as they continue to benefit from the study medications."
33249611|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
33249612|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
33249613|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
33249614|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
33249615|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
33249616|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
33249617|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
33249618|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.~Analyze comorbidities and patterns of use of health services by tumor characteristics."
33249619|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
33249620|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
33249621|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
33249622|NCT04144023|Experimental|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33249623|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
33249624|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
33249625|NCT02545179|No Intervention|control|Previous therapy
33400243|NCT03960840|Experimental|CLL/SLL|Dose escalation and expansion of YTB323 in combination with ibrutinib
32721765|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
32721766|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
32721767|NCT03876483|No Intervention|Standard of Care|Youth enrolled in care at control facilities will receive current standard of care related to HIV care and transition to adult care.
32721768|NCT03876483|Experimental|Virtual peer support group|Youth enrolled in care at intervention facilities will be invited to participate in a virtual peer support program
33249626|NCT03961204|Other|Cohort A|The participants previously enrolled in parent studies CLARITY (NCT00213135), CLARITY-EXT (NCT00641537), ORACLE (NCT00725985) and had received Cladribine tablet and Placebo were invited up to 2 visit for follow-up/data collection.
33249627|NCT00749034|Experimental|1|VPM1002 in three dosages
33249628|NCT00749034|Active Comparator|2|BCG
33249629|NCT00856713|Experimental|1 YM|Healthy young males
32721769|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
33249630|NCT00856713|Experimental|2 EM|Healthy elderly males
33249631|NCT00856713|Experimental|3 YF|Healthy young females
33249632|NCT00856713|Experimental|4 EF|Healthy elderly females
33249633|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
33249634|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
33249635|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
33249636|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).~The sampling study will last for 12 weeks and samples collected include:~A self-taken low vaginal swab~A self-taken rectal swab~Menstrual cup fluid~Serum sample~Urine pregnancy tests"
33249637|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
33249638|NCT00856869|Experimental|1 YM|Healthy young males
33249639|NCT00856869|Experimental|2 EM|Healthy elderly males
33249640|NCT00856869|Experimental|3 YF|Healthy young females
33249641|NCT00856869|Experimental|4 EF|Healthy elderly females
33249642|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
33249643|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
33249644|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
33249645|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
33249646|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
33400244|NCT03960840|Experimental|DLBCL|Dose escalation and expansion of YTB323 single agent in DLBCL
33400245|NCT03960840|Experimental|Adult ALL|Dose escalation and expansion of YTB323 single agent in adult ALL
33400246|NCT04765969||Severe COPD patients|GOLD C and D group patients
32923558|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
32923559|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
32923560|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
32923561|NCT01824901|Experimental|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32923562|NCT01824901|Experimental|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
32923563|NCT01824901|Experimental|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32923564|NCT01824901|Experimental|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33249647|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
33249648|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
32923565|NCT01825057|Active Comparator|See One|"Providers in See One only receive MI workshop training, giving them an opportunity to see the MI intervention and learn how to conduct it. The trainer encourages them to screen their patients for substance misuse and apply MI as indicated."
32923566|NCT01825057|Experimental|Do One|Following workshop training, MI-trained CL clinicians directly supervise providers' live bedside provision of MI to patients twice before beginning the trial and once midstream. In addition, providers have the option to request additional live supervision from CL clinicians during the trial, consistent with the apprenticeship model.
33249649|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33249650|NCT04041765|Experimental|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
33249651|NCT04041765|Placebo Comparator|Placebo Group|Antibiotics only
33249652|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
33249653|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
32923567|NCT01825057|Experimental|Order One|"Following the workshop, providers either administer MI themselves or order a MI for delivery by one of the MI-trained CL clinicians. Only providers in Order One can specifically request MI through a separate CL order in the electronic health record. The physicians or PAs directly place MI orders. Nurses contact physicians or PAs to place the MI order. The CL clinicians are trained in MI via a clinical trials training approach: 1) a 2-day skill-building workshop; 2) three post-workshop supervised practice cases based on review of audio recorded sessions; and 3) follow-up monthly group supervision to maintain and monitor the CL clinicians' MI practice. CL clinicians also learned supervisory practices to provide live supervision to providers in Do One."
33249654|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
33249655|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
33249656|NCT04057014|Active Comparator|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
33249657|NCT04057014|Experimental|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
33249658|NCT04057014|Experimental|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
33249659|NCT00946738|Active Comparator|physical therapy|
33249660|NCT00946738|No Intervention|control|
33249661|NCT00857103|No Intervention|1|Standard care
33249662|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
33249663|NCT00364351|Active Comparator|1|Erlotinib
33249664|NCT00364351|Experimental|2|Vandetanib
33249665|NCT05279872|Experimental|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
32767700|NCT03964909|Experimental|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
32767701|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
32767702|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
32767703|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
32767704|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
32767705|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
32767706|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
32767707|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
32767708|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
32767709|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
32767710|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
32767711|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
32767712|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
32767713|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
32767714|NCT04210687|Active Comparator|Trapeziectomy|Standard simple trapeziectomy, no pins.
32767715|NCT04210687|Active Comparator|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
32767716|NCT04201873|Experimental|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
33249666|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
33249667|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
33249668|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
33249669|NCT00755820||SP|Supportive psychotherapy
33249670|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
33249671|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
33249672|NCT00854217|Placebo Comparator|placebo, hemodilution|
33249673|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
33249674|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
33249675|NCT00755898|Active Comparator|2|Healthy adult volunteers
33249676|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
33249677|NCT00952198|Experimental|ARRY-403|
33249678|NCT00952198|Placebo Comparator|Placebo|
33249679|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
33249680|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
33249681|NCT00946816|Active Comparator|Anorexia Nervosa|
33249682|NCT00946816|Active Comparator|Obesity|
33249683|NCT00946816|Active Comparator|Healthy volunteers|
33249684|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
33249685|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
33249686|NCT04012060|Active Comparator|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
33249687|NCT04012060|Experimental|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
33249688|NCT04012060|Other|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.~All patients will undergo aortic valve replacement through median full sternotomy."
33249689|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI>15 in a sleep study)
33249690|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
33249691|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
33249692|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
32923568|NCT05747209||Standard High-load resistance training|Standard exercise regimen utilizes a mixture of compound and isolated movements, focusing on compound exercises. The regimen is a typical standard of care resistance training program and sports performance and strength and conditioning facilities. The observed classes will take place three times per week. Warm-up exercises focused on mobility, flexibility and core activation will be performed to reduce the risk of injury. Each individual exercise workout will generally progress from most intense, CKC, compound, and athletic movements to least intense throughout the workout to maximize safety. Additionally, each workout will provide full body resistance training to focus on functional exercises, intensity, and efficiency. Each workout will take approximately 45 minutes. The total exercise regimen will last 3 months.
32923569|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32923570|NCT05747131|Experimental|Emotion Detectives In-Out|Emotion Detectives In-Out consists of 15 weekly sessions with the children (9 face-to-face group sessions, 4 online sessions and 2 videoconference sessions).
32923571|NCT05747131|Active Comparator|Coping Cat|Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents.
32923572|NCT05027113|Experimental|Mind-Us|"Use of the 10% Happier app to complete at least one meditation daily -with the possibility of exceeding this goal by choosing additional meditations- for 4 weeks. Participants will be asked to complete The Basics and The Basics II courses to familiarize themselves with the principles of mindfulness meditation. Each audio-recorded session begins with a short video providing psychoeducation around mindfulness meditation and teaching specific techniques (e.g., using the breath as an anchor, redirecting attention, noting thoughts and emotions). For the last two weeks of the program, participants will be invited to complete the Essential Advice course. This additional course is composed of 14 sessions ranging in length from 15 to 18 minutes."
32923573|NCT05027113|No Intervention|Assessments First|Wait-list control group. Individuals in this group will complete baseline, mid-, and post-treatment assessments before receiving the intervention (i.e., 4 weeks after randomization).
32721770|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
32721771|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
32721772|NCT04430673|Experimental|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
32721773|NCT04658173|Experimental|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
33249693|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
32923574|NCT04993651|Experimental|Continuous Positive Airway Pressure|Those randomized to CPAP will be fitted with CPAP face mask or nasal device by the respiratory therapist and permitted to trial the machine to ensure proper use and fit. CPAP settings: CPAP AUTO 5-20 cm H20 will be utilized. The CPAP device will then be removed. The subject will then be placed in the supine position with a standard roll placed under the right maternal hip. Those randomized to CPAP will have the device applied and machine turned on. For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
32923575|NCT04993651|No Intervention|Nasal Cannula|For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
33249694|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
33249695|NCT00861159||1|
33249696|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
33249697|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
32721774|NCT04658173|Active Comparator|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1.5 to 2mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
32721775|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
32721776|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
32721777|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
32721778|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
32721779|NCT03636165|Experimental|MP plus RP group|Patients in RP/MP group will receive a peri-incisional scalp infiltration with 0.125% methylprednisolone and 0.2% ropivacaine and normal saline miscible liquids. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
32721780|NCT03636165|Active Comparator|RP group|Patients in RP group will receive peri-incisional scalp infiltration with 0.2% ropivacaine alone. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
32923576|NCT01826227|Experimental|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
32923577|NCT04970563|Experimental|Patients infected by SARS-COV-2 (RT-PCR +) and asymptomatic|
32923578|NCT04970563|Other|"Control group: patients infected by SARS-COV-2 (RT-PCR +) and symptomatic"|
32923579|NCT04970563|Other|"Healthy controls group: not infected by SARS-COV-2 (RT-PCR-) and asymptomatic."|
32923580|NCT04969627|Active Comparator|Metformin (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
32721781|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
32721782|NCT03635151|Experimental|TASK III Group|The Telephone Assessment and Skill-Building Kit (TASK III) group
32923581|NCT04969627|Experimental|Metformin (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
32721783|NCT03635151|Active Comparator|ISR Group|The Information, Support, and Referral (ISR) group
32923582|NCT04969627|Experimental|Combination (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
32721784|NCT04766632|Experimental|one group|patients with high grade glioma
32721785|NCT02310191||Stenting|Carotid stenting
32923583|NCT04969627|Experimental|Combination (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
32923584|NCT04953325|Experimental|Experimental Group|180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older）will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28
32923585|NCT04953325|Placebo Comparator|Control Group|90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
32923586|NCT05747053|Experimental|AlloSure Assay prediction of Anti-body Mediated Rejection|Determine whether AlloSure predicts the incidence of active, chronic Anti-body Mediated Rejection and cellular rejection in high risk patients
32923587|NCT04928131||Anorectal|Patients presenting with anorectal pain.
32721786|NCT03769519|No Intervention|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
32721787|NCT03769519|Experimental|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
32721788|NCT03521037|Experimental|no name|Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
32721789|NCT02310347|Experimental|Marinol|"generic name: dronabinol~dosage: 0.1 mg/kg~frequency: 2 times a single dose~duration: acute adminstration"
32923588|NCT04928131||TMJ|Patients presenting with temporomandibular joint pain.
32923589|NCT04928131||Foot/Ankle|Patients presenting with foot and ankle pain.
32923590|NCT01826851|Experimental|Exparel|266 mg Exparel, single-dose injection.
32923591|NCT01826851|Placebo Comparator|Placebo|0.9% Normal saline, single-dose injection.
32923592|NCT04893967|No Intervention|No Intervention: RMS mean hip abduction, dynamometer|Isometric peak force hip abduction pre measurement. No tape.
32923593|NCT04893967|No Intervention|No Intervention: Average force hip abduction, dynamometer|Isometric average force hip abduction pre measurement. No tape.
32923594|NCT04893967|No Intervention|No Intervention: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction pre measurement. No tape.
32923595|NCT04893967|No Intervention|No Intervention: RMS mean hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean. No tape.
32721790|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
32721791|NCT05097963|Experimental|Subjects undergoing EUS shear wave elastography|Subject who are eligible will undergo EUS for clinical indications. EUS shear wave measurements will be gathered and studied to determine diagnostic accuracy when compared to MR Elastography.
33249698|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
33249699|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
32721792|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
32721793|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
32721794|NCT03124875|Experimental|Treatment|Treated with the LimFlow Stent Graft System
32721795|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
32721796|NCT05096247|Experimental|Treatment with RF Device|Subjects in this arm of the study will be treated with the radiofrequency device, and will receive up to 4 treatments on the face.
33249700|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
32923596|NCT04893967|No Intervention|No Intervention: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean per second. No tape.
32923597|NCT04893967|No Intervention|No Intervention: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) Max. contraction test. No tape.
32923598|NCT04893967|Experimental|Experimental: peak force hip abduction, dynamometer|Isometric peak force hip abduction post experimental application measurement with Magnetic Tape application
32923599|NCT04893967|Experimental|Experimental: Average force hip abduction, dynamometer|Isometric average force hip abduction post experimental application measurement with Magnetic Tape application
32923600|NCT04893967|Experimental|Experimental: time to maximum force hip abduction, dynamometer|Time to maximum force hip abduction post experimental application measurement with Magnetic Tape application
32923601|NCT04893967|Experimental|Experimental: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) with Magnetic Tape application.
32923602|NCT04893967|Experimental|Experimental: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) mean per second. With Magnetic Tape application.
32923603|NCT04893967|Experimental|Experimental: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) max. contraction test. With Magnetic Tape application.
32923604|NCT04893967|Placebo Comparator|Placebo: peak force hip abduction, dynamometer|Isometric peak force hip abduction post placebo measurement with kinesiology tape application
32721797|NCT05096247|Experimental|Treatment with IPL and RF Device|Subjects treated in this arm of the study will receive 2 treatments with just the radiofrequency device and then 2 treatments with both the radiofrequency and the IPL laser.
32721798|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
32923605|NCT04893967|Placebo Comparator|Placebo: Average force hip abduction, dynamometer|Isometric average force hip abduction post placebo application measurement with kinesiology tape application
32923606|NCT04893967|Placebo Comparator|Placebo: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction post placebo application measurement with kinesiology tape application
33073385|NCT02233829|Active Comparator|Morning MRI/PET/Raclopride/IV Methylphenidate Session|Morning Session [11C]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for [11C]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
33249701|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
32721799|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
32721800|NCT05374161|Experimental|Brief ACT-based intervention|A 6- week ACT intervention for depression and physical pain will be delivered.
32721801|NCT05374161|Other|Waitlist control group (WL)|The WL control group will receive treatment as usual, just like women in the experimental condition.
32721802|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
32721803|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
32721804|NCT02758431|Placebo Comparator|Group 1: Acyline plus placebo (No Testosterone Add-Back)|Acyline plus placebo gel and placebo tablet.
32721805|NCT02758431|Active Comparator|Group 2: Acyline plusTestosterone|Acyline plus transdermal testosterone gel plus placebo tablet.
32721806|NCT02758431|Active Comparator|Group 3: Acyline plus Testosterone plus Arimidex)|Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.
32721807|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
32721808|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
32721809|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
32721810|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
32721811|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
32721812|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
32721813|NCT03505463||Injured participants|
32721814|NCT03505463||Healthy participants|
32721815|NCT04429425|Other|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
32721816|NCT04429425|No Intervention|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
32721817|NCT04997187|Experimental|Bacillus coagulans group|This group takes Bacillus coagulans for 12 weeks.
32721818|NCT04997187|Placebo Comparator|Control group|This group takes placebo for 12 weeks.
32721819|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
32721820|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
32721821|NCT04533477|Experimental|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
32767717|NCT04201873|Active Comparator|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
32767718|NCT04196335|Experimental|single-arm|
32923607|NCT04893967|Placebo Comparator|Placebo: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean. With kinesiology tape application.
32923608|NCT04893967|Placebo Comparator|Placebo: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean per second. With kinesiology tape application.
32767719|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
32767720|NCT04183699|Experimental|MRI targeted + systematic random biopsy|
32767721|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
33249702|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
32923609|NCT04893967|Placebo Comparator|Placebo: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) max. contraction test. With kinesiology tape application.
32923610|NCT05746897|Experimental|NM1F Injection/pembrolizumab Injection|NM1F monotherapy dose escalation(Phase 1a) NM1F dose escalation in combination with a fixed dose of pembrolizumab(Phase 1b)
32923611|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
32923612|NCT02499497|Active Comparator|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
32923613|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
32923614|NCT02499497|Active Comparator|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
32923615|NCT01827475|Active Comparator|Ibuprofen|Ibuprofen 800 mg
32923616|NCT01827475|Active Comparator|Acetaminophen|Acetaminophen 1 gm
32923617|NCT01827475|Experimental|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
32923618|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
32923619|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
32923620|NCT05746741|Experimental|Telehealth solution|Telehealth solution offered
32923621|NCT05746741|No Intervention|Control|Usual care
32923622|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
32923623|NCT04828837|Experimental|Bubble positive expiratory pressure training|The experimental group receives the Bubble PEP training.
32923624|NCT04828837|No Intervention|general care|The control group receives the division of chest ward routine care.
32923625|NCT04809493||patients will be receiving conventional dialysis|Patients will be receiving conventional dialysis treatment followed by isonatremic dialysis treatment during an observational period of 2 months for each treatment
33249703|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
33249704|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
32923628|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
32923629|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
32923630|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
32923631|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
32923632|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
32923633|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
32923634|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
33249705|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
32923635|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
32923636|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
32721822|NCT04533477|Active Comparator|Routine surgery|The participants undergo routine standardized surgery.
32721823|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
32721824|NCT04463537|Experimental|experiment group|"Firstly, patients selected with convenience sampling. In the sampling method, the order of the patients' enrollment to the emergency room was used. Then, patient's age, sex and presence of otitis media were recorded in the Personal Information Form.~After recording, measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale. The auricle on the same side was used during both measurements."
32721825|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
32721826|NCT05375487|Experimental|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
32923637|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
32923638|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
32923639|NCT02437487|Placebo Comparator|Placebo|Placebo
32923640|NCT01827787|Experimental|Cohort 1: HR+/HER2-|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
32923641|NCT01827787|Experimental|Cohort 2: TNBC|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
32721827|NCT05375487|Placebo Comparator|Low Mineral Water|750 mL/day of low mineral water.
32721828|NCT05375409||Postoperative Delirium (+)|
32721829|NCT05375409||Postoperative Delirium (-)|
32721830|NCT05375409||Healthy Control|
32721831|NCT03745651|Placebo Comparator|Vehicle Control (VC) Period: Vehicle Cream BID|Participants received ruxolitinib matching vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
32721832|NCT03745651|Experimental|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
32923642|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
32923643|NCT04747249|Experimental|Psychological support|Monthly psychological support
32923644|NCT02247427|Experimental|Off-pace group|Deactivated device group
32721833|NCT03745651|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
32721834|NCT03745651|Experimental|Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
32721835|NCT03745651|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
32923645|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
32923646|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
32923647|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
32923648|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
32923649|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
32923650|NCT02553395|Experimental|Phenacite contact lens|Study Test Contact Lens
32923651|NCT02553395|Active Comparator|comfilcon A contact lens|Control Contact Lens
32923652|NCT01829503|Experimental|decitabine and cytarabine|
33400247|NCT05029999|Experimental|Cohort A|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
33400248|NCT05029999|Experimental|Cohort B|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle starting on cycle 2 until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
33400249|NCT05029999|Experimental|Cohort C|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle starting on cycle 2 until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 2 and 3 only."
33400250|NCT05679544|Experimental|Subjects occupationally exposed to PAHs|
33400251|NCT03959202|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
33400252|NCT03959202|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
33400253|NCT04055818|Experimental|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
33400254|NCT04055818|Experimental|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
32767722|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
32767723|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
32767724|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
32767725|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
32767726|NCT02996305|Placebo Comparator|Placebo|Twice daily
32767727|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
32767728|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
32767729|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
32767730|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
32767731|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
32767732|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
32767733|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
32767734|NCT03102853|Active Comparator|Nordic diet|
32767735|NCT03102853|Other|Control diet|
33400255|NCT05597670|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
33400256|NCT05597670|Experimental|group B|Patients in this group will receive the same program as group (A) plus proximal stabilization exercise
33400257|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
33400258|NCT04353271|Experimental|Hydroxychloroquine|Subjects in this arm will receive the study drug
33400259|NCT04353271|Placebo Comparator|Placebo|Subjects in this arm will take placebo for 6 days
33400260|NCT03417882|Experimental|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
33400261|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
33400262|NCT01374568|Placebo Comparator|Placebo|Placebo
33400263|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
33400264|NCT03706183||Control Group|The IMA levels will be determined.
32923653|NCT04691167|Active Comparator|group 1, Active intervention group|
32923654|NCT04691167|Sham Comparator|group 2, sham controlled group|
32923655|NCT04654507|Active Comparator|Adjuvant dexamethasone|Drug: Dexamethasone
33249706|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
32923656|NCT04654507|Placebo Comparator|Placebo|Drug: Placebo
32923657|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
32923658|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
32923659|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
32923660|NCT05744089|Experimental|Cancer patients suffering severe or critically painful|
32923661|NCT05742763|Active Comparator|Ibuprofen and PRP|Weight based Ibuprofen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
32923662|NCT05742763|Active Comparator|Acetaminophen and PRP|Weight based Acetaminophen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
32923663|NCT05742763|Placebo Comparator|Placebo and PRP|Placebo provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
32923664|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
32923665|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
32923666|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
32923667|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
32923668|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
33249707|NCT00947050|Active Comparator|exercise first|ex first
32923669|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
32923670|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
32923671|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
32923672|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~Brentuximab Vedotin intravenously on predetermined days per cycle~Adriamycin intravenously on predetermined days per cycle~Dacarbazine intravenously on predetermined days per cycle"
32923673|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
32923674|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
32923675|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
32923676|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
32923677|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
32923678|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
32923679|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
32923680|NCT05131607|Experimental|Supine MRI|
32923681|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
32923682|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
33400265|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
33249708|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
33249709|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
33249710|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
33400266|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
32767736|NCT04866485|Experimental|HBM4003+pembrolizumab|HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors
32767737|NCT04858373|Experimental|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
33400267|NCT05509036||Critically ill patients|Critically ill adults > 50 admitted to the ICU and receiving a life support intervention
33400268|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
33400269|NCT03114826||Renal cell carcinoma in renal transplant patients|
32767738|NCT04858373|Experimental|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32767739|NCT04858373|Experimental|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32767740|NCT04858373|Experimental|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32767741|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
32767742|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
32767743|NCT04858139|Placebo Comparator|placebo|patients will be injected with placebo
32767744|NCT04858139|Active Comparator|Lactate|patients will be injected with lactate solution
32767745|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
32767746|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
32767747|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
32767748|NCT04864691|Experimental|endovascular recanalization plus standard medical treatment|patients with symptomatic non-acute intracranial artery occlusion treated by endovascular recanalization and standard medical treatment after procedure
32767749|NCT04864691|Active Comparator|standard medical treatment|Patients take aspirin 100 mg/day or clopidogrel 75mg/day for the entire follow-up period (EVR patients take aspirin 100 mg/day and clopidogrel 75mg/day for 30-90 days after procedure)
32767750|NCT02838745|Experimental|Pemetrexed (300 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
32767751|NCT02838745|Experimental|Pemetrexed (400 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
32923683|NCT05734729|Experimental|Pleural Arm|Patient's maximum volume is 1 litre per hour, not to exceed total 4 litres over 4 hours
32923684|NCT05734729|Experimental|Ascites arm|Patient's maximum volume is 3 litre per hour, not to exceed total 15 litres over 5 hours
32923685|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
32923686|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
32923687|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
32923688|NCT04580095|Experimental|With AI algorithm|"In the With AI algorithm arm, the sonographer will perform the echocardiographic exam using the AI algorithm."
32923689|NCT04580095|No Intervention|Without AI algorithm|"In the Without AI algorithm, the echocardiographic exam will be performed without the use of the AI algorithm."
32923690|NCT04561297|Experimental|Biopsied Patients|Patients scheduled for a breast biopsy will have breast tissue dielectric constant measurements made prior to the biopsy
32923691|NCT05006963|Experimental|face-to-face group|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
32923692|NCT05006963|Active Comparator|telerehabilitation|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, by telerehabilitation lasting 40 minutes each.A physiotherapist through video call via WhatsApp application. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms. Patients will be instructed to perform extra-oral and intra-oral self-massage and in the cranio-cervical musculature, bone mobilization hyoid, which would replace the mobilization unspecific articulation performed in person.Exercise will also be carried out mouth opening with tongue on the palate, exercises proprioceptives with hyperboloid. The conducts will be adapted according to the needs of each patient.The conducts will be adapted according to the needs of each patient.The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene
32923693|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
32923694|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
32923695|NCT04550377|Active Comparator|Cannabidiol Group 1|40 participants will be titrated to a maximum dose of oral cannabidiol 800 mg daily over 2 weeks for a total of 8 weeks treatment.
32923696|NCT04550377|Active Comparator|Cannabidiol Group 2|40 participants will be titrated to a maximum dose of oral cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.
32923697|NCT04550377|Placebo Comparator|Placebo Group|40 participants will be given a placebo for a total of 8 weeks treatment.
32721836|NCT03745651|Experimental|LTS Period: Ruxolitinib 0.75% Cream BID|Participants who applied ruxolitinib 0.75% cream during the VC Period, continued applying ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
32721837|NCT03745651|Experimental|LTS Period: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during the VC Period, continued applying ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
32721838|NCT05098353|Experimental|Quetiapine 25-75 mg|"There is one arm in this study. Patients will take quetiapine in dose 25-75 1-3 times a day.~Dose and its frequency can be adjusted by researcher during first 2 weeks (till visit 2), after that patients will take stable dose of quetiapine till week 6 (visit 3)."
32923698|NCT04479085|Experimental|experimental group|The nursing attempt to organize the home environment for the experimental group will take 17 weeks. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. Children in this group will be given an anti-allergic duvet cover. Home environment arrangements of mothers and changes in the quality of life of children will be examined at the beginning and end of the study. Children's symptoms will be monitored weekly for 17 weeks.
32721839|NCT05098119|Experimental|Sintilimab+ Carboplatin + Nab-paclitaxel|"Neoadjuvant therapy (the total cycles of the treatment is 3) ：~Cycle1（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1; Carboplatin (IV), dose=300mg/m2, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1.~Adjuvant therapy（will be dictated by surgical pathology and occurs after standard of care surgery）：~Sintilimab will be given intravenously once every 3 weeks for up to 1 year if participant is considered high-risk based on surgical pathology（high risk features：positive margins or extracapsular extension).~These doses of Sintilimab will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
32721840|NCT04437849|Experimental|Telemonitoring|
32721841|NCT04437849|No Intervention|Usual Care|
32721842|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
32721843|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
32767752|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
32767753|NCT04143919|Experimental|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
32767754|NCT00136435|Other|Only Arm for this study|Only Arm for this study
32767755|NCT04857905|Other|Microsurgical Resection of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling~-> Patients who after counseling decide for microsurgical resection of their brain metastasis"
32767756|NCT04857905|Other|Radiosurgery of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling~-> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis"
33400273|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
33400274|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
33400275|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
33400276|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
33400277|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
33400278|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
33400279|NCT05486572|Active Comparator|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
33400280|NCT05486572|Other|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
33400281|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
33400282|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
33400283|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
33400284|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
33400285|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
33400286|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
33400287|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
33400288|NCT05367895||Exposure group 1|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022 and received a three-dose homologous vaccination with CoronaVac. Specifically, ≥14 days after receipt of the third vaccine dose using a homologous regimen with CoronaVac.
32721844|NCT04880109|Experimental|APX-115|Oral administration of APX-115 100mg, daily for 14 days
32721845|NCT04880109|Placebo Comparator|Placebo|Oral administration of Placebo, daily for 14 days
32721846|NCT04830501|Experimental|Dose Escalation|This study adopts an accelerated titration design (ATD) and utilizes an accelerated dose escalation phase in order to minimize suboptimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD.
32721847|NCT03587493|Experimental|EXPERIMENTAL GROUP|"110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.~Blood sample analysis will be performed"
32721848|NCT04815681|Experimental|Common Elements Toolbox (COMET)|
32721849|NCT04815681|Active Comparator|Active Control Condition|
32721850|NCT04373707|Active Comparator|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
32721851|NCT04373707|Experimental|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
32721852|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
32721853|NCT05097573|Experimental|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, stretch marks and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
32721854|NCT05374083|Experimental|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as demineralized dentin block graft and inserted in the extraction socket and covered then suturing
32721855|NCT05374083|Active Comparator|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non-restorable teeth, then the socket will be packed by particulate deproteinized bovine bone graft and covered then suturing
32721856|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
32721857|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
32721858|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
32923699|NCT04479085|No Intervention|control group|No intervention will be made on the control group. The humidity and temperature changes in the home environment of the children in this group and their symptoms will be monitored on a weekly basis during the study.
32923700|NCT04768933|Experimental|Toddler Milk Group|All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
32721859|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
32721860|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
32721861|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
32721862|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
32923701|NCT05726851|Experimental|Part A, Cohort 1: E2025 Dose 1 or Placebo|Participants will receive E2025 Dose 1 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
32923702|NCT05726851|Experimental|Part A, Cohort 2: E2025 Dose 2 or Placebo|Participants will receive E2025 Dose 2 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
32923703|NCT05726851|Experimental|Part A, Cohort 3: E2025 Dose 3 or Placebo|Participants will receive E2025 Dose 3 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
32721863|NCT05097417|Experimental|traditional Chinese medicine combined with thermal or cold ablation|
32721864|NCT05097417|Active Comparator|thermal or cold ablation|
32721865|NCT05097339||Patients with type 1 diabetes|Patients with type 1 diabetes perform a morning Symptom Limited Maximal Exercise Test (CPET) or a 60-minute morning Aerobic Test (AEX) at 60% VO2peak
32721866|NCT04289311|Experimental|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
32721867|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
32721868|NCT03397719|Active Comparator|Control Group|This group will receive treatment as usual. Each participant will receive three hours of in-vivo parent coaching per week for 6 months.
32923704|NCT05726851|Experimental|Part A, Cohort 4: E2025 Dose 4 or Placebo|Participants will receive E2025 Dose 4 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
32923705|NCT05726851|Experimental|Part B, Cohort 5: E2025 Dose 2|Participants will receive E2025 Dose 2 administered as an IV infusion on Day 1.
32923706|NCT05726851|Experimental|Part B, Cohort 6: E2025 Dose 3|Participants will receive E2025 Dose 3 administered as an IV infusion on Day 1.
32923707|NCT05726851|Experimental|Part B Cohort 7: E2025 Dose 4|Participants will receive E2025 Dose 4 administered as an IV infusion on Day 1.
32721869|NCT03397719|Experimental|Treatment Condition|This group will receive an additional component which will involve videotaping parent/child interactions at home for thirty minutes a week. Each week, the therapist will select sections of the video to review with the parent during one of the parent coaching sessions.
32721870|NCT04455919|Experimental|Yoga|Yoga classes once a week for eight weeks
32721871|NCT04455919|Other|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
32721872|NCT03237819|Placebo Comparator|Placebo|Glucose serum (3 ampoules)
32721873|NCT03237819|Experimental|Magnesium Sulfate|20/5000 magnesium sulfate (4 ampoules, 1,5g each)
32721874|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
32721875|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
32923708|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
32923709|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
33400289|NCT05367895||Exposure group 2|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received a two-dose vaccination with CoronaVac and did not receive any booster vaccine. Specifically, ≥14 days after receipt of the second vaccine dose and before the third dose of CoronaVac.
33400290|NCT05367895||Exposure group 3|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received only one dose vaccination with CoronaVac and did not receive any other vaccine dose. Specifically, ≥14 days after receipt of the first vaccine dose and before the second dose of CoronaVac.
32923712|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
32923713|NCT05707897|Experimental|Fed condition|Period in which subjects receive a single oral dose of TS-142 tablet in fed condition.
32923714|NCT05707897|Experimental|Fasted condition|Period in which subjects receive a single oral dose of TS-142 tablet in fasted condition.
32923715|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
33400291|NCT05367895||Non-Exposure group|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who were not vaccinated. No history of vaccination for any type of COVID-19 vaccine, or <14 days after receipt of the first vaccine of CoronaVac.
32923716|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
32923717|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
32923718|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
32923719|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
32923720|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
32721876|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
32742948|NCT04949217|Experimental|Inlay Bristow Group|Inlay Bristow procedure
32923721|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
32923722|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
32923723|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
32923724|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
32923725|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
32742949|NCT04949217|Active Comparator|Onlay Bristow Group|Onlay Bristow procedure
33400292|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
33400293|NCT05466994|Other|Group 1(Spellbound)|Participants will play the game using the iPad's standard camera, which will show you your hospital room and the decals as they appear in the real world.
32742950|NCT04960449||patients with partial-thickness rotator cuff tendon tears|Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
32923726|NCT04743323||Study Participants|"Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time.~Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant.~Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease."
32721877|NCT03505385|Experimental|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
32923727|NCT04950881|Sham Comparator|Control group|Conventional monitor and treatment The surgery is performed after patient is under general anesthesia. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate.
32923728|NCT04950881|Experimental|Nerve block group|After the patient is under general anesthesia, an attending physicians perform the ultrasound-guided cervical vagus nerve block (using a 50mm Braun nerve stimulation needle, and the patients were injected with 10ml of lidocaine or ropivacaine ). Then the operation starts. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate. After endotracheal tube is removed, the patient will be followed up for next 24 hours.
32721878|NCT03505385|No Intervention|Usual care|
32721879|NCT05356221||Ponto Users|Users that have been fitted with a Bone Anhcored Sound Processor, Ponto
32923729|NCT04341077|Experimental|SHR3162|A single dose of fluzoparib was administered orally
32721880|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
32721881|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
32721882|NCT05089851|Active Comparator|Peptide Antiaging Serum|"Dosage Form: Serum composed of water, thickener, and bioactive ingredients including peptides and antioxidants.~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
32721883|NCT05089851|Placebo Comparator|Placebo Serum|"Dosage Form: Serum composed of water and thickener~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
32721884|NCT00515671|Experimental|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
32721885|NCT00515671|Placebo Comparator|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
32721886|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
32721887|NCT02311127|Active Comparator|StatLock|Adhesive securement
32721888|NCT04657809|Experimental|Insulin fast dissolving film|Formulated bioadhesive fast dissolving film contains 100IU of insulin
32721889|NCT04657809|Placebo Comparator|Plain fast dissolving film|Formulated bioadhesive fast dissolving film contains no drug
32721890|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
32721891|NCT04457167|Experimental|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
32721892|NCT04457167|Active Comparator|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
32721893|NCT05350917|Experimental|Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate|One arm study
32923730|NCT04914767|Experimental|Nigella|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
33400294|NCT05466994|Other|Group 2 (Spellbound)|Participants will play the game using augmented reality
33400295|NCT05354245|Experimental|Fibre mixture group|Use of a fibre mixture (3 times daily, 5 grams per gift, total of 15 grams per day) during 12 weeks
33400296|NCT05354245|Placebo Comparator|Placebo group|Use of a placebo (maltodextrin, isocaloric manner, 3 times daily) during 12 weeks.
32721894|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32721895|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32923731|NCT04914767|Placebo Comparator|Placebo Group|"The patient will also receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
32923732|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
32923733|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
32923734|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
32923735|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
32923736|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
32923737|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
32923738|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
32923739|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
32923740|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
32721896|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32742951|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
32923741|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
32923742|NCT04887779|Experimental|Intervention|Patient viewing ex-planted organ and microscopy with pathologist
32923743|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
32923744|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
32923745|NCT04796129||patients with hip osteoarthritis|the patients who aged 45 and older and have paint in the hips. and also without having any other comorbidities about inflammatory status.
32923746|NCT04796129||control|the participants who have any other comorbidities for impact on the inflammatory status and also no hip pain.
32923747|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
32923748|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
32742952|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
32923749|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
32923750|NCT05446883|Experimental|QL1706+chemotherapy± bevacizumab|QL1706 (5 mg/kg) + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
32923751|NCT05446883|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
32923752|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
32923753|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
32923754|NCT05445167|Experimental|KLH-2109|
32923755|NCT05445167|Placebo Comparator|Placebo|
32923756|NCT04631939|Experimental|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
32923757|NCT04631939|Sham Comparator|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
32923758|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
32923759|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
32923760|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
32923761|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
32923762|NCT04563923|Experimental|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks~They receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
32923763|NCT04563923|Other|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
32923764|NCT04484285|Active Comparator|Younger Cohort|Healthy individuals aged 18 - 55
32721897|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32721898|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32721899|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
32721900|NCT05390905|Experimental|HSK21542|HSK21542 injection
32923765|NCT04484285|Active Comparator|Older Cohort|Healthy individuals aged 56 - 85
32923766|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
32923767|NCT00558103|Active Comparator|arm 1|Lapatinib
32721901|NCT05390905|Experimental|tramadol|Tramadol hydrochloride injection
33400297|NCT05464888|Experimental|+Short AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog prior to their oral exam.
33400298|NCT05464888|Experimental|+Long AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog throughout their entire visit.
33400299|NCT05464888|Active Comparator|Active control; NO dog|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 control patients who will not be interacting with the dog during their visit and will color a dog picture for 3 minutes instead.
33400300|NCT03165214|Active Comparator|coil group|micro coils
32721902|NCT05390905|Placebo Comparator|placebo|placebo
32742953|NCT04960527|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK, 100% Montmorency) diluted with 220 mL water (totalling 250 mL). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries.
32742954|NCT04960527|Other|Water|250 mL water (neutral control)
32923768|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
32923769|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
32923770|NCT02974361|Active Comparator|Part A Ibuprofen control|
32923771|NCT02974361|Experimental|Part A Ibuprofen-LDH|
32923772|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
32923773|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
32923774|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
33400301|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
33400302|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
33400303|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
33400304|NCT05464030|Experimental|M9140|
32923775|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
32923776|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
32923777|NCT02974361|Active Comparator|Part B Ibuprofen|
32923778|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
32721903|NCT03019497|Experimental|CBT-E|CBT-E refers to Cognitive Behavioral Therapy with specific modules. In the CBT-E condition and following the identification of the needs identified during the evaluation, additional strategies will be added to the CBT strategies for PTSD to address one or more of the seven related problem types that emerged as a result of the traumatic event: 1) major depression, 2) sleep disorders, 3) pain, 4) stressors, 5) inadequate social support, 6) substance use disorder, and 7) anxiety disorder.
32721904|NCT03019497|Active Comparator|CBT-C|CBT-C refers to Cognitive Behavioral Therapy without specific modules. CBT-C participants will be offered only cognitive-behavioral intervention strategies to alleviate the symptoms of each of the PTSD diagnostic criteria.
32721905|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
32721906|NCT05064657|Experimental|Experimental Group|"Experimental Group (ball squeezing) The group were used a ball squeezing method during the blood collection process.~The children were given a ball during the blood draw and told to tighten and loosen it."
32721907|NCT05064657|Active Comparator|Active Comparator|Active Comparator ( bubble blowing) The group were used a bubble blowing method during the blood collection process. During the blood collection process, the children were asked to blow bubbles by giving the apparatus inside the foam bubble to their free arm.
32721908|NCT05064657|No Intervention|Control Group|No intervention
33400305|NCT04716127|Experimental|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
32721909|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
32721910|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
32721911|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
33400306|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
32721912|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
32721913|NCT05390749|Experimental|POR-ROMTX|The experimental arm will be treated with 4 cycles of POR regimen （Pomalidomide 4mg d1-d14, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle). The response will be evaluated every 2 cycles. The patients with PD will drop out of the study.Patients with CR/PR/SD after 4 cycles of POR treatment will be treated with 2 cycles of RO-MTX regimen（methotrexate 3.5g/m2 civ d1, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle).
32721914|NCT02813655|Experimental|Experimental arm|Tetracosactide (Synacthène®)
32721915|NCT02813655|Placebo Comparator|Control arm|placebo saline (0.9% NaCl)
32721916|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
32721917|NCT04936113|Experimental|FB-401|FB-401 applied topically
32721918|NCT03468829|Experimental|ALX-0171 Dose 1|
32721919|NCT03468829|Experimental|ALX-0171 Dose 2|
32721920|NCT03468829|Placebo Comparator|Placebo|
32721921|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
32721922|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
32721923|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
32721924|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
32721925|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
32721926|NCT04912791||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
32721927|NCT04217473|Experimental|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
32721928|NCT05334927||Medicine Overuse Headache/New Daily Persistent Headache|The first 18 months were followed up once a month,then followed up once at the 24th month,follow-up visits were made annually after 24 months
32721929|NCT05334927||Chronic Migraine|The patients were followed up at 1, 2, 3, 6, 9, 12, 18 and 24 months,then follow-up visits were made annually
32721930|NCT05334927||Patients with other types of primary headache|The patients were followed up at 3, 6, 9months
32721931|NCT02316197|Experimental|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721932|NCT02316197|Experimental|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32923779|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
32923780|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
32923781|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
32923782|NCT02974361|Active Comparator|Part C Ibuprofen|
32923783|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
32923784|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
32923785|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
32923786|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
32923787|NCT05690815||gbMSM|This study will enroll gay, bisexual men who have sex with men (gbMSM), transgender and gender non-binary participants.
32923788|NCT04282603|Experimental|Experimental Meal Replacement|Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
32923789|NCT04282603|Active Comparator|Bariatrics Advantage Meal Replacement|Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
32923790|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~6 months of treatment; or~24 months of treatment (if continued on chronic suppressive therapy)"
33400307|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
32721933|NCT02316197|Experimental|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721934|NCT02316197|Experimental|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721935|NCT02316197|Experimental|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721936|NCT02316197|Experimental|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721937|NCT02316197|Experimental|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
32721938|NCT04010851|Experimental|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
32721939|NCT04010851|Other|Control group|The control goup will receive treatment as usual.
32721940|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
32721941|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
32721942|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
32721943|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
32721944|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
33400308|NCT04693039|Experimental|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
33400309|NCT04693039|Experimental|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
32721945|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
32721946|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
32721947|NCT02314091|Experimental|Onlay|Onlay mesh repair group
32721948|NCT02314091|Experimental|sublay|Sublay mesh repair group
32923791|NCT04198675|Active Comparator|Supervised EMG Biofeedback Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
32923792|NCT04198675|Active Comparator|Home-Based Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
32923793|NCT04198675|Sham Comparator|Posture Training/Ergonomic Regulations Group|1 session, no further intervention until second evaluation for 6 weeks.
32923794|NCT04093297|Active Comparator|Group Ring|Patients in Group Ring will undergo tricuspid rigid ring annuloplasty
32923795|NCT04093297|Active Comparator|Group Band|Patients in Group Band will undergo flexible band annuloplasty
32923796|NCT04477733|Experimental|Butorphanol group|
32923797|NCT04477733|Placebo Comparator|control group|
32923798|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
32923799|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
33400310|NCT04693039|Experimental|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
33249711|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
33249712|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
33249713|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
32767757|NCT04857749|Active Comparator|Control group|Data from patients in the control group will be collected as in the experimental group. In the first interview, the patients in the control group will be given a training booklet. Apart from this, the standard approach, treatment and care of the clinic will be applied to all patients.
32767758|NCT04857749|Experimental|Navigation grup|While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group. The navigation program will be started on the first day of radiotherapy by giving a 30-minute visual training and handbook related to expected side effects. Afterwards, patient follow-up will continue with phone reminders and weekly follow-up for seven weeks.
32767759|NCT05045209||Virtual rehabilitation|Virtual pulmonary rehabilitation will be provided by a tablet with connection to a physiotherapist for monitored exercise sessions with educational videos provided on the tablet.
33249714|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
32767760|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
32767761|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
32767762|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
32767763|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
32767764|NCT04866251|Active Comparator|Healthy young subject|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767765|NCT04866251|Active Comparator|Healthy older subjects|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767766|NCT04866251|Active Comparator|Acute stroke patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767767|NCT04866251|Active Comparator|Patients with Parkinson´s Disease|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767768|NCT04866251|Active Comparator|Patients with Multiple Sclerosis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767769|NCT04866251|Active Comparator|Patients with Myasthenia gravis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767770|NCT04866251|Active Comparator|Geriatric patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
32767771|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
33249715|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
33249716|NCT00861315|Active Comparator|Intravenous amikacin|
33249717|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
33400311|NCT04693039|Experimental|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
32767772|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
32767773|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
32767774|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
32923800|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
32923801|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
32923802|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
32923803|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
32923804|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
33249718|NCT00388297|Experimental|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
32721949|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
32721950|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
32721951|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
32721952|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
32721953|NCT04470063|Experimental|group A|
32721954|NCT04470063|Experimental|group B|
32721955|NCT04470063|Experimental|group C|
32721956|NCT05331807|Experimental|Group (A)|Participants will be received daily omega-3 fatty acid (two capsules of 1000mg fish oil daily). Each soft gel capsule contains 300 mg of omega-3 fatty acids in the bioactive triglyceride (TG) and 180mg EPA and 120 mg DHA. (Omega3 complex, Jamieson Laboratories, Canada)
32721957|NCT05331807|Experimental|Group (B)|Participants will be received only vitamin D (one capsule of 50,000IU weekly). Each film coated tablet of vitamin D contains 50,000 IU Vitamin D3 (Cholecalciferol). (J-Dee, Jerusalem Pharmaceutical Company, West bank, Palestine).
32721958|NCT05331807|Experimental|Group (C)|Participants will be received both omega-3 fatty acids capsules and vitamin D3 capsule. (one capsule of D3 50,000 IU weekly + two omega-3 fatty acids capsules daily (each capsule contains 300 mg of omega-3 fatty acids)
32721959|NCT05331807|No Intervention|Group (D)|Participants will not be received any supplements and just receive oncology treatment as an usual oncology patient.
32721960|NCT05390593|Experimental|iTBS-1800|The active group will receive 1800 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
32721961|NCT05390593|Experimental|iTBS-1200|The active group will receive 1200 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
32721962|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
32721963|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
32721964|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive tragus stimulation for 8 hours per day during hospital stay.
32721965|NCT02898181|No Intervention|Control group|No tragus stimulation will be done
32721966|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
32721967|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
32721968|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
32721969|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
32721970|NCT03502499|Experimental|Half-normal saline|
32721971|NCT03502499|Active Comparator|Normal saline|
32721972|NCT04402827||Cases|HCW highly exposed (defined as more than 15 days of continued personal attention in ICU, anaesthesia, or Infectious Diseases wards) to patients with a diagnosis of COVID-19 (PCR confirmed), who remained asymptomatic and with a negative serology (IgM and IgG negative). Transient entry or stay in the zone (kitchen personnel, rehab members,...) will be not included.
32721973|NCT04402827||Controls|HCW highly exposed to PCR-confirmed patients with a diagnosis of COVID-19, as defined above, matched by age and sex, who had suffered confirmed SARS CoV-2 disease (positive PCR or after, positive IgG)
32721974|NCT02630641||Prostate cancer patients|
32721975|NCT04707261|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
32721976|NCT04707261|Placebo Comparator|Placebo|Standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
32721977|NCT02547337||Type 1 diabetes|
32721978|NCT02547337||Healthy subjects|
32721979|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
32721980|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
33249719|NCT00388297|Placebo Comparator|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
33249720|NCT00388297|Experimental|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
32923805|NCT04010747|Experimental|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
32923806|NCT04010747|Active Comparator|Mental Health Services Consultation and Waitlist|This consultation will consist of a 30 minute appointment in which participants can speak with a clinician knowledgeable about psychosis treatment resources. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will then be placed on a 6-week waitlist, after which they will have the opportunity to participate in the active intervention (four sessions of MILO).
32923807|NCT05688943|Active Comparator|General Anesthesia|This arm will receive general anesthesia for vNOTES surgery.
32923808|NCT05688943|Experimental|Spinal Anesthesia|This arm will receive spinal anesthesia for vNOTES surgery.
32923809|NCT04218773|Experimental|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
32923810|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
32923811|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
33249721|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
32923812|NCT04169009|Active Comparator|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
32923813|NCT04169009|Active Comparator|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
33249722|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4~600 mg of atazanavir to be taken once daily~400 mg of raltegravir to be taken twice daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~600 mg of atazanavir to be taken once daily~800 mg of raltegravir to be taken once daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
32721981|NCT04671381|Experimental|Audiology Best Practices plus Aural Rehabilitation (ABP+AR)|This experimental group will receive a hearing evaluation, an over-the-counter hearing aid fitting and orientation, and four-weeks of an aural rehabilitation program conducted by specially-trained community health workers. Additionally, these adults will complete pre- and post-questionnaires and speech perception testing.
32721982|NCT04671381|Active Comparator|Audiology Best Practices (ABP)|This comparison group of adults with hearing loss will receive a hearing evaluation and over-the-counter hearing aid fitting and orientation. The aural rehabilitation program will not be provided initially. These participants will complete pre- and post-questionnaires and speech perception testing.
32721983|NCT04671381|Active Comparator|Over-the-Counter Only (OTC-Only)|This comparison group of adults with hearing loss will receive a hearing evaluation. They will be provided with over-the-counter hearing aids but the audiologist will not assist with fitting the aids or providing an orientation. This arm mimics what would happen when a consumer privately purchases over-the-counter hearing aids. They will complete pre- and post-questionnaires and speech perception testing.
32721984|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivacaine
32721985|NCT02513329|Sham Comparator|Saline|Saline injection
32721986|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
32721987|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
32721988|NCT05101941|Experimental|immediate dental implants|
32721989|NCT02314481|Experimental|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly for 24 cycles monotherapy~Or in combination with chemotherapy:~For non-squamous: Cisplatin or Carboplatin plus pemetrexed & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly for 20 cycles~For squamous: Carboplatin plus paclitaxel & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly for 20 cycles~Until progression, unacceptable toxicity or completion of a total of 24 cycles."
32721990|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
32721991|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
32721992|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
32721993|NCT05160337|Other|Healthy Volunteers|Healthy Volunteers will be recruited into the study
32721994|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
32721995|NCT04437459|Experimental|Abbreviated Fat Tolerance Test|
33249723|NCT00861393|Other|CBT|
32721996|NCT04437459|Active Comparator|Oral Glucose Tolerance Test|
32721997|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
33249724|NCT00861393|Other|Waitlist|
33249725|NCT00854685|Experimental|1|
33249726|NCT00854685|Experimental|2|
32721998|NCT04428567|Experimental|Treadmill Exercise + Cognitive Training (Dual-Task)|The Dual-Task group will be provided with treadmill training with added simultaneous cognitive training during treadmill exercise training.
32923814|NCT04169009|Active Comparator|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
32923815|NCT04169009|Active Comparator|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
32923816|NCT03899753|Experimental|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
32923817|NCT03899753|Active Comparator|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
32923818|NCT03796793|Experimental|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
32923819|NCT03796793|Active Comparator|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
32923820|NCT04057105|Active Comparator|MusicGlove and Active HD-tDCS|During Active HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds and it will be turned ON for the remainder of 20 minutes.
32923821|NCT04057105|Sham Comparator|MusicGlove and Sham HD-tDCS|During Sham HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds to simulate the real-tDCS based skin sensation.
33249727|NCT00854685|Experimental|3|
32721999|NCT04428567|No Intervention|Control Group|The control group will be assessed as the intervention group at the same time intervals without the intervention.
32722000|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
32722001|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
32722002|NCT04371861||Treatment of lower extremity lesion via transradial access.|Interventions performed are standard of care for treatment of a peripheral lesion.
32722003|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
32722004|NCT05390515|Experimental|Tildrakizumab treatment|Biological/vaccine: tildrakizumab
32722005|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
32722006|NCT04345887||Spironolactone|2 x 100 mg spironolactone
32722007|NCT04345887||Placebo|2 x 1 placebo
32722008|NCT03818971|Experimental|alcohol consumption with alcohol use disorder (AUD)|subjects with regular alcohol consumption with AUD according to the DSM 5 without any other substance use disorder (except alcohol) without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
32722009|NCT03818971|Other|alcohol consumption without alcohol use disorder|subjects with regular alcohol consumption without AUD according to the DSM 5 without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
32722010|NCT03818971|Other|no alcohol consumption|subjects without alcohol consumption without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
32722011|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
32722012|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
32722013|NCT04339023|Experimental|OLP-Group|patients will receive in addition to TAU, 2 open-label Placebo (OLP) injections (containing each 5 ml of NaCl 9%) per day for two consecutive days following minimally invasive TLIF
32722014|NCT04339023|Other|TAU-group|The treatment as usual (TAU) group will serve as control group and will control for the natural course of postoperative pain under usual medication intake, following minimally invasive TLIF
33400312|NCT04693039|Placebo Comparator|Placebo-150mg|Drug：Placebo；Dosage：150mg；
33400313|NCT04693039|Placebo Comparator|Placebo-300mg|Drug：Placebo；Dosage：300mg；
32923822|NCT04125251|Active Comparator|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
32923823|NCT04125251|Active Comparator|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
32923824|NCT04125251|No Intervention|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
32923825|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
32923826|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
32923827|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
32923828|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
32923829|NCT03868657|Active Comparator|Moxifloxacin|Per os, 800 mg, once daily for 4 days
32923830|NCT03868657|Placebo Comparator|Placebo|Per os, 800 mg, once daily for 4 days
33400314|NCT04693039|Placebo Comparator|Placebo-600mg|Drug：Placebo；Dosage：600mg；
33400315|NCT04693039|Placebo Comparator|Placebo-900mg|Drug：Placebo；Dosage：900mg；
32923831|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:~First trimester~Pregnancy"
32923832|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:~First trimester~Pregnancy"
32923833|NCT03936335||Unexposed cohort|"Not exposed to systemic medications (including dupilumab) or phototherapy; and~Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:~First trimester~Pregnancy"
32923834|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
32923835|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
32923836|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection.~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin>99th centile within previous 48-hour period)."
32923837|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin >99th centile within the previous 48-hour period) at the time of recruitment.~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
32722015|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
32722016|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
32722017|NCT02314715||Controls|Participants without knee osteoarthritis
32722018|NCT05390437|Placebo Comparator|control group|starch (placebo) 4 grams per day for 60 days
32722019|NCT05390437|Experimental|Interventional group|Prebiotics (GOS) Galactooligosaccharides 4 gram per day for 60 days
32722020|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
32722021|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
32923838|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
32923839|NCT05670925|Experimental|Camrelizumab plus Famitinib with/without nab-palitaxel|
32923840|NCT04707989|Experimental|Ketone-Promoting Food Ingredient 1|Novel ketone-promoting food ingredient (#1) administered in a beverage once daily for 28 days.
32923841|NCT04707989|Placebo Comparator|Ketone Free Placebo|Beverage matched for appearance, volume, taste and texture to experimental arm (ketone promoting food ingredient #1) that does NOT contain a ketone ingredient. Consumed once daily for 28 days.
32923842|NCT04707989|Active Comparator|Ketone-Promoting Food Ingredient 2|Previously characterized ketone-promoting food ingredient (#2) administered in a beverage once daily for 28 days.
32923843|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
32923844|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
32923845|NCT04707833|Experimental|Patient infected or cured from covid19|"Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,~Nurses at the Rouen University Hospital infected with COVID 19, and cured,~Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR"
32923846|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
32923847|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
32722022|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
32722023|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
32722024|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
32722025|NCT01727011|Experimental|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
32722026|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
32722027|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
32722028|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
32923848|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
33249728|NCT00854685|Experimental|4|
32923849|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
32923850|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
32923851|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
32923852|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
32923853|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
32923854|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
32923855|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
32923856|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
32923857|NCT00364325||001|
32923858|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
32923859|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
32923860|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
33249729|NCT00854685|Placebo Comparator|5|
32722029|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
32722030|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
32722031|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
32722032|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
32722033|NCT00928447|Experimental|rHuPH20|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the nickel sulfate concentration (NSC) (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing rHuPH20 (3,000 Units [U]) will be administered once daily (QD) for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with drug rHuPH20 (3,000 U) at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing rHuPH20 will be then administered QD for 5 days.
32742955|NCT04941885|Experimental|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab(8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days) plus cyclophosphamide metronomic chemotherapy(50mg once a day orally) plus aromatase(once a day orally).
32742956|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
32923861|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
32923862|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
32923863|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
32923864|NCT03583541|Experimental|Treatment arm: HIVRR+S+FL|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate). They will also receive 6 financial literacy (FL) sessions provided twice a week for 3 weeks
33400316|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
33249730|NCT00854685|Placebo Comparator|6|
33249731|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients (n = 59) assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
32923865|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|"Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.~*Revision note: Following COVID-19, with approval from NIMH (on record if requested), the HIVRR+S+FLM treatment of the study has been combined with the HIVRR+S+FL treatment arm. The total sample size has been revised to 532 participants, with approval from NIMH."
32923866|NCT04743011|Placebo Comparator|Placebo|Participants will receive inhalation with 5mL 0.9% saline solution (placebo), 4/4h, during the day period (5 doses).
32923867|NCT04743011|Active Comparator|Heparin sodium|Participants will receive inhalation with 5mL 0.9% saline solution + 2,5mg of high molecular weight heparin - enriched heparin, 4/4h, during the day period (5 doses).
32923868|NCT03840733||Participants from NCT01985568|All subjects who previously enrolled in the Parent Study's behavioral weight loss intervention (NCT01985568).
32923869|NCT03528941||Lamivudine|Patients who received lamivudine
32923870|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
32923871|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
32923872|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
32722034|NCT00928447|Placebo Comparator|Placebo|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the NSC (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing placebo will be administered QD for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with placebo at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing placebo will be then administered QD for 5 days.
32722035|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
32722036|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
33400317|NCT05131945|Experimental|Group 1: Standard Suction Thoracentesis|treatment techniques suction is a standard of care and used for draining fluid around the lung.
32722037|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
32722038|NCT05159635|Experimental|Active Living programme and wearable technical aids|Active Living programme and wearable technical aids
32722039|NCT05159635|Active Comparator|Wearable technical aids|Wearable technical aids
32722040|NCT02317055|Other|Patient|Imaging
32722041|NCT02317055|Other|healthy subject|Imaging
32722042|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
32722043|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
32722044|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
32722045|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
32722046|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.~Intervention: Blood samples Intervention: Stool samples"
32722047|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.~Intervention: Blood samples Intervention: Stool samples"
32722048|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.~Intervention: Blood samples Intervention: Stool samples"
32722049|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
32923873|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
32923874|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
32923875|NCT00364403|Experimental|1|Low glycemic load diet
32923876|NCT00364403|Active Comparator|2|Low fat diet
32923877|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
32923878|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
33400318|NCT05131945|Experimental|Group 2: Gravity Thoracentesis.|treatment techniques (gravity ) is a standard of care and used for draining fluid around the lung.
33400319|NCT03162718|Other|single arm|exercise
32722050|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
32923879|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
32923880|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
32923881|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
32923882|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
32923883|NCT03672331|Other|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
32722051|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
32722052|NCT04925128|Experimental|Interventional Group|Hot pack for 10 min OR Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique Treadmill walk for 30 to 150 minutes
32923884|NCT03672331|Experimental|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
32923885|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
32923886|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
32923887|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
32923888|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
32923889|NCT05665621|Experimental|Training group|Eight-week in-school strength and balance training program
32722053|NCT04925128|No Intervention|Control Group|Hot pack or Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique
32722054|NCT04463303||group 1|patient who will develop weaning induced pulmonary adema
32722055|NCT04463303||group 2|patient who will nor develop weaning induced pulmonary adema
32722056|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
32923890|NCT05665621|No Intervention|Control|No intervention, normal activities.
32722057|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
32722058|NCT04463147|Other|new residents|new residents in ultrasound-guided central vascular catheterization.
32722059|NCT04463147|Other|experienced residents or ICU practitioners|experienced residents or ICU practitioners in ultrasound-guided central vascular catheterization.
32722060|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
32722061|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
32722062|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
32722063|NCT04455763|Experimental|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
32722064|NCT04455763|Active Comparator|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
32722065|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
32722066|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dietitians.
32923891|NCT05665309|Experimental|With 3D anatomical model|Surgery prepared using 3D anatomical model of the aneurysm
32923892|NCT05665309|No Intervention|Without 3D anatomical model|Surgery prepared without 3D anatomical model of the aneurysm (routine care)
32923893|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
32923894|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
32923895|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
32923896|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
33249732|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (n = 65), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (n = 53) will receive six weekly sessions of CBT-I administered individually by a professional.
32722067|NCT05159323|Experimental|Diffusion Spectrum Imaging|All participants accept diffusion spectrum imaging, the quantitative parameters of the diffusion spectrum imaging are obtained. The quantitative parameters are compared in different subgroups based on the pathologic examination results.
32722068|NCT05237999|Experimental|Intervention: KopOpOuders-PTSD|KopOpOuders-PTSD is a blended care (i.e., partially online and partially in person) intervention that addresses the enhancing of protective factors within the family setting (reducing negative parental self-perceptions; parent-child interaction quality, social support, child adaptive functioning/coping, and child understanding of the parent's illness) from a combination of transdiagnostic and PTSD-specific perspectives. It consists of 8 sessions (5 online self-help modules, 3 in-person sessions with a professional) to be completed in a maximum period of 9 weeks.
32722069|NCT05237999|No Intervention|Control: No intervention|The control group receives no parenting intervention during their participation.
32722070|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
32722071|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
32722072|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
32722073|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
32722074|NCT02317367||adult women|Women who drink seven or more drinks per week
32722075|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
32722076|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
32722077|NCT05159167|Experimental|Intervention group|Participants in the intervention group received two months of Baduanjin exercise training provided by the specialist coach 3 days per week in Hubei Cancer Hospital, and they were also required to do Baduanjin exercise at home for the remaining 4 days each week for at least 20 min per day. All the participants are requested to monitor and record adverse effects during their exercise sessions.
32722078|NCT05159167|Placebo Comparator|Control group|Participants in the control group were requested to maintain their original daily physical activity for no less than 20 min per day over the following 6-month period and record their daily activity at home by themselves. These data were collected by a researcher during the participants' time in the study and at the 6-month follow-up at the hospital. After the 6-month follow-up, the participants were provided with 1-month professional Baduanjin exercise guidance by the trial's specialist coach for free if they wished.
33249733|NCT00857571|Experimental|Suspension|PF-02413873 suspension
33249734|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
33249735|NCT00943774||All subjects|All subject participants
33249736|NCT00943930||Marijuana-dependent volunteers|
32722079|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
32742957|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
33249737|NCT00854763||Hypertension|
32923897|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
32923898|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
32923899|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
32923900|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
32923901|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
32923902|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
32923903|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
32923904|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
33249738|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
33249739|NCT00944008|Experimental|Depocyte|
33249740|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
33249741|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
32722080|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
32722081|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
32722082|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
32722083|NCT05390281||Pre-diabetic group|Patients with preoperative HbA1c 5.7-6.4% (group A) (prediabetics)
32722084|NCT05390281||Diabetic group|Patients with preoperative HbA1c > or = 6.5% till 7% or > 7% in case of emergency surgery or rapidly progressive cases with no time for long-term glycemic control (group B) (diabetics)
32722085|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.~Treatment was not changed as a result of the investigation in itself."
32722086|NCT05150431|Experimental|Parecoxib|Parecoxib 40mg will be administered to this group 15 minutes before the end of the surgery.
32722087|NCT05150431|Placebo Comparator|Placebo|2ml normal saline will be administered to this group 15 minutes before the end of the surgery.
32722088|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
32722089|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
32722090|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
32722091|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
32722092|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
32722093|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
32722094|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
32722095|NCT01169259|Active Comparator|Vitamin D + fish oil|
32722096|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
32722097|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
32722098|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
32722099|NCT05163691|Experimental|Group A - 6 mg single-dose|A single, inhaled dose of GH001 6 mg or placebo (randomized as 8 active and 2 placebo subjects)
32722100|NCT05163691|Experimental|Group B - 12 mg single-dose|A single, inhaled dose of GH001 12 mg or placebo (randomized as 8 active and 2 placebo subjects)
32722101|NCT05163691|Experimental|Group C - 18 mg single-dose|A single, inhaled dose of GH001 18 mg or placebo (randomized as 8 active and 2 placebo subjects)
32722102|NCT05163691|Experimental|Group D - Individualized Dosing Regimen, 1-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 1-hour dose interval (8 subjects)
32722103|NCT05163691|Experimental|Group E - Individualized Dosing Regimen, 2-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 2-hour dose interval (8 subjects)
32722104|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
32722105|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
32722106|NCT01634152|Placebo Comparator|Placebo QD|
32722107|NCT01634152|Experimental|Tiotropium low dose QD|
32722108|NCT01634152|Experimental|Tiotropium medium dose QD|
32722109|NCT05391217||Transgender people with history of cancer|Self-reported cancer history and/or treatment for cancer within the last 5 years.
32722110|NCT05391217||Transgender people without history of cancer|People living with other chronic conditions
32722111|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
32722112|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
32722113|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
32722114|NCT05120323|Experimental|vDOT Intervention Group|The VDot group will submit videos via app to Emocha to have their inhaler technique graded to assess their inhaler technique.
32722115|NCT05120323|No Intervention|Standard Asthma Care Group|Participants in the standard asthma care group will receive standard of care asthma education conducted by a respiratory therapist in the specialty clinics at Arkansas Children's Hospital at the baseline visit. Education will include standard of care instruction on the participant's prescribed asthma medications, how to use an asthma action plan, as well as training and demonstration of proper inhaler technique. They will not have any additional study activities until the 3-month visit. They will be instructed to take their medications as prescribed.
32722116|NCT05063227||Study group|As this is a single-group, observational study all patients will be monitored with all three nociception monitoring systems (the Surgical Pleth Index (SPI), the Pupillary Pain Index (PPI) and the Nociception Level (NOL)) and data on heart rate changes as a variable used in current clinical practice to choose the opioid dosage during general anesthesia will be obtained additionally.
32722117|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
32722118|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
32722119|NCT05390125||4B ward staff|Multidisciplinary staff members from a surgical ward in Cork University Hospital.
32923905|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
32923906|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
32722120|NCT05390125||Cedar ward staff|Multidisciplinary staff members from the Cedar ward in University Hospital Waterford with a similar case mix of patients to ward 4B in CUH.
32923907|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
32923908|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
32923909|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
32923910|NCT01837069|No Intervention|Control|Standard of care
32923911|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
32923912|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
32923913|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
32923914|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
32722121|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
32722122|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
32722123|NCT04338555|Experimental|TEAS group|Patients in the TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30min every hour. The stimulation will repeat until the end of surgery.
32722124|NCT04338555|No Intervention|control group|In patients from the control group, the electrodes will only be attached to the corresponding sites, with no TEAS electrical stimulation given during the operation.
32722125|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
32722126|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:~5 mg saxagliptin is given 60 min before a test meal,"
32722127|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:~100 mg acarbose is given with a test meal"
32722128|NCT02315495|No Intervention|control|
32722129|NCT04286139|Experimental|SHAPE Intervention|This group will receive the online group based self-management course develop self-management skills in areas including decision making, symptom management and social interaction and to provide information on the disease process and the development of healthy behaviours in a supportive learning environment to prevent problems that are common in the later stages of the disease. Key themes of the intervention will include positive actions to improve and maintain health, how to talk about the impact of the disease on the life of the person with dementia, fear of losing independence and how to tackle and solve other sensitive issues. Running in parallel there will be an e-learning resource available to the carers which covers the similar material covered in the group sessions for the person with dementia, as well as some additional resources and signposting to help them in their role supporting the person with dementia.
32923915|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
32923916|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
32923917|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
32923918|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
32923919|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
32923920|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
32923921|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
32923922|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
32923923|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
32923924|NCT01837537||no treatment|no treatment, prospective observational
32722130|NCT04286139|No Intervention|Treatment as usual|Participants in the TAU arm will receive normal services such as clinical reviews, psychiatric appointments and other services when needed. With TAU as the comparator condition ensures that participants receive any needed services and enable comparison between current best practice and the new intervention of SHAPE
32722131|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
32923925|NCT04350385|Experimental|Group 1|Agility Training
32722132|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
32722133|NCT03862807|Experimental|Patisiran|Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
32722134|NCT04274751||Transaxillary|TAVI, transaxillary approach
32923926|NCT04350385|Active Comparator|Group 2|.Conventional intervention
33400320|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
32722135|NCT04274751||Transfemoral|TAVI, transfemoral approach
32722136|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
32722137|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
32722138|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
32722139|NCT04262895|Experimental|TTI-0102 2 mg/day|TTI-0102 2 mg/day
32722140|NCT04262895|Experimental|TTI-0102 4 mg/day|TTI-0102 4 mg/day
32722141|NCT04262895|Placebo Comparator|Placebo|Placebo
32722142|NCT02522455|Other|Preterm infants with RDS|
32722143|NCT05101785|Active Comparator|Lidocaine|Lidocain hydrochloride 2 %with epinephrine 1:100000
32722144|NCT05101785|Experimental|Articaine|Articaine chloride 4% with epinephrine 1:100000
32722145|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
32722146|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
32722147|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
32722148|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
32722149|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
32722150|NCT04228731|Experimental|Outpatient|Patients in the outpatient group (same day discharge following TKA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
32722151|NCT04228731|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following TKA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
32722152|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
32722153|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
32722154|NCT05366725||Adult patients with locally advanced or metastatic urothelial cancer|
32722155|NCT04437693|Experimental|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
32722156|NCT04437693|Placebo Comparator|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
32722157|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
32923927|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
32923928|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
32923929|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
32923930|NCT03032471||DCI group|"Patients that experience DCI, defined as~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
32722158|NCT05009667||IMR first group|In this group, IMR based on pressure wire and arterial physiological detector will be measured first, and then caIMR base on angiography images and pressure sensor will be measured secondly.
32923931|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
32722159|NCT05009667||caIMR first group|In this group, caIMR based on angiography images and pressure sensor will be measured first, and then IMR based on pressure wire and arterial physiological detector will be measured secondly.
32923932|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients without Diabetes|
32923933|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients with Diabetes|
32923934|NCT05249231|Active Comparator|Hall technique|group of carious primary molars to be treated by hall technique
32923935|NCT05249231|Experimental|silver diamine fluoride|group of carious primary molars to be treated by silver diamine fluoride
32923936|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
32722160|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
32923937|NCT05249153|No Intervention|Sufen|PCIA: continue with 0.05ug/kg/h sufentanil, 0.05ug/kg sufentainil bolus
32722161|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
32722162|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
32722163|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
32722164|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
32722165|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
32722166|NCT05389891|Experimental|Group 1|Experimental Group (n=54) The implementation phase was achieved through sessions within Feb-April2017 second semester of the academic year 2016/2017.Each session started by the objectives of the new session and summary of previous one. Motivation and reinforcement during session were used to enhance participation and sharing in this study. The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
32923938|NCT05249153|Experimental|Sufen with low DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine bolus
32722167|NCT05389891|No Intervention|Group 2|Control Group (n=54) The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
32722168|NCT03855111|Experimental|Standard (fixed) protocol Acu/Moxa - Active|"Standard (Fixed) Acupuncture / Moxibustion Active Protocol~Subjects receive active standard Acu/Moxa protocol aimed at reducing neuropathic pain/discomfort."
32722169|NCT03855111|Experimental|Individualized (tailored) protocol Acu/Moxa - Active|"Individualized (Tailored) Active Acupuncture / Moxibustion Protocol~Subjects receive active individualized Acu/Moxa protocol based on traditional Chinese medicine assessment aimed reducing neuropathic pain/discomfort."
32722170|NCT03855111|No Intervention|Sham Acu/Placebo Moxa (Control)|"Sham Acu/Placebo Moxa (Control)~Note. All subjects randomized to the Control will be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
32722171|NCT03855111|No Intervention|WaitList (Control)|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Acupuncture / Moxibustion.~Note. All subjects randomized to the Control will then be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
32722172|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
32722173|NCT03419221|Active Comparator|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
32722174|NCT03419221|Placebo Comparator|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
32923939|NCT05249153|Experimental|Sufen with high DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine bolus
32722175|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
32722176|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
32923940|NCT05248685|Experimental|Dual CD33/CLL1 CAR T|All patients who receive Dual CD33/CLL1 CAR T Cell infusion
32923941|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
32923942|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
32722177|NCT04454983|Experimental|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
32722178|NCT04454983|Experimental|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
32722179|NCT04462757|Active Comparator|Subcutaneous Arm|100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
32722180|NCT04462757|Active Comparator|Intravenous Arm|100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
32722181|NCT04535505||pertussis test population|People with clinical diagnosis of suspected pertussis in outpatient and ward in the Children's Hospital of Fudan University will be collected as study subjects. Their nasopharyngeal swabs will be collected. Bordetella isolation culture and identification method is the gold standard, and the new CPA platform based on CRISPR technology is the method to be tested. Diagnostic values of this research platform would be detected.
32923943|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
32923944|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
32722182|NCT04462679|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
32722183|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
33249742|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
32722184|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
32722185|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
32722186|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
32722187|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
32722188|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
33249743|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
33249744|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
32722189|NCT04934943||Intervention _mini_FC|"The fluid challenge consists of 4 ml*Kg of Crystalloids' solution infused over 10 minutes, administered via either a central or a peripheral line.~The patient is already connected to the PICCO monitoring for clinical purpose of hemodynamic monitoring (before study enrollment)~The MOSTCARE system is connected to the MONITOR of the patient (and not to the patient itself) by means of a cable inserted into the connections system.~The echocardiography will be performed by a senior intensivist/cardiologist. The stroke volume is calculated by measuring VTI and diameter at the same point. This is best performed by measuring the diameter of the LVOT in the parasternal long axis (PLAX) view"
32722190|NCT05037409|Experimental|PF-06823859 low|Participants will receive single intravenous infusion.
32923945|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
33249745|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
33249746|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
33249747|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
33249748|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
33249749|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
33249750|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
33249751|NCT00854997||1|AMI with OSA
33249752|NCT00854997||2|AMI without OSA
33249753|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
33249754|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
33249755|NCT00947362|Experimental|ETC + DAC N-055|
33249756|NCT00947362|Active Comparator|ETC + physiological saline|
33249757|NCT00861861|Active Comparator|1|pitavastatin group
33249758|NCT00861861|Active Comparator|2|atorvastatin group
33249759|NCT01529866|Experimental|New abutment connection implant|Implant with new abutment connection
32923947|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
32923948|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
32923949|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
32923950|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
32923951|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
32923952|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
32923953|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
32923954|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
32923955|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
32923956|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
32923957|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
32923958|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
32722191|NCT05037409|Experimental|PF-06823859 high|Participants will receive single intravenous infusion.
32722192|NCT05037409|Placebo Comparator|Placebo|Participants will receive single intravenous infusion.
32722193|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
32722194|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
32923959|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
32923960|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
32923961|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
33400321|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
33400322|NCT03164590|Active Comparator|ketamine|
32722195|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
33400323|NCT03164590|Active Comparator|dexmedetomidine|
32722196|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
32722197|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
32722198|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
32923962|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
32923963|NCT05248451||Normal Renal Function|Patients undergoing inpatient non-cardiac surgery at St. Paul's Hospital with normal preoperative Estimated Glomerular Filtration Rate (eGFR) results. eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates.
32923964|NCT05248451||Renal Dysfunction, Chronic Kidney Disease (CKD)|Patients undergoing non-cardiac surgery with abnormal preoperative Estimated Glomerular Filtration Rate (eGFR). eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates. As eGFR is not accurate in the setting of dialysis, patients receiving dialysis for at least 90 days prior to their surgical procedure will also be included as a separate eGFR category.
32923965|NCT05248295|Experimental|Intervention|All participants will repeat sentences under four speech conditions, in a 2x2 design
32923966|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
32722199|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
32722200|NCT03353233|Experimental|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
32722201|NCT03353233|Placebo Comparator|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
32722202|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
32722203|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
32722204|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
32722205|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
32722206|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
32722207|NCT04455607|Experimental|experimental group|Random perturbation training
32722208|NCT04455607|Active Comparator|control group|Block perturbation training
32923967|NCT05248217|Other|healthcare workers|doctors, nurses, medical secretaries, security guards, and cleaning staff
32923968|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
32923969|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
32923970|NCT05433090|Experimental|Experimental|Patients will participate in an advanced care practitioner-led inpatient advance care planning intervention.
33249760|NCT01529866|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
32722209|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
32722210|NCT03052855|Other|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
32722211|NCT05256745|Experimental|Cohort 1: TTP488 (Azeliragon) co-administered with dose dense paclitaxel (ddAC/ddT)|Cohort 1: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2).
33249761|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
33249762|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
33249763|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
33249764|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
33249765|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
33400324|NCT03164590|Placebo Comparator|bupivacaine|
32722212|NCT05256745|Experimental|Cohort 2: TTP488 (Azeliragon) co-administered with TC|"TC: docetaxel and cyclophosphamide~Cohort 2a (6 cycles): Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).~Cohort 2b (4 cycles): Cycle 3 Day 14 (C3D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
32722213|NCT05256745|Experimental|Cohort 3: TTP488 (Azeliragon) co-administered with TCHP|TCHP: docetaxel, carboplatin, trastuzumab, and pertuzumab Cohort 3: Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).
32722214|NCT05256745|Experimental|Cohort 4: TTP488 (Azeliragon) co-administered with chemotherapy regimen that includes ddAC|"given at the end of the chemotherapy plan [can include: (1)weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide]~Cohort 4: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
32722215|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
32722216|NCT03498365|Experimental|Online MCDA|
32722217|NCT03498365|Active Comparator|Online Delphi|
32722218|NCT05234593|Other|Lightning Stick|Feasibility and acceptability
32722219|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
32722220|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
32722221|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
32722222|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
32722223|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
32722224|NCT05167903|Experimental|Time-restricted eating|Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm (8 h eating window with 16 h of fasting)
32722225|NCT05167903|Experimental|Normal Diet (ND)|The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum)
32722226|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
32722227|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
32722228|NCT01322971|Active Comparator|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
32722229|NCT01322971|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
32722230|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
32722231|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
32722232|NCT04454281|Experimental|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
32722233|NCT04454281|Experimental|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
32722234|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.~The content of an experimental day is described in the study design."
32722235|NCT05389579|No Intervention|Control Group|After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured blood pressure. the SPO2 probe was put on the patients' fingers after blood pressure measurements and counted respiratory rates for one minute while waiting for the SPO2 measurements. After this measurement, the researcher evaluated shivering by observation, and recorded these data on the DCIF. the temperature and humidity in the room on a thermohygrometer were read and recorded on the evaluation form. Body temperature, pulse rate, respiration rate, arterial blood pressure, pulse pressure, oxygen saturation, feeling cold and shivering were examined both experimental and control group before their surgeries, every 15 minutes after surgeries until being 36 0C.
32742958|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
32923971|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
32923972|NCT05649930||Spastic paresis|Children with spastic paresis
32923973|NCT05432466|Experimental|ACER-002 (celiprolol) 200 mg BID|"ACER-002 200 mg twice daily (BID) (after titration):~200 mg morning and 200 mg evening: 400 mg total daily dose~Titration:~Day 1 to Month 1 - 100 mg once daily (QD) evening: 100 mg total daily dose Month 2 to Month 3 - 100 mg morning and 100 mg evening: 200 mg total daily dose Month 3 to Month 4 - 100 mg morning and 200 mg evening: 300 mg total daily dose Month 4 to End of Treatment Period (BID) - 200 mg morning and 200 mg evening: 400 mg total daily dose"
32923974|NCT05432466|Experimental|Placebo BID|Placebo twice daily (BID) Placebo given orally to mimic ACER-002 (celiprolol) administration
32923975|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
32923976|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
32923977|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
32923978|NCT05247983||experimental group|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
32923979|NCT05247983||control group|Tension-free repair of inguinal hernia with traditional method
33249766|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
32923980|NCT05372471|Other|mHealth|Intervention group (mHealth platform users).
32923981|NCT05372471|Other|Control|Usual Care
32923982|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
32923983|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
32923984|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
32923985|NCT05247749|Experimental|Convivo Imaging|The brain area that the operating surgeon plans to resect will be scanned using the CONVIVO device
32923986|NCT05628103|Experimental|SEP-363856|SEP-363856 flexibly dosed
32923987|NCT05247671||Case|All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
32923988|NCT05247515|Experimental|Treated group: Nexpowder application on the scar after EMR with coagulation of visible vessels|To compare of the risk of bleeding after EMR application of nexpower (not a drug but a device with CE mark) on the resect area (scar) to cover the whole surface of mucosal resection.
32923989|NCT05247515|No Intervention|standard procedure : EMR with coagulation of visible vessels|After EMR with coagulation of visible vessels, if the patient is randomized in the comparative group, not nexpowder will be applied on the scar (common practice)
32923990|NCT05627557|Experimental|Obinutuzumab (Group A)|Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram [kg] for participants <45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).
32923991|NCT05627557|Experimental|MMF (Group B)|Participants in Group B will receive oral MMF 600 mg/m^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.
33249767|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
32923993|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
32923994|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
32923995|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
32923996|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
32923997|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
32923998|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
32923999|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
32924000|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
32924001|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
32924002|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
32924003|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
32924004|NCT01839799|Experimental|Arm 1 - FOLFIRINOX|"FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy.~On Day 1(+ 2days to accommodate scheduling difficulties):~Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated"
32924005|NCT01839799|Experimental|Arm 2 - Gemcitabine / Abraxane|"Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy. On Day 1 (+ 2days to accommodate scheduling difficulties) Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles, if tolerated"
32924006|NCT05372159||Cognitively healthy adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
32924007|NCT05372159||Cognitively impaired adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
32924008|NCT03062059|Placebo Comparator|Normal saline|Intravesical 52.6ml normal saline instillation during radical nephroureterectomy followed by normal saline bladder irrigation
32924009|NCT03062059|Experimental|Gemcitabine|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
32924010|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
32924011|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
32924012|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~NYMC X-179A reassortant of A/California/7/2009 (H1N1)~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
32722236|NCT05389579|Experimental|Intervention Group|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
32722237|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
32924013|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
32722238|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
32924014|NCT05371769|Sham Comparator|Control group|The students in the control group will be given a pre-test, and two weeks later, the post-test will be applied. After the chronic pain education group completes the research, the chronic pain education program will be opened to the students in the control group, too.
32924015|NCT05371769|Experimental|Chronic pain education group|The pre-test will be opened to the students in the chronic pain education group simultaneously with the opening of the post-tests for the control group.After the students in the chronic pain education group completed the pre-test, the chronic pain management training program developed for nursing students will be applied for 2 weeks. Post test will be applied at the end of all training videos and evaluation questions.
32924016|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
32722239|NCT00424099|Experimental|Group 1: Methylphenidate + NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Nursing Telephone Intervention (NTI). NTI calls from study nurse 3 times weekly to ask about side effects and other symptoms.
32722240|NCT00424099|Placebo Comparator|Group 2: Placebo + NTI|Placebo capsule orally as needed for 14 days + NTI, calls from study nurse 3 times weekly to ask about side effects and other symptoms.
32722241|NCT00424099|Experimental|Group 3: Methylphenidate + Non NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Non NTI, calls from research staff 3 times weekly.
32722242|NCT00424099|Experimental|Group 4: Placebo + Non NTI|Placebo capsules as needed with Non NTI, calls from research staff 3 times weekly.
32722243|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
32722244|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
32924017|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
32924018|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
32924019|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
32924020|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
32924021|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
32924022|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
32924023|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
32924024|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
32924025|NCT02287584|Experimental|DSP-5423P Placebo-to-Flex|Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
32924026|NCT02287584|Experimental|DSP-5423P Active-to-Flex|Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
32924027|NCT05654909||PAU group|The PAU group were patients calling 1-1-2 assigned for the prehospital assessment unit,
33249768|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
32924028|NCT05654909||non PAU group|The non PAU group were selected from the 1-1-2 calls (the European version of 9-1-1) EMS and were collected based on the same criteria as the patients assessed by the PAU. The control ratio was 1:10 for cases to increase power. Controls were matched on sex and age (within 5-year ranges). Matching was performed using incidence density sampling, where controls were selected for each case on the week of 1-1-2 call.
32924029|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
32924030|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
32924031|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
32924032|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
32924033|NCT04741529|Experimental|Massed condition|Participant will be asked to use the HMP app for 20 minutes per day in one 20-minute meditation session.
32924034|NCT04741529|Experimental|Spaced condition|Participant will be asked to use the HMP app for 20 minutes per day in two 10-minute meditation sessions.
32924035|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with helical tomotherapy (54 Gy) followed by surgery in retro-peritoneal liposarcomas.
33249769|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
32924036|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
32924037|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
33249770|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
32924038|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
32924039|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
32924040|NCT00364559|Experimental|B|A, Active B, Historical Register
32924041|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
32924042|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
33249771|NCT00944164|Experimental|Healthy eating/physical activity|
32722245|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
32924043|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
32924044|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
32924045|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
32924046|NCT03833011|No Intervention|no intervention|
32924047|NCT03833011|Experimental|Osteopathic manipulation|
32924048|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
33249772|NCT00944164|Active Comparator|Safety/Injury prevention|
32924049|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
32924050|NCT05371535|Experimental|Experimental group|Those in the experimental group will receive MatrixOssTM Bone Graft plus Bio-Gide membrane.
32924051|NCT05371535|Active Comparator|Control group|Those in the control group will receive Bio-Oss Bone Graft plus Bio-Gide membrane
32924052|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
32924053|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
32924054|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
32924055|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
32924056|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
32924057|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
32924058|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
32924059|NCT00365339|Active Comparator|A|
32924060|NCT00365339|Experimental|B|
32924061|NCT00365339|Experimental|C|
32924062|NCT00365339|Experimental|D|
32924063|NCT00365339|Experimental|E|
32924064|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
32924065|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
32924066|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
32924067|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
32924068|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
32924069|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
32924070|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
32924071|NCT05371379|Experimental|CM338 75 mg, subcutaneous injection|Qquaque week
32924072|NCT05371379|Experimental|CM338 150 mg, subcutaneous injection|Qquaque week
32924073|NCT05371379|Experimental|CM338 300 mg, subcutaneous injection|Qquaque week
32924074|NCT05371379|Experimental|CM338 300 mg, intravenous infusion|Qquaque week
32924075|NCT05371379|Placebo Comparator|Placebo|placebo
32924076|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
32924077|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
32924078|NCT05589181|Active Comparator|Buprenorphine Standard Dose|The standard arm will receive an induction dose of 12mg of buprenorphine (BUP) split as 8mg at time=0 and 4mg at time=30-60 min.
32924079|NCT05589181|Experimental|Buprenorphine High Dose|The experimental arm tests the safety and tolerability of 32mg of BUP split as 16mg at time=0 and 16mg at time=30-60 min as an induction dose.
32924080|NCT05371301|Experimental|NACT-IDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation≥4 Neoadjuvant chemotherapy: platinum-based combination regimen 3 courses
32924081|NCT05371301|Active Comparator|PDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation<4
32924082|NCT02285166||Ever User of Omega-3 fatty acid ethyl esters 2 g|The usual adult dosage for oral use was 2 g of omega-3 fatty acid ethyl esters administered once daily or twice daily immediately after meals for treatment of hyperlipidemia. Participants received both interventions and standard antihyperlipidemic therapy as part of routine medical care.
32924083|NCT02285166||Never User of Omega-3 fatty acid ethyl esters 2 g|Participants received standard antihyperlipidemic therapy without omega-3 fatty acid ethyl esters 2 g as part of routine medical care.
32924084|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
32924085|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
32924086|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
32924087|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
32924088|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
32924089|NCT05371067|Other|Healthy volunteers|
32924090|NCT02606903|Experimental|BI 695501 prefilled syringe|
32924091|NCT02606903|Experimental|BI 695501 autoinjector|
32924092|NCT05607719|Experimental|Bretzri followed by Bevespi Group|Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi.
32924093|NCT05607719|Experimental|Bevespi followed by Bretzri Group|Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri.
32924094|NCT05607173|Experimental|Participants with mild HI|Mild HI is defined as a total score ranging from 5 to 6, inclusive (Child-Pugh score A)
32722246|NCT05095597|Other|Umbilical cord PRP donors|"Women who are going to give birth to a healthy live newborn at the Hospital Universitario y Politécnico La Fe.~Donors will donate their umbilical cord blood to obtain the hUC-PRP. A total of 30±15 donors will be recruited."
32722247|NCT05095597|Experimental|Group B- Asherman with PRP treatment and estrogen therapy|Women with thin endometrium/endometrial atrophy and/or Asherman's syndrome with fertility problems and reproductive desires, desires that could be achieved by their participation in the present study. A total of 15 patients will be included; all of them will receive the investigational treatment as well as estrogen therapy.
32924095|NCT05607173|Experimental|Participants with moderate HI|Moderate HI is defined as a total score ranging from 7 to 9, inclusive (Child-Pugh score B)
32924096|NCT05607173|Experimental|Participants with normal hepatic function|Participants with normal hepatic function matched to participants
32924097|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
32924098|NCT05364827|Experimental|CTCA prior to CTO PCI|A diagnostic CTCA will be conducted prior to CTO PCI by at a level 2 CTCA trained operator. The results will be discussed with the CTO operator prior to the CTO PCI.
32924099|NCT05364827|No Intervention|No CTCA prior to CTO PCI|Patients will be listed directly for the CTO PCI procedure without undergoing CTCA prior
32722248|NCT05095597|Other|Group A1- POI with PRP treatment and estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the investigational treatment as well as estrogen therapy.
32722249|NCT05095597|Other|Group A2- POI with estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the estrogen therapy.
32722250|NCT05095597|Other|Group A3- POI without PRP treatment nor estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. None of them will receive either the investigational treatment nor estrogen therapy.
32722251|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
32722252|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
32722253|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.~Arthroscopic dissection of the superior transverse scapular ligament"
32722254|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
32722255|NCT01378429|Placebo Comparator|Placebo|
32924101|NCT05592197|Experimental|RT+TACE+Lenvatinib|Patients in RT+TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib. RT will begin within 4 weeks after the first TACE.
32924102|NCT05592197|Active Comparator|TACE+Lenvatinib|Patients in TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib.
32924103|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
32924104|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
32924105|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
32722256|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
32722257|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
32722258|NCT01599754|Experimental|Axitinib|
32722259|NCT01599754|Placebo Comparator|Placebo|
32722260|NCT05400343|Active Comparator|Standard care (control group)|fluid therapy will be guided by conventional ICU policies to maintain an adequate intravascular volume and good urine output
32722261|NCT05400343|Experimental|US-guided ﬂuid management (active group)|Fluid therapy will be guided by measurements of lung and IVC sonography
32722262|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
32722263|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
32924106|NCT05591729|Experimental|Pilates exercise|pilates exercise will be received twice a week for four weeks
32924107|NCT05591729|Active Comparator|postural correction exercise|postural correction exercises will be received twice a week for four weeks
32924108|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
32924109|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
32924110|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
32924111|NCT05442281||Vegan diet|Children fed vegan diet from 6 months of life
32924112|NCT05442281||Mixed diet|Children fed mixed diet from 6 months of life
32924113|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
32924114|NCT02409589|Active Comparator|Conventional|Surface prediction length method
32924115|NCT02274805||Adults presenting for surgery in the neck area|
33400325|NCT05119075|Experimental|Dopaminergic ON-drug state first, dopaminergic OFF-drug state second|"The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
32767775|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
32767776|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
32767777|NCT04056013|Active Comparator|Absorbable|Wound repaired with Vicryl Rapide absorbable suture
32767778|NCT04056013|No Intervention|Nonabsorbable|Wound repaired with traditional nonabsorbable suture
32767779|NCT04053907|No Intervention|CCM:Standard of Care|Community Case Management (CCM), with passively monitored malaria incidence by community health workers using standard RDTs and artemisinin-based combination therapy (ACT), artemether-lumefantrine (AL) according to national guidelines.
32767780|NCT04053907|Experimental|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained village health workers (VHW) recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
32767781|NCT04053907|Experimental|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
32767782|NCT04053907|Experimental|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
32767783|NCT04857125|Active Comparator|Multicomponent intervention|Pre-, intra- and postoperative interventions applied using the Fast-IM method.
32767784|NCT04857125|No Intervention|Standard care|Patients are receiving standard care.
32767785|NCT04864379|Experimental|RFA+PD-1+iNeo-Vac-P01|Patients will undergo radiofrequency ablation. At Week 3, patients will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks. At Week 12,all patients,regardless of their disease status,iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
32767786|NCT04864379|Experimental|RFA+iNeo-Vac-P01+PD-1|Patients will undergo radiofrequency ablation. At Week 12, patients will receive iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. At Week 16, patients,regard of their disease status,will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks.
32767787|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
32767788|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
32767789|NCT04132375|Active Comparator|Stage 1 - high treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
32767790|NCT04132375|Active Comparator|Stage 1 - Low treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
32767791|NCT04132375|Placebo Comparator|Stage 1 - Placebo arm|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
32767792|NCT04132375|Active Comparator|Stage 2 - Selected active treatment arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of 4 mg/kg INM004 and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).~In the case, the low treatment regime is selected subjects will receive an intravenous dose of 4 mg/kg INM004"
32767793|NCT04132375|Active Comparator|Stage 2 - Placebo arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo, each dose separated by 24 h (± 2 h)~In the case, low treatment regime is selected subjects will receive a single intravenous dose of Placebo"
32767794|NCT04336241|Experimental|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
32722264|NCT05400187|Experimental|Body composition assessment and smart-phone based counselling group|"In this study, we consider body composition measurement together with an immediate brief counselling after the measurement as part of the intervention. The body composition measurement will allow the participants to get familiar with their own anthropometric data and serve as cues to actions of healthy diet adoption and weight management and control. Based on the measured body fat and anthropometric data, a trained research assistant will give brief individualized dietary and weight management counselling to the participants.~The Whatsapp-based counselling and communication will heighten the awareness through reinforcing the need and benefits of body composition and weight control, the importance of energy balance, as well as providing professional and tailor-made advice on healthy eating and weight management. Qualitative dietary counselling will be offered every two weeks through the Whatsapp."
32722265|NCT05400187|No Intervention|Control group|Participants in the control group will receive the simple body composition measurement only, without an immediate counselling after the measurement. Whey will be informed the values of anthropometric data and body composition parameters, no detailed interpretation of the values will be delivered to them. They will also not receive the professional consultant of the healthy diet and weight management from the diatetitian during the intervention period.
32722266|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
32722267|NCT05389501|Experimental|Intervention Group|"The Experiment Group will receive the following services from the community social worker:~1. Developing Database on Digital App 2. Community Needs Assessment 3 Pre-Post Test Survey 4. Existing services by government of Pakistan (BHU/ LHW)~Additionally, the Experiment Group will receive the following services from the health social worker:~Psychosocial needs assessment and mental health awareness~Measurement of Basic Health Clinical Indicators~33. Health Awareness & Literacy for following areas:~Reproductive and Child Health~Hygiene and Sanitation & Nutrition and Immunity Building~Health-Risk Behavior Modification"
32722268|NCT05389501|Active Comparator|Control Group|"The Control Group will receive the following services from the community social worker:~Developing Database on Digital App~Community Needs Assessment 3 Pre-Post Test Survey~4. Existing services by government of Pakistan (BHU/ LHW)"
32722269|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
32722270|NCT05165953||Group 1: COVID-19 positive with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
32722271|NCT05165953||Group 2: COVID-19 positive with no asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
32722272|NCT05165953||Group 3: COVID-19 negative with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
32722273|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
32722274|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
32722275|NCT04868968|Experimental|DFV890|DFV890
32722276|NCT05399797|Experimental|Pharmacists in the intervention group|The pharmacist will be given an online educational training on management of acute uncomplicated urinary tract infections
32722277|NCT05399797|No Intervention|Pharmacists in the control group|pharmacists in this group will not be trained, until after the completion of the study.
32722278|NCT04462445|Experimental|pazopanib|Pazopanib 800 mg (2x400mg ) taken orally daily as per clinical practice
32722279|NCT04764370|Experimental|WeFlow-Arch Moduler Embedded Branch Stent Graft System|
32722280|NCT05389267|Experimental|T4090|
32722281|NCT05389267|Placebo Comparator|Placebo|"named Vehicle in the study protocol."
32722282|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
32722283|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
32767795|NCT04336241|Experimental|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
32767796|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
32722284|NCT05399719||Tumor tissue from BMT recipients|tumor tissue sections from patients received allogeneic bone marrow transplantation before
32722285|NCT05399719||Peripheral blood from healthy volunteer|peripheral blood from peripheral blood stem cell donors or healthy control
32722286|NCT04462523|Experimental|Group 1 Pre-surgery Dextenza insert|Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
32924116|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
32924117|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
32924118|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
32924119|NCT01843465||Cryoablation of atrial fibrillation|
33249773|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Cetuximab, 400 mg/m^2, IV, Day 1~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
33249774|NCT03963375|Other|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
33249775|NCT03963375|Other|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
33249776|NCT03963375|Other|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
33249777|NCT03963375|Other|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
33249778|NCT04280536|Experimental|Cohort A|Patients with prior exposure to fluoropyrimidines
33249779|NCT04280536|Experimental|Cohort B|Patients without prior exposure to fluoropyrimidines
33249780|NCT00363649|Experimental|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
33249781|NCT00363649|Experimental|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
33249782|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
33249783|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
33249784|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
33249785|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
33249786|NCT00952978|Experimental|10 mg ilaprazole|
32722287|NCT04462523|Experimental|Group 2 Surgery Day Dextenza insert|Ten patients will receive dexamethasone intracanalicular insert on the day of surgery. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
32767797|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
33249787|NCT00952978|Active Comparator|20 mg omeprazole|
33249788|NCT01046851|Active Comparator|Nopan|
33249789|NCT01046851|Placebo Comparator|Placebo|
33249790|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
33249791|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
33249792|NCT01046929|Experimental|limonene|
33249793|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
33249794|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
33249795|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
33249796|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
33249797|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
33249798|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
33249799|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
33249800|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
33249801|NCT00862017|Placebo Comparator|Control|
33249802|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
33249803|NCT00858039||Her-2 positive ESBC|
33249804|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
33249805|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
33249806|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
33249807|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
33249808|NCT00947596|Active Comparator|Atropen Autoinjector|
33249809|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
33249810|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
33249811|NCT00956410|Experimental|CAD106|
32722288|NCT04462523|Experimental|Group 3 Post op Day 1 Dextenza insert|Ten patients will receive DEXTENZA insert Day 1 post-operatively. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
32722289|NCT04462523|Active Comparator|Group 4 Topical steroid|Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
32722290|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
32722291|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
32722292|NCT04462211|Experimental|Management pharmacological protocol and bundle's|"The elaboration of the protocol according to the evidence-based approach, updated evidence found from both search engines such as MEDLINE, EMBASE, Cochrane Library, OVID and ScIELO will be used through the research question using the PICO method (Patient interest, Intervention, Comparation and Outcome).~the ready-made protocol will be adjusted to the pharmacological options that are available in the hospital."
32722293|NCT04642261|Experimental|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
32722294|NCT04642261|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
32722295|NCT05399407|Experimental|Experimental group: health e-coaching|"Personalised and secure access to the health e-coaching platform for 12 months.~Follow-up by professionals who are specialized in the subject matter (at a distance): a psychologist, a dietician and a teacher of adapted physical activity.~Personalised activities offered to each young adult throughout their follow-up: synchronous and asynchronous activities (video, animation, quizzes, etc.), individual and collective on different themes (expression of emotions, my weight and me, eating well to start with, my image and me, making choices, my way of moving, etc.). The personalisation of the activities will be done in consultation between the professionals and the young adult according to the needs expressed and identified."
32722296|NCT05399407|No Intervention|Control group: Usual Care System|"Control group : - Referral to health professionals in the health care system and, in priority, to the GP declared by the young adult.~- Transmission of the data collected during follow-up visit No. 3 (T3) to the GP with relay for the implementation of a care plan."
32722297|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32722298|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
32722299|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
32722300|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
32722301|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
32722302|NCT04851691|Experimental|EHR CDS tool|Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD
32722303|NCT04851691|Experimental|Control|Physicians will not receive intervention and perform duties as usual.
32722304|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
32722305|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
32722306|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
33249812|NCT00865137|Experimental|1 FK506E|
33249813|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
33249814|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
33249815|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
33249816|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
33249817|NCT00947674|Experimental|Cellsorba EX|
33249818|NCT00947674|Sham Comparator|Sham treatment|
33249819|NCT00862095|Placebo Comparator|Placebo|Placebo group
33249820|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
33249821|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
33249822|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
33249823|NCT04054128|Experimental|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
32924120|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
32924121|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
32924122|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
33249824|NCT04054128|Active Comparator|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
33249825|NCT00956566|Active Comparator|low fat hypocaloric diet|
33249826|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
32722307|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
32722308|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
32722309|NCT02318849|Experimental|Web intervention|Online intervention that uses information, engaging contests, and advocacy drives to encourage college students to become designated organ donor on driver's license
32722310|NCT02318849|No Intervention|Control|No intervention provided
33249827|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
33249828|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
33249829|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
32722311|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
33249830|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
33249831|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
33249832|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
33249833|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
33249834|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
33249835|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
33249836|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
33249837|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
33249838|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
33249839|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
33249840|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
33249841|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
33249842|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
33249843|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
33249844|NCT00858273|Placebo Comparator|Placebo|
33249845|NCT00750594||1|
33249846|NCT00750594||2|
33249847|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
33249848|NCT00858351|Active Comparator|Discussion|
33249849|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
32924123|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.~The industry standard diabetic innersole will be used as the active comparator"
32924124|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
32924125|NCT05547373|Experimental|Intervention|The investigators will select HCWs from the selected departments at the national hospitals, provincial hospitals, and district referral hospitals to participate in the pilot intervention. The participants will also include representatives from the Communicable Disease Control Department and the Department of Hospital Services of the Ministry of Health, the provincial hospitals, and the district referral hospitals in Cambodia and Lao PDR.
32924126|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
32924127|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
32924128|NCT02608463|Other|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
32924129|NCT02608463|Other|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
32722312|NCT04955197||the histo-pathological picture|"In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion reference standard. That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions"
32722313|NCT04462913||Healthy control|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
32722314|NCT04462913||Patients with sports injuries|According to the previous clinical diagnosis, patients who has suffered the sports injuries(including hip, knee, and ankle joint diseases).
32924130|NCT02608463|Other|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
32924131|NCT02608463|Experimental|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
32924132|NCT05649618|Experimental|Tumor Infiltrating Lymphocytes|TIL cells (2.5×10^9-5×10^10) will be infused i.v. to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
33249850|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
32722315|NCT04462913||Patients with degenerative osteoarthritis|According to the previous clinical diagnosis, patients who has suffered the degenerative osteoarthritis.
32722316|NCT04936399||Cohort 1|Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab
32722317|NCT04936009|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
32722318|NCT04936009|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
32722319|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
32722320|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
32722321|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
32722322|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
32722323|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
32722324|NCT02319239|Experimental|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
32722325|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
32722326|NCT02321579|Placebo Comparator|Negative control|Dextrins
32722327|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
32722328|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
32722329|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
32722330|NCT04852120||Compound Sodium Picosulfate Granules|
32722331|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
32722332|NCT03499925|No Intervention|Comparison Group|Routine product inspection
32722333|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
32722334|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
32924133|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
32924134|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
32924135|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
32924136|NCT05357183||PEG-IFN optimized treatment group|Patients received optimized treatment of NAs (ETV + TDF or ETV + TAF) combined with PEG-IFN ETV 0.5 mg, TDF 300 mg or TAF 25 mg, oral once a day, PEG-IFN 180 or 135 micrograms, subcutaneous injection once a week, with a personalized course of treatment of 24 weeks.
32924137|NCT05357183||NAs optimized treatment group|Patients received NAS (ETV + TDF or ETV + TAF) combination therapy and continued NAs maintenance therapy.
32924138|NCT05649462||supplementary group|take vitamin D supplementation (400 IU/day) during VDZ treatment
32722335|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
32722336|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
32722337|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
32722338|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
32924139|NCT05649462||non-supplementary group|
32924140|NCT05649384||0/1-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
32924141|NCT05649384||0/3-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
32924142|NCT04741763|Placebo Comparator|Placebo|Maltodextrin Placebo: Experimental is 1:2
32924143|NCT04741763|Experimental|Active|Eye Promise Visual Edge containing 8 mg zeaxanthin & 4 mg lutein Placebo: Experimental is 1:2
32924144|NCT04743089|Experimental|Spyglass arm|Patients who underwent IHD/EHD stone removal by ERCP with SpyGlass™ DS Direct Visualization System.
32924145|NCT04743089|Other|PTCS arm (historical cohort)|Patients who underwent IHD/EHD stone removal by PTCS
32722339|NCT04814368|Experimental|LNA043|Placebo to canakinumab + LNA043
32722340|NCT04814368|Placebo Comparator|Placebo|Placebo to canakinumab
32722341|NCT04814368|Experimental|canakinumab + LNA043|canakinumab + LNA043
32722342|NCT04814368|Experimental|canakinumab|canakinumab
32924146|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
32924147|NCT02974205|Active Comparator|Rehabilitation without orthosis|
32924148|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
32722343|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
32722344|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
32722345|NCT03499847|No Intervention|Control|
32722346|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
32722347|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
32722348|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
32722349|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
32722350|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
32722351|NCT04774744|Experimental|Group I (digital health coaching program)|Patients receive the PACK Health digital health coaching program over 3 months consisting of communication initiated by either the PACK Health coach or the patient through either text, e-mail, or phone call, to provide education and support related to a specific topic such as fatigue, nutrition, or exercise.
32722352|NCT04774744|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services consisting of a telephone triage line that patients may call when experiencing physical or psychological concerns, or with any other questions related to their disease or treatment.
32722353|NCT03497351|Experimental|Group N|the group treated with nicardipine
32722354|NCT03497351|Experimental|Group U|the group treated with Urapidil
32924149|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
32924150|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
32924151|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
32924152|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
32924153|NCT05543083|Experimental|Cognitive-Behavioral Therapy followed by Exercise Training|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by a 6-week exercise training intervention of 6 weekly 1-hour group sessions
32924154|NCT05543083|Active Comparator|Exercise Training followed by Cognitive-Behavioral Therapy|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by a 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
32924155|NCT05543083|Active Comparator|Exercise Training Only|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by an additional 6-week exercise training intervention of 6 weekly 1-hour group sessions
32924156|NCT05543083|Active Comparator|Cognitive-Behavioral Therapy Only|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by an additional 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
32924157|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
32924158|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
32924159|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
32924160|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
32924161|NCT04823299|Active Comparator|Cryoballoon ablation|Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)
32924162|NCT04823299|Experimental|RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation|Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation
32924163|NCT04879524||Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|100 units of Botulinum toxin type A (Botox, Allergan, Ireland) injection into the puborectalis muscle to each side of the midline, achieving a total of 200 units
32924164|NCT05302115||S-ICD|
32722355|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
32924165|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
32924166|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
32722356|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
32722357|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
32722358|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
32722359|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
32722360|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
32722361|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
32722362|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
32722363|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
32722364|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
32722365|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
32722366|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
32722367|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
32767798|NCT04336241|Experimental|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
32924167|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
32924168|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
33400326|NCT05119075|Experimental|Dopaminergic OFF-drug state first, dopaminergic ON-drug state second|"The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
32924170|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
32924171|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
32924172|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
32924173|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
32924174|NCT05154773|Experimental|KidneyTIME|KidneyTIME is a self-directed digital intervention. It contains 26 animated videos, each 1-3 minutes in length, designed to address knowledge gaps and concerns about kidney transplantation and living donation that were identified in literature reviews, formative research, and video development studies as critical for optimal prospective kidney recipient and donor participation in LDKT. We chose 6 videos from the entire series to be delivered sequentially for a total duration of 13 minutes. After completing the proscribed videos and an immediate-post exposure survey, everyone then received a link to access all 26 videos centralized on a website where the videos were activated for sharing through various modalities, including text, email, Facebook, and Twitter. The website could be accessed using this link from any electronic device throughout the study. Prompts to use the intervention were sent once a week for 3 weeks and then monthly for 12 months.
32722368|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
32722369|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
32722370|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
32722371|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
32722372|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
32722373|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
32722374|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
32722375|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
32722376|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
32722377|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
32722378|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
32722379|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
32722380|NCT04803604|Experimental|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
32722381|NCT04803604|Experimental|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
32722382|NCT04803604|Experimental|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
32722383|NCT04803604|Experimental|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
33400327|NCT04440046|Experimental|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
32722384|NCT04803604|Experimental|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
32722385|NCT04803604|Experimental|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
32722386|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
32722387|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
32924175|NCT05154773|No Intervention|Usual Care|Routine educational materials from non-study sources through usual Transplant Center protocols including booklets, nurse communications, and the usual care video, a nurse-narrated power-point presentation outlining recipient and donor evaluation, surgery, and recovery processes and outcomes.
32924176|NCT05732207|Experimental|Cathodal cerebellar transcranial direct current stimulation (ctDCS)|For ctDCS, the cathodal (-) electrode will be positioned over the right cerebellum 1 cm below and 3 cm lateral to the inion, and the anodal (+) electrode will be placed on the contralateral supraorbital area (FP2 EEG location).
32924177|NCT05732207|Experimental|Anodal cerebellar transcranial direct current stimulation (atDCS)|For atDCS, anode/cathode locations are reversed from those of ctDCS..
32924178|NCT05732207|Sham Comparator|Sham cerebellar transcranial direct current stimulation (stDCS)|For stDCS, the electrodes will be configured randomly as atDCS 50% of the time, and as ctDCS 50% of the time.
32924179|NCT03023449|Experimental|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
32924180|NCT03023449|Experimental|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
33249851|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
32924183|NCT05533411|Experimental|Donanemab|Donanemab administered intravenously (IV).
32924184|NCT05533411|Placebo Comparator|Placebo|Placebo administered IV.
32924186|NCT05513053|Experimental|Group 9 to 17 years old|Participants of 9 to 17 years old who will receive RIV4 single intramuscular (IM) injection at D01
32722388|NCT04803604|Experimental|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
32722389|NCT04803604|Experimental|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
32722390|NCT04803604|Experimental|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
32722391|NCT04803604|Experimental|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
32722392|NCT04803604|Experimental|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
32722393|NCT04803604|Experimental|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
32722394|NCT05165719||Vaccinated|SARS-CoV-2 vaccination with 'Sputnik V' (Gam-COVID-Vac) in a period 7-14 days after the second vaccination before recruitment
32722395|NCT05165719||Convalescents|PCR (polymerase chain reaction) confirmed COVID-19 in a period 14-45 days before recruitment
32722396|NCT05165719||Healthy donors|No self-reported COVID-19 infection
32722397|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
32722398|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
32722399|NCT05376709|Experimental|Short-Term Calorie Reduction(SCR)|To determine the short-term impact of calorie modification on patient outcomes by measuring and comparing the following parameters between two groups a week after starting each R-CHOP cycle: symptoms, hematologic parameters (i.e., erythrocyte-, thrombocytes-, and leucocyte counts), metabolic parameters (i.e., insulin, glucose, insulin growth factor 1), inflammatory response (C-reactive Protein, CRP), and nutrition status (i.e., weight, albumin level, and lean body mass (LBM)).
32722400|NCT05376709|No Intervention|Control|Participated patients will be recruited and randomized to two groups: comparison group who receive standard care and experimental group who receive the SCR intervention. The standard care at NTUH includes encouraging patients to eat healthy and clean diet (e.g., avoid raw or undercooked food). There are no calorie restriction to the comparison group. The next paragraph describes the SCR intervention for experimental group.
32722401|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
32722402|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
32924187|NCT05513053|Experimental|Group 18 to 49 years old|Participants of 18 to 49 years old who will receive RIV4 single intramuscular (IM) injection at D01
32924188|NCT04742855||Group A|It will consist of 10 adults and 5 children. They will get the yogurt strains
32924189|NCT04742855||Group B|It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
32924190|NCT04742855||Group C|It will consist of 10 adults and 5 children. They will get the placebo.
32924191|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32924192|NCT05731973|Experimental|Intercostal nerve cryoablation|When a patient is allocated to the intercostal nerve cryoablation group, cryoablation will be performed prior to bar placement. In brief, cryoablation will be performed at the level of the bar and two levels above and below, bilaterally. For this, a second portal access will be placed for video guidance on the contralateral side, and the cryoprobe (cryoICE, Atricure, Masion, OH, USA) will be inserted through the thoracic incisions that are already made for bar placement. The probe will be placed at the inferior aspect of the ribs, posterior to the midaxillary line, directly on the neurovascular bundle. One freezing cycle takes 2 minutes, and a temperature of -60 ⁰C will be applied. The probe will be warmed to room temperature before removing it from the pleura to prevent additional trauma. Furthermore, intercostal nerve cryoablation will be combined with single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks placed just anterior to the side of the cryoablation.
32924193|NCT05731973|Active Comparator|Thoracic epidural (local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Prior to surgery, an anesthesiologist will place the thoracic epidural at T5-T6 or T6-T7 interspace in the awake patient. After correct placement, a local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml) will be started. At the third postoperative day, thoracic epidural analgesia will be ceased and transitioned to oral pain medication at discretion of the pain management team. In general, opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours as needed) will be provided 12 hours before thoracic epidural analgesia is ceased.
32924194|NCT05502367|Experimental|ABI-2280 0.1mg|0.1mg vaginal tablet
32924195|NCT05502367|Experimental|ABI-2280 0.3mg|0.3mg vaginal tablet
32722403|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
32722404|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
32722405|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
32722406|NCT05165563|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
32722407|NCT05165563|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
32924196|NCT05502367|Experimental|ABI-2280 1.0mg|1.0mg vaginal tablet
32722408|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
32924197|NCT05068349|Experimental|A group of patients with ischemic stroke were treated with butylphthalide injection and capsules|Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.
32924198|NCT05515445|Experimental|Normal Hepatic Function|Subjects with normal hepatic function will receive a single 48 mg oral dose of Chiglitazar
32924199|NCT05515445|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
32924200|NCT05515445|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
32924201|NCT05515445|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
33400328|NCT04440046|Sham Comparator|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
33400329|NCT04440046|Sham Comparator|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
32722409|NCT04680403|Experimental|supervised exercise plan|patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.
32722410|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
32722411|NCT04780204|Experimental|Antiviral Treatment|Tenofovir Alafenamide 25mg once daily , Oral
32722412|NCT04780204|Other|Observation|Best supportive care
32722413|NCT05165407|Experimental|Sintilimab Combined With IBI310 and Surufatinib|Surufatinib at a dose of 250mg QD, with Sintilimab injected intravenously 200mg per 3 weeks and IBI310 injected intravenously 1mg/kg per 6 weeks until disease progresses or unacceptable tolerability occurs
32722414|NCT02322203|Experimental|Niacin ER in healthy participants and its effects on lipoprotein composition and function|Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
32722415|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
32722416|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
32722417|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
32722418|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
32722419|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32722420|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32722421|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32722422|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32924202|NCT04740931|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
32924203|NCT04740931|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
32924204|NCT05066789|Active Comparator|Biodegradable Polymer DES|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use Orsiro Mission stent during the index procedure."
32924205|NCT05066789|Active Comparator|12-month DAPT|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily)."
32924206|NCT05066789|Experimental|Polymer-free DCS|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use BioFreedom Ultra stent during the index procedure."
32924207|NCT05066789|Experimental|Prasugrel monotherapy|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone."
32924208|NCT04984421|Active Comparator|Basic|All schools will receive the HSS program. Schools randomly assigned to group 1 will receive implementation strategy bundle 1 (Basic).
32924209|NCT04984421|Experimental|Enhanced|All schools will receive the HSS program. Schools randomly assigned to group 2 will receive implementation strategy bundle 1+2 (Enhanced).
32924210|NCT05731817||COVID-19 patients|COVID-19 patients
32924211|NCT04936919|Experimental|Treatment Arm|
32924212|NCT05731739||RESPONDERS|The investigators will define responders as patients achieving Numerical Rating Score (NRS) reductions of 30% or greater based on literature defined criteria for meaningful reductions in pain scores
32924213|NCT05731739||NON RESPONDERS|When a patient failed to respond to the lidocaine infusion, they were given the option to have repeat infusion after four weeks. If no response was obtained, despite two infusions, this was considered as a failure of treatment and no further lidocaine infusions were conducted. Patient will be labelled as a non responder
32924214|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
32924215|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
33249852|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
32722423|NCT04638751||High risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening considered at high risk for CRC due to either 1) one or more first degree relatives with a history of CRC, or 2) a personal history of colorectal cancer, advanced adenoma as defined by USMSTF guidelines on colorectal cancer, or 3 or more non-advanced adenomas in a single screening or surveillance encounter (synchronous).
32722424|NCT04638751||Low risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening, who are not considered high risk for CRC based on family history or prior colonoscopy findings.
32722425|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
32722426|NCT02319629|Placebo Comparator|placebo|placebo twice a day
32722427|NCT04455373||orthopedic surgery group|Planned tumor resection
32722428|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
32722429|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
32924216|NCT05731661|Experimental|Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care|
32924217|NCT05731661|Active Comparator|Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care|
32924218|NCT05731661|Other|Observational cohort|
32722430|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
32722432|NCT04691362|Active Comparator|Oral Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
32722433|NCT04691362|Active Comparator|Intravenous Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
32722434|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
32722435|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
32722436|NCT01421290|Active Comparator|Conservative treatment|
32722437|NCT01421290|Active Comparator|Surgery|
32722438|NCT04561453||Resected Biliary Duct Cancer|
32722439|NCT04559893|Experimental|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
32722440|NCT04559893|No Intervention|Control|Patients in this arm will receive enhanced usual care.
32722441|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
32722442|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
32722443|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
32722444|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
32722445|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
32722446|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
32924219|NCT04665037|Experimental|Panel A: POS IV|Posaconazole 6 mg/kg body weight administered in a single dose by IV infusion on Day 1.
32722447|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
32722448|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
32722449|NCT05165017|Active Comparator|Intervention Arm 1|AlloRx Stem Cells IV infusion treatment
32722450|NCT05165017|Placebo Comparator|Intervention Arm 2|IV infusion of normal saline
32722451|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
32722452|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
32722453|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
32722454|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
32722455|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
32722456|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
32722457|NCT04878601|Experimental|hbART|Home-Based ART initiation and continuation for 3-months with male-specific counseling and assisted facility navigation at 4-months.
32722458|NCT04878601|Active Comparator|fbART|Facility-Based ART initiation and continuation with male-specific counseling.
32722459|NCT01368718|Other|Active/Sham CPAP|
32722460|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
32722461|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
32722462|NCT04831801||Female patients with overactive bladder (OAB)|Patients with urgency and frequency syndrome with or without pelvic pain (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
32722463|NCT04831801||Female control patients without LUTS|Patients without LUTS (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
32722464|NCT01368250||1|Patients with native aortic stenosis undergoing TAVI
32722465|NCT01368250||2|Patients with native aortic regurgitation undergoing TAVI
32722466|NCT01368250||3|Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
32722467|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
32924220|NCT04665037|Experimental|Panel B: POS IV/PFS|Posaconazole at a dose to be determined administered twice daily by IV infusion on Day 1, and then once daily from Day 2 to a maximum 84 days. Following a minimum of 7 days IV dosing, participants as clinically able will be transitioned from POS IV to POS PFS on Day 8, once daily to a maximum 84 days.
32924221|NCT05464199|Experimental|Participants receiving neurofeedback intervention|Self administered neurofeedback training - Use of Headset and tablet with software App for playing a selected neurofeedback game. The EEG headset and tablet-based application is designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own EEG signals associated with activity in brain networks related to pain perception and pain modulation.
32924222|NCT04621279||Mild HIE|Mild HIE identified in the first 6 hours of life according to the published PRIME study definition: newborn with evidence of encephalopathy (using the validated Sarnat Exam) NOT meeting prior cooling trials criteria.
32924223|NCT05452577|Experimental|Chinese medicine group|"Participants received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks.~Subjects who had previously taken Western medicine hypnotics continued to take them, and those who did not take them did not add Western medicine hypnotics."
32924224|NCT05452577|Active Comparator|Western medicine group|Participants received Estazolam 1mg tablet orally once daily for 4 weeks.
32924225|NCT04591717|Experimental|Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC|0.5 mL of hAd5-S-Fusion+N-ETSD SC (5 × 10e10 VP/dose) on days 1 and 22
32924226|NCT04591717|Experimental|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) on days 1 and 22
32924227|NCT04591717|Experimental|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
32924228|NCT04591717|Experimental|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; no vaccine on day 22
32924229|NCT04591717|Experimental|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
32722468|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
32924230|NCT04591717|Experimental|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on days 15 and 29
32924231|NCT05464615|Experimental|Amoxicillin Graded Challenge|"Obtain baseline vitals (heart rate, O2 saturation, blood pressure and respiratory rate).~Administer 1 ml (50 mg) of amoxicillin 250 mg/ 5ml orally followed by 30 minutes of observation for allergy symptoms and other adverse reactions (e.g., itching, hives, swelling, coughing, wheezing, throat tightness, difficulty breathing, abdominal pain, vomiting, lightheadedness, hypotension, low oxygen saturation, tachycardia)~If no allergy or adverse symptoms are noted, administer 4 ml (200 mg) of amoxicillin followed by 90 minutes of observation"
32924232|NCT05731583||Recovering COVID|Subjects with hospitalization due to a confirmed diagnosis of Sars-CoV-2 infection, that were considered eligible for home monitoring.
32924233|NCT05731583||Ongoing COVID|Subjects with confirmed new diagnosis of Sars-CoV-2 infection, not requiring immediate hospitalization.
33249853|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
33249854|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
32722469|NCT04506385|Active Comparator|A - L. delbrueckii LDD01 probiotic bacterial strain administered in sachets of 2 grams|L. delbrueckii LDD01 probiotic bacterial strain
32722470|NCT04506385|Active Comparator|B - Bifidobacterium longum DLBL probiotic bacterial strain administered in sachets of 2 grams|Bifidobacterium longum DLBL probiotic bacterial strain
32722471|NCT04506385|Active Comparator|C - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum 04: low dosage; probiotic bacterial strains blend
32722472|NCT04506385|Active Comparator|D - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage; probiotic bacterial strains blend
32722473|NCT05398861|Experimental|HER-2 Negative Advanced Breast Cancer|Utidelone Combined with Bevacizumab
32722474|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
32722475|NCT04586101|Experimental|Training intervention|
32722476|NCT04586101|No Intervention|Control interverntion|
32722477|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
32722478|NCT05398549|Active Comparator|Conventional physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise.
32722479|NCT05398549|Experimental|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414.Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training Baseline treatment protocol hot pack and ultrasound was applied to both groups. Treatment duration for both groups was 30 minutes. Each subjects were receive a total 4 week protocol with 03 treatment sessions per week.
32767799|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
32924234|NCT05460793|Experimental|Surgical treatment|Minimally invasive endoscopy-guided surgery in addition to standard medical management for the treatment of spontaneous supratentorial intracerebral hemorrhage performed within 8 hours of symptom onset.
32924235|NCT05460793|No Intervention|Standard medical management|Standard medical treatment for the treatment of spontaneous supratentorial intracerebral hemorrhage (treatment of blood pressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration).
32924236|NCT05731427||Pseudomonas aeruginosa colonization group|Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
32924237|NCT05731427||Non-Pseudomonas aeruginosa colonization group|No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
32924238|NCT05731427||Before treatment with macrolides|Before treatment with macrolides in patients with bronchiectasis
32924239|NCT05731427||After treatment with macrolides|After 6 months of treatment with macrolides for patients with bronchiectasis
32924240|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
32924241|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
32924242|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
32924243|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
32924244|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
32924245|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
32924246|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
32924247|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
32924248|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
32924249|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
32924250|NCT05438849||Women Veterans receiving primary care in VISN-7 of the VA Healthcare Administration (VHA)|This project will include English-speaking, community-dwelling women Veterans 20 years or older with a diagnosis of UI (all types) and access to the internet via a mobile device or computer. Women Veterans who are currently pregnant or less than 12 weeks postpartum will be excluded. PURSUIT utilizes a mobile health application, called MyHealtheBladder, to connect patients with nonsurgical treatment options.
32722480|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
32722481|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
32722482|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
32924251|NCT05438849||Health care providers in community-based outpatient clinics in VISN-7 of the the VHA|Community-Based Outpatient Clinics (CBOCs) from VA Integrated Service Network (VISN) 7 will be targeted, spanning the states of Alabama, Georgia, and South Carolina. VISN 7 CBOCs, serving at least 50 women Veterans with primary care services, will be recruited.
32924252|NCT04660019|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
32924253|NCT04660019|Placebo Comparator|sham acupuncture|Auricular points sticker
32924254|NCT05429177|Experimental|SAD Cohort 1(0.1% QY101 ointment or vehicle apply to 5%BSA)|3 subjects use 0.1% QY101 ointment，1 subject uses vehicle topical applied to 5% Body Surface Area，assessed until 72 hours postdose
32924255|NCT05429177|Experimental|SAD Cohort 2(0.1% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.1% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
32924256|NCT05429177|Experimental|SAD Cohort 3(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
32924257|NCT05429177|Experimental|SAD Cohort 4(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
32924258|NCT05429177|Experimental|SAD Cohort 5(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
33400330|NCT05309707||Patients with aortic arch pathologies treated by branch stent graft systems|Patients with aortic arch pathologies treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
32722483|NCT03498833|Other|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
32722484|NCT05398393|Other|group A|normal blood lipid level at baseline
32722485|NCT05398393|Other|group B1|baseline blood lipid is elevated and treat with lipid-lowering drugs
32722486|NCT05398393|Other|group B2|baseline blood lipid is elevated and without lipid-lowering drugs treatment
32722487|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
32722488|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
32924259|NCT05429177|Experimental|SAD Cohort 6(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，assessed until 72 hours postdose
33249855|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.~*TCS = topical corticosteroids."
33249856|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
33249857|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
33249858|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
32722489|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
32722490|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
32722491|NCT04353583||ICU patients|Patients with COVID-19 requiring ICU care
32722492|NCT04353583||Non-ICU patients|In-hospital patients with COVID-19 not requiring ICU care
32722493|NCT04333147|Experimental|Participants receiving GSK3196165 in qualifying study|Participants receiving GSK3196165 in their qualifying study will continue to receive GSK3196165 at the same dose level (90 mg or 150 mg weekly) in this study.
32722494|NCT04333147|Experimental|Participants receiving comparator in qualifying study|Participants receiving a comparator (e.g. tofacitinib or sarilumab) in their qualifying study will be re-randomized to receive either GSK3196165 90 mg or 150 mg weekly in this study.
32722495|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
32722496|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
32722497|NCT03498677|Active Comparator|Method of presentation one|
32722498|NCT03498677|Active Comparator|Method of presentation two|
32722499|NCT04190134|Experimental|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
32722500|NCT04190134|Active Comparator|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
32722501|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
32722502|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
32722503|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
32722504|NCT02320019|Placebo Comparator|Placebo group|Placebo
32722505|NCT02320019|Experimental|Group A|YH14618 A mg/disc
32722506|NCT02320019|Experimental|Group B|YH14618 B mg/disc
32722507|NCT02320019|Experimental|Group C|YH14618 C mg/disc
32722508|NCT02320019|Experimental|Group D|YH14618 D mg/disc
32722509|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
32722510|NCT02320331|Experimental|PILI Lifestyle Program|
32722511|NCT02320409|Experimental|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
32722512|NCT02320409|Experimental|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
32722513|NCT05164861|Experimental|"Intervention/kombucha-based beverage Black currant with juniper"|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha Black currant with juniper, enriched with inulin and vitamins"
32722514|NCT05164861|No Intervention|Control|Subjects of this group will receive standard diet with similar quantity of water as in experimental group
32722515|NCT05164861|Experimental|"Intervention/kombucha-based beverage Strawberries with lime"|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha Strawberries with lime, enriched with inulin and vitamins"
32722516|NCT04462133|Active Comparator|Empirical therapy for H. pylori infection|The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
32722517|NCT04462133|Experimental|Tailored therapy for H. pylori infection|The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
32722518|NCT05164627|Active Comparator|Group A|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
32722519|NCT05164627|Active Comparator|Group B|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
32924260|NCT05429177|Experimental|MAD Cohort 7(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
32924261|NCT05429177|Experimental|MAD Cohort 8(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
32924262|NCT05429177|Experimental|MAD Cohort 9(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
32722520|NCT05164627|Placebo Comparator|Group C|Patients will receive Normal Saline 0.9% infusion
32722521|NCT04461977|Experimental|A - true acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen 2011) and on previous studies (Jeong, 2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment."
32722522|NCT04461977|Sham Comparator|B - sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet."
32722523|NCT04454359|Experimental|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of <65 kg, 65-75 kg and >75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
32924263|NCT05429177|Experimental|MAD Cohort 10(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，twice daily for 7 days and once in the morning on D8
32924264|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
32924265|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
32924266|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
33249859|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
32924268|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
32924269|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
32722524|NCT04454359|Placebo Comparator|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
32722525|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
32722526|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
32924270|NCT05408663|Experimental|Experimental- EXT608|Up to 6 sequential dose escalation cohorts will receive a single dose of EXT608 administered as a subcutaneous injection
32924271|NCT05408663|Placebo Comparator|Placebo comparator|Up to 6 participants will receive matching placebo administered as a subcutaneous injection
32924272|NCT05442151|Other|FAPI-PET/CT group|
32924273|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
33249860|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
33249861|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
33249862|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
33249863|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
32722527|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
32722528|NCT05398315|Experimental|Empathic Statements, MI, Male, No Backstory|Presence of empathic statements and MI techniques. Male narrator. No narrator backstory.
32722529|NCT05398315|Experimental|No Empathic Statements, No MI, Female, No Backstory|No empathic statements, MI techniques or narrator backstory. Female narrator
32722530|NCT05398315|Experimental|No Empathic Statements, No MI, Female, Backstory|No empathic statements or MI techniques. Presence of narrator backstory. Female narrator
32722531|NCT05398315|Experimental|Empathic Statements, MI, Female, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Female narrator
32722532|NCT05398315|Experimental|No Empathic Statements, No MI, Male, No Backstory|No empathic statements, MI techniques or narrator backstory. Male narrator
33249864|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
33249865|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
33249866|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
33249867|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
32722533|NCT05398315|Experimental|Empathic Statements, MI, Male, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Male narrator.
32722534|NCT05398315|Experimental|No Empathic Statements, MI, Female, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Female narrator.
32722535|NCT05398315|Experimental|Empathic Statements, No MI, Male, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Male narrator.
32722536|NCT05398315|Experimental|No Empathic Statements, MI, Male, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Male narrator.
32722537|NCT05398315|Experimental|Empathic Statements, No MI, Female, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Female narrator.
32924274|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
32924275|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
32924276|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
32924277|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
32722538|NCT05398315|Experimental|Empathic Statements, MI, Female, No Backstory|Presence of empathic statements and MI techniques. Female narrator. No narrator backstory.
32722539|NCT05398315|Experimental|No Empathic Statements, No MI, Male, Backstory|Presence of narrator backstory. No empathic statements or MI techniques. Male narrator.
32722540|NCT05398315|Experimental|Empathic Statements, No MI, Female, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Female narrator.
32722541|NCT05398315|Experimental|Empathic Statements, No MI, Male, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Male narrator.
32924278|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
32722542|NCT05398315|Experimental|No Empathic Statements, MI, Female, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Female narrator.
32722543|NCT05398315|Experimental|No Empathic Statements, MI, Male, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Male narrator.
32722544|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
32722545|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
32722546|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
32722547|NCT05111743||Brolucizumab|Participants received brolucizumab injection during the index period
32722548|NCT04254289|Active Comparator|Usual Care|Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
32722549|NCT04254289|Experimental|Home-based exercise program|Home-based individualized exercise program based on heart rate reserve (HRR).
32722550|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32722551|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32722552|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32722553|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32924279|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
32924280|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
33249868|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
33400331|NCT03162016|Experimental|Transplants of acellular matrix|
33400332|NCT03162016|Active Comparator|Transplants of connective tissue|
32924281|NCT04741373|Placebo Comparator|Group of health education|
32924282|NCT04741373|Active Comparator|Group of health education and rehabilitation exercise|
32924283|NCT04741373|Experimental|Group of health education,exercise and ONS|
33400333|NCT05081245|Experimental|ML-004 (IR)/(ER) tablet|ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
33400334|NCT05081245|Placebo Comparator|ML-004 Placebo|Matched placebo oral tablets will consist of same excipients as the investigational drug but without any ML-004. Placebo taken orally once daily to match tablet number of ML-004 dose levels for 12 mg (1 tablet), 24 mg (1 tablet), 48 mg (2 tablets), and 72 mg (3 tablets).
32924284|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:~General medical management according to AHA/ASA guidelines~Admission to monitored or intensive care unit for at least 24 hours~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines~Follow-up imaging study required in any patient with neurologic deterioration"
32924285|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
32924286|NCT04433195|Active Comparator|Immediate NAA by clinician|Nucleic acid amplification test requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB
32924287|NCT04433195|Experimental|Immediate NAA as intervention|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, but Xpert MTB/RIF is performed as intervention in this study (intervention group)
32924288|NCT04433195|No Intervention|No immediate NAA|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, and Xpert MTB/RIF is not performed as the initial diagnostic test in this study (control group). Nucleic acid amplification test may be ordered at a later point in time by clinicians as an add-on test after sputum smear microscopy
32722554|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32722555|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
32722556|NCT05096143||Naive Sacubitril/valsartan|Participants who were prescribed with Naive Sacubitril/valsartan
32722557|NCT05096143||Naive ACEi/ARB|Participants who were prescribed with Naive Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
32722558|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
32924289|NCT05392985||FES+-|MBC patients with both FES positive(+) and negative(-) lesions.
32924290|NCT05363813|Experimental|Laparoscopic Surgical Patients|"Adult subjects, male or female, ≥18 years old~Subjects who have been scheduled for a laparoscopic surgery using the clip~Subjects who had provided written informed consent form~Ability and willingness to comply with all study requirements to be evaluated for each study visit"
32924291|NCT05731349|Experimental|NEWS-1 care|During the interventional period, the 2018 Sepsis Hour-1 Bundle will be initiated in the ED if NEWS2 score ≥ 5.
32924292|NCT05731349|No Intervention|Standard care|During the standard care period, emergency physicians will assess the patients based on history, physical examination, laboratory tests, chest radiography or other imaging studies, and will offer treatment based on clinical expertise, intuition, and local or international guidelines
32924293|NCT05731115|Experimental|Experimental Vaccine-lot 1|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 1.
32924294|NCT05731115|Experimental|Experimental Vaccine-lot 2|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 2.
32924295|NCT05731115|Experimental|Experimental Vaccine-lot 3|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 3.
32924296|NCT04410731|Experimental|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
32924297|NCT04742465|Experimental|Augmented reality|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
32722559|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
32722560|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
32924298|NCT05730959|Other|malfunctioning IPAA|Patients with malfunctioning IPAA
32924299|NCT05328947|Experimental|Normal Controls|
32722561|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
32722562|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
32722563|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
32767800|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
32722564|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
32722565|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
32722566|NCT04191031|Experimental|Superficial Genicular Nerves|Subjects will receive iovera° cryoneurolysis treatment of superficial genicular nerves (anterior femoral cutaneous nerve [AFCN] and infrapatellar branches of the saphenous nerve [ISN]) of the target knee
32722567|NCT04191031|Sham Comparator|Sham Comparator|Subjects will receive sham iovera° treatment of superficial genicular nerves (AFCN and ISN) of the target knee
32722568|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
32767801|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
32722569|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
32722570|NCT04102189|Experimental|Semaglutide|2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
32722571|NCT04102189|Placebo Comparator|Placebo|Placebo injected s.c. once weekly .
32722572|NCT03494387|Experimental|1|
32722573|NCT03494387|Experimental|2|
32722574|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
32722575|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle~These injections will be uni or bilateral, it will depend on clinical diagnosis.~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
32722576|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
32722577|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
32722578|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
32722579|NCT05398081|Experimental|Cefuroxime|Cefuroxime (Zinnat®) will be used as prophylactic antibiotic in this arm
32722580|NCT05398081|Active Comparator|Ceftriaxone|Ceftriaxone (Rocephin®) will be used as prophylactic antibiotic in this arm
32722581|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32722582|NCT04487431|Experimental|BAY1817080 Part A|Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
32722583|NCT04487431|Experimental|[14C]BAY1817080 Part B|Healthy male participants will receive BAY1817080 blended with [14C]BAY1817080 given as an oral solution (study Part B).
32722584|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
32722585|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
32722586|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
32722587|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
32722588|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
32722589|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
32722590|NCT05681845|Experimental|Arm 1 (Pilot part)|Participants will receive a single dose of Mim8 using a 32G, 4 mm pen-needle with the DV3407-C1 pen injector.
32722591|NCT05681845|Experimental|Arm 2 (Pilot part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
32722592|NCT05681845|Experimental|Arm 3 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 4 mm pen-needle with the DV3407-C1 pen injector.
32722593|NCT05681845|Experimental|Arm 4 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
32722594|NCT03496415|Experimental|Remote ischemic conditioning|
32722595|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
32722596|NCT05397925|Experimental|ADSProgram|"This is the experimental arm of the study. This includes receiving the novel/experimental ADSProgram. Therapy description withheld to protect the integrity of the study.~Intervention: ADSprogram"
32722597|NCT05397925|Active Comparator|Treatment as usual|"This is the control arm of the study. This includes receiving the standard of care on nursing Consultations on a medication-based program and multidisciplinary regular care. Therapy description withheld to protect the integrity of the study.~Intervention: Nursing Consultation"
32722598|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
32722599|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
32722600|NCT03821545|Active Comparator|Lidocaine Group|
32722601|NCT03821545|Active Comparator|Ketamine Group|
32722602|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
32722603|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
32722604|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:~50% of the hourly dose is given as a basal infusion~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
32722605|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
32722606|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
32722607|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
32722608|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
32722609|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
32722610|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
32722611|NCT03739723|No Intervention|Control Arm|Programs will continue to conduct normal educational activities.
32722612|NCT03739723|Experimental|Intervention Arm|The intent of the intervention arm is to provide programs with data and resources to inform and improve surgical learning environments and resident wellness.
32722613|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
32722614|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
32722615|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
32722616|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
32722617|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
32722618|NCT03496025|Experimental|Electrical stimulation|
32722619|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
32722620|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
32722621|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
32722622|NCT02325167|Experimental|EBT|
32722623|NCT02325167|Experimental|Treatment-as-usual|
32722624|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
32722625|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
32722626|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
32722627|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)~Asthma (defined as severe) - (n=20)~CF (FEV1% predicted baseline <50%) - (n=20)~COPD (FEV1% predicted baseline <50%) - (n=20)~Idiopathic Pulmonary Fibrosis (n=20)"
32722628|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
32722629|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
32722630|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
32767802|NCT04864457||Normal|Patients without coronary atherosclerotic burden
33400335|NCT03387852|Experimental|SAR440340|Participants received 2 injections of SAR440340 300 milligram (mg) along with 1 injection of dupilumab placebo, subcutaneous (SC) once every 2 weeks (Q2W) for 12 weeks.
33400336|NCT03387852|Active Comparator|Dupilumab|Participants received 1 injection of dupilumab 300 mg along with 2 injections of SAR440340 placebo, SC Q2W for 12 weeks.
33400337|NCT03387852|Experimental|SAR440340 + Dupilumab|Participants received 2 injections of SAR440340 300 mg along with 1 injection of dupilumab 300 mg, SC Q2W for 12 weeks.
33400338|NCT03387852|Placebo Comparator|Placebo|Participants received 2 SC injections of SAR440340 placebo along with 1 SC injection of dupilumab placebo Q2W for 12 weeks.
32767803|NCT04864457||Chronic coronary syndrome (CCS)|"CCS covers the different stages of development of coronary heart disease in addition to the clinical manifestations dominated by acute coronary thrombosis, including asymptomatic myocardial ischemia, vasospasm, and microcirculatory lesions. The six most common types of CCS include:Suspected coronary heart disease and stable angina symptoms, whether or not patients with dyspnea; Patients with newly emerged heart failure or left ventricular dysfunction suspected of CAD; Patients with no symptoms or stable symptoms within 1 year after ACS, or patients with recent revascularisation; Patients with or without symptoms more than 1 year after initial diagnosis or revascularization; Patients with angina pectoris, suspected vasospasm or microcirculatory diseases; Asymptomatic patients with coronary heart disease are found during screening."
32767804|NCT04864457||Acute coronary syndrome (ACS)|ACS is a group of clinical syndromes commonly characterized by acute myocardial ischemia, including unstable angina pectoris (UA); Acute non-ST-segment elevation myocardial infarction (NSTEMI); Acute ST-segment elevation myocardial infarction (STEMI).
32767805|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
32767806|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
32767807|NCT04849559|Experimental|Tradipitant|Oral Capsule
32767808|NCT04849559|Placebo Comparator|Placebo|Oral Capsule
32767809|NCT02543905||Family History Cohort|"Caucasian men with a family history of prostate cancer defined as:~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
32767810|NCT02543905||Black African / Black Caribbean Cohort|"Men of black African or black Caribbean ancestry defined as:~Both parents and all 4 grandparents from that origin."
32767811|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity who have been found to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol).
32767812|NCT03044561|Experimental|Sildenafil citrate|
32767813|NCT03044561|Placebo Comparator|placebo|
32767814|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
32767815|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
32767816|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
32767817|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
32767818|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
32767819|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
32767820|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
32767821|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
32767822|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
32767823|NCT04864301|Active Comparator|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
32767824|NCT04864301|Active Comparator|Conventional Measurement technique|The control group (N=12) will receive no intraoperative ICI. Following maximal corporal dilatation, cylinder length will be estimated conventionally by adding up the internally measured distal and proximal corpora to the length of the corporotomy.
32767825|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
32767826|NCT04429529|Experimental|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
33400339|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
32722631|NCT05618899|Experimental|HIGH INTENSITY INTERVAL TRAINING|High intensity interval training basicaaly short bursts of intense exercise alternating with low intensity recovery periods. Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
32722632|NCT05618899|Experimental|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
32722633|NCT03819361||Suspected OSA|
32722634|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
32722635|NCT05397613|Experimental|STAIR|Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
32722636|NCT05397613|Experimental|Waitlist control|First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures. Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
32722637|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
32722638|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
32722639|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
32722640|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist~The CARE intervention contain 3 component~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~a self-care component to promote caregiver health and well-being"
32722641|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care~Social work consults to help caregivers only upon request"
32722642|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
32722643|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
32722644|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
32722645|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
32722646|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
32722647|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
32722648|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
32722649|NCT05236231|Experimental|Treatment Sequence ABC|Participants will receive single oral dose of fixed dose combination (FDC) of macitentan/tadalafil under fasting conditions in (test) (Treatment A) Treatment Period 1 followed by single oral dose of FDC of macitentan/tadalafil under fed conditions (test) (Treatment B) in Treatment Period 2 and then single oral dose of macitentan/tadalafil under fasting conditions (reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722650|NCT05236231|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722651|NCT05236231|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722652|NCT05236231|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722653|NCT05236231|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722654|NCT05236231|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment C in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
32722655|NCT02325557|Experimental|Part A|Patients will receive ADXS31-142 monotherapy. Dosing will start at 1 x 10^9 cfu IV and escalate to 1 x 10^10 if appropriate.
32722656|NCT02325557|Experimental|Part B/Expansion|Patients will receive ADXS31-142 and pembrolizumab (MK-3475) in combination. Dosing of ADXS31-142 will start at one dose level less that appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate
33249869|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
32722657|NCT05397379|Experimental|HEC96719 0.25 mg|Oral dose once daily for 12 weeks
32722658|NCT05397379|Experimental|HEC96719 0.35 mg|Oral dose once daily for 12 weeks
32722659|NCT05397379|Experimental|HEC96719 0.5 mg|Oral dose once daily for 12 weeks
32722660|NCT05397379|Experimental|HEC96719 0.25 mg bid|Oral dose twice daily for 12 weeks
32722661|NCT05397379|Placebo Comparator|Placebo|Oral dose once or twice daily for 12 weeks
32722662|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle~LY3300054 is administered intravenously twice per cycle"
32722663|NCT05615311|Experimental|Vitamin D group|
32722664|NCT05615311|Placebo Comparator|Control group|
32924300|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
32722665|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
32722666|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
32722667|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
32722668|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
32722669|NCT02997709||Radiation Therapy Group|Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated
32722670|NCT02997709||Prostatectomy Group|Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated
32722671|NCT05510245|Experimental|Group 1|Participants without renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
33249870|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
33249871|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
33249872|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
33249873|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
33249874|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
32722672|NCT05510245|Experimental|Group 2|Participants with mild renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
32722673|NCT05510245|Experimental|Group 3|Participants with moderate renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
32722674|NCT05510245|Experimental|Group 4|Participants with severe renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
32722675|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
32722676|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
32722677|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
32722678|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
32722679|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
32722680|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
32722681|NCT05397301|Active Comparator|sedoanalgesia(SA group)|Sedoanalgesia was applied to the SA group
32722682|NCT05397301|Active Comparator|general anaesthesia (GA group)|General anaesthesia was applied to the GA group
32722683|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
32722684|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32722685|NCT05217901|Experimental|14C-labeled ASP0367|Participants will receive a single oral dose of [14C]ASP0367 solution under fasting conditions on day 1.
32722686|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
32722687|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
32722688|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
32722689|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
32722690|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
33249875|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
32767827|NCT04429529|Placebo Comparator|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
32767828|NCT04429529|Experimental|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
32767829|NCT04429529|Placebo Comparator|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
32767830|NCT04429529|Experimental|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
32767831|NCT04429529|Placebo Comparator|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
32767832|NCT04429529|Experimental|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
32767833|NCT04429529|Placebo Comparator|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
32767834|NCT04429529|Experimental|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
32767835|NCT04429529|Placebo Comparator|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
32767836|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
32767837|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
32767838|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
32767839|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
32767840|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
32767841|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
32767842|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
32767843|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
32767844|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
32767845|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
32767846|NCT03102463|Sham Comparator|Water Control|
32767847|NCT03102463|Active Comparator|Milk derived hydrolysate|
32767848|NCT03102463|Active Comparator|Parent Protein|
32767849|NCT04863989|Experimental|Small sized chest tube|Insertion of small sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
32767850|NCT04863989|Active Comparator|Large sized chest tube|insertion of large sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
32767851|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
32767852|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
32767853|NCT04863755|Other|DASH diet only|Patients receive a DASH diet and orientation to maintain their physical activity
32767854|NCT04863755|Other|DASH diet with pedometer|Patients receive a DASH diet and orientation to increase their physical activity with a pedometer steps count
32767855|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
32767856|NCT04863599|Other|OMS procedure under general anesthesia or sedation|Questionnaire
32767857|NCT04108429|Experimental|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
32767858|NCT04857515||Cigarette Smokers|Adult cigarette smokers who only smoke combustible cigarettes
32767859|NCT04857515||Dual-Users|Adult smokers who smoke both combustible cigarettes and vape
32767860|NCT04857047|Experimental|Group A|"[Period1] administration of BR9003A 1mg twice a day for six days~- Wash out for 9days -~[Period2] administration of BR9003 2mg once a day for six days"
32767861|NCT04857047|Experimental|Group B|"[Period1] administration of BR9003 2mg once a day for six days~- Wash out for 9days -~[Period2] administration of BR9003A 1mg twice a day for six days"
32767862|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
32767863|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
32767864|NCT04856969|Active Comparator|Arm A|ATB-1011: 1tab/d for 5days , ATB-1011+ATB-1012: each 1tab/d for 5days
32767865|NCT04856969|Active Comparator|Arm B|ATB-1012: 1tab/d for 5days / ATB-1011+ATB-1012: each 1tab/d for 5days
32767866|NCT04856735|Active Comparator|IPLA:intraperitoneal local anesthetic|intraperitoneal local anesthetic:after the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon. The 20 ml solution containing bupivacaine and lidocaine was injected into the uterine peritoneal region by spraying 5 mL to each quadrant of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer was sutured or left open at the surgeon's preference. At the end of the operation, 20 ml of saline solution was applied subcutaneously in the form of LWI instead of the incision before the skin was closed.
33249876|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
33249877|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
32767867|NCT04856735|Active Comparator|LWI:Surgical wound infiltration|Surgical wound infiltration:a solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed.
32767868|NCT04856735|Active Comparator|C: CONTROL GROUP|one of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
32767869|NCT04108039|Active Comparator|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering.
32767870|NCT04108039|Experimental|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
32767871|NCT04856501|Experimental|PALS intervention condition|
32767872|NCT04856501|Active Comparator|Control condition|
32767873|NCT05037175|Experimental|CPT-Text + Incentive|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Retention Incentive (RI). Participants will be told at baseline that they can earn discounts for other users with PTSD if they message with their therapist regularly."
32767874|NCT05037175|Experimental|CPT-Text + Reminder As Usual|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
32767875|NCT05037175|Active Comparator|Culturally Informed Trauma Treatment (CITT) + Incentive|"CITT will be conducted by Talkspace therapists with a specialty in PTSD culturally informed PTSD treatment.~Retention Incentivefor other users with PTSD in subsequent months if they message with their therapist regularly."
32767876|NCT05037175|Active Comparator|CITT+ Reminder as Usual|"CITT will be conducted by Talkspace therapists with a specialty in culturally informed PTSD treatment.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
32767877|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
32767878|NCT03981211|Experimental|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
32767879|NCT03981211|Experimental|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
32767880|NCT04856579|Other|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
32767881|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
32767882|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
32767883|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
32767884|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
32767885|NCT03938311|Experimental|very early rehabilitation|early mobilization initiates within 24h from the onset of the disease
32767886|NCT03938311|Experimental|relative early rehabilitation|early mobilization initiates between 24-72h from the onset of the disease
32767887|NCT03938311|Experimental|late mobilization group|early mobilization initiates after 72h from the onset of the disease
32767888|NCT03041597|Experimental|Immediate loading|
32767889|NCT03041597|Active Comparator|delayed loading|
32767890|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
32767891|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
32767892|NCT04856345|Experimental|Music with synchronising|walking to music that one can synchronise to
32767893|NCT04856345|Active Comparator|Music without synchronising|walking to music that one cannot synchronise to
32767894|NCT04856345|Sham Comparator|No music|walking without music.
32767895|NCT04089865|Experimental|Oral Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1950 mg of oral TXA in the pre-operative area.
32767896|NCT04089865|Active Comparator|Intravenous (IV) Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1 g of intravenous (IV) TXA upon transfer to the operating room.
32767897|NCT04856267||Systemic AL Amyloidosis study cohort|"Eligible patients will undergo subcutaneous implantation of a cardiac monitor device (Brand name - LINQ device, Medtronic - referred to in the application as implantable loop recorder or ILR)"
32767898|NCT03919045|Experimental|Sodium chloride injection|Sodium chloride 9mg/ml by injection
32767899|NCT03919045|Placebo Comparator|Needle sting|Brief needle stings without injection
32924301|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
33249878|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
33249879|NCT00953446|Experimental|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"ASL MRI~Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
33249880|NCT02560818|Active Comparator|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:~10 women to recover breast tissue (from surgical waste) : populations A and C~10 women to recover ovarian tissue (from surgical waste) : population B"
33249881|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
32767900|NCT04856111|Active Comparator|Pirfenidone|Pirfenidone will be started at a dose of 600 mg/day. The dose will be escalated by 600 mg/day every 3-7 days up to a targeted dose of 2400 mg/day. The subjects will be administered the maximum tolerated dose for a total period of 24 weeks from randomization.
33249882|NCT03058250|No Intervention|Control|Standard of care, no intervention
33249883|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
33249884|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
33249885|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
33249886|NCT00756834||Mammography Image Collection|Acquired images
33249887|NCT00756834||CAD Radiologist Reader|Retrospective reader study
32722691|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
32722692|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
33249888|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
33249889|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
33249890|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
33249891|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
33249892|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
33249893|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
33249894|NCT04066244|Other|Cohort 5 Arm #1|Dose 4, Regimen 1 of BLZ945
33249895|NCT04066244|Other|Cohort 5 Arm #2|Dose 4, Regimen 2 of BLZ945
33249896|NCT04066244|Other|Cohort 5 Arm #1 extended treatment period|Dose 4, Regimen 1 of BLZ945
33249897|NCT04066244|Other|Cohort 5 Arm #2 extended treatment period|Dose 4, Regimen 2 of BLZ945
32722693|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
32722694|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
32722695|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
33249898|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
33249899|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
33249900|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
33249901|NCT04985864|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
33249902|NCT04985864|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
33249903|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
33249904|NCT00956800|Experimental|telemedicine/study group|
33249905|NCT00956800|Active Comparator|control group|
33249906|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
33249907|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
33249908|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
33249909|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
33249910|NCT00953758|Experimental|1|
33249911|NCT04065776|Experimental|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
33249912|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
33249913|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
32722696|NCT02323919|Placebo Comparator|Usual Care|Usual Care
32722697|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
32722698|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
32722699|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;~Hepatocellular carcinoma confirmed pathologically;~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
33400340|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
33400341|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 200×10^6 anti-CD19 chimeric antigen receptor (CD19-CAR+) viable natural killer (NK) cells, single-dose, intravenously, once on Day 0.
32767901|NCT04856111|Active Comparator|Nintedanib|Subjects in this group will be administered nintedanib at a dose of 150 mg twice daily. The liver function tests will be monitored as above. The dose will be reduced to 100 mg twice daily, if there is intolerance to 300 mg/day dose.
32767902|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
32767903|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
32767904|NCT04856423||Us-qFIT group|People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
32767905|NCT03881683|Experimental|HRD and BRCA mutations|
32767906|NCT04856033|Experimental|TM|Transcendental Mediation
32767907|NCT04856033|Active Comparator|PCT|Present Centered Therapy
32767908|NCT04077541|Experimental|The experimental group|The trauma care bundles combined with the internet platform.
32767909|NCT04077541|No Intervention|The control group|Only trauma care bundles.
32767910|NCT04855565|Active Comparator|ALY688-SR|single dose subcutaneous injection
32767911|NCT04855565|Placebo Comparator|Matching placebo for ALY688-SR|single dose subcutaneous injection
32767912|NCT03864289|Experimental|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours.
32767913|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
32767914|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
32767915|NCT04855877|Active Comparator|Oral Tranexamic Acid|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
32767916|NCT04855877|Placebo Comparator|Placebo|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
33249914|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
33249915|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
32767925|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
32767926|NCT04855331|Active Comparator|Minimally invasive radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent laparoscopic or robotic radical pancreatectomy.
32767927|NCT04855331|Active Comparator|Open radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent open radical pancreatectomy.
32767928|NCT03102073||Radner test|reading speed evaluation
33249916|NCT00865917|Active Comparator|1|beta-blocker
33249917|NCT00865917|Experimental|2|I(f)-blocker
32767929|NCT01371981|Experimental|Arm A|See Detailed Description
32767930|NCT01371981|Experimental|Arm B|See Detailed Description
32767931|NCT01371981|Experimental|Arm C (Cohort 1)|See Detailed Description
32767932|NCT01371981|Experimental|Arm C (Cohort 2)|See Detailed Description.
32767933|NCT01371981|Experimental|Arm C (Cohort 3)|See Detailed Description. Different dose.
32767934|NCT01371981|Experimental|Arm D|See Detailed Description. May reassigned to Arm C.
32767935|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
32767936|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
32767937|NCT04855409||Bipolar Depression|Subjects with bipolar type I disorder depressive episode diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
32767938|NCT04855409||Healthy|Healthy control subjects matched with bipolar depressive patients by age and sex
32767939|NCT04849247|Experimental|177Lu-DOTA-FAPI dose escalation therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. Patients with sufficient lesion uptake of 68Ga DOTA-FAPI PET/CT will be offered therapy. Escalating doses of 30-150 mCi of 177Lu-DOTA-FAPI will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
32767940|NCT04849247|Experimental|Recommended Phase 2 dose 177Lu-DOTA-FAPI therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. 10 patients will be enrolled in the dose expansion cohort and received the highest dose achieved in the 177Lu-DOTA-FAPI dose escalation therapy study
32767941|NCT02845453|Experimental|Quetiapine|Quetiapine
32767942|NCT02845453|Placebo Comparator|Placebo|Placebo
32767943|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
32767944|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
32767945|NCT01799629|No Intervention|Control|Normal care
33249918|NCT00865917|Placebo Comparator|3|Placebo
33249919|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
33249920|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
33249921|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
33249922|NCT00865995||2|patients with tracheostomy
33249923|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
32767946|NCT04849403|Other|The group USG was applied|USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
32767947|NCT05431621||Digestive system cancer group|A total of about 1035 cases are expected to be enrolled, including 432 cases in stage I and 603 cases in II-IV.
32767948|NCT05431621||Negative group|985 healthy individuals.
32767949|NCT05431621||High risk group|410 cases with precancerous diseases.
32767950|NCT04848701|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
32767951|NCT04428827||Surgery|Patients treated with surgery
32767952|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
32767953|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
32767954|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
32767955|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
32767956|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
32767957|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
32767958|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
32767959|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
32767960|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
32767961|NCT04848545||Live-born sons (with and without testicular cancer diagnosis) from a Danish pregnancy Cohort|"Pregnancy cohort: Biological samples from 128,702 of pregnant women were stored for research purposes in the Danish National Biobank, in the period from 1976-2004.~Present study: live-born sons (with/without testicular cancer ascertained via data linkage in the Danish Cancer Registry)"
32767962|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
32767963|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
32767964|NCT01506973|Experimental|Gemcitabine/Abraxane/Hydroxychloroquine|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15 Hydroxychloroquine: 1200 mg/day PO daily (600mg BID) Daily from D1
32767965|NCT01506973|Experimental|Gemcitabine/Abraxane|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15
32767966|NCT04380545|Experimental|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32767967|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
32767968|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
32767969|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
32767970|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
32767971|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
32767972|NCT04848467|Experimental|Group 1: Co-ad group|Participants will receive CVnCoV at the same visit as QIV: first dose of CVnCoV and a dose of QIV in opposite arms at Day 1, the second dose of CVnCoV at Day 29, and a placebo injection at Day 57.
32767973|NCT04848467|Experimental|Group 2: Control group|Participants will receive QIV and CVnCoV at two different visits: one dose of placebo and one dose of QIV in opposite arms at Day 1, the first dose of CVnCoV at Day 29 and the second dose of CVnCoV at Day 57.
32767974|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
32767975|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
32767976|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
32924302|NCT04340765|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
33249924|NCT00956878||Cancer Pain Patients|
32722700|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
33400342|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0.
32722701|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
32722702|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
32722703|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
32722704|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
32722705|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
32722706|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
32722707|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
32722708|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
32722709|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
32722710|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
32722711|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
32722712|NCT03494699|Experimental|Intervention group|
32722713|NCT03494699|No Intervention|Control group|
32722714|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
32722715|NCT05118737|Active Comparator|colchicine|Intervention arm: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
32722716|NCT05118737|Placebo Comparator|Control|COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab according to local protocol
32722717|NCT05132543|Experimental|Wireless µECoG Prosthesis for Speech|
32722718|NCT05107973|Experimental|intervention|in this arm of participants will be receiving the Baduajin intervention.
32722719|NCT05107973|No Intervention|control|in this arm of participants will not receive any intervention
32722720|NCT05038163|No Intervention|Control Arm|In Part II of the experiment, subjects are not presented with nutrition or warning labels when choosing between beverages.
32722721|NCT05038163|Experimental|Nutrition Labels Arm|In Part II of the experiment, subjects are shown enlarged nutrition labels when choosing between beverages.
32722722|NCT05038163|Experimental|Text Warning Labels Arm|In Part II of the experiment, subjects are shown a warning message about the health risks of sugary beverages when choosing between beverages.
32722723|NCT05038163|Experimental|Graphic Warning Labels Arm|In Part II of the experiment, subjects are shown a graphic warning message about the health risks of sugary beverages when choosing between beverages. The message, for example, could include photos of tooth decay and other negative health outcomes.
32722724|NCT05129111|Active Comparator|STIMULATOR OF THE SALIVARY EXCRETION BASED ON PHYSICAL VIBRATION|Measurement of salivary secretion at rest and stimulated conditions.
32722725|NCT05129111|Placebo Comparator|STIMULATOR OF THE SALIVARY EXCRETION PLACEBO|Measurement of salivary secretion at rest and stimulated conditions.
32722726|NCT05053451|Experimental|dlPFC/TPJ Stimulation + Rest|20 minutes of 2 mA direct current stimulation during rest.
32722727|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
32722728|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
32722729|NCT04987931||Primary population: Talazoparib-treated patients with HER2- ABC with gBRCA1/2m|HER2-negative ABC patients with gBRCA1/2 mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
32722730|NCT04734275|Experimental|Treatment A (Test Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A), in fasted condition.
32722731|NCT04734275|Experimental|Treatment B (Test Formulation): AZD5718 Dose A, fed|Subjects will receive single dose of AZD5718 (Dose A) in fed condition
32722732|NCT04734275|Active Comparator|Treatment C (Reference Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A) in fasted condition
32722733|NCT04714151|Experimental|Treatment A|K-877 ER 0.2 mg/day (once daily)
32722734|NCT04714151|Experimental|Treatment B|K-877 ER 0.4 mg/day (once daily)
32722735|NCT04714151|Active Comparator|Control A|K-877 IR 0.2 mg/day (twice daily)
33249925|NCT00858897|Experimental|1|Normoglycemia (80-140 mg/dL)
32722736|NCT04702217|Experimental|POTS patients|All POTS patients in the study will perform a 16 week-training program. The present study will be using longitudinal comparisons, meaning that the 100 POTS patients are their own controls. The questionnaires and exercise capacity will be compared before and after the 16-weeks training program.
32722737|NCT04894019|Experimental|Continuous monitoring group|In patients randomized to the continuous monitoring group, continuous invasive arterial blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
32722738|NCT04894019|Active Comparator|Intermittent monitoring group|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous invasive arterial blood pressure monitoring.
32722739|NCT04831307|Experimental|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
32722740|NCT04441931|Experimental|LY3832479|Participants received single Intravenous (IV) doses of 700, 2800 and 7000 milligrams (mg) LY3832479.
32722741|NCT04441931|Placebo Comparator|Placebo|Participants received single IV dose of Placebo.
32722742|NCT03492983|No Intervention|Control group|No intervention
32722743|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
32722744|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
32722745|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
32722746|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
32722747|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
32722748|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
32722749|NCT04461197|Experimental|ESWT + orthotic insole|(shock waves + orthotic insole +Stretches of the posterior muscle chain)
32722750|NCT04461197|Placebo Comparator|ESWT + flat insole|(shock waves + flat insole + Stretches of the posterior muscle chain)
32722751|NCT04254809|Experimental|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
32722752|NCT04254809|Sham Comparator|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
32722753|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
32722754|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
32722755|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
32722756|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
32722757|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
32722758|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
32722759|NCT04039841|Other|Motor imagery evaluation|cohort study
32722760|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
32722761|NCT03901391||Retinitis Pigmentosa|
32722762|NCT04600895|Experimental|Favipiravir|Favipiravir 200mg tablet
32722763|NCT04600895|Placebo Comparator|Placebo|Placebo 200mg tablet
32722764|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
32722765|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
32722766|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
32722767|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
32722768|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
32924303|NCT05298449|Experimental|HU-045 group|"HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each.~HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
32924304|NCT05298449|Active Comparator|Xeomin® group|"Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each.~Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
32722769|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
32722770|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
32722771|NCT04499729|Active Comparator|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
32722772|NCT04499729|Experimental|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
32722773|NCT03491423|Experimental|Patients|
32722774|NCT02717611|Experimental|ACP-196 (acalabrutinib)|ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
32722775|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
32722776|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
32722777|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
32722778|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
32722779|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
32722780|NCT05479045|Experimental|NY-ESO-1 Peptide vaccine plus Nivolumab|
32722781|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
32722782|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
32722783|NCT05396989||First-onset of depressed patients|first attack
32722784|NCT05396989||Patients with recurrent depression|relapse
32722785|NCT04461353|Active Comparator|Hydroxychloroquine Sulfate|The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
32722786|NCT04461353|Placebo Comparator|Placebo|Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
32722787|NCT05191615|Experimental|Intervention Group|"The proposed study will be implemented as an intervention study at two levels within the organization, managerial and registered nurses. The intervention comprises three major phases: a pre-intervention phase, an implementation-intervention phase, and a post-intervention phase. The interventions will be provided face-to-face by trained interventionists. At baseline, all participants will complete questionnaires and get labs completed, blood pressure checked, and weight/height measured.~Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work."
32722788|NCT05191615|No Intervention|Control Group|Participants randomized to the control group will complete the baseline questionnaires and lab tests at baseline and three follow-up times. Lab values will be collected using the current standard of care and American Heart Association (AHA) guidelines (2019).
32722789|NCT04034459|Active Comparator|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.~Repeat administration every 2 weeks for a maximum of 12 cycles~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
32742959|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
32924305|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
32924306|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
33249926|NCT00858897|Experimental|2|Hyperglycemia (200-250 mg/dL)
32767977|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
32767978|NCT04848311|Experimental|ICG group|Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
32767979|NCT04848311|No Intervention|CLgroup|Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
32767980|NCT05431231||psychiatric ward|Adults consenting to treatment, who are admitted in the psychiatric ward at the Sheba Medical Health Center, whose first hospitalization has been up to five years before their current referral.
32767981|NCT05431231||Online hospitalization|adults consenting to treatment in their homes, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral. All the therapeutic treatments, assessment and follow-up meetings that are included in the service are provided online.
32767982|NCT05431231||Soteria|adults consenting to treatment in a house in the community, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral.
32767983|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
32767984|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
32767985|NCT04863365|Placebo Comparator|Placebo treatment|A matching placebo ophthalmic solution, TID
32767986|NCT04863365|Experimental|PHP-201 treatment|PHP-201 0.5% ophthalmic solution, TID
32767987|NCT04847765|Experimental|Combined pressure measurement and MRI|Gastric motility is evaluated simultaneously by means of the investigational medical device and by means of cine-MRI.
32767988|NCT03104179|Experimental|Treatment|CPB with Cytosorb
32767989|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
32767990|NCT04855175|Active Comparator|Autograft group|The autologous group will receive bone harvested from the patient's own body
32767991|NCT04855175|Active Comparator|Allograft group (ClearFit)|The allograft group will receive a synthetic bone known as ClearFit
32767992|NCT05430997|Active Comparator|Group A: conventional management|The ambient temperature of the operating room was set at 23±2 ℃ and the relative humidity was 50% to 60%. Intraoperative infusion fluids, blood products and rinsing fluid were warmed. Patients were given quilts to cover after entering the operating room, and the quilts covered from the neck to both the feet.
32767993|NCT05430997|Experimental|Group B: Hypothermia Risk Prediction Joint Active Insulation Management|"In the test group, after the assessment of the Intraoperative Hypothermia Risk Prediction APP, patients who were prompted/recommended to use active warming measures were actively warmed by inflatable warming (IOB Warming Unit (WU505) + Inflatable Warming Blanket) after admission to the room. Warming Unit (WU505) + Warming Blanket (IOB Warming Blanket)) was used for active warming. The air inlet was connected to the air catheter, and the host temperature was set at 38 ℃ with high air speed. During the operation, the thermal blanket is covered with non-surgical sterilization area (such as both shoulders, torso, healthy limbs, etc.), and the host temperature is adjusted to 38 ℃ for thermal insulation. The temperature and wind speed were adjusted in time to maintain the oropharyngeal temperature at 36.2℃～37.2℃ by monitoring the body temperature at any time during the operation."
32767994|NCT05376423|Experimental|OBI-833/OBI-821|"OBI-833 consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as a carrier protein.~OBI-821 is a purified saponin adjuvant~Dosage form: solution Dosage:30 μg OBI-833/100 μg OBI-821, subcutaneous injection, Frequency: weekly for 4 doses (weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (weeks 6, 8), then every 4 weeks for 4 doses (weeks 12, 16, 20, 24), and then every 8 weeks until disease recurrence, intolerable adverse events/toxicity, consent withdrawal, death, or up to 80 weeks from randomization."
32767995|NCT05376423|No Intervention|Observation|Patients will be randomized into OBI-833/OBI-821 (experimental) arm or observation arm.
32767996|NCT00484471|Experimental|1|
32767997|NCT00484471|Placebo Comparator|2|
32767998|NCT03041051|Experimental|PCV13|
32767999|NCT03041051|Experimental|PPV23|
32768000|NCT05401929|Experimental|Active|
32768001|NCT05401929|Sham Comparator|Sham|
32768002|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
32768003|NCT03835273||Minimally invasive surgery|Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
32768004|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
32768005|NCT04854785||Group 1 (DNP-mild)|Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
32768006|NCT04854785||Group 2 (DNP-moderate)|Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
32768007|NCT04854785||Group 3 (Healthy Control Participants)|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
32768008|NCT05401461|Experimental|Intervention|Evening mobilisation delivered between 7pm and 9pm
32768009|NCT05401461|No Intervention|Control|Patients in the control arm will receive standard care which incorporates physiotherapy and mobilisation as appropriate between 8am and 5pm
32924307|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
32924308|NCT05730725|Experimental|BMS-986322 Dose 1|
32924309|NCT05730725|Experimental|BMS-986322 Dose 2|
32924310|NCT05730725|Experimental|BMS-986322 Dose 3|
32768010|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
33249927|NCT00921362||1|Schizophrenia patients under Seroquel treatment
33249928|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
32768013|NCT05591547|Experimental|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|Patients will be treated with a novel IMRT/VMAT-based accelerated partial breast irradiation regimen.
32768014|NCT04847999|Experimental|Conventional Dark Chocolate|A standard dark chocolate bar.
32768015|NCT04847999|Experimental|Ross Dark Chocolate|A dark chocolate bar sweetened with stevia, erythritol, and inulin.
32768016|NCT05430841|Experimental|18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
32768017|NCT05375721|Experimental|ST36 acupoint injection group|Patients in this group will received bilateral ST36 injection with scopolamine 1ml/point
32768018|NCT05375721|Placebo Comparator|pharmacoprophylaxis group|Patients in this group will received bilateral ST36 acupoint injection with normal saline 1ml/point
32768019|NCT04863053||Stable CHD patient|Patients aged ≥ 18 years who have a history of stable coronary heart disease (CHD) receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily)
32768020|NCT05430763||Williams syndrome|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
32768021|NCT05430763||Control, age matched|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
32768022|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
32768023|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
32768024|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
32768025|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
32768026|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
32768027|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
32768028|NCT04847921|Experimental|people who use drugs with severe Gram-positive infections|As per inclusion and exclusion criteria
32768029|NCT05400525|Active Comparator|YMETA|Y META is a combination of gut health focused bioactives that target both the metabolic activity of existing microbiota (Bifidobacterium spp. targeting prebiotic galacto-oligosaccharides mixture)
32768030|NCT05400525|Placebo Comparator|Maltodextrin|
32768031|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
32768032|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
32768033|NCT04847687||Group 1|Patients who are started on 1 mg/kg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
32768034|NCT04847687||Group 2|Patients who are started on 250 mg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
32768035|NCT05430685|Experimental|Ashwagandha|Generic name: ashwagandha root extract Dose form: Chloroform capsule Dose: 1 capsule 350 mg ashwagandha root extract Frequency: 2 times per day (one capsule in the morning, one capsule in the evening). Total: 700 mg ashwagandha root extract per day Duration: 30 days
32768036|NCT05430685|Placebo Comparator|Placebo|Generic name: placebo Dose form: Glycerin equivalent weight to ashwagandha Dose: 1 capsule Frequency: one capsule, 2 times per day (one capsule in morning and one in evening) Duration: 30 dys
32768037|NCT01729455||BENLYSTA cohort|Participants with active, autoantibody-positive SLE treated with BENLYSTA at Baseline.
32768038|NCT01729455||Comparison cohort|Participants with active, autoantibody-positive SLE treated without BENLYSTA at Baseline.
32768039|NCT04854473|Experimental|Impedance measurement|Subjects with Exero's Smart Drain Device Attached This arm contains subjects which will have Exero's leak detection Device used: Exero Smart Drain is placed on their large bowel during colonic resection surgery (either open, laparoscopic or robotic). The study aims to demonstrate that the parameters measured by the device in in-vivo, non-disrupted tissue are different than parameters measured in ischemic tissue. Once this data is collected a detection algorithm can be trained. This procedure will add no more than 20 minutes to the existing procedure that is performed per hospital standard overall and will enable collection of control vs. ischemia induced clinical data, essential to developing the detection algorithms.
32768040|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
33249929|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
33249930|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
33249931|NCT00862329|Experimental|Casein|
32722790|NCT04034459|Experimental|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8~Repeat administration every two weeks up to a maximum of 12 cycles.~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
32722791|NCT03284021|Other|Fraxel laser|
32768041|NCT04428983|Experimental|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
32722792|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
32722793|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
32722794|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
32722795|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
32722796|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
32722797|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
32722798|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
32722799|NCT03490955|Active Comparator|Salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
32722800|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
32722801|NCT03490955|Active Comparator|Salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with dressing (canola oil) and with black pepper one time in the morning
32722802|NCT03490955|Active Comparator|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with dressing (olive oil) and with black pepper one time in the morning
32722803|NCT03490955|Active Comparator|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with dressing (corn oil) and with black pepper one time in the morning
32722804|NCT03490955|Active Comparator|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with dressing (sunflower oil) and with black pepper one time in the morning
32722805|NCT03490955|Active Comparator|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with dressing (flaxseed oil) and with black pepper one time in the morning
32722806|NCT03779243|Experimental|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
32722807|NCT03779243|Placebo Comparator|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
32722808|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722809|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722810|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722811|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722812|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722813|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32722814|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
32768042|NCT04428983|Placebo Comparator|placebo|placebo capsules 1 table tid orally per day for 24 months
32722815|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
32722816|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
32722817|NCT03669497|Experimental|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
32722818|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
32722819|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
32722820|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
32722821|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
32722822|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
32722823|NCT03490721|No Intervention|Control|Standard care non clustered.
32722824|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
32722825|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
32722826|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
32722827|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
32722828|NCT05477563|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.
32722829|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
32722830|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
32722831|NCT05396911|Experimental|Youth Brief Tobacco Intervention + Automated Text Messaging|
32722832|NCT05396911|Experimental|Youth Brief Tobacco Intervention|
32722833|NCT05396911|Experimental|Automated Text Messaging|
32722834|NCT05396911|No Intervention|No Treatment Control|
32722835|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
32722836|NCT05396677|Experimental|Acetaminophen Condition|1000 mg acetaminophen
32722837|NCT05396677|Placebo Comparator|Placebo Condition|1000 mg microcrystalline cellulose
32722838|NCT03490643|Other|TMD Group|people who has TMD
32722839|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
32722840|NCT01087333||1|Patients with hematologic malignancies or solid tumors.
32722841|NCT01087333||2|Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
32722842|NCT04461743||Patients with normal lac|
32722843|NCT04461743||Patients with abnormal lac|
32722844|NCT04786405|Experimental|Mindfulness Meditation|Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.
32722845|NCT04786405|Active Comparator|Clinical Hypnosis|Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.
32722846|NCT02906033|Experimental|Intervention group|New perioperative practice model.
32722847|NCT02906033|No Intervention|Control group|Traditional practice model.
32722848|NCT05396521|Active Comparator|Standard of Care|
32722849|NCT05396521|Experimental|Blood Flow Restriction Supplemented|
32722850|NCT05131867|Active Comparator|triple H group|The patients will receive nimodipine (60 mg/4 hours) orally or via nasogastric tube from the first day of admission, then after the diagnosis of vasospasm is confirmed, Triple H therapy (hypertension, hypervolemia and hemodilution) will be started. norepnnephrine (0.01-0.2ug/kg/min) to mentain main arterial blood pressure >100mmhg and hypervolemia to maintain the CVP around 12---14 mmHg and hemodilution to maintain the haematocrit between 30% and 33%.
32722851|NCT05131867|Active Comparator|Milrinone group|"The patients will receive oral Nimodipine (60 mg/4) will be given orally or in the gastric tube also from the first day of admission, then after the diagnosis of vasospasm is confirmed, start milrinone bolus of 0.1-0.2 mg/kg followed by 0.75mcg/k/min, if no response after 30min increase the infusion to 1-25mcg/kg/min with maintaining CVP 5:8.~Norepinephrine (0.01-0.2ug/kg/min) is used only to restore the mean arterial pressure (MAP) to its previous values If there was no recurrence of symptoms after 72 h, we decreased the milrinone infusion by 0.25 mcg/kg/min every 24 or 48 h until discontinuation. If there are any recurrent of symptoms of vasospasm, the patients are placed back on the dose they were previously receiving. If required, another Milrinone bolus is administered if the patient's deficits do not revert12."
32722852|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32768043|NCT04376255|Experimental|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
32768044|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
32768045|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
32768046|NCT04847375|Experimental|Nebulized Surfactant|The patients in this group will receive exogenous surfactant using nebulizer mask as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19; in addition they will receive standard care based on the national guidelines
32768047|NCT04847375|No Intervention|Standard Care|The patients in this group will receive standard care based on the national guidelines as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19
32768048|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
32768049|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
32768050|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
32768051|NCT03044015|Active Comparator|Control|Intervention as usual
33400343|NCT05020015|Experimental|Part 1: Dose Expansion: LBCL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
33400344|NCT05020015|Experimental|Part 1: Dose Expansion: iNHL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Indolent Non-Hodgkin Lymphoma (iNHL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
33400345|NCT05020015|Experimental|Part 2: Cohort 1- LBCL|Participants with LBCL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
32768052|NCT05430607|Experimental|Intervention group|The intervention group will participate in a 9-week running program and will also continue their routine treatment program at the psychiatric ward.
32768053|NCT05430607|No Intervention|Control group|The control group will continue their routine treatment program at the psychiatric ward.
32768054|NCT04847219|Placebo Comparator|Professional flash glucose mornitoring|Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
32768055|NCT04847219|Active Comparator|Personal flash glucose mornitoring|Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
32768056|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
32768057|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
32768058|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
32768059|NCT05588583|Experimental|Supportive Care with Mepilex Up|All Subjects will use a soft, silicone, non-bordered, adhesive, foam dressing called Mepilex Up as the absorbent primary dressing.
32768060|NCT04847297||Preoperative biliary drainage and pancreatoduodenectomy|Patients receiving preoperative biliary drainage before the removal of the tumor.
32768061|NCT04847297||Pancreatoduodenectomy only|Patients undergoing only surgical intervention, without preoperative drainage.
32768062|NCT04737343|Active Comparator|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg QD for 18 months combined with rednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period.All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intoleran.t
32768063|NCT04737343|Experimental|Leflunomide treatment arm|Patient will be treated with Leflunomide 30mg QD for 18 months combined with prednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period. All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intolerant.
32768064|NCT05579769|Active Comparator|ArmA- Lymphoid|Total Body Irradiation and cyclophosphamide (TBI/Cy)
32768065|NCT05579769|Active Comparator|ArmB-Myeloid|TBF with comparable NRM in comparison to busulfan and cyclophosphamide (BuCy)
32924311|NCT05730725|Placebo Comparator|Placebo|
32924312|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
32924313|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
33400346|NCT05020015|Experimental|Part 2: Cohort 2- iNHL|Participants with iNHL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
33400347|NCT04674319|Experimental|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
33400348|NCT03141684|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline.
32722853|NCT05213689|Experimental|HIV self-testing + educational comic book|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics. Participants will also receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
32722854|NCT05213689|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics.
32722855|NCT05213689|Active Comparator|Educational comic book|Participants will receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
32722856|NCT05213689|No Intervention|Standard of Care|PNs will provide information about HIV testing, care and support services at local clinics.
32722857|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
32722858|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
32722859|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
32722860|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
32722861|NCT05007145|Experimental|PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin|Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.
32722862|NCT05007145|Active Comparator|Albumin-bound paclitaxel+cisplatin+radiotherapy|Participants receive albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.
32722863|NCT04661878|Experimental|MASI|Participants randomized to the intervention condition will receive access to MASI, the smartphone app customized for this study. MASI is an adapted version of HealthMpowerment, a theory-based smartphone app with features including an anonymous interactive discussion forum, a medication and adherence tracker, a platform to ask questions to an expert, a section with engaging activities (including quizzes, self-assessments, and goal-setting activities), and a multi-media resource center.
32722864|NCT04661878|Active Comparator|Information-only version of MASI|Participants randomized to the control condition will an information-only version of MASI which will include the Resources feature and the home page.
32722865|NCT04952857|Experimental|Intervention|Vitamn D 6 lakh IU oral stat
32722866|NCT04952857|Placebo Comparator|Placebo|Placebo equal volume/ weight
32722867|NCT05440279|No Intervention|Standard Care (SC)|Treatment in the control group takes place as standard care that includes an education session with a respiratory therapist about OSA and its consequences, proper use and maintenance of the CPAP device and mask, and therapy and study expectations, provision with a fixed or auto CPAP device (prismaSMART/ prismaSOFT, Löwenstein Medical Technology GmbH & Co. KG), a heated humidifier (prismaAQUA, Löwenstein Medical Technology GmbH & Co. KG) if needed, and a fitting interface, the initiation of therapy with anamnesis, diagnosis night, titration night, education, etc., as well as standardized therapy control after 12 weeks.
32722868|NCT05440279|Active Comparator|Standard Care (SC) + digital patient support (DPS) tool|"Treatment in the intervention group takes place as standard care (please see description of arm 1 - control group) and electronic therapy support in addition. The electronic therapy support consists of:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~electronic questionnaires (web-based) on possible problems during therapy, personal adherence goals and subjective therapy success,~possibility to set personal adherence goals every week,~links to explanations and videos on therapy and the handling of therapy equipment and accessories,~provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
32722869|NCT02220712|Experimental|Drug: OPC-14597 IMD|
32722870|NCT04923295|Experimental|Pre Treatment and post treatment|Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin
32722871|NCT04908163|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one month. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured."
32924314|NCT05271383||Study group|Male and female, major or minor, who will be treated by orthognathic surgery (maxillary, mandibular, maxillomandibular or/with genioplasty). The bone maturity of the participants (assessed by investigators) need to be sufficient for the treatment.
32924315|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
32722872|NCT04908163|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group will receive a written nutrition educational information as well as eight online nutritional and cooking classes during the one-month intervention period. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Participants will receive 8 culinary workshops between visit 2 and visit 3. In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Volunteers will be also contacted by phone after 6 months of the end of the intervention to collect information about food and culinary habits."
32722873|NCT05396209|Active Comparator|Hydrated Amniotic Membrane Plug|Patients suffering from refractory macular holes as documented by spectral-domain OCT will undergo pars plan vitrectomy with Hydrated Amniotic Membrane insertion into the macular hole.
33249932|NCT00862329|Experimental|MSP|
33249933|NCT00862329|Experimental|Casein/MSP|
32722874|NCT05396209|Active Comparator|ILM filling|The ILM filling technique, in which free ILM is plug into the macular hole area
32722875|NCT05396209|Active Comparator|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
32722876|NCT05396131|Active Comparator|Collateral Ventilation Negative|Collateral Ventilation Negative participants will have endobronchial valve implant
32722877|NCT05396131|Experimental|Collateral Ventilation Positive|Collateral Ventilation Positive participants will have the lung sealant applied and the endobronchial valve implant
32722878|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
32722879|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
32722880|NCT04453813|Experimental|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
32722881|NCT04453813|Active Comparator|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
32722882|NCT04209985|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
32722883|NCT04209985|No Intervention|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
33249934|NCT00862329|Experimental|Soy protein|
33249935|NCT00956956|Experimental|PF-04455242 treatment|
33249936|NCT00956956|Placebo Comparator|Placebo|
33249937|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
33249938|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
33249939|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
33249940|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
32722884|NCT05393557|Active Comparator|Upfront|"Immediately after restoration of distal flow, they will receive:~i. Small dose Tirofiban (intra-coronary bolus of 25µg/Kg),[22] ii. Nitroglycerin 100-200 µg,[12] iii. Verapamil 100-200 µg (excluding patients with 2nd or 3rd degree AV block, bradycardia HR < 60, or systolic BP <100 mmHg)[5] iv. Two cycles of balloon up-balloon down (15 seconds occlusion, 15 seconds open artery; repeated two times).~v. The rest of the procedure will be completed as standard practice."
32722885|NCT05393557|No Intervention|Control|pPCI procedure will be performed as per standard practice.[2] Bail-out use of any pharmaceutical products will be allowed as per guidelines recommendations (such as: GPi in case of no-reflow or thrombotic complications).
32722886|NCT01138696||Stryker Dacron synthetic graft|
32722887|NCT01138696||Trevira synthetic graft|
32722888|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
32722889|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
32722890|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D
32722891|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment)
32722892|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment)
32722893|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
32722894|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
32722895|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
32722896|NCT04631965||Cohort in Finland|253 young patients who attend clinics in Finland with no hospital-wide transition support service available
32722897|NCT04631965||Cohort in Australia|250 young patients who attend clinics in Victoria, Australia and who have received support from a hospital-wide transition support service
32722898|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
32722899|NCT04454125|Active Comparator|Routine Care|
32722900|NCT04454125|Experimental|AQI Intervention|
32722901|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
33400349|NCT03141684|Experimental|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline.
32722902|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
32722903|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
32722904|NCT05439733||Exposed group|Women with a history of cesarean section and with a base-line attempt after planned cesarean section (TVBAC).
32722905|NCT05439733||Non-exposed group|Women with a history of cesarean section and scheduled cesarean section after cesarean section (CPAC).
32722906|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
32722907|NCT04592575||TBI that are positive on screening tool|Patients that are identified on the AbilityLab Vestibular screening tool as possibly having vestibular dysfunction
32722908|NCT04592575||TBI patients not positive on screening tool|Patients that are not identified on the Ability Lab Vestibular screening tool as possibly having vestibular dysfunction
32722909|NCT04527289|Experimental|Amantadine Group|Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.
32722910|NCT04527289|Placebo Comparator|Placebo Group|Group II are patients who will be managed with the standard regimen.
32722911|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
32722912|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
32722913|NCT05439577||Mucopolysaccharide Polysulfate Cream|Prescribed only for patients with Mucopolysaccharide Polysulfate Cream.
32722914|NCT05439577||Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients whose prescriptions contain Mucopolysaccharide Polysulfate Cream and glucocorticoids (Combination therapy, but not always).
32722915|NCT05387005|Experimental|UBT|
32722916|NCT05387005|Experimental|HpSA|
32722917|NCT05387005|Experimental|Both|
32722918|NCT05387005|Experimental|Two-stage screening method|
32722919|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
32722920|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
32722921|NCT05385523|Experimental|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
32722922|NCT05385523|Experimental|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
32722923|NCT05385523|Experimental|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
32722924|NCT04481347||Patients undergoing general anesthesia|Patients eligible for interventional neuroradiology or surgery performed under general anesthesia. Patients will be included if they are admitted for a non-emergency scheduled procedure.
32722925|NCT04318561|Experimental|Gallium-68 NODAGA-LM3 group|Patients will undergo a Gallium-68 NODAGA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
32722926|NCT04318561|Experimental|Gallium-68 DOTA-LM3 group|Patients will undergo a Gallium-68 DOTA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
32722927|NCT05439265||Prior to 11/01/2014|Group prior to the implementation of an electronic medical record order panel and pharmacy resident involvement
32722928|NCT05439265||After 11/30/2014|Group after implementation of an electronic medical record order panel and pharmacy resident involvement
32722929|NCT04655053|Active Comparator|Goal intention condition|"Participants in this condition are asked to form the goal condition: I will walk as fast as I can for as long as I can"
32722930|NCT04655053|Experimental|Implementation intention (behavior initiation) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if I do the task, then I will walk as much as I can!)"
32722931|NCT04655053|Experimental|Implementation intention (goal preference management) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if at this moment I prefer not to walk because of my pain (or fatigue; depending on person), then I will accept that I have this difficulty and I will walk as much as I can!)"
32722932|NCT03910621|Experimental|Miglustat|Miglustat is administered three times a day as an oral capsule
32722933|NCT03950401|Active Comparator|Monocryl|Closure of the skin at the completion of surgery by interrupted subcuticular technique with absorbable Monocryl suture.
32722934|NCT03950401|Active Comparator|Nylon|Closure of the skin at the completion of surgery by interrupted technique on top of the skin with non-absorbable Nylon suture. These will be removed at the first postoperative visit.
32722935|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
32722936|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
32722937|NCT03762655|Experimental|Neuro-Spinal Scaffold Arm|Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.
32722938|NCT03762655|No Intervention|Comparator Arm|Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.
32768066|NCT04480723|Other|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
32768067|NCT04862819|Active Comparator|scaling root planning|patients in this group will have a scaling root planing procedure only
32768068|NCT04862819|Experimental|scaling root planning with new local drug delivery|patients in this group will have a scaling root planing procedure and a drug administered
32768069|NCT03776149|Experimental|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
33400350|NCT05681455|Experimental|Experimental group|"A two-phase microcurrent with a frequency between 1.14 Hertz and 14.29 Hertz and currents between 0.1 and 0.9 mA will be applied.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with microcurrents will last 60 minutes."
32722939|NCT05439109|Experimental|Topographical landmark technique|Surface anatomic landmarks of an individual's trachea will be measured from the mid-thyroid level (corresponds to vocal cords) to manubriosternal joint (corresponds to carina) in the sagittal plane to estimate tracheal length. Three centimeters will be deducted from the estimated tracheal length to provide the length of the endotracheal tube from the tube tip to be inserted inside the trachea.
32722940|NCT05439109|Active Comparator|Intubation guide mark technique|Already established and commonly practiced technique, in this technique, the guide mark present above the proximal end of the endotracheal tube cuff will be placed just beyond the vocal cords.
32722941|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
32722942|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
32722943|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
32768070|NCT03776149|Placebo Comparator|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
32722944|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
32722945|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
32722946|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
32722947|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
32722948|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
32722949|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
32722950|NCT03530995|Experimental|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
32722951|NCT03530995|Experimental|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
32768071|NCT04854239|Experimental|Machine-driven group|In the machine-driven group, after guided implant bed preparation, implant insertion was performed with contra-angled handpiece.
32768072|NCT04854239|Experimental|Manual group|In the manual group, after guided implant bed preparation, implant insertion was performed with torque-wrench.
32768073|NCT04161157|Experimental|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
32768074|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
32768075|NCT03760783|Other|Effect of microgravity on human sperm|Simulated microgravity flight
32768076|NCT05373849|Experimental|Aromatherapy first then no intervention|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
33249941|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
32722952|NCT03530995|Experimental|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
32722953|NCT03530995|Experimental|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
32722954|NCT03530995|Experimental|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
32722955|NCT03530995|Experimental|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
32722956|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
32722957|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
32722958|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
32722959|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
32722960|NCT05439031|Experimental|Stereotactic Arrhythmia Radiotherapy|Patients will undergo stereotactic arrhythmia radiotherapy and subsequent follow-up.
32722961|NCT05373979||Narcolepsy|Narcolepsy type 1 (NT1 or narcolepsy with cataplexy) and Narcolepsy type 2 (NT2 or narcolepsy without cataplexy)
32722962|NCT05373979||Obstructive Sleep Apnea|mild to moderate obstructive sleep apnea (OSA; obstructive AHI of 1-15/hour)
32722963|NCT05438875|Active Comparator|Eltrombopag|The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The highest is 75mg/d, if the dose is higher than 200×109/L, the dose is reduced. When the dose is higher than 400×109/L, the drug is temporarily discontinued, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
32722964|NCT05438875|Experimental|ATRA and Eltrombopag|ATRA 10 mg, 2 times a day, orally; The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The maximum dose is 75 mg/d, the dose is reduced if it is higher than 200×109/L, and the drug is temporarily discontinued when it is higher than 400×109/L, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
32722965|NCT05371483||Narcolepsy Type 1|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
32722966|NCT05371483||Narcolepsy Type 2|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
32722967|NCT05371483||Idiopathic Hypersomnia|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
32722968|NCT04740307|Experimental|Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab via intravenous (IV) infusion every 6 weeks (Q6W) for up to 2 years, plus lenvatinib orally (based on actual body weight at screening) until progressive disease or unacceptable toxicity for up to 5 years. In the event of discontinuation of pembrolizumab/quavonlimab due to intolerable toxicity, re-initiation of treatment with pembrolizumab may be considered.
32722969|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
32722970|NCT05438797|Experimental|adoptive TIL-TCM transfer|TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators.TIL-TCM cells are transfused to patients in a dosage escalated manner.The total dose was 1× 109-1 ×1010 cells.After cell infusion, IL-2 was administered at 720000 IU/kg (based on whole body weight) by intravenous (I.V.),every 8 hours for up to 4 days.
32722971|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
32722972|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
32722973|NCT05438641||Conventional Benzodiazepine-based treatment group|Conventional Benzodiazepine-based group includes any subject primarily treated with BZDP agents (e.g., diazepam, lorazepam, chlordiazepoxide).
32722974|NCT05438641||Benzodiazepine-Sparing|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants).
32722975|NCT04735081||First group before practice change|Infectious spondylodiscitis when prolonged immoblization in bed was recommanded in our hospital
32722976|NCT04735081||Second group after practice change|Infectious spondylodiscitis when early verticalization was recommanded in our hospital
32722977|NCT05359315||Experimental|Ingaron + basic TB therapy 500,000 IU once daily for 3 months followed by 3 months follow-up
32722978|NCT05359315||No Intervention|only basic anti-tuberculosis therapy
33249942|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
32722979|NCT05351671|Experimental|Arm A|RLS-0071 lower dose group
32722980|NCT05351671|Experimental|Arm B|RLS-0071 higher dose group
32722981|NCT05351671|Placebo Comparator|Arm C|Placebo group
32722982|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
32722983|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
32722984|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
32722985|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
32722986|NCT05331391|Experimental|Brief mobile SMART Exercise Support Program|Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.
32722987|NCT05331391|Placebo Comparator|General Hygiene Information (GHI)|Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.
32722988|NCT05326711|Experimental|Telerehabilitation-based motor imagery training|"The first 2 weeks of the treatment period, will reserved for implicit motor imagery / lateralization training. It will be performed by the noi group application application that can be downloaded to the participants' mobile devices. Participants will be asked to use the app 3 times a day. In each application session, the right / left discrimination of the region in the photograph will be requested within 5 seconds and 30 photographs will be shown for each painful region. Each session will last 2-3 minutes on average. For 3rd to 8th weeks of the treatment period telehabilitation-based motor imagery training will be given to the participants individually, in synchronization, using the Google Meet videoconference platform, under the guidance of a physiotherapist. The duration of the sessions will last 20-30 minutes."
32722989|NCT05326711|No Intervention|Control|No specific intervention
32722990|NCT05307289|Other|melanoma inclusion|Biopsy of a metastasis allowing melanoma diagnosis and realization of primary cultures for metabolomics. An additional 20ml blood sample will also be taken to quantify circulating metabolites and to isolate PBMC.
32722997|NCT04697173|No Intervention|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
32722998|NCT04697173|Experimental|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
32722999|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
32723000|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
32723001|NCT02207374|Experimental|Semaglutide 0.5 mg|
32723002|NCT02207374|Experimental|Semaglutide 1.0 mg|
32723003|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
32723004|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
32723005|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
32723006|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
32723007|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
32723008|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir) with RBV|Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
32723009|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir)|Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
32723010|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir) with RBV|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
32723011|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir)|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
32723012|NCT02786537|Active Comparator|PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only)|"Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg."
32723013|NCT02786537|Active Comparator|PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir)|Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)
32723014|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
32723015|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
32723016|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
33249943|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
33249944|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
32723017|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
32723018|NCT05433727||Mycosis fungoides group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with mycosis fungoides will be included. Patients who only have mycosis fungoides patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy, capillaroscopy (lesional) and histopathological data will be recorded.
32723019|NCT05433727||Parapsoriasis group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with parapsoriasis will be included. Patients who only have parapsoriasis patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy,capillaroscopy (lesional) and histopathological data will be recorded.
32723020|NCT05433259|Experimental|CRT type lens|Subjects fitted with CRT type lenses
32723021|NCT05433259|Experimental|VST type lens|Subjects fitted with VST type lenses
32723022|NCT04762186|Experimental|Dose escalation|SARS CoV-2 infected participants will receive a single infusion over 15 to 30 minutes
32723023|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
32723024|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
32723025|NCT05432557|Experimental|Group E|patients will receive ultrasound guided external oblique intercostal plain block.
32723026|NCT05432557|Experimental|Group T|patients will receive ultrasound guided subcostal transversus abdominis plane block.
32723027|NCT05432557|Placebo Comparator|Group C|patients won't receive LA injection
32723028|NCT05432479|Experimental|Active|Arm receiving investigation product (probiotic)
32723029|NCT05432479|Placebo Comparator|Placebo|Arm receiving placebo
32723030|NCT05298397|Experimental|Intervention - EAT|This study has one arm (it is an open trial). All participants will receive the intervention (EAT-PTSD adapted for youth).
32723031|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
32723032|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
32723033|NCT05430451|Experimental|Brief cessation advice (AWARD) + simple physical exercise with Instant Messaging (IM) support|The integrated intervention of brief cessation advice (AWARD), and simple physical exercise practices with Instant Messaging (IM) support for craving management
32723034|NCT05430451|Active Comparator|Brief cessation advice (AWARD)|Brief cessation advice (AWARD)
33249945|NCT04982588|Experimental|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~EnVeo™ PRO Delivery Catheter System (DCS)~EnVeo™ PRO Loading System (LS)"
33249946|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
33249947|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
33249948|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
32723035|NCT04461665|No Intervention|Control|Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
32723036|NCT04461665|Experimental|VitD supplement|Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
32723037|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
32723038|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
32723039|NCT05292781|Experimental|CHOICES|Experimental arm: receives the web-based reproductive education for individuals with sickle cell disease or sickle cell trait
32723040|NCT05292781|Sham Comparator|eBook|Control arm with eBook education focused on sickle cell disease and sickle cell trait.
32723041|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
32723042|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
32723043|NCT05277259|Active Comparator|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
32723044|NCT05277259|Active Comparator|Kinesiotaping|The Kinesiotaping method is a therapeutic taping technique which alleviates pain.
32723045|NCT05277259|Active Comparator|Conventional Physical Therapy|Hotpack, therapeutic ultrasound and tens applications.
32723046|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
32723047|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
32723048|NCT05277103|Experimental|Stay-Play-Talk with iPad Intervention|Peers without disabilities will be taught to be active communication partners using an iPad with voice output app as a speech-generating device, then paired up to play with one child with ASD for 16 sessions over 8 weeks. Focal child behaviors are assessed in different pre-treatment contexts (i.e., eye tracking, structured play, and naturalistic classroom settings), and rate of communication will be collected to predict gains children make in social communication with peers after treatment.
32723049|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
32723050|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
32723051|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
32723052|NCT05271331|Experimental|ESP block|Patient will receive ESP block one level above surgery with ropivacaine 0.35% 20 ml per side Patient will receive preoperative wound infiltration with Saline 40 ml
32723053|NCT05271331|Active Comparator|Wound infiltration|Patient will receive ESP block one level above surgery with Saline 20 ml per side Patient will receive preoperative wound infiltration with ropivacaine 0.35% 40 ml
32723054|NCT02206828||1 GROUP|Only 1 group not predetermined
32723055|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
32723056|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
32723057|NCT05267197||3D Telemedicine|Clinical consultation conducted with 3D Telemedicine
32723058|NCT05267197||2D Telemedicine|Clinical consultation conducted with 2D Telemedicine
32723059|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
32723060|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
32723061|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
32723062|NCT01209767|Experimental|cryolipolysis|
32723063|NCT01209767|Active Comparator|subcision|
32723064|NCT01209767|Active Comparator|Control|Areas with cellulite that had no treatment performed were considered the control arm.
32768077|NCT05373849|Experimental|No intervention first then Aromatherapy|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
32723065|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
32723066|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
32723067|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
32723068|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
32723069|NCT05430373|Other|GT101 treatment group|Autologous tumor infiltrating lymphocyte injection
32723070|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
32723071|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
32723072|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
32723073|NCT05391373|Experimental|Laughter Therapy Group|The women with breast cancer in the intervention group received two sessions of laughter therapy per week for eight weeks.Each laughter therapy session lasted 40 minutes.
32723074|NCT05391373|No Intervention|Control group|The control group did not receive any intervention during the study period.
32723075|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
32723076|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
32723077|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
32723078|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
32723079|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
32723080|NCT05382715||Cohort 1|
32723081|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
32723082|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
32723083|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
32723084|NCT05380687|Experimental|Training A - PEEP 10-5-5-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training A, the 4 blocks are~A1. PEEP 10 cmH2O | A2. PEEP 5 cmH2O | A3. PEEP *5* cmH2O | A4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
32723085|NCT05380687|Experimental|Training B - PEEP 10-5-0-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training B, the 4 blocks are~B1. PEEP 10 cmH2O | B2. PEEP 5 cmH2O | B3. PEEP *0* cmH2O | B4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
32723086|NCT05138393|Experimental|Active self-corrective exercises|An active self-correction tailored to the individual type of curve and clinical presentation will be applied with the aim to correct the scoliosis in all three planes. Patients will also be informed and educated in task oriented activities of daily living. Training goals are directed towards postural control, spinal stability, muscular stabilization and endurance in corrective postures. Patients will have outpatient sessions once every two weeks the first 3 months and perform the exercises at home in 30-minutes sessions three times per week. Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily. Compliance will be monitored through a mobile application (Physitrack) where the patients record their sessions and can have contact with the research personnel. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
32723087|NCT05138393|Active Comparator|Observation|Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
32723088|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
32723089|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
32723090|NCT02508571|Sham Comparator|Control|Two 15-minute sessions of sham intervention/day, five days a week
32924316|NCT05259839|Experimental|Arm A (ABBV-383 with Pomalidomide and Dexamethasone)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 with Pomalidomide and Dexamethasone.
32924317|NCT05259839|Experimental|Arm B (ABBV-383 with Lenalidomide and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Lenalidomide and Dexamethasone.
32924318|NCT05259839|Experimental|Arm C (ABBV-383 with Daratumumab and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Daratumumab and Dexamethasone.
32924319|NCT05259839|Experimental|Arm D (ABBV-383 with Nirogacestat)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Nirogacestat.
33249949|NCT04051398|Experimental|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
33249950|NCT04051398|Placebo Comparator|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
33249951|NCT00953914|Experimental|Pyridostigmine|
33249952|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
33249953|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
33249954|NCT00756912|Experimental|1|
33249955|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
32723091|NCT02508571|Experimental|DST group|One session of DST and the other of sham intervention/day, five days a week
32723092|NCT02508571|Experimental|DST+OSMS group|One session of DST and the other of OSMS/day, five days a week
32723093|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
32723094|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir
32723095|NCT04453735|Active Comparator|Intervention|Atorvastatin mylan 40 mg once daily
32723096|NCT04453735|No Intervention|Control|No statin therapy
32723097|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
32723098|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
32723099|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
32723100|NCT05349409|Experimental|Treatment group|SHR-A1811, Fluzoparib
32723101|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
32723102|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
32723103|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
32723104|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
32723105|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
33249956|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
32723106|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
32723107|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients~Venous blood sampling Hematology and chemistry~Genotyping: apolipoprotein E (apoE) polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
33249957|NCT00756990|Experimental|Single group|Depot Naltrexone
32742960|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
32924320|NCT04484623|Experimental|Arm A: Belantamab mafodotin plus Pomalidomide and Dexamethasone|
33249958|NCT05301244|Experimental|laughter yoga practice|Laughter yoga practiced by a researcher with a laughter yoga practitioner certificate
33249959|NCT05301244|Experimental|Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
33249960|NCT05301244|Experimental|Laughter yoga session parts-2|Warm-up exercises (10 minutes)
33249961|NCT05301244|Experimental|Laughter yoga session parts-3|Childish games (10 minutes)
33249962|NCT05301244|Experimental|Laughter yoga session parts-4|Laughter exercises (15 minutes)
32723108|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
32924321|NCT04484623|Experimental|Arm B: Bortezomib plus Pomalidomide and Dexamethasone|
32723109|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
32723110|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
32924322|NCT04741295|No Intervention|Control Group|Adenomyosis patients in control group have normal luteal progesterone support.
32924323|NCT04741295|Experimental|Low molecular weight heparin Group|Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.
32924324|NCT04090853|Other|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
32924325|NCT05730101|No Intervention|No treatment waitlist group|Participants receive neither cognitive-behavioral nor imaginary pill treatment and are told that they are in the no treatment waitlist group. They are told that they can receive one of the treatments at the end of the study. The treatment they receive will be chosen based on study results.
32924326|NCT05730101|Active Comparator|Cognitive-behavioral treatment group (CBT)|"Participants receive two individual and six group sessions with a therapist following the treatment manual Prokrastination."
32924327|NCT05730101|Active Comparator|Imaginary pill treatment group (IP)|In accordance with the imaginary pill technique, participants are instructed to take an imaginary pill. This instruction consists of a procedure including five steps (i.e., 1) identifying the IP sensitive problem, 2) building trust/belief/reality of the IP, 3) constructing a personally meaningful IP, 4) taking the IP, 5) suggestions for self-administering the IP in real life and building adherence. The session is repeated with small modifications seven weeks later.
32924328|NCT05729867|Experimental|fully covered self-expanable metal stent with HCC|This prospective cohort is comprised of patients with malignant biliary obstruction caused by hepatocellular carcinoma who were treated with endoscopic biliary drainage using fully covered self expandable metal stent.
32924329|NCT05729321||Epicutaneo-caval catheter removed electively|This is a pilot study designed to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour in order to assess the feasibility of possible Taurolidine lock-terapy in Epicutaneo-Caval Catheters.
32924330|NCT05729165|Experimental|Experimental group (S-G)|"20 minutes of local vibration treatment with the Novafon® Pro medical device followed by 20 minutes of traditional speech therapy, for a total duration of 40 minutes. Therefore, using this instrument, local vibration therapy will be applied at the level of (i) the orbicular muscles of the upper and lower lips, (ii) the masticatory muscles (masseter, temporalis, pterygoid), and (i) local intra-oral and tongue. The Novafon® Pro medical device will be used with the following external and intraoral heads: set senses roller, ball head, disc head, ball head, arrow head, spoon head, and tongue depressor head.~Traditional speech therapy treatment will be carried out with the same tools and activities already described in the C-G."
32924331|NCT05729165|Active Comparator|Control group (C-G)|40 minutes of conventional speech treatment. Specifically, maneuvers will be performed for (i) extra-oral and intra-oral passive thermal stimulation, (ii) extra-oral and intra-oral passive tactile stimulation, and for (iii) elicitation of active bucco-lingual and laryngeal muscle movements. The following instruments will be used for this purpose: ice cubes, ice tubes, sterile gauze, tongue depressors, swabs, 10 mm laryngeal mirrors.
32924332|NCT04828577|Experimental|Real Time Neurofeedback|Real time neurofeedback will be based on a classifier of increasing or decreasing delay discounting fMRI patterns. Participants will try to modulate their discounting rate based on neurofeedback via a visual dial, during an fMRI scan. Participants will be told they will be controlling the visual dial.
32924333|NCT04828577|Sham Comparator|"Idealized/Sham Neurofeedback"|"Rather than using the output of a classifier, the visual dial will display perfect modulation of increasing and decreasing delay discounting and participants will told that they will not be controlling the visual dial."
32924334|NCT04826939|Experimental|Device usage|All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
32924335|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
33400351|NCT05681455|Placebo Comparator|Placebo group|"Microcurrent machines shall be operated in such a way that they have a light signal but do not emit current. Neither the physical therapists who place them nor the subjects will be able to distinguish current-emitting machines from placebo machines.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with placebo will last 60 minutes."
32723111|NCT01704209|Experimental|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
32723112|NCT01704209|Placebo Comparator|Vehicle|The vehicle will be injected randomly to the other side of the face.
32723113|NCT03489785||Movement|If there is unexpected movement
32723114|NCT03489785||No movement|If there is no unexpected movement
32723115|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
32723116|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
32723117|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
32723118|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
32723119|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
32723120|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
32723121|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
32723122|NCT05335447|Experimental|Period 1 - Absolute Bioavailability|
32723123|NCT05335447|Experimental|Period 2 - Mass Balance|
32723124|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
32723125|NCT04112407|Experimental|Control|Standard preparation of the surgical site without P. acnes pretreatment
32723126|NCT04112407|Experimental|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
32723127|NCT04112407|Experimental|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
32723128|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
32723129|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
32723130|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
32723131|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
32723132|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
32723133|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
32723134|NCT04108897|Experimental|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
32723135|NCT04108897|Experimental|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
32723136|NCT04108897|Experimental|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
32723137|NCT04108897|Experimental|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
32723138|NCT04108897|Experimental|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
32723139|NCT04108897|No Intervention|Control|No intervention will be performed.
32723140|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:~Patients in this group were administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
32723141|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:~Patients received placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab continued to be assigned to patients"
32723142|NCT03462199|Placebo Comparator|Placebo|
32723143|NCT03462199|Experimental|Actazin High Dose|
32723144|NCT03462199|Experimental|Actazin Low Dose|
32723145|NCT03462199|Active Comparator|Control Formula|
32723146|NCT03462199|Experimental|Livaux High Dose|
32723147|NCT03462199|Experimental|Livaux Low Dose|
32723148|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
32723149|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
32723150|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:~Schema 1:~400 mg BIA 5-1058~1200 mg BIA 5-1058~Placebo~Moxifloxacin~Schema 2:~1200 mg BIA 5-1058~Placebo~400 mg BIA 5-1058~Moxifloxacin"
32723151|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:~Schema 1~1200 mg BIA 5-1058~Moxifloxacin~400 mg BIA 5-1058~Placebo~Schema 2:~Placebo~Moxifloxacin~1200 mg BIA 5-1058~400 mg BIA 5-1058"
32723152|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:~Schema 1~Placebo~400 mg BIA 5-1058~Moxifloxacin~1200 mg BIA 5-1058~Schema 2~400 mg BIA 5-1058~1200 mg BIA 5-1058~Moxifloxacin~Placebo"
32723153|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:~Schema 1~Moxifloxacin~Placebo~1200 mg BIA 5-1058~400 mg BIA 5-1058 Schema 2~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
32723154|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
32924336|NCT04801043|Experimental|Cohort 1: Healthy young females|Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
32924337|NCT04801043|Experimental|Cohort 2: Healthy elderly males|Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
32723155|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
32723156|NCT03462043|Active Comparator|Sequence A|
32723157|NCT03462043|Active Comparator|Sequence B|
32723158|NCT03462043|Active Comparator|Sequence C|
32723159|NCT03462043|Active Comparator|Sequence D|
32723160|NCT01631812|Experimental|SPM 962|
32723161|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
32723162|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
32723163|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
32723164|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
32723165|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
32723166|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
32723167|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
32723168|NCT04645927|Placebo Comparator|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
32723169|NCT04645927|Experimental|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
32723170|NCT04641949|Active Comparator|Methoxyflurane|Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.
32723171|NCT04641949|Active Comparator|Fentanyl|Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
32723172|NCT04641949|Placebo Comparator|Placebo|Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.
32723173|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
32723174|NCT01941719|Experimental|enhanced foot care education|In addition to the standard diabetic foot self-care instruction, the importance of daily foot self-care was reinforced at baseline by viewing personal barefoot plantar pressure in gait
32723175|NCT01941719|Active Comparator|Standard Foot Care Education|Reviewed the standard diabetic foot self-care instructions, including daily foot inspection and proper footwear at all times.
32723176|NCT02215252|Experimental|PF-05089771|
32723177|NCT02215252|Experimental|Placebo|
32723178|NCT02215252|Experimental|Pregabalin|
32723179|NCT02215252|Experimental|PF-05089771 + Pregabalin|
32723180|NCT04630093|Experimental|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
32723181|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
32723182|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
32723183|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
32723184|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
32723185|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
32723186|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
32723187|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
32723188|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
32723189|NCT04894721|Experimental|Experimental Group|The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care
32723190|NCT04894721|Placebo Comparator|Control Group|The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care
32723191|NCT05258539|Experimental|Women aged 18 to 85 years who come to the CRMP for a breast cancer risk assessment.|
32723192|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
32723193|NCT03129607||Observation group|Patients without POPF will be included into observation group.
32742961|NCT04960293|Experimental|Spherical gelfoam|Patients who receive uterine artery embolization for symptomatic fibroids
32924338|NCT04801043|Experimental|Cohort 3: Healthy elderly females|Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
32924339|NCT04801043|Placebo Comparator|Placebo to XNW 4107 & imipenem/cilastatin|Matching placebo for XNW4107 and imipenem/cilastatin
32924340|NCT04425577|Other|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
32924341|NCT05706701|Experimental|Nicotine vaping group visit 1|Subjects will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their first of two visits. In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order. Participants will be instructed to attend the lab for a second visit, to test the four fluxes but with the other nicotine form.
32924342|NCT05706701|Experimental|Nicotine vaping group visit 2|The same subjects from visit 1 will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their second study visit, using the opposite nicotine form that was used during the first visit.
32924343|NCT04795505||Intervention group|A tertiary A-level hospital WeChat-based intervention
32924344|NCT04795505||Control group|Traditional community hospital intervention
32924345|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
32924346|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
32924347|NCT04734197|Experimental|SURF-100 (a combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
32924348|NCT04734197|Experimental|Mycophenolic Acid 0.1%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
32924349|NCT04734197|Experimental|Mycophenolic Acid 0.3%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
32924350|NCT04734197|Experimental|Betamethasone Sodium Phosphate 0.01%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
32924351|NCT04734197|Placebo Comparator|Vehicle|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
32723194|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
32723195|NCT05149079|Placebo Comparator|Placebo (whey protein supplement)|Participants will consume 18 g of the placebo whey protein supplement each day for 12 weeks.
32723196|NCT05149079|Active Comparator|Cod protein hydrolysate supplement|Participants will consume 18 g of the cod protein supplement each day for 12 weeks.
32723197|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
32723198|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
32723199|NCT04043377|Experimental|All patients|
32723200|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
32723201|NCT03488459|Other|Routine preoperative information from a nurse|
32924352|NCT04734197|Active Comparator|Cyclosporine 0.05% Ophthalmic Emulsion|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
32924353|NCT04734197|Active Comparator|Lifitegrast 5% Ophthalmic Solution|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
32723202|NCT03488459|Experimental|Additional information support from a psychologist|
32723203|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
32723204|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
32723205|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
32723206|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
32723207|NCT05139173|Experimental|Experimental: Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
32723208|NCT05139173|Active Comparator|Active Comparator: OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
32723209|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
32723210|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
32723211|NCT04772092||Seniors|70 years of age and over, inpatients or outpatients
32723212|NCT04588051|Experimental|Cabozantinib|
32924354|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
32924355|NCT05696717|Active Comparator|Ampreloxetine (Open Label)|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 12 weeks.
32924356|NCT05696717|Placebo Comparator|Ampreloxetine (Randomized Withdrawal)|After completing the open label, participants are randomized to either ampreloxetine or placebo receiving a single, oral, daily dose of active drug or placebo for a further 8 weeks.
32924357|NCT05696717|Active Comparator|Long-Term Extension Period|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 104 weeks.
32924358|NCT05688215|Experimental|Treatment (zimberelimab, quemliclustat, chemotherapy)|Patients receive zimberelimab IV, quemliclustat IV, oxaliplatin IV, leucovorin calcium IV, and inrinotecan IV on study. Patients undergo collection of blood samples and CT throughout the trial. Patients with borderline-resectable pancreatic cancer undergo collection of tissue samples. Patients with locally advanced pancreatic cancer undergo core biopsy.
32924359|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
32924360|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
32924361|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
32924362|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
32924363|NCT04741685||SAP with LGS|Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function
32924364|NCT05211869|Experimental|T1D-CATCH|The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.
32924365|NCT05211869|No Intervention|Usual Care Control Condition|Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.
32924366|NCT04740983|Experimental|Heliotherapy|will receive 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values along with olive oil (in-house formulation)
32924367|NCT04740983|No Intervention|Control|only will receive olive oil (in-house formulation)
32924368|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
32924369|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
32924370|NCT00366353|Other|2|No sedation during spontaneous breathing trial
32924371|NCT05350969|Experimental|CDR132L 5 mg|CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
33400352|NCT05162833|Experimental|Maintenance group|"Subjects that completed the clinical study Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms that were in the active treatment group will be offered to extend treatment for 3 months."
33400353|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
32723213|NCT04255511|Experimental|Twin block|Removable Functional appliance
33400354|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
33400355|NCT01312285|Placebo Comparator|Placebo|
32924372|NCT05350969|Experimental|CDR132L 10 mg|CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
32924373|NCT05350969|Placebo Comparator|Placebo|Placebo intravenous in single dose on Day 1, Day 29 and Day 57
32924374|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
33400356|NCT01312285|Experimental|Resonator Device|
32924375|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
32924376|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
32924377|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
33400357|NCT03900468|Experimental|Active Deep Brain Stimulation (DBS)|
33400358|NCT05053321|Experimental|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
33400359|NCT05044897|Experimental|Study treatment|"SI-B001 is a bispecific antibody targeting EGFR and HER3, which is administered weekly by intravenous infusion（QW）.~The 4-week cycle was maintained until disease progression or cessation due to intolerable toxicity or other reasons (e.g., withdrawal of informed consent or death). From C1D1, efficacy was evaluated every 8 weeks ±7 days in the first year and every 12 weeks ±7 days in the second year."
33400362|NCT04974619||Aim 1 Only: Online Survey group|Spanish speaking young Latino men who have sex with men (YLMSM), ages 18-26 (approximately 260 in Florida and Puerto Rico) will be asked to complete a Qualtrics survey.
33400363|NCT04974619||Aim 2 Only: Interview group|Individual interviews will be conducted with key healthcare stakeholders (i.e.,healthcare clinical leadership, providers and staff, community-based organization staff)
33400364|NCT04974619||Aim 3 Only: Focus Groups|Each site will conduct focus groups or individual interviews with English or Spanish speaking young Latino men who have sex with men (YLMSM). The total participants will be 24 with 12 participants per site.
33400365|NCT04961437||Patients with de novo acute respiratory failure|"The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively):~A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm.~A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48."
32924378|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
32723214|NCT04255511|Active Comparator|Fixed appliance|Preadjusted fixed appliance
32723215|NCT05154370||MS/CIS|Diagnosis of MS and CIS based on the 2017 McDonald MS diagnostic criteria.
32723216|NCT05154370||ADEM|Diagnosis of ADEM based on the 2012 IPMSSG diagnostic criteria for ADEM
32723217|NCT05154370||MOGAD|Diagnosis of MOGAD based on the 2020 Chinese Expert Consensus.
32723218|NCT05154370||NMOSD|diagnosis of NMOSD according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
32723219|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
32723220|NCT03488381|Experimental|Soccer Heading|
32723221|NCT03488381|Sham Comparator|Kicking-Control|
32723222|NCT04771858||Study Group|No intervention
32723223|NCT05230849|Active Comparator|control group|conventional physiotherapy treatment
32723224|NCT05230849|Experimental|dry needling treatment|group that includes a dry needling treatment on the tibialis anterior and posterior muscles.
32723225|NCT04461431|Experimental|Knee joint lateral reconstruction group|
32723226|NCT03465475||Group 1|The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
32723227|NCT03465475||Group 2|The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
32723228|NCT03465475||Group 3|The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
32723229|NCT04461119|Experimental|Evenamide 7.5 mg bid|Evenamide capsules 7.5 mg BID for a total of 28 dosing days
32723230|NCT04461119|Experimental|Evenamide 15 mg bid|Evenamide capsules 15.0 mg BID for a total of 28 dosing days
32723231|NCT04461119|Placebo Comparator|Placebo|Matching placebo capsules BID for a total of 28 dosing days
32723232|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
32723233|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
32723234|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
32723235|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
32723236|NCT03488303||Main group|Study has only one group
32723237|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
32723238|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
32723239|NCT03461575|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
32723240|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
32723241|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
32723242|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
32723243|NCT04125173|Active Comparator|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
32723244|NCT04125173|Active Comparator|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
32723245|NCT04125173|Active Comparator|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
32723246|NCT05072561|Experimental|Experimental|
32723247|NCT02213380|Other|group GA|General anesthesia
32723248|NCT02213380|Other|group RA|Regional anesthesia
32723249|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
32723250|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
32723251|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
32723252|NCT05234801||DARCO™ Headed Cannulated Screw|Patients who received a device from the DARCO™ Headed Cannulated Screw family of devices during routine lower limb surgery.
32723253|NCT05234801||ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|Patients who received a device from the ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System family of devices during routine lower limb surgery.
32723254|NCT05234801||ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|Patients who received a device from the ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module family of devices during routine lower limb surgery.
32723255|NCT03797261|Experimental|Venetoclax + AMG 176|Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
32723256|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
32723257|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
32723258|NCT03487835|Experimental|Kinesiotape group|
32723259|NCT03487835|Experimental|Control group|
32723260|NCT03447041||the keratoplasty group|Patients with limbal dermoid who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
32723261|NCT03447041||the normal group|normal children without ocular disease
32723262|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
32723263|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
32723264|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
32723265|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
33400366|NCT05147311|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~At approximately 100-days post-HSCT, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~-Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
32723266|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
32723267|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
32723268|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
32723269|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
32723270|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
32723271|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
32723272|NCT04870775|Experimental|Experimental group|The intervention administered to the experimental group will be a mindfulness training program
32723273|NCT04870775|No Intervention|Control group|The control group will not receive any intervention
32723274|NCT04761250|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
32723275|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
32723276|NCT04804709|Experimental|FUS using Oral Panobinostat|All patients enrolled in the study will be treated with oral Panobinostat after receiving Focused Ultrasound treatment (FUS) with microbubbles and neuro-navigator-controlled sonication.
32723277|NCT04708535||Bariatric Cohort|For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.
32723278|NCT04690673|Experimental|Study group|All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
32723279|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
32723280|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
32723281|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~A molded plastic headpiece containing the antenna array, and~A processing control unit that contains:~The driving electronics for the array;~A spectrum analyzer coupled with a computer; and,~The operating software that controls the device function and data acquisition, processing and archiving.~For this study, the research personnel will place the headset over the subject's head. The headset will be sized to fit snuggly. Each headset is marked with a unique headset identification number. The patient-contacting components of the molded plastic form are made from a medical grade (USP Class VI), biocompatible plastic and foam."
32723282|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
32723283|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
32723284|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
32723285|NCT02907983|Sham Comparator|Saline|Saline injection
32742962|NCT04960293|Active Comparator|Microsphere|Patients who receive uterine artery embolization for symptomatic fibroids
32742963|NCT04941495|Active Comparator|Control Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education
33400367|NCT05147311|No Intervention|Usual Care Control|Participants in the Usual Care Control arm will receive regular social work assessments as part of HSCT recovery and work does not focus on PPWB skill building or cognitive strategies.
32924379|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
32924380|NCT05349643|Experimental|AMB-05X|Subjects will receive an injection of AMB-05X once every 4 weeks for 24 weeks (for 6 treatments total). Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose.
32723286|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
32723287|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
32723288|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
32723289|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
32723290|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
32723291|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
32723292|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
32723293|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
32723294|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
32723295|NCT03487523|No Intervention|Intervention 3|no intervention
32723296|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
32723297|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
32924381|NCT05344261|Active Comparator|Control Arm|Standard Post-Amputation Surgical Care: Briefly, the transected nerves will be blindly tucked into surrounding bulky soft tissue to protect the nerve ends before the wound is closed.
32924382|NCT05344261|Experimental|Targeted Muscle Re-innervation|Briefly, each transected nerve is identified after amputation using 6-0 Prolene suture and is dissected proximally for length. With minimal dissection, a nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby tagged amputated nerve.
32924383|NCT05344261|Experimental|Regenerative Peripheral Nerve Interface|Briefly, a muscle graft (usually from the amputated limb) is wrapped around the clean ends of the transected nerve(s).
32924384|NCT04685213|Active Comparator|Active E-Stim|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
32723298|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
32723299|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
32723300|NCT04388501|Experimental|Treatment Sequence ABC|Participants will receive milvexian capsule once daily (qd) for 5 days (Treatment A) in Period 1 followed by Atorvastatin tablets qd for 5 days (Treatment B) in Period 2 followed by milvexian capsules qd and atorvastatin tablets qd for 5 days (Treatment C) in Period 3. Each period is separated by a washout period of 7 days.
33400368|NCT05309473|Experimental|Subjects Who Received Acoustic Stimulation|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive acoustic stimulation via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive acoustic stimulation via the Philips Smart Sleep device during slow-wave sleep again.
32723301|NCT04388501|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
32924385|NCT04685213|Sham Comparator|sham E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
32924386|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
32924387|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
32924388|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
32924389|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
32924390|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
32924391|NCT04768699|Experimental|TQG203(30µg/kg)|
32924392|NCT04768699|Experimental|TQG203(90µg/kg)|
32924393|NCT04768699|Active Comparator|NovoSeven®(90µg/kg)|NovoSeven®,manufactured by Novo Nordisk Inc.
32924394|NCT04768699|Experimental|TQG203(180µg/kg)|
32924395|NCT04749277||Endoscopist characterization on WLI and BLI modes|Optical characterization of an identified polyp, first in WLI and then in BLI mode, with CAD EYE® OFF. This evaluation should be systematically performed by two independent endoscopists in the exam room, preferably (but not necessarily) an experienced endoscopist and a trainee. The presence of at least one experienced endoscopist is mandatory. An independent evaluation is guaranteed. First step - The 1st endoscopist (who performing colonoscopy) request the polyp evaluation and record written by the 2nd endoscopist (who not performing the colonoscopy) - blinded evaluation since 1st endoscopist doesn't verbalize his evaluation); 2nd step - when the 2nd endoscopist signals that he completed his record, the 1st endoscopist verbally explicit his classification, which is recorded by the 2nd endoscopist. This evaluation should include polyp histological type (hyperplastic, adenoma, sessile serrated lesion or other type) and the level of confidence of the evaluation performed (high or low).
32924396|NCT04749277||CAD EYE® characterization on BLI mode|Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
32924397|NCT05185271|Experimental|Dyad- focused strategy training intervention|"The dyad-focused strategy training intervention protocol will be developed to help dyads manage the needs that they have as transitioning to the community.~The following theoretical frameworks and guidelines will be used to guide the development of the intervention: (1) the strategy training guideline outlined by Skidmore et al; (2) Bodenmann's framework of dyadic coping; and (3) Self-efficacy theory."
32723302|NCT04388501|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
32723303|NCT04388501|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Period 1 followed by Treatment B in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
32723304|NCT04388501|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Period 1 followed by Treatment C in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
32723305|NCT04388501|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Period 1 followed by Treatment A in Period 2 and Treatment C in Period 3. Each Period is separated by a washout period of 7 days.
32723306|NCT03485807|Experimental|Mindfulness Training (MT)|
32723307|NCT03485807|Experimental|Active Coping Training (CT)|
32723308|NCT04339595|Experimental|Tildrakizumab|
32723309|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
32723310|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
32723311|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
32723312|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
32723313|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
32742964|NCT04941495|Experimental|Experimental Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education. It also include the cervical proprioceptive training
33249963|NCT04048616|Active Comparator|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
32742965|NCT04941417|Experimental|neoadjuvant PD-(L)1 inhibitor with chemotherapy followed by PD-(L)1 inhibitor for up to 1 year|
32924398|NCT04749199|Experimental|Enhanced mirror therapy group|Participants in this group will perform complex and randomized finger opposition and reposition movements based on the training protocol, along with enhanced complexity and altered clarity of the displayed image.
32924399|NCT04749199|Sham Comparator|Standard mirror therapy group|Participants in this group will perform simple and sequential finger opposition and reposition movements, along with a clear image showing the exercising hand of the participants.
32924400|NCT04749121|Experimental|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes.The protocol was conducted in accordance with the protocol from the OSHA respiratory protection standard , including the number, type, and duration of the exercise, and the seal checks in accordance with the manufacturer's instructions[15] 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol)
32924401|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
32924402|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
32924403|NCT04657679|Active Comparator|African American/Black|Subject who self identify as African American or Black with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
32924404|NCT04657679|Active Comparator|Non-Hispanic White|Subjects who self-identify as non-Hispanic White with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
32924405|NCT05130593||Nutrasorb bar evaluation|Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters and bioactive compounds.
32924406|NCT04768621|Experimental|Winter residents of Southern and Antartic French Lands,|people exposed to stressors over long periods including winter
32924407|NCT04768621|Active Comparator|Country people going to Southern and Antartic French Lands|people going to Southern and Antarctic French Lands who benefit from milder conditions and only make short stays
32924408|NCT05299099|Experimental|IN-C006 inj.|IN-C006 inj. 1970 mL
32924409|NCT05299099|Active Comparator|RCN301|RCN301 1820 mL
32924410|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
32924411|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
32924412|NCT04339985|Experimental|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
32924413|NCT04339985|Experimental|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
32924414|NCT04339985|Experimental|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
32924415|NCT02265913|Experimental|Test Product|acyclovir cream
32924416|NCT02265913|Active Comparator|Reference Product|acyclovir cream
32924417|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
32924418|NCT04634435|Experimental|Newly diagnosed multiple myeloma patients|Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)
32924419|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
33400369|NCT05309473|Sham Comparator|Subjects Who Received Sham (no Acoustic Stimulation)|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive Sham (no acoustic stimulation) via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive Sham (no acoustic stimulation) via the Philips Smart Sleep device during slow-wave sleep again.
33400370|NCT05009251|No Intervention|No-Contact Control|Subjects in the no-contact control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
33400371|NCT05009251|Experimental|Reminder Control|Subjects in the reminder control arm will receive messages reminding them to get the flu shot without being advised of their risk status.
33400372|NCT05009251|Experimental|High Risk Only|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
33400373|NCT05009251|Experimental|High Risk with Explanation Based on Medical Records|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
33400374|NCT05009251|Experimental|High Risk with Explanation Based on Algorithm|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
33400375|NCT05309317|Experimental|CAUTI-VSG|Preventing Catheter-Associated Urinary Tract Infections with a Virtual Simulation Game
33400376|NCT05309317|Active Comparator|Control group|"Training on CAUTI Prevention"
33400377|NCT05308225|Experimental|STI-6129|Seven dosing cohorts will be evaluated: 0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
33400378|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
32924420|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
32924421|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
32924422|NCT04627025|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
32924423|NCT04627025|Placebo Comparator|Placebo|Placebo for apraglutide, SC injection once weekly
32924424|NCT04191499|Experimental|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
32924425|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
32723314|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
32723315|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
32723316|NCT01428635|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
32723317|NCT05150561||Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
32723318|NCT05150561||Cohort II - Patients newly diagnosed with acute leukaemia (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
32723319|NCT05150561||Cohort III - Patients newly diagnosed with multiple myeloma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
32723320|NCT04006769|Experimental|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet (Orion pharma,Switzerland) by mouth, three times a day and then escalated to final dose of 1.0 grams three times per day within one week, until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
32723321|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
32723322|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
32723323|NCT03485339||Case|Ketamine user with psychotic disorders
32723324|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
32723325|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
32723326|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
32723327|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
32723328|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
32723329|NCT05150405|Experimental|QLF31907|single arm with QLF31907 treatment
32723330|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
32723331|NCT03641339|Experimental|Cohort A: One vector feeding and three biopsies|Undergo one vector feeding and three biopsies on Day 0
32723332|NCT03641339|Experimental|Cohort B: Four vector feedings and three biopsies|Undergo 4 vector feedings over 8 weeks and 3 biopsy procedures after the 4th and final feeding
32723333|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
32723334|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
32723335|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
32723336|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
32723337|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
32723338|NCT00701207|No Intervention|2.|control group-no intervention
32723339|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
32723340|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
32723341|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
32723342|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
32742966|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
32924426|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
32924427|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
32924428|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
32924429|NCT05106101|Experimental|L-glutamine|Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks
32723343|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
32924430|NCT04600973|Active Comparator|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
32924431|NCT04600973|Active Comparator|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
32924432|NCT04600973|Active Comparator|Technical Assistance No Surveillance|TA will be offered to 3 teams. TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
32924433|NCT04600973|Active Comparator|EBIP Coaching No Surveillance|EBIP will be offered to 3 teams. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Surveillance toolkit will only be used for transmission data collection.
32924434|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
32924435|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
32924436|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
32924437|NCT04566731|Active Comparator|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
32924438|NCT04566731|Sham Comparator|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
32924439|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
32924440|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
32924441|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
33249964|NCT04048616|Active Comparator|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
32723344|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
33249965|NCT04048616|Active Comparator|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
33400379|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
32723345|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
32723346|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
32723347|NCT04943198|Experimental|R1 time of vemurafenib treatment|vemurafenib will be given to 6 months after BRAF negativization
32723348|NCT04943198|Experimental|R2 time of vemurafenib treatment|vemurafenib will be given to 12 months after BRAF negativization
32723349|NCT04863677|Experimental|High Intensity Interval Training(HIIT)|The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE <10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
32723350|NCT04863677|Experimental|Moderate Intensity Continuous Training(MICT)|Patients perform 40-50 minutes at a RPE of 12 to 14(a total of 4 groups, each group 5-8 min, interspersed with 2-minute rest)
33400380|NCT04537741|Experimental|NSTEMI scheduled for angiography|
33400381|NCT05177497|Experimental|treatment arm|
33400382|NCT04480255|Active Comparator|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
33400383|NCT04480255|Active Comparator|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
33400384|NCT04470427|Experimental|mRNA-1273|"Part A (Blinded): Participants will receive 1 intramuscular (IM) injection of 100 microgram (μg) mRNA-1273 on Day 1 and on Day 29.~Part B (Open-label): Participants who receive mRNA-1273-matching placebo during Part A and choose to be unblinded by participating in Part B, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1 and Day 29. Participants who are only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1, if the participant chooses.~Part C: Eligible participants in Part B who choose to receive booster dose of mRNA-1273, will receive 1 IM injection of 50 μg mRNA-1273 on Day 1."
33400385|NCT04470427|Placebo Comparator|Placebo|Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.
33400386|NCT05231473|No Intervention|Standard|The participants are assigned according to the implanted and functioning program of each center. In this case, without Nurse Enhanced Recovery After Surgery Coordinator. It will be the control group. ERAS program will be working without this role.
33400387|NCT05231473|Experimental|Nurse Coordinator|The participants are assigned according to the implanted and functioning program of each center. In this case, with Nurse Enhanced Recovery After Surgery Coordinator. It will be the intervention group. ERAS program will be working with this role.
33400388|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
33400389|NCT04969861|Experimental|BEMPEG + Pembrolizumab|Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
33400390|NCT04969861|Active Comparator|Pembrolizumab Monotherapy|Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
32723351|NCT04863677|No Intervention|Control Group|No additional rehabilitation treatment or physical exercise was added in Control Group.
32723352|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
32723353|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
32723354|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
33400391|NCT04967521|Experimental|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
33400392|NCT04967521|Placebo Comparator|Placebo Arm|Patients will be randomized 1:1 and will receive placebo if they are randomized to the placebo arm of the study. Each cycle is 28 days.
33400393|NCT05308849|Other|Pediatric Peritonitis|Patient (from 3 to 17 years-old) treated for appendicular peritonitis. It includes surgical treatment (appendicectomy, peritoneal toilet) and antibiotherapy according to French recommendation.
32723355|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
32723356|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
32723357|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
32723358|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
32723359|NCT03876119|Experimental|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
32723360|NCT03876119|Placebo Comparator|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
32723361|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
32723362|NCT04774913|Experimental|Invest CTO PCI|A pre-planned two staged procedure in high-risk CTO PCI
32742967|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
32742968|NCT04948125|Experimental|treatment group|camrelizumab combined with apatinib
32742969|NCT04960137|Experimental|Button Plates fixation system|Patients receiving surgery fixed with Button Plates fixation system
32742970|NCT04960137|Active Comparator|Non-absorbable Suture Anchor|Patients receiving surgery fixed with Non-absorbable suture anchor
32742971|NCT04410315||Tumorcraniotomy patients|
32742972|NCT04960371||anxiety group|the score of Self-rating Anxiety Scale greater than 50
33400394|NCT04952623|Experimental|E-learning Group|Participants will enroll in a 4-week e-learning program immediately after completing the pre-intervention assessment measures.
32768078|NCT03754231|Experimental|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
33400395|NCT04952623|Active Comparator|Wait-list Control Group|Participants will enroll in a 4-week e-learning program, 4-5 weeks after completion of the pre-intervention assessment measures.
33400396|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
33400397|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
33400398|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
33400399|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
33400400|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
32768079|NCT05400213|Active Comparator|Group 1 Vallos|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
32768080|NCT05400213|Active Comparator|Group 2 Vallomix|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
32768081|NCT05400213|Active Comparator|Group 3 Vallos-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
32768082|NCT05400213|Active Comparator|Group 4 Vallomix-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
32768083|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
32768084|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
32768085|NCT05430217|Experimental|Buspirone, sustained-release tablets, 15 mg|15 mg/day
32768086|NCT05430217|Placebo Comparator|Placebo|1 placebo tablet/day
32768087|NCT05430061|Experimental|Raw corn starch|Raw corn starch is a slow digesting carbohydrate, corn starch, a commonly consumed food ingredient, considered GRAS (generally recognized as safe) CFR 182.70- 182.90 will be used as the test meal treatment. Participants will receive 21 individual containers of raw corn starch (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one starch container mixed in apple sauce at 10 a.m.; each day for 21 days.
32768088|NCT05430061|Sham Comparator|Maltodextrin DE-10|Maltodextrin dextrose equivalent 10 is a fast digesting carbohydrate, is a non-sweet nutritive polymer that consists of D-glucose units linked primarily by [alpha]-1-4 bonds and that has a dextrose equivalent (D.E.) of less than 20. It is regarded as Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration for direct use as a food ingredient (GRAS, 21CFR184.1444).DE-1 Maltodextrin is commercially available. Participants will receive 21 individual containers of maltodextrin (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one maltodextrin container mixed in apple sauce at 10 a.m.; each day for 21 days.
32768089|NCT05373771|Active Comparator|Post-intervention|
32768090|NCT05373771|No Intervention|Delayed intervention|
32768091|NCT04853927|Active Comparator|Proxalutamide + Standard of Care|Proxalutamide + standard of care as determined by the PI
32768092|NCT04853927|Placebo Comparator|Placebo + Standard Care|Placebo + Standard of care as determined by the PI
32768093|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
32768094|NCT04846751|Active Comparator|AEROBIC EXERCISE|50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max
32768095|NCT04846751|Placebo Comparator|PLACEBO REST|No exercise, resting during 50 min.
32768096|NCT05417685||Musculoskeletal disorder|
32768097|NCT04853771|Experimental|experiment|28-29. Between the weeks of gestation, one-time progressive muscle relaxation exercise training prepared by the researcher will be given to the pregnant women. Exercise will be demonstrated in training. Later, pregnant women will be asked to explain and practice the exercise. Women will be repeated until they do the exercise completely correctly (Check-list 1). After the training, pregnant women will be asked to do progressive relaxation exercises at least 3 times a week (every other day). With the progressive muscle relaxation exercise daily follow-up schedule prepared by the researcher, the pregnant women will be followed for 8 weeks and weekly reminders will be made (via whatsapp® or text message). The final test application (36-37 weeks) will be done online at the end of 8 weeks to the pregnant women. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
32768098|NCT04853771|No Intervention|control|No intervention will be applied to pregnant women, other than the routine training given in the pregnancy school. In the maternity school, training is given on physiological and psychological changes that occur during pregnancy, baby care, postpartum period, family planning. However, pregnant women are not given any information about RLS, coping methods, creating a healthy lifestyle, and progressive muscle relaxation exercises. Final test application to pregnant women; 36-37. It will be held online between weeks. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
32768099|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
32768100|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
32768101|NCT02720185|Experimental|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
32768102|NCT04846673|Experimental|Pregabalin and alpha-lipoic acid combination therapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
32924442|NCT04135807|Experimental|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
32924443|NCT05215093|Experimental|Direct physiotherapy pathway|People with acute low back pain will directly go to a physiotherapist, who will treat the patient without prescription of the general practitioner.
32924444|NCT05215093|Active Comparator|Usual care pathway|People with low back pain will receive usual care by the general practitioner (with or without referral to physiotherapy).
32924445|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
32924446|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
32924447|NCT02629991|Experimental|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
32924448|NCT02629991|Placebo Comparator|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
32924449|NCT05157529|Experimental|Aquablation|The participant will undergo aquablation procedure for Benign Prostate Hypeplasia (BPH) treatment using the AQUABEAM Robotic System and Ultrasound Accessories
32924450|NCT05154955|Experimental|10XB-101 Solution for Injection, 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
32924451|NCT05154955|Experimental|10XB-101 Solution for Injection, 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
32924452|NCT05154955|Experimental|10XB-101 Solution for Injection, 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
32924453|NCT05154955|Placebo Comparator|10XB-101 Vehicle Solution for Injection|Participants receive 10XB-101 Vehicle Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
32924454|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
32924455|NCT02633735|No Intervention|Usual Care|
32924456|NCT05142709||ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.|
32924457|NCT05018663||Prospective enrollment|All subjects will be enrolled prospectively. Subjects will be included in the study after eligibility is assessed and informed consent is obtained. The slide scanner will scan the slides on site and the images will be securely saved and sent for interpretation by the AI software at a different location. The results of the AI interpretation of the slides will be blinded to the on-site procedure team including the endoscopist and cytopathologist until the final pathology report is complete.
32924458|NCT03949231|Experimental|PD1/PDL1 inhibitor hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse PD1/PDL1 inhibitor in 30 minutes.
32924459|NCT03949231|Experimental|PD1/PDL1 inhibitor vein infusion|Regular IV infusion of PD1/PDL1 inhibitor in 30 minutes.
32924460|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment will receive one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
32924461|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment will receive 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) may replace PE, at the discretion of the investigator.
32924462|NCT04992143|Experimental|TACE combined Tilelizumab and Sorafenib|TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
32924463|NCT04741061|Active Comparator|Sputnik Light Vaccine|study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
32924464|NCT04741061|Placebo Comparator|Placebo Group|control group (1500 subjects receiving placebo)
32924465|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
32924466|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
32924467|NCT04485065|Experimental|IBI188+azacitidine|
32924468|NCT04969289|Experimental|Dr. Eric Digital Health Intervention|"Participants will interact with an ED-based iPad and the Dr. Eric app for a recorded period of time. After completion, an animated video will explain the ERIC texting program and live office hours. The participant enters his phone number and then receives a welcome text. Weekly texts are sent directly to the participant phone via short message service (SMS)."
32924469|NCT04969289|No Intervention|Standard of Care|Participants randomized to the SC arm will receive standard medical care as determined by the ED provider, which is typically referral to a primary care or adolescent provider. Mobile telephone numbers will be collected for follow up purposes.
32924470|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
33400401|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
32924471|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
32924472|NCT00366509||1|Lung Disease
32924473|NCT00366509||2|Healthy volunteer
32924474|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
32924475|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
32924476|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
32924477|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
32924478|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
33400402|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
32723363|NCT04751045|Active Comparator|Percutaneous Liver biopsy|"Technique: The preprocedure time out protocol will be completed prior to initiation of the procedure. The patient will be positioned supine and right hepatic lobe was localized with ultrasound. Conscious sedation with Versed and fentanyl will be initiated and the patient's vital signs were monitored by an independent trained observer during the procedure.~After placing a mark on the skin overlying the right upper quadrant, the skin was then prepped and draped in the usual sterile fashion. Maximum sterile barrier technique used at the procedure. Under direct sonographic guidance, a 15 gauge percutaneous liver biopsy needle will be used with a 2 cm throw was advanced into the right hepatic lobe. The biopsy samples will be obtained and submitted to pathology."
32723364|NCT04751045|Active Comparator|Endoscopic ultrasound guided liver biopsy|Procedure details: patients will be screened preoperatively to assess cardiovascular health prior to undergoing procedure as this is standard of care. Patients will follow all standard preoperative instructions prior to anesthesia. Upon undergoing general anesthesia, a videoendoscope will be introduced into the esophagus under direct vision. Once endoscope is in position near the liver, a 19-gauge sharkcore needle will be used to puncture the left lobe with a 3 accentuation and another pass from right lobe with 4 accentuation. Doppler study will be used to interrogate for any significant doppler signals in needle path. Post procedure, patients will be provided instructions to avoid NSAIDs for 4 days and perform lightweight activity for 4 days. Patients will be observed for bleeding and significant abdominal pain postoperatively
32723365|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
32723366|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
32723367|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
32723368|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
32723369|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
32723370|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
32723371|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
32742973|NCT04960371||non-anxiety group|the score of Self-rating Anxiety Scale less than 50
32924479|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
32924480|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
32924481|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
32924482|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
32924483|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
32924484|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
32924485|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
32924486|NCT04957589|Experimental|VLCD & HIIT|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) No additional protein supplementation
32924487|NCT04957589|Active Comparator|VLCD only|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) No additional exercise or protein supplementation
32924488|NCT03759847|Experimental|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
32924489|NCT04484051||Routine clinical care with Genotropin treatment|Data collection throughout routine clinical care with subcutaneous injections Genotropin, 0.6-0.8 mg/day. Participants start with 0.2 mg/day and the dose increases with 0.2 mg/day per month to a maximum dose of 0.6-0.8 mg/day.
32924490|NCT04482569|Experimental|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
32924491|NCT04482569|Experimental|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
32924492|NCT04482569|Experimental|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
32924493|NCT05104723|Experimental|XELJANZ (tofacitinib)|Tofacitinib is self-administered orally at 5 mg twice per day for 3 months.
32924494|NCT05075551|Experimental|Acupuncture|Before participants accept the treatment, they are acquired to finish the clinical scales (including NIH-CPSI scale, HADS, VAS, SSRS, SES, IPSS and QoL) and then get the fMRI scan. Hwato brand disposable acupuncture needles will be used. Sanyinjiao (SP6), Zhibian (BL54), Shenshu (BL23), and Huiyang (BL35) are selected as acupoints. The course of treatment is 2 times a week in three months (totally 24 times). At the ending of the treatment, all the volunteers will be asked to finish the clinical scales and get the fMRI scan again. As the step of following up, all the patients will be asked to finish the clinical scales and get the fMRI scan again to evaluate the efficacy of avoiding the recurrence of acupuncture.
32924495|NCT05075551|Sham Comparator|Sham Acupuncture|In the sham acupuncture group, these volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23, and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35). The Hwato brand disposable acupuncture needles will be inserted with a depth of 2-3 mm without any manipulation.The procedure of finishing scales and get fMRI scanning will be the same as the group of acupuncture.
33249966|NCT04048616|Placebo Comparator|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
32723372|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
32924496|NCT04470011||Patients who initiated HIV treatment|
32924497|NCT04470011||Service providers at study facilities|
32924498|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
32924499|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
32924500|NCT05044585|Experimental|Remote Automated Monitoring System|Two MultiSense® patches will be placed on each volunteer. The monitoring will last no more than 3 hours, during an induced and controlled hypoxia.
32924501|NCT04467593|Experimental|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
32924502|NCT04467593|Experimental|Cohort A2|One patient with advanced solid cancer will receive 3 hyperthermia treatments of 4 hours per treatment. The next patient with advanced solid cancer will receive 3 hyperthermia treatments of 6 hours per treatment.
32924503|NCT04467593|Experimental|Cohort B|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (2 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
32924504|NCT04467593|Experimental|Cohort C|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (4 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
32924505|NCT04467593|Experimental|Cohort D|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (6 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
32924506|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
32924507|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
32924508|NCT04436081|Active Comparator|Hemp-based CBD oil Gelcaps|The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
33249967|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
33249968|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
32742974|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
32742975|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
33249969|NCT04047602|Experimental|Reduced Dose Stereotactic Radiosurgery|Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
33249970|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
32723373|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
32723374|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.~Each treatment should take about 10-20 minutes."
32723375|NCT04929236|Experimental|Panzyga High Dose|
32723376|NCT04929236|Experimental|Panzyga Low Dose|
32723377|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
32723378|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
32723379|NCT03092219|Experimental|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
32723380|NCT03092219|No Intervention|No Treatment|No treatment control group (n=52).
32723381|NCT04634123|Experimental|Primary anterior teeth pulpotomy by White Portland Cement|
32723382|NCT04634123|Other|Primary anterior teeth pulpotomy by White MTA|
32723383|NCT04460261|Experimental|COPD Group|Patients with COPD
32723384|NCT04460261|Experimental|Non-COPD Group|Non-COPD
32723385|NCT04460105|Experimental|Lanadelumab|Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
32723386|NCT04460105|Placebo Comparator|Placebo|Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
32723387|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
32723388|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
32723389|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
32723390|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
32723391|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
32723392|NCT03485027|Experimental|XELOX regimen|oxaliplatin 130mg/m2，intravenous，on Day1 capecitabine 1000mg/m2，oral，bid，on Day1-14 every three weeks
32723393|NCT03485027|Experimental|FOLFOX regimen|oxaliplatin 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
32723394|NCT03485027|Experimental|FOLFIRI regimen|irinotecan 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
32723395|NCT03485027|Experimental|IRI regimen|irinotecan single agent 180mg/m2，intravenous，on Day1 every two weeks
32723396|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
32723397|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
32723398|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
32723399|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
32723400|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
32723401|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
32723402|NCT03484949|No Intervention|routine screening|
32723403|NCT02432846|Experimental|Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib|Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
32742976|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
32924509|NCT04436081|Placebo Comparator|Oral placebo Gelcaps|Participants in the control group will receive oral placebo Gelcaps that are identical in appearance to the CBD oil Gelcaps. Dosing will be identical to the intervention arm.
32924510|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
32924511|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
32924512|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
32924513|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
32924514|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
32924515|NCT04916587|Active Comparator|Multifaceted Implementation Strategy|The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
32924516|NCT04916587|Other|ACEs Screening|"Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before age 18, such as maltreatment, harsh migration experiences or exposure to violence. ACEs screening are increasingly recommended to prevent and address physical and mental health conditions associated with ACEs. To promote ACEs screening uptake, the state of California issued the ACEs Aware 2020 policy; a fee-for-service health policy that provides a financial incentive to Medicaid-serving clinics to promote yearly ACEs pediatric screenings in primary care settings. This study will focus on screening children ages 0-5, in line with the partnering FQHC's ACEs screening priorities."
32924517|NCT04901611|Experimental|Parental touch (pre-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance will be administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just before the control procedure and clinical heel lance.
32924518|NCT04901611|Placebo Comparator|Parental touch (post-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance was administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just after the control procedure and clinical heel lance.
32924519|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
32924520|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
32924521|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
32924522|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
32723404|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
32723405|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
32723406|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
32723407|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
32924523|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
32924524|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
32924525|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
32723408|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
32723409|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
32723410|NCT01546571|Placebo Comparator|POL-103A without API|
32723411|NCT01546571|Experimental|POL-103A|
32742977|NCT04948281||Infection Group|A group of joint infection patients after arthroscopic ACL reconstruction surgery , diagnose was made according to American CDC criteria of joint infection
32723412|NCT04460807|Experimental|Exemestane|"Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
32723413|NCT04460807|Placebo Comparator|Placebo|"Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
32723414|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
32723415|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
32723416|NCT03484559||1|
32723417|NCT04916990|Active Comparator|CARES Intervention|All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone.
33400403|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
33400404|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
32723418|NCT04916990|No Intervention|Usual Care|All participants will complete surveys to assess Quality of Care and Patient Reported Outcomes. Patients will receive a standardized list of resources.
32723419|NCT05388383||free-hand|spine surgery without robot
32723420|NCT05388383||robot-assisted|Robot-assisted open surgery
32723421|NCT05388383||mi|Robot-assisted minimally invasive surgery
32723422|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
32723423|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
32723424|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
32723425|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
32723426|NCT04928222|Placebo Comparator|Placebo-containing MNA|A placebo-containing array will be applied to subjects.
32723427|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 50 µg|A doxorubicin-containing array of 50 µg will be applied to subjects.
32723428|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 100 µg|A doxorubicin-containing array of 100 µg will be applied to subjects.
32723429|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 200 µg|A doxorubicin-containing array of 200 µg will be applied to subjects.
32723430|NCT04928222|Experimental|Placebo MNA for Training|Training phase for application of arrays
32723431|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
32723432|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
32723433|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
32723434|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
32723435|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
32723436|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
32723437|NCT00805961|Experimental|Intervention|"Combined Modality Treatment and Systemic Therapy~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
32723438|NCT02202538|Experimental|Indego|Indego
32723439|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
32723440|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
32723441|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
32723442|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
32723443|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
32723444|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
32723445|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
32723446|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
32723447|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
32723448|NCT05152433|Active Comparator|Conventional therapy|Length of period: 2 weeks
32723449|NCT05152433|Experimental|Therapy assisted by a humanoid robot (E-BRAiN)|Length of period: 2 weeks Fixed dose: 10 therapy sessions with E-BRAiN
32723450|NCT05152355|Experimental|Budesonide HFA MDI (Treatment A)|Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks
32723451|NCT05152355|Active Comparator|Budesonide DPI (Turbuhaler) (Treatment B)|Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks
32924526|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
32924527|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
32924528|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies).
32924529|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
32924530|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
32924531|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
32924532|NCT04896073|Experimental|1/Minnelide|Minnelide 2mg Days 1-21 of 28 day cycle (x12)
32924533|NCT04894045|Other|Personalized management group|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
32924534|NCT04894045|No Intervention|Control group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients in the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
33400405|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
32723452|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
32723453|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
32723454|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
32723455|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
32723456|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
32723457|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
32723458|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
32723459|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
32723460|NCT04188574|Experimental|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
32723461|NCT04188574|Experimental|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
32723462|NCT04188574|Experimental|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
32723463|NCT04188574|Other|Vehicle Control|0.3% polyhexanide/ 20% ethanol/ water formulation.
32723464|NCT03484169|No Intervention|Control group|No intervention
32723465|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
32723466|NCT04508153|Other|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
32924535|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
32924536|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
33249971|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
33249972|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
33249973|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
32924537|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
32924538|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
33400406|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
32924539|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
32924540|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
32924541|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
32924542|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
32924543|NCT05735899||Core Treatment Group|This is the only group in this study. Participants will receive full standard of care meniscal repair, followed by assessment interventions- ultrasound, MRI, and physical assessment to document healing progress. Participants will return for standard of care post-operative visits with the physician- 6 weeks, 6 months, and 1 year after the operation is performed- at which point the aforementioned interventions will be completed.
32924544|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
32924545|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
32924546|NCT02721589|Experimental|Injection SHR-1210 1mg/kg Cohort|
32924547|NCT02721589|Experimental|Injection SHR-1210 3mg/kg Cohort|
32924548|NCT02721589|Experimental|Injection SHR-1210 200mg Cohort|
32924549|NCT02721589|Experimental|Injection SHR-1210 10mg/kg Cohort|
32924550|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
33400407|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
33400408|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
33400409|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
33400410|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
33400411|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
33400412|NCT03343704|Experimental|Group A - patients with uncontrolled or life-threatening bleeding|
33400413|NCT03343704|Experimental|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
33400414|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
33400415|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
33400416|NCT02677922|Experimental|AG-120 + Azacitidine|
33400417|NCT02677922|Experimental|AG-221 + Azacitidine|
33400418|NCT02677922|Experimental|Azacitidine|
33400419|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
33400420|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
33400421|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
33400422|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
33400423|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
33400424|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
33400425|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
33400426|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
32924551|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
32924552|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
32924553|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
32924554|NCT02263963|No Intervention|No TAP Block|
32924555|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
32924556|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
32924557|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
32924558|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
32924559|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
32924560|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
32924561|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
32924562|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
32924563|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
32924564|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
32924565|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
32924566|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
32723467|NCT04508153|Other|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
32723468|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
32723469|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
32723470|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
32723471|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
32723472|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
32723473|NCT02454530||Cancer patients treated with Nivestim®|
32723474|NCT04460651|Active Comparator|Active treatment|Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
32723475|NCT04460651|Placebo Comparator|Placebo|Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
32723476|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
32924567|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
33400427|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
32924568|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
32924569|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
32924570|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
32924571|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
32924572|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
33400428|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
33400429|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
32924573|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
32924574|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
32924575|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409|
32924576|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
32924577|NCT04894097|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
33249974|NCT04061096|Active Comparator|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
33249975|NCT04061096|Active Comparator|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
33249976|NCT04061096|Placebo Comparator|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
33249977|NCT04061096|Placebo Comparator|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
33249978|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
33249979|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
33249980|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
33249981|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
32723477|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
32723478|NCT04460729|Experimental|Cohort 1|Participants who are asymptomatic and without prior brain therapy
32723479|NCT04460729|Experimental|Cohort 2|Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
32723480|NCT05151887|Experimental|Meat meal|Minced beef, potato, string beans, apple sauce, and herb butter
32723481|NCT05151887|Experimental|Plant meal|Quinoa, soy beans, chickpeas, broad beans, and soy sauce
32723482|NCT04927832|Experimental|Patient with chronic autoimmune pathology|
32723483|NCT04927832|Experimental|Patients with unexplained pain syndrome|
32723484|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
32723485|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
32723486|NCT04927442||Covid-19 patients|Patients, male or female, 18 to 65 years old, who tested positive for COVID-19 (PCR or rapid test) =5 days before enrollment.
32723487|NCT04492241|Experimental|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
32723488|NCT04492241|Placebo Comparator|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
32723489|NCT04927286|Experimental|Mentoring+Mindfulness|
32723490|NCT04927286|Active Comparator|Mentoring as usual|
33249982|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
33249983|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
33249984|NCT00751062|Active Comparator|Timolol|
33249985|NCT00751062|Experimental|PhXA41|
32723491|NCT05151575|Experimental|group-based walking intervention with professional trainer's supervision|Participants will conduct the intervention in groups under the supervision of a professional fitness trainer.
32723492|NCT05151575|Active Comparator|individual-based walking intervention without professional trainer supervision|Participants will conduct the intervention individually, without the supervision of a professional fitness trainer
33249986|NCT04031456|Experimental|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
33400430|NCT05431582|Experimental|Regimen A|ZN-c3 in combination with bevacizumab
33249987|NCT04031456|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
32768103|NCT04846673|Experimental|Pregabalin monotherapy|Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
32768104|NCT04846673|Active Comparator|Alpha-lipoic acid monotherapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
32768105|NCT05417451|Experimental|Acupuncture|All subjects will receive active acupuncture. The acupuncture intervention will consist of 10 acupuncture sessions, twice weekly for 5 weeks. There will be at least 1 day in between session.
32768106|NCT04846283||Biomarker-group|We considered for the study all patients aged >16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
32768107|NCT05398497|Experimental|Early stage breast cancer up to 2.5 cm|Patients treated with Cryocare SL followed by traditional surgery, radiotherapy and adjuvant systemic therapy.
32768108|NCT03040739||case|
33249988|NCT00948376||Patients|All ages
33249989|NCT00948376||Fetuses|
33249990|NCT04030052|Experimental|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
32768109|NCT03040739||control|
32768110|NCT04498273|Active Comparator|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
32768111|NCT04498273|Active Comparator|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
32768112|NCT04498273|Active Comparator|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
32768113|NCT04498273|Placebo Comparator|Placebo|Placebo
32768114|NCT01660971|Experimental|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32768115|NCT04853615||Group 1|1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
32768116|NCT04853615||Group 2|2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
32768117|NCT04853615||Group 3|3rd group will receive the SGLT2i empagliflosin 25 mg once daily
32768118|NCT04853615||Group 4|4thwill receive allopurinol and empagliflosin.
32768119|NCT04853537|Experimental|study group|• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
32768120|NCT04853537|No Intervention|control group|• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
32768121|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
32768122|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
32768123|NCT04440475|Experimental|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
32768124|NCT04440475|No Intervention|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
32768125|NCT04862273||Native T1 CMR|Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)
32768126|NCT05573607|Placebo Comparator|Placebo|Consists of a maltodextrin tablet
32768127|NCT05573607|Active Comparator|Active|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
32768128|NCT04435483|Experimental|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
32768129|NCT04435483|Experimental|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
32768130|NCT04861883||76 healthy the Middle and Third Trimester pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
32768131|NCT04861883||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
32768132|NCT05372445|No Intervention|Reference Group|"People between 30-60 years old, without obesity, prediabetes or type 2 diabetes.~The purpose of this group is to characterize gut microbiota and microbiome to set the reference values of the argentinian local population."
32768133|NCT05372445|Active Comparator|Obesity Group A|People between 30-60 years old, diagnosed with obesity assigned to the non-intensive intervention.
32768134|NCT05372445|Experimental|Obesity Group B|People between 30-60 years old, diagnosed with obesity assigned to the intensive intervention.
33249991|NCT04030052|Experimental|Treated any moderate HA with existing inhibitors|Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
33249992|NCT00752700|No Intervention|1|Control group
33249993|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
33249994|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
32924578|NCT04894097|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy
32924579|NCT04893629|Experimental|intervention group|children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells
32924580|NCT04893629|Active Comparator|control group|children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment
32924581|NCT04892849||Trial cohort|"The study cohort consist of patients suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and other solid tumors (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin [depending on the current drug approval]) which will be treated with ICI (PD-1/PD-L1) and potential radiation of metastases at Department of Radiation Oncology of Universitätsklinikum Erlangen."
32924582|NCT04891991|Active Comparator|Infliximab group|This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.
32924583|NCT04891991|Sham Comparator|Standard of care group|This group will undergo standard pars plana vitrectomy.
32924584|NCT04849169|Experimental|Experimental Arm|Adult subjects who experience a perforation of a coronary vessel during percutaneous coronary intervention (PCI) and require management of hemorrhage until a definitive treatment is determined.
32924585|NCT01936519|Active Comparator|Calcineurin Inhibitor with Mycophenolic Acid|Calcineurin inhibitor immunosuppression with mycophenolic acid
32924586|NCT01936519|Experimental|Everolimus with Mycophenolic Acid|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
32924587|NCT04509557|Experimental|50mCi|Using a drug product for which dose is determined (50±5 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
32924588|NCT04509557|Experimental|75mCi|Using a drug product for which dose is determined (75±8 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
32924589|NCT04509557|Experimental|100mCi|Using a drug product for which dose is determined (100±10 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
32924590|NCT04509557|Experimental|125mCi|Using a drug product for which dose is determined (125±13 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
32924591|NCT04509557|Experimental|150mCi|Using a drug product for which dose is determined (150±15 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
32924592|NCT04507841|Experimental|Niraparib group|Niraparib was used in patients with newly diagnosed ovarian cancer before any treatment. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design.
32723493|NCT05151575|No Intervention|control group|No intervention will be given to the control group.
32723494|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
32924593|NCT04475783|Experimental|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
32924594|NCT04475783|Active Comparator|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
32924595|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
32924596|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
32924597|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
32924598|NCT04389203|Experimental|Study group|Unilateral tubal disconnection and waiting for pregnancy for 2 years after laparoscopy
32723495|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
32723496|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
32723497|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
32723498|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
32742978|NCT04948281||Control Group|A group of patients which were matched to infections group retrospectively one-to-three who did not sustain any kind of infection after ACL reconstruction.
32742979|NCT04940793||Group 1|Patients indicated for cataract surgery who are candidates for a trifocal IOL implantation and have corneal astigmatism over 1.00 D will be selected for inclusion by the investigators
32742980|NCT03094247|Active Comparator|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
32924599|NCT04389203|Experimental|Control group|Unilateral tubal disconnection and ICSI
33400431|NCT05431582|Experimental|Regimen B|ZN-c3 in combination with bevacizumab and pembrolizumab
33400432|NCT03086460|Experimental|Treatment A|"Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
33400433|NCT03086460|Experimental|Treatment B|"Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
32723499|NCT04460417|Experimental|Enhanced care|Participants will take part in an approximate one-hour health and smoking feedback session at the University of Chicago in Dr. King's Clinical Addictions Research Laboratory (CARL). The session will follow the Courage to Quit™ (CTQ) Roadmap program (developed by Dr. King with the Respiratory Health Association). This roadmap shorter version of the larger CTQ program has been specifically designed as an inpatient bedside or outpatient brief intervention guide to assess smoking cessation motivation, consequences of smoking, facts and myths about smoking, barriers to making a change, approved medications, de-bunking myths about medications or treatments without scientific evidence (e-cigarette, laser treatments, herbals, etc.), and gaining social support.
32924600|NCT04386941|Active Comparator|Greenlight XPS Vaporization|Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
32924601|NCT04386941|Active Comparator|Xpeeda Fibre Laser Vaporesection|Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
32924602|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
32924603|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
32924604|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
32924605|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
32924606|NCT01939405|No Intervention|standard physical activity counseling|
32924607|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
32924608|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
33249995|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
32723500|NCT04460417|Active Comparator|Treatment as Usual|"Participants will receive the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information."
32723501|NCT05151419|Other|bronchoscope ,forceps,cryo-biopsy|biopies were taken from the lung mass using forceps and cryo-biopsy to evalute diagnostic yield of cryo-biosy versus forceps in the diagnosis of lung cancer
32723502|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
32723503|NCT03483467|Experimental|1|Application of Omnigen
32723504|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
32723505|NCT05151341|Experimental|Case|Patient in whom newly diagnosed, or recurring / progressing bladder cancer is strongly suspected after initial fibroscopy
32723506|NCT05151341|Experimental|Control|Patient attending or hospitalized for urolithiasis, urinary infections, superior excretory stones or with non suspect urinary symptomatology
32723507|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
32723508|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
32723509|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
32924609|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
32924610|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
32924611|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
32924612|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
32924613|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
32924614|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
32924615|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
33249996|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
33249997|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
33249998|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
33249999|NCT00751374|Other|group A|Topical gentamicin cream
32723510|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
32723511|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
32723512|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
32723513|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
32723514|NCT03482999||Control|Standard Wound Closure with drains
32723515|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
32723516|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
32723517|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
32723518|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
32723519|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
32723520|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
32723521|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
32723522|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
32723523|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
32723524|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
32723525|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
32723526|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
32723527|NCT01654250|Experimental|Active|NWP09
32723528|NCT01654250|Placebo Comparator|Placebo|Placebo
32723529|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
32723530|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
32742981|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
32742982|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
32742983|NCT04947891||Study group|Patients will be treated with intensive recovery method after surgery.
32742984|NCT04947891||Control group|Patients will be treated with regular recovery method after surgery.
32742985|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
32742986|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
32742987|NCT04947969|Experimental|Rear laser acupuncture group|Patients in the Real laser acupuncture group will receive real laser pen irradiation.
32742988|NCT04947969|Sham Comparator|Shame laser acupuncture group|Patients in the Shame laser acupuncture group will receive shame laser pen irradiation.
32742989|NCT03250403|Experimental|PRP injection|
32742990|NCT03250403|Active Comparator|medical treatment|
32742991|NCT04947423|Experimental|DPI-386 Nasal Gel|Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
32742992|NCT04947423|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
32924616|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
32924617|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
32924618|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
32924619|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
32924620|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
32924621|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
32924622|NCT04272593|Experimental|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
32924623|NCT04272593|Active Comparator|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
32924624|NCT04740749|Other|Prospective group|Patients who have to undergone the implant surgery
32924625|NCT04740749|Other|Retrospective group|Patients that have already undergone the implant surgery
32924626|NCT04221737|Active Comparator|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
32924627|NCT04221737|Experimental|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
32723531|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
32723532|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
32723533|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
32723534|NCT04349579|Experimental|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
32723535|NCT04349579|Active Comparator|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
32723536|NCT04234529|Active Comparator|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
32723537|NCT04234529|Active Comparator|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
32924628|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
32924629|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
32924630|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
32924631|NCT04047251|Experimental|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32924632|NCT04047251|Experimental|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32924633|NCT04047251|Experimental|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32723538|NCT04234529|Placebo Comparator|Placebo|3x 450mg capsules of microcellulose
32723539|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
32723540|NCT05154071||ECMO VV dedicated unit|Patient having benefited from an ECMO within the structured care unit
32723541|NCT05154071||ECMO VV without dedicated unit|Patient having benefited from an ECMO without the structured care unit
32768135|NCT05372445|Active Comparator|Prediabetes Group A|People between 30-60 years old, diagnosed with prediabetes assigned to the non-intensive intervention.
32768136|NCT05372445|Experimental|Prediabetes Group B|People between 30-60 years old, diagnosed with prediabetes assigned to the intensive intervention.
32924634|NCT04047251|Experimental|Cohort E1: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced ovarian cancer: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32924635|NCT04047251|Experimental|Cohort E5: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced Merkel cell carcinoma: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
32924636|NCT04045613|Experimental|Derazantinib monotherapy [Substudy 1]|Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 1.
32924637|NCT04045613|Experimental|Derazantinib + atezolizumab: Dose finding [Substudy 2]|Dose finding and dose expansion in patients with solid tumor.
32924638|NCT04045613|Experimental|Derazantinib + atezolizumab: First line [Substudy 3]|Patients with urothelial cancer will be treated with a combination of derazantinib and atezolizumab.
32924639|NCT04045613|Experimental|Derazantinib +/- atezolizumab: Second line [Substudy 4]|Patients with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomized to receive either derazantinib alone or a combination of derazantinib and atezolizumab.
32924640|NCT04045613|Experimental|Derazantinib monotherapy [Substudy 5]|Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 2.
32924641|NCT05588999|Active Comparator|Group A (Cryotherapy Alone)|Patients in this Group were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart
32924642|NCT05588999|Active Comparator|Group B (Cryotherapy plus Salicylic Acid)|Patients in this Group were subjected to cryotherapy plus salicylic acid for a maximum of eight weeks
32924643|NCT04288115|Active Comparator|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
32723542|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
32723543|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
32924644|NCT04288115|Placebo Comparator|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
32924645|NCT04339283|Experimental|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
32924646|NCT04339283|No Intervention|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
32924647|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
32924648|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
32723544|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
32723545|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
32723546|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
32723547|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
32723548|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
32924649|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
32924650|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
32924651|NCT04254575||body dysmorphic disorder (BDD)|Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
32924652|NCT01643928|Experimental|Rituximab-Pfizer|
32924653|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
32924654|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
32924655|NCT04234997|Experimental|Suvorexant 20 mg|
32924656|NCT04234997|Placebo Comparator|Suvorexant 0mg|
32924657|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
32924658|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
32924659|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
32924660|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
32924661|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
32924662|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
32924663|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
32924664|NCT05588765|Experimental|Respiratory muscle endurance training|Volume oriented incentive spirometer improves respiratory muscle endurance and chest expansion.
32924665|NCT05588765|Active Comparator|Diaphragmatic breathing exercises|Improvement in diaphragm contraction, chest wall symmetry and reduce activity of accessory muscle due to diaphragmatic breathing technique causes respiratory muscle endurance to improve.
32924666|NCT04339829|Other|Dacomitinib 45mg PO ,QD|Single arm
32924667|NCT05588687|No Intervention|Control group|Children in the control group will be received standard care. Control group children will not receive any distraction techniques.
32924668|NCT05588687|Experimental|Virtual reality group|The children in the VR groups will watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, will watch Ice Age.
32723549|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
32723550|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
32723551|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
32924669|NCT05588687|Experimental|Tablet group|The children in the tablet groups will watch the video during the blood draw with tablet. They will watch Ice Age.
32924670|NCT04167917|Experimental|NTX-301|
32924671|NCT04740281||Medical Doctors at Aarhus University Hospital, Denmark|Medical Doctors from different subspecialties at Aarhus University Hospital, Denmark. Blinded for the purpose of the trial, their footwear will be evaluated by trial responsible personal.
32924672|NCT05588531|Active Comparator|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g)|Four healthy subjects in group A1, two males and two females, without control, were administered the test drug
32924673|NCT05588531|Active Comparator|YK-1169 1.25 g (containing cefepime 1.0 g and avibactam 0.25 g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
32924674|NCT05588531|Active Comparator|YK-1169 2.5g (containing cefepime 2.0g and avibactam 0.5g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
32924675|NCT05588531|Placebo Comparator|YK-1169 3.75g (containing cefepime 3.0g and avibactam 0.75g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
32924676|NCT05588531|Active Comparator|YK-1169 5.0g (containing cefepime 4.0g and avibactam 1.0g)|8 healthy subjects, 6 of whom were administered the investigational product and 2 of whom were administered placebo, half males and half females
32924677|NCT05588531|Active Comparator|Drug Interaction Studies|18 subjects (single gender not less than 1/3) were randomly divided into D1, D2 and D3 groups, 6 subjects for each group
32924678|NCT04158089|No Intervention|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
32924679|NCT04158089|Experimental|Attachment Exercises|"Participants in the Attachment Exercises group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
32723552|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
32723553|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
33250000|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
32924680|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
33400434|NCT03086460|Experimental|Treatment C|"Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
32924682|NCT05588375|Experimental|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams. The exercise process is supervised and guided by a trained critical care nurse. The experimental group participated in a telehealth physical activity training program. The telemedicine physical activity training program included a 3-month online intervention (exercise diary, exercise training education, and 24 exercise sessions for patients) and a 3-month follow-up after exercise.
32723555|NCT05153993|Experimental|Stretch fascia plantaris|
32723556|NCT05153993|No Intervention|Control group|
32723557|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
33250001|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
33250002|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
33250003|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
33250004|NCT00954148|Other|conventional follow-up|NCCN recommendations
33250005|NCT03951194|Experimental|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
32924683|NCT05588375|Active Comparator|walk 2-3 days a week|Maintain daily physical activity and lifestyle and walk for 30 minutes 2-3 days a week for three months
32924684|NCT05588297|Experimental|Nivolumab + Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles; Nivolumab：Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles;"
32924685|NCT05588219|Experimental|Experimental arm|The therapeutic schedule of the experimental arm: External irradiation 45~50Gy/25f+ Brachytherapy 28~30Gy/4~5f; Chemotherapy: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles; Tislelizumab injection[10ml:100mg]: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
32924686|NCT05587985||Experimental Group|"After randomization, 34 patients will be included in the experimental group. This group is the group to be mobilized early after surgery.~During the data collection process, the pain level of the experimental group will be evaluated at the 8th hour after the operation, then the level of mobility will be evaluated by providing mobilization.~At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
32723558|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
32723559|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
32723560|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
32723561|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
33400435|NCT03086460|Experimental|Treatment D|"Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
32924687|NCT05587985||Control Group|"After randomization, 34 patients will be included in the control group. This group is the group that did not undergo early mobilization.~The control group will only be evaluated for pain at the 8th hour after surgery, and they will not be mobilized.~At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
32924688|NCT04339673|Active Comparator|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
32924689|NCT04339673|Active Comparator|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
32924690|NCT04339673|Placebo Comparator|DN-dry needling|dren needling to masseter
32924691|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
32924692|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
32924693|NCT03899831|Experimental|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
32924694|NCT03899831|Active Comparator|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
32924695|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
32924696|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
32723562|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
32723563|NCT03982901|Experimental|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
32723564|NCT03982901|Sham Comparator|healthy women|women without chest pain and coronary artery stenosis less than 50%
32723565|NCT03937583|No Intervention|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
32723566|NCT03937583|Experimental|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
32924697|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
32924698|NCT05587907|Experimental|Group 1|18 soccer players follow a 6-month exercise program with visual stimuli, 5 times a week and lasting 15 minutes each time, which precedes their regular soccer training program.
32924699|NCT05587907|No Intervention|Group 2|20 soccer players follow a regular soccer training program.
32924700|NCT05587829|Experimental|Group A|Group A: will be treated with basic breathing technique.
32924701|NCT05587829|Experimental|Group B|Group B: will be treated by will be breathing technique along with diaphragm and abdominal training.
32924702|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
32924703|NCT05587361|Placebo Comparator|Placebo Patch/Placebo Propranolol|Placebo Nicotine Patch Placebo Propranolol
32924704|NCT05587361|Experimental|Placebo Patch/Active Propranolol|Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)
32924705|NCT05587361|Experimental|Active Patch/Placebo Propranolol|Active Nicotine Patch (14 mg) Placebo Propranolol
32924706|NCT05587361|Experimental|Active Patch/Active Propranolol|Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)
32924707|NCT04740203|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
32924708|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 3 mg/kg|
32924709|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 10 mg/kg|
32723567|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
32723568|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
32723569|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
32924710|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 20 mg/kg|
32924711|NCT01943461|Experimental|Expansion Cohort: Avelumab 10 mg/kg|
32924712|NCT01397669|Other|HIV infection and non HIV infection|
32924713|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
32924714|NCT03679247|Experimental|Intervention|Intervention arm will receive guidance within electronic health record from clinical decision support system.
32924715|NCT03679247|Experimental|Control|The control arm will continue to provide usual care.
32924716|NCT01927783||Group 1|Healthy Volunteer
32924717|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
32924718|NCT01927783||Group 3|Focus Group
32924719|NCT01927783||Group 4|Focus Group- Mobile App
32924720|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
32924721|NCT01927783||Group 6|Community Organization Survey focus Group
32924722|NCT01222351|Experimental|BAY 94-9172|BAY 94-9172 PET/CT
32924723|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
32924724|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
32924725|NCT05586971|Experimental|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 12 months
32924726|NCT05586971|Experimental|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 12 months
32723570|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
32723571|NCT05153681||Peloid Therapy|Peloidotherapy is a special balneotherapy method made with natural mud. In both domestic and international scientific studies on peloid treatment, it has been shown that pain in patients decreases, physical functions improve, quality of life increases, and the amount of painkillers use decreases.
32723572|NCT05153681||Kinesio Tape|Kinesio tapes, which have been used in the conservative treatment of plantar fasciitis in recent years, are elastic tapes similar to the structural properties and flexibility of human skin, without limiting joint movements.
32723573|NCT05153681||Home exercise|In addition to the cold application, gastrocnemius and plantar fascia stretching and strengthening exercises were applied to patients with plantar fasciitis.
32723574|NCT02523989||study group|children confirmed to have developmental delays
32924727|NCT05586971|Experimental|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months
33400436|NCT03086460|Experimental|Treatment E|"Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
32723575|NCT02523989||control group|children with typical development
32768137|NCT05372445|Active Comparator|Type 2 Diabetes Group A|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the non-intensive intervention.
32924728|NCT05586971|Active Comparator|Titrated allopurinol (100-800mg)|Allopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg.
32924729|NCT05586971|Placebo Comparator|Placebo|Placebo, three times a day (TID) for up to 6 months.
32924730|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
32924731|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
32924732|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
32924733|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
32924734|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
32924735|NCT00719719||Drug Anaphylaxis|Drug Anaphylaxis
32924736|NCT00719719||Food Anaphylaxis|Food Anaphylaxis
32924737|NCT00719719||Idiopathic Anaphylaxis|Idiopathic Anaphylaxis
32924738|NCT00719719||Venom Anaphylaxis|Venom Anaphylaxis
32924739|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
32924740|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
32924741|NCT05559437|Experimental|Quadratus Lumborum Block group|Quadratus lumborum group (Q) (n=30): patients will receive Quadratus Lumborum Block using 20 mL of 0.25% Levo-bupivacaine
32924742|NCT05559437|Experimental|Ilioinguinal/Iliohypogastric Nerve Block group|Ilioinguinal/Iliohypogastric Nerve Block group (I) (n=30): patients will receive Ilioinguinal/Iliohypogastric Nerve Block using 5 mL of 0.25%Levo- bupivacaine
32924743|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
32924744|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
32924745|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
32924746|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
32924747|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
32924748|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
32924749|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
32924750|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
32924751|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
32924752|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
32924753|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
32924754|NCT02646917|Active Comparator|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
32924755|NCT02646917|Active Comparator|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
32924756|NCT02650193|Experimental|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
32924757|NCT04339361|Experimental|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
32924758|NCT04339361|Active Comparator|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
32924759|NCT04339361|Placebo Comparator|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
32924760|NCT05397197|Other|Longitudinal follow-up|Follow-up of children at 40 weeks of corrected age for all children and then regularly until 24 months
32924761|NCT05369351|Experimental|Standard treatment+mirabegron|In addition to standard treatment, mirabegron 50 mg/d will be given as the first dose within 24 hours of symptom onset for 14 consecutive days.
33400437|NCT03086460|Active Comparator|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
32768138|NCT05372445|Experimental|Type 2 Diabetes Group B|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the intensive intervention.
32924762|NCT05369351|Placebo Comparator|Control group|Patients will receive usual care
33250006|NCT03951194|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
33250007|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
33250008|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
32924766|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
33250009|NCT00757224|No Intervention|non-smoking|
33250010|NCT00757224|No Intervention|smoking parents A|
33250011|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
33250012|NCT03892694|Active Comparator|Treatment|MCS
33250013|NCT03892694|Sham Comparator|Sham Control|Sham
33250014|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
33250015|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
33250016|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
33250017|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
33250018|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
33250019|NCT00363415|Experimental|A|
33250020|NCT00363415|Active Comparator|B|
33250021|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
33250022|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
33250023|NCT00757380|Active Comparator|Group 1|Trypan Blue
33250024|NCT00757380|Active Comparator|Group 2|Brillant Blue
33250025|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
33250026|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
33250027|NCT00751452||1|
33250028|NCT00751452||2|
33250029|NCT00954382||IQ trend|all subjects
33250030|NCT00752934|Experimental|group a|Baclofen followed by Placebo
33250031|NCT00752934|Experimental|group b|Placebo followed by Baclofen
33250032|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
33250033|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
33250034|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
32723576|NCT04926896|Experimental|Minimally invasive bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use the cortical bone opening device to open two bone holes with a diameter of 7.5 mm side by side in the iliac bone cortex ,place disposable battery-powered bone harvesting device for iliac crest bone harvesting operations.~The direction of the tool bit should be parallel to the outer iliac plate, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~.Scrap and collect the cancellous bone by tool bit during operation.~. After collecting sufficient amount of cancellous bone, turn off the power, screw out the cabin, and pour out the cancellous bone.~. Suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage."
32723577|NCT04926896|Placebo Comparator|Traditional iliac crest bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use a bone chisel to open a lid on the iliac crest ridge cortex ,open the cover length at 3cm.~Lift the iliac crest ridge cortex plate cover, use bone knife and scraper to harvest bone in the iliac bone marrow cavity.~Avoid violence when using bone knives and scrapers, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~After collecting sufficient amount of cancellous bone, suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage"
32723578|NCT03798041|Experimental|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
32723579|NCT03798041|No Intervention|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
32723580|NCT05153603||Olaparib mono-maintenance therapy group|Olaparib monotherapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
32723581|NCT04459325|Experimental|Study drug and best available care|Best available care and Tigerase®/nebulised dornase alfa [2.5 mg BID] for 7 days
32723582|NCT04459325|Other|Control group (best available care)|Patients will receive the usual care in accordance with good practice.
32723583|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
32723584|NCT05153369|Experimental|Level 1|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with no lifetime suicidal behaviors and ideations will be enrolled in Level 1. Participants with a score of < 73 on the DERS AND a score of ≤ 8 on the CALS (youth report) will be enrolled in Level 1.
32723585|NCT05153369|Experimental|Level 2|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with < 3 lifetime non-suicidal self-injurious (NSSI) behaviors with one behavior occurring in the past 3 months or ≥ 3 lifetime NSSI behaviors with none in the past 3 months AND no lifetime suicide attempts (actual, interrupted and/or aborted) AND a score of ≥ 16 and < 24 on the SIQ AND lifetime suicidal ideations will be enrolled in Level 2. Participants with a score of ≥ 73 and < 105 on the DERS OR a score of > 8 and < 20 on the CALS (youth report) will be enrolled in Level 2.
32768139|NCT05425849|No Intervention|control group|No attempt was made to reduce pain in the patients in the control group. Standard PIVC insertion procedure was applied.
33400438|NCT05422066|Experimental|Selinexor-R-CHOP|Selinexor po 60mg once weekly, Rituximab iv 375 mg/sqm on day 1, Cyclophosphamide iv 750 mg/sqm on day 1, Doxorubicin iv 50 mg/sqm on day 1, Vincristine iv 0.5 mg/kg on day 1, Prednisone po 100mg on days 1-5 in a 21 days per cycle.
33400439|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
33400440|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
33400441|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
33400442|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
33400443|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
33400444|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
33400445|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
33400446|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
33400447|NCT03670706|No Intervention|Group C|Control group
33400448|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
33400449|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
33400450|NCT03678818|No Intervention|Handling Medium as it is.|
32723586|NCT05153369|Experimental|Level 3|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with at least 1 lifetime suicide attempt (actual, interrupted, and/or aborted) OR ≥ 3 lifetime NSSI behaviors, with one behavior occurring in the past 3 months OR a score of ≥ 24 on the SIQ will be enrolled in Level 3. Participants with a score of ≥ 105 on the DERS OR a score of ≥ 20 on the CALS (youth report) will be enrolled in Level 3. Participants who meet youth threshold for at least 2 impulsive behavior categories on question #4 from the SIDP-IV or 1 category is identified as severe will be enrolled in Level 3.
32723587|NCT04459949|Active Comparator|Sharkskin Arm|
33400451|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
33400452|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
33400453|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
33400454|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
33400455|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
32924783|NCT05318573|Experimental|Safety Run-in Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
32924784|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
32924785|NCT04340297|Experimental|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
32924786|NCT04340297|Placebo Comparator|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
32924787|NCT02653391|Experimental|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
32924788|NCT02653391|Experimental|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
32924789|NCT02653391|Placebo Comparator|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
32924790|NCT02653391|Placebo Comparator|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
32924791|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
32924792|NCT05303987|Experimental|Propofol sedation|2.5 mg/kg loading dose, then continue at an infusion of 250 mcg/kg/minute.
32924793|NCT05303987|Experimental|Dexmedetomidine sedation|1 mcg/kg loading dose, then continue at an infusion of 1 mcg/kg/hour
33250035|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
33250036|NCT00751608|Experimental|1|
33400456|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
33400457|NCT03186638|Experimental|Arm I (ibuprofen)|Patients receive ibuprofen PO BID for 6 weeks.
33400458|NCT03186638|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 weeks.
32723588|NCT04459949|Placebo Comparator|Grieshaber Arm|
32723589|NCT05153213|Experimental|Finger Lengths|Vernier caliper was used to determine the length of Index Finger to record Vertical Dimensions of Occlusion
32723590|NCT05153213|Active Comparator|Conventional method|Willis gauge was used to determine the Length from Base of the nose to Base of the chin to record Vertical Dimensions of Occlusion
32723591|NCT05152901|Active Comparator|EpiPen ®.|Dosage Form- Intra muscularly (IM), Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via IM on day, Visit 2.
33400459|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
33400460|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
33400461|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
33400462|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
33400463|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
33400464|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
33400465|NCT03678584|No Intervention|handling Medium as it is.|
33400466|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
33400467|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
32768140|NCT05425849|Experimental|rose oil group|After the patients in the rose aromatherapy group were placed in a sitting position, a face mask with 1-2 drops of rose oil was placed on the nose area. Then, the standard PIVC insertion procedure was applied. After the procedure, the patient's rose-scented mask was replaced with a standard mask.
33250037|NCT00751608|Active Comparator|2|
33400468|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
32768141|NCT05425849|Experimental|hand holding group|After the patients in the hand-holding group were placed in a sitting position, the patient's family was asked to hold the patient's hand and not let it go until the procedure was over. Standard PIVC insertion procedure was applied.
32768142|NCT04846205||Patients who underwent a systematic etiological|Patients who underwent a systematic etiological assessment in the context of their cryptogenic ischemic stroke between 2015 and 2020. A collect data in medical record will be realized.
32768143|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
32768144|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
32768145|NCT04862039|Experimental|Virtual Reality (VR) devices|intervention group (VR).
32768146|NCT04862039|No Intervention|control group|the standard of care (control group, no VR)
32768147|NCT04862117|Active Comparator|Active stimulation QD|
32768148|NCT04862117|Active Comparator|Active stimulation QID|
32768149|NCT03691909|Experimental|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
32768150|NCT04861649|Experimental|Effect and mechanism of fecal microbiota transplantation on patients with COPD malnutrition|"During COPD stable period, nasal and intestinal tubes were placed and fecal bacteria were transplanted from healthy people (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
32768151|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
32768152|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
32768153|NCT05416749|Experimental|8MW2311|
32768154|NCT05423431||Radiation with Hydrogel Spacer|Males at least 18 years of age, who underwent radiation therapy with a hydrogel spacer in place.
32768155|NCT04853303|Experimental|Hypnosis VR|The experimental group will receive a 15-minute hypnosis using virtual reality when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain.
32768156|NCT04853303|No Intervention|Control|The control group will receive no intervention.
32768157|NCT05416437|Active Comparator|Device arm|The patients in the device arm will get the Pneumocool device to channel medical air to their face to alleviate dyspnea
32768158|NCT05416437|Placebo Comparator|Standard of Care arm|The patients in the standard of care arm can get a fan or any other supportive care that is currently available in the hospital for alleviating dyspnea
32768159|NCT05412355||Incomplete ERAS|Incomplete ERAS was defined as ERAS compliance < 70%.
32768160|NCT05412355||Non-ERAS|non-ERAS was defined as not executing any ERAS programs.
32768161|NCT04853069|Active Comparator|Oestrogen Therapy|Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
32768162|NCT04853069|No Intervention|Control Group|Patients will receive only standard care.
32768163|NCT04259853|Experimental|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
32768164|NCT04259853|Active Comparator|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
32768165|NCT05245279|Experimental|Normal placenta-entitle|The 3-DPD indices was measured in the entire placenta volume.
32768166|NCT05245279|Experimental|Normal placenta-sonobyopsy|The 3-DPD indices was measured at cord insertion in placenta by sonobiopsy
32768167|NCT04852913|Experimental|Bowen's Technique|Bowen's Technique The session lasted for 20 minutes, 3 sessions/week 6th week
32768168|NCT04852913|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy with myofascial release The session lasted for 20 minutes, 3 sessions/week 6th week
32768169|NCT04846049||Comprehensive Care|"Veterans with complex medical conditions that may need more help. This intervention will provide extra care coordination after a complete assessment of their health.~Research team will assess veteran's memory, physical function, strength, balance, and from there, find the areas they need the most help with and coordinate services at home. This is in addition to their regular primary care provider."
32768170|NCT04846049||Standard Care|Veterans receiving standard of care
33250038|NCT00751608|Placebo Comparator|3|
33250039|NCT00958048|Experimental|2|ALS with non-invasive ventilation
33250040|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
33250041|NCT00751686||RV GE Group|
33250042|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
33250043|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
33250044|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
33250045|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
33250046|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
33250047|NCT04056156|No Intervention|Control|Standard of care (no specific intervention)
32723592|NCT05152901|Experimental|Epinephrine (0.3mg)|Dosage Form- Inhaled, Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via inhalation on day 2 of Visit 2.
32723593|NCT05152901|Experimental|Epinephrine (1.3mg)|Dosage Form- Inhaled, Dosage- 1.3mg, Dosage Frequency and Duration- Single dose of 1.3mg epinephrine via inhalation on Visit 3.
32723594|NCT05152901|Experimental|Epinephrine (4mg)|Dosage Form- Inhaled, Dosage-4mg, Dosage Frequency and Duration- Single dose of 4mg epinephrine via inhalation on Visit 4.
32723595|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of naltrexone for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
32723596|NCT02137252|Placebo Comparator|Sugar Pill|The treatment schedule includes a daily dose of equivalent placebo for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
33250048|NCT04056156|Experimental|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
32723597|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
32723598|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
33250049|NCT04056156|Experimental|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
33250050|NCT00751764|Experimental|1|
33250051|NCT00757458|Active Comparator|1|TCI with EDTA
33250052|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
33250053|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
33250054|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
33250055|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
33250056|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
33250057|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
33250058|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
33250059|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
33250060|NCT00757536|Active Comparator|Group 1|
32723599|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
32768171|NCT05396001|Active Comparator|LowSalt4Life|
33250061|NCT00757536|Active Comparator|Group 2|
33250062|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
32768172|NCT05396001|Experimental|LowSalt4Life + just-in-time adaptive intervention (JITAI)|
32768173|NCT03685045|Experimental|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
33400469|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
32723600|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
32723601|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
32924794|NCT05288309|Other|RAİNSTİCK|In the 1st experimental group, the sound of the rain stick was played to distract attention. The rainstick, used by traditional societies, is a rhythm instrument that makes the sound of rain by moving it up and down. The length of the rain stick made of bamboo is 40 cm. There are spiral-shaped spines inside the tool, which is closed at both ends. It makes the sound of drizzling rain by moving it up and down.
32924795|NCT05288309|Other|KALEİDOSCOPE|In the second experimental group, kaleidoscope was used to distract attention. A kaleidoscope, or kaleidoscope, is a device that sees colorful patterns when looked into. Inside, there are three mirrors adjacent to each other with an inclination of 60 degrees between them. There are pieces of colored glass between the mirrors. When viewed from one end of this binocular, shape-shifting polygons are seen, often with images that will never be the same again. These patterns are created by the reflection of light and change constantly as the binoculars are moved.
32924796|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
32924797|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
32924798|NCT03237845|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
32924799|NCT03237845|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
32924800|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
32924801|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
33400470|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
32723602|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
32723603|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
32723604|NCT05152745|Placebo Comparator|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
32723605|NCT05152745|Experimental|Intervention (OGTT plus Ginger extract)|The intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose).
32723606|NCT05152667||Arm 1|Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI
32723607|NCT05152667||Arm 2|"Women with adenomyosis pretreated with oral progestin Dienogest and proceeding with the ICSI"
32723608|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
32723609|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
32723610|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
32723611|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
32723612|NCT03185663|Placebo Comparator|a pillow between the legs|
32723613|NCT03185663|Experimental|traction-stuck|
32723614|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
32723615|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
32723616|NCT05152589||gestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of gestational diabetes in the peritanotogy clinic
32924802|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
32924803|NCT05167487||Experimental: platinum-based neoadjuvant treatment and surgery.|Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
32924804|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
33250063|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
33250064|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
33250065|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
33250066|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
33250067|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
32723617|NCT05152589||pregestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of pregestational diabetes in the peritanotogy clinic
32723618|NCT05152589||non diabetic mother|Hearing tests of babies whose mothers do not have gestational or pregestational diabetes
32723619|NCT05152511||All male children who had penile ischaemia after circumcision were included in the study|It is a cohort prospective study. All male children who had penile ischaemia after circumcision were included in the study between April 2017 and October 2020.
32723620|NCT04459481|Experimental|70-degree bending angle group|intubation with a 70-degree bending angle
32723621|NCT04459481|Experimental|90-degree bending angle group|intubation with a 90-degree bending angle
32723622|NCT02135848|Experimental|GSK1278863|Study Drug
33250068|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
33250069|NCT00757770|Experimental|Group HRV Lot A|
33250070|NCT00757770|Experimental|Group HRV Lot B|
33250071|NCT00757770|Experimental|Group HRV Lot C|
33250072|NCT00757770|Active Comparator|Group Placebo|
33250073|NCT04847648|Active Comparator|Control - Mechanical instrumentation of implant surface|The control group will be subjected to non-surgical decontamination including the use of hand instruments and polishing cups aiming at the removal of all supra-mucosal soft and hard deposits from the implant surfaces.
33250074|NCT04847648|Experimental|Test - Mechanical instrumentation and air-polishing of implant surface|In the test group the mechanical instrumentation will be supplemented by the use of an air-polishing device during non-surgical therapy.
33250075|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
33250076|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
33250077|NCT00753168|Experimental|1|OT-730 ophthalmic solution
33250078|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
32723623|NCT02135848|Placebo Comparator|Placebo|Placebo
33250079|NCT00753168|Placebo Comparator|3|placebo eye drops
32723624|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33250080|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
33250081|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
33250082|NCT00866463|Experimental|Experimental Tablet With Water|
32723625|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
32723626|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
32723627|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
32723628|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
32723629|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
32723630|NCT03480737|Experimental|10 Hz rTMS|
32723631|NCT03480737|Sham Comparator|Sham rTMS|
32723632|NCT03480737|Experimental|iTBS rTMS|
33250083|NCT00866463|Experimental|Experimental Tablet Without Water|
33250084|NCT04051164|Experimental|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
32723633|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
32924805|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
32924806|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
32924807|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
32924808|NCT05094011|Experimental|Single Arm Study|Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease
32924809|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
32924810|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
32924811|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
32924812|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
32924813|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
32924814|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
32924815|NCT03069521|Other|EndoArt®|EndoArt® Artificial Endothelial Layer
32924816|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.~Optional research biopsy at baseline and progression~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
32924817|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
32924818|NCT04739501||TACE in HCC group 1|the patient did undergo tace
32924819|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
32924820|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
32924821|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
32924822|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
32924823|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
32924824|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
32924825|NCT05044871|Experimental|Arm 1: Pamiparib+ Bevacizumab|Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1 (q3w.).
32924826|NCT05044871|Experimental|Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 + Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).
32924827|NCT05044871|Experimental|Arm 3: Bevacizumab + Nab-paclitaxel|Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and <3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 + Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).
32924828|NCT05044871|Experimental|Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 + Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).
33250085|NCT04051164|Active Comparator|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
33250086|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
33250087|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
32924829|NCT05044871|Experimental|Arm 5: Bevacizumab + Nab-paclitaxel|Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: <3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
32924830|NCT05009849|Experimental|Exercise I|Yogic and Routine Exercises (referred to as exercise I) Phase I: 1-7 days (Minimum attendance 4 days), Phase II: 8 - 14 days (Minimum attendance 4 days), Phase III: at 6-9 months or 12-15 months 1 year up gradation of exercises at 6-9 month or 12-15 months 1 year (Depending upon compliance to phase II exercises) Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months Exercise evaluation will be done at 6-9, 12-15, 30-33, 48-51 and 66-69 months
32924831|NCT05009849|Active Comparator|Exercise II|Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months
33250088|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
33250089|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
33250090|NCT00862407||1|Non-pulsatile Group (conventional)
33250091|NCT00862407||2|Pulsatile group (Alternate)
33250092|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
33250093|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
33250094|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
33250095|NCT00695864|Experimental|Ondansetron|Ondansetron
33250096|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
33250097|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
32924832|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
33250098|NCT00862485||StudyGroup|
33250099|NCT04841408|Experimental|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
33250100|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
33250101|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
33250102|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
33250103|NCT05325008|Experimental|Immunosuppression reduction/modification + Intravenous Immunoglobulin|Receives Immunosuppression reduction/modification + Intravenous Immunoglobulin
33250104|NCT05325008|Other|Immunosuppression reduction/modification|Receives Immunosuppression reduction/modification as part of standard of care.
33250105|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
33250106|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
33250107|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
33250108|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
33250109|NCT00695786|Experimental|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
33250110|NCT00695786|Experimental|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33250111|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
33250112|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
33250113|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
33250114|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
33250115|NCT04049838|Active Comparator|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
33250116|NCT04049838|Active Comparator|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
33250117|NCT04049838|Active Comparator|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
33250118|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
33250119|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
33250120|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
33250121|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
32723634|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
32723635|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
32924833|NCT01643850|Placebo Comparator|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
32924834|NCT01643850|Experimental|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
32924835|NCT01643850|Experimental|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
32924836|NCT01643850|Experimental|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
32924837|NCT01643850|Experimental|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
32723636|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
32723637|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
32723638|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
32924838|NCT01643850|Experimental|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
32924839|NCT04931693|Active Comparator|control|conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg and atracurium top ups at a dose of 0.1mg/kg. every 30 minutes.
32924840|NCT04931693|Active Comparator|PECs|Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block and atracurium top ups upon request.
32924841|NCT04340453|Active Comparator|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
32723639|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
32723640|NCT04900103|Experimental|Tech-volunteer|"A complex intervention with two phases is proposed.~First phase: volunteers new technologies training (tech-volunteering). Volunteers will be trained in the use of NT and their interconnectivity as tools to support their volunteer work. This training will be integrated into the PC volunteer training programme.~Second phase: using the NT with patients and relatives."
32723641|NCT04900103|No Intervention|Usual volunteer|the control group will receive standard volunteer service.
32723642|NCT04884893|Experimental|Intermittent nitrous oxide|10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen
32723643|NCT04884893|Experimental|Continuous nitrous oxide|20 min 50% nitrous oxide + 20 min 100% oxygen
32723644|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
32924842|NCT04340453|Experimental|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
32924843|NCT04866641|Experimental|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks. T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.
32723645|NCT04839809|Experimental|CC-92480-02 (Formulation A) with Placebo|CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
32924844|NCT04834973|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2 given every 28 days (+1 to 14days) in combination with three weekly 200 mg intravenous doses of pembrolizumab.
32924845|NCT02271594|Active Comparator|Intervention|Intensive education on injection technique
32723646|NCT04839809|Experimental|CC-92480 (Formulation B)- fasted condition|A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
32723647|NCT04839809|Experimental|CC-92480-02 (Formulation A) - fasted condition|A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
32723648|NCT04839809|Experimental|CC-92480 (Formulation B) - Low-fat meal|A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
32924846|NCT02271594|Placebo Comparator|Control|Standard education on injection technique
32723649|NCT04839809|Experimental|CC-92480-02 (Formulation A) - high-fat meal|A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
32723650|NCT04830839|Experimental|Recovery after Stress Toolkit (ReSeT)|"ReSeT is comprised of interactive web-based psychoeducational modules that are developmentally tailored for school age children (8-17 years) for use with synchronous e-health therapy sessions with a trained therapist.~Participants in the ReSeT treatment will complete 8 modules and therapy sessions. Parents will also have access to 4 modules During the study, children/youth will be asked to complete all eight sessions of the online treatment together with the therapist over an 8 -12 week time period (to allow for scheduling/cancellations). For younger children, parents will participate in the beginning and end of each session. Sessions will last approximately 30-60 minutes and will occur approximately every week for an anticipated 4-8 hour time commitment. Parents of older children will be permitted to review the content independently and participate in feedback sessions."
32723651|NCT04664309||Participants|Adults who are receiving a COVID-19 vaccine
32723652|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
32723653|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
32924847|NCT04817969|Other|Persona Ti-Nidium|Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
32924848|NCT04879212|Experimental|PCIA +Acupuncture group|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, but no electricity. Acupuncture was given once a day. PCIA（patient controlled intravenous analgesia）.
33250122|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
33400471|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
32768174|NCT04845971|Experimental|Adult male and female patients who are hospitalized with COVID-19-induced pneumonia.|Eligible patients will be treated with Saisei MAF capsules stronger version, oral administration 2-3 capsules, 3 times per day, 30 minutes before food or in the morning, afternoon and before bed time. The treatment duration will be 21 days. Patients are also provided with nutritional supplementation of Vitamin D3, 10.000 IU per day, monitoring the blood levels of such a vitamin. Efficacy and safety assessments will be performed on Days 0, 7, 14, 21, and 28.
32768175|NCT05245045|Experimental|Shengtaibufen Photodynamic Therapy(STBF-PDT)|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 0.5mg/ml Shengtaibufen solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
32768176|NCT05245045|Placebo Comparator|Red light|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying normal saline solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
32768177|NCT05416281|Experimental|Robotic Vacuum Intervention|This will include a home visit for environmental assessment AND a robotic vacuum intervention. Silicone wristbands will be used to evaluate exposure before and after a cleaning intervention.
32768178|NCT05416281|No Intervention|No Intervention|This will include a home visit for environmental assessment.
32768179|NCT03663595|Experimental|PFPS: Model 1 (Hip and Knee)|Females symptomatic for PFPS. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
32768180|NCT03663595|Experimental|PFPS: Model 2 (knee, foot and ankle)|Females symptomatic for PFPS This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
32768181|NCT03663595|No Intervention|Healthy group|Healthy females not submitted to intervention
32768182|NCT05416203|Experimental|BEAST Condition|A one-session intervention that can be delivered effectively by a clinician via telehealth and supplemented with a mobile app to provide opportunities to practice the skills learned in the face-to-face session.
32768183|NCT04852523|Experimental|18F fluciclovine Administration|"Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB.~Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests.~The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft."
32768184|NCT04846361|Experimental|Hygiene wash plus metronidazole|Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
32768185|NCT04846361|Placebo Comparator|placebo wash plus metronidazole|Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
32768186|NCT04846361|No Intervention|Healthy control|Asymptomatic healthy women with BV negative test
32768187|NCT05416125|Placebo Comparator|Lifestyle therapy plus placebo|Individuals randomized to this arm will receive lifestyle therapy plus placebo for 24 weeks.
32768188|NCT05416125|Active Comparator|Lifestyle therapy plus lisdexamfetamine|Individuals randomized to this arm will receive lifestyle therapy plus lisdexamfetamine for 24 weeks.
32768189|NCT04429373|Experimental|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
32768190|NCT04429373|Active Comparator|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
32768191|NCT05371977|Experimental|Glaucoma patient|
32768192|NCT05244811|Placebo Comparator|use of placebo in treatment of functional ovarian cyst|trial the effect of placebo in treatment of functional ovarian cyst
32768193|NCT05244811|Active Comparator|use of cocs in treatment of functional ovarian cyst|trial of the effectiveness of cocs in the treatment of functional ovarian cyst
32768194|NCT05244811|Active Comparator|use of progesterone in treatment of functional ovarian cyst|comparison between the effect of progesterone in the treatment of functional ovarian cyst with the effect of cocs
32768195|NCT05564403|Active Comparator|Arm 1 (mFOLFOX6)|Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
32768196|NCT05564403|Experimental|Arm 2 (binimetinib, mFOLFOX6)|Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
32768197|NCT04845659|Experimental|Intervention|Avatrombopaq administration
32768198|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
32768199|NCT05244421|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
32768200|NCT04861493||Smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and smoking at least 10 cigarettes /day for a minmum of 5 years.
32768201|NCT04861493||Non-smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and they are never smoked before.
32924849|NCT04879212|Experimental|PCIA +2 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 2Hz, continuous wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
32924850|NCT04879212|Experimental|PCIA +20/100 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 20 / 100Hz, density wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
32924851|NCT05649228|Experimental|Capsaicin Palmitate|Vehicle cream containing 0.25% capsaicin palmitate will be applied to an 8 cm2 area of skin on the subject's forearm
32723654|NCT04331483|Experimental|Physical activity intervention|"The intervention consists of an adapted physical activity (APA) program defined at baseline, incorporating supervised sessions with an APA teacher, as well as autonomous sessions. The program is individualized according to age, aerobic capacity, and PA preferences.~The total duration of the intervention is a maximum of 3 months (during the period of hospitalization in a sterile room)."
32723655|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
32723656|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
32924852|NCT05649228|Active Comparator|Non-Palmitated Capsaicin|Vehicle cream containing 0.25% non-palmitated capsaicin will be applied to an 8 cm2 area of skin on the subject's forearm
32924853|NCT05649228|Placebo Comparator|Vehicle Cream|Vehicle cream placebo will be applied to an 8 cm2 area of skin on the subject's forearm
32924854|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
32924855|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
32924856|NCT05649150||Healthy group|For healthy group A.K.As adults without LBP are: (1) aged from 20 to 65 years old, (2) no specific low back pain in the past 6 months.
32924857|NCT05649150||LBP group|The inclusion criteria for adults with LBP are: (1) aged from 20 to 65 years old, (2) persistent LBP for more than 3 months.
32924858|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
32924859|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
32924860|NCT04769921||All-on-4 TiUltra and Xeal|Patients rehabilitated in the edentulous maxilla or mandible with an implant supported prosthesis through the All-on-4 Concept (2 anterior implants in the axial position and 2 posterior implants inserted with distal tilting). The implants used will be NobelParallel Conical Connection, with TiUltra surface. The abutments used will be Multi-unit abutments of internal connection with Xeal surface. The immediate prosthesis will be a high-density acrylic and 4 titanium cylinders. The definitive prosthesis will be a Titanium infrastructure with acrylic resin artificial gingiva and either acrylic or ceramic crowns.
32924861|NCT04697225|Experimental|weight loss program|
32924862|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
32924863|NCT02270736|Experimental|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
32723657|NCT03479879|Experimental|Estradiol + Misoprostol|
32723658|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
32723659|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
32723660|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
32723661|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
32723662|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
32723663|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
32723664|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
32768202|NCT04861493||Healthy patients|patients free from periodontitis or any systemic disease and never smoked before.
32768203|NCT05404555||acute myocardia infarction patients with right coronary artery occlusion|
32924864|NCT02270736|Experimental|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram [U/kg] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
32768204|NCT05404555||acute myocardia infarction patients with non-right coronary artery occlusion|
32768205|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
32924865|NCT02270736|Experimental|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
32924866|NCT02270736|Experimental|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
32924867|NCT02270736|Experimental|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
32924868|NCT04672031|No Intervention|Control Arm|Patients in the control arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the control arm will be defined as follows: fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL (i.e. conventional targets). Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
32924869|NCT04672031|Experimental|Interventional Arm|Patients in the experimental arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the intervention arm will be defined as follows: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL. Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
32924870|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
32924871|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
32924872|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
32924873|NCT05649072|Other|Genetic Testing and Counseling|Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing. The kit includes all standard paperwork and instructions for collecting the sample and shipping the kit back to the genetic testing company (Invitae).
33400472|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
33400473|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
32924874|NCT05649072|Other|Screening Form|Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers.
32924875|NCT01585805|Experimental|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21 of each cycle. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32924876|NCT01585805|Active Comparator|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33400474|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
33400475|NCT05597280|Experimental|BE-PEP|"Intervention arm in which BE-PEP will be provided to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts.~BE-PEP: bedaquiline (400 or 800 mg depending on weight band) combined with rifampicin (10 mg/kg) will be provided as post-exposure prophylaxis~Both arms will target anyone living within 100 meters of an index case or the entire village if more than 50% are eligible. The dosage form of rifampicine is 150 mg and 300 mg, for bedaquiline it's 20 mg or 100 mg."
33400476|NCT05597280|Active Comparator|SDR PEP|"WHO recommended standard PEP will be provided, i.e. 10 mg/kg of rifampicin in a single dose. In both arms anyone living within 100 meters of an index case will be targeted or the entire village if more than 50% are eligible.~The dosage form of rifampicine is 150 mg and 300 mg."
33400477|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
33400478|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
33400479|NCT03674684||gelatin|Patients who received gelatin
33400480|NCT03674684||crystalloids|Patients who received crystalloids
32768206|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
32768207|NCT05395065||SDF/FV|Topical Application of 38% silver diamine fluoride and 2.5% sodium fluoride varnish at baseline and 6 months
32723665|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
32723666|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
32723667|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
32723668|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
32723669|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
32723670|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
32723671|NCT03479567|Other|MiD|older adults with mild dementia
32723672|NCT03479567|Other|MoD|older adults with moderate dementia
32723673|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
32723674|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
32723675|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
32723676|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
32723677|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
32723678|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
32723679|NCT04134455|Active Comparator|Onlay Mesh Reinforcement group|The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
32723680|NCT04134455|Experimental|RTL reinforcement group|The RTL suture is placed parallel at a distance of 0.5 cm from the fascial margin. Ideally the thread should lie between the anterior and the posterior rectus muscle sheath; there should be no contact with the rectus muscle. A nonabsorbable monofilamental polypropylene thread and a 65-mm ½ needle are used. Around this longitudinal thread, the continuous suture for fascial closure is introduced immediately lateral to the thread; with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis
32723681|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
32723682|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
32723683|NCT03475901|Experimental|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
32723684|NCT03479333|Experimental|Short implant|
32723685|NCT03479333|Active Comparator|standard implant with sinus lift|
32723686|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
32723687|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
32723688|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
32723689|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
32723690|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
32723691|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
32723692|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
32723693|NCT03475745||Control|Healthy controls
32723694|NCT03946553||Allergic Rhinitis Group|Individuals with allergic rhinitis
32723695|NCT03946553||Control Group|Individuals without allergic rhinitis
32723696|NCT05259215||non-walking group|
32723697|NCT05259215||independently walking group|
32723698|NCT03475589|Other|single group|
32723699|NCT03929471|Experimental|Intervention group|Patients to be subjected to a fluid overload correction protocol.
32723700|NCT03929471|No Intervention|Control group|Patient will be followed but no fluid overload correction protocol will be applied.
32723701|NCT03478709||Volume expansion|
32723702|NCT03478709||norepinephrine|
32723703|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
32723704|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
32723705|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
32723706|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
32723707|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
32723708|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
32723709|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
32924877|NCT01585805|Experimental|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32924878|NCT04878198|Experimental|Jogging intervention|This intervention will be a 10-week jogging program consisting of 50 sessions (5 sessions per week, 30 min per session) in each participating school. The jogging program is confined to morning sessions based on the favourable sleep outcomes from previous study. To counteract the possible influence of natural sunlight exposure, all jogging sessions will be confined to indoor setting. Each session will be conducted in an identical format with 5 minutes of warm-up activities, followed by 20 minutes of jogging (intervention), and 5 minutes of cool-down activities. Participants are instructed to jog at a moderate intensity level. The intensity level of jogging will be measured by heart rate monitor (Polar H1). Meanwhile, questionnaire will be given to the research staff assisting the jogging intervention to assess the adherence of the intervention at T2.
32924879|NCT04878198|Experimental|Melatonin supplement group|Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
32924880|NCT04878198|Experimental|Combination group|Participants will receive the jogging program and supplemental melatonin dose with identical format as that in the intervention A and B (e.g., identical duration, identical manpower, identical warm-up and cool-down, identical dose, identical acclimation procedure before the intervention adherence of the intervention for this group will also be assessed at T2.
32924881|NCT04878198|No Intervention|Control group|Participants in the placebo control group will receive no jogging and melatonin supplement dosing activity. However, they will be given a placebo flavored similar to the melatonin supplement (compounded by Pharmacare, Mt. Juliet, NT®). Meanwhile, they will also be required to wear an actigraph to control for their physical activity level at the assessment points (i.e. T1, T2, and T3). They will be expected for following their daily routine without participating in any additional formal physical exercise training program throughout the whole study period (T1-T3). After T3, they will be assisted with jogging program to recognize their contribution as controls.
32924882|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
32924883|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
32924884|NCT04651595|Experimental|Caudal|
32924885|NCT04651595|Active Comparator|Control|
32924886|NCT04645511|Experimental|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
32924887|NCT04645511|Sham Comparator|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
32723710|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
32723711|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
32723712|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
32723713|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
32924888|NCT04645511|Experimental|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
32924889|NCT04645511|Sham Comparator|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
32924890|NCT04630067|Experimental|AZD3427: Cohort 1a|Participants will receive single SC dose A of AZD3427 on Day 1.
32924891|NCT04630067|Experimental|AZD3427: Cohort 2a|Participants will receive single SC dose B of AZD3427 on Day 1.
32924892|NCT04630067|Experimental|AZD3427: Cohort 3a|Participants will receive single SC dose C of AZD3427 on Day 1.
32924893|NCT04630067|Experimental|AZD3427: Cohort 4a|Participants will receive single SC dose D of AZD3427 on Day 1.
32924894|NCT04630067|Experimental|AZD3427: Cohort 5a|Participants will receive single IV dose E of AZD3427 on Day 1.
32924895|NCT04630067|Experimental|AZD3427: Cohort 6a|Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.
32723714|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
32723715|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
32723716|NCT03475199|No Intervention|Control group|General dietary recommendations.
32924896|NCT04630067|Experimental|AZD3427: Cohort 7a|Participants will receive single SC dose F of AZD3427 on Day 1
32924897|NCT04630067|Placebo Comparator|Part A: Placebo|Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.
32924898|NCT04630067|Experimental|AZD3427: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
32723717|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
32924899|NCT04630067|Experimental|AZD3427: Cohort 2b|Participants with HF with EF ≥ 41% will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
32924900|NCT04630067|Experimental|AZD3427: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
32924901|NCT04630067|Experimental|AZD3427: Cohort 4b|Participants with HF with EF ≥ 41% will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
32924902|NCT04630067|Experimental|AZD3427: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
32924903|NCT04630067|Experimental|AZD3427: Cohort 6b|Participants with HF with EF ≥ 41% will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
32924904|NCT04630067|Placebo Comparator|Part B: Placebo|Participants with HFrEF or HF with EF ≥ 41% will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
32924905|NCT04589039||Participants with Ovarian Cancer|Participants diagnosed with ovarian cancer (including fallopian tube or primary peritoneal cancer) who have been prescribed with niraparib for the first time in a real-world setting, and who are in a complete or partial response to first-line platinum-based chemotherapy or who had complete or partial response to 2 or more line of platinum-based chemotherapy or who have been treated with 3 or more prior chemotherapy regimens with either breast cancer susceptibility gene (BRCA) mutation (irrespective of platinum sensitivity) or platinum-sensitive homologous recombination deficiency (HRD) positive will be observed prospectively over 24-month period, or until treatment discontinuation, or until end of study, which occurs first.
32924906|NCT04586387|Experimental|Active brain stimulation|
33400481|NCT05596656||allergic type 1 DM children|45 cases were considered allergic based on written questionnaire taken by the resident. Diagnosis of atopy was confirmed by skin prick testing
32723718|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
33400482|NCT05596656||Non-allergic type 1 DM children|Forty-five Non-allergic type 1 DM children were selected as age and sex matched control group.
33400483|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
32723719|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
32723720|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
33400484|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
33400485|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
32723721|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
32723722|NCT03478319|Experimental|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
33400486|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
33400487|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
33400488|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
32723723|NCT03478319|Experimental|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
32723724|NCT03478319|Experimental|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
32723725|NCT03478319|Experimental|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
32723726|NCT03478319|Experimental|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
32723727|NCT03478319|Experimental|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
32723728|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
32723729|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
32723730|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
32723731|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
32723732|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
32723733|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
32768208|NCT04852445||Stroke|We will include: 60 patients aged 18 years or older with clinical symptoms of hemispheric ischemic stroke due to occlusion of a large cerebral blood vessel, onset within 48 hours and NIHSS of 1 or more;
32723734|NCT05258123|Active Comparator|active drug|A fixed titration to 360mg （or nine tables） daily of Ginkgo biloba extract was administered with three times daily dosage throughout the study
32723735|NCT05258123|Placebo Comparator|placebo|A nine tables of placebo were administered with three times daily dosage throughout the study
32723736|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
32723737|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
32723738|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
32723739|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
32723740|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
32723741|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
32723742|NCT02200042|No Intervention|Observation|No radiation therapy
32723743|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
32723744|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
32768209|NCT04852445||Controls|30 healthy controls, age- and sex- matched with stroke study population
32924907|NCT04586387|Sham Comparator|Inactive brain stimulation|inactive TMS
32723745|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
32723746|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
32723747|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
32723748|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
32924908|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
33250123|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
33250124|NCT00757926|Experimental|1|
33250125|NCT00757926|Placebo Comparator|2|
32723749|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group A: Cohort A1|Participants with unresectable or metastatic melanoma (MEL) were planned to be included in this cohort, who did not receive prior systemic therapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
32723750|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group A: Cohort A2|Participants with advanced or metastatic non-small cell lung cancer (NSCLC) were planned to be included in this cohort, who have received no more than 1 prior line of platinum-based chemotherapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
32723751|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group B: Cohort B1|Participants with recurrent or metastatic serotonin norepinephrine reuptake inhibitor (SCCHN) were planned to be included in this cohort, who received no more than 1 prior line of platinum-based chemotherapy for recurrent or metastatic disease to receive epacadostat in combination with nivolumab and lirilumab at the MTD/PAD determined from dose escalation phase.
32723752|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
32723753|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
32723754|NCT05258045||SUV ratio of mediastinal blood pool to the lesion and SUV ratio of liver to lesion|Avidity of SUV of blood pool
32723755|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
32723756|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
32723757|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
32723758|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
32723759|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
32723760|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
32723761|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
32723762|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
32723763|NCT02817815|Active Comparator|Group 1|Volunteers
32723764|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
32723765|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
32723766|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
32723767|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
32723768|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
32723769|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
32723770|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
32723771|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
33250126|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
33250127|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
33250128|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
32924909|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
32924910|NCT04739579||Anastomotic Leak|
32924911|NCT04739579||Non-Anatomotic Leak|
32924912|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
32924913|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
32924914|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
32924915|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
33250129|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
33250130|NCT00387127|Placebo Comparator|Placebo|orally daily
33250131|NCT00683592|Experimental|1|vilazodone
32924916|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
33250132|NCT00683592|Placebo Comparator|2|
32924917|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
32723772|NCT05084729||Imagio OA/US|Imagio optoacoustic
32723773|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
32723774|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
32723775|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
32723776|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
32924918|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
32924919|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
33250133|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
32723777|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
32723778|NCT04987697|Other|Counseling and Surveys|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
32723779|NCT04961723|Experimental|MSM Postal delivery|Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing
32768210|NCT04852445||Carotid arterectomy after stroke|10 patients undergoing carotid endarterectomy within 30 days after stroke
32924920|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
32924921|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
32924922|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
32924923|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
32924924|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
32924925|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
33250134|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
33250135|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
33250136|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
33250137|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
33250138|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
33250139|NCT05434884|Experimental|OV group|Patients will receive occlusal veneer restorations
33250140|NCT05434884|Experimental|EN group|Patients will receive endocrown restorations
33250141|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
32924926|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
32924927|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
32924928|NCT00586391|Experimental|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.~*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
32924929|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
32924930|NCT04340375|Experimental|AP green tea extracts|8 weeks
32924931|NCT05436275|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks
32924932|NCT05436275|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks
32924933|NCT04707755|Experimental|Motor imagery technique|Motor Imagery technique Plus Conventional Physical therapy
32924934|NCT04707755|Active Comparator|Conventional Physical therapy|passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
32924935|NCT05432843|Active Comparator|Pregabalin|Treatment with pregabalin in the treatment of globus sensation
32723780|NCT04961723|Experimental|MSM Peer delivery|Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
32723781|NCT04961723|No Intervention|MSM control|Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
32723782|NCT04961723|Experimental|PWID peer delivery|Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
32924936|NCT05432843|Placebo Comparator|Placebo|Treatment with placebo in the treatment of globus sensation
32924937|NCT05411471|Experimental|Arm 1 (1 dose Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain(1200 SOU).
33250142|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
33250143|NCT05388006|Experimental|Treatment (acalabrutinib, durvalumab, venetoclax)|"Patients receive acalabrutinib PO BID on days 1-28, durvalumab IV over 1 hour on day 1, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-90. Treatment repeats every 90 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
32723783|NCT04961723|No Intervention|PWID control|Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
32723784|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
32723785|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
33250144|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
32723786|NCT02523521|No Intervention|Healthy children|Nothing.
32723787|NCT04458779|Experimental|CPAP group|Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.
32924938|NCT05411471|Experimental|Arm 2 (2 doses Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
32924939|NCT05411471|Experimental|Arm 3 (1 dose Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (1200 SOU).
32924940|NCT05411471|Experimental|Arm 4 (2 doses Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
32924941|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
32924942|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
32924943|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
32924944|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
32924945|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
32924946|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
32924947|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
32924948|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
32924949|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
32924950|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
32924951|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
32924952|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
32924953|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
32924954|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
32924955|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
32924956|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
32924957|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
32723788|NCT04458779|No Intervention|Usual-care group|Subjects will receive optimal standard therapy for acute stroke.
32723789|NCT01296581|Experimental|X-82|
32723790|NCT03223805|Other|Control Arm|Usual Care
32723791|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
33250145|NCT05354544|Experimental|SVF for treating scarred vocal folds|Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.
33250146|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
32924958|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
33250147|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
33250148|NCT04049916|Active Comparator|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
33250149|NCT04049916|Experimental|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
33250150|NCT04049916|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
33250151|NCT04049916|Active Comparator|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
32723794|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
32723795|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
32723796|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
32723797|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
32723798|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
32723799|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
32723800|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
32723801|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
32723802|NCT04404101|Active Comparator|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
32723803|NCT04404101|Active Comparator|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
32723804|NCT04339049|Experimental|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
32924959|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
32924960|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
32924961|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
32924962|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
32924963|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
32924964|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
32924965|NCT04878120|Active Comparator|Standard Hybrid Closed Loop Control (USS Virginia)|Use of Standard Hybrid Closed Loop Control
32723805|NCT04339049|Active Comparator|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
32924966|NCT04878120|Experimental|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Use of Hybrid Closed Loop Control with Enhanced Prandial Dosing
32723806|NCT04339049|Placebo Comparator|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
32723807|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
32924967|NCT02694029|Active Comparator|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
32924968|NCT02694029|Active Comparator|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
32924969|NCT04739033|Experimental|Experimental group|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
32924970|NCT04739033|Active Comparator|Control Group|The control group will receive the same webbased lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
32924971|NCT05407961|Experimental|LY3532226 + Dulaglutide (Part A)|LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC.
32924972|NCT05407961|Placebo Comparator|Placebo + Dulaglutide (Part A)|Placebo administered SC followed by dulaglutide administered SC.
32924973|NCT05407961|Active Comparator|Dulaglutide + Placebo (Part B)|Dulaglutide administered SC in combination with placebo given SC.
32924974|NCT05407961|Experimental|LY3532226 + Dulaglutide (Part B)|LY3532226 administered SC in combination with Dulaglutide given SC.
32924975|NCT05407961|Experimental|LY3532226 + Placebo (Part B)|LY3532226 administered SC in combination with placebo given SC.
32924976|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
32924977|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
33250152|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
32924978|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
32924979|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
32924980|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
32924981|NCT05406245||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
32924982|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
32924983|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
32924984|NCT05394545|Experimental|Nu-V3 treatment arm|Treatment with the Nu-V3 Device.
32924985|NCT05394545|No Intervention|Observation treatment arm (SOC, control)|Observation following stable standard of care.
32924986|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
33250153|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
33250154|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
32723808|NCT02198794|Experimental|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
32924987|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
32924988|NCT05373485|Experimental|Vaccine Group, low dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
32723809|NCT02198794|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
32723810|NCT02198794|Active Comparator|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
32924989|NCT05373485|Experimental|Vaccine Group, low dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
32924990|NCT05373485|Experimental|Vaccine Group, high dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
32924991|NCT05373485|Experimental|Vaccine Group, high dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
32924992|NCT05373485|Placebo Comparator|Placebo Group, low dose, 18-59 year-old|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
32924993|NCT05373485|Placebo Comparator|Placebo Group, low dose, 60 year-old and above|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
32723811|NCT02198794|Experimental|Part C: SD-809|EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
32924994|NCT05373485|Placebo Comparator|Placebo Group, high dose, 18-59 year-old|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
32924995|NCT05373485|Placebo Comparator|Placebo Group, high dose, 60 year-old and above|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
32924996|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
32924997|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
32924998|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
32924999|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
32925000|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
32925001|NCT05369897|Experimental|VR training|VR training for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least ~12 hours of training in total) for each participant, spread across three months. Each session will focus on cognitive training.
32925002|NCT05369897|Sham Comparator|VR activity|VR activity for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least ~12 hours of training in total) for each participant, spread across three months, with 360º images and videos but without the interactive cognitive training.
32925003|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
32925004|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
32723812|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
32723813|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
32723814|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
32723815|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
32723816|NCT04750252|Experimental|Subjects with moderate to severe OA of the Knee|
32723817|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
32723818|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
32723819|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
32925005|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
32925006|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
32925007|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
32925008|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
32925009|NCT05335187|Experimental|micro-macro electrode|In this single-arm, open-label study, all patients receive one or a handful of micro-macro electrode (MME) in place of conventional intracranial EEG electrodes.
32925010|NCT05648994|Experimental|TCR-T cells|TCR-T cells will be infused to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
32925011|NCT04869384|Experimental|Intervention|Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application
32925012|NCT04869384|Active Comparator|Usual care|Subjects do not receive reminders and feedback, but receive treatment as usual.
32925013|NCT04869306|Active Comparator|Hyaluronic acid|hyaluronic acid gel application after lower third molar removal
32925014|NCT04869306|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier after lower third molar removal
32925015|NCT04869306|No Intervention|Standard treatment|standard treatment after lower third molar removal (i.e., blood clot only)
32925016|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
32925017|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
32925018|NCT05648760|Other|Usual training|Participants randomized to the control condition received a standard training of how to communicate bad news to patients
32925019|NCT05648760|Experimental|Simulation training|Participants randomized to the simulation training group received simulation training based on a standard training of how to communicate bad news to patients
32925020|NCT05648682|Experimental|Saline|The patients in the group gargling with saline were given in a 500 ml bottle at each visit for one week of use. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
32925021|NCT05648682|Experimental|Sodium Bicarbonate|The sodium bicarbonate solution prepared by the researcher by mixing one teaspoon of baking soda (4.5 grams) into 500 ml of distilled water by the researcher was given to the patients in the group gargling with sodium bicarbonate for a one-week use at each interview. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
32925022|NCT05648682|Experimental|Thyme Honey|20 ml of honey was diluted in 100 ml distilled water bottles by the researcher to the patients in the group gargling with thyme honey. For a week's use, the patient was given five honey solutions in 100 ml bottles at one time at each visit. Patients were told that they should gargle using approximately two tablespoons of the solution given for each use.
32925023|NCT05648682|Experimental|Control|No solution was given to the patients in the control group by the researcher.
32925024|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
32925025|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
32723820|NCT04418128|No Intervention|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
32723821|NCT04418128|Experimental|Conventional therapy + Nafamostat mesylate|"The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).~Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.~Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.~Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
33250155|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
33250156|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
32925026|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
32925027|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
32925028|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
33250157|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
33250158|NCT05434650||Treatment group|Single arm group to receive ablation
33250159|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
33250160|NCT03625544|Active Comparator|Autograft|Autologous bone graft
32723822|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Qualified participants who receive first course of pembrolizumab but continue to experience disease progression may, at investigator's discretion, initiate a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to ~1 year).
32723823|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
32723824|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
32723825|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1|This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT
32768211|NCT04852445||Carotid endarterectomy for asymptomatic stenosis|3 patients without stroke undergoing carotid endarterectomy for asymptomatic carotid stenosis.
32925029|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
32925030|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
32925031|NCT05648604|Experimental|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardener mentor bi-monthly, and attending a gardening informational workshop once monthly.
32925032|NCT04859946|Experimental|Supportive care (itacitinib)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.~STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID."
33250161|NCT00575328|Experimental|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
33250162|NCT00575328|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo.
32768212|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
32768213|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
32768214|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
32768215|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
32768216|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
32768217|NCT04844645|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
32925033|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
32925034|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
32925035|NCT04738955|Experimental|High dose group|micafungin sodium ≥ 200, ≤ 300 mg/time, once a day, intravenous drip
32925036|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
32925037|NCT04182113|Experimental|1 Hz rTMS Stimulation|
32925038|NCT04182113|Experimental|20 Hz rTMS Stimulation|
32925039|NCT04182113|Sham Comparator|Sham rTMS Stimulation|
32925040|NCT04859400|Experimental|Intervention|"standardized nutritional program including a nutritional supplement~standardized exercise program~app for monitoring."
32925041|NCT04859400|No Intervention|Control|"standard of care~limited version of the app (e.g. without the help function)."
32925042|NCT04176575|Experimental|Acupuncture|"Eligible participants:~have advanced stage cancer and associated pain~will receive up to 12 acupuncture sessions~will attend sessions at UPMC's Center for Integrative Medicine~will complete study assessments at each visit~will complete a follow-up 4 to 6 weeks after their last acupuncture visit. Total study involvement will range from 16 to 18 weeks."
32768218|NCT04844645|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
32768219|NCT04259229|Experimental|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
32768220|NCT04259229|Active Comparator|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
33250163|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
33250164|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
33400489|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
32768221|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
32925043|NCT05648526|Experimental|ACTH4-10PRO8-GLY9-PRO10|The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of a short fragment of adrenocorticotropic hormone (ACTH). It is free from hormonal effects and has neuromodulatory effects.
33250165|NCT05434494|Active Comparator|remifentanil group|"Start the continuous infusion of 25cc of remifantanil (labeled as a test drug) by TCI mode ( the target effect site concentration is 2.0).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
32925044|NCT05648526|Active Comparator|ketamine 40 mg/kg BW subcutaneously|ketamine results in impaired brain function associated with neuroapoptosis injury in the immature brain.
32925045|NCT04170725|Experimental|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
32925046|NCT02268084|Sham Comparator|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
32723826|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2|This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.
32723827|NCT00908687|Experimental|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
32925047|NCT02268084|Active Comparator|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
32723828|NCT00908687|Experimental|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
32723829|NCT00908687|Experimental|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
32723830|NCT00908687|Experimental|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
32723831|NCT00908687|Experimental|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
32723832|NCT00908687|Experimental|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
32925048|NCT05333783|Experimental|Augmented Reality Exposure Therapy Based on ExposXR software|The intervention arm will receive the assigned intervention in one session. Participants will be called for 2 times for post-assessment.
32925049|NCT05333783|No Intervention|Treatment as Usual|The control arm has no intervention. However, the participants are not given any instruction limiting their encounters with the phobic stimuli. The participants in the control arm will receive the intervention after the post-assessments are completed.
32925050|NCT05561478||Test device (Synthesis Plus Toric)|Requiring bilateral cataract surgery with pre-existing astigmatism
32925051|NCT05561478||Control device (Synthesis Plus)|Requiring bilateral cataract surgery
32925052|NCT05320601|Experimental|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation 1 session
32925053|NCT05320601|Experimental|Dry Needling|Dry Needling 1 session
32925054|NCT05300711|Experimental|Opportunistic salpingectomy|The participating surgeons will attempt to perform bilateral salpingectomy in addition to the colorectal surgery.
33250166|NCT05434494|Placebo Comparator|control group|"Start the continuous infusion of 25cc of normal saline (labeled as a test drug).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
33250167|NCT05433792|Experimental|Myolens CN|Subjects' will be allocated to Myolens CN study arm in a 1:1:1 ratio.
32723833|NCT05155475||Patient with jaundice|
32723834|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
32723835|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
32723836|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
32723837|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
32723838|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
32723839|NCT05154617|Other|Standard surgical monitoring, along with the Flo Trac® system monitoring.|
32723840|NCT03990077|Experimental|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
32723841|NCT03896789|No Intervention|Baseline|All sites will collect usual care data from 9 months to 21 months.
32723842|NCT03896789|Experimental|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
32723843|NCT03896789|No Intervention|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
32925055|NCT05300711|Active Comparator|Colorectal surgery only|Participants will receive the standard of care, that is colorectal surgery.
32925056|NCT04420338|Experimental|Chronic hemodialysis patients|
32925057|NCT04420338|Experimental|Caregivers of chronic hemodialysis patients|
32925058|NCT04015817|Experimental|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
32925059|NCT05558748|Active Comparator|Pediatric patients undergoing inguinal surgeries with USG-guided Caudal block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Caudal block for analgesia
33250168|NCT05433792|Experimental|Myolens CF|Subjects' will be allocated to Myolens CF study arm in a 1:1:1 ratio.
32723844|NCT05134415|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS tobacco flavor 1 Period 2 - RELX ENDS tobacco flavor 2
32925060|NCT05558748|Active Comparator|Pediatric patients undergoing inguinal surgeries with USG-guided Ilioinguinal/Iliohypogastric block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Ilioinguinal/Iliohypogastric block for analgesia
32925061|NCT05557968|Active Comparator|Conventional Therapy|"Active range of motion exercises.~Passive range of motion exercises~Balance exercises.~On-ground gait training without watching videos"
32925062|NCT05557968|Experimental|Action Observation Therapy (AO)|Conventional therapy in addition to observing images related to stair walking will be observed and physical training will performed to imitate tasks with a physical therapist. While observing the image, they will be instructed to think that their body was performing the movement of the image
32925063|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
32925064|NCT05648370||oligometastatic disease|Dynamic blood samples before and after surgery and tissue samples from oligometastatic NSCLC undergone surgery will be obtained for exploratory analysis.
32925065|NCT05648292||Clinical group|45 individuals with relapsing-remitting multiple sclerosis
32925066|NCT05648292||Control group|45 individuals with no chronic disease, matched in age, gender and level of education
32925067|NCT04868994|Experimental|ENMG and muscle analyses on whole body muscles MRI.|Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
32925068|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
32925069|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
32925070|NCT01643772|Experimental|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
32925071|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
32925072|NCT01643772|Experimental|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
32925073|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
32925074|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
32925075|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
32925076|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
32925077|NCT05299853|Experimental|Robotic Rehabilitation|
32925078|NCT05299853|Active Comparator|Conventional Rehabilitation|
32925079|NCT04868838|Experimental|Daratumumab|Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).
33250169|NCT05433792|Active Comparator|MiSight®|Subjects' will be allocated to MiSight® study arm in a 1:1:1 ratio.
33250170|NCT00753870|Experimental|A|Otherwise healthy smokers
33250171|NCT00553696|Experimental|A|
33250172|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
32925084|NCT05286359|Experimental|NxTekTM Malaria Plus Rapid Diagnostic Test (RDT) Devices|
32925085|NCT05278715|Experimental|optic pathway glioma|
32925086|NCT05233085|Experimental|AZD4041|Daily oral dose given by syringe directly into the mouth
32723845|NCT05134415|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS tobacco flavor 2 Period 2 - RELX ENDS tobacco flavor 1
32925087|NCT05233085|Placebo Comparator|Placebo|Daily oral dose given by syringe directly into the mouth
32925088|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
33250173|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
33250174|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
33250175|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
33250176|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
33250177|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
33250178|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
33250179|NCT00754026|Active Comparator|1|
33250180|NCT00754026|Active Comparator|2|
33250181|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
33250182|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
33250183|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
33250184|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
33250185|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
33250186|NCT00754104|Experimental|A|
33250187|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
32925089|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
32925090|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
32925091|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
32925092|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
32925093|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
32925094|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
32925095|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
32925096|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
32925097|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
32925098|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
32925099|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
32925100|NCT05215925|Experimental|A|
33250188|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
33250189|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
33250190|NCT05300230||Patients with Zti Opticon Cochlear Implant|Patients that are users of Neuro Zti and Neuro 2 processor with a minimum of 6 months of habituation after the implementation.
33400490|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
33400491|NCT05594706||Newly diagnosed patients with T1DM|The investigators will do prospective measures in 10 to 15 children aged 2 to 18 years, at the time of diagnosis, four months after diagnosis and one year after diagnosis.
32925101|NCT05215925|Experimental|B|
32925102|NCT05215925|Experimental|C|
32925103|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
33250191|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
33250192|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
33250193|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
33250194|NCT05352412|Active Comparator|Baseline Counseling As Usual|Patients randomized to the baseline counseling as usual arm will receive provision of one of 3 MAT options, prescription and referral to community providers; overdose prevention education and access to naloxone kits; harm reduction counseling (e.g safe injection practices, referral to PrEP); lab testing for HIV, HBV, HCV infection, and routine vaccinations (e.g. Hepatitis A). That includes wrap-around services modeled on the Ryan White Program, with access to social worker, case manager, and mental health counselor who follow up with patients, enroll them in insurance as eligible, and provide ongoing support. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.
32723846|NCT05134415|Experimental|Product Use Sequence 3|Period 1 - RELX ENDS menthol flavor 1 Period 2 - RELX ENDS menthol flavor 2
32723847|NCT05134415|Experimental|Product Use Sequence 4|Period 1 - RELX ENDS menthol flavor 2 Period 2 - RELX ENDS menthol flavor 1
32723848|NCT03461861|Experimental|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
32723849|NCT03461861|Experimental|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
32723850|NCT04458389|Experimental|TY101|"Dose escalation：Humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg (fix dose) until disease progresses or unacceptable tolerability occurs.~Dose expansion：After completion of the DLT observation, the sponsor and principal investigator will select a possible dose（RP2D）for dose expansion to further confirm the efficacy and safety of RP2D."
32925104|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
32925105|NCT05159687|Active Comparator|Atomoxetine|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine.
32723851|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.~Triple therapy regimen:~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
32723852|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
32723853|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
32925106|NCT05159687|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
33400492|NCT05594706||Patients with T1DM of different duration|As the functional beta-cell mass gradually declines as disease duration increases, the investigators will do measurements in a cohort of children aged ≤ 18 years, with increasing diabetes duration. The investigators plan to analyze groups of 5 patients with a disease duration of 3 (36 - 47 months), 5 (60 - 71 months) and 10 years (120 - 131 months), respectively.
32723854|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
32723855|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
32723856|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
32723857|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
32723858|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
32723859|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
32723860|NCT04902677||School|
32723861|NCT04749173|Experimental|Cohort 1 (96 mg)|- Ventrogluteal area: 48 mg/0.2 mL x 2 sites
32723862|NCT04749173|Experimental|Cohort 2 (432 mg)|"Deltoid area: 72 mg/0.3 mL x 2 sites~Ventrogluteal area: 144 mg/0.6 mL x 2 sites"
32723863|NCT04749173|Experimental|Cohort A (144 mg)|- Deltoid area: 72 mg/0.3 mL x 2 sites
32723864|NCT04749173|Experimental|Cohort B (144 mg)|- Ventrogluteal area: 72 mg/0.3 mL x 2 sites
32723865|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
32723866|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
32723867|NCT04745897|Experimental|eTB Catalogue of Recommendation (eTB)|New eTB catalogue of recommendations website (eTB).
32723868|NCT04745897|Active Comparator|World Health Organization Tuberculosis Website (WHO TB)|Current method of accessing tuberculosis (TB) recommendations using World Health Organization (WHO) website (WHO TB).
32723869|NCT04670159|Experimental|Online Education Group|
32723870|NCT04670159|Experimental|Brochure Group|
32723871|NCT04461821||obstructive bronchitis/bronchiolitis|
32723872|NCT04461821||pneumonia|
32723873|NCT04461821||asthma|
32723874|NCT04461821||neurological diseases|
32925107|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
32925108|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
32925109|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
32925110|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
32723875|NCT04461821||type 1 diabetes (T1D)|
32723876|NCT04461821||pharmacotherapy with bronchodilators|
32723877|NCT04461821||pharmacotherapy with antibiotics|
32925111|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
32925112|NCT03754127|Experimental|Active group|tDCS
32925113|NCT03754127|Sham Comparator|Sham group|Sham tDCS
32925114|NCT03730883|Experimental|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
32925115|NCT03730883|Active Comparator|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
32925116|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
32925117|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
32723878|NCT04461821||pharmacotherapy with antiviral medication|
32723879|NCT04461821||pharmacotherapy with antifungal medication|
32925118|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
32723880|NCT04461821||pharmacotherapy with antiepileptic medication|
32925119|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
32723881|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
32723882|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
32723883|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
32723884|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
32723885|NCT04396691||Students group|Group of students at the reactor school.
32723886|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
32723887|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
32723888|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
32723889|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
32723890|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
32723891|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
32723892|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
32723893|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
32723894|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
32723895|NCT03665363|Experimental|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
32723896|NCT03665363|Active Comparator|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
33400495|NCT04797000|Experimental|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
32723897|NCT03665363|No Intervention|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
32723898|NCT05159141|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
32723899|NCT05159141|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
32925120|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
32925121|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
32925122|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
32925123|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
32925124|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
32925125|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
32723900|NCT05158985|Experimental|group A|diclofenac sodium phonophoresis using continuous ultrasound with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
32723901|NCT05158985|Experimental|group B|diclofenac sodium phonophoresis using pulsed US with 1:1 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
32723902|NCT05158985|Experimental|group C|diclofenac sodium phonophoresis using pulsed US with 1:4 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 10 minutes
32723903|NCT05158985|Experimental|group D|exercises only in form of (strengthening, stretching and occupational exercises).
32723904|NCT03602495|Experimental|Donafenib|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
32723905|NCT03602495|Placebo Comparator|Placebo|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
32723906|NCT03259373|Experimental|Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
32925126|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
32925127|NCT05109143|Active Comparator|Group B|Standard Medical Treatment
32723907|NCT03259373|Experimental|Control|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
32723908|NCT03226847|Experimental|Pulmonary Vein Isolation|ablation
32723909|NCT05158673|Placebo Comparator|Group A (Placebo)|The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks.
32723910|NCT05158673|Active Comparator|Group B (Flavonoid)|Two capsules of 500 mg of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours for 12 weeks.
32723911|NCT03208907|Active Comparator|CQ coadministered with PQ|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine was administered for 14 days (0.50mg/kg/day)
32723912|NCT03208907|Experimental|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine was administered according to the weight and Primaquine (0.50mg/kg/day)
32723913|NCT03208907|Experimental|CQ and PQ starting on Day 42|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine started on Day 42 for 14 days (0.50mg/kg/day)
32723914|NCT03208907|Experimental|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine was administered for 3 days according to the weight and Primaquine started on Day 42 for 14 days (0.50mg/kg/day)
32723915|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
32723916|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
32723917|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
32723918|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
32723919|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
32723920|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
32723921|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
32723922|NCT05157893|Experimental|VR analgesic therapy|Patients receive a single VR therapy lasting 15 min.
32723923|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
32723924|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
32925128|NCT05109143|Experimental|Group A|Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
32925129|NCT03614663|Experimental|ZYN002 - Cannabidiol transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg cannabidiol Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg cannabidiol Q12H or placebo."
32925130|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
32925131|NCT05648136|Experimental|patients|"Women aged 18 to 39 years~with a history of RIF or unexplained RM~with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)~with a basal FSH level <10IU/l and AMH level >1.5ng/ml~with a regular menstrual cycle of 30+/-5 days~receiving a new cycle of in vitro fertilization (IVF) +/- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +/-ICSI for patients in the RM group~received written and oral information and signed an informed consent"
32925132|NCT05648136|Active Comparator|control|"Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)~Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+/-ICSI procedure for secondary infertility~Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication."
33400496|NCT04797000|Placebo Comparator|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
33400497|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
32925135|NCT03614507|Experimental|FreeO2 group|Automatic oxygen flow titration
32925136|NCT03614507|Active Comparator|Manual group|Manual oxygen flow titration
32925137|NCT00085735|Experimental|Arm I (3-7 years of age, LDCSI, IFRT)|See Detailed Description (Arm I)
32925138|NCT00085735|Experimental|Arm II (3-7 years of age, LDCSI, PFRT)|See Detailed Description (Arm II)
32925139|NCT00085735|Experimental|Arm III (3-7 years of age, SDCSI, IFRT)|See Detailed Description (Arm III)
32925140|NCT00085735|Active Comparator|Arm IV (3-7 years of age, SDCSI, PFRT)|See Detailed Description (Arm IV)
32925141|NCT00085735|Experimental|Arm V (8-21 years of age, SDCSI, IFRT)|See Detailed Description (Arm V)
32925142|NCT00085735|Active Comparator|Arm VI (8-21 years of age, SDCSI, PFRT)|See Detailed Description (Arm VI)
32925143|NCT04868370||Multiple Sclerosis (MS)|
32925144|NCT04868370||Healthy Subject|
32925145|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
32723925|NCT05157815|Experimental|Soluble Corn Fibre|12g compound per Sachet (providing 10g fibre) consumed twice per day
32723926|NCT05157815|Placebo Comparator|Maltodextrin|Calorie matched control of 2 g compound per sachet (0 g fibre), composed of: Maltodextrin, consumed twice per day
32723927|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
32925146|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
32925147|NCT05548452|Experimental|Intestinal Microbiota Transplant capsules|Capsules will be provided twice during the trial
32723928|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
32925148|NCT05548452|Placebo Comparator|Placebo capsules|Capsules will be provided twice during the trial
32925149|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
32723929|NCT05157737||BFNS group|(1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.
32723930|NCT05157737||DEE group|(1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.
32723931|NCT04457921|Experimental|Deep tissue massage|deep tissue massage applied group
32723932|NCT04457921|No Intervention|Standard of care|group without deep tissue massage
32723933|NCT02180243|Experimental|Yoga/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
33400498|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
33400499|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
33400500|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
33400501|NCT03674450|Experimental|Interventional|
32723934|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
32743436|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
32925150|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
32723935|NCT05157347|Experimental|Robot-assisted Training Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks. The robot-assisted training group is given 30 min conventional gait training and another 30 min (excluding robot attachment and detachment time) gait training using an exoskeletal wearable robot, while the control group is given 1 hr conventional gait training for the same time as the robot-assisted training group. In all participants in each group, no other robot-assisted rehabilitation such as Lokomat, Erigo, or Morning Walk could be performed.
32723936|NCT05157347|Other|Control Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks.
32723937|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
32723938|NCT05138315|Experimental|Study Group|Alleye App and M-chart examinations will be performed pre- and postsurgically.
32723939|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
32723940|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
32723941|NCT05121857||ACLR group|Individuals who are 7 months post primary ACLR
32723942|NCT05121857||healthy control group|Healthy uninjured individuals who are actively playing sport and have not sustained any knee injuries, ankle injuries or concussions.
32723943|NCT05115071|Experimental|Experimental|
32723944|NCT05115071|No Intervention|No intervention|
32723945|NCT04457609|Placebo Comparator|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
32723946|NCT04457609|Experimental|Experiment Group|Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
32723947|NCT05157269|Active Comparator|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
32723948|NCT05157269|Placebo Comparator|Placebo|Placebo tablets
32723949|NCT04457765|Experimental|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
32723950|NCT04457375||Healthy Adults|Healthy
32723951|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
32723952|NCT03130907|Active Comparator|Stent|
32723953|NCT03130907|Experimental|No stent|
32723954|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
32723955|NCT03130751|Experimental|Mobile application|
32723956|NCT05156801|Experimental|ArchSinus stent|Post-FESS implantation of the study device (ArchSinus) into ethmoid sinus cavity
32723957|NCT05156801|Active Comparator|Propel stent|Post-FESS implantation of the comparator device (Propel) into ethmoid sinus cavity.
32723958|NCT05156801|Active Comparator|NasoPore packing|Post-FESS implantation of the comparator device (NasoPore) into ethmoid sinus cavity.
32723959|NCT04865393|Experimental|SPR206|SPR206 100mg single-dose IV infused over 1 hour
32723960|NCT04806971||Periodontitis|Patients with grade B / C, stage III periodontitis were classified based on the new classification criteria.Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the root middle third. Grade was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (Grade B=0.25-1.0, Grade C= >1.0).
32723961|NCT04806971||Healthy|The periodontally healthy subjects without any clinical sign of inflammation,not showing a history of periodontitis; PD ≤3 mm; <10% of sites with BOP; an absence of detectable bone loss and/or attachment ; without extensive caries or restorations and presence of at least 28 permanent teeth. In addition, all the control subjects showed the absence of any local or systemic pathology.
32723962|NCT04805879|Active Comparator|FMT capsules|"Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.~PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that"
32723963|NCT04805879|Placebo Comparator|Placebo oral Capsules|Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.
32723964|NCT04457999|Experimental|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
32723965|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
32723966|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
32723967|NCT05156489|Experimental|Fractionated Laser|
32723968|NCT05156021|Experimental|pre-vitrectomy anti-VEGF injection group|Intravitreal injection of anti-VEGF drugs 3-5 days before surgery, followed by PPV combined with PRP and pressure-reducing valve implantation
32723969|NCT05156021|Experimental|post-vitrectomy anti-VEGF injection group|At the same time as the PPV combined with PRP and pressure reducing valve implantation was completed, intravitreal injection of anti-VEGF drugs was performed
32723970|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
32723971|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
32723972|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
32723973|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
33250195|NCT05352412|Active Comparator|Shared Decision Making Aid|Patients randomized to the decision aid arm will receive all of the above as well as a shared decision making aid. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.The provider will have access to then have access to this summary in making final care decisions with the patient.
32925151|NCT05546502|Experimental|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
32723974|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
32723975|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
32925152|NCT05546502|Active Comparator|Active Comparator|2 doses of Covovax® - administered with 28 days interval (0.5 mL per dose)
32925153|NCT04338737|Active Comparator|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
32925154|NCT04338737|Active Comparator|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
32925155|NCT04338737|Active Comparator|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
33250196|NCT00859365|Experimental|Acupuncture|Real Acupuncture
32925156|NCT05544786|Active Comparator|Treatment A: Nirmatrelvir/ritonavir|Nirmatrelvir and ritonavir tablets
32925157|NCT05544786|Experimental|Treatment B: Nirmatrelvir/ ritonavir|Nirmatrelvir/ritonavir with water
32925158|NCT05544786|Experimental|Treatment C: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with infant formula
32925159|NCT05544786|Experimental|Treatment D: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with vanilla pudding
32925160|NCT05544786|Experimental|Treatment E: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with food and vanilla pudding
32925161|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
32925162|NCT05544396|Experimental|probiotic group|Routine eradicate treatment H. pylori, and probiotics (2 packs per day) for 6 months.
32925163|NCT05544396|Placebo Comparator|control group|Only routine eradicate treatment H. pylori.
32925164|NCT04420104|Experimental|esp block group|
33250197|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
32925165|NCT04420104|Active Comparator|control group|
33250198|NCT00859365|No Intervention|3 No treatment|No treatment performed
33400502|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
32723978|NCT05151497|Experimental|Experimental group: Halliwick + Método Watsu|"The experimental group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 45 minutes of Halliwick, 15 minutes of Watsu and finally 15 minutes of immersion in hot water. .~In the application of the Halliwick Concept, it will be carried out in a pool at a temperature of 30ºC, and through the Ten Points Program.~To carry out Watsu, the pool water must be at a temperature of 35ºC. The Watsu Basic Maneuver will be performed, consisting of a sequence of various positions where the subject must be as relaxed as possible, placed in a supine position, floating with eyes closed, and supported by the physiotherapist who is standing, with a wide base of support."
32723979|NCT05151497|Active Comparator|Control group:Halliwick|The control group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 60 minutes of Halliwick and 15 minutes of immersion in hot water. Treatment using the Halliwick Concept is carried out in a pool where the water temperature is 30ºC, following the Ten Points Program.
32743437|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
32925166|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
32925167|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
32925168|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
32925169|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
32925170|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
32925171|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.~Standard wound care is given independent of this study."
32925172|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
32925173|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
33400503|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
33400504|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
33400505|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
33400506|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
32925174|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
32925175|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
32925176|NCT01881373|Other|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
32925177|NCT01881373|No Intervention|Temporal|Communities assessed for temporal trends in anthropometry.
33400507|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
33400508|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
32925178|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
32925179|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
32925180|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
32925181|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
32723980|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - NHL|Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Mantle Cell Lymphoma (MCL), large cell lymphoma (LCL), and peripheral T-cell lymphoma (PTCL). Subjects must have relapsed or be refractory to at least 2 prior lines of therapy and have either failed or were not eligible for any available therapies expected to provide clinical benefit.
32925182|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
32925183|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
32925184|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
32723981|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - AML|Subjects with relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria, who have either relapsed or are refractory to previously available therapy.
32723982|NCT04476251|Experimental|Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy|E7 TCR T Cell Therapy
32723983|NCT05075681|Experimental|Ruxolitinib combined with Chidamide|All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
32723984|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
32723985|NCT03472001|Active Comparator|Lecture group|1-hour lecture
32723986|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
32723987|NCT05005793|Experimental|Sodium bicarbonate|Oral sodium bicarbonate at a dose of 0.5 mEq/kg-lean body weight/day
32723988|NCT05005793|Placebo Comparator|Placebo|Oral placebo at a dose of 0.5 mEq/kg-lean body weight/day
32723989|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
32723990|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
32723991|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
32723992|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
32723993|NCT04939181|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
32723994|NCT04939181|Placebo Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
32925185|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
32925186|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
32925187|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
32925188|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
32925189|NCT05107427|Experimental|MRx0518 + Avelumab|Subjects will receive 1 capsule of MRx0518 BID throughout the treatment period and IV infusion of Avelumab every 2 weeks in 4-week cycles
32768222|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
33073402|NCT02193425|Experimental|PET FDG &amp; MRI Scans|The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
33073403|NCT02190266||Patients|Patients with confirmed refractory and/or disseminated coccidioidomycosis.
33400509|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
33400510|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
33400511|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
33400512|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
32925190|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
32925191|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
32925192|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
32925193|NCT05061407||Paediatric surgical patients|All patients < 18 years old, admitted to participating hospitals during the study period who undergo elective and non-elective surgery
32925194|NCT03445949|Other|30 days DAPT and long-term treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
32925195|NCT03445949|Other|6 months DAPT and long-term treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
32925196|NCT03445949|Other|30 days DAPT and 6 months treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
32925197|NCT03445949|Other|6 months DAPT and 6 months treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
32925198|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
32925199|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
32925200|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
32925201|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
32925202|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
32925203|NCT03424499|Experimental|Reused catheter with 0.5% benzalkonium chloride|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization and stored in a container with 0.5% benzalkonium chloride.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
32723995|NCT04776473|Experimental|Open (i.e. surgical) treatment|"This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient MMF~arch bars / screws / splint use for passive mobilization of the mandible"
32723996|NCT04776473|Other|Closed (i.e. conservative) treatment|"To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max)~arch bars / screws / splint use for passive mobilization of the mandible"
32723997|NCT03902093|Experimental|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
32723998|NCT03855449|Other|Task Analysis Intervention Group|DECIDE problem-solving curriculum will be delivered in a group setting.
33400513|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
32925204|NCT03424499|Experimental|Reused catheter with soap and water|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
32925205|NCT05735743|No Intervention|Standard of Care|Standard of Care
32925206|NCT05735743|Experimental|Participants receiving intervention|Motivational interviewing intervention
32925207|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
32925208|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
32925209|NCT05020145||Immunocompromised|Vaccinated Subject with 1 or >1 immunocompromising conditions.
32925210|NCT05020145||Non-Immunocompromised|Vaccinated subjects without evidence of immunocompromising condition.
32925211|NCT05020145||Total Population (immunocompromised and non)|Vaccinated Subjects with or without 1 or >1 immunocompromising conditions.
32925212|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
32925213|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
32925214|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
32925215|NCT04984109|Sham Comparator|Control group|Patients will receive preoperative US-guided will receive sham PENG with an injection of just 1mL saline.
33073404|NCT02169310|Experimental|1|up to 40 adult TBI patients between the ages of 18 and 60
33400514|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
32925216|NCT04984109|Experimental|PENG Group|Patients will receive preoperative US-guided will receive real PENG with an injection of 20mL of bupivacaine 0.25%+ 0.2mg/mL dexamethasone.
32724000|NCT03795233|Experimental|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
32724001|NCT03795233|Active Comparator|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
32724002|NCT03645863|Experimental|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
32724003|NCT03645863|Experimental|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
32724004|NCT03645863|Experimental|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
32724005|NCT03564119|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
32724006|NCT03564119|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
32724007|NCT04457063|Experimental|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
32724008|NCT04531241|Experimental|Test/Control|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
32724009|NCT04531241|Experimental|Control/Test|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
32724010|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
32724011|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
32724012|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
32724013|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
32724014|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
32724015|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
32724016|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
32724017|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
32724018|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
32724019|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
32724020|NCT04351061|Experimental|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
32724021|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
32724022|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
32724023|NCT04318145|Experimental|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
32724024|NCT04318145|Experimental|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
32724025|NCT04206761|Experimental|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
32724026|NCT04206761|Active Comparator|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
32724027|NCT03931187|Experimental|Women intervention arm|Intervention will be applied to the women within the couple.
32724028|NCT03931187|Experimental|Couple intervention arm|Intervention will be applied to the couple, both men and women.
32724029|NCT03931187|No Intervention|Control arm|The couple will receive the normal nursing care.
32724030|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
32724031|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
32724032|NCT02726009|Experimental|Degarelix|
32724033|NCT03914105|Active Comparator|Without music|Test without music
32724034|NCT03914105|Experimental|With music|
32724035|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32925217|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
32925218|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
32925219|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
32925220|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
32925221|NCT05735665|Experimental|study group: the bowel Ultrasound-based treat to target arm|"At W12 ± 4 and W24 ± 4, subjects will perform FC and bowel US and PRO will be recorded.~If rectal bleeding > 2 + stool frequency > 2 AND FC > 250 mcg/g AND/OR MUC > 6.2, treatment will be changed according to GCP and international guidelines."
32925222|NCT05735665|Other|control group: the routine Colonoscopy treat to target arm.|"At W12 ± 4 and W24 ± 4, subjects will perform FC and PRO will be recorded for all patients.~If rectal bleeding > 2 + stool frequency > 2 AND FC > 250 mcg/g, treatment will be changed according to GCP and international guidelines. If rectal bleeding > 0 + stool frequency > 2 AND FC will be ≥ 50 mcg/g and ≤ 250 mcg/g, a RSS will be done in order to decide any treatment switch."
32925223|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
32925224|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
32925225|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
32925226|NCT02737397|Placebo Comparator|placebo|placebo and placebo
32925227|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
32925228|NCT04983875|Experimental|BAC-enhanced group|944 participants will receive a post-mammography results letter which includes information on their BAC results.
32925229|NCT04983875|Other|Waitlist control group|944 participants will receive a post-mammography results letter without BAC information, which is the current standard of care. These patients will receive BAC information following study completion (approximately 6 months after mammography).
32925230|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32925231|NCT04938323|Experimental|BCG Vaccine|Participants randomized to the BCG Vaccine Arm will receive the vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
32925232|NCT04938323|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines': upper arm.
32724036|NCT03668639|Other|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
32925233|NCT05446493|Active Comparator|Tadalafil group|Each patient will be treated by tadalafil 5mg daily for 3months
32925234|NCT05446493|No Intervention|control group|Estimation of serum YKL-40, platelet indices and serum total testosterone in healthy individuals in camparing with tadalafil group
32925235|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
32925236|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
32724037|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
32724038|NCT03556319|Placebo Comparator|Placebo|Placebo
32724039|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
32724040|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
32724041|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
32724042|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
32724043|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
32724044|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
32724045|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
32925237|NCT05446103|Experimental|BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with low-load resistance BFR training (30% of 1 RM)
32925238|NCT05446103|Sham Comparator|Sham BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with high-load resistance training with sham BFR (65% of 1 RM)
32925239|NCT04934033|Other|Healthy volunteers|The participants will constitue a cohort of healthy volunteers, they will have a MRI, and language and cognitive assessment.
32925240|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
32925241|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
32925242|NCT04895501|Active Comparator|running with stiff shoes|21 km of running with stiff shoes followed by a time-to-exhaustion run.
32925243|NCT04895501|Experimental|running flexible shoes|21 km of running flexible shoes followed by a time-to-exhaustion run.
32925244|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
32724046|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
32724047|NCT03471689|Experimental|Mindfulness|
32724048|NCT03471689|Active Comparator|Positive reappraisal|
32724049|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
32724050|NCT05160857|Experimental|test group|
32724051|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
32724052|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
32925245|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
32925246|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
32925247|NCT04879355|Experimental|Spinal needle|Fine needle aspiration from thyroid nodules using af spinal needle.
32724053|NCT05160779|Active Comparator|Mild/asymptomatic cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed mild or asymptomatic conditions.
32724054|NCT05160779|Active Comparator|Serious cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed severe pathology.
32724055|NCT05160623|Experimental|Study eyes|Once-daily eyelid hygiene with povidone-iodine 1%
32925248|NCT04879355|Active Comparator|Conventional fine needle|Fine needle aspiration from thyroid nodules using af conventional fine needle, which is traditionally used.
32925249|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
32925250|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
32925251|NCT05445635|Experimental|Iriscope|
32925252|NCT05445635|Active Comparator|EBUS|
32925253|NCT05445635|Experimental|Combined Iriscope + EBUS|
32925254|NCT00368771|Active Comparator|1|IBS Stress Management
32925255|NCT00368771|Active Comparator|2|IBS Symptom Management
32925256|NCT00368771|Active Comparator|3|IBS Educational Training
32925257|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
32925258|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
32925259|NCT04864145|Active Comparator|Medical therapy|Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
32925260|NCT04864145|Experimental|Transcatheter Aortic Valve Implantation|Patients in TAVR group will receive transcatheter aortic valve replacement.
32925261|NCT04738565|Experimental|Probiotic|The mixture of 3 probiotic strains in the following proportions: 50% Lactobacillus casei ŁOCK 0919, 25% Lactobacillus rhamnosus ŁOCK 0908, 25% Lactobacillus rhamnosus ŁOCK 0900 (Latopic® preparation, Biomed S.A., Cracow, Poland).
32724056|NCT05160623|Active Comparator|Control eyes|Once-daily eyelid hygiene with available lid wipes
32724057|NCT03469661||Immune Thrombocytopenia Diagnosis|
32724058|NCT03469661||Myelodysplastic Syndrome Diagnosis|
32724059|NCT04713137|Active Comparator|Erythritol|20 volunteers receive 50g erythritol dissolved in 300mL tap water as an oral pre-load.
32925262|NCT04738565|Placebo Comparator|Maltodextrin|Maltodextrin - a substance in which probiotic strains have been suspended.
32925263|NCT02573753|Experimental|sleep restriction|Sleep restriction
32925264|NCT02573753|No Intervention|normal sleep|Normal sleep
32925265|NCT02573753|Experimental|weight gain|Weight gain
32925266|NCT04855253|Experimental|Dose level 1 : E7777 at 5 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
32925267|NCT04855253|Experimental|Dose level 1 : E7777 at 7 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
32925268|NCT04855253|Experimental|Dose level 1 : E7777 at 9 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
32925269|NCT04855253|Experimental|MTD from phase 1|Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
32724060|NCT04713137|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
32925270|NCT04818671|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
32925271|NCT05445011|Experimental|TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Patients will receive lymphodepletion with fludarabine (25 mg/kg) and cyclophosphamide (250 mg/kg) for 3 days on day -7~-2, followed by the infusion of TAA05 Cell with the dose of 1×10^8, 2×10^8 or 4×10^8 cells on day 0. If no dose-limited toxicity(DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. After the end of dose climbing, if the maximum dose group(MTD) is still not observed, the highest dose group is defined as MTD.
33400515|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
32724061|NCT04713137|Active Comparator|Sucralose|20 volunteers receive 0.0558g sucralose dissolved in 300mL tap water as an oral pre-load.
32724062|NCT04713137|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
32925272|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
33073405|NCT02169310|Active Comparator|2|up to 40 adult healthy volunteers between the ages of 18 and 60
33400516|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
33400517|NCT03107520|Experimental|DDH Surgical Reduction Patients|Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.
32768223|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
32768224|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
32768225|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
32768226|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
32768227|NCT04851743|Experimental|Dry needling Group|Participants will be used as their own controls, with 1 lower extremity randomly receiving intervention. The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
32768228|NCT04851743|No Intervention|Control Group|Participants will be used as their own controls, with 1lower extremity randomly receiving intervention. The control extremity did not receive any intervention, and outcomes were assessed 2 minutes apart.
32768229|NCT05392959|Placebo Comparator|Placebo group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive a placebo (1 tablet) administered orally daily during 24 weeks
32768230|NCT05392959|Experimental|dapagliflozin group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive Dapagliflozin 10 mg (1 tablet) administered orally daily during 24 weeks
32768231|NCT04851977|Experimental|Cohort 1: low dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
32768232|NCT04851977|Placebo Comparator|Cohort 2: low dose|IM injection on Day 0 and at Day 30 (12 active, 3 placebo) with follow up at 7 days post vaccination (Day 7 ± 1 day and Day 37 ± 1 day) and Day 60 ± 5 days and a final follow up/ EOS teleconference assessment at Day 90 ± 5 days.
32768233|NCT04851977|Experimental|Cohort 3: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
32768234|NCT04851977|Placebo Comparator|Cohort 4: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
32768235|NCT04851431|Experimental|One-to-One Peer Mentoring|Caregiver will be matched based on characteristics such as age, date of patient injury, level of patient injury, cause of patient injury, marital status, work status before and after patient injury, interests, and leisure activities. After participant is matched with a peer mentor, they will be required to have at least one weekly one-to-one interaction from time of match until 30 days post- discharge.
32768236|NCT04851431|Active Comparator|Usual Care|Participants received the usual discharge planning and family support services offered by the ABI program. These services include nurse instruction in care routines, case management support for discharge, peer support services, referral to family counseling and community services as indicated, and general information resources about brain injury. Participants in both the intervention and usual care groups also had access to the online peer support community created for ABI caregivers (facebook.com/shepherdbi.peers). In addition, usual care participants could request one-to-one visits with peer mentors and, indeed, most usual care participants received at least one peer mentoring visit.
32768237|NCT05370495|Experimental|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
32768238|NCT05370495|Experimental|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
32768239|NCT05370495|Experimental|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
32768240|NCT05370495|Placebo Comparator|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
32768241|NCT05370417|Placebo Comparator|Control Group|Participants in this group will receive fluoride toothpaste, simulated laser therapy and sealants.
32768242|NCT05370417|Active Comparator|Photobiomodulation Group|Participants in this group will receive fluoride toothpaste, active laser therapy and sealant simulation.
32768243|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
32768244|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
32768245|NCT05370339||Adolescents|Adolescents with type 1 diabetes between the ages of 11 and 17 years.
32768246|NCT03043937||cardiac patients WHO class 1,2|
32768247|NCT03043937||cardiac patients WHO class 3,4|
32768248|NCT05369949|Experimental|DEX group|Participants will receive an intraoperative and postoperative DEX infusion. In addition a low dose of sevoflurane will be administered.
32768249|NCT05369949|Active Comparator|Control group|Participants will receive general anesthesia with sevoflurane according to institutinal's practice.
33073406|NCT02156115||healthy volunteers|healthy volunteers
32925273|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
32925274|NCT04782245|Experimental|Treatment group Daplagliflozin|
32925275|NCT04782245|Placebo Comparator|Control group|
32925276|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
32925277|NCT04770155|Active Comparator|Beetroot juice (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
32724063|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
32724064|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
32724065|NCT05159921|No Intervention|Standard Consent|Standard consent procedure: The rationale, risks, benefits, and alternatives for the intended procedure (diagnostic or screening OGD or colonoscopy) will be discussed in the outpatient clinic by a consultant general surgeon (DOK) or members of the surgical team. Patients will be given the opportunity to ask questions. All patients will receive a written information leaflet, which includes contact details for the endoscopy department should patients wish to ask further questions (supplemental data). Those undergoing colonoscopy will receive further instructions along with prescribed colonoscopy 'prep' medication by post. On the day of the procedure, patients are required to sign a standardised consent form.
32724066|NCT05159921|Experimental|Standard consent + access to an automated conversational agent (SurgInfoBot)|Patients in the SurgInfoBot arm will be consented as above, but will also be granted access to the SurgInfoBot, which they will be invited to use between their outpatient appointment and their endoscopy procedure date. Participants will be provided with an access link and Unique Study Identifier in order to pseudonymise participant data. Participants will be able to access the SurgInfoBot as many times as they wish, and can ask any questions they see fit.
32724067|NCT04676009|Experimental|Exercise arm :|"Patient randomized to the Exercise arm will receive physical activity recommendations at inclusion and nutritional assessment will be carried out during the first and last treatment cure. Patients will receive an acute physical exercise just before immunotherapy and chemotherapy infusion.They will have a home walking program and will have to wear an activity tracker during the 3 months of intervention.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3)."
32925278|NCT04770155|Placebo Comparator|Placebo (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
32925279|NCT04770155|Active Comparator|L-citrulline (Aim 1b)|Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
32925280|NCT04770155|Placebo Comparator|Placebo (Aim 1b)|Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
32925281|NCT04770155|Active Comparator|Sildenafil (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
32925282|NCT04770155|Placebo Comparator|Placebo (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
32925283|NCT04770155|Active Comparator|Bosentan (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
32925284|NCT04770155|Placebo Comparator|Placebo (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
32925285|NCT04744181||cases|patients who fulfill the inclusion criteria
32925286|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
32925287|NCT05444543|No Intervention|Control|Participants in this arm will continue with their normal standard of care regimen of daily topical steroids
32925288|NCT05444543|Experimental|Intervention|Participants in this arm will cycle their topical steroid therapy in a three-months on three-months off fashion
32724068|NCT04676009|No Intervention|Control arm|"Patients will receive physical activity recommendations at inclusion and a nutritional assessment will be carried out during the first and last treatment cure. They will receive the usual care and standard treatment protocol (immunotherapy and chemotherapy).~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place 40 min before the administration of treatments (1), just before the administration of treatments (2) and 12 hours after the start of treatment (3)."
32925289|NCT05444387|Experimental|Upper Limb Loading Group|Partial body weight support treadmill training with upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
32724069|NCT05159843|Experimental|Diabetes Self-Management education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
32925290|NCT05444387|No Intervention|Control Group|Partial body weight support treadmill training without upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
33073407|NCT02156115||lymphatic patients|lymphatic patients
33073408|NCT02156115||relatives|relatives
32925291|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
32925292|NCT01970345|Placebo Comparator|Placebo|Placebo
32925293|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
32925294|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
32925295|NCT04717115||Genetic diagnosis|
32724070|NCT05159843|Experimental|Usual care|Participants in control group receive usual services offered in University Hospital and other local health systems for patients with diabetes, which include regular visits with a diabetes provider (primary care or endocrine) and standard Spanish Diabetes Society information pamphlets. Consultation care is centralized in the pharmacological treatment regimen, dosage and guidelines.
32724071|NCT04456985|Active Comparator|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
32925296|NCT04635839|Active Comparator|Standard Dosing|Standard dose of unfractionated heparin
32925297|NCT04635839|Active Comparator|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
32925298|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
32925299|NCT00619931|Experimental|1|APD791 or placebo
32925300|NCT00619931|Experimental|2|APD791 or placebo
32925301|NCT00619931|Experimental|3|APD791 or placebo
32925302|NCT00619931|Experimental|4|APD791 or placebo
32925303|NCT00619931|Experimental|5|APD791 or placebo
32925304|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
32925305|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
32925306|NCT05452655|Experimental|Intensive Outpatient Integrated Motor-Cognitive and Aerobic Exercises Rehabilitation Program|Intervention of highly challenging motor and cognitive training for 6 consecutive weeks.
32925307|NCT05452655|Active Comparator|Home-Based Stretching Exercises|Home-based self-treatment program for 40 '/ day for 6 consecutive weeks
32925308|NCT04739111|Experimental|Experimental Arms|All participants will receive treatment with LDP combined with CDP1. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase.
32925309|NCT05444231|Experimental|Active|The Active Group will receive access to all online training content after baseline testing.
32925310|NCT05444231|Placebo Comparator|Delayed Active|The Delayed Active Group will receive access to all online training content after their second BrainHealth Index (3 months).
32925311|NCT05444075||subjects with preparatory education level|Ten subjects have a preparatory education level
32925312|NCT05444075||subjects with high school education|ten subjects with a high school education or its equivalent
33400518|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
33400519|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
33400520|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
32724072|NCT04456985|Placebo Comparator|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
32925313|NCT05444075||subjects with university education|ten subjects who have a university education, or are still in a university education stage
32925314|NCT05443997|Experimental|A&T- intensive|"Capacity building will involve offsite training conducted by Vitamin Angels and short capsule trainings delivered by government staff~Supportive supervision will involve training and handholding of supervisors on use of job aids and mobile application~Strategic use of data will involve setting up processes to review key data, review meetings and short trainings on gap areas.~Engagement of Panchayati Raj Institutions (PRI) around convergence where PRI members will be equipped with job aids, including an App~Improved food supplements where THR offering for pregnant and lactating women and children 6 months and older will be revisited and improved solutions will be explored."
33400521|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
32925315|NCT05443997|No Intervention|A&T-non intensive|Only receives standard government services
32925316|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
32925317|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
32925318|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
32925319|NCT04621331|Experimental|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
32925320|NCT04768231|Experimental|R35HZE|Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.
32925321|NCT05443607||Mother infected/newborn not infected|
32925322|NCT05443607||Mother infected/newborn infected|
32925323|NCT05443607||Mother not infected/newborn not infected|
32925324|NCT05443607||Mother not infected/newborn infected|
32925325|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
32925326|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
32925327|NCT05452421|Experimental|Group A|
32925328|NCT05452421|Experimental|Group B|
32925329|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
32925330|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
33400522|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
32724073|NCT05159609|Active Comparator|Stim First|Participants slept for one night while auditory sounds were played at specific points during slow wave sleep. At least one week later, an identical procedure occured with no acoustic sounds.
32724074|NCT05159609|Sham Comparator|Sham First|Participants slept for one night while no acoustic sounds were played. At least one week later, an identical procedure occured while acoustic sounds were played at specific points during slow wave sleep.
32724075|NCT04456907|Experimental|PPR group|Receive PRP injection
32724076|NCT04456907|Sham Comparator|Saline group|Receive saline injection
32724077|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
32724078|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
32724079|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
32724080|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
32724081|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
32724082|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
32724083|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
32724084|NCT05159531|Experimental|Standard model of care|Delivery of PrEP care through the local standard of care.
32724085|NCT05159531|Active Comparator|mHealth model of care|Delivery of PrEP care through the Freddie® mobile Health (mHealth) platform.
32724086|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
32724087|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
32768250|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
32925331|NCT04608851|Experimental|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
32925332|NCT04608851|Placebo Comparator|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
32925333|NCT04599491|Experimental|INTELLiVENT-ASV with sidestream capnography|Patients randomized into the 'Sidestream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring.
32925334|NCT04599491|Active Comparator|INTELLiVENT-ASV with mainstream capnography|Patients randomized into the 'Mainstream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring.
32925335|NCT05452343|Experimental|CM310|600 mg (first dosing) + 300 mg (subsequent dosing), once every two weeks
32925336|NCT05452343|Placebo Comparator|Placebo|once every two weeks
32925337|NCT05452265||endoscopic resection (ER)|ER with backup surgery was indicated for patients with endoscopic intent, and a small tumor size tolerated endoscopic retrieval.
32925338|NCT05452265||laparoscopic resection (LR)|LR was indicated for patients with surgical intent, and those with the following conditions, which were not suitable for ER: (1) large tumor size with difficult endoscopic retrieval ; (2) symptoms of gastrointestinal tract bleeding with difficulty in endoscopic visualization; (3) suspicion of tumor rupture that required intra-abdominal exploration; and (4) histologic diagnosis of GIST with initial treatment of target therapy.
32925339|NCT04594031|Experimental|ECT-001-CB|"An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.~Patients will receive standard supportive care and GVHD prophylaxis"
32925340|NCT05452187||Patients with IBD and chronic HCV infection treated with DAAs and/or interferon.|Cohort patients with IBD and chronic HCV infection treated with DAAs and/or interferon collected from the ENEIDA database.
32925341|NCT05443373||experimental group (narcolepsy Type 1)|experimental group (narcolepsy Type 1, 300 subjects)
32925342|NCT05443373||experimental group (narcolepsy Type 2)|experimental group (narcolepsy Type 2, 100 subjects)
32925343|NCT05443373||experimental group (KLS)|experimental group (KLS, 100 subjects)
32925344|NCT05443373||experimental group (IH)|experimental group (IH,50 subjects)
32925345|NCT05443373||healthy control group|healthy control group (age and gender matched healthy subjects,50 subjects)
32925346|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
32925347|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
32925348|NCT04541849||Critically ill patients|
32925349|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
32925350|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
32925351|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
32925352|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
32724088|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
32724089|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
32724090|NCT05096039||Treatment Group 1 (use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
32724091|NCT05096039||Treatment Group 2 (use of ACEI or ARB and no use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
32724092|NCT05096039||Treatment Group 3 (no use of ACEI, ARB, or sacubitril/valsartan)|Beneficiaries who did not qualify for Group 1 or Group 2 were assigned a value of '1'; patients that did not meet this criteria were assigned a value of '0'
32724093|NCT05096039||Cohort Group 1 (Overall cohort)|"The beneficiaries who met the inclusion criteria and were divided into the three treatment groups were considered Cohort Group 1 or the overall cohort."
32768251|NCT05369793|Active Comparator|Alpha-lipoic acid arm|Administration of alpha-lipoic acid 600 mg orally once daily for 3 months.
32768252|NCT05369793|Experimental|Roflumilast arm|Administration of roflumilast 500 mcg orally once daily for 3 months.
32925353|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
32925354|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
32925355|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
32925356|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
32925357|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
32925358|NCT04529291|Other|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
32925359|NCT04529291|Other|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
32925360|NCT04480307|Experimental|temelimab 18 mg/kg|Monthly IV repeated dose
32925361|NCT04480307|Experimental|temelimab 36 mg/kg|Monthly IV repeated dose
32925362|NCT04480307|Experimental|temelimab 54 mg/kg|Monthly IV repeated dose
32925363|NCT04480307|Placebo Comparator|Placebo|Monthly IV repeated dose
32925364|NCT05451407|Experimental|TQB2618 injection combined with Terprizumab injection|TQB2618 injection combined with Terprizumab injection，21 days as a treatment cycle.
32925365|NCT04458545|Placebo Comparator|Placebo Vaccine|
32925366|NCT04458545|Experimental|Low Dose Vaccine (100 μg)|
32925367|NCT04458545|Experimental|High Dose Vaccine (400 μg)|
32925368|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD|Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
32724094|NCT05096039||Cohort Group 2 (subgroup 1)|Patients with evidence of systolic HF defined as: having at least 2 medical claims (on different dates) with an ICD-9/-10 diagnosis code for systolic HF in any position during the lookback period and/or during the entire 90-day episode window (for BPCA) and CY2017 and/or CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
32724095|NCT05096039||Cohort Group 3 (subgroup 2)|Patients with evidence of Heart Failure Reduced Ejection Fraction (HFrEF) identified based on a published algorithm
32724096|NCT05604131|Active Comparator|Hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
32724097|NCT05604131|Active Comparator|Non-hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
32724098|NCT05604131|Placebo Comparator|Hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
32724099|NCT05604131|Placebo Comparator|Non-hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
32724100|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
32724101|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
32724102|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
32724103|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
32724104|NCT05391035||Symptomatic patients attending a sexual health clinic.|A cohort of 160 symptomatic people attending a sexual health clinic in the UK will be recruited to this observational study.
32724105|NCT05162963|Active Comparator|Patients treated with fixed implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Fixed denture is considered the standard protocol.
32768253|NCT04861337|Experimental|Remimazolam Group|Remimazolam infusion is initiated after induction of general anesthesia at a rate of 0.25 mg/kg/h and stopped 15 minutes before the end of surgery.
32724106|NCT05162963|Experimental|Patients treated with removable implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Removable denture is considered the experimental protocol.
32724107|NCT03500237|Experimental|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
32724108|NCT03500237|Active Comparator|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
32724109|NCT05142059|Experimental|Experimental cohort|Participants will be involved in an evaluation program combining physical tests and self-administered questionnaires. Participants will be followed for 1 year with evaluations taking place at 6 months (occurrence of a fall) and at 1 year (the same evaluation, as initial).
32724110|NCT03361865|Experimental|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
32724111|NCT03361865|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
32724112|NCT05106725||Neurological patients|This cohort will include patients having been diagnosed with a neurological condition.
32724113|NCT05106725||Control|This cohort will include patients who have not been diagnosed with a neurological disorder.
32724114|NCT05053763|Other|Experimental: age<65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
32724115|NCT05053763|Other|Active Comparator:age ≥65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
32724116|NCT05113043||Ischemic stroke|Young patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
32724117|NCT05113043||Hemorrhagic stroke|Young patients who suffered from acute hemorrhagic stroke within 12 hours for the first time before entry into the study.
32724118|NCT05113043||Healthy Controls|Healthy young people
32724119|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
32724120|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
32724121|NCT04996901||derivation cohort|Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital，and Wuhan Third Hospital will be used as a derivation cohort.
32724122|NCT04996901||validation cohort|Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.
32724123|NCT04363697|Experimental|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
32724124|NCT04363697|Placebo Comparator|Placebo|Matching placebo administered orally once daily for 2 months
32925369|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
32925370|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
32925371|NCT04449029|Experimental|Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
32925372|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
32925373|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
32925374|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
32925375|NCT04449029|Experimental|Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
32925376|NCT05451173|Experimental|Cohort A|SBRT to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
32724125|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
32724126|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
32925377|NCT05451173|Experimental|Cohort B|Hypo-fractionated radiotherapy to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
32925378|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
32925379|NCT04408625|Experimental|Low dose|
32925380|NCT04408625|Experimental|Medium dose|
32925381|NCT04408625|Experimental|High dose|
32925382|NCT05450939||Ruptured group|Group of subarachnoid hemorrhage after rupture of intracranial aneurysm
32925383|NCT05450939||Unruptured group|Group of inexperience of aneurysmal rupture during specific period
32925384|NCT05442437|Experimental|Low-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5×10^7 cells.
32925385|NCT05442437|Experimental|medium-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0×10^7 cells.
32925386|NCT05442437|Experimental|High-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0×10^8 cells.
32925387|NCT05441969||Current major depressive episode group|Adult individuals (18-65 yrs) diagnosed with current major depressive episode (MDE), under treatment or medication naif, starting a new antidperessant strategy (n≈30).
32925388|NCT05441969||Maintenance antidepressant treatment group|Adult individuals (18-65 yrs) previously diagnosed with major depressive episode (MDE) currently remitted under continuation or maintenance antidepressant treatment (n≈30).
32925389|NCT05441969||Healthy subjects group|Adult individuals (18-65 yrs) without current diagnosis of major neuropsychiatric disorders, inlcluding MDE, hence not under any antidepressant medication. The same exclusion criteria will be applied as in the two clincial groups.
32925390|NCT05450861|Experimental|SF DNA Treatment|the scalp conditioning solution with SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
32925391|NCT05450861|Placebo Comparator|Placebo|the scalp conditioning solution without SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
32925392|NCT05450783||Patients group|Patients and their relatives affected with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20
32925393|NCT04366973||Participants with Hepatitis C Virus With or Without Treatment|"This study includes 3 populations for analysis:~Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.~Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.~Safety Population (SP): Defined as all participants who received at least one dose of G/P."
32925394|NCT05450627||Case|Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology
32724127|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
32724128|NCT02149121|Active Comparator|Rituxan|US-licensed referece product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
32724129|NCT02149121|Active Comparator|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
32724130|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist [LAMA] + long-acting beta-agonist [LABA])
32724131|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid [ICS]/ long-acting beta-agonist [LABA] + long-acting muscarinic antagonist [LAMA])
32724132|NCT01353521|Experimental|Contrast-enhanced ultrasound|
32724133|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
32724134|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
32724135|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
32724136|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
32925395|NCT05450471|Experimental|L-lactide and trimethynele carbonate Terpolymers polymer implant|The polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed. The polymer in this study is biocompatible. The polymers will be made in the biomaterials laboratory located at the Pontifical Catholic University of São Paulo (PUC-SP), located in the city of Sorocaba-SP. Polymers will be provided free of charge for the study.
32925396|NCT05450471|Placebo Comparator|Placebo polymer implant|Placebo polymer implant
32925397|NCT05437601|Experimental|Astaxanthin|Patients will receive three capsules of astaxanthin (4mg) daily for 8 weeks.
32925398|NCT05437601|Placebo Comparator|Control|Patients will receive three capsules of placebo daily for 8 weeks.
32925399|NCT05437445||Cases Data|subjects having abnormal plasma amino acid profiles with either one or more amino acid concentrations beyond (high or low) the locally defined age-specific reference ranges
32724137|NCT05162885|Active Comparator|implant placement in defective Sockets preserved with alendronic acid sponge|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
32724138|NCT05162885|Active Comparator|Implant placement in Defective sockets preserved with sticky bone|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
32724139|NCT05390957|Experimental|Single Arm|All participants in this pilot study will complete the active treatment
32724140|NCT05162417|No Intervention|Control group|patient in this arm will receive scaling and root planning treatment only.
32724141|NCT05162417|Experimental|Test group (toluidine Blue O)|patients in this arm will receive Toluidine Blue O as an adjunctive to scaling and root planing.
32724142|NCT05162417|Experimental|Methylene blue|Patients will receive Methylene blue as adjunctive to scaling and root planning.
32724143|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)~All patients will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
32724144|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls~All healthy subjects will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
32724145|NCT04101617|Experimental|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
32724146|NCT04101617|No Intervention|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
32724147|NCT03973151|Experimental|HL-085|HL-085 will be administered as BID with specified dose.
32724148|NCT03966989|Experimental|Performance Feedback|Feedback offline either via email or text
32724149|NCT03966989|No Intervention|Control|Standard practice control
32925400|NCT04339907|Sham Comparator|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
32925401|NCT04339907|Sham Comparator|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
33073412|NCT02097420|Other|Single device arm|Mitral valve replacement
33073413|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
32925402|NCT04339907|Experimental|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
32925403|NCT04339907|Experimental|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
32925404|NCT04339907|Experimental|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
32925405|NCT05447975|Experimental|Tai Chi group|
32925406|NCT05447975|No Intervention|Control|
32925407|NCT05450315|Experimental|TARG|Group will receive physical activity information targeted to young adult cancer survivors
33073414|NCT02055209||1|Adults only, all genders, US born African American
33250199|NCT05402592|Placebo Comparator|Control Group|Patients will be given 800 ml of water by the blind caregiver until 24:00 at night before the surgery, and 400 ml of water 2-3 hours before the surgery in the morning.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
33400523|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
32724150|NCT05162339||IBD patients|
32724151|NCT05162183||Glimepiride|Reference Group
32724152|NCT05162183||Liraglutide|Exposure group
32724153|NCT05161949||group 1|200 patients with suspected ovarian cancer
32724154|NCT05161949||group 2|40 non oncological patients of witch 20 with endometriosis
32724155|NCT05390489|Experimental|Cascara pulp arabica gayo coffee cream|The installation of a patch test for the cascara pulp cream of Gayo Arabica coffee with a concentration of 10% was carried out on the upper arm and waited for 30 minutes to see if there were any side effects. If no side effects occur, the patch test is left for 48 hours. After 48 hours, patch test was opened and the skin condition was assessed for irritation/redness and skin moisture. This condition was also re-evaluated at 72 and 96 hours later.
32724156|NCT03770741|Experimental|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
32724157|NCT03770741|Other|Treatment as usual|Treatment according local guidelines and practices.
32724158|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
32724159|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
32724160|NCT03755687|Experimental|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
32724161|NCT05161559|Experimental|Fuji Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Fuji Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
32724162|NCT05161559|Experimental|Riva Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Riva Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
32724163|NCT05161559|Experimental|Single Bond Universal (self-etch adhesive)|Patients received in Class V cavity preparation Single Bond Universal (self-etch adhesive) on one tooth of the mouth
32724164|NCT05161559|Experimental|Clearfill S3 Bond (self-etch adhesive)|Patients received in Class V cavity preparation Clearfill S3 Bond (self-etch adhesive) on one tooth of the mouth
32724165|NCT05161559|Experimental|OptiBond FL (three step etch & rinse adhesive)|Patients received in Class V cavity preparation OptiBond FL (three step etch & rinse adhesive) on one tooth of the mouth
32724166|NCT03736655|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
32724167|NCT05161403|Active Comparator|Hyaluronic acid.|1mm layer of hyaluronic acid on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
32724168|NCT05161403|Active Comparator|Honey|1mm layer of Honey on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
32724169|NCT05161403|Placebo Comparator|Saline|a piece of gauze moistened with normal saline will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
32724170|NCT05161325||Cohort 1|Participants with untreated advanced or recurrent non-small cell lung cancer (NSCLC) receiving first-line nivolumab plus ipilimumab with or without chemotherapy
32724171|NCT05077397|Active Comparator|Group 1|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 1 will be monitored by the InSpectra Tissue Spectrometer, StO2, added to standard ASA monitorisation."
32724172|NCT05077397|Active Comparator|Group 2|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by O3TM Regional Oximeter System, added to standard ASA monitorisation."
32724173|NCT05077397|No Intervention|Group 3|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by standard ASA monitorisation."
32724174|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
32925408|NCT05450315|Active Comparator|CPAG|Group will receive the Canadian Public Health Guidelines
32925409|NCT05450159|Experimental|Intervention group|Participants in the intervention group will watch their respective training video individually approximately four to six weeks after their baseline visit. Each training video will be 20-25 minutes in length where they will recieve voice-over feedback on their driving from a member of the study team alongside video clips taken from the device of their behind-the-wheel performance. They will also receive a written summary of their feedback to keep at the end of their feedback session.
32925410|NCT05450159|Active Comparator|Control group|Four to six weeks after their first baseline visit, control group participants individually will watch a 30-minute (generic) video that describes the benefits and challenges of aging-in-place that discusses the importance of community mobility in later life. At the end of their session, participants will be given a government brochure on this topic.
32925411|NCT05449925|Experimental|TEST GROUP|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
32925412|NCT05449925|No Intervention|CONTROL GROUP|no periodontal intervention
32925413|NCT04307615|Experimental|Oxygen + CPAP-treatment|
32925414|NCT04307615|Active Comparator|Oxygen-treatment|
32925415|NCT05449847||Complicated HCV|
32925416|NCT05449847||Non Complicated HCV|
32925417|NCT05449691|Active Comparator|Biological Matrix|Participants will undergo immediate breast reconstruction using biological matrix and implant
32925418|NCT05449691|Experimental|Synthetic Mesh|Participants will undergo immediate breast reconstruction using synthetic mesh and implant
32925419|NCT04287101|Experimental|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
32925420|NCT04287101|Active Comparator|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
32925421|NCT04287101|No Intervention|conventional care group|usual care
32925422|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
32925423|NCT05449613|Active Comparator|acupoint application|The acupoint application is applied each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
32925424|NCT05449613|Placebo Comparator|placebo|The placebo is applied the same acupuncture points, each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
32925425|NCT05449145|Placebo Comparator|Placebo|MCT oil (first 4-week) plus Omega-3 FA (second 4-week)
32925426|NCT05449145|Experimental|Vitamin D|Vit D (first 4-week) plus Omega-3 FA (second 4-week)
32925427|NCT05447429|Experimental|TAP Block|In this group ,TAP block will be performed with 0.5% 15 ml bupivacaine + 5 ml .
32925428|NCT05447429|Placebo Comparator|Placebo|In this group , 20 ml saline solution will injected into the transversus abdominis plane.
32724175|NCT03561701|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
32724176|NCT03561701|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
32724177|NCT04455893|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
32724178|NCT04455893|Experimental|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
32724179|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
32724180|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
32724181|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
32724182|NCT04923269|Experimental|LY3532226|Single ascending doses of LY3532226 administered subcutaneously (SC).
32724183|NCT04923269|Placebo Comparator|Placebo|Placebo administered SC.
32925429|NCT05447351||Treated|Counselling, personalized dietary strategy aimed at increasing the adherence to Mediterranean diet, personalized physical activity program with a personal trainer, use of digital tools (i.e., games, apps) aimed at improving the adherence to dietary/lifestyle indications.
32925430|NCT05447351||Control|generic dietary indications oriented to weight reduction; generic invitations to increase physical activity, routine monitoring
32925431|NCT05449067|Experimental|Group A: APD first then CAPD|12 weeks of APD or CAPD with crossover to the other
32925432|NCT05449067|Experimental|Group B: CAPD first then APD|12 weeks of APD or CAPD with crossover to the other
32925433|NCT04743557|Experimental|Cohort 1|Weekly infusions of DYN101 at the starting dose level
32925434|NCT05447039|Active Comparator|Montelukast treated|
32925435|NCT05447039|No Intervention|Standard treatment|
32925436|NCT05446961|Active Comparator|covid 19 LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
32925437|NCT05446961|Placebo Comparator|covid 19 placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
32925438|NCT05446961|Active Comparator|Healthy LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
32925439|NCT05446961|Placebo Comparator|Healthy Placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
32925440|NCT05446805||depression|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
32925441|NCT05446805||control|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
32925442|NCT05446727|Experimental|QLB|Experimental: Quadratus Lumborum block group Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Ropivacaine 0.375%
32925443|NCT05446727|Experimental|ESP|Ultrasound-guided continuous ESP block with opioid PCA A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine
32925444|NCT05446649|Experimental|dry needling|the patient will receive dry needling and conventional therapy three times per week for four weeks
32925445|NCT05446649|Experimental|instrumented assisted soft tissue mobilization|the patient will receive instrumented assisted soft tissue mobilization and conventional therapy three times per week for four weeks
32925446|NCT05446649|Active Comparator|conventional therapy|the patient will receive conventional therapy three times per week for four weeks
32925447|NCT05446415|Other|Prospective analisys|"Immunohistochemical assays : biopsy sampled from each site was immediately fixated and then embedded in paraffin, cut in thin slide sections and dewaxed. Subsequently, antigen retrieval was performed, with incubations with (1) specific primary antibodies, (2) a second layer of antibodies and (3) a third layer of an avidin-biotin complex. Finally, counterstaining was performed, generating biopsy slides with cells positive for peptide YY (PYY), GLP-1, respectively.~Quantitative real-time polymerase chain reaction (qPCR) : the mRNA expression of the genes of interest glp-1,PYY 3-36 genes as well as the genes used for normalisation 18S were investigated. One biopsy sample from each biopsy site was immediately incubated in RNAlater solution (to preserve mRNA quality) (dna/rna Shield, USA). Subsequently, standard RNA purification, cDNA synthesis and quantitative PCR (qPCR) analysis were performed ."
32925448|NCT05448833|Experimental|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
32925449|NCT05448521||Low lactate|Patients with a low lactate level defined by logistic regression analysis.
32925450|NCT05448521||High lactate|Patients with a high lactate level defined by logistic regression analysis.
32925451|NCT05448443|Experimental|AD981|AD981
32925452|NCT05448443|Placebo Comparator|Placebo|Placebo
32925453|NCT05448365|Active Comparator|EGCG, Vit D, DCI, Vit B6|Women with uterine fibroids randomized to treatment group
32925454|NCT05448365|Placebo Comparator|Placebo|Women with uterine fibroids randomized to placebo group
32925455|NCT05448053|Experimental|Ilizarov device|Ilizarov fixation in open type III pediatric tibial shaft fractures
32925456|NCT04728347|Experimental|ARCT-021|Participants will receive a single dose of ARCT-021 on Day 1
32925457|NCT04728347|No Intervention|Long-term follow up from ARCT-021-01|Participants will not receive intervention but will be followed for safety.
32925458|NCT03183791|Experimental|RELAX group|
32925459|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
33400524|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
33400525|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
33400526|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
33400527|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
33400528|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
33400529|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
33400530|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
33400531|NCT03163420|Placebo Comparator|Placebo|placebo
33400532|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
33400533|NCT04744272|Active Comparator|Intervention|Participants randomised to the intervention arm will be provided with access to the digital web-based application (app) myAsthma.
33400534|NCT04744272|No Intervention|Control|Participants randomised to the control arm will continue with standard care processes
32768254|NCT04861337|Placebo Comparator|Placebo Group|Placebo (0.9% saline) infusion is initiated after induction of general anesthesia at the same rate as in the remimazolam group and stopped 15 minutes before the end of surgery.
33400535|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
33400536|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
33400537|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
33400538|NCT04440436|Experimental|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
33400539|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
33400540|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
33400541|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
32925460|NCT04713995|Other|All Study Participants|"Enrolled with: AxSpA diagnosis, HLA-B27 positive, mASDAS > or = 1.3 and HLA-B27 positive. Will complete surveys online or on an app, about mental and physical health and how they are doing, submits and collection of samples (blood, stool, saliva, urine, fasting blood test at local lab). Receives results of some of the analysis of samples. Participants that qualify and complete the first set of samples can be eligible for the 3 and 6 month longitudinal follow-up collection kits.~All participants receive dietary recommendations based on samples collected and the analysis of the microbiome."
32925461|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
32925462|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
32925463|NCT04709939||Patient Participants|Adults patients who are discharged from the hospital on outpatient parenteral antibiotic therapy.
32925464|NCT04709939||Physician Participants|Infectious disease physicians who prescribe OPAT to their patients but were not involved in the study.
32724184|NCT03205553|Active Comparator|Standard of Care (SoC) Treatment Group|The SoC group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice and subsequently serially reduced in silo (staged silo reduction) until the bowel contents are at the level of fascia and deemed suitable for closure. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons.
32724185|NCT03205553|Experimental|Direct Peritoneal Resuscitation (DPR) Treatment Group|The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
32925465|NCT04705025|Experimental|Supportive care (BNT001 app, CBSM, interview)|Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
32925466|NCT03137771|Active Comparator|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32925467|NCT03137771|Experimental|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
32925468|NCT04687553|Experimental|Patients with vegetative state|Patients with vegetative state were assessed by the SECONDs and CRS-R for two days.
32925469|NCT04687553|Experimental|Patients with minimally conscious state|Patients with minimally conscious state were assessed by the SECONDs and CRS-R for two days.
32925470|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
32925471|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
32925472|NCT04687475|Experimental|Clinical Tool (Mobile Spirometry and Survey)|All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.
32925473|NCT04686383|Experimental|Cohort 1: 20 mg CAL056 mesylate|Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
32925474|NCT04686383|Experimental|Cohort 2: 40 mg CAL056 mesylate|Patients will receive oral dose of 40 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
32925475|NCT04686383|Experimental|Cohort 3: 80 mg CAL056 mesylate|Patients will receive oral dose of 80 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
32925476|NCT04686383|Experimental|Cohort 4: 120 mg CAL056 mesylate|Patients will receive oral dose of 120 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
32925477|NCT04686383|Experimental|Cohort 5: 160 mg CAL056 mesylate|Patients will receive oral dose of 160 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
32925478|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
32768255|NCT04844333|Experimental|Extubation under deep anesthesia|When the patient is in sedation or anesthesia state, including no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the endotracheal tube is removed.
32925479|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
32724186|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
32724187|NCT05390255|Experimental|Nasal spray hormone therapy|This group of patients received nasal steroid therapy throughout the study. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
32925480|NCT04600817|Experimental|TJ107|
32925481|NCT04600817|Placebo Comparator|TJ107Placebo|
32925482|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
32925483|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
32925484|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
32925485|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
32925486|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
32925487|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
32925488|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
32925489|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
32925490|NCT04593953|No Intervention|CONTROL|Standard general anesthesia
32925491|NCT04593953|Experimental|TLIP|Standard general anesthesia + TLIP block
32925492|NCT04560335|Experimental|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
33250200|NCT05402592|Experimental|Carbonhydrate-rich drink|Patients will be given 800 ml of carbohydrate-containing beverage until 24:00 at night before the surgery by the blind caregiver, and 400 ml of carbohydrate-containing beverage in the morning 2-3 hours before the surgery.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
32925493|NCT04560335|Other|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
33250201|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
33250202|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
33250203|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
33250204|NCT03993145|Experimental|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
33250205|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
33400542|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.
32925494|NCT04738253||Study group|Stroke patients with limitation of range of motion on the affected shoulder.
32925495|NCT05445089|Experimental|Isothymol or Carvacrol group|"Each ml contains 6mg of Isothymol or Carvacrol (2-Methyl-5-(1-methylethyl)-phenol modified) at 1% v/v. (GRAS lipophilic modified with isothymol).~Oral solution (dispersion L/L). Dilute lipophilic aqueous solution of light or medium yellow.~Excipients: Cis-9-octadecenoic acid with Squalene (99%)."
32925496|NCT05445089|Placebo Comparator|Control|•Placebo
32925497|NCT05444777|Experimental|Ketamine group (Group K)|Group K was given ketamine @ 0.5mg/kg (prepared by dilution in 0.9% normal saline in 10 ml syringe) at the time of wound closure.
32925498|NCT05444777|Other|Saline group (Group S)|Group S was given saline in 10 ml syringe
32925499|NCT04548713|Experimental|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
32925500|NCT04548713|Active Comparator|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
32925501|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
32925502|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
32925503|NCT04515953|Active Comparator|Control|Standard practice of pain management for post-TKA
32925504|NCT04515953|Experimental|ND-340|ND-340 90mg~320mg at dose escalations
32925505|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
32925506|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
33250206|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
33250207|NCT04272736|Experimental|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
33250208|NCT05396898|Experimental|LCP-tacrolimus (Envarsus®)|"Patients in this arm start (after randomization) on LCP-tacrolimus therapy.~At midterm of study participation (16 weeks), a switch is made to twice-daily tacrolimus (Prograf® ) therapy.~The duration of the trial for each subject is expected to be 32 weeks."
33250209|NCT05396898|Active Comparator|twice-daily tacrolimus (Prograf®)|"Patients in this arm start (after randomization) on twice daily tacrolimus (Prograf®) therapy.~At midterm of study participation (16 weeks), a switch is made to LCP-tacrolimus (Envarsus®) therapy. The duration of the trial for each subject is expected to be 32 weeks."
33250210|NCT00694304|Experimental|Vortioxetine|
32724188|NCT05390255|Experimental|Nasal spray hormone therapy + oral hormone therapy|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of nasal spray hormone treatment throughout the course. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
32724189|NCT05390255|Experimental|Nasal spray hormone therapy + omalizumab therapy|The patients in this group were injected with omalizumab once a month under the background of nasal spray hormone therapy, for a total of 6 times. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
32724190|NCT04456829|Experimental|Resveratrol drink|
32724191|NCT04456829|Placebo Comparator|Placebo drink|
32724192|NCT05390177|Experimental|First health video|This video presents health information for one study condition.
32724193|NCT05390177|Active Comparator|Second health video|This video presents health information for one study condition.
32724194|NCT04856891|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
32724195|NCT04856891|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
33250211|NCT05352334|Experimental|High Intensity Interval Training|
32724196|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
32724197|NCT02810171|Other|Relaxation Therapy|
32724198|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after ~16 weeks, but without any intervention (i.e., no therapy).
32925507|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
32925508|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
32925509|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
32925510|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab~Ramucirumab 8mg/kg, d1~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
33250212|NCT05352334|Experimental|Aerobic Exercise|
33250213|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
33250214|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
33250215|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
32925511|NCT05444309|Active Comparator|Quadratus lumborum block group|"The child will be positioned in the lateral position, with the operative side non-dependent. Under complete aseptic precautions, QL block will be given by anterior approach at the level of L4. A linear high-frequency probe of Sonosite M Turbo ultrasonography will be applied vertically above the iliac crest, and a 22G, 80 mm spinal needle will be inserted in the plane from the posterior edge of the probe through the QL muscle in an anteromedial direction. The needle tip will be placed between the Psoas major (PM) muscle and the QL muscle.~After negative aspiration, injection of 0.5 mL of normal saline to the space between PM and QL muscles .~An injection of 0.5 mg/kg of 0.25% bupivacaine into the fascial plane and the local anesthetic appears to press down the PM muscle in the ultrasound image, the patients will be repositioned to a supine position immediately after the block."
32925512|NCT05444309|Active Comparator|Pericapsular Nerve Group (PENG) block group|"PENG block will be done while the child in supine position. Then, a high-frequency (8-15 MHz) ultrasound linear probe of Sonosite M Turbo ultrasonography (FUJIFILM Sonosite, Inc., Bothell, WA, USA) will be placed over the anterosuperior iliac spine and then rotating it 45 degrees to acquire images from lateral to medial of the anterior inferior iliac spine, iliopubic eminence, psoas tendon, and the femoral artery.~Then, a 22G, 80 mm spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.~After negative aspiration and a test does (0.5 mL of normal saline), an injection of 0.5 mg/kg of 0.25% bupivacaine into the space between the psoas tendon and the iliopubic eminence."
32925513|NCT05444309|No Intervention|control group|The child will not receive any block.
32925514|NCT05443217||patients with response to systemic therapies|
32925515|NCT05443217||patients with no response to systemic therapies|
32925516|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
33250216|NCT05386836|Experimental|Healthy adult volunteers|All subjects within this single arm of the study will undergo the validation experiment as described in the description
33250217|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
32925517|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
32925518|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
32925519|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
32925520|NCT05442905|Active Comparator|Quadratus lumborum block group|will receive quadratus lumborum block the patient will be placed in lateral position, the probe will be placed on the crista iliaca anterior superior. After the external oblique, internal oblique, and transversus abdominis muscles will be seen, the probe will be moved to the posterior and the quadratus lumborum muscle will be observed. A 22-gauge, 80 mm insulated Quince-type needle (Uniplex; Pajunk, Geisingen, Germany) will be moved from the anterolateral plane to the posteromedial plane, and confirmation will be made using 0.5 mL/kg saline; after a negative aspiration, 0.7 mL/kg (0.25%) bupivacaine will be applied to the posterior of the quadratus lumborum muscle and the thoracolumbar fascia in between the quadratus lumborum and latissimus dorsi muscles.
33400543|NCT05405686|Active Comparator|Control arm|In the control group, 225 IU of recombinant FSH will be administered in a fixed antagonist protocol.
33400544|NCT05405686|Experimental|Study arm|In the study group, 225 IU of recombinant FSH plus 112,5 IU of recombinant LH will be administered.
32724199|NCT04802681|Other|Wirecath - PressureWire X|Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.
32724200|NCT01865617|Experimental|ALL (high tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg"
32724201|NCT01865617|Experimental|ALL (high tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
32925521|NCT05442905|Active Comparator|Transversus abdominis block group|will receive TAP block with 0.7mL/kg of 0.25% bupivacaine under US guidance. A linear high frequency ultrasound probe (6-13 MHz) will be placed transversely in the mid axillary line between the iliac crest and the costal margin. The three layers of muscles, the external oblique, the internal oblique, and the transversus abdominis will be identified. Using the in-plane technique, needle will be inserted (from anterior to posterior direction) until the tip of the needle will reach between the internal oblique and the transversus abdominis. Hydro dissection with 1-2 mL saline will be done to separate the fascial layers. After the correct localization, 20 mL of the drug will beinjected with repeated aspiration to avoid the accidental intravascular injection.
32925522|NCT05442905|Active Comparator|Caudal block group|will receive caudal block with 1mL/kg of 0.25% bupivacaine, with children in left lateral position. with all aseptic measures caudal block will be performed using 25 G needle in left lateral decubitus position. Needle position will be confirmed by the pop felt during penetration of the sacrococcygeal ligament, further ensured by doing whoosh test using 0.5 mL of air injection 0.25% bupivacaine 1mL/kg will be administered after negative aspiration of blood and CSF. Intraoperative hemodynamic parameters will be recorded throughout the surgery at fixed intervals (at time of skin incision then after every 5 min till the end of surgery).
32925523|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
32925524|NCT04338425|No Intervention|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
32925525|NCT04338425|Active Comparator|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
32925526|NCT04338425|Active Comparator|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
32925527|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
32925528|NCT04503317|Experimental|active acupuncture low level laser and aerobic exercise|active acupuncture, low level laser and aerobic exercise
32925529|NCT04503317|Active Comparator|aerobic exercise|aerobic exercise
32925530|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
33250218|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
32925531|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
32925532|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
32925533|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
32925534|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
32925535|NCT05735431|Experimental|Formoterol 6 mcg/fluticasone 125 mcg|Formoterol 6 mcg/fluticasone 125 mcg Eurofarma.
32925536|NCT05735431|Active Comparator|Alenia® 6 mcg/200 mcg|Alenia® 6 mcg/200 mcg.
32925537|NCT05441189||training cohort|30 patients undergoing resection between March 2015 and December 2016 at Chinese PLA General Hospital in Beijing, China
32925538|NCT05441189||validation cohort|40 patients from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
32925539|NCT04483583|Active Comparator|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
32925540|NCT04483583|Experimental|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
32925541|NCT04483583|Active Comparator|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
32925542|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
32925543|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
32925544|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
32925545|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
33250219|NCT04685876|Active Comparator|liposomal bupivacaine|40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
32925546|NCT05438069||Patients with elevated LDL-cholesterol (hypercholesterolemia)|Application of si RNA Inclisiran to reduce serum LDL-cholesterol levels.
33250220|NCT04685876|Active Comparator|plain bupivacaine|50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
32925547|NCT04449965|Experimental|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
32925548|NCT04449965|Placebo Comparator|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
32925549|NCT04449965|Experimental|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
32925550|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
32925551|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
32925552|NCT05433389|Active Comparator|Breath Counting|
32925553|NCT05433389|Experimental|Body Scan|
32925554|NCT05433389|Experimental|Mindful Breathing|
32925555|NCT05433389|Experimental|Mindfulness of Pain|
32724202|NCT01865617|Experimental|ALL (high tumor burden) dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg"
32724203|NCT01865617|Experimental|ALL (low tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg"
32724204|NCT01865617|Experimental|ALL (low tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
32724205|NCT01865617|Experimental|CLL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg"
32724206|NCT01865617|Experimental|CLL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg"
32925556|NCT05433389|Experimental|Mindful Savoring|
32724207|NCT01865617|Experimental|CLL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg"
32724208|NCT01865617|Experimental|CLL (ibrutinib) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg"
32925557|NCT05431673|Active Comparator|Doxycycline|• Subjects in this group will be treated with Doxycycline (100mg/day for 8 weeks).[1]
32925558|NCT05431673|Active Comparator|Doxycycline & Ciprofloxacin|• Subjects in this group will be treated with combination of Doxycycline (100mg/day for 8 weeks) & Ciprofloxacin (250mg twice daily for 4 weeks).[1]
32925559|NCT05431673|Active Comparator|Rifampicin|• Subjects in this group will be treated with Rifampicin (600mg/day for 6 weeks)
32925560|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
32925561|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
32925562|NCT05424341|Experimental|Group A|This group will receive muscle energy technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
32925563|NCT05424341|Active Comparator|Group B|This group will receive counterstrain technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
32925564|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting at randomization."
32925565|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting 24 weeks after randomization."
32925566|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
32925567|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
32925568|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
32925569|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
32925570|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
33250221|NCT04685876|Placebo Comparator|Normal Saline|patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.
32925571|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
32925572|NCT05735353|Experimental|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training for 12 consecutive weeks.
32925573|NCT05735353|Experimental|High-Speed Multidirectional Yoga Group|Participants in this group will receive high-speed multidirectional yoga for 12 consecutive weeks.
32925574|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
32724209|NCT01865617|Experimental|NHL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg"
32724210|NCT01865617|Experimental|NHL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
32724211|NCT01865617|Experimental|NHL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg"
32724212|NCT01865617|Experimental|NHL (dose dense) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
32724213|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
32724214|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
32724215|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
32925575|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
32925576|NCT04421495|Experimental|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
32925577|NCT01895647|Experimental|Biceps stimulation|EMS
32925578|NCT01895647|Experimental|Quadriceps stimulation|EMS
32925579|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
32925580|NCT02034461|Experimental|Acute surgical implantation|The investigators will conduct three acute surgeries where a Utah slanted Electrode Array (USEA) will be implanted in volunteers who are about to undergo limb amputations. These acute implantations will provide the PI with human surgical experience in implanting USEAs and evaluating the containment system the investigators will be using to immobilize the implanted USEA in the nerve.
32925581|NCT02034461|Experimental|Implantation of a Utah Electrode Array|The arm which has been amputated or has peripheral nerve trauma. Intervention include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.
32925582|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
32925583|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
32925584|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
32925585|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
32925586|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
33400545|NCT04711122||Role of prophylactic antibiotics in childscore A|Role of prophylaxis against infections in progression of cirrhotic patients with childscore A
32925588|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
32925589|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
32925590|NCT02987569|Experimental|Group One|Intervention
32925591|NCT02987569|Active Comparator|Group Two|Control
32925592|NCT05735197|Active Comparator|Dapagliflozin group|Includes 50 patients, they will receive SGLT2i as add on drug, Dapagliflozin 10 mg will be used once daily with or without food.
32925593|NCT05735197|Placebo Comparator|Placebo group|Includes 50 patients, they will receive placebo plus their medication.
32925594|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
32925595|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
32925596|NCT00370253|Active Comparator|2|Terlipressin
32925597|NCT00370253|Experimental|1|Noradrenalin
32925598|NCT05391737||patients with SIPE|"Adult patients (age ≥18 years) with SIPE-diagnosis during Vansbrosimningen and peripheral oxygen saturation ≤95%. SIPE-diagnosis based on pulmonary edema on lung ultrasound."
32925599|NCT05391737||control group|"Swimmers completing Vansbrosimningen without respiratory symptoms or signs of pulmonary edema on lung ultrasound. Matched to patients with SIPE for age and gender."
32925600|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
32724216|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
32724217|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
32724218|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
32724219|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
32925601|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
32925602|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
32925603|NCT04412525|Active Comparator|27 gauge needle vitrectomy surgery|ultra-small gauge
32925604|NCT04412525|Active Comparator|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|23-gauge and 25-gauge instruments are a little larger in size
32925605|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
32925606|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
32724220|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
32724221|NCT05200195||International Cohort Training Set|The Training Set of the International Cohort (N=3,670) was composed of the 80% (n=2936) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
32925607|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
32925608|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
32925609|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
32925610|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
32925611|NCT04359953|Experimental|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
32724222|NCT05200195||International Cohort Test Set|The Test Set of the International Cohort (N=3,670) was composed of the 20% (n=734) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
32724223|NCT05200195||Validation Cohort|The external Validation Cohort was composed of 356 HCC patients transplanted at the Columbia University, New York, during the period 2000-2018.
32724224|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
32724225|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
32724226|NCT05389943|Experimental|Postmenopausal women with low BMD|patient with serum 25-hydroxy vitamin D [25(OH)D] less than 32 ng/ml. Vitamin D3 5000 IU/d per oral for the period of 3 months will be administered
32724227|NCT05389943|Active Comparator|Postmenopausal women|Postmenopausal women having serum 25-hydroxy vitamin D [25(OH)D] greater than 32 ng/ml will provided with milk and dietary modifications.
32724228|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
32724229|NCT04575961|Other|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin)
32925612|NCT04359953|Experimental|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
32925613|NCT04359953|Experimental|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
32925614|NCT04359953|No Intervention|Usual Care|No intervention
32925615|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
32925616|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
32925617|NCT05364515|Active Comparator|Conventional treatment|0.05% Clobetasol propionate
32925618|NCT05364515|Experimental|PRGF|"0.05% Clobetasol propionate + PRGF~PRGF: 4 infiltrations (first two months) + topical administration (from third month)"
32925619|NCT04353869||Group 1|"Patients with uncomplicated diabetes and low cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
33250222|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
32724230|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
32925620|NCT04353869||Group 2|"Patients with uncomplicated diabetes and high cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
33250223|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
33250224|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
33250225|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
32925621|NCT04353869||Group 3|"Patients with complicated diabetes~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
32925622|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
32724231|NCT04542109|Experimental|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
32724232|NCT04542109|Active Comparator|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
32925623|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
32925624|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
32925625|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
32925626|NCT04334369|Sham Comparator|Single Vision Contact Lenses|
32925627|NCT04334369|Experimental|Multifocal Contact Lenses|
32925628|NCT04326179||Age 0 to 4 at day of visit|This study is based on chart reviews of data collected as part of clinical care. Data collected as part of this study will not directly inform the care of participating patients and families.
32925629|NCT04338191|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
32925630|NCT04338191|Active Comparator|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
32925631|NCT04317053|No Intervention|Site-Directed Care (SDC)|Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
32925632|NCT04317053|Experimental|Relay program (peer navigation)|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
32925633|NCT04303559|Active Comparator|Eloctate|Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
32925634|NCT04303559|Experimental|Emicizumab|Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.
32925635|NCT05303051|Experimental|Study Population|The investigators will conduct an electronic medical record (EMR) query of individuals in the University of California, San Francisco (UCSF) primary care clinics without a prior diagnosis of DM and who are undergoing, or who have recently undergone, a lab measured HBA1c before or after 1 month of enrollment. sample size estimation for testing the estimated AUROC in the validation sample vs. the null value of AUC 0.7. The investigators will target an enrollment of 5006 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.07 (i.e. AUROC = 0.76 [95%CI 0.725, 0.795]). The investigators assume that ~4% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
32724233|NCT05389865||Surgical cohort|Adult patients (18 years of age and above) who have had a surgical intervention on the proximal aorta in the three Scottish Cardiothoracic Surgery units based in Glasgow, Edinburgh, Aberdeen.
32724234|NCT05389865||Non-surgical cohort|"- Adult patients (18 years of age and above) who have a diagnosis of proximal aortopathy, but have not had surgical intervention (non-surgical/un-intervened proximal aortopathy). This cohort will be obtained from three sources:~Scottish national radiological database based on specific imaging codes~Regional genetic/inherited cardiac conditions services~Public Health Scotland via specific diagnostic ICD-10 codes."
32724235|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
32724236|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
32724237|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
32724238|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
32724239|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
32724240|NCT03980899||Patients with PPI|
32724241|NCT04310735|Experimental|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
32925636|NCT05303051|Experimental|Alternative Sample Group|The investigators also aim to perform a sensitivity analysis to estimate the DNN performance in a target general population without a diabetes diagnosis. The investigators will recruit patients from the UCSF EHR system without a history of diabetes, no prior HBA1c measured, and no history of known diabetic risk factors. The investigators will target an enrollment of 1000 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.18 (i.e. AUROC = 0.76 [95%CI 0.67, 0.85]). The investigators assume that ~3% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
32925637|NCT05295095|No Intervention|control group|Classical extubation technique : ETT was removed with continuous endotracheal suction
32925638|NCT05295095|Experimental|VSPEP|ETT was removed with APL valve set to 20cmH2O
32925639|NCT05295095|Experimental|VSAIPEP|ETT removed with ventilator parameters were set for PSV mode (inspiratory pressure of 10cmH2O and PEEP identical to that administered in the operating room
33250226|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
33250227|NCT04011904|Experimental|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%).
33250228|NCT04011904|Placebo Comparator|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
33250229|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
33250230|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
33250231|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
33250232|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
33250233|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
33250234|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
33250235|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
33250236|NCT04040595|Experimental|Adipocyte measurement|Abdominal fat biopsy
33250237|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
33250238|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
33250239|NCT03992365|Experimental|Quiklean®|Quiklean® (32 tablets)
33250240|NCT03992365|Active Comparator|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
33250241|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
33250242|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
33250243|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
33250244|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
33250245|NCT00921804|Experimental|1|AZD8529 40 mg
33250246|NCT00921804|Placebo Comparator|2|Placebo
33250247|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
33250248|NCT00949468||Keratitis group|37 patients with keratitis
33250249|NCT00949468||Control Study Group|37 control volunteers
33250250|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
33250251|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
33250252|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
33250253|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
33250254|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
33250255|NCT00859755|Experimental|ARRY-403|
33250256|NCT00859755|Placebo Comparator|Placebo|
33250257|NCT04011280|Experimental|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
33250258|NCT04011280|Active Comparator|Standard Dose Varenicline|1.0 mg twice daily with standard titration
33250259|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
33250260|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
33250261|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
33250262|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
33250263|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
33250264|NCT00385723|Experimental|1|1.25 g/d
33250265|NCT00385723|Experimental|2|2.496 g/d
33250266|NCT00385723|Placebo Comparator|3|
33250267|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
33250268|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
32925640|NCT00481091|Experimental|Phase 1: Dose Escalation Portion|Participants will receive escalating doses of ABT-263 to determine the recommended phase 2 dose (RPTD). Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
32925641|NCT00481091|Experimental|Phase 2a: Dose Expansion Portion|Participants will receive ABT-263 at the RPTD determined in Phase 1 portion. Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
32925642|NCT05454917||Patients undergoing surgery|Mechanical measures, VQ mismatch evaluation
32925643|NCT05454761|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
32925644|NCT05454761|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
32925645|NCT05454761|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
32925646|NCT00371033|Active Comparator|1|Pregabalin
32925647|NCT00371033|Placebo Comparator|2|Placebo
32925648|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
32925649|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
32925650|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
32925651|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
32925652|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
32925653|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
32925654|NCT05286203|Active Comparator|Standard of Care|Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.
32925655|NCT05286203|Experimental|MDS|Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.
32724242|NCT04310735|Experimental|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
32724243|NCT04508803|Experimental|The main research|Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
32724244|NCT04508803|Experimental|Ancillary Exploration research 1|Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
32724245|NCT04508803|Experimental|Ancillary Exploration research 2|Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
32724246|NCT04508803|Experimental|Ancillary Exploration research 3|Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
32724247|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
32724248|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
32724249|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
32724250|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.~Elotuzumab will be administered by intravenous (IV) infusion~Bortezomib as a subcutaneous injection~Lenalidomide single daily oral dose~Dexamethasone as oral tablets and IV infusion~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.~Subjects may elect to stop E-RVD Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.~- The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
32724251|NCT04492033|Experimental|CTX-009 (ABL001) and Paclitaxel (P1b)|
32724252|NCT04492033|Experimental|CTX-009 (ABL001) and Irinotecan (P1b)|1 cycle = 4weeks
32724253|NCT04492033|Experimental|CTX-009 (ABL001) and Paclitaxel (P2)|1 cycle = 4weeks
32925656|NCT05275361|Experimental|Patient: Scheduled for mammogram|"Will be asked to choose 2 social contacts (adult family member or friend identified by the participant as someone who could be engaged by the research team to encourage the participant to attend her mammogram appointment)~Will receive reminder(s) from social contact about the screening mammogram appointment~Will receive reminder from Breast Health Center about screening mammogram appointment~Will be contacted to provide experience with the study"
32925657|NCT05275361|No Intervention|Social Contact of Patient|"Facilitate enrolled patient to complete the screening mammogram.~Will receive information about screening mammograms and resources available at the Breast Imaging Center.~Will be contacted approximately 3 days prior to the patient's mammogram appointment.~Will be contacted to provide experience with the study"
32925658|NCT04202003|Experimental|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
32925659|NCT05242523|No Intervention|Control|No exposure to smells.
32925660|NCT05242523|Experimental|Olfactory Condition - 1|Participants in this condition will be exposed to the smell of natural wood scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
32768256|NCT04844333|No Intervention|Awake extubation|When the patient is in awake state, including bispectral index >70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, the cough and swallowing reflex are obvious and the circulation is stable, the endotracheal tube is removed.
32925661|NCT05242523|Experimental|Olfactory Condition - 2|Participants in this condition will be exposed to the smell of Bergamot scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
32925662|NCT05235425|Active Comparator|Standard NDPP|12-month long, calorie-restricted NDPP
32925663|NCT05235425|Experimental|Very low-carbohydrate diet (VLCD)|VLCD is an adaptation of the standard NDPP curriculum, which preserves all features with the exception of altered dietary advice.
32925664|NCT05233943||Parkinson's patients|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
32925665|NCT05233943||Healthy control group|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
32925666|NCT05229887|Active Comparator|Nostril-Tragus-Length|
32925667|NCT05229887|Experimental|Vocal cord markings|
32925668|NCT05454683|Experimental|Melatonin plus Zinc|"Dietary Supplement:~53 patients treated with melatonin 1 mg plus Zinc 10 mg"
32925669|NCT05454683|Placebo Comparator|Placebo|53 patients treated with isomaltose and magnesium stearate (excipients)
32925670|NCT05454605||group 1, ex vivo|"Assessment of the degree of cartilage damage according to the International Cartilage Regeneration & Joint Preservation Society (ICRS) classification.~Optical spectroscopy of patient tissue samples.~Study of the mechanical properties of intra-articular tissues and cartilage thickness with an indenter.~Histological assessment of tissues according to the Osteoarthritis Research Society International (OARSI) classification."
32925671|NCT05454605||group 2, in vivo|"Assessment of the degree of cartilage damage according to the ICRS classification.~Optical spectroscopy during arthroscopy/arthroplasty.~Magnetic resonance imaging (MRI)."
32925672|NCT04175249|Experimental|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
32925673|NCT05454449||symptomatic group|Individuals with patellar tendon pain last for 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score ≦80
32925674|NCT05454449||asymptomatic group|Individuals without any lower extremity pain in past 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score >80
32925675|NCT05206331|Experimental|contrast enhanced mammography|Women who have been recently diagnosed with a suspicious abnormality for which they have scheduled a breast biopsy and meet inclusion criteria will be invited to have a contrast enhanced mammography before their scheduled biopsy procedure.
32925676|NCT04146857|Placebo Comparator|Normoxia|20.9% oxygen
32925677|NCT04146857|Active Comparator|Hypoxia 1|15.0% oxygen
32925678|NCT04146857|Active Comparator|Hypoxia 2|12.8% oxygen
32925679|NCT05193071|Experimental|double antiplatelet group|aspirin 100mg plus clopidogrel 300mg
32925680|NCT05193071|Placebo Comparator|control group|aspirin placebo plus clopidogrel placebo
32925681|NCT05186051|Experimental|ZYIL1 Capsule|subject will receive 50 mg twice daily (BD) dose for 7 days
32925682|NCT05180825|Experimental|Trametinib experimental arm|the experimental arm will be Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
32925683|NCT05180825|Active Comparator|Vinblastine control arm|the control arm will be the weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
32925684|NCT04707521|Experimental|3M tape ship-shaped combined with strap fixing method|"Cutting method of 3M adhesive tape of ship shape: cut a piece of 20cm×3cm elastic adhesive tape, fold it in half to form a rectangle of 10cm×3cm, cut 5cm straight line from the middle point of the crease, cut it at an Angle of 45°, fold and open the 3M elastic adhesive tape in half, which is the adhesive tape required for fixing. The final shape is similar to that of a ship, and it is named as 3M adhesive tape of ship shape.~Fixation method: The ship shape with 3M adhesive tape was pasted upward on the opposite cheek (near zygomatic), and the endotracheal intubation was wound around for two rounds and then glued to the near cheek (near zygomatic).Put the tooth pad next to the endotracheal intubation and wrap the tooth pad and catheter together for two turns with a short 3M adhesive tape of 12cm×1.5cm.Finally, fasten it with a lacing."
32925685|NCT04707521|No Intervention|traditional X-shaped tape and string fixing|traditional X-shaped tape and string fixing
32925686|NCT04145453|Experimental|intervention group|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables. The information about genotype will be given at the beginning of study.
33250269|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
33250270|NCT04011124|Experimental|Rifampicin + Fluzoparib|
33250271|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
33250272|NCT00954772||Staged Bilateral STN DBS|
33250273|NCT00954772||Simultaneous Bilateral STN DBS|
33250274|NCT01047397|Experimental|Group 1|Active Drug
32768257|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
32925687|NCT04145453|Sham Comparator|control group 1|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables, but the information about genotype will be given at the end of study.
32925688|NCT04145453|Active Comparator|Control group 2|Participants with AVI haplotype will receive general recommendations regarding consumption of fruit and vegetables.
33250275|NCT01047397|Placebo Comparator|Group 2|Placebo
32925689|NCT04128761|Experimental|Scarcity Narrative|Participants assigned to the scarcity group will be asked to read and consider a hypothetical narrative about a sudden loss of resources.
32925690|NCT04128761|Sham Comparator|Neutral Narrative|Participants assigned to the neutral group will be asked to read and consider a hypothetical narrative about a neutral change in resources.
32925691|NCT05454059|Active Comparator|Group 1 (HH)|17 systemically healthy + periodontally healthy (normoglycemic)
32925692|NCT05454059|Experimental|Group 2 (HP)|17 systemic healthy + grade A periodontitis
32925693|NCT05454059|Active Comparator|Group 3 (T2D+H)|17 T2DM (HbA1c<%7) + periodontally healthy
32925694|NCT05454059|Experimental|Group 4 (T2D+P)|17 T2DM (HbA1c<%7) + grade B periodontitis
32925695|NCT05454059|Active Comparator|Group 5 (T2D-H)|17 T2DM (HbA1c≥%7) + periodontally healthy
32925696|NCT05454059|Experimental|Group 6 (T2D-P)|17 T2DM (HbA1c≥%7) + grade C periodontitis
32925697|NCT05161637|Experimental|TLC590 490mg|TLC590 490mg (20mL)
32925698|NCT05161637|Experimental|TLC590 588mg|TLC590 588mg (24mL)
32925699|NCT05161637|Active Comparator|Bupivacaine 75mg|Bupivacaine HCl 75mg (30mL)
32925700|NCT05161637|Active Comparator|Ropivacaine|Ropivacaine HCl 150mg (30mL) (Part 1)
32925701|NCT05161637|Placebo Comparator|Normal saline|Normal Saline 0.9% (20mL or 24mL)
32925702|NCT04110353|Active Comparator|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
32925703|NCT04110353|Active Comparator|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
32724254|NCT04458233|Active Comparator|long axis|
32925704|NCT04110353|Active Comparator|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
32925705|NCT05139095|Experimental|Cohort A|Population: ultra high-risk gestational trophoblastic neoplasia
32925706|NCT05139095|Experimental|Cohort B|Population: high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia
32925707|NCT05453669|Experimental|CD19-CAR-DNT cells|9 patientsare planned to be enrolled in the dose-escalation trial (1×10^6 CD19-CAR-DNT cells/kg, 3×10^6 CD19-CAR-DNT cells/kg, 9×10^6 CD19-CAR-DNT cells/kg) and 3 patients in the dose-expansion trial.
32925708|NCT04108247|Experimental|Abiraterone+SHR3162|
32925709|NCT04021355|Experimental|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
32724255|NCT04458233|Active Comparator|short axis|
32724256|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
32925710|NCT04021355|Experimental|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
32925711|NCT01955473|Experimental|Sym004|
32724257|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
32724258|NCT04453423|Other|First-line Treatment|
32724259|NCT04453423|Experimental|Maintenance Treatment A|
32724260|NCT04453423|Experimental|Maintenance Treatment B|
32724261|NCT04453423|Experimental|Maintenance Treatment C|
32743438|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
32925712|NCT05453435|Experimental|Entecavir prophylaxis|0.5mg qd
32925713|NCT05453279|Active Comparator|Active (experimental)|Delcetravir inhalation via dry powder inhaler device administered up to 4 single ascending doses. According to tolerability of single ascending doses, delcetravir is then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
32925714|NCT05453279|Placebo Comparator|Placebo comparator|Placebo inhaler, identical in appearance to the active comparator, administered doses up to 4 single ascending doses. According to tolerability of single ascending doses, placebo doses are then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
32925715|NCT05453123|Active Comparator|paper-handout arm|the paper-handout arm is the control group taking the home exercise printed in the paper handout.
32925716|NCT05453123|Experimental|intervention arm|the intervention arm is the experimental group where they take home exercise and motivational text messages by WhatsUp
32925717|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
32925718|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
32925719|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
32925720|NCT05451719|Experimental|Fruquintinib Plus Capecitabine|Maintenance therapy with Fruquintinib Plus Capecitabine
32925721|NCT05451719|Active Comparator|Capecitabine|Maintenance therapy with Capecitabine
32925722|NCT05131373|Experimental|Experimental 1|C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.
32925723|NCT05131373|Placebo Comparator|Placebo 1|Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections
32925724|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
32925725|NCT05126927|Experimental|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
32925726|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
32925727|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
32925728|NCT05110703|Active Comparator|Dietary supplement: Prebiotic fiber meal replacement shake|Prebiotic fiber meal replacement shake
32925729|NCT05110703|Placebo Comparator|Dietary supplement: Placebo meal replacement shake|Placebo meal replacement shake
32925730|NCT05110703|Other|Dietary guidelines|Dietary guidelines
32925731|NCT05105087|Experimental|Diagnostic (perflubutane microbubble, ultrasound)|Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.
32724262|NCT04453189|Experimental|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
32925732|NCT01898689|Experimental|RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
32925733|NCT01898689|Active Comparator|RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.
32724263|NCT04453189|Experimental|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
32724264|NCT05158855|Experimental|neutralizing antibody booster for vaccinated participants|participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract
33250276|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
33250277|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
32925734|NCT05104697|Other|TMS at visit 1, Sham at visit 2|At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location.
33250278|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
32724268|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
32724269|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
32724270|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
32724271|NCT05103085||Experimental|Patient undergoing digestive endoscopy and aged 50 years and over
32925735|NCT05104697|Other|Sham at visit 1, TMS at visit 2|At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location.
32925736|NCT05090267|Experimental|Dietary Supplement (e.g., vitamins, minerals)|Visbiome probiotic supplement
32925737|NCT05090267|Active Comparator|Device (including sham)|Transcutaneous Vagal Nerve Stimulation (tVNS)
33250279|NCT00954850||Severe asthmatics|Main study group
32925739|NCT04021121|Experimental|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
32925740|NCT04021121|Experimental|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
33250280|NCT00954850||Mild-moderate asthmatics|Control group
33250281|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
33250282|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
33250283|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location~1 hour of Ulnar nerve stimulation"
32724272|NCT03461107||patients with heart failure|
32724273|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
32724274|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
32925741|NCT04021121|Experimental|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
32925742|NCT04021121|Active Comparator|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
32925743|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
32925744|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
32925745|NCT05086757|Experimental|TRRP|Enrollment in TRRP which includes 3 major steps: (1) in-hospital education, brief risk reduction session, and tracking patients' emotional recovery via an automated text-messaging system, (2) conducting a 30-day screen via telephone to identify patients who are good candidates for psychological treatment, and (3) providing referral to formal mental health services, if needed.
32925746|NCT05086757|Active Comparator|Enhanced Usual Care|Receive brief education about mental health after traumatic injury, educational materials about mental health recovery, and local referral information to assist treatment-seeking patients in seeking care
32925747|NCT00370409|Experimental|1|Cryotherapy
32925748|NCT00370409|Placebo Comparator|2|
32925749|NCT05062577|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
32925750|NCT05062577|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
32925751|NCT05450003|Other|xp endo finisher file|
33250284|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
33250285|NCT05352100|Experimental|Hospitalized patients|This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
32925752|NCT05450003|Other|new sonic EDDY system|
32925753|NCT05450003|Other|syringe needle irrigation|
33250286|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
32724275|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
32724276|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
32724277|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.~We require a minimum of 5 seizures to occur during this phase."
32724278|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
32724279|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
32724280|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
32724281|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
32724282|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
32724283|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
32724284|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
32925754|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
32925755|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
32925756|NCT01956097|Placebo Comparator|Placebo|Placebo
33250287|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
33250288|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
32925757|NCT05449379|Experimental|Post COVID experimental group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients plus additional resistance respiratory training with the use of respiratory muscle trainer (Philips Respironics Threshold IMT).
32925758|NCT05449379|Placebo Comparator|Post COVID control group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients. No resistance set on respiratory muscle trainer (Philips Respironics Threshold IMT).
32925759|NCT05735041|Experimental|Cognitive digital therapy group|Computer-based cognitive training for 30 minutes at least 5 times a week for 12 weeks; At the end of the 12 weeks, the subjects were randomly divided into two groups. One group continued the training for 12 weeks, at least five times a week for 30 minutes each time, and the other group stopped the training.
32925760|NCT05735041|Active Comparator|Positive control group|Computer-based cognitive training tasks with low or no difficulty variation for 30 minutes at least five times a week for 12 weeks
32925761|NCT05448989|Experimental|1% atropine 5+3|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct used for 5 consecutive nights in the first week of each month, one night per week in the 2nd, 3rd, and 4th weeks; after 3 months of monocular application, change to the contralateral eye Total treatment time 1 year
32925762|NCT05448989|Placebo Comparator|1% atropine weekly|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct once a week in both eyes Total treatment time 1 year
32925763|NCT05447195|Experimental|CAN008|CAN008 IV infusion weekly
32925764|NCT05447195|Placebo Comparator|placebo|Placebo IV infusion weekly
33250289|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
32925766|NCT05441657||dyspnoeic patients with post-acute COVID-19 syndrome|Patients with persisting dyspnoeic symptoms after COVID-19 disease were examined by Electric Impedance Tomography (EIT).
32925767|NCT05441657||control group|Healthy volunteers with no lung disease and non-smokers were voluntarily examined by Electric Impedance Tomography.
32925768|NCT05049161|Experimental|Temelimab 18 mg/kg|Monthly IV repeated dose
32925769|NCT05049161|Experimental|Temelimab 36 mg/kg|Monthly IV repeated dose
32925770|NCT05049161|Experimental|Temelimab 54 mg/kg|Monthly IV repeated dose
32925771|NCT05039723|Experimental|Treatment|Treatment with Xeomin, Radiesse, and/or Belotero
32925772|NCT03996005|Experimental|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
32925773|NCT05429879|Experimental|Preferred Music Arm|This arm will allow patients to listen to their preferred music choice during their cystoscopy.
32724285|NCT05066113|Experimental|Healthy Participants|Electrothermolysis treatment using varying levels of RF energies
32724286|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
32724287|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
32724288|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
32724289|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
32925774|NCT05429879|Experimental|Classical Music Arm|Patients will listen to a standard playlist of copyright free classical music.
32925775|NCT05429879|No Intervention|No music Arm|Patients will not listen to music during cystoscopy.
32925776|NCT05391191|Experimental|MitrAssist TRISKELE® transcatheter aortic valve system|Device: MitrAssist TRISKELE® transcatheter aortic valve system
32925777|NCT03993509|Experimental|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
32925778|NCT03993509|Experimental|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
32925779|NCT03970655|Experimental|Group 1|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine with epinephrine 1:200.000 with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa fo 4 milliliters of 0.5% Bupivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side)
32925780|NCT03970655|Experimental|Group 2|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine with epinephrine 1:200.00 with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side).
32724290|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
33250290|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~the green tea extract TEAVIGO, high in EGCG and~placebo"
33250291|NCT00867555|Placebo Comparator|placebo|
33250292|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
33250293|NCT02378246|Experimental|Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily|"Table of contents:~Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg"
33250294|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin, 1 tablet daily|"Table of contents:~Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg"
33250295|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
33250296|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
33250297|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
33250298|NCT02544165|No Intervention|Control group|no intervention group
32724291|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
32724292|NCT04414345|Experimental|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
32724293|NCT04414345|Placebo Comparator|Matching Placebo|"Administration: Oral~Dosage: 2 bottles daily"
32724294|NCT05030155|Experimental|Patients with FFS=0 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336
32724295|NCT05030155|Placebo Comparator|Patients with FFS=0 - Placebo|Placebo of Mepolizumab every 4 weeks until D336
32724296|NCT05030155|Experimental|Patients with FFS≥1 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112
32724297|NCT05030155|Placebo Comparator|Patients with FFS≥1 - Placebo|Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360
32724298|NCT05010577|Experimental|BX004-A|Participants will be randomized to receive standard dose of nebulized bacteriophage
32925781|NCT05370989|Experimental|Technology-Based Parent School Program.|Technology-Based Parent School Program. This program, developing parents' self-efficacy and parenting skills in child care with the Parent School Program
32724299|NCT05010577|Placebo Comparator|Placebo|Participants will be randomized to receive nebulized placebo
32925782|NCT05370989|Active Comparator|Control group|the control group will continue to receive routine check-ups.
32925783|NCT05356247|Experimental|LTP-B Intervention|Families will take part in an online semi-structured assessment and video feedback paradigm of family interactions, with an emphasis on co-parenting and parent-child relations.
32925784|NCT05286281|Experimental|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
32925785|NCT03904823|Experimental|famitinib, HS-10296|
32925786|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
32925787|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
32925788|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
32925789|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
32925790|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
32925791|NCT05276453|Experimental|GMove Suit|Participants randomised to a group including normal therapy (physiotherapy) and the use of a lower-limb compression (GMove) Suit. All participants have previously completed normal NHS therapy.
32925792|NCT05276453|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
32925793|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
32925794|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
32925795|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
32925796|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
32925797|NCT05269745|Active Comparator|Immobilization group (IG)|One group - immobilization group (IG) - will receive the standard treatment.
32925798|NCT05269745|Experimental|Immobilization/Activity Group (IAG)|The other group - Immobilization/Activity Group (IAG) - will be treated with a new approach.
32925799|NCT05269745|Other|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned.
32925800|NCT05267171|Experimental|Intervention group|
32925801|NCT05267171|No Intervention|Control group|
32925802|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
33073415|NCT02024243||miR210 and Punch Tissue Biopsy|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
32724300|NCT04965337|Experimental|ASC42 Dose A|ASC42 tablet Dose A, once daily
32724301|NCT04965337|Placebo Comparator|Placebo Dose A|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
32724302|NCT04965337|Experimental|ASC42 Dose B|ASC42 tablet Dose B, once daily
32724303|NCT04965337|Placebo Comparator|Placebo Dose B|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
32724304|NCT03460795|Experimental|Conventional plus MSC and Tregs treatment|
32724305|NCT04452799|Experimental|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
32724306|NCT04452799|Active Comparator|standard|standard care therapy in quarantine hospitals
32724307|NCT04453111|Experimental|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
32724308|NCT04453111|Experimental|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
32724309|NCT04453111|Active Comparator|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
32724310|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
32925803|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
32925804|NCT03789617|Experimental|EBViNT Cell|
32925805|NCT05166473|Experimental|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
32925806|NCT05166473|Active Comparator|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
32925807|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
32925808|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
32925809|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
32925810|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
32925811|NCT05150483||Patients with de novo acute hypoxemic respiratory failure|We will consider for inclusion patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). De novo AHRF is defined as the requirement of oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more in a patient who does not receive long term oxygen therapy.
32925812|NCT05137925|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in a group based, videoconference format with 90 minute sessions 1x/week.
32925813|NCT05137925|Active Comparator|Treatment as Usual (TAU)|TAU, or the control group, provides information about the benefits of mindfulness in pregnancy, offers referrals for psychotherapy in the community, and involves monthly phone or videoconference calls to maintain engagement.
32925814|NCT05734963||Group 1|"Patients with histologically confirmed cancer~Tissue, blood and saliva samples collected before and after surgery and before and after any adjuvant therapy. Molecular profiling, DNA sequencing, gene expression analysis"
32925815|NCT04992611|Experimental|Circadian-Aligned Sleep Extension|A sleep extension period that roughly conforms to a given participant's circadian phase (i.e., fits the schedule of a Morning Lark vs. Night Owl).
32925816|NCT04992611|Experimental|Circadian-Misaligned Sleep Extension|A sleep extension period that does not conform to a given participant's circadian phase. In other words, this condition asks Morning Larks to extend their sleep by sleeping in later, or asks Night Owls to extend their sleep by going to bed earlier.
32925817|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
32724311|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
32724312|NCT03464851||Known ICA Fibromuscular Dysplasia|
32724313|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
32724314|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
32724315|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
32724316|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
32724317|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
32724318|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
32768258|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
33400546|NCT05272696|Experimental|Experimental|"All enrolled patients will receive two cycles of chemotherapy consisting of nab-paclitaxel (260 mg/m² on days 1), cisplatin (75 mg/m² on days 1), and Pembrolizumab (200 mg on days 1). Each cycle is repeated every 21 days.~After induction therapy, patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly. After surgery, adjuvant CRT will be given for patients with high-risk factors.~After induction therapy, patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive CRT. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment."
33400547|NCT05563116||People living with HIV (PLHIV)|"Adults over 18 living with HIV. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~PLHIV are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
32768259|NCT04423185|Experimental|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
32768260|NCT04423185|Experimental|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
32768261|NCT04423185|Experimental|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
32768262|NCT04423185|Experimental|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
32768263|NCT04423185|Experimental|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
32768264|NCT04423185|Experimental|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
32768265|NCT04423185|Experimental|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
32768266|NCT04423185|Experimental|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
32768267|NCT04423185|Experimental|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
32768268|NCT04423185|Experimental|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
32768269|NCT04423185|Experimental|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
32768270|NCT04423185|Experimental|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
32768271|NCT04423185|Experimental|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
32768272|NCT04423185|Experimental|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
32768273|NCT04423185|Experimental|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
32768274|NCT04423185|Experimental|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) & Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
32768275|NCT04423185|Experimental|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
32768276|NCT04851275|Experimental|Shared decision making for men with lower urinary tract symptoms|Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
32768277|NCT04851275|Active Comparator|No shared decision making for men with lower urinary tract symptoms|Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
32768278|NCT05392179|Experimental|ADX-2191 Three Injections|
32768279|NCT05392179|Experimental|ADX-2191 Six Injections|
32768280|NCT04373057|Experimental|Galacto-oligosaccharide|"Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.~Phase II: Subjects will receive GOS, at dose levels 0.25*MTD, 0.5*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant."
32768281|NCT04373057|Placebo Comparator|Maltodextrin|Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
32768282|NCT04851041|Experimental|Potato group|The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
32768283|NCT04851041|Active Comparator|Pasta/rice|"The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.~The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes."
32768284|NCT05391477|No Intervention|Human optical diagnosis (HOD)|The examinator will provide a HOD for every lesion (regardless of their size) found during the examination (adenoma vs non-adenoma) following one of the available validated classifications (NICE, JNET, BASIC). He/she will also give a level of confidence in his/her diagnosis (high/low confidence). However, only diminutive lesions will be considered when analyzing the main outcome. The time to get a HOD will be recorded. An in situ surveillance interval will be provided if possible.
32925818|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
32925819|NCT04969211|Experimental|Sequence A: VHX-896 then iloperidone|
32724319|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
32925820|NCT04969211|Experimental|Sequence B: Iloperidone then VHX-896|
32925821|NCT05734885|Experimental|Midwife Massage Experimental Group (1)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the research midwife. Midwife massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
32925822|NCT05734885|Experimental|Spouse Massage Experimental Group (2)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the spouse of the pregnant woman. Massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
32925823|NCT05734885|No Intervention|Control Group|It will be perform routine practice who the women in the control group.
32925824|NCT03779867|Experimental|Arm I (acute exercise)|Participants undergo a moderate-intensity acute exercise bout over 45 minutes.
32925825|NCT03779867|Active Comparator|Arm II (rest)|Participants rest by sitting for 45 minutes.
32925826|NCT05090345||Biorepository trial of children and adolescents/young adults (AYA)|undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
32925827|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
32925828|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
32925829|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
32925830|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
32925831|NCT05049005|Active Comparator|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
32925832|NCT05049005|Experimental|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
32925833|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
32724320|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
32724321|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
32724322|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
32724323|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
32925834|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
32724324|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
32724325|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
32724326|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
32724327|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
32724328|NCT04453345|Experimental|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
32724329|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
32724330|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
32724331|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
32724332|NCT01633541|Experimental|platinum/docetaxal + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
32768285|NCT05391477|Experimental|Artificial intelligence optical diagnosis (AIOD):|GI-Genius will provide an artificial intelligence diagnosis (AIOD) for every lesion detected (adenoma vs non-adenoma). Only diminutive lesions will be considered for the analysis of the main outcome. However, data on larger lesions will be recorded to describe GI-Genius´ performance in detail (secondary outcome). The time to get an AIOD will be recorded. An in situ surveillance interval will be provided if possible
32768286|NCT04851197|Experimental|control group|"The students in the control group will be filled with the Introductory and Self-Testicular Examination Characteristics Question Form, Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale, which will be prepared with Microsoft teams forms before the training. Later, the students will be given an average of 20-30 minutes of training from Powerpoint presentation and video presentation. Students' questions will be answered in the last 10 minutes. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and KKTM Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled out."
32768287|NCT04851197|Experimental|Intervention|"Before the training, the students in the intervention group will fill the Introductory and Characteristics Question Form on Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale. Educational materials (lecture presentation, video) will be loaded on the system in accordance with the inverted learning model, and students will be asked to come prepared for the planned lesson. Classical presentations will not be made to the students, and the education will be given in the form of question and answer discussion. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and Self Testicular Examination Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled."
32768288|NCT05414877|Experimental|Ephedrine|receive ephedrine (configured concentration 2 mg/mL). The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
32768289|NCT05414877|Experimental|Phenylephrine|receive intravenous infusion of phenylephrine (configured concentration 0.1 mg/mL) The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
32768290|NCT05414877|Experimental|norepinephrine|intravenous infusion of norepinephrine (configured concentration of 6 μg/ml).The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
32768291|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
32768292|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
32768293|NCT04423419|Other|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
32768294|NCT04423419|Other|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
32768295|NCT04423419|Other|C|will receive ordinary IV analgesia during operation hip arthroscopy
32768296|NCT04850885|Experimental|Dexamethasone Group ( Group DXN)|Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
32768297|NCT04850885|Active Comparator|Adreanaline Group ( Group ADN)|Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
32768298|NCT05390385|Placebo Comparator|Control placebo|
32768299|NCT05390385|Experimental|KE1 5g|
32768300|NCT05390385|Experimental|KE1 10g|
32768301|NCT05390385|Experimental|KE4 5g|
32768302|NCT05390385|Experimental|KE4 10g|
32768303|NCT04851353|Active Comparator|GT+VC|Gentle touch +Verbal comfort
32768304|NCT04851353|Experimental|GT+VC+Smell|Gentle touch +Verbal comfort+ Smell breast milk
32768305|NCT04851353|Experimental|GT+VC+Smell+Taste|Gentle touch +Verbal comfort+ Smell breast milk+ Taste milk
32768306|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
32768307|NCT05388981|Experimental|SBT115301|Escalating single doses of SBT115301
32768308|NCT05388981|Placebo Comparator|Placebo|Single dose of matched placebo
32768309|NCT04844177|Experimental|intervention/treatment|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
32768310|NCT04844255|Other|Pre and post intervention group|Same individuals are examined before and after taking 2 tablets of salt
32768311|NCT04843865|Experimental|Chinese Herbs|Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.
32768312|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
32768313|NCT04850417|Experimental|Beta-blockers and Short Antiplatelet Therapy|"Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
32925835|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
33400548|NCT05563116||HIV negative subjects|"Adults over 18 without HIV infection. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~HIV- subjects are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
32724333|NCT01633541|Active Comparator|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
32724334|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
32724335|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
32724336|NCT04456595|Experimental|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
32724337|NCT04456595|Experimental|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
32724338|NCT04456595|Placebo Comparator|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
32724339|NCT04456595|Placebo Comparator|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
32724340|NCT03896269|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
32724341|NCT03883165|Experimental|high-intensity neck strengthening group|
32724342|NCT03883165|Experimental|low-intensity neck strengthening group|
32724343|NCT03883165|Other|Control group|
32724345|NCT04934371|Active Comparator|active TDCS and listening therapy|TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
32724346|NCT04934371|Sham Comparator|sham TDCS and listening therapy|The sham stimulation will also last for 20 min with 15 sec ramp-up and ramp-down, except the current will be turned down gradually to 0 milliamperes (mA) after 30 seconds. The sham procedure provides the same tingling and itching sensation felt during active tDCS. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
32724347|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
32724348|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
32724349|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
32724350|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
32724351|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
32724352|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
32724353|NCT05166005|Active Comparator|High dose|High dose Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week of hospitalization
32724354|NCT05166005|Placebo Comparator|Low dose|Vitamin D therapy will prescribe at a dosage of 2,000 IU/day
32724355|NCT05389397|Placebo Comparator|Mailed Letter|
32724356|NCT05389397|Active Comparator|Secure Message|
32724357|NCT05389397|Active Comparator|Telephone Outreach|
32724358|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
32724359|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
32724360|NCT02522741|Experimental|Parenting STAIR|
32724361|NCT05383781|Active Comparator|Hip and Knee exercise group|Individuals in this group will perform exercises for the Hip and knee only.
32724362|NCT05383781|Experimental|Hip , Knee exercise and SFE group|Individuals in this group will perform exercises for Hip , knee and also short foot exercise
32724363|NCT05381441|Experimental|SAFE Loop Arm|Nursing units involved in the intervention arm will participate in an iterative educational and quality improvement process that encourages improved reporting of medication safety events deemed important to their individual nursing units.
32724364|NCT05381441|No Intervention|Control Arm|Nurses in this study will continue standard practice protocol.
32724365|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
32724366|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
32724367|NCT05388071||Intervention: Treatment with the aid of telemedicine|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
33250299|NCT05343156|Experimental|DexNP Eye Drop|The study eye received 1 DexNP eye drop 3 times a day (every 8 hours) for 12 weeks.
33250300|NCT05343156|Placebo Comparator|Vehicle Eye Drop|The study eye received 1 vehicle eye drop 3 times a day (every 8 hours) for 12 weeks.
33250301|NCT00955162|Active Comparator|Subutex|
33250302|NCT00955162|Experimental|Suboxone|
33250303|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
32724368|NCT05388071||No intervention: Usual treatment|Treatment will be performed as usual without the usage of telemedicine.
32724369|NCT04877743||Prospective Cohort|This prospective cohort study will include participants who receive the AZD1222 vaccine. Enrolment is permitted within 28 days of the first dose of AZD1222 and can be completed at the vaccination site or remotely.
32724370|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
32724371|NCT03936413|Experimental|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
32724372|NCT03936413|Active Comparator|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
32724373|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
32724374|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
32724375|NCT05165615|Experimental|AndroidAPS versus Control-IQ|Patients with use of the Control-IQ system (closed-loop hybrid system) and previous users of AndroidAPS (closed-loop hybrid system)
33250304|NCT00867633||RCC|the DNA sample extracted from RCC
33250305|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
33250306|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
33250307|NCT00742664|Placebo Comparator|2|
32724376|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
32724377|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
32724378|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
32724379|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
33250308|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
33250309|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
33250310|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
33250311|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
33250312|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
33250313|NCT05291364|Active Comparator|Group 1|injection of ethanol and lidocaine with dexmedetomidine
33250314|NCT05291364|Active Comparator|Group 2|injection of ethanol and lidocaine Without dexmedetomidine
33250315|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
33250316|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
33250317|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
33250318|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
33250319|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
33250320|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
33250321|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
33250322|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
33250323|NCT04019379|Experimental|Sequence A|Low Ca/High Phos crossover to Low Ca/Low Phos
33250324|NCT04019379|Experimental|Sequence B|Low Ca/Low Phos crossover to Low Ca/High Phos
33250325|NCT05351788|Experimental|SKB264+KL-A167|Participants received SKB264 followed by KL-A167
33250326|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
33250327|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
33250328|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
33250329|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
33250330|NCT00385255|Experimental|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
33250331|NCT00385255|Experimental|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
33250332|NCT04009005|No Intervention|Usual care|Participants will receive usual care from their treating neurologist
32724380|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
32724381|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
32724382|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
32724383|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
32724384|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
32724385|NCT03460249|Active Comparator|as above|as above
32724386|NCT03788213|Active Comparator|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
32724387|NCT03788213|Experimental|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
32724388|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
32724389|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
32724390|NCT04870801|No Intervention|Low Oxygen Visits without Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
32724391|NCT04870801|Experimental|Low Oxygen Visits with Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
32724392|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
32724393|NCT03468439|Other|femoral nerve block|
32724394|NCT05165303|Experimental|lidocaine with propofol|
32724395|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
32724396|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
32724397|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
32724398|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
32724399|NCT05340179|Active Comparator|Interlaminar cervical epidural steroid injection|
32724400|NCT05340179|Experimental|Cervical selective nerve root block|
32724401|NCT03129841|Experimental|early dinner+Diet|
32724402|NCT03129841|Experimental|late dinner+Diet|
32724403|NCT05165147||physical examination population|From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
32724404|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
32724405|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
32724406|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
32724407|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
32724408|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
32724409|NCT05165069|Experimental|Mecobalamin group|Mecobalamin (0.5mg / time, 3 times / day) for 6 months
32724410|NCT05165069|Placebo Comparator|Placebo group|placebo (0.5mg / time, 3 times / day) for 6 months
32724411|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
32724412|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
32724413|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
32724414|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
32724415|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
32724416|NCT03459703|Experimental|Early Time-Restricted Feeding|
32724417|NCT03459703|Active Comparator|Control Schedule|
32724418|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
33073418|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
32724419|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
32724420|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
32724421|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
32724422|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
32724423|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
32925836|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
32925837|NCT04947527|Experimental|Test Varnish|Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
32925838|NCT04947527|Active Comparator|Control Varnish|Control Varnish. 5% (w/v) Sodium Fluoride .
32925839|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
32925840|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
32925841|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
32925842|NCT05740189|Experimental|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
32925843|NCT04929743|Experimental|5.5 mm implants|
32925844|NCT04929743|Active Comparator|>6.5 mm implants|
32925845|NCT04707599|No Intervention|OFF intervention|No reminder plus (telephone reminder from therapist) but standard test message reminder (SMS) from second admission
32925846|NCT04707599|Experimental|ON intervention|Reminder plus (telephone reminder from therapist) AND standard test message reminder (SMS) from second admission
32925847|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
32925848|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
32925849|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514|Participants will receive ABBV-514.
32925850|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 in combination with pembrolizumab.
32925851|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.
33400549|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
33400550|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
33400551|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
33400552|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
33400553|NCT05254990|Experimental|Reparixin + standard of care|"Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days.~The three daily doses will be administered maintaining an interval between doses of about 8 hours."
32724424|NCT05164913||Control group|No general anesthesia between 0-3 years old or 0-5 years old
32925852|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with pembrolizumab
32925853|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Budigalimab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.
32925854|NCT05734651||Intervention|
32925855|NCT04994327|Experimental|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
32925856|NCT04994327|Placebo Comparator|Control bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
32925857|NCT05740033|Active Comparator|STSG arm|"Patient demographics will be recorded during the enrollment visit. During the participant's surgery in which the radial forearm free flap (RFFF) has been used, surgeons will perform a split-thickness thigh graft to close the forearm donor site. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
32925858|NCT05740033|Active Comparator|Hatchet flap arm|"Patient demographics will be recorded during the enrollment visit. The hatchet flap closure of the forearm donor site will be performed following the RFFF's usage. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
32925859|NCT04957823||Diseased|type II diabetic patients with documented coronary artery disease.
32925860|NCT04957823||Control|type II diabetic patients without coronary artery disease.
32925861|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
32925862|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
32925863|NCT04921007|Active Comparator|Group (A) Sacral ESP block|Ultrasound guided sacral erector spinae plane (ESP) block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
32925864|NCT04921007|Active Comparator|Group (B) Caudal block|Ultrasound guided caudal block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
32925865|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
32925866|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
32724425|NCT05164913||Single anesthesia group|Only once general anesthesia between 0-3 years old or 0-5 years old
32724426|NCT05164913||Multiple anesthesia group|More than once general anesthesia between 0-3 years old or 0-5 years old
32724427|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
32724428|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
32724429|NCT03468725|Experimental|XPF-008|Single oral dose
32724430|NCT03468725|Active Comparator|Placebo|Single oral dose
32724431|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
32724432|NCT05164679|Experimental|MMT|Intervention group performing multimodal training (MMT) 1-2 hours weekly
32724433|NCT05164679|No Intervention|CON|Sedentary control group
32724434|NCT03459157|Other|HIV prevention package including PrEP|
33073420|NCT01964989|Experimental|aQIV|flu vaccine
32724435|NCT05153135||Ribociclib|Participants who initiated CDK4/6i therapy
32724436|NCT05153135||Palbociclib|Participants who initiated CDK4/6i therapy
32724437|NCT05153135||Abemaciclib|Participants who initiated CDK4/6i therapy
32724438|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
32724439|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
32724440|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
32724441|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
32724442|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
32724443|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
32724444|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
32724445|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
32724446|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
32724447|NCT05091749|Experimental|chronic coronary syndromes|
32724448|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
32724449|NCT02616185|Experimental|Dose Escalation|PF-06753512
32724450|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
32724451|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
32724452|NCT05697419|Other|DPT students at YSU|
32724453|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
32724454|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
32724455|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
32724456|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
32724457|NCT05697341|Active Comparator|Ultra-Mini-PCNL Group (A)|In The Ultra-Mini-percutaneous nephrolithotomy group, a 5 Fr open-ended ureteral catheter was introduced and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anesthesia. Patients were then repositioned to the prone position. Ultra-mini-PCNLs were done in a prone position by a single consultant. The desired calyx was punctured with a Cook diamond tip 18G puncture needle under fluoroscopy guidance using standard bull's eye technique. Single tract dilatation with One Step Dilator (11Fr), with central channel for guide wires with its Operating Sheath (Storzz Dilator and Operating Sheaths for MIP XS) under fluoroscopy guidance. Storzz Nephroscope for MIP XS / S along with Swiss Lithoclast master pneumatic lithotripter with 1/0.8 mm probe was used for stone fragmentation. Stone fragments are flushed out on rapid removal of the endoscope, due to a 'vortex' effect and with wash through the operating sheath using a 6 Fr. nelaton catheter.
33073421|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
32724458|NCT05697341|Active Comparator|Stented SWL Group (B)|In the stented ESWL group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anathesia. JJ is applied either 5-26 or 5-28 accorging to the patient. Extracorporeal shock wave lithotripsy ESWL was administered with an electromagnetic shockwave lithotripter (Siemens electromagnetic lithotripters devices). Patients were positioned supine with the shock head from the back. Fluoroscopy was used for the localization and monitoring of stone fragmentation. All patients received shocks at a frequency of 60/min. An average of approximately 2500-3000 shocks was targeted in all patients.
32724459|NCT04857307|Experimental|Staccato alprazolam|The study participants will receive a single dose of Staccato alprazolam.
32724460|NCT03463291||Study group|All patients with bony lesions
32724461|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
32724462|NCT04230967|Experimental|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
32724463|NCT04230967|Active Comparator|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
32724464|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
32724465|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
32724466|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
32724467|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
32724468|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
32724469|NCT05170711|Experimental|hypotensive anesthesia|hypotensive anesthesia group
32724470|NCT05170711|Active Comparator|normotensive anesthesia|normotensive anesthesia group
32724471|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
32724472|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
32724473|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
32724474|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
32724475|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
32724476|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
32724477|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
32724478|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
32724479|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
32724480|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
32724481|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
32724482|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
32724483|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
32724484|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
32724485|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
33073422|NCT01953016||immunodeficiency|Individuals of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
33073423|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
33073424|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
32925867|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
32925868|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
32925869|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
32925870|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
33400554|NCT05254990|Placebo Comparator|Placebo + standard of care|Placebo tablets are identical in appearance to the active formulation. Placebo will be administered with the same treatment schedule.
33400555|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
33400556|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
33400557|NCT05547906|Experimental|ASCA101 IV|The study drug, ASCA101(300mg/vial), will be reconstituted in water for injection and diluted with saline to a dose calculated according to individual body surface area or body weight.
32724486|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
32925871|NCT03562637|Experimental|Adagloxad simolenin + OBI-821 in conjunction with SOC|"Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.~Patient will also receive standard of care (SOC) treatment."
33400558|NCT03709758|Experimental|Venetoclax+Daunorubicin+Cytarabine|"Venetoclax administered orally on days 1 to 11 daily~Daunorubicin administered intravenously on days 2-4~Cytarabine administered on days 2-8 by continuous IV infusion"
33400559|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
33400560|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
33400561|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
33400562|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
33400563|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
33400564|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as Arm I and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
33400565|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
32925872|NCT03562637|Active Comparator|Standard of Care treatment|"Study visit intervals will be identical to those in Arm 1.~Patient will receive standard of care (SOC) treatment."
32925873|NCT01905241|Experimental|Anatomic TSA using RTI|During Anatomic Total Shoulder Arthroplasty (TSA), the surgeon will have use of the SmartBone and the bone cement mold made from the SmartBone (the RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
32925874|NCT04903223|No Intervention|Baseline Mevalonate and MRI Imaging|
32925875|NCT04903223|Experimental|Mevalonate Change After Rosuvastatin|
33400566|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
33400567|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
33400568|NCT05250856|Experimental|CNP-201 1 mg|intravenous infusion on Day 1 and Day 8: 1 mg CNP-201
33400569|NCT05250856|Experimental|CNP-201 2 mg|intravenous infusion on Day 1 and Day 8: 2 mg CNP-201
33400570|NCT05250856|Experimental|CNP-201 4 mg|intravenous infusion on Day 1 and Day 8: 4 mg CNP-201
33400571|NCT05250856|Experimental|CNP-201 8 mg|intravenous infusion on Day 1 and Day 8: 8 mg CNP-201
33400572|NCT05250856|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
33400573|NCT01971008|Experimental|Elastic abdominal binder, then placebo binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 1 and a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 3, after wash-out on day 2"
33400574|NCT01971008|Experimental|Placebo binder, then elastic abdominal binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 1 and an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 3, after wash-out on day 2"
33400575|NCT04691544|Active Comparator|Fecal microbiota transplant from donor A|One FMT delivered by enema
33400576|NCT04691544|Active Comparator|Fecal microbiota transplant from donor B|One FMT delivered by enema
33400577|NCT04691544|Active Comparator|Fecal microbiota transplant from donor C|One FMT delivered by enema
33400578|NCT04691544|Placebo Comparator|Fecal microbiota transplant from autologous feces|One FMT delivered by enema
33400579|NCT05397496|Experimental|PIT565 Group A (dose escalation part)|PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure
33400580|NCT05397496|Experimental|PIT565 Group B (dose escalation part)|PIT565 in adult R/R ALL patients
33400581|NCT05397496|Experimental|PIT565 Group A1 (dose expansion part)|PIT565 in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients who did not receive CD19-directed CAR-T therapy
33400582|NCT05397496|Experimental|PIT565 Group A2 (dose expansion part)|PIT565 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients who received CD19-directed CAR-T therapy
33400583|NCT05397496|Experimental|PIT565 Group B1 (dose expansion part)|PIT565 in adult R/R ALL patients
33400584|NCT04058912||PATİENCE GROUP|"To be in the range of 18-40 years~Patients with an operation indication with >=5 cm endometrioma~Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)~Patients who will be followed for IVF cycle due to infertility"
33400585|NCT04058912||PATİENCE-CONTROL GROUP|"To be in the range of 18-40 years~Patients with operation plan due to non-endometrioma ovarian pathologies~Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)~Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
33400586|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
33400587|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
33400588|NCT05243836|Active Comparator|MiSight®|MiSight® Contact Lens (Omafilcon A, 60% water)
33400589|NCT05243836|Experimental|S.T.O.P® F2|S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
33400590|NCT05243836|Experimental|S.T.O.P® DT|S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
33400591|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
33400594|NCT04759846|Experimental|Group with normal hepatic function|Normal hepatic function
33400595|NCT04759846|Experimental|Group with moderate hepatic impairment|Moderate hepatic impairment (Child-Pugh Class B)
33400596|NCT04759846|Experimental|Group with severe impairment|Severe impairment (Child-Pugh Class C)
33400597|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
33400598|NCT03032172|Experimental|Risdiplam|Participants will receive multiple doses of risdiplam orally once daily for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label extension (OLE) phase.
33400599|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
33400600|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
33400601|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
33400602|NCT01383798|Experimental|Ferrous sulfate|
33400603|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
32724487|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
32724488|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
32724489|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
32724490|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
32724491|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
32724492|NCT05682937|Experimental|HFOV-sigh mode|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention.
32724493|NCT04754893|Experimental|Group A|Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)
32724494|NCT04754893|No Intervention|Group b|Standard of care by staying one night in the hospital before returning home (group B)
32724495|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
32724496|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
32724497|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
32724498|NCT03453541|Experimental|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
32724499|NCT03453541|Placebo Comparator|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
32724500|NCT03453463|Experimental|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
32724501|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
32724502|NCT05072041|Experimental|Test group|Degradable embolic microsphere (Nexsphere™)
32724503|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
32724504|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
32724505|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
32724506|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
32724507|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
32724508|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
32724509|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
32724510|NCT03462589|Placebo Comparator|SY-008 matching placebo|from 6mg to 30mg
32925876|NCT04735835|Experimental|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
32925877|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
32925878|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
32925879|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
32925880|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
32925881|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
32925882|NCT04730921|Experimental|LBBAP group|AV block patients randomized to left bundle branch area pacing
32925883|NCT04730921|Active Comparator|RVP group|AV block patients randomized to right ventricular pacing group
32925884|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
32925885|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
32925886|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
32724511|NCT04944277|No Intervention|Without ThoughtFullChat Application|Participants will not use the app during the 3 months
32724512|NCT04944277|Experimental|With ThoughtFullChat Application|Participants will be using the app during the 3 months
32724513|NCT00893789|Experimental|1|Armodafinil 50 mg/day
32724514|NCT00893789|Experimental|2|Armodafinil 150 mg/day
32724515|NCT00893789|Experimental|3|Armodafinil 250 mg/day
32925887|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
32925888|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
32925889|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
32925890|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
32724516|NCT00893789|Placebo Comparator|4|Placebo
32724517|NCT04864483|Experimental|Early sahoor with predawn snack|"To take the Sahoor meal 1:30-2 hours before dawn with insulin dose then a pre-dawn snack with no insulin~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
33250333|NCT04009005|Experimental|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
32724518|NCT04864483|Experimental|Late Sahoor meal (within 30 minjted of dawn) with insulin dose|"To take sahoor meal as late as possi le with usual insulin dose~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
32724519|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
32724520|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:~3mg/kg Ropivacain 1%~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
32724521|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
32724522|NCT04858867|Other|Cohort 1|"Study procedures~Lenvatinib during week 1-12~rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 6, 12, 24 and 36~Tg levels at week 0, 6, 12, 24 and 36~QoL assessment at week 0, 6, 12, 24 and 36"
32724523|NCT04858867|Other|Cohort 2|"Study procedures (in case of 12-wk lenvatinib):~Lenvatinib during week 1-12~rhTSH-stimulated I-124 dosimetry at week 0 and 12~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 12, 24 and 36~Tg levels at week 0, 6, 12, 24 and 36~QoL assessment at week 0, 6, 12, 24 and 36~Study procedures (in case of 6-wk lenvatinib)~Lenvatinib during week 1-6~rhTSH-stimulated I-124 dosimetry at week 0 and 6~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36~Tg levels at week 0, 6, 12, 24, 30 and 36~QoL assessment at week 0, 6, 12, 24, 30 and 36"
32724524|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
32925891|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
32925892|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
32925893|NCT01907269|No Intervention|Usual care|
32925894|NCT04697849|Experimental|CREST|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
32925895|NCT04697849|Active Comparator|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
32925896|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
32925897|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
33250334|NCT05299996|Experimental|all patients having stones in the upper tract of anomalous kidney|"patients having stones in abnormal anatomy , example horse-shoe kidney ,malrotation, crossed fusion , duplex collecting system. The stone size is 1 cm to 2.5 cm or 3.5 cm with variable density , located in calyx or the pelvis , single or multiple.~the patient complain may be abdominal pain , loin pain, uremic symptoms .ct-kub non contrast , full lab & fitness before the operation."
33250335|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
32925898|NCT04679831|Experimental|Ujiplus® porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
32925899|NCT04679831|Active Comparator|Praziquantel 400mg|Arm receiving the approved Praziquantel treatment of 400mg once with plain porridge daily (without papaya seeds)
32925900|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
32925901|NCT00371423|Experimental|Arm 1|
32925902|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
32925903|NCT04882397|Experimental|Instrument Assisted Soft Tissue Mobilization|In the application group, Instrument Assisted Soft Tissue Mobilization will be applied to the Trapezius and Sternocleideomastoideus muscles for 90 seconds.
32925904|NCT04882397|Sham Comparator|Sham Instrument Assisted Soft Tissue Mobilization|In the sham application group, 90 degrees to 90 seconds will be applied to the Trapezius and Sternocleideomastoideus muscles without applying pressure.
32925905|NCT04882397|No Intervention|Control|No application will be made to the control group.
33250336|NCT04005339|Experimental|Single Arm|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
33250337|NCT00949780|Active Comparator|chloral hydrate , sedative|
33250338|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
33250339|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
32925906|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
33250340|NCT04061408|Experimental|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
33250341|NCT04011670|Active Comparator|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
33250342|NCT04011670|Placebo Comparator|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
32925907|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
33250343|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
33400604|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
33400605|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
33400606|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
33400607|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
33400608|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
33400609|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
33400610|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
33400611|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
33400612|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
33400613|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
33400614|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
33400615|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
33400616|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
33400617|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
33400618|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
33400619|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
33400620|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
33400621|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
33400622|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
33400623|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
33400624|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
33400625|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
33400626|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
33400627|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
33400628|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
33400629|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
33400630|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
33400631|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
33400632|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
33400633|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
33400634|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
33400635|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
33400636|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
33400637|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
32925908|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
32925909|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
32925910|NCT04873115|Active Comparator|Sialanar|Sialanar administered as per the SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
32925911|NCT04873115|Placebo Comparator|Placebo|Placebo administered as per the Sialanar SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
32925912|NCT00370721|Experimental|I|
32925913|NCT03459521|Experimental|Fendrix HBV vaccine or HBVaxpro 40|"Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 20mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1, 2 and 6 months.~Drug: HBVaxpro 40 Sanofi Pasteur MSD Route of administration, dose regimen: Intra-muscular Dose: 40mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1 and 6 months."
32925914|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
32925915|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
32925916|NCT04558229|No Intervention|Standard of Care Clinician Counseling|
32925917|NCT04558229|Experimental|Additional Standardized Counseling|
32925918|NCT04527887|Active Comparator|Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)|intracanalicular dexamethasone insert
32925919|NCT04527887|Placebo Comparator|ProLong™ collagen plugs|collagen plug
32925920|NCT04486859|Other|mechanical prevention|patients were managed with IPC
32925921|NCT04486859|Other|mechanical plus anticoagulant drugs prevention|patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery
32925922|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
32925923|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
32925924|NCT04404959|Active Comparator|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
32925925|NCT04404959|Placebo Comparator|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
32925926|NCT05739877|Experimental|Sequence A(Before→ After)|
32925927|NCT05739877|Experimental|Sequence B(After→ Before)|
32925928|NCT04403711|Active Comparator|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
32925929|NCT04403711|Placebo Comparator|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
32925930|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
32925931|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
32724525|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
32724526|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
32724527|NCT05697263|Experimental|Follicle phase based training|Follicular phase-based training five times a week during the follicular phase (the first two weeks of the menstrual cycle) and thereafter once a week for the rest of the cycle.
32724528|NCT05697263|Experimental|Luteal phase based training|Luteal phase-based training five times a week during the luteal phase (from ovulation to next menstruation) and once a week in the follicular phase.
32925932|NCT04403087|Experimental|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
32925933|NCT04403087|No Intervention|Control group|Bismuth-containing quadruple regimen
32925934|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
32724529|NCT05697263|Experimental|Regular training|Regular training three times a week throughout the menstrual cycle (control group).
32925935|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
32925936|NCT04399421||Conventional pedicle screw fixation|Patients undergoing conventional pedicle screw fixation without the use of bone cement.
32925937|NCT04399421||Cement-augmented pedicle screw fixation|Patients undergoing pedicle screw fixation augmented with bone cement.
32925938|NCT04389671|Experimental|Lyophilized Lucinactant|Lyophilized Lucinactant reconstituted with sterile water for injection
32925939|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
32925940|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
32925941|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
32925942|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
32925943|NCT04358393|Experimental|APG-115 monotherapy|Monotherapy given in part 1
32925944|NCT04358393|Experimental|APG-115 + 5-azacitidine combination|Combination therapy given in part 2
33400638|NCT02802384||Cases|People with active Paget's Disease of Bone
33400639|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
32724530|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
32724531|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
32724532|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
32768314|NCT04850417|Experimental|Beta-blockers and Long Antiplatelet Therapy|"Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
32768315|NCT04850417|Experimental|No Beta-blockers and Short Antiplatelet Therapy|"No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
32768316|NCT04850417|Active Comparator|No Beta-blockers and Long Antiplatelet Therapy|"No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
32768317|NCT04843943|Experimental|Sintilimab+Bevacizumab|
32768318|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 1|Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.
32768319|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 1|Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.
32768320|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 2|Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.
32768321|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 2|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.
32768322|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 3|Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.
32768323|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 3|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.
32768324|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 4|Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.
32768325|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 4|Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.
32768326|NCT04850261|Active Comparator|Intervention A: hCG injection|Ovulation induction by subcutaneous injection of 5.000 IU hCG
32768327|NCT04850261|Experimental|Intervention B: nasal application of Nafarelin|Ovulation induction by nasal application of 200 microgram Nafarelin
32768328|NCT04850027||Lower rectal cancer patients with a LLN ≥ 5mm|Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.
32768329|NCT04850183|Experimental|Intervention group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.
32768330|NCT04850183|No Intervention|Control group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
32768331|NCT04849949|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
32768332|NCT04849949|Experimental|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
32768333|NCT04849949|Experimental|English Walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
32768334|NCT04843553|Active Comparator|active|Participants receiving oral vitamin B-3
32768335|NCT04843553|Placebo Comparator|placebo|Participants receiving oral inactive pill
32768336|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
32768337|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
32768338|NCT02684461|Active Comparator|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
32768339|NCT04843475||MPNs patients who have echocardiographic probability of PH.|
32768340|NCT04843475||MPNs patients who do not have echocardiographic probability of PH|
32768341|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
32768342|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
32768343|NCT05373199|Experimental|BC Combo THDB0207|Single administration of BC Combo THDB0207
32768344|NCT05373199|Active Comparator|Lantus®|Single administration of Lantus®
32768345|NCT05373199|Active Comparator|Humalog®|Single administration of Humalog®
32768346|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
32925945|NCT05739799|Active Comparator|Group A Intense pulse light laser|IPL laser Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded
32925946|NCT05739799|Active Comparator|Group B Diode laser|Diode laser patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
32925947|NCT04354727|Experimental|APG-1252|
32925948|NCT04354727|Experimental|APG-1252 + Ruxolitinib|
32925949|NCT05739721|Experimental|Zoom meeting (camera off)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
32925950|NCT05739721|Experimental|In person meeting (blindfolded)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
32925951|NCT05739721|Experimental|Zoom meeting (camera on)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
32925952|NCT05739721|Experimental|In person meeting (no blindfold)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
32925953|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
32925954|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
32925955|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
32724533|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
32724534|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
32724535|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
32724536|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
32724537|NCT03449251|Experimental|Substudy 5 - Relaxin/Saline|In sub-study 5 Healthy participants will be allocated to 1 of 4 Relaxin dosing groups and will receive dorsal hand vein infusion of 3 incremental doses of Normal Saline/ D5W and Relaxin
32724538|NCT05696483|Experimental|Active|Active OLX-07010 in single ascending and multiple ascending dose cohorts
32724539|NCT05696483|Placebo Comparator|Placebo|OLX-07010 placebo in single ascending and multiple ascending dose cohorts
32925956|NCT05739643|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Group 1: N=3 patients with Infantile Krabbe disease with previous HSCT will receive a single infusion at the low dose Group 2: N=3 patients with Late Infantile Krabbe disease with previous HSCT will receive a single infusion at the low dose
32925957|NCT05739643|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Group 1: N=3 patients with Infantile Krabbe disease with previous HSCT will receive a single infusion at the high dose Group 2: N=3 patients with Late Infantile Krabbe disease with previous HSCT will receive a single infusion at the high dose
32925958|NCT04330859|Experimental|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
32925959|NCT04330859|Placebo Comparator|Routine care|Routine care per unit guidelines
32925960|NCT04748887||nonsmokers copd cases ,|Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
32925961|NCT04748887||non smokers healthy control|Thirty subjects of non smokers healthy control
32724540|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
32724541|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
32724542|NCT04800133|Experimental|BNT162b2 (adult/adolescent)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (or intradermal for immunocompromised patients; or by graded challenge with history of non-severe allergy to PEG-containing drugs) 30ug/0.3ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
32724543|NCT04800133|Experimental|CoronaVac (intramuscular)|CoronaVac by SinoVac Intramuscular injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
32724544|NCT04800133|Experimental|CoronaVac (intradermal)|CoronaVac by SinoVac Intradermal injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
32925962|NCT04748575|Experimental|Acai smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the acai smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the placebo smoothie.
32925963|NCT04748575|Experimental|Placebo smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the placebo smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the acai smoothie.
32925964|NCT04792463||Patients with personal and/or family history suggestive of hereditary BAP1|Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
32724545|NCT04800133|Experimental|BNT162b2 (paediatric)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (for immunocompromised patients only) 10ug/0.1ml per dose 4 doses for immunocompromised patients
32724546|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
32925965|NCT04792463||Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance|"Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members~Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1"
32925966|NCT05739487||IAT therapy|patients with central retinal artery occlusion received selective intra-arterial thrombolysis
32925967|NCT04785443|Experimental|ICG group|Patient receiving 2 or 3 intraoperative injections of indocyanine green.
32925968|NCT04785443|Other|Control group|Patient benefiting from the traditional surgical act
32925969|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
32925970|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
32925971|NCT03298451|Experimental|Arm 1|Durvalumab
32925972|NCT03298451|Experimental|Arm 2|Durvalumab in combination with tremelimumab (Regimen 1)
32925973|NCT03298451|Experimental|Arm 3|Durvalumab in combination with tremelimumab (Regimen 2)
32925974|NCT03298451|Active Comparator|Arm 4|Sorafenib
32925975|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
32925976|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
32925977|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
32925978|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
32724547|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
32724548|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
32724549|NCT05164601||Observation group|
32724550|NCT05322499|Experimental|Combined chemotherapy group|"Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w);~Chemotherapy (considered by investigator on a patient-by-patient basis):~Irinotecan: 100-125mg/m2, d1, d8; q21d; Paclitaxel: 135-175mg/m2, d1, Q3W; Docetaxel: 60-75mg/m2, d1, Q3W Albumin paclitaxel: 100-135mg/m2, d1, d8, Q3W. Treat until disease progression or intolerable toxicity"
32724551|NCT05322499|Experimental|Combined anlotinib group|Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w); Anlotinib: 12mg, qd, d1-d14, q3w; Treat until disease progression or intolerable toxicity.
32925979|NCT04780685|Experimental|hMSCs|hMSCs will be given via IV administration.
32925980|NCT04780685|Placebo Comparator|Lactated Ringer's Solution|Lactated Ringer's Solution will be given via IV administration.
32925981|NCT04778501|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
32925982|NCT05739409|Experimental|LILRB4 STAR-T cells injection|"The study was divided into two phases: dose climbing and dose extension. Dose climbing stage: adopt the 3 + 3 dose climbing design principle, and the dose group is set as follows, in which, dose group-A is the backup dose reduction dose group, and dose group A is the starting dose:~Dose Group-A: 3×105STAR+T cells / kg； Dose group A: 1×106STAR+T cells / kg； Dose group B: 3×106STAR+T cells / kg； Dose group C: 6×106STAR+T cells / kg； Dose group D: 1×107STAR+T cells / kg。"
32925983|NCT04776239|Experimental|Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group|Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
32925984|NCT04776239|Experimental|Group 2: Placebo Group|Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
32925985|NCT05732701|Experimental|Intervention|Algorithm-guided DAPT duration
32925986|NCT05732701|Active Comparator|Standard|Standard-of-care DAPT duration
32925987|NCT04768985|Experimental|Treatment sequence 1: Treatment AB|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
32724552|NCT05164523||Patients with type 2 diabetes treated with SGLT2 inhibitors|metformin using patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
32724553|NCT05164523||Patients with type 2 diabetes treated with other oral agents|metformin using patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
32925988|NCT04768985|Experimental|Treament sequence 2: Treatment BA|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
32925989|NCT05739253||Transfemoral TAVR for AS|Patients undergoing transfemoral transcatheter aortic valve replacement for aortic stenosis
32925990|NCT04210037|Experimental|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
32925991|NCT04210037|Experimental|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
32724554|NCT05661617||Czech healthy women tested in normative study|"Czech healthy women aged 20-24 years tested in study called Establishing Czech Norms of Selected Standardized Tests."
32925992|NCT04210037|Experimental|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
33250344|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
33250345|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
33250346|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
33250347|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
32925993|NCT05739175|Experimental|Intervention group receiving interactive nurse support based on mobile application|Experimental: Intervention Group The mobile application containing an interactive nurse support program will be uploaded to the telephone of the intervention group patients. Patients will be informed on how to use the mobile application. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy. Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23, Beck Anxiety Scale and Mobile Application evaluation form will be used to collect data.
32925994|NCT05739175|No Intervention|Control group receiving standard care and no intervention|No Intervention: Control Group The patients received routine care and training in the polyclinic, and no additional intervention was applied. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy.Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23,Beck Anxiety will be used to collect data.
32925995|NCT04184609|Experimental|Exercise test|"All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:~Control~Albuterol~Ipratropium Bromide"
32925996|NCT05739097||non-anemic women|Pregnant women consecutively observed at Ob/Gyn Dept
33250348|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
33250349|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
33250350|NCT00754728|Experimental|I|
33250351|NCT05301166|Experimental|Interventional Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~Students in the intervention group will participate in the Technology-Based Motivation Education Program. This program will last 4 months.~Students in the intervention group will conduct semi-structured individual motivational interviews, consisting of 6 sessions in total, prepared according to the components of the Health Belief Model.~Students in the intervention group will access the web-based education and motivation program that supports motivational interviews by logging into the website prepared for the study."
33250352|NCT05301166|Other|Control Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~Students in the control group will only participate in the web-based education of the Technology-Based Motivation Education Program prepared according to the Health Belief Model for obesity.~Students in the control group will be given face-to-face or online interviews once a month for 4 months, lasting 10-15 minutes, in accordance with the web-based education content."
33250353|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
33250354|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
33250355|NCT05435430||women with previously SARS-COV2 infection.|"2 group from 2 IVF CENTER with egual criteria :~INCLUSION CRITERIA:~Women 24-43 years of age~Previous history of COVID-19 infection~INFERTILITY DIAGNOSIS~ESCLUSION CRITERIA:~women with current symptoms of COVID-19 infection~Positive for HIV or the presence of active viral hepatitis~Previosuly ovarian cancer, removal of ovaries or gonadotoxic treatments"
33250356|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
33250357|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
33250358|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
33250359|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
33250360|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
33250361|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
33250362|NCT01050049||Before guidelines implemented|
33250363|NCT01050049||After guidelines implemented|
33250364|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
33250365|NCT04040985|Other|Legion Primary|Legion Primary TKA
33250366|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
33250367|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
33250368|NCT05261100|Placebo Comparator|Active group|Conventional Physical therapy
32724555|NCT05661617||Czech healthy women (experimental group)|Czech healthy women aged 20-24 years (inclusive) who participated in the research in the period from January 2023.
32724556|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
32724557|NCT03823001|Experimental|Virtual prostate biopsy (VB) monitoring|"Prostate-specific antigen (PSA) and digital rectal exam (DRE) are standard of care for monitoring patients on active surveillance or at risk of having low-risk prostate cancer. A novel virtual biopsy (VB) monitoring protocol will be implemented:~PSA bi-annually or more often according to the discretion of the urologist.~Annual DRE.~Visit with the urologist bi-annually.~Multi-parametric MRI (mpMRI) every year for 3 years.~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
32724558|NCT04760041|Active Comparator|nebulized midazolam group|36 children will receive nebulized midazolam 0.2 mg/kg in 3 ml normal saline plus 5 ml clear juice 30 min before undergoing general anesthesia
32724559|NCT04760041|Active Comparator|oral midazolam group|36 children will receive oral midazolam 0.5 mg/kg in 5 ml clear juice plus nebulizer of 3 ml normal saline 30 min before undergoing anesthesia
32724560|NCT05164445|Active Comparator|Transbronchial forceps biopsy|Patients, whose transbronchial forceps biopsy was performed
32925997|NCT05739097||anemic women|Pregnant women at Ob/Gyn Dept
32925998|NCT05739097||bleeders|Pregnant women at Ob/Gyn Dept
32925999|NCT04177355|Experimental|Part A, Group 1 (T1): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 1 mcg of 3M-052-AF and 500 mcg of Aluminum Hydroxide Suspension (Alum), as one intramuscular (IM) injection at Months 0 and 2.
32926000|NCT04177355|Placebo Comparator|Part A, Group 1 (P1): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
33400640|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
33400641|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
32926001|NCT04177355|Experimental|Part A, Group 2 (T2): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 5 mcg of 3M-052-AF and 500 mcg of Alum, as one IM injection at Months 0 and 2.
32926002|NCT04177355|Placebo Comparator|Part A, Group 2 (P2): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
32926003|NCT04177355|Experimental|Part B, Group 3 (T3): BG505 SOSIP.664 gp140 + CpG 1018 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 300 mcg of CpG 1018 and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
32724561|NCT05164445|Active Comparator|Transbronchial forceps biopsy+Transbronchial cryobiopsy|Patients, whose transbronchial forceps biopsy and transbronchial cryobiopsy were performed as well
32724562|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
32926004|NCT04177355|Placebo Comparator|Part B, Group 3 (P3): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
32926005|NCT04177355|Experimental|Part B, Group 4 (T4): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with either 1 mcg or 5 mcg of 3M-052-AF (the highest tolerated dose from Part A), and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
32926006|NCT04177355|Placebo Comparator|Group 4 (P4): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
32926007|NCT04177355|Experimental|Part B, Group 5 (T5): BG505 SOSIP.664 gp140 + GLA-LSQ|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with GLA-LSQ (GLA 5 mcg, and QS-21 2 mcg), as one IM injection at Months 0, 2, and 6.
32926008|NCT04177355|Placebo Comparator|Part B, Group 5 (P5): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
32926009|NCT04177355|Experimental|Part B, Group 6 (T6): BG505 SOSIP.664 gp140 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 500 mcg of Alum, administered as one IM injection at Months 0, 2, and 6.
32926010|NCT04177355|Placebo Comparator|Part B, Group 6 (P6): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
32926011|NCT01923805|Experimental|Treatment Group|Vitagel
32926012|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
32926013|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
32926014|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
32926015|NCT01923961|Experimental|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
32724563|NCT05391347|Experimental|Intervention|3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process
32724564|NCT05391347|No Intervention|Control|
32926016|NCT01923961|Experimental|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
32926017|NCT01923961|Experimental|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
32926018|NCT04116281|Experimental|Supervised group|Supervised group
32926019|NCT04116281|Other|No supervised group|Control group
32926020|NCT04750733||Multiple Sclerosis|Ambulatory MS patients
32724565|NCT05322421|Experimental|Olive Oil|Will include10 patients receiving topical olive oil application, twice daily
32724566|NCT05322421|Active Comparator|Sodium Bicarbonate|Will include 10 patients receiving Sodium bicarbonate 5% solution, twice daily
32724567|NCT05163977|Active Comparator|Cattell Warren Anastomosis|
32724568|NCT05163977|Experimental|Blumgart Anastomosis|
32724569|NCT04754035|Experimental|venetoclax + ibrutinib|
32724570|NCT05269433|Active Comparator|PSE + OCAT-sham|Psycho-education video + an active placebo training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is an undirected scrambled sentences task with online contingent feedback (only) on the speed with which the sentences were made. In this condition, participants will not receive feedback on emotional attention.
32926021|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
32926022|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
32724571|NCT05269433|Experimental|PSE + OCAT|Psycho-education video + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
32724572|NCT05269433|Experimental|PSE + OCAT+|Psycho-education video + short motivational video before each training session + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
32724573|NCT04452643|Active Comparator|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
32926023|NCT00371501|Active Comparator|treatment arm 1|
32926024|NCT00371501|Placebo Comparator|Treatment arm 2|
32926025|NCT00371501|Active Comparator|treatment arm 3|aspirin
32926026|NCT00371501|Placebo Comparator|treatment arm 4|placebo
32926027|NCT05730595|Experimental|D2 lymph node dissection|The D2 lymph node region are dissected. And 1-3 lymph nodes of the D2 region will be selected for intraoperative frozen section. If no lymph node metastasis is found in freezing, the D3 region lymph nodes in the root of the submesenteric artery were preserved.
32926028|NCT05730595|Active Comparator|D3 lymph node dissection|Thorough dissection of lymph nodes in the D3 region.
32926029|NCT03251651|Experimental|PPF|Patient who received propofol during the operation
32926030|NCT03251651|Experimental|DEX|Patient who received dexmedetomidine during the operation
32926031|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
32926032|NCT05349461|Active Comparator|Complete contact|
32926033|NCT05349461|Active Comparator|Incomplete contact|
32926034|NCT05738863|Experimental|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.
32926035|NCT05738863|Placebo Comparator|Sham rTMS Protocol|It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.
32926036|NCT04048421|Experimental|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
32926037|NCT05738785||Home health care patients|Home health patients registered in the Anatolian side of Istanbul
32926038|NCT04023461|No Intervention|Clinical Treatment Group|
32926039|NCT04023461|Experimental|Interventional Ablation Group|
32724574|NCT04452643|Placebo Comparator|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
32724575|NCT04455659|Experimental|TENS + Conventional physical therapy exercise|
32724576|NCT04455659|Active Comparator|conventional physical therapy exercise|
32724577|NCT05322265||complicated patients|patients underwent to laparoscopic renal and adrenal surgery with intraoperative complications
32724578|NCT05322265||uncomplicated patients|patients underwent to laparoscopic renal and adrenal surgery with no complication during surgical procedure
32724579|NCT04455581|Experimental|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
32724580|NCT05322187|Experimental|PLEN(PD-1/PD-L1 inhibitor and LENvatinib)|Treatment of PD-1/PD-L1 Inhibitor and LENvatinib would be employed in PLEN
32724581|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
32724582|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
32724583|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
32926040|NCT03917927|Experimental|Eztetic dental implant|Eztetic 3.1mm diameter, lengths 8, 10, 11.5, 13, 16 mm
32926041|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
32926042|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~localization of lymph nodes draining a primary tumor in patients with~breast cancer or malignant melanoma when used with a hand-held gamma counter.~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
32926043|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
32926044|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
32926045|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
32926046|NCT05738707||Recombinant protein vaccine|
32926047|NCT05738707||Adenovirus vector vaccine|
32926048|NCT05738629|Experimental|PSC-MSC-Exo Eye Drops Treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drop intervention for 12 weeks.
32926049|NCT05349149|Experimental|Tocilizumab|Participants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche). The dose will be 8 mg/kg bodyweight or a maximum of 800mg. Tocilizumab is dissolved in 100 mL 0.9% saline.
32926050|NCT05349149|Placebo Comparator|Saline|As placebo, participants will receive one 30 min intravenous infusion of 100 mL 0.9% saline.
32926051|NCT05738551|Experimental|STRESS BALL|Starting 5 minutes before the access to the vascular access, the patient will be asked to squeeze the stress ball in the palm until the blood collection is completed.
32926052|NCT05738551|Experimental|CHEWİNG GUM|Starting 5 minutes before the vascular access, the patient will be allowed to chew gum until the blood collection is completed.
33250369|NCT05261100|Experimental|Experimental group|Conventional Physical therapy with Core stability
32926053|NCT05738551|No Intervention|ROUTINE APPLICATION|Only within the scope of routine practice of the patient, vascular access will be provided and the blood collection process will be completed.
32926054|NCT04337645|Experimental|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
32926055|NCT04337645|Active Comparator|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
32926056|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
32724584|NCT05163743|Experimental|Ketogenic Diet-obese|LCKD (1200-1400kcal/day) low in carbohydrates (<50g per day) with a moderate protein intake (1-1.5g/kg of ideal body mass) but otherwise no other dietary restrictions. The participants will be counselled by a trained nutritionist at baseline and every two weeks, and compliance will be assessed through a 3-day dietary recall at each follow up visit and capillary beta hydroxybutyrate levels as well as urinary acetoacetate levels. The follow up visits take place at the time of the first vaccine dose, two weeks after the first vaccine dose, one week after the second vaccine dose. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
32724585|NCT05579249|Experimental|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.
32926057|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
32926058|NCT03702413|No Intervention|Best medical treatment|Best medical treatment
32926059|NCT03702413|Experimental|Endovascular treatment|Best medical treatment plus endovascular treatment
32926060|NCT04338035||Patients with rectosigmoid endometriosis|
32926061|NCT05726617|Experimental|Experimental: Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
32926062|NCT05349071|Experimental|methylprednisolone group|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
32926063|NCT05349071|Active Comparator|physiological saline group|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
32926064|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
32926065|NCT03490253|Active Comparator|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
32926066|NCT03490253|Experimental|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
32926067|NCT03490253|No Intervention|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
32926068|NCT05738473||pregnant women colonized by Group B Streptococcus (GBS) and undergoing IAP|vaginal microbiome of pregnant women colonized by Group B Streptococcus (GBS)、Pregnant women undergoing IAP
32724586|NCT05579249|Active Comparator|Other anti-obesity medication|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
32724587|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
32724588|NCT05549609|Experimental|XSTEM-VLU|Single topical dose of XSTEM-VLU
32724589|NCT05549609|Placebo Comparator|Vehicle|Single topical dose of CryoStor CS10
32724590|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
32724591|NCT05163587|Placebo Comparator|Control|control group will be provided with the commercially available whole-wheat flour for their consumption during the study period.
32724592|NCT05163587|Experimental|Intervention|intervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day.
32724593|NCT05163509|Experimental|MR-Linac Guided Adaptive Radiotherapy|Patients will receive Adaptive Radiotherapy on the MR-Linac treatment machine.
32926069|NCT05738473||pregnant women does not colonized by Group B Streptococcus (GBS) and not undergoing IAP|Group B streptococcus (GBS) does not colonize the vaginal microbiome of pregnant women、Pregnant wome
32926070|NCT04335461|Placebo Comparator|Placebo|Placebo group, with no regional nerve blockade administered.
32926071|NCT04335461|Experimental|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
32926072|NCT04335461|Experimental|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
32926073|NCT05726227|Experimental|Group Kids|Participants in the age group 6 to less than (<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
32926074|NCT05726227|Experimental|Group Teens|Participants in the age group 12 to < 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
32724594|NCT02194387|Experimental|Supportive care (energy balance interventions)|"TELEPHONE COACHING VS EMAIL COACHING: Participants receive telephone coaching once per week for 16 weeks or 1 email per week for 16 weeks (with follow-up responses if the participant responds) from a coach trained in motivational interviewing.~TEXT MESSAGES: Participants receive daily text messages promoting adherence to diet and exercise recommendations daily 1-3 times per day or no text messages.~SOCIAL NETWORKING: Participants are invited to an online forum for study participants available for 16 weeks or do not receive an invitation for social networking.~SELF-MONITORING: Participants are asked to record their dietary intake 4-7 days per week or 1 day per week on a website or smartphone app."
32926075|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
32926076|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
32926077|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
32926078|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
32926079|NCT05725135||Males|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
32724595|NCT05386589|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral 800mg dose of molnupiravir.
32724596|NCT05386589|Experimental|Healthy-Matched Control Group|Healthy matched participants will receive a single oral 800mg dose of molnupiravir.
32724597|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
32724598|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
32724599|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
32724600|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
32926080|NCT05725135||Females|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesi
32926081|NCT05718271|Experimental|Explicit instructions before + after extinction|
32926082|NCT05718271|Experimental|Explicit instructions before extinction|
32926083|NCT05718271|Experimental|Explicit instructions after extinction|
32926084|NCT05718271|No Intervention|No explicit instructions|
33250370|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
33250371|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
33250372|NCT00867867|Placebo Comparator|3|Ferrous sulphate
33250373|NCT00955318|Experimental|KW-6500|
33250374|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
33250375|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
33250376|NCT00860223|Experimental|1|Digoxin alone
33250377|NCT00860223|Experimental|2|Digoxin plus neratinib
33250378|NCT05223504||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
33250379|NCT01044823||Adult RA|
33250380|NCT01044823||pediatric JRA|
33250381|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
33250382|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
33250383|NCT00860301|Experimental|Acupuncture group|
32926085|NCT05738317|Experimental|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|"Adebrelimab: 20 mg/kg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Albumin Paclitaxel: 100 mg/m2 Albumin Paclitaxel is given on days 1, 8, and 15 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
32926086|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
32926087|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.~Age ≥18 years and able to give written informed consent to the study~On chronic hemodialysis for ≥ 90 days at time of enrollment~Ability to read~Consent to have video recording taken during study visit"
32724601|NCT04455191|Experimental|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
32926088|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
32926089|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
32926090|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
32926091|NCT05738239|Experimental|Active|Application of photo-biomodulation
32926092|NCT05738239|Placebo Comparator|Placebo|Inactive PBMT
32926093|NCT05498389|Experimental|Part 1 Dose Escalation (Phase Ib), Part 2 Dose Expansion (Phase II)|"In Part 1 dose escalation, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached, or all planned doses are administered.~In Part 2 dose expansion, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28 at the recommended phase II dose (RP2D) regimen. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity."
32926094|NCT05495737||Phase 1: Nurse Participants|n=8-10 nurses
32926095|NCT05495737||Phase 1: Patient Participants|n=8-10 patients
32926096|NCT05495737||Phase 2: Nurse Participants|n=8-10 nurses
32926097|NCT05495737||Phase 2: Patient Participants Meaning-Centered Psychotherapy/MCP-PC Intervention Arm|n=30
32926098|NCT05495737||Phase 2: Patient Participants Treatment As Usual/TAU Intervention Arm|n=30
33250384|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
32926100|NCT04335617|Experimental|Investigational|Patients receive MMPF 500mg for one year
32926101|NCT04335617|Placebo Comparator|Placebo|Patients receive Placebo for one year
32926102|NCT05717413||Patients after arthroplasty of the 1st metatarsophalangeal joint|
32926103|NCT05717413||Patients after arthrodesis of the 1st metatarsophalangeal joint|
32926104|NCT02973971||Healthy subjects|
32926105|NCT02973971||Alzheimer patients|
32724602|NCT04455191|Experimental|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
32724603|NCT04707937|Experimental|Online education|Participants will gain access to the online education modules in addition to receiving current standard of care education (pamphlets and one on one teaching with health care provider)
32926106|NCT05736601||UKA MAKO|Prospective group- Patient Reported Outcomes (PROs) will be assessed using the FocusMotion app survey
32926107|NCT05736601||TKA MAKO|Control group-Already collected data on patient reported out comes using the FocusMotion app survey
32926108|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
32724604|NCT04707937|Active Comparator|Regular standard of care education|Participants only receive current standard of care education (pamphlets and one on one teaching with health care provider)
33250385|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
32724606|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
32926109|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
33250386|NCT01047631|Active Comparator|Health education and independent walking|
32724607|NCT04688749||Healthy Control|Individuals without skin damage (melanoma, BCC, SCC, etc)
32724608|NCT04688749||Skin lesion|Individuals diagnosed with confirmed skin damage by Dermatologists
32724609|NCT05321797|Experimental|Aerobic Training Group|Cycling exercise group along with Conventional therapy
32724610|NCT05321797|Active Comparator|Conventional Physiotherapy|Strectching with ROM and gait training
32724611|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
32724612|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level >2.5 mg/dl
32926110|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
32926111|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
32926112|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
32926113|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
32926114|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
32926115|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
32926116|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
32926117|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
32926118|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
32926119|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
32926120|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
32926121|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
32926122|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
32926123|NCT05736445||Students at the University of Michigan|Students enrolled in the Winter 2023 academic semester at the University of Michigan
32926124|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
32926125|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
32926126|NCT05705401|Active Comparator|Standard of Care Adjuvant Breast Radiation|Patients continue to receive their current planned adjuvant breast radiation and systemic HER2-targeted therapies
32926127|NCT05705401|Active Comparator|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|Patients continue to receive their current systemic HER2-targeted therapy without breast adjuvant radiation
32926128|NCT05736367|Experimental|Metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer|"Administration of U-13C-glucose to participants with early-stage HR+/Her2- breast cancer fitting criteria, will be done intraoperatively at the time of resection, as well as blood sample collection.~This will allow for in depth evaluation of glycolysis as well as TCA cycle, lipid and amino acid metabolism and comprehensive genomic analyses to complement the metabolic assays that will be done by the Ludwig Institute of Cancer Research. HR+/Her2- breast cancer subtype is chosen for this feasibility pilot study given that metabolic studies have not been done in this subtype of breast cancer and it makes up the majority of breast cancer cases."
33250387|NCT05216796|Experimental|Low-carbohydrate diet|Participants assigned to the Low-carbohydrate diet will be instructed to limit carbohydrate intake to <30 g/d.
32724613|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level <2.5 mg/dl
32724614|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
32724615|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
32724616|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
32724617|NCT03857867|Experimental|Tactile Stimulation Glove|Patient will receive active stimulation for a minimum of 3 months and a maximum of 13 months
32724618|NCT04637425|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
32724619|NCT04637425|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
32724620|NCT05128331|Experimental|Spermidine supplementation|Study participants are provided with spermidine supplementation
32724621|NCT05128331|Placebo Comparator|Placebo supplementation|Study participants are provided with a placebo supplementation
32768347|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
32724622|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
32724623|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
32724624|NCT05329649|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
32724625|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
32724626|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
32724627|NCT03679091|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
32724628|NCT03679091|Active Comparator|clopidogrel|To observe the safety and efficacy between low-dose ticagrelor and standard-dose clopidogrel.
32926129|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
32926130|NCT05463601|Experimental|Mecapegfilgrastim +dalpiciclib + endocrine therapy|Mecapegfilgrastim / dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
32926131|NCT05463601|Active Comparator|dalpiciclib + endocrine therapy|dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
32926132|NCT04737629|Experimental|Expectancy and Water Condition|
32926133|NCT04737629|Experimental|No Expectancy and Water Condition|
32724629|NCT04627831|Experimental|CE-Iohexol|Subject is randomized to receive CE-Iohexol Injection
32926134|NCT04737629|Experimental|No Water Condition|
32926135|NCT05736289||Percutaneous mitral valve repair|Patients undergoing percutaneous mitral valve repair under general anesthesia for mitral valve regurgitation.
32926136|NCT05736289||Surgical mitral valve repair or replacement|Patients undergoing surgical mitral valve repair or replacement for mitral valve regurgitation.
32926137|NCT04768465||Combined Immunotherapy|"MG patients are treated with tacrolimus combined with low-dose prednisone (0.25mg/kg/d).~Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d)."
32926138|NCT04768465||Tacrolimus monotherapy|MG patients are treated with tacrolimus as initial immune monotherapy. Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d).
32926139|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
32926140|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
32724630|NCT04627831|Active Comparator|Omnipaque™ (Iohexol)|Subject is randomized to receive Omnipaque™ Iohexol Injection
32724631|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
32724632|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
32724633|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
32724634|NCT05321641|Experimental|Text SMS|Adherence messages presented in both text form.
32724635|NCT05321641|Experimental|Graphic SMS|Adherence messages presented in graphic form.
32724636|NCT05321641|Experimental|Both text and graphic|Adherence messages presented in both text and graphic form.
32724637|NCT05321641|Placebo Comparator|Control|Messages on public health promotion not related to epilepsy
32743439|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
32926141|NCT05698693|Experimental|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor. The first session will last 60 minutes and the content will include psychoeducation about the importance of sleep, sleep guidelines and target setting, and basic sleep hygiene. Participants in this condition will receive hardcopy weekly daily diary worksheets, and receive an online version of the sleep daily diary every morning to complete via text messaging. Sessions 2-4 will be between 15-30 minutes where Dr. Wu or a trained counselor will review the sleep diary, problem solve barriers to weekly goals, and sleep promoting behaviors will be reinforced. Material that would be covered during a missed session will be included in the next session the participant attends.
33250388|NCT05216796|Active Comparator|Low-calorie diet|Participants assigned to the Low-calorie diet will be instructed to reduce their energy intake to match the LoCHO block (we are predicting ~1200 kcal/d for women and ~1500 kcal/d for men, following current recommendations for treatment of NAFLD).
33250389|NCT04018287||HPP-Group|"genetical verified hypophosphatasia~age >18 years~written informed consent~complete serological and radiological examinations"
33250390|NCT04018287||Control-Group|"healthy men and women without any history of musculoskeletal diseases~Alkaline phosphatase (AP) in reference range~written informed consent~complete serological and radiological examinations"
33250391|NCT00698204|Experimental|I- Celecoxib|
33250392|NCT00698204|Placebo Comparator|II|
33250393|NCT00867945||1. Pregnant Women|
33250394|NCT00867945||2. Non-Pregnant Controls|
33250395|NCT00867945||3. IVF controls|
33250396|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
32724638|NCT04649957||Cohort Observation|"Study investigators will identify eligible participants within 72 hours of expected discharge from hospital. Eligibility will be determined using the criteria outlined in section 5.1 which incorporates the Post-COVID-19 Functional Status (PCFS) Scale, a tool which has been developed and endorsed by the European Respiratory Society to measure functional status over time following COVID-19 infection. Patients graded 2, 3 or 4 on the PCFS will be eligible for participation. Eligible patients will be provided with a detailed explanation of the study including the provision of written information (PIS). Patients will be given time to consider participation in the research study before being approached again by the research team.~If the patient expresses an interest in study participation the research team will invite participants to a baseline data collection session that will be held at the University of Derby (Kedleston Road campus) in the days following discharge."
32926142|NCT05698693|Active Comparator|Contact control|The content of the contacts for this intervention condition will be based on the National Center for Healthy Housing's Healthy Homes program, a program designed by the UT School of Public Health. Participants in this condition will meet with Dr. Wu or a trained research staff member. They will meet through Zoom once a week for four sessions to go through each educational module. Sessions will conclude with the development of an action plan for participants. Staff will check in with participants regarding whether they were able to complete the tasks on their action plan, and if not, the reasons for this and potential strategies that may facilitate completion.
32926143|NCT05736211|Experimental|Phase 2 intervention|In this arm the study will implement an organization-level Youth Engagement prevention strategy by systematically incorporating Youth Engagement into prevention efforts in a community setting.
32926144|NCT05736211|No Intervention|Phase 2 control|This arm will receive no intervention. Control group organizations will continue their normal prevention strategy without the inclusion of a Youth Engagement component
32926145|NCT01744223|Experimental|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
32926146|NCT01744223|Experimental|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
32926147|NCT01744223|Experimental|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
32926148|NCT01744223|Experimental|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
32926149|NCT05448547|Experimental|immediate curative therapy|Patients randomized to the intervention arm will receive immediate curative therapy in the form of either radiotherapy to the prostate in combination with hormone therapy (ADT or monotherapy) or surgery (radical prostatectomy). Standard treatment in this arm is radiotherapy + hormone therapy. Surgery is reserved for patients with strong preferences against radiotherapy.
32926150|NCT05448547|Active Comparator|initial observation/ hormone therapy|Patients in this arm will either be observed (with localized high-risk prostate cancer) or receive hormone therapy (locally advanced prostate cancer; ADT or monotherapy). Further local or systemic therapy is given at doctor's discretion triggered by local or/ and systemic progression.
32724639|NCT04623853|Experimental|Aim 2|Participants will carry out a protocol comprised of treadmill walking in a laboratory setting while wearing the Dynamic AFO device.
32724640|NCT04623853|Experimental|Aim 3|"Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a locked mode that functions similar to their own orthotic--the order in which they are tested will be randomized."
32724641|NCT05313659|Experimental|group-K|At the end of surgery and immediately after the inhalational agent was discontinued, 2mL of normal saline containing 0.7 mg/kg racemic ketamine was administered intramuscularly to Group-K
32724642|NCT05313659|No Intervention|group-S|At the end of surgery and immediately after the inhalational agent was discontinued, 2 mL of normal saline was administered intramuscularly.
32724643|NCT04609579|Experimental|SNX281 Monotherapy|"SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.~Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab. Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time)."
32768348|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
32926151|NCT01614665|Active Comparator|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
32926152|NCT01614665|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
32926153|NCT05443945|Experimental|Advanced Water -100 ionized nasal spray|3 sprays in each nostril, 3 times a day during 14 days
32926154|NCT05443945|Placebo Comparator|Nasal spray with purified water|3 sprays in each nostril, 3 times a day during 14 days
32926155|NCT05348447|Experimental|Cryoanalgesia with standard of care pain control|subjects will receive standard of care pain control + cryoanalgesia in the intercostal spaces during routine surgery
32926156|NCT05348447|Active Comparator|Standard of care pain control|subjects will receive standard of care pain control only
32926157|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)~Fill the DLQI and CU-Q2oL questionnaire"
32926158|NCT05348135|Active Comparator|Functional strength training|
32926159|NCT05348135|Active Comparator|Cognitive training|
32926160|NCT05348135|Active Comparator|Combined treatment|
32926161|NCT05348135|Placebo Comparator|Conventional physical therapy|
32926162|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
32926163|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
32926164|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
32926165|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
33250397|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
32724644|NCT04609579|Experimental|SNX281 in Combination with Pembrolizumab|SNX281 will be administered in 3 of the 4 weeks in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 68 participants will take part in this arm of the study.
32724645|NCT05321563|No Intervention|Observation Phase|Schools will continue to apply their standard disciplinary response to school-based substance use infractions during the 'unexposed' study period.
32724646|NCT05321563|Experimental|Intervention Phase|Schools will have the opportunity to deliver the iDECIDE curriculum in lieu of or as part of the standard disciplinary response to school-based substance use infractions during the 'exposed' study period.
32724647|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
32724648|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
32724649|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
32724650|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
32724651|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
32724652|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
32724653|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
33250398|NCT00549718|Experimental|Lurasidone 40mg|
32768349|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
32926166|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
33250399|NCT00549718|Experimental|Lurasidone 80mg|
33250400|NCT00549718|Experimental|Lurasidone 120mg|
33250401|NCT00549718|Placebo Comparator|Sugar Pill|
32926167|NCT04337801|Experimental|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
33250402|NCT00863187|Experimental|rituximab|b cell depletion drug
33250403|NCT00743132||1|Postoperative no renal dysfunction
33250404|NCT00743132||2|Postoperative renal dysfunction
33250405|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
33250406|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
33250407|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
33250408|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
33250409|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
32724654|NCT04396717|Experimental|Pritumumab|"Dose Escalation phase (3+3 patients):~Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.~Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity."
32724655|NCT03129217||Patients weaning from mechanical ventilation|
32724656|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
32724657|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
32724658|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
32724659|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
32724660|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
32926168|NCT04337801|Placebo Comparator|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
32926169|NCT04337801|No Intervention|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
33250410|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
33250411|NCT05435274|Experimental|HS-10376|"Phase 1a：Dose Escalation：Subjects with advanced NSCLC will be enrolled in dose escalation cohorts. Dose escalation of HS-10376 will be done to determine maximum tolerated dose.~Phase 1b：Dose Expansion：Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced NSCLC having a EGFR/HER2 Exon 20 insertion mutation.~Phase 2：Subjects with locally advanced or metastatic EGFR Exon 20 insertion NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10376 as monotherapy."
32724661|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
32724662|NCT02164318|No Intervention|Control group|Standard of care
32724663|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
32724664|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
32724665|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
32926170|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
32724666|NCT03436199|Experimental|ADS-5102, 137 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
32724667|NCT03436199|Experimental|ADS-5102, 274 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
32724668|NCT03436199|Other|Placebo|placebo, administered once daily at bedtime from Week 4 through Week 16
32724669|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
32724670|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
32724671|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
32724672|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
32724673|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
32724674|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
32724675|NCT05095883||healthy|Children in this group will be healthy category according to CDC chart which ranged from BMI-for-age 5th to 85th percentiles
32724676|NCT05095883||overweight|Children in this group will be overweight category according to CDC chart which ranged from BMI-for-age 85th to 95th percentiles
32724677|NCT05095883||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
32724678|NCT05095883||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
32724679|NCT04455269|Experimental|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:~Decontamination of soft tissues with air-polishing and erythritol powder;~Supra-gingival removal biofilm with air-polishing and erythritol powder;~Sub-gingival removal of biofilm with air-polishing and erythritol;~Calculus removal with a piezoceramic scaler."
32926171|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
32926172|NCT05691829|Experimental|Untreated Patients With Stage IV NSCLC|Participants will receive radiation in concert with starting chemotherapy with pembrolizumab for up to 6 cycles (18 weeks), followed by continued treatment with pembrolizumab (standard of care). Patients will be followed for 1 year following the completion of the core study period of 6 cycles.
32926173|NCT05348057|Experimental|Ivabradine group|The starting dose is 5 mg twice a day. After 2 weeks of treatment, if the patient's resting heart rate continues to be higher than 70 beats per minute, increase the dose to 7.5 mg twice a day. If the patient's resting heart rate continues to be less than 50 beats per minute or symptoms related to bradycardia occur, reduce the dose to 2.5 mg
32926174|NCT05348057|No Intervention|The control group|
32926175|NCT05736133|Experimental|Physiotherapist-led primary care model for hip and knee pain|The index intervention will incorporate a PT within the primary care team at the first point of contact for people with hip or knee pain. Participants in this model will be given the choice of seeing the PT or primary care provider. They will be encouraged to book with the PT except when the primary reason for the visit is medication renewals or additional health concerns that need attention from their physician. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
32926176|NCT05736133|Active Comparator|Usual physician-led primary care model for hip and knee pain|Participants will be seen by a primary care physician or a nurse practitioner, depending on the current practice at the clinic. Participants in both groups will be permitted to seek additional care outside of the primary care clinic.
33250412|NCT05351398||PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
33250413|NCT05351398||Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
33250414|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
33250415|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
33250416|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
32724680|NCT04455269|Active Comparator|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:~Full-mouth ultrasonic debridement with piezoceramic scaler;~Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
32724681|NCT04749394|Experimental|Experimental Arm|Camrelizumab plus apatinib as consolidation therapy
32724682|NCT05276297|Experimental|ASO24-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
32724683|NCT05276297|Active Comparator|ASO24 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
32724684|NCT05276297|Experimental|ASO12-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
32724685|NCT05276297|Active Comparator|ASO12 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
32724686|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
32724687|NCT03846427|Experimental|Zanubrutinib|
32724688|NCT05074511||healthy|Children in this group will be healthy category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 5th to 85th percentiles
32724689|NCT05074511||overweight|Children in this group will be overweight category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 85th to 95th percentiles .
32724690|NCT05074511||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
32724691|NCT05074511||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
32724692|NCT05400707||patients admitted to emergency ward of the University Hospital Basel.|
32724693|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
32724694|NCT05321485|Experimental|MedicijnWijs|All participants will undergo the same intervention of using MedicijnWijs, and they will serve as their own control.
33250417|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
33250418|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
33250419|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
32926179|NCT05735977|Other|Indocyanine Green|Cohort study using one arm, no comparator group is possible or feasible
32926180|NCT00371735|Experimental|Arm 1|
32926181|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
32926182|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
32926183|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
32926184|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
32926185|NCT04337333|Other|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
32926186|NCT05688475|Experimental|CC-122 and Dexamethasone|
32926187|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
32926188|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
32926189|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
32926190|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
32926191|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
32926192|NCT05052307||Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine|Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
32724695|NCT05321407||X-linked agammaglobulinemia (XLA)|This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
32724696|NCT05159219|Experimental|Oral Colchicine, 0.5mg once daily|Active colchicine tablet
32724697|NCT05159219|Placebo Comparator|Oral matching placebo, once daily|Matching placebo tablet
32724698|NCT03590899||Healthy patients|Healthy volunteers without retinal disease, glaucoma, previous ocular surgery, laser photocoagulation, or optical media opacities that would disturb imaging.
32724699|NCT04453943|Experimental|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
32724700|NCT04453943|Experimental|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
32724701|NCT05321329|Experimental|Single Arm|Capecitabine will be taken orally at dose of 1250 mg/m2 PO BID on days 1→14 every 3 weeks Cycles are to be repeated every 21 days for a total of 8 cycles
32926193|NCT04337567|Active Comparator|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
32724702|NCT05400239||Cohort 1|Surgically resectable disease, followed by adjuvant radiotherapy +/- chemotherapy
32724703|NCT05400239||Cohort 2|Primary radiotherapy +/- concurrent chemotherapy
32724704|NCT05400239||Cohort 3|Recurrent or metastatic HNSCC undergoing platinum based chemotherapy +/- cetuximab
32724705|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
32724706|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
32926194|NCT04337567|Active Comparator|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
32926195|NCT05332457|Active Comparator|Arm A|"Phase I : Participants will undergo first CPET (Day 0) at trough concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at peak concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
33250420|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
33250421|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
33250422|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
33250423|NCT00868023|Placebo Comparator|5|Placebo
33250424|NCT05300386||generalized anxiety with oxygen desaturation index less than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of less than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
32926196|NCT05332457|Active Comparator|Arm B|"Phase I : Participants will undergo first CPET(Day 0) at peak concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at trough concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
32926197|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
32926198|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
32926199|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
32926200|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
32926201|NCT05681143|Active Comparator|Crisis Prevention Arm|
32926202|NCT05681143|Placebo Comparator|Control|
32926203|NCT05028439|Experimental|RAF combined with gemcitabine and S-1 group|Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with gemcitabine and S-1 within 1 month after RFA.
32926204|NCT05028439|Placebo Comparator|RFA-only gruop|Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
32926205|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
32926206|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.~After the postpartum period, the women in the control group did not perform regulated physical activity."
32926207|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
32926208|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
32926209|NCT05675059|Active Comparator|Group 1: STRONG Intervention|The STRONG program includes consultation with a Moffit dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
32926210|NCT05675059|Active Comparator|Group 2: Usual Care|Participants will be referred to dieticians based on clinical discretion. Participants will also be asked to wear a Fitbit for 12 weeks to passively collect data on activity level.
32926211|NCT05012605||SLEEPR cohort|Individuals within first 3 months following stroke who did not have obstructive sleep apnea within the first 15 days following stroke
32926212|NCT05009797||Patients undergoing atrial fibrillation catheter ablation|Patients undergoing scheduled atrial fibrillation catheter ablation.
33400642|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
32724707|NCT03448003|Experimental|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
32724708|NCT03448003|Active Comparator|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
32724709|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
32724710|NCT04455035|Active Comparator|Retrospective Group(Control)|
32724711|NCT04455035|Experimental|Prospective Group|
32724712|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
32724713|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
32724714|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
32724715|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
32724716|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
32926213|NCT05417659|Placebo Comparator|Control|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
32926214|NCT05417659|Active Comparator|Exercise plus carbohydrate|A high carbohydrate drink (1.6g/kg) to be consumed 1 hour prior to exercise and further drinks (0.2g/kg) every 15 minutes during exercise.
32926215|NCT05417659|Experimental|Exercise plus niacin|A dose of niacin (10mg/kg) to be consumed 30 minutes prior to exercise and two further doses (5mg/kg) at the onset of exercise and 30 minutes into exercise.
32926216|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
32926217|NCT05668585|Experimental|Phase 1: Arm A: CFT1946|Approximately 40 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma, ATC)
32926218|NCT05668585|Experimental|Phase 1: Arm B: CFT1946 + trametinib|Approximately 28 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma)
32926219|NCT05668585|Experimental|Phase 2: Arm A1: CFT1946|Approximately 30 subjects with V600 melanoma or NSCLC (post BRAF inhibitor)
32926220|NCT05668585|Experimental|Phase 2: Arm B1: CFT1946 + trametinib|Approximately 20 subjects with V600 melanoma or NSCLC (post BRAF Inhibitor)
32724717|NCT05399771|Experimental|Thermofield temperature controlled radiofrequency device|Participants will serve as their own control, by heating one leg and not the other. The radiofrequency device consists of a 4 by 6 inch heating pad connected to a temperature controller. The pad will be applied to the back of the leg and will covered using a compression stocking. The other leg will receive a pad and compression stocking, but radiofrequency will not be applied (no heating).
32724718|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
32724719|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
32926221|NCT05668585|Experimental|Phase 2: Arm B2: CFT1946 + trametinib|Approximately 20 subjects with V600 NSCLC (BRAF inhibitor naive)
32926222|NCT04996225|Experimental|Group (A): (study group)|Group (A): (study group) 15 patients received aerobics exercises and balancing exercises in addition to relaxation exercises for 4 weeks, 3sessions/week.
32926223|NCT04996225|Placebo Comparator|Group (B): (Control group)|2-Group (B): (Control group) 15 patients received relaxation exercises in the form of physical relaxation exercise for 4 weeks, 3 sessions/week. the participants who received aerobics exercises and balancing exercises in addition to relaxation exercises (experimental group A), showed significant decrease in anxiety and dizziness more than (placebo group B)
32926224|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
32926225|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
32926226|NCT04991389|Experimental|Phase 1 - Contrast 129Xe MRI ages 5-18|The research team will collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Phase contrast MRI of inhaled gas. (4) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
32926227|NCT04991389|Experimental|Phase 2 - Contrast 129Xe MRI ages 3-18|The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
32926228|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
32724720|NCT05399225||Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio in patients with sepsis
32724721|NCT05399225||Procalcitonin group|Procalcitonin in patient with sepsis
32724722|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
32724723|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
32724724|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
32724725|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
32724726|NCT04928183|Sham Comparator|Room Air Rebreathe|Rebreathe protocol will be completed with a room air syringe rather than CO
32724727|NCT04928183|Experimental|CO Rebreathe|Rebreathe protocol will be completed with Carbon Monoxide
32724728|NCT05321017|Experimental|MEP Wrist Extensor Up-Conditioning|
32724729|NCT05399147|Other|classic group (CL group)|20 patients will be enrolled to be intubated using the classic usual technique
32724730|NCT05399147|Other|tube 1st group (TF group)|20 patients will be enrolled to be intubated using the tube 1st technique
32724731|NCT05320861|Experimental|[14C]SJP-0008|
32768350|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
32724732|NCT04622189|Experimental|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
32724733|NCT04311073|Experimental|Tranexamic Acid|Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
32724734|NCT04311073|Placebo Comparator|Placebo|Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
32926229|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
32926230|NCT05658835||Patient suffering from ischemic stroke|
32724735|NCT05398991|Experimental|Experimental Arm|Subjects in experimental group will be implanted with the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.
32724736|NCT05320783|Active Comparator|music intervention|Headphone was placed on the each patient. The classical music was started to the patients with individual comfortable volume.
32926231|NCT05284487|Active Comparator|Group 1: Jalosome® Soothing gel|"Jalosome® soothing gel ((L-Acetyl Carnitine chloridrate, Allantoin, Hydrogenated phosphatidylcholine, Sodium Hyaluronate) will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
32926232|NCT05284487|Placebo Comparator|Group 2: Placebo|"Placebo will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
32926233|NCT05215535|Experimental|MRI group|An abbreviated MRI of the liver/abdomen
32926234|NCT05215535|Active Comparator|CT group|A combined single venous and 3 min equilibrium phase CT of the abdomen/liver
32926235|NCT05649397|Experimental|cervical manipulation|in the cervical manipulation, provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
32926236|NCT05649397|Active Comparator|conventional therapy|"15 mins moist hot pack~Neck Isometric exercise~hold for 5-8 seconds and repeat 10 times~Cervical range of motion~10 repetitions of movement in rotation within pain free range"
33400643|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
33400644|NCT04657302|Experimental|R/R DLBCL|Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
32926237|NCT04336709|Active Comparator|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
32926238|NCT04336709|Active Comparator|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
32926239|NCT04934137|Active Comparator|Sensoria first intervention|Group 1 participants will receive the Sensoria intervention during the first intervention phase for 4 weeks, and then the AW-Shift intervention during the second intervention phase for 4 weeks.
32926240|NCT04934137|Active Comparator|AW-Shift first intervention|Group 2 participants will receive the AW-Shift intervention during the first intervention phase for 4 weeks, and then the Sensoria intervention during the second intervention phase for 4 weeks.
32926241|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
32926242|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
32926243|NCT04928677|Experimental|Codrituzumab|For Phase A of the study, we will use the 3+3 study design, with 2 planned dose levels, starting at 50% of the adult RP2D to confirm the pediatric RP2D/MTD. 6-9,43 Phase B will include an expansion cohort for patients with hepatoblastoma.
32926244|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
32724737|NCT05320783|Placebo Comparator|control|Headphone was placed on the each patients, but the music player was not started.
32743440|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
32724738|NCT04453865|Experimental|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
32926245|NCT05375071|Experimental|Conventional rehabilitation plus blood flow restriction (BFR) therapy|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy. Additionally, a BFR Cuff will be applied during physical therapy.
32724739|NCT04453865|Other|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
33250425|NCT05300386||generalized anxiety with oxygen desaturation index more than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of more than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
32926246|NCT05375071|Active Comparator|Conventional rehabilitation|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy.
32926247|NCT05647993|Placebo Comparator|Control group (Placebo)|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and placebo(0.9% NaCl 100 ml intravenously) before the incision
32926248|NCT05647993|Experimental|azithromycin|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
32926249|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
32926250|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
32724740|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
32724741|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
32743441|NCT03236675||EML4-ALK|ALK positive patients
32926251|NCT05643469|Experimental|Intervention group|Each subject will receive a specially designed leaflet for smokers with cancer. subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Subjects who opt to quit progressively will receive a smoking reduction leaflet. Over the next 6 months, the research nurse will help them to adhere to their schedules by sending WhatsApp/WeChat messages. subjects will receive four independent 1-minute videos (one video will be sent in weeks 1, 5, 9, and 13) via WhatsApp/WeChat.
32926252|NCT05643469|Placebo Comparator|Control group|Subjects will receive a brief intervention using the AWARD model. However, all subjects will be advised to quit immediately. Control group subjects will receive the same leaflet for smokers with cancer as intervention group subjects. Subjects will receive a placebo intervention that follows the same WhatsApp/WeChat schedule as the intervention group, but the messages will contain only general health advice, such as to perform more physical activity and eat more fruit and vegetables. The control group will not receive any videos.
32926253|NCT05361499|Experimental|Streptococcus pneumoniae 6B (Sp_6B) inoculated|
32926254|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
32926255|NCT04907305||Feed-forward PRO|Participants in this group will participate in monthly learning collaborative webinars. Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
33250426|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
33250427|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
33250428|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
33250429|NCT01528982|No Intervention|Control|Psychoeducation
33250430|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
33250431|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
32926256|NCT04907305||Control Group (Usual Care)|Participants in the control group will receive usual care practices during the clinical encounters.
32926257|NCT00372203|Experimental|Endobronchial ultrasound|
32926258|NCT04900597|Experimental|Elecare - Nourish - Real Foods Blends|Elecare for first bolus, Nourish for second bolus, Real Foods Blends for third bolus
32926259|NCT04900597|Experimental|Nourish - Real Foods Blends - Elecare|Nourish for first bolus, Real Foods Blends for second bolus, Elecare for first bolus
32926260|NCT04900597|Experimental|Real Foods Blends - Elecare - Nourish|Real Foods Blends for first bolus, Elecare for second bolus, Nourish for third bolus
32926261|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
32926262|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
32926263|NCT05192603|Experimental|Dietary intervention with Low FODMAP|The participants are given oral and written instructions on which diet that contains low contents of FODMAP.
32926264|NCT05192603|Experimental|Dietary intervention with SSRD|The participants are given oral and written instructions on which diet that contains SSRD.
32926265|NCT04894903|Experimental|Intervention|"Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention.~."
32926266|NCT04894903|No Intervention|Usual Care|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
32926267|NCT04336553|Experimental|Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS). SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
32724742|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
32724743|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
32724744|NCT04602533|Experimental|Durvalumab|"Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)~Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities."
32724745|NCT04602533|Other|standard of care|"Induction phase: Radiochemotherapy according to guideline~Maintenance: Standard of care"
32724746|NCT05398835|Experimental|Intervention|Online interventions promoting home-based HIV self-testing
32724747|NCT04601909|Active Comparator|FX-322|FX-322, 1 dose (N=24)
32724748|NCT04601909|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
32724749|NCT04923659|Experimental|LIFUS|Low Intensity Focussed ultrasound.
32926268|NCT05637151|Other|ICC in pregnant women with ICP|Immediate cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
32926269|NCT05637151|Experimental|DCC in pregnant women with ICP|Delayed cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
32724750|NCT05398679|Active Comparator|OPAT|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve parenteral antibiotics until the end of treatment.
32926270|NCT05637151|Other|ICC in normal pregnant women|Immediate cord clamping group in normal pregnant women
32926271|NCT05637151|Experimental|DCC in normal pregnant women|Delayed cord clamping group in normal pregnant women
32926272|NCT05356117|Experimental|Resistance Training (RT) and Protein Supplementation (PS)|"Participants will be randomly assigned to the Resistance Training (RT) and Protein Supplementation (PS) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week with daily protein supplementation for the duration of their chemotherapy with a maximum of 16-weeks of exercise. Exercises will be tailored to the participants' fitness levels.~Sessions will last ~60 minutes including 5-minute warm-up and 5-minute cool-down.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
32724751|NCT05398679|Experimental|Oral Therapy|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve oral antibiotics until the end of treatment.
32724752|NCT04818749|Placebo Comparator|Placebo|Participants allocated to this arm will have placebo administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
32724753|NCT04818749|Active Comparator|Dexamethasone 12 mg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
32724754|NCT04818749|Experimental|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and dexmedetomidine 1 mcg/kg administered intravenously after induction of general anaesthesia.
32724755|NCT04817501||Breast cancer|At least eighty five subjects with breast cancer
32724756|NCT04817501||Ovarian cancer|At least 32 subjects with ovarian cancer
32724757|NCT04817501||Endometrial Cancer|At least 33 subjects with endometrial cancer
32724758|NCT04817501||Healthy control|30 healthy volunteers
32926273|NCT05356117|Experimental|Resistance Training (RT)|"Participants will be randomly assigned to the Resistance Training (RT) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week. Exercises will be tailored to the participants' fitness levels.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
32724759|NCT04817501||Suspected malignant tumor non-verified|Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
32724760|NCT04634279|Experimental|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
32926274|NCT05356117|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to the Attention Control (AC) group and receive instruction on a home-based, 3 days a week stretching program.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.~The attention control group will be given the option to participate in the exercise intervention after their treatment is completed, with a cap of a 16-week period."
32926275|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
32926276|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
32926277|NCT05162807|Experimental|Palliative Care Education|The intervention arm will view a psychoeducational video on palliative care.
32926278|NCT05162807|Placebo Comparator|Attention Control|The control arm will view an educational video on nutrition as an attention control.
32926279|NCT05630677|Experimental|Treatment A|Subjects will receive AZD5055 solution as a 20-minute infusion in overnight fasted state on Day 1 in Period 1.
32926280|NCT05630677|Experimental|Treatment B|Subjects will receive oral suspension of AZD5055 in an overnight fasted state on Day 1 in Period 1.
32926281|NCT05630677|Experimental|Treatment C|Subjects will receive AZD5055 film-coated tablet in overnight fasted state on Day 1 (Study Day 4) in Period 2.
32926282|NCT05630677|Experimental|Treatment D|Subjects will receive a standardized high-fat breakfast 30 minutes before film-coated tablet of AZD5055 administered as On Day 1 (Study Day 8) in Period 3.
32926283|NCT05630677|Experimental|Treatment E|Subjects will receive rabeprazole twice daily on Day 10. On Day 1 (Study Day 13), AZD5055 film-coated tablet will be administered, under fasted conditions, together with rabeprazole and rabeprazole dosing will continue twice daily in Period 4.
32926284|NCT05630677|Experimental|Treatment F|Subjects will receive a low-fat breakfast 30 minutes before AZD5055 film-coated tablet administered together with rabeprazole on Day 17. Rabeprazole will continue twice daily, the last dose is on the evening of Study Day 18 in Period 5.
32926285|NCT05129735|Experimental|Meal replacement shake|Teatis meal replacement shake
32926286|NCT05354323|Experimental|NECVAX-NEO1|Personalized patient-individual oral DNA vaccine
32926287|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
32926288|NCT05350657|Experimental|Ketogenic Diet|Subjects will be provided with foods following a ketogenic diet for 15 consecutive days.
32926290|NCT05124041|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis
32926291|NCT05124041|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma
32926292|NCT05113901|Active Comparator|Methylprednisolone taper|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks
32926293|NCT05113901|Placebo Comparator|Placebo taper|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM <90° at 8 weeks
32926294|NCT05630521|Experimental|Telehealth Intervention Group|"The intervention components are: 1) educational modules and 2) bi-weekly telehealth visits for managed problem solving for 12 weeks.~All intervention participants will be provided four educational modules, electronically and in print form. The modules are adapted from evidence-based materials developed by the American Heart Association, American College of Cardiology, and Centers for Disease Control and Prevention and cover (1) the causes of HTN, (2) how HTN raises risks for other chronic conditions, (3) medications for effectively managing high BP, and (4) how to manage barriers to medication adherence.~Telehealth visits will supplement and reinforce the educational modules, addressing participants' specific knowledge needs and enhancing self-efficacy."
32926295|NCT05630521|No Intervention|Control|The study will use a usual-care control group. The standard of care for this patient population does not involve any type of medication adherence intervention or monitoring beyond regular clinic follow-up visits with their health care provider. Control group participants will be given printed handouts on the American Heart Association's Life's Simple 7 lifestyle changes for reducing cardiovascular risk, along with the instructions for using the MEMS cap. If control group participants ask about their antihypertensive medications during the study, they will be referred to their prescribing provider or pharmacist for any information that could not be obtained from the medication label or pharmacy packaging.
32926296|NCT04863859||Grandchildren|Granddaughter or Grandson of the person living with dementia who serves as the primary caregiver
32724761|NCT04634279|No Intervention|Control|Patients in this arm will receive enhanced usual care.
32724762|NCT05398367|Experimental|Oat Mama Lactation Supplement|Participants will receive a 20 day supply of oat mama lactation supplement for consumption per the manufacturer instructions
32743442|NCT03236675||T790M EGFR|T790M positive patients
32724763|NCT05398367|Experimental|Moringa Supplement|Participants will receive a 20 day supply of moringa supplement for consumption per the manufacturer instructions
32724764|NCT05398367|Experimental|Shatavari Supplement|Participants will receive a 20 day supply of shatavari supplement for consumption per the manufacturer instructions
32926297|NCT04863859||Siblings|Brother, sister, brother-in-law or sister-in-law of the person living with dementia who serves as the primary caregiver
32926298|NCT04863859||Nieces/Nephews|Niece or nephew of the person living with dementia who serves as the primary caregiver
32926299|NCT04863859||Step-Kin|Step-kin (step-daughter, step-son, step-sister, step-brother or other step-kin) of the person living with dementia who serves as the primary caregiver
32926300|NCT04863859||Adult Child|Adult child (son or daughter) of the person living with dementia who serves as the primary caregiver
32926301|NCT04863859||Spouse|Spouse (husband or wife) of the person living with dementia who serves as the primary caregiver
32926302|NCT05343949|Experimental|HIIT protocol ABC|"HIIT protocol A, then HIIT protocol B, then HiIT protocol C. Patients first received HIIT A -High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a rest of at least 2 days they received HIIT B: High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 days they received HIIT C-High-intensity duration and intensity: 30 seconds, Rest duration: 240 seconds, Number of Repetitions: 9 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
32926303|NCT05343949|Experimental|HIIT protocol CAB|"HIIT protocol C, then HIIT protocol A, and lastly HIIT protocol B. Patients first received HIIT C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After a rest of at least 2 days they received HIIT A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 day they performed HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
32926304|NCT05343949|Active Comparator|HIIT protocol BCA|"HIIT protocol B, then HIIT protocol C, and lastly HIIT protocol A. Patients firstly received HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~Following at least 2 days rest the patient will receive HIIT protocol C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After at least another 2 days rest they will lastly receive Protocol A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
32926305|NCT05627791|Experimental|Oxytocin gel|Oxytocin gel 400IU per 1 ml (on HPMC 4,000 cps base gel), applied at vaginal canal 1 ml per day for 8 weeks
32926306|NCT05627791|Placebo Comparator|Placebo gel|Placebo gel (HPMC 4,000 cps base gel) , applied at vaginal canal 1 ml per day for 8 weeks
32926307|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
32926308|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
32926309|NCT05326243|Experimental|CD19-targeted chimeric antigen receptor T-cell|Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.
32926310|NCT04855747|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
32926311|NCT04855747|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
32926312|NCT00372281|Experimental|Cliavist|
32724765|NCT05398367|Placebo Comparator|Placebo|Participants will receive a 20 day supply of placebo pills containing a mixture of flour and brown sugar. Participants will consume 2 placebo pills once per day for 20 days.
32724766|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
32724767|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
32724768|NCT04867421||TANOs|Adult patients with osteosarcoma or chondrosarcoma
32724769|NCT05398133||COPD patients|
32724770|NCT05398133||asthma patients|
32724771|NCT05398133||control subjects|
32724772|NCT05398055|Experimental|A|Azithromycine group
32724773|NCT05398055|Placebo Comparator|B|Placebo group
32724774|NCT05397977|Experimental|mechanical traction group|use of device chattanooga tru trac
32724775|NCT05397977|Active Comparator|manual traction group|use of manual traction with physiotherapist hands
32724776|NCT04818281|Experimental|Low-Dose Group (Group A)|12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
32724777|NCT04818281|Experimental|High-Dose Group (Group B)|12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
32743443|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
32926313|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
32926314|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
32926315|NCT05457101|Experimental|with AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS.
32926316|NCT05457101|No Intervention|without AI-based biliopancreatic EUS navigation system|The endoscopists in the contrpl group performs the examination routinely without special prompts.
32926317|NCT05306587||Multiple Myeloma|40 patients with Multiple Myeloma in Department of Hematology at Odense University Hospital, Denmark
32926318|NCT04337879|Experimental|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
32926319|NCT04337879|Experimental|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
32926320|NCT05613049||Observational group|Patients have 2 or more miscarriage or repeated implantation failure (RIF), or infertile women would be invited to do endometrial sampling (ES) procedure. The ES will be conducted randomly or when women undergo hysteroscopy or obtained precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.
32926321|NCT05294419|Other|cardiovascular integrated risk score (CVD-IRT)|The CVD IRT device will generate a result based on the polygenic risk score derived from participant genomic information
32926322|NCT04336631|Other|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
32926323|NCT04336631|No Intervention|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
32926324|NCT05456945|Experimental|Acupressure|Before the injection, patients will be asked to lie in the prone position. The acupressure point (UB32) will be located on the side to be injected. The UB32 point is located in the sacrum region, below the medial and posterior superior iliac spine, in the second sacral foramen. The acupressure point UB32 will be pressed circularly with a stopwatch for 1 minute. Then the acupressure point will be pressed three times in sequence with the thumb directly (pressure equal to 4.5 kg/cm2). Diclofenac sodium (75mg/3ml) will be injected after acupressure.
32926325|NCT05456945|Experimental|Shotblocher|Before the injection, patients will be asked to lie in the prone position. The protruding surface of the Shotblocker will be placed in the area just before the injection so that the point of entry with the needle will not be contaminated. Pressure will be applied by keeping the Shotblocker constant throughout the process. The injector will be quickly inserted through the gap in the middle of the shortblocher. Shotblocker will be removed after drug administration.
32926326|NCT05456945|No Intervention|Control group|No intervention will be applied before the injection
32926327|NCT05288491||Participants With Malignant Lymphoma|All participants diagnosed with histopathologically confirmed malignant lymphoma will be enrolled and observed retrospectively. Complete medical information will be collected at the time of enrollment via chart review.
32926328|NCT05456789|Experimental|Combined interventional treatment|Combined catheter-based fibrinolysis and thrombectomy plus conventional treatment
32926329|NCT05456789|Active Comparator|conventional treatment|Conventional treatment
32926330|NCT05274217|Experimental|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
32926331|NCT05274217|Experimental|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
32926332|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
32926333|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
32926334|NCT04778839|Experimental|Paclitaxel Micelles for Injection|In the First Period, Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2, 260 mg/m2, 320 mg/m2, and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hours,three weeks constituted one course of treatment.
33400645|NCT05746390|Experimental|Home Alone Intervention|"Home Alone is a semi-structured intervention, tailored to address the individual needs and concerns of the older adult. The participant will engage in about seven psychoeducational coaching sessions, each lasting approximately one hour.~The intervention has two key foci:~increasing or maintaining home safety and comfort~increasing scheduled social engagements and activities.~Sessions are also designed to identify formal and informal services and supports to improve to increase assistance and ability to live independently for as long as safely possible. The sessions take place either in-person or remotely (via secure video conferencing or telephone). Ad hoc/ongoing sessions may be provided as needed."
32926335|NCT04778839|Active Comparator|Paclitaxel Injection|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection,175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
32926336|NCT05456711||knee osteoarthritis|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
32926337|NCT05456711||healthy control|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
32926338|NCT05602207|Experimental|Abrocitinib 100 mg tablet (marketed drug)|
32926339|NCT04765189|Placebo Comparator|Placebo|
32926340|NCT04765189|Experimental|Verum A|
32926341|NCT04765189|Experimental|Verum B|
32926342|NCT04765189|Experimental|Verum C|
32926343|NCT04739761|Experimental|Trastuzumab Deruxtecan|Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
32926344|NCT05261425|Active Comparator|Monocryl (FDA Approved) buried running|Upper extremity primary surgical wound closure via suture with Monocryl (FDA Approved) buried running
32926345|NCT05261425|Active Comparator|Monocryl buried interrupted|Upper extremity primary surgical wound closure via suture with Monocryl buried interrupted
32926346|NCT05261425|Active Comparator|Monocryl not buried interrupted|Upper extremity primary surgical wound closure via suture with Monocryl not buried interrupted
32926347|NCT05261425|Active Comparator|Monocryl not buried running|Upper extremity primary surgical wound closure via suture with Monocryl not buried running
32926348|NCT05261425|Active Comparator|Gut (FDA Approved) not buried interrupted|Upper extremity primary surgical wound closure via suture with Gut (FDA Approved) not buried interrupted
32724778|NCT04818281|Placebo Comparator|Placebo Group|12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
32926349|NCT05261425|Active Comparator|Nylon (FDA Approved) not buried interrupted|Upper extremity primary surgical wound closure via suture with Nylon (FDA Approved) not buried interrupted
32926350|NCT05261425|Active Comparator|Nylon not buried running|Upper extremity primary surgical wound closure via suture with Nylon not buried running
32926351|NCT05248321|Experimental|Extra treatment (ET) group|In the extra treatment (ET) group, standard endoscopic therapy will be performed to the bleeding peptic ulcer by local injection of diluted epinephrine 1:10 000 in combination with either heater probe coagulation, hemoclipping and/or rubber band ligation. Afterwards, we will apply 2g tranexamic acid powder via the endoscopy to the peptic ulcer before the end of endoscopic exam. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
32926352|NCT05248321|No Intervention|standard treatment (ST) group|In the standard treatment (ST) group, the endoscopic exam ends after standard endoscopic therapy. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
32926353|NCT05598619|Experimental|Low dose|Daily dose of 80 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
32926354|NCT05598619|Experimental|Mid dose|Daily dose of 200 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
32926355|NCT05598619|Experimental|High dose|Daily dose of 500 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
32724779|NCT04519541|Experimental|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
32724780|NCT04421339|Experimental|Melatonin|
32926356|NCT05598619|Placebo Comparator|Placebo|One capsule of 570 mg (consisting microcrystalline cellulose) once a day for 12 weeks
32926357|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
32926358|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
32926359|NCT04738357|Experimental|HSK21542|
32926360|NCT04738357|Placebo Comparator|placebo|
32926361|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
32926362|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
32926363|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
33400646|NCT03051464|Experimental|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
33400647|NCT03051464|Experimental|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
33400648|NCT05452902|Experimental|EXCAP Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
32926364|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
32926365|NCT04336319|Experimental|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
32926366|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
32926367|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
32926368|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
32926369|NCT05590195|Experimental|PreforPro|Preforpro Dosage form - capsule Dosage - participants will consume one capsule per day for 2 months treatment period
32724781|NCT04421339|Placebo Comparator|Placebo|
33400649|NCT05452902|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
32926370|NCT05590195|Placebo Comparator|Placebo|placebo will come in a capsule, which has to be consumed one capsule per day for 2 months treatment period
32926371|NCT04336007|Experimental|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
32926372|NCT04336007|Placebo Comparator|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
32926373|NCT04336007|Sham Comparator|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
32926374|NCT04719403|Experimental|VIDEO|Participants receive access to video recordings of their clinic visits
32926375|NCT04719403|No Intervention|Usual Care|Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary
32926376|NCT05456633||Capri Cervical 3D Static|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
32926377|NCT05456633||Capri Cervical 3D Expendable|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
32926378|NCT05456633||Capri Thoracolumbar Expandable|Subjects who have undergone or will undergo VBR in the thoracolumbar spine (T1 to L5) with Capri Thoracolumbar Expandable to replace collapsed, damaged, or unstable vertebral bodies due to tumor or trauma (i.e., fracture)
32926379|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
32926380|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
32926381|NCT05587855|Experimental|eCulinary Medicine Group (E-group)|The intervention group will receive weekly cooking demonstrations and education videos via electronic links to use herbs and spices to increase vegetables and reduce sodium in the diet over six weeks
32724782|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
32926382|NCT05587855|No Intervention|Control Group (C-group)|The control group participants will receive usual care from their physician's clinic and the recipes but without the eCulinary intervention over 6 weeks.
32926383|NCT05224531|Experimental|CS1 480 mg dose group|480 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
32926384|NCT05224531|Experimental|CS1 960 mg dose group|960 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
32926385|NCT05224531|Experimental|CS1 1920 mg dose group|1920 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
33400650|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
32724783|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
32724784|NCT04365101|Experimental|Phase I|CYNK-001 infusions on Days 1, 4, and 7
32724785|NCT04365101|Active Comparator|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
32724786|NCT04811651|Experimental|Treatment group|intravenous umbilical cord derived mesenchymal stem cells
32724787|NCT04811651|Placebo Comparator|Placebo Comparator|intravenous placebo solution with the same appearance as the treatment group.
32724788|NCT04301843|Experimental|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
32724789|NCT05397665|Active Comparator|AT-007|AT-007 is an Aldose reductase inhibitor
32724790|NCT05397665|Sham Comparator|Placebo|Is an non-active control
32724791|NCT05397509|Experimental|Olive Leaf Tea|Olive Leaf Tea
32724792|NCT05397509|Placebo Comparator|Placebo tea|Placebo tea
32724793|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
32926386|NCT04711135|Experimental|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
32926387|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
33400651|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
32926388|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
32926389|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
33250432|NCT05435196|Experimental|Experimental|"Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).~Receive a multimodal training that will consist of: resistance exercises for the main muscle groups of the extremities. In the plan, lumbopelvic, scapulothoracic and craniocervical neuromuscular efficiency exercises will also be included."
33250433|NCT05435196|Active Comparator|Control|Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).
33250434|NCT00955396|Other|Period 1|
33250435|NCT00955396|Other|Period 2|
33250436|NCT00863499|Active Comparator|A|Short Acting methylphenidate
33250437|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
33250438|NCT00863499|No Intervention|C|Healthy Controls
32724794|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
33250439|NCT04061642|Experimental|Clinical Decision Aid|
33250440|NCT03992053|Active Comparator|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
33250441|NCT03992053|Active Comparator|Group 2|3-D CT guidance as the first choice of guidance
33250442|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
32724795|NCT05397275|Experimental|experimental group|progressive muscle relaxation exercises + breathing exercise
32724796|NCT05397275|Experimental|control group|only breathing exercise
32724797|NCT04070105|Active Comparator|Conventional Prosthetic Foot|In this condition, participants will walk and run with their standard prosthetic feet
32724798|NCT04070105|Experimental|CAESER Prosthetic Foot|In this condition, participants will walk and run with a new prosthesis designed to switch orientation of the foot with a push of a button. They will only wear this device in the lab for an approximately 4 hour period of time
32724799|NCT04070105|Active Comparator|Commercial High Activity Foot|In this condition, participants will run and walk with a commercial foot designed for high activity (AllPro, Fillauer, Chattanooga, TN)
32724800|NCT05396963|Other|Egg white - Whey protein - Maltodextrin|Participants will receive egg white, whey protein, and maltodextrin in this order.
33250443|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
33250444|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
33250445|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
33250446|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
32724801|NCT05396963|Other|Egg white - Maltodextrin - Whey protein|Participants will receive egg white, maltodextrin, and whey protein in this order.
32724802|NCT05396963|Other|Whey protein - Egg white - Maltodextrin|Participants will receive whey protein, egg white, and maltodextrin in this order.
32926390|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
32926391|NCT04709341|Experimental|Group A|
32926392|NCT04709341|Active Comparator|Group B|
33250447|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
33250448|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
33250449|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
33250450|NCT03963960|Experimental|Hemodialysis with low dialysate flow|
33250451|NCT03963960|Active Comparator|Conventional triweekly high-flow hemodialysis|
33250452|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
33250453|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
33250454|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
33250455|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
33250456|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
33250457|NCT05008146|Experimental|PET|[C-11]NOP-1A
32926393|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
32926394|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
32926395|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
32926396|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
32926397|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
32926398|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
32926399|NCT05455151|Active Comparator|Conservative therapy|This is Group 1, whose patients received electrical impulse therapy using a BTL-4000 Premium G device (BTL Medical Technologies, Czech Republic) starting from day 5-7 of menstrual cycle for 10-12 days daily.
32926400|NCT05455151|Experimental|PRP injection|This is Group 2, whose patients received single intraendometrial injections of autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
32926401|NCT05455151|Experimental|Injection of PRP after conservative therapy|This is Group 3, whose patients received electrical impulse therapy identically with Group 1 during the first menstrual cycle. In the second cycle, the patients received autologous PRP injections identically with Group 2.
32926402|NCT05455151|Experimental|Injection of PRP with endometrial cells|This is Group 4, whose patients received single intraendometrial injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
32926403|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
32926404|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
33250458|NCT05226741|Experimental|Head protection|Participants are given a form of head protection
33250459|NCT04010890|Experimental|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
33250460|NCT04010890|Active Comparator|Standard CBT|Participants in this group will receive standard CBT
32724803|NCT05396963|Other|Whey protein - Maltodextrin - Egg white|Participants will receive whey protein, maltodextrin, and egg white in this order.
32724804|NCT05396963|Other|Maltodextrin - Egg white - Whey protein|Participants will receive maltodextrin, egg white, and whey protein in this order.
32724805|NCT05396963|Other|Maltodextrin - Whey protein - Egg white|Participants will receive maltodextrin, whey protein, and egg white in this order.
32724806|NCT04298177|Experimental|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:~**< 3.5-mm LAWT (red, and yellow colors): vHPSD ablation will be performed. If <1-mm LAWT (red color): Power 90 W; the duration of RF applications will be reduced to 2 seconds. If 1-3.5 mm LAWT (yellow color): Power 90 W; the duration of RF applications will be 4 seconds, according to the QDOT-FAST protocol.~**> 3.5-mm LAWT (green color): QMODE ablation will be performed. 50 W with AI target = 500"
32724807|NCT04298177|Active Comparator|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
32724808|NCT04288193||Trinity Health LIFE New Jersey PACE|Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia
32724809|NCT03967379|Experimental|Mobile app plus enhanced standard care|"Patients will received enhanced standard care in addition to access to the sexual health mobile app.~The app will also prompt patients to engage their partners with specific exercises."
32926405|NCT05455073|Experimental|Full package intervention arm|"Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid) and;~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming~Water, sanitation and hygiene (WASH) intervention: ensure availability (or provision) of water, sanitation, and hygiene supplies~Menstrual hygiene management (MHM) intervention: support for menstrual hygiene, including sale of menstrual products in schools~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices (KAP) of WASH and menstrual hygiene management (MHM)"
32926406|NCT05455073|Experimental|Limited package intervention arm|"Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid; weekly school provision of WIFA tablets) and;~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming"
32926407|NCT05455073|No Intervention|Control|No intervention.
32926408|NCT04334993|Experimental|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
32926409|NCT05562193|Experimental|Physical activity intervention coupled with standard post-cancer directed treatment care group|
32926410|NCT05562193|Other|Standard post-cancer directed treatment care control group|
32926411|NCT04335071|Experimental|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
32926412|NCT04335071|Placebo Comparator|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
32926413|NCT04350229|Experimental|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
32926414|NCT04350229|Active Comparator|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
32926415|NCT04704583|Experimental|Treatment group (active)|Individuals in this group will start treatment after the initial assessment, without a delay.
32926416|NCT04704583|Active Comparator|Wait-list control group|Individuals in this group will start treatment after the initial assessment, with a delay of thirteen weeks.
32926417|NCT05349929|Experimental|Ibuprofen|Ibuprofen(Gelofen) 400mg capsules, Dana pharma company, every 6hours
32926418|NCT05349929|Experimental|Anahil|Bromelain(Anahil) 200 mg capsules, Permon Amin Health Company,every 6hours
32926419|NCT04335227|Experimental|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
32926420|NCT04335227|Experimental|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
32926421|NCT04335227|Experimental|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
32926422|NCT04335227|Active Comparator|Control group|Nutritional management uniquely prepared by dietitian
32926423|NCT04692103|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
32926424|NCT05349851||Renal failure patiens|Patients with advanced renal failure
32926425|NCT05203471|No Intervention|Historical controls|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study prior to launching the integrated care intervention.
32926426|NCT05203471|Active Comparator|Integrated care|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study after launching the integrated care intervention. Only patients who provide informed consent and enroll in the study will be treated with our integrated care model. All other patients with a participating primary care provider will be treated using a standard care model and will not be considered study participants.
32926427|NCT05200819||COVID 19 Patients|Patients who have survived COVID-19 infection, including those included in the Michigan Medicine COVID-19 Cohort (M2C2) will be eligible to participate.
32926428|NCT05455463|Experimental|Online aphasia-adapted physical activity class|Will receive the physical activity intervention.
32926429|NCT05455463|No Intervention|Usual routine control|Engage in physical activity per usual routine.
32926430|NCT04737941|Experimental|Immediate foam sclerotherapy|Immediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
32926431|NCT04737941|Active Comparator|Scheduled treatment|Scheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
32926432|NCT05192941|Experimental|Inclisiran sodium 300 mg s.c. + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
33250461|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
33400652|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
32926433|NCT05192941|Placebo Comparator|Corresponding placebo + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
32926434|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
32926435|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
32926436|NCT05455307|Experimental|single arm|single arm without placebo control
32926437|NCT04335851|Experimental|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
33400653|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
32926438|NCT04335851|No Intervention|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
32926439|NCT04202393|Experimental|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
32926440|NCT04202393|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
33400654|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
32724810|NCT03967379|Other|Enhanced Standard Care|"Patients will receive Enhanced Standard Care~Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD~Patients will not have access to the sexual health mobile app"
32724811|NCT03855995||Active surveillance (DTP sub-Group)|Children enrolled in the active surveillance (AS), <18 months of age who were identified at any administration of DTP/HepB/Hib (usually given at 6, 10 and 14 weeks of age) or at hospitalisation before administration of 3rd dose of DTP/HepB/Hib and vaccinated with at least one dose of DTP/HepB/Hib; including both RTS,S/AS01E vaccinated and unvaccinated children (from exposed or unexposed clusters), living in the HDSS area are eligible for enrolment in the DTP sub-group of active surveillance.
32724812|NCT03855995||Active surveillance (Catch-up sub-Group)|Children enrolled in the active surveillance (AS), <18 months of age who were identified at 1st RTS,S/AS01E dose administration and who either received all DTP/HepB/Hib doses before study start or received at least one dose of DTP/HepB/Hib and are older than the age corresponding to the 3rd DTP/HepB/Hib dose at study start; including only RTS,S/AS01E vaccinated children from exposed clusters who could not be recruited at the time of DTP/HepB/Hib administration because the study had not yet started, living in the HDSS area are eligible for enrolment in the Catch-up sub-group of active surveillance.
32724813|NCT03855995||Enhanced Hospitalisation Surveillance Group|Children at least 6 weeks and <5 years of age, within the study areas in both exposed and unexposed clusters, not already enrolled in the active surveillance (because parents/ Legally Acceptable Representative (LARs) declined enrolment in active surveillance or because recruitment had been completed) or not eligible for active surveillance at the time of hospitalisation, living in the HDSS area are eligible for enrolment in the Enhanced Hospital Surveillance (EHS) group.
32724814|NCT05396651|Experimental|LOW FODMAP Diet group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis, and didn't have any of the following :o Abdominal pain or diarrhea that wakes the child from sleep~Delay in onset or progression of puberty.~Faltering growth.~Family history of inflammatory bowel disease, celiac disease.~History of significant weight loss .~Bleeding per rectum.~Persistence of severe vomiting or diarrhea~. Persistent joint pain.~Recurrent unexplained fever.~Unexplained pallor they followed the low fodmapdiet for 6 weeks"
32724815|NCT05396651|Placebo Comparator|NICE guidelines group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis and didn't have one of the following : o Abdominal pain or diarrhea that wakes the child from sleep~Delay in onset or progression of puberty.~Faltering growth.~Family history of inflammatory bowel disease, celiac disease.~History of significant weight loss .~Bleeding per rectum.~Persistence of severe vomiting or diarrhea~. Persistent joint pain.~Recurrent unexplained fever.~Unexplained pallor~they followed NICE guidelines for irritable bowel syndrome for 6 weeks"
32724816|NCT05396573|Experimental|RQ3013|
32724817|NCT05396573|Active Comparator|Comirnaty|
32724818|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
32724819|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
32724820|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
32724821|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
32724822|NCT03812471|Experimental|Main study: 3D volumes acquisitions|3D volume acquisitions
32926441|NCT04334447|Experimental|Intervention Group Patients|All HF patients that experience a HF education session
33400655|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
32926442|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
32724823|NCT03812471|Experimental|Ancillary study: 2D and 3D acquisitions|2D standard measurements and 3D volumes acquisitions
32724824|NCT01093573|Experimental|Dose Level 1|Aza at 75 mg/m2 D1-7 & Midostaurin 25 mg BID D 8-21
32724825|NCT01093573|Experimental|Dose Level 2|Aza at 75 mg/m2 D1-7 & Midostaurin 50 mg BID D 8-21
32724826|NCT01093573|Experimental|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 & Midostaurin 75 mg PO BID D 8-21
32724827|NCT03484039|Experimental|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
32724828|NCT05396339|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
32724829|NCT05396339|Experimental|Phase Ia - Dose escalation(3+3 Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
32724830|NCT05396339|Experimental|Phase Ib - Dose extension|Phase Ib is an open, non-random, single-arm, multi-center research design.
32724831|NCT05396339|Experimental|Phase IIa - Clinical Exploratory Stage|The Phase IIa is planned to be divided into three indication groups, all of which are open, non-randomized, single-arm research design.
32724832|NCT03367741|Experimental|Arm A (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32724833|NCT03367741|Experimental|Arm B (nivolumab)|Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32724834|NCT05396261|Experimental|Treatment arm|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
32724835|NCT03402503|Experimental|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
32724836|NCT03402503|Placebo Comparator|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
32724837|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
32768351|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
32768352|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
32768353|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
32768354|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
32768355|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
32768356|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
32724838|NCT05396183||3D-PCT group|Participant will receive three-dimensional printing co-planar template (3D-PCT) assisted CT-guided head and neck neoplasm biopsy and prospective accuracy and safety data will record.
32724839|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
32926443|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 IN|GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
32926444|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 15 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
32926445|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 80 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
32926446|NCT04336085|Experimental|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
32926447|NCT04336085|Experimental|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
32926448|NCT05559931|Experimental|Part A: Single Dose Active|Subjects will receive a single IV dose of DMT, administered as a bolus loading dose followed by a 6-h infusion. The starting dose will be 1.5 mg bolus, followed by a 0.105 mg/min infusion. Subsequent doses will be based on the safety and tolerability data from previous groups.
32926449|NCT05559931|Placebo Comparator|Part A: Single Dose Placebo|Subjects will receive a single IV dose of placebo, administered as a bolus loading dose followed by a 6-h infusion.
32926450|NCT05559931|Experimental|Part B: Multiple Dose Active|Subjects will receive a total of 6 doses of DMT, given as a bolus loading dose, followed by a IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period. Dose to be determined from single dose phase.
32926451|NCT05559931|Placebo Comparator|Part B: Multiple Dose Placebo|Subjects will receive a total of 6 doses of placebo, given as a bolus loading dose, followed by IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period.
32926452|NCT04162847|Experimental|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
32926453|NCT04162847|No Intervention|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
32724840|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
32926454|NCT05174767|Experimental|Acute DeBakey Type I Dissection|In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.
32926455|NCT04120415|Experimental|Vaccine and Vedolizumab infusion|"Vaccine:~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
32724841|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
32724842|NCT05320315|Other|ACTIVE and UNTREATED|This was an intraindividual comparison study. Active (DM sunscreen) treated zone and Untreated zone are compared
32926456|NCT04120415|Experimental|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
32926457|NCT04120415|Placebo Comparator|Placebo vaccine and placebo infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Placebo infusion:~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
32926458|NCT04335695|Other|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
32926459|NCT05169073|Experimental|Virtual Reality MRCP|The MRCP images will be transferred into a 3D VR rendering software (Specto VR TM) for each patient. Residents will have the opportunity to use the virtual reality environment the day before surgery until a sufficient understanding of the anatomy is achieved.
32724843|NCT04155203|Experimental|Perrigo active|
32724844|NCT04155203|Active Comparator|Reference Active|
32724845|NCT04155203|Placebo Comparator|Vehicle control|
32724846|NCT05320081|Experimental|Camrelizumab combined with CD30 CAR-T|This study have only one arm that is Camrelizumab combined with CD30 CAR-T experimental arm.
32724847|NCT04238143|Experimental|tSVF + PRP Arm1|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
32724848|NCT04238143|Experimental|tSVF + PRP + cSVF Arm 2|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
32724849|NCT04238143|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction
32724850|NCT05394467||Lipedema|Women with diagnosed lipedema
32724851|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
32724852|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
32724853|NCT05392439|Experimental|taVNS treatment|The taVNS treatment is performed at auricular cymba concha. The stimulation parameters are set as follows: train on-time of 2 seconds and off-time of a 3-second pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude of 0-2 milliamp (at the maximum level tolerated by the subject).
32926460|NCT05169073|Active Comparator|Conventional MRCP|Controls will have regular access to the conventional MRCP images.
32926461|NCT04822883|Experimental|Dose-escalation - RL-007|Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
32926462|NCT04822883|Placebo Comparator|Dose-escalation - matching Placebo|Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
32724854|NCT05392439|Sham Comparator|sham-taVNS treatment|Sham-taVNS is performed with the same parameters as taVNS except that electrical stimulation is applied at the elbow area.
32926463|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
32926464|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
32926465|NCT05439083|Experimental|Immunosuppressed Group|"N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow up at Hospital La Paz in Madrid Spain.~9-valent HPV vaccine: three-dose schedule: Months 0-2-6."
32926466|NCT05439083|Other|Control Group|N=30 Healthy controls aged 9-14 9-valent HPV vaccine: two-dose schedule: Months 0-6.
32926467|NCT04669171|Experimental|Cohort 1|Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 for 6 weeks followed by addition of lenalidomide week 7 and rituximab week 19 (depending on response). Four to 18 evaluable (previously treated) patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) will be Included based on safety findings
32724855|NCT04073615|Experimental|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day on Days 1 through 28 of each 28-day cycle.
32724856|NCT04073615|Active Comparator|Trifluridine/tipiracil|Participants will receive an oral dose of Trifluridine/tipiracil twice per day with food, on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.
32926468|NCT04669171|Experimental|Cohort 2|15 Previously untreated patients with FL Or MZL. Evaluation of EO2463 monotherapy at the established dose in Cohort 1
32926469|NCT04669171|Experimental|Cohort 3|15 Previously untreated patients with FL or MZL. Evaluation of EO2463 at the established dose in cohort 1 as monotherapy for 6 weeks and in combination with rituximab from week 7
32926470|NCT04669171|Experimental|Cohort 4|15 Previously treated patients with FL Or MZL. Evaluation of EO2463 at the established dose in Cohort 1 in combination with lenalidomide and with addition of rituximab from week 19 onwards (depending on response)
32926471|NCT05427227||Gastrointestinal cancer (GI) patients receiving immunotherapy|
32724857|NCT04073615|Experimental|Rivoceranib and trifluridine/tipiracil|Participants will receive a daily oral dose of rivoceranib on Days 1 through 28 and the recommended phase 2 dose (RP2D) of trifluridine/tipiracil twice per day between Days 1 to 5 and 8 to 12 of each 28-day cycle.
32724858|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
32724859|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
32724860|NCT04060199|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
32724861|NCT04060199|Placebo Comparator|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
32926472|NCT05427227||GI patients receiving anti-HER2 therapy|
32926473|NCT05427227||GI patients receiving anti-CLDN18.2 therapy|
32724862|NCT05173675|Experimental|Program arm|"Usual Care+~Phase 1 (6 months, months 1-6), Program. Includes empathetic communications (phone & letter), health-promoting incentives, educational materials.~Phase 2 (6 months, months 7-12) No Program. During this follow-up period they will receive monthly SMS texts with customized messages encouraging health promoting behaviors."
32724863|NCT05173675|Other|Control arm|"Usual Care+~Phase 1 (6 months, months 1-6), No Program.~Phase 2 (6 months, months 7-12) Material components of program including health-promoting incentives and educational materials."
32724864|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
32724865|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
32724866|NCT05387447|Experimental|Conversational Voice Assistant-Standard|Participants will complete a standard interactive routine with the voice assistant.
32724867|NCT05387447|Experimental|Conversational Voice Assistant-Enhanced|Participants will complete a personalized and tailored interactive routine with the voice assistant.
32742993|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
32926474|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
32926475|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
32926476|NCT05421455|Other|Biologic group|treat paticipants with up to 2 biologics
32926477|NCT05421455|Other|Surgery group|treat paticipants with surgery
32926478|NCT04662151|Experimental|Phase 1b open-label AT-100|Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
32926479|NCT04662151|Sham Comparator|Phase 1b open-label air-sham|Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
32926480|NCT05414591|Experimental|Sequence group A|DWP16001 A mg 1T
32926481|NCT05414591|Experimental|Sequence group B|DWP16001 B mg 3T
32926482|NCT05412407|Other|Questionnaire : Taken analgesics|the patient will complete a questionnaire
32926483|NCT04657081|Experimental|Oral administration of ASTX727 and venetoclax combination|"Cycle 1: ASTX727 according to a prescribed dosing regimen and venetoclax on day 1 (100 mg daily), day 2 (200 mg daily), and days 3-28 (400 mg daily) of a 28-day cycle.~Cycle 2 and beyond: ASTX727 according to a prescribed dosing regimen and venetoclax on days 1-28 (400 mg daily) of a 28-day cycle."
32926484|NCT04814225|Experimental|Pea Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
32926485|NCT04814225|Experimental|Pea & Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
32926486|NCT04814225|Experimental|Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
32926487|NCT04814225|Active Comparator|Whey Protein Isolate|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
32926488|NCT05545891|Placebo Comparator|Placebo|5mg once daily of placebo for three weeks, then 10mg once daily for the remaining three weeks.
32926489|NCT05545891|Experimental|Aripiprazole|5mg once daily of aripiprazole for three weeks, then 10mg once daily for the remaining three weeks.
32926490|NCT04807205|Experimental|Elite IQ Laser|The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.
32926491|NCT05441033|Experimental|Group-FHB|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby by listening to the fetal heart beats for 5 consecutive nights, the measurement tools will be obtained at the end of the 5th night by re-measurements. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
32926492|NCT05441033|Experimental|Group-GIT|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby with the guided imagery technique performed for 5 consecutive nights with the measurement tools, the data will be obtained by re-measurements at the end of the 5th night. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
32926493|NCT05441033|No Intervention|Control group|"It is planned to conduct two interviews in total with the couples included in the control group. Written and verbal consent will be obtained by explaining the purpose of the research at the first interview to be held in the pregnant outpatient clinics with the couples to be included in the control group. Later on, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAPAS), Antenatal Father Attachment Scale BABI, Richard Campbell Sleep Scale Pre-test data will be obtained by means of the State Anxiety Scale and the State Anxiety Scale. Measurement tools will be repeated at the end of the 5th night in parallel with the experimental groups and a total of 2 measurements will be obtained together with the pre-test measurements. It is planned that the application of the measurement tools will take approximately 15 minutes for each couple."
32926494|NCT05541679|Experimental|Group A|
32926495|NCT05541679|Experimental|Group B|
32926496|NCT05146999|Active Comparator|Active arm - QM1114-DP|a Botulinum Toxin Type A (BoNT-A)
33250462|NCT05351320|Experimental|WX-0593 single arm|"Part 1: Participants will receive WX-0593 monotherapy until disease progression or unacceptable toxicity.~Part 2: Participants will receive 1 or 2 cycles of WX-0593 monotherapy and subsequently with concurrent chemoradiation, followed by WX-0593 monotherapy until disease progression or unacceptable toxicity."
33250463|NCT00868413|Active Comparator|A|FCR+ABT-263
33250464|NCT00868413|Active Comparator|B|BR+ABT-263
33250465|NCT05351008|Experimental|Cognitive Physical Therapy group|The group will receive 4 months 3 times per week of cognitive physical therapy.
32724868|NCT05320003|Other|Adults with pes planus|Detailed clinical examination of cases with pes planus will be performed. Inky foot analysis of both feet will be performed to confirm the diagnosis of pes planus in the subjects included in the study. Staheli arch index and Chippaux-Smirak Index will be calculated for each foot based on the footprints obtained. According to the Staheli Arc Index 1 and above, according to the Chippaux-Smirak Index 0.45 and above will be considered as pes planus, static foot pressure measurement will be performed with a pedobarography device in all cases. Peak pressure, maximum force and total foot area values will be obtained. Balance assessment of the patients will be performed with a computerized static posturography device. Individuals will be graded according to the fall index results, as low, medium and high risk. It will be determined whether there is a fall risk with the Timed Up and Go Test, which is one of the clinical balance tests.
32926497|NCT05146999|Placebo Comparator|Inactive arm - Placebo|
32926498|NCT03947957|Other|collection of expectoration, stools and blood|
33250466|NCT05351008|Active Comparator|Physical therapy group|The group will receive 4 months 3 times per week of physical therapy.
33250467|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
33250468|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
32768357|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
32768358|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
32768359|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
32768360|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
32768361|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
32768362|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
32768363|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
32768364|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
32768365|NCT03043235||African American Females|No intervention
32768366|NCT03043235||African American Males|No intervention
32768367|NCT03043235||Caucasian Females|No intervention
32768368|NCT03043235||Caucasian Males|No intervention
32768369|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
32768370|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
32768371|NCT05357833|Experimental|SPMS Cohort|Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.
32768372|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
32768373|NCT05339113|Experimental|68Ga-FAPI-46 PET/CT + 18-FDG PET/CT|18FDG PET/CT scan is followed by [68Ga]FAPI-46 PET/CT within 2-3 days.
32768374|NCT04843163|Experimental|Wave A (Immediate NAMI Basics)|Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
32768375|NCT04843163|No Intervention|Wave B (Waitlist Control)|Participants in the 8-week delay condition will be able to participate in a NAMI Basics class immediately following the 8-week time frame. Participants in the 8-week delay group (Wave B) will be assessed before the 8-week delay, after the 8-week delay (prior to their Basics course), and after the Basics course.
32768376|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
32768377|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
32768378|NCT04840433|Experimental|MACE|Patients will receive MACE for IDA.
32768379|NCT05332795|Active Comparator|group 1: gouty patients on metformin.|metformin users: include gouty patients, who will receive metformin tablets (1000 mg) once daily for about 3 months.
32768380|NCT05332795|Placebo Comparator|gouty patients on placebo.|placebo users: include gouty patients, who were on placebo tablets once daily for about 3 months.
32768381|NCT04370483|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32768382|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
33250469|NCT04010500|Experimental|Rugby Players|
32926499|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
33400656|NCT05746312|Experimental|Multiple-baseline study|All participants in this study received the same protocol. First, we had a baseline control period (no intervention) during which we assessed state anxiety levels every two minutes. Subsequently, we administered the intervention and continued to assess state anxiety at two minute intervals. Participants were randomized to baseline periods that varied in length (10,12,14, or 16 minutes of baseline).
33400657|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
32724869|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
32724870|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
32724871|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
32724872|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
32724873|NCT05303311|Active Comparator|Bupivacaine group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% alone.
32724874|NCT05303311|Active Comparator|pethidine plus dexamethasone group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 1mg/kg preservative-free pethidine plus 4mg dexamethasone diluted to a volume of 3 ml with 0.9% sodium chloride
32724875|NCT03447223||ADHD-patients|The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
32724876|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 6-15 years old children and adolescent.
32724877|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
32724878|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
32724879|NCT03447145|Experimental|TQ-B3203|
32724880|NCT05297071|Other|Dental Loupes|The surgeon will use dental loupes with a head lamp during the subject's tooth extraction and socket grafting.
32724881|NCT05297071|Other|Surgical microscope|The surgeon will use a surgical microscope (with built-in lighting) during the subject's tooth extraction and socket grafting.
32724882|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
32724883|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
32724884|NCT03728881|Experimental|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
32724885|NCT03728881|Active Comparator|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
32724886|NCT05287087|Active Comparator|My Symptoms 1 (MySt-1)|"GPs will receive an introduction to the overall content of the eHealth programme MySt-1. The information will be given to participating GPs and their staff during a 1½-hour session in the practice. The research assistant will go through the logistics of the patient recruitment and evaluation step-by-step and GPs and relevant staff will subsequently have access to the programme.~The patients will get access to a basic eHealth programme (My Symptoms 1). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
32724887|NCT05287087|Experimental|My Symptoms 2 (MySt-2)|"GPs will attend a one-day training course of 7 hours including: in depth insight into the My Symptoms 2 eHealth programme, comprehensive understanding of PPS, training of communication skills and the use of contextual (non-specific/common psychological) factors. The training programme has been developed in cooperation with the national GP association offering CME (PLO-e). Lecturers and trainers will be GPs and psychologists from the research team.~The patients will get access to an advanced eHealth programme (My Symptoms 2). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
32724888|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
32724889|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
32724890|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
32926500|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
32926501|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
32926502|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
32926503|NCT04787939|Experimental|Early Feeding Arm|Early Feeding Group
32926504|NCT04757675|Experimental|0.3 SK iv|0.3 μg/kg intravenous injection s-ketamin
32926505|NCT04757675|Experimental|0.5 SK iv|0.5 μg/kg intravenous injection s-ketamin
32926506|NCT04757675|Experimental|2 SK in|2 μg/kg intranasal s-ketamin
32926507|NCT04757675|Experimental|1 SK in + 1 DEX in|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
32926508|NCT04757675|Experimental|0.5 SK in + 2 DEX in|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
32926509|NCT04731311|Other|Usability Evaluation of the BrightGo system|Participants with rate the device in each of 4 usability evaluation sessions.
32926510|NCT04611529|Experimental|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 2gm
32926511|NCT04611529|Active Comparator|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
32926512|NCT04611529|Active Comparator|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 2gm
32926513|NCT04603807|Experimental|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
32926514|NCT04603807|Active Comparator|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
32926515|NCT04726163|No Intervention|Tele-expertise|Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
32926516|NCT04726163|Experimental|Standard|Standard treatment and adaptation of insulin doses according to the usual management of the unit
32926517|NCT04722341|Experimental|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
32926518|NCT04722341|Active Comparator|Control|More than equal to a 12-hour daily eating period
32724891|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
32926519|NCT05323721|No Intervention|Control - No SMC|This arm will not receive any SPAQ
32724892|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
32926520|NCT05323721|Active Comparator|Intervention SMC - SPAQ|This arm will receive SPAQ as seasonal malaria chemoprevention
32926521|NCT05323721|Active Comparator|Intervention SMC - SP|This arm will receive SP as seasonal malaria chemoprevention
32926522|NCT04601779|Other|Cluster I|Cluster I is randomized to start the VIPP-PUF intervention phase May 1, 2022
32926523|NCT04601779|Other|Cluster II|Cluster II is randomized to start the VIPP-PUF intervention phase November 1, 2022
32724893|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
32724894|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
32724895|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32926524|NCT04601779|Other|Cluster III|Cluster IiI is randomized to start the VIPP-PUF intervention phase March 1, 2023
33277354|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
32724896|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32724897|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
32724898|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
32724899|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
32926527|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant A in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
32926528|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant B in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
32724900|NCT03446755|Experimental|Intrauterine balloon (Cook medical)|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
32724901|NCT02733367|Experimental|Infacort|Infacort® granules
32724902|NCT03446677|Experimental|Asymptomatic persons with HIV|
32724903|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
32724904|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
32724905|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
32724906|NCT05230225|Experimental|Notification Letter Arm|Providers that will receive an electronic Physician Notification Letter.
32724907|NCT05230225|No Intervention|Control Group|Providers that will not be contacted.
32724908|NCT04064749|No Intervention|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
32724909|NCT04064749|Experimental|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
32724910|NCT05202145|Experimental|Part 1 - Cyclosporine|"Participants will receive ALXN2050 and cyclosporine in a fixed sequence over 3 periods.~Period 1: Participants will receive multiple doses of ALXN2050.~Period 2: Participants will receive multiple doses of cyclosporine.~Period 3: Participants will receive multiple doses of ALXN2050 co-administered with multiple doses of cyclosporine.~There will be a washout period between the last dose of ALXN2050 in Period 1 and the first dose of cyclosporine in Period 2 and between the last dose of cyclosporine in Period 2 and the first dosing in Period 3."
32724911|NCT05202145|Experimental|Part 2 - Tacrolimus|"Participants will receive tacrolimus and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of tacrolimus.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of tacrolimus.~There will be a washout period between the dose of tacrolimus in Period 1 and the first dose of ALXN2050 in Period 2."
32724912|NCT05202145|Experimental|Part 3 - MMF|"Participants will receive MMF and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of MMF.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of MMF.~There will be a washout period between the dose of MMF in Period 1 and the first dose of ALXN2050 in Period 2."
32724913|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
32724914|NCT03979183|Experimental|Intervention|Therapeutic exercise
32724915|NCT03979183|No Intervention|Control|Usual care
32724916|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
32724917|NCT05164783|Experimental|Participants|Intervention: use of SCP
32724918|NCT05136859|Experimental|preserve|preserve the perivascular fat of the target cephalic vein
32724919|NCT05136859|No Intervention|remove|remove from perivascular fat of the target cephalic vein
32724920|NCT03970525||Venturi pump|This cohort will receive femtosecond laser cataract surgery with Venturi pump.
32724921|NCT03970525||Peristaltic vacuum pump|This cohort will receive femtosecond laser cataract surgery with peristaltic pump.
32724922|NCT03916783|Experimental|Combination intervention|"Selected families will be assigned to the treatment condition (delivered over 9 months) to receive BSC plus a family EE intervention comprising of a matched family development account (FDA) for health-related expenses, including transport to UCI, food/nutrition, and health insurance. Combined with the Family EE will be four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education. The sessions will be conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.~*Due to insufficient sample size, the open clinical trial is not being conducted."
32724923|NCT03782623||Intensive care patients after elective open aortic surgery|
32724924|NCT03782623||Intensive care patients after bilateral lung transplantation|
32724925|NCT03782623||Anesthetic intensive care patients, unplanned admission|
32724926|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
32724927|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
32724928|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
32724929|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
32724930|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
32724931|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
32724932|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
32724933|NCT03446443|Experimental|Honghe Fujie lotion group|
32724934|NCT03446443|Active Comparator|Metronidazole Suppositories group|
32724935|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
33277355|NCT05356832||continent|able to hold urine during sports
32724936|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
32724937|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
32724938|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
32724939|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
32724940|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
32724941|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
32724942|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
32724943|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
32724944|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
32724945|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
32724946|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
32724947|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
32724950|NCT02087423|Experimental|MEDI4736|see below
32724951|NCT03688555|Experimental|ACT-774312|Participants will receive ACT-774312 (400 mg twice daily) in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
32724952|NCT03688555|Placebo Comparator|Placebo|Participants will receive placebo twice daily in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
32724953|NCT05102071||Treatment with empagliflozin|as add-on therapy with metformin
32724954|NCT05102071||Treatment with a sulfonylurea|as add-on therapy with metformin
32724955|NCT05386199||Healthy controls|Healthy volunteers without conditions altering serotonin content in blood.
32724956|NCT05386199||Sepsis group|Patients with sepsis or septic shock admitted to ICU and receiving mechanical ventilation.
32724957|NCT05386199||Cardiac arrest group|Patients with cardiac arrest and ROSC admitted to ICU and receiving mechanical ventilation.
33277356|NCT05356832||incontinent|leaking urine during sports
33277357|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
33277358|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
32724958|NCT05386199||Multiple trauma group|Patients with severe multiple trauma admitted to ICU and receiving mechanical ventilation.
32724959|NCT05386199||ICU control group|Patients with isolated neurological disease admitted to ICU and receiving mechanical ventilation.
32724960|NCT03684889|Experimental|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
32724961|NCT03684889|Experimental|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
32724962|NCT01351103|Experimental|LGK974|LGK974
32724963|NCT01351103|Experimental|LGK974 in combination with PDR001|LGK in combination with PDR001
32724966|NCT03443869|Experimental|Letermovir|Letermovir (LET) 480mg (or 240 mg when co-administered with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
32724967|NCT03443869|Active Comparator|Valganciclovir|900 mg Valganciclovir (VGCV) tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
32724968|NCT05383937|Experimental|intensive arm|The children included in this arm will receive two weeks of daily care during which two daily speech therapy sessions of one hour each will be performed. This will be done between M2 and M4 of inclusion in order to avoid potential measurement bias. These sessions will be carried out by a state-qualified speech therapist employed at the CRRF of Bregille. They will guide the intensive rehabilitation of dyslexic children by focusing the exercises on their main difficulties.
32724969|NCT05383937|Active Comparator|classic arm or gold standard|"The speech therapy session will be provided only by private practitioners, with a weekly consultation of 30 minutes. The private speech therapist who initially referred the patient for inclusion in the research protocol will be responsible for his or her classic rehabilitation. The therapy will continue during the 6 months of research."
32724970|NCT05006339|Experimental|Dental Monitoring|Orthodontic retention review via dental monitoring only
32724971|NCT05006339|Active Comparator|Clinic Review|Orthodontic retention review via in-office visits as per routine care
32724972|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
32724973|NCT05345405|Active Comparator|Dyadic CARE|Participants will receive dyadic CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
32724974|NCT05345405|Active Comparator|Supporter-Only CARE|Participants will receive supporter-only CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
33250470|NCT04040829|Active Comparator|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
33250471|NCT04040829|Experimental|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
33250472|NCT03897348|Experimental|Crossover Sequence A: Placebo, then Lacosamide 200 mg, then Lacosamide 100 mg|Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
32768383|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
32768384|NCT05224453|Other|Physical training and high protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d).
32768385|NCT05224453|Other|Physical training and low protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group B received a low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
32768386|NCT04843397||Single Arm|Patients referred for clinically indicated EGD, without known precancerous condition. Patients will receive endoscopy with standardised biopsy and photodocumentation protocol
32768387|NCT05218837||First vaginal birth|The first vaginal birth in nulliparous women
32768388|NCT05218837||Vaginal birth after cesarean section (VBAC)|The first vaginal birth after one or more prior cesarean sections (VBAC)
32768389|NCT05218837||Second vaginal delivery|The second vaginal delivery
32768390|NCT05211193||eTNM arm|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1- 42.
32768391|NCT04861103|Experimental|Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing|Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
32768392|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
32768393|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
32768394|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
32768395|NCT05178355|Experimental|Part A - KVD824 - 10 mg|6 participants were administered10 mg of KVD824 in capsule form (1 x 10 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32768396|NCT05178355|Experimental|Part A - KVD824 - 20 mg|6 participants were administered 20mg of KVD824 in capsule form ( 2 x 10 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
32768397|NCT05178355|Experimental|Part A - KVD824 - 40 mg|6 participants were administered 40mg of KVD824 in capsule form (1 x 40 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32768398|NCT05178355|Experimental|Part A - KVD824 - 80 mg|6 participants were administered 80mg of KVD824 in capsule form (2 x 40 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
32768399|NCT05178355|Experimental|Part A - KVD824 - 160mg|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32768400|NCT05178355|Experimental|Part A - KVD824 - 320 mg|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32926529|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant C in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
33250473|NCT03897348|Experimental|Crossover Sequence B: Lacosamide 200 mg, then Lacosamide 100 mg, then Placebo|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 100 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
33250474|NCT03897348|Experimental|Crossover Sequence C: Lacosamide 200 mg, then Placebo, then Lacosamide 100 mg|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Placebo. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
32926530|NCT05288075|Active Comparator|Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule|Each subject will receive 2 capsules of Ultibro® Breezhaler® (=Indacaterol/glycopyrronium) as a single dose in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
32926531|NCT04424251|Experimental|stage I：HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg； intravenous injection
32926532|NCT04424251|Experimental|stage I：HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg；intravenous injection
32926533|NCT04424251|Experimental|stage I：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
32926534|NCT04424251|Experimental|stage I：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
32926535|NCT04424251|Experimental|stage II：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
32926536|NCT04424251|Experimental|stage II：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
32926537|NCT04424251|Placebo Comparator|Postoperative: Placebo|Placebo；intravenous injection
33250475|NCT03897348|Experimental|Crossover Sequence D: Lacosamide 100 mg, then Lacosamide 200 mg, then Placebo|Participants receives a single dose of Lacosamide 100 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
32926538|NCT05272787|Experimental|Left face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the left side of the face, then the Facial Moisturizer B (Control) will be applied on the right side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
32926539|NCT05272787|Experimental|Right face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the right side of the face, then the Facial Moisturizer B (Control) will be applied on the left side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
32926540|NCT04593277|Experimental|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
32926541|NCT04593277|Active Comparator|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
32926542|NCT05215145|Active Comparator|Baby Navigator Bundle|Parent and child measures, including a home observation video, will be collected at baseline, after which study staff will use Motivational Interviewing techniques to engage families to access resources and support (Baby Navigator Bundle) when parents first learn their child has social communication/language delay. Families may use the Baby Navigator Bundle as little or as much as desired. The Baby Navigator Bundle includes: Social Communication Growth Charts and the Baby Navigator webinar series.
32926543|NCT05215145|Active Comparator|Baby Navigator Bundle + Individual-ESI|At 18-21months of age, slow responders (communication delay still below the 10th percentile) will be randomized to continue the Baby Navigator Bundle with or without Individual-ESI, and responders (communication above the 10th percentile) will continue with Baby Navigator Bundle. For Individual ESI, trained coaches or family navigators will coach families using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Family navigators will also engage the family in the How-to Guide for Families online course. The family navigator will use zoom or other telehealth platform to meet with parents 1 time per week for 30-60 minutes per session for 6 months.
32926544|NCT04349683|Experimental|Experimental group|basic treatment combined with Jinshuibao
32926545|NCT04349683|Placebo Comparator|Control group|basic treatment and placebo
32926546|NCT05145569|Experimental|Carboplatin/paclitaxel + Bintrafusp alfa (M7824)|Bintrafusp alfa (M7824) (2400 mg flat dose IV), in combination with chemotherapy including carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
32926547|NCT05145569|Active Comparator|Carboplatin/paclitaxel|Carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
32926548|NCT04566991|Experimental|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
32926549|NCT04566991|Experimental|Deferoxamine higher dose|Deferoxamine 48 mg/kg
32926550|NCT04566991|Placebo Comparator|Placebo|normal saline
33277359|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
32926551|NCT05143853|Active Comparator|group with tape augmentation of acromioclavicular (AC) joint|patients randomised in this group will have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
32926552|NCT05143853|Sham Comparator|group without tape augmentation of AC joint|patients randomised in this group will not have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
32926553|NCT04412083|Other|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
32926554|NCT05136833|Experimental|Group A (RUTI)|Subjets will receive one inoculation of the RUTI® vaccine at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 mL
32926555|NCT05136833|Placebo Comparator|Group B (Placebo)|Subjets will receive one inoculation of normal saline at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region.
32724975|NCT05345405|No Intervention|Waitlist Control|After completing baseline, participants will be invited to schedule a CARE session in 3 months (i.e., after the completion of all study assessments). The version of CARE received at that point will be selected by the survivor. Participants will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
32926556|NCT04547725|Experimental|CRS-IP (Arm-A)|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index [PCI] ≤ 10)
32926557|NCT04547725|Experimental|CRS-IP (Arm-B)|Stage IV gastric cancer with positive peritoneal wash cytology (CY1/P0)
32926558|NCT05086289|Experimental|LY3526318|LY3526318 administered orally
32926559|NCT05086289|Placebo Comparator|Placebo|Placebo administered orally
32926560|NCT04535401|Experimental|Treatment (elimusertib, FOLFIRI)|Patients receive elimusertib PO BID on days 1, 2, 15, and 16 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity.
32926561|NCT04665089|Active Comparator|Erythromycin arm|The erythromycin arm (n=40) receives, in addition to the standard antimicrobial therapy, erythromycin 1 g three times per day intravenously: each gram is diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
32926562|NCT04665089|Placebo Comparator|Placebo arm|The placebo arm (n=40) receives, in addition to the standard antimicrobial therapy, isotonic saline, intravenously, 20 ml diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
32926563|NCT04645823|Active Comparator|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
32926564|NCT04645823|Experimental|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
32926565|NCT05440955|Experimental|active tDCS|tDCS (transcranial Direct Current Stimulation subjects) is a noninvasive brain stimulation technique that involves the passage of a small electric current through the scalp and skull to modulate brain activity [10]. The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device).
32926566|NCT05440955|Sham Comparator|sham tDCS|The sham procedure is developed by the tDCS device manufacturer, which allows using the same tDCS device and the same procedure (i.e., 10 sessions delivered during five consecutive days) for both the active and sham procedures. In the sham condition, the electrodes will be placed in the same positions as in the active group; however, the stimulator will be only active for initial and final ramp up/ramp down periods, in order to mimic the sensation of active stimulation. In addition, brief pulses of 110 μA will be administered every 550 ms in order to control impedance and keep the manipulator blinded to the active or sham condition.
32926567|NCT04622345|Experimental|VSJ-110 Solution|
32926568|NCT04622345|Placebo Comparator|Placebo Solution|
32926569|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
32724976|NCT05006599|Experimental|Humulin® R U-100|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.
32724977|NCT05006599|Placebo Comparator|Placebo|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.
32926570|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
32926571|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
32926572|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
33250476|NCT04010734|Active Comparator|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
32724978|NCT05342441|Experimental|QT-graft|Quadriceps tendon autograft (n=50)
32724979|NCT05342441|Experimental|St/Gr-graft|Semitendinosus/gracilis autograft (n=50)
32724980|NCT05342441|Experimental|BPTB-graft|Patella tendon autograft (n=50)
32926573|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
32926574|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
32926575|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
32926576|NCT03892187|No Intervention|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
32926577|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
32926578|NCT04939805|Experimental|Selective CRP apheresis as an adjunct to standard of care|Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
32926579|NCT04939805|No Intervention|Standard of care according to current guideline recommendations|
32926580|NCT05082883||Cognitively Normal|No cognitive impairment, medically stable
32926581|NCT05082883||Mild Cognitive Impairment|Meets NIA-AA criteria for MCI
32926582|NCT05082883||Mild Dementia|Meets NIA-AA criteria for dementia
32724981|NCT05341661|Active Comparator|Active|The active arm patients undergo the Butterfly device procedure.
32724982|NCT05341661|Sham Comparator|Sham Comparator|The sham control arm patients undergo a rigid cystoscopy procedure.
32724983|NCT05341661|Other|Cross over|Sham arm patient is allowed to crossover and undergo the Butterfly procedure
32724984|NCT04742777|Experimental|Rapamycin|Rapamycin 1mg for 8 weeks
32724985|NCT03349723|Experimental|BI 1265162|BI 1265162
32724986|NCT03349723|Placebo Comparator|Placebo|Placebo
32724987|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
32724988|NCT05332769||Infertile women have IVF/ICSI cycle|All Vietnamese infertile women who have IVF/ICSI cycle with at least 8 follicles ≥ 10 mm on ultrasonography at induced ovulation date agreed to freeze-all day 5-6 embryos at IVFMD and IVFMD PN will be enrolled in the study.
32724989|NCT04981795||Adults (> or = 18 years of age)|Adults (> or = 18 years of age) diagnosed with relapsed or refractory DLBCL and initiating second- or third-line therapy meeting inclusion criteria.
32724990|NCT03130673||hip fracture|fracture of proximal femur
32724991|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
32724992|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
32724993|NCT05327933|Experimental|Surgery plus endovascular MMA embolization|
32724994|NCT05327933|Active Comparator|Surgery alone|
32724995|NCT04452409|Active Comparator|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
32724996|NCT04452409|Other|control (Mediterranean diet only)|diet
32724997|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
32724998|NCT03130517|Other|Control group|Control group will recieve phototherapy only
32724999|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
32725001|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
32725002|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
32725003|NCT04548791|Experimental|Cohort 1|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, and 60 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 20 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
32768401|NCT05178355|Experimental|Part A - KVD824 - 640 mg|6 participants were administered 640 mg of KVD824 in capsule form (2 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32926583|NCT04334213|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
32926584|NCT04334213|Experimental|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
32926585|NCT04334213|Experimental|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
32926586|NCT04334213|Experimental|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
32926587|NCT05077579||metabolically abnormal overweight & obese|
32926588|NCT05077579||metabolically normal overweight|
32926589|NCT05077579||obese and metabolically normal lean|
33277360|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
32725004|NCT04548791|Experimental|Cohort 2|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
33277361|NCT05360342|Experimental|Vitamin K supplement|Administration of a single dose vitamin K
32725005|NCT04548791|Experimental|Cohort 3|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
32725006|NCT04950439|Other|Myocardial CT|The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
33277362|NCT00989846||lung disease|patients with various chronic or acute lung diseases
32725007|NCT04938115|Experimental|CD7 CAR-T|
32725008|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
32725009|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
32725010|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
32725011|NCT03208387||Age-Matched Healthy Children Controls|
32725012|NCT04676243|Experimental|Quizartinib plus standard of care (SOC)|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Quizartinib
32725013|NCT04676243|Active Comparator|Physician's choice|Physician's choice (usually Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Midostaurin)
32725014|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
32725015|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
32725016|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
32725017|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
32725018|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
32725019|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
32725020|NCT03093961|Experimental|Intervention|IASD Implantation
32926590|NCT04524013||School aged children|
32926591|NCT04524013||Pregnant women|
32725021|NCT04285307|Experimental|Study group|Study group
32725022|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
32725023|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
32926592|NCT04885595|Active Comparator|Forceps-Cryo 1.1 mm|Forceps biopsy following cryobiopsy with a 1.1mm cryoprobe are obtained within the same session
32926593|NCT04885595|Active Comparator|Forceps-Cryo 1.7 mm|Forceps biopsy following cryobiopsy with a 1.7mm cryoprobe are obtained within the same session
32725024|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
32725025|NCT05291351|Experimental|Pea|Treatment 1: crackers made with 25% whole pea flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse pea flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine pea flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
32725026|NCT05291351|Experimental|Lentil|Treatment 1: crackers made with 25% whole lentil flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse lentil flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine lentil flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
32926594|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
33400658|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
33400659|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
33400660|NCT04612062|Experimental|Healthy Subjects (Part A)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
32926598|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
32926599|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
32926600|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
32725027|NCT05291351|Experimental|Oats|Treatment 1: porridge made with whole oat flour; Treatment 2: porridge made with coarse oat flour; Treatment 3: porridge made with fine oat flour; Treatment 4: porridge made with whole oats (control)
32725028|NCT05089825|Active Comparator|Receive routine instructions|Participants will receive routine instructions included in the myLAB Box Clinical Laboratory Improvement Amendments (CLIA) certified collection kit
32725029|NCT05089825|Active Comparator|Telehealth Visit|Participants will have a telehealth-based instructional visit and receive routine instructions included in the myLAB Box commercially available, CLIA certified collection kit
32725030|NCT05279027|Experimental|PET imaging|This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.
32725031|NCT04451629|Experimental|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
32725032|NCT04451629|No Intervention|control group|students will be watched without any intervention
32725033|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
32725034|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
32725035|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
32725036|NCT05253911||Cohort 1|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 1st or 2nd palliative therapy line.
32725037|NCT05253911||Cohort 2|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 3rd or 4th palliative therapy line.
32725038|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
32725039|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
32725040|NCT05241197|Experimental|Low load training with blood flow restriction (LL-BFR) group.|All participants in this arm will use a BFR tourniquet system during the execution of two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 20% 1 repetition maximum (RM), being progressively increased by 5% every four weeks. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. For each exercise, each participant will perform four sets with 30 repetitions the first set and 15 repetitions in the subsequent three sets, counting a total of 75 repetitions. All exercises will be performed in full range of motion (full plantar flexion to full dorsal flexion), with an interset rest period of 1 minute. Three minutes rest was provided between exercises.
33277363|NCT05356754|Experimental|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals. The VLDBPM captures PPG signals using the existing camera systems on iPhones. These PPG signals are normalized and processed to determine markers of blood pressure change. These markers, when transformed using a predetermined model, are capable of determining blood pressure changes from a known (calibration) set-point.
33400661|NCT04612062|Experimental|Atopic Dermatitis (Part B)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
33400662|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
32926601|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
32926602|NCT05064007|Experimental|1|this group will be exposed to condition A first, then B, and C
32926603|NCT05064007|Experimental|2|this group will be exposed to condition B first, then C, and A
32926604|NCT05064007|Experimental|3|this group will be exposed to condition C first, then A, and B
32926605|NCT04396873|Other|Only one arm|All subjects receive the same tests
32926606|NCT04829045|Experimental|Acupuncture plus diabetic routine care|Subjects will receive acupuncture treatment using press needles
33250477|NCT04010734|Active Comparator|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
32725041|NCT05241197|Active Comparator|High load training (HLT) group.|The HLT group will performed the same exercises than the BFR group, however with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. All exercises will be performed in full range of motion, with an interset rest period of 1 minute and a rest period between exercises of 3 minutes.
32725042|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
32725043|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
32768402|NCT05178355|Experimental|Part A - KVD824 - 1280 mg|6 participants were administered 1280 mg of KVD824 in capsule form (4 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
32926607|NCT04829045|Placebo Comparator|Placebo plus diabetic routine care|Subjects are given placebo
32926608|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
32926609|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
32926610|NCT04737863|Experimental|selective root canal retreatment|retreatment process is performed to the affected root only
32926611|NCT04737863|Active Comparator|traditional root canal retreatment|retreatment process is performed to all roots
32926612|NCT04365049||Nab-Paclitaxel+Gemcitabine+Camrelizumab+Radiotherapy|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8). Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy. Radiotherapy started after two cycles of chemotherapy. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
32926613|NCT04365049||Nab-Paclitaxel+Gemcitabine|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8).
32926614|NCT04606901|Active Comparator|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
32926615|NCT04606901|Active Comparator|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
32926616|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
32926617|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
32926618|NCT04589585|Experimental|DiVeRt treatment|DiVeRt device to be used in the single arm
32926619|NCT04573205|Experimental|> 50 years|"Healthy individuals > 50 years of age divided into age groups 50-59 years, 60-69 years and >70 years, approximately 20 participants in each group.~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals > 50 years of age, at time 0, 1, 2 and 7 months."
32926620|NCT04573205|Active Comparator|< 40 years|Healthy individuals < 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
32926621|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
32926622|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
33250478|NCT04010578|Experimental|MK-7 and vitamin D3 supplementation|Patients will receive a daily MK-7 and vitamin D3 supplementation for 3 months.
32926623|NCT04572035|Experimental|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
32926624|NCT04572035|Experimental|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
32926625|NCT04572035|Experimental|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
32926626|NCT04554173||surgical resection neurogenic tumors|
32926627|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
32926628|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
32926629|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
32926630|NCT04772807||Healthy|
32926631|NCT04772807||Patients infected by COVID- 19 with no symptoms|
32725044|NCT05239949|Experimental|Hypopressive exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of hypopressive exercises (HE). A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform HE in an upright position. For this maneuver, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage. Four sets of 10 repetitions with a 3-minute interval between each set will be performed."
32743444|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
32926632|NCT04772807||Patients infected by COVID- 19 with symptoms|
32926633|NCT04772807||Patients diagnosed with atrial fibrillation|
32926634|NCT04772807||Hypertensive patients|
32926635|NCT04772807||Heart failure patients, EF < 40%|
32926636|NCT04772807||Heart failure patients, EF > 40% and < 60%|
32926637|NCT04772807||Heart failure patients, EF > 60%|
32926638|NCT00372515|Experimental|High dose gefitinib|
32926639|NCT04333979|Experimental|Drain replacement|Effects of drainage
32926640|NCT04333979|No Intervention|Drain not placed|Effects of not using drain
32926641|NCT04448119|Experimental|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
32926642|NCT04448119|Placebo Comparator|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
32926643|NCT04706507|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge
32926644|NCT04706507|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge
32926645|NCT04342429|Experimental|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
32926646|NCT04508309|Experimental|Cecolin® at 0 and 6 months|Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
32926647|NCT04508309|Experimental|Cecolin® at 0 and 12 months|Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose
32926648|NCT04508309|Experimental|Cecolin® at 0 and 24 months|Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose
32926649|NCT04508309|Active Comparator|Gardasil® at 0 and 6 months|Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
32926650|NCT04508309|Other|Gardasil® at 0 and Cecolin® at 24 months|One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.
32926651|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
32926652|NCT04502615|Experimental|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
32926653|NCT04502615|Active Comparator|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
32926654|NCT04502615|Active Comparator|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
33250479|NCT04010578|Placebo Comparator|Placebo|Patients will receive a daily placebo for 3 months.
33250480|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
33250481|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
32768403|NCT05178355|Experimental|Part B - KVD824 - 80 mg Multi-Dose|6 participants were administered 80 mg of KVD824 in capsule form (2 x 40 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
33250482|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
33250483|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
32768404|NCT05178355|Experimental|Part B - KVD824 - 160 mg Multi-Dose|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
32768405|NCT05178355|Experimental|Part B - KVD824 - 320 mg Multi-Dose|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
32768406|NCT05178355|Experimental|Part B - KVD824 - 640 mg Multi-Dose|6 participants were administered 640mg of KVD824 in capsule form (2 x 320 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
32768407|NCT05178355|Experimental|Part C - KVD824 - 320 mg Fasted|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 in a fasted state.
32768408|NCT05178355|Experimental|Part C - KVD824 - 320 mg High fat breakfast|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 following consumption of a high fat breakfast.
32768409|NCT04429295|Experimental|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine [PCV] [Prevnar 13®] and oral rotavirus vaccine [ORV-1] [Rotarix™] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 15-18 months
32768410|NCT04429295|Active Comparator|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine [IPV] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age SHAN6™ administered alone as a booster dose at 15-18 months of age
32768411|NCT05258851|Experimental|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 grams intravenous (IV) every 8 hours infused over two hours for a duration of 7-14 days, with dose adjustment for renal impairment according to the FDA prescribing information. Patients who have a positive Xpert Carb-R screening test or culture for CRE with metallo-beta-lactamases will receive aztreonam added to ceftazidime-avibactam.
32768412|NCT05258851|Active Comparator|Colistin|Colistin (9-million-unit loading dose IV followed with 9 million units IV daily divided into 3 doses), for 7 to 14 days. Patients with renal impairment will receive antibiotics with adjusted doses based on their glomerular filtration rate or the use and type of renal replacement therapy according to the 2019 International Consensus Guidelines for the Optimal Use of the Polymyxins.
32768413|NCT04843085||O1|the more aggressive subgroup of oligodendroglioma samples of 30 patients
32768414|NCT04843085||O2|subgroup 2 of oligodendroglioma samples of 30 patients
32768415|NCT04843085||O3|subgroup 3 of oligodendroglioma samples of 30 patients
32768416|NCT04843085||IDH-mutant astrocytomas|patients with IDH-mutant astrocytomas, samples of 15 patients
32768417|NCT04843085||IDH-wildtype glioblastomas|patients with IDH-wildtype glioblastomas, samples of 15 patients
32768418|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
32768419|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
32768420|NCT04810481|No Intervention|Standard Practice|Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.
32768421|NCT04810481|Active Comparator|BIS Group|Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.
32768422|NCT05186233|Active Comparator|Non-personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their habitual sleep schedule. Participants will follow these recommendations over the course of two weeks.
32768423|NCT05186233|Experimental|Personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their activity levels. Participants will follow these recommendations over the course of two weeks.
32768424|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 3.75mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
32768425|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 1.88mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
32768426|NCT04840745|Experimental|CKD-841 D(=leuprorelin acetate 2.92mg)|Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
32768427|NCT04840745|Active Comparator|Leuplin Inj.(=leuprorelin acetate 3.75mg)|Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
32768428|NCT05073757||Orthognatic surgery|Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator.
32768429|NCT04840355||Subjects with no irAEs|
32768430|NCT04840355||Subjects with degree 1-2 irAEs|
32768431|NCT04840355||Subjects with degree 3-4 irAEs|
32926655|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
32926656|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
32926657|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
32926658|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
32926659|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
32926660|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
32725045|NCT05239949|Experimental|Pelvic floor muscle exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of pelvic floor muscle exercises. A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform pelvic floor muscle exercises in a sitting position. The patient is instructed to hold each contraction for 6 seconds, with three to four contractions added on the top. Four sets of 10 repetitions with a 2-minute interval between each set will be performed."
32725046|NCT05082259|Experimental|Part A-Escalation|"Increasing doses of ASTX660 in combination with a fixed dose of pembrolizumab to establish the maximum tolerated dose (MTD) of ASTX660 and Pembrolizumab when given in combination in patients with advanced solid tumours.~escalating doses of ASTX660 will be investigated in combination with a fixed dose of Pembrolizumab (200mg). ASTX660 administration will follow a 7 day on / 14 day off pattern (ie dosing for 7 consecutive days leading up to administration of the immune check-point inhibitors). Therefore in Cycle 1, ASTX660 will be given alone from Day 1 to Day 7, followed by a 14 day break, then taken again in Cycle 2 . Each cycle will run for a period of 21 days, with ASTX660 taken always on Days 1 to 7 and Pembrolizumab given always on Day 8.~Up to 4 dose levels of ASTX660 will be explored."
32725047|NCT05082259|Experimental|Part B-Expansion|"Patients in Part B will be treated at the RP2D as determined by the SRC after the initial dose escalation (Part A) has been completed. The treatment schedule will be the same as that for Part A, i.e. each cycle will be 21 days-long. Pembrolizumab will always be administered on D8 of every cycle. ASTX660 will be taken daily on Days 1-7.~Part B will be split into 3 cohorts; Cohort B1, Cohort B2 and Cohort B3.~Cohort B1: Patients with Immune-checkpoint refractory tumours Cohort B2: Patients with PD-L1 positive Cervical Cancer Cohort B3: Patients with Triple Negative Breast Cancer"
32725048|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
32725049|NCT03879551|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere on the hand motor area for 10 consecutive sessions totally over period of 10 days.
32725050|NCT03879551|Sham Comparator|Sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere with coil perpendicular on scalp for 10 consecutive sessions totally over period of 10 days.
32725051|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
32725052|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
32743445|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
32926661|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
32926662|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
32926663|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
32926664|NCT03069131|Experimental|Active rifaximin|
32926665|NCT03069131|Placebo Comparator|Rifaximin placebo|
32926666|NCT04707365|Experimental|digestive cancers|Colorectal and pancreatobiliary cancers
32926667|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
33073425|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"Will perform 68Ga-DOTATATE PET scans on subjects. The same anatomic areas will be imaged with 68Ga-DOTATATE PET and 111In-penteoctreotide Scintigraphy to ensure relevant comparison of lesion detection.~The images from 68Ga-DOTATATE PET/CT will be reported by an experienced nuclear medicine physician who will be unaware of the results of the previous 111Inpenteoctreotide study. Areas of abnormal focal uptake will be documented. These areas of abnormal uptake will be compared with cross-sectional imaging (CT or MRI)to confirm the presence of lesions. The images from 111In- penteoctreotide Scintigraphy will be reported independently by another experienced nuclear medicine physician."
33073426|NCT01867411||ex-smokers|former smokers who have quit
33073427|NCT01867411||never smokers/vapers|never smoked/vaped nicotine
32926668|NCT04381559|Experimental|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
32926669|NCT04381559|Active Comparator|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
32926670|NCT04608773|Other|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
32926671|NCT04608773|Other|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
32926672|NCT04438213|Experimental|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
32926673|NCT04438213|Experimental|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
32926674|NCT04438213|Placebo Comparator|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
32926675|NCT04310449|Experimental|Connective tissue graft and customized healing abutment|Immediate implant placement with CTG and customized healing abutment.
32926676|NCT04310449|Experimental|Bone graft and customized healing abutment|Immediate implant placement with bone graft till the crest of the bone and customized healing abutment
32926677|NCT04310449|Experimental|Bone graft and ovate pontic|bone grafts in the socket and ovate Pontic
32926678|NCT04310449|Active Comparator|Bone graft in dual zone and customized healing abutment|immediate implant placement with bone grafts in the dual zone and customized healing abutment
32926679|NCT04480931|Experimental|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
32926680|NCT04480931|Sham Comparator|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
32926681|NCT04465253|Experimental|Health services research (discussion, interview)|Patients participate in a discussion with an occupational therapist via videoconferencing over 15 minutes QW for 4 weeks about their experience with lymphedema and the occupational services they received. After 4 weeks, some patients may also participate in an interview with an occupational therapist via videoconferencing over 60 minutes. During the first week of the study, patients also receive occupational therapy per standard of care.
32926682|NCT04448171|Active Comparator|Activated TENS Unit with standard pain control measures|Activated TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
32926683|NCT04448171|Placebo Comparator|Sham TENS Unit with standard pain control measures|Sham TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
32926684|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
32926685|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
32926686|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
32926687|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
32926688|NCT04768387|Experimental|Personalized microbiome diet|Six weeks of AI-based microbiome diet was introduced.
32926689|NCT04768387|Active Comparator|Standard IBS diet|Six weeks of standard IBS diet was introduced.
32926690|NCT02917993|Experimental|Itacitinib + osimertinib|
32725053|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
32725054|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
32725055|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
32725056|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
32926691|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
33073428|NCT01867411||non-treatment seeking smokers/vapers|smokers/vapers not interested in quitting nicotine
32926692|NCT04405349|Experimental|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
32926693|NCT04265053|Experimental|Male NOS|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
32926694|NCT04265053|Experimental|Male COX|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
32926695|NCT04265053|Experimental|Female NOS|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
32926696|NCT04265053|Experimental|Female COX|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
32926697|NCT04332497|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
32926698|NCT04332497|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
32926699|NCT04332497|Active Comparator|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
32926700|NCT02840383|Active Comparator|Delayed Intervention|Schools not receiving intervention until two years after implementation.
32926701|NCT02840383|Experimental|Intervention|Schools receiving intervention at the beginning of study.
32926702|NCT04322981|Experimental|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
32926703|NCT04322981|Active Comparator|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
32926704|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
32926705|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
32926706|NCT02548715|Placebo Comparator|Control|Daily placebo
32926707|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
32926708|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.
32926709|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
32926710|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
32926711|NCT04258397|Active Comparator|Experimental, pirfenidone|"Pirfenidone 267 mg capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
32926712|NCT04258397|Placebo Comparator|Placebo, pirfenidone|"Pirfenidone placebo capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
32926713|NCT01988857|Experimental|dTpa Group|
32926714|NCT04707209|Experimental|Intravitreal Sirolimus|
32926715|NCT04295213|Experimental|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
32725057|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
32926716|NCT04295213|Placebo Comparator|placebo group|Placebo comparator, total duration of study is 13 weeks
32926717|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
32926718|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
32926719|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
32926720|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
32926721|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
32926722|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
32768432|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
32926723|NCT04254185|Active Comparator|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
32926724|NCT04254185|Active Comparator|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
32926725|NCT04223141|Experimental|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
32926726|NCT01991821|Experimental|APD421|IV APD421 single dose
32926727|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
32926728|NCT04209569|Active Comparator|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
32926729|NCT04209569|Experimental|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
32926730|NCT04209569|No Intervention|Control|No Intervention
32926731|NCT04197635|Active Comparator|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
32926732|NCT04197635|Placebo Comparator|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
32926733|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
32926734|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
33250485|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
33250486|NCT00860925|Experimental|active clonidine and active ASA|
33250487|NCT00860925|Experimental|active clonidine and ASA placebo|
33250488|NCT00860925|Experimental|Clonidine placebo and active ASA|
32725058|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
32725059|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
32725060|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
32725061|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
32725062|NCT04453553|Active Comparator|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
32725063|NCT04453553|Experimental|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
32725064|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
32725065|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
32725066|NCT05206097|Experimental|Physical Activity Program|
32725067|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
32725068|NCT05201495|Experimental|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
32725069|NCT04932031||Study group|Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel
32725070|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
32743446|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
32926735|NCT02576431|Experimental|Arm 1_NSCLC|Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
32926736|NCT02576431|Experimental|Arm 2_Thyroid|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
32926737|NCT02576431|Experimental|Arm 3_Sarcoma|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
32926738|NCT02576431|Experimental|Arm 4_Colorectal|Patients with solid colorectal tumors harboring NTRK fusions (arm closed)
32926739|NCT02576431|Experimental|Arm 5_Salivary|Patients with solid salivary tumors harboring NTRK fusions (arm closed)
32926740|NCT02576431|Experimental|Arm 6_Biliary|Patients with solid biliary tumors harboring NTRK fusions (arm closed)
32926741|NCT02576431|Experimental|Arm 7_Primary CNS|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
32926742|NCT02576431|Experimental|Arm 8_Other tumors|Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions (arm closed)
32926743|NCT02576431|Experimental|Arm 9_Solid tumors without confirmed NTRK fusion|Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
32926744|NCT02576431|Experimental|Arm 10- Prospective cohort|Patients with melanoma, non secretory breast and colorectal cancer or other tumor types harboring NTRK fusions, except soft tissue sarcoma, salivary gland and thyroid cancer (closed)
32926745|NCT02576431|Experimental|Arm 11_Bone health cohort|Patients with all tumor types harboring NTRK fusions, not eligible for the main prospective cohort, including patients with non-measurable disease
32926746|NCT04188665|Experimental|MASL treated|Patients treated with lozenge containing MASL
32926747|NCT04188665|Placebo Comparator|Placebo treated|Patients treated with lozenge without MASL
32926748|NCT04186247|Other|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
32926749|NCT04186247|Experimental|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.~Azithromycin (weeks 4-12)~Metronidazole (weeks 4-12)"
32926750|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
33073429|NCT01867411||Treatment seeking smokers/vapers|smokers/vapers interested in quitting nicotine
33073431|NCT01861093|Experimental|1|at least one
33250489|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
33250490|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
33250491|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
33250492|NCT05350930||R-CHOP or G-CHOP chemotherapy|Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
33250493|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
33250494|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
33250495|NCT05350852|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
33250496|NCT05350852|Experimental|ThisCART19A 8×10^6 cells/kg for dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
33250497|NCT05350852|Experimental|ThisCART19A 12×10^6 cells/kg for dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
33250498|NCT03936777|Experimental|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
33250499|NCT00955786|Experimental|CX-3543|
33250500|NCT04237012|Experimental|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
33250501|NCT04237012|Active Comparator|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
33250502|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
33250503|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
33250504|NCT05299450|Experimental|Exercise intervention|12 week personalised exercise intervention with personal trainer and gym membership, fitbit
33250505|NCT05299450|Experimental|Beetroot juice|12 weeks daily Beet It (beetroot shots) containing nitrate, fitbit
33250506|NCT05299450|Experimental|Exercise and Beetroot|12 week personalised exercise intervention with personal trainer and gym membership and daily Beet It (beetroot shots) containing nitrate, fitbit
33250507|NCT05299450|Active Comparator|Control group|No intervention, fitbit
33250508|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
33250509|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
33250510|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
33250511|NCT00863967||1|no cardiovascular events
33250512|NCT00863967||2|proven cardiovascular events
33250513|NCT00863967||3|possible cardiovascular events
33250514|NCT00677352|Experimental|1|
33250515|NCT00677352|Active Comparator|2|
33250516|NCT04010422||ASD group|"Inclusion Criteria:~Having a clinical diagnosis of autism spectrum disorder~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old"
32926751|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
32926752|NCT04181255|Experimental|Curosurf|
32926753|NCT04181255|Placebo Comparator|Sham (air)|
32926754|NCT04258813|Experimental|Control|40 PCP clinics; 400 patients
32926755|NCT04258813|Experimental|iGuide Intervention|40 PCP clinics; 400 patients
32926756|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
32926757|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
32725071|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
32725072|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
32725073|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
32725074|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
32725075|NCT05676229|Placebo Comparator|Placebo|Volunteers supplemented with maltodextrin
32725076|NCT05676229|Active Comparator|Probiotic Blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858 - Final concentration: 1 x 10e10 UFC/ day
32725077|NCT05439785|Experimental|Group 1|Dental floss
32725078|NCT05439785|Experimental|Group 2|Interdental brush
32725079|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
32725080|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
32926758|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
32926759|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
32725081|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
32725082|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
32926760|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
32926761|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
32926762|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
32926763|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
32926764|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
32725083|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
32725084|NCT04731545|Active Comparator|thin buccal bone|
32725085|NCT04731545|Active Comparator|thick buccal bone|
32725086|NCT03442543|Experimental|charcoal|
32725087|NCT03442543|Experimental|silver wire|
32725088|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
32725089|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
32725090|NCT03444805||NISSC-2|SSC patients treated with AHSCT
32725091|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
32725092|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
32725093|NCT04725773||PD DBS|Patients with Parkinson's disease and deep brain stimulation
32725094|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725095|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725096|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725097|NCT02811523|Experimental|Doxorubicin 11 mcg/ml|Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32926765|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
32926766|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
32926767|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
32926768|NCT01719497||Obese|Subjects diagnosed with obesity
32725098|NCT02811523|Experimental|Doxorubicin 13 mcg/ml|Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725099|NCT02811523|Experimental|Doxorubicin 15 mcg/ml|Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725100|NCT02811523|Experimental|Doxorubicin 17 mcg/ml|Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725101|NCT02811523|Experimental|Doxorubicin 20 mcg/ml|Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
32725102|NCT05439473|Placebo Comparator|Placebo|
32725103|NCT05439473|Active Comparator|Treatment|
32926769|NCT01719497||High Stress|Subjects diagnosed with high stress
32926770|NCT01719497||Healthy|Subjects deemed medically healthy
32926771|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
32926772|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
32926773|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
32926774|NCT02503423|Experimental|Phase 1 - Part 1 (completed)|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
32926775|NCT02503423|Experimental|Phase 1 - Part 2 (completed)|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
32926776|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
32926777|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
33250517|NCT04010422||TD Group|"Inclusion Criteria:~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old.~Having a clinical diagnosis of autism spectrum disorder"
33250518|NCT00861081|Experimental|1: Care management|
33250519|NCT00861081|Active Comparator|2: Written Materials|
33277364|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
33277365|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
32725104|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
32725105|NCT04453241|Experimental|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
32725106|NCT04453241|Active Comparator|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
32725107|NCT05439239|Placebo Comparator|Normoxic group females|The participants in this group (12 females) will perform a repeated sprint training in normoxia.
32725108|NCT05439239|Experimental|Hypoxic group females|The participants in this group (12 females) will perform a repeated sprint training in hypoxia.
32725109|NCT05439239|Placebo Comparator|Normoxic group males|The participants in this group (12 males) will perform a repeated sprint training in normoxia.
32725110|NCT05439239|Placebo Comparator|Hypoxic group males|The participants in this group (12 males) will perform a repeated sprint training in hypoxia.
32725111|NCT03444571|No Intervention|Control|
32725112|NCT03444571|Experimental|DNA based diagnosis|
32725113|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
32725114|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
32725115|NCT02572765||Normotensive|Normotensive subjects
32725116|NCT02572765||Hypertensive|Hypertensive subjects
32725117|NCT04898803||conventional gastroscopy training course|physicians receive the DGVS-recommended training, consisting of a 2-day course with 1 hour of simulator training
32725118|NCT04898803||extended simulator course|physicians receive a two-day simulator course with a minimum of 6 hours of simulator training per trainee, structured in stages in the sense of progressive or mastery learning. The initial part of the training will be part-task training.
32768433|NCT04842695|Active Comparator|kegel´s exercise (pelvic floor exercise)|A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
32768434|NCT04842695|Experimental|Electroacupuncture group|"Acupuncture point called bilateral R7 receive acupuncture with 0.25*40 mm needle with a perpendicular puncture 1.5 cun. The electrical stimulator is applied to bilateral R7, with dilatation wave 50 Hz and direct electric current of 1 milliamperes.. Each session lasts 30 minutes per day. Participants are treated 1 time per week for 12 weeks, total 12 sessions for each patient.~Equipment:~Electroacupuncture device.~device made in China"
32768435|NCT05073289|Experimental|SAPC|SAPC is a acronmy that defines Sandplay activity in psychiatry clinic
32768436|NCT05073289|Active Comparator|Control Group|
32768437|NCT04840043|Experimental|Osteopathy Group|Stimulation on the sympathetic truncus and prevertebral ganglia
32768438|NCT04840043|Sham Comparator|Control Group|Stimulation on similar areas with lighter touch and shorter duration
32768439|NCT04534933|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
32768440|NCT04534933|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
32768441|NCT04842617|Experimental|Treatment group A|
32768442|NCT04842617|Placebo Comparator|Treatment group B|
32768443|NCT04860557||problematic video game player|
32768444|NCT04860557||control subjects|
32768445|NCT05073211|Experimental|SJW-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
32768446|NCT05073211|Active Comparator|IAA-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
32768447|NCT04842539|Experimental|FMT Arm|FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.
32768448|NCT04842539|Other|Standard of care (SOC) Arm|Standard of care treatment with nutritional supplementation and other supportive care
32768449|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with platelet rich plasm|patients with chronic shoulder pain injected with platelet rich plasm ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
32768450|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with Hyaluronic acid|patients with chronic shoulder pain injected with Hyaluronic acid ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
32768451|NCT04860479||Infants: 28 days - 12 month|inguinal sonoanatomy
32768452|NCT04860479||small children: 13 months - 36 months|inguinal sonoanatomy
32768453|NCT04860479||preschool age: 37 months - 72 months|inguinal sonoanatomy
32768454|NCT04860479||school age: 73 months - 9 years|inguinal sonoanatomy
32768455|NCT04860479||Preadolescant: >9 years - 12 years|inguinal sonoanatomy
32768456|NCT04860479||Adolescants: >12 years - 18 years|inguinal sonoanatomy
32768457|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
32768458|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
32768459|NCT04842305||G1: Control group|SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
32768460|NCT04842305||G2: COVID-19 infected|Persons who have had COVID-19
32768461|NCT04842305||G3: COVID-19 vaccinated|Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
32768462|NCT04842305||G4: COVID-19 infected and vaccinated|Individuals who have been infected with COVID-19 and subsequently been vaccinated
32768463|NCT04839653|No Intervention|Control group: standard care|Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.
32768464|NCT04839653|Experimental|Selective digestive decontamination group|"Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h~In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h~A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd"
32768465|NCT05072587|Active Comparator|Group A - Standard ADA dietary guidelines (SADA)|Participants in this group will be given prepared meals based on standard ADA dietary guidelines for 12 weeks.
32768466|NCT05072587|Experimental|Group B - Plant Based ADA diet with no oxysterols (PB-ADAØ).|Participants in this group will be given prepared meals based on ADA guidelines but with no dietary cholesterol oxides/oxysterols - Plant-based ADA diet
32768467|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
32926778|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
33277366|NCT05290220|Experimental|Arm A: As first-line therapy|HLX07 1500 mg + HLX10 300 mg + HLX04 15mg/kg iv q3w
32725119|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
32725120|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
32725121|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
32725122|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
32725123|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~Eight-week longitudinal tailored CBT-based text-message program."
32725124|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
32725125|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.~Eight-week longitudinal tailored CBT-based message program delivered via app."
32725126|NCT05438771|Active Comparator|Bicarbonate|"1.Correct method of brush Platelet value suitable for tooth brushing Feature of toothbrush (soft, nylon bristled, rounded tip, standard size) Fluoride toothpaste, its amount and use in dry brushes In toothbrush 45 degree, the contact of the bristles with the gums, 4 times contact with the inner, outer, chewing surface, tongue cleaning The benefits of correct brushing (preventing dental plaque and gingival recession, etc.) Importance of brushing teeth twice a day (breakfast and after dinner) Preparation of mouth wash Boiled and cooled water at 100°C Putting 5 measures of boiled and cooled water in a teacup with the 20 ml measuring cup provided.~Adding 1 teaspoon (6 g) of sodium bicarbonate to water Making a mouthwash Teaching how to gargle with 20 ml of bicarbonate 4 times a day at 6-hour intervals and being asked to spit it out without swallowing,"
32743447|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
32743448|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean~Combine, this is expected to increase safety planning by clinicians."
32743449|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
32743450|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
32743451|NCT03236363|No Intervention|Control|No intervention
32743452|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
32743453|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
32743454|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
32743455|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
32743456|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
32743457|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~Followed by one day face to face CME activity"
32743458|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
32743459|NCT03235895|No Intervention|Wait listed|No CME activity will be given
32743460|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
32743461|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
32743462|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
32743463|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
32743464|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
32743465|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
32743466|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
32743467|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
32743468|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
32926779|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
32926780|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
32926781|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
32926782|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
32926783|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
32926784|NCT05096273|Experimental|CPT- Pain relief lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
32926785|NCT05096273|Experimental|CPT- Pain sensitivity lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
32926786|NCT05096273|Active Comparator|ReACT for PNES- Booster therapy sessions|After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.
32926787|NCT05096273|Experimental|ReACT for PNES- No Booster therapy sessions|After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
32926788|NCT05096273|No Intervention|Healthy Control|Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
32926789|NCT03936257|Placebo Comparator|Breast milk|group receiving breastfeeding
32926790|NCT03936257|Active Comparator|infant formula conventional BIO|infant formula with conventional whey BIO
32926791|NCT03936257|Active Comparator|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
32926792|NCT02500381|Experimental|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
32926793|NCT02500381|Experimental|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
32926794|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
32926795|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
32926796|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
32725127|NCT05438771|Experimental|Ankaferd Blood Stopper|"Correct method of brush Preparation of the mouthwash Boiled and cooled water at 100°C Putting 4 ml of water in the 5 ml measuring cup given to the patient Putting Ankaferd Blood Stopper on the remaining 1 ml portion of the 5 ml beaker Giving information about making and using mouthwash Use on an empty stomach 2 hours before meals in the morning and at least 2 hours after dinner After rinsing your mouth thoroughly with a mouthwash containing 5 ml of Ankaferd Blood Stopper prepared 2 times a day, you can swallow the solution in your mouth.~It is said that there is a solution-related discoloration in the mouth and teeth, but that it will return to its original state after tooth brushing."
32725128|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
32725129|NCT03466931|No Intervention|Historical cohort|Standard care
32725130|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
32725131|NCT05438459|Experimental|GAIA-102 as a single agent|GAIA-102: 1 vial (2 x 10^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.
32725132|NCT05438459|Experimental|GAIA-102 and pembrolizumab in combination|"GAIA-102: 1 vial (2 x 10^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.~Pembrolizumab：200 mg on Day 1."
32725133|NCT05438381|Active Comparator|ART group|Atraumatic restorative technique: excavation of caries then application of Glass ionomer capsule (GC, USA)
32725134|NCT05438381|Experimental|SMART group|SMART technique: excavation of caries and application of silver diamine fluoride (SDF 38%) then glass ionomer cement
33277367|NCT05290220|Experimental|Arm B: As second-line therapy|HLX07 1500 mg iv Q3w + Lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW <60 kg) po qd
32926797|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
32926798|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
32926799|NCT00707213|Experimental|All Participants|All Participants will be assessed by FDG-PET to identify possible sites of infection
32926800|NCT01993849|Active Comparator|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
33277368|NCT05290220|Experimental|Arm C:As third-line or above therapy|HLX07 1500 mg iv Q3w
32926801|NCT01993849|Placebo Comparator|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
32926802|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
32926803|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
32926804|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
32926805|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
33250520|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
33250521|NCT00864045|Experimental|Sertindole|
33250522|NCT00864045|Active Comparator|Olanzapine|
32926806|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
32926807|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
33250523|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
33250524|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
32926808|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
32926809|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
32926810|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
32926811|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
32926812|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
32926813|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
32926814|NCT04982237|Experimental|AK104+chemotherapy± bevacizumab|AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
32926815|NCT04982237|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
32926816|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
33250525|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
33250526|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
33250527|NCT00755508|Placebo Comparator|Placebo|
33250528|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
32926817|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
33250529|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
33250530|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
33250531|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
33250532|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
33250533|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
33250534|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
33250535|NCT03673800|Experimental|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
33250536|NCT03673800|Sham Comparator|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
33250537|NCT00864201|Experimental|bosentan|
33250538|NCT05350618||Asymptomatic controls|A single transperineal ultrasound assessment session will be conducted by two independent physiotherapists with an expertise in pelvic floor rehabilitation
33250539|NCT05350618||Women with provoked vestibulodynia|A single transperineal ultrasound assessment session will be conducted by one physiotherapist with an expertise in pelvic floor rehabilitation
33250540|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
33250541|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
33250542|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
33250543|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
33250544|NCT05299372|Other|Telemonitoring via Careportal®|Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
33250545|NCT00755586|Experimental|A|
33250546|NCT00755586|Experimental|B|
33250547|NCT00755586|No Intervention|C|
33277369|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
32926818|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
32926819|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent~Delivery system (Rapid Exchange [RX] Coronary System)~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
32926820|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
32926821|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
32926822|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
32926823|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
32926824|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
32926825|NCT02462629|Experimental|BLZ-100|
32926826|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
32926827|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
32926828|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
32926829|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
32926830|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
32926831|NCT02784275|Placebo Comparator|Dose D|Placebo
32926832|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
32926833|NCT04227847|Experimental|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
32926834|NCT04227847|Experimental|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
32926835|NCT04227847|Experimental|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
32926836|NCT04227847|Experimental|Part D|SEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or AML arising from MDS, and previously untreated higher-risk MDS
32926837|NCT04227847|Experimental|Part E|SEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS
32926838|NCT04227847|Experimental|Part F|SEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or AML arising from MDS
32926839|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
32926840|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
32926841|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
32926842|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
33250548|NCT05350462||Agboville, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
33250549|NCT05350462||Bangolo, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
32926843|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
32926844|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
32926845|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
32926846|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
32926847|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
32926848|NCT03696017||Group 1|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse opioids (40 patients per group).
32926849|NCT03696017||Group 2|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse benzodiazepines (BZD) (40 patients per group).
32926850|NCT03696017||Group 3|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse BZD/opioid (40 patients per group).
32926851|NCT04981613|Experimental|Experimental group|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
32926852|NCT04981613|No Intervention|Control group|irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
32926853|NCT04964375|Experimental|ABSK043|"Dose escalation of oral ABSK043 with a starting dose of 200mg once daily will be guided byBOIN escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 in repeated 28-day cycles. Starting dose level will be 200 mg QD. Cohort 3 on 800mg will be switched to 400mg BID.Then, patients will continuously receive ABSK043 （total daily dose） in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles."
32926854|NCT02303977|Experimental|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
32926855|NCT04952597|Experimental|Arm A: Ociperlimab + Tislelizumab|Ociperlimab + tislelizumab + cCRT for 4 cycles followed by ociperlimab + tislelizumab
32926856|NCT04952597|Experimental|Arm B: Tislelizumab|Tislelizumab + cCRT for 4 cycles followed by tislelizumab alone
32926857|NCT04952597|Experimental|Arm C: Concurrent Chemoradiotherapy (cCRT)|cCRT for 4 cycles
32926858|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
32926859|NCT01997515|Placebo Comparator|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
32926860|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
33073434|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
32725136|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
32725137|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
32725138|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
32725139|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
32725140|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
33073435|NCT01799538|Experimental|1|Nebullizer
33073436|NCT01799538|Active Comparator|2|Inhaler
32725141|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
32725142|NCT03466307||Group C|Healthy controls
33250550|NCT05350462||Man, Côte d'Ivoire|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
32725143|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
32725144|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
32725145|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
32725146|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
32725147|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
32725148|NCT05433233|Experimental|HAPA|Participants assigned additional 3,000 steps/day on 5 days/week. Participants also received an additional 15 minutes of structured conversation with research personnel following the Health Action Process Approach Theory for behavior change.
33073439|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
33073440|NCT01776840|Placebo Comparator|Treatment Arm A|
33073441|NCT01776840|Experimental|Treatment Arm B|
32926861|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
32926862|NCT04333823|Experimental|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
33277370|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
32725149|NCT05433233|Experimental|No HAPA|Participants assigned additional 3,000 steps/day on 5 days/week and general conversation with researchers in regard to behavior change, not following a structured dialogue.
32725150|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
32725151|NCT05430893||Athletic pubalgia|Patients with chronic athletic pubalgia for whom medical and/or surgical treatments have failed and who were treated with an intra-muscular injection of botulinum toxin A injection under ultrasound guidance
32725152|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
32725153|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
32725154|NCT03465839|Active Comparator|Control|Education for improving handovers quality
32725155|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
32725156|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
32725157|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
32725158|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
32725159|NCT05420519|Experimental|CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
32725160|NCT05419973||Pregnant Women|Women in third semester of pregnancy who are willing to include their babies as samples for the next study, no history of abortion, and not suffering from hypertension and preeclampsia.
32725161|NCT05419973||Infants|Babies born from mothers who are willing to be included in the study, aterm, with birth weight more than 2500 grams. No congenital abnormalities at birth and no acute infection at birth.
32725162|NCT05412095||Cardiology patient|Patient requiring cardiac surgery with bypass
32725163|NCT05412095||Pneumology patient|Patient requiring lung surgery with resection of at least one lobe
32725164|NCT05391971|Experimental|Stellate Ganglion Block (SGB) Group|
32926863|NCT04333823|Placebo Comparator|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
32926864|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
32926865|NCT04938089||ICS|Irregular compliant smoker
32926866|NCT04938089||RCS|Regular compliant smoker
32926867|NCT04938089||ICN|Irregular compliant non-smoker
32926868|NCT04938089||RCN|Regular compliant non-smoker
32926869|NCT04211935|Experimental|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
32725165|NCT05391971|Placebo Comparator|Control Group|
32725166|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
32725167|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
32725168|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
32725169|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
32725170|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
32725171|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
32725172|NCT02557139|Experimental|Regimen A|Single-dose belumosudil 200 mg tablet in the fasted state
32725173|NCT02557139|Experimental|Regimen B|Single-dose belumosudil 200 mg tablet in the fed state
32725174|NCT02557139|Experimental|Regimen C|Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
32725175|NCT02546921|Experimental|MOv18 IgE Cohort 1|
32725176|NCT02546921|Experimental|MOv18 IgE Cohort 2|
32725177|NCT02546921|Experimental|MOv18 IgE Cohort 3|
32725178|NCT02546921|Experimental|MOv18 IgE Cohort 4|
32926870|NCT04211935|Experimental|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
32926871|NCT04211935|Experimental|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
32926872|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
32926873|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
32926874|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
32725179|NCT02546921|Experimental|MOv18 IgE Cohort 5|
32725180|NCT02546921|Experimental|MOv18 IgE Cohort 6|
32725181|NCT02546921|Experimental|MOv18 IgE Cohort 7|
32725182|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
32926875|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
32725183|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
32725184|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
32725185|NCT05338385|Experimental|Intervention|Participants will receive mental skills training in addition to receiving standard-of-care ACL reconstruction and follow-up care. The goal of mental skills training is to help athletes maximize performance, reach self-determined goals, and build confidence in their fields of play. Many of the same tools that benefit athletes in sport performance also translate to their injury experience. Mental conditioning helps athletes navigate the many ups and downs that accompany ACL injury and recovery. Athletes are taught techniques to maintain their sport mindset by capitalizing on motivation, consistency, and resilience. One-on-one sessions are athlete-centered, and are designed to encourage exploration and growth through tangible mental skills strategies.
32725186|NCT05336903|Experimental|APP-led model of care for chronic pain management|The APP-led model of care involves integrating an APP as the first point of contact within an interprofessional chronic pain clinic setting. This is in contrast to the usual physician- or nurse practitioner-led model of care.
32725187|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
32926876|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
32926877|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
32926878|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
32926879|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
32926880|NCT04175977|Experimental|Wave 1: Usual Care for Months 1-7, Transition for Months 8-9, Intervention for Months 10-26|PWD at the hospice sites randomized to Wave 1 will receive usual care for 7 months, followed by the 2-month-long transition to the intervention over months 8 and 9, followed by the QAPI intervention for 16 Months from Month 10-26.
32926881|NCT04175977|Experimental|Wave 2: Usual Care for Months 1-8, Transition for Months 9-10, Intervention for Months 11-26|PWD at the hospice sites randomized to Wave 2 will receive usual care for 8 months, followed by the 2-month-long transition to the intervention over months 9 and 10, followed by the QAPI intervention for 15 months from Month 11-26.
32926882|NCT04175977|Experimental|Wave 3: Usual Care for Months 1-9, Transition for Months 10-11, Intervention for Months 12-26|PWD at the hospice sites randomized to Wave 3 will receive usual care for 9 months, followed by the 2-month-long transition to the intervention during months 10 and 11, followed by the QAPI intervention for 14 months from Months 12-26.
32926883|NCT04175977|Experimental|Wave 4: Usual Care for Months 1-10, Transition for Months 11-12, Intervention for Months 13-26|PWD at the hospice sites randomized to Wave 4 will receive usual care for 10 months, followed by the 2-month-long transition to the intervention during months 11 and 12, followed by the QAPI intervention for 13 months from Months 13-26.
32725188|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
32725189|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
32725190|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
32926884|NCT04175977|Experimental|Wave 5: Usual Care for Months 1-11, Transition for Months 12-13, Intervention for Months 14-26|PWD at the hospice sites randomized to Wave 5 will receive usual care for 11 months, followed by the 2-month-long transition to the intervention during months 12 and 13, followed by the QAPI intervention for 12 months from Months 14-26.
32926885|NCT04175977|Experimental|Wave 6: Usual Care for Months 1-12, Transition for Months 13-14, Intervention for Months 15-26|PWD at the hospice sites randomized to Wave 6 will receive usual care for 12 months, followed by the 2-month-long transition to the intervention during months 13 and 14, followed by the QAPI intervention for 11 months from Months 15-26.
32926886|NCT04175977|Experimental|Wave 7: Usual Care for Months 1-13, Transition for Months 14-15, Intervention for Months 16-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 13 months, followed by the 2-month-long transition to the intervention during months 14 and 15, followed by the QAPI intervention for 10 months from Months 16-26.
32926887|NCT04175977|Experimental|Wave 8: Usual Care for Months 1-14, Transition for Months 15-16, Intervention for Months 17-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 14 months, followed by the 2-month-long transition to the intervention during months 15 and 16, followed by the QAPI intervention for 9 months from Months 17-26.
32926888|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
32926889|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
32926890|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
32926891|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
32926892|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
32926893|NCT04913519|Experimental|SAD Cohorts 1 -3 TDM-105795 topical solution|Single dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01%
32926894|NCT04913519|Placebo Comparator|Placebo for TDM-105795 topical solution|Single dose administration of Placebo forTDM-105795 Topical Solution
32926895|NCT02290951|Experimental|Part A|DLBCL post CAR-T
32926896|NCT02290951|Experimental|1N Part B|FL
32725191|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
32725192|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
32725193|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
32926897|NCT02290951|Experimental|2N Part B|DLBCL
32725196|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
32725197|NCT05302427|Experimental|Massage group|The massage group will be shown live one-to-one baby massage training via Microsoft Teams by the researcher, and the mother will be asked to apply it to her baby at the same time. Baby massage training; It consists of leg massage, face-abdominal massage, arm-chest massage and back massage and will be completed in four weeks.
32725198|NCT05302427|No Intervention|Control group|Infant massage training will not be given to the mothers of the babies in the control group until the 20th week.
32725200|NCT04660227|Experimental|Exercise Group|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour.
32926898|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
32926899|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
32926900|NCT04899089|Experimental|Video Game Training Condition|Participants complete an 8 week long computerized cognitive training intervention. Participants play the games for 45 minutes, three times per week.
32926901|NCT04899089|Active Comparator|Trivia Training Condition|Participants complete an 8 week long computerized trivia training. Participants complete the trivia training for 45 minutes, three times per week.
32926902|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
32926903|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
32926904|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
32926905|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
32926906|NCT02795117|Experimental|Test product|
32926907|NCT02795117|Active Comparator|Reference product|
32926908|NCT02795117|Placebo Comparator|Placebo product|
32926909|NCT02333071|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
32926910|NCT02333071|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
32926911|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
32926912|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
32926913|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
32926914|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
32725201|NCT04660227|Other|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks.
32725202|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
32725203|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
32725204|NCT05375019|Experimental|Intervention group|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program.
32926915|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
32926916|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
32725205|NCT05375019|Active Comparator|Active control group|while the active control group was provided with 8 weekly 90 minute sessions of free interaction.
32725206|NCT05375019|No Intervention|No-contact group|No intervention was performed with the no-contact control group.
32725207|NCT05263895|Active Comparator|Treatment A: PF-0732133/ritonavir|PF-07321332 ritonavir
32725208|NCT05263895|Experimental|Treatment B: PF-07321332/ritonavir|PF-07321332 ritonavir
32725209|NCT05263895|Experimental|Treatment C: PF-07321332/ritonavir|PF-07321332 ritonavir
32725210|NCT05263895|Experimental|Treatment D: PF-07321332/ritonavir|PF-07321332 ritonavir
32725211|NCT05263895|Experimental|Treatment E: PF-07321332|PF-07321332
32725212|NCT03134781|Experimental|Control|Participated only in measurements at baseline, at 20 weeks and at 40 weeks.
32725213|NCT03134781|Experimental|Training|Participated in a supervised 40-week DoIT workout exercise training program and in measurements at baseline, at 20 weeks and at 40 weeks.
32725214|NCT03134781|Experimental|Training-Detraining|Participated in a supervised 20-week DoIT workout exercise training program and then entered a 20-week detraining period. They also participated in measurements at baseline, at 20 weeks and at 40 weeks.
32926917|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
32926918|NCT04879589|Experimental|SC ATRS-2002|3 different dosages [25mg (0.13mL) , 75mg (0.4mL) and 200mg (1.05mL)] will be tested as single SC injection into the abdomen.
32926919|NCT04879589|Active Comparator|Oral Abiraterone Acetate|A single dose of 1000mg of commercially available oral formulation of abiraterone acetate will be administered to enrolled participants in Cohort 4
32725215|NCT05233241|Experimental|Patients with acute drug-induced interstitial nephritis|Patients with acute drug-induced interstitial nephritis
32725216|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
32725217|NCT03344991|Active Comparator|Cardboard Cot Care|Stable infant will be transferred to cardboard cot, lined with reflective film for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
32725218|NCT03344991|Placebo Comparator|Open Crib|Stable infant will be transferred to standard of care open crib for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
32725219|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
32725220|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
32725221|NCT04565535|Experimental|Intervention arm|Liver donors undergoing lifestyle optimisation
32725222|NCT04565535|No Intervention|Control arm|Liver donors who continue normal lifestyle.
32725223|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
32926920|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
32926921|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
32926922|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
32926923|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
32926924|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
32926925|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
32926926|NCT02882711|Experimental|ketamine|
32926927|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
32926928|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
32926929|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
32725224|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
32725225|NCT03268083|Experimental|Group A1|3 to 6 years
32926930|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
33250551|NCT05350462||Homa Bay, Kenya|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
33250552|NCT05350462||Kwale, Kenya|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
33250553|NCT05350462||Hoima, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
33250554|NCT05350462||Bugiri, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
33250555|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
33250556|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
32725226|NCT03268083|Experimental|Group A2|3 to 6 years
32725227|NCT03268083|Experimental|Group A3|3 to 6 years
32725228|NCT03268083|Experimental|Group B1|2 to 35 months
32725229|NCT03268083|Experimental|Group B2|2 to 35 months
33250557|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
33250558|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
33250559|NCT04141150|Experimental|[18F]APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
33250560|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
32725230|NCT03268083|Experimental|Group B3|2 to 35 months
32725231|NCT04458467|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
32725232|NCT04458467|Experimental|Automated Boluses|Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
33250561|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
33250562|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
33250563|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
33250564|NCT00956098|Placebo Comparator|placebo|
33250565|NCT00956098|Experimental|oltipraz|
33250566|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
33250567|NCT04824846|Experimental|Ambulance drivers with received Integrated back pain module (IBPM)|Behavioral: Integrated back pain module (IBPM)
33250568|NCT04824846|Other|Ambulance drivers with received Health Educational Pamphlet.|Other: Health Educational Pamphlet.
33250569|NCT00870441|Experimental|1. ASP2151|
33250570|NCT00870441|Active Comparator|2. Valacyclovir|
32725233|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
32926931|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
33250571|NCT00870441|Placebo Comparator|3. Placebo|
33250572|NCT04079452|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
33250573|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
33250574|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
33250575|NCT00760890|Experimental|A|Medicinal Iron
33250576|NCT00760890|Experimental|B|Iron fortified wet pack cereal
33250577|NCT00760890|No Intervention|C|Control
33250578|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
33250579|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
32926932|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
32926933|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
32926934|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
32926935|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
32926936|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
32926937|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
32725234|NCT04560543|Experimental|McCall suture|Uterus removal by laparoscopy with usual vaginal closure and additional (McCall) suture, which is intended to prevent descent.
32725235|NCT04560543|Sham Comparator|standard cuff closure|Uterus removal by laparoscopy with usual vaginal closure without additional (McCall) suture. (as performed so far)
32926938|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
32926939|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
32926940|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
32926941|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
32725236|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
32725237|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
32725238|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
32725239|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
32725240|NCT04280991|Experimental|Moderate intensity exercise under mild normobaric hypoxia|The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
32725241|NCT04280991|Placebo Comparator|Moderate intensity exercise under normoxia|The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation.
32725242|NCT05185895|Sham Comparator|Start with: Concentric (normal) cycling|
32725243|NCT05185895|Experimental|Start with: Eccentric cycling|
32725244|NCT03170817||N13-ammonia Cardiac Rest/Stress PET/CT|Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
32725245|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
32725246|NCT04453319|Experimental|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
32725247|NCT04453319|No Intervention|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
32725248|NCT03025425|Experimental|MPV-arm|Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
32926942|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
32926943|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
32926944|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
32926945|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
32926946|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
32725249|NCT05093699|Active Comparator|Control Group|Arterial line placement via standard mechanism; utilization of a single-plane ultrasound probe
33400663|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
32926947|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
32926948|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
32926949|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
32926950|NCT01938001|Experimental|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but < 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
32926951|NCT01938001|Active Comparator|Rituximab and Placebo|Participants received riituximab 375 mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
32926952|NCT04349293|Experimental|Patients with cancer|
32926953|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
32926954|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
32926955|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
32725250|NCT05093699|Experimental|Butterfly iQ+ ultrasound probe|Arterial line placement utilizing dual-plane, Butterfly iQ+ ultrasound probe
32725251|NCT05101005|Experimental|Drug-coated balloon|Drug-coated balloon is used to treat coronary artery stenosis lesions and improve myocardial blood flow.
32725252|NCT05101005|Active Comparator|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
32725253|NCT04453007|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
32926956|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
32926957|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
32926958|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days"
32926959|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug~Once daily for 3 days"
32926960|NCT04147351|Experimental|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
32926961|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
32926962|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
32926963|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
32926964|NCT02004613|Placebo Comparator|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
32926965|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
32926966|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
32926967|NCT01754779|Placebo Comparator|Placebo|Placebo tablets twice daily
32926968|NCT01754779|Active Comparator|Citric Acid|Citric acid tablets twice daily
32926969|NCT01754779|Active Comparator|Potassium Citrate|Potassium Citrate tablets twice daily
32926970|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
32725254|NCT04453007|Active Comparator|Intervention plus 2-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 2 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
32725255|NCT04453007|Active Comparator|Intervention plus 6-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 6 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
32926971|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
32926972|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
32926973|NCT02234219|Active Comparator|Circular Anastomosis|
32926974|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
32926975|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
32926976|NCT01696513|Experimental|Subcision & Suction|Standard treatment for acne scars followed by suction.
32926977|NCT01696513|Active Comparator|Subcision|Standard treatment for acne scars only
32926978|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
32926979|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
32926980|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
32926981|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
32926982|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
32926983|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32926984|NCT02005549|Experimental|Neoadjuvant Therapy|
32926985|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
32926986|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
32725256|NCT04453007|Active Comparator|Intervention plus 10-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 10 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
32743469|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
32926987|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
32926988|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
32926989|NCT03645356|Active Comparator|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
32926990|NCT03645356|Experimental|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
32926991|NCT04349696|Active Comparator|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.~Intervention: Drug: Mitiglinide Tablets 10 mg"
32926992|NCT04349696|Experimental|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.~Intervention:Drug: Mitiglinide Tablets 10 mg"
32926993|NCT03028675||Multiple Sclerosis|
32926994|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
32926995|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
32926996|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
32926997|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
32926998|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
32926999|NCT01529983|Experimental|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
32927000|NCT01529983|Active Comparator|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
32927001|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
32927003|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
32927004|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
32725257|NCT04453007|Active Comparator|Intervention plus 14-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 14 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
32725258|NCT04453007|Active Comparator|Intervention plus repeated feedback boosters|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the multiple feedback booster emails, 2, 6, 10, and 14 weeks later. Each time, the email contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
32725259|NCT05100693|Experimental|Procedure FETO with the Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon. Balloon removal procedure by peripheral course around the MR scanner
32927005|NCT04768309|Experimental|CKD group|CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
32927006|NCT04768309|Other|Healthy volunteers group|Adult without chronic treatment, without renal dysfunction
32927007|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
32927008|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
32927009|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
32927010|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
32927011|NCT04349462|Other|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
32927012|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
32927013|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
32927014|NCT01716806|Experimental|Part A: Brentuximab Vedotin in HL Patients|
32927015|NCT01716806|Experimental|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
32927016|NCT01716806|Experimental|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
32927017|NCT01716806|Experimental|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
32927018|NCT01716806|Experimental|Part E: Brentuximab Vedotin in HL Patients|
32927019|NCT01716806|Experimental|Part F: Brentuximab Vedotin in PTCL Patients|
32927020|NCT04492358|Experimental|colchicine + prednisone|Prednisone should be administered for 3 consecutive days (60 mg/d) together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function) for 3 days and maintained for 14 days in total (0.5 mg/d).
32927021|NCT04492358|Active Comparator|Standard treatment|The standard treatment used in each site will be administered to the patients assigned to the control group.
32927022|NCT04480970|Experimental|Nasogastric tube placement|
32927023|NCT04470128|Experimental|Stage I: HSK21542 0.5 μg/kg|intravenous injection
32927024|NCT04470128|Experimental|Stage I: HSK21542 1 μg/kg|intravenous injection
32927025|NCT04470128|Experimental|Stage II : HSK21542 0.5 μg/kg|intravenous injection
32927026|NCT04470128|Experimental|Stage II : HSK21542 1 μg/kg|intravenous injection
32927027|NCT04470128|Experimental|Stage II : HSK21542 2 μg/kg|intravenous injection
32927028|NCT04470128|Placebo Comparator|Stage II : placebo|intravenous injection
32927029|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
32927030|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
32927031|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
32927032|NCT01081951|Experimental|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
32927033|NCT01081951|Active Comparator|2|paclitaxel iv and carboplatin iv
32927034|NCT03447704|Experimental|BCD-085 (netakimab)|
32927035|NCT03447704|Placebo Comparator|Placebo|
32927036|NCT02901275|Placebo Comparator|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
32927037|NCT02901275|Active Comparator|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
33250580|NCT05279716|Experimental|omidenepag isopropyl 0.02mg|Instill 1 drop of Eybelis ophthalmic solution 0.002% once a day into the affected eye.
32927038|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
32927039|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
32927040|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
32927041|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
32927042|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
32927043|NCT03440372|Experimental|Administration of oral Ozanimod|
32927044|NCT03440372|Placebo Comparator|Administration of Placebo|
32927045|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
32927046|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
32927047|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
32927048|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
32927049|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
32927050|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
32927051|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
32927052|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
32927053|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
32927054|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
32927055|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
33250581|NCT04619628|Placebo Comparator|Saline|Normal saline
33250582|NCT04619628|Experimental|Low dose cohort 1|COVI-VAC, single dose
32743470|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
32927056|NCT01066663|Experimental|DL1: Pyrimethamine 12.5 mg|Pyrimethamine single daily oral 12.5 mg dose.
32927057|NCT01066663|Experimental|DL2: Pyrimethamine 25 mg|Pyrimethamine single daily oral 25 mg dose.
32927058|NCT01066663|Experimental|DL3: Pyrimethamine 50 mg|Pyrimethamine single daily oral 50 mg dose.
32927059|NCT04093921|Experimental|Intervention|Receive motivational enhancement training based, telehealth-delivered 6-8 session intervention aimed at increasing readiness to engage in pain self-management, in addition to all recommended outpatient treatments.
32927060|NCT04093921|Active Comparator|Standard Care|Participate in all recommended outpatient pain treatments while awaiting PPRC admission.
32927061|NCT04464200|Experimental|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 4 planned flat-dose levels: 25x10^6, 50 x 10^6, 100 x 10^6 and 200 x 10^6 CAR T cells and one de-escalation dose: 12.5 x 10^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
32927062|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
32927063|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
32743471|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
32927064|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
32927065|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
32927066|NCT04443686|Experimental|ALA / Fractions of Radiotherapy|Subjects will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed.
32927067|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
32927068|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
32927069|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
32927070|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
32927071|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
32927072|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
32927073|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
33250583|NCT04619628|Experimental|Medium dose cohort 1|COVI-VAC, single dose
33250584|NCT04619628|Experimental|High dose cohort 1|COVI-VAC, single dose
33250585|NCT04619628|Experimental|Low dose cohort 2|COVI-VAC, two doses 28 days apart
33250586|NCT04619628|Experimental|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
32927074|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
32927075|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
32927076|NCT03422822|Experimental|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
33250587|NCT04619628|Experimental|High dose cohort 2|COVI-VAC, two doses 28 days apart
32743472|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
32927077|NCT03422822|Experimental|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
33250588|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
33250589|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
32927078|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32927079|NCT04333589|Experimental|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
32927080|NCT04333589|No Intervention|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
32927081|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
32927082|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
32927083|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
32927084|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
32927085|NCT04737161|Experimental|T regulatory cell infusion|Infusion will be administered to the patient within 72 hours of collection from donor.
32927086|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
33250590|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
32927087|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
32927088|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
32927089|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
32927090|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
32927091|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
32927092|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
32927093|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
33250591|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
33250592|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
33250593|NCT04604652|Experimental|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
32927094|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
32927095|NCT01192568|Experimental|Oxybutynin Chloride|
33250594|NCT00870519|Experimental|I 123-MNI-168|
33250595|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
33250596|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
33250597|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
33250598|NCT05348668|Experimental|Hybrid dose-fraction Radiotherapy Arm|Patients in this arm would receive hybrid dose-fraction radiotherapy combined with immune checkpoint inhibitors.
33250599|NCT05309044|Active Comparator|Planetary Health Diet Group|Diet proportional to the EAT-Lancet reference diet, in addition to a behavioral change protocol.
32927096|NCT04349228|Experimental|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
32927097|NCT04349228|Placebo Comparator|Placebo|Exposed health care professionals working in the intensive care unit
32927098|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
32725260|NCT04437719|Experimental|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
32927099|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
32927100|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
32927101|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
32927102|NCT02815709|Experimental|Treatment 1 Oliceridine|
32927103|NCT02815709|Experimental|Treatment 2 Oliceridine|
33250600|NCT05309044|Active Comparator|Low-fat diet group|Low-fat, low-calorie diet and a behavioral change protocol
33250601|NCT05309044|Placebo Comparator|Waiting list group|Waiting list group
32927104|NCT02815709|Experimental|Treatment 3 Oliceridine|
32927105|NCT02815709|Placebo Comparator|Placebo|
32927106|NCT02815709|Active Comparator|Morphine|
32927107|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
32927108|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
32927109|NCT02816723|Active Comparator|Brain Health|Brain Health education class
32927110|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
33250602|NCT00864825|Experimental|Allopurinol|
32927111|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
32927112|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
32927113|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
32927114|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
32927115|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
32927116|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
32927117|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
32927118|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
32927119|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
32927120|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
32927121|NCT01990820|Active Comparator|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
32927122|NCT01990820|Experimental|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
32927123|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
32927124|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
33250603|NCT00864825|Placebo Comparator|Placebo|
33250604|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
33250605|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
33250606|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
33250607|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
33250608|NCT00956176|Experimental|Cidofovir|
33250609|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
33250610|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
33250611|NCT00371683|Active Comparator|A1|+ placebo
33250612|NCT00371683|Experimental|A2|+ placebo
33250613|NCT05286580|Experimental|Intervention|o Sequential deployment of standardized M&M toolkit at a regional M&M conference.
33250614|NCT00876057|Active Comparator|TH|Total hysterectomy
32927125|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
32927126|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
32927127|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
32927128|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
33250615|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
32725261|NCT05100615|Other|hydroxyappatite|hydroxyapatite powder used for enhancement of bone regeneration
32725262|NCT05100615|Other|nanohydroxyapatite|nanohydroxyapatite powder used for enhancement of bone regeneration
32725263|NCT05100615|Other|PRF with nanohydroxyapatite|platelet rich fibrin mixed with nanohydroxyapatite used for enhancement of bone regeneration
32725264|NCT04387877|Experimental|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
32725265|NCT04387877|Sham Comparator|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
32725266|NCT04366817|Experimental|women in postpartum period|
32725267|NCT05091983||Restrictive eating disorder group|Adolescents between 12 and 18 y.o. Restrictive eating disorders diagnosis (Anorexia Nervosa or ARFID) answering DSM-5 criteria
32725268|NCT05091983||Control group|Adolescents between 12 and 18 y.o. No eating disorders
32725269|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
32725270|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
32725271|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
32725272|NCT04452773|Experimental|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
32725273|NCT04452773|Placebo Comparator|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
32725274|NCT04452851|Experimental|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
32725275|NCT04452851|Active Comparator|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
32725276|NCT04452851|Placebo Comparator|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
32927129|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
32927130|NCT01960465|Experimental|African Americans|138 Self identified African American
32927131|NCT01960465|Active Comparator|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
32927132|NCT01991990|Placebo Comparator|Placebo|
32927133|NCT01991990|Experimental|RoActemra/Actemra|
32927134|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
32927135|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
32927136|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
32927137|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
32927138|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
32927139|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
33250616|NCT05276128|Other|WWB Reference|White wheat bread (WWB) without lipid supplements. The effects of this high glycaemic product on postprandial glucose and insulin responses are well studied.
33250617|NCT05276128|Experimental|WWB 5g active lipids|WWB supplemented with 5 g active lipids, and 10 g control lipids
33250618|NCT05276128|Experimental|WWB 10g active lipids|WWB supplemented with 10g active lipids, and 5 g control lipids
32768468|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
32768469|NCT04842149|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
33250619|NCT05276128|Experimental|WWB 15g active lipids|WWB supplemented with 15g active lipids, and 0 g control lipids
32768470|NCT04842149|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
33250620|NCT05276128|Active Comparator|WWB 15 g control lipids|WWB supplemented with 15g control lipids
33250621|NCT00956332|Experimental|MGA - Low therapeutic dose|
33250622|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
33250623|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
32768471|NCT04919941|Experimental|Decision aid|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
32768472|NCT04919941|No Intervention|Control|Did not receive the decision aid.
33250624|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
32768473|NCT04839263|Active Comparator|"FAST TRACK protocol"|"FAST TRACK protocol Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
32768474|NCT04839263|No Intervention|"Conventional setting protocol"|"Conventional setting protocol~Preoperative strategy:~Hospitalization on surgery day~Fasting as of midnight prior to the day of surgery~Perioperative strategy:~- Balanced anaesthesia via halogens gases~Postoperative strategy:~Same day refeeding and mobilization minimum 6 hours post operation~Bladder catheter and Venflon removal on day 1"
32768475|NCT04353895|Experimental|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
33250625|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
33250626|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
33250627|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
33250628|NCT05254600|Experimental|Intervention group|Intervention group will attend the RISE for Nurse Leaders program, which consists of nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC)
33250629|NCT05254600|Active Comparator|Wait-list control group|Control group will attend the RISE for Nurse Leaders program after the 3-month wait-list period
32768476|NCT04353895|Active Comparator|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
32768477|NCT04842383|Active Comparator|Half strength Hemp Oil Preparation|The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
32768478|NCT04842383|Active Comparator|Full strength Hemp Oil Preparation|The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
32905613|NCT04067726|Placebo Comparator|Placebo|"Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
33250630|NCT05214742||Silver-Russell Syndrome|
33250631|NCT05214742||Beckwith-Wiedemann Syndrome|
33250632|NCT05214742||Temple Syndrome|
33250633|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
33250634|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
33250635|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
33277371|NCT03956329|No Intervention|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
32725277|NCT04452851|Experimental|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
32725278|NCT04452851|Experimental|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
32725279|NCT04452851|No Intervention|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
32725280|NCT05069363|Experimental|Intervention Group|All participants in this feasibility trial will receive a course of whole-body photobiomodulation therapy (18 sessions over 6 weeks)
32725281|NCT05015387|Active Comparator|MINST group|Patients with periodontitis received minimally invasive non-surgical therapy .
32725282|NCT05015387|Experimental|MINST+PACNs group|Patients with periodontitis received minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins.
32725283|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
32725284|NCT03464825|No Intervention|Control|Care as usual
32725285|NCT04984343|Experimental|5 radiation treatments - ARM 1|Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.
32725286|NCT04984343|Active Comparator|2 radiation treatments - ARM 2|Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.
32725287|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
32725288|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
32725289|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
32725290|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
32725291|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
32725292|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.~The fMRI will be carried out following the inclusion visit after all the necessary checks"
32725293|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
32725294|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
32725295|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
32725296|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
32725297|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
32725298|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
32725299|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
32725300|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
32725301|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
32725302|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
32725303|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
32905614|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
32905615|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
32725304|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
32725305|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
32725306|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
32725307|NCT04911023||Patients operated by fissurectomy|
32725308|NCT04911023||Patients operated by fissurectomy with anoplasty|
32725309|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
32725310|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
33250636|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
33250637|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
33250638|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
33250639|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
32905616|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
32905617|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
32905618|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
32905619|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
32905620|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
32905621|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
32905622|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
32905623|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
32905624|NCT02476968|Other|Olaparib|Open Label Drug
32905625|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
32905626|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
32905627|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
32905628|NCT01514513|Experimental|Licefreee Spray|
32905629|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
32905630|NCT04981860|Experimental|Treatment naïve participants First Group L|Treatment naïve participants randomized to receive Betadine on the left eye and Avenova on the right Eye
32905631|NCT04981860|Experimental|Treatment naïve participants Second Group R|Treatment naïve participants randomized to receive Avenova on the left eye and Betadine on the right Eye
32905632|NCT04981860|Experimental|Participants undergoing intravitreal injection First Group L|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group L are patients that are having intravitreal injections and will receive betadine in the left eye and Avenova in the right eye.
32905633|NCT04981860|Experimental|Participants undergoing intravitreal injection Second Group R|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group R are patients that are having intravitreal injections and will receive betadine in the right eye and Avenova in the left eye.
32905634|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
32905635|NCT02476578|No Intervention|Control|No email is sent.
32905636|NCT01432145|Experimental|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
32905637|NCT04979520|Experimental|Brodalumab treated moderate-to-severe HS patients|Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
32905640|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
32927140|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
32927141|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
32927142|NCT02057042|Active Comparator|EUC|Enhanced usual care
32927143|NCT01961167|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
32725311|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
32725312|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
32725313|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
32725314|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
32725315|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
32725316|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
32725317|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
32725318|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
32725319|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
32725320|NCT03468101||Dairy farmers COPD|
32725321|NCT03468101||Non farmers COPD|
32725322|NCT03463187|Experimental|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
32725323|NCT03463187|Experimental|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
32725324|NCT03463187|Experimental|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
32725325|NCT03463187|Experimental|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
32725326|NCT03463187|Experimental|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
32725327|NCT03463187|Experimental|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
32725328|NCT03463187|Experimental|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
32725329|NCT03463187|Experimental|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
33073446|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32725330|NCT04222595|No Intervention|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
32725331|NCT04222595|Active Comparator|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
32725332|NCT04222595|Active Comparator|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
32725333|NCT04222595|Active Comparator|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
32725334|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
32725335|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
32725336|NCT04176185|Experimental|Active|HDM SLIT-tablet once daily for approximately 24 weeks
32725337|NCT04176185|Placebo Comparator|Placebo|Placebo tablet once daily for approximately 24 weeks
32725338|NCT04856189|Experimental|Treatment (selinexor, pembrolizumab)|Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
32927144|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
32927145|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI~Visit 3 (on last day of EBRT): PSA blood test~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
33250640|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
33250641|NCT03563482|Experimental|Experimental|Biopsy and PET scan
33250642|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
33250643|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
33250644|NCT04039815|Experimental|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
33250645|NCT04039815|Placebo Comparator|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
33250646|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
33250647|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
33250648|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
33250649|NCT00876525|Experimental|Freedom SOLO stentless valve|
32768479|NCT05072353|Experimental|Treatment|DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.
32768480|NCT04839497|Experimental|Volar Fibroblast Treatment|Volar fibroblasts are injected into the residual limb of transtibial amputees
32768481|NCT04839497|No Intervention|Cryoprotectant|Vehicle Control. Interdermal injection of cryoprotectant
32768482|NCT04884139|Experimental|Dovato arm|DTG/3TC
32768483|NCT04884139|Active Comparator|Biktarvy arm|BIC/FTC/TAF
32768484|NCT04860167|No Intervention|Group A|The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
32768485|NCT04860167|Active Comparator|Group B|The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
32768486|NCT04860167|Active Comparator|Group C|Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
32768487|NCT04880785|Experimental|Dovato (Dolutegravir+lamivudine)|Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks
32768488|NCT04841993|Experimental|Oral formulation: Cannabis decoction|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%) ,cannabis decoction will be prepared at the moment by putting female inflorescences in cold water brought to a boil, boiling for 15 minutes and using 500 mg of medicinal cannabis for 500 ml of water.
32768489|NCT04841993|Experimental|Oral formulation: Cannabis oil|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), cannabis oil is prepared the day before the experimental session with 500 mg of female inflorescences in 5 ml of olive oil from the European Pharmacopoeia, heating in a water bath (approximately 98 ° C) for 120 minutes and cooling the oil samples. at room temperature.
32768490|NCT04841993|Experimental|Vaporized formulation: Cannabis vaporized|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), 100 mg of Cannabis inflorescences of FM2 standardized cannabis were administered through Volcano vaporizer .
32768491|NCT05072431|Experimental|Experimental group|The participants in the experimental group received the 3D VR training program.
32768492|NCT05072431|No Intervention|Control group|The control group did not receive any intervention.
32768493|NCT04839341|Experimental|A Phase I, open-labeled multicenter study|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
32768494|NCT05071885|Experimental|Game-based Exercise program|"Each exercise session would last 45 minutes and supervised by study staff at First Step Wellness center you will be shown how to handle and move the joystick and how to play a group of computer games. The game activities will require you to move the joystick at various speeds, movement' amplitudes and in different directions. Each game will be played for 2-3 minutes.~A variety of therapy handles of different shapes and sizes have been produced that Snap-On to joystick handle. These are designed to practice a broad range of manual dexterity skills involving the thumb, fingers, wrist and elbow, o Different games will also be used to vary the movement types and precision levels. To note you will be able to choose the types of movement exercises and games to use."
32768495|NCT05071885|Active Comparator|Range of motion and Strength Exercise program.|"This will involve stretching, range of motion and strength exercises as set out by training staff at the First Step Wellness center.~On completion of the ten week exercise program, you will be invited to take part in a 30-minute interview to discuss the experiences you had on receiving the specific hand exercise program. The whole interview session will be audio taped. Your identity will be protected and your privacy will be maintained. All the information discussed and shared during the interview will be kept confidential and safely protected."
32768496|NCT04841915|Experimental|Micellar Cassein Isolate High-Protein Diet|4weeks eucaloric intake on high-protein diet with micellar cassein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
33250650|NCT00870987|Experimental|1|DNA vaccine prime Given at 0, 4, and 8 weeks
33250651|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost Given at 24 weeks
33250652|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
32927146|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
32927147|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
32927148|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
32927149|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
32927150|NCT01992380|Experimental|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
32927151|NCT01992380|Experimental|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
32927152|NCT01992380|Experimental|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
32725339|NCT04153955|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
32725340|NCT04153955|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
32725341|NCT04830215|Other|Brexpiprazole|Brexpiprazole as a flexible dose; 0.5 to 2 mg/day and patient will continue on the stable dose of ADT that they were taking at screening.
32725342|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
32927153|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
32927154|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
32725343|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
32927155|NCT04348994|Experimental|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
32927156|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
32927157|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
32725344|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
32927158|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
32927159|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
32927160|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
32927161|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
32927162|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
32927163|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
32927164|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
32927165|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
32927166|NCT00374621|Active Comparator|Misoprostol|
32927167|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
32927168|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
32927169|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
32927170|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
32927171|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
32927172|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
32927173|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
32927174|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
33250653|NCT00871065|Experimental|A|Trial Arm (single arm study)
33250654|NCT00876603||1|
33250655|NCT00876603||2|
33250656|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
33250657|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
33250658|NCT00371137|Placebo Comparator|1|
32725345|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
32725346|NCT04803149|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
32725347|NCT04803149|Active Comparator|Conventional Radiofrequency|Conventional radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
32725348|NCT04802603|Other|Radiotherapy|Cohort 1 (De novo) No Prior radiotherapy Cohort 2 (Prior radiotherapy) Prior radiotherapy
32725349|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
32725350|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
32725351|NCT04259151|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
32725352|NCT04259151|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
32725353|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
32725354|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
32725355|NCT05100303|Experimental|Mitoxantrone Hydrochloride liposome and cytarabine|"Chemotherapy will be given in 28-day cycles, and total treatment period is 2 cycles.~Dose escalation phase:~Patients will receive 24 mg/m^2, 30 mg/m^2 or 36mg/m^2 of mitoxantrone hydrochloride liposome daily by intravenous (IV) injections on the first day and 1.5 g/m^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5).~Dose expansion phase:~Patients with newly diagnosed AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 100~200 mg/m^2 of cytarabine by IV for 7 days (day 1~7). Patients with R/R AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 1.5 g/m^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5). The dose size of mitoxantrone hydrochloride liposome will be determined by the investigator and the sponsor based on the results of the previous study."
32725356|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
32725357|NCT05100147|Experimental|Group 1|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked involving all uterine layers and a second, continuous non-locking imbrictating layer is applied over the first suture.
32725358|NCT05100147|Experimental|Group 2|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked not including decidua and a second, continuous non-locking imbrictating layer is applied over the first suture.
32725359|NCT05100147|Experimental|Group 3|The uterotomy suture technique is continous ,double layer with the first layer unlocked, excluding the decidua and including the deep part of the myometrium, and the second layer unlocked including the remaining part of the myometrium.
32725360|NCT05097105||urilogic patients|
32725361|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
32725362|NCT04035759|Experimental|APPEAL Program|Participants receive the APPEAL program, consisting of three one-on-one sessions, each lasting approximately one hour, and spaced one month apart. Sessions are designed to promote positive affect. Participants receive optional weekly check-ins to support behavior change efforts. All participants continue to receive standard of care.
32725363|NCT04035759|No Intervention|Standard of care|Participants receive standard of care.
32768497|NCT04841915|Experimental|Whey Protein High-Protein Diet|4weeks eucaloric intake on high-protein diet with whey protein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
33250659|NCT00371137|Experimental|2|
33250660|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
32725364|NCT04781465|Experimental|Immersive Virtual Reality|"The patients are divided into groups of 3. Each group of patients will attend 2 days of care per week (for 4 weeks) Group N ° 1: Monday and Thursday. Group N ° 2: Tuesday and Friday.~At each visit, the patient will participate in:~[a Kinesitherapy treatment and a Virtual Immersion treatment] + [a Balneotherapy treatment or an Adapted Physical Activity treatment). Each treatment lasts 1 hour 10 minutes.~Each patient will therefore come to the center 8 times over 1 month, or 4 hours 40 minutes a week, not counting virtual reality.~If the groups are not full or according to the advice of the healthcare team, only one group will be selected (always 3 patients) and will attend 3 days per week."
32725365|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
32725366|NCT05096871||Group I|patients with epilepsy
32725367|NCT05096871||Group II|apparently healthy controls with no chronic illness of matched age and sex
32725368|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
32725369|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
32927175|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
32927176|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
32927177|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
32927178|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
33250661|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
33250662|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
32927179|NCT04768400|Experimental|rocuronium|Neuromuscular blockade will be performed using rocuronium.
32927180|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
32927181|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
33250663|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
32927182|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
32927183|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
32927184|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
32768498|NCT04841915|Placebo Comparator|Normal Diet|4weeks eucaloric diet with normal protein content (15E%) followed by 20weeks hypocaloric intake on equivalent diet.
32927185|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
32927186|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
32927187|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
32927188|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
32768499|NCT04483921|Experimental|Exercise|Participants will complete a prescribed exercise bout.
32768500|NCT04483921|No Intervention|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
32768501|NCT02514031|Experimental|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
32768502|NCT04841603|Active Comparator|Treatment as usual|Treatment as usual
32768503|NCT04841603|Experimental|Mindshift CBT|Treatment as usual + Access to Mindshift CBT app
32768504|NCT04823533|Experimental|Probiotic|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
32768505|NCT04823533|Placebo Comparator|Placebo|Placebo formulation containing only the excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
32768506|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
32768507|NCT03042845|Experimental|Tiger cardiac catheter|
32768508|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
32768509|NCT04841681|Experimental|Video-based Psychotherapy|The group received the intervention of video-based psychotherapy.
32768510|NCT04793815|Experimental|Cryo-activation and anti-PD-1 monotherapy combination|
32768511|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
32768512|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
32768513|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
32768514|NCT04751461|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
32927189|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
32927190|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
32927191|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
32927192|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
32927193|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
32927194|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
32725370|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
32725371|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
32927195|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
32927196|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
32927197|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
32927198|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
32927199|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
32927200|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
32927201|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion~Day 0, stem cell transplant."
33250664|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
32725372|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
32725373|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
32725374|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
32725375|NCT05096715|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Study will begin with a safety lead of 6 participants to determine the maximum tolerated dose (MTD) of Stereotactic beam radiation therapy (SBRT) with atezolizumab and bevacizumab followed by study expansion to 14 more participants after maximum tolerated dose (MTD) is established.~Safety Lead-In: 6 cycles/18 weeks (study cycle is 3 weeks/21 days)~Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~Cycles 2-6: Atezolizumab + Bevacizumab (1x) every 3 weeks~Expanded Study:~Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~Cycles 2-End:Atezolizumab + Bevacizumab (1x) every cycle"
32725376|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
32725377|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
32725378|NCT05096637|No Intervention|control group|Patients receive the best medical care according to current guideline recommendations without access to the app
32725379|NCT05096637|Experimental|intervention group|Patients receive the best medical care according to current guideline recommendations with full access to the app. This includes access to relevant findings including ultrasound images of the carotid artery, lipid profile, blood pressure values, and weight.
32725380|NCT04984889|Experimental|TAK-662 80 IU/kg|TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.
32927202|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
32927203|NCT02304757|Experimental|99Tc-MDP|15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
32927204|NCT02304757|Active Comparator|Fosamax|70mg po every week for 12 months.
32927205|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
32725381|NCT04966481|Experimental|Arm 1: Palbociclib + Cetuximab|"Palbociclib by mouth 125 mg/daily on Days 1-21 of each 28 day cycle~Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly"
32927206|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
32927207|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
32927208|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
32927209|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
32927210|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
32927211|NCT02002832|Experimental|Lurasidone group|
32927212|NCT02002832|Active Comparator|Risperidone group|
32927213|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
32927214|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
32927215|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
32927216|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
32725382|NCT04966481|Active Comparator|Arm 2: Cetuximab|-Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly
32725383|NCT05099601|Experimental|Silymarin alone versus silymarin and microneedling|There will be one group of patients. Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.
32927217|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
32927218|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
32927219|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
32927220|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
32725384|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
32725385|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
32725386|NCT05099523|Placebo Comparator|group I|50%Fio2
32725387|NCT05099523|Active Comparator|group II|30%Fio2
32927221|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
32927222|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
32725388|NCT05104203|Active Comparator|Thoracolumbar Interfascial Plane block|Patient will receive Thoracolumbar Interfascial Plane block
32725389|NCT05104203|Experimental|Modified Thoracolumbar Interfascial Plane block|Patient will receive modified Thoracolumbar Interfascial Plane Block
32725390|NCT04958057|No Intervention|Routine prenatal care|Routine prenatal care: All women participating in the study will receive routine prenatal care by their obstetric provider, consisting of 1 prenatal visit a month up to 28 weeks of gestation, 1 prenatal visit every 2 weeks during 28-36 weeks and weekly visits during 36-40 weeks.
32768515|NCT04751461|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
32927223|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
32927224|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
32927225|NCT01966796||PSI II|PSI less than 70 or equal to 70
32927226|NCT01966796||PSI III|PSI 70-90
32927227|NCT01966796||PSI IV|PSI 90-130
32927228|NCT01966796||PSI V|PSI more than 130
32927229|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
32927230|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
32927231|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
32927232|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg~Interventions:~Drug: Feraheme Procedure: MR Scan"
32927233|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
32927234|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
32725391|NCT04958057|Experimental|SAIL intervention|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
32927235|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
32927236|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
32927237|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
32927238|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
32927239|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
32927240|NCT02062580|Other|Early BCG|BCG at birth; standard of care
32927241|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32725392|NCT04437147|Placebo Comparator|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
32927242|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32927243|NCT01968356|Active Comparator|ChloraPrep Hi-Lite Orange|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32725393|NCT04437147|Active Comparator|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
32725394|NCT04437147|Active Comparator|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
32725395|NCT04907669|Experimental|Group 1a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized into Group 1a and Group 1b to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
32725396|NCT04907669|Experimental|Group 1b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
32725397|NCT04907669|Experimental|Group 1c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c.
32927244|NCT01968356|Placebo Comparator|Normal Saline|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32927245|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
32927246|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
32927247|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
32927248|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
32927249|NCT02006888|Placebo Comparator|Placebo|Placebo
33250665|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
33250666|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
32927250|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
32927251|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32927252|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
32927253|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally~1 tablet, 3 times a day"
32927254|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
32927255|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
32927256|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
32927257|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
32927258|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
32725398|NCT04907669|Experimental|Group 2a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a.
32725399|NCT04907669|Experimental|Group 2b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
32725400|NCT04907669|Experimental|Group 2c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
32725401|NCT03736629|Placebo Comparator|Placebo|8 weeks of placebo capsule once daily by mouth
32725402|NCT03736629|Active Comparator|Azithromycin|8 weeks of Azithromycin (250 mg) capsule once daily by mouth
32725403|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
32725404|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
32768516|NCT04751461|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
32927259|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
33250667|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
32927260|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
32927261|NCT01969916|Other|Regadenoson|
32927262|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
32927263|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
32927264|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
32927265|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
32927266|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
32927267|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
32725405|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
32725406|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
32725407|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
32725408|NCT04853693|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
32725409|NCT04853693|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
32725410|NCT03656367|Experimental|All subjects|"Cross-over study (all subjects receive all interventions)~Cheddar cheese~Blended and homogenized cheddar cheese~An analog milk~An analog cheese"
32725411|NCT03656367|Other|Healthy subjects only (subgroup)|"If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.~All subjects receive all interventions)~Cheddar cheese~Blended and homogenized cheddar cheese~An analog milk~An analog cheese"
32725412|NCT04796363|Experimental|ESPB Bubivacaine 0.25%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 20 ml bupivacaine 0.25 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
32725413|NCT04796363|Active Comparator|ESPB Bubivacaine 0.125%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 40 ml bupivacaine 0.125 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
32725414|NCT04796363|Placebo Comparator|No ESPB|20 patients will undergo standard general anaesthesia as a control group and postoperative analgesia with intravenous morphine patient controlled analgesia (PCA) and rescue analgesia if required.
32725415|NCT03593109|Experimental|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6 CAR-T cells/kg.
32725416|NCT03566433|Active Comparator|Endoscopic TEP surgery|Routine total extraperitoneal technique surgery for inguinal hernia
32725417|NCT03566433|Active Comparator|Open Lichtenstein hernioplasty|Routine lichtenstein surgery for inguinal hernia
32725418|NCT03522753|Experimental|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
32725419|NCT03522753|Active Comparator|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
32927268|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
32927269|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
32927270|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
33250668|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
32725420|NCT03522753|Other|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
32725421|NCT04753853|Experimental|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
32725422|NCT05103813|Experimental|Beraprost Sodium Tablets|
32725423|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
32725424|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
32725425|NCT03435939|Experimental|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
32725426|NCT04452929|Active Comparator|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
32927271|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
32927272|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
32927273|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
32927274|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
32927275|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
32927276|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
32927277|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
32927278|NCT02014129|Experimental|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
32927279|NCT02014129|Experimental|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
32927280|NCT02014129|Experimental|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
32927281|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
32927282|NCT04333355|Experimental|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
32927283|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
32927284|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
32927285|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
32927286|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
32927287|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
32927288|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
32927289|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
32927290|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
32927291|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
32927292|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
32927293|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
32927294|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:~Standard dosing regime"
32927295|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
32927296|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
32927297|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
32927298|NCT01971086||acute rhinitis|
32927299|NCT04737551||No adjuvant treatment|Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
32927300|NCT04737551||Adjuvant chemotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
32927301|NCT04737551||Adjuvant chemoradiotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
32927302|NCT04737551||Adjuvant chemoradiotherapy + adjuvant chemotherapy|Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
32927303|NCT04737395|Experimental|"Device-assisted therapy (Meditouch,MSQUARE)"|40 hours of therapy with the the Hand Tutor (MediTouch) device and a wearable vest (MSQUARE) for arm rehabilitation
32927304|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
32927305|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
32927306|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
32927307|NCT02016235|Experimental|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
32927308|NCT02016235|Experimental|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
33250669|NCT05175417||Case|Patients being considered for functional neurosurgical procedures, such as deep brain stimulation (DBS), radiofrequency ablation (RFA), gamma knife radiosurgery (GKR), or magnetic resonance-guided focused ultrasound (MRgFUS).
33250670|NCT05175417||Control|Healthy control volunteers.
33250671|NCT01047787||CHF Patients|Congestive Heart Failure Patients
33250672|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
33250673|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
33250674|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
33250675|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
33250676|NCT00962026|Experimental|Rilonacept|
33250677|NCT03753789|Experimental|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
33250678|NCT05212012|Experimental|D,L-methadonehydrochloride + mFOLFOX6|"Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)~Treatment with mFOLFOX6 every two weeks; will be administered:~Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)"
33250679|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
33250680|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
33250681|NCT05299840|Experimental|Oncogramme group|The oncologist has access to the results of the Oncogramme® Device and decides on the treatment according to the recommendations of the Oncogramme® Device
33250682|NCT05299840|Other|Control group|The oncologist does not have access to the results of the Oncogramme® Device and decides on the treatment according to the standard of care.
32725427|NCT04452929|Placebo Comparator|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
32725428|NCT04452929|Other|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
32725429|NCT05095701|Experimental|Experimental Group|349 subjects who enrolled in the experimental group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0~3.5ml at 5 and 8 years after primary immunization.
32725430|NCT05095701|Placebo Comparator|Control Group|354 subjects who enrolled in the control group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0~3.5ml at 5 and 8 years after primary immunization.
32725431|NCT03461471|Experimental|Intervention Group|Exercise intervention
32768517|NCT04751461|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
32927309|NCT02016235|Placebo Comparator|Dent Disease Observation|Dent disease subjects will not get phosphorus
32927310|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
33250683|NCT03991897|Experimental|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
33250684|NCT03991897|Active Comparator|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
33250685|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
32927311|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
32725432|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
32725433|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
32725434|NCT04708223|Experimental|Fast-curing composites|
32725435|NCT04708223|Other|Conventionally applied composites|
32725436|NCT05103579||Patients with AFib|Patients with AFib
32725437|NCT05103579||Normal patients|Normal patients without AFib
32725438|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
32725439|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
32725440|NCT05103501|Experimental|experimental arm|PF regimen (cis-platinum of 75mg/m2/d, d1; 5-fluorouracil of 600mg/m2d1-4) combined with PD-1 inhibitors（pembrolizumab，200mg d1） every 3 weeks for 4 cycles followed by PD-1 inhibitors（pembrolizumab，200mg d1）every 3 weeks up to 2 years in a standard manner.
32725441|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
32725442|NCT02763111|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
32725443|NCT02763111|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
32725444|NCT02763111|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
32725445|NCT02763111|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
32725446|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
32725447|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
32725448|NCT05103111||FHP group (study group)|it will be consisted of 50 women, suffering from FHP (CVA is less than 48°)
32725449|NCT05103111||control group (without FHP)|it will be consisted of 50 women, not having FHP (CVA is more than 48°).
32725450|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
32725451|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
32725452|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
32725453|NCT04657211||Group A|Participants will receive treatment from settled general practitioners (GPs) (GPs, primary care, practitioner/registered doctor).
32725454|NCT04657211||Group B|Participants will receive treatment from settled pulmonologists (specialists, primary or secondary care).
32725455|NCT04657211||Group C|Participants will receive treatment at outpatient lung centers (clinics, ambulances, acute care centers).
32725456|NCT03947177|Placebo Comparator|Control|GMIT
32725457|NCT03947177|Experimental|Intervention|Modified GMIT + Parenting support groups
32725458|NCT04628429||Episodic Migraine|All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
32725459|NCT04628429||Chronic Migraine|All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
32725460|NCT04628429||Healthy Control|Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
32725461|NCT05204589|Experimental|Group A|Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
32725462|NCT05204589|Experimental|Group B|Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
32725463|NCT05204589|Experimental|Group C|Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.
32725464|NCT05020509|Active Comparator|Touhy needle group|medial branch block with touhy needle
32725465|NCT05020509|Placebo Comparator|Quincke needle group|medial branch block with Quincke needle
32725466|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
32725467|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
32725468|NCT04526613||'healthy' LTBI+ controls who are negative for all of the conditions|'healthy' LTBI+ controls who are negative for all of the listed conditions
32927312|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
32927313|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
32927314|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
32927315|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
32927316|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
32725469|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
32725470|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology)
32725471|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
32927317|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
32927318|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
32927319|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
32725472|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c >8%)
32725473|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
32927320|NCT02837237|Experimental|KBP-5074|Single oral dose
32927321|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
32927322|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
32927323|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
32725474|NCT04601987|Active Comparator|Counseling about the Maternal Benefits of Breastfeeding|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the maternal health benefits of breastfeeding.
32725475|NCT04601987|Active Comparator|Counseling about the benefits of Smoke-free Homes|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the health benefits of smoke free homes.
32725476|NCT05090163|Active Comparator|PREP group|Control group
32725477|NCT05090163|Experimental|PREP Plus group|Intervention group
32725478|NCT04585217|Active Comparator|Plain gut suture on right eyelid|Plain gut suture closure of blepharoplasty incision
32725479|NCT04585217|Active Comparator|Polypropylene suture on right eyelid|Polypropylene suture closure of blepharoplasty incision
32725480|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
32927324|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
32927325|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
32927326|NCT02314598||No treatment|
32927327|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
32927328|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
32927329|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
32725481|NCT04571567|Experimental|Secukinumab|300mg subcutaneously
32927330|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
32927331|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
32927332|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
32927333|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
32725482|NCT04670757|Experimental|CPL409116|"PART A. IMP is to be administered orally in single ascending dose in the groups consisting of 3 volunteers according to '3+3' design'. Dose escalation scheme is to be determined based on preclinical results and due to dose limiting observation (DLT).~PART A additional. Assessing the effect of food on bioavailability of CPL409116. IMP is to be administered orally in single dose in fasted and fed state in the group of 12 volunteers.There is to be one week wash-out between two treatment periods for this cohort."
32725483|NCT04670757|Experimental|PLACEBO|PART B. Two participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
32725484|NCT04557527|Other|control|Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
32725485|NCT04557527|Active Comparator|treatment|Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.
32725486|NCT04525989|Experimental|Proton therapy|5 x 5 Gy External radiation therapy with Protons
32725487|NCT04525989|Active Comparator|Photon therapy|5 x 5 Gy External radiation therapy with Photons
32725488|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
32725489|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
32725490|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
32725491|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
32725492|NCT04950855||Pregnant Women|Healty pregnant women between 18-45 years,with no history of eye surgery and systemical disease.In 1st , 2nd and 3rd trimesters the measurements will be repeated
32725493|NCT04950855||Control Group|Healty non-pregnant women between 18-45 years with no history of eye surgery and systemical disease.
32725494|NCT04520087|Experimental|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
32725495|NCT04669197|Other|Treatment|Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine
32725496|NCT04505111|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
32725497|NCT04505111|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
32725498|NCT04522947|Experimental|fMRI|Participants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
32725499|NCT04707495|Experimental|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
32725500|NCT04707495|Active Comparator|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
32725501|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
32725502|NCT05107791|Experimental|Stulln Eyedrops|Augentropfen Stulln Mono Eye Drops (Stulln eyedrops) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
32725503|NCT05107791|Sham Comparator|Theta Tears|Thera Tears (Sodium Carboxymethylcellulose 0.25%) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
32768518|NCT04751461|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
32768519|NCT04751461|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
32927334|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
32927335|NCT02925143|Experimental|E-learning course|
32927336|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
32927337|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
32927338|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
32927339|NCT02018809|Other|Usual Care|Usual care with GlowCap.
33250686|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
32927340|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
32927341|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
32927342|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
32927343|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
32927344|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
32725504|NCT04430699|Experimental|Pembrolizumab, Cisplatin and Radiation Therapy|"Treatment period is 36 weeks with 21 day study cycles.~Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.~First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.~Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks."
32725505|NCT05107323|Experimental|CMT-T|The CMT-T is a Compassionate Mind Training program tailored for teachers, delivered in a group format across eight sessions of approximately 2.5 hours each. In each session, besides presenting relevant theoretical constructs addressed in that session, participants are invited to complete experiential exercises, compassion and mindfulness meditation practices, and work in small groups to share their experiences, followed by a plenary session. There are six different modules addressed during the 8-sessions CMT-T
32725506|NCT05107323|No Intervention|Waiting list|Participants in the waiting list control group were not offered an intervention.
32725507|NCT04404569|Experimental|Continued Treatment|"Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study.~The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose."
32725508|NCT04522791|Experimental|RFB+VSOP|"For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
32725509|NCT04522791|Active Comparator|IR+VSOP|The control IR strategy will be used, set-up of which will be the same as the RFB + VSOP intervention group with IR replacing RFB. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
32725510|NCT04522791|Placebo Comparator|IR only|Participants randomized to this condition will receive weekly in-person check-in visits, and perform daily 10-minute IR, so that the number of treatment contacts (though not duration) will be equivalent. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
32725511|NCT05111769|Experimental|rhBNP in the treatment of sepsis complicated with heart failure|Recombinant human brain natriuretic peptide (rhBNP) on sepsis complicated with heart failure
32725512|NCT05111769|No Intervention|Conventional treatment group|Do not use recombinant human brain natriuretic peptide (rhBNP) to treat sepsis with heart failure
32725513|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
32725514|NCT04358003|Experimental|Plasma Adsorption Cartridge|Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
32725515|NCT05166603|Experimental|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
32725516|NCT05166603|No Intervention|Usual Care|Patients receive usual care
32725517|NCT03460613|Other|FGID Patients|
32725518|NCT03460613|No Intervention|Hepatology Control Group|
32725519|NCT03460613|No Intervention|Healthy Volunteers|
32725520|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
32725521|NCT03568409|Placebo Comparator|Group B: Placebo|
32927345|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
32927346|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
32927347|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
32927348|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
32927349|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
32927350|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
32927351|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
32927352|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
32927353|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
32927354|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
32927355|NCT00374153|Experimental|1|Online personal feedback report.
32927356|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
33073447|NCT01708941|Experimental|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
33073448|NCT01708941|Experimental|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
33073449|NCT01708941|Experimental|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
32725522|NCT04642677|Experimental|Group A|"Patients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock)."
32725523|NCT04642677|No Intervention|Group B|Patients and caregivers were received palliative sedation without intervention.
32725524|NCT05111067||Nova scotia TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
32725525|NCT05111067||Nigerian TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
32725526|NCT03541187|Experimental|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
32725527|NCT03541187|Placebo Comparator|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
32725528|NCT04519905|Experimental|chemoradiotherapy|50.4Gy/28Fx; Paclitaxel plus carboplatin
32725529|NCT04519905|Active Comparator|radiotherapy|61.2Gy/34Fx
32725530|NCT04289285|Experimental|IBI306 450mg SC Q4W|
32725531|NCT04289285|Placebo Comparator|Placebo SC Q4W|
32725532|NCT04289285|Experimental|IBI306 600mg SC Q6W|
32725533|NCT04289285|Placebo Comparator|Placebo SC Q6W|
32725534|NCT04477473||Vulnerable subjects|Patients under long-term non-invasive ventilation (respiratory support) at home for chronic respiratory failure
32725535|NCT03460457|Experimental|TQB2450|
32725536|NCT04474743||Liver Cirrhosis|Patients diagnosed with liver cirrhosis.
32725537|NCT04474743||Chronic Pancreatitis|Patients diagnosed with chronic pancreatitis.
32725538|NCT04474743||Short Bowel Syndrome|Patients diagnosed with short bowel Syndrome.
32725539|NCT04474743||Control Patients|Otherwise healthy patients visiting hospital with other non-severe diseases.
32725540|NCT04474743||Healthy Controls|Healthy subjects recruited from the general population.
32725541|NCT03129659|Experimental|CT-group|Coronary CT angiography
32725542|NCT04423341|Active Comparator|Group A - active medication followed by placebo|
32725543|NCT04423341|Active Comparator|Group B - placebo followed by active medication|
32725544|NCT05106699|Experimental|Carbon ion followed by Proton radiotherapy|All patients received whole pelvis and prostate region radiotherapy. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique.
32725545|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
32725546|NCT04163367|Active Comparator|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
32725547|NCT04163367|Experimental|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
32725548|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
32725549|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
32725550|NCT04187183|Experimental|Fresh PRP with concentrate Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes~1 infiltration weekly, for 3 weeks."
32725551|NCT04187183|Active Comparator|Fresh PRP without concentrated Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte.~1 infiltration weekly, for 3 weeks."
32927357|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
32927358|NCT00374153|No Intervention|4|Assessment only
32927359|NCT00374153|No Intervention|5|Delayed Assessment
32725552|NCT05101395||Patients with Gastritis|Patients who underwent sleeve gastrectomy and the histopathology result of resected gastric specimen showed the presence of gastritis in it.
32725553|NCT03460223|Experimental|Conventional plus MSC treatment|
32927360|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
32725554|NCT04963959|Other|Healthy donor|
32725555|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.~VAS- Anxiety scores pre and post inhalation."
32725556|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
32725557|NCT04125771|Other|Diclofenac + HBB|Women who will receive Diclofenac + HBB
32725558|NCT04125771|Other|Diclofenav + placebo|Women who will receive Diclofenav + placebo
32725559|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
32725560|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
32725561|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
32725562|NCT05027997|Experimental|Dipraglurant 50 mg|
32725563|NCT05027997|Experimental|Dipraglurant 100 mg|
32725564|NCT05027997|Placebo Comparator|Placebo|
32725565|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
32725566|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
32725567|NCT04530825|No Intervention|Providers|"All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline~A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
32725568|NCT04530825|No Intervention|Parents|-Semi-structured interviews
32725569|NCT04530825|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
32743473|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
32743474|NCT03235583|Other|MotionPod Validation|Medical device validation
32743475|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
32927361|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
32927362|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details."
32927363|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details."
32927364|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
32927365|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
32725570|NCT04530825|Experimental|Patients - PREVENT tool|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
32725571|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
32725572|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
32725573|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
32725574|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
32725575|NCT05115123|Active Comparator|Intervention|patients scheduled for elective LC will receive 60 mg duloxetine before surgery
32725576|NCT05115123|Placebo Comparator|Control|patients scheduled for elective LC will receive placebo before surgery
32725577|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
32927366|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
32927367|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
32927368|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
32725578|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
32725579|NCT04821999|Experimental|group I|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
32927369|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
32927370|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
32927371|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
32725580|NCT04821999|No Intervention|group II|No treatment
32725581|NCT03209063||Group I|195 Patients having history of two or more miscarriages.
32725582|NCT03209063||Group II|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy
32725584|NCT04636671|Experimental|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~C. From day 9 and beyond:~If not intubated patient and PaO2/FiO2 > 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;~If intubated patient or PaO2/FiO2 <= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 > 200 then taper as in a)"
32725585|NCT04636671|Active Comparator|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).~B. After day 10 study treatment is interrupted."
32725586|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
32725587|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
32725588|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
32725589|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
32725590|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
32725591|NCT05106621||Surgical Patients|
32725592|NCT05081817||ICU|ICU patients on insulin drip
32725593|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
32768520|NCT04751461|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
32927372|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
32725594|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
32725595|NCT04867083|Experimental|Arm 1: 4 days/7|4 days/7 Patients included in this arm will take their ARV treatment 4 consecutive days per week during 48 weeks.
32725596|NCT04867083|Active Comparator|Arm 2: 7 days/7|Patients included in this arm will take their ARV treatment 7 days per week during 48 weeks
32725597|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
32725598|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
32725599|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32725600|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
32725601|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
32725602|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
32725603|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
32725604|NCT03645603|Experimental|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
32725605|NCT03645603|Placebo Comparator|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
32725606|NCT02878499|Other|ASD|
32725607|NCT05059041|Experimental|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
32725608|NCT05059041|Experimental|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
32725609|NCT04912323|Experimental|MAGNITUDE® Scaffold|Subject with up to three study lesions treated by implanting a maximum of 3 R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffolds
32725610|NCT04033757||Sub-cohort 1|1,469 participants were enrolled in 2015. Three follow-ups have been completed in 2016, 2017, and 2020. They will be asked to participate in follow-up in 2023 and 2026.
32725611|NCT04033757||Sub-cohort 2|1,267 participants were enrolled in 2018. They will be asked to participate in follow-up in 2021, 2024, 2027, and 2030.
32725612|NCT04033757||Sub-cohort 3|1,340 participants were enrolled in 2019. They will be asked to participate in follow-up in 2022, 2025, 2028, and 2031.
32725613|NCT04019873||Subjects receiving 2DR treatment|Data will be collected from HIV positive male or female adult subjects who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014.
32725614|NCT04890639|Experimental|AIH group|Hypoxia will be administered via a specialized face mask attached to a gas mixing device (HYP123, Hypoxico Inc.), which controls oxygen content in inhaled air. The hypoxia administering unit will be manually adjusted to supply O2 at the target level for a given session (approximately 21%-normal room air, 17%, 13%, and 9% respectively). Each session will include 15 cycles of hypoxia, each lasting up to 60 seconds, interspersed with up to 90-second normoxic episodes. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).
32725615|NCT03909893|Experimental|Adaptive Radiation Therapy|
32725616|NCT04771689|Active Comparator|Buprenorphine/Naloxone|Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.
33073450|NCT01708941|Experimental|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
32725617|NCT04771689|No Intervention|Standard Medication Regiment|Subjects will take conventional intravenous or oral opioid management.
32725618|NCT04879797|Other|Maternal Safety Bundles Implementation|The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
32725619|NCT04879797|Other|Doula Services|The second intervention that this study evaluates is doula services. Investigators are evaluating doula services that are offered by two doula organizations at three hospitals. Investigators will provide top-up training to these doulas in order to provide some standardization and quality assurance of the services delivered. The training is developed and delivered by an obstetrician (Meadows) and doula (Gebel) and will take place among providers (staff associated with three chosen hospitals), patient navigators, and two doula groups, Birth Sisters and Accompany Doula Care, on factors that comprise the risk profile and how to offer targeted doula services to women who fit the risk profile. All sites will use standardized data instruments to evaluate the number of factors in the risk profile being met as well as standardized language and recruitment materials for mothers.
32927373|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
32927374|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
32927375|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
32725620|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
32725621|NCT04674345|Experimental|Sorafenib group|Sorafenib will be administered at 45-60 days post-transplantation and taken for one year.
32725622|NCT04674345|No Intervention|Non-maintenance group|Neither sorafenib nor other FLT3 inhibitors will be used, unless the patient experiences relapse.
32725623|NCT03853811|Experimental|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
32725624|NCT03853811|No Intervention|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
32725625|NCT04165239|Experimental|Treatment A|Oral administration of 50 mg KH176 twice daily
32725626|NCT04165239|Experimental|Treatment B|Oral administration of 100 mg KH176 twice daily
32725627|NCT04165239|Placebo Comparator|Treatment C|Oral administration of matching placebo twice daily
32725628|NCT03329079|Experimental|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
32725629|NCT03329079|Active Comparator|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
32725630|NCT02732951|Experimental|BI 1026706|
32725631|NCT02732951|Active Comparator|Placebo|
32725632|NCT02999373|Experimental|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
32725633|NCT02999373|No Intervention|control|
32725634|NCT04474587||OHS-NIV|Patients with obesity-hypoventilation syndrome (OHS) treated with non-invasive ventilation (NIV).
32725635|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
32725636|NCT05106543|Experimental|kinesiologic tape|"first group of 20 people (experimental group) T max branded kinesiology tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the experimental group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
32927376|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
32927377|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
32927378|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
32927379|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
32927380|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
32725637|NCT05106543|Placebo Comparator|patch tape|"second group of 20 people (control group) Roll branded patch tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the control group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied to both groups before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
32725638|NCT04576767||Experimental group|interventions:general anesthesia drugs:propofol、muscle relaxant、pain relievers(fentanbyl、sufentanil)
32725639|NCT04576767||control group|interventions:intraspinal anesthesia drugs:ropivacaine、pain relievers(fentanbyl、sufentanil)
32725640|NCT04471311|No Intervention|Primary closure of midline laparotomy|Primary closure of midline laparotomy
32725641|NCT04471311|Experimental|Sub-lay mesh supported closure|Sub-lay permanent mesh supported the closure
32725642|NCT04454931||Intensive care patients who underwent neurosurgery|Cerebral oxygenation status will be monitored during and after endotracheal suctioning in each patient included in the study. Non-invasive regional oximetry probes are placed in the frontal region of the patient and the patient will be positioned at the head height of 15 degrees with a 3-motor angle determining bearing system. Then, when the patient's need for endotracheal suctioning arises, endotracheal suctioning will be performed and the cerebral oxygenation status before the procedure, 1 minute, 5 minutes and 30 minutes after the procedure will be recorded on the monitor of the non-invasive regional oximeter device operating with NIRS technology. The same procedure will be applied to the patient at head heights of 30 and 45 degrees. Cerebral oxygenation status measured at each head height will be compared with appropriate statistical methods and the most appropriate head height will be determined.
32725643|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
32725644|NCT01377233|Experimental|Zicronapine 10 mg daily|
32725645|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
32725646|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
32725647|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
32725648|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
32725649|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
32725650|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
32927381|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
32927382|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
32725651|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
32725652|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
32927383|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
32927384|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
32725653|NCT03265379||patients with an isolated recurrence in the chest wall|
32725654|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
32927385|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
32927386|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
32725655|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
32725656|NCT03265379||patients refusing to undergo surgery|
32725657|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
32725658|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
32725659|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
32725660|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
32725661|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
32927387|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
32927388|NCT04026529|Experimental|walking at incline|Subjects will walk on treadmill at slope and speed to equal 60% of their peak work rate as determined on baseline cardiopulmonary exercise test.
32927389|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
32927390|NCT02932787|No Intervention|Control|
32927391|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
32725662|NCT03148379|Experimental|Customized patient instruments|Experimental group: Patients randomized into this group will undergo surgery utilizing single-use Efficiency Instruments with patient-specific technique (MyKnee® patient-matched cutting blocks)
32725663|NCT03148379|Active Comparator|Traditional metal instruments|Control Group: Patients will undergo conventional surgical technique
32725664|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
32725665|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
32725666|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
32725667|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
32725668|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
32725669|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
32725670|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
32725671|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
32927392|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
32927393|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
32927394|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
32927395|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
32927396|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
32927397|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
32927398|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
32725672|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
32725673|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
32725674|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
32768521|NCT04751461|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
32927399|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
32927400|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
32927401|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
33073453|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
33073454|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
32725675|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
32725676|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.~oral swab for polymorphism exploration"
32725677|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
32725678|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
32725679|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
32725680|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
32725681|NCT05154929|Other|Control arm|Participants in the control group will be provided a smartwatch and home blood pressure monitor. They will also be provided with general instructions on how to download and install a physical activity and diet regulation applications (apps) available to the general public. They will still be asked to perform the blood pressure monitoring at regularly scheduled time periods, but do not receive the intervention components notifications in myBPmyLife app developed for the experimental group.
32743476|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
32743477|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
32743478|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
32743479|NCT02124772|Experimental|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
32743480|NCT02124772|Experimental|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
32743481|NCT02124772|Experimental|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
32743482|NCT02124772|Experimental|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
32743483|NCT02124772|Experimental|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
33073455|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
32743484|NCT02124772|Experimental|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
32743485|NCT02124772|Experimental|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
32743486|NCT02124772|Experimental|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
32743487|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for <12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
32743488|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
32743489|NCT02124772|Experimental|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
32743490|NCT02124772|Experimental|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
32743491|NCT02124772|Experimental|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
32743492|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
32743493|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
32725682|NCT05154929|Experimental|Dietary plus physical activity JITAI|Participants in the experimental group will be provided a smarthwatch and home blood pressure monitor. They will then receive the myBPmyLife app that includes push notifications to promote increased physical activity and improve low sodium food choices. The app also provides goal setting for weekly step count and information on low-sodium food choices, as well as feedback on achieving the goals using a dashboard with visualization tools within the mobile application.
32725683|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
32725684|NCT05322395|Experimental|ESC 0/1 pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
32725685|NCT05322395|Active Comparator|ESC 0/3 hour pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
32725686|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
32725687|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
32725688|NCT03129425|Experimental|Intervention group|Sessions in groups
32725689|NCT03129425|Sham Comparator|Control group|Sessions in groups
32725690|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
32725691|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
32725692|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
32725693|NCT01774409|Experimental|Blood and tumor samples|
32725694|NCT05322161|No Intervention|Control|Parents will experience usual care including all available parental support as practiced in the specific site NICU.
32725695|NCT05322161|Experimental|Yoga Group|In addition to usual care, the parents randomized to the intervention group will be provided a yoga mat and participate in 30-min online led yoga sessions done at least twice weekly at the parent's pace using a secure, virtual platform (website).
32725696|NCT05322083||HIV patients|All patients will be prescribed treatment drugs in accordance with the national protocol by the doctors of the AIDS centers. The decision to prescribe Doravirine will also be made by doctors.
32725697|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
32725698|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
32725699|NCT01487603||confirmed or suspected lung cancer|
32725700|NCT01454843|Active Comparator|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser.
32725701|NCT01454843|Active Comparator|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using AMO CustomVue excimer laser.
32725702|NCT02712905|Experimental|INCB059872|
32743494|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
32743495|NCT05269030|Experimental|Case group|The patients will receive ivermectin nasal drops
32743496|NCT05269030|Active Comparator|Control group|The patients will receive local steroid spray
32725703|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
32927402|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
32927403|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
32927404|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
32725704|NCT04339803|Experimental|mirror therapy|lower limb mirror therapy using ankle exercise
32725705|NCT01166633|Experimental|Pitavastatin 2 mg|
32725706|NCT01166633|Active Comparator|Atorvastatin 10mg|
32725707|NCT05322005|Experimental|Arm A: augmentation to surgery|Patients will be surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel, during an arthroscopic procedure. After 6 weeks the patients attend a second injection session, during an ambulatorial visit. At 8 weeks from the surgery the patients attend the third ambulatorial injection session
32725708|NCT05322005|Experimental|Arm B: conservative treatment|The patients are going to receive three injections session (polynucleotide gel) performed with a time interval of 2 weeks.
32725709|NCT04025541|Other|COHORT 1 BREAST TUMOR/PALBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib~BLOOD SAMPLING"
32725710|NCT04025541|Other|COHORT 2 BREAST TUMOR / RIBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib~BLOOD SAMPLING"
32927405|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
32725711|NCT05321849||Use Fluoroscopy (Control)|PDA closure in 30 patients with fluoroscopy guide
32725712|NCT05321849||No fluoroscopy (test)|PDA closure in 30 patients with echocardiography guide, without fluoroscopy
32927406|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
32725713|NCT05106075|Experimental|biologic sample collection|Blood samples or gingival exsudat collection
32927407|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
32927408|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
33400664|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
32927409|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
32927410|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
32725715|NCT04315311|Experimental|CREON|Participants will receive daily dose of CREON.
32725716|NCT05321693|Active Comparator|Active tPCS|
32725717|NCT05321693|Sham Comparator|Sham tPCS|The currentwill only be applied forthe first 30 seconds. Patients may notice the same sensation of initial stimulation butwill not receive the current for the remaining time.
32725718|NCT04245657||Breast Cancer Survivors|Female breast cancer survivors who underwent unilateral breast cancer surgery ( total or conservative) and completed their adjuvant therapies such as chemotherapy and radiotherapy prior to participation in this study.
32725719|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
32725720|NCT04269161|Experimental|Automatic Oxygen Control|In this arm, an automatic oxygen control device will be used to make adjustments to the blend of oxygen and air supplied to the subject.
33400665|NCT01383642||individuals age >=70|
33400666|NCT03167944|Experimental|Conventional electrocautery|
32927411|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
32927412|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
32927413|NCT02864069|Experimental|Walking Intervention|
32927414|NCT02864069|Experimental|Cognitive Training Intervention|
32927415|NCT02864069|Experimental|Combined Intervention|
32927416|NCT02013050|Placebo Comparator|Placebo|Control
32927417|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
32927418|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
32927419|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
32927420|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise~walking exercise: treadmill gait with tolerable gait speed~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
32927421|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
32725721|NCT04269161|No Intervention|Manual Oxygen Control|In this arm, a nurse will manually make adjustments to the blend of oxygen and air supplied to the subject as in the standard of care.
32725722|NCT03875001|Experimental|BI 1358894|
32725723|NCT03875001|Placebo Comparator|Placebo|
32725724|NCT05105373|Experimental|Intervention-Parenting for Respectability|Randomisation in the cRCT will be conducted at the cluster level. PfR is a 16-session manualised programme starting with nine single sex sessions followed by seven mixed sex sessions, delivered once a week by two local facilitators who receive one week's training. Activities were developed specifically for PfR or adapted from other parenting programs, including Project H, Stepping Stones, Mema kwa Jamii, The International Child Development Programme and Parenting for Lifelong Health. The programme addresses four familial processes associated with GBV and VAC: poor parental bonding and child attachment; harsh parenting; inequitable socialisation by gender and parental conflict. A particular goal is to involve fathers, whom most parenting programmes find hard to recruit, and the first nine sessions are delivered in single-sex groups.
32725725|NCT05105373|Active Comparator|Control-Parenting for Respectability in a nutshell|Randomisation in the cRCT will be conducted at the cluster level immediately after baseline data collection. Parents allocated to the control arm will receive a two-hour structured lecture called Parenting in a Nutshell on parenting and partner relationships. Three topics will be covered: 1) child development; 2) positive parenting; and 3) resolving partner conflicts. Facilitators delivering this lecture will have same/similar expertise with the facilitators engaged in PfR. .
32725726|NCT04256915|Experimental|CBT-I + Bright Light|n = 50
32725727|NCT04256915|Active Comparator|CBT-I + Placebo Light|n = 50
32725728|NCT04256915|No Intervention|Wait-list Control|n = 50
32725729|NCT05105295|Experimental|Experimental Group|Subjects receive a third dose of inactivated COVID-19 vaccine
32725730|NCT05321459||Comatose patients in intensive care unit|Patient admitted in the intensive care unit (ICU) for post cardiac arrest (CA) coma, persistent for at least 3 days after CA.
32725731|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
32725732|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
32725733|NCT03867435||Individuals with DM1|Individuals with myotonic dystrophy type 1 (DM1)
32927422|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise:treadmill gait with tolerable gait speed"
32927423|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)~Only educate the flexibility exercise(stretching exercise)~Don't educate the walking exercise method and stabilization exercise method"
32725734|NCT03867435||Individuals with DM2|Individuals with myotonic dystrophy type 2 (DM2)
32725735|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
32725736|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
32725737|NCT03596073|Experimental|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
32725738|NCT03596073|Placebo Comparator|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
32927424|NCT04012411|Active Comparator|Patient with LP|Huntington's disease patients who agreed to have LP
32927425|NCT04012411|Active Comparator|Patient without LP|Huntington's disease patient with contraindication to LP or refusal to have LP
33250687|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
33250688|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
33400667|NCT03167944|Experimental|Low thermal electrosurgery system|
32725739|NCT05320757|Experimental|Olaparib|Olaparib: 300mg BID orally for 10 - 28 days (stop 3 - 4 days before definitive treatment)
32725740|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
32927426|NCT04012411|No Intervention|Control Group|Retrospective study with biologic samples of patients without Huntington's disease
32725741|NCT03449693|No Intervention|No Supplement|No Intervention
33250689|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
33250690|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
33250691|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
33250692|NCT05167539||Mechanical aortic valve replacement|simple procedure but need long term of anticoagulant
33400668|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
33400669|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
33400670|NCT03631212|No Intervention|Waitlist control|Wait-list control group
32725742|NCT04525911||Symptomatic COVID-19 infection confirmed or probable|Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
32725743|NCT03651063|Experimental|social robot group|
32725744|NCT03651063|Active Comparator|computer group|
32725745|NCT03651063|No Intervention|contro: no intervention|This group will only be a follow up: clinical examination at the entrance and follow 5 weeks with clinical examination 5 weeks post, with no intervention.
32725746|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
32725747|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
32927427|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
32927428|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
32927429|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
32927430|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
32927431|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
32927432|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
33400671|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
33400672|NCT03162874|Placebo Comparator|PLACEBO|
33400673|NCT03162874|Experimental|PXT002331 - 10mg|
33400674|NCT03162874|Experimental|PXT002331 - 30mg|
33400675|NCT02617056||Observational group|Subjects with dementia
33400676|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
33400677|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
32927433|NCT02939105|Experimental|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
32927434|NCT02025439|Experimental|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
32927435|NCT02025439|Experimental|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
32927436|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
32927437|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
32927438|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
32927439|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
33250693|NCT05167539||Aortic root replacement|complicated procedure but without anticoagulant
33250694|NCT01047943|Experimental|Psoriasis therapy|
32927440|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
32927441|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
32927442|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
32927443|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
32927444|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
32927445|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
33250695|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
33250696|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
32725748|NCT03538119|Experimental|HIIT program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
32927446|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
32927447|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
32927448|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
32725749|NCT03538119|Experimental|Moderate continuous training program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
32725750|NCT03538119|No Intervention|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
32725751|NCT05320523|Active Comparator|GPi stimulation + NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with globus pallidus internus (GPi) stimulation using Vercise deep brain stimulation
32725752|NCT05320523|Sham Comparator|GPi stimulation + sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
32725753|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
32725754|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
32927449|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
32927450|NCT02026687|Experimental|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
32927451|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
32927452|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
33250697|NCT00876837||Adults with pediatric-onset SCI|
33250698|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
33250699|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
33250700|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
32927453|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
32725755|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
32927454|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
32927455|NCT02028247|Other|Treatment as Usual|Participants randomized to the TAU condition will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions) for a 16-week period. Treatment changes (e.g., medication increase, starting psychotherapy in community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
32927456|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
32927457|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
32927458|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
32927459|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
32927460|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
32927461|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
32927462|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
32927463|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
32927464|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
32927465|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
32725756|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
32725757|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
32725758|NCT05005065|Experimental|Treatment AB|Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
32725759|NCT05005065|Experimental|Treatment BA|Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
32725760|NCT05005065|Experimental|Treatment CD|Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
32725761|NCT05005065|Experimental|Treatment DC|Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
32725762|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
32743497|NCT02622321|Experimental|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
32768522|NCT04751461|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
32927466|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
32927467|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
32725763|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
32725764|NCT05320055||IPOM|receiving laparoscopic intraperitoneal onlay mesh repair
32927468|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
32725765|NCT05320055||rTARUP|recieving robotic assited retromuscular repair
32725766|NCT05001633|Experimental|Intervention|modified media content experience
32725767|NCT05001633|Active Comparator|Control|media content experience
32725768|NCT05307185|Experimental|Tritordeum-based Food (TBD)|A controlled TBD will be provided to each patient. The daily menu will be breakfast, mid-morning snacks, lunch, afternoon snacks, and dinner. This intervention diet implies that each patient in the study has to consume flour, bread, breakfast biscuits, taralli, and pasta prepared exclusively with Tritordeum. The diets will be designed by matching basal metabolism and daily energy consumption with anthropometric data of all patients to assign suitable and tailored dietary regimens. The software utilized to assess the daily intake of macronutrients (50% carbohydrates, 30% lipids, and 20% proteins) will be the same as LFD.
32725769|NCT05307185|Active Comparator|Low-FODMAPs diet (LFD)|A personalized LFD will be assigned after reviewing a food diary and having a one-on-one personal consultation with a nutritionist. Diet will match the basal metabolic rate and daily energy expenditure. A detailed weekly structured menu based on three meals (breakfast, lunch, and dinner) and two snacks (morning and afternoon) will be provided. Patients also will receive a booklet detailing what foods are allowed, which foods to avoid and which foods to reduce based on the classifications used by Monash University and cut-off values for each FODMAPs subgroup. Nutritionists have already created a leaflet for patients in the study with details on where to buy specific products. Besides, nutritionists will guarantee adequate fiber intake, also offering advice on cooking without onions and garlic and other high-FODMAP foods. Drinking alcohol will not be recommended, although it is not high in FODMAPs.
32725770|NCT05307185|Active Comparator|Specific dietary advice for IBS|"According to NICE BDA Irritable bowel syndrome dietary advice, a controlled diet will be provided. All the food items (bread, pasta, taralli - local salty biscuits, and breakfast biscuits) will be prepared using durum wheat flour commercially available and anonymized to guarantee masking. Dietary recommendations include eating slowly, limiting alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoiding chewing gums and sweeteners containing polyols; small and frequent meals, stressful conditions."
32725771|NCT04997265|Experimental|Low Intensity Anticoagulation|For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians.
32725772|NCT04997265|Active Comparator|Moderate Intensity Anticoagulation|For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians.
32927469|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
32927470|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
32927471|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
32927472|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
32927473|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
32927474|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
32725773|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
32725774|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
32725775|NCT03479931|Experimental|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
33250701|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
33250702|NCT00871533|Experimental|2|No intervention / no injection control.
32725776|NCT03479931|Active Comparator|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
32725777|NCT05306795||Observational cohort|Observational prospective cohort of kidney transplant allograft biopsies
32725778|NCT03444909|Experimental|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
32725779|NCT03444909|Experimental|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
32927475|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
32927476|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
32927477|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
32927478|NCT02870309|Experimental|Alpha-1 MP|Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.
32927479|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
32927480|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
32725780|NCT03444909|Experimental|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
32725781|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
32927481|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
32725782|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
32725783|NCT03374943|Experimental|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
32725784|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
32725785|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
32725786|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
32725787|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
32725788|NCT03371979|Experimental|Pegzilarginase plus Pembrolizumab|Phase 1 & 2
32725789|NCT04958577||Wing A (Ada WRA)|Patients in this group will be filling out the Ada assessment themselves and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
32725790|NCT04958577||Wing B (Ada HDA)|Patients in this group will be asked questions from the Ada assessment by a health care practitioner and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
32725791|NCT05104593|Experimental|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system.
32927482|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
32927483|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
32725792|NCT05104593|No Intervention|Control group|Control group, no intervention
32927484|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
32927485|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
32927486|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
32927487|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
32927488|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
32927489|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
32927490|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
32927491|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
32927492|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
32927493|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
32927494|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
32927495|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
32927496|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
32927497|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
32725793|NCT05104437|Experimental|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
32927498|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
32725794|NCT05104437|Experimental|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
32927499|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
32927500|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
32927501|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
32927502|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
32927503|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
32927504|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
32927505|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
32725796|NCT05096793|Experimental|Control|the distance in the 6-MRT compared to baseline
32927506|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
32725797|NCT05096793|Experimental|Low doses|the distance in the 6-MRT compared to baseline
32725798|NCT05096793|Experimental|High doses|the distance in the 6-MRT compared to baseline
32725799|NCT03338829|No Intervention|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
32725800|NCT03338829|Experimental|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
32725801|NCT03338829|Experimental|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
32725802|NCT05116215|Experimental|Hydrogen inhalation|Participants in the gas group will then undergo exposure to 2% H2 in medical air via a high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month.
32927507|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
32927508|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
32927509|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
32927510|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
32927511|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
32927512|NCT01981057||Individual|individually prescribed parenteral receipt
32927513|NCT02022020||Group 1|
32927514|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
32927515|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
32725803|NCT05116215|Experimental|Hydrogen capsules|Participants in capsule group will receive either 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for one month.
32725804|NCT05116215|Experimental|Hydrogen water|Participants in the water group will be suggested to drink 1 L hydrogen-rich water every day for one month.
32725805|NCT04866069|Experimental|Low-Dose Group (Group A)|20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
32725806|NCT04866069|Experimental|High-Dose Group (Group B)|20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
32927516|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
32927517|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
32927518|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
32927519|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
32927520|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
32927521|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
32927522|NCT01980914|Experimental|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
32927523|NCT01982695|Active Comparator|Lisinopril|
32927524|NCT01982695|Active Comparator|Losartan|
32927525|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
32725807|NCT04866069|Placebo Comparator|Placebo Group|10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
32725808|NCT05090319||Viral Group|known viral infection
32725809|NCT05090319||Bacterial group|known bacterial infection
32725810|NCT05115747|Experimental|"Zero percentage weight off-loading group-A"|This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the full weight-bearing for three months.
32725811|NCT05115747|Experimental|"Twenty-five percentage weight off-loading group-B"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the twenty-five percentage weight off-loading for three months."
32927526|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
32927527|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
32927528|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
32927529|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
32927530|NCT01982240|Active Comparator|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
32725812|NCT05115747|Experimental|"Fifty percentage weight off-loading group-C"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the fifty percentage weight off-loading for three months."
32725813|NCT05115747|Experimental|"Seventy-five percentage weight off-loading group-D"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the seventy-five percentage weight off-loading for three months."
32725814|NCT05115747|No Intervention|Control group-E|Participated no aerobic exercise training.
32725815|NCT03179943|Experimental|Atezolizumab + Guadecitabine|
32927531|NCT01982240|Active Comparator|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
32725816|NCT05115435|No Intervention|control group|No intervention was applied on the control group patients
32927532|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
32927533|NCT01982240|Other|Bisacodyl|Rescue medication
32927534|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
32927535|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
32927536|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
32927537|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
32927538|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
32725817|NCT05115435|Experimental|experimental group|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
32927539|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
32927540|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
32927541|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
32927542|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
32927543|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
32927544|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
32927545|NCT02312713|No Intervention|Wait list control|no intervention
32927546|NCT03945175|Experimental|Treatment|After a two-week, single-blinded, placebo lead-in, all patients will receive four weeks of order-fixed treatment with Mydayis.
32927547|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
32927548|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
32927549|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
32927550|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
32927551|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
32725818|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
32725819|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
32927552|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
32927553|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
32927554|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
32725820|NCT04528173|Active Comparator|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
32927555|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
32927556|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
32927557|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
32927558|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
32927559|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
32927560|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
32927561|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
32927562|NCT02024204|Active Comparator|Uncontrolled LRS|Patients who have uncontrolled lower respiratory symptoms (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
32927563|NCT02024204|Other|Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
32927564|NCT04349137|Experimental|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
32927565|NCT04349137|Active Comparator|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
32725821|NCT04528173|Experimental|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
32725822|NCT05115279|Other|Breast conservative Surgury after neuadjvant chemotherapy|Breast conservative Surgury
32725823|NCT02789553|Experimental|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
32927566|NCT04349137|Sham Comparator|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
32927567|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
32927568|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions~+ HDR brachytherapy boost 15 Gy"
32927569|NCT03019055|Experimental|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
32927570|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
33073463|NCT01631617|Active Comparator|1A/Cephalexin|Cephalexin + Placebo bleach
33073464|NCT01631617|Active Comparator|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
32927571|NCT03019055|Experimental|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
32927572|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
32927573|NCT03930745|Experimental|Arm 1|TOL-463 insert administered vaginally twice a week for twelve weeks. N=125
32725824|NCT02789553|Experimental|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
32725825|NCT02468739|Experimental|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
32725826|NCT02468739|Placebo Comparator|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
32927574|NCT03930745|Placebo Comparator|Arm 2|Matching placebo insert administered vaginally twice a week for twelve weeks. N=125
32725827|NCT05017779|Experimental|Intervention (Unstuck & On Target: High School)|School staff will receive training on the Unstuck and On Target: High School (UOT:HS) curriculum, and deliver lessons to students during the school day. Interventionists will have the option to participate in ongoing check-ins with study staff. Parents are provided home extensions for each lesson and have the option to participate in trainings delivered by study staff to support generalization of skills to the home environment.
32725828|NCT05017779|Other|Usual Care|Participants in schools assigned to the TAU condition will continue to receive the standard school-based Individualized Education Plan (IEP) accommodations and school supports that would typically be provided.
32927575|NCT02033317|Experimental|patiromer|
32927576|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
32927577|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
32927578|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
32927579|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
32927580|NCT02034175|Experimental|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
32725829|NCT05114499||Donepezil monotherapy group|Donepezil 5mg qd
32927581|NCT02034175|Active Comparator|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
32927582|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~First hour - Administer 1 percent of total dose (5ml with tubing primed)~Second hour - Administer 9 percent (45 mL)~Third hour - Administer 90 percent (450 mL)"
32927583|NCT01985971|Experimental|EF5|
32927584|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
32927585|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
32927586|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
32927587|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
32927588|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
32927589|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
32927590|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
32927591|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
32927592|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
32927593|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
32927594|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
32927595|NCT02059057|Experimental|LVRC System|
32927596|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
33250703|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
32725830|NCT05114499||GV-971 monotherapy group|GV-971 450mg bid
32927597|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
32927598|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
32927599|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
32927600|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
32927601|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
32927602|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
32927603|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
32927604|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
32927605|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
32927606|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
32927607|NCT02030288|Experimental|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
32927608|NCT02030288|No Intervention|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
32927609|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
32927610|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
32927611|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
32927612|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
32725831|NCT05114499||Donepezil combined with GV-971 group|Donepezil 5mg qd+GV-971 450mg bid
32725832|NCT04520997|Experimental|Down-up|Participants in this group will receive injections in the chin area at baseline and in the nasolabial folds (NLFs) and marionette lines (MLs) at week 3.
32725833|NCT04520997|Experimental|Top-down|Participants in this group will receive injections in the nasolabial folds (NLFs) and marionette lines (MLs) at baseline and in the chin area at week 3.
32725834|NCT04649385|Experimental|Phase 1a: Dose Escalation|"Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses~Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )"
32725835|NCT04649385|Experimental|Phase 1b: Dose Expansion|Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a
32725836|NCT04795323|Experimental|Non-pharmacological followed by addition of pharmacological self-management support|
32725837|NCT04520373|Experimental|Treatment Group 1: AD-MSC Injection|Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
32768523|NCT04751461|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
32927613|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
32927614|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
32927615|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
32927616|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:~a commercially available gel that contains carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
32927617|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:~a commercially available gel that does not contain carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
32927618|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
32927619|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
32927620|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
32725838|NCT04520373|Active Comparator|Treatment Group 2: Best Medical Management|Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
32927621|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
32927622|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
32927623|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
32927624|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
32927625|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
32927626|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
32927627|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
32927628|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
32927629|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
32725839|NCT05114343|Experimental|Exercise group|Participants will be instructed to perform 3 sessions of weight-bearing exercise per week, for 12 weeks. Exercise intensity and duration will be low-to-moderate in the first 4 weeks, and will progressively increase during the program. Participants will be supported by educational materials, a heart rate monitor, and by means of periodic contact with an exercise specialist via video and phone calls, and text messages.
32725840|NCT05114343|No Intervention|Usual care (control group)|Participants in the control group will receive usual care and general instructions about physical activity.
32725841|NCT04568499||Suspected and Confirmed COVID-19 cases|Suspected and confirmed COVID-19 cases (age 5 years and above) identified at health facilities or via mobile teams in Juba, South Sudan and in Eastern Democratic Republic of the Congo.
32927630|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
33250704|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
33250705|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
32927631|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
32927632|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
32927633|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
33073465|NCT01631617|Active Comparator|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
33250706|NCT05157022|Active Comparator|Focus extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
32725842|NCT04958499|Experimental|Bio-Healthy Park|This group is the experimental group. The intervention program consisted in the realization of the program on bio-healthy machinery.
32768525|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
32927634|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
32927635|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
32927636|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
32725843|NCT04958499|No Intervention|Control|Adults and older assigned to the control group will not received any structured exercise programme. They will maintain their usual physical activities.
32927637|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
32927638|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
32927639|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
32927640|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
32927641|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
32927642|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
32725844|NCT05114109|Experimental|Isatuximab|Isatuximab will be given intravenously.
32725845|NCT04450797|Active Comparator|US -G VPS placement|
32725846|NCT04450797|Active Comparator|Stereotactic navigation for VPS placement|
32725847|NCT05114031|Experimental|FB101|Active intervention with microbial product FB101
32927643|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
32927644|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
32927645|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
32927646|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
32927647|NCT02061397|Experimental|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
32927648|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
32927649|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
32927650|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
32927651|NCT04349761|Experimental|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
32927652|NCT04349761|Experimental|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
32927653|NCT04349761|Experimental|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
32927654|NCT04349761|Experimental|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
32927655|NCT04349761|Experimental|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
32725848|NCT05114031|Placebo Comparator|Placebo|Non-microbial placebo intervention
32725849|NCT04336215||Healthcare Workers|500 HCW with high intensity direct patient care from two RBHS-affiliated academic hospitals: Robert Wood Johnson University Hospital (New Brunswick, NJ) and University Hospital (Newark, NJ) and Rutgers School of Dental Medicine (Newark, NJ) . Since rates of asymptomatic carriage, clinical infection, and morbidity likely vary by age and sex, the aim is to recruit 125 HCW in each of the following 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; and females ages ≥60.
32725850|NCT04336215||Non-Healthcare Workers|250 non-healthcare workers (NHCW) from Rutgers faculty, postdoctoral students, students, other trainees, administrators, and staff who do not have patient contact. The aim is to recruit even numbers of NHCW from each of these 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; females ages ≥60.
32927656|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
32927657|NCT02401022|Active Comparator|AZD8529 high dose|40mg
32927658|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
32927659|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
32927660|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
32927661|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
32927662|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
32927663|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
32927664|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
32927665|NCT02036840||Penicillin allergy|
32927666|NCT02951195|Placebo Comparator|Part 1: Placebo|
32927667|NCT02951195|Experimental|Part 1 Cohort 1A: TC|
32725851|NCT04336215||Household Members|Complementing the HCW cohort study, approximately 540 household members in a subset of the participants who test positive and negative for SARS-CoV-2 will be invited to be followed prospectively to assess patterns of viral transmission. The target population will be multigenerational households (e.g., with children and/or parents) from up to 6 infected HCW, 6 infected NHCW, 4 uninfected HCW, and 4 uninfected NHCW at each timepoint. The participant will ask household members to contact research staff if they wish to volunteer for the study. Research coordinators will individually consent adult members of the household for questionnaire and serial samples collection. When children are in the home, parental permission as well as assent for children ages 7 and older (written at ages 12 and older) will be the course of action. The estimated 540 participants assumes 20 houses per timepoint, 9 timepoints, and an average of 3 participants per house.
32725852|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
32927668|NCT02951195|Experimental|Part 1 Cohort 1B: TC|
32927669|NCT02951195|Experimental|Part 1 Cohort 1C: TC|
32927670|NCT02951195|Active Comparator|Part 2 Cohort 2A: TEZ/IVA|
32927671|NCT02951195|Experimental|Part 2 Cohort 2A: TC|
32927672|NCT02951195|Active Comparator|Part 2 Cohort 2B: TEZ/IVA|
32927673|NCT02951195|Experimental|Part 2 Cohort 2B: TC|
32927674|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
32927675|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
32927676|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
32927677|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
32927678|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
32725853|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
32725854|NCT05113875||COVID-19 Patients|Completed Sample of all patients admitted to the Mitchells Plain Hospital of Hope COVID-19 Field Hospital between January 1st and February 29th 2021. All patients were diagnosed with COVID-19 prior to admission to the hospital and were transferred directly from a referring hospital.
32725855|NCT05112783|Experimental|Henan Tuoren Endotracheal Tube group|Uses the Henan Tuoren endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
32725856|NCT05112783|Experimental|Smiths Portex Tracheal tubes group|Uses the Smiths Portex endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
32725857|NCT05109585||participants willing to receive a 3-dose vaccination schedule|participants who received a 2-dose vaccination schedule, willing to receive a 3rd dose
32725858|NCT05109585||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
32725859|NCT04788303|Active Comparator|Full intervention|Full intervention: school meal, garden, education, and community workshops
32725860|NCT04788303|Active Comparator|Partial intervention|Partial intervention: garden, education, and community workshops
32725861|NCT04788303|No Intervention|Control|Control: standard of care
32725862|NCT03949959|Experimental|Physiotherapy (PRPt)|The 6-week exercise program (2 sessions in each of weeks 1-4 and 1 session in each of weeks 5 and 6) will comprise specific individually-tailored exercises to improve the movement and control of the neck and shoulder girdle. The exercises will be of a low load nature and designed to be pain free. At the same time, the physiotherapist will provide pragmatic multimodal physiotherapy to facilitate ability to pursue exercises and guide the participant's return to normal activities. This specific treatment program has been described in detail (Jull et al., 2008; Ritchie et al., 2015b) and focuses on activating and improving the coordination and endurance capacity of the neck flexor, extensor and scapular muscles in specific exercises and functional tasks. Participants will also perform the exercises at home, once per day. Written and illustrated exercise instructions will be provided. The exercise program follows Australian guidelines for the management of chronic whiplash (TRACsa, 2008).
32927679|NCT02037776|Active Comparator|Rikkunshito|
32927680|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
32927681|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
32927682|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
32927683|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
32927684|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
33073466|NCT01631617|Active Comparator|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
32927685|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
32927686|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
32927687|NCT02404532|Experimental|1|
32927688|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
32725863|NCT03949959|No Intervention|Wait and See (PRPu)|"Individuals randomized to usual care will be provided with an advice booklet Whiplash Injury Recovery: A Self Help Guide (MAIC, Qld, 2nd edition). It provides information about whiplash; assurance about prognosis; advice to stay active and resume working as well as information on correct posture; pictorial descriptions of specific exercises for the neck and upper limbs and information on resuming functional daily activities. The booklet is based on the recommendations of the current Australian Guidelines for Whiplash Management (SIRA, 2014).~Usual care involves a 'wait and see' approach (in combination with provision of home exercises) and will include weekly review appointments with a medical doctor, primarily to review the information in the booklet and progress the 'general' exercises and activity recommendations within the booklet. No hands-on physiotherapy will be provided. Education regarding PRP and associated healing cycles will also be provided during this time period."
32927689|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
32927690|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
32927691|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
32927692|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
32725864|NCT02142803|Experimental|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32927693|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
32725865|NCT04436445|Active Comparator|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
32725866|NCT04436445|Active Comparator|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).~8 hour sleep at night 40 minutes of walking 3time per week."
32725867|NCT05283161|Placebo Comparator|Placebo|10 participants will receive placebo (vehicle). The placebo will match the study drug in odor, taste, color and appearance. The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
32725868|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (0.1 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (0.1 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
32725869|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (1.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (1.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
32725870|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (10.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (10.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
32725871|NCT03843489|Experimental|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
32725872|NCT03843489|Sham Comparator|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
32927694|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
32927695|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
33073467|NCT01631617|Active Comparator|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
33073468|NCT01631617|Placebo Comparator|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
32725873|NCT03695939|Experimental|Experimental Treatment: Xeno-Skin®|In the experimental arm, patients are treated with the investigational drug, Xeno-Skin®, in a side-by-side comparison to the active comparator, thus, each patient serves as their own control. The designated Xeno-Skin® product size will be placed on the burn wound and secured in place via suturing or stapling. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites.
32768526|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
32768527|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
33073469|NCT01631617|Placebo Comparator|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
33073470|NCT01631617|Placebo Comparator|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
33073471|NCT01631617|Active Comparator|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
32725874|NCT03695939|Active Comparator|Active Comparator: Human Allograft Skin|"In the active comparator arm, patients are treated with human cadaver allograft, in a side-by-side comparison to the investigational drug, thus, each patient serves as their own control.~The allograft active comparator will be placed adjacently to the investigational drug, in the same anatomical location, on wound sites following debridement and secured via suture or staples. All other treatment aspects were consistent with the standard of care. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites."
32725875|NCT03691311|Experimental|Denosumab|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
32725876|NCT03691311|No Intervention|Control|Control group
32725877|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
32927696|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
32725878|NCT03690453|Experimental|Healthy volunteer for Clinical Trial|
32725879|NCT03690453|No Intervention|Healthy volunteer for blood donor|
32725880|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
32927697|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
32927698|NCT02955329|Experimental|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
32927699|NCT02955329|Experimental|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
32927700|NCT02955329|Experimental|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
32927701|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
32725881|NCT05234567||Participants with Pediatric-onset HPP|Each participant will be followed for a minimum of 5 years or, if applicable, until early withdrawal. Biochemical, clinical, imaging (if clinically indicated), and functional/quality of life outcomes relevant to HPP will be assessed.
32725882|NCT04931745|Experimental|Virtual Reality|The Oculus 2 headset will be used during port access. The device features a stereoscopic display mounted on a lightweight wireless head mounted display weighing 503 g with built-in 3D audio and an adjustable head strap and adjustable lens distance. The software used will be the Might Pebbles VR Game developed by ManageXR. It is a child-friendly VR game that does not require the use of hand controllers. It also provides an option to increase the cognitive load, making it appropriate for children of all ages. The experimental group will be given up to 10 minutes to familiarize themselves with the device, assisted by the research assistant and will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
32725883|NCT04931745|Active Comparator|Tablet|The child will watch a video on a tablet or iPad that is appropriate for their age during port access. They will begin using it 5-10 minutes prior to port access. The content of the video will be at the discretion of the child life specialist, nurse, or caregiver. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
32927702|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
32927703|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32927704|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
33250707|NCT05157022|Active Comparator|Radial extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
32725884|NCT04931745|Active Comparator|No or non-technologic distraction|This is no distraction or non-technologic distraction measures such as bubbles, etc., facilitated by the child life specialist, nurse, or caregiver during port access. The measure will be documented for the purposes of analysis. They will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
32725885|NCT04527393|Experimental|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
32725886|NCT04527393|Active Comparator|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
32725887|NCT03487575|Experimental|Open trial|
32725888|NCT05211635|Experimental|Vitamin D|Vitamin D3 capsule 50 µg
32725889|NCT05211635|Placebo Comparator|Placebo|Placebo capsule with identical appearance to the experimental drug
32725890|NCT03464409|Active Comparator|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
32725891|NCT03464409|Active Comparator|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
32725892|NCT03464409|Active Comparator|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
32725893|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
32725894|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
32725895|NCT05184335|Active Comparator|RP5063 15 mg once daily|administered OD for 28 days then flexibly 15-50mg over a period of 52 weeks.
32725896|NCT05184335|Active Comparator|RP5063 (brilaroxazine) 50 mg once daily|administered OD for 28 days, then flexibly 15-50mg over a period of 52 weeks
32725897|NCT05184335|Placebo Comparator|Placebo|administered OD for 28 days.
32725898|NCT03439527|Experimental|MPC-group|All patients are treated by the same product: Autologous MPCs
32725899|NCT03439527|Other|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
32725900|NCT05104905|Experimental|Renal cell intervention 1.0 mg/kg|
32725901|NCT05104905|Experimental|Renal cell intervention 3.0 mg/kg|
32725902|NCT05104905|Experimental|Renal cell intervention 10 mg/kg|
32725903|NCT05104905|No Intervention|Renal cell Observation|
32725904|NCT05104905|Experimental|Colon cancer intervention 1.0 mg/kg|
32725905|NCT05104905|Experimental|Colon cancer intervention 3.0 mg/kg|
32725906|NCT05104905|Experimental|Colon cancer intervention 10 mg/kg|
32725907|NCT05104905|No Intervention|Colon cancer Observation|
32725908|NCT05108727|Active Comparator|Active Diode Laser Therapy+ Modified Widman Flap|Diode laser with a wavelength of 810±5 nm and a power of 1 watt in continuous mode was applied to the Modified Widman Flap at the test sites
32725909|NCT05108727|Sham Comparator|Sham Diode Laser Therapy+ Modified Widman Flap|Control sites were treated with MWF alone
32725910|NCT05102331|Experimental|Lavender Oil Aromatherapy Treatment Arm (LOA)|"Participants will complete baseline assessments including 20 minutes of questionnaires and vitals assessment, including EEG activity (baseline measured with Bispectral Index (BIS) device). Participants will be given a dental bib with three lavender oil drops and instructed to relax for 20 minutes. BP and a brief self-report measure will be obtained. BIS recordings will be collected continuously during study and biopsy.~At procedure, participants will continue to wear bib with drops. BIS machine will stay attached and recording. Participants will be asked to verbally report pain and anxiety on visual analogue scale between the bone marrow aspirate and biopsy. EEG and heart rate (HR) will be collected continuously. An event marker and notation will indicate times when participant does something that may influence EEG activity (e.g. speak, move, etc.) or diagnostic images are taken. At procedure end, BIS device will be removed, final questionnaires administered, and vitals measured."
32725911|NCT05102331|Placebo Comparator|Placebo Aromatherapy Control Arm (PA)|Participants assigned to PA Clinic staff will have the same procedures as listed in LOA arm except the oil used will be a refined jojoba oil which has no color or smell. The BMAB procedure will follow the SOC provided by the clinic. This includes warning participants of upcoming stimuli, encouraging patients to remain calm, and generally expressing empathy to participants. Participants in this group will receive the same collection of questionnaires before, during, and after the procedure as the LOA group. BP, HR, and EEG measurements will similarly be collected continuously before, during, and after the procedure.
32725912|NCT04808193|Experimental|Brugada Survey|Survey will be answered by all participants
32725913|NCT05058573|Experimental|Myofascial relaxation technique + Temporomandibular joint release techniques group (n=22)|medical treatment + temporomandibular joint relaxation (temporalis, masseter, and suboccipital muscles) + myofasial release/trigger points (trapezius, rhomboideus, and levator scapulae, sternocleidomastoideus muscles),
32725914|NCT05058573|Experimental|Temporomandibular joint release techniques group (n=22)|only temporomandibular joint relaxation will be performed in this group (temporalis, masseter, and suboccipital muscles).
32725915|NCT05058573|Experimental|Control group (n=22)|only medication treatment will be applied
32768528|NCT04748107|No Intervention|Provider preference: Control group|Provider will prescribe blood pressure medication based on his professional expertise.
32725916|NCT04756791|Active Comparator|Local infiltration anesthesia|Patients will receive local infiltration anesthesia with ropivacaine placed by surgeon.
32725917|NCT04756791|Experimental|Serratus anterior plane block|Patients receive a SAPB with ropivacaine placed by anesthesiologist.
32725918|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
32725919|NCT04741659|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their actual low oxygen flow
32725920|NCT04741659|Active Comparator|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe with HFNC of 40 L/min
32725921|NCT04741659|Active Comparator|Helmet CPAP|the patients will be asked to breathe with the Helmet CPAP
32725922|NCT04741659|Active Comparator|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
32768529|NCT04748107|Experimental|ICG directed therapy group|ICG directed therapy will be used to determine which blood pressure medication is received.
32725923|NCT04451759|Active Comparator|healthy controls|
32725924|NCT04451759|Experimental|Anorexia|
32725925|NCT04451759|Experimental|Obesity|
32725926|NCT03129191|Active Comparator|AB arm|"Sequence:~Aided with non-invasive bone conduction hearing aid A~Aided with non-invasive bone conduction hearing aid B"
32725927|NCT03129191|Active Comparator|BA arm|"Sequence:~Aided with non-invasive bone conduction hearing aid B~Aided with non-invasive bone conduction hearing aid A"
32725928|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
32725929|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
32725930|NCT04696419|Other|ANIMAL CONTACT 1|Only one arm - within-subject design
32725931|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
32725932|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
32725933|NCT04583319||SARS-CoV-2 Positive|patients tested positive for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
32725934|NCT04583319||SARS-CoV-2 Negative|participants tested negative for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
32725935|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
32725936|NCT04583163||Neuro-critical Care Patients|"Up to 12 subjects will be recruited over a 1 year period. Patients enrolled in the study are recruited from the pool of neuro-critical care patients admitted to the surgical intensive care unit (SICU).~To meet study inclusion, transcranial Doppler (TCD) testing will be ordered as part of the standard of care for these patients. The test will not be ordered solely for research purposes. There are no known side effects from the non-invasive measurement of cerebral blood flow using ultrasound.~Three different TCD technicians will perform triplicate readings on 3 consecutive days on up to 12 patients already undergoing TCD as ordered by their treating team. Standard of care on specific neuro critical care patients (such as cerebral aneurysms) is to undergo daily TCD monitoring to assess for possible vasospasm. Patients will be in the supine position while measurements are obtained. The probe will be placed in the preauricular region of the temporal window."
32725937|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
32725938|NCT04562181|Experimental|Interventions|Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
32725939|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
32725940|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
32725941|NCT04561245|Experimental|ALT-801 (Part 1)|Escalating doses of ALT-801 administered once
32725942|NCT04561245|Placebo Comparator|Placebo (Part 1)|Placebo administered once
32725943|NCT04561245|Experimental|ALT-801 (Part 2)|Escalating doses of ALT-801 administered once weekly for 12 weeks
32725944|NCT04561245|Placebo Comparator|Placebo (Part 2)|Placebo administered once weekly for 12 weeks
32725945|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
32725946|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
32725947|NCT04438083|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
32927705|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
32927706|NCT02359916||A|Snacks sold under equal pricing, no delays
32927707|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
32927708|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
32725948|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
32725949|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
32927709|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
32927710|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
32927711|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
32725950|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
32927712|NCT02359916||G|Snacks sold under equal pricing, no delays
32927713|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
32927714|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
33073472|NCT01631617|Placebo Comparator|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
32725951|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
32725952|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
32725953|NCT05069805|Active Comparator|PECS II block group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
32725954|NCT05069805|Active Comparator|ESP block group|Patients in ESP group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
32725955|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
32725956|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
32725957|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
32725958|NCT05066529|Experimental|dry-needling group|"32 participants in this group Dry-needling treatment will be applied once a week for three weeks. Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
32725959|NCT05066529|Other|exercise group|"32 participants in this group Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
32725960|NCT03448055|Other|Interventional|Immunocal 20gm daily
32725961|NCT05059665||HCC Subjects|"All subjects will be recently diagnosed with hepatocellular carcinoma as defined by at least one of the following criteria:~Subject has a ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance by MRI and/or CT.~Subject has a lesion of any size indicated to be HCC due to capsule appearance by 4 phase CT scan and/or multiphase contrast enhanced MRI.~Subjects with a suspicious lesion of less than 2 cm must have HCC confirmed by both MRI and CT.~Subject has a biopsy that is positive for HCC.~Diagnostic imaging by multiphasic MRI or CT indicates a suspicious lesion on the liver, which is subsequently confirmed to be HCC by another method (biopsy, or surgical pathology)."
32725962|NCT05059665||Surveillance Subjects|At-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC.
32725963|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
32725964|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
32725965|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
32725966|NCT04909905|Experimental|Group EN (standard enteral nutrition)|Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission
32927715|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
32927716|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
32927717|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
32927718|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
32725967|NCT04909905|Experimental|Group GN (glutamine supplemented enteral nutrition)|Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.
32725968|NCT05057091|Experimental|Lomber Roll techniques group|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
32927719|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
32927720|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
32725969|NCT05057091|Experimental|Posterior- anterior central vertebral manipulation techniques group|Another technique that we will use as a specific vertebral manipulation technique will be Maitland's posterior-anterior central vertebral manipulation and posterior - anterior unilateral central vertebral mobilization technique.
32927721|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
32927722|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
32927723|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
32927724|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
32725970|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
32725971|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
32725972|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
32725973|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
32725974|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
32725975|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
32725976|NCT01301807|Experimental|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
32725977|NCT04962893|Experimental|VLP-Wuhan group (Group V1)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
32725978|NCT04962893|Experimental|VLP-Alpha (British) variant group (Group V2)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
32725979|NCT04962893|Experimental|VLP-Wuhan+Alpha group (Group V3)|"110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.~Initial vaccination with Wuhan followed by a booster of Alpha variant."
32725980|NCT02521571|Experimental|Intervention Group|
32725981|NCT02521571|Placebo Comparator|Control Group|
32725982|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
32725983|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
32927725|NCT03110471||Neuadd Drymmau Care Home|As above
32927726|NCT03110471||Monkstone House,|As above
32927727|NCT03110471||Danygraig House|As above
32927728|NCT03110471||Ty Coch|As above
32927729|NCT03110471||Swn y mor|As above
32927730|NCT03110471||Hengoed court|As above
32927731|NCT03110471||Hengoed park|As above
32927732|NCT03110471||Cefn Lodge care home|As above
32927733|NCT02957357||National Cancer Data Base|Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
32927734|NCT02957357||NC ProCESS|The North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) is a prospective population-based cohort of >1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
33073474|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
33073475|NCT01617395||GEMS cohort|Individuals at risk for developing MS
33250708|NCT05157022|Sham Comparator|Sham extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
33250709|NCT00877149|Experimental|A|
33400678|NCT05420220|Experimental|KN046+Axitinib|Eligible subjects will receive KN046 5 mg/kg Q3W IV in combination with Axitinib 5 mg bid po, until progressive disease as judged by the investigator per RECIST v1.1
33400679|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
32725984|NCT04937543|No Intervention|No intervation|patients receiving standart of care
32725985|NCT04937543|Active Comparator|Experimental intervation one|patients receiving standart of care + inhaled beclometasone
32725986|NCT04937543|Active Comparator|Experimental intervation two|patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
32905641|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
32905642|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
32905643|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
32905644|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
32905645|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
32905646|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
32905647|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
32905648|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
32905649|NCT00890162|Active Comparator|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
32905650|NCT00890162|Placebo Comparator|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
32905651|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
32905652|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
32905653|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
32905654|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
32905655|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
32905656|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
32905657|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
32905658|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
32905659|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
32905660|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
32905661|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
32905662|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
32905663|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
32905664|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
32905665|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
32905666|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
32905667|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
32905668|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
32725987|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.~To achieve the blood pressure target, fluid or vasoactive substances will be used."
32725988|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
32725989|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
32725990|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
32725991|NCT04928105|Experimental|CD7 CAR-T|
32725992|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
32725993|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
32725994|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
32725995|NCT04923737|Active Comparator|Dexmedetomidine group|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
33073476|NCT01617395||Healthy volunteer cohort|healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
33073477|NCT01617395||MS patient cohort|MS patients whose first-degree relatives are enrolled in this study
32725996|NCT04923737|Placebo Comparator|Control group|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
32725997|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 33 enrolled)"
32725998|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
32725999|NCT04921943|Experimental|Hypertonic saline|Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.
32726000|NCT04921943|Active Comparator|Standard of Care|Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.
32726001|NCT04915859|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
32726002|NCT04915859|Placebo Comparator|No Intervention|"Participants will participate in passive cooling where they sit in a chair during rest"
32726003|NCT04904471|Experimental|Experimental|Three doses of recombinant SARS-CoV-2 vaccine (Sf9 Cell) on Day 0, Day 21and Day 42.
32726004|NCT04904471|Placebo Comparator|Placebo Comparator|Three doses of placebo on Day 0, Day 21and Day 42.
32726005|NCT04926662||Aim 1: Focus Groups|Focus groups will be conducted in 2 New Hampshire and 2 Vermont towns to better understand patient knowledge, attitudes, and preferences regarding access to lung cancer screening.
32726006|NCT04926662||Aim 2: Cross Sectional Survey|Based on focus group feedback, the investigators will visit each proposed site to survey on 2 separate dates to confirm days and times of high traffic. The investigators will also survey patrons at the proposed locations to further determine prospective patient mobile screening preferences and evaluate willingness to participate in screening.
32726007|NCT04926662||Aim 3: Survey with follow up data|The investigators will pilot mobile lung cancer screening clinics at each chosen location using the knowledge acquired from focus group experience and local patient survey. Surveys will be conducted at these clinics, and patients will be followed for up to 5 years.
32726008|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
32726009|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
32726010|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
32726011|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
32726012|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
32726013|NCT05190575|Experimental|TST001|Drug: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
32726014|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
32726015|NCT05188157|Other|control group|conventional physiotherapy
32726016|NCT05188157|Experimental|mirror therapy group|conventional physiotherapy and mirror therapy
32726017|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
32726018|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
32927735|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
32726019|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
32927736|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
32927737|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
32927738|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
32726020|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
32927739|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
32927740|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
32927741|NCT03114683|Experimental|IBI308|
32927742|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
32927743|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
32927744|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
32726021|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
32726022|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
32927745|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
32927746|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
32927747|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
32726023|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
32726024|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
32726025|NCT03442361||Intralipid|Standard soybean oil-based therapy
32726026|NCT03442361||Clinoleic|Olive oil based therapy
32927748|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
32927749|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
32927750|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
32927751|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
32726027|NCT03442283||Supplementation|
32726028|NCT03442283||No Supplementation|
32726029|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
32726030|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
32726031|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
32726032|NCT03442205|Experimental|Group A|
32726033|NCT03442205|Experimental|Group B|
32726034|NCT03442205|Experimental|Group C|
32726035|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
32726036|NCT03447197|No Intervention|Off-Pump|
32726037|NCT03442127|Other|Patient Group|Program users
32726038|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
32726039|NCT02521805|Experimental|PAF|Animal protein added fiber
32927752|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
32927753|NCT02039726|Experimental|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
32927754|NCT02039726|Active Comparator|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
32927755|NCT03036293|Experimental|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
32927756|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
32927757|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
32927758|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
32927759|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
32927760|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
32726040|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
32726041|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
32726042|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
32726043|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
32726044|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
32726045|NCT03442049|Active Comparator|Control Group|Home exercise program
32726046|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
32726047|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
32726048|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
32726049|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
32927761|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
32927762|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
32927763|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
32726050|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
32726051|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
32726052|NCT02427464|Experimental|Engensis (VM202)|"Subjects randomized to the Engensis (VM202) treatment arm received the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 / calf~Day 14 - 16 injections of 0.5mL of VM202 / calf~Day 90 - 16 injections of 0.5mL of VM202 / calf~Day 104 - 16 injections of 0.5mL of VM202 / calf"
32726053|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group received the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
32726054|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
32726055|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
32726056|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
32726057|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32726058|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32927764|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
32927765|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
32927766|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
32927767|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
32927768|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
32927769|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
32927770|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
32726059|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32726060|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32726061|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32927771|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
32726062|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
32726063|NCT02426684|Experimental|IdeS®|Twenty patients will receive 0.24mg/kg (n=20)
32726064|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
32726065|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
32726066|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
32726067|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
32726068|NCT04884191|Experimental|Pacritinib 100 mg QD|
32726069|NCT04884191|Experimental|Pacritinib 100 mg BID|
32726070|NCT04884191|Experimental|Pacritinib 200 mg BID|
32726071|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
32726072|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
32726073|NCT05164835|Experimental|Experimental|
32927772|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
32726074|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
32726075|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
32927773|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
32927774|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
32927775|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
32927776|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
32927777|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
32927778|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
32927779|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
32726076|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
32726077|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
32726078|NCT05159063||Right heart catheterization|
32726079|NCT05156567||routine physicians|
32726080|NCT05156567||DLS|
32726081|NCT05370170|No Intervention|Routine antenatal care|the control group will receive routine antenatal care and will not receive the guidelines group included 30 cases
32726082|NCT05370170|Experimental|Ottawa guidelines|study group will receive routine antenatal care in addition to the Ottawa nutritional guidelines group included 30 cases
32726083|NCT05144789|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
32726084|NCT05144789|Active Comparator|Active TBS-DMPFC|The active group will receive theta-burst TMS stimulation.
32927780|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
32927781|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
32927782|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
32927783|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
32927784|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
32726085|NCT05144789|Sham Comparator|Sham TBS-DLPFC or DMPFC|The sham group will receive sham theta-burst TMS stimulation.
32726086|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
33400680|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
32726087|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
32726088|NCT04881149|Experimental|All Study Participants|The TempSure will be used on the flanks during this study. Subjects will receive 1 biopsy in the treatment area on the flank. Subjects will also receive 1 biopsy sample on the contralateral side, where they did not receive treatment. Each subject had 1 control sample (tissue that was taken from an area where no treatment was received), and 1 treatment sample (tissue taken from an area that had been subjected to the treatment).
32726089|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
32726090|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
32726091|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
32726092|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
32726093|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
32726094|NCT04841291|Experimental|Virtual Simulation-Based Arm|Access virtual simulation-based diabetes foot care education once for 30 minutes plus the standard care.
32726095|NCT04841291|No Intervention|Standard Care Arm|Participants will continue utilizing the usual follow-up diabetes care which occurs every month.
32927785|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
32927786|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
32927787|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
32927788|NCT04737005|Other|Nano-ceramic hybrid (Grandio Blocs) Endo-crown.|Nano-ceramic hybrid ( intervention)
32927789|NCT04737005|Active Comparator|Lithium di-silicate Ceramic (E.max CAD blocks) Endo-crown|Lithium di-silicate Ceramic ( Control)
32927790|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
32726096|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
32726097|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
32726098|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
32927791|NCT03038867|Placebo Comparator|Placebo|Placebo
32927792|NCT03039179|Experimental|Polyurethane foam|
32927793|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
32927794|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
32927795|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
32927796|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
32927797|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
32927798|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
32927799|NCT03119831|Experimental|C31G (Group A)|C31G
32927800|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
32927801|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
32927802|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
32927803|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
32927804|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
32927805|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
32927806|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
32726099|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
32726100|NCT05116397|Experimental|4% CO2|Inspired gas containing 4% CO2, 21% O2, balance N2
32726101|NCT05116397|Experimental|2% CO2|Inspired gas containing 2% CO2, 21% O2, balance N2
32726102|NCT05116397|Sham Comparator|0% CO2|Inspired gas containing 0% CO2, 21% O2, balance N2
32726103|NCT02657343|Experimental|Cohort A: Ribociclib + T-DM1 [3+3 Design]|"Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. During dose escalation, patients received doses of ribociclib of Period 1: 300 mg (n = 3), Period 2: 400 mg (n = 3), Period 3: 500 mg (n = 3), and Period 4: 600 mg (n = 3). Maximum dose-escalation of Ribociclib will be up to 600 mg. Dose-escalation will stop if DLT exceed limit.~T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time."
32726104|NCT02657343|Experimental|Cohort B: Ribociclib + Trastuzumab [Phase 1b/2 Study]|"Ribociclib will be given orally once day (400 mg per day on a continuous schedule) for a 21-day cycle of treatment.~Trastuzumab will be given as IV infusions over 6 mg/kg every 3 weeks."
32726105|NCT02657343|Experimental|Cohort C: Ribociclib + Trastuzumab + Fulvestrant [Phase 1b/2 Study]|"Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle).~Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care."
32726106|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
32726107|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
32726108|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
32726109|NCT05107271||Chronic Liver Disease|
32726110|NCT05107271||Post Liver Transplantation|
32726111|NCT05105633|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
32726112|NCT05105633|Active Comparator|Standard Care (which may include intravenous Alteplase)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).
32726113|NCT04784091|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
32726114|NCT04784091|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
32726115|NCT03440645|Experimental|Family or Household Members|
32726116|NCT04552275|Other|HALT Cohort|Patients who develop HALT
32927807|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
32927808|NCT03124121|Other|Induction cohort|Golimumab induction therapy
32927809|NCT03124121|Other|Maintenance cohort|Golimumab maintenance therapy
32927810|NCT04333277|Experimental|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
33073478|NCT01575860|Experimental|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
33250710|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
32726117|NCT04552275|Other|Control Group|Patients who do not develop HALT
32726118|NCT04807673|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m^2 IV on Day 2 Q3W, and cisplatin 80 mg/m^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.~Surgery: McKeown esophagectomy"
32927811|NCT04333277|Placebo Comparator|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
32927812|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
32927813|NCT03041909|Experimental|Single Arm|Single Arm / open label
32927814|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
32927815|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
32927816|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
32927817|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
32726119|NCT04807673|Experimental|neoadjuvant chemoradiotherapy+ Surgery (114)|"neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.~Surgery: McKeown esophagectomy"
32927818|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
32726120|NCT04496817|Experimental|Enriched Egg Group|Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
32726121|NCT04496817|Placebo Comparator|Regular Egg Group|Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.
32726122|NCT04803383|Experimental|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
32726123|NCT04803383|No Intervention|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
32726124|NCT04453215|Experimental|test group|SLE patients treated with infrared laser irradiation
32726125|NCT04453215|Placebo Comparator|placebo group|SLE patients treated with red laser irradiation
32726126|NCT04453215|No Intervention|control group|no therapy group
33250711|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
33250712|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
32726129|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
32726130|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
32726131|NCT05084105||Cannabis Group|A total of 30 older (age 50-80 years) men and women who are using cannabis.
32726132|NCT05084105||Control Group|A total of 30 older (age 50-80 years) men and women who are not using cannabis.
32726133|NCT05061537|Experimental|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07263689 once a week for 4 doses
32726134|NCT05061537|Experimental|Combination dose escalation (Part 1B)|Participants will receive PF-07263689 intravenous (IV) once week for 4 doses in combination with sasanlimab subcutaneous (SC) once every 4 weeks
32927819|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
32927820|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
32927821|NCT00374777|Experimental|1|
32927822|NCT00374777|Experimental|2|
32927823|NCT00374777|Active Comparator|3|
33250713|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
32726135|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
32726136|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
32726137|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm C|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
32726138|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
32726139|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
32726140|NCT05060055|Experimental|Test Group|Customized healing abutment inserted in immediate implant placement in association with the use of a connective tissue graft.
32927824|NCT00374777|Placebo Comparator|4|
33250714|NCT05149846|Other|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
33250715|NCT05149846|No Intervention|Controll|No pre-conditioning, standard care
33250716|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
33250717|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
33250718|NCT05279248|Experimental|Group A|Participants in this arm will be simultaneously administrated with one dose of HPV 16/18 bivalent vaccine and one dose of MMR vaccine. six month later, they are going to receive a second dose of HPV 16/18 bivalent vaccine.
32927825|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
33250719|NCT05279248|Active Comparator|Group B|Participants in this arm will be receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months) first. After finished HPV vaccination, they are going to receive MMR vaccine at the 7th month.
32726141|NCT05060055|Active Comparator|Control Group|Customized healing abutment inserted in immediate implant placement.
32726142|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
32726143|NCT03445871|Active Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
32726144|NCT04581447|Experimental|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
32726145|NCT04581447|Other|Standard Care|"All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
32726146|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
32726147|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
32726148|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
32726149|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
32726150|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
32726151|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
32726152|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
32726153|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
32726154|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
32726155|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
32726156|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
32726157|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
32726158|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
32726159|NCT04452071||prepubertal|patients born in 2012-2011
32726160|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
32726161|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
32726162|NCT04724213|Other|Testing of reliability / validity of new questionnaire|
33250720|NCT05279248|Active Comparator|Group C|Participants in this arm will be receieve MMR vaccine first. One month later, they are going to receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months)
33250721|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
33250722|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
33250723|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
32927826|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33250724|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
32927827|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
32927828|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
32927829|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
33250725|NCT00877305|Placebo Comparator|CONTROL|Control
33250726|NCT04039659|No Intervention|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
32726169|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
32927830|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
32726170|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
32927831|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
33250727|NCT04039659|Active Comparator|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
33250728|NCT02715388|Experimental|Silicon oil removal 3D visualization|
33250729|NCT05119894|Experimental|Brexpiprazole LAI: Dose 1|
33250730|NCT05119894|Experimental|Brexpiprazole LAI: Dose 2|
33250731|NCT05119894|Experimental|Brexpiprazole LAI: Dose 3|
33250732|NCT05119894|Experimental|Brexpiprazole LAI: Dose 4|
32726171|NCT03445169|Experimental|Fasting|Belzutifan tablets taken after fasting
32726172|NCT03445169|Experimental|Non-Fasting|Belzutifan taken after eating a high calorie meal
32726173|NCT04418895|Experimental|Single Arm: Standard of Care|Investigator's choice of total neoadjuvant therapy (TNT) comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection; or neoadjuvant chemoradiation followed by surgical resection and then adjuvant chemotherapy.
32726174|NCT04715633|Experimental|PD-1 inhibitors plus VEGF inhibitors|Patients will be given 4 cycles of Camrelizumab (200mg iv every 3 weeks) plus Apatinib (250mg QD day1-14) before being evaluated for response.
32726175|NCT04236999|Experimental|YSLQQ group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Unplugged in its original name, but the adaptation made by the research team for Chile is called Yo Sé Lo Que Quiero (YSLQQ). 12 one-hour sessions taught once a week by class teachers, previously trained in a 3-day course. Each session will be delivered during the time of Orientation lessons."
32726176|NCT04236999|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
32726177|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
32726178|NCT04152915|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (semaglutide D, test formulation)
32726179|NCT04152915|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (semaglutide reference formulation)
32726180|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
32726181|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
32726182|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
32726183|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
32927832|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
32927833|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
32927834|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
32927835|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
32927836|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
32927837|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
32927838|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
32927839|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
33250733|NCT00877539|Experimental|PF-03526299|
32927840|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
32927841|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
32927842|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
32927843|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
32927844|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
32726184|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
32726185|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
32726186|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
32726187|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
32726188|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
32726189|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
32726190|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
32726191|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
32726192|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
32726193|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
32726194|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
32726195|NCT05082155|Experimental|Right sided catheter bupivacaine 0.25% and left sided catheter normal saline|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Bupivacaine 0.25 will be administered through the right-sided catheter while normal saline will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
32726196|NCT05082155|Experimental|Right sided catheter normal saline and left sided catheter bupivacaine 0.25%|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Normal saline will be administered through the right-sided catheter while bupivacaine 0.25% will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
32726197|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
32726198|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
32726199|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
32726200|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
32726201|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
32726202|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
32726203|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
32726204|NCT04913493|No Intervention|Control group|Patients will only receive FloTrac/Vigileo monitoring which is standard of care.
32726205|NCT04913493|Experimental|Experimental group|Patients will receive an additional medical imaging intervention. Namely sublingual microcirculation imaging with Cytocam-IDF.
32927845|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
32927846|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
33250734|NCT00877539|Placebo Comparator|Placebo|
32726206|NCT04561401|Experimental|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
32726207|NCT04561401|Active Comparator|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
32726208|NCT04706039|Experimental|Outpatients without hospitalisation criteria|Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon
32726209|NCT04451369|No Intervention|Control group|Group without prehabilitation program before surgery
32726210|NCT04451369|Experimental|Prehabilitation group|Group will follows a prehabilitation program before surgery
32726211|NCT04402515||Tiotropium plus Olodaterol treatment regimen|
32726212|NCT04402515||Inhaled corticosteroids-containing treatment regimen|
32726213|NCT04451447|Experimental|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
32726214|NCT04451447|Other|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
32726215|NCT04516941|Active Comparator|Edoxaban|Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
32726216|NCT04516941|Active Comparator|Colchicine|Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days).
32726217|NCT04516941|No Intervention|No Edoxaban and No Colchicine|No intervention
32726218|NCT04516941|Active Comparator|Edoxaban and Colchicine|"Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).~Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days)."
32726219|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
32726220|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
32726221|NCT04542837|Experimental|KN046 plus Lenvatinib|
32726222|NCT04451603||Surgical resection|
32726223|NCT04451603||Y-90 therapy|
32726224|NCT04451603||Systemic Therapy|
32726225|NCT04524585|Experimental|Partial NMB|
32726226|NCT04700579||TB Cases|"n= 50 (25 HIV positive and 25 HIV negative)~Xpert MTB/RIF Ultra-confirmed TB"
32726227|NCT04700579||Healthy Household Contacts|"n= (25 HIV positive and 25 HIV negative)~Culture negative TB result"
32726228|NCT04700579||Sick controls|"n=50~Diseases: Asthma, Chronic obstructive pulmonary disease (COPD), Cancer, Bronchiectasis (including post-TB) and Pneumonia"
32726229|NCT05072145||Non-tele-ED hospital|Patients receiving care in an ED that does not provide any tele-ED service
32726230|NCT05072145||Tele-ED hospital|Patients receiving care in an ED that uses tele-ED services, but patient care did NOT utilize this service
32726231|NCT05072145||Tele-ED used|Patient care was provided through tele-ED services
32726232|NCT04019145|Experimental|Fiber Reinforced bulk fill resin composite|Fiber reinforced bulk fill resin composite dentine substitute, capped occlusally and proximally (closed centripetal technique) by nanohybrid resin composite.
32726233|NCT04019145|Active Comparator|nanohybrid resin composite incrementation|Nanohybrid resin composite layering to fill the whole cavity, using closed centripetal technique.
32726234|NCT03444389||Study group|Patients with hemorrhoids
32726235|NCT03444389||Control group|Healthy participants without hemorrhoids
32726236|NCT03966495||PRisM program|"Pluriprofessional primary care offices with the PRiSM RM program:~Nine of the pluriprofessional primary care offices which implemented the RM program tested in the PRiSM study (2015-2017). The program consisted in: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent in the office; 3) The conduct of six incident review meetings.~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
32726237|NCT03966495||Control|"Pluriprofessional primary care offices without the PRiSM RM program:~Nine of the offices pluriprofessional primary care offices which didn't implement the RM program tested in the PRiSM study (2015-2017). They belonged to the PRisM study control group.~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
32726238|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
32726239|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
32726240|NCT04663529||CLADE|contact lens wearers with DED
32726241|NCT04663529||non-CLADE|DED without contact lens wear
32726242|NCT04663529||NC|normal control
32726243|NCT05073731|Experimental|Synchronized Telerehabilitation|Physical activity training aiming to increase hand/arm function and fine motor function will be applied via videoconference for 8 weeks, 2 days a week, in 45-60 minute sessions.
32726244|NCT05073731|Active Comparator|Asynchronous Telerehabilitation|Exercise videos and exercise tracking form will be sent.
32726245|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
32726246|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
32726247|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
32726248|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
32726249|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
32726250|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
32726251|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
32726252|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
32726253|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
32726254|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
32726255|NCT03439163||PD patients|the entire group underwent MRI scan
32726256|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
32726257|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
32726258|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
32726259|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
32726260|NCT03890133|Experimental|Ba-Duan-Jin group|The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital; Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks.
32726261|NCT03890133|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
32726262|NCT03890133|No Intervention|Healthy control group|
32726263|NCT03871647||POAF group|Patients who will experience AF at any time during the first six days after the operation.
32726264|NCT03871647||Non POAF group|Patients with a sinus rhythm during the first six days after the operation.
32726265|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
32726266|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
32726267|NCT03781245|Experimental|Early|Intervention is administered for cycle 1 and 2 with researchers and following this the company continues intervention independently.
32726268|NCT03781245|Active Comparator|Lagged|Intervention is not administered for cycle 1; researchers administer intervention in cycle 2 and following this the company continues intervention independently.
32726269|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
32726270|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
32726271|NCT04304703||Internal Medicine resident subjects|Subjects who are categorical Internal Medicine residents at Penn State Hershey Medical Center (PGY1-PGY3), and meet inclusion/exclusion criteria, will be enrolled in this study and wear the WHOOP strap 3.0 for real-time measurement of physiologic metrics.
32726272|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
32726273|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
32726274|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
32726275|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
32726276|NCT04240587|Active Comparator|TrueTear™ intranasal neurostimulator (ITN) Active Arm|TrueTear™ intranasal neurostimulator (ITN) with active tips - The tips carry the current from the base to the nasociliary nerve.
32726277|NCT04240587|Placebo Comparator|TrueTear™ intranasal neurostimulator (ITN) Placebo/Sham Arm|"TrueTear™ intranasal neurostimulator (ITN) with sham tips - The sham tips and do not properly carry the current."
32726278|NCT04655651||Frailty|patients with a FRAIL Scale of 3 to 5
32726279|NCT04655651||Non-frailty|patients with a FRAIL Scale of 0 to 2
32726280|NCT03756753|Experimental|Intervention group- results known|Providers of patients enrolled in this arm of the study will be notified of the point of care respiratory testing results
32726281|NCT03756753|No Intervention|Control group- results not known|Providers of patients enrolled in the study will not be notified of the point of care respiratory testing results
32726282|NCT03438305||Group D|
32726283|NCT03438305||Group N|
32927847|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
32726284|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
32726285|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
32726286|NCT03714633|Experimental|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Home-based post-discharge intervention for extreme premature babies and their parents. The intervention consists of one hospital visit, nine home-visits and two telephone calls during the first year corrected age, specifically from one week before discharge to 12 months corrected age. The intervention is strengths-based working with the infant-parent interaction, supporting infant development and strengthening the parent in his/her role.
32726287|NCT03714633|No Intervention|Control|The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
32726288|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
32726289|NCT04318197|Active Comparator|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
32726290|NCT04318197|Experimental|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
32726291|NCT04318197|No Intervention|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
32726292|NCT03438617|Experimental|Peer Support Intervention|9 CHCs will receive the peer support intervention for the full duration of the study period (12 months). Baseline assessment, 12-month and 18-month evaluation to assess the effectiveness and sustainability of the intervention.
32726293|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
32726294|NCT04633187|Experimental|EDP-938|
32726295|NCT04633187|Placebo Comparator|Placebo|
32726296|NCT04006509|Experimental|Antenatal Education Group|Patients will receive a prenatally delivered lactation educational program.
32726297|NCT04006509|No Intervention|Standard of Care Group|Patients will receive standard of care and not a prenatally delivered lactation educational program.
32726298|NCT03457935||Control|No lung diseases
32726299|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
32726300|NCT03457935||IPF|Naive patients with no IPF treatment
32726301|NCT04646213|Experimental|Therapy|psychotherapeutic intervention
32726302|NCT03944811|Active Comparator|Transcrestal sinus floor elevation using Summers technique|
32726303|NCT03944811|Experimental|Transcrestal sinus floor elevation using piezoelectric surgery|
32726304|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
32768530|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
32768531|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
32768532|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
32768533|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
32768534|NCT04622917|Active Comparator|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
32768535|NCT04622917|Placebo Comparator|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
32768536|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
32768537|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
33250735|NCT00877539|Active Comparator|Fluticasone propionate|
32927848|NCT02975297|Placebo Comparator|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
32927849|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
32927850|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
32927851|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
32927852|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
32726305|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
32726306|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
32726307|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
32726308|NCT04512339|Active Comparator|Dupilumab|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
32726309|NCT04512339|Placebo Comparator|Placebo|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive placebo injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
32726310|NCT03835923|Experimental|lifestyle intervention|Telemedicine-supported lifestyle intervention trough individual structured exercise training (endurance and strength training), increase in daily physical activity, and individual nutritional recommendations
32726311|NCT03835923|Active Comparator|usual care|general exercise and nutritional recommendations according to current guidelines
32726312|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
32726313|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
32726314|NCT03783351|No Intervention|Conventional Therapy|Patients randomized to the Conventional Therapy arm will receive either clopidogrel or ticagrelor, according to the clinical and procedural characteristics of patients. CYP2C19 genotyping will be performed at the end of study.
32927853|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
32927854|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
32927855|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
32927856|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
32927857|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
32927858|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
32927859|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927860|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927861|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927862|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927863|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927864|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927865|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
32927866|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
32927867|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
32927868|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
32927869|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
32927870|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~Not demented"
33073483|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT) and have not been treated with antibiotics in the last 30 days.
33250736|NCT04039737|Experimental|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
33250737|NCT04039737|No Intervention|Control Group|
32726315|NCT03783351|Active Comparator|CYP2C19 Genotyping|CYP2C19 genotyping will be performed within 48 hours after randomization. CYP2C19 *2 or *3 reduced function allele patients will receive ticagrelor 90 mg bid, whereas non-*2 or -*3 CYP2C19 patients will receive clopidogrel 75 mg once daily.
32726316|NCT03438071||Control group|
32726317|NCT03438071||Videoconference group|
32927871|NCT03134963||Alzheimer disease|"NIA/AA criteria~Meets the criteria for dementia~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~Insidious or gradual onset~Clear history of worsening cognition by report or observation~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~Amnestic: impaired learning and recall of recently learned information~Non amnestic: language/visuospatial/executive dysfunction"
32927872|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~One or more of:~Onset of dementia within 3 months of a diagnosed stroke~Abrupt deterioration in cognitive function~Fluctuating, stepwise progression of cognitive deficits"
32927873|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~No evidence of subjective or objective memory impairment on cognitive testing~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
32927874|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
32726318|NCT03342417|Experimental|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
32726319|NCT03342417|Experimental|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
32726320|NCT03342417|Experimental|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
32927875|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
32726321|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
32927876|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
32726322|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
32726323|NCT03244995|Experimental|Group I (CBMB program)|Patients undergo CBMB program consisting of 4-5 deep-breathing and meditation exercise sessions over 60 minutes and 2 weekly telephone calls over 15 minutes for 6 weeks. Patients also complete questionnaires regarding health, mood, sleeping habits, relationship, health care, work productivity, and quality of life.
32726324|NCT03244995|Active Comparator|Group II (waitlist control)|Patients complete questionnaires as in Group I. Patients may undergo CBMB program after completion of study.
32726325|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
32927877|NCT02412956|No Intervention|Control|pamphlet
32927878|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
32927879|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
32927880|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
32927881|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
32927882|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
32927883|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
32927884|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
32927885|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
32927886|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
33231705|NCT04102566|No Intervention|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~The standard of care group will get the following prescriptions on discharge:~Oxycodone 5mg every 4 hours as needed pain - 15 tabs~Acetaminophen 1000mg every 8 hours standing for two days then as needed~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
32726326|NCT03234309|Experimental|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
32726327|NCT04515459|Other|Patients treated for bone or soft-tissue sarcoma of the limbs|
32927887|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
32927888|NCT04737473|Experimental|Opiod Free Anesthesia (OFA) group|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
32927889|NCT04737473|Active Comparator|General anesthesia (GA) group|The GA protocol described in the intervention arm
32927890|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
32726328|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
32726329|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
32726330|NCT03830931||Primary knee arthroplasty patients|Fasting Plasma Glucose test will be obtained the morning after surgery and the frequency of hyperglycemia in non diabetic and diabetic patients will be evaluated
32726331|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
32927891|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
32927892|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
32927893|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
32927894|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
32927895|NCT04707287||Breast Cancer Patients|All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
32927896|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
32927897|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
32927898|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
32927899|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
32726332|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
32726333|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
32726334|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
32726335|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
32726336|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
32726337|NCT04944953|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®) 100 Unit
32726338|NCT04944953|Experimental|Botulinum toxin type A(HG-102)|Botulinum toxin type A(HG-102) 100 Unit
32726339|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
32726340|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
32726341|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
32726342|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average >3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
32927900|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
32927901|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
32726343|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants will take ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone will not be defined by the protocol but according to the package insert of each drug.
32726344|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
32927902|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
32927903|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
32927904|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
32927905|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
32927906|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
32726345|NCT03437525|No Intervention|Control|Usual care
33250738|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
32726347|NCT03797469|Active Comparator|Nicotinamide and Pyruvate (N&P)|This group will receive two separate sets of tablets containing 3 x 1000 mg of Vitamin B3 (nicotinamide) and 2 x 1500 mg of Pyruvate.
33250739|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
33250740|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
33250741|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
33250742|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
33250743|NCT00872313||1|Psychoses within the first 3 months postpartum
33250744|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
33250745|NCT00877617||QOL Questionnaire|
33250746|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
32927907|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
32726348|NCT03797469|Placebo Comparator|Placebo|This group will receive an equal number of tablets as the N&P group.
32726349|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
32927908|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
32927909|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
33400681|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
32927910|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
32927911|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
33400682|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
32726350|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
32726351|NCT03294993|Experimental|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
32742994|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
32927912|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
32927913|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
32927914|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
32927915|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
32927916|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
32927917|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
32927918|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
32927919|NCT03141281|Experimental|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
32927920|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
32927921|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
32927922|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
32927923|NCT03144089|Active Comparator|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
32927924|NCT03144089|Experimental|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
32927925|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
32927926|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
32927927|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
33400683|NCT05383560|Experimental|mRNA-1273.214 + mRNA-1273.214|Fourth & Fifth doses of an investigational mRNA vaccine, 56 days apart N ≈ 60
33400684|NCT05383560|Experimental|mRNA-1273.214 + Placebo|Fourth dose of an investigational mRNA vaccine followed by a fifth dose of placebo, 56 days apart N ≈ 60
32927928|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
32927929|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
32927930|NCT05719298|Experimental|Respiratory interface|Use of the new respiratory interface and accessories to deliver non-invasive therapy
32927931|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
32726352|NCT04534829|Experimental|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
32726353|NCT04534829|Active Comparator|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
32726354|NCT02809989||Ovaleap®|Single group prospective treatment cohort
32726355|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
32726356|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
32726357|NCT04435899|Experimental|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
32726358|NCT04435899|Experimental|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
32726359|NCT04435899|Experimental|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
32742995|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
32742996|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
32927932|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
32927933|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
32927934|NCT05719220||Group preoperative pelvic floor training|Patients will receive group preoperative PFT, 4 weeks prior to HoLEP.
32927935|NCT05719220||No preoperative pelvic floor training|The control group will receive standard care, which may include patient education about postoperative care and pelvic floor muscle exercises, but will not receive structured group PFT.
32927936|NCT00354692|Experimental|Experimental|
32927937|NCT03146585||Patients on artificial ventilation|
32927938|NCT03146585||Patients on renal replacement therapy|
32927939|NCT03146585||Patients with targeted temperature management|
32927940|NCT05719142|Experimental|Sweet Food (SW)|Exposure to pictures of sweet food.
32927941|NCT05719142|Experimental|Savoury Food (SA)|Exposure to pictures of savoury food.
32927942|NCT05719142|Experimental|Non-Food (NF)|Exposure to pictures of non-food items.
32927943|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
32927944|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
32927945|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
32927946|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
32927947|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
32726360|NCT04435899|Experimental|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
32726361|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
32927948|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
32927949|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
32927950|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
32927951|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
32927952|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
32726362|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
32726363|NCT02616081||Clean Intermittent Catheterization|Participants performing intermittent catheterization of their bladder, having not had augmentation cystoplasty or creation of a catheterizable channel
32927953|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
32927954|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
32927955|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
32927956|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
32726364|NCT02616081||Indwelling Catheter|Participants utilizing an Foley catheter or a suprapubic tube (cystostomy)
32726365|NCT02616081||Surgery|Undergoing any of the following surgeries: augmentation cystoplasty with or without a catheterizable channel, creation of catheterizable channel alone, urinary diversion (conduit or continent catheterizable pouch)
32726366|NCT02616081||Voiding|Participants with volitional control, voiding into diapers or a condom catheter via crede, valsalva, or spontaneous leakage
32726367|NCT04515095|Experimental|Water-only Fasting Group|Participants who voluntarily elect and are approved to water-only fast.
32726368|NCT02565537|Active Comparator|iDesign WFG LASIK|Wavefront-guided LASIK
32927957|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
32927958|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
32927959|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
32927960|NCT05719064|Experimental|Adaptive Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources) and responsive human coaching (phone calls, test messages, in-app messaging) to improved medication adherence.
32927961|NCT05719064|Experimental|Computer-Delivered Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources)
32927962|NCT05719064|Active Comparator|Automated Text Reminders|Scheduled one-way text automated message reminders to take medication
32927963|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
32927964|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
33073488|NCT01498276||General population|Members of the general population
33073489|NCT01498276||Members of under-resourced communities|Participants recruited from under-resourced communities in the Washington, DC area AND in the Southeastern US
32927965|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:~suicide risk assessment~supportive listening~provision of professional and crisis contact information~referral to mental health treatment and community resources~verbal contract for safety"
33400685|NCT05383560|Active Comparator|mRNA-1273 + Placebo|Fourth dose of the commercial mRNA vaccine, followed by a fifth dose of placebo, 56 days apart N ≈ 30
32927966|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
32927967|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify reasons for living~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
32927968|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
32927969|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
32927970|NCT03858205|Experimental|Treatment (low-dose radiation therapy)|Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.
32927971|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
32927972|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
32927973|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
32927974|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
32726369|NCT02565537|Active Comparator|Wavelight WFO LASIK|Wavefront-optimized LASIK
32726370|NCT02384577||Single group prospective treatment|
32726371|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
32726372|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
32726373|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
32726374|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
32726375|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
32726376|NCT02215941|Experimental|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
32726377|NCT02215941|Experimental|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
32726378|NCT02215941|Experimental|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
32726379|NCT02215941|Placebo Comparator|Placebo|
32726380|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
32726381|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
32726382|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
32726383|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
32726384|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
32726385|NCT02030457|Experimental|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
32726386|NCT02030457|Experimental|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
32726387|NCT02030457|Experimental|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
32927975|NCT02042911|Experimental|SyB L-0501|
32927976|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
32927977|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
33400686|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
33400687|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
33400688|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
32726388|NCT03991247|Experimental|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
32726389|NCT03991247|Active Comparator|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
32726390|NCT01847859|Experimental|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
32742997|NCT04947267|Experimental|3% mepivacaine|3% mepivacaine was administered via inferior alveolar nerve block.
32742998|NCT04947267|Active Comparator|2% mepivacaine with 1:100,000 epinephrine|2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
33073496|NCT01445509|Experimental|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
33073497|NCT01445509|Experimental|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
33073499|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
33073500|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
33073501|NCT01443468||3|Unaffected family members.
33073502|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
33073503|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
33073504|NCT01434368||children age 8-17 years admitted to pilot brain imaging studies|children age 8-17 years admitted to pilot brain imaging studies
33073505|NCT01434368||healthy adults|healthy adults ages 25 - 35 years at the time of enrollment
33073506|NCT01434368||typically developing children (with evidence of advanced bone age|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
33073507|NCT01434368||typically developing children ages 12/13 17 years|typically developing children ages 12 or 13 - 17 years
33073508|NCT01434368||typically developing children ages 8 17 years|typically developing children ages 8 - 17 years
33073509|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
33073510|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions.
33073511|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
33073512|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
33073513|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
33073514|NCT01419561|No Intervention|1|Evaluation for Alternative Causes of KICS Symptoms
33073515|NCT01419561|No Intervention|2|Natural History/Observation Arm
33073516|NCT01419561|Experimental|3|High dose zidovudine + valganciclovir
33073517|NCT01419561|Experimental|4|Rituximab with or without liposomal doxorubicin
33073518|NCT01419561|Other|5|Standard and alternative rational therapies
33073519|NCT01416831|Active Comparator|Arm A: IL-2 Monotherapy|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2. Crossover patients will be included in Arm A.
33073520|NCT01416831|Experimental|Arm B: SBRT + IL-2|Patients will receive two doses of radiation before receiving high-dose IL-2.
33073521|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
33400689|NCT02642562|No Intervention|Standard care|Participants in this arm will receive their usual care
33400690|NCT02642562|Experimental|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000 / ferric derisomaltose.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb <10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg."
33400691|NCT03623204||Patients with bariatric surgery for obesity|
32726391|NCT04514133|Experimental|Action Civics program|Students in this arm will take part in an Action Civics (AC) program. AC delivers action civics programming to young people from diverse backgrounds nationwide. AC offers a school-based action civics curriculum in which classes collectively choose a local issue, learn strategies and skills for taking civic action, develop an action plan, and take action on their selected local issue. Students, as a class, tackle topics ranging from health-related (e.g., health of school lunches) to safety-related (e.g. lack of crosswalks) to community social issues (e.g., community-police relations).
32927978|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
32726392|NCT04514133|No Intervention|No Action Civics program|Students in this arm will receive no intervention.
32726393|NCT03437135||Witness patients|Healthy Volunteers
32726394|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
32726395|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
32726396|NCT04514055|Experimental|De-epithelialized connective tissue graft wall|"Simplified papilla preservation flap will be applied in the narrow interproximal spaces (≤2 mm), where an oblique incision starting from the gingival margin at the buccal-line angle of the involved tooth reaching the mid-interproximal portion of the papilla under the contact point of the adjacent tooth will be performed using a 15c blade.~A free gingival graft will be obtained from the hard palate and de-epithelized extra-orally.~A Coronally advanced flap will be performed. The de-epithelialized FGG will be sutured coronally using a 6-0 vicryl suture to the anatomical papillae of the two teeth adjacent to the defect and apically to the periosteum left in place apical to the exposed bone.~The flap will be sutured using internal Horizontal mattress suture at the base of the simplified papilla and a vertical mattress suture will be placed in a more coronal position so complete soft tissue closure can be obtained."
32726397|NCT03980405|Experimental|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
32726398|NCT03980405|Experimental|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
32726399|NCT04685109|Experimental|Alocross|Cross-linked HA 0.2% + Aloe Vera 0.1% solution (N=40) Posology: One Drop in each eye 4 times daily for 84 days
32726400|NCT04685109|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
32726401|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
32726402|NCT03437057|Experimental|Patients treated with acethylsalicylic acid 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
32726403|NCT03579693|Active Comparator|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
32726404|NCT03579693|Active Comparator|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
32726405|NCT03579693|Placebo Comparator|Placebo|Placebo, inactive sugar pill for 6 weeks
32726406|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
32726407|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
32726408|NCT02991807|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
32726409|NCT02991807|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
32726410|NCT04470869|Experimental|OLAF group|The interventional group (OLAF) benefit from a psychiatric follow up, from virtual visiting of the patient and video interview with ICU team.
32742999|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
32743000|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
32927979|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
32927980|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
32927981|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
32927982|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
32927983|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
33400692|NCT04601610|Experimental|Cohort 1|Subjects who have not received first-line system treatment previously;
33400693|NCT04601610|Experimental|Cohort 2|Subjects who have received at least first-line system treatment
33400694|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
33400695|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.~Interventions: Strokefinder MD100 measurement"
32927984|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
32927985|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
32927986|NCT05405933|Experimental|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
32927987|NCT05405933|Experimental|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
32927988|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
33400696|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.~Interventions: Strokefinder MD100 measurement"
32927989|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
32927990|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
32927991|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
32927992|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
32927993|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
32927994|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
32927995|NCT02376530|No Intervention|Usual shopping|No change in condition.
33400697|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.~Interventions: Strokefinder MD100 measurement"
33400698|NCT03668912|Experimental|Guided participation group|
33400699|NCT03668912|No Intervention|Usual care group|
32726411|NCT04470869|Placebo Comparator|Control|The control group contains the relatives of patients hospitalized after the confinement measure but before the OLAF intervention. This group benefit from phone contact with the ICU team at the admission in ICU then two contact per week minimum to one contact per day maximum during the stay, excepting the specific phone calls associated with favorable or unfavorable evolution.
32726412|NCT05106933|Placebo Comparator|Plain water|Group A patient will be given 400cc of plain water, 2 hours prior to gastroscopy
32726413|NCT05106933|Experimental|Carborie|Group B patient will be given 400cc of carborie (carbohydrate drink), 2 hours prior to gastroscopy
32726414|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
32726415|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
32726416|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
32726417|NCT01331187|Active Comparator|Usual care|Usual care diagnostics. No routinely ultrasound examination
32726418|NCT01331187|Experimental|Routinely ulasonography|Patients will routinely be examined with ultrasound at admittance in addition to usual care diagnostics
32726419|NCT01081197||Out-day patients' clinic|Alcohol abusers referred to out-day patients' clinic which consent to participate in the study
32726420|NCT01081197||Control|Control group for the cardiac arm of the study will be matched controls from the Nord-Trøndelag Health Study (HUNT)
32927996|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
32726421|NCT04419857|Experimental|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
32726422|NCT04419857|No Intervention|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
32726423|NCT00845013||HIV Infection|HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures
32726424|NCT00829803|Experimental|SNAP Monitor EEG signals|
32726425|NCT00829803|Active Comparator|BIS Monitor EEG signals (VISTA)|
32726426|NCT05118321|Other|Refinement and Feasibility Trial|"It is intra - individual comparison study~Arm 1: participant wore the custom-made upper limb exosuit and hand exoskeleton to perform the series of tasks Arm 0: participant perform the same tasks without the custom-made upper limb exosuit and hand exoskeleton."
32927997|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
32927998|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
32927999|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
32928000|NCT03161327|Other|ABI|ABI will be performed in patient
32928001|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
32928002|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
32726427|NCT04380311|Experimental|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
32726428|NCT05018013|Active Comparator|Duloxetine group|The eligible subjects will receive duloxetine hydrochloride enteric-coated capsules plus placebo to Ammoxetine.
32726429|NCT05018013|Placebo Comparator|Placebo group|The eligible subjects will receive placebo to Ammoxetine and placebo to Duloxetine.
32726430|NCT05018013|Experimental|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
32726431|NCT05018013|Experimental|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
32928003|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
33400700|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
33400701|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
32928004|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
32928005|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
32928006|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
32928007|NCT05718986||Bnai Zion Medical Center|Bnai Zion Medical Center
32928008|NCT05718986||Tel Aviv Sourasky Medical Center - Ichilov Hospital|Tel Aviv Sourasky Medical Center - Ichilov Hospital
32928009|NCT05718986||Galil Medical Center|Galil Medical Center
32928010|NCT05718986||Ziv Medical Center|Ziv Medical Center
32928011|NCT05718986||Emek Medical Center|Emek Medical Center
32928012|NCT05718986||Beilinson Hospital|Beilinson Hospital
32928013|NCT05718986||Meir Medical Center|Meir Medical Center
32928014|NCT05718986||Kaplan Medical Center|Kaplan Medical Center
32928015|NCT05718986||Sheba Medical Center|Sheba Medical Center
32928016|NCT05718986||Rambam Medical Center|Rambam Medical Center
32928017|NCT05718986||Shaare Zdek Medical Center|Shaare Zdek Medical Center
32726432|NCT05018013|Experimental|Ammoxetine group-cohort 3|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
32726433|NCT05018013|Experimental|Ammoxetine group-cohort 4|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
32726434|NCT05118165|No Intervention|control group|
32726435|NCT05118165|Experimental|intervention group|
33400702|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
33400703|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
32726436|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
32726437|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
32928018|NCT05718986||Hadassah Medical Center|Hadassah Medical Center
32726438|NCT04678245|Experimental|Immediate Above the Influence-Vaping Intervention|School receives Above the Influence-Vaping (ATI-V) prevention program training after baseline assessment. Training and intervention continue over two school years (approximately 18 months). Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade).
32726439|NCT04678245|Active Comparator|Delayed Above the Influence-Vaping Intervention|Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
32726440|NCT02344485|Experimental|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
32726441|NCT02344485|No Intervention|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
32726442|NCT04364529|Experimental|Intervention (pit crew model group)|13 groups being taught the pit crew model
32928019|NCT05718986||Shamir Medical Center (Assaf Harofeh)|Shamir Medical Center (Assaf Harofeh)
32928020|NCT05718986||Soroka Medical Center|Soroka Medical Center
32928021|NCT05718986||Assuta Ashdod Hospital|Assuta Ashdod Hospital
32928022|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
32928023|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
32928024|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
32928025|NCT03069677|Active Comparator|Music group|research-selected music
32928026|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
33400704|NCT04584528|Other|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
32928027|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
32928028|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
32928029|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
32928030|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
32928031|NCT02044393|Experimental|Reference|single dose BI 691751
32928032|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
32928033|NCT05718830||patients with traumatic lung injury (TLI)|
32928034|NCT05718830||patients with inhalation injury (ILI)|
33400705|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
33400706|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
32726443|NCT04364529|No Intervention|control (traditional ALS education)|13 groups being taught along traditional ALS education
32726444|NCT04375397|Experimental|Ibrutinib 420 mg + SOC|420 mg ibrutinib administered once daily as three hard gelatin capsules (140 mg each) with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
32726445|NCT04375397|Placebo Comparator|Placebo + SOC|Three hard gelatin placebo capsules administered once daily with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
32726446|NCT05112471|Experimental|Guided Biofilm Therapy|Airflow with erythritol powder to remove supra and sub gingival biofilm and plaque, perioflow with erythritol powder at deep pathological pockets (PPD > 4mm) and ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus.
32726447|NCT05112471|Active Comparator|Scaling and Root Planning - Ultrasonic Debridement|Ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus, manual debridement with curettes at deep pathological pockets (PPD > 4mm) and rubber cup with polishing to remove supra gingival biofilm and plaque.
32726448|NCT05112393||Development Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to develop a new estimating Glomerular Filtration Rate (eGFR) equation that produce accurate eGFR specifically in Malaysian multiracial population.
32726449|NCT05112393||Validation Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to validate the newly developed estimating Glomerular Filtration Rate (eGFR) equation.
32726450|NCT05117697|Experimental|main group|Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.
32726451|NCT05117697|Experimental|control group|In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.
32726452|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
32726453|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
32743001|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
32743002|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
32743003|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
32928035|NCT05718830||health controls(HCs)|
32928036|NCT05405465||UC patients with exposure to golimumab|The investigators retrospectively analyzed all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
32928037|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
32928038|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
32928039|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
32928040|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
32928041|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
32928042|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
32928043|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
33400707|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
33400708|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
32928044|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
32928045|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
32928046|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
32928047|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
32928048|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
32928049|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
32726454|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
32726455|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
32726456|NCT04360421|Experimental|Intraoperative liposomal bupivacaine field block|Patients will receive the maximum dosage of liposomal bupivacaine allowed for their body weight or the full vial, whichever is less. Injected once, along the incision before closure of the skin.
32726457|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
32726458|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
32726459|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
32726460|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
32726461|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
32726462|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
32726463|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
32726464|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
32726465|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
32726466|NCT03941717|Experimental|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
32726467|NCT03941717|Sham Comparator|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, & Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, & Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
32743004|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
32928050|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
32928051|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
32928052|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
32928053|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
32928054|NCT05396027|No Intervention|Control Group|Participants (healthy or physically disabled) in the control group do not require to perform audio-guided deep breathing for 14 days continuously
32928055|NCT05396027|Experimental|Experimental Group with Audio-guided deep breathing|Participants (healthy or physically disabled) in the interventional group need to perform 5 mins audio-guided deep breathing with 6 deep breaths per minute for 14 days continuously
32928056|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
32928057|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
32928058|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
32928059|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
32928060|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
32928061|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
32928062|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
32928063|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
32928064|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
32928065|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
32928066|NCT05380583|Experimental|CRAFT-EP + TAU|Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) with 8 weekly sessions of 60-90-minute coaching + Treatment as Usual (TAU).
32928067|NCT05380583|Active Comparator|Treatment as Usual|Treatment as Usual
32928068|NCT00375557|Active Comparator|1|Quetiapine
32928069|NCT00375557|Active Comparator|2|Divalproex ER
32928070|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
32928071|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
32928072|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
32928073|NCT05282069|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
33400709|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
33400710|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
33400711|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
32928074|NCT05282069|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
32928075|NCT05282069|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
32928076|NCT05282069|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
32928077|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
33277372|NCT03956329|Experimental|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
33400712|NCT04546620|Active Comparator|Arm A Control|6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.
33400713|NCT04546620|Experimental|Arm B Experimental|1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.
32928078|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
32928079|NCT05159999|Experimental|Home Systolic Blood Pressure <140 mmHg|Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <140 mmHg.
33400714|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
33400715|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
33400716|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
33400717|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
33400718|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
33400719|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
33400720|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
33400721|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
33400722|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
33400723|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
32928080|NCT05159999|Active Comparator|Pre-Dialysis Systolic Blood Pressure <140 mmHg|Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of <140 mmHg.
32928081|NCT05159999|Other|Home Systolic Blood Pressure <130 mmHg|This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <130 mmHg.
32726468|NCT03929081|Experimental|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
32726469|NCT03929081|Active Comparator|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
32928082|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
32928083|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
32928084|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
32928085|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
32928086|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
32726470|NCT03929081|No Intervention|No intervention (healthy controls)|The healthy control group will receive no intervention.
32726471|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
32726472|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
32726473|NCT04899635||Diseased cardiac tissue|Heart muscle or cells (cardiomyocytes) will be obtained from patients undergoing cardiac surgery, namely coronary artery bypass grafting or for severe valvular heart disease.
32726474|NCT04899635||Healthy cardiac tissue|Healthy donor hearts from deceased individuals that are not transplantable due to technical reasons
32726475|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
32726476|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
32726477|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
32726478|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
32743005|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
32928087|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
32928088|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
32928089|NCT04737083||clubfoot fetuses|
32928090|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
32928091|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
32928092|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
32928093|NCT05141513|Other|Intra Operative Radiation Therapy (IORT) Group|The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy.
32928094|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
32928095|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
32928096|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
32928097|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
32928098|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
32928099|NCT05091047|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm laser application
32928100|NCT05718674||ECP patient|Patients with chronic or acute GvHD after allogeneic haematopoietic stem cell transplantation undergoing extracorporeal photopheresis
32928101|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
32928102|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
32928103|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
32743006|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
32928104|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
32928105|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
32928106|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
32928107|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
32928108|NCT05364359|Active Comparator|Intervention group|The patients will receive a individual dietary counseling based on the taste-test
32928109|NCT05364359|Placebo Comparator|Standard dietary counseling|The patients will receive a individual standard dietary counseling not based on the taste-test
32928110|NCT05364281||Study Group|Patients younger than 18 years, who were scheduled for elective adenoidectomy or adenotonsillectomy operation.
32928111|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
32928112|NCT04976231||Treatment Naive|subjects who are naïve to ERT and start treatment with idursulfase
32928113|NCT04976231||Treatment less than 3 years|Subjects who have received ERT for <3 years
32928114|NCT04976231||Treatment over 3 years|Subjects who have received ERT for 3 or more years
32928115|NCT05363891|Experimental|Natrunix with MTX(+Folate)|Natrunix 400mg, subcutaneous injection in combination with Methotrexate (+Folate).This arm will enroll 100 subjects.
33277373|NCT03956329|Experimental|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
33277374|NCT01583413|Experimental|Opt Out Protocol|
32928116|NCT05363891|Placebo Comparator|Placebo with MTX(+Folate)|Placebo in combination with Methotrexate (+Folate). This arm will enroll 50 subjects.
32928117|NCT05718596|Experimental|Sweeps laser|use of sweeps laser irrigation activation
32928118|NCT05718596|Experimental|pasif ultrasonic irrigation (PUI)|Pasif ultrasonic irrigation (PUI) -VDW Ultra
32928119|NCT05363735||Ultrasound Elastography|Patients will be examined by ultrasound elastography.
32928120|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
33277375|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
33400724|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
33400725|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
33400726|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
33400727|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.~Isokinetic evaluation."
33400728|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.~Isokinetic evaluation."
33400729|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
33400730|NCT03668522||children|age<=17
32928121|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
32928122|NCT05363657||Renal tumor patiens|Patients with any renal tumor diagnosed with conventional imaging (computed tomography or magnetic resonance imaging) and undergoing to a clinical management in a hugh-volume center.
32928123|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
32928124|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
32928125|NCT03094325|Experimental|Septal myectomy|
32928126|NCT05718440||patient with spinal dysraphism|
32928127|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
32928128|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
32928129|NCT03095885|Other|Test Meal|controlled oxalate-rich test meal
32928130|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
32928131|NCT05718362|Experimental|Intervention Group|Ayres Sensory Integration Therapy and Home Program
32726479|NCT04897607|Active Comparator|Treatment Plan Option 1 (Standard Care)|Standard smoking cessation counseling will be offered + participant choice of nicotine patches or varenicline. Participants are also free to decline either medication.
32726480|NCT04897607|Experimental|Treatment Plan Option 2 (Precision Pharmacotherapy)|Standard smoking cessation counseling will be offered + a recommendation to take either the nicotine patch or varenicline based on the results of the NMR test. Regardless of the recommendation, it would still remain the participant's choice to be prescribed either nicotine patches or varenicline. Participants are also free to decline either medication.
32743007|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
32928132|NCT05718362|Active Comparator|Control Group|Home Program
32928133|NCT03096353|Experimental|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
32928134|NCT03096353|Experimental|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
32928135|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
32928136|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
32928137|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
32928138|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
32928139|NCT05363579|Other|Physiotherapy|It is a form of therapy.
32928140|NCT05363579|Other|Tuina Therapy|It is a form of therapy.
32928141|NCT05363579|Other|Physiotherapy mixed with Tuina|It is a form of therapy.
32928142|NCT05718284|Experimental|HFNC|Administration of high flow nasal oxygen after extubation for 48 hours
32928143|NCT05718284|Other|STANDARD OXYGEN|Administration of oxygen through standard devices (nasal cannulae, venturi mask, none)
32928144|NCT05504798|Active Comparator|Group (A)|will receive a selected physical therapy program.
32928145|NCT05504798|Active Comparator|Group (B)|will receive interrupted progressive serial casting in addition to a modified selected physical therapy program during casting.
33400731|NCT03668522||adult|age>17
33400732|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
32768538|NCT04113499|Active Comparator|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
33400733|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
32768539|NCT04113499|Active Comparator|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
33400734|NCT03668132||Normal control|Not have the ischemic brain damage
32905669|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
33400735|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
32905670|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
33400736|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
33400737|NCT02250300|Experimental|MLN9708 Phase I (2.3 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
33400738|NCT02250300|Experimental|MLN9708 Phase I (3.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
33400739|NCT02250300|Experimental|MLN9708 Phase I (4.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
33400740|NCT04403490|Experimental|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
33400741|NCT04403490|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
32905671|NCT01519271|Placebo Comparator|Placebo Patch|
32905672|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
33400742|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
32905673|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
32905674|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
32905675|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
32905676|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
33400743|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
33400744|NCT01381770|Experimental|Platelet-derived repairing factors|
33400745|NCT01383564|Active Comparator|CPAP group|CPAP group
33400746|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
32905677|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
32905678|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
32905679|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
32905680|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
32905681|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
32905682|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
32905683|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
32905684|NCT01437449|Experimental|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
32905685|NCT00836888|Experimental|Cohort|
32905686|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
32905687|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
32905688|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
32905689|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
32905690|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
32905691|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
32905692|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
32905693|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
32905694|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
33250747|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
32726481|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
33250748|NCT00877695|No Intervention|delayed|
32726482|NCT04902092|Active Comparator|High Intensity Physical Training|12-week, 36 session, cardiorespiratory-focussed physical exercise program delivered by an accredited exercise physiologist
32726483|NCT04902092|Active Comparator|Low Intensity Physical Training|12- week, 36 session, strength-focussed physical exercise program delivered by an accredited exercise physiologist
33250749|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
33250750|NCT00877851|Experimental|1 CD-ROM|Use of CD-ROM for 12 weeks
33250751|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
33250752|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
33250753|NCT00872469|Active Comparator|Tranexamic acid|
33250754|NCT00872469|Placebo Comparator|placebo|
33250755|NCT00872547|Active Comparator|1|Resurfacing system
33250756|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
33250757|NCT05225883||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
33250758|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
33250759|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
33250760|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
32726484|NCT04323449|Experimental|Vision-guided control|New custom control method
32726485|NCT04323449|Experimental|Default control|Default control method (joystick or switch)
33250761|NCT00878007|No Intervention|4|
33250762|NCT00872625|Experimental|Cyberknife|
33250763|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
33250764|NCT00878085|Active Comparator|2|Standard Occupational Therapy
33250765|NCT00872703||1|
33250766|NCT00872703||2|
32726486|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
32726487|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
32726488|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
33250767|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
33250768|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
33250769|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
33250770|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
33250771|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
33250772|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
33250773|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
33250774|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
33250775|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
33250776|NCT00872859|Experimental|1|Dermamatrix with radiation
33250777|NCT00872859|Experimental|2|Dermamatrix without radiation
33250778|NCT00872859|Experimental|3|Alloderm with radiation
33250779|NCT00872859|Experimental|4|Alloderm without radiation
33250780|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
33277376|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
33277377|NCT01094041|Experimental|Gluten free diet|
33277378|NCT01094041|Experimental|Gluten rich diet|
33250781|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
32726489|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
32726490|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
32726491|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
32726492|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
32726493|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
32726494|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
32726495|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
32726496|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
32726497|NCT04283981|Active Comparator|Control Group|
32726498|NCT04283981|Experimental|Treatment Group|
32726499|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
32726500|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
32726501|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
32726502|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
32726503|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
32726504|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
32726505|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
32726506|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
32726507|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
32726508|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
32726509|NCT02819635|Placebo Comparator|SS1: Placebo|During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
32726510|NCT02819635|Experimental|SS1: Upadacitinib 7.5 mg|During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
32726511|NCT02819635|Experimental|SS1: Upadacitinib 15 mg|During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
32726512|NCT02819635|Experimental|SS1: Upadacitinib 30 mg|During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
32726513|NCT02819635|Experimental|SS1: Upadacitinib 45 mg|During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
32726514|NCT02819635|Experimental|SS2: Placebo/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
32905695|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
32726515|NCT02819635|Experimental|SS2: Upadacitinib 45 mg/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
33400747|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
32726516|NCT02819635|Experimental|SS3: M14-675 clinical responders|Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth [QD], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.
32726517|NCT04282343|Other|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
32726518|NCT04282343|Other|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
32726519|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
32726520|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
32726521|NCT04912544|Experimental|Arm 1|Patient talking with microphone first turned on and then off
32726522|NCT04912544|Experimental|Arm 2|Patient talking with microphone first turned off and then on
32726523|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
32726524|NCT04911530||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
32768540|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
32726525|NCT04914572|Experimental|Therapeutic rainforest & MIndful walking|The first arm uses mindful walking through a 2km forest trail in Singapore. All Interventional and Control arms will conduct their walk between 8 am to 11 am for five occasions weekly. At the T1, participants will attend a Zoom orientation session to familiarize themselves with the route. During this session, participants will need to answer the self-report questionnaire and provide the first saliva sample for the baseline measurement. In T2, a pre-intervention and post-intervention saliva sample will be taken before the walk. This will follow by T3 the following week. At T4, participants will attend a 60 mins reflection session and answer the self-report questionnaire. On T5 and T6, the participants will continue with the therapeutic rainforest mindfulness walk. On T7, a pre-intervention and post-intervention saliva sample will be taken. On T8, participants will attend a 60 mins reflection session and answer the self-report questionnaire.
32726526|NCT04914572|Experimental|Therapeutic rainforest walk|The second arm of the intervention includes walking through a guided forest trail suggested by NParks Board. The collection of samples and answering of the self-report questionnaire will follow the same sequence as the 1st arm of the 3-arm RCT.
32726527|NCT04914572|Active Comparator|Campus green walk|The control for this study includes guided casual walking around the campus green trial conducted at the same intervals as per the interventions. The collection of samples and answering of the self-report questionnaire will also follow the same sequence as the 1 arm of the 3-arm RCT.
32726528|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
32726529|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
32726530|NCT04914416|Placebo Comparator|Verum T1|
32726531|NCT04914416|Experimental|Verum T2|
32726532|NCT04914416|Experimental|Verum T3|
32726533|NCT04914416|Experimental|Verum T4|
32726534|NCT04914416|Experimental|Verum T5|
32726535|NCT04914416|Experimental|Verum T6|
32726536|NCT04914416|Experimental|Verum T7|
32726537|NCT04914416|Experimental|Verum T8|
32726538|NCT04914416|Experimental|Verum T9|
32726539|NCT04914416|Experimental|Verum T10|
32726540|NCT04914416|Experimental|Verum T11|
32726541|NCT04914416|Experimental|Verum T12|
32726542|NCT04914416|Experimental|Verum T13|
32726543|NCT04914416|Experimental|Verum T14|
32726544|NCT04914416|Experimental|Verum T15|
32726545|NCT04914416|Experimental|Verum T16|
32726546|NCT04914416|Placebo Comparator|Verum T17|
32726547|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
32726548|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
32726549|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
32726550|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
32726551|NCT03435575|No Intervention|Control group|Standard care
32726552|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
33400748|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
33400749|NCT00892866|Other|Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
33400750|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
32768541|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
32768542|NCT04103593|Experimental|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
32768543|NCT04103593|No Intervention|control group|Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter ?delayed? exercise training to assure that all participants can receive exercise training.
32905696|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
32905697|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
32905698|NCT03839030|Experimental|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
32905699|NCT03839030|No Intervention|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
32905700|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
32905701|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
32905702|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
32905703|NCT00889226|Experimental|Pitavastatin Group|
32905704|NCT00889226|Active Comparator|Atorvastatin Group|
32905705|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
32905706|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
32905707|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
32905708|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
32905709|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
32905710|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
32905711|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
32905712|NCT00837590|Experimental|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
32905713|NCT00837590|Experimental|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
32905714|NCT00837590|Experimental|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
32928146|NCT05504798|Active Comparator|Group (C)|will receive interrupted progressive serial casting and the modified selected physical therapy as group (B) in addition to neuromuscular electrical stimulation for ankle dorsiflexors and knee extensors muscles through cast windows
32928147|NCT05363501|Active Comparator|Naloxone IM Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
32928148|NCT05363501|Active Comparator|Intranasal Naloxone Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
33250782|NCT04039581|Experimental|Group Kinesio Taping and TENS|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique). In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.~In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises."
33250783|NCT04039581|Active Comparator|Group TENS|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. Therapeutic exercises will consist of active shoulder evolution, active cervical rotations, active cervical lateral flexion movement and active shoulder flexion and abduction exercises.
33250784|NCT04039581|Active Comparator|Group Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
32928149|NCT05363501|Experimental|Single 8 mg naloxone nasal swab-Swirl method|Single 8 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
33250785|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
33250786|NCT01050361|Experimental|EGHEM|The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.
33250787|NCT01050361|No Intervention|SHEM|"The control group will be~called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution."
33250788|NCT01048021||Supraclavicular Block|
32928150|NCT05363501|Experimental|Single 4 mg naloxone nasal swab-Swirl method|Single 4 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
32928151|NCT05363501|Experimental|Single 12 mg naloxone nasal swab-Swirl method|Single 12 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
32928152|NCT05363501|Experimental|Single 12 mg naloxone nasal swab-Squeeze method|Single 12 mg naloxone nasal swab administered into the nasal cavity - administered in one nostril and using two fingers to squeeze outside of both nostrils.
32928153|NCT05363501|Experimental|Single 12 mg naloxone nasal swab in each nostril-Squeeze method|Two 12 mg naloxone nasal swabs in both nostrils- administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
33250789|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
33250790|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
33250791|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
33250792|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
32928154|NCT05363501|Experimental|Single 8 mg naloxone nasal swab in each nostril-Squeeze method|Two 8 mg naloxone nasal swab in both nostrils - administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
32928155|NCT05363501|Experimental|Single 12.5 mg naloxone nasal swab-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1(12.5 mg) administered as one swab in one nostril, using the insert into nostril and squeeze method of administration
32928156|NCT05363501|Experimental|Single 12.5 mg naloxone nasal swab in each nostril-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1 (12.5 mg) using the insert into each nostril and squeeze method of administration (two doses given in total).
32928157|NCT04736927|Experimental|GLPG3667 + Midazolam|
32928158|NCT02387294|Experimental|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
32726553|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
32726554|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
32726555|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
32726556|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.~These will be tested by diagnostic tests under evaluation:~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
32726557|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
32726558|NCT04914338|Experimental|Supportive care (MDT-intervention)|Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.
32726559|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
32726560|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
32726561|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
32726562|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
32726563|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
32726564|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
32726565|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
32726566|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
32726567|NCT03435263||home management group A|home management
32726568|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
32726569|NCT03430817|Experimental|Group C|Citicholine Drug
32726570|NCT03430817|Experimental|Group A|Amantadine Drug
32726571|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
32726572|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 3 times) in our IVF institute.
32726573|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
32726574|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
32726575|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
32726576|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
32726577|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
32726578|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
32726579|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
32726580|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
32726581|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
32726582|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
32726583|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
32726584|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
32726585|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
32726586|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
32726587|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
32726588|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
32726589|NCT04896307||Physicians at The Ottawa Hospital|Online survey completed by physicians working at The Ottawa Hospital consisting of the 2-item Maslach Burnout Inventory, a Satisfaction Questionnaire and the 12-Item Participatory Management Leadership Score.
32726590|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
32905715|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
32905716|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
32905717|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
32905718|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
32905719|NCT00837902|Experimental|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
32905720|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
32905721|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
32905722|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
32905723|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
32905724|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
32905725|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
32905726|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
32905727|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
32905728|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
32905729|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
32768544|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
32768545|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
32768546|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
33250793|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
32768547|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
32768548|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
33250794|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
33277379|NCT04076072|Active Comparator|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
32768549|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
32768550|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
32768551|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
32768552|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
32768553|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
32768554|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
32768555|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
32768556|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
32768557|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
32768558|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
32768559|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
32768560|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
32768561|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
32768562|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
32768563|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
32768564|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
32768565|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
32768566|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
32768567|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
32905730|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
32905731|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
33250795|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33400751|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
33400752|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
33400753|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
33400754|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
33400755|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
33400756|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
33400757|NCT05420298|Experimental|cervical mobilization|session will include3-5 repetitions of muscle energy technique in combination of facet joint mobilization of unilateral antro-posterior glide and extension repetitions
33400758|NCT05420298|Active Comparator|cervical manipulation|patients will receive high velocity low amplitude thrust
33400759|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
32768568|NCT05071573|Experimental|Intervention arm|"Quality improvement package Identification of a viral load champion whose role will include tracing and recalling patients who need further assessments of their VL or switch to second-line regimen.~QIP to address process and clinic impediments to VLM as well as training in antiretroviral treatment monitoring guidelines Training in the use of enhanced TIER.Net technology developed as part of the trial and how to access reports on the dashboard system.~Augmentation of TIER.Net with a dashboard system VL results will be imported into TIER.Net daily from the National Health Laboratory Service which will be linked to patients in TIER.Net based on multiple exclusive and linked deterministic rules using a combination of variables such as name, surname, sex, date of birth, date of visit, NHLS lab number, facility and folder number. The information contained in TIER.Net will be used to develop a dashboard which summarises viral load data at individual and clinic level."
32905732|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
32905733|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
32905734|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
32905735|NCT02873468|Experimental|Florence 30|
32905736|NCT02873468|Experimental|Florence 60|
32905737|NCT02873468|Experimental|Florence 90|
32905738|NCT02873468|Placebo Comparator|Placebo|
32905739|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
32905740|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
32905741|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
32905742|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
32905743|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
32905744|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
32905745|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
32905746|NCT01541891|Experimental|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
32905747|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
32905748|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
32905749|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
32906603|NCT01574807|Experimental|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
33250796|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
33277380|NCT04076072|Active Comparator|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
32928159|NCT02387294|Experimental|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
32928160|NCT05352269|Experimental|Cohort 1 XBI-302|40 XBI-302 capsules in 1 day
32928161|NCT05352269|Placebo Comparator|Cohort 1 Placebo|40 placebo capsules in 1 day
32928162|NCT05352269|Experimental|Cohort 2 XBI-302|80 XBI-302 capsules over 2 days
32928163|NCT05352269|Placebo Comparator|Cohort 2 Placebo|80 placebo capsules over 2 days
32928164|NCT05352269|Experimental|Cohort 3 XBI-302|40 XBI-302 capsules per day, once a week for 4 weeks.
32928165|NCT05352269|Placebo Comparator|Cohort 3 Placebo|40 placebo capsules per day, once a week for 4 weeks.
32928166|NCT05352269|Experimental|Cohort 4 XBI-302|80 XBI-302 capsules over 2 days, once a week for 4 weeks.
32928167|NCT05352269|Placebo Comparator|Cohort 4 Placebo|80 placebo capsules over 2 days, once a week for 4 weeks.
32928168|NCT04942379|Experimental|Asthma Link|Site providers will be trained to efficiently discuss school-supervised medication administration with families and school nurses. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment in Asthma Link to provide school-supervised asthma therapy. Ongoing communication occurs between the pediatric practice, school nurse and families through electronic medical record messaging and phone communication. Data will be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
32928169|NCT04942379|Active Comparator|Enhanced Usual Care|Sites will receive pediatric pulmonologist-delivered training and a workbook for pediatric practices to provide to patients on behavioral strategies to help promote asthma medication adherence. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment to this Enhanced Usual Care condition of study (receipt of workbook). Data will also be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
32928170|NCT05718206|Experimental|Coronary stenosis|
32928171|NCT05718206|Other|Control|
32928172|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
32928173|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
33277381|NCT04026230|Experimental|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance.
32928175|NCT04940585|Experimental|Rose Program Group|ROSE is a 7-session intervention. Participants will attend 6 weekly group sessions virtually, through a program on the computer called WebEx or at the clinic, and then one individual session after delivery. Participants will complete a few questionnaires at three different timepoints, including demographics, stress, social support, physical and mental health, and trauma.
32928176|NCT04940585|No Intervention|Comparison Group|Participants will complete three sets of questionnaires including demographics, stress, social support, physical and mental health, and trauma.
32928177|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
32928178|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
32928179|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
32928180|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
32928181|NCT04819997|Experimental|Supportive care (videoconference, questionnaire, survey)|Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks.
32928182|NCT05491382|Experimental|Does muscle temperature influence heat loss responses independently from core and skin temperature?|The study will consist of three experimental trials, conducted in a randomized order, where participants will be required to run for one hour at ~60% of their maximal oxygen consumption on one of three different inclines: 1) flatland, 2) uphill, and 3) downhill. Environmental conditions will be maintained at 34°C/93°F and 20% relative humidity.
32928183|NCT05491382|Experimental|Does muscle temperature influence muscle blood flow independently from core and skin temperature?|Following the exercise protocol described above in Arm 1, the participants will then lay supine for one hour while their muscle and skin blood flow, as well as blood pressure are measured.
33073522|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
33277382|NCT04026230|Placebo Comparator|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 10 years or until development of castration resistance
33277383|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
33277384|NCT00536510|Placebo Comparator|2|placebo
33277385|NCT04526600|No Intervention|No fidget|
32726591|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
33277386|NCT04526600|Experimental|With fidget|The participant is given a specially designed fidget ball
32726592|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
32726593|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
32726594|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
32726595|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
32726596|NCT05370638|Experimental|rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day.
32906604|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
32906605|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
32906606|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
32906607|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
32906608|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
32906609|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
32906610|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
32906611|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32906612|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32906613|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
32906614|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
32906615|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
32906616|NCT03408002|No Intervention|control group|no intervention
32906617|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
32906618|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
32906619|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are >0.7 proceed to group 2 evaluation with the same intervention.~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
32906620|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
32906621|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
32906622|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
32906623|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
32906624|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
32726597|NCT05370638|No Intervention|usual practice|Usual practice was categorized as: seeing discharging patients first, sickest patients, decompensating patients, new patients (i.e. patients admitted to their team overnight), or based on geography.
32726598|NCT03430583||MZ101|Dosing per treatment regimen
32726599|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
32726600|NCT03442075||Group 2|Group 2 was administered analgesic orally
32726601|NCT03442075||Group 3|Group 3 was given trans rectal gel
32726602|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
32726603|NCT03442075||Group 5|Group was performed by placebo oral
32726604|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
32726605|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
32928184|NCT05491382|Experimental|What factors contribute to exercise-induced skeletal muscle damage?|For those participants who additionally agree to participate in the muscle microdamage portion of the study, participants will be asked to return to the lab 24h and 48h post-trial. During these subsequent follow-up sessions, an additional blood sample will be drawn from the participants, the participants maximal voluntary contraction and muscle pain will be assessed, and they will be asked to fill out the muscle soreness scale.
32928185|NCT05304455|Experimental|Apixaban group|From postoperative day 3, Patients will receive oral Dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.
32928186|NCT05718050|Experimental|Flexure|Dentate patients, 18 years of age or older, in good health and, in need of implant treatment
32928187|NCT04332965|Experimental|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
32928188|NCT04332965|Experimental|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
32726606|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
32726607|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
32726608|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
32726609|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
32726610|NCT04450589|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
32726611|NCT04450589|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
32726612|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
32726613|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
32726614|NCT02234323|Experimental|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (>=) 50 exposure days (ED: 24-hour period in which >=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (>=5.00 Bethesda Units per milliliter [BU/mL]) or positive low titer inhibitor (>=0.60 and <5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
32726615|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
32726616|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
32726617|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
32726618|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
32928189|NCT04332965|No Intervention|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores <10%.
33073523|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
32726619|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
32928190|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
32928191|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
32726620|NCT05078203|Experimental|Exercise|36 minutes of exercise
32726621|NCT05078203|Placebo Comparator|Rest|36 minutes of rest
32726622|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
32726623|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
32726624|NCT03128645||Group 1|Standard method group
32726625|NCT03128645||Group 2|Abdominal corset group
32726626|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
32726627|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
32928192|NCT04747691||Patients assessed with postoperative bedside gastric ultrasound|This patient population will include postoperative patients who received a gastrointestinal surgery and are being assessed with the bedside gastric ultrasound.
32928193|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
32928194|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
32928195|NCT05242055||Integrated group|Patients in the integrated group should be the patients getting integrated diagnosis and treatment during following up period. Integrated diagnosis and treatment includes control of hypertension, hyperglycemia, hyperlipidemia, anemia, CKD-MBD, and malnutrition by regular follow-up according to the guidelines of Kidney Disease- Improving Global Outcomes and of Chinese Medical Association in 2021.
32928196|NCT05242055||Unintegrated group|Patients in the unintegrated group are those who do not follow the contents of guidelines in some items of the integrated diagnosis and treatment during follow-up.
32726628|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
32726629|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
32726630|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
32928197|NCT05717972|Experimental|A Group|
32726631|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
32726632|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
32928198|NCT05717972|Other|B Group|Waiting list
32928199|NCT05233007||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
32928200|NCT05717894|Experimental|Treatment ( primary )|
32928201|NCT05717894|No Intervention|Control|
32928202|NCT05231681|Experimental|Eye Concealer|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer
32928203|NCT04661657||COVID-19|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
32928204|NCT04661657||Control|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
33073527|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
32928205|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
32928206|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
32928207|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
32928208|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
32928209|NCT05185583|Experimental|Sequence A: Methylphenidate, Placebo|Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
32928210|NCT05185583|Experimental|Sequence B: Placebo, Methylphenidate|Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
32726633|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
32726634|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
32726635|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
32928211|NCT04645121||Hemodialysis group|Subjects receiving maintenance hemodialysis for at least three months
32928212|NCT04645121||Case group|Healthy subjects with eGFR above 60 ml/min/1.73m2
32928213|NCT05470712||Plasma from women with preeclampsia|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed for mechanism of NETs formation.
32928214|NCT05470712||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed for mechanism of NETs formation.
32928215|NCT05462444||Children with food allergy|
32928216|NCT05462444||Children with food intolerance|
32726636|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
32726637|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
32726638|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
32726639|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
32726640|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
32726641|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
32726642|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
32726643|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
32726644|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
32726645|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
32726646|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
32726647|NCT04449419||CONTROL|Non-copd control group
32928217|NCT05462444||Children with other allergies (reference group)|
32928218|NCT04603937|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
32726648|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
32726649|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
32726650|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
32726651|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
32726652|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
32726653|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
32726654|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
32726655|NCT04253171|Active Comparator|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
32928219|NCT04603937|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
32726656|NCT04253171|Active Comparator|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
32726657|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
32928220|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
32928221|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
32726658|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
32726659|NCT04247399|Experimental|Simulation-based learning + clinical training|
32928222|NCT04586153|Experimental|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
32726660|NCT04247399|No Intervention|Clinical training|
32726661|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
32726662|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
32726663|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
32726664|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
32726665|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
32726666|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
32726667|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
32726668|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
32726669|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
32726670|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
32726671|NCT04450433||Baseline table of patients|
32928223|NCT04586153|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
32928224|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
32928225|NCT05717738||TACE-Len-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.
32928226|NCT05717738||TACE-A-T cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.
33073528|NCT01350648||Hepatitis B|Hepatitis B alone
33073529|NCT01350648||Hepatitis C|Hepatitis C alone
33073530|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
32726672|NCT04450433||Differential metabolites of two groups of control patients|
32726673|NCT04450433||Functional verification of differential metabolites|
32726674|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
33073531|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
33073532|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
32928227|NCT05717738||TACE-B-S cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab biosimilar (Byvasda, B) and Sintilimab (Tyvyt, S) antibody as conversion therapy for downstaging.
32928228|NCT05717738||TACE-Apa-C cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.
32928229|NCT05717738||TACE-Sor-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.
32928230|NCT05717738||TACE-Don-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.
32928231|NCT05717738||TACE-Reg-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.
33277387|NCT04496258|Experimental|Positive VR Scene|Participants will explore a virtual reality (VR) environment of a beach scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
32928232|NCT04484987|Other|TRE group|Time-restricted eating group
33277388|NCT04496258|Experimental|Neutral VR Scene|Participants will explore a virtual reality (VR) environment of a neutral office scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
33400760|NCT03635099|Placebo Comparator|Part I - Placebo (fasted)|Part I - Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 75 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
32928233|NCT04484987|Other|Control group|Time-unrestricted eating group
32928236|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
32928237|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
32928238|NCT04988867|Experimental|Drug - trofinetide|Oral dose of trofinetide
32928239|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
32928240|NCT05443490|Experimental|Probiotic group|Probiotic mixture
32928241|NCT05443490|Placebo Comparator|Placebo group|Maltodextrine
32928242|NCT04949477|Active Comparator|Group (D)|The patient will receive intranasal dexmedetomidine.
32928243|NCT04949477|Active Comparator|Group (P)|The patient will receive paracetamol orally.
32928244|NCT05441306|Experimental|Access to Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL and the standard of care patient portal (Epic®MyChart).
32928245|NCT05441306|Active Comparator|Control - MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
32928246|NCT05437796|Active Comparator|Hypnotic virtual reality support|Hypnotic virtual reality support using hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
32928247|NCT05437796|Sham Comparator|Without hypnotic virtual reality support|
32928248|NCT04873895|Experimental|TACE+axitinib+HCQ|2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.
32928249|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
33277389|NCT04424264|Experimental|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600*/300mg
33277390|NCT03790670|Experimental|Leukine Treatment|36 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
33277391|NCT05355662||OLDs|Older liver donors (OLDs) and recipients were defined as individuals whose donor age was equal to or greater than 60 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
33277392|NCT05355662||ILDs|Ideal or young liver donors (ILDs) and recipients were defined as donors aged 18-40 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
33277393|NCT05355662||ALDs|Average liver donors (ALDs) and recipients were defined as donor age 40-59 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
33277394|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
32726675|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
32928250|NCT04786223|Other|C-11 ER176 PET/CT|C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
32928251|NCT05717660|Active Comparator|Control|Androgen Deprivation therapy and Apalutamide
32928252|NCT05717660|Experimental|Treatment|Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease
32928253|NCT05717582|Experimental|maximal-cytoreductive therapy|Patients with de novo mCSPC who achieve ≤10 oligopersistent metastases on PSMA PET CT after initial 3-month systemic treatment with apalutamide plus ADT will receive cytoreductive radical prostatectomy with/without PLND and metastasis-directed therapy with radiation.
32928254|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
32928255|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
32928256|NCT04939298|Experimental|Patients under mechanical ventilation|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation
32928257|NCT04935710|Experimental|R34#1 Aim 2 COPE2Thrive Intervention|Youth identified as being at risk but without a major mental health disorder will be randomized to receive a resilience based digital intervention, COPE2Thrive.
32928258|NCT04935710|Active Comparator|Control arm|The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.
32928259|NCT02069041|Experimental|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:~FOLFOX4 every 2 weeks:~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2~Participants may continue to receive treatment until discontinuation criteria are met."
32928260|NCT04920344|Active Comparator|GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))|After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
32928261|NCT04920344|Experimental|GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)|Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
32928262|NCT04920344|Experimental|GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)|"Patients whose tumor has a positive margin, which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity."
32928263|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
32726676|NCT04450121|Active Comparator|GA (n =22)|Patients will be intubated using Air-Q airway
32726677|NCT04450121|Active Comparator|GF (n =22)|Patients will be intubated using Fekry airway
32726678|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.0g/kg IV over one hour weekly for 5 weeks
32726679|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.0g/kg IV over one hour weekly for 5 weeks
32726680|NCT03433937|Experimental|Negative pressure wound therapy|
32726681|NCT03433937|Active Comparator|Control|Micropore tape
32726682|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
32726683|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
32726684|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
32726685|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
32726686|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
32726687|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
32726688|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
32726689|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
32726690|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
33250797|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
32726691|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
32726692|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
32726693|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
33250798|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
33250799|NCT03524430|Experimental|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
33250800|NCT04048902|Placebo Comparator|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
33073533|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
32726694|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
32726695|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
32726696|NCT03429179|Experimental|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were >10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
32726697|NCT03429179|Placebo Comparator|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were >10, and received an infusion of the same volume of 0.9% saline
32726698|NCT03429179|Experimental|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
32726699|NCT03429179|Placebo Comparator|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
32726700|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
32726701|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
32726702|NCT04173689|Active Comparator|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
32906625|NCT04377386|Experimental|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
33073534|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
33250801|NCT04048902|Active Comparator|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
32928264|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
32928265|NCT05423834||TAF-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Tenofovir alafenamide
32928266|NCT05423834||ETV-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Entecavir
33250802|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
33250803|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
33250804|NCT05024097|Experimental|Radiation therapy and etrumadenant (AB928)|Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily. this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
32928269|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
32928270|NCT05717504|Active Comparator|Disclosure|Group A (disclosure arm): patients and physicians will be informed about all AF episodes identified on ILR lasting for ≥6 minutes.
32928271|NCT05717504|Active Comparator|Non-Disclosure|Group B (non-disclosure arm): patients and physicians will be only informed about AF episodes identified on ILR lasting for ≥24h. This longer threshold is selected because of its association with increased risk of systemic embolism.
33073539|NCT01313442||1/ Cohort 1|Subjects with a diagnosis of cancer
33073540|NCT01306019|Other|cohort a|First 8 Patients Treated
33073541|NCT01306019|Other|cohort b|Patients 9 and Beyond
33073542|NCT01303341|Experimental|Treatment (riluzole and sorafenib tosylate)|Patients receive riluzole PO BID and sorafenib tosylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33073543|NCT01273168|Experimental|1|Z-endoxifen will be administered orally once a day in 28-day cycles
33073544|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33073558|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
33073559|NCT01218854|Experimental|L-NASS|laser assisted needle angle selection system
33073560|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
33073561|NCT01212029|Experimental|1/All Subjects|Imaging studies related to functional brain activation
32768569|NCT05071573|No Intervention|Control arm|Viral load results are manually captured on to the TIER.Net system with filing of the paper results in patients' clinical notes for nurses' review during routine appointments. This is used to produce a monthly enrolment and quarterly cohort reports for the central monitoring of the ART programme.
33250805|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
33250806|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
32928272|NCT04918472|Experimental|MCCE|Magnetically controlled capsule endoscopy will be performed before UGI endoscopy.
32928273|NCT05406635|No Intervention|Standard imaging monitored treatment|Standard care + biomarkers, which are blinded until end of study.
32928274|NCT05406635|Experimental|Intervention biomarker monitored treatment|biomarker monitored treatment + imaging, which is blinded until end of study
32928275|NCT05717426|Active Comparator|Open chain exercises group|Group A(Open chain exercises group) will receive open kinetic exercises 3 times a week for 3-4 weeks.
32928276|NCT05717426|Active Comparator|Closed kinetic chain exercises group|Group B(Closed kinetic chain exercises group) will receive close kinetic exercises 3 times a week for 3-4 weeks.
33250807|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
33250808|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
32928277|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
33250809|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
33250810|NCT03364296|Other|Patients hospitalized for stroke|
33250811|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
33250812|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
32928278|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
33250813|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
33250814|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
32928279|NCT04139135|Experimental|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
33250815|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
32928280|NCT04139135|Placebo Comparator|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
33250816|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
32928281|NCT05714696|Experimental|Weight discrimination experience|"Participants in the experimental condition will:~Learn that their group mates are biased against overweight people (i.e., they have negative attitudes toward people with higher body weight),~Receive feedback about their personal attributes that is consistent with negative weight-based stereotypes (e.g., lacking self-discipline), and~Not be selected as a partner for the remaining lab tasks (i.e., this experience may prompt feelings of social exclusion)."
33250817|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
33073564|NCT01200680||chordoma cohort|Chordoma patients
33073565|NCT01168271||Children Ages 0-3 years|Children aged 0-3 years in Ouelessebougou,
33250818|NCT04585464|Experimental|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
33250819|NCT04585464|Experimental|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
33250820|NCT04585464|Experimental|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy~Interventions:~Drug: EDG-5506 Drug: Placebo"
33250821|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
33250822|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
33250823|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
33250824|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
33250825|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
33250826|NCT00760968|Active Comparator|Methotrexate|
33250827|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
33250828|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
33250829|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
33250830|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
32928282|NCT05714696|Active Comparator|Control experience|"Participants in the control condition will:~Learn that their group mates are very accepting of overweight people (i.e., they have positive attitudes toward people with higher body weight),~Receive positive feedback about their personal attributes that is not consistent with negative weight-based stereotypes, and~Will be told that one of their group members had to leave early for an emergency so the pairs cannot be assembled as usual (i.e., this experience should not prompt feelings of social exclusion)."
32928283|NCT05406557|Active Comparator|Partial pulpotomy|Removal of superficial 2-3 mm of pulp tissue from entire pulp chamber
32928284|NCT05406557|Active Comparator|Miniature pulpotomy|Removal of superficial 2-3 mm of pulp tissue from only affected pulp horn
32928285|NCT04904354|Experimental|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
32928286|NCT04904354|Experimental|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
32928287|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
32928288|NCT04899830|Experimental|Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
32928289|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
32928290|NCT05440877|Experimental|Intervention group|Provided with a tutorial guide, and VR-based teaching materials in the tutorial session
32928291|NCT05440877|Experimental|Control group|Provided with the tutorial guide in the tutorial session.
32928292|NCT05712434|Experimental|Long CHG Intervention|2 months of iodine protocol, followed by 4 months of CHG protocol, followed by 6 months of CHG plus protocol.
32928293|NCT05712434|Experimental|Mid-length CHG Intervention|4 months of iodine protocol, followed by 4 months of CHG protocol, followed by 4 months of CHG plus protocol.
32928294|NCT05712434|Experimental|Short CHG Intervention|6 months of iodine protocol, followed by 4 months of CHG protocol, followed by 2 months of CHG plus protocol.
32928295|NCT04899284|Experimental|Infants eligible for Early Intensive Bimanual Stimulation|Infants between 3 and 12 months of age at the time of inclusion, with unilateral brain injury and clinical signs of underuse of one of the two upper limbs
32726703|NCT04173689|Active Comparator|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
32726704|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
32726705|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
32726706|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
32726707|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
32726708|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
32726709|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
32726710|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
32726711|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
32726712|NCT04116203|Other|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
32726713|NCT04116203|Other|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
32726714|NCT04116203|Other|Fish Oil and Metformin|Combo of other 2 arms
32726715|NCT04449107|Experimental|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
32726716|NCT04449107|No Intervention|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
32726717|NCT04048343|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
32726718|NCT04016753|Experimental|Monotherapy|
32726719|NCT04449887|Experimental|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
32726720|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
32768570|NCT04860011|Experimental|SGLT2i|Sodium-glucose Co-transporter-2 inhibitors
32768571|NCT04860011|Experimental|Thiazide|Thiazide or thiazide like diuretic
32928296|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
32928298|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
32928299|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
33250831|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
32768572|NCT05071417|Experimental|Semaglutide|Patients on semaglutide
32768573|NCT04859777|Experimental|Part A:|Dose-escalation oral MPT-0118 BID
32768574|NCT04859777|Experimental|Part B:|Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)
32768575|NCT04859777|Experimental|Part C:|Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)
33250832|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
33250833|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
32928300|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
32928301|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
32928302|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
32928303|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
32928304|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
32928305|NCT04858256|Experimental|Cohort 1: PTCL, NOS|Patients will receive single agent pacritinib.
32928306|NCT04858256|Experimental|Cohort 2: AITL/TFH PTCL|Patients will receive single agent pacritinib.
32928307|NCT04858256|Experimental|Cohort 3: CTCL (MF/SS)|Patients will receive single agent pacritinib.
32928308|NCT04858256|Experimental|Cohort 4: Less common PTCL subtypes|Patients will receive single agent pacritinib.
32928309|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
33250834|NCT01045525|Active Comparator|Lifestyle and diet advices|
32768576|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
32768577|NCT05563779|Active Comparator|Volume Control mode|During invasive mechanical ventilation in a study location, Volume Control will be used as the mode for continuous mandatory ventilation.
32768578|NCT05563779|Active Comparator|Pressure Control mode|During invasive mechanical ventilation in a study location, Pressure Control will be used as the mode for continuous mandatory ventilation.
32768579|NCT05563779|Active Comparator|Adaptive Pressure Control mode|During invasive mechanical ventilation in a study location, Adaptive Pressure Control will be used as the mode for continuous mandatory ventilation.
32768580|NCT05562609|Experimental|Intramuscular TXA|1g TXA as 2 x 5 ml IM injections (100mg/ml) and slow IV injection of placebo (1 x 10 ml of 0.9% sodium chloride)
32768581|NCT05562609|Active Comparator|Intravenous TXA|1g TXA by slow IV injection and 2 x 5 ml IM injections of placebo
32768582|NCT05562609|Placebo Comparator|Placebo|Placebo by 1 x slow 10ml IV injection and 2 x 5 ml IM injections
32928310|NCT00355862|Experimental|2|Sirolimus containing regimen
32928311|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
32928312|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
32928313|NCT03772847|No Intervention|control|alteplase
32928314|NCT05345834|No Intervention|Usual Care|Participants will participate in usual prenatal care throughout the duration of study.
32928315|NCT05345834|Experimental|Patient Navigation and treatment|"In the patient navigation arm, women who do not meet diagnostic criteria (Group 2a) can participate in: (1) group-based CBT preventative intervention; (2) peer support group (virtual); or (3) both. Women in the threshold risk group, meeting diagnostic criteria for depression/anxiety (Group 2b) at baseline can participate in: (1) individual CBT treatment (2) peer support group (virtual) (3) both~Prevention group includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Individual treatment includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations."
32928316|NCT02049151|Experimental|Tecemotide|
32928317|NCT02049151|Placebo Comparator|Placebo|
32928318|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
32928319|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
32928320|NCT05341310|Experimental|ADHDCoach|Participants in the experimental group will have access to an individually-tailored Internet intervention developed for the present study. The intervention in clinician-guided and it consists of nine modules delivered for four weeks. The Internet Intervention, called ADHDCoach, is based on an existent Behavioral Parent training protocol, an intervention that was previously tested in a randomized controlled trial with Romanian children. The contents for parent modules were developed according to Rational Emotive and Behavioral Therapy.
32928321|NCT05341310|Active Comparator|Treatment as usual|Treatment as usual at the outpatient clinic
32928322|NCT00355550|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
32928323|NCT00355550|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
32928324|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
32928325|NCT05688410|Experimental|Assisted Exercise and I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
32726721|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
32726722|NCT04449809|Experimental|Exercise|Exercise program
32726723|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
32726724|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
32726725|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
32726726|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
32726727|NCT05063747||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 is defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis U07.1 in the nationwide Swedish intensive care registry.
32726728|NCT05063747||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up not including patients in the COVID-19 ICU cohort. COVID-19 is defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
32726729|NCT05063747||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. ICU and hospital admitted COVID-19 patients are not included.
32928326|NCT05688410|Experimental|Voluntary Exercise and I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
32928327|NCT05688410|Experimental|Assisted Exercise and No I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
33250835|NCT00873483|Experimental|Arm 1|
32726730|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
32726731|NCT05045495||Healthy Volunteer|120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
32726732|NCT05045495||CSID Case|50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
33250836|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
32726733|NCT02732561|Sham Comparator|Sham Device|Sham device
32928328|NCT05688410|Experimental|Voluntary Exercise and No I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
32928329|NCT05688410|Experimental|No Exercise and I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
33250837|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
33250838|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
32726734|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
32726735|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
32726736|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
32726737|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
32928330|NCT05688410|No Intervention|No Exercise and No I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
32928331|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
32928332|NCT02049307|Placebo Comparator|Placebo|Matching placebo
32928333|NCT05319236|Other|Gabi System|Subjects will wear the Gabi system each time they go to sleep or are resting, to measure and record their SpO2, pulse rate, respiratory rate and movements.
32928334|NCT05314556|Experimental|Intervention|Group psychotherapy
32928335|NCT05311592|Experimental|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
32726738|NCT03428633|Active Comparator|Group B|Morphine IV
32726739|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
32726740|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
32726741|NCT02521337||pregnant women not in active labor|
32726742|NCT02521337||pregnant women in preterm labor|
32726743|NCT02521337||pregnant women in term labor|
32726744|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
32928336|NCT05311592|Experimental|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
32928337|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
32928338|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
32928339|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
32928340|NCT05670704|Experimental|ARGX-119|Patients receiving ARGX-119 IV or SC
32928341|NCT05670704|Placebo Comparator|Placebo|Patients receiving Placebo IV or SC
32928342|NCT03717155|Experimental|Avelumab and Cetuximab|Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
32928343|NCT03789097|Experimental|Combination therapy|Vaccination with Flt3L, Radiation, and Poly ICLC combined with Pembrolizumab
32726745|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
32768583|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7.
32928344|NCT05311046||Retrospective EHR-data only group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department between the years 2016-2021 and screened positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol and receive a blood culture order. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
33073566|NCT01168271||Febrile Hospitalized Children|Febrile hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
33073567|NCT01168271||Later Childhood and Adolescence|Re-enrollees who were originally enrolled at birth and completed the Pregnant Women and Newborn Cohort
33073568|NCT01168271||Non-Hospitalized Children|Febrile non-hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
33073569|NCT01168271||Pregnant Women + Newborns|Pregnant women presenting for antenatal consultations and delivery and their newborns
33073570|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
33073571|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils > 5 mm below the foramen magnum 79 without associated syringomyelia.
33250839|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
32928345|NCT05311046||Prospective EHR and Biomarker data group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department during the study enrollment period, screen positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol, receive a blood culture order and provide informed consent/assent for the collection of a 1-5 mL blood sample to be used to measure PERSEVERE biomarkers. Members of this cohort will have also consented to the reuse of their medical record data for the research. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
32928346|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
32928347|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
32928348|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
32928349|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
32928350|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
32928351|NCT04820036|Other|Patients with Obesity and NASH scheduled/recommended for P-ESG Procedure|We will perform a 12-month prospective, single-center, pilot observational study on patients with obesity and NASH with advanced fibrosis who are undergoing P-ESG. A total of 15 patients will undergo EUS-LB with EUS-PPG measurement in a single session prior to and at 12 months following P-ESG
32928352|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
33250840|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
32726746|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
32928353|NCT04795856|Active Comparator|chronic compensated moderate-severe primary mitral regurgitation (PMR)|
32928354|NCT04795856|Active Comparator|Healthy Volunteers|
32928355|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
32726747|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
32928356|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
32928357|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
32928358|NCT00355940|Experimental|1|
32928359|NCT00355940|Active Comparator|2|
32928360|NCT05275478|Experimental|Dose Escalation|Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD
32928361|NCT05275478|Experimental|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D
32928362|NCT05275478|Experimental|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D
32928363|NCT05275478|Experimental|Dose Expansion in Cholangiocarcinoma|Participants with MTAP-deleted cholangiocarcinoma will receive TNG908 at the identified RP2D
32928364|NCT05275478|Experimental|Dose Expansion in MPNST|Participants with MTAP-deleted malignant peripheral nerve sheath tumor (MPNST) will receive TNG908 at the identified RP2D
33250841|NCT01050595|Placebo Comparator|Placebo|
32726748|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
32768584|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7.
32928365|NCT05275478|Experimental|Dose Expansion in solid tumors|Participants with MTAP-deleted solid tumors will receive TNG908 at the identified RP2D
32726749|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
32726750|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
32726751|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo~Other names:~(Placebo for Brufen) (Placebo for Cital)~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
32726752|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
32726753|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
32726754|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
32928366|NCT05275478|Experimental|Dose Expansion in Glioblastoma|Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D
32928367|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
32928368|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
32928369|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
32928370|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
32726755|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
32726756|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
32928371|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
32928372|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
32928373|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
32928374|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
33073572|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length > 1spinal segment.
32726757|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
32726758|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
32726759|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
32726760|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
32726761|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
32726762|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
32726763|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
32726764|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
32726765|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
32726766|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.~Intervention: Device: Drager VN500 Ventilator"
32726767|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.~Intervention: Device: Drager VN500 Ventilator"
32928375|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
32928376|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
32928377|NCT05650658|Active Comparator|His/Left Bundle Branch Pacing (His/LBBP)|"Patients with LVEF≤35% at entry will receive a His/LBB defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system.~Patients with LVEF 36-50% at entry will receive His/LBB pacemaker which includes implantation of two leads, an endocardial right atrial lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system."
32928378|NCT05650658|Active Comparator|Biventricular Pacing (BiVP)|"Patients with LVEF≤35% at entry will receive a BiV defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~Patients with LVEF 36-50% at entry will receive BiV pacemaker which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular pacing lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus."
32928379|NCT04791254||A - main study cohort|"This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.~They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment"
32928380|NCT04791254||Sub-cohort B|This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
32726768|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
32726769|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
32928381|NCT04791254||sub-cohort C|This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
32726770|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
32726771|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
32726772|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
32726773|NCT02922725|No Intervention|Healthy Control|
32928382|NCT04791254||Cohort D|This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
32928383|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
32928384|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
32726774|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
32726775|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
32726776|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
32726777|NCT03422081||growth hormone deficiency|
32928385|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
32928386|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
32928387|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
32928388|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
32726778|NCT03422081||small for gestational age|
32928389|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
32928390|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
32928391|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
32726779|NCT03422081||matched controls|
32726780|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
32726781|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
32726782|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
32726783|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
32726784|NCT03127553|No Intervention|A - control|Free diet with standard bread
32928392|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
32928393|NCT04745546|Experimental|WeFlow-JAAA Stent Graft System|Participants will be treated with WeFlow-JAAA Stent Graft System
32928394|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
32928395|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
32928396|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
32928397|NCT05269160|Experimental|Dermaprazole 1% (Arm A:Head and neck)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
32928398|NCT05269160|Experimental|Dermaprazole 1% (ArmB: Breast)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
32928399|NCT05269160|Experimental|Dermaprazole 2% (Arm A: Head and neck)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
32726785|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
32726786|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
32928400|NCT05269160|Experimental|Dermaprazole 2% (Arm B: Breast)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
32928401|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
32928402|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
32928403|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
32928404|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
32928405|NCT05258630|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
32928406|NCT05258630|Active Comparator|D-Homes comparison|Brief diabetes educational session by a diabetes wellness coach.
32928407|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
32928408|NCT05643014||Firefighters over 18 years old|This is a within subject, observational study of firefighters. This study will involve three sample collections including buccal cells and urine samples; one collection pre and two collections post-structural fire exposure.
32928414|NCT04779866|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
32928415|NCT04779866|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
32928416|NCT05638880|Experimental|Control Group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily for 3 months
32928417|NCT05638880|Active Comparator|Levocetirizine group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily plus Levocetirizine 5 mg once daily in the evening titrated according to creatinine clearance for 3 months.
32928418|NCT03411707||Mutiple screening test group|
32726787|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
32726788|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
32928419|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
32928420|NCT05637086|Experimental|Control Group|This group will receive 100 mg of phenytoin 3 times daily for 6 months.
33250842|NCT03991975|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
32726789|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
32726790|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
33250843|NCT04039269|Active Comparator|Multiple (watch > 3 times)|Preoperative video information
33250844|NCT04039269|Active Comparator|single (watch 1 time)|Preoperative video information
33250845|NCT04039269|No Intervention|conventional (do not watch)|Do not watch video
33250846|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
33250847|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
33250848|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
33250849|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
33250850|NCT00873561|No Intervention|4 placebo|Placebo injection
33250851|NCT04039425||cancer patient|"Recently diagnosed cancer stage 1, 2, or 3~Assigned to receive immunosuppressive chemotherapy treatment~Natural hair that has not been dyed or permed in the past 3 months"
32726791|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
32726792|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
33250852|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
33250853|NCT02534389|No Intervention|control group|without intervention
33250854|NCT00873639||A|
33250855|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
33250856|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
33250857|NCT00879099|Active Comparator|Paroxetine|
32928421|NCT05637086|Active Comparator|Pentoxifylline group|This group will receive 100 mg of phenytoin 3 times daily plus pentoxifylline 400 mg two times daily for 6 months
32726793|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
32726794|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
32726795|NCT04449185|Experimental|HP eradication group|"HP eradication group~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
32726796|NCT03427151|Experimental|IPP-201101|every 4 weeks
32928422|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
32726797|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
32726798|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
32768585|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.
32768586|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28.
33073577|NCT01132898||cross-sectional TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 5 years from injury. Seen at only one visit.
33250858|NCT00879099|Placebo Comparator|Gelatine capsule|
33250859|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
33250860|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
33250861|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33250862|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
33250863|NCT01050751|Experimental|Lersivirine (new formulation)|
33250864|NCT01050751|Active Comparator|Lersivirine (old formulation)|
33250865|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
33250866|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
33250867|NCT01050829|Experimental|Arm 1|
33250868|NCT01050829|Active Comparator|Arm 2|
33250869|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
33250870|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
33250871|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
33250872|NCT00873717|No Intervention|Control|usual care
33250873|NCT00676338|Experimental|Exenatide Once Weekly|
33250874|NCT00676338|Active Comparator|Metformin|
32726799|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
32928423|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
32928424|NCT04737044|No Intervention|Study 1: Normal sugar|Control group will be required to continue consuming normal sugar intake for 8 weeks.
32928425|NCT04737044|Experimental|Study 1:Minimally refined brown sugar (MRBS)|Intervention group will be required to consume MRBS as added sugar based on their habitual diet for 8 weeks intervention.
32928426|NCT04737044|No Intervention|Study 2: Normal sugar intake|- The control group will have no intervention and will continue with their normal daily intake for six months.
32928427|NCT04737044|Experimental|Study 2: White sugar|"Intervention group I will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group I will be given white sugar for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
32928428|NCT04737044|Experimental|Study 2: MRBS|"Intervention group II will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group II will be given MRBS for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
32928429|NCT05230394|Experimental|Level 1 In Lab Polysomnography|
32928430|NCT05230394|Experimental|Level 2 In Home Polysomnography|
32928431|NCT03243461|Experimental|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
32928432|NCT05224778||Congenital Myotonic Dystrophy (CDM)|CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
32928433|NCT05224778||Childhood Myotonic Dystrophy (ChDM)|ChDM group includes those aged 1 to 4 years, 11 months at enrollment. Individuals must have a diagnosis of ChDM, which is defined as symptoms associated with DM1, absence of symptoms at birth, and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
32928434|NCT05209568|Experimental|Celiac Disease|Individuals with a confirmed diagnosis of celiac disease based on serology and/or histology
32928435|NCT05209568|Experimental|Healthy Controls|Individuals without a diagnosis of celiac disease
32928436|NCT05628194||Men who have sex with men (MSM)|
33073578|NCT01132898||HV|Healthy Volunteer with no history of TBI
33073579|NCT01132898||Prospective TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 1 year from injury.
33250875|NCT00676338|Active Comparator|Sitagliptin|
33250876|NCT00676338|Active Comparator|Pioglitazone|
32726800|NCT02837159|No Intervention|Usual care|Usual care
32726801|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
32726802|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
33250877|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
33250878|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
33250879|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
33250880|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
32928437|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
32928438|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
32928439|NCT05618444|Experimental|Automated Management (AM)|Receipt of text-based behavioral intervention
32928440|NCT05618444|No Intervention|Usual Care|Control group receiving usual care for obstructive sleep apnea
32928441|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
32928442|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
32928443|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
32726803|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
32726804|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
32726805|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
32726806|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
32726807|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
32726808|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
32726809|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
32726810|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
32726811|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
32726812|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
32726813|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
32726814|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
32726815|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
32726816|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
32726817|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by DHS- Children's Services.
32726818|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.~."
32726819|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
32726820|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
32726821|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
32726822|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
32726823|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
32928444|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
32928445|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
32928446|NCT03831776|Experimental|Bosutinib-Ropeginterferon combination|
32928447|NCT03831776|Active Comparator|Bosutinib monotherapy|
32928448|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
32928449|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
32726824|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
32928450|NCT05607134|Sham Comparator|Physical and occupational therapy group|The group will receive a Physical and occupational therapy program
32928451|NCT05607134|Active Comparator|Shock Wave group|The group will receive a radial Extracorporeal Shock Wave sessions
32928452|NCT05607134|Active Comparator|Peripheral Magnetic Stimulation group|The group will receive a Peripheral Magnetic Stimulation sessions
32928453|NCT04736693||Raloxifene|Reference Group
32928454|NCT04736693||Zoledronic Acid|Exposure Group
32726825|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
32928455|NCT04655378||Acute Rheumatoid Purpura|
32928456|NCT04655378||Rheumatoid Purpura in Remission|
32726826|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
32726827|NCT02636387||Placebo|Placebo Comparator
32726828|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
32726829|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
32928457|NCT04655378||Controls|Without infection, inflammatory or auto-immune pathology
32928458|NCT04652414|Experimental|Prednisone|Patients randomized to the intervention arm will receive prednisone 50mg PO daily for 7 days.
32726830|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
32726831|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
32928459|NCT04652414|Placebo Comparator|Placebo|Patients will receive matching placebo PO daily for 7 days.
32726832|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
32726833|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
32928460|NCT04736069|Active Comparator|Inpatient physical therapy program|The group received 21 sessions of physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program at inpatient clinic.
32928461|NCT04736069|Active Comparator|Outpatient physical therapy program|The group received the same physical therapy program including electrotherapy, superficial-deep heat applications and basic knee exercise program at outpatient clinic.
32928462|NCT04630964|Experimental|psilocybin|25 mg Single Oral Dose
32726834|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
32726835|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
32726836|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
32726837|NCT03425513||Hepatitis B group|
32928463|NCT04630964|Active Comparator|placebo|100 mg Single Oral Dose
32928464|NCT04736459|Experimental|Washed Catheter|Washed catheter arm: will be washed with culture medium before insemination
32928465|NCT04736459|Sham Comparator|Unwashed Catheter|Unwashed catheter arm: will not be washed with culture medium.
32928466|NCT05196230|Experimental|Experimental Condition (360° Video)|The 360° video (experimental) group will be mailed a study tablet with the 360° video prior to the dental visit.
32928467|NCT05196230|Active Comparator|Control Condition (Social Story)|The treatment-as-usual (control) group will be mailed a study tablet with a social story prior to the dental visit.
32928468|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
32928469|NCT05605886|Placebo Comparator|first group: (Control group)|"EMG will be performed for masseter & temporalis muscles at the diagnosis appointment.~Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections.~Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
32928470|NCT05605886|Active Comparator|second group. (intervention group)|"EMG will be performed for masseter & temporalis muscles at the diagnosis appointment.~Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.~Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
32726838|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
32726839|NCT04815161|Other|Pilloxa pillbox|Patients receiving the Pilloxa pillbox for drug administration
32726840|NCT04794803|Experimental|Reparixin|Reparixin oral tablets 1200 mg TID for 7 days
32928471|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
32928472|NCT05595044|Experimental|Vitamin D therapy and habilitation|40 ASD children receiving Vitamin D therapy and habilitation
32928473|NCT05595044|Other|Habilitation|40 ASD children receiving habilitation
32726841|NCT04794803|Active Comparator|Standard of care|Standard of care
32726842|NCT04756349|Active Comparator|Clearfil SE|Group containing 10-MDP and HEMA monomers
32726843|NCT04756349|Active Comparator|Optibond All-in-One|Group containing HEMA monomer
32726844|NCT04756349|Active Comparator|Prime & Bond Universal|Control Group containing other monomers
32928474|NCT05169242|Experimental|Intervention group|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
32928475|NCT05169242|No Intervention|Control group|In the control arm, no endoclip will be applied to all post-polypectomy sites, with the exceptions of uncontrolled immediate PPB or pre-treatment in very large pedunculated polyps as specified above. The subjects with endoclips applied due to safety reasons will be included in the subsequent intention-to-treat analysis, but not the per-protocol analysis.
32928476|NCT04736381||Kidney transplanted patients treated with Nulojix|Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
32726845|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
32726846|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
32726847|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
32726848|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
32726849|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
32726850|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
32726851|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
32726852|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
32726853|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
32905822|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
32905823|NCT05316662||Semaglutide|Participants with T2D will be assessed for clinical parameters associated with the once-daily use of oral semaglutide who have not previously been treated with injectable glucose-lowering medication in routine clinical practice.
32905824|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
32905825|NCT01830998||control, MCI|control and MCI group.Glycaemic control
32905826|NCT01830998||control and MCI|treatment and without treatment
32905827|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
32905828|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
32905829|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
32905830|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
32905831|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
32905832|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
32905833|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
32905834|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
32905835|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
32905836|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
32905837|NCT01445873||PAH patients receiving Sitaxentan|
32905838|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
32905839|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
32905840|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
32928477|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
32928478|NCT02906657|No Intervention|Control|Usual Care
33250881|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
32726854|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
33250882|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
32726855|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
32726856|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
32726857|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
32726858|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
32726859|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
32726860|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
32726861|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
32726862|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
32726863|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
32726864|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
32726865|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
32726866|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
32726867|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
32726868|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
32726869|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
32726870|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
32726871|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
32726872|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
32726873|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
32726874|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
32726875|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
32726876|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
32726877|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
32928479|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
32928480|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
32928481|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
32928482|NCT04610138|Experimental|Active treatment with 60 ml low-dose ZnAg|(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
32928483|NCT04610138|Experimental|Active treatment with 60 ml high-dose ZnAg|(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
33250883|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
32726878|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
32928484|NCT04610138|Placebo Comparator|60 ml matching placebo|60 ml matching placebo, po q12 hours
32928485|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
32928486|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
32928487|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
32928488|NCT04584320||Premature neonates with necrotizing enterocolitis|
32928489|NCT04584320||Premature neonates without necrotizing enterocolitis|
32726879|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
32928490|NCT05594576|Experimental|ENDOCUFF VISION® Endoscopic Cap coupled with GI GENIUS™ Artificial Intelligence (AI)|
32928491|NCT05594576|Active Comparator|GI GENIUS™ Artificial Intelligence (AI) alone|
32928492|NCT05594576|Active Comparator|ENDOCUFF VISION® endoscopic cap alone|
32928493|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
32928494|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
32726880|NCT02064803|Active Comparator|Control group: A|Gastro-entero anastomosis only
32726881|NCT02064803|Experimental|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
32726882|NCT01791595|Experimental|AZD3965 Cohort 1 (5 mg OD)|
32726883|NCT01791595|Experimental|AZD3965 Cohort 2 (10 mg OD)|
32726884|NCT01791595|Experimental|AZD3965 Cohort 3 (20 mg OD)|
32726885|NCT01791595|Experimental|AZD3965 Cohort 4 (30 mg OD)|
33250884|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
32726886|NCT01791595|Experimental|AZD3965 Cohort 5 (15 mg BD)|
32726887|NCT01791595|Experimental|AZD3965 Cohort 6 (10 mg BD)|
32726888|NCT01791595|Experimental|AZD3965 Expansion Cohort (10 mg BD)|
32726889|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
32726890|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
32726891|NCT05061433|No Intervention|Usual Care|Participants receive standard of care.
32928495|NCT05585762|Experimental|Ketone ester|Flavored ketone ester beverage 75 mL. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
32928496|NCT05585762|Placebo Comparator|Non-ketone placebo|Flavored beverage with bitter additive 75 mL. Matched for appearance, taste and calories. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
32928497|NCT02792465|Experimental|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
32928498|NCT02792465|Experimental|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
32928499|NCT02792465|Experimental|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
32928500|NCT04568486|Other|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
32928501|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
32928502|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
32928503|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
32928504|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
32928505|NCT05573828|Experimental|Angiography group|Patients undergoing initially ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then, post-thyroidectomy ICG angiography to predict immediate parathyroid function.
33250885|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
32928506|NCT05573828|No Intervention|Control group|Patients who underwent post-thyroidectomy ICG angiography to predict immediate parathyroid gland function by scoring the degree of fluorescence of the parathyroid glands
32928507|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
32726892|NCT05061433|Experimental|Intervention|"Initial Home Visit: MIH/CP provider team will visit the patient's home at the scheduled time following a specific General Followup Protocol involving 1. Assessment of patient understanding of recent illness and medical therapy including reinforcement of medical adherence, 2. Any other disease-specific concerns, 3. Performance of a home safety evaluation, 4. If patients have concerns relating to their ability to manage their disease process at home, 5. MIH/CP providers and an on-call social worker will provide assistance in the form of on-site, telephone, and electronic referrals or provision of appointments with appropriate services.~Subsequent visits: The MIH/CP team will decide in conjunction with Medical Control and the PMD if further followup is needed, and the most appropriate followup interval., At 30 days from initial hospital discharge, the patient will be discharged from the MIH/CP program in conjunction with the PMD."
32726893|NCT05056597||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
32726894|NCT05056597||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype
33400761|NCT03635099|Experimental|Part I - BI 25 mg (fasted)|Part I - 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 50 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
33400762|NCT03635099|Experimental|Part I - BI 50 mg (fasted)|Part I - 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 100 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
33400763|NCT03635099|Experimental|Part I - BI 100 mg (fasted)|Part I - 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
32726895|NCT05056597||BN|Participants that meet DSM-V criteria for Bulimia Nervosa.
32726896|NCT05056597||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
33400764|NCT03635099|Experimental|Part I - BI 200 mg (fasted)|Part I - 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
32726897|NCT04451941|Experimental|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
32726898|NCT04451941|Sham Comparator|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
32726899|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
32726900|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
32726901|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
32928508|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
32726902|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c >64 mmol/mol"
32726903|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c <64 mmol/mol"
32928509|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
32928510|NCT04536350|Experimental|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
32928511|NCT04536350|Placebo Comparator|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
32928512|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
32928513|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
32726904|NCT03441919||Healthy subjects|"Absence of disease, no use of medication~Matched for age, gender and BMI~HbA1c <42 mmol/mol"
32726905|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
32726906|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
32726907|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
32928514|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
32928515|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
32928516|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
32928517|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
32928518|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
32928519|NCT04530890|Experimental|One arm only|Only one arm with blood samples
32928520|NCT05132504|Experimental|Neoadjuvant Folfirinox and Pembrolizumab followed by sx for patients with pancreatic cancer|Patients will receive 6 cycles of Folfirinox (Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 180 mg/m2, 5-Fluorouracil 2,400 mg/m2) with 2 cycles of Pembrolizumab 400 mg before surgical resection. Following surgery patients will receive 5-Fluorouracil based chemotherapy for up to 6 cycles with 7 more cycles of Pembrolizumab. Patients will receive a total of 9 doses of Q6week cycles of Pembrolizumab.
32928521|NCT04525820|Experimental|High Dose Vitamin D|"Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D.~The medication be administered orally"
32928522|NCT04525820|Placebo Comparator|Placebo|Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
32928523|NCT05570708|Experimental|Personal experience of substance-assisted therapy using psilocybin, MDMA, and LSD|
32726908|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
32726909|NCT04891705||Pleural Effusion|Adult and pediatric subjects with suspicion of pleural effusion
32726910|NCT04891705||Lung Consolidation|Adult and pediatric subjects with suspicion of lung consolidation
32726911|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
32726912|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
32726913|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
32726914|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
32726915|NCT03443947|Experimental|D group|
32726916|NCT04890145|Experimental|Mild to severe hearing loss|
32726917|NCT02667067|Other|Anterior cervical discectomy & fusion (ACDF)|
32726918|NCT02667067|Experimental|Simplify Disc|Simplify Disc
33400765|NCT03635099|Placebo Comparator|Part II - Placebo (fed)|Part II - 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
32726919|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
32928524|NCT05122286|Experimental|Bailout angioplasty|If the patient is randomized into the bailout angioplasty arm, the choice of balloon dilation or stenting will be left to the discretion of the interventionalist.
32928525|NCT05122286|Active Comparator|Standard therapy|If the patient is randomized into the standard therapy arm, the interventionalist will decide whether to stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters.
32726920|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].~All the operating surgeons will receive proper training in the operative procedure before study start."
32726921|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
32726922|NCT02594215|Experimental|Experimental|Experimental
32726923|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
32726924|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
32726925|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
32928526|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
32928527|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
32928528|NCT05570162|Experimental|Low Flash adherence|Adult (>18 yrs old) type 1 diabetes patients with 4 or less daily Flash scans
32928529|NCT05117450|Active Comparator|HeprAN first|Each included patient will have hemodialysis sessions with HeprAN membrane and then HYDROLINK
32726926|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
32726927|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
32726928|NCT04881175|Experimental|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
32726929|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
32726930|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
32726931|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
32726932|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
32726933|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
32726934|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
32726935|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
33073580|NCT01132898||Remote Select Exposure Samples|Participants who are unable to travel to the NIH Clinical Center to participate can remote consent, answer questionnaires remotely, and have biospecimens sent to our lab for analysis.
32906626|NCT04377386|Placebo Comparator|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
32906627|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
32906628|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
32906629|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.~This means a distribution of carbohydrate as follows:~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
32906630|NCT04377230|Experimental|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
32906631|NCT04377230|Active Comparator|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
32906632|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
32906633|NCT03407846|Experimental|Total abdominal hystrectomy|
32906634|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
32906635|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
32906636|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
32906637|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
32906638|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
32906639|NCT01728818|Experimental|Arm A|
32726936|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
32726937|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
32726938|NCT04547569|Experimental|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
32726939|NCT04547569|Experimental|Speech production|fMRI measurement of brain activity during normal speech production
32726940|NCT04547569|Experimental|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
32726941|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
32726942|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
32726943|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
32726944|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
32726945|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
32726946|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
32726947|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
32726948|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
32726949|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
32726950|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
32906640|NCT01728818|Active Comparator|Arm B|
32906641|NCT04377542|Active Comparator|LIFT|Ligation of intersphincteric fistula tract
32906642|NCT04377542|Active Comparator|Parks|Modified Parks technique
32906643|NCT04377542|Active Comparator|Seton|Two-stage seton placement
32906644|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
32906645|NCT01728896|No Intervention|Conventional management|
32906646|NCT03407690||PIN2 study participants|All those giving swabs for the study
32906647|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
32906648|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
32906649|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
32906650|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
32906651|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
32906652|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
32906653|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
32906654|NCT01729052|No Intervention|Standard treatment|General anaesthesia
32906655|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
32906656|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
32906657|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
32906658|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
32906659|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
32906660|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
32906661|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
32906662|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
32906663|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
32906664|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
32906665|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
32906666|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
32726951|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
32726952|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
32726953|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
32726954|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
32726955|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
32726956|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
32726957|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
32726958|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
32726959|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
32726960|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
32726961|NCT03449563|Placebo Comparator|Placebo group (group G)|
32726962|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
32726963|NCT03449563|Experimental|open TPVB group(group E)|
32928530|NCT05117450|Active Comparator|HYDROLINK first|Each included patient will have hemodialysis sessions with HYDROLINK and then HeprAN membrane
33400766|NCT03635099|Experimental|Part II - BI 400 mg once daily (fed)|Part II - 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
33400767|NCT03635099|Experimental|Part II - BI 200 mg twice daily, 400 mg total (fed)|Part II - 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
32928533|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
32928534|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
32928535|NCT05552690|Other|Thalassemia screening positive|In this study only 1 group of participants. No comparative. Only description
32726964|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
32928536|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo conventional surgery.~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
32928537|NCT05107856|Experimental|PRT1419 Monotherapy|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned.
32928538|NCT05107856|Experimental|PRT1419/Azacitidine Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Azacitidine will be administered by intravenous or subcutaneous on Days 1 through 7 (or alternatively on Days 1 through 5, 8 and 9) of each 28-day treatment cycle.
32928539|NCT05107856|Experimental|PRT1419/Venetoclax Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Venetoclax will be administered orally after either a 3-day or 5-week ramp-up period to reach 400 mg daily administration, prior to commencing PRT1419 administration.
32928540|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
32726965|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
32726966|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
32928541|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
32928542|NCT02192021|Experimental|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
32928543|NCT04473326|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
32928544|NCT04473326|No Intervention|Control Arm|Up to daily, untailored text messages.
32928545|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
32928546|NCT05550428|Experimental|Treatment group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of PEMF exposure in total.
32928547|NCT05550428|Sham Comparator|Sham group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of sham exposure in total.
32928548|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to provide specimens for genetic testing, next-generation sequencing, and other related studies.
32928549|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1 mutation.
32928550|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
32928551|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
32928552|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
32928553|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
32928554|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
32726967|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
32726968|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
32928555|NCT05099042|Experimental|Group intervention - questionnaire and recommendations|The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
32928556|NCT05099042|No Intervention|Group control - questionnaire without recommendations|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations.
32928557|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg QD
32928558|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg BID
33073581|NCT01132898||Select Exposure Group|US government associated personnel experiencing TBI-like symptoms arising after possible exposure to a non-natural energy source
32726969|NCT03437551||no intervention|Cross-sectional Observation study
32726970|NCT03437473|Active Comparator|Active stimulation QD|
32726971|NCT03437473|Active Comparator|Active stimulation QID|
32726972|NCT03437473|Sham Comparator|No stimulation|
32726973|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
32928559|NCT02055781|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry.
32928560|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
32928561|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
32928562|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
32928563|NCT05096156|Experimental|All participants are fit with the study daily disposable lenses|All subjects are re-fit into their habitual monthly replacement contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days. Upon return, subjects are refit into the daily disposable contact lenses.
32928564|NCT05094440|Experimental|Immediate Treatment|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app intervention will be primarily monitored for one month, but followed for up to 3 months, and will be supplemented with a walk through manual and links to DBT worksheets. The intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program or greater community.
32928565|NCT05094440|Active Comparator|Waitlist and Delayed Treatment|Waitlist control whereby outpatients or members of the community will wait 1 month (4 weeks) to receive the intervention and then receive the Pocket Skills webapp for the subsequent 2 months (8 weeks). The waitlist period and subsequent intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program.
32928566|NCT04429100||liver fibrosis stage F0|
32928567|NCT04429100||early-stage liver fibrosis (F1-2)|
32928568|NCT04429100||late-stage liver fibrosis (F3-4)|
32928569|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
32928570|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
32928571|NCT03849326|Experimental|"Non-fatigued patients"|
32928572|NCT03849326|Experimental|"Fatigued patients"|
33250886|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
32928573|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
32726974|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
32928574|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
32928575|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group D."
32928576|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group C."
32928577|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
32928578|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
32928579|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
32928580|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
32928581|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
32928582|NCT03839420|Experimental|CZM IOL|
32928583|NCT03839420|Active Comparator|Competitor IOL|
32928584|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
32928585|NCT04368806|Experimental|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
32928586|NCT04368806|Placebo Comparator|Placebo|Normal Saline with Autologous Serum
32928587|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
32928588|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
33073582|NCT01132898||Select Exposure Matched Unaffected|a longitudinal control group comprised of unaffected volunteers matched to the Select Exposure group
32726975|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
32726976|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
32928589|NCT04776395|Experimental|Arm A (iberdomide hydrochloride, dexamethasone)|Patients receive iberdomide hydrochloride PO QD on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32928590|NCT04776395|Active Comparator|Arm B (iberdomide hydrochloride)|Patients receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32928591|NCT04341194|No Intervention|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
32928592|NCT04341194|Experimental|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
33073585|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
33073586|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
33250887|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
33250888|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
33250889|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
33250890|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
33250891|NCT00874185||Questionnaire|filling in questionnaires
33250892|NCT00761358|Experimental|Z-338|
33250893|NCT00761358|Placebo Comparator|placebo|
33250894|NCT05213637|Experimental|EAL Treatment Group|The patients with primary HCC will receive 12~20 doses of EAL infusion (1×10^9~2×10^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.
33073587|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
33073588|NCT01065454|Placebo Comparator|Placebo|Participants received placebo tid.
33073589|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
33400768|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
33400769|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
32726977|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
32726978|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
32726979|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
32726980|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
32726981|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
32726982|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.~Phase 2 : Administration of the scale of life's quality for validation."
32906667|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
32726983|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
32906668|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
32906669|NCT03407222|No Intervention|Control group|Control group does not receive text message
32906670|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
32906671|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
32906672|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
32906673|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
32906674|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
32906675|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
32906676|NCT01729520|Experimental|Knee extension strength training|
32906677|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
32906678|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
32906679|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
32906680|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
32906681|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
32906682|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
32906683|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
32906684|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
32906685|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
32906686|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
32906687|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
32906688|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
32906689|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
32906690|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
32906691|NCT04378946|Experimental|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
32906692|NCT04378946|Active Comparator|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
32906693|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
32906694|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
32906695|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
32906696|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
32928593|NCT04341194|Experimental|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
32726984|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
32726985|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
32928594|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
32928595|NCT04334954||Healthy Volunteers|Healthy Volunteers
32928596|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
32726986|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
32726987|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
32726988|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
32726989|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
32726990|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
32726991|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
32726992|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
32726993|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
32726994|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
32726995|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
32928597|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
32928598|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
32928599|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
32928600|NCT04332926|Active Comparator|Own Brand Cigarette|
32928601|NCT04332926|Experimental|ECIG 30 Watts, 0 mg/ml nicotine|
32928602|NCT04332926|Experimental|ECIG 30 Watts, 8 mg/ml nicotine|
32928603|NCT04332926|Experimental|ECIG 30 Watts, 15 mg/ml nicotine|
32928604|NCT04332926|Experimental|ECIG 30 Watts, 30 mg/ml nicotine|
32928605|NCT04324034|Experimental|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
32928606|NCT04324034|Active Comparator|laparoscopy|conventional laparoscopy
32928607|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
32928608|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
32928609|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
32928610|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
33250895|NCT05213637|Active Comparator|Control Group|The patients with primary HCC will receive a single TACE after radical resection.
32726996|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
32726997|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
32726998|NCT04420585|Experimental|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
32726999|NCT04415281|Experimental|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
32727000|NCT04415281|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
32727001|NCT04451239|Other|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
32727002|NCT04406935|Active Comparator|475 KHz|NuEra device treatment using 475 KHz
32727003|NCT04406935|Active Comparator|1 MHz|Arm 2: NuEra device treatment using 1 MHz
32727004|NCT04406935|Active Comparator|2 MHz|NuEra device treatment using 2 MHz
32727005|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
32928611|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
32928612|NCT04319588|Experimental|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
32928613|NCT04319588|Active Comparator|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
32928614|NCT05078528|Experimental|Experimental group - MMC|Imaging of study participants will be performed during the colposcopy examination. The mobile colposcope and the confocal imaging probe, together referred to as the Multimodal Mobile Colposcope (MMC), will be used to image and/or record videos the cervix. Cervical biopsies will be performed using biopsy forceps per standard protocols.
32727006|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
32727007|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
32928615|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
32928616|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
32727008|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
32928617|NCT05068622||patients with nasogastric tube before surgery|
32928618|NCT05068622||patients without nasogastric tube before surgery|
32928619|NCT04739969|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
32727009|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
32727010|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
32727011|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
32727012|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
32727013|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
32727014|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and >0 asexual P. falciparum parasites if they are aged < 1 year, or > 2,500 asexual parasites/µl of blood if they are aged > 1 year
32727015|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
32727016|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
32727017|NCT05121025||Helicobacter pylori patients|Patients with gastric biposies which was positive for Helicobacter pylori in culture
32727018|NCT05121025||Helicobacter pylori asymptomatic carriers|Healthy controls who are positive for Helicobacter pylori antigen in stool and have no symptoms of gastritis
32727019|NCT05121025||Healthy controls|Healthy controls who are negative for Helicobacter pylori antigen in stool and have no symptoms of gastritis
32727020|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
32727021|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
32928620|NCT04739969|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
32928621|NCT05065736|Experimental|18F-Clofarabine|18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy
32727022|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
32727023|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
32727024|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
32727025|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
32727026|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
32727027|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
32727028|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
32727029|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
32727030|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
32727031|NCT03436693|Experimental|Canagliflozin 100mg|
32727032|NCT03436693|Placebo Comparator|Placebo|
32727033|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
32727034|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
32727035|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
32727036|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
32727037|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
32727038|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
32727039|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
32727040|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
32727041|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
32727042|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
32727043|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
32727044|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
32928622|NCT05060354||MS Kesimpta (ofatumumab)|MS patients treated with Kesimpta (ofatumumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
32928623|NCT05060354||MS Ocrevus (ocrelizumab)|MS patients treated with Ocrevus (ocrelizumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
32928624|NCT05060354||MS Gilenya (fingolimod) and Mayzent (siponimod)|MS patients treated with Gilenya (fingolimod) or Mayzent (siponimod) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
32928625|NCT05060354||Healthy Control|Individuals with major autoimmune disorders or current treatment with immunosuppressive or immunomodulatory drugs Received SARS-CoV2 vaccination (completed regimen) within 2-6 months of enrollment Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
32928626|NCT05057702|Experimental|Individualized Treatment Recommendation|Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.
32727045|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
32727046|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
32727047|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
32727048|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
32928627|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
32928628|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
33277395|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
32727049|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
32727050|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
32727051|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
32727052|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
32727053|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
32727054|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
32727055|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
32727056|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
32727057|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
32727058|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
32727059|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
32727060|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
32727061|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
32727062|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
32727063|NCT03440203||no Diabetic neuropathy|
32727064|NCT03440203||Diabetic peripheral neuropathy|
32727065|NCT03440203||Diabetic peripheral neuropathic pain|
32727066|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
32727067|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
32727068|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
32727069|NCT04294225|Experimental|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 >= 1.3 pg/ml and E2 >= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32727070|NCT03435991||OAB patients|
32727071|NCT03435991||Healthy volunteers|
32727072|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
32727073|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).~1 mmHg = 1,36 cmH20.~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
32727074|NCT04906135|Experimental|Usher Syndrome|Adult and pediatric cochlear implant users with Usher syndrome
32727075|NCT04906135|Active Comparator|Idiopathic Hearing Loss|Adult and pediatric cochlear implant users with idiopathic hearing loss
32928629|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
32928630|NCT05040464|Experimental|AZA group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg
32727076|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
32727077|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
32727078|NCT04881487|Experimental|Additional stereotactic body radiation therapy|SBRT in addition to standard of care.
32727079|NCT04881487|No Intervention|Standard of care|Treatment according to current clinical practice.
32727080|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
32727081|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
32727082|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
32727083|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
32727084|NCT04855825|Experimental|Robotic Exoskeleton Therapy|Gait rehabilitation provided using a wearable robotic exoskeleton
32727085|NCT04855825|Active Comparator|Conventional Gait Therapy|Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT
32727086|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
32727087|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
32727088|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
32727089|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
32727090|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
32727091|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
32928631|NCT05040464|Experimental|MTX group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week
32727092|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
32727093|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
32727094|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
32928632|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
32928633|NCT03817814||Women with Breast Cancer|This is a cross-sectional survey of young women with breast cancer (YWBC) who received a consultation with an MSK Fertility Nurse Specialist before starting cancer treatment.
33277396|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
32727095|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
32727096|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
32928634|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
32928635|NCT05032664|Experimental|Intervention Group|Home-based aromatherapy programme
32928636|NCT05032664|Other|Control Group|Wait-list control
32928637|NCT03589651|Experimental|Group A|INCMGA00012 with epacadostat.
32727097|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
32928638|NCT03589651|Experimental|Group B|INCMGA00012 with INCB050465.
33073590|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
33250896|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
33250897|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
32727098|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
32727099|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
32727100|NCT04451395|Experimental|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
32727101|NCT04451395|No Intervention|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
32906697|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
32906698|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
32906699|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
32906700|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
32906701|NCT03002129|Other|fluid challenge|
32906702|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
32906703|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
32906704|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
32906705|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
32906706|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
32906707|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
32906708|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
32906709|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
32928639|NCT04298606|Experimental|Prevention (recombinant human EGF-rP64K/montanide ISA 51)|"LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity."
32928640|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
32928641|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
32928642|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
32928643|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
32928644|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
32928645|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
32928646|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
32928647|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
32928648|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
32928649|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
32928650|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
32928651|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
32928652|NCT04230668|Experimental|CPT + SRM|Participants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.
32928653|NCT04230668|Experimental|TAU + SRM|Participants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.
32928654|NCT04624295|Active Comparator|Early Antiplatelet Therapy|
32928655|NCT04624295|Placebo Comparator|Non-Early Antiplatelet Therapy|
32727102|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
32928656|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
32928657|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
32928658|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
32928659|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
32928660|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
32928661|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
32928662|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
32928663|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
32928664|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
32928665|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
33250898|NCT03992989|Experimental|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
32928666|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
32928667|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
32928668|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
32928669|NCT04197908|Experimental|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
33400770|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
33400771|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
32928670|NCT04605263|Active Comparator|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
32928671|NCT04605263|Experimental|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
32928672|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
32928673|NCT04450355|Experimental|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
32928674|NCT04450355|Placebo Comparator|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
32928675|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
32928676|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
32928677|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
32928678|NCT03676010||Sarcoma and GIST|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Sarcoma and GIST
32928679|NCT03676010||Breast cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Breast cancer
32928680|NCT03676010||Pancreatic cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Pancreatic cancer
32928681|NCT03676010||Renal cell carcinoma|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Renal cell carcinoma
32928682|NCT03676010||Colon Cancer (adjuvant setting)|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Colon Cancer (adjuvant setting)
32928683|NCT03676010||Solid tumours undergoing image-guided tumor ablation|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Solid tumours undergoing image-guided tumor ablation
32928684|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
32928685|NCT02352259|Experimental|Electrochemotherapy|
32928686|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
32928687|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
32928688|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
32928689|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
32928690|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
32928691|NCT04952870||COVID-19 group|Perinatal COVID-19 infection group, including newborns born from COVID-19 infected mothers and newborns with postnatal COVID-19 infections;
32928692|NCT04952870||NO group|Newborns admitted in NICU and receiving inhaled NO for respiratory failure
33400772|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
33400773|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
33400774|NCT04595786|Active Comparator|TXA group|The TXA group will receives Tranexamic acid intraoperative.
33400775|NCT04595786|Placebo Comparator|Placebo group|The TXA group will receives 0.9% saline intraoperative.
33400776|NCT04584164|No Intervention|Control arm|This arm involves patients applying the basic hygiene rules (with mouthwashes) without the sialendoscopy method.
33400777|NCT04584164|Experimental|Sialendoscopy arm|This arm involves patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
33400778|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
33400779|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
32905841|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
32905842|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
32905843|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
32905844|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
32905845|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
32905846|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
32905847|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
32905848|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
32905849|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
32905850|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905851|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905852|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905853|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905854|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905855|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
32905856|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
32905857|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
32905858|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
32905859|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
32905860|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
32928693|NCT04952870||Control group|Newborns admitted in NICU for respiratory failure not receiving iNO and not infected with COVID-19;
32928694|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
32928695|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
33250899|NCT03992989|Active Comparator|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
32727103|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
32727104|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
32727105|NCT04451083|Experimental|FOY-305|
32727106|NCT04450849|Experimental|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
32727107|NCT04450849|Active Comparator|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
32727108|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
32727109|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
32727110|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
32727111|NCT03435133|Active Comparator|Prasugrel|
32727112|NCT03435133|Active Comparator|Ticagrelor|
32727113|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
32727114|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
32727115|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
32727116|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
32727117|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
32727118|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
32928696|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
32928697|NCT04948580|Experimental|ICC-T|5.5 days with 8 hours of training for teachers aiming at changing attitudes towards violence and equipping teachers with non-violent discipline strategies
32928698|NCT04948580|No Intervention|Monitoring condition|No intervention
32928699|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
32928700|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
33250900|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
33250901|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
33250902|NCT00874341|No Intervention|1|
33250903|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
33250904|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
33250905|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
33250906|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
33250907|NCT00547378|Other|1|InterStim Therapy
33250908|NCT00547378|Active Comparator|2|Standard Medical Therapy
32727119|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
33400780|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
33400781|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
32727120|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
32727121|NCT03431155|Experimental|Experimental group|Nursing intervention
32727122|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
32727123|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
32727124|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
32727125|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
32727126|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
32727127|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
32727128|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
32727129|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
32727130|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
32727131|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
32905861|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
32905862|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
32905863|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
32905864|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
32905865|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
32905866|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
32905867|NCT05315102|Experimental|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
32905868|NCT05315102|Sham Comparator|Control group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
32905869|NCT01550471|Experimental|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
32905870|NCT01550471|Experimental|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
32905871|NCT01550471|Experimental|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
32905872|NCT01550471|Experimental|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
32905873|NCT01550471|Experimental|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
32905874|NCT01550471|Experimental|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
32905875|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
32905876|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
32905877|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
32905878|NCT03215264|Experimental|Single Arm|
32905879|NCT05312684||High anticholinergic burden|ACB scale score 1 or >1 as a high anticholinergic buden
32928701|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
32928702|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
32928703|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
32928704|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
32727132|NCT04450615|Experimental|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
32727133|NCT04450615|No Intervention|Control group|The participants of this group will follow their typical daily routine
32727134|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
32727135|NCT04450537|Experimental|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
32727136|NCT04450537|No Intervention|Sun Safety Control|Participants will be exposed 10 sun safety messages
32727137|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
32727138|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
32727139|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
32727140|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
32727141|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
32727142|NCT04689295|Other|experiment group|Three dimensional scoliosis therapy method (Schroth) will be applied to the participants for 6 weeks. It consist of 15 different exercises combined with rotational breathing exercise.
32727143|NCT04689295|Other|control group|Traditional scoliosis exercises will be applied to the participants for 6 weeks. It consist of 6 different exercises
32727146|NCT03434587|Experimental|Syndactyly|Syndactyly
32928705|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
32727147|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
32727148|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
32727149|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
32727150|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
32928706|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
32928707|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
33400782|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
32727151|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
32727152|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
32727153|NCT04255381|Experimental|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
32727154|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
32727155|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
32727156|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
32727157|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
32727158|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
32928708|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
32928709|NCT04121780|Experimental|Growth Hormone|Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
32928710|NCT04121780|Placebo Comparator|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
32928711|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
32928712|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
32928713|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
32928714|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
32928715|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
32928716|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
32928717|NCT05723120|Experimental|Neuromuscular Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
32727159|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
32928718|NCT05723120|Experimental|Respiratory Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
32928719|NCT04392635|Experimental|Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
32928720|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
32928721|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
32928722|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
33400783|NCT05419752|Experimental|endo sequence bioceramic sealer|obturation using Endo-sequence BC sealer
32727160|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
33400784|NCT05419752|Experimental|MTA fill apex calcium silicate base sealer|obturation using calcium-silicates based MTA fill-apex sealer
32768587|NCT05388201||FACEFIT|Participants will enter a chamber where they will undergo 3D facial scanning using a dedicated camera system and be trained to don a N95 respirator properly. The fitted filtering efficiency (FFE) of 4 types of face coverings: a N95 respirator, a KN95 respirator (with and without a clip), a surgical mask (with and without a clip), and a KF94 respirator (with and without a clip) will be tested using the OSHA quantitative fit testing protocol for filtering face pieces. Participants will measure their peak expiratory flow pre and post mask fit testing using a disposable peak flow meter.
32768588|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
33400785|NCT05419752|Experimental|AH plus resin sealer|obturation using AH Plus sealer
33400786|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
33400787|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
33400788|NCT05419596||Major Urologic Surgery Group|Elder patients who undergo major urologic surgery will be investigated for the change in genomic protein that are related to cognition. These proteins are APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 (complement receptor 1) , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2)
33400789|NCT03633929||KIOS OUD|
33400790|NCT04373148||COVID-19|Participants diagnosed with COVID-19
33400791|NCT04373148||Controls|Participants not diagnosed with COVID-19
32928725|NCT03203681|Other|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
32928726|NCT04111874|Experimental|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
32928727|NCT04111874|Active Comparator|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
32928728|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
32928729|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
32928730|NCT03632798|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
32928731|NCT03632798|Experimental|ChemoID-guided treatment|"Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
32928732|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
32928733|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
32928734|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
32928735|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
32928736|NCT04089566|Experimental|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
32928737|NCT04089566|Active Comparator|12/12 mg Randomized Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
32928738|NCT04089566|Experimental|50/28 mg Randomized Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
32928739|NCT04089566|Experimental|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
32928740|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
32928741|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
32928742|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
33250909|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
32727161|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
32727162|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
32727163|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
32928743|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
32928744|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
32928745|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
32928746|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
32928747|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
32928748|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
32928749|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
32928750|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
32928751|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
32928752|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
32928753|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
32928754|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
32928755|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
32928756|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
32928757|NCT05723042|Experimental|EMS with CIMT group|
32928758|NCT05723042|Active Comparator|EMS Group|
32928759|NCT05722964|Experimental|SHR-1906，-Dose A|
32727164|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
33400792|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
32727165|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
32928760|NCT05722964|Experimental|SHR-1906，- Dose B|
32928761|NCT05722964|Placebo Comparator|Placebo|
32727166|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
32928762|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
32928763|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
32727167|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
32727168|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
32727169|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
32727170|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
32928764|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
32928765|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
32928766|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
32928767|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
32928768|NCT03994874|Experimental|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
32928769|NCT03994874|Active Comparator|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
32928770|NCT03987776|Experimental|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
33400793|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
33400794|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
32727171|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
32727172|NCT04240249|Experimental|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
32928771|NCT03987776|Experimental|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
32928772|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
32928773|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
33400795|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
33400796|NCT04322994|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
32727173|NCT04240249|Experimental|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
32727174|NCT04240249|No Intervention|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
32727175|NCT04655911||ABO-101|Participants from prior interventional trials involving the administration of ABO-101.
32727176|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
33250910|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
33250911|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
32727177|NCT04450303|Experimental|Telehealth Therapy|
32727178|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
32727179|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
33250912|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
33250913|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
33250914|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
32727180|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
32727181|NCT03430297|Experimental|JS001 240mg Q2W|
32727182|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
32727183|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
32727184|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
32905880|NCT05312684||Normal anticholinergic burden|ACB scale score <1 as a control group
33250915|NCT04010656|Experimental|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
33250916|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
33250917|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
33250918|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
33250919|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
33250920|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
33250921|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
33250922|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
33250923|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
33250924|NCT00962494|Experimental|online workshop|
33250925|NCT04010032|Experimental|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
33250926|NCT04010032|Active Comparator|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
33250927|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
33250928|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
33250929|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
33250930|NCT04858971||Control|No source will be indicated on information provided for review
33250931|NCT04858971||Government source|A government logo will be shown on information provided for review
33250932|NCT04858971||Medical source|A medical logo will be shown on information provided for review
33250933|NCT04858971||Social media source|A social media logo will be shown on information provided for review
33250934|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
33250935|NCT02247388|No Intervention|Standard Care|Standard Care
33250936|NCT00874575|Placebo Comparator|1|Control
33250937|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
33250938|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
33250939|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
33250940|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
33250941|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
33250942|NCT05205213||lateral retromuscular preperitoneal group|All patients undergoing open lateral retromuscular preperitoneal repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
32727185|NCT04224883|Active Comparator|24-hours group|"The critical patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
32727186|NCT04224883|Experimental|16-hours group|"The critical patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
32727187|NCT04224883|Experimental|intermittent group|The critical patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60min or 120min through stomach tube.Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days
32727188|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
32727189|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
32727190|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
32928779|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
32928780|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
32727191|NCT04219735|Experimental|Minocycline|Minocycline 100 mg BID
32727192|NCT04219735|Placebo Comparator|Placebo|Placebo capsules identical to experimental arm
32727193|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
32928781|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
32928782|NCT02978690|Experimental|BI655130|
32928783|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
32928784|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
32928785|NCT05722730|Experimental|Pilates|The Pilates exercise protocol was designed based on protocols contained in previously published clinical trials whose objective had been muscle strengthening or improvement of muscle fatigue. Thus, the protocol will perform exercises from the classic repertoire of the Pilates Method, using equipment exclusive to the Method - such as Cadillac, Lader Barrel, Chair and Reformer. The sessions will take place twice a week, in a group of up to 3 participants, always in the morning lasting 60 minutes, with 10 minutes of warm-up, 40 minutes of load exercises and 10 minutes of relaxation exercises and calm down. All sessions were carried out by a physiotherapist specialized in the method, in a specific outpatient clinic. The professional who conducted the Pilates sessions, performed the proposed protocol, is unaware of the outcomes studied by the project.
32928786|NCT05722730|No Intervention|Control|Only follow-up of the clinical evolution will be carried out
32928787|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
32928788|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
32928789|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
33250943|NCT05205213||Reverse TAR group|All patients undergoing open reverse TAR repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
33277397|NCT05280860|Experimental|Group R: bilateral RSB under ultrasound guidance after general anesthesia|Group R was subjected to a bilateral RSB under ultrasound guidance after general anesthesia.
33277398|NCT05280860|No Intervention|Group G: simple general anesthesia|Group G received simple general anesthesia.
32727194|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
32727195|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
32727196|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
32768589|NCT04429451|Experimental|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
33400797|NCT04322994|Experimental|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.~Intervention: Device: High-flow nasal cannula"
32768590|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
32768591|NCT05367219|Experimental|Air sterilizer|The invesitigators will monitore smoke and try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the experimental group.
32768592|NCT05367219|No Intervention|Control|The control group was monitored for smoke during the endoscopic gastrointestinal surgery without any intervention.
32768593|NCT04838873|Active Comparator|Open Radical Cystectomy|Standard open radical cystectomy.
32768594|NCT04838873|Experimental|Laparoscopic-assisted radical cystectomy.|Laparoscopic-assisted radical cystectomy.
32768595|NCT05413941|Experimental|Internet-based Cognitive Behavioral Therapy|
32768596|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
32768597|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
32768598|NCT04544839|Experimental|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
32768599|NCT04544839|Active Comparator|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
32768603|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
32768604|NCT05071339|Experimental|Participants|"Patients treated at the IVF unit at Shamir Medical Center planned for an antagonist cycle will undergo blood test and US exam at day 2-3 of their menstrual cycle. Patients will be recruited if a leading follicle 10-13 is shown in the presence of E2 > 200-350 pmol/L.~Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-5 days intervention."
32768605|NCT05366829|Experimental|Tislelizumab in conjunction with radiation therapy|"Participants will receive local therapy including TACE+ RT or Ablation (tumors with incomplete ablation) + RT or RT alone (for patients not eligible for TACE or Ablation) and will be screened for eligibility prior to enrollment.~Once eligibility has been confirmed, Tislelizumab will be started before radiation therapy and will continue after radiation therapy.~Participants who do not receive Tislelizumab for a total of two cycles will be replaced and interpreted for only toxicity analysis."
32768606|NCT04838483|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
32768607|NCT04521829|Experimental|VR-enhanced treadmill walking|Participants will be tested during 2 sessions of VR-enhanced treadmill walking.
32768608|NCT05386485||Group A (asymptomatic infection)|Absence of clinical manifestation during the acute phase of SARS-CoV-2 infection until discharge.
32768609|NCT05386485||Group B1 (mild symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate < 30/minute; peripheral oxygen saturation (SpO2) >94%) and no radiological evidence of pneumonia
32768610|NCT05386485||Group B2 (moderate symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate < 30/minute; peripheral oxygen saturation (SpO2) >94%) and radiological evidence of pneumonia
32768611|NCT05386485||Group B3 (severe symptomatic infection)|Clinical manifestation of the infection with severity signs (respiratory rate > 30/minute; peripheral oxygen saturation (SpO2) <94%) and radiological evidence of pneumonia
32905881|NCT05312528||Study Group|Stage 3 and 4 endometriosis patients
32905882|NCT05312528||Control Group|Patients without endometriosis, who required surgery for tubal ligation, benign ovarian cysts or uterine fibroids were included.
32905883|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
32905884|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
32727197|NCT04450147|Experimental|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
32727198|NCT04450147|Active Comparator|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
32928790|NCT04316975|Other|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.~Laboratory Biomarker Analysis: Correlative studies~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
32928791|NCT05722496|Experimental|High Intensity Interval Training Group (Group A)|"Each training session consist of three parts of 30 minutes:~Warm up (5 minutes) free active exercise of the lower extremities,~Training continued with three exercise intervals lasting 3 min each, at an exercise intensity of 85%-95% of HRpeak equalling 15-17 on the Borg scale. Each interval was separated by 4 min of active breaks at an intensity of 60%-70% of HRpeak.~Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
32928792|NCT05722496|Experimental|Moderate intensity continous training group (Group B)|"Each training session consist of three parts of 30 minutes:~Warm up (5 minutes) free active exercise of the lower extremities,~Training continued with cycling at low-to-moderate exercise intensity of 50%-60% of HRpeak, representing 11-13 on the Borg scale.~Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
32928793|NCT05722340|Experimental|NIVATS|Lung biopsy is performed using non-intubated video-assisted thoracic surgery (NIVATS).
33277399|NCT04364360|Experimental|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
32727199|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
32727200|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
32727201|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
32727202|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
32727203|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
32727204|NCT03433495|No Intervention|Waiting list|No intervention
32727205|NCT04070365||FLEX Vessel Prep followed by angioplasty|
32727206|NCT04067479|Experimental|Young|"21-30 year old men and women Inclusion/Exclusion Criteria~All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~Age: 21-30 years~Body mass index <35 kg•m-2,~Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
32743498|NCT02622321|Active Comparator|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
32928794|NCT05722340|Active Comparator|IGAVATS|Lung biopsy is performed using Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS).
32928795|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
32928796|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
32928797|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
32928798|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
33277400|NCT04361942|Experimental|Experimental|Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline
33277401|NCT04361942|Placebo Comparator|Placebo|Intravenous injection of 100 ml of saline containing no cells
33277402|NCT04286516|Experimental|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
32727207|NCT04067479|Experimental|Older Adults|"Inclusion/Exclusion Criteria~All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~Age: 60-75 years~Body mass index <35 kg•m-2~Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
32727208|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
32727209|NCT03375853|Experimental|Experimental Condition|"Participants will complete computer-based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer-based training, participants will be instructed to respond or inhibit responses to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention. To optimize the intervention, we narrowed the low-calorie food stimulus set to make a better distinction between high-calorie and low-calorie foods and we changed the filler images (water and furry mammals) in the go/no-go task from 100% go to 50% go and 50% no-go to measure learning of stimulus-specific respond associations."
32727210|NCT03428737|Other|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
32727211|NCT03428737|Other|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
32727212|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
32727213|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
32727214|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
32727215|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
32727216|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
32727217|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
32727218|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
33250944|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
33250945|NCT05205057||Pre-menopausal|Pre-menopausal women
33250946|NCT05205057||Post-menopausal women|post-menopausal women
33250947|NCT00874653||Group 1|
33250948|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
32727219|NCT04012723|Experimental|MY01 Device|"Device: MY01 Device~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
32727220|NCT04449757|Experimental|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
32727221|NCT04449757|Experimental|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
32727222|NCT04008745|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
32727223|NCT04008745|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
32727224|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
33250949|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
33250950|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
33250951|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
33250952|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
32727225|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
32928799|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
33250953|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
32727226|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
32928800|NCT03210701|Other|Patients requesting a HIV screening test|
32727227|NCT05076643||University students|University students in Universiti Tunku Abdul Rahman Sungai Long Campus
32928801|NCT04345016|Experimental|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
32928802|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
32928803|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
32928804|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
32928805|NCT03337724|Experimental|Placebo + Paclitaxel|
32928806|NCT04295447|Other|Standard of care|"Observation only or~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
32928807|NCT04295447|Experimental|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
32928808|NCT04190147||Moderate-to-late preterm group|
32928809|NCT04190147||Full-term group|
32928810|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
32928811|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
32928812|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
32928813|NCT03340337|Experimental|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
32928814|NCT03340337|Experimental|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
33250954|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
33250955|NCT04400214|Experimental|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
33250956|NCT04400214|Active Comparator|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
32928818|NCT05722106|Experimental|Control - Info only|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
32928819|NCT05722106|Experimental|Deontological|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. We all need to do this, however difficult, because it is the right thing to do: it is our duty and responsibility to protect our families, friends, and fellow citizens."
32928820|NCT05722106|Experimental|Empathy|"Participants read a flyer containing the following message:~The sick, elderly, and immunocompromised need our help. We all have a choice. If we don't take the right actions, we risk the lives of others. But we can protect those most likely to be harmed. We can protect those who are vulnerable by taking simple steps:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. Take action to protect those who are vulnerable!"
33250957|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
32727228|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
32727229|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
33400798|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
33400799|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
32727230|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
32727231|NCT03423667|Experimental|N-acetylcysteine|
32727232|NCT03423667|Placebo Comparator|Lactose powder|
32727233|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
32905885|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
32905886|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
32905887|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
32905888|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*~Day 2:~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
32905889|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*~CRF 2, Adult ASRS and WAIS subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*~Day 2 (after 14 - 40 days):~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*~CRF 3, ASRS and EHI.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
32905890|NCT03215420|Experimental|Certain or probable Meniere's disease|
32905891|NCT04380818|Active Comparator|Control group|a control group only receive pharmacological treatment
32905892|NCT04380818|Experimental|Experimental group|an experimental group will receive low-dose lung irradiation
32905893|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
32905894|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
32905895|NCT05312294|Experimental|FLU-M w/o/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (without preservative) intramuscularly in a dose of 0.5 mL.
32905896|NCT05312294|Experimental|FLU-M w/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (with preservative) intramuscularly in a dose of 0.5 mL.
32905897|NCT05311982|Active Comparator|DLPFC-L F3 (Block A)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A)
32905898|NCT05311982|Active Comparator|tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)
32905899|NCT05311982|No Intervention|Sham (Block C)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS Sham
32905900|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
32905901|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
32905902|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
32905903|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
32905904|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
32905905|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
32905906|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
32727234|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
32727235|NCT01559363|Experimental|Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing|Participants received tesevatinib 50 milligrams (mg) tablet orally once daily (QD) for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum duration: up to 36 months).
32727236|NCT01559363|Experimental|Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing|Participants received tesevatinib 100 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
32727237|NCT01559363|Experimental|Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing|Participants received tesevatinib 150 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
32727238|NCT01559363|Experimental|Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing|Participants received tesevatinib 150 mg tablet orally bi-weekly in alternative dosing schedules on Monday and Thursday for initial 25 days. After initial 25 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
32727239|NCT01559363|Experimental|Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing|Participants received tesevatinib 150 mg tablet orally tri-weekly in alternative dosing schedules on Monday, Wednesday and Friday for initial 26 days. After initial 26 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
32905907|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
32905908|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
32905909|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
32905910|NCT01832012|No Intervention|No intervention|Group 2
32905911|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
32905912|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
32905913|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
32905914|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
32905915|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
32905916|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
32905917|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
32905918|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
32905919|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
32905920|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
32905921|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
32905922|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
32905923|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
32905924|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
32905925|NCT05311514|Experimental|Allogeneic Platelet Lysate eye drops 50%|Patients with ocular chronic severe graft versus host disease receive 50% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
32905926|NCT05311514|Active Comparator|Allogeneic Platelet Lysate eye drops 20%|Patients with ocular chronic severe graft versus host disease receive 20% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
32928821|NCT05722106|Experimental|Identifiable victim|"Participants read a flyer containing the following message:~A few weeks ago, Sam was a healthy 26-year-old with no medical complications. The he suddenly came down with a bad cough and a feeling like he could not breath. He tested positive for COVID-19, and is now hospitalized, receiving oxygen from a ventilator, and fighting for his life. This could be any of us. Reduce the risk to yourself and other:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. If we take these actions, we can prevent more people from suffering the way Sam has."
32928822|NCT05722106|Experimental|Goal proximity|"Participants read a flyer containing the following message:~The recent development of safe and effective vaccines gives us great hope. We see the light at the end of the tunnel, but we are not quite there yet. Until a large proportion of the population is immunized, we must remain vigilant and double our efforts to prevent the spread of COVID-19.~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
33400800|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
33400801|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~Preoperative counselling by surgeon, dietician and physiotherapist~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~Avoid use of drains~Early resumption of diet~Early mobilisation with physiotherapist~Dietary counselling by dietician~Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
32928823|NCT05722106|Experimental|Reciprocity|"Participants read a flyer containing the following message:~Doctors, nurses, and other healthcare workers are working around the clock, often risking their lives to care for patients with the coronavirus. Working long hours in highly infectious environments, many of them are falling ill. As our healthcare workers put their lives on the line, we can do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. Our brave healthcare workers have sacrificed to help others. We should take action too."
32928824|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
32928825|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
32928826|NCT05722028||Patients with benign uterine findings (polyp / retained products of conception)|Female patients undergoing diagnostic hysteroscopy with a diagnosis of uterine polyp or retained products of conception. These patients are then invited to a surgical office procedure without anaesthesia to remove these findings.
32928827|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
32928828|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
32928829|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
32928830|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
33400802|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~No preoperative counselling~No Preoperative carbohydrate-loaded drink~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~Routine use of drains~Diet will be resumed when there is flatus clinically~Mobilisation as per patient's wish~Dietary counselling by dietician~Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
33400803|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
33400804|NCT03162640||P|for cannabis
33400805|NCT03162640||C|for the control group
33400806|NCT05419440|Active Comparator|laparoscopic drainage of appendicular abscess|laparoscopic drainage of appendicular abscess laparoscopy drainage of pus ,excision of appendix and putting a drain
33400807|NCT05419440|No Intervention|interventional radiology for management of appendicular abscess|insertion of a drain or pig tail under sonar or ct guided
33400808|NCT05746156|Experimental|lymphatic map|Lymphatic mapping will be performed
33400809|NCT05419284|Experimental|patient|GAPP+Care
33400810|NCT05419284|Experimental|caregiver|+Care
33400811|NCT05419284|Other|healthcare professional of the ward|observation of GAPP+Care
32727240|NCT01559363|Experimental|Phase 2a: Safety in Larger Kidneys (SILK) Cohort: Tesevatinib 50 mg Once Daily Dosing|Participants with autosomal dominant polycystic kidney disease (and Baseline estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 35 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) and less than or equal to (<=) 80 mL/min/1.73 m^2, and height-adjusted total kidney volume (htTKV) >=1000 mL were enrolled and received tesevatinib 50 mg tablet orally QD for initial 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
32727241|NCT03605719|Experimental|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32727242|NCT03605719|Experimental|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32727243|NCT03605719|Experimental|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32727244|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
32928831|NCT03838484|Experimental|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
32727245|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
32727246|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
32727247|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
32727248|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
32928832|NCT03838484|Experimental|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
32928833|NCT03838484|Experimental|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
32928834|NCT03838484|Experimental|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
32928835|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
32928836|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
32928837|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
32928838|NCT03307616|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
32928839|NCT03307616|Experimental|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
32928840|NCT03307616|Experimental|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
32928841|NCT03307616|Experimental|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
32727249|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
32727250|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
32727251|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
32727252|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
32727253|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
32727254|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
32727255|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
32727256|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
32727257|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
32727258|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
32928842|NCT05721872|Experimental|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 1|"Participants will receive single intravenous administration as monotherapy of D-isoascorbic acid (D-VC) with dose escalation (0.05, 0.1, 0.2 g/kg/day) and with arsenic trioxide (ATO).~Patients who have satisfactorily tolerated the study drug in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial."
32928843|NCT05721872|Experimental|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 2|After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.
33250958|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
33250959|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
33250960|NCT04376268|Active Comparator|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
33250961|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
33250962|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
33400812|NCT05179486||Observational (biospecimen collection, questionnaire)|Participants complete a questionnaire over 20 minutes. Participants also undergo collection of blood and leftover tissue samples.
32727259|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
32727260|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
32727261|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
32727262|NCT03428425|Experimental|apatinib paclitaxel S-1|
32727263|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
32727264|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
32727265|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
32727266|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
32727267|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
32727268|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
33277403|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
32905927|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
32905928|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
32905929|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
32905930|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
32905931|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
32905932|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
32905933|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
32905934|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
32905935|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
32905936|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
32905937|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
32905938|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
32905939|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
32905940|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
32905941|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
32905942|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
32905943|NCT01832714||mTBI|Subjects who undergo an mTBI event
32905944|NCT01832714||Control|Subjects who do not undergo an mTBI
33250963|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
33400813|NCT05419206||COVID-19 cases with anticytokine therapy|Considering the use of anti-cytokines in these patients, it was found that 53 received tocilizumab, 27 received anakinra, and 10 received both. CMV DNA was positive in 38 (22.7%) of the patients included in the study. CMV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
33400814|NCT05419206||COVID-19 cases without anticytokine therapy|MV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
33400815|NCT05746000|Other|Control Group|Participants in the control group will attend three standard diet counselling.
33400816|NCT05746000|Other|Intervention Group|Participants in the intervention group will attend three individual diet counselling and will be educated about sugar calculation (sugar exchange).
33400817|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
33400818|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
33400819|NCT04719832|Experimental|Participants receiving GSK3511294 (Depemokimab)|
33400820|NCT04719832|Placebo Comparator|Participants receiving placebo|
33400821|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
33400822|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
33400823|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
33400824|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
33400825|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
33400826|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
33400827|NCT05157724||PLASMA|This technique consists of an endoscopic intervention, through the natural route (urethra).
33400828|NCT05157724||HOLEP|"This is a recent and difficult technique of endoscopic prostate enucleation, requiring a greater learning curve for the operators compared to PLASMA. The principle remains the same technically as the PLASMA procedure, the energy used is not electrical energy, but a laser.~Once the adenoma has been enucleated, it can only be removed by a morcellator (additional material) which can lead to complications such as bladder perforation. This is a blade that rotates in a tube that has to cut the adenoma once it has been freed from the prostate when it is in the bladder and it can happen that this blade catches on the bladder wall and causes a bladder wound or even a perforation."
33400829|NCT05177341||Amputees with acceptable phantom sensation|
33400830|NCT05177341||Amputees with no phantom sensation|
33400831|NCT05177341||Control group|
33400832|NCT05308771|Experimental|Epidural anesthesia using VPC syringe|Epidural anesthesia detection using VPC syringe
33400833|NCT05676190|Experimental|CIK combined with chemotherapy group|Combination of CIK cells and chemotherapy
33400834|NCT05676190|Experimental|CIK combined immunotherapy group|Combination of CIK cells and immunotherapy
33400835|NCT05676190|Experimental|CIK combined targeted therapy group|Combination of CIK cells and targeted therapy
33400836|NCT05676190|Experimental|CIK in combination with other therapies|CIK in combination with any two or three of these (i.e., chemotherapy, immunotherapy, and targeted therapy) treatments
33400837|NCT04917211|Experimental|virtual reality mask|During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
33400838|NCT05138809|Experimental|Exercise|Use online exercise platform
33400839|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
33400840|NCT05681299|Active Comparator|Growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Injections will be performed from the night of day 0 to the night of day 20.
33400841|NCT05681299|Active Comparator|Liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly. Injections will be performed from the night of day 0 to the night of day 20.
33400842|NCT05681299|Active Comparator|Growth hormone and liraglutide|"GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.~Injections will be performed from the night of day 0 to the night of day 20."
32727269|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
32727270|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
32727271|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
32727272|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
33250964|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
33250965|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
32928844|NCT05721872|Active Comparator|Standard therapy (FOLFOX/FOLFIRI)-Phase 2|"Drug: FOLFOX/FOLFIRI regimen FOLFOX - oxaliplatin 85mg/m2 1 day, Leucovorin 200mg/m2 IV 2h, 1, 2 days, 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days, 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI - Irinotecan 180 mg/m2 IV, Leucovorin 400 mg/m2 IV, Fluorouracil bolus 400 mg/m2 IV, Fluorouracil infusional 2400 mg/m2 IV. Courses are held every 2 weeks"
32928845|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
32928846|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
32928847|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
32928848|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
32928849|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
32928850|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
33277404|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
33277405|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
32928851|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
32928852|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
33277406|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
32727273|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
32928853|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
32727274|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
32727275|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
32928854|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
32928855|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
32727276|NCT03429595|Placebo Comparator|Group 5: Vehicle|
32727277|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
32727278|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
32727279|NCT03428347|Experimental|Group 2|7 mg/kg body weight
32727280|NCT03428347|Experimental|Group 3|14 mg/kg body weight
32727281|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
32727282|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
32727283|NCT03429517||Patients|ACS Lipogram
32727284|NCT03429517||Controls|Normal LDL-C level Lipogram
33250966|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
33277407|NCT00667823|Experimental|ACT-064992|ACT-064992
32928856|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
32928857|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
32928858|NCT05721560|Experimental|SINEFIX|Rotator cuff repair with the SINEFIX implant, using the SINEFIX instruments
32928859|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
32928860|NCT02411461||Healthy siblings|Control group
32928861|NCT02411461||Obese patients|Control group
32928862|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
32928863|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
32928864|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
32928865|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
32928866|NCT05715632|Experimental|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of Carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical surgery for gastric cancer
32928867|NCT05721404|Experimental|ICO (icodextrin)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the ICO arm will be prescribed icodextrin (Extraneal) for long night dwell to improve fluid overload till their re-measurement of ECW/TBW < 0.40.
32928868|NCT05721404|Other|CON (control)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the CON arm will be prescribed hypertonic Dextrose solution for long night dwell to improve fluid overload till their ECW/TBW < 0.40
32928869|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
32928870|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
32928871|NCT05721326|Experimental|Sequential Communications|This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.
32928872|NCT05715554|Experimental|Homeopathy Group|Individualized Homeopathy Treatment provided by homeopathic physicians
32928873|NCT05715554|No Intervention|Standard Group|Usual care provided by primary care physicians were followed by patients in the standard group
32928874|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
32928875|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
32928876|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
32928877|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
32928878|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
32928879|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
32928880|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
32727285|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.~Interventions:~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
32727286|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.~Interventions:~Procedure: antiviral therapy"
32727287|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
32727288|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
32727289|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
32727290|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
32727291|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
32727292|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
33277408|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
32928881|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
32928882|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
32928883|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
32928884|NCT05715476|Active Comparator|sea levelaltitude|Pregnant women living in Giresun(sea levelaltitude),Turkey and undergoing cesarean section under elective conditions.
32928885|NCT05715476|Active Comparator|moderate altitude|Pregnant women living in Çorum(moderate altitude),Turkey and undergoing cesarean section under elective conditions.
32928886|NCT05715476|Active Comparator|high altitude|Pregnant women living in Van(high altitude),Turkey and undergoing cesarean section under elective conditions.
32928887|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
32727293|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
32928888|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
32928889|NCT03499327|No Intervention|Control|no study products
32928890|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
32928891|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
32928892|NCT05715398|Experimental|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle, Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
32928893|NCT05715320|Experimental|Group A|CM310, subcutaneous
32928894|NCT05715320|Experimental|Group B|CM310, subcutaneous
32928895|NCT05715242|Experimental|Condition 1|Weight Loss Goal (easier) + Step Goal (easier) + Calorie Goal (easier) + Eating Window Goal (easier)
32727294|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
32727295|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
32727296|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
32928896|NCT05715242|Experimental|Condition 2|Weight Loss Goal (easier) + Step Goal (easier) + Calorie Goal (easier) + Eating Window Goal (harder)
32928897|NCT05715242|Experimental|Condition 3|Weight Loss Goal (easier) + Step Goal (easier) + Calorie Goal (harder) + Eating Window Goal (easier)
32928898|NCT05715242|Experimental|Condition 4|Weight Loss Goal (easier) + Step Goal (easier) + Calorie Goal (harder) + Eating Window Goal (harder)
32928899|NCT05715242|Experimental|Condition 5|Weight Loss Goal (easier) + Step Goal (harder) + Calorie Goal (easier) + Eating Window Goal (easier)
32928900|NCT05715242|Experimental|Condition 6|Weight Loss Goal (easier) + Step Goal (harder) + Calorie Goal (easier) + Eating Window Goal (harder)
32928901|NCT05715242|Experimental|Condition 7|Weight Loss Goal (easier) + Step Goal (harder) + Calorie Goal (harder) + Eating Window Goal (easier)
32928902|NCT05715242|Experimental|Condition 8|Weight Loss Goal (easier) + Step Goal (harder) + Calorie Goal (harder) + Eating Window Goal (harder)
32928903|NCT05715242|Experimental|Condition 9|Weight Loss Goal (harder) + Step Goal (easier) + Calorie Goal (easier) + Eating Window Goal (easier)
32928904|NCT05715242|Experimental|Condition 10|Weight Loss Goal (harder) + Step Goal (easier) + Calorie Goal (easier) + Eating Window Goal (harder)
32928905|NCT05715242|Experimental|Condition 11|Weight Loss Goal (harder) + Step Goal (easier) + Calorie Goal (harder) + Eating Window Goal (easier)
32928906|NCT05715242|Experimental|Condition 12|Weight Loss Goal (harder) + Step Goal (easier) + Calorie Goal (harder) + Eating Window Goal (harder)
32928907|NCT05715242|Experimental|Condition 13|Weight Loss Goal (harder) + Step Goal (harder) + Calorie Goal (easier) + Eating Window Goal (easier)
32928908|NCT05715242|Experimental|Condition 14|Weight Loss Goal (harder) + Step Goal (harder) + Calorie Goal (easier) + Eating Window Goal (harder)
32928909|NCT05715242|Experimental|Condition 15|Weight Loss Goal (harder) + Step Goal (harder) + Calorie Goal (harder) + Eating Window Goal (easier)
32928910|NCT05715242|Experimental|Condition 16|Weight Loss Goal (harder) + Step Goal (harder) + Calorie Goal (harder) + Eating Window Goal (harder)
32928911|NCT05721170|Active Comparator|Beta-blockers continuation|Patients assigned in the beta-blockers continuation arm will be receiving per os beta blocker medication for at least 72 hours before TAVI without interruption after it.
32727297|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
32727298|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
32727299|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
32727300|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
32727301|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
32727302|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
32727303|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
32727304|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
32727305|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
32727306|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
32727307|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
32727308|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
32727309|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
32727310|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
32727311|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
32727312|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
32905945|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
32905946|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
32905947|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
32906710|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
32906711|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
32906712|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
32906713|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
32906714|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
32928912|NCT05721170|Active Comparator|Beta-blockers interruption|Patients assigned to interrupt the beta-blockers treatment will abstain from beta blockers for at least 7 days after TAVI.
33277409|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
32906715|NCT01577537|Experimental|VivaGel|
32906716|NCT01577537|Placebo Comparator|HEC Placebo|
32906717|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
32906718|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
32906719|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
32906720|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
32906721|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
32906722|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
32906723|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
32906724|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
32906725|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
32906726|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
32906727|NCT01723202|Experimental|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
32906728|NCT01723202|Experimental|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
32906729|NCT01723202|Other|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
32906730|NCT01578317|Experimental|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
32906731|NCT01578317|Experimental|unadjuvanted|Administer day 1 and booster at Day 21
32906732|NCT03406130|Active Comparator|Insignia orthodontic treatment|
32906733|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
32906734|NCT04965012|Experimental|CBT with MET treatment group|Participants in this arm will be provided with an MET-therapist guided introduction, in addition to the online CBT treatment.
32906735|NCT04965012|Experimental|CBT without MET treatment group|Participants in this arm will be provided with a brief non-MET research assistant-led welcome to the program, in addition to the online CBT treatment.
32906736|NCT04965012|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about cannabis and wellbeing.
32906737|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
32906738|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
32906739|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
32906740|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
32906741|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
32906742|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
32906743|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
32906744|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
32906745|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
32906746|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
32906747|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
32906748|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
32906749|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
32906750|NCT01720160|Experimental|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
32928913|NCT03134690|Experimental|delayed start antagonist|60 women with poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
33250967|NCT04376268|Active Comparator|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
32928914|NCT03134690|Experimental|conventional antagonist|60 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
32928915|NCT05721014|Experimental|OsteoStrong|Training following the OsteoStrong-method.
33250968|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
33250969|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
33250970|NCT00761436|Experimental|Arm 1|
33250971|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
33250972|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
32928916|NCT05721014|Active Comparator|Individually Adapted and Combined Physical Training|Training based on current recommendations on exercise for people with osteoporosis.
32928917|NCT05714618||Cases (Ischemic stroke): Left and right middle cerebral artery ischemic stroke|Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke.
32928918|NCT05714618||Controls (TIA): Patients with acute focal neurological symptoms without brain infarct on MRI.|Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct.
32928919|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
32928920|NCT03059264||Control|Healthy Children
33400843|NCT05681299|Placebo Comparator|Placebo|Placebo will be administered as one nightly subcutaneous self-injection at 9-11pm from the night of day 0 to the night of day 20.
33400844|NCT04378153|Experimental|HS-Discontinue (Study A)|Discontinuation of current hypertonic saline (HS) therapy in Study A
33400845|NCT04378153|Active Comparator|HS-Continue (Study A)|Continuation of current hypertonic saline (HS) therapy in Study A
33250973|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
33400846|NCT04378153|Experimental|Dnase-Discontinue (Study B)|Discontinuation of current dornase alfa (dnase) therapy in Study B
32928921|NCT05720858|Experimental|Hospital group|A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. In the hospital-based group, a supervised aerobic exercise program will be applied in the hospital. There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks.
33250974|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
33250975|NCT00874965|Active Comparator|ES|Electrostimulation
33250976|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
33400847|NCT04378153|Active Comparator|Dnase-Continue (Study B)|Continuation of current dornase alfa (dnase) therapy in Study B
33400848|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
33400849|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
33400850|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
33400851|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
33400852|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
33400853|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
33400854|NCT04908787|Experimental|BD0801+chemotherapy|BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
33400855|NCT04908787|Placebo Comparator|Placebo+chemotherapy|Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
33400856|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
33400857|NCT04923139||Japanese VTE patients including Ca-VTE patients|Include a large number of adult VTE patients (including Ca-VTE patients) prescribed rivaroxaban who visited facilities covered by the MDV database
33400858|NCT04891627||Healthy control groups|individuals with clinically healthy gingiva BOP score less than 10% and PD≤3mm
33400859|NCT04891627||Periodontitis group|interdental AL ≥5 mm
33400860|NCT04891627||Periodontitis with diabetes group|HbA1c ≥6.5%
33400861|NCT04365829|Experimental|Virtual reality|
33400862|NCT04692688|Experimental|APX3330|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
33400863|NCT04692688|Placebo Comparator|Placebo|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
33400864|NCT05681221|Active Comparator|LSTR in necrotic primary second molar using TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
32768612|NCT05386485||Group B4 (critical symptomatic infection)|"Clinical manifestation of the infection with severity signs (respiratory rate > 30/minute; peripheral oxygen saturation (SpO2) <94%) and at least one of the following:~I) Acute Respiratory Distress Syndrome: defined under Berlin Criteria mostly defined by a PaFi<200, II) Shock: Patient diagnosed with sepsis that despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and lactate values >2 mmol/L (>18 mg/dL) or III) Organ dysfunction that requires ICU admission"
32768613|NCT04368455|Experimental|Primary Care Clinic|Physician participants will receive the self-directed app based curriculum. The physician participants will engage in the VR simulations independently.Next, we will implement VICTORI with staff including nurses and medical assistants in groups of up to 15-20 participants (phase II; secondary outcome). Staff will watch a 5-minute video on evidence-based practices in recommending the HPV vaccine and observe a facilitator and clinician participating in the VICTORI VR simulations, and then engage in a 5-minute debriefing.
33250977|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
33250978|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
32928922|NCT05720858|Experimental|Telerehabilitation group|"A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. Supervised sessions will be held with the telerehabilitation group via phone or computer video conference (For patients who agree to participate, the physiotherapist will initially conduct the first session face-to-face).~There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks."
32768614|NCT04368455|Active Comparator|Control Primary Care Clinic|Physician participants will receive the self-directed app based curriculum component of VICTORI though will not undergo the VR simulations.
32768615|NCT05071105|Experimental|40Gy/5fx|The starting dose level will be 8Gy x 5 fractions, i.e., 40 Gy/5 nonconsecutive once-daily fractions.
33250979|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
33250980|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
33250981|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
33250982|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
32928923|NCT05720858|No Intervention|Control group|They will continue their routine activities. After the study, those who wish will be included in the exercise program.
33250983|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
33250984|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
33250985|NCT04772859|Experimental|Online Lifestyle Intervention|Online sessions of nutrition education, physical activity, and family participation.
32928924|NCT03038672|Active Comparator|Group I (nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
32768616|NCT05071105|Experimental|42.5Gy/5fx|The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
32768617|NCT05071105|Experimental|45Gy/5fx|The higher dose level will be 9Gy x 5 fractions, i.e. 45Gy/5 nonconsecutive once-daily fractions
32768618|NCT05413239|Experimental|Intervention Group|The Intervention Group will receive the monthly intervention sessions during the first year of the study.
32768619|NCT05413239|No Intervention|Control Group|The Control Group will receive the monthly intervention sessions during the second year of the study (after assessment of primary outcomes at 1 year).
32928925|NCT03038672|Experimental|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
32928926|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
32928927|NCT05711030|Active Comparator|Thoracic paravertebral block multiple (3) injections|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 centimeters (cm) lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge echogenic SonoPlex needle from Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the 3-level technique, injections will be done at the levels of T2-T3, T3-T4, and T4-T5 with 10 ml of ropivacaine 0.5% at each level."
32727313|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
32727314|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
33250986|NCT04772859|Other|Control Group|General nutrition recommendations
33250987|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
32727315|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
32727316|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
32727317|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
32727318|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
32727319|NCT03422419|Experimental|TIPS+Anticoagulation|
32727320|NCT03422419|Active Comparator|Anticoagulation|
32727321|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
32727322|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
32727323|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
32727324|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
32727325|NCT04449289|Active Comparator|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
32727326|NCT04449289|Active Comparator|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
32727327|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
32727328|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
32727329|NCT03128203|Experimental|Oxytocin|
32727330|NCT03128203|Placebo Comparator|Placebo|
32727331|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.~Intervention will be the Comparison between GenePOC CR and Reference Method."
32727332|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.~Intervention will be the Comparison between GenePOC CR and Reference Method."
32727333|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
32727334|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
32727335|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
32727336|NCT03469999|Experimental|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
32727337|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
32727338|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
33250988|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
33250989|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
32727339|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
32727340|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
32727341|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
32727342|NCT03422107||cAVR|Conventional Valve Replacement
32727343|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
32727344|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
32727345|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
32727346|NCT02935309|Experimental|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
32727347|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
32727348|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
32727349|NCT04900922||Healthy tennis players|Participants in this group need to perform arm elevation in the scapular plane three times and successful flat tennis serve three times before and after a fatigue protocol. Surface electromyography on infraspinatus, pectoralis major, anterior deltoid ,and latissimus dorsi will be used to detect muscle activity related to fatigue.
32727350|NCT04900064|Experimental|Diagnostic Assessment - Given self-help CBT|"The diagnostic assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview (MINI - International Neuropsychiatric Interview) and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients receiving treatment with self-help CBT are included."
32727351|NCT04900064|Active Comparator|Contextual Assessment - Suitable for self-help CBT but given brief interventions|"The contextual assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary analysis, only patients suitable for self-help CBT are included. This is decided by an algorithm based on data from their screening, which takes into account symptom severity and type, patient preference and known variables that make self-help CBT a worse fit."
32727352|NCT04900064|Experimental|Diagnostic Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they receive treatment with self-help CBT or brief interventions."
32727353|NCT04900064|Active Comparator|Contextual Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they are deemed suitable for self-help CBT or not."
32727354|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
32727355|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
32727356|NCT04899440|Experimental|Test Regimen|Oral Irrigator + Manual toothbrush + toothpaste Subjects will brush their teeth twice daily and will use the oral irrigator once in the evening daily
32727357|NCT04899440|Sham Comparator|Control Regimen|Manual toothbrush + toothpaste Subjects will brush their teeth twice daily
33250990|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
32727358|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
32727359|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
32727360|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
32727361|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi
32727362|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
32727363|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
32727364|NCT04910984|Experimental|Chatbot group|
32727365|NCT04910984|Placebo Comparator|TAU group|
32727366|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
32727367|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
32727368|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
32727369|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
32727370|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
32727371|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
32727372|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
32727373|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
32727374|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
32727375|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
32727376|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
32727377|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
32727378|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
32727379|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
32727380|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
32727381|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
32727382|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
32727383|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
32727384|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
32727385|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
32727386|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
32727387|NCT03427957|Active Comparator|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
32727388|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
32727389|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
32727390|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
32928928|NCT05711030|Experimental|Thoracic paravertebral block single injection|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 cm lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the single-injection technique, injection of 30 ml of ropivacaine 0.5% will be done at the T3-T4 paravertebral space after negative aspiration."
32928929|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
32928930|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
32928931|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
32928932|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
32928933|NCT00358202|Active Comparator|1 cefepime|
32928934|NCT00358202|Active Comparator|2 ceftriaxone|
32928935|NCT05720468|Experimental|Exercise|Participants randomized to the exercise group will receive 24 weeks of home-based, combined endurance and resistance training program under guidance and virtual supervision from exercise trainers. Exercise will be performed 5 days per week, with 3 days of endurance training using treadmill and 2 days of resistance training.
32928936|NCT05720468|Placebo Comparator|Waitlist Control Group|The control group will continue usual level of physical activity the participants were doing prior to enrollment in the study. At the end of the 24 week study period, participants will be offered the chance to participate in the same home-based, combined endurance and resistance training program.
32928937|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
32727391|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
32928938|NCT02818400|Experimental|Composite tissue allotransplantation|
33277410|NCT03649178|Other|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
32727392|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater than or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
32727393|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater to or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
32727394|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
32727395|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
32727396|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
32727397|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
32727398|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
32727399|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
32727400|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
32727401|NCT03427723|Active Comparator|Standard care|visualization and palpation
32727402|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
32727403|NCT03416647|Experimental|SMAS patients|
32727404|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
32727405|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
32727406|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
32727407|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
32727408|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
32727409|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
32727410|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL|HPC 250 mg/mL in oil
32928939|NCT05720312|Experimental|Dorsolateral Prefrontal Cortex (DLPFC)|36 sessions of high frequency (10Hz) rTMS
32928940|NCT05720312|Experimental|Ventromedial Prefrontal Cortex (vmPFC)|36 sessions of low frequency (1Hz) rTMS
32928941|NCT05720234|Experimental|Treatment group|53 subjects will be enrolled with the indicated treatment dose of avatrombopag.
32928942|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 150 eggs|150 Trichuris trichiura eggs
32928943|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 300 eggs|300 Trichuris trichiura eggs
32928944|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 450 eggs|450 Trichuris trichiura eggs
32928945|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
32928946|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
32928947|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
32928948|NCT02770040|Active Comparator|Intensified Infliximab Induction|Infliximab 10mg/kg at Week 0 and Week 1
32928949|NCT02770040|Active Comparator|Accelerated Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 1 and Week 3
32928950|NCT02770040|Active Comparator|Standard Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 2 and Week 6
32928951|NCT04142489|Other|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
32928952|NCT05720078|Experimental|Adaptive, two-phase RT|
32727411|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
32928953|NCT04736225|Experimental|ISTE Group|This program includes a 60-min small-group lesson, a 20-min individual instruction. The education program's goal is to teach patients to self-titrate their insulin doses every six days to maintain their six-day average blood glucose levels < 120 mg/dl
32928954|NCT04736225|Placebo Comparator|Non-ISTE Group|The usual care (a 15-min individual education) was giving at the Diabetes Health Education Center. They were taught how to self-inject insulin and test and record their before-breakfast and before-dinner blood glucose levels daily at home.
32928955|NCT04345172|Active Comparator|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
32928956|NCT04345172|Active Comparator|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
32727412|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
32727413|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
32727414|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
32727415|NCT03416257||WIHS|Women's Interagency HIV Study
32727416|NCT03416257||MACS|Multicenter AIDS Cohort Study
32727417|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
32727418|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
32727419|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
32727420|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
32727421|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
32727422|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
32727423|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
32727424|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
32727425|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
32727426|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
32727427|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
32928957|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
32727428|NCT04596475|Experimental|Treatment Arm|
32727429|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
32928958|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
32928959|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
32727430|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
32727431|NCT03421015||Control Group|patients without biochemical recurrence (control group)
32928960|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:~Onset: distinguishes slow onset or onset tachycardias from sudden onset~Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.~Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
33277411|NCT03649178|Other|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
32928962|NCT05720000|Experimental|PDO thread with active red LED photobiomodulation (PBM)|Participants will receive the PDO thread and the intervention with PBM using red light (Newskin, MMO) 150 mW, 2J per point, 4J/cm2, 10 points, twice a week.
32727432|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
32727433|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
32727434|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
32727435|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
32727436|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
32727437|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
32928963|NCT05720000|Sham Comparator|PDO thread with sham photobiomodulation (PBM)|Participants will receive the PDO thread and the simulated intervention with PBM using Newskin, MMO.
32928964|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
32928965|NCT05719922|Experimental|Low-load blood flow restriction training (LL-BFR)|Twice daily LL-BFR for 3 weeks
32928966|NCT05719922|Active Comparator|Heavier load resistance training (HL-RT)|Three sessions per week for 3 weeks
32727438|NCT04449445|Other|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
32727439|NCT04449445|Experimental|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
32727440|NCT04594213|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection
32928967|NCT02579954|No Intervention|control group|
32928968|NCT02579954|Experimental|intervention|Rehabilitation
32928969|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
32928970|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
32928971|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
32928972|NCT03348683|Experimental|Propranolol|2mg of IV push
32928973|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
32928974|NCT04344782|Experimental|Bevacizumab|
32928975|NCT04344782|No Intervention|Standard of Care|
32928976|NCT05693558|Experimental|NVD-003 bone graft implant|"The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages~Stage 1: A screening, adipose tissue collection & NVD 003 manufacturing period.~Stage 2: Grafting surgery and 12-month post-GS follow-up period.~Stage 3: long-term safety follow-up period (from post-month 12 to month 24)."
32928977|NCT05693480|Experimental|Intervention Group|Older adults with zero time of falls in the past twelve months will be treated as the reference group. Older adults with at least one time of falls in the past twelve months will use the device to assess their balance ability by attending three rounds of the tests.
32928978|NCT03946241||Pre-reform study populations|Children from 1st to 9th grade (n ~ 2,600) from four different school-based studies collecting objective physical activity data. The four studies are 1) The European Youth Heart Study (EYHS) conducted in 1997-98, 2003-04 and 2009-10, 2) When Cities Move Children (WCMC) conducted in 2010 and 2012, 3) Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS-DK) conducted in 2009, 2010 and 2012, and 4) School site, Play Spot, Active transport, Club fitness and Environment (SPACE) conducted in 2010 and 2012. A total of 44 schools where included in the studies.
32928979|NCT03946241||Post-reform study population|Children from 1st to 9th grade in 2017-18 from the same schools as included in the pre-reform research studies (n ~ 2,600). Two of the pre-reform research studies (CHAMPS-DK and SPACE) introduced PA promoting initiatives as part of the study. To minimize any influence from participation in these interventions we chose only to include and recruit participants from control schools from these studies. A total of 36 schools where invited and 31 subsequently accepted to participate. Parents and teachers of the children were included as well.
32928980|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
32928981|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
32928982|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
32928983|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
32727441|NCT04594213|Experimental|MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL|Intramuscular injection
32727442|NCT04594213|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection
32727443|NCT04594213|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection
32928984|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
32727444|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
32727445|NCT04449133|Experimental|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
32727446|NCT04449133|Experimental|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
32727447|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
32727448|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
32727449|NCT03416023|Experimental|Single|
32727450|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
32727451|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
32727452|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
32727453|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
32727454|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
32727455|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
32727456|NCT03420469|Experimental|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
32727457|NCT03420469|Experimental|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
32727458|NCT03420469|Experimental|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
32727459|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
32928985|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
32928986|NCT05691452|Experimental|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
32928987|NCT05691452|No Intervention|Control Group|The control group will receive usual medical care and American Heart Association's Healthy Living booklet
32928988|NCT00357188|Active Comparator|A|
32928989|NCT00357188|Active Comparator|B|
32928990|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
32727460|NCT03420391|Placebo Comparator|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
32727461|NCT03420391|Active Comparator|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
32727462|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
32727463|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
32727464|NCT03420391|Active Comparator|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
32727465|NCT03420391|No Intervention|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
32727466|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
32727467|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
32727468|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
32727469|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
32727470|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
32727471|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
32727472|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
32727473|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
32727474|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
32727475|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
32727476|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
32727477|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
32928991|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
32928992|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
32727478|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
32928993|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
32928994|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
32928995|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
32928996|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
32928997|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
32928998|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
32928999|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
32929000|NCT05719688|Experimental|Mechanical thrombectomy:Thrombectomy system|Subjects will be treated with Thrombectomy system,Thrombectomy system is an intraarterial thrombectomy removal device that can be re-inserted into the sheath to restore blood flow by removing blood clots in occluded vessels.
32929001|NCT05719688|Active Comparator|Intracranial thrombectomy stent :Solitaire FR Revascularization Device|Subjects will be treated with Solitaire FR Revascularization Device ,the Device made by Micro Therapeutics Inc. DBA ev3 Neurovascular
32727479|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
32727480|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
32727481|NCT03127735|Experimental|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
32929002|NCT05719610|Experimental|Cawthorne Cooksey Exercises|
32929003|NCT05719610|Experimental|Swiss Ball Exercises|
32929005|NCT05719454|Experimental|CNT Setup Algorithm Version 1|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
32929006|NCT05719454|Experimental|CNT Setup Algorithm Version 2|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
32929007|NCT05719454|Other|CNT therapy optimization without use of the Setup Algorithm|For this optimization procedure, each subject's blood pressure is measured with a continuous blood pressure measurement system while the BackBeat-CNT is activated, and system parameters are varied according to a specified sequence until the desired blood pressure reduction is achieved. The parameter values that provide the desired blood pressure reduction will be recorded, for possible use by the investigator following trial completion
32929008|NCT05679674|Experimental|Stereotactic Ablative Body Radiation (SABR) and Tumor Treating Fields (TTF)|50 Gy in five fractions SABR (once per day for 5 days) and use of the TTF system for 18 hours per day starting on the first day of SABR and continuing until abdominal disease progression
32727482|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
32929009|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
32929010|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
32727483|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
32727484|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
32727485|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
32929011|NCT02360371|Placebo Comparator|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
32727486|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
32727487|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
32929012|NCT02360371|Experimental|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
32929013|NCT02360371|Experimental|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
32929014|NCT02360371|Experimental|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
32929015|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
32929016|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
32929017|NCT05719376|Experimental|Experimental|
32929018|NCT05719376|Other|control|Follow the criteria for investigational product
32929019|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
32929020|NCT05718908||Fibromyalgia patients|All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.
32929021|NCT00354991|Experimental|1|Losartan/HCTZ
32929022|NCT05718752||Healthy men|no intervention
32727488|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
32727489|NCT03415321|No Intervention|Control Group|Routine care
32727490|NCT03420079|Experimental|Dose escalation cohort of FCN-411|"FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
32727491|NCT03420079|Experimental|Dose expansion cohort of FCN-411|"FCN-411 will be orally administrated at MTD.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
33277412|NCT05356676|Experimental|Isometrics|They will be treated with progressive isometric exercises added to 60 min of combined therapy (excluding scapular stabilizing exercises) treatment session at alternative 3 days/week for 8weeks
32929023|NCT05718752||Healthy women|no intervention
32929024|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
32929025|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
32929026|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
32929027|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
32929028|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
32929029|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
32929030|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
32929031|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
32929032|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
32929033|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
32929034|NCT05676554|Experimental|Intervention|This arm will watch the growth mindset session
32929035|NCT05676554|No Intervention|Waitlist|This arm will receive the intervention once they have completed the follow up at 4 weeks.
32929036|NCT05675696|Experimental|ARDS Patients Intubated on Mechanical Ventilation|ARDS patients in the ICU who are intubated on mechanical ventilation will be included. During ventilation, an esophageal catheter will be used to measure the esophageal pressure, which estimates pleural pressure at the level of the catheter. The esophageal catheter's position will be confirmed by a chest radiograph once inserted. The ventilator settings may be changed to see if these ventilator adjustments can reduce potential lung stress in ARDS patients. There is no set criteria for adjusting the ventilator settings based on the study device, but the goal would be to adjust the volume until the inspiratory effort measured by the catheter disappears so as to protect the patient. A one-to-two-hour study session will be performed for data collection. The esophageal catheter will be removed at the end of the study session or can be left in place for use as a feeding tube if needed for patient care.
32929037|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
32929038|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
32929039|NCT01958762|Other|Screening for cancers in the oral cavity|
32929040|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
32929041|NCT05717270||Prospective group|Acute Achilles tendon Rupture undergoing surgical repair.
32929042|NCT05717270||comparison group|Patients group from a previous trial (NCT04263493).
32929043|NCT05717192|Active Comparator|InterVapor®-System|The intervention to be tested is bronchoscopic lung volume reduction (BTVA) using thermal ablation (InterVapor®, Uptake Medical, California, USA). This is performed in addition to standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. The intervention can consist of a maximum of two partial interventions
33277413|NCT05356676|Experimental|Combination Therapy|They will be treated with both isometric and scapular stabilizing exercises.and will get 60minutes of treatment sessions at alternative 3 days/week for 8weeks
33277414|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
33277415|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
33277416|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
33277417|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
33277418|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
32727492|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
32727493|NCT03420001||controls|women after one vaginal delivery
32727494|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
32727495|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
32929044|NCT05717192|No Intervention|Standard of care|Standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines without the use of a BTVA (patient-specific documentation of therapeutic measures).
32929045|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one or two nights
33277419|NCT00057811|Experimental|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
33277420|NCT00057811|Experimental|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
32727496|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
32929046|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
32929047|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
32929048|NCT01863446|Experimental|Lighting4|Ocular light exposure to a red wavelength light on day1 and to a blue-green wavelength light on day 2
32727497|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
32929049|NCT05717114|Placebo Comparator|Group I|received plan bupivacaine1ml/Kg
32929050|NCT05717114|Active Comparator|Group II|received plain bupivacaine 1ml/Kg plus dexmetomedine0.5 µg/Kg
32929051|NCT05717114|Active Comparator|GroupIII|received plain bupivacaine 1ml/Kg plus dexmetomedine1µg/Kg
32929052|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
32929053|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
32929054|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
32929055|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
32929056|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
32929057|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
32929058|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
32929059|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
32929060|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
32929061|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
32929062|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
32929063|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
32727498|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
32929064|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
32929065|NCT05717036||TS Meter-DSP Measurement and Refractix DSP Measurement|The study will involve blood serum samples from (36) participants. Participants will be those presenting at a plasma collection center for routine plasma donation. Ordinary pre-screening for plasma donation includes a fingerstick and the collection of one small capillary tube (<0.085ml) of blood. Participants will be asked to provide a second capillary tube (<0.085ml) of blood from this fingerstick.
32929066|NCT05719285|Active Comparator|1: Single-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.
32929067|NCT05719285|Active Comparator|2: Multi-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection. The same antibiotic will be continued for 3 days of total antibiotic administration with additional doses prescribed to the patient's pharmacy.
32929068|NCT05719207|Experimental|Balloon dilation of eustachian tube|These patient will undergo balloon dilation dilation of the eustachian tube.
32929069|NCT05719207|Sham Comparator|Sham procedure|These patients will undergo a sham procedure, where the motions of balloon dilation of the eustachian tube will be simulated.
32929070|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
32929071|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
32929072|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI>0 or mHEART>2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
32727499|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
32727500|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
32929073|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days~Patients with TIMI=0 and mHEART<=2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
32929074|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
32929075|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
32929076|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
32727501|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
32727502|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
32727503|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
32929077|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
32929078|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
32929079|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
32929080|NCT02367391|Experimental|Motivational Text Messages|
32929081|NCT02367391|Sham Comparator|Control|
32929082|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
32929083|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
32929084|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
32929085|NCT05719129||DWD participants|Individuals that voluntarily chose to participate in DWD seminar.
32929086|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Reducing Nipple Sparing Mastectomy"
32929087|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Sparing Mastectomy"
32929088|NCT05719051||High-dose group|Total Intravenous albumin infusion >1.5g/kg per week while hospitalization
32929089|NCT05719051||Medium-dose group|Total Intravenous albumin infusion 1.0 to 1.5g/kg per week while hospitalization
32929090|NCT05719051||Low-dose group|Total Intravenous albumin infusion <1.0g/kg per week while hospitalization
32929091|NCT05718973|Experimental|Intervention Arm|"At Time 1, the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital and, immediately thereafter, complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
32929092|NCT05718973|No Intervention|Scale-Exposed Control Arm|"The Scale-Exposed Control Arm will watch no video content at Time 1, but will complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
32929093|NCT05718973|Placebo Comparator|Attention Placebo Control Arm|"The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial, before completing the CPC-12R, the GQ-6 and the single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
32727504|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
32929094|NCT05718973|No Intervention|Un-exposed Control Arm|"The Un-exposed Control Arm will neither watch video content, nor complete the CPC-12R, the GQ-6 and the single-item validated happiness scale at Time 1.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
32929095|NCT05718895|Experimental|ATG-022|"Dose Escalation Phase:~for subjects with solid tumors,approximately 16-36 subjects will be enrolled .~Dose Expansion Phase:~The tumor types in the Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. The total number of patients in dose expansion will be up to approximately 120 patients."
32929096|NCT03342937|Experimental|Oxaliplatin+Capecitabine+Pembrolizumab|
32727505|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
32727506|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
32727507|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
32929097|NCT05718817|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
32727508|NCT03426397||Study population|
32929098|NCT05718739|Experimental|FOG@Home|Patients with Parkinson's disease who agreed to be monitored using cameras and acceleration measurements during daily life.
32929099|NCT05718661|Experimental|Virtual Reality Glasses Group|The intervention group will watch a virtual reality video with mobile virtual glasses by the researcher (SŞ) and the stress level on the smart wristband will be recorded. In addition, necessary variables will be recorded with the data collection form.
32929100|NCT05718661|Placebo Comparator|Non-Virtual Reality Glasses Group|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded. In addition, necessary variables will be recorded with the data collection form.
32929101|NCT05718661|No Intervention|Control Group|Anxiety control will be done by the researcher (SU) for the control group.
32929102|NCT05718505|Active Comparator|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
32929103|NCT05718505|Experimental|Atmo Motility Gas Capsule System|"The Atmo Motility Gas Capsule System (Atmo Biosciences) offers a novel method for measuring GET, SBTT, SLBTT, CTT and WGTT. This device measures temperature, relative humidity, hydrogen concentration and carbon dioxide concentration, along with indicators of fermentation activity, capsule tumble and antenna reflectance as it transit through the GI tract.~It has the added benefit of recording information on the fermentation and gas profiles within the GI tract."
32929104|NCT05718349||Non-cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who do not have cholestasis preoperatively.
32727509|NCT03414931|Experimental|NMDAE|An NMDA enhancer
32727510|NCT03414931|Active Comparator|SSRI|Sertraline
32727511|NCT03414931|Placebo Comparator|Placebo|Placebo
32727512|NCT03414853||With algorithm use|
32727513|NCT03414853||No algorithm use|
32727514|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
32929105|NCT05718349||Drained|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who had cholestasis and underwent ERCP (endoscopic retrograde choledochopancreatography) with stenting to normalize the enterohepatic circulation.
32929106|NCT05718349||Cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who have cholestasis preoperatively and did not undergo drainage.
32929107|NCT00354757|Active Comparator|2 arms|PPI 1
32929108|NCT00354757|Active Comparator|PPI|PPI 2
32929109|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the depression-specific acupoints were first targeted (12 sessions over six weeks), followed by the pain-specific acupoints (12 sessions over six weeks)
32727515|NCT03426241||smoking chronic periodontitis|
32727516|NCT03426241||non-smoking periodontitis|
32727517|NCT03426241||smoking healthy|
32727518|NCT03426241||non-smoking healthy|
32727519|NCT03033823|Experimental|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
32727520|NCT03033823|Placebo Comparator|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
32929110|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the pain-specific acupoints (six weeks 12 sessions) were first targeted followed by the depression-specific acupoints (six weeks 12 sessions).
32929111|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
32929112|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
32929113|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
32929114|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
32929115|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
32929116|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
32929117|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
32929118|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
32929119|NCT05718193|Experimental|The DeFrame Group|Subjects in the DeFrame group were treated with a real-time computer-aided polyp detection system named DeFrame during colonoscopy.
32929120|NCT05718193|Experimental|The Classified DeFrame Group|Subjects in the Classified DeFrame group were treated with a real-time computer-aided polyp detection and classification system named Classified DeFrame during colonoscopy.
32929121|NCT05718193|Experimental|The Control Group|Subjects in the control group underwent standard colonoscopy.
32929122|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
33277421|NCT03502148|Experimental|Open-Label, Single Arm Study of PRV111|Subjects received 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery.
32929123|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
32929124|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
32929125|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
32929126|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
32929127|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
32929128|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
32727521|NCT04699591|Other|Overall Study|Receive domperidone 4 times a day, weight-dependent dose
32727522|NCT04669639|Experimental|The block group (a)|Patients were randomized in a 1:1 :1ratio, group (a) will receive SSN. The nerve blocks The procedure will be performed after induction of anaesthesia and endotracheal intubation.
32929129|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
32929130|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
32929131|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32929132|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32929133|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32929134|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
32727523|NCT04669639|Experimental|The block group (b)|Patients were randomized in a 1:1:1 ratio. group (b) will receive the Erector spinae plane block. The procedure will be performed after induction of anesthesia and endotracheal intubation.
32727524|NCT04669639|Placebo Comparator|control group|Patients were randomized in a 1:1:1 ratio. this group will receive general anesthesia (GA) only
32727525|NCT03414697|Other|Control group|Routine rehabilitation treatments
32727526|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
32727527|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
32929135|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32929136|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
32929137|NCT05718037|Experimental|LY|Young adult subjects received low dose of BV211
32929138|NCT05718037|Experimental|HY|Young adult subjects received high dose of BV211
32929139|NCT05718037|Placebo Comparator|Placebo|Young adult subjects received placebo
33400865|NCT05681221|Experimental|LSTR in necrotic primary second molar using nano silver particles and calcium hydroxide|Nano silver particles have a strong anti-bacterial properties due to its ability to target the bacteria on different cellular levels. Calcium hydroxide has been used for so long as an intra canal medication in odontogenic infections due to its strong alkalinity that gives it its anti bacterial properties. This combination might be a future alternative to antibiotics, in an attempt to decrease the bacterial antibiotic resistance and antibiotics use.
32929140|NCT05718037|Experimental|LO|Old adult subjects received low dose of BV211
32929141|NCT05718037|Experimental|HO|Old adult subjects received high dose of BV211
32727528|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
32727529|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
32727530|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
32727531|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
32727532|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
32727533|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
32727534|NCT04448821|Experimental|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
32727535|NCT04448821|Experimental|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
32727536|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
32727537|NCT03414619|Experimental|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
32727538|NCT04448509|Other|Healthy donor|Healthy donor
32727539|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
32727540|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
32727541|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
32727542|NCT04448899|Active Comparator|Ivabradine|"Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study."
32727543|NCT04448899|Placebo Comparator|Control|Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.
32727544|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
32727545|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
32929142|NCT05718037|Active Comparator|Control Vaccine|Old adult subjects received control vaccine
32929143|NCT05717959|Experimental|intervention group|We conducted a once a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device
32929144|NCT05717959|Sham Comparator|control group|Mandibular advancement device
32929145|NCT05717881|Experimental|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
32929146|NCT05717881|Placebo Comparator|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
32727546|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
32727547|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
32727548|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
32727549|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
32727550|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
32727551|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
33277422|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
32727552|NCT04649047|Experimental|Intervention|All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity
32727553|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
32929147|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
32929148|NCT05717725|Active Comparator|Pulsed-field ablation arm|Patients will undergo catheter ablation using for atrial fibrillation using pulsed-field energy
32929149|NCT05717725|Sham Comparator|Sham procedure arm|Patients will receive sham procedure (no ablation)
32929150|NCT05717647||Paediatric patients with severe traumatic brain injury undergoing multimodality monitoring|"Patients admitted with brain injury requiring ventilation and ICP monitoring~Age group: 3 years and 16 years (children under the age of three years are excluded as the triple bolt for multimodality monitoring is not currently used for this age group)"
32929151|NCT05717569|Active Comparator|Group A|Group A: Stoss vitamin D therapy
32929152|NCT05717569|Active Comparator|Group B|Group B: Oral vitamin D therapy .
32727554|NCT02835157|Experimental|Balanced crystalloid or multiple electrolyte solution group|After enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
32929153|NCT05717491||Main group|Cross-sectional study
32929154|NCT05717491||Sub group|Case control study
32929155|NCT05716633||Acute Pancreatitis|Patients with acute pancreatitis will undergo serial MRI
32929156|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
32929157|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
32929158|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
32929159|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
32929160|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
32929161|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
32929162|NCT05712655||Study group|Post-pubertal females with forward head posture and temporomandibular disorders
32929163|NCT05712655||Control group|Post-pubertal females with neutral head posture and with no temporomandibular disorders
32929164|NCT05711953|Experimental|Egyfil Pain Lotion|Interventional study on Egyil 50mL will be topically administered ad libitum for three days.
32929165|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
32929166|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
32929167|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
32929168|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
32929169|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
32929170|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
32929171|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
32929172|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
32929173|NCT05706649|Experimental|Plant-based diet|Subjects will receive a handbook on plant-based diet including recipe recommendations. They will follow a strict plant-based diet for 21 day.
32929174|NCT05689879|No Intervention|REMAIN arm|Infliximab 3 to 5 mg/kg every 4-8 weeks, methotrexate 7.5-10 mg/week (or azathioprine 1 mg/Kg/day), steroids < or = 10 mg/day
32929175|NCT05689879|Other|STOP arm|Methotrexate 0.3 mg/kg/week (or azathioprine 2 mg/kg/day (or 1 mg/kg/day if intermediary metabolism TMPT) (the dose of methotrexate will not exceed 25mg/kg/week wathever the weight of the patient), steroids < or = 10 mg/d
32929176|NCT05504395|Experimental|CSTI-500 10mg|All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2
32929177|NCT05686213|Experimental|combined aerobic exercise + resistance exercise intervention (AE + RE)|Physical exercise during neaodjuvant chemoradiation
32929178|NCT05686213|Experimental|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Physical exercise during neaodjuvant chemoradiation
32929179|NCT05686213|No Intervention|Usual care control (UC)|The control group will receive usual care and will be requested to maintain their usual daily physical activities.
32929180|NCT05684575|Other|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
32929181|NCT04923763||Tongue_examination|The general public will be invited for tongue examination. The data will be used to establish the automatic tongue video analysis system.
32929182|NCT00355771|Experimental|Treatment Group 1|
33250991|NCT00880815|Experimental|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
33250992|NCT00369343|Experimental|A|
32929183|NCT00355771|Placebo Comparator|Treatment Group 2|
32929184|NCT05502679|Active Comparator|Traditional Group|6-week non-weight bearing of the affected lower limb rehabilitation protocol (TG)
32929185|NCT05502679|Experimental|Weight-bearing Group|Immediate lower limb weight bearing to tolerance rehabilitation protocol (WBG)
32929186|NCT05500885|Experimental|Active PEMF therapy for CAI/Ankle Sprain|Participants will be randomized into 1:1 allocation, blocked randomization with 30 participants in the PEMF group and 30 participants in the sham group. Each allocation will be assigned with a unique RFID (generated during block randomization by the PEMF supplier service) recognizable by the PEMF machine.
32929187|NCT05500885|Sham Comparator|Sham PEMF therapy for CAI/Ankle sprain|Control group will receive sham treatment on top of a standard rehabilitation (muscle strengthening and balance training).
33250993|NCT00369343|Placebo Comparator|B|
33250994|NCT00880971|Experimental|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
33250995|NCT00880971|No Intervention|Non-PORT|Patients undergo postoperative chemotherapy.
33250996|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
33250997|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
33250998|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
33250999|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
33251000|NCT00369265|Placebo Comparator|Sugar pill|placebo
33251001|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
33251002|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
32929188|NCT05500885|Experimental|Active PEMF therapy for Hallux Valgus|Participants will be randomized into 1:1 allocation, blocked randomization with 30 participants in the PEMF group and 30 participants in the sham group. Each allocation will be assigned with a unique RFID (generated during block randomization by the PEMF supplier service) recognizable by the PEMF machine.
33251003|NCT04474483|Placebo Comparator|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
33251004|NCT04474483|Experimental|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
33251005|NCT00614055|Active Comparator|Insulin glargine|
33251006|NCT00614055|Experimental|SIAC 30 (B)|
33251007|NCT00614055|Experimental|SIAC 45 (B)|
32929189|NCT05500885|Sham Comparator|Sham PEMF therapy for Hallux Valgus|Control group will receive sham treatment on top of a short foot exercise, toe spread out exercise and heel raise exercise.
32929190|NCT05495503|Experimental|Prototype (814A-v1)|Application of the prototype (814A-v1) at D0 and D7.
32929191|NCT05495503|Experimental|Prototype (814B-v1)|Application of the prototype (814B-v1) at D0 and D7.
33251008|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
32929192|NCT05495503|Experimental|Prototype (814C-v1)|Application of the prototype (814C-v1) at D0 and D7.
32929193|NCT05495503|Experimental|Prototype (814D-v1)|Application of the prototype (814D-v1) at D0 and D7.
32929194|NCT05664139|Experimental|Experimental Arm|"Recombinant Human Adenovirus Type 5 Injection: 1ml or 2ml, d1, q3w, 4 cycles;~Camrelizumab: 200mg, d2, q3w;~Nab-paclitaxel: 260mg/m2, d1, q3w, 4-6 cycles;"
32929195|NCT05463211|Experimental|Trexo Plus Pediatric Exoskeleton|Experimental lower-limb wearable pediatric exoskeleton used biweekly in clinical and school settings.
32929196|NCT03224351|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
32929197|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
32929198|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
32929199|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
32929200|NCT03224351|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
32727555|NCT02835157|Active Comparator|0.9% saline or saline group|After enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
32727556|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
32727557|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
32929201|NCT03224351|Experimental|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
32727558|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
32929202|NCT03224351|Placebo Comparator|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
32727560|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
32727561|NCT03418831|Placebo Comparator|Placebo|placebo tablet
32727562|NCT04448587|Experimental|Sitagliptin|
32727563|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
32929203|NCT03224351|Experimental|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
32727564|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration~Best Medical Treatment and maximum supportive care"
32727565|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
32727566|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
32727567|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
32727568|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
32727569|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
32727570|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
32727571|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
32727572|NCT03127891|Placebo Comparator|control group|no intervention
32929204|NCT05658055|Active Comparator|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
32929205|NCT05658055|Experimental|Probiotics combined with vonoprazan and amoxicillin|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and probiotics three times a day. These three drugs were taken continuously for 14 days.
32929206|NCT04745533||SARS-CoV2 contacts|Subjects considered close contacts of COVID-19 patients according to the definition of the Ministry of Health in the health area of Cáceres.
32929207|NCT03911375|Experimental|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
32929208|NCT03911375|No Intervention|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
32929209|NCT05642923|Active Comparator|Synthetic Vitamin B1|Synthetic Vitamin B1, 400 mg per day
32929210|NCT05642923|No Intervention|No intervention|No intervention
32929211|NCT03906071|Experimental|Nivolumab and Sitravatinib|Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.
32929212|NCT03906071|Active Comparator|Docetaxel|Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.
32929213|NCT04865419|Experimental|Module 1: AZD0466 monotherapy|Participants will receive intravenous infusion of AZD0466 monotherapy once weekly during Cycle 1 (35 days), Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
32929214|NCT04865419|Experimental|Module 2: AZD0466 + Voriconazole|Participants may receive IV infusion of AZD0466 in combination with or without voriconazole during Cycle 1 (21 days), and Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
33251009|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
32929215|NCT05462041|Other|DBD Donor Heart Transplantation|If the heart offer is from a DBD donor, the heart will be retrieved per standard of care.
33251010|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
32727573|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
32727574|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
32727575|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
32929216|NCT05462041|Other|DCD Donor Heart Transplantation|If the heart offer is from a DCD donor, the heart will be retrieved using one of two strategies: Normothermic Regional Perfusion (NRP) or Direct Procurement and Perfusion (DPP). NRP procedures will be used to procure all DCD hearts unless contraindicated or prohibited by the donor hospital. In the event the donor hospital does not allow NRP for cardiac organ procurement, or the target number of eight DCD transplants with NRP has been achieved, DPP with the Organ Care System (OCS) should be utilized.
32727576|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
32743499|NCT02622321|Experimental|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
32929217|NCT05459155|Experimental|Pharmacist team post-intervention|The direct subjects will be the inpatient pharmacists who round with general medicine teams and approve inpatient medication orders. They will be given full access to the Synapse Medicine medication decision support platform.
32929218|NCT05459155|No Intervention|Pharmacist team pre-intervention|Pre-intervention, the inpatient pharmacists will round with general medicine teams and approve inpatient medication orders under conditions of usual care. They will base their recommendations on their knowledge and training and any tools (electronic or otherwise) that they choose to use.
32929219|NCT01721876|Experimental|Volasertib and Cytarabine|
32929220|NCT01721876|Placebo Comparator|Placebo and Cytarabine|
32929221|NCT05635045|Experimental|Cohort 1|"Subjects with grade 1 Tc99-PYP scans who have clinical features suggestive of ATTR-CM or have grade 1 Tc99-PYP scans but endomyocardial biopsy evidence of TTR cardiac amyloidosis will be administered single dose evuzamitide <1mCi.~Heart failure with a preserved ejection fraction (EF>40%)~Grade 1 Tc99-PYP scan performed for clinical suspicion of ATTR-CM~No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~Left ventricular septal OR inferolateral wall thickness ≥12 mm"
32929222|NCT05635045|Experimental|Cohort 2|"Subjects with TTR variant such as Phe64Leu, late onset Val30Met, etc.) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM will be administered single dose evuzamitide <1mCi.~Tc99-PYP scan performed for clinical suspicion of ATTR-CM that is not diagnostic of ATTR-CM~No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~Left ventricular septal OR inferolateral wall thickness ≥12 mm with echocardiographic features of ATTR-CM (low tissue doppler velocities, preserved apical strain, elevated E/E') or CMR features of an infiltrative cardiomyopathy (increased wall thickness with delayed enhancement or difficulty nulling of the myocardium)"
32929223|NCT05635045|Experimental|Cohort 3|"Subjects with ATTR-CM from either ATTRwt or Val122Ile variant who have biopsy proven evidence of extra-cardiac TTR amyloidosis or clinical suspicion of extracardiac disease, including but not limited to peripheral neuropathy, carpal tunnel syndrome, spinal stenosis will be administered single dose evuzamitide <1mCi..~ATTR-CM defined by the following~Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining OR technetium scintigraphy with 99m Tc-pyrophosphate with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio,~End-diastolic interventricular septum thickness of > 12 mm on previous echocardiogram~TTR genotype shown to be either Val122Ile or wild type."
32929224|NCT05455411|Experimental|Group-based Parent-implemented Social Communication Training|A group-based parent-implemented social communication treatment program for up to 8 parents of children with autism spectrum disorder
32929225|NCT05455411|Active Comparator|Individual-based Parent-implemented Social Communication Training|An individual-based parent-implemented social communication treatment program for a parent of a child with autism spectrum disorder
32929226|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
32929227|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
32929228|NCT05452681|Experimental|Y-AMBIENT|"Y-AMBIENT is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. All themed education and follow-up sessions are conducted according to the respective Y-AMBIENT session outlines and audio-recorded. Session 1, titled My Self, My Soul, covers topics related to spiritual growth and finding meaning in illness. Session 2, titled My Body, covers topics related to breast changes, aches/pains, fatigue, and weight changes. Session 3, titled My Mind and My Relationships, covers topics related to anxiety, fear, and relationships with others. The sessions will take approximately one hour, with follow-ups lasting about 20 minutes. Participants will receive both printed and electronic PDF versions of written materials, in addition to video links, to reinforce content delivered during Sessions."
33251011|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
33251012|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
33251013|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
32929229|NCT05452681|Active Comparator|Attention Control|"The control condition will consist of receiving a culturally-targeted cookbook applied by an adapted Food for Thought cookbook, a guide to grocery shopping smart, and telephone socialization calls. We opted to use the cookbook and guide as conversation pieces given cultural practices associated with food and avert financial constraints with shopping tips. During three, one-hour socialization calls, we will use scripted questions to encourage discussion about the participant, cookbook and guide, and obtain information about survivorship concerns without providing coaching. The follow-up calls will last about 20 minutes."
32929230|NCT05627869|Active Comparator|Transversus thoracic muscle plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
32929231|NCT05627869|Active Comparator|Pecto-intercostal fascial plane block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
32929232|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
32929233|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
32929234|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
32929235|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
32929236|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
32929237|NCT04832659|Active Comparator|CEASE|Those assigned to the Active Comparator arm will receive the CEASE intervention.
32727577|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
32727578|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
32768620|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
32929238|NCT04832659|Experimental|CEASE + BIO|Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
32929239|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
32929240|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
32929241|NCT05437159|Experimental|Sub-syllabic learning and fMRI|60 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words learned during training and with a set of unfamiliar words also formed by non-native phoneme combinations.
32929242|NCT05437159|Experimental|Sub-syllabic learning and anodal tDCS of inferior frontal sulcus|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations. During the training, anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's left inferior frontal sulcus.
32929243|NCT05437159|Experimental|Sub-syllabic learning and anodal tDCS of cerebellum|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During the training, continuous anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's right cerebellum.
32929244|NCT05437159|Sham Comparator|Sub-syllabic learning and sham tDCS|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During training, Sham transcranial direct current stimulation stimulation (tDCS) will be delivered to the subject's brain.
32929245|NCT05437159|Experimental|Multisyllabic learning and fMRI in adults|30 adults persistent developmental stuttering (AWS) and 30 adults with neurotypical speech development (ANS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 3 syllables that are legal in American English during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words formed by pairing 2 learned 3-syllable strings learned during training and those formed by pairing 2 unfamiliar 3-syllable strings. Behavioral measures extracted from the data will be used to compare performance before and after training and across the AWS and ANS participants.
32929246|NCT05437159|Experimental|Multisyllabic learning in children|45 children with persistent developmental stuttering (CWS) and 45 children with neurotypical speech development (CNS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 2 syllables that are legal in American English during 6 training sessions over 2 days. Behavioral measures extracted from the data will be used to compare performance before and after training and across the CWS and CNS participants.
32929247|NCT05437159|Experimental|Sub-syllabic learning in PPA|30 adults with primary progressive aphasia (PPA) will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 8 training sessions over 2 days. Following training, subjects will complete a behavioral test to compare their performance on the words learned during training with a set of unfamiliar words also formed by non-native phoneme combinations.
32929248|NCT05662514|Experimental|Probiotic group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, probiotic once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
32929249|NCT05662514|Placebo Comparator|Placebo group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, placebo once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
32727579|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
32929250|NCT04825795||DPP4-inhibitor|Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
32929251|NCT04825795||No DPP4-inhibitor|Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
32929252|NCT03225599|Experimental|Procedure|
32929253|NCT05662202|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Red light photodynamic therapy (PDT)"
32929254|NCT05662202|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Red light photodynamic therapy (PDT)
32929255|NCT02029443|Experimental|Relapsed/Refractory Cohort|Phase 1 (dose-escalation) and Phase 2 (dose-expansion) will be conducted for participants with relapsed/refractory CLL or SLL. In Phase 1, participants will receive oral once daily (QD) acalabrutinib at Dose 1 (Cohort 1), Dose 2 (Cohort 2a), Dose 3 (Cohort 3), and Dose 4 (Cohort 4a), and twice daily (BID) acalabrutinib at Dose 1 (Cohort 2b) and Dose 5 (Cohort 4b) for 28 days (1 cycle). In Phase 2, participants will receive oral acalabrutinib at Dose 1 BID (Cohort 2b) or Dose 5 QD (Cohort 2c, later will be switched to Dose 1 BID per protocol amendment 6) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest. Participants from Phase 1 will be continued to receive Dose 1 BID until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
32929256|NCT02029443|Experimental|Treatment-naive Cohort|Treatment-naïve participants with confirmed CLL or SLL, will receive oral acalabrutinib Dose 5 QD (Cohort 7, later will be switched to Dose 1 BID per protocol amendment 6) or Dose 1 BID (Cohort 11) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
32929257|NCT02029443|Experimental|Ibrutinib-intolerant Cohort|Participants with confirmed CLL or SLL and were not tolerating ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 8a, later switched to Dose 1 BID per protocol amendment 4) or Dose 1 BID (Cohort 8b) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
32929258|NCT02029443|Experimental|Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort|Participants with diffuse large B-cell lymphoma (DLBCL) Richter's transformation (RS) or prolymphocytic leukemia (PLL) transformation, will receive oral acalabrutinib Dose 5 BID (Cohort 9) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
32929259|NCT02029443|Experimental|Ibrutinib Relapsed/Refractory Cohort|Participants with confirmed CLL/SLL and had relapsed/refractory to ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 10) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
32929260|NCT05623579|Experimental|Intervention|Pain Education plus Exercise
32929261|NCT05623579|Active Comparator|Control|Exercise
32929262|NCT05659238||1|those who exposed early to TV (before 1 year age)with long time of exposure/day (6hours\day or more)
32929263|NCT05659238||2|those who exposed later to TV (after 2 years of age) with short time of exposure/day.(2 hours \day or less)
32929264|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
32929265|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
32929266|NCT05620771|Experimental|Y90 + Atezolizumab and Bevacizumab|
32929267|NCT05620771|Experimental|Y90 + TKI|
32929268|NCT05716880|Experimental|KA+MPD|Ketosteril + Medium Protein Diet (MPD) for 12 months
32929269|NCT05716880|Active Comparator|MPD|Medium Protein Diet (MPD) for 12 months
32929270|NCT04735991|No Intervention|Control group|The patient's family members need to fill in the family member quality of life questionnaire during the screening and follow-up period. They are able to contact the doctor for questions in terms of medical treatment.
32929271|NCT04735991|Experimental|Study group|The family members of the patients need to fill in the family member quality of life questionnaire during the screening period and follow-up period, and are involved in an interactive management program on the mobile terminal, full participation required.
32929272|NCT05419297|Active Comparator|Active drug arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided placebo buprenorphine buccal film that mimics the actual drug comparator and is continued by a blinded individual throughout the duration of the trial.
32929273|NCT05419297|Placebo Comparator|Placebo arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided active buprenorphine buccal film that is titrated to the effective dose and continued by a blinded individual throughout the duration of the trial.
33251014|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
33251015|NCT04040127|Experimental|Cord blood stem cells|cord blood stem cells from Invitrx
33251016|NCT04040127|Placebo Comparator|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
33251017|NCT04039971|Active Comparator|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
33400866|NCT04647214||Bimatoprost intracameral implant (DURYSTA) 10μg|Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
33400867|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
32929274|NCT05716802|Active Comparator|dance/movement therapy (DMT), twice a week, 12 weeks,|The multiple-session DMT intervention was applied to participants twice a week as a total of 24 sessions of 60 minutes over three months. The DMT intervention protocol was developed based on the therapist's experience, the theoretical frameworks, and the DMT approach described in a previous study (Bryl and Goodill 2019).
32929275|NCT05716802|Placebo Comparator|Treatment as usual (TAU), twice a week, 12 weeks,|The TAU group sessions were conducted by the licensed professional employed at the hospital. The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
32727580|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
32929276|NCT05612581|Experimental|STRIVE: Cohort 1a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
32929277|NCT05612581|Experimental|STRIVE: Cohort 2a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
32929278|NCT05612581|Experimental|STRIVE: Cohort 3a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total
32929279|NCT05612581|Experimental|STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total
32929280|NCT05612581|Experimental|STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)|Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total
32929281|NCT05612581|Experimental|THRIVE: Cohort 1b (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks
32929282|NCT05612581|Experimental|THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total
32929283|NCT03226457|Active Comparator|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
32929284|NCT03226457|Active Comparator|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
32727581|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
32768621|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
32929285|NCT04344626|Experimental|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
32929286|NCT05610787|Experimental|Active Driver Primary Arm|Up to 40 patients whom receive the Active Driver from implant.
32929287|NCT05610787|No Intervention|IKUS Comparator|All patients whom receive the (FDA approved) IKUS Driver from implant and are entered into the ACTION Registry.
32929288|NCT04344548|Experimental|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score >4
32929289|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
32929290|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
32929291|NCT05606887|Experimental|Intervention|In addition to completing 3 surveys over the course of 6 months, participants in the intervention arm will be asked to wear a wearable device (Garmin VivoSmart) and complete texting-based ecological momentary assessments to gauge real-time feelings of stress.
32929292|NCT05606887|No Intervention|Control|Participants randomized to this arm will receive digital surveys over the course of 6 months (one at baseline, one at 3 months, and one at 6 months). These surveys will be the same as the intervention arm and will ask questions related to burnout, anxiety, depression, PTSD, and stress.
32929293|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
32929294|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
32929297|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
32929298|NCT03228017|No Intervention|Healthy Control|
32929299|NCT04793035|Experimental|Enrolled patients|Single-arm study for enrolled GERD patients to be treated with an Omega-Cuff device
32929300|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
32929301|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
32929302|NCT03706833|Experimental|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
32929303|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
33251018|NCT04039971|Active Comparator|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
32727582|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
32929304|NCT03706833|Experimental|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
32929305|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
32929306|NCT03706833|Experimental|Edwards PASCAL System - Single-Arm Registry|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with mitral regurgitation who were deemed non-randomizable by a central screening committee (CSC) due to complex anatomical features described in the current MitraClip Instructions for Use (IFU) but were considered suitable for the PASCAL system.
32929307|NCT00357422|Active Comparator|surgery|
32929308|NCT00357422|Active Comparator|local therapy|
32929309|NCT05418049|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo, baclofen, roflumilast or memantine with a two-week washout period between doses.
32929310|NCT05647538||control group|underwent normal cesarean section without Postpartum hemorrhage after delivery
32929311|NCT05647538||case group|cases underwent bilateral uterine artery ligation after Postpartum hemorrhage or Intrapartum hemorrhage after cesarean section.
32727583|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
32929312|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
32929313|NCT05414383||CADx|Histopathology prediction by CADx device
32929314|NCT05414383||Endoscopist|Real-time histopathology prediction by expert and non-expert endoscopists
32929315|NCT05716568|Active Comparator|Standard contrast dose|Standard contrast dose administration
32929316|NCT05716568|Active Comparator|Calculated contrast dose|Contrast dose by calculation
32727584|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
32929317|NCT05716568|Active Comparator|Calculated contrast dose -50%|Contrast dose by calculation, with extra dilution by 50%.
32929318|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
32929319|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
32929320|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
32929321|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
32929322|NCT00376337|Experimental|2|infusion for 3-12 weeks
32929323|NCT05716490|Active Comparator|Standard|Control group which will cover surgical wound with conventional wound dressing
32929324|NCT05716490|Experimental|PICO|Group that will use Pico® device for wound dressing
32929325|NCT05716490|Experimental|PREVENA|Group that will use Prevena® device for wound dressing
32929326|NCT05413525||Women undergoing USG- MVA for the treatment of early pregnancy loss|Medical notes of all women undergoing USG- MVA for the treatment of early pregnancy loss with gestation < 12 weeks at the Department of Obstetrics and Gynaecology in The Prince of Wales Hospital and Union Hospital will be reviewed.
32929327|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
32929328|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
32929329|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
32929330|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
32929331|NCT05395195|Experimental|Erythropoietin|Intravenous or subcutaneous injections of erythropoietin (500 U/kg/dose). Total of 9 doses will be administered. First dose will be given within 6 hours of birth. Second dose between 12 to 24 hours from the first dose. Subsequent 7 doses every 24 hours from the second dose.
33251019|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
32929332|NCT05395195|Sham Comparator|Control|Mock administration of injections (pretend) behind a screen by a dedicated personal
33251020|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
33251021|NCT04038723|Experimental|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
33251022|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
33251023|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
32929333|NCT05723510|Experimental|Edoxaban 60mg|Multiple dosing of edoxaban alone once daily for 5 days
32929334|NCT05723510|Experimental|Edoxaban 60mg + Tegoprazan 50mg|Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days
32929335|NCT05723510|Experimental|Apixaban 5mg|Multiple dosing of apixaban alone twice daily for 5 days
33251024|NCT04543695|Active Comparator|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
32929336|NCT05723510|Experimental|Apixaban 5mg + Tegoprazan 50mg|Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days
33251025|NCT04543695|Experimental|consolidation chemotherapy group|concurrent chemoradiotherapy → consolidation chemotherapy → TME (experimental group)
33251026|NCT04543695|Experimental|induction chemotherapy group|induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).
33251027|NCT00881283||cured Cushing's disease|
33251028|NCT00882843||Group 1|Healthy Able bodied Control
33251029|NCT00882843||Group 2|Spinal Cord Injury
32929337|NCT05723510|Experimental|Rivaroxaban 20mg|Multiple dosing of rivaroxaban alone once daily for 5 days
33251030|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
32929338|NCT05723510|Experimental|Rivaroxaban 20mg + Tegoprazan 50mg|Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days
33251031|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
33251032|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
33251033|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
32929339|NCT04329273|Experimental|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
32929340|NCT04329273|No Intervention|Control group|The participants in this group will follow only the usual training program
32929341|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
32929342|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
32929343|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
32929344|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
32929345|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
32929346|NCT05716412||Adopted adolescents and their adoptive parents|Adopted before the age of one, currently between 12 to 18 years old
32929347|NCT05716412||Adolescents and their biological related parents|Matched to adoptive adolescents
32929348|NCT05716412||Additional community sample|
32929349|NCT05641610|Experimental|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
32929350|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
33251034|NCT00881439|Placebo Comparator|Placebo|
33251035|NCT00881439|Active Comparator|Aliskiren|
33251036|NCT01573390||1|Healthy participants.
33251037|NCT00881517|Experimental|Cytotect|
32727585|NCT04637971|Experimental|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
32727586|NCT04637971|Active Comparator|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
32727587|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
32727588|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
32727589|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
32929351|NCT00376493|Placebo Comparator|2|Use of placebo
32929352|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
32929353|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
32929354|NCT05640674|Active Comparator|Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.
32929355|NCT05640674|Experimental|Non-Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.
32929356|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10 mg/day )
32929357|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
32929358|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
32929359|NCT05385289|Experimental|First wave with 6 participants|"Once selected, an individual online information session will be scheduled with each selected participant to explain the project and its practical implications. At this time, six of the twelve participants will be provided a link to complete online measures as the A-baseline phase, to constitute their own non-intervention control condition on the target behavior (i.e., rumination) and on positive and negative emotions. The other six participants will be entered into a 3-week waiting list period with a sequential introduction, to provide another non-intervention control condition.~The A-baseline phase length will include at least 5 measures and most 10 measures, resulting in 10 potential starting point for the B-experimental phase. This range will be determined to estimate autocorrelation and its associated bias."
32929360|NCT05385289|Experimental|Second wave with 6 other participants|After three weeks, the six participants on the waiting list will also begin the same A-baseline phase as the six participants of the first wave.
32929361|NCT05723276|Experimental|Study arm|Psilocybin with therapeutic support
32929362|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
32929363|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
32929364|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
32929365|NCT05384587|Experimental|Asciminib|80 mg initial oral dose taken once a day with possible dose escalation
32929366|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
32929367|NCT05574530|Experimental|Colon-delivered multivitamin supplement|Colon-delivered multivitamin mix with vitamin B2, B3, B6, B9, vitamin C and D3. These vitamins are delivered as capsules coated by a eudragit S100 coating layer, in order to prevent systemic absorption of the vitamins in the small intestine.
32929368|NCT05574530|Placebo Comparator|Placebo supplement|Placebo supplement containing microcrystalline cellulose, coated in the same way as the experimental product in order to prevent systemic absorption in the small intestine.
32929369|NCT05716334||Rituximab originator recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with rituximab (RTX) originator for induction and/or maintenance.
32929370|NCT05716334||Rituximab biosimilar recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with RTX biosimilars (e.g. Ruxience, Truxima, Riximyo, etc) for induction and/or maintenance.
32929371|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
32929372|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
32727590|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
32727591|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
32929373|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
32929374|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
32929375|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
32929376|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
32929377|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
33251038|NCT00881517|Placebo Comparator|placebo|
33251039|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
33251040|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
33251041|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
32905979|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
32905980|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
32905981|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
32905982|NCT01833260|No Intervention|Without music|
32905983|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
32905984|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
32905985|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
32905986|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
32905987|NCT05313464|Experimental|nutrition pushed by parents|enteral nutrition pushed by parents
32905988|NCT05313464|Active Comparator|syringe pump|Enteral nutrition with syringe pump
32905989|NCT05310500|Experimental|ProTaper Gold (F2) - NaOCL|ProTaper Files without NaOCL
32905990|NCT05310500|Experimental|ProTaper Gold (F2) + NaOCL|ProTaper Files with NaOCL
32905991|NCT05310500|Experimental|Dia-X ProTaper (D4) - NaOCL|Dia-X ProTaper (D4) without NaOCL
32905992|NCT05310500|Experimental|Dia-X ProTaper (D4) + NaOCL|Dia-X ProTaper (D4) with NaOCL
32905993|NCT03213860|Active Comparator|eye mask|
32905994|NCT03213860|No Intervention|Control|
32905995|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
32905996|NCT01534013|Active Comparator|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
32905997|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
32905998|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
32905999|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
32906000|NCT01450397|Other|XIAFLEX|XIAFlEX
32906001|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
32906002|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
32906003|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
32906004|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
32906005|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
32906006|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
32906007|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
32906008|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
32906009|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
32906010|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
32906011|NCT01833728|Experimental|nefopam-propacetamol combination group|
32906012|NCT01833728|Active Comparator|propacetamol alone group|
32906013|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
32727592|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
32727593|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
32929378|NCT05716256|Experimental|Ulinastatin|The experimental groups （Rocuronium-Ulinastatin group and Cisatracurium-Ulinastatin group）received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
32929379|NCT05716256|Sham Comparator|Conventional treatment group|The control groups（Rocuronium-Saline group and Cisatracurium-Saline group） received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
32929380|NCT03667365|Experimental|aortic valve replacement|
32929381|NCT03667365|Active Comparator|strict clinical surveillance|
32929382|NCT05348785|Experimental|BIIB122 225 mg|Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks.
32929383|NCT05348785|Placebo Comparator|BIIB122 225 mg-Matching Placebo|Participants will receive BIIB122, 225 mg-matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
32929384|NCT03666273|Experimental|Dose escalation_Monotherapy|Patients with solid tumor types considered immunosensitive
32929385|NCT03666273|Experimental|Dose escalation_Combination therapy|Patients with solid tumor types considered immunosensitive
32929386|NCT03666273|Experimental|Expansion HNSCC_Combination therapy|Patients with head and neck squamous cell carcinoma (HNSCC)
32929387|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
32929388|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
32929389|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
32929390|NCT05630144|Experimental|All Participants|
32929391|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
32929392|NCT01730781||Cannabis dependence|Frequent users of cannabis
32929393|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
32929394|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
32929395|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
32929396|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
32929397|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
32929398|NCT00356083|Experimental|switch from morphine to methadon|
32929399|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
32929400|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
32929401|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
32929402|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
32929403|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
32929404|NCT05577091|Experimental|Autologous Tris-CAR-T cell|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity.
32929405|NCT04344236|No Intervention|Control|
32929406|NCT04344236|Experimental|Saline oral/nasal rinse|
32929407|NCT04344236|Experimental|0.5% Povidone/Iodine oral/nasal rinse|
32929408|NCT04344236|Experimental|0.12% Chlorhexidine oral/nasal rinse|
32727594|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
32727595|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Alectinib, orally, twice a day, per cycle~Bevacizumab, iv, once per cycle~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
32727596|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
32929409|NCT01543659|Experimental|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
32929410|NCT05571553|Experimental|Intervention group|"Phase 1~Participants will assess their health status, at home, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
33251042|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
33251043|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
33251044|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
33251045|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
32727597|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
32727598|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
33251046|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
32727599|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
32727600|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
32727601|NCT03418519|Experimental|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)~24-hour restraint for 3 weeks"
32727602|NCT03418519|No Intervention|Control group|no CIMT
32727603|NCT02735707|Other|Antibiotic Domain|Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions
32727604|NCT02735707|Other|Macrolide Duration Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
33251047|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
32727605|NCT02735707|Other|Corticosteroid Domain|"Patients with community acquired pneumonia admitted to participating intensive care units will be randomised to a steroid use strategy~Note: this domain is now closed to patients with suspected or proven COVID-19"
32727606|NCT02735707|Other|Influenza Antiviral Domain|Patients with community-acquired pneumonia admitted to participating intensive care units with suspected or microbiological testing confirmed influenza infection will be randomised to one of three interventions
32768624|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
32768625|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board~3 months"
32768626|NCT05412927||Patients who have had prior ACS events.|Patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be implanted with PMA P150009 AngelMed Guardian® System and enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events.
32768627|NCT04859855|Experimental|Restrictive strategy (arm A)|Transfusion of RBC if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
32768628|NCT04859855|Experimental|Liberal strategy (arm B)|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL.
32768629|NCT04859621|Experimental|Vitamin D3 4000 IU|4000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
32768630|NCT04859621|Experimental|Vitamin D3 2000 IU|2000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
32768631|NCT04859621|Placebo Comparator|Placebo|Placebo Oral Tablet plus standard antibiotic therapy
32768632|NCT04859387|Experimental|group A|set of pragmatic shoulder techniques
32768633|NCT04859387|Active Comparator|group B|traditional physical therapy
32768634|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
32768635|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
32768636|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
32768637|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
32768638|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
32768639|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
32768640|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
32906014|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
33251048|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
33251049|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
33251050|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
33251051|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
33251052|NCT00881673|Experimental|1|
33251053|NCT00881673|Active Comparator|2|
33251054|NCT00881673|Placebo Comparator|3|
33251055|NCT00881829||Healthy volunteer|Smoker or non-smoker
32727607|NCT02735707|Other|COVID-19 Antiviral Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin.~Note: lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine interventions are now closed."
32727608|NCT02735707|Other|COVID-19 Immune Modulation Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions.~Note: this domain is now closed"
32727609|NCT02735707|Other|Anticoagulation Domain|"Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy.~Note: the local standard venous thromboprophylaxis and therapeutic anticoagulation interventions are now closed."
32727610|NCT02735707|Other|Immunoglobulin Domain|"Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive convalescent plasma.~Note: this domain is now closed"
32727611|NCT02735707|Other|Vitamin C Domain|Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C
32727612|NCT02735707|Other|Simvastatin Domain|Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin.
33251056|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
32727613|NCT02735707|Other|Antiplatelet Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.~Note: this domain is now closed"
32727614|NCT02735707|Other|Mechanical Ventilation Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
32768641|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
33251057|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)~Tonsil - Stage: cT1-3, cN0 or N1 (single node)~Unknown primary - Stage: cT0 N1 (single node)~Radiation also given if indicated by intermediate or high risk features following surgery."
33251058|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2~Tonsil - Stage: cT1-3, N1 (2-4 nodes)~Radiation also given if indicated by intermediate or high risk features following surgery."
33251059|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:~Tonsil - Stage: cT1-3, N2~Unknown Primary - Stage: cT0, N2"
33251060|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N~Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3~Tonsil - Stage: cT1-3, N3~Tonsil - Stage: cT4, any N~Unknown Primary - Stage: cT0, N3"
33251061|NCT00961714|Experimental|OsseoFix|Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
33251062|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
32768642|NCT03037853||Healthy volunteers|Healthy volunteers
32906015|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
33251063|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
33251064|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
33251065|NCT04487925|Active Comparator|Up to 3 modified natural cycles|
33251066|NCT04487925|Experimental|Controlled ovarian stimulation|
33251067|NCT05003583|Experimental|Experimental Condition|Speaking while viewing images with negative and neutral valence
33251068|NCT00547300|Experimental|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
33251069|NCT00547300|Active Comparator|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
33251070|NCT04386759||Healthcare workers|"Up to protocol v2.0: Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study. For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis.~From protocol v3.0: After performing a RT-PCR or an antigenic test for COVID diagnosis, the healthcare workers will complete a unique self-questionnaire about individual and contextual risks factors during the 15 days preceding the test."
33251071|NCT00958516|Experimental|LEO 29102 cream|
33251072|NCT00881985|Active Comparator|continuous positive airway pressure|
33251073|NCT00881985|No Intervention|observation|
33251074|NCT04975906||Participants|All inpatient admissions with serum lactate, ketones and/or salicylates performed, and with urea, electrolytes and creatinine at the same time. The patients will be grouped into patients with organic (gap) acidosis (elevated serum lactate, ketones and/or salicylates) and patients with no organic acidosis.
33251075|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
33251076|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
33251077|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
33251078|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
32727615|NCT02735707|Other|COVID-19 Immune Modulation (2) Domain|Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions
32727616|NCT02735707|Other|ACE2 RAS Domain|Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to three renin-angiotensin system blockade strategies.
32727617|NCT02735707|Other|Cysteamine Domain|Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine
32727618|NCT01236521|Experimental|Arm 1: Pharmacological (MED)|Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
32727619|NCT01236521|Experimental|Arm 2: Behavioral treatment (CBT)|Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
32727620|NCT01092143|Experimental|BI 671800 (low dose)|Patients receive BI 671800 (low dose) capsules twice daily
32727621|NCT01092143|Active Comparator|Fluticasone propionate|Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily
32727622|NCT01092143|Placebo Comparator|Placebo|Patients receive placebo capsules twice daily
32727623|NCT01092143|Experimental|BI 671800 (medium dose)|Patients receive BI 671800 (medium dose) capsules twice daily
32727624|NCT01092143|Experimental|BI 671800 (high dose)|Patients receive BI 671800 (high dose) capsules twice daily
32727625|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
32727626|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
32727627|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
32727628|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
32727629|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
32727630|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
32727631|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
32727632|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
32727633|NCT03421223||Case|Individuals diagnosed with chronic pain
32727634|NCT03421223||Control|Individuals without chronic pain
32727635|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
32727636|NCT00816491|Experimental|B|Chromoendoscopy
32727637|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
32727638|NCT00950989|Placebo Comparator|Placebo|Placebo on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
32727639|NCT00950989|Experimental|Brodalumab 70 mg|70 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
32727640|NCT00950989|Experimental|Brodalumab 140 mg|140 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexateand folic acid supplementation (at least 5 mg per week).
32727641|NCT00950989|Placebo Comparator|Brodalumab 210 mg|210 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
32727642|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
32727643|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
32727644|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
32727645|NCT04537715|Experimental|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|Subjects may discontinue from the study after completion of Cycle 1 or can continue (Cycle 2+ onwards) Tazemetostat treatment at the recommended therapeutic dose (oral 800 mg Tazemetostat twice daily [12 hours apart]) in 28 day cycles. Safety and tolerability will be assessed throughout the subject's participation.
32727646|NCT04537715|Experimental|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|Subjects may discontinue from the study after completion of Cycle 1 or can continue (Cycle 2+ onwards) Tazemetostat treatment at the recommended therapeutic dose (800 mg Tazemetostat twice daily [12 hours apart]), in 28 day cycles. Safety and tolerability will be assessed throughout the subject's participation.
32929411|NCT05571553|No Intervention|Control group|"Phase 1~Participants will assess their health status, by telephone, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
32929412|NCT05629286||Intervention Group 1|McConnell taping first and then patella stabilizing brace applied to healty participants and patients with PFPS
33251079|NCT04038801|Active Comparator|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
33251080|NCT04038801|Experimental|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
32929413|NCT05629286||Intervention Group 2|first patella stabilizing brace and then applied McConnell taping to healty participants and patients with PFPS
32929414|NCT05629286||No Intervention Group|no intervention to healty participants and patients with PFPS
32929415|NCT05558293|Placebo Comparator|Periodontitis quadrant Scaling root planing|Patients undergo non surgical quadrant scaling and root planing performed per quadrant
32929416|NCT05558293|Active Comparator|Periodontitis full mouth scaling root planing|Patients undergo non surgical full mouth scaling and root planing
32929417|NCT00355537|Experimental|Active|
32929418|NCT00355537|Placebo Comparator|Placebo|
32929419|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
32929420|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32929421|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32929422|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32929423|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32929424|NCT05553925|Experimental|Intervention Implementation|At least 5,000 patients from the participating BWH practices/sites will receive the combined intervention (online weight management program with patient navigator support and personalized coaching) as part of standard of care for overweight and obesity.
32929425|NCT00003387|Experimental|Chemo + radiation|
32929426|NCT00003387|Experimental|Induction chemo + chemo & radiation|
32929427|NCT05627492|Experimental|Youth with bipolar disorder|120 youth aged 14 to 24 with bipolar disorder (type I, type II, not otherwise specified/NOS) will be enrolled in the dialectical behavioral therapy booster session intervention.
32929428|NCT05332639|Experimental|Intervention Arm|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool
32929429|NCT05332639|Active Comparator|Comparator arm|Standard Crohn's Disease Education
32929430|NCT03430349|Experimental|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
32929431|NCT03430349|Experimental|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
32929432|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
32929433|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
32929434|NCT05552443|Experimental|Intrathecal Hydromorphone 2.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929435|NCT05552443|Experimental|Intrathecal Hydromorphone 2.75 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.75 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929436|NCT05552443|Experimental|Intrathecal Hydromorphone 3 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929437|NCT05552443|Experimental|Intrathecal Hydromorphone 3.25 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.25 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929438|NCT05552443|Experimental|Intrathecal Hydromorphone 3.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929439|NCT05552443|Experimental|Intrathecal Hydromorphone 4 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929440|NCT05552443|Experimental|Intrathecal Hydromorphone 4.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
32929441|NCT05552443|Experimental|Intrathecal Hydromorphone 5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
33251081|NCT04038801|Experimental|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
33251082|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
33251083|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
33251084|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
32929442|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
33251085|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
33251086|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
33251087|NCT04362189|Experimental|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
33251088|NCT04362189|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
33251089|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
33251090|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
33251091|NCT00882141|Experimental|1|Weight loss
33251092|NCT00882141|Experimental|2|Exercise plus weight loss
33251093|NCT04902274|Experimental|Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
32768643|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
32768644|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
32768645|NCT04838093||Patient cohort:|all patients with vascular disorders consecutively admitted at our tertiary care hospital from March 16 to December 07, 2020
32768646|NCT04838093||Control cohort:|data of two nationwide PCR-based studies conducted in a representative random sample, from April 1-6, and November 12-14, 2020, collected by the Austrian Ministry of Science and the Austrian Red Cross to estimate the spread of SARS-CoV-2 infection among the non-hospitalized Austrian population.
32768647|NCT04838093||HCP cohort:|HCP worker data, including nurses, nurse technicians, physicians, surgical personal, physical therapists, nurse practitioners, environmental service workers, administrative staff, and dietitians, working in close proximity to admitted patients at our tertiary care hospital from March 16 to December 07, 2020.
32768648|NCT04859309|Experimental|ActiveHip Intervention|"The ActiveHip tele-rehabilitation mobile application.~The program consists of a multidisciplinary home-based tele-rehabilitation program delivered through a mobile application. It is comprised by an occupational therapy program and a physical exercise program.~The intervention group have the opportunity to perform three online-based sessions per week (two sessions of physical exercise and one of occupational therapy), each lasting 30-60 min. It is able to realize a fourth session, called bonus session.~In addition, the intervention group will receive the educational program, which has a total of 7 modules. 5 modules are for patients and caregivers, and 2 modules are specific for caregivers."
33251094|NCT04902274|Sham Comparator|Sham Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
33251095|NCT00958906|Experimental|Intravitreal infliximab|
32768649|NCT04859309|Active Comparator|Standard care|Participants of this group will receive the standard care for hip fracture patients at hospital discharge.
32768650|NCT04859543|Other|Diagnostic group|Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.
33251096|NCT00882219|Experimental|Xience V®|
33251097|NCT04318665|Experimental|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
33251098|NCT00959062|Experimental|clonidine|
32768651|NCT04789967|Active Comparator|Guided Imagery (GI)|A 8 minute audio that focuses on evoking mental images in reducing the abdominal bloating sensation in patients
32768652|NCT04789967|Active Comparator|Progressive Muscle Relaxation (PMR)|A 8 minute audio that focuses on contracting certain muscle groups and relaxing it progressively in reducing the abdominal bloating sensation in patients
32768653|NCT04789967|Placebo Comparator|Audiobook|A 8 minute audio that focuses on providing educational information regarding functional gastrointestinal disorders and related knowledge.
32727647|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
32727648|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
32727649|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
32727650|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
32906016|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
32906017|NCT03838172||Parents|Parents who have a burned child
32929443|NCT01542021|Experimental|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
33400868|NCT04638088||robot-assisted laparoscopy|radical prostatectomy performed by robot-assisted laparoscopy
33400869|NCT04638088||conventional laparoscopy|radical prostatectomy performed by conventional laparoscopy
33400870|NCT04638088||laparotomy|radical prostatectomy performed by laparotomy
33400871|NCT04303507|Experimental|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.~In Europe, the participant will receive hydroxychloroquine~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
32727651|NCT03420599||health control|healthy controls are all from normal volunteers
32727652|NCT03420599||splenectomy|Traumatic patients after total splenectomy
32727653|NCT03420443|Experimental|Oat bran|45 g oat bran
32727654|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
32727655|NCT03420443|Other|No oral supplementation|No oral supplementation.
32727656|NCT03415997|Active Comparator|Total Body Weight|
32727657|NCT03415997|Active Comparator|Lean Body Weight|
32727658|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
32727659|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
32727660|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
32727661|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
32727662|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
32727663|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
32727664|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
32727665|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
32727666|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
32727667|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
32727668|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
32727669|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
32727670|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
32727671|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
32727672|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
32727673|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
32727674|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
32727675|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
32727676|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
33251099|NCT00959062|Placebo Comparator|placebo|
32727677|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
32727678|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
32727679|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
32727680|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
32727681|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
32727682|NCT03420131||FFR-iFR-QFR group|
32727683|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
32727684|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
32727685|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
32727686|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
32727687|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
32727688|NCT03419975|Experimental|TJO-002|
32727689|NCT03419975|Active Comparator|latanoprost|
32727690|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
32727691|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
32727692|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
32727693|NCT03414749|Experimental|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
32727694|NCT03414749|Experimental|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
32727695|NCT03419663||gastric cancer|
32727696|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
32727697|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
32727698|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
32727699|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
32727700|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
32727701|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
32727702|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
33251100|NCT00963040|Experimental|Syntocinon®|
33251101|NCT00963040|Placebo Comparator|Sterile water|
33400872|NCT04303507|Placebo Comparator|Placebo|
32727703|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
32727704|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
32727705|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
32727706|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
32727707|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
32727708|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
32727709|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
32727710|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
32727711|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
32727712|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
32727713|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
32727714|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
33400873|NCT04296643|Experimental|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
32727715|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
32727716|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
32727717|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
32727718|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
32727719|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
32727720|NCT03413527|Experimental|rTMS Treatment|
32727721|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
32727722|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
32727723|NCT05117541||Observational (interview, biospecimen collection)|Patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. Patients' medical records are also reviewed.
32727724|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
32727725|NCT05112159|Experimental|IPG1094 100mg|Four subjects in this cohort will receive a single dose of IPG1094 100 mg qd and two subjects will receive a single dose of placebo 100mg qd orally. Sentinel subjects (i.e. 1 subject will be dosed with IPG1094 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
32727726|NCT05112159|Experimental|IPG1094 300mg|Six subjects in this cohort will receive a single dose of IPG1094 300 mg qd and two subjects will receive a single dose of placebo 300mg qd orally.
32727727|NCT05112159|Experimental|IPG1094 600mg|Six subjects in this cohort will receive a single dose of IPG1094 600 mg qd and two subjects will receive a single dose of placebo 600mg qd orally.
32727728|NCT05112159|Experimental|IPG1094 900mg|Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.
32727729|NCT05112159|Experimental|IPG1094 1200mg|Six subjects in this cohort will receive a single dose of IPG1094 1200 mg qd and two subjects will receive a single dose of placebo 1200 mg qd orally.
32727730|NCT05112159|Experimental|IPG1094 1500mg|Six subjects in this cohort will receive a single dose of IPG1094 1500 mg qd and two subjects will receive a single dose of placebo 1500mg qd orally.
33251102|NCT04296981|Experimental|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
33251103|NCT04009564|Experimental|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
33251104|NCT04009564|Experimental|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
33251105|NCT04009564|Placebo Comparator|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
33251106|NCT04038411|Experimental|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
33251107|NCT04009642||Type 2 Diabetes|
32727731|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
33251108|NCT04009642||Non Diabetic|
33251109|NCT00882297|Active Comparator|1|Transversal approach guided placement
33251110|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
32727732|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
33251111|NCT04155424|Experimental|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
33251112|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
33251113|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
33251114|NCT00883467|Other|3|short time preconditioning, other details according arm 2
33251115|NCT00883467|Other|4|long time preconditioning, other details according arm 2
33251116|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
33251117|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
33251118|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
32906018|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
32906019|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
33251119|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
33251120|NCT00882375|Experimental|Nicotine|Nicotine
33251121|NCT00882375|Placebo Comparator|Placebo|Placebo
33251122|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
33251123|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
33251124|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
33251125|NCT00882453||Group 1|
33251126|NCT04871074|Active Comparator|Cognitively unimpaired|Results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
33251127|NCT04871074|Active Comparator|Mild Cognitive Impairment|Abnormal cognitive status of MCI as judged by consensus or expert review using NIA-AA 2018 criteria.
33251128|NCT04871074|Active Comparator|Mild dementia|Abnormal cognitive status of dementia as judged by consensus or expert review using NIA-AA 2018 criteria.
33251129|NCT04860778|Experimental|BDNF Essentials|A proprietary blend of botanical extracts and isolates.
33251130|NCT00883545|Experimental|Woman endoscopist|
33251131|NCT00883545|Active Comparator|Usual care|
33251132|NCT04812340|Active Comparator|High intensity Circuit training|Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
33251133|NCT04812340|Active Comparator|Low intensity interval training|the intervention will consist of 4 series of Low-intensity exercises with 3 minutes of rest. the series will comprise of jogging and walking. the Exercise volume will be increased gradually.
33251134|NCT00882531|Experimental|Isotretinoin|
33251135|NCT00882531|Placebo Comparator|placebo|
33251136|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
32727733|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
32727734|NCT04145895|Other|Physician-directed Postoperative Activity Restriction|Postoperative activity restrictions prescribed by physician.
32727735|NCT04145895|Other|Self-directed Postoperative Activity Restriction|Postoperative activity restrictions self-determined (parent/guardian and/or patient).
32727736|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
33251137|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
32727737|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
32727738|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
32727739|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
32727740|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
32727741|NCT05117073||spontaneous bacterial peritonitis|cirrhotic patients diagnosed with SBP
32727742|NCT05117073||spontaneous fungal peritonitis|irrhotic patients diagnosed with SFP
32727743|NCT05116995|Active Comparator|Rivaroxaban first|Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.
32727744|NCT05116995|Active Comparator|Ticagrelor first|Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
32727745|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
32727746|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
32727747|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
32727748|NCT03992001|Experimental|Sequence A-B|Patients in this arm will receive blood component A for 6 months and blood component B for the next 6 months
32727749|NCT03992001|Experimental|Sequence B-A|Patients in this arm will receive blood component B for 6 months and blood component A for the next 6 months
32727750|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
32727751|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
32727752|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
32727753|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
32727754|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
32727755|NCT03677115|Experimental|dexmedetomidine group|a combination of ropivacaine and dexmedetomidine
32727756|NCT05116449||Patient seeking supportive care|
32727757|NCT05116449||Patient without any supportive care|
32727758|NCT03413293||Nosocomial infected cirrhotic patients|
32727759|NCT05116371||Group 1: Same day initiation option|1) ENG implant with initiation of concurrent COC use for bleeding control at time of insertion
32727760|NCT05116371||Group 2: Delayed initiation option|"2) ENG implant alone with option for delayed initiation of COC if bleeding concerns develop"
32727761|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
32727762|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
32727763|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
32727764|NCT03008811|Active Comparator|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
32727765|NCT03008811|Active Comparator|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
32727766|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
32727767|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
33251138|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
32768654|NCT04833569|Experimental|Indocyanine green mediated photodynamic therapy (ICG-PDT)|Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
33251139|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
32768655|NCT04833569|Placebo Comparator|Peri-implant mechanical debridement|Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.
33251140|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
33251141|NCT05272618||MINOCA with CMD|MINOCA patients with CMD proven by invasive or non-invasive method
33251142|NCT05272618||MINOCA without CMD|MINOCA patients without CMD
33251143|NCT00883623|Experimental|Treatment Arm|Treatment Arm
33251144|NCT00959218|Experimental|Dronabinol|
33251145|NCT00959218|Placebo Comparator|Placebo|
32768656|NCT04837781|Experimental|Normal vitamin D|Include patients with normal vitamin D level (above 30ng/ml). Vitamin D level will be measured at the beginning of treatment if there is deficiency then the patient refer to specialized physician to be supplied with vitamin D supplement to optimized the level to normal then start orthodontic treatment
32768657|NCT04837781|Experimental|Vitamin D deficiency|Include patients with unknown vitamin D level until time of canine retraction where we measure level if deficiency exist (below 30ng/ml) then the patient will be referred to specialized physician to be supplied with vitamin D supplement.
33251146|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation >3 day )
33251147|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation <=3 day )
32768658|NCT04837781|Experimental|Control|includes patients with unknown vitamin D level until the completion of canine retraction where we measure level. If deficiency exists (below 30ng/ml) then we will refer the patient to specialized physician to be supplied with vitamin D supplement
32768659|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
32768660|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
32768661|NCT04334057||Patients with haemophilia A|New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.
32768662|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
32768663|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
33251148|NCT00678210|Experimental|1|
33251149|NCT00678210|Experimental|2|
33251150|NCT00678210|Experimental|3|
33251151|NCT00678210|Placebo Comparator|4|
33251152|NCT04754776|Experimental|Low dose|5 x 10^9 vp ChAdOx1 RVF delivered intramuscularly
33251153|NCT04754776|Experimental|Medium dose|2.5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
33251154|NCT04754776|Experimental|High dose|5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
33251155|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
33251156|NCT00611715|Experimental|First line/hormone-therapy naive|
33251157|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
33251158|NCT00963352||Patients operated for colon cancer|
33251159|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
33251160|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
33251161|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
33251162|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
33251163|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
33251164|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
33251165|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
33251166|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
33251167|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
33251168|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
33251169|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
33251170|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
33251171|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
33251172|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
33251173|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
32929444|NCT01542021|Experimental|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
32929445|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
32929446|NCT05626712|Experimental|CELZ-201 Treatment Group|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.
32929447|NCT05626712|Placebo Comparator|Control Group|Participants in this group will receive standard of care for Type 1 Diabetes only.
32929448|NCT04706897|Sham Comparator|Normal saline (Control) group|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1 mic/kg of IBW).
32929449|NCT04706897|Experimental|Dexmedetomidine, ketamine and lidocaine (Study) group|A loading infusion of syringe (B) containing the mixture was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
32727768|NCT05171413||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
32929450|NCT05552053|Active Comparator|Maternal Wellness Self Help (MWSH) Application|The Maternal Wellness Self Help (MWSH) app was created to help individuals to identify and manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
32727769|NCT05171413||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
32727770|NCT04436211||TKA (mechanical alignment)|
32727771|NCT04436211||TKA (kinematic alignment)|
32727772|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 milligrams (mg) administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
32727773|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
32727774|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
32727775|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
32727776|NCT04262505|Experimental|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline teleconsultation and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with resources specifically designed to explain the components of the Mediterranean diet and how it will be followed.
32727777|NCT04262505|Experimental|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website.
32727778|NCT05089305|Experimental|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications for the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07.
32727779|NCT04448275|Experimental|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
32727780|NCT04448275|Experimental|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps in heamophilic patient The iliopsoas & quadriceps muscles strength exercise
32727781|NCT05059197|Experimental|AP collagen peptide|Each subject takes one active bottle per day for 12 weeks. Each bottle contains AP collagen 1000 mg
32727782|NCT05059197|Placebo Comparator|Placebo|Each subject takes one active bottle per day for 12 weeks.
32727783|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
32727784|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
32727785|NCT04448353||Development / training|Selected by stratified partitioning
32727786|NCT04448353||Sequestered / test|Selected by stratified partitioning
33251174|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
33251175|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
33251176|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
33251177|NCT04722718|Experimental|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Drug:Sintilimab;Drug:Apatinib;Drug:Albumin-Bound Paclitaxel(Nab-Paclitaxel);Drug:Carboplatin
32727787|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
33251178|NCT00883701||COPD patients|COPD patients who undergo exacerbation
33251179|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
33251180|NCT04649710|Experimental|Cohort 1: Dose 1 or placebo|Chinese participants
33251181|NCT04649710|Experimental|Cohort 2: Dose 2 or placebo|Chinese participants
33251182|NCT04649710|Experimental|Cohort 3: Dose 1 or placebo|Korean participants
33251183|NCT04649710|Experimental|Cohort 4: Dose 2 or placebo|Korean participants
33251184|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
33251185|NCT00761670|Active Comparator|1|
33251186|NCT00761670|Active Comparator|2|
33251187|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
33251188|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
33251189|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
32727788|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
32727789|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
33251190|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
33251191|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
33251192|NCT05267236|Experimental|Treatment-On Demand Format|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
33251193|NCT05267236|Experimental|Control-Virtual or In-Person Format|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
33251194|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
33251195|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
33251196|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
33251197|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
32727790|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
33251198|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
33251199|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
33251200|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
33251201|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
32727791|NCT04448041||Ghana|
32727792|NCT04448041||India|
33251202|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
33251203|NCT00963898|Experimental|Mental Retardation|
33251204|NCT00761904|Experimental|receipt of free generic samples|
33251205|NCT00761904|No Intervention|usual prescribing|
33251206|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
33251207|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
33251208|NCT04238520|Other|Control|10 PWD/CG dyads
33251209|NCT04238520|Experimental|Interventional|30 PWD/CG dyads
33251210|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
32727793|NCT04448041||Philippines|
32727794|NCT04448041||Zambia|
33251211|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
33251212|NCT02559258|Experimental|Cohort 1|
33251213|NCT02559258|Experimental|Cohort 2|
33251214|NCT02559258|Experimental|Cohort 3|
33251215|NCT02559258|Experimental|Cohort 4|
33251216|NCT02559258|Experimental|Cohort 5|
33251217|NCT00964132|Experimental|NRX194204|
33251218|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
33251219|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
33251220|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
33251221|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
33251222|NCT04038177|Experimental|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
32727795|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
32727796|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
32727797|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
32727798|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
32727799|NCT04447885|Experimental|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
32727800|NCT04447885|Active Comparator|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
32727801|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
32727802|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
32727803|NCT05122455|Experimental|ASA baseline|Patients in chronic use of ASA
33277423|NCT03957811|No Intervention|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
33400874|NCT04296643|Active Comparator|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
32929451|NCT05552053|Experimental|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
32929452|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
32929453|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
32929454|NCT05716100|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
32727804|NCT05122455|Experimental|ASA + Edoxaban|During this intervention phase, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days.
32929455|NCT05716100|Experimental|XEN1101 15 mg/day|XEN1101 15 mg/day
32929456|NCT05716100|Placebo Comparator|Placebo|Placebo
32727805|NCT05122455|Experimental|Clopidogrel|Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA).
32727806|NCT05122455|Experimental|Clopidogrel + Edoxaban|Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days
32727807|NCT05122455|Experimental|Edoxaban|Finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered.
32727808|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
32727809|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
32929457|NCT04735289||GROUP 1 - 215 Patients and 430 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included~Localized and metastatic~Male and female~Control cases matched by age, sex and italian geographic area"
33277424|NCT03957811|Experimental|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
33277425|NCT05269472||Trigeminal Electrophysiology|
33277426|NCT05269472||Controls|
33277427|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
32727810|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
32727811|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
32727812|NCT05120817|No Intervention|Control Group|Participants do not undergo any intervention. Pre-and post data collection only.
32768664|NCT04833725||COPD combined with OSA|All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc. This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
32768665|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
32768666|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
32768667|NCT05069779|Experimental|Diazepam|Oral
32768668|NCT05069779|Placebo Comparator|Placebo|Oral
32929458|NCT04735289||GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female~Control cases matched by age, sex, and geographic area"
32929459|NCT05550181||with hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was < 35 mm Hg at any point during surgery, from start of the study till end of the study
32929460|NCT05550181||without hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was < 35 mm Hg at any point during surgery, from start of the study till end of the study, and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
32768669|NCT04833491||Senile cataract|
32768670|NCT04833491||Traumatic cataract|
32768671|NCT04833491||Congenital cataract|
32768672|NCT04833491||Lens dislocation group|
32768673|NCT04833491||Complicated cataract|
32768674|NCT04837469|Experimental|Universal Adhesive|universal adhesive
32768675|NCT04837469|Experimental|Etch-And-Rinse Adhesive|Etch-And-Rinse Adhesive
32768679|NCT04837625||Myasthenic Crisis Cohort|
32768680|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
32768681|NCT04824755|Experimental|Demographics and clinic characteristics of children in different ages|
32768682|NCT04824755|Experimental|PedEyeQ domain scores|
32768683|NCT04824755|Experimental|Boxes represent first, median, and third quartile values.|
32768684|NCT04824755|Experimental|Parent of kids aged 0-4y and 5-11y PedEyeQ domain scores|
32768685|NCT04837391||Urologic oncology surgery in elderly|Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years
32768686|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
32929461|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
32929462|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
32929463|NCT05716022||Hiatal Hernia Group|The subject has a history of acid reflux and/or hiatal hernia undergoing surgical repair by thoracic surgery at the University of Virginia.
32768687|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
32768688|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
32768689|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
32768690|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
32768691|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
32768692|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
32768693|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
32768694|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
32727813|NCT05120817|Experimental|Personal|Participants are exposed to the message about the personal benefits (and costs) of vaccination which refers to their own safety, their freedoms, their worries about the well-being of their significant others.
32727814|NCT05120817|Experimental|Social|Participants are exposed to the message about the social benefits (and costs) of vaccination which refers to public safety, the well-being of others in their community, the vulnerable groups, etc.
32929464|NCT05716022||Control Group|Patients undergoing bronchoscopy for clinical purposes at the University of Virginia endoscopy suite without a clinical diagnosis of hiatal hernia and/or pulmonary fibrosis.
32929465|NCT03847675|Experimental|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.~After each visit participants will receive an age appropriate book for their child.~Focus groups will be conducted by a qualitative researcher"
33400875|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
32929466|NCT03847675|No Intervention|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
32929467|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
32929468|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
32929469|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
32929470|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
32929471|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
32929472|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
32929473|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
32929474|NCT04656223||MF/IND/GLY Breezhaler® plus Propeller Health|patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
32929475|NCT04656223||Other FDC therapy|patients receiving ICS+LABA+LAMA FDC therapy according to label
32929476|NCT05715944|Experimental|AZD 1222|"AZD1222 vaccine~Dose Formulation:~10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6~Current/Former names/alias(es):ChAdOx1 nCoV-19"
32929477|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
32929478|NCT05624684||ICU patients with severe pneumonia|Critically ill patients with severe pneumonia under mechanical ventilation including ventilator-associated pneumonia, community-acquired or hospital-acquired pneumonia.
32929479|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
32929480|NCT05624060|Active Comparator|Control Group|Pelvic Floor Dysfunction Prevention Training
32929481|NCT05624060|Experimental|Experimental Group 1|Pelvic Floor Dysfunction Prevention Training and Perineal Massage
32929482|NCT05624060|Experimental|Experimental Group 2|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise
32929483|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
32929484|NCT05623748||Cancer for CTC culture|participants are cancer patients with transitional cell carcinoma
32929485|NCT05623748||Healthy for CTC culture|enroll participants without cancer
32929486|NCT05310019|Experimental|Physiotherapy plus Electroacupuncture Group|The physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
33251223|NCT04038177|Active Comparator|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
33251224|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
33251225|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
33251226|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
33251227|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
32727815|NCT05120817|Experimental|Personal + Social|Participants are exposed to the message about both personal and social benefits (and costs) of vaccination. The message alludes to personal safety as well as public safety and the strain on the healthcare system associated with the uncontrollable spread of the virus.
32727816|NCT05170087||Breast malignancies|Those diagnosed with breast malignancies
32929487|NCT05310019|Active Comparator|Physiotherapy Group|The physiotherapy protocol will be the same as the active group. Protocol: warm compress with facial thermal blanket (5 min), respiratory muscle mobility training and cervical muscle relaxation (5 min) facial lymphatic drainage (10 min), start of myolyphokinetic exercises for the orbicularis oris, zygomatic major and minor, levator labii superioris and nasal ala, buccinator and platysma (5 min), release of intraoral adhesions (5 min) vacuum therapy at 60 mmHg (5 min), active exercises free of mandibular movements of right and left laterality, protrusion and mandibular opening (5 min), maintenance of mandibular opening with wooden tongue depressors (10 min).
33400876|NCT05308693|No Intervention|Control-Classical patient education|Before the operation, the stoma area is marked, the patient is educated with the classical method brochure
33400877|NCT05308693|Experimental|Experimental-Patient Compatible Stoma Educational Material|The stoma area is marked before the operation; A brochure is given to the patient. Practical training is given on the patient's own body with patient-compatible stoma training material.
32929488|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
32929489|NCT03822793|Placebo Comparator|Placebo|Patient will be included in this group by randomization and they will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.
32727817|NCT05170087||Head and Neck malignancies|Those diagnosed with head and neck malignancies
32929490|NCT03822793|Experimental|Group 1: perfusion of 500 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
32929491|NCT03822793|Experimental|Group 2: perfusion of 1000 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
32727818|NCT05170087||Brain malignancies|Those diagnosed with brain malignancies
32727819|NCT05170087||Gynecological malignancies|Those diagnosed with gynecological malignancies
32929492|NCT03822793|Experimental|Group 3: perfusion of 1500 mg Exacyl|Patient will be included in the group 3 by randomization and they will receive a perfusion of 1500 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
32929493|NCT03822793|Experimental|Group 4: perfusion of 3000 mg Exacyl|Patient will be included in the group 4 by randomization and they will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
32929494|NCT04735523||Warfarin|Reference group
32929495|NCT04735523||Dabigatran|Exposure group
32929496|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
32929497|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
32929498|NCT03809299|Other|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
32929499|NCT03809299|Other|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
32929500|NCT05715866|Experimental|non-invasive neurostimulation experimental group (NEG)|The non-invasive neuromodulation experimental group, made up of 10 participants, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
32929501|NCT05715866|Experimental|Experimental group Therapeutic Exercise (TEG)|The experimental group of therapeutic exercise, made up of 10 participants, receives 3 weekly sessions of one hour duration for 16 weeks, and 1 weekly session until week 20, of an adapted program of cardiovascular exercises in a small group format, supervised by a physical therapist.
32727820|NCT05122377||GnRHa 3-month|Patients using GnRHa 3-month depot
32727821|NCT05122377||GnRHa 1-month|Patients using GnRHa 1-month depot
32727822|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
32727823|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
32727824|NCT05122299|Other|Negative control group|
32727825|NCT05122299|Active Comparator|Positive control group|
32929502|NCT05715866|Sham Comparator|Control group (CG)|The control group, made up of 10 participants, the caregivers receive recommendations about sleep habits through an information brochure.
32929503|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
32929504|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
33277428|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
32727826|NCT05122299|Experimental|Study group|
32727827|NCT04891185|Experimental|Primary Debulking Surgery|
32727828|NCT04891185|Experimental|Interval Debulking Surgery|
32727829|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
32727830|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
32727831|NCT04865601||CRC|Patient affected by any sporadic colorectal cancer
32727832|NCT04865601||FAP|Patients affected by familial adenomatous polyposis coli
32727833|NCT04865601||HNPCC|Patient affected by hereditary non polyposis colorectal cancer
32929505|NCT04329351|Experimental|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
32929506|NCT04329351|Placebo Comparator|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
32727834|NCT04865601||Lynch|patient affected by lynch syndrome
33251228|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
32727835|NCT04865601||others|Patients affected by ulcerative colitis, chron disease, diverticulitis and other colon diseases, which represent the control
32727836|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
32727837|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
32727838|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
32727839|NCT05120115|Experimental|Walking Speed|Changing speed of treadmill
32727840|NCT05120115|Experimental|Weight distribution|Changing where weight is distributed on belt around pelvis, specifically, bilaterally, 4th lumbar area, unilaterally on the left side.
32727841|NCT05120115|Experimental|Weight amount|Changing the amount of weight used in belt around pelvis, 0 kg, 2 kg, 4 kg, and 6 kg.
32727842|NCT04796727||OHCA|300 OHCA admitted directly to the cathlab and alive at discharge during a 2 years period of enrolement.
32727843|NCT04753437|Active Comparator|Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, bismuth potassium citrate 600 mg, tablets, orally, twice daily, and esomeprazole 20 mg, capsules, orally, twice daily on Days 1 to 14.
32727844|NCT04753437|Experimental|Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, bismuth potassium citrate 600 mg, tablets, orally, twice daily, and vonoprazan 20 mg, tablets, orally, twice daily on Days 1 to 14.
32727845|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
32929507|NCT05715788||patients ventilated in prone position|Patients ventilated in prone position
32929508|NCT05715788||Patients ventilated in prone position with NO inhalation|Patients ventilated in prone position with NO inhalation
32929509|NCT04596163|Active Comparator|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
32929510|NCT04596163|Placebo Comparator|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
32929511|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
32929512|NCT05372588|Experimental|Group A (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
32929513|NCT05372588|Experimental|Group B (NVX-CoV2373 )|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
32929514|NCT05372588|Experimental|Group C (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
32929515|NCT05372588|Experimental|Group D (NVX-CoV2373)|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
32929516|NCT05372588|Experimental|Group E (BA.1 Bivalent Vaccine)|1 intramuscular (IM) injection of Bivalent Vaccine (NVX-CoV2373 + NVX-CoV2515) of 0.5 mL injection volume on Day 0.
32727846|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
32727847|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
32727848|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
32727849|NCT04616079|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of REGN6490 or matching placebo
32727850|NCT04616079|Experimental|IV Cohort 2|Single IV dose 2 of REGN6490 or matching placebo
32727851|NCT04616079|Experimental|IV Cohort 3|Single IV dose 3 of REGN6490 or matching placebo
32727852|NCT04616079|Experimental|IV Cohort 4|Single IV dose 4 of REGN6490 or matching placebo
32727853|NCT04616079|Experimental|IV Cohort 5|Single IV dose 5 of REGN6490 or matching placebo
32727854|NCT04616079|Experimental|SC Cohort 1|Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo
32727855|NCT04616079|Experimental|SC Cohort 2|Single SC dose 2 of REGN6490 or matching placebo
32727856|NCT04616079|Experimental|SC Cohort 3|Single SC dose 2 of REGN6490 or matching placebo
32727857|NCT03411109||Opioid Only Intrathecal|
32727858|NCT03411109||Opioid + Local Anesthetic Intrathecal|
32727859|NCT05121987|Active Comparator|Erector spinae plane block|
32727860|NCT05121987|Active Comparator|Continuous wound infusion|
33400878|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
33400879|NCT05308459|Experimental|Step 1: Allocated to start the Data Health VET intervention phase January 2022|Participants receive the Data Health VET intervention in all its steps starting in January 2022
32929517|NCT05372588|Experimental|Group F (NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
32929518|NCT05372588|Experimental|Group G (NVX-CoV2373)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
32929519|NCT05372588|Experimental|Group H (NVX-CoV2373 + NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
32929520|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
32929521|NCT04586959|Experimental|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
32929522|NCT04586959|Active Comparator|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
32929523|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
32929524|NCT05372276||Inactive|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is <600 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
32929525|NCT05372276||Low Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is 600 - 3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
32929526|NCT05372276||Adequate Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is >3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
32929527|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
32929528|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
32929529|NCT04735211||Children whom develop chronic postsurgical pain|Children whom had chronic pain at 3 moths after surgery
32929530|NCT04735211||Children whom not develop chronic postsurgical pain|Children whom not develop chronic pain at 3 moths after surgery
32929531|NCT05562830|Experimental|Zilovertamab vedotin|Participants will receive zilovertamab vedotin 2mg/kg administered on Day 1 and Day 8 of each 3 week cycle (Q3W) until documented disease progression or any other discontinuation criterion is met.
32929532|NCT05303779|Experimental|experimental group|experimental group will receive eye exercises in addition to medication and eye glasses post strabismus surgery
32929533|NCT05303779|Active Comparator|control group|control group will receive medication and eye glasses post strabismus surgery
32929534|NCT04734899|Active Comparator|Control grup|"All individuals participating in the study will be taught the exercises given to strengthen weakened muscles, stretch shortened structures and increase proprioception by the physiotherapist and will be asked to do these exercises at least twice a day for 8 weeks.~The home program will be followed by the exercise daily form."
32929535|NCT04734899|Experimental|Foot core grup|In addition to the exercise program given to the control group, foot core training will be added and taught by the physiotherapist and they will be asked to do these exercises at least twice a day for 8 weeks.
32929536|NCT05559320|Experimental|Single Joystick Ride-on-car Navigation Training|Participants will first participate in a 6-week control phase followed by a 6-week intervention phase. During the intervention phase, they will receive the ride-on-toy navigation training program. The training will be provided by the researchers twice a week, 30-45 minutes/session for 6 weeks. Caregivers will be asked to provide 2 additional sessions/week during the intervention phase. In this study design, the participants will serve as their own controls.
32929537|NCT05294809|Experimental|PsyPills|"The participants randomized in this condition will receive the mobile health application PsyPills."
32929538|NCT05294809|Experimental|OCAT|"The participants randomized in this condition will receive the mobile health application OCAT."
32929539|NCT05294809|Placebo Comparator|OCAT sham|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
32929540|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
32929541|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
32929542|NCT05614076|Experimental|Conservation of the demineralized chalky white enamel margin of class V cavities|for cavity design in this arm we Conserved the demineralized chalky white enamel margin of class V cavities then application of resin composite restoration
32929543|NCT05614076|Active Comparator|Total removal of demineralized enamel margin of class V cavities|for cavity design in this arm is Total removal of demineralized enamel margin of class V cavities and restoration with resin composite
32929544|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
32929545|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
32929546|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
32929547|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
32929548|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
32929549|NCT05367596|Experimental|Continuous Energy Restriction (CER)|Continuous energy restriction (CER; 1,200-1,500 kcal/day). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
32727861|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
32727862|NCT04564599||alcohol- and drug-related motor vehicle collisions|Number of alcohol- and drug-related motor vehicle collisions
32727863|NCT04564599||auto-ped alcohol- and drug-related collisions|Number of auto-ped alcohol- and drug-related collisions
32727864|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
32929550|NCT05367596|Experimental|Alternate-Day Moderate Fasting (ADMF).|Alternate-Day Moderate Fasting (ADMF). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
32929551|NCT05545514|Experimental|Verum|"Individualized homeopathy (iHOM):~One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000, individually selected as indicated per homeopathic treatment principles. The HMPs are sucrose pillules, impregnated with the specific homeopathic substance and potency and will be administered once at baseline: 5 pillules sublingually. The dosage of the HMP can be repeated or adapted according to the homeopathic treatment principles three times during the course of the study and, in addition, in the event of an acute UTI."
32929552|NCT05545514|Placebo Comparator|Placebo|Non-impregnated sucrose pillules, identical to the HMP (verum) in appearance, taste and size.
32727865|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
32727866|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
32929553|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
32727867|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
32929554|NCT05366426|Experimental|Experimental group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback.
32929555|NCT05366426|Sham Comparator|Sham Group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback as a sham.
32929556|NCT05366426|Other|Control Group|Pelvic floor muscle training program will be applied as home exercise
32929557|NCT05365490||Standard-risk patients requiring carotid intervention|Symptomatic or asymptomatic patients with a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA), who require carotid artery revascularization.
32929558|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
32929559|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
32929560|NCT05355272|Experimental|Growth Hormone Replacement Therapy|"Drug: Somatropin After randomization patients will be started at a dose of 200-300 mcg/d of daily injections of GHRT. A biweekly titration period of 6 weeks will be performed in increments of 100 mcg/d as needed until IGF-1 levels are between +1 and +2 standard deviation score, up to a maximum dose of 2,000 mcg/d, provided the dose is well tolerated.~Participants will be randomized in a 1:1 ratio to rhGH versus placebo for six months, stratified by participating site. Study participants and study team will be blinded to treatment assignment. Participants will complete in-clinic follow-up visits at Days 14, 40, 65, 90, and 180. The primary outcome will be the change in truncal fat mass percentage from baseline to six months measured by dual-energy x-ray absorptiometry (DEXA)."
32929561|NCT05355272|Placebo Comparator|Placebo|"Drug: Placebo After randomization patients will be started at a dose of 200-300 mcg/d of daily injections of GHRT. A biweekly titration period of 6 weeks will be performed in increments of 100 mcg/d as needed until IGF-1 levels are between +1 and +2 standard deviation score, up to a maximum dose of 2,000 mcg/d, provided the dose is well tolerated.~Participants will be randomized in a 1:1 ratio to rhGH versus placebo for six months, stratified by participating site. Study participants and study team will be blinded to treatment assignment. Participants will complete in-clinic follow-up visits at Days 14, 40, 65, 90, and 180. The primary outcome will be the change in truncal fat mass percentage from baseline to six months measured by dual-energy x-ray absorptiometry (DEXA)."
32929562|NCT05350280|Experimental|Low-intensity electrical current (LIEC)|A removable device containing a small electrical circuit will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
32929563|NCT05350280|Active Comparator|Traditional fixed orthodontic appliance|The maxillary arch will be levelled and aligned. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
32929564|NCT05606042||IM Implant|Male and female patients who present with a pelvic ring and/or acetabular fracture that has recently undergone surgery to be fixed with a CurvaFix IM Implant.
33400880|NCT05308459|Experimental|Step 2: Allocated to start the Data Health VET intervention phase August, 2022|Participants receive the Data Health VET intervention in all its steps starting in August 2022
32727868|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
32727869|NCT05119725||Patients with atrial fibrillation|Patients with previous diagnosis of atrial fibrillation
32727870|NCT05119725||Non-AF patients with high stroke risk|Non-AF patients with high stroke risk
33251229|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
33251230|NCT00675948|Experimental|Sativex|Active treatment
33251231|NCT00675948|Experimental|GW-2000-02|Active treatment
33251232|NCT04037787|No Intervention|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
33251233|NCT04037787|Experimental|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
33251234|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
33251235|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
32727871|NCT03412825|Experimental|Nutrition Supplementation|
33251236|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
32727872|NCT03412825|No Intervention|Control|
33251237|NCT04077762|Active Comparator|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
32727873|NCT01111565|Experimental|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the Week 1 (end of Week 1) based upon tolerability profile, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
32768695|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
33251238|NCT04077762|Active Comparator|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
33251239|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
33251240|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
33251241|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
33251242|NCT04049448|Experimental|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
33251243|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
33251244|NCT04038645|Active Comparator|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
33251245|NCT04038645|Placebo Comparator|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
33251246|NCT00884013||1|Quality Payment and all clinical reminders turned on
33251247|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
32929565|NCT05349734|Experimental|overbody blanket|
32929566|NCT05349734|Active Comparator|underbody blanket|
33251248|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
33251249|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
33251250|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
33251251|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
33251252|NCT00884091||Healthy Adults|"Chinese in origin~Healthy~No medication at least two weeks before the study"
33251253|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
33251254|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
33251255|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
33251256|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
33251257|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
33251258|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
33251259|NCT00886041|Other|laparoscopy group|laparoscopy
33251260|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
33400881|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
33400882|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
32727874|NCT01111565|Experimental|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in HAM-D17 Total Score; or a HAM-D17 Total Score of <14 at Week 8 or a Clinical Global Impression of Improvement (CGI-I) Score of <3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B, for an additional 6 weeks (Up to Week 14), in Phase B+.
32727875|NCT01111565|Experimental|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
32727876|NCT01111565|Experimental|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
32727877|NCT01111565|Experimental|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily for 6 weeks (Up to Week 14), in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any visit, based upon tolerability.
32727878|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
32727879|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
32727880|NCT04564365||with beta-blocker|
32727881|NCT04564365||without beta-blocker|
32929567|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
32929568|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
32929569|NCT05349188|Experimental|Melatonin 3 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 3 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 3mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 3 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 3 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
32929570|NCT05349188|Active Comparator|Melatonin 0.5 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 0.5 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 0.5 mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 0.5 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 0.5 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
32929571|NCT05349188|Placebo Comparator|Placebo Pill|"Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
32929572|NCT05599490|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
32929573|NCT03441581|Experimental|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
32929574|NCT03441581|Experimental|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
32929575|NCT05534984|Experimental|Arm A|
32929576|NCT05534984|Placebo Comparator|Arm B|
32929577|NCT05534984|Experimental|Arm C|
32929578|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
32929579|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
32929580|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
32929581|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
32929582|NCT04735601|Experimental|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome
32929583|NCT04735601|Active Comparator|Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve will be implanted alone with no PLGA
32929584|NCT05589194|Experimental|Intervention Group|After the first interview with the patients in the intervention group, a phone call will be made for regarding the implementation of nursing interventions based on the Comfort Theory, and they will be informed about the planned dates for the implementation. The implementation phase of nursing interventions based on Comfort Theory will be carried out for 6 weeks at the Communication Laboratory of the Faculty of Nursing of Akdeniz University on the planned dates with the patients. In addition, a handbook will be given to the patients at the beginning of the practice, and the Home Yoga Diary in the handbook will be expected to be filled in daily by the patients during the research. Immediately after the implementation of the nursing interventions based on Comfort Theory (week 6), patients will be asked to fill in ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale. During this whole process, patients will continue their planned routine care and treatment.
33251261|NCT04038021|Experimental|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
33251262|NCT04038021|Active Comparator|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
32727882|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
32727883|NCT04523571|Experimental|Low-dose, 18-55 years of age|
32727884|NCT04523571|Experimental|High-dose, 18-55 years of age|
32727885|NCT04523571|Placebo Comparator|Placebo, 18-55 years of age|
32727886|NCT04523571|Experimental|Low-dose, 65-85 years of age|
33251263|NCT05278923|No Intervention|clean airway|CPR and endotracheal intubation in an airway without regurgitation
33251264|NCT05278923|Experimental|regurgitation airway|CPR and endotracheal intubation in an airway with regurgitation
32727887|NCT04523571|Experimental|High-dose, 65-85 years of age|
33251265|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
33251266|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
33251267|NCT00672984|Active Comparator|Moxifloxacin HCl|
32727888|NCT04523571|Placebo Comparator|Placebo, 65-85 years of age|
32727889|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
32727890|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
33251268|NCT00672984|Placebo Comparator|Placebo|
33251269|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
33251270|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
33251271|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
33251272|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
32727891|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
33251273|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
33251274|NCT00758472||Hip Resurfacing|
33251275|NCT00886275|Experimental|Dexmedetomidine|
33251276|NCT00886275|Active Comparator|Midazolam|
33251277|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
33251278|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
33251279|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
33251280|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
33251281|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
33251282|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
33251283|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
33251284|NCT04037709|Placebo Comparator|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. Periodontal treatment will be performed by only one experienced researcher, who will not do the periodontal exams. Periodontal reassessment will be performed after 7 and 21 days.~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
33251285|NCT04037709|Experimental|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.~However the PDT will be done using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
32727892|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
32727893|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
32727894|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
32727895|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
32727896|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
32727897|NCT05121597|Experimental|Videolaryngoscope Group|The group that we will use a videolaryngoscope for nasotracheal intubation.
32727898|NCT05121597|Active Comparator|Control Group|The group that we will use a direct laryngoscope for nasotracheal intubation.
32727899|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
32727900|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
32727901|NCT02520583|Experimental|MICROBAC|Bacterial cultures
32727902|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
32727903|NCT04170933|Experimental|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
32727904|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
32727905|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
32906020|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
33400883|NCT04800913|Experimental|Multimodal imaging|"Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
32906021|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
32906022|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
32906023|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
32906024|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
32906025|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
32906026|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
32906027|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
32906028|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
32906029|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
32906030|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
32906031|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of > 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
32906032|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of > 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
32906033|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
32906034|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
32727906|NCT05121207|Other|Dry skin condition|2. The second arm will consist of 50 patients with benign dry skin conditions (eczema, psoriasis, skin grafts, scars etc.) and will compare the water content of their skin before and after application of a propriety emollients in common usage (e.g. E45®, Aveeno®, Doublebase®). This will add to the existing dataset that has been recorded from healthy non-patient volunteers (unpublished data, University of Warwick). This may help to guide patient-specific emollient selection in the future.
32929585|NCT05589194|No Intervention|Control Group|After the first interview with the patients in the control group, the routine care and treatment practices planned by the polyclinic physician and nurse will continue. No additional intervention is planned for the patients in this group. A new interview will be planned with the patients in the control group 6 weeks after the first interview, and they will be asked to fill in the ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale.
32929586|NCT04735757||Healthy volunteers|Healthy volunteers, matched by age and gender to patient groups.
32929587|NCT04735757||COVID-19 patients|Patients discharged from the ICU after invasive ventilation for COVID-19.
32929588|NCT04735757||ICU patients|Patients discharged from the ICU after invasive ventilation for ARDS.
32929589|NCT05583344|Experimental|High Dose GSK4532990|
33082329|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
33400884|NCT04800913|Experimental|Standard imaging|"Preoperative 2D/3D TOE OR MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
32929590|NCT05583344|Experimental|Low Dose GSK4532990|
32929591|NCT05583344|Placebo Comparator|Placebo|
32929592|NCT03384329|Experimental|Resveratrol Pill|
32929593|NCT03384329|Placebo Comparator|Placebo|
32929594|NCT02959034||BMI > 95%|No Intervention
32929595|NCT02959034||Healthy Weight Siblings|Control
32929596|NCT02959034||Healthy Weight Unrelated|Control
32929597|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
32727907|NCT05121207|Other|Skin cancer|1. One arm will consist of 100 patients with known or suspected skin cancer (skin cancer defined as: incompletely excised BCC with histologically proven radial margin involvement; biopsy proven BCC, or pigmented lesions suspicious of malignant melanoma). Images will be taken in the clinic prior to planned skin surgery and later compared to the formal histology results after the primary (melanoma) or residual (BCC) tumour has been removed.
32727908|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
32929598|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
32929599|NCT05328752|Experimental|XXB750 Cohort 1|XXB750, single dose
32929600|NCT05328752|Placebo Comparator|Placebo Cohort 1|Placebo, single dose
32929601|NCT05328752|Experimental|XXB750 Cohort 2|XXB750, multiple doses
32929602|NCT05328752|Placebo Comparator|Placebo Cohort 2|Placebo, multiple doses
32929603|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
32929604|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
32929605|NCT05327972|Experimental|1- Botulinum toxin|"The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).~The dosage is:~Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance."
32929606|NCT05327972|Placebo Comparator|2- PLACEBO|"The placebo comparator represents a saline solution containing an inactive lyophilisate.~The dosage is:~Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance."
32929607|NCT05532722|Experimental|ABC008 Dose Level 1 Cohort|"0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 4 or any cohort is determined to have exceeded the maximum tolerated dose."
32929608|NCT05532722|Experimental|ABC008 Dose Level 2 Cohort|"0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 4 or any cohort is determined to have exceeded the maximum tolerated dose."
32929609|NCT05532722|Experimental|ABC008 Dose Level 3 Cohort|"1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 4 or any cohort is determined to have exceeded the maximum tolerated dose."
32929610|NCT05532722|Experimental|ABC008 Dose Level 4 Cohort|"3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 4 or any cohort is determined to have exceeded the maximum tolerated dose."
32727909|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
32727910|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
32727911|NCT05119491||cases ultra sound and spirometry|observation by ultra sound and spirometry for cases
32727912|NCT05119491||heathy subjects ultra sound and spirometry|observation ultra sound and spirometry for control heathy subjects
32727913|NCT04797091||Patients with SARS-CoV-2-infection|Patients with evidence of SARS-CoV-2-infection
32727914|NCT04797091||Control group|Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
32727915|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
32727916|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 1)|Dose level 1 is 40 x 10^6
32727917|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 2)|Dose level 2 is 160 x 10^6
33251286|NCT04017897|Experimental|Experimental|
33251287|NCT02543541|Active Comparator|Standard Supportive Care|
33251288|NCT02543541|Experimental|Structured Supportive Care|
32727918|NCT04482699|Active Comparator|RAPA-501 cells|RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)
32727919|NCT04482699|Placebo Comparator|Placebo-control Cohort|Placebo
32727920|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
32727921|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
32906035|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
32906036|NCT00899600|Placebo Comparator|Normal saline|
32906037|NCT00899600|Experimental|Ketamine|
32906038|NCT04379882|Experimental|Digital sedation|30 minutes Silva module
32906039|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
32906040|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
32906041|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
32906042|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
32906043|NCT01554371|Experimental|Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
32906044|NCT01554371|Experimental|Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
32906045|NCT01554371|Experimental|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.
32906046|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
32906047|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
32906048|NCT01450787||diabetics|diabetics
32906049|NCT01450787||non diabetics|non diabetics
32906050|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
32906051|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
32906052|NCT01451411|Experimental|Conivaptan hydrochloride|
32906053|NCT01451411|Placebo Comparator|Placebo|
32929611|NCT05325476|Experimental|JomPrEP App Group|Participants in the TAU group will receive the JomPrEP app with major intervention features inactivated; information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The Research Assistant will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
32929612|NCT05325476|Active Comparator|Treatment as usual|Participants in the JomPrEP group will be provided with full app access. The Research Assistant will use an onboarding checklist to orient participants to download the app and its use. Participants will be encouraged to explore and use all components of the app. Participants will be able to personalize the frequency, timing, and content for daily adherence support and weekly behavioral feedback messages and receive reminders for regular PrEP care. Participants can also contact the Research Assistant using the chat function for support and assistance with linkage to services.
32929613|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
32929614|NCT03256799|Experimental|Ivacaftor/Ataluren|
32929615|NCT05315258|Experimental|Cutaneous melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
32929616|NCT05315258|Experimental|Uveal melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
32929617|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
32929618|NCT01238211|Experimental|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity >= 20% and leukemia blasts >= 5%) receive a second course of induction therapy.~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
32929619|NCT00375947|Experimental|1|Home-based hand exercise program
33400885|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
33400886|NCT05018299|Placebo Comparator|FB704A placebo|placebo
33400887|NCT05018299|Experimental|FB704A|Anti-IL6 antibody
33400888|NCT04289935|Experimental|single arm|"Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy~rCR / near-rCR in MRI~Registration~US-guided VAB~Breast conserving surgery / mastectomy~Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
33400889|NCT03179761|Experimental|Group I (HD-TIV)|Patients received HD-TIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
33400890|NCT03179761|Active Comparator|Group 2(SD-QIV)|Patients received SD-QIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
32929620|NCT00375947|Placebo Comparator|2|Sham hand cream
32929621|NCT05521568||Index test : Abbott ID NOW STREP A 2|
32929622|NCT05521568||Reference standard test : Composite of culture and PCR-based tests based on a throat swab|
32929623|NCT05521568||Comparator test : Rapid antigen detection test (usual care)|
32929624|NCT04735445|Active Comparator|Conventional screening|Standard screening in the participating centers, adjusted to the recommendations of the European AIDS Society (EACS).
32929625|NCT04735445|Experimental|Enhanced screening|Expanded screening for early detection of lung, liver, anal, cervical, breast, prostate, colorectal and skin cancer.
32929626|NCT04344314|Other|Small gauge arm|2 PIVCs of same gauge and different lengths
32929627|NCT04344314|Other|Large gauge arm|2 PIVCs of same gauge and different lengths
32929628|NCT05520008|Experimental|Active group (AG)|Active group (AG). The AG (n=15) will play game-based foot and ankle exercises via a mobile application on a tablet. They will be asked to wear a foot sensor that is connected to the tablet during the exercise. They will be asked to play the game for 5-minutes, daily. They will do this in conjunction with wearing a compression garment for a period of 4 weeks.
32929629|NCT05520008|No Intervention|Control group (CG)|Control Group (CG). The CG (n=15) will wear a compression garment for four weeks.
32929630|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
32929631|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
32929632|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
32929633|NCT05131646||Cohort 2 (Low-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.10 mg CLS-AX in cohort 2 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
32929634|NCT05131646||Cohort 3 (High-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.50 mg CLS-AX in cohort 3 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
32727922|NCT04457817||CRI Monitoring/Management|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
32727923|NCT03412357|Experimental|pleurectomy/decortication|
32727924|NCT03412357|Experimental|indwelling pleural catheter|
32727925|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
32727926|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
32727927|NCT04370379|Experimental|low dose of IBI302|
32727928|NCT04370379|Experimental|high dose of IBI302|
32727929|NCT04370379|Active Comparator|2mg aflibercept|
32929635|NCT05131646||Cohort 4 (High Dose) Extension|Subjects who were administered by suprachoroidal injection 1.0 mg CLS-AX in cohort 4 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
32929636|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
32929637|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
32929638|NCT05515250|Other|Patient open label intervention arm|
32929639|NCT05128136|Experimental|Silicone IVR 46mm external diameter|Non-medicated 46 mm ring.
32929640|NCT05128136|Experimental|Silicone IVR 56mm external diameter|Non-medicated 56mm ring.
32727930|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
32727931|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
32727932|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
32727933|NCT03410641||Control|No intervention
32727934|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
32727935|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
32727936|NCT05109819|No Intervention|Arm A: standard radiotherapy treatment|Patients in arm A will receive standard radiotherapy treatment for metastatic spinal cord compression.
32727937|NCT05109819|Experimental|Arm B: esophagus sparring radiotherapy treatment|Patients in arm B will receive esophagus sparring radiotherapy treatment.
32929641|NCT05128136|Experimental|Silicone IVR 66mm external diameter|Non-medicated 66mm ring.
32929642|NCT05440721|Active Comparator|Treatment A (device Clickotine®)|User will open and use Treatment A (Clickotine® device) several times a day up to their quit date to complete a program of 21 Missions.
32929643|NCT05440721|Sham Comparator|Treatment B (smoking education)|Treatment B app provides education and support to smokers seeking to quit. When a user has a craving or wants support or education, they can log into the app.
32929644|NCT04344158|Experimental|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32929645|NCT04344158|Active Comparator|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
32929646|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
32929647|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
32929648|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
32929649|NCT04329663|Experimental|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
32929650|NCT03744637|Experimental|Panel A: MK-5475 120 ug/165 ug/240 ug/240 ug/240 ug (Parts 1 and 2)|Participants in Panel A will receive a single inhaled dose of MK-5475 120 ug in Period 1 of Part 1, followed by MK-5475 165 ug in Period 2, followed by MK-5475 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a functional respiratory imaging (FRI).
32727938|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
32727939|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
32727940|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
32727941|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
32727942|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
33251289|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
33251290|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
33251291|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
33251292|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
33251293|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
33251294|NCT00886665|Placebo Comparator|Placebo|
33251295|NCT00886665|Experimental|JWHGWT|
32929651|NCT03744637|Experimental|Panel B: 300 ug/360 ug/360 ug (Part 2)|Participants in Panel B will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
32727943|NCT03127397|No Intervention|Standard of Care|
32727944|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
32727945|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
32727946|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
32727947|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
32727948|NCT03410563||Healthy participants|
33251296|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
32929652|NCT03744637|Experimental|Panel C: 300 ug/360 ug/360 ug (Part 2, Expansion)|Participants in Panel C will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
32929653|NCT03744637|Experimental|Panel D: 480 ug/120 ug/120 ug (Part 2)|Participants in Panel D will receive a single inhaled dose of MK-5475 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
32727949|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
32727950|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
32727951|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
32727952|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
32727953|NCT05027451|Experimental|IXT-m200|3 g of IXT-m200 given once by 30-min intravenous infusion
33251297|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
33251298|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
33277429|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
32727954|NCT05027451|Placebo Comparator|Placebo|Normal saline
32727955|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
32929654|NCT03744637|Placebo Comparator|Placebo (Part 1)|Participants will receive a single inhaled dose of matching placebo in Part 1.
33277430|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
32929655|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
32929656|NCT05299658|Experimental|Open label extension|This is an unblinded open-label extension, all participants will be on active drug.
32929657|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
32929658|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
32929659|NCT05288582|Other|Perfluorohexyloctane eye drop|Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
32929660|NCT05503238|Experimental|Skin-to-skin contact group|Provide maternal-infant skin-to-skin contact for preterm infants in the neonatal intensive care unit.
32929661|NCT05503238|Other|Routine care group|Perform routine nursing care for preterm infants in the neonatal intensive care unit.
33251299|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
33251300|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
33082330|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
33277431|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
32929664|NCT05503082|Placebo Comparator|w/o CGRPmAb|w/o CGRPmAb
32929665|NCT05503082|Active Comparator|Tx w/ CGRPmAb|Tx w/ CGRPmAb
32929666|NCT03712813|Experimental|Macrodyne LivMD plate|
32929667|NCT03712813|No Intervention|Wait-Listed Control|
32929668|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
32929669|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
32929670|NCT05286788|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
32929671|NCT04530409|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
32929672|NCT04530409|No Intervention|Late CS|Dexamethasone is to be used lately upon the deterioration of cases i.e. sPO2 < 92%
32929673|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
32929674|NCT04528303|Experimental|Whole genome sequencing|
32929675|NCT04528303|Active Comparator|Whole exome sequencing|
32929676|NCT04524403|Experimental|Miricorlilant - 600 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
32929677|NCT04524403|Experimental|Miricorlilant - 900 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
32929678|NCT04524403|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
32929679|NCT05107934|Experimental|RPH-104 80 mg|Patients will receive RPH-104 dose 160 mg subcutaneously on Day 0, and 80 mg on Day 7, Day 14 and thereafter once in two weeks.
32929680|NCT05107934|Placebo Comparator|Placebo|Patients (who achieved clinical response defined above by the randomized withdrawal baseline) will receive placebo subcutaneously once every 2 weeks.
32929681|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~Heart Failure~COPD~Cancer"
32929682|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~Heart Failure~COPD~Cancer"
32929683|NCT04343690|Experimental|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
32768696|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
32768697|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
32768698|NCT04837157|Experimental|Intervention Group|9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
32768699|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
32768700|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
32768701|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
32768702|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
32768703|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
32768704|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
32768705|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
32768706|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
32768707|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
32768708|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
32768709|NCT04785287|Experimental|Arm I (BMS-986218, SBRT)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 IV over 30 minutes on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT on days 36-39 (days 8-11 of cycle 2).
32768710|NCT04785287|Experimental|Arm II (BMS-986218, SBRT, nivolumab)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 and SBRT as in Arm 1. Beginning cycle 2, patients also receive nivolumab IV over 30 minutes starting on day 1. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32768711|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
32768712|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
32768713|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
32768714|NCT04824287|Experimental|Experimental|pelvic floor exercise
32768715|NCT04824287|No Intervention|control group|no intervention
32768716|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
32768717|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
32768718|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
32768719|NCT04774523|Active Comparator|Control group|This group will be made up of patients implanted with CRT-D devices without the CRT AutoAdapt feature, or with the CRT AutoAdapt feature deactivated.
32768720|NCT04774523|Experimental|AutoAdapt group|This group will be made up of patients implanted with CRT-D devices that have the CRT AutoAdapt feature available. It is mandatory that all patients within this group have the feature activated, independently of other characteristics.
32768721|NCT04429139|Experimental|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
32768722|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
32727956|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
32727957|NCT04260477|Experimental|6EH³R3Z|(Rifampicin (R)/ Isoniazid (H) / Pyrazinamide (Z)/Ethambutol (E)) 6-month high-dose treatment; New high-dose isoniazid / high-dose rifampicin retreatment regimen (6EH³R3Z) - that includes triple-dose rifampicin (R3; 30 mg/kg), and triple-dose isoniazid (H3; 15 mg/kg), complemented with pyrazinamide (Z) and ethambutol (E).
32929684|NCT04504981|Other|Y2Prevent Intervention|Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans.
32929685|NCT05102006|Experimental|LBL-007&Toripalimab|LBL-007 Injection; dose A or dose B; Q3W
32929686|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
32929687|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
32929688|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
32929689|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
32929690|NCT05477888||Questionnaires assessed e-cigarette users|"≥18 years old;~Those who used e-cigarettes at least once a week for the past month;~Be able to read and communicate in Chinese."
32929691|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
32929692|NCT05099588||Infants treated for ROP|
32929693|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
32929694|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
32929695|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
32929696|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
33251301|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
33251302|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
32929699|NCT05267821|Active Comparator|Anakinra 4 mg/kg/day|IV Anakinra 4mg/kg/day x 7 days
32929700|NCT05267821|Active Comparator|Anakinra 8 mg/kg/day|IV Anakinra 8 mg/kg/day x 7 days
32929701|NCT05267821|Active Comparator|Anakinra 12 mg/kg/day|IV Anakinra 12 mg/kg/day x 7 days
32929702|NCT05267821|Active Comparator|Anakinra 16 mg/kg/day|IV Anakinra 16 mg/kg/day x 7 days
32929703|NCT05267821|Placebo Comparator|Placebo|IV placebo x 7 days
32929704|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
32929705|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
32929706|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
32929707|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
32929708|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
32929709|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
32929710|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
33251303|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
33251304|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
33251305|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
33251306|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
33251307|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
33251308|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
33251309|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
33251310|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
33277432|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
33277433|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
33277434|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
32929711|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
32929712|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
32929713|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
33251311|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
32727958|NCT04260477|Active Comparator|6EHRZ|Standard of care: 6-month 6RHZE regimen with dose combination tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E)
32727959|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
32929714|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
32929715|NCT04412863|Experimental|Cohort 1d|VIR-2218 given by subcutaneous injection
32727960|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
32929716|NCT04412863|Experimental|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929717|NCT04412863|Experimental|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929718|NCT04412863|Experimental|Cohort 1e|VIR-2218 given by subcutaneous injection
32929719|NCT04412863|Experimental|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929720|NCT04412863|Experimental|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32727961|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
32727962|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
32929721|NCT04412863|Experimental|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929722|NCT04412863|Experimental|Cohort 2f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929723|NCT04412863|Experimental|Cohort 3f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
32929724|NCT05498298|Experimental|Gtec|
32929725|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
32929726|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
32929727|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
32929728|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
32929729|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
32727963|NCT02964377|Experimental|Cohort 1|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day,
32727964|NCT02964377|Experimental|Cohort 2|8-weeks open-label (+)- Epicatechin at 25mg/day three times per day
32727965|NCT02964377|Experimental|Cohort 3|8-weeks open-label (+)- Epicatechin at 75mg/day at two times per day
32727966|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
32929730|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
32929731|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
32929732|NCT04873674||ASD group|240 ASD patients (aged 4-25 years)
32929733|NCT04873674||Unaffected siblings of ASD|60-100 unaffected siblings of ASD probands
32929734|NCT04873674||TD group|120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
32929735|NCT05647668|Active Comparator|laparoscopic Nissen fundoplication|Creation of a 360° fundoplication wrap over a 30-Fr intra-esophageal bougie.
32929736|NCT05647668|Active Comparator|laparoscopic Toupet fundoplication|Creation of a 270° fundoplication wrap over a 30-Fr intra-esophageal bougie.
32929737|NCT00359918|Experimental|Prehospital facilitated PCI|
32929738|NCT00359918|Active Comparator|Primary PCI|
33400891|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
32929739|NCT04373629|Experimental|attention modulation|
32929740|NCT04373629|Experimental|perceptual modulation|
32929741|NCT04373629|Experimental|naturalistic viewing|
33251312|NCT02542917||All patients|IBDoc home test for faecal calprotectin
33251313|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
33251314|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
33251315|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
33251316|NCT00884559|Active Comparator|Technical|Technical Instructions
33251317|NCT00884559|Experimental|Leadership|Leadership-Instructions
32929742|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
32929743|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
32929744|NCT05088980|Experimental|VOLBELLA with Lidocaine|Participants will receive VOLBELLA with Lidocaine on Day 1 and followed for 12 months.
32929745|NCT05088980|Placebo Comparator|Control Group|Participants will be followed for 3 months. Participants can opt to receive VOLBELLA with Lidocaine after 3 months and followed for 9 months.
32929746|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-Pneumocystis pneumonia (PCP) prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo. There is no IV option for SAR anti-PCP prophylaxis.
33251318|NCT00884637||CNV subjects|
33251319|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
33251320|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
33400892|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
33400893|NCT04762537|Active Comparator|Standard Induction Method|The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
33400894|NCT04762537|Experimental|Rapid Induction Method|The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
32929747|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant graft versus-host disease (GVHD), to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily. There is no IV option for SAR anti-PCP prophylaxis.
32929748|NCT05087498|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after process. Cell dose for all patients was 1-10×107 cells per kilogram.
33400895|NCT01772472|Active Comparator|Trastuzumab|
32929749|NCT05087498|Placebo Comparator|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume per kg.
32929750|NCT05270096||Relapsed leukemia|"T-ALL:~First relapse with high MRD after re-induction Newly diagnosed with high MRD after consolidation~B-ALL:~1st relapse high risk group, Second or higher relapse, post CAR-T or post HSCT~AML:~Second or higher relapse"
32929751|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
32929752|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
32929753|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
32929754|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
32929755|NCT05477420|Experimental|Experimental group|"Participants in the experimental group will be expected use the decision aid developed in this study. They will be assessed at two different time points:~(1) before intervention (T0) and (2) post-intervention (T1)."
32929756|NCT05477420|No Intervention|Attention control group|"The control group participants will be asked to search information related to Depression and therapies for Depression online. They will be assessed at two different time points:~(1) at baseline (T0) and (2) after searching for information (T1)."
32929757|NCT03612271|Experimental|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
32929758|NCT03612271|No Intervention|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
32929759|NCT00376727|Experimental|Phase I dose escalation study|
32929760|NCT03609853|Placebo Comparator|Placebo|Placebo (5mL distilled water)
33251321|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
32929761|NCT03609853|Experimental|Vaporized low THC|15mg of pure THC
32929762|NCT03609853|Experimental|Vaporized high THC|30mg of pure THC
32929763|NCT03609853|Experimental|Vaporized low d-limonene|1mg of d-limonene
32929764|NCT03609853|Experimental|Vaporized high d-limonene|5mg of d-limonene
32929765|NCT03609853|Experimental|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
32929766|NCT03609853|Experimental|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
32929767|NCT03609853|Experimental|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
32929768|NCT03609853|Experimental|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
32929769|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
32929770|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
32929771|NCT05239585|Experimental|Remote EEG monitoring|All subjects will pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
32929772|NCT05265416|Experimental|Piezosurgery|Piezocision will be applied in this group of patients using a piezosurgery knife.
32929773|NCT05265416|Experimental|Low-level laser therapy|Low-level laser therapy will be applied in this group of patients using a diode laser device.
32929774|NCT05265416|Active Comparator|Traditional treatment|No acceleration method will be performed in this group.
32929775|NCT04335331||PreDM CDS|The PreDM CDS is a passive electronic health record button that appears automatically under the Assessment/ Plan only for patients with prediabetes. When clinicians choose to click on this button, the PreDM CDS displays the last three measurements of weight, body mass index (BMI), hemoglobin A1c (HbA1c), fasting glucose, random glucose, and creatinine. This tool included order options enabling prediabetes management in a single location within the electronic health record.
32929776|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
32929777|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
32929778|NCT05236153|Other|RV mapping|Participants will undergo a sinus rhythm electroanatomic RV substrate map prior to TPVR.
32929779|NCT05468606|Experimental|GA2 group (unadjuvanted group)|Immunization with 50 GA2-infected mosquito bites
32929780|NCT05468606|Placebo Comparator|Infectivity controls (placebo group)|Mock-immunization with 50 uninfected-mosquito bites
32929781|NCT05468606|Experimental|BCG group|Immunization with 50 GA2-infected mosquito bites and a standard intradermal BCG vaccination (0.1 mL)
32929782|NCT05468606|Experimental|YF-17D group|Immunization with 50 GA2-infected mosquito bites and a one fifth fractional (0.1 mL) intradermal YF-17D vaccination
32929783|NCT05468606|Experimental|Imiquimod group|Immunization with 50 GA2-infected mosquito bites and 250mg imiquimod cream 5%
33400896|NCT01772472|Experimental|Trastuzumab emtansine|
33400897|NCT04932265|Active Comparator|Red ginseng HRG80|16 subjects will receive 200 mg of red ginseng preparation HRG80 in one capsule
33400898|NCT04932265|Experimental|Red ginseng HRG80 incorporated in gamma-cyclodextrin|16 subjects will receive 200 mg of red ginseng preparation HRG80 incorporated in gamma-cyclodextrin in two chewable tablets
33400899|NCT04779229|Experimental|Parent Activation|This group of JPOs will deliver Parent Activation as a service to the juveniles and families on their caseloads.
33400900|NCT04779229|Active Comparator|Usual Services|This group of JPOs will deliver services as usual to the juveniles and families on their caseloads.
33400901|NCT05292625|Experimental|UC-MSC infusion via intravenous route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
33400902|NCT05292625|Experimental|UC-MSC infusion via intrathecal route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
33400903|NCT05292625|Other|control arm|standard stroke treatment and rehabilitation therapy
33400904|NCT04755673|Experimental|Experimental: Atrantil (Medical Food)|All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
33400905|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
33400906|NCT04920643|Experimental|High-Exchange Ultrafiltration|Subzero-Balance Simple Modified Ultrafiltration (60ml/kg/hour)
33400907|NCT04920643|Active Comparator|Low-Exchange Ultrafiltraiton|Subzero-Balance Simple Modified Ultrafiltration (6ml/kg/hour)
33400908|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
33400909|NCT05291143|Experimental|Intervention arm|This arm will get the educational video intervention
33400910|NCT01381380|Other|single-arm studies|Manual therapy for one group
33400911|NCT04909645|Experimental|Clearsight (finger cuff)|
33400912|NCT04011618|Placebo Comparator|Placebo|16 patients to receive 1 homologated placebo capsule (calcined magnesia 500 mg) every 12 hours along 12 weeks
33400913|NCT04011618|Experimental|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
33400914|NCT04163809|No Intervention|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
33400915|NCT04163809|Experimental|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
33400916|NCT04153279|Experimental|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.
33400917|NCT04788667|Experimental|Experimental Group|A health education programme using a telerehabilitation platform
33400918|NCT04788667|Active Comparator|Control Group|General recommendations using a telerehabilitation platform
32929784|NCT04301401|Experimental|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
32929785|NCT05080244|Experimental|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
32929786|NCT05080244|Placebo Comparator|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
32768723|NCT01654159|Experimental|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
32768724|NCT01654159|Experimental|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
32929787|NCT04293289|Other|Treatment|"BNCT(Boron Neutron Capture Therapy)~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
32929788|NCT05079230|Experimental|Magrolimab + Venetoclax + Azacitidine|"Participants will receive~magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
32929789|NCT05079230|Placebo Comparator|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive~magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
32929790|NCT04290871|Experimental|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
32929791|NCT04290871|Sham Comparator|Control Group|The delivery system will be set up anyway without study gas administration
32929792|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
32929793|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
32929794|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
32929795|NCT03501979|Experimental|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
33400919|NCT04138615|Experimental|Morphine|Morphine will be administered intravenously
33400920|NCT04138615|Placebo Comparator|Placebo|Saline will be administered intravenously
33400921|NCT01381302||Parkinson|Early onset of disease
33400922|NCT01383330|Experimental|Megace|800mg
33400923|NCT01383330|Active Comparator|DW-ES(A)|625mg
33400924|NCT01383330|Active Comparator|DW-ES(B)|625mg
33400925|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
33400926|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
33400927|NCT03631368|Experimental|Botox|
33400928|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
33400929|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
33400930|NCT05398380|Experimental|Transplantation|Liver transplantation for the treatment of unresectable colorectal cancer liver metastases
33400931|NCT05379738|Experimental|adapted physical activity|6 sessions of physical activity
33400932|NCT03174535||Exposure group|The exposure group was the patients who were treated with Qilong capsules (QLC). The willingness of the patients and the objective judgment of the clinician were comprehensively considered to decide whether to use QLC for intervention. Patients who chose to use QLC for intervention would take it immediately after being deemed eligible for enrollment. The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks. QLC was produced by Jining Huaneng Pharmaceutical Factory Co., Ltd. All participants in the exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
33400933|NCT03174535||Non-exposure group|The non-exposure group was the patients who did not take QLC. All participants in the non-exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
33400934|NCT04776499|Experimental|Healthy volunteers receiving propylthiouracil, riociguat, and perphenazine|Eight healthy volunteers will be included. Up to 15 healthy volunteers will be screened to reach the goal of 8 exposed volunteers. Sex is not expected to have an impact on the short-term evaluation of the potential drug-drug interactions. Therefore female and male participants will be included in an undefined proportion.
33400935|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
32727967|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
32929796|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
32727968|NCT03424837|Experimental|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
33251322|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
32727969|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
32727970|NCT05230407||Women after Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES)|Study population will include all women after hysterectomy or adnexal surgery by vNOTE technique
33251323|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
33251324|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
32727971|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
32727972|NCT02839811|Experimental|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
33251325|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
33251326|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
32727973|NCT05230329||Completemesocolic excision by laparoscopy for right sided cancer|
32727974|NCT05230329||Completemesocolic excision by robot for right sided cancer|
32727975|NCT05230329||Standard right hemi colectomy excision by laparoscopy for right sided cancer|
32727976|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
32727977|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
32727978|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
32768725|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
32768726|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
33251327|NCT00887445|Experimental|A|
33251328|NCT00887445|Placebo Comparator|B|
32929797|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
32929798|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
32929799|NCT05071352|Experimental|Nefopam group|"Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.~Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours."
32929800|NCT05071352|Placebo Comparator|Control group|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
33251329|NCT00964288|Other|Period 1|
33251330|NCT00964288|Other|Period 2|
33251331|NCT00964288|Other|Period 3|
33251332|NCT00964288|Other|Period 4|
33251333|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
33251334|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
33251335|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
33251336|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
33251337|NCT00964756|Experimental|Gene therapy|
33251338|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
33251339|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
33251340|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
33251341|NCT00612105|Experimental|1|Retigabine
33251342|NCT00612105|Placebo Comparator|2|Placebo
33251343|NCT04017741|Active Comparator|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
33251344|NCT04017741|Placebo Comparator|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
33251345|NCT00546052|Experimental|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
33251346|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
33251347|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
33251348|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
33277435|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
33277436|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
33277437|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
33251349|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
32727979|NCT03413579|Experimental|Nimotuzumab|"Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
32929801|NCT05235763|Placebo Comparator|Control|A sham activity coach will be installed on the Optilogg system, slightly changing its appearance.
32929802|NCT05235763|Experimental|Intervention|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
32929803|NCT05261828|Experimental|A|Short multidisciplinary program including education and rehabilitation and a personalized follow-up program
32929804|NCT05261828|Active Comparator|B|Reassuring messages and advices in agreement with the current recommendations.
32929805|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
32929806|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
32929807|NCT05259878||Control|A Control group of students at CFB Borden will be recruited to complete questionnaires.
32929808|NCT05259878||Patients with chronic pain|Patients are active service members, ranging from the age of 18-60 years old, referred primarily from the National Capital Region, CFB Petawawa, CFB Kingston, and CFB Trenton for consultation and management
32929809|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
32929810|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
32727980|NCT03413579|Placebo Comparator|Placebo|"Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
32727981|NCT04824807|Experimental|Clinical Pilates Group|Individuals in the this group will receive 24 sessions of Clinical Pilates training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
32727982|NCT04824807|Experimental|Yoga Group|Individuals in the this group will be given 24 hours of yoga training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
32727983|NCT04824807|Other|Control Group|Individuals in the this group will not receive any treatment. Individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
33251350|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
33251351|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
32929813|NCT05248880|Experimental|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
32929814|NCT05248880|Experimental|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
32929815|NCT04281979|Experimental|Study Agent|
32929816|NCT04281979|Placebo Comparator|Placebo|
32929817|NCT03404219|Experimental|Intervention|Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
32929818|NCT05466890|Experimental|PL8177|PL8177 will be given orally and daily from baseline until end of study.
32929819|NCT05466890|Placebo Comparator|Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
32929821|NCT01640808|Experimental|NIK-333(peretinoin)|
32929822|NCT01640808|Placebo Comparator|Placebo|
32929823|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
32929824|NCT05247788|Experimental|Intoxicated risk awareness training session|Participants will complete an intoxicated risk awareness training session in which they receive a controlled alcohol dose with structured feedback and training to accurately appraise the impairing effects of alcohol and estimate their blood alcohol concentration (BAC).
32929825|NCT05247788|Active Comparator|Alcohol exposure only|Participants assigned to the alcohol-exposure-only condition undergo the same alcohol dose exposures over the session but receive a general body scan and do not receive feedback concerning BAC or performance.
33251352|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
32929826|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
32929827|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
32929828|NCT05068310||Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors|Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors who are scheduled for skin biopsy or excision
33251353|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
32727984|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
32727985|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
32727986|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
32727987|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
32727988|NCT04814745|Active Comparator|morphine|morphine 150 mcg will be administered intrathecally before surgery by using a 25 Gauge with acre spinal needle
32727989|NCT04814745|Active Comparator|tramadol|tramadol 400 mg will be administered by using an elastomeric pump for 24 hours after surgery
32727990|NCT04814745|Active Comparator|ropivacaine|at the end of surgery transversus abdominis plane block will be performed bilaterally and ropivacaine 80 mg will be used
32727991|NCT03412123|Experimental|gLiFE pilot group|
32727992|NCT03413345||subjects without a history of cardiac disease|
32727993|NCT03413345||subjects with a history of cardiac disease|
32727994|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
32727995|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
32727996|NCT04757103||Above S3|Lesion located above the third sacral vertebra
32727997|NCT04757103||Below S3|Lesion located below the third sacral vertebra
32727998|NCT04448093|Experimental|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
32727999|NCT04448093|No Intervention|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
32728000|NCT04640571|Experimental|placebo, then metformin, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32728001|NCT04640571|Experimental|metformin, then polysorbate 80, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32728002|NCT04640571|Experimental|polysorbate 80, then placebo, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32728003|NCT04640571|Experimental|polysorbate 80, then metformin, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32728004|NCT04640571|Experimental|placebo, then polysorbate 80, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32929829|NCT03404609|Experimental|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
32929830|NCT05154643||patients with liver fibrosis|
32929831|NCT05154643||healthy controls|
32929832|NCT05464160|Experimental|G-FMV (Group Focal Muscular Vibration)|"Patients allocated in the G-FMV, in addition to conventional rehabilitation treatment, will be treated for 3 weeks with FMV, applied to the upper and/or lower limb, depending on the clinical status.~The G-FMV will perform the treatment at a frequency of 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes. Specifically, four different trains of stimulation lasting 5 minutes each will be performed, interspersed with 1 minute of rest (20 minutes of treatment + 3 minutes of rest). FMV will be applied on agonist (major spasticity) muscles of the lower limb and/or upper limb, either single-district or multiple-district, according to clinical evidence of intervention. Stimulation will be conducted in a stand-alone session as an adjunctive modality to the rehabilitation project of physiotherapy and occupational therapy."
32929833|NCT05464160|Active Comparator|G-CON (Group Conventional)|"Patients allocated in the G-CONwill be treated for 3 weeks by specific conventional rehabilitation based on the clinical status.~The G-CON will carry out the normal physiotherapy and occupational therapy rehabilitation treatment, as per the rehabilitation project, for an equal total treatment time to the G-FMV. Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)"
32929834|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
32929835|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
32929836|NCT04200391|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
33251354|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
33251355|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
33251356|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
33251357|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
33251358|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
32929837|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
32728005|NCT04640571|Experimental|metformin, then placebo, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
32728006|NCT02801825|Experimental|Axillary artery.|Cannulation of the axillary artery.
32728007|NCT02801825|Experimental|Femoral artery.|Cannulation of the femoral artery.
32728008|NCT04593147|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with Sn-2 Palmitate, Alpha Lactalbumin and Lactoferrin to better mimic human milk.
32728009|NCT04593147|Active Comparator|Brand|A commercially available Infant Formula, for healthy term infants 0 to 2 months of age (Enfamil TM, Milk-Based Powder with Iron).
32728010|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
32728011|NCT04431141|Experimental|Teneligliptin|
32929838|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
32929839|NCT03406325||urticaria|Patients with this condition
32929840|NCT03406325||asthma|Patients with this condition
32929841|NCT03406325||eczema|Patients with this condition
32728012|NCT04431141|Experimental|Empagliflozin|
32929842|NCT03406325||food allergy|Patients with this condition
32929843|NCT03406325||anaphylaxis|Patients with this condition
32929844|NCT03406325||mastocytosis|Patients with this condition
32929845|NCT03406325||mast cell activating syndrome|Patients with this condition
32929846|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
32929847|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
32929848|NCT05463848|Experimental|Cohort 1 (Safety Lead In): pembrolizumab plus olaparib and temozolomide|"Following a 3 + 3 dose escalation design 6-18 participants will receive:~Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
32929849|NCT05463848|Experimental|Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus olaparib and temozolomide|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group A participants will receive pembrolizumab, olaparib, and temozolomide before and after surgery.~Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
32929850|NCT05463848|Experimental|Cohort 2 (Surgical Cohort): Arm B - Pembrolizumab monotherapy|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group B participants will receive pembrolizumab monotherapy before and after surgery.~Pembrolizumab Before Surgery: Day 1 of the pre-surgical treatment cycle.~Pembrolizumab After Surgery: Day 1 of every other 21-day cycle (once every 6 weeks)."
32929851|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
33251359|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
33251360|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
33251361|NCT00887757|Experimental|gemcitabine +ABT-263|
33251362|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
33251363|NCT00965224|Experimental|standard therapy + vaccination|
33251364|NCT00965224|No Intervention|standard therapy|
32728013|NCT04431141|Experimental|Teneligliptin and Empagliflozin|
32728014|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
32929852|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
32929853|NCT05244278|Experimental|Artificial intelligence Medtronic-GI genius for real-time detection|A standard colonoscopy will be performed according to the standard of routine care. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps and classification. All optically diagnosed polyps will be removed and sent to the hospital pathology laboratory for histopathological evaluation according to institutional standards.
32929854|NCT05244278|No Intervention|Real time polyp detection using a standard colonoscopy without Medtronic-GI genius|In the control group (standard colonoscopy), the participating endoscopists will detect and classify colorectal lesions without using any AI modules. Although no CAD modules are used for detecting and classifying polyps in this group, the endoscopists will annotate the procedure in real-time (documenting all procedural steps), which will be documented by a research assistant in the room on CRFs.
32929855|NCT05647512|Experimental|LM-305 Dose Escalation|Administered intravenously
32929856|NCT05647512|Experimental|LM-305 Combination Expansion|LM-305 Administered intravenously Dexamethasone Orally
32929857|NCT05242640|Experimental|Mindful attention|16 sessions over 8 weeks (2x/week) of mindful attention audio recordings delivered via headphones
32929858|NCT05242640|Experimental|Exercise|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking
32929859|NCT05242640|Experimental|Exercise with mindful attention|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking utilizing mindful attention audio recordings delivered via headphones
32768727|NCT05069077|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
32768728|NCT05069077|Other|non-music group|Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
32768729|NCT04833257|Experimental|GP combine with Tislelizumab neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
32768730|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
32768731|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
32768732|NCT03099889|No Intervention|Control arm|Receive general health mailings
32768733|NCT04823507||Concussion patients treated with Photobiomodulation|"Patients between the ages of 15-65 years clinically diagnosed with a mild Traumatic Brain Injury by a health professional and currently not undergoing any treatment during a 1 year period from January 2018 to December 2018.~Documentation of the history of a qualifying mild Traumatic Brain Injury within 3 months of traumatic incident and/or diagnosis with persistent symptomatology after 3 months. For reference, International Classification of Diseases, Tenth Revision (ICD-10) clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol4."
32768734|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
32768735|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
32768736|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
32768737|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
32768738|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
32768739|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
32768740|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
32768741|NCT04833179|Experimental|fecal transplant|Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. The treatment will be given in the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.
32768742|NCT04833179|Placebo Comparator|placebo|Placebo capsule that can not be differentiate from the focal transplant capsule will be given in the same interval as the fecal transplant procedure written above.
32768743|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
32768744|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
32768745|NCT05069233||UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
32768746|NCT04833101|Experimental|"0-28 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 28, and a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
32768747|NCT04833101|Placebo Comparator|"0-28 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 28, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
32768748|NCT04833101|Experimental|"0-56 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
32768749|NCT04833101|Placebo Comparator|"0-56 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
32768750|NCT03100903|Experimental|BI 655130|
32768751|NCT04837313|Experimental|Parkinson's Disease with Constipation|Fecal microbiota transplantation will be performed.
32768752|NCT05068765|No Intervention|control group|Once enrolled and consent is documented, eligible subject's will participate in the study for approximately six months.
32768753|NCT05068765|Experimental|communication skills psychoeducation|Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
32768754|NCT05068765|Experimental|general psychoeducation|General psychoeducation group will be given a general psychoeducation program for four weeks, one session per week, in total. Session groups will be formed from a single session of 60-90 minutes for each topic.
32768755|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
32768756|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
32768757|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
33251365|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
33251366|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
33251367|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
33251368|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
33251369|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
33251370|NCT04392921|Experimental|Intervention Arm|Patients randomized to amiodarone treatment
32929860|NCT05242640|No Intervention|No intervention|No intervention sessions
32929861|NCT05485038|Experimental|Awake surgery|Critical steps of brain mapping and tumor removal will be performed in awake patient
32929862|NCT05485038|Active Comparator|General anesthesia|Brain mapping and tumor removal will be performed in asleep patient
32929863|NCT00356473|Placebo Comparator|Placebo|Placebo
32929864|NCT00356473|Experimental|Atorvastatin|Atorvastatin
32929865|NCT05461742|Experimental|Physical activity intervention|All participants will receive a physical activity intervention consisting of goal setting, in-person physical activity sessions, and written materials.
32929866|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
32929867|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
32929868|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
32929869|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
32929870|NCT05461508|Active Comparator|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
32728015|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
32728016|NCT05229627||healthy control|healthy controls, screened by K-SADS-PL
32728017|NCT05229627||MPH induced Remission|patients show remission after 8-12 weeks of treatment with MPH
32728018|NCT05229627||non responder to MPH|patients don't show remission after 8-12 weeks of treatment with MPH
32929871|NCT05461508|Experimental|Amoxicillin combined with vonoprazan and fucoidan|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and fucoidan 1000mg twice a day. These three drugs were taken continuously for 14 days.
33251371|NCT04392921|Placebo Comparator|Control Arm|Patients randomized to placebo treatment
32929872|NCT05459324|Experimental|Study Group|Twenty-four patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
32728019|NCT05229627||ATX induced remission|patients show remission after 8-12 weeks of treatment with ATX
32929873|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
33251372|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
32728020|NCT05229627||non responder to ATX|patients don't show remission after 8-12 weeks of treatment with ATX
33251373|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
33251374|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
33251375|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
33251376|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
32728021|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
32728022|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
32929874|NCT05456672|Experimental|Dietary intervention|Dietary intervention using standardized test meals
32929875|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
32929876|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
32929877|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
32929878|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
32929879|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
32929880|NCT05455658|Experimental|Prevention (STEMVAC vaccine, sargramostim)|Patients receive STEMVAC vaccine with sargramostim ID every month for 3 months in the absence of disease progression or unacceptable toxicity. Patients then receive STEMVAC vaccine with sargramostim ID booster injections 3 months after the 3rd vaccination and 6 months after the 1st booster vaccination.
32929881|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
32929882|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
32929883|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
33400936|NCT04698187|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
32768758|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32768759|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32768760|NCT04836611|Other|regular cannabis consumer patients|
32929884|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
32929885|NCT03245593||Shared Decision making for care|
32929886|NCT03245593||Standard decision making for care|
32929887|NCT05042960|Experimental|50% brightness group|Participants will be using a computer screen reducing screen brightness 50%.
32768761|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32768762|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
32768763|NCT04823819|Active Comparator|rTMS stimulation|20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
32929888|NCT05042960|Experimental|Light App group|Participants in this group will use a modulating computer screen tone with flux or night shift app.
32929889|NCT05042960|No Intervention|Control group|Participants in this group will be a control with no change in screen features
32929890|NCT03580343|Experimental|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
32929891|NCT05445440|Experimental|Part 1|
32929892|NCT05445440|Experimental|Part 2|
32929893|NCT05041322|Placebo Comparator|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
32929894|NCT05041322|Active Comparator|Buspirone|"Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.~Other Names:~Buspar"
32929895|NCT00422825|Experimental|Imatinib 800mg|
32929896|NCT00422825|Active Comparator|Imatinib 400mg|
32929897|NCT05039528|Experimental|Intervention|Participants will receive the personalized OSA messages.
32929898|NCT05039528|Placebo Comparator|Control|Placebo participants will receive no treatment during the experiment.
32929899|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
32929900|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
32929901|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
32929902|NCT05230940|Experimental|TURKOVAC|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
32929903|NCT05230940|Active Comparator|CoronaVac|The dose of the CoronaVac vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
32929904|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
32929905|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
33400937|NCT03623048|Experimental|Propolis extract|intervention
32929906|NCT05229614|Experimental|Solid cancers with stable disease|"Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.~Patients diagnosed with NSCLC, HNSCC, melanoma and urothelial carcinoma will be eligible for the study."
32929907|NCT05031416|Experimental|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
32929908|NCT05445128|Experimental|Part A: Single Day Dosing/Apheresis|Single dose of MGTA-145 in combination with plerixafor followed by apheresis
32929909|NCT05445128|Experimental|Part B: 2-Day Dosing/Apheresis|MGTA-145 in combination with plerixafor followed by apheresis on two consecutive days
32929910|NCT05433194|Experimental|Phase I Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid region of the upper arm of subjects on D0.
32929911|NCT05223920|Experimental|Bomedemstat|All patients will be dosed with bomedemstat daily for 169 days with additional treatment continuing in patients deriving clinical benefit.
32929912|NCT05219396||mobile bearing (MB)|
32929913|NCT05219396||medial congruent (MC)|
32929914|NCT05219396||posterior stabilized (PS)|
32929915|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
32929916|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
33400938|NCT03623048|Experimental|Pomegranate extract|intervention
33400939|NCT03623048|Active Comparator|Chlorhexidine|comparator
32929917|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
32929918|NCT05427422||Recovery|We would use recovery rate defined as difference between Fugl-meyer scores in the end of follow-up(eF) and in the enrollment (sF) normalized by sf to indicate the recovery Level of a patients, i.e., (eF-sF)/sF. A previously reported recovery rate, i.e., proportional recovery((eF-sF)/sF=0.7) was chosen as a standard of recovery. Hierarchial cluster method would be used to divide patients into Recovery and Non-recovery group. The Recovery group indicates that patients showed proportional Recovery determined by hierarchial cluster.
33251377|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
33400940|NCT03623048|Placebo Comparator|Saline|comparator
32768764|NCT04823819|Active Comparator|tDCS stimulation|The stimulation time will be 20 minutes, the current intensity will be 2mA.
32768765|NCT04823819|Sham Comparator|Sham rTMS stimulation|20 sessions of stimulation, but without current.
32768766|NCT04823819|Sham Comparator|Sham tDCS stimulation|The stimulation time will be 20 minutes, but without current.
32768767|NCT03098719|Experimental|Intervention|
32929919|NCT05427422||Non-Recovery|The Non-Recovery group indicates that patients fail to show proportional recovery.
32929920|NCT05427422||Healthy Control|Age/sex matched healthy subjects enrolled to compare with group of patients.
32929921|NCT05421650|Active Comparator|Control group|Concurrent chemoradiation therapy (CCRT)
32929922|NCT05421650|Experimental|Experimental group|Surgical debulking of bulky or multiple lymph node followed by CCRT
32929923|NCT05211284|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks)
32929924|NCT05211284|Placebo Comparator|Placebo Arm|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks).
32929925|NCT05483010|Experimental|Atorvastatin|"Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~Atorvastatin dosing starts at 80 mg once daily.~In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment."
32929926|NCT05483010|Experimental|Rosuvastatin|"Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~Rosuvastatin dosing starts at 40 mg once daily.~In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment."
32929927|NCT05210582|Experimental|Afamelanotide|
32929928|NCT05009420|Experimental|Avocado|Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
32929929|NCT05479812|Experimental|WTX-124 monotherapy dose escalation|
32929930|NCT05479812|Experimental|WTX-124 monotherapy dose expansion in advanced or metastatic cutaneous malignant melanoma|
32929931|NCT05479812|Experimental|WTX-124 monotherapy dose expansion in advanced or metastatic RCC|
32929932|NCT05479812|Experimental|WTX-124 in combination with pembrolizumab dose escalation|
32929933|NCT05479812|Experimental|WTX-124 in combo with pembro dose expansion in advanced/metastatic cutaneous malignant melanoma|
32929934|NCT05479812|Experimental|WTX-124 in combination with pembrolizumab dose expansion in advanced or metastatic RCC|
32929935|NCT05408156|Experimental|Customized insoles group|The participant allocated in the CIG will receive a semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate. -ethylene vinyl (EVA) and manufactured by researcher C. The insole will be used on both feet to maintain symmetry between the limbs and generate greater comfort, since this will not be a corrective intervention.
32929936|NCT05408156|Sham Comparator|Sham Insoles Group|The SIG will receive the same unmolded insole with a semi-flexible base and 2.5mm coverage with Shore A 28, but without the bars used in the intervention group.
32929937|NCT04856826|Experimental|echo guidance|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
32929938|NCT04856826|No Intervention|conventional|insertion of a peripheral venous catheter conventionally
32929939|NCT04995536|Experimental|Treatment (radiation therapy, CAS3/SS3)|Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
32929940|NCT05647356|Experimental|Bicalutamide|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited.
32929941|NCT05200676||Main group|"All included in the study will offered to participate in:~ePatch-monitoring~Blood pressure measurement~Cardial vagal tone~Questionnaire-assessment"
32929942|NCT05200676||Subgroup|"Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.~Only a subgroup of the study population will be offered to participate due to the cost of this examination."
32929943|NCT05647278|Experimental|Tegoprazan 50mg QD|Tegoprazan 50mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks
32929944|NCT05647278|Active Comparator|Esomeprazole 20 mg BID|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
33251378|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
33400941|NCT01312597|Experimental|Fruit beverage|
33400942|NCT01312597|Experimental|Control beverage|
32768768|NCT03098719|No Intervention|Control|
32728023|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
32728024|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
32728025|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
32728026|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
32728027|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
32929945|NCT05200520|Experimental|Appetite Self-Regulation|Participants will attend 12-weekly classes, delivered through virtual small group sessions (via zoom), self-monitor the participant's episodes of hunger and satiety with digital eating behavior website, weigh daily with a wireless Wi-Fi enabled scale, and use a FitBit to track physical activity. Participants will also receive weekly tailored feedback on eating, physical activity, and weight trends. Assessments will be conducted at 0, 3, and 6 months.
32929946|NCT05647200|Active Comparator|T (Treatment)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional albumin during cardiopulmonary bypass.
32929947|NCT05647200|Sham Comparator|C (control)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional ringers during cardiopulmonary bypass.
32929948|NCT05407142|Experimental|The study group consisted of 3,500 volunteers who received the CoviVac vaccine|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days and revaccinated at 6 months with one dose of the KoviVac vaccine.~Cohort 1 - The first 1000 volunteers of the study group will be used to assess the efficacy + safety + immunogenicity of the vaccine under study.~Cohort 2 - Next 1100 volunteers of the study group will be used to analyze the efficacy + safety of the vaccine under study.~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.~The data of 1400 volunteers vaccinated three times with an interval of 21 days will be used to assess the effectiveness + safety + immunogenicity of the vaccine under study."
32728028|NCT04298151|Experimental|zirconomer improved|zirconia reinforced glass ionomer restoration
32929949|NCT05407142|Other|Control group|The data from volunteers from the control group will be used to evaluate the effectiveness of the investigational vaccine.
32929950|NCT04994054|Experimental|silkworms (Bombyx mori L.) pupae extracts group|This group takes silkworms (Bombyx mori L.) pupae extracts for 12 weeks.
32929951|NCT04994054|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
32929952|NCT04986800|Experimental|Intervention Group|Participants in the Intervention Group will receive up to 10 sessions of the PROACTIVE Parent intervention.
32929953|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
32728029|NCT04298151|Active Comparator|ketac molar aplicap|conventional viscous glass ionomer restoration
32728030|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
32929954|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
32929955|NCT04343924|Experimental|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
32929956|NCT04343924|Active Comparator|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
32929957|NCT04343924|No Intervention|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
32929958|NCT05181800||FIRMAGON Cohort|
32929959|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
32929960|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
32929961|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
32929962|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
32929963|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
32929964|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
32929965|NCT05181020|Experimental|Maternal Voice Exposure|Infants enrolled will be exposed to maternal voice for 20 min immediately prior to being offered oral feedings. This exposure will be conducted 2 times a day until infant starts taking all enteral feeds orally.
33251379|NCT00673920|Placebo Comparator|Placebo|"Participants received matching placebo:~on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)"
33251380|NCT00673920|Experimental|Ocrelizumab 400mg|Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
32929966|NCT05396924|Active Comparator|Room Group|Room temperature irrigation fluids will be used routinely for Group 1. Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
32929967|NCT05396924|Active Comparator|Warmed Group|Irrigation fluids heated up to 36-38 degrees will be used for Group 2.Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
33400943|NCT03016598|Experimental|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
32728031|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
32929968|NCT05178992|Experimental|Socially Assistive Robot Activity|Participants will attend two sessions per week and interact with the robot. Four weeks with a humanoid robot and four weeks with a dog robot. Participants can continue to join other activities held within the facility.
32929969|NCT05178992|Active Comparator|Usual Activity Program|Participants will attend at least two sessions per week at activities held within the facility. They will not be exposed to the robot activities.
32929970|NCT05383664|Experimental|Clinical Screening|Subjects will be screened for systemic blood markers responsive to 3-4 subsequent UV exposure over the course of 4-5 laboratory visits over the course of one week.
32929971|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32929972|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
32929973|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
32929974|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
32728032|NCT04448015|Experimental|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
32728033|NCT05229315|Experimental|PD-1 Immune Checkpoint Inhibitor Combined With IMRT|IMRT Combined with toripalimab in the treatment of nasopharyngeal carcinoma，once every 2 weeks, 10 cycles in total
32728034|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
32728035|NCT04511325|Other|Potato Regimen Arm|All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
32768769|NCT04823429|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
32768770|NCT04823429|Experimental|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
32768771|NCT04823429|No Intervention|Control group|Without any exercise training
32768772|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
32929975|NCT05161364||A: PFA|partial foot amputation secondary to peripheral neuropathy
32929976|NCT05161364||B: PN|peripheral neuropathy
32929977|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
32929978|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
32929979|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
32929980|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
32728036|NCT04511325|Other|Refined Grain Regimen Arm|All participants will be randomly assigned to the calorie-matched refined grain daily for the 12-week treatment period, separated by a 2-week washout.The refined grain (100 grams of long grain white rice) regimen will be matched to the potato regimen for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day. Long-grain boiled white rice also has a similar glycemic index to that of a baked white potato.
32728037|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
32728038|NCT03418493|Experimental|LY3316531 (Part A)|LY3316531 administered IV and/or SC.
32728039|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
32728040|NCT03418493|Experimental|LY3316531 (Part B)|LY3316531 administered IV and/or SC.
32728041|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV and/or SC.
32728042|NCT03418493|Experimental|LY3316531 (Part C)|LY3316531 administered IV and/or SC.
33400944|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
32728043|NCT05229159||BiPOCS group|All patients of our centers admitted for postoperative care after cardiac surgery with cardiopulmonary bypass and receiving a bioelectrical impedance analysis at the admission.
32728044|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
32728045|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
32929981|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
32929982|NCT04866108|Experimental|Experimental|Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off
32929983|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
32929984|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
32929985|NCT04343768|Active Comparator|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
32728046|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
32728047|NCT05229081|Other|Vaccine education|The intervention arm refers to the arm in which the pharmacist gives vaccination education.
32728048|NCT05229081|No Intervention|Standard of Care|The control arm refers to the arm that includes patients who receive routine health care services without vaccination education provided by the pharmacist.
32728049|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
32728050|NCT05029557|No Intervention|Control group patients|The patients in the Control Group will continue their routine procedures.
32768773|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
33251381|NCT00673920|Experimental|Ocrelizumab 200mg|Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
32768774|NCT05068843|Active Comparator|Arthroscopic partial meniscectomy|"In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy (APM) within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.~Other Names:~APM meniscal surgery surgery"
32768775|NCT05068843|Other|Physical therapy|The physical therapy program consisted of a physical therapist-led incremental exercise program containing of coordination/balance, closed kinetic chain strengths and cardiovascular exercises (see Appendix 1). The program was designed for 8 weeks with a total of 16 treatment sessions, each with a duration of 30 minutes. All 16 sessions were reimbursed. If knee symptoms persisted following the physical therapy program (e.g., knee pain, limitations in daily activities or mechanical dysfunction ), the patient could attend additional physical therapy sessions (not reimbursed by the study) or have meniscal surgery, depending on a shared decision after consultation with their orthopaedic surgeon.
32768776|NCT05618405||Children who undergo anesthesia because of surgery|Children, aged between 1-11 years, who undergo general anesthesia because of surgery.
32768777|NCT05618405||Children who undergo anesthesia because of an MRI|Children, aged between 1-11 years, who undergo general anesthesia because of an MRI.
32768778|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
32768779|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
32768780|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
32768781|NCT05068453|Experimental|OH2+HX-008+RT|Patients will get OH2 （once every two weeks）and HX-008 (once every three weeks)and radiotherapy (totally 3 times).
32768782|NCT00751075|Active Comparator|1|MFNS once daily
32768783|NCT00751075|Experimental|2|MFNS twice daily
32768784|NCT00751075|Active Comparator|3|Amoxicillin
32768785|NCT00751075|Placebo Comparator|4|Placebo
32768786|NCT04823741||PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
32768787|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
32768788|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
32768789|NCT04836299|Experimental|Ivermectin|Participants will receive a single 600 µg / kg dose of ivermectin.
32768790|NCT04836299|Placebo Comparator|Placebo Comparator|Participants will receive a single dose of placebo.
32768791|NCT00651391|Experimental|Ezetimibe + Simvastatin|
32768792|NCT00651391|Active Comparator|Simvastatin|
32768793|NCT00651391|Placebo Comparator|Placebo|
32768794|NCT04823351|Other|FFP2 Mask|Universal FFP2-masking for every healthcare worker with patient contact, compared to selective FFP2-masking, which means that FFP2 masks are worn only during aerosol-generating procedures such as tube manipulation;
32768795|NCT04823351|Other|Surgical Mask|Universal surgical mask IIR type masking for healthcare workers in contact with COVID-19 patients.
32768796|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
32768797|NCT04823117||Music therapy group|Music therapy lasted 30 minutes every day for a total of 20 days.
32768798|NCT04823117||Control group|No treatment given.
32768799|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
32768800|NCT00650689|Active Comparator|Atorvastatin|
32768801|NCT04835831|Experimental|adapted physical activity + Dietetic advice|
32768802|NCT04835831|No Intervention|Dietetic advice only|
32768803|NCT05067517|Active Comparator|Nintedanib|Nintedanib 150 mg administered PO twice daily
32768804|NCT05067517|Placebo Comparator|Placebo|Placebo administered PO twice daily
32768805|NCT05067361|Experimental|Experimental Group|
32768806|NCT05067361|Active Comparator|Active control Group|
32768807|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
32768808|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
32768809|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
32906095|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
33251382|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 200mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
33251383|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 400mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
33251384|NCT00673920|Experimental|Ocrelizumab 400mg/ Ocrelizumab 400mg|Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
33251385|NCT00673920|Experimental|Placebo/ Ocrelizumab 200mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
33251386|NCT00673920|Experimental|Placebo/ Ocrelizumab 400mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
33251387|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
33251388|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
32768810|NCT05059561||Patients group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. According to the Cobb method, individuals with a Cobb angle greater than 10° were diagnosed with Idiopathic Scoliosis. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the study and control groups completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
32906096|NCT01556633|Experimental|Volunteers on dialysis|
32906097|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
32906098|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
32906099|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
32906100|NCT03218774|Other|Home Group|
32906101|NCT03218774|Experimental|Center Group|
32906102|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)~cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
32906103|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
32906104|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
32906105|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
32906106|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
32906107|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
32906108|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
32906109|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
32906110|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
32906111|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
32906112|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
32906113|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
32906114|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
32906115|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
32906116|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
32906117|NCT03212378||CHIP 1 - low risk patients|
32906118|NCT03212378||CHIP 2 - medium risk patients|
32906119|NCT03212378||CHIP 3 - high risk patients|
32906120|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
32906121|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
32906122|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
32906123|NCT03212300|No Intervention|treatment as usual|standard treatment
32906124|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
32906125|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
32906126|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
32906127|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
32906128|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
32906751|NCT01720160|Active Comparator|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
32728051|NCT05029557|Experimental|Education and telephone follow ups based on the Chronic Care Model|Intervention Group will be given training (0 months) with the training booklet, which is prepared by the researcher based on the Chronic Care Model, and which includes information and suggestions about self-management strategies. The training will be organized in one single session in a way not to exceed approximately 45-50 minutes. The patients, who will be included in the Intervention Group, will be followed up by phone every two weeks. Also, reminders and informative information based on the training booklet will be sent to patients every week in the form of a short message.
32728052|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
32728053|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
32728054|NCT05004129|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
32728055|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
32728056|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
32728057|NCT04435977|Experimental|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
32728058|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
32728059|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
32728060|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
32728061|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
32728062|NCT04510857|Experimental|MOVE-IT Home Exercise Program (HEP)|Participants will be asked to employ the MOVE-IT system for upper extremity practice at home 1 hour/day, 5 days/week over a 10-week period.
32728063|NCT04510857|Active Comparator|Usual Care Treatment (UCT) Control|Children in the UCT group will be followed as they continue to receive their previously prescribed therapy services. These children will not receive any treatment services through the study as UCT group participants.
32728064|NCT02608307||AYA patients|Adolescence and young adults (AYA) who meet eligibility criteria and consent to participate in the study.
32728065|NCT02608307||Parents of AYA patients|Parents of AYA patients who meet eligibility criteria and consent to participate in the study.
32728066|NCT02608307||Health Care Providers (HCPs)|Health care providers who meet eligibility criteria and consent to participate in the study.
32728067|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
32728068|NCT04236843|Active Comparator|Smal intestine once|90-g fecal transplant given into the small intestine once.
32728069|NCT04236843|Active Comparator|Small intestine twice|90-g fecal transplant given into the small intestine twice with 1 week interval.
32728070|NCT04236843|Active Comparator|Large intestine once|90-g fecal transplant given into the large intestine once.
32728071|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
32728072|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
32728073|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
32728074|NCT05168293||Entecavir group|
32728075|NCT05168293||Tenofovir group|
32728076|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
32728077|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
32906752|NCT03405896|Experimental|Normal subjects|
32906753|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
32906754|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
33251389|NCT04588948|Experimental|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
33251390|NCT04588948|Experimental|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
33251391|NCT00758628|Active Comparator|1|Bromfenac
33251392|NCT00758628|Placebo Comparator|2|Blink
33251393|NCT00959998|Active Comparator|Relaxation acupressure|
33251394|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
33251395|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
33251396|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
33251397|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
33251398|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
33251399|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
33251400|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
33251401|NCT00965536||1|Seroquel
33400945|NCT04618315|Active Comparator|Audiology-Based Best Practice|Hearing aids will be fit using current best practices used by audiologists to fit hearing aids.
32768811|NCT05059561||Control group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
32768812|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
32768813|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
32768814|NCT02530905|Experimental|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
32768815|NCT00552097|Experimental|EZ/Simva|
32768816|NCT00552097|Placebo Comparator|Placebo/Simva|
32768817|NCT05067049|Experimental|Connected EORTC-C30 arm (quality of life questionnaires on pad, phone,...)|The patients in this arm will have connected mobile app at home and they will regularly fill questionnaires. There are two different questionnaires : one with 14 questions about patient's quality of life and about the evolution of his surgical scar. One with 9 questions only about quality of life. They will also have meetings with physicians.
32768818|NCT05067049|Other|No QoL online follow-up arm|The patient haven't any questionnaires to fill at home. This is the normal management of the pathology. They only have different meeting with the specialist,as usual.
32768819|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
32768820|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
32768821|NCT02603393|Experimental|QVA149|
32768822|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
32768823|NCT05067205|Sham Comparator|open release|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using open carpal tunnel release method with duration of 6 months estimated.
32768824|NCT05067205|Experimental|mini CTS releaser|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using mini CTS releaser method with duration of 6 months estimated.
32768825|NCT05365269|Experimental|Computer-generated feedback on health risk behaviors|Proactive Automatized Lifestyle intervention Frequency: 3 times (month 0, 1, 3) Dosage: Individually tailored feedback corresponding to about 1-6 pages Duration: 3 months
32768826|NCT04832945||Ivermectin Group|Healthcare personnel receiving Ivermectin weekly PrEP
32768827|NCT04832945||Control Group|Healthcare personnel not receiving Ivermectin
32768828|NCT05618327|Experimental|JS203|
32768829|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
32768830|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
32768831|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
33251402|NCT00965536||2|Seroquel Prolong
33251403|NCT01743391|No Intervention|Control|Standard treatment
33251404|NCT01743391|Experimental|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
33251405|NCT05279638||psoriasis vulgaris patients|psoriasis vulgaris patients , both sex , 18,55 years old
33251406|NCT05279638||healthy participants|
33251407|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
33251408|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
33251409|NCT00762684|Experimental|TAK-559 32 mg QD|
33251410|NCT00762684|Placebo Comparator|Placebo QD|
33251411|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
32728078|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
32728079|NCT03814317|Experimental|Study Group|"Sarcoidosis patients with interstitial lung disease and precapillary pulmonary hypertension based on right heart catheterization (RHC).~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
32728080|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
32728081|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
32728082|NCT03411811|Active Comparator|Usual Care|
32728083|NCT03411811|Experimental|Dextrose|
32728084|NCT04505163|Active Comparator|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
32906755|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
32906756|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
32906757|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
32906758|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
32906759|NCT04964388|Experimental|GLP-1 cohort|Participants on GLP-1 receptor agonists
32906760|NCT04964388|No Intervention|Non GLP-1 cohort|Participants not on GLP-1 receptor agonists
32906761|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
32906762|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
32906763|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
32906764|NCT02468778|Experimental|HeartMate PHP (Roll-in)|Participants who receive a HeartMate PHP device without randomisation will be included in this arm
32906765|NCT02468778|Experimental|HeartMate PHP (Randomised)|Participants who receive a HeartMate PHP device after randomisation will be included in this arm
32906766|NCT02468778|Active Comparator|Any Abiomed Impella® (Randomised)|Participants who receive any Abiomed Impella® Device approved for use in high-risk PCI after randomisation will be included in this arm
32906767|NCT04963842|No Intervention|Conventional phase (use of conventional food packaging material)|During the conventional phase, participants are asked to maintain their usual habits for 5 days.
32906768|NCT04963842|Experimental|Intervention phase (use of bio-plastic and no plastic food packaging material)|During the 5-day long intervention period, all participants will be asked to: i) refrain from packaged (cans, plastic, paper) ready to consume foods, and foods from take away/delivery/fast food and ii) use the bio-based food packaging material to package their food.
32906769|NCT01727336|Experimental|Dalantercept 0.9 mg/kg plus axitinib|Subcutaneous (SC) injection of dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.
32906770|NCT01727336|Placebo Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing
32906771|NCT01727336|Experimental|Dalantercept 0.6 mg/kg|Part 1 dose escalation arm 0.6 mg/kg dalantercept once every 3 weeks
32906772|NCT01727336|Experimental|Dalantercept 0.9 mg/kg|Part 1 dose escalation arm 0.9 mg/kg dalantercept once every 3 weeks
32906773|NCT01727336|Experimental|Dalantercept 1.2 mg/kg|Part 1 dose escalation arm 1.2 mg/kg dalantercept once every 3 weeks
32906774|NCT01727336|Experimental|Dalantercept 1.5 mg/kg|Part 1 dose escalation arm 1.5 mg/kg dalantercept once every 3 weeks
32906775|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
32906776|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
32906777|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
32906778|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
32906779|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
32906780|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
32906781|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
32906782|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
32906783|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
32906784|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
32906785|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
32906786|NCT04963764|Placebo Comparator|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (10 days)
32906787|NCT04963764|Active Comparator|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (10 days)
32906788|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
32906789|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
32906790|NCT03007043||Normal responders|Normal response following IVF
32728085|NCT04505163|Experimental|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
33251412|NCT00960232|Placebo Comparator|Placebo|Placebo
33251413|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
33251414|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
33251415|NCT04577014|Experimental|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous Retifanlimab at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3). All visits are to be done +/-3 days of the scheduled timepoints.
33251416|NCT04577014|Experimental|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.~Dose Level 1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
33251417|NCT04577014|Experimental|Phase I: Dose De-escalation Level -1|"Dose Level -1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
33251418|NCT04577014|Experimental|Phase I: Dose De-escalation Level -2|"Dose Level -2:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
33251419|NCT04577014|Experimental|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints."
33251420|NCT04577014|Experimental|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
33251421|NCT04577014|Experimental|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
33251422|NCT04577014|Experimental|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
33251423|NCT04577014|Experimental|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
33251424|NCT05282550|Active Comparator|Trazodone First|Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
33251425|NCT05282550|Placebo Comparator|Placebo First|Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
33251426|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
33251427|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
33251428|NCT00610155|Placebo Comparator|1|
33251429|NCT00610155|Experimental|2|
33251430|NCT00610155|Experimental|3|
33251431|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
33251432|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
33251433|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
33251434|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
32728086|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
32728087|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
32728088|NCT03424369||Eustachian tube unobstructed|
32728089|NCT03424369||Eustachian tube dysfunction|
32728090|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
32728091|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
32728092|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
32728093|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
32728094|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
32728095|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
32728096|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
32728097|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
32728098|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
32728099|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
32728100|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
33251435|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
32728101|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
32728102|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
32728103|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
32728104|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
32728105|NCT03771885|Experimental|Group A|4 weeks place followed by 4 weeks IMP
32728106|NCT03771885|Experimental|Group B|4 weeks IMP followed by 4 weeks placebo
32728107|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
32728108|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
32728109|NCT03652077|Experimental|INCAGN02390|
32728110|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
32728111|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
32728112|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
32728113|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
32728114|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
32728115|NCT04470687|Experimental|Carotid plaque or stenosis ultrasound enhanced UF assesment|symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
32768832|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
32906791|NCT03007043||Suboptimal responders|Suboptimal response following IVF
32728116|NCT05171309|Experimental|Camrelizumab in combination with apatinib plus NK cell|"Drug: Apatinib 250 mg once daily (QD) oral dosing.~Other Names:~• Apatinib Drug: Camrelizumab 200 mg intravenously every 2 weeks.~Other Names:~• Camrelizumab Drug: NK cell Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days"
32728117|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
32728118|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
32728119|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
32728120|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
32728121|NCT03570489|Active Comparator|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
32728122|NCT03570489|Sham Comparator|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
32728123|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
32929986|NCT05647044|Active Comparator|active iTBS|Subjects receiving active iTBS treatment
32728124|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
32929987|NCT05647044|Placebo Comparator|placebo iTBS|Subjects receiving placebo (sham) iTBS treatment
32929988|NCT04964492||responders to treatment|A patient will be defined as a responder to hydroxocobolamin infusion if there is an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
32929989|NCT04964492||non-responders to treatment|A patient will be defined as a non-responder to hydroxocobolamin infusion if there is not an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
32929990|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
32929991|NCT05475600|Experimental|Classical APA group|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on Rated Perceived Exertion (RPE) Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
32929992|NCT05475600|Experimental|APA with Exergaming device|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
32929993|NCT05475600|Experimental|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with an Exergaming device 3 - Cool down: 20 min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
32929994|NCT04031911|Other|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
32929995|NCT04031911|Experimental|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
32929996|NCT05475522|Experimental|Ultrasound|Intraoperative extent of tumor resection will be assessed using sonography
32929997|NCT05475522|Active Comparator|Fluorescence|Intraoperative extent of tumor resection will be assessed using fluorescence with 5-aminolevulinic acid
32929998|NCT05474274||Post-Surgery data collection system|Subjects undergoing standard of care low-risk plastic surgery be provided with wearable sensors to take home and start recording heart rate, body temperature and body movements
32929999|NCT05472558|Experimental|CB CAR-NK019|All subjects were intravenously administrated with CAR-NK019
32930000|NCT05470374|Experimental|Ultrasound|Glioma resection with intraoperative sonography
32930001|NCT05470374|No Intervention|Non-ultrasound|Glioma resection without intraoperative sonography
32930002|NCT05646966|Active Comparator|healthy subjects|healthy subjects
32930003|NCT05646966|No Intervention|stroke patients|first time stroke patients
33251436|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
33251437|NCT04559620|Experimental|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
33251438|NCT04559620|No Intervention|Control|NO intervention between week 2 and 3
33251439|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
32728125|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
32728126|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
32728127|NCT03332121|Experimental|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
32728128|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
33251440|NCT00765414|Experimental|1|
32728129|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
32728130|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
33251441|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
33251442|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
32728133|NCT03411655|Active Comparator|Ambu® Aura-ITM|
32728134|NCT03411655|Active Comparator|Ambu Aura GainTM|
32728135|NCT05170451|Active Comparator|Active Comparator: Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
32728136|NCT05170451|Active Comparator|Active Comparator: Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
32728137|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
32728138|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
32728139|NCT03408691|No Intervention|No product|no product
32728140|NCT05170373|Active Comparator|ESP group|
32728141|NCT05170373|No Intervention|control group|
32728142|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
32728143|NCT04413513|Experimental|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
32728144|NCT04413513|Placebo Comparator|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
32728145|NCT04447859|Active Comparator|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
32728146|NCT04447859|Experimental|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
32728147|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
32906792|NCT04935840|Experimental|FertyBiotic Pregnancy|Participants received FertyBiotic Pregnancy one capsule a day
32906793|NCT04935840|Placebo Comparator|Control|Participants received 400 mcg of folic acid once a day
33251443|NCT04049136||Healthy pregnant women with BMI <30|
33251444|NCT04049136||Healthy pregnant women with BMI >=30|
33251445|NCT04037631||Patients without clinically significant age-related cataract|
33251446|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
33251447|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
33251448|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
33251449|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
33251450|NCT00765492|Experimental|1|
33251451|NCT00765492|Placebo Comparator|2|
33251452|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
33251453|NCT02541747|No Intervention|control|Rest as control
33251454|NCT04488952|Experimental|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
32728148|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
32728149|NCT04412889|Experimental|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
32728150|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
32728151|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
32930007|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
32930008|NCT04864626||patient with eating disorder|
32930009|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline and may undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
32930010|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
32728152|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
32728153|NCT03255993|Experimental|SPH3127 100mg|A single dose of SPH3127 50 mg*2 qd *7 days
32728154|NCT03255993|Placebo Comparator|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg*2 qd *7 days
32930011|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
32930012|NCT03994705|Experimental|Dose-Escalation|
32930013|NCT03988621|Experimental|Intervention|Caregivers randomized to the intervention ViCCY will receive 10 front-loaded sessions of virtual health coaching by trained registered nurses over 6 months with content based on the theoretical framework (based on the Transactional Model of Stress and Coping) and prior research. Sessions are provided using tablets. Initially, sessions are weekly but the frequency decreases over time as needed. We help caregivers gain the knowledge and skills needed to achieve self-identified health goals through self-care using motivational interviewing. We focus on identifying personal values, solving problems, and transforming goals into action. ViCCY is standardized in a treatment manual. Because stress does not affect all people equally, the intervention is tailored to individual appraisals and the factors most likely to influence demand and perceived burden.
32930014|NCT03988621|No Intervention|Health Information|The Health Information (HI) group will receive health resource information delivered through the internet.
32930015|NCT03984487|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
32930016|NCT03984487|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
32930017|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
32930018|NCT03960541|Experimental|Efprezimod alfa Treatment|Participants received an intravenous infusion of 240 mg of efprezimod alfa on Days 0, 14, and 28.
32930019|NCT03960541|Placebo Comparator|Placebo|Participants received an intravenous infusion of placebo (sterile saline solution) on Days 0, 14, and 28.
32930020|NCT03905239|Experimental|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
32930021|NCT03905239|No Intervention|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
33251455|NCT04488952|Experimental|spinal anesthesia group|Patients in this group receive spinal anesthesia.
33251456|NCT04488952|Placebo Comparator|control group|This group is used to obtain the learning effect.
33251457|NCT04037475|Placebo Comparator|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
32930022|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
33400946|NCT04618315|Experimental|Consumer Decides|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying loudness levels.
33400947|NCT04618315|Experimental|Efficient Fitting|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying base and treble settings.
33400948|NCT04857931|Active Comparator|Colchicine 0.5 mg die|Colchicine 0.5 mg die
32930023|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
32930024|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
32930025|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
32930026|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
32930027|NCT03901261|Experimental|Down syndrome patients|
32930028|NCT03866785|Other|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
32930029|NCT03866785|Other|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
32930030|NCT03866785|Other|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.~They will receive the Physical Activity Program."
32930031|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
32930032|NCT05723263|Experimental|Standard Pay-it-forward|"free testing~minimal engagement"
32930033|NCT05723263|Experimental|Community engaged Pay-it-forward|"Free testing~Stronger engagement"
32930034|NCT05723263|Other|Control arm|"Test available for a fee~No engagement"
32930035|NCT03416621|Active Comparator|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
32930036|NCT03416621|Placebo Comparator|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
32930037|NCT03416621|Experimental|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
32930038|NCT05723029|Experimental|Group A: Bowen Technique|The subjects will receive Bowen Technique. The treatment session will be 3 times per week for 4 weeks for 20 minutes. The Bowen technique is a subtle and precise mobilization called Bowen moves. The mobilization is applied by using the fingers and thumbs over muscles, tendon, nerves and fascia. Only gentle non-invasive pressure is applied. A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position. The therapist has a sense of tissue tension, and this enables his/her to feel where stress has built up in the tissue.
32930039|NCT05723029|Experimental|Group B: Post Isometric Relaxation Technique|The subjects will receive Post Isometric Relaxation Technique. Treatment session includes 3 times per week for 4 weeks for 20 minutes. Evaluation will be done before and after the treatment at the end of the 4th week. The outcome will be measured by the Active Knee Extension test, Numeric pain Rating Scale, and Goniometer. Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles. The intervention is performed three times in a single session with 30 seconds rest intervals.
33251458|NCT04037475|Experimental|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
33251459|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
33251460|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
33251461|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
33400949|NCT04857931|Active Comparator|Colchicine 0.5 mg bid|Colchicine 0.5 mg bid
32930040|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
32930041|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
32930042|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
32930043|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
32930044|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
32930045|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
32930046|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
32930047|NCT04332809|Active Comparator|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
32930048|NCT04332809|Active Comparator|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
32930049|NCT04332809|No Intervention|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
32930050|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
32930051|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
32930052|NCT04355117|Experimental|Treatment: TEV-48125|
32930053|NCT04357379|Experimental|IQOS group|
32930054|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
32930055|NCT04484207|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
32930056|NCT04484207|Experimental|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
32930057|NCT04484207|No Intervention|Control|Only assessment, no intervention arrm
32930058|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
32930059|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
32930060|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
32930061|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
32930062|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
32930063|NCT04734509|Experimental|Porter Brown Breathing system|"The Porter Brown has a double mask system that is characterized by a mask-within-a-mask scavenging system. The system includes easy to remove inner masks which vent into the outer mask. This helps in cleaning and sterilization. The soft inner part of the mask system provides a comfortable fit and an excellent seal around the patient's nose.~This mask is routinely used in inhalation sedation for children's dental treatment.~This is a sterilisable system."
32930064|NCT04734509|Experimental|Silhouette Breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
32930065|NCT03467477|Experimental|Flortaucipir PET Scan|
32930066|NCT04555031|Experimental|kalifilcon A lenses|
32930067|NCT04555031|Active Comparator|Dailies Total 1|
32930068|NCT04555031|Active Comparator|Precision 1|
32930069|NCT04555031|Active Comparator|Biotrue ONEday|
32930070|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
32930071|NCT03472469|Active Comparator|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
32930072|NCT03472469|Active Comparator|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
32930073|NCT04926233||COPD patients from US IBM Marketscan database|
33400950|NCT04857931|Placebo Comparator|Placebo|Placebo
33400951|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
32930074|NCT04926233||COPD patients from UK CPRD GOLD database|
33251462|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
32930075|NCT04943159|Experimental|Afamelanotide group A|
33251463|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
32930076|NCT04943159|Experimental|Afamelanotide group B|
32930077|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
32930078|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
32930079|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
32930080|NCT04734665|Experimental|experimental|Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous
32930081|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
32930082|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
32728155|NCT03255993|Experimental|SPH3127 200mg|A single dose of SPH3127 100 mg*2 qd *7 days
32930083|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
32930084|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
32930085|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
32930086|NCT04864470|Experimental|Intervention|"Stroke Odysseys is a performing arts intervention for people who have had strokes which provides an opportunity for communication of experiences of stroke to an audience through acquired skills in movement, music, song and the spoken word.~Stroke Odysseys comprises three distinct stages:~weekly workshops over 12 weeks for stroke participants facilitated by an integrated team of expert artists and ambassadors from the charity Rosetta Life~a smaller group of ambassadors recruited from the workshops will be trained to become co-facilitators (stroke ambassadors)~a performance tour including education and taster workshops for audiences."
32930087|NCT05460234||Single Cohort|Data from medical records up to 3 months prior treatment start will be retrospectively collected (if available), to provide baseline data and to serve as a basis for evaluating the treatment decision. If relevant baseline data is not available within 3 months preceding treatment start, retrospective documentation can extend to up to 6 months. The observational period (both retrospective and prospective) is scheduled up to 18 months after treatment start.
32930088|NCT05458362|Experimental|EMI group|"For two weeks after the intervention session, participants will report on their anxiety level four times per day. When participants endorse elevated anxiety, they will receive a message relevant to their most stressful symptom at the moment reminding them of the topics covered in the intervention session.~As the efficacy of the EMI component is being tested, only the EMI group will receive EMI."
32930089|NCT05458362|Active Comparator|Control group|The control group will not receive EMI prompts and will be offered to complete EMI after the follow-up assessment.
32930090|NCT05448768|Active Comparator|Amyloid-positive MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
32930091|NCT05448768|Active Comparator|Amyloid-negative MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
32930092|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
32930093|NCT05441514|Experimental|Treatment (cobimetinib, enasidenib mesylate)|Patients receive cobimetinib PO QD on days 1-21 and enasidenib mesylate PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
32930094|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
32930095|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
32930096|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
32930097|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
33251464|NCT02541591|Active Comparator|Control|MAP>65mmHg
33251465|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
32728156|NCT03255993|Placebo Comparator|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg*2 qd *7 days
32728157|NCT03255993|Experimental|SPH3127 400mg|A single dose of SPH3127 100 mg*4 qd *7 days
32930098|NCT05131789|No Intervention|Control group|"The dementia case managers in the control group perform routine case management.~The family caregivers in the control group receive routine services."
32930099|NCT05131789|Experimental|Information System Group|"The dementia case managers in the experiment group use information system to perform case management.~The family caregivers in the control group receive case management with an information system."
32930100|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
32728158|NCT03255993|Placebo Comparator|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg*4 qd *7 days
32930101|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
32930102|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
32930103|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
32930104|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
32930105|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
32930106|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
32930107|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
32930108|NCT05440110|Active Comparator|active and active|The patients will be subjected to TBS for 5 daily interventions per week for four consecutive weeks.
32930109|NCT05440110|Sham Comparator|sham and active|The patients will be subjected to TBS for 5 daily interventions per week for the first two weeks, followed by an open-label trial for the next two weeks.
32930110|NCT05646810|Active Comparator|Lidocaine|Nerve block
32930111|NCT05646810|Placebo Comparator|Isotonic saline|Nerve block
32930112|NCT04449263|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
32930113|NCT04449263|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
32930114|NCT04449263|Active Comparator|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
32930115|NCT05646732|Experimental|TMS-fMRI|Participants will undergo simultaneous TMS-fMRI as part of this study. There will be two locations stimulated: one control region and one target region. Participants will be randomized with respect to the order of receiving stimulation at the locations, but all participants will receive stimulation at both locations as part of the study. All participants will be considered as one group but we will evaluate order effects as an explanatory variable.
32930116|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
32930117|NCT04734743|Other|Cystic fibrosis|
32930118|NCT04960202|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
32930119|NCT04960202|Placebo Comparator|Placebo|Orally administered placebo
32930120|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
32930121|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
32930122|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
32930123|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
32930124|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
32930125|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
32930126|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
32930127|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
32728159|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
32728160|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
32728161|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
32728162|NCT03249753|Experimental|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
32728163|NCT03249753|Experimental|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
32728164|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
32728165|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
32728166|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
32728167|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
32728168|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
32728169|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
32728170|NCT05170555|Experimental|68Ga-PSMA, PET/CT and 177Lu-EB- PSMA-617 therapy|All patients diagnosed with RCC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
33251466|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
33251467|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
33251468|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
33251469|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
33251470|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
33251471|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
32728171|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
32728172|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
32728173|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
32728174|NCT05228223|Active Comparator|Group S|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
32728175|NCT05228223|Active Comparator|Group SN1|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
33251472|NCT02542371||HIV infected with known subclinical atherosclerosis|
33251473|NCT02542371||HIV infected without known subclinical atherosclerosis|
33251474|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
33251475|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
33251476|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
33251477|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
33251478|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
33251479|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
33251480|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
33251481|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
33251482|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
33251483|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
33251484|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
32728176|NCT05228223|Active Comparator|Grup SN2|Patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
32728177|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
32728178|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
32728179|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
32728180|NCT05170217|Experimental|CBD:THC 0:1|Inhalation of cannabis containing only THC
32728181|NCT05170217|Experimental|CBD:THC 1:1|Inhalation of cannabis containing THC and CBD
32728182|NCT05170217|Experimental|CBD:THC 2:1|Inhalation of cannabis containing THC and CBD
32728183|NCT05170217|Experimental|CBD:THC 3:1|Inhalation of cannabis containing THC and CBD
32728184|NCT04356105|Active Comparator|Minimal Stimulation Group|Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist
32728185|NCT04356105|Active Comparator|Microflare Group|Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH
32728186|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
32728187|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
32728188|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
32728189|NCT04347681|Experimental|Treatment Group|We are aiming to include 40 patients (recipients) who have COVID 19 but have not recovered yet as per the inclusion criteria.
32728190|NCT04347681|No Intervention|control group|Patients who only consent for sharing their clinical and laboratory data will serve as a control group to compare the efficacy of the convulsant plasma. Age and sex matched historical control could be used if need.
32728191|NCT05170061|Active Comparator|Nebivolol|Nebivolol, 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily
32728192|NCT05170061|Active Comparator|Valsartan|Valsartan, 160 mg daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1-week down-titration to 160 mg daily
32728193|NCT05170061|Active Comparator|Nebivolol/valsartan|Combination of nebivolol/valsartan 20/160 mg daily for 1 week followed by 40/320 mg daily for 3 weeks, followed by 1-week down-titration to 20/160 mg daily
32728194|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
32728195|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
32728196|NCT04235205|Experimental|Elobixibat and cholestyramine|The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
32728197|NCT04235205|Experimental|Elobixibat|The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
32728198|NCT04235205|Experimental|cholestyramine|The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
32728199|NCT04235205|Placebo Comparator|Placebo|The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
32728200|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
32728201|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
32728202|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
32728203|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
32743500|NCT02622321|Experimental|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
33251485|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
33251486|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
33251487|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
33251488|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
32930128|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
32930129|NCT05377034|Experimental|Study Arm|SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab
33251489|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
33251490|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
32930130|NCT05377034|Experimental|Control Arm|SIRT-Y90 + placebos (IV)
32930131|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
32930132|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
32930133|NCT04957550|Experimental|Treatment group A|SHR0302 tablets dose 1+ Placebo dose 2
32930134|NCT04957550|Experimental|Treatment group B|SHR0302 tablets dose 2+ Placebo dose 1
32930135|NCT04957550|Placebo Comparator|Treatment group C|Placebo dose1 + placebo dose 2
32930136|NCT03622619|Experimental|Manuka eye drops|
32930137|NCT03622619|Active Comparator|Systane Ultra|
32930138|NCT04951778|Experimental|Participants with R/R AML and R/R HR-MDS - Part A|Part A (Dose Escalation) of the study will enroll R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and R/R HR-MDS (Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes) participants and will evaluate the safety and tolerability of escalating doses of CC-91633, administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
32930139|NCT04951778|Experimental|Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML participants.
32930140|NCT04951778|Experimental|Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R HR-MDS participants.
32930141|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
32930142|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
32930143|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
32930144|NCT04885244||Operative|Multicenter, prospective, nonrandomized analysis of ASD patients w/diagnosis of congenital, degenerative, idiopathic, neuromuscular, inflammatory or iatrogenic spinal deformity. Participants must be scheduled to have 3 or more levels of Percutaneous posterior spinal instrumentation or 3 level stand alone lateral surgery within next 6 months.
32930145|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
32930146|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
32930147|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
32930148|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
32930149|NCT04943120|Experimental|"Snow-Plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
32930150|NCT04943120|Active Comparator|Bulk Fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
32930151|NCT04942028|Experimental|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
32930152|NCT04942028|Active Comparator|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
32930153|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
33251491|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
33251492|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
33251493|NCT05278767|Experimental|application group|The mobile health application (https://play.google.com/store/apps/details?id=com.sanberk.bariatriksurgery) prepared for patients undergoing bariatric surgery was completed in 6 stages. After the mobile application has been developed, a short (20-minute) brief contains information about the mobile application in the pre-operative polyclinic for the patients who are planned for bariatric surgery. The patient was followed for three months. Data were collected from the patient every month (4 times).
33400952|NCT04052737|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
33400953|NCT04052737|Experimental|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
33400954|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
33400955|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
32930154|NCT04415489|No Intervention|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
33400956|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
32930155|NCT05646654|Active Comparator|Erector spinae plane block group|3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected.
32930156|NCT05646654|Active Comparator|Interscalene group|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
32930157|NCT04872452|Experimental|Gastrointestinal dysmotility participants|
32930158|NCT04872452|Other|Healthy participants|
32930159|NCT04937036||COMISA group|Patients with diagnosed COMISA.
32930160|NCT04937036||Healthy controlls|Healthy indyviduals.
32930161|NCT05436054|Active Comparator|Picoprep|"Picoprep®:~Active substances: An envelope Picoprep® contains 10 mg sodium picosulfate, 3,5 g magnesium oxide, and 12 g citric acid.~Mechanism of action: Sodium picosulfate is a peristaltic agent that increases the peristalsis of the intestine. Magnesium oxide and citric acid are osmotic agents to increase water content in the bowel.~Dosage and administration: consist of 2 envelopes, the first envelope, after dissolving in 150 ml water, should be taken 10-18 hours before the colonoscopy, then at least 250mlX5 clear fluid (not only water) over the next hours before the second dose is taken. The second envelope should be taken 4-6 hours before colonoscopy followed by 250mlX3 clear fluid (not only water) over the next hours before colonoscopy. The total fluid intake is approximately 2.3 L."
32930162|NCT05436054|Experimental|Plenvu|"Plenvu®:~Active substances:~Dose nr. 1~1 envelope contains 1 g potassium chloride, 100 g macrogol 3350, 2 g sodium chloride, and 9 g sodium sulfate.~Dose nr. 2 1 envelope A contains 1,2 g potassium chloride, 40 g macrogol 3350, and 3,2 g sodium chloride.~1 envelope B contains 7,54 g ascorbic acid (Vit. C) and 48,11 g sodium ascorbate.~Mechanism of action: Macrogol 3350 is an osmotic laxative. The added electrolytes are to prevent electrolyte shifting and systemic disturbances.~Dosage and administration: two separate nonidentical 500 ml doses are given. 2-day regime: dose nr.1 envelope is dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock evening before colonoscopy day. Dose nr.2 envelope A and B are dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock on the morning of colonoscopy day.~After each dose of the dissolved Plenvu®, the patient should drink at least 500ml clear fluid."
32930163|NCT03488849|Experimental|SureCRIC|SureCRIC-aided cricothyroid membrane identification
32930164|NCT03488849|Active Comparator|Freehand|Freehand cricothyroid membrane identification
32930165|NCT04864106|Experimental|Study Group|Participants will undergo a endoscopic airway assessment in addition to the airway classification using the Mallampati score.
32930166|NCT04932434|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately two weeks apart, with preparation sessions before and integration sessions after.
32930167|NCT04383665|Sham Comparator|STN DBS off|
32930168|NCT04383665|Experimental|STN DBS 10Hz|
32930169|NCT04383665|Active Comparator|STN DBS 130Hz|
32930170|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
32930171|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
32930172|NCT04925882|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levopubivacaïne for the realization of the erector spinae plane block."
32930173|NCT04925882|Placebo Comparator|Placebo|"The Placebo group corresponds to the reference group, that is to say that it will consist of patients who benefit from an injection of physiological serum for the realization of the erector spinae plane block."
32930174|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
32930175|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
32930176|NCT01642914|Placebo Comparator|Placebo|Matching placebo
32930177|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
33400957|NCT04691869|No Intervention|Control|Patients will be randomized into a control group and study group. The control group will receive an informational discussion with the nurse-practitioner regarding steps to reduce the risk for osteoporosis, as well as an informational handout in their discharge papers.
33400958|NCT04691869|Experimental|Interventional|The study group will undergo the QUS (performed by a member of the study team) and receive the same informational discussion and handouts, with the addition of a QUS screening to take to their follow-up appointment. The QUS screening will come with a half-page description, describing the screening and what their results mean. A discussion lead by the nurse-practitioner, who is a member of the study staff, regarding the results will happen prior to discharge.
33400959|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
32930178|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
33400960|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
33251494|NCT05278767|No Intervention|control group|Standard care and follow-up protocols were applied to the patients.The patient was followed for three months. Data were collected from the patient every month (4 times).
33251495|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
33251496|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
33400961|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
33400962|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
32728212|NCT05169827||PD-OFF|"Patients with PD who have previously been included in the Personalized Parkinson Project return for fMRI measurements in an off-medicated state (12h withdrawal). N = 60.~The PD-OFF group undergoes a single testing session."
32728213|NCT05169827||Healthy controls|"Healthy individuals who are matched on age and sex with respect to the PD-OFF group. N = 60.~The healthy group undergoes baseline and two year follow-up testing sessions."
32728214|NCT05169827||PD-ON|"Patients with PD who are included in the Personalized Parkinson Project. N = 360.~Available data will be used. There will be no further data collection in this group."
32728215|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
32728216|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
32728217|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
32728218|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
32728219|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
32728220|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
32728221|NCT03404869|Other|Treatment with ORL-1M - D-mannose|
32728222|NCT04184349|Active Comparator|Local Anesthetic (LA Group)|
32728223|NCT04184349|Active Comparator|B group|
32728224|NCT05169749|Other|Control-Service Nurse Group|Patient education lasting 20-30 minutes was provided by the nurse who gives care in the surgical inpatient floor before the surgery. The nurse provided the patient's admission to the postoperative surgical inpatient floor and follow-up.
32728225|NCT05169749|Experimental|Experimental-Nursing Visiting Group|The nursing visit was done by the operating room nurse who will be involved in the patient's surgery, and the patient education lasted 20-30 minutes. The nurse, who carried out the nursing visit, welcomed the patient in the operating room, was next to the patient before anesthesia, and followed the patient to the recovery room after surgery.
32728226|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
32728227|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
32728228|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
32728229|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
32728230|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
32728231|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
32728232|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
32728233|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
32728234|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
32728235|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
32728236|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
32930179|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
32930180|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
32930181|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
32930182|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
32930183|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
32930184|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
32930185|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
32930186|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
32930187|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
32930188|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
32930189|NCT04925024|Experimental|Lomecel B Group|Participants randomized to receive Lomecel-B injections during their Stage II palliation.
32930190|NCT04925024|No Intervention|No Study Intervention Control Group|Participants randomized to receive no study intervention during their Stage II palliation.
32930191|NCT04497116|Experimental|RP-3500 (camonsertib) alone|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration alone"
32930192|NCT04497116|Experimental|Expansion cohorts with RP-3500 (camonsertib)|"Phase 2:~Expansion cohorts with RP-3500 (camonsertib)"
32930193|NCT04497116|Experimental|RP-3500 (camonsertib) with Talazoparib or Gemcitabine|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine"
32930194|NCT04486352|Experimental|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with no specified gene signatures will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930195|NCT04486352|Experimental|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930196|NCT04486352|Experimental|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930197|NCT04486352|Experimental|Atezolizumab and Trastuzumab emtansine (TDM-1) Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with tumors that with an amplification of ERBB2/HER2 will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930198|NCT04486352|Experimental|Atezolizumab and Tiragolumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with tumor type MSI-H and/or tTMB >=10 mut/mb will be assigned to this cohort. Twenty participants will be enrolled initially. Once twenty participants are enrolled, the cohort may be expanded if a positive signal is shown. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930199|NCT04486352|Experimental|Inavolisib and Letrozole Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, participants with tumors that with PIK3CA activating mutations in the absence of PTEN loss-of-function alterations or AKT1 activating mutations will be assigned to this cohort. Twenty-four participants will be enrolled. Once twenty-four participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
32930200|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
32930201|NCT04858412|Active Comparator|HMB enriched amino acid arm|The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.
32930202|NCT04858412|Placebo Comparator|Balanced amino acid arm|The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.
32930203|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
32930204|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
32930205|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
32930206|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
32930207|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
32728237|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
32728238|NCT03411161|Active Comparator|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
32728239|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
32930208|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
32930209|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
32930210|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
32930211|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
32930212|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
32930213|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
32930214|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
32728240|NCT05228067|Active Comparator|Anodal stimulation|Anodal tDCS of the hypothalamus network
32728241|NCT05228067|Active Comparator|Cathodal stimulation|Cathodal tDCS of the hypothalamus network
32930215|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
32930216|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
32930217|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
32930218|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
32728242|NCT05228067|Sham Comparator|Sham stimulation|Sham tDCS of the hypothalamus network
32728243|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
32728244|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
32728245|NCT05227911||Abdominal Surgery Group|Participant undergoing abdominal surgery for any indication
32728246|NCT04833933||Control group|"Initially in DISCO trial : no intervention, usual care~In DISCO-SET trial : survey (the same in the 4 groups)"
32930219|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
32930220|NCT04848194|Other|All patients|All patients with psoriasis recruted by dermatological departement.
32728247|NCT04833933||Questionnaire|"Initially in DISCO trial : Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~In DISCO-SET trial : survey (the same in the 4 groups)"
32930221|NCT05646498|Active Comparator|implant retained removable overdentures|"Procedure: Long implant and partial overdentures insertion of long implants anterior to the maxillary sinus to retain partial overdentures~Device: Partial overdentures Distal extension metallic partial dentures retained by attachments to the implants"
32930222|NCT05646498|Active Comparator|implant supported fixed screw retained prosthesis|"Procedure: Sinus lift and long implant performing sinus lift surgical procedure with simultaneous placement of limplants to support screw-retained prosthesis~Device: Metal ceramic prosthesis on long implants porcelain fused to metal fixed screw-retained prosthesis supported by implants"
32930223|NCT04470518|Active Comparator|Intervention: Diagnostic algorithm|diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
32930224|NCT04470518|No Intervention|Usual care|"In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.~Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.~They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children)."
32930225|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
32930226|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
32930227|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
32930228|NCT04921358|Experimental|Arm A: Tislelizumab in combination with Sitravatinib|tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
32930229|NCT04921358|Active Comparator|Arm B: Docetaxel|docetaxel 75 mg/m2 intravenously once every 3 weeks
32930230|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
33251497|NCT00885183|Other|Usual care|Control group (usual care) receives standard chemotherapy alone
32930231|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
32930232|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
32930233|NCT05646264|No Intervention|Monotherapy group|Single use of second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.)
32930234|NCT05646264|Experimental|Joint group|second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.) Add Agomelatine
32930235|NCT04841954|Experimental|Prick-test|
33251498|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
33251499|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
32930238|NCT04734431||Survivors|Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
32930239|NCT04734431||Death|Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
32930240|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
32930241|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
32930242|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
32930243|NCT04904978|Experimental|Trial Group|Use of Blanx Black Toothpaste
32930244|NCT04904978|Active Comparator|Control Group|Use of Colgate Sensation White toothpaste.
32930245|NCT04903574|Experimental|Sedentary behavior smartphone app|This arm will be assigned to download and use a smartphone app that prompts you to stand up when your smartphone detects 30 minutes of sitting.
32930246|NCT04903574|Active Comparator|Pregnancy smartphone app|This arm will download and use a commercially available pregnancy smartphone app that does not attempt to change activity behavior.
32930247|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
32930248|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
32930249|NCT05421702|Active Comparator|Group A Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic conventional colectomy
32930250|NCT05421702|Active Comparator|Group B Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic complete mesocolic excision
32930251|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
32930252|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
33251500|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
33251501|NCT00759720|Active Comparator|Glyburide QD|
33251502|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
33400963|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
33400964|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
33400965|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
33400966|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
33400967|NCT03638401|No Intervention|Standard treatment|
33400968|NCT03638401|Active Comparator|Intervention arm|
32930253|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
33400969|NCT04747873|Experimental|e-CBT|12 weekly sessions with approximately 30 slides and interactive content, delivered through OPTT designed to mirror in-person standard CBT. Participants go through the content and complete homework at the end of the session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases. On average, developing this feedback takes a therapist 15-20 minutes per patient. In addition to the weekly feedback, participants have the option to message their therapist through the platform throughout the week regarding any questions or concerns they may have.
32728248|NCT04833933||Coordination|"Initially in DISCO trial : Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
32728249|NCT04833933||Questionnaire + Coordination|"Initially in DISCO trial :~Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
32728250|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
32930254|NCT04343612|Experimental|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
32930255|NCT04343612|Experimental|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
32930256|NCT04343612|Experimental|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
32930257|NCT04343612|Placebo Comparator|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
32930258|NCT05417490||Group with PRADO|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M (6 months) visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire : The objective is to measure the medication compliance of patients during treatment~SSQ6 (Social Support Questionnaire 6) : which measures two dimensions of social support (satisfaction and availability). SSQ6 is an abbreviated form of SSQ (Social Support Questionnaire). A high SSQ score indicates more optimism about life than a low score."
32930259|NCT05417490||Group with PRADO + remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire~SUTAQ (Service User Technology Acceptability Questionnaire) : only for patients with remote monitoring.~the questionnaire has 22 items, measured on a Likert scale from 1 to 6, reflecting respectively more or less agreement with the statements of the items. The questionnaire has 5 subscales, each containing between 3 and 9 items.~SSQ6"
32728251|NCT04447573|Experimental|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
32728252|NCT04841759|Experimental|"Post COVID-19 fatigue at baseline yes"|SARS-CoV2 survivor who attends the exercise program and suffers from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
32930260|NCT05417490||Group with remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire on therapeutic compliance~SUTAQ inspired digital tools acceptability questionnaire: only for patients with remote monitoring~SSQ6 social support questionnaire"
32728253|NCT04841759|Active Comparator|"Post COVID-19 fatigue at baseline no"|SARS-CoV2 survivor who attends the exercise program and doesn't suffer from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
32728254|NCT03972579|Active Comparator|Graded exposure therapy|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
32728255|NCT03972579|Active Comparator|Pacing + mindfulness|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
32930261|NCT05417490||Group without intervention|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire on therapeutic compliance~SSQ6 social support questionnaire"
33251503|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
33251504|NCT00763230|Experimental|active|Full active tDCS treatment
33251505|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
32930266|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
32930267|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
32898411|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32930268|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
32930269|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
32930270|NCT05646186|Experimental|Personalised diet based on microbiome analysis|Personalized diet application based on artificial intelligence-assisted microbiome analysis. After the microbiome analysis is made from the stool samples to be taken from the individuals, a personalized diet program will be created with an artificial intelligence-based algorithm and a diet will be applied for 6 weeks with the support of a professional dietitian.
32930271|NCT05646186|Active Comparator|Low FODMAP diet|After the microbiome analysis is made from the stool samples to be taken from the individuals, low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet will be applied for 6 weeks with the support of a professional dietitian.
32930272|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
32930273|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
32930274|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
32930275|NCT04443530||Coronary artery stenosis|Patients with coronary artery disease
32930276|NCT03491891||derivation cohort|no interventions will be administrated
32930277|NCT03491891||validation cohort|no interventions will be administrated
32930278|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
32930279|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
32930280|NCT04439396|Placebo Comparator|Control|Saline injection administered during surgical procedure
32930281|NCT04439396|Experimental|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
32930282|NCT04439396|Experimental|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
32930283|NCT03493607|Experimental|AMO-01|Intravenous Infusion
32930284|NCT04896632|Experimental|INE963|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
32930285|NCT04896632|Placebo Comparator|Placebo group|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
32930286|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
32930287|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
32930288|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
32930289|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
32930290|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
32930291|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
32930292|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
32930293|NCT04889924|Experimental|Axillary radiotherapy without lymphadenectomy|Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy
32768833|NCT04832633|Experimental|test bolus(TB) I|We use the TB method with biphasic injection, followed by the saline flush. Initially, we inject the 10 ml of test contrast media with a velocity of 3ml/s and apply the ROI at the bifurcation of PA and descending aorta at the same level. The dynamic curve demonstrates the time to peak enhancement of P second and A second. The first phase of contrast media injection uses a velocity of 2ml/s and the volume of contrast is measured as 2ml/s multiply (A-P) second. The second phase of contrast media injection uses a velocity of 3ml/s and the volume of contrast media is 70ml minus the amount of first phase injection. The total volume of the contrast media is 80ml, including the 10ml for pre-diagnostic test bolus images. We performed the saline flush following the administration of the contrast media with 20 ml normal saline. The start time of the diagnostic scan is at the A second.
32768834|NCT04832633|Experimental|test bolus(TB) II|This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
32768835|NCT04832633|Experimental|bolus-tracking(BT) I|Initially, 10ml of test contrast media was administrated but no calculation was performed for these pre-diagnostic test bolus images in this group. Unlike the TB method, we use 10 seconds as the fixed interval of (A-P) in this group. The first phase of contrast media injection uses a velocity of 2ml/s and thus the volume of contrast is 20ml. The second phase of contrast media injection is administered with a velocity of 3ml/s and the volume of the contrast media is 70ml minus 20ml. The total volume of the contrast media is 80 ml. The following saline flush uses 20 ml of normal saline. The tracking scan started after contrast injection was initiated for 15 seconds. The ROI is placed in the descending aorta at the same level of PA bifurcation and the diagnostic CT scan is triggered when the density in the ROI achieves the baseline density plus 150HU.
33251506|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
33251507|NCT03948334|Experimental|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
33251508|NCT03948334|Experimental|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
33251509|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
33251510|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
33251511|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
32768836|NCT04832633|Experimental|bolus-tracking(BT) II|This group is similar to the BT I. The first phase of injection is the same as the BT I group. We use lesser contrast media in the second phase of contrast injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus 20ml. The total volume of the contrast media is 70 ml, including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The protocol for triggering diagnostic CT scan is the same as that in BT I.
32768837|NCT04835909|Experimental|Behavioral: modern board and card games|Participants will play modern board and card games in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
32768838|NCT04835909|Active Comparator|Behavioral: paper and pencil tasks|Participants will do cognitive paper and pencil tasks in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
32768839|NCT04835909|No Intervention|Wait-list|Participants will be in a wait-list over a period of 16 weeks. Then, they received the board and card games' or paper and pencil tasks' intervention.
32768840|NCT05363631|Experimental|Seleno-L Methionine (SLM) in Combination with Axitinib and Pembrolizumab|SLM only will be taken by mouth during a two-week run in period. Then patients will receive SLM and Axitinib drugs by mouth, and Pembrolizumab intravenously (IV), at the start of each 21 day cycle.
32768841|NCT05032729|Placebo Comparator|Placebo beverage|"Flavor~Non-nutritive sweetener~Color added to match whey appearance"
32768842|NCT05032729|Experimental|Higher tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~40g whey~0.855g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
33251512|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
33251513|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
33251514|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
33251515|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
33251516|NCT00961246|Active Comparator|general health information group|participants received general health information
33251517|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
33251518|NCT05288712|Experimental|Experimental: Training protocol with the cervical device for treatment (CDAT).|"Endurance and stabilization training program of deep cervical flexors with the cervical device for treatment.~Endurance and stabilization training program of deep cervical extensors with the cervical device for treatment."
33251519|NCT05288712|Active Comparator|Conventional training protocol:|"Endurance and stabilization training program of deep cervical flexors with conventional protocol.~Endurance and stabilization training program of deep cervical extensors with conventional protocol."
33251520|NCT05288712|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
33251521|NCT00889083||Control|Non septic patients needing hepatic surgery
32930294|NCT04889924|Active Comparator|Axillary lymph node dissection|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
32930295|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
33251522|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
33251523|NCT01048489|Other|Lifestyle counseling|
33251524|NCT01048489|No Intervention|No counseling|
33251525|NCT00961324|Experimental|IDeg|
32728256|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
32930296|NCT05414760|Active Comparator|Womed Leaf group|Womed Leaf is inserted immediately after completion of the endometrial ablation.
32930297|NCT05414760|No Intervention|No adhesion prevention group|Standard of care: no IUA prevention, no placebo after ablation
32930298|NCT05369754|Experimental|YBSW015 injection 180mg|
32930299|NCT05369754|Experimental|YBSW015 injection 450mg|
32930300|NCT05369754|Experimental|YBSW015 injection 900mg|
32930301|NCT05369754|Experimental|YBSW015 injection 1800mg|
32930302|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
32930303|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
32930304|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
32930305|NCT04825496|Experimental|ssCART-19 Cells|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
32930306|NCT05646030|Other|Subjects with known elevated serum CEA|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
32930307|NCT05646030|Other|Subjects currently undergoing colorectal cancer related follow-up|The subjects of arm B are requested to perform automated capillary and lancet capillary sampling at home following their next two outpatient visits. During these outpatient visits, a reference value blood CEA measurement will be obtained using venipuncture by the personnel of the clinical laboratory of Erasmus MC. The required materials will be sent to the home address of the patient. Sampling will be performed at home and by the subjects themselves. Subjects will have access to the tutorial videos for automated and lancet capillary sampling.
32930308|NCT05646030|Other|Volunteers|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
32930309|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
32930310|NCT05645952||Patients diagnosed with DCMP during study period|Patients newly diagnosed with DCMP between January 2015 and December 2020
32930311|NCT04434092|Experimental|Arm A (Crovalimab)|Adult Participants will receive an initial intravenous (IV) loading dose on Week 1 Day 1, followed by 4 weekly crovalimab subcutaneous (SC) doses on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter, for a total of at least 24 weeks of study treatment.
32930312|NCT04434092|Active Comparator|Arm B (Eculizumab)|Adult Participants will receive initial IV weekly doses for 4 weeks which will be followed by Q2W (every 2 weeks) IV administrations starting on Week 5.
32930313|NCT04434092|Experimental|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
32930314|NCT05651256|Experimental|TREATMENT|BEFORE TREATMENT/AFTER TREATMENT A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed with a total dose of 100 U (Type A toxinum botulinum, Allergan) in each patient, distributed at the different injection sites: 40 U in the masseter muscle, (0.1 cc=10 U), 20 U in the area of greatest hypertrophy (anterior inferior masseter), 10 U in the direction of the mandibular inferior border and 10 U in the area of the posterior inferior masseter; 20 U in the lateral pterygoid muscle (10 U extraorally between the zygomatic arch and sigmoid notch and 10 U intraorally, behind the maxillary tuberosity); 20 U in the TMJ, 10mm anterior to the tragus and 2mm below the zygomatic arch and 20 U in the anterior part of the temporalis muscle.
32930315|NCT00377195|Experimental|1|
32930316|NCT04433780|Experimental|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
32930317|NCT04297631|Experimental|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
32930318|NCT04297631|Experimental|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
32930319|NCT05645874||Control (no underlying neurological disorder)|
33251526|NCT00961324|Experimental|IGlar|
33251527|NCT00766350|Active Comparator|amitriptyline|
33251528|NCT00766350|Experimental|quetiapine|
33251529|NCT03992755|Experimental|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
33251530|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
32930320|NCT05645874||Neurodevelopmental disorder_Genetic cause known|
32930321|NCT05645874||Neurodevelopmental disorder_Acquird (cause known)|
32930322|NCT05645874||Neurodevelopmental disorder_Cause unknown|
33251531|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
33251532|NCT00889239|Experimental|A|ceramic crown
32930323|NCT04818632|Experimental|AZD9833 monotherapy dose escalation|
32930324|NCT04818632|Experimental|AZD9833 monotherapy dose expansion|
32930325|NCT04818632|Experimental|AZD9833 with palbociclib dose expansion|
32930326|NCT04818632|Experimental|AZD9833 with everolimus dose expansion|
32930327|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
33251533|NCT00760032|Experimental|Active|Ciprofloxacin
32930330|NCT04430582||Hypoglycemia after upper gastrointestinal (GI) surgery|Participants with hypoglycemia after upper GI surgery, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
32930331|NCT04430582||Asymptomatic post-bariatric participants|Participants with a history of bariatric surgery, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia. They will be recruited by advertisement flyers at postoperative surgical clinics at local hospitals (e.g. Brigham and Women's and Beth Israel Deaconess Hospitals) and from other hypoglycemia studies at Joslin.
33251534|NCT00760032|Placebo Comparator|Placebo|Placebo
33251535|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
33251536|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
33251537|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
32768843|NCT05032729|Experimental|Lower tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~30g whey~0.641g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
32930332|NCT04430582||Hypoglycemia no upper GI surgery & no diabetes (DM) or pre-DM|Participants with hypoglycemia and no history of upper gastrointestinal surgery, and NO current diagnosis of diabetes or pre-diabetes, recruited from the Joslin Hypoglycemia Clinic, or from other hypoglycemia studies at Joslin.
32930333|NCT04430582||Controls, no hypoglycemia or history of upper GI surgery|Participants without hypoglycemia or upper gastrointestinal surgery (controls), recruited by local advertisement. Some participants may be recruited from other hypoglycemia studies at Joslin.
32930334|NCT05645562|Experimental|Intervention group|Intervention group will receive a pain neuroscience education program (once time per month, during 4 months). This program will include information about biological, psychological and perceptual aspects of pain in the sport context.
32930335|NCT05645562|Active Comparator|Control group|The control group will receive a self-care education program (once time per month, during 4 months). This program will include information about health habits in the sport.
32930336|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
32930337|NCT05393388||PET/CT|PET.CT using the radiotracer [18F]AV-1451
32930338|NCT04812470|Experimental|Autologous tumor infiltrating lymphocytes (TIL)|Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.
32930339|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
32930340|NCT04428554|No Intervention|Control arm|Standard of care
32930341|NCT04428554|Experimental|Experimental arm|
32930342|NCT05651178|Experimental|Human CD19-CD22 Targeted T Cells Injection|Single administration: 1.0×10^6 CAR+T cells/kg, 3.0×10^6 CAR+T cells/kg, 5.0×10^6 CAR+T cells/kg
32930343|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
32930344|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
32930345|NCT04800458|Experimental|thrombocytopenic patients|
33251538|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
33251539|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
33251540|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
33251541|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
33251542|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
33251543|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
32930346|NCT04343300|Other|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
32930347|NCT04343300|Experimental|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
32906794|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
32906795|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
32906796|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
32906797|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
32930348|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930349|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930350|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930351|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930352|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930353|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
32930354|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
32930355|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
32930356|NCT04797884|Experimental|TheraBionic Arm - Active Arm|For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
32930357|NCT04797884|Placebo Comparator|Placebo Arm|For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
32930358|NCT04409288|Experimental|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
32930359|NCT04409288|Experimental|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
32930360|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
32930361|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
32930362|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
32930363|NCT04342910|Experimental|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
33251544|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
33251545|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
33251546|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
33251547|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
33251548|NCT00889317||healthy adults|
33251549|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
32930364|NCT04342910|Active Comparator|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
32930365|NCT03504839|Other|Intervention|S-ICD implantation.
32930366|NCT04793360||LiverCare Surveillance|Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study
32930367|NCT04714073|Experimental|Reference: BI 706321 alone|First treatment period
32930368|NCT04714073|Experimental|Test: BI 706321 + Itraconazole|Second treatment period
32930369|NCT04342676|Experimental|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
33400970|NCT04747873|Experimental|e-CBT + Stepped Care|"1 - Participant will receive message from assigned care provider on OPTT who check-in with them about strategies and techniques they have discussed and remind them of weekly homework due date.~2.- Participant will receive phone call from therapist who will check-in on them, remind them of therapy strategies, and verbally remind them of weekly homework due date.~3 - Participant will receive phone call from assigned care provider who will check-in on them, remind them of some therapy strategies and techniques and weekly session due date, and provide CBT summary of previously reviewed CBT concepts.~4 - articipant will receive video call (Microsoft Teams) from their therapist who will check-in on them, remind them of weekly session due date, and provide CBT content support to participant.~5 - Participant will receive CBT sessions in live video call (Microsoft Teams) with research psychiatrist involved in care."
33400971|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
32930370|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
32930371|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
32930372|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
32930373|NCT04400318|Experimental|Dupilumab|2 x loading dose on Day 1, followed by 1 x maintenance dose every 2 weeks (Q2W) during 24 weeks
32930374|NCT04400318|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 24 weeks
32930375|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
32930376|NCT04398368|Experimental|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
32930377|NCT05651100|Experimental|arm 1|sequential CD19 and CD22 targeted CAR-T cells treat
32930378|NCT04393844|Placebo Comparator|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
32930379|NCT04393844|Experimental|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
32930380|NCT04393532|Experimental|Laparoscopic hernia repair using Su2ura Approximation Device|"Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered at induction of anesthesia. A single surgeon, the PI, will perform the procedure. A surgical assistant will be selected by the PI from the surgical staff of the department.~The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura Approximation device and fixation of mesh with tacks over the closed defect.~Study follow up visits: at post operation discharge, 14 days, 3 months, 6 months."
32930381|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
32930382|NCT05364762|Experimental|Prevention (PBSCs, cyclophosphamide, itacitinib, tacrolimus)|Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide IV QD on days 3 and 4, itacitinib PO QD on days 5-100, and tacrolimus IV or PO on days 6-65.
33251550|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
33251551|NCT01051297||VTE-Retrospective|patients with VTE , chart review
32930385|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
32930386|NCT05358990|Experimental|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
32930387|NCT05358990|Active Comparator|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
32930388|NCT04871958|Experimental|rtCGM/MDI|Real-time CGM, insulin therapy by multiple daily injections managed according to CGM
32930389|NCT04871958|Experimental|rtCGM/V-Go|Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM
32930390|NCT04871958|No Intervention|blindCGM/MDI|Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)
32930391|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
33251552|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
33251553|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
33400972|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
32930392|NCT04342598||Household contact controls|
32930393|NCT04342598||Non-household contact controls|
33251554|NCT04036539|Placebo Comparator|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
33251555|NCT04036539|Experimental|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
33251556|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
32728257|NCT04737603|Experimental|ED-initiated treatment with buprenorphine/naloxone.|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh <= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
33251557|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
32930394|NCT03645785|Active Comparator|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
32930395|NCT03645785|Experimental|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
32728258|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
32728259|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
33251558|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
33251559|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
33251560|NCT00892593|No Intervention|2 Usual Care - Surveillance|
33251561|NCT00892593|No Intervention|3 Usual Care - Screening|
32728260|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
32728261|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
32728262|NCT03918369|Experimental|Laparoscopic Intracorporeal anastomosis|Laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis.
32728263|NCT03918369|Active Comparator|Laparoscopic extracorporeal anastomosis|Laparoscopic right hemicolectomy with extracorporeal anastomosis.
32930396|NCT05650944||Covid-19 Survivor groups|Covid-19 survivor groups are hematological parameters
32930397|NCT05650944||Covid-19 Non-survivor groups|Hematological parameters in patients with severe COVID-19 who have died.
33251562|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
33251563|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
33251564|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
32930398|NCT04783220|Experimental|Intervention|The parents of babies in this group will receive an educational and intervention program
32930399|NCT04783220|No Intervention|Control|The parents of babies in this group will receive the standard parent education and follow-up.
32930400|NCT04862208|Experimental|Carbohydrate-based breakfast + exercise|maltodextrin
32930401|NCT04862208|Experimental|Protein-based breakfast + exercise|whey
32930402|NCT04862208|Experimental|Fasted breakfast + exercise|water
32930403|NCT04862208|Sham Comparator|Carbohydrate-based breakfast + no exercise|maltodextrin
32930404|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
32930405|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
32930406|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
32930407|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
32930408|NCT05650866|Experimental|Implanted group|The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday.
32930409|NCT05650866|No Intervention|Control group|Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.
32930410|NCT04372238|Experimental|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
32930411|NCT04372238|Active Comparator|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
32930412|NCT05650788|Experimental|Bipolar disorder group|Patients with a diagnosis of bipolar II mood disorder stabilized in remission, according to DSM 5 criteria, with mood stabilizer treatment (lithium, anticonvulsant or antipsychotic) at an effective dose, with possible antidepressant treatment (SSRI, SNRI, tricyclics )
32930413|NCT05650788|Experimental|Mood depressive disorder group|Patients with a diagnosis of unipolar mood disorder stabilized in remission, according to DSM 5 criteria, with or without antidepressant treatment (SSRI, SNRI, tricyclics)
32930414|NCT05650788|Experimental|Healthy volunteer|People for whom no psychiatric diagnosis can be retained, according to DSM 5 criteria and naïve to psychotropic treatments
32930415|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
32930416|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
32930417|NCT04778930|Experimental|Group A_Intervention Group|It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
33251565|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
32930418|NCT04778930|Experimental|Group B_Control Group|The subjects in this group will receive their usual Physical Therapy intervention regimen for 6 weeks at their referral center and the same telehealth Therapeutic Education program of the intervention group.
32930419|NCT04871022|Active Comparator|Double layer unlocked uterine closer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
32930420|NCT04871022|Experimental|Purse uterine closer|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
32930421|NCT04362254|Experimental|Spesolimab arm|
32930422|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
32930423|NCT03511937|Other|Neutral Label|
32930424|NCT04771130|Experimental|Parts 1 and 2: AML Cohorts|Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
32930425|NCT04771130|Experimental|Parts 1 and 2: MDS Cohorts|Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
32930426|NCT04771130|Experimental|Part 3: AML and MDS Cohorts|Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
32930427|NCT04771130|Experimental|Part 3: AML and MDS Cohort|Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
32930428|NCT05640258|Experimental|seasickness susceptibility and vestibular time constant|"All study participants underwent rotatory chair testing in a velocity step protocol to determine the Vestibular time constant.~testing were preformed at baseline, before commencing active duty on a ship, 3 month and 6 month follow up after the beginning of active sailing."
32930429|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
32930430|NCT00361478|Active Comparator|2|Education only
32930431|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
32930432|NCT01641198|Active Comparator|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
32930433|NCT01641198|Experimental|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
32930434|NCT01641198|Experimental|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
32930435|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
32930436|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
32930437|NCT04012814|Experimental|Subject treatment group|Treatment group receiving up to 4 diode treatments and up to 8 RF treatments.
32930438|NCT04770506||Lithiasis patients|Lithiasis patients: diagnosis of recurrent NL confirmed by URO CT with presence of idiopathic hypercalciuria and metabolic workup available.
33251566|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
33251567|NCT00966004|Experimental|YM178 group|oral
33251568|NCT00966004|Placebo Comparator|Placebo group|oral
33251569|NCT00966004|Active Comparator|tolterodine group|oral
33251570|NCT00892671||medical students|
33251571|NCT04048590|No Intervention|Control|Control subjects will receive care at a skilled nursing facility.
32728264|NCT05168137|Placebo Comparator|Placebo|prescribed placebo of colchicine
33251572|NCT04048590|Active Comparator|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
33251573|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
32930439|NCT04770506||Control group|Control group: patients without NL matched for age and sex and who had a bone mineral densitometry or abdominal CT.
32930440|NCT05637918||Group 1 (Patients who recorded as Grade 0)|"Patients whose antrum appears empty in supine and right lateral decubitus (RLD) positions by gastric ultrasound (Grade 0). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination.~The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
32930441|NCT05637918||Group 2 ( Patients who recorded as Grade 1)|"Patients whose antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position by gastric ultrasound (Grade 1). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
32930442|NCT04762082|Experimental|Treatment A: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
32930443|NCT04762082|Active Comparator|Treatment B: Reference|Single oral dose of tadalafil oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
32930444|NCT04762082|Experimental|Treatment C: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
32930445|NCT04762082|Experimental|Treatment D: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with no water, under fasted conditions
32930446|NCT04762082|Experimental|Treatment E: Test|Single oral dose of tadalafil gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
32728265|NCT05168137|Active Comparator|Colchicine|Prescribed colchicine 0.6 mg PO daily
32728266|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
32930447|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
32930448|NCT03514277|Active Comparator|Local infiltration of Exparel|
32930449|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
32930450|NCT05635578|Experimental|Experimental:|reiki will be aplicated
32930451|NCT05635578|No Intervention|Control|Routine maintenance will be applied.
32728267|NCT03410771||ICU patients on piperacillin/tazobactam|
32728268|NCT03410771||ICU patients on meropenem|
32728269|NCT03410771||ICU patients on vancomycin|
32728270|NCT05226819|No Intervention|H. pylori negative group|No Intervention
32768844|NCT04835753|Experimental|study group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training plus shock wave on the muscle belly of the planter flexor hypertonic muscles.
32930452|NCT04861740|Experimental|Screening + Autism ALERT|Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
32930453|NCT04861740|Active Comparator|Screening Only|Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
32930454|NCT04227119|Experimental|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
32930455|NCT04861428|Experimental|IQOS / Smoking as usual|Two weeks of IQOS, followed by two weeks of cigarette smoking as usual.
32930456|NCT04861428|Active Comparator|Smoking as usual / IQOS|Two weeks of cigarette smoking as usual, followed by two weeks of IQOS.
32930457|NCT04006652|Experimental|Recipient|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician~Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
32930458|NCT04006652|No Intervention|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
32930459|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
32930460|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
32930461|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
32930462|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
32930463|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
32930464|NCT05334108|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Substrate Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
32930465|NCT05334108|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Substrate given on 2 separate days:~- bupropion: 100mg oral tablet"
32930466|NCT05334108|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Substrate Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
32930467|NCT04342832|Active Comparator|Early invasive treatment (cryoballoon ablation)|
32930468|NCT04342832|No Intervention|Standard medical care|
32930469|NCT04419792||Narcolepsy|
32930470|NCT03984656|Active Comparator|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
32930471|NCT03984656|Experimental|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
32930472|NCT05305872|Experimental|Treatment group|Gandouling
32930473|NCT05305872|Placebo Comparator|Control group|Zinc gluconate
32930474|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
32930475|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
32930476|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
32930477|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
32930478|NCT05299944|Active Comparator|Full-spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
32930479|NCT05299944|Active Comparator|Broad-spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing 0%THC.
32930480|NCT05299944|Placebo Comparator|Hemp Seed Oil Placebo|210mg/day of hemp-seed oil with no cannabinoids present.
32930481|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
32930482|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
32930483|NCT04329494|Experimental|Arm I (PIPAC, doxorubicin, cisplatin)|Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with doxorubicin IP, followed by cisplatin IP. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
32930484|NCT04329494|Experimental|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal or appendiceal cancer undergo PIPAC with oxaliplatin IP. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
32930485|NCT04329494|Experimental|Arm III (PIPAC, mitomycin, FOLFIRI)|Patients with colorectal or appendiceal cancer who have undergo at least 4 months (or 8 cycles) of first-line standard of care chemotherapy but have not progressed on second line chemotherapy undergo PIPAC with mitomycin IP. Patients also receive standard of care irinotecan IV over 90 on day 1, leucovorin IV over 30 minutes on day 1, and fluorouracil IV on days 1-2 during weeks 2, 4, 8, 10, 14 and 16. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
32930486|NCT05298384|Experimental|Study Group|Individuals with nocturia as a result of idiopathic edema and autonomic failure will be assigned to wearing knee high then thigh high compression stockings to assess the effect on weight gain during the day and the number of nocturia events.
32930487|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
32930488|NCT05288790|Experimental|Study Supplement|Probiotic
32930489|NCT05288790|Placebo Comparator|Study placebo|Placebo
32930490|NCT04318106|Experimental|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
32930491|NCT04318106|Placebo Comparator|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
32930492|NCT05282004|Experimental|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
32930493|NCT04342988|Other|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
32930494|NCT05279430|No Intervention|Control arm|Patients allocated to the control arm will not receive inspiratory muscle training. They will be checked each week by a physiotherapist responsible for training intervention who will measure their maximal inspiratory pressure
32930495|NCT05279430|Active Comparator|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
32930496|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
32728271|NCT05226819|Other|H. pylori positive and successful eradication group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is eradicated. At the same time, Patients with successful eradication are instructed to conduct 13C-UBT examination after 6 months,1year and every year after drug withdrawal.
32930497|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
32930498|NCT04861350|Experimental|motor imagery with action observation|The subjects will perform the exercises mentally for 3 sets with video, 10 reps for 1 set.
32930499|NCT04861350|Experimental|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator, 10 reps for 1 set.
32930500|NCT04861350|Experimental|combine physical training and motor imagery with action observation|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally, 10 reps for 1 set.
32930501|NCT04291898|Active Comparator|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
32930502|NCT04291898|Active Comparator|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
32930503|NCT04291898|Active Comparator|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
32930504|NCT04740476|Experimental|STK-001 multiple dose levels|Enrollment of patients after completion of study STK-001-DS-101 if eligible for additional dosing in this extension study. Patients will receive IT administration of study drug STK-001 at the dose level they received while participating in Study STK-001-DS-101, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an STK-001 Phase 1/2 study, and doses above 30 mg/dose in this study require approval from the Food and Drug Administration (FDA). Patients will initially receive 3 doses, one every approximately 4 months (16 weeks). Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug. Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.
32728272|NCT05226819|Other|H. pylori positive and eradication failure group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is not eradicated.
32728273|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
32728274|NCT05216757|Active Comparator|Iguratimod group|subjects with Iguratimod
32728275|NCT05216757|Placebo Comparator|placebo group|subjects with placebo
32728276|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
32728277|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
32728278|NCT03397823||control group|age gender matched subjects
32728279|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
32728280|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
32728281|NCT05206227|Experimental|Exercise|Blood and skeletal muscle microdialysate collected during dynamic knee-extension exercise
32728282|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
32728283|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
32728284|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
32728285|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
32728286|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
32930505|NCT05630586|Active Comparator|Semaglutide 0.5 mg|"Inj. Semaglutide 0.5 mg s.c., 0.5 mg per week for 4 weeks~+ standard care"
32930506|NCT05630586|Other|Control|Standard care
32930507|NCT05625594|Experimental|Treatment (leukapheresis, CD19-CAR T cells)|Patients may undergo catheterization, undergo leukapheresis, may receive fludarabine IV and cyclophosphamide IV, and receive CD19-CAR T cells ICV on study. Patients also undergo MRI, PET, CT, collection of blood samples, and CSF aspiration throughout the trial, and lumbar puncture as clinically indicated.
33251574|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
33251575|NCT00766740|Active Comparator|1|thrombectomy
32930510|NCT04870866|Experimental|NR treated|Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™
32930511|NCT04262102|Active Comparator|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
32930512|NCT04262102|Experimental|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
32930513|NCT04262102|Experimental|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
32930514|NCT04262102|Experimental|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
32930515|NCT05620758|Experimental|Nd YAG laser|
32728287|NCT05167747|Active Comparator|Active Comparator|Dietary supplement
32728288|NCT05167747|Placebo Comparator|Placebo comparator|Placebo
33251576|NCT00766740|Active Comparator|2|Standard PCI
32930516|NCT05620758|Experimental|Diode laser 980 nm|
33400973|NCT03987217|Experimental|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
32728289|NCT04736147|Experimental|JNJ-64300535|Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine.
32930517|NCT05620758|Experimental|Diode laser 940 nm|
32930518|NCT05620758|Experimental|Diode laser 660 nm|
32728290|NCT05167357|Experimental|COVID+ group|As the performance of the Richalet test is done by both arms, the intervention rather is the having undergone COVID19.
32728291|NCT05167357|No Intervention|Control group / COVID- group|Performance of the Richalet test is done by both arms, the control in this study here is the having stayed clear of COVID19.
32728292|NCT05169281|No Intervention|Control|Usual care consisted of a text message hyperlink to nearby disposal locations.
32930519|NCT05620758|Experimental|Diode laser 635 nm|
32930520|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
32930521|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
32728293|NCT05169281|Experimental|Intervention|Intervention participants were mailed an at-home disposal packet timed to arrive between post-operative days four and seven based on prior data collection on reported use.
32728294|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
32930522|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
32930523|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
32728295|NCT04787809|Experimental|Living Well Intervention Group|Participants in the Living Well treatment group will receive a brief digital intervention informed by Acceptance and Commitment Therapy.
32930524|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
32930525|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
32930526|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
32930527|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
32930528|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
32930529|NCT04243616|Experimental|Drug Treatment|Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
32930530|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
32930531|NCT00361556|Active Comparator|1|The Back Book
32930532|NCT00361556|Active Comparator|2|The Back Guide
32930533|NCT00361556|Active Comparator|3|General health book
32930534|NCT05650242|Experimental|BA1106|"Part A (Dose-Escalation): Mixed solid tumors participants will receive ascending doses of BA1106. BA1106 will be administered by intravenous (IV) infusion. The observation period of Dose Limiting toxicity (DLT) is 28 days, then the participants will receive BA1106 every three weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years.~Part B (Dose-Expansion): Participants of selected tumors will receive a fixed dose of BA1106 that selected according to the results of Part A once every 3 weeks (Q3W) or once every 2 weeks (Q2W), until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years."
32930535|NCT04205669|Active Comparator|Individual Treatment|
32930536|NCT04205669|Active Comparator|Household Treatment|
32930537|NCT03954314|Active Comparator|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
32930538|NCT03954314|Active Comparator|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
32930539|NCT01601652|Experimental|Omeagven|
32930540|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
32930541|NCT03516227|No Intervention|Control|Usual Care
32930542|NCT05431608|Experimental|Dose Level -1B|MCARH125 dose 50 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
32930543|NCT05431608|Experimental|Dose Level -1A|MCARH125 dose 50 million CAR+ cells MCARH109 dose 0 total CAR+ cells
32930544|NCT05431608|Experimental|Dose Level 0|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 0 total CAR+ cells
32930545|NCT05431608|Experimental|Dose Level 1|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
32930546|NCT05431608|Experimental|Dose Level 2|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 150 million total CAR+ cells
32930547|NCT04704674||0.5 - 5 years|Age bracket for infants/children up to age five years
32930548|NCT04704674||10 - 18 years|Age bracket for children 10 - 18 years
32930549|NCT04704674||19 + years|Age bracket for adults over 19 years
32930550|NCT04704674||5 - 10 years|Age bracket for children ages 5 - 10 years
32930551|NCT05611476|Experimental|Single group|This group will receive Cognitive Muscular Therapy for low back pain
32930552|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
33251577|NCT00892749|Experimental|1. ASP1585|
33251578|NCT04095442|Active Comparator|Cepacol|
33251579|NCT04095442|Sham Comparator|Tom's Natural Mouthwash|
33251580|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
33251581|NCT00763542|Active Comparator|II|CBT for SUD only
32930553|NCT05107440|Experimental|BREATHE|This is an eight-week intervention involving two sessions per week, hosted virtually on Zoom. The main session is scheduled to last 60 min and the session hosts remain online for an additional 15 minutes to answer individual questions on the management of symptoms and activities that have not been addressed during the main session. The content was developed based on clinical experience, best available evidence for the management of specific symptoms (chronic fatigue, post-exertional malaise, breathing discomfort) in other conditions, including post-viral syndromes, and the current understanding and recommendations for rehabilitation of people living with long COVID. Long COVID can be isolating, and challenges often interfere with everyday lifestyle and socialization. The investigators have incorporated breakout rooms (where the group is divided into two smaller groups based on current activity limitations) to include elements of peer support.
32930554|NCT05590494|Other|Repair a partially torn rotator cuff|Subjects will undergo an ultrasonic tenotomy to repair a partially torn rotator cuff per standard of care as clinically indicated
33400974|NCT03987217|Experimental|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
33400975|NCT03666650|Other|Rotem|
32930557|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
32930558|NCT03952130|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
32930559|NCT03952130|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL insulin lispro SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
32728296|NCT04787809|No Intervention|Control Group|Participants in the control group will not receive any intervention. These individuals will have the option to access the intervention at the conclusion of their study participation.
32728297|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
32728298|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
32930560|NCT04852068|Experimental|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
32728299|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
32728300|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
32728301|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
32930561|NCT04852068|Experimental|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
32930562|NCT04852068|Active Comparator|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
32728302|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
32728303|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
32728304|NCT03393949|Experimental|Group C|Patients in Group C received isotonic saline 1mg•kg-1
32930563|NCT04852068|Active Comparator|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
32930564|NCT03661541|Experimental|Group A, 6 or more outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
32930565|NCT03661541|No Intervention|Group B, 1 or 2 outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
32930566|NCT03661541|No Intervention|Group C, zero outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
33400976|NCT04679857|Experimental|UC|Total Knee Arthroplasty with an ultracongruent insert
32930568|NCT05584722||Idiopathic or Heritable Pulmonary Arterial Hypertension|Patients diagnosed with pulmonary arterial hypertension, either idiopathic or heritable, defined according to standard criteria.
33400977|NCT04679857|Active Comparator|PS|Total Knee Arthroplasty with posterior stabilized design
33400978|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
32930569|NCT05584722||Unaffected Mutation Carriers|Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo.
32930570|NCT05584722||Healthy Controls|Healthy individuals without cardiopulmonary disease
32930571|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
32930572|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
32728305|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
32728306|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
32930573|NCT02975648|Active Comparator|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
32930574|NCT02975648|Experimental|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
32728307|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
32930575|NCT05575362|Experimental|Epley Manuver group|Group A is Experimental group will receive Epley's maneuver and Cawthorne Cooksey exercise for two weeks.
32930576|NCT05575362|Active Comparator|half somersault group|Group B is Control group will receive Half somersault maneuver and Cawthorne Cooksey exercise for two weeks.
32930577|NCT04735133|Experimental|intervention grpup|pNPWT device was placed in the pNPWT group for seven days. The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
32930578|NCT04735133|No Intervention|control group|"The wound of the control group was covered with a sterile gauze dressing. After the wound was left closed for 48 hours in the clinical routine, the surgical site was left open, supporting healing. Therefore, the dressing of the control group was removed after 48 hours, and the wound was left open.~The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI."
32930579|NCT03925532|Experimental|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
32930580|NCT04851912||General|Participants with or without psychiatric disorders
32930581|NCT05430828||Group 1|Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
32930582|NCT03922490|Experimental|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
32930583|NCT03922490|Other|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthroscopy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
32930584|NCT05236764|Experimental|Alpha beta+ T cell depleted CD34+ stem cells|The patient will be receiving a donor stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The investigators will be specially treating the donor's blood cells used for the stem cell transplant.
32930585|NCT05573334|No Intervention|Routine Care|The Routine Care arm is a control group receiving no study intervention. They receive whatever routine care is standard for the study PI's treatment of usual recurrent UTI patients, including antibiotics for active infections, estrogen and supplements for prevention of infection.
32930586|NCT05573334|Experimental|Flourish HEC|"The experimental (or intervention) arm uses 3 products in a vaginal hygiene system in addition to any routine care they would normally receive. These 3 products are a vulvar wash (for external use), a vaginal moisturizing gel (BioNourish), and a vaginal homeopathic suppository with probiotics.~The vulvar wash is used daily or as often as a participant bathes/showers. The vaginal moisturizing gel, which is formulated to match healthy vaginal secretions for pH, osmolality, and lactic acid levels, is used every day before bed.~The vaginal homeopathic suppository with probiotics is used every 3rd day before bed. This suppository contains native vaginal probiotic species associated with healthy vaginal microbiomes."
32930587|NCT04242680|Experimental|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
32930588|NCT04242680|Experimental|Brainstim PPC|tRNS over bilateral PPC + cognitive training
32930589|NCT04242680|Sham Comparator|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
32930590|NCT05080842|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
32930591|NCT04680260|Active Comparator|A: Standard of care|Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.
32930592|NCT04680260|Experimental|B: ctDNA guided therapy approach|Post ablation ctDNA results will be used for treatment decision.
32930593|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
32728308|NCT04678947|Experimental|BARF scale|"Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient.~The nurse will then log the patient's response in the patient's electronic medical record"
32728309|NCT04678947|No Intervention|No intervention|-Patients in the control group will proceed with their inpatient chemotherapy admissions without any interventions. These admissions will take place prior to the admissions of the experimental group, so as not to bias providers.
32930594|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
32930595|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
32930596|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
32930597|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
32930598|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
32930599|NCT04343066|Experimental|External hex implant|External hexagone implant connection
32930600|NCT04343066|Experimental|Internal hex implant|Internal implant connection
32930601|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
32930602|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
32930603|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
32930604|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
33251582|NCT00889629|Experimental|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
32768845|NCT04835753|Other|control group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training .these traditional therapy had been approved by previous studies its effectiveness in management cerebral palsy child
32768846|NCT05059171|Active Comparator|Rotary motion using OneShape single file|File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
32768847|NCT05059171|Active Comparator|Reciprocating motion using WaveOne Gold single file|A Primary file size 25 a taper of 0.07 was installed to pre-programmed reciprocation angles and speed for the WaveOne system handpiece of an endomotor (X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). After ensuring a passive fit of the hand file along the predetermined WL, the RC coronal two-thirds was initially instrumented then followed by the full WL.
32768848|NCT04822805|Experimental|Treatment with Anlotinib|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
32930605|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
32930606|NCT05430048|Active Comparator|Desmopressin group (Group D)|patients will received single puff (10 μg) of nasal desmopressin in the nasal cavity at the side of surgery 30 min preoperative.
32930607|NCT05430048|Active Comparator|Bisoprolol group (group B)|patients will receive Oral bisoprolol 2.5 mg (Concor 2.5 mg; Merck/Amoun) 90 min preoperative.
32930608|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
32768849|NCT05059249|Experimental|Manual Traction|Moist heat packs & TENS for ten minutes followed by Manual Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient.
32768850|NCT05059249|Experimental|Mechanical traction|Moist heat packs & TENS for ten minutes followed by Mechanical Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient
32768851|NCT04095637|Experimental|Mako medial UKA|Mako medial unicondylar knee arthroplasty
32768852|NCT04095637|Active Comparator|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
32768853|NCT04832555|Experimental|Open: non elective irradiation|Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost
32768854|NCT04832789|No Intervention|Best conventional ventilation|
32768855|NCT04832789|Experimental|Ultra-protective ventilation with ECMO|
32768856|NCT05066893|Active Comparator|standard of care|standard of care will be given as per usual care
32768857|NCT05066893|Experimental|intensive monitoring|intensive monitoring every week will be given to participants
32768858|NCT04832711||the low-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
32768859|NCT04832711||the high-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
32728310|NCT04707677|Active Comparator|CONTROL GROUP|Implant surgery placement. Tissue Level SLA Titanium implant (Straumann Standard Plus Narrow Neck CrossFit®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
32930609|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
32930610|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
32728311|NCT04707677|Experimental|TEST GROUP|Implant surgery placement. Tissue Level Ceramic monotype implant was placed (Straumann PURE Ceramic implants®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
32728312|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
32728313|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
32728314|NCT04447365||control|10 patients who have had no device-monitored for ventricular tachycardia/ ventricular fibrillation the 3 months prior to recruitment will comprise a group of controls
32728315|NCT04447365||high burden of ventricular arrhythmias|20 patients will comprise a group of patients with high burden of ventricular arrhythmias, defined as patients with at least one sustained episode of VT/VF requiring ICD therapies in the 3 months preceding study enrollment.
32728316|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
32728317|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
32728318|NCT05169125|Active Comparator|Group A: standard hemodialysis.|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
32728319|NCT05169125|Active Comparator|Group B: lower dialysate sodium hemodialysis.|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L).
32728320|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
32728321|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
32728322|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
32768860|NCT04435093||MFM completion|
32930611|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
32930612|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
32930613|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
32930614|NCT05230602|Experimental|Study Group|The participants will fill the study scales and will be instructed to eat the tzabar fruit twice a day for two weeks
32930615|NCT05230602|No Intervention|Control Group|The participants will fill the study scales and will be instructed not to change their diet for two weeks
32930616|NCT05428644|Active Comparator|reflexology hand massage group|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
32728323|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
32728324|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
32728325|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
32728326|NCT03397693||3|Control fertile women with no treatment given.
32728327|NCT03402529|Other|CESM|
32728328|NCT04447391|Experimental|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
32728329|NCT04447391|Placebo Comparator|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
32728330|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
32728331|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
32930617|NCT05428644|Placebo Comparator|placebo hand massage group|In addition to the standard nursing care of the hospital, individuals in the placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
32930618|NCT04184999|Experimental|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
32930619|NCT04184999|Active Comparator|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
32930620|NCT03912428|Other|Single arm|all groups get the same studies
32930621|NCT05220384|Other|Personalized In-person therapy|
32930622|NCT05220384|Other|Generalized, Video-based therapy|
32930623|NCT03907748|Experimental|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
32930624|NCT03907748|Active Comparator|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
32930625|NCT03907748|No Intervention|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
32930626|NCT05369520|Experimental|Group 1 - Thoracic stimulation|Participants will receive 8 weeks TCSCS at the mid/low thoracic spinal cord levels.
32930627|NCT05369520|Experimental|Group 2- Lumbosacral stimulation|Participants will receive 8 weeks TCSCS at the lumbosacral spinal cord levels.
32930628|NCT03524339|Placebo Comparator|Placebo|
32930629|NCT03524339|Experimental|Tamsulosin|
32930630|NCT03895112|Experimental|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
32930631|NCT05203302|Experimental|Late Adult Cochlear Implant (LateAdultCI)|Post-lingually implanted adults, 18+ years
32930632|NCT05203302|Experimental|Early Child Cochlear Implant (EarlyChildCI)|Early implanted children, ages 7-17 years
32930633|NCT05203302|Experimental|Early Adult Cochlear Implant (EarlyAdultCI)|Early implanted adults, ages 18 to 35 years
32930634|NCT05203302|Experimental|Cochlear Implant (CI)|CI children, ages 7-17 years, with aided residual hearing (bimodal/contralateral, electric+acoustic/ipsilateral)
32930635|NCT05203302|Active Comparator|Normal Hearing Children (NHC)|Ages 7-17 years, Control Group
32930636|NCT05203302|Active Comparator|Normal Hearing Adults (NHA)|18+ years, Control Group
32930637|NCT05440370|Experimental|MegaCarti® application after microfracture|The experimental group is applied with MegaCarti® after microfracture. Afterwards, they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires. Long-term follow-up Study is performed to subject that completes 48-week visit, at every 6 months for 5 years.
32930638|NCT05440370|Active Comparator|Microfracture only|The control group undergoes microfracture and they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.
32930639|NCT05196516||Cases|Individuals at age 18 to 65 with a SARS-CoV-2 infection proven by a polymerase chain reaction (PCR) test at least 12 weeks prior to inclusion and who have been referred to the clinic of post-COVID conditions.
32930640|NCT05196516||Controls|Healthy volunteers at age 18 to 65 with a SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion.
32930641|NCT04201106|No Intervention|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
32930642|NCT04201106|Experimental|Open Label Placebo Group with Rationale|
32930643|NCT04201106|Active Comparator|Open Label Placebo Group without Rationale|
32930644|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
32930645|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
32930646|NCT04675242|Experimental|NCX 4251|NCX 4251 Ophthalmic Suspension
32930647|NCT04675242|Placebo Comparator|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension
32930648|NCT04668248|Experimental|Simulation intervention|Providers assigned to the intervention arm will participate in a short simulation training at the beginning of their 2-week block (planned for their second day). The training will take place at the Neil and Elise Wallace STRATUS Center for Medical Simulation at Brigham and Women's Hospital and will follow all of their recommended and hospital-recommended practices on social distancing, including the learning limits.
33251583|NCT00889629|Placebo Comparator|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
33251584|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
33251585|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
33251586|NCT00766818|Experimental|1|Kaletra
33251587|NCT04009252|Experimental|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
33251588|NCT04009252|No Intervention|Control Group|The CT image will be shown to the patients along with teaching
33251589|NCT04036383|Active Comparator|vestibüler|vestibular exercise training
33251590|NCT04036383|Experimental|balance training|vestibular exercise training+ balance training with computerized balance system
33251591|NCT04036383|Experimental|square-step|vestibular exercise training+ square step exercise
33251592|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video."
33251593|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video.~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
33251594|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
33251595|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
33251596|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
33251597|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)~with shock due sepsis/SIRS, cardiac failure or hemorrhage~age > 18 years,~noradrenalin support~< 24 hours of ICU admission~Signed informed consent"
33251598|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)~without shock, without vasopressor support and without fluid dependent circulation~age > 18 years~< 24 hours of ICU admission~Signed informed consent"
33251599|NCT00967720||Barriers, Adherence, Asthma|
32728332|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
32728333|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
32728334|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
32728335|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
32728336|NCT03759015|Other|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
32930649|NCT04668248|Active Comparator|Online education intervention|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines.
33251600|NCT05278533|Experimental|BioPlete™ Advanced Formula|"BioPlete™ Advanced Formula in Capsule~Intervention: Dietary Supplement: Multi-Vitamin"
33251601|NCT05278533|Placebo Comparator|Placebo|"Rice Flour in a capsule~Intervention: Other: Placebo"
32728337|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
32728338|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
32728339|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
32768861|NCT04832399||Natalizumab|Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.
32930650|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
32930651|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
33251602|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
32728340|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
32728341|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
32728342|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
32728343|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
32728344|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
32728345|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
32728346|NCT02064309|Experimental|Human islets in Beta-Air device|
32930652|NCT05427474|No Intervention|standard protocol of manaegement|traumatic brain injury protocol in Emergency ICU without adding propranolol or gabapentin
32930653|NCT05427474|Active Comparator|propranolol group|addding propranolol to the traumatic brain injury protocol in Emergency ICU
32728347|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
32930654|NCT05427474|Active Comparator|combined propranolol and gabapentin|adding propranolol and gabapentin to the traumatic brain injury protocol in Emergency ICU
32930655|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
32930656|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
32930657|NCT05380050|Experimental|Inpatient GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted in-person weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist in the clinic. Participant completed 5-6 hours of homework between sessions.
32930658|NCT05380050|Experimental|Telehealth GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted over the VA VideoConnect weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist via VA VideoConnect. Participant completed 5-6 hours of homework between sessions
32930659|NCT05380050|Placebo Comparator|Brain Health Workshop|Brain Health Workshop includes educational information about the brain to control for GMT and National Geographic Movies is used as a control to equate time with therapist in Attention Training. Each session occurs weekly for 2-hours over 10-weeks.
32930660|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
32930661|NCT04735055||Artificial intelligence (AI) machine learning group|"90% machine learning part has also been divided into 2 parts as 70% for AI learning and 30% for testing the learning.~70% of the acute pancreatitis patients (approximately 840 pts) will form the model training group of the study. 30% of the acute pancreatitis patients (approximately 360 pts) will form the testing group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
32930662|NCT04735055||Validation group|"10% of the acute pancreatitis patients (approximately 134) will form the validation group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
32930663|NCT00361088|Experimental|Phase I|
32930664|NCT00361088|Experimental|Phase II|
32930665|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
32930666|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
32935876|NCT05447858|Active Comparator|Managerial support in using systematic work environment evaluation and adjustment (SWEA)|Managerial support in using SWEA and the Prehab guide to enhance employees' work situation. Individual work adaptations are adaptations to everyone´s ability in the physical, organisational, and social work environment that aim to enable an employee with reduced ability to perform the normal work, continue working, or plan for a sustainable return to work. The Prehab guide contains a self-assessment test for the employee based on the requirements of the work and one's own ability that can be used in the dialogue with the manager. It also contains suggestions for activities to create a healthier workplace, such as discovering early signals of stress or pain, creating a caring workplace culture and boundaries, regular contact with an employee that is on sick-leave, clear and established safety procedures and routines for the work environmental work, routines for cooperation with other parties, and to learn from one's own and colleague's experiences in an open, permissive climate.
33251603|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
33251604|NCT00966394||healthy|Healthy children ASA1
32930667|NCT05425524|Experimental|Care Bundle Group|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
32930668|NCT05425524|No Intervention|Control Group|
32930669|NCT04160975|Experimental|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
33251605|NCT04049292|Experimental|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
33251606|NCT04049292|Active Comparator|Usual care|Athletes will receive usual care as determined by their treating health care professional
32930670|NCT04160975|Experimental|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
32930671|NCT04160975|Experimental|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
32930672|NCT04160975|Experimental|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
32930673|NCT04160975|Experimental|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
32930674|NCT04160975|Experimental|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
32930675|NCT04833816|Experimental|Ketamin|Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour
32930676|NCT04833816|Placebo Comparator|Placebo|Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour
32930680|NCT04172402|Experimental|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.~BSA < 1.25 m2: 80 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day~BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
32930681|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
32930682|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
32930683|NCT04165616||Individuals with stroke|
32930684|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
32930685|NCT04662242|Experimental|low serum selenium with selenium supplement|Patients having low serum selenium with selenium supplement given
32930686|NCT04662242|Placebo Comparator|low serum selenium with placebo supplement|Patients having low serum selenium with placebo given
32930687|NCT04662242|Active Comparator|non-low serum selenium with selenium supplement|Patients having normal serum selenium with selenium supplement given
32930688|NCT04662242|Placebo Comparator|non-low serum selenium with placebo supplement|Patients having normal serum selenium with placebo given
32930689|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
32930690|NCT05373342||iCount Device|A novel external device which can count the swabs and surgical tampons used during childbirth in an objective and validated manner.
32930691|NCT05373342||User Feedback Survey|"Feedback will be taken from 20 users including midwives/ doctors.~Users will be emailed an online survey or given the same survey as a printout to complete.~All 20 users will also then also be approached to have a semi-structured interview.~10 of the users who first express interest will be interviewed."
32930692|NCT04658966||cases|Women with a history of pre-eclampsia
32930693|NCT04658966||controls|Women with no history of hypertensive disorder during pregnancy
32930694|NCT04848792|Experimental|SFN supplement|The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
32930695|NCT04848792|Placebo Comparator|Placebo|Placebo capsules provided by Cell-Logic.
33251607|NCT00892827|Experimental|Single Arm Study|Rituximab
32728348|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
32728349|NCT03612921|Active Comparator|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
32728350|NCT03612921|Active Comparator|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
32728351|NCT03612921|Placebo Comparator|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
32728352|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
32728353|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
32728354|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
32728355|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
32728356|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
32728357|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
32728358|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
32728359|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
32728360|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
32728361|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
32728362|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
32728363|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
32728364|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
32728365|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
32728366|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
32728367|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
32728368|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
32728369|NCT05168345|Experimental|IBD patients|"Arm 1: IBD patients, patients of other chronic GI disease' and healthy volunteers~Both groups will be asked to fill in the knowledge questionnaire and the self-assessment of knowledge questionnaire once, during their routine visit to the GI department. Results of the questionnaire will be compared between the groups.~IBD Patient's knowledge will also be subjectively assessed by their treating physician during their routine clinical visit, and knowledge scores will be compared (physician and questionnaire). Patients who will agree, will be asked to fill in the knowledge questionnaire a second time after two weeks for reliability testing. Patients will be recruited to represent all stages of diagnosis and all patient age groups. This will be done by recruitment of six main participant groups stratified by age (18-23 years, 24-36 years, 42-52 years, 53-70 years) and disease duration (<1 year since diagnosis, ≥1 year since diagnosis)"
32728370|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
32728371|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
32728372|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
32728373|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
32728374|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
32728375|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
32728376|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
32728377|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
32728378|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
32728379|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
32728380|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
32768862|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
32768863|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
32768864|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
32728381|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
32728382|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
32728383|NCT04708327|Placebo Comparator|Placebo|Dosing Period 1: Placebo (five capsules) Dosing Period 2: Placebo (one capsule)
32728384|NCT04708327|Experimental|STAT-205|Dosing Period 1: 22.5 mg STAT-205 (five 4.5 mg capsules) Dosing Period 2: 4.5 mg STAT-205 (one capsule)
32728385|NCT04651361|Active Comparator|Naldebain group|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
32728386|NCT04651361|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
32728387|NCT04439409||Patients with Cluster Headache (CH)|Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.
32728388|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
33251608|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
33251609|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
32728389|NCT05188053|Experimental|HTX-011 Treatment Group|Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia
32728390|NCT05188053|Active Comparator|Standard Block Control Group|Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia
33251610|NCT00889941|Active Comparator|small|
33251611|NCT00889941|Active Comparator|medium|
33251612|NCT00889941|Active Comparator|large|
33251613|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
33251614|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
33251615|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
33251616|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
33251617|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
33251618|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
33251619|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
32728391|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
32728392|NCT03396965|No Intervention|Standard|
32728393|NCT05193721|Experimental|Treatment group|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
32728394|NCT05184309|Experimental|Conventional exercise group|Conventional Exercises
33251620|NCT04018131|Active Comparator|Cimetidine|
33251621|NCT04018131|Placebo Comparator|Placebo|
33251622|NCT00767052|Experimental|Active|AZD1236 tablet
33251623|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
33251624|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
33251625|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
33251626|NCT00973882|Experimental|Carboplatin-Etoposide|
33251627|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
33251628|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
33251629|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
33251630|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33251631|NCT05278455|Experimental|Lifestyle Medicine Group|Lifestyle medicine smartphone app The lifestyle medicine app contains eight weekly modules that cover healthy eating, exercise, stress management, sleep management, lifestyle psychoeducation, and goal setting.
32728395|NCT05184309|Experimental|Serious game group|Serious Games
32768865|NCT03100435|No Intervention|No Treatment|No treatment (control)
32728396|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
32728397|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
32930704|NCT04332185|Experimental|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
32930705|NCT04846764|Active Comparator|Healthy volunteers|"60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
33251632|NCT05278455|No Intervention|Waitlist Control Group|The waitlist control group will receive access to the lifestyle medicine app at the end of the study.
33251633|NCT02558088|Experimental|salmeterol|
32728398|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
32728399|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
32728400|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
32728401|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
32728402|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
32728403|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
32728404|NCT05110807|Experimental|TQB3617|0.1mg, once daily, was used as the initial dose, and the medication stage was divided into single administration and continuous administration stages. The single administration was given once, and the continuous administration stage was entered 7 days after drug withdrawal. The drug was administered continuously until the disease progressed.
32728405|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
32728406|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
32728407|NCT04566965||Full-Time CCHMC Employees|All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
32728408|NCT04353765||cabozantinib arm|
33251634|NCT05279482||group treated with standard dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
33251635|NCT05279482||group treated with mega dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
32728409|NCT04353765||non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm|
32728410|NCT03410069|Experimental|IKORUS UP|
32728411|NCT04010097|Experimental|Horton group|The test involves chewing a chewing gum for 4 minutes plus a standard Horton disease diagnostic
32728412|NCT04010097|Active Comparator|N Horton Group|The test involves chewing a chewing gum for 4 minutes
32728413|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
32728414|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
32728415|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
32728416|NCT04533581|Experimental|ME-401|
32728417|NCT03268473|Experimental|Experimental: Non-surgical periodontal therapy|"Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months~Intervention: Procedure: Non-surgical periodontal therapy"
32728418|NCT03268473|Active Comparator|Delayed non-surgical periodontal therapy|No periodontal treatment for 3 months
32728419|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
32728420|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
32728421|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
32728422|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
32728423|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
32728424|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
32728425|NCT03397303|Other|controls|
32728426|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
32728427|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
32728428|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
32728429|NCT04512989||Patients undergoing cardiac surgery|
32728430|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
32728431|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
32728432|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
32728433|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
32728434|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
32728435|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
32728436|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
32728437|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
33251636|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
33251637|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
32728438|NCT04504097|Experimental|HIV self-testing + m-Health|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics. We will provide a 24-hour contact number to text, managed through WelTel system that will flag these messages in real-time. Participants will also receive a weekly bidirectional SMS hosted by WelTel to check how they are.
32728439|NCT04504097|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics
32728440|NCT04504097|No Intervention|Standard of Care|Participants will receive information about HIV testing, care and support services at MARPI clinics and provide a pamphlet of information about HIV & HIV prevention strategies.
32728441|NCT05161429||DPP4|Patients receiving second line diabetes treatment with dipeptidyl peptidase-4 inhibitors (DPP4) following metformin
32728442|NCT05161429||GLP1-RA|Patients receiving second line diabetes treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) following metformin
32728443|NCT05161429||Basal insulin|Patients receiving second line diabetes treatment with basal insulin following metformin
32728444|NCT05161429||SLGT2|Patients receiving second line diabetes treatment with sodium-glucose cotransporter-2 inhibitors (SLGT2) following metformin
32728445|NCT05161429||SU|Patients receiving second line diabetes treatment with sulfonylureas (SU) following metformin
32728446|NCT03984045|Experimental|SPG block|SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min
32728447|NCT03984045|Active Comparator|Control|Delivered through IV access obtained in all patients.
32728448|NCT05154799|Experimental|Dyspraxic children|Children with Developmental coordination disorder
32728449|NCT05154799|Experimental|Control children|Healthy children
33251638|NCT00767130||1|receiving atorvastatin
32728450|NCT05154799|Experimental|Dyspraxic adults|Adults with with Developmental coordination disorder
33251639|NCT00767130||2|receiving simvastatin
33251640|NCT00767130||3|receiving rosuvastatin
32728451|NCT05154799|Experimental|Control adults|Control adults
32728452|NCT03895359|Active Comparator|Transarterial Chemoembolization (TACE)|Transarterial Chemoembolization (TACE)
32728453|NCT03895359|Active Comparator|TACE Plus Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT)
32728454|NCT05134753|Experimental|Study arm|Patients will undergo sinus augmentation with advanced PRF
32728455|NCT05134753|Placebo Comparator|Controlled arm|Patients will undergo sinus augmentation with PRF
32728456|NCT03661047|Active Comparator|Omega-3 treatment|Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
32728457|NCT03661047|Placebo Comparator|Placebo|Identical placebo
32728458|NCT05125861|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice within 6 to 24 hours from thrombolysis.
32906834|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
32906835|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
32906836|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
32906837|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
32906838|NCT05517083|Experimental|Ultrathin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure for EGFR mutation (including T790M positivity) evaluation.
32906839|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
32906840|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
32906841|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
32906842|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
32906843|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
32906844|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
32728459|NCT05125861|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis.
32728460|NCT05060991|Experimental|Immunosuppression reduction|Reduction of immunosuppression before and after administration of a third dose of SARS-CoV-2 mRNA vaccine
33251641|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
33251642|NCT00767208|Experimental|type 2 diabetic subjects|
33251643|NCT00767208|Experimental|overweight healthy subjects|
33251644|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
32728461|NCT05060991|No Intervention|Standard of care|No change to immunosuppression before or after receipt of a third dose of SARS-Co-2 mRNA vaccine
32930706|NCT04846764|Experimental|Patients with neurological diseases of the central nervous system|"36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
33251645|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
33251646|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
33251647|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
33251648|NCT00760422||With fever|
33251649|NCT00760422||Without fever|
33251650|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
33251651|NCT00760500||1|
33251652|NCT00545818|Experimental|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
32930707|NCT05026008|Experimental|SR1375 Capsule|Ascending single and multiple doses of SR1375 capsules orally
33251653|NCT00545818|Other|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
33251654|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
33251655|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
33251656|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
33251657|NCT04048980|No Intervention|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
33251658|NCT04048980|Experimental|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
32930708|NCT05026008|Experimental|Matching placebo|Ascending single and multiple doses of placebo capsules orally
32930709|NCT05172960|Experimental|TAVR - Main Cohort|Subjects will undergo transcatheter aortic valve replacement (TAVR)
33251659|NCT00966628|Active Comparator|Ringer's lactate|
33251660|NCT00966628|Experimental|Hypertonic sodium lactate|
33251661|NCT05259774|Experimental|Relizema cream|Relizema cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
33251662|NCT05259774|No Intervention|Vehicle|Cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
33251663|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
33251664|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
33251665|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
33251666|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
33251667|NCT05208762|Experimental|SGN-PDL1V|SGN-PDL1V monotherapy
33251668|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33251669|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33251670|NCT00763776|Other|1|Liver transection by clamp crushing technique
33251671|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
33251672|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
33251673|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
33251674|NCT00763932|Experimental|1|
33251675|NCT00890331|Active Comparator|Diabetes Education|
33251676|NCT00890331|Experimental|TeamWork CS Sessions|
33251677|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
33251678|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
33251679|NCT00767442||1|Health volunteer
33251680|NCT00767442||2|Patient with suspected oral mucosa lesion
33251681|NCT00974272|Experimental|Exenatide|
33251682|NCT00974272|Placebo Comparator|Placebo|
33251683|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
33251684|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
32728462|NCT05115253|Experimental|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one online behavioural counselling session and daily personalized SMS text message boosters with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of an action plan and the development of coping strategies to increase sedentary behaviour breaks. The SMS text message boosters will be personalized based on participant's preferences of timing, type, frequency, and length. The boosters will framed through HAPA principles with content focusing on risk awareness, outcome expectancy, action and coping planning, barriers and resources, and self-efficacy. The intervention will last for three weeks.
32728463|NCT05115253|Experimental|JITAI Group|This intervention group will receive push notifications from a EMA behaviour monitoring mobile application that will be downloaded to each participants' mobile phones. The application will measure and monitor a participant's sedentary behaviour and once a pre-set condition of 30 consecutive sedentary minutes has been reached, the application will administer a push notification notifying the participant to break their sedentary behaviour. The push notifications will ask the participants to stand up, stretch, or lightly walk around to break their current behaviour. The intervention will last for three weeks.
32728464|NCT05115253|No Intervention|Control Group|The control group will receive no intervention or further instruction past the letter of information.
32728465|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
32728466|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
32728467|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
32728468|NCT03399409|Experimental|Motivational Interviewing|
32728469|NCT03399409|Active Comparator|Anti-inflammatory information program|
32728470|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
32728471|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
32728472|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
32728473|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
32728474|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
32728475|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
32728476|NCT03399097||non-obese|non-obese
32728477|NCT03399097||obese|obese
33251685|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
33251686|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
32728478|NCT03399097||previously obese|previously obese
32728479|NCT03397147|No Intervention|Usual Care|Usual Care
32728480|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
32728481|NCT04498247|Experimental|Panel A|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of 1x10^5 50% tissue culture infectious dose (TCID50) V591 or placebo
32728482|NCT04498247|Experimental|Panel B|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Days 1 and 57) of 1x10^6 TCID50 V591 or placebo
32728483|NCT04498247|Experimental|Panels C, G|Participants in this 18 to 55 year old cohort (Panel C) or >55 year old cohort (Panel G) will receive 1 dose of 1x10^5 TCID50 V591 or placebo.
32728484|NCT04498247|Experimental|Panels D, H|Participants in this 18 to 55 year old cohort (Panel D) or >55 year old cohort (Panel H) will receive 1 dose of 1x10^6 TCID50 V591 or placebo.
32728485|NCT04498247|Experimental|Panel E|Participants in this 18 to 55 year old cohort will receive 1 dose of 1x10^7 V591 or placebo.
32728486|NCT04498247|Experimental|Panel F|Participants in this 18 to 55 year old cohort will receive 2 doses (Days 1 and 169) of V591 or placebo. Day 1 will be 1x10^4 TCID50 V591 or placebo and Day 169 will be 1x10^5 TCID50 V591 or placebo.
32728487|NCT04498247|Experimental|Panel I|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10^5 TCID50 V591 or placebo
32728488|NCT04498247|Experimental|Panel J|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10^6 TCID50 V591 or placebo
32768866|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
32768867|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
32768868|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
32768869|NCT04835051|Other|Breastfeeding promotion|The breastfeeding promotion intervention included training for health workers, interpersonal communication (in person and digital) between providers and pregnant/breastfeeding women, and mass media.
32768870|NCT04835051|No Intervention|Comparison|
32768871|NCT04001101|Active Comparator|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.~Pembrolizumab will be given as standard of care in both arms"
32768872|NCT04001101|Placebo Comparator|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
32768873|NCT04299893|Experimental|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.~Other Names: O3"
33251687|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
32728489|NCT04498247|Experimental|Panel K|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10^5 TCID50 V591 or placebo
32728490|NCT04498247|Experimental|Panel L|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10^6 TCID50 V591 or placebo
32728491|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
32728492|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
32728493|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
32728494|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
32728495|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
32728496|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
32728497|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
32728498|NCT03405623|Active Comparator|Conventional long-axis|
32728499|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
32728500|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
32728501|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
32728502|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
32728503|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
32728504|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
32728505|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
32728506|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
32728507|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
32728508|NCT03399019|Active Comparator|Propofol|"Propofol~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
33251688|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
33251689|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
33251690|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
32930710|NCT05172960|Experimental|TAVR - Bicuspid Registry|Subjects with bicuspid aortic valve morphology will undergo TAVR
32930711|NCT04160546|Experimental|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
32930712|NCT03675581|Experimental|All subjects|
32930713|NCT05157438|Experimental|Group I (virtual reality group)|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, the system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment.
32930714|NCT05157438|Active Comparator|Group II (screen program group).|the screens shows such as cartoons, animation movies or recorded video games are used for distraction during dental treatments. They could be seen on tablets, iPads or LCD screen.
32930715|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
32930716|NCT05142228|Active Comparator|Erenumab-aooe|"Erenumab-aooe 140 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
32930717|NCT05142228|Placebo Comparator|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 andvisit 3 for a total of 3 cycles.~Other name: Placebo"
32930718|NCT04154540|Experimental|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
32930719|NCT04154540|Experimental|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
32930720|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
32930721|NCT03821636|Sham Comparator|Standard Roux-en-Y|
32930722|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
32930723|NCT05122026|Experimental|Arm 1: One month of daily isoniazid and rifapentine (4 weeks)|"DTG 50 mg orally BID~DTG 50 mg + 2 NRTI each morning (non-study)~2nd dose: DTG 50 mg each evening (during 1HP)~1HP: INH 300 mg + RPT 600 mg each morning for 4 weeks"
32930724|NCT05122026|Experimental|Arm 2: Three months of once-weekly isoniazid and rifapentine (12 weeks)|"DTG 50 mg orally BID~DTG 50 mg + 2 NRTI each morning (non-study)~2nd dose: DTG 50 mg each evening (during 3HP)~3HP: INH 900 mg + RPT 900 mg each week for 12 weeks"
32930725|NCT04658498|Experimental|Usual Care (UC)|Intermittent spontaneous breathing periods
32930726|NCT04658498|Experimental|UC + High-intensity inspiratory muscle training (HI-IMT)|
32930727|NCT04658498|Experimental|UC + Low-intensity inspiratory muscle training (LI-IMT) (sham IMT)|
32930728|NCT04655430|Experimental|3-second SDF application|3-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930729|NCT04655430|Experimental|5-second SDF application|5-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930730|NCT04655430|Experimental|10-second SDF application|10-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930731|NCT04655430|Experimental|15-second SDF application|15-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930732|NCT04655430|Experimental|30-second SDF application|30-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930733|NCT04655430|Experimental|45-second SDF application|45-second application time of silver diamine fluoride (38% SDF) in arresting tooth decay (dental caries) in the primary teeth of preschool children.
32930734|NCT04655430|Experimental|60-second SDF application|60-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930735|NCT04655430|Experimental|120-second SDF application|120-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930736|NCT04655430|Experimental|180-second application time|180-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
32930737|NCT04651296|Experimental|compassion meditation|10 week, group-based manualized compassion meditation training
32930738|NCT04651296|Active Comparator|health education|10 week, group-based manualized health education protocol
32930739|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
32930740|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
32930741|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
32930742|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
32930743|NCT04154384|Experimental|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse. Participants will be followed for one year post operation. An official pain management protocol will be developed during the pilot portion of this study.
33251691|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
33251692|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
33251693|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
33251694|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
33251695|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
32768874|NCT04299893|Placebo Comparator|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.~Other Names: O2"
32768875|NCT05066581|No Intervention|Philips band|It is a medical device that collects, among other things, movement data by means of an accelerometer, from which it accelerometer, from which it estimates the total time of sleep (TTS) and wakefulness, and waking time, also offering the efficiency of the same (time asleep in relation to time in bed). time in bed). In addition, it collects data not related to sleep, such as energy expenditure (in kilocalories), energy expenditure (in kilocalories) (in kilocalories), heart rate, and daily activity (in steps), among others.
32930744|NCT04154384|Experimental|Life Care Specialist (LCS) Intervention|In addition to receiving current standard-of-care for pain management in the aftermath of trauma, participants will have the full communication of opioid risk - via the validated Opioid Risk Tool (ORT) and a detailed substance abuse and mental health screening. As part of the daily LCS intervention, the inpatients will engage in behavioral pain management, opioid education and harm-reduction strategies (naloxone education), while also being screened for eligibility for respective referrals for complex needs, such as mental health and substance use disorders. Upon discharge, each participant will be educated by the LCS on future available modes of contact (telephone, email, video-call, follow up- visits at 2-, 6- and 12-weeks).
32930745|NCT04154384|Active Comparator|Standard of Care with Clinical Coordination|Participants will receive the current standard-of-care for pain management in the aftermath of trauma, including a standardized prescription protocol, and hospital-system approved discharge instructions which provide written instruction on how to taper opioid use and links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
32930746|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
32930747|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
32930748|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
32930749|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
32930750|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
32930751|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
32930752|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
32930753|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
32930754|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
32930755|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
32930756|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
32930757|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
32930758|NCT05114460|Placebo Comparator|Naloxone 0 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana
32930759|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana
32930760|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
32930761|NCT05114460|Active Comparator|Naloxone 4 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
32930762|NCT05114460|Experimental|Naloxone 4 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
32930763|NCT05114460|Experimental|Naloxone 4 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
32930764|NCT04844814|Experimental|Anakinra|Anakinra 100 mg/d+Placebo of Prednisone
32930765|NCT04844814|Active Comparator|Prednisone|Prednisone 30 mg/d+Placebo of Anakinra
32930766|NCT04833270|Experimental|KM non-pharmacological treatment group|Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
32930767|NCT04833270|Active Comparator|Pharmacological treatment group|Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
32930768|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
32930769|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
32930770|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
33251696|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
32930771|NCT05011656|Experimental|1- Seraph-100 plus State of the Art Care|The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
32930772|NCT05011656|Active Comparator|2 - State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
32930773|NCT04652726|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
32930774|NCT04652726|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
33251697|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
33251698|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
32930775|NCT04833114|Experimental|Experimental Arm: Pola-R-ICE|combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application
32728509|NCT03399019|Active Comparator|Midazolam|"Midazolam~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
32930776|NCT04833114|Active Comparator|Standard Arm: R-ICE|conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)
32930777|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
32930778|NCT04651868|Experimental|CCK + GLP-2|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
32930779|NCT04651868|Experimental|CCK + placebo|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with isotonic NaCl
32930780|NCT04651868|Experimental|Placebo + GLP-2|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
32930781|NCT04651868|Experimental|Placebo + placebo|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl
32930782|NCT05356416|Experimental|Ischemic compression|Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds.
32930783|NCT05356416|Active Comparator|Dry Needling|Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses.
32930784|NCT04734587||Chronic Total Occlusion|Chronic total occlusion patients undergoing percutaneous coronary intervention.
32930785|NCT04734587||Non-Chronic Total Occlusion|Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
32930786|NCT04651010|Experimental|Multimodal MRI|
32930787|NCT04195308|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
32930788|NCT04195308|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
32930789|NCT05314673|Active Comparator|Preoperative intralesional injection of bevacizumab + pterygium excision+ autograft|Patients receiving intralesional injection of 0.05 ml (1.25 mg) of Bevacizumab, one month before surgical treatment. Surgical treatment consisted of lesion excision and conjunctival autograft performed by a single trained surgeon.
32930790|NCT05314673|Active Comparator|pterygium excision+ autograft|Patients undergoing only pterygium surgical treatment.
32930791|NCT04634318|Active Comparator|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
32930792|NCT04634318|Experimental|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
32930793|NCT05314595|Experimental|modified technique|women were underwent modified technique (PPC+ bilateral uterine artery ligation)
32930794|NCT04190550|Experimental|Treatment (navtemadlin, cytarabine, idarubicin)|Patients receive navtemadlin PO QD on days 1-7, cytarabine IV BID over 3 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of navtemadlin, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
32930795|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
32930796|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
32930797|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
32930798|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
32930799|NCT04633304|Other|AVF|Single arm study using primary and secondary end points as comperators between subjects.
32728510|NCT04452383|Active Comparator|propofol (P)|patients will receive only propofol intravenous for sedation
32728511|NCT04452383|Active Comparator|propofol ketamine (pk)|patients will receive ketamine in addition to propofol intravenous for sedation
32930800|NCT04823208|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
32930801|NCT04823208|Placebo Comparator|Placebo|Placebo administered SC
32930802|NCT04419636|Experimental|Part A Single doses|Lu AG06466 in fast and fed state
32930803|NCT04419636|Experimental|Part B Repeated doses|Lu AG06466 after light meal
32930804|NCT05440292|Experimental|Hotspot-rTMS Group|rTMS stimulate on the hotspot of unaffected hemisphere
32930805|NCT05440292|Experimental|fMRI-rTMS Group|rTMS stimulate on the motor task activation poin (targeted by fMRI) of unaffected hemisphere
32930806|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
32930807|NCT04823130|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 2 weeks (Q2W).
32930808|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
32930809|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
32930810|NCT04622046|Experimental|ALXN2060|Participants will receive ALXN2060.
32930811|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
32930812|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
32930813|NCT04603482|Experimental|Self-Management|
32930814|NCT04603482|Active Comparator|Attention Control Condition|
32930815|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
32930816|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
32930817|NCT03785210|Experimental|1/Arm 1|Nivolumab, tadalafil and oral vancomycin
32930818|NCT04990596||Age Group 50 to 59|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
32930819|NCT04990596||Age Group 60 to 69|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
32930820|NCT04990596||Age Group 70 to 79|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
32930821|NCT04990596||Age Group 80 to 89|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
32930822|NCT04990596||Age Group 90 to 100|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
32930823|NCT04617080|Active Comparator|SUPRACOR Regular|
32930824|NCT04617080|Experimental|SUPRACOR Strong|
32930825|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
32930826|NCT04583514|Experimental|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
32930827|NCT04583514|Experimental|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
32930828|NCT04744922|Experimental|Auraptene and Naringenin Arm|One capsule a day for 9 months
33251699|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
33251700|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
32930829|NCT04744922|Placebo Comparator|Control Arm|One capsule a day for 9 months
32930830|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
32930831|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
32930832|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
32930833|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
32930834|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
33251701|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
33251702|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
33251703|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
33251704|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
33251705|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
32728512|NCT05036941|Experimental|Arm 1|Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community)
32728513|NCT05036941|Active Comparator|Arm 2|Standard system (standard N95 masks during shifts+ fabric masks in community)
32728514|NCT04447547|Experimental|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
32728515|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
32930835|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
32930836|NCT05350410|Experimental|HALT-AD|"This arm includes cognitively normal midlife and older-adult participants with the following inclusion criteria:~Signed informed consent must be obtained and documented (from the participant)~Sufficient proficiency in English or Spanish to undergo clinical assessment and participate~Ages 50-85~Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22~Technical ability to participate~Sufficient vision and hearing to participate~Ability to sit comfortably for a period of at least 30 minutes~A total of 20 participants will be enrolled at UCSD~10 will complete the English version~10 will complete the Spanish version~Aim is to recruit 50% women and to enroll a diverse participant sample across varied age ranges within both language groups."
32930837|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
32930838|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
32930839|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
32930840|NCT04832100||Patients with primary fibromyalgia|Adults with complaints of chronic widespread pain at the outpatient department of KMUH were consecutively enrolled over a 5-year period from July 2017 to June 2022. Participants were interviewed by experienced neurologists , and those who fulfilled the 2011 American College of Rheumatology (ACR) criteria for FM were recruited .
32930841|NCT04832100||Healthy controls|Age- and sex-matched subjects without pain and soreness were also prospectively recruited as healthy controls.
32728516|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
32728517|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
32930842|NCT04106492|Experimental|Dose Escalation Cohort (10 mL SQL70)|Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
32930843|NCT04106492|Experimental|Dose Escalation Cohort (20 mL SQL70)|Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
32930844|NCT04106492|Experimental|Cohort A|Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive a lower dose than RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
32930845|NCT04106492|Experimental|Phase 2a Expansion Group 1 (Extremity STS)|Participants with soft tissue sarcomas of the extremity AJCC Stage III OR IV (>5 cm injectable tumors locally advanced and or metastatic, not amendable to primary surgical intervention and who are anthracycline naïve.
33251706|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
32930846|NCT04106492|Experimental|Phase 2a Expansion Group 2 (Unresectable STS)|Locally advanced, unresectable or metastatic, soft tissue sarcomas who are anthracycline naïve.
32930847|NCT04106492|Experimental|Phase 2a Expansion Group 3a (Head and Neck)|Participants with histologically or cytologically confirmed relapsed or metastatic squamous-cell carcinoma of the head and neck, who have exhausted curative intent therapies or patients with distant metastases who may have received one or less chemotherapy regimen.
33251707|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
33251708|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
32930848|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
32930849|NCT04100720|Experimental|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
32930850|NCT02976272||patients with myeloma multiple|
32930851|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
33251709|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
33251710|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
33251711|NCT05227300|Experimental|Buffered 2% lidocaine with 1:100,000 epinephrine|Buffered local anesthetic (addition of sodium bicarbonate to make a 10% buffered solution)
33251712|NCT05227300|Active Comparator|Unbuffered 2% lidocaine with 1:100,000 epinephrine|Standard local anesthetic
33251713|NCT00890487|Other|hyaluroni acid pill|
33251714|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
32930852|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
32930853|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
33251715|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
33251716|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
33251717|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
33251718|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
33251719|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
33251720|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
33251721|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
33251722|NCT00890643|Experimental|Arm 1|Persons with PTSD
33251723|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
33251724|NCT00893217|Active Comparator|Arm 1|
33251725|NCT00893217|Experimental|Arm 2|
33251726|NCT00767598|Active Comparator|A|Vardenafil
33251727|NCT00767598|Active Comparator|B|Sildenafil
33251728|NCT00767598|Active Comparator|C|Udenafil
33251729|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
33251730|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
33251731|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
33251732|NCT00764166|Experimental|1|
33251733|NCT00764166|Active Comparator|2|
33251734|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
33251735|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
33251736|NCT00767754|Other|paroxetine cr|single arm
32930854|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
32930855|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
32930856|NCT00361790|Other|1|
32930857|NCT04570332|Experimental|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles.
32930858|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
32930859|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
32930860|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
32930861|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
32930862|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
32930863|NCT04821102|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
32930864|NCT04821102|Placebo Comparator|Saline|saline
32930872|NCT04143438|Experimental|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
32930873|NCT00361868|Experimental|1|
32930874|NCT00361868|Active Comparator|2|
32930875|NCT04131738|Experimental|Baricitinib 2 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100~After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
32930876|NCT04131738|Experimental|Baricitinib 4 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100~After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
32930877|NCT04990362|Experimental|MD + Seed oil|"Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol~Intervention:~Mediterranean diet, Pomegranate oil"
32930878|NCT04990362|Active Comparator|MD|Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet
32930879|NCT04564872|Experimental|HSK7653 10 mg|
32930880|NCT04564872|Experimental|HSK7653 25 mg|
32930881|NCT04564872|Active Comparator|Linagliptin 5 mg|
32930882|NCT04079348|Active Comparator|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
32930883|NCT04079348|Active Comparator|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
32930884|NCT05416554|Other|Neuropsychological testing|Participants will take neuropsychological testing in-person or via telehealth video
32930885|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
32930886|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
32930887|NCT04343144|Experimental|Nivolumab|
32930888|NCT04343144|No Intervention|Standard of Card|
32728518|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
32930889|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
32930890|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
32728519|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
32728520|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
32728521|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
32930891|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
32930892|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
32930893|NCT05415696|Other|Prostatic artery embolization (PAE)|Study participants will be treated with a single PAE procedure performed with Embosphere microspheres.
32930894|NCT04581512|Experimental|EP0042|
32930895|NCT04579094||1/elderly dependent persons|
32930896|NCT04579094||2/healthcare workers (HCW)|
32930897|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
32930898|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
32930899|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
32930900|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
32930901|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
32930902|NCT05346666|Active Comparator|Control Group|Group 1 received the conventional treatment for Status Epilepticus including propofol (loading dose is 3 to 5 mg/kg with maintenance of 1 to 15 mg/kg/h), phenobarbital (initial loading dose is 5 to 15 mg/kg over 1 hour. Infusion rates can be maintained at 0.5 to 15 mg/kg/h), and midazolam (a loading dose of 0.2 mg/kg is given with maintenance doses ranging between 0.05 and 2.0 mg/kg/h).
32930903|NCT05346666|Experimental|Tocilizumab Group|Group 2 received the same treatment in group 1 in addition to tocilizumab that was initiated at a dose of 4mg/kg administered twice monthly with 1-week intervals for 3 months. A monthly dose (8mg/kg) of tocilizumab was added if needed.
32930904|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
32930905|NCT04549974|Experimental|Passive heat exposure|
32930906|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
32930907|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
32930908|NCT05413278|Other|Training|Patient education, empowerment, and information
32930909|NCT03669146|Experimental|Hyperopic subjects receiving glasses|Randomized +5.00 to +7.00 diopter hyperopic subjects that will receive partial refractive correction and will be instructed to do accommodation exercises on a daily basis.
32930910|NCT03669146|No Intervention|Hyperopic subjects uncorrected|Randomized +5.00 to +7.00 diopter hyperopic subjects that will serve as the control to the experimental arm who will receive no correction but be observed for the duration of the study.
32930911|NCT03669146|Active Comparator|Highly hyperopic subjects corrected|If a subject is found to be greater than +7.00 diopters hyperopic during the screening phase of the study, they will receive glasses correction and be followed during the study period.
32930912|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
32930913|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
32930914|NCT03421184|Active Comparator|Healthy control|30 healthy control women
32930915|NCT04842864|Experimental|Young|10 healthy men and women 18-35 yo.
32930916|NCT04842864|Active Comparator|Older adults|10 healthy men and women 65-85 yo
32930917|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
32930918|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
32930919|NCT05369364|Experimental|Zanubrutinib and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and Zanubrutinib 80mg qd po, 6 consecutive weeks
33251737|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
33251738|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
32728522|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
32930920|NCT05369364|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
32930921|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
32930922|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
32930923|NCT04542642|Active Comparator|reSET-O|Prescription Digital therapeutic
32930924|NCT04542642|Experimental|PEAR-008|Investigational Digital Therapeutic
32930925|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
32930926|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
32930927|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
32930928|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
32930929|NCT05344326|Experimental|CAT-GSH|Participants, who provide informed consent, will be provided an assessment session, six fortnightly CAT-GSH sessions, and one follow-up session.
32930930|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
32930931|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
32930932|NCT04532034|Experimental|Peer-Delivered Decision Support Intervention|
32930933|NCT04067232|Experimental|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
32930934|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
32930935|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
32930936|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
32930937|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
32930938|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
32930939|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
32930940|NCT05293860|Experimental|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
32930941|NCT05293860|Placebo Comparator|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
32930942|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
32930943|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
32930944|NCT04968522|Placebo Comparator|Placebo comparator 2|Participants will be allocated a randomly allocated sequence of treatment. The randomisation will be in two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle (over 8 weeks). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (8 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
32930945|NCT04968522|Experimental|Stimulant|"The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 8-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:~Methylphenidate IR~Methylphenidate LA~Dexamphetamine~Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules)."
32930946|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
32930947|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
32930948|NCT04047810|Experimental|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
32930949|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
32930950|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
32930951|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
32930952|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
32930953|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Treatment Period 1: On Day 1, a single oral dose of 80 milligrams (mg) LY2140023 (parent compound) followed by a single 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) [14C]-LY2140023.
32930954|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Treatment Period 2: On Day 1, a single oral dose of 80 mg LY2140023 (parent compound) followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039 (active metabolite).
32768876|NCT05066581|Active Comparator|Philips Band + Live chat|In the Intervention group, in addition to having the philips band, the subjects will interact through the live chat system that they will have to download to their mobile phones. This live chat offers the possibility to consult in real time, thus initiating a process of relationship between researcher/subject.
32930955|NCT04055519|Other|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
32930956|NCT04055519|Other|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
32930957|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
32930958|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
32930959|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
32930960|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
32930961|NCT04539392||Infertile couple|
32768877|NCT04834895|Active Comparator|mhealth exercise group|home exercise program is given to patients via mobile application
33251739|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
33251740|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
33251741|NCT00764244|Active Comparator|1|Vitrectomy
33251742|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
32930962|NCT04831944|Experimental|Treatment Group 1 : Severe hepatic impairment|Child Pugh (CP) assessment score of 10-14 points
32930963|NCT04831944|Experimental|Treatment Group 2 : Moderate hepatic impairment|Child Pugh (CP) assessment score of 7-9 points
32930964|NCT04831944|Experimental|Treatment Group 3 : Mild hepatic impairment|Child Pugh (CP) assessment score of 5-6 points
32930965|NCT04831944|Experimental|Treatment Group 4 : Normal hepatic impairment|Normal hepatic function
33251743|NCT00764244|Active Comparator|3|Laser photocoagulation
32930966|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
32930967|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
32930968|NCT05411406||Study cohort|Patients undergoing ENT or OMS surgery with general anesthesia with facemask ventilation and tracheal intubation (observational)
32930969|NCT04526340|Experimental|Nutrient day|on the nutrient day the subjects will take the testing food/nutrient capsules with 500 ml water
32930970|NCT04526340|Placebo Comparator|Control day|on the control day the subjects will take 500 ml water without nutrient/food capsules
32930971|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
32930972|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
32930973|NCT04523142|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
32930974|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
32930975|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
32930976|NCT04819152||Exposed|Several studies will be performed based on this cohort. I each study the exposed group will be a group of tobacco users evaluatedin the relevant study. This could be a vulnarable group tobacco users such as: users without a job, with short or no education, without permanent housing, diagnosed with mental illness, diagnosed with chronic obstructive pulmonary disease (COPD), undergoing surgery, adolescents, elderly, migrants, or pregnant women.
32930977|NCT04819152||Unexposed|In each study the unexposed group will consist of tobacco user from the study cohort without the condition examined in the relevant study.
32930978|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
32930979|NCT04537520|Experimental|Experimental Group|treatment with the device Kerecis Omega3 Wound
32930980|NCT04537520|No Intervention|Control Group|treatment with SOC treatment
32930981|NCT05339958|Experimental|Nutraceutical Dietary Supplement Capsule|The nutraceutical capsules are comprised of standardized, natural, medical-grade ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
32930982|NCT05339958|Placebo Comparator|Placebo Capsule|The placebo capsules contain no active ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
32930983|NCT04527380|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
32930984|NCT04527380|Active Comparator|Adalimumab|Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
32930985|NCT04957368|Experimental|Nitrous Oxide + saline solution|
32930986|NCT04957368|Active Comparator|Oxygen + Midazolam|
32930987|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
32930988|NCT04818450|Experimental|Gabapentin|Start gabapentin 100 mg at 9.00 PM on the second night of ICU admission and titrate gabapentin dose as needed. Maximum gabapentin dose in this study is 300 mg/day.
32930989|NCT04818450|No Intervention|Standard care|Not receiving gabapentin.
32930990|NCT04841148|Experimental|HCQ|Patients will receive HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
32930991|NCT04841148|Experimental|Avelumab|Patients will receive Avelumab, 10 mg/kg, IV, D1 and D15 of each 28-day cycle.
32930992|NCT04841148|Experimental|Palbociclib and Avelumab|Patients will receive Palbociclib 125 mg daily, by mouth on D1-21 concurrently with Avelumab, 10 mg/kg IV on D1 and D15 of each 28-day cycle
33251744|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
33251745|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
33251746|NCT00764400|Experimental|Errorless Naming Treatment|
33251747|NCT00764400|Experimental|Verbal+Gestural Facilitation|
32728523|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
32728524|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
33400979|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
33400980|NCT04672291|Experimental|Safety Cohort|A randomized (4:1) initial safety cohort of 13 patients will receive 2 cycles of drug (N=10) or placebo (N=3)
33400981|NCT04672291|Experimental|Expansion Cohort|A randomized (4:1) expansion cohort will receive 3 cycles of drug (N=24) or placebo (N=6). A total of 30 patients will be accrued.
33400982|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
32728525|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
32728526|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
32768878|NCT04834895|Experimental|brochure exercise group|home exercise program is given to patients via brochure
32930993|NCT04841148|Experimental|Palbociclib and HCQ|Patients will receive Palbociclib 75 mg daily, by mouth on D1-28 concurrently with HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
32930994|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
32930995|NCT04035161|Experimental|Investigational Product|Skin will be prepared with investigational product
32930996|NCT04035161|Other|Reference Standard|Skin will be prepared with reference standard
32930997|NCT04035161|Active Comparator|Active Control|Skin will be prepared with active comparator
32930998|NCT04035161|Other|Negative Control|Skin will be prepared with negative control
32930999|NCT04830462|Other|LTBI and DM|Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
32931000|NCT04830462|Other|LTBI without DM|Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
32931002|NCT05369286|Experimental|dose level 1 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
32931003|NCT05369286|Experimental|dose level 2 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
32931004|NCT05369286|Experimental|dose level 2 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
32931005|NCT05369286|Experimental|dose level 3 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
32931006|NCT05369286|Experimental|recommend dose of max-40279 combined recommend dose level of toripalimab|"MAX-40279-01 and toripalimab"
32931007|NCT03603002|Experimental|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
32931008|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
32931009|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
32931010|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
32931011|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
32931012|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
32931013|NCT04493502|Experimental|LY3041658|LY3041658 given intravenously (IV).
32931014|NCT04493502|Placebo Comparator|Placebo|Placebo given IV. Participants will switch to LY3041658 given IV after week 16.
32931015|NCT04508192|Experimental|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
33251748|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
32728527|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE~ZSP1601 50 mg/Placebo for 14 Days."
32728528|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.~ZSP1601 100 mg/Placebo for 14 Days."
32728529|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
32931016|NCT04508192|Active Comparator|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
32931017|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
32728530|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
32931018|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
32931019|NCT04829760|Experimental|Psyllium|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to at least 8 ounces (240 mL) of cold water or a beverage that is typically consumed. Participants will ingest the intervention each morning and evening for eight weeks.
32931020|NCT04829760|Experimental|Coarse wheat bran|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to a food they normally eat.
32931021|NCT04829760|Placebo Comparator|Maltodextrin|Volume equivalent to the psyllium. Participants will be instructed to divide the daily dose into 2 doses and ingest by adding the product to a food or to 8 ounces (240 mL) of a beverage that is typically consumed.
32931022|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
32931023|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
32931024|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
32931025|NCT05289804|Experimental|Active NITESGON|One electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task.
32931026|NCT05289804|Sham Comparator|Sham NITESGON|For sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
32931027|NCT05289804|Active Comparator|Active NITESGON + local anesthesia|For active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied.
32931028|NCT05289804|Active Comparator|Active C5/C6|For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied.
32931029|NCT03719885|Experimental|Intervention|
32931030|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
32931031|NCT04021368|Experimental|RVU120(SEL120)|The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.
32931032|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
32931033|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
32931034|NCT05448872||Sacubitril/Valsartan|Heart Failure (HF) patients treated with Sac/Val
32931035|NCT04817826|Experimental|Cohort 1|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~Patients in Cohort 1 will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed by an active follow-up every 12 weeks for two years and then a standard follow-up every six months until the end of the fifth year from surgery."
32931036|NCT04817826|Experimental|Cohort 2|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~In Cohort 2, patients with no evidence of complete clinical response will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed up. Patients with complete clinical response will undergo a non-operative management (NOM) with an active follow-up phase every 12 weeks for two years, followed by standard follow-up every six months until the end of the fifth year. At any time during follow-up, in case of clinical suspicion or confirmation of residual gastric cancer, patients will undergo standard surgery according to the clinical practice at their Centre."
32931037|NCT04909710|Experimental|Autism Case Group|Autistic participants will receive mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
32728531|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
32728532|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
32728533|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
32728534|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
32728535|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
32728536|NCT05002153|Experimental|Fecal Microbiota Transplantation (FMT)|FMT capsules administration - intervention arm
32728537|NCT05002153|Placebo Comparator|Placebo|Placebo capsules administration
32931038|NCT04909710|Other|Neurotypical Sibling Control Group|Neurotypical control participants will receive the same mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
32728538|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
32931039|NCT00362726|Active Comparator|A|
32931040|NCT00362726|Active Comparator|B|
32931041|NCT00362726|Active Comparator|C|
32931042|NCT00362726|Active Comparator|D|
32931043|NCT00362726|Active Comparator|E|
32931044|NCT04011774|Experimental|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
32931045|NCT04011774|Active Comparator|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
32931046|NCT04005534|Placebo Comparator|Standard group|Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
32931047|NCT04005534|Experimental|Preemptive group|Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
32931048|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
32931049|NCT04194450|Experimental|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 g/kg body weight)
32931050|NCT04194450|Placebo Comparator|Placebo|Acute dose of flavour-matched placebo.
32931051|NCT05332236||Community sample|Adolescents (10-18 years) and their parents, recruited via schools or online sampling, from the general population
32931052|NCT05332236||At-risk sample|Parents seeking parenting advice in information centres/helplines.
32931053|NCT05332236||Clinical sample|Children and parents are recruited among in- and outpatients at the Clinic for Child and Adolescent Psychiatry of the University Medical Center Hamburg-Eppendorf
32931058|NCT04474470|Experimental|Dose escalation of NT219 as a single agent|
32931059|NCT04474470|Experimental|Dose escalation of NT219 in combination with ERBITUX®|
32931060|NCT04474470|Experimental|Expansion cohort of NT219 in combination with ERBITUX®|
33400983|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
32931062|NCT03530072||Cases|Subjects with Fever and Neutropenia
32931063|NCT04471194|Experimental|Self-Sampling Intervention|Participants in this group will receive cervical and colorectal cancer self-sampling kits, instructions for completing the self-sampling kits, and educational materials about cervical and colorectal cancer.
32931064|NCT04471194|No Intervention|Control|Participants in this group will receive a standardized letter informing them that they are out-of-date for both cervical and colorectal cancer screenings and should schedule an appointment with their provider to receive these screenings.
32931065|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
32931066|NCT04467996|Active Comparator|6 hour IUBT placement|
32931067|NCT04467996|Active Comparator|18 hour IUBT placement|
32931068|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
33400984|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
33400985|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
32931069|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
33251749|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
32931070|NCT05330754||Control group|No caffeine intake
32931071|NCT05330754||Safe level Group|Caffeine daily intake ≤200 mg/day
32931072|NCT05330754||Unsafe level group:|Caffeine daily intake >200 mg/day
33400986|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
32931073|NCT04465344|Experimental|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
32931074|NCT04465344|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
33400987|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
32728539|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
32931075|NCT02374112|Experimental|Experimental|Creatine supplementation
32931076|NCT02374112|Placebo Comparator|Control|Placebo supplementation
32728540|NCT03392701|Placebo Comparator|Placebo|NaCl
32728541|NCT05168189||Ivabradine Group|patients with chronic coronary syndrome using Ivabradine for heart rate control or as anti-anginal treatment.
32728542|NCT05168189||Non-Ivabradine Group|patients with chronic coronary syndrome NOT using Ivabradine for heart rate control or as anti-anginal treatment.
32728543|NCT03398941|Experimental|Combined group|
32728544|NCT05168111||patients of Diquat poisoning|
32728545|NCT05168111||normal persons|
32728546|NCT05000671|Experimental|Cohort 1|Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
32728547|NCT05000671|Experimental|Cohort 2|Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
32728548|NCT04413773|Active Comparator|Treatment as usual|Treatment as Usual, Explanation of standard procedures before, during and after surgery by nurse
32728549|NCT04413773|Experimental|Treatment as usual + Video|Treatment as usual and additionally Video
32728550|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
32728551|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
32728552|NCT05167799||Cardiac Amyloidosis patients|"Patients with established diagnosis of amyloid TTR Cardiomyopathy, baseline ejection fraction ≥25% and ≤45%, at least one hospitalization due to worsening heart failure over the year before entry into the registry.~Already implanted with ICD or PM if needed, fullfilling the indication for CCM implantation."
32728553|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
32728554|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
32728555|NCT04369547|Experimental|Roflumilast|Participants will ingest a capsule containing 250mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
32768879|NCT05066425|Experimental|Soluble Corn Fiber|22g Soluble Corn Fiber/day for 4 weeks
32768880|NCT05066425|Placebo Comparator|Maltodextrin|22g Maltodextrin/day for 4 weeks
32931077|NCT03967158||Consecutive percutaneous coronary intervention|
32931078|NCT03507686|Experimental|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of <6 months, 6-12 months, or >12 months.
32931079|NCT04908774|Experimental|Fasting Mimicking Diet Group|The intervention group follows a fasting mimicking diet for 5 days every 6-8 weeks (a total of 3 times in 5 months).
32931080|NCT04908774|No Intervention|Control Group|This group maintains their individual diet during the whole time of the study. After 6 months they are offered a fasting intervention.
32931081|NCT02317328||Affected participants|Participants with ocular conditions
32931082|NCT02317328||Healthy Volunteers|Healthy volunteers
32931083|NCT04829136|Experimental|Arm I (enteral nutrition)|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
32931084|NCT04829136|Active Comparator|Arm II (standard of care)|Patients receive standard of care nutritional support.
32931085|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
32931086|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
32931087|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
32931088|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
32931089|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
32728556|NCT04369547|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
32728557|NCT03392623|Other|Control group|Macules of melasma without any treatment
33251750|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
32931090|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
32931091|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
32931092|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
33251751|NCT00770796|Placebo Comparator|Placebo|placebo
33251752|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
32931093|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
32931094|NCT03752177|Experimental|LY3415244 Dose Escalation|Participants received 3 milligrams (mg) LY3415244 (Cohort A1), 10 mg LY3415244 (Cohort A2), 30 mg LY3415244 (Cohort A3) and 70 mg LY3415244 (Cohort A4) as an intravenous (IV) infusion on day (D)1 and D15 of each 28-day cycle every 2 weeks (Q2W).
32931095|NCT03752177|Experimental|LY3415244 Dose Expansion|Phase 1b dose expansion was planned but not initiated as dose escalation ended at cohort A4. Study did not achieve its primary objective of establishing a recommended phase 2 dose (RP2D) due to early termination of the study by Cohort A4.
32931096|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
32728558|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
32728559|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
32728560|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
32728561|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
32931097|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
32931098|NCT01601496|Experimental|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
32931099|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
32931100|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
32931101|NCT04839900|Active Comparator|Proactive iCCM|Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
32931102|NCT04839900|No Intervention|Standard Passive iCCM|Community health workers (CHWs) will provide case management per national iCCM policy to all who are brought for consultation, but will not conduct household visits to provide active case detection. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
32931103|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
32931104|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
32931105|NCT04828668|Experimental|Formula C|30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.
32931106|NCT04828668|Placebo Comparator|Placebo|30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.
33251753|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
32931107|NCT04448184|No Intervention|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
32931108|NCT04448184|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
32728562|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
32728563|NCT04976491||CD-C-Food group|During the first 3 months，participants received EEN；In the second 3months , CD-C-Food group received received CD-C-food .
32728564|NCT04976491||EEN group|During the period, participants received EEN for 6 months.
32728565|NCT04359797|Active Comparator|Usual Care|Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.
32931109|NCT04427592|Experimental|pregnant women with placenta accreta spectrum|The participants were subjected to ultrasound to diagnose placenta accreta spectrum followed by new conservative surgical technique.
32931110|NCT04426968|Experimental|Hepalatide 2.1mg+Pegylated Interferon|
32931111|NCT04426968|Experimental|Hepalatide 4.2mg+Pegylated Interferon|
32931112|NCT04426968|Experimental|Hepalatide 6.3mg+Pegylated Interferon|
32931113|NCT04426968|Active Comparator|placebo+Pegylated Interferon|
32931114|NCT05278962|Active Comparator|SGLT2i|Participants will be asked to take an SGLT2i for 6 months. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
32931115|NCT05278962|Active Comparator|No SGLT2i|Participants will not be asked to take an SGLT2i. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
32931116|NCT03892824|Experimental|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
32931117|NCT04887948|Experimental|Coadministration Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
32931118|NCT04887948|Active Comparator|20vPnC-only Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
32931119|NCT04887948|Active Comparator|BNT162b2-only Group|Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
32931120|NCT03761537|Experimental|Tralokinumab + TCS|4 subcutaneous (SC) injections of tralokinumab 150 mg as a loading dose on Day 0, followed by 2 SC injections of tralokinumab 150 mg every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
32931121|NCT03761537|Placebo Comparator|Placebo + TCS|4 subcutaneous (SC) injections of placebo as a loading dose on Day 0, followed by 2 SC injections of placebo every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
32931122|NCT05275608|Experimental|VLCKD|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
32931123|NCT05275608|Active Comparator|Hypocaloric Mediterranean Diet|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
32931124|NCT04882800|Experimental|First Intervention|Participants will be fit with currently available Lyric extended wear hearing aid device A in right ear and Lyric extended wear hearing aid with fitting modification device B in left ear for 14 days (Day 1 - Day 14 of study). They will then switch and be fit with Lyric extended wear hearing aid with fitting modification device B in the right ear and the commercially available Lyric device A in the left ear for 14 days (Day 15-Day 28 of study)
32931125|NCT03866460||Hearing evaluation DPOAE|Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.
32931126|NCT04854564||End-stage liver disease (ESLD) patients|These potential liver transplant candidates are patients with end-stage liver disease (ESLD) who have been assigned to the liver transplant waitlist.
32931127|NCT04854564||Caregivers of potential liver transplant candidates|They are the primary caregivers for the patients.
32931128|NCT03799289|Experimental|Iyengar Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
32931129|NCT03799289|Active Comparator|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
33251754|NCT00767988|Placebo Comparator|B|Capsule 1:1
33251755|NCT00545740|Experimental|SPD476 (1.2 g)|
33251756|NCT00545740|Experimental|SPD476 (2.4 g)|
33230549|NCT05146804|Other|Affilla Cress/Broccocress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
32728566|NCT04359797|Active Comparator|Prone|Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.
32728567|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
32728568|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
32728569|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
32728570|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
32728571|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
32728572|NCT03396029|No Intervention|Control|No contact with the participant.
32728573|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
32728574|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
32728575|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
32728576|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
32931130|NCT04851444|Experimental|SI-F019|SI-F019 administered intravenously (IV).
32931131|NCT03810053|Experimental|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
32931132|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
32931133|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
32931134|NCT03883607|Experimental|Elafibranor 80 mg|Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
32931135|NCT03883607|Experimental|Elafibranor 120 mg|Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
32931136|NCT04848090|Other|Neonate WGS Testing|Neonate subjects who are eligible and whose parents consent to study will undergo blood sampling which will be sent for whole genome sequencing and bioinformatics analysis, filtering first a targeted panel of 1722 genes most likely to cause genetic disorders in the first year of life, and then with a whole exome filter if no obvious diagnosis is determined using the 1722 gene panel filter.
32931137|NCT04846296||study group|Between 10-16 years old Cobb angle 10-40 degrees Being treated with conservative treatment (brace- exercise) for scoliosis Accepted to answer the questionnaire
32931138|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
32931139|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
32931140|NCT04826796|Experimental|Whatsapp intervention group|In addition to standard care, participants will be included into a peer support Whatsapp group on Whatsapp with other participants and trained peer supporters after study entry. Standard weekly prompt text messages will be sent to the group by peer supporters to encourage questions and discussion related to breastfeeding. Peer supporters will provide breastfeeding and emotional support. Intervention will last for 6 months after birth.
32931141|NCT04826796|No Intervention|Control group|Participants in the control group will continue to receive standard care.
32931142|NCT03926039|Experimental|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
32931143|NCT03926039|No Intervention|Description of traditional treatment options|Description of conventional traditional treatment options
32931144|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
32931145|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
32931146|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
32728577|NCT04616443|Experimental|Dose escalation|"The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively.~OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week."
32728578|NCT03403907|Experimental|Probiotic|Probiotic administration
32728579|NCT04300595|Active Comparator|general anesthesia (Group G)|Patients receive general anesthesia with intravenous opioids and local infiltration of saline (Group G)
32728580|NCT04300595|Active Comparator|Local anesthesia (Group L)|Patients receive general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).
32728581|NCT04610593|Experimental|Intervention Group|This group will receive a Mindfulness-based intervention for 8 weeks, and after the intervention this participants will continuous their treatment as usual
32728582|NCT04610593|No Intervention|Treatment as Usual|Patients in the control group received treatment as usual in the hemodialysis setting: Carry out hemodialysis sessions three times a week, on alternate days, for approximately 4 hours added to appointments and procedures performed by professionals from different areas (medicine, nursing, nutrition, physical education, social work, pharmacy, psychology).
32728583|NCT04294199|Active Comparator|Immobilization|Patients in this group will be given a knee immobilizer to wear for 2 weeks and then receive outpatient physical therapy evaluation and treatment
32728584|NCT04294199|Experimental|Early range of motion|Patients in this group will be allowed to move the knee and start outpatient physical therapy and treatment immediately.
32728585|NCT04608019|Experimental|Immediate Antibiotics|increased airway clearance plus early initiation of oral antibiotics
32728586|NCT04608019|Experimental|Tailored Therapy|increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve
32931147|NCT05369052|Experimental|contezolid acefosamil/contezolid|
32931148|NCT05369052|Active Comparator|linezolid|
32931149|NCT04815564|Experimental|Intervention|Subjects with a PAR score between 15 and 40 and fulfilling the other eligibility criteria will be offered participation in the trial.
32931150|NCT04815564|No Intervention|Natural History|Subjects with a PAR score outside of 15-40 will be offered the opportunity to remain on study for the Natural History arm.
32931151|NCT04823988||Adults 18 and over|Adults 18 and over
32931152|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|15 units (U) Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
32931153|NCT04049123|Experimental|LY900014|7 U, and 15 U LY900014 administered once, SC, in two of three study periods.
32931154|NCT03785262|Sham Comparator|Sham|Inactive uroshield device
32931155|NCT03785262|Experimental|Active Uroshield|Active uroshield device
32931156|NCT04382196||Health care workers|Health care workers at university hospital
32931157|NCT04051463|Active Comparator|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
32931158|NCT04051463|Placebo Comparator|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
32931159|NCT04826328|Experimental|FX301 Low Dose Low Volume|65 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
32931160|NCT04826328|Experimental|FX301 Low Dose High Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
32931161|NCT04826328|Experimental|FX301 High Dose Low Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
32931162|NCT04826328|Experimental|FX301 High Dose High Volume|260 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
32931163|NCT04826328|Placebo Comparator|Normal Saline|Low or high matching volume of preservative-free normal saline given as a single injection adjacent to the sciatic nerve of the popliteal fossa
32931164|NCT04054661|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
32931165|NCT04132973|Experimental|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
32931166|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
32931167|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
32931168|NCT04713839||Participants|The participants were invited to the study, then each participant was asked to complete the self-report questionnaires.
32931169|NCT04031885|Experimental|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
32931170|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
32931171|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
33230550|NCT05630196|Experimental|LY3857210|Participants will receive LY3857210
33230551|NCT05630196|Placebo Comparator|Placebo|Participants will receive placebo
33251757|NCT00545740|Experimental|SPD476 (4.8 g)|
32931172|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
32931173|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
32931174|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
33251758|NCT00545740|Placebo Comparator|Placebo|
33251759|NCT05208190|Experimental|Clozapine|treatment with clozapine naturalistically administered (as per clinical guideline).
33251760|NCT05208190|Active Comparator|Treatment as usual|open label naturalistic treatment as usual with any antipsychotic other than clozapine
33251761|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
32931175|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
32931176|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
33251762|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
32931177|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
32931178|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
32931179|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
32931180|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
32931181|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
32931182|NCT04211909|Experimental|SOF/VEL|Participants with chronic HCV infection (genotype 1 or 2), who are treatment-naive or treatment-experienced with interferon (IFN)-based treatments will receive SOF/VEL for 12 weeks.
32931183|NCT04211909|Experimental|SOF/VEL/VOX|Participants with chronic HCV infection (genotype 1), who are treatment-experienced with nonstructural protein 5A (NS5A) direct-acting antiviral (DAA)-based treatments of at least 4 weeks duration will receive SOF/VEL/VOX for 12 weeks.
32931184|NCT03559205|No Intervention|MSK-Tracker (before)|Before - (Usual care in clinic consultations)
32931185|NCT03559205|Active Comparator|MSK-Tracker (after)|After - (MSK-Tracker in clinic consultations)
32931186|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
32931187|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
32931188|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
32931189|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
32931190|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
32931191|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
32931192|NCT05722951|Active Comparator|Control group|levetiracetam
32931193|NCT05722951|Experimental|Treatment group|metformin
33230552|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
33230553|NCT04111302|Experimental|IV-PCA|use IV-PCA for postoperative pain
33230554|NCT04111302|Experimental|IV-dezocine|use IV-dezocine for postoperative pain
33230555|NCT04111302|Experimental|IV-PCA+AA|use IV-PCA and AA for postoperative pain
33230556|NCT04111302|Experimental|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
33230557|NCT00457249|Experimental|Adacel Vaccine Group|
33230558|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
33230559|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
33251763|NCT00968422|Experimental|Low dose ABT-384|
33251764|NCT00968422|Experimental|Mid dose ABT-384|
33251765|NCT00968422|Experimental|High dose ABT-384|
33251766|NCT00968422|Placebo Comparator|Placebo|
33251767|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
33251768|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
33251769|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
33251770|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
33251771|NCT00890877|Experimental|1|
32768881|NCT04832243|Experimental|Experimental: V1: List No. 1|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted."
32768882|NCT04832243|Experimental|Experimental: V2: List No. 2|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The second version of the questionnaire includes 6 sets of 4 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully for 3 of the true-false statements. One statement in each set relates to food and water insecurity and is designed to determine the extent to which social desirability bias may influence responses to food and water insecurity questions."
32768883|NCT04832321|No Intervention|No intervention: V1: Control|This version of the survey questionnaire depicts a young man with no symptoms of alcohol use disorder
32768884|NCT04832321|Experimental|Experimental: V2: Alcohol Use Disorder|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder."
32768885|NCT04832321|Experimental|Experimental: V3: Alcohol Use Disorder + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with complete response."
32768886|NCT04832321|Experimental|Experimental: V4: Alcohol Use Disorder + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with partial relapse."
32768887|NCT04832321|Experimental|Experimental: V5: Alcohol Use Disorder + Economic Impact|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances."
32768888|NCT04832321|Experimental|Experimental: V6: Alcohol Use Disorder + Economic Impact + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with complete response."
32768889|NCT04832321|Experimental|Experimental: V7: Alcohol Use Disorder + Economic Impact + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with partial relapse and continued negative economic impact."
32768890|NCT04478227|Experimental|Arm A|"Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood/Myelodysplastic Syndrome(MDS) without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure.~Arm A: Start at 5 microgram/kg/dose per week along with standard of care and escalate with 2.5 microgram/kg/dose increments (per week at physician's discretion depending on the clinical and laboratory response) (Maximum: 20 microgram/kg/dose) based on response for at least 24 weeks or until hematopoietic response is seen, whichever comes first. If patient shows response, therapy will be continued for a total of 52 weeks."
32768891|NCT04478227|Experimental|Arm B|"Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT).~Arm B: Starting dose 2 microgram/kg/dose per week with increments at 1 microgram/kg/dose (Maximum: 10 micrograms/kg/dose) depending on the laboratory response."
32768892|NCT04296071||Group 1|patients who tend to have longer CPB
32768893|NCT04296071||Group 2|Patients who have shorter CPB
32768894|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
32768895|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
32768896|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
33082182|NCT04622761|Experimental|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
33251772|NCT00890877|Experimental|2|
33251773|NCT00890877|Experimental|3|
33251774|NCT00890877|Experimental|4|
33251775|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
33251776|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
33251777|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
32931194|NCT05127733|Experimental|Online Cogntivie Behavioural Therapy|"Breaking Free Online (BFO) is an online intervention, supporting adults struggling with substance use. It provides psychoeducation and skills building exercises in CBT and compatible approaches. The intervention strategies contained within BFO are provided via a six-domain biopsychosocial model used in CBT. Each domain of the model corresponds to a module in the BFO program which contains psychoeducation and an 'action' strategy to facilitate behaviour change. Data captured at the baseline assessment is used by the program to provide feedback to the individual on their levels of functioning across the six domains. The program then guides the user to concentrate on intervention strategies for domains with the greatest level of impairment.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
32931195|NCT05127733|Experimental|Online Cognitive Behavioural Therapy Plus Individual Peer Support|"BFO delivered with peer support will comprise BFO with at least weekly contact with a peer with lived experience. Peer support workers will receive training on how to facilitate participant engagement with and progress through the BFO program, as well as a weekly session plan. As part of this training, peer support workers will be given their own access code to use BFO and be encouraged to use the program. Session One constitutes an initial orienting to the program. Subsequent sessions review each information and action strategy in the BFO program, with a series of prompts to guide peer support of this content.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
32931196|NCT05127733|Active Comparator|Group Peer Support|"The control condition will consist of group peer support facilitated by trained peers and offered through the Community Addictions Peer Support Association (CAPSA). The group meets weekly and will offer participants a space to share their experiences and receive support.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
32931197|NCT04838652|Experimental|Pembrolizumab plus Chemotherapy|All patients will receive 1 dose of 200 mg pembrolizumab IV as single agent upfront, followed by 2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide) and a PET/CT-based restaging. Following a PET-guided treatment strategy, patients will then receive either another 2 cycles of IV P-ICE in case of a negative PET (i.e., Deauville score 1-3), or 2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin) in case of a positive PET (i.e., Deauville score > 3). After completion of treatment with P-ICE or P-DHAP, respectively, patients will receive a consolidation therapy with pembrolizumab for another 6 cycles. In case of non-CR after at least 4 cycles of combination therapy (4x P-ICE or 2x P-ICE + 2x P-DHAP), physicians may decide to go for HDCT or an alternative standard of care treatment option.
32931198|NCT05722795|Experimental|Short term Imatinib|Imatinib 400 mg x 1 for 10 days before surgery.
32931199|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice~Bisoprolol up to a total dose of 10 mg daily~Carvedilol up to a total dose of 50 mg daily~Metoprolol succinate up to a total dose of 200 mg daily~Nebivolol up to a total dose of 10 mg daily"
32728587|NCT04169243|Experimental|Intervention|Women randomized to the New Nordic Diet meet the study dietician at week 30 for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods. Participants will prepare their own food but are provided with recipes and food bags containing all the foods to be consumed during the two-week intervention At gestational age 32 weeks, women meet with a dietitian and will be instructed to continue with the New Nordic Diet diet throughout pregnancy on their own.
32728588|NCT04169243|Active Comparator|Control|The control women receive diet advice according to usual care.
32728589|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
32728590|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
32728591|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
32768897|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
32768898|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
32931200|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
32931201|NCT05119699|Experimental|Active rTMS treatment|Patients will receive accelerated TBS
32931202|NCT04822740|Experimental|Novel strategy|"Inserting the CGMS device with use of the results of the device in real time by the health care team~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Transmission of real-time data to the nurse and use of the alarms of the device~Adaptation of insulin according to blood glucose measured by the CGMS device and according to the same protocol as the conventional arm~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
32931203|NCT04822740|Active Comparator|Conventional strategy|"Inserting the CGMS device without the use of the results by the health care team: blinded CGMS (use of these results only at the end of the participation to analyze the main criterion)~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Adaptation of insulin according to the capillary blood glucose levels performed every hourly if insulin dose change, every 2 hours if stable insulin dose according to local recommendations~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
32931204|NCT05722717||MIS-C|Children with a history of MIS-C: as defined according to WHO criteria, who were 0-18 at the time of MIS-C.
32931205|NCT05722717||Post COVID-Condition|Children with post-COVID condition who were 0-18 at the time of SARS-CoV-2 infection: as defined according to the WHO case definition.
32931206|NCT05722717||Control|'Exposed' control group: children with a history of proven SARS-CoV-2 infection (RT-PCR, antigen test or serology positive) who were 0-18 at the time of SARS-CoV-2 infection.
32931207|NCT04810494|Experimental|test drug|2% Lidocaine
32931208|NCT04810494|Placebo Comparator|Placebo|0.9% Normal Saline
32931209|NCT05722639||Representative sample of the U.S. population|"Subjects will be fitted with two electrophysiology acquisition systems (one is FDA-approved, and the other is the one evaluated).~Signals from both systems will be acquired simultaneously while the subjects rest and perform no cognitive tasks.~Following, the signals from both devices will be assessed by an electrophysiology expert to determine if they are of equal quality."
32931210|NCT05722561|Experimental|Electronic Cigarette|Participants in the Electronic Cigarette (EC) arm will receive telehealth motivational counseling for 6 weeks plus the standardized research e-cigarette (SREC).
32931211|NCT05722561|Active Comparator|Nicotine Replacement Therapy|Participants in the Nicotine Replacement Therapy (NRT) arm will receive telehealth motivational counseling plus combination NRT (patch and lozenge).
33251778|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
32728592|NCT05167097|Experimental|Deliberative Mindset|Participants receive a paper/pencil questionnaire that evokes a deliberative mindset. The questionnaire asks participants to deliberate upon the positive and negative short- and long-term consequences of acting vs. not acting toward a goal. This procedure is based on previous research on the mindset theory of action phases.
32728593|NCT05167097|Experimental|Implemental Mindset|Participants receive a paper/pencil questionnaire that evokes an implemental mindset. The questionnaire asks participants to plan the when, where, and how of taking five steps toward a goal. This procedure is based on previous research on the mindset theory of action phases.
32728594|NCT05167097|Experimental|Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. The decisional balance element describes Steps 6-9 of the ten steps of the manual. They include probing for the positive and negative sides of alcohol consumption, weighing them against each other, focusing on the negative sides, and asking participants how concerned they are regarding the negative sides.
32728595|NCT05167097|Experimental|No Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. This is the short-form of the ASSIST-linked Brief Intervention. It drops the decisional balance element that is described above.
32728596|NCT05167097|Other|Control Group|Participants perform a filler task in the control group, crossing out a specific letter in paragraphs of nonsense text.
32728597|NCT04647643||Paclitaxel Drug Coated Balloon|Patients treated with paclitaxel drug-coated balloon
32728598|NCT04647643||Paclitaxel Drug Coated Stent|Patients treated with paclitaxel drug-coated stent
32728599|NCT05166941|Experimental|Experimental group|It is a closed group in which the training program is implemented.
32728600|NCT05166941|No Intervention|Control Group|No training program was applied to this group.
32728601|NCT04167761|Experimental|Ertugliflozin|
32728602|NCT04167761|Active Comparator|Glipizide|
32768899|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
32931212|NCT05270928|Experimental|IBI346|Single arm
32931213|NCT04332588|Experimental|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced [18F]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
32931214|NCT04332588|Experimental|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced [18F]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
32931215|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
32931216|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
32931217|NCT04798248|Experimental|Momentary Affect Regulation - Safer Sex Intervention|Momentary Affect Regulation - Safer Sex Intervention (MARSSI) is the treatment condition. MARSSI aims to enhance an individual's motivation to change risk behaviors, provides skills to address depression's effects on behavior, and prompts and reinforces healthy affect regulation, cognitive behavioral skill use, and behavior change in daily life.
32931218|NCT04798248|Sham Comparator|Podcast Health Group|The Podcast Health Group is the control counterfactual condition.
32931219|NCT05112601|Experimental|Arm I (nivolumab and ipilimumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity."
32931220|NCT05112601|Active Comparator|Arm II (nivolumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity."
33400988|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
32768900|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
32931221|NCT04317534|Experimental|Arm A- Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks x 9 cycles
32931222|NCT04317534|No Intervention|Arm B - Observation|Observation only
32931223|NCT04313712||Participants|All study participants will be observed before and after they receive exposure to tabernanthe iboga in other countries.
32931224|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
32931225|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
33400989|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
33400990|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
33400991|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
33400992|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
33400993|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
33400994|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
33400995|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
33400996|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
33400997|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
33400998|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
33400999|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
33401000|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
33401001|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
33401002|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
32931226|NCT04838106||Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency with confirmed COVID-19 between 1st January to 1st July 2020.
32931227|NCT04838106||Non Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency without confirmed COVID-19 between 1st July 2016 and 1st July 2020.
32931228|NCT05722483|Experimental|Virtual Intensive Outpatient Program|
32931229|NCT05405868|Experimental|Nicotinamide|Participants will receive Nicotinamide for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
32931230|NCT05405868|Placebo Comparator|Matching Placebo|Participants will receive matching placebo for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
32931231|NCT05109169|Sham Comparator|Self-guided multidomain lifestyle intervention|In this group, participants will build their own healthy lifestyle program based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits, covering four main components (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring). The intervention duration is 2 years.
32931232|NCT05109169|Active Comparator|FINGER 2.0 multidomain lifestyle-based intervention|"Within this group, participants will receive a structured intensive lifestyle intervention through individual consultations and group meeting sessions. Four main lifestyle components will be included (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring) as well as social interaction through the group meetings/sessions.~In this group, participants eligible for metformin treatment will be further randomised to either:~2000mg/day~1000mg/day~placebo.~Metformin and placebo will be dispensed every 3 months, both administered orally. The intervention duration is 2 years"
32931233|NCT04291014|Experimental|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
32931234|NCT04291014|Experimental|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
32931235|NCT04291014|Experimental|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
33251779|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
33401003|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
32728603|NCT04567381|Active Comparator|Treatment as Usual|Treatment as Usual (TAU)/Control. Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
32931236|NCT04291014|Experimental|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
32931237|NCT05722405|Other|Ixazomib|Ixazomib as the single drug for maintenance. This group as control arm
32931238|NCT05722405|Experimental|Ixazomib plus low-dose lenalidomide|Ixazomib combined with low-dose lenalidomide(10mg) for maintenance
32931239|NCT05722327|Experimental|Stage 1 ( MRTX849 and Irinotecan)|Participants assigned to Stage 1, participants dose levels of MRTX849 and irinotecan will depend on when the participants joined the study. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
32931240|NCT05722327|Experimental|Stage 2 ( MRTX849 and Irinotecan)|Participants assigned to Stage 2 will receive MRTX849 and irinotecan at the dose level that was recommended during Stage 1. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
32931241|NCT04259658|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for cutaneous metastases.
32931242|NCT04780074|Active Comparator|Standard product (SP): USP CoQ10 powder, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
32728604|NCT04567381|Experimental|Enhanced Services|Enhanced Services/Treatment (ES). Participants randomized to the ES intervention will receive intensive community-based case management.
32728605|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
32931243|NCT04780074|Experimental|Investigational product 1 (IP1): CoQ10 in soybean oil, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
32931244|NCT04780074|Experimental|Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
32728606|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
32931245|NCT04780074|Experimental|Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
32728607|NCT04152785|Experimental|GHG|Information given regarding greenhouse gas emissions via a GHG score
32728608|NCT04152785|Experimental|Nutrition|Information given regarding nutrition via a nutrient profiling score
32728609|NCT04152785|Experimental|GHG+nutrition|Information given regarding GHG and nutrition via a combined score
32728610|NCT04152785|Placebo Comparator|No logo|No information given
32728611|NCT04446715|Experimental|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
32728612|NCT04446715|Experimental|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
32768901|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
32931246|NCT04780074|Experimental|Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
32931247|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).~EEG NIRS MRI"
32931248|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .~EEG NIRS MRI"
32931249|NCT05098873||Group gifted teens|
32931250|NCT05098873||Group no gifted teens|
32931251|NCT04770090|Experimental|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
32931252|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
32931253|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
32931254|NCT05404932|Experimental|Intervention arm (aliquoted plasma application into the conjunctiva)|"This is the only arm of the study. The intervention is administration of aliquoted plasma provided by Canadian Blood Services in eye droppers (3 ml aliquots in 7 ml vials) in the patient's conjunctiva.~The duration of therapy can be 2 to 6 months depending on response The intra-ocular drops will be administered every 1-5 hours daily in the affected eye based on disease severity and may be repeated"
32931255|NCT05722249|Experimental|Arm A, Study Period 1 (Mindfulness and Sleep Hygiene):|"Immediately after the sleep hygiene content, the overview of the mindfulness intervention will be offered. All enrolled participants in Arm A, Study Period 1, will attend a 15 minute in-person Introduction to Mindfulness session after randomization."
32931256|NCT05722249|Active Comparator|Arm B, Study Period 1 (Physical Activity and Sleep Hygiene):|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods.
32931257|NCT04419324|Other|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
32931258|NCT05722171|Experimental|gdT cell injection targeting B7-H3 chimeric atigen receptor|UTAA06 injection
32728613|NCT04079387|Experimental|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°."
32728614|NCT04079387|Active Comparator|ENDOTRACHEAL TUBE ALONE|The control group consists in intubating the trachea with an endotracheal tube alone (i.e, without stylet).
32931259|NCT04419246|Active Comparator|Group I|interscalene block + General anesthesia
32728615|NCT04069247|Experimental|E-based cognitive behavioral therapy for insomnia (eCBT-I)|The eCBT-I will be delivered by a mobile application (eSleep) developed by BestCare & SuMian BioTech Co., Ltd. which contains a digital, self-paced, and highly interactive programme. It consists of six weekly sessions with animated elements, including an overview of sleep, sleep restriction, stimulus control, cognitive therapy, structured worry time and relapse prevention. Participants will have access to the eCBT-I treatment for 12 weeks.
32728616|NCT04069247|Active Comparator|Health education (HE)|The HE, a psychoeducation/information-approach, also consists of six consecutive sessions which contains information about general sleep knowledge, functions of human organs, nutrition, environmental health, brain health, identification and treatments of common diseases, but the contents are not related to any active therapeutic components of cognitive behavioral therapy for insomnia (CBT-I).Participants will have access to the intervention for 12 weeks.
32728617|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
32931260|NCT04419246|Active Comparator|Group T|Tranexamic acid +General anesthesia
32931261|NCT04419246|Sham Comparator|Group S|General anesthesia
32931262|NCT05722093|Experimental|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
32931263|NCT05722093|Placebo Comparator|placebo group|Administration cycle of Manzhi Guben granules simulator: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
32931264|NCT05400174|Other|Sitting cognitive testing first|"The cognitive testing sessions will be alternated between sitting and upright positions.~This group will perform cognitive testing sessions in the following order: 1) sitting, 2) upright, 3) sitting, 4) upright."
32931265|NCT05400174|Other|Upright cognitive testing first|"The cognitive testing sessions will be alternated between sitting and upright positions.~This group will perform cognitive testing sessions in the following order: 1) upright, 2) sitting, 3) upright, 4) sitting."
32931266|NCT05083039||750 volunteers who will be vaccinated with the BiVac polio vaccine|Group 1 - 750 volunteers, Vaccine 0.2 ml, post-vaccination observation period of 12 months.
32931267|NCT05083039||750 volunteers who will be given a Placebo.|Group 2 - 750 volunteers, Vaccine 0.2ml, post-vaccination observation period of 12 months.
32931268|NCT04837014|Experimental|Acetaminophen and naproxen only arm|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
32931269|NCT04837014|Active Comparator|Acetaminophen, naproxen and dilaudid arm|Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
32931270|NCT05721781|Experimental|Participants receiving a dental cleaning and oral hygiene instruction|Participants randomized to this arm will receive a standard dental cleaning and education on proper toothbrushing and flossing technique and asked to follow these toothbrushing and flossing techniques for the duration of the study period. They will receive periodic phone call reminders to maintain these practices during the study period.
32931271|NCT05721781|No Intervention|Control|Participants randomized to this arm will be instructed to continue with their usual oral hygiene practices for the duration of the study period.
32931272|NCT04758312|Experimental|MY-Skills Mobile Intervention|MY-Skills Mobile is an 8-week intervention merging yoga and self-management offered via remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. The self-management content is delivered primarily through asynchronous tools that include educational videos and interactive activities for goal setting, action plan, monitoring goals, and problem-solving practice. Yoga is offered synchronously via Zoom two-times per week for 60 minutes (120 minutes per week). The synchronous yoga sessions will be offered at a time that best accommodates participants' schedules. Yoga will become progressively challenging over the eight weeks and will include seated and standing postures.
32931273|NCT05721625|Experimental|Exercise group|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
32931274|NCT05721625|Active Comparator|Massage group|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While postpartum women are in the sitting position, this massage will be applied on whole back.
32931275|NCT04195698|Experimental|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
32931276|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
32931277|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
32931278|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
32931279|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
32931280|NCT04411134|Experimental|Arm 1|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
32931281|NCT04411134|Experimental|Arm 2|The MTD from among dose level 1 and dose level 2
33401004|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
33401005|NCT03009344|Experimental|Tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later) (Cycle 0 duration=4 days) (Cycle 1 and later duration= 28 days).
32931284|NCT04229303|Experimental|Part 1 - ZP-059 5mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 1: 5mg (1 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
32728618|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
32728619|NCT04060823|Experimental|Easy Breathing|Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes.
32728620|NCT04931485|Experimental|Intervention: REDUCE Protocol|Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
32728621|NCT04931485|Active Comparator|Standard of Care|Fluid resuscitation and de-resuscitation according to the standard of care
32728622|NCT03991403|Experimental|Atezolizumab group|
32728623|NCT03991403|Active Comparator|Control group|
33073596|NCT01011712||1|patients without known or not fully characterized immunodeficiency, who have severe, persistent, or treatment-refractory viral infections
33073597|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
32728624|NCT04559035|Other|Betadine|"Intervention - twice-a-day nasal lavage Twice-a-day virucidal group: Participants randomized to betadine will receive 2 gallon jugs of distilled water, two NeilMed Sinus Irrigation bottles and 28 salination packets (with some extras), OR one Navage unit with 28 SaltPods (and some extras), and a cardboard receptacle labeled used saline containers to keep track of adherence.~Those randomized to receive betadine will also receive one bottle of povidone-iodine, a one-sheet instruction with photographs demonstrating how to add ½ tsp betadine in addition to the salination packet to the sinus irrigation bottle or Navage unit reservoir prior to SaltPod, along with a ½ tsp measuring spoon."
32728625|NCT04559035|Other|Baking Soda|"Twice-a-day alkalinized group: Participants randomized to alkalinization will receive 2 gallon jugs of distilled water, two Neilmed bottles with 28 saline packets, OR one Navage unit with 28 SaltPods, and a cardboard receptacle labeled used saline containers to keep track of adherence. Those randomized to alkalinization will also receive a box of baking soda, ½ tsp measuring spoon and instructions on how to add the baking soda."
32728626|NCT04535791|Experimental|cholecalciferol (Vitamin D)|cholecalciferol 4,000 IU orally daily (1 capsule) for 30 days
32728627|NCT04535791|Placebo Comparator|Starch|Starch 500 mg orally daily (1 capsule) for 30 days
32728628|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
32728629|NCT04529629||primary aldosteronism|
33073598|NCT01000753||Observational (specimen collection)|See Detailed Description
33073600|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
33073601|NCT00942981||healthy volunteers|healthy volunteers
33073602|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
32728630|NCT04529629||pheochromocytoma|
33073606|NCT00924027|Experimental|1/Radiation Therapy|Radiation therapy given as HDR Brachytherapy.
32728631|NCT04529629||adrenocortical carcinoma|
32728632|NCT03916835|Other|Music Therapy during cleaning care 1|"This group receives music therapy during cleaning care 1 and not during the cleaning care 2.~Each patient will act as their own control"
32728633|NCT03916835|Other|Music Therapy during cleaning care 2|"This group receives music therapy during cleaning care 2 and not during the cleaning care 1.~Each patient will act as their own control"
32728634|NCT04447625|Active Comparator|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
32728635|NCT04447625|Experimental|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
32728636|NCT03392389|Experimental|mRNA-1653|
32728637|NCT03392389|Placebo Comparator|Placebo|
32728638|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
33073607|NCT00923442||1|patients (from >/= 1 to 75 years old) diagnosed with any hematologic malignancy or pre-malignant condition
33073610|NCT00900198||1/Standard|Standard
33073611|NCT00900198||2/Standard and Preclinical Models|Standard and Preclinical Models
33073612|NCT00900198||3/Preclinical Models|Preclinical Models
33073613|NCT00900198||4/Preclinical Models, Pediatric|Preclinical Models, Pediatric
33073614|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33073615|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
33073616|NCT00867269||Household Contacts|Household contacts of ICL subjects
33073617|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
32728639|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
32728640|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
32728641|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.~Traditional Over ground Gait Trainings include:~Sit-to-Stand tasks~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.~CG patients will not use any other robots or treadmill for gait training."
32728642|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
32728643|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
32728644|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
32728645|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
32728646|NCT03396523|Experimental|Losartan group|
32728647|NCT03396523|Placebo Comparator|Placebo group|
32728648|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
32728649|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
32728650|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
32728651|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
32728652|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
32728653|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
32728654|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
32728655|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
32728656|NCT03398005|Experimental|CaPre|
33073618|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
33073619|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
33073620|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
33073621|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
33073622|NCT00814827||Group 5|Blood Specimen Donors.
33073626|NCT00713492|Experimental|1|Alcohol
33073627|NCT00702533||Healthy volunteers|Healthy volunteers between 18 and 60 years of age
33073628|NCT00702533||patients with gastric acid secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
33401006|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
32931285|NCT04229303|Experimental|Part 1 - ZP-059 10mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 2: 10mg (2 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
32931286|NCT04229303|Experimental|Part 1 - ZP-059 20mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 3: 20mg (4 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
32931287|NCT04229303|Experimental|Part 1 - ZP-059 40mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 4: 40mg (8 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
32931288|NCT04229303|Experimental|Part 2 - ZP-059 10mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Days 1 to 10.~Cohort 1: 10mg (2 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
32931289|NCT04229303|Experimental|Part 2 - ZP-059 20mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 2: 20mg (4 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
32931290|NCT04229303|Experimental|Part 2 - ZP-059 40mg qd|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 3: 40mg (8 x 5 mg capsule) ZP-059 once daily (qd) administered via DPI (RS01 monodose device) on Days 1 to 10."
32931291|NCT04229303|Experimental|Part 3 - ZP-059 / Oral Voriconazole|Crossover treatment period: Single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI, and a single dose of oral voriconazole (200 mg Vfend® tablet) on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
32931292|NCT04229303|Experimental|Part 3 - Oral Voriconazole / ZP-059|Crossover treatment period: Single dose of oral voriconazole (200 mg Vfend® tablet), and a single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
32931293|NCT04419012||Patients with AF treated with VKA|
32931294|NCT04419012||Patients with AF treated with NOAC|
32931295|NCT05721547||RC Repair Group|Participants who had undergone the same arthroscopic RM surgical procedure and technique; had undergone acromioplasty and/or tenodesis with RM repair; had undergone arthroscopic RM surgery from the upper extremity of the dominant side; had completed six months following surgery
32931296|NCT05721547||Healthy Group|Participants who had not undergone any shoulder surgery, had no history of shoulder-related pain, discomfort, or trauma in the last year
32931297|NCT05266092||Participants with chronic kidney disease undergoing hemodialysis|
32931298|NCT05266092||Participants with chronic kidney disease, not in dialysis|
32931299|NCT05266092||Participants with chronic kidney disease undergoing peritoneal dialysis|
33401007|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
33073631|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobic exercise training plus education (AET) or education only (Ed-only) treatments
33073632|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD-only) will also undergo the AET arm
33073635|NCT00635700|Experimental|Ziprasidone|Patients will be treated with Ziprasidone for 6 months
33073636|NCT00635700|Placebo Comparator|Placebo|Patients will be treated with placebo for 6 months
33073637|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
33073638|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
33073645|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
33073646|NCT00558961|Experimental|I|Gleevec Chlorambucil
32931300|NCT05266092||Healthy participants|
33082183|NCT04622293|Experimental|Solriamfetol|Those who are receiving solriamfetol will receive 37.5 mg, 75 mg, or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
33082184|NCT04622293|Placebo Comparator|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
33251780|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
33251781|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
33251782|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
32931303|NCT05263986|Experimental|Assigned Interventions|In the 5-day PK lead-in period, patients will receive a single oral dose of 600 mg MRTX849 on Day 1 and there will be no drug administration in the subsequent 4 days. Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an interval of approximate 12 hours between 2 doses) orally in 3-week cycles until disease progression, unacceptable AEs, patient refusal, or death. Dosing schedules may be adjusted depending on safety results.
32931304|NCT05398302|Experimental|Diagnostic (image-guided biopsy)|Patients undergo an image-guided biopsy at baseline and 2-4 weeks after cycle 2 of 177Lu-PSMA-617 therapy.
33251783|NCT04008550|No Intervention|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
32931305|NCT05072665|Experimental|PATIENT WITH Irritable Bowel Syndrome|"2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection.~A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped"
32931306|NCT04812912||Participants with Colon Cancer|This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
33251784|NCT04008550|Other|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
33251785|NCT00975052|Active Comparator|A|Sitagliptin alone
33251786|NCT00975052|Active Comparator|B|Metformin alone
33251787|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
33251788|NCT00975052|Placebo Comparator|D|Placebo
33251789|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
33251790|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
32728657|NCT03398005|Placebo Comparator|Placebo|
32728658|NCT03397927|Experimental|orthosis|
32728659|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
32728660|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
32728661|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
32728662|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
32728663|NCT04928521|Active Comparator|ESP block with 20 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 20 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
32728664|NCT04928521|Active Comparator|ESP block with 30 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
32728665|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
32728666|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
32728667|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
32728668|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
32931307|NCT04812912||Participants with Rectal Cancer|This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
32931308|NCT04232358|Experimental|Corticosteroid injections + resistance training|Corticosteroid injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
32931309|NCT04232358|Placebo Comparator|Local anesthesia injections + resistance training|Local anesthesia injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
32931310|NCT05721391||Non Frail Group|The patients in no frail group did not have any component of Frailty criteria
32931311|NCT05721391||Pre Frail Group|The patients in prefrail Group had 1-2 component of Frailty criteria.
33251791|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
33251792|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
33251793|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
33251794|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
32728669|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
32728670|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
32728671|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
32728672|NCT03396133|Experimental|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
32931312|NCT05721391||Frail Group|The patients in Frail Group had 3-5 component of Frailty criteria.
32931313|NCT00377507|Experimental|catechin|mask containing catechins
32931314|NCT05395494|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) during 4 weeks of rTMS treatment (20 sessions) 60-120 minutes prior to rTMS treatment.
32931315|NCT05395494|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) 60 - 120 minutes prior to rTMS treatment.
32931316|NCT00357721|Active Comparator|A1|
32931317|NCT00357721|Active Comparator|A2|
32931318|NCT00357721|Active Comparator|A3|
32931319|NCT04227600|Experimental|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation
32931320|NCT04227600|Experimental|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose
32931321|NCT02471287||Affected Participants|Participants with eye disease
32931322|NCT02471287||Healthy volunteers|Unaffected first degree relatives of participants with a known or suspected inherited eye disease.
32931323|NCT03504410|Experimental|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + High Dose Cytarabine and Mitoxantrone~CPI-613 at 2,000 mg/m2/day from day 1 to 5.~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine."
32931324|NCT03504410|Active Comparator|Control (HAM) and control sub-groups (MEC and FLAG)|"High Dose Cytarabine and Mitoxantrone~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.~Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6~Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
32931325|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
32931326|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
32931327|NCT02464969|Experimental|Apixaban|Subjects between birth to <18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
32931328|NCT04739982|Experimental|Treatment|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
32931329|NCT04739982|No Intervention|Treatment as Usual|Participants in control group will continue their treatment as usual.
33082185|NCT04622371|Experimental|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
33082186|NCT04622371|Experimental|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
33251795|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
33401008|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
33401009|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
33401010|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
33401011|NCT04621981|Experimental|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
32768902|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
32768903|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
32768904|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
32768905|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
32931330|NCT05392530|Experimental|Treatment Sequence ABC|Participants will receive single oral dose of final marketing image (FMI) candidate #1 of macitentan (Treatment A [test]) under fed condition in Treatment Period 1, followed by single oral dose of FMI candidate #2 of macitentan (Treatment B [test]) under fed conditions in Treatment Period 2, and then single oral dose of the reference formulation of macitentan (Treatment C) under fed conditions in Treatment Period 3. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931331|NCT05392530|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931332|NCT05392530|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931333|NCT05392530|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931334|NCT05392530|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931335|NCT05392530|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in treatment period 2, and then Treatment C in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
32931336|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
32931337|NCT03498014|Active Comparator|Prescription as standard|
32931338|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
32931339|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of breast neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
32931340|NCT04210128||Pancreatic cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of pancreatic chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
32931341|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
32931342|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
32931343|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
32931344|NCT04735614|Experimental|ThoraxBelt|Received ThoraxBelt after the surgery. Standard care for pain management will be the same as the Standard Care Arm.
32931345|NCT04735614|No Intervention|Standard care|Standard care with IV PCA and on-request oral painkiller.
32931346|NCT04256603|Other|Gabapentin early|Gabapentin prior to admission
33401012|NCT04621981|Active Comparator|Normal Saline|"Intravenous drip, 500~1000ml per time. Dosage depends on age、weight and symptoms.~Infusion speed: According to the department process or clinician's decision."
33401013|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
33401014|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
33401015|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
33401016|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
32728673|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
32728674|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
32728675|NCT03887117|Active Comparator|IQOS-1|"IQOS + Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program."
32931347|NCT04256603|Other|Gabapentin late|Gabapentin during admission
32728676|NCT03887117|Active Comparator|IQOS-2|"IQOS without Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program."
32728677|NCT03887117|Active Comparator|Cigarette Smoking|"Cigarette Smoking + Exercise Training Program~Subjects randomized to continued cigarette smoking and participation in an exercise training program."
32728678|NCT03887117|Active Comparator|Smoking Abstinence|"Smoking Abstinence + Exercise Training Program~Subjects randomized to smoking abstinence and participation in an exercise training program."
32728679|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
32728680|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
32728681|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
32728682|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
32728683|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
32728684|NCT02819791|Active Comparator|Control group|
32728685|NCT02819791|Experimental|Intervention group|
32728686|NCT04447495||SARS-CoV-2 positive|We will enroll patients within a larger clinical validation study of the iAMP® test against the gold standard (the CDC-recommended test) until we have prospectively collected a total of 100 positive cases.
32728687|NCT04447495||Controls|Current SARS-CoV-2 positivity in the region is approximately 20%, therefore, approximately 400 negative control samples will be needed.
32728688|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
32728689|NCT03395561|Placebo Comparator|control|2 capsuls
32728690|NCT04244773|Experimental|Intervention group: ENDS and smoking cessation|
32728691|NCT04244773|Active Comparator|Control group: Smoking cessation counseling|
32728692|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
32728693|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
32728695|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
32728696|NCT04414189||Arm A|Patients with suspected sepsis at the time of admission to the ICU
32728697|NCT04414189||Arm B|Patients not currently suspected but at high risk for sepsis.
32728698|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
32728699|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
32728700|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
32728701|NCT04446637|Experimental|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
32728702|NCT04446637|Active Comparator|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
32728703|NCT02520401|Experimental|Test|Probiotic tablet
32728704|NCT02520401|Placebo Comparator|Control|Control tablet
32728705|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
32728706|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
32728707|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
32728708|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
32728709|NCT03389425|Experimental|SIMPLE weightloss group|
32728710|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
33082187|NCT00220337|Experimental|1|Open label active treatment
33082188|NCT04622215|Other|ICIQ questionnaire|
32931348|NCT04256603|Other|No gabapentin|No gabapentin
32931349|NCT05061823|Experimental|Bintrafusp alfa|
32931350|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
32931351|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
33401017|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
32931352|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
32931353|NCT05721313|Experimental|Patients with advanced periodontal furcation involvement|
32931354|NCT03560141|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
32931355|NCT03560141|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
32931356|NCT05363514|Experimental|Low Dose Naltrexone|Low Dose Naltrexone 4.5mg OD PO. Capsules are masked and provided in blister packs.
32931357|NCT05363514|Placebo Comparator|Placebo|Microcrystalline cellulose 4.5mg OD PO. Capsules are masked and provided in blister packs.
32931358|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
32931359|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
32931360|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
32931361|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
32931362|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
32931363|NCT04418700|Experimental|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
32931364|NCT04418700|No Intervention|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
32931365|NCT05721079|Experimental|ECP with standard triple IST|
32931366|NCT05721079|Active Comparator|standard triple IST|
32931367|NCT03562559||TKA Patients|
32931368|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
32931369|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
32931370|NCT04727970|Experimental|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
32931371|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
32931372|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
32931373|NCT05239104||Children aged 1 month - 14 years 11 months with a severe illness/injury|"Children aged 1 month - 14 years 11 months presenting to hospital with symptoms of an acute severe illness/injury that started within the last 2 weeks. Severe defined as a child showing emergency signs or requiring hospital admission for treatment."
32931374|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
32931375|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
32931376|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
32931377|NCT03458546|Experimental|Roflumilast and R-CHOP|
32931378|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32931379|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32931380|NCT02159066|Experimental|LGX818 + MEK162|
32931381|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
32931382|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
32931383|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
32931384|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
32931385|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
32931386|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
33251796|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
32768906|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
32768907|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
32768908|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
32768909|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
32768910|NCT04831931|Experimental|Supervised Exercise Group|"Telerehabilitation will be applied in this group, which will last 4 weeks, and include the following processes~Exercises that will be performed every Monday will be taught and applied face-to-face under the supervision of the therapist with online videoconferencing method. Then, videos of weekly exercises that will be prepared by the therapist will be transmitted online to patients.~Patients will be asked to perform these exercises 4 days a week in the same week, on Wednesdays, Fridays and Sundays.~Also, a video call will be made on Fridays to evaluate whether the movements are done effectively and correctly, and questions of patients (if any) will be answered.~Patients will be informed by the physiotherapist that they should send messages on Wednesdays and Sundays to show that they are doing the exercises.~The exercise program of new week will be taught every Monday for 4 weeks, the prepared video will be sent, and the program will be advanced and completed."
32768911|NCT04831931|Active Comparator|Exercise Group|Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
32768912|NCT04831931|No Intervention|Control Group|No exercise application will be done in this group.Evaluation tests will be applied for 4 weeks only online.
32768913|NCT05066035|Active Comparator|Neostigmine|"The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
32768914|NCT05066035|Active Comparator|Neostigmine and Sugammadex|"In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
32768915|NCT04428593|Experimental|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
32768916|NCT04428593|Experimental|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
32768917|NCT04428593|Experimental|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
32768918|NCT04428593|Placebo Comparator|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
32768919|NCT03852667|No Intervention|Control|No intervention between the two test sessions
32768920|NCT03852667|Active Comparator|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
32768921|NCT03852667|Experimental|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
32768922|NCT04822649|Other|Heart failure with preserved ejection fraction|Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients. Left ventricular end-diastolic pressure will be assessed during coronary angiography.
32768923|NCT03753373|Experimental|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
32768924|NCT03753373|Active Comparator|Home Exercise Only|The prescribed home exercise program alone
32768925|NCT04831853|Experimental|Supervised self-swabbing followed by conventional swabbing|the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
32768926|NCT04831853|Experimental|Conventional swabbing followed by supervised self-swabbing|the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
32768927|NCT05058625|Experimental|Needly Group|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
32768928|NCT05058625|Active Comparator|Control Group|Normal volleyball training
33251797|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
33251798|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
33082189|NCT04622137|No Intervention|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
33251799|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
33251800|NCT00891189||1 Control|Healthy participants without asthma
32931387|NCT04809402|Other|Telemonitoring|Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.
32931388|NCT04809402|No Intervention|Usual care|Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.
33251801|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
33251802|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
33251803|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
33251804|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
32931389|NCT04711590||Successful extubation|The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
32931390|NCT04711590||Failed extubation|The patients pass the spontaneous breathing trial and are successful extubated with reintubation within 72 hours. .
32768929|NCT04831463|Experimental|experimental group|The experimental (N = 49) received a short-term IHAPIM program by one-on-one interview (5 week, 1 hr per week, 10 hr in total).
32931391|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
32931392|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
32768930|NCT04831463|No Intervention|control group|Firstly, Pre-tests were applied to the men in the control group. No intervention was applied to this group. Post-tests were made 3 months after finished intervention which applied to experimental group.
32768931|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
32931393|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
32931394|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
32931395|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
32931396|NCT03138512|Experimental|Part A, Arm A: nivolumab + ipilimumab|
32931397|NCT03138512|Placebo Comparator|Part A, Arm B: nivolumab placebo + ipilimumab placebo|
32931398|NCT03138512|Experimental|Part B, Arm A: nivolumab + ipilimumab|
32931399|NCT03138512|Placebo Comparator|Part B, Arm B: nivolumab placebo + ipilimumab placebo|
32931400|NCT03138512|Experimental|Part B, Arm C: nivolumab + ipilimumab placebo|
32931401|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
32931402|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
32931403|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
32931404|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
32931405|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
32931406|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
32931407|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
32931408|NCT01934660||Group 1|Healthy volunteers
32931409|NCT01934660||Group 2|Subjects diagnosed with diabetes
32931410|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
33251805|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
33251806|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
33251807|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
33251808|NCT04036617|Experimental|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
33251809|NCT04036617|Experimental|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
33251810|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
33251811|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
33251812|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
32768932|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
32768933|NCT04822571|Other|Adolescent volunteers|Adolescent males aged 12-16 years old
32931411|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
32931412|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
32931413|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
32931414|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
32931415|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
32931416|NCT02306161|Experimental|Regimen A (VDC/IE)|See Design Details.
32931417|NCT02306161|Experimental|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT.~MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles."
32931418|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
33401018|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
32768934|NCT04822571|Other|Adult volunteers|Adult males aged 25-35 years old
32768935|NCT03722095|Active Comparator|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
32931419|NCT02444936|No Intervention|Control|There is no drug given in this arm.
32931420|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
32931421|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
32931422|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
32931423|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
32931424|NCT05720923||MFS_f|Patients with Marfan syndrome with fatigue
32931425|NCT05720923||MFS_nf|Patients with Marfan syndrome without fatigue
32931426|NCT05720923||EDS_f|Patients with Ehlers Danlos syndrome with fatigue
32931427|NCT05720923||EDS_nf|Patients with Ehlers Danlos syndrome without fatigue
32931428|NCT05720923||Volunteers|Healthy adult volunteers without fatigue
32931429|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
32931430|NCT05052853|Experimental|NMDAE|An NMDA enhancer
32931431|NCT05052853|Placebo Comparator|Placebo|Placebo
32931432|NCT05030701||cancerous patients|
32931433|NCT05030701||non cancerous patients|
32931434|NCT05720845|Active Comparator|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia
32931435|NCT05720845|Experimental|VESPA|ventilatory strategy to prevent atelectasis for General Anesthesia
32931436|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
32931437|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
32931438|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
32931439|NCT05720533|Experimental|Disitamab Vedotin Combined With Sintilimab|Treatment regimen is Disitamab vedotin 2.5mg/kg and Sintilimab 200mg every 21 days, until disease progression or intolerable adverse reactions or death.
32931440|NCT05720455|Experimental|Fexofenadine HCL + pseudoephedrine HCL|Participants will take a tablet containing fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 10 days (+/- 3 days based on investigator's clinical judgement)
32931441|NCT04744766|Active Comparator|Hadfield technique group|central/mammary duct excision is done by the ordinary method described by Hadfield
32931442|NCT04744766|Active Comparator|Al Masad technique group|same procedure with de-epithelization of the upper pararaeolar area
32931443|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
33082190|NCT04622137|Active Comparator|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
33251813|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
33401019|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
32728711|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
33251814|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
33251815|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
33251816|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
33251817|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
33251818|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
33251819|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
33251820|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
33251821|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
33251822|NCT00893529|Experimental|dietary intervention 1|
33251823|NCT00893529|Experimental|dietary intervention 2|
33251824|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
33251825|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
33251826|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
33251827|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
33251828|NCT04035382|Experimental|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
33251829|NCT00891501|Experimental|Single|Clinical case series
33251830|NCT00967564||001|epidemiologic study QoL assessment
33251831|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
33251832|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
33251833|NCT05131282||PE group|Women with a confirmative diagnosis of PE
33251834|NCT05131282||Normal pregnancy group|Normal pregnant women
33251835|NCT04036149|Experimental|LUCIA|CT LUCIA 611P - Intraocular lens
33251836|NCT04036149|Active Comparator|ASPHINA|CT ASPHINA 409MP - Intraocular lens
33251837|NCT00975442|Experimental|Eccentric training|
33251838|NCT00975442|Placebo Comparator|Forearm band|
33251839|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
33251840|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
33251841|NCT00968734|Experimental|Low fat meal|
33251842|NCT00968734|Experimental|Hight fat meal|
33251843|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
33251844|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex or generic] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
33251845|NCT04008316|Experimental|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
32768936|NCT03722095|Sham Comparator|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
33251846|NCT04008316|Placebo Comparator|placebo|placebo 1 tablet / day during 6 months
33251847|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
33251848|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
33251849|NCT00969046|Experimental|Bolus|20 min bolus infusion
33251850|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
33251851|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
33251852|NCT05011708|Experimental|Test (I-DROP MGD)|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
33251853|NCT05011708|Active Comparator|Control - Thealoz Duo|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
33251854|NCT00893685|Experimental|Home telemonitoring|
33251855|NCT00893685|No Intervention|Usual care (control group)|
33251856|NCT05008354|Active Comparator|Pyridoxine|
33251857|NCT05008354|Placebo Comparator|Placebo|
33251858|NCT03599661||Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
33251859|NCT00975754|Experimental|1|Pulmicort pMDI
33251860|NCT00975754|Experimental|2|Budesonide pMDI
33251861|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
33251862|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
32728712|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
32728713|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
32728714|NCT03396055|No Intervention|Control|No intervention
32728715|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
33251863|NCT00975754|Experimental|5|Pulmicort Turbohaler
33251864|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
33251865|NCT00868647|Other|Radiofrequency Ablation|
33251866|NCT00975832||women with polycystic ovary syndrome|
33251867|NCT00975832||women without polycystic ovary syndrome|
33251868|NCT00975832||women from 18-40 years of age|
33251869|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
33251870|NCT00975910|Placebo Comparator|Saline|
33251871|NCT00975910|Active Comparator|Lidocaine|
33251872|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
33251873|NCT01048567|Placebo Comparator|Placebo|
33251874|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
33251875|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
33251876|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
32728716|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
33251877|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
33251878|NCT05073328||COVID-19 patients|COVID-19 patients discharged from all French hospitals from 01 February to 30 June 2020
33251879|NCT05073328||"sub group The long COVID patients"|"this cohort will include patients with at least 4 weeks of claims and specific health care use after hospital admission from the initial cohort (COVID-19 patients)~According to the Haute Autorité de Santé (HAS), the most frequent symptoms in the context of long COVID are the following :~Major fatigue~Dyspnoea, cough~Chest pain, often tightness type, palpitations~Problems with concentration and memory, lack of words~Headache, paraesthesia, burning sensation~Disorders of smell, taste, tinnitus, dizziness, odynophagia~Muscle, tendon or joint pain~Sleep disorders (especially insomnia)~Irritability, anxiety~Abdominal pain, nausea, diarrhea, decrease or loss of appetite~Pruritus, urticaria, pseudo-frostbite~Fever, chills"
33251880|NCT05073328||"sub group non long COVID patients"|all other patients from the initial cohort (COVID-19 patients )
33251881|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
33251882|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
33251883|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
32728717|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
32728718|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
33251884|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
33251885|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
33251886|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
33401020|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
33401021|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
33401022|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
32728719|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
32728720|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
32728721|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
32728722|NCT03821519|Experimental|Relapsed after Haplo transplant|
32728723|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
32728724|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
32728725|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
33082191|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
32931444|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
33082192|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
33401023|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
32931445|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
32931446|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
32931447|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
32931448|NCT04344691|No Intervention|Control|5 minutes waiting time
32931449|NCT04344691|Experimental|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
32728726|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
32931451|NCT05720377|Experimental|Obese, receives access to exercise phone application|obese, receives access to exercise phone application and interval contact by health provider in between clinic visits , receives continuous glucose monitor
32931452|NCT05720377|No Intervention|Obese, no intervention|obese, receives continuous glucose monitor
32931453|NCT05720377|Experimental|Prediabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
32728727|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
32728728|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
32728729|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
32931454|NCT05720377|No Intervention|Prediabetes, no intervention|prediabetes, receives continuous glucose monitor
32931455|NCT05720377|Experimental|Type 2 diabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
32931456|NCT05720377|No Intervention|Type 2 diabetes, no intervention|Type 2 diabetes, receives continuous glucose monitor
32931457|NCT05021653||Men who have sex with men (MSM)|Chinese men who have sex with men living with HIV infection and attending the service of HIV specialist service in Hong Kong
32931458|NCT05021653||non-MSM|Chinese heterosexual men and women living with HIV infection and attending the service of HIV specialist service in Hong Kong
32931459|NCT05720299|Experimental|low-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
32931460|NCT05720299|Experimental|high-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
32728730|NCT05239325|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
32728731|NCT05239325|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2022 (first timers) and have not yet received health education information."
32931461|NCT05720299|Placebo Comparator|Placebo group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
32931462|NCT05720221||Adalimumab group|"Patients receive adalimumab (Humira) at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 40 mg every other week.~The efficacy of the drug will be assessed."
32931463|NCT05720221||Ustekinumab group|"Patients receive ustekinumab (Stelara) through intravenous infusion with a weight based dose for treatment induction, followed by a subcutaneous dose injection with a fixed dose (90 mg) for maintenance every 8 weeks.~The efficacy of the drug will be assessed."
32931464|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
32931465|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
32931466|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
32931467|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
32931468|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
32931469|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
32931470|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
32931471|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
32931472|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
32931473|NCT05013307|Experimental|CASE|In this prospective study the investigators aim to quantify participants' responses to physical activity. Participants will be asked to engage in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.
32931474|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
32931475|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
33073647|NCT00542451|Experimental|Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab could be continued on a weekly basis, or the regimen could be changed to 6 mg per kilogram every 3 weeks for 40 weeks to complete a full year of intravenous treatment with trastuzumab.
33073648|NCT00507923|Experimental|Group I (Tibetan yoga)|Participants participate in Tibetan yoga sessions consisting of deep breathing or stretching exercises over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions.
33073649|NCT00507923|Active Comparator|Group II (stretching)|Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
33073650|NCT00507923|Active Comparator|Group III (usual care)|Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
33073653|NCT00450788||Golestan Cohort|Cohort of adults from Golestan region in Iran
33073654|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
33073657|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
33073658|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
33073659|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
33073660|NCT00369421||Healthy Volunteers|Healthy Volunteers
33073661|NCT00369421||Patients|Patients with unique disorders
33073662|NCT00369421||Unaffected family members|Unaffected family members of patients
32931476|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
32931477|NCT03496662|Experimental|Part A - Experimental Dose Level 0|"BMS-813160 300 mg twice per day~Nivolumab 30-minute intravenous (IV) infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cyclesore cycles"
32768937|NCT04822415|Experimental|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
32768938|NCT04822415|Active Comparator|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
33073663|NCT00362843||healthy volunteers|healthy volunteers
33073664|NCT00362843||patients|Patients with Fragile X Syndrome
33073665|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
32768939|NCT03661333|Experimental|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
33251887|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
33251888|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
33251889|NCT03557619|Experimental|Ethinyl estradiol/Levonorgestrel and Venetoclax|Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.
32931478|NCT03496662|Active Comparator|Part A - Control (chemotherapy only)|"Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
32931479|NCT03496662|Experimental|Part B - Dose expansion|"BMS-813160 300 mg twice per day~Nivolumab 30-minute IV infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
32931480|NCT05002309|Experimental|Psychotherapy|Cognitive-behavioural therapy
32931481|NCT05002309|Experimental|Pharmacotherapy|Antidepressant medication
32931482|NCT05720065|Active Comparator|Botulinum toxin|Single bilateral injection into three standardized points of the masseter muscles and two of the anterior temporalis muscle. The total dose administered is 100 U (10 U/point) which is dissolved in 1 mL of isotonic saline. Thus, 0.1 ml of botulinum toxin solution is injected in each point.
32931483|NCT05720065|Placebo Comparator|Isotonic saline|Single injection of 1 mL isotonic saline (0.9 mg/mL) into the same five points per side in a similar manner as for botulinum toxin.
32931484|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
32931485|NCT04965649||Chronic Myeloid Leukemia|There will be approximately 10 patients with Chronic Myeloid Leukemia in this group
32931486|NCT04965649||Philadelphia+ Acute Lymphoblastic Leukemia|There will be approximately 20 patients with Philadelphia chromosome-positive Acute lymphocytic leukemia in this group
32931487|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
32931488|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
32931489|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
32931490|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
32931491|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
32931492|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
32931493|NCT05719831|Experimental|H-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
32931494|NCT05719831|Experimental|L-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)"
32931495|NCT05719831|Active Comparator|H-VA-dual-14|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
32931496|NCT05719753|Placebo Comparator|Standard of Care|Bard Catheter
32931497|NCT05719753|Experimental|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
32931498|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
32931499|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
32931500|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
32931501|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
32931502|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
32931503|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
32931504|NCT04693338|Experimental|Supportive care (ICP)|Patients complete surveys for 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile app to help with bothersome symptoms. Patients also complete questionnaires.
32931505|NCT00709033|Experimental|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
33073666|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
33073667|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
33082193|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
32728732|NCT02678143|Experimental|Recipients|"The recipient of one antigen mismatch unrelated HSCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 300 cGy of total body irradiation (TBI) on Day -2.~The recipient of haplo-SCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, fludarabine on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 400 cGy of TBI on Day -2.~For both types of HSCT, the frozen peripheral blood stem cells will be thawed and infused on Day 0 per institutional guidelines. GVHD prophylaxis will consist of cyclophosphamide on Days +3 and + 4, mycophenolate mofetil (MMF) three times a day on Days +5 through +35 then tapered off over 1 week provided there is no evidence of GVHD, and sirolimus starting on Day +5 and continuing for one year. Sirolimus can be tapered at one year only if donor T-cell chimerism reaches more than 50% in the absence of GVHD."
32728733|NCT05238701|Experimental|LPM3770164|LPM3770164 sustained-release tablets will be administrated with single dose from 0.5mg to 60mg
32728734|NCT05238701|Placebo Comparator|Placebo|LPM3770164 sustained release tablet simulant will be administrated with single dose
32931506|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
32728735|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
32728736|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
32728737|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
32728738|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
32728739|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
32728740|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
32728741|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
32728742|NCT04330183|Placebo Comparator|Normal Saline|Patients here will be administered 3cc of normal saline as placebo
32728743|NCT04330183|Experimental|Ketamine Interventions|Patients will be administered weight based 0.3mg/kg of ketamine
32728744|NCT05097053|Experimental|MVC-COV1901 vaccine (3-month Interval)|There will be approximately 100 participants (Group A) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 1
32931507|NCT04948489|Experimental|LNG IUD+ Norethindrone Acetate|All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
32728745|NCT05097053|Experimental|MVC-COV1901 vaccine (6-month Interval)|There will be approximately 100 participants (Group B) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 85.
32728746|NCT04323475|Active Comparator|Standard of Care|Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
32931508|NCT04948489|Placebo Comparator|LNG IUD+Placebo|All eligible participants will have the LNG-IUD. Participants in the placebo comparator group will also receive a placebo tablet, 1 tablet by mouth daily for 12 months.
32931509|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
32728747|NCT04323475|Experimental|Cocktail-SPK and standard of care|The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
32728748|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
32728749|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
32728750|NCT04295863|Experimental|standard interval dosing|
32931510|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
32931511|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
32931512|NCT05222802|Experimental|Dose Escalation (Part 1)|ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
32931513|NCT05222802|Experimental|Dose Expansion (Part 2)|ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.
32931514|NCT05719597|Experimental|PEP (Positive Expiratory Pressure)|Group A
32931515|NCT05719597|Experimental|IS (Incentive Spirometry)|Group B
32931516|NCT05652972|Experimental|Ketogenic diet|40 women which will follow the ketogenic diet with 1700 kcal daily for 8 weeks
32931517|NCT05652972|Active Comparator|Control diet|40 women which will follow the standard diet with 1700 kcal daily for 8 weeks
32931518|NCT05715697|Experimental|Renal denervation and maintenance of heart failure medications|Renal denervation in patients with HFpEF and uncontrolled hypertension
32931519|NCT05715697|Sham Comparator|Sham intervention, maintenance of heart failure medications|Sham Treatment. After 1 year, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
32931520|NCT05719519|Other|Smokers|
32931521|NCT05719519|Experimental|Non smokers|
32931522|NCT05719441|Experimental|Arm 1: VRC07-523LS + PGT121.414.LS + ART|
32728751|NCT04295863|Experimental|extended interval dosing|
32728752|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
32728753|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
32728754|NCT04249297||IVF/Dydrogesteron|Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology
32728755|NCT05063825|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
32931523|NCT05719441|Placebo Comparator|Arm 2: Placebo + ART|
32931524|NCT05719363|Experimental|POC ON|6MWT with Inogen One® G5 POC turned ON
32931525|NCT05719363|Sham Comparator|POC OFF|6MWT with Inogen One® G5 POC turned OFF
32931526|NCT05723497|Experimental|Elderberry juice|Participants will consume elderberry juice twice/day for 1-week.
32728756|NCT05063825|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
32728757|NCT04236739|Experimental|IMPACT|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) during one surgical procedure.
32728758|NCT04236739|No Intervention|Control|Optional physical therapy or pain medication, according to participants' desire for 9 months.
32931527|NCT05723497|Placebo Comparator|Placebo beverage|Participants will consume placebo beverage twice/day for 1-week.
32931528|NCT01593254|Active Comparator|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
32931529|NCT01593254|Active Comparator|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
32931530|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
32931531|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
32931532|NCT05715619|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
32931533|NCT05715619|Active Comparator|VRELysin™|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
32743501|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
32768940|NCT04834817|Experimental|LED treatment|LED treatment with Celluma POD device after laser test area
32768941|NCT04834817|No Intervention|Control|No treatment after laser test area
32931534|NCT05723341|Active Comparator|Paravertebral Block Group|In this group, preoperative ultrasound-guided paravertebral block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 in the paravertebral space.
32931535|NCT05723341|Active Comparator|Subcostal Transversus Abdominis Plane Block Group|In this group, preoperative ultrasound-guided subcostal transversus abdominis plane block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 into the fascial plane between erector spine muscle and transverse process
32931536|NCT05723341|Active Comparator|Intravenous Patient Controlled Analgesia|In this group, postoperative patient controlled analgesia with morphine will be preferred for postoperative analgesia method.
32931537|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
32931538|NCT05718583|Experimental|RA Patients who are Inadequate Responders to Current RA Treatment|Oral butyrate will be taken at 1000 mg three times daily with meals by RA patients who have active disease and are currently taking methotrexate (MTX) at prescriber's recommended dose. There will be no dose escalation of the study supplement. Clinical data to assess for adverse events, stool, urine samples and peripheral blood will be collected at baseline, 1 month, and with an optional 2-month time-point.
32931539|NCT05717335||Patients with ventricular entry during surgery (vascular, tumoral and epilepsy).|Group of patients operated on for periventricular lesions with ventricular entry and placement of TachoSil directly over the area of ventricular opening in order to avoid complications.
32931540|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
32931541|NCT00363428|Experimental|Lifestyle intervention|
32931542|NCT05717257|Experimental|Dapagliflozin|Dapagliflozin will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
32931543|NCT05717257|No Intervention|Control|Participants assigned to this group will continue the standard optimized medical therapy
33073669|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
33251892|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
33251893|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
33251894|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
33251895|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
33251896|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
33251897|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
33251898|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
33251899|NCT04008472|Experimental|Telemedecine|Patients benefiting from telemedicine
33251900|NCT04008472|No Intervention|Control|routine care without telemedecine
33251901|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
33251902|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
32768942|NCT05065177|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
33251903|NCT00368641|Experimental|Intervention|peritoneal dialysis
33251904|NCT00368641|No Intervention|Standard of Care|
33251905|NCT00976222|Other|1 Arm Ranibizumab|
33251906|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
33251907|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
33251908|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
33251909|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
33251910|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
33251911|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
33251912|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
33251913|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
33251914|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
32931544|NCT04341818|Experimental|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
33251915|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
33251916|NCT00976534|Experimental|1|
33251917|NCT00976534|Placebo Comparator|2|
33251918|NCT00979966|Experimental|A|Temsirolimus
32931545|NCT04341818|Experimental|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
32931546|NCT04341818|Experimental|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
33251919|NCT00979966|Experimental|B|Sunitinib
33251920|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
33251921|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
33251922|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
32931547|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
33251923|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
33251924|NCT04007926|No Intervention|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
32931548|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
33251925|NCT04007926|Experimental|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
33251926|NCT04007926|Experimental|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
33251927|NCT00969904|Active Comparator|1|
33251928|NCT00969904|Placebo Comparator|2|
33251929|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
33251930|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
33251931|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
33251932|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
33251933|NCT00608985|Experimental|1|almorexant 200 mg
33251934|NCT00608985|Experimental|2|almorexant 100 mg
33251935|NCT00608985|Placebo Comparator|3|Placebo
33251936|NCT00608985|Active Comparator|4|zolpidem 10 mg
33251937|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
33251938|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
32931549|NCT05715541|Other|Comparison of INR Control and Drug Compliance Values by Groups|"Follow-up of the patients in the control group continued in the outpatient clinic.~This application includes an interface where patients can enter drug treatment information such as INR values, disease diagnosis, how many times a day and how many mg they take, and a chat box section where they can communicate with their physicians, including emergencies. The doctor reviewed the patient's INR findings once they were relayed by the patient, then told them to adjust the patient's warfarin dosage and schedule the next INR check. The application sent notifications to the patients every day about when and how many mg of the drug they would take"
32931550|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
32931551|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
32728759|NCT05063123|Other|Single arm - Flotetuzumab|1 - 3 cycles of Flotetuzumab. Flotetuzumab will be administered intravenously via continuous (pump) administration. At least for the first 7 days of cycle 1, the drug will be administered in an inpatient hospital setting, but afterwards may be administered in an outpatient setting using an ambulatory pump configuration. Flotetuzumab will be dosed using multi-step increments in dosing over the first week as follows: 30, 60, 100, 200, 300, and 400 ng/kg/day each for 24 hours. On day 7, the dose will be increased to 500 ng/kg/day and administered as a continuous infusion for the remainder of cycle 1. After 1 cycle of flotetuzumab patients will proceed with alloHCT. However if there is a delay in access to transplantation, patients are allowed to receive up to 2 additional cycles flotetuzumab provided all non-hematologic toxicities have resolved to Grade <2.
32728760|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
32728761|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
32728762|NCT05238077|Other|VL-UVA1 vs NB-UVB|Participants will be treated with both VL-UVA and NB-UVB on different areas
32728763|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
32931552|NCT05576701|Experimental|Laughter Therapy|Laughter therapy consists of group-based interventions that include yoga breathing exercises and stillness. Laughter education is a form of exercise with gratuitous laughter and childlike play. Laughter therapy practices consist of four steps. These; warming exercises, deep exercises, playing childlike games and entertainment (eg greeting laughter, lion laughter, milk waving sounds, quiet laughter, etc.). Laughter therapy sessions in the study were carried out for 4 weeks and three times a week. Laughter therapy has been applied by researchers who have a leader certificate.
32728764|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
32728765|NCT03394937|Experimental|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
32728766|NCT03394937|Experimental|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
32728767|NCT03394937|Experimental|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
32728768|NCT03394937|Experimental|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
32728769|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue with dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue with drain
32728770|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue without dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue without drain
32728771|NCT04177381|Active Comparator|non closure of subcutaneous tissue with drain|In the drain group,a closed non vacuum drain will be inserted in the tissue and exit from the skin through a separate opening and stitch to the skin
32728772|NCT04177381|Active Comparator|non closure of subcutaneous tissue and no drain|75 women without subcutanous sutures and without drain
32931553|NCT05576701|Active Comparator|Control|"The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. The patients were followed for four weeks. Before the study, data collection tools were applied to the patients. Again, after the study started and the study ended, all other data collection tools were applied, except the Patient Information Form."
32728773|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
32728774|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
33251939|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
33251940|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
33251941|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
33251942|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
33251943|NCT02540967||BAY86-4875|Gadovist administration goup
32728775|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
32728776|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
32728777|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
32728778|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
32728779|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
32728780|NCT04042285|Active Comparator|Extracorporeal shockwave therapy|The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).
32728781|NCT04042285|Placebo Comparator|Standard wound care|Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.
32728782|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
32931557|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
32728783|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
32728784|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
32728785|NCT04038385|Experimental|Intervention|This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period [June 19 to August 19]), and 2) monthly trips to an area farmers' market (between September 1, 2019 and November 30, 2019 [the end of the local growing season]).
32931558|NCT05717179|No Intervention|Clinical decision strategy|All patients receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use at week 12 is at the discretion of the investigator.
32931559|NCT05717179|Experimental|Clinical plus ultrasound-based decision strategy|All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background csDMARD(s) will be continued.
32931560|NCT05714527|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
32931561|NCT05714527|Active Comparator|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
32931562|NCT05717101||Observational (medical records)|Patients who have undergo contrast-enhanced harmonic endoscopic ultrasound imaging have their medical records reviewed.
32931563|NCT03172494|Experimental|Insulin degludec/liraglutide|
32931564|NCT03172494|Active Comparator|Insulin degludec|
32931565|NCT03172494|Active Comparator|Liraglutide|
32931566|NCT05717023|Experimental|Online guided self-help intervention for sexual distress following sexual assault|The intervention only has one arm. All participants will be provided 4 sessions of guided self-help intervention to be completed once weekly.
32931567|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
32931568|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
32931569|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
32931570|NCT05716945|Experimental|Intervention STEP I (Year 1 after DMEK)|
32931571|NCT05716945|Active Comparator|Control STEP I (Year 1 after DMEK)|
32931572|NCT05716945|Experimental|Intervention STEP II (Year 2 after DMEK)|
32931573|NCT05716945|Active Comparator|Control STEP II (Year 2 after DMEK)|
32931574|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
32931575|NCT05716867||Children with early childhood caries aged between 36-71 month|
32931576|NCT05716867||Caries free children aged between 36-71 month|
33073671|NCT00341497||Cohort|Persons seen at dental clinics at 6 Veterans Affairs Medical Centers who had clinically visibleoral lesions
33073672|NCT00339495||Non-Screening|Participants received their usual care
32768943|NCT05065177|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
32768944|NCT04821947|Active Comparator|RIB Group|Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
32768945|NCT04821947|Active Comparator|LA Group|Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
32931577|NCT04341584|Experimental|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
32931578|NCT04341584|No Intervention|Standard of care|
32931579|NCT05716711|Experimental|GROUP 1|"GROUP 1~1st GROUP LAVENDER OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY FOR 1 MONTH WITH 20 DROPS A DAY INTO THE STOMA BAG"
32931580|NCT05716711|Experimental|GROUP 2|2nd GROUP MINT OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY DURING 1 MONTH.
32931581|NCT05716711|No Intervention|CONTROL GROUP|20 PATIENTS WITH COLOSTOMY WITH NO INTERVENTION
32931582|NCT04745000||Pulmonary Hypertension Participants|Children with Primary Pediatric Pulmonary Arterial Hypertension
32931583|NCT04745000||Control Participants|Children with a healthy heart and lungs
32931584|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
32931585|NCT05570929||Kidney Donor|Defined as a human individual donating a kidney
32931586|NCT05570929||Kidney Recipient|Defined as a patient suffering from chronic kidney disease being the recipient of a kidney transplant
32931587|NCT04341428|Experimental|DWP14012 20mg|Orally, once daily
32931588|NCT04341428|Active Comparator|Lansoprazole 15mg|Orally, once daily
32931589|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
32931590|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
32931591|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
32931592|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
32931593|NCT02978053|Experimental|Bright light|10 000 lux
32931594|NCT02978053|Placebo Comparator|Red light|400 lux
32931595|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
32931596|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
32931597|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
32931598|NCT03140670|Experimental|Single Arm|
32931599|NCT05568901|Active Comparator|LMC Alone|Caregivers who received standardized lethal means counseling (LMC) from the study team as well as a 1-page handout summarizing the counseling recommendations
32931600|NCT05568901|Experimental|LMC + Gun Locks|Caregivers who received standardized lethal means counseling (LMC) from the study team, 1-page handout summarizing the counseling recommendations, as well as the additional provision of 2 cable-style gun locks
32931601|NCT05714137|Experimental|Proximal massage and fist clenching|The experimental group of 36 patients underwent proximal massage and fist clenching after IV insertion. Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers. Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of twice a day for four days, lasting between 30 seconds - 1 minute. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
32931602|NCT05714137|No Intervention|Standard care for PVC|The standard care group of 36 patients received typical nursing PVC care. Standard nurse PVC care: Only standard PVC care and follow-up were provided. It was carefully avoided that the patients would interact with one another or be in the same patient room. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
32931603|NCT05712889|Experimental|Dose Escalation of VIP236|Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer
32931604|NCT05716399|Experimental|Transcutaneous electric stimulation pretreatment group|30 minutes before the implementation of spinal anesthesia, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
32728786|NCT04038385|No Intervention|Control|This group will receive routine services provided by WIC only.
32728787|NCT05237921|Experimental|Combined Exercise and Dietary Intervention|Behavioral Intervention
32728788|NCT05237921|Other|Control|Standard Care
32728789|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
32728790|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
32931605|NCT05716399|Active Comparator|Transcutaneous acupoint electrical stimulation treatment group|Within 30 minutes after the occurrence of hypotension, TEAS (density wave 10/50Hz, one side of Neiguan point and Quchi point connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
32931606|NCT05716399|Sham Comparator|Transcutaneous acupoint pseudo electric stimulation group|Paste the electrode, turn on the power, but no current output.
32931607|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
32728791|NCT03985189|Experimental|ME-401|ME-401 administered orally
32728792|NCT03391219|Active Comparator|intravitreal Bevacizumab|
32728793|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
32931608|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
32931609|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
32728794|NCT04446923|Experimental|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
32931610|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
32931611|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
32931612|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
32931613|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
32931614|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
32931615|NCT00358033|No Intervention|usual care|usual care
32931616|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
32931617|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
32931618|NCT03107286||Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
32931619|NCT05712343|Experimental|valacyclovir group|"Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) (Valacyclovir group)."
32931620|NCT05712343|Active Comparator|Control group|"Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days (Control group)."
32931621|NCT05215158|Active Comparator|Peribulbar dexmedetomidine|Peribulbar block will done using mixture of Lidocaine 2%, bupivacaine 0.5% plus 0.5 μg / kg dexmedetomidine perineurally (30 patients).
32931622|NCT05215158|Active Comparator|Intravenous dexmedetomidine|The peribulbar block will be done using a mixture of Lidocaine 2%, bupivacaine 0.5% plus 0.5 μg / kg dexmedetomidine in 50 mL of normal saline administered as an infusion over 10 min and is given 10 min before the start of the peribulbar block(30 patients).
32931623|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
32931624|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
32728795|NCT04446923|Active Comparator|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
32728796|NCT04447001|Experimental|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
32728797|NCT04447001|No Intervention|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
32728798|NCT03953053|Experimental|FLACS Group|Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)
32728799|NCT03953053|Active Comparator|Manual Group|Gold Standard Method with manual rhexis with pinzette and phaco emulsification
32728800|NCT05237843|Placebo Comparator|Group A (control group)|"35 women in this group will receive only the standard treatment in the form of :~low- dose aspirin (LDA) 81 mg/day orally (Jusprin® 81mg which manufactured by Future Pharmaceutical Company),~LMWH (Enoxaparin, Clexane® which manufactured by SANOFI company) with a dose ( .5 mg/kg) subcutaneously injected/24 hr .~LDA ought to be begun before origination, while LMWH ought to be begun after confirmation of pregnancy by detecting fetal viability by ultrasound till age of viability (20wks)~-PLUS Placebo specially manufactured tablets in Ain shams faculty of pharmacy will start once known she is pregnan"
32728801|NCT05237843|Experimental|Group B ( Hydroxychloroquine group )|This group included 35 women who will administered Hydroxychloroquine 200 mg (Hydroquine® 200mg which fabricated by MinaPharm Company) one tablets / day once known she is pregnant in addition to the standard therapy (LMWH + LDA )
33073673|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer
33073675|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
33073676|NCT00326456|Active Comparator|carboplatin and paclitaxel|
33073677|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
33073678|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
33073679|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
33073686|NCT00244842|Placebo Comparator|Placebo Comparator: 1|Placebo
33073687|NCT00244842|Active Comparator|Voclosporin 0.2 mg/kg po BID|Voclosporin 0.2 mg/kg po BID
33073688|NCT00244842|Active Comparator|Voclosporin 0.3 mg/kg po BID|Voclosporin 0.3 mg/kg po BID
33073689|NCT00244842|Active Comparator|Voclosporin 0.4 mg/kg po BID|Voclosporin 0.4 mg/kg po BID
32728802|NCT05237843|No Intervention|Study Director|Only those directing the study know the treatment that each participant receives Placebo OR Hydroxychloroquin
32728803|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
32728804|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
33073691|NCT00106925||1|allogeneic stem cell transplant recipients
32728805|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
32728806|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
32728807|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
33073692|NCT00106925||2|Donors
33073693|NCT00098072|No Intervention|Pilot|Pilot
33073694|NCT00097474|Experimental|Combination|Both HC 30 and ML 5 will be administered
32728808|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
32728809|NCT04447105|Experimental|TIVA group|Patients receiving total intravenous anesthesia with propofol.
32728810|NCT04447105|Active Comparator|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
33073695|NCT00097474|Experimental|Hydrocortisone|30mg Hydrocortisone will be administered
33073696|NCT00097474|Experimental|Melatonin|5 mg Melatonin will be administered
33073697|NCT00097474|Placebo Comparator|Placebo|Placebo
33073701|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
33073702|NCT00067054||1|Sample collection only
33073703|NCT00065676|Experimental|1 gram quercetin|1 gram quercetin with 6 hour OGTT
33073704|NCT00065676|Experimental|2 grams quercetin|2 gram quercetin with 6 hour OGTT
33073705|NCT00065676|Experimental|placebo|placebo with 6 hour OGTT
33073706|NCT00059748||Patients affected with autoinflammatory diseases|Subjects with known or suspected diagnosis of NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still s disease, Behcet s disease, JDM, and other autoinflammatory diseases.
33073711|NCT00050752||1 / Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
33073712|NCT00050752||2 / Family Members|Family members (related by blood) of patients who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
33073713|NCT00050752||3 / Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
32931625|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
32931626|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
32931627|NCT03101748|Experimental|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
32931628|NCT03101748|Experimental|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
32931629|NCT03101748|Experimental|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
32931630|NCT04744142|No Intervention|Placebo|Received 10% protein in nutrition + placebo supplement
32931631|NCT04744142|Experimental|Ketone|Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day
32931632|NCT04744142|Experimental|High protein|Received 30% protein in nutrition + placebo supplement
33401024|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
33401025|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
33401026|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
32931633|NCT04744142|Experimental|High protein + ketone|Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day
33401027|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
32931634|NCT05716243|Active Comparator|Group A|Group A will receive a standard intraoperative analgesia protocol
33401028|NCT04056104|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
33401029|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
33401030|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
33401031|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
33401032|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
33401033|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
33401034|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
33401035|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
33401036|NCT04055246|Experimental|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
33401037|NCT04055246|Placebo Comparator|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
32768946|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
32931635|NCT05716243|Experimental|Group B|Group B will receive a NOL-guided analgesia protocol
32931636|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
32931637|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
32931638|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
33401038|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
33401039|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
33401040|NCT03666260|Experimental|Quadratus Lumborum Block arm|
33401041|NCT03666260|Active Comparator|Femoral block arm|
32768947|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
32931639|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.
32931640|NCT05710783|Experimental|Phase II - Experimental|AVX-COVID/12 Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response, Cellular response
32931641|NCT05710783|Active Comparator|Phase II - Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response, Cellular response
32931642|NCT05710783|Experimental|Phase III - Experimental|AVX-COVID/12 Intramuscular Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response
32931643|NCT05710783|Active Comparator|Phase III - Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response
32931644|NCT05710783|Experimental|Phase III - Security|AVX-COVID/12 Intramuscular Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety.
32931645|NCT05710783|Experimental|Phase II- Experimental|AVX-COVID/12 Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response.
32931646|NCT05710783|Active Comparator|Phase II- Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response.
32931647|NCT05716165|Experimental|self-comparison|"Volunteers will be asked to wear a knee brace on each limb during one of the training sessions. At the end of this training session, a questionnaire will be given to the volunteer to evaluate knee stability, range of motion, confidence when walking, and fear of falling.~The volunteers will then have to participate in 2 test sessions: one with and one without knee braces.~The patient will perform tests (Unipodal balance on flat ground, 30s chair stand test, 2,5m up and go test, 6 min-walk) with and without the proprioceptive knee brace in a randomized order.~At the end of the tests with and without knee brace, a questionnaire will be given to the volunteer to evaluate the stability of the knee, the range of motion, the confidence when walking, the fear of falling, as well as a satisfaction questionnaire about the device.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
32931648|NCT03362502|Experimental|PF-06939926|
32931649|NCT05716087|Experimental|LP-168|Subjects who have previously received BTK inhibitors treatment failed or relapsed after remission or intolerated
32931650|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
32931651|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
32931652|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
32931653|NCT05233410|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
32931654|NCT05233410|Placebo Comparator|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
32931655|NCT05716009|Experimental|Phase 1a Dose Escalation of tagraxofusp-erzs in r/r AML|"Tagraxofusp-erzs and gemtuzumab ozogamicin (GO) will be administered every 4 weeks with 28 days defined as a treatment cycle. Tagraxofusp-erzs dose escalation for cycles 1-4 in combination with fixed dose GO.~This is a dose escalation design . The dose-limiting toxicity (DLT) period will be the 28 days following the first dose of GO. The initial dose level 1 (DL1) cohort will receive GO 3mg/m2 (capped at a maximum dose of 4.5mg) intravenously (IV) on cycle 1 days 1, 4, and 7 and tagraxofusp-erzs at an initial dose of 7μg/kg/day on days 10, 11, 12. For subsequent cycles of DL1, GO will continue to be administered at a dose of 3mg/m2 IV on day 1 and tagraxofusp-erzs will be administered IV at a dose of 7μg/kg/day on days 4,5,and 6. Subsequent escalation dose levels will receive tagraxofusp-erzs doses of 7mcg/kg/day, 9mcg/kg/day or 12mcg/kg/day. Initial cycle doses of tagraxofusp at these levels will be given on Days 5,6 and 7, then in subsequent cycles on days 1,2 and 3."
32931656|NCT05716009|Experimental|Phase 1b recommended Phase 2 dose (RP2D) of tagraxofusp- erzs in r/r AML|This is dose expansion at the RP2D of tagraxofusp. Participants with relapsed or refractory acute myeloid leukemia (r/r AML) will receive the RP2D of tagraxofusp-erzs, as determined in Phase 1a, and gemtuzumab at a dose of 3mg/m2 (max absolute dose of 4.5mg) on days 1,4, and 7 of cycle 1 and day 1 of subsequent cycles.
32931657|NCT04602390|Experimental|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
32931658|NCT04602390|Experimental|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
32931659|NCT04602390|Experimental|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
32931660|NCT04602390|Experimental|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
32931661|NCT04602390|Experimental|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
32931662|NCT05710471|Experimental|Brolucizumab|new drug (brolocizumab) and novel treatment protocol
32931663|NCT05710471|Active Comparator|Aflibercept|aflibercept and continuing on the traditional T&E protocol. There will also be a rescue option for those in the aflibercept arm who are not responding well to also switch to brolocizumab
32931664|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
32931665|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
32931666|NCT05652894|Experimental|HX008|Subjects receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
32931667|NCT05652894|Active Comparator|Investigator's Choice Chemotherapy|"mFOLFOX6~mFOLFOX6+Bevacizumab~mFOLFOX6+Cetuximab~FOLFORI~FOLFORI+Bevacizumab~FOLFORI+Cetuximab"
32931668|NCT04591080|Experimental|GUMMETAL TiNbTaZr|"TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires. We will be using an archwire with the size of 0.016 x 0.022"
32931669|NCT04591080|Active Comparator|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
32931670|NCT05652816|Sham Comparator|STSG (Split-Thickness Skin Graft)|Patients treated with the standard treatment; autologous skin graft
32931671|NCT05652816|Experimental|Amnion Bilayer Only|Patients treated with artificial graft only
32728811|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
32931672|NCT05652816|Experimental|Amnion Bilayer seeded with co-culture|Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
32931673|NCT05702593|Other|Surface EMG Data Collection|For each subject, EMG activity was recorded from the left and right superficial masseter muscles using a multichannel EMG device.The EMG recordings were obtained with three repetitions during mandibular rest, and maximal voluntary isometric contractions (MVIC) in intercuspation (isometry) pre and post-treatment. The EMG data were recorded for 5 seconds, and three trials with 30 seconds of rest between contractions were performed [Tosato, SENIAM].
32931674|NCT05702593|Other|Pressure pain threshold|The pressure pain threshold was measured using a mechanical pressure algometer (model Baseline® Dolorimeters - Fabrication Enterprises Inc) with a contact head of 1 cm2 area.
32931675|NCT05702593|Other|Maximum Active Mouth Opening (MMO)|A tape measure was used to determine the maximum active mouth opening (MMO).
32931676|NCT05702593|Other|Hamstring Flexibility|The Maximal Hip Flexion Active Knee Extension (MHFAKE) Test, which is an adapted active knee extension test, was performed to evaluate the hamstring flexibility of the participant.
32931677|NCT05702593|Other|Tragus Wall Distance|Tragus wall distance measurement was used to evaluate spinal mobility.
32931678|NCT05702593|Experimental|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles
32931679|NCT05702593|Experimental|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms.
32931680|NCT04566042|Experimental|ACT video game|
32931681|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
32931682|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
32931683|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
32931684|NCT05370469|Experimental|Cohort A|Subjects who, at enrollment, have been on a TKI for less than 4 weeks will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, 1 Week, 2 Weeks, 4 Weeks, 8 Weeks, 16 weeks, and 24 weeks.
32931685|NCT05370469|Experimental|Cohort B|Subjects who, at enrollment, have been on a TKI for 4 weeks or more will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, Week 1, and then every 8 weeks for 24 weeks.
32931686|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
32931687|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
32931688|NCT05544175|Experimental|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation therapy (low-voltage electrical stimulation of the posterior roots of the spinal cord) by electrodes inserted epidurally from a laminotomy in the lumbosacral region.~Intensive, four hour per day, individual physiotherapy (soft techniques, methods based on neurophysiology, so-called neuroproprioceptive facilitation, inhibition (Vojta's reflex method, Motor programs activating therapy, Proprioceptive neuromuscular stimulation, Bobath concept) will be combined with methods of acquiring motor skills (individualized therapy using the knowledge of sensorimotor learning) will take minimally one month."
32931689|NCT00358423|Experimental|A|
32931690|NCT00358423|Placebo Comparator|B|
32931691|NCT02896712|Active Comparator|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
32931692|NCT02896712|Active Comparator|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
32931693|NCT02896712|Experimental|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
32931694|NCT02896712|Active Comparator|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
32728812|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
32728813|NCT04447261|Experimental|BI 1356225|
32931695|NCT02896712|Active Comparator|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
32728814|NCT04447261|Placebo Comparator|Placebo|
32728815|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
32728816|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
32728817|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
32931696|NCT02896712|Experimental|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
32931697|NCT02977585|Active Comparator|group 1|high level support
32931698|NCT02977585|No Intervention|group 0|low level support
32931699|NCT05540899|Experimental|Hypofractionated Postoperative Radiotherapy (H-PORT)|H-PORT of 50 Gy given over 4 weeks.
32931700|NCT04744064|Experimental|Soccer and protein supplementation|Soccer training and post exercise supplementation of protein enriched beverage
32931701|NCT04744064|Experimental|Soccer and carbohydrate supplementation|Soccer training and post exercise supplementation of carbohydrate enriched beverage
32931702|NCT04744064|No Intervention|Control group|A preliminary control group continueing normal lifestyle
32931703|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
32931704|NCT05700331|Experimental|Chronic Widespread Pain patients|3 FMT infusions, 2 weeks apart Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.
33401042|NCT03665714|Experimental|Impact Oral|"Preoperatively:~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
32931705|NCT05346601|Other|Chiauranib(In the fasting state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet
32931706|NCT05346601|Other|Chiauranib(In the high fat diet state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state
32768948|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
32768949|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
32931707|NCT04744844|Experimental|DNA-amplification selection|In the experimental arm, all blastocysts will undergo routine morphological assessment, with the 3 top-scoring blastocysts undergoing blastocoel fluid biopsy (BF-biopsy) and whole-genomic amplification. A single blastocyst with no DNA amplification will be selected for transfer in a frozen embryo transfer cycle.
32931708|NCT04744844|Active Comparator|Morfological-score selection|In the active comparator arm, all blastocysts will undergo routine morphological assessment. The (single) top-scoring blastocyst will be selected for transfer in a frozen embryo transfer cycle.
32931713|NCT02797184|Experimental|10mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
32931714|NCT02797184|Experimental|20mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
33401043|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
33401044|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
33401045|NCT04730947|Experimental|Dapagliflozin Group|Subjects with HFpEF will take the study drug dapagliflozin daily
33401046|NCT04730947|Placebo Comparator|Placebo Group|Subjects with HFpEF will take a placebo daily
33401047|NCT03559699|Experimental|AG-348|Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
33401048|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
33401049|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
32931715|NCT05336695|Experimental|Cognitively Normal Subjects and ADRD subjects|Cognitively Normal Subjects and ADRD subjects
32931716|NCT05330221|Experimental|Intervention Group|"PAL2 Intervention~Drug Therapy"
32931717|NCT05330221|No Intervention|Usual Care Group|Participants that are randomized into usual care will be assisted with arrangement of follow-up, either with existing primary care provider (PCP) or a Wayne Health provider. All subsequent medical treatment will be at the discretion of the PCP.
32931718|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
32931719|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
32931720|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
32931721|NCT05325073|Other|EPO Arm|
32931722|NCT00708890|Experimental|Intervention group|
32931723|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
32931724|NCT05321719|Experimental|Experimental: BeReady2Smile Video, App, & Coach|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
32931725|NCT05321719|Experimental|Assess the Contributions of BRS2 Components|Outcomes of video, app, and coach
32931726|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
32931727|NCT00669266||control group|Biomaterial from patients without adrenal tumor
32931728|NCT05525455|Experimental|Single agent TT-816|Escalating doses followed by expansion targeting advanced cancers
33251944|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33251945|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33251946|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32931729|NCT05525455|Experimental|Combination TT-816 plus a PD-1 inhibitor|Escalating doses followed by expansion targeting advanced cancers
33251947|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
32931730|NCT00669188|Experimental|Information Type 1|genetic risk information
32931731|NCT00669188|Sham Comparator|Information Type 2|information absent
32931732|NCT05524285|Experimental|experimental group|Intracranial Support Catheter
32931733|NCT05524285|Active Comparator|control group|Guide Catheter
32931734|NCT05693155||Individuals with a gambling problem|Recruited from a gambling disorder treatment unit and/or from social media advertising addressing individuals with a gambling problem.
32931735|NCT05693155||Concerned significant others|Recruited as concerned signifiant others of patients at a gambling disorder treatment unit and/or in social media advertising addressing concerned significant others of individuals with a gambling problem.
33251948|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
33251949|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
33251950|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
32728818|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
32931736|NCT05522881||HPV positive-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
32931737|NCT05522881||HPV negative-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
32931738|NCT05522881||HPV positive-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
32931739|NCT05522881||HPV negative-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
32931740|NCT04344379|Active Comparator|Arm Title : hydroxychloroquine|
32931741|NCT04344379|Placebo Comparator|Placebo of hydroxychloroquine|
32931742|NCT04344379|Active Comparator|azythromycin|
32931743|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
32931744|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
32931745|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
32931746|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
32931747|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
33251951|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
33251952|NCT00980356|Placebo Comparator|Placebo pill|
33251953|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
33251954|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
33251955|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
33251956|NCT00869115|Placebo Comparator|4|PLACEBO
33251957|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
33251958|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
33251959|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
33251960|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
33251961|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
33251962|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
32931748|NCT05448703||Group 1|Lung cancer patients treated with thoracic radiotherapy
32931749|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
32931750|NCT02465372|No Intervention|Control|Standard practice.
32931751|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
32931752|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
32931753|NCT05688709|Active Comparator|Control group|"Psychosocial services (PSS) are offered by a trained health worker in a designated space within the health facility. They assess youth for PSS needs and depending on the identified needs, health workers determine the relevant approach for providing PSS. Health workers refer PSS they cannot offer to established referral networks. Specifically, for ART adherence, health workers use the 5As principles to offer adherence psychosocial support. These are;~Assess patient psychosocial concerns and needs that may hinder adherence to ART.~Advise on the benefits of disclosure and support systems to adherence.~Assist patients identify the support systems that will enable them to adhere to treatment.~Agree on family and community support systems (expert client in the community).~Arrange for the patient to join psychosocial support groups and use support systems."
32931754|NCT05688709|Experimental|Intervention|In addition to MOH standard care, we will enrol YLHIVA on a WhatsApp PSG and assign them trained peer counsellors. We will allocate YLHIVA to a WhatsApp group depending on their age and the health facility where they seek care (12). YLHIVA will interact with each other and their peer counsellors through one-on-one private communications and on the group chat.
32931755|NCT05686603|Experimental|P-MLA|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece (P-MLA for short)
32931756|NCT05686603|Sham Comparator|AF-Er|ablative fractional 2940-nm Er:YAG laser (AF-Er for short)
32931757|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
32728819|NCT03398603||Group 1|25 women with age of 18-25 years
32728820|NCT03398603||Group 2|25 women with age of 26-40 years
32931758|NCT05682625||Participants|Adults who are receiving a COVID-19 vaccine
32931759|NCT05158452||Observational (focus group)|Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
32728821|NCT05237765|Experimental|midwife-controlled massage|
32728822|NCT05237765|Experimental|self-controlled massage|
32728823|NCT05237765|No Intervention|control group|
32931760|NCT05301673||Adults with ADHD|
32931761|NCT05301673||Partner, family member or close friend of the individuals with ADHD|
32931762|NCT04486326|Experimental|crofelemer|125mg bid
32931763|NCT04486326|Placebo Comparator|placebo|bid
32931764|NCT05297773|Experimental|Aerobic Training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform moderate-intensity cycling exercise.
32931765|NCT05297773|Experimental|Resistance training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform weight-machine strength exercises of the upper and lower body.
32931766|NCT05297773|Active Comparator|Control Group|One session per week of relaxation/stretching.
32931767|NCT05652426||Group 1|Basal cerebral oximetry levels between 41-60%
33073718|NCT00046202||normal subjects|subjects in whom no disorder of cholesterol is suspected related to affected individuals
33073719|NCT00046202||subjects suspected of cholesterol disorder|subjects in whom a disorder of cholesterol metabolism is suspected
32728824|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
32743502|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
32743503|NCT03056937||Obese with metabolic syndrome|bariatric surgery
32743504|NCT03056937||Obese without metabolic syndrome|bariatric surgery
32743505|NCT03056937||Healthy|Control
32931768|NCT05652426||Group 2|Basal cerebral oximetry levels > 61%
32931769|NCT05295901|Experimental|experimental group|"In the pre-test phase (first interview) - Patient Diagnosis Form, COPD Self-efficacy Scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale average 15-20 min. will be implemented.~After the pre-test, the mCOPD mobile application will be installed on the phones of the patients and it will be checked whether the mobile application is working. mobile application content will be explained. In addition, a pulse oximeter device will be given to the patients by the researcher to record their pulse and saturation values and its use will be explained.~In the final test phase (final interview); The COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (mMRC) Dyspnea Scale and the Satisfaction Questionnaire will be applied to determine the degree of satisfaction"
32931770|NCT05295901|No Intervention|control group|"In the pre-test phase (first interview); Patient Diagnosis Form, COPD self-efficacy scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (MRC) Dyspnea Scale will be applied. No action will be taken after the interview.~In the final testing phase (final interview); After applying the COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (MRC) Dyspnea Scale, the mCOPD application will be installed on their phones and training"
32931771|NCT04450836|Experimental|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
32931772|NCT04450836|Experimental|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
32931773|NCT05511025|Experimental|Cohort 1|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC
33073720|NCT00046189||1|Patients with XP
32931774|NCT05511025|Experimental|Cohort 2|Participants will receive a single dose of AZD6234 via an SC injection and matching volume of the placebo as a solution via SC injection
32931775|NCT05511025|Experimental|Cohort 3|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
32931776|NCT05511025|Experimental|Cohort 4|Participants will receive single ascending doses of AZD6234 via IV injection and matching volumes of the placebo as a solution via IV injection
32931777|NCT05511025|Experimental|Cohort 5|One dose level for SC administration is planned to be investigated for Japanese participants only
32931778|NCT05511025|Experimental|Cohort 6|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
33251963|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
33251964|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
32931779|NCT05511025|Experimental|Cohort 7|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
32931780|NCT05511025|Experimental|Cohort 8|Japanese participants will receive AZD6234 via SC injection and matching volumes of placebo as a solution via SC injection
32931781|NCT04436406|Experimental|Advanced malignant disease (non-small cell lung cancer or malignant melanoma)|"Group 1: Participants with non-small cell lung cancer (NSCLC) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 9 weeks.~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks.~Group 2: Participants with malignant melanoma (MM) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 12 weeks.~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
32931782|NCT05679193|Experimental|Propranolol|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule/20mg propranolol twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules/40mg propranolol twice daily) for the rest of the treatment period.
33251965|NCT00980434||1|patients with neurological symptoms
33251966|NCT00980434||2|patients without neurological symptoms
33251967|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
33251968|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
32931783|NCT05679193|Placebo Comparator|Placebo|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules twice daily) for the rest of the treatment period.
32931784|NCT04795752|Experimental|TearCare Group (Study Device)|
32931785|NCT04795752|Active Comparator|Restasis Group (Control)|
32931786|NCT05501353||Group1|Patients with various types of metastatic colorectal cancer who had underwent the radical resection of colorectal cancer and were planning to undergo radical resection of metastasis
32931787|NCT04795128|Other|IBI322|Single arm
32743506|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
32743507|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
32931788|NCT05292001|Experimental|Treatment|Single infusion of low molecular weight Iron Dextran
32931789|NCT05292001|Placebo Comparator|Placebo|Single infusion of normal saline
33251969|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
33251970|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
32931790|NCT01634178|Experimental|Sequence 1: Apremilast Fasted / Fed|In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
33251971|NCT02541123||Cohort E|Uninjured control group
32743508|NCT04934085||Study group|subjects who had tested positive and recovered from COVID-19
33073721|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
33251972|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
33251973|NCT00980512|No Intervention|Control|Control group
33251974|NCT02534077|Experimental|1|Drug: Omegaven
33251975|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
33251976|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
33251977|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
33251978|NCT00378079|Experimental|3|
33251979|NCT00378079|Active Comparator|1|
33251980|NCT00378079|Experimental|2|
33251981|NCT00970450|Experimental|Paracetamol|
33251982|NCT00970450|Experimental|Paracetamol/Tropisetron|
33251983|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
33251984|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
33251985|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
33251986|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
33251987|NCT00970528|Experimental|Arm 1|
33251988|NCT00970528|Active Comparator|Arm 2|
32931791|NCT01634178|Experimental|Sequence 2: Apremilast Fed / Fasted|In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.
32931792|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
32931793|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
32931794|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
32931795|NCT04418934|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
32931796|NCT04418934|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
32931797|NCT04794894||Telerehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at home via telecommunication technologies.
32728825|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
32728826|NCT05237375||The MIDWIZE model|"Pregnant women giving birth during at Naguru maternity ward during the intervention period~It's only Sub/study 2 in this PhD project which is a clinical trial and which is described onwards.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward during the implementation phase.~Data will be collected during the implementation of the quality improvement components."
32728827|NCT05237375||The MIDWIZE model - postintervention|"Pregnant women giving birth at Naguru maternity ward 6 months post intervention period.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward 6months after the implementation phase.~Data will be collected after implementing the quality improvement components. The post-measurement data will be collected on the chosen components six months after project implementation to measure if the midwife-led quality improvement project has been sustained."
32728828|NCT03398369|Experimental|Intervention|CMR-Guided CRT
32931798|NCT04794894||Clinic-based rehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at a local facility.
32931799|NCT05652192|Experimental|Experimental|"SBRT: Metastases were treated with SBRT, GTV 45Gy/3F/3d, each course of radiotherapy only treated metastases within 1 organ.~Chemotherapy(GP or TP) was combined with tislelizumab for 4-6 cycles and tislelizumab was maintained until 2 years or disease progression or intolerable toxicity or death.~Maintain: (1) For newly diagnosed metastatic patients, nasopharyngeal and metastatic lymph node irradiation was started 4 weeks after systemic therapy, using IMRT technique, only radiating the GTV of the nasopharyngeal and cervical region, DT 66 Gy/30 F/6 weeks was recommended. Tislelizumab was continued during radiotherapy and tislelizumab was used during maintenance."
32931800|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
32728829|NCT03398369|No Intervention|Control|Standard CRT
32728830|NCT05237219|Experimental|Passive heating|Patients will be randomized to receive whole-body passive heating via 38°C natural thermal mineral water baths.
32931801|NCT04782804|Active Comparator|Capecitabine|Capecitabine as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
32931802|NCT04782804|Experimental|Capecitabine+PD-1 Antibody（Tislelizumab）|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
32728831|NCT05237219|Active Comparator|Thermoneutral|Patients randomized to the comparator group will dip in thermoneutral natural thermal mineral water (30-32°C).
32728832|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
32931803|NCT05284435|Experimental|iCBT-Email (iCBT-E)|Parents will receive a weekly email from a therapist over the 12 weeks of treatment.
32728833|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
32728834|NCT05216315|Experimental|tDCS. Transcranial direct current stimulation|The stimulation time was 20 minutes, with an initial and final ramp of 30 seconds so that the participant could adapt to the sensation of the current. 10 sesions. Constant current intensity of 2 mA The anode was placed on position F7, coinciding with the dorsolateral prefrontal cortex, and the cathode was placed on Fp2, coinciding with the right supraorbital area (rSO).
32728835|NCT05216315|Sham Comparator|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.
32728836|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
32728837|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
32728838|NCT03398057|Placebo Comparator|Control group|Placebo health education.
32728839|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
32931804|NCT05284435|Active Comparator|iCBT-Email and Videoconferencing (iCBT-EV)|Parents will receive a weekly email and six 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
32931805|NCT04418388|Experimental|A|
32931806|NCT04418388|Experimental|B|
32931807|NCT04418388|Experimental|C|
32931808|NCT05282017||Case Group|Meets the COVID-19 like case definition AND Tests positive for at least one SARS-CoV-2 RT-PCR test or Quick-Test (Antigen) with specimens collected between 14 days prior to and including within 24 hours of the day of hospital admission (day 0).
32931809|NCT05282017||Control Group|Meets the COVID-19 case definition AND Tests negative for all SARS-CoV-2 RT-PCR or Quick-Test (Antigen) tests with specimens collected between 14 days prior to and including a negative test the day at hospital admission (day 0).
32931810|NCT04781400|Experimental|Remote service delivery model PLUS mobile phone support|Remote service delivery plus mobile intervention via SMS will include weekly check-ins from study staff, calls from a trained counsellor on request, and access to a two-way messaging feature.
32931811|NCT04781400|Active Comparator|Remote service delivery model|Remote service delivery model.
32931812|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
32931813|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
32931814|NCT05651880|Experimental|Patient treated with baricitinib|Patient treated with baricitinib at a dose of 4 mg per day, taken orally in the morning, with one tablet per day for 6 months.
32931815|NCT05280535|Experimental|Study Protocol|All participants will receive all laboratory protocol components in a within-person randomized order across two sequential laboratory sessions.
32931816|NCT04781166|Experimental|Intervention|Participants will be immediately assigned to the intervention.
32768950|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
32768951|NCT04834739|Active Comparator|Study group (30 volunteer healthcare workers who had Covid-19|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included.
32768952|NCT04834739|Active Comparator|Control group (30 volunteer healthcare workers who had not have Covid-19)|In control group, 30 volunteer healthcare workers who were matched for age ande gender with study group were included and these persons had not have Covid-19.
32768953|NCT05058235|Experimental|Active Release Technique|Hot pack, TENS, Quadriceps Isometric strengthening, Active Release Technique
32768954|NCT05058235|Active Comparator|Bent leg raise|Hot pack, TENS, Quadriceps Isometric strengthening, Bent leg raise
32768955|NCT04831541|Experimental|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
32768956|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
32768957|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
32768958|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
32768959|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
32768960|NCT05005039||Obese postmenopausal women who will undergo RYGB|
32768961|NCT05005039||Obese postmenopausal women who will undergo SG|
32768962|NCT05028205|Experimental|Prevention Plus|Child's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverages (e.g., regular carbonated soft drinks, sports drinks, lemonades, ice teas, flavored milk, juice drinks < 100% juice, and punches) servings /wk, ≥1 1 2 cups/day of whole vegetables and ≥ 1 cup/day of whole fruit, engage in ≥ 60 minutes/day of moderate- to vigorous-intensity physical activity, and reduce TV viewing to < 2 hours/day. The caregiver's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverage servings/wk, ≥ 2 1 2 cups/day of whole vegetables and ≥ 1 1 2 cups/day of whole fruit, engage in ≥ 150 minutes of moderate- to vigorous-intensity physical activity per week and reduce TV viewing to < 10 hours/wk.
32768963|NCT05058079|Active Comparator|Hand-held group|Patients hand will be held by the anesthesia provider during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will have their hand under the folded blanket holding the patient's hand.
32768964|NCT05058079|No Intervention|No hand holding group|No physical contact for comfort or reassurance during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will be next to the patient's hand.
32931817|NCT04781166|Other|Waitlist control|Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.
32931818|NCT05674825|Experimental|Group 1: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
32931819|NCT05674825|Experimental|Group 1: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
33251989|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
32931820|NCT05674825|Experimental|Group 2: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
32931821|NCT05674825|Experimental|Group 2: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
32931822|NCT05674825|Experimental|Group 3: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
32931823|NCT05674825|Experimental|Group 3: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
33251990|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
33251991|NCT04009486|Experimental|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
33251992|NCT05279404|Experimental|Group A - electroacupuncture|"electroacupuncture group Insert stainless steel acupuncture needles into Neiguan (cathode) and Jianshi (anode) on both sides and twist the needles.~After that, the electroacupuncture machine was connected and 2 Hz electrical stimulation was administered for 30 minutes.~The stimulation intensity was mainly based on slight muscle contractions and no pain in the subjects. At this time, cardiac function and electrogastrogram were recorded at the same time."
32931824|NCT04227288|Experimental|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
32931827|NCT04807374|Experimental|Single arm- HCL Therapy|Single arm study with all participants being treated with HCL for 6 months given the non-randomized interrupted time series study design.
32931828|NCT05651802|Active Comparator|Control arm|Patients who are randomized to control arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive PCI and regular brain MRI follow-up.
32931829|NCT05651802|Experimental|Study arm|Patients who are randomized to study arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive regular brain MRI follow-up alone.
32931830|NCT05265169|Experimental|Microwave ablation with margin confirmation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) of 1-3 colorectal cancer metastases with any FDA cleared/CE Marked Microwave Ablation System in accordance with the study site's standard-of-care (SOC) practices.
32931831|NCT05673967||Cohort 1|Real-world (RW) patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR), meet similar inclusion/exclusion criteria used to establish phase 2 cohort 2 of the R5458-ONC-1826 trial, and are initiating currently available therapies.
32931832|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered by weight-band dosing regimen.
32931834|NCT05668429|Experimental|Single dose of [14^C]-Ibrexafungerp|Each subject will receive a dose of [14C]-Ibrexafungerp at 12 h intervals for 7 doses in total.
32931835|NCT05259865||Patients with chronic pain|Patients seen in clinic agreeing to participate in trial by completing clinical questionnaires and genetic testing
32931836|NCT05252767|Experimental|Cohort A - Patient Engagement Tools|Participants will be enrolled from the a pain management clinic. Participants randomized into the experimental cohort will receive access to a clinic brochure, clinic website, as well as 'My Pain Passport' and 'My Treatment Plan' tools.
32931837|NCT05252767|Sham Comparator|Cohort B - Educational Guide|Participants randomized into the control cohort will receive a brief educational guide on general pain management.
32931838|NCT04158648|Experimental|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
32931839|NCT05473039|Experimental|Seidivid Ferty4|Patients included in this group will be administered dietary supplement Seidivid Ferty4 (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH a).
32728840|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
32931840|NCT05473039|Placebo Comparator|Placebo|Patients included in this group will be administered placebo (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH-a).
32931841|NCT05250115||Evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib|"This is a 36-month, prospective, non-interventional, multicenter study to evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib in patients with moderate to severe AD in a real-world setting.~Eligible patients will be followed up from the date of first Abrocitinib prescription for 12 months. Patients who are switched from the initial Abrocitinib therapy to other therapies will be further followed. Patient documentation is expected quarterly as per standard clinical practice."
33251993|NCT05279404|Sham Comparator|Group B - Sham electroacupuncture|Sham electroacupuncture group The method was the same as that of the electroacupuncture group, but the needles were only acupuncture under the skin of Neiguan and Jianshi without twisting the needles. The electroacupuncture machine was connected but no electrical stimulation was administered.
33251994|NCT05191576||epileptic children|All patients were diagnosed based on the International League Against Epilepsy (ILAE) operational clinical definition criteria for epilepsy and pediatric neurologists made the diagnosis. The patients had been receiving treatment for at least one year. Epileptic patients were grouped into idiopathic generalized or self-limiting focal epilepsy syndromes according to the International League Against Epilepsy (ILAE) criteria for epileptic seizures and syndromes and guidelines for epidemiological studies for diagnosis and classification.
32931842|NCT05668195|Experimental|aerobic exercise group|The patients aged 6-12 with a diagnose of ADHD of this group receive systematic aerobic exercise and intelligent monitoring system in executive skill training for 13 weeks, including those taking methylphenidate or not.
32931843|NCT05668195|Active Comparator|executive skill training group|The patients aged 6-12 with a diagnose of ADHD of this group receive executive skill training for 13 weeks, including those taking methylphenidate or not.
32931844|NCT04806516|Experimental|Summit RC+S DBS Implant for OCD|All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
32931845|NCT04806516|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
32931846|NCT05245825|Experimental|Flaxseed and dietary plan|30 g of ground flaxseed daily and a dietary plan
32931847|NCT05245825|Other|Control|Dietary plan controlled in alpha-linolenic acid consumption
32931848|NCT05651646|Experimental|Interventional Arm|A total of 50 subjects who are undergoing dorsal column stimulator trial will be studied and placed on the SECURE study where their trial leads will be anchored using the StimfixTM system. The trial duration will be for seven days as per standard of care.
32931849|NCT05651490|Experimental|Intervention Group (PST-D)|Participants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
32931850|NCT05651490|Active Comparator|Attention control group|The participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
32931851|NCT02698254|Experimental|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
32931852|NCT02698254|Active Comparator|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
32931853|NCT02978443|Experimental|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
32931854|NCT04343911|No Intervention|conventional positioning|positioning with shoulder braces
32931855|NCT04343911|Active Comparator|positioning on Pink Pad ®|
32931856|NCT04150380|Experimental|Supplement|8 weeks of dietary augmentation with oral LGG 1.0 x 1010 colony forming units (CFU) once daily (delivered in a size 1 capsule)
32931857|NCT04150380|Placebo Comparator|Placebo|8 weeks of dietary augmentation with placebo once daily (delivered in a size 1 capsule)
32743509|NCT04934085||Control group|healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age
32931858|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
32931859|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
32931860|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
32931861|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
32931862|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
32931863|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
32931864|NCT00358345||1|Intermediate AMD
32931865|NCT00358345||2|Newly diagnosed CNV
32931866|NCT04000152|Active Comparator|Control group (group 1)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to morphology.
32931867|NCT04000152|Experimental|Intervention group (group 2)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
32931868|NCT04192500|Experimental|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
32931869|NCT04192500|Experimental|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
32931870|NCT04192500|Active Comparator|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
32931871|NCT05662423|Active Comparator|Expressive Writing about Childbirth|Subgroup of participants will write about their recent childbirth.
32931872|NCT05662423|Placebo Comparator|Neutral Writing|Subgroup of participants will write about neutral daily events.
32931873|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
32931874|NCT04780542|Experimental|Clinician-Guided iCBT|Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians
32931875|NCT04780542|Active Comparator|Treatment as usual|Help-seeking students recruited from university clinics will remain on waitlist until they receive treatment as usual. Non-help-seeking students recruited from needs assessment survey and outreach will be referred to university health clinic.
32931876|NCT04780542|Active Comparator|Self-guided iCBT|Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.
32931877|NCT05661097|Active Comparator|Small hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire<3cm
32931878|NCT05661097|Active Comparator|Small hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings<3cm
32931879|NCT05661097|Active Comparator|Large hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire>3cm
32931880|NCT05661097|Active Comparator|Large hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings>3cm
32931881|NCT05661097|Experimental|Large hernia ring group with continuous suture and discontinuous full-thickness suture|Continuous suture with barbed thread and discontinuous full-thickness suture to close hernia rings>3cm
32931882|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
32931883|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
32931884|NCT05230693|Experimental|SPARC Group|
32931885|NCT05230693|Active Comparator|Enhanced Standard Care Control Group|
32931886|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
32931887|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
32728841|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
32931888|NCT04744688||48 cytoreductive surgery with HIPEC patients|48 patients with peritoneal metastases from colorectal cancer undergoing cytoreductive surgery with HIPEC (cytoreductive surgery with HIPEC patients)
32931889|NCT04744688||48 minimally invasive patients|48 rectal cancer patients undergoing minimally invasive rectal cancer resection
32931890|NCT05657275|Experimental|Intervention period|Patient management will be guided by a multimodal algorithm integrating the performance of biological and iconographic examinations
32931891|NCT05657275|No Intervention|Control period|Patient management will be done according to the usual practices of centers and emergency physicians
32931892|NCT04192344|Experimental|ABSK021|"Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by3+3 escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles."
32931893|NCT05230537|Experimental|Iptacopan (LNP023)|Iptacopan (LNP023) oral use capsules
32931894|NCT05230537|Placebo Comparator|Placebo|Placebo matched to study drug, oral use capsules
32931895|NCT04802382|Experimental|Arm 1 - CimetrA-1|a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
32728842|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
32728843|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
32728844|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
32728845|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
32931896|NCT04802382|Experimental|Arm 2 - CimetrA-2|a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
32931897|NCT04802382|Placebo Comparator|Arm 3 - Placebo|composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
32931898|NCT05648916||Patients with and without HO before Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) before the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2009-2012.
32931899|NCT05648916||Patients with and without HO after Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) after the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2013-2020.
32931900|NCT05462587|Experimental|AVTX-803|Approximately 4 subjects will receive AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day for 8 weeks.
32931901|NCT05462587|No Intervention|Withdrawal|Subject will be in withdrawal for 8 weeks.
32931902|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
32931903|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
32931904|NCT05458609|Active Comparator|Lemborexant plus Naltrexone|10 milligrams of Lemborexant will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
32931905|NCT05458609|Placebo Comparator|Placebo plus Naltrexone|10 milligrams of placebo will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
32931906|NCT05648058|Experimental|nefopam|administration of intravenous nefopam to prevent Rituximab Transfusion Reaction
32728846|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
32728847|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
32728848|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
32728849|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
32728850|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
32728851|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
32931907|NCT05648058|Active Comparator|diphenhydramine|administration of intravenous diphenhydramine to prevent Rituximab Transfusion Reaction
32931908|NCT05653609||Telemonitoring|Patients monitored by the Cureety digital platform
32931909|NCT02502318|Experimental|Lobectomy or segmentectomy using video-thoracoscopy|
32931910|NCT02502318|Active Comparator|Lobectomy or segmentectomy using thoracotomy|
32931911|NCT05218135||Intervention|Breakthrough improvement collaborative
32931912|NCT05647902||Healthy Group|70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
32931913|NCT05647902||Myocard Infactus Group|40 patients with myocardial infarction; 20 healthy gingiva is divided into 2 subgroups, 20 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
32931914|NCT05215561||Cosentyx|Cosentyx for Subcutaneous Injection
32931915|NCT04791306|Experimental|Exercise Training|All participants should increase their physical activity level to at least 150 min per week, guided with once a week supervised in-house training as well as an application for planning and documentation for home-based physical activity
32931916|NCT05212831|No Intervention|Standard of Care (SOC)|SOC is defined as the patient symptoms or complications based treatment.
32728852|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
32728853|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
32931917|NCT05212831|Experimental|Portable Oxygen Concentrator|"Inogen One® G4 Portable Oxygen Concentrator (POC) is used on a prescriptive basis by subjects requiring supplemental oxygen. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the subject.~Inogen One® G4 is designed to provide a flow of high purity oxygen. Inogen One® G4 may be used in home, institution, vehicle and various mobile environments."
32931918|NCT05639712|Placebo Comparator|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo (0.9% NaCl intravenously). This is carried out on the operating table right before anesthesia
32931919|NCT05639712|Active Comparator|Morphine 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
32931920|NCT05639712|Active Comparator|Morphine 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously. This is carried out on the operating table right before anesthesia
33251995|NCT05191576||healthy controls|healthy controls without any complaint (e.g., behavior problems, depression, or anxiety) that could interfere with sleep.
32931921|NCT05639712|Active Comparator|Morphine 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously. This is carried out on the operating table right before anesthesia
32931922|NCT05639712|Active Comparator|Oxycodone 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
32931923|NCT05639712|Active Comparator|Oxycodone 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously. This is carried out on the operating table right before anesthesia
32931924|NCT05639712|Active Comparator|Oxycodone 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously. This is carried out on the operating table right before anesthesia
32728854|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
32728855|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
32931925|NCT05639712|Active Comparator|Fentanyl 0.025 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously. This is carried out on the operating table right before anesthesia
32931926|NCT05639712|Active Comparator|Fentanyl 0.05 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously. This is carried out on the operating table right before anesthesia
32931927|NCT05639712|Active Comparator|Fentanyl 0.1 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously. This is carried out on the operating table right before anesthesia
33251996|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
32931928|NCT05451589|Experimental|RESET intervention|Participants will engage in a 7-week positive psychology and self-management group telephone-based program.
32728856|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
32931929|NCT05451589|Active Comparator|Wellness check control|Participants will receive educational information and an individual wellness check phone call from a Community Health Worker to screen for unmet social needs.
32931930|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
32931931|NCT05449561||Discrete Choice qualitative interview|We will invite at least 20 participants with at least mild level of depressive symptoms to participate in individual interviews. The interviews will be in semi-structured format. Upon provision of informed consent and completion of demographics survey, we will ask respondents a single question of what matters to them when considering the use of psychotherapy, with adequate probes during the conversation. This will ensure uniformity of the topics to be discussed, and the level of digression allowed.
32931932|NCT05210101|Other|Sotrovimab|Two intravenous (IV) doses of sotrovimab were be administered in total - the first on Treatment Day 1 (500mg) and the second on Treatment Day 2, approximately 8-14 weeks after the first dose, at a higher 2000mg dose, in light of the reduced antiviral susceptibility of the BA.2 subvariant to sotrovimab, with the dosing interval determined by theoretical modeling of the duration of efficacy of sotrovimab as antiviral prophylaxis based on the rising prevalence of the Omicron BA.2 subvariant.
32931933|NCT05208697|Experimental|Tele-Harm Reduction (THR)|THR utilizes 2 components. Component 1: telehealth technology facilitated by a peer harm reduction counselor to connect the participant with medical case managers and enroll patients in Ryan White/AIDS Drug Assistance Program (ADAP). Component 2: utilizes the syringe services program (SSP)-based peer harm reduction counselor to work with participants in identifying individual-specific barriers and facilitators to medication adherence.
32931934|NCT05208697|Active Comparator|off-site linkage to HIV care|introduces the participant to an SSP HIV/HCV linkage specialist and discusses linkage to a traditional Ryan White clinic
32728857|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
32728858|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
33073726|NCT00026884||Family Members|Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder
32728859|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
32728860|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
32728861|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
32728862|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
32728863|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
32728864|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
32728865|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
32728866|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
33251997|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
32728867|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
32728868|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
32728869|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
32728870|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
32728871|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
32728872|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
32728873|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
32931935|NCT05206279|Experimental|ureteral ICG injection|There is only one arm of the study. All patients will undergo normal laparoscopy. After examining the abdominal structures for presence of endometriosis as well as performing photographic documentation, cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
32931936|NCT04344067|No Intervention|Control Group|
33251998|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
32728874|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
32931937|NCT04344067|Experimental|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
32931938|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
32931939|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
32931940|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
32931941|NCT05449873|Experimental|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
32931942|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
32931943|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
32931944|NCT02977819|No Intervention|No intervention|Follow-up without Meditation courses or English Learning courses
32931945|NCT05647213|Experimental|Treated|Subjects in Treated arm will receive one dose of Investigational Product. Within this arm are three dose levels. Dose level selection will be determined by product availability subjects have available product and when they can be treated. Dose levels will escalate in order of treatment date.
32931946|NCT05647213|No Intervention|Control|Subjects who enroll but do not receive Investigational Product will be placed in the treatment arm.
32931947|NCT05190991|Experimental|RPH-104 80 mg q2w (160 mg q2w) depending on the dose in the core CL04018065 study|RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously (In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose 160 mg based at the discretion of the investigator. A dose of 160 mg should be administered by two subcutaneous injections in two different quadrants.)
32931948|NCT05642533||Without a history of Type 2 diabetes|Adults with obesity
32931949|NCT05642533||With a history of Type 2 diabetes|Adults with obesity
32931950|NCT05183503||TMD group|Patients diagnosed with TMD
32931951|NCT05434585|Experimental|Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
32931952|NCT05434585|Experimental|Test group 2: ABO-CoV.617.2|Intramuscularly injecting 15 μg of ABO-CoV.617.2 into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
32931953|NCT05434585|Placebo Comparator|Control group: Placebo|Intramuscularly injecting placebo into lateral deltoid of the upper arm of subjects on D0 and D28, respectively
32931954|NCT05433181|Experimental|ACE2 Chewing Gum|
32931955|NCT05433181|Placebo Comparator|Placebo Chewing Gum|
32931956|NCT05427955|Active Comparator|One-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process.
32931957|NCT05427955|Active Comparator|Bi-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T4 spinous process, 15 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process. Next, the needle will be withdrawn till subcutaneously and the linear US probe will be placed 2-3 cm lateral to the T6 spinous process. Finally, 15 ml of 0.25% bupivacaine hydrochloride will be injected cranio-caudally into the interfacial space below the erector spinae muscle, above the transverse process.
32931958|NCT05426161|Experimental|Botulinum Toxin A|Open-label study
32931959|NCT05426005|Experimental|Cadonilimab|Cadonilimab alone
32931960|NCT05179057|Experimental|Posoleucel + SoC|Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
32931961|NCT05179057|Placebo Comparator|Placebo + SoC|Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria
32931962|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Not Receiving Active Treatment|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931963|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment Break for BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931964|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931965|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment with BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931966|NCT05170399|Experimental|Follicular Lymphoma|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931967|NCT05170399|Experimental|Follicular Lymphoma Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931968|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931969|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
32931970|NCT05170399|Experimental|Participants diagnosed with Chronic Lymphocytic Leukemia (CLL)|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
32931971|NCT05630833|Experimental|Gepotidacin + Placebo|
33251999|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
33252000|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
33252001|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
32931972|NCT05630833|Active Comparator|Nitrofurantoin + Placebo|
32931973|NCT00359671|Experimental|1|Arm 1: study drug
32931974|NCT00359671|Other|2|Arm 2: study drug + comparator
32931975|NCT05157061|Experimental|GOS arm|A single daily dose of a food supplement containing GOS for 8 weeks
33252002|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
32931976|NCT05157061|Placebo Comparator|Placebo arm|A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
32931977|NCT05413291||family members|family members who are 2 years old or older of people with movement disorders
32931978|NCT05413291||patients|subjects with movement disorders who are 2 years old or older
32931979|NCT02978209|No Intervention|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
32931980|NCT02978209|Active Comparator|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
32931981|NCT05153863|Experimental|Single Arm C-Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
32931982|NCT04744909|Experimental|Percutaneous tracheotomy using a new device|
32931983|NCT05409391|Experimental|AI|Insulin Titration System Based on Deep Learning
32931984|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
33252003|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
33252004|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
33252005|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
33252006|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
32931985|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
32931986|NCT05627323|Experimental|Treatment (CAR T cell therapy) 1|"Arm 1 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
32931987|NCT05627323|Experimental|Treatment (CAR T cell therapy) 2|"Arm 2 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
32931988|NCT05404321||Patient with early stage triple negative breast cancer|
32931989|NCT04343833|Active Comparator|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
33073727|NCT00026884||Patients|Patients with biopsy-proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited genitourinary malignant disorder
33252007|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
33252008|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
33252009|NCT00970918|Experimental|1|
32931990|NCT04343833|Experimental|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
32931991|NCT05403151||1|Healthy Adults
32931992|NCT05141539|Experimental|Rehabilitation assessment software|This arm applies the developed rehabilitation assessment software by using two web cameras placed in the front and the side of the subject. The subject sits between two cameras. The observer asks the subject to move the head in each direction, to open the mouth, and to move the tongue. The software will measure CROM, mouth opening, and tongue movement.
32931993|NCT05141539|Experimental|video-fluoroscopic swallowing and FOIS.|This arm applies video-fluoroscopic swallowing (VFSS) and functional oral intake scale (FOIS) to measure the direct, dynamic view of oral, pharyngeal, and upper esophageal function during swallowing with food and liquid mixed with barium, and the functional intake of dysphagic patients, respectively.
32931994|NCT05141149|Experimental|Cohort 1M|1 mg/kg of PBP1510 as monotherapy will be administered
32931995|NCT05141149|Experimental|Cohort 1C|1 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
32931996|NCT05141149|Experimental|Cohort 2M|3 mg/kg of PBP1510 as monotherapy will be administered
32931997|NCT05141149|Experimental|Cohort 2C|3 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
32931998|NCT05141149|Experimental|Cohort 3M|6 mg/kg of PBP1510 as monotherapy will be administered
32931999|NCT05141149|Experimental|Cohort 3C|6 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
32932000|NCT05141149|Experimental|Cohort 4M|10 mg/kg of PBP1510 as monotherapy will be administered
32932001|NCT05141149|Experimental|Cohort 4C|10 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
32932002|NCT05141149|Experimental|Cohort 5M|15 mg/kg of PBP1510 as monotherapy will be administered
32932003|NCT05141149|Experimental|Cohort 5C|15 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
32932004|NCT05133115|Experimental|Intervention Group|Schools with adolescents aged 12 to 15 in a context at risk. They will follow the intervention for 6 weeks (6 sessions, once a week).
32932005|NCT05133115|No Intervention|Control Group|Schools in the control group will be all waitlisted to receive the intervention during the following academic year should it prove effectiveness. They will fill in the same research questionnaires as the Intervention group and at the same time period (January to December 2022).
32932006|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
32932007|NCT05129059|Experimental|Logotherapy|Participants will receive individual logotherapy counseling by the investigator for 8 visits in 4 weeks.
32932008|NCT05129059|No Intervention|Control|Participants will receive routine care.
32932009|NCT05128201|Experimental|System treatment plus consolidative radiotherapy and Maintenance treatment|4-6 Cycles System chemotherapy (Camrelizumab , Gemcitabine and cisplatin or nedaplatin) ; And local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F) and Maintenance of Camrelizumab (total 2 years; from first cycles of System chemotherapy to last cycles of miantenance of camrelizumab)
32932010|NCT05119231|Experimental|Pulmonary Vein Isolation|"Pulmonary Vein Isolation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standards:~Trial participants will assigned to the PVI-arm will undergo catheter ablation within 48 hours after baseline evaluation, with the aim to achieve isolation of all pulmonary veins and restore sinus rhythm.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
32932011|NCT05119231|Sham Comparator|Sham Control Arm|"Sham Pulmonary Vein Isolation~Trial participants will assigned to the SHAM-arm will undergo their procedure within 48 hours after baseline evaluation. The Sham procedure will include deep sedation according to the respective PVI protocol for at least one hour, femoral vein/artery puncture with introduction of sheaths and an electrical cardioversion in presence of persistent atrial fibrillation.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
32932012|NCT05115019|Experimental|Group A (RUTI)|Participants will receive one dose of RUTI® vaccine at the baseline visit, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 m
32932013|NCT05115019|Placebo Comparator|Group B (Placebo)|Participants will receive one dose of sterile physiological serum at the baseline visit, which will be administered subcutaneously in the deltoid region.
32932014|NCT05114941|Experimental|Immunoadsorption group|Protein A immunoadsorption therapy
32932015|NCT05114941|Active Comparator|intravenous immunoglobulin group|Treatment with intravenous immunoglobulin
32932016|NCT05102383|Active Comparator|Habitual lens optimization|All subjects are re-fit with habitual Biofinity Toric lenses to optimize vision.
32932017|NCT05102383|Active Comparator|Daily disposable lenses|All subjects are fit with daily disposable lenses with water surface treatment.
32932018|NCT00359905|Experimental|Silodosin|
32932019|NCT00359905|Active Comparator|Tamsulosin|
32932020|NCT00359905|Placebo Comparator|Placebo|
32932021|NCT05086939|Experimental|Autologous Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.
32932022|NCT05086939|Experimental|Allogenic Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.
32932023|NCT05086939|Active Comparator|Active Control|Hyaluronic Acid 60mg/3ml administered intra-articularly.
32932024|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
32932025|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
32932026|NCT05389189|Active Comparator|CBT Care|"Intervention content~The CoMIRA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour).~Booster sessions, at 4 and 12 weeks after completion of the first phase"
32932027|NCT05389189|No Intervention|TAU Care|Usual Care respecting international recommendations for the management of RA.
32932028|NCT05387863|Experimental|Decision Aid (DA) Web Tool|
32932029|NCT05387863|Active Comparator|Institutional Pamphlet|
32932030|NCT04344223|Experimental|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
32932031|NCT04344223|Active Comparator|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
32932032|NCT04344613|Experimental|Blood samples|
32932033|NCT05081635||Delphi panel|The Delphi panel will include 30 Portuguese experts in post-graduate medical education. The expert panel will include participants from the residency programs directors' coordination group, from the medical residents representing committee, from patients representing associations, from health institutions management teams, from the Portuguese Medical Association and also authors of relevant scientific articles on medical education. Study participants will be required to answer the questions of 3 questionnaires included in each of the 3 rounds of the study.
32932034|NCT05603455|Experimental|Bifidobacterium adolescentis group|Bifidobacterium adolescentis supplementation
32932035|NCT05603455|Placebo Comparator|Placebo group|Placebo supplementation
32932036|NCT05071027|Experimental|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
32932037|NCT05071027|No Intervention|Non-app Using Group|Patients in this group receive the same standard of care [i.e. endovascular stent-based treatment of unruptured aneurysms] as the other group, but do not receive app dual antiplatelet reminders.
32932038|NCT05602363|Experimental|Dose Escalation|"Dose escalation (3+3 design) and determination of MTD and DLTs~CLL/SLL or B-cell NHL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet at multiple dose levels twice daily for 24 cycles (1 cycle = 28 days)."
32932039|NCT05602363|Experimental|Dose Expansion Cohort 1|CLL/SLL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part.
32932040|NCT05602363|Experimental|Dose Expansion Cohort 2|B-cell NHL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part.
32932043|NCT05585983|Experimental|Influenza vaccination|Influenza vaccine, 0.5 mL.
32932044|NCT05585983|Placebo Comparator|Placebo|Placebo, 0.5 mL saline.
33252010|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
33252011|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
32932047|NCT05064085|Experimental|Dose Level 1|Cemiplimab 350mg + Capecitabine 800 mg/m^2
32932048|NCT05064085|Experimental|Dose Level 2|Cemiplimab 350mg + Capecitabine 1000 mg/m^2
32932049|NCT04343599|Experimental|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
32932050|NCT04343599|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
32932051|NCT05057923|Experimental|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
32932052|NCT05057923|Experimental|neutralizing antibody booster for vaccinated participants|participants after 4-month vaccinated with Sinovac received 1 capsule of 1×10^11 CFU of B. subtilis spore
32932053|NCT05035225|Experimental|Specialty Pharmacy Patient|Patients who have been prescribed at least one selected specialty medication
32932054|NCT04884061||Experimental|Patients hospitalized with SARS-CoV2 infection proven by RT-PCR test
32932055|NCT04884061||Comparator|Patients hospitalized with lower respiratory tract infections unrelated to SARS-CoV2 (RT-PCR negative for SARS-CoV2)
32932056|NCT04884061||Comparator 2|Patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (RT-PCR negative for SARS-CoV2).
33252012|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
32932057|NCT04871191|Active Comparator|Rituximab + cDMARD|Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
32932058|NCT04871191|Experimental|Tocilizumab|Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
33252013|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
33252014|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
33252015|NCT00869193|Active Comparator|Grape seed|Grape seed extract
32728875|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
32932059|NCT04871191|Experimental|Abatacept|Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
32932060|NCT04871113|Experimental|Part 1: Participants receiving GSK3810109A 40 mg/kg (Cohort 1)|Participants will be administered GSK3810109A as a single IV infusion of 40 mg/kg dose in Part 1.
32932061|NCT04871113|Experimental|Part 1: Participants receiving GSK3810109A 280 mg (Cohort 2)|Participants will be administered GSK3810109A as a single IV infusion of 280 mg dose in Part 1.
32932062|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 3)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.
33252016|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
32728876|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
32728877|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
32728878|NCT05181527|Placebo Comparator|Control group|Patients in the control group will get an identical-looking capsule containing placebo (starch) once daily in addition to SSRI.
32728879|NCT05181527|Experimental|Test group|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment.
32728880|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
32728881|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
32768965|NCT04987879|Experimental|Exercise Arm 1|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
32932063|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 4)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1
32932064|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 5)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.
32932065|NCT05582551|Experimental|Patients: CDS Alert System for Sensory Deficit Screening|"The primary oncology team will utilize the CDS alert system to identify patients who are at risk for sensory deficits based on prior treatment. The alert system will generate a report of eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study.~Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff."
32932066|NCT05582551|No Intervention|Providers: CDS Alert System for Sensory Deficit Screening|-Providers will complete a survey regarding their views of the CDS Alert System. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.
32932067|NCT05582551|No Intervention|Parents: CDS Alert System for Sensory Deficit Screening|
32932068|NCT04864795||Single Cohort|Patient data will be collected from patient records and/or during a routine clinical visit. This will include treatments prescribed, routine assessments and measurements collected at routine clinical visits, as well as hospitalisations and other relevant patient data.
32932069|NCT05024851||Patients with Psychogenic pruritus|
32932070|NCT05024851||Patients with Neuropathic Pruritus|
32932071|NCT04505371|No Intervention|Control - Standard Care|The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
32932072|NCT04505371|Experimental|Intervention - Wellness Intervention for Smokers with HIV|The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
32932073|NCT05016505|Experimental|Compliance through reduction (relocation and reduction of personal smoking) and cessation|Smokers will be referred by the survey team to peer educators from a community-based organization trained to provide peer to peer health education including tobacco cessation support. The peer educator will coordinate smoking cessation support, including serving as a liaison between participant and research team, providing information regarding the smoke-free policy and opportunities for relocation, and connecting participant to access to tobacco replacement therapy and/or physician support if deemed appropriate.
33073728|NCT00026663||1/Patients with cancer|Cancer patients providing tissue for research studies
33073729|NCT00026663||2/Normal Volunteers|normal volunteers providing samples for research studies
33252017|NCT04009018|Other|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
33252018|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
33252019|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
33401050|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
32932074|NCT05016505|Experimental|Compliance through resident endorsement|Buildings assigned will be targeted for a series of 2 in-residence programs that involve community forums and the creative arts to garner resident endorsements of smoke-free living environments. Premised on resident engagement, this arm seeks to impact social and physical dimensions of the residential environment to achieve compliance. The sessions will: 1) inform residents of risks associated with smoking and secondhand smoke; 2) identify reasons to have a smoke-free home, 3) ask residents to sign a pledge on paper and/or virtually; 4) display smoke-free signage on doors and/or social media pages with an original hashtag (#Smokefree[building address]); and 5) refer residents to the Smoke-free NYCHA website for information on the policy and existing cessation resources.
32932075|NCT05016505|Experimental|Compliance through reduction/cessation plus resident endorsement (combined)|The combined intervention will be carried out in the buildings assigned to this RCT arm, which will provide in-residence programs based on the resident endorsement treatment and the smoking relocation/cessation treatment. Both will occur simultaneously with one geared toward all building residents (resident endorsement) and the other targeting smokers (smoking relocation/cessation) with the goal of reducing both personal smoking and secondhand smoke exposure.
32932076|NCT05016505|No Intervention|Standard NYCHA approach (control)|Buildings and study participants assigned to this arm will be recruited and followed over a 12-month period to assess outcomes. No additional programs or services will be delivered to the buildings or residents assigned to this arm beyond standard programs that NYCHA may provide to support the smoke-free mandate. Field staff will document any policy-related signage, activities or information to which these participants are exposed.
32768966|NCT04987879|Experimental|Exercise Arm 2|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
32768967|NCT04987879|No Intervention|Standard of Care|This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.
32932077|NCT05015023|Experimental|Intervention|The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, provision of IEC materials/Leaflets, and home visits.
32932078|NCT05015023|No Intervention|Control|The routine care will be continued in the control group.
32932079|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
32932080|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
32932081|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
32932082|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
32932083|NCT04853017|Experimental|ELI-002 2P Cohort 1|ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
32932084|NCT04853017|Experimental|ELI-002 2P Cohort 2|ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
32932085|NCT04853017|Experimental|ELI-002 2P Cohort 3|ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
32932086|NCT04853017|Experimental|ELI-002 2P Cohort 4|ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
32932087|NCT04853017|Experimental|ELI-002 2P Cohort 5|ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
32768968|NCT04986865|Experimental|ATG-101|"Dose Escalation Phase:~Will be conducted with an enhanced PDx cohort.~Dose Expansion Phase:~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
32768969|NCT04982575|Experimental|Cagrilintide 2.4 mg and semaglutide 2.4 mg|Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
32932088|NCT04844281|Experimental|Daily Disposable Toric Contact Lens|All subjects are fit into Precision1® toric contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
32932089|NCT04835623|Experimental|Cyclosporine|Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
32932090|NCT04500613|Active Comparator|ESPB with Bupivacaine and Dexamethasone|12 pediatric spinal fusion surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.25% bupivacaine with 2mg preservative free dexamethasone with a maximum of 30 mL total per side, depending on the patient's weight.
32932091|NCT04500613|Placebo Comparator|No ESPB|12 pediatric spinal fusion surgery patients will be randomized to not receive an intraoperative ultrasound-guided bilateral ESPB. These patients will still receive the standard anesthesia regimen during and after surgery.
32932092|NCT04833907|Experimental|3.7 x 10^13 v.g. rAAV-Olig001-ASPA|3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 2 pre-defined intracerebroventricular sites
32932093|NCT04498585|Experimental|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
32768970|NCT04982575|Active Comparator|Cagrilintide 2.4 mg and placebo (semaglutide)|Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
33252020|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
33252021|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
32768971|NCT04982575|Active Comparator|Semaglutide 2.4 mg and Placebo (cagrilintide)|Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
32932094|NCT04498585|No Intervention|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
32932095|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
32932096|NCT04492345|Experimental|Experimental|Patient with conventional rehabilitation session and isokinetic reeducation during 7 weeks
32932097|NCT04492345|Other|Control|Patient with conventional rehabilitation session during 7 weeks
32932098|NCT04984681|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based stress reduction sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
32932099|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
32932100|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
32932101|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
32932102|NCT04485013|Experimental|Phase 1a, Monotherapy Dose Escalation|
32932103|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Arm 1 will enroll subjects with advanced/metastatic, prior checkpoint inhibitor treated Head and Neck Squamous Cell Carcinoma (HNSCC)
32932104|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Arm 2 will enroll subjects with advanced/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
32932105|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Arm 3 will enroll subjects with advanced/metastatic colorectal cancer (CRC)
32932106|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), prior anti-EGFR therapy|Arm 4 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild-type colorectal cancer (CRC) who have progressed on a prior anti-EGFR therapy
32932107|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), no prior anti-EGFR therapy|Arm 5 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild type colorectal cancer (CRC) who have not received a prior anti-EGFR therapy
32932108|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Arm 6 will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
32932109|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Arm 7 will enroll subjects with advanced/metastatic prior checkpoint inhibitor treated non-small cell lung cancer (NSCLC)
32932110|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 as monotherapy OR in combination with pembrolizumab|"Arm 8: TTX-080 monotherapy:~Advanced/metastatic, prior checkpoint inhibitor treated renal cell carcinoma with predominance of clear cell component~Advanced/metastatic acral melanoma~Arm 8: TTX-080 in combination with pembrolizumab:~• Advanced/metastatic triple-negative breast cancer (estrogen and progesterone receptor negative and HER2 negative) who has received a prior checkpoint inhibitor"
32932111|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
33252022|NCT03893487|Experimental|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
33252023|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
33252024|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
33252025|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
32728882|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
32728883|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
32728886|NCT05168969||Patient carrying a CTNNB1 syndrome|Recruitment of subjects with CTNNB1 syndrome will be done through health care providers, but also by contacting families through social media and specialized databases.
32728887|NCT00783263|Experimental|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
32728888|NCT00783263|Active Comparator|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
32728889|NCT00783263|Experimental|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
32932112|NCT04474015|Active Comparator|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
32932113|NCT04474015|Active Comparator|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
32728890|NCT00783263|Active Comparator|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
32932114|NCT04474015|Active Comparator|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
32932115|NCT04474015|Active Comparator|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
32932116|NCT04474015|Active Comparator|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
32932117|NCT04474015|Active Comparator|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
32932118|NCT04474015|Active Comparator|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
32932119|NCT04975399|Experimental|Administration of CC-92328|CC-92328 administered intravenously in 28-day cycles
32932120|NCT04975243|Experimental|Unwanted Fine Facial Hair|Up to three (3) treatments with GentleMax Pro/ GentleMax Pro Plus TM for Laser Hair Removal
32932121|NCT04814095|Experimental|Targeted therapy|
32932122|NCT04813783||Control group|The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
32932123|NCT04813783||Intervention Group|In the study, in order to prevent/minimize the flow of information between the control and intervention groups, the data of the control group will be collected first. Data collection will be suspended in the clinic for three months after the control group data is completed. After this period, data of the enterprise group will be collected. Participants in the intervention group will be provided with mucositis training within the scope of the Mucositis Care Protocol in line with the MASCC / ISOO 2019 Recommendations.
32932124|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
32932125|NCT04469803|Experimental|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
32932126|NCT04469803|Experimental|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
32728891|NCT00664937|Placebo Comparator|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
32728892|NCT00664937|Placebo Comparator|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
32728893|NCT00664937|Placebo Comparator|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
32728894|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
32728895|NCT04951661|Experimental|All Participants|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
32728896|NCT00540839|Experimental|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged >6 months to <2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive montelukast 4 mg CT QD for 24 weeks.
32728897|NCT00540839|Active Comparator|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged >6 months to <2 years receive placebo packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive placebo CT QD for 24 weeks.
32728898|NCT03389087|Experimental|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
32728899|NCT04446299|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
32932127|NCT04469803|Experimental|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
32932128|NCT04469803|Experimental|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
32932129|NCT04469803|Experimental|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
32932130|NCT04469803|Experimental|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
32932135|NCT04968847|Experimental|FemaSeed|Investigational device and procedure
32932136|NCT04467619|Active Comparator|Early Illusory Movements|"Phase 1: A patient enrolled in group A will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist from the start of the study (Day 1), and also FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 15).~Phase 2: From Day 16 onwards, the patient will undergo standard rehabilitation only according to the instructions of the attending surgeon and performed by an independent physiotherapist for 14 days (Day 30)."
32932137|NCT04467619|Active Comparator|Deferred Illusory Movements|"Phase 1: A patient enrolled in group B will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist, from the start of the study (Day 1) for 14 days (Day 15).~Phase 2: Then, from Day 16 onwards, in addition to standard physiotherapy, FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 30)."
32932138|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
32932139|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
32932140|NCT04798261||Patients with acute pulmonary embolism|
32932141|NCT04949737||Helicobacter Pylori detection|Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
32932142|NCT04945447|Experimental|Intervention group - Medical clinics|Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
32728900|NCT04446299|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
32728901|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
32728902|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
32728903|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
32728904|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
32728905|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
32728906|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
32728907|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
32728908|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
32728909|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
32728910|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
32728911|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
32728912|NCT04746521||Severe COVID-19 hospitalized patients|A total of 50 severe COVID-19 patients admitted to the Sub-Intensive Care Unit of A.O.R.N. Ospedali dei Colli, Cotugno Hospital, Naples (Italy) will be recruited, of which N=50 with thromboembolic complications (PE+) and N=50 without thromboembolic complications (PE-) balanced for age and sex of individuals.
32728913|NCT04746521||Healthy controls (comparator group)|"As control group (CTRL), we will recruit a total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, L. Vanvitelli University of Campania (Naples, Italy)."
32728914|NCT04746521||COVID-19 patients compared with vaccinated subjects|"Patients with previous Sars-CoV-2 infection who did not undergo vaccination;~Patients with previous Sars-CoV-2 infection who undergone vaccination~Subjects without previous Sars-CoV-2 infection who undergone vaccination"
32728915|NCT00472745|Experimental|WL|weight loss (WL) with nutrition/behavior modification counseling
32728916|NCT00472745|Active Comparator|WM|Weight Maintenance (WM)
32728917|NCT03987919|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
32728918|NCT03987919|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
32728919|NCT03987919|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
32728920|NCT03987919|Active Comparator|1 mg Semaglutide|1 mg semaglutide administered SC once a week.
32728921|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
32728922|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
32728923|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
32728924|NCT03904069|Experimental|Comparison of different cell doses of AMG 553|Subjects will receive IV infusion of AMG 553
32728925|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
32728926|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
32728927|NCT03390829||Patients|
32728928|NCT03390829||Doctors|
32728929|NCT02520271|Active Comparator|Depression|Behavioral activation only
32728930|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
33073739|NCT00011648||non-SCD|200 Men and Women without a diagnosis of sickle cell disease 18 years of age or older
33073740|NCT00011648||SCD|1000 Men and Women with a diagnosis of sickle cell disease
33073741|NCT00007150|Other|1/HH patients|HH patients
33073742|NCT00006518||1|Patients with HIV infection, KSHV infection, or with cancer
33252026|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
32728931|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
32728932|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
32728933|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
32728934|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:~Identification of epigenetic signatures~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood~Glucose, insulin and lipids in mothers during pregnancy~Anthropometry and blood pressure"
32728935|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
32728936|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:~Stability of epigenetic signatures in offspring through childhood and adolescence~Relation of these signatures with phenotype"
32728937|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
32932143|NCT04945447|No Intervention|Control group - medical clinics|All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
32932144|NCT04945447|Experimental|Intervention group - patient level|"The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.~The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant"
32932145|NCT04945447|No Intervention|Control group - patient level|The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
32932146|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
32932147|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
32932148|NCT04793269||Long COVID|Patients with long COVID syndrome
32932149|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
32932150|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
32932151|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
32932152|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
32932153|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
32932154|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
32932155|NCT00360841|No Intervention|C|No treatment received.
32932156|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
32932157|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
32932158|NCT00360451|No Intervention|3|Control
33252027|NCT00377611|Experimental|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
33252028|NCT00377611|Experimental|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
33252029|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
33252030|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
33252031|NCT00869427|No Intervention|2|Usual Care
33252032|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
33252033|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
33252034|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
33252035|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
33252036|NCT00892359|Experimental|Anidulafungin|
33252037|NCT00978406||Healthy volunteers|Healthy volunteers
33252038|NCT00892515|Experimental|exercise|
32932166|NCT04343131|Active Comparator|Mediterranean diet|Mediterranean diet for 7 days
32728938|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
32728939|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
32932167|NCT04343131|Active Comparator|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
32932168|NCT04343131|Active Comparator|Reference diet|Reference diet for 7 days
32932169|NCT04382911|Experimental|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
32932170|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
32932171|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
32932172|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
32932173|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
32932174|NCT04904575|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levobupivacaine for the realization of the erector spinae plane block."
32932175|NCT04904575|Placebo Comparator|Placebo|"The placebo group corresponds to the reference group, that is to say that it will consist of patients who will benefit from an injection of physiological serum for the realization of the erector spinae plane block."
32932176|NCT04898647|Experimental|Patients with confirmed HVS|presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity
32932177|NCT04898647|Active Comparator|Patients with confirmed absence of HVS|
32932178|NCT04898647|Experimental|Remaining patients|
32932179|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
32932180|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
32932181|NCT04895839|Experimental|Intervention Arm|
32932182|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
32932183|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
32932184|NCT04886245|Experimental|facial palsy|Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated
32932185|NCT04886245|Sham Comparator|healthy volunteers|- Subject without major facial sequelae
32932186|NCT04061083|Experimental|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
32932187|NCT04061083|Experimental|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
32932188|NCT04061083|No Intervention|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
32932189|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
32932190|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
32932191|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
32932192|NCT04034329||EVLA-group|GSV diameter > 6 mm
32932193|NCT04032301|Experimental|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
32932194|NCT04032301|Placebo Comparator|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
32932195|NCT04010305|Placebo Comparator|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
32932196|NCT04010305|Experimental|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
32932197|NCT04010305|Experimental|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
32932198|NCT04010305|Experimental|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
33252039|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
33252040|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
33252041|NCT01051531|Experimental|Paliperidone palmitate|
33252042|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
33252043|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
33252044|NCT00971308|Experimental|BMS-824393 (Panel 1)|
32728940|NCT00535405|Experimental|1|Each patient will receive 1 active treatment dose & 2 Placebo (Pbo) doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
32932199|NCT04010305|Experimental|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
32932200|NCT00361933|Experimental|1|
32932201|NCT03987763|Experimental|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
32932202|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
32932203|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
32932204|NCT04786093|Active Comparator|Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm|SAbR with each radiation treatment fraction delivered every other day
32932205|NCT04786093|Experimental|Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalumab arm|PULSAR with each radiation treatment fraction delivered every 4 weeks
32932206|NCT04785859||Moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, with the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
32932207|NCT04785859||no moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, without the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
32932208|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
32932209|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
32932210|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
32932211|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
32932212|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
32932213|NCT04731025|Placebo Comparator|Irrigation of implants with sterile isotonic saline|The placebo solution will consist of 500 mL of sterile isotonic (9%) saline contained in a infusion bag.
32932214|NCT04731025|Experimental|Irrigation of implants with a triple antibiotic solution|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in 500 mL sterile isotonic (9%) saline
32932215|NCT04730635|Experimental|Donepezil|Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.
32932216|NCT04730635|Placebo Comparator|Placebo|Participants receive placebo QD, orally for Days 1-56. The total treatment duration is 56 Days.
32932217|NCT04726189|Active Comparator|Standard care exercises|This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
32932218|NCT04726189|Experimental|Early progressive strength exercise|This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
32932219|NCT04723225|Experimental|Experimental|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided.
32932220|NCT04723225|No Intervention|Control|In control intervention group usual care will be provided.
32932221|NCT00360919|Experimental|A|Cheese
32932222|NCT00360919|Placebo Comparator|B|Fruits and vegetables
32932223|NCT04703569|Experimental|Monolayer high compression elastic bandage|An elastic bandage of cotton, viscose, nylon and elastane
32932224|NCT04703569|Active Comparator|Unna boot|A wet bandage with zinc oxide
32932225|NCT04686799|Experimental|SD-doxycycline group|12 weeks SD-doxycycline: doxycycline hyclate 20 mg tablet by mouth twice daily
32932226|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
32932227|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
32932228|NCT04680481|Experimental|Stimulation Theta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition).
32932229|NCT04680481|Experimental|Stimulation Beta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition).
32932230|NCT04676347||Eligible population|All patients admitted in the semi-intensive care units attending the study. Be basing on the average number of patients yearly treated in those units, we expect to have at least 39000 patients during the 5 years of the study.
32932231|NCT04676035|Experimental|SHR3680+ Midazolam, Warfarin, Omeprazole, VitaminK1|administrate Midazolam, Warfarin, Omeprazole, VitaminK1 on Day1 and Day22, SHR3680 on day 6-27.
32932232|NCT03926299|Experimental|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
32932233|NCT03926299|Active Comparator|Topical steroid|clobetasol propionate 0.05% cream
32932234|NCT03917797|Experimental|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
33252045|NCT00971308|Experimental|BMS-824393 (Panel 2)|
32932235|NCT03917797|Placebo Comparator|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
32932236|NCT04342507|Other|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
33252046|NCT00971308|Experimental|BMS-824393 (Panel 3)|
33252047|NCT00971308|Experimental|BMS-824393 (Panel 4)|
32932237|NCT04342507|Experimental|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
32932238|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
32932239|NCT03898297||Healthy control|60 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
32932240|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
32932241|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
32932242|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
32932243|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
32728941|NCT00535405|Experimental|2|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
32728942|NCT00535405|Experimental|3|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
32932244|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
32932245|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
32932246|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
33252048|NCT00971308|Experimental|BMS-824393 (Panel 5)|
32932247|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
32932248|NCT04668157|Experimental|TAK-536|TAK-536 granule formulation, orally once daily before or after breakfast. The initial dose of TAK-536 will be 0.1 mg/kg (not exceeding 2.5 mg/day). After the initial dose, TAK-536 will be titrated to 0.2 mg/kg (not exceeding 5 mg/day), 0.4 mg/kg (not exceeding 10 mg/day), and 0.8 mg/kg (not exceeding 20 mg/day) if the subjects do not achieve the target blood pressure and no concerns are found in safety and tolerability.
32932249|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
32932250|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
32932251|NCT04328857|Experimental|Treatment|Upper limb rehabilitation with pseudoelastic orthosis
32932252|NCT04328857|No Intervention|Control|Upper limb rehabilitation without pseudoelastic orthosis
32932253|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
32932254|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
32932255|NCT03844633|No Intervention|Open arm|No intervention provided
32932256|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
33252049|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
32932257|NCT00362089|No Intervention|Nutrition counseling|Control group
32932258|NCT04342741|Active Comparator|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
32932259|NCT04342741|Active Comparator|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
32932260|NCT04666987||Xultophy®|Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy
32932261|NCT04661215||Symptoms of gastroparesis|Participants with symptoms of gastroparesis with minimum GCSI score of 2.0 (18/45 x 5)
32932262|NCT04661215||Control participants|Participants undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of PAGI-SYM questionnaire.
32932263|NCT04328701|Experimental|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
32932264|NCT04328701|No Intervention|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
33252050|NCT00869583|No Intervention|2|
33252051|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
33252052|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
33252053|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
33252054|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
33252055|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
32932265|NCT04660669|Other|ESDM 15h|This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
32932266|NCT04660669|Other|ESDM 8h + MOOC|This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.
32932267|NCT04318717|Experimental|Pembrolizumab + Hypofractionated radiation therapy|"Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).~Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
32932268|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
33252056|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
32932269|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
32932270|NCT03821935|Experimental|Dose Escalation: ABBV-151|Various doses of ABBV-151 administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
32932271|NCT03821935|Experimental|Dose Escalation: ABBV-151 + Budigalimab|Various doses of ABBV-151 + Budigalimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
32932272|NCT03821935|Experimental|Dose Expansion: ABBV-151 + Budigalimab|Participants will receive ABBV-151 at the RP2D plus budigalimab Dose A administered Q4W.
32932273|NCT03821935|Experimental|Biopsy Cohort: ABBV-151 Dose A|Participants will receive ABBV-151 Dose A.
32932274|NCT03821935|Experimental|Biopsy Cohort: ABBV-151 Dose B|Participants will receive ABBV-151 Dose B.
32932275|NCT03820687|Active Comparator|Intervention Group|Participants in the intervention group will receive 3 components: 1) a culturally tailored clinical trial educational video, 2) a brochure and 3) support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
32932276|NCT03820687|Active Comparator|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
32932277|NCT04298437|Experimental|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
32932278|NCT04298437|No Intervention|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
32932279|NCT05444101|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
32932280|NCT05444101|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
32932281|NCT05444101|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
32932282|NCT05444101|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
32932283|NCT05444101|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component in different orders. Total number of sessions: 4 (4 contact hours).
32932284|NCT05444101|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
32932285|NCT05444101|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
32932286|NCT05444101|Experimental|Mindful attention + Decentering + Values and committed action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component in different orders. Total number of sessions: 6 (6 contact hours).
32932287|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
32932288|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
32932289|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
32932290|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
32932291|NCT04342819|Experimental|SGLT2i|Empagliflozin 25 mg per oral once daily
32932292|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
32932293|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
33073746|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
33252057|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
33252058|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
33252059|NCT03992911|Experimental|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
33252060|NCT03992911|Active Comparator|EP/EC|Etoposide plus Cisplatin or Carboplatin
33252061|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
33252062|NCT00895479|No Intervention|Control|Graft placement surgery alone
33252063|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
33252064|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
33252065|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
33252066|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
33252067|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33252068|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33252069|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33252070|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33252071|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33252072|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33073748|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
33252073|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
33252074|NCT00377455|Experimental|Bosentan|
33252075|NCT00377455|Placebo Comparator|Placebo|
33252076|NCT00895557|Active Comparator|chantix|
33252077|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
33252078|NCT00869895|Experimental|1|
33252079|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
33252080|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
33252081|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
33252082|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
33252083|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
33252084|NCT00869973|Experimental|1|Aprepitant
33252085|NCT00869973|Active Comparator|2|dexamethasone
33252086|NCT04955158|Experimental|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack
33252087|NCT04955158|Experimental|Ketamine|50 mg ketamine soaked pharyngeal pack
33252088|NCT04955158|Experimental|Saline placebo|20 ml 0.9% saline soaked pharyngeal pack
33252089|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
33252090|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
33252091|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
33252092|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
32932294|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
32932295|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
32932296|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
32932297|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
32728943|NCT00535405|Experimental|4|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
32728944|NCT00535405|Experimental|5|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
32728945|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
32728946|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
32728947|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
32728948|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
32728949|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
32728950|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
32728951|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
32728952|NCT00271817|Active Comparator|Part 1 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
32728953|NCT00271817|Active Comparator|Part 1 -Arm 2|ezetimibe/simvastatin
32932298|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
32932299|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
32932300|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
32932301|NCT03762018|Active Comparator|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
32932302|NCT03762018|Experimental|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
32932303|NCT05628636|Experimental|Arm 1|Days 1-3: 5 g BID 4-6: 10 g BID 7-9: 15 g BID 10-21: 20 g BID
32932304|NCT05628636|Experimental|Arm 2|Days 1-3: 10 g BID 4-6: 10 g BID 7-9: 10 g BID 10-21: 20 g BID
32932305|NCT05628636|Experimental|Arm 3|Days 1-3: 15 g TID 4-6: 10 g TID 7-9: 10 g TID 10-21: 15 g TID
32728954|NCT00271817|Active Comparator|Part 1 - Arm 3|Niacin (ER)
32728955|NCT00271817|Active Comparator|Part 2 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
32728956|NCT00271817|Placebo Comparator|Part 2 - Arm 2|ezetimibe/simvastatin combination tablet + niacin (Pbo)
32728957|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
32728958|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
32728959|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
32932307|NCT05616468|Experimental|BGT007 Cell Injection|"In this study, 23 patients diagnosed with recurrent/metastatic nasopharyngeal carcinoma will receive a single intravenous infusion of BGT007 cells after enrollment, with a dose of 5.0 × 10^5cells/kg，1.0 × 10^6cells/kg，3.0 × 10^6cells/kg，6.0 × 10^6cells/kg，1.0 × 10^7cells/kg。 One subject was enrolled in each of the first two dose groups, and the other three dose groups were enrolled in accordance with the conventional 3+3 dose increase."
33252093|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
32932308|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
32932309|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
32932310|NCT04790682|Experimental|NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.|
32932311|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
32932312|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
32932313|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
32768972|NCT05057377||Post-TBI Participants|Over a 2-day period post-TBI adults age 18 years and older, will undergo overground assessments with a questionnaire regarding motivation during day 1, followed by robotic safety-environment assessments during day 2.
32932314|NCT05197842|Experimental|Group A|BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide
32932315|NCT05197842|Experimental|Group B|BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide
32768973|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
32932316|NCT05197842|Active Comparator|Group C|Standard dose glucocorticoids in combination with cyclophosphamide
32932317|NCT05195970|Experimental|Walnut Consumption|Following enrollment, participants will start a 7-day wash-out period where they will be asked to avoid foods and beverages high in ellagitannins. These include pomegranates, hazelnuts, pistachios, walnuts (besides the samples given by the researchers), strawberries, raspberries, blackberries, oak-aged wines and spirits; a full list of foods and beverages to avoid will be provided. Then, participants will consume 2 ounces of walnuts daily with their usual diet while continuing to avoid ellagitannins for 21 days prior to their routine colonoscopy.
33252094|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment [EUCRISA] applied twice a day for 8 weeks
32768974|NCT05064475||Recurrent breast cancer patients with elevated tumor markers|PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18F-FDG. Its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting BC recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18F-FDG PET/CT is frequently used for BC evaluation. However, data on its value in evaluating BC recurrence in patients with elevated tumor markers are limited and unclear
32768975|NCT05057299||Patients with extramedullary leukemia(eAML) with myeloid neoplasms|
32768976|NCT05057455||ICU patients diagnosed with sepsis or septic shock|compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
32768977|NCT05063773|Experimental|Group 1|
33252095|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
33252096|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
33252097|NCT04008394|Experimental|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
33252098|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
33252099|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
33252100|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
33252101|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
33252102|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
33252103|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
33252104|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
32932322|NCT04285723||alpelisib|Patients treated with alpelisib
32932323|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
32932324|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
32728960|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
32932325|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
32932326|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
32932327|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
32932328|NCT03764293|Active Comparator|Control|Sorafenib
32932329|NCT04284553|Experimental|Base Order Entry Alert|
32728961|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
32728962|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
32728963|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
32728964|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
32728965|NCT00092989|Experimental|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
32728966|NCT00092989|Placebo Comparator|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
32728967|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
32728968|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
32728969|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
32932330|NCT04284553|Experimental|Base Open Encounter Alert|
32932331|NCT04284553|Experimental|Order Entry + Follow-up booster Alert|
32932332|NCT04284553|Experimental|Open Encounter + Follow-up booster Alert|
32932333|NCT04284553|Experimental|Order Entry + Cold State outreach|
32932334|NCT04284553|Experimental|Open Encounter + Cold State outreach|
32932335|NCT04284553|Experimental|Order Entry + Simplified|
32932336|NCT04284553|Experimental|Open Encounter + Simplified|
32932337|NCT04284553|Experimental|Order Entry + Sign-off alert|
32932338|NCT04284553|Experimental|Open Encounter + Sign-off alert|
32932339|NCT04284553|Experimental|Order Entry + Pre-commitment|
32728970|NCT03388489|No Intervention|Usual care|maintain their daily activity
32728971|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
32728972|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
32728973|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
32932340|NCT04284553|Experimental|Open Encounter + Pre-commitment|
32932341|NCT04284553|Experimental|Order Entry + Different Risks|
32932342|NCT04284553|Experimental|Open Encounter + Different Risks|
32932343|NCT04284553|Experimental|Standard Epic Basic Alert|
32932344|NCT04284553|No Intervention|No Alert (Usual Care)|
32932345|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
32932346|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
32932347|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
32932348|NCT03659136|Experimental|Xentuzumab/everolimus/exemestane|
32932349|NCT03659136|Placebo Comparator|Placebo/everolimus/exemestane|
32932350|NCT04779294||Fetus in labour at risk of acedimia|The Group of patients studied are fetuses in labour at risk of hypoxia with internal fetal monitoring and scalp lactate bloodsamples ( standard monitoring).
32932351|NCT04779294||Fetus in labour at risk of acedemia with STAN analysis|Same group of fetuses in labour at risk of hypoxia with internal fetal monitoring and STAN analysis(ST waveform analysis of the fetal electrocardiogram, opened after study inclusion finished)
33252105|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
33252106|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
33252107|NCT00894153|Active Comparator|chemo only|chemotherapy group
33252108|NCT00894153|Active Comparator|radio|radiotherapy
33252109|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
33252110|NCT01048801|Other|Treatment without rapid daignostic test|
33252111|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
33252112|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
33252113|NCT00971542|Experimental|high dose of antigen|
33252114|NCT00895713|Experimental|im HBIG Grifols|
33252115|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
33252116|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
33252117|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
33252118|NCT00894231|Placebo Comparator|placebo|Sugar tablet
33252119|NCT00894231|Active Comparator|Xyzal|
33252120|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
32728974|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
32728975|NCT04702529|Experimental|Three treatments to hypertrophic scar with RAP device|RAP treatments will be administered to the scar every +/- 2 weeks for a total of 3 treatments
32728976|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
32932352|NCT03654768|Active Comparator|Arm I (bosutinib, dasatinib, nilotinib, imatinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32932353|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib, imatinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32932354|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
33252121|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
32932355|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
32932356|NCT04267705|Active Comparator|Black bean|A cup of black bean 7 days/week over a 12-week period
32728977|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
32728978|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
32932357|NCT04267705|Active Comparator|Chickpea|A cup of chickpea 7 days/week over a 12-week period
32728979|NCT04685993|Experimental|Treatment A|LPCN 1144
32728980|NCT03858049|Experimental|Crinone|
32728981|NCT03858049|Experimental|Crinone plus Duphaston|
32728982|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
32728983|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
32728984|NCT03838939|Experimental|interventional group|"M3 (group with 3 to 10 patients) Intensification Biotherapy Education Workshops : Subcutaneous injection education and biotherapy management"
32932358|NCT04267705|Placebo Comparator|Control|A cup of white rice 7 days/week over a 12-week period
32932359|NCT03681769|Experimental|Intermittent Theta Burst Stimulation (iTBS) to the left dlPFC|For intermittent theta burst stimulation (iTBS) (Aim 1), participants will receive 20 trains of stimulation over the dlPFC (middle frontal gyrus) (F3) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P).
32932360|NCT03681769|Sham Comparator|Sham iTBS to the left dlPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
32932361|NCT03681769|Experimental|cTBS to the mPFC|For continuous theta burst stimulation (Aim 2), participants will receive 1 train of stimulation over the left frontal pole (FP1) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P). This protocol has been shown to attenuate the mPFC and striatum in cocaine dependent individuals in the past (61-63) and has been more effective than 1200 or 1800 pulses of cTBS in attenuating depression (The time between the end of the TBS procedures and the beginning of the behavioral assessments, as well as the scalp-to-cortex distance (which effects the actual TMS dose given to the cortex) will be compiled and used as covariates in subsequent analyses.
32932362|NCT03681769|Sham Comparator|Sham cTBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
32728985|NCT03838939|Placebo Comparator|Control group|"M3 (individual) Intensification Biotherapy Education: Subcutaneous injection education and biotherapy management."
33073753|NCT00001853||Healthy volunteers|Healthy adult African Americans born in the United States, with American born parents or born in Africa with African born parents.
32728986|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
32728987|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
32932363|NCT05440123||bronchopulmonary cancer|"The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation.~For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care."
32728988|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
32932364|NCT03678805|Experimental|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
32932365|NCT03678805|Active Comparator|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.~Traditional withdrawal techniques will be used."
32728989|NCT03388073|Placebo Comparator|Placebo|
32728990|NCT03390205||Patients|
32728991|NCT03390205||Controls|
32728992|NCT03797911|Experimental|active resistive capacitive monopolar radiofrequency|"Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): The intervention group will receive the treatment with activated resistive capacitive monopolar radiofrequency system, with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
32743510|NCT04929717|Experimental|Intervention|The personal information form and BSES-SF were administered to women in the hospital before the intervention. Breastfeeding education and counseling were provided via social media (WhatsApp) to support women for breastfeeding and to ensure the continuity of breastfeeding in the postpartum period. Breastfeeding education was given to women in the first four weeks after discharge from the hospital. After the breastfeeding education was completed via social media, the counseling process started. Counseling was conducted via social media with a question-answer method between the first and 6th months of postpartum.
32932366|NCT05561790|Experimental|Intervention|Administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy.
32932367|NCT05561790|No Intervention|Control|Wait-list control; access to treatment after final measurement
32932368|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
32932369|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
32932370|NCT03583710|Experimental|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
32932371|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32932372|NCT04418154|Experimental|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
32932373|NCT05195034|Active Comparator|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
32932374|NCT05195034|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
32728993|NCT03797911|Placebo Comparator|Inactive resistive capacitive monopolar radiofrequency|"Application of the technique in the control group (inactivated resistive capacitive monopolar radiofrequency therapy): The control group will receive the treatment with inactivated resistive capacitive monopolar radiofrequency system (placebo), with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
32728994|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
32932375|NCT04790058||Physicians using CSRS practice recommendation to treat syncope patients in ED.|During the control period, there will be no interventions. The intervention is the knowledge translation of the CSRS practice recommendations. The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g. troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. The ED physician or non-ED physician performing consultation on the patient can apply all the components of the practice recommendation and decide disposition of the patients who are eligible to be studied.
32728995|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
32768978|NCT05063773|No Intervention|Group 2|
32768979|NCT05057065||Hyperlipidemia|"HBsAg(+) patients~TC>5.17mmol/L（200mg/dl）and（or）TG>2.3mmol/L（200mg/dl）"
32932376|NCT05193942|Experimental|Intervention|From baseline to 4-month post-test, participants in the intervention arm will have access to the Our Plan web app program.
32932377|NCT05193942|Other|Informational control|From baseline to 4-month post-test, participants in the informational control arm will not have access to the Our Plan web app program. Participants will instead receive a webpage with information about HIV/STI prevention options and resources to represent the current equivalent of a standard of care for online HIV resources.
32932378|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 every 3 months (Q3M).
32932379|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 every 3 months (Q3M).
32932380|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 every 3 months (Q3M).
32932381|NCT04418544||Control|Do not test positive for COVID
32932382|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
32932383|NCT05474508|Experimental|Diaphragmatic breathing along with aerobic exercises|Experimental Group (Group A) will receive both aerobic exercises and diaphragmatic breathing exercise. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks. Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks
32932384|NCT05474508|Active Comparator|Diaphragmatic breathing only without aerobic exercises|Active comparator (Group B) will receive only diaphragmatic breathing exercises. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
32932385|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
32932386|NCT04789902|Experimental|Hospital site 1|This site will provide usual ED care during the control period which will last for the first six months of the study. After six months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
32932387|NCT04789902|Experimental|Hospital site 2|This site will provide usual ED care during the control period which will last for the first 12 months of the study. After 12 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
32932388|NCT04789902|Experimental|Hospital site 3|This site will provide usual ED care during the control period which will last for the first 18 months of the study. After 18 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
32932389|NCT04789902|Experimental|Hospital site 4|This site will provide usual ED care during the control period which will last for the first 24 months of the study. After 24 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
32932390|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
32932391|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
32932392|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
32932393|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
32932394|NCT04192968||Patients with disappointing language development or poor cortical responses|Children having participated in the main ImplantHear3 study and who present with disappointing language development or poor cortical responses.
32932395|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
32932396|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
32932397|NCT03489252|Experimental|Device Feasibility (Fitbit Charge 3)|Participants wear the Fitbit Charge 3 device from the time of CT simulation for RT planning throughout the entire RT course.
32728996|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
32728997|NCT03392987|Experimental|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
32728998|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
32728999|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
32729000|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
32729001|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
32729002|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
32729003|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
32729004|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
32729005|NCT05239273|Experimental|Complex Decongestive Therapy (CDT) Group|Phase 1 of CDT will be applied to CDT group. This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue 5 days a week for 3 weeks.
32729006|NCT05239273|Other|Control group|Waiting list will included in control group.
32729007|NCT03711617||CKD-ND|patients with non-dialysis CKD
32729008|NCT03711617||CKD-MHD|patients with maintenance hemodialysis
32729009|NCT03125759||Control|patients without any history of stroke
32729010|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
32932398|NCT04776798|Experimental|Biomechanical Taping|"Anti pronation taping will apply bilaterally with Dynamic Tape®. The tape will attach to the dorsal aspect of the foot.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
32932399|NCT04776798|Placebo Comparator|Placebo Taping|"Placebo Taping will apply bilaterally to each individual in the control group by the same physiotherapist, without any effect on increased pronation.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
32932400|NCT04789668|Experimental|Treatment (bintrafusp alfa, pimasertib)|Patients receive bintrafusp alfa IV over 1 hour every 2 weeks and pimasertib PO BID on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
32932401|NCT05180838||BioSticker|This cohort will place BioStickers at least 3 days prior to completion of standard of care therapy and discharge home post therapy.
32932402|NCT05180058|Experimental|Wrapping + Breastmilk Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of breast milk will be given by the researcher with a sterile syringe 2 minutes before the OGT insertion to the same newborn. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
32932403|NCT05180058|Experimental|Wrapping + Oral Sucrose Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of 20% oral sucrose will be given to the same newborn by the researcher with a sterile syringe 2 minutes before OGT insertion. Oral sucrose will be slowly introduced into the mouth of the preterm newborn on the upper part of the tongue through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at 1 minute before the procedure, during and after the procedure at 1 minute and 2 minutes (4 measurements).
32932404|NCT05180058|Experimental|Fetal Position + Breastmilk Group|The fetal position will be given to the preterm newborn immediately after 2 ml of breast milk is given by the researcher 3 minutes before OGT insertion. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure. Newborns will be recorded with a video camera before, during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
33073763|NCT00001505||1/Single Cohort|Healthy individuals (including employees and other patients) and patients with selected skin or other diseases
32729011|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
32729012|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
32729013|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
32729014|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
32729015|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
32729016|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
32729017|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
32729018|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
32729019|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
32932405|NCT05180058|Experimental|Fetal Position + Oral Sucrose Group|The fetal position will be given to the preterm newborn immediately after 2 ml of oral sucrose is given by the researcher 3 minutes before OGT insertion. Oral sucrose will be slowly injected into the mouth of the preterm newborn on the upper part of the tongue by means of an injector. At the end of the 3rd minute, the clinic nurse will insert the OGT as part of the treatment. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure.
32932406|NCT05179824||Group 1: Standard of Care (SOC) CGP|This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
32729020|NCT03387839||Medial-Pivot Knee Prosthesis|
32729021|NCT03387839||Posterior-Stabilized Knee Prosthesis|
32729022|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
32932407|NCT05179824||Group 2: Disease or Profile Specific Cohorts|"Group 2 will consist of specific cohorts that will facilitate collection of paired clinical and molecular data done outside of the standard of care, longitudinal CGP, or narrowly defined cohorts based on mutations or treatment settings. The goal of Group 2 is to capture specific participants in specific cohorts to better understand longitudinal outcomes across institutions and standards of care.~Protocol contains complete eligibility criteria."
32932408|NCT04789278|Experimental|Notification|"Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or postal mail that will inform them of the CAC identified on their previous chest CT. It will provide an overview of CAC, an image of their chest CT, and a recommendation that they discuss this finding with their clinician. These clinicians will be notified of these findings via an earlier EHR message. Any treatment decisions will be made by the patient and their clinician.~Patients randomized to notification who are not prescribed a statin medication and do not have a documented discussion regarding statin therapy within three months will be sent a second message at that time. Their primary care providers will receive a second EHR message concurrently."
32932409|NCT04789278|No Intervention|Usual Care|Both arms have previously had their CT scans reported according to standard clinical practice. This may include notification of the CAC in the imaging report. The usual care arm will not receive any additional notification beyond this standard of care during the project.
32932410|NCT05178966|Experimental|Bp OneDay programm|The BP One-Day program is based on a single day of psychoeducation .
32932411|NCT05178966|No Intervention|Waiting List|Patients assigned in control group will be placed in waiting list and will benefit from the program after their participation to this study. During study participation, they will receive treatment as usual.
32932412|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
32932413|NCT05408754|Experimental|Pulsed Field Ablation (PFA) group|PsAF patients treated by PFA
32932414|NCT05408754|Experimental|Pulsed Field CryoAblation (PFCA) group|PsAF patients treated by PFCA
32932415|NCT04801524|No Intervention|Holdout Arm|In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
32932416|NCT04801524|Experimental|Self-benefit sub-arm|In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
32932417|NCT04801524|Experimental|Prosocial-benefit sub-arm|In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
32932418|NCT04801524|Experimental|Early-access and self-benefit sub-arm|In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
32729023|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
32932419|NCT04801524|Experimental|Early-access and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
32932420|NCT04801524|Experimental|Fresh start and self-benefit sub-arm|In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
32932421|NCT04801524|Experimental|Fresh start and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
32932422|NCT05178342|Other|CA-4948 treatment|Single-arm design. all patients are treated with IMP
32932423|NCT05343936||Active surveillance|This is a multicentric active surveillance prospective cohort study. The eligibility criteria defined are: low-risk prostate adenocarcinoma (clinical stage of cT1-T2a / Group Grade 1 (Gleason score less or equal to 6) / PSA less or equal to 10 ng/ml), transrectal prostate biopsy with at least 12 cores, estimated life expectancy over 10 years, clinical conditions for definitive treatment, multiparametric prostate MRI performed or planned.
32729024|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
32932424|NCT04448886|Experimental|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days~Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle~Pembrolizumab (iv) fixed dose administered once per cycle"
32932425|NCT04448886|Experimental|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
32932426|NCT04448886|Experimental|Retreatment|Participants who have attained a confirmed complete response (CR) who have been treated for at least 24 weeks on protocol therapy and had at least three cycles (with pembrolizumab and sacituzumab govitecan (Arm A) or sacituzumab govitecan alone (Arm B)) beyond the date when the initial CR was declared may be eligible for additional sacituzumab govitecan and/or pembrolizumab therapy if they progress after stopping study treatment. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets protocol-specified conditions.
32932427|NCT05172882|Experimental|Wound Infiltration|Wound infiltration will be applied to the surgical incision site for patients in this group. Infiltration fluid will contain 20 ml 0.25% bupivakain.
32932428|NCT05172882|Experimental|Transversalis Fascia Plane Block|Transversalis fascia plane block will be performed on only one periinguinal side for patients in this group. Block fluid will contain 20 ml 0.25% bupivakain.
32932429|NCT02666118|Active Comparator|Preemptive Interscalene Block - Single Shot|
32932430|NCT02666118|Active Comparator|Postoperative Interscalene Block - Single Shot|
32932431|NCT02666118|Active Comparator|Preemptive Interscalene Block - Catheter|
32932432|NCT02666118|Active Comparator|Postoperative Interscalene Block - Catheter|
32729025|NCT04586621|Experimental|Atoldys/ Lexilens - SHAM|
32932433|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
32932434|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
32932435|NCT05337774|Experimental|Blast-related mTBI group|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
32932436|NCT05337774|Experimental|mTBI not blast-related (control group 1)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
32932437|NCT05337774|Experimental|no history of TBI (control group 2)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
32932438|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
32729026|NCT04586621|Experimental|SHAM- Atoldys/ Lexilens|
32729027|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
32729028|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
32729029|NCT03652181||CASH (Cavernous Angiomas with Symptomatic Hemorrhage)|The adjudicated definition of CASH (Cavernous Angiomas with Symptomatic Hemorrhage) requires diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms.
32729030|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
32729031|NCT04562363||Low risk of herniation.|Use of any method of suturing, including modified.
32729032|NCT04562363||The average risk of hernia formation|The application of modified methods of closure of laparotomy wound.
32729033|NCT04562363||high risk of herniation|The use of alloplastic methods of closure of laparotomy wound.
32729034|NCT04562363||The presence of eventrations|The use of alloplastic methods of suturing a laparotomic wound in the absence of suppuration.
32932439|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
32932440|NCT05291988|Experimental|Screening (S2S education, FIT kit)|Participants receive S2S online screening education and FIT kit for sample collection.
32729035|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
32729036|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
32729037|NCT04506983|Experimental|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
32932441|NCT02508324|Other|Intervention|"All potential recipients will have complete (HLA) typing and determination of HLA antibodies. An appropriate umbilical cord blood unit (CBU) will be identified or in the absence of an appropriate CBU, a haplo-identical cells (donor) will be identified.~Within 72 hours after completion of the chemotherapy regimen, and no sooner than 24 hours after administration of the last dose of chemotherapy, umbilical cord graft or haplo-graft will be administered."
33252122|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
33252123|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
32729038|NCT04501211|Other|Patch arm|Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks
32729039|NCT04465331||patients with knee arthrosis|Painful Knee Osteoarthritis with presence of osteophytes on radiography
32729040|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
32729041|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
32729042|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
32729043|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
32768980|NCT05057065||diabetes|"HBsAg(+) patients~FPG>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h."
32768981|NCT05057065||CHB without metabolic disease|"HBsAg(+) patients~without diabetes/ obesity/hyperlipidemia"
32768982|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
32932442|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
32729044|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
32932443|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
32932444|NCT02381886|Experimental|IDH305|
32932445|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
33252124|NCT05030974|Active Comparator|stratum A1 - one extra dose of mRNA-1273|Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m)
32932448|NCT05343858|Experimental|Group 1: Spirulina platensis|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Spirulina platensis
32932449|NCT05343858|Experimental|Group 2: Chlorella vulgaris|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Chlorella vulgaris
32729045|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
32729046|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
32729047|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
32729048|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
32729049|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
32729050|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
32729051|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
32729052|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
32729053|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
32729054|NCT03387215|Placebo Comparator|Placebo|Single oral dose
32729055|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
32729056|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
32729057|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
32729058|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
32729059|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
32729060|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
32729061|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
32729062|NCT04253483|Experimental|Arm I (HDR)|Patients undergo HDR.
32729063|NCT04253483|Experimental|Arm II (SABR)|Patients undergo SABR every other day for 5 treatments.
32729064|NCT03479957|Experimental|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
32729065|NCT03479957|Other|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
32932450|NCT05343858|Placebo Comparator|Group 3: Control|10 volunteers will consume 16g / day (in 2 doses of 8g) of a control supplement
33252125|NCT05030974|Active Comparator|stratum A2 - one extra dose of mRNA-1273 with discontinuation of MMF/MPA|patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the extra dose
33252126|NCT05030974|Active Comparator|stratum B1 - 3rd dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
33252127|NCT05030974|Active Comparator|statum B2 - 3rd double dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms
33252128|NCT05030974|Active Comparator|stratum B3 - Ad26.COV2.S vaccine|patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)
32932451|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
32729066|NCT04236791|Experimental|Intervention group|
32729067|NCT04236791|Active Comparator|Control group|
32729068|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
32932452|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
32932453|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
32932454|NCT03662659|Experimental|BMS-986213 + investigator's choice chemotherapy|BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
32932455|NCT03662659|Experimental|Nivolumab + investigator's choice chemotherapy|Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
32932456|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
33252129|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
32729069|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
32729070|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
32729071|NCT04167371|Experimental|Biofeedback|
32729072|NCT04167371|Placebo Comparator|Placebo|
32729073|NCT04014413|Experimental|Crohn's disease|Fecal Microbiota Transplant will be performed.
32932457|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
32932458|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
32932459|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
33252130|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
33252131|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
33252132|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
33252133|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd.
33073764|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
33073766|NCT00001252||healthy volunteer|Normal/healthy volunteers
33073767|NCT00001252||Impaired volunteer|volunteers with impairments of the neuromusculoskeletal system.
32729074|NCT04014413|Experimental|Ulcerative colitis|Fecal Microbiota Transplant will be performed.
32729075|NCT04014413|Experimental|Celiac disease|Fecal Microbiota Transplant will be performed.
33252134|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
32932462|NCT04598893||Teplizumab|Participants who received teplizumab in the PROTECT study
32729076|NCT04014413|Experimental|Irritable bowel syndrome|Fecal Microbiota Transplant will be performed.
32729077|NCT04014413|Experimental|Functional dyspepsia|Fecal Microbiota Transplant will be performed.
32932463|NCT04598893||Placebo|Participants who received placebo in the PROTECT study
32932464|NCT04592419|Experimental|KSI-301 (Arm A)|"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.~In the Extension Phase, participants randomized to KSI-301 (5 mg) in the Primary Study will continue to receive KSI-301 (5 mg) based on protocol-defined disease activity criteria."
32729078|NCT04014413|Experimental|Constipation|Fecal Microbiota Transplant will be performed.
32932465|NCT04592419|Active Comparator|Aflibercept (Arm B)|"Intravitreal injection of aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Week 24 to Week 44.~In the Extension Phase, participants randomized to aflibercept in the Primary Study will cross over to treatment with KSI-301 (5 mg). They will receive their first dose of KSI-301 (5 mg) at Week 48 and will receive additional treatment with KSI-301 (5 mg) based on protocol-defined disease activity criteria."
32932466|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
32729079|NCT04014413|Experimental|Metabolic disease (diabetes mellitus or obesity)|Fecal Microbiota Transplant will be performed.
32932467|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
32729080|NCT04014413|Experimental|Multidrug-resistant infection|Fecal Microbiota Transplant will be performed.
32932468|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
32932469|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
32932470|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
32729081|NCT04014413|Experimental|Hepatic encephalopathy|Fecal Microbiota Transplant will be performed.
32729082|NCT04014413|Experimental|Multiple sclerosis|Fecal Microbiota Transplant will be performed.
32729083|NCT04014413|Experimental|Pseudo-obstruction|Fecal Microbiota Transplant will be performed.
32768983|NCT05046925||24-hour PACU group|closely monitor in post-anesthetic unit (PACU) and the stay time is less than 24 hours, then patients can be discharged to floor
32932471|NCT04263493|Active Comparator|Early mobilization (loading)|"This constitutes the currently accepted regime and is therefore considered the control group.~Cast/orthopedic boot for 6 weeks No weight bearing: week 0-2 Partiel weightbearing from week 3 Full weightbearing from week 7 ROM exercises 5 times a day from week 3"
32932472|NCT04263493|Experimental|Delayed mobilization (loading)|Loading of the Achilles tendon is delayed for 6 weeks. Cast/orthopedic boot for 12 weeks No weight bearing: week 0-6 Partiel weightbearing from week 7 Full weightbearing from week 13 ROM exercises 5 times a day from week 3
32932473|NCT04246489|Experimental|Bintrafusp alfa|
32932474|NCT02032524|Experimental|Avalglucosidase alfa|administered intravenously every 2 weeks
32932475|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
32932476|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
32932477|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
32729084|NCT04014413|Experimental|CRE infection|Fecal Microbiota Transplant will be performed.
32729085|NCT04014413|Experimental|VRE infection|Fecal Microbiota Transplant will be performed.
32932478|NCT04786548|Experimental|Celecoxib Treatment|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
32932479|NCT04245397|Experimental|Oral Dose of S-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
33252135|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
32729086|NCT04014413|Experimental|Multiple organ dysfunction|Fecal Microbiota Transplant will be performed.
32729087|NCT04014413|Experimental|Dysbiotic bowel syndrome|Fecal Microbiota Transplant will be performed.
32729088|NCT04014413|Experimental|MRSA enteritis|Fecal Microbiota Transplant will be performed.
32729089|NCT04014413|Experimental|Pseudomembranous enteritis|Fecal Microbiota Transplant will be performed.
32729090|NCT04014413|Experimental|Alopecia|Fecal Microbiota Transplant will be performed.
32729091|NCT04014413|Experimental|Autism|Fecal Microbiota Transplant will be performed.
32932480|NCT04786080|Experimental|Parent Positive|This is an app developed for use on a smartphone providing a flexible digital space where parents can get support and advice to help them manage their children's behaviour. The app will be free and parents will be able to access the information when needed and in the order they choose. Parents in the intervention group will receive access during the immediate post-randomisation period.
32932481|NCT04786080|No Intervention|Follow-Up as Usual|FAU was selected as a comparator because of the pragmatic nature of the trial. Individuals randomised to FAU will receive no intervention for the first 10 weeks while the data for baseline (T1), T2 and T3 are collected. They will then be given access to all three zones of the app.
32932482|NCT00421837||controls|household and other close contacts
32729092|NCT04014413|Experimental|Graft-versus-host disease|Fecal Microbiota Transplant will be performed.
32729093|NCT04014413|Experimental|Idiopathic thrombocytopenic purpura|Fecal Microbiota Transplant will be performed.
32729094|NCT04014413|Experimental|Atopy or allergy|Fecal Microbiota Transplant will be performed.
32729095|NCT04014413|Experimental|Liver disease|Fecal Microbiota Transplant will be performed.
32729096|NCT04014413|Experimental|Alcohol dependence|Fecal Microbiota Transplant will be performed.
32729097|NCT04014413|Experimental|Antibiotic-associated diarrhea|Fecal Microbiota Transplant will be performed.
32932483|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
32932484|NCT04575025||Tabrecta tablets|Patients administered Tabrecta by prescription
32932485|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
32932486|NCT00361543|Placebo Comparator|2|placebo tablet
32932487|NCT04568239||M184V + group and M184 - group|
32932488|NCT00565851|Active Comparator|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
32932489|NCT00565851|Experimental|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
32932490|NCT00565851|Experimental|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
32729098|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
32729099|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
32729100|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
32729101|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
32932491|NCT00565851|Experimental|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
32932492|NCT04329429|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
32729102|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
32729103|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
32729104|NCT04446767|Experimental|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
32729105|NCT04446767|Active Comparator|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
32729106|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
32729107|NCT03416543||Puncture|Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
32932493|NCT04329585|Experimental|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
32932494|NCT04329585|Placebo Comparator|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
32932495|NCT00384267||Neonates|Inpatient
32932496|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
32932497|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
32932498|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
32932499|NCT00002829|Experimental|Bone Marrow Transplantation|
32932500|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
33073769|NCT00001231||Healthy Women|The purpose of this protocol is to allow for the careful screening of healthy volunteers for participation in research protocols.
33252136|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
33252137|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
33252138|NCT00896259||THA control|those with THA not participating in exercise and education program
33252139|NCT00896259||THA exercise|those with THA and participating in exercise and education program
33252140|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
33252141|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
32768984|NCT05046925||24-hour ICU group|closely monitor in intensive care unit (ICU) and the stay time is less than 24 hours, even patients die within 24 hours in ICU
32768985|NCT04470973||Cefuroxime/Amikacin|20 patients will be included in the cefuroxime cohort and 20 patients in the amikacin cohort.
33252142|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
33252143|NCT00894621|Experimental|Norepinephrine|
33252144|NCT00894621|Placebo Comparator|Placebo|
33252145|NCT03915418|Experimental|Connected tools|1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.
33252146|NCT04036227|Experimental|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
33252147|NCT04036227|Placebo Comparator|Placebo|Matching placebo oral solution
33252148|NCT00901095|No Intervention|Control|Usual Care
33252149|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
33252150|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
33252151|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
33252152|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
33252153|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
33252154|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
33252155|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
33252156|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
32768986|NCT05046457|Experimental|3mg BCX supplement|One 3mg BCX capsule + one placebo capsule to be taken once per day for 8 weeks
32768987|NCT05046457|Experimental|6mg BCX supplement|Two 3mg BCX capsules to be taken once per day for 8 weeks
32768988|NCT05046457|Placebo Comparator|0mg BCX supplementation|Two placebo capsules to be taken once per day for 8 weeks
33252157|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
33252158|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
33252159|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
33252160|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
33252161|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
33252162|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
32768989|NCT05056675|Experimental|PENG block for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of 0.5% ropivacaine iv is injected.
32932501|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
32932502|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32932503|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
32932504|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
32932505|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
32932506|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
32932507|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
32932508|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32932509|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32932510|NCT04563403|Experimental|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
32932511|NCT04563403|Experimental|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
32932512|NCT00002835|Experimental|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
32932513|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
32932514|NCT04562233|Experimental|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each onto Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30-45-minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20-25-minute workout; 5-10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location incase of an emergency.
32932515|NCT04562233|Other|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.~Participants randomized to the control arm will also be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
32932516|NCT04560673|Experimental|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
32932517|NCT04560673|Experimental|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
32932518|NCT04560673|Experimental|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
32932519|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
32932520|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
32932521|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
32932522|NCT00361153|Placebo Comparator|2|placebo
32932523|NCT04342117||Duvelisib|Patients who take duvelisib.
32729108|NCT04446533|Experimental|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
32729109|NCT04446533|Active Comparator|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
32729110|NCT04446533|Placebo Comparator|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
32932524|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
32932525|NCT04225585|Experimental|Coping Skills Training for Persistent Post-Surgical Pain|novel pain coping skills training intervention designed specifically for people with persistent pain (PP) following breast cancer surgery
32932526|NCT04225585|Active Comparator|General health education with a coach|general health education intervention
32932527|NCT04225585|Active Comparator|Self-guided health education|general health education intervention
32932528|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32932529|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
32932530|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
32729111|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
32729112|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
32932531|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
32932532|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
32729113|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
32932533|NCT04220827|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
32932534|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
32932535|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
32932536|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
32932537|NCT03567109||control|healthy subjects
32932538|NCT04159857|Active Comparator|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
32932539|NCT04159857|Experimental|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
32932540|NCT04552795|Experimental|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
32932541|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
32932542|NCT04192357|Experimental|WLM3P|Participants will receive the M3F program. The M3F program is divided into three phases, being the first two of weight loss and the third phase of weight maintenance.
32932543|NCT04192357|Active Comparator|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
32932544|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
32932545|NCT04154943|Experimental|Cemiplimab|Will receive IV infusion Q3W
32932546|NCT04530487|Experimental|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.~TRANSPLANT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
32932547|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
32932548|NCT04342351|Experimental|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
32932549|NCT04342351|Active Comparator|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
32932550|NCT04342273|Experimental|KW-6356 therapeutic dose|Oral administration
32932551|NCT04342273|Experimental|KW-6356 supratherapeutic dose|Oral administration
32932552|NCT04342273|Placebo Comparator|Placebo|Oral administration
32932553|NCT04342273|Active Comparator|Moxifloxacin|Oral administration
32932554|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32932555|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
32932556|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
32932557|NCT03504241|Experimental|MSCs 10^6 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks.
32932558|NCT00003375|No Intervention|Observation|Observation only.
32729114|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
32729115|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
32729116|NCT04446689|Active Comparator|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
32729117|NCT04446689|No Intervention|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
32729118|NCT04446455|Experimental|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
32932559|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
32932560|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
32932561|NCT04329195|Experimental|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
32932562|NCT04329195|Active Comparator|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
32932563|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
32932564|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
32932565|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
32932566|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
32932567|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
32932568|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
32932569|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
32932570|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
32932571|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
32729119|NCT04446455|Active Comparator|Functional Power Training|Training sessions began with 40 minutes of functional power training.
32729120|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
32729121|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
32729122|NCT03391739|Experimental|Arm 1|CART-19 cells treat
32729123|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
32729124|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
32729125|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
32729126|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
32729127|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
32729128|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
32729129|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
32729130|NCT03391661|Placebo Comparator|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
32729131|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
32729132|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
32729133|NCT03386201|Experimental|Intravenous methylene blue|
32729134|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
32729135|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
32729136|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
32729137|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
32729138|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
32729139|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
32729140|NCT03298217|Other|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
32729141|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
32729142|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
32729143|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
32729144|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
33073770|NCT00001231||premenopausal depressed women patients|The purpose of this protocol is to allow for the careful screening of patients for participation in research protocols.
33073771|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
32932572|NCT03482557|Experimental|CESM VS MRI|"Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.~MRI: Breast MRI will be performed, if not already performed as part of clinical care.~CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.~Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.~Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers."
32729145|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
32932573|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
32932574|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
32932575|NCT03476239|Experimental|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
32932576|NCT04074993|Experimental|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
32729146|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
32729147|NCT03268811|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
32729148|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
32932577|NCT04073043|Experimental|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
32932578|NCT04073043|No Intervention|Control Group|The control group will have access only to the web-based intervention without telephone support
32932579|NCT00004875||Standard Heparin|
32932580|NCT00004875||Enoxaprin|
32729149|NCT03391271|Placebo Comparator|Placebo group|No PBMT
32729150|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
32729151|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
32729152|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
32729153|NCT03131531||Hodgkin lymphoma|
32729154|NCT03131531||Non-Hodgkin lymphoma|
32729155|NCT03131531||Myeloma|
32729156|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
32729157|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
32729158|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
32729159|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
32729160|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
32729161|NCT03966677||P-GHR|Patients with persistent severe pain after groin hernia repair.
32729162|NCT03966677||NP-GHR|Patients without pain after groin hernia repair.
32729163|NCT03966677||NP|Healthy non-operated controls
32729164|NCT03390803||patients with hemifacial spasm|
32932581|NCT04071171|Active Comparator|Phoxilium®|
32932582|NCT04071171|Experimental|Biphozyl®|
32932583|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
33073772|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
32729165|NCT03390803||healthy control subjects|
32729166|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
32729167|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
32729168|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
32729169|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
32729170|NCT03390413|Active Comparator|Robot|
32932584|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
32932585|NCT03468985|Active Comparator|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32932586|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32932587|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32932588|NCT03468985|Experimental|Arm T (Targeted cohort; nivolumab, cabozantinib)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32932589|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
32932590|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
32932591|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
32932592|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
32932593|NCT04520425|Experimental|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
32729171|NCT03390413|Experimental|Cryo|
32932594|NCT04188379|Experimental|efgartigimod|Patient receiving efgartigimod
32932595|NCT04188379|Placebo Comparator|Placebo|Patients receiving placebo
32932596|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
33073773|NCT04688827|Experimental|training group 1: low-intensity resistance training|
33073774|NCT04688827|Experimental|training group 2: moderate-intensity resistance training|
33073775|NCT04688437||Patients with degenerative scoliosis|
32729172|NCT03390179||diabetes|Patient with non insulin diabetes
32729173|NCT03390179||control|Patient without diabete
32729174|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
32743511|NCT04929717|Other|Control|The women in the control group were pre-tested at the hospital before discharge. The BSES-SF was re-administered by phone at the 3rd and 6th postpartum months. The control group received the routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures. Except for routine breastfeeding training, no intervention was applied to the control group.
32729175|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
32932597|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
32729176|NCT03093701|Experimental|Group 1|TLC399 (ProDex) 0.36mg DSP with 100 mM PL
32729177|NCT03093701|Experimental|Group 2|TLC399 (ProDex) 0.6 mg DSP with 100 mM PL
32729178|NCT03093701|Experimental|Group 3|TLC399 (ProDex) 0.6 mg DSP with 50 mM PL
32932598|NCT04513951|Experimental|mFOLFOXIRI + Cetuximab + Avelumab|"Avelumab, 800 mg intravenous [IV] dose over 60 minutes, day 1, followed by~Cetuximab, 500 mg/m2 IV dose over 2 hours at cycle 1 (if well tolerated, it is administered over 90 minutes at cycle 2 and over 60 minutes by cycle 3), day 1, followed by~Irinotecan 150 mg/ m2 IV dose over 60 minutes day 1, followed by~Oxaliplatin 85 mg/m2 IV dose over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/ m2 IV dose over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/m2 IV dose 48 h-continuous infusion, starting on day 1; to be repeated every 14 days for a maximum of 12 cycles. If no progression occurs during the induction treatment, patients will receive maintenance with 5-FU/LV plus cetuximab and avelumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus cetuximab and avelumab will be repeated biweekly until disease progression, unacceptable toxicity, patient's refusal or consent withdrawal."
32932599|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
32932600|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
32932601|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
32932602|NCT00004011|Active Comparator|Surgery alone|conventional surgery
32932603|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
32932604|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
32932605|NCT03448393|Experimental|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses
32729179|NCT03093701|Experimental|Group 4|TLC399 (ProDex) 0.84 mg DSP with 50 mM PL
32729180|NCT03789461|Experimental|Fecal Microbiota Transplantation|FMT infusion
32729181|NCT03048461|Experimental|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
32729182|NCT03048461|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
32729183|NCT03708419|Experimental|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
32729184|NCT03708419|Experimental|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
32932606|NCT03448393|Experimental|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
32932607|NCT04184635|Experimental|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
32932608|NCT04184635|No Intervention|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
32932609|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders.
32932610|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
32932611|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
32932612|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
32932613|NCT04174105|Experimental|Initial Dose Cohort|3x10^13 vg/kg of AT845 administered via intravenous infusion
32932614|NCT04174105|Experimental|Second Dose Cohort|6x10^13 vg/kg of AT845 administered via intravenous infusion
32932615|NCT04174105|Experimental|Third Dose Cohort|1x10^14 vg/kg of AT845 administered via intravenous infusion
32932616|NCT00362323|Experimental|1|
32932617|NCT00362323|Active Comparator|2|
32932618|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
32932619|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
32932620|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
32932621|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
32932622|NCT04160065|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Exposure Escalation:~The first 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection); 3/3 patients recruited.~The second 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 2 time points 7 days apart (28-day follow-up post last injection); 1/3 patients recruited.~The third 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending.~Cohort Expansion:~The remaining 11 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending."
32932623|NCT02371681|Experimental|1|TB drugs
32932624|NCT02363335|Placebo Comparator|Placebo|randomized, double-blind, placebo-controlled cross-over study
32932625|NCT02363335|Experimental|Roflumilast|randomized, double-blind, placebo-controlled cross-over study
32932626|NCT02363335|Experimental|Roflumilast/Sitaglip|randomized, double-blind, placebo-controlled cross-over study
32932627|NCT02363335|Experimental|Sitagliptin|randomized, double-blind, placebo-controlled cross-over study
32932628|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
32932629|NCT02317783|Experimental|All Participants|All enrolled subjects will complete three imaging sessions on separate days that consist of: 1) [18F]Flutemetamol-PET/CT, 2) FDG-PET/CT, and 3) MRI. The order of the performance of these studies will be based upon subject and radioisotope availability, but they will all be completed within 2 months of each other.
32932630|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
32932631|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritis status by clinically relevant subgroups.
32932632|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~Patients receive amifostine IV twice a day on days -7 to -3.~PBSCs are reinfused on day 0.~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~Patients are followed monthly for the first 2 months and then for survival."
32932633|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
32932634|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
32932635|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
32768990|NCT05056675|Placebo Comparator|Placebo for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of NaCL 0.9% is injected.
32768991|NCT05063071|Experimental|TAF monotherapy without HBIG|The standard dose of TAF 25mg daily was used. TAF can be used on the first day after orthotopic liver transplantation. No HBIG was used before, during, or after transplantation; and therapeutic vaccination was not routinely used.
32932636|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
32932637|NCT04712487||Routine discectomy|Patients undergoing routine spine surgery due to degenerative disease of the spine
32932638|NCT00384579|Experimental|1|Botulinum Toxin B
32932639|NCT00384579|Placebo Comparator|2|Placebo
32932640|NCT00384657|Experimental|Group I|iv iron sucrose
32932641|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
32932642|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
32932643|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
32932644|NCT00003693|Experimental|MTD Group|
32932645|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
32932646|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
32932647|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
32932648|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
32932649|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
32932650|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
32932651|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
32932652|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
32768992|NCT05056285||Down syndrome less than four years Group|
32768993|NCT05045911|Experimental|Endoscopic Barbed-clips Suturing|Patients will be closed the mucosal defect after colorectal ESD using Endoscopic Barbed-clips Suturing.
32768994|NCT05045989|Experimental|Residence-based asymptomatic SARS-CoV-2 testing|The aim of the RB-TPP was to increase and maintain participation of students in regular COVID-19 testing in university residences. The R-TPP was delivered over 4 weeks in April-May 2021 and required asymptomatic students to take a saliva test for COVID-19, twice weekly for four weeks. This was combined with relaxed social restrictions within the residence during the study period (i.e., removing the need for 2 metre distancing between students living in the same residence), surge testing and enhanced support for students who were required to self-isolate (i.e., welfare and financial support).
32932653|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
32932654|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
32932655|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
32932656|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
33252163|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
32932657|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
32932658|NCT00384735||1A|Intensive - 3 monthly follow up
32932659|NCT00384735||1B|Intensive - 6 monthly follow up
32932660|NCT00384735||IIA|Cost Effective - 3 monthly follow up
32932661|NCT00384735||IIB|Cost Effective - 6 monthly follow up
32932662|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
33073776|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
33073777|NCT02915926|Active Comparator|OT|standard OT
33252164|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
33252165|NCT05178628|Experimental|Patients treated with Innohep® and chemotherapy|The patients in this arm will receive Innohep and chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
33073778|NCT02915926|Experimental|OT+OPC|occupational performance coaching
33252166|NCT05178628|Active Comparator|Patients treated with chemotherapy|The patients in this arm will receive chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
33252167|NCT00896571|Experimental|Arm 1|
33252168|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
33252169|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
33252170|NCT00901251||1|
33252171|NCT00901329|Experimental|1: Gender prosthesis|
33252172|NCT00901329|Active Comparator|2: LPS flex prosthesis|
33252173|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
33252174|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
33252175|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
33252176|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
33252177|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
33252178|NCT00981994|No Intervention|Usual Care|Usual Care
32932663|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
33401051|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
33401052|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
32932664|NCT00004263|Experimental|Cytarabine + UCN-01|
32932665|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
32932666|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
32932667|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
32932668|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
33401053|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
33401054|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
32932669|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
32932670|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
32932671|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
32932672|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
32932673|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
32932674|NCT00005145||Observational, no interventions|
32932675|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
32932676|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
32932677|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
32932678|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
32729185|NCT02950961|Other|Arm 1: nonrandomized stepped wedge|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In the context of the nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) at a site makes her/his first referral to the CCWV care manager. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
32729186|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
32729187|NCT02938325||No intervention: Sedation|"Fourty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
32729188|NCT02938325||No Intervention - Awake Volunteers|EEG and BIS will be recorded in twenty volunteers, for 10 minutes, in supine position, while their eyes are closed. This recording will be utilized as for positive control for recall.
32932679|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
32932680|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
32932681|NCT04712799|Experimental|COPD patients|Wlaking tests before and afrer 1 spray with oxymetazoline
32932682|NCT00384969|Experimental|1|RAD001 and Sorafenib
32932683|NCT00004467|Placebo Comparator|Placebo|
32932684|NCT00004467|Experimental|N-acetylcysteine (NAC)|
32932685|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
32932686|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
32932687|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
32932688|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label: For Age Groups 1 and 2, either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. For Age Group 3, either 1) 0.4 mg/kg or 2) 1.6 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril provided locally by the study site, or standard of care also provided locally by the study site, for heart failure treatment, if patient intended to participate in Part 2.
32932689|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose). Administered in a double-blind fashion.
32932690|NCT02678312|Experimental|Part 2: LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight. Administered in a double-blind fashion.
32932691|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
32932692|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
32932693|NCT00422006|Experimental|2|Patient with metabolic syndrome
32932694|NCT00422006|Experimental|3|Patients with type II diabetes
32932695|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
32932696|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
32932697|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
32932698|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
32932699|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
32932700|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
32932701|NCT02468804|Experimental|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
32932702|NCT02468804|Experimental|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
32932703|NCT02468804|Sham Comparator|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
32932704|NCT02468804|Sham Comparator|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
33073779|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
32729189|NCT02922881|Experimental|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
32729190|NCT03702257|Other|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
32729191|NCT02520245|Experimental|Open-Label|
32729192|NCT02864303|Other|Patients with Alzheimer disease|Saliva samples were collected on this patients
32729193|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
32729194|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
32729195|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
32729196|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
32729197|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
32729198|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
32729199|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
32729200|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
32729201|NCT03603353|Experimental|Intervention group|
32729202|NCT03603353|Active Comparator|Control group|
32729203|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
32729204|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
32729205|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
32729206|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
32729207|NCT03439085|Experimental|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
33073780|NCT03160378|Other|Control|Control participants will receive treatment as usual.
32729208|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
32932705|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
32932706|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
32932707|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
32729209|NCT02581709|Experimental|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
32729210|NCT02554331|Experimental|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
32729211|NCT02554331|Other|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
32729212|NCT01999595|Experimental|High frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
32932708|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
32932709|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
33073781|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
33073782|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
33401055|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4-12 weeks before starting therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone), Chemotherapy-18 (if chemoradiation therapy), or Bone Radiotherapy (if other) module at baseline, every other week throughout therapy, and during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 12 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
33073783|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
33073784|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
32729213|NCT01999595|Experimental|Low frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
32729214|NCT01999595|Experimental|High frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
33073785|NCT02915653|No Intervention|Control|Control: not receiving any intervention
33401056|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|TH-4000 150 mg/m2 will be administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
32729215|NCT01999595|Experimental|Low frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
32729216|NCT01999595|Placebo Comparator|Control TENS|"TENS=transcutaneous electrical nerve stimulation~Control TENS was the application of electrical stimulation via skin with no current"
32729217|NCT01999595|Sham Comparator|Sham TENS|"TENS=transcutaneous electrical nerve stimulation~Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told that the TENS was turn-on whether you feel it or not"
32729218|NCT02370797|Experimental|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
33401057|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
33401058|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
32729219|NCT01964807|Experimental|Cigarette smokers|Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with <0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
32729220|NCT01964807|Experimental|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
32729221|NCT01964807|Experimental|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
32729222|NCT01964807|Experimental|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
32729223|NCT02317289|Experimental|Detection of freezing|freezing parkinsonian patients
32729224|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
32729225|NCT02263235|Experimental|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
32729226|NCT02263235|Experimental|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
33073786|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
33073787|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
33073788|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
33073789|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
33073790|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
33073791|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
33073792|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
33073793|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
32729227|NCT02263235|Experimental|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
32932710|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
32729228|NCT01441115|Experimental|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer
32729229|NCT02006147|Experimental|TLC399 (Group 1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
32729230|NCT02006147|Experimental|TLC399 (Group R1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
32729231|NCT02006147|Experimental|TLC399 (Group 2)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
32729232|NCT02006147|Experimental|TLC399 (Group 3)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
32729233|NCT03385499|Other|negative control group|blood additional samples on negative control group
32729234|NCT03385499|Other|positive control group|blood additional samples on positive control group
32729235|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
32729236|NCT01164995|Experimental|MK-1775 and carboplatin|MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes
32729237|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
32932711|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
32932712|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
32932713|NCT00363116|Active Comparator|Control|no antibody induction
32932714|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
32932715|NCT02570984|Active Comparator|Active|omalizumab 0.016 mg/kg/IU total IgE
32729238|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
32729239|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
32729240|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
32729241|NCT03380741||Group 5|Normal cervix at colposcopy
32729242|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
32729243|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
32729244|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
32729245|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
32729246|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
32729247|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
32729248|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
32729249|NCT03380663|No Intervention|Control - Healthy|No intervention.
32729250|NCT03380663|No Intervention|Control - HF|No intervention.
32729251|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
32932716|NCT02570984|Placebo Comparator|Placebo|looks like active drug
33401059|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
32932718|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
32932719|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
32932720|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
32932721|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
33073794|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
33073795|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
33073796|NCT02915419|Active Comparator|group A|prp revascularization
33073797|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
33073798|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
33073799|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
33073800|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
33073801|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
32729252|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
32729253|NCT04715321||Training cohort|HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.
32729254|NCT04715321||Validation cohort|HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.
32729255|NCT00999401|Experimental|sapacitabine and seliciclib|Sequential or concomitant administration of sapacitabine and seliciclib
32729256|NCT04446065|Experimental|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
32729257|NCT04446065|Placebo Comparator|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
32729258|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
32729259|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
32729260|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
32729261|NCT00225095|Active Comparator|Chondrogen - dose 1|Chondrogen - 50 million cells
32729262|NCT00225095|Active Comparator|Chondrogen - dose 2|Chondrogen - 150 million cells
32729263|NCT00225095|Other|Vehicle Control|Vehicle Control
32729264|NCT05174429|Experimental|Risk-Targeted Behavioral Activation|The treatment program consisted of a 10-week standardized behavioral activation intervention supplemented by techniques to target two psychosocial risk-factors for delayed recovery, namely, catastrophic thinking and perceptions of injustice.
32729265|NCT04682873|Experimental|Enisamium iodide|Hospitalized patients who were randomized in to this treatment group will receive enisamium iodide containing capsules (Amizon® Max).
32729266|NCT04682873|Placebo Comparator|Placebo|Hospitalized patients who were randomized in to this treatment group will receive placebo containing capsules.
32729267|NCT02732119|Experimental|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
32729268|NCT02732119|Experimental|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
32729269|NCT02732119|Experimental|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
32729270|NCT02732119|Experimental|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
32729271|NCT02732119|Experimental|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
32729272|NCT03384797||Healthy Volunteers|
32729273|NCT03384797||Parkinson's Disease|
32729274|NCT04529915||Lung cancer|
32729275|NCT04529915||Healthy|
32729276|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
32932722|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
32932723|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
32932724|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibiting depressive symptoms
32729277|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
32729278|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
32729279|NCT04476329|Active Comparator|A|"Arm A: Regorafenib Cycle 1:~80 mg daily Week 1~120 mg daily Week 2~160 mg daily week 3 then 1 week off followed by Cycle 2+ (160 mg for 21 days/1 week off) Subsequent Treatment Cycles~160 mg daily for 21 days, then 1 week off."
32729280|NCT04476329|Active Comparator|B|"Arm B: Regorafenib Cycle 1:~160 mg daily for 21 days/then 1 week off Subsequent Treatment Cycles~160 mg daily for 21 days, then 1 week off"
32729281|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
32729282|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
32729283|NCT04448717||Children and adolescents|Children and adolescents in primary and secondary schools (aimed sample size: 2500)
33401060|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32932725|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibiting depressive symptoms
32932726|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
32932727|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
32932728|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
32932729|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
33252179|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
33252180|NCT04017585|Active Comparator|patients with IBS treated with gluten|patients receiving gluten
33252181|NCT04017585|Placebo Comparator|patients with IBS treated with placebo|patients receiving placebo
33252182|NCT04910464|Experimental|Tranexamic acid|Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.
32932734|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
32932735|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
32729284|NCT04448717||Parents|Parents of participating children (aimed sample size: 3000)
32932736|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
32932737|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
32932738|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
32932739|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
32932740|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
32932741|NCT02496104||Term newborns|Infant born at term
33252183|NCT04910464|Placebo Comparator|Saline placebo|Give the same volume (100 ml normal saline) and same duration (first three days).
33252184|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
33252185|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
33252186|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
33252187|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
33252188|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
33252189|NCT04035993|Experimental|Intervention group|
33252190|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
33252191|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
33252192|NCT04006912|Experimental|Minimal residual theoretical astigmatism group|
33252193|NCT04006912|Active Comparator|Steep meridian incision design group|
33252194|NCT02540889|Experimental|trial arm|100 hours of therapy.
33252195|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
33252196|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
33252197|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
33252198|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
32729285|NCT04448717||School personnel|School personnel (teaching, administrative, maintenance, etc.) (aimed sample size: 2500)
32729286|NCT03850951|Experimental|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
32729287|NCT03850951|Experimental|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
32729288|NCT05174195|Active Comparator|ESI (Implanon NXT® subdermal implant)|In this group, the implant was inserted immediately after thorough explanations of the potential side effects and possible adverse events
32729289|NCT05174195|Experimental|DSG + ESI(Desogestrel +Implanon NXT® subdermal implant)|In this group, patients were given a 3 months' supply of 75µg of DSG to be started immediately after which insertion of an ESI was proposed. Similarly, explanations of the potential side effects and possible adverse events were presented to the patient before treatment initiation.
32729290|NCT05238727|Active Comparator|1.8 ml mepivacaine IANB|
32729291|NCT05238727|Experimental|3.6 ml mepivacaine IANB|
32729292|NCT05238727|Experimental|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI|
32729293|NCT05174117|Experimental|single irradiation group|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
32729294|NCT05174117|Active Comparator|Double irradiation group|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
32729295|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
32932742|NCT04744610|Other|4-hour delayed radiographs|The follow-up radiographs was taken 4 h after the HSG operation.
32932743|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
32932744|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
32932745|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
32932746|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
32932747|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
32932748|NCT00001316||Individuals with HIV|Individuals with HIV
32932749|NCT00001316||Individuals without HIV|Individuals without HIV
32932750|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
32932751|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
32932752|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
32932753|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
32932754|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
32932755|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
32932756|NCT00005289||1988-1991|
32932757|NCT00005289||2003-2004|
32932758|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
32932759|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
32932760|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
32932761|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
32932762|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
32932763|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
32932764|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
33073802|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
32729296|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
32932765|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
33073803|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
32729297|NCT05173571|Experimental|Nutritional and physical activity program|Homecare IPF patient educational, nutritional and physical activity training based on patient's needs
32932766|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
32932767|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
32932768|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
32729298|NCT03754153|Experimental|Balanced Binocular Viewing (BBV)|The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.
32729299|NCT03754153|Active Comparator|Standard Therapy - Occlusion (patching) or blurring (atropine)|The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.
32932769|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
32768995|NCT05045599|Experimental|Integration of Family planning in Maternal, Newborn and Child Health|Strengthening of capacity of LHWs and Health care provider in providing integrated services Ensure Sustained supplies are available Community Mobilization Infrastructure support to ensure privacy and confidentiality Improvement of data recording, reporting and use
32932770|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
32932771|NCT04040361|Experimental|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
32768996|NCT05045599|Active Comparator|Standard of care|
32932772|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
32932773|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
32932774|NCT02415998||TEE|
32932775|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
32932776|NCT00005379||Children who receive primary care at Bellevue Hospital|
32932777|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
32932778|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
32932779|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
32932780|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
33073804|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
32729300|NCT03731923|Experimental|High risk group of HCC|High risk group of HCC with chronic hepatitis or liver cirrhosis. Participants undergo biannual ultrasonography and annual abbreviated liver MRI.
32729301|NCT04371887|Experimental|Local Tailoring|The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
32768997|NCT05062681|Active Comparator|Dexamethasone group|Patients will receive dexamethasone 8 mg q12hours
32768998|NCT05062681|Experimental|methylprednisolone group|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
32768999|NCT05045521|Experimental|plyometric warm up group|set of active exercises used as warm up protocol.
32769000|NCT05045521|Experimental|resistance warm up group|warm up protocol on treadmill wearing weighted jacket
32769001|NCT05045521|Active Comparator|control|warm up protocol on treadmill without weights
33073805|NCT04724148|Experimental|Injecting 1~2mg/kg fentanyl intravenously.|"Measuring HVPG after the preparation of TIPS in patients with portal hypertension;~Measuring HVPG again 5 minutes later after injecting 1~2mg/kg fentanyl intravenously."
33073806|NCT00405899||Immunotherapy|Patients starting immunotherapy
33073807|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
33073808|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
33073809|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
33073810|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
33073811|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
33073812|NCT00405977|Placebo Comparator|Physiologic saline|
33073813|NCT00405977|Active Comparator|Magnesium sulphate|
33073814|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
33073815|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
33073816|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
33073817|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
32729302|NCT04371887|No Intervention|Hybrid Usual Care|The hybrid-usual care arm will consist of six KPSC service areas randomly assigned to this arm. The hybrid usual care arm will receive regional educational activities for the transition (as will the intervention arm) before the roll out of primary HPV testing. However, they will not receive any research-led intervention or adaptation guidance after primary HPV screening opens at KPSC. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
32729303|NCT03727633|Experimental|Treatment arm|hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol
32729304|NCT05173181|Other|Adult with fracture distal ulna|
32729305|NCT03785275||Subjects with stable near-normal T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
32729306|NCT03785275||Subjects with unstable T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
32729307|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
33073818|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
33401061|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
33401062|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
33401063|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
33401064|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
33401065|NCT04127539|Experimental|Intervention|Will start a Strong & Steady group exercise programme immediately after baseline testing.
32729308|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
33073819|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
33073820|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
33073821|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
33073822|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
33073823|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
33073824|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
33073825|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
33073826|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
33073827|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
33073828|NCT00150098|Experimental|lifestyle counselling|Education
33073829|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
32932781|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
32932782|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
32932783|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
32932784|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
32729309|NCT03712267|Experimental|Electronic Media Enhanced|Research assistants will collect information on participants' electronic messaging behavior and content and provide that for use to participants' clinicians.
32729310|NCT03712267|Placebo Comparator|Treatment As Usual|Participants will not have their electronic messaging reviewed prior to their typically scheduled clinical appointments.
32729311|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
32729312|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
32729313|NCT05238259|Other|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
32729314|NCT05238259|Other|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the patient to easily roll wrist back and forth focusing on the wrist and arm
32729315|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
32729316|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
32729317|NCT05238181||The autoimmune gastritis group|Autoimmune gastritis is diagnosed if the anti-parietal cell antibody titer is positive and higher than 1:10 (ImmuGloTM COMVI mouse kidney/stomach IFA kit, Immco Diagnostics, Inc. Buffalo NY, USA).
32769002|NCT05056519|Experimental|Experimental group|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine
32932785|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
32932786|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
32932787|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
32932788|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
32932789|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
32932790|NCT02256631|Experimental|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
32932791|NCT02256631|Experimental|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
32932792|NCT02256631|Experimental|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
32932793|NCT02256631|Experimental|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
32932794|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
32932795|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
32932796|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932797|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932798|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932799|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
33073830|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
32729318|NCT05238181||The controls|The patients who are enrolled to validate pathogenesis after H. pylori infection. H. pylori infection is diagnosed by histological assessment. The matched controls are needed to be confirmed to have negative anti-parietal cell antibody.
32729319|NCT05173025|Experimental|Fimasartan|- Fimasartan group: Fimasartan, 60 mg once a day, oral administration
32932800|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
33252199|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
33252200|NCT00984646|Experimental|Intradermal Prevascar|
33252201|NCT00984646|Placebo Comparator|Placebo (vehicle)|
33252202|NCT03991585|Experimental|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
33252203|NCT03991585|Experimental|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
33252204|NCT00901407|Experimental|1|lamotrigine
33252205|NCT00901407|Placebo Comparator|2|placebo
33252206|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
33252207|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
33252208|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
33252209|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
33252210|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
33252211|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
33252212|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
33252213|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
33252214|NCT04035915|Experimental|Limited driving pressure ventilation|
33252215|NCT04035915|Experimental|Conventional mechanical ventilation strategies|
33252216|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
32729320|NCT05173025|Active Comparator|Amlodipine|- Comparator group: Amlodipine, 5 mg once a day, oral administration
32932801|NCT02247349|Experimental|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932802|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932803|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932804|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
32932805|NCT02247349|Experimental|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
32932806|NCT02247349|Experimental|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
33252217|NCT00984802|Experimental|Low dose|
33252218|NCT00984802|Experimental|Mid Dose|
33252219|NCT00984802|Experimental|High Dose|
33252220|NCT00984802|Placebo Comparator|Placebo|
33252221|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
33252222|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
33252223|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
33252224|NCT00972556|Experimental|GMTA|
33252225|NCT00972556|Active Comparator|20% FC|
33252226|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
32729321|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
32729322|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
32932807|NCT02247349|Experimental|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
32729323|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
32729324|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
32729325|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
32729326|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
32729327|NCT02520193|No Intervention|Standard mobilization strategy|
32729328|NCT02520193|Experimental|protocolized early mobilization strategy|
32932808|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
32932809|NCT03407443|Experimental|Exposure to Make the Connection messages|
32729329|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
32932810|NCT03407443|Active Comparator|Active Control group|
32932811|NCT03407443|No Intervention|No exposure control group|
32932812|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
32932813|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
32932814|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
32932815|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
32932816|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
32932817|NCT04156945|Experimental|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
32932818|NCT04156945|Experimental|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
32932819|NCT04156945|Experimental|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
32932820|NCT04155775|Experimental|Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
32932821|NCT04155775|No Intervention|No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
32932822|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
32932823|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
32932824|NCT04343053|Other|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as >14 days
32932825|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
32932826|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
32932827|NCT02974933|Experimental|apatinib|combined with pemetrexed
32932828|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
32932829|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
32932830|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
32932831|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
32932832|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
32932833|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
32932834|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
32932835|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
33252227|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
33073831|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
33073832|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
32932836|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
32932837|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
32932838|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
32932839|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
32932840|NCT00386373|Experimental|Imatinib Mesylate|
32932841|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
32932842|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
32932843|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
32932844|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
32932845|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
32932846|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
32932847|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
32932848|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32932849|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
32932850|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
32932851|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
32932852|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
32932853|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
32932854|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
32932855|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
32932856|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
32932857|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
32932858|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
32932859|NCT05140161|Experimental|Collagen 1|Medium porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
32932860|NCT05140161|Experimental|Collagen 2|High porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
32932861|NCT05140161|No Intervention|Control group|No hemostatic device is used in the nail grooves. No hemostatic device is used in the nail grooves. Only non-stick dressing, five gauze pads and cohesive bandage are used
33073833|NCT04688281|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
32729330|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
32932862|NCT05140317||Group 1|The direct stargegy group included patients with implanation of the THV without predilatation The reference group included patients with direct implanation of tne THV withour predilaation
32932863|NCT05140317||Group 2|the echographists were blinded regarding the groups of the patients
32729331|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire~Balloon angioplasty and/or stenting~Intraarterial thrombolysis~Aiming to correct any residual angiographic lesion as:~Residual thrombus~Retained embolus~Atheromatous plaque"
32932864|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
32932865|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
32932866|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
32932867|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
32932868|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
32932869|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
32932870|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
32932871|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
32932872|NCT05140083|Experimental|68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA Evans Blue will be injected subcutaneously. PET/CT imaging will be performed at 5-30 min post- injection. Visual and quantitative method will be used to assess the PET/CT images.
32932873|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32932874|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32932875|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32932876|NCT04823247||Tildrakizumab|Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.
32932877|NCT02151175|Experimental|LIFUP|
32932878|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
32932879|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
32932880|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
32932881|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
32932882|NCT01915225||1/ Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
32932887|NCT02279745|Experimental|Oral Ralinepag|Ralinepag immediate-release (IR) capsules of 10, 20, 30, 40, and 100 mcg or extended-release (XR) tablets of 50, 250, and 400 mcg for oral administration.
32932888|NCT01862731||1/Control Volunteers|Healthy controls
32932889|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
32932890|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
32932891|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
32932892|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
33073834|NCT04688281|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
33073835|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
33073836|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
33073837|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
32932893|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32932894|NCT04829955|No Intervention|Observation phase|After screening and randomization for either the eccentric orientated intervention group or the concentric orientated intervention group, all measurements will be made for the first time by investigators at point A1. An observational phase for six weeks will follow to achieve an intern acceptance sampling for the measurements which will be used.
33073838|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
33073839|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
33073840|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
33073841|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
32729332|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
33073842|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
33073843|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
33073844|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
33073845|NCT00171171|Experimental|Deferasirox|
33073846|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
33073847|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
32729333|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
32729334|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
32729335|NCT05172635||Patients, who received a VEGF antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
33073848|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
33073849|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
33073850|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
32729336|NCT05172635||Patients, who received a EGFR antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
32729337|NCT03671785|Experimental|Active group treated with healthy fecal microbiota|
32729338|NCT03671785|Experimental|Placebo group|
32729339|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
32729340|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
32729341|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
32743512|NCT04955613|Active Comparator|Standard care|"12 sessions in total: sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:Mirror therapy (standard care) for a total of 10 sessions over a period of 5 weeks (15-20 minutes per session).~sessions 12: Meeting with a doctor and physical therapist."
32743513|NCT04955613|Active Comparator|MyMove/VR system|"sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:MyMove devices and VR gear for a total of 10 sessions over a period of 5 weeks 15-20 minutes per session.~sessions 12: Meeting with a doctor and physical therapist."
32932895|NCT04829955|Active Comparator|Eccentric training group|"Subjects in the eccentric training group (GEC) will attend six weeks of eccentric orientated training. The eccentric orientated training will use the cadence 3-0-1 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
33073851|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
33073852|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
33252228|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
33252229|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
33252230|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
33252231|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
33252232|NCT02540421||Case|Recurrent lesions
33252233|NCT02540421||Control|Absence of lesions
33252234|NCT00984958|Other|Bulkamid|Injection with Bulkamid
33252235|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
33252236|NCT04007302|Experimental|walking with distraction|the patient walks in front of a screen with virtual reality simulation
33252237|NCT04007302|Active Comparator|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
33252238|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
33252239|NCT00901797|Active Comparator|ABR+ARIC|
33252240|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
33252241|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
32932896|NCT04829955|Active Comparator|Concentric training group|"The concentric training group (GCO) will attend six weeks of concentric orientated training. Each group will perform a manual resistance/bodyweight resistance training accentuating the concentric phase of the movement. The concentric orientated training will use the cadence 1-0-3 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
33252242|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
33252243|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
33252244|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
33252245|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
33252246|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
32932897|NCT04826523||Participants treated with Venetoclax|Participants who were prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) will be enrolled for this study.
33252247|NCT04035603|Experimental|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
33252248|NCT04035603|Placebo Comparator|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
33252249|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
33252250|NCT00606801|Placebo Comparator|Placebo|placebo
32932898|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
32932899|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
32932900|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
32932901|NCT04821609|Experimental|Resistance training group|Twice a week sessions supervised and group, during 12 weeks
32932902|NCT04821609|No Intervention|Control Group|The control group will follow the usual physical therapy management, which does not include resistance training
32932903|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
32932904|NCT00361699|No Intervention|No intervention|Patient has no intervention.
32932905|NCT04829799|Active Comparator|Control Group|Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis
32932906|NCT04829799|Experimental|Study Experimental Group|Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure
32932907|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
32932908|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
32932909|NCT04824417|Active Comparator|Control|Oral itraconazole
32932910|NCT04824417|Experimental|Intervention|Oral voriconazole
32932911|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
33252251|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
33252252|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
33252253|NCT04007458|Active Comparator|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
33252254|NCT04007458|Experimental|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
33252255|NCT04008862|Experimental|Partnership-based care|Each patient will serve as his/her own control
33252256|NCT00901875|Experimental|Suboxone, maximum 8mg|
32932912|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
32932913|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
33252257|NCT00901875|Experimental|Buprenorphine + naloxone|
33252258|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
33252259|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
32932914|NCT04827459|Experimental|MI Sleep Coach Mobile Application|The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.
32932915|NCT04117477|Experimental|Xylitol wipes|
32932916|NCT04117477|Placebo Comparator|Placebo wipes|
32932917|NCT04824027|Experimental|HMI Group|Women undergoing standard neoadjuvant chemotherapy for breast cancer
32932918|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
32932919|NCT04820049|Placebo Comparator|Placebo group|
32932920|NCT04820049|Experimental|F573 group|
32932921|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
32932922|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
32932923|NCT04820595||Control group|Patients who have RASS < +2 and have not delirium according CAM-ICU immediately upon emergence from anesthesia
32932924|NCT04820595||Agitated non-delirious group|Patients who have RASS = +2 or more and have not delirium according CAM-ICU immediately upon emergence from anesthesia
32932925|NCT04820595||Agitated delirium group|Patients who have RASS = +2 or more and have delirium according CAM-ICU immediately upon emergence from anesthesia
32932926|NCT04829877|Experimental|Web-based mind-body intervention with HRVB|Both standard usual care and the web-based mind-body intervention with HRV biofeedback (MBI-HRVB) will be provided to the participants. The web-based mind-body intervention with HRV biofeedback program consisted of 5-week training sessions and breathing training.
32932927|NCT04829877|Experimental|Web-based mind-body intervention|Both standard usual care and the web-based mind-body intervention will be provided to the participants. The web-based mind-body intervention program consisted of 5-week training sessions.
32932928|NCT04829877|No Intervention|Control|The women in the control group will receive the standard usual care provided at the fertility clinic. The standard care protocols encompass elements such as routine assessment and health education at each visit. Participants enrolled in the control group will be approached once a week by a nurse to provide health consultation about fertility treatment, medication, signs, and symptoms of discomfort for five weeks.
32932929|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
32932930|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
32932931|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
32932932|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
32932933|NCT04821375|Experimental|Bazedoxifene plus conjugated estrogens immediately|Immediate receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
32932934|NCT04821375|Other|Bazedoxifene plus conjugated estrogens wait list|After a 6-month waiting period, receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
32932935|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
32932936|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
32932937|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
33073853|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
33073854|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
32932938|NCT04116541|Experimental|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
32932939|NCT04116541|Experimental|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.
32729342|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
32729343|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
32729344|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
32729345|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
32729346|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
32729347|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
32729348|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
32729349|NCT03660865|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's primary eye will receive the light adjustable lens.
32729350|NCT03660865|Active Comparator|Control IOL|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's fellow eye will receive the control IOL.
32729351|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
32729352|NCT03384017|Experimental|TSCS and gait training|
32729353|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
32729354|NCT03389971|Active Comparator|multi-sidehole catheter|
32729355|NCT03389971|Experimental|USAT catheter|
32729356|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
32729357|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
32729358|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
32729359|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
32932940|NCT04116541|Experimental|Alectinib|Patient with ALK alterations: translocation, mutation or amplification
32932941|NCT04116541|Experimental|Regorafenib|Patient with activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, Platelet Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor 1-2 (FGFR1-2), FLT3 and/or Colony Stimulating Factor 1 Receptor (CSF1R), and/or amplification of the ligands, and/or biallelic inactivation of SMAD4
32932942|NCT04116541|Experimental|Trametinib|Patient with activating mutation and/or amplification of KRAS, NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF
32932943|NCT04116541|Experimental|Trametinib + Dabrafenib|Patient with BRAF V600 mutation
32932944|NCT04824651||Solid cancer|objective : 800 participants for adult cohort, 100 for pediatric cohort (solid cancer and malignant hemopathy)
32932945|NCT04824651||Solid organ transplantation|objective : 700 participants for adult cohort, 50 for pediatric cohort
32932946|NCT04824651||Allogeneic hematopoietic stem cell transplantation|objective : 350 participants for adult cohort, 50 for pediatric cohort
32932947|NCT04824651||Chronic renal failure|Patients with chronic renal failure stage 4, 5 who receive dialysis or not. objective : 350 participants for adult cohort, 30 for pediatric cohort
32729360|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
32729361|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
32729362|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
33252260|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
33252261|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
32769003|NCT05056519|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
32932948|NCT04824651||Autoimmune and autoinflammatory systemic diseases|Systemic lupus erythematosus ,Systemic Vasculitides,... objective : 750 participants for adult cohort, 130 for pediatric cohort
33252262|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
33252263|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
33252264|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
33252265|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
32769004|NCT05045443|Active Comparator|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
32769005|NCT05045443|Placebo Comparator|Standard of nutritional care|Standard of nutritional support care
32769006|NCT05045287|Experimental|hypofractionated radiation therapy|receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks
32769007|NCT05045131|Experimental|PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring|Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
32769008|NCT04473469|Experimental|Cystometrogram|The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.
32769009|NCT05045053|Experimental|xiidra group|patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
32769010|NCT05045053|No Intervention|control group|patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
32769011|NCT05062525||Immunotherapy|
32769012|NCT05062525||Non-Immunotherapy|
32769013|NCT05044741||Perforated group|
32769014|NCT05044741||Controlled group|
32932949|NCT04824651||Multiple sclerosis/ Neuromyelitis optica diseases|MS defined by Mac Donald et al. 2017 and Neuromyelitis optica defined by Wingerchuk et al. 2015 ; objective : 600 participants for adult cohort
32932950|NCT04824651||Chronic inflammatory rheumatism|Ankylosing spondylitis and rheumatoid polyarthritis objective : 600 participants for adult cohort
32932951|NCT04824651||Hypogammaglobulinemia|objective : 300 participants for adult cohort
32932952|NCT04824651||Obese non diabetic|BMI ≥ 30 objective : 1400 participants for adult cohort, 100 for pediatric cohort
32932953|NCT04824651||Diabetic (type I and II) obese or not|objective : 1400 participants for adult cohort, 100 for pediatric cohort
32932954|NCT04824651||People living with HIV-1|objective : 1400 participants for adult cohort
32932955|NCT04824651||Senior group (free from chronic conditions of interest listed above)|≥75 years objective : 450 participants for adult cohort
32932956|NCT04824651||Control group (free from chronic conditions of interest listed above)|18 to 74 years objective : 1400 participants for adult cohort, 100 for pediatric cohort (from 5 to 17 years old)
32932957|NCT04824651||Control AZ-PF group (free from chronic conditions of interest listed above)|Participants with first dose of Astra-Zeneca vaccine AZD1222 and second dose of Pfizer ARNm vaccine BNT162b2 objective : 200 participants for adult cohort
32932958|NCT04824651||Major sickle cell syndrome|100 for pediatric cohort (from 5 to 17 years old)
32932959|NCT05138913|Experimental|Study group|Arthroscopic treatment with TXA injection
32932960|NCT05138913|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
32932961|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
32932962|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
32932963|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
32932964|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
32932965|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
32932966|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
32769015|NCT05044663||NASH related cACLD|NASH related cACLD (Liver Stiffness ≥10 kPa).
32769016|NCT05044663||Viral hepatitis (HBV / HCV) related cACLD|Viral hepatitis (HBV / HCV) related cACLD
32769017|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
32769018|NCT05055739|Experimental|SW|Patients undergoing sternal closure with steel wires
32769019|NCT05055739|Experimental|RP|Patients undergoing sternal closure with a rigid plate
33073855|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
33073856|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
32769020|NCT05055895||early onset deliryum on dementia|It was earlier than The median time of onset of delirium superimposed dementia
32769021|NCT05055895||Delirium on dementia (normal)|It was equal or later than The median time of onset of delirium superimposed dementia
32769022|NCT05055583|Experimental|Toripalimab in Combination With Platinum-based Chemotherapy|Participants receive totally 3-4 cycles of toripalimab combined with platinum-based chemotherapy neoadjuvant treatment during preoperative period. After the last treatment (Day 21 of Cycle 4), surgery will be performed within 4-6 weeks. Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention was to receive maintenance therapy within 6-12 weeks of the MDT assessment.
32769023|NCT05061511||Healthy gingival tissue|healthy patients with absence of gingivitis (full-mouth bleeding score <10%), no history of periodontal disease, having ≥20 teeth, and ≤1 tooth with interdental clinical attachment loss.
32769024|NCT05061511||Periodontitis patients|patients with stage III or IV periodontitis, which means that these patients would have deep periodontal lesions that extend at least to the mid portion of the roots and whose management is complicated by the presence of intrabony defects, furcation involvement, history of periodontal tooth loss and localized ridge defects.
32769025|NCT05061511||Peri-implantitis patients|patients affected by peri-implantitis, defined as radiographic evidence of bone loss ≥3 mm and probing pocket depth ≥6 mm around implants in conjunction with bleeding on probing; or defined as bleeding and/or suppuration on probing, increased probing pocket depth from a previous examination and loss of peri-implant bone.
32769026|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
32769027|NCT05060809|Experimental|Hemodialysis patient with high level of dp uc-MGP|one hundred and twenty hemodialysis patients with high level of dephosphorylated uc-MGP received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by Kauppila score.In addition, study patients were subjected to an echocardiography at baseline as well as 6 months post vitamin K1 supplementation. Echocardiography was performed by the same operator.
32769028|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
32769029|NCT03097549|Other|Tät®II Information app|"Information only.~."
32769030|NCT05055505|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
32769031|NCT05055505|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
32769032|NCT05055115|Experimental|Balloon Eustachian Tuboplasty|Patients with long-lasting symptoms of ETD, who benefits from tympanostomy tube insertion, will be offered Balloon Eustachian Tuboplasty (BET) of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
32769033|NCT05055349|Active Comparator|corneal collagen cross linking and intrastromal corneal keraring segments.|20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after Femtosecond laser assisted intrastromal corneal keraring segments
32769034|NCT05055349|Active Comparator|toric phakic posterior IOL implantation and corneal collagen cross linking|20 eyes will undergo toric phakic posterior IOL implantation 1 year after corneal collagen cross linking (epithelium off).
32769035|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
32769036|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
32769037|NCT05061043|Active Comparator|Group A|Routine physical therapy treatment
32769038|NCT05061043|Experimental|Group B:|Routine physical therapy along with orofacial therapy
33252266|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
33073857|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
33252267|NCT00606177|Experimental|1|
33252268|NCT00606177|Placebo Comparator|2|
33252269|NCT00985270|Active Comparator|Rifampicin|
33252270|NCT00985270|Placebo Comparator|Placebo|
33252271|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
33252272|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
33252273|NCT00901953||1|migrainous vertigo
33252274|NCT00901953||2|migraine without vertigo
33073858|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
33401066|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
33073859|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
33073860|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
33073861|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
33073862|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
33073863|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
33073864|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
33073865|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
33073866|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
33401067|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
32729363|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
32729364|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
32729365|NCT03383705|Experimental|Treatment arm|
32729366|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
32729367|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
32729368|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
32729369|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
32729370|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
32729371|NCT03383471|Placebo Comparator|Placebo|Placebo control
32729372|NCT03636451|Experimental|40cc 0.5% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 38mL of 0.5% lidocaine buffered with 2mL 8.4% sodium bicarbonate and 2 units Vasopressin
32729373|NCT03636451|Active Comparator|20cc 1% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 18mL of 1% lidocaine buffered with 2mL 8.4% sodium bicarbonate in and 2 units Vasopressin
32729374|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
32729375|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
32729376|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
32729377|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
32729378|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
32729379|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
32729380|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
32729381|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
32729382|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
33073867|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
33073868|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
33073869|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
33073870|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
33073871|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
33401068|NCT01569048|Active Comparator|remifentanil|
32769039|NCT05060653|Experimental|SBRT followed by surgical stabilization within 48 hours|SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
33252275|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
33252276|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
33252277|NCT03992287|Experimental|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
32932967|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
32932968|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
32932969|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
32932970|NCT04822467|Active Comparator|Standard Wipe|Participants will receive a supply of ethanol-based wipes for daily use
32932971|NCT04822467|Experimental|SQ53 Wipe|Participants will receive a supply of SQ53 wipes for daily use.
32932972|NCT04113811|Experimental|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
32932973|NCT04821219|Experimental|Tumoroid generation|Single arm, including all the patients enrolled to generate tumor models
32932974|NCT04825353|Experimental|ECIRS-Group|
32932975|NCT04825353|Active Comparator|SPCNL-GRoup|
32932976|NCT04106089|Experimental|Observation-Intervention-Observation|5 days of observation, 5 days of extended vitals check, 5 days returning to regular vitals checks
32932977|NCT04106089|Experimental|Observation-Observation-Intervention|5 days of observation, 5 more days of observation, 5 days of extended vitals check
32932978|NCT03320317||Colorectal cancer|
32932979|NCT03319849|Experimental|NT-501|
32932980|NCT03319849|Sham Comparator|Sham|
32932981|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
32932982|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
32932984|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
32932985|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
32932986|NCT04101955|Other|Incisionless Threaded Carpal Tunnel|
32932987|NCT04101955|Other|Standard Mini-Open Carpal Tunnel|
32932988|NCT04097275||Participants with an Inborn Error of Metabolism|
32932989|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
32932990|NCT03299959|Experimental|Agili-C|
32932991|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
32932992|NCT01246765||Pregnant women using atypical antipsychotic(s)|Pregnant women who have taken at least one type of atypical antipsychotic at some point during this pregnancy.
32932993|NCT01246765||Pregnant women not using atypical antipsychotics|Pregnant women who have not taken an atypical antipsychotic during pregnancy.
32932994|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
32932995|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
32932996|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
32932997|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
32932998|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
32932999|NCT04087213|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
33252278|NCT03992287|Placebo Comparator|Placebo|Placebo for 12 weeks
33252279|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
33252280|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
33252281|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
33252282|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
33252283|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
33252284|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
33252285|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
33252286|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
33252287|NCT00902031|Experimental|Docusate + Sennoside|
32729383|NCT05171621||Macular holes|
32729384|NCT05171621||Epiretinal membranes|
32729385|NCT04446949||Undocumented migrants|
32729386|NCT04446949||Immigrants with Norwegian ID|
32729387|NCT04446949||Norwegian residents|
32729388|NCT04445285|Experimental|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
32729389|NCT04445285|Placebo Comparator|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
32729390|NCT03379025|Experimental|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
32729391|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
32933000|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.~After ICU:~Nutrition management will be as per usual site management at that hospital.~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
32933001|NCT03292237|Experimental|Intensive Arm|"Intervention~In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
32933002|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
32933003|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
32933004|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
32933005|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
32933006|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
32933007|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
32933008|NCT04072549|Experimental|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
32933009|NCT04072549|No Intervention|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
32933010|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
32933011|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
32933012|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
32933013|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
32933014|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
33252288|NCT00902031|Placebo Comparator|Sennoside + Placebo|
32729392|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
32729393|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
32729394|NCT05171543|Experimental|Periapical surgery with placement of an allograft and a membrane|Patients will undergo periapical surgery and an allograft and a membrane will be placed inside the bony crypt and over the denuded root surface respectively before closure of the flap.
32729395|NCT05171543|No Intervention|Periapical surgery with no placement of any graft or membrane|Patients will undergo periapical surgery with no placement of any graft or membrane in the control group.
33252289|NCT03991039|Active Comparator|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
33252290|NCT03991039|Active Comparator|MVD Group|Patients treated with microvascular decompression
33252291|NCT03991117|Experimental|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
33252292|NCT03991117|Experimental|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
33252293|NCT03991117|Experimental|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
32933015|NCT03255031|Active Comparator|Diet Randomization - Active Comparator|Ketogenic diet (KD) liquid diet consists of snacks and shakes 3x p/day (high in fat). SA will receive the same KD solid snacks, in order to keep the diets blind to participants. KD will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
32933016|NCT03255031|Placebo Comparator|Diet Randomization - Placebo Comparator|Standard American (SA) diet consists of KD snacks and shakes 3x p/day (high in fat) in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants. SA will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
32933017|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
32933018|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
33252294|NCT03991117|Experimental|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
33401069|NCT01569048|Experimental|dexmedetomidine|
33401070|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
32933019|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
32729396|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
32933020|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
32933021|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
32933022|NCT00493831|Experimental|NRT|any form of nicotine replacement would be allowed at subject discretion
32933023|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
32933024|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
32933025|NCT04341415|Experimental|Auricular neuromodulation|
32933026|NCT04341415|Sham Comparator|Control|
32933027|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
32933028|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
32933029|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
32933030|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
32933031|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
32933032|NCT00362479|Experimental|1|
32933033|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
32933034|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
32933035|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
32933036|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
33073872|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
33073873|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
33073874|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
33073875|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
33073876|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.~Participants will be instructed to use the CGM as per the FDA labeling."
33073877|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
33252295|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
33252296|NCT00985348|Experimental|Treatment 1/Treatment 2|
33073878|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
33073879|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
33073880|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
33073881|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
33073882|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
33073883|NCT02912611|Other|Moderate and High risk for AKI|
33073884|NCT02912416|Experimental|Probiotics|Capsule with probiotics
33073885|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
33073886|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
33252297|NCT00985348|Experimental|Treatment 2/Treatment 1|
33252298|NCT03990961|Experimental|Pembrolizumab Treatment|
33252299|NCT00973336|Experimental|Calcium and vitamin D|Intervention
33073887|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
33073888|NCT02912494|Experimental|JR-131|
33073889|NCT02912494|Active Comparator|Darbepoetin alfa|
33073890|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
33252300|NCT00973336|No Intervention|No treatment (control)|
33252301|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
33252302|NCT03991273|Experimental|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
33252303|NCT03991273|Experimental|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
33252304|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
33252305|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
33252306|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
33252307|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
33252308|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
33252309|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
33252310|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
33252311|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
33073891|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
33073892|NCT02912260|Experimental|MGL-3196|Study Drug
33252312|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
33252313|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
33252314|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
33252315|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
33252316|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
33252317|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
33252318|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
33252319|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
33252320|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
33252321|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
33252322|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
33252323|NCT01049269||1:one group|
33252324|NCT05279326|Experimental|Intervention arm|Participants will receive virtual SMAs and usual care. Virtual SMAs will last 90 minutes, every 3 weeks, in 18 weeks through an online platform, at no cost to participants beyond the use of the device and the internet.
33252325|NCT05279326|No Intervention|Control arm|Participants will be at usual care and follow their usual contact with health services.
33252326|NCT04674358|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.|
33073893|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
32933037|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
32933038|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
33073894|NCT02912533|Experimental|JR-131|
32729397|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
32729398|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
32729399|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
32729400|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
32729401|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
32729402|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
32933039|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
32933040|NCT00018889||1|Patients age 2 years and older with a clinical or suspected diagnosis of movement disorder
32933041|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
32933042|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
32933043|NCT00001471||Healthy Volunteers|Healthy Volunteers
32933044|NCT00001471||HIV-infected|HIV-infected individuals
32933045|NCT00001471||ICL|Idiopathic CD4 lymphopenia
32933046|NCT00001309|Other|Pharmacokinetics and Biodistribution of Ascorbic Acid|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
32933047|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.~The inhaler technique is also evaluated by study staff prior to an education demonstration."
32933048|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
32933049|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
32933050|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
32933051|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem cell transplantation (HSCT)
32933052|NCT04744753|Active Comparator|study group|. This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores
32933053|NCT04744753|No Intervention|control group|This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores
33073895|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
33073896|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
33073897|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
33073898|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
33073899|NCT02912338|Active Comparator|Control Group|not change lifestyle
32729403|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
32729404|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
33252327|NCT04674358|Placebo Comparator|Vehicle Ophthalmic Solution administered over two consecutive days.|
32729405|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
32933054|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
32933055|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
32933056|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
32933057|NCT02421055||Group 2|Sleeve Gastrectomy
32933058|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
32933059|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
32933060|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
32933061|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
32933062|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
32933063|NCT02421757|Placebo Comparator|Sham Device|Sham Device
32933064|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
32933065|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
32933066|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
32933067|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
32933068|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
32933069|NCT03091075|Experimental|Treatment Group|Oxandrolone
32933070|NCT03091075|Placebo Comparator|Placebo Group|placebo
32933071|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
32933072|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
32933073|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
32933074|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
32933075|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
32933076|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP~1 repeat dose will be allowed if repeat dosing criteria are met."
32933077|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
32729406|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
32933078|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
32933079|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
32933080|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
32933081|NCT02424968|Experimental|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
32933082|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
32729407|NCT05152121|Other|carb counting|Patients using insulin infusion pumps will be placed CGMS for 2 days before starting the study to check whether they are within the target blood glucose levels and normoglycemia will be provided. The content of the first day of the study; The test meal, which is 80 g carbohydrate (29.3%), 70.2 g fat (57.9%), 34.7 g protein (12.7%), will be consumed in the evening meal and normal bolus insulin will be given according to carbohydrate counting. On the second day of the study, instead of the normal bolus for the test meal, the additional insulin for fat-protein by dual wave bolus that.The data obtained will be analyzed by evaluating the CGMS data of all patients by a pediatric endocrinologist experienced in diabetes, CGMS and insulin infusion pump therapy.
32729408|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
32729409|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
32729410|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
32729411|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
32933083|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
32729412|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
32933084|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
32933085|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
32933086|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
32933087|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32933088|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
32933089|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
32933090|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
32933091|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
32933092|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
32933093|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
32933094|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
32933095|NCT02429869|Experimental|Everolimus|
32933096|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
32933097|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
32933098|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
32933099|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
32933100|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
32933101|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
32933102|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
32933103|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
32933104|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
32933105|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
32933106|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
32933107|NCT04341493|Experimental|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
32729413|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
32729414|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
32729415|NCT04445675|Experimental|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
32729416|NCT04445675|No Intervention|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
32729417|NCT04079465|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation
32729418|NCT04079465|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.
32729419|NCT04967963|Experimental|Transplantation of HAM|HAM was used after sequestrectomy in patients with stage-2 MRONJ
32729420|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
32729421|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
32933108|NCT04341493|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
32933109|NCT04341740|Experimental|Renal Cell Carcinoma or Urothelial Carcinoma Patients|Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
32933110|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
32933111|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
32933112|NCT02432287|Experimental|Placebo|Placebo
32933113|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933114|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933115|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933116|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933117|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933118|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933119|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933120|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
32933121|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
32933122|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
32933123|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
32933124|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
32933125|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
32933126|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
33073900|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
33252328|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
32933127|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
32933128|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
33252329|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
33252330|NCT02540733||Diabetic stroke|
33252331|NCT02540733||Non-diabetic storke|
33401071|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
32729422|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
32933129|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
32933130|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
32933131|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
32933132|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
32933133|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
32933134|NCT03022825|Experimental|BCG+N-803|
32933135|NCT04743986|Experimental|Platelet Rich Plasma (PRP)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. Injection was 3-5ml at the site of tendon pathology with the remainder of the PRP preparation infiltrated into the subacromial space. A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500g for 5 mins to yield approx 5.5ml of 80% platelets at 1.6x concentration. The supernatant was then resuspended by inverting the tube several times and was drawn into a separate 5-ml syringe for subacromial injection.
32933136|NCT04743986|Active Comparator|Corticosteroid (CS)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. The blood sample was kept for a similar time delay for centrifugation prior to injection, and was then discarded. 1ml of 40-mg/ml triamcinolone was suspended in 2ml of 0.5% bupivicaine. Injection was performed through a lateral subacromial approach after needle fenestration of the supraspinatus tendon under ultrasound visualization. CS was infiltrated into the subacromial bursa and not the tendon itself.
32933137|NCT04743752||Group OSA+NSCLC|According to the baseline sleep monitor results, participants will be divided into Group OSA+NSCLC if apnea hypopnea index(AHI) no less than 15.
32933138|NCT04743752||Group NSCLC|According to the baseline sleep monitor results, participants will be divided into Group NSCLC if apnea hypopnea index(AHI) less than 15.
32933139|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
32933140|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
32933141|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
32933142|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
32933143|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
32933144|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
32933145|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
32933146|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
32933147|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
32933148|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
32933149|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
32933150|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
32933151|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
32933152|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans~First one prior to estradiol challenge test~Second one immediately following one day of estradiol challenge test~(1) FDG-PET/CT scan at screening~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
32933153|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
32729423|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
32729424|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
32729425|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
32729426|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
32729427|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
32729428|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
32933154|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
32933155|NCT02457403|Experimental|ROTEM|Transfusion guided by ROTEM during OLT
32729429|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
32729430|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
32933156|NCT02457403|Active Comparator|Conventional|Transfusion guided by conventional labs
32933157|NCT02533934|Experimental|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
32933158|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
32729431|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
32729432|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
32729433|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
32729434|NCT04923815||AVNRT|atrioventricular nodal reentrant tachycardia
32729435|NCT04923815||AVRT|atrioventricular reentrant tachycardia, including Wolff-Parkinson-White syndrome（WPW）
32933159|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
32933160|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
32933161|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
32933162|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
32933163|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
32933164|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
32933165|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
32933166|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
32933167|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
32933168|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
32933169|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
32933170|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
32933171|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
32933172|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
32729436|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
32729437|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
32729438|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
32729439|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
32729440|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
32729441|NCT03993197|Experimental|Patients suffering from severe endometriosis and chronic pain|Patients suffering from severe endometriosis and chronic pain that have been identified during a gynecological consultation (individual or during a multidisciplinary team meetings) or during a pain consultation on the same site of the Croix-Rousse Hospital and having signed a consent form
32729442|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
32729443|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
32729444|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
32729445|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
32729446|NCT01327885|Experimental|Arm A|
32729447|NCT01327885|Active Comparator|Arm B|
32729448|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
32933173|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
32933174|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
33252332|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
33252333|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
33252334|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
33252335|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
32933175|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
32933176|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
32933177|NCT02459197|Active Comparator|T4P1001|
32933178|NCT02459197|Sham Comparator|Placebo|
32933179|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
32933180|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
32933181|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
32933182|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
33073901|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
33252336|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
33401072|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
32933183|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
32933184|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
32933185|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
32933186|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
32729449|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
32729450|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
32729451|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
32933187|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
32933188|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
32933189|NCT02498834|No Intervention|Control group|Standard of care will be used
32729452|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
32729453|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
32729454|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
32729455|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
32933190|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
32933191|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
32933192|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
32933193|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
32933194|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
32933195|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
32933196|NCT04743739|Active Comparator|Rituximab monotherapy|Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
32729456|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
32729457|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
32729458|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
32933197|NCT04743739|Experimental|Rituximab combined with cyclosporine|"Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count.~cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period."
32933198|NCT02499380||Treatment|Patients treated with PneumRx Coil System
32933199|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
32933200|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
32933201|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
32729459|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
32729460|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
32729461|NCT03381755|Experimental|half-dose ticagrelor|
32933202|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
32933203|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
32933204|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
32933205|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
32933206|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
32933207|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
32933208|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
32729462|NCT03381755|Active Comparator|standard-dose ticagrelor|
32729463|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
32729464|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
32933209|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
32933210|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
32933211|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
32933212|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
32933213|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
32933214|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
32933215|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
32933216|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
32933217|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
32933218|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
32933219|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
32933220|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
32933221|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
32933222|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
32933223|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
32933224|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
32933225|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
32933226|NCT02821741|Experimental|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear, and thermal stimulation is applied to the arms.
32933227|NCT02821741|Active Comparator|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear, and thermal stimulation is applied to the arms.
32729465|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
32933228|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
33073902|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
33252337|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
33252338|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
33252339|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
33252340|NCT00902421|Active Comparator|Antimuscarinics|
33252341|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
33252342|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
33252343|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
33252344|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
33252345|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
33252346|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
33252347|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
33252348|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
32933229|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
33252349|NCT04006054|Experimental|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
32933230|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.~Some included neonates will also have rhinomanometry measurements."
32933231|NCT04341649|Active Comparator|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
32933232|NCT04341649|Active Comparator|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
32933233|NCT04341649|Active Comparator|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
33252350|NCT04006054|Active Comparator|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
33252351|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
33252352|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
33252353|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
32933234|NCT04341649|Active Comparator|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
33252354|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
32933235|NCT04341649|Active Comparator|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
32933236|NCT04341649|Active Comparator|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
32933237|NCT04341649|Sham Comparator|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
32933238|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
32933239|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
32933240|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
33252355|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
33252356|NCT00985816|Placebo Comparator|Placebo|
33252357|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
33252358|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
33252359|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
32933241|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
32933242|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
32933243|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
32933244|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
33073903|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
33073904|NCT02912026|Experimental|Oral|Oral AUC0-infinity
33073905|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
33073906|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
32933245|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
33073907|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
33073908|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
33073909|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
33401073|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
32933246|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
32933247|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
33073910|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
33073911|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
33073912|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
33073913|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
33073914|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
33073915|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
33073916|NCT00150488|Experimental|1|Uracyst®
33073917|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
33073918|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
33073919|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
33073920|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
33073921|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
33401074|NCT03941574|Experimental|HLX10|
32933248|NCT02464657|Experimental|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
32729466|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
32729467|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
32729468|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
32729469|NCT03377309|Experimental|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
32729470|NCT04446403|Experimental|circumflex|patients will undergo ultrasound guided SSN+circumflex
32729471|NCT04446403|Experimental|posterior cord|patients will undergo ultrasound guided SSN+circumflex
33073922|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)"
33073923|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule"
32729472|NCT03377231|Experimental|Prevention|
32729473|NCT03377231|Experimental|Treatment|
32729474|NCT05237791|Experimental|magnesium group|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
32729475|NCT05237791|Placebo Comparator|control group|normal saline 100ml (loading for 10 minutes), 15mg/kg/hr (continuous infusion)
32729476|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
32729477|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
32729478|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
32729479|NCT03377153|Placebo Comparator|control|
32729480|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
32729481|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
32729482|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
32729483|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
32729484|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
32729485|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
32729486|NCT03898817||Taking of cutaneous cells by biopsy|Taking of cutaneous cells by biopsy and a sample of blood
32729487|NCT03385369|Placebo Comparator|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
32729488|NCT03385369|Experimental|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
32729489|NCT03385369|Experimental|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
33073924|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~Normal appearing vestibule"
33073925|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~Pelvic floor muscles are tight and tender~Primary or Secondary PVD"
33401075|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
33401076|NCT01384344|Active Comparator|witness|no mnesic complaint
33401077|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
33401078|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
33401079|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
33401080|NCT03935880|Active Comparator|Cartiva Hemiarthroplasty|Cartiva implant
32729490|NCT03385369|Experimental|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
32729491|NCT03385369|Experimental|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
32729492|NCT03385369|Experimental|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
32729493|NCT03381365|Experimental|investigational arm|
32729494|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
32729495|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
32729496|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
32729497|NCT03461887|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
32729498|NCT03461887|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
32729499|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
32933249|NCT02464657|Experimental|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
32933250|NCT02464657|Experimental|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
32933251|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
32933252|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
32933253|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
32933254|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
32933255|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
32933256|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
32933257|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
32933258|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
32933259|NCT00363961|Experimental|1|resistance exercise
32933260|NCT00363961|Sham Comparator|2|flexibility exercises
32933261|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
32933262|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
32933263|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
32933264|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
32933265|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
32933266|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
32933267|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
33252360|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
33252361|NCT05277987|Experimental|HEC-016|Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells
33252362|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
32933271|NCT02769949||Family members|Family members (adult and pediatric; affected and unaffected) may be enrolled for the purpose of determining the molecular lesion(s) responsible for genetic disorders.
32933272|NCT02769949||Genetic disorders|subjects with genetic disorders
32933273|NCT02758951|Experimental|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
32933274|NCT02758951|Active Comparator|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
33252363|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
32729500|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
32729501|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
32729502|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
32729503|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
32729504|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
32729505|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
32729506|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
32729507|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
32729508|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
32729509|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
32729510|NCT01913587|Experimental|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
32729511|NCT01913587|Active Comparator|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
32729512|NCT03377075||Healthy subjects|
32729513|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
32729514|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
32729515|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
32729516|NCT03460015|Experimental|Sevoflurane group|
32729517|NCT03460015|Active Comparator|Propofol group|
32729518|NCT03376919|Experimental|CLs++|CLs ++ gait training
32729519|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.~Intervention for outpatient group was to go home."
32729520|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.~Intervention for inpatient group was to stay at ward."
32729521|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
32729522|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
32729523|NCT03125135|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
32729524|NCT03376685|Experimental|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
32729525|NCT03376685|Experimental|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
32729526|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
32729527|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
32729528|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
32729529|NCT03812159|Experimental|Presurgical planning|Undergo crania-vault reconstruction following the presurgical planning (iCSPlan)
32729530|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
32729531|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
33401081|NCT03935880|Active Comparator|Cheilectomy|Bone spur removal
32729532|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
32729533|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
32729534|NCT03375515|Experimental|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
32729535|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
32729536|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
32729537|NCT03449771|Experimental|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
32729538|NCT03436433|Active Comparator|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
33073926|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule~Pelvic floor muscles are tight and tender"
33073927|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)~Pelvic floor muscles are tight and tender"
33073928|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
33252364|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
33252365|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
32729539|NCT03436433|Active Comparator|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
32729540|NCT03436433|No Intervention|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
32729541|NCT03371615|Active Comparator|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
32729542|NCT03371615|Placebo Comparator|Fermented IF +LBG|Fermented infant formula with Locust bean gum
32729543|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
33252366|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
32729544|NCT03124667|Active Comparator|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
32729545|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
32729546|NCT03124277|Other|Control group|Best local diet
32729547|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
32729548|NCT03270917|Other|Open|Open liver surgery
32729549|NCT03270917|Other|Laparoscopy|Laparoscopic liver surgery
32729550|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
32729551|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
32729552|NCT03099863|Placebo Comparator|Standard Care|Standard cystoscopy with normal saline solution.
32729553|NCT03099863|Active Comparator|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
32729554|NCT03375047|Experimental|Low Dose|8 mg MRT5005
32729555|NCT03375047|Experimental|Low/Mid Dose|12 mg MRT5005
32729556|NCT03375047|Experimental|Mid Dose|16 mg MRT5005
32729557|NCT03375047|Experimental|Mid/High Dose|20 mg MRT5005
32729558|NCT03375047|Experimental|High Dose|24 mg MRT5005
32729559|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
33252367|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
33401082|NCT05304234|Active Comparator|Ultrasound + AFP|Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
33401083|NCT05304234|Active Comparator|aMRI + AFP|Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
33401084|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
32729560|NCT03375047|Experimental|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
32933275|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
32729561|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
32729562|NCT03374969|Active Comparator|Developmental Education for Families|
32729563|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
32729564|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
32729565|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
32729566|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
32729567|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
32729568|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
32729569|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
32729570|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
32933276|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
32933277|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
32933278|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
32933279|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
32933280|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
32933281|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
32933282|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
32933283|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
32933284|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
32933285|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
32933286|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
32933287|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
32933288|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
32933289|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
32933290|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
32933291|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
32933292|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
32933293|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
32933294|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
32933295|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
32933296|NCT04341272|Active Comparator|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
32933297|NCT04341272|Other|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
32933298|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
32933299|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
32729571|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
32729572|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
32729573|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
32729574|NCT04175873|No Intervention|Group C|Control group.
32933300|NCT02440178|Experimental|micafungin prophylaxis|Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count > 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.
32933301|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
32933302|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
33252368|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
33252369|NCT00902655|Experimental|Desmopressin|
32933303|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
32933304|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
32933305|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
32729575|NCT04175873|Experimental|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
32729576|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
32933306|NCT02743351|Experimental|ProTmune|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and >or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor that were programmed ex vivo with ProTmune."
32729577|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
32729578|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
32729579|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
32729580|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
32729581|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
32729582|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
32933307|NCT02743351|Active Comparator|Control Arm|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and >or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive unmanipulated mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor."
32933308|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
32729583|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
32729584|NCT02814695|No Intervention|Control|First fraction was control, 0.1ml of liquefied semen mixed with 0.1ml Ham's F10 medium and incubated at 37o C for 30 minutes.
32729585|NCT02814695|Experimental|Vit E supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
32933309|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
32933310|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
32933311|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
32933312|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
32933313|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
32933314|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
33073929|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
32769040|NCT05054959|Experimental|consolidation chemotherapy|"chemoradiation: intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~6 cycles of CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1."
33073930|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
33073931|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
32769041|NCT05054959|Active Comparator|induction chemotherapy|"4 cycles of induction CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1.~Chemoradiation:intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~2 cycles of consolidation CAPOX chemotherapy."
32933315|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
32933316|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
32769042|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
32933317|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
32933318|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
32933319|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
32933320|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
32933321|NCT05073068|Experimental|AM exercise|
32933322|NCT05073068|Experimental|PM exercise|
32933323|NCT05073068|Active Comparator|Control|
32933324|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
32933325|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
32933326|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
32933327|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
32933328|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
32933329|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
32933330|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
32933331|NCT04904822|Experimental|Study group|Vaginal bisection of uterus
32933332|NCT04904822|Experimental|Control group|Abdominal bisection
32933333|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
32933334|NCT04787354|Active Comparator|Control arm|"Standard adjuvant XELOX 8 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles"
32933335|NCT04787354|Experimental|Study arm|"Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles~followed by~Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles"
32933336|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
32933337|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
32933338|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
32933339|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
32933340|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
32933341|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
33073932|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
32729586|NCT02814695|Experimental|Yeast supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) Yeast extraction and incubated at 37o C for 30 minutes.
32729587|NCT02814695|Experimental|Vit C supplementation|fractions (Vit. C. 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02, 0.04, 0.06 mg/ml) Vitamin C respectively and incubated at 37o C for 30 minutes.
32729588|NCT03420781|Placebo Comparator|Treatment Period: Placebo|Placebo-matching relamorelin injected subcutaneously twice daily for up to 40 weeks.
32933342|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
32729589|NCT03420781|Experimental|Treatment Period: Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 40 weeks.
32729590|NCT03420781|Experimental|Randomized Withdrawal Period: Placebo then Relamorelin 10 μg|Participants who received placebo-matching relamorelin injected subcutaneously twice daily for 40 weeks, followed by relamorelin 10 μg injected twice daily for up to 6 weeks in the Randomized Withdrawal (RW) Period.
32729591|NCT03420781|Experimental|Randomized Withdrawal Period: Relamorelin 10 μg then Relamorelin 10 μg|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by relamorelin injected twice daily for up to 6 weeks in the RW Period.
32729592|NCT03420781|Experimental|Randomized Withdrawal Period: Relamorelin 10 μg then Placebo|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo-matching relamorelin injected twice daily for up to 6 weeks in the RW Period.
32729593|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
32729594|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
32729595|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
32729596|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
32729597|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
32933343|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
32933344|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
32769043|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
32933345|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
32933346|NCT02553746|Experimental|Ultrasound|
32933347|NCT02553746|Active Comparator|Landmarks|
32933348|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
32933349|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
32933350|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
32933351|NCT04654130|Experimental|Neurofeedback (NFB)|Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
32933352|NCT04654130|No Intervention|Wait List|Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
32933353|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
32933354|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
32933355|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
32933356|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
32933357|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
33073933|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
33073934|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
33073935|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
33073936|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
33073937|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
33073938|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
33073939|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
33073940|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
33073941|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
32933358|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
33073942|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
33073943|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
33073944|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
32933359|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
32729598|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
32729599|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
32729600|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
32933360|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
32933361|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
32729601|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
32729602|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
32729603|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
32729604|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
32729605|NCT05237635|Experimental|Threshold estimates|Descriptive case-scenarios
32729606|NCT05237635|Active Comparator|Alternative threshold estimates|Descriptive case-scenarios
32933362|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
32933363|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
32933364|NCT04025060|Experimental|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
32933365|NCT04025060|Experimental|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
32933366|NCT04025060|Active Comparator|Regular Soda|Consumption of regular soda daily for two weeks
32933367|NCT04631510|Experimental|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
32933368|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
32933369|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
33073945|NCT00150644|Experimental|1|
33073946|NCT00150644|Experimental|2|
33073947|NCT00150644|Placebo Comparator|3|
33073948|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
33073949|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
33073950|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
33073951|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
33073952|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
33073953|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
33073954|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
33073955|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
32933370|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
32933371|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
33073956|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
33401085|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
32933372|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
33401086|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
33401087|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
32769044|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
32769045|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
32769046|NCT05060419|Experimental|Meropenem-FL058 (180min infusion)|
32769047|NCT05060419|Active Comparator|Piperacillin-Tazobactan (30min infusion)|
32769048|NCT05055193||Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia|Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)
32769049|NCT05055193||Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia|No corticosteroids
32933373|NCT04542434|Experimental|Niclosamide|
32933374|NCT04542434|Placebo Comparator|Placebo|
32933375|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
32933376|NCT02557178|No Intervention|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
32933377|NCT04415528|Experimental|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
32933378|NCT04415528|Active Comparator|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
32933379|NCT03943628|Experimental|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
32933380|NCT03943628|Other|Community Practice|Consists of community practice.
32933381|NCT04186286|Active Comparator|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
32933382|NCT04186286|Active Comparator|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
32933383|NCT04186286|Active Comparator|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
32933384|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
32933385|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
32933386|NCT04341038|Experimental|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.~In addition, these patients can receive all the treatments considered necessary for their clinical management."
32933387|NCT04341038|No Intervention|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
32933388|NCT04743050|Active Comparator|Control Group|The control group will be a group without EFA supplementation.
32933389|NCT04743050|Experimental|1st Experimental Group|The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
33073957|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
33401088|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
33401089|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
33401090|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
32769052|NCT05060185|Other|single arm|the patients will be treated by the trial device
32769053|NCT05044351|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted thyroid lobectomy
32933390|NCT04743050|Experimental|2nd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen EPA+DHA containing 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
32933391|NCT04743050|Experimental|3rd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen MAMA containing 2.9 g of ALA, 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
32933392|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
32933393|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
32769054|NCT05044351|Active Comparator|(B): Conventional surgery|Patients undergoing conventional thyroid surgery without NIRAF-assistance
32769055|NCT05060107|Experimental|Experimental group - sEVs|Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
32769056|NCT05060263|Experimental|Cohort 1|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32769057|NCT05060263|Experimental|Cohort 2|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32933394|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
32933395|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
32933396|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
32769058|NCT05060263|Experimental|Cohort 3|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32769059|NCT05060263|Experimental|Cohort 4|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32769060|NCT05060263|Experimental|Cohort 5|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32933397|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
32933398|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
32933399|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
32933400|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
32933401|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
32933402|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
32933403|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
32933404|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
32933405|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
32933406|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
32933407|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
32933408|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
32933409|NCT02467777|Active Comparator|Forced Air|Bair Hugger
32933410|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
32933411|NCT02564432||POP 10 patient cohort|This is an observational study
32933412|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
32769061|NCT05060263|Experimental|Cohort 6|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32769062|NCT05060263|Experimental|Cohort 7|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
32933413|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
32933414|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
32769063|NCT05036551||Stage 2 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
32769064|NCT05036551||Stage 3 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
32933415|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
32933416|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
32933417|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
32933418|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
32933419|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
32933420|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
32933421|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
32933422|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32933423|NCT04708184|Experimental|GLPG3970 solution|Single oral dose of GLPG3970 in fasted conditions
32933424|NCT04708184|Experimental|GLPG3970 tablet fasted|Single oral dose of GLPG3970 in fasted conditions
32933425|NCT04708184|Experimental|GLPG3970 tablet fed|Single oral dose of GLPG3970 in fed conditions
32933426|NCT04707950|Active Comparator|study group will be given tranexamic acid|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
32933427|NCT04707950|Placebo Comparator|Control group|The control group will not be given Tranexamic acid but only the standard management ( Oxytocin )
32933428|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
32933429|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
32933430|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
32933431|NCT04044560|Experimental|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
32933432|NCT02569892|Experimental|Laser Arm|Participants receive treatment with sub-threshold macular laser photocoagulation
32933433|NCT02569892|Sham Comparator|Sham Laser Arm|Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)
32933434|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
32933435|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
33401091|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
33401092|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
33401093|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
33401094|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
32933436|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
32933437|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
32933438|NCT02573402|Sham Comparator|Control|Sham stimulation.
32933439|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
32933440|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
32933441|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
32933442|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
33401095|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
33401096|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
33401097|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
33401098|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
33401099|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
33401100|NCT03926520|Experimental|ECT+UC group|
32729607|NCT05237323|Experimental|main group|Group 1 included 25 patients who received mycophenolate mofetil 2 g per day per os and methylprednisolone in an average starting dose 24 [24; 32] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required)).
32933443|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
32933444|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
32933445|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
32933446|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
32933447|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
32933448|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
32933449|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat.
32729608|NCT05237323|Active Comparator|control group|Group 2 included 25 patients who received azathioprine at an average dose of 150 [75; 150] mg per day per os and methylprednisolone in an average starting dose 24 [24; 32] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required))
32729609|NCT05226715|Experimental|Intervention|Received a bilateral, lower extremity manipulation series
32933450|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
32933451|NCT02582216|Experimental|Open label|3D augmented reality
32729610|NCT05226715|No Intervention|Control|30 seconds of lying supine on a chiropractic bench (control) without manual manipulation
32729611|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
32729612|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
32729613|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
32729614|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
32729615|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
32729616|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
32729617|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
32729618|NCT03385213||Remission|Patients who get remission after curative surgery
32729619|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
32729620|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
32729621|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
32933452|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
32933453|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
32933454|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
32933455|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
32933456|NCT00365222|Experimental|1|
32933457|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
32933458|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
32933459|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
32933460|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
32933461|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
32933462|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
32933463|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
32933464|NCT04340804|Experimental|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
32933465|NCT04340804|Experimental|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
32933466|NCT04340804|Experimental|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
33401101|NCT03926520|Sham Comparator|S-ECT+UC group|
32933467|NCT04340804|No Intervention|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
33401102|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
32729622|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
32729623|NCT03380533|Active Comparator|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
32729624|NCT03380533|Active Comparator|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
32729625|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
32729626|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
32729627|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
32729628|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
32729629|NCT03269695|Experimental|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
32933468|NCT04741958|Experimental|ultra sound guided percutaneous core needle biopsy|60 patients that had radiographic evidence of thoracic mass suspected of malignancy .Twenty masses were in the lung, seventeen lesions were in the pleura, ten masses were in the mediastinum, eleven enlarged palpable lymph nodes, and two masses were in chest wall. The sensitivity, PPV and accuracy for detection of chest tumors in chest wall, mediastinum, lung, and pleura were (100 %) for all, and in LN (88.9, 100 and 90.9 %) respectively. The overall diagnostic performance of sonar guided true cut needle biopsy in diagnosis was 97.78 % sensitivity, 98.18% accuracy, and 100 % PPV
32933469|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
32729630|NCT03269695|Placebo Comparator|Placebo|PF-06687234 matched Placebo SC QW x 12 doses
32729631|NCT01098331|Other|Arm Rx1: Radical Prostatectomy|Arm Rx1: Radical Prostatectomy
32729632|NCT01098331|Other|Arm Rx2: Brachytherapy|Arm Rx2: Brachytherapy
32729633|NCT03231085|Active Comparator|Ferrous fumarate or ferrostrane|"The oral treatment should begin 21 days before surgery.~Recommended Dosage ferrous fumarate according to the SPC in force:~5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate~8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate~10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate~Ferrostrane ® (syrup) Laboratory TEOFARMA SRL Either 34mg of iron per teaspoon~Recommended dosage according to the SPC in force:~Infant 5 to 8 kg (about 1 to 6 months): 2 teaspoons a day,~Infant from 8 to 12 kg (about 6 to 30 months): 3 teaspoons a day."
32729634|NCT03231085|Experimental|Ferric carboxymaltose|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
32729635|NCT03118921|Experimental|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
32729636|NCT04640857|Experimental|Test group: Silk'n Toothwave with vibration and electromagnetic field|Silk'n Toothwave with vibration and electromagnetic field use twice a day for 3 months.
32933470|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
32933471|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
32933472|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
32933473|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
32933474|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
32933475|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
32933476|NCT05249504|Experimental|1. Intervention group|"AMICOPE multicomponent intervention:~Physical activity (VIVIFRAIL program): 10 hours.~Nutrition: 6,5 hours.~Psychology: 6,5 hours.~Personal autonomy: 4,5 hours~Learn about community resources: 2, 5 hours"
32933477|NCT05249504|Active Comparator|2. Control group|Control group participants will receive usual advice on healthy lifestyle habits and a follow-up phone call from healthcare professionals.
33401103|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
33401104|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
32729637|NCT04640857|Sham Comparator|Control group: Silk'n Toothwave with-out an electromagnetic field ( only vibration)|Silk'n Toothwave without an electromagnetic field (only vibration ) use twice a day for 3 months.
32729638|NCT04640857|Active Comparator|Silk'n Toothwave with an electromagnetic field and without vibration|Silk'n Toothwave with an electromagnetic field and without vibration use twice a day for 3 months.
32729639|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
32933478|NCT05248256|Experimental|Radiation Dose Limitations to VMAT|Patients confirmed to have T1-T3 N1-N3 (Stage IIIA-IIIC) or select Stage IV primary adeno- or squamous cell-carcinoma of the lung will be treated per standard of care; concurrent chemoradiotherapy for 6 to 6.5 weeks, followed by consolidative immunotherapy. A CT simulation scan is obtained with the patient in the treatment position allowing the radiation oncologist to delineate intended tumor targets and organs at risk (OAR). Using specialized treatment planning software, a radiation plan is generated with the goal of maximizing tumor coverage with intended prescription dose and minimizing unintended radiation dose to OARs below established thresholds. The primary intervention of this trial will be sparing the thoracic bone marrow. This will be done by delineating the thoracic bone marrow on the CT simulation scan and applying vertebral marrow-specific OAR constraints during treatment planning to optimally spare radiation dose to this structure during treatment
32933479|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
32933480|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
32933481|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
32933482|NCT02791568||Pilot Study|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
32729640|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
32729641|NCT02766335|Experimental|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
32729642|NCT02766335|Active Comparator|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
32729643|NCT02766335|Experimental|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
32729644|NCT00462943|Experimental|OMA|"Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months."
32729645|NCT04475185|Experimental|MakAir|
32729646|NCT04436965|Experimental|Standard nutrition therapy|Dynamic nutrition assessment will be performed to patients. If malnutrion happened, patients would receive oral nutritional supplements (ONS) first, then feeded with nasal feeding tube or PEG when ONS wasn't enough. If all the these enteral nutrition methods couldn't make up for patient's nutritional deficiencies, parenteral nutrition would be considered.
32729647|NCT04436965|Active Comparator|Conventional nutrition therapy|Dynamic nutrition assessment will be performed to patients throughout whole treatment, and symptomatic treatment would be performed if needed.
32729648|NCT04420741|Experimental|Iloprost|Patients randomized to active treatment (n=40 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
32933483|NCT02791568||Main Study- Control Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
32933484|NCT02791568||Main Study- Study Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
32933485|NCT02791568||Main Study- Ferumoxytol Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection~Ferumoxtyol Infusion"
32933486|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
32933487|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
32933488|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
32933489|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks at the dose each patient was receiving at the end of their previous olipudase alfa study, for 9 years or until olipudase alfa becomes commercially accessible, whichever comes first, unless the patient decides to enter another olipudase alfa clinical trial within the 9-year period prior to when olipudase alfa is commercially accessible.
32933490|NCT05248022|Experimental|Combination Treatment Group|Drug-eluting Beads Bronchial Arterial Chemoembolization combined with Programmed Cell Death Protein 1 Inhibitor was used for treatment.
32933491|NCT05248022|Active Comparator|Single Treatment Group|Only receive drug-eluting beads bronchial arterial chemoembolization treatment.
32933492|NCT05371730|Experimental|NK cells|
32933493|NCT05247944||F-BEVAR|Patients with complex abdominal aortic aneurysm who underwent fenestrated and branched endovascular aortic repair (F-BEVAR) at the Aortic Center of Lille (ACL; Lille, France).
32933494|NCT05247944||OPEN SURGERY REPAIR|Patients with complex abdominal aortic aneurysm who underwent open surgery repair the Unit of Vascular Surgery of Policlinic Gemelli (FPUG; Rome, Italy).
32933495|NCT05247710||Patients diagnosed with non-superficial basal cell carcinoma|
32933496|NCT05247554|Experimental|Hydroxychloroquine+low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
32933497|NCT05247554|Active Comparator|Medium-dose prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to M6).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
32729649|NCT04420741|Placebo Comparator|Isotonic saline|Patients randomized to placebo treatment (n=40 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
32729650|NCT04409041|Experimental|Low-dose naltrexone group|All participants were prescribed low-dose naltrexone at 3mg oral daily.
32729651|NCT03090997|Placebo Comparator|Group 1|vitamin C (500 mg/day/orally) + placebo
32933498|NCT05217368|Experimental|experimental group/mandala painting|Mandala painting will be done in addition to routine antenatal education.
32729652|NCT03090997|Placebo Comparator|Group 2|resveratrol (500 mg/day/orally) + placebo
32729653|NCT03090997|Active Comparator|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
32729654|NCT03069469|Other|Experimental Treatment|"Dose Escalation Phase: Increasing doses of DCC-3014 beginning at 10 mg QD for 28 day cycles until disease progression or unacceptable toxicity.~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the Dose Escalation Phase of the study."
32729655|NCT03062995|Experimental|Active product: partially hydrolysed formula + synbiotics|partially hydrolysed formula + synbiotics
32729656|NCT03062995|Active Comparator|Control product: standard formula (intact protein)|standard formula (intact protein)
32729657|NCT03009331|Experimental|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
32729658|NCT03009331|Active Comparator|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
32729659|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
32933499|NCT05217368|No Intervention|antenatal education class|Only routine antenatal education will be done.
32933500|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
32933501|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
32729660|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
32729661|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
32729662|NCT02615951|Other|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
32729663|NCT02615951|Other|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
32729664|NCT02615951|Other|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
32729665|NCT02615951|Other|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
32729666|NCT02615951|Other|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
32729667|NCT04446013|Experimental|Group General Anesthesia|C-Section under general anesthesia
32729668|NCT04446013|Experimental|Grup Spinal Anesthesia|C-Section under spinal anesthesia
32729669|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
32729670|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
32933502|NCT05208320|Experimental|intervention ward|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
32933503|NCT05208320|No Intervention|control ward|Patients received usual care, consisted of existing services in the community
32933504|NCT00364442|Experimental|Arm 1|investigational drug
32933505|NCT00364520||Shanghai Workers|Shanghai Workers
32933506|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
32933507|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
32933508|NCT05371574|Active Comparator|Tranexamic acid|Each participant will receive 1gram of tranexamic acid
32933509|NCT05371574|Active Comparator|clonidine|Each participant will receive 0.2mg of oral clonidine
32933510|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
32933511|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
32933512|NCT05371418|Experimental|guided regeneration (GTR) followed by orthodontic intrusion|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by GTR followed by Orthodontic intrusion
32933513|NCT05371418|Experimental|Orthodontic intrusion followed by GTR|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by orthodontic intrusion followed by GTR
32933514|NCT05371340|Experimental|Postmenopausal women: Experimental group|Quercetin 500 mg. One capsule once a day.
32729671|NCT04446091|Experimental|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
32729672|NCT04446091|Experimental|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
32729673|NCT04445935|Active Comparator|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.~The patients will not be treated with Bivalirudin (the investigational drug)."
32729674|NCT04445935|Experimental|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
32729675|NCT03373643|Experimental|Patient suspected for NAFLD|
32933515|NCT05371340|Placebo Comparator|Postmenopausal women: Placebo group|Placebo (methylcellulose E4M) 500 mg, once capsule once a day.
32729676|NCT03385057|Active Comparator|Ibuprofen Arm|
32729677|NCT03385057|Active Comparator|Acetaminophen|
32933516|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
32933517|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
32933518|NCT05371262|Active Comparator|10-12.5 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 10-12.5 μg/kg/day.
32933519|NCT05371262|Active Comparator|12.6-15 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 12.6-15 μg/kg/day.
32933520|NCT02602496|Experimental|Control|3 servings of refined grains per day.
32933521|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
32933522|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
32933523|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
32933524|NCT00366002|Experimental|1|Darifenacin
32933525|NCT05371184|Experimental|cases|• 30 patients will receive glutamine in a dose of 0.3 gm /kg/dose twice daily orally (up to a maximum of 15 g/dose) for 24 weeks as an add on to the SOC
32933526|NCT05371184|Active Comparator|control|30 patients will be assigned as a control group to receive standard of care therapy without glutamine intake.
32933527|NCT05366972|Active Comparator|Patients diagnosed with low back pain|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
32933528|NCT05366972|Active Comparator|Healthy volunteers|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
32933531|NCT05624606|Experimental|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low dose|participants will receive a single dose (low) of QIV mRNA vaccine
32933532|NCT05624606|Experimental|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium dose|participants will receive a single dose (medium) of QIV mRNA vaccine
32933533|NCT05624606|Experimental|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose|participants will receive a single dose (high) of QIV mRNA vaccine
32933534|NCT05624606|Active Comparator|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
32933535|NCT05624606|Active Comparator|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
32933536|NCT05624606|Active Comparator|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine
32933537|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
32933538|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
32933539|NCT05365880|Experimental|Liquid Lidocaine|The investigational treatment is 1.5 mL of aqueous 2% lidocaine.
32933540|NCT05365880|Placebo Comparator|Sham Placebo|The placebo arm is 1.5mL of aqueous of saline.
32933541|NCT05365334|Experimental|low-intensity continuous exercise|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
32933542|NCT05365334|Experimental|moderate-intensity continuous exercise|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
32933543|NCT05365334|Experimental|high-intensity interval exercise|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
32933544|NCT04741490|Experimental|treatment group|The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles
32933545|NCT05603468|Experimental|Platelet Rich Plasma group|patients rejected with platelet rich plasma
32933546|NCT05603468|Active Comparator|Corticosteroid group|patients rejected with corticosteroid
32933547|NCT05603468|Placebo Comparator|Normal saline group|patients rejected with normal saline
32933548|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
32933549|NCT05365256|Active Comparator|Standard time occupation of treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care (doing nothing, discussion, reading, games, etc.).
32933550|NCT05365256|Experimental|time occupation of treatment period by virtual reality|Use of virtual reality as a distraction during chemotherapy sessions. A virtual reality headset will be worn for 15 minutes per hour of treatment (with a maximum of three sessions per cycle of chemotherapy)
33252370|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
32729678|NCT02051309|Experimental|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
32729679|NCT02051309|Placebo Comparator|Placebo|Placebo matching capsule
32729680|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
33252371|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
33252372|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
33252373|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
33252374|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
33252375|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
33252376|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
33252377|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
33252378|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
33252379|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
32729681|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
32729682|NCT00372073|Active Comparator|Arm 1 with seliciclib|Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
33252380|NCT04035681|Experimental|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
33252381|NCT04035681|Active Comparator|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
33252382|NCT05278143||type1diabetes patients who use CGM|Males and females diagnosed with T1D, aged less than 18 years old who are currently under the care of the Unit of Endocrinology and Diabetes of Bambino Gesù Children's Hospital, Rome, Italy and who already use continuous glucose monitoring (CGM) systems are eligible to be involved in the study. Participants will wear an additional non-invasive wearable device, Medtronic Zephyr BioPatch, for recording physiological data for three days.
33252383|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
33252384|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
33252385|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
33252386|NCT04034823|Experimental|KN035 in combination with trastuzumab and docetaxel|
33252387|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
33252388|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
33252389|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
33252390|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
33252391|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
33252392|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
32729683|NCT00372073|Placebo Comparator|Arm 2 with placebo control|Randomized to placebo after run-in period.
33252393|NCT00337675|Active Comparator|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
33252394|NCT00337675|Active Comparator|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
33252395|NCT00337675|Placebo Comparator|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
33252396|NCT00898521|Experimental|DGD|
32729684|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
32729685|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
32729686|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
32729687|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
32729688|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
32729689|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
32729690|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
32729691|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
32729692|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
32729693|NCT03379987|Experimental|PVB morphine|
32729694|NCT03379987|Active Comparator|PVB bupivacaine|
32729695|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
32729696|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
32729697|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
32729698|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
32729699|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
32729700|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
32729701|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
32729702|NCT02855125|Active Comparator|TAS-114 + S-1|Participants received 400 milligrams (mg) of TAS-114 tablets orally twice daily (BID) along with 30 milligrams per meter square (mg/m^2) of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks).
32933551|NCT05602454|Experimental|Digital Heart Failure Medication Titration|The Story Health platform will remotely receive daily vital signs directly from a blood pressure cuff and scale provided to the participant. Participants will also report any symptoms. All of this data will be transmitted, via the platform, to the treating clinician at the site, who will create care plans for medication titration and make clinical decisions. The care plans will be implemented with assistance from health coaches from Story Health Inc.
32933552|NCT05602454|No Intervention|Usual Care|Routine clinical care will be followed. Participants will also receive a blood pressure cuff and scale, though the data will not be routinely fed back to the treating clinicians unless requested.
32933553|NCT05362994|Active Comparator|Plain old balloon (POB) arm|"Balloon catheter used in the POB arm will be the Medtronic Euphora Rapid Exchange Balloon Dilatation Catheter, with diameters from 1.5 mm to 4.0 mm, and length from 6 to 30 mm,"
32933554|NCT05362994|Experimental|Drug-eluting balloon (DEB) arm|The Selution SLR™ sirolimus-eluting balloon catheter system comprises of a semi-compliant polyamide balloon catheter with low tip profile coated with sirolimus drug (concentration: 1.00 μg/mm2 of balloon surface). Selution sustained limus release (SLR™) sirolimus-eluting balloon provides controlled and 90-day sustained release of sirolimus given its MicroReservoir technology made from biodegradable polymer intermixed with sirolimus. The balloon platform is the percutaneous transluminal coronary angioplasty (PTCA) rapid exchange catheter, with diameters from 2.0 to 4.5 mm and length from 15 to 30 mm.
32933555|NCT05599100|Experimental|STAR-VTF|Participants will receive the STAR-VTF intervention.
32933556|NCT05574062|Experimental|AHCL therapy (i.e. MiniMed 780G system in Auto Mode)|Subjects will start using the MiniMed™ 780G system in Auto Mode for 12 weeks.
32933557|NCT05574062|Active Comparator|Predictive low-glucose suspend (i.e. 780G system in Manual Mode with SBL activated)|Subjects will use the MiniMed™ 780G system in Manual Mode with SBL activated for 12 weeks.
32933558|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
32933559|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
32933560|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
32933561|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
32933562|NCT05563298|Active Comparator|Active Neuro Rx Device|The active device will deliver light for the 20 minutes session duration.
32933563|NCT05563298|Sham Comparator|Sham Neuro Rx Device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
32933564|NCT05206292|Other|Patient cohort|There is only one patient arm. It corresponds to the cohort of included patients, all of whom had psychotic disorders with no known organic etiology.
32729703|NCT02855125|Active Comparator|S-1 (Monotherapy)|Participants received 30 mg/m^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks).
32729704|NCT02845531|Experimental|ICD implantation and optimal medical therapy|
32933565|NCT05140538|Active Comparator|Group 1|SRP + Biorepair Total Protective Repair toothpaste for home oral hygiene twice a day
32729705|NCT02845531|Active Comparator|optimal medical therapy|
32729706|NCT02827279|Other|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
32729707|NCT02827279|Other|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
32729708|NCT02791321|Other|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
32729709|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
32729710|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
32729711|NCT02678533|Experimental|Fanconi anemia|G-CSF and Plerixafor
32729712|NCT02601937|Experimental|Open-label Tazemetostat|"Dose Escalation: Level 1 (Starting Dose) Oral Tazemetostat 240 mg/m^2 BID; Level 2 Oral Tazemetostat 300 mg/m^2 BID; Level 3 Oral Tazemetostat 400 mg/m^2 BID; Level 4 Oral Tazemetostat 520 mg/m^2 BID; Level 5 Oral Tazemetostat 700 mg/m^2 BID; Level 6 Oral Tazemetostat 900 mg/m^2 BID; Level 7 Oral Tazemetostat 1200 mg/m^2 BID~Dose Expansion:~Cohort 1: Oral tazemetostat 1200mg/m2 BID Cohort 2: Oral tazemetostat 520mg/m2 BID Cohort 3: Oral tazemetostat 520mg/m2 BID Cohort 4: Oral tazemetostat 800mg/m2 TID (2400mg/m2/day)"
32729713|NCT03384667|Experimental|MMDT group|
32933566|NCT05140538|Experimental|Group 2|SRP + Biorepair Total Protective Repair toothpaste + Biorepair mouthwash (3 in 1) for home oral hygiene twice a day
32933567|NCT05548244|Experimental|MDD patients|Participants will be seen for a maximum of 16 sessions over 16 weeks. Two extra sessions will be allowed during treatment.
32729714|NCT03384667|Placebo Comparator|Placebo group|
32729715|NCT02557477|Active Comparator|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
32933568|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
32933569|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
32933570|NCT05104658|Experimental|Intervention arm|"Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).~In addition:~Information book on rehabilitation and physical activities in local community~1:1 conversation with patient supporters from the Heart Association~Employer material on post-treatment and potential work adjustments~Support café for relatives~Supported transition to local sports associations~Motivating phone calls from physiotherapists supporting physical activities.~In addition for patients with vulnerabilities:~patient education in small groups~pro-active counselling with a cardiac nurse, a psychologist, or a social worker from the Heart Association~paid transportation to the municipal rehabilitation Center"
32933571|NCT05104658|No Intervention|Control arm|Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).
32933572|NCT05104502|Experimental|Fasting|Dietary fasting.
32933573|NCT05094362|Experimental|Validation of the new training system|The researchers will measure changes in H-reflex size achieved with the use of the new system and compare these measures with the existing results in 25 spastic individuals with chronic incomplete SCI. Each participant completes 6 baseline sessions and 30 conditioning sessions. In the 30 conditioning sessions, the soleus H-reflex will be down-conditioned to decrease the activity of the hyperactive spinal stretch reflex pathway in people with spasticity that is characterized by exaggerated reflex activity. It is anticipated that the magnitude of reflex change obtained with the use of the new system would be greater or at least the same as the bench-marked values from the previous studies that used the old prototype reflex conditioning system.
32933574|NCT05083988|Experimental|audiovisual distraction|
32933575|NCT05083988|Experimental|audiodistraction|
32933576|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
32933577|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
32933578|NCT05732246|No Intervention|Conventional treatment group|"Hot pack and TENS at neck for 10minutes. Therapeutic ultrasound for 5 minutes Soft tissue techniques (gliding and kneading) will be applied at a slow speed for 5 minutes over the neck muscles.~Gentle stretching and strengthening exercises"
32933579|NCT05732246|Experimental|First rib mobilization with balloon breathing exercises group|Patient will lie in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject will place a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient will then be asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient will be asked to inhale and exhale deeply again. The examiner will continue applying pressure to hold the first rib in a position of relative depression during inhalation, and further depress the first rib as able during exhalation.
32729716|NCT02557477|Placebo Comparator|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
32729717|NCT03379597|Experimental|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.~Bifico: 840mg Bid."
32729718|NCT03379597|No Intervention|Control Group|No probiotics or dietary fiber group.
32729719|NCT03379597|Experimental|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
32729720|NCT03379597|Experimental|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
32729721|NCT05173909|Experimental|group H|BIS closed-loop target controlled infusion group with BIS value of 55
32933580|NCT05537168||Pediatric cardiac surgery|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 will be included
32933581|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
32933582|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
32933583|NCT04741724|Experimental|transcutaneous electrical diaphragmatic stimulation (TEDS)|"Subjects received daily TEDS (30min/day, 5days/week ) until the end of the weaning trial.~During TEDS, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was performed by applying biphasic waves at a stimulation frequency of 30 Hz, pulse width of 400 μs. TEDS intensity was gradually increased until visible muscle contraction was observed. Each session lasts for 30 min day."
32729722|NCT05173909|Experimental|group L|BIS closed-loop target controlled infusion group with BIS value of 45
32729723|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
32933584|NCT04741724|No Intervention|Control group|Subjects in the control group did not received TEDS program. Subjects in the control group received the same pre- and post-measurement as those in TEDS group. The control group received medical treatment as those in TEDS group. The pulmonary function was measured at the beginning and end of the intervention.
32933585|NCT05073302|Experimental|Treatment Group|Implantation of the Device-Less sentinel units. Ultrasound Monitoring. Islet Transplantation. Explantation of Device-Less Sentinels. Standard of Care. Concomitant Care. Post Transplant Testing and Visits. Participant Retention (nine month follow up assessment).
32933586|NCT04955756|Experimental|mNGS group|
32933587|NCT04955756|Experimental|PCR group|
32933588|NCT05525858||Tier 1. Therapeutic use of investigational products (KOSMOS-II drugs)|If there are no drugs available under current regulation or patients are not feasible to any clinical trials, and If tumors have actionable genetic alterations and approved drug in any indications but tumor type is not indicative, the MTB may recommend one of KOSMOS-II drugs, therapeutic use of investigational products.
32933589|NCT05525858||Tier 2: Alternative treatments|If there are no KOSMOS-II drugs (Tier 1) or clinical trials (Tier 3) appropriate for patients, the MTB may recommend alternative treatment options (e.g., conventional therapy, radiotherapy, or supportive care).
32933590|NCT05525858||Tier 3: Clinical trial|If patient is eligible for clinical trials matched for actionable genomic alterations found in NGS testing, the MTB will recommend enrollment to clinical trials.
32933591|NCT05732012|Experimental|Group-1|Interventions applied on Group-1 participants.
32933592|NCT05732012|No Intervention|Group-2|No interventions applied on Group-2 participants.
32933593|NCT04936334|Experimental|Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomy|1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery
32933594|NCT05731934|Experimental|HX301|Study treatment: during each cycle (28 days), HX301 is dosed QD for 3 weeks (21 days) followed by 1 week (7 days) off therapy.
32933595|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
32933596|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
32933597|NCT05493098|Experimental|Experimental group|The experimental group will include 18 participants with episodic tension-type headache. The treatment will include dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis, and temporalis muscles and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week.
32933598|NCT05493098|Placebo Comparator|Control group|"The control group will include 18 participants with episodic tension-type headache. The treatment will include sham dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis and temporalis muscles and routine physical therapy. The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week."
32933599|NCT04870034|Experimental|Treatment (palbociclib, binimetinib)|Patients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
32933600|NCT05731856|Experimental|Apollo Intervention Arm|Eligible UPMC Physicians and Residents who consent to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology that can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable), as this is where the TVS seems most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature. The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
33252397|NCT03985579|Experimental|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
32729724|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
32729725|NCT05173363||Older adults with frailty and mild cognitive impairment|
32729726|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:~PD,~unacceptable toxicity,~investigator choice,~patients IC withdrawal,~up to a maximum of 24 months (35 administrations) Experimental"
32729727|NCT03379441|No Intervention|Observation|
32729728|NCT02479321|No Intervention|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative period hemodynamic monitoring will be done by management of blood pressure, heart rate and oxygen saturation
32729729|NCT02479321|Experimental|GDT noninvasive monitoring group|GDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
32729730|NCT02464345|Experimental|HAPIFED|HAPIFED therapy
32933601|NCT04828772||Cohort 1|COVID-19 participants receiving anticoagulants
32729731|NCT02464345|Active Comparator|CBT-E|CBT-E therapy
32729732|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
32729733|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
32933602|NCT04828772||Cohort 2|COVID-19 participants not receiving anticoagulants
32933603|NCT05731778|Experimental|Stannous fluoride test toothpaste|Currently marketed as the new Colgate Total SF containing Stannous Fluoride
32933604|NCT05731778|Placebo Comparator|Colgate flouride toothpaste|Colgate Dental Cream containing Stannous Sodium Fluoride
32729734|NCT02056873|Experimental|Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
32729735|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
32933605|NCT05477264|Experimental|Tislelizumab therapy|"Induction therapy: Tislelizumab combined with radiation~Maintenance therapy(after termination of combination therapy)"
32933606|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
32933607|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
32933608|NCT05731700|Experimental|Drug eluting balloon|Treatment of a single in-stent restenosis coronary artery lesion with drug eluting balloon
32933609|NCT04827680|Experimental|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
32933610|NCT04710602||Minimally invasive|Patients who underwent surgery with a muscle sparing, minimally invasive technique for unstable chest wall after trauma.
32933611|NCT04710602||Historical control|Patients who underwent surgery with large incisions and simultaneous thoracotomy for unstable chest wall after trauma.
32933612|NCT05731466|Other|CardioMems (Clinical Indication)|Single Arm, CardioMems implantation on clinical indication. No control group. Every participant is his/her own control (longitudinal follow-up)
32933613|NCT04622540|Experimental|Experimental group|Application of external biliary drainage
32933614|NCT04622540|No Intervention|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
32933615|NCT04741880|Experimental|Group L (Lidocaine)|Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
32933616|NCT04741880|Placebo Comparator|Group S (saline solution)|Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
32933617|NCT05447234|Experimental|TCRX-T|"① 1x10^7/m2 ;~3x10^7/m2；~1x10^8/m2；~3x10^8/m2；~1x10^9/m2。"
32933618|NCT05437406|Experimental|PBT-AC|PBT-AC includes the elements of family based behavioral treatment for obesity, delivered exclusively to caregivers as the agents of change, via telehealth.
32933619|NCT05437406|Active Comparator|Health Education|This program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress via telehealth.
32729736|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
32933620|NCT05433818|Experimental|Skin-to-skin care|"Pregnant women will assigned to SSC were inform about SSC. SSC will ensured postpartum in a supported diagonal-flexion position continuously by the researchers for 45-120 minutes. Mothers in group A also benefit from the hospital's routine breastfeeding education service.~As a result, after the SSC application, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale."
32933621|NCT05433818|Active Comparator|Breastfeeding Education|Group B will received face-to-face breastfeeding education in the first phase of labor. A copy of the brochure will given to the pregnant women. In the early postpartum period, breastfeeding will encouraged practically and observed by the researchers. Participants' questions will answered. As a result, after the breastfeeding education, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale.
32729737|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
32729738|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
32743514|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A|"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12) 6 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)~Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on day 1, 8, 15, 22"
32933622|NCT05433818|No Intervention|Kontrol|No intervention will made to Group C by the researchers. Participants will benefit from the hospital's routine care and breastfeeding education services. As a result, postpartum mother will be evaluated with breastfeeding efficiency scale and maternal attachment scale.
32933623|NCT04621838|Experimental|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
32933624|NCT04615130|Experimental|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
32933625|NCT04615130|No Intervention|Control|Patients will receive no intervention throughout the 6 weeks period.
32933626|NCT04551326|Experimental|hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
32933627|NCT04490486|Experimental|Group 1: (UCMSCs)|Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.
32933628|NCT04490486|Placebo Comparator|Group 2: (Placebo)|Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.
32933629|NCT05421728|Experimental|Participants: ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
32933630|NCT05421728|Active Comparator|Participants: Mailed Resources|Participants will receive printed advance care planning resources by mail.
32933631|NCT05421728|No Intervention|Clinic Stakeholders|"Clinic stakeholders providing care for participants enrolled in the Participants: Enact Group Visits arm. Demographics, and adverse event data will not be collected for this arm."
32933632|NCT05421728|No Intervention|Caregivers|Caregivers will be consented via postcard consent to facilitate patient participants' engagement in the trial and group visits. Outcome measure, demographics, and adverse event data will not be collected for this arm, however caregivers will assist participants in providing outcome measure data (responding to surveys, etc.)
32933633|NCT04742504||BENRA Treated Patients|Patients with severe eosinophilic asthma who will be treated with benralizumab (Fasenra®, Astra Zeneca) will be able to participate in a volunteer manner in the study after sing informed consent.
32933634|NCT04742504||Non BENRA TREATED PATIENTSP|patients with controlled severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without oral corticosteroids) but without request of benralizumab (Fasenra®, Astra Zeneca) treatment will be recruited
32933635|NCT00365924|Other|Forteo|
32933636|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
32933637|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
32933638|NCT05731310|Experimental|Angong Niuhuang Pill Group|Take half an Angong Niuhuang pill every day for 4 weeks
32933639|NCT05731310|Experimental|Angong Niuhuang pill combined with music electroacupuncture group|Take half an Angong Niuhuang pill every day for 4 weeks and Daily music scalp acupuncture treatment
32933640|NCT05731310|No Intervention|General control group|no intervention
32729739|NCT05172739|Active Comparator|Opioid-Based Anaesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/ kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
32933641|NCT05404958|Experimental|Intervention clinics that implement the Systems Analysis and Improvement Approach|Mombasa County public health staff will facilitate SAIA
32933642|NCT05404958|No Intervention|Usual procedures|
32933643|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
32933644|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
32933645|NCT04303286||Control Group|The patients on benign disease of the liver
32933646|NCT05360030|Experimental|active stimulation of M1|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
32933647|NCT05360030|Experimental|active stimulation of DLPFC|pcTBS was administered to the left DLPFC at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
32933648|NCT05360030|Sham Comparator|SHAM stimulation|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
32933649|NCT05731232|Placebo Comparator|Pacebo|Capsules containing maize starch with identical appearance as verum. One capsule taken per day before bedtime. Treatment duration 12 weeks.
32933650|NCT05731232|Experimental|Vivatlac Synbiotikum|Vivatlac Synbiotikum for twelve weeks. One capsule containing a mixture of nine different probiotic bacteria with a total amount of 4.5 x 10˄9 colony forming units taken per day before bedtime. Treatment duration 12 weeks.
32933651|NCT05731154||thyroid eye disease group|"Patients who were diagnosed as thyroid eye disease. Periorbital images are taken by DSLR camera in the studio. Periorbital selfie images are taken by the patients with 6 smartphones including various camera modules.~CAS of TAO is evaluated by 3 ophthalmologists based on the periorbital digital images taken by DSLR camera and symptoms."
32933652|NCT05731076|Experimental|Self-management support nutrition and exercise group|Educate how to plain regular exercise and eat enough protein diet with self-management support.
32933653|NCT05731076|No Intervention|Routine health education group|Routine health education.
32933654|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
32933655|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
32933656|NCT05730998|Experimental|Intervention group|1 capsule (120 mg) of Anthocran phytosome will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
32933657|NCT05730998|Placebo Comparator|Placebo group|1 capsule of placebo will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
32933658|NCT04158362|Experimental|Standard Chemotherapy regimen|"* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.~OR~* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
32933659|NCT04158362|Experimental|Standard Endocrine therapy (ET) regimen + Abemaciclib|"* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing >1 year after the end of adjuvant ET.~OR~* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice."
32933660|NCT05341778|Experimental|Pilates exercises|The Pilates method's exercises emphasize breathing and the activation of the deep stabilizing muscles of the trunk in coordination with the PFM. The pilates method consists of exercises that emphasize pelvic stability, mobility, and body alignment. PMFE are performed in tandem with breathing, with concurrent trunk muscle recruitment in various positions.
32933661|NCT05341778|Active Comparator|Pelvic floor exercise|These exercises are intended to strengthen weak perineal and pelvic floor muscles.
32933662|NCT04742426|Active Comparator|WHO group|minimal setting of personal protective equipment (COVID 19) recommended by WHO
32933663|NCT04742426|Experimental|Super-safe setup|maximal super-safe setup of personal protective equipment
32933664|NCT04740944|Experimental|Intervention group|the intervention group was subjected to salutogenic approach-based interview consisting of 16 sessions twice a week.
32933665|NCT04740944|No Intervention|Control group|The control group continued their routine activities and was interviewed face-to-face 5 times.
32933666|NCT05730764|Experimental|Support systems assist doctors in decision-making|Doctors judge the risk of fertilization disorders and make clinical decisions with the support of a decision-making system.
32933667|NCT05730764|Other|Clinicians follow a routine protocol|Doctors judge the risk of fertilization disorders and make clinical decisions based on clinical experience
32933668|NCT05730218|Experimental|Treatment Group A|ONL1204 Ophthalmic Solution Dose A administered by intravitreal injection
32933669|NCT05730218|Experimental|Treatment Group B|ONL1204 Ophthalmic Solution Dose B administered by intravitreal injection
32933670|NCT05730218|Sham Comparator|Treatment Group C|Sham injection is performed by touching the eye surface with a syringe without a needle
32743515|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B|"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2) 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
32933671|NCT05297552|Experimental|RC48-ADC + JS001|Participants received 6 preoperative cycles of RC48-ADC PLUS JS001, followed by surgery, followed by up to 20 cycles of postoperative JS001.
32933672|NCT05272202|Experimental|Median nerve stimulation|
32933673|NCT04741412||Hypohidrotic Ectodermal Dysplasia|all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
32933674|NCT04741412||Control|individuals of the same age group, but without HED, including pregnant women
32933675|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
32933676|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
32933677|NCT05251454|Experimental|Electrical stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase). They will always be tested beforehand to ensure that they do not cause participants any discomfort or distress.
32933678|NCT05248802|Placebo Comparator|Control|Placebo DLBS2411 2 x 1 caplet daily, given everyday for 4 weeks of study period
32933679|NCT05248802|Experimental|DLBS2411|DLBS2411 caplet 2 x 250 mg daily, given everyday for 4 weeks of study period
32933680|NCT04718792|Experimental|Psilocybin|10 patients will receive a single administration of psilocybin
32933681|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve using 5 cc of 5% dextrose.
32933682|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 5 cc normal saline.
32933683|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 10 cc 5% dextrose.
32933684|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve from , using 10 cc normal saline.
32933685|NCT05726474|Experimental|Combined exercise|
32933686|NCT05726474|Experimental|High interval training|
32933687|NCT05726474|No Intervention|Usual care|
32933688|NCT04668638|Other|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
32933689|NCT04668638|Other|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
32933690|NCT05707442|Experimental|Stent Implantation|The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure.
32933691|NCT05707442|Active Comparator|Medical Therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
32933692|NCT05213078|Experimental|Supportive Care (teaching intervention, questionnaire)|Participants attend 2 teaching sessions with a research nurse. Participants also complete questionnaires at baseline, 3, and 7 weeks.
32933693|NCT04604132|Experimental|Derazantinib|In Substudies 1 and 3.1, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib.
32933694|NCT04604132|Experimental|Derazantinib-paclitaxel-ramucirumab|In Substudies 2 and 3.2, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-paclitaxel-ramucirumab in combination.
32933695|NCT04604132|Experimental|Derazantinib-atezolizumab|In Substudy 3.3, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-atezolizumab in combination.
32933696|NCT04604132|Active Comparator|Standard of care|In Substudy 3.4, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive the Standard of Care drugs paclitaxel-ramucirumab in combination.
33252398|NCT03985579|No Intervention|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
32933697|NCT04785534|Experimental|Screening (survey, biomarker analysis, fibroscan)|Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.
32933698|NCT04799808||BioNTech cohort|The BioNTech cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by comirnaty vaccine from BioNTech. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised solid organ transplant recipients, and the staff caring for them in the nephrology dispensaries.
33252399|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
33252400|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
33252401|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
32769065|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
32769066|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
32769067|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
32769068|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
32933699|NCT04799808||Moderna cohort|The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
32933700|NCT05193188|Experimental|Anlotinib combined with PD-1 monoclonal antibody|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off; PD-1 monoclonal antibody，PD-1 inhibitor，Intravenous injection，once 3 week.
32933701|NCT05193188|Active Comparator|Anlotinib monotherapy|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off.
32933702|NCT04799262|Experimental|Tofacitinib+Prednisone|Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if<10 the GC daily dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
32933703|NCT04741022||CAD with OSA|coronary artery disease with Obstructive sleep apnea
32933704|NCT04741022||CAD without OSA|coronary artery disease without Obstructive sleep apnea
32933705|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
32933706|NCT05698550|Experimental|EZTG group|
32933707|NCT05698550|Placebo Comparator|Control group|
32933708|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
32933709|NCT05698316||Age related macular degeneration|Collection of both retrospective and prospective data collection in 3 visits.
32933710|NCT00851136|Experimental|1|
32933711|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
32933712|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
32933713|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
32933714|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
32933715|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
32933716|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
32933717|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
32933718|NCT04798482|Experimental|Dexmedetomidine|This is a single arm, open label, interventional study examining the effects of dexmedetomidine on anal manometry. All subjects will be administered dexmedetomidine following their baseline manometry measurements. Following dexmedetomidine administration, anal manometry measurements will be observed for 15 minutes.
32933719|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to high frequency oscillating ventilator.
33252402|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
32769069|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
32933720|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to high frequency oscillating ventilator.
32933721|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to HFJV.
32933722|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to HFJV.
32933723|NCT04774458|Experimental|Fluoroscopic-guided cervical epidural access|Cervical epidural access with loss of resistance technique using CLO view at 50 degree under fluoroscopic guidance.
32933724|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
32933725|NCT00366470|Placebo Comparator|B|
32933726|NCT04773210||Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment.
32933727|NCT04773210||Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment.
32933728|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
32933729|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
32933730|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
32933731|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
32933732|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
32933733|NCT01116804|Other|inoperable liver cancer patients|
32933734|NCT04537286|Experimental|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
32933735|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
32933736|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
32933737|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
32933738|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
32933739|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
32933740|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
32933741|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
32933742|NCT05206734||Cases|All incident cases of Inflammatory Bowel Disease (IBD); comprising of Ulcerative Colitis, Crohn's Disease and IBD Unclassified in children, adolescents and young adults up to their 25th birthday. Cases will be defined based on an algorithm using diagnostic codes from the electronic medical record (EMR).
32933743|NCT05206734||Controls|People without a diagnosis in their electronic medical record (ERM) of Inflammatory Bowel Disease, matched on age group, sex, ethnicity (consistent with UK census categories: White, Asian, Black, Mixed, Other), index of multiple deprivation based on postcode, and by practice where numbers allow.
32933744|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
32933745|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
32933746|NCT04740788||Monofocal IOL|Patients already implanted with a monofocal IOL
32933747|NCT04522856||A|Local
32933748|NCT04522856||B|Nested
32933749|NCT04740554||Duchenne Muscular Dystrophy group with Deflazacort|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of deflazacort.
32933750|NCT04740554||Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of Prednisone/Predinisolone.
32933751|NCT04740554||Duchenne Muscular Dystrophy group without Corticosteroids therapy|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which don't use of corticosteroids.
32933752|NCT04740554||Control Group Typically Developing|Individuals with typical development age 11 to 18 years which don't use of corticosteroids.
32933753|NCT04506086|Experimental|Blinatumomab|
32933754|NCT04480736|Placebo Comparator|Placebo|Participants will receive matching placebo of JNJ-64281802 orally.
32933755|NCT04480736|Experimental|JNJ-64281802 High dose|Participants will receive high dose of JNJ-64281802 orally.
32933756|NCT04480736|Experimental|JNJ-64281802 Medium dose|Participants will receive medium dose of JNJ-64281802 orally.
32933757|NCT04480736|Experimental|JNJ-64281802 Low dose|Participants will receive low dose of JNJ-64281802 orally.
32933758|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen X|Participants will receive dosing regimen X of JNJ-64281802 orally.
32933759|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Y|Participants will receive dosing regimen Y of JNJ-64281802 orally.
32933760|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Z|Participants will receive dosing regimen Z of JNJ-64281802 orally.
32729740|NCT05172739|Active Comparator|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 150mg 1x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/ kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at ~1 MAC, Dexmedetomidine 0.5-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os 1x1 and 25mg 1x1, Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
32729741|NCT03375463|Experimental|Tirzepatide Test Part A|SC dose of tirzepatide solution formulation
32729742|NCT03375463|Experimental|Tirzepatide Reference Part A|SC dose of tirzepatide lyophilized formulation
32729743|NCT03375463|Experimental|Tirzepatide Formulation Part B|IV dose of tirzepatide formulation
32729744|NCT03375463|Experimental|Tirzepatide Part C|Titrated SC doses of tirzepatide solution formulation
32729745|NCT03375463|Placebo Comparator|Placebo Part C|SC dose of placebo matching tirzepatide dose
32729746|NCT04445623|Active Comparator|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
32729747|NCT04445623|Placebo Comparator|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
32933761|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
32933762|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
32933763|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
32933764|NCT05123534|Experimental|Cohort 1|5 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
32933765|NCT05123534|Experimental|Cohort 2|5 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
32933766|NCT05123534|Experimental|Cohort 3|5 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
32933767|NCT05123534|Experimental|Cohort 4|10 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
32933768|NCT05123534|Experimental|Cohort 5|10 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
32933769|NCT05123534|Experimental|Cohort 6|10 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
32933770|NCT05123534|Experimental|Cohort 7|15 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
32933771|NCT05123534|Experimental|Cohort 8|15 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
32933772|NCT05123534|Experimental|Cohort 9|15 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
32933773|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
32933774|NCT05068232|Experimental|Participants With Extensive Small Cell Lung Cancer (All Participants)|"This arm will involve all participants in the study who have extensive small cell lung cancer that has not responded to previous treatments. All participants will receive the same treatment of study drugs and radiation treatment in cycles (a specific window of time).~You will receive up to four 21-day cycles of chemotherapy using carboplatin, etoposide and durvalumab (immunotherapy) as part of a standard care treatment plan recommended by your doctor. These drugs will be combined with ablative radiation treatment during the second cycle of chemotherapy.~After completing these four cycles of chemotherapy (with radiation treatment added in cycle 2), you will continue to receive a fixed dose of durvalumab until your cancer progresses, you experience serious side effects, you decide to no longer be part of the study or the study doctor request to take you off the study for medical reasons."
32933775|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
32933776|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
32933777|NCT04455230|Experimental|Participants who have received gene therapy vector (FLT190)|
32933778|NCT02254278|Experimental|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
32933779|NCT02254278|Experimental|IMRT 5 weeks|IMRT 5 weeks
32933780|NCT05055596|Experimental|Gentle Movement|
32933781|NCT05055596|Active Comparator|Health Coaching|
32933782|NCT04326764|Experimental|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
32933783|NCT04326764|No Intervention|Standard of Care|Treatment according to local standards
33252403|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
32933785|NCT04741178||Patient with Covid-pneumonia|Patient with CT scan of pulmonary infiltrates suggestive of Covid pneumonia
32933786|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
32933787|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
32933788|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
32933789|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
32933790|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of PSP patients|All eligible PSP patients will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 10 PSP patients will be required to complete the study arm.
33252404|NCT00898599|Placebo Comparator|Maltodextrin|
33252405|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
33252406|NCT00903045|Experimental|1|
33252407|NCT00903045|Placebo Comparator|2|
33252408|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
33252409|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
33073958|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
33401105|NCT05094466|Experimental|Arm I (parent intervention)|Parents receive health coaching sessions over 50-60 minutes monthly for 6 months. Parents also receive navigation sessions with a lay LHW monthly for 6 months and church-based peer support monthly for 6 months.
32729748|NCT04445311|Experimental|Ivermectin group|group that will receive ivermectin plus standard of care ttt
32729749|NCT04445311|No Intervention|Control group|group that will receive standard of care ttt
32729750|NCT05172583|Active Comparator|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU
32729751|NCT05172583|Experimental|Experimental|Interventions for this group are based on the Dynamic Symptom Model and scientific evidence
32769070|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
32933791|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of NDC subjects|All eligible non-demented control (NDC) subjects will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 NDC subjects will be required to complete the study arm.
33073959|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
33073960|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
33073961|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
33073962|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
32933792|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
32933793|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
33073963|NCT02910427|Placebo Comparator|Na salt|regular salt
33073964|NCT02910427|Active Comparator|K salt|potassium-enriched salt
32933794|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
32933795|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
32933796|NCT04325282|Experimental|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
32933797|NCT04289792|Experimental|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
32933798|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
32933799|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
32933800|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
32933801|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
32933802|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
32933803|NCT00368082|Experimental|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
33073965|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
33252410|NCT00337285|Experimental|1|
33252411|NCT04035525|Experimental|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
32729752|NCT05172427|Active Comparator|CLUE intervention (EMA + EMI)|"Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA, which will include EMI prompts that they come up with at the end of the CLUE intervention (framed as key takeaways). After the two week period of EMA/EMI, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention."
32729753|NCT05172427|Active Comparator|CLUE intervention (EMA only)|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention.
32729754|NCT05172427|No Intervention|Waitlist control|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, participants will be assigned 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline. One month after the post-intervention questionnaires, participants will complete a one-month follow up questionnaire battery, that will include parallel questions from baseline and post-intervention. As these participants did not receive the intervention following their baseline EMA, they will be given the opportunity to schedule an appointment for the intervention after they have completed their one-month follow up questionnaire.
32729755|NCT03384355||Class 0|no visible or palpable varicose veins
32729756|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
32729757|NCT03384355||Class 2|varicose veins
32933804|NCT05178186|Other|Thyroid carcinoma|Patients with thyroid carcinoma submitted to thyroidectomy
32933805|NCT05101200|Experimental|High Dose Neural Mobilization Technique|Patients in this Group will receive High Dose Neural Mobilization Technique
32933806|NCT05101200|Experimental|Low Dose Neural Mobilization Technique|Patients in this Group will receive Low Dose Neural Mobilization Technique
32933807|NCT02246478|Placebo Comparator|Placebo|
32933808|NCT02246478|Active Comparator|TAS-205 low dose|
32933809|NCT02246478|Active Comparator|TAS-205 middle dose|
32933810|NCT02246478|Active Comparator|TAS-205 high dose|
32933811|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
32933812|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
32933813|NCT05066100|Experimental|Pregnant women with FIRN|Women desiring to breastfeed and identified during their pregnancy as having flat, inverted or retracted nipples
32933814|NCT04784442|Experimental|ETC-1002 180mg|
32933815|NCT04784442|Experimental|ETC-1002 120mg|
32933816|NCT04784442|Experimental|ETC-1002 60mg|
32933817|NCT04784442|Placebo Comparator|Placebo|
32933818|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
32933819|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
32933820|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
32933821|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
32933822|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
32933823|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
32933824|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
32933825|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
33401106|NCT05094466|Experimental|Arm II (family intervention)|Family members receive health coaching sessions over 50-60 minutes monthly for 6 months. Family members also receive navigation sessions with a LHW monthly for 6 months and church-based peer support monthly for 6 months.
32933826|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
33401107|NCT05094466|Active Comparator|Arm III (delayed comparison)|Participants receive a handbook that includes core content from the parent and family interventions, but without individual support from coaches, LHWs or the church.
33401108|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
33401109|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
32933827|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
32729758|NCT03384355||Class 3|edema
32729759|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
32729760|NCT03384355||Class 5|healed venous ulcer
32729761|NCT03384355||Class 6|active venous ulcer
32729762|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
32729763|NCT03375229|Active Comparator|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
32933828|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
32933829|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
32933830|NCT02244996|Placebo Comparator|Placebo|Placebo
32933831|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
32729764|NCT03375229|Active Comparator|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
32933832|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
32729765|NCT03375229|Placebo Comparator|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
32729766|NCT03378895|Experimental|adults aged 35 to 55 years|
32729767|NCT03384121|Experimental|Rifampin|All subjects
32729768|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
32933833|NCT02661451|Experimental|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
32933834|NCT02661451|Active Comparator|OHFT|Optimal Heart Failure Therapy
32933835|NCT02643667|Experimental|Safety Run-In: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
32933836|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
32933837|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
32933838|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
32933839|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
32933840|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
32933841|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
32933842|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
32933843|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
32933844|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
32933845|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
32933846|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
32933847|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
32933848|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
32933849|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
33401110|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
33401111|NCT04439890|Experimental|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
33073966|NCT04687930|Active Comparator|Active genicular nerve block group|group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
33073967|NCT04687930|Other|intra-articular steroid injection group|while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.
33073969|NCT03783325|Other|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
33073970|NCT03783325|Experimental|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
33073971|NCT03783325|Experimental|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
32729769|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
32729770|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
32729771|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
32729772|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
32729773|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
32729774|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
32729775|NCT03367429|Experimental|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
32933850|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
32933851|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
32933853|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
33073972|NCT03782740|Experimental|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
33073973|NCT03782740|Experimental|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
33073974|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
33073975|NCT03759925|Experimental|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
33073976|NCT03759925|No Intervention|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
33073977|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
33073978|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
33073979|NCT03732820|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
32769071|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
33401112|NCT04439890|Placebo Comparator|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
33401113|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
32729776|NCT03367429|Experimental|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
32729777|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
32729778|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
32729779|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
32729780|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
32729781|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
32729782|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
32729783|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
32729784|NCT03378583||control,|control normal ventilation
32729785|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
32729786|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
32729787|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
32729788|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
32729789|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
32729790|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
32729791|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
32729792|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
32729793|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
32729794|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
32729795|NCT03383497||Idiopathic Parkinson Disease|
32729796|NCT03383497||Other Parkinsonian syndromes|
32729797|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
32729798|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
32729799|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
32729800|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
32729801|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
32729802|NCT05172115|Experimental|Conventional catheter-directed thrombolysis (CDT)|Conventional catheter-directed thrombolysis (CDT) will be the interventional arm. CDT will be administered using fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours (0.5 mg/h per catheter if bilateral or 1 mg/h per unilateral catheter) with 500 unit per hour of infusion of unfractionated heparin during the thrombolytic therapy. The therapeutic dose of heparin will immediately be substituted the CDT after termination, and twice-daily subcutaneous enoxaparin (1mg/kg) for the first 48 hours after the thrombolytic therapy will be administered. Direct oral anticoagulation will be in ones with no clinical deterioration.
32729803|NCT05172115|Active Comparator|Anticoagulation-only therapy|The anticoagulation-only therapy will be the assigned treatment in the control arm. Control patients will receive subcutaneous enoxaparin (twice-daily, 1mg/kg) in the first 48hours of enrollment. Direct oral anticoagulation will be in ones with no clinical deterioration.
33252412|NCT04035525|Active Comparator|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
33252413|NCT04035525|Active Comparator|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
32729804|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
33252414|NCT04035057|Experimental|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
33252415|NCT04035057|Active Comparator|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
32729805|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
32729806|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
33252416|NCT04034979|No Intervention|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
33252417|NCT04034979|Experimental|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
33252418|NCT04034979|Experimental|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
33252419|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
32729807|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
32769072|NCT05036239|Experimental|Exercised|One bout of 50 eccentric biceps curls
32769073|NCT05036239|No Intervention|Control|No eccentric biceps curls
32769074|NCT05043727|Experimental|Exer gaming treatment plan|Exer gaming treatment plan
32769075|NCT05043727|Active Comparator|conventional treatment plan|conventional treatment plan
33401114|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
32729808|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
32729809|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
33401115|NCT03635892|Experimental|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
32933854|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
32729810|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
32729811|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
32729812|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
32933855|NCT04744675|Experimental|Treatment|"The intervention group will receive:~Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog~Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog~Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog"
32933856|NCT04744675|Placebo Comparator|Placebo|"Placebo~The placebo group will receive:~Suprascapular nerve injection - 4 mL of normal saline~Median nerve injection - 4 mL of normal saline~Ulnar nerve injection - 4 mL of normal saline"
32933857|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
32933858|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
32933859|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
32933860|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
32933861|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
32933862|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
32933863|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
32933864|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
32933865|NCT04341337||expert|interviews of expert of pipac about ethical issues
32933866|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
32933867|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
32933868|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
32933869|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
32933870|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
32933871|NCT02472223|Active Comparator|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
32933872|NCT02472223|Placebo Comparator|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
32933873|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
32933874|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
32933875|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
32933876|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
32933877|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
32933878|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
32933879|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
33401116|NCT03635892|Experimental|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
33401117|NCT03635892|Experimental|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
33401118|NCT03635892|Experimental|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
32933880|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
32933881|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
32933882|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
32933883|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
32933884|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
32933885|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
32933886|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
32933887|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
32933888|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
32933889|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
32933890|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
32933891|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
32933892|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
32933893|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
32933894|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
32933895|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
32933896|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
32933897|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
32933898|NCT04740866|Active Comparator|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy [IMRT] technique.
32933899|NCT04740866|No Intervention|Observation after radical Cystectomy|observation following radical cystectomy
32933900|NCT04340414|Experimental|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
32933901|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32933902|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32933903|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32933904|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
32933905|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
32933906|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
32933907|NCT04943822|Placebo Comparator|conventional education service program|Including the written and verbal health education on preoperative preparation, stoma surgery and postoperative stoma care. At discharge, ET nurses offered teaching information and support for patients, including selection of pouching appliances, drug instructions, health education At each outpatient follow-up, both stomas and patients needed to be assessed. The condition of stoma and peristomal skin, nature and volume of effluent, date of pouch appliances and stoma complications were recorded by ET nurses.
33073980|NCT03732820|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
33073981|NCT04723914|Experimental|Treatment group|Dual target CAR-T cell therapy
33073982|NCT03719092|Experimental|Prevention (vitamin A compound)|"Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.~once over a given 24 hour period with or without food. We will re-dose at 2000 IU/kg (maximum 120,000 IU) if Week 2 Vitamin A levels remain within 10% of baseline Vitamin A."
33073983|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
33073984|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
33073985|NCT03715504|Experimental|Single Arm TP-3654|TP-3654 by oral administration
33401119|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
33401120|NCT03633695|Experimental|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye. The AcuFocus IC-8 IOL implanted in the second eye.
33401121|NCT03633695|Active Comparator|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted.
33401122|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
33401123|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
33401124|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
33401125|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
33401126|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
33401127|NCT05165472|Experimental|Intervention|Real transcranial magnetic stimulation applied
33401128|NCT05165472|Sham Comparator|Sahm-control|Sham transcranial magnetic stimulation applied
33401129|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
33401130|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
33401131|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
33401132|NCT02675998|Placebo Comparator|Placebo|Placebo
33401133|NCT01384188|Experimental|E1|ONO-5334
33401134|NCT01384188|Experimental|E2|ONO-5334
33401135|NCT04588519|Experimental|Active Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA
33401136|NCT05666063||Study Group|Patients who underwent ambulatory urodynamic studies due to lower urinary tract symptoms
33401137|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
33401138|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
33401139|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
33401140|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
33073986|NCT03669367|Experimental|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
33073987|NCT03669367|Active Comparator|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
33073988|NCT03665116|Experimental|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
33073989|NCT03665116|No Intervention|No Intervention|no supplement for 6 months
33073990|NCT03531892|Experimental|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
33073991|NCT03531892|Placebo Comparator|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
33073992|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
33073993|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
33073994|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
33073995|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
33073996|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
33073997|NCT00532207|Experimental|A|
33073998|NCT04723836|Active Comparator|TT genotype active comparator group|5mg riboflavin per day from 16th gestational week
33073999|NCT04723836|Experimental|TT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
32729813|NCT03374605|Experimental|Active tDCS|
32729814|NCT03374605|Sham Comparator|Sham tDCS|
32729815|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
32729816|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
32729817|NCT03374527||Control group|Healthy subjects
32729818|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
32729819|NCT03980743|Active Comparator|iOTA text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly meetings with a study health coach to develop reasonable health goals and interactive text messaging to provide daily support and self-monitoring of behavior change goals between in-person visits. Participants may receive phone calls between visits from their health coach for additional support if needed. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
32933908|NCT04943822|Experimental|mobile care device|The participants in the intervention group were given the same routine care as the control group pre- and postoperatively. ET nurses taught patients and their family members how to use the home care mobile app before discharge. The home care mobile app was designed and developed for the discharged stoma patients by the research team and an information technology company in March 2021. Patients could receive stoma care from ET nurses through this mobile app at home, not just going to an outpatient clinic. The Major function modules of this mobile app were as follows: (a) appointment: The app users were able to complete the basic personal and medical information and make an appointment with the ET nurse; (b) photograph diagnosis: The ET nurses could make a diagnosis based on the patients' uploaded stoma photographs; and (c) consultation: Patients were able to contact their ET nurses for help and support. This mobile app was used to supplement the outpatient follow-up.
32933909|NCT05026320|Experimental|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
32933910|NCT05026320|Active Comparator|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
32933911|NCT05026320|Placebo Comparator|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
32933912|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
32933913|NCT04771806||Observational (MRI)|Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
32933914|NCT04740320||Healthy Volunteers|Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.
32933915|NCT04170374||Patients who initiated HIV treatment|
32933916|NCT04170374||Service providers at study facilities|
32933917|NCT04153292|Experimental|TMVR - Main Cohort|Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
32933918|NCT04153292|Experimental|TMVR - Failed TEER Registry|Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
32933919|NCT04153292|Experimental|TMVR - MAC Registry|Subjects with mitral annular calcification (MAC) will have TMVR.
32933920|NCT04092686|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
32933921|NCT04092686|Experimental|SEP-363856 100mg|SEP-363856 100mg dosed once daily
32933922|NCT04092686|Placebo Comparator|Placebo|Placebo dosed once daily
32933923|NCT04840784|Experimental|ETH-155008|Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
32933924|NCT04086524|Experimental|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
33074000|NCT04723836|Placebo Comparator|TT genotype placebo group|Placebo supplement from 16th gestational week
33074001|NCT04723836|Active Comparator|CT genotype active comparator group|5mg riboflavin per day from 16th gestational week
33074002|NCT04723836|Experimental|CT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
33074003|NCT04723836|Placebo Comparator|CT genotype placebo group|Placebo supplement from 16th gestational week
33074004|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
33074005|NCT00532246|Experimental|A|raloxifene
33074006|NCT00532246|Placebo Comparator|B|placebo
33074007|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
33074008|NCT03143374|Experimental|Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease|Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology. Healthy control subjects will also be recruited for this study.
33074009|NCT03138733|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg
33074010|NCT03138733|Active Comparator|Daptomycin|Daptomycin 6 mg/kg, with or without Aztreonam
33074011|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
33074012|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
33074013|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
33074014|NCT02716012|Experimental|MTL-CEBPA Monotherapy|MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.
33074015|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (combination)|MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.
33074016|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (sequential)|MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib
33074017|NCT05467696|Experimental|Sequence 1 Fed:Fasted|Period 1: CTP-543 12 mg fed Period 2: CTP-543 12 mg fasted
33074018|NCT05467696|Experimental|Sequence 2 Fasted:Fed|Period 1: CTP-543 12 mg fasted Period 2: CTP-543 12 mg fed
33074019|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
33074020|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
32729820|NCT03980743|Placebo Comparator|Health Education text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly in-person visits with a health coach to learn about healthy eating and activity behaviors, including developing readiness for health behavior change. Participants will not set specific health goals, but will receive weekly text messages about general health tips related to their in-person visits. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
32729821|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
33074021|NCT05467618|Experimental|Intra-Oral Surgical approach|The mandibular fracture was reduced using an intra-oral surgical approach.
33074022|NCT05467618|Experimental|Extra-Oral Surgical approach|An External/Facial approach was used to reduce the mandibular bone fracture.
32729822|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
32729823|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
32729824|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
32729825|NCT03377881|Other|Traditional|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
32729826|NCT03377881|Experimental|STHLM3+MRI/Fusion|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
32729827|NCT04177849|Active Comparator|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
32729828|NCT04177849|Experimental|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
33074023|NCT05467579|Active Comparator|Healthy subjects|Healthy patients that will serve as controls will recruited having the same demographic characteristics of the experimental group i.e., age, sex, vertebral maturation stage and the same cranio-facial features, skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern.
33074024|NCT05467579|Experimental|JIA subjects|Young people aged from 10 to 14 years old with skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern, and affected by juvenile idiopathic arthritis
33074025|NCT05467540|Experimental|Pain reduction in patients with vertebral metastatic lesions treated with SPINERY System|
33074026|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
33074027|NCT00151112|Active Comparator|2|standard positioning
33074028|NCT05467501|Experimental|Ultrasound group|Therapeutic ultrasound application. US parameters are 0.8 W/cm for intensity, 3 MHz for frequency and 5 min application. The device that will be used is medserve, England (the head of the device is 5cm). The physical therapy will by 6 sessions (every day). PT sessions will be done by the same physical therapist.
33401141|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
32933925|NCT04086524|Active Comparator|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
32729829|NCT04155619|Active Comparator|No change in eating or light exposure habits|
32729830|NCT04155619|Experimental|Early Time-Restricted Feeding|
32729831|NCT04155619|Experimental|Timed Light Therapy|
32729832|NCT04155619|Experimental|Early Time-Restricted Feeding and Timed Light Therapy|
32933926|NCT04086524|Experimental|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
32933927|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
32933928|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
32729833|NCT04152109|Other|Without laying on of hands|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or do count math during 5 minutes, around 8 weeks.
32729834|NCT04152109|Sham Comparator|Laying on of hands with healing intent and without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, 8 weeks.
32933929|NCT04086056||Children with craniosynostosis|Children with craniosynostosis who will be operated in prone position.
32729835|NCT04152109|Experimental|"Laying on of hands with healing intent and Spiritual connection by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
32729836|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
32729837|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
32729838|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
32729839|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
32729840|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
32729841|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
32729842|NCT05105971|Experimental|BAT6026 0.01mg/kg|BAT6026 0.01mg/kg,intervenous infusion,sample size 1
32729843|NCT05105971|Experimental|BAT6026 0.03mg/kg|BAT6026 0.03mg/kg,intervenous infusion,sample size 1
32729844|NCT05105971|Experimental|BAT6026 0.1mg/kg|BAT6026 0.1mg/kg,intervenous infusion,sample size 3~6
32933930|NCT04068272|Experimental|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
32933931|NCT04068272|Placebo Comparator|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
32933932|NCT04058756|Experimental|PDR001|All subjects in all combination will be entered in one arm
32933933|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
32933934|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
32933935|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
32933936|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
32933937|NCT04052828|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
32933938|NCT04050410|Experimental|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
32933939|NCT04050410|Placebo Comparator|Placebo|Patients will receive a single oral dose of placebo.
32933940|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
32933941|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
32933942|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
32933943|NCT04452500|Experimental|CORT108297|CORT108297- 180mg daily for 7 days
32933944|NCT04452500|Placebo Comparator|Placebo|Placebo- 180mg daily for 7 days
32933945|NCT04016636||Single Group Study. Patients with CLL receiving ibrutinib.|"In this study the investigator does not assign specific interventions to the study participants. Participants will receive interventions as part of routine medical care, and the investigator will observe the effect of the intervention.~This study will collect prospective real-world data to describe the quality of life (QOL) in patients with CLL receiving ibrutinib in routine Argentinian clinical practice over a 12-month follow-up period.~The primary data source for this observational study will be the medical records of each enrolled patient, as well as questionnaires concerning quality of life. Data will be collected at baseline and on months 1,3,6 and 12 during a prospective period."
33401142|NCT05675878|Experimental|Dietary Intervention Group|Subjects will undergo a 2-hour in-depth training via Zoom on how to follow the diet and will receive a binder with helpful information. They will be give the weekend to prepare and then will start the diet the following Monday, and will continue following it for 4 weeks before being reassessed in the lab.
33401143|NCT05675878|No Intervention|Waitlisted Control Group|The waitlisted control group will follow their usual diet for one month and then will be reassessed (as a comparator group) before being trained on the dietary intervention which they will then follow for the next month.
33401144|NCT05675800|Experimental|Psilocybin Active Dose Treatment A|Psilocybin
33401145|NCT05675800|Experimental|Psilocybin Active Dose Treatment B|Psilocybin
33401146|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
33401147|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
33401148|NCT05044312|Other|Sleep Disturbances|Difficulty Sleeping
32933946|NCT04436978|Active Comparator|First month DAPT|"30-day DAPT (aspirin + P2Y12 inhibitor). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
32933947|NCT04436978|Active Comparator|Guideline-directed therapy|"Standard guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
32933948|NCT04014374||Transplant Arm|Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT
32933949|NCT04014374||Control Arm|Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT
32933950|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
32933951|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
32933952|NCT03976076|Experimental|JBPOS0101 (investigational product)|During Treatment Period 1, the IP was administered at 6 mg/kg, per oral (PO), twice a day (BID), once in the morning and 12 hours following the morning dose during the first 7 days of Treatment Period 1. Starting from the PM dose on Visit 3, the dose was escalated and patients received the Investigational Product (JBPOS0101) (IP) at a dose of 9 mg/kg orally BID. Starting on Day 15, the dose was escalated again and patients received the IP at a dose of 15 mg/kg orally BID until the end of Treatment Period 1 (Day 28). Each dose of the IP was administered after at least a 2-hour fast. Food was given 2 hours after dosing.
32933953|NCT04933500||Conventional epidural|epidural needle: Tuhoy needle 1.3mm (18 G) with 20G multi-orifice epidural catheter
32933954|NCT04933500||Dural puncture epidural|epidural needle;Tuhoy needle 1.3mm (18G)with 20G multi-orifice epidural catheter and 25G Whitacre spinal needle
32933955|NCT05588882|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK for myopia and myopic astigmatism
32933956|NCT05588882|Active Comparator|Topography-guided LASIK|Topography-guided LASIK for myopia and myopic astigmatism
32933957|NCT03973268|Experimental|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
32933958|NCT03973268|Experimental|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
32933959|NCT03973268|Experimental|3|Individuals in Arm 3 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
32933960|NCT05588804|Experimental|Group 1: Broncho-munal®|Participants will receive the study drug Broncho-munal®, capsules, 7 mg (Sandoz dd, Slovenia), 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
32933961|NCT05588804|Placebo Comparator|Group 2: Placebo|Participants will receive a placebo, 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
32933962|NCT03941834|Active Comparator|BHV3000|
32933963|NCT03941834|Placebo Comparator|Placebo|
32933964|NCT05588726|Active Comparator|Sleep Hygiene|
32933965|NCT05588726|Experimental|Mindfulness|
32933966|NCT04235036|Experimental|Rituximab + Ibrutinib|Eligible patients will be those with a first episode of symptomatic cGVHD, requiring systemic immunosuppression for control of symptoms. Following study entry, patients will be started on rituximab plus ibrutinib.
32933967|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
32933968|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
32933969|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
32933970|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
32933971|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
32933972|NCT03786770|Experimental|Cohort 1: Dose A|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
32933973|NCT03786770|Experimental|Cohort 2: Dose B|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
33401149|NCT05231434|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol
32933974|NCT03786770|Experimental|Cohort 3: Dose C|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
32933975|NCT03786770|Experimental|Cohort 4: Dose D|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
33074029|NCT05467501|Active Comparator|placepo group|group B will have a non-steroidal anti-inflammatory drug as prescribed by the same orthopedist and 2 session of massage with the head of ultrasound.
33074030|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
33074031|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
33074032|NCT05467384|Experimental|Newly Diagnosed Hypertensive patients|These are the patients that have been clearly diagnosed with diabetes for the first time.
33074033|NCT05467384|No Intervention|Healthy Controls|Healthy Control Group
32729845|NCT05105971|Experimental|BAT6026 0.3mg/kg|BAT6026 0.3mg/kg,intervenous infusion,sample size 3~6
32729846|NCT05105971|Experimental|BAT6026 1mg/kg|BAT6026 1mg/kg,intervenous infusion,sample size 3~6
32933976|NCT04219280|Active Comparator|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 10mg/20mg/30mg/40mg for children 20-25kg, 20mg/30mg/40mg/50mg for children 26-30kg, and 20mg/33mg/46mg/60mg for children > 30 mg.
32933977|NCT04219280|Placebo Comparator|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
32933978|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
32933979|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
32933980|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
32933981|NCT05441852||Ambulatory Emergency Department Patients at risk for hyperkalemia|Patients who are at elevated risk for hyperkalemia identified during a visit to the emergency department. Elevated risk individuals are defined in this study as: >50 years of age, eGFR <45, or prior K >5.2
32933982|NCT05588570|Experimental|CAT|Participants will receive behavioral treatment for anxiety.
32933983|NCT05588492|Experimental|Rifamycin containing regimen|Rifamycin containing regimen
32933984|NCT05588492|Experimental|Rifamycin-free regimen|Rifamycin-free regimen
32933985|NCT05588414|Other|Indocyanine Green fluorescence method as first step|Systematic double identification of the sentinel lymph node, by sequential use of ICG fluorescence technique as first step followed by isotopic technique.
32933986|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
32933987|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
32933988|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
32933989|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
32933990|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
32933991|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
32933992|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
32933993|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
32933994|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
32933995|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
32933996|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
32933997|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
32933998|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
32933999|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
32934000|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
32934001|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
32934002|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
32934003|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
32934004|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
33082194|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
33082195|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.~Patients diagnosed by EUS, CT scan or surgically removed lesions."
32729847|NCT05105971|Experimental|BAT6026 3mg/kg|BAT6026 3mg/kg,intervenous infusion,sample size 3~6
32934005|NCT03732638|Experimental|DBT Rimegepant/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (as needed [PRN] dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
32934006|NCT03732638|Placebo Comparator|DBT Placebo/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of placebo matching to rimegepant tablet EOD for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (PRN dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
32934007|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
32729848|NCT05105971|Experimental|BAT6026 6mg/kg|BAT6026 6mg/kg,intervenous infusion,sample size 3~6
32729849|NCT05105971|Experimental|Amplification group|BAT6026 10mg/kg,intervenous infusion,sample size 3~6
32729850|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
32729851|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
32729852|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
32729853|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
32729854|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
32729855|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
32934008|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
32934009|NCT02564029|Placebo Comparator|Placebo|Single dose
32934010|NCT02564029|Active Comparator|Lorazepam|2mg single dose
32729856|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
32729857|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
32729858|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
32729859|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
32729860|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
32934011|NCT05588336|Active Comparator|10 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision, 10 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
32934012|NCT05588336|Active Comparator|7 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision 7 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
32934013|NCT05588258|Active Comparator|Pharmacy cream 10% urea|Use of pharmacy cream in prevention
32934014|NCT05588258|Active Comparator|Supermarket cream 10% urea|Use of supermarket cream in prevention
32934015|NCT04073420||Surgical Valve Replacement and/or Repair Patients|
32934016|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
32934017|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
32934018|NCT03957278|Experimental|DAISe System|The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.
32934019|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
32934020|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
32934021|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
32934022|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
33082196|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
32729861|NCT05089279|Experimental|Sequence 1|Period 1: D113/ Period 2: CKD-349
32934023|NCT03926624|Experimental|Experimental|DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles
32934024|NCT03926624|Active Comparator|Control|"Non-Intensive:~LoDAC: 20 mg SC BID 10 days~Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)~Decitabine: CIV 20 mg/m²x5 days~Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.~Intensive:~High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²~FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 & G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)~MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr & cytarabine 1g/m² IV 6hr.~CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.~Intermediate DAC: cytarabine 20 mg/m² IV dailyx5"
32934025|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
32729862|NCT05089279|Experimental|Sequence2|Period 1: CKD-349/ Period 2: D113
32729863|NCT02775409|Active Comparator|Subcutaneous|Subcutaneous placement of tissue expander
32934026|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
32934027|NCT05588102|Experimental|Selective Serotonin Reuptake Inhibitor（SSRIs）combined with Electronic cognitive training|SSRIs（Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with Electronic cognitive training (60min, once a day)
32934028|NCT05588102|Placebo Comparator|SSRIs antidepressants combined with blank control Electronic training for 52 weeks|SSRIs drug treatment （Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with the blank control Electronic training(subjects were allowed to use electronic products to browse the web and watch the news for 1 hours every day)
32934029|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
32729864|NCT02775409|Active Comparator|Submuscular|Submuscular placement of tissue expander
32729865|NCT05048329|Experimental|Soft Launch|The study will include ten eligible patients into the soft launch to test and reconfigure workflow, protocol, alerting structure and other operation related factors.
32729866|NCT05048329|Experimental|Pilot|After the soft launch, the study will include 45 eligible patients into the pilot to conduct the rest of the study
32729867|NCT05019547||Axial Spondyloarthritis|Participants with Axial Spondyloarthritis
32729868|NCT02440945|Experimental|collection of blood|160 old people for the collection of blood
32934030|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
32934031|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
32934032|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
32934033|NCT05588024||Head Up CPR based bundle of care|All patients in the registry receive the Head Up CPR based bundle of care.
32934034|NCT04744597|Experimental|Real execution group|The real execution group will perform the acute intervention by the actual performance of the Fitt's law task.
32934035|NCT04744597|Experimental|Motor imagery group|The motor imagery group will perform the acute intervention by simulating (mental process) the Fitt's law task.
32934036|NCT04744597|Active Comparator|Control group|The control group will perform skip counting.
32934037|NCT05155423||group 1|patient using mask for immobilization
32934038|NCT05155423||group 2|patients using Elekta BodyFix
32934039|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
32934040|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
32934041|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32934042|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32934043|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32934044|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
32934045|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
32934046|NCT05126485|Experimental|Randomizing Control and Biofeedback Phases|"The gait training and data collection procedure is split into two phases: a control phase and a biofeedback phase. The order of these phases is randomized across participants to reduce the probability of systematic error due participants warming-up or fatiguing between trials. Each phase consists of a pre-test, gait retraining session, and one or more post-tests."
33074034|NCT05467306|Experimental|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
33074035|NCT05467306|No Intervention|Standard PrEP services|Standard PrEP services
33074036|NCT05467228|Experimental|Low dose / continuous VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
33074037|NCT05467228|Experimental|Low dose / speech activated VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; VTS during connected speech
33074038|NCT05467228|Experimental|High dose / continuous VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
33074039|NCT05467228|Experimental|High dose / speech activated VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; VTS during connected speech
33074040|NCT05467189||treatment|The use of antineoplastic agents depends on the clinical practice.
33074041|NCT05467072||Discectomy + annular closure|All patients treated with lumbar discectomy and implantation of an annular closure device
33074042|NCT05466760||Patient recently diagnosed breast cancer who will undergo surgery|surgery treatment only
33074043|NCT05466760||Patients with recently diagnosed breast cancer who will undergo NAC.|Patients with recently diagnosed breast cancer who will undergo NAC before surgery.
33074044|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
33074045|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
33074046|NCT05466721|Other|Hydrustoma C3 - Control Device|The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.
33252420|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
33252421|NCT00905931|Experimental|Active|
33252422|NCT00905931|Placebo Comparator|Placebo|
33252423|NCT02540187||haemophilia A|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
33252424|NCT02540187||Haemophilia B|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
33252425|NCT04035291|Active Comparator|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
33252426|NCT04035291|Experimental|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
33252427|NCT04035291|No Intervention|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
33252428|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
33252429|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
33252430|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
33074047|NCT05466721|Other|Control Device - Hydrustoma C3|The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
33074048|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
33074049|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
33074050|NCT05466604|Experimental|hyaluronidase|
33074051|NCT05466604|No Intervention|hyaluronidase control|
33074052|NCT05466604|Experimental|dexamethasone|
33074053|NCT05466604|No Intervention|dexamethasone control|
33074054|NCT05466565||Nucleoside analog alone group|planning or ongoing treatment with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and no addition or switch Patients on the pegylated interferon alfa-2b program
33082197|NCT00247182|Other|Step 1|Minimal Intervention
33074055|NCT05466565||In the continuous treatment group of peginterferon|the subjects started oral antiviral drugs from the 2nd day after operation, and simultaneously took peginterferon alfa-2b in combination from the 4th to 8th week after operation, and stopped after 96 weeks. Continue oral antiviral drugs with peginterferon
33401150|NCT05231434|Experimental|Hydration protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery
33401151|NCT03113812|Experimental|ABvac40|
33401152|NCT03113812|Placebo Comparator|Placebo|
33401153|NCT04605874|Experimental|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
32769076|NCT02605967|Experimental|Spartalizumab 400 mg Q4W|anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab
32769077|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
32769078|NCT05043571|Experimental|Single arm|Single arm Phase I Clinical Trial
32934048|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
32934049|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
32934050|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
32934051|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
32934052|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
32934053|NCT05587790|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 45-minutes. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
32934054|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
32934055|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
32934056|NCT04743427|Experimental|physical therapy inervention|"hot pack~Three active exercises"
32934057|NCT04743427|Experimental|Body-blade exercises in addition to physical therapy intervention|"Three Body-blade exercises will be performed in random order (Two sets of, 3-minute exercise and 5-minute break, for each exercise )~hot pack~Three active exercises"
32934058|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
32934059|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
32934060|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
32934061|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
32934062|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
32934063|NCT02572609|Experimental|Mucosolvan ® adult syrup|
32934064|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
32934065|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
32934066|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
32934067|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
32934068|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
32934069|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
32934070|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
32934071|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
33074056|NCT05466565||In the pegylated interferon pulse medication group|the subjects started oral antiviral drugs from the second day after the operation, and at any time point from the 4th to the 8th week after the operation, the subjects were combined with peginterferon alfa-2b. After every 8 weeks of combined use, stop for 4 weeks (continuous oral NA is maintained during the period), and perform periodically until pegylated interferon is stopped after 96 weeks, and oral antiviral drugs are continued
32934072|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
32934073|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
32934074|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
32934075|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
32934076|NCT02577991|No Intervention|Control group|No steroid
32934077|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
32934078|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
32934079|NCT05024227|Experimental|Experimental: nursing education interventions|nursing education interventions (including e-health platform assistance)
32934080|NCT05024227|No Intervention|No Intervention: Routine care|Only the original form of nursing education leaflets are given
32934081|NCT04956133|Experimental|Physical activity|Participants will be offered online, individualized physical activity sessions 2-3 times/week for 15-45 minutes/session for 8-12 weeks.
32934082|NCT04847167|Experimental|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
32934083|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
32934084|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
32934085|NCT04712383|Experimental|Fitbit Care intervention arm|The experimental arm will receive the full Fitbit Care product suite (Fitbit wrist-worn device, Fitbit connected weight scale, and Fitbit Premium + Health Coaching service). Participants in the experimental arm will also be offered support in improving health behaviors that are important to them, including activity, nutrition, sleep, stress management, and medication adherence.
32934086|NCT04712383|No Intervention|Fitbit study control arm|Participants in the control arm will have access to standard healthcare benefits available to all employees, but will not have access to any of the Fitbit Care interventions
32934087|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
32934088|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
32934089|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
32934090|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
32934091|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
32934092|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
32934093|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
32934094|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
32934095|NCT00422149|Placebo Comparator|2|Placebo treatment
32934096|NCT03452228|Experimental|evinacumab|
33074057|NCT05466487|Experimental|Active tACS|
32729869|NCT03872089|Experimental|Study participants|Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)
32729870|NCT03860935|Experimental|acoramidis 800 mg|Subjects will receive acoramidis 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The frequencies of deaths, cardiovascular-related hospitalizations, and change in distance walked on the 6MWT will be assessed after 30 months of treatment.
32729871|NCT03860935|Placebo Comparator|Placebo|Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The frequencies of deaths, cardiovascular-related hospitalizations, and change in distance walked on the 6MWT will be assessed after 30 months of treatment.
32729872|NCT04445857|Active Comparator|Group 1|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
32729873|NCT04445857|Active Comparator|Group 2|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
32729874|NCT04445857|Placebo Comparator|Group 3 (control group)|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
32729875|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
32729876|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
32934097|NCT03452228|Experimental|Placebo|
32934098|NCT04436731|Experimental|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
32934099|NCT04341727|Active Comparator|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
32934100|NCT04341727|Active Comparator|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
32934101|NCT04341727|Active Comparator|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
32934102|NCT04341727|Active Comparator|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
32934103|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 (PF-07265803) tablet orally OR matching placebo tablet orally
32934104|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 (PF-07265803) tablet orally
32934105|NCT04320901|Experimental|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
32934106|NCT04320901|Experimental|Ligasure|Endoscopic procedure will be done by Ligasure
32934107|NCT04272385||Focus Group|Qualitative research done with a group of patients with TN. Patients will describe their experience of living with the disease and what outcomes of treatment they consider to be important.
32934108|NCT04272385||Delphi survey|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment in a 3 round Delphi survey.
32934109|NCT04272385||Consensus meeting|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment and finalise the COS for Trigeminal Neuralgia.
32934110|NCT04247737|Experimental|gluten free diet|six week gluten free diet
32934111|NCT04244227|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
32934112|NCT04244227|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
32934113|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
32934114|NCT04340102|Experimental|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
32934115|NCT05587478|Experimental|EDP-323 SAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, orally, once daily in one single administration
32934116|NCT05587478|Experimental|EDP-323 MAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3 and Dose 4 orally, once daily for 7 days
32934117|NCT05587478|Placebo Comparator|EDP-323 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
32934118|NCT05587478|Placebo Comparator|EDP-323 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
32934119|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
32934120|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
32934121|NCT05587400|Experimental|patients with pulmonary artery hypertension and/or right ventricular dysfunction|
33074058|NCT05466487|Sham Comparator|Sham tACS|
33074059|NCT05466448|Experimental|RZL-012 50mg/ml|small synthetic molecule for submental fat reduction
33074060|NCT05466331|Experimental|Mobile Tele-HCV Care|Direct Acting Antiviral (DAA) treatment for HCV on a mobile van via telemedicine
33074061|NCT05466331|Active Comparator|Enhanced Usual Care|Referral with care navigation to a local or regional HCV treatment provider
32769079|NCT05036005|Experimental|Ontruzant + Pertuzumab (optional) + Chemotherapy|"All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.~Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication."
33074062|NCT05466253|Experimental|Group 1 EARLY|In experimental group Orthodontic treatment will be started (early) 10 days after periodontal surgery
33074063|NCT05466253|Experimental|Group 2 DELAYED|control group will receive orthodontic intervention(delayed) 3 months after periodontal surgery
33074064|NCT04723875|Experimental|Adjuvant chemotherapy group|"Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm"
33074065|NCT04723875|No Intervention|Control group|The participants receive no intervention.
33074066|NCT05466136|Experimental|Mental fatigue condition|Performing a completed incongruent version of Stroop task for 30min.
33074067|NCT05466136|Experimental|Control condition|Performing a completed congruent version of Stroop task for 30min.
33074068|NCT05466019|Experimental|Toripalimab combined with FLOT regimen|The enrolled patients will receive 3 cycles of FLOT regimen +Toripalimab treatment before surgery, and every 2 weeks is a treatment cycle (Q2W). After completing the 3 cycles of treatment, the patient undergoes surgical resection.Toripalimab combined with FLOT regimen were maintained for 4 cycles after surgery.
33074069|NCT05465902|Experimental|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
33074070|NCT05465902|Active Comparator|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
33074071|NCT05465902|Experimental|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
33074072|NCT05465902|Active Comparator|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: mRNA COVID-19 vaccine (Moderna)
33401154|NCT04605874|Experimental|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
33401155|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
32769080|NCT04473079|Experimental|Experimental group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus probiotic formulation (commercially-available as Lacidofil) for 12 weeks.
33074073|NCT05465902|Experimental|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
33074074|NCT05465902|Active Comparator|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)
33401156|NCT02674204|Placebo Comparator|Control|One matching placebo daily
33401157|NCT05675644|Experimental|Dose finding|Drospirenone-only pill single-dose ranging from 16mg to 32mg
33401158|NCT05675644|Experimental|Primary ovulation inhibition testing|Drospirenone-only pill single-dose at dose determined by dose finding arm
32769081|NCT04473079|Placebo Comparator|Placebo group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus placebo for 12 weeks.
33074075|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
33401159|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
33074076|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
33074077|NCT05465863|Active Comparator|Patients|
33074078|NCT05465863|Active Comparator|Healthy controls|
33074079|NCT05465785|Experimental|Pilot batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
33074080|NCT05465785|Active Comparator|Commercial batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
33074081|NCT04687462|Experimental|Experimental|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
32769082|NCT05036161||Predicting treatment failure of Nasal High Flow in newborns|newborns with respiratory distress treated with NHF
32769083|NCT05036161||Predicting treatment failure of Continuous Positive Airway Pressure in newborns|newborns with respiratory distress treated with CPAP
32769084|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
32769085|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
32934122|NCT05587244|Experimental|Total Hip Arthroplasty Treatment Group|This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.
32934123|NCT04339868|Active Comparator|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease terlipressin until stop
32934124|NCT04339868|Placebo Comparator|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease placebo until stop
32934125|NCT05585216|Experimental|PRP combined with leg swing and quadriceps strengthening exercise|Group A received twice intra-articular injection of platelet-rich plasma (2 ml, 2 weeks apart) and regular leg swing and quadriceps strengthening exercise for three months.
32934126|NCT05585216|Active Comparator|intra-articular combination injections of PRP and HA|Group B received twice intra-articular combination injections of PRP (2 ml) and HA (2 ml) every 2 weeks.
32934127|NCT03334526|Experimental|healthy volunteers|
32934128|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
32934129|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
32934130|NCT05574452|Experimental|Pilot group|Pilot group undergoing ACL reconstruction using the SONAR Femoral Aimer PSI
32934131|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
32934132|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
32934133|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
32934134|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
32934135|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
32934136|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
32934137|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
32934138|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
32934139|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
32934140|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
32934141|NCT03266588|Experimental|Rimegepant|
32934142|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
32934143|NCT02587351|Placebo Comparator|Placebo|Matched placebo
32934144|NCT05553314|Experimental|Carvedilol-group|Patients receiving carvedilol
32934145|NCT05553314|Placebo Comparator|Placebo-group|Patients receiving placebo
32934146|NCT05249491||Group 1|Children with black tooth stain
32934147|NCT05249491||Group 2|Children without black tooth stain
32934148|NCT05538338|Active Comparator|Intervention Group|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group
32934149|NCT05538338|Placebo Comparator|Control Group|an intrauterine infusion of normal saline will be administered to this group
32934150|NCT05249413||Endophthalmitis after primary cataract surgery.|Cases diagnosed as acute post-operative endophthalmitis after primary cataract surgery.
32934151|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
32934152|NCT05249335|Experimental|OST|2 days split dosing regimen
32934153|NCT05249335|Active Comparator|2L-PEG/Asc|2 days split dosing regimen
32934154|NCT04101487|No Intervention|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
32934155|NCT04101487|Experimental|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
32934156|NCT04101487|Experimental|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
33252431|NCT04035135|Experimental|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
32769086|NCT03096769|Other|Study Arm|
32769087|NCT04834427|Experimental|S (+)-Ketamine group|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.
32769088|NCT04834427|Active Comparator|Control group|Patients who undergo conventional therapy without S (+)-Ketamine hydrochloride injection during perioperative period.
32769089|NCT05035849|Active Comparator|Group A|Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
32769090|NCT05035849|Active Comparator|Group B|Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
32934157|NCT04034797|Experimental|Photo|
32769091|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
32769092|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
32934158|NCT04034797|Active Comparator|No photo|
32934159|NCT03992209|Other|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
32934160|NCT03992209|Active Comparator|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
32934161|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
32934162|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
32934163|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
32934164|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
32934165|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
32934166|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
32934167|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
32934168|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
32934169|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
32934170|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
32934171|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
32934172|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
32934173|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
32934174|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
33074082|NCT04687462|Active Comparator|Control|TKRA operation undergoing 2-mm thickness variance polyethylene insert total knee arthroplasty system (Lospa, Corentec)
33082198|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
33252432|NCT04035213|Experimental|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
33252433|NCT04035213|No Intervention|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
33252434|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
33252435|NCT00903279|Placebo Comparator|Placebo|
33252436|NCT00903279|Experimental|Altabax|
33252437|NCT02540109|Experimental|High-Definition tDCS (Active)|
33252438|NCT02540109|Experimental|High-Definition tDCS (Sham)|
32769093|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
32769094|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
33252439|NCT00898989||Inclusion Body Myositis|
33252440|NCT00898989||Control|
32769095|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
32769096|NCT04821479|Experimental|Repeated MSCs treatment in ALS patients|Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline.
32934175|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
32934176|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
32934178|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
32934179|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
32934180|NCT05249179|Experimental|Group 1 (Oral stimulation)|The group that will receive oral stimulation with the Backman method once a day from the 29th week
32934181|NCT05249179|Experimental|Group 2 (Pacifier)|The group that will be given a pacifier three times a day from the 29th week
32934182|NCT05249179|Experimental|Group 3 (oral stimulation + pacifier)|Starting from the 29th week, the group will be given a pacifier three times a day and a Backman oral stimulation will be applied once a day.
32934183|NCT05249179|No Intervention|Group 4 (Enteral feeding by tube)|The group fed enterally by tube in routine practice, in which no intervention will be made.
32934184|NCT05249023|Experimental|Irritable Bowel Syndrome (IBS) participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
32934185|NCT05249023|Experimental|Healthy participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
32934186|NCT04743037|No Intervention|Standard of Care (SOC)|The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
32934187|NCT04743037|Experimental|iSMART|"The 15 iSMART participants will engage in video conference sessions between the pre and post visits. A health coach will collaboratively work with the participant to practice treatment strategies and set goals in weekly individual sections. In addition, all participants will engage in weekly group sessions with a health coach in order to learn and practice specific self-management skills and strategies in a group context. In addition, iSMART entails using an interactive SMS to provide ongoing support and self-monitoring of behavior change goals. The SMS is programmed to touch participants daily; the SMS system prompts participants to report their daily activities and progress in achieving goals via check-in messages and sends immediate, tailored feedback about their progress. If a participant is making progress toward their goal, the SMS system will suggest a change to the participant's goal between visits."
32934188|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
32934189|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
32934190|NCT02495623|Placebo Comparator|Placebo|Placebo
32934191|NCT05248087|Experimental|The rapid maxillary expansion|The rapid maxillary expansion will be applied using a McNamara-type (bonded) appliance.
32934192|NCT05248087|Active Comparator|The slow maxillary expansion|The slow maxillary expansion will be applied using a removable palatal expansion appliance.
32934193|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
32934194|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
32934195|NCT05247931||CASE|patients experiencing a recurrent stroke while on ASA therapy
32934196|NCT05247931||CONTROL|ASA-naïve patients experiencing a first atherothrombotic stroke
32934197|NCT05247775|Experimental|Patients with prostate cancer|We performed urethral pressure profilometry prior to open retropubic radical prostatectomy (ORRP). Patients were interviewed about the urinary incontinence by the usage of pads and International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) prior to ORRP and at 2, 8, 16 and 24 weeks after ORRP.
32934198|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
33082199|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
33252441|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
33252442|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
33252443|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
33074083|NCT05465746||Adults with an indication of SAH screening|Patients who attend the physician's office or the emergency room (ER) with signs and symptoms of high systemic arterial blood pressure will be indicated for ABPM and TTE
33074084|NCT04687618|Experimental|Automatic control of FiO2|Infants randomized to this arm will be monitored using automatic oxygen control system on the High Flow Nasal Cannula. When infants oxygen saturation are out of the target range the OAM module on HFNC will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation in the target range.
33074085|NCT04687618|Active Comparator|Manual Control of FiO2|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
33074086|NCT05465707|Experimental|CM313 2 mg/kg|Once 1 week, intravenous infusion.
32729877|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
32729878|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
32729879|NCT04445779|Experimental|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
33074087|NCT05465707|Experimental|CM313 4 mg/kg|Once 1 week, intravenous infusion.
32729880|NCT04445779|Placebo Comparator|Placebo|Patients will receive per-orally placebo in three divided doses.
33074088|NCT05465707|Experimental|CM313 8 mg/kg|Once 1 week, intravenous infusion.
33074089|NCT05465707|Experimental|CM313 16 mg/kg|Once 1 week, intravenous infusion.
32729881|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
33074090|NCT05465707|Placebo Comparator|Placebo|Once 1 week, intravenous infusion.
33074091|NCT05464654|Experimental|Polynucleotides-based therapy improves genitourinary syndrome of menopause. A pilot study|"At the request of the hospital ethics committee, a first pilot study was carried out, where 30 participants with the diagnosis of genitourinary syndrome were recruited from the climacteric and bone metabolism clinic of the Regional Hospital October 1st-ISSSTE . 15 participants were non-randomly assigned to the control group, receiving local estrogen-based therapy and the other 15 participants were assigned to the experimental group, receiving local polynucleotide-based therapy. Both groups were evaluated initially and a follow-up evaluation was performed at 3 months."
33074092|NCT05464654|Experimental|Polynucleotides-based therapy improves genitourinary syndrome of menopause. Randomized control trial|"After completing the pilot study, it was possible to continue with the work with the approval of the ethics committee, thereby a randomized clinical trial is being carried out. In this arm, 120 participants of the climacteric and bone metabolism clinic of the Regional Hospital October 1st-ISSSTE with the diagnosis of genitourinary syndrome of menopause will be enrolled . 60 patients will be randomly assigned to a control group that will receive local estrogen-based therapy, while the other 60 participants will receive local polynucleotide-based therapy. An initial evaluation will be carried out, as well as another follow-up at 3 months."
33074093|NCT05462431|Experimental|web-based deep relaxation exercise intervention|
33074094|NCT05462431|No Intervention|control|
33074095|NCT05460481|Experimental|Experimental: Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
33074096|NCT05451433|Experimental|Intervention Group|Get intervention drug Normagut capsule twice a day
33074097|NCT05451433|Placebo Comparator|Control Group|Get placebo capsule twice a day
33074098|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
33074099|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
32769097|NCT05043493|Active Comparator|Injection (study) group|This group will receive platelet rich plasma (PRP) injection
33074100|NCT05420740|Experimental|COPD patients with Small Airway Disease|Subjects will be given Aerobika OPEP and IOS, CAT score, Spirometry, 6MWT and Exacerbation were assessed at Week 0, Week 12 and Week 24
33074101|NCT05404360|Experimental|Treatment Group|During the acute treatment phase, subjects will receive daily prefrontal Deep TMS treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly Deep TMS stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
32729882|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
32729883|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
32769098|NCT05043493|Placebo Comparator|Control group|This group will receive normal saline (NS) injection
33074102|NCT05404360|Sham Comparator|Sham Control Group|During the acute treatment phase, subjects will receive daily prefrontal sham treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly sham stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
32769099|NCT04821635|Experimental|Rower|Single group of 35 traumatic paraplegic patients meeting the inclusion criteria will benefit from the FES-ROW protocol during 9 months
32769100|NCT05043181|Experimental|Homozygous Familial Hypercholesterolemia|
33074103|NCT00406016|Experimental|1|
33401160|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
33401161|NCT05010772|Experimental|Arm A (decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
33074104|NCT05399173|Experimental|an infrared (gallium aluminum arsenide laser)|Each female in study group will be treated by laser acupuncture for 3 sessions per week, for 6 weeks. An infrared (gallium aluminum arsenide) laser will be used at a wavelength of 808 nm and a power of 200 m W applied for 26 s to produce energy of less than 4 J/cm. participants will receive the same medical treatment (desmopressin acetate) and advice as in control group in addition to low level laser therapy 3 session / week for 6 weeks.
33074105|NCT05399173|Active Comparator|conventional therapy|They will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) & advice.
33074106|NCT05392738||Vivity with i-Stent|Patients with Glaucoma or Ocular Hypertension undergoing simultaneous cataract and i-Stent implantation, with Vivity intraocular lens
33074107|NCT05392738||Glaucoma with Vivity|Patients with Glaucoma or Ocular Hypertension undergoing isolated phacoemulsification with Vivity intraocular lens
33074108|NCT05392738||Healthy with Vivity|Patients with undergoing isolated phacoemulsification with Vivity intraocular lens
32934199|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
32934200|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status~Stool sampling before preventive gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
32934201|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
32934202|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
32934203|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
32934204|NCT05217277||patient with juvenile idiopathic arthritis and gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and gingivitis, have not used medication yet.
32934205|NCT05217277||healthy patient group with gingivitis|It is a group of healthy patients with gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
32934206|NCT05217277||healthy patient group without gingivitis|It is a group of healthy patients without gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
32934207|NCT05217277||patient with juvenile idiopathic arthritis and without gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and without gingivitis, have not used medication yet.
32934208|NCT05216497|Experimental|Ingavirin®, 90 mg capsules|Ingavirin®, 90 mg capsules will be administered on top of standard therapy: days 1-3: 180 mg (2 capsules once a day); days 4-7: 90 mg (1 capsule 1 time per day).
32934209|NCT05216497|Placebo Comparator|Placebo|Placebo capsules will be administered on top of standard therapy: days 1-3: 2 capsules once a day; days 4-7: 1 capsule 1 time per day.
32934210|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
32934211|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
32934212|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
32934213|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
32934214|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
32934215|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
32934216|NCT05473832|Experimental|Group 1|
32934217|NCT05473832|Experimental|Group 2|
32934218|NCT05473832|Experimental|Group 3|
32934219|NCT05473832|Experimental|Group 4|
32934220|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
32934221|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
32934222|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
33074109|NCT05388799|Experimental|application group|Before the operation, training will be given in line with the training brochure prepared by the researcher in the outpatient clinic and the printed version of the training brochure will be given to the patient. The training will be repeated by calling the patients the day before the surgery.
33074110|NCT05388799|No Intervention|control group|Standard care will be applied.
33074111|NCT05387746|Other|Caring Science, Mindful Practice and Reiki Training|
33074112|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
33074113|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
32729884|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
32729885|NCT04445467|Experimental|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
32729886|NCT04445467|Placebo Comparator|Placebo|Matched Placebo
32729887|NCT03382795|Experimental|EGFR retreat group|
32729888|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
32729889|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
33074114|NCT00532558|Placebo Comparator|Placebo QD|
33074115|NCT05386849|Experimental|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
33074116|NCT05385601||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
33074117|NCT05385601||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
33074118|NCT05377099|Active Comparator|Laser In situ Keratomileusis (LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after LASIK
33074119|NCT05377099|Active Comparator|Femto-second assisted LASIK (FS-LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after Femto LASIK
33074120|NCT05377099|Active Comparator|Photorefractive Keratectomy (PRK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after PRK
32729890|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
32729891|NCT03382717|Experimental|Excilor Forte|
32729892|NCT03382717|Active Comparator|Loceryl 5%|
32729893|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
32729894|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
33074121|NCT05364268||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
33074122|NCT04687384|Experimental|Robotic-assisted surgery|Patients undergoing robotic-assisted colectomy for colonic neoplasm
33401162|NCT05010772|Experimental|Arm B (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32729895|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
32729896|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
32729897|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
32769101|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
32769102|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
32769103|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
32729898|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
32729899|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
32729900|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
32934223|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
32934224|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
32729901|NCT03376945||trail cohort|n-3 FAs
32934225|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
32729902|NCT03376945||control cohort|Structolipid
32729903|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
32729904|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
32729905|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
32729906|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
32769104|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
32934226|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
32934227|NCT02505919|Experimental|Treatment|AQUABEAM System
32934228|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
32934229|NCT03963817||Normals|Imaging normal subjects for equipment refinement
32934230|NCT03963817||Subjects with AMD|Imaging subjects with AMD
32934231|NCT03916159|Experimental|Extrauterine Placental Transfusion EPT|Intervention group
32934232|NCT03916159|Active Comparator|Delayed cord clamping DCC|Control group
32934233|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
32934234|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
32934235|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
32934236|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
32934237|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
32934238|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
32934239|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
32934240|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
32934241|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
32934242|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
32934243|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
32934244|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
32934245|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
32934246|NCT00580736|Experimental|Optical Clearing|Optical Clearing
32934247|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
32934248|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
32934249|NCT05400980|Experimental|Urocross implant group|The investigational products in this trial are the Urocross Expander Implant as delivered by the Urocross Expander System and the Urocross Retrieval Sheath used to retrieve the implant after 6 months following its implant.
32934250|NCT05400980|Sham Comparator|Sham-control group|The sham-control in this trial is cystoscopy only.
32934251|NCT05379218|Experimental|Intervention Arm - Remote Ischemic Conditioning|Remote Ischemic Conditioning
32934252|NCT05379218|No Intervention|Control Arm - No Remote Ischemic Conditioning|No intervention. A blood pressure cuff will be placed on the infant's arm but will not be inflated.
32729907|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Merestinib~LY2874455"
32729908|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
32934253|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik"
32934254|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo"
33252444|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
32729909|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
32729910|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
33252445|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
33252446|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
32729911|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
32729912|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
32729913|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
32729914|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
32729915|NCT03373201|Experimental|Tasimelteon|
32729916|NCT03373201|Placebo Comparator|Placebo|
32729917|NCT03382405|Experimental|mRNA-1647|
32729918|NCT03382405|Experimental|mRNA-1443|
32729919|NCT03382405|Placebo Comparator|Placebo|
32769105|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
32934255|NCT05345210|Active Comparator|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po Clarithromycin 500mg bid po for 14 days
32934256|NCT05345210|Experimental|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 14 days
32934257|NCT05345210|Experimental|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 7 days
32934258|NCT05345210|Experimental|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 14 days
32934259|NCT05345210|Experimental|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 7 days
32934260|NCT00540566||Optical Biopsy|Optical Biopsy imaging
32934261|NCT05335148|No Intervention|Standard of care arm - placebo colchicine pill|The standard of care arm will receive a placebo colchicine pill once a day
32934262|NCT05335148|Experimental|Experimental arm - oral colchicine once a day|The experimental arm will receive 0.6 mg of oral colchicine once a day
32934263|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
32934264|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
32934265|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
32729920|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
32729921|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
32729922|NCT03717727|Experimental|Exergame|Home-based exergame intervention and usual treatment.
32729923|NCT03717727|Experimental|Control|Home-exercise by standard protocol and usual treatment.
32729924|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
32729925|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
33074123|NCT04687384|Active Comparator|Laparoscopy|Patients undergoing conventional laparoscopic colectomy for colonic neoplasm
33074124|NCT00151580|Experimental|1|Ribavirin maintenance treatment
33074125|NCT00151580|Placebo Comparator|2|
33074126|NCT00532597|Experimental|O|
33074127|NCT00532597|Active Comparator|L|
33074128|NCT00532636|Active Comparator|1|Children 1-5 years of age
32729926|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
32729927|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
33074129|NCT00532636|Active Comparator|2|Children 6-10 years of age
33074130|NCT05341960|Experimental|Food Delivery|Food box delivered to participant home every 2 weeks until 6 weeks post delivery
33074131|NCT05341960|Experimental|Financial Support and Navigation|$30 provide on gift card every two weeks until 6 weeks post delivery + neighborhood food retail navigation support.
33074132|NCT05341960|No Intervention|Control Group|Selected from claims data, matched.
33074133|NCT00171912|Experimental|imatinib mesylate (STI571)|
33074134|NCT05338567||Open/laparoscopic surgery|Small bowel length measurement by laparoscopy or laparotomy
33074135|NCT05338567||3D reconstruction|Small bowel length measurement by 3D digital model
33074136|NCT05332015|Active Comparator|Oral hydration with normal water|Oral hydration with drinkable normal water daily additional 2 liters for 5 days
32729928|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
32729929|NCT03372811|Active Comparator|TC cream (10%)|
33074137|NCT05332015|Active Comparator|Oral hydration with distilled water|Oral hydration with distilled water daily 2 liters for 5 days
33074138|NCT05324761|Active Comparator|Pregabalin|A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
33074139|NCT05324761|Active Comparator|Gabapentin|A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm
33074140|NCT00532675|Experimental|PAN 5 mg|Panobinostat 5 mg
33074141|NCT00532675|Experimental|PAN 10 mg|Panobinostat 10 mg
33074142|NCT00532675|Experimental|PAN 20 mg|Panobinostat 20 mg
33074143|NCT00532675|Experimental|PAN 25 mg|Panobinostat 25 mg
32729930|NCT03372811|Placebo Comparator|Vehicle|
32729931|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
32729932|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
32729933|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
32729934|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
33074144|NCT05300659|No Intervention|Standard Care|
33074145|NCT05300659|Experimental|ARNI care|
33074146|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
33074147|NCT00164619|Active Comparator|2|Standard STD clinic services
33074148|NCT05299957||oropharyngeal squamous cell carcinoma|a total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker, or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Each enrolled patients will undergo detail clinical examination, including human papillomavirus test.
33074149|NCT05293600|Placebo Comparator|Placebo|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
33082200|NCT04622059|Experimental|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
33082201|NCT04622059|No Intervention|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
33082202|NCT04621903|Experimental|Ayurveda|
33252447|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
33252448|NCT00903747|Experimental|1|Prucalopride
33401163|NCT05010772|Experimental|Arm C (decitabine and cedazuridine, gilteritinib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32934266|NCT01712191|Experimental|NUsurface Meniscus Implant|
32934267|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
32934268|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
32934269|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
32934270|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
32934271|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.~Pain medication according to national protocol."
32934272|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
32934273|NCT04707859||Cohort|"Participants consenting to the study will undergo:~a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years~Patients with suspicion of coronary stenosis detected by CCTA will after undergo:~b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)"
32934274|NCT02713646||patients with primary trigeminal neuralgia|
32934275|NCT02713646||healthy subjects|
32934276|NCT04708093|Experimental|whole body vibration training (WBVT)|whole body vibration group
32934277|NCT04708093|No Intervention|Controlled|advised about healthy dieting
32934278|NCT05237180|Experimental|patient group|8 training sessions on spatial localisation
32934279|NCT05237180|No Intervention|control croup|Non training sessions
32934280|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
32934281|NCT00596401||1|HP eradication group
32934282|NCT00596401||2|No eradication group
32934283|NCT00596401||3|No Hp group
32934284|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
32934285|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
32934286|NCT00534469|Experimental|HD ARA-C with or without Idarubicin|"This study was designed as a single-arm study.~Strata were:~HD ARA-C w/ Idarubicin, CR<6 months N = 24 patients. HD ARA-C w/ Idarubicin, CR>6 months N=1. HD ARA-C consolidation, CR<6 months N=5. HD ARA-C consolidation, CR>6 months N= 0."
32934287|NCT03757351|Experimental|DNL747 First, Placebo Second|
32934288|NCT03757351|Experimental|Placebo First, DNL747 Second|
32934289|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
32934290|NCT04341805|Active Comparator|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
32934291|NCT04341805|Experimental|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
32934292|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
32934293|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
32934294|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
32934295|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
32934296|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
32934297|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
32934298|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
32934299|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
33401164|NCT05010772|Experimental|Arm D (decitabine and cedazuridine, enasidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32729935|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
32729936|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
32729937|NCT03715231|Experimental|Glaucoma & Glaucoma Suspect Patients|Patients with Glaucomatous optic neuropathy
32729938|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
32729939|NCT03376243|No Intervention|Control|Only structured parent education
32729940|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
32769106|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
32934300|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
32934301|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
32934302|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
32934303|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
32934304|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
32934305|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
32934306|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
32934307|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
32934308|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
32934309|NCT04341961|Experimental|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
32934310|NCT03545035||Study group|All patients being observed during the study duration.
32934311|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
32934312|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
32934313|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
32934314|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
32934315|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
32934316|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
32934317|NCT04743115|Experimental|the Dose Escalation Level|"In the first 3-patient cohort, the dose of BS HH 002.SA will be 0.2 mg/m2/day. Enrollment to the next higher dose cohort will be initiated only if none of the 3 patients exhibits a DLT in the first 28-day cycle. Dose escalation will proceed according to a modified Fibonacci scheme, eg, increments of 100%, 100%, 66%, and 33% and the dose of BS-HH-002.SA will be 0.4, 0.8, 1.3, 1.7 mg/m2/day.~The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle."
32934318|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
32729941|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
32729942|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
32729943|NCT03700411|Active Comparator|Morphine|Morphine-based perioperative analgesia
33074150|NCT05293600|Active Comparator|Interventional arm|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
33074151|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
33074152|NCT05283070||Control|Volunteers without preexisting chronic pain and/or mental health issues
33074153|NCT05283070||Patients with chronic pain|Patients with chronic pain and/or mental health issues
33252449|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
33252450|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
33252451|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
33252452|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
33252453|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
33252454|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
33074154|NCT00151736|Experimental|Chlorambucil|Regime A
33074155|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
33074156|NCT05257174|Experimental|Jing Si Herbal Tea LIQUID PACKETS|one packet oral twice daily for three months
33074157|NCT05257174|Placebo Comparator|Placebo|one packet oral twice daily for three months
33074158|NCT05254210|Experimental|Treatment with RF Device|Subjects may receive up to 3 treatments with the RF device if they are willing to receive treatment for brow lifting and/or present with conditions such as, but not limited to; wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, loose skin on the face, neck and/or body
33252455|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
33252456|NCT00899457||Healthy, non-smokers|
33252457|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
33252458|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
33082203|NCT04621942|Experimental|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
33082204|NCT04621942|Active Comparator|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
32729944|NCT03700411|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
33252459|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
33252460|NCT00903903||1|RA patients with at least one active synovitis
33252461|NCT00903903||2|Non-RA patients with at least one active synovitis
33252462|NCT00903981|Experimental|Avanafil 100mg|
33252463|NCT00903981|Experimental|Avanafil 200mg|
33252464|NCT00903981|Placebo Comparator|Placebo|
33252465|NCT00904059|Experimental|Treatment Group A|
33252466|NCT00904059|Experimental|Treatment Group B|
33252467|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
33252468|NCT00348673|Experimental|Stage 1|
33252469|NCT00348673|Experimental|Stage 2|
33252470|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
32729945|NCT03700411|Active Comparator|Epidural|Perioperative epidural analgesia containing an opioid
32729946|NCT03691051|Experimental|Pyrotinib Plus Capecitabine|Pyrotinib + Capecitabine
32729947|NCT03372577|Experimental|patient and partner|
32729948|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
33252471|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
33252472|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
33252473|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
33252474|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
33252475|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
33252476|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
33252477|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)
33252478|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
33252479|NCT00337207|Experimental|Avastin|
33252480|NCT01052857|Experimental|1|acupuncture daily fo 7 days
33252481|NCT01052857|No Intervention|2|observation
33252482|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
33252483|NCT01055743|Active Comparator|Radical resection|
33252484|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
33252485|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
32729949|NCT03372577|Active Comparator|Treatment as usual|
33252486|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
33252487|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
33252488|NCT01055821|Experimental|Arm C|vaccine and standard of care
32934319|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
33252489|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
33252490|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
33252491|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
33252492|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
33252493|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
33252494|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
33252495|NCT03985423|Experimental|Emapalumab|
33252496|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
32729950|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
32729951|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
32729952|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
32934320|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
32729953|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
32729954|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
32934321|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
32934322|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
32934323|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
32934324|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
32934325|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
32934326|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
32934327|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
32934328|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
32934329|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
32934330|NCT05372575|Other|PCV13 group and non PCV13 group|This study plan to recruit those young patients who have or not have got PCV13 vaccine before study start
32934331|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
32934332|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
32934333|NCT05372497|Experimental|intervention group|
32934334|NCT05372497|Experimental|control group|
32934335|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32934336|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32934337|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32934338|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32934339|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32729955|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
33252497|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
32729956|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
32729957|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
32729958|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
32729959|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
32729960|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
32934340|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
32934341|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
32934342|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
32934343|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~Residual stenosis after lesion preparation : %DS <20%~Delivery time : < 30 seconds~Total inflation time : > at least 1 minute~Previous BVS : DEB diameter ratio : > 1.0:1~Maximum inflation pressure : at least above nominal pressure of DEB"
32934344|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
32934345|NCT05673811|Active Comparator|Arm 1-SoC|Nab-paclitaxel and gemcitabine as SoC.
32934346|NCT05673811|Experimental|Arm 2 -VCN-01 + SoC|A maximum of two (2) doses of VCN-01 administrated as a single IV infusion in combination with nab-paclitaxel and gemcitabine as SoC.
32934347|NCT04340869|Experimental|Theobromine|Natural extract from Cocoa
32934348|NCT04340869|Active Comparator|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
32934349|NCT04340869|Experimental|Combination|Remin Pro and Theobromine
32934350|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for approximately 72 patients enrolled in dose-finding and second portions and 84 weeks for approximately 28 patients enrolled in third portion)
32934351|NCT05668819|Experimental|TH-001|
32934352|NCT05668819|No Intervention|Control|
32934353|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
32934354|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
32934355|NCT02460835|Experimental|Adaptive Radiation Therapy|
32934356|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
32934357|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy"
32934358|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy~Associated with hormonal therapy by degarelix:~beginning in parallel to radiotherapy for 6 months~First dose of 240 mg~Maintenance dose of 80 mg"
32934359|NCT05619289|Active Comparator|Vitamin D2 (Ergocalciferol)|One time, oral dose of Vitamin D2 administered via 6 50,000 IU Ergocalciferol capsules. Capsules will be encapsulated and masked to be indistinguishable from placebo.
32934360|NCT05619289|Placebo Comparator|Placebo|One time, oral dose of 6 placebo capsules filled with inert powder and encapsulated and masked to be indistinguishable from active comparator.
32934361|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
32934362|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
32934363|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
32934364|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
32934365|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
32934366|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
32934367|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
33252498|NCT00900549|Experimental|CRT|
33252499|NCT00900549|Sham Comparator|No CRT|
33252500|NCT00904449|Experimental|Open Label|
33401165|NCT05010772|Experimental|Arm E (decitabine and cedazuridine, ivosidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33401166|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
33401167|NCT02464696|Experimental|Arm A (NIPPV therapy)|Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
32934368|NCT05578261|Experimental|Active|"All of the participants will accept one session iTBS over right Crus I/II. The total pulses of every session are 1200 pulses (600 pulses with 15 minutes interval)~*iTBS = intermittent theta burst stimulation."
32934369|NCT02599441||Ankle fracture cases|
32729961|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.~Interventions:~Blood sample for serum and plasma biomarkers:~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
32934370|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
32934371|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
32729962|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
32729963|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
32769107|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
32934372|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
32934373|NCT04743193||sevoflurane 8 %|In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
32934374|NCT04743193||sevoflurane 2.5 %|In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
32934375|NCT05371249|Experimental|Vonoprazan-based triple therapy group|Including patients receiving vonoprazan-based triple therapy (vonoprazan 20mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days)
32934376|NCT05371249|Active Comparator|Extended sequential therapy group|Including patients receiving extended sequential therapy (lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days)
32934377|NCT05371171|Experimental|skin graft|
32934378|NCT05371171|Placebo Comparator|no skin graft|
32934379|NCT05370937|Active Comparator|ELEVATOR|After knotting the posterior root of the medial meniscus with a fiber rope, a tunnel will be opened for the rope to pass through the medial of the proximal crest of the tibia. Then, arthroscopically, the rope will be taken through the joint and passed through the tunnel, and the knot will be fixed to the tibia by using the endobutton elevator system
32934380|NCT05370937|Active Comparator|FREE KNOT|The first stage of fixation is the same, and fixation to the tibia will be done with an endobutton by tying a free knot without using an elevator system.
32934381|NCT05366491|Active Comparator|bronchial asthma patients|patients diagnosed with bronchial asthma
32934382|NCT05366491|Active Comparator|healthy controls|healthy subjects with age and sex matched to bronchial asthma patients
32934383|NCT05574127|Experimental|Older Adult Cancer Survivors (OACS) - Behavioral Activation (BA)|Older adult cancer survivors (OACS) will receive a Behavioral Activation intervention
32934384|NCT05574127|Experimental|Older Adult Cancer Survivors (OACS) - Supportive Psychotherapy (SP)|Older adult cancer survivors (OACS) will receive a Supportive Psychotherapy intervention
32934385|NCT05572645||PyroH|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
32934386|NCT05572645||PertH|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
32934387|NCT05362591|Experimental|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
32934388|NCT05362591|Active Comparator|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation on tooth enamel
32934389|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
32934390|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
32934391|NCT05555095||OSF HealthCare|Subjects from OSF HealthCare
32934392|NCT05555095||Federally Qualified Health Center (FQHC) - 1|Subjects from Eagle View Community Health System enrolled in MIC Program
32934393|NCT05555095||Federally Qualified Health Center (FQHC) - 2|Subjects from Chestnut Health System Inc. enrolled in MIC Program
32934394|NCT05555095||Federally Qualified Health Center (FQHC) - 3|Subjects from Heartland Community Health System enrolled in MIC Program
32934395|NCT05555095||Federally Qualified Health Center (FQHC) - 4|Subjects from Aunt Martha's enrolled in MIC Program
32934396|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
32934397|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
32934398|NCT05554861|Experimental|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
33074159|NCT05242939|Experimental|The Group of Cartoons|The cartoons that are suitable for the child's age and gender will be watched. The child will be asked which cartoon he would like to watch. The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher. Due to the COVID-19 pandemic, cartoons will be watched on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will watch cartoons on their parent's phone.
33074160|NCT05242939|Experimental|The Group of Game|723 / 5.000 Çeviri sonuçları The group whose video games will be played will be told to choose the game they want before the process. Due to the COVID-19 pandemic, video games will be played on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will play the video game on their parent's phone.
33252501|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
33252502|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
33252503|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
33252504|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
33252505|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
32729964|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
32729965|NCT03381547|Active Comparator|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
32729966|NCT03381547|Active Comparator|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
32729967|NCT03381547|Active Comparator|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
32729968|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
32729969|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
32729970|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
32729971|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
32729972|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
32729973|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
32729974|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
32729975|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
32729976|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
32729977|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
32729978|NCT03381391|Experimental|Feedback intervention condition|
32729979|NCT03381391|No Intervention|Assessment-only control condition|
32729980|NCT03375931|Experimental|prayer group|
32729981|NCT03375931|Active Comparator|non-prayer group|
32729982|NCT03550183|Experimental|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
32729983|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
32729984|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
32729985|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
32729986|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
32729987|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
32769108|NCT05035381|Experimental|Experiment Group|
32729988|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
32729989|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
32729990|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
32729991|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
32729992|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
33074161|NCT05242939|No Intervention|Rutin Care Group|In the control group, the institution's routine nebula application will be performed and no intervention will be made. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
33252506|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
33252507|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
33252508|NCT00904761|Experimental|exercise|arm: intervention
32729993|NCT03381157||Cystic Fibrosis Group|
33074162|NCT00164697|Experimental|1|Parenting group
33074163|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
33074164|NCT05236075|Experimental|patients with polysomnography diagnostic of obstructive sleep disorders moderate to severe|
33074165|NCT04725578|Experimental|Telehealth Single Session Consultation|
33074166|NCT04687345||Propeller Flap|The propeller flap is based on a perforator that serves as a pivot joint, allowing the flap to rotate up to 180°. It provides the advantages of greater freedom of movement and versatility in flap design.
32729994|NCT03381157||Control Group|
33074167|NCT04687345||Rotation Flap|The rotation flap is primarily supplied by the perforator artery accompanied by the random supply from the skin base. It is also associated with a lower venous congestion risk.
33074168|NCT00532792|Experimental|Group 1|
33074169|NCT00532792|Experimental|Group 2|
33074170|NCT00532792|Experimental|Group 3|
33074171|NCT00532792|Experimental|Group 4|
33074172|NCT00532792|Experimental|Group 5|
33074173|NCT00532792|Experimental|Group 6|
32729995|NCT04527133|Experimental|Stage 1/Group 1|Intravenous Aprotinin in addition to standard care: 1 000 000 KIU IV daily during 3 days
33074174|NCT00532792|Experimental|Group 7|
33074175|NCT00532792|Experimental|Group 8|
33074176|NCT00532792|Experimental|Group 9|
33074177|NCT00532792|Placebo Comparator|Group 10|
33074178|NCT04687423|Experimental|Experimental: phase I dose exploration|FCN-011 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
32729996|NCT04527133|Experimental|Stage 2/Group 2|Inhaled Aprotinin in addition to standard care: 625 KIU 4 times per day during 5 days
32729997|NCT04527133|Experimental|Stage 2/Group 3|Intravenous Aprotinin in addition to standard care that includes Favipiravir: 1 000 000 KIU IV daily during 5 days
32729998|NCT03371563||elderly patients|
32729999|NCT03371563||middle-aged patients|
32730000|NCT03371563||controls|
32730001|NCT03371563||young patients|
32730002|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
32730003|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
32730004|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
32730005|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
32730006|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
32730007|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
32730008|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
32730009|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
32730010|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
32730011|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
33074179|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
33074180|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
33074181|NCT04687189|Experimental|Women with a known history of submucosal fibroids|
33074182|NCT04687189|Experimental|Women recruited from a general population subject to I/E criteria|
33074183|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
33074184|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
33074185|NCT00406094|Experimental|1|montelukast
33074186|NCT00406094|Placebo Comparator|2|placebo
33074187|NCT00532870|Active Comparator|1|laparoscopy
33074188|NCT05178121|Experimental|Project WISE eLearning Training in Suicide Safety Planning|
33074189|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
33074190|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
33074191|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
33074192|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
33252509|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
33074193|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
33074194|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
32730012|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.~HR is monitored throughout each session and stored for analysis."
33074195|NCT04725383|Active Comparator|amitriptyline|Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 12 weeks.
32730013|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.~HR is monitored throughout each session and stored for analysis."
33074196|NCT04725383|Placebo Comparator|placebo|Subjects in this arm will receive placebo compounded into capsules that resemble the compounded amitriptyline capsules, up to 4 capsules a day (1 qam, 1 q4pm and 2 capsules qhs), for 12 weeks.
33074197|NCT05177146|Experimental|Intravenous Ketamine (IV)|
33074198|NCT05163730|Other|Panbio™ COVID-19/ Flu A&B Rapid Panel|"One nasal swab sample will be collected from both nostrils by operators and will be used to perform the Panbio™ COVID-19/ Flu A&B Rapid Panel test either in a laboratory or in a non-laboratory setting (e.g. GP centre or hospital clinic). Each Panbio™ COVID-19/ Flu A&B Rapid Panel result will be photographed by the observer at the time of test interpretation.~Nasopharyngeal samples will be collected and used for RT-PCR testing as per local procedures.~Nasal samples must always be collected prior to the Nasopharyngeal sampling."
33074199|NCT05142046||Pediatric cardiac surgery|The group consists of all the children who undergo cardiac surgery in our institution from 2008 to 2018. The age limit was from birth to 16 years old.
32730014|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
32730015|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
32730016|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
32730017|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
32730018|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
32730019|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
32730020|NCT03125317||The control group|no intervention
32730021|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
32730022|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
33074200|NCT00172068|Experimental|Treatment Group|
33074201|NCT00172068|Active Comparator|Control Group|
32730023|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
32730024|NCT03369925|Placebo Comparator|Placebo|
32730025|NCT03369925|Experimental|Cognizin|
32730026|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
32730027|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
32730028|NCT04526743||BS patients|Candidates to primary BS undergoing laparoscopic gastric bypass (LGBP) or laparoscopic sleeve gastrectomy (LSG) from September 2020 to September 2021. Patients will be evaluated prior to BS and at 4 months, 1, 3 and 5 years after BS.
32730029|NCT04526743||no BS patient|A control group of subjects with obesity not candidates to BS matched with the intervention group for age, sex and BMI prior to BS. Patients will be evaluated once.
32730030|NCT04526431||Tacrolimus once-daily|Patients receiving tacrolimus as a once-daily formulation (Envarsus)
32730031|NCT04526431||Tacrolimus bid|Patients receiving tacrolimus as a twice-a-day formulation.
32730032|NCT04526353|Experimental|Oxybutynin during 9 months.|0.1mg / kg 2x / day from inclusion and for 9 months.
32730033|NCT04526353|No Intervention|No oxybutynin|No treatment affecting bladder function
32730034|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
32730035|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
32730036|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
33074202|NCT05120830|Experimental|Phase 1 Study Arm|Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
33074203|NCT05120830|Experimental|Phase 2 Experimental Study Arm|Participants randomized to NTLA-2002 (2 dose levels), will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
33074204|NCT05120830|Placebo Comparator|Phase 2 Placebo Comparator Study Arm|Participants randomized to placebo will receive IV normal saline on Day 1 and will then be followed for up to 104 weeks. Primary observation period is 16 weeks.
33074205|NCT05119816|Experimental|music therapy group|Patients receive an individual intervention of receptive music therapy during biopsy
33074206|NCT05119816|No Intervention|Control group|Patients receive standard care
33074207|NCT05117164|No Intervention|control group|Patients will receive enteral feeding based on the practice of the leading physician.
33074208|NCT05117164|Experimental|intervention|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
33074209|NCT05095987|Experimental|One day discharge after laparoscopic Appendectomy|
33074210|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
33074211|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
33074212|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
33074213|NCT05087641|Experimental|IAB System|Patients will be treated with IAB(s)
32730037|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
32730038|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
32730039|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
32730040|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
32730041|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
33074214|NCT05077501|Experimental|ACD856|
33074215|NCT05077501|Placebo Comparator|Placebo|
32730042|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
32730043|NCT03363451||Infection Group|Patients with end stage liver disease with infection
32730044|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
32730045|NCT04525963|Experimental|Experimental: Intervention Arm|":In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read.~Assigned Interventions The level of anxiety experienced by the patients increases the postoperative perception and analgesic need, increasing the sequence and anesthetic substance. For these reasons, there is a need for studies to reduce pain distribution and severity by directly dealing with pre- and postoperative anxiety and anxiety levels. Similarly, the role of the operating room nurse in reducing patient anxiety is increasingly recognized. It is observed that the pre-operative visit and education reduce the pre-operative anxiety level in patients undergoing surgical intervention, and the pre-operative visit of the operating room nurse is on the agenda."
32730046|NCT04525963|No Intervention|No Intervention|There will be no intervention in the control group. The procedures of the institution will be applied before and after the operation.
32730047|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
32730048|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
32730049|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
32730050|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
32730051|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
33074216|NCT05075317|Active Comparator|Standard cardiac rehabilitation|The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
33074217|NCT05075317|Experimental|Standard cardiac rehabilitation + TRE|Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counselled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
33074218|NCT05074771|Experimental|ARC intellicare|"Study participants will use ARC intellicare at home, to carry out usability tests and a collection of useful data in order to optimise the system. After enrolment and training session, patients will receive an ARC unit to be used autonomously for the following 30 days.~45 minutes 5 days / week for 4 weeks of personalized training will be carried out by the enrolled subjects: 4 weekly sessions will be unsupervised, while one will be supervised remotely by a therapist in telepresence, thanks to the integrated audio-video channel."
33252510|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
33252511|NCT02538705|Experimental|Neovasculgen|
33252512|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
32934399|NCT05554861|Active Comparator|Intermittent Theta Burst Stimulation (iTBS) Protocol|It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
33252513|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
32934400|NCT05554861|Placebo Comparator|Sham rTMS Protocol|It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.
32934401|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
33252514|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
33252515|NCT00605085|Experimental|1|IC51
32730052|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
32730053|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
32730054|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :~Sulodexide (250ULS, twice daily , oral administration)~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
32730055|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
32730056|NCT04525807||Multiomics arm|Guide therapy based on multi-omics
32769109|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
32934402|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
32934403|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
32934404|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
32934405|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
32934406|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
32934407|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
32934408|NCT05553769|Experimental|10 week training, 10 week detraining, 10 week retraining|Participants (healthy untrained men and women, age 18-40) will conduct 10-week RT intervention and a 10-week DT period and the exact same 10-week RT intervention again. RT consists of two training sessions per week of total body workouts.
32934409|NCT05553769|Experimental|10 week non-training, 20 week continuous training|Participants (healthy untrained men and women, age 18-40) start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts.
32934410|NCT05552287|Experimental|Intensified induction scheme with Infliximab|Intensified induction scheme with Infliximab. IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks.
32934411|NCT05550571|Experimental|Patients treated with the device|
32934412|NCT05226169|Experimental|Active treatment arm : IV FCM|Intravenous ferric carboxymaltose
32934413|NCT05226169|Active Comparator|Control treatment arm: Conservative management|"Conservative management~Absolute IDA: oral ferrous sulfate~Functional IDA: no treatment or oral ferrous sulfate according to the physician's choice~Other IV iron or PRC transfusion or ESA therapy is not allowed"
32934414|NCT05539573||Treatment|Patients with planned transcatheter treatment of severe aortic stenosis with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.
32934415|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
32934416|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
32934417|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
32934418|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
32934419|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
33401168|NCT02464696|Active Comparator|Arm B (high flow oxygen therapy)|Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
32934422|NCT05528419|Experimental|Sacubitril valsartan|
32934423|NCT05528419|Active Comparator|Valsartan|
32934424|NCT04340713|Experimental|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
33252516|NCT00605085|Placebo Comparator|2|Placebo
33074219|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
33074220|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
33074221|NCT05062876|Active Comparator|R-T|Period 1 : Test Drug(AD-214) Period 2 : Reference Drug(AD-2141)
33074222|NCT05062876|Active Comparator|T-R|Period 1 : Reference Drug(AD-2141) Period 2 : Test Drug(AD-214)
33252517|NCT00905463||Transplantation|Lung transplantation candidates
33074223|NCT05060068|Placebo Comparator|Placebo group|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
33074224|NCT05060068|Experimental|Low-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
33074225|NCT05060068|Experimental|High-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
33074226|NCT04687111|Active Comparator|Control|Valsartan 40mg bid titrated to maximum dose of 160mg bid
33074227|NCT04687111|Experimental|Intervention|Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid
33252518|NCT00905541|No Intervention|No treatment|Phase A: No treatment
33252519|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
33074228|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
33074229|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
33074230|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
33252520|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
33252521|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
33074231|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
33074232|NCT00152126|Other|1|
32730057|NCT04445077|Experimental|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
32730058|NCT04445077|Other|Control group|Printed materials will be given to the participants in the control group for their self-study.
32730059|NCT03370627|Experimental|Patient|
32730060|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
33074233|NCT05045677|Experimental|Digital DBT intervention group|Digital intervention group plus standard care
33074234|NCT05045677|Active Comparator|Standard care|Standard care alone
33074235|NCT05043883|Experimental|Single Group|Index EP Procedure: Ablation of atrial fibrillation
33074236|NCT05039593|Experimental|first group|The patients in the first group will be given oral care with 0.12% chlorhexidine twice a day.
33252522|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
33252523|NCT00905619||Control|No kidney disease
33252524|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
33252525|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
33252526|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
32730061|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
32730062|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
32730063|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
33074237|NCT05039593|Experimental|second group|The patients in the second group will be given oral care with 0.12% chlorhexidine 3 times a day.
33074238|NCT05039593|Experimental|third group|The patients in the third group will be given oral care with 0.12% chlorhexidine 4 times a day.
33252527|NCT03987295|Experimental|Granulin|IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]
33252528|NCT03987295|Experimental|C9orf72|IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]
33252529|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
33252530|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
33252531|NCT00906633||Outcome of combination antifungal therapy|
33252532|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
33252533|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
33252534|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
32730064|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
32730065|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
32730066|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
32769110|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
33074239|NCT00425451|Experimental|PerioChip Plus|
33074240|NCT00425451|Experimental|Flurbiprofen Chip|
33074241|NCT00425451|Active Comparator|PerioChip|
33074242|NCT00425451|Placebo Comparator|Placebo Chip|
33074243|NCT05031637|Experimental|treatment by night-time BP|titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of <120 mmHg; intervention group)
33074244|NCT05031637|Other|treatment by daytime BP|Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of <135 mmHg; control group)
33074245|NCT05001451|Experimental|GDX012 Suspension for IV Infusion|Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells
33074246|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
33074247|NCT00152204|No Intervention|2|
33074248|NCT04686877|Experimental|STAPLE group|For patients in STAPLE group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided aspiration followed by urokinase clot irrigation (every 12 h for up to 5 days or until reduction of ICH to ≤10 mL). CT will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset. On the 1st, 3rd, 5th, and 7th day of post-operation, patients will be re-examined using CT. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
33074249|NCT04686877|No Intervention|Conservative treatment group|We used the 2015 ASA/AHA and 2020 Chinese multidisciplinary expert consensus recommendations for treatment of spontaneous intracerebral hemorrhage, including a standard approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacological treatment of intracranial mass effect. Patients allocated to the standard medical care group had follow-up CT scans and other monitoring assessments on the same schedule as those in the STAPLE group. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
33074250|NCT04956445||Population 1|Once a positive diagnosis of COVID-19 has been made in the clinical setting, the clinical team caring for the patient will ask the patient / family whether they would be willing to be contacted by the study team about the study. If so, a trained member of the study team will describe the study in person or by telephone. Community members who see the study flyer will also be able to reach out to the study team to learn more about the study and to find out if they meet eligibility criteria. If the eligible patient / legally authorized representative / legal guardian would like to participate. The verbal informed consent / verbal HIPAA, assent, and/or parental permission (as appropriate) will then be obtained in person.
33074251|NCT04956445||Population 2|Persons with a history of past (>14 days ago) diagnosis of COVID-19 infection will be invited to participate in this study. In addition, persons who have had significant exposure to a patient with COVID-19 (contact at a distance of less than 6 feet without personal protective equipment) and have remained asymptomatic for 14 days following exposure will be recruited. Candidates will be identified through initial enrollment in Population 1, or by clinicians who have been informed of the study but are not part of the study team. Then, the clinical care team will ask the patient if he/she is willing to be contacted by the study team. Community members who see the study flyer or are otherwise informed of the study will also be able to reach out to the study team. Additionally, individuals with no defined past COVID-19 infection, but the potential to have been exposed to, and mounted antibodies against, COVID-19 will also be enrolled in Population 2 for this study.
33074252|NCT00152243|Experimental|1|UFT (uracil, tegafur)
33074253|NCT00152243|Other|2|Surgery alone
33074254|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
33074255|NCT00172107|Experimental|2|50 mcg PTH(1-84)
33074256|NCT00172107|Experimental|3|75mcg PTH(1-84)
33074257|NCT00172107|Experimental|4|100 mcg PTH(1-84)
33074258|NCT04945837|Other|unique study arm|Initial socio-demographic questionnaire 5 timepoints psychologic and self-administered questionnaires
33074259|NCT04686955|Experimental|Group A|Group A will receive Xiao-Xian-Gui-Fu-Tang three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks. Post-follow-up will be 4 weeks later.
33074260|NCT04686955|Placebo Comparator|Group B|Group B will receive a placebo three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang for another 6 weeks. Post-follow-up will be 4 weeks later.
33074261|NCT04933474|Experimental|painTRAINER (2D mHealth intervention)|Participants will use one of the most widely-validated mHealth interventions for pain management called painTRAINER®, which is a standardized, 56-day program delivering skills training and Cognitive behavioral therapy (CBT)-related treatments through daily virtual experiences.
33074262|NCT04933474|Experimental|Skills-based VR Therapy|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
33074263|NCT00152282|Experimental|1|
33074264|NCT00152282|Experimental|2|
33074265|NCT00152282|Experimental|3|
33252535|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
33252536|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
33252537|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
33252538|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
33252539|NCT00336505|Active Comparator|Clarithromycin|
32730067|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
32730068|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
32730069|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
33252540|NCT00336505|Experimental|Cethromycin|
32730070|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
32730071|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
32730072|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
32934425|NCT04340713|No Intervention|Routine care group|The control group was given routine information communication.
32934426|NCT05731921|Experimental|Experimental group|The exercise program with the 'Empathy Dress'
32934427|NCT05731921|No Intervention|Control group|No intervention
32934428|NCT04741867|Experimental|receiving health education|
32934429|NCT04741867|Experimental|Level of compliance|
32934430|NCT04741867|Experimental|Coping with stress|
32934431|NCT05731843|Experimental|BEM vs BEM + Ruzasvir n=16|
32934432|NCT05731843|Experimental|Ruzasvir vs Ruzasvir + BEM n=16|
32934433|NCT05506891|Experimental|Astragalus group|
32934434|NCT05506891|Active Comparator|Physical therapy group|
32934436|NCT04340791|No Intervention|Default proportion & no labelling|"No intervention:~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~No labelling."
32934437|NCT04340791|Experimental|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
32934438|NCT04340791|Experimental|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
32934439|NCT04340791|Experimental|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
32934440|NCT05731765||Patients aged ≥18 years with presumed normal intracranial pressure|
32934441|NCT05731765||Patients aged ≥18 years with suspected raised intracranial pressure|
32934442|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
32934443|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
32934446|NCT05487625|Experimental|Narratives|High-ventilated cigarette smokers will be exposed to a narrative about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
32934447|NCT05487625|Experimental|Fact sheet|High-ventilated cigarette smokers will be exposed to fact sheet about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
32934448|NCT05487625|Experimental|Control|High-ventilated cigarette smokers will be not be exposed to any messages and will complete all of the conditions described in the intervention section.
33074266|NCT00152282|Placebo Comparator|4|
33252541|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
32934449|NCT05485831||Lennox Gastaut and Dravet Syndrome|Participants aged 6-17 years of age diagnosed with LGS and DS.
32934450|NCT05483413|Experimental|Progressive Relaxation Exercises|Progressive relaxation exercises will be applied to this group for 8 weeks.
32934451|NCT05483413|No Intervention|Standard of Care|This group will continue their routine coping habits against sleep and fatigue problems in the postmenopausal period for 8 weeks.
32934452|NCT05480293|Experimental|SCT510A|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks
32730073|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
32730074|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
32934453|NCT05480293|Active Comparator|Ranibizumab|Ranibizumab(0.5mg), Vitreous injection, injection once every 4 weeks
32730075|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
32730076|NCT04525651|Experimental|Digital Acupuncture Instrument Group|The needles will be stimulated manually to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness) and then paired electrodes from the digital acupuncture instrument will be attached to the needle handles and another two adjunct acupoints by the research assistant. The electric current will be increased until the needles begin to vibrate slightly.
32730077|NCT04525651|Active Comparator|Manual Acupuncture Group|Patients in the MA group will undergo similar procedures as the EA group except that no current will be output from the instrument.
32730078|NCT04525651|Sham Comparator|Sham Acupuncture Group|Patients in the SA group will receive non-invasive acupuncture to avoid de qi.
32730079|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
32730080|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.~Intervention administered: Walking program with 3 different moments."
32730081|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
32730082|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
32934454|NCT05731609|Experimental|Resistance Intensive Personal Training (RIPT)|All participants will participate in this arm involving 12 weeks of training 2-3 days/week in a group setting with each session involving 1:1 support for each participant's power training.
32934455|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications~Small for gestational age at birth"
32934456|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
32934457|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~Congenital cardio-respiratory disease~Severe developmental delay"
32934458|NCT05461417||D-SAD group|Patients equipped with Panthera D-SAD MAO
32934459|NCT05731531|Other|Group A|Group of 50 patients who undergo BIG placement
32934460|NCT05731531|Other|Group B|Group of 50 patients who undergo endoscopic sleeve gastroplasty
32934461|NCT05731531|Other|Group C|Group of 50 patients who undergo Surgical sleeve gastrectomy
32934462|NCT05731531|Other|Group D|Group of 50 patients who undergo RYGB
32934463|NCT05731531|Other|Group E|Group of 50 healthy subjects
32934464|NCT05455489||FUNCTIONAL MR|Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy
32934465|NCT05455489||DEGENERATIVE MR|Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm)
32934466|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
32934467|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
32934468|NCT05449327|Experimental|Rivaroxaban|The participants are provided with Rivaroxaban 10mg
32934469|NCT05449327|No Intervention|Control|The participants are provided without antithrombotics
32934470|NCT05731375||Study population|Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with (R-)CHOP
32934471|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
32934472|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
32934473|NCT00364741|Active Comparator|B|FiO2 = 0.80
32730083|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32730084|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
32730085|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
32730086|NCT03362593|Experimental|MEDI7219|Experimental Drug
32730087|NCT03362593|Placebo Comparator|Placebo|Placebo
32730088|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
32730089|NCT03358459||EP|For diagnosis non-acquired epilepsy;
32730090|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
32934474|NCT05405413|Experimental|Subjects evaluated by Molecular Tumor Board|Subjects whose cases are evaluated by Molecular Tumor Board
32934475|NCT04743817|Experimental|OtoSet - Ear Cleaning Sytem|
32769111|NCT05043025|Active Comparator|Neck extension group|The cricothyroid membrane is identified in a neck extended position.
32934476|NCT04704973|Experimental|Transdiagnostic short-term psychotherapy|
32934477|NCT05731297||women victims of CRSV|"Inclusion criteria: Women victims of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~Exclusion criteria: Pregnant women and women under 18 years old."
32934478|NCT05731297||women without a history of CRSV|"Inclusion criteria: women without a history of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~Exclusion criteria: Pregnant women and women under 18 years old."
32934479|NCT05731219|Experimental|B7-H3 target, CAR gene modified gdT cell injection|UTAA06 injection After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 10^8，3.0 × 10^8 and 6.0 × 10^8 CAR gdT groups were administered once.
32934480|NCT05731063|Other|Ridge augmentation surgery|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts in anterior atrophic maxilla
32934481|NCT05730985|Experimental|Intevention group|Experimental formula (Miotrof®) to take 1 sachet per day for 4 months
32934482|NCT05730985|Placebo Comparator|Placebo group|Placebo formula to take 1 sachet per day for 4 months
32934483|NCT05384665|Experimental|Group A (placebo + remifentanil)|
32934484|NCT05384665|Experimental|Group B (sufentanil + placebo)|
32934485|NCT05384665|Placebo Comparator|Group C (placebo + placebo)|
32934486|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
32934487|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.~Patients will answer the MAR-Scale once every three months for a year."
32934488|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
32934489|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.~Patients will answer the MAR-Scale once every three months for a year."
32934490|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.~Patients will answer the MAR-Scale once every three months for a year."
32934491|NCT04441567|No Intervention|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
32934492|NCT04441567|Experimental|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
32934493|NCT05730751||Group F|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 % and 25 µg fentanyl [6].
32934494|NCT05730751||Group C|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 %
32934495|NCT05730517|Active Comparator|Test group 1 (CP5HA Group)|Participants will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL).
32934496|NCT05730517|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 15 mL: collagen: 0 mg, HA: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
32934497|NCT05730517|Active Comparator|Test group 2 (CP5 Group)|Participants will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 15 mL).
32934498|NCT05729347|Experimental|Virtual Reality|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
32934499|NCT05729347|No Intervention|Control|No intervention (i.e. virtual reality headset) will be applied to the participant.
32934500|NCT05355337|Active Comparator|Pramipexole|Pramipexole prolonged-release tablet, 0.26 mg base to 3.15 mg base / day for 9 weeks (individually varying dose titrating during these weeks).
32934501|NCT05355337|Placebo Comparator|Placebo|Tablets in appearance identical to the active comparator tablets, but without the the active substance (pramipexole).
32934502|NCT04340401|Experimental|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
32934503|NCT05281471|Experimental|Olvi-Vec + Platinum-doublet & bevacizumab|"Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0~Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5"
32934504|NCT05281471|Active Comparator|Platinum-doublet & bevacizumab|Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 0
33252542|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
33252543|NCT03990337|No Intervention|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
32730091|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
32730092|NCT04522297|Experimental|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
33252544|NCT03990337|Active Comparator|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
33252545|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
32730093|NCT04522297|Active Comparator|Nor-epinephrine|Intravenous infusion norepinephrine
32730094|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
32730095|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
32934505|NCT05726149|Experimental|Real UHCDS a-TDCS + Therapeutic Exercise|Real unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
32934506|NCT05726149|Sham Comparator|Sham UHCDS a-TDCS + Therapeutic Exercise|Sham unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
32934507|NCT05726149|Active Comparator|Therapeutic Exercise|Therapeutic exercise.
32934508|NCT05725837|Placebo Comparator|Placebo|
32934509|NCT05725837|Sham Comparator|Fluoxetine|Fluoxetine, as paroxetine, has activity upon serotonin uptake, but not on GRK-2
32934510|NCT05725837|Experimental|Paroxetine|
32934511|NCT05691751|Experimental|limited application|Will go primary unilateral TKA with the tourniquet inflated only during cementation and final components of the prosthesis application
32934512|NCT05691751|Experimental|full-time application|will go unilateral primary TKA with inflating the tourniquet prior to incision and releasing it after closure and compression bandage application
32934516|NCT04340635||Multi-center data collection|Without intervention
32934517|NCT05261191|Experimental|Part 1A: Dose level 1|Single dose MGD020
32934518|NCT05261191|Experimental|Part 1A: Dose level 2|Single dose MGD020
32934519|NCT05261191|Experimental|Part 1A: Dose level 3|Single dose MGD020
32934520|NCT05261191|Experimental|Part 1A: Dose level 4|Single dose MGD020
32934521|NCT05261191|Experimental|Part 1A: Dose level 5|Single dose MGD020
32934522|NCT05261191|Experimental|Part 1A: Dose level 6|Single dose MGD020
32934523|NCT05261191|Experimental|Part 1B: MTD/MAD -1 MGD020 and MGD014|Single dose MGD020 and MGD014
32934524|NCT05261191|Experimental|Part 1B: MTD/MAD MGD020 and MGD014|Single dose MGD020 and MGD014
32934525|NCT05261191|Experimental|Part 2: MGD020 and MGD014|Multiple doses of MGD020 and MGD014
32934526|NCT05231785|Experimental|Part A: ALN-APP|Participants will be administered a single dose of ALN-APP.
32934527|NCT05231785|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of placebo.
32934528|NCT05231785|Experimental|Part B:|Participants will be administered multiple doses of ALN-APP.
32934529|NCT04143607|Experimental|ASK120067+ placebo Gefitinib|ASK120067 (80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
32934530|NCT04143607|Active Comparator|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (80 mg orally, twice daily), in accordance with the randomization schedule.
33074267|NCT04927741|Experimental|Method 1: Sweet Marjoram Essential Oil + Grapeseed Oil with Massage|Subjects randomized will receive dilution of sweet marjoram essential oil (mixed with grapeseed oil), which will be applied topically with massage after IUD insertion.
33074268|NCT04927741|Active Comparator|Method 2: Grapeseed Oil with Massage|Subjects randomized will grapeseed oil applied topically with massage after IUD insertion.
33074269|NCT04927741|No Intervention|Method 3: Control Group (no oil or massage)|Subjects will serve as control and no essential oils or massage will be applied.
33074270|NCT04922983|Sham Comparator|Group I: Placebo isometric measure, no injection|Group I: no isometric yoga-like exercise, no injection given.
33252546|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
33252547|NCT03990259||Male|The male individuals of the study population
33252548|NCT03990259||Female|The female individuals of the study population
33252549|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
33074271|NCT04922983|Placebo Comparator|Group II Isometric yoga-like exercise, placebo injection given|Group II isometric yoga-like exercise, injection of preservative-free normal saline.
33074272|NCT04922983|Active Comparator|Group III: True isometric exercise, botulinum injection|Group III: Isometric yoga-like exercise, botulinum injection given
33074273|NCT04922983|Active Comparator|Crossover|After the three months, Arm I and Arm II patients will be given botulinum injections, and Group I will be given the proper yoga-like exercise. These two arms will constitute a further comparator with their own performances in the first 3 months of the study.
33252550|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
33252551|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
33252552|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
33252553|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
33252554|NCT01053091|Experimental|Exercise|exercise
33252555|NCT01053091|No Intervention|Control|control
33252556|NCT03987061|Experimental|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
33252557|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
33252558|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
33252559|NCT01059253|Experimental|Training|15 training sessions
33252560|NCT01059331|Experimental|Pregabalin|
33252561|NCT01059331|Placebo Comparator|Sugar pill|
33074274|NCT04916041||Vivity|Patients who have undergone bilateral implantation of Vivity intraocular lens
33074275|NCT04916041||Eyhance|Patients who have received bilateral implantation of an Eyhance intraocular lens
33074276|NCT04916041||EMV|Patients who have undergone bilateral implantation of Vivity intraocular lens
32730096|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
32730097|NCT04521907||Group 1|Group 1 includes patients who underwent cataract surgery with primary IOL implantation
32730098|NCT04521907||Group 2|Group 2 includes patients who underwent cataract surgery with secondly IOL implantation
33252562|NCT03985345|Experimental|EMY Probe|
33252563|NCT01059409|Experimental|Meniscal Allograft|
33074277|NCT04916041||Panoptix|Patients who have undergone bilateral implantation of Panoptix intraocular lens
33074278|NCT04916041||Rayner Trifocal|Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
33252564|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
32730099|NCT04521907||Group 3|Group 3 includes patients who underwent cataract surgery without IOL implantation.
32769112|NCT05043025|Experimental|Modified ramped position group|The cricothyroid membrane is identified in a modified ramped position.
33074279|NCT00152321|Experimental|A|Multifaceted intervention
33074280|NCT00152321|Active Comparator|B|Usual Care
33074281|NCT04914364||Patients who have tested positive for COVID-19|"Patients who are designated as COVID recovered in the electronic medical record and who fit the inclusion criteria."
33074282|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
33074283|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
33074284|NCT04687150|Active Comparator|The study group|The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit
33074285|NCT04687150|Placebo Comparator|The control group|The control group will be given colored water at same timepoints
33074286|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
33252565|NCT01059721|Experimental|Soft tissue realignment|group cohort label
33074287|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
33252566|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
33252567|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
33252568|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
33252569|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
33252570|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
33252571|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
33252572|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
33252573|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
32730100|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
32730101|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
32730102|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
32730103|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
32934531|NCT04126291|Experimental|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
32934532|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
32934533|NCT04802863|Experimental|Five doses of XNW4107 with imipenem/cilastatin|Each subject will receive a total of five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin via IV infusion administered every 6 hours with each administration infused over 60 minutes.
32934534|NCT04756843|Experimental|Early treatment|Treatment started in the early mixed dentition phase
32934535|NCT04756843|Experimental|Late treatment|Treatment started in the late mixed dentition phase
32934536|NCT04738279|Experimental|Phase I: Soft Launch (120 days)|The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
32934537|NCT04738279|Experimental|Phase II: Calibration (210 days)|After learning from the soft launch and updating the protocol, the study will continue to enroll 15 HF patients for calibration purposes
32934538|NCT04682431|Experimental|Part A: PY159 Single agent dose level 1|PY159 dose level 1 IV administration, Q3 weekly until consent withdrawal, intolerable toxicity or investigator decision.
32934539|NCT04682431|Experimental|Part A: PY159 Single agent dose level 2|PY159 dose level 2
32934540|NCT04682431|Experimental|Part A: PY159 single agent dose level 3|PY159 dose level 3
32934541|NCT04682431|Experimental|Part A: PY159 single agent dose level 4|PY159 dose level 4
32934542|NCT04682431|Experimental|Part A: PY159 single agent dose level 5|PY159 dose level 5
32934543|NCT04682431|Experimental|Part A: PY159 single agent dose level 6|PY159 dose level 6
32934544|NCT04682431|Experimental|Part A: PY159 single agent dose level 7|PY159 dose level 7
32934545|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 1|PY159 dose level 1 in combination with pembrolizumab
32934546|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 2|PY159 dose level 2 in combination with pembrolizumab
32934547|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 3|PY159 dose level 3 in combination with pembrolizumab
32934548|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 4|PY159 dose level 4 in combination with pembrolizumab
32934549|NCT04682431|Experimental|PY159 Part B: Single agent dose expansion cohort(s)|PY159 Single agent dose expansion cohort(s)
32934550|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 1|PY159 in combination with pembrolizumab dose expansion cohort 1 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
32934551|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 2|PY159 in combination with pembrolizumab dose expansion cohort 2 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
32934552|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 3|PY159 in combination with pembrolizumab dose expansion cohort 3 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
32934553|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 4|PY159 in combination with pembrolizumab dose expansion cohort 4 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
32934554|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 5|PY159 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
33252574|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
33252575|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
33252576|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~Patients may have one or all of the following sequences in addition to the standard MRI imaging:~MR Spectroscopy~Fat-saturation and Diffusion-Weighted Imaging~Dynamic Contrast Enhancement MRI (MR-DCE)~Diffusion Tensor Imaging (DTI)"
33252577|NCT01060189|Experimental|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
33252578|NCT01060189|Experimental|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
33252579|NCT01060189|Placebo Comparator|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
33252580|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
33252581|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
33252582|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
33252583|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
32934555|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 6|PY159 in combination with pembrolizumab dose expansion cohort 6 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
32934556|NCT05205031|Active Comparator|Intravenous|The intervention will consist of attempts to successfully establish a peripheral intravenous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
32934557|NCT05205031|Experimental|Intraosseous|The intervention will consist of attempts to successfully establish an intraosseous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
32934558|NCT04677751|Experimental|Experimental group|
32934559|NCT04652869|Experimental|Mindfulness Training|Mindfulness training
32934560|NCT04652869|Experimental|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
32934561|NCT04652869|Experimental|Mindfulness + tDCS|Mindfulness training with transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
32934562|NCT04643899|No Intervention|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
32934563|NCT04643899|Experimental|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
32934564|NCT04622839|Experimental|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
32934565|NCT04622839|Experimental|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
32934566|NCT04622839|Experimental|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
32934567|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
32934568|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
32934569|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
32934570|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
32934571|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
32934572|NCT00366379|Experimental|1|
32934573|NCT00366379|Experimental|2|
32934574|NCT00366379|Experimental|3|
32934575|NCT00366379|Experimental|4|
32934576|NCT00366379|Experimental|5|
32934577|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
32934578|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
32934579|NCT04592809|Active Comparator|Ketamine|0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
32934580|NCT04592809|Active Comparator|Midazolam|0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
32934581|NCT05164705|Active Comparator|Intermittent Hypoxia|Participant will visit our center 2-4 times per week for three weeks to receive Acute Intermittent Hypoxia.
33074288|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
33074289|NCT00533143|Experimental|2|Non-invasive ventilation
33074290|NCT04686994|Experimental|ASC41|ASC41 two tablets, once daily, from Day 1 to Day 28.
33074291|NCT04686994|Placebo Comparator|ASC41 placebo|ASC41 placebo two tablets, once daily, from Day 1 to Day 28.
33074292|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
33074293|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
33074294|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
33074295|NCT00172224||osteoporosis|
33074296|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
32730104|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
33074297|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
33074298|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
33074299|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
33074300|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
33074301|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
33074302|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
33074303|NCT00152438|Experimental|1|Oral micronized progesterone
33074304|NCT00152438|Placebo Comparator|2|Placebo
33074305|NCT02937961|Experimental|Early SLED|
33074306|NCT02937961|Active Comparator|Late SLED|
33074307|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
33074308|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
33074309|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
33074310|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
33074311|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
33074312|NCT04725461|Experimental|Low cost lower limb socket testing|Fabrication and testing of a low cost lower limb prosthetic socket and ensure this socket has appropriate suspension, comfort and f unction for a transtibial amputee.
33074313|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
33074314|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
33074315|NCT02937883|No Intervention|regular care|Regular care, care as usual
33074316|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
33074317|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
33074318|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
33074319|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
32934582|NCT05164705|Sham Comparator|Sham Intermittent Hypoxia|Participants will visit our center 2-4 times per week for three weeks to receive Sham Intermittent Hypoxia.
32934583|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
32934584|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
32934585|NCT04741165|Experimental|Experimental: HX008+Bevacizumab|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
32934586|NCT04741165|Experimental|Experimental: HX008+Lenvatinib|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD).
32934587|NCT04741243|Experimental|Extracorporeal shock wave therapy|was used for 15 minutes in a prone position for both groups (A&B) before the treatment. shock wave were used to heat small areas, and allow for decrease pain, muscle spasm, and provide vasodilatation of the blood vessels supplying the area
32934588|NCT04741243|Experimental|dietary modification|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level.
32934589|NCT05142787|Other|axillary lymph nodes requiring localisation prior to surgical excision|"The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
32934590|NCT05142787|Other|breast lesions requiring localisation|"The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
32934591|NCT05138497|Experimental|HILIT group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 50 min per session. The exercises to be carried out will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 30 minutes (where each exercise should be performed for 20 to 30 seconds as intense or fast as possible without generating joint impact, and then take a break for 10 to 15 seconds, before repeating it); and the return to calm, based mainly on stretching exercises with a total duration of 10 minutes.
32934592|NCT05138497|No Intervention|Control group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
32934593|NCT05111041|Experimental|Smokeless Tobacco Reduction Group|Participants in this group will receive a mobile gradual smokeless tobacco reduction intervention
32934594|NCT05111041|Active Comparator|Control Group|Participants in this group will receive tobacco cessation materials
32934595|NCT04468399||Patients who initiated HIV treatment|
32934596|NCT04468399||Service providers at study facilities|
32934597|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
32934598|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
32934599|NCT04410133|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
32934600|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
32934601|NCT05092477|Experimental|Integrated Intervention|4 intervention sessions over 6 months using an educational and counseling intervention developed by the study team.
32934602|NCT05092477|Active Comparator|Control|Attention Control group - Supportive counseling for DM management
32934603|NCT04391023|Sham Comparator|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
32934604|NCT04391023|Experimental|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
32934605|NCT04391023|Experimental|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
32934606|NCT05442229||Normally developing child|Normal development is defined as children without intellectual development disorders, developmental speech or language disorders, ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder).
32934607|NCT05442229||Abnormally developed child|Abnormal development is defined as that hospital visits of children were professionally assessed for MR (mental retardation), ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder). Diagnostic criteria were all referred to Diagnostic and Statistical Manual of Mental Disorders，DSM-5.
33074320|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
32934608|NCT04363801|Experimental|Part A First Line Treatment|Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily [BID]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
32934609|NCT04363801|Experimental|Part B1 Second Line Treatment|"Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
32934610|NCT04363801|Experimental|Part B2 Second Line Treatment|"Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
33074321|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
33252584|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
33252585|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
33252586|NCT03984721|Experimental|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
33252587|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
33252588|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
33252589|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
33252590|NCT01060657||conventional (C) group|
33252591|NCT01060657||low dose (L) groups|
33252592|NCT00670488|Experimental|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
33252593|NCT00670488|Experimental|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
33252594|NCT00670488|Experimental|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
33252595|NCT00670488|Experimental|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
32730105|NCT04525729|Experimental|Rituximab+RASi(ACEI and/or ARB)|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.
33252596|NCT00670488|Experimental|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
33252597|NCT00670488|Experimental|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
33252598|NCT00670488|Experimental|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
33252599|NCT00670488|Experimental|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
33252600|NCT00670488|Experimental|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
33252601|NCT00670488|Experimental|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
33252602|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
33252603|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
33252604|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
33252605|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
33252606|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
33252607|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
33252608|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
33252609|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
33252610|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
33252611|NCT02557464|Active Comparator|control group|24 age matched controls participants
33252612|NCT00542386|Experimental|1|
33252613|NCT00542386|Placebo Comparator|2|
33252614|NCT00768612|Experimental|1|Lowest dose
33252615|NCT00768612|Experimental|2|Middle dose
33252616|NCT00768612|Experimental|3|Highest dose
33252617|NCT00768612|Active Comparator|4|Positive Control
33252618|NCT00604383|Experimental|Ruboxistaurin|
33252619|NCT00604383|Placebo Comparator|Placebo|
33252620|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
33252621|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
33074322|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
33074323|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
33074324|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
33074325|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
33074326|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
33074327|NCT00165009|Experimental|'Resolution clip|'Resolution clip
33252622|NCT00771186||children with vocal fold immobility|
33074328|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
33074329|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
33074330|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
33074331|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
33074332|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
33074333|NCT04725422||disease modifying anti-rheumatic drug, DMARD|
33074334|NCT04725422||tumor necrosis factor inhibitor, TNFi|
33074335|NCT04725422||bisphosphonate|
33074336|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
33074337|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
33074338|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
33074339|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
33074340|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
32934611|NCT04363801|Active Comparator|Part C Control First Line Treatment|Part C control patients will receive only tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
33074341|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
33074342|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
33074343|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
33074344|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
33074345|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
33074346|NCT02937064||Controls|Controls
33074347|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
33074348|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
33074349|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
33074350|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
33074351|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
33252623|NCT00906711||Group I|(G1): 10 - 18 years old
33252624|NCT00906711||Group II|(G2): 20 - 35 years old
33074352|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
33074353|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
33252625|NCT00906711||Group III|(G3): 45 - 60 years old
33252626|NCT00906711||Group IV|(G4): 65 - 85 years old
33252627|NCT04048200|Other|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
33252628|NCT04048200|Experimental|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
33252629|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
33252630|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
33252631|NCT04034589|Experimental|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
33252632|NCT04048434|No Intervention|Standard of care (SOC)|
32730106|NCT04525729|Other|RASi(ACEI and/or ARB）|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.
32730107|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
32730108|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
32730109|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
32934612|NCT04363801|Experimental|Part C Experimental First Line Treatment|Part C experimental patients will receive DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
32934613|NCT04362631||Adults|Adults 18 years or older
32934614|NCT02625571|Experimental|Intervention|
32934615|NCT05046223|Experimental|high-flow nasal oxygen|THRIVE( Transnasal humidified rapid-insufflation ventilatory exchange), a method of high-flow nasal oxygen (HFNO), is planned to applied for bronchoscopic interventions
32934616|NCT05046223|Active Comparator|supraglottic devise|iGel, a supraglottic devise with tip in upper esophagus, is planned to applied for bronchoscopic interventions
32730110|NCT04525495|Experimental|Dopamine treatment|
32730111|NCT03362359|Experimental|Ga-68-PSMA-11|
32730112|NCT04525417|Other|hospital healthcare workers|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
32934617|NCT04315363|Experimental|Intervention|Brain MRI and Motivational Behavioral Intervention
32730113|NCT04525417|Other|private health professionals|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
32730114|NCT04525027||survivors|
32730115|NCT04525027||non survivors|
32730116|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
32934618|NCT04315363|Active Comparator|Active control|Brain MRI and Control Behavioral Intervention
32934619|NCT04741321||Pre-test group|After translation to Spanish, VQ-6 questionnaire is given to 20 patients to assess understanding by the patient.
32730117|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
32934620|NCT04741321||Test and re-test group|80 patients will be recruited to answer VQ-6 questionnaire and SF-12 questionnaire. After 3-4 weeks, these patients will be re-asked with the same questionnaires.
32934621|NCT04740853|Experimental|Sensory Integration Therapy+Special Education|"The therapy program was prepared and applied according to the Ayres theory and based on the basic principles of sensory integration therapy prepared by Parham depending on the evaluation results. Therapy was applied to the intervention group, with a 45-minute session+15 minutes of family information once a week for eight weeks, in addition to the special education sessions they received twice a week in special education institutions. The sensory integration therapy included sensory diet practices and activities consisting of vestibular, tactile, proprioceptive, auditory and visual stimuli.~The intervention group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. In the special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied."
32934622|NCT04740853|Active Comparator|Special Education|The control group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. Within the scope of special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied.
32934623|NCT05028283|Experimental|participants|patients with atrophic acne scars on the cheeks who will reviewing the dermatological clinics at the Dermatology and Venereology Hospital at least 69 patients they will be undergo fat grafting for one session and will be follow up for 6 months after the procedure
32934624|NCT05004727|Experimental|Guselkumab + Topicals (GUS)|
32934625|NCT05004727|Placebo Comparator|Placebo + Topicals (PBO)|
32934626|NCT05004727|No Intervention|Standard-of-Care Therapy (SOC)|"In this third, non-randomized arm, patients would continue treatment with topical therapy or UVB, as part of our ongoing natural history of disease registries. This arm will include participants fulfilling RM-PsASon criteria but also those that do not (to serve as negative controls)."
32934627|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
32934628|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
32730118|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
32730119|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
33074354|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
33252633|NCT04048434|Experimental|Cyotosorb|
33252634|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
33252635|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
33252636|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
32730120|NCT03362281|Experimental|Ilaprazole|
32730121|NCT03362281|Active Comparator|omeprazole|
32934629|NCT04990609|Experimental|Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA)|
32730122|NCT04521985||thoracolumbar kyphosis|patients undergoing thoracolumbar kyphosis surgery
32730123|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
32730124|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
32730125|NCT04032093|Experimental|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
32730126|NCT04032093|Experimental|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
32730127|NCT04032093|Experimental|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
32730128|NCT04032093|Experimental|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
32730129|NCT04032093|Placebo Comparator|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
32730130|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
32730131|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
32730132|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
32730133|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
32730134|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
32934630|NCT02630017|Experimental|ADHD group|Adults with ADHD
32934631|NCT02630017|Experimental|non-ADHD group|Adults without ADHD
32934632|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
32934633|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
32934634|NCT04979377||Adult premenopausal women with type 1 diabetes mellitus|One-hundred and fifty women aged from 18 to 45 years old consecutively recruited from a type 1 diabetes clinic at a tertiary hospital of Madrid, Spain
32934635|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
32934636|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
32934637|NCT04920175||NICU Cohort|Participants will undergo a standard polysomnogram
32934638|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
32934639|NCT04159519|Experimental|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
32934640|NCT04159519|Experimental|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
33252637|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
33252638|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
33074355|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
33074356|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
33252639|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
33252640|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
33252641|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
33252642|NCT04006990|Experimental|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
33074357|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
33074358|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
33252643|NCT04006990|No Intervention|Control|Subjects are treated with standard care
33252644|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
33252645|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
33252646|NCT00775008|Experimental|podcast|
33252647|NCT00775008|Active Comparator|Web group|
33252648|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
33074359|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
33074360|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
33074361|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
33074362|NCT02936830|Placebo Comparator|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
33074363|NCT02936830|Active Comparator|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
33074364|NCT02936830|Experimental|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
33074365|NCT04756414|Experimental|Treatment group|Patients recieve treatment from standard protocol at a gastroenterology unit. No specific adjustments is made for study purposes. Baseline data is collected before treatment and then again after treatment (POST).
33252649|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
33074366|NCT04690270|Experimental|Sumatriptan 100 mg|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
33074367|NCT04690270|Placebo Comparator|Placebo|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
33074368|NCT02936518|Experimental|Intervention|
33074369|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
33074370|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
33074371|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
33074372|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33074373|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
33074374|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
33074375|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
33074376|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
33074377|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
33074378|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
33074379|NCT02936167|Experimental|Ringer Lactate|fluid
33074380|NCT02936167|Experimental|Plasmalyte|fluid
33074381|NCT00152828|Experimental|Celecoxib|Celecoxib
33074382|NCT02936089|Experimental|Risk Stratification-directed Therapy|AE AML patients first received IA or DA induction therapy, and then received two courses of IDAC (Ara-C 1-2 g/m2 q12 h ×6 cycles). Subsequently, different subgroups of AE AML received different treatment based on risk stratification. For low-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or autologous HSCT. For intermediate-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or allogeneic HSCT. High-risk AE AML all received allogeneic HSCT.
33252650|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
33252651|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
33252652|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
33252653|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
33074383|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
32730135|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
32730136|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
32730137|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
32730138|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
32934641|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
32730139|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
32730140|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
32730141|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
32730142|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
32934642|NCT04913311||Observational (biospecimen collection, standard treatment)|Patients undergo collection of blood, stool and saliva samples at baseline. Patients will also have a 6 minute walk and standard of care pulmonary function test at baseline. Patients receive standard of care treatment consisting of concurrent chemoradiation from baseline up to week 10 and immune checkpoint inhibitors from week 10-62. Patients also undergo the collection of blood, stool, saliva and No BAL sample is collected at week 10. During the course of treatment, patients also complete routine tests and procedures to monitor for side effects per standard of care including CT within 4 weeks, lung function tests including home spirometry TIW from week 10-62, bronchoscopy and/or a nasal wash to check for viral infection. Patients also complete questionnaires about symptoms and quality of life QW for weeks 1-10, BIW during weeks 10-62.
32730143|NCT03361969|Active Comparator|estetrol|
32730144|NCT03361969|Placebo Comparator|placebo|
32934643|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
32934644|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
32934645|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
32934646|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
32934647|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
32934648|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
32934649|NCT03998527|Experimental|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
32934650|NCT03998527|Experimental|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
32934651|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
32934652|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
32934653|NCT04400071|Experimental|Active Music Engagement|See intervention description.
32934654|NCT04400071|Active Comparator|Audio Storybooks|See intervention description.
32934655|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
33074384|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
33074385|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
33252654|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
33074386|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
32730145|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
32730146|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
32730147|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
33074387|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
33074388|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
33074389|NCT00152867|Active Comparator|1|Dexamethasone
32730148|NCT03361891|No Intervention|Control|Patients receive no intervention
33074390|NCT00152867|Placebo Comparator|2|Placebo
33074391|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
33074392|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
33074393|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
33074394|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
33074395|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
32730149|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
32730150|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
32730151|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
32730152|NCT02983695|Experimental|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol.TIL-TC150 Oil is the study product The active ingredients in TIL-TC150 Oil are THC and CBD, present in a 1:50 ratio. These active ingredients are derived from Cannabis sativa L. strains produced by Tilray, and suspended in a grape seed oil. This suspension is administered at a dose of 2mg/kg/day CBD divided BID and titrated up to a maximal dose of 16mg/kg/day CBD (or maximal tolerated).
33074396|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
33074397|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
33074398|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
33074399|NCT04702555||Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine|An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.
33074400|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
33074401|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
33074402|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
33074403|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
33074404|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
33074405|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
33074406|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
33074407|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
33074408|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
33074409|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
33074410|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
33252655|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
33252656|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
33074411|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
33074412|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
33074413|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
33074414|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
33074415|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
33074416|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
33074417|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
33074418|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
33074419|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
33074420|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
33074421|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
33074422|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
33074423|NCT02934919|Experimental|nalmefene|
33074424|NCT00172419|Experimental|Atorvastatin|
33074425|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
33074426|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
33074427|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
33074428|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
33074429|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
33074430|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
33074431|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
33074432|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
33074433|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
33074434|NCT04689958|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin D 5000 IU once daily (experimental group).
33074435|NCT04689958|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline
33074436|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
33252657|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
33252658|NCT00908427|Active Comparator|1|PVP group
33252659|NCT00908427|Active Comparator|2|TURP group
33252660|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
33252661|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
33252662|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
32730153|NCT02549781|Experimental|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
32730154|NCT02549781|Active Comparator|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
32730155|NCT02549781|Placebo Comparator|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
32730156|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
32730157|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
32730158|NCT04203069|Placebo Comparator|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
33074437|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
32730159|NCT04203069|Experimental|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
32730160|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
32730161|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
32730162|NCT02929485|Experimental|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
32730163|NCT02929485|Placebo Comparator|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
32730164|NCT02929485|Experimental|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
32730165|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
32730166|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
32730167|NCT04523623|Experimental|Ibuprofen Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
32730168|NCT04523623|Experimental|Oxycodone Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
32730169|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
32730170|NCT02959047|Placebo Comparator|Placebo|Matched placebo
32730171|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
32730172|NCT04521595|Experimental|weigh smart intervention|open treatment arm to receive group based lifestyle intervention via telehealth.
32730173|NCT04977063|Other|SmartPill and Atmo capsule|The SmartPill and Atmo gas capsule will be tested simultaneously. This will allow the ability of the Atmo gas capsule to measure gastrointestinal transit time to be compared to the SmartPill. The order of swallowing will be randomised using a computer-generated list. The two capsules will be swallowed within 5 minutes of each other
32730174|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
32730175|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32730176|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32730177|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
32730178|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~Optical Coherence Tomography (OCT)~Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
33252663|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
32934656|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
32934657|NCT00367393|Experimental|1|Pimecrolimus cream 1%
33252664|NCT00908505|Experimental|physiotherapy|
33252665|NCT00988546|Other|1|exam documentation performed using dictation
33252666|NCT00988546|Experimental|2|exam documentation performed using computer based template
33252667|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
33252668|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
33252669|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
33252670|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
33252671|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
32730179|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
32730180|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
32730181|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
32730182|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
32934658|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
32934659|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
32934660|NCT03876769|Experimental|Single dose of CTL019|"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
32934661|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
32934662|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
32934663|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
32934664|NCT04396483|Experimental|"Tubal sterilization Pomeroy's method"|
32934665|NCT04396483|Active Comparator|Salpingectomy|
32934666|NCT04389853|Active Comparator|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
32934667|NCT04389853|Active Comparator|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
32934668|NCT04380883|Experimental|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
32934669|NCT04380883|Active Comparator|TRB alone|
32934670|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
32730183|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
32730184|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
32730185|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
32730186|NCT04521751|Experimental|EMP16-02 120 mg orlistat/40 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 120 mg O/40 mg A (given as 2 capsules EMP16-02-60/20). Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
32730187|NCT04521751|Experimental|EMP16-02 150 mg orlistat/50 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 150 mg O/50 mg A (given as 1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).~Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
32730188|NCT04521751|Placebo Comparator|Placebo|"Dosage form: Matching, oral capsule. Identical in appearance but contain only cellulose.~Dosage: Placebo (given as 2 placebo capsules) Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
32730189|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
32730190|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
32730191|NCT04521517|Experimental|Pamphlet with timing of family planning|"Pamphlet with timing of family planning and Routine service"
32730192|NCT04521517|No Intervention|Only routine service|Receive only routine service
32730193|NCT04521673||infectious uveitis|Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap
32730194|NCT04521673||Control group|Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases
32730195|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
32730196|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
32730197|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
32730198|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
32730199|NCT03361501|Experimental|CaPre|
32730200|NCT03361501|Placebo Comparator|Placebo|
32730201|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
32730202|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
32730203|NCT03123523||Patients group|35 patients
32730204|NCT03123523||Healthy volunteers|20 healthy volunteers
32730205|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
32730206|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
32730207|NCT04521205|Experimental|Standardized FMT|The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.
32730208|NCT04521205|Placebo Comparator|Without FMT|The patients will receive FMT with blank capsule.
32730209|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
32743008|NCT04959747|Experimental|acupuncture group|"Subject will be scheduled for a total of 8 sessions of acupuncture treatment, to be done by the 30 minutes for each session, twice per week over a 4-week period.~Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
33074438|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
33074439|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
33252672|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
33252673|NCT00986050|Active Comparator|Bare metal stent (BMS)|
33252674|NCT00986050|Active Comparator|Drug eluting stent (DES)|
33252675|NCT00986050|Active Comparator|Abciximab|
33074440|NCT04684420|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants will receive a single oral dose of 500 milligrams (mg) of test GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There will be separate washout period of 7 days between each treatment period.
33074441|NCT04684420|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants will receive a single oral dose of 500 mg of reference GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR tablet on Day 8 in treatment period 2 under fasting conditions. There will be separate washout period of 7 days between each treatment period.
33252676|NCT00986050|No Intervention|No abciximab|
33252677|NCT00986128|Experimental|001|
33252678|NCT00986128|Experimental|002|
33252679|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
33252680|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
33252681|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
33252682|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
33252683|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
33252684|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
33074442|NCT04684420|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants will receive a single oral dose of 500 mg of test GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There will be separate washout period of 7 days between each treatment period.
33074443|NCT04684420|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants will receive a single oral dose of 500 mg of reference GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR tablet on Day 8 in treatment period 2 under fed conditions. There will be separate washout period of 7 days between each treatment period.
33074444|NCT04680130||Neurodegenerative symptoms|
33074445|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
33252685|NCT00988624|Experimental|Period 1|
33074446|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
33252686|NCT00988624|Experimental|Period 2|
33252687|NCT00988624|Experimental|Period 3|
33074447|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
33074448|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
33074449|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
33252688|NCT00988624|Experimental|Period 4|
33252689|NCT00988624|Experimental|Period 5|
33252690|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
33252691|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
33252692|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
33252693|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
33252694|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
33252695|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
33252696|NCT00771420|Placebo Comparator|7|Placebo
33252697|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
33252698|NCT04767256|Experimental|DD group|co-administered intravenous dexamethasone 10 mg and dexmedetomidine 1 ug/kg
33252699|NCT04767256|Placebo Comparator|D group|intravenous dexmedetomidine 1 ug/kg
33252700|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
33252701|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
33252702|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
33252703|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
33252704|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
33252705|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
33252706|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
33252707|NCT00768846|Active Comparator|2|Xience V Stent
33252708|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
33252709|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
33252710|NCT00768924||1|Spinal fusion patients
33252711|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
33252712|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
32730210|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
33252713|NCT00769080||1|Standard Treatment plus PSP
33252714|NCT00769080||2|Standard Treatment
33252715|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
33252716|NCT00986518|Experimental|adaptive cell immunotherapy|
33252717|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
33252718|NCT00769158|Placebo Comparator|Placebo|
32730211|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
32730212|NCT02265939|Placebo Comparator|0% NPO-13|Placebo
33252719|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
32730213|NCT02265939|Active Comparator|0.2% NPO-13|Low dose
32730214|NCT02265939|Active Comparator|0.4% NPO-13|Medium dose
32730215|NCT02265939|Active Comparator|0.8% NPO-13|High dose
32730216|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
32730217|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
32730218|NCT02459847|Experimental|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
32730219|NCT02459847|Experimental|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
33252720|NCT00983164|No Intervention|group I|group I - controls
33252721|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
33252722|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
33252723|NCT00769236|Other|1|Patients with crohn disease
33252724|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
33252725|NCT00769236|Other|3|Patients controls
33252726|NCT00988936|Experimental|[F-18]RDG-K5|
33252727|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
33252728|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
33252729|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
33252730|NCT00771732|Experimental|1|Light therapy
33252731|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
33252732|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
33252733|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
33252734|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
33252735|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
33252736|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
33252737|NCT03808870|Experimental|NBM-BMX|
33252738|NCT00771888|Other|1|lanreotide
33252739|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
33252740|NCT00989170|Active Comparator|No enhanced Family Program|
33252741|NCT00771966|Placebo Comparator|Standard treatment|
33252742|NCT00771966|Active Comparator|SV maximization|
32934671|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
33252743|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
32730220|NCT04521049|Active Comparator|saxagliptin|patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
32730221|NCT04521049|No Intervention|control|patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
32730222|NCT02267343|Experimental|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32730223|NCT02267343|Placebo Comparator|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32730224|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
32730225|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
32730226|NCT04520581|No Intervention|Control|Use in the shape of an endotracheal tube.
32730227|NCT04520581|Experimental|"Group O"|"Just before the induction of medicine is injected, the assistant makes endotracheal tube into O shape."
32730228|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
32730229|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
32730230|NCT04914819|Active Comparator|Online Behavioral Weight Loss|Participants will attend a virtual introduction to weight loss session and be enrolled in a 16-week online behavioral weight loss program. Participants will complete a virtual weigh-in at the start and end of the study.
32730231|NCT04914819|Active Comparator|Usual Care|Participants will complete a virtual weigh-in at the start and end of the study. No additional intervention will be provided.
32730232|NCT03357133|Experimental|Tirofiban and alteplase|
32730233|NCT03357133|Placebo Comparator|Alteplase|
32730234|NCT05128305|Experimental|group 1|traditional chinese medicine 1 and traditional chinese medicine 2 simulant
32730235|NCT05128305|Experimental|group 2|traditional chinese medicine 1 simulant and traditional chinese medicine 2
32730236|NCT05128305|Experimental|group 3|traditional chinese medicine 1 and traditional chinese medicine 2
32730237|NCT05128305|Placebo Comparator|group 4|traditional chinese medicine 1 simulant and traditional chinese medicine 2 simulant
32730238|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
32730239|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
32730240|NCT04909047|Experimental|Parasacral transcutaneous electrostimulation outpatient|electrostimulation device
32730241|NCT04909047|Experimental|transcutaneous tibial electrostimulation outpatient|electrostimulation device
32730242|NCT04909047|Experimental|home parasacral electrostimulation|electrostimulation device
32730243|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
32730244|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
32730245|NCT04885101|Experimental|LISWT Group|Participants who will submitted to active procedure with Low Intensuty Shockwave Therapy.
32730246|NCT04885101|Experimental|NARFT Group|Participants who will submitted to active procedure with Non-Ablative Radiofrequency Therapy
32730247|NCT04885101|Sham Comparator|Sham Group|Participants who submitted to sham procedure with vaccum therapy.
32730248|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
32743009|NCT04959747|Placebo Comparator|sham-acupuncture group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated."
32743010|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
32743011|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
32769113|NCT04153747|Active Comparator|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.~Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI>=6 or Ablation index >=500.~Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI>=5 or Ablation index >=350."
33401169|NCT04503694|Experimental|Single arm|"Induction treatment: treatment with nivolumab (240 mg intravenously on day 1 and 15) and regorafenib (80 mg/day orally from day 1 to 14)~Standard SCRT: consists of 25 Gy delivered in 5 fractions (from day 22 to 26)~Consolidation treatment: treatment with nivolumab (240 mg intravenously on day 29, 43 and 57) and regorafenib (80 mg/day orally from day 29 to 49)~Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT). As an alternative to surgery, subjects who achieve cCR can be offered a watch & wait approach.~Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (collection of tumour biopsies, blood and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects."
33401170|NCT04461106|Active Comparator|Social Marketing Campaign|Select egg hubs will receive social marketing campaign which aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women.
33074450|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
33074451|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
33401171|NCT04461106|No Intervention|No Social Marketing Campaign|Other egg hugs will not receive social marketing campaign.
33074452|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
33074453|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
33074454|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
33074455|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
33074456|NCT00153257|Other|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
33074457|NCT00153257|No Intervention|No device|standard anterior colporrhaphy
33074458|NCT02934334||MDD|Major Depressive Disorder
33074459|NCT02934490|Experimental|Treatment group|
33074460|NCT00165282|No Intervention|Usual Care|Normal standard of care
33074461|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
33074462|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
33074463|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
33074464|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
33074465|NCT02934373|No Intervention|Subject's own sound processor|
33074466|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
33074467|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
33074468|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
33074469|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
33074470|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
33074471|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
33074472|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
33074473|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
33074474|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
33074475|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
33074476|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
33074477|NCT02934295|Experimental|Pregnant women|
33074478|NCT02934022|Other|Maraviroc|
33074479|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
33074480|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
33074481|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
33074482|NCT04651543||no control X-Ray|patients with a proximal humeral fracture without one-week X-Ray control
33074483|NCT04651543||one-week X-Ray control|patients with a proximal humeral fracture with one-week X-Ray control
33074484|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
33074485|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
33074486|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
33074487|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
33074488|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
33074489|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
33074490|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
33074491|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
33074492|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
33074493|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
33074494|NCT02933827|Experimental|Low dose:|ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)
33252744|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
33252745|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
32730249|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
33252746|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
33252747|NCT00772044|Active Comparator|Provent|Those receiving the active device
32730250|NCT04796259|No Intervention|Negative control|Water
33252748|NCT00772044|Sham Comparator|Sham|Those receiving sham device
33074495|NCT02933827|Experimental|Middle dose|ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)
33074496|NCT02933827|Experimental|High dose|ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)
33074497|NCT02933593|Active Comparator|labetalol|labetalol
33074498|NCT02933593|Active Comparator|hydralazine|Hydralazine
33074499|NCT02933593|Active Comparator|nifedipine|nifedipine
33074500|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
33074501|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
33074502|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
33074503|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
33074504|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
33074505|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
33074506|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
33074507|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
33074508|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
33252749|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
33252750|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
33252751|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
33252752|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
32730251|NCT04796259|Active Comparator|Positive control|Non-alcoholic beer solids
33074509|NCT00153530|Experimental|2|chemotherapy without radiotherapy
33074510|NCT04690075|Experimental|Intervention|To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
33074511|NCT04690075|Placebo Comparator|Control|To receive routine nutrition management for 12 weeks.
33074512|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
33074513|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
33074514|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
33074515|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
33074516|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
33074517|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
33074518|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
33252753|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
33252754|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
32934672|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
33252755|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
33252756|NCT04006678|Experimental|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
33252757|NCT04006678|Active Comparator|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
33252758|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33252759|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33252760|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33252761|NCT04854382|Active Comparator|Intervention group|Tailored information about coronavirus using information videos followed by a teach-back procedure
32730252|NCT04796259|Experimental|Intervention 1|Malt ingredient I
32730253|NCT04796259|Experimental|Intervention 2|Malt ingredient II
32730254|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
32730255|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
32730256|NCT00584025|Experimental|1|Keppra IV
32730257|NCT00584025|Placebo Comparator|2|Placebo
32730258|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
32730259|NCT05124015||Patients with pulmonary arterial hypertension|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
32730260|NCT05124015||Healthy controls|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
32730261|NCT04520893|Experimental|VCV pause|volume controlled ventilation with pause time 30%
32730262|NCT04520893|Active Comparator|VCV|volume controlled ventilation (without pause)
32730263|NCT04520893|Active Comparator|PCV-VG|pressure controlled ventilation - volume guaranteed
32730264|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
32730265|NCT04520737|Active Comparator|16W group|Multimodal prehabilitation program (MPP) will be implemented during 16 weeks, 12 weeks during chemotherapy (CT) and 4 weeks while waiting for surgery.
32934673|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
32934674|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
32934675|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
32934676|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
32730266|NCT04520737|Active Comparator|4W group|Multimodal prehabilitation program (MPP) will start at the end of preoperative chemotherapy (CT) until surgery (4 weeks in total).
32730267|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
32934677|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
33252762|NCT04854382|No Intervention|Control group|Controls have access to information videos, but do not receive the teach-back procedure (the intervention)
33252763|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
33252764|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS >10
33252765|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS <=10
33252766|NCT00922038|Experimental|High reward|
33252767|NCT00922038|Experimental|Low reward|
33252768|NCT00922038|No Intervention|Control|
33252769|NCT00983320|Experimental|medication|quetiapine
33252770|NCT00983320|Placebo Comparator|placebo|placebo
33252771|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
33252772|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
33252773|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
33252774|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
33252775|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
33252776|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
33252777|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
33252778|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
32730268|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
32730269|NCT03360877|Other|Health-care associated infection|
32743012|NCT04959669|No Intervention|Control group|Usual care
32934678|NCT04863222|Experimental|MTA, then Biodentine|The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.
32934679|NCT04863222|Experimental|Biodentine, then MTA|Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.
32934680|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
33252779|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
33252780|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
33252781|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
33252782|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
33252783|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
33252784|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
33252785|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
33252786|NCT05277675|Experimental|Neoadjuvant therapy+ RFA|After confirmation of HCC recurrence by imaging exam, subjects will receive neoadjuvant therapy (immune checkpoint inhibitors + targeted therapy) and then RFA
33252787|NCT05277675|Active Comparator|RFA alone|After confirmation of HCC recurrence by imaging exam, subjects will receive RFA treatment only.
33252788|NCT00769626|Experimental|Early Treatment|
33252789|NCT00769626|Active Comparator|Usual Care|
33252790|NCT03984409|Active Comparator|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
33252791|NCT03984409|Active Comparator|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
33252792|NCT00900939|Experimental|Low-fat, vegan diet|
33252793|NCT00900939|Placebo Comparator|Control|
33252794|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
33252795|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
33252796|NCT04005820|Experimental|children and young adults supported in one of SFCE's centers|
33252797|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
33252798|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
33252799|NCT00983554|No Intervention|Placebo|
33252800|NCT00983554|Experimental|Anastrazole and Testosterone|
33252801|NCT00983554|Experimental|Dutasteride and Testosterone|
33252802|NCT00983554|Experimental|Testosterone|
33252803|NCT04741516|Experimental|Medication arm|
33252804|NCT05004987|Active Comparator|Escitalopram (ESC)|
33252805|NCT05004987|Placebo Comparator|Placebo (PBO)|
33252806|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
33252807|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
32730270|NCT05405049|Active Comparator|Group intraperitoneal instillation of local anesthetic + local anesthetic infiltration (IPLA+ LWI)|local anesthetic infiltration into all layers of the anterior abdominal wall and peritoneal instillation
32730271|NCT05405049|Active Comparator|Group morphine ( M )|intrathecal injection of morphine with local anesthesic
33252808|NCT05712694|Experimental|ADIGemDoc|ADI-PEG 20: 36 mg/m2 on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 600 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 60 mg/m2 on day 8 of each 21-day cycle
33252809|NCT05712694|Placebo Comparator|PBOGemDoc|Placebo: matched PBO on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 900 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 75 mg/m2 on day 8 of each 21-day cycle
33252810|NCT00908817|Active Comparator|triamcinolone|
33252811|NCT00908817|Placebo Comparator|chlorhexidine|
33252812|NCT04005898|Experimental|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
33252813|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
33252814|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
32730272|NCT04520503||Pre EEG group|This cohort includes all participants in this study. EEG sensor will be attached to the patient's forehead before induction of anesthesia. Patterns of EEG and data will be obtained
33074519|NCT02932813|Experimental|Intervention Group|"THINK intervention:~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
33252815|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
33252816|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
33252817|NCT05712616|Active Comparator|Strontium group|Trial drug given in the form of sachet 2gm/sachet once every day
33252818|NCT05712616|Placebo Comparator|Placebo (Lactose)|Look, smell, taste alike lactose 2gm/sachet in form of sachet
33252819|NCT00907023||SOT|Patients that have had a solid organ transplant
33252820|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
33252821|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
33252822|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
33252823|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
33252824|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
33252825|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
33252826|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
33252827|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
33252828|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
33252829|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
33252830|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
33252831|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
33252832|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
33252833|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
33252834|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
33252835|NCT00983788|Experimental|Bezafibrate|
33252836|NCT00983788|Placebo Comparator|Placebo|
33252837|NCT00909051||Group 1|
33252838|NCT00983866|Experimental|Tailored Telephone Counseling|
33252839|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
33252840|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33252841|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
33252842|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
33252843|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
33252844|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
33074520|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
33074521|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
33074522|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
32730273|NCT04698369|Experimental|low frequency low amplitude|The vibration frequency is 60 Hz and amplitude is 0.2 mm
32730274|NCT04698369|Experimental|low frequency high amplitude|The vibration frequency is 60 Hz and amplitude is 2 mm
32730275|NCT04698369|Experimental|high frequency low amplitude|The vibration frequency is 120 Hz and amplitude is 0.2 mm
32730276|NCT04698369|Experimental|high frequency high amplitude|The vibration frequency is 120 Hz and amplitude is 2 mm
32730277|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
32730278|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
32730279|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
32730280|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
32730281|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
32730282|NCT02848131|No Intervention|Group 1: Observational|Observational Only
32730283|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
32730284|NCT04525105||Study group|wıth URGE INCONTINANCE
32730285|NCT04525105||Control group|not urge incontinance
32730286|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.~Tumor tissues will be collected if available."
32730287|NCT04523467|Experimental|Combined group|Anti-angiogenic targeted drug + Rg3 + TACE
32730288|NCT04523467|Active Comparator|Single group|TACE alone
32730289|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected."
32730290|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
32730291|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
32730292|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
32730293|NCT03360643|Active Comparator|Radiology-performed ultrasound|
32730294|NCT02801097|Experimental|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
32730295|NCT04636983|Experimental|BV100|BV100 intravenous infusion
32730296|NCT04636983|Placebo Comparator|Placebo|Saline intravenous infusion
32730297|NCT03367273|Experimental|vitiligo patients|
32730298|NCT03367273|Experimental|controls|
32730299|NCT04601805||Group (1) : Patient diagnosed with IBD with no treatment received|
32730300|NCT04601805||Group(2): Patient diagnosed with IBD and received treatment for a long time|
32730301|NCT04520269|Experimental|Patient with (cfDNA) 1q21.3 copy number amplification|The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
32730302|NCT04589091||Group(1): Patient who underwent PRK|
32730303|NCT04589091||Group(2): Patient underwent LASIK|
32730304|NCT03356743|Experimental|Ex-Vivo|
32730305|NCT05404659|Active Comparator|Oscillatory Mobilizations|
32730306|NCT05404659|Experimental|Mckenzie Retraction Exercises|
32730307|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
32730308|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
32730309|NCT04579653|Experimental|Group A: Experimental|Within-subjects design with a randomization of the order of tVNS administered parameters
32730310|NCT04579653|Active Comparator|Group B: Active Comparator|Within-subjects design with a randomization of the order of tVNS administered parameters
32730312|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
32730313|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
32730314|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
32730315|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
32730316|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
32730317|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
32730318|NCT04213911||Morbid obese|BMI>40 kg/m2
33252845|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
33252846|NCT00927537||Group 1|
33252847|NCT00927537||Group 2|
33252848|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
33252849|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
33252850|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
33252851|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
33252852|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
33252853|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
33252854|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
33252855|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
33252856|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
33252857|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
32730319|NCT04213911||Non-obese|BMI<30 kg/m2
33252858|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
33252859|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
33252860|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
33252861|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
33252862|NCT04733404|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
33252863|NCT05277363||Prospective cohort|Parents/caregivers of participants with SURF1 deficiency will provide information regarding diagnosis, onset of symptoms, and course of the disease and participants will be assessed prospectively over time using standardized qualitative and quantitative tools.
33252864|NCT03990181|Experimental|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
33252865|NCT03990181|Experimental|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
33252866|NCT03990181|Placebo Comparator|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
33252867|NCT03990181|Placebo Comparator|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
33252868|NCT05712148|Experimental|Retinitis Pigmentosa patients|Suprachoroidal mesenchymal stem cell implanted Retinitis pigmentosa patients
33252869|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
33252870|NCT01053403|Active Comparator|MDMA|
33252871|NCT00987142|Experimental|CX501|Cultured chimeric skin
33252872|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
33252873|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
33252874|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
33252875|NCT03990103|Experimental|Experimental arm|S1+Paclitaxel (IV&IP)+Bevacizumab (IP)
33252876|NCT03990103|Active Comparator|Control arm|S1+Oxaliplatin (IV)
33252877|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
33252878|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
33252879|NCT00987220||Placebo|
33252880|NCT00987220||donepezil (Aricept)|
33252881|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
32730320|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
32730321|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32730322|NCT04523389||colorectal cancer|
33252882|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
33252883|NCT00909285|Experimental|Treatment Group (#1)|
32769114|NCT04153747|Experimental|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force > 5 g.
32769115|NCT04152187|Experimental|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
32769116|NCT04152187|No Intervention|Control|No additional intervention
32769117|NCT04821323|Experimental|Indomethacin Challenge|Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
32769118|NCT04821557|Experimental|Microbial Protease Supplement|A microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) is taken with a 25g pea protein beverage. The test article will be provided in 250mg capsule form. Capsules will be opened and mixed into protein shake 5 minutes before ingestion.
32769119|NCT04821557|Placebo Comparator|Placebo (Maltodextrin)|The placebo (maltodextrin) article will be provided in 250mg capsule form. Capsules will be opened and mixed into 25g pea protein shake 5 minutes before ingestion.
32769120|NCT04434703|Active Comparator|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
32769121|NCT04434703|Experimental|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
32769122|NCT04434703|Placebo Comparator|blood clot|normal healing of the wound without adding any biomaterial
32769123|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
32769124|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
32769125|NCT04469881|Experimental|Virtual Reality|Wear VR glasses and watch movies during surgery
32769126|NCT04834037|Experimental|Experimental|"Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs.~As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed."
32769127|NCT04834037|No Intervention|No intervention|Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
32769128|NCT05035069|Experimental|Ciprofol|
32769129|NCT05035069|Active Comparator|Propofol|
32769130|NCT05042557||Sun Yat-sen University Cancer Center|
32769131|NCT05042557||hanghai Chest Hospital|
32769132|NCT05042557||Tianjin Cancer Hospital|
32769133|NCT05042557||Fudan University Shanghai Cancer Center|
32769134|NCT05042557||Anhui Cancer Hospital|
33074523|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
33252884|NCT00909285|Sham Comparator|Control group (#2)|
32769135|NCT05042557||Shandong Cancer Hospital|
32769136|NCT05042557||Hunan Cancer Hospital|
32769137|NCT05042557||Yunnan Cancer Hospital|
32769138|NCT05042557||Chinese Academy of Medical Sciences|
32769139|NCT05035147|Experimental|Low dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8 q3w
32769140|NCT05035147|Active Comparator|High dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8,15 q4w
32769141|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
32769142|NCT05042713|Active Comparator|Wave One Gold|The Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
32769143|NCT05042713|Active Comparator|One Flare and Wave One Gold file system|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
32769144|NCT05042713|Active Comparator|One Curve|The One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
32769145|NCT05042713|Active Comparator|One Curve with One Flare|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
32769146|NCT03036761|Experimental|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
32769147|NCT03036761|No Intervention|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
32769148|NCT04821167|Other|Laparoscopic orchiopexy for intra-canalicular (emergent or peeping) testis|This is a prospective study conducted on male children with intermittent palpable (peeping) UDT to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent or peeping) testis.
32769149|NCT05054101|Experimental|VieCovid2020 smartphone application|The VieCovid2020 smartphone application in add-on to usual psychiatric intervention
32769150|NCT05054101|Placebo Comparator|Usual psychiatric intervention|Usual psychiatric intervention alone
33074524|NCT04648852||Participants in the third wave of the HUNT study|General population participating in the third wave of the HUNT study
33074525|NCT04648852||Participants in the second wave of the HUNT study|General population participating in the second wave of the HUNT study
33074526|NCT04647409|Other|participants|
33252885|NCT04005976||Patients with heritable thoracic aortic disease (H-TAD)|Patients with heritable thoracic aortic disease (H-TAD) with causal mutations in the known H-TAD genes.
33252886|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
33074527|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
33074528|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
33252887|NCT05712070|Experimental|smart group|Smartphone App-based healthcare
33252888|NCT05712070|Active Comparator|control group|a book-based self-education
33252889|NCT00927771|Experimental|Azelaic Acid|
32730323|NCT05123781|Experimental|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
32730324|NCT05123781|Active Comparator|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
33074529|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
33074530|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
33074531|NCT04642378|Experimental|iNCDSS group|Artificial intelligence assisted insulin titration system group
33074532|NCT04642378|Active Comparator|Routine treatment group|Physician decided insulin titration group
33252890|NCT00927771|Active Comparator|Hydroquinone|
33252891|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
33252892|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
33252893|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
33252894|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
33252895|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
33074533|NCT04608136|Experimental|Yolk ketogenic diet|consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
33074534|NCT04608136|Experimental|White ketogenic diet|consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
33074535|NCT04608136|Active Comparator|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
33074536|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
33074537|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
33074538|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
33252896|NCT01053637|Placebo Comparator|Sugar water|Placebo
33252897|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
33252898|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
33252899|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
33252900|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
33252901|NCT00909519|Active Comparator|naproxen|
32730325|NCT04523233||Neural tube defects (NTDs)|NTDs are a group of birth defects in which an opening in the spine or cranium remains from early in human development. Neural tube defects may be diagnosed during the ultrasound scan that is carried out around week 12 of the pregnancy or, more likely, during the anomaly scan that is carried out at around weeks 19 to 20.
32730326|NCT04523233||Control group|The control group will be included pregnant women with healthy fetuses (n = 70), who were matched for gestational weeks and maternal age and underwent amniocentesis because of age-related risk or increased risk in the triple test.
32730327|NCT05127447|Experimental|ES group|External neuromuscular electrical stimulation was applied to the patients in supine position. It was applied for 30 minutes 3 days a week for 8 weeks. This stimulation consists of a total of eight external electrodes, including 2 sheaths wrapped around the thigh area and 4 electrodes for each leg. Electrodes were placed on the anterior and posterior proximal thighs, buttocks, and outside of the hips. The treatment protocol was applied with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 seconds of contraction and 5 seconds of rest.
33252902|NCT00909519|Experimental|naproxcinod|
33252903|NCT00909519|Placebo Comparator|placebo|
33252904|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
33252905|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
33252906|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
32769151|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
32769152|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
32769153|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
32769154|NCT05034757|Experimental|Hyaluronate|HA injection
32769155|NCT05034757|Experimental|HA + ESWT|HA + ESWT
32769156|NCT05618093|Experimental|Patients diagnosed with PAH or CTEPH|Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy.
32769157|NCT04834115|Experimental|Ivermectin|Ivermectin 200mcg/kg single dose, maximum dose 18mg
32769158|NCT04834115|Placebo Comparator|Placebo|Inactive medication tablets indistinguishable from ivermectin tablets
32769159|NCT04820777|Experimental|perturbation based training|External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
32769160|NCT04820777|Active Comparator|Conventional' balance training|"Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor.~Rehash with your correct leg, exchanging to and fro between legs for a sum of 20 repitions (10 on every leg).~Situated Marching Starting with a situated position, lift your effected leg towards your chest, making an honest effort to keep up controlled development."
32769161|NCT04821011||Newborn birth between 28 and 40 Weeks of Gestational Age (wGA)|"Newborn birth between 28 and 40 Weeks of Gestational Age (wGA) will be included. The mother's newborn will be have a record of her heartbeats.~The newborn will be have an acoustic listening of their mother's heartbeat and a record of their own heartbeats."
32769162|NCT01505465|Experimental|Study: Melatonin|
32769163|NCT01505465|Placebo Comparator|Control: Placebo|
32769164|NCT05618015|Experimental|Supervised progressive resistance training|Supervised PRT was conducted face-to-face at the clinic
32769165|NCT05618015|Active Comparator|Home-based progressive resistance training|Home-based PRT was conducted at home without supervision
32769166|NCT04833881||The control group|
32769167|NCT04833881||Experimental group|
32769168|NCT04833647|Other|Term|7-10 years old born at 37-42 weeks gestation
32769169|NCT04833647|Other|Late preterms|7-10 years old born at 34.0-36.6 weeks gestation
32769170|NCT04833647|Other|Preterms with BPD|7-10 years old born before 30 weeks gestation with the diagnosis of BPD: the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation
32769171|NCT04833647|Other|pretermas without BPD|7-10 years old born before 30 weeks gestation without the diagnosis of BPD (without the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation)
32769172|NCT04830683||ICU Covid-19 patients|Covid-19 patients admitted for refractory respiratory failure despite conventional oxygen therapy requiring Intensive Care Unit (ICU) admission and oxygenation through either High Flow Nasal Cannula (HFNC) therapy or endotracheal intubation with mechanical ventilation
32769173|NCT04830683||non-ICU Covid-19 patients|Covid-19 patients admitted at hospital requiring conventional oxygen or continuous positive airways pressure (cpap)
32769174|NCT04830683||matched control subjects|Healthy subjects matched for similar cardiovascular risk factors than ICU Covid-19 patients
32769175|NCT04830683||ICU septic shock patients|Septic shock patients corresponded to refractory hypotension in response to an infection, in non Covid-19 patients, requiring ICU hospitalisation for vasopressors to maintain mean arterial pressure (MAP) > 65mm Hg despite adequate volume resuscitation according to the Surviving Sepsis Campaign
32769176|NCT04830449|Experimental|HCP1904-2|
32769177|NCT04830449|Active Comparator|RLD2001-2|
32769178|NCT04820933|Experimental|Doravirine plus emtricitabine and tenofovir alafenamide fumarate|PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months
32769179|NCT05617937|Experimental|Connective tissue massage gruop|In addition, a total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Connective tissue massage was only performed to the patients in the experimental group. A total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Depending on the area of procedure, each session varied between 15 minutes and 20 minutes.
32769180|NCT05617937|No Intervention|Conventional Physiotherapy and Rehabilitation Group|Standard medical treatment, care and pulmonary rehabilitation program were applied to bonventional Physiotherapy and Rehabilitation Group.The patients were mobilized as early as possible. Starting on the postoperative zeroth day, a postoperative rehabilitation program including pulmonary rehabilitation and early mobilization was applied to every patient in the control and experimental groups by a therapist for 1 week as in routine
32934681|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
32934682|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
33252907|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
33252908|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
33252909|NCT00928317|Placebo Comparator|Placebo arm|
33252910|NCT05014815|Experimental|Arm A: Ociperlimab + tislelizumab histology-based chemotherapy|
32743013|NCT04959669|Experimental|Intervention group|DeSSBack (Decision Support System for Low Back Pain)
32743014|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
32743015|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
32743016|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
32743017|NCT04940715|Experimental|Passive joint mobilization|Patients lay down on a prone position, with their hands around the body and neck placed comfortable. The therapist performed a postero-anterior joint mobilization using Maitland's technique, applying pressure to spinous process of targeted vertebra (the one who reproduces patient's symptoms).
32743018|NCT04940715|Experimental|Mobilization with movement|Patients perform their painful movement (flexion, extension…). If pain wasn't reproduced, a combination of movements will be performed (flexion + rotation…). The most painful vertebral level was assessed too with passive accessory vertebral movements. Afterwards, with the patient on a seated position on a stretcher with feet supported and a belt around the waist, the therapist performed a sustained glide on the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level.
32743019|NCT04940715|No Intervention|Control group|"Patients were measured at baseline and then were placed on wait list until the end of the study. At this time, they were measured again."
32743020|NCT04947111|Other|Serological survey|A blood sample will be taken to estimate the specific serotype prevalence for dengue virus in groups of 5 to 35 years in areas of low and high dengue endemicity.
32743021|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
32743022|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
32743023|NCT04947345|Experimental|Experimental group: Remimazolam Besylate|Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of Remimazolam is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.2-1 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and Remimazolam, no analgesic or sedative could be used during the experimental time period.
32743024|NCT04947345|Active Comparator|Positive control group: Propofol|"Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of propofol is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.3-4.0 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and propofol, no analgesic or sedative could be used during the experimental time period.~Rescue therapy for experimental group During the treatment of the experimental group, if the RASS cannot be maintained at 0 to -2 points at the maximum Remimazolam maintenance dose of 1 mg/kg/h, a loading dose of propofol (0.2 mg/kg) can be given intravenously. If RASS fails to satisfied after three loading doses of propofol, Remimazolam is discarded and 0.3-4.0 mg/kg/h of propofol are used as rescue therapy for experimental group."
32743025|NCT04947189|Experimental|Seviteronel, dexamethasone and docetaxel|"Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.~Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly."
32743026|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
32743027|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
32743028|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
32743029|NCT04413123|Experimental|Cabozantinib|"Eligible patients will be enrolled and receive treatment with~Cycle 1-4 (cycles of 21 days)~Cabozantinib predetermined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks~Ipilimumab predetermined protocol dosage via IV every 3 weeks~After the first four cycles of therapy,~Cabozantinib determined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
32743030|NCT04940559|Experimental|Group 1: Sequence 1|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
32743031|NCT04940559|Experimental|Group 1: Sequence 2|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
33252911|NCT05014815|Placebo Comparator|Arm B: Placebo + tislelizumab + histology-based chemotherapy|
33252912|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
33252913|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
33252914|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
32730328|NCT05127447|Sham Comparator|Sham group|In the Sham group, for 45 minutes, 2 days a week, a vacuum electrode was connected from combined vacuum electrotherapy device over the pelvis and thigh, and only vacuum was applied while the patient was in the supine position, and no current was given from the applied device.
32730329|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
33252915|NCT00355615|Placebo Comparator|Placebo|Placebo
33252916|NCT00355615|Other|rosuva ol|rosuvastatin open label
33252917|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
33252918|NCT00347269|Experimental|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
33252919|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
33252920|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
33252921|NCT01053793|Active Comparator|Glucose Standard|
33252922|NCT01053793|Experimental|Potato Variety|
32934683|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
33252923|NCT04034433|Experimental|Exercise|
33252924|NCT04034433|No Intervention|Control|
33252925|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
33252926|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
33252927|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
33252928|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
32730330|NCT05123625|No Intervention|RC combined with lymph node dissection|When radical cystectomy was performed, pelvic lymph node dissection was also performed.
32934684|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
32934685|NCT03585595|Experimental|Intensive treatment group|Systolic BP target <120 mmHg for the intensive treatment group
32934686|NCT03585595|Active Comparator|Standard treatment group|Systolic BP <140 mmHg for the standard treatment group
32934687|NCT04333615|Sham Comparator|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
32934688|NCT04333615|Experimental|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
32934689|NCT04333615|Active Comparator|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
32934690|NCT04339699|Active Comparator|NobleStitch EL|Participants treated with the NobleStitch EL device
32934691|NCT04339699|Active Comparator|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
32934692|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
32934693|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
32934694|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
32934695|NCT04339309|Active Comparator|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
32934696|NCT04339309|Active Comparator|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
32934697|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
33252929|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
33252930|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
33252931|NCT00924105|Experimental|1|
33252932|NCT00924105|Placebo Comparator|2|
33252933|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
33252934|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
32934698|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
32934699|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
32934700|NCT02239926|Placebo Comparator|Placebo|Placebo
32934701|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
33252935|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
33252936|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
32730331|NCT05123625|Experimental|Only RC|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
32730332|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
32730333|NCT05127369|Experimental|Test group|Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride
32730334|NCT05127369|Active Comparator|control group|Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule
32730335|NCT05127213|Experimental|Intragastric balloon system group|"Operation way: intragastric balloon system~Using the intragastric balloon system to treat obesity."
32730336|NCT05127213|Experimental|Sleeve gastrectomy group|"Operation way: sleeve gastrectomy~Using the sleeve gastrectomy to treat obesity."
32730337|NCT03360409|Experimental|grade 1|ACD
32730338|NCT03360409|Active Comparator|grade 2|ACDF
32730339|NCT03360409|Active Comparator|grade 3|ACDA
32730340|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
32730341|NCT05127135|Experimental|ThisCART7 cells injections|In this study, allogeneic anti-CD7 CAR T Cells(ThisCART7 cells) is used to treat patients with refractory or relapsed CD7 positive T cell malignancies.
32730342|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
32730343|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
32730344|NCT05126901|Experimental|1 month to 2 year old subjects (infants)|"Subjects aged 1 month to less than 2 years will enter a Pre-assignment phase: baseline pre-dose blood and urine sample are collected and subjects will take a single dose of 0.1 ml/kg ferric maltol suspension under supervision. Further 3 PK blood samples up to 6 h and urine samples from 2 timepoints will be taken.~Subjects showing evidence of absorption, metabolism of serum iron and elimination of maltol will enter the treatment phase and be assigned to the ferric maltol arm.~Subjects will be assigned to receive ferric maltol oral suspension and start the 0.1 ml/kg BID dose on V2 and continue for 7-10 days. On V3 they will perform the same PK assessments as on Pre-assignment PK visit."
32730345|NCT05126901|Experimental|2 to 17 year old subjects - Ferric Maltol|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~The first 18 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs) will enter a PK phase with 2 PK days.~Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
32730346|NCT05126901|Active Comparator|2 to 17 year old subjects - Ferrous Sulfate|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~The first 18 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs) will enter a PK phase with 2 PK days.~Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
32730347|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
32730348|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
32730349|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
32730350|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
32730351|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
32934702|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
32934703|NCT00367705|Active Comparator|T|VSL-#3
32934704|NCT00367705|Placebo Comparator|P|
33252937|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
33252938|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
33252939|NCT00928551|Experimental|1|
33252940|NCT01053871|Experimental|1|sedation using propofol
33252941|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
33252942|NCT00984178|No Intervention|Control group|standard treatment
32934705|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
32934706|NCT04340089||control group|The patients can move freely
32934707|NCT04783506||Suicidal Behavior|Adolescents who have suicidal behavior, which for this study, is defined by a recent (within 3 months of enrollment) suicide attempt or suicidal ideation warranting urgent evaluation.
32934708|NCT04783506||At Risk for Mood Disorders|Adolescents at risk for mood disorders, which for this study, is defined by either personal history of anxiety disorder or substance use disorder or a history of trauma, or a first degree relative with a history of a mood disorder or suicidal history.
32934709|NCT04783506||Healthy Control|Healthy adolescents with no lifetime history of any psychiatric or substance use disorders or a history of trauma. Additionally, no first-degree family member with a history of a mood disorder or suicidal history.
32934710|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
33252943|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
33252944|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
33252945|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
33252946|NCT04034277|Experimental|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
33252947|NCT04034277|Active Comparator|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
32934711|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
32934712|NCT04860414|Experimental|Major Cognitive Impairment|
32934713|NCT04860414|Experimental|Minor Cognitive Impairment|
32934714|NCT04860414|Active Comparator|No Cognitive Impairment|
32934715|NCT04853238||Cohort 1: Participants with newly and previously diagnosed stable disease|
32934716|NCT04853238||Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization|
32934717|NCT04853238||Cohort 3: Participants requiring hospitalization for an acute exacerbation|
32934718|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
32934719|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
32934720|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
32934721|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
32934722|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
32934723|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
32934724|NCT04781088|Experimental|Treatment (paclitaxel, lenvatinib, pembrolizumab)|Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
32934725|NCT04159909|Experimental|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
33074539|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
33074540|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
33074541|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
33252948|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
33252949|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
33252950|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
32934726|NCT04159909|Sham Comparator|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
32934727|NCT04121221|Experimental|GA Depot|Monthly IM injection
32934728|NCT04121221|Placebo Comparator|Placebo|Monthly IM injection
32934729|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
32934730|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
32934731|NCT04074265|Active Comparator|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
32934732|NCT04074265|Placebo Comparator|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
32934733|NCT05342376|Active Comparator|Dexmedetomidine|This is group D, which will receive 10 micro-gram Dexmeditomidine diluted in 02 ml normal saline to be administered intravenously in 10 minutes after umbilical cord is clamped..
32934734|NCT05342376|Active Comparator|Saline|This group S will receive 02 ml normal saline intravenously as placebo in 10 minutes after umbilical cord is clamped..
32934735|NCT03954535|Experimental|Intervention|9 sessions and website with entertainment features and resources
32934736|NCT03954535|Placebo Comparator|Control|website with entertainment features and resources
32934737|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
32934738|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
32934739|NCT02239224|Experimental|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
32934740|NCT02239224|Experimental|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
32934741|NCT02239224|Experimental|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
32934742|NCT02239224|Placebo Comparator|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
32934743|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
32934744|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
32934745|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
32934746|NCT03330847|Active Comparator|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
32934747|NCT03330847|Active Comparator|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
32934748|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
32934749|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
32934750|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
32934751|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
32934752|NCT03953755|No Intervention|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
32934753|NCT03953755|No Intervention|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
32934754|NCT03953755|Experimental|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
32934755|NCT03953755|No Intervention|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
32934756|NCT03901807|Experimental|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
32934757|NCT03901807|No Intervention|Control|Standard medical care alone
32934758|NCT04418310|Active Comparator|Lay open and curettage|Lay open and curettage in Pilonidal sinus
32934759|NCT04418310|Active Comparator|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
33252951|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
32769181|NCT04820543|Experimental|Simplified Method|In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
33252952|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
33252953|NCT00987376|Experimental|1|Prostate cancer patients
33252954|NCT03984019|Other|A|Radiotherapy; SBRT Additional cardiac diagnostics
33252955|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
33252956|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
32769182|NCT04820543|Experimental|Individualized Method|In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished. And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment. For mild GS (3 to< 5mm), 2 U BTX-A was injected at bilateral LLSAN. For moderate (5 to < 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U). And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
32769183|NCT04816487|Active Comparator|Silver Diamine Flouride|Discoloration of primary carious teeth treated by SDF
32769184|NCT04816487|Experimental|Glutathione|Discoloration rate of primary carious teeth treated by SDF + Glutathione
32769185|NCT04816487|Experimental|Potassium iodide|Discoloration rate of primary carious teeth treated by SDF + KI
32769186|NCT04360577|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
32769187|NCT04360577|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
32769188|NCT04360577|No Intervention|Usual care|Chemotherapy without acupuncture
32769189|NCT04831229|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
32769190|NCT04831229|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
32769191|NCT04358315||Observational (smell or puff e-liquids)|Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.
32769192|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #1)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
32769193|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #2)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
32769194|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #3)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
32769195|NCT04830371|Active Comparator|Arm D (Typbar-TCV)|Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.
32769196|NCT04820699|Experimental|post isometric relaxation|Group A received Post isometric relaxation technique (MET).The participants performed isometric contractions using 20% of their strength, 5 second holds with 5 seconds rest time in between each contraction
33074542|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
33252957|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
33252958|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
33252959|NCT03986983|Experimental|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
32730358|NCT04520035|Experimental|neoadjuvant chemotherapy with camrelizumab|"paclitaxel and cisplatin~Carilizumab 200 mg, every 3 weeks, 2 cycles.~Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles~Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles"
32730359|NCT05404269||Group AGC|The FLOW-i anesthesia machine (Maquet, Solna, Sweden) can be equipped with automated gas control (AGC), an automated low flow tool with target control of the inspired oxygen concentration (FIO2) and end-expired concentration (FA) of a potent inhaled anesthetic. İnitially before induction, we set the minimal fresh gas flow to 0.5 L min-1 and target end-expired agent concentration for 1 MAC (minimal alveolar concentration). Shortly after intubation of the patient, we switched to AGC mode.
32730360|NCT05404269||Group Minimal Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 0.5 L min-1 after sevoflurane concentration reaching to 1 MAC.
33252960|NCT03986983|Experimental|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
33252961|NCT03986983|No Intervention|Control group|The participants do not perform any type of intervention.
32769197|NCT04820699|Experimental|mulligan bent leg raise|Group B: Mulligan bent leg raise technique. Isometric contraction of hamstring muscle for progressively five greater position of hip flexion; three pain-free repetitions with 5 second hold was performed by participants
32769198|NCT04816409|Experimental|(Neurodevelopmental therapy)|"Starting Posture Start and evaluate the supreme effective posture to move from(usually straight) Reassemble to mid plane (head/trunk)~•Neutral position of body Identify the Missing Components Detect starting posture and compare to normal.~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.~Developmental movement patterns training:~Obstacle crawl, hold swing's ropes in kneeling anhalf kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of sustaining exercise positions in children.4. Ambulation training, suitable to the motor"
32769199|NCT04816409|Active Comparator|Conventional treatment|Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
32769200|NCT04816331||Neonatal Encephalopathy (NE)|This study is a follow up of children at 2-3 years of age who were enrolled in the HRB-funded Neonatal Inflammation and Multiorgan dysfunction and Brain injUry reSearch group (NIMBUS) project. These babies had Neonatal Encephalopathy and required Therapeutic Hypothermia and are matched with controls. Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management were collected. In addition, details of Therapeutic Hypothermia treatment including initiation, duration and clinical examination, investigations including cranial USS, MRI, EEG and placental histology analysis performed as were recorded.
32769201|NCT04816331||Controls|The controls include age-matched normal children born at term with a normal delivery and postnatal course.
32769202|NCT04830059|Experimental|High intensity intermittent training|HIIT exercise program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes.
32769203|NCT04830059|Experimental|HIIT with pollution reduction|HIIT program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
32769204|NCT04830059|Experimental|Moderate intensity continuous training|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise.
32769205|NCT04830059|Experimental|MICT with pollution reduction|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
32769206|NCT04830059|Experimental|Stretch control group|Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
32769207|NCT04830059|Experimental|Control with pollution reduction|"Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.~Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10."
32769208|NCT04820621|Experimental|Participants with mild hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
32769209|NCT04820621|Experimental|Participants with moderate hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
32769210|NCT04820621|Experimental|Participants with normal hepatic function|All participants will receive a single oral dose in the fasted state on Day 1.
32769211|NCT04816253|Placebo Comparator|Normal saline|Normal saline irrigation after extraction and No drug placed in tooth socket
32769212|NCT04816253|Active Comparator|Gengigel|Gengigel (Hyaluronic acid) placed after extraction
32769213|NCT04816253|Active Comparator|Methylprednisolone|Methylprednisolone will be given intravenous to a patient half an hour before the surgery
32769214|NCT04816253|Active Comparator|Methylprednisolone and Gengigel|Methylprednisolone will be given intravenous to a patient half an hour before the surgery and Gengigel (Hyaluronic acid) placed after extraction
33252962|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
32769215|NCT04820231|Other|PRP injection group|"Intra-articular PRP injection with ultrasound guidance~Three times PRP injections with an interval of one week"
32769216|NCT04816097|Active Comparator|Steroid Group|Participants will receive 4 doses of dexamethasone 6mg IM 48h before elective CS.
32769217|NCT04816097|No Intervention|No Steroid Group|Participants will receive No treatment before elective CS.
32769218|NCT04815941|Experimental|Soft ball tissue release exercises|
32934760|NCT04776096|Experimental|Bepotastine besilate 1,5% preservative free|Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.
33252963|NCT00924417|Other|Routine care|Patient managed as routine care.
33252964|NCT04015245|Experimental|SNMC|
33252965|NCT04015245|No Intervention|non-SNMC|
33252966|NCT03983785|Experimental|Pilates|
33252967|NCT03983785|Experimental|Elastic Taping|
33252968|NCT03983785|No Intervention|Wait List Control|
33252969|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
33252970|NCT00924495|Active Comparator|Cortical regulation|
33252971|NCT04005664|No Intervention|Bolus group|Hypotension occurring under spinal anaesthesia (SBP < 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
33252972|NCT04005664|Active Comparator|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
33252973|NCT00928785|Experimental|REPEVAX|
32769219|NCT04363619|Placebo Comparator|Controls|
33252974|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
33252975|NCT00330967||Group 1|healthy subjects
33252976|NCT00330967||Group 2|healthy subjects different from group 1
33252977|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
32769220|NCT04363619|Experimental|ICH|
32769221|NCT04363619|Experimental|aSAH|
32769222|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
32769223|NCT04363073|Experimental|Anaabella|Milk will be expressed using Annabella breast pump.
32769224|NCT04363073|Active Comparator|Control pump|Milk will be expressed using a control breast pump.
32769225|NCT05617781||Control|
32769226|NCT05617781||Patient|
32769227|NCT04820153|Other|Study Participants|Study participants will participate in both the Physical Activity Monitoring Device intervention and the Lifestyle Redesign Coaching intervention simultaneously. Both interventions are complementary to one another.
32769228|NCT04819529|Experimental|Experimental Group - Early and intensive Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
32769229|NCT04819529|No Intervention|Control group - Standard Analgesia,Sedation, Delirium and Mobilization (ASDM) Protocol|The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
32769230|NCT04815863||Elderly|Over 60 years old
32769231|NCT04815863||Non-Elderly|Under 60 years old
32769232|NCT04815707|Other|Surgery|Occult hernia found will be repaired at the same time as the initial inguinal hernia
32769233|NCT04815707|No Intervention|Expectant Management|No surgery will be done if an occult hernia is found during the initial inguinal hernia surgery
32769234|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
32769235|NCT04819685|Experimental|test group|Intervention:Anti-radiation spray (liquid dressing)
32769236|NCT04819685|No Intervention|control group|
32769237|NCT04815785|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and loading system
32769238|NCT04819607||BMFS patients|Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.
32769239|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
32769240|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
32769241|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
32769242|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
32769243|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
32769244|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
32769245|NCT04829279|Experimental|Case|Emergency patient transferred by CONNECT AI system
32769246|NCT04829279|No Intervention|Control|Emergency patient transferred by conventional EMS
32769247|NCT05053789|Experimental|Group 1|After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2). Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit. If the NEI grading is ≤1 OR the OSDI score <20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
32769248|NCT05053789|Active Comparator|Group 2|The study days are conducted in the same way as for the study group. Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
32769249|NCT04829435|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
33252978|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
33252979|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
32769250|NCT04829435|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
32769251|NCT05042635|Experimental|Ixekizumab (4 weeks) + Jueyin Granules (12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin Granules was used in the 12-week traditional Chinese medicine treatment period.
33252980|NCT03983629||CDA patients|
33252981|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
33252982|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
33252983|NCT00924573|Experimental|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
33252984|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
33252985|NCT01054027|Experimental|0 Drop|Left eye dose
33252986|NCT01054027|Experimental|1 Drop|Left eye dose
33252987|NCT01054027|Experimental|2 drop|Left eye dose
33252988|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
33252989|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
32769252|NCT05042635|Placebo Comparator|Ixekizumab (4 weeks) + Jueyin placebo Granules(12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin placebo Granules was used in the 12-week traditional Chinese medicine treatment period.
32769253|NCT04815395|Experimental|Oral Oxytocin|Oxytocin (24IU) orally
32769254|NCT04815395|Experimental|Intranasal Oxytocin|Oxytocin (24IU) intranasally
32769255|NCT04815395|Placebo Comparator|Oral Placebo|Placebo orally
32769256|NCT05042323|Experimental|TF-CBT-Skills|Step 1: 4-5 sessions with stabilization/skill building Step 2: 4-5 sessions with narrative and cognitive processing
32769257|NCT05042323|Active Comparator|TF-CBT-Narr|Step 1: 4-5 sessions with narrative and cognitive processing Step 2: 4-5 sessions with stabilization/skill building
32769258|NCT04819139|Active Comparator|Thumb exercises +orthosis|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain."
32769259|NCT04819139|Experimental|Thumb exercises +orthosis+ proprioceptive program exercises|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain. In addiction, patients will received a proprioceptive program exercises using also a online program with a laptop."
32769260|NCT05034679||Vaciinated|First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination.
32769261|NCT05034679||Infected patients by covid-19 and not vacinated|Second group patients who were infected by Covid-19 ant therefor were not vaccinated
32769262|NCT05034679||Not infected nor vacinated|Ptients who who were not infected nor vacinated by Covid-19.
32769263|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
32769264|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
32769265|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
32769266|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
32769267|NCT05034445||Sputum group|Sputum samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (sputum 1000X)
32769268|NCT05034445||Tissue group|Clinical data review to obtain corresponding tissue samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (tissue 1000X)
32769269|NCT05034445||Plasma group|Clinical data review to obtain corresponding plasma samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (plasma 10000X)
32934761|NCT04776096|Active Comparator|Olopatadine hydrochloride 0,2% with BAK|Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.
33252990|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
33252991|NCT05711758||PSAM Treatment Patients|Subjects having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
32934762|NCT03899155|Experimental|Nivolumab Dose 1|Specified Dose on Specified Days
33252992|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
33252993|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
33252994|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
33252995|NCT00987688|No Intervention|Normothermia|Standard management
33074543|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
33074544|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
33074545|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
33074546|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.~Intervention: Cardiac training program"
33074547|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
33074548|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
33074549|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
33252996|NCT05277597|Experimental|The group (ET+S )|Participants exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
32730361|NCT05404269||Group Medium Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 2 L min-1 after sevoflurane concentration reaching to 1 MAC.
32730362|NCT04519801|Other|REHAB|Standard post-operative rehabilitation regimen (REHAB) (Control)
32730363|NCT04519801|Experimental|REHAB + BFR|Standard rehabilitation regimen with BFR therapy (REHAB + BFR) (Experimental)
32730364|NCT05123235|Experimental|Physical Activity|The intervention will last 11 weeks, and participants in the intervention group will have individual weekly web-meeting using a video conferencing platform. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will report on the past week's physical activity goals, failures and successes, set goals for the next week, discuss that week's behavioral strategy to promote physical activity for that week, and engage around 5 minutes of physical activity. The topics that will be discussed in the newsletters and weekly meetings will include behavioral strategies for physical activity changes. Those in the control group will also be contacted weekly for 11 weeks and will be asked about their physical activity levels for the past week. These meetings will also occur using video conferencing and last 5 minutes.
32730365|NCT05123235|No Intervention|Control|During the 11 weeks the participants in the control group will have a weekly check in meeting using a video conferencing platform. The weekly meeting is expected to last approximately 5 minutes. During this meeting, participants will report on the past week's physical activity levels.
32730366|NCT04519567|Experimental|CTI-1601|
32730367|NCT04519567|Placebo Comparator|Placebo|
32730368|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
32730369|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
32730370|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
32730371|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
32730372|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
32730373|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
32730374|NCT04208997|Experimental|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
32730375|NCT04208997|No Intervention|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
32730376|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
32730377|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
32730378|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
33074550|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
33252997|NCT05277597|Active Comparator|The group (ET)|Participants exercised 60 minutes, 3 times per week
33252998|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
32934763|NCT03899155|Experimental|Nivolumab Dose 2|Specified Dose on Specified Days
33252999|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
33253000|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
33253001|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
33253002|NCT00984412|Experimental|AATT|
33253003|NCT04005430|Experimental|Phase 1|Phase I open label study
33253004|NCT00330187|Experimental|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
32730379|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
32730380|NCT05126667||Breast-conserving surgery|Patients who underwent breast-conserving surgery plus whole-breast irradiation
32934764|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
32730381|NCT05126667||Mastectomy|Patients who underwent mastectomy
32730382|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
32730383|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
32730384|NCT03355963|Active Comparator|Group C|"The treatment group C:~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
32730385|NCT05122923|Experimental|Patients with Serious Game|
32730386|NCT05122923|No Intervention|Patients without Serious Game|
32743032|NCT04940559|Experimental|Group 1: Sequence 3|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
32934765|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
32934766|NCT04765488|Experimental|Study group|"A group of patients in relation to whom the Wash In / WashOut procedure will be applied. In this group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
32934767|NCT04765488|No Intervention|Control group|A group of patients in relation to whom will be applied the traditional method of recovery from anesthesia. In this group during the period of awakening we stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
32934768|NCT04684212|Experimental|Device Arm|The LAmbre PlusTM Left Atrial Appendage Closure System (LAmbre device)
32934769|NCT04684212|Active Comparator|Control Arm|Market approved oral anticoagulation (OAC)
32934770|NCT04684212|Other|Registry Arm|250 subjects. Patients that meet all of the exclusion and inclusion criteria except for eligibility for long-term OAC or anatomical requirements.
32934771|NCT04684212|Other|Roll-in Arm|225 roll-in subjects
32934772|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
32934773|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
32934774|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
32934775|NCT05588947|Experimental|Tele-TaCAS|Two Take Charge sessions delivered by telehealth six weeks apart, the first being at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
32934776|NCT05588947|Active Comparator|Control|Life After Stroke: Survivor Stories video played by telehealth at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
32934777|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
32934778|NCT03271489|Placebo Comparator|Placebo|Placebo
32934779|NCT03260491|Experimental|Dose Escalation: Cohort 1, 3.2 mg/kg|Participants in the Dose Escalation Cohort 1 will receive U3-1402 intravenously (IV) once every three weeks at 3.2 mg/kg.
32934780|NCT03260491|Experimental|Dose Escalation: Cohort 2, 4.8 mg/kg|Participants in Dose Escalation Cohort 2 will receive U3-1402 intravenously (IV) once every three weeks at 4.8 mg/kg.
32934781|NCT03260491|Experimental|Dose Escalation: Cohort 3, 5.6 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 5.6 mg/kg.
32934782|NCT03260491|Experimental|Dose Escalation: Cohort 4, 6.4 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 6.4 mg/kg.
32934783|NCT03260491|Experimental|Dose Expansion: Cohort 1, EGFR mutant|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
32934784|NCT03260491|Experimental|Dose Expansion: Cohort 2, EGFR wild-type|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
32934785|NCT03260491|Experimental|Dose Expansion: Cohort 3a, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
32730387|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
32730388|NCT05122845|Experimental|Healthy volunteers comparators to dialysis subjects|Creation of a biological collection for biological analysis
32730389|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
32730390|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
32730391|NCT04519489|Experimental|PAP therapy with telemonitoring|This arm will consist of 86 subjects.
32730392|NCT04519489|Other|Control group|This arm will consist of 43 subjects.
32730393|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
32730394|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
32730395|NCT05114889|Experimental|Single Ascending Dose Healthy Volunteer|BSI-045B
32730396|NCT05114889|Experimental|Multiple Ascending Dose Healthy Volunteer|BSI-045B
32730397|NCT05114889|Experimental|Single Dose Atopic Dermatitis patients|BSI-045B
32730398|NCT04518475|Experimental|efficacy of eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
32730399|NCT04518475|Active Comparator|efficacy of eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
32730400|NCT05114811|Experimental|Physiotherapist massage|Perineal massage was applied by a physiotherapist expert in urogynecology and obstetrics during a total of 6 to 10 sessions (from 34th gestation week until delivery) of 30 minutes each on a weekly basis.
32730401|NCT05114811|Experimental|Self-massage intervention|Self-massage group received permanent instructions on perineal massage during pregnancy: it should be applied at least twice a week (on alternate days) during 10 minutes using a water-based lubricant from the 34th gestation week until delivery.
32730402|NCT05114811|No Intervention|Control|Group receiving standard obstetric care (consultation and check-ups with the gynaecologist and midwife). No contact with the research physiotherapists.
32730403|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
32730404|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
32730405|NCT05109663|Experimental|Dose Escalation Cohort 1: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 50 mg on Day 1.
32730406|NCT05109663|Experimental|Dose Escalation Cohort 2: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1.
32730407|NCT05109663|Experimental|Food Effect Cohort A: SKLB1028, fasted dosing followed by fed dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1 in a fasting state, and a single dose of SKLB1028 150 mg on Day 11 in a fed state, with a 10-day washout period between the 2 doses.
32730408|NCT05109663|Experimental|Food Effect Cohort B: SKLB1028, fed dosing followed by fasted dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 4 in a fed state, and a single dose of SKLB1028 150 mg on Day 14 in a fasting state, with a 10-day washout period between the 2 doses.
32730409|NCT04517539|Experimental|SBRT+GM-CSF+INF-αb|Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
32730410|NCT05101863||Normal-weight, NON-food addicted|
32730411|NCT05101863||obese food addicted|
32730412|NCT05101863||obese NON-food addicted|
32730413|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
32730414|NCT04444219|Other|Breakfast meal_1|100 g white bread, 40 g yellow cheese and Κing Oyster mushrooms (test meal)
32730415|NCT04444219|Other|Breakfast meal_2|100 g white bread, 40 g yellow cheese and 6-7 cherry tomatoes (control meal)
32730416|NCT04304001|Experimental|Community Health Advisor|Intervention arm participants will be scheduled to receive the CHA intervention within 4 to 6 weeks after enrollment, a FIT kit, a mailed targeted CRC brochure, and a follow-up telephone survey at 3- and 12-months post-intervention
33253005|NCT00330187|Active Comparator|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
33253006|NCT00330187|Active Comparator|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
33253007|NCT00330187|Placebo Comparator|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
33253008|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
33253009|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
33253010|NCT04006132|Experimental|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
33074551|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
33074552|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
33074553|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
33074554|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
33074555|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
33074556|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
33074557|NCT04690309|Active Comparator|Patients treated with human insulin preparations|Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.
33253011|NCT03986905|Experimental|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
33253012|NCT03986905|Placebo Comparator|Placebo|placebo nasal gel + placebo patch
33253013|NCT03986905|Active Comparator|TDS Patch|placebo nasal gel + TDS patch
33253014|NCT05711602|Experimental|Pilates group|This group receives physical training based on pilates exercises
33401172|NCT05676970|Experimental|Telehealth Arm: Wellness with Vaccine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
33074558|NCT04690309|Active Comparator|Patients treated with insulin analogues|Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.
33074559|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
33074560|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
33074561|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.~The patients will receive usual standard of care and no intervention."
33074562|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
33074563|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.~Device: K5 Power Breath"
33074564|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
33074565|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
33253015|NCT05711602|No Intervention|No intervention group|This group does not receive any treatment
33253016|NCT04713280|Active Comparator|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary posterior dento-alveolar intrusion
33253017|NCT04713280|Experimental|Bi-maxillary posterior dento-alveolar intrusion|Mini-screw supported bi-maxillary posterior dento-alveolar intrusion
33401173|NCT05676970|Active Comparator|Telehealth Arm: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
33253018|NCT00987922|Experimental|Hypothermia|
33401174|NCT03291067|Experimental|MT-8554 1mg|
33401175|NCT03291067|Experimental|MT-8554 5mg|
33401176|NCT03291067|Experimental|MT-8554 10mg|
33253019|NCT00987922|No Intervention|Control|
33253020|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
33253021|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
33401177|NCT03291067|Placebo Comparator|Placebo|
33401178|NCT02941627|Experimental|Neuro Cochlear Implant System study group|All patients will receive a Neuro Zti implant and fitted with Neuro One sound processor
32934786|NCT03260491|Experimental|Dose Expansion: Cohort 3b, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive U3-1402 IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
33253022|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
33253023|NCT04914286|Experimental|GFH018+Toripalimab|Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
33253024|NCT04864444|Experimental|MDA with DHA-PPQ + SLD-PQ|Participants in intervention villages will be given three rounds of MDA with DHA-PPQ and SLD-PQ. Prior to the intervention, participants will have received piperonyl butoxide (PBO) treated LLINs and proactive community case management. Unlike control villages, MDA-randomized villages will not receive SMC.
33253025|NCT04864444|No Intervention|Standard malaria control interventions|Participants in the control villages will receive standard malaria control interventions as implemented by the Senegal PNLP. This will include the distribution of PBO LLINs, proactive case management, and SMC.
33253026|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range~1 x 500 ml water oral, 1 x~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
33253027|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
33253028|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
33253029|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
33253030|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
33253031|NCT03989635|Experimental|QAW039|QAW039 450mg
33253032|NCT03989635|Placebo Comparator|Placebo|Placebo to QAW039
33253033|NCT03986827|Experimental|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
32730417|NCT04304001|Active Comparator|Usual care|Control group participants will receive a FIT kit, a mailed targeted CRC brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
32730418|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
32730419|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
32730420|NCT04278651|Active Comparator|Oral Iron|325mg oral iron (ferrous sulfate) twice daily
33401179|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
33401180|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
32730421|NCT04278651|Experimental|Intravenous Iron|510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.
32730422|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
32730423|NCT05125965|Experimental|Patient undergoing immunotherapy with an indication for cardiac MRI|Patient undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or myocarditis or other cardiovascular complications
32730424|NCT04523155|Experimental|Treatment Sequence AB|Participants randomized to sequence AB will receive 3 months of meals, followed by a 3 month washout period and a 3 month intervention period with no meals.
32730425|NCT04523155|Experimental|Treatment Sequence BA|Participants randomized to sequence BA will receive 3 months of no meals followed by a 3 month washout period and a 3 month intervention period with meals.
32730426|NCT03975465|Experimental|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
32934787|NCT03260491|Experimental|Dose Expansion: Cohort 4, EGFR mutant|Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive U3-1402 IV at 5.6 mg/kg every 3 weeks.
32934788|NCT03250273|Experimental|Arm A - Cholangiocarcinoma|
32934789|NCT03250273|Experimental|ARM B - Pancreatic Cancer|
32934790|NCT02203032|Experimental|Open-label ustekinumab|
32934791|NCT02203032|Experimental|Double-blind guselkumab|
32934792|NCT02203032|Experimental|Double-blind ustekinumab|
32934793|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
32934794|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
32934795|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
32934796|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
32934797|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
32934798|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
33253034|NCT03986827|Active Comparator|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
33253035|NCT05711524|Active Comparator|Patients given Traditional Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given traditional cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
33253036|NCT05711524|Experimental|Patients given PR Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given PR cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
33253037|NCT01054261|Other|Normal|Normal renal function
33253038|NCT01054261|Other|Mild|Mild renal impairment
33253039|NCT01054261|Other|Moderate|Moderate renal impairment
33253040|NCT05711446|Experimental|Double Voiding|The participant will be instructed to void twice.
32730427|NCT03975465|Active Comparator|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
32730428|NCT05125575|Experimental|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
32934799|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
32934800|NCT03213457|Placebo Comparator|Placebo|Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
32934801|NCT03213457|Experimental|Elagolix / Elagolix + E2/NETA|Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
32934802|NCT03213457|Experimental|Elagolix + E2/NETA|Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
32934803|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
32934804|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
32934805|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
32934806|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
32934807|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
32934808|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
32934809|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
32934810|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
32934811|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
32934812|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
32934813|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
32934814|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
32934815|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
32934816|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
32934817|NCT03485365|Placebo Comparator|Part A: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
32934818|NCT03485365|Experimental|Part B: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
32934819|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC route.
32934820|NCT04188288|Experimental|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
32934821|NCT04188288|Other|Control feedback|Three imaging (fMRI) sessions of control feedback.
32934822|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
32934823|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
32934824|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
32934825|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
33253041|NCT05711446|Active Comparator|Regular Voiding|The participant will be instructed to void normally.
33253042|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
33253043|NCT03989791|Active Comparator|Absolute diet|
33253044|NCT03989791|Experimental|Normal diet|
32730429|NCT05125575|Active Comparator|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
32730430|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
32730431|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
32730432|NCT03971799|Experimental|CD33CART|All patients who receive CD33CART cell infusion
32730433|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
32934826|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
33253045|NCT05587504|Experimental|Cigarette and/or e-Cigarette users|Each participant will participate in 4 sessions. During each session, participants will first complete a 10-puff product use period with the ECIG assigned for that session, then a 30-minute ad lib product use period, and then a cigarette/e-cigarette challenge paradigm.
33253046|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
32730434|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
32730435|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
32730436|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
32730437|NCT04444297|Active Comparator|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
32730438|NCT04444297|Experimental|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
32730439|NCT02550093|Experimental|Oxytocin, then Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 13 days the same subject will then receive a nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 2 (day 14).
32934827|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
32934828|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
32730440|NCT02550093|Experimental|Normal Saline, then Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 14 to 15 days the same subject will then receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 2 (day 14).
32934829|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
32730441|NCT04444063|Experimental|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
32730442|NCT04444063|Active Comparator|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
32730443|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
32730444|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
32730445|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
32730446|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
32730447|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
32730448|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
32934830|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
32934831|NCT02609828|Experimental|Arm 1|Tanezumab 20 mg subcutaneously
32934832|NCT02609828|Placebo Comparator|Arm 2|Placebo matched to active treatment subcutaneously
32934833|NCT05588713|Other|Brief assessment protocol|"The brief protocol will contain a minimum according to guidelines for assessing ADHD:~review of medical records, a validated diagnostic interview (MINI-KID), a structured medical history, a pedagogical statement including suspicion of intellectual disability, and rating scales for symptoms such as ADHD, oppositional defiant disorder, autism, anxiety, and depression directed to children (≥ 13 years), parents, and teachers."
32934834|NCT05588713|Other|Comprehensive assessment protocol|The comprehensive protocol will extend the brief protocol by adding an approximately three-hour long battery of neuropsychological tests (WISC-V and CPT 3) and biomarkers (heart-rate variability, pupil dilation and the pupillary light reflex) assessed during the CPT 3.
32934835|NCT03206047|Experimental|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
33253047|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
33253048|NCT05711368|Active Comparator|interventional group|Nursing students who participated in distress tolerance training session
33253049|NCT05711368|No Intervention|control group|Nursing students not participating in distress tolerance training session
33253050|NCT04769362|Experimental|β-blocker discontinuation arm|Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction
32730449|NCT03359317|Experimental|jogging|At least 5 times/week
33253051|NCT04769362|No Intervention|β-blocker maintenance arm|Continuation of β-blocker therapy after acute myocardial infarction
33253052|NCT03983551|Experimental|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
33253053|NCT03983551|Active Comparator|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
33253054|NCT05709574|Experimental|Tadalafil + chemotherapy|Subjects will receive Tadalafil monotherapy for 2 weeks followed by Tadalafil in combination with neoadjuvant FLOT chemotherapy for 8 weeks in the window between their cancer diagnosis and surgical intervention.
33253055|NCT05706142|No Intervention|Control group|No motor imagery will be shown to these students. The same massage will only be shown as practically at class.
33253056|NCT05706142|Experimental|Intervention Group|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
33253057|NCT03909100|Experimental|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
33253058|NCT04740034|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
33253059|NCT04740034|Experimental|Dose Expansion|An expansion cohort in subjects with mCRPC will be enrolled after RP2D is established.
33253060|NCT04732936|Experimental|Device Usability|Device usability and safety will be evaluated.
33253061|NCT04732936|Experimental|Preliminary Efficacy|Preliminary treatment efficacy will be evaluated.
33253062|NCT05546242|Experimental|CAB LA + RPV LA Arm|"The first 4 weeks of the treatment differ depending on whether participant opts for direct to injection (DTI) or Oral lead-in (OLI).~DTI: participants will remain on daily oral ART for 4weeks after randomization and will receive the 1st injection of IM CAB LA 600mg+RPV LA 900mg at the Month 1 visit. 2nd injections administered at Month 2, followed by maintenance injections every 2 months (Q2M)~OLI: participants will receive the study intervention in 2 phases:~Participants will receive CAB 30mg+RPV 25mg OD for 4weeks to be taken daily with food. The purpose of the optional OLI Phase is to allow an opportunity for participants to assess tolerability of the combination prior to administration of the injectables. There is no proven benefit to this approach~After 4weeks participants return for the Month 1 visit to receive the 1st IM CAB LA 600mg+RPV LA 900mg injections. The 2nd injections administered at Month 2 and then continuation injections will be administered Q2M"
33253063|NCT05546242|Active Comparator|ART Group|Participants will take a daily oral combination of 2 NRTIs plus DTG 50mg. Ideally, the single tablet fixed-dose combination regimen of (tenofovir disoproxil fumarate [TDF] 300 mg + lamivudine [3TC] 300 mg (or emtricitabine [FTC] 200 mg) + DTG 50 mg) will be used as per local country guidelines up to Month 24. If there are preexisting reasons why TDF or 3TC cannot be used as the NRTI backbone then alternative NRTIs are acceptable. Participants will be permitted to switch daily oral ART drugs in case of toxicity, after discussion with the coordinating center.
33253064|NCT04004494|Experimental|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
33253065|NCT04004494|No Intervention|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
33253066|NCT05705908|No Intervention|Control Group - No foot bath|"24 hours after surgery - did not give foot bath to patients~Pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
33253067|NCT05705908|Experimental|Experimental Group- Hot Foot Bath 1|"Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath~Patient was seated in an upright position.~FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~It was filled with 40 degrees water, 20 cm (4 lt. of water)~Soaked in hot water up to the ankles~The foot bath was continued for 20 minutes with the feet in the device.~After 20 minutes, the patient's feet were dried with a towel.~After the foot bath pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
33253068|NCT05705908|Experimental|Experimental Group- Hot Foot Bath 2|"Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath with Lavender Essential Oil~Patient was seated in an upright position.~FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~It was filled with 40 degrees water, 20 cm (4 lt. of water)~Soaked in hot water up to the ankles~The foot bath with Lavender Essential Oil was continued for 20 minutes with the feet in the device.~After 20 minutes, the patient's feet were dried with a towel.~After the foot bath with Lavender Essential Oil pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
33253069|NCT05690464|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
32730450|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
33253070|NCT05690464|Placebo Comparator|placebo|placebo supplement
33253071|NCT04268914|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for IV placement and induction of anesthesia. Current standard of care practices at CHLA for outpatient surgery induction will include the following steps. Children may receive midazolam, parental presence during induction and any other intervention or medication chosen by the HCP. The research team will have no input to the decision regarding the use of any therapy.
33253072|NCT04268914|Experimental|VR Randomization|When a child is assigned to the VR condition s/he will have the added component of VR distraction during pre-surgical preparation. Children in the VR condition will interact with an immersive 3D virtual environment presented via a HMD (head-mounted display), a helmet with computer screens for each eye. This study will use two HMDs at two possible time points: (1) Prior to and during IV placement, participants will play using the Oculus Go; (2) Prior to and during anesthesia induction, participants will play using the Mira Prism.
33253073|NCT04697212|Experimental|Healthcare team- + patient-directed intervention|Team education and patient tool
33253074|NCT04697212|Active Comparator|Healthcare team-directed intervention|Team education
33074566|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
33074567|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
33253075|NCT03150004|Experimental|CLAG-M regimen|Patients' treatment cycle is 30 days.
33253076|NCT00540124|Experimental|Tadalafil|
33253077|NCT00540124|Placebo Comparator|Placebo|
33253078|NCT00540124|Active Comparator|Tamsulosin|
33253079|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
33253080|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
33253081|NCT05525572|Experimental|Shockwave Therapy (SWT) + Platelet-Rich Plasma (PRP) Group|Participants will receive a combination of 5 weekly extracorporeal shockwave therapy sessions (SWT) and two sessions of autologous platelet-rich plasma (PRP) penile injection.
33253082|NCT05677126|Active Comparator|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
33253083|NCT05677126|Active Comparator|a fixed-dose trace element combination product of zinc, copper, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
33253084|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
33253085|NCT04613830|Active Comparator|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
33253086|NCT04613830|Placebo Comparator|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
32730451|NCT05125497||In Vitro Fertilisation (IVF)-Patients|Patients aim to do In-Vitro-Fertilisation (IVF)
33074568|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
33253087|NCT04599166|Experimental|Participant arm|Participants will be recruited to complete the WWYC intervention.
33253088|NCT04573660||Coronary and peripheral stents|Participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
33253089|NCT04573660||Pacing catheters|Participants in the Pacing catheters arm will receive Pacing catheters
33253090|NCT04573660||Vascular plugs|Participants in the Vascular plugs arm will receive Vascular plugs
33253091|NCT04573660||Measurement and imaging (FFR and OCT)|Participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
33253092|NCT04573660||Peripheral dilatation catheters|Participants in the Peripheral dilatation catheters arm will receive Peripheral dilatation catheters
33253093|NCT04573660||Coronary dilatation catheters|Participants in the Coronary dilatation catheters arm will receive Coronary dilatation catheters
33253094|NCT04573660||Coronary and peripheral guidewires|Participants in the Coronary and peripheral guidewires arm will receive Coronary and peripheral guidewires
33253095|NCT04573660||Vessel closure/compression devices|Participants in the Vessel closure/compression devices arm will receive Vessel closure/compression devices
33253096|NCT04573660||Vascular access introducers|Participants in the Vascular access introducers devices arm will receive Vascular access introducers
33253097|NCT05676892|Experimental|The experimental group in benign gallbladder disease|"inclusion criteria~Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~intravenous ibuprofen 800mg/8ml was used after surgery."
32730452|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
33253098|NCT05676892|Experimental|The controled group in benign gallbladder disease|"inclusion criteria~Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used after surgery."
33253099|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
33253100|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
33253101|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
33253102|NCT04238728|Experimental|Silverlon arm|
33253103|NCT04528576|Experimental|DragonFly-M|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Meditech Co., Ltd
33253104|NCT05661682|Active Comparator|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
33253105|NCT05661682|Active Comparator|a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
33253106|NCT04545736|Experimental|Metformin|Oral administration of metformin
33253107|NCT02961322|Experimental|lobo isthmectomy|
33253108|NCT05279170|Experimental|children|"Compression of adjacent vessels (jugular vein and carotid artery), near the left paratracheal area. The risk of compression of the vessels will be assessed before performing the maneuver.~At the screening time before the intervention, we will perfom an ultrasonography measurement while we applied the maneuver in order to eliminate a risk of compression of the vessels, defined as a reduction in diameter of 50%."
33253109|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
33253110|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
33253111|NCT05655598|Experimental|Level 0 Starting Palbociclib with TAS-116|
33253112|NCT05655598|Experimental|Level -1 Palbociclib with TAS-116|
33253113|NCT05655598|Experimental|Level -2 Palbociclib with TAS-116|
33253114|NCT04508530|Experimental|Panzyga|Panzyga 10% IVIG
33253115|NCT04508530|Placebo Comparator|Placebo|Placebo
33253116|NCT05485714||Patient with non-alcoholic fatty liver with advanced liver fibrosis|Patient with non-alcoholic fatty liver with advanced liver fibrosis with F3 or F4 stage on Fibroscan without any evidence of previous decompensation like ascites, jaundice or encephalopathy
33253117|NCT05473234|Experimental|Azithromycin|Children in this arm will receive one dose of amoxicillin.
33253118|NCT05473234|Active Comparator|Amoxicillin|Children in this arm will receive a 5-day course of amoxicillin (standard care).
33253119|NCT04500418|Active Comparator|Cenicriviroc (CVC)|Approximately 122 patients. Day 1: CVC 450 mg (300 mg AM; 150 mg PM; if patients receive their first dose on Day 1 past 2 PM, then their evening dose will be 300 mg and their next dose will be the following AM.) Days 2-28: CVC BID 150 mg (AM/PM). Every dose should be taken with food (within 30 min).
33253120|NCT04500418|Placebo Comparator|Placebo|Approximately 61 patients. A matching placebo will be given to the patients in the Placebo group at an equal volume and at the same schedule.
33253121|NCT05473156|Experimental|Dose-Escalation|
33253122|NCT05473156|Experimental|Dose-Expansion (Non Small Cell Lung Cancer, NSCLC)|
33253123|NCT05473156|Experimental|Dose-Expansion (Head and Neck Squamous Cell Carcinoma, HNSCC)|
33253124|NCT05473156|Experimental|Dose-Expansion (Esophageal Squamous Cell Carcinoma, ESCC)|
33253125|NCT00671034|Experimental|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 4 years.
33253126|NCT00671034|Active Comparator|Arm II (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 4 years.
33253127|NCT04483648|Experimental|Exercise Group|A progressive home-based cervical stabilization exercise program was delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) in a weekly basis.
33253128|NCT04483648|No Intervention|Control Group|Patients in control group did not receive any exercise intervention.
33253129|NCT04622228|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
33253130|NCT04452292|Active Comparator|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
33253131|NCT04452292|Experimental|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
33253132|NCT04432792||Clinical Records Review|We will receive clinical chart data from the telehealth providers on 3,000 patients (which could include the survey study participants, but we will not know their identities) which will include date of birth, zip code, and dates of service - but will otherwise be de-identified.
33401181|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
32730453|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
32730454|NCT04186455|Active Comparator|insertion time|lma pro seal and basks-mask in patients undergoing ups
32730455|NCT04186455|Active Comparator|oropharyngeal leak pressure|lma baska-mask undergoing urs
32730456|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
32730457|NCT03366571||Non anti-viral therapy group|History study from literature
32730458|NCT05125107||Group 1|Predominant focal residual disease without major gradient
32730459|NCT05125107||Group 2|Predominant focal residual disease with major gradient
32730460|NCT05125107||Group 3|Predominant diffuse residual disease without major gradient
32730461|NCT05125107||Group 4|Predominant diffuse residual disease with major gradient
32730462|NCT04523311|Experimental|Hypnosis + usual care|An online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis. Participants will continue with whatever usual care they receive/undertake.
32730463|NCT04523311|Other|Waitlist control + usual care|The control group will receive no intervention beyond whatever usual care they receive/undertake. After the study is complete, they will be offered the option of participating in the hypnosis intervention.
32730464|NCT05055765|Experimental|TEST GROUP I|Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
32730465|NCT05055765|Active Comparator|TEST GROUP II|Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
32730466|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
32730467|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
32730468|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
32730469|NCT05052099|Experimental|mFOLFOX6 combined with Atezolizumab and Bevacizumab|"Patients will receive mFOLFOX6 combined with Atezolizumab 840 mg and Bevacizumab 10 mg/kg in 14-day cycles.~Treatment will be continued until disease progression, unacceptable toxicity or voluntary withdrawal."
32730470|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
32730471|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
32730472|NCT05124951|Experimental|iGCTS|"Stratum I (Germinoma) Patients who achieved complete response after induction chemotherapy will receive WVI 2400cGy/15f plus primary boost 640cGy/4f.~Stratum II (NGGCTs) At the time of response evaluation before radiotherapy, those with complete response or residue disease <1.5cm will receive WVI 3060cGy/17f plus primary boost 2340cGy/13f."
32730473|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
32730474|NCT04375449|Active Comparator|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
32730475|NCT04375449|Active Comparator|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
32730476|NCT04375449|Placebo Comparator|Placebo|maltodextrin single dose
32730477|NCT04523077||Oral lichen planus|Female patients of the Department of Oral Medicine with oral lichen planus
32730478|NCT04523077||Control|Female patients of the Department of Oral Medicine without oral lichen planus or other immune disorders
32730479|NCT05124717|Experimental|Treatment A|Test Product Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)
32730480|NCT05124717|Active Comparator|Treatment B|Reference Product Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
32730481|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
32730482|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
32730483|NCT05116839|Placebo Comparator|the first 15 minutes with PSV|"All patients will breath at the first 15 minutes with PSV:triggered by minute volume <3 Liter,with with no frequency .~Monitoring: (basal&every 3minutes)~Tidal volume (inspiratory & expiratory).~End tidal co2.~Mean air way pressure.~Leakage %.~Respiratory rate .~Spo2.~Heart rate.~Blood pressure (mean arterial pressure"
32730484|NCT05116839|Active Comparator|the following 15 minutes ventilation will be changed to CPAP mode|"then the following 15 minutes ventilation will be changed to CPAP mode at 10 cm H2o .~Monitoring: (basal&every 3minutes)~Tidal volume (inspiratory & expiratory).~End tidal co2.~Mean air way pressure.~Leakage %.~Respiratory rate .~Spo2.~Heart rate.~Blood pressure (mean arterial pressure)."
32730485|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
32730486|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
33253133|NCT04432792||Study Survey Participants|We aim to enroll at least 3,000 participants to complete the study surveys.
33253134|NCT00743522||Control|PROVE Trial settings
33253135|NCT00743522||Experimental|Pre-selected settings
33253136|NCT05623462|Active Comparator|Control Group|"Participants in the control group will receive conventional gait training (conventional physical therapy program) for one hour as the following.~Part (1) Treadmill gait training without virtual reality. (for 30 minutes)~Rest for 15 minutes between the first part and the second part.~Part (2) Indoor open environment gait training exercises(over-ground gait training exercises.). (for 30 minutes)"
33253137|NCT05623462|Experimental|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~There will be 15 minutes rest between parts one and two of the training program~The second part (conventional training program) (30 minutes) will include: Indoor open environment gait training exercises (over-ground gait training exercises.). (30 minutes)"
33253138|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
33253139|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
33253140|NCT04425070|Experimental|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
33253141|NCT04425070|Experimental|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
33253142|NCT04425070|Experimental|ATG-010 + Tislelizumab|ATG 010 40mg/once, will be given on Days 1, 8, and 15 of each cycle
33253143|NCT04607954|Experimental|Treatment (durvalumab, lurbinectedin)|Patients receive durvalumab IV over 60 minutes on day 1 and lurbinectedin IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33253144|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
33253145|NCT04421014|Active Comparator|Ketone Ester drink/ Arm 1|25 participants
32934836|NCT03206047|Experimental|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32934837|NCT03206047|Experimental|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33253146|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
33253147|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
32730487|NCT04139655|Experimental|Colchicine Group|Administration of oral colchicine at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
32730488|NCT04139655|Placebo Comparator|Placebo Group|Participants allocated to the control group will receive a placebo pill at the same dosing regimen as with treatment group. Perioperative and surgical care will not be different from standard clinical practice.
33253148|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
32730489|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
33253149|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
32730490|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
32730491|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
32730492|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
33253150|NCT05604508|Active Comparator|Status Quo|This condition will allow for many posters with pricing information to be displayed.
32730493|NCT04113057|Experimental|Remote Coaching|All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The remote coaching arm will receive regular provider feedback based on LIVMOR data.
32730494|NCT04113057|No Intervention|Remote health monitoring without provider feedback|"All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The no intervention arm will have access to LIVMOR data, but without provider feedback on the LIVMOR data."
32934838|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
32934839|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
32934840|NCT05588635||With live birth group|patients with live birth following frozen-thawed embryo transfer
32934841|NCT05588635||Without live birth group|patients without live birth following frozen-thawed embryo transfer
32934842|NCT02771977|No Intervention|Usual Care|No alert will be fired.
32934843|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
32934844|NCT05588557|Active Comparator|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|Marcaine® at 150 mg in each cohort.
32934845|NCT05588557|Experimental|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|ND-340(90-320 mg) at dose escalations
32934846|NCT02672917|Experimental|Group A|MVT-5873 monotherapy dose escalation, initial to maximum tolerated dose
32934847|NCT02672917|Experimental|Group B|MVT-5873 is administered in Group B every 1 week in combination with gemcitabine and nab-paclitaxel
33253151|NCT05604508|Experimental|Reduced Poster|This condition will allow for a reduced number of posters with pricing information to be displayed.
33253152|NCT05604508|Experimental|No price|This condition will allow for many posters with no pricing information to be displayed.
33253153|NCT04409080|Experimental|Part A and Part B|Part A: Single ascending dose Part B: Preferred dose
32730495|NCT04515511|Experimental|standard care|ICU septic shock patients with refractory hypotension with indwelling pulmonary artery catheter received five sequential intravenous boluses of 100 mL 4% gelatin. Cardiac output measured by thermodilution of PAC before fluid challenge (baseline) and three minutes after each bolus. Fluid responsiveness (FR) was defined as an increase in CO greater than 10% after 500 mL fluid infusion. The smallest volume which can perform an effective fluid challenge was analyzed.
32730496|NCT04109547|Experimental|Oral semaglutide 3mg|Subjects will remain on 3 mg for the entire treatment period (26 weeks)
33253154|NCT00772278|Active Comparator|CAS|carotid artery stenting
33253155|NCT00772278|Active Comparator|CEA|carotid endarterectomy
33253156|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
33253157|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
32730497|NCT04109547|Experimental|Oral semaglutide 7mg|Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
32730498|NCT04109547|Experimental|Oral semaglutide 14mg|Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
32730499|NCT04109547|Placebo Comparator|Placebo (oral semaglutide)|Subjects will receive placebo tablets for the entire treatment period
32730500|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
32730501|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
32730502|NCT03366181||heart failure patients|
32730503|NCT03358849|Experimental|experimental group|
32730504|NCT05403411|Experimental|Intervention group|Distance education for nursing students on critical thinking
32730505|NCT05403411|No Intervention|Control group|The control group was given a booklet for critical thinking.
32730506|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
32730507|NCT05403333|Experimental|Utidelone|Drug: utidelone Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
32730508|NCT04514887|Experimental|Mild Hyperventilation|In this study arm, patients were mildly hyperventilated intraoperatively so their end-tidal CO2 levels are brought down to 30-32 mmHg.
32730509|NCT04514887|No Intervention|Control|In this study arm patients' ventilation is managed according to guidelines with end-tidal CO2 levels kept in the normal range of 35-40 mm Hg
32730510|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
32730511|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:~Ensure patient has demonstrated adequate inhaler technique~Send discharge summary to family physician office and arrange follow-up~Optimize and reconcile prescription of respiratory medications~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions~Refer to pulmonary rehabilitation~Screen for frailty and comorbid condition(s)~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
32730512|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
32730513|NCT05403255||Multiple or isolated pituitary hormone deficiency group|Patient with multiple pituitary deficiency or isolated pituitary deficiency diagnosed for at least 6 months.
32730514|NCT04513405|Other|subjects with skin tears (Group A)|"A sample of peripheral venous blood will be taken to measure the levels of estrone and estradiol.~A skin biopsy on the intact skin area near the skin tear will be performed."
32730515|NCT04513405|Other|subjects without skin tears (Group B)|"A sample of peripheral venous blood will be taken to measure the levels of estrogen.~A skin biopsy (thin layer) on the intact skin area of the arm will be performed in order to evaluate skin estrogen receptors."
32730516|NCT05403099|Active Comparator|control|Each implant was placed into the prepared implant site.
32730517|NCT05403099|Experimental|Hyaluronic acid|Each implant was placed after topical application of HA on its surface
32730518|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
32730519|NCT05404035|Experimental|Family Connections for relatives of people with eating disorders and personality disorders|The intervention lasts 3 months and includes 14 two-hour sessions with a group format on a weekly basis. The FC program is divided into 7 modules: 2 of Psychoeducation (ED and PD criteria, explanatory theories, available treatments, comorbidity with PD, etc.) and 5 modules of Dialectical Behavioral Therapy skills training (Relationship mindfulness, effective communication, aceptation, validation, problem management and meaning of life).
32730520|NCT05404035|Active Comparator|Optimized Treatment As Usual|Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, with 3 two-hour psychoeducation sessions in group format each week (ED and PD, explanatory theories, available treatments, comorbidity with PD).
32730521|NCT05403957|Experimental|TID video|
32730522|NCT05403957|Active Comparator|TID worksheet|
32730523|NCT05403957|Placebo Comparator|SSB worksheet|
33401182|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
33253158|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
33253159|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
33253160|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
33253161|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
33253162|NCT04404478|Experimental|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
33253163|NCT04404478|Active Comparator|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
33253164|NCT00772356|Experimental|A|
33253165|NCT00772356|Active Comparator|B|
33253166|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
32730524|NCT04512469|No Intervention|Control Group|The control group will undergo standard running fascial closure with PDS .
33253167|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
33253168|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
33253169|NCT04360096|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
33253170|NCT04360096|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
33253171|NCT04048356|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
33253172|NCT04048356|Active Comparator|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
33253173|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
33253174|NCT04005040|Active Comparator|Mobile X-ray|Intervention: X-ray examination in the patients own home
33253175|NCT04005040|Placebo Comparator|X-ray at the Hospital|Control: X-ray at the hospital
33253176|NCT04048044|Active Comparator|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
33253177|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
33253178|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
33253179|NCT04397536||Cohort|Patients diagnosed with MDR-TB
33253180|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
33253181|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
32730525|NCT04512469|Experimental|Treatment Group - Mesh|The treatment group will undergo standard running fascial closure with PDS plus a low molecular weight mesh extending 3 cm from the fascial incision.
33253182|NCT03762850|Experimental|sparsentan|Double-blind: Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400- mg and continue treatment to Week 110.
33253183|NCT03762850|Active Comparator|irbesartan|Double-blind: Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
33253184|NCT03762850|Experimental|dapagliflozin + sparsentan (Sub study)|OLE Sub study: Dapagliflozin will be administered daily as a 5-mg oral tablet, in addition to 400-mg of Sparsentan, for a period of 12 weeks.
33253185|NCT03762850|Experimental|sparsentan (Sub Study)|OLE Sub study: Sparsentan will be administered daily as a dose of 400-mg for a period of 12 weeks.
33253186|NCT04004650|No Intervention|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
33401183|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
32730526|NCT04512157|Experimental|PATHS, Intervention preschools|These preschools implement PATHS for one school year
33253187|NCT04004650|Experimental|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
32730527|NCT04512157|No Intervention|Waitlist control preschools|Preschool as usual, which does have some social emotional learning but not PATHS specifically
32934848|NCT02672917|Experimental|Group C|MVT-5873 is administered in Group C every 4 weeks by intravenous infusion following a lead in dose. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.
33253188|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
32934849|NCT02672917|Experimental|Group D|MVT-5873 is administered in Group D every 2 weeks by intravenous infusion following a lead in dose. During dose escalation, doses of MVT-5873 will be increased to defined he MTD. Up to 30 patients will be treated at the RP2D.
33253189|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
33253190|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
33253191|NCT04394182|Experimental|An experimental group receiving radiotherapy|an experimental group with a poor or no response to standard medical treatment and without invasive mechanical ventilation (IMV) will receive ultra low-dose lung radiotherapy (0.8 Gy single dose)
33253192|NCT05386576|Experimental|Venetoclax in Combination With Chemotherapy|All patients will complete Induction I and II of the treatment regimens, consisting of several chemotherapy agents including Peg-ASP.
33253193|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
33253194|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
33401184|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
32730528|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
32730529|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
32730530|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
32730531|NCT04932213|Active Comparator|Tropicamide 0.5%|This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.
32730532|NCT04932213|Active Comparator|Tropicamide 1%|This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.
32730533|NCT04522999|Experimental|Photobiomodulation|Valeda™ Light Delivery System
32730534|NCT03684213|Active Comparator|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
32730535|NCT03684213|Experimental|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
32730536|NCT03684213|Experimental|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
32730537|NCT03684213|Experimental|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
32730538|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
32730539|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
32730540|NCT04049097|Experimental|Arimoclomol|1200 mg/day arimoclomol citrate (400 mg t.i.d.)
32730541|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
32730542|NCT04032795|Experimental|Lycium barbarum polysaccharide (LBP)|Experimental group takes LBP tablet (300mg/day) for 6 weeks
32730543|NCT04032795|Placebo Comparator|Placebo|Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
32730544|NCT03365401|Experimental|grade 1|Decompression surgery
32730545|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
32730546|NCT04925271|Experimental|X-Tack|The gastrointestinal tract mucosal or submucosal defect is closed using the X-Tack device.
32730547|NCT04925271|Active Comparator|Overstitch|The gastrointestinal tract mucosal or submucosal defect is closed using the Overstitch device.
32730548|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
32730549|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
32730550|NCT04923165||patients with stroke|Inpatients and outpatients admitted to the investigators' rehabilitation facility .
32730551|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~Propulsion speed of a wheelchair."
32730552|NCT04182867|Experimental|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant. The diet will be consumed across 3 consecutive night shifts.
33253195|NCT05378620|Other|Project Dulce + Dulce Digital|Patients will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
33253196|NCT05376124||original therapy|ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
33253197|NCT05376124||rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
33253198|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
33253199|NCT04244890||Uninterrupted CPAP|Newborn infants in need of respiratory support directly after birth
32934850|NCT02672917|Experimental|Group E - metastatic|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
33253200|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
33253201|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
32934851|NCT02672917|Experimental|Group F - adjuvant|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
32934852|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
32934853|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
32934854|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
33253202|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
33253203|NCT04223206|Experimental|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
33253204|NCT04223206|No Intervention|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
33253205|NCT05359042|Experimental|ePRO Assessment Tool|Participants will receive either a text message or an email inviting them to engage in the health chat. Participant assessments including HRQOL and user experience will be administered via the platform. Participants will also be able to participate in short, interactive patient education modules related to the infusion and side effect management.
32934855|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
32934856|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
32934857|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
32934858|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
32934859|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
32934860|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
32934861|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
32934862|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
32934863|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
33253206|NCT05359042|No Intervention|Standard of Care|Participants in the standard of care arm will report symptoms via standard of care messaging through UCSF MyChart or telephone calls throughout the study period, and complete standard of care HRQoL surveys.
33253207|NCT04146922|Active Comparator|IV Group|Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.
32730553|NCT04182867|Other|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain ~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.The diet will be consumed across 3 consecutive night shifts.
32730554|NCT03828045||Psoriatic Arthritis patients on Apremilast|Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.
33082205|NCT04621591|Experimental|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
33253208|NCT04146922|Experimental|Oral Group|Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.
33253209|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
33253210|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
33253211|NCT05325580|Placebo Comparator|Placebo Group|1g paracetamol + 20 min infusion of 150ml of saline serum
33253212|NCT05325580|Experimental|magnesium group|1g paracetamol + 20 min infusion of 2g magnesium in 150 ml of serum saline
33253213|NCT04180696|Experimental|AdaptivCRT ON (aCRT ON, treatment group)|"AdaptivCRT programmed to Adaptive Bi-V and LV The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise."
33253214|NCT04180696|Active Comparator|AdaptivCRT OFF (aCRT OFF, control group)|"AdaptivCRT programmed to Nonadaptive CRT (standard CRT). Control group subjects will be optimized per physician's discretion. The method of AV and VV optimization in the control group will be collected."
33253215|NCT04179448|Experimental|Side Access Mucosal Releasing Incision (SAMRI)|SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
33253216|NCT04179448|Active Comparator|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
33253217|NCT04144348|Experimental|mRNA-1653, Adult participants|Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
33253218|NCT04144348|Experimental|mRNA-1653 Pediatric participants|Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
33253219|NCT04144348|Placebo Comparator|Placebo, Adult participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
33253220|NCT04144348|Placebo Comparator|Placebo, Pediatric participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
33253221|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
33253222|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
33253223|NCT04126408|Sham Comparator|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
33253224|NCT04126408|Active Comparator|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
33253225|NCT03907072|Experimental|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
33253226|NCT03907072|Experimental|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
33253227|NCT03907072|Placebo Comparator|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
33253228|NCT04092010|Experimental|Stepped-care intervention (SCI) group|In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
33253229|NCT04092010|Active Comparator|Usual care control group|Families in the control group will receive usual Head Start services.
33253230|NCT04209322|Experimental|Pulsed Radiofrequency|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. PRF treatment was administered at 5 Hz and a 2 ms pulsed width for 10 minutes at 45V under the constraint that the electrode tip temperature not exceed 42°C. Finally, patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
33253231|NCT04209322|Active Comparator|Transforaminal Epidural Steroid Injection|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. After 10 minutes await (as per pRF), patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
33253232|NCT04004572|Experimental|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
33253233|NCT04050436|Experimental|Cemiplimab in combination with RP1|Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks
33253234|NCT04050436|Active Comparator|Cemiplimab|Cemiplimab administered intravenously as a single therapy every 3 weeks
33253235|NCT04045912|Experimental|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
33253236|NCT04045912|Active Comparator|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
33253237|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
33253238|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
33253239|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
33253240|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
33253241|NCT04008628|Active Comparator|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
33253242|NCT04008628|No Intervention|Standard care|Infants will be reassured as currently performed in routine clinical practice
33253243|NCT02566148||HIV group|group living with HIV
33253244|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
33253245|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
33253246|NCT04004806|No Intervention|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
33253247|NCT04004806|Experimental|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
33253248|NCT04004806|No Intervention|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
33253249|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
33253250|NCT05309200|Placebo Comparator|OCE-205 Cohort 1|Placebo, intravenous infusion
33253251|NCT05309200|Experimental|OCE-205 Cohort 2|OCE-205, 8 µg/hr, intravenous infusion
33253252|NCT05309200|Experimental|OCE-205 Cohort 3|OCE-205, 15 µg/hr, intravenous infusion
33253253|NCT05309200|Experimental|OCE-205 Cohort 4|OCE-205, 30 µg/hr, intravenous infusion
33253254|NCT05309200|Experimental|OCE-205 Cohort 5|OCE-205, 50 µg/hr, intravenous infusion
33253255|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
33253256|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
33253257|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
33253258|NCT05306080|Experimental|Tadekinig alfa|"Injection #1/Day 1: As clinically indicated in accordance with Figure 1.1-1.~Repeat Injection(s): Missed doses will not be made up.~Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.~Retreatment (Optional): May be considered"
33253259|NCT04060472|Experimental|albumin-bound paclitaxel + oxaliplatin|
33253260|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
33253261|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
33253262|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
33253263|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
33253264|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
33401185|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
33253265|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
32934864|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
33253266|NCT00743990|Active Comparator|A|
32730555|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
33253267|NCT00743990|Placebo Comparator|B|
32730556|NCT03354793||non endometriosis|Survey on first pregnancy
32730557|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
32730558|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
32730559|NCT04522609|No Intervention|Control group|Guideline recommended pharmacologic therapy
32730560|NCT04522609|Experimental|NMES group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
32730561|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
32730562|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
32730563|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
32730564|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
32730565|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
32730566|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
32730567|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
32730568|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
32730569|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
32730570|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
32730571|NCT03365089|No Intervention|Control|No collateral vein ligation.
32730572|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
32730573|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
32730574|NCT04509895|Experimental|lateral extensile approach in calcaneal fractures fixation|Lateral extensile approach is the standard approach for intra-articular calcaneal fractures .
32730575|NCT04509895|Experimental|minimally invasive sinus tarsi approach in calc.fixation|Sinus tarsi approach become one of the most frequently applied minimally invasive approaches.
32934865|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
32934866|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
32934867|NCT05441995|Experimental|Cryotherapy|
32934868|NCT05441995|Active Comparator|Inferior alveolar nerve block|
32934869|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :~Physical activity~Home assessment and modification"
32934870|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :~Physical activity~Home assessment and modification~Cognitive behavioral therapy"
32934871|NCT05588245|Active Comparator|Comparison Group (Standard of Care)|Participants will receive the standard of care.
32934872|NCT05588245|Experimental|Intervention Group|Participants will receive a community-based patient navigator with 3 prenatal contacts and 5 postpartum contacts; during each contact, the community-based patient navigator will offer health assessment and education, along with group education and social support.
32934873|NCT05140226|Experimental|Physical Training (PT)|Participants in the PT group will perform eight weeks of home-based physical exercise training.
32934874|NCT05140226|Experimental|Cognitive-Physical Training (C-PT)|Participants in the C-PT will perform eight weeks of home-based cognitive and physical training.
33082206|NCT00412568|Active Comparator|1|PRK control group
33082207|NCT04621669|Experimental|digoxin, Rosuvastatin calcium,SHR3680|
33253268|NCT00743990|No Intervention|3|no intervention
33253269|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
32730576|NCT04509817|Experimental|Acupuncture+Usual care|Subjects in experimental group will receive a standardized acupuncture treatment, 10 times per 4 weeks for 16 weeks with a total of 40 sessions in addition to usual care.
33253270|NCT04595006|Experimental|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
33253271|NCT04595006|Experimental|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
33253272|NCT04595006|Experimental|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
32934875|NCT05588089|No Intervention|Control group|"After the birth of the control group, the Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers as pre-tests in the clinic. After the training, the fathers will be called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Fathers' Participation in Baby Care Chart will be applied 5 times during 12 weeks. In addition, Father-Infant Attachment Scale and Infant Care Questionnaire were applied to fathers at 12 weeks as posttests.~Personal Information Form for Mothers will be filled by mothers in the postpartum clinic, mothers are called at 4th, 8th and 12th weeks and Edinburgh Postpartum Depression Scale and Postpartum Quality of Life Scale are applied."
33253273|NCT04004728|Other|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
33253274|NCT01056757|Experimental|Ribavirin|
32730577|NCT04509817|Active Comparator|Usual care|Subjects in control group will receive usual care only.
32730578|NCT04509583|Experimental|PROFortil group|"Men with increased sperm DNA fragmentation (>=30%) will be indicated for multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months then checked again post-treatment for DF).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
33253275|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
32730579|NCT04509583|Other|Vitamin E group|"Any case with high DNA fragmentation index (DFI >=30%) will be randomized indicated only Vitamin E (Enat 400 once per day) in 3 months then checked again post-treatment for (DFI).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
32730580|NCT04509661|Experimental|Experimental group|Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.
32730581|NCT04509661|Placebo Comparator|Control group|Placebo treatment for the airway limitation.
32730582|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
32730583|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
32730584|NCT04509271||Normal aged|
32934876|NCT05588089|Experimental|Intervention group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers. After the training, the fathers were called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Paternals' Participation in Baby Care Chart was applied 5 times during 12 weeks. In addition, the fathers were called at the 12th week and the Infant Care Questionnaire Form was applied as a post-test and the Father-Infant Attachment Scale was applied.~Personal Information Form for Mothers was applied to the mothers after the birth in the clinic, and the mothers were called at the 4th, 8th and 12th weeks and the Edinburgh Postpartum Depression Scale and the Postpartum Quality of Life Scale were applied."
32934877|NCT05588011|Active Comparator|LivaNova Inspire|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
32934878|NCT05588011|Active Comparator|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
32934879|NCT05587933|Experimental|operative|
32934880|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
32934881|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
32934882|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
32934883|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
32934884|NCT05442073||Type I: ΔPes≥30%ΔPEEP|
32934885|NCT05442073||Type II: ΔPes<30%ΔPEEP|
32730585|NCT04509271||MCI due to AD|
32730586|NCT04509271||Mild AD|
32730587|NCT04509271||Moderate AD|
32934886|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
32934887|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
32934888|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
32934889|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
32934890|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
33253276|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
33253277|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
33253278|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
33253279|NCT00744068|No Intervention|5|
33253280|NCT05288452|Experimental|Arm 1|Digital coaching+ Food delivery+ RPM
33253281|NCT05288452|Active Comparator|Arm 2|Digital coaching
33253282|NCT05288452|Active Comparator|Arm 3|Digital coaching+ Food delivery
33253283|NCT05288452|Active Comparator|Arm 4|Digital coaching+ RPM
33253284|NCT05288452|Active Comparator|Arm 5|Food delivery+ RPM
33253285|NCT05288452|Active Comparator|Arm 6|The participant's will not receive any Intervention
33253286|NCT05288452|Active Comparator|Arm 7|Food delivery
33253287|NCT05288452|Active Comparator|Arm 8|RPM
33253288|NCT01056835|No Intervention|control|
33253289|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
33074569|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
33253290|NCT03986515|Experimental|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
33253291|NCT05286658|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
33253292|NCT03989479|Active Comparator|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
33253293|NCT03989479|Experimental|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
33253294|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
33253295|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
33253296|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
33253297|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
33253298|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
33253299|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
32934891|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
33253300|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
33253301|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
33253302|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
33253303|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
33253304|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
33253305|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
32934892|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
32934893|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
32934894|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
32934895|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
32934896|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
32934897|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
32730588|NCT04509271||Severe AD|
32730589|NCT04509271||Dementia with Lewy body|
32730590|NCT04509271||Frontotemporal dementia|
32934898|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
32934899|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
32934900|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
32934901|NCT05100836||Single arm all comers supported with Impella 5.5|
32934902|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
33253306|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33253307|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33253308|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
33253309|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
33253310|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
32934903|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
32934904|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
32934905|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
32730591|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
32730592|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
32730593|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
32934906|NCT05075564|Experimental|Part 1 dose escalation|ES002023 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
32934907|NCT05075564|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
32934908|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
32730594|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
32730595|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
32730596|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
32730597|NCT04524793|Other|Endovenous Microwave Ablations|Patients that have undergone Endovenous Microwave Ablation from ECO (Nanjing ECO Microwave System Co., Ltd) to treat primary great and short saphenous vein reflux
32730598|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
32730599|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
32730600|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
32934909|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
32934910|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
32934911|NCT05071976||Participants undergoing a pelvic or abdominal wall reconstruction procedure|Women undergoing a pelvic or abdominal wall reconstruction procedure after radical gynecologic surgery for any indication at Memorial Sloan Kettering Cancer Center
33253311|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
33253312|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
33253313|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
33253314|NCT00907491||A|
33253315|NCT00929097|Experimental|Implementation aids|
33253316|NCT00929097|Active Comparator|Control|
32730601|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
32730602|NCT04443517|Experimental|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
33253317|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
33253318|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
33253319|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
32730603|NCT04443517|Active Comparator|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
32730604|NCT04443517|Active Comparator|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
32730605|NCT04443517|No Intervention|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
32730606|NCT04524559|Placebo Comparator|conventional physical therapy training|received 90 minutes conventional physical therapy training focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms.
32934912|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
32934913|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
32934914|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
32934915|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
32934916|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
32934917|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
32934918|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
32934919|NCT02652416|Experimental|Placebo (SRD part)|placebo
32934920|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
32934921|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
32934922|NCT01756118|Experimental|BEZ235|
32934923|NCT04959968|Experimental|Intervention group|An eye patch and earplug will be applied to the intervention group in the intensive care unit on the day of craniotomy and on the post-operative 1st day between 22:00 and 06:00
32934924|NCT04959968|No Intervention|Control group|Standard care procedure will be applied to the control group
32934925|NCT04339712|Experimental|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
32934926|NCT04339712|Experimental|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:~absolute neutrophil count less than 2,500/mm3;~absolute platelet count less than 100,000/mm3; and~AST or ALT more than 1.5 x the upper normal limit"
32934927|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
32934928|NCT04909970|Experimental|Self hypnosis|Self-hypnosis program associated to usual practice of stress management
32934929|NCT04909970|Other|control group (waiting list)|Usual practice of stress management. This group will practice self-hypnosis after the intervention group has practiced self-hypnosis (waiting list).
32934930|NCT02656160|Placebo Comparator|Placebo|
32934931|NCT02656160|Active Comparator|Dalfampridine|
32934932|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
32934933|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
32934934|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
32934935|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
32934936|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
32934937|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
32934938|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
32934939|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
33082208|NCT04621669|Experimental|metformin hydrochloride ,SHR3680|
33074570|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
33253320|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
33253321|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
33253322|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
33253323|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
33074571|NCT02931916||healthy group|recruited for evaluation of system reliability
33074572|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
33074573|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
33074574|NCT02931799|Active Comparator|Minimal Intervention|
33074575|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
33074576|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
33253324|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
33253325|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
33253326|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
33253327|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
33253328|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
33253329|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
33253330|NCT00925041|Experimental|Kxl Vedera|
33253331|NCT00775788|Experimental|Implant Failure|
33253332|NCT00775788|Experimental|Post mastectomy breast reconstruction|
32730607|NCT04524559|Experimental|oral stimulation|received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time. The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol
32730608|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
33074577|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
33074578|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
33074579|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
33253333|NCT00775788|Experimental|Congenital malformations|
33253334|NCT00775788|Experimental|Breast Ptosis|
33253335|NCT00775788|Experimental|Micromastia|
33253336|NCT00775788|Experimental|Asymmetric Breasts|
33074580|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
33074581|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
33074582|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
33074583|NCT00180219||1|20 to 22 years
33074584|NCT00180219||2|30 to 32 years
33074585|NCT00180219||3|40 to 42 years
33074586|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
33074587|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
33074588|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
33074589|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
33074590|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
33074591|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
33253337|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
33074592|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
33253338|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
33253339|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
33074593|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
33074594|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
33074595|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
33253340|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
33253341|NCT00772512|Experimental|A|
33074596|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
33074597|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
33074598|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
33074599|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
33074600|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
32730609|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
32730610|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
32730611|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
33074601|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
33074602|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
33074603|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
33253342|NCT00772512|Experimental|B|
33253343|NCT00772512|Placebo Comparator|C|
33074604|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
33074605|NCT00154076|Experimental|1|
33074606|NCT00154076|Active Comparator|2|
33074607|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
33074608|NCT02924740|Active Comparator|control|pelvic floor muscle training
33074609|NCT02924740|Experimental|intervention|vaginal tampon training.
33074610|NCT00154115|Experimental|1|Levosimendan
33074611|NCT00154115|Placebo Comparator|2|
33074612|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
33074613|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
33253344|NCT00775866|Experimental|MRI guided prostate biopsy|
33253345|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
33074614|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
33074615|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
33253346|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
33253347|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
33253348|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
33253349|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
33253350|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
33253351|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
32730612|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
33074616|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
33074617|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
33074618|NCT00154154|Active Comparator|A|General Psychiatric Management
33074619|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
33074620|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
33074621|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
33074622|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
33401186|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial remote ischemic conditioning: prehospital phase, all included patients~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy"
33401187|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.~Initial Sham remote ischemic conditioning: prehospital phase, all included patients~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy."
33401188|NCT04763707||Group 1 : Hepatocellular carcinoma HCC patients with HCV|40 HCV-related liver cirrhosis patients with HCC on top (Group 1).
32934940|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
32934941|NCT04857008|Experimental|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
32934942|NCT04796246|Experimental|Leap Motion Controller|Intervention Group: which will receive treatment with Leap Motion Controller
32934943|NCT04796246|Active Comparator|Conventional Physiotherapy|Control Group: who will receive treatment with conventional physiotherapy.
32934944|NCT04339400|Experimental|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
33401189|NCT04763707||Group 2 : Cirrhotic patients with HCV|30 HCV-related liver cirrhosis patients(Group 2).
33401190|NCT04763707||Group 3 : Healthy control|20 healthy volunteers will be included as controls(Group 3).
33401191|NCT04702789|Experimental|Arm 1; Dorzolamide-timolol-brimonidine and latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
32934945|NCT04693832|Experimental|5inD|All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
32934946|NCT04693832|No Intervention|Control group|All children receive routine antiemetic therapy before chemotherapy.
32934947|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
32934948|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
32934949|NCT04670042|Experimental|SPRINT® Peripheral Nerve Stimulation (PNS) System|SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
32934950|NCT04739618|Experimental|Single arm. Subjects receiving treatment.|Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria
32934951|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
32934952|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
33253352|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
33253353|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
33253354|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
33253355|NCT00772824|Active Comparator|2|Intravenous glutamine
32730613|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
32730614|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
33253356|NCT00772824|Experimental|3|Oral Glutamine
32730615|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
33253357|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
33253358|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
33253359|NCT04047732|Experimental|Topical KB105|HSV1-TGM1 vector (KB105)
32730616|NCT04443595|Experimental|Experimental|Treatment of Acute Severe Pancreatitis with DPN
33253360|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
33253361|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
33253362|NCT02557152||Patients that were treated with the GentleWave System|
32730617|NCT04509349|Active Comparator|Real tACS|For transcranial stimulation, a stimulation method called high-definition tACS (HD-tACS) will be applied to target the primary motor cortex (M1), an area of the brain that is involved in controlling movement, using gel electrodes placed on the scalp. Participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage, to create focused stimulation over the M1 region. A stimulator will be connected to the electrodes to deliver a low-intensity stimulating current to the scalp.
32730618|NCT04509349|Placebo Comparator|Sham tACS|For the transcutaneous ACS, the procedure for real and sham stimulation will be identical to HD-tDCS, but ACS will be delivered to the upper arm contralateral to hand attached to the accelerometer.
32730619|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
32730620|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
32730621|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
33253363|NCT00779220|Placebo Comparator|1|
33253364|NCT00779220|Experimental|2|
33253365|NCT00779220|Experimental|3|
33253366|NCT00779220|Experimental|4:|
33253367|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
33253368|NCT00776256|Active Comparator|1|effect of beta-glucan
33253369|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
33253370|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
33253371|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
33253372|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
33253373|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
33253374|NCT00779454|Other|KRAS wildtype|
33253375|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
33253376|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
33253377|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
33253378|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
33253379|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
33253380|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
33253381|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
33253382|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
33253383|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
33253384|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
33253385|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
33253386|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
33253387|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
33253388|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
33253389|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
33253390|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
33253391|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
33253392|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
33253393|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
33253394|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
33253395|NCT00779844|Experimental|1|obese patients
33253396|NCT00779844|Active Comparator|2|lean patients
33253397|NCT00773214|Experimental|exercise|
33253398|NCT05109702|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for 8 weeks.
33253399|NCT05109702|Placebo Comparator|Placebo|Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for 8 weeks.
32934953|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
33253400|NCT00776568|Active Comparator|2|
33253401|NCT00776568|Experimental|1|
33253402|NCT00779922|Experimental|group 1 to 5|
33253403|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
33253404|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
33253405|NCT00780078||1|Patients intubated orotracheally for over 6 days
33253406|NCT00773448|Active Comparator|Limited Malignancy Screening|
33253407|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
32934954|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
32934955|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
32934956|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
32934957|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
32934958|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
32934959|NCT04339010|Experimental|Hypopressive|"st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.~nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.~rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
32934960|NCT04339010|Active Comparator|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
32934961|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
32934962|NCT04739774|Experimental|Treatment R|Single dose of CHF6001
32934963|NCT04739774|Experimental|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Itraconazole
32934964|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
32934965|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
32934966|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
32934967|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
32934968|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be collected at the following time points for patients presenting for induction of labor:~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 1 sample.~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 1 sample will be taken.~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
33253408|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
33253409|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
33253410|NCT00773526|Experimental|1|
33253411|NCT00776802|Experimental|GCS-10|
33253412|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
33253413|NCT00780312|Experimental|1|physiotherapy
33253414|NCT00776880||1|Patients assessed with ASA physical status scale
33253415|NCT00776880||2|Patients assessed with PPS scale
33253416|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
33253417|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
33253418|NCT00780468|Active Comparator|1|Existing diet plan
33253419|NCT00780468|Experimental|2|New diet plan
33253420|NCT00773760||dosing|
33253421|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
33253422|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
33253423|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
33253424|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
33253425|NCT00774150|Active Comparator|2. Client Centered Therapy|
33253426|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
33253427|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
33253428|NCT00774228|Experimental|I-ZIP Ocular Bandage|I-Zip bandage application
33253429|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|Oasis shield application
33253430|NCT05298150|Experimental|Dynamic cycling|The cycling parameters will change according to motor performance of the participants. Motor performance will be measured by assessing the change in tremor and movement speed.
33253431|NCT05298150|Active Comparator|Forced cycling|The cycling parameters will not change regardless of the motor performance. Motor performance will be measured by assessing the change in tremor and movement speed.
33253432|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
33253433|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
32769270|NCT05042479|Experimental|Standard treatment then virtual reality then choice between the two|"Efficiency of VR will be evaluated for each patient across 3 potentially painful care-procedures :~For the first treatment, the child will benefit usual distraction and pain prevention techniques.~For the 2nd, the child will use a VR headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age and parental agreement.~For the 3rd treatment, the child will choose his/her favorite technique."
32934969|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be taken at the following endpoints:~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 1 sample will be taken.~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
32934970|NCT01500733|Experimental|Elderly greater than 65|
32934971|NCT01500733|Experimental|17p Deletioin|
32934972|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
32934973|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
32934974|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
32934975|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
32934976|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
32934977|NCT01328587|Experimental|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
32934978|NCT01192555|Experimental|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
32934979|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
32934980|NCT05441761|Experimental|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory peripheral T-cell lymphoma will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with gemcitabine, dexamethasone, and cisplatin for 6 cycles (planned) (21 days per cycle).
32934981|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
32934982|NCT04740073||Patients|Persons undergoing total knee arthroplasty
32934983|NCT04740073||Controls|Persons not undergoing total knee arthroplasty who are age and sex-matched to the patient group.
33253434|NCT04047498|Experimental|Within-subjects comparison of constant and alternating DBS|
33253435|NCT00780702|Experimental|Arm 1|
33253436|NCT00780702|Placebo Comparator|Arm 2|
33253437|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
33253438|NCT00780780|Other|2|Triamcinolone intravitreal injection
33253439|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
33253440|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
33253441|NCT00776958||Ovarian or Breast Cancer Study Registry|
33253442|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
33253443|NCT00774384|No Intervention|2|No vaccine
33253444|NCT00777114|Experimental|All patients|
33253445|NCT00669396|Experimental|1|IUD
33253446|NCT00669396|Active Comparator|2|Oral levonorgestrel
33253447|NCT00774462|Experimental|1|
33074625|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
32730622|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
32730623|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
32730624|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
33253448|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
33253449|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~2 mg/m^2 pentostatin IV on days 8 and 22;~3 mg alemtuzumab subcutaneously (SC) on day 3;~10 mg alemtuzumab SC on day 4;~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~2 mg/m^2 pentostatin IV on days 1 and 15;~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
33253450|NCT00781092|Experimental|1|Systane Ultra
33253451|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
33253452|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
33253453|NCT00774540|Experimental|1|Ketorolac
33253454|NCT00774540|Placebo Comparator|2|saline
33253455|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
33253456|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
33253457|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
33253458|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
33253459|NCT00777426||Thai HAD individuals (25 cases)|
32730625|NCT04508959||Screened patients|All individuals screened using the hospital's microbiology laboratory.
33253460|NCT00777426||Thai Non-HAD individuals (25 cases)|
33253461|NCT00777426||Thai Non-infected individuals (10 cases)|
33253462|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
33253463|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
33253464|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
33253465|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
33253466|NCT00774774|Placebo Comparator|2|No intervention
33253467|NCT00774774|Experimental|1|Mask
32730626|NCT04508959||Outpatient (Emergency Department) cases|All individuals seen in the emergency department who test positive for COVID-19.
32730627|NCT04508959||Inpatient (General Medical or Intensive Care) cases|All individuals admitted to a general or intensive care bed who test positive for COVID-19.
32730628|NCT04508569|Experimental|Big Decisions|
33253468|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
33253469|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
33253470|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
33074626|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
33074627|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
33074628|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
33074629|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
33253471|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
33253472|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
33253473|NCT00354770|Placebo Comparator|2|Placebo
33253474|NCT00001850||Children|with reproductive disorders
33253475|NCT00001850||Men|with reproductive disorders
33074630|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
33253476|NCT00001850||Woman|with reproductive disorders
33253477|NCT00741494|No Intervention|1|HBA score over 65% control
33074631|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 + nivolumab (Q2W)~Dose Level 2: Sym004 + nivolumab (Q2W)~Dose Level -1: Sym004 + nivolumab, if needed"
33074632|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
33074633|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:~Receiving nivolumab monotherapy (Q2W)"
33074634|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
33074635|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
33253478|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
33253479|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
33253480|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
33253481|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
33253482|NCT00744146|Experimental|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
33074636|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
33074637|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
33074638|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
33074639|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
33074640|NCT00154193|Active Comparator|Cyclosporine|
33074641|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
33074642|NCT02923843|No Intervention|control|Standard care
33253483|NCT00744146|Experimental|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
33253484|NCT00744146|Experimental|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
33253485|NCT00744146|Experimental|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
33253486|NCT00744146|Experimental|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
33074643|NCT00187863||Exercise induced pain perception|
33074644|NCT00187863||Surgical pain perception|
33074645|NCT04100044|Experimental|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
33082209|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
33253487|NCT00744224|Placebo Comparator|1|
33253488|NCT00744224|Active Comparator|2|
33253489|NCT00744224|Active Comparator|3|
33253490|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
33074646|NCT04046848|Experimental|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
33074647|NCT04046848|Experimental|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
33074648|NCT04046848|Experimental|Cohort 3|"50 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 50 IU/kg OCTA101 profiled up to 72 hours in adult male patients with severe hemophilia A.~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
33074649|NCT04046848|Experimental|Cohort 5|(n=4): Three-period investigation of single sc doses of 20, 40, and 60 IU/kg OCTA101 profiled up to 72 hours after dosing. Treatments were to be administered in fixed dose-ascending sequence.
33074650|NCT04046848|Experimental|Cohort 6|(n≥16): Following an initial 4 to 6-week run-in period with Nuwiq iv prophylaxis, >3-6 months daily prophylactic treatment with 12.5 IU/kg OCTA101 sc, then 25 IU/kg OCTA101 sc for a further 6-7 months (exact dosing depends on available vial sizes). In case of two spontaneous bleeding episodes, after having completed at least 3 months with 12.5 IU/kg OCTA101 daily treatment the individual treatment dose will be increased from 12.5 to 25 IU/kg. Site of administration (abdomen or thigh) to be chosen by the patient. A further treatment phase with 40 IU/kg OCTA101 will be discussed with the DMC, once results of earlier dosing phases are available.
33074651|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
33074652|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
33074653|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
33074654|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
32730629|NCT04508569|Active Comparator|Youth Voices|
33074655|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
33074656|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
33074657|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
33074658|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
32730630|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
32730631|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
32730632|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
32730633|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
33074659|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
33074660|NCT00154349|Experimental|imatinib mesylate|
33074661|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
32730634|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
32730635|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
32730636|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
32730637|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
32730638|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
32730639|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
33074662|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
33074663|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
33074664|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
32730640|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
32730641|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
32730642|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
32730643|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
32730644|NCT05378295|Active Comparator|isocaloric fermentable oligosaccaride|isocaloric fermentable oligosaccaride
33074665|NCT02923765|No Intervention|healthy participant (HP)|healthy control
33074666|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
32730645|NCT05378295|Experimental|Personalized fiber mixture|12 g for 2 weeks, followed by 24 g for 10 weeks
32730646|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
32730647|NCT03630003|Experimental|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
32769271|NCT05034211|Active Comparator|Programmed intermittent Bolus Epidural technique|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered every 60 minutes via an epidural catheter placed for labor analgesia on L2-L3/L3-L4 level
33074667|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
33074668|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
33074669|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
33074670|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
33074671|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
33074672|NCT02923609|Experimental|SC Group|In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).
33074673|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
33074674|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
33074675|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
33074676|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
33074677|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
33074678|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
33074679|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
33074680|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
33074681|NCT02923297|Other|Parkinson's disease patients|blood sampling
33074682|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
33074683|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
33074684|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
33074685|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
33074686|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
33074687|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
33074688|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
33074689|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
33074690|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
33074691|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
33074692|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
33074693|NCT04705688||Left Atrial Appendage Occlusion|Patients undergoing left atrial appendage occlusion.
32730648|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
32730649|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
32730650|NCT03547869|Experimental|Active tDCS|Active tDCS
32730651|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
32730652|NCT04504279|Experimental|FB-401|FB-401 applied topically for 16 weeks.
32730653|NCT04504279|Placebo Comparator|Placebo|Placebo applied topically for 16 weeks.
32730654|NCT04176939|Experimental|HZ/su Group|Eligible participants who had a complete 2-dose HZ/su vaccination course in the primary study (NCT02058589) will be enrolled in this extension study, to receive 2 doses of HZ/su vaccine- first dose at Month 24 and second dose at Month 25 and will be followed up until the study end.
33074694|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
33074695|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
33074696|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
33074697|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
33074698|NCT04706000||Study group|endometrial polyp
33074699|NCT04706000||Control group|normal endometrium
33074700|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
33074701|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.~Subjects will have blood drawn but it will not be tested for DNA damage."
33074702|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.~Subjects will have blood drawn and the feedback will be presented at Visit 2."
33074703|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
33074704|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
33074705|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
33074706|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
33074707|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
33074708|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
33074709|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
33074710|NCT02922517||controls|patients without HCM
33074711|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
33074712|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
33074713|NCT04705610|Experimental|Radiologically Isolated Syndrome (RIS)|
33074714|NCT04705610|Experimental|Clinically Isolated Syndrome (CIS)|
33074715|NCT04705610|Experimental|Relapsing-Remitting MS (RRMS)|
33074716|NCT04705610|Experimental|Secondary Progressive MS (SPMS)|
33074717|NCT04705610|Experimental|Primary Progressive MS (PPMS)|
33074718|NCT04705610|Experimental|Healthy volunteer|
33074719|NCT00188058|Active Comparator|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
33082210|NCT00247221|Active Comparator|2) MI only|
33253491|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
33253492|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
33253493|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33253494|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
33253495|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
33253496|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
33253497|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
33253498|NCT00781248|Experimental|1|starting with active NG Shield
33253499|NCT00781248|Experimental|2|Starting with inactive NG Shield
33253500|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
33253501|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
32769272|NCT05034211|Active Comparator|Provider administered bolus epidural technique on patient request|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered by the provider on patient request
33253502|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
33253503|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
33253504|NCT00925275|Experimental|Dosimetric|
33253505|NCT00907725|Other|1|serum BhCG follow-up
32769273|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
32934984|NCT05587777||Mild Cancer Related Fatigue|After treatment(6 months from inclusion) is ended a fVAS < 50
32934985|NCT05587777||Cancer related Fatigue|After treatment (6 months from inclusion) with fVAS ≥ 50 mm or a rise of fVAS of ≥ 25 mm.
32934986|NCT05587777||Healthy control|"Healthy women matches with age~50-70: women attending the mammography screening~19-50: invitation in newspaper, flyers and posters"
32934987|NCT05587699|Experimental|Group - A1(Part 1)|CKD-843 A 45mg
32934988|NCT05587699|Experimental|Group - A2(Part 2)|CKD-843 A 45mg
32934989|NCT05587699|Experimental|Group - B1(Part 1)|CKD-843 A 55mg
32934990|NCT05587699|Experimental|Group - B2(Part 2)|CKD-843 A 55mg
32934991|NCT05587699|Active Comparator|Group - R(Part 1)|CKD-843-R
32934992|NCT00581503||diagnostic|oct imaging
32934993|NCT04739215|Experimental|Clinical Trial: Experimental Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.
32934994|NCT04739215|Placebo Comparator|Clinical Trial: Placebo Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.
32934995|NCT04739215|No Intervention|Descriptive Study|Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).
32934996|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
33401192|NCT04702789|Experimental|Arm 2; Dorzolamide-timolol and latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
33074720|NCT00188058|Experimental|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
33074721|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
33401193|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 8 months to 400 mg, for up to 21.2 months.
33074722|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
33074723|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
33074724|NCT02922244|No Intervention|Standard skin care|standard skin care
33074725|NCT02922244|Placebo Comparator|Control|Moisture Cream
32730655|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
32730656|NCT04175301|Experimental|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
33074726|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
33074727|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
32730657|NCT04175301|Placebo Comparator|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
32730658|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
32743033|NCT04940559|Experimental|Group 2: Sequence 1|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
33074728|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
33074729|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
33074730|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
33074731|NCT04705493||CASE GROUP|Lidco rapid examination and echo examination were done to septic shock patients then the passive leg raising test was done and fluid responder cases were given mini fluid challenge and fluid challenge
33074732|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
33074733|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
33074734|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
33074735|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
33074736|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
33074737|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
33074738|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
33074739|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:~A 'Threshold' Inspiratory Muscle Trainer~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
33074740|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
33074741|NCT04689100|Experimental|Dose Escalation Cohort|"Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
33074742|NCT04689100|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
33074743|NCT02921698||FRED®|
33074744|NCT00406250|Experimental|Bevacizumab|
33074745|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
33074746|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
33074747|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
33074748|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
33082211|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
33253506|NCT00907725|Other|2|ultrasonographic follow-up
33253507|NCT00603915|Experimental|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
33253508|NCT00929487|Experimental|Contact lens solution #1|
33253509|NCT00929487|Experimental|Contact lens solution #2|
33253510|NCT00929487|Experimental|Contact lens solution #3|
32730659|NCT04174989|Experimental|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
33074749|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
33074750|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
32730660|NCT04174989|Other|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
32730661|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
33074751|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
33074752|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32730662|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
32730663|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
32730664|NCT04524169|Experimental|Thymosin Alpha 1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
32730665|NCT04524169|No Intervention|Standard Care|Participants under the regularly treatment
32730666|NCT03568929||Idelalisib|Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
32743034|NCT04940559|Experimental|Group 2: Sequence 2|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
32743035|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
33074753|NCT02921542||Homogenous Lesions|
33074754|NCT02921542||Heterogenous Lesions|
33074755|NCT02921542||Calcific Lesions|
33074756|NCT02921542||Restenotic Lesions|
33074757|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
33074758|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
33074759|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
33074760|NCT00406484|Active Comparator|2|Standard drug counseling
33074761|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
33082212|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
33082213|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
33082214|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
33253511|NCT00929487|Experimental|Contact lens solution #4|
33253512|NCT00929487|Active Comparator|Saline/blister pack solution|
33253513|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
33253514|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
33253515|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
33253516|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
33253517|NCT04015089|Experimental|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
33253518|NCT04015089|Active Comparator|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
33253519|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
33253520|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
33253521|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
33253522|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
33253523|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
33253524|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
33074762|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
33074763|NCT03812302|Experimental|DOTATATE|All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
33074764|NCT02921464||Group A|Group A - without known pre-existing SIHD
33074765|NCT02921464||Group B|Group B - with known pre-existing SIHD.
33074766|NCT00188214|Other|CT perfusion scan|
33074767|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
33074768|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
33074769|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
33074770|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
33074771|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
33074772|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
33074773|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
33074774|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
33074775|NCT00180843|Placebo Comparator|saline control|nebulized saline
33074776|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
33074777|NCT02921152|Other|all|All patients with early breast cancer
33074778|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
33074779|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
33253525|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
33253526|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
33074780|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
33074781|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
33074782|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
33074783|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
33074784|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
33074785|NCT00188292||Control|Those who had less than highgrade histologic anal disease
33074786|NCT02920762||Buprenorphine|
33074787|NCT02920762||Fentanyl|
33074788|NCT02920762||Hydromorphone HCl|
33074789|NCT02920762||Morphine Sulfate|
33074790|NCT02920762||Morphine Sulfate Beads|
33074791|NCT02920762||Oxycodone HCl|
33074792|NCT02920762||Oxymorphone HCl|
33074793|NCT02920762||Tapentadol|
33074794|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
33074795|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
33074796|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
33074797|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
33074798|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
33074799|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
33074800|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
33074801|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
32730667|NCT03354247|No Intervention|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
32730668|NCT03354247|Experimental|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
33074802|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
32730669|NCT04503967|Experimental|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients
32730670|NCT04841499|Experimental|Treatment Arm|7 days of BASIS™ orally
32730671|NCT04503889|Experimental|Real taVNS intervention|taVNS will be administered to cymba conchae of both ears using ECO2-TENS device
32730672|NCT04503889|Sham Comparator|Sham|aVNS will be administered to lobes of both ears using ECO2-TENS device
32730673|NCT04822935|No Intervention|Posterior Spinal Instrumentation|
32730674|NCT04822935|Experimental|Vertebral Body Tethering|
32730675|NCT04808817|Experimental|patients|
32730676|NCT05028465|Experimental|EP combined with RFA|Endoscopic Papillectomy Combined with Endobiliary Radiofrequency Ablation
32730677|NCT04773405|Other|Selective Trunk Block|Selective trunk block will be done under ultrasound guidance to patients scheduled for upper extremities surgeries. Local anaesthetic agents (a 1:1 mixture of 2% lidocaine with 5ug/ml of epinephrine and 0.5% levobupivacaine) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anaesthetize the whole upper limb.
32730678|NCT04991571|Experimental|Part 1|Participants will be administered with zibotentan once daily for 5 days.
33074803|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
33074804|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
33074805|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
32730679|NCT04991571|Experimental|Part 2: Treatment Sequence ABC|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
32730680|NCT04991571|Experimental|Part 2: Treatment Sequence BCA|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
32730681|NCT04991571|Experimental|Part 2: Treatment Sequence CAB|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
32743036|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
33074806|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:~Pediatopic treatment cream during acute stages of atopic dermatitis and~Pediatopic body lotion during stable stages"
33074807|NCT00154622|No Intervention|pain/ disability survey|
33074808|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
33074809|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
33074810|NCT02920372|Experimental|EPOETIN ALFA|
33074811|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
33074812|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
33074813|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
33074814|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
33074815|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
33074816|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
32730682|NCT03191019|Experimental|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
32730683|NCT03191019|Placebo Comparator|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
32730684|NCT03176979|Experimental|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
32730685|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
33253527|NCT00926055|No Intervention|Control|
33074817|NCT00188331||2|non-chemotherapy group
33074818|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
33074819|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
33074820|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
33074821|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
33074822|NCT02920021|Experimental|ANB020|ANB020, administration of ANB020
33074823|NCT02920021|Placebo Comparator|Placebo|Placebo, administration of Placebo
33074824|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
33074825|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
33074826|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
33253528|NCT00926055|Active Comparator|Ezetimibe|
33253529|NCT00926055|Experimental|Ezetimibe/Simvastatin|
33074827|NCT04688983|Active Comparator|Arm 1|Ponatinib plus standard induction and consolidation
33074828|NCT04688983|Active Comparator|Arm 2|Imatinib plus standard induction and consolidation (comparator arm)
32730686|NCT01376245|Placebo Comparator|placebo|matching placebo
32730687|NCT04754061|Experimental|Psilocybin Microdosing|Participants will receive a 4-week psilocybin microdosing intervention (1-3mg/day, Monday-Friday for up to 4 weeks; start at 1mg with opportunity to increase dose each week)
32730688|NCT04508881|Active Comparator|External ligation|External ligation of the valve tube by vicryl sutures
32730689|NCT04508881|Active Comparator|intraluminal stenting|stenting of the valve tube by prolene suture
33253530|NCT04015635||Study group|"80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
33253531|NCT04015635||Control|"80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
33253532|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
33253533|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
33401194|NCT03521934|Placebo Comparator|Placebo|Matching placebo to sotagliflozin 200 mg once daily, with possible up-titration in the first 8 months to matching placebo to sotagliflozin 400 mg, for up to 21.6 months.
32730690|NCT05403645|Experimental|Movement With Mobilization among patients with knee osteoarthritis in household females|using the techniques of Movement With Mobilization among patients with knee osteoarthritis in household females
33074829|NCT04688983|Experimental|Arm 3|Ponatinib plus Blinatumomab
33074830|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
33074831|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
33074832|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
33074833|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
33074834|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
33074835|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
33074836|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
33074837|NCT02919514|Active Comparator|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
33074838|NCT02919514|Experimental|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
33074839|NCT02919514|Experimental|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
33074840|NCT00154778|Experimental|A|
33253534|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
33253535|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
33253536|NCT04034199|Experimental|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
33253537|NCT04034199|Active Comparator|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
33074841|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
33074842|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
33074843|NCT02919748|Experimental|Intervention arm|Choral Singing
33253538|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
33253539|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
33074844|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
33074845|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
33074846|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
33074847|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
33074848|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
33253540|NCT00691028|Experimental|TA-650 3 mg/kg|
33253541|NCT00691028|Experimental|TA-650 6 mg/kg|
33074849|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
33074850|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
33074851|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
33253542|NCT00691028|Experimental|TA-650 10 mg/kg|
33253543|NCT05280327|Experimental|experimental group|virtual reality application
33253544|NCT05280327|No Intervention|control group|standard care group
33253545|NCT00741572||1|
33253546|NCT00741572||2|
33401195|NCT03434353|Experimental|Group 1: Inarigivir Soproxil 50 mg + TAF|Viremic participants will be administered inarigivir soproxil 50 mg (2 x 25 mg capsules) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks.
33074852|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
33074853|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
33074854|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
33074855|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
33074856|NCT02919358|Other|Control|No intervention; standard care.
33074857|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
33074858|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
33074859|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
33074860|NCT02919085|Experimental|Mobilization|
33074861|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
33253547|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
33074862|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
33401196|NCT03434353|Experimental|Group 2: TAF|Viremic participants will be administered TAF 25 mg tablet once daily orally with food for 48 weeks.
33074863|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
33074864|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
33074865|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
33074866|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
32906845|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
33074867|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
33074868|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
33074869|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
33074870|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
33074871|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
33074872|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
33074873|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
33074874|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
33074875|NCT02918578|Experimental|"Phone group"|see intervention description
33074876|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
33074877|NCT02918578|Active Comparator|"single writing group"|see intervention description
33074878|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
33074879|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
33074880|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
33074881|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
33074882|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
33074883|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
33074884|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
33074885|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
33074886|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
33074887|NCT02910193||alcohol-dependent patients|
33074888|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
33074889|NCT02910193||healthy control subjects|
33074890|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
33074891|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
33074892|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
33253548|NCT04533230|Experimental|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
33253549|NCT04533230|Active Comparator|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
33074893|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
33253550|NCT04533230|No Intervention|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
33253551|NCT00908193|Experimental|1|robot-assisted coelioscopy
33253552|NCT00908193|Active Comparator|2|conventional coelioscopy
33253553|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
33253554|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
33253555|NCT00926445||Preterm (BW < 1500 grams)|
33253556|NCT00926445||Critically ill term newborn|ventilation > 48 hours
33253557|NCT00926445||Healthy term newborn|
33253558|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in Taiwan during 2018 to 2019.
33253559|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
33253560|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
33253561|NCT05461586||MR #1/MR #2|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR #1/MR #2) sequence and receive two different maximum refractive techniques one at a time consecutively.
33253562|NCT05461586||MR#2/MR#1|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR#2/MR#1) sequence and receive two different maximum refractive techniques one at a time consecutively.
33253563|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
33253564|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
32730691|NCT05403645|Experimental|Exercise Therapy among patients with knee osteoarthritis in household females|using the techniques of Exercise Therapy among patients with knee osteoarthritis in household females
32730692|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
33253565|NCT00741650|Experimental|1|Information and peer advisor
33253566|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
33253567|NCT00741650|No Intervention|3|Treatment as usual
33253568|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
33253569|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
33253570|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
33253571|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
32730693|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
33074894|NCT02910076|Experimental|Healthy volunteers|
33253572|NCT00744458|Active Comparator|1|
33253573|NCT00744458|Active Comparator|2|
33253574|NCT00744458|Active Comparator|3|
33253575|NCT00781794|Experimental|1|Dose 1
33253576|NCT00781794|Experimental|2|Dose 2
33253577|NCT00781794|Placebo Comparator|3|
32730694|NCT04508491|Experimental|Rhythm control|Rhythm control with medication or any procedure
32730695|NCT04508491|Active Comparator|Rate control|Rate control with medication or any procedure
32730696|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
32730697|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
32730698|NCT04936581||Open Total Mesorectal Excision|Patients undergoing open low anterior resection
33253578|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
32730699|NCT04936581||Laparoscopic Total Mesorectal Excision|Patients undergoing laparoscopic low anterior resection
32730700|NCT04936581||Robotic Total Mesorectal Excision|Patients undergoing robotic low anterior resection
32730701|NCT04936581||Transanal Total Mesorectal Excision|Patients undergoing transanal Total Mesorectal Excision (taTME)
32730702|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
33253579|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
33253580|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
33253581|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
33074895|NCT02910076|Experimental|Diabetes patients|
33253582|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
33253583|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
33074896|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
33082215|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
33253584|NCT05028972|Experimental|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
32730703|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
32730704|NCT04724577|Experimental|Carbon ion treatment|dose escalation study with five dose levels [54GGyE(Gray equivalent)/12Fx,55.2GyE/12Fx,56.4GyE/12Fx,57.6GyE/12Fx and 58.8GyE/12Fx ].
33253585|NCT05028972|Other|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
33253586|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
32730705|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
32730706|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
32730707|NCT04861155|Experimental|Intervention Arm|The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
32730708|NCT05477719|Experimental|Compression stockings - No Compression|The patient will wear specific compression stockings in the first phase, and no compression in the second phase of the study
32730709|NCT05477719|Experimental|No Compression - Compression stockings|The patient won't wear anything in the first phase, and specific compression stockings in the second phase of the study
32730710|NCT05403567|Experimental|Bootle Blast Intervention|Children will play the Bootle Blast game at home for 8 continuous weeks.
32730711|NCT05452525|Experimental|Sequence 1|Period 1: Test drug(CKD-379 I) Period 2: Test drug(CKD-379 II) Period 3: Reference drug(D759+D745+D150)
32730712|NCT05452525|Experimental|Sequence 2|Period 1: Test drug(CKD-379 I) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 II)
32730713|NCT05452525|Experimental|Sequence 3|Period 1: Test drug(CKD-379 II) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 I)
33082216|NCT00562510|Experimental|Raltegravir|
33082217|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
33082218|NCT00562549|Experimental|1|SLx-2101
33253587|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
33253588|NCT00777738|Experimental|bortezomib|bortezomib
33253589|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
33253590|NCT00926523||Affected|Subjects have Pulmonary Hypertension
33253591|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
33253592|NCT00781872|Experimental|Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously|Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments
32730714|NCT05452525|Experimental|Sequence 4|Period 1: Test drug(CKD-379 II) Period 2: Test drug(CKD-379 I) Period 3: Reference drug(D759+D745+D150)
33253593|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
33253594|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
33253595|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
33253596|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
33253597|NCT00908271|Other|Dapagliflozin|PO and IV
33074897|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
32730715|NCT05452525|Experimental|Sequence 5|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 I) Period 3: Test drug(CKD-379 II)
32730716|NCT05452525|Experimental|Sequence 6|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 II) Period 3: Test drug(CKD-379 I)
32730717|NCT04584567|Experimental|DOXY ZINC|Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)
32730718|NCT04584567|Placebo Comparator|DOXY PLACEBO|Doxycycline daily dosing (100mg) placebo of Zinc
32730719|NCT04584567|Placebo Comparator|PLACEBO|placebo of Doxycycline daily dosing placebo of Zinc
33074898|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
33074899|NCT04688086||Women with no personal history of breast cancer|Women who came in for a breast mammography between ages 30 and 80 years were invited to take part in the study. All the women included in the study underwent breast cancer screening first by Thermalytix, the AI-based thermal imaging test, followed by mammography.
33074900|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
33253598|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.~Insulin administered to patients either by subcutaneous injections or by pump."
33253599|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.~Insulin administered to patients either by subcutaneous injections or by pump."
33253600|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
32730720|NCT04508257|Experimental|Investigational Formula (Stage 1&2)|Investigational formula contains DHA，ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants.
33253601|NCT00741806|Placebo Comparator|SPGN buffer|
33277438|NCT05355506||The Development and Effectiveness of Heart Failure Self-Health Management Application|"Heart Failure can cause physical disability and death. According to the Ministry of Health and Welfare, there were 20,644 deaths from heart disease, ranking second among the top 10 causes of death [1]. The World Health Organization (WHO) has advocated nursing guidance with the concept of empowerment, where patients can play an active and aggressive role in managing their health [2]. This paperless nursing health education guidance information can be designed through the application, which features non-professional expressions and visualization methods. The users can participate in feedback-based interactions and complete the questionnaires after receiving nursing guidance. This study used the Technology Acceptance Model (TAM) to evaluate patients' acceptance of the nursing guidance application and the effectiveness of such nursing guidance."
33277439|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
33277440|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
32730721|NCT04508257|Active Comparator|Control formula (Stage 1&2)|Control formula have comparable macronutrients and micronutrients, but does not contain DHA，ARA and MFGM.
32730722|NCT04508257|Other|Breast feeding|Breast fed of human milk
32730723|NCT04814901|Experimental|Study group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae using FAMM and assessment of success regarding patient satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection.
32730724|NCT04814901|Active Comparator|Comparator group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae and its effect on patient's satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection
32730725|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
32730726|NCT03354091|No Intervention|Control|Patient education program only.
32730727|NCT04777461|Experimental|Group 1|Pilot the structured education in women with PCOS
32730728|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
32730729|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
32730730|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
33253602|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
33074901|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
33074902|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
33074903|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
33074904|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
33074905|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
33074906|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
33074907|NCT02522260|Active Comparator|Group 3|Standard supportive care
33074908|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
33074909|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
33074910|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
33253603|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
32730731|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
32730732|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
32730733|NCT04691505||Methotrexate|Reference group
32730734|NCT04691505||Hydroxychloroquine|Exposure group
32730735|NCT04507945|Experimental|living quality|
32730736|NCT04507945|Experimental|complication|
32730737|NCT04653363||1|study1 is the patients who will be assessed by first rater.
32730738|NCT04653363||2|study2 is the patients who will be assessed by second rater.
32730739|NCT04653363||3|Theh are healty peers control patients who will be assessed by first rater.
32730740|NCT05400265|Experimental|Dose Cohort 1|In this cohort, the dose of HLX26 is 500mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
32730741|NCT05400265|Experimental|Dose Cohort 2|In this cohort, the dose of HLX26 is 800mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
32730742|NCT04504383|Experimental|PN-943 450 mg BID|Oral administration of PN-943 450 mg BID
32730743|NCT04504383|Experimental|PN-943 150 mg BID|Oral administration of PN-943 150 mg BID
32730744|NCT04504383|Placebo Comparator|Placebo BID|Oral administration of matching placebo
32730745|NCT05374993|Experimental|3TBA Procedure|
32730746|NCT05364619|Experimental|QHD group|Qingre Huashi Granules 1 package twice daily, Rabeprazole 20mg triple daily, Amoxycillin 1g triple daily. The duration is 14 days.
32730747|NCT05364619|Active Comparator|Control group|Rabeprazole 20mg twice daily, bismuth potassium citrate 220mg twice daily, Amoxycillin 1g twice daily, clarithromycin 500mg twice daily. The duration is 14 days.
33074911|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
33074912|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
33074913|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
33082219|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
33253604|NCT00929877|Placebo Comparator|Matching placebo|
33253605|NCT00741884|Experimental|Arm 1|
33253606|NCT00741884|Experimental|Arm 2|
33253607|NCT00741884|Experimental|Arm 3|
33253608|NCT00741884|Active Comparator|Arm 4|
33253609|NCT00741884|Placebo Comparator|Arm 5|
33253610|NCT00777816|Active Comparator|1|
33253611|NCT00777816|Placebo Comparator|2|
33253612|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
33253613|NCT00741962|Experimental|1|
33253614|NCT00741962|Placebo Comparator|2|
33253615|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
33253616|NCT00782028|Other|Centering parenting/Group well child care|
33253617|NCT04014621|Active Comparator|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
33253618|NCT04014621|Sham Comparator|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
33074914|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
33074915|NCT02909608||Controls|
33074916|NCT02909608||Children With Pulmonary Hypertension|
33253619|NCT00742040|Experimental|1|
33253620|NCT00742040|Active Comparator|2|
33074917|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
33074918|NCT02909491||Cases|Inpatient with severe behavioural disorders
33074919|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
33074920|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
33074921|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
33074922|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
33074923|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
33253621|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
33253622|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
33253623|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
33074924|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
33074925|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
33074926|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
32730748|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
32730749|NCT04433013|Experimental|Treatment group|
32730750|NCT04433013|Placebo Comparator|Control group|
32730751|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
32730752|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
32769274|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
33074927|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
33074928|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
33074929|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
33082220|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
33253624|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
33253625|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
33253626|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
33253627|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
33253628|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
33253629|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
32730753|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
33253630|NCT00929955|Active Comparator|Ondansetron|
32730754|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
33253631|NCT00929955|Active Comparator|Simvastatin|
33253632|NCT00929955|Placebo Comparator|Placebo|
33253633|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
32730755|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
32730756|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
32730757|NCT04499859|Experimental|ezetimibe 10 mg plus rosuvastatin 5 mg|Rosuzet 5/10 mg , once a day for 24 months
33253634|NCT00742118|Other|3|patient having no symptoms
33253635|NCT00742118|Experimental|1|patient with irritable bowel syndrome
32730758|NCT04499859|Active Comparator|rosuvastatin 20 mg only|Any brand drugs of rosuvastatin 20mg, once a day for 24 months
32730759|NCT05344989|Active Comparator|APNmAb005 (5mg/kg) vs Placebo|Single Ascending Dose (SAD)
32730760|NCT05344989|Active Comparator|APNmAb005 (10 mg/kg) vs Placebo|Single Ascending Dose (SAD)
33253636|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
33253637|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
33253638|NCT00742196||1|No parapapillary atrophy
33253639|NCT00742196||2|Parapapillary atrophy
33253640|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
33253641|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
33253642|NCT04060238||Normal colour vision|Normal trichromopsia
33253643|NCT04060238||Inherited red blindness|Protanopia
33253644|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
33253645|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
33253646|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
32730761|NCT05344989|Active Comparator|APNmAb005 (25 mg/kg) vs Placebo|Single Ascending Dose (SAD)
32730762|NCT05344989|Active Comparator|APNmAb005 (50 mg/kg) vs Placebo|Single Ascending Dose (SAD)
32730763|NCT05344989|Active Comparator|APNmAb005 (70 mg/kg) vs Placebo|Single Ascending Dose (SAD)
32730764|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
33253647|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
32730765|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
32730766|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
32730767|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
32730768|NCT01073475||Pregnant women|Pregnant women in the MNH cluster
32730769|NCT01073475||Male and Female Infants|Male and Female Infants delivered in the clusters
32730770|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.~Each session is expected lasts 30 mins to 1 hour."
32730771|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
32730772|NCT05306899|Active Comparator|Ketamine infusion|Intravenous Ketamine
32730773|NCT05306899|Placebo Comparator|Placebo infusion|
32730774|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
32730775|NCT00807651|Active Comparator|insulin therapy|The participants not accepted written informed consent will receive insulin therapy
33253648|NCT00745160||1|Never-smokers with lung cancer
33253649|NCT05450978||Lamotrigine (LTG)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with lamotrigine (LTG)
33253650|NCT05450978||Levetiracetam (LEV)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with Levetiracetam (LEV)
33253651|NCT04060550||Normal controls|No history of skin disease and atopy
33253652|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
33253653|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
33253654|NCT00921674|Experimental|Ivermectin|ivermectin
33253655|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
33253656|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
33253657|NCT00742352||Breast cancer patients|
33253658|NCT00742352||Lung cancer patients|
33253659|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
33253660|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
33253661|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
33253662|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
33253663|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
33253664|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
33253665|NCT00745238|Experimental|Myotonic Dystrophy 1|
33253666|NCT00785070||1|Perioperative
33253667|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
33253668|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
32730776|NCT00807651|Experimental|AHSCT|The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)
32730777|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
32730778|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
32730779|NCT00752193|Experimental|1|Probiotic lactobacilli
32730780|NCT00752193|Placebo Comparator|2|Placebo
32730781|NCT05272267|Active Comparator|AI-assisted|AI-assisted models providing diagnosis and prognostic information
32730782|NCT05272267|Placebo Comparator|Usual care|usual care without AI-assisted models providing diagnosis and prognostic information
32730783|NCT00700791|Placebo Comparator|Group I Single Site Randomization|Patients with 1 surgical scar will be given both oral placebo and topical cream placebo
32730784|NCT00700791|Active Comparator|Group II Single Site Randomization|Single surgical site will be given oral placebo and topical TCT
32730785|NCT00700791|Active Comparator|Group III Single Site Randomization|Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream
32730786|NCT00700791|Active Comparator|Group IV Single Site Randomization|Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).
32730787|NCT00700791|Placebo Comparator|Group I: Bilateral Site Randomization|Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.
32730788|NCT00700791|Active Comparator|Group II: Bilateral Site Randomization|Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.
32730789|NCT00700791|Active Comparator|Group III: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.
32730790|NCT00700791|Active Comparator|Group IV: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.
32730791|NCT00700791|No Intervention|Normal Skin and Adipost Tissue Group|Normal human skin and adipose tissue will be collected
32730792|NCT04502329|Experimental|IER|Intermittent Energy Restriction
32730793|NCT04502329|No Intervention|CER|Continous Energy Restriction
32730794|NCT05344365|Experimental|Iloperidone (Cohort 1)|
32730795|NCT05344365|Experimental|Iloperidone (Cohort 2)|
32730796|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
32730797|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
32730798|NCT05129553|Experimental|Single Use|The participants will then be given the Béa Applicator and Béa Cervical Cap with accompanying instructions for single-use in a home use environment.
32730799|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
32730800|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
32730801|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
32730802|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
32730803|NCT05343273||Healthy|
32730804|NCT05343273||Periodontitis|
32730805|NCT05129085|Experimental|Group ESI|Patients in group ESI will undergo epidural steroid injection.
32730806|NCT05129085|Active Comparator|Group EPRP|Patients in group EPRP will undergo epidural PRP injection.
32730807|NCT04467333||All lung cancer patients|There will not be an intervention.
32730808|NCT05129007||Study group|All patients
32730809|NCT05128851|Active Comparator|High Tibial Osteotomy and arthroscopy|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions.
32730810|NCT05128851|Sham Comparator|High Tibial Osteotomy|Descending High Tibial Osteotomy with arthroscopy without treatment of intraarticular lesions.
32730811|NCT05128851|Active Comparator|High Tibial Osteotomy, arthroscopy and microfractures|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions and microfracture.
32730812|NCT05128695||Covid-19 positive|Adults who tested Covid-19 positive
32730813|NCT05128695||Covid-19 negative|Adults who tested Covid-19 negative
32730814|NCT04501419|Experimental|Trained radiologists|Trainers will successfully train Nigerian radiologists
32730815|NCT04501419|Experimental|Patients with a suspicious breast mass|Women that present to the hospital with a suspicious breast mass
32730816|NCT04457115|Experimental|TPV Block|Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.
32730817|NCT04457115|Experimental|ESP Block|Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.
32730818|NCT05120583|Experimental|study group|Patients in the study group received Pilates exercises (25 minutes/ session). There are different types of equipment to be used in Pilates exercises to achieve different purposes; mat, Pilates band or elastic bands, and Pilate's ball were used.
32730819|NCT05120583|Experimental|control group|Participants in control group received the traditional physical therapy program program (60 minutes/session, three sessions /week for three months).
32730820|NCT04400877||SARS-CoV-2 pos|Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
32730821|NCT04400877||SARS-CoV-2 neg|Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
32730822|NCT04373733|Experimental|Favipiravir & Standard of Care|Favipiravir: Day 1 1800mg twice per day, Days 2-10 800mg twice per day
33074930|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
33074931|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
33074932|NCT04688008|Other|Treatment sequence #1|29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2
32730823|NCT04373733|Other|Standard of care|No trial intervention
33074933|NCT04688008|Other|Treatment sequence #2|29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2
33074934|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
33074935|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
33074936|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
32730824|NCT04047771|Experimental|SCB-313|
32730825|NCT05403489||Group B (bronchoalveolar lavage)|"Patients who underwent BAL* were named Group B~* BAL: bronchoalveolar lavage"
32730826|NCT05403489||Group E (endotracheal aspirate)|"Patients who received ETA** were named Group E.~** ETA: Endotracheal aspirate"
33074937|NCT02939677|No Intervention|care as usual|home based exercises
33074938|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
32730827|NCT05032521|Active Comparator|standard practice|
32730828|NCT05032521|Experimental|algorithm|
32730829|NCT05039385|Experimental|ESATRAL Group|They will perform the supervised physical exercise program. The supervised exercise program (ESATRAL) will last 24 weeks with 2-3 non-consecutive weekly sessions. The duration of each session will be 30 minutes and will progressively increase depending on the phase in which we are until reaching 60 minutes.
32730830|NCT05039385|No Intervention|Control Group|They will follow their daily treatment without added exercise
32730831|NCT04968717||HIV elite controllers|"Non-viremic elite controller:~HIV-positive , > 1 year without cART AND with >3 consecutive HIV-RNA < 75 copies/ml spanning >12 months AND stable CD4> 500 cells/uL.(i.e. >75% of measurements)~OR on cART, but before start cART > 1 year without cART AND with >3 consecutive HIV-RNA < 75 copies/ml spanning >12 months AND stable CD4> 500 cells/uL. (i.e. >75% of measurements)~Viremic elite controller:~HIV-positive >5 year without cART AND with always HIV-RNA >50-10.000 copies/ml AND always CD4> 500 cells/uL.~OR on cART, but before start cART >5 year without cART AND with always HIV-RNA >50-10.000 copies/ml AND always CD4> 500 cells/uL"
32730832|NCT04968717||First-degree relatives of HIV elite controllers|
32730833|NCT04968717||cART-treated non-controller HIV patients|
32730834|NCT04968717||First-degree relatives of cART-treated non-controller HIV patients|
32730835|NCT04987515||Fenestration decompression combined with secondary curettage (FDSC)|Design of the opening window reasonably；Making cyst plug；secondary curettage
33074939|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
33074940|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
33074941|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
33074942|NCT04865029|Experimental|Treatment Arm|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
33074943|NCT04865029|Other|Control Arm|"Standard of Care along with placebo injection and placebo pill~Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines"
33074944|NCT04853173|Experimental|ambulatory protocol after adult tonsillectomy|prescription of analgesics for outpatient procedure with hospital surveillance
33074945|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
33074946|NCT04838587||6750 Children <3 years ( 5 sites)|A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.
33074947|NCT04833400|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The ICRS is very likely to the conventional stationary biking, but with an algorithm that automatically controls the resistance of pedalling, considering the instant heart rate and cadence, to keep the heart rate within the targeted heart rate zone.
33074948|NCT04833400|Active Comparator|Traditional aerobic exercise training (TAET)|"The TAET is performed with stationary biking, with intensity being set as subjective rating of perceived exertion at a somewhat hard to hard level. The resistance of pedaling is ad-justed by the user or physical therapist."
33074949|NCT04808323|Experimental|Cohort A|Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
33074950|NCT04808323|Experimental|Cohort B|Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
33074951|NCT04808323|Experimental|Cohort C|Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
33074952|NCT00533299|Experimental|1|Topotecan hydralazine valproate
33074953|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
33074954|NCT04788823|No Intervention|Control|Group 1 will represent controls and will not receive prednisone in the 3-year post-op period.
33253669|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
33253670|NCT00745472||1|
33074955|NCT04788823|Experimental|Prednisone Monthly - Scheduled|Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
33074956|NCT04788823|Experimental|Prednisone Monthly - As Needed|Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
33253671|NCT00745472||2|
33253672|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
33253673|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
33253674|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
32730836|NCT04987515||local curettage (LC)|The tumor was removed by local curettage only
33253675|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
33253676|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
33253677|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
33253678|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
33253679|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
33253680|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
33253681|NCT02563418|Experimental|Patient with Huntington's disease|
33253682|NCT00749060|Other|1|conventional treatment
33074957|NCT04788823|Experimental|Prednisone Every Other Week|Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
33074958|NCT04785391||Patients with KDIGO stage 2 or 3 AKI|
33074959|NCT00181584|Active Comparator|Group 1|
33074960|NCT00181584|Placebo Comparator|Group 2|
33074961|NCT04769440|Active Comparator|M group (Mg sulphate )|patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes
33253683|NCT00749060|Other|2|kyphoplasty by balloons
33253684|NCT00749060|Other|3|vertebroplasty
33253685|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
33253686|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
33253687|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
33253688|NCT05001906|No Intervention|Control group|The control group (CG) will consist of pregnant women with standard prenatal care, who attending theoretical classes on childbirth (CG, n = 35). The control group will not exercise. The sedentary participants will continue their regular daily activities and life habits.
33253689|NCT05001906|Experimental|Exercise group|The exercise group (EG) will consist of pregnant women who will attend theoretical classes and prenatal exercises in the program of psychophysical preparation for childbirth (EG, n = 35). The experimental group will exercise for 45 minutes, three times a week.
33253690|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
33253691|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
33253692|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
33253693|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
33253694|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
33253695|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
33253696|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
32730837|NCT04977765||Transgender Males|Individuals assigned female gender at birth but considering gender-affirming testosterone therapy. May self-identify as transgender or nonbinary etc.
32730838|NCT04977765||Cisgender Controls|Individuals assigned male or female at birth. May identify as cisgender or nonbinary etc. These individuals should not be undergoing or considering any form of hormone therapy.
32730839|NCT04969731|Experimental|Immuncell-LC/Gemcitabine|Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)
32730840|NCT04969731|Active Comparator|Gemcitabine|Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)
33074962|NCT04769440|No Intervention|C group (control )|patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes
33074963|NCT04765072|Experimental|Survivorship care|Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.
33074964|NCT04762693||Cough monitoring|All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
33074965|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
33074966|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
33253697|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
33253698|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
33253699|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
33253700|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
32730841|NCT04921761|Placebo Comparator|Group A|Women who received the conventional epidural technique (group A). Intervention: Procedure: Conventional epidural
32730842|NCT04921761|Active Comparator|Group B|Women who received the dural puncture epidural technique (group B). Intervention: Procedure: Dural puncture epidural
33253701|NCT00782808||1 HIV DNA will be stratified by high|
32730843|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
32730844|NCT04807647|Experimental|music band|"The starting person will first talk about white noise and explain how he can direct breastfeeding, and fill the Informed Volunteer Form, Patient Identification Form and Application Registration Form. The mother and baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. During the second breastfeeding, 30 newborn group Orhan OSMAN's Kolik album will be played on the music player Your Baby Don't Cry. After the process is completed, a written response will be received for the data Premature Baby Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form."
32730845|NCT04807647|No Intervention|control|First, the mother will be informed about the study. Then the appropriate position will be given. The informed volunteer form, the Patient Identification Form and the Application Registration Form will be filled. The mother and the baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. No intervention will be applied during the second breastfeeding. After the procedure is completed, a written response will be received with the data Premature Infant Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form.
32730846|NCT04839315|Other|mRNA COVID19 vaccines|mRNA-based COVID19 vaccines
33074967|NCT04725409||Epilepsy patients|All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed.
33253702|NCT00782808||2 HIV DNA will be stratified by low|
33074968|NCT04696042||Lanreotide|Patients treated with lanreotide
33074969|NCT04678141|Other|Composite and compomer materials|Children aged 5-6 years with at least two carious proximal surface primary molars
33074970|NCT00155558|Experimental|A|
33074971|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
33074972|NCT00533494|Active Comparator|A|Feedback information to physicians
33074973|NCT04658914|No Intervention|rotarix only|Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
33074974|NCT04658914|Experimental|P2 VP8 only|Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
33074975|NCT04658914|Experimental|Rotarix + 1 dose P2-VP8|Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
33074976|NCT04658914|Experimental|Rotarix + 3 doses P2-VP8|Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
33253703|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
33253704|NCT00785382|Placebo Comparator|1|
33253705|NCT00785382|Experimental|2|
33253706|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
33082221|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
33253707|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
33253708|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
33253709|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
33253710|NCT00785460|Experimental|Benfotiamine and Smoking|
33253711|NCT00785460|Placebo Comparator|Smoking alone|
33253712|NCT00778518|Active Comparator|1|low dose
33253713|NCT00778518|Active Comparator|2|Medium dose
33253714|NCT00778518|Active Comparator|3|High Dose
33253715|NCT05264844|Experimental|masking tape group|Masking tape will be used
33253716|NCT05264844|No Intervention|standard catheter dressing group|Medical plaster to be used (It is routine practice in the clinic.)
33253717|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
32730847|NCT04489251||PH subjects|"Pediatric subjects ages 2-17 years~Subjects undergoing a clinically indicated cardiac catheterization.~Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†~Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure >20mmHg, pulmonary vascular resistance index >3 Woods units*m2, and wedge pressures <15mmHg."
32730848|NCT04489251||Control subjects|"Pediatric subjects ages 2-17 years~Subjects undergoing a clinically indicated cardiac catheterization.~Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria."
32730849|NCT05301231||NAFLD group without fibrosis|Group diagnosed to have NAFLD without fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years) ,
33074977|NCT04658446|Experimental|Augmented Reality-Assisted Bonding|The quadrant of the upper arch that shall use the AR-assisted bonding method. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
33074978|NCT04658446|Active Comparator|Digitally-Asssited Indirect Bonding|The quadrant of the upper arch that shall use the digitally-assisted bonding method utilizing a 3D printed tray. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
33253718|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
33253719|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
33074979|NCT04628104||COVID-19 patients presented with myocardial infarction|
33253720|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
33253721|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
33253722|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
33253723|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
33253724|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
32730850|NCT05301231||NAFLD group with fibrosis (potential NASH)|Group diagnosed to have NAFLD with fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years),
32730851|NCT05301231||Healthy group|Healthy control group age and sex-matched with the previous group (75 adults aged 30-60 years, 75 children aged 12-18 years),
32730852|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
32730853|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
33074980|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
33082222|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
33082223|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
33253725|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
33253726|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~Dose-level 0: 5 mg/d, day 1-21~Dose-level 1: 10 mg/d, day 1-21~Dose-level 2: 15 mg/d, day 1-21"
33253727|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
33253728|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
33253729|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
33253730|NCT00926835|Active Comparator|Paroxetine+Bupropion|
33253731|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
33253732|NCT00926835|Active Comparator|Paroxetine+Lithium|
33253733|NCT00926835|Active Comparator|escitalopram+mirtazapine|
33253734|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
33253735|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
33253736|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
33253737|NCT00930033|Experimental|B|Sunitinib alone
33253738|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
33253739|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
33253740|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
33253741|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
33253742|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
33253743|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
33253744|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
33253745|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
33253746|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
33253747|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
33253748|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
32934997|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
33253749|NCT00931671|Other|Exercise|Exercise
33253750|NCT00931749|Experimental|Low intensity Ultrasound group|
33253751|NCT00931749|Sham Comparator|Sham ultrasound group|
33253752|NCT00783042|Active Comparator|1|
33253753|NCT00783042|Placebo Comparator|2|
33253754|NCT02556528|Experimental|Health Coaching|
33253755|NCT00926913||Group 1|
33253756|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
33253757|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
33253758|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
33253759|NCT00926991||traumatic rib fractures|
33253760|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
33253761|NCT00936819|Experimental|Autologous EPCs|
33253762|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
33253763|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
33253764|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
33253765|NCT04013997|Experimental|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
33253766|NCT04013997|No Intervention|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
33253767|NCT00931827||Group 1|
33253768|NCT00931827||Group 2|
33253769|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
33253770|NCT04015323|Experimental|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
33253771|NCT04015323|Experimental|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
33253772|NCT04015323|Experimental|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
32934998|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
32934999|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
32935000|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
33253773|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
33253774|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
33253775|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
33253776|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
33253777|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
32935001|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
32935002|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
32935003|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
32935004|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
32935005|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
32935006|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
32935007|NCT05587387||Cohort 1|Without Nal-IRI/FL; From Jan. 2012 to Jan. 2018 (Before launch of nal-IRI)
32935008|NCT05587387||Cohort 2|With Nal-IRI/FL; From Jan. 2018 to Dec. 2021 (After launch of nal-IRI)
32935009|NCT00367861|Experimental|interruption of Glivec®|
32935010|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
32935011|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
33082224|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
33253778|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
33253779|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
33253780|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
32730854|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
32730855|NCT04899219|Experimental|Group A (subjects with severe renal impairment)|
32730856|NCT04899219|Experimental|Group B (control subjects)|
32730857|NCT04478409||Children or adult with Familial Mediterranean fever|"Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype.~The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients."
32730858|NCT04478409||Healthy blood donor|Healthy blood donor
32730859|NCT04473885|Experimental|Perturbation-based balance training group|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
32730860|NCT04473885|No Intervention|Control group|Participants in the control group will remain their regular activity without additional training.
32730861|NCT04458363|Experimental|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria) convalescent plasma will be administered
33253781|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
33253782|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
33253783|NCT04014933||healthy controls|individuals with normal optic disc and IOP </21mmHg and normal visual fields
32730862|NCT04662411|Placebo Comparator|Placebo|
33253784|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
33253785|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
33253786|NCT04059614|Active Comparator|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
33253787|NCT04059614|Experimental|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
33253788|NCT00930345|Other|SUTENT before nephrectomy|
33253789|NCT00786006|Experimental|Arm 1|FOLFIRI.3
33253790|NCT00786006|Active Comparator|Arm 2|FOLFOX
33253791|NCT02562326|Experimental|BioChaperone insulin lispro|
33253792|NCT02562326|Active Comparator|Humalog®|
33253793|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
33253794|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
33253795|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
33253796|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
33253797|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
32730863|NCT04662411|Experimental|butyrate and hexanoate amount 1|1325 mg of butyrate and hexanoate
32730864|NCT04662411|Experimental|butyrate and hexanoate amount 2|
32730865|NCT04662411|Experimental|butyrate and hexanoate amount 3|
32730866|NCT05203965|Experimental|FHP; Mavoglurant-Placebo|Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
32730867|NCT05203965|Experimental|FHP; Placebo-Mavoglurant|Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
32730868|NCT05203965|Experimental|FHN; Mavoglurant-Placebo|Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
33082225|NCT04621513|Experimental|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
33082226|NCT04621513|Active Comparator|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
33074981|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
33253798|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
33253799|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
33074982|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
33074983|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
33074984|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
33253800|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
33253801|NCT00783276|Active Comparator|SYN115|
33253802|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
33253803|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
33401197|NCT03434353|Experimental|Group 3: Inarigivir Soproxil 200 mg + TAF|Viremic participants will be administered inarigivir soproxil 200 mg (2 x 100 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks
32730869|NCT05203965|Experimental|FHN; Placebo-Mavoglurant|Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
32730870|NCT04332861||Prospective observational cohort|"For data analysis, the cohort will be subdivided as follows:~Identification and Validation cohorts~Patients with and without complicating factors~Patients with and without measured inflammatory marker levels"
33074985|NCT04575844|Experimental|Exercise Alone|24 weeks of treatment
33074986|NCT04575844|Experimental|Liraglutide Alone|24 weeks of treatment
33074987|NCT04575844|Experimental|Exercise + Liraglutide|24 weeks f treatment
33074988|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
33074989|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
33074990|NCT04545346|No Intervention|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
33074991|NCT04545346|Experimental|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
33074992|NCT04538755|Placebo Comparator|Placebo|Placebo capsule 4 hours before sleep
33253804|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
33253805|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
33253806|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
33253807|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
33253808|NCT00937287||youth and caregivers|
33253809|NCT00665652|Experimental|Lenalidomide|
33253810|NCT00749294||Observation|
33253811|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
33253812|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
33401198|NCT03434353|Experimental|Group 4: Inarigivir Soproxil 100 mg + commercially available NUCs|Virally suppressed participants receiving commercially available nucleoside/nucleotide (NUC) will be administered inarigivir soproxil 100 mg tablet once daily orally 1 hour before or 1 hour after a meal for 12 weeks. Participants will continue commercially available NUCs for 48 weeks.
33401199|NCT03434353|Experimental|Group 5: Inarigivir Soproxil 400 mg + TAF|Viremic participants will be administered inarigivir soproxil 400 mg (2 x 200 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed TAF 25 mg tablet once daily orally with food for 36 weeks.
33401200|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
33401201|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
33401202|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
33401203|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
33401204|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
33401205|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
33401206|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
32730871|NCT01674621|Experimental|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
32730872|NCT01674621|Experimental|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
32730873|NCT01674621|Experimental|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
33401207|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
32730874|NCT01674621|Active Comparator|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
32730875|NCT01674621|Placebo Comparator|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
32730876|NCT04644705|Active Comparator|Part A: verum niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)"
32730877|NCT04644705|Placebo Comparator|Part A: placebo to niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)"
32743037|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
32743038|NCT04940325|Experimental|DS-1062a|All participants included in the study will receive a starting dose of 6 mg/kg of DS-1062a every 3 weeks until progression or until unacceptable toxicity
32743039|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
33074993|NCT04538755|Active Comparator|DAW2020|DAW2020 capsule 4 hours before sleep
33074994|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
33074995|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
33074996|NCT04511572|No Intervention|Standard Care: burr hole surgery|Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
33074997|NCT04511572|Active Comparator|embolisation middle meningeal artery|Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
33074998|NCT04686721||Patients at risk of developing tracheal stenosis after prolonged intubation or tracheostomy|Patients older than 18 years of age who underwent either prolonged intubation or tracheostomy will be enrolled. A minimum of 2 months follow-up from hospital discharge is required. Patients tested negative for SARS-CoV-2 will be used as a control group
33074999|NCT04508023|Experimental|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
33075000|NCT04508023|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
33075001|NCT04475809|Placebo Comparator|Group C|high intra-abdominal pressure
33075002|NCT04475809|Active Comparator|Group L|low intra-abdominal pressure
33075003|NCT04475809|Active Comparator|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
33075004|NCT04475809|Active Comparator|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
33075005|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
33075006|NCT00409227|Active Comparator|1|double blind placebo control
33075007|NCT00409227|Placebo Comparator|2|placebo control blinded arm
33075008|NCT04475380||All-comer patients requiring PCI|All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES
33075009|NCT04473781|Experimental|Treatment (interstitial brachytherapy)|Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks.
33075010|NCT04470037|Experimental|DAAOI-P|DAAOI-P 250-1500mg
33075011|NCT04470037|Placebo Comparator|Starch pill|
33075012|NCT04462627|Experimental|Covid 19 positive patients|
33075013|NCT04462627|Experimental|Covid 19 negative patients|
33075014|NCT04462627|Experimental|Untested healthy volunteers|
33075015|NCT04460794|Experimental|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
33075016|NCT04460794|Other|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
33401208|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
33075017|NCT04442971|Experimental|Music Stimulation|Patients preferred music is presented via headphones.
33401209|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
33401210|NCT03611712|No Intervention|CCRT alone arm|
32730878|NCT04644705|Active Comparator|Part B: verum as solution (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
32730879|NCT04644705|Active Comparator|Part B: verum as chewing tablet (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
32730880|NCT04644705|Active Comparator|Part C: verum (niclosamide and camostat)|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
32730881|NCT04644705|Placebo Comparator|Part C: placebo to niclosamide and camostat|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
32743040|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
33075018|NCT04442971|Active Comparator|Alternative Auditory Stimulation|An audio book is presented via headphones.
32743041|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
33075019|NCT04442971|Sham Comparator|No Auditory Stimulation|Silence is presented via headphones.
32743042|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
33075020|NCT04442347|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
33075021|NCT04442347|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
33075022|NCT00406679|Experimental|1|
33075023|NCT00406679|Placebo Comparator|2|
33075024|NCT00406679|Active Comparator|3|
33075025|NCT04441216|No Intervention|Consultation only|Review by Chinese Medicine practitioner only
33075026|NCT04441216|Active Comparator|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
33075027|NCT04441216|Active Comparator|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
33075028|NCT04441216|Active Comparator|JM-LD|JQJT plus low doses Ophiopogonis Radix
33075029|NCT00181857||1|Children of Adults with ADHD NOS
33075030|NCT04431154|No Intervention|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include provision of an HIV self-screening test kit, the standard linkage officer follow-up call following report of a positive HIVSS test and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
33075031|NCT04431154|Experimental|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
33075032|NCT04423159|Experimental|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
33075033|NCT04724954|Experimental|Rehabilitation Therapy on Experimental Robotic Table and standard of care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited for experimental group.~The investigators will also recruit the 10 caregivers of the experimental subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
33075034|NCT04724954|Sham Comparator|Rehabilitation Therapy as part of Standard of Care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited as a control group.~The investigators will also recruit the 10 caregivers of the control subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
33075035|NCT04422457|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
33075036|NCT04420429||Cohort|All patients
33075037|NCT04686448|Active Comparator|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
33075038|NCT04686448|Active Comparator|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
33075039|NCT04405765|Active Comparator|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
33075040|NCT04405765|Active Comparator|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
33075041|NCT04402840|Experimental|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
33253813|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
33253814|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
33253815|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
33253816|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
33253817|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
32730882|NCT04263363|Experimental|CDS pathway|When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
32730883|NCT04248855|Experimental|SAD Cohort 1|All enrolled patients will receive one dose of KAN-101 Dose A
32730884|NCT04248855|Experimental|SAD Cohort 2|All enrolled patients will receive one dose of KAN-101 Dose B
32730885|NCT04248855|Experimental|SAD Cohort 3|All enrolled patients will receive one dose of KAN-101 Dose C
32730886|NCT04248855|Experimental|SAD Cohort 4|All enrolled patients will receive one dose of KAN-101 Dose D
32730887|NCT04248855|Experimental|MAD Cohort 5|All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
32730888|NCT04248855|Experimental|MAD Cohort 6|All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
32730889|NCT04248855|Experimental|MAD Cohort 7|All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo
33075042|NCT04390087|Experimental|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
33075043|NCT04390087|No Intervention|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
33075044|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
33075045|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
33253818|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
33253819|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
33253820|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
33253821|NCT04046952|Active Comparator|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
32730890|NCT04207281|Active Comparator|Honey|Raw honey (1.5 tablespoons)
32730891|NCT04207281|Placebo Comparator|Comparator|Honey comparator(1.5 tablespoons)
32730892|NCT04412733|Experimental|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
32730893|NCT04412733|Sham Comparator|Sham Group|Control group received sham ultrasound with the same protocol.
32730894|NCT04095975|Active Comparator|Baking Soda|Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
32730895|NCT04095975|Active Comparator|LithoLyte|Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
33075046|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
33075047|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
33075048|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
33253822|NCT04046952|Experimental|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
33253823|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
33253824|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
33253825|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
33253826|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
33253827|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
33253828|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
33253829|NCT03975387|Experimental|ASTX295|
33253830|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
33253831|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
33253832|NCT00937755||olanzapine|olanzapine 10-20 mg/day
33075049|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
33075050|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
33075051|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
33075052|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
33075053|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
33075054|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
33075055|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
33075056|NCT04893148|Active Comparator|iGlar/Lixi|"Switching to IGlarLixi from insulin glargine iGlar/Lixi starts with the following doses depending on the existing insulin glargine dose: 1) insulin glargine <20 unit/day = iGlar/Lixi 10 unit/day, 2) insulin glargine >=20 unit/day = iGlar/Lixi 20 unit/day.~Training to increase the iGlar/Lixi dosage every 3 days to meet the target fasting blood glucose level to 80~130 mg/day"
33075057|NCT04893148|Active Comparator|Dulaglutide plus insulin glargine|Adding Dulaglutide to insulin glargine. Keep insulin glargine and dulaglutide start at 0.75 mg per week and increase to 1.5 mg per week after 1 month with evaluating compliance and tolerability.
33075058|NCT04883632|Experimental|Volume Lidocaine HQ|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma HQ Facility
33253833|NCT00937755||quetiapine|quetiapine 300-600 mg/day
33253834|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
33075059|NCT04883632|Active Comparator|Volume Lidocaine C1|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma C1 Facility
33075060|NCT04878874|No Intervention|No Intervention:hip flexion|hip flexion pre measurement with extension knee will be performed
33253835|NCT00786240|Experimental|A|
33253836|NCT00786240|Experimental|B|
33253837|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
33253838|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
33253839|NCT00779064|Experimental|Arm 1|
33253840|NCT00779064|Experimental|Arm 2|
33253841|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
33253842|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
33253843|NCT04046874|Other|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
33075061|NCT04878874|Experimental|Experimental: hip flexion|hip flexion post experimental application measurement with Magnetic tape Application with extension knee will be performed
33082227|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
33253844|NCT04046874|Other|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
33253845|NCT00789906||1|350 healthy women , aged from 18 to 89
33075062|NCT04878874|Placebo Comparator|Placebo Comparator: hip flexion|hip flexion post placebo application measurement with kinesiology tape Application with extension knee will be performed
33075063|NCT04872517|Experimental|34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.|Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.
33075064|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
33075065|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
33075066|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
33253846|NCT00789906||2|350 healthy men, aged from 18 to 89
33253847|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
32730896|NCT04045353|No Intervention|Standard of care|Subjects will receive standard counseling on obesity as part of routine postpartum care.
32730897|NCT04045353|Active Comparator|Low carbohydrate diet education|Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
32730898|NCT04045353|Active Comparator|Low carbohydrate diet education with behavioral component|Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.
32730899|NCT04038489|Experimental|Tamoxifen and Aspirin with AC-T Chemotherapy|AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
32730900|NCT05134077|Experimental|kidneys with simple cysts|Patients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
32730901|NCT05134077|Active Comparator|contralateral kidneys without cyst|Рatients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
32730902|NCT04768647||Main cohort|Main cohort of all patients
32730903|NCT04768647||Subgroup of patients with imbalance|Subgroup of patients with imbalance
32730904|NCT04468425|Experimental|Pharmacokinetic Study|"Period 1 (Day 1) and 2 (Day 8 - Day 21) separated by 7-day washout period. Period 1: A single 5 mg tofacitinib tablet will be administered orally on Day 1.~Period 2: Repeat dosing of Tofacitinib Citrate Topical Gel 3.2% to approximately 10% BSA in the morning of Day 8 and twice daily from Day 9 to Day 20 with the last dose in the morning of Day 21."
32730905|NCT05133843|Other|Coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
32730906|NCT03891771|No Intervention|Usual Care|Patients allocated to usual care will receive standard follow-up procedures at their primary care facility.
33075067|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
33075068|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
33075069|NCT04686370|Active Comparator|sandblasted acid-etched implants|implant will be installed intraforaminal
33075070|NCT04686370|Experimental|laser treated implants|implant will be installed intraforaminal
33253848|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
33253849|NCT00786318|Experimental|ziprasidone|
33253850|NCT00786318|Active Comparator|Standard therapy|
32730907|NCT03891771|Experimental|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
32730908|NCT03830619||lung cancer patients|
32730909|NCT03830619||normol volunteers|
33075071|NCT00182052|Active Comparator|Group 1|
33075072|NCT00182052|Placebo Comparator|Group 2|
33075073|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
33082228|NCT00562705|Active Comparator|2|growth hormone
33082229|NCT04621006||UC group|Patients with active ulcerative colitis
33082230|NCT04621162|Experimental|Positive Expectations (initial)|
33082231|NCT04621162|Experimental|Negative Expectations (initial)|
33082232|NCT04621162|Placebo Comparator|Neutral Expectations (initial)|
33253851|NCT00783666|Experimental|1|Lactic Acid
33253852|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
33253853|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
33253854|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
32730910|NCT04287855|Experimental|Intervention|Isatuximab, Carfilzomib, Pomalidomide and Dexamethasone
32730911|NCT03710265|Experimental|SHR-1701|
33075074|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
33075075|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
33075076|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
32730912|NCT03640455|Placebo Comparator|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
33075077|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
33075078|NCT00156026|No Intervention|2|Colposcopic Follow-up
32730913|NCT03640455|Experimental|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
32730914|NCT03640455|Experimental|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
32730915|NCT03531099|Experimental|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
33075079|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
32935012|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
32935013|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
32935014|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
32935015|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
32935016|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
32935017|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
32935018|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
32935019|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
32935020|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
32935021|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
32935022|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
32935023|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
32935024|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
32935025|NCT05587231|Experimental|Dextenza 0.4Mg Ophthalmic Insert|Dextenza (a dexamethasone ophthalmic insert manufactured by Ocular Therapeutix) will be inserted immediately after PRK surgery to administer a post surgery steroid regimen. No steroid drops will be adminstered.
32935026|NCT05587231|Active Comparator|Topical Fluorometholone|"Standard of care topical Fluorometholone drops will be used by the subjects after PRK Surgery. There will be a taper as follows:~i. 1 drop in each eye QID for 1st week postop. ii. 1 drop in each eye TID for 2nd week postop. iii. 1 drop in each eye BID for 3rd week postop. iv. 1 drop in each eye qD for 4th week postop."
32935027|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
32935028|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
32935029|NCT02667704|Experimental|Nintedanib|
32935030|NCT02667704|Experimental|Bosentan|
32935031|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
32935032|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
32935033|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
32730916|NCT03531099|Active Comparator|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
32730917|NCT05133609|Experimental|Group 1|Health professionals who will receive vaccine in the vaccination campaign against SARS-CoV-2.
33075080|NCT01715974|Experimental|GM-CSF group|patients with recurrent implantation failure treated with GM-CSF (30 micrograms/day) from the day of embryo transfer through the day of beta hCG test
33075081|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
33075082|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
33075083|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
33075084|NCT00535756|Experimental|1|
33075085|NCT00535756|Placebo Comparator|2|
33075086|NCT00156182|Experimental|1|
33075087|NCT05471479|Experimental|AC as per the Clinical Toxicology Recommendations Collaborative recommendations|
33075088|NCT05471479|Active Comparator|AC as per current practice|
33253855|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
33253856|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
33075089|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
33075090|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
33253857|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
33253858|NCT04014699|Experimental|modified 2.2mm micoincision|
33253859|NCT04014699|Active Comparator|conventional 2.2mm microincision|
33253860|NCT00937911|Experimental|YM150 group|
32730918|NCT05133609|Experimental|Group 2|Patients with immune-mediated inflammatory diseases who will receive vaccine in the vaccination campaign against SARS-CoV-2.
33075091|NCT05471362||Cases women who used IUD|Cases: women who had immediate Copper IUD inserted since October 2021 at the 4 public hospitals
33075092|NCT05471362||Control women who didn't use IUD|Controls: women who gave birth at the same hospitals and not using the immediate Copper IUD
33075093|NCT05471284|Sham Comparator|Control|The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
33075094|NCT05471284|Experimental|Proximal x Cost x Loss|Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
33075095|NCT05471284|Experimental|Proximal x Cost x Gain|Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
33075096|NCT05471284|Experimental|Proximal x Benefit x Gain|Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
33075097|NCT05471284|Experimental|Proximal x Benefit x Loss|Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
33277441|NCT05263310|Experimental|Educational Video and Action Plan handout|"Patients in the intervention arm will be given access to an educational video (Prepare for Your Diabetes Care) and will be supported in viewing the video and the Action Plan handout.~This program will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps with the participant's primary care provider."
33277442|NCT05263310|Active Comparator|Usual Care|Patients in the control arm will continue with usual care and also complete baseline, 6-month, and 12-month surveys
33277443|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
32730919|NCT05133375|Experimental|GROUP A|Macintosh laryngoscope was used for endotracheal intubation.
32730920|NCT05133375|Experimental|GROUP B|McCoy laryngoscope was used for endotracheal intubation.
32730921|NCT04258761|Experimental|10XB-101 Solution for Injection 1.25%|Participants receive 10XB-101 Solution for Injection, 1.25% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
32730922|NCT04258761|Experimental|10XB-101 Solution for Injection 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
32730923|NCT04258761|Experimental|10XB-101 Solution for Injection 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
33075098|NCT05471284|Experimental|Distal x Cost x Gain|Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
33075099|NCT05471284|Experimental|Distal x Cost x Loss|Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
33075100|NCT05471284|Experimental|Distal x Benefit x Loss|Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
33075101|NCT05471284|Experimental|Distal x Benefit x Gain|Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
33075102|NCT05471167||Birth cohort 2010|Children born from 01/07/2010 followed up until 30/06/2016
33253861|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
33253862|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
33253863|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
33253864|NCT04014777|Experimental|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
33075103|NCT05471167||Birth cohort 2011|Children born from 01/07/2011 followed up until 30/06/2017
33075104|NCT05471167||Birth cohort 2012|Children born from 01/07/2012 followed up until 30/06/2018
33253865|NCT04014777|Experimental|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
33253866|NCT04014777|Experimental|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
33253867|NCT04014777|Experimental|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
33253868|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
33075105|NCT05471167||Birth cohort 2013|Children born from 01/07/2013 followed up until 30/06/2019
33075106|NCT05471167||Birth cohort 2014|Children born from 01/07/2014 followed up until 30/06/2020
33075107|NCT05471167||Birth cohort 2015|Children born from 01/07/2015 followed up until 30/06/2021
33075108|NCT05471167||Birth cohort 2016|Children born from 01/07/2016 followed up until 30/06/2022
33075109|NCT05471167||Birth cohort 2017|Children born from 01/07/2017 followed up until 30/06/2022
33253869|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
33253870|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
33253871|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
33253872|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
33075110|NCT05471167||Birth cohort 2018|Children born from 01/07/2018 followed up until 30/06/2022
33075111|NCT05471167||Birth cohort 2019|Children born from 01/07/2019 followed up until 30/06/2022
33253873|NCT00938379|Placebo Comparator|lotion without repellent active|
33253874|NCT00938535|Experimental|Obesity Prevention|
33253875|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
33253876|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
33253877|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
32730924|NCT04258761|Experimental|10XB-101 Solution for Injection 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
32730925|NCT04258761|Experimental|10XB-101 Solution for Injection 6.0%|Participants receive 10XB-101 Solution for Injection, 6.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
33253878|NCT00932529|Active Comparator|Olanzapine|
33253879|NCT00932529|Active Comparator|Quetiapine|
33253880|NCT00932529|Active Comparator|Risperidone|
33253881|NCT00932529|Active Comparator|Ziprasidone|
33253882|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
33253883|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
33277444|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
33277445|NCT02866682|Other|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
32730926|NCT02952885|Experimental|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
33075112|NCT05471167||Birth cohort 2020|Children born from 01/07/2020 followed up until 30/06/2022
33075113|NCT05471050|Experimental|tacrolimus and Danazol|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
33075114|NCT05471050|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
33075115|NCT05470972|Experimental|Ovarian Endometrioma|Ovarian endometrioma (OE) is in women of reproductive age
33075116|NCT04686019|Experimental|Intervention group|"2 x IMT (5-10 min) 2 times a day 7 days a week for 3 weeks with or without supervision~Log-book~Conventional neurorehabilitation"
33075117|NCT04686019|Active Comparator|Control group|Conventional neurorehabilitation
33075118|NCT04686058|Active Comparator|TCI propofol|Target controlled infusion propofol titrated by the investigator intra-procedure, based on the Modified Observer's Assessment of Alertness and Sedation Scale
33075119|NCT04686058|Active Comparator|PCS propofol|Patient-controlled sedation titrated by the patient to comfort level
33075120|NCT04686058|Active Comparator|midazolam and pethidine|Midazolam and pethidine bolus doses administered by the investigator based on clinical parameters and observation
33075121|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
33075122|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
33075123|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
33075124|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
33075125|NCT00535951|Experimental|LBH589|
33075126|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
33075127|NCT00156338|Experimental|1|volume and sodium restriction
33253884|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
33253885|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
33253886|NCT00783822|Other|intervention|rapid genetic counseling and testing
33253887|NCT00783822|No Intervention|control|usual care
33253888|NCT00932685|Active Comparator|2. Video Game|
33253889|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
33253890|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL quarter in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day
32730927|NCT02183727|Experimental|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
32730928|NCT02183727|Active Comparator|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
32730929|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
32730930|NCT01959087|Experimental|1: Single port surgery|Surgery with single port
32730931|NCT01959087|Active Comparator|2: Multiport surgery|Surgery with multiport
32730932|NCT04082481|Experimental|TAK-988: Part A|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety/tolerability, PK, and PD data from previous cohorts.
32730933|NCT04082481|Experimental|TAK-988: Part B|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety/tolerability, PK, and PD data from previous cohorts and Part A.
32730934|NCT04082481|Experimental|TAK-988: Part C|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
32730935|NCT04082481|Experimental|TAK-988: Part D|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to HE non-Japanese participants. Dose will be determined based on previous MRD cohorts.
32730936|NCT04082481|Experimental|TAK-988: Part E|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1, followed by a washout period of 2 days and twice daily (6- hour interval) on Day 3 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts.
32730937|NCT04435587|Experimental|ivermectin|"Combination of~oral ivermectin 600 mcg/kg/day once daily for 3 days~Zinc sulfate (100mg/tab) 2 tab every 12 hours for 3 days"
32730938|NCT04435587|Active Comparator|ART/hydroxychloroquine|"Combination of~Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5~Darunavir/ritonavir (400/100mg) every 12 hours for 5 days~Zinc sulfate (100/tab) 2 tab every 12 hours for 5 days"
32730939|NCT03849105|Experimental|Single administration of 131I-IPA (1f group)|Study participants with GBM receive a single administration of 4-L-[131I]iodo-phenylalanine (131I-IPA), followed by 18 cycles of external radiotherapy, each cycle being of 2 Gy.
33253891|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL bis in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation twice a day + placebo by inhalation twice a day
33253892|NCT05000346|Placebo Comparator|Comparator: placebo|No active drug - administered by inhalation 4 times a day
33253893|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
33253894|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
33253895|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
33253896|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
33253897|NCT04014543|Experimental|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
33253898|NCT00783900|Active Comparator|metoprolol|
32730940|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-parallel group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
32743043|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
33075128|NCT00156338|Active Comparator|2|volume restriction
33253899|NCT00783900|Active Comparator|biatrial pacing|
33253900|NCT00932841|Placebo Comparator|Placebo|
33253901|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
33253902|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
33253903|NCT00783978||1|Children with chronic lung disease
33253904|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
33253905|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
33253906|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
33075129|NCT00156338|Active Comparator|3|liberal fluid management
32730941|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-sequential group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above 1- 3 days prior to 1st XRT. The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.
32730942|NCT03849105|Experimental|Dose escalation of fractionated dosing|Dose escalation will be made in steps of 2.0 GBq, i.e. 4.0 (3*1.33 GBq), 6.0 GBq (3*2.0 GBq), up to 8.0 GBq (3*2.67 GBq) until the maximum tolerated dose (MTD) is reached, using cohorts of N=3 patients.
33075130|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
33075131|NCT05470660|Experimental|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing
33075132|NCT05470660|Active Comparator|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
33075133|NCT05470582|Experimental|Flu-M, children aged 3-9 years|
33253907|NCT00786552|Experimental|chemotherapy|
33253908|NCT00938691|Experimental|Tepha|
33253909|NCT00938691|Active Comparator|Vicryl|
33075134|NCT05470582|Active Comparator|Vaxigrip, children aged 3-9 years|
32730943|NCT04499391|Experimental|ECHO plus|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Participants in this arm will receive a 2 month (8 sessions total) refresher course in Fall 2021. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
32730944|NCT04499391|Active Comparator|ECHO|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
32730945|NCT04498221|Experimental|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
32730946|NCT04498221|Experimental|Surgical Phase|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
32730947|NCT04498065||A|COVID positive and Troponin positive
32730948|NCT04498065||B|COVID positive and Troponin negative
32730949|NCT04497909|Experimental|Pre-clerkship cohort|First- and second-year medical students
32730950|NCT04497909|Experimental|Clerkship cohort|Third- and fourth-year medical students
32730951|NCT04497909|Experimental|Resident cohort|Medical residents
32730952|NCT04497363|Experimental|Focused Ultrasound|On the day of the ultrasound appointment, patients will undergo ten minutes of ultrasound targeting the anterior cingulate. The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
32730953|NCT05132751|Experimental|Group A|Machine Learning Ventilator Decision System Ventilation
32730954|NCT05132751|Active Comparator|Group B|Standard Controlled Ventilation
32730955|NCT03685929||Pressure ulcers|Patients with pressure ulcers category II/III at sacrum or trochanter
32730956|NCT03685929||Incontinence-associated dermatitis|Patients with incontinence-associated dermatitis category IIA at sacrum (or trochanter)
33075135|NCT05470582|Experimental|Flu-M, children aged 6-35 months|
33075136|NCT05470582|Active Comparator|Vaxigrip, children aged 6-35 months|
33082233|NCT04621162|Experimental|Positive Expectations (during intervention)|
33253910|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
33253911|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
33253912|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
33253913|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
33253914|NCT04047186|Experimental|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
33253915|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
33253916|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
33253917|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
33253918|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
32730957|NCT03685929||Combined lesion|Patients with pressure ulcer category II/III and incontinence-associated dermatitis category IIA at sacrum or trochanter
32743044|NCT04940091||Epidural labor analgesia|All participants will receive epidural analgesia during labor.
33075137|NCT05470231|Active Comparator|Beetroot juice|The swimmers ingested a shot of Beet-It 70 ml beetroot juice (BJ)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
33075138|NCT05470231|Placebo Comparator|Placebo|The swimmers ingested a shot of Beet-It (70 ml placebo (PL)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
33075139|NCT00536185|Experimental|1|
33253919|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
33253920|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
33075140|NCT00536185|Placebo Comparator|2|
33075141|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
33253921|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
33075142|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
33075143|NCT00536224|Active Comparator|2|Minimal counseling
33253922|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
32730958|NCT05131893||LuminalA|"tamoxifen (+ LHRH analogue for premenopausal participant)~non-steroidal aromatase inhibitor (+ LHRH analogue for premenopausal participant)~Non-steroidal aromatase inhibitor in non-resectable tumor (+ LHRH analogue in premenopausal participant) + CDK4 / 6 inhibitor"
33253923|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
33253924|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
33075144|NCT00536224|Experimental|1|Full counseling
33075145|NCT05470192|Experimental|Qigong Exercise Training and Conventional Physiotherapy and Rehabilitation Group|In addition to the conventional physiotherapy and rehabilitation program, qigong exercise training will be given to the qigong exercise training group by a certified physiotherapist who has received qigong training.
33253925|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
33075146|NCT05470192|No Intervention|Conventional Physiotherapy and Rehabilitation Group|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions. . The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
33253926|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
33253927|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
33253928|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
32743045|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
33075147|NCT00536302|Experimental|1|Collagen Hydrolysate
33253929|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
33253930|NCT00565773|Experimental|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
33253931|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
33075148|NCT00536302|Placebo Comparator|2|
33075149|NCT05469880|Active Comparator|moisturizing cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every evening and the moisturizing cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
33075150|NCT05469880|Experimental|anti-acne face cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every other night and the anti-acne face cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
33075151|NCT00408525|Experimental|1|Donepezil
33082234|NCT04621162|Experimental|Negative Expectations (during intervention)|
33253932|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
33253933|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
33253934|NCT03999658|Experimental|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
33253935|NCT03999658|Experimental|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
32743046|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
33075152|NCT05469763|Experimental|Circuit training exercise plus calcium tablets group|Study Group: they will receive circuit training exercise, 3 sessions per week for 12 weeks, in addition to calcium supplements.
33075153|NCT05469763|Other|Calcium tablets group|Control Group: they will receive daily dosage of calcium supplements 1-3 g/ day
33253936|NCT03999658|Experimental|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
33253937|NCT03999658|Experimental|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
33253938|NCT00570492|Placebo Comparator|Placebo nasal spray|
33253939|NCT00570492|Experimental|Fluticasone furoate nasal spray|
33253940|NCT00931281|Active Comparator|1|ABT-450/ritonavir
33253941|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
33075154|NCT05469529|No Intervention|Bupivacaine|Participants to be given 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
33075155|NCT05469529|Active Comparator|Bupivacaine + Dexmedetomidine|Participants to be given 5mcg dexmedetomidine in addition to 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
32730959|NCT05131893||LuminalB (Her2 negative)|"12 times weekly paclitaxel (80 mg / m˄2) followed by 4 times every 3 weeks epirubicin (E) (90-100 mg / m˄2) + cyclophosphamide (C) (600) (preferred)~4x 3 weekly E (90-100mg / m˄2) + C (600mg / m˄2), then~docetaxel (90-100 mg / m˄2) 4 times in every 3 weeks or~12x weekly paclitaxel (80mg / m˄2)~4x every 2 weeks Epirubicin (E) (90-100mg / m˄2) + Cyclophosphamid (C) (600mg / m˄2), then~4 times every 2 weeks with paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2)~TC: docetaxel (75 mg / m˄2) + cyclophosphamide (600 mg / m˄2) every 21 days with GCSF prevention (6 cycles)"
32730960|NCT05131893||Her2 positive|"4x 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly) or~4x 3 weekly docetaxel (100mg / m˄2) + trastuzumab +/- pertuzumab~Docetaxel (75 mg / m˄2) + carboplatin (AUC6) + trastuzumab +/- pertuzumab 6 times every 3 weeks c) E (90-100mg / m˄2) + C (600mg / m˄2) 4x every 2 weeks, then 12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly)"
33253946|NCT04204330|Experimental|CardioQVARK group|"Inclusion criteria:~Males and females aged 20 to 96 years having one or more of the following risk factors:~hypertensive heart disease;~history of ischemic stroke or transient ischemic attacks;~type 1 and 2 diabetes;~class 1-3 obesity;~heart failure or decreased tolerance to physical activity due to dyspnea;~coronary artery disease (CAD) or chest pain without established CAD diagnosis;~peripheral artery atherosclerosis;~abnormal heart rhythms (episodes of palpitations, pauses in heartbeat).~A patient's consent to participate in the study and the ability to sign an informed consent form.~Exclusion criteria:~acute coronary syndrome;~acute ischemic or hemorrhagic stroke;~mental illness;~severe concomitant disease with life expectancy less than 2 years.~Withdrawal criteria:~1. Refusal to participate in the study."
32730961|NCT05131893||Triple-negative breast cancer|"Paclitaxel (80 mg / m˄2) +/- carboplatin (AUC2) 12 times weekly, then E (90-100 mg / m˄2) + C (600 mg / m˄2) 4 times three weekly (preferred)~4x every 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4x docetaxel (90-100mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2 )~4x every 2 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4 times every 2 weeks paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2)"
33253947|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
33075156|NCT05469217||Fentanyl dependent patients|15 participants who were treated for fentanyl dependence in treatment centers in Israel
33075157|NCT05469217||Control participants|Healthy control participants from the general public
33075158|NCT05469100|Experimental|Cohort 1: Selpercatinib (Healthy participants)|Single oral dose of Selpercatinib administered in a fasted state to participants with normal renal function.
33253948|NCT03958630|Experimental|PET scan|Healthy and Patients
33253949|NCT04014855|Active Comparator|obese children 1|iron supplementation
33253950|NCT04014855|Active Comparator|obese children 2|lactoferrin supplementation
33253951|NCT03401320|Experimental|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
33253952|NCT03401320|Experimental|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
33253953|NCT03401320|Experimental|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
33253954|NCT03401320|Experimental|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
33253955|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
33253956|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
33253957|NCT00571922|Active Comparator|Acamprosate|
33253958|NCT00571922|Placebo Comparator|Placebo|
33253959|NCT00786630|Experimental|Case Management|
33253960|NCT00786630|Experimental|Facilitated Treatment Alliance|
33253961|NCT00933231|Active Comparator|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
33253962|NCT00933231|Active Comparator|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
33253963|NCT00933231|Experimental|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
33253964|NCT00933231|Experimental|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
33253965|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
33253966|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
33253967|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
33253968|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
33253969|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
32730966|NCT03522519||Assessment of real world performance|
32730967|NCT03343041|Active Comparator|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:~5% carb, 41% protein, 54% lipid."
32730968|NCT03343041|Active Comparator|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
32730969|NCT05130879|Experimental|BRAW intervention group|BRAW is designed as an online intervention comprising of six sessions over six weeks. The six sessions are: (1) happiness and positivity, (2) cognitive restructuring, (3) behavioural activation, (4) emotion regulation, (5) positive work climate and (6) problem solving.
33253970|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
33253971|NCT04054466|Experimental|Experimental group|Intervention with counselling designed
33075159|NCT05469100|Experimental|Cohort 2: Selpercatinib (Participants with mild renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with mild renal impairment.
33075160|NCT05469100|Experimental|Cohort 3: Selpercatinib (Participants with moderate renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with moderate renal impairment.
33075161|NCT05469100|Experimental|Cohort 4: Selpercatinib (Participants with severe renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with severe renal impairment and not on dialysis.
33253972|NCT04054466|Other|Control group|Intervention with habitual counselling
32730970|NCT05130879|No Intervention|Waitlist control group|Participants will receive the intervention after the follow-up assessment.
32730971|NCT05122065||Asymptomatic/non-HRT|Samples derived from women in menopause who do not self-reportedly experience GSM (Genitourinary Syndrome of Menopause) and who do not take HRT (Hormone Replacement Therapy).
32730972|NCT05122065||Asymptomatic/HRT|Samples derived from women in menopause who do not self-reportedly experience GSM and who take HRT
32730973|NCT05122065||GSM/non-HRT|Samples derived from women in menopause who self-reportedly experience GSM and who do not take HRT
32730974|NCT05122065||GSM/HRT|Samples derived from women in menopause who self-reportedly experience GSM and who take HRT
32730975|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
32730976|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
32730977|NCT03069807|Experimental|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
32730978|NCT03069807|Active Comparator|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
32730979|NCT05163639|Experimental|1. Uninjured participants - Immediate and lasting effects of non-invasive paired stimulation|Participants will take part in the following to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
32730980|NCT05163639|Experimental|2. Intraoperative participants - Immediate effects of paired stimulation|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Intraoperative pairing of cortical and spinal stimulation.
32730981|NCT05163639|Experimental|3. Intraoperative participants - Lasting effects of SCAP|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP).
32730982|NCT05163639|Experimental|4. Chronic cervical SCI participants - Lasting effects of non-invasive SCAP|Participants with chronic cervical SCI will take part in the following, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
32730983|NCT05163639|Experimental|5. Intraoperative participants - Lasting effects of SCAP at or below myelopathic region|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region.
32730984|NCT03014583|Experimental|HF/TCS/BURST|HF/TCS/BURST
32730985|NCT03014583|Experimental|HF/BURST/TCS|HF/BURST/TCS
32730986|NCT03014583|Experimental|BURST/HF/TCS|BURST/HF/TCS
32730987|NCT03014583|Experimental|BURST/TCS/HF|BURST/TCS/HF
32730988|NCT03014583|Experimental|TCS/BURST/HF|TCS/BURST/HF
32730989|NCT03014583|Experimental|TCS/HF/BURST|TCS/HF/BURST
32730990|NCT05113407||Coronary angioplasty performed using the Shockwave Medical C2 Coronary Lithotripsy System|
32730991|NCT05128461|Experimental|Exercise Group|The group will receive modified-Constraint Induced Movement Therapy via telerehabilitation and a home exercise program.
32730992|NCT05128461|Active Comparator|Control group|The group only will be given a home exercise program.
33082235|NCT04621162|Placebo Comparator|Neutral Expectations (during intervention)|
33082236|NCT04621357|Experimental|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
33253973|NCT00786786||1|Spinal Cord Injury
33253974|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
32730993|NCT05096013|Experimental|individual nutrition therapy|Individualized nutrition therapy: Specialists in nutritional counseling determine the patient's individual energy and protein needs and create targeted individual measures to achieve them. Measures can include, for example, adjustments to the menu, food enrichment or supplementation. The measures are discussed with the patients on an ongoing basis and adjusted as necessary.
32730994|NCT05096013|No Intervention|usual care|Usual care: Participants in the control group receive a standardized food fortification of the soups with fat and protein, as well as an energy- and protein-rich dessert. No additional advice or adjustments are made by the iNT.
32730995|NCT02901405|Experimental|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
32730996|NCT02901405|Active Comparator|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
32730997|NCT02889237|No Intervention|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
32730998|NCT02889237|Active Comparator|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
32730999|NCT02889237|Active Comparator|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
32731000|NCT02889237|Active Comparator|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
32731001|NCT02889237|No Intervention|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
33075162|NCT05469061|Experimental|Tislelizumab plus Chemotherapy|In the single experimental arm, patients with locally nonresectable disease were subjected to receive neoadjuvant tislelizumab (200mg) plus chemotherapy (FP regimen) for conversion therapy. If conversion therapy succeeds, patients would proceed to surgery and adjuvant therapy. Otherwise, if patients were still not resectable after the conversion therapy, they will be treated by tislelizumab plus chemotherapy with or without palliative radiotherapy .
33075163|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
33253975|NCT03489525|Experimental|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
33253976|NCT03489525|Experimental|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
33253977|NCT00784212|Experimental|Cohort 1|
33075164|NCT00408642|Active Comparator|2|standard adherence support
33075165|NCT05469022|Experimental|Neoadjuvant Lazertinib|Lazertinib as neoadjuvant treatment is administrated for 9 weeks before surgery. After surgical intervention the treatment is administrated upto 3 years to the patients with over stage 2 tumor. Treatment is discontinued in case of unacceptable toxicity or disease progression.
33253978|NCT00784212|Experimental|Cohort II|
33253979|NCT00784212|Experimental|Cohort III|
33253980|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
33253981|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
32731002|NCT02689167|Active Comparator|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
32731003|NCT02689167|Experimental|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
32731004|NCT04678635|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with cathode will be positioned at contralateral to the dominant limb and the anode charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. The stimulation will happen simultaneously to aerobic exercises for 20 minutes. Total number of stimulation associated with aerobic exercise sessions: 10
32731005|NCT04678635|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session. However, the patients will do aerobic exercises for 20 minutes. Total number of sham-stimulation associated with aerobic exercise sessions: 10
32743047|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
32743048|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
32743049|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
32743050|NCT04939857|Experimental|experimental group|Trimetazidine was given 2 weeks before radiotherapy, 20 mg each time, three times a day for 3 months.
33075166|NCT05468983|Other|BioHpp hybrid prosthesis( fixed )|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
33075167|NCT05468983|Other|BioHpp bar supported and retained overdenture|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
33075168|NCT05468944|Experimental|Transanal group|Participants in this group underwent robotic surgery with transanal specimen extraction
33075169|NCT05468944|Active Comparator|Transabdominal group|Participants in this group underwent robotic surgery with transabdominal specimen extraction
33253982|NCT04201600||Middle-aged and Older adults with Prediabetes|Middle-aged and Older adults with Prediabetes
33253983|NCT00784290|Experimental|1|Orantinib
33277446|NCT02866682|Other|Generic A Only|Arm 2 will receive specific generic tacrolimus for the entire study
33075170|NCT05468905||Cognitive normal Aging (CN)|Normal aging subjects with normal cognitive function
33075171|NCT05468905||Subjective cognitive impairment (SCI)|"Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
33075172|NCT05468905||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
33075173|NCT05468905||Alzheimer's disease (AD)|Mild to moderate sporadic and familial Alzheimer disease subjects
32731006|NCT02582697|Active Comparator|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:~Bleomycin 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients < 16 years old and weighs ≥ 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16 years old and weighs < 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10^9/ L~The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.~Each cycle is 3 weeks (21 days).~The planned total duration of treatment is 12 weeks."
32731007|NCT02582697|Experimental|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:~Bleomycin 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1- 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs ≥45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs <45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10^9/ L~Each cycle is 2 weeks (14days)~Following 4xBEP cycles, patients will receive additional bleomycin as follows:~- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses~* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.~The planned total duration is 12 weeks."
32731008|NCT05009511|Experimental|Traumatic Brain Injury (TBI)|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13.
32731009|NCT05009511|Experimental|Traumatic Brain Injury (TBI) with MDD|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13. In addition, individuals will have a diagnosis of major depressive disorder (MDD) as per DSM-5.
32731010|NCT05009511|Experimental|Major Depressive Disorder (MDD)|Individuals meeting criteria for major depressive disorder (MDD) including qualifiers 'in partial remission' or 'in full remission' if they are actively in treatment for the condition and still carry the depression diagnosis.
32731011|NCT05009511|Experimental|Healthy Individuals|Healthy individuals without psychiatric and neurological conditions.
32731012|NCT05292417|Experimental|Experimental Group|hypofractionation radiotherapy combined with sintilimab,GM-CSF and Fruquintinib in the third-line or above treatment of MSS Metastatic Colorectal Carcinoma(mCRC)
32731013|NCT05285241|Experimental|Multidirectional exercise group|Multidirectional stepping exercises along with conventional physiotherapy were provided to the patients. Conventional physiotherapy included one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min).
32731014|NCT05285241|Active Comparator|Conventional Physiotherapy Group|One-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min) were provided to the patients.
32731015|NCT02137473|Active Comparator|Bovine protein-based fortifier|
32731016|NCT02137473|Experimental|Human milk-based fortifier|
32731017|NCT01503489||Bipolar depressed patients|Bipolar I or II outpatients, current major depressive episode (HDRS-17 over 20).
32731018|NCT04492683|Experimental|Disease group|One active patch and one control patch applied to subjects with clinical symptoms suggestive of non-IgE mediated CMA
32731019|NCT04492683|Experimental|Control group|One active patch and one control patch applied to subjects without any history of allergic disease
32743051|NCT04939857|No Intervention|control group|No intervention
33075174|NCT05468905||Vascular cognitive impairment (VCI)|Cognitive impairment subjects caused by cerebral vessel disease
33075175|NCT05468866|Active Comparator|group (I)|Group (I): represents the healthy control individuals (30 person) (recruited from the blood donors at the blood bank)
33075176|NCT05468866|Active Comparator|Group (II)|Group (II): represents the cases of immune thrombocytopenia (70 cases).
33075177|NCT05468788|Experimental|Integrative Community Therapy (ICT) Intervention Arm|Participants will perform scenes related to having a chronic medical condition and they will be guided through conversations about their feelings and coping methods.
33075178|NCT05468788|Sham Comparator|Improvisational Theatre Arm|Participants will perform generic improvisational theatre with no instruction on feelings or coping methods.
33075179|NCT05468515||High altitude group|altitude level range from 2500 to 4500 meters
33075180|NCT05468515||mild altitude group|altitude level range from 500 to 2500 meters
33075181|NCT05468476||PCOS group|This study enrolled 30 PCOS women with obesity
33075182|NCT05468476||Non-PCOS group|This study enrolled 30 age- and body mass index (BMI)-matched subjects with normal menstrual cycles
33075183|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
33075184|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
33075185|NCT05468437|Experimental|Immediate treatment|Three months of treatment followed by a 3 month durability phase
33075186|NCT05468437|Experimental|Delayed Treatment|A 3 month waitlist period followed by 3 months of treatment
33075187|NCT05468398|No Intervention|Control|The control group will receive a genicular RFA with local anesthetic as per the standard-of-care
33075188|NCT05468398|Experimental|VR Intervention|The VR Intervention group will receive a genicular RFA with local anesthetic as per the standard-of-care and the use of the Soothe VR device.
33075189|NCT00536419|Placebo Comparator|2|4 days of placebo
33075190|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
32731020|NCT04490655|Experimental|Active somatosensory training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that focuses on the retraining of both motor and somatosensory functions, for a maximum of one hour per session.
32731021|NCT04490655|Active Comparator|Motor-based training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that is purely motor based, for a maximum of one hour per session.
33075191|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
33075192|NCT00536458|Active Comparator|B|MINI CHEP
33075193|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
33075194|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
33075195|NCT05468281||Before Period|The before period (12 months) serves as the control period prior to implementation; data will be collected by health records review.
32731022|NCT05137977||SIR|All adult intensive care patients. Data from the The Swedish intensive care registry
32731023|NCT05264337||Radical Cystectomy|Patients undergoing radical cystectomy with pelvic lymph node dissection for urinary bladder cancer
32731024|NCT05264337||Radical Prostatectomy|Patients undergoing radical prostatectomy with pelvic lymph node dissection for prostate cancer
32731025|NCT05264337||Retroperitoneal|Patients undergoing retroperitoneal lymph node dissection for testicular cancer
32731026|NCT05264337||Other|Patients undergoing other urologic surgery with lymph node dissection of inguinal, iliacal or retroperitoneal lymph nodes
32731027|NCT05250609|Experimental|"Intervention: Endocrown composite."|Composite Endocrown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
32731028|NCT05250609|No Intervention|Comparator / Control: Stainless steel crown.|Stainless steel crown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
32731029|NCT05137821|Experimental|non tested comparative group|two sealed new implants as a control
32731030|NCT05137821|Experimental|Er: YSGG laser tested group|24 infected implants divided into four subgroups that will be decontaminated by Er: YSGG laser in various peri-implant defects
32743052|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
33075196|NCT05468281||After Period|The after period (12 months) will be when patients are prospectively enrolled, and outcomes assessed.
33075197|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
33075198|NCT05468203|Experimental|SGLT-2 inhibitor|Dapaliflozin 10mg administered once per day
33075199|NCT05468203|Placebo Comparator|Matched Placebo|Matched placebo capsules taken administered once per day
33075200|NCT05468164|Experimental|Selpercatinib and omeprazole administered in ABCD treatment sequence|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
33075201|NCT05468164|Experimental|Selpercatinib and omeprazole administered in ABDC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
33075202|NCT05468164|Experimental|Selpercatinib and omeprazole administered in BACD treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
33075203|NCT05468164|Experimental|Selpercatinib and omeprazole administered in BADC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
33075204|NCT05468086|Experimental|Solace VR|This arm will include software that provides immersive distraction based content for pain reduction.
33075205|NCT05468047|Experimental|Ketamine administration|These individuals will be provided a personal ketamine-assisted therapy experience as part of an in-person training weekend within a psychedelic-assisted training program.
33075206|NCT05468047|No Intervention|No ketamine administration|These individuals will undergo the same psychedelic-assisted training program as those who receive the ketamine experience and will attend the same in-person training weekend; however, these individuals have opted out of ketamine administration by choice or due to contraindication and will not participate in the personal experience.
33075207|NCT04686214|Experimental|study group|
33253984|NCT03946228|Experimental|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
33253985|NCT03946228|No Intervention|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
33075208|NCT04686214|No Intervention|control group|
33075209|NCT05467969||Traditional teaching|A group of participants learned the skills on site
33253986|NCT00752414|Experimental|1|MP-376 Inhalation Solution
33253987|NCT00752414|Placebo Comparator|2|Placebo
33253988|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
33075210|NCT05467969||Teleteaching|A group of participant who joined the workshop synchronously through the online multiscreen display teleconference platform
33075211|NCT05467930||Participant|Individuals who were positive for COVID-19 and visited CUIMC/ New York Presbyterian (NYP) Hospital
33253989|NCT00790530|No Intervention|Usual Care|Usual Care
33253990|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
33253991|NCT04059224|Experimental|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
33253992|NCT04059224|Experimental|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
33253993|NCT00786942|Active Comparator|1|autologous bone graft
33253994|NCT00786942|Experimental|2|without bone graft
33253995|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
33253996|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
33075212|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
33075213|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
33253997|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
33075214|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
33075215|NCT05467852|Active Comparator|Didroxyprogesterone treatment group|Since the first menstrual cycle after surgery, dydrogesterone was administered orally 10mg bid on the 14th to 27th day of each menstrual cycle, planned to be used for 6 menstrual cycles (if the patient conceived naturally during medication, the drug could be stopped), and the patient was instructed to try pregnancy, the observation period was 12 menstrual cycles after surgery.
33253998|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
32731031|NCT05059587|Experimental|MBA-P01|MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.
32731032|NCT05059587|Active Comparator|BOTOX®|BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.
32731033|NCT05137509||Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)|Patients Infected by COVID -19 diagnosed by Reverse transcriptase polymerase chain reaction and computerized tomography
33075216|NCT05467852|No Intervention|control|No medication was used after surgery, and the observation period was 12 menstrual cycles after surgery
33253999|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
33254000|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
33254001|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
33254002|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
33254003|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
33254004|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
33254005|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
33254006|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
33254007|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
33254008|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
33254009|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
33254010|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
33254011|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
33254012|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
33277447|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
33254013|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
33254014|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
33254015|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
33075217|NCT05467813|Experimental|clinic-setting MT preceding AR-first group|In the experimental group, the participants will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive home-based rehabilitation.
33254016|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
32731034|NCT05137509||patients suffering from chronic lung disease|Diagnosed by clinical manifestation and Computerized tomogarphy
33254017|NCT03374956|Experimental|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
33254018|NCT03374956|Active Comparator|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
33254019|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
32731035|NCT05137509||Healthy Individuals|They must be without prior history of chronic inflammation in the lung
32731036|NCT05137197|No Intervention|TAU|Treatment as Usual: The treating clinician will decide on what antidepressant to prescribe based on the clinical evaluation.
33075218|NCT05467813|Active Comparator|home-based MT preceding AR-first group|The comparison group will receive home-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
33075219|NCT05467813|Active Comparator|clinic-setting MT preceding conventional therapy group|The control group will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
33254020|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
33075220|NCT05467774|Experimental|Training group|
33075221|NCT05466058|Other|cases|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
33075222|NCT05466058|Other|control|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
33075223|NCT05465590|Experimental|MB1707 Single Dose Phase 1|Phase 1 MB1707 given as a single intravenous (IV) dose of 0.3 mg/kg
33254021|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
32731037|NCT05137197|Active Comparator|PGT|Predictix Guided Treatment: The treating clinician will decide on what antidepressant to prescribe based on clinical evaluation and the Predictix report
32731038|NCT04560309|Experimental|Glutamine|Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
32731039|NCT04560309|Placebo Comparator|Control|Intravenous NaCl 0.9%
32731040|NCT05200221||Donafenib|Patients with uHCC taking donafenib in clinical treatment
32731041|NCT05192031|Experimental|Smoking cessation support|
32731042|NCT05192031|No Intervention|Usual care|
33254022|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
33254023|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
33254024|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
33254025|NCT03882034|Experimental|1|Intervention arm, Patient received pegvisomant
33254026|NCT00663858|Experimental|Cetrorelix 78+78|
33254027|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
33254028|NCT00663858|Placebo Comparator|Placebo|
33254029|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
33254030|NCT03304678||taking sirolimus|Subjects will come to the NIH and begin taking sirolimus 2mg
33254031|NCT04060004|Other|Control group|Electrotherapy + therapeutic exercise
33254032|NCT04060004|Experimental|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
33254033|NCT04060004|Placebo Comparator|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
32731043|NCT05135715|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
32731044|NCT05054907||Wearable devices + Smartphone|The only arm in the study.
32731045|NCT05185167|Experimental|Desflurane Group|Desflurane 1,0 minimum alveolar concentration will be administered during anesthesia maintenance
32731046|NCT05185167|Experimental|Propofol Group|Propofol 6 mg//kg/hour will be administered during anesthesia maintenance
32731047|NCT04474119|Experimental|Experimental arm|KN046 plus Carboplatin and Paclitaxel
32731048|NCT04474119|Placebo Comparator|Control arm|Placebo plus Carboplatin and Paclitaxel
33254034|NCT02562014|Other|Lean|Participants with body mass index <=25
32731049|NCT05134389||Israel|OAGB patients from Israel
32731050|NCT05134389||Spain|OAGB patients from Spain
32731051|NCT05134389||Portugal|OAGB patients from Portugal
32731052|NCT05133453|Active Comparator|Pirfinedone group|asbestosis patients given pirfenidone drug
32731053|NCT05133453|No Intervention|Conventional group|Asbestosis patients on conventional treatment
32731054|NCT05165823|Experimental|Sodium restriction|
32731055|NCT05165823|No Intervention|Usual diet|
32731056|NCT05125185|Active Comparator|current counseling|counseling by diabetic educators on insulin injection technique, hypoglycemia, SMBG and insulin dose optimization
32731057|NCT05125185|Experimental|counseling using module|counseling by diabetic educators on insulin injection technique, hypoglycemia, SMBG, insulin dose optimization and subtopic on nonadherence
33254035|NCT02562014|Other|Overweight|Participants with body mass index >25
33254036|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
33075224|NCT05464693||Patients with obstructive biliary disease|Patients admitted to hospital due to obstructive biliary disease secondary to benign and malign etiologies, undergoing ERCP, will be selected. Bile sample will be taken in ERCP procedure with sterile technique. Its macroscopic appearance will be assessed and biliary culture will be performed.
33075225|NCT05604040|Experimental|Self-monitoring and education program for lifestyle changes|Participants will send self-reports of their home BPs, diet, physical activity and emotions while attending a 6-week education program of lifestyle changes and coping skills. Participants will get summary reports of their home BP and lifestyle monitoring. Participants primary care physicians will be notified of persisting high BPs and final average home BP levels. Researchers will monitor home BP levels and change in hypertension control state
33254037|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
33254038|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
33254039|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
33075226|NCT00156962|Active Comparator|Epoetin alfa RB|
33075227|NCT00156962|Experimental|Epoetin alfa DT|
33254040|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
33254041|NCT00749528||1|Children vith recurrent wheezing
33254042|NCT00749528||2|Healthy children
32731058|NCT05008341|Experimental|Solriamfetol|Participants will receive a single oral dose of solriamfetol 150 mg with 240 mL water at 0 hour on the morning of Day 1, 2 hours after completion of a light breakfast.
33254043|NCT00790686|Experimental|1|Memokath 051
33254044|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
33075228|NCT05603806||RA new treatment starts|Adult rheumatoid arthritis patients starting treatment on adalimumab or upadacitinib
33075229|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
33254045|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
32731059|NCT05121363|Experimental|TQB2858 injection + Anlotinib Hydrochloride capsules|"TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
32731060|NCT04244877|Experimental|Rifaximin|Rifaximin 550 mg by mouth twice daily for eight weeks.
32731061|NCT05129319|Active Comparator|OLD (4 U per 0.1 mL)|The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
33075230|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
33075231|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
32731062|NCT05129319|Active Comparator|COLD (4 U per 0.02 mL group)|The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.
32731063|NCT05305833|Experimental|umbilical cord derived mesenchymal stem cells transplantation group|taking umbilical cord derived mesenchymal stem cells
32731064|NCT05305833|Experimental|stromal vascular fraction cells application group|taking stromal vascular fraction cells
32731065|NCT05128617||Epirubicin-cyclophosphamide|Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide
32731066|NCT05128617||Paclitaxel|Woman with early breast cancer receiving a first cycle of paclitaxel
33075232|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
33254046|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
32731068|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
33254047|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
33254048|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
33254049|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
33254050|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
33254051|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
33254052|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
33075233|NCT05599438||Current users anabolic steroids|Current users of anabolic steroids with a use of more than 4 weeks
32731069|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
32731070|NCT04494945|Other|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
32731071|NCT05118945||SWITCH group: Change from Basal IQ to Control IQ|"The patients of the SWITCH group used the X:s insulin pump with the Basal IQ algorithm until the start of the study and switched to the Control IQ algorithm at study start."
33075234|NCT05599438||Former users of anabolic steroids|Former users of anabolic steroids with a use of more than 4 weeks
33075235|NCT05599438||Healthy controls|"100 participants with no former use of anabolic steroids~80 Male~20 Female"
33075236|NCT05599399|Active Comparator|Patients receiving gum acacia|Group one will receive gum acacia extract as an add-on therapy on daily basis
33254053|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
33254054|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
33254055|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
33254056|NCT00790920|Experimental|Desmoteplase|
33075237|NCT05599399|No Intervention|Patients receiving no intervention|Group two will not receive add-on therapy; they will receive standard care only.
33075238|NCT04685512|Experimental|TDF / FTC|2 tablets on Day-1 then 1 tablet/day for 6 days
33075239|NCT04685512|No Intervention|usual care|Standard of Care
33075240|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
33254057|NCT00790920|Placebo Comparator|Placebo|
33277448|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
33075241|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
33075242|NCT05596318|Experimental|Digital cognitive behavior therapy for insomnia (CBT-I)|
33075243|NCT05596318|Active Comparator|Digital sleep hygiene education (SHE)|
33075244|NCT05595382|Experimental|Emotional Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
33075245|NCT05595382|Experimental|Rational Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
33075246|NCT05592691||Study Cohort|Patients undergoing fascial blocks in elective cardio-thoracic and abdominal surgery.
32731072|NCT05118945||START group: Change from conservative therapy to Control IQ|"The patients of the START group have a conservative Insulin therapy (MDI = multiple daily injections or CSII = Continuous subcutaneous insulin infusion) until the start of the study, but will switched to the Control IQ algorithm at study start."
32731073|NCT05114655|Experimental|Intervention 1|Participants apply an herbaceous, earthy based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
32731074|NCT05114655|Experimental|Intervention 2|Participants apply a light, citrus-based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
32731075|NCT05114655|Placebo Comparator|Placebo|Participants apply an inert blend including fractionated coconut oil to the jawline three times each day for 7 days.
32731076|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
32731077|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
32731078|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
32731079|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
33075247|NCT05579899|Experimental|EVO101 Cream|Active Treatment, BID, 8 weeks
33254058|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
33254059|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
33075248|NCT05579899|Placebo Comparator|Vehicle Cream|Vehicle Treatment, BID, 8 weeks
33075249|NCT04293328|Experimental|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
33075250|NCT04293328|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
33254060|NCT04053218|Active Comparator|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
33254061|NCT04053218|Placebo Comparator|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
33075251|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
33075252|NCT00182520|Experimental|1|Topiramate
33075253|NCT00182520|Placebo Comparator|2|placebo
33075254|NCT04269850|Experimental|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
33075255|NCT04257487|Active Comparator|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
33075256|NCT04257487|Active Comparator|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
33075257|NCT04257487|Placebo Comparator|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
33075258|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
33075259|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
33075260|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
33075261|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
33254062|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
33254063|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
33254064|NCT00747032|Active Comparator|1|NYC 0462 Ointment
33254065|NCT00747032|Placebo Comparator|2|Placebo
33254066|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
33254067|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
33254068|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
33254069|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
33254070|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
33254071|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
33254072|NCT03741907|Active Comparator|MLC|Gold Standard
33254073|NCT00787410|Experimental|1|
33254074|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
33254075|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
33254076|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
33254077|NCT03989557|Experimental|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
33254078|NCT03989557|Experimental|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
33254079|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
33254080|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
33254081|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
33254082|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
33254083|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
33254084|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
33254085|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
33254086|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
33075262|NCT04247347|Experimental|Self-Management|
33254087|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
33254088|NCT00787878||A|
33254089|NCT00787878||B|
33254090|NCT00787878||C|
33254091|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
33254092|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
33254093|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
33254094|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
33254095|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
33254096|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
33254097|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
33254098|NCT00752960||A|Patients receiving olanzapine
33254099|NCT00752960||B|patients receiving risperidone
32731080|NCT05105763|Other|feedback training on single joint first|Participants in Subgroup 1 will first undergo Condition B in the first visit and then Condition A in the second visit.
32731081|NCT05105763|Other|sequential feedback training on multi-joint first|Participants in Subgroup 2 will start with Condition A in the first visit and then undergo Condition B in the second visit.
33075263|NCT04247347|Active Comparator|Usual Care|
33254100|NCT00752960||C|Patients receiving quetiapine
33254101|NCT00752960||D|Patients receiving aripiprazole
33254102|NCT00752960||E|patients receiving ziprasidone
33254103|NCT03983473|Other|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
33254104|NCT03983473|Other|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
33254105|NCT03983473|Other|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
33254106|NCT03983473|Other|healthy controls|Patients without spondyloarthritis and Crohn 's disease
33254107|NCT00663702|Experimental|1|
33254108|NCT03986281|Active Comparator|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
33254109|NCT03986281|Active Comparator|Arterial Line|Readings from the arterial line
32731082|NCT05305131|Experimental|Induction cisplatin and gemcitabine|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
33254110|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
33254111|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
33254112|NCT03990025|Other|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
32731083|NCT05305131|Experimental|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
33254113|NCT03990025|Other|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
33254114|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
33254115|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
33254116|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
33254117|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
33277449|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
32731084|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
32731085|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
33075264|NCT04232254|Active Comparator|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
33075265|NCT04232254|Experimental|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
32731086|NCT05101317|Active Comparator|HMI-115 60mg|Once Every 2 weeks, subcutaneously injection
32731087|NCT05101317|Active Comparator|HMI-115 120mg|Once Every 2 weeks, subcutaneously injection
32731088|NCT05101317|Active Comparator|HMI-115 240mg|Once Every 2 weeks, subcutaneously injection
32731089|NCT05101317|Placebo Comparator|Placebo|Once Every 2 weeks, subcutaneously injection
32731090|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
32731091|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
32731092|NCT05099913|Experimental|2-week group|Patients were treated with antidepressants for 10-14 days combined with first-class medication(anti-acid drugs, prokinetics), followed by on demand.
32731093|NCT05099913|Experimental|4-week group|Patients were treated with antidepressants for 4 weeks combined with first-class medication(anti-acid drugs, prokinetics).
32731094|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
32731095|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
32731096|NCT05304975|Active Comparator|intervention|"Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline and review study visits.~The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise resource that has been designed for older adults.~Cognitive stimulation will be delivered using Brain HQ®, a computer based cognitive training platform, which utilises visuospatial and auditory games to enhance attention, mental processing speed, learning, memory, and low mood.~Participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary.~The 4-month active intervention will be followed by a 2-month self-directed consolidation phase and all participants will be left to their own initiative for a further 3 months"
32731097|NCT05304975|Other|control|this will be routine management of the diabetes condition as per current recommended practice
32731098|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
32731099|NCT05060601|Experimental|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
32731100|NCT05060601|Active Comparator|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
32731101|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
32731102|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
32731103|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
32731104|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
32731105|NCT04987905|Experimental|Experimental Group|"In the study, for 60 minutes once a week for 8 weeks the MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice). In addition to these, nurses will be required to keep a diary of the program. This app contains basic mindfulness exercises and does not pose any health risks to practitioners. While the MIND-BE program is carried out in the online environment, the cameras of the nurses in the experimental group will be turned on and the researcher who made the application will be able to see each nurse."
32731106|NCT04987905|No Intervention|Control Group|No intervention will be made to the control group, only the data will be collected at the same time as the study group. After all data are collected (after the 12th week), the training content will be explained to the nurses in the control group and the MIND-BE program will be started for them as well. In this way, both groups will benefit from this program.
32731107|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
32731108|NCT04564521|Experimental|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
32731109|NCT04564521|Active Comparator|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
32731110|NCT05158621||Advanced/Metastatic Colorectal Cancer|Eligible patients include those with newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine. Patients with sufficient neoantigens will have vaccine manufactured while receiving FOLFOX or CAPEOX/bevacizumab.
32743053|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
32743054|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
33277450|NCT01089283||healthy|Healthy volunteers
33075266|NCT04232254|Experimental|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
33075267|NCT04232254|Experimental|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
33254118|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
33254119|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
33254120|NCT03816358|Experimental|Arm I (anetumab ravtansine, nivolumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
33254121|NCT03816358|Experimental|Arm II (anetumab ravtansine, nivolumab, ipilimumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
33254122|NCT03816358|Experimental|Arm III (anetumab ravtansine, nivolumab, gemcitabine)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
33254123|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
33254124|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
33254125|NCT04058522|Experimental|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
33254126|NCT04058522|Active Comparator|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
33254127|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
33254128|NCT00795834|Placebo Comparator|Beverage|
33254129|NCT00795834|Active Comparator|High Polyphenol Beverage|
33254130|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
32731111|NCT05158621||Localized Colon Cancer|Eligible patients include those with high-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA following surgical resection. Patients with MRD will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine.
32731112|NCT05035797|Active Comparator|CaRe-ECMO group|Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program.
32731113|NCT05035797|Placebo Comparator|Control group|Usual care and ECMO therapy
32731114|NCT05304429|Experimental|nutritional counseling group|This group will have nutrition education sessions every fifteen days and will keep track of 10 healthy behaviors through goal setting and self-monitoring.
32731115|NCT05304429|No Intervention|group without nutritional counseling|This group will have sessions every fifteen days of reading, knitting and other activities unrelated to health.
32731116|NCT05150821||experimental|patients during lockdown
32731117|NCT05150821||control group|patients before lockdown
32731118|NCT05126797|Other|3D printed stent+ MDASI-3D Oral Stents Questionnaire|Patients wear a customized 3D printed oral stent over 5-10 minutes in the supine position at the time of radiation simulation, before starting radiation therapy, and in the 3rd to 5th week of radiation therapy. Patients may also optionally wear the commercially-made stent called TruGuard at these timepoints. Ancillary Studies (MDASI-3D Oral Stents Questionnaire)
32731119|NCT03348891|Other|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
32731120|NCT03348891|Other|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
32731121|NCT05304117|Experimental|Advance Care Planning Experimental|Community Information Session on advance care planning and private one-on-one Sharing Session about advance care planning.
32731122|NCT05304117|Other|Advance Care Planning Waitlist|Waitlist Group- Baseline control measures will be collected at the same time as Cohort 1 completes their pretest. Six Months after Cohort 1, participants will be pretested again before attending a Community Information Session on advance care planning and an one-on-one Sharing Session about Advance Care Planning.
32731123|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
32731124|NCT03348397||Contegra patients|
32731125|NCT03348397||Pulmonary homograft patients|
32743055|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
33075268|NCT04229797|Active Comparator|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
33075269|NCT04229797|Experimental|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
33075270|NCT00534274|Experimental|TEP FLT|
33075271|NCT00189618|Placebo Comparator|1|
33075272|NCT00189618|Active Comparator|2|
33254131|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
33254132|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
33075273|NCT04177030|Experimental|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
33075274|NCT04177030|Experimental|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
33075275|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
33254133|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
33254134|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
33075276|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
33075277|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
33254135|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
33254136|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
33254137|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
33254138|NCT00795912|No Intervention|2|Usual medical care of heart failure
33254139|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
33254140|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
33254141|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
33254142|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
33254143|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
33075278|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
33075279|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
33075280|NCT00534586|Active Comparator|1|remifentanil
32731126|NCT02956317|Active Comparator|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
32731127|NCT02956317|Placebo Comparator|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
32743056|NCT04959513|Experimental|GBR with L-PRF bone block|Guided bone regeneration using Leukocyte and platelet-rich fibrin
33075281|NCT00534586|Active Comparator|2|propofol
33075282|NCT00534586|Active Comparator|3|sevoflurane
33075283|NCT00534586|Active Comparator|4|s-ketamine
33254144|NCT05360134|Experimental|Carica Papaya Arm|1100mg of Carica Papaya Leaf extract administered three times daily for upto one week preoperatively and from post-operative day 3 to day 7.
33254145|NCT05360134|Placebo Comparator|Placebo Arm|Placebo administered 3 time daily for upto one week preoperatively and from post-operative day 3 to day 7.
33254146|NCT00788034|Experimental|Lu AA21004|
33254147|NCT00788034|Placebo Comparator|Placebo|
33254148|NCT04058444|Experimental|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
33254149|NCT04058444|Experimental|Control Group|Perioperative management follows the conventional program
33254150|NCT05208814|Experimental|Renal Insuffiency|Subjects with various degrees of renal insuffiency
33254151|NCT05208814|Experimental|healthy subjects|healthy subjects
33254152|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
33254153|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
33254154|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
33254155|NCT00788112|Experimental|Vorinostat|
33254156|NCT03112174|Experimental|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
33075284|NCT00534625|Placebo Comparator|1|
33075285|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
33075286|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
33075287|NCT04134208|Experimental|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
33075288|NCT04110769|Experimental|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
33075289|NCT04110769|Active Comparator|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
33075290|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
33075291|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
33075292|NCT04106830||Health control(HC)|Healthy people without any neuroinflammation disease
33075293|NCT00406913|Experimental|Mupirocin ointment|
33075294|NCT00406913|Active Comparator|Standard of Care sterilization|
33075295|NCT04100122||Wheat-allergic|"The diagnosis of IgE-mediated wheat allergy was made if they have one of the following criteria~a convincing clinical history of the reactions within 4 hours after wheat ingestion during the past 12 months combined with positive skin prick test (SPT) and/or the level of specific IgE (sIgE) to wheat or~a positive oral food challenge (OFC) result to wheat during the past 12 months"
32731128|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
32731129|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
32731130|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
32743057|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
32743058|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
33075296|NCT04100122||Wheat tolerant|Patients with wheat tolerant confirmed by negative oral food challenge (OFC) result to wheat during the past 12 months
33254157|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
33254158|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
33254159|NCT03112174|Experimental|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.~Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
33254160|NCT04058600|Experimental|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
33254161|NCT04058600|No Intervention|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
33254162|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
33254163|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
33254164|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
33254165|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
33254166|NCT04058132|Other|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
33254167|NCT04058132|Other|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
33075297|NCT04100122||Wheat oral immunotherapy|Patients with IgE-mediated wheat allergy and underwent wheat oral immunotherapy for at least 6 months or at the maintenance phase of the treatment
33254168|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion with a sum of 10,000 IU/day over the next 24, 48, or 96 hours.
33254169|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24, 48, or 96 hours.
33254170|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33254171|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33075298|NCT04722900||non-GDM|
33075299|NCT04722900||GDM|
33075300|NCT04090879|Experimental|RC 1 only|Research Cigarettes #1
33075301|NCT04090879|Experimental|RC 2 only|Research Cigarettes #2
33075302|NCT04090879|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
33075303|NCT04090879|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
33075304|NCT04076800|Experimental|Acupuncture|
33075305|NCT04076800|Sham Comparator|Sham acupuncture|
33075306|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
33075307|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
33075308|NCT04061161|Active Comparator|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
33075309|NCT04061161|Placebo Comparator|Placebo respimat|Placebo respimat two actuations once daily
33254172|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33254173|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33254174|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33254175|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
33254176|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
33254177|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
33254178|NCT05178784||Active Stimulation|Adults exposed to active external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
33075310|NCT04049149|Other|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
33254179|NCT05178784||Sham Stimulation|Adults exposed to sham external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
33254180|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
33254181|NCT05171686|Experimental|Diuretic augmentation|The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.
33254182|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
33254183|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
33075311|NCT04049149|Other|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
33075312|NCT03966586|Experimental|Enhanced Care|Usual clinical care + intervention components
33254184|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
33254185|NCT00990028|Placebo Comparator|Placebo|
32743059|NCT04959357||coronary microvascular dysfunction group|
32743060|NCT04959357||obstructive coronary artery disease|
32743061|NCT04959357||control group|
33075313|NCT03966586|Active Comparator|Usual Care|Usual clinical care and counseling
33075314|NCT03962335|Experimental|VD group|Group that starts with Vegetarian diet (VD)
33075315|NCT03962335|Experimental|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
33075316|NCT03962335|Active Comparator|MD group|Group that starts with Mediterranean diet (MD)
33075317|NCT00182832|Experimental|1|
33075318|NCT00182832|Active Comparator|2|
33075319|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
33075320|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
33254186|NCT04052906|Experimental|Intervention Group|Planned Inhaler Medication Training
33254187|NCT04052906|No Intervention|Control Group|usual care
33254188|NCT05361226|Experimental|s-CAIS (static computer aided implant surgery)|For the s-CAIS group, Cone Beam Computed Tomography (CBCT) and full-arch optical scan were performed to provide digital information for implant planning software (coDiagnostix 9, Dental Wings GmbH, Chemnitz, Germany). The virtual implant was set on a three dimensional (3D) virtual jaws according to the prosthetically driven protocol by one postgraduate dentist and was confirmed by one experienced dentist. Static surgical template covering on occlusal part of 4 teeth anteroposteriorly was then fabricated via 3D printing machine (surgical guide resin, Form 2, Formlabs, Somerville, Massachusetts, USA). This surgical template would be used during surgery.
33277451|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
32743062|NCT04487015|No Intervention|Part I: Non-Digital (Control)|Participants who currently receive performance nutrition support, via a qualified practitioner as indicated by a member of the sports science team at their sporting organisation, will be assigned to the non-digital approach (control). These participants will not receive any intervention from the research team for the duration of this study (6 weeks).
33075321|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
33075322|NCT04724993|Experimental|Online Aerobic Dance Exercises|In this group, aerobic dance exercises will be applied online under the supervision of a physiotherapist. And participants will record their physical activities on the Physical Activity Tracking Chart.
33277452|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
33277453|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
33277454|NCT02774642|Experimental|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
33075323|NCT04724993|Experimental|Physical Activity Counseling|In this group, participants will be informed online about physical activity and exercise. And they will record their physical activities on the Physical Activity Tracking Chart too.
33254189|NCT05361226|Active Comparator|c-LIS (conventional laboratory-guided implant surgery)|"For the c-LIS group, a radiographic template (ORTHO Plast, prominent®, Chonburi, Thailand) was fabricated covering on occlusal part of 4 teeth anteroposteriorly according to diagnostic wax-up on the study model. A radiographic marker (gutta percha) was then filled in the created hole of the template and for used while taking CBCT image to verify marker position.~Next, a study model was scanned by laboratory surface scan (D900m, 3Shape, Copenhagen, Denmark). The STL file was imported to 3D printing devices and the resin model was fabricated (Dental LT clear resin, Form 2, Formlabs, Somerville, Massachusetts, USA).~Next, the same template that had been used for CBCT was used to place implant replicas in a resin model. The position of the implant replicas in the models were assumed as pre-operative planned implant position."
33254190|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
33254191|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
33075324|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
33075325|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
33254192|NCT00683384||1|
33254193|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
32731131|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
32731132|NCT05303961|Experimental|SA001|"Part 1: 24 subjects are assigned to single dose groups(240mg, 480mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1:1 and receiving each dose of SA001 in the period 1.~Part2: 18 subjects are assinged to multiple dose groups(360mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1 and receiving each dose of SA001."
32731133|NCT05303961|Active Comparator|Rebamipide|Part 1: 12 subjects are assigned to single dose groups(200mg, 600mg of Rebamipide) in a ratio of 1:1 and receiving each dose of Rebamipide in the period 2.
32731134|NCT05303961|Placebo Comparator|Placebo|"Part 1: 8 subjects receiving a single dose of Placebo in the period 1.~Part2: 6 subjects receiving multiple dose of Placebo."
32731135|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
32731136|NCT04974333|Experimental|Mobile health application|"Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments.~The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12)."
32731137|NCT04974333|No Intervention|Standard care|Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.
32731138|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
32731139|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
32731140|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
32731141|NCT04970433|Experimental|Electroacupuncture (EA)|Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.
32731142|NCT04970433|Active Comparator|Laser acupuncture (LA)|Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.
33254194|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
33254195|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
33254196|NCT04003714|Experimental|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
33254197|NCT04003714|Sham Comparator|Sham Group|Control group received sham r-TMS with the same protocol.
33075326|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
32731143|NCT04970433|Sham Comparator|Sham laser acupuncture (SLA)|Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.
33075327|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:~At least 6 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
33075328|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program~At least 4 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
33075329|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.~To control post-op pain, subject will use medication per standard of care, including PCA pump."
33075330|NCT04686643|Experimental|Treatment|AGSAVI
33075331|NCT04686643|Active Comparator|Reference|AGLS
33075332|NCT00534781|Experimental|A|plasma microtenotomy
33075333|NCT00534781|Active Comparator|B|Standard Surgical Debridement
33075334|NCT03770572|Experimental|Open-label, single-dose, dose-escalation study of AT-GTX-502|"Cohort 1: AT-GTX-502 Low-Dose~Cohort 2: AT-GTX-502 High-Dose"
33075335|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
33075336|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
32731144|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
32731145|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
33254198|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
33254199|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
33254200|NCT05361148||DIVIDS (Delhi Infant Vitamin D Supplementation) study, India|"The DIVIDS cohort were born low birth weight (LBW, <2.5 kg) at term in 2007-2010. They had monthly follow-up until 6m then at 5 and 11 years. Anthropometry was collected at all visits, body composition in the 5 and 11 years, and blood samples at 6 months and 5 and 11 years. For SAMPA, the DIVIDS cohort acts as a positive control since we expect adverse long-term non-communicable disease consequences of being born LBW.~Sample numbers at previous follow-ups and expected:~Birth: 2079 total, all LBW~Age 5 y: 911 total, 764 (84%) BMIZ>-2, 138 (15%) BMIZ -2 to -3, 9 (1%) BMIZ<-3~Age 11 y (ongoing): 647 total, 482 (75%) BMIZ>-2, 117 (18%) BMIZ -2 to -3, 48 (7%) BMIZ<-3~Expected for SAMPA: 800 total"
33254201|NCT05361148||SAM (Severe Acute Malnutrition) Lusaka|"This group comprises children with or without prior MALN in early childhood. Some are from a study which identified 1195 children with MALN (mean age 16 months, 11.6% HIV-infected) in a house-to-house survey in a low-income area, Misisi, Lusaka in 2009. Some children are from a study of body composition and indicators of chronic diseases (HbA1c, lipids); 100 were hospitalised with MALN when < 2 years and 76 are never-malnourished neighbourhood controls.~Sample numbers at previous follow-ups and expected:~Age < 2 y: 400 total, 200 WHZ<-3, 200 well-nourished~Age 9 y: 186 total, 110 previous MALN, 76 no MALN; currently 17 (9%) BMIZ <-2~Expected for SAMPA: 400 total"
32731146|NCT05303259|Experimental|HNC patients with radiation-induced brain injury.|Bevacizumab 2.5mg/kg， q2w，4 cycles.
33254202|NCT05361148||CICADA (Chronic Infections, Co-morbidities and Diabetes in Africa), Mwanza, Tanzania|"The CICADA cohort comprises HIV-infected and uninfected recruited since 2010. CICADA involved 3 annual visits for data on HbA1c, OGTT, insulin, anthropometry, body composition, and diabetes lifestyle risk factors. CICADA has the most detailed longitudinal diabetes data of the project cohorts, archived fasting samples, and are the oldest so have had longer to develop diabetes; therefore, this cohort will be used for the in-depth and longitudinal components (hypotheses 3 and 4).~Sample numbers at previous follow-ups and expected:~12 y prior: 447 total, 300 (67%) BMI > 18.5 kg/m2, 74 (17%) BMI 17 to 18.5 kg/m2 73 (16%) BMI <17 kg/m2~10 y prior: 704 total, 304 (43%) BMI 17 to 18.5 kg/m2, 400 (57%) BMI<17 kg/m2~3 y prior: 1947 total, 1519 (78%) BMI > 18.5 kg/m2, 275 (14%) BMI 17 to18.5 kg/m2, 152 (8%) BMI <17 kg/m2~Expected for SAMPA: 1200 total"
33254203|NCT05361148||NUSTART Lusaka|"We will trace and recruit 200 previously malnourished HIV-infected adults from the NUSTART Lusaka participants plus 100 non-HIV-infected neighbourhood controls to the SAMPA study. As for NUSTART Mwanza, there was a high mortality rate during the first 12 weeks of ART.~Sample numbers at previous follow-ups and expected:~10 y prior: 1111 total, 437 (39%) BMI 17 to 18.5 kg/m2, 674 (61%) BMI<17 kg/m2~Expected for SAMPA: 300 total"
33277455|NCT02774642|Active Comparator|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
33277456|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
32731147|NCT05303259|No Intervention|HNC patients without brain injury after radiotherapy.|No treatment.
32731148|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
32731149|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
32731150|NCT05051787|Experimental|Breastfeeding women|Mothers over 18, treated with amoxicillin alone or associated with clavulanic acid for at least 2 days, breastfeeding their child.
32731151|NCT04507789|Experimental|exercise intervention group|This group will be taken an exercise intervention during their radiotherapy programme.
32731152|NCT04507789|Active Comparator|routine radiotherapy protocol|This group will not be taken into an exercise intervention during their radiotherapy programme.
32731153|NCT05050383|Other|Drug-Induced Sleep Endoscopy|Drug-Induced Sleep Endoscopy
32731154|NCT04502251|Active Comparator|LDN + tDCS|Low Dose Naltrexone and Transcranial Direct Current Stimulation
33075337|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
33254204|NCT05361148||St-ATT (Starting Anti-TB Treatment) Cohort, Philippines|"Between Aug 2018 and Feb 2020, the St-ATT cohort recruited 900 adults within 5 days of starting a new 6 or 9 month anti-TB regimen in three provinces: Cebu, Negros Occidental and Metro Manila, encompassing urban, peri-urban and rural populations. 17% had HbA1c >=7.0% (probable diabetes in TB) with an additional 30% with HbA1c 5.8%-7.0% ('prediabetes'/mild TB-induced hyperglycaemia). Post-treatment follow-up is ongoing. This cohort will be involved in in-depth analyses for hypothesis 3.~Sample numbers at previous follow-ups and expected:~1-2 y prior: 900 total, 495 BMI >18.5 kg/m2, 189 (21%) BMI 17.0 -18.5 kg/m2, 216 (24%) BMI <17 kg/m2~Expected for SAMPA: 600 total"
33254205|NCT05361148||CLHNS (Cebu Longitudinal Health and Nutrition Survey), Philippines|"The cohort was recruited in 1983-84. Since the original follow-up to age 2 years, there have been 8 follow-up surveys including in 2019 when 1300, ~40% of the initial cohort, were available. Loss from the cohort over time is mostly from out-migration and those remaining are more rural and of lower socioeconomic status. In follow-up surveys, data collection included: anthropometry, diet (24-hr recall), health history, blood pressure and other chronic disease risk factors, school achievement, and, for older ages, reproductive history. This cohort represents our longest follow-up of MALN diagnosed by anthropometry resulting primarily from poor nutrition, not specific severe infections.~Sample numbers at previous follow-ups and expected:~Birth: 28 LBW of the 144 with childhood MALN~Age < 2 y: of 420 total to be included, 144 (34%) WHZ<-3~Expected for SAMPA: 420 total"
33254206|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
33254207|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
33254208|NCT00788346|No Intervention|Usual Care|Usual Care
33254209|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
33254210|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
33254211|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
33254212|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
33254213|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
33254214|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
33254215|NCT00747110|Experimental|A|9mg budesonide OD
33254216|NCT00747110|Active Comparator|B|3g mesalazine OD
33254217|NCT05359900|Experimental|Pain neuroscience education|Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
33254218|NCT05359900|Active Comparator|Red flag education|Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
33254219|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
33254220|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33254221|NCT00753818|Experimental|1|
33254222|NCT00753818|Experimental|2|
33254223|NCT00753818|Experimental|3|
33254224|NCT00753818|Other|4|Control
33254225|NCT05359744|Experimental|Elite cyclists, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (2 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
33254226|NCT05359744|Experimental|Recreational athletes, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
33075338|NCT03748810||Triple OADs failure|Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.
33254227|NCT05359744|Experimental|Recreational athletes, female|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
33254228|NCT05359744|No Intervention|Control, male|Venous blood specimens will be collected at the same time points in the absence of exercise.
33075339|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
33254229|NCT00747188|Experimental|2|
33254230|NCT00747188|No Intervention|A, 2, III|
33254231|NCT04046016|Experimental|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
33254232|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
33254233|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
33254234|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
33075340|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
33075341|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
33075342|NCT03669523|Experimental|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
33075343|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
33075344|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
33254235|NCT02687464|Experimental|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
33254236|NCT02687464|Active Comparator|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
33254237|NCT04046718|Experimental|electroacupuncture|the study group received electroacupuncture stimulation at different points
33254238|NCT04046718|No Intervention|control group|a control group with no intervention
33254239|NCT02561858|Experimental|acid load test|
33254240|NCT05124418|Other|Palatal masticatory mucosa thickness measurement|
33254241|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
33254242|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
33254243|NCT00747422|Experimental|I|
33254244|NCT04003870|Experimental|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
32731155|NCT04502251|Sham Comparator|LDN + Sham tDCS|Low Dose Naltrexone and Sham Transcranial Direct Current Stimulation
32731156|NCT04502251|Placebo Comparator|Placebo + tDCS|Placebo and Transcranial Direct Current Stimulation
33254245|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
33254246|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
33254247|NCT04057274|Experimental|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
33254248|NCT04057274|No Intervention|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
33254249|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
33254250|NCT02686060|No Intervention|without in-line filters.|
33254251|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
33254252|NCT00791856|Experimental|2|14 cm2 testosterone patch
33277457|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
33277458|NCT00992342|Experimental|PF-03893787 5 mg|
33277459|NCT00992342|Experimental|PF-03893787 15 mg|
33254253|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
33254254|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
33075345|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
33075346|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
33075347|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
33254255|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
33254256|NCT00796692|Experimental|Group 2|Low molecular weight heparin
33254257|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
33254258|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
33254259|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
33254260|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
33254261|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
33254262|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
33254263|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
33254264|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
32731157|NCT04502251|Other|Placebo + Sham tDCS|Placebo and Sham Transcranial Direct Current Stimulation
33075348|NCT00189852|No Intervention|Control|No telemonitoring system in place
33075349|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
33075350|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
33254265|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
33254266|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
33254267|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
33254268|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
33254269|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
33254270|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
33254271|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
33254272|NCT00788814|Other|Control|Control group
33254273|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
33075351|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organized but outside this trial."
33254274|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
33254275|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
33075352|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organised but outside this trial."
33075353|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
33075354|NCT00535210|Other|1|
33254276|NCT00792090|Experimental|1|Fermented milk
33075355|NCT00535210|Other|2|
32935034|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
33075356|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
33075357|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
33075358|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
33075359|NCT00189930|Active Comparator|1|High dose
33075360|NCT00189930|Active Comparator|2|Low dose
33075361|NCT00189930|Placebo Comparator|3|
33075362|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
33075363|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
33254277|NCT00792090|Active Comparator|2|Standard milk
33254278|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
33254279|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
33254280|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
33254281|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
33254282|NCT00792168|Active Comparator|1. Venlafaxine|
33254283|NCT00792168|Placebo Comparator|2. Placebo|
33254284|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
33254285|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
33277460|NCT00992342|Experimental|PF-03893787 50 mg|
33277461|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
33277462|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
33254286|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
33075364|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
33075365|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
33254287|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
33254288|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
33254289|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
33254290|NCT00990496|Experimental|GBM Treatment|
33254291|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
33254292|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
33254293|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
33254294|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
33254295|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
33254296|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
33254297|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
33254298|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
33075366|NCT03391921|Active Comparator|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
33075367|NCT03391921|Experimental|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
33075368|NCT00158171|Experimental|1|Nicotine patch
33075369|NCT00158171|Experimental|2|Nicotine gum
33075370|NCT00158171|Placebo Comparator|3|Folic acid
33075371|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
33075372|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
33075373|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
33254303|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
33254304|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
33254305|NCT00797004||endoscopic sinus procedure candidates|
33254306|NCT00539500|Experimental|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
33254307|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
33254308|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
33254309|NCT05070988||Rare diseases|Children and adult patients with rare diseases and followed at the Necker Enfant Malades Hospital, Paris
33254310|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
33254311|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
33254312|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
33254313|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
33254314|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
33254315|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
33254316|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
33254317|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
33254318|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
33254319|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
33254320|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
33254321|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
33254322|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~Diabetic patients~Coronary insufficiency"
33254323|NCT00755144|Experimental|1|ROCC
33254324|NCT00755144|Active Comparator|2|LCS
33254325|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
33254326|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
33254327|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
33254328|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
33254329|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
33254330|NCT04003792|Experimental|single arm prospective trial|
33254331|NCT00747890|Active Comparator|I|
33254332|NCT00747890|Other|II|
33254333|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
33254334|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
33254335|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
33254336|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
33254337|NCT00755300||1|Standard Total Knee Replacement
33254338|NCT00755300||2|Computer Guided Knee Replacement
33254339|NCT00755378|Experimental|1|
32731158|NCT04962087|Experimental|Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
32731159|NCT04962087|No Intervention|Psychoeducation Control|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia.
33254340|NCT00755378|Placebo Comparator|2|
33254341|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
33254342|NCT00789204|Experimental|GPR|Global Postural Re-Education
33254343|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
32731160|NCT04962087|Experimental|Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
32731161|NCT04962087|No Intervention|Psychoeducation Control - Deprescribing|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia and information about the benefits of medication de-prescribing for those in Trial 2.
32731162|NCT04502017|Active Comparator|Standard Antithrombotic Therapy|OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone
32731163|NCT04502017|Active Comparator|Genetic-Tailored AntiThrombotic Strategy|OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone
33254344|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
33254345|NCT00797394|Experimental|Treated|
33254346|NCT00797394|Active Comparator|Control|
33254347|NCT00792480|Experimental|Intensive Counseling Group|
33254348|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
33254349|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
33254350|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
33254351|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
33254352|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
33254353|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
33254354|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
33254355|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
33254356|NCT00797472|Active Comparator|Arm II: ABVD|
33254357|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
33254358|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
33254359|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
33254360|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
33254361|NCT00792558|Experimental|Single Arm|
33254362|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
32731164|NCT04502017|Active Comparator|Half-Dose NOAC|Half Dose of Novel OAC
32731165|NCT03348319||Cadaver organs|
32731166|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
32731167|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
32731168|NCT02648217|Experimental|IDegAsp U100 BID|
33254363|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
33254364|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
33075374|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
33075375|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
33075376|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
33075377|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
33254365|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
33254366|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
33075378|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
33075379|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
33075380|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
33075381|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
33075382|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of <20 ng/ml
33254367|NCT04980456|Other|TOTAL30, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses as randomized. Each study product will be worn bilaterally (in both eyes) for approximately 30 days for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
33254368|NCT04980456|Other|Biofinity, then TOTAL30|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each study product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
33254369|NCT05359432|Experimental|Empagliflozin|
33254370|NCT05359432|Experimental|Vildagliptin|
33254371|NCT00755456|Active Comparator|Glucose solution|
33254372|NCT00755456|Experimental|Glucose and L-carnitine solution|
32731169|NCT02648217|Active Comparator|BIAsp U100 BID|
32731170|NCT04507399|Experimental|Protein Beverage|Whey Protein Beverage
32731171|NCT04507399|Experimental|Control Beverage|Whey Permeate Beverage
32731172|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
32731173|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
32731174|NCT04943679||Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b|Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years
32731175|NCT04507165|Experimental|opioid-free general anesthesia|under opioid-free general anesthesia
32731176|NCT04507165|Active Comparator|opioid based general anesthesia|under opioid based general anesthesia
32731177|NCT05097703|Experimental|Sleep Resource Intervention|"Half the participants in the study will be allocated to the intervention group. The resource will be sent to participants in this group, along with information about the research study and instructions for completing outcome measures. This will be followed up by a telephone call to ensure participants understand what is required of them and to answer any questions. All carers will be asked to complete questionnaires at baseline, immediately post intervention and at one-month post intervention; as well as sleep diaries for their child for the duration of the intervention period. Carers in the intervention group will also be asked to complete a diary of resource use as well as a feedback survey on their experience of using the resource.~Carers in the intervention group will be asked that they use the resource with their child at bedtime for a minimum of three-days a week over a one-month period."
33075383|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of >30 ng/ml
33075384|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
33075385|NCT00535444|Active Comparator|Control|assisted appointment with physician
33075386|NCT00535522|Experimental|TAK-285|
33075387|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
33075388|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
33075389|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
33075390|NCT00158327|Active Comparator|2|Participants will receive usual care
33075391|NCT03249220|Experimental|CBMS|
33075392|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
33075393|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
33254373|NCT00789516||1|Normal control
33254374|NCT00789516||2|B thalassemia regular transfusion
33254375|NCT00789516||3|B thalassemia post transplantation
33254376|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
33254377|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
33277463|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
33277464|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
33254378|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33075394|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
33254379|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33254380|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
33254381|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
33254382|NCT05004688|Experimental|BCG|Active BCG immunization
33254383|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
33075395|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
33254384|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
33254385|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
33254386|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
33075396|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
33075397|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
32731178|NCT05097703|No Intervention|Control|Participants randomised to the wait-list control group will be asked to complete pre, post and follow-up measures, as well as keep a sleep diary for the duration of the intervention period. They will then be sent the resource after the final outcome measures have been collected to use as they wish.
33254387|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
33254388|NCT00797706|Placebo Comparator|Vehicle|
33254389|NCT00797706|Experimental|Low dose|
33254390|NCT00797706|Experimental|High dose|
33254391|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
33254392|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
33254393|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
33254394|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
33254395|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
32731179|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
32731180|NCT05585437||gastric cancer specialist training program|
33075398|NCT02905357||MINOCA|OCT and CMR imaging
32731181|NCT04507087|Experimental|Intervention|See detailed preregistration: https://osf.io/xrckh/registrations
33254396|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
32731182|NCT04507087|Sham Comparator|Control|See detailed preregistration: https://osf.io/xrckh/registrations
33075399|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
33075400|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
33254397|NCT01054651|Active Comparator|Praziquantel|
33254398|NCT04961554||Adult patients presenting with limited mouth opening|Adult patients presenting with limited mouth opening not allowing intubation by videolaryngoscopy, on mandibular surgical pathology requiring general anesthesia.
33254399|NCT04059692|Experimental|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
33254400|NCT04059692|Placebo Comparator|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
33254401|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
33254402|NCT00789594|Experimental|Result management|Result management
33254403|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
33254404|NCT00789594|No Intervention|Usual care|Usual care
33254405|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
33254406|NCT05360914|Experimental|Hospital at Home (HaH) treatment|The patients in this arm will receive the intervention.
33075401|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
33075402|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
33254407|NCT05360914|Active Comparator|Standard hospital admission|The patients in this arm are the control group and will receive the standard hospital treatment.
33254408|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
33254409|NCT01563640|Placebo Comparator|normal school uniforms|washing only
33254410|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
33254411|NCT00792870|Experimental|SURI Enhanced|
33254412|NCT00792870|Active Comparator|SURI Standard|
33075403|NCT05275738|Active Comparator|Nicotinamide|Participants will receive 750mg nicotinamide tablets 1+1 per day (1.5g) for 6 weeks and after that 2+2 per day (3.0g).
33075404|NCT05275738|Placebo Comparator|Placebo|Participants will receive 750mg placebo tablets 1+1 per day for 6 weeks and after that 2+2 per day.
33075405|NCT05265481|No Intervention|Baseline|In this phase, the investigators will not apply any venodilation method.
33254413|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
33254414|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
33254415|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
33254416|NCT00750620|Experimental|4. Normal renal function|normal renal function
33075406|NCT05265481|Active Comparator|Tourniquet applied|The investigators will apply a blood pressure cuff tourniquet inflated to 60 mmHg pressure.
33075407|NCT05265481|Active Comparator|Tourniquet plus manual tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein manually.
33075408|NCT05265481|Experimental|Tourniquet plus device tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein with a massage device.
33075409|NCT05256667|Other|Root canal treatment in single visit - RCT-SV|Group 1- RCT-SV: Endodontic treatment in a single visit using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
33075410|NCT05256667|Other|Root canal treatment in two visits with intracanal dressing - RCT-TVWD|Group 2- RCT-TVWD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by intracanal dressing (calcium hydroxide powder, CPMC, glycerine) and temporary restoration (glass ionomer cement) for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
33075411|NCT05256667|Other|Root canal treatment in two visits without intracanal dressing - RCT-TVWOD|Group 3- RCT-TVWOD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by temporary restoration (glass ionomer cement) for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
33254417|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33254418|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
32743063|NCT04487015|Experimental|Part I: MP+ Call + MesC [6 weeks]|For part one of study, participants who currently do not receive performance nutrition support, will be given access to an app-based menu planner (MP) for 6 weeks with coach support that gives ad-hoc messaging and calls.
33075412|NCT05255731|Active Comparator|Laser Group (GL)|Patients will be submitted to a low power laser application immediately after suturing of the surgical area. The radiation emission shall be conducted according to protocol.
33075413|NCT05255731|Placebo Comparator|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
33075414|NCT00158522|Experimental|1|
33254419|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
33254420|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
33254421|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
33254422|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
33254423|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
32743064|NCT04487015|Experimental|Part II: Stage 1- MP [1week]|For the pilot SMART trial (part two of study), participants (not the same participants as part one) who currently do not receive performance nutrition support, will be given access to a menu planner app (MP) for 4 weeks. In the first 1 week, participants will only receive MP.
32743065|NCT04487015|Experimental|Part II: Stage 2 - R1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1week, this group of participants are considered responders (R1) so they continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
33075415|NCT05250544|Experimental|Stress ball group|For the adolescents in the stress ball group; Before the procedure, the adolescent's fear (with Childeren's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the stress ball will be introduced to the adolescents and they will be asked to hold it in their desired hands. After explaining how to squeeze the stress ball, the PCR Test will start a few seconds after the adolescent starts to squeeze. As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
33254424|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
33254425|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
33075416|NCT05250544|Experimental|Breathin exercise group|For the adolescents in the breathing exercise group; Before the procedure, the adolescent's fear (with Child's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the breathing exercise will be introduced and applied to the adolescents. After explaining how to do the breathing exercise, the adolescent will be expected to complete the exercises. The PCR Test process will begin immediately after the exercise is complete. As soon as the process starts, the stopwatch will be started and will be stopped when the process is finished. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
33075417|NCT05237869|Sham Comparator|Physical Therapy|For patients enrolled in the control group, the participants will undergo calibration of the Delfi Personalized Tourniquet System to measure limb occlusion pressure and will wear the cuff during completion of the exercises with minimal inflation (approximately 5%), to hold the cuff in place during treatment. This will act as a sham.
33075418|NCT05237869|Active Comparator|Blood Flow Restricted Physical Therapy|Physical therapy assisted by blood flow restriction per standard physical therapy protocol.
33075419|NCT05195047|Experimental|Probiotics-Placebo-Placebo|1 week of consecutively consuming oral probiotics (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
33075420|NCT05195047|Experimental|Placebo-Probiotics-Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then consuming oral probiotics (1 time/day) for 1 week and placebo (1 time/day) for 1 week (1 time/day) respectively.
33075421|NCT05195047|Experimental|Placebo-Placebo-Probiotics|1 week of consecutively consuming oral placebo (1 time/day) followed SARS-CoV-2 vaccination, then consuming oral placebo for 1 week (1 time/day) and probiotics for 1 week (1 time/day) respectively.
33075422|NCT05195047|Placebo Comparator|Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
33254426|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
33075423|NCT05169229|Experimental|Treatment arm|Combination of vancomycin and tobramycin mixed with allograft and locally administered during revision surgery after total hip arthroplasty.
33075424|NCT05169229|Placebo Comparator|Placebo|Saline locally added to allograft and locally administered during revision surgery after total hip arthroplasty.
33075425|NCT05160415|Experimental|Treatment|Drug: EDG-5506
33254427|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
33254428|NCT05360836|Active Comparator|Group 1|Conservative Treatment Program
33254429|NCT05360836|Active Comparator|Group 2|Conservative Treatment + Motor Imagery Program
33254430|NCT03983395|Experimental|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
33254431|NCT03983395|Experimental|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
33254432|NCT03983395|Experimental|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
32731183|NCT05585359|Experimental|injectable platelet rich fibrin with Vitamin C|Injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells the will be mixed with 250 micromole of Vitamin C.
32731184|NCT05585359|Active Comparator|Injectable platelet rich fibrin alone|injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells
33254433|NCT03983395|Experimental|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
32731185|NCT05060575|Experimental|EDUTC|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
32731186|NCT05060575|Active Comparator|Control Group|Routine hospital care.
33254434|NCT03983395|Experimental|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
33254435|NCT03983395|Experimental|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
33075426|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
33254436|NCT03983395|Experimental|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
33254437|NCT03983395|Experimental|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
33075427|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
33075428|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
33075429|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
33075430|NCT00538057|Experimental|arm 1|study drug
33075431|NCT00538096|Experimental|1|MEDI-538
33075432|NCT00538096|Experimental|2|MEDI-538
33075433|NCT00538096|Experimental|3|MEDI-538
33254438|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
33082237|NCT04621123|Experimental|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 300 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
33254439|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
33254440|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
33254441|NCT00345553||1|Biliary atresia subjects who have their native liver
33254442|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
33254443|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
33254444|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
33254445|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
33254446|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
33254447|NCT05426174|Experimental|Group 1 mRNA NA: Low dose Level|Participants will receive a low dose of mRNA vaccine
33082238|NCT04621123|Placebo Comparator|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300 ml of sterile saline solution 0.9%.
33254448|NCT05426174|Experimental|Group 2 mRNA NA: Medium dose level|Participants will receive a medium dose of mRNA vaccine
33254449|NCT05426174|Experimental|Group 3 mRNA NA: High dose level|Participants will receive a high dose of mRNA vaccine
33254450|NCT05426174|Active Comparator|Group 4: QIV-HD|Participants will receive QIV-HD (high dose quadrivalent influenza) vaccine
33254451|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
33254452|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
33254453|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
33254454|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
33277465|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
33254455|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
32731187|NCT04503421|Experimental|BFR|"Patient will use the following rehabilitation protocol while incorporating blood flow restriction therapy:~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~Sling immobilization with active wrist and shoulder ROM~Active extension of biceps to 30 degrees, No active flexion~6-9 weeks full active extension in brace~Maintain wrist and shoulder flexibility~Begin rotator cuff/deltoid isometrics, progress active extension in brace~Weeks 9-12: Gently advance ROM to tolerance~Discontinue sling~Begin active flexion and extension against gravity.~Advance strength to light resistance, maintain flexibility/ROM~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
32731188|NCT04503421|No Intervention|Control (no BFR)|"patients will use following rehabilitation protocol without the use of blood flow restriction therapy:~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~Sling immobilization with active wrist and shoulder ROM~Active extension of biceps to 30 degrees, No active flexion~6-9 weeks full active extension in brace~Maintain wrist and shoulder flexibility~Begin rotator cuff/deltoid isometrics, progress active extension in brace~Weeks 9-12: Gently advance ROM to tolerance~Discontinue sling~Begin active flexion and extension against gravity.~Advance strength to light resistance, maintain flexibility/ROM~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
32731189|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
32935035|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
32935036|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
33254456|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
33254457|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
33254458|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
33254459|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
33254460|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
33254461|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
33254462|NCT00326209|Experimental|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
33254463|NCT00537940|Active Comparator|A|
33254464|NCT00537940|Active Comparator|B|
33254465|NCT00661362|Experimental|1|Metformin + Saxagliptin
33254466|NCT00661362|Placebo Comparator|2|Metformin + Placebo
33277466|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
32935037|NCT02690168||Healthy Men|
32935038|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
32935039|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
32935040|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
32935041|NCT02696083|Experimental|Active Treatment|
32935042|NCT05585203|Experimental|Contingency management|In addition to receiving usual care at the recovery house, participants assigned to this arm will receive contingency management by trained recovery house staff in addition to their usual care. Contingency management sessions will be led by a trained recovery house staff member who is also a research participant in the study. Contingency management will occur once weekly for sessions of approximately 10-15 minute duration for up to 12 weeks. Participants will plan three recovery-oriented activities with the staff member each week, and upon verification of completion of the tasks, the resident participant can earn prize draws of varying monetary amounts.
32935043|NCT05585203|Active Comparator|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery houses are safe, healthy, family-like substance-free living environments that support individuals in recovery from addiction. Although recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
32935044|NCT02650219||gaucher disease type 1|"Inclusion criteria:~Adult patients >= 18 years old~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
32935045|NCT02650219||Control|healthy subjects intervention: genetic analyses
32731190|NCT05043337|Experimental|Maternal voice|Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
32731191|NCT05043337|Experimental|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Brahms Lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
33254467|NCT05392946|Experimental|Treatment (iberdomide, bortezomib, dexamethasone, daratumumab)|"INDUCTION PHASE: Patients receive iberdomide PO QD on days 1-21, bortezomib SC on days, 1, 8, 15, and 22, and dexamethasone PO on days 1, 8, 15, 22. Patients also receive daratumumab SC on days 1, 8, 15, 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 13-36 CYCLES: Patients receive iberdomide PO QD on days 1-21. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity."
33254468|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
33254469|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
33254470|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
33254471|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
33254472|NCT00325897|Placebo Comparator|Placebo|Inactive
33254473|NCT04926142||Patients planned for percutaneous PFO closure|Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
33254474|NCT00756392|Other|1|
33254475|NCT03989089|Experimental|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
32731192|NCT05043337|Experimental|Maternal voice combined with lullaby|Recording the maternal voice in reading children's books and giving mother listening to the lullaby at the same time, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Maternal voice combined with Brahms lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
32731193|NCT05043337|No Intervention|Control group|When the premature infants undergoing heel lance procedure , the control group was under routine care . Measuring with the Respiration , heart rate , oxygen saturation , and neonatal infant pain scale (NIPS ) were recorded 3 minutes before , during , 1st , 3rd , and 10th minutes after the heel lance puncture .
32731194|NCT02164695|Active Comparator|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
32731195|NCT02164695|Sham Comparator|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
32731196|NCT04506697|Experimental|Patients with LUTS|Patients who are indicated for uroflowmetry
32731197|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
32731198|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
32731199|NCT05303181|Experimental|Group1|training used Russian Current carrier frequency at 2500-Hz alternating current.
32731200|NCT05303181|Experimental|Group2|training used Russian Current carrier frequency at 3750-Hz alternating current.
32731201|NCT05303181|Experimental|Group3|training used Russian Current carrier frequency at 5000-Hz alternating current.
32731202|NCT05303181|Experimental|Group4|training used Russian Current at different mode.
32935046|NCT05574439|Active Comparator|Non-responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
33254476|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
33254477|NCT00756626|No Intervention|2|Control standard of care
33254478|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
33254479|NCT05406856|Active Comparator|IMRT/VMAT group|This group receives standard of care curative treatment with primary external beam radiation therapy (IMRT/VMAT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
33254480|NCT05406856|Experimental|IMPT group|This group receives curative treatment with primary external beam radiation therapy (IMPT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
33254481|NCT00756704|No Intervention|Baseline Period|
33254482|NCT00756704|Experimental|Intervention Period|
33254483|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
33254484|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
33254485|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
33254486|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
33254487|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
33254488|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
33254489|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
33254490|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
33254491|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
33254492|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
33254493|NCT00750932||T|Control
33254494|NCT00750932||M|Minor with cystic fibrosis
33254495|NCT00750932||A|Adult with cystic fibrosis
33254496|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
32935047|NCT05574439|Placebo Comparator|Non-responders: TCOC+ placebo|Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
33254497|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
33254498|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
33254499|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
33254500|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
33254501|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
33254502|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
33254503|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
33254504|NCT00748280|Experimental|1|ORCT
33254505|NCT00748280|Experimental|2|PCEM/PMTA
33254506|NCT00798642|Active Comparator|Hypnotherapy|
33254507|NCT00798642|Placebo Comparator|Standard care|
33254508|NCT00798642|Placebo Comparator|Mind Body Therapy|
33254509|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
33254510|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
33254511|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
33254512|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
33254513|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
33254514|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
33254515|NCT00748358|Experimental|drug|drug
33254516|NCT05204160|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33254517|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
33254518|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
33254519|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
33254520|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
32935048|NCT05574439|Active Comparator|Insufficient responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
32935049|NCT05574439|Placebo Comparator|Insufficient responders: TCOC+ placebo|Placebo: 2.4mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
32935050|NCT05574439|No Intervention|Excellent Responders|
32935051|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
33254521|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
32935052|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32935053|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32935054|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
32935055|NCT02698735|Placebo Comparator|Placebo|Vehicle control
33075434|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
33075435|NCT00538135|Active Comparator|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
33075436|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
33075437|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
33075438|NCT00538174|Experimental|Arm 1|2.5 mg
32731203|NCT04506541|Experimental|Kangaroo Care Group|"The pregnant women who were in the kangaroo care group of the study and who were 36-38 weeks of gestation were given 20 minutes of kangaroo care and breastfeeding training by the researcher. A video about kangaroo care and breastfeeding was sent to pregnant women to remind them two weeks after the training. Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room. In the first, third, sixth, and ninth months after the discharge of the mothers who started applying kangaroo care, kangaroo care application status, breastfeeding status, baby's growth, and development status were evaluated. In each follow-up, the baby's height, weight, and head circumference were measured with a standard measuring tool."
32731204|NCT04506541|No Intervention|Control Group|The pregnant women in the control group were not trained other than breastfeeding training given in the hospital. In the maternity room, routine care practices were performed after delivery of the pregnant women. As in mothers in the kangaroo care group, in the first, third, sixth, and ninth months after the discharge of mothers, kangaroo care application situations, breastfeeding conditions, growth, and development of the baby were evaluated.
32731205|NCT05011903|Experimental|PFI+CDF with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) and Cross-tailored Dynamic Feedback (CDF) related to alcohol use and related sexual behavior. They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
33075439|NCT00538174|Experimental|Arm 2|10 mg
33075440|NCT00538174|Experimental|Arm 3|20 mg
33075441|NCT00538174|Placebo Comparator|Arm 4|
33075442|NCT05149573|Active Comparator|4-Week Treatment with no Maintenance Period|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
33075443|NCT05149573|Sham Comparator|4-Week Sham Treatment with no Maintenance Period|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B. Body mat on any flat surface and lay on the mat with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the sham device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
33075444|NCT05149573|Active Comparator|4-Week Treatment with 1-Week-Per-Month Maintenance Period for an Additional 3 Months|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will keep the device and use it for 1 week (7 days) during the last week of the month for the following 3 months. Each participant in this group will be asked to complete a set of electronic questionnaires immediately following their week-long maintenance treatment during the last 3 months of the study.
33075445|NCT05139823|No Intervention|Control|Controls receive usual care, which is a digital communication to the local home care team including a discharge care plan to the home care system, including information about the discharge diagnoses, and recommendations for particular attention to specific bodily functions and medical treatment regime. The patient's PCP receives a discharge summary from the treating hospital physician as usual.
33075446|NCT05139823|Experimental|Intervention|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-5 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
33082239|NCT04621240|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
33254522|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
33254523|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
33075447|NCT04724486|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33075448|NCT04724486|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
32731206|NCT05011903|Experimental|PFI+GHI with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior, and generic health information (GHI). They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
33254524|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
33254525|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
33254526|NCT00751244|Other|3|90-day wait-list group
33254527|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
32731207|NCT05011903|Experimental|PFI-only with no diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior. They do not complete weekend diary surveys.
33254528|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
33254529|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
33254530|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
33254531|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
33254532|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
33254533|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
33254534|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
33254535|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
33254536|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
33254537|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
33254538|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
33254539|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
33254540|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
33254541|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
33254542|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
33254543|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
33254544|NCT00751556|Experimental|Arm 1|
33254545|NCT00751556|Active Comparator|Arm 2|
33254546|NCT00748592|Placebo Comparator|Placebo|
33254547|NCT00748592|Experimental|PD 0200390, 5 mg|
33254548|NCT00748592|Experimental|PD 0200390, 15 mg|
33254549|NCT00748592|Experimental|PD 0200390, 30 mg|
33254550|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
33254551|NCT00757406||1|Test group - Lymphedema sufferers
33254552|NCT00757406||2|Control group - healthy volunteers
33254553|NCT00748670|Experimental|A|
33254554|NCT00757640|No Intervention|B|no cholecystectomy
33254555|NCT00757640|Experimental|A|cholecystectomy
33254556|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
33254557|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
33254558|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
33254559|NCT02562560|Experimental|TGA|
33254560|NCT02562560|Experimental|Controls|
33254561|NCT03976401|Experimental|EFX Dose 1|Main Study
33254562|NCT03976401|Experimental|EFX Dose 2|Main Study
33254563|NCT03976401|Experimental|EFX Dose 3|Main Study
33254564|NCT03976401|Placebo Comparator|Placebo|Main Study
33254565|NCT03976401|Experimental|EFX Dose (Cohort C)|
33254566|NCT03976401|Placebo Comparator|Placebo (Cohort C)|
33254567|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
33254568|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
33254569|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
33075449|NCT05120479|Experimental|Experimental arm|"The intervention will be the application of a Kinesiotape (KT) strip on the anterior side of the forearm.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension)."
32731208|NCT05011903|No Intervention|Control|Participants in this condition get no intervention and do not complete weekend diary surveys.
32731209|NCT04475991|Active Comparator|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
33075450|NCT05120479|Sham Comparator|Control arm|"The intervention will be the application of a tape strip on the anterior side of the forearm. Sham tape appears to be kinesiotape but is an inelastic tape.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Sham tape: exactly the same procedure is followed as experimental arm, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain)."
33075451|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
32731210|NCT04475991|Experimental|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
32731211|NCT04475991|Experimental|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
32731212|NCT04475991|Experimental|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
32731213|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
32731214|NCT04437225|Experimental|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 5:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 7:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 10 hours, following a priming dose. From 7:30 am to 5:30 pm, urine collections will occur hourly, and from 8:30 am to 5:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 5:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
32743066|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
33075452|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
33075453|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
33075454|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
33075455|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
33075456|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
33075457|NCT00538486|Experimental|Group T|Telmisartan
33075458|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
33075459|NCT00538486|Experimental|Group C|Candesartan
33075460|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
33075461|NCT00538486|Active Comparator|Group A|Amlodipine
33075462|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
33075463|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
33075464|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
33075465|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
33075466|NCT04685161|Experimental|Surgical extrusion|Novel and alternative treatment option for horizontal crown root fractured maxillary incisors
33075467|NCT04685161|Active Comparator|Fibre post|Treatment modality normally used for crown-root fractured tooth
33075468|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
33075469|NCT05553886|Experimental|S086 piece|Sacubitril alisartan calcium tablets,60mg,120mg,180mg,240mg
33075470|NCT05553886|Active Comparator|Sacubitril valsartan sodium tablets|Sacubitril valsartan sodium tablets,50mg,100mg
33075471|NCT00536926|Active Comparator|A|home spirometry alone
33075472|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
33075473|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
33075474|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
33075475|NCT05526937|Experimental|Sprouted wholemeal bread|
33075476|NCT05526937|Active Comparator|Unsprouted wholemeal bread|
33075477|NCT05526937|Placebo Comparator|White bread|
33075478|NCT05493280|Other|Healthy Participants|Subjects who are interested in treatment for hyperpigmentation will be enrolled for this study
33075479|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
33075480|NCT05472064|Experimental|Group 1|Primary care doctor persona with direct messages
33075481|NCT05472064|Experimental|Group 2|Breast cancer survivor persona with direct messages
33075482|NCT05472064|Experimental|Group 3|Primary care doctor with indirect messages
33075483|NCT05472064|Experimental|Group 4|Breast cancer survivor persona with indirect messages
33075484|NCT05472064|No Intervention|Group 5|Control
33075485|NCT00183573|Experimental|1|Brief Motivational Intervention only
33254570|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
33254571|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
33254572|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
33075486|NCT00183573|Experimental|2|Brief Informational Intervention only
33075487|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
33254573|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
33254574|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
33254575|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
33254576|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
33075488|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
33254577|NCT04013607|Experimental|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
33254578|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
33254579|NCT04875156|Other|normal volunteers|normal volunteers between 18 and 40 years old, men and women. Measurement of the range of motion of the metacarpophalangeal joint with a goniometer and pinch strength of the thumb with a dynamometer
33254580|NCT00685334|Experimental|1|Participants will take olanzapine
33254581|NCT00685334|Active Comparator|2|Participants will take aripiprazole
33254582|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
33075489|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
33254583|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
33254584|NCT04013919||Type 1 Diabetes|
33254585|NCT04013919||Type 2 Diabetes|
33254586|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
33254587|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
33254588|NCT04864548|Experimental|Group 1A: Low dose challenge|"Intranasal viral challenge with 1 x 10^1 TCID_50 in previously infected volunteers~N= 6-8 participants"
33254589|NCT04864548|Experimental|Group 1B: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously infected volunteers~N= 6-8 participants"
33075490|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
33075491|NCT05432947|Experimental|68Ga-P16-093 and 18F-FDG PET/ CT scan|Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.
33254590|NCT04864548|Experimental|Group 1C: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously infected volunteers~N= 6-8 participants"
33254591|NCT04864548|Experimental|Group 1D: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously infected volunteers~N= 4-8 participants"
33254592|NCT04864548|Experimental|Group 1E: High dose challenge|"Intranasal viral challenge with 1 x 10^5 TCID_50 in previously infected volunteers~N= 4-8 participants"
33254593|NCT04864548|Experimental|Group 2: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 1a-e (1x10^1, 1x10^2, 1x10^3, 1x10^4, or 1x10^5 TCID_50)~N=10-30 participants"
33254594|NCT04864548|Experimental|Group 3a: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously uninfected, vaccinated volunteers~N=6-8 participants"
33254595|NCT04864548|Experimental|Group 3b: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
33075492|NCT05413642|Experimental|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
33075493|NCT05413642|Active Comparator|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
33075494|NCT00190203|Experimental|A|HEMICRANIECTOMY
33075495|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
33254596|NCT04864548|Experimental|Group 3c: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
32935056|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
33254597|NCT04864548|Experimental|Group 3d: High dose challenge|"Intranasal viral challenge with 1 x 10^5 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
33254598|NCT04864548|Experimental|Group 4: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 3a-d (1x10^2, 1x10^3, 1x10^4 or 1x10^5 TCID_50)~N=10-30 participants"
33254599|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
33254600|NCT03743181||control|will received standard care by physician in attendance
33254601|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
33254602|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
32935057|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
33254603|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
33254604|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
33254605|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
33254606|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
32935058|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
33254607|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
33254608|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
33254609|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
33254610|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
33254611|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
33254612|NCT00793494|Placebo Comparator|Placebo|
33254613|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
33254614|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
33254615|NCT03986359|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
33254616|NCT03986359|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
33254617|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
32935059|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
32935060|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
32935061|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
32935062|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
32935065|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
32935066|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
32935067|NCT02691962|Experimental|Xen Matrix AB|Subjects treated with Xen Matrix AB
32935068|NCT05542303|Experimental|ZB001 for injection|Treated different dose cohorts with single intravenous injection of ZB001
32935069|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
32935070|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
32935071|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
32935072|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
32935073|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
32935074|NCT05502211|Experimental|Lidocaine|
32935075|NCT05502211|Active Comparator|Fentanyl|
32935076|NCT04339244|Active Comparator|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60~70 mmHg
33075496|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
33254618|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
33254619|NCT00933309|Experimental|Group 1|Exemestane alone
33254620|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
33254621|NCT00352885|Experimental|Escitalopram|Participants will receive escitalopram and IL-2 treatment
33254622|NCT00352885|Placebo Comparator|Placebo|Participants will receive placebo and IL-2 treatment
33254623|NCT00933387|Experimental|open label|an open-labelled, single-arm
33254624|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
33254625|NCT00660660|Placebo Comparator|Placebo|
33254626|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
33254627|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
33254628|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
33254629|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
33254630|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
33254631|NCT00757874|Experimental|Tacrolimus cream|
33075497|NCT04685434||pediatric patients diagnosed with rheumatic diseases.|The Shriners Hospital for Children Upper Extremity Evaluation, the Jebsen-Taylor Hand Function Test, and the Childhood Health Assessment Questionnaire will be administered in children with rheumatic diseases. The Shriners Hospital for Children Upper Extremity Evaluation will be administered two weeks after the first examination and the results will be compared.
33075498|NCT00537355|Active Comparator|TOLAMBA™|
33075499|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
33075500|NCT05402995|Active Comparator|Standard operative debridement and spanning external fixator (reference/control group)|This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.
33075501|NCT05402995|Experimental|Spanning external fixator with Irrisept irrigation (treatment group 1)|Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.
33075502|NCT05402995|Experimental|Antibiotic-coated medullary nail with saline irrigation (treatment group 2)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.
33075503|NCT05402995|Experimental|Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).
33075504|NCT05397106||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
33075505|NCT05395936|Experimental|Intraoperative Data Collection Arm|Participants scheduled for mastectomy with or without breast reconstruction during the course of their breast surgery treatment will have breast skin temperatures taken using a myocardial probe in different anatomical breast areas at multiple time points during the surgery.
33075506|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
33075507|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
33075508|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
33075509|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
33254632|NCT00757874|Active Comparator|Clobetasol cream|
33254633|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
33254634|NCT04050254|Experimental|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
33254635|NCT04050254|Sham Comparator|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
33254636|NCT04050254|No Intervention|Control|No treatment.
33254637|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
33254638|NCT05359354|Experimental|Personalized neoantigen vaccine or neoantigen tumor vaccine + PD-1|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with PD-1.
33254639|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
33254640|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
32769275|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
33075510|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
33075511|NCT05388643|Experimental|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
33075512|NCT05388643|Active Comparator|Standard of Care GDM Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
33075513|NCT05381623|Experimental|Simplified suture-less approach|Infiltration of local anesthetic (articaine 4% 1:100.000 epinephrine) around the harvesting site and attendance for the establishment of a competent coagulum.
33075514|NCT05381623|Active Comparator|Conventional approach|Application of hemostatic sponges over the donor site and placement of tooth-suspended compressive sutures over the area.
33075515|NCT00537472|Experimental|I|
33075516|NCT00537472|Active Comparator|II|
33075517|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
33075518|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
33075519|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
33254641|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
33254642|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
33075520|NCT00159107|Experimental|3|Acamprosate + treatment as usual
33075521|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
33254643|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
33254644|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
33254645|NCT00801450|Experimental|Intravitreal (IVI)|
32769276|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
33075522|NCT05370859||Mme Study Participants|Participants will complete a baseline survey, 11 weekly surveys, and a follow-up survey at 12 weeks
33075523|NCT05370274|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
33075524|NCT05370274|Experimental|Cranial nerve non-invasive neuromodulation (CN-NINM)|CN-NINM will be applied during each session of the strength training intervention
33075525|NCT05357365||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
33075526|NCT05357365||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
33075527|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
33075528|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
33075529|NCT05355259|Experimental|GECKO Active Guidewire Use|All patients will be treated using the GECKO guidewire to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.
33075530|NCT05340868|Experimental|Semaglutide (oral)|In the project, each participant will receive oral semaglutide for three months. 3 mg a day for the first two weeks, then 7 mg a day for the next two weeks, until reaching a dose of 14 mg a day, which will be taken for the next eight weeks.
33075531|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
33075532|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
33075533|NCT00537667|Active Comparator|A|anakinra
33075534|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
33254646|NCT00801450|Experimental|SubTenon´s (STI)|
33254647|NCT05434988||Laparoscopic appendectomy|The laparoscopic appendectomy group is the group that includes patients who underwent appendectomy using the laparoscopic approach
33254648|NCT05434988||Open appendectomy|The open appendectomy group is the group that includes patients who underwent appendectomy using laparoscopic approach
33254649|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
33254650|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
33277467|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
33075535|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
33075536|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
33254651|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
33254652|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
33254653|NCT02554578|No Intervention|Routine healthcare by the transplant team|
33254654|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
33254655|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
33254656|NCT00991666|Experimental|1|AMD Patients
33254657|NCT00991666|Active Comparator|2|healthy controls
33254658|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
33254659|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
33254660|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
33254661|NCT04003402|Experimental|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
33254662|NCT04003402|Experimental|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
33254663|NCT04003402|Experimental|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
33254664|NCT04003402|Experimental|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
33254665|NCT04045860|Experimental|CDT for head and neck lymphedema|Complete Decongestive Therapy
32731215|NCT04437225|Experimental|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
33254666|NCT04045860|Other|Standard of Care for head and neck lymphedema|Observation
33254667|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
33254668|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
33254669|NCT05360602|Experimental|Control group|30 STEMI patients undergoing PCI who will receive standard of care for 1 week that will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
33254670|NCT05360602|Experimental|Test group|30 STEMI patients undergoing PCI who will receive the standard of care in addition to IV Alpha Lipoic Acid 600 mg before PCI then 600 mg orally for 1 week after PCI
33254671|NCT00793728|Active Comparator|Antrectomy|
32731216|NCT04437225|Experimental|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
32935077|NCT04339244|Active Comparator|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90~100 mmHg
32935078|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
32935079|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
32935080|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
32935081|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
32935082|NCT04708106|Experimental|RELX ENDS Tobacco Flavor|Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days
33254672|NCT00793728|Active Comparator|Without antrectomy|
33254673|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
33254674|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
33254675|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
33254676|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
33254677|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
33254678|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
33254679|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
33254680|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
33254681|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
33254682|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
33254683|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
32731217|NCT05010265||Use of advanced neurotechnologies to detect consciousness and predict recovery|Treating clinicians, family members (caregivers) and patients recovering from a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
32731218|NCT05302713|Experimental|Ionic Calcium|Ionic calcium (IC) is a calcium in a free ionic state. Participants will be instructed to take 8mg of IC/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
32731219|NCT05302713|Active Comparator|Calcium Carbonate|Participants will be instructed to take 8mg of calcium carbonate/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
32731220|NCT04992949|Experimental|CPX351|Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.
32935083|NCT04708106|Experimental|RELX ENDS Menthol Flavor|Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days
32935084|NCT04708106|Experimental|RELX ENDS Tobacco and Menthol Flavors|Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days
32935085|NCT04708106|No Intervention|Continue-smoking|Continue smoking combustible cigarettes for 56 days
32935086|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
32935087|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
32935088|NCT04707560|Experimental|Heparin Wet first group|Heparin based wet suction method of EUS FNB will go first for 2 passes and then shift to dry suction method for another 2 passes.
32935089|NCT04707560|Experimental|Dry suction first group|Dry suction method of EUS FNB will go first for 2 passes and then shift to heparin base wet suction method for another 2 passes.
32935090|NCT05421104||Ruxolitinib (RUX)|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
32935091|NCT05421104||Best available therapy (BAT)|PV patients who were resistant to or intolerant of Hydroxyurea (HU) (as defined on the index date) and continued HU treatment or switched to other available therapies other than RUX in the post-index period.
32935092|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
33075537|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
33075538|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
33254684|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
33254685|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
33254686|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
33254687|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
33254688|NCT00798954|Active Comparator|TAXUS|
33254689|NCT00798954|Active Comparator|Cypher|
33254690|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
33254691|NCT00989482|Experimental|Computer Kiosk Eduction|
33254692|NCT04348981|Experimental|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
33254693|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
33254694|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
33254695|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
33254696|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
33254697|NCT04040504|Experimental|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
32731221|NCT05584969|Experimental|Moms-only treatment arm|In this treatment arm, 10 Care Groups comprised of only mothers (10 - 20 participants per group) engaged in the peer-led intervention that consisted of infant feeding guidelines [16], cooking demonstrations, and backyard farming demonstrations conducted over 10 months. The peer-led trainings lasted 60 - 90 minutes and were conducted every two weeks and supervised by a selected VHT.
32731222|NCT05584969|Experimental|Moms and Dads treatment arm|This treatment arm received a similar peer-led intervention to the Moms-only treatment arm, however, this arm comprised both moms and dads (a couple)
32731223|NCT05584969|No Intervention|Control arm|This was the comparison arm of the study. No intervention was provided to the participants of this arm. However, all study arm participants accessed the standard of care which was the routine health services delivered through the government health centers.
32731224|NCT05136105|Experimental|Preventive Narrative Exposure Therapy (PreNET) family intervention|"The intervention group receives treatment as usual in the first aid center for survivors of sexual abuse. This includes medical and judicial assistance if necessary. Furthermore, they receive the psychological family focused intervention.~The intervention consists of a total of three sessions with the aim of reestablishing and validating the relationship between sexually abused children and their parents. The intervention focuses on psychoeducation regarding shame and other trauma related disorders. Further, the acknowledgement of shame and embarrassment as well as parental skills are intended to be improved."
32731225|NCT05136105|No Intervention|No Intervention group|The control group will receive only the assessments, and treatment as usual in a first aid center for survivors of sexual abuse. This includes usually a brief assessment of what happened as well as medical and judicial assistance if necessary.
32731226|NCT05136027|Experimental|Intervention group|Intervention group: In the physical exercise session will carry out a concurrent training in four parts, low- intensity interval training in a bicycle, resistance circuit training, ow- intensity interval training in a bicycle, and CORE exercises.
32731227|NCT05584891||group 1|radical mastoidectomy
32731228|NCT05584891||group2|mastoid obliteration operation.
33075539|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
33075540|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
33254698|NCT04040504|Active Comparator|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
33254699|NCT01055119|Active Comparator|Omega-3 fatty acids|
33254700|NCT01055119|Placebo Comparator|Olive oil|
33254701|NCT00934167|Experimental|Test|Hipolabor
33254702|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
33254703|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
33254704|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
33254705|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
33254706|NCT00801606|Placebo Comparator|Placebo|Placebo only
33254707|NCT05408806||Virtual Reality Games Group with Nintendo Wii Balance Platform|In addition to neurodevelopmental treatment, the cases are treated with virtual reality (VR) games on nintendo wii balance board for 8 weeks, 2 sessions a week. The VR games are performed twice in the first four weeks at the beginner level. During the following four weeks, advanced levels of the same games are selected and virtual reality therapy is performed with 2 repetitions.
33254708|NCT05408806||Hippotherapy Simulator Group|In addition to neurodevelopmental treatment, the cases are treated on a hippotherapy simulator for 8 weeks, 2 sessions a week. In the first 4 weeks, the warm-up and 1 speed intensities of the hippotherapy simulator are applied. During the next 4 weeks, cases are treated warm-up, 1, 2, 3, speed intensities, respectively.
33254709|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
33254710|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
33254711|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
33254712|NCT05394532|Experimental|Steno Diabetes Dialogue Cards|
33254713|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
33254714|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
33254715|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
33254716|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
33254717|NCT05393440|Experimental|Dose-escalation cohort|Three subjects will be enrolled in this cohort. First subject will receive first injection in dose level of 1 million CCID50/mL. If tolerated, second injection for this subject will be accelerated to 10 millions CCID50/mL. If tolerated, the third injection will be further accelerated to 100 million CCID50/mL. The maximum volume for per injection time point is 8 mL. Injection will repeat every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. If dose limiting toxicity (DLT) happens in any dose level, the injection dose will be decrease to the last tolerable level.
33254718|NCT05393440|Experimental|Dose-expansion cohort|Fifteen subjects will be enrolled in this cohort. The maximal tolerable dose (MTD) confirmed in the first stage will be utilized in 15 patients. This stage should not be initiated before the completion of dose escalation of all three subjects in the first stage. Treatment will be repeated every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Dose interruption, not reduction, is permitted. Treatment will be terminated if toxicity-related treatment interrupt is longer than 28 days. Radiology assessment will be conducted every six weeks.
33254719|NCT00939549|Experimental|High-dose cyclohosphamide|
33254720|NCT00799032|Other|Stent|Catania Stent
32731229|NCT05302557|Experimental|Interventional|"During the two weeks prior to the ileostomy closure procedure, daily stimulation of the efferent loop will be performed by irrigation with 500 ml of physiological saline or 500 ml of warm water, preferably bottled, associated with a nutritional thickener. The patient will be instructed by a stomatotherapy nurse. Stimulation will be performed up to the day before the intervention. Kegel exercises will be suggested.~Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
32731230|NCT05302557|No Intervention|Control|"Direct standard surgery. Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
32731231|NCT05584813|No Intervention|ground control binocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with both eyes three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
33254721|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
33254722|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
33254723|NCT00989560|Active Comparator|Active arm|
32731232|NCT05584813|No Intervention|ground control monocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with one eye at a time three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
32769277|NCT05033977|Experimental|Center-based Exercise|"patients did exercises with a physical therapist in a clinic 3 days and 45 minute in a week for 6 weeks.~The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings."
32769278|NCT05033977|Experimental|Home-based exercise|Patients did exercises at home every day and 3 times per day. The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings.
33254724|NCT00989560|No Intervention|Standard care arm|
33254725|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
33254726|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
33254727|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
33254728|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
33254729|NCT00575666|Experimental|A|Intranasal Insulin Treatment
33254730|NCT00575666|Placebo Comparator|B|Drug: Placebo
32731233|NCT05584813|Experimental|10,000 ft, 60 min, monocular pre-peri-post|"Intervention: Hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~post intervention with no hypoxia administered"
32731234|NCT05584813|Experimental|15,000 ft, 15 min, binocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 15 minutes~Procedures: Colour vision tests were performed with both eyes, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 15000 ft. for 15 minutes~post intervention with no hypoxia administered"
32731235|NCT05584813|Experimental|15,000 ft, 60 min, monocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~post intervention with no hypoxia administered"
32731236|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
32731237|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
32731238|NCT04922853|Experimental|2 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.
33075541|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
33075542|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
32731239|NCT04922853|Other|4 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
32731240|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
32731241|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
32731242|NCT05302401|Experimental|Women receiving uninterrupted midwife support during the intrapartum period|28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. Researcher Meserret Aslan will provide six hours of online pregnancy training to pregnant women in the experimental group and provide uninterrupted midwife support during the intrapartum period.Within the first half hour of postpartum after birth, saliva cortisol samples of women will be repeated by researcher Meserret Aslan. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the experimental group.
32731243|NCT05302401|No Intervention|Women who do not receive uninterrupted midwife support during the intrapartum period|Between the 28th and 36th weeks, the pregnancy diagnosis form will be applied by the researcher to the pregnant women in the control group. 28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. After birth, postpartum from control groups will be repeated by researcher Meserret Aslan in the first half hour. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the control groups.
32731244|NCT04921033|Experimental|Exclusive Enteral Nutrition|35kcal/kg/day EEN (Nestle Modulen®) - Subjects will take medicine and EEN solution orally themselves.
32731245|NCT04921033|Active Comparator|Standard of care|"Budesonide 9mg/day for mild disease~Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~Patients with moderate-to-severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
32731246|NCT05302245||Caregivers of ABI survivors|Unpaid caregivers of acquired brain injury survivors living in Nova Scotia
33075543|NCT00539149|Active Comparator|1|
33254731|NCT05378230|Experimental|Probiotic mixture|Arm that received Lactobacillus plantarum mixture (CECT 7527, CECT 7528 and CECT 7529)
32731247|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
32731248|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
32731249|NCT04915833|Experimental|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients >45 years of age submitted for diagnostic colonoscopy
32769279|NCT04818983||NSCLC cohort|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
32731250|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
33075544|NCT00539149|Placebo Comparator|2|
33075545|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
33075546|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
33075547|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
33075548|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
33075549|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
33254732|NCT05591014|Experimental|Software Tutorial|Participants will be asked to interpret a series of ROTEM studies before and after a tutorial on a novel ROTEM interpretation software.
33254733|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
33254734|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
33254735|NCT00658632|Experimental|1|
33254736|NCT00658632|Active Comparator|2|
33254737|NCT05408650|Experimental|Aromatherapy massage group|The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position.
33075550|NCT00539344|Experimental|1|
33075551|NCT00539383|Experimental|1|
33075552|NCT00539422||I|group I of 15 women with benign breast lesion
33254738|NCT05408650|No Intervention|control group|The patients will receive the routine care of the ICU (such as decreased movements of the staff and soft light in the area at night).
33254739|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
33254740|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
33254741|NCT05408494|Sham Comparator|Non-gamified program with sham ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with sham.
33254742|NCT05408494|Active Comparator|Non-gamified program with Active ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with active neurotraining.
33254743|NCT05408494|Experimental|Gamified program with sham ICT|One group will receive fully-gamified version of the program with a sham.
33254744|NCT05408494|Experimental|Gamified program with Active ICT|One group will receive fully-gamified version of the program with active neurotraining.
32731251|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
33075553|NCT00539422||II|group II of 16 women with breast cancer
33075554|NCT00539422||III|13 women were taken as a control group
33254745|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
33254746|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
33254747|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
33254748|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
33254749|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
33254750|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
33254751|NCT00989638||Women at high risk for breast cancer|
33254752|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
33254753|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
33254754|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
33075555|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
33075556|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
33075557|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
33075558|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
33075559|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
33075560|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
33075561|NCT05092399||RYGB|Patients undergoing Roux-en-Y gastric bypass surgery
33075562|NCT05092399||SG|Patients undergoing Sleeve Gastrecomy surgery
33075563|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
33254755|NCT04013295|Experimental|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
33254756|NCT04013295|No Intervention|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
33254757|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
32731252|NCT05136573|Experimental|Combined Exercises on Symptoms of CIPN, Fatigue, and Quality of Life in Colon Cancer Patients|The control group received routine care and maintenance of general daily activities; the experimental group received routine care and maintenance of general daily activities, and also received combined exercises
32731253|NCT05136495|Experimental|Caffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
33254758|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
33254759|NCT05408416|Active Comparator|preoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy were assigned to preoperative group
32731254|NCT05136495|Experimental|Decaffeinated coffee|Drink decaffeinated coffee one morning and drink caffeinated coffee the other morning
33075564|NCT00540202|Active Comparator|2. Coartem|Tablets
33075565|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
33075566|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
33075567|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
32731255|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
33075568|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
33075569|NCT00540280|Active Comparator|Surgery alone|Surgery alone
33075570|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
33075571|NCT00540631|Experimental|A|Active treatment with house dust mite extract
33075572|NCT00540670|Experimental|1|
32731256|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
32731257|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
32731258|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
32731259|NCT04853121|Active Comparator|tapered implant|
32731260|NCT04853121|Placebo Comparator|straight implant|
32731261|NCT05584735||Participants with Inflammatory Bowel Disease (IBD)|Participants with IBD who are receiving a flu vaccine
32731262|NCT05136261|Active Comparator|Treatment|Ceradan Advanced Moisturising Skin Barrier cream - applied twice a day
33075573|NCT00540670|Experimental|2|
33075574|NCT00540670|Experimental|3|
33075575|NCT00540670|Placebo Comparator|4|
33075576|NCT05090293|Active Comparator|Lifestyle Intervention (LI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss.
33075577|NCT05090293|Experimental|Lifestyle Intervention with Body Image Treatment (LIBI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss supplemented with a novel body image intervention designed to address body image issues in the context of weight loss.
33075578|NCT00540748|Experimental|A1|
33075579|NCT00540748|No Intervention|A2|
33075580|NCT00540787|Active Comparator|Drug Treatment|
33075581|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
33075582|NCT00159380|Experimental|Healthy volunteers|8 non smokers non asthmatic
33075583|NCT00159380|Experimental|Asthma volunteers|8 asthmatic mild
33075584|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
33075585|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
33075586|NCT00540826||B|B: ADHD-patients receiving stimulants
33075587|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
33075588|NCT00540865|Active Comparator|B|Participants will receive case management
33075589|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
33075590|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
33254760|NCT05408416|Experimental|intraoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy were assigned to intraoperative group
33254761|NCT00940251|Placebo Comparator|CORN STARCH|
33254762|NCT00940251|Active Comparator|Mersina, Diet and exercise|
33254763|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
33254764|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
33254765|NCT05408338|Experimental|Low Added Sugar Meal|Participants will be provided a meal low in added sugars.
33254766|NCT05408338|Experimental|High Added Sugar Meal|Participants will be provided a meal high in added sugars.
33254767|NCT04013373||BIS home-based monitoring|
33254768|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
32731263|NCT05136261|Placebo Comparator|Control|Aqueous Cream - applied twice a day
33254769|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
32731264|NCT04503187||Chronic Stroke|Participants who suffered a single event of cerebral vascular accident at least six months ago before study enrollment.
33254770|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
33254771|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
33254772|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
33254773|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
33254774|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
33254775|NCT02559128||HF-T2D-|20 healthy control volunteers
32731265|NCT04503187||Multiple Sclerosis|Participants who has been diagnosed with multiple sclerosis
33075591|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
33075592|NCT02963259||SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system|Subjects will be implanted with SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
33254776|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
33254777|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
33254778|NCT05590858||non-diabetes|patients without diabetes
32731266|NCT04503187||Healthy control|Age-matched healthy adults who are self-reported healthy and has no known musculoskeletal, neuromuscular, and cardiovascular diseases.
32731267|NCT04488315|Experimental|The dexamethasone lipid microsphere plus ropivacaine group|
32731268|NCT04488315|Active Comparator|The ropivacaine alone group|
32731269|NCT04506307|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
32731270|NCT05136183|No Intervention|Standard of care|"Patients randomized to this arm are treated with standard of care for patients with septic shock, including~Fluid resuscitation and vasoactive agents~Hemodynamic monitoring in intensive care units~Antibiotics and infection source control, when applicable~Supportive therapies and devices, including mechanical ventilation and renal replacement therapy~Immunoregulatory medications, including systemic corticosteroids~All treatment provided are according to treating physicians"
32731271|NCT05136183|Experimental|Standard of care, with hemoperfusion with HA-330|Patients randomized to this arm are treated with standard of care for patients with septic shock as described for 'Standard of care' arm, along with hemoperfusion with HA-330 Disposable Hemoperfusion Cartridge, as detailed under 'Interventions'
33075593|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
33075594|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
33075595|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
33075596|NCT00159497|Experimental|2|HA coated Trilogy cup
33075597|NCT00541177|Experimental|1|use 0.25% atropine once a week
33254779|NCT05590858||well-regulated diabetes|patients with diabetes and HbA1c ≤ 7%
33254780|NCT05590858||poorly regulated diabetes|patients with diabetes and HbA1c > 7%
33075598|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
33254781|NCT03704948|Experimental|Listening Visits|Listening Visits delivered by a nurse via zoom
33254782|NCT00799188|No Intervention|1|reduction of immunosuppression
33254783|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
33254784|NCT05590780||Control|Evaluation of plasma cfDNA levels
33254785|NCT05590780||Periodontitis|Evaluation of plasma cfDNA levels
33254786|NCT05590780||Cardiovascular disease|Evaluation of plasma cfDNA levels
33254787|NCT05590780||Periodontitis + cardiovascular disease|Evaluation of plasma cfDNA levels
33254788|NCT00799344||Stent|Catania Stent
33254789|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
33254790|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
33254791|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
33254792|NCT00794274|Experimental|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
33254793|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
33075599|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
33075600|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
33254794|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
33254795|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
33254796|NCT00799500|No Intervention|Observation|Usual care
33075601|NCT00541333|Active Comparator|Copaxone|
32769280|NCT04818983||ED-SCLC cohort|Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
33075602|NCT00541333|Sham Comparator|Sham|
33075603|NCT00541372|Experimental|1|Needle 5 mm
33075604|NCT00541372|Active Comparator|2|Needle length 8 mm
33075605|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
33075606|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
33075607|NCT03456973|Experimental|Nurse AMIE|
33075608|NCT00541489|Placebo Comparator|1|
32769281|NCT05034055|Experimental|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
33075609|NCT00541489|Active Comparator|2|Naproxen 500 mg
33075610|NCT00541489|Experimental|3|Naproxcinod 750 mg
33075611|NCT00190437|Experimental|1|Amoxicillin-clavulanic
33075612|NCT00159575|Experimental|M: Metformin P: Placebo|
33075613|NCT00541567|Placebo Comparator|1|
33075614|NCT00541567|Experimental|2|
33254797|NCT05590546||Obese|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
33075615|NCT00541567|Experimental|3|
33075616|NCT00541567|Experimental|4|
33075617|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
33075618|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
33075619|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
33075620|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
33075621|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
33075622|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
33075623|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
33075624|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
33075625|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
33075626|NCT00541918|Active Comparator|1|propofol
33254798|NCT05590546||Control|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
33254799|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
33254800|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
33254801|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
33254802|NCT04050020|Active Comparator|Group A|
33254803|NCT04050020|Placebo Comparator|Group B|
33254804|NCT05408104||tolvaptan (TLV)|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Eligible patients took tolvaptan 15 mg daily as part of a routine care treatment plan.
33254805|NCT05408104||no tolvapton (no-TLV)|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Eligible patients did not take tolvaptan as part of routine care.
33254806|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males ages 40 years or older~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
33254807|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~Individuals with family history of prostate cancer~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
33075627|NCT00541918|Experimental|2|sevoflurane
32731272|NCT05135793|Experimental|A test|Test drug (Topoprazan) 1 tablet contains 20 mg vonoprazan
32731273|NCT05135793|Active Comparator|B reference|Reference drug (Takecab) 1 tablets contains 20 mg vonoprazan
33254808|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
33254809|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
33254810|NCT04837716|Experimental|Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)|"INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33254811|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
32731274|NCT04841889|Other|Associated factors with decannulation|Collection of demographic, biological, ventilatory, respiratory and extra-respiratory parameters at the admission and the end of stay in the respiratory weaning center. Lung and diaphragm ultrasound, swallowing and muscles assessment will be performed.
32731275|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
32731276|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
32731277|NCT04568811|Experimental|Adenovirus Type-5 Vectored COVID-19 Vaccine|
32731278|NCT04503031|Active Comparator|cylindrical tube group|The patient in cylindrical tube group (n=26) were intubated with cylindrical shaped endotracheal tube.
32731279|NCT04503031|Experimental|tapergaurd tube group|The patient in taperguard tube group (n=26) was intubated with TaperGuard endotracheal tube.
32731280|NCT04806555|Experimental|Compression ultrasound|All recruited patients
32731281|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
32731282|NCT05135637||Kharotabad 1 - Intervention Union Council (UC)|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
32731283|NCT05135637||Ward 11 - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
32731284|NCT05135637||Bhana Mari - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
32731285|NCT05135637||Sheikh Junaidabad - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
32731286|NCT05135637||Bakhmal Ahmedzai - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
32731287|NCT05135637||Pahar Khel Thal|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
32731288|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
33075628|NCT00541957|Other|2|Medication prescribed by PCP
33075629|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
33075630|NCT00190515|Active Comparator|1|5-FU/l-LV
33075631|NCT00190515|Experimental|2|UFT/LV
33075632|NCT00542074|Experimental|1|
33075633|NCT00542074|Active Comparator|2|
33075634|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
33075635|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
33075636|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
32731289|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
33254812|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
33254813|NCT05360212|Placebo Comparator|Standard fitting|The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9
32731290|NCT04561713|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
32731291|NCT04561713|Sham Comparator|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
32731292|NCT04710979|Experimental|Yoga Intervention Group|
32731293|NCT04710979|No Intervention|Control Group|Control participants will receive no guidance from the research staff to change their behavior.
32731294|NCT04548063|Experimental|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
32731295|NCT04548063|Experimental|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
32731296|NCT04548063|Experimental|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
32731297|NCT04664257|Experimental|e-CBT|All e-CBT sessions will be administered through OPTT and will consist of approximately 30 slides per week. The content and format of each weekly online session will be designed to mirror in-person CBT for the treatment of BAD-II. Participants will complete the module and submit the assigned homework to their clinician through OPTT where the clinician will be able to provide personalized feedback. These pre-designed engaging and multimedia modules will be able to streamline the therapy process, helping care providers save time on repeating similar materials to all patients and focusing on delivering personalized feedback to each patient. The slides will highlight a different topic each week and include general information, an overview of skills, and homework that is to be completed within that week. All weekly sessions have an estimated completion time of 50 minutes. During the 12 weeks, both groups will continue with their TAU.
32731298|NCT04664257|No Intervention|Treatment as Usual|Participants will continue with treatment as usual and any lifestyle activities (diet, exercise, medication, etc.)
32731299|NCT05584501|Placebo Comparator|Dental Team|ETE activity implementation with existing Dental Team only (i.e. practitioners, dental assistants, hygienists)
33254814|NCT05360212|Experimental|Anatomy-based fitting|In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9
33254815|NCT05360212|Experimental|Within-subject design: Standard fitting + ABF|The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting.
32731300|NCT05584501|Active Comparator|Care Navigator|ETE activity implementation with additional Care Navigator resource
32731301|NCT04502953|Active Comparator|Vertical plication|Vertical plication of the rectovaginal septum was done
32731302|NCT04502953|Active Comparator|Horizontal plication|Horizontal plication of the rectovaginal septum was done
32731303|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
33075637|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
32731304|NCT04502875|Experimental|Treatment Arm|Intracavernosal infusion of Platelet Rich Plasma
32731305|NCT04502875|Active Comparator|Control Arm|Intracavernosal infusion of Platelet Poor Plasma
32731306|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
32731307|NCT04546971|Active Comparator|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
32731308|NCT04546971|Experimental|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
33075638|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
33277468|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
33277469|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
33075639|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
33075640|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
33075641|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
33075642|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
33075643|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
33075644|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
33075645|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
33075646|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
33075647|NCT00542737|Active Comparator|Early Intervention Group|
33075648|NCT00542737|Active Comparator|Delayed Intervention Group|
33075649|NCT00542776||1|IBD patients on immunosuppressive therapy
33075650|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
33075651|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
33075652|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
33075653|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
33075654|NCT00542932|No Intervention|I|
33075655|NCT00542932|Active Comparator|II|Exercise
33075656|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
33401211|NCT03633227|Experimental|Obeticholic Acid (OCA)|Participants will initiate treatment with OCA 5 milligrams (mg) tablets orally once weekly. At Week 12, if there are no safety concerns, the dose will be up-titrated to OCA 5 mg twice weekly. Every 6 weeks thereafter, based on tolerability assessments, further up-titration of dose will be considered. At each titration visit, the participants will start the higher dose regimen no earlier than 2 days after the prior dose. The maximum dose titration will be OCA 10 mg twice weekly at least 3 days apart. The minimum treatment duration will be 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
33401212|NCT03633227|Placebo Comparator|Placebo|Participants will receive OCA matching placebo orally once weekly or twice weekly for the duration of at least 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
32731309|NCT04502797|Experimental|Interventional: Electronic Patient Visit Assessment (ePVA)|Participants diagnosed with head and neck cancer randomized to Electronic Patient Visit Assessment intervention
33075657|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
33075658|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
33075659|NCT04685005|Experimental|Wake up|Drinking regular formula of Wake Up
33075660|NCT04685005|Active Comparator|Caffeine|Drinking 100mg of Caffeine
33075661|NCT04685005|Placebo Comparator|Placebo|Drinking Placebo (only water with sugar)
33075662|NCT04685005|Experimental|Wake up Double Dose|Drinking formula of Wake Up with double doses of guarana, green tea, elderberry and Fruit-up
33075663|NCT04685005|Experimental|Wake up tripple dose|Drinking formula of Wake Up with tripple doses of guarana, green tea, elderberry and Fruit-up
33075664|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
33075665|NCT04684966|Experimental|Experimental group (EG)|"Randomized intervention in the NMES (GE) group:~Patients in the NMES group will receive, in addition to conventional rehabilitation, combined quadriceps femoris and triceps surae NMES.~Detail of the NMES :~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (possibility of 16 electrodes).~One device per lower limb of each patient is necessary: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 50hz.~Pulse duration: 400 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscular contraction and must be well supported. by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
33075666|NCT04684966|Sham Comparator|Control group (CG)|"Patients in the control group (GC) will receive, in addition to the classical rehabilitation, the combined sham NMES of the quadriceps femoris and triceps surae.~Detail of the NMES :~It is carried out 5 times a week for 4 weeks, supervised by a physiotherapist.~The device used will be the same as in the EG group.~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (16 electrodes can be used).~One device per lower limb of each patient is required: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 5hz.~Pulse duration: 100 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscle contraction and must be well supported by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
33254816|NCT04894396|Experimental|Prefabricated Orthotics with metatarsal pad|Participants in Group A will receive the Orthotic with the metatarsal pad (L 2305) according to participants shoe size (https://www.aetrex.com/search?q=l2305&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities.
33075667|NCT04684732||Apixaban dose concordant to leaflet|Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
33254817|NCT04894396|Active Comparator|Prefabricated Orthotics without metatarsal pad.|Participants in Group B will receive the neutral Orthotic with a cupped heel (L 2300) according to participants shoe size (https://www.aetrex.com/search?q=l2300&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the Orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities
33254818|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
33254819|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
33254820|NCT05407870|Active Comparator|Propofol|induction - 0.5mg/kg Propofol maintenance - 0.25mg/kg Propofol
33254821|NCT05407870|Experimental|Etomidate|induction - 0.25mg/kg Propofol + 0.05mg/kg Etomidate maintenance - 0.05mg/kg Etomidate
33401213|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
33254822|NCT03988231|Active Comparator|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
33254823|NCT03988231|Placebo Comparator|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
32769282|NCT05617703|Experimental|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|"Glass Hybrid restorative systems in the clinical point of view are self-cure bulk fill materials laminated with a nano-filled, self-adhesive resin coat.~Nowadays, a new glass hybrid innovation called Advanced Glass Hybrid technology was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using prefractive indexes."
33254824|NCT00794742||Burn Wounds|Patients with burn wounds
33254825|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
33254826|NCT05407636|Experimental|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
33254827|NCT05407636|Experimental|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
32769283|NCT05617703|Active Comparator|Resin Modified Glass Ionomer (Fugi II LC, GC, Japan).|
33075668|NCT04684732||Apixaban dose discordant to leaflet|Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
33254828|NCT05407636|Active Comparator|Control Arm|Aflibercept administered via intravitreal injection approximately every 8 weeks
33254829|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
33254830|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
33254831|NCT05407402|Experimental|laughter yoga|laughter yoga
33254832|NCT05407402|Experimental|funny videos,|funny videos,
33254833|NCT05407402|No Intervention|control|control group. routine nursing care will be applied.
33254834|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
33254835|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
33254836|NCT05407246|Active Comparator|Hemay005 75mg BID group|75mg BID of Hemay005; daily oral administrtion for 16 weeks
33254837|NCT05407246|Active Comparator|Hemay005 60mg BID group|60mg BID of Hemay005; daily oral administrtion for 16 weeks
33254838|NCT05407246|Placebo Comparator|placebo group|Placebo of Hemay005; daily oral administrtion for 16 weeks
33254839|NCT00799890|Experimental|Sunphenon|
33254840|NCT00799890|Placebo Comparator|Placebo|
33254841|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
33254842|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
33254843|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
33254844|NCT05358340|Experimental|Diagnostic (DSC MRI)|
33254845|NCT00799968|Active Comparator|Group 1|UK-12h group
33254846|NCT00799968|Experimental|Group 2|UK-2h group
33254847|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
33254848|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
33254849|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
33277470|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
33254850|NCT05590312||Low Flow Group - Group D|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 1 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
33254851|NCT05590312||High Flow Group - Group Y|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 4 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
33075669|NCT04684888|Active Comparator|Visumax Femto-flap|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. Refractive surgery was planned for both eyes and they chose the Visumax Femto-LASIK after a complete explanation of all the possible complications, costs, and differences. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
33254852|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
33254853|NCT04002544|Active Comparator|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
33254854|NCT04002544|Placebo Comparator|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
32731310|NCT04502797|No Intervention|Usual care|Participants diagnosed with head and neck cancer randomized to usual care.
32731311|NCT04541121|Experimental|3D printed model|Mother is given 3D printed model of fetus' face
32731312|NCT04541121|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
32731313|NCT05584345|Active Comparator|CONTROL|Traditional physiotherapy applications will be applied.
32731314|NCT05584345|Experimental|MULLIGAN MOBILIZATION GROUP|In addition to traditional physiotherapy applications, mulligan mobilization wiil be applied.
33254855|NCT04829214|Experimental|OTO-313|
32731315|NCT05584345|Experimental|MULLIGAN MOBILIZATION AND RESPIRATORY EXERCISES GROUP|In addition to traditional physiotherapy and mulligan mobilization applications, respiratory exercises wiil be applied.
32731316|NCT04316481|Other|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
32731317|NCT04506229||COVID-19 positive|
32731318|NCT04506229||COVID-19 negative|
32731319|NCT04804839|Experimental|First research arm (Combined group)|Combined group with 8 weeks of pelvic floor muscle training, knack maneuver and lifestyle recommendations.
32731320|NCT04804839|Experimental|Second research arm [PFMT (including knack maneuver) group]|Only 8-week PFMT (including knack maneuver)
32731321|NCT04804839|Active Comparator|Third research arm (PFMT alone group)|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
33254856|NCT04829214|Placebo Comparator|Placebo|
33254857|NCT04690348|Active Comparator|Resection without brachytherapy|Patients will undergo craniotomy.
33254858|NCT04690348|Experimental|Resection plus brachytherapy|Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
33254859|NCT00802230|Active Comparator|1|Carvedilol IR
33254860|NCT00802230|Active Comparator|2|Metoprolol Succinate
33254861|NCT04650256|Experimental|CAM arm|Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.
33254862|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
33254863|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
33254864|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
33254865|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
33254866|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
32731322|NCT04582357|Experimental|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
32731323|NCT04800393|Experimental|Inhalation anesthesia|
32731324|NCT04800393|Active Comparator|Total intravenous anesthesia|
33254867|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
33254868|NCT05358496||NAFLD cohort|
33254869|NCT05358496||Validation cohort|
33254870|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
33254871|NCT05407090|Experimental|Probiotic|Patients will take 4 capsules of a multi-strain probiotic preparation daily. Product characteristics: 1 capsule of the preparation contains ≥2.5 x 10^9 CFU / g of live bacteria (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidillum W23)
33254872|NCT05407090|Placebo Comparator|Placebo|Patients will take 4 capsules of a placebo preparation daily.
33254873|NCT05406934||healthy group|the healthy group, not diagnosed IBD
33254874|NCT05406934||IBD patients controlled by conventional treatment|controlled by conventional treatment and divided to UC group and Crohns group
33254875|NCT05406934||uncontrolled IBD patients on biological's treatment|divided to uc received biological and Crohns received biolgical
33254876|NCT00800124|No Intervention|1|Cemented hemiprosthesis
33254877|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
33254878|NCT04610788||SSc-PAH Group|Scleroderma patients referred for a clinically indicated right heart catheterization (RHC).
33254879|NCT04610788||IPAH Group|Presumed/known IPAH patients referred for a clinically indicated right heart catheterization (RHC).
33254880|NCT00940329|Active Comparator|Treatment A|
33254881|NCT00940329|Active Comparator|Treatment B|
33254882|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
33254883|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
33254884|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
33254885|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
33254886|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
33254887|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
33254888|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
33254889|NCT00934557|Experimental|Good prognosis/matched donor/BM|
33254890|NCT00934557|Experimental|Good prognosis/matched donor/PB|
33254891|NCT05357092|Experimental|Intervention group|"Patients treated with clear aligners to bring cleft segments closer previous to primary lip surgery.~An average of 15 aligners will be needed although it depends on the cleft."
33254892|NCT05357092|No Intervention|Gold Standard|The reference therapeutic action (no pre-surgical orthopedic intervention previous to primary lip surgery)
33082240|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
33254893|NCT00800280|Experimental|Single dose PD 0332334|
33254894|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
33254895|NCT04014153||Group 1 (5-year prognosis)|
33254896|NCT04014153||Group 2 (1-year prognosis)|
33254897|NCT04996576|Active Comparator|intranasal injection approach sphinopalatine ganglion block|Then in one nasal side (intranasal injection group) will be chosen randomly (right or left) by closed envelopes method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia and 2 ml saline will be injected in the same place in the other nasal side (to prevent surgeon expectation of intra nasal group by seeing injection site in one side only) by surgeon assistant who will be blind for the injection content.
33254898|NCT04996576|Active Comparator|infrazygomatic approach sphinopalatine ganglion block|"In the side saline only given by the intranasal injection A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
33254899|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
33254900|NCT00800358|Active Comparator|2|Calcitriol
33254901|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
33254902|NCT05358262|Experimental|Intervention using the Airvo device|Patients randomized to this group will receive the standard of care as well as wear the Airvo (equipment to provide high heated humidity) starting on Day 0 of their transplant for a minimum of 4 hours a day (to be worn in one continuous block of time). The humidity is delivered by nasal cannula that goes into your nose, similar to wearing oxygen. The equipment stands on a pole and plugs into a power outlet. Patients may take off the equipment for short periods of time. Eg to go to the bathroom.
33254903|NCT05358262|No Intervention|Standard of Care|"Patients randomized into this group will receive the usual standard of care for mucositis.~The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes."
33254904|NCT00934869||Metacarpal Shaft Fractures|
33254905|NCT00802698|Experimental|Group 1|
33254906|NCT00935025|Experimental|1, AZD1305|
33254907|NCT00935025|Placebo Comparator|2, Placebo|
33254908|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
33254909|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
33254910|NCT00939861|Experimental|1|laparoscopy
33254911|NCT00939861|Experimental|2|laparotomy
33254912|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
33254913|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
33254914|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
33254915|NCT00935103|No Intervention|Control|The control group will not take any intervention
33254916|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
33254917|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
33254918|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
33254919|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
33075670|NCT04684888|Active Comparator|Sub Bowman's keratomileusis (SBK )-Flap group|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. They chose LASIK with mechanical SBK microkeratome surgical approach to be their refractive surgery for both eyes after all the possible complications, costs and differences had been explained clearly. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
33075671|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
33254920|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
33254921|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
33254922|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
33254923|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
33075672|NCT03456739||suppurative otitis media with effusion|
33075673|NCT03456739||non suppurative otitis media with effusion|
33254924|NCT00794976|Experimental|3|Dexamethasone Passive Patch
33254925|NCT00794976|Placebo Comparator|4|Placebo Patch
33075674|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
33075675|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
33075676|NCT05079295||Group 1|Patients taking anticoagulants or antithrombotics
33075677|NCT05079295||Group 2|Controls
33075678|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
33075679|NCT00184119|Active Comparator|Whole acute unit|
33075680|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
33254926|NCT00939939|Experimental|sitagliptin|
33254927|NCT00939939|Active Comparator|glimepirid|
33075681|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
33075682|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
33075683|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
32731325|NCT05584189|Experimental|At least 30 persons 14-65+ years of age who test themselves|Participants between the ages of 14-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection and testing under the supervision of qualified site personnel in person.
33075684|NCT05075005|Active Comparator|Treatment Cohort|Treatment Cohort: Will utilize a minimalist shoe (Vibram® Fivefingers) and follow the training protocol described below for training on natural terrain.
33075685|NCT05075005|Experimental|Control Cohort|Control Cohort: Will utilize the same minimalist shoe and follow the same training schedule as the treatment group, with the modification of training on hardscapes.
33075686|NCT00159926|Experimental|1|With cell saver
33075687|NCT00159926|Active Comparator|2|Without cell saver
33075688|NCT00543634|Active Comparator|1|
33254928|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
33254929|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
33254930|NCT00537082|Placebo Comparator|Placebo|
33254931|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
33254932|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
33254933|NCT04012983||diabetic patients with periodontitis|
33254934|NCT04012983||periodontitis patients|
33254935|NCT04012983||healthy control|
33254936|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
33254937|NCT03988153|Experimental|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
33254938|NCT03988153|Placebo Comparator|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
33254939|NCT04014309|Experimental|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
33254940|NCT04014309|Placebo Comparator|Usual care|No routine distress screening will be performed.
32769284|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
33254941|NCT04978012|Experimental|Combination of Fluzoparib and Camrelizumab|Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w
33254942|NCT00803088|Experimental|1|Treatment of airways with the Alair System
33254943|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
33254944|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
33254945|NCT00803166||Cohort Group 1|Subjects number 1 to 30
33254946|NCT00803166||Cohort Group 2|Subjects number 31 to 60
33254947|NCT04578574|Experimental|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
33254948|NCT04578574|Sham Comparator|BI-TDCS (Sham) Stimulation Group|Participants in this group will receive the BI and TDCS (Sham) interventions for 10 sessions over two weeks.
33075689|NCT00543634|Active Comparator|2|
33254949|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
33254950|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
33254951|NCT04855422||Stable SPK recipients without rejection and/or BKV viremia|All SPK transplant recipients are monitored for routine labs twice a week first month, weekly at 2nd and 3rd month, every 2 weeks between 3-6 months, once a month between 6-12 months and then once every 2 months.
33254952|NCT04855422||Acute T-Cell Mediated Rejection (TCMR )|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
33254953|NCT04855422||Antibody Medicated Rejection (ABMR)|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
33254954|NCT04855422||BKV viremia|All patients will be monitored for BKV viremia monthly after transplantation up to 6 months and at 9, 12 and 24 months. Luminex SAB will be monitored at 1, 3, 12 and 24 months. Spot urine protein and creatinine and HbA1c will be monitored every 3 months after transplantation
33075690|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
33075691|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
33075692|NCT00543673|Other|Reference|Human milk
33254955|NCT04855422||Follow-up of subjects with acute TCMR, ABMR and BKV viremia after treatment|BKV viremia, Luminex SAB, spot urine protein and creatinine is studied at the time clinically indicated biopsy and/o worsening kidney function and proteinuria.
33254956|NCT04002232|Experimental|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
33075693|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
33075694|NCT00184197|Experimental|Botox|
33075695|NCT00184197|Placebo Comparator|placebo|
33075696|NCT00543790|Experimental|1|
33075697|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
32731326|NCT05584189|Experimental|At least 30 persons 18-65+ years of age who test another participant|Participants between the ages of 18-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection on another participant aged 2-65+ years and testing of the candidate Ag self-test kit under the supervision of qualified site personnel in person.
33075698|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
33075699|NCT00160043|Experimental|Arm 1|
33075700|NCT00160043|Experimental|Arm 2|
33075701|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
33075702|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
33075703|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
33075704|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
33075705|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
33254957|NCT04002232|Placebo Comparator|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
33254958|NCT04013451|Experimental|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
33254959|NCT04013451|No Intervention|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
33254960|NCT04846140|Experimental|tDCS group|This group is defined as the participants who will receive tDCS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
33075706|NCT04684927|Experimental|MID-C treatment|Follow-up measurements during 5 years post MIC-C system implantationin order to evaluate safety and efficacy parameters.
33075707|NCT00544219|Other|R-Chop 14|Standard treatment
33075708|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
33075709|NCT00544336||Supportive|
33075710|NCT04685083||Patients with Depression in consolidation phase|
33075711|NCT04685083||Patients with Depression in acute onset|
33075712|NCT04685083||Healthy subjects|
33254961|NCT04846140|Experimental|tACS group|This group is defined as the participants who will receive tACS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
33254962|NCT04846140|Experimental|tRNS group|This group is defined as the participants who will receive tRNS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
33075713|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
33075714|NCT00544492|Experimental|A1|Buttonhole cannulation technique
33254963|NCT04846140|Experimental|sham group|This group is defined as the participants who will receive sham stimulation at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
33254964|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
33254965|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
33075715|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
32769285|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
33075716|NCT00544492|Experimental|B1|Catheter with bevel point
33075717|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
33075718|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
33254966|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
33254967|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
33254968|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
33075719|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
33254969|NCT00941109|Experimental|1|
32769286|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
32769287|NCT04829201||Obstructive sleep apnea (OSA)|OSA patients who are eligible for either functional septorhinoplasty or oropharyngeal/orthognathic surgery
32769288|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
32769289|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
33254970|NCT00941109|Experimental|2|
33254971|NCT00941109|Experimental|3|
33254972|NCT00941109|Experimental|4|
33254973|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
33254974|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
33254975|NCT00935415|Placebo Comparator|Placebo|matched placebo
33254976|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
32769290|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
33254977|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
32769291|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
32769292|NCT05042245|Experimental|ornithine aspartate granule group|Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).
33075720|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
33254978|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
33254979|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
33254980|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
33254981|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
33254982|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
33254983|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
33254984|NCT04045782|Other|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
33254985|NCT02553720|Experimental|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
33254986|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
33254987|NCT00935727|Other|1|normally functioning transplanted kidneys
33254988|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
33254989|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
33254990|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
33254991|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
33254992|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
33075721|NCT00544687|Active Comparator|3|0.1% mometasone furoate
33075722|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
33075723|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
33075724|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
33075725|NCT00544726|Active Comparator|1|Physical training
33075726|NCT00544726|Placebo Comparator|2|No physical training
33075727|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
33075728|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
33254993|NCT03983239|Experimental|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
32769293|NCT05042245|Active Comparator|silymarin capsule group|Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .
32769294|NCT04427657|Active Comparator|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
33254994|NCT03983239|Experimental|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
33254995|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
33254996|NCT03986125|Experimental|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
33254997|NCT03986125|Experimental|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
33254998|NCT03986125|No Intervention|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
33254999|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
33255000|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
33255001|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
33255002|NCT01055431|Placebo Comparator|Control|Control bread
33075729|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
33075730|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
33255003|NCT01055431|Active Comparator|Teff bread|Teff bread
33255004|NCT00936039|Experimental|unloading|2 weeks of unloading
33255005|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
33277471|NCT04002440|Active Comparator|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
33277472|NCT04002440|Placebo Comparator|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
33075731|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
33277473|NCT05294939|Experimental|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
33277474|NCT05294939|Placebo Comparator|Control product|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
33277475|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
33277476|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
33277477|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
33277478|NCT05267132|Experimental|Kindness to Others with Reflection|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others and will also complete a reflection component. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day. At the end of each intervention week, they will be asked to reflect upon their experience of performing kind acts for others.
33277479|NCT05267132|Active Comparator|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
33277480|NCT05267132|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
33277481|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
33075732|NCT00544921|Experimental|50 mg|
33075733|NCT00544921|Experimental|100 mg|
33075734|NCT00544921|Experimental|250 mg|
33075735|NCT00544921|Experimental|500 mg|
33277482|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
33255006|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
33075736|NCT00544921|Experimental|750 mg|
33075737|NCT00544921|Experimental|1000 mg|
33075738|NCT00544921|Placebo Comparator|Placebo|
33075739|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
33075740|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
33255007|NCT00936195|Active Comparator|Atripla (R)|
33255008|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
33075741|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
33075742|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
33075743|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
33075744|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
33255009|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
33255010|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
33255011|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
33255012|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
32731327|NCT04785573|Active Comparator|Intervention group|Participants with metabolic disorders will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
32731328|NCT04785573|No Intervention|Control group|Participants with metabolic disorders will be subjected to nutritional counsel for a total of 3 months.
32743067|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP + Call + MesC [1 week]|"For participants in Part II: Stage 1- MP [1 week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to have MP and additional coach support for another 1 week. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
33075745|NCT04684771|Active Comparator|MYOSTIM®|MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
33075746|NCT04684771|Placebo Comparator|PLACEBO|PLACEBO 2 bars/day during 12 weeks
33075747|NCT00160316|Experimental|1|
33075748|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
33277483|NCT05356286|Experimental|Electrical Stimulation group|Epidural Electrical Stimulation of the Cervical Spinal Cord
33075749|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
33075750|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
33075751|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
33075752|NCT03456466|Experimental|TQB2303|
33075753|NCT03456466|Active Comparator|Rituximab|
33075754|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
33075755|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
33075756|NCT03456349|Experimental|Low dose|HTL0018318
33075757|NCT03456349|Experimental|Medium dose|HTL0018318
33075758|NCT03456349|Experimental|High dose|HTL0018318
33075759|NCT03456349|Placebo Comparator|Placebo|Placebo
33075760|NCT00160355|Other|1|
33075761|NCT00184353||brain metastases|6 patients
33075762|NCT00184353||healthy|13 volunteers
33075763|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
33075764|NCT00545311|Experimental|1|NVA237
33075765|NCT00545311|Experimental|2|NVA237
33075766|NCT00545311|Experimental|3|NVA237
33075767|NCT00545311|Experimental|4|NVA237
33075768|NCT00545311|Placebo Comparator|5|Placebo
33075769|NCT00545350|No Intervention|1|Usual activity / care
33075770|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
33075771|NCT04684693|Experimental|Laser Group|
33075772|NCT04684693|Active Comparator|Control Group|
33075773|NCT00545428|Experimental|1|Rhinoplasty
33255013|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
33075774|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
33075775|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
33255014|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
33255015|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
33255016|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
33255017|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
33255018|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
33255019|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
33255020|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
33255021|NCT00936507|Experimental|Low-ED, small portion|
33255022|NCT00936507|Experimental|Low-ED, large portion|
33255023|NCT00936507|Experimental|High-ED, small portion|
33255024|NCT00936507|Experimental|High-ED, large portion|
33255025|NCT00352417|Experimental|VIA-2291|
33255026|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
33075776|NCT00160433|Experimental|1|
33075777|NCT00160433|Experimental|2|
33075778|NCT00160433|Experimental|3|
33075779|NCT00160433|Placebo Comparator|4|
33255027|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
33401214|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
33401215|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
33075780|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
33075781|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
33255028|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
33255029|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
33075782|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
33255030|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
33075783|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
33075784|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
33075785|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
33075786|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
33075787|NCT00545701|Experimental|1|
33075788|NCT00545857|Experimental|Pioglitazone|
33075789|NCT00545857|Placebo Comparator|Placebo control|
33075790|NCT00184431|Experimental|A|Intensive task specific balance training
33075791|NCT00184431|Active Comparator|B|Traditional physical therapy
33075792|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
33075793|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
33075794|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
33401216|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
33075796|NCT05057260||Long Covid cohort|Long Covid patients managed in the 10 participating sites
33255031|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
33255032|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
33255033|NCT00805896|Experimental|1|Songyou Granule
33255034|NCT00805896|Placebo Comparator|2|
33255035|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
33255036|NCT05434832|Experimental|Virtual Reality Group|watching the cartoon by wearing virtual reality glass to the child during the intramuscular injection
33255037|NCT05434832|Experimental|Local cold-vibration Group|The local cold-vibration device is placed 5 cm above the area to be injected
33255038|NCT05434832|No Intervention|Control Group|standart care
33075797|NCT05047237|No Intervention|Control|Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.
33255039|NCT01057927|Experimental|OC000459|
33255040|NCT01057927|Placebo Comparator|Placebo|
33255041|NCT01058083|Experimental|BMS-770767 (Treatment A)|
33255042|NCT01058083|Experimental|BMS-770767 (Treatment B)|
33075798|NCT05047237|No Intervention|Active Decliners|Subjects who decline intervention. Standard of care treatment with month 6 follow up.
33075799|NCT05047237|Experimental|Active Intervention|Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face [F2F] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.
33075800|NCT05047042|Experimental|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The intervention will take place in participants' homes, at times convenient for the participant. Programming will be administered virtually through the University of Alberta's Cancer Rehabilitation Clinic, which is fully equipped for virtual delivery of services. The study intervention will be tailored to the individual with respect to their baseline strength, symptom profile and prior experience with exercise. Pre- and post-testing will be done virtually. The mode, intensity and duration of each exercise session will be based on the participant's baseline fitness and status that day. Variations on each exercise will be provided to ensure an appropriate movement and intensity and to allow for individual prescription. Resistance bands will be used to provide resistance during strengthening and balance retraining exercises. The interactive group class will be led virtually by an exercise or rehabilitation specialist.
33075801|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
33075802|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
33255043|NCT01058083|Experimental|BMS-770767 (Treatment C)|
33075803|NCT00546169||A|
33255044|NCT01058083|Experimental|BMS-770767 (Treatment D)|
33255045|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
33255046|NCT05434676|Experimental|IVL group|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 or S4
33255047|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
33255048|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
33255049|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
33255050|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
33255051|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
33255052|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
33255053|NCT00944775|Experimental|exercise training|10-month exercise training program
33255054|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
33401217|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
33401218|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
33401219|NCT03297372|Experimental|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
33401220|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
33401221|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
33401222|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
33401223|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
33401224|NCT02913326|Experimental|Dabigatran etexilate|
33401225|NCT02913326|Active Comparator|Warfarin|
33401226|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
33401227|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
33401228|NCT04055948|No Intervention|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
33255055|NCT03988075|Active Comparator|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
33255056|NCT03988075|Experimental|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
33255057|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
33255058|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
33255059|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
33255060|NCT03987997|Active Comparator|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
33255061|NCT03987997|Other|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
33255062|NCT03985891|Experimental|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
33255063|NCT03985891|Active Comparator|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
33255064|NCT00350779|Experimental|1|Sitagliptin
33255065|NCT00350779|Placebo Comparator|2|Placebo
33255066|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
33255067|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
33255068|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
33255069|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
33255070|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
33255071|NCT00676520||1|Single-arm study
33255072|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
33255073|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
33255074|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
33255075|NCT05434520||Preoperative biliary drainage|Patients who had undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
33255076|NCT05434520||No preoperative biliary drainage|Patients who had not undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
33255077|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
33255078|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
33255079|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
33255080|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
33255081|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
33255082|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
33255083|NCT05427266|Other|Study Group - Tap Block|"Study Group: Study group: Laparoscopic Transversus Abdominis Plane in four points: above and below the umbilicus in both right and left sides; dose calculation 2.5mg per body weight.~After the appendicectomy is done and just before withdrawing port and deflating the abdomen, the operating surgeon will advance a needle into the abdominal wall to the level of the preperitoneal space. Once the needle tip is seen, it is withdrawn slowly and gently about 0.5cm above/superficial to the transversus abdominis (TA) muscle. The surgeon then infiltrates the local anaesthetic into the plane, and the right plane is confirmed by visualising a uniform protrusion downwards of the TA muscle fibres (Doyle's bulge). Seeing a preperitoneal or muscle blister laparoscopically indicates that the infiltration is deeper to this plane, and the needle should be withdrawn more superficially."
33255084|NCT05427266|Other|Control Group - Standard port site infiltration|Patients will be randomised after diagnosis either clinically or radiologically of appendicitis (both complicated and uncomplicated) Control Group _ standard port site infiltration using 0.25% plain bupivacaine. The dose is calculated to 2.5mg/per kg body weight. After the appendicectomy is done, after removal of ports and deflating the abdomen, the total calculated dose volume will be infiltrated into the subcutaneous plane at the umbilicus and the other 2 ports sites
33277484|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
33075804|NCT04684342|Experimental|cirrhotic ICU Patients|about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
33075805|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
33075806|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
33075807|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
33075808|NCT00546325|Experimental|1|Rimonabant
33075809|NCT00546325|Placebo Comparator|2|Placebo
32731329|NCT04536519|Active Comparator|Lateral Heel Wedged Insole Alone with physical therapy|"the lateral heel wedged insole (19) comprised non-custom, high density based on insoles of ethyl-vinyl acetate distributed bilaterally, preferably, covered in leather, were used in the study. The insole were equipped with a lateral wedge of 50 to 60.~In the case of unilateral knee osteoarthritis, the non-wedge insole were used to compensate for possible leg length discrepancy in the contra-lateral leg. Shoes used was based on gymnast type to keep wedge insole in place. This further finalized individual to individual with unanimous decisions of Cordwainers, orthotics, and principal researcher, physiotherapist."
32731330|NCT04536519|Active Comparator|Lateral aand medial Heel Wedged Insole with physiotherapy|medial arch support part were combine with aforementioned lateral heel wedged support, full length support. There is a debate, however, 4 to 6 mm of full length support is considered to be effective for required alteration in mechanics
32731331|NCT04505995|Experimental|Intervention group|
32731332|NCT04486911|Experimental|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
33075810|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
32731333|NCT05135247|Experimental|continuous aerobic training (CA)|The CA group was trained with 70% of maximum heart rate (MHR) for 30 minutes.
32731334|NCT05135247|Experimental|resistance training (R)|The R sessions consisted of a set of each proposed exercise: sitting bench press, legpress, back row, leg extension, shoulders high pull, seated leg curl, biceps curls, standing calf, triceps in the pulley, and abdominal crunches, with 8 - 10 repetitions with 75% 1MR.
32731335|NCT05135247|Experimental|interval aerobic training (IA)|The IA group was submitted to exercise intensities of 60% for 2 minutes and 80% for 2 minutes, alternately, with a total of 30 minutes.
32731336|NCT05135247|No Intervention|control (C)|Individuals in the control group maintained their usual activities.
32731337|NCT04526977||Cases|HIV-1 infected individuals with previous or current diagnosis of SARS-CoV-2 infection, defined as the presence of suggestive symptoms and a positive PCR from the nasopharyngeal swab.
32731338|NCT04526977||Controls|HIV-1-infected individuals of the same age (range, 5 years) and sex, who not have been diagnosed of clinical (asymptomatic) or confirmed SARS CoV-2 infection, but were positive for IgG antibodies (controls group 1) or with no evidence of SARS-CoV-2 infection (no previous neither current symptoms, negative for IgM/IgG antibodies, controls group 2)
32731339|NCT04526067|Active Comparator|Cognitive Adaptation Training (CAT)|A home delivered adherence intervention used by managed care used to improve outcomes across multiple conditions.
32731340|NCT04526067|Active Comparator|Remote Cognitive Adaptation Training (R-CAT)|A primarily remotely delivered workable adherence intervention used by managed care used to improve outcomes across multiple conditions.
32731341|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
32731342|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
32731343|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
32731344|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
32731345|NCT04779957|Experimental|Tocilizumab|Evaluation of the use of Tocilizumab after allograft nephrectomy.
32731346|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
33075811|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
33075812|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
33255085|NCT04793334||Obese + OSA|"Inclusion Criteria:~Men and women~Ages >= 30-65 years old~BMI 35-40 kg/m2~Scheduled for sleeve gastrectomy (bariatric surgery)~OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
33255086|NCT04793334||Obese without OSA|"Inclusion Criteria:~Men and women~Ages >= 30-65 years old~BMI 35-40 kg/m2~Scheduled for sleeve gastrectomy (bariatric surgery)~No OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
33255087|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
32731347|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
32731348|NCT05135013||Cases|1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
32731349|NCT05135013||Matched Controls|2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
32731350|NCT04522713|Experimental|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
32731351|NCT02518243|Experimental|Alzheimer's Disease|
32731352|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
32731353|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
32731354|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
32731355|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
32731356|NCT04505917|Experimental|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
32731357|NCT04505917|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
32731358|NCT04505917|Placebo Comparator|placebo|Placebo Comparator: placebo 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
32935093|NCT05420714|Experimental|Professional CGM Trial|Participants will be asked to wear Dexcom Professional Continuous Glucose Monitoring (Pro-CGM) Device for 10 days. They will have 2 clinic visits with a certified diabetes care and education specialist (CDCES): initial visit for placement of the Pro-CGM and final visit to review the data with CDCES and their diabetes clinic provider. They will be asked to complete a short survey at the end of the 10 days about their experience using the Pro-CGM device and how it impacts their diabetes self-care practices.
32731359|NCT04412967|Active Comparator|Standard Technique PVC placement|Standard PVC placement technique
32731360|NCT04412967|Experimental|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
32731361|NCT04234971|Experimental|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
32731362|NCT04234971|Active Comparator|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
32731363|NCT04495959||68Ga-HTK03149 PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
32731364|NCT04505761|Experimental|Intervention group|Participants will receive Virtual Reality as an add-on to standard physiotherapy after COVID-19.
32731365|NCT04185909|Experimental|All Subjects|Subjects will be treated with the Renuvion Dermal System.
32731366|NCT04505683|Experimental|test drug arm|Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
32731367|NCT04505683|Active Comparator|active control arm|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
33255088|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
32731368|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
32731369|NCT05580055||Capillary Sample|This group donates finger prick blood samples to Entia for the purpose of development.
32731370|NCT05580055||Venous Sample|This group donates venous blood samples to Enta, taken by a registered nurse.
32731371|NCT05576155|Experimental|Local losartan perfusion|~1 hour of losartan is perfused through an intradermal microdialysis fiber
32731372|NCT05576155|Other|Local lactated Ringer's (control) perfusion|~1 hour of lactated Ringer's is perfused through an intradermal microdialysis fiber
32731373|NCT04505215|Experimental|Mulligan Technique|In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
32731374|NCT04505215|Experimental|Muscle Energy Technique|In addition to the exercises applied to the participants in the control group, the Janda method (Post Isometric Relaxation Technique) from Muscle Energy Technique (3 times a week) was used 3 times a week for 4 weeks.
32731375|NCT04505215|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the forearm extensors were shown to the participants in the control group for 4 weeks every day of the week.
32731376|NCT04443855|Active Comparator|Water quality|90 clusters, approx. 720 newborns
32731377|NCT04443855|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
32731378|NCT04443855|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
32731379|NCT04443855|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
32731380|NCT04443855|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
32731381|NCT04443855|Active Comparator|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
32731382|NCT04443855|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
32731383|NCT04443127|Experimental|Game-Based Rehabilitation|
32731384|NCT04443127|Placebo Comparator|Conventional Rehabilitation|
32731385|NCT04501783|Experimental|TL-FVP-t (favipiravir) Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.
32731386|NCT04501783|Active Comparator|Standard of Care Arm|Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days
33255089|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
33255090|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
33255091|NCT01058161|Other|Healthy control|
33255092|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
33255093|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
32731387|NCT04440735|Experimental|DSP107 monotherapy in advanced solid tumors|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
33255094|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
33255095|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
33255096|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
33255097|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
33255098|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
33255099|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
33255100|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
32731388|NCT04440735|Experimental|DSP107 in combination with atezolizumab in advanced solid tumors|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
32731389|NCT04440735|Experimental|DSP107 in combination with atezolizumab in non-small cell lung cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
32731390|NCT04440735|Experimental|DSP107 monotherapy in colorectal cancer|DSP107 10mg/kg will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles..
32935094|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
32935095|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
32935096|NCT05419154|Experimental|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
32935097|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
32935098|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
32935099|NCT05418920|Experimental|the trial group (left-opening single-flap group)|left-opening single-flap group
33255101|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
32769295|NCT04427657|Experimental|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
33255102|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
33255103|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
33255104|NCT00803868|Experimental|1|Varenicline
33255105|NCT00803868|Placebo Comparator|2|Placebo
33255106|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
33255107|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
33255108|NCT04504708|Experimental|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
33255109|NCT04504708|Experimental|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
33255110|NCT04504708|Experimental|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
33255111|NCT04504708|Experimental|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
33255112|NCT04504708|Experimental|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
33255113|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
32769296|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
32769297|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
33255114|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
33255115|NCT00655980|Other|Standard of care|standard of care
33255116|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
33255117|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
33255118|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
33255119|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
33255120|NCT04491136|Experimental|ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months|"Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months~Angiotensin receptor neprilysin inhibitor treatment in next 6 months"
33255121|NCT01063621|Experimental|KW-6500|
33255122|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
33255123|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
33255124|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
33255125|NCT05589454|Experimental|High-dose atorvastatin|atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study
33255126|NCT05589454|Active Comparator|Low-dose atorvastatin|atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study
33255127|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
33255128|NCT00803946|Active Comparator|Test Product|
33255129|NCT00803946|Active Comparator|Reference Product|
33255130|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
33255131|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
33255132|NCT04874818||lymphopenia|lymphocyte counts (<1.0 x10e9/L)
33255133|NCT04874818||normal lymphocyte numbers|lymphocyte counts ((1.0 - 3.5 x10e9/L))
33255134|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
33255135|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
33255136|NCT04317820|Experimental|DBR Condition|Involves 8 weekly sessions of DBR treatment.
33255137|NCT04317820|No Intervention|Wait-list Condition|No intervention for approximately 8 weeks.
33255138|NCT00804024||ClearWay™ RX|
33255139|NCT00809874|Active Comparator|Casein|
33255140|NCT00809874|Active Comparator|Whey Isolate|
33255141|NCT00809874|Active Comparator|Whey Hydrolysate|
33255142|NCT00809874|Active Comparator|Alphalact-Albumin|
33255143|NCT00809952||Recombinat FSH|
33255144|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
32769298|NCT03095209||Standard of care concurrent chemo-radiation therapy|
33255145|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
33255146|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
33255147|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
33255148|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
33255149|NCT00676052|Placebo Comparator|Arm 6|Placebo
33255150|NCT03011372|Experimental|Pemigatinib|
33255151|NCT05436002|Active Comparator|With Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Cross-linked Hyaluronic Acid and Subepithelial Connective Tissue Graft.
33255152|NCT05436002|Placebo Comparator|Whitout Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Subepithelial Connective Tissue Graft.
33255153|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
33255154|NCT00921752||Patients at high cardiovascular risk|
33255155|NCT05435690|Experimental|Computer-assisted arthroplasty|
33255156|NCT05435690|No Intervention|Conventional arthroplasty|
33255157|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
33255158|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
33255159|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
33255160|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
33255161|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
33255162|NCT00921830|Experimental|Ibuprofen|ibuprofen
33255163|NCT05435612|Experimental|single-sided deafness group（SSD Group）|The single-sided group（SSD group）consists of 20 SSD patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
33255164|NCT05435612|Experimental|asymmetric hearing loss group（AHL Group）|The asymmetric hearing loss group（AHL group）consists of 10 AHL patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
32769299|NCT05617547||Pulse Oximetry Observational Cohort|
32935100|NCT05418920|Active Comparator|the control group (double-flap group)|double-flap group
32769300|NCT05034133|Experimental|Study arm|Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.
32769301|NCT04828967|Experimental|Hypnosis group|Hypnosis is added to the conventional group.
32769302|NCT04828967|No Intervention|conventional group|only conventional group
32935101|NCT05483023|Experimental|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
32935102|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
32935103|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
32935104|NCT05400824||general population|Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion
32935105|NCT04738994|Experimental|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
32935106|NCT04738994|Active Comparator|Control group|Standard hospital diet
32935107|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
32935108|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
32935109|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
32935110|NCT02653417|Placebo Comparator|Regimen 4|Placebo
32935111|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
32935112|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
32935113|NCT04338997|Experimental|IZD174|Intra subject dose escalation of IZD174
33255165|NCT05435534|Experimental|Multicomponent intervention|Participants randomly assigned to the Multicomponent intervention group will received a multifactorial intervention.
33255166|NCT05435534|Active Comparator|Usual care group|Participants randomly assigned to the usual care group will received normal outpatient care, including physical rehabilitation when needed.
33255167|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
33255168|NCT05435456|Experimental|Experimental Group|Performed strengthening and relaxation exercises 3 times a week for 8 weeks.
33255169|NCT05435456|No Intervention|Control Group|There is no intervention
33255170|NCT04836832|Experimental|Treatment (acalabrutinib, duvelisib)|Patients receive acalabrutinib PO BID, and duvelisib PO BID on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 19, patients receive acalabrutinib PO BID for up to 60 months in absence of disease progression or unacceptable toxicity.
33255171|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
33255172|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
33255173|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
33255174|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
33075813|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
33255175|NCT05222438|Experimental|Loncastuximab tesirine|Patients will start loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles). Patients will receive IV infusion of loncastuximab tesirine 150 μg/kg at Q3W for the first 2 cycles followed by 75 μg/kg at Q3W for the remaining 6 cycles.
32769303|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
32769304|NCT04814693|Experimental|Interventional arm|Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.
32769305|NCT04814693|Active Comparator|Control arm|Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.
32906129|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
32906130|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
32906131|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
32906132|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
33255176|NCT05358184|Experimental|High frequency percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to oxygen therapy at high flow through nasal cannula
32906133|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
32906134|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
32906135|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
32906136|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
32906137|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
32906138|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
32906139|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 1)|Participants with AML will receive intevenous (IV) infusion of AZD2811 Dose 1 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906140|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 2)|Participants with AML and myelodysplastic syndrome (MDS) will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906141|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 3)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906142|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 4)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906143|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 5)|Participants with AML will receive IV infusion of AZD2811 Dose 5 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906144|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 2)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
32906145|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 6)|Participants with AML will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
33075814|NCT00546832|Placebo Comparator|1|placebo
33075815|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
33075816|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
33075817|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
33075818|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
33075819|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
33075820|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
33075821|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
33075822|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
33075823|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
33255177|NCT02783300|Experimental|Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet|Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
33255178|NCT02783300|Experimental|Part 2: Disease-Specific Expansion cohort|Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
33075824|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
33075825|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
33075826|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
33075827|NCT05030935|Experimental|Intervention Group|This group will be able to use the mHealth App.
33075828|NCT05030935|No Intervention|Control group|The Instructions Manual consists of a hard copy of the mHealth App bibliographical content. In addition, a calendar that can be used as a reminder for patient position switching is present and a hard copy explanation of the scale which can be used by the caregiver and through handwriting, determine the need for support surfaces.
33075829|NCT05015764|Experimental|Reprieve Cardiovascular System|
33075830|NCT05015764|Active Comparator|Standard of Care|
32731391|NCT04440735|Experimental|DSP107 in combination with atezolizumab in colorectal cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
32731392|NCT04501471|Experimental|SAAF-T|Participants received a 5 session, 10-hour family centered prevention program designed to prevent substance use, conduct problems, and risky sexual behavior
32731393|NCT04501471|Placebo Comparator|Fuel for Families|Participants received a 5 session, 10 hour family centered program that focused on healthy nutrition and exercise.
32731394|NCT04439643||Development / training|Selected by stratified partitioning
32731395|NCT04439643||Sequestered / test|Selected by stratified partitioning
32731396|NCT04505137|Experimental|GMA301 1500mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
32731397|NCT04505137|Experimental|GMA301 2000mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
32731398|NCT04424745|Active Comparator|Attention Bias Modification Training with real tDCS|
32731399|NCT04424745|Placebo Comparator|Attention Bias Modification Training with sham tDCS|
32731400|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
32731401|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
32731402|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
32731403|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
32731404|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
32731405|NCT04501315||ICU TBI|Patients treated on the ICU with brain injury
32731406|NCT04501315||ICU tumor|Patients treated on the ICU because of intracranial tumor
33075831|NCT05012956|Active Comparator|POP group|Pelvic organ prolapse patients enrolled for sacrocolpopexy surgery at UZ Leuven.
32731407|NCT04501315||ICU surgery|Patients treated on the ICU following surgery without brain injury
33075832|NCT05012956|Active Comparator|Control group|Patients assigned to gynecologic laparoscopic surgery, other than sacrocolpopexy, at UZ Leuven.
33075833|NCT00547144|Experimental|Gemcitabine|
33075834|NCT00547183|Active Comparator|2|2.5 mg tadalafil
33075835|NCT00547183|Active Comparator|3|5 mg tadalafil
32731408|NCT04501315||ICU control|Patients treated on the ICU without TBI, tumor or surgery
32731409|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
32731410|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
32769306|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
32769307|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
32769308|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
32769309|NCT03096223|Experimental|KHK4083|
32769310|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
32769311|NCT04814303|Active Comparator|ITM|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added.
32769312|NCT04814303|Active Comparator|ACB|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, the short-bevel echogenic needle is advanced in-plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in this group received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
32769313|NCT04814303|Active Comparator|PAI|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. PAI intra-operatively will be performed with 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone.
32769314|NCT05053477|Active Comparator|Control Group|Patients will receive median nerve perineural injection of bupivacaine with mehylprednisolone under ultrasound guidance
32769315|NCT05053477|Active Comparator|PRF Group|Patients will receive median nerve pulsed radiofrequency (PRF) and median nerve perineural injection of bupivacaine under ultrasound guidance
32769316|NCT05053477|Active Comparator|PRP Group|Patients will receive median nerve perineural injection of platelet-rich plasma (PRP) under ultrasound guidance
32769317|NCT04814459|Experimental|HOP-UP-PT Program|HOP-UP-PT Program group will participate in the 7-month HOP-UP-PT program
32769318|NCT04814459|No Intervention|Normal Level of Activity|Normal Level of Activity group will be instructed to continue their normal level of activity throughout the 7-months after which they will be offered the opportunity to receive the HOP-UP-PT program
32769319|NCT05033587|Experimental|AK105 injection with anlotinib and radiotherapy|"AK105 200mg intravenously (IV) on day 1 of each 21-day cycle until disease progression or treatment intolerance, the dose can not be adjusted.~Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.~The conventional radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy."
32769320|NCT05053009|Experimental|Ibuprofen sustained release|Single dose of 800 mg Brufen Retard oral premedication will be administered 1 hour before local anesthesia
32769321|NCT05053009|Placebo Comparator|Placebo|1 capsule of 500 mg of glucose oral premedication will be adminstered 1 hour before local anesthesia
32769322|NCT03095131|Experimental|12-lead ECG|
32769323|NCT05617235|No Intervention|Conventional Physiotherapy and Rehabilitation|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions.The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
32769324|NCT05617235|Experimental|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. All tapes were applied by the same physiotherapist on clean and shaved skin (if necessary). Investigators applied kinesiology taping as described below:~In order to stimulate the facilitation of the diaphragmatic function, a 5 cm wide kinesiological tape was applied on the skin.~Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~In addition, kinesiology taping can be performed on the trigger pain point of the patient (usually above the pectoralis major).~The kinesiology tape can stay for 3-4 days if the patient does not develop any discomfort. After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
32769325|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
32769326|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
32769327|NCT04813835||suicidal depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
32769328|NCT04813835||depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
33075836|NCT00547183|Placebo Comparator|1|
32769329|NCT04813835||control|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
32769330|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
32769331|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
32769332|NCT04813913|Experimental|bevacizumab|bevacizumab in combination with IV fluoropyrimidine chemotherapy.
32769333|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
33255179|NCT02783300|Experimental|Part 3: GSK3326595 in combination with pembrolizumab|Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
32769334|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
32769335|NCT04828889|Experimental|research|The subjects in the study group will undergo a series of 4 treatments by 2 certified physiotherapists for pelvic floor treatment that will include instruction in self-use of anal dilators once a week for four weeks. The anal dilation will be performed using Dilatan® anal dilators (Enterprises Sapimed, Alessandria) in varying sizes of 22, 23 and 27 mm. In the first week, a 20 mm dilator will be inserted twice a day for at least 10 minutes. In the second week, a 23 mm extender will be inserted into the anus, twice a day for at least 10 minutes. In the last two weeks, a 27 mm extender will be inserted twice a day for at least 10 minutes. To facilitate the insertion of the extender, patients will use lubricating cream. At the end of each week, patients will meet with a pelvic floor physiotherapist to make sure that the insertion is done properly, that there are no side effects and that it is possible to move on to the next step.
32769336|NCT04828889|No Intervention|waiting|The subjects in the waiting group will be able after a month to choose to undergo surgery or also receive treatment by extenders.
32769337|NCT04828889|Active Comparator|surgery|The subjects in the surgery group will undergo surgical treatment only.
32769338|NCT05033509||ECMO and AKI|
32769339|NCT04828655|No Intervention|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity. Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
32769340|NCT04828655|Experimental|EXPERIMENTAL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning. Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
32769341|NCT05033197|Experimental|CBBS intervention group|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
32769342|NCT04828499|Experimental|Progressive Cracking Technique|Patients with hard nucleus cataract were treated with Progressive Cracking Technique.
32769343|NCT04828499|Experimental|Conventional Chop Technique|Patients with hard nucleus cataract were treated with Conventional Chop Technique.
32769344|NCT05042089||pathological tumor stage 1-2 (pT1-2)|Stage pT1 and pT2 according to pathology results of patients who underwent partial or radical nephrectomy.
32769345|NCT05042089||pathological tumor stage ≥pT3a|Stage ≥pT3a according to pathology results of patients who underwent partial or radical nephrectomy.
33255180|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
33255181|NCT05356000|Other|Subjects who will follow low-oxalate diet followed by visit to research clinic|30 stone-forming participants will be recruited to this study.
33255182|NCT04293484|Experimental|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
32769346|NCT04819061|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training
33255183|NCT04293484|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
33255184|NCT04273594|Experimental|FemBloc|Investigational device and procedure
32769347|NCT04819061|Sham Comparator|Sham group|In the group G2 will be administered: tDCS sham + dual-task motor training
32769348|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.5% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~20cc 0.25% bupivacaine~2 mg IV dexamethasone."
33255185|NCT05355922|Sham Comparator|Aussie current (placebo) and Exercises|
33255186|NCT05355922|Experimental|Aussie current and Exercises|
33255187|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
33255188|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
33255189|NCT04272034|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
33277485|NCT05219942|Placebo Comparator|low dose insulin infusion +Subcutaneous saline|low dose insulin infusion +Subcutaneous saline
33255190|NCT04272034|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
33075837|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
33255191|NCT04272034|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
33255192|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
33075838|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
33255193|NCT04001920|Experimental|Training program|12-week strength and endurance training program
33255194|NCT05435378|Experimental|vitamin B3|Vitamin B-3 capsule consists of Manufacturer: DSM Nutritional products Ltd generic name: nicotine amide Constituent components: 100mg of nicotine amide Route of administration: orally dosing schedule:1capsule/day/ before meal duration: for 30 days
33255195|NCT05435378|Experimental|Vitamin B-9|Vitamin B-9 capsule Manufacturer: Hebei Jiheng pharmaceutical Co. Ltd generic name: folic acid. Constituent components: 5 mg of folic acid. Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
33255196|NCT05435378|Placebo Comparator|Placebo capsule|Placebo capsule Manufacturer: Shivangan Foods & Pharma Products Pvt. Ltd Constituent components: inactive fillers Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
33075839|NCT04684186||Endovascular fiducial marker insertion|Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
33255197|NCT04002622|Experimental|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
33255198|NCT05435300||Schizophrenia/Schizoaffective Disorder|Participants with Schizophrenia/Schizoaffective Disorder and currently enrolled in the tDCS-adherence parent study (REB# 103-2018).
33075840|NCT04684186||Bronchoscopic fiducial marker insertion|Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route
33075841|NCT00547417|Active Comparator|1|tadalafil
33255199|NCT04003324|Experimental|Intervention group|Self-monitoring tool (Activator) and general information
33255200|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
33255201|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
33075842|NCT00547495|Placebo Comparator|1|Placebo tablet
33075843|NCT00547495|Active Comparator|2|5 mg tadalafil
33255202|NCT02560454|No Intervention|Control|Control ( waiting list)
33255203|NCT05589220|Experimental|Music intervention and NRT|The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in the third month. In this group, music intervention will be associated to NRT.
33075844|NCT00547495|Active Comparator|3|10 mg tadalafil
33075845|NCT00547495|Active Comparator|4|20 mg tadalafil
33075846|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
33075847|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
33075848|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
33075849|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
33255204|NCT05589220|Active Comparator|NRT group|Nicotine Patch, Nicotine Gum As in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.
33075850|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
33075851|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
33075852|NCT00547573|Placebo Comparator|1|placebo tablet
33075853|NCT00547690|Experimental|1|Acupuncture and strength training
33075854|NCT00547690|Other|2|Strength training
33075855|NCT05000632|Experimental|Smoke Free SafeCare (SFSC)|Providers randomized to this group will receive additional SFSC training and will disseminate SFSC program to families who report having a smoker in the home.
33075856|NCT05000632|Active Comparator|Standard SafeCare|Providers randomized to this group will disseminate the Standard SafeCare program to families who report having a smoker in the home.
33075857|NCT04983238|Experimental|BYON5667 & SYD985|BYON5667 eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
33075858|NCT04983238|Placebo Comparator|Placebo & SYD985|Placebo eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
33255205|NCT03895840|Experimental|Intra-articular Zilretta injection|32 mg Zilretta in a 5ml diluent for each knee, per manufacturer guidelines
33255206|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
33277486|NCT05219942|Active Comparator|low dose insulin infusion +subcutaneous Glargine insulin|low dose insulin infusion +subcutaneous Glargine insulin
33075859|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
33075860|NCT04982419|Active Comparator|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
33075861|NCT04982419|Sham Comparator|Sham remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
33075862|NCT04974385|Experimental|Liposomal Bupivacaine|Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.
33075863|NCT04974385|Active Comparator|Non-liposomal Bupivacaine|Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine
33255207|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
33255208|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
33255209|NCT01061281|Active Comparator|Tecnis MF IOL|
33255210|NCT01061281|Active Comparator|Crystalens AO IOL|
33255211|NCT02532985|Placebo Comparator|Negative control|No added fiber
33255212|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
33255213|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
33075864|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
33075865|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
33075866|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
33075867|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
33075868|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
33082241|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
33255214|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
33082242|NCT04620967|Experimental|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
33082243|NCT04620967|Experimental|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
33082244|NCT04620655|Experimental|RD13-01 cell infusion|
33255215|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
33082245|NCT04620811|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
33255216|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
33255217|NCT01063777|Active Comparator|1|
33255218|NCT01063777|Active Comparator|2|
33255219|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
33255220|NCT03985969|Experimental|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
33255221|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
33255222|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
33255223|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
33255224|NCT00575588|Experimental|Saxagliptin|
33255225|NCT00575588|Experimental|Glipizide|
33255226|NCT01058317|Experimental|Children treated with propranolol|
33255227|NCT01058473||Sickle Cell Disease|
33255228|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
33255229|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
33255230|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
33255231|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
33255232|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
33255233|NCT00804102|Active Comparator|Retinitis pigmentosa|
33255234|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
33255235|NCT00804102|Active Comparator|Primary open angle Glaucoma|
33255236|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
33255237|NCT00804102|Active Comparator|Treated Retina detachment|
33255238|NCT00804102|Active Comparator|Retinal Artery Occlusion|
33255239|NCT00804102|Active Comparator|Retinal Vein Occlusion|
33255240|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
33082246|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
33082247|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
33255241|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
32731411|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
32935114|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
33255242|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
33255243|NCT00804102|Active Comparator|Ischemic Macula edema|
33255244|NCT00804102|Sham Comparator|Non-stimulated|
33255245|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
33255246|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
32731412|NCT04381533|Experimental|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
33255247|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
32731413|NCT04381533|Active Comparator|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
32731414|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
32731415|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
33255248|NCT05405426|Active Comparator|Indication-based red blood cell transfusion strategy|Red blood cell transfusion will occur if the center-specific hemoglobin/hematocrit threshold for transfusion is met AND at least one of the following conditions is present: a) moderate or severe bleeding; b) reduced tissue oxygen delivery, defined as serum lactate >3 mmol/L; or c) hemoglobin < 8 g/dL or hematocrit < 25% or, for children with single ventricle heart disease, 5% lower than institutional standard hematocrit threshold for transfusion during ECMO.
33277487|NCT04002206|Experimental|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
32731416|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
32731417|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
32731418|NCT05118555||Type 1|"Patients scheduled to undergo a routine clinical MR examination of the relevant anatomical regions and/or disease type will be identified from MRI department schedules.~The new MR technique will be used to acquire additional data in patients undergoing a routine MR examination. The routine MR examination will be conducted according to the standard protocol."
32935115|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
32935116|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
32935117|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
32935118|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
32935119|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
32935120|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
32935121|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
32935122|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
32935123|NCT02706925|Experimental|BI 443651|
32935124|NCT02706925|Placebo Comparator|Placebo|
33075869|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
33075870|NCT04973683|Experimental|Treatment (AL101)|Patients receive AL101 IV over 60 minutes QW for 6-8 weeks in the absence of disease progression or unacceptable toxicity. Within 24-72 hours after the last infusion of AL101, patients undergo surgery per standard of care. Patients may continue AL101 after surgery at the discretion of the study doctor.
33075871|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
33075872|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
33075873|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
33075874|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
33075875|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
33075876|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
33082248|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
33255249|NCT05405426|Other|Center-specific hemoglobin/hematocrit threshold-based red blood cell transfusion strategy|Red blood cell transfusion will occur according to each study center's standard of care strategy, typically based on a particular hemoglobin threshold or hematocrit threshold. When hemoglobin or hematocrit decrease to the threshold, red blood cell transfusion is administered.
33255250|NCT04049396|Experimental|Berberine|Berberine (6.25 g/day)
33255251|NCT04049396|No Intervention|Control|No intervention
33255252|NCT00760916|Placebo Comparator|Placebo|placebo
33255253|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
33255254|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
33255255|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
33255256|NCT05166200|Experimental|Experimental Formula|One 237 ml serving of study product
33255257|NCT05166200|Active Comparator|Test Meal|48 g Instant oatmeal
33255258|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
33255259|NCT05011760|Experimental|PET|[C-11]NPA PET Scan
33255260|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
33255261|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
33255262|NCT00758654||1|Patients with suspected or known stable coronary artery disease
33255263|NCT00758654||2|Healthy subjects as a control group
33401229|NCT04055948|Experimental|Intervention|"All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)~Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
33401230|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
33401231|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
33255264|NCT05008718|Active Comparator|38% SDF group|38% silver diamine fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
33255265|NCT05008718|Placebo Comparator|5% NaF group|5% sodium fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
33255266|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
33255267|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
33255268|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
33255269|NCT02558738||Normison ear spray|treatment according to instruction for use
33255270|NCT00758732|Experimental|1|Docetaxel/carboplatin
33255271|NCT00758732|Experimental|2|Docetaxel/Caelyx
33255272|NCT00758810||1|Patients without cardiac rehabilitation
33255273|NCT00758810||2|Patients with cardiac rehabilitation
33255274|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
33255275|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
33255276|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
33255277|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
33255278|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
33255279|NCT00759044||AMD|Patients diagnosed with AMD
33255280|NCT00759044||DME|Patients diagnosed with DME
33255281|NCT00761540|Experimental|A1|
33255282|NCT00761540|Placebo Comparator|A2|
33255283|NCT00761540|Experimental|B1|
33255284|NCT00761540|Placebo Comparator|B2|
32731419|NCT05118555||Type 2|"Patients with the relevant disease type and no contraindications to MRI will be identified by delegated radiologists in clinics.~An additional MR examination will be scheduled; this examination is in addition to any examinations that the patient may undergo as part of their clinical care. The MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
33255285|NCT00761540|Experimental|C1|
33075877|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
33075878|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
33075879|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
33075880|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
33255286|NCT00761540|Placebo Comparator|C2|
33255287|NCT04913636|Experimental|Test Group|
33075881|NCT04953637|Experimental|Physiotherapy group|Participants assigned to the physiotherapy group will receive physiotherapy treatment at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks. They will begin to receive the physiotherapy treatment at 4 months following their surgery and once their DBS settings are optimized.
33075882|NCT04953637|No Intervention|Control group|Participants assigned to the control group will not receive any additional intervention and will be precluded from starting formal physiotherapy for the duration of the study. However, they will be encouraged to keep an active lifestyle. In order to stay active, they will be recommended to do simple home exercises following a home exercise video that will be presented to them. They will be asked to do it 3 times/week for 8 weeks and keep an exercise log to help them stay on track.
33075883|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
33255288|NCT04913636|Sham Comparator|Control Group|
33255289|NCT00761696|Experimental|IPI-926|Oral daily dosing
33255290|NCT00759122|Active Comparator|1|VENLAFAXINE
32731420|NCT05118555||Type 3|"Normal volunteers who are members of staff or students at RMH/ICR will be invited to participate using a mailing list. Exceptionally employees of other NHS Trusts and Academic Institutions will be allowed to participate if they are in collaboration with RMH/ICR.~An MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
32731421|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at one year on 50 patients.~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
32731422|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
32731423|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
32731424|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
32731425|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
32731426|NCT04351659||Blood donors|Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
33255291|NCT00759122|Placebo Comparator|2|
33255292|NCT00759200|Experimental|alb-interferon arm 1|
33255293|NCT00759200|Experimental|alb-interferon arm 2|
33255294|NCT00759200|Experimental|alb-interferon arm 3|
33255295|NCT00759200|Experimental|alb-interferon arm 4|
33255296|NCT00759200|Active Comparator|peg-interferon|
33255297|NCT00557505|Experimental|PF-03732010|Single Arm study
33255298|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (-->progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
33255299|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
33255300|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
33255301|NCT01299753|Placebo Comparator|Control|
33255302|NCT01299753|Experimental|Beta blockade|
33255303|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
33255304|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
33255305|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
33255306|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
32731427|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
32731428|NCT03346525|No Intervention|Control Arm|No prophylaxis
32731429|NCT05070273|Experimental|Hypoglossal nerve conduction study.|
32731430|NCT05060523|Experimental|Tolvaptan with Midodrine|
32731431|NCT05060523|Active Comparator|Tolvaptan with Placebo|
32731432|NCT04502641|Experimental|Arm I|Patients receive induction chemotherapy with docetaxel-based, with or without cisplatin or fluorouracil. Treatment repeats every 21 days for 3 courses. Then, patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
32731433|NCT04502641|Active Comparator|Arm II|Patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
32731434|NCT05555797|Experimental|group of patients with psoriasis vulgaris|"in each patient lesions will be divided into 3 groups; Group 1: treated with Excimer laser alone(1-2 sessions/ week for 12 sessions according to induration protocol*).~Group 2: treated with Excimer laser combined with topical tazarotene gel 0.1% Group3: treated with Excimer laser combined with topical betamethasone valerate ointment 0.1%"
32731435|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
33075884|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
33075885|NCT00548743|Experimental|1|Intervention arm
33075886|NCT00548743|Placebo Comparator|2|Usual care
32731436|NCT04502485|Experimental|Gastric water exchange|Air will be minimally insufflated to partially open the lumen and any residual fluid will be suctioned when the scope passes through the esophagus. Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further. Air will be opened when the scope enter the prepylorus area where there is usually an air pocket. The scope will enter the duodenal bulb and 2nd portion of duodenum where withdrawal inspection will start.
32731437|NCT04502485|Active Comparator|Traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
33075887|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
32731438|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
33075888|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
33075889|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
33075890|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
33075891|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
32731439|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
32731440|NCT04076943|Experimental|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 16 weeks.
32731441|NCT04219033||with postoperative cognitive dysfunction|
32731442|NCT04219033||without postoperative dysfunction|
33075892|NCT04939480|Experimental|Atezolizumab|Pre-operative administration of atezolizumab 1200 mg followed by definitive resection of the tumor, followed by standard of care radiotherapy or radio-chemotherapy.
33075893|NCT00549016|Experimental|1|
33075894|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
33075895|NCT00549406|Experimental|1|computer-based visual-training program UFOV
33075896|NCT00549406|Experimental|2|video-game based visual training
33075897|NCT00549406|Placebo Comparator|3|computerized word puzzles
33075898|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
33075899|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
33075900|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
33255307|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
33277488|NCT04002206|Active Comparator|Static Stretch|Static stretching was given in control group
33075901|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
33075902|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
33277489|NCT04002284|Experimental|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
33255308|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
33255309|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
33075903|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
33075904|NCT00549484||1|10 mL/kg platelet transfusion
33255310|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
33255311|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
33255312|NCT04861220|Experimental|Pre-habilitation group + neoadjuvant treatment|The patients in the Pre-habilitation group + neoadjuvant treatment (Group A), will undergo neoadjuvant cancer therapy and be instructed to practice physical exercises at home 03 times a week, during neoadjuvant therapy, until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
33075905|NCT00549484||2|15 mL / kg platelet transfusion
33075906|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
33255313|NCT04861220|Experimental|Prehabilitation Program + immediate surgical treatment|The patients in the Pre-habilitation group + immediate surgical treatment (Group B), will be instructed to practice physical exercises at home 03 times a week until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
33401232|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
33075907|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
33075908|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
32731443|NCT04325763|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33075909|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
33075910|NCT04684225|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
33075911|NCT04684225|Experimental|Home-exercises|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied by their own at home for 3 sessions per week.
32731444|NCT04325763|Experimental|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32731445|NCT04325763|Placebo Comparator|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32731446|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
32731447|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
32731448|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
32731449|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
32731450|NCT03955575|Active Comparator|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
32731451|NCT03955575|Active Comparator|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
33075912|NCT04684225|No Intervention|Control|They will have no intervention for 8 weeks. After the period, they will do home exercises.
33075913|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
33075914|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
33075915|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
33075916|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
33075917|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
33075918|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
32731452|NCT04204759|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
32731453|NCT04204759|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
33075919|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
33075920|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
33255314|NCT04861220|No Intervention|Usual activities + neoadjuvant treatment|Patients allocated to this group (Group C) will not participate in the pre-habilitation program and will be instructed to continue their usual activities during the neoadjuvant cancer therapy, until the date of surgery.
33255315|NCT04861220|No Intervention|Usual activities + immediate surgical treatment|Patients allocated to this group (Group D) will not participate in the pre-habilitation program and will be instructed to continue their usual activities until the date of surgery.
33255316|NCT00202761|Experimental|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
33255317|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
33255318|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
33255319|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
33255320|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
33255321|NCT00940563|Experimental|Imatinib|
33255322|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
33255323|NCT00759512|No Intervention|Arm 2|Standard of Care
33255324|NCT00940641|Experimental|1|IV dose of AZD7325
33255325|NCT00940641|Experimental|2|14C oral dose of AZD7325
33255326|NCT00761852|Active Comparator|1|Ruboxistaurin
33255327|NCT00761852|Placebo Comparator|2|Placebo
33255328|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
32731454|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
32731455|NCT04163419|Experimental|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
32731456|NCT04163419|Placebo Comparator|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
32731457|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
32731458|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
32731459|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
32731460|NCT04282629|Experimental|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
32731461|NCT04282629|Placebo Comparator|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
32731462|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
32731463|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
33255329|NCT04795232|No Intervention|Control|Participants in this arm will receive no intervention
33255330|NCT04795232|Experimental|COD45|Participants in this arm will participate in a COD training session consisted of 45 degrees changes of direction
33255331|NCT04795232|Experimental|COD90|Participants in this arm will participate in a COD training session consisted of 90 degrees changes of direction
32935125|NCT05378438|Experimental|Intervention Arm|Participants allocated in this arm will be approached for a workshop related to microbe literacy. Using a microscope, live demonstration of the biological samples brought by the participants will be carried out by the team of researchers. Participants will be assisted to place biological materials under the microscope, manipulate the slides and discover the profusion of microbial life from the immediate environment. The session will be followed by question and answer round related to concurrent hygiene practices and basic sanitation to prevent infections including vaccines.
33255332|NCT00940797|Experimental|DMMET-01|
33255333|NCT00940797|Placebo Comparator|Control|
32731464|NCT04698057|Active Comparator|Amoxicillin clavulanate + ciprofloxacin|Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days
33255334|NCT00759590||1|ALI/ARDS patients
33255335|NCT04012905|Experimental|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
33255336|NCT04012905|Active Comparator|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
33255337|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
33255338|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
33255339|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
33255340|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
33255341|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
32731465|NCT04698057|Experimental|Amoxicillin clavulanate + Placebo|Treatment with amoxicillin-clavulanate 1g tib for 5 days
32731466|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
32731467|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
32731468|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
32731469|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
32731470|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
33255342|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
32731471|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
33255343|NCT04012515|Experimental|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
33075921|NCT00549874|Experimental|1|
33255344|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
33255345|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
32731472|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
33255346|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
32731473|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
32731474|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
32731475|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
33075922|NCT00549874|Experimental|2|
33075923|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
33255347|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
33255348|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
33255349|NCT00940953|Placebo Comparator|Placebo|
33255350|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
33255351|NCT04012593||premenopausal women|diary
33255352|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
33255353|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
33255354|NCT04049240|Active Comparator|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33075924|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
33075925|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
33075926|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
33075927|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
33255355|NCT04049240|Active Comparator|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33255356|NCT04049240|Active Comparator|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33255357|NCT04049240|Active Comparator|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33075928|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
33075929|NCT00550030|Experimental|left/right|half-body comparison
33075930|NCT04904068||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease.
33075931|NCT04904068||Healthy|Healthy individuals with no known neurological disorders.
33255358|NCT04049240|Active Comparator|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33255359|NCT04049240|Active Comparator|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33075932|NCT00550108|No Intervention|A|Observation of pancreatic cysts
33255360|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
33255361|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
33255362|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
33255363|NCT00762008||Heart Failure|
32731476|NCT04217109|Experimental|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
32731477|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
32731478|NCT04485507|Experimental|Nature-VR|Viewing 3D pictures of natural environments
32731479|NCT04485507|Active Comparator|Urban-VR|Viewing 3D pictures of urban environments
32731480|NCT04274049|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
32731481|NCT04274049|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
32731482|NCT04204707||Conservative surgery|
32731483|NCT04204707||Radical surgery (segmental resection)|
32731484|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
32731485|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
32731486|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
32731487|NCT04132791|Other|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
32935126|NCT05378438|No Intervention|Control arm|Participants in this arm will be consented for the study and baseline data collection will be made but there will not be any intervention. Data will be collected for baseline as well as post interventional vaccination status among the studied population.
32935127|NCT04739228|Experimental|Guided Written Disclosure Protocol Group|Guided Written Disclosure Protocol is a short-term psychological intervention that stimulates emotional expression, promotes a cognitive reworking of stressful illness events and facilitates the integration between emotional and cognitive processing of traumatic experiences. Intervention aimed at enhancing patients' quality of life, psychological well-being, and emotional regulation, and reducing psychosocial distress.
33075933|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
33075934|NCT00550186|Placebo Comparator|1|No preload
33255364|NCT00762242||1|Blood sampling and brachial artery ultrasound
33255365|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
33255366|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
33255367|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
33255368|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
33075935|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
33075936|NCT00550186|Active Comparator|3|Preload with collid infusion
33255369|NCT04605458|Experimental|Contingency Management|
33255370|NCT04605458|Active Comparator|Standard Care|
32731488|NCT04132791|Experimental|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
32731489|NCT04263987|Active Comparator|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
32731490|NCT04263987|Experimental|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
32731491|NCT04662879|Experimental|Intervention Arm|"Two interventions are performed:~Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is >0,~Have abdominal imaging performed."
32731492|NCT04662879|No Intervention|Observation Arm|Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.
32731493|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
32731494|NCT03350971|Active Comparator|Control|chest physical therapy
32731495|NCT04065009|Placebo Comparator|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
32731496|NCT04065009|Experimental|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
32731497|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
32731498|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
32731499|NCT04250493|Experimental|MSA patient|Patients will be recruited at the French Reference Center for MSA.
32731500|NCT04250493|Other|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
32731501|NCT04501003|Other|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm.
32731502|NCT04064229|Experimental|Infiltrated Tissue|The ivWatch Model 400 sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
32731503|NCT04501159||End-stage renal disease (ESRD)|Patients with end-stage renal disease undergoing regular haemodialysis 3 times weekly.The investigation will measure cardiac output (CO), oxygen saturation (SaO2), arterial blood gases (ABG) and white blood cell (WBC) count during HD to assess changes in haemodynamics, pH, leukostasis and hypoxia. Patients undergoing regular HD will be recruited with arterial blood samples for gas analysis drawn over three consecutive HD treatments. Arterial samples will be taken at the start, 15 minutes and end of HD treatment for ABG and WBC analysis. Dialysis membrane, ultrafiltration volume, serum and dialysate bicarbonate levels will also be recorded. Regression analysis will be performed with pH, ABG and SaO2. A subset of patients will be used to assess an if cardiac output, WBC or pH better predicts PaO2 during HD.
32731504|NCT04218591|Active Comparator|PRP|Intra-articular injection PRP
32731505|NCT04218591|Placebo Comparator|Saline|Intra-articular injection Saline
32731506|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
32731507|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
32731508|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
32731509|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
32731510|NCT01868451|Experimental|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
33082249|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
32743068|NCT04487015|Experimental|Part II: Stage 3 - R2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered responders (R2) so they continue with MP only for 2 weeks.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
32935128|NCT04739228|Active Comparator|Active Control Group|
32935129|NCT05470465|Placebo Comparator|Treatment A: Placebo|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
32935130|NCT05470465|Experimental|Treatment B: Paroxetine|Participants will receive paroxetine on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
32731511|NCT01868451|Experimental|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin & AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 & 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin & AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin & AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck & diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
32731512|NCT04501237|No Intervention|Bruxers without sleep hygiene instructions|
32731513|NCT04501237|Experimental|Bruxers with sleep hygiene instructions|
32731514|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
32731515|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
32731516|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
32731517|NCT04500925||UPSCALED|
32731518|NCT04500925||NOT UPSCALED|
32731519|NCT04645329|Experimental|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
32731520|NCT04645329|Active Comparator|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
32731521|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
32731522|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
32731523|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
32731524|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
32731525|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
32731526|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
32731527|NCT04619355||TVC K-Registry|
32731528|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
32731529|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
32731530|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
32731531|NCT03833479|Experimental|No further treatment|No further treatment
32731532|NCT03833479|Experimental|TSR-042|TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).
32731533|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
32935131|NCT05470465|Experimental|Treatment C: Escitalopram|Participants will receive escitalopram on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
32731534|NCT01119807|Experimental|Intra Venous Access|Patient initially receives IV access during resuscitation
32731535|NCT01119807|Experimental|Humeral IO|Patient receives humeral IO access during resuscitation
32731536|NCT01119807|Active Comparator|Tibial IO|Patient receives tibial IO access during resuscitation
32731537|NCT05583331|Active Comparator|Cataract surgery then Vitrectomy|Patients will undergo first the cataract surgery then the vitrectomy, as a combined surgery performed on the same day.
32731538|NCT05583331|Experimental|Vitrectomy then cataract surgery|Patients will undergo first the vitrectomy then the cataract surgery, as a combined surgery performed on the same day.
32731539|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
33401233|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
33401234|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
33401235|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
33401236|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
33401237|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
33401238|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
33401239|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
33401240|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
33401241|NCT03630978||Liver resection|
33401242|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
33401243|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
33401244|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
33401245|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
33401246|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
33401247|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
33401248|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
33401249|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
33401250|NCT03393546|Experimental|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
33401251|NCT03393546|Experimental|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
33401252|NCT01379430|Experimental|Group 1|Intramuscular arm
33401253|NCT01379430|Experimental|Group 2|Intradermal arm
33401254|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
33401255|NCT01380444|Active Comparator|2|Sliding Hip Screws
33401256|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
33401257|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
33401258|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
33401259|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
32731540|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
32731541|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
32731542|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
32731543|NCT04147221|Experimental|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
32731544|NCT03427047|Active Comparator|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
32731545|NCT03427047|Active Comparator|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
32731546|NCT04499365|Experimental|Experimental: 68Ga-DOTA/NOTA-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
32731547|NCT04435509|Experimental|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
32731548|NCT04435509|Placebo Comparator|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
32731549|NCT03630289|Experimental|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
32731550|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
32731551|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
32731552|NCT05618509|Active Comparator|Patient with STENDO|
32731553|NCT05618509|Placebo Comparator|Patient with placebo|
32731554|NCT04142307|Active Comparator|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
33075937|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
32731555|NCT04142307|Sham Comparator|Group B (control)|"The simulated biofeedback training for Group B involves the following procedure:~For four weeks, presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button. Participants will be given take-home efficiency reading exercises."
32731556|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
32731557|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
32731558|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
33075938|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
32731559|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
32731560|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
32731561|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
32731562|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
32731563|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
32731564|NCT04130529|Experimental|Adjusted group CBT-i for Bipolar disorder|"The experimental group receives group-CBT-i adjusted for Bipolar disorder. This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the population with Bipolar Disorder. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the Bipolar population.~Treatment is given as 8 weekly group sessions."
32731565|NCT04130529|Active Comparator|Sleep lectures|The control group is offered a series of 3 lectures on sleep during the same time-period.
32731566|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
32731567|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
32731568|NCT03968913|Placebo Comparator|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
32731569|NCT03968913|Active Comparator|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
32731570|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
32731571|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
32731572|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
32731573|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
32731574|NCT04481451|Experimental|Erector spinae supplemental block|Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
32731575|NCT04481451|Active Comparator|Quadratus lumborum supplemental block|Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
32731576|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks (colorectal cancer patients only)"
32731577|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks"
32731578|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly"
32731579|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
32731580|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
33401260|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
33401261|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
32731581|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
32731582|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
32731583|NCT04120467|Experimental|Dance|Dance Standard rehabilitation post-stroke
32731584|NCT04120467|Active Comparator|Control|Standard rehabilitation post-stroke
32731585|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
32731586|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
32731587|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
33082250|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
32731588|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
32731589|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
32731590|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
32731591|NCT03882021|Other|Mapping protocol with GRID catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
32731592|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
32731593|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
32731594|NCT03259815|Experimental|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is <0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
32731595|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
32731596|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR >60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
32731597|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
32935132|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
33401262|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
32731598|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
32731599|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
32731600|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR <15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
32731601|NCT04102371|Experimental|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and PlasmaLyte, will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
32731602|NCT04102371|Active Comparator|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
32731603|NCT04094103|Experimental|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
32731604|NCT04094103|Placebo Comparator|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
32731605|NCT04094103|Active Comparator|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
32731606|NCT04086147|Experimental|Low dose tenecteplase|
32731607|NCT04086147|Experimental|High dose tenecteplase|
32731608|NCT03179397|Experimental|Model SC9|Investigational IOL
32731609|NCT03179397|Active Comparator|Model LI61SE|FDA Approved IOL
32731610|NCT03161223|Other|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
32731611|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
32731612|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
32731613|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
32731614|NCT03105921|Experimental|Electrodes|Electrodes
32731615|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
32731616|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
32731617|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
32731618|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
32731619|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
32731620|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
32731621|NCT05431959|Experimental|Self-controlled|"The skin microbiome was collected by swabbing method from the crook of the arm (normal skin) and the nearest plaque's surface.~Balneotherapy in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l."
32731622|NCT01285557|Experimental|S-1+Cisplatin|Participants received S-1 25 milligrams per meter square (mg/m^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
32731623|NCT01285557|Active Comparator|5FU+Cisplatin|Participants received 5-Fluorouracil (5-FU) 800 mg/m^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
32731624|NCT01032603|Active Comparator|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
32731625|NCT01032603|Active Comparator|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
32731626|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
32731627|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
32731628|NCT03406975|Active Comparator|Control Group: Lifestyle Modification|Participants randomized to the control group (lifestyle modification only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation.
32935133|NCT00368030|Placebo Comparator|B|Placebo tablet
32935134|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
32731629|NCT03406975|Experimental|Treatment Group: Overstitch ESG Procedure|Participants randomized to the treatment group will proceed to have the Overstitch Endoscopic Sleeve Gastroplasty (ESG) at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
32731630|NCT03406975|Experimental|Crossover Group: Lifestyle Intervention to ESG Procedure|Control group participants (lifestyle modification only) who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program of 12 months.
33082251|NCT04620616|Experimental|Product Use Sequence 1|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
33401263|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
32731631|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
32731632|NCT05431569|Experimental|6MW3211|6MW3211injection,30mg/kg,Q2W
32935135|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
32935136|NCT05352698||Non-Cardiac Surgery Patient|Our study population will be comprised of any patient undergoing non-cardiac surgery who meets standard of care criteria for BNP testing. This includes patients who are a) >65 years old, b) revised cardiac risk index (RCRI) ≥1 or c) >45 years old with significant cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebral vascular disease, congestive heart failure, obstructive intracardiac disease such as severe aortic stenosis, severe mitral stenosis or severe hypertrophic obstructive cardiomyopathy)
32935137|NCT05419063|Experimental|weight loss program|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress. The weight loss program will provide asynchronous support (information, automated texting feedback, tailored emails) for adopting and maintaining lifestyle-based strategies for safe and effective weight loss.
32935138|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
32935139|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
32935140|NCT05351762|Experimental|study arm|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
32935141|NCT05346536|Experimental|Metastatic pancreatic cancer treatment-naive patients|Newly diagnosed major patients with metastatic pancreatic cancer, naïve of any treatment for metastatic disease
33401264|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
33401265|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
33401266|NCT04835298||Myotonic dystrophy type 1|adult patients with myotonic dystrophy type 1
32935142|NCT05339594||NeuraGen Nerve Guide|Integra NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
32935143|NCT05339594||NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
32935144|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
32935145|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
32935146|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
32935147|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
32935148|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
32935149|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
32935150|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
32935151|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
32935152|NCT02708186|Placebo Comparator|Placebo|Placebo
32935153|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
32935154|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
32935155|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
32731633|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
32731634|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
32731635|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
32731636|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
32731637|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
32731638|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
32731639|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
32731640|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
32731641|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
32731642|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
32731643|NCT03218137|Other|Adenosine/ Verapamil Arm|"Adenosine: 0.84 mg/kg IV (140 mcg/kg/minute IV for 6 minutes) Verapamil: 0.15 mg/kg IV~Adenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation."
32731644|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
32731645|NCT03346213||Major surgery|"Adult patients undergoing elective surgery~Having a CPET as part of routine care~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.~Able to provide written informed consent."
32731646|NCT03345043|Experimental|VAL-339851|
32731647|NCT03345043|Placebo Comparator|Placebo|
32731648|NCT05638399|Experimental|Denosumab|denosumab (60 mg subcutaneously, per 6 month)
32731649|NCT05638399|Active Comparator|zoledronate|zoledronate (5mg, intravenous infusion once a year)
32731650|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
33075939|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
33075940|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
32731651|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
32731652|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
32731653|NCT05627011|Experimental|Clinical Decision Support Tool|Practices assigned to iPOP-UP intervention which involves EHR-based CDS tools refined through a formative evaluation and user-centered design.
32731654|NCT05627011|No Intervention|Control|Practices assigned to usual care that will not have access to the iPOP-UP CDS tool but will have access to many opportunities available to all pediatric clinicians nationally around the release of the new American Academy of Pediatrics guidelines for obesity management.
32731655|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
32731656|NCT04499443|Experimental|Single-dose experimental group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
32731657|NCT04499443|Placebo Comparator|Single-dose control group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
33075941|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
32731658|NCT04499443|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
32731659|NCT04499443|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
32731660|NCT04499443|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
32731661|NCT04499443|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
32731662|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
32731663|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
32731664|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
32731665|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
32731666|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
32731667|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
32731668|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
32731669|NCT04500691||FBSS patients|FBSS patients who are treated with high frequency Spinal Cord Stimulation
32731670|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
32731671|NCT03436875||Healthy|Healthy people either with (FH+) or without (FH-) a family history of diabetes or Alzheimer's Disease.
32731672|NCT03436875||unhealthy|People type 2 diabetes or Alzheimer's Disease that have either: a family history of that disease (FH+) or no family history of T2D or Alzheimer's for two generations (FH-).
32731673|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
32731674|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
32731675|NCT03394365|Experimental|SOT cohort -Subgroup A|Participants who have failed rituximab will receive IV tabelecleucel.
32731676|NCT03394365|Experimental|SOT cohort -Subgroup B|Participants who have failed both rituximab and chemotherapy will receive IV tabelecleucel.
32731677|NCT03394365|Experimental|HCT cohort|Participants who have failed rituximab will receive IV tabelecleucel.
32731678|NCT02512315|Active Comparator|CCRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CCRT).
32731679|NCT02512315|Experimental|NACT-CCRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CCRT.
32731680|NCT02507401||Total laryngectomy patients|Users of voice prostheses
32731681|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
32731682|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
32731683|NCT05431413|Placebo Comparator|Control group: Fluoxetine and Placebo|Fluoxetine(20mg) was used for four weeks once everyday. 0.9% sodium chloride was used for two weeks twice a day.
32731684|NCT05431413|Experimental|Experimental group: Fluoxetine and ATP|Fluoxetine(20mg) was used for four weeks once everyday. ATP(100mg) was used for two weeks twice a day.
32731685|NCT05431413|Experimental|Experimental group: Fluoxetine and Phosphocreatine|Fluoxetine(20mg) was used for four weeks once everyday. Phosphocreatine(1g) was used for two weeks twice a day.
32731686|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
32731687|NCT05431335|Experimental|Structured exercise program|The structured exercise program will be applied for 8 weeks, 2 days a week, for 45 minutes by a physiotherapist.
32731688|NCT05431335|Other|Aerobic exercise program|The aerobic exercise program will be applied for 8 weeks, 2 days a week, for 45 minutes by a physiotherapist.
32731689|NCT02517307|Experimental|glycerol/saline|Glycerol/Saline infusion
32731690|NCT02517307|Experimental|intralipid|Intralipid/Heparin infusion
32731691|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
32731692|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
32731693|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
33082252|NCT04620616|Experimental|Product Use Sequence 2|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
32731694|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
32731695|NCT05431257|Experimental|Elderly/unfit AML patients or sec. and R/R AML patients|
32731696|NCT02516995|Experimental|Patients with prostate cancer|
32731697|NCT05431023|Experimental|Patients with pneumonia who receive only treatment for pneumonia|They receive only treatment for pneumonia
32731698|NCT05431023|Experimental|pneumonia patients receive treatment for pneumonia and lactoferrin|They receive treatment for pneumonia and lactoferrin
32731699|NCT05430945|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
33075942|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
32731701|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
32731702|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
32731703|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
33075943|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
32731704|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
32731705|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
32731706|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
32731707|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
33075944|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
32731708|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
32731709|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
32731710|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
33075945|NCT00550264|Experimental|1|
33075946|NCT00550264|No Intervention|2|
33075947|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
33075948|NCT00550381|Placebo Comparator|1|10mg
33075949|NCT00550381|Placebo Comparator|2|20mg
32731711|NCT04484727||ICU-patients in ventilator treatment|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each is performed and data on airway pressure and tidal volume changes collected. The data is transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes, suctioning, inhalation, CO2 insufflation etc. is performed, and repeated during the whole period of ventilator treatment."
33075950|NCT00550381|Placebo Comparator|3|40mg
33075951|NCT00550381|Placebo Comparator|4|80mg
32731712|NCT04484727||Surgery-patients during general anaesthesia|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each, is performed in the same way as described for ICU patients. Data of airway pressure and volumes are transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes or suctioning is performed, and before and after implementation of pneumoperitoneum."
33075952|NCT00550381|Placebo Comparator|5|160mg
33075953|NCT00550381|Placebo Comparator|6|240mg
33075954|NCT00550381|Placebo Comparator|7|400mg
33075955|NCT00550381|Placebo Comparator|8|640mg
33075956|NCT00550381|Placebo Comparator|9|960mg
33075957|NCT00550381|Placebo Comparator|10|placebo
33075958|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
33082253|NCT04620616|Experimental|Product Use Sequence 3|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
32731713|NCT02507167|Placebo Comparator|mixed meal|
32731714|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
32731715|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
32731716|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
32731717|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
32731718|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
32731719|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
32731720|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
32731721|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
32731722|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
32731723|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
32731724|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
32731725|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
32731726|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
33255371|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
32731727|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
32731728|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
32731729|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
32731730|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
32731731|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
32731732|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
32731733|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
32731734|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
32731735|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
32731736|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
33075959|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
33075960|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
32731737|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
32731738|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
32731739|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
32731740|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
32731741|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
32731742|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
32731743|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
32731744|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
32731745|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
32731746|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
32731747|NCT04497571|Experimental|Piezoelectric osteotomy|Implant placement by piezoelectric osteotomy
32731748|NCT04497571|Active Comparator|Conventional drilling|Implant placement by conventional drilling
32731749|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
32731750|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
32731751|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)~First phase: Afatinib montherapy~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
32731752|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
32731753|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
32731754|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
32731755|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
32731756|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
32731757|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
32731758|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be~R test~Nuubo~TECHNOMED pocket ECG~ZIO xt patch~MoMe"
32731759|NCT04497805|Experimental|ALLO-ASC-SHEET|ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
32731760|NCT04497805|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
32731761|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
32731762|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: 20mL each side~Weight greater than or equal to 70kg: 20mL each side"
32731763|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
32731764|NCT02506543|Active Comparator|Wait-list control|No intervention
32731765|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
32731766|NCT02516293|Experimental|Intervention group|"Physical exercise intervention~Nutritional counseling~Pharmaceutical counseling"
33075961|NCT04900675|Experimental|bright white light intervention|exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
33075962|NCT04900675|Placebo Comparator|dim reddish light intervention|exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
32731767|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
32731768|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
32731769|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
32731770|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
32731771|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
32731772|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
32731773|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
32731774|NCT02516215||8_Anemia|Patients with diagnosed anemia
32731775|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
33075963|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
32731776|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
32731777|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
32731778|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 mg (MILIGRAM)bid p.o till disease progression
32731779|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
32731780|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
32731781|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
32731782|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
32731783|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
32731784|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
32731785|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
32731786|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
32731787|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
32731788|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
32731789|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
32731790|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
32731791|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
32731792|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
32731793|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
32731794|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
32731795|NCT04499287|Placebo Comparator|Control|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice (active) and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption . One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption
32742831|NCT04951869|Experimental|Protescal group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, 1 mL Protescal gel was applied at the uterine suture site in Protescal group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). Protescal gel (0.5 mL) was applied over the subcutaneous tissue prior to skin closure in Protescal group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
33075964|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
33075965|NCT00550849|Experimental|1|RTA 402
33075966|NCT00550849|Experimental|2|RTA 402
33075967|NCT00550849|Experimental|3|RTA 402
32731796|NCT04499287|Active Comparator|Fiber|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. 9 grams of soluble viscous fiber from psyllium husk (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) was mixed with the apple juice. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption. One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo).
32743069|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to use MP only for another 2 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
32935156|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
32935157|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
32935158|NCT04189796|Active Comparator|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
32935159|NCT04189796|Sham Comparator|Camembert|Daily intake of Camembert Cheese in 6 weeks
32935160|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
32935161|NCT02711839|Experimental|Treatment Group|White sweet potato formula
32935162|NCT04738838|Experimental|Oxytocin Nasal Spray|Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
32935163|NCT04738838|Placebo Comparator|Placebo Nasal Spray|Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
32935164|NCT04738916|Experimental|Vibration Group|The vibration group was included in the low frequency (25 Hz), low amplitude (2mm), fixed six-week training on two non-consecutive days of the week.
32935165|NCT04738916|No Intervention|Control Group|No training was given to the control group.
32935166|NCT05331404|Experimental|Presbycusis|Patients with presbycusis who receive rehabilitation with hearing aids
32935167|NCT05331404|Active Comparator|Aged control group|Aged control group: 15 subjects with normal or near-normal hearing thresholds
32935168|NCT05331404|Active Comparator|Young control group|Young control group: 15 subjects with normal hearing thresholds
32935169|NCT04739917|Experimental|Arm N Vaccine|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
32935170|NCT04739917|Placebo Comparator|Arm N Placebo|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
32935171|NCT04739917|Experimental|Arm S Vaccine|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
32935172|NCT04739917|Placebo Comparator|Arm S Placebo|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
32935173|NCT05315726|Experimental|Pahse 1|
32935174|NCT05315726|Experimental|Phase 2: Intervention group|
32935175|NCT05315726|Active Comparator|Phase 2: control group|
32935176|NCT05343481|Experimental|Experimental: Group 1 ChAdOx1-HBV, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
32935177|NCT05343481|Experimental|Experimental: Group 2 ChAdOx1-HBV, MVA-HBV and nivolumab, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
32935178|NCT05343481|Experimental|Experimental: Group 3 ChAdOx1-HBV, MVA-HBV, nivolumab, MVA-HBV|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection Day 36: Nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10^8 pfu IM injection
32935179|NCT05303636|Experimental|Cohort 1 (adolescents aged 14-17) LF111 (drospirenone) Arm|Drospirenone 4 mg tablet daily on Days 1 -24; inert tablet daily on Days 25-28
32935180|NCT05303636|No Intervention|Cohort 1 (adolescents aged 14-17) Non-Hormonal Contraceptive Arm|Non-hormonal contraceptive methods
32935181|NCT05303636|Experimental|Cohort 2 (adults aged 18-45) LF111 (drospirenone) Arm|Drospirenone 4 mg tablet daily on Days 1 -24; inert tablet daily on Days 25-28
32935182|NCT05303636|No Intervention|Cohort 2 (adults aged 18-45) Non-Hormonal Contraceptive Method Arm|Non-hormonal contraceptive methods
32935183|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
32935184|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
32935185|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
32935186|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
32935187|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
32935188|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
32935189|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
32731797|NCT04499287|Experimental|Walk|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes. Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo comparator). One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (active comparator).
32731798|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
32731799|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
32731800|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
32731801|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
32731802|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
32731803|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
32731804|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
32731805|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
32731806|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
32731807|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
32731808|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
32731809|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
32731810|NCT04500535||Cohort 1|Immuno-oncology (IO)-naïve patients
32731811|NCT04500535||Cohort 2|IO-experienced patients for whom last IO discontinuation was not primarily related to IO-toxicity
32731812|NCT04500535||Cohort 3|IO-experienced patients for whom last IO discontinuation was primarily due to IO-toxicity
32731813|NCT04500457|Experimental|Intervention|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
32731814|NCT04500457|No Intervention|Wait-List Control|Participants in this condition will not receive treatment.
32731815|NCT04500145|Active Comparator|SIB-IMRT|patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.
32731816|NCT04500145|Other|routine|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
32731817|NCT02510755|Other|PTSD group|PTSD group
32731818|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
32731819|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
32731820|NCT03345745||Periodontally healthy subjects|Salivary samples
32731821|NCT03345745||Chronic periodontitis patients|Salivary samples
32731822|NCT03345745||Gingivitis patients|Salivary samples
32731823|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
32731824|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
32731825|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
32731826|NCT04499989|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
32731827|NCT04499989|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.
32731828|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
32731829|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
33082254|NCT04620616|Experimental|Product Use Sequence 4|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
32731830|NCT04500067|Experimental|Study Group (IVIG)|Patients receive IVIG (trade name - Bioven) with base therapy
32731831|NCT04500067|No Intervention|Control group|Patients receive base therapy only
32731832|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
32731833|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
32731834|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
32731835|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
32731836|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.~Use of other examinations like chest CT if necessary"
32731837|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
32731838|NCT04497649|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir with standard of care treatment
32731839|NCT04497649|No Intervention|Standard of care treatment|Standard of care treatment
32731840|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
32731841|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
32731842|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
32731843|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
32731844|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
32731845|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
32731846|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
32731847|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
32731848|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
32731849|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
32731850|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
32731851|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
32731852|NCT02510833|Experimental|Continuing Intervention Group|
32731853|NCT02510833|Active Comparator|Control Group|
32731854|NCT04500223|Experimental|Cervical Cranioflexion exercise plus cardiopulmonary exercise|subjects who received Cervical Cranioflexion exercise plus cardiopulmonary exercise
32731855|NCT04500223|Active Comparator|Cervical stretch exercise plus cardiopulmonary rehabilitation|subjects who received Cervical stretch exercise plus cardiopulmonary rehabilitation
32731856|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
32731857|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
32731858|NCT02510911|Placebo Comparator|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
32731859|NCT04499911|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
32731860|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
32731861|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
32731862|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
32731863|NCT03343873|Experimental|Midarolam|midarolam sensation group
32731864|NCT03343873|Experimental|Propofol|propofol sensation group
32731865|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
32731866|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
32731867|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
32731868|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
32731869|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
32731870|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
32731871|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
32731872|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
32731873|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
32731874|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
32731875|NCT03343795|Experimental|study group 1|oral progesterone
32731876|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
32731877|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
33082255|NCT04620616|Experimental|Product Use Sequence 5|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
32731878|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
32731879|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
32731880|NCT02505139||Study Group|
32731881|NCT04499755|Experimental|Nucleo CMP forte|Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
32731882|NCT04499755|No Intervention|Supportive treatment|Supportive treatment only.
32731883|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
32731884|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
32731885|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
32731886|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
32731887|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
32731888|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
32731889|NCT03345355||patient with axial spondyloarthritis|
32731890|NCT02505061|Experimental|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
32731891|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
32731892|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
32731893|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
32731894|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
32731895|NCT02510209|Experimental|Teen Outreach Program|
32731896|NCT02510209|No Intervention|Control|Business as usual.
32731897|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
32731898|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
32731899|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
32731900|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
32731901|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
32731902|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
32731903|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
33255372|NCT04581824|Experimental|Participants receiving dostarlimab plus chemotherapy|Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
32731904|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
32731905|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
32731906|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
32731907|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
32731908|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
32731909|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
32731910|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
32731911|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
32731912|NCT02504515|Active Comparator|Homeopathy|
32731913|NCT02504515|Active Comparator|Allopathy homeopathy control|
32731914|NCT02504515|Active Comparator|Acupuncture|
33255373|NCT04581824|Active Comparator|Participants receiving pembrolizumab plus chemotherapy|Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
32731915|NCT02504515|Active Comparator|Allopathy acupuncture control|
32731916|NCT02504515|Active Comparator|Anthroposophic medicine|
32731917|NCT02504515|Active Comparator|Allopathy anthroposophy control|
32731918|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
32731919|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
32731920|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
32731921|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
32935190|NCT05330611|Experimental|Ultrasound-guided Cryoneurolysis: Group A|"Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be18-64 years of age and will be randomized (1:1) to the ultrasound-guided cryoneurolysis group within 72 hours of admission to the ED.~Intervention is ultrasound guided cryoneurolysis of intercostal nerves creating lost lasting pain relief. Device used for cryoneurolysis is Iovera Smart tip 190"
33255374|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
33255375|NCT04552886|Experimental|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
33255376|NCT04552886|Experimental|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10^6.
32731922|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
32731923|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
32731924|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
32731925|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
32731926|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
32731927|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
32731928|NCT01376089|Other|Arm 1-Iodixanol|
32731929|NCT01376089|Active Comparator|Arm 2-Iopamidol|
33255377|NCT04552886|Experimental|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10^6.
33255378|NCT04552886|Experimental|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10^7.
32731930|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
32731931|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
32731932|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
32731933|NCT02509741|No Intervention|control|Routine diet recommendation
32731934|NCT02514967|Experimental|Blisibimod|
32731935|NCT02514967|Placebo Comparator|Placebo|
32731936|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
32731937|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
32731938|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
32731939|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
33255379|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
33255380|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
33255381|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
32935191|NCT05330611|Active Comparator|Standard-of-Care : Group B|Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be18-64 years of age and will be randomized (1:1) to Standard of Care which typically includes multi-modal pain therapy and pulmonary toilet.
32935192|NCT05303701|Placebo Comparator|Placebo (with extention period: GV1001 1.12mg)|Placebo SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase. Then GV1001 1.12 mg will be administered once weekly for 4 weeks (from Week 26 to Week 29) then every 2 weeks through Week 49 for open extension phase.
33255382|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
32935193|NCT05303701|Experimental|GV1001 0.56 mg (with extention period: Placebo&GV1001 1.12mg)|GV1001 0.56 mg SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase. Placebo and GV1001 1.12 mg will be administered alternately every week for 4 weeks (from Week 26 to Week 29), then GV1001 1.12 mg will be administered every 2 weeks through Week 49 for open extension phase.
32935194|NCT05303701|Experimental|GV1001 1.12 mg (with extention period: Placebo&GV1001 1.12mg)|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase. Placebo and GV1001 1.12 mg will be administered alternately every week for 4 weeks (from Week 26 to Week 29), then GV1001 1.12 mg will be administered every 2 weeks through Week 49 for open extension phase.
32731940|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
32935195|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
32935196|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
32935197|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
32935198|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
32935199|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
32935200|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
32935201|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
32935202|NCT04339231|Active Comparator|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
32935203|NCT04339231|Placebo Comparator|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
32935204|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
32935205|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
32935206|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
32935207|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
32935208|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
32935209|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
32935210|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
32935211|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
32935212|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
32935213|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
32935214|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
32731941|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
32731942|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
32731943|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
32731944|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
32731945|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
32731946|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
32731947|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
32731948|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
32731949|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:~the first with Control-to-Range algorithm (CTR),~the second with Threshold Low Glucose Suspend (TLGS)."
32731950|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:~the first with Threshold Low Glucose Suspend (TLGS),~the second with Control-to-Range algorithm (CTR)."
32731951|NCT04497181|Experimental|Experimental group|
32731952|NCT04497181|Sham Comparator|Control group|
32731953|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
32731954|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
32731955|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
32731956|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
32731957|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
32731958|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
32731959|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
32731960|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
32743070|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP + Call + MesC [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to have MP and additional coach support for another 2 weeks. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
33075968|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
33075969|NCT00161720||All participants|Participants with severe congenital protein C deficiency who were treated under an emergency use IND.
32743071|NCT04939779|Experimental|Group A|Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
32935215|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
32935216|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
33075970|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
33075971|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
32731961|NCT04497025|Experimental|Immersive virtual reality-based vestibular training.|"Subjects in this group will receive the same intervention than the other group of study, but they will wear a 3D head mounted display (Oculus Quest glasses) and will receive real-time gaming feedback in terms of visual and audio output while using the training system.~Participants will receive a total of 20 sessions (3 sessions of 50 minutes per week, 7 weeks). These sessions will be divided in 10 initial sessions (based on the three first blocks of Cawthorne-Cooksey protocol) and 10 advanced sessions in which vestibular exercises are gradually get more complicated by modifiying the following exercise parameters: base of support width, standing on unstable surface, alternatives single leg support, tandem position, increased velocity of head movements, higher head range motion and coordinated movements with arms and trunk.~Same location, tailoring parameters and physical therapist supervision than conventional vestibular training."
32731962|NCT04497025|Active Comparator|Conventional vestibular training.|"Subjects in the control group will receive a total of 20 sessions of 50 minutes (3 sessions per week, 7 weeks). They will receive traditional Cawthorne-Cooksey vestibular rehabilitation exercises. This program improves vestibular compensation through a mechanism of neuroplasticity known as adaptation, habituation and substitution. Just like the virtual reality intervention it will be divided in 10 initial sessions and 10 advanced sessions. For the advanced phase of intervention exercises parameters were the same described for the virtual vestibular rehabilitation intervention.~A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the difficulty level. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
32731963|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
32731964|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
32731965|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
32731966|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
32731967|NCT04499209|Experimental|Period 1- XG005|XG005 capsule in 4 dose level
32731968|NCT04499209|Active Comparator|Period 2- Naproxen and Pregabalin|Combination of Naproxen and Pregabalin
32731969|NCT04499209|Placebo Comparator|Period 1- Placebo|XG005 matching placebo
32731970|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
32731971|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
32731972|NCT04497259|Experimental|Interventional|Patients in the teleconsultation arm will benefit from a tele-evaluation (a questionnaire filled through a chatbot link) and teleconsultation (skype-like connection) at 6 and 9 months after surgery.
32731973|NCT04497259|Experimental|Control|Patients in the consultation arm will benefit from a tele-evaluation (a questionnaire filled at home after the file was sent by secured mail) and a classical face to face consultation at 6 and 9 months after surgery.
32731974|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
32731975|NCT02503579|No Intervention|control|"1 training at the beginning of the study~1 training at the end of the study"
32731976|NCT04497103|Active Comparator|control|The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children.
32731977|NCT04497103|Experimental|task oriented training|Task-oriented training TOT group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
32731978|NCT04497103|Experimental|Xbox kinect|Xbox training group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
32731979|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
32731980|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
32731981|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
32731982|NCT02509351|Active Comparator|placeboo|women receiving placebo
32731983|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
32731984|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
33075972|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
33082256|NCT04620616|Experimental|Product Use Sequence 6|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
32731985|NCT04496791|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing instrument (HI) with modified precalculation.
32731986|NCT04496791|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent RIC device from Phonak which will be fitted to the participants individual hearing loss.
32731987|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
32731988|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
32731989|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
32731990|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
32731991|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
32731992|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
32731993|NCT04496635|No Intervention|Baseline phase|Patients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
32731994|NCT04496635|Experimental|Implementation phase|Patients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
32731995|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
32731996|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
32731997|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
32731998|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
32731999|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
32732000|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
32732001|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
32732002|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
32732003|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
32732004|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
32732005|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
32732006|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
32732007|NCT02503189|Experimental|KCT-0809|
32732008|NCT02503189|Placebo Comparator|Placebo|
32732009|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
32732010|NCT02508727|Other|Healthy volunteers|Healthy volunteers
32732011|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
32732012|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
32732013|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
32732014|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
33082257|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
33082258|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.~Active comparator"
32732015|NCT04498975||Patients with IHD|No intervention
32732016|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
32732017|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
32732018|NCT02502565||Uric Acid Level|
32732019|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
32732020|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
32732021|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
32732022|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
32732023|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
32732024|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
32732025|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
33082259|NCT04620499|Experimental|Experimental|EEG-guided drug prescription
32732026|NCT04498819|Experimental|Single Arm|Only one arm, one intervention; this is a feasibility study.
32732027|NCT04498897|Active Comparator|Test group|Vortioxetine + Acamprosate
32732028|NCT04498897|Placebo Comparator|Placebo Group|Placebo + Acamprosate
32732029|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
32732030|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
32732031|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
32732032|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
32732033|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
32732034|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
32732035|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
32732036|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
32732037|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
32732038|NCT02502331|Active Comparator|comparator group|Euvichol®
32732039|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
32732040|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
32732041|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
33401267|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
33401268|NCT01379352||High MELD group|Preoperative MELD score greater than 20
32732042|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
32732043|NCT03343327|Experimental|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
32732044|NCT03343327|Active Comparator|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
32732045|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
33082260|NCT04620499|No Intervention|Control|Will receive EEG, but drugs will be prescribed as usual
32732046|NCT03121183||Patients who have undergone an extraction of implantable pace|
32732047|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
32732048|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
32732049|NCT04496323||LOW|Golf Skill level high, handicap below 11.5
32732050|NCT04496323||HIGH|Golf Skill level low, handicap 18.5 - 26.4
32732051|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
32732052|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
32732053|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
32732054|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
32732055|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
32732056|NCT04495387||patients with colon cancer|
32732057|NCT04495387||patients with breast cancer|
32732058|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
32732059|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
32732060|NCT04495075|Experimental|Visuomotor Therapy|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
32732061|NCT04495075|Active Comparator|Passive Motion|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
32732062|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
32732063|NCT04495309|No Intervention|Standard|Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)
32732064|NCT04495309|Experimental|Experimental|Standard of care (standard systemic therapy) + study intervention
32732065|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
32732066|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
32732067|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
32732068|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
32732069|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:~ABA therapy enhanced with V-Motive software~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
32732070|NCT02500693|Experimental|Screening|
32732071|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
32732072|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
32732073|NCT02500615|Experimental|0 PG: 100 VG|
32732074|NCT02500615|Experimental|30 PG: 70 VG|
32732075|NCT02500615|Experimental|50 PG: 50 VG|
32732076|NCT02500615|Experimental|70 PG: 30 VG|
32732077|NCT02500615|Experimental|100 PG: 0 VG|
32732078|NCT04496011|Experimental|Experimental Group|In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.
32732079|NCT04496011|No Intervention|Group Control|"In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service.~It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs"
32732080|NCT03344107|Active Comparator|Vortek double-J stent|Vortek double-J stent after RIRS.
32732081|NCT03344107|Active Comparator|Polaris Loop stent|Polaris Loop ureteral stent after RIRS.
32732082|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
32732083|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
32732084|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
32732085|NCT04496557|Experimental|Patients diagnosed with PTSD|7-15 men and women with PTSD will be recruited from the community and from local clinical programs through a multi-modal outreach program.
32732086|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
32732087|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
32732088|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
32732089|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|SARS-CoV-2 Sclamp antigen 5 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart.(Cohorts 1 & 4)
32732090|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|SARS-CoV-2 Sclamp antigen 15 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 2 & 5)
32732091|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|SARS-CoV-2 Sclamp antigen 45 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 3 & 6)
32732092|NCT04496089|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
33401269|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
32732093|NCT04495465|Experimental|Experimental group: manual therapy + shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of extracorporeal radial shock waves therapy on painful points of neck muscles at 2 bars and 10 Hetzs.
32732094|NCT04495465|Placebo Comparator|Control group: manual therapy + placebo shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
32732095|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
32732096|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
32732097|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
32732098|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
32732099|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.~Memory intervention will be used."
32732100|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
32732101|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
32732102|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
33401270|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
32732103|NCT04498039|Experimental|Active|Electrical stimulation to the tongue is delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Active subjects will be able to feel the sensation.
33401271|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
33401272|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
33401273|NCT04752462|No Intervention|Standard of Care with provider|Participant will continue follow up for sleep apnea with provider.
32732104|NCT04498039|Sham Comparator|Control|Electrical stimulation to the tongue will be delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Control subjects will be informed that while they may not feel the electrotactile stimulation, they are in-fact receiving a low level signal.
32732105|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
32732106|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
32732107|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
32732108|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
32732109|NCT04498195|Experimental|Increase physical activity and exercise|
32732110|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
32732111|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
32732112|NCT04494997||Dentists|Practicing Dental Health Professionals who are either General Dentists &/or Specialists Dentists are part of the Cohort. They should have held or currently hold Social Media account for their Professional purpose. They should have used or currently using their Social Media account for Professional purpose. The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media &/Or email to seek responses. The link will be available for single response for a single respondent.
32732113|NCT05460637|Experimental|Intervention Group|Participants receive a Fitbit and access to a 10 week educational course that accessible through the web or app. While participants can complete the program at their own pace, there is a suggested schedule with 1-2 modules/lessons completed per week. Each module has a different topic related to promoting adoption and maintenance of physical activity.
32732114|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
32732115|NCT03120637|No Intervention|Standard Treatment|
32732116|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
32732117|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.~Patients for lymph node imaging:~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
32732118|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
32732119|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
32732120|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
32732121|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
32732122|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
32732123|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
32732124|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
32732125|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
32732126|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.~- Examination and diagnosis (15 min).~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
32732127|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
32732128|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
32732129|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
32732130|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
32732131|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
32732132|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
32732133|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
32732134|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
32732135|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
32732136|NCT04443049|Active Comparator|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
32732137|NCT04443049|Experimental|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
32732138|NCT02499133|Other|adult who suffered traumatic brain injury|
32732139|NCT02499133|Other|control group|
32732140|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
32935217|NCT05267756|Experimental|intervention Group|"Patient will be receive .~usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~The intervention group will have in addition to the usual care, virtual reality immersive based-exercise game, the participants will download (kurki-application), and will given VR glasses"
32935218|NCT05267756|No Intervention|Control Group|"Patient will be receive .~usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~The control group will have in addition to usual care that included the education patients, a Brochure for LBP therapeutic exercises"
32935219|NCT04130438|Active Comparator|Beta Blocker (nebivolol)|
32935220|NCT04130438|Active Comparator|Calcium Channel Blocker (diltiazem)|
32935221|NCT04130438|Placebo Comparator|Placebo|
32935222|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
33401274|NCT04752462|Experimental|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
33255383|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
32732141|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
32732142|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
32732143|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
32732144|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
32732145|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
32935223|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
33255384|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
32732146|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
32732147|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
32732148|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
32732149|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
32732150|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
32732151|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
32732152|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
32732153|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
32732154|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
32732155|NCT03336463||Controls|No intervention
32732156|NCT03336463||Cases|No intervention
32732157|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
32732158|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
32732159|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
32732160|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
32732161|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
32732162|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
32732163|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
32732164|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
32732165|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
32732166|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
32732167|NCT02494843|Active Comparator|Online haemodiafiltration|
32732168|NCT02494843|Active Comparator|Haemodialysis|
32732169|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
32732170|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
32732171|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
32732172|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
32732173|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
32732174|NCT03336229|Active Comparator|Intervention|
32935224|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
32732175|NCT03336229|No Intervention|Control|
32732176|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
32732177|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
32732178|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
32732179|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
32732180|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
32732181|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
32732182|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
32732183|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.~TME surgery after radiotherapy."
32732184|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.~TME surgery after radiotherapy."
32732185|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
32732186|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
32732187|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
32732188|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
32732189|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
32732190|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
32732191|NCT02498509|Experimental|Treatment|CKD-342
32732192|NCT02498509|Active Comparator|Control 1|Mometasone furoate
32732193|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
32732194|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
32732195|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
32732196|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
32743072|NCT04939779|Experimental|Group B|Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
32935225|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
32935226|NCT05165329|Active Comparator|Probiotic and Peanut Oral Immunotherapy (PPOIT)|Probiotic and peanut oral immunotherapy taken daily for 18 months
33255385|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
33255386|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
32732197|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
32935227|NCT05165329|Active Comparator|Placebo Probiotic and Peanut Oral Immunotherapy|Placebo probiotic and peanut oral immunotherapy taken daily for 18 months
33255387|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
33255388|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
33255389|NCT00560937|Active Comparator|1|Pregnenolone
33255390|NCT00560937|Placebo Comparator|2|Placebo
33255391|NCT00945165|Experimental|Exercise|
33255392|NCT00945165|Experimental|No exercise|
33255393|NCT04012437|Experimental|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
33255394|NCT04012437|Active Comparator|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
33255395|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
33255396|NCT00945399|Active Comparator|Microfracture|
33255397|NCT00941187||patients after a first episode of pulmonary embolism|
33255398|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
33255399|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
33255400|NCT04012047|Active Comparator|Levcromakalim|
33255401|NCT04012047|Placebo Comparator|Saline|
33255402|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
33255403|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
33255404|NCT00941343|Experimental|1|XATRAL 10mg OD
33255405|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
33255406|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
33255407|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
33255408|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
33401275|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
33401276|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
33401277|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
33401278|NCT01380288|Active Comparator|without white matter change|
32732198|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
32935228|NCT05165329|Placebo Comparator|Placebo Probiotic and Placebo Oral Immunotherapy|Placebo probiotic and placebo oral immunotherapy taken daily for 18 months
32935229|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
32935230|NCT05153551|Experimental|PEARS assessment|
32935231|NCT05261672|Active Comparator|Group QL1|quadratus lumborum block will be done. 20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
32732199|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
32732200|NCT03341611||Adults 55 and younger|
32732201|NCT03341611||Adults 55 and older|
32732202|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
32732203|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
32732204|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.~Specifically, capacity building, training and support will be provided to~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
32732205|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
32732206|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
32732207|NCT04494919||Ultrafine Endoscope Assisted|The self-expanding metal stent (SEMS) implantation was conducted using an ultrafine endoscope (UFE) (GIF-XP260NS; Olympus, Tokyo, Japan). The UFE researched the stricture, and a guidewire was inserted into the endoscopic working channel. The guidewire was left. And the endoscope was withdrawn. The normal colonoscope was exchanged under the reverse guidance of the guidewire. Finally, a metal, uncovered SEMS was placed along the guidewire.
32732208|NCT04494685|Experimental|Robotic rehabilitation|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland).
32732209|NCT04494685|Active Comparator|Conventional physiotherapy|The protocol will be based on lower limb exercises, aiming at maintaining and gaining muscle strength through passive, assisted or active mobilization, when possible, on the affected side.
32732210|NCT04494607|Experimental|Test arm|Determination of Glycemic and Insulinemic curves under different alimentary intake
32732211|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
32732212|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
32732213|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
32732214|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
32732215|NCT03335605||Healthy controls|Age and gender-matched control subjects
32732216|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
32732217|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
32732218|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
32732219|NCT02494453||Cardiac MRI|
32732220|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
32732221|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
32732222|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
32732223|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
32732224|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
33401279|NCT01380288|Active Comparator|with white matter change group|
32732225|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
32732226|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
32732227|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
32732228|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
32732229|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
32732230|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
32743073|NCT04940169|Experimental|quadriceps tendon autograft|Ramdomized half of the patient underwent quadriceps graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
32743074|NCT04940169|Experimental|hamstring tendon autograft|Ramdomized half of the patient underwent hamstring graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
32743075|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
33401280|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
32732231|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
32732232|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
32732233|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
32732234|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
33401281|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
32732235|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
32732236|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
32732237|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
32732238|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
32732239|NCT02492815||Population with condition and without condition|Participating in EAP
32732240|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
32732241|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
32732242|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
32732243|NCT02492893|No Intervention|Treatment as Usual|
32732244|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
32732245|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
32732246|NCT03120481||Normal control|
32732247|NCT02498119||Normal|Patient sample within the normal range of blood results.
32732248|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
32732249|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
32732250|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
32732251|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
32732252|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
32732253|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
32732254|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
32732255|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
32732256|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
32732257|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
32732258|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) in capsule formulation in a 2-period crossover design with a 2-week washout/follow-up period
32732259|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) in tablet formulation in a 2-period crossover design with a 2-week washout/follow-up period
32732260|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
32732261|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
32732262|NCT03335215|No Intervention|usual care|
32732263|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
32732264|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
32732265|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
32732266|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
32732267|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
32732268|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
32732269|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
32732270|NCT00707161|Experimental|All participants|
32732271|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
32732272|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
32732273|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
32732274|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
32732275|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
32732276|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
32732277|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
32732278|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
32732279|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
32732280|NCT05465473|Active Comparator|Group I|will include 10 patients undergo distalization according to a standardized protocol
32732281|NCT05465473|Active Comparator|Group II|will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol
32732282|NCT02494375|Experimental|Sleep and glucose assessement.|
32732283|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
32732284|NCT05438407|Experimental|Leniolisib|Leniolisib - Film Coated Tablets Leniolisib tablets in 10 and 30 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.
32732285|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
32732286|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
32732287|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
32732288|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
32732289|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
32732290|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
32732291|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
32732292|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
32732293|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
32732294|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
32732295|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
32732296|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
32732297|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
33401282|NCT04438499|Experimental|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
32732298|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
32732299|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
32732300|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
33075973|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
33075974|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
32732301|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:~Parents Connect for Healthy Living (PConnect)~Enhanced Nutrition Support~Media Resources"
33075975|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
33075976|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
33255409|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
33255410|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
33255411|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
33255412|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
32732302|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
32732303|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
32732304|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
32732305|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
32732306|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
33075977|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
33075978|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
32732307|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
32732308|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
33075979|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
32732309|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
32732310|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
32732311|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
32732312|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
32732313|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
32732314|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
32732315|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
32732316|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
33255413|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
33255414|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
33255415|NCT00308737|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
33255416|NCT00308737|Other|Usual care|Usual care
33255417|NCT00308737|No Intervention|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
33255418|NCT04711902|Active Comparator|Arm 1|Arm 1 - Secukinumab Dose level 1
33255419|NCT04711902|Placebo Comparator|Arm 2|Arm 2 Secukinumab Placebo
32732317|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
32732318|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
32732319|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
32732320|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
32732321|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
32732322|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
32935232|NCT05261672|Active Comparator|Group QL2|quadratus lumborum block will be done. ) 20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
32935233|NCT05152849|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
32935234|NCT05152849|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
32935235|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
33255420|NCT04711902|Active Comparator|Arm 3|Arm 3 Secukinumab Dose level 1 and Placebo
33255421|NCT04711902|Active Comparator|Arm 4|Arm 4 Secukinumab Dose level 2
32732323|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
32732324|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+dabrafenib150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by intravenous (IV) infusion on Days 1 and 22 of each 6-week cycle (Q6W); 150 mg/day total dabrafenib orally, in a divided dose, twice a day (BID) starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally once a day (QD) starting on Day 1 and continuing up until study treatment discontinuation.
32732325|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+trametinib 2 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732326|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732327|NCT02130466|Experimental|Part 2:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32935236|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
32935237|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
32935238|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
32935239|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
32935240|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
32935241|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
32935242|NCT05221502|Experimental|Arm 1|Delamanid + Bedaquiline + OPC-167832 10 mg
32935243|NCT05221502|Experimental|Arm 2|Delamanid + Bedaquiline + OPC-167832 30 mg
32935244|NCT05221502|Experimental|Arm 3|Delamanid + Bedaquiline + OPC-167832 90 mg
32935245|NCT05221502|Active Comparator|Arm 4|RHEZ
32935246|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
32935247|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
32935248|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
32935249|NCT03938324|Experimental|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
32732328|NCT02130466|Experimental|Part 2:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732329|NCT02130466|Experimental|Part 3:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732330|NCT02130466|Placebo Comparator|Part 3:placebo+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received saline placebo administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732331|NCT02130466|Experimental|Part 4:trametinib 2 mg for 4 weeks+pembrolizumab 200 mg+trametinib 2 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 of each 3-week cycle (Q3W) and a concurrent dosing schedule of 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732332|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732333|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 4 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732334|NCT02130466|Experimental|Part 4:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
32732335|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 1.5 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
32732336|NCT02130466|Experimental|Part 5:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
32732337|NCT02130466|Experimental|Part 5:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
32732338|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
32732339|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
32743076|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
32743077|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
33255422|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
33255423|NCT00945711||2|Eating Disorder only patients
33255424|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
33255425|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
33255426|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
33255427|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
33255428|NCT04752384|Experimental|Drug Treatment|The main objective of this study is to provide preliminary evidence that FDA approved dose of transdermal buprenorphine in conjunction with oral tramadol can provide adequate analgesia of radiation-induced mucositis pain during treatment and follow up period in head and neck cancer patients.
33401283|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
33401284|NCT03751085|Experimental|AW frame|AW frame biopsy
33401285|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
33401286|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
33401287|NCT00002874|Experimental|Bicalutamide|Radiation therapy + bicalutamide
33401288|NCT00002874|Placebo Comparator|Placebo|Radiation therapy + placebo
32732340|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
32732341|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.~Electrical parameters:~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
32732342|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
32732343|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
32732344|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
32732345|NCT03334279||non smokers|
32732346|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
32732347|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
32732348|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
32732349|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
32732350|NCT02493829|Experimental|AML Cell Vaccine|
32732351|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
32732352|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
32732353|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
32732354|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
32732355|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
32732356|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
32732357|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
33401289|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
32732358|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
32732359|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
32732360|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
32732361|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
32732362|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
32732363|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
32732364|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
32732365|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
32732366|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
32732367|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
32732368|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
32732369|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
32732370|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
32732371|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
32732372|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
32732373|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
32732374|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
32732375|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
32732376|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
32732377|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
32732378|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
32732379|NCT02496325|Other|perineal technic|
32732380|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
32732381|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
32732382|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
32732383|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
32732384|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
32732385|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
32732386|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
32732387|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
32732388|NCT03342079|Experimental|Group 1|local anesthetic + placebo
32732389|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
32732390|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
33255429|NCT04743804|Experimental|Ravulizumab|
32732391|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
33255430|NCT04743804|Placebo Comparator|Placebo|
32732392|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
32732393|NCT04755790|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
32732394|NCT04755790|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
33255431|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
33255432|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
33255433|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
33255434|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
33255435|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
33255436|NCT04737096|Experimental|tDCS+DAOIB|
33255437|NCT04737096|Placebo Comparator|tDCS+placebo|
33255438|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
32732395|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
32732396|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
32732397|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
32732398|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
32732399|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
32732400|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
32732401|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
33075980|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
33255439|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
33255440|NCT04725006|Experimental|Stimulation in individuals with implanted stimulation systems|During psychophysical stimulation trials, an external stimulator will be connected to the SCS lead, a volley of stimulation will be performed, and the subject will be asked to respond to standard psychophysical questions, as well as to provide any additional comments.
33255441|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.~Frequency: one injection per week Duration: until the end of the study"
33255442|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.~Frequency: one injection per week Duration: until the end of the study"
33255443|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
33255444|NCT00950079|Active Comparator|Saline|saline infusion
33255445|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
33255446|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
33255447|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
33255448|NCT00655746|Experimental|1|
33255449|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
32732402|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32732403|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
32732404|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
32732405|NCT04494763|Experimental|Propanolol|Dose: 1 to 8 mg/kg/day in 1 to 2 divided doses adjusted to achieve target reduction in resting heart rate by 25% from baseline Frequency: once to Twice daily Route of Administration: Oral Duration: 18 months
32732406|NCT04494763|Placebo Comparator|Placebo|Placebo in a similar manner
32732407|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
32732408|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
32732409|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
32732410|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
32732411|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
32732412|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
32732413|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
32732414|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
32732415|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
32732416|NCT02493907||heart failure|heart failure patients with CRT
32732417|NCT03338413|Experimental|Goal Management Training|
32732418|NCT03338413|Experimental|Computerized Cognitive Training|
33255450|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
33255451|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
33401290|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
33401291|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
32732419|NCT04494529|Placebo Comparator|Single-Dose (12 mg betamethasone + placebo)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection instead of the standard 2nd dose of 12 mg of betamethasone (i.e. they will receive the experimental single-dose regimen, total 12 mg of betamethasone only from the first injection)."
32732420|NCT04494529|Active Comparator|Double-Dose (12 mg betamethasone + 12 mg betamethasone)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the Double-Dose arm will receive the standard 2nd dose of 12 mg of betamethasone injected intramuscularly (i.e. they will receive the standard double-dose regimen, total 24 mg of betamethasone)."
32732421|NCT04494139|Active Comparator|Canteen Only|Train canteen staff and implement canteen intervention in the canteen space: interventions targeting food quality and quantity, intervention targeting food choice at point of sale, interventions target improved supply, interventions targeting price and promotional material.
32732422|NCT04494139|Experimental|Behavioral and Canteen intervention|The behavioral intervention will be comprised of a combination of intensive education sessions and goal setting and monitoring based on a validated worksite curriculum tailored to local needs. The curriculum includes 24 sessions: 16 core weekly sessions during the first four months of the intervention followed by 8 weekly maintenance sessions (text messages). Each session will be facilitated by a nutritionist/dietitian and a peer educator; and will last one hour. Broadly, the curriculum covers the subject matters of importance of healthy weight, eating a healthy diet, increasing physical activity, stress management, and challenges of lifestyle changes. Participants will be encouraged to keep food and activity diaries throughout the course of the study. During the maintenance period, the focus will be on overcoming declines in motivation and on maintaining long-term healthy behaviors.
32732423|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
32732424|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
32732425|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
32732426|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
32732427|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
32732428|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
32732429|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
32732430|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
32732431|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
32732432|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
32732433|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
32732434|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
33401292|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
32732435|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
32732436|NCT04494451|Experimental|Vitamin C + Standard Medical Treatment|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
32732437|NCT04494451|Active Comparator|Standard Medical Treatment|iv antibiotics alone
32732438|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
32732439|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
32732440|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
32732441|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
32732442|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
32732443|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
32732444|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
32732445|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
32732446|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
32732447|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
32732448|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
32732449|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
32732450|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
33401293|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
32732451|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
32732452|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
32732453|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
33255452|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
32732454|NCT05464927||Participants pre CDT|"Participants with lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2~BMI range = 18 to 40 kg/m2"
32732455|NCT05464927||Controls|"Participants without lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2"
32732456|NCT05464927||Participants post CDT|"Participants with lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2~BMI range = 18 to 40 kg/m2"
32732457|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
32732458|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
32732459|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
32732460|NCT04494373|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
32732461|NCT04494373|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
32732462|NCT05464849||Resistant hypertension|Patients presenting with resistant hypertension
32732463|NCT05464849||non-resistant hypertension|Patients presenting with non-resistant hypertension
32732464|NCT05464849||normotensive subjects|control group including normotensive volunteers
32732465|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
32732466|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
32732467|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
32732468|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
32732469|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
32732470|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
33075981|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
32732471|NCT03337867|Active Comparator|Real-iTBS|
32732472|NCT03337867|Sham Comparator|Sham-iTBS|
32732473|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
32732474|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
32732475|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
33075982|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
33255453|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
33255454|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
33255455|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
33255456|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
33255457|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
33255458|NCT00806208|Placebo Comparator|5|Placebo
33255459|NCT05301309|Experimental|Breastfeeding Consultation|"The intervention group would receive integrative early breastfeeding support and intervention programs, including breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support."
32732476|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
32732477|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
32732478|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
32732479|NCT03337789|Experimental|Polygonatum sibiricum|
32732480|NCT03337789|Placebo Comparator|Placebo|
32732481|NCT03332485|Experimental|ECP Colon Prep Kit|
32732482|NCT03332485|Active Comparator|MoviPrep®|
32732483|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
32732484|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
32732485|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
33255460|NCT05301309|Active Comparator|routine care|"The control group only receive breastfeeding for prematurity brochure and routine care."
33075983|NCT00551434|Experimental|1|
33255461|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
33255462|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
33255463|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
33255464|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
33255465|NCT00678392|Experimental|Axitinib|
33255466|NCT00678392|Active Comparator|Sorafenib|
33255467|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
33401294|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
33401295|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
33401296|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
33401297|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
33401298|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
33401299|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
33401300|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
33401301|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
33401302|NCT05422716|Experimental|Surgically implanted epidural stimulation for spasticity|"The epidural stimulation (ES) group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity. In each subsequent 6 months we will enroll cohorts of (n=5) voluntary research participants to allow for the final cohort to complete their 6 month follow up with a remaining 3 months for final data analyses and dissemination for the grant period.~Spinal cord epidural stimulation is administered by a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord."
33401303|NCT05422716|Experimental|Surgically implanted Intrathecal baclofen pump, the standard of care control group|"Individuals randomized to the baclofen pump (BP) group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments).~The Baclofen pump will be surgically implanted by a member of the clinical SCI medical team."
33401304|NCT03728777|Placebo Comparator|Placebo|
33401305|NCT03728777|Experimental|Resveratrol|Over the counter supplement
33401306|NCT05422404|Experimental|Chronic GERD patient reciving Anti-Reflux Mucosal Ablation|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosal Ablation.
33401307|NCT05422404|Active Comparator|Chronic GERD patient reciving Anti-Reflux Mucosectomy|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosectomy
33401308|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
33401309|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
33401310|NCT02646228||molecular profiling, patient derived cells|
33401311|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
33401312|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
33401313|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
33401314|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
33401315|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
33401316|NCT04701138|Experimental|Dietary Supplement|All subjects will receive the intervention (SPM Active Supplement)
32732486|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
32732487|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
32732488|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
33255468|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
33255469|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
33255470|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
33255471|NCT00804414|Experimental|1|
33255472|NCT00804414|Placebo Comparator|2|
33255473|NCT00942435|Experimental|YM150 group|
33255474|NCT00942435|Active Comparator|mechanical prophylaxis group|
33255475|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
33255476|NCT05301075|Sham Comparator|control group|patients will receive sham block.
33255477|NCT05301075|Active Comparator|RISS group|will receive Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
33255478|NCT00950547|Active Comparator|Control|Traditional Chest drains
33255479|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
33255480|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
33255481|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
33255482|NCT00946257|Experimental|Cohort 1|0.3 mg dose
33255483|NCT00946257|Experimental|Cohort 2|0.6 mg dose
33255484|NCT00946257|Experimental|Cohort 3|1.2 mg dose
33255485|NCT00946257|Experimental|Cohort 4|1.8 mg dose
33255486|NCT00946257|Experimental|Cohort 5|2.4 mg dose
33255487|NCT00946257|Experimental|Cohort 6|3.0 mg dose
33255488|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
33255489|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
33255490|NCT04461158|Experimental|Interventional Group|
32732489|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
32732490|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
32732491|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
32732492|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
32732493|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
32732494|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
32732495|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
32732496|NCT03330379|No Intervention|usual care|patients with usual care
32732497|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
32732498|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.~Controls: cohort of matched disease-free individuals"
32732499|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
32732500|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
33255491|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
33255492|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
33255493|NCT00760292||1|Type 2 Diabetic Patients
33255494|NCT00760292||2|Non-diabetic individuals
33255495|NCT04049630|Experimental|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
33255496|NCT04049630|Experimental|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
32732501|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
32732502|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
32732503|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
32732504|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
32732505|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
32732506|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
32732507|NCT05232721||Fecal Immunochemical Test|People in this group will detect hemoglobin in stool before colonoscopy by the new instrument
32732508|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
32732509|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
32732510|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
32732511|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
32732512|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
32732513|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
32732514|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
32732515|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
32732516|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
32732517|NCT03331861|Experimental|Metformin|Metformin for 6 months
32732518|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 6 months
32732519|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
32732520|NCT03329755|Experimental|Experimental|
32732521|NCT03329755|Other|Standard|
32732522|NCT03329443|Placebo Comparator|placebo|
32732523|NCT03329443|Active Comparator|Spironolactone|
32732524|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
32732525|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
32732526|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
32732527|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
32732528|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
32732529|NCT03325075|Experimental|VAL-181388|
32732530|NCT03325075|Placebo Comparator|Placebo|
32732531|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
32732532|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
32732533|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
32732534|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
32732535|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
32732536|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
32732537|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
32732538|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
32732539|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
32732540|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
33075984|NCT00551434|Experimental|2|
33075985|NCT00551434|Experimental|3|
33075986|NCT00551434|Placebo Comparator|4|
32732541|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
32732542|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
32732543|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
32732544|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
32732545|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
32732546|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
32732547|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
32732548|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
32732549|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
32732550|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
32732551|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
32732552|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
32732553|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
32732554|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
32732555|NCT04484415|Experimental|Cevira® treatment|The Cevira® treatment is an integrated combination of drug and device
32732556|NCT04484415|Placebo Comparator|Placebo ointment|The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.
32732557|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
32732558|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
32732559|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
32732560|NCT02491801|Experimental|Control 1|Skim milk
32732561|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
32732562|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
32732563|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
32732564|NCT03324763||stool sampling|
32732565|NCT05430711|Experimental|Dinoprostone|Participants will receive dinoprostone 10 mg vaginal delivery system for up to 24 hours.
32732566|NCT05430711|No Intervention|Expectant management|Participants will not receive drugs to induce labour, they will be managed expectantly for up to 24 hours.
32732567|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.~The difference between the four patches is that they are made of four different adhesives.~The primary endpoint is measured after 8 hours and 24 hours."
32732568|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
32732569|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
32732570|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
32732571|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
32732572|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
32732573|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
32732574|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
32732575|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
32732576|NCT03331549||Myocardial infarction|
32732577|NCT03331549||Control group|
32732578|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
32732579|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
32732580|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
32732581|NCT03328585|Active Comparator|CBT-I in person|
32732582|NCT03328585|Experimental|CBT-I via telemedicine|
32732583|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
32732584|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
32743078|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
32743079|NCT04946565||Sinopharm vaccine group|Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
32732585|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
32732586|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
32732587|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
32732588|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
32732589|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
32732590|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
32732591|NCT03331237|Active Comparator|LVS group|interscalene injection
32732592|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
32732593|NCT00977691|Experimental|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
32732594|NCT00977691|Experimental|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
32732595|NCT00977691|Experimental|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
32732596|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
32732597|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
32732598|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.~Strengthening Exercises for deep neck flexor muscle"
32732599|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
32732600|NCT05430633||Pregnant patients who underwent laparoscopic appendectomy|Pregnant patients who underwent laparoscopic appendectomy
32732601|NCT05430633||Pregnant patients who underwent open appendectomy|Pregnant patients who underwent open appendectomy
32732602|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
32732603|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
32732604|NCT05430321|Experimental|Effect of facilitated tucking after preterm labor|Implementation of facilitated tucking after preterm labor
32732605|NCT05430321|No Intervention|Supine position after preterm labor|Implementation of supine position after preterm labor
32732606|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
32732607|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
33255497|NCT04049630|Experimental|LEV 2,5 mg/kg|Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
32732608|NCT03323983||Normal lung clearance index|
32732609|NCT03323983||Elevated lung clearance index|
32732610|NCT02488603|Experimental|Decision aids|
32732611|NCT02488603|No Intervention|usual care|
32732612|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
32732613|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
32732614|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
32732615|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
32732616|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
32732617|NCT03328117|Active Comparator|Intervention|
32732618|NCT03328117|Placebo Comparator|Placebo|
32732619|NCT05430165||Aim 1 Prospective Cohort|All eligible admitted trauma patients in the trauma registry and a qualitative study of 110 in-depth interviews (IDIs).
32732620|NCT05430087|Experimental|Vitamin D + Placebo|The first group received 400 IU cholecalciferol (Nature Plus) t.i.d (three times a day) and placebo (Saccharum lactis) t.i.d.
32732621|NCT05430087|Experimental|Curcumin-Piperine + Placebo|The second group received a tablet containing curcumin (632 mg) - piperine (15,800 mg) (Bioglan) one time daily and a placebo (Saccharum lactis) t.i.d.
32732622|NCT05430087|Experimental|Vitamin D + Curcumin-Piperine|The third group received 400 IU cholecalciferol (Nature Plus) t.i.d and curcumin (600 mg) - piperine (15,800 mg) (Bioglan) one time daily
32732623|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
32732624|NCT05424159|Experimental|Patients with locally advanced unresectable pancreatic cancer|Patients with locally advanced unresectable pancreatic cancer without invasion of the gastrointestinal tract, cT4N0-2M0 Stage III (AJCC/UICC Version 8).
33075987|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
32732625|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
32732626|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
32732627|NCT03102489|Experimental|BP101|Treatment with BP101
32732628|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
32732629|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
32732630|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
33075988|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
33075989|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
33075990|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
33075991|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.~In the subsequent randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
33255498|NCT04049630|Placebo Comparator|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
33255499|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
33255500|NCT00942591|Active Comparator|2|Interferon beta-1b
33255501|NCT00950781||Group|Group
33255502|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
33255503|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
33255504|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
33255505|NCT00762944||Biomet TMJ Replacement System|All patients required total reconstruction of the temporomandibular joint (unilateral or billateral)
33255506|NCT04436510|Experimental|Verdiperstat|Verdiperstat is administered twice daily p.o. for 24 weeks.
33255507|NCT04436510|Placebo Comparator|Matching Placebo|Matching placebo is administered twice daily p.o. for 24 weeks.
33255508|NCT00763022|Experimental|TAK-559 16 mg QD|
33255509|NCT00763022|Experimental|TAK-559 32mg QD|
33255510|NCT00763022|Placebo Comparator|Placebo QD|
33255511|NCT04392284|Experimental|Diet Counseling|Delivery of nutrition counseling intervention to improve diet quality.
32732631|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
32732632|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
32732633|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
32732634|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
32732635|NCT03323593|Active Comparator|iv|
32732636|NCT03323593|Active Comparator|drip|
32732637|NCT03323593|Active Comparator|atomizer|
32732638|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
32732639|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
32732640|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
32732641|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
33255512|NCT04392284|Experimental|Exercise Counseling|Delivery of exercise counseling intervention to increase engagement in physical activity..
33255513|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
32732642|NCT05415813|Active Comparator|Ischemic Compression|Ischemic Compression will be applied to the upper trapezius trigger points in patients recruited in group 1.
32732643|NCT05415813|Experimental|Ischemic compression and Muscle Energy Technique|ischemic compression along with muscle energy technique will be applied to the upper trapezius trigger points in patients allocated to group 2.
32732644|NCT04492813|Experimental|Obese patients|Severe and morbidly obese patients (35²≤BMI <55)
32732645|NCT04492813|Active Comparator|Non Obese patients|Patients with normal weight or slightly overweight (19 <BMI <30).
32732646|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
32732647|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
32732648|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
32732649|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
32732650|NCT02441751||bleeding|intraoperative blood loss > 500 ml
32732651|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
32732652|NCT05406687|Other|People experiencing homelessness|All homeless adults, aged 18 years and over, who visit the CANCERLESS pilot sites will be asked to participate (convenience sampling). We define individuals as being homeless if they fall under one of the categories listed in the European typology of homelessness and housing exclusion.
32732653|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
32732654|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
32732655|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
32732656|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
32732657|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
32732658|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
32732659|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
32732660|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
32732661|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
32732662|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
32732663|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
32732664|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
32732665|NCT03327259|Active Comparator|Activity Planning Only|
32732666|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
32732667|NCT04412577|Experimental|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
32732668|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
32732669|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
32732670|NCT04044495|Experimental|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
32732671|NCT04039347|Experimental|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
32732672|NCT04039347|Experimental|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
32732673|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
32732674|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
32732675|NCT05253573|Experimental|Automated Treatment|AT consists of all SC components plus a fully automated smartphone-based JITAI that involves proactive, interactive, and personalized messages, images, or videos in Lao.
32732676|NCT05253573|Active Comparator|Standard Care|"SC consists of brief advice to quit smoking delivered by research staff, self-help written materials (the WHO's A guide for tobacco users to quit that we have translated to and validated in Lao), and a 2-week supply of NRT (transdermal patches)."
32732677|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
32732678|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
33401317|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
32732679|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
32732680|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
32732681|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
32732682|NCT00594789|No Intervention|Control|Usual care.
32732683|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
32732684|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
32732685|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
32732686|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
32732687|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
32732688|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
32732689|NCT03327025|Experimental|Intervention|
33075992|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
33401318|NCT01380132|Experimental|Anal injection of Nasha Dx|
32732690|NCT05226039|Other|Young adult group|One group will consist of 20 to 30 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
32732691|NCT05226039|Other|Older adult group|The other group will consist of 60 to 70 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
32732692|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
32732693|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
32732694|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
32732695|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
32732696|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
32732697|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
32732698|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
32732699|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
32732700|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
32732701|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
32732702|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
32732703|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
33075993|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
33075994|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
33401319|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
33401320|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
32732704|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
32732705|NCT03320005|No Intervention|Non training group|sedentary elderly
32732706|NCT05187975|Experimental|Integrated rehabilitation group|This group will include 101 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation .
32732707|NCT05187975|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of paroxetine hydrochloride (20 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
32732708|NCT05464303||Postoperative cholangitis|Patients who had conducted kasai procedure and suffered from postoperative cholangitis after surgery
32732709|NCT05464303||None postoperative cholangitis|Patients who had conducted kasai procedure and followed up in a clinic，at which time they didn't present signs of cholangitis
32732710|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
32732711|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
32732712|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
32732713|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
32732714|NCT05042427||primigravida women|Weight management health literacy of primigravida women.
32732715|NCT04443283||LTBI Group|IGRA(+)
32732716|NCT04443283||No LTBI Group|IGRA(+)
32732717|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
32732718|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
32732719|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
32732720|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
32732721|NCT04435275|Active Comparator|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
32732722|NCT04435275|Active Comparator|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
32732723|NCT04435275|Active Comparator|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
32732724|NCT04435275|Active Comparator|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
32732725|NCT05232643||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants administered oral anticoagulants (OAs)
32732726|NCT05232643||Cohort 2|Non-valvular atrial fibrillation (NVAF) participants not administered oral anticoagulants
32732727|NCT04000269|Experimental|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
32732728|NCT04000269|Sham Comparator|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
32732729|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
32732730|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
32732731|NCT03992235|Experimental|Study Group|Chest physiotherapy + educational material
32732732|NCT03992235|Other|Control group|Chest physiotherapy
32732733|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
32732734|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
32732735|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
32732736|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
33401321|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
33401322|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
32732737|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
32732738|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
33255514|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
32732739|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
32732740|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
33255515|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
33255516|NCT00763178|Experimental|PTSD|Duloxetine
32732743|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
32732744|NCT03953625|No Intervention|no delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~if the patient is included and depending on the week of inclusion, he will then be randomized to either the no booklet or the booklet group.~If it is randomized to the arm 1 no booklet group, the patient will have classic management.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
32732745|NCT03953625|Experimental|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If the patient is included and depending on the week of inclusion, the patient will then be randomized to either the no booklet or the booklet group.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
32732746|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
32732747|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
33255517|NCT04391348|Experimental|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
33255518|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
33255519|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
32732748|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
32732749|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
32732750|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
32732751|NCT02487667|No Intervention|Control Group|No treatment
32732752|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
32732753|NCT05418205|Experimental|Intervention Group (IG)|Families with FGP support (families with disabled and/or chronically children under 18 in the greater area of Mainz, Saarbrucken and Munich (Germany)
32732754|NCT05418205|No Intervention|Control Group (CG)|Families without FGP support (standard care) under the same conditions
32732755|NCT03326635||frailty group|frailty score ≤ 3
33255520|NCT04351178|Experimental|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
32732756|NCT03326635||non-frailty group|frailty score >3
33255521|NCT04351178|Active Comparator|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
33255522|NCT00308581|Experimental|Active 1|"Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
33255523|NCT00308581|Experimental|Active 2|"Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol"
32732757|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
32732758|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
33255524|NCT00678080|Experimental|Metformin|Metformin therapy as prescribed by their health care provider
33255525|NCT00678080|Active Comparator|Insulin|Insulin as prescribed by their health care provider
33401323|NCT05421468|Active Comparator|Pre-Iftar (Breaking the fast)|To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).
32732759|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
32732760|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
32732761|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
32732762|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
32732763|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
32732764|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
32732765|NCT02487511|Active Comparator|14 days|14 days treatment regimen
32732766|NCT02487511|No Intervention|7 days|7 days treatment regimen
32732767|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
32732768|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
32732769|NCT03326167||Patients with or suspected coronary heart disease|
32732770|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
32732771|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
32732772|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
32732773|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
32732774|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
32732775|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
32732776|NCT05463835|Experimental|RubusElite dairy beverage|The active treatment is a novel beverage, which has been formulated and developed by food Scientists at UCC. The RubusElite beverage is a science-led formulation of blackberry puree and high protein milk.
32732777|NCT05463835|Active Comparator|'Protein rich' dairy beverage|The high protein dairy beverage will be a commercially available high protein milk which is commercially produced.
32732778|NCT05463835|Sham Comparator|'Low Protein' dairy beverage|The control beverage will be commercially available Taranis Dalia liquid commercially available low protein milk which will be purchased from the manufacturer for use in this study.
32732779|NCT03319225||Tetraplegia|Persons with Tetraplegia
32732780|NCT03319225||Paraplegia|Persons with Paraplegia
32732781|NCT03319225||Neurologically-intact|Neurologically-intact controls
32732782|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
32732783|NCT03319147|Active Comparator|Active|4g of essential amino acids
32732784|NCT03322111|Experimental|Cyclofusion|
32732785|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
32732786|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
32732787|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
32732788|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
33075995|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
33075996|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
32732789|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
33075997|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
32732790|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
32732791|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
32732792|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
32732793|NCT04493125|Experimental|Mosapride group|Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
32732794|NCT04493125|Placebo Comparator|Placebo group|Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
32732795|NCT04442893|Experimental|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
32732796|NCT04442893|Other|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
32732797|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
32732798|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
32732799|NCT04493983|Other|Investigation|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
32732800|NCT04493593|Experimental|Space for Sleep Group|SilverCloud internet-delivered CBT intervention for Insomnia
32732801|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
32732802|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
32732803|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
32732804|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
32732805|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
32732806|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
32732807|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
32732808|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
32732809|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
33075998|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
32732810|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
32732811|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
32732812|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
32732813|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
32732814|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
32732815|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
32732816|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
32732817|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
32732818|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
32732819|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
32732820|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
32732821|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
32732822|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
32732823|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
32732824|NCT01876953|Experimental|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
33075999|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
32732825|NCT01876953|Experimental|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
32732826|NCT04493359|Experimental|Switch therapy|Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
32732827|NCT04493359|No Intervention|Maintenance therapy|Renin-angiotensin system inhibitors will be kept during in-hospital stay
32732828|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
32732829|NCT01793805||Metastatic Colorectal Cancer Patients|
32732830|NCT04493437|Experimental|Telerehabilitation group A|Device: Telerehabilitation Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
32732831|NCT04493437|Experimental|Telerehabilitation group B|"Device: Telerehabilitation + rehabilitation at health care center Telerehabilitation: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).~Rehabilitation at health care center: The rehabilitation will consist of four closed group sessions focusing on patient education. The groups will consist of both patients and relatives. The program at the health care center will not include any psychological tests or data control. Duration is 4 x 2 hours sessions over a period of 1 month."
32732832|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
32732833|NCT04493281|Experimental|MT-1186|Healthy subjects were administered a single dose of Edaravone oral suspension
32732834|NCT04493281|Active Comparator|MCI-186|Healthy subjects were administered a single dose of Edaravone intravenous formulation
32732835|NCT01764711|Experimental|Low Salt Diet POTS|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
32732836|NCT01764711|Experimental|Low Sodium Diet Controls|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
32732837|NCT04493047|Experimental|Counselling on pneumonia prevention|Recruited caregivers will be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject.
32732838|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
32732839|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
32732840|NCT04493515|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
32732841|NCT04493515|Placebo Comparator|Oral Placebo|Placebo orally (24 IU, identical ingredients, except the active agent)
32732842|NCT04493749||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
32732843|NCT04493749||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
32732844|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
32732845|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
32732846|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
32732847|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
32732848|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
32732849|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
32732850|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
32732851|NCT01556139|No Intervention|Control|Control group with a placebo device
32732852|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
32732853|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
32732854|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
32732855|NCT01137123|Active Comparator|standard two field +follow-up|
32732856|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
32732857|NCT01137123|Experimental|total two field+follow-up|
32732858|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
32732859|NCT01137123|Experimental|three field+follow-up|
32732860|NCT01137123|Experimental|three field+adjuvant chemotherapy|
32732861|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
32732862|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
32732863|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
32732864|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
32732865|NCT03933423|Active Comparator|Intervention|Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
32732866|NCT03933423|No Intervention|Control|No intervention will be deliver
32732867|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
32732868|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
32732869|NCT04941573|Experimental|Hyperpolarized Xenon MRI for lung transplant diagnosis|"All post lung transplant patients will undergo hyperpolarized 129-Xenon MRI and conventional proton MR imaging of the lung. Recent HRCT and spirometry measurements as part of clinical care will be available in the medical history for comparison. There will be multiple administered inhalation of HP Xenon during an imaging session. Maps of xenon ventilation (distribution) will be used for analyzing function of the lungs. These maps will be compared against 3D high-resolution CT images for regional correlations, and against spirometry as global measurements of lung health status. Additionally, xenon dissolved in lung parenchyma and blood, allows for measurement of gas exchange properties.~Each subject will have a secondary imaging session after six-months for evaluating potential changes in the lung function and early detection of lung transplant complications such as CLAD."
32732870|NCT03316339|Experimental|Dexmedetomidine|
32732871|NCT03316339|Active Comparator|Control|
32732872|NCT02484625|Experimental|Potato chips|Commercial potato chips, 180 kcal
32732873|NCT02484625|Experimental|Greek yogurt|Greek yogurt, 180 kcal
32732874|NCT02484625|Experimental|Cookies|Sandwich-type cookies, 180 kcal
32732875|NCT02484625|Experimental|Cheese|Mozzarella cheese, 180 kcal
32732876|NCT02484625|Experimental|Milk (fluid)|Milk, 2% m.f., 180 kcal
32732877|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
32732878|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
32732879|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
32935250|NCT03938324|Sham Comparator|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
33076000|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
32732880|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
32732881|NCT02490787|Experimental|Concizumab|
32732882|NCT02490787|Placebo Comparator|Placebo|
32732883|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
32732884|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
32732885|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
32732886|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
32732887|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
32732888|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
32732889|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
32732890|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
32732891|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline~Midline position~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg~Maintain cerebral perfusion pressure >50 mm Hg~Target pump flow 2.5 L/m2/min~If rSO2 persistently below treatment threshold:~FiO2 is increased~or propofol 50-100 mg bolus is administered~If Hct below 20% packed red blood cells will be transfused~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
32732892|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
32732893|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
32732894|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
32732895|NCT02486731||Controls|Healthy subjects
32732896|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
32732897|NCT02484313|Experimental|Cookies|25 g available carbohydrates
32732898|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
32935251|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
32935252|NCT03889106||Lassa fever|
32732899|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
32732900|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
32732901|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.~Intervention Type: Behavioral (tutored learning)"
32732902|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
32732903|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
32732904|NCT04492579|Experimental|Supplementation of Gentle-UHT donor milk|Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers.
32732905|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.~Inclusion Criteria:~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
32732906|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
32732907|NCT02484235|Experimental|Group Strength|Only Strength Training
32732908|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
32732909|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
32732910|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
32732911|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
32732912|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
32732913|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
32732914|NCT02486419||Summer|
32732915|NCT02486419||Winter|
32732916|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
32732917|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
32732918|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
32732919|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
32732920|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
32732921|NCT02486341|Experimental|Long-acting basal insulin analogues|
32732922|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
32732923|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
32732924|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
32732925|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
32732926|NCT02483923|Experimental|Group S|
32732927|NCT02483923|Placebo Comparator|Group C|
32732928|NCT02647359|Experimental|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
32732929|NCT02647359|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
32732930|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
32732931|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
32732932|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
32732933|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
32732934|NCT03102021|Active Comparator|1|erythropoeitin
32732935|NCT03102021|Placebo Comparator|2|saline placebo
32732936|NCT03317587|Experimental|INSPIRE|
32732937|NCT04916691|Other|EPSB for rib fractures|EPSB for rib fractures
32732938|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
32732939|NCT04904835||Unselected blood donors|leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays
32732940|NCT04904835||Hospitalized patients|Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays
32732941|NCT04904835||Presumed HBsAg positive patients|"Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (>26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research &Development to fit with Common Technical Specification requirements.~Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays"
32732942|NCT04904835||Patients having recovered from natural HBV infection, presumed Anti-HBs positive|"Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.~Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays"
32732943|NCT04904835||Patients having received HBV vaccination, presumed Anti-HBs positive|Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays
32732944|NCT04904835||Presumed Anti-HBc Total positive patients|"Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling).~Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays"
32732945|NCT04904835||Presumed Anti-HBc IgM positive patients|"left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.~Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays"
32732946|NCT04904835||Presumed HBeAg positive patients|"Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.~Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays"
32732947|NCT04904835||Presumed Anti-HBe positive patients7|"Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.~Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays"
32732948|NCT04904835||Patients with chronic HBV infection|Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay
32732949|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
33255526|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
33401324|NCT05421468|Experimental|Pre-Fajr (Starting the fast)|To take thyroxine immediately before start of fast at predawn time regardless of last meal time.
32732950|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
32732951|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
32732952|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
32732953|NCT05117385|Experimental|Acerola|"dietary supplement : acerola extract self administrated by mouth for 28 days~1 capsule per day"
32732954|NCT05117385|Experimental|Panax ginseng extract|"dietary supplement : panax ginseng extract self administrated by mouth for 28 days~1 capsule per day"
32732955|NCT05117385|Experimental|Echinacea extract|"dietary supplement : echinacea extract self administrated by mouth for 28 days~1 capsule per day"
32732956|NCT05117385|Experimental|Quillaja extract|"dietary supplement : quillaja extract self administrated by mouth for 28 days~1 capsule per day"
32732957|NCT05117385|Placebo Comparator|Maltodextrin|"dietary supplement : maltodextrin supplement self administrated by mouth for 28 days~1 capsule per day"
32732958|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
32732959|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
32732960|NCT05105139||A1: Allantoin / Coal Tar / Clioquinol (Sebryl®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 5.0 g/ 3.0 g Administration way: For scalp use
32732961|NCT05105139||A2: Allantoin/ Coal Tar/ Clioquinol/ Triclosan (Sebryl Plus®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 3.0 g/ 3.0 g/ 0.3 g Administration way: For scalp use
32732962|NCT04492423||Prasugrel|Patients taking prasugrel
32732963|NCT04492423||Ticagrelor|Patients taking ticagrelor
32732964|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
32732965|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
32732966|NCT05001555|Experimental|Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)|"Group A:~Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days."
32732967|NCT05001555|Active Comparator|Group B: Dexketoprofen|Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
32732968|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
33076001|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
32732969|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
32732970|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
32732971|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
32732972|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
32732973|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
32732974|NCT03862833|Experimental|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg~Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
32732975|NCT03862833|No Intervention|control group|no experimental treatment
32732976|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
32732977|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
32732978|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
32732979|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
32732980|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
32732981|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
32732982|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
32732983|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
32732984|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
32732985|NCT04482855|Experimental|Group 1 (laser group)|Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
32732986|NCT04482855|No Intervention|Group 2 (wait-list control group)|Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
32732987|NCT05463445||A|"patients diagnosed with Primary Sclerosing Cholangitis which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines Management of cholestatic liver diseases in 2009."
32732988|NCT05463445||B|patients diagnosed with IgG4-related Sclerosing Cholangitis which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria.
32732989|NCT04435353|Active Comparator|Time-day of respiratory fail|Objective data
32732990|NCT04435353|Active Comparator|Oxygen status|Facultative data
33255527|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
33255528|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
32732991|NCT04435353|Active Comparator|Oxugen support|FiO2
32732992|NCT04435353|Active Comparator|Adverse outcomes|Complication
32732993|NCT05386927||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
32732994|NCT05386927||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
32732995|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
32732996|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
32732997|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
32732998|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
32732999|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
32733000|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
32733001|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Saline solution"
32733002|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Saline solution"
33255529|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
33255530|NCT04137614|Placebo Comparator|Digital substraction angiography|
33255531|NCT04137614|Experimental|Drug-coated balloon|
33255532|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
33255533|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
32743080|NCT04939155||Patients infected with SARS-CoV-2|The first part of this study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after they contracted SARS-CoV-2
33255534|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
33255535|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
33255536|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
33255537|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
33255538|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
33255539|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
33255540|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
33255541|NCT04049006|Experimental|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
32733003|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Steroid"
32733004|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Steroid"
32733005|NCT04571385|Experimental|Part 1: AP30663|Participants will receive single dose of AP30663.
32733006|NCT04571385|Placebo Comparator|Part 1: Placebo|Participants will receive placebo matched to AP30663.
32733007|NCT04571385|Experimental|Part 2: AP30663|Participants will receive a single dose of one of the multiple dose levels of AP30663.
32733008|NCT04571385|Placebo Comparator|Part 2: Placebo|Participants will receive placebo matched to AP30663.
32733009|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
32733010|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
32733011|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
32733012|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
32733013|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
32733014|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
32733015|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
32733016|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
32733017|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
32733018|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
32733019|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
32733020|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
32733021|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
32733022|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
32733023|NCT04548141|Experimental|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
32733024|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted as a replacement of the human crystalline lens during cataract surgery
32733025|NCT05154903|Active Comparator|Citicoline|the Citicoline group will receive citicoline in continuous Iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks
32733026|NCT05154903|No Intervention|control|the control group will not receive citicoline
33255542|NCT04049006|No Intervention|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
32733027|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
32733028|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
32733029|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
32733030|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
32733031|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
32733032|NCT02486107||ACDF|anterior cervical discectomy and fusion
32733033|NCT04888611|Experimental|Neoadjuvant PD-1 inhibitor plus DC vaccine|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, DC vaccines and further PD-1 inhibitor treatment until toxicity or progression.
32733034|NCT04888611|Active Comparator|Neoadjuvant PD-1 inhibitor plus Placebo|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, placebo and further PD-1 inhibitor treatment until toxicity or progression.
32733035|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
32733036|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
32733037|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
32733038|NCT04828239|Experimental|Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
32733039|NCT04828239|Active Comparator|Manual Acupuncture Group|Acupuncture point: PC-6 and PC-7 Responses elicited: de qi sensation Manual: twirling with lifting-thrusting method stimulation Needles retained for 30 min Needle type: C&G, gauge and size: 0.25x40mm
32733040|NCT04828239|Sham Comparator|Sham Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 Sham laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
32733041|NCT02483221|Active Comparator|TCI-PCA|
32733042|NCT02483221|Active Comparator|PCA|
32733043|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
32733044|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
32733045|NCT04766697|Experimental|Receive Intervention|All 20 couples will receive the 8-session adapted intervention.
32733046|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
32733047|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
32733048|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
32733049|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
32733050|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
32733051|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
32733052|NCT02489461|Experimental|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
32733053|NCT02489461|Experimental|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
32733054|NCT02489461|Active Comparator|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
32733055|NCT05129475|Experimental|Treatment A|Single oral dose of ritonavir at -12 hours prior to PF-07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
32733056|NCT05129475|Experimental|Treatment B|Single oral dose of ritonavir at -12 hours prior to PF 07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
33076002|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
32733057|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Quality of Life|mindfulness stress reduction program reduces menopausal complaints.
32733058|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Menopausal Symptoms|mindfulness stress reduction program improves the quality of life of women in the menopausal period.
32733059|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
32733060|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
32733061|NCT05048043|Experimental|Computer-assisted Behavior Intervention|A serious game paired with teacher consultation to address common needs related to ADHD in the classroom.
32733062|NCT05048043|Active Comparator|Challenging Horizons Program, School Consultation|An established teacher consultation program to help teachers address ADHD in the classroom.
32733063|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
33401325|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
33401326|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
33401327|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
32733066|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
32733067|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
32733068|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
32733069|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
33255543|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
32733070|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
32733071|NCT04923321||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
32733072|NCT04923321||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
32733073|NCT04923321||Non exposure|Non-pharmacological treatment (psychotherapy)
32733074|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
32733075|NCT05457907|Experimental|Parameter testing|In order to test parameters, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 3 interventions with varying intensity, frequency, and duty cycle.
32733076|NCT05457907|Experimental|Anatomical targeting|In order to test anatomical targeting, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 2 interventions, varying the anatomical targets.
33255544|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
32733077|NCT04572165||semaglutide|New users of Ozempic® or Rybelsus®
32733078|NCT04572165||Active comparator|First-time ever users of an active comparator drug
32733079|NCT05463367|Experimental|Chronic Back Pain with Opioid Use|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
32935253|NCT04738604|Active Comparator|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) is the ideal choice for single-tooth restorations, both in the anterior and the posterior region. It has an ultrafine, radiopaque porcelain filler for use in adhesive filling treatment. It can be polished to a high lustrer due to the ultra- fine particle filler, extremely homogeneous restorations can be placed which are easily polished to a high luster. The mechanical properties of a light-cured dental composite material are particularly dependent on its filler content, the type of incorporated fillers and the efficiency of the filler-resin coupling, so high Vickers hardness, compressive strength and flexural strength are recorded refereed to Zenit filler content 83% by weight (70% by volume) and size 0.7 microns
32935254|NCT04738604|Experimental|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany)|contains organically modified ceramic nanoparticles (2 to 3 nm) and nano-fillers (10 nm) that are combined with conventional glass fillers (mean particle size: 1.1 to 1.5 μm). Nanoparticles and nano-fillers comprise a polysiloxane backbone and have methacrylate groups available for polymerization. According to the manufacturer's data, filler concentration is 76% by weight and 57% by volume. Furthermore, most of the conventional resin matrix is replaced by a matrix full of highly dispersed methacrylate modified polysiloxane particles (2- 3 nm).These nano-ceramic particles are inorganic-organic hybrid particles. Both, nano-ceramic particles and nano- fillers have methacrylate groups available for polymerization. CeramX does not contain triethylene glycol dimethacrylate (TEGDMA) as it was found mutagenic and cytotoxic in vitro
32935255|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
32935256|NCT02730403||Opioid Use Disorder Patients|
32935257|NCT05207618|Experimental|IBS PATIENTS|Natural specific tannin, chestnut
32935258|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
32935259|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
32935260|NCT05144906||Blind women|The blind women group will include women who are congenitally blind or that were blinded early in life (up to the age of 7).
33255545|NCT00760760|Experimental|n-3 PUFA|
32743081|NCT04939155||Patients who have received an mRNA vaccination|The second part of the study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after SARS CoV-2 mRNA vaccine injection.
32733080|NCT05463367|Experimental|Chronic Back Pain with Opioid Misuse Disorder|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
32733081|NCT04569123|Active Comparator|Vibration|The device will deliver imperceptible vibration for the treatment group.
32733082|NCT04569123|Sham Comparator|No Vibration|The device will deliver no vibration for the control group.
32733083|NCT04568031|Active Comparator|Part I|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
32733084|NCT04568031|Placebo Comparator|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
32733085|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
32733086|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
32733087|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
32733088|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
32733089|NCT04847271|Experimental|Physical activity on prescription|Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
32733090|NCT02485639|Experimental|Arm 1|All study participants will receive licensed inactivated influenza vaccine intramuscularly on Day 1.
32733091|NCT02483065||inpatients with dementia|
32733092|NCT02483065||inpatients without dementia|
32733093|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
32733094|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
32733095|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
32733096|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
32733097|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
32733098|NCT04758741|Experimental|Acceptance and commitment treatment|The members of the intervention group receive one session of acceptance and commitment treatment per week according to Hayes (2006) approach in groups of 10 in 8 sessions of 90 minutes by a trained counselor (researcher) in Mashhadalkoubeh Health Center.
32733099|NCT04758741|Sham Comparator|Health Education|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience.
32733100|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
32733101|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
32733102|NCT04666467|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
32733103|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
32733104|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
32733105|NCT04519203|Active Comparator|SPI group|Group of patients where opioid consumption will be guided using SPI target
32733106|NCT04519203|Active Comparator|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
32733107|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
32733108|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
32733109|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
32733110|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
32733111|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
32743082|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
32743083|NCT04939077|Experimental|CABG with hUC-MSC treatment group|In the CABG with hUC-MSC treatment group, 1×10^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.
32733112|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
32733113|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
33255546|NCT00760760|Placebo Comparator|Control|
32733114|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
32733115|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
32733116|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
32733117|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
32733118|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
32733119|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
32733120|NCT04554927|Experimental|WEB-application|
32733121|NCT04554927|Active Comparator|Standard accompaniment|
32733122|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
32733123|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
32733124|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
32733125|NCT02485405||stressed|stressed volunteers perform Trier social stress test
32733126|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
32733127|NCT02489071|Experimental|Brain Training|8-session cognitive training program
32733128|NCT02489071|Experimental|Brain Health|8-session cognitive education program
32733129|NCT02489071|No Intervention|Control|Wait-list control group
32733130|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
32733131|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
32733132|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
32733133|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
32733134|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
32733135|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
32733136|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
32733137|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
32733138|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:~Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
32733139|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:~high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
32733140|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
32733141|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
32733142|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
32733143|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
32733144|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
32935261|NCT05144906||Sighted women|Women with normal or corrected-to-normal eye sight.
33255547|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
32733145|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
32733146|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
32733147|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
32733148|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
32733149|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
32733150|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
32733151|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
32733152|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
32733153|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
32733154|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
32733155|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
32733156|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
32733157|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
32733158|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
32733159|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
32733160|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
32733161|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
32733162|NCT05534191|Experimental|Intervention|This group will use a functional training system developed specifically for football players to improve their physical strength and movement abilities on the field.
32733163|NCT05534191|Active Comparator|Positive control|This group will use general strength exercises with the purpose of improving physical strength.
32733164|NCT05534191|No Intervention|Negative control|Control group A group that is not treated
32733165|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
32733166|NCT05529589||control group|Diabetic macular edema patient with inner limit membrane
32733167|NCT05529589||experimental group|Diabetic macular edema patient with inner limit membrane peeling
32733168|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
32733169|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
32733170|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
32733171|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
32733172|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
32733173|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
32733174|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
32733175|NCT04248465|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
32733176|NCT04248465|Placebo Comparator|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
32733177|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
32733178|NCT02480335|No Intervention|Usual care|Usual care only.
32733179|NCT05456269|Experimental|Stratum 1|"Bisantrene infused daily for 7 days of induction cycle 1; followed by bisantrene infusion on Days 1 and 2 and cytarabine arabinoside continuous infusion on Days 1 to 5 of each consolidation cycle for up to 3 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
32733180|NCT05456269|Experimental|Stratum 2|"Decitabine/cedazuridine daily on Days 1-5, Bisantrene infusion on Days 3 and 5 in 28 day cycle. Treatment repeats every 28 days up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Each has potential to expand to 42 days to allow for full hematologic recovery."
32733181|NCT05245383|Other|Single arm|
32935262|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
32935263|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
32935264|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
32733182|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
32733183|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
32733184|NCT03314467||Control|diabetic patients without ocular abnormalities
32733185|NCT05245305|Experimental|MBSR Intervention|The intervention group will take part in mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. The MBSR program was structured as 11 weeks, taking into account the characteristics of the participants.
32733186|NCT05245305|No Intervention|Control|No intervention was applied to the control group. Data will be collected from the control group simultaneously with the study group.
32733187|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
32733188|NCT02479945|Other|Selective internal iliac vein sampling|
32733189|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
32733190|NCT02476825|No Intervention|Observational|Observation
32733191|NCT05245227|Active Comparator|Intravenous Oxytocin only|Patients will receive standard postpartum Oxytocin IV per protocol
32733192|NCT05245227|Experimental|Misoprostol plus intravenous Oxytocin|Patients will receive standard postpartum Oxytocin IV per protocol and also be given Misoprostol 400 mcg sublingual
32733193|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
32733194|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
32733195|NCT05245149||Prospective Cohort|Patients with a clinical indication for coronary CT angiography will undergo this scan on a photon counting detector CT (PCD-CT).
32733196|NCT05245149||Retrospective Cohort|For comparison, a matched retrospective cohort will be created of patients who had undergone coronary CT angiography on prior CT scanner generations (with energy-integrating detector CT, EID-CT)
32733197|NCT04533399|Experimental|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
32733198|NCT04533399|Placebo Comparator|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
32733199|NCT04533399|Experimental|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
32733200|NCT04533399|Placebo Comparator|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
32733201|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
32733202|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
32733203|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
32733204|NCT04435197|Experimental|Arm A|"Arm 1:~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~D: Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
32733205|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
32733206|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
32733207|NCT05244837|Experimental|Arm A:Resectable Stage IIB-IIIA Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 3-4 cycles before surgical resection, followed by adjuvant intravenous tislelizumab monotherapy for 1 year ( 200 mg every 3 weeks for 2 cycles, followed by 200 mg every 4 weeks for 12 cycles).
32733208|NCT05244837|Experimental|Arm B：Unresectable Stage IIIA/IIIB/IIIC or IV Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 4-6 cycles , followed by adjuvant intravenous tislelizumab monotherapy ( 200 mg every 3 weeks )，until disease progression or intolerable toxicity If surgery is not possible；If surgery is possible after assessment, subsequent treatment at the discretion of the investigator
32733209|NCT03103893|Experimental|Rapamycin|Rapamycin
32733210|NCT05497375|Active Comparator|Group Hypocapnia|End-tidal carbon dioxide level will be 30±2 mmHg in the capnography, and the respiratory rate will be 14-20/minutes in the hypocapnia group.
32733211|NCT05497375|Active Comparator|Group Hypercapnia|End-tidal carbon dioxide level will be 40±2 mmHg in the capnography, and the respiratory rate will be 10-14/minutes in the hypercapnia group.
32733212|NCT05244759|Experimental|Arm 1|Single oral dose of [14C]-BLU-5937
32733213|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
32733214|NCT03314311|No Intervention|Control|Usual care control arm
32733215|NCT04281225|Placebo Comparator|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
32743084|NCT04939077|No Intervention|CABG group|CABG was performed under general anesthesia.
32743085|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
32733216|NCT04281225|Experimental|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
32733217|NCT04281225|Experimental|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
32733218|NCT04281225|No Intervention|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
32733219|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
32733220|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
32733221|NCT05244603|Experimental|Normal Hearing|Listeners with normal hearing
32733222|NCT05244603|Experimental|Hearing Impaired|Listeners with hearing loss
32733223|NCT05714293|Experimental|Surgical Aortic Valve Replacement|Patients undergoing surgical aortic valve replacement with a bioprosthesis will be asked to perform a thorax CT scan before surgery and one more at least 90 days after surgery.
32733224|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
32733225|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
32733226|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
32733227|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
32733228|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
32733229|NCT04266639|Active Comparator|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial Remote Ischemic Conditioning: < 2 hours from inclusion~Remote Ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy"
32733230|NCT04266639|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.~Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion~Sham Remote ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy."
32733231|NCT04266639|No Intervention|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
32733232|NCT05374681|Other|Medical treatment alone|Medical treatment without embolization of the MMA.
32733233|NCT05374681|Other|Surgical treatment alone|Surgical treatment without embolization of the MMA.
32733234|NCT05374681|Experimental|Medical treatment associated with an embolization of the MMA|Medical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
32733235|NCT05374681|Experimental|Surgical treatment associated with an embolization of the MMA|Surgical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
32733236|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
32733237|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
32935265|NCT05128370||Stroke group|Stroke patients who can walk independently for at least 10 meters without rest. Unilateral walking aids are allowed.
32935266|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
32733238|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
32733239|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
32733240|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
32935267|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
32733241|NCT05361733|Active Comparator|XFB-19|"Part A: XFB-19 SC injection at the following dose levels:~Cohort 1: 5 mg~Cohort 2: 10 mg~Cohort 3: 20 mg~Part B: XFB-19 SC injection at the 2 highest acceptable dose levels from Part A:~Cohort 4: second highest acceptable dose level from Part A~Cohort 5: highest acceptable dose level from Part A"
32733242|NCT05361733|Placebo Comparator|Placebo|10 healthy volunteers will be randomized and assigned to the Placebo arm in Part A (Cohorts 1, 2 and 3) and Part B (Cohorts 4 and 5).
32935268|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
32935269|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
32935270|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
32935271|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
32935272|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
32935273|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
32935274|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
32935275|NCT04339153|Experimental|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
32935276|NCT04339153|No Intervention|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
32935277|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
32935278|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
32935279|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
32935280|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
32935281|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
32935282|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
32935283|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
32935284|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
32935285|NCT05086406|No Intervention|In-Office Visit Group|This control group will undergo standard in-office pre-operative counseling visit.
32935286|NCT05086406|Experimental|Virtual Visit Group|This study group will receive pre-operative counseling via video, created by the Department of Gynecology at Cleveland Clinic Florida, followed by a virtual visit with a gynecologic surgery provider.
32935287|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
32935288|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
33076003|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
33076004|NCT00185172|Placebo Comparator|1|2 week placebo run-in
33076005|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
33255548|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
33255549|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
33255550|NCT00810654|Placebo Comparator|Placebo|
33255551|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
33255552|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
33255553|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
33255554|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
33255555|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
33255556|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
33255557|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
33255558|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
33255559|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
33255560|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
33255561|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
33255562|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
33255563|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
33255564|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
33255565|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
33255566|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
33255567|NCT00807066|Experimental|A|Gefitinib
33255568|NCT00807066|Active Comparator|B|Platinum based chemotherapy
33255569|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
33255570|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
33255571|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
33255572|NCT00805116|Experimental|1|Whale blubber oil
33255573|NCT00805116|Active Comparator|2|Cod liver oil
32743086|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
33401328|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
33076006|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
33076007|NCT04863118|Experimental|Strength training protocol performed in shallow water and dry land|Parkinson Disease and healthy individuals
33076008|NCT04863118|Experimental|High-intensity training protocol performed in shallow and deep water|Parkinson Disease and healthy individuals
33255574|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are more than six hours."
33255575|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are less than two hours."
33255576|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
33255577|NCT00807222|Placebo Comparator|placebo|
33255578|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
33255579|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
33255580|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
33255581|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
33255582|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
33255583|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
33255584|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
33255585|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
33401329|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
33401330|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
33401331|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
33076009|NCT04836286|Experimental|single group repeated design|The Emotive Intelligent Spaces (EIS) leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
33076010|NCT04827355|Sham Comparator|Control|Participants allocated to the control arm will be fit with the UES Compression Device at a pressure known not to provide intervention.
33076011|NCT04827355|Experimental|Experimental|Participants allocated to the experimental arm will be fit with the UES Compression Device according to manufacturer guidelines.
33076012|NCT04798885|No Intervention|Enhanced usual care|Participants will be informed about typical Post Concussion Symptoms and the process of typical recovery as well as given reassurance concerning the prognosis. Advice concerning the use of pain relief medication will also be provided.
33076013|NCT04798885|Experimental|GAIN 2.0 intervention|An eight-week, interdisciplinary intervention program based on principles from cognitive behavioural therapy (CBT) and gradual return to activities.
33076014|NCT00551668|Experimental|1|Operative
33076015|NCT00551668|Experimental|2|Nonoperative
33076016|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
33076017|NCT00551785||2|Women prescribed estrogen therapy
33076018|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
33076019|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
33076020|NCT00185250|Experimental|Arm 1|
33076021|NCT00185250|Experimental|Arm 2|
33076022|NCT00185250|Placebo Comparator|Arm 3|
33255586|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
33255587|NCT00805272|Experimental|1|
32733243|NCT04227951|Sham Comparator|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
32733244|NCT04227951|Experimental|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
32733245|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
33076023|NCT00185250|Placebo Comparator|Arm 4|
33076024|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
32733246|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
33076025|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
33076026|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
33076027|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
33076028|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
33076029|NCT00185289|Experimental|Arm 1|
33076030|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
33076031|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
33076032|NCT00552214|Other|Human Blood Donor Plasma Specimens|
33076033|NCT00185328|Experimental|Arm 1|
33076034|NCT04766164||Males and Females ages 18-26|Participants between the ages of 18-26 will complete a survey
33076035|NCT04766164||Males and Females ages 27-45|Participants between the ages of 27-45 will complete a survey
33076036|NCT00552253|Experimental|1|under eltroxin
33076037|NCT00162110|Active Comparator|1|
33076038|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
33255588|NCT00764972|Experimental|Sorafenib and Vinorelbine|
33255589|NCT04042532|Active Comparator|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
33255590|NCT04042532|Sham Comparator|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
33255591|NCT04042532|No Intervention|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
33255592|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
33255593|NCT00673790|Active Comparator|Nebivolol|Nebivolol with concomitant losartan or lisinopril
33255594|NCT00673790|Active Comparator|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
33255595|NCT00673790|Placebo Comparator|Placebo|Placebo with concomitant losartan or lisinopril
33255596|NCT00770276||Bariatric surgery|Bariatric surgery
33255597|NCT00770276||conservative Therapie|diet and exercise
33076039|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
32733247|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
32733248|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
33076040|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
33076041|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
33255598|NCT00763724||1|Duloxetine
33255599|NCT00763724||2|Venlafaxine
33255600|NCT00763724||3|SSRI
33255601|NCT00763724||4|TCA
33255602|NCT00763724||5|Multiple Antidepressants
33255603|NCT00763724||6|Depressed (not antidepressant treated)
33076042|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
33076043|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
33076044|NCT00162149|No Intervention|A1|
33255604|NCT00763724||7|General population
33255605|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
32733249|NCT04140903|Experimental|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
32733250|NCT04140903|Active Comparator|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
32733251|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
32733252|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
32733253|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
32743087|NCT04946487||group 1|patients in this group destructed the posterior ligamentous complex of the adjacent segment
32743088|NCT04946487||group 2|patients in this group did not destruct the of the posterior ligamentous complex of the adjacent segment
32743089|NCT04946331|Experimental|Control|participants receive no surgical treatment
32743090|NCT04946331|Experimental|Rib Fixation Surgery|participants receive surgical treatment
32743091|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
33076045|NCT00162149|Experimental|A2|
33076046|NCT00162149|Experimental|A3|
33076047|NCT00162149|No Intervention|B1|
33076048|NCT00552526|Active Comparator|Ketogenic diet|
33076049|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
33076050|NCT00552565|Placebo Comparator|1|
33076051|NCT00552565|Experimental|2|
33076052|NCT00552565|Experimental|Rezular 37.5mg|
33076053|NCT00552565|Experimental|Rezular - 75mg|
33076054|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
33076055|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
33076056|NCT00552643|Experimental|1|Treatment with Polyheal 1
33076057|NCT00552643|Active Comparator|2|Saline
33076058|NCT04755088|Experimental|Cohort 1|Subjects with Normal Renal Function: All patients to receive study drug (Surufatinib 300mg) on Day 1
33076059|NCT04755088|Experimental|Cohort 2|Subjects with Moderate Renal Impairment: All patients to receive study drug (Surufatinib 300mg) on Day 1
33082261|NCT04620772|Experimental|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
33255606|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
33255607|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
33255608|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
33255609|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
33255610|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
33255611|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
33255612|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
33255613|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
33255614|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
33255615|NCT00770354|Experimental|1|AS1402 plus letrozole
33255616|NCT00770354|Active Comparator|2|Letrozole
33255617|NCT00805428||2|control group
33255618|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
33255619|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
33255620|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
33255621|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
33255622|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
33255623|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
33076060|NCT04751890|Experimental|Structured home-based exercise|Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
33076061|NCT04751890|Active Comparator|Walking advice|Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
33255624|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
33255625|NCT00646776|Active Comparator|A|
33255626|NCT00646776|Active Comparator|B|
33255627|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
32733254|NCT05713981|Experimental|non-invasive Meibomian gland (MG) expression|"Baseline testing of visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured.~The intervention will be standard clinical expression of Meibomian superior and inferior glands (MG) using a sterile cotton tip applicator to apply gentle pressure in a rolling motion in the direction of the MGs along the upper and lower eyelid margins to allow oil secretion of the tested eye. One drop of sterile saline will be instilled following the intervention to remove debris. The subject's visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured before and after this intervention."
32733255|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
32733256|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
32733257|NCT03101397||stable group|not included in improved group or deteriorated group
32733258|NCT05243589|Experimental|group A/ routine physical therapy and proprioceptive training|Routine physical therapy and proprioceptive training is performed
32733259|NCT05243589|Active Comparator|Group B/ routine physical therapy|Routine physical therapy
32733260|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
32733261|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
32733262|NCT05243355|Experimental|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w. Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles. Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total.
32733263|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
33255628|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
32733264|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
32733265|NCT05334511|Experimental|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
33255629|NCT04048928|Experimental|Strength group|Receives maximal strength training
33255630|NCT04048928|No Intervention|Control group|receives no active treatment
33255631|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
33255632|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
33255633|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
33255634|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
33255635|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
33401332|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
33401333|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
33255636|NCT02558114|Other|Group B|"Patients will receive:~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
33255637|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
33255638|NCT00770666|Active Comparator|2|Nicotine patch
33255639|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
33255640|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
33255641|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
33255642|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
33255643|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
33255644|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
33255645|NCT00811200|Active Comparator|1: Lucentis|
33255646|NCT00811200|Active Comparator|2: Kenalog|
33255647|NCT00811200|Sham Comparator|3: No treatment|
33255648|NCT00811278||step1|asthma patients on step 1 therapy
33255649|NCT00811278||step 2|asthma patients on step 2 therapy
32733266|NCT05196945|Experimental|VA-dual|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
32733267|NCT05196945|Active Comparator|EACP - quadruple|14days(Esomeprazole 20mg/ time, 2 times/day, oral+Amoxicillin 1g/ time, 2 times/day, oral+Clarithromycin 0.5g/ time, 2 times/day, oral+Bismuth potassium citrate 220mg/ time, twice a day, orally)
32733268|NCT03810105|Experimental|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
32733269|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
32733270|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
32733271|NCT03808467|Experimental|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
32733272|NCT03808467|Other|TAU only|Treatment As Usual
32733273|NCT03804021||1|Patients who received ADVM-043 in a treatment protocol
32733274|NCT05715151|Experimental|CQI intervention|The proposed CQI cohort consists of three activities carried out iteratively until the improvement objectives are achieved.
32733275|NCT05715151|Active Comparator|Audit and feedback|Clinics in the control group will receive feedback on six key AA indicators, patients reported experience about access and selected AA processes.
32733276|NCT03800979|Experimental|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
32733277|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
32733278|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
32935290|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
32935291|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
33255650|NCT00811278||healthy|non-asthmatics
33255651|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
33255652|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
33255653|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
33255654|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
33255655|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
33255656|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
33255657|NCT00770744|Experimental|Zicronapine|
33255658|NCT00770744|Active Comparator|Olanzapine|
33076062|NCT04709926||Paramedics that were eligible to take part in the PRESTO study|Paramedics that are employed by one of the four Ambulance Services involved in the PRESTO study and were eligible to complete the training provided by Manchester University NHS Foundation Trust to take part in the PRESTO study.
33255659|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
33255660|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
33255661|NCT00764348||no treatment|
33255662|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
32733279|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
32733280|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
32733281|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
33255663|NCT04047992|Experimental|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
33255664|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
32733282|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
32733283|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
33255665|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
33255666|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
32733284|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
32935292|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
33255667|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
33255668|NCT00807300|Active Comparator|brachytherapy|
33255669|NCT00807300|Other|TACE|transarterial chemoembolization
33255670|NCT00813540|Experimental|1|Exercise
33255671|NCT00813540|Other|2|Usual Care, no intervention
33255672|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
32935293|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
32935294|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
32733285|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
32733286|NCT03766971|Experimental|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
32733287|NCT03766971|Experimental|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
32733288|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
32733289|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
32733290|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
32935295|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
32935296|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
32935297|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
32935298|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
32935299|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
32935300|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
32935301|NCT02734849|Experimental|25 mg AK001|25 mg AK001 will be administered as multiple doses
32935302|NCT02734849|Experimental|250 mg AK001|250 mg AK001 will be administered as multiple doses
32935303|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
32935304|NCT04707547|Experimental|Radiofrequency Ablation|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
32935305|NCT04707547|Placebo Comparator|Radiofrequency Ablation combine with Nivolumab|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab
33255673|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
33255674|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
33255675|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
33255676|NCT00766298|Experimental|1|Weight Loss
33255677|NCT00766298|Experimental|2|Exercise
33255678|NCT00766298|Experimental|3|Exercise and Weight Loss
33255679|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
33255680|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
33255681|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
33255682|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
33255683|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
32733291|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
32733292|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~Creatinine Clearance (CrCl)~Presence of Geriatric Syndromes"
33255684|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
33255685|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
33255686|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
33255687|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
33255688|NCT00807378||1|AIDS PATIENTS
33255689|NCT00807378||2|NON-AIDS PATIENTS
33255690|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
33255691|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
33255692|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
33255693|NCT04048772|Experimental|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
33255694|NCT04048772|Other|Control|Standard of care in vitro fertilization patients at our institution.
32733293|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
32733294|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
32935306|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
32935307|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
32935308|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
32935309|NCT05035160||Group 1|Pregnant and postpartum birthing persons with perinatal pathology.
33255695|NCT00764582|Experimental|1|
33255696|NCT00764582|Active Comparator|2|
33255697|NCT00813618|Experimental|1|MEDI-507
33255698|NCT00813618|Experimental|2|MEDI-507
33255699|NCT00813618|Experimental|3|MEDI-507
32733295|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
32733296|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
32935310|NCT05035160||Group 2|Healthy pregnant and postpartum birthing persons.
32935311|NCT05035160||Group 3|Healthy non-pregnant persons (healthy volunteers).
32935312|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
32935313|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
32935314|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
33255700|NCT00771212||001|
33255701|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
33255702|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
33255703|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
33255704|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
33255705|NCT03868332||inflammatory bowel diease patients|
33255706|NCT03868332||normal indivuals|
33401334|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
33255707|NCT04048226|Placebo Comparator|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
33255708|NCT04048226|Experimental|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
33255709|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
32733297|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
32733298|NCT05452759|Experimental|new type of tracheotomy high-flow oxygen therapy (NTHF)|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
33255710|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
33255711|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
33255712|NCT00766766|Experimental|1|Experimental Intervention Group
33255713|NCT00766766|No Intervention|2|Standard Care Control
33255714|NCT04048070|Experimental|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
33255715|NCT04048070|Experimental|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
33255716|NCT04048070|Experimental|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
33255717|NCT04048070|Experimental|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
33255718|NCT04048070|Placebo Comparator|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
33255719|NCT00655356|Experimental|Active|
33255720|NCT00655356|Placebo Comparator|Placebo|
33255721|NCT00571064|Experimental|1|
32743092|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
32743093|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
32743094|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
32935315|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
32935316|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
32935317|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
32935318|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
32935319|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
32935320|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
32935321|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
32935322|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
32935323|NCT05446610|Experimental|Gut barrier function treatments|Stressor, fibre, combination of treatments.
32935324|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
32935325|NCT00369356|Sham Comparator|1|Bare Metal Stenting
32935326|NCT00369356|Active Comparator|2|Stenting with DES
32935327|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
33255722|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
33255723|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
33255724|NCT04045626|Active Comparator|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
33255725|NCT04045626|Active Comparator|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
33255726|NCT04045392|Experimental|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
33255727|NCT04045392|No Intervention|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
33255728|NCT00811980||Heathy Subjects|
32733299|NCT05452759|Active Comparator|Respiratory Humidification Treatment（ AIRVO TM 2）|Use AIRVOTM2 (Fisher & Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
32733300|NCT05434663|Experimental|Treatment Group|
32733301|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
32733302|NCT03101319|Placebo Comparator|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
33255729|NCT00766844|Experimental|Active|Spinal cord stimulation
33255730|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
33255731|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
33255732|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
33255733|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
33255734|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
33255735|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
32733303|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy.~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
33255736|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
33255737|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
33255738|NCT02551926|Active Comparator|Control|control group will be included without any intervention
33255739|NCT00775034|Experimental|1|Study group (Tisseel®)
33255740|NCT00775034|Other|2|Control group
32743095|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
32743096|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
33255741|NCT00813696|Experimental|A|cisplatin + gemcitabine
33255742|NCT00813696|Active Comparator|B|gemcitabine
33255743|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
33255744|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
33255745|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
33255746|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
33255747|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
33255748|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
33255749|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
33255750|NCT00775112|Experimental|1|with pillow
33255751|NCT00775112|No Intervention|2|without pillow
33255752|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
33255753|NCT02551848|Experimental|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
33255754|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
33255755|NCT00807534|Placebo Comparator|placebo|placebo nebulization
33255756|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
33255757|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
33255758|NCT05589142|Experimental|eTRE with BCAA|participants allocated to this group will only consume calories during 0800h and 1600h daily. Prior to sleep, participants will consume a single bolus of 5.6g of BCAA.
33255759|NCT05589142|Active Comparator|eTRE|participants allocated to this group will only consume calories during 0800h and 1600h daily.
33255760|NCT05589064|Experimental|Dietary intervention and nutritional supplements (group A)|Patients in group A will receive four consultations with a dietitian over eight weeks, in addition to conventional physiotherapy treatments. These patients will receive nutritional counselling and omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements prescribed by their doctor.
33255761|NCT05589064|Active Comparator|Nutritional supplements (group B)|Patients in group B will be prescribed omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements and receive physiotherapy treatments over eight weeks.
33255762|NCT05589064|Other|Physiotherapy treatment (control group)|Patients in the control group will receive physiotherapy treatments over eight weeks.
33255763|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
33255764|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
33255765|NCT05355844|Sham Comparator|Patients without Benzoyl peroxide|
32733304|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
32733305|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
32733306|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
33255766|NCT05355844|Experimental|Patients with Benzoyl peroxide|
33401335|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
33401336|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
33401337|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
32733307|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
33076063|NCT04705012|Experimental|Test - increased frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
33076064|NCT04705012|Active Comparator|Control - conventional frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
33076065|NCT04701580|Experimental|HD patients|At baseline and 2-year follow-up
33076066|NCT04701580|Active Comparator|Healthy controls|At baseline and 2-year follow-up
33076067|NCT04711031||Usual care + FLUS|At index consultation, patients will receive a FLUS examination in addition to the GP's usual care of adults presenting with symptoms of an acute LRTI.
32733308|NCT01832181||Metformin|
32733309|NCT01832181||Control|
32733310|NCT02479399||Suglat group|Tablets
33076068|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
33076069|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
33076070|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
33082262|NCT04620772|Other|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
32733311|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
32733312|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
33076071|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
33255767|NCT04197700|Other|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:~Pre-operative anesthesia or surgical consultation;~Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;~Inpatient measurement the night before surgery;~Pre-anesthetic MAP~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively."
33255768|NCT04197700|Other|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
33255769|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33255770|NCT04114786|Experimental|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
33255771|NCT04114786|Active Comparator|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
33255772|NCT00669110|Experimental|A|
33255773|NCT04604860|Experimental|EL-FIT|Patients using the EL-FIT app
33255774|NCT00654732|Experimental|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33076072|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
33255775|NCT00654732|Active Comparator|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
33076073|NCT04678414||Observational (focus group, survey)|"FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.~SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.~TELEPHONE SURVEY: Patients complete a telephone survey."
33076074|NCT04678297|Experimental|Physical activity + emotion regulation group|Participants randomized to the experimental group attend two group-based class sessions per week, each 1.25hours long, that are led by certified instructors who guide participants through various exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
33076075|NCT04678297|Active Comparator|Physical activity control group|Participants randomized to the control group attend two group-based class sessions per week, each 1.25hours long, that are led by trained therapists who guide participants through a series of stretching exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
33076076|NCT00185367|Experimental|Arm 1|
32733313|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
32733314|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
32733315|NCT01230879|Experimental|60 - 70 years old|EFR and TDM
32733316|NCT01230879|Experimental|71 - 80 years old|EFR and TDM
32733317|NCT01230879|Experimental|81 - 95 years old|EFR and TDM
33076077|NCT00185367|Active Comparator|Arm 2|
33082263|NCT04620421|Experimental|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
32733318|NCT05714995||hypnosis|patients in the hypnosis group will perform self-hypnosis sessions
32733319|NCT05714995||hypnosis with aromatherapy|patients in the hypnosis with aromatherapy group will perform self-hypnosis sessions with inhalation of an essential oil
32733320|NCT03750747|Experimental|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
33076078|NCT04663633|Experimental|Core stability training|"The EG performed an 8-week core stability training, consisting in 30 min of core stability and plyometric exercises 3 days per week, 24 sessions in total.~The CST sessions were conducted in a gym suitable for RG practise and the safety of the participants will be maintained. The equipment necessary for the training was provided to the participants.~The coaches are RG professionals with national coach level in RG and volunteered to lead the specific CST designed by a RG national coach and an expert core stability physiotherapist.~Before each session EG and CG performed a 15 min warm up. The load of the session was calculated by the RPE (rate of perceived exertion). And was modulated in order to maintain 7-8 intensity."
33255776|NCT04553068|Experimental|EVO100 gel|EVO100 vaginal gel, 5 g
33255777|NCT04553068|Placebo Comparator|Placebo gel|Placebo vaginal gel, 5 g
33255778|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
32733321|NCT03750747|No Intervention|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
32733322|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
32733323|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
33255779|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
33255780|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
33255781|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
33255782|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
33255783|NCT05358028|Experimental|Hand arm Bimanual intensive Technique including Lower extremity (HABIT-IL)|Hand arm Bimanual activities involving Lower extremity
33255784|NCT05358028|Active Comparator|Hand Arm bimanual intensive Technique (HABIT)|Hand arm Bimanual activities without involvement of lower extremity
33255785|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
33255786|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
33255787|NCT00649428|Experimental|Active|
33255788|NCT00649428|Placebo Comparator|Control|
33255789|NCT04090762|No Intervention|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
33255790|NCT04090762|Active Comparator|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
33255791|NCT04090762|Active Comparator|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
33255792|NCT04090762|Active Comparator|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
33255793|NCT00767390||ACL Patch|
33255794|NCT02552082||Scorpio NRG|
33255795|NCT04000438|Experimental|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
32733324|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
32733325|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
33076079|NCT04663633|No Intervention|Traditional RG training|The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
33255796|NCT04000438|Experimental|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
33255797|NCT04000438|Experimental|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
33255798|NCT04000438|Placebo Comparator|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
33255799|NCT00771680||A|
33255800|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
33255801|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
33255802|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
33255803|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
33255804|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
33255805|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
33255806|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
32935328|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
33255807|NCT05074914|Experimental|Adenocarcinoma of the oesophagus|curative oesophagectomy
33255808|NCT05074914|No Intervention|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
33255809|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
33255810|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
33255811|NCT04001998|Experimental|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
33255812|NCT04001998|Experimental|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
33255813|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
33255814|NCT04490200|Experimental|Novel chitosan semi facial respirator (VESTA)|VESTA is a semi facial respirator that follows the same technical specifications of a N95 class PFF2 respirator. However, the VESTA respirator has nanoparticles in the filtering element, which is manufactured with a product of 50 gsm melt blown polypropylene-treated with an electrostatic charge. This filtering element deposits nanoparticles of polymeric biodegradable material known as chitosan. Chitosan can act as a surface for adsorption and viral inactivation.
33401338|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
32906182|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
33401339|NCT02997176|Experimental|Group A (control, normal hepatic function)|
33401340|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
33401341|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
33401342|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
33401343|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
33401344|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
32906183|NCT01836146|Experimental|Renal Artery Ablation|
32906184|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
32906185|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
32906186|NCT03212066|No Intervention|Wait-List Control|Business as usual
32906187|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
32906188|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
32906189|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
32906190|NCT03211676|Active Comparator|Theranova-500|
32906191|NCT03211676|Sham Comparator|Elisio-21H|
32906192|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~Both carotid artery on left and right of the neck.~Both superficial temporal artery on the left and right of forehead.~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
32906193|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
32906194|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
32906195|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
32906196|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
32733326|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
32733327|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
32733328|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
32733329|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
32733330|NCT05714917||Confirmed diagnosis of NOS-induced neurological damage|"Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-30) as of 01/04/2023.~Patients who can read and write in English, so that they can complete the questionnaires."
32733331|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
32733332|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
32733333|NCT05073159|Active Comparator|0 degree Head-of-Bed (HOB) position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
32733334|NCT05073159|Active Comparator|Elevated (30-degree or more) head-of-bed|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
32733335|NCT05713591|Experimental|Transition care model|Patients in the experimental arm will receive the TC intervention which encompasses three main pillars that guided a standardized and structured clinical pathway to ensure an optimal transition from childhood care to adult care. Briefly, the first pillar was designed to improve the understanding of the clinical condition through tailored education. Healthcare providers delivered specific information and education strategies. The second pillar aimed to support the development of functional coping strategies by discussing with a counselor and/or a psychologist. The TC encompassed for this pillar both structured face-to-face discussions and counseling moments. The third pillar hoped to improve the engagement of CHD adolescents and their families.
32733336|NCT05713591|No Intervention|Usual care|Patients in the control arm will receive a usual care approach without the high focus on standardization given by the experimental arm (e.g. without flyers and booklets or standardized moments of face-to-face counseling). Data collection will be performed using a consistent approach with the one described in the experimental arm: every three months in a year (T0, T1, T2, T3, and T4).
32935329|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
32935330|NCT05446441|Experimental|Intervention;|Endoscopic thyroidectomy was performed in a standardized fashion by multi-institutional Chinese experienced surgeons using the same gasless unilateral transaxillary approach.
32935331|NCT05446441|Active Comparator|Control|Conventional open surgery was performed in a standardized fashion by multi-institutional Chinese experienced surgeons.
32935332|NCT03375164|Experimental|Cohort A: SRP-9001|Participants will receive a single IV infusion of SRP-9001 on Day 1.
32935333|NCT03375164|Experimental|Cohort B: SRP-9001|Participants will receive a single IV infusion of SRP-9001 on Day 1.
32935334|NCT04947085|Active Comparator|IV SDK|intravenous ketamine administration in sub-dissociative doses (SDK) administered at 0.3 mg/kg over 15 minutes to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
32935335|NCT04947085|Active Comparator|K-BAN|nebulized ketamine at 0.75mg/kg administered via BAN to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
32935336|NCT05446532||Not apply|None. Just registration epidemiology dates
32935337|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
32935338|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
32935339|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
32935340|NCT04958798|Experimental|Culturally Centered MOUD Implementation|Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
32935341|NCT04947020||Rectal cancer|Patients with primary rectal cancer operated on between 2013 and 2019.
33076080|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
33076081|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
33076082|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
33076083|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
33255815|NCT04490200|Active Comparator|Conventional N95 semi facial respirator|The N95 PFF2 respirators are manufactured from TNT as defined in ABNT NBR 15052: 2004 and in the resolution of ANVISA RDC No. 356. The filtering element is usually formed by a layer of thin polypropylene fibers arranged at random. This configuration influences the particles (which constitute aerosols) to move along an extensive and tortuous path in relation to their size; thus, increasing the probability of them coming into contact with the fibers and being retained. A number of mechanisms influence the interception of particles by the fibers of the filter element. In addition to the mechanical interception mechanisms, the presence of charges on the surface of the filter material can enhance the association of particles with its fibers and optimize the efficiency of the respirator.
33255816|NCT04045314|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
33255817|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
33255818|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
33255819|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
33255820|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
33255821|NCT03905668||ICU Patients|Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
33255822|NCT03905668||ICU Patient Friends/Family Members|Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
33255823|NCT04652622|Experimental|Intervention arm|Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care
33255824|NCT04652622|No Intervention|Control Arm|Participants will be monitored over a 4 hour period of standard care interventions
33255825|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
33255826|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
33255827|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
33076084|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
33255828|NCT05582668||Cohort 1|Cohort 1: Older patients with overweight, obesity after bariatric surgery
33255829|NCT05582668||Cohort 2|Cohort 2: Older patients with overweight, obesity without bariatric surgery
33255830|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
33255831|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
33255832|NCT05582356|Experimental|Carbohydrate group (Group OC)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OC will consume carbohydrate fluid at 22.00 p.m. and two hours before the surgery
33255833|NCT05582356|Sham Comparator|Placebo group (Group OP)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OP will consume an equal amount of water 22:00 p.m. and two hours before the surgery.
33255834|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
32743097|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
32743098|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
32743099|NCT04938531|Experimental|Exercise|Exercise, passive
32743100|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
32743101|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
33255835|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
33255836|NCT00670046|Other|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
33255837|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
33255838|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
33255839|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
33255840|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
33255841|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
32743102|NCT04938843|Experimental|F. prausnitzii and D. piger|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
32743103|NCT04938843|Placebo Comparator|Placebo|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
33076085|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
32743104|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
33076086|NCT04653337|Experimental|Robot-assisted accelerated iTBS-1800 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-1800(10 sessions per day over 5 consecutive days). This group is in order to determine the safety, tolerability and feasibility of accelerated iTBS protocol.
33082264|NCT04620421|No Intervention|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
33255842|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
33255843|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
33255844|NCT00812214|Experimental|1|
33255845|NCT00812214|Placebo Comparator|2|
33255846|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
33255847|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
33255848|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
33255849|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
33255850|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
33255851|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
33255852|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
33255853|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
32743105|NCT04938453|Experimental|Treatment sequence 1 (T-R)|first test (T), then reference (R) treatment
32743106|NCT04938453|Experimental|Treatment sequence 2 (R-T)|first reference (R), then test (T) treatment
32743107|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
33255854|NCT00767780||3|Patients suffering from ankle fractures and instability
33255855|NCT00767780||4|Patients suffering from hip osteoarthritis
33255856|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
33255857|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
33255858|NCT00767780||2|Patients suffering fron non specific low back pain
33255859|NCT00775736||A|
33255860|NCT04047914|Experimental|experimental PDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time. Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application (one point on each of the 4 walls).
33255861|NCT04047914|Active Comparator|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
32743108|NCT04946097|Experimental|study group|received the conventional selected exercise program in addition to gross Myofascial Release
32935342|NCT04940221|Experimental|Phone-delivered decision-counseling program for shared decision making in lung cancer screening|All individuals who are eligible for lung cancer screening according to USPSTF criteria were invited to participate in the study and all patients who accepted the invitation and consented were slated to receive the intervention which was a phone-delivered on line decision-counseling program (DCP) and there was no one randomized or enrolled into a control group, nor was anyone randomized or enrolled into a usual care group.
32935343|NCT05446064|Experimental|Enhanced Treatment|Participants will receive the stigma-reduction intervention as well as typical services including care co-ordination and linkage to public health nurses in local communities.
32935344|NCT05446064|No Intervention|Treatment-as-Usual|Participants will receive typical services including care co-ordination and linkage to public health nurses in local communities.
32743109|NCT04946097|Experimental|control group|the control group which received the conventional selected exercise program
32935345|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
32935346|NCT04915508|Experimental|Treatment (SBRT, hormone therapy)|Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
32935347|NCT05445973|Experimental|Real-Time Contrast-Enhanced Ultrasonography-CT/MRI Fusion Guidance|To investigate whether CEUS-CT/MRI fusion imaging improved the visualization of small (≤ 3 cm) primary and secondary malignant liver tumors that were inconspicuous on B-mode US for percutaneous RFA.
32935348|NCT05445986||group1|socket with intact buccal bone plate
32935349|NCT05445986||group 2|socket with damaged buccal bone plate
32935350|NCT05445908|Experimental|SKB264+KL-A167（Part1）|Participants received SKB264 followed by KL-A167
32935351|NCT05445908|Experimental|SKB264（Part2）|Participants received SKB264
32935352|NCT05445908|Experimental|SKB264+KL-A167（Part2）|Participants received SKB264 followed by KL-A167
32935353|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
32935354|NCT02681809|Experimental|Ocriplasmin 0.125mg|
32935355|NCT02681809|Sham Comparator|Sham injection|
32935356|NCT05445661|Experimental|Injectable poly-L-lactic acid|One of the subject's arms will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
32935357|NCT05445661|Sham Comparator|Normal Saline|One of the subject's arms will be treated with injectable normal saline
33076087|NCT04653337|Active Comparator|Robot-assisted accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-600(6 sessions of iTBS with 30 min interval per day over 5 consecutive days).
33076088|NCT04653337|Sham Comparator|Sham accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation and depression will receive antidepressants combined with sham accelerated iTBS-600(6 sessions of sham iTBS with 30 min interval per day over 5 consecutive days).
33076089|NCT04652089|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg capsule once a day for 7 days
33076090|NCT04652089|Placebo Comparator|Control arm: Placebo|Placebo capsule once a day for 7 days
33076091|NCT04684303|Experimental|Lumbar medial branch RF neurotomy|Procedure lumbar medial branch RF neurotomy By raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be > 4 )
33076092|NCT04684303|Experimental|Lumbar medial branch cryoablation|"Procedure lumbar medial branch cryoablation Decreasing the temperature of the electrode to - 85 C for 120 seconds in two cycles.~Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be =/> 4 )"
33255862|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
33255863|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
33255864|NCT00537238|Active Comparator|B|
33255865|NCT00537238|Active Comparator|A|
33255866|NCT00772226|Active Comparator|music|
33255867|NCT00772226|Placebo Comparator|Pillow without music|
33076093|NCT00552721|Experimental|A|Physical therapy with strength training.
33255868|NCT00946413|Experimental|CBT plus parent education|
33255869|NCT00946413|Experimental|CBT alone|
33255870|NCT03982771|Experimental|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
33255871|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
33255872|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
33255873|NCT03966885|Experimental|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
33076094|NCT00552721|Active Comparator|B|Physical therapy without strength training.
33255874|NCT03966885|Experimental|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
33255875|NCT04048148|Other|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months and then test lenses for another 6 months
33255876|NCT04048148|Other|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 12 months
33255877|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
33255878|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
33255879|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
33255880|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
32743110|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
33082265|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
33082266|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
33082267|NCT04620850|Experimental|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
33082268|NCT04620850|No Intervention|No acupressure|Standard post-operative care
33255881|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
33255882|NCT00776048||Healthy Controls|Age matched healthy controls
33255883|NCT03863470|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
33255884|NCT03863470|Active Comparator|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
33255885|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
33255886|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
33255887|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
33255888|NCT03336190|Experimental|Intervention|Receives the full program, including the toolkit training and avatar interaction
33255889|NCT00776204|Active Comparator|1|Drug Eluting Stent
33255890|NCT00776204|Active Comparator|2|Drug Eluting Stent
33255891|NCT00776204|Active Comparator|3|Drug Eluting Stent
32733337|NCT05073081|Experimental|Prehabilitation|The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
32733338|NCT05073081|Active Comparator|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice. This generally consists of one session with an anesthesiologist, a nurse and access to our online videos.
32733339|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system~Other names:~Mirena."
32733340|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:~Other name: Implanon Releasing 20μg/day."
32733341|NCT05072925|Active Comparator|Combustible Cigarette|The usual brand of combustible cigarette smoked by study subjects, with a minimum Federal Trade Commission tar yield of 8mg
32733342|NCT05072925|Experimental|BIDI Stick ENDS Arctic flavor|BIDI Stick ENDS containing 6% nicotine and Arctic flavor
33076095|NCT04637581|Experimental|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
33076096|NCT04637581|No Intervention|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
33076097|NCT04609306|Experimental|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
33076098|NCT04609306|No Intervention|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
33076099|NCT00407147|No Intervention|Control|Standard treatment
32733343|NCT05072925|Experimental|BIDI Stick ENDS Classic flavor|BIDI Stick ENDS containing 6% nicotine and Classic flavor
32733344|NCT05072925|Experimental|BIDI Stick ENDS Zest flavor|BIDI Stick ENDS containing 6% nicotine and Zest flavor
32733345|NCT05072925|Experimental|BIDI Stick ENDS Regal flavour|BIDI Stick ENDS containing 6% nicotine and Regal flavor
32733346|NCT05072925|Experimental|BIDI Stick ENDS Winter flavour|BIDI Stick ENDS containing 6% nicotine and Winter flavor
32733347|NCT05072925|Experimental|BIDI Stick ENDS Solar flavor|BIDI Stick ENDS containing 6% nicotine and Solar flavor
33076100|NCT00407147|Experimental|PCT|PCT guided arm
33076101|NCT04597879||Severe traumatic brain injury|
33076102|NCT04597879||Severe trauma without brain trauma|
33076103|NCT04597879||Healthy controls|
33076104|NCT04710680||group A|
32733348|NCT05072925|Active Comparator|JUUL ENDS Virginia Tobacco flavor|JUUL ENDS containing 5% nicotine and Virginia Tobacco flavor
33076105|NCT04710680||group I|
33076106|NCT04684498|Experimental|Tamiflu (Oseltamivir Phosphate Capsules)|Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)
33076107|NCT04684498|Other|no intervention|Standardized STEMI treatment + no intervention
33076108|NCT04541602||Dysphagia-positive|"critically ill patients more than 17 years of age~matching study inclusion criteria~confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
33076109|NCT04541602||Dysphagia-negative|"critically ill patients more than 17 years of age~matching study inclusion criteria~newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
33076110|NCT04541602||Controls|"healthy volunteers without any neuromuscular disease~swallowing dysfunction ruled out using FEES"
33076111|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
33076112|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
33076113|NCT00409071|Experimental|1|cocculine
33076114|NCT00409071|Placebo Comparator|2|placebo
33076115|NCT04524325|Active Comparator|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
33076116|NCT04524325|No Intervention|control|cisgender women not receiving testosterone and with normal sex hormone levels
33076117|NCT00162305|Active Comparator|1|
33076118|NCT00162305|Active Comparator|2|
33076119|NCT00162305|Active Comparator|3|
33076120|NCT00162305|Placebo Comparator|4|
33076121|NCT04513015|Experimental|Antioxidant diet|Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
33255894|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
33255895|NCT05355610|Experimental|Vestibular severity index improvement|Improvement in vestibular symptoms with intratympanic gentamicin
33255896|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
33255897|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
33255898|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
33255899|NCT00768014||2|Healthy term pregnant women received TENS
33255900|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
33255901|NCT04241848|Experimental|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
33255902|NCT04241848|Active Comparator|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
33076122|NCT04513015|Active Comparator|Normal diet|Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
33255903|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
33255904|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
33255905|NCT04099810|Other|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
33255906|NCT00768170|Experimental|1|MK0633
33255907|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
33255908|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
33255909|NCT05553106||Study Group|Patients who are hospitalized in the coronary intensive care unit, who can take simple commands, and whose condition is physiologically stable.
33255910|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
33255911|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
33255912|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
33255913|NCT05488678|Experimental|Group 1 - Control|Healthy control participants will be matched by gender, age, and BMI to participants with renal impairment
33255914|NCT05488678|Experimental|Group 2 - Mild Renal Impairment|Mild Renal Impairment
33255915|NCT05488678|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
33255916|NCT05488678|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
33255917|NCT05488678|Experimental|Group 5 - End Stage Renal Disease|End Stage Renal Disease undergoing chronic intermittent hemodialysis
33255918|NCT00768326|Experimental|Zicronapine. Study Part A|
33255919|NCT00768326|Experimental|Zicronapine. Study Part B|
33255920|NCT00768326|Experimental|Zicronapine. Study Part C|
33255921|NCT00768326|Experimental|Zicronapine. Study Part D|
33255922|NCT00768326|Experimental|Zicronapine. Study Part E|
33255923|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
33255924|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
33255925|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
33255926|NCT05406700|Experimental|Arm A Treatment with Niraparib|Patients randomized to arm A will receive niraparib daily and undergo tumor resection after 28 days (+/- 7 days) of treatment. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent
33255927|NCT05406700|Active Comparator|Arm B No Treatment with Niraparib|Subjects in arm B will not receive niraparib prior to surgery. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
33255928|NCT00768404|Experimental|A|
33255929|NCT00951795||Adults|Adult men and women over age of 18
33255930|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
33255931|NCT05406622|Experimental|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants who receive the MOTIV device will be included in this arm
33255932|NCT05406622|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receive PTA treatment will be included in this arm
33255933|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
33255934|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
33255935|NCT00943293|Experimental|Vaccine|
33255936|NCT05385718||Observational|The observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional.
33076123|NCT04488133|Experimental|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
33082269|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
33255937|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
33076124|NCT04453774|Experimental|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
33076125|NCT04419805|Experimental|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
33076126|NCT04419805|Experimental|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
33255938|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
33255939|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
33076127|NCT04395625|Experimental|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
33255940|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
33255941|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
33255942|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
33255943|NCT00772694|Experimental|sorafenib|drug
33255944|NCT00951873|Experimental|A|
33255945|NCT00951873|Placebo Comparator|B|
33076128|NCT04395625|Experimental|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
33255946|NCT00951873|Experimental|C|
32733349|NCT02479477|Experimental|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
32733350|NCT02479477|No Intervention|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
33076129|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
33076130|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
33255947|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
33255948|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
33076131|NCT04382326|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33255949|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
33255950|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
33255951|NCT00943371|Experimental|1|MK6349
33255952|NCT00943371|Placebo Comparator|2|Placebo to MK6349
33255953|NCT05352646|Experimental|NewishT|This study is divided into two dose groups and two phases. Phase Ia climbed from low-dose group to high-dose group in turn according to the 3+3 dose escalation principle. Phase Ib extended 10 subjects each group.
33255954|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
33255955|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
33255956|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
33255957|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
33255958|NCT00943449|Experimental|4SC-201|
33255959|NCT00943449|Experimental|4SC-201 + Sorafenib|
33255960|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
33255961|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
33076132|NCT04382326|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33076133|NCT00162383|Experimental|Cocktail|
33255962|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
33255963|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
33255964|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
33255965|NCT05300685|Active Comparator|Group 1: Standard of care|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~No further infiltration of local anesthetic in mouth"
33255966|NCT05300685|Experimental|Group 2: Standard of care + Long acting local|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~Up to a maximum of 10mL of 0.5% bupivacaine infiltration in the buccal graft site"
33255967|NCT05300685|Experimental|Group 3: Standard of care + Buccal block|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~Up to a maximum of 10mL of 0.5% bupivacaine infiltration as a buccal block"
33255968|NCT00560313|Experimental|4CMenB|
33255969|NCT00560313|Experimental|MenACWY CRM|
33255970|NCT00667862|Experimental|Panobinostat|Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
33076134|NCT04683874|Experimental|3D printed tray|3D printed tray
32733351|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
32733352|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
33076135|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
33255971|NCT00952107|Experimental|Imaging system operation|
33076136|NCT04355143|Experimental|Colchicine plus current care|Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians
33076137|NCT04355143|Active Comparator|Current care alone|Current care per UCLA physicians alone (control arm)
33076138|NCT04343365||Participants Reviewed by ETB|Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
33076139|NCT00185445|Experimental|Arm 1|
33255972|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
33076140|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
33076141|NCT04309981|Experimental|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
33076142|NCT04305340|Experimental|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
33255973|NCT00776516|Experimental|1|mirabegron alone
33076143|NCT04305340|Experimental|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
33076144|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
33255974|NCT00776516|Experimental|2|mirabegron and rifampin
33255975|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
33255976|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
33255977|NCT00768638|Active Comparator|Atorvastatin 10mg|
33076145|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
33076146|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
33255978|NCT00768638|Active Comparator|Atorvastatin 40mg|
33255979|NCT00952263|Experimental|MBL-HCV1|
33076147|NCT04297111|Placebo Comparator|Placebo|Maltodextrin containing capsule
33076148|NCT04297111|Experimental|Probiotic|Probiotic containing capsule
33255980|NCT00773006||A|Stable/elective PCI patients
33076149|NCT00552877|Active Comparator|1|Cypher Select plus stent
33076150|NCT00552877|Active Comparator|2|Xience V stent
33082270|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
33082271|NCT04620460|Active Comparator|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
33082272|NCT04620460|Sham Comparator|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
33255981|NCT00773006||B|NSTEMI PCI patients
33255982|NCT00773006||C|STEMI PCI patients
33255983|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
33255984|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
33255985|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
33255986|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
33255987|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
33255988|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
33255989|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
33255990|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
33255991|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
33255992|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
33255993|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
33255994|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
33255995|NCT00534976|Experimental|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
33255996|NCT00534976|Experimental|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
33255997|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
33255998|NCT00773162|Placebo Comparator|1|
33255999|NCT00773162|Active Comparator|2|
33256000|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
33256001|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
33256002|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
33256003|NCT04048330||Women of reproductive age|Women 15 to 49 years of age who are not pregnant or lactating
33256004|NCT00769028|Experimental|AIMSPRO|
33256005|NCT00769028|Placebo Comparator|Placebo|
33256006|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
32733353|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
32733354|NCT05384509||Chemotherapy|Cancer Patients underwent chemotherapy
32733355|NCT05384509||Targeted therapy|Patients underwent targeted therapy
32935358|NCT05445583|Experimental|Motivational Enhancement System (MES) and Physical Activity Tracking (PAT)|MES is a web-based, mobile asthma management intervention delivered to participants' personal mobile devices. There are 4 sessions, completed over 10 weeks, with each session taking approximately 15-20 minutes. During Session 1, participants will identify asthma-related problems they may encounter and will receive asthma information and motivation. Between Session 1 and Session 2, participants will be asked to complete an electronic daily diary for 7 days. Session 2 allows participants to select up to 2 goals to address. Session 3 occurs over the course of 4 weeks and provides tailored messages based on problem and goal selection. The final session (Session 4), asks participants for feedback on how well they feel they accomplished their goal. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
32935359|NCT05445583|Experimental|Supportive Accountability (SA) and PAT|SA is an asthma management intervention delivered by asthma nurses trained in targeted MI skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). Sessions with the nurse will be approximately 15-20 minutes in length and will focus on ways to improve asthma care. There are 4 sessions with the nurse, over the course of 10 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
33082273|NCT04620031|Experimental|HSK3486|HSK3486 for Sedation
33082274|NCT04620031|Active Comparator|Propofol|Propofol for Sedation
33082275|NCT00243282|No Intervention|1|Control (Support Group)
33082276|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
33256007|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33256008|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33256009|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
33082277|NCT04620109|Placebo Comparator|SDE Placebo|Subjects will receive placebo (drops without drug).
33082278|NCT04620109|Active Comparator|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
33256010|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
33256011|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
33256012|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
32733356|NCT05384509||Immunotherapy|Patients underwent immunotherapy
32733357|NCT05384509||Disease-free|Cancer patients have been disease-free for ≥ 6 months group
32733358|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
32733359|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
32733360|NCT05072769|Experimental|Experimental group|After the fetus and placenta are born, feeding 100 gr (5-6 pieces) dates to the experimental group
32733361|NCT05072769|No Intervention|Control group|The group that was not attempted any intervention in the postpartum period
32733362|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.~The initial dosage can be then adjusted on the base of response."
32733363|NCT05072691||Patients with Multiple sclerosis and Optic Neuritis|Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis
32733364|NCT05072691||Patients with non-inflammatory neurologic diseases (NIND)|Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture
32733365|NCT05072691||Patients with other inflammatory neurologic diseases (IND)|Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture
32733366|NCT05071989|Experimental|Sleep education group do not supported with social media reminders|Sleep education do not supported with social media reminders
32935360|NCT05445583|Experimental|Text Messaging (SMS) and PAT|SMS will target asthma knowledge. One-way SMS messages will be sent to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Text messages will be sent twice a week for the first 5 weeks and once a week for the last 5 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
33256013|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
33256014|NCT04002466||Children (6-59 months)|
33256015|NCT04002466||Women of Reproductive Age (15-49 years)|
33256016|NCT04002466||Adult Men (15-49 years)|
33256017|NCT00776906|Experimental|1|PTX-coated balloon
33256018|NCT00776906|Active Comparator|2|Bare balloon
33256019|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
33256020|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
33256021|NCT00773240|Experimental|1|Grazax
33256022|NCT00773240|Placebo Comparator|2|
32733367|NCT05071989|Experimental|Sleep education group supported with social media reminders|Sleep education group supported with social media reminders
32733368|NCT05071989|No Intervention|Control group|No intervention was made in the control group.
32935361|NCT05445583|Experimental|MES_SMS_PAT|Participants will receive a combination of the MES and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
33256023|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
33256024|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
33256025|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
33256026|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
33256027|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
33256028|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
33256029|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
33256030|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
33256031|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
33256032|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
33256033|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
33256034|NCT05327296|Experimental|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
33256035|NCT05327296|Active Comparator|Propofol|Propofol administered as intravenous infusion
33256036|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
32733369|NCT05714839|Experimental|Part 1 - Dose Escalation Phase in Participants with RRMM|Bela will be administered in participants with RRMM until progressive disease (PD). Participants may switch to Belamaf in case of PD.
33082279|NCT04620109|Active Comparator|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
33256037|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
33256038|NCT01064089|Experimental|HSP990|dose escalation
33256039|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
33256040|NCT03946306|Active Comparator|Group 1|5,25% NaOCl with syringe needle irrigation alone
33256041|NCT03946306|Active Comparator|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
33256042|NCT05184452|Experimental|PGDM1400LS 5 mg/kg IV|Participants will receive PGDM1400LS 5 mg/kg by intravenous (IV) infusion at Month 0
33256043|NCT05184452|Experimental|PGDM1400LS 20 mg/kg IV|Participants will receive PGDM1400LS 20 mg/kg by IV infusion at Month 0
33256044|NCT05184452|Experimental|PGDM1400LS 20 mg/kg SC|Participants will receive PGDM1400LS 20 mg/kg by subcutaneous (SC) infusion at Month 0
33256045|NCT05184452|Experimental|PGDM1400LS 40 mg/kg IV|Participants will receive PGDM1400LS 40 mg/kg by IV infusion at Month 0
33256046|NCT05184452|Experimental|PGDM1400LS 40 mg/kg SC|Participants will receive PGDM1400LS 40 mg/kg by SC infusion at Month 0
33256047|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg IV|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
33256048|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg SC|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by SC infusion sequentially in this order at Month 0 and Month 4
33256049|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram IV|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by IV infusion sequentially in this order at Month 0 and Month 4
33256050|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram SC|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by SC infusion sequentially in this order at Month 0 and Month 4
33256051|NCT05184452|Experimental|PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg IV|Participants will receive PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
33256052|NCT05356624|Experimental|Mulligan Mobilization|Mobilization with movement (3 sets per 10 repetitions).
33256053|NCT05356624|Experimental|Soft tissue mobilization|Soft tissue mobilization (3 sets per 10 repetitions)
33256054|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
33256055|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
33256056|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
33256057|NCT00308113|No Intervention|4|Enhanced standard of care.
33256058|NCT03903640|Experimental|Optune + Ipilimumab + Nivolumab|"Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.~Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses~Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.~Treatment may continue for up to 1 year"
33256059|NCT05157386||Participants in Braining, years 2017-2020|"Braining was primarily open for patients with a main or secondary diagnosis within affective disorder or anxiety syndromes, sleep disturbance or stress.~Participants in Braining (n≈600), who have participated in three or more training sessions 2017-2020 (n≈250), and who agree to contribute to this study, will be included."
33256060|NCT03982849|Active Comparator|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
33256061|NCT03982849|Experimental|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
33256062|NCT05357872|Experimental|BIS 40-50 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50
33256063|NCT05357872|Experimental|BIS 50-60 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 50-60 during the operation.
33256064|NCT05147402|Active Comparator|Fasted Treatments with 100 mg of MDMA|Following an overnight fast of at least 10 hours, participants will be administered 100 mg MDMA (equivalent to 120 mg MDMA HCl) with 240 mL of water. No food should be allowed for at least 4 hours post-dose.
33256065|NCT05147402|Active Comparator|Fed Treatments with 100 mg of MDMA|A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal will be used as a test meal for food-effect evaluation. Following an overnight fast of at least 10 hours, participants will start the recommended meal 30 minutes prior to administration of the drug product. Participants will eat this entire meal in 30 minutes or less. 100 mg MDMA (equivalent to 120 mg MDMA HCl) will be administered 30 minutes after start of the meal with 240 mL of water.
33256066|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
33256067|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
33076151|NCT04233034|Active Comparator|HCL and placebo|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
33076152|NCT04233034|Active Comparator|HCL and verapamil|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
33082280|NCT04620109|Active Comparator|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
33256068|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
33256069|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
33256070|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
33256071|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
33256072|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
32733370|NCT05714839|Experimental|Part 2 - Combination Treatments in Participants with RRMM|Participants with RRMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment for Multiple Myeloma.
33256073|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
33256074|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
33256075|NCT00777218|Active Comparator|1|
32733371|NCT05714839|Experimental|Part 3 - Combination Treatments in Participants with TI-NDMM|Participants with TI-NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment for Multiple Myeloma.
33256076|NCT00777218|Active Comparator|2|
33256077|NCT00777218|Active Comparator|3|
33256078|NCT05357716||Arm A|Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.
33256079|NCT05357716||Arm B|Up to 10 patients will be enrolled in Arm B.Subjects will wear the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Holter subjects will record diary information on their activities and any relevant symptoms.
33256080|NCT04047758|Experimental|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
33256081|NCT04047758|Placebo Comparator|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
32733372|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
32733373|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
33256091|NCT00922064|Experimental|ECT|
33256092|NCT05355064|Experimental|Single arm|Single treatment, no placebo.
33256093|NCT00307801|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
33256094|NCT00307801|Placebo Comparator|Placebo|Matching placebo to be taken orally daily.
32733374|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
32733375|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
32733376|NCT05378425|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|NTX-1088 administered as a 60-minute IV infusion at escalating doses as a monotherapy. NTX-1088 will be administered on Day 1 of a 21-day cycle.
33256095|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
33256096|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
33256097|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
33256098|NCT05354986|Placebo Comparator|Control-Control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
33277490|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33076153|NCT04233034|Active Comparator|non-HCL and verapamil|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
33082281|NCT04620109|Active Comparator|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
33256099|NCT05354986|Experimental|Control-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
33401345|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
32733377|NCT05378425|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"NTX-1088 administered as a 60-minute IV infusion in escalating doses in combination with pembrolizumab. NTX-1088 will be administered on Day 1 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion, within 2 hours following NTX-1088 administration, at a dose of 200 mg on Day 1 of every 21-day cycle."
32733378|NCT05378425|Experimental|Part 2 - Dose Expansion (Monotherapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion as a monotherapy.
32733379|NCT05378425|Experimental|Part 2 - Dose Expansion (Combination Therapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose.
32733380|NCT03736395|Active Comparator|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
32733381|NCT03736395|Experimental|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
32733382|NCT05377255|Other|Arm 1 Interventional Therapy|Subjects will first receive 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device (Arm 1) before the washout period.
32733383|NCT05377255|Other|Arm 2 Reference Therapy|Subjects will first receive 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device (reference therapy, Arm 2) before the washout period.
32733384|NCT03719547|Experimental|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
32733385|NCT03719547|Active Comparator|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
33076154|NCT04233034|Placebo Comparator|non-HCL and placebo|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
33076155|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
33076156|NCT00552916|Other|2|The intervention group will receive 'true' FES
33076157|NCT00185484|Experimental|Arm 1|
32733386|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
32733387|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
32733388|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
32733389|NCT05072223|Experimental|Group A|
32733390|NCT05072223|Active Comparator|Group B|
32733391|NCT05071443|Experimental|Negative pressure wound therapy (NPWT)|Negative pressure wound therapy (NPWT): an NPWT device will be applied hermetically from randomization to skin grafting.
32733392|NCT05071443|Active Comparator|Conventional dressing|Conventional dressing will be performed from randomization to skin grafting. The dressings will be performed following usual procedures of investigating centers
33076158|NCT04218721|Experimental|eHealth application|Participants get access to the eHealth application InvolveMe
33076159|NCT04218019|Experimental|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
33076160|NCT04218019|Active Comparator|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
33076161|NCT04710290|Experimental|Solid beverage powder|Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
33256100|NCT05354986|Experimental|Test-control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
33256101|NCT05354986|Experimental|Test-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
33256102|NCT00769418|Experimental|1|odanacatib (MK0822)
33256103|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
33256104|NCT05257252|Experimental|"Persons With Disability Friendly Nursing Education Program"|Intervention group after determining the students according to the research criteria, they were randomized into intervention and control groups. Firstly, pre-tests were applied to the students in the experimental group.
33256105|NCT05257252|No Intervention|"non-Persons With Disability Friendly Nursing Education Program"|Firstly, Pre-tests were applied to the students in the control group. No intervention was applied to this group. Posttests were made 3 months after pre-test.
32733393|NCT05071521|Active Comparator|Eating disorders prevention|"The Body Project. The Body Project is a dissonance-based eating disorders prevention programme. It is a manualised evidence-based programme that targets eating pathology and body image dissatisfaction in young women. The objective of the programme is to create cognitive dissonance to encourage participants to decrease pursuing ideal-thinness. It includes group discussion, written and behavioural exercises and role-play to achieve cognitive dissonance (Stice, Rohde, & Shaw, 2013). It involves four group sessions for an hour each in consecutive weeks. At the beginning of each meeting, the facilitator reinforces voluntary commitment. Homework is explained and given at the end of each meeting and reviewed at the beginning of the following meeting.~References:~Stice, E., Rohde, P., Shaw, H. (2013). The body project a dissonance-based eating disorders prevention intervention (updated edition). New York: Oxford University Press."
32733394|NCT05071521|Sham Comparator|Healthy eating education|"The control group were asked to read educational material in Arabic about healthy nutrition and active lifestyle from the Saudi branch of the World Obesity Federation (Kayl Association for Combatting Obesity, 2021). The material includes information about body mass index; easy ways to measure food units without a scale; benefits of working out; means to adopt healthier daily habits; and healthier food alternatives. The material was chosen because it was designed to be easy to understand by any individual.~References:~Kayl Association for Combatting Obesity. (2021). Kayl association for combatting obesity. Retrieved from https://www.kayl.org.sa"
32733395|NCT05714683||Participants with T2DM|All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS).
32733396|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
32733397|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
32733398|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
32733399|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
32733400|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
32733401|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
32733402|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
32733403|NCT05714605|Experimental|THRIVE Intervention|1 month intensive post discharge case management and care coordination.
32733404|NCT05714605|No Intervention|Usual Care|Discharge to home without intensive post acute case management or care coordination.
32733405|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
32733406|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
32935362|NCT05445583|Experimental|SA_SMS_PAT|Participants will receive a combination of the SA and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
32935363|NCT05445583|No Intervention|Usual Care_PAT|Participants will continue to receive standard clinical asthma care. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
33256106|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
33256107|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
33256108|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
32935364|NCT05445505|Active Comparator|Early-start single iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
32935365|NCT05445505|Active Comparator|Early-start double iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
32935366|NCT05445505|Sham Comparator|Delayed-start single iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: daily sham/iTBS, 12 weeks
32733407|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
32733408|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 2 (intervention): local anesthesia + virtual reality"
32733409|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
32733410|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
32733411|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
32733412|NCT05070897||Population A|18 to 64 years old
32733413|NCT05070897||Population B|65 years old and more
32935367|NCT05445505|Sham Comparator|Delayed-start double iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: twice daily sham/iTBS, 12 weeks
32935368|NCT05445271|Active Comparator|Group 1|30 patients who will be intubated with a video laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a video laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
33256109|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
33076162|NCT04710290|Experimental|Capsule|Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
33256110|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (>=) 65 years.
33256111|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged >= 65 year.
33256112|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
33256113|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
33256114|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
33256115|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged >= 65 years.
33256116|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
33256117|NCT00769496|Experimental|Arm 1|
33256118|NCT05354908||Colombian research groups in surgery|Colombian research groups in surgery
33256119|NCT04098653|Experimental|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32935369|NCT05445271|Active Comparator|Group 2|30 patients who will be intubated with a normal laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a normal laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
33076163|NCT04710290|Placebo Comparator|Placebo|placebo use 1 powder for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
33256120|NCT04098653|Active Comparator|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
33256121|NCT00769574|Experimental|1|Patients with coronary syndrome
33256122|NCT00769574|Other|2|Subjects without coronary syndrome
33256123|NCT04002154|Experimental|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
33256124|NCT04002154|Experimental|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
33256125|NCT04002154|No Intervention|C - standard of care|Arm C: usual clinical practice: no treatment
33256126|NCT00777374|Experimental|1|Allergen containing patch
33256127|NCT00777374|Placebo Comparator|2|Placebo patch
33256128|NCT05297123|Experimental|ATRA/arsenic Group|"ATRA 20mg 3 times a day for 8 weeks Arsenic can be given intravenously (ATO) or oral Realgar-Indigo naturalis formula(RIF) ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given) RIF 60 mg/kg/d for 8 weeks The total dose can be appropriately adjusted according to the side-effects of the drug. 4 weeks for 1 course. If the patient has obvious side effects, the treatment should stop for 2 weeks. Each patient will be received at least two courses.~Quality of life assessments are performed every 2 months. After the end of the course of treatment, the condition is mainly evaluated based on the platelet count and bone marrow smear. If the treatment is effective, the above regimen can be continued; if not, the study is withdrawn."
33256129|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
33256130|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
33256131|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
33256132|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
33256133|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
33256134|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
33256135|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
33076164|NCT04202809|Experimental|Chemo- and Radiochemotherapy + Durvalumab|
33256136|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
33256137|NCT03683836||Study Group|
33076165|NCT04202809|No Intervention|Chemo- and Radiochemotherapy|
33076166|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
32769349|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.25% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~a. 20cc 0.25% bupivacaine~Adductor canal block technique (supine position, post IV sedation)~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
33076167|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
33076168|NCT04187053|Experimental|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
33256138|NCT00777452||1|active surveillance
33256139|NCT00777452||2|radical prostatectomy
33256140|NCT00777452||3|external beam radiotherapy
33256141|NCT00777452||4|high intensity focused ultrasound
33256142|NCT05353114|No Intervention|Standard Therapeutic Footwear prescription group|1) Patients that will acquire the therapeutic footwear size and model according to aesthetic preferences
33256143|NCT05353114|Experimental|Therapeutic Footwear prescription based on a 3D Foot scanner|2) Patients that will acquire a specific size and model according to result of a novel mobile app 3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).
33256144|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\dl).
33256145|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\dl).
33256146|NCT04016922||Group C|Patients with severe anemia (Hb concentration: >7.0 g\dl).
33256147|NCT03646474|Active Comparator|tranexamic acid group|
33256148|NCT03646474|Placebo Comparator|placebo group|
33256149|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
33256150|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
33256151|NCT00307489|Experimental|1|TDF
33256152|NCT00307489|Experimental|2|FTC/TDF
33256153|NCT04001764|Active Comparator|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
33256154|NCT04001764|Experimental|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
33256155|NCT04001764|Experimental|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
33256156|NCT04003168|Experimental|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
32733414|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
32733415|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
32733416|NCT02088333|Experimental|mCRC intervention|intervention arm
32733417|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
32733418|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
32733419|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
32733420|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
32733421|NCT05070507|Experimental|Enzyme containing lozenge|
32733422|NCT05070507|Placebo Comparator|Placebo lozenge|
32733423|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
32733424|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
32733425|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
32733426|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
32733427|NCT04492501|No Intervention|Supportive Arm|As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.
32733428|NCT04492501|Experimental|TPE arm|addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.
32733429|NCT04492501|Experimental|TPE in combination with other investigational treatments|During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir
32733430|NCT04492501|Experimental|Either alone or combination of MSC, Remdesivir and Tocilizumab|A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination
32733431|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
32733432|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
32733433|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
32733434|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
32733435|NCT03606759|Experimental|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
32733436|NCT03606759|Active Comparator|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
32733437|NCT05070195|Experimental|The DDI of SKLB1028 and Midazolam|Eligible subjects received a single dose of Midazolam 15 mg on Day 1, and took a single dose of Midazolam 15 mg and a single dose of SKLB1028 150 mg with dosing interval of 0.5 h on Day 3.
32733438|NCT05714449|Experimental|Patching group|part-time patching following PEDIG guidelines.
32733439|NCT05714449|Experimental|foveation therapy|After-image foveation therapy training is 10 mins; MIT training is 5 minutes.
32733440|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
32733441|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
32733442|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
33256157|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
33256158|NCT00667628|Placebo Comparator|Placebo|Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
33256159|NCT00667628|Experimental|TAC-101|Participants were administered with TAC-101 tablets, 20 milligram per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
33076169|NCT04187053|Sham Comparator|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
33076170|NCT00162461|Experimental|Phenytoin|
33076171|NCT04167124|Experimental|multi-sensor lifestyle intervention|
33076172|NCT04165096|Experimental|Pembrolizumab + MK-5890|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-5890 IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of MK-5890 with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).
33256160|NCT05274646||E1784K (glu1784lys) in SCN5A expressing either Long QT syndrome type 3 or Brugada syndrome|
33256161|NCT05274646||E1784K (glu1784lys) in SCN5A expressing both syndromes (Long QT syndrome and Brugada syndrome)|
33256162|NCT00812370|Experimental|open label|
33256163|NCT00645840|Experimental|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing >25 kg at the time of enrollment received 100 mg daily, whereas those weighing <25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
33256164|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
33256165|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
33256166|NCT00307333|Experimental|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
32733443|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
32733444|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
33256167|NCT00307333|No Intervention|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
33256168|NCT00762359|Experimental|Lansoprazole 15 mg QD|
33256169|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
33256170|NCT04003090|Experimental|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
32733445|NCT05069883|Experimental|Oral Steroid|In this group oral steroids were given after Direct vision internal urethrotomy
33256171|NCT00777530|Experimental|1|
33256172|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
32733446|NCT05069883|Placebo Comparator|No Oral Steroids|In this group no oral steroids were given after Direct vision internal urethrotomy
32733447|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
32733448|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
32733449|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
33256173|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
33256174|NCT04002856|Experimental|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
32733450|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
32733451|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
33256175|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
32733452|NCT05713435|Active Comparator|Mona Lisa Touch CO2 laser|"Power: 30 W.~Dwell time: 1000 μs.~Spacing: 1000 μm.~Depth: SmartStack parameter from 1 to 3 depending on the treatment status.~D-pulse mode.~At the introitus the power will be reduced to 24 W"
33076173|NCT04165096|Experimental|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).
33076174|NCT04165096|Experimental|Pembrolizumab + MK-0482|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years).
33076175|NCT04159324|Experimental|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
33256176|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33256177|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
33256178|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
33256179|NCT05350306|Experimental|Chincup|Patients will be treated with occipital chincup and bonded bite block.
33076176|NCT04159324|No Intervention|control group|routine aftercare stroke treatment
33256180|NCT05350306|Active Comparator|Untreated subjects|Patients will not undergone any treatment for 16 months.
33256181|NCT03978949|Experimental|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
33256182|NCT03978949|Placebo Comparator|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
33256183|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
33256184|NCT05356234|Experimental|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|Experimental: A series of workshops addressing responsible parenting and marriage and relationships as well as a complement of employment services and comprehensive case management will be conducted over a 12-week period.
33256185|NCT05356234|No Intervention|Wait-List Control|The Wait-List Control group will be placed on a wait-list and offered services as soon as they complete the study's final 24-week follow-up measures. Wait-List Control participants will not be assigned a Case Manager and will not receive any comparable services from our agency until they complete their 24-week measures.
33256186|NCT01061827||Dementia|
33256187|NCT01061827||Depression|
33256188|NCT01061827||Control|
33256189|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
33256190|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
33256191|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
33256192|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
33256193|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
33256194|NCT03982615|Experimental|Laser-Lok abutment|Laser-etched abutment
32733453|NCT05713435|Active Comparator|Fotona Smooth erbium:YAG laser|"Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 10 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
33256195|NCT03982615|Active Comparator|Standard Healing abutment|Standard abutment which is not laser-etched
33256196|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
32733454|NCT05713435|Sham Comparator|sham treatment|"The blocking device is inserted over the laser outlet before attaching the application speculum. With this device the laser beam is blocked entirely.~Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 1,5 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
32733455|NCT05069025|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
32733456|NCT05069025|Other|non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
32733457|NCT05713279|Experimental|FM +VV116 +SOC|
32733458|NCT05713279|Placebo Comparator|FM安慰剂+VV116+SOC|
32733459|NCT05713279|Experimental|FM+SOC|
32733460|NCT05713279|Placebo Comparator|FM安慰剂 +SOC|
33076177|NCT04118491|Sham Comparator|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
33256197|NCT00654186|Experimental|1|
33256198|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
33256199|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
33256200|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
32733461|NCT05714371||Immunotherapy (IO)|Patients receiving IO
32733462|NCT05714371||Targeted therapy (TT)|Patients receiving TT
33256201|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
33256202|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
33256203|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
33256204|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
33256205|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
33256206|NCT00814554|No Intervention|control|no intervention was carried out in high school
33256207|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
33256208|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
33256209|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
32733463|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.~50 subjects with pulmonary fibrosis secondary to collagen diseases."
32733464|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~75 subjects with collagen disease without pulmonary fibrosis."
33256210|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
33256211|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
33256212|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
33256213|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
33256214|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
33256215|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
33076178|NCT04118491|Active Comparator|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
33076179|NCT04683835||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
33256216|NCT00774020|Experimental|1|
33256217|NCT04100447|Experimental|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
33256218|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
33256219|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
33076180|NCT04684030|Experimental|CGMS group|Using continuous glucose monitoring system(CGMS) group
32733465|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
32733466|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
32733467|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
32733468|NCT05047783|Experimental|Masitinib 3.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
32733469|NCT05047783|Experimental|Masitinib 4.5 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
32733470|NCT05047783|Experimental|Masitinib 6.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
32733471|NCT05047783|Placebo Comparator|Placebo|Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
32733472|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
32733473|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
32733474|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
32733475|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
32733476|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
33076181|NCT04684030|Active Comparator|SMBG group|Self-monitoring of blood glucose group (conventional fingerpricking method)
33256220|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
33256221|NCT05493449|No Intervention|Control Group|In this group, no milk (intervention) was provided
33256222|NCT05493449|Experimental|UHT Milk|In this group, UHT Milk intervention was provided
33256223|NCT05493449|Experimental|Flavored Milk|In this group, flavored milk was provided to participants
33256224|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
33256225|NCT00774098|Experimental|GICP|
33256226|NCT00761891|Experimental|Chewable aspirin|81 mg daily for 2 weeks
33256227|NCT00777842|Experimental|1|Device
33256228|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
33256229|NCT00774176||2|Phase 2: COPD group
33256230|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
33256231|NCT04002076|Experimental|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
33256232|NCT04002076|Active Comparator|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
33256233|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
33256234|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
33256235|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
33256236|NCT05348200|Active Comparator|Monad 1 cream|Topical cream applied to the peri-anal area twice daily for seven days.
32733477|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
32733478|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
32733479|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
32733480|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
32733481|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
32733482|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
33256237|NCT05348200|Active Comparator|Monad 2 cream|Topical cream applied to the peri-anal area twice daily for seven days.
33256238|NCT05348200|Active Comparator|Monad 3 cream|Topical cream applied to the peri-anal area twice daily for seven days.
33256239|NCT05348200|Experimental|Combination-CITI-002 (low dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
33256240|NCT05348200|Experimental|Combination-CITI-002 (high dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
33256241|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
32733483|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
32733484|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
32733485|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
32733486|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
32733487|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
32733488|NCT04491799||Nosocomial diarrhea|Patients who are hospitalized and develop diarrhea after 72 hours of hospitalization.
32733489|NCT05713201||Index PCI|Patients with an aneurysmatic right coronary artery undergoing index PCI in the acute setting.
32733490|NCT05713201||Staged PCI|Patients with an aneurysmatic right coronary artery undergoing staged PCI in the acute setting.
32733491|NCT05002387|Experimental|Unicompartmental OA or equivocal findings in XR|After obtaining informed consent, patients will undergo needle arthroscopy, performed in the operating room prior to undergoing arthroplasty
32733492|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
33256242|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
33256243|NCT05196412|Experimental|Main study group|Normal subjects of at least 65 years of age
33256244|NCT05196412|Experimental|Endurance athlete group|Group consists of active endurance athletes of at least 50 years of age
32733493|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
32733494|NCT05272423||Cohort 1A|Patients who are currently progressing on a KRAS G12C inhibitor. Plasma for ctDNA analysis will be collected.
32733495|NCT05272423||Cohort 1B|Patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history. Plasma for ctDNA analysis will be optional.
32733496|NCT04887025|Experimental|Dose Escalation|Subjects will be treated with RGV004 as a single injection, one time.
32733497|NCT04879615|Experimental|Alteplase with standard therapy|
33256245|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
33256246|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
33256247|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
33256248|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
33256249|NCT04002778|Active Comparator|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
33256250|NCT04002778|Other|non-ROSE|Submitted to fine-needle aspiration.
33256251|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
33256252|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
33256253|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
32733498|NCT04879615|No Intervention|Standard therapy|
32733499|NCT05068947|Experimental|Study drug: GV101|50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the treatment group, cohort 1 to 4. 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the treatment group, cohort 5 to 7.
33256254|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
33256255|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
33256256|NCT00306787|Experimental|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
33256257|NCT00306787|Active Comparator|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
33256258|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
33256259|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
33256260|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
33256261|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
33256262|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
33256263|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
33256264|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
33256265|NCT01066195|Experimental|gefitinib|
33256266|NCT01066195|Active Comparator|pemetrexed|
33256267|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
33256268|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
33256269|NCT03979027|No Intervention|No Breakfast|Fasting. Ad libitum water intake permitted.
33256270|NCT03979027|Experimental|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
33256271|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
33256272|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
33256273|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
33256274|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
33256275|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
33256276|NCT05123092|Active Comparator|Group ( ultrasound guided erectae spinae block)|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block. In the group ESP, a high frequency linear US probe (HFL_50, 15_6MHz) will be placed vertically and nearly 3 cm lateral to the vertebra in the middle of the incision line. The transverse process and the overlaying erector spinae muscles (ESM) will be identified under parasagittal scanning A22 G,50 mm block needle (SONOTAP,Pajunk, Geisingen,Germany) will be inserted at a 30-40° angle in the cranial to caudal direction via an in-plane approach and advanced into the plane between the fascia of ESM and transverse process under sterile conditions. The correct needle position will be confirmed after a hydro dissection with 3 ml of isotonic saline, and then 20 ml of 0.25% bupivacaine will be injected in the interfascial plane between the rhomboideus major muscle and ESM. The local anesthetic spread will be visualized in a fascial longitudinal pattern deep to the ESM.
33256277|NCT05123092|Active Comparator|Group (Intrathecal morphine)|In the group of intrathecal morphine , a lumbar puncture will be done in the lateral position via a midline approach into the level of the vertebra which exists in the middle of the incision with complete aseptic condition using 25 gauge Quincke spinal needle to give 0.3 mg of morphine (preservative free form) suspended in 0.4 ml of normal saline .
33256278|NCT05356156|Experimental|Closure of the mesenteric defects|Closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
32733500|NCT05068947|Placebo Comparator|Placebo|Matched placebo control 50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the control group, cohort 1 to 4. Matched placebo control 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the control group, cohort 5 to 7.
32733501|NCT05713123|Experimental|Person suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq)|The study will be offered to patients suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq). When they come in nuclear medicine to have the iodine scan in Anger's camera, if they signed the consent, they will the SPECT/CT whole body in VERITON-CT camera
32769350|NCT04814381|Experimental|Ketamine + Magnesium|patients in the experimental group will receive 0.5mg/kg of ketamine over 2 hours, diluted in 50cc of NaCl 0.9% and 3g of magnesium sulfate over 30 minutes diluted in 250cc of NaCl 0.9%.
33256279|NCT05356156|Active Comparator|Non-closure of the mesenteric defects|Non-closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
33256280|NCT04001530|Experimental|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
33256281|NCT04001530|Active Comparator|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
33256282|NCT05344846|Experimental|Guided imagery Group|Guided imagery after cesarean
32733502|NCT05069103|Experimental|Intervention|"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~At least one image of their surgical wound(s).~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."
33256283|NCT05344846|No Intervention|Standard care|The participants in the control group will perform routine care of the clinic.
33256284|NCT05096494|Experimental|SP-103|One SP-103 transdermal system is worn 12 hours per day for 28 days on the lower back.
33256285|NCT05096494|Placebo Comparator|Placebo|One placebo transdermal system is worn for 12 hours per day for 28 days on the lower back
33256286|NCT05282056|Experimental|CAD analysis|The XVision COVID-19 computer aided diagnostic software is used by radiologist at CT analysis time
33256287|NCT05282056|No Intervention|No CAD analysis|No CAD analysis is shown to radiologist.
33256288|NCT05278936|Other|A simplified sclero-cornel tunnel/incision in performing the congenital/pediatric cataract surgery|Participitant
33256289|NCT00991900||Healthy subjects|
33256290|NCT00769067|Active Comparator|A|
33256291|NCT00769067|Experimental|B|
33256292|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33256293|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
32935370|NCT05445271|Active Comparator|Group 3|30 patients who will be ventilated with a laryngeal mask airway (LMA) and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). The optic nerve sheath diameter of both eyes is measured and recorded 5 minutes after LMA is placed on the patient (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
32935371|NCT04805125|Active Comparator|Moderna mRNA COVID-19 vaccine|"The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.~ARM CLOSED"
33256294|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33256295|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
33256296|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
33256298|NCT04001608|Experimental|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
33256299|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
33256300|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
33256301|NCT04103021|Experimental|Port-a-cath|Ultrasound guided Port-a-cath insertion
33256302|NCT05357326|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years
33256303|NCT05357326|Experimental|0.04% atropine|use atropine sulfate 0.04% eye drop every night before sleep for two years
33256304|NCT05357326|Experimental|orthokeratology|wear orthokeratology lens every night for two years
33256305|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
33256306|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
32935372|NCT04805125|Active Comparator|Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine|"Active:~The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.~Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later.~ARM CLOSED"
32935373|NCT04803955|Experimental|16mg,KB|Group A:16mg,Q8h±3min,Day1-Day7
32935374|NCT04803955|Placebo Comparator|Placebos|Group B:Placebos,Q8h±3min,Day1-Day7
32935375|NCT04339075||Venablock|Patients that have undergone Venablock treatment
32935376|NCT05445115|Experimental|Treatment|Actual treatment device
32935377|NCT05445115|Sham Comparator|Sham|Sham/placebo device
32935378|NCT05444959|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a two 21-days periods HMB supplementation.~HMB will be administered in the form of blinded liquid containing 1 mL HMB free acid per 30 drops. The liquid HMB will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg HMB/kgFFM/day of liquid HMB free acid in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation the supplement will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the supplements will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
33256307|NCT05055778|Experimental|SmokfreeTXT|Research version of the publicly available SmokefreeTXT program
32733503|NCT05713045||intramuscolar injection|intramuscolar injection of 1 mg vitamin K at birth
32733504|NCT05713045||intramuscolar injection following by oral low dose|intramuscolar injection of 1 mg vitamin K at birth followed by 50 μg/die orally from the second to the fourteenth week of life
32733505|NCT05713045||intramuscolar injection following by oral high dose|intramuscolar injection of 1 mg vitamin K at birth followed by 150 μg/die orally from the second to the fourteenth week of life
32733506|NCT05713045||oral administration|oral dose of 2 mg vitamin K at birth, followed by a second dose at 4 weeks, and a third dose at 12 weeks
33076182|NCT04114864|Experimental|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
33256308|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
33076183|NCT04114864|Placebo Comparator|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
33076184|NCT04104607|Experimental|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
33076185|NCT04095364|Experimental|Arm I (paclitaxel, carboplatin, letrozole)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole PO QD in the absence of disease progression or unacceptable toxicity.
33256309|NCT00569946|Experimental|AG-013736|
33256310|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
33256311|NCT00778544|Active Comparator|2|Augmentin ES-600
33256312|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
33256313|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
33256314|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
33256315|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
33256316|NCT05330494|Experimental|S1|TEAS treatment initiated at 30 minutes before induction and lasted for 30min,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
33401346|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
32733507|NCT00653835|Experimental|Ezetimibe + Simvastatin|
32733508|NCT00653835|Active Comparator|Simvastatin|
32733509|NCT05068557|Active Comparator|Intervention group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with fish oil (3 capsules daily. Containing EPA+DHA: 1.8 g). (n=40)
32733510|NCT05068557|Placebo Comparator|Control group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with chia/linseed oil (3 capsules daily. Containing ALA 1.6 g). (n=40)
32733511|NCT05712967||PATIENTS WITH MM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for MM
32733512|NCT05712967||PATIENTS WITH sMM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for SMM
32733513|NCT05712967||Controls|healthy controls
32733514|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
32733515|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
32733516|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
32733517|NCT05268289|Active Comparator|Iptacopan + standard of care (part 1)|Iptacopan + standard of care
32733518|NCT05268289|Placebo Comparator|Placebo matching iptacopan + standard of care (part 1)|Placebo matching iptacopan standard of care
32733519|NCT05268289|Active Comparator|Iptacopan + standard of care (part 2)|Iptacopan + standard of care
32733520|NCT05268289|Active Comparator|Iptacopan + placebo (part 2)|Iptacopan + placebo standard of care
32733521|NCT05268289|Active Comparator|Placebo matching iptacopan + standard of care (part 2)|Placebo matching iptacopan + standard of care
32733522|NCT05249569|Experimental|Axitinib / Avelumab /Bavituximab|Axitinib 5 mg PO BID Avelumab 10 mg/kg IV every 2 weeks (2 doses in a 4-week cycle) Bavituximab 3 mg/kg IV every 1 week (4 doses in a 4-week cycle) Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
32733523|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
32769351|NCT04814381|Active Comparator|Control|patients in the control group will receive 25mg of hydroxyzine over 2 hours, diluted in 50cc of NaCl 0.9% and 250cc of NaCl 0.9% over 30 minutes
32733524|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
32733525|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
32733526|NCT05712811|Active Comparator|Group A cryotherapy|Cryotherapy Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
32769352|NCT05041777||Prospective data collection, retrospective OCT image evaluation|From February 2017-June 2017 patients were included prospectively. OCT images were evaluated retrospectively in conjunction with clinical images. A deep learning algorithm is developed with use of this dataset including 676 OCT images.
32733527|NCT05712811|Active Comparator|Group B Topical TCA 90%|Topical TCA 90 % Warts in Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline
32733528|NCT05711797|Experimental|ZX-7101A 80mg Mild or moderate liver insufficiency|
32733529|NCT05711797|Experimental|ZX-7101A 80mg Normal liver function|
32733530|NCT05068245|No Intervention|Routine pain control|The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
32733531|NCT05068245|Experimental|Routine pain control plus music|Patients randomized to receive music in addition to routine pain control measures, will be instructed to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. Preselected classical music will be played for this group throughout the procedure.
32733532|NCT05244577|Experimental|Olanzapine|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Olanzapine 5mg Po D1-7
32769353|NCT05041777||Prospective data collection and OCT image evaluation|From January 2021-April 2021 patients were included prospectively. OCT images were evaluated prospectively in a clinical setting. The deep learning algorithm will be prospectively validated with use of this dataset including 287 OCT images.
32769354|NCT04819217|Other|Active bamboo charcoal|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
32769355|NCT04819217|Other|Probiotics|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
32769356|NCT05041465|Experimental|French Green Clay Mask|
33401347|NCT04056416|Experimental|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
32733533|NCT05244577|Placebo Comparator|Placebo|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Placebo 5mg Po D1-7
32733534|NCT03099837||Pregnant mothers|
32733535|NCT03099837||infants|
32733536|NCT03099837||children|
32733537|NCT05710237|Experimental|Risperidone 1 mg plus Psilocybin 25 mg|
32733538|NCT05710237|Experimental|Placebo plus Psilocybin 25 mg|
32733539|NCT05710237|Active Comparator|Risperidone 1 mg plus Placebo|
32733540|NCT05068323|Other|Epilepsy|Newly diagnosed epileptic patients
32733541|NCT05068323|Sham Comparator|Control|healthy subjects
32733542|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
32733543|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
32733544|NCT04215003|Active Comparator|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
32733545|NCT04215003|Experimental|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
32733546|NCT04215003|Experimental|CL1|If patients were HR+ and HER2- without PI3K-AKT pathway mutation
32733547|NCT04215003|Experimental|CL2|If patients were HR+ and HER2- with PI3K-AKT pathway mutation
32733548|NCT04215003|Experimental|CLH1|If patients were HR+ and HER2+ without PI3K-AKT pathway mutation
32733549|NCT04215003|Experimental|CLH2|If patients were HR+ and HER2+ with PI3K-AKT pathway mutation
32769357|NCT05041465|Experimental|Rhassoul Clay Mask|
32769358|NCT05041465|Experimental|Bentonite Clay Mask|
32769359|NCT04818905|Experimental|Helichrysum italicum infusion|1 g of milled plant material (Helichrysum italicun) immersed in hot water (200 mL, 100 °C) for 10 minutes.
32769360|NCT04818905|Placebo Comparator|Hot water|The control beverage contained only hot water (200 mL, 100 ˚C).
32733550|NCT04215003|Experimental|CH1|If patients were HR- and HER2+ without PI3K-AKT pathway mutation
32733551|NCT04215003|Experimental|CH2|If patients were HR- and HER2+ with PI3K-AKT pathway mutation
32733552|NCT04215003|Experimental|CT1|If patients were HR- and HER2- with LAR subtype
32733553|NCT04846387||Females with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A urinary pouch will be used to collect the participant's urine while in the scanner."
32769361|NCT05052619|Experimental|Preventive use of advanced antibiotics group|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
33401348|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
33256317|NCT05330494|Experimental|S2|TEAS treatment initiated immediately after induction and stopped at the end of surgery,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
33076186|NCT04095364|Experimental|Arm II (letrozole)|Patients receive letrozole PO QD in the absence of disease progression or unacceptable toxicity.
33256318|NCT05330494|Experimental|S3|TEAS treatment initiated immediately after extubating and lasted for 30 minutes,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
33076187|NCT00185601|Other|on-line self management intervention|
33076188|NCT00185601|No Intervention|usual care control group|
33076189|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
33076190|NCT00162656|Active Comparator|Standard LMB B|
33076191|NCT00162656|Experimental|LMB B without COPADM3|
33076192|NCT00162656|Experimental|LMB B with half cyclophosphamide|
33076193|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
33076194|NCT00162656|Active Comparator|LMB C standard|
33076195|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
32733554|NCT04846387||Males with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A condom catheter will be used to collect the participant's urine while in the scanner."
32733555|NCT05067699||Patients|recurrent pityriasis versicolor
32733556|NCT05067699||Controls|Healthy age and sex matched
32733557|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
32733558|NCT04191993|Experimental|Direct Superior Approach (DSA)|Direct superior incision during surgery
32733559|NCT04191993|Active Comparator|Posterior Approach (PA)|Posterior approach incision during surgery
32733560|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
32733561|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
32733562|NCT05067153|Experimental|Intervention|Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.
32733563|NCT05067153|Active Comparator|Control|Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.
32733564|NCT05709145|Experimental|Written recommendation|Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within 1 year.
33076196|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
33076197|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
33076198|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
33076199|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
33076200|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
33076201|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
33076202|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
33076203|NCT04083937|Active Comparator|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
33076204|NCT04083937|Experimental|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
33076205|NCT04083937|Experimental|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness [RBE]).
33076206|NCT00162890||Patient with degenerative cervical disease|
33076207|NCT04064242|Experimental|CMK389|CMK389
33076208|NCT04064242|Placebo Comparator|Placebo|Placebo
33076209|NCT04025749|Experimental|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
33076210|NCT04025749|Other|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
33256319|NCT05330494|Sham Comparator|control|the control group was given all manipulations without electrical stimulation, electrodes were placed on the same acupoints, but no current was given
33256320|NCT05265910|Active Comparator|Pataday® Once Daily Relief Extra Strength and Placebo tablet|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and Placebo tablet will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
33076211|NCT04015414|Active Comparator|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
33256321|NCT05265910|Active Comparator|Tears Naturale® II and Claritin® Tablet 24-Hour|Tears Naturale® II will be administered bilaterally and Claritin® Tablet 24-Hour (loratadine 10 mg) will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
33256322|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
33256323|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
33256324|NCT00814866|Other|Adalimumab|Open label
33401349|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
33076212|NCT04015414|Active Comparator|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
33076213|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
33076214|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
33076215|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
33076216|NCT03985267|Experimental|Mindfulness Based Swinging Technique (MBST)|Standard guided imagery combined with Mindfulness and breathing technique will be applied. Additionally, the directives will be given to participants to imagine themselves swinging in a green peaceful environment where they will face no harm but healing and full of wellness. Every time they imagine their swing goes up, patient will be asked to physically take a deep breath (taking the breath will be physically (actually) done, not imagining), and when going down patient will be asked to physically release their breath (releasing breath will be physically (actually) done, not imagining).
33076217|NCT03985267|Active Comparator|Standard Treatment|Participants will receive a session of standard psycho-social care for anxiety (50 minutes length). The standard psycho-social care interventions involve the most well-known talking therapy approach of Cognitive Behavioural Therapy (CBT).
33076218|NCT03979495|No Intervention|Standard of care|standard of care
33076219|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
33076220|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
33076221|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
32733565|NCT05709145|No Intervention|Non Written recommendation|Patients in the control group will receive a report of the colonoscopy without a written recommendation that the colonoscopy should be repeated within 1 year.
32733566|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
32733567|NCT05224921||Very low birth weight infants|Include very low birth weight infants admitted into NICU in Children's hospital of Fudan University, and prospectively observe whether they get late onset sepsis.
33076222|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
33076223|NCT00192543|Placebo Comparator|control|regular diet
33076224|NCT03970603|Active Comparator|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
33076225|NCT03970603|Active Comparator|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
32733568|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
32733569|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
32733570|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
33076226|NCT03970330|Experimental|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
32733571|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
32733572|NCT05338255||Patients who have undergone surgery at the MAZ hospital for knee/hip replacement.|
33256325|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
33256326|NCT05328076||Surgical group|Patients who undergo thyroid surgery and receive indocyanine green angiography
33256327|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
32733573|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
32733574|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
33256328|NCT04001140|Active Comparator|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
33256329|NCT04001140|No Intervention|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
33256330|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
33256331|NCT05326672|Experimental|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
33076227|NCT03970330|Placebo Comparator|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
33256332|NCT05326672|Placebo Comparator|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
33256333|NCT00295633|Experimental|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
33256334|NCT00295633|Experimental|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
33256335|NCT00295633|Placebo Comparator|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
33256336|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
32733575|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
32733576|NCT05067309||Missed abortion received letrozole then misoprostol|
32733577|NCT05067309||Missed abortion received misoprostol alone|
32733578|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
32733579|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
32733580|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
32733581|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
32733582|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
32733583|NCT04092153|Active Comparator|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
32733584|NCT04092153|Experimental|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
32733585|NCT05066841|Experimental|CM group|
32733586|NCT05066841|Placebo Comparator|placebo group|
32733587|NCT04090515|Experimental|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
32733588|NCT04090515|Placebo Comparator|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
32733589|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
32733590|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
32769362|NCT05052619|Other|Routine group|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
33076228|NCT04724408|Experimental|VieScope|intubation with the VieScope laryngoscope
33076229|NCT04724408|Active Comparator|Conventional|intubation with MacIntosh-type laryngoscope
33256337|NCT05068596|Experimental|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
33256338|NCT05068596|Other|control group|received a designed physical therapy program
33256339|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
33256340|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
33401350|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
32906241|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
33256341|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
33256342|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
33256343|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
33076230|NCT03859063|Experimental|Intervention|Regular follow up by a community based stroke coordinator
33256344|NCT05013502|Experimental|Empagliflozin 10mg PO daily for 12 weeks|Single arm trial
33256345|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
33076231|NCT03859063|Active Comparator|Control|Usual care
33076232|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
33256346|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
33256347|NCT04992052|Active Comparator|Treatment arm|This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
33256348|NCT04992052|No Intervention|Control Arm|This arm will serve as the control group. Bone wax will not be used in this group.
33256349|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
33256350|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
33256351|NCT04991038|Experimental|DAISe Thrombectomy Device|Mechanical Thrombectomy with DAISe
33256352|NCT04991038|Active Comparator|Stent Retriever|Mechanical Thrombectomy with TREVO or Solitaire Device
33076233|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
33076234|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
33076235|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
33076236|NCT04724174||Pancreaticogastrostomy (PG) group|Patients underwent pancreatoduodenectomy with the PG technique
33076237|NCT04724174||Pancreaticojejunostomy (PJ) group|Patients underwent pancreatoduodenectomy with the PJ technique
33256353|NCT00779714|Experimental|A (individualized combined chemotherapy)|
33076238|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
33256354|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
33256355|NCT00812760|Experimental|1|
33256356|NCT05253196|Experimental|Use of Foley Catheter Assistive Device|All participants will use Foley Catheter Assistive Device
33256357|NCT00814944|Experimental|Dose Group 1|
33256358|NCT00814944|Experimental|Dose Group 2|
33256359|NCT00814944|Experimental|Dose Group 3|
33256360|NCT00814944|Placebo Comparator|Dose Group 4|
33256361|NCT05308498||ESView software with ProScan|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
33256362|NCT05308498||Rapid software with SBI|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
33256363|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
33256364|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
33256365|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
33256366|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
33256367|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
33256368|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
33256369|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
33256370|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
33256371|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
33256372|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
33256373|NCT02315326|Experimental|Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).
32898295|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
33076239|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
33076240|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background graft-versus-host disease (GvHD) prophylaxis regimen.
33076241|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background GvHD prophylaxis regimen.
33076242|NCT00163046|Experimental|Gabapentin|
33076243|NCT00163046|Placebo Comparator|Placebo|
33076244|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
33256374|NCT02315326|Experimental|Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
33256375|NCT02315326|Experimental|Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
33256376|NCT02315326|Experimental|Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
33256377|NCT00774722|Experimental|Metronidazole|
33256378|NCT00774722|Placebo Comparator|Placebo|
33256379|NCT00808392|Experimental|1|
33256380|NCT00808392|Active Comparator|2|
33256381|NCT00779948||Targon FN|
33256382|NCT00779948||DHS|
33256383|NCT04045548|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
33256384|NCT04045548|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
33256385|NCT02262988|Experimental|Tourniquet used with intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and intramedullary rod.
33256386|NCT02262988|Experimental|No tourniquet with intramedullary rod|Patients will undergo a total knee replacement without a tourniquet and with an intramedullary rod.
33256387|NCT02262988|Experimental|Tourniquet without intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and without an intramedullary rod.
33256388|NCT02262988|Experimental|No tourniquet without intramedullary rod|Patients will undergo a total knee replacement without a tourniquet nor an intramedullary rod.
33256389|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
33256390|NCT00808548||Lifestyle counseling|
33256391|NCT04920136|Experimental|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|"A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.~A strip of a free gingival graft is then harvested from the patient's palate. This strip is only 2 to 3 mm wide ,1 to 1.5 mm thick and has an appropriate length to cover the full apical extension of the recipient site. The strip is sutured immediately with 6-0 monocryl sutures. Coronal to the strip, the periosteal bed is covered with ADM, which is already rehydrated in sterile saline for 10 min, trimmed and customized to fit the available space. The ADM is then stabilized on the periosteal bed with the epithelium side facing upward. The ADM is fixed on the recipient bed by periosteal 6-0 monocryl sutures."
33256392|NCT04920136|Active Comparator|Free gingival graft.|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area will be sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
33256393|NCT00780104|Experimental|Rapamycin + MEC|
33256394|NCT00815100|Placebo Comparator|Placebo|
33256395|NCT00815100|Active Comparator|Ivabradine|
33256396|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
33256397|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
33256398|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
33256399|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
33256400|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
33256401|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
33256402|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
33256403|NCT00815178|Experimental|Inspiratory muscle training|
33256404|NCT00815178|Placebo Comparator|Placebo|
33256405|NCT00774878|Experimental|Arm A|
33256406|NCT00774878|Active Comparator|Arm B|
33256407|NCT04917172||Pancreaticoduodenectomy patients|Patients scheduled to receive elective Pancreaticoduodenectomy (PD) (according to Kausch-Whipple or Longmire-Traverso) for all kinds of pancreatic disease (benign, malignant or premalignant) will be enrolled, after having signed a proper informed consent. Each patient will undergo PD once checked the presence of a resectable mass as provided by the normal clinical practice through high-quality cross-sectional imaging. Pre-operative management will follow institutional standards, serum pancreatic amylase and lipase activity will be measured as a part of the standard pre-operative evaluation.
33256408|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
33256409|NCT00774956|Experimental|1|Subject with shoulder impingement
33256410|NCT00774956|Active Comparator|2|Healthy persons
33256411|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
33256412|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
33256413|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
33076245|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
32906276|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
33076246|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
33256414|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
33256415|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
33256416|NCT00815412|Active Comparator|Counseling in use of health care|
33256417|NCT00815412|Active Comparator|Counseling in diet, exercise|
33256418|NCT00815412|Placebo Comparator|Contol group|
33256419|NCT00305773|Experimental|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33256420|NCT00305773|Experimental|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33256421|NCT00778856|Experimental|Hand Transplant|
33256422|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
33256423|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
33256424|NCT00812994|Placebo Comparator|Placebo|
33256425|NCT00812994|Experimental|Escitalopram|
33256426|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
33256427|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
33256428|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
33256429|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
33256430|NCT00778934|Experimental|1|Intimate Health Gel
33256431|NCT04047524|Other|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
33256432|NCT04047524|Other|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
33256433|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
33256434|NCT00305695|Experimental|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
33256435|NCT00305695|No Intervention|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
33256436|NCT00784472|Active Comparator|oxycodone|
33256437|NCT00784472|Active Comparator|morphine|
33256438|NCT00779012|Experimental|Remicade|
33256439|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
33256440|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
33256441|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
33256442|NCT00647556|Active Comparator|adapalene|adapalene
33076247|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
33076248|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
32733591|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
32733592|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
32733593|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
32733594|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
32733595|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
32733596|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
32733597|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
32733598|NCT03098901|Other|no other arm|
32733599|NCT03108781|Active Comparator|Lavender Oil|
32733600|NCT03108781|Placebo Comparator|sunflower oil|
32733601|NCT05419609|Experimental|Office-based limited facelift|Patients will undergo a limited facelift in the office. Patients will receive local anesthesia and optionally may receive an antianxiety medication.
32733602|NCT05419609|Active Comparator|Hospital-based full facelift|Patients will undergo a full facelift in the hospital or ambulatory surgical center. Patients will receive either general anesthesia or intravenous sedation.
33082282|NCT04620109|Active Comparator|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
33082283|NCT04620109|Active Comparator|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
33256443|NCT00647556|Active Comparator|tretinoin|Tretinoin
33256444|NCT03978559|Experimental|CAS with TMP/SMZ|
33256445|NCT03978559|Active Comparator|TMP/SMZ|
33256446|NCT03981133|Experimental|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
32733603|NCT05066763||People with Parkinson's disease|
32733604|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
32733605|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
32733606|NCT03098823|Experimental|RAYOS®|
33256447|NCT03981133|Active Comparator|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
32733607|NCT03098823|Active Comparator|IR prednisone|
32733608|NCT05703919|Experimental|Titrated Oxygen|"If the treating EMT or paramedic finds indications for inhaled bronchodilators, this will be done with compressed air 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 (end-tidal carbon dioxide) meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time oxygen can be titrated through this to a target SpO2 of 88-92%. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP (standard operating procedures).~Following scenarios regarding SpO2 can occur during treatment:~SpO2 <88%: Supplemental oxygen via the EtCO2-meter up to 10 l/min, if higher oxygen levels are needed oxygen will be used as driver for the nebulizer. If the SpO2 remains under 88% additional oxygen can be added via the EtCO2-meter.~SpO2 88-92%: No intervention.~SpO2 >92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
32733609|NCT05703919|Active Comparator|Standard Oxygen|"If the treating EMT or paramedic finds indication for inhaled bronchodilators, this will be done with oxygen 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time mask the patient for group allocation. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP.~Following scenarios regarding SpO2 can occur during treatment:~SpO2 <88%: Supplemental oxygen via the EtCO2 -meter up to 10 l/min.~SpO2 88-92%: No intervention.~SpO2 >92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
32733610|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
32733611|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
32733612|NCT04788277||Diagnostic (biospecimen collection)|Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
32733613|NCT04478487|Experimental|Study Participants|all preterm infants ≤ 32 weeks and 0 days gestational age (GA) with a birth weight 700 g to 1500 g at the hospital, who are enterally fed human milk in the neonatal intensive care unit (NICU) for at least 7 days. Various blending ratios of the fortifier with either the mother's expressed milk or donor milk will be used to deliver macro and micronutrients based on established guidelines to be adjusted according to the infant's tolerance for volume and calories. The estimated time for each subject's participation is approximately from 1 week through 8 weeks, depending on the weight and age at enrollment. Historic control cases treated by another human milk based human milk fortifier will be obtained from medical records, matched on birth weight and gender, with sample size twice (n=80) that of the study population.
32733614|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
32733615|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
32733616|NCT05689099|Experimental|Sequence A|Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2.
32733617|NCT05689099|Experimental|Sequence B|Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2.
32906277|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
33256448|NCT00813072|Experimental|1. PEP02|liposome irinotecan
33256449|NCT00813072|Active Comparator|2. irinotecan|
33256450|NCT00813072|Active Comparator|3. docetaxel|
33256451|NCT03980821|Experimental|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
33256452|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
33082284|NCT04620109|Active Comparator|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
33082285|NCT04620109|Placebo Comparator|RDE Placebo|Subjects will receive placebo (drops without drug).
33082286|NCT04620265|Experimental|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
33256453|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
33256454|NCT00813306|Experimental|A|AZD2066
33256455|NCT00813306|Placebo Comparator|B|Placebo
33256456|NCT00813306|Experimental|C|AZD2066
33256457|NCT00813306|Experimental|D|AZD2066
33256458|NCT00813306|Placebo Comparator|E|Placebo
33256459|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
33256460|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
33256461|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
33256462|NCT00808626|Experimental|99mTc-rBitistatin|
33256463|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
33256464|NCT00817518|Experimental|1|
33256465|NCT00817518|Experimental|2|
33256466|NCT00320515|Experimental|A|
33256467|NCT02551458|Experimental|Arm A: Systematic surgery|
32733618|NCT03913845|Experimental|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
32733619|NCT03913845|Active Comparator|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
32733620|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
32733621|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
32733622|NCT00705523|Active Comparator|1|
32733623|NCT00705523|Placebo Comparator|2|
32733624|NCT03903939|Experimental|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
32733625|NCT03903939|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
32733626|NCT05676931|Experimental|A1: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
32733627|NCT05676931|Experimental|A2: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
33256468|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
33082287|NCT04620265|Experimental|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
32733628|NCT05676931|Experimental|A3: Quemliclustat + Zimberelimab|Quemliclustat and Zimberelimab, both administered by IV infusion
32733629|NCT05676931|Experimental|B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Quemliclustat, and platinum doublet chemotherapy, all administered by IV infusion
32733630|NCT05676931|Experimental|B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
32733631|NCT05676931|Experimental|B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
32733632|NCT05676931|Experimental|C1: Quemliclustat + Zimberelimab + Docetaxel|Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion
32733633|NCT05676931|Experimental|C2: Domvanalimab + Zimberelimab + Docetaxel|Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion
32733634|NCT03749499|No Intervention|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
32733635|NCT03749499|Active Comparator|Educational and Empowerment Intervention|"Participants receive:~HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.~Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.~Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.~A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
32733636|NCT05065905|Experimental|Interferon|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
32733637|NCT05065905|Experimental|Interferon daily|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
32733638|NCT05065905|No Intervention|Control|"All participants receive only basic antimicrobial treatment~Interventions:~Drug: Antituberculosis complex therapy"
32906278|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
32906279|NCT00901316|Experimental|Routine Measures|
33082288|NCT04620265|Experimental|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
33082289|NCT04620265|Experimental|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
33256469|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
33256470|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
33256471|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
33256472|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
33256473|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
32733639|NCT03718221|Active Comparator|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
32733640|NCT03718221|Experimental|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
32733641|NCT03703323|Experimental|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
32733642|NCT03100305||Extremely preterm infants|
32733643|NCT03100305||Very preterm infants|
32733644|NCT03100305||Moderately preterm infants|
32733645|NCT03100305||Late preterm infants|
32733646|NCT05064969|Experimental|Single-arm non-randomised|This study includes a baseline assessment, a 9-week (with the possibility of extension to 12 weeks) blended intervention period, a post-intervention assessment, and two follow-ups at 3 and 6 months. Informal caregivers of people with dementia (with at least 18-year-old) with no restriction in terms of sex, educational level, or ethnic background will be included.
32733647|NCT05059275|Experimental|Modified operation group|Undergo the modified ostium obstruction surgery due to symptomatic TCs.
32733648|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
33256474|NCT02550834|Experimental|Experimental : Curling group|
33256475|NCT02550834|No Intervention|Control : Usual care group|
33256476|NCT03982381|Active Comparator|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
33256477|NCT03982381|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily
33256478|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
33256479|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
32733649|NCT05019027|Other|Off On Off On Sequence|This arm will follow an Off On Off On sequence. This is the only arm in the study. Subjects will begin in the Off phase (Period 1), downtitrating their beta-blocker by 50% each week until they are completely off the drug for a total of two weeks. At the end of Period 1, Subjects will have the opportunity to crossover into Period 2, where they will begin the On phase. Subjects will restart their beta-blocker by starting a low dose and then doubling this dose every week until reaching their original dose. They will then have the opportunity to continue to Period 3 (Off phase) and Period 4 (On phase).
32733650|NCT05005221|Active Comparator|Unidirectional Text Reminders|"Participants in the unidirectional text reminder arm will receive automated text messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection.~N=15"
32733651|NCT05005221|Experimental|Bidirectional Text Communication|"Participants in the bidirectional text communication arm will also receive automated messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection but they will be asked to confirm the planned day or reschedule. On the day of sample collection participants will also reply with the time the samples are collected to trigger future reminder messages for each of the 4 samples.~N=30"
32733652|NCT05010915|Experimental|dorsolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
33082290|NCT04620265|Sham Comparator|Conventional program|This group received the conventional exercise program only.
33082291|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
33082292|NCT04620226|No Intervention|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
33256480|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
33256481|NCT00817674||1|CKD subjects
33256482|NCT00817674||2|Healthy Controls
33256483|NCT04045002|Experimental|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
33256484|NCT04045002|No Intervention|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
33256485|NCT00305227|Experimental|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
33256486|NCT00305227|Placebo Comparator|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
33256487|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
33256488|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
33256489|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
33256490|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
33256491|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
33256492|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
33082293|NCT04620226|Experimental|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
33256493|NCT00817752|Experimental|1|Receives Ashwagandha herb.
33256494|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
33256495|NCT00808938|Experimental|Active Treatment|
32733653|NCT05010915|Experimental|ventrolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
32733654|NCT05010915|Placebo Comparator|sham comparator|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
32733655|NCT05010681|Experimental|Lenvatinib plus Sintilimab|
32733656|NCT05009823||Stabilization phase|"The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
32733657|NCT05009823||Transition phase|The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.
32733658|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
32733659|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
32733660|NCT05064891||Stroke patients|
32733661|NCT05064891||Participants without stroke|
32733662|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
32733663|NCT05064189|No Intervention|Group 1|15 patients will be included in group 1 (no additional treatment)
33256496|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
33256497|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
33256498|NCT03980431|Experimental|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
33256499|NCT03980431|Experimental|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
33256500|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
32733664|NCT05064189|Experimental|Group 2|15 patients will be in group 2 (treatment directly after cataract surgery in the surgical theatre)
32733665|NCT05064189|Experimental|Group 3|15 patients will receive treatment after local anaesthesia (pre-operatively) and directly after cataract surgery (group 3)
32733666|NCT05064033|Experimental|GROUP A|Pragmatic Set of intervention and posterior capsular stretch
32733667|NCT05064033|Active Comparator|GROUP B|Pragmatic Set of intervention and Sleeper Stretch
32733668|NCT05058495|Experimental|mobile programme users|Patients will receive and use Mobile Lymphedema Self-Care Support Program application and will receive standart lymphedema education.
32733669|NCT05058495|Active Comparator|control group|Patients who will receive standart lymphedema education
33256501|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
32733670|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
32733671|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
32733672|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
32733673|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
32733674|NCT05058183|Experimental|All participants|All participants
32733675|NCT05063799|Experimental|a case included pulmonary rehabilitation program|
32733676|NCT03099993|Other|A: Healthy volunteers|
32733677|NCT03099993|Other|B: Patient with heamiplegia|
32733678|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
32733679|NCT05063721|Experimental|Intra-arterial delivery of autologous MABs|Autologous mesoangioblasts (MABs) will be intra-arterially delivered to lower leg of participant
32733680|NCT05063721|No Intervention|No intervention|intra-subject control
32733681|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
32733682|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
32733683|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
32733684|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
33082294|NCT04620148|Experimental|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
33256502|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
33256503|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
33256504|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
33256505|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
32733685|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
32733686|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
33401351|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
33401352|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
32733689|NCT05058105|Experimental|FL058 500mg and Meropenem 1000mg|"FL058 500mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
32733690|NCT05058105|Experimental|FL058 1000mg and Meropenem 1000mg|"D1~FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects);~D4~Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects);~D7~ D15~FL058 1000mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
32733691|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 120min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
32733692|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 180min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
32733693|NCT05058105|Experimental|FL058 2000mg and Meropenem 2000mg|"FL058 2000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
32733694|NCT05058027|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 6g prefilled syringe after surgery
32733695|NCT05058027|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
32733696|NCT05063955||Chronic Heart Failure|Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
33256506|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
33401353|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
32733697|NCT05063955||Controls|Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
32733698|NCT05063409|Active Comparator|1:1 Ratio of FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:1 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
32733699|NCT05063409|Active Comparator|1:4 Ratio FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
32733700|NCT05046405|Experimental|home-based remotely supervised tDCS|The intervention combines home-based tDCS (1 or 2 cycles of 15 daily sessions for 3 weeks/cycle at 2 mA for 30 minutes) with tele-health for remote supervision and e-health for self-monitoring of depressive symptoms.
32733701|NCT05046483||Diabetes Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and diabetes mellitus type 1 or type 2 according to criteria of the German Diabetes Society (DDG) (HbA1c ≥ 6.5 % or orale glucose tolerance test), aged 18-80 years at inclusion into the study
32733702|NCT05046483||Normal Glucose Tolerance (NGT) Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and normal glucose tolerance (HbA1c < 5.9 % and normal oral glucose tolerance test), aged 18-80 years at inclusion into the study
33401354|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
33401355|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
32733703|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
32733704|NCT05063253|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once weekly.
32733705|NCT05063253|Experimental|TG103, 22.5 mg|TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.
32906280|NCT00901316|Experimental|Bleach Baths|
33401356|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
33401357|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
33401358|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
33401359|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
33401360|NCT04349332|Active Comparator|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
33076249|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
33076250|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
33076251|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
33076252|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
33076253|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days~+ 1 placebo capsule, once daily for 7-9 days"
33076254|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days~+ 3 placebo tablets, once daily for 7-9 days"
33076255|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
33076256|NCT00185991|Active Comparator|Once daily Gentamicin|
33076257|NCT00185991|Active Comparator|Every eight hour Gentamicin|
33076258|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
33076259|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
33076260|NCT03434158|Experimental|Olaparib|600 mg/day
33076261|NCT03429907|Experimental|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
33076262|NCT03429907|Other|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
33076263|NCT00552994|Active Comparator|1|Cypher Select plus stent
33076264|NCT00552994|Active Comparator|2|Xience V stent
33076265|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
33076266|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
33076267|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
33076268|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
33076269|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
33076270|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
33076271|NCT04684069|Active Comparator|syringe free long axis in-plane|
33076272|NCT04684069|Sham Comparator|Short axis out-of-plane|
33076273|NCT00553033||A|
33082295|NCT04620148|Placebo Comparator|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
33256507|NCT04045080|Experimental|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
33076274|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
33256508|NCT04045080|Active Comparator|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
33256509|NCT00789932|Experimental|CBT|
33256510|NCT00789932|Active Comparator|Usual Care|
33256511|NCT04047212||Smokers|
33256512|NCT04047212||non-Smokers|
33256513|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~Cetuximab 250 mg/m2 IV over 60 minutes Day -7~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~Combined with radiation therapy for six weeks.~Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
33256514|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
33256515|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
33256516|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
33256517|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
32733706|NCT05063253|Experimental|TG103, 30 mg|TG103 (30 mg) will be administered via subcutaneous injection once weekly.
32733707|NCT05063253|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly.
32733708|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
32733709|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
32733710|NCT05062941|Active Comparator|Control group|Conventional therapy (CT) was applied to all participants. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS) in conventional mode, 5 minutes of ultrasound (1.5 W/cm2, 1 MHz), 20 minutes of interference current with vacuum electrodes (80 Hz pulse frequency, 1/1 rectangular spectrum), and exercises (all exercises were applied as 1 set of 10 repetitions in each direction: Codman exercises (3-directions), wand exercises (4-directions), exercises using the shoulder wheel (2-directions), exercises with exercise band (5-directions), exercises on the finger ladder (1 set of 10 repetitions in both directions); and shoulder capsule stretching exercises performed (1 set of 12 repetitions) by asking the subjects to wait 20 seconds where the tension was felt).
32733711|NCT05062941|Active Comparator|Study group|"Same conventional therapy (CT) that was applied to control group was also applied to all participants in this group. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and the same exercises.~In addition to the CT program, only study group has received HILT (BTL 6000, BTL Industries, Inc., USA) application to the shoulder area (analgesic mode, 25 Hz,10 W, 12 j/cm2) for 2 minutes."
33256518|NCT00780650|Experimental|1|
33256519|NCT00780650|Placebo Comparator|2|
33076275|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
33076276|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
33256520|NCT00653328|Experimental|Therapeutic Intervention|
33256521|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
33256522|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
33256523|NCT00780728|Active Comparator|Sildenafil|
33256524|NCT00809172|Active Comparator|1|Ciclosporin
33256525|NCT00809172|Experimental|2|Methotrexate
33256526|NCT05032196|Experimental|WVE-003 (Dose A) or placebo|
33256527|NCT05032196|Experimental|WVE-003 (Dose B) or placebo|
33256528|NCT05032196|Experimental|WVE-003 (Dose C) or placebo|
33256529|NCT05032196|Experimental|WVE-003 (Dose D) or placebo|
33256530|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
33256531|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
33256532|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
33256533|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
33256534|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
33256535|NCT00815880|Active Comparator|Implantable Counterpulsation Therapy|The study is a single arm study with 20 patients being treated with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
32733712|NCT05057325|Experimental|Wave One Gold|Receporcating single file used for preparation of root canals in primary molars
32733713|NCT05057325|Experimental|One shape|Rotation single file used for preparation of root canals in primary molars
32733714|NCT05649943|Other|APA + ADT + RP/RT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT) plus clinician-driven choice local treatment with Radiotherapy or Radical Prostatectomy, six months after starting treatment with apalutamide
32733715|NCT05649943|Other|APA + ADT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT)
32733716|NCT05045781|Experimental|Eptinezumab 100 mg|
32733717|NCT05045781|Experimental|Eptinezumab 300 mg|
32733718|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
32733719|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
32733720|NCT05045859|Experimental|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning.
33256536|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
33076277|NCT03016819|Experimental|Indication A: ASPS AL3818 Arm - CLOSED|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33076278|NCT03016819|Experimental|Indication B: LMS AL3818 Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33256537|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
33256538|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
32733721|NCT05045859|No Intervention|No Intervention: Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 15-weeks waiting period. At the end of that period received the exact intervention as the study group.
32733722|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
33256539|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
33076279|NCT03016819|Active Comparator|Indication B: LMS Dacarbazine Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
33256540|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
32733723|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
32733724|NCT05046015|No Intervention|non diabetic|Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed
33256541|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
32733725|NCT05046015|Experimental|moderate dryness-diabetic|"Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness~10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
33076280|NCT03016819|Experimental|Indication C: SS AL3818 Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33076281|NCT03016819|Active Comparator|Indication C: SS Dacarbazine Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
33256542|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
33256543|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
33256544|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
32733726|NCT05046015|Experimental|severe dryness- diabetic|"Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® Fuss Salbe 10% Urea on both feet once daily in the evening by themselves."
32733727|NCT04652557|Experimental|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 82 days depending on the individual scheduling of each subject."
32906281|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
32733728|NCT04652557|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
32733729|NCT05062551|Experimental|intervetion group|50 patients complained of post-menstrual bleeding with confirmed presence of isthmocele. After written consent, the patient will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
32733730|NCT05185297|No Intervention|Standard care|Participants will continue with standard care provided by the family physician.
32733731|NCT05185297|Experimental|Recreational Futsal, plus standard care|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
32733732|NCT04474353|Experimental|Novo-TTF|"Day 1: Subjects will wear the Optune (TTFields device) for ≥ 18 hours/day. They will take off the device when receiving stereotactic radiosurgery and brain MRI scans.~Days 1 to 8: Subjects will take oral temozolomide 75 mg/m2/day Days 2 to 8: Subjects will receive stereotactic radiosurgery (total of 35 Gy) divided equally over 5 days~• After the interventional treatment, subjects will receive standard of care adjuvant chemotherapy and routine surveillance brain MRI scans."
32733733|NCT05639569||Patients with Descending Thoracic Aneurysm (DTA) or Type B Aortic Dissection (TBAD)|"All patients who signed informed consent and are used with Ankura™ TAA Stent Graft Systems will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:~Before discharge, 30days after the procudure, 3-6 months after the Procedure, 12 months after the procedure, 24 months after the procedure, 36 months after the procedure"
33076282|NCT03016819|Placebo Comparator|Indication D: LMS AL3818 or Placebo Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).
33076283|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
33256545|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
32733734|NCT05045469|Active Comparator|group A (dian dao san group)|Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
32733735|NCT05045469|Placebo Comparator|group B( topical medicine without therapeutic effects)|Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
32733736|NCT05636371|Experimental|Written Communication|ICU care providers will initiate the process for providing written communication to families. Study investigators will facilitate the creation and distribution of written communication
32733737|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
32733738|NCT05062395||Observational (diet, FDG PET CT)|Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.
32733739|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:~BVS Absorb implantation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
32733740|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
32733741|NCT05056935|Experimental|LB1148|active
32733742|NCT05056935|Placebo Comparator|Placebo|placebo
32733743|NCT05056701|Experimental|patient with preeclampsia|Patient meeting preeclampsia criteria according to International Society for the Study of Hypertension in Pregnancy (ISSHP) 2018 definitions
32733744|NCT05062239|Active Comparator|Continuance|Continuance prior statin therapy.
32733745|NCT05062239|Experimental|Discontinuance|Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
32733746|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733747|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733748|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32906282|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
33256546|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
33256547|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
33256548|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
33256549|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
33256550|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
33256551|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
33256552|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
33256553|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
33256554|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
33256555|NCT00790166|Active Comparator|CPAP + Conventional humidity|
33256556|NCT00790166|Active Comparator|CPAP + No added humidity|
32733749|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733750|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733751|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733752|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733753|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733754|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733755|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
32733756|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733757|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733758|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733759|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733760|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733761|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
32733762|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
32733763|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
32733764|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
32733765|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
32733766|NCT05062005|Other|Induction Chemotherapy+Chemoradiotherapy|
32733767|NCT05062005|Other|Chemoradiotherapy|
33076284|NCT00163280|Experimental|1|ATL-104 50mg
33076285|NCT00163280|Experimental|2|ATL-104 100mg
33076286|NCT00163280|Experimental|3|ATL-104 150mg
33256557|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
33256558|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
33256559|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
33076287|NCT00163280|Placebo Comparator|4|Placebo
33256560|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
33076288|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
33256561|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
33076289|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
33256562|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
33256563|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
33256564|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
33256565|NCT00815958|Active Comparator|B|Reaming with conventional reamer
33256566|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
32733768|NCT05061459||Group1:|28 control
32733769|NCT05061459||Group 2:|68 T2DM patients
32733770|NCT05044533||Cohort 1|Participants with atrial fibrillation (AF) experiencing a bleed
32733771|NCT05061615||acne vulgaris patients|
32733772|NCT05061225|Experimental|Intervention|Participants invited to the private Facebook group
32733773|NCT05061225|No Intervention|Waiting list|Waiting list. Will be invited to Facebook group after finalising the study and will receive same intervention.
32733774|NCT04755634|Experimental|Single Arm|This is a prospective, single-arm, single-center study
32733775|NCT05061147|Experimental|Max-40279-01 in combination with Azacitidine (AZA)|"This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:~Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.~Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.~All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA)."
32733776|NCT04434651|Experimental|Block group (A)|"26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using 2 % lidocaine before induction of anesthesia.~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
32733777|NCT04434651|Sham Comparator|control sham group (B)|26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using normal saline.The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
32733778|NCT05177107|Experimental|Group 1: Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
32733779|NCT05177107|Placebo Comparator|Group 2: Placebo|Placebo (normal saline) will be administered using the same schedule and techniques as for Group 1 (phage therapy).
33076290|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
33256567|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
33256568|NCT00821340|Experimental|rAAV2-hRPE65|
33256569|NCT00790322|Experimental|Active|
33256570|NCT00790322|Placebo Comparator|Placebo|
33256571|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
33256572|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
33256573|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
33256574|NCT04001296|Experimental|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
32733780|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
32733781|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
32733782|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
33076291|NCT02858869|Experimental|Arm A (pembrolizumab, SRS 6 Gy, CLOSED):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
33076292|NCT02858869|Experimental|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
33256575|NCT04001296|No Intervention|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
32733783|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
32733784|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
32733785|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
32733786|NCT05056389|Experimental|NIPEX-OXA arm|20 patients treated with NIPEC-OXA after CRS and HIPEC.
32733787|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
32733788|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
32733789|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
32733790|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
32733791|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
32733792|NCT04759612|Experimental|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
32733793|NCT04759612|Experimental|Action Observation (AO Group)|Participants will watch another person's actions during an upper extremity functionality test.
32733794|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
32733795|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
32733796|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
32733797|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
32733798|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
32733799|NCT05060757|Experimental|colonoscopy|Participants will be patients undergoing colonoscopy
32733800|NCT05405179|Experimental|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized flap during jaw reconstruction
32733801|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
32733802|NCT05395507|Active Comparator|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
32733803|NCT05395507|Experimental|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
32733804|NCT05055687|Experimental|Part A：FL058|a single ascending dose (SAD) of intravenous (IV) FL058(2500mg~3000mg)
32733805|NCT05055687|Placebo Comparator|Part A：Placebo|FL058 Placebo
32733806|NCT05055687|Experimental|Part B：FL058|a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg~2000mg)
33256576|NCT00992290|Experimental|Lactobacillus GG|
32733807|NCT05055687|Placebo Comparator|Part B：Placebo|FL058 Placebo
32733808|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
32733809|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
32733810|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
32733811|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
32733812|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
32733813|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
32733814|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
32906283|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
33256577|NCT00992290|Placebo Comparator|Placebo|
33256578|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
33256579|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
33256580|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
33256581|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
33256582|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
33256583|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
32733815|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
32733816|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
32733817|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
32733818|NCT04470843|Active Comparator|Acetazolamide|Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
32733819|NCT04470843|Placebo Comparator|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
32733820|NCT04566601|Experimental|BI 1358894 dose group 1|
32733821|NCT04566601|Placebo Comparator|Placebo|
32733822|NCT04566601|Experimental|BI 1358894 dose group 2|
32733823|NCT04566601|Experimental|BI 1358894 dose group 3|
32733824|NCT04566601|Experimental|BI 1358894 dose group 4|
32733825|NCT03097263||Patients|Patients included for rehabilitation program
32733826|NCT05055141|Experimental|Care to Share Poster|"The intervention was an 18x18 poster board with a large blank surface for patients to share information about who they are as people and what is important to them. The Care to Share poster was co-designed with ten medicine inpatients during pilot testing. The goal of the poster was to equip Caregivers with humanizing information about their patients, thereby provoking more genuine empathetic interactions. Based on input from pilot testing, the researcher wrote on the poster for the patient to ensure ease of completion and legibility. The posters were displayed on the wall behind patients' beds, so Caregivers entering the room could easily see the information when facing the patient."
32733827|NCT05055141|No Intervention|Control|Study participants hospitalized on the two control units had no Care to Share poster.
32733828|NCT05161741|Experimental|Uncontrolled diabetes requiring Insulin|
32733829|NCT05036889|Experimental|MND|Subject's physician in this group will be using the Mind.Px report as a treatment reference for prescribing the subject's biologic.
32733830|NCT05036889|No Intervention|TAU|Treatment as usual. This group will have the biologic prescribed with results given to the physician at the end of the subject's participation and will not be used as a reference for the subject's treatment.
32733831|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
32733832|NCT05044143||Women who remained undelivered after their first episode of threatened preterm labor|Women admitted to the hospital due to their first episode of threatened preterm labor (i.e onset of spontaneous labor < 34 weeks gestation), who did not deliver prematurely as labor stopped (with or without interventions such as tocolysis). Those with a cervical length < 25 mm at the time of hospital discharge are eligible to participate in the study
32733833|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
32733834|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
32733835|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
32733836|NCT05055219||Group 1: Overweight or Obese Group (visits #1-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight. Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
32906284|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
32906285|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
32906286|NCT01839734|No Intervention|Arm B|No intervention
33256584|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
33256585|NCT01141738|Experimental|Caregiver Problem-Solving Intervention (CPSI)|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, problem-solving (PS) skills).
32733837|NCT05055219||Group 2: Overweight or Obese Group (visits #3-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase). Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
32733838|NCT05055219||Group 3: Normal Weight Control Group|Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family. Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
32733839|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
32733840|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
32733841|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
32733842|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
32733843|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
32733844|NCT05035953|Experimental|Edaravone|Edaravone Dexborneol injection
32733845|NCT05035953|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
32733846|NCT05583487|Active Comparator|Control/non-experimental group|The control/nonexperimental group will consist of multidisciplinary teams, who will not be given the nurse-led protocol and will be asked to mobilize the assigned ventilated neurosurgery patient according the facility's standard mobility procedures.
32733847|NCT05583487|Experimental|Experimental/interventional group|The experimental/interventional group will consist of multidisciplinary teams who will use a given nurse-led protocol (intervention) to mobilize the assigned patient.
32733848|NCT05044299|Active Comparator|Isoped mobilization with resistance load|Use of Isoped with movement at 3 levels of resistance load: zero, low, high, each condition lasts 3 minutes at 9 minutes total work
32733849|NCT05044299|Active Comparator|Isoped mobilization without resistance load|Use of Isoped with movement at zero resistance load lasts 9 minutes of work
32733850|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
32733851|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
32733852|NCT05036031||EASL-CLIF ACLF patients|
32733853|NCT05036031||APASL ACLF patients|
32733854|NCT05036031||Non-ACLF patients|
32733855|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
32733856|NCT05043987|Experimental|Part A|"Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg).~Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period)."
32733857|NCT05043987|Experimental|Part B-Arm 1|Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
32733858|NCT05043987|Experimental|Part B-Arm 2|Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
32733859|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
32733860|NCT02471131|Experimental|WATCHMAN Implantation|
33076293|NCT02858869|Experimental|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
33076294|NCT02812420|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1 of weeks 1 and 4. Beginning 4-6 weeks after the last infusion, patients undergo cystectomy with pelvic lymph node dissection surgery.
33076295|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
33076296|NCT02789800|No Intervention|Group B|Control group (n = 163)
33076297|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
33076298|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
33076299|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
32733861|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
32733862|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
32733863|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
32733864|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
32733865|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
32733866|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
32733867|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
32733868|NCT04374877|Experimental|Part A Monotherapy Dose Escalation|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors.
33256586|NCT01141738|Active Comparator|Wait List Control (WLC)|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to caregivers (CGs) of stroke survivors.
33256587|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
32733869|NCT04374877|Experimental|Part B Indication-specific SRF388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC, up to 40 patients with HCC, and up to 40 patients with NSCLC.
32733870|NCT04374877|Experimental|Part C SRF388 in Combination with Pembrolizumab|Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in combination with pembrolizumab in patients with advanced RCC or HCC, or anti-PD(L)1 relapsed/refractory advanced NSCLC.
32733871|NCT04347811|Experimental|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
32733872|NCT04347811|No Intervention|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
32733873|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
32733874|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
32733875|NCT02473081|Other|Usual care|Participants in this group received usual care only.
32733876|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
32733877|NCT03549871|Experimental|Fitusiran|Cohort A [inhibitor]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B [non-inhibitor]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate [ABR] >=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.
32733878|NCT03108703|Experimental|SBRT|RCC patients
32733879|NCT03403621|Experimental|Topical agent A|Topical Pentamidine Isethionate will be randomized to be applied to either the proximal or distal end of the incision. The patient is his/her own control.
32733880|NCT03403621|Placebo Comparator|Topical agent B|Silicone Gels base will be randomized to be applied either to the proximal or distal end of the incision. The patient is his/her own control
32733881|NCT04238455|Sham Comparator|Control Group|Sham serratus anterior plane block plus usual car
32733882|NCT04238455|Active Comparator|Treatment Group|Serratus anterior plane block plus usual care
32733883|NCT04231513|Experimental|SAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
32733884|NCT04231513|Experimental|SAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
32733885|NCT04231513|Experimental|SAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
32733886|NCT04231513|Experimental|SAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
32733887|NCT04231513|Experimental|SAD, Cohort 5: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
32733888|NCT04231513|Experimental|MAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
32733889|NCT04231513|Experimental|MAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
32733890|NCT04231513|Experimental|MAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
32733891|NCT04231513|Experimental|MAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
32733892|NCT04220125|Experimental|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
33076300|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
33076301|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
33256588|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
32733893|NCT04220125|Active Comparator|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
32733894|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
32733895|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
32733896|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
32733897|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
32733898|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
32733899|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
32733900|NCT02472769|Placebo Comparator|Placebo|Sterile water
32733901|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules.
32733902|NCT03247309|Experimental|IMA201 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA201 product will be infused intravenously. Up to four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
32733903|NCT04089943|Experimental|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
32733904|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited as control group
33256589|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
32733905|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
33256590|NCT04001218|Experimental|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
33256591|NCT04001218|Experimental|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
32906287|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
32906288|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
33076302|NCT04683952|Experimental|Rehabilitation with HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
33256592|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
33256593|NCT00992524|Active Comparator|Vaginal Misoprostol|
33256594|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
33256595|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
33256596|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
33256597|NCT00998842||healthy subjects|five male, five female, ages 18-64
33256598|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
33256599|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
33256600|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
32733910|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
32733911|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
32733912|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
32733913|NCT03311035|Experimental|Group B|patients undergoing Seton method
32733914|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
32733915|NCT03065335|Experimental|Phase I|Medication taper, drug-free period, and baseline assessments
32733916|NCT03065335|Experimental|Phase II, Arm 1|Double-blind, single dose of 0.5 mg/kg IV ketamine
32733917|NCT03065335|Experimental|Phase II, Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG or MEG
32733918|NCT03065335|Placebo Comparator|Phase II, Arm 2|Double-blind, single dose of 0.5 mg/kg IV saline
32733919|NCT03065335|Placebo Comparator|Phase II, Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
32733920|NCT03065335|Experimental|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
32733921|NCT03065335|No Intervention|Phase IV|Follow-up evaluations
32733922|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
32733923|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
32733924|NCT00705367|Placebo Comparator|Placebo|
32733925|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
32733926|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
32733927|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
32733928|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
32733929|NCT04020055|Experimental|Cohort 1: Severe Renal Impairment|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
32733930|NCT04020055|Experimental|Cohort 2: End-Stage Renal Disease|All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.
32733931|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
32733932|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
32733933|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
32733934|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
32733935|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
32733936|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
32733937|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
32733938|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
32733939|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
32733940|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
32733941|NCT05306431|Experimental|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant. It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity. PHMB 0.2% has been recently used as a root canal irrigant in vitro and has shown promising results of antimicrobial effectiveness of > 99.9% for both PHMB and Sodium hypochlorite
32733942|NCT05306431|Experimental|Sodium Hypochloride|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter.
32733943|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
32733944|NCT03905707|Experimental|Glepaglutide SC injections twice weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.~In this long term safety study, there is no placebo arm."
32733945|NCT03905707|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.~In this long term safety study, there is no placebo arm."
32733946|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
32733947|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
32906289|NCT00907088|Active Comparator|1|
32906290|NCT00907088|Experimental|2|
33082296|NCT04619641|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
33256601|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
33256602|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
32733948|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
32733949|NCT03310567|Experimental|Epacadostat + pembrolizumab|
32733950|NCT03900949|Experimental|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS < 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS >= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
32733951|NCT02864251|Experimental|Nivolumab+Platinum doublet chemotherapy|
32733952|NCT02864251|Experimental|Nivolumab + Ipilimumab|Enrollment is closed for this arm
32733953|NCT02864251|Active Comparator|Platinum doublet chemotherapy|
32733954|NCT02757859|Active Comparator|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-S lavage 10 times over 15 minutes.
32733955|NCT02757859|Active Comparator|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-D lavage 10 times over 15 minutes.
32733956|NCT02757859|Sham Comparator|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
32733957|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
32733958|NCT03310489|Active Comparator|Psychoeducation about anxiety|
32733959|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
32733960|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
32733961|NCT02470195|Experimental|workshop|workshop of procedural simulation
32733962|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
32733963|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
33256603|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
32733964|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
32733965|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
32733966|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
32733967|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
32733968|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
32733969|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
32733970|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
33256604|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
32733971|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
32733972|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
32733973|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
32733974|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
32733975|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
32733976|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
33256605|NCT00642018|Active Comparator|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
32733977|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
32733978|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
32733979|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
33256606|NCT00642018|Experimental|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
33256607|NCT00532948|Experimental|1|
33256608|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
33256609|NCT00998920|Experimental|20 mg BID|
33256610|NCT00998920|Experimental|40mg BID|
33256611|NCT00998920|Experimental|80 mg BID|
33256612|NCT00998920|Experimental|160 mg BID|
32733980|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
32733981|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
33076303|NCT04683952|Active Comparator|Control Group rehabilitation without HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
33256613|NCT00998920|Placebo Comparator|Placebo|
32733982|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
32733983|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
32733984|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
32733985|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
32733986|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
33256614|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
33256615|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
33256616|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
33256617|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
33256618|NCT00999076||Sputum with positive AFB smear|
33256619|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
33256620|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33256621|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
33256622|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
33256623|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
33256624|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
33256625|NCT00999232|Experimental|Erythromycin|
33256626|NCT00999232|Placebo Comparator|Placebo|
33256627|NCT00999310||Klinefelter syndrome|
33256628|NCT00999310||Control men|
33256629|NCT00999310||Control women|
33256630|NCT00999310||parents of Klinefelter groupe|
33256631|NCT00993070|Experimental|Capsaicin|
33256632|NCT00993070|Placebo Comparator|placebo|
33256633|NCT00993304|Experimental|A|
33256634|NCT00993304|Placebo Comparator|B|
33256635|NCT05189002|Experimental|Group 1a|Patients from groups 1a took the study product once a day in doses 40 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
33256636|NCT05189002|Experimental|Group 1b|Patients from groups 1b took the study product once a day in doses 60 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
33256637|NCT05189002|Active Comparator|Group 2|Patients from the control group (group 2) were received Fragmin in accordance with the instruction for medical use (5000 IU s/c once a day with 24-hour interval) and six Placebo tablets masked as study product Dimolegin - DD217 once a day.
33256638|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
33256639|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
33256640|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
33256641|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
33256642|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
33256643|NCT00993538|Experimental|1|
33256644|NCT00821418|Experimental|PulsHaler first|
33256645|NCT00821418|Placebo Comparator|Placebo first|
32733987|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
32733988|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
33256646|NCT04000828|Other|single Arm|all patients receive the measurement with Sensimed Triggerfish
33256647|NCT00640926|Experimental|1|Radezolid 300 mg
33256648|NCT00640926|Experimental|2|Radezolid 450 mg
33256649|NCT00640926|Experimental|3|Radezolid 450 mg BID
32733989|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
32733990|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
32733991|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
32733992|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
32733993|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
33256650|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
33256651|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
33076304|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
33256652|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
33256653|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
33256654|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
32733994|NCT03744793|Experimental|Treatment (pemetrexed, avelumab)|Patients receive pemetrexed IV over 10 minutes on day 1. Starting cycle 2, patients also receive avelumab IV over 60 minutes. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33076305|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical~See intervention descriptions."
33256655|NCT00821496|Experimental|Oral Contraceptive|
33256656|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
33256657|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
33256658|NCT03891862|Experimental|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
33256659|NCT03891862|Placebo Comparator|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
33256660|NCT03891862|Experimental|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
33256661|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
33256662|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
32733995|NCT03713593|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
33076306|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical~See intervention descriptions."
33076307|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)~-Haplo-Identical Only~See intervention descriptions."
32733996|NCT03713593|Active Comparator|lenvatinib plus placebo|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
32733997|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
32733998|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
32733999|NCT01720147|Experimental|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
32734000|NCT02469883|Experimental|Sinotecean|
32734001|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
32734002|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
32734003|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
32734004|NCT02469727|No Intervention|Usual care control|No intervention provided.
32734005|NCT05190055|Experimental|Minimally invasive spinal fusion surgery|A filler tube with an integrated threaded rod, which can be connected to a surgical drill, was used for rapid and continuous graft filling.
32734006|NCT05190055|Active Comparator|traditional spinal fusion surgery|Bone substitutes were filled in the disc space manually using a bone grafting funnel.
32734007|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
33076308|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
32734008|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
32734009|NCT00806065|Experimental|ENMD-2076|Oral capsules, once daily in 28-day cycles
32734010|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
32743111|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
33076309|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
33076310|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
33076311|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
33076312|NCT02125786|Experimental|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
33076313|NCT02125786|Experimental|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
33076314|NCT02125786|Experimental|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
33256663|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
33256664|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
33256665|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
33256666|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
33256667|NCT00818298|Experimental|1|ziprasidone
33256668|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
33256669|NCT00821574|Experimental|2|Valsartan
33256670|NCT00821574|Experimental|3|Hydrochlorothiazide
33256671|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
33256672|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
33256673|NCT00993850|Other|Bipolar disorder education|Psychoeducation
33256674|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
33256675|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
33256676|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
33256677|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
33256678|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
33256679|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
33256680|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
33256681|NCT00761657|Experimental|Roxadustat 0.7 mg/kg BIW|Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
33256682|NCT00761657|Experimental|Roxadustat 0.7 mg/kg TIW|Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
33256683|NCT00761657|Experimental|Roxadustat 1.0 mg/kg BIW|Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
32734011|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
32734012|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
32734013|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
32734014|NCT05285605||Emergency Contraceptive Group|Group of participants receiving emergency contraception in the form of 3 packages of ulipristal acetate to use at home if needed.
32734015|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
32734016|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
32734017|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
32734018|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
32734019|NCT03304483|Experimental|Athletes|246-km running
32734020|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
32734021|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
32734022|NCT05232409|Experimental|Zeaxanthin Monotherapy|Zeaxanthin administered orally on daily basis.
32734023|NCT05232409|Experimental|Zeaxanthin plus Pembrolizumab|Zeaxanthin administered orally on daily basis in addition to intravenous pembrolizumab infused every 42 days at fixed dose of 400 mg.
32734024|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
32734025|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
32734026|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
33256684|NCT00761657|Experimental|Roxadustat 1.0 mg/kg TIW|Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
33256685|NCT00761657|Experimental|Roxadustat 1.5 mg/kg BIW|Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
33256686|NCT00761657|Experimental|Roxadustat 1.5 mg/kg TIW|Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
33256687|NCT00761657|Experimental|Roxadustat 2.0 mg/kg BIW|Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
33256688|NCT00761657|Experimental|Roxadustat 2.0 mg/kg TIW|Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
33076315|NCT02125786|Experimental|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is >36 months at time of enrollment to <21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
33256689|NCT00761657|Placebo Comparator|Placebo|Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
32734027|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
32734028|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
33256690|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
32734029|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
32734030|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
32734031|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
32734032|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
32734033|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
33256691|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
33256692|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
32734034|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
32734035|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
32734036|NCT03309085|Experimental|Single arm|Repeated CT scan
32734037|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
32734038|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
33256693|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
33256694|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
33256695|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
33256696|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
33256697|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
32734039|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
32734040|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
32734041|NCT03304015|No Intervention|Control: No intervention|
33256698|NCT00818532||1|Measurement device
32734042|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
32734043|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
32734044|NCT03313765|Experimental|Intervention|
33076316|NCT02086864|No Intervention|Usual care|
33256699|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
33256700|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
33256701|NCT00818610|Experimental|Monotherapy|
33256702|NCT00818610|Active Comparator|Bi-therapy|
33076317|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
33076318|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
33256703|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
32734045|NCT03313765|Active Comparator|Standard-of-care|
33256704|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
33256705|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
33256706|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
33256707|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
33256708|NCT01000090||Acromegaly patients, somatostain analogues|
33256709|NCT01000090||Acromegaly patients, surgery|
33256710|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
33256711|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
33256712|NCT04100525|Active Comparator|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
33256713|NCT04100525|Experimental|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
33256714|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
33256715|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
32734046|NCT04442035|Experimental|The teatment group|5-element misic therapy
32734047|NCT04442035|Experimental|The control group|health education
32734048|NCT04441723|Active Comparator|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
32734049|NCT04441723|Active Comparator|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
32734050|NCT04441801|Experimental|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
32734051|NCT04441801|Experimental|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
32734052|NCT04441801|Experimental|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
32734053|NCT04441801|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end.
32734054|NCT03313531||Study group 1|Patients with severe hemophilia A
32734055|NCT03313531||Study group 2|Healthy volunteers
33256716|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
33256717|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
32734056|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
32734057|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
32734058|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
32734059|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
32734060|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
32734061|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
32734062|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
33076319|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
33076320|NCT02086630|No Intervention|Control|Treatment as usual
33076321|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
33256718|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
33256719|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
32734063|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
32734064|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
32734065|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
32734066|NCT05067907||Control|COVID-19 ICU-admitted patients that did not received physiotherapy interventions during ICU stay.
33256720|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
33256721|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
32734067|NCT05067907||Physiotherapy|COVID-19 ICU-admitted patients that received physiotherapy interventions during ICU stay.
32734068|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
32734069|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
32734070|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
32734071|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
32734072|NCT05289973|Experimental|TruNatomy Files|Newly introduced endodontic file
33076322|NCT01628029|Experimental|Arm I (methylphenidate, melatonin, light therapy, CBT)|Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
33076323|NCT01628029|Experimental|Arm II (placebo, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
33076324|NCT01628029|Experimental|Arm III (methylphenidate, melatonin, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
33076325|NCT01628029|Experimental|Arm IV (methylphenidate, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
33256722|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
33256723|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
32734073|NCT05289973|Experimental|Hyflex EDM|Endodontic file
32734074|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
32734075|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
32734076|NCT03308227||Experimental Group|septic shock patients;
32734077|NCT03308227||Conrol Group|non-septic shock patients;
32734078|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
32734079|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
32734080|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
32734081|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
32734082|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
32734083|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
32734084|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
33076326|NCT01628029|Experimental|Arm V (placebo, melatonin, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
33076327|NCT01628029|Experimental|Arm VI (placebo, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
33076328|NCT01628029|Experimental|Arm VII (methylphenidate, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
33076329|NCT01628029|Experimental|Arm VIII (placebo, melatonin, sham light intervention, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
33076330|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
33076331|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
33076332|NCT01269190|Experimental|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
32734085|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
32734086|NCT03303313|Experimental|Cemdisiran|
33076333|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
33076334|NCT00717652|Active Comparator|2|Triluma
33076335|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
33076336|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
33076337|NCT00165256|Experimental|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
33076338|NCT05454826|Experimental|Cold application group|applied relaxation exercise+ cold pack
33076339|NCT05454826|Experimental|control group|applied relaxation exercise
33076340|NCT00163553|Experimental|P|Epidural pethidine group
33076341|NCT00163553|Placebo Comparator|N|placebo group
33076342|NCT05420818|Experimental|Active Group|Patients who underwent transversalis fascia inversion during TEP
33076343|NCT05420818|No Intervention|Control Group|Patients who did not undergo transversalis fascia inversion during TEP
33076344|NCT05415475|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
33076345|NCT05415475|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
33076346|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
33076347|NCT05402449|Placebo Comparator|Placebo group|Subjects received two placebo sachets per day
33076348|NCT05402449|Experimental|Probiotic group|Subjects received two probiotic sachets per day
33076349|NCT05399680|Experimental|Interventional|Treatment with SMART RADIANZ, BRITE TIP RADIANZ and SABERX RADIANZ devices
33076350|NCT05396287||Controls|Healthy controls
33076351|NCT05396287||Vertebral Artery Hypoplasia|Healthy individuals with vertebral artery hypoplasia
33076352|NCT04683445||HR+/HER2- advanced breast cancer|Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer
33076353|NCT04683445||HER2+ advanced breast cancer|Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer
33076354|NCT04683445||triple negative advanced breast cancer|Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer
33076355|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
33076356|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
33076357|NCT05385016|Experimental|Education Arm|Participants will attend weekly two hour small group instruction sessions. All sessions will have an education component, a hands-on nutrition/cooking lesson, and a group exercise session. Two health educators will be present during group sessions with one leading
33076358|NCT00163670||Motor vehicle accident|
33076359|NCT00163670||Control|
33076360|NCT05381194|Experimental|single arm (investigational arm)|BPaL
33076361|NCT05380414|Experimental|Metastatic/advanced PDAC Patients|Tumor samples
33076362|NCT05380102||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device). Data from all devices will be measured simultaneously."
33076363|NCT05377879|Experimental|OPTIVF predicted drug dosage|In our study, we will be using the patient's age and day three serum day AMH and FSH levels to decide the starting dose for the patient's cycle. We will use the first two days of data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool OPTIVF for this intervention in the clinical trial.
33076364|NCT05377879|No Intervention|Traditional drug treatment|Patients where drug dosage is decided by the physician based on ultrasound and estrogen levels for each day of the cycle.
33076365|NCT05356975|Experimental|Superset|This group will perform three strength circuit training. Each circuit training consists of three exercises (lower, middle, and upper body exercises) performed in a supersets fashion. This order makes it less complex, which is important given the characteristics of the population.
33076366|NCT05356975|Active Comparator|Concurrent|This group will perform six resistance exercises in a traditional fashion (three exercises for the lower body, three exercises for the upper body) and three aerobic exercises (floor tap squat, jumping jacks, and skaters).
33076367|NCT05351476|Experimental|Resistance Exercise|Participants do regular resistance exercise for 12 weeks.
32734087|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
33256724|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
33256725|NCT03978013|Experimental|Pomegranate|
33256726|NCT03978013|Active Comparator|Apple|
33076368|NCT05351476|Experimental|Endurance Exercise|Participants do regular endurance exercise for 12 weeks.
33076369|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
33256727|NCT00996112||Historical|
33256728|NCT00996112||Prospective|
32734088|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
32734089|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
32734090|NCT04442113|Active Comparator|Control group|Pulmonary vein isolation alone (by catheter ablation)
32734091|NCT04442113|Experimental|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
32734092|NCT05127499|Experimental|Experimental:|will do progressive relaxation exercises
32734093|NCT05127499|No Intervention|No Intervention|won't do progressive relaxation exercises
32734094|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
32734095|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
32734096|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
32734097|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
32734098|NCT03302923|No Intervention|Control group|No brisk walking session
32734099|NCT04490629|Other|DURAFORM|DURAFORM was used in repairing cerebral dura mater.
32734100|NCT04490629|Experimental|Lyoplant Onlay|Lyoplant Onlay was used in repairing cerebral dura mater.
32734101|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
32734102|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
32734103|NCT03089983|Experimental|Buprenorphine/Naloxone|Participants who choose buprenorphine/naloxone will receive an induction phase for 10 days and then move on to receiving it in the community for 6 months. Buprenorphine/naloxone has been authorized and is available for use in Malaysia.
32734104|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
32734105|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
32734106|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
32734107|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
32734108|NCT03313141|Experimental|Subjects|Only one arm is considered
32734109|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
32734110|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
32734111|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
32734112|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
32734113|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
32734114|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
32734115|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
32734116|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
32734117|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
32734118|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
32734119|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
33076370|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
33076371|NCT05345743||Positive AIR-test|Patients with a positive intraoperative AIR-test result
33076372|NCT05345743||Negative AIR-test|Patients with a negative intraoperative AIR-test result
33076373|NCT00553111|Experimental|1|pre survey, intervention, post test survey
33076374|NCT00553111|No Intervention|2|pre test survey and post test survey
33256729|NCT04000984|Experimental|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
33256730|NCT04000984|Active Comparator|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
33256731|NCT04000984|No Intervention|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
33256732|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
33076375|NCT00553111|Experimental|3|video intervention and post test survey
33256733|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
33256734|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
33256735|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
32935379|NCT05444959|Placebo Comparator|Placebo treatment|"The experimental procedure for each participant in this group includes a two 21-days periods Placebo supplementation.~PLA (liquid placebo similar in appearance, taste and smell to HMB, but containing no HMB) will be placed in the blinded liquid form. PLA will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg PLA/kgFFM/day of liquid PLA in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation, the PLA will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the PLA will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
33256736|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
33256737|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
33256738|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
33256739|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
33256740|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
33256741|NCT00816504|Experimental|1|Galactose
32935382|NCT04685473|Experimental|T-1101 (Tosylate)|
33076376|NCT00553111|No Intervention|4|post test survey
33256742|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
33256743|NCT05177536|Experimental|Iberdomide|Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle
33256744|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
33256745|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
33256746|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
33256747|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
32935383|NCT00368017|Active Comparator|1|
32935384|NCT00368017|Placebo Comparator|2|
32935385|NCT04672447|Experimental|L-Citrulline + Glutathione|Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks
32935386|NCT04672447|Experimental|L-Citrulline|Citrulline: 6 grams/day
32935387|NCT04672447|Placebo Comparator|Placebo|Maltodextrin: 6 grams/day
32935388|NCT05444647||HER2-positive|patients with newly diagnosed early stage HER2-positive breast cancer with an indication for standard trastuzumab-containing neoadjuvant treatment.
32935389|NCT04739137||Study group|100 patients with diagnosed macular edema will be enrolled
32935390|NCT05444491||MRD positive group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If gene methylation levels in the samples exceeded the threshold, the patients were enrolled in the MRD positive group. The 2-year total tumor recurrence rate of patients in the MRD positive group was calculated, and the positive prediction rate of postoperative plasma ctDNA methylation-MRD detection results for 2-year tumor recurrence rate after colorectal cancer radical resection was calculated.
32734120|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
33076377|NCT05335720|Active Comparator|Cohort 1|"EASYEF® + moist gauze EASYEF® is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
33256748|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
33256749|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
33256750|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
33256751|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
33256752|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
33256753|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
33256754|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
33256755|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
33256756|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
33256757|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
33256758|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
33256759|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
32734121|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
32734122|NCT03307681|Experimental|Meal skipping|No food given
32734123|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
32734124|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
32734125|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
32734126|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
32734127|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
32734128|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
32734129|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
33256760|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
33256761|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
33256762|NCT01001260||No Aspirin Treatment|
33256763|NCT01001260||81 mg Aspirin Treatment|
33256764|NCT01001260||325 mg Aspirin|
33256765|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
33256766|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
33256767|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
33256768|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
33256769|NCT05220280|No Intervention|Local standard of care|
33256770|NCT05220280|Experimental|Imatinib + local standard of care|
33256771|NCT05220280|Experimental|Infliximab + local standard of care|
32734130|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
32734131|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
33076378|NCT05335720|Active Comparator|Cohort 2|"EASYEF® + tulle gauze + moist gauze EASYEF® is applied directly on the wound surface then tulle gauze and moist gauze is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
33256772|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase 20,000 U|Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
33256773|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase 60,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
33256774|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase 200,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
33256775|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase 400,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
33256776|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase 800,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
33256777|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
33256778|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
33076379|NCT05324137|Experimental|CM326 55mg|55mg for 6 doses, every 2 weeks, subcutaneous (SC)
33076380|NCT05324137|Experimental|CM326 110mg|110 mg for 6 doses, every 2 weeks, subcutaneous (SC)
33256779|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
33256780|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
33256781|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
33256782|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
33256783|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
33256784|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
33256785|NCT00318565|Experimental|Navistar ThermoCool Catheter|
33076381|NCT05324137|Experimental|CM326 220mg|220mg for 6 doses, every 2 weeks, subcutaneous (SC)
33076382|NCT05324137|Placebo Comparator|Placebo|Placebo for 6 doses, every 2 weeks, subcutaneous (SC)
33256786|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
33256787|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
33256788|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
33256789|NCT03983083|Experimental|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
33256790|NCT03983083|No Intervention|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
33256791|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
33256792|NCT01325389|Placebo Comparator|Placebo|
33256793|NCT00994630||BP I patients manic phase|
33256794|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
33256795|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
33256796|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
33256797|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
33076383|NCT05302492|Experimental|Sleep apnea group with CPAP|"Intervention group: CPAP for 3 months in elderly diagnosis with sleep apnea and AHI > 15/h.~Control group: sleep apnea and patient refuse treatment or poor compliance."
33076384|NCT05302492|Experimental|sleep disturbance without sleep apnea nor PLMS|Intervention group: light box on elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS control group: elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS refuse light box or poor compliance
33076385|NCT05298241|Experimental|Hand-grip Strength Game|Participants will receive a hand-grip strength game for 5-20 minutes twice a day for consecutive three days.
33076386|NCT05298241|No Intervention|routine care|The control group will not involve hand-grip strength game at night.
33256798|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
33256799|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
33256800|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
33256801|NCT00304915|Experimental|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
33256802|NCT00304915|No Intervention|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
33256803|NCT05217004|Experimental|Dementia Talk|Participants in this group will be asked to use the mobile app Dementia Talk over a 2-week period.
32734132|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
32734133|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
32734134|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
32734135|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
32734136|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
32734137|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
32734138|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
32734139|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
32734140|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
32734141|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
32734142|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
32734143|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
32734144|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
32734145|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
32734146|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
33076387|NCT05295199|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise
32734147|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
32734148|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
32734149|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
32734150|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
33076388|NCT05295199|No Intervention|Control|Routine maintenance
33076389|NCT00163826||Trauma Patients|Major trauma patients
33076390|NCT03455452||Cohort 1: Nivolumab|Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
33256804|NCT05217004|Experimental|CLEAR Dementia Care|Participants in this group will be asked to use the mobile app CLEAR Dementia Care over a 2-week period.
33256805|NCT05217004|No Intervention|Waitlist Control Group|Participants in this group will not use any of the apps.
33256806|NCT05206786|Experimental|Control group. Conventional preventive work out|
33256807|NCT05206786|Experimental|Intervention group. Gluteus maximus strengthening specific program|
33256808|NCT03980197|Experimental|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
33256809|NCT03980197|Active Comparator|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
33256810|NCT00997048|Experimental|Laying open|
33256811|NCT00997048|Active Comparator|Sinus excision|
33256812|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33076391|NCT03455452||Cohort 2: Nivolumab + Ipilimumab|Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
33076392|NCT05283343||Adults 20 years old or older|
33256813|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256814|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256815|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256816|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
32734151|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
33076393|NCT05277961|Experimental|UVR Dose 1x3SED|UVR Dose 1x3 standard erytheme dose (SED)
33076394|NCT05277961|Experimental|UVR dose 3x1SED|UVR dose 3x1 standard erythema dose (SED)
33076395|NCT00193011|Experimental|1|Docetaxel
33076396|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
32734152|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
32734153|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
33076397|NCT05276791|Active Comparator|Endoscopic submucosal dissection|
33076398|NCT05276791|Active Comparator|Endoscopic mucosal resection|
33076399|NCT00163865||Clinical Group|clinical adolescent group
33076400|NCT00163865||Community Group|community adolescent group
33076401|NCT05272228|Active Comparator|Coenzyme Q10 (ubiquinone)|Synonyms: Co-Q10; Ubiquinone; Ubidecarenone; 2,5-Cyclohexadiene-1,4-dione, 2- [(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-,6,10,14,18,22,26,30,34,38- tetracontadecaenyl]-5,6-dimethoxy-3-methyl CAS number: 303-98-0 Molecular formula: C59H90O4 USP standard Content: Co-Q10 (ubiquinone), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), anti-adherents (magnesium stearate and anhydrous silica) Dosage: 2 capsules, total 100 mg Co-Q10
33076402|NCT05272228|Experimental|Q10 MICROENCAPSULATED|IP1:Q10 MICROENCAPSULATED. ENG: Ingredient BMT® Coenzyme Q10 Content Co-Q10 (ubiquinone), stabiliser (gum arabic), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsules, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
32734154|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
32734155|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
32734156|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
32734157|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
32734158|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
32734159|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
32734160|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
32734161|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
32734162|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
32734163|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
32734164|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
32734165|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
32734166|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
32734167|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
32734168|NCT03301987|Experimental|Therapeutic exercise|
32734169|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
33076403|NCT05272228|Experimental|Final formulated product BQSM®|IP2: Final formulated product BQSM® Ingredients: Rosehip (Rosa canina) fruit extract standardised to min. 70 % of vitamin C (L-ascorbic acid), capsule (HPCM- hydroxypropyl methyl cellulose), BMT® Coenzyme Q10 (ubiquinone), vitamin E (D-alfa tocopheryl acetate), vitamin A (retinyl acetate), L-selenomethionine, bulking agent (maltodextrin), stabiliser (gum arabic), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsule, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
33076404|NCT05269498|Experimental|CORTEXPLORER MED|Mixed-reality assisted planning of aneurysm clipping with the optical navigation system CORTEXPLORER MED.
33076405|NCT05260216|Experimental|Experimental subgroup of Cariostat|Use Cariostat as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
33076406|NCT05260216|Experimental|Experimental subgroup of Cariogram|Use Cariogram as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
33256817|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256818|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256819|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
33256820|NCT01002196|Experimental|stimulus fading procedures|
33256821|NCT01002196|Active Comparator|guidance of defocused communication|
33256822|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
33256823|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
33256824|NCT03978247|Experimental|NASHMIR group|Validation of the NASHMIR Test
33256825|NCT05200390|Experimental|Continuous Glucose Monitor|Adult patients with Type 2 Diabetes on any anti-diabetic regimen utilizing continuous glucose monitors for 3 months
33076407|NCT05260216|Placebo Comparator|Control group|Use Cariogram and as the caries risk assessment tool to divide the children into different risk levels. All children will receive routine prevention including wice fluoride foam each year and oral hygiene guidance.
33076408|NCT05256082|Active Comparator|with mask (FFP2 mask or surgical mask)|Patient is Walking with mouth/nose-mask for 6 Minutes.
33076409|NCT05256082|Placebo Comparator|without mask|Patient is Walking without mouth/nose-mask for 6 Minutes.
33076410|NCT05215600||Anaverse Shoulder System subjects|Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed.
33256826|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
33256827|NCT00994786|Experimental|pregabalin|
33256828|NCT00994786|Placebo Comparator|Placebo|
33256829|NCT01002430|Experimental|Gene therapy|
33256830|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
33256831|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
32734170|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
32734171|NCT03306667|Experimental|Normal group|Healthy control subjects
32734172|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
32734173|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
32734174|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
32734175|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
32734176|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
32734177|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
32734178|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
32734179|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
32734180|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
32734181|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
32734182|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
33256832|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
33256833|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
33256834|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
33256835|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
33256836|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
33256837|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
33256838|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
33256839|NCT00997360|Experimental|1|PKI-179
33256840|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
33256841|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
33256842|NCT01002898|Experimental|lopinavir/ritonavir|
33256843|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
32898296|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
33076411|NCT05208307|Experimental|Treatment (belantamab mafodotin, pomalidomide, dexamethasone)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 of every other cycle, pomalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33256844|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
33256845|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
33256846|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
33256847|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
33256848|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
33256849|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
33256850|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
33256851|NCT01004224|Experimental|BGJ398|
33256852|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
33256853|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
33256854|NCT01004302|Sham Comparator|Sham surgery|
33076412|NCT05205460|Experimental|Home-based telehealth exercise training|After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes). Then, the participants will start a home-based telehealth exercise training program (30minutes/session, 3 sessions/week for 12weeks, with a total of 36 sessions) combined with heart rate sensing clothes. Exercise type: brisk walking, jogging, or stationary ergometer exercise.
33256855|NCT01004302|Active Comparator|Active radiosurgery|
33256856|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
33256857|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
33256858|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
33256859|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
33256860|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
33256861|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
33256862|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
33256863|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
33256864|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
33256865|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
33256866|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
33256867|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
33256868|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
33256869|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
33256870|NCT04000204|Experimental|HYAJOINT Plus|
33256871|NCT04000204|Active Comparator|Durolane|
33256872|NCT01003834|Placebo Comparator|Control|Screening only
33256873|NCT01003834|Active Comparator|Assessment|Screening plus assessment
33256874|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
33256875|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
33256876|NCT04000126|Active Comparator|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
33256877|NCT04000126|Experimental|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
33256878|NCT04000126|Placebo Comparator|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
33256879|NCT01004926|Experimental|Echelon|
33076413|NCT05205460|Active Comparator|Education and self-exercise|"After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes).~Then, the patients will receive weekly reminders and monthly outpatient follow-ups during the exercise program."
32769363|NCT04813679||Neutropenic Enterocolite patients assessed with bed side ultrasound sonography|"From March 2007 through the entire study period all patients admitted eighter in our chemotherapy-ward or BMT-ward to receive intensive chemotherapy (chemo) for any hematological malignancies, or chemotherapy (CHT) for both auto transplant (ASTC) and allogeneic transplant (AlloTx), were prospectively enrolled in the study. When the patient received more than one chemo cycle, each ward access was considered a new observational period.~Patients who received CHT and experienced CHT-induced neutropenia (CHTNP) were enrolled in the study. We defined one observational period each admission on the ward to receive CHT, in which CHT and length of stay could vary from the previous admission. One observational period ended with the discharge of the pts form the ward. If a pts experienced a new chemo related NECe during another admission, it was considered as e new NECe."
33076414|NCT05171296||abdominal trauma patients|blunt abdominal trauma patients planned for conservation.
32769364|NCT04813679||Neutropenic Enterocolite negative patients assessed with bed side ultrasound sonography|NEC negative patients received bed-side ultrasound sonography after three days of neutropenia.
33076415|NCT05169697|Experimental|YH002 in combination with YH001|Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.
33076416|NCT05167045||No Dementia|
33076417|NCT05149690|Experimental|monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
33256880|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
33256881|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
33256882|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
33256883|NCT01005082|Experimental|Low salt diet plus water therapy|
33256884|NCT01005082|Active Comparator|water therapy alone|
33256887|NCT01008982|Experimental|single arm|
33256888|NCT03999736|Experimental|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).~4 x sessions over the course of a two week maintenance treatment."
33256889|NCT01005160|Experimental|CKD501|
33256890|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
33256891|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
33256892|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
33256893|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
33256894|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
33256895|NCT05230810|Experimental|Ib Safety Cohort /II Expansion Cohort|In phase Ib, the tolerability of tucatinib and alpelisib combination will be confirmed and maximum tolerated dose determined. Therapy will be administered in 28 day cycles of tucatinib 300 mg PO BID and alpelisib 250 mg PO daily (dose level 1). Treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. Fulvestrant will also be administered in patients with HR+/HER2+ metastatic breast cancer. Once RP2D is determined, the study will be continued to phase II, and new patients will enroll at RP2D. All patients in phase IB part, who are remaining on study at the time of initiation of phase II, will be rolled over to phase II. At that time, their study drug doses will be modified as follows: (1) if a patient is on the drug doses lower than RP2D, doses will not be increased; (2) if a patient is on a higher doses compared to RP2D, doses of study drugs will be changed to RP2D.
32769365|NCT05052775|Active Comparator|Chlorhexidine Group|These patients were control group given chlorhexidine mouthwash 2 times per day for 15 days
33256896|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
33256897|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
32769366|NCT05052775|Experimental|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
32769367|NCT05052775|Experimental|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
32769368|NCT04427423|Experimental|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
33256898|NCT01009216|Experimental|ABT-384|
33256899|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
33256900|NCT05224414|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of a digital cognitive training targeting interpretation bias
32769369|NCT04427423|Active Comparator|Stabilization Exercise group|control group will be treated with stabilization exercises only.
32769370|NCT05052463||sodium (hypo-hyper-normonatremia)|
33256901|NCT05224414|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of digitized psychoeducation
33256902|NCT05087290||Cases|SARS-CoV-2 +ve cases
33256903|NCT05087290||Control|SARS-CoV-2 -ve cases
33076418|NCT05149690|Active Comparator|Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
33256904|NCT01005472|Experimental|sunitinib malate, temozolomide|
33256905|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
33076419|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
33256906|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
32769371|NCT05052463||potassium (hypo-hyper-normokalemia)|
32769372|NCT05052463||calcium (hyper-hypo-normocalcemia)|
32769373|NCT05052463||magnesium (hyper-hypo-normocalcemia)|
32769374|NCT05052463||phosphor (hypo-hyper-normophosphatemia)|
33076420|NCT00164021||Control|
33076421|NCT05129371|Active Comparator|Breathing Exercise Group|This group will be given breathing exercises in accordance with the determined protocol.
32769375|NCT04813367||Twisted fallopian tubes cohort|Description of girls who went through surgery for twisted fallopian tubes
32769376|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
32769377|NCT04818437|Experimental|Balance training|"Balance training~Trunk, head, and upper limbs rotation from kneeling.~Upper limbs flexion and extension with simultaneous head movement from kneeling.~Pelvic bridging followed by raising one lower limb and extending knee.~Lifting opposite upper and lower limbs from Quadruped position.~6-Heel and toe raises, alternate rising ofthe right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed"
33076422|NCT05129371|Placebo Comparator|Placebo Breathing Group|Normal breathing of this group will be monitored.
33076423|NCT05129371|No Intervention|Control Group|No application will be made to this group.
33076424|NCT05117398|Experimental|Dalbavancin|Dalbavancin (Xydalba®) 1500 mg - One unique dose
33076425|NCT05117398|Experimental|Standard documented antibiotic therapy for 14 days according to national guidelines.|As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
33076426|NCT04683523|Experimental|Anaerobic exercise training|
33256907|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
33256908|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
33256909|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
33256910|NCT03999580|Experimental|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
33256911|NCT03999580|Active Comparator|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
33256912|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
33256913|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
33256914|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
33256915|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
33256916|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
33256917|NCT05734222|Active Comparator|Control Group|The control group is retrospective. It will include patients who have been operated on for POVG in the surgical department No. 1 of the KPH during the last 3 years (25-35) and 5-10 patients who will be operated on within the next 6-8 months.
33256918|NCT05734222|Experimental|Established group|The established group - patients who will be operated on in the surgical department No. 1 of the KPH over the next 1.5 - 2 years, using the developed techniques.
33256919|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
33256920|NCT01005784|Active Comparator|fixed|
33256921|NCT01005784|Experimental|flexible|
33256922|NCT05734144|Active Comparator|"Laparo-endoscopic rendezvous technique"|the first group was treated by a single-step procedure combining LC and IOES
33256923|NCT05734144|Other|POES followed by LC|the second (control) group was treated by 2-stage (sequential treatment) POES followed by LC.
33076427|NCT04683523|Active Comparator|Aerobic exercise training|
33076428|NCT05115292|Experimental|Arm1|BJ-005 dose escalation
33076429|NCT05115292|Experimental|Arm 2|BJ-005 cohort expansion
33076430|NCT05093452|Experimental|Motivational interviewing|Educational session based on the motivational interviewing
33076431|NCT05093452|Other|Information flyer|Information flyer on childhood vaccines
33076432|NCT05088421|Experimental|BWC0977|"SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. Planned doses to be studied are 120, 240, 480, 720, and 1050mg.~MAD Cohorts: Subjects will receive multiple doses of 240mg TID 7 days, 350mg TID 7 days BWC0977 via IV infusion over 2 hours in the first 2 cohorts. The dose for the B3 cohort will be determined based on safety and tolerability data from the previous two cohorts Up to three dose groups will be studied."
33076433|NCT05088421|Placebo Comparator|Placebo|"Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hour.~MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hour for 10 consecutive days. Frequency of infusions will be determined based on safety, tolerability and PK data obtained for BWC0977 in SAD Cohorts."
33076434|NCT05077969|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
33256924|NCT05069584|Experimental|transperineal biopsy|The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
33256925|NCT05069584|Active Comparator|transrectal biopsy|The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
33256926|NCT05154136|Experimental|Etrumadenant then Etrumadenant + Itraconazole|"Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).~A washout period of 5 days will be maintained between the two treatments."
33256927|NCT01005862|Experimental|PF-04360365|
33076435|NCT05077969|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.
33256928|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
33256929|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
33256930|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
33076436|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
33076437|NCT05063734|Experimental|Part A, THR-687 dose level 1|
33076438|NCT05063734|Experimental|Part A, THR-687 dose level 2|
33076439|NCT05063734|Experimental|Part B, treatment naïve subjects, THR-687 selected dose level|
32734183|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
32734184|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
32734185|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
32734186|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
32734187|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
32734188|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
32734189|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
33076440|NCT05063734|Active Comparator|Part B, treatment naïve subjects, aflibercept|
32734190|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
32734191|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
32734192|NCT04491565|No Intervention|standard education|
32734193|NCT04491565|Active Comparator|educational video|
33256931|NCT01006096|Experimental|Erlotinib|
33256932|NCT01006096|Placebo Comparator|Placebo tablets|
33256933|NCT05064592||Patients|Medical records of minor patients hospitalized between 2015 and 2020 in PICU and having been under sedation and prolonged invasive mechanical ventilation (> 72h).
33256934|NCT05733832|No Intervention|Control group|Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.
33256935|NCT05733832|Active Comparator|Transitional Liver Clinic (TLC)|Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.
33256936|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
33256937|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
33256938|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
33256939|NCT01006330||Elderly medical inpatients|
32734194|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
32734195|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
33076441|NCT05063734|Experimental|Part B, previously treated subjects, THR-687 selected dose level|
33076442|NCT05063734|Active Comparator|Part B, previously treated subjects, aflibercept|
33076443|NCT05062564|Experimental|LipiFlow group|Single preoperative treatment with the thermal pulsation system LipiFlow within two months before cataract surgery
33256940|NCT05733598|Experimental|1L:RP3 w/atezolizumab + bevacizumab in advanced HCC not amenable to resection/locoregional therapies|RP3 will be injected by direct or image-guided injection into injectable tumors (eg,primary sitehepatic tumors, hepatic metastases, non-hepatic metastases, visceral, or nodal tumors).
33256941|NCT05733598|Experimental|2L:RP3 w/atezolizumab + bevacizumab in advanced HCC not amenable to locoregional thrpy after PD(L)1|RP3 will be injected by direct or image-guided injection into injectable tumors (eg,primary sitehepatic tumors, hepatic metastases, non-hepatic metastases, visceral, or nodal tumors).
33076444|NCT05062564|Active Comparator|Control group|Eyelid warm compresses plus eyelid massage twice a day for the preoperative month
33256942|NCT05733520|Experimental|Brain CareNotes App|
33256943|NCT05733520|Active Comparator|Attention Control App|
33076445|NCT05061472||COC|Pre-menopausal women with overweight or obesity who are newly initiating the combined oral contraceptive pill, Sprintec (norgestimate/ethinyl estradiol 0.25mg/35mcg)
33076446|NCT05061472||NHC|Pre-menopausal women with overweight or obesity who are using non-hormonal methods of birth control
33076447|NCT04722510|Experimental|Effect of repeated TMS on aggressive impulse behavior in patients with BPD.|A protocol of 15 sessions of repeated Transcranial Magnetic Stimulation at 1 Hz on right dorsolateral prefrontal cortex.
33076448|NCT05056987|Other|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
33076449|NCT05056987|Other|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
33256944|NCT05733442|Active Comparator|Treatment as Usual (TAU)|The TAU condition will entail the current CNHS MAT program for OUD.
33256945|NCT05733442|Experimental|CHaRRM-CN|The CHaRRM-CN condition comprises changes and additions to TAU codesigned with a community advisory board and taking into account suggestions from MAT patients and community members impacted by OUD with the goal of improving MAT retention in culturally aligned and community-driven ways.
33256946|NCT05733364|Experimental|Investigational Product (Capsules with B vitamins & taurine)|IP will be administered orally once daily in capsule form, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
33256947|NCT05733364|Placebo Comparator|Microcrystalline cellulose placebo|Placebo will be administered orally once daily in identical capsule form as the IP, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
33256948|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
33256949|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
33256950|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
33256951|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
33256952|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
33256953|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
33256954|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
33256955|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
33256956|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
33256957|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
33256958|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
32734196|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
33256959|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
33256960|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
33256961|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
33256962|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
33256963|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
33256964|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
33256965|NCT01006720||Saline|Saline group: Saline as placebo
33256966|NCT05733052|Experimental|Polyester suture arm|A No 3 polyester suture will be inserted into the external urethral ligament, into the uurethral part of pubourethral ligament and into the pubic part of the pubourethral lgament then will be tied, but not tightly. The interventions will be carried on either side of the urethra that will be opened up by an 2.5 cm incision in the periurethral sulci.
33256967|NCT05136352|Active Comparator|adductor canal block|loco-regional analgesia with adductor canal block (ACB) method (for anterior cruciate ligament reconstruction )
33256968|NCT05136352|Experimental|iPACK block|loco-regional analgesia with iPACK block (infiltration between the popliteal artery and the capsule of the posterior knee) ((for anterior cruciate ligament reconstruction )
33256969|NCT05732974||Resected early stage non small cell lung cancer|Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery
33256970|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
32734197|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
32734198|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
32734199|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
32734200|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
32734201|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
32734202|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
32734203|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
33256971|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
33256972|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
32734204|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
33256973|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
32734205|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
32734206|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
32734207|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
32734208|NCT03305965|Experimental|Patient navigation|
32734209|NCT03305965|No Intervention|Care as usual|
33256974|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
33256975|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
32734210|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
32734211|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
32734212|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
32734213|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
32734214|NCT03300895|Experimental|High-intensity interval training|
32734215|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
32734216|NCT04491019|Experimental|Balance exercise group|Balance exercises will be carried out with a physiotherapist.
32734217|NCT04491019|Experimental|Strengthening exercise group|Strengthening exercises will be performed with a physiotherapist.
32734218|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
32734219|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
32734220|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
33256976|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
33256977|NCT05043220|Experimental|Telemedicine|Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
33256978|NCT05732896|No Intervention|control group|standard care group
33256979|NCT05732896|Active Comparator|study group|NOL guided group
33256980|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
33256981|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
33256982|NCT05732818|Experimental|Lumbar Disc Nucleus Replacement following discectomy|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
33256983|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
33256984|NCT01007188|Other|Base|average American diet without almonds
32734221|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
33256985|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
33256986|NCT05037136||Ablation|Participants recruited from the LoTO_CASA_AF trial (ClinicalTrials.gov Identifier: NCT04280042) who underwent either conventional catheter ablation or thoracoscopic surgical ablation to treat their long standing persistent AF with be asked to continue downloading data from their implanted loop recorder and monitor their heart rate and physical activity level (step count) using a wrist worn activity tracker.
33256987|NCT05035576|Active Comparator|400 mg OPN-019|
33256988|NCT05035576|No Intervention|Standard of Care (SOC)|
33256989|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
33256990|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
33076450|NCT05043961||study group|"Patients who report >50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.~Intervention:~Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles"
33076451|NCT05039671|Experimental|Measurement-based care|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
33076452|NCT05038891||Digital Cervical Assessment performed first|A digital cervical exam will be performed by an experienced senior obstetrics and gynecology resident, using index finger and middle finger to measure the dilation and thickness of the cervix. This is the gold standard measurement utilized to assess the labor course. In this group, the digital cervical exam is done first, followed by a participant-performed ultrasound imaging assessment of the cervix.
33076453|NCT05038891||Ultrasound Assessment performed first|Ultrasound imaging will be first taught by an experienced RN, then self-performed by the participant in the presence of junior obstetrics and gynecology resident and the RN. The junior resident will ensure the ultrasound device is functioning properly and the images are saved. In this group, the participant-performed imaging assessment is done first, followed by a digital cervical exam performed by an experienced senior obstetrics and gynecology resident.
33256991|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
33256992|NCT05732662|Experimental|SBRT combined with PD-1/CTLA-4 dual antibody|
32734222|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
32734223|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
32734224|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
32935391|NCT05444491||MRD negative group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If the gene methylation level detected in the samples did not exceed the threshold, the patients were enrolled in the MRD negative group. The 2-year total tumor recurrence rate of patients in the negative MRD group was calculated, and the negative prediction rate of postoperative plasma ctDNA methylation-MRD test results for 2-year tumor recurrence rate after radical resection of colorectal cancer was calculated.
32935392|NCT05444335|Other|Intervention arm|Women older than 70 who would wear the Zio patch for 2 weeks
33076454|NCT05023642|Experimental|resistance training|"Participants will not be offered the exercise program in the three months before data collection.~From then on, participants will perform exercises during the resistance training protocol intervention."
33076455|NCT05023642|No Intervention|control group|Individuals in the control group will not be offered the exercise program in the three months before data collection and during the entire period corresponding to the 12-week intervention.
33256993|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
33256994|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
33256995|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
33256996|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
32734225|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
32935393|NCT04633759|Experimental|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
32935394|NCT05436223|Experimental|Human CD19 Targeted T Cells Injection|Single administration：2.0×10^6 CAR+T/kg
32935395|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
32935396|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
32935397|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
33256997|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
33256998|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
33256999|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
32734226|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
32734227|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
32734228|NCT05195281|Experimental|Repetition of EUS-FNA or FNB for RNA extraction|
32734229|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
32734230|NCT02468089|Active Comparator|Carbepenem+albumin|
32734231|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
32734232|NCT03311347|Experimental|Air breathing|Primary aim, item 1
32734233|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
33257000|NCT05027620|Experimental|Home training|Participants train 3 times weekly in their home environment with help of a digital training app, over a 10-week period.
33257001|NCT05732584|Experimental|Family voice stimulation|Patients in this group were provided with structured family voice stimulation
33257002|NCT05732584|Experimental|Unfamiliar voice stimulation|Patients in this group were provided with structured unfamiliar voice stimulation
32734234|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
32734235|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
32734236|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
32734237|NCT04491097|Experimental|Experimental: Panavia V5 resin cement|Resin cement with non-MDP monomer
32734238|NCT04491097|Active Comparator|Experimental: Panavia F2.0 resin cement|Resin cement with MDP monomer
32734239|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
32734240|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
32734241|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
32734242|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
32734243|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
32734244|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
32734245|NCT02733991|Active Comparator|Control|MiniMed™640G alone
32734246|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
32734247|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
33257003|NCT05732584|No Intervention|Control group|Patients in this group will receive no specific voice stimulation
33257004|NCT05732506||Patients|Elderly patients diagnosed with nonvalvular atrial fibrillation who meet the frailty criteria and who had been receiving anticoagulant treatment with Edoxaban for no more than 6 months prior to inclusion in the study.
33257005|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
33257006|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
33257007|NCT01007422||Supportive Care|
33257008|NCT05732350||Group 1|Patients in group 1 already receive a DOAC and will start treatement with an SMI. Blood samples will be drawn before start of the SMI and during concomittant use with the SMI.
32734248|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
32734249|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
33257009|NCT05732350||Group 2|Patients in group 2 already use a potentially relevant DOAC-SMI combination or already use an SMI and start with a DOAC. In this group, blood samples are taken after the start of concomittant use of the DOAC-SMI combination.
32734250|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
32734251|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
32734252|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
32734253|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
32734254|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
33257010|NCT01007500|Experimental|Group Dexamethasone|
33257011|NCT01007500|Active Comparator|Group Ondansetron|
33257012|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
33257013|NCT05730322|Experimental|Intervention|Participation consisted of a baseline assessment one-week prior to starting the program, and a follow-up assessment one-week following completion of the program. The expectation was that students complete two lessons a week of the computer-based program over a four-week period.
33257014|NCT05730322|Experimental|Control|Students in control schools completed the baseline and follow-up assessments during the same week as students in their yoked intervention school. The expectation was that students would participate in the standard tobacco curriculum over this period.
33076456|NCT05003362|No Intervention|usual care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.
33076457|NCT05003362|Active Comparator|ACT|An 8-week mindfulness-based group therapy.
33076458|NCT04683406|Experimental|ZSP1273 600 mg + Oseltamivir Placebo BID|Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
33257015|NCT05130814|Active Comparator|Control Group|"The Control Group will follow the standard treatment indicated three times a week for the 4 weeks of observation.~The standard treatment for 2° and 3° stage PU consists of: cleansing with saline or ringer's lactate, hyaluronic acid gauze plus polyurethane foam every 48 hours or as needed. In addition, zinc cream or hyaluronic acid sodium salt + metallic silver is applied to prevent and/or treat the skin maceration of the surrounding area, and eventual debridement of the lesion, application of topical treatment indicated for that stage of the lesion (as provided by the Protocol on pressure ulcers' dressing intended as the standard of care of the structure) and subsequent bandage (that generally consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system), are planned."
33257016|NCT05130814|Experimental|EmoLED Group|"The Experimental Group will undergo, in addition to the standard treatment, treatment with Emoled three times a week for 4 consecutive weeks.~This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the lesion has a greater extension than the irradiated area, multiple repeated applications will be performed, on adjacent areas, until the entire area is covered.~The treatment with EmoLED will be carried out in correspondence with the dressing change of the lesion."
33257017|NCT05726188||Stage I colon cancer|Patients aged 18 years or above with pT1 or pT2 N0 colon cancer (up to the recto-sigmoid junction) who underwent curative resection between January 2010 and December 2019
33257018|NCT05725252|Experimental|NVP-2203|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
33257019|NCT05725252|Active Comparator|NVP-2203-R|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
33257020|NCT05725096|Active Comparator|CCTA-based strategy group|Subjects will be managed following the CCTA -based coronary heart disease prevention strategy for lipid-lowering treatment and follow-up.
33076459|NCT04683406|Active Comparator|Oseltamivir 75mg + ZSP1273 Placebo|Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
33076460|NCT04683406|Placebo Comparator|Placebo Comparator|Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
33076461|NCT04683328|Experimental|SCTA01 Group|SCTA01+Best Supportive Care
33076462|NCT04683328|Placebo Comparator|Placebo Group|Placebo+Best Supportive Care
33076463|NCT04683016||Periodontitis patients|Patients with a diagnosis of periodontitis, irrespective of its stage and grade.
33257021|NCT05725096|Sham Comparator|China-PAR Score only|The baseline assessment will be completed on the same day as consent is gained. Every subjects will complete a comprehensive assessment including questionnaires and objective assessments.
33257022|NCT05724004|Experimental|Radiotherapy + alectinib|All patients receive consolidation radiation therapy to all active tumour lesions after induction treatment with alectinib.
32734255|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
32734256|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
32734257|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
33076464|NCT04981405||Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg|450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
33076465|NCT04981405||Patients referred to Medical Institute named after Berezin Sergey for computed tomography|Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
33076466|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
32734258|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
32734259|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
32734260|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
32734261|NCT04442191|Experimental|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers >1:64.
33076467|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
33076468|NCT04977232|Experimental|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
33076469|NCT04977232|Active Comparator|Escitalopram|Escitalopram treatment for 8 weeks
33076470|NCT04974814|Placebo Comparator|control group|in this group patients will not receive statin before primary PCI
33076471|NCT04974814|Active Comparator|atorvastatin group|in this group patients will receive 80 mg atorvastatin single dose before primary PCI
33076472|NCT04974814|Active Comparator|rosuvastatin group|in this group patients will receive 40 mg rosuvastatin single dose before primary PCI
33076473|NCT04923334|Experimental|Brief Pain Teleconsult|Participants randomized to Brief Pain Teleconsult will receive the brief teleconsult intervention in Phase 1 (1-12 weeks) Responder status to the Phase 1 treatment will be examined at the 12 week assessment. Participants determined to be non-responders will receive the Telehealth Physical Therapy intervention. Responders receive no additional treatment.
33076474|NCT04923334|Experimental|Brief Pain Teleconsult plus Telehealth Physical Therapy|Participants randomized to Brief Pain Teleconsult plus Telehealth Physical Therapy will receive the brief teleconsult intervention in Phase 1 followed by the 10-week physical therapy intervention. No additional treatment is provided after the 12 week assessment.
33076475|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
33076476|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
33076477|NCT04921345|Experimental|Cohort 1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
33076478|NCT04921345|Experimental|Cohort 2: Participants aged 2-6 years|Participants aged 2-6 years will receive nemolizumab for 52 weeks.
33076479|NCT04910815|Experimental|Primary recruitment|Capsules will be ingested within 30 minutes prior to endoscopy pre- and post-antimicrobial intervention (if the patients has had a treatment) to determine if it can be used to identify increased microbial load through gas detection, and to identify responders to therapy.
33076480|NCT04910815|Active Comparator|Active SIBO Arm - Rifaximin|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of Rifaximin (550g) 1 capsule twice a day for 14 days. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
33076481|NCT04910815|Placebo Comparator|Active SIBO Arm - Placebo|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of placebo capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
33076482|NCT00193635|Active Comparator|1|oral MMF
33076483|NCT04903249|Experimental|Affect-regulated exercise prescription|"Participants receive instructions to adjust their pace of exercise so that they feel fairly good or better (i.e., a rating of +1 or higher on the Feeling Scale) while exercising and to avoid any increases in intensity that promote feeling fairly bad or worse. If no intensity of exercise feels at least fairly good participants will be told to exercise at an intensity that feels as positive as possible."
33076484|NCT04723979||Exposed to recombinant FVIIa (NovoSeven®)|all women exposed to NovoSeven® during sPPH
33076485|NCT04723979||Standard of Care|Women with postpartum hemorrhage not exposed to NovoSeven®.
33076486|NCT04902703|Experimental|Sargramostim|250 mcg/m2/day subcutaneously 5 days/week for 24 weeks
33076487|NCT04902703|Placebo Comparator|Placebo Control - Saline|Placebo comparator (saline) subcutaneously 5days/week for 24 weeks
33076488|NCT00193674|Experimental|1|
33076489|NCT00193674|Placebo Comparator|2|
33076490|NCT04899778|Experimental|Oral Contraceptive Pill|Oral contraceptive, 1/day, for one year
33076491|NCT04899778|No Intervention|No Oral Contraceptive|No intervention
33076492|NCT04885231|Experimental|Opioid-Limiting Perioperative Pain Management Education and Counseling|"Patients will be instructed to take oxycodone only as a last resort if the pain becomes unbearable. The goal should be to take as little oxycodone as possible."
33076493|NCT04885231|Active Comparator|Traditional Perioperative Pain Management Education and Counseling|"Patients will be instructed to take opioids as needed for severe pain to manage and stay ahead of the postoperative pain"
33076494|NCT04878211|Experimental|Ofatumumab - vaccine 2 weeks prior|RMS participants will receive non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (20 mg subcutaneous)
33076495|NCT04878211|Experimental|Ofatumumab -vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least four weeks after start of ofatumumab (20 mg subcutaneous)
33076496|NCT04878211|Active Comparator|Interferon or glatiramer acetate - vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least 4 weeks after start of prescribed interferon or glatiramer acetate
33076497|NCT04869280||Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment|Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
33076498|NCT04869280||Cohort-2: Pregnant Women Not Exposed to Prucalopride|Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
33076499|NCT04861246|Experimental|Experimental|Epidermal pigmented lesion
33401361|NCT04349332|No Intervention|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
33401362|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
33401363|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
33401364|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
33401365|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
33401366|NCT03664700||LMA Protector|The LMA Protector will be used
33401367|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
33076500|NCT04857502|Experimental|Diagnostic (99mTc-PSMA-I&S, SPECT/CT)|The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I&S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&S IV before standard of care surgery.
33076501|NCT04855981|Experimental|whole body vibration|the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
33076502|NCT04855981|Experimental|aerobic exercise|the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
33076503|NCT04855981|Active Comparator|supplementations|the subjects will receive supplementations three times per week for twelve weeks
33076504|NCT04841356|Experimental|ICG|Immediate Compression Garment
33076505|NCT04835545|Experimental|Wet Perlite, 2L air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with 2L air pocket
33076506|NCT04835545|Experimental|Wet Perlite 2L air pocket with resistance compensation|Breathing in the simulated avalanche snow. Breathing into model of wet perlite 2L air pocket with resistance compensation
33076507|NCT04835545|Experimental|Wet Perlite, no air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with no air pocket
33076508|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
33076509|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
33076510|NCT04832425|Experimental|PRAX-114|40 mg PRAX-114 once daily
33076511|NCT04832425|Placebo Comparator|Placebo|Placebo once daily
33076512|NCT04724135||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
33076513|NCT04827433||Women having a persistent low-lying placenta with an IOD between 6 and 20 mm|Women having a persistent low-lying placenta with an IOD between 6 and 20 mm who will be offered a vaginal birth, considering 3 subgroups: 1) 6-10 mm; 2) 11-20mm; 3) > 20 mm (resolution of previa or low-lying placenta)
33076514|NCT04827433||Women with normal located placenta|Women with a normally located placenta at the II trimester scan will represent the control group.
33076515|NCT04825639||Sepsis|"Patients admitted to PICU who are selected from registry based on primary diagnoses with codes for the following search codes were selected:~Sepsis is defined as per the International Consensus Conference pediatric sepsis definition (2005) [citation 1].~In silico analysis will be carried out in the sepsis cohort comparing admissions with Acute Kidney Injury (AKI) and those without AKI to identify factors associated with AKI.~In those selected admissions to PICU, information on Renal Function, Chloride levels, clinical outcome and medication use as well as fluid resuscitation will be collected from hospital online resources such as discharge summaries, results portal and the PICANet database. In addition the Paediatric Index of Mortality 3 severity of illness scores will be reported for all admissions.~Sepsis will be defined based on the International Pediatric Consensus Conference definition of sepsis (2005)"
33076516|NCT04825639||Diabetic Ketoacidosis (DKA)|"This group is defined based on the British Society of Paediatric Endocrinology and Diabetes.case definition for Diabetic Ketoacidosis [citation 2].~The data collected will be similar to the sepsis cohort. In silico analysis will be carried comparing those with AKI and without AKI in the DKA cohort."
33076517|NCT04818658||Preformed Metal Crowns using Hall Technique|
33076518|NCT04818658||Compomer Restoration|
33076519|NCT04683484|Experimental|Low dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
33076520|NCT04683484|Experimental|Middle dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
33076521|NCT04683484|Experimental|High dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
33076522|NCT04683484|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
33076523|NCT04683367|Experimental|clinical hernia|developing clinical hernia
33076524|NCT04683289|Experimental|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy
33076525|NCT04683289|Active Comparator|viscotrabeculotomy|Viscotrabeculotomy
33076526|NCT04683172|Experimental|Active tDCS|Active tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
33076527|NCT04683172|Sham Comparator|Sham tDCS|Sham tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
33257023|NCT05721742|Active Comparator|pre-existing online group education program for IBS|This arm will be enrolled in the online course run by Happy Bellies Nutrition https://www.happybelliesnutrition.com/ibs-gentle-group-program. The Happy Bellies nutrition course has 5.5 hours of total video content and optional biweekly group calls via Zoom (45-minutes per session). This course is designed to take 12 weeks to complete. The participants would have access to the content for one year.
32734262|NCT04442191|Placebo Comparator|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
32734263|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
32734264|NCT05478265||Axial Spine only, Age 65+|
32734265|NCT05478265||Axial Spine only, Age 18-64|
32734266|NCT05478265||Peripheral Joint only, Age 65+|
32734267|NCT05478265||Peripheral Joint only, Age 18-64|
32734268|NCT05478265||Axial + Peripheral Joint, Age 65+|
32734269|NCT05478265||Axial + Peripheral Joint, Age 18-64|
32734270|NCT05728021|Experimental|Recovery Record Aftercare|Intervention group (IG)
32734271|NCT05728021|Active Comparator|Treatment as usual (TAU)|Control group (CG)
32734272|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
32734273|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
32734274|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
32734275|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
32734276|NCT05476237|Active Comparator|TAU|Psychologists or PsyTechs in mental health services of primary care clinics will provide individual psychotherapy to depressed adolescents in the TAU arm. Local mental health professionals providing depression treatment in the TAU arm will not have been trained on IPT for adults or adolescents. Also, the two Ministry of Health psychologists trained as trainers of IPT-AG will not provide treatment in the TAU Arm.
32734277|NCT05476237|Experimental|IPT-AG|Group IPT-AG will be facilitated by the trained providers at each YFHS using the IPT-AG manual adapted to the Mozambican context. Adolescents will participate in 12 weekly sessions. The first and last sessions will be one-on-one with the provider. The first session is used for the participant and provider to develop a treatment plan and the last session is to prepare for treatment termination. All other sessions will be conducted in groups of 6-8 adolescents.
32734278|NCT05471401|Experimental|Occlusion balloon catheter|-Each participant will have an embolectomy balloon that is FDA approved for peripheral and neurovasculature temporary occlusion placed by nose or mouth. Anatomical position of balloon will be verified by on-board MR or CT imaging in to assess feasibility of using a duodenal balloon in this population. Participants who are imaged on the MR treatment machine will also be imaged with 4 or 8 frame per second sagittal imaging to assess real-time stomach and balloon respiratory motion. Participants imaged on CT based imaging (i.e. Ethos/Halcyon ring gantry system) will have CBCTs acquired at timed intervals (approximately 5-10 minutes between scans). After imaging, the balloon will be deflated and removed at that time.
32734279|NCT04791475|Experimental|Dexmedetomidine with 0.5% bupivacaine|1mcg/kg dexmedetomidine as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
32734280|NCT04791475|Active Comparator|Dexamethasone with 0.5% bupivacaine|4mg dexamethasone as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
32734281|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
32734282|NCT03299803|No Intervention|Control group|Telephone contact only
32734283|NCT03299725|Experimental|Treatment arm|
32734284|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
32734285|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
32734286|NCT05015881|Active Comparator|Ketone ester + echocardiogram + PET FDG scanning visit.|"Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan."
32734287|NCT05015881|Other|Echocardiogram + PET FDG scanning visit.|Subjects will complete a echocardiogram + PET scanning visit. 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.
32734288|NCT04490551|Experimental|Intervention group|This group will be screened with the risk-based model. The input of the model will be gathered with the FIT, a validated questionnaire, and from data of the Dutch general population registry. The threshold of the model will be set at a calculated risk of 0.10. To comply with ethical guidelines, all participants in this group with a FIT result of >=15 mcg Hb/g faeces and a calculated risk of <0.10 will also be offered a colonoscopy.
33076528|NCT04683133|Other|Single arm|Optical coherence tomography evaluation of coronary arteries with intermediate to severe stenosis.
32734289|NCT04490551|Active Comparator|Control group|This group will be screened with the FIT. The threshold of the FIT will be set at >= 15 mcg Hb/g faeces.
32734290|NCT05727943|Experimental|add - on clioquinol|"Add-on clioquinol to concomitant anti seizure medications.~Clioquinol - magistral suspension preparation (100mg/ml) - oral intake Exposure 2 weeks to low dose: 1 mg/kg/day Exposure 6 weeks to higher dose: 4 mg/kg/day"
33076529|NCT00193908|Experimental|1|
33076530|NCT00193908|Experimental|2|
33076531|NCT04810858|Other|HIV+ marijuana user|Participants with HIV who report marijuana use
33076532|NCT04810858|Other|HIV+ non-drug user|Participants with HIV who report no drug use
33076533|NCT04810858|Other|HIV- marijuana user|Participants without HIV who report marijuana use
33076534|NCT04810858|Other|HIV- non-drug user|Participants without HIV who report no drug use
33076535|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
33401368|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
33257024|NCT05721742|Experimental|virtual dietitian consults for IBS patients|This arm will receive consults with a virtual dietitian (60 minutes initial + 4 x30-minute follow-up appointment) by a dietitian who has had additional training in the dietary management of IBS.
33257025|NCT05129722|Experimental|Patients receiving low dose combination polydiuretic therapy|This patient group will receive a low dose combination polydiuretic therapy treatment consisting of: bumetanide 0.5 mg (loop diuretic), eplerenone 25 mg (mineralocorticoid receptor antagonist) and empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
33257026|NCT05129722|Active Comparator|Comparator group receiving monotherapy empagliflozin|This comparator patient group will receive empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
33257027|NCT00642954|Experimental|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
33257028|NCT00642954|Experimental|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
33257029|NCT00642954|Experimental|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
33076536|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
33257030|NCT00642954|Experimental|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
33257031|NCT00642954|Experimental|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
33257032|NCT01007734||1|
33257033|NCT00822276||ADEH+ participants colonized with MSSA|
33257034|NCT00822276||ADEH+ participants colonized with MRSA|
33257035|NCT00822276||Uncolonized ADEH+ participants|
33257036|NCT00822276||ADEH- participants colonized with MSSA|
33257037|NCT00822276||ADEH- participants colonized with MRSA|
32734291|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
32734292|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given."
32734293|NCT05445427|Experimental|VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will have vagal nerve stimulator applied to the neck for 2 minute intervals with two sets administered three times daily
32734294|NCT05445427|No Intervention|Non-VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will receive current standard of care
32734295|NCT05441683|Experimental|HEI|PAOO with horizontally extending incisions on both sides
33076537|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
33257038|NCT00822276||Uncolonized ADEH- subjects|
33257039|NCT00822276||Non-atopic uncolonized S. aureus participants|
33257040|NCT00816660|Experimental|1|
33257041|NCT00816660|Active Comparator|2|
33257042|NCT05713630|Experimental|Standard care + TXA|Non-surgical patients will be given a single oral or IV loading dose of 1g TXA within three hours of being randomized. For surgical patients, the same loading dose will be administered whenever possible prior to surgery. After 12 hours of the loading dose, patients will be given 500 mg TXA by mouth (or nasogastric tube for those unable to swallow or IV) three times a day, totalling 1500 mg/day, for 45 days.
33257043|NCT05713630|Placebo Comparator|Standard care + placebo|Non-surgical patients will be given a single oral or IV loading dose of 1g placebo within three hours of being randomized. For surgical patients, the same loading dose will be administered whenever possible prior to surgery. After 12 hours of the loading dose, patients will be given 500 mg placebo by mouth (or nasogastric tube for those unable to swallow or IV) three times a day, totalling 1500 mg/day, for 45 days.
33257044|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
33257045|NCT00640146|Experimental|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
33257046|NCT00640146|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
33257047|NCT05701150||MIN Data Set|Patients who did not receive a targeted therapy based on NGS results (outside of a clinical trial)
33257048|NCT05701150||EXT Data Set|Patients who received a targeted therapy based on NGS results (outside of a clinical trial)
33257049|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
33257050|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
33257051|NCT01007968|Experimental|HDACi|
33257052|NCT00822432||1|
33076538|NCT04810117||COVID-19 PCR positive patients who are not yet vaccinated|Patients test positive with PCR and recovered from COVID-19
33076539|NCT04810117||COVID-19 patients with obvious symptoms who are not yet vaccinated|COVID-19 patients with obvious symptoms but PCR test was not conducted for them
33076540|NCT04810117||COVID-19 suspected patients with no symptoms who are not yet vaccinated|COVID-19 suspected patients with no symptoms but came in obvious contact with infected environmental/biological samples
33076541|NCT04810117||COVID-19 PCR positive patients who are vaccinated|COVID-19 suspected patients who have got either one or two doses of vaccine
33076542|NCT04810117||Healthy Individuals who are vaccinated|Control group
32734296|NCT05441683|Active Comparator|VRI|PAOO with vertical releasing incisions on both sides
32734297|NCT05727787|Experimental|Single fraction SBRT 27 Gy|vGRID SBRT 3+3 dose escalation, single fraction, one day cycle length
32734298|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
32734299|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
32734300|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
32743112|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
33076543|NCT04810117||Healthy Individuals who are not vaccinated|Control group
33076544|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
33257053|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
33257054|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
33076545|NCT04789252||Patients with NSCLC or with colon cancer|"The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent.~The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice.~It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes"
33076546|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
33257055|NCT00819312|Active Comparator|Arm 1|
33257056|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
33257057|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
33257058|NCT05006560|Experimental|Usual care rehabilitation and aftercare|Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
33257059|NCT05006560|Experimental|Rehabilitation and aftercare (aligned)|"Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.~During rehabilitation, participants already get familiarized with components of the after care program."
33076547|NCT04748809|Active Comparator|Arm_1|Anti-inflammatory diet 1
33076548|NCT04748809|Experimental|Arm_2|Anti-Inflammatory diet 2
33257060|NCT05005624||Validation group 1 (VG-1)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.1 logMAR (Snellen 20/25)
33076549|NCT04743934|Experimental|Flibanserin + ADT|Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
33076550|NCT04743934|Placebo Comparator|Placebo + ADT|Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
33076551|NCT00176241|Experimental|1|
33076552|NCT04742959|Experimental|Monotherapy Cohorts|TT-00420 tablets will be administered once daily in 28-day cycles.
33076553|NCT04742959|Experimental|Dose Escalation Cohorts (Combination Therapy)|TT-00420 tablets will be administered once daily in 28-day cycles. Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Day 1, 8, and 15 of each 28-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
33076554|NCT04742959|Experimental|PK Run-in Cohorts|TT-00420 tablets will be administered once or twice daily in 28-day cycles according to assigned cohort.
33076555|NCT04732897|No Intervention|Control arm|wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
33076556|NCT04732897|Experimental|Interventional arm|wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint
33257061|NCT05005624||Validation group 2 (VG-2)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.4 logMAR (Snellen 20/50)
33076557|NCT04727203|Experimental|Intervention|Partcipants in this group will receive the 8 week healthy lifestyle program
33076558|NCT04727203|No Intervention|Control|Participants in this group will not receive any intervention
33076559|NCT04719793|Experimental|Wharton's Jelly|Intraarticular injection of Umbilical Cord-derived Wharton's Jelly
33076560|NCT04719013|Experimental|treatment|
33257062|NCT05005624||Validation group 3 (VG-3)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.7 logMAR (Snellen 20/100)
33257063|NCT05107726|Experimental|TRE Group|In the TRE group, study staff will instruct the family unit on limiting the eating window to 10-12 hours per day, during which they can eat ad libitum. Notably, in the TRE group, participants (children and adults) will be instructed to brush their teeth with a WIFI-enabled toothbrush in the morning and specifically within ½ hour after their evening meal. This will serve as a cue to stop evening eating, and information from the WIFI-enabled toothbrush will be accessed by study staff to approximate the eating window. The adult from each family unit will receive a daily REDCap-administered email to indicate the timing of the first meal of the day and the last meal of the day for the parent and child, which will also serve as an estimate of the eating window.
33257064|NCT05107726|No Intervention|Standard of Care Group|The standard of care control group will receive dietary instruction that is based on a 1200-1500 calorie diet, as is typical of family-based interventions. Calorie counting will not be encouraged. However, families will be encouraged to follow appropriate portion sizes; increase vegetable, fruit and lean protein consumption; as well as decrease consumption of energy-dense but low-quality items (e.g., sugar sweetened beverages). Families in this group will also receive a WIFI-enabled toothbrush and daily REDCap surveys but will not be instructed on when to brush teeth or to shorten their eating window
33257065|NCT05658328|Experimental|Intervention Group|Caregivers (MCI or healthy) randomized into this group walk 3x/week for 16 weeks with their care-partner (person living with early-stage dementia - PLWD) and their caregiver support person (MCI or healthy). Caregivers (and optionally for PLWD), wears an actigraphy watch, uses an under-the-mattress sleep sensor, and on a weekly basis completes weight and a health update survey. Mid- and end-study focus groups evaluate program effectiveness and needed adaptations.
33076561|NCT04704271|Active Comparator|Delta-9-Tetrahydrocannabinol (THC)|4 mg vaporized THC will be administered.
33076562|NCT04704271|Placebo Comparator|Placebo|Inhaled placebo (no active cannabinoids)
33257066|NCT05658328|Active Comparator|Waitlist Control|Caregivers (MCI or healthy) randomized into this group first complete baseline measures for 16 weeks, consisting of wearing an actigraphy watch, using an under-the-mattress sleep sensor, and, on a weekly basis, completing weight and a health update survey. These baseline measures are optional for PLWD. After 16 weeks of baseline data collection, the primary caregiver continues these measures while walking 3x/week for 16 weeks with their triad. The PLWD optionally completes measures and optionally wears the watch and sleep sensor. Mid- and end-study focus groups during the walking phase evaluate program effectiveness and needed adaptations.
33257067|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
33257068|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
33257069|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
33257070|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
33257071|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
33257072|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
33257073|NCT03982303|Experimental|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
33257074|NCT03982303|Experimental|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
33257075|NCT03982303|Experimental|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
33257076|NCT03982303|Experimental|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
33257077|NCT03982303|Experimental|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
33257078|NCT03982303|Experimental|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
33076563|NCT04723940|Active Comparator|Oral Antibiotics|Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
33076564|NCT04723940|Active Comparator|Intravenous Antibiotics|Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
33076565|NCT04684849||Healthy subjects|Subjects who are healthy without disease
33076566|NCT04684849||Gas and Bloating patients|Patients with symptoms of gas and bloating
33076567|NCT04680793|Other|EDS Patients|No intervention during the control period (9 weeks) and then experimental during the rehabilitation stage (9 weeks).
33076568|NCT04678570|Experimental|Intervention Group-1|White Noise intervention and standard care, procedures will be applied.
33076569|NCT04678570|Experimental|Intervention Group- 2|The swaddling method and standard care, procedures will be applied.
33076570|NCT04678570|Experimental|Intervention Group- 3|White Noise, swaddling method, and standard care, procedures will be applied.
33076571|NCT04678570|No Intervention|No Intervention Group|Standard care and procedures to be applied.
33257079|NCT03982303|Experimental|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
33257080|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
33257081|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
33257082|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
33076572|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
33257083|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
33257084|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
33257085|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
33257086|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
33257087|NCT01064869|No Intervention|usual care|Standard asthma management
33257088|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
33257089|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
33401369|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
32734301|NCT05727631|Experimental|gentle human touch|In the study, after the mother in the experimental group was dressed in a clean apron, she was allowed to wash and disinfect her hands. When the temperature of the mother's hand was measured with a non-contact thermometer, it was allowed to warm it under a radiant heater until it reached 34 ºC. The mother, who was informed about the method before, was allowed to place the palm of one hand on the baby's crown, with her fingertips touching the eyebrow line. She placed her other hand on her lower abdomen, encircling the baby's waist and hips. It has been provided to perform sensitive touch operation without pressure and massage. The mother started the gentle touch method 5 minutes before the blood draw, and continued to do the touching during the blood draw and 5 minutes after the blood draw was finished.
32734302|NCT05727631|No Intervention|Control group|"The standard procedure of the clinic was applied to preterm infants in the control group. In the standard procedure of the clinic, the mother was with her baby in the blood collection room and did not perform any procedure.~IN ALL BABIES IN THE CONTROL AND EXPERIMENTAL GROUP., Before the procedure, 5 minutes after the procedure and 20 minutes after the procedure, the mother filled out the STAI-I form. The NIPS scale to measure the infant's pain was scored by two independent observers before, during, and five minutes after the procedure. KTA, SPO2 values of the baby were recorded before, during and five minutes after the procedure. The baby's crying time was started when the crying started, and stopped when the crying stopped."
32734303|NCT03299491|Experimental|MWA+IEC intervention|
32734304|NCT03299491|Experimental|IEC intervention|
32734305|NCT03299491|No Intervention|Control|
32734306|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
32734307|NCT04939909|Other|Patients treated with Botulinum toxin type A|Patients were treated with Botulinum toxin type A
32734308|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
32734309|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
32734310|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
32734311|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
32734312|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
32734313|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
32734314|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
32734315|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
32734316|NCT05727397|Experimental|RC28-E|RC28-E 2 mg will be initially injected 3 times at 4 week intervals, then each subject will be injected every 12 weeks unless there is disease activity. If disease activity is identified, the subject will be reassigned to receive injections every 8 weeks thereafter, up to study exit.
33257090|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
33257091|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
33076573|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
33076574|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
33257092|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
33257093|NCT05643196|Experimental|Pulsed Low-Intensity Focused Ultrasound (PLIFUS), then Sham|Participants will receive PLIFUS sonication on the first intervention visit, then sham sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
32734317|NCT05727397|Active Comparator|Aflibercept|Aflibercept 2 mg will be injected 3 times at 4 week intervals, followed by injections every 8 weeks.
32734318|NCT05378269|Placebo Comparator|Placebo|Vaginal insert
32734319|NCT05378269|Experimental|DARE-VVA1 1mg|vaginal insert
32734320|NCT05378269|Experimental|DARE-VVA1 5mg|vaginal insert
32734321|NCT05378269|Experimental|DARE-VVA1 10mg|vaginal insert
32734322|NCT05378269|Experimental|DARE-VVA1 20mg|vaginal insert
32734323|NCT05728099|Experimental|Expiratory muscle strength training + SpiroGym application|The experimental arm will undergo 24 weeks of expiratory muscle strength training coupled with SpiroGym app.
32734324|NCT05728099|Active Comparator|Expiratory muscle strength training|The experimental arm will undergo 24 weeks of expiratory muscle strength training.
32734325|NCT05367973|Experimental|IVR: Estradiol 80 ug/day + progesterone 4mg/day|12-week IVR 80/4
32734326|NCT05367973|Experimental|IVR Estradiol 160 ug/day + progesterone 8 mg/day|12-week IVR 160/8
32734327|NCT04806451|Experimental|Crinecerfont|Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.
32734328|NCT04806451|Placebo Comparator|Placebo|Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.
32734329|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
32734330|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
32734331|NCT04804735|Experimental|REV : local anesthesia and virtual reality|Use of virtual reality device in Implanted Venous Access Device (IVAD) procedure under local anesthesia
32734332|NCT04804735|Experimental|MUS : local anesthesia and music therapy|Use of musicotherapy tool in Implanted Venous Access Device (IVAD) procedure under local anesthesia
32734333|NCT04804735|No Intervention|CONTROL : standard local anesthesia|Implanted Venous Access Device (IVAD) procedure under local anesthesia as standard of care
32734334|NCT04794595||sepsis group with CBP|The child with sepsis should be treated with CBP， but could not receive this treatment for various reasons
32734335|NCT04794595||sepsis group without CBP|The child with sepsis should be treated with CBP and received this treatment
32734336|NCT05727241||The study cohort (total sample)|All women will undergo ultrasound examination for three-dimensional umbilical cord index.
32734337|NCT05319535|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in the investigators' prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
33257094|NCT05643196|Experimental|Sham, then Pulsed Low-Intensity Focused Ultrasound (PLIFUS)|Participants will receive sham sonication on the first intervention visit, then PLIFUS sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
33257095|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
33257096|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
33257097|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
33257098|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
33076575|NCT04641247|Experimental|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
33076576|NCT04635007|Experimental|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
33076577|NCT04635007|Experimental|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
33257099|NCT05099692||CHD patients participating in the cardiac rehabilitation|
33076578|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
33076579|NCT04546945||control cases|normal healthy person
32734338|NCT05319535|Experimental|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites randomized to receive Enhanced REP will continue with Foundational REP and also receive higher intensity support for a period of approximately 4 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
32734339|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
32734340|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
32734341|NCT05727163|Experimental|HAI group|"FOLFOX given via Hepatic Artery Infusion (HAI) in Combination With intravenous Irinotecan With or Without Bevacizumab.~Dexamethasone 25 mg via HAI (Pre-chemotherapy) Anisodamine (654-2) 10 mg HAI (Pre-chemotherapy) Oxaliplatin 85 mg/m2 via HAI over 3 hours Leucovorin 200 mg/m2 via HAI FU 400 mg/m2 via HAI FU 2.4g/m2 via HAI over 48 hours Irinotecan 150 mg/m2 intravenously Bevacizumab 5 mg/kg intravenously~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
32734342|NCT05727163|Active Comparator|Systemic Chemotherapy group|"Systemic FOLFOXIRI With or Without Bevacizumab~Irinotecan 150mg/m2 intravenously Oxaliplatin 85 mg/m2 intravenously over 3 hours Leucovorin 200 mg/m2 intravenously FU 400 mg/m2 intravenously 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours Bevacizumab 5 mg/kg intravenously~Note: (UGT*28 7/7, UGT*6 A/A, UGT*28 6/7 and UGT*6 A/G patients, Irinotecan dosage was reduced to 130 mg/m2)~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
32734343|NCT05727085||twins|
32734344|NCT05259709|Experimental|Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part A:~Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment."
32734345|NCT05259709|Experimental|Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part B:~Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A."
32734346|NCT05727007|Experimental|MRI in colon cancer|All prospectively included patients with colon cancer will be preoperatively submitted to MRI for staging. The evaluation of the diagnostic accuracy will be based on the cross-examination with the CT scan and the pathology results
32734347|NCT05302531|Experimental|Amoxicillin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
32734348|NCT05302531|Experimental|Ofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
32734349|NCT05302531|Experimental|Levofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
32734350|NCT05302531|Experimental|Sulfamethoxazole trimethoprim|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
33076580|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
33076581|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
33257100|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
33257101|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
33257102|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
33076582|NCT04503343|Other|intervention group|subjects are randomly divided into the intervention group. and they will be given a one-time non-drug intervention(mindfulness training, relaxation training or electrical cerebellar stimulation).
33076583|NCT04503343|No Intervention|control group|subjects are randomly divided into the control group and regularly followed up.
33076584|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
33076585|NCT04467970|Experimental|Unicompartmental Knee Replacement|
33076586|NCT04467970|Experimental|High Tibial Osteotomy|
32734351|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
32734352|NCT05302453|Experimental|Basic Body Awareness Therapy Group|BBAT exercises to the participants in the study group, were performed under the leadership of two physiotherapists with internationally valid training certificates. In the face-to-face training, BBAT exercises were taught to the participants. Then the training went on via Google Meet. The lying exercises were shown on one participant before each group study and participants were asked to do lying exercises at home. Sitting and lying exercises were performed as a hybrid at one hour/in a week for 12 weeks. At the beginning and end of each group training, feedback was received from the participants' own experiences of the effects of the exercises on the body, emotions, and thoughts.
32734353|NCT05302453|No Intervention|Control Group|The Control group was warned to continue with daily routines and not to take any training that includes body-mind approaches such as yoga or Tai chi for 12 weeks.
32734354|NCT04839679|Active Comparator|Standard of Care Mayo Clinic booklet|Subjects will receive the standard Mayo Clinic educational booklet in preparation for clinically indicated radiation therapy treatment
32734355|NCT04839679|Experimental|Culturally Oriented Education|Subjects will receive a culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner in addition to the standard Mayo Clinic booklet
32734356|NCT05293951|Experimental|Mirror Therapy + Cross Education|"Cross Education: Experimental participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Mirror Therapy: Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
32734357|NCT05293951|Active Comparator|Mirror Therapy Alone|"Mirror Therapy: Control participants will perform non-resisted task-specific upper limb exercises. Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
32734358|NCT04691947|Experimental|Low dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
32734359|NCT04691947|Experimental|Medium dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
32734360|NCT04691947|Placebo Comparator|Placebo|Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
32734361|NCT00702325|Experimental|1|
32734362|NCT00702325|Active Comparator|2|
33076587|NCT04427917|Experimental|PF-06835919|
33076588|NCT04427917|Placebo Comparator|Placebo|
33076589|NCT04426825|Experimental|Atezolizumab plus Bevacizumab|Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
33076590|NCT00194103|No Intervention|TAU|
33076591|NCT00194103|Active Comparator|Telephone Monitoring|
33076592|NCT00194103|Experimental|Telephone Monitoring and Counseling|
33076593|NCT04421989|Experimental|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
33076594|NCT04421989|Active Comparator|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
33076595|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
33076596|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
32734363|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
33076597|NCT04418557||Pregnant women vaccinated for COVID-19|Women who are vaccinated against COVID-19 at any point during their pregnancy
33257103|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
33257104|NCT05628766||Women diagnosed with primary infertility (n:41)|Women which followed up with infertility of unknown cause.
33076598|NCT04682782|Experimental|Esketamine|Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation
33257105|NCT05628766||Control group ( n:41)|Healthy women who are not infertile
33076599|NCT04682782|Placebo Comparator|Saline|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation
33076600|NCT04682665||Experimental|Patients randomized to the experimental arm of the EMT2 trial, receiving Icosapent Ethyl (EPA-EE) according to the EMT2 protocol.
33076601|NCT04682665||Placebo comparator|Patients randomized to the placebo comparator arm of the EMT2 trial, receiving placebo capsules according to the EMT2 protocol.
33076602|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
33076603|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
33076604|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
33257106|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
33257107|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
33257108|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
33076605|NCT04409353|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
33076606|NCT04409353|Active Comparator|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
33076607|NCT04409353|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
33076608|NCT04378933|Experimental|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
33257109|NCT05609188|Experimental|Cash now|"Participants allocated to the cash now arm will receive a $500/month Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) and no GI in the second twelve months of follow-up (Phase 2)."
33257110|NCT05609188|Other|Cash in a year|"Participants allocated to the cash in a year arm will receive no Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) but will receive a $500/month GI in the second twelve months of follow-up (Phase 2)."
32734364|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
33076609|NCT04378933|Active Comparator|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
33076610|NCT04330339|Experimental|Fasting|"Eligible participants will undergo baseline assessments prior to starting the intervention.~Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.~Participants will fast for 13 hours nightly for 12 weeks.~Assessments will be repeated at the completion of the 12-week intervention."
33076611|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
33257111|NCT01062529|Experimental|somatostatin|
33076612|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
33076613|NCT04322695|Experimental|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
33076614|NCT04322695|Other|Usual care|Usual care
33076615|NCT04307953|Experimental|AZD0530|
33076616|NCT04307953|Experimental|Placebo/AZD0530|
33076617|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
33076618|NCT00165152|Active Comparator|Genetic Counseling|
33076619|NCT00165152|Active Comparator|Informed Consent Counseling|
33076620|NCT04297267|Experimental|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
33076621|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
33257112|NCT05617846||Intervention group|Patients who received antiosteoporosis therapy after bone tumor resection
33257113|NCT05617846||Control group|Patients who underwent bone tumor resection without antiosteoporosis therapy
33257114|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
32734365|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
32734366|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
32734367|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
32734368|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
33257115|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
33257116|NCT03977545|Other|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
33257117|NCT03977545|Other|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
32734369|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
32734370|NCT05726929|Experimental|Osteopathic treatment (OT)|Osteopathic treatment, 3 sessions of 1h + Treatment As Usual (TAU)
32734371|NCT05726929|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual, Capsaicin Qutenza Patch (Conventionnal Treatment in algology in supportive care)
32734372|NCT04682353|Experimental|Group 1 - 120 mg/0.4 mL|
32734373|NCT04682353|Experimental|Group 2 - 180 mg/0.6 mL|
32734374|NCT04682353|Experimental|Group 3 - 240 mg/0.8 mL|
32734375|NCT04682353|Active Comparator|Group 4 - 104 mg/0.65 mL|
32734376|NCT05266495||Brolucizumab|patients who received their first injection of Brolucizumab either during the active recruitment period (1 year prospective) or during the 6 months pre-start of the recruitment (6 months retrospective)
32734377|NCT05220241|Other|Case : patient with 1st episode of COVID-19 and persistence of neurocognitive complaint|Patient with a 1st episode of COVID-19 in the 12 months preceding inclusion and presenting persistence of neurocognitive complaint beyond 4 weeks
32734378|NCT05220241|Other|Control : Patient with a 1st episode of COVID-19 cured and without neurocognitive complaint|Patient with a cured 1st episode of COVID-19 (without persisting symptoms beyond 4 weeks) in the 12 months preceding inclusion and without neurocognitive complaint
32734379|NCT02722525|Experimental|Diagnostic (cardiac MRI, skeletal muscle PMRS)|Patients undergo a treadmill stress CMR focused on cardiac muscle comprised of resting MRI over 10-15 minutes followed by treadmill exercise until peak stress. Patients then undergo MRI and gadopentetate dimeglumine perfusion imaging immediately after exercise and after a 6-8 minute recovery period. Within 24 hours of treadmill CMR exam, patients also undergo skeletal muscle PMRS while at rest, during, and in the recovery phase of resistive lower extremity exercise which patients complete over 30 seconds. Both procedures are performed before initiation of ADT treatment (baseline) and 4-7 months after initiation of ADT treatment.
32734380|NCT04490473|Other|volunteer group|Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
32734381|NCT05726695||Heart failure with reduced ejection fraction.|"Patients indicated for biochemical analysis due to a suspected heart disease, with HFrEF diagnosed on echocardiography with left-ventricular ejection fraction lower than 35%.~Diagnostic Test: MicroRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
32734382|NCT05726695||Control group|"Patients with no known heart disease (hypertrophy or dilatation), which has been confirmed on echocardiography.~Diagnostic Test: microRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
32734383|NCT05726539|Active Comparator|Intervention|participants receive group-based peer support
32734384|NCT05726539|No Intervention|Waitlist|participants wait to receive peer support until pre and post assessments are complete with their matched intervention group
32734385|NCT04755907||Group A|colorectal cancer patients at resectable stage II/III who will receive adjuvant chemotherapy after surgery
32734386|NCT04755907||Group B|colorectal cancer patients at locally advanced stage who will receive neoadjuvant chemotherapy before surgery and adjuvant chemotherapy after surgery
32734387|NCT04755907||Group C|colorectal cancer patients with liver metastases
32734388|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
32734389|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
32734390|NCT05275231|Experimental|Dyads|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. The intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this dyad-based group, participant's social partner must commit to attend all in-person sessions.
32734391|NCT05275231|Active Comparator|Men Only|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. the intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this group just the participant will receive the intervention.
32734392|NCT05268055|Experimental|"Sign Here training intervention"|"Participants randomized to the experimental condition will view the new Sign Here training film for healthcare providers."
32734393|NCT05268055|Other|Intervention as usual|"Participants randomized to intervention as usual will review Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
33257118|NCT03977545|Other|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
33257119|NCT03977545|Other|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
33257120|NCT00302731|Active Comparator|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
33257121|NCT00302731|Experimental|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
33401370|NCT03312907|Placebo Comparator|Belimumab + Placebo|Eligible subjects will receive Belimumab 200 milligrams (mg) to be administered subcutaneously (SC) on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab-placebo to be administered by intravenous (IV) infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids tapered down to prednisone equivalent of less than or equal to (<=) 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
32734394|NCT04590079|Experimental|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
32734395|NCT04590079|Experimental|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
32734396|NCT04590001|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
32734397|NCT04740385||Lung cancer patients|Correct position of double lumen endotracheal tube will be assessed using lung sonography, routine chest auscultation and fiberoptic brochoscopy
32734398|NCT05163223|Experimental|AST-301(pNGVL3-hICD)+Chemotherapy|"AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
32734399|NCT05163223|Active Comparator|Placebo + Chemotherapy|"Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
32734400|NCT04522219|Experimental|Case group|Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
32734401|NCT04522219|Experimental|Control group|Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group
32734402|NCT04491175|Active Comparator|DuoTherm|A low back pain relief device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
32734403|NCT04491175|Active Comparator|Multimodal TENS|An 8-channel TENS unit (LG Smart). Patients will be instructed to use the TENS twice a day for 20 minutes.
32734404|NCT05722873|Experimental|Fasting|Subjects will fast one-day per week for 12 weeks
32935398|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
32935399|NCT05444179|Active Comparator|Intervention group|"The participant will be provided an educational module entitled Mommies can Eat and Exercise with No Stress (MomEENS), in which the module will be delivered through a booklet and video. The MomEENS module consist of five key recommendations: 1. Eat healthy foods ;2. Eat foods rich in iron and folic acid; 3. Eat foods rich in omega-3 fatty acids; 4. Increase steps in a day and; 5. Increase body flexibility and strength. All the key recommendations will be explained in the booklet, while the video will provide full guidance on how to exercise during postpartum at home, explaining key recommendations 4 and 5. Face-to-face consultation with the participants will be held during baseline and 4th week to enhance the participation. Besides, Whatsapp and Facebook page group is developed as a step to enhance the compliance of participants. All the participants will be contacted once for every two weeks, lasting for about 5 to 10 minutes for each call to monitor the participant's progress."
32935400|NCT05444179|No Intervention|Control group|The participants in the control group will be received advice on the standardised Malaysian food pyramid and be instructed to follow their usual standard care as suggested by their healthcare provider. Postpartum women in Malaysia typically attend postpartum healthcare visits with an exam on day 30 after childbirth but receive no other routine care following this appointment unless a specific health problem has been identified. Participants in the control group performed the same evaluations. They received the same incentives as those in the intervention group, but they did not receive any educational module and contact from the investigator during the 8 weeks follow-up.
32935401|NCT04738903|Active Comparator|Custom Q treatment group|For every patient, the eye with the greater myopic spherical equivalent (SE) will be assigned for the Custom-Q treatment group.
32935402|NCT04738903|Active Comparator|Wave-front optimized (WFO) group|For every patient, the other eye with the lesser myopic SE will be assigned for the WFO treatment group
32935403|NCT05443867||MPX-Assess|Contacts of MPX index cases
32935404|NCT05434897|Experimental|2% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 2% dose AK3280 cream b.i.d. for 12weeks.
32935405|NCT05434897|Experimental|4% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 4% dose AK3280 cream b.i.d. for 12weeks.
32734405|NCT05722873|Experimental|Fasting with weight maintenance|Subjects will fast one-day per week for 12 weeks and maintain body weight
32734406|NCT05722873|Placebo Comparator|Counseling|Subjects will be counseled on optimal diet and activity recommendations to maintain/achieve a normal BMI (standard of care)
32734407|NCT04490317||Acute CO poisoning|A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
32734408|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
32734409|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
32734410|NCT05123911|Experimental|Product Kit: Shampoo, Conditioner and Combining Cream (Investigational Products [IPs])|The parents/legally acceptable representative (LAR) of the participants will receive a product kit containing the 3 investigational products (shampoo, conditioner and combining cream) and will bathe the child participant with shampoo followed by conditioner and then apply combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
32734411|NCT05719987|Experimental|Biodentine Group|study group
32734412|NCT05719987|Other|MTA Group|control group
32734413|NCT05122351|Experimental|Group of Bupivacaine infiltration at the Quadratus Lumborum muscle|Patients will receive Quadratus Lumborum Block by infiltration of Bupivacaine as post operative analgesia in Open Inguinal Hernia surgery
32734414|NCT05122351|Experimental|Group of paracetamol injection|Patients will receive post operative 1 gm paracetamol injection as analgesia in Open Inguinal Hernia surgery
32734415|NCT05118919|Experimental|Active|
33257122|NCT00302731|Experimental|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
33257123|NCT00302731|Experimental|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
33257124|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
33257125|NCT05596630|Experimental|Stereotactic body radiation therapy|Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
33257126|NCT01581229|Experimental|NPPV|
33257127|NCT01581229|Active Comparator|Control|
33257128|NCT03999034|Experimental|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
32734416|NCT05118919|Placebo Comparator|Placebo|
32734417|NCT04445155|Experimental|Modified DECIDE|DECIDE has two primary components: 1) three parent training sessions designed to help patients effectively ask questions and participate in decisions about care: and 2) a 12-hour workshop and up to 4 individual coaching sessions for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation
32734418|NCT04445155|No Intervention|Usual Care|Usual Care consists of standard outpatient mental health care, including individual treatment for the adolescent (i.e., therapy, and/or medication) or family treatment for adolescents and parents, delivered in a variety of settings (e.g., clinics, schools, homes).
32734419|NCT04437511|Experimental|Donanemab|Donanemab given intravenously (IV).
32734420|NCT04437511|Placebo Comparator|Placebo|Placebo given IV.
32734421|NCT05716789|Experimental|CPR asseement|determine the success rate of CPR in Emergency room and factors predicting successful CPR
32734422|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 followup weight data also will be collected through medical record abstraction."
32734423|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
32734424|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
32743113|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
32734425|NCT05713903|Experimental|Laparoscopic right colectomy|In laparoscopic right colectomy subgroup, the patient will be placed in a lithotomy position. Entrance in the peritoneal cavity will be completed via the open Hasson method. Overall, 4 ports will be used: 10mm at the umbilicus for optical entry, 12mm in the left midclavicular line below the umbilicus as the main working port, 5mm at the McBurney point, and 5mm between the umbilicus and the xiphoid process. Dissection of the peritoneal fold, under the terminal ileum, will be performed based on the medial to lateral approach. Similar to the open approach, the ileocolic vessels, as well as the right branches of the middle colic will be ligated at their origin for cecal and proximal ascending tumors. For hepatic flexure cancers, the medial colic vessels will be ligated. The ileocolic anastomosis will be completed either intracorporeally or extracorporeally, using staples or sutures.
32734426|NCT05713903|Active Comparator|Open right colectomy|In the open right colectomy group, the operation will start with a midline incision and dissection based on the lateral to medial approach. The lateral peritoneal fold along Toldt's line will be incised and the ascending colon will be mobilized from the retroperitoneum according to the embryological dissection planes. Dissection will continue until the anterior surface of the superior mesenteric vessels at the third duodenal part. Ileocolic and right colic vessels will be ligated at their origins. For hepatic flexure tumors, the middle colic vessels will be also ligated at their origin. The ileocolic anastomosis will be performed using an automatic stapler. The anastomosis will be completed either with staples or sutures.
32734427|NCT05232331|No Intervention|Control|This group will receive non-surgical periodontal treatment, however they will not receive any modification to their diet
32734428|NCT05232331|Experimental|Intervention|This group will receive non-surgical periodontal treatment, and also as a treatment of interest, will receive the indication to consume ~ 350 mg of nitrate from vegetables, as well as an accompaniment to achieve this objective.
32734429|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
33257129|NCT03999034|Experimental|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
33257130|NCT01065025|Experimental|4SC-205|
33257131|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
32734430|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
32734431|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
32734432|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
32734433|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Saline for nerve blockades for both nerves mentioned."
33257132|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
33257133|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
33257134|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
32734434|NCT04368403|Experimental|KHK4827|
32734435|NCT04358185|Experimental|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
32935406|NCT05434897|Experimental|8% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 8% dose AK3280 cream b.i.d. for 12weeks.
32935407|NCT05434897|Active Comparator|Placebo cream|The same subject will be randomized to receive topical administration of AK3280 cream or placebo cream at S1 and S3, respectively.
33257135|NCT05559112|Experimental|Mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily for 12 weeks.
33257136|NCT05559112|Placebo Comparator|No Mushrooms|This is a behavioral control where no change in Vitamin D status is expected to occur. Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily for 12 weeks.
33257137|NCT01065103|Experimental|FFR measurement|
33257138|NCT05558098|Active Comparator|Standard of Care|Current standard of care for critically ill patients.
33257139|NCT05558098|Active Comparator|Standard of care plus dapagliflozin|Current standard of care for critically ill patients plus open-label dapagliflozin 10 mg per day for 14 days or until ICU discharge
33257140|NCT04273685|Experimental|Intervention Condition|Cognitive remediation training, cognitive behavioural therapy, social recovery therapy
33257141|NCT04273685|Active Comparator|Control Condition|Treatment as usual (TAU),non-directive counselling
33257142|NCT00302107|Active Comparator|Arm 1|Mirtazapine
33257143|NCT00302107|Placebo Comparator|Arm 2|Placebo
33257146|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
32734436|NCT04343521|Experimental|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
32734437|NCT04343521|No Intervention|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
32734438|NCT05241847|Experimental|Pediatric liver transplant recipients|"As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm.~Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center."
32734439|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
32734440|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
32734441|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
32734442|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
32734443|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
32734444|NCT04331977|Experimental|Quadhelix Group|
32734445|NCT04331977|Active Comparator|Hyrax Group|
32734446|NCT04298203|Experimental|Meal Replacement Therapy|Participants who are enrolled in the study will be administered a short-term (six weeks) meal replacement induction period. Because the trial is deigned to evaluate weight loss maintenance, participants must achieve at least 5% BMI reduction at week six of the meal replacement period in order to be randomized. Subjects will be asked to strictly follow the eating regimen, which will include a total of approximately 1,000 kcals per day of commercially-available liquid shakes (breakfast and lunch), pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables. Shakes/meals will be provided free of charge - fruits/vegetables will be purchased by the participants. Guidance will be provided regarding the use of the meal replacement shakes at school, and participants will be encouraged to engage in family meal sessions despite eating different foods.
32734447|NCT04298203|Active Comparator|Phentermine/Topiramate|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to phentermine/topiramate will start treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days, then increased to 7.5 mg/46 mg orally once daily in the morning for 14 days, then be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days, then increased to 15 mg/92 mg orally once daily in the morning for the remainder of the trial. Following the final study visit, participants will be down-titrated gradually by taking medication every other day for seven days before stopping treatment altogether.
32734448|NCT04298203|Placebo Comparator|Placebo|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to the placebo will receive inert tablets that look like the active comparator. In order to mimic the active comparator arm, subjects randomized to the placebo arm will up titrate their placebo at the beginning of the study treatment and will down titrate as in the active comparator arm. Participants will be instructed to take the medication under the supervision of a parent/guardian and pill counts of returned product will serve as a proxy of treatment compliance.
33257147|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
32734449|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
32734450|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
32734451|NCT02464189||Children with asthma|
32935408|NCT05443789|Experimental|Proton pump inhibitor education|The general practices in this arm will receive the education visits about Proton pump inhibitor.
32935409|NCT05443789|Placebo Comparator|Other education|The general practices in this arm will receive an educational visit on another topic (asthma).
33257148|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
33257149|NCT04097483|Experimental|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
32935412|NCT04738981|Experimental|UC-MSC and anti-CD25 mAb|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
33257150|NCT04097483|No Intervention|Control group|Control group with treatment as usual (TAU).
33257151|NCT04925206|Experimental|ET-01|
32734452|NCT05709067|Experimental|Probiotic Arm|
32734453|NCT05709067|Placebo Comparator|Control|
32734454|NCT05686759|Experimental|Undiluted intravenous infusion of I.V.-Hepabig inj|Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes
32734455|NCT05686759|Active Comparator|Diluted intravenous infusion of I.V.-Hepabig inj|Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour
32734456|NCT05686681|Experimental|Brief Behavioral Activation for Improving Social Connectedness|Active, 6 session Brief Behavioral Activation for Improving Social Connectedness
32734457|NCT05679895|Experimental|Experimental: CD1a-CAR T|CD1a CAR T cells transduced with a lentiviral vector to express CD1a chimeric receptor domain on T cells administered with a dose-escalation approach.
32734458|NCT05679661|Experimental|Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
32734459|NCT05679661|Experimental|Group B (immunonutrition and routine oral care, IN&RC)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and routine oral care.
32734460|NCT05679661|Experimental|Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)|Patients will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
32734461|NCT05679661|No Intervention|Group D (routine nutrition advice and routine oral care, RN&RC)|Patients will be advised to follow a standard nutrition advice and routine oral care.
33257152|NCT04908358|Sham Comparator|Sham preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
32734462|NCT05678179|Experimental|Telehealth|
33257153|NCT04908358|Sham Comparator|Sham preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
32734463|NCT05678179|Active Comparator|In Person (Face-2-Face)|
32734464|NCT04813315|Experimental|Kendall exercise|Experimental group 1 got this intervention containing Kendall exercise for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
33257154|NCT04908358|Experimental|Stimulation preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
33257155|NCT04908358|Experimental|Stimulation preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
33257156|NCT04908358|Other|cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
32734465|NCT04813315|Experimental|Gong's mobilization|Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
32734466|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
32734467|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
32734468|NCT05661409|Active Comparator|Sugammadex 2 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
32743114|NCT04959045|Experimental|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
33257157|NCT04908358|Other|cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
32743115|NCT04959045|No Intervention|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
32743116|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
32743117|NCT04945785||control|Before switch Advagraf to Envarsus
32743118|NCT04945785||case|After switch Advagraf to Envarsus
33257158|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
33257159|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
33257160|NCT04097405|Active Comparator|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
32734469|NCT05661409|Experimental|Sugammadex 1 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
32734470|NCT05661409|Experimental|Sugammadex 0.5 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
32734471|NCT05661409|Experimental|Sugammadex 0.25 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
32734472|NCT05661409|Experimental|Sugammadex 0.125 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
32734473|NCT05661409|Placebo Comparator|Placebo|The inclusion of a placebo group would allow the study team to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
32734474|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
32734475|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
32734476|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
32734477|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
32734478|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
32734479|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
32734480|NCT05044039|Experimental|Dose Escalation Stage: Duvelisib|"Duvelisib is an oral medication taken on a twice daily basis on all dosing days. Doses being explored in this study are 15 mg BID (starting dose), 25 mg BID, and 15 mg QD. In the dose escalation stage, patients will receive duvelisib from Day -2 through Day 28.~CAR T-cells will be given per standard of care."
32734481|NCT05044039|Experimental|Cohort A Dose Expansion Stage: Duvelisib|"Patients in Cohort A will receive duvelisib from Day -2 to Day 28. The dose that will be given will be determined in the dose escalation stage (the maximum tolerated dose).~CAR T-cells will be given per standard of care."
32734482|NCT05044039|Experimental|Cohort B Dose Expansion Stage: Duvelisib|"Patients in Cohort B will receive duvelisib from Day -2 to Day 180. The dose that will be given will be one dose level below the maximum tolerated dose determined in the dose escalation stage.~CAR T-cells will be given per standard of care."
33257161|NCT04097405|Placebo Comparator|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
33257162|NCT04097405|Experimental|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
33257163|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
33257164|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
32734483|NCT04489693|Active Comparator|Ambulatory Care Coordinator Team (ACCT)|Patients randomized to ACCT receive care from different doctors in clinic and in the hospital. ACCT patients who have been hospitalized twice, had 4 emergency department (ED) visits in the last year or are referred by their primary care physician are offered ACCT care coordination services (ACCT-CC) from nurses and social workers who manage their care with the larger clinical team. Patients are graduated from ACCT if the ACCT team thinks they are no longer high risk.
32734484|NCT04489693|Active Comparator|Comprehensive Care Physician (CCP)|Patients randomized to the CCP group are assigned to a Comprehensive Care Physician and are asked to see their assigned CCP for their primary care. The patients receive their care from the same CCP in the outpatient clinic and also if they were to be hospitalized.
32734485|NCT04489693|Active Comparator|Comprehensive Care, Community & Culture Program (C4P)|Patients randomized to C4P receive care from a CCP in both the hospital and the clinic as well as the following: 1) systematic screening of 17 domains of unmet social needs, 2) access to a community health worker and 3) access to community-based arts and culture programming.
32734486|NCT05641129||Main Cohort|Consecutive adult patients (≥18 years of age) presenting acutely (i.e. unplanned and non-elective presentation to hospital for urgent or emergency reasons) for symptoms of known or unknown colorectal cancer assessed by hospital surgical teams. Patients should be included regardless of operative or non-operative management, and curative or palliative intent.
32734487|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
32734488|NCT05029141|Experimental|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
32734489|NCT05029141|Placebo Comparator|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
32734490|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
32734491|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
32734492|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
32734493|NCT02465749|Other|control|Routine drug treatment
32734494|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
32734495|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
32734496|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
32734497|NCT04950127|Experimental|Participants receiving linerixibat|
32734498|NCT04950127|Experimental|Participants receiving linerixibat followed by placebo|
32734499|NCT04950127|Placebo Comparator|Participants receiving placebo|
32734500|NCT04950127|Experimental|Participants receiving placebo followed by linerixibat|
32734501|NCT05618587|Experimental|Lithium|Lithium 10mg po qd
32734502|NCT05618587|Placebo Comparator|Placebo|Placebo identically matching the lithium pills
32734503|NCT05617807|Experimental|Nanoscopic Partial Meniscectomy|This is the experimental group. patients will have a partial meniscectomy performed using the arthrex nanoscope
32734504|NCT05617807|Active Comparator|Standard Partial Meniscectomy|Patients will have a partial meniscectomy performed using standard arthroscopic equipment which is the current gold standard
32734505|NCT05599711|Experimental|Transitioning Together|Participants in this arm will receive the Transitioning Together intervention in English or Spanish either at BMC, at BMC's Supporting Parents & Resilient Kids (SPARK) Center or on BMC Zoom.
32734506|NCT05599711|Active Comparator|Usual Care|Participants in this arm will receive a referral to usual transition-related care through the BMC Developmental and Behavioral Pediatrics (DBP) clinic/the BMC Autism Program.
32734507|NCT05599009|Experimental|RIC group|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
32734508|NCT05599009|Sham Comparator|control group|Sham RIC+Standard medical treatment. Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg.
32734509|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
32734510|NCT04166851|Experimental|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
32734511|NCT04166851|Active Comparator|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
32734512|NCT04162171|Experimental|Imaging & SBRT Treatment for Ventricular Tachycardia|
32734513|NCT04692337|Experimental|Ommaya Reservoir placement|Subjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
32734514|NCT02463565||hospitalized patients|
32734515|NCT04931563|Placebo Comparator|placebo|Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
32734516|NCT04931563|Active Comparator|anifrolumab|Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
32734517|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
32734518|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
32734519|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
32734520|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
32734521|NCT04927975|Experimental|Dose A of Upadacitinib|Participants in this group will receive dose A of upadacitinib orally once daily (QD) for 52 weeks.
32734522|NCT04927975|Experimental|Dose B of Upadacitinib|Participants in this group will receive dose B of upadacitinib orally QD for 52 weeks.
32734523|NCT04927975|Experimental|Dose C of Upadacitinib|Participants in this group will receive dose C of upadacitinib orally QD for 52 weeks.
32734524|NCT04927975|Experimental|Placebo Followed by Dose A of Upadacitinib|Participants in this group will receive placebo for 24 weeks followed by dose A of upadacitinib orally QD for 28 weeks.
32734525|NCT04927975|Experimental|Placebo Followed by Dose B of Upadacitinib|Participants in this group will receive placebo for 24 weeks followed by dose B of upadacitinib orally QD for 28 weeks.
32734526|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
32734527|NCT04924933|Experimental|Patients (Epilepsy group)|Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
32734528|NCT04924933|Active Comparator|Healthy volunteers (control group)|Age-matched healthy volunteers
32734529|NCT04913467|Experimental|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups.
32734530|NCT04913467|Experimental|ColoVit capsule|2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery
32734531|NCT04913467|Placebo Comparator|Placebo capsule|2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
32734532|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)~reference procedure (video-rigid thoracoscope)"
32734533|NCT04889833|Experimental|Hypnosis Therapy Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a pre-recorded video (~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before & after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again & answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
32734534|NCT04889833|No Intervention|Usual Care Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a daily questionnaire about their pain & anxiety over the last 24 hours. On the day of surgery, before they are given any anesthesia, they will answer questions about their average anxiety & pain levels. Starting the next morning on the day following surgery and every day for the subsequent week, they will be given questionnaires about their pain & anxiety levels, medication use, satisfaction, and sleep disturbance due to pain. Their postoperative course will be otherwise completely standard of care, including a first postoperative clinic visit at 10 days after surgery, where the patients will be given these same questionnaires. Finally, patients will answer them one more time on postoperative day 49 and this will constitute a study endpoint. The whole process each day should take approximately 10 minutes.
32734535|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
32734536|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
32734537|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
32935413|NCT04738981|Active Comparator|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.
32935414|NCT04738747|Experimental|Study arm (receive a WHOOP device)|Participants randomized to the WHOOP group will be given WHOOP wrist and arm bands to wear 24/7 after an orientation on their use
32935415|NCT04738747|No Intervention|Control arm (no intervention)|The control group will not have any intervention
32935416|NCT05428969|Experimental|Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML|Standard of care azacitidine as per label; bexmarilimab 4 dose levels at once every week (Q1W) followed by once every 2 weeks (Q2W); 28-day cycle
32935417|NCT05428969|Experimental|Phase 1 - Newly diagnosed AML patients non-fit for induction therapy|Standard of care azacitidine and venetoclax as per label; bexmarilimab 4 dose levels Q1W followed by Q2W; 28-day cycle
32935418|NCT05428969|Experimental|Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML|Standard of care venetoclax and/or azacitidine as per label plus bexmarilmab
33257165|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
33257166|NCT04988152|Experimental|Part 1 Sotrovimab intravenous infusion, single dose|
33257167|NCT04988152|Placebo Comparator|Part 1 Volume-matched placebo, intravenous infusion|
33257168|NCT04988152|Experimental|Part 2 Sotrovimab intramuscular injection, single dose|
33257169|NCT04988152|Placebo Comparator|Part 2 Volume-matched placebo, intramuscular injection|
32734538|NCT04150705|Experimental|FDG PET/MRI|-Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.
32734539|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
32734540|NCT05491603|Experimental|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with onychomycosis.
32734541|NCT05491603|Experimental|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with onychomycosis.
32734542|NCT05491603|Placebo Comparator|Aqueous Gel|Topical application of aqueous gel on foot/feet affected with onychomycosis.
32734543|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
32734544|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
32734545|NCT04857229||All patient|All recruited patient will have their margins assessed with the confocal microscope with comparison of accuracy against gold standard histology.
32734546|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
32734547|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
32734548|NCT02462707|Experimental|PF-03084014|
32734549|NCT03714451|Experimental|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
32734550|NCT03714451|Active Comparator|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
32734551|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
32935419|NCT05443477|Experimental|Hericium Erinaceus Mycelium|patients with premenstrual syndrome received supplementation of Hericium Erinaceus Mycelium capsules
33257170|NCT04854148||Experimental|Each participant will perform a Smartphone movement health assessment and a series of 12 gold standard tests under the supervision of a licensed physical therapist or other research study staff
32734552|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
32734553|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
32734554|NCT04042831|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
32734555|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
32734556|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
32935420|NCT05443477|Experimental|Probiotic|patients with premenstrual syndrome received supplementation of Probiotic capsules
32935421|NCT05443477|Placebo Comparator|control|patients with premenstrual syndrome received supplementation of placebo capsules
32935422|NCT05424523||Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
32935423|NCT05443321|No Intervention|Baseline|The baseline arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year pre-intervention phase. They will not receive any intervention, but rather usual care
32935424|NCT05443321|Experimental|Intervention|The intervention arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year intervention phase. They will receive the intervention, which will include utilization of the developed health information exchange platform to transfer clinical information between transferring and accepting hospital. The intervention will not interact directly with the patient, but rather their clinical data.
32935425|NCT05443243||Varus Stems|Patients with a THA Stem implanted in Varus position
32935426|NCT05443243||Neutral stems|Patients with a THA Stem implanted in Neutral position
33257171|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
33257172|NCT00586625|Placebo Comparator|Placebo|vehicle
33257173|NCT05523700|Experimental|Interventional Arm|Use of Mobile Application
33257174|NCT05523700|No Intervention|Control Arm|Routine care and symptom management
33257175|NCT03999502|Experimental|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
33257176|NCT00636168|Active Comparator|A|
32734557|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
32734558|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
32734559|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
32734560|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
32734561|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
32734562|NCT03670615|Experimental|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
33257177|NCT00636168|Placebo Comparator|B|
32734563|NCT03670615|Other|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
33257178|NCT04098263|Active Comparator|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
33257179|NCT04098263|Active Comparator|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
33257180|NCT04098263|Active Comparator|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
33257181|NCT04098263|Other|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
33257182|NCT04978480||Stroke patients|patients with suspected severe acute stroke
33257183|NCT04102631|Experimental|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
33257184|NCT04102631|Sham Comparator|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
33257185|NCT03872908||Cohort 1|Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.
32734564|NCT03670615|Other|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
32734565|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
32734566|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
32734567|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
33076622|NCT04296604|Experimental|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33257186|NCT03872908||Cohort 2|Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.
33257187|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
33257188|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
33257189|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
33257190|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
33257191|NCT00528424|Experimental|AA4500 0.58 mg|
33257192|NCT05476510|Active Comparator|Group M-TAPA = M-TAPA Block Group|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 60 ml (30 ml for each side) of %0,25 bupivacaine.
33257193|NCT05476510|Active Comparator|Group OSTAP = OSTAP Block Group|In the supine position, the transducer is placed in the subcostal region in an oblique plane, and a 15-20 cm needle is first inserted between the rectus abdominis and the transversus abdominis muscle and advanced towards the iliac crest in the interfascial plane. The block location will be confirmed with 5 ml of saline. After the block location is confirmed, a total of 30 ml + 30 ml of 0.25% bupivacaine (total of 60 ml for both sides) will be injected bilaterally.
33257194|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
33257195|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
33257196|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
33257197|NCT03687736|Other|AbobotulinumtoxinA|Open-label
33076623|NCT04296604|Experimental|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33076624|NCT04296604|Experimental|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33257198|NCT04861324|No Intervention|Prenatal Care/Nutrition Education|Standard prenatal care with primary care physician with USDA-based federal guidelines
33257199|NCT04861324|Experimental|Fruit/veggie + postprandial physical activity|Nutrition education on increasing fruit and vegetable consumption and physical education on increasing postprandial physical activity for the duration from GDM diagnosis till delivery
33257200|NCT04857580|Experimental|CTS device|
33257201|NCT04857580|No Intervention|Control|
33257202|NCT00779675||Infliximab 5 mg/kg|
33257203|NCT05446324|Experimental|68Ga-tilmanocept PET/CT|All participants receive 68Ga-tilmanocept PET/CT imaging in adjunct to standard-of-care (SLN mapping with intraoperative ICG).
33257204|NCT03980119|Experimental|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
33257205|NCT03980119|No Intervention|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
33257206|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
33257207|NCT05465213||Retrospective cohort|Patients who have initiated treatment with dapagliflozin for HFrEF between 1st of March 2021 and 31st of October 2021 (prior to study initiation date).
33257208|NCT05465213||Prospective Cohort|Patients who have started treatment with dapagliflozin for HFrEF from 1st April 2022 onwards. At least 30 days must have elapsed (but no more than 60 days) from first prescription of dapagliflozin before a patient can be enrolled.
33257209|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
33257210|NCT04828330||Observational cohort|This is a case-crossover study nested within a cohort study.
33257211|NCT04097171|Experimental|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
33257212|NCT04097171|Experimental|Ketogenic Diet|Participants will consume a low carbohydrate diet (<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
33257213|NCT04827394|Experimental|Intervention group|In the intervention group, the infant will be placed on the thermal mattress, then wrapped.
33257214|NCT04827394|No Intervention|Control group|In the non-intervention group, the infant will be delivered onto the sterile field as per standard of care.
33257215|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
33257216|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
33076625|NCT04296604|Experimental|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33257217|NCT03998722|Experimental|Vagivital|Vagivital once Daily for 12 weeks
33257218|NCT04102943|Experimental|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
33257219|NCT04102943|Active Comparator|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
33257220|NCT05471843|Experimental|Single Arm|Participants will receive BGB-11417
33257221|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
33257222|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
33257223|NCT00300781|Experimental|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
33257224|NCT00300781|Experimental|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
33257225|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
33257226|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
33076626|NCT04296604|Experimental|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33076627|NCT04296604|Experimental|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33257227|NCT00528970|Experimental|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
32734568|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
32734569|NCT04824391|Experimental|3 mcg/0.5 ml Vaccine|Low dose vaccine
33076628|NCT04296604|Experimental|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33257228|NCT00528970|Experimental|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
33257229|NCT00528970|Placebo Comparator|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
33257230|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
33257231|NCT00759395|Placebo Comparator|Placebo|Placebo BID
33257232|NCT00293293|Active Comparator|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
33257233|NCT00293293|Experimental|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
33076629|NCT04296604|Active Comparator|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
33401371|NCT03312907|Experimental|Belimumab + Rituximab|Eligible subjects will receive Belimumab 200 mg to be administered SC on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab 1000 mg to be administered by IV infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of <= 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
33076630|NCT04283968|Experimental|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
33076631|NCT04283968|Placebo Comparator|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
33076632|NCT04267003|Experimental|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
33076633|NCT04267003|Experimental|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
33076634|NCT04267003|Sham Comparator|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
33257234|NCT05774639|Experimental|ADL-018 300 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
33257235|NCT05774639|Active Comparator|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
33257236|NCT05774639|Experimental|ADL-018 150 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
33257237|NCT05774639|Active Comparator|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
33257238|NCT05774639|Experimental|ADL-018 300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to ADL-018 300 mg in the Main Treatment period.
32734570|NCT04824391|Experimental|6 mcg/0.5 ml Vaccine|Medium dose vaccine
32734571|NCT04824391|Placebo Comparator|Placebo|Placebo
32734572|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
33257239|NCT05774639|Experimental|Xolair-300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
33257240|NCT05774639|Active Comparator|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
33257241|NCT05774639|Experimental|ADL-018 150 mg Main / ADL-018 150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to ADL-018150 mg in the main treatment period.
33257242|NCT05774639|Experimental|Xolair-150 mg Main / ADL-018150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
33257243|NCT05774639|Active Comparator|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
33257244|NCT05774626||DMPA-SC|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training). Those opting for DMPA-SC will receive training on self-injection procedures and an opportunity to practice injection procedures on a model (e.g. condom filled with salt) to demonstrate confidence and proficiency to inject herself under the supervision of a healthcare provider. Clients will then be shown how to use a calendar to determine when their next injection is due, and provided a calendar/reminder card, job aids that illustrate self-injection steps (including safe disposal of needles), and 3 doses of DMPA-SC to take home for future use.
33257245|NCT05774626||DMPA-IM|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training).
33257246|NCT05774613|Placebo Comparator|Placebo|beverage with physical and sensory characteristics to the treatment beverage without the bioactive compounds corresponding to the study.
33257247|NCT05774613|Experimental|Hibiscus-based drink|beverage in patent process with application number MX/a/2022/010704
33257248|NCT05774600|Experimental|SSW Works|SSW Works, is a virtual learning environment (VLE) for automated, comprehensive, on-demand, tailored distribution of the SSW program to private and public employers with outdoor workers. It will be delivered in both English and Spanish to managers and employees who work outdoors to reduce risk for skin cancer.
33257249|NCT05774600|Active Comparator|Minimal Information Control|Workplaces randomized to the control condition will receive a set of printed materials on occupational sun safety (1 mailing per year) as an attention control. These will include posters on personal protection and skin cancer incidence, risk assessment brochure, American Academy of Dermatology SPOT bookmark showing the ABCDEs of melanoma and skin self-examination, and a sun safety tip card from OSHA.
33257250|NCT05774587|Active Comparator|Active control|Participants will complete a 3-month cardiac rehabilitation programme supported by the onsite CR service
33401372|NCT03312907|Other|Belimumab + Standard therapy|Eligible subjects will receive open-label Belimumab 200 mg administered SC on Day 1 and then weekly (i.e., every 7 days) until Week 104. Subjects will also receive standard therapy including immunosuppressant, anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of <= 5 mg/day until Week 104.
32734573|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
32734574|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
32734575|NCT04489303|Experimental|Virtual Patient Behavioral Response Training|Caring Response mobile app with a behavioral training.
32734576|NCT04489303|Active Comparator|Educational Training|Traditional educational program.
32734577|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
33076635|NCT04267003|Sham Comparator|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
33076636|NCT04231357|Experimental|Platelet rich plasma (PRP)|3 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
33076637|NCT04231357|Active Comparator|control|needle tenotomy with lidocaine
32734578|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
32734579|NCT03297073|Experimental|hepatic surgery recovery|
32734580|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
32734581|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~In the Safety arm's first dose cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
33257251|NCT05774587|Experimental|mHealth technology assisted exercise counselling (mHealth)|Participants will complete a walking mHealth technology assisted exercise counselling intervention. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
32734582|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
33076638|NCT04224571|Experimental|rituximab and bortezomib|to test whether adding rituximab in CD20 positive patients will have improvement in remission rate. (this arm terminated in October 2020) to add bortezomib in high risk patients at Induction to improve remission rate.
33257252|NCT05774574|Experimental|CBD|1 mL hemp oil containing 60 mg/mL CBD, daily.
33257253|NCT05774574|Placebo Comparator|Placebo|1 mL hemp oil containing 0 mg/mL CBD, daily.
33257254|NCT05774561|Active Comparator|Arm A - Oropharyngeal cancer patients|In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years.
33257255|NCT05774561|Active Comparator|Arm B - Cervical cancer patients|Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years.
33076639|NCT04210492|Experimental|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
33076640|NCT04175041|Other|ADHD|Patients with ADHD.
33076641|NCT04175041|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
33076642|NCT04166500|Experimental|Intervention|
33257257|NCT05774535||Experimental|Patients who will undergo thyroidectomy
33257258|NCT05774522|Experimental|Suspicion of sleep apnea syndrome|All patients, consulting Bichat sleep center for suspected sleep apnea syndrome
33257259|NCT05774509|Experimental|Treated group|"A maximum of 12 patients will be included in the study following a dose-escalating design:~Cohort 1 (4 patients) will receive 20x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 60x10E9 particles/kg;~Cohort 2: in the absence of safety issues in Cohort 1, 8 patients will receive 40x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 120x10E9 particles/kg."
33257260|NCT05774496||Congenital toxoplasmosis women|Women older than 21 suffering from congenital toxoplasmosis, with or without children.
32734583|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
33076643|NCT04166500|No Intervention|Control|
32734584|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
32734585|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
32734586|NCT03296761||ESM-1<5ng/ml|
32734587|NCT03296761||ESM-1≥5ng/ml|
32734588|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
32734589|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
32734590|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
32734591|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
32734592|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
33076644|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
33076645|NCT04155034|Active Comparator|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
33076646|NCT04155034|Experimental|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
33076647|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
33076648|NCT00176748|Experimental|1|
33076649|NCT04118140|Experimental|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
33076650|NCT04118140|Sham Comparator|Sham SA group|Receiving sham somatic acupressure+usual care
33076651|NCT04118140|Other|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
33076652|NCT00194415|Other|1|HSV-2 antepartum testing
33076653|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
33076654|NCT04090723|Experimental|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
32769378|NCT04818437|Active Comparator|Core stability exercise|"Core stability exercises:~Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing 6-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying."
33257261|NCT05774457|Experimental|Traditional intervention|Participants will receive traditional training in voice, in a standard clinical environment.
33257262|NCT05774457|Experimental|Virtual reality intervention|Participants will receive voice training under virtual reality conditions.
33257263|NCT05774444|Placebo Comparator|Vegetable oil + Carbohydrate|The vegetable oil will be a placebo control for the Krill oil (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
33257264|NCT05774444|Experimental|Vegetable oil + Krill protein|The vegetable oil will be a placebo control for the Krill oil (4g/day). Krill protein will be our active intervention (20g)
33257265|NCT05774444|Experimental|Krill oil + Carbohydrate|The Krill oil will be the active supplement for the intervention (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
33257266|NCT05774444|Experimental|Krill oil + Krill protein|Both the Krill oil (4g/day) and the Krill protein will be the active intervention supplements (20g)
33257267|NCT05774418||vaccinated|Healthcare workers (aged ≥18 years) working at hospital sites who could provide written informed consent and who will complete the immunization program with the administration of the second dose after approximately 21 days from the first dose at the FPG
33257268|NCT05774418||unvaccinated|unvaccinated health workers
33257269|NCT05774392||Disease Cohort|
33257270|NCT05774392||Engaged Cohort|
33257271|NCT05774379|Experimental|virtual reality and fatigue education|watching the application by wearing virtual glasses for 3 days and Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
33257272|NCT05774379|Experimental|fatigue education|Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
33257273|NCT05774340|Experimental|CM326 Low Dose|CM326 220 mg/2 mL, subcutaneous at low dose
33257274|NCT05774340|Experimental|CM326 High Dose|CM326 220mg/2mL, subcutaneous at high dose
32769379|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
33257275|NCT05774340|Placebo Comparator|Placebo|Placebo 2mL, subcutaneous
32769380|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
33257276|NCT05774327|Experimental|Foam Roller+Foot Core Exercises Group|Participants in the foam roller+exercise group underwent foam roller application, which is a self-myofascial release method, 2 days a week for 6 weeks in addition to exercises. Medium-hard foam rollers were used in the applications. Foam roller application was performed on thoracolumbar fascia, iliotibial band, hamstring, gastro-soleus, peroneals and plantar fascia for 60 seconds on each region. A metronome was used to determine the rhythm during foam roller application. The rhythm of the metronome was set to 60 beats per minute (60 rpm). When determining the amount of load on the tissue, the participants were told to give the maximum amount of load possible.
33257277|NCT05774327|Experimental|Foot Core Exercises Group|The foot core exercises in the treatment program for young adults with pes planus were taught to the participants one by one. It was checked that each exercise in the program was performed correctly by the participants. An exercise brochure was prepared and given to all participants so that the participants could learn the exercises better and perform them correctly. The exercise program follow-up of the participants and gradual progression of the difficulty levels were performed by the responsible researcher. The exercises were performed two days a week for six weeks under the supervision of the researcher. On the other days, the exercise program follow-up was checked daily via an online platform.
33257278|NCT05774314|Experimental|Community Health Worker Intervention|
33257279|NCT05774314|No Intervention|No Community Health Worker Intervention|
33257280|NCT05774288|Experimental|Cera™ patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
33257281|NCT05774288|Active Comparator|Another patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
33257282|NCT05774275|Experimental|Treatment Arm|"There will be 52 patients with high-risk localized extremity and trunk soft tissue sarcoma recruited.~In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 4 cycles of Doxil or doxorubicin hydrochloride, sintilimab and radiotherapy.~In phase II: Doxil in RP2D, sintilimab and radiotherapy will be applied as before."
33257283|NCT05774262|Active Comparator|Group A - PACEMAKER|"Group A, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group A is early elective pacemaker implantation (PM) strategy in functional AVB."
33257284|NCT05774262|Active Comparator|Group B - CARDIONEUROABLATION|"Group B, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group B will undergo strategy of postponed/deferred PM implantation in functional AVB. Patients wil be implanted and monitored with ILR (in case of severe symptomatic AVB always the emergency system will be called). After cardiovascular autonomic testing (CAT), electrophysiological study (EPS), extra cardiac vagal nerve stimulation (ECVS) and cardioneuroablation will be performed. If CNA is succesful, pacemaker implantation will be cancelled. If CNA is unsuccessful, second session of CNA will be planned. In case of inefficient second attempt, patients will be referred for PM implantation. They will cross-over to PACEMAKER arm."
33257285|NCT05774249|Active Comparator|Ultrasound guided pectointercostal fascial plane block group|using 20 mL of 0.25% bupivacaine with adrenaline 1:400,000
33257286|NCT05774249|Placebo Comparator|control group|using 20 mL of normal saline 0.9%
33076655|NCT04082650|Experimental|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
33257287|NCT05774236|Experimental|Cook´s balloon|Silicone 80 mL double-balloon cervical ripening catheter with an adjustable-length malleable stylet
33257288|NCT05774236|Active Comparator|Vaginal dinoprostone|Vaginal delivery system containing 10 mg dinoprostone (Prostaglandin E2) dispersed throughout its matrix and releasing approximately 0.3 mg/hour dinoprostone over a 24-hour period.
33257289|NCT05774197|Experimental|STAMP+CBT app|"This app will allow the patient to access daily surveys designed to assess pain, stress, mood, and related symptoms.~Based on patient-reported symptoms, this app will disseminate tailored education to manage the symptoms."
33257290|NCT05774184|Active Comparator|Barzolvolimab (CDX-0159)|300 mg subcutaneous administration every 8 weeks through week 24
33257291|NCT05774184|Placebo Comparator|Placebo then barzolvolimab (CDX-0159) 300mg|Matching placebo subcutaneous administration every 8 weeks through week 16, then 300mg subcutaneous administration every 8 weeks through week 24
33257292|NCT05774171||Cancer patients with SARS-CoV-2 vaccination|Cancer patients with SARS-CoV-2 vaccination
33257293|NCT05774171||Cancer patients without SARS-CoV-2 vaccination|Cancer patients without SARS-CoV-2 vaccination
33257294|NCT05774158||Adult Congenital Heart Diseases|
33257295|NCT05774132|Active Comparator|ultrasound guided Subgluteal sciatic nerve block group|using 0.25% bupivacaine ( 0.3ml/Kg )
33257296|NCT05774132|Active Comparator|ultrasound guided Caudal block group|using 0.25% bupivacaine ( 1ml/Kg)
33257297|NCT05774119|Experimental|breakfast with coffee|250 mL of water with 6 mg/caffeine/kg
33076656|NCT04082650|Placebo Comparator|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
33076657|NCT04060966|Experimental|Cold - Pressor Task|
33257298|NCT05774119|Placebo Comparator|breakfast with water|250 mL of water
33257299|NCT05774106|Experimental|Participatory Action Research (PAR).|"Two circular spirals following Kemmis & Mctaggart PAR principles. Each spiral includes the following stages: planning, action, observation and reflection.~Four discussions groups and two reflective diaries will be carried out in total.~Note: the PAR process will be conducted only with case managers."
33076658|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
33257300|NCT05774106|No Intervention|Regular Practice|The other group will continue working as usual in their daily practice.
33257301|NCT05774093||COVID-19 Antibody Group 1|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are positive.
33257302|NCT05774093||COVID-19 Antibody Group 2|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are negative.
33257303|NCT05774028|Experimental|P-GEMD group|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
32734593|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
32734594|NCT01612351|Experimental|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
33257304|NCT05774015|Active Comparator|Interventional group (Mg oxide supplementation):|Interventional group (Mg oxide supplementation): Patients in this group will receive Mg oxide tablet 500 mg (302 mg elemental), with a dosage regimen of 1 table once daily as per the recommended range of the daily dose (from 250 to 500 mg elemental) (29, 31, 41, 45). Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
33257305|NCT05774015|Placebo Comparator|Control group (placebo tablets)|Control group (placebo tablets): Patients in this group will receive placebo tablets labeled as 500 mg (302 mg elemental), with a dosage regimen of 1 tablet once daily. Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
33257306|NCT05774002|No Intervention|standard of care control groups no psychological intervention|standard of care control groups no psychological intervention
33257307|NCT05774002|Experimental|psychological intervention ADAPT|The psychological intervention plan is based on the Aim to Decrease Anxiety and Pain Treatment (ADAPT) model.
33257308|NCT05773989|Experimental|Genotype guided P2Y12 monotherapy|Patients will be tested for the CYP2C19 genotype. Patients without a loss-of-function (LOF) allele will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
33257309|NCT05773989|Active Comparator|Standard DAPT|Patients will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
33257310|NCT05773937|Experimental|9MW2821|
33257311|NCT05773924|Other|Trilift system treatment arm|Single arm with Before & After photos, triLift treatment protocol study design.
32734595|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
32734596|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
32734597|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|"PHASE Ia: Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.~PHASE Ib/II: Patients receive liposomal irinotecan IV over 90 minutes and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity."
33257312|NCT05773911|Experimental|Test|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally with adjunct 4% chitosan gel (pH 3.48).
33257313|NCT05773911|Active Comparator|Control|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally
33257314|NCT05773898||person close to the deceased|Relatives will be invited to participate in two semi-structured research interviews in the form of a storytelling interview with an interviewer. All interviews will be conducted after obtaining the participants' non-objection. The interviews will be recorded and, once transcribed, will be analysed.
33257315|NCT05773885|Experimental|Experimental Group (EG)|The Experimental Group (EG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet home TR system (Khymeia srl, Noventa Padovana, Italy).
33257316|NCT05773885|Active Comparator|Control Group (CG)|The Control Group (CG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.
33257317|NCT05773859|Experimental|XP-DC vaccinations|Patients in this arm will receive XP-DC vaccination in addition to standard-of-care treatment.
33257318|NCT05773846|Experimental|PRF-110|PRF-110 3.6% ropivacaine, to be applied into the surgical wound
32734598|NCT03332095|Experimental|Cohort 1: DOR|Participants received a single dose of DOR at study entry (Day 0).
32734599|NCT03332095|Experimental|Cohort 2: DOR/3TC/TDF|Participants received DOR/3TC/TDF from Day 0 through Week 96.
32935427|NCT04164277|Experimental|Intervention|"The 16-week intervention includes three components:~Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face or virtual caregiver meetings: MSU research staff will lead the meetings at Head Start centers (weeks 1, 8, & 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.~Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.~Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators."
33257319|NCT05773846|Placebo Comparator|Saline .9%|Saline .9%, to b be applied into the surgical wound
32935428|NCT04164277|No Intervention|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face or virtual caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
32935429|NCT05413759|Experimental|Pharmaceutical care in multiprofessional collaboration|Medication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion).
32935430|NCT05413759|No Intervention|Control group (usual practices group)|Usual follow-up during the 12-month follow-up.
32935431|NCT04147039|Experimental|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
32935432|NCT04147039|No Intervention|Control|Receives standard care through primary child health care
32935433|NCT05443165|Experimental|Symptom self-management with an online decision support system|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be applying symptom self-management with an online decision support system, will be expected to additionally manage their symptom self-management using with this system. Participants in the intervention group will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses, and to use the decision support system for symptom self-management according to symptom severity. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
33076659|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
33076660|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
33257320|NCT05773846|Active Comparator|Ropivacaine|Ropivacaine Hydrochloride 0.5%, up to 10 mL, to be applied into the surgical site
33257321|NCT05773833|Experimental|"Go Healthy Intervention Group"|"Go Healthy program"
33257322|NCT05773833|No Intervention|Wait-list Control Group|"Monetary compensation equal in value to the Go Healthy program"
33257323|NCT05773820|Experimental|WJB001 capsules|Once a day (QD).
33257324|NCT05773807|Experimental|BIS group|In the BIS group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes to maintain the BIS value at 45-60.
33257325|NCT05773807|Placebo Comparator|OAAS/S group|In the OAAS/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes maintain the OAA/S value at 1 point.
33257326|NCT05773794|Experimental|Dietary flavonoids (soymilk, green tea, or blueberry) consumption|Each subject takes breakfast with 460 ml of soymilk, green tea, or blueberry in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administrations of soymilk, green tea, or blueberry blend.
32734600|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
32734601|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
32734602|NCT04489381|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
32734603|NCT04489381|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
32734604|NCT05241223|Sham Comparator|Control group|This group will receive an education program which will cover information regarding asthma, physical activity and sedentary behavior.
33257327|NCT05773794|Placebo Comparator|Control group|Each subject takes breakfast with 460 ml of milk or water in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administration of milk or water.
33076661|NCT04047589||Subjects|Cancer patients with curable or previously treated malignancies
33257328|NCT05773781|Active Comparator|PuraBond®|Surgery with PuraBond® application to surgical field.
33257329|NCT05773781|No Intervention|No PuraBond®|Surgery without PuraBond® application to surgical field.
33257330|NCT05773768|Experimental|New care program|The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.
33257331|NCT05773768|No Intervention|Routine clinical care|The health care provider follows current clinical practice with regards to history taking, physical examination etc.
33076662|NCT04047589||Providers|Physicians seeing patients in the outpatient clinics at the IU Simon Cancer Center
33257332|NCT05773755|Experimental|Deep Brain Stimulation (DBS) for Treatment Resistant Depression|Open label active Deep Brain Stimulation (DBS)
33257333|NCT05773742|Experimental|Low-volume irrigation|The patients will be instructed to irrigate once daily at a fixed time for 6 weeks. The patients will be instructed to use the irrigation 30 min after breakfast, capitalizing on the gastrocolic response; however, should this not fit in with the individual's lifestyle, then an alternative time of the day may be used. Preferably shortly after a large meal. The patients should fill the pump with 180 milliliters (a full pump) and irrigate with a volume of 160 milliliters of water.
33257334|NCT05773729|Experimental|BD211 Adult Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10*6 cells /kg ~ 10×10*6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211 for adults
33257335|NCT05773716|Experimental|Electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using unified standards, and electroacupuncture therapy for 6 weeks.
33257336|NCT05773716|Sham Comparator|Sham electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using the same approach as that in experimental group, and sham electroacupuncture for 6 weeks.
33257337|NCT05773690|Experimental|Movement Quality group|movement quality training based on mobility, stability and motor control exercises
33257338|NCT05773690|Experimental|Conventional resistance training group|traditional strength training exercises
32734605|NCT05241223|Experimental|Experimental group|In addition to the educational program, this group will receive weekly individual and/or group online sessions for 12 weeks of motivation-based on behavior change intervention to promote physical activity and reduce sedentary behavior, based on both self-determination theory and transtheoretical model. They will also receive a pedometer with specific strategies related to it.
32734606|NCT04489849|Experimental|Apixaban|Apixaban 2.5mg BID
32734607|NCT04489849|Active Comparator|Control|Other treatment except oral anticoagulant
32734608|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
32734609|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
32734610|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
33076663|NCT04036942|Active Comparator|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
33257339|NCT05773664|Experimental|Arm I (azeliragon, dexamethasone)|Patients receive azeliragon PO and dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
33257340|NCT05773664|Active Comparator|Arm II (dexamethasone)|Patients receive dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
33257341|NCT05773625|Other|Test group of app|All participants will first use the app one week without receiving just-in-time notifications. Their movement patterns are collected through GPS. In the second week, they will receive just-in-time notifications based on their chosen goal. Participants will act as their own control group.
33257342|NCT05773612|Other|Rock Steady Boxing classes|The Rock Steady Boxing classes are 60-90 minutes in duration twice a week and include the following 4 components: (1) active warm up (2) functional mobility exercises (3) whole body strengthening exercises and (4) non-contact boxing exercises.
33257343|NCT05773599|Experimental|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. 4 sessions of laughter yoga will be applied to the experimental group with a low sleep quality score, one day apart. Afterwards, sleep quality and life satisfaction will be evaluated with the posttest.
33257344|NCT05773599|No Intervention|kontrol|A pre-test will be applied to evaluate sleep quality and life satisfaction. The control group with a low sleep quality score will not receive any intervention. In parallel with the experimental group, sleep quality and life satisfaction will be evaluated again with the posttest.
33082297|NCT04619641|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
33257345|NCT05773573|Experimental|Experimental group|Hyrax-type rapid maxillary expander anchored on the 2nd deciduous molars (V)
33257346|NCT05773573|Active Comparator|Control group|Hyrax-type rapid maxillary expander anchored on the 1st permanent molars (6)
33257347|NCT05773560|Experimental|Patients receiving rehabilitation with virtual reality.|Single Group Assignment Patients after a major amputation would received at least 10 days of rehabilitation with the assistance of virtual reality. Before the operation, patients consent, life quality, pain score and motivation score were be evaluated. The rehabiliation with virtual reality started on the second postoperative day. The pain score would be evaluated everyday before and after the rebilitation. On the fifth and tenth day, motivation, life quality and functional index would be carried out again as the evaluation of the outcome of training.
33257348|NCT05773547||Professional|Two investigators who have performed over 200 MSOT measurements.
32734611|NCT04488367|Experimental|Early TXA|Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
32734612|NCT04488367|Other|Control|Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
33257349|NCT05773547||Trainee-personal teaching|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received a personal teaching from one professional.
33257350|NCT05773547||Trainee-video|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction from video.
33257351|NCT05773547||Trainee-instruction in paperform|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction in paperform.
33257352|NCT05773534||healthy group|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of one leg in healthy volunteers~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
33257353|NCT05773534||Patients with PAD in Fontaine stage II|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
32734613|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
32734614|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
32734615|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
32734616|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
32734617|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
32734618|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
32935434|NCT05443165|Active Comparator|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
32935435|NCT04338607||All study patients|All study patients will be in one group.
32935436|NCT05442931|Experimental|Pregabaline|Preoperative oral dose of pregabalin for control blood pressure and decrease dose of nitroglycerine consumption
32935437|NCT05442931|Experimental|Magnesium sulfate|Preoperative intravenous dose for control blood pressure and heart rate
32935438|NCT05442931|Experimental|Nitroglycrine|Measuring the total dose of nitroglycerine used, using a syringe pump
33257354|NCT05773521||SILAP patients|This cohort is composed by all pediatric patients operated on for SILAP between January 1st, 2012 and August 31, 2022.
33257355|NCT05773508||Group with video-regulation and using of the emergency kit|Use of video regulation and/or emergency kit → addressing modified by the use of one or the other
33257356|NCT05773508||Group without video-regulation and using of the emergency kit|no video-regulation and no use of the emergency kit → addressing patients according to the standard of care
33257357|NCT05773495|Experimental|Usual Care Followed by I-SITE Intervention|
33257358|NCT05773456|Experimental|Sushi and wakame salad|231 microgram of iodine per serving
33257359|NCT05773456|Active Comparator|Potassium iodide supplement|225 microgram of iodine per tablet
33257360|NCT05773443||Ambroxol: Digital biomarkers|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550))
33257361|NCT05773443||Placebo: Digital biomarkers|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
33257362|NCT05773443||Caregivers|Primary family caregivers to participants
33257363|NCT05773430|Experimental|Targeted Neurocognitive Training|BrainHQ (POSIT Science Inc.) computerized cognitive training modules will be used as in our other studies; but these will focus on the two cognitive domains in which the participants exhibited the worst performance at baseline. Twenty hours or training will administer to each participant target these two cognitive domains (10 hours each). These programs have gaming components that encourage adherence. BrainHQ cognitive training products are tested and endorsed by the scientific community. A meta-analysis of computerized cognitive training in older adults found optimal therapeutic effects occurred when training sessions last at most 60 minutes and are administered 1-3 times per week - dosage parameters already incorporated in our study. This self-administered program uses touch-screen technology with tablets which allows computer novices to engage with the training exercises.
33257364|NCT05773430|No Intervention|No-Contact Control Group|These participants will not receive any intervention.
33257365|NCT05773417||Low Flow|0.5 L/minute
32734619|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
33257366|NCT05773417||High Flow|4 L/minute
32734620|NCT04489459|Active Comparator|colistin-tigecycline|this group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12h
32734621|NCT04489459|Active Comparator|colistin-meropenem|received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
32734622|NCT03296137|Experimental|All participants|
33257367|NCT05773391|Experimental|Diarrhea group|Patients with diarrhea after taking pyrrolidine/naratinib，implement intervention (Yihuo 0.2g po bid+ Gold bifidum 2g po tid)
33257368|NCT05773391|No Intervention|No diarrhea group|Patients without diarrhea after taking pyrrolidine/naratinib
33257369|NCT05773378|Experimental|Pessary Intervention|"Participants randomized to this group will receive an Uresta Incontinence Pessary to use each time they run over a 12-week period. They will be instructed to use the pessary only while running and remove it and wash it with soap and water when the training is over.~Uresta is a reusable and removable device made of hypoallergenic medical-grade resin that is inserted into the vagina to provide mechanical support. It comes with a starter kit with 3 different sizes which work for over 80% of women. Participants will be instructed on how to test the 3 sizes to find out which one is right for them."
33257370|NCT05773378|Experimental|Tampon Intervention|Participants randomized to this group will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period. The tampon should be used only while running and removed and discarded when the training is over.
33257371|NCT05773378|No Intervention|Control Group|Participants randomized to this group won't receive any intervention and will be asked to continue their running training as usual for 12-weeks. They will also be instructed to not begin any treatment for urinary incontinence until their reassessment. After 12-weeks, they will be reassessed and will be offered the opportunity to receive a pessary if they desire so.
32734623|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
32734624|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
32734625|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
33257372|NCT05773365|Experimental|Pericapsular Nerve Group Block plus local infiltration|"Group A (study group) will receive both PENG block and local infiltration at the end of the surgery.~Spinal anaesthesia will be administered to the patient using 7.5-12.5 mg heavy 0.5% bupivacaine at L3-L5 lumbar spine using 25 G spinal needle.~If spinal anaesthesia is contraindicated or failed, patients will have general anaesthetics.~General anaesthesia will be induced with 2-3 mcg/kg fentanyl, Propofol 1-2 mg/kg titrated to effect, and muscle relaxant if required.~PENG block will be administered according to the description by injecting 20 ml of 0.25% bupivacaine below the psoas tendon.~A 20 ml of 0.25% bupivacaine will be infiltrated by the surgeons to the tissues at the end of the surgery."
33257373|NCT05773365|Active Comparator|Pericapsular Nerve Group Block|In Group B, only PENG block will be administered in this arm
33257374|NCT05773326|Experimental|Single infusion of Temsirolimus|
33257375|NCT05773313|Experimental|The Open Table Model|Subjects identified as having their health negatively impacted by Social Determinants of Health (SDOH) will meet with The Open Table members to determine their specific needs, decide on a plan for overcoming this need and following up to ensure resolution.
33257376|NCT05773287|Experimental|Targeted Health Coaching Group|
33257377|NCT05773287|Placebo Comparator|Standard Care Group|
32734626|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
32734627|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
32734628|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
32734629|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
32734630|NCT03290755||MSM co-infected HIV-HCV|
32734631|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform~Patients will undergo cryoablation as a standard procedure~cryoablation will be performed with a three-cycle freeze-thaw phase protocol~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
33257378|NCT05773274|Experimental|Arm I (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV on study. Patients also undergo CT scan and collection of blood samples on study.
33076664|NCT04036942|Active Comparator|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
33076665|NCT04012099|Experimental|BMT101|BMT101 injection (treatment)
33076666|NCT04012099|No Intervention|control|Un-treated control
33257379|NCT05773274|Active Comparator|Arm II (everolimus)|Patients receive everolimus PO on study. Patients whose cancer worsens may receive re-treatment with 177Lu-DOTATATE IV on study. Patients also undergo CT scan and collection of blood samples on study.
33076667|NCT03997201|Other|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
33076668|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
33076669|NCT03991936|Placebo Comparator|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
33076670|NCT03991936|Experimental|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
33257380|NCT05773261|Active Comparator|MobilLINK TrabecuLINK cup|"The investigational device in this study is the newly developed MobilLINK TrabecuLINK cup. It will in this study be combined with a uncemented LCU stem.~The MobilLINK TrabecuLINK cups are made from Tilastan, a Ti6A4V alloy. The MobileLINK press-fit shells are hemispheric and polar flattened. An equatorial press-fit is built into the shells for primary stability after cementless implantation. All shells have a polar hole, which is used to connect an impactor handle for implantation of the shell. This polar hole can be closed with a polar screw. The MobileLINK TrabecuLINK shells have a 3D printed trabecular surface structure with a pore size of 610 to 820 μm and a porosity of 70 %."
33257381|NCT05773261|Active Comparator|Pinnacle Gription Series 100 cup|"For the control group a Pinnacle Gription cup series 100 with a apex hole eliminator will be used together with a neutral cross-linked polyethylene (XLPE) Marathon liner (DePuy Synthes by Johnson & Johnson, Norderstedt, Germany). The Pinnacle Gription cup is a hemispherical, single-geometry, titanium press-fit cup with a solid body. The outer surface consists of a porous coating with 300 μm sintered titanium beads coated with an extra layer of irregularly shaped pure titanium pieces. In cases where no initial stability can be reached when using the Pinnacle 100 series, the Pinnacle Gription sector cup with additional bone screws will be used. The cross-linked Marathon insert is made of 1050 GUR resin, irradiated with 50 kGy, remelted and plasma sterilized.~The Pinnacle Gription cup will be implanted together with a Corail stem (DePuy Synthes)."
33257382|NCT05773235||Patients with intracerebral hemorrhage|Patients with symptomatic intracranial hemorrhage (defined as non-traumatic intracerebral hemorrhage or convexity, non-aneurysmal subarachnoid hemorrhage) enrolled in the PRO-SVD study
33257383|NCT05773235||Healthy controls|Clinically healthy persons of at least 55 years of age
33076671|NCT03991936|Experimental|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
33076672|NCT03991936|Experimental|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
33257384|NCT05773183||OBS1 [Observational Cohort 1]|20 Eugonadal Healthy men 20 Men with Testosterone Deficiency not currently on Testosterone replacement therapy
33257385|NCT05773183||IC1 [Interventional Cohort 1]|20 Men with Testosterone Deficiency progressed from OBS1 6 months post initiation of testosterone replacement therapy
33076673|NCT03991936|Experimental|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
33076674|NCT03978871|Experimental|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
33076675|NCT03978871|Active Comparator|Brain Education|Neutral education about functions of different parts of the brain
33076676|NCT03978208|Active Comparator|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
33076677|NCT03978208|Active Comparator|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
33076678|NCT03978208|Active Comparator|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
33076679|NCT03978208|Placebo Comparator|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
33076680|NCT03936829|Experimental|Interventional|Drug:Cyclophosphamide Dosage form: intravenous infusion Dosage: 500 mg/m2 of BSA Frequency: every 4 weeks Duration: 24 weeks
33076681|NCT03935893|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
33257386|NCT05773183||IC2 [Interventional Cohort 2]|20 men with prostate cancer planned for GnRH analogue therapy
33257387|NCT05773170||Pharmacological cardioversion with Refralon|"Refralon® 0.1% solution administration at a dose of 10 μg/kg of body weight intravenously (IV) for 2-3 minutes; It is allowed to divide the first Refralon® bolus into two consecutive injections: the first dose administration - 5 μg/kg of body weight, if the AF/AFL persists, administer the second dose - 5 μg/kg of body weight (total dose 10 μg/kg) in 15 minutes.~If no effect is registered (no sinus rhythm restoration), repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 20 μg/kg of body weight) in 15 minutes;~If no effect is registered, repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 30 μg/kg of body weight) in 15 minutes.~In case of AF/AFL recurrence after the sinus rhythm restoration (with no contraindications), it is possible to re-administer Refralon®, while the maximum total drug daily dose (from the first administration) should not exceed 30 μg/kg of body weight."
33257388|NCT05773157|Other|Receive Online Modules|All participants receiving the same online modules intervention.
33076682|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
33076683|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
33257389|NCT05773144|Sham Comparator|Attention control|Static stretching
33257390|NCT05773144|Experimental|75 min/wk aerobic exercise|Aerobic exercise at a dose of 75 minutes per week
33257391|NCT05773144|Experimental|150 min/wk aerobic exercise|Aerobic exercise at a dose of 150 minutes per week
33257392|NCT05773144|Experimental|225 min/wk aerobic exercise|Aerobic exercise at a dose of 225 minutes per week
33257393|NCT05773144|Experimental|300 min/wk aerobic exercise|Aerobic exercise at a dose of 300 minutes per week
33257394|NCT05773131|Experimental|VR collaborative visualization group|In this intervention system, the stimulation materials, communication interface, collaboration tasks, and immersive 360-degree scenario will be played inside a commercially available head-mounted display on the patient side, as well as these materials will be played in the smartphone on the family members' side.
33076684|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
33257395|NCT05773131|No Intervention|Standard ICU Care|Patients will be treated with standard ICU care and not receive VR stimulation.
32734632|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
32734633|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
33257396|NCT05773118|Experimental|orthokeratology lens|The subjects will wear an orthokeratology lens with 3-zone reverse geometry design. The subjects are instructed to wear the lenses for at least eight hours every night and are removed during daytime hours.
33257397|NCT05773118|Experimental|multifocal soft contact lens|The subjects will wear a multifocal soft contact lens during daytime hours and remove the lens at night
33257398|NCT05773118|Active Comparator|single vision spectacle|The subjects will wear single vision spectacle lens as control.
33257399|NCT05773105|Experimental|Cadonilimab+regorafenib|
33257400|NCT05773092|Experimental|Intervention|Oral S-1 + Oral Osimertinib
33257401|NCT05773040|Experimental|Part 1 (dose escalation)|Part 1, the dose of JV-213 participants receive will depend on when you join this study. Up to 3 dose levels of JV-213 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of JV-213. Each new group will receive a higher dose of JV-213 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of JV-213 is found.
33257402|NCT05773040|Experimental|Part 2 (dose expansion)|Participants will receive JV-213 at the recommended dose that was found in Part 1.
33257403|NCT05773027|Experimental|Sexual Assault and Alcohol Feedback and Education (SAFE)|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
33257404|NCT05773027|Active Comparator|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
33257405|NCT05773014|Active Comparator|Speculum Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a sterile speculum exam. A sterile speculum with lubricating jelly will be inserted into the patient's vagina to visualize the cervix and visually estimate cervical dilation and effacement.
32734634|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
32734635|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
33257406|NCT05773014|Active Comparator|Digital Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a digital exam. The provider will wear sterile gloves with lubricating jelly and will palpate the cervix to assess cervical dilation, effacement, and station.
33257407|NCT05773001|Other|Cohort 1|No history of SARS-CoV-2
33257408|NCT05773001|Other|Cohort 2|Documented mild SARS-CoV-2 infection
32734636|NCT04444999|Experimental|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
32734637|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
33257409|NCT05773001|Other|Cohort 3|SARS-CoV-2 pneumonia
33257410|NCT05772988|Experimental|Beta-alanine|Beta-alanine to be given for three weeks
33257411|NCT05772988|Placebo Comparator|Maltodextrin|Placebo to be given for three weeks
32743119|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
33257412|NCT05772975|Experimental|E-PRF|After the impacted mandibular third molar has been surgically removed E-PRF is placed in the dentoalveolar defect and the wound is primarily closed.
33257413|NCT05772975|Experimental|H-PRF|After the impacted mandibular third molar has been surgically removed H-PRF is placed in the dentoalveolar defect PRF made with horizontal centrifuge and the wound is primarily closed.
33257414|NCT05772975|No Intervention|CONTROL|After the impacted mandibular third molar has been surgically removed, the wound is primarily closed.
33257415|NCT05772962||Children enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children enrolled at CAC.
33257416|NCT05772962||Children not enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children that have not been enrolled at CAC. This is a control group, matched by age and gender.
33076685|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
33076686|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
33076687|NCT00194493|No Intervention|2|
33076688|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
33076689|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.~After 3 months, it become supervised arm"
33257417|NCT05772949|Experimental|Experimental group|The experimental group will use the smart hearing aid for 6 weeks.
33257418|NCT05772949|Experimental|Wait-list control group|The wait-list control group will follow existing practice (i.e. using no hearing aids or using hearing aids other than the smart hearing aids) for 6 weeks and then use the smart hearing aids for 6 weeks.
32734638|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
33257419|NCT05772936|Experimental|single arm non-randomized|all enrolled subjects will participate in the perturbation-induced step training, 1 or 6 sessions about 1-1.5 hour (30-90 trials) each session.
32734639|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
32734640|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
32734641|NCT04331119|Experimental|Duvelisib Maintenance|"Duvelisib maintenance at 25 mg PO BID after count recovery (approximately 30 days after transplant) for one year. If the patient is in a complete remission at day +100, with no evidence of disease on PET/CT, then the dosing schedule of duvelisib may be changed to 25 mg BID for 14 days, then 14 days off in 28 day cycles (at the treating physician's discretion). If the patient has residual disease, duvelisib will continue at 25 mg BID until they have a negative PET CT. PET CTs will be completed every 3 months for patients with residual disease. Duvelisib maintenance will be continued for one year post-transplant.~Starting on 06/10/2021, all new participants will be enrolled to take 25 mg BID of duvelisib on days 1-14 of a 28 day cycle."
33076690|NCT04682899|Experimental|PCT-guided antibiotic therapy (PCT group)|Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT>0.25 ng/ml, Strongly recommended.
33076691|NCT04682899|Active Comparator|Guideline-guided antibiotic therapy (guideline group)|Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
33257420|NCT05772923|Experimental|Contact x-ray brachytherapy|Contact x-ray brachytherapy will be given applied after randomisation with a maximum interval of 14 weeks after finishing the neoadjuvant (chemo)radiation. Contact x-ray brachytherapy consists of three fractions of 30Gy per fraction applied to the tumour, with a 2 week interval between each boost. Response evaluation takes place every 3 months thereafter. Patients in whom a clinical complete response is detected during follow-up are offered a watch-and-wait approach; patients in whom an incomplete response or disease progression is noted, completion or salvage TME-surgery is advised.
33257421|NCT05772923|Experimental|Extending the waiting interval, with or without local excision|The waiting interval will be extended with 6-8 more weeks after the first response evaluation, followed by a second (or third in case of ongoing response) re-assessment. Patients with a clinical complete response at the time of the second (or third) response evaluation will be offered a watch-and-wait approach without any surgical treatment. Patients with a remaining small lesion will be offered transanal local excision. Depending on the final pathological staging after local excision, patients are categorized as low-risk or high-risk, and will be offered a watch-and-wait strategy or completion TME-surgery, respectively.
33257422|NCT05772884|Experimental|Supervised Exercise Intervention|Participants will be asked to complete 3 walking sessions per week for 12 weeks. We will ask them to complete at least 1 of these sessions in-person on-site and they will be given the option to complete up to 2 walking sessions per week off-site. Exercise training on-site will be performed on an indoor walking path, 50 min/session (plus 5 min. for each warm-up and cool down).
32734642|NCT04326049|Experimental|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
32734643|NCT04326049|Active Comparator|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
32734644|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
33257423|NCT05771961|Active Comparator|Rotational Atherectomy|Patients who are scheduled to have rotational atherectomy will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the rotational atherectomy procedure.
33257424|NCT05771961|Active Comparator|Conventional Stenting|Patients who are scheduled to have conventional stenting will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the conventional stenting procedure.
33257425|NCT05771571|Placebo Comparator|Control|The meal contained mashed potatoes, homogenized with refined olive oil.
33076692|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
33076693|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
33076694|NCT03774238|Experimental|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
33076695|NCT03774238|Experimental|Healthy subject|FMD analysis Endothelial progenitors Exercise test
32734645|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
32734646|NCT03295825|Other|Biomarker|Blood sampling
33076696|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
33257426|NCT05771571|Other|Interventional|The meal contained mashed potatoes, homogenized with the functional olive oil, enhanced with orange peel extract
32734647|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
32734648|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
32734649|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
32734650|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
32734651|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
32734652|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
32734653|NCT02831335||Group 1|normal 21-35 years old participants
32734654|NCT02831335||Group 2|normal 36-50 years old participants
32734655|NCT02831335||Group 3|normal 51-65 years old participants
33076697|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
32734656|NCT02831335||Group 4|normal 66- 80 years old participants
32734657|NCT04489069|Other|Clinical, neuropsychological and MRI evaluations|
32734658|NCT02764489|Experimental|Part 1:FEIBA 85±15 U/kg at Regular Volume Then 50% Reduced Volume at 2 U/kg/min Rate or Vice Versa|Participants who were eligible were randomized to receive: 3 infusions (infusions 1, 2 and 3) of factor eight inhibitor bypassing activity (FEIBA) 85 ± 15 U/kg, reconstituted in regular volume sterile water for injection (SWFI) followed by 3 infusions (infusions 4, 5 and 6) of FEIBA 85 ± 15 U/kg reconstituted in 50% reduced volume SWFI (Sequence A) or: 3 infusions (infusions 1, 2 and 3) of FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI, followed by 3 infusions of FEIBA 85 ± 15 U/kg, reconstituted in regular volume SWFI (Sequence B). All infusions in Part 1 were given at the standard infusion rate of 2 U/kg/min.
32734659|NCT02764489|Experimental|Part 2:FEIBA 85±15U/kg 50% Reduced Volume at 4U/kg/min Rate Then at 10U/kg/min Rate|Participants who completed Part 1, received FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 4 U/kg/min for infusions 7, 8, and 9, followed by FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 10 U/kg/min for infusions 10, 11, and 12.
33257427|NCT05771519|Experimental|HIV disclosure intervention|"Participants assigned to the intervention group will likely participate in the following:~Sexual health education~Cognitive behavioral therapy strategies~Problem-solving skills building~Motivational interviewing~Developing a personalized HIV disclosure plan~Communication skills building~Role-playing disclosure strategies Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint."
33257428|NCT05771519|No Intervention|Control|Participants assigned to the control group will likely participate in educational topics related to healthy living for men living with HIV. Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.
33257429|NCT05771467||Trauma Group|Non-Trauma Eye After Open-Globe Injury
33257430|NCT05771467||Control Group|Age-, sex-matched healthy volunteers
33257431|NCT05771389|Active Comparator|Psoriatic arthritis|Patients meeting the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria
33257432|NCT05771389|Active Comparator|Axial spondyloarthritis|Patients meeting the ASAS classification criteria for axial spondyloarthritis
33257433|NCT05771389|Placebo Comparator|Healthy controls|Healthy people who do not have inflammatory conditions.
33257434|NCT05769894||Fracture neck of femur|"Trauma and Orthopaedics wards and the Emergency department will be screened for new admissions with fractured neck of femur proven by X-ray on admission, thereby identifying 20 participants according to eligibility criteria.~Suitable patients will be approached about the study and given an information sheet. Later, when they have had enough time to consider, they will be enrolled if they are happy to provide written informed consent.~Blood samples will be taken on the ward on admission, 24, 48 and 72 hours from admission and at 1 month.~Blood will be collected in 4 tubes on each occasion. (1 x2ml 3.2% sodium citrate vacutainer, 1 x 6ml lithium heparin vacutainer. 2 x 5ml SST tubes for Inflammatory markers.) A detailed description of this is laid out below."
33257435|NCT05769894||Patients > 70 years age admitted with chest infection|"The Emergency department, Acute Medical Unit and medical wards will be screened for eligible participants whose primary diagnosis is chest infection (Acute bronchitis or Pneumonia). Aiming to recruit 20 participants.~Acute Bronchitis is a lower respiratory tract infection causing inflammation in the bronchial airways It is a clinical diagnosis characterised by a cough with no evidence of pneumonia. The chest X-ray can be normal.~Pneumonia is an infection of the lung tissue in which the air sacs in the lungs become filled with microorganisms, fluid and inflammatory cells, affecting the function of the lungs. 39 Patients will be selected according to symptoms, clinical diagnosis +/- Chest X-ray findings (Pneumonia only)."
33076698|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
33257436|NCT05769894||Healthy volunteers following COVID booster|Aiming to recruit 20 participants due to have a COVID vaccine at Southampton General Hospital. We are aiming to recruit 20 healthy volunteers meeting the criteria as per study eligibility.
33257437|NCT05769894||Patient admitted with AMI within 6 weeks of inflammatory condition|Screening will include patients admitted with Type 1 or Type 2 MI or myocardial injury, as defined by the 4th Universal Definition, if they are within 6 weeks of one of the inflammatory conditions listed above.40 Suitable patients will be approached about the study and given an information sheet.
33257438|NCT05769894||AMI secondary to stent thrombosis|"Eligible patients will have been admitted with definite stent thrombosis according to the Academic Research Consortium definition. 41 Stent thrombosis is a complete occlusion of the artery secondary to thrombus inside the stent. ARC (Academic research consortium) has identified stent thrombosis detected by angiography as Definite stent thrombosis (ST). They also categorised stent thrombosis as early (up to 30 days from deployment), or late (30 days to 12 months from deployment).~Suitable patients will be approached about the study and given an information sheet."
33257439|NCT05769868|Experimental|Single Arm|1 conventional echocardiography without esmolol administration followed by 1 echocardiography with esmolol administration at Baseline and other study visits.
33257440|NCT05769296||Concussed|Diagnosis of concussion
33257441|NCT05769296||Controls|Athletes with no concussion within the preceding year
33257442|NCT05769062|Experimental|Single-digit pelvic exam|"Patients will have a pelvic floor muscle exam performed by their gynecologic radiation oncologist prior to treatment, at treatment mid-point (after 3 weeks of treatment), at the end of treatment (after 6 weeks of treatment), and at a follow-up visit 6 months after the end of treatment. Patients will also complete the Pelvic Floor Impact Questionnaire 7 (PFIQ-7), Pelvic Floor Disability Index (PFDI-20), and the EORTC QLQ-CX24 at these time points.~The patient will also undergo a standard of care MRI prior to starting treatment."
33076699|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
33076700|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
33257443|NCT05768893|Experimental|Group 1: Combined Er:YAG laser and long-pulsed Nd:YAG laser group|This group included 120 wart lesions, treated with Er:YAG laser followed by LP Nd:YAG laser after 1-2 minutes. Cryo 6 (Zimmer Medizin Systems) was used to cool the lesions before, during and after applying the Nd:YAG laser.
33257444|NCT05768893|Active Comparator|Group 2: Er:YAG laser group.|This group included 120 wart lesions, treated with Er:YAG laser only.
33076701|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
33076702|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
32734660|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
32734661|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
32734662|NCT04488991||the woman who has just HPV infection|the woman who is between 30-65 years old, who is participate this research, and has just HPV infection in cervix.
33257445|NCT05768165|Experimental|Intervention group|Cardiorespiratory and strength exercise training 2-3 sessions per week
33257446|NCT05768165|No Intervention|Care as usual|Care as usual and information of health enhancing physical activity according to general recommendations
33257447|NCT05767866|Experimental|Part 1: Dose Escalation Component|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50, 100, 150, 200 to 250 mg/day (3+3 design).
33257448|NCT05767866|Experimental|Part 2: Expansion Cohort 1|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257449|NCT05767866|Experimental|Part 2: Expansion Cohort 2|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 100mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257450|NCT05767866|Experimental|Part 2: Expansion Cohort 3|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257451|NCT05767866|Experimental|Part 3: ExTension Cohort 4|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
33076703|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
33257452|NCT05767866|Experimental|Part 3: ExTension Cohort 5|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257453|NCT05767866|Experimental|Part 3: ExTension Cohort 6|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257454|NCT05767866|Experimental|Part 3: ExTension Cohort 7|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257455|NCT05767866|Experimental|Part 3: ExTension Cohort 8|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
33257456|NCT05767866|Experimental|Part 3: ExTension Cohort 9|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mgBID and who have no active, measurable central nervous system (CNS) metastases.
33257457|NCT05767398|Experimental|Sequence 1|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
33076704|NCT03682900|Experimental|Click City Tobacco Prevention Program|Click City program used as part of school curriculum
33257458|NCT05767398|Experimental|Sequence 2|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
33257459|NCT05766995|Experimental|Manual toothbrush and water flosser with standard jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
32898297|NCT03189719|Experimental|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
33257460|NCT05766995|Experimental|Manual toothbrush and water flosser with targeted jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
33257461|NCT05766995|Active Comparator|Manual toothbrush and dental floss|Brush with a standard ADA manual toothbrush twice daily followed by dental flossing once in the evening
33257462|NCT05766943|Active Comparator|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
33257463|NCT05766943|Placebo Comparator|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
33076705|NCT03682900|No Intervention|Usual Tobacco Prevention Curriculum|Will vary by school district.
33076706|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
33257464|NCT05766280|Experimental|Treatment|Soft Skills Training Intervention via telehealth
33257465|NCT05766280|No Intervention|Control|Treatment as Usual (TAU)
33277491|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33076707|NCT03546361|Experimental|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
33076708|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
33076709|NCT03421639|Active Comparator|GnRH analog alone|control group treated with GnRH analog alone
33076710|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
33257466|NCT05765942||Implant surgery for harvesting healthy implant tissue (group HP)|the preoperative mucosal thickness will be measured clinically using a periodontal probe. A crestal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants measuring 4.5 or 5.0 mm in diameter will be placed. The implant platform will be positioned 0.5 mm below the bone level. A narrow-diameter healing abutment designed specifically for this study will be screwed in at 20 N, and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Healthy tissue samples will be harvested after 2 months of healing. Before the surgery, a guide pin will be connected to each healing abutment, attached to a circular punch 5 mm wide and with a cutting edge, which screwed apically around the abutment. Hence, a 1.5 mm thick collar of peri-implant soft tissue will be harvested Then, a new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly.
33257467|NCT05765942||Implant surgery for harvesting peri-implantitis tissue (group PP)|In each patient, at least one implant site demonstrating signs of peri-implantitis will be selected for biopsy. The site will be anesthetized and two parallel incisions, about 3mm apart, will be made with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of the implant. The biopsies, including the entire supra-crestal soft tissue portion of the diseased site, will be carefully retrieved
33257468|NCT05765903|Active Comparator|Standard of Care|"Standard of Care Interventions specified in the Transitional Care/Nurse Navigator Program protocol at the University of Maryland Medical System Charles Regional Medical Center (Policy Number: 9770-001. Care includes:~Verbal 1:1 patient education by the Transitional Nurse Navigator (TNN) and a folder with Epic (electronic medical record) printed education and other patient and disease-specific handouts.~Follow-appointment scheduling assistance, including transportation to the appointment. If the patient consents, the Community Health Worker (CHW) or TNN will schedule the appointments for their Primary Care Provider and other specialists within 1-week post-discharge when available.~Offer resources in the community to meet specific access to care challenges identified for that patient by the TNN~Offer weekly follow-up calls for one month call by TNN; other calls are completed by the TNN, or delegated to the CHW depending on the discretion of the TNN"
33257469|NCT05765903|Experimental|Enhanced Care|"Enhanced Care interventions include Standard of Care that Active Comparator arm receives plus:~Community Health Worker (CHW) Social Determinants of Health (SDoH) assessment followed by CHW finding opportunities to individualize care per the participants' needs.~Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH). All three programs involve home visits to the participant, environmental assessments, and medication reconciliation.~Additional educational training using computer tablet devices and/or teach-back components to reinforce the individualized disease and medication specific education. Computer tablets, such as an iPad, are programmed with patient education from The Patient Channel. The education will be completed by the Transitional Nurse Navigator, CHW, or the Diabetes Pharmacy Technician."
33257470|NCT05764265|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 52 weeks
33257471|NCT05764239|Experimental|RWP (Part 2)|
33257472|NCT05764239|Placebo Comparator|RWP/Part 2|
33257473|NCT05764213|No Intervention|Screening Brief Intervention & Referral to Treatment (SBIRT)|This group will receive in-person screening and referral to treatment assessment.
33257474|NCT05764213|Experimental|Listening to Women & Pregnant & Postpartum People (LTWP)|This group will receive text-message-based SBIRT with phone-based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, and other drugs including prescription medication), and domestic violence.
33257475|NCT05763615|Experimental|Patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of a tumor or cervico-facial malformation and at the first postoperative follow-up MRI if indicated for the care during a period of 12 months.
33257476|NCT05763615|Experimental|Control patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of an ENT pathology other than that of the patient group.
33257477|NCT05763004|Experimental|IOS-1002 Monotherapy|
33257478|NCT05763004|Experimental|IOS-1002 Combination Therapy with PD-1 mAb|
33257479|NCT05761119|Experimental|Early Initiated Physiotherapy Intervention|All participants will recieve the intervention (see Intervention for description) to investigate the feasibility.
33257480|NCT05761106|Experimental|Oculomotor Therapy|The procedures for oculomotor therapy will be arranged sequentially, from easiest to most difficult. It will consist of a convergence technique (Brock Cord and Barrille Cartouche) and an accommodative technique (Eccentric circles or lifesaving cards) and Eye Relaxation.
33257481|NCT05761106|Active Comparator|Therapy for Temporomandibular Disorder|"Extra-oral and intra-oral massage: The main objective is to reduce pain as well as re-establish proper muscle length and flexibility. The patient will be instructed to use diaphragmatic breathing to promote relaxation during these massage procedures.~Myofascial release of the masseter, temporalis and sternocleidomastoid muscles, release of neck soft tissues, cervical pomp, suboccipital inhibition, passive anteroposterior mobilization of the upper cervical, cervical exercises, Temporomandibular Joint exercises (mouth opening exercise with tongue on palate) , Proprioceptive exercises)."
33257482|NCT05746130|Experimental|plastic-free nutrition program|Plastic-free nutrition program will include plastic-free diet, peer mentoring, interactive education and BPA exposure feedback.
33257483|NCT05746130|Active Comparator|Interactive education group|This group will take peer mentoring, interactive education and BPA exposure feedback.
33257484|NCT05746130|Active Comparator|BPA feedback group|This group will take only BPA exposure feedback.
33257485|NCT05743335|Experimental|Investigational product|Patients randomized to this arm will be given the investigational product (JCXH-221).
33257486|NCT05743335|Placebo Comparator|Placebo|Patients randomized to this arm will be given a placebo vaccine.
33257487|NCT05743335|Active Comparator|Active Comparator|Patients randomized to this arm will be given an active FDA approved COVID-19 Vaccine (Pfizer, Moderna, etc.).
33076711|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg~Patient will be followed for 5 years post relapse."
33076712|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
33257488|NCT05742438|Active Comparator|Lidocaine group|A loading dose of 1.5mg/kg lidocaine will be infused for 10 minutes during anesthesia induction. During the surgery and post-anaesthesia care unit (PACU) stay, 1.5 mg/kg/h of lidocaine were continuously infused until the patient was transferred to the general ward.
33257489|NCT05742438|Active Comparator|Dexmedetomidine group|A loading dose of 0.3mcg/kg dexmedetomidine will be infused for 10 minutes during anesthesia induction. During the surgery and PACU stay, 0.3 mcg/kg/h of dexmedetomidine were continuously infused until the patient was transferred to the general ward.
33257490|NCT05742438|Active Comparator|Intrathecal Morphine group|150~200mcg of Intrathecal morphine will be injected at the anesthesia induction for colorectal surgery.
33257491|NCT05739513|Other|Patients with COVID-19|blood sampling for miRNA analysis
33257492|NCT05739513|Other|Patients without COVID-19|blood sampling for miRNA analysis
33257493|NCT05738837|Experimental|A-EAAA (Adolescent Enhanced Assess, Acknowledge, Act) immediately|Adolescent adaptation of EAAA sexual assault resistance education (4, 3-hr sessions) begun immediately after baseline randomization
32734663|NCT04488991||the woman who has just nabothian cyst|the woman who is between 30-65 years old, who is participate this research, and has just nabothian cyst in cervix.
33076713|NCT03335839|Experimental|Intracoronary tPA 10 mg|
33076714|NCT03335839|Experimental|Intracoronary tPA 20 mg|
33257494|NCT05738837|Active Comparator|Waitlist Control|Usual care 30-min session (brief presentation on consent/sexual assault; access to local resource pamphlets) immediately after baseline randomization; A-EAAA (4, 3-hr sessions) at 6-months post-randomization
33257495|NCT05737706|Experimental|Phase 1/1B|Dose Escalation/Evaluation
33257496|NCT05737706|Experimental|Phase 2|MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors
33257497|NCT05737147||100 adult patients of both genders scheduled for cardiac surgery|100 adult patients of both genders scheduled for cardiac surgery with CPB for either coronary artery bypass grafting (CABG), aortic valve replacement (AVR), mitral valve replacement (MVR) or CABG + AVR.
33076715|NCT03335839|Placebo Comparator|Placebo|saline
33076716|NCT03303742|Experimental|feather edge finish line marginal design|intervention
33076717|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
33257498|NCT05736796|Other|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
33257499|NCT05736796|Experimental|Lumber Extension Excersie|Lumber Extension Excersie will be done to prevent the lumber straighten.
33257500|NCT05736471||Test Group|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
33257501|NCT05732298|Experimental|active treatment|intermittent theta burst stimulation
33257502|NCT05732298|No Intervention|waiting list|patients waiting for intervention
33257503|NCT05732051|Active Comparator|Treatment Arm|The patients randomised into this arm of the trial will receive 500 mg Nicotinamide Riboside b.i.d. The duration of blinded therapy will depend on the duration of anthracycline therapy, and will for some patients last for 3 months, others for 6 months.
33257504|NCT05732051|Placebo Comparator|Placebo Control Arm|The patients randomised into this arm of the trial will receive a matching placebo b.i.d. The duration of treatment is equivalent to the description in the treatment arm.
33257505|NCT05731479|Experimental|Diathermy + exercise group|Application of diathermy and a therapeutic exercise protocol.
33257506|NCT05731479|Placebo Comparator|Diathermy placebo + exercise group|Application of the diathermy device without energy emission and a therapeutic exercise protocol.
33257507|NCT05728970||symptomatic|Self-reported symptoms by the subject and/or preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 and/or Influenza at the time of the study visit. The subject must present as symptomatic, exhibiting one or more of the following signs and symptoms: fever, cough, shortness of breath, difficulty breathing, muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of taste or smell congestion or runny nose, diarrhea, nausea or vomiting. The onset of these symptoms will be recorded and will be within the last twelve (12) days
33257508|NCT05728970||asymptomatic|The subject is neither currently exhibiting signs or symptoms of SARS-CoV-2 nor has experienced signs or symptoms within the past fourteen (14) days, has not knowingly been exposed to someone with a positive test result within the last fourteen (14) days, and remains without symptoms fourteen (14) days after testing.
33257509|NCT05727332|Experimental|Intervention|The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks.
33257510|NCT05727332|No Intervention|Time-Matched Control|The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks.
33257511|NCT05720130|Experimental|[212Pb]Pb-ADVC001|There is only a single treatment arm. Participants with metastatic Castration Resistant Prostate Cancer that have received prior Androgen Receptor Pathway Inhibitors (e.g., Abiraterone, Enzalutamide) and chemotherapy (or can have declined chemotherapy), who have not been previously treated with [177Lu]Lu-PSMA radioligand therapy. Four cohorts will receive escalating doses of 60 MBq, 90 MBq, 120MBq and 150MBq of [212Pb]Pb-ADVC001. Participants will receive a dose via intravenous injection every 6 weeks (+/- 2 weeks) for no more than 4 cycles.
33257512|NCT05720039|Experimental|Robotic NSM with da Vinci SP|Subjects randomized to this arm will undergo robotic NSM (RNSM) procedures
33257513|NCT05720039|Active Comparator|Open NSM|Subjects randomized to this arm will undergo conventional open NSM procedures
33257514|NCT05717088|Experimental|Oral sucrose + soother group (group A)|"Group A: Infants will receive oral sucrose (24%) followed by a soother 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight < 1500g, 1500-2500g, and > 2500g respectively."
33257515|NCT05717088|No Intervention|Soother alone group (group B)|Group B (control group): infants will receive a soother 2 minutes before LUS scan.
33257516|NCT05715099|Active Comparator|mild-moderate ulcerative colitis for low dose|2 low dose (25 mg \dose) per day N= 20
32734664|NCT04488991||the woman who has both nabothian cyst and HPV infection|the woman who is between 30-65 years old, who is participate this research, and has both nabothian cyst in cervix.
32734665|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
33257517|NCT05715099|Active Comparator|mild-moderate ulcerative colitis for high dose|2 high dose (50 mg \dose) per day N=20
32734666|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
32734667|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
32734668|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
32734669|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
32734670|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
32734671|NCT04441645|Experimental|the acupoint-on-head group|pressing acupoints only on head
32734672|NCT04441645|Experimental|the acupoint-on-body group|pressing acupoints only on body
32734673|NCT04441645|Experimental|the acupoint-on-head-and-body group|pressing acupoints on head and body
32734674|NCT04441645|No Intervention|the control group|routine care
32734675|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
32734676|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
32734677|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
33257518|NCT05715099|Active Comparator|healthy subjects for low dose|2 low dose (25 mg \dose) per day N= 10
33257519|NCT05715099|Active Comparator|healthy subjects for high dose|2 high dose (50 mg \dose) per day N=10
33257520|NCT05715099|Placebo Comparator|mild-moderate ulcerative colitis for placebo|2 dose placebo per day N=20
33257521|NCT05715099|Placebo Comparator|healthy subjects for placebo|2 dose placebo per day N=10
33257522|NCT05712278|Experimental|SAR445419|Treatment consists of chemotherapy with fludarabine 30mg/m2/day and cytarabine 2g/m2/day administered for 5 days (Day -6 to Day -2), followed by 6 doses of SAR445419 given thrice weekly for 2 weeks beginning Day 1.
33257523|NCT05711979|Experimental|AARC Intervention|Participants in the AARC Intervention Arm will receive a 10 week intervention.
33257524|NCT05710224|Experimental|V181|Participants will receive a single 0.5 mL subcutaneous (SC) injection of V181 on Day 1.
33257525|NCT05710224|Experimental|Butantan-DV|Participants will receive a single 0.5 mL SC injection of Butantan-DV on Day 1.
33257526|NCT05709977|Experimental|Acupuncture arm|Fixed set of acupuncture points
32734678|NCT02001623|Experimental|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
32734679|NCT01910051||Generally healthy|Generally healthy
32734680|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
32734681|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
32734682|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer.~."
32734683|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
32734684|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
32734685|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
32734686|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
32734687|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
33257527|NCT05709977|Active Comparator|Control (Carelastin®) arm|Carelastin® (1 mg/ml) azelastine nasal spray, 1 spray puff (0.14 ml) per nostril twice daily (totally 0.56 ml per day)
33257528|NCT05708716|Experimental|Diet and Cognitive Training|The arm will follow a modified ketogenic diet using an exogenous ketogenic formula (KetoCal) and use the online cognitive training program Lumosity at time of enrollment on the study.
33257529|NCT05708716|Active Comparator|WaitList Control|The arm will only use the online cognitive training program Lumosity 3 months after enrollment in the study.
33257530|NCT05708586|Active Comparator|Control|Standard comfort given
33257531|NCT05708586|Experimental|Virtual Reality (VR)|
33257532|NCT05707195|Experimental|Experimental:children hospitalized in pediatric intensive care unit|All parents of children aged 0 to 18 who have been hospitalized in the pediatric intensive care unit over a period of 24 months will be offered the study.
33257533|NCT05696782|Experimental|Quick Start Durvalumab|Standard of care test and procedures for cancer treatments along with Durvalumab treatment at physician's discretion
32734688|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
33076718|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
33076719|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
33076720|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
33076721|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
33076722|NCT00166010|Experimental|Nesiritide|
33076723|NCT03183388|Experimental|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
33076724|NCT03104491|Experimental|Inotuzumab Ozogamicin|"Phase I:~A maximum of 12 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for ALL participants is 0.1-0.6mg/m^2 and for NHL participants 0.2-0.8mg/m^2~Dosing in the NHL cohort will start at Dose Level 0 (0.3mg/m^2) or one dose level below the ALL cohort maximum tolerated dose (MTD), whichever is higher.~Phase II:~ALL and NHL participants: Will be enrolled until all Phase I ALL/NHL participants (respectively) have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. Repeat cycles every 28 days for up to 12 cycles"
33076725|NCT04685824|Active Comparator|Biofeedback Training|"Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks."
33257534|NCT05695027|Experimental|Nicotinamide and Pyruvate|The N&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).
33257535|NCT05695027|Placebo Comparator|Placebo|The placebo group will receive placebo for 87 weeks (20 months).
33257536|NCT05692999|Experimental|Pulse Arm|
33257537|NCT05692999|Active Comparator|Control Arm|
33257538|NCT05691166|Experimental|Progressive resistance training|Twice weekly high-intensity progressive resistance training for 12 months
33257539|NCT05691166|Active Comparator|Control|Referred to general practitioner
33257540|NCT05690386|Experimental|Lonapegsomatropin at 0.24 mg hGH/kg/week|Lonapegsomatropin at 0.24 mg hGH/kg/week administered once-weekly by subcutaneous injection
32734689|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
32734690|NCT03372863||Cardiac surgery patients|
32734691|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
32734692|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
33257541|NCT05690386|Experimental|Lonapegsomatropin at 0.30 mg hGH/kg/week|Lonapegsomatropin at 0.30 mg hGH/kg/week administered once-weekly by subcutaneous injection
33257542|NCT05690386|Experimental|Lonapegsomatropin at 0.36 mg hGH/kg/week|Lonapegsomatropin at 0.36 mg hGH/kg/week administered once-weekly by subcutaneous injection
32734693|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
32734694|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
32734695|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
32734696|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
32734697|NCT00985205|Experimental|Enteral Glutamine|0.5 g/kg/day mixed in water and given via nasogastric or feeding tube as boluses q 4 hrs or TID or QID if po
32734698|NCT00985205|Placebo Comparator|Placebo|Mixed in with water and given via nasogastric or feeding tube as boluses q 4hrs or TID or QID if po
32734699|NCT04526873|No Intervention|Control|No intervention control group
33257543|NCT05690386|Active Comparator|Somatropin at 0.05 mg/kg/day|Somatropin at 0.05 mg/kg/day administered once-daily by subcutaneous injection
33257544|NCT05687903|Experimental|TAK-861 Dose 1|Participants will receive TAK-861 dose 1, orally, from Day 1 up to Weeks 8 or 12.
33257545|NCT05687903|Experimental|TAK-861 Dose 2|Participants will receive TAK-861 dose 2, orally, from Day 1 up to Weeks 8 or 12.
33076726|NCT04685824|Experimental|Biofeedback Training + Immersive VR|"Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks~Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total)."
33257546|NCT05687903|Experimental|TAK-861 Dose 3|Participants will receive TAK-861 dose 3, orally, from Day 1 up to Weeks 8 or 12.
33257547|NCT05687903|Experimental|TAK-861 Dose 4|Participants will receive TAK-861 dose 4, orally, from Day 1 up to Weeks 8 or 12.
33076727|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
32769381|NCT04813757|Experimental|intervention group|Participants in the intervention group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy. The exercise program will include 2 scapular and rotator cuff strengthening exercises emphasizing scapular upward rotation and posterior tilt and one additional flexibility exercise. These exercise will be repeated at home on the days in between the therapy sessions.
33076728|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
33076729|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
33076730|NCT04685395|Active Comparator|Benzydamine hydrochloride|"group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dose :5 ml every time dosage form ; mouth wash"
33257548|NCT05687903|Placebo Comparator|Placebo|Participants will receive TAK-861 matching placebo tablets, orally, from Day 1 up to Weeks 8 or 12.
33257549|NCT05687396|Experimental|Virtual reality|Virtual reality while cycling with ergometer in addition to conventional pulmonary rehabilitation. virtual reality designed as cylcling in the forest.
33257550|NCT05687396|Experimental|Conventional pulmonary rehabilitation|Deep diafragmatic breathing exercise, chest expansion exercies, pursed lip exhalation, coughing and huffing, upper limp exercies with deep breathing exercise, standing up-right position, cycling with ergometer.
33076731|NCT04685395|Active Comparator|Rebamipide|"group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dosage form ; mouth wash"
33257551|NCT05685771|Other|Auditory stimulation first|This study group receives auditory stimulation in the first intervention week (second week of trial) and sham stimulation in the second intervention week (fourth week of trial).
33257552|NCT05685771|Other|Sham stimulation first|This study group receives sham stimulation in the first intervention week (second week of trial) and auditory stimulation in the second intervention week (fourth week of trial).
33076732|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
33076733|NCT00537784|Placebo Comparator|2|No injection
33076734|NCT00166088|Experimental|Mediterranean Diet Arm|
33257553|NCT05681637|Experimental|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
33257554|NCT05679024|Active Comparator|Apixaban 2.5 mg twice daily and standard of care|Apixaban 2.5 mg twice daily (low dose) and all other standard of care
33257555|NCT05679024|No Intervention|Standard of care and no anticoagulation|All other Standard of care and no anticoagulation
33257556|NCT05677139||Prospective Cohort|Participants with severe uncontrolled asthma will receive tezepelumab. Relevant demographics, baseline clinical data, and asthma control questionnaire-6 (ACQ-6) will be retrospectively collected. All patient reported outcomes (PROs) will be prospectively collected. Other outcomes of interest (tezepelumab patterns of utilization, lung function, asthma exacerbations, medication use, and healthcare resource utilization [HRU]) will be collected at baseline (retrospective collection for 52-week pre-index period during enrolment) and prospectively collected during enrolment for participants who enroll into the study before the first dose of tezepelumab, and for a period of up to 52 weeks (at Weeks 4, 12, 24, and 52) after the index date. The index date is defined as the date when participants receive the first dose of tezepelumab.
33257557|NCT05675449|Experimental|Dose Escalation|Elranatamab plus Carfilzomib and Dexamethasone
33257558|NCT05671848|Experimental|experimental arm|Patient with ET and Receiving deep brain stimulation treatment with implantation of the PERCEPT™ device
33257559|NCT05671159|Experimental|bacterial infection|
33257560|NCT05671159|Other|viral infection|
33257561|NCT05669027|Experimental|Experimental Condition|Mobile Neurofeedback intervention arm
33257562|NCT05669027|Placebo Comparator|Control Condition|Sham-control arm
33257563|NCT05667922||Remission|
33257564|NCT05667922||Non-remission|
33257565|NCT05667909||Remission|
33257566|NCT05667909||Non-remission|
33257567|NCT05667896||Remission|
33257568|NCT05667896||Non-remission|
33257569|NCT05667883||Remission|
33257570|NCT05667883||Non-remission|
33257571|NCT05667805|Active Comparator|Liberal substitution of human prothrombin complex and/or platelet concentrates|If INR < 1,5: 10 I.E. human prothrombin complex/kg bodyweigt/0,5 INR AND/OR If platelets < 50 G/l: ((50 G/l - measured thrombocyte concentration G/l) x total blood volume) platelet concentrate
33257572|NCT05667805|Experimental|Restrictive substitution of human prothrombin complex and/or thrombocytes|No substitution of blood products described in the Active Comparator group.
32898298|NCT03189719|Placebo Comparator|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
32898299|NCT03126630|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
33257573|NCT05667246|Active Comparator|Caffeinated Group|Caffeinated coffee, 1 cup, 8 oz water setting, 95 mg caffeine
33076735|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
33076736|NCT00166088|No Intervention|Control Arm|
33257574|NCT05667246|Placebo Comparator|Decaffeinated Group|Decaffeinated coffee, 1 cup, 8 oz water setting
33257575|NCT05660746|Active Comparator|Conventional dosing|Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.
33076737|NCT05336812|Experimental|Arm I (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 13 and day 1 of cycles 14-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
33257576|NCT05660746|Experimental|Precision dosing|Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
33257577|NCT05660460|Other|Socially vulnerable individuals in contact with a mobile clinic|After obtaining informed consent, a project nurse in the mobile clinic reviews the online-questionnaire with the participant and performs a lung function examination requiring the individual to blow into a plastic tube. If the participant is identified as having obstructive reduction of lung function, they are offered a referral and patient support to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease. In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality).
33257578|NCT05660174||Patient with a digestive surgery procedure|
33076738|NCT05336812|Experimental|Arm II (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive venetoclax PO QD on days 1-28 days of cycles 13-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
33257579|NCT05660174||Patient with a vascular surgery procedure|
33076739|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
33257580|NCT05659381|Experimental|HIPEC|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cisplatin 100 mg/m2 IP over 90 minutes at 42 degrees C
33257581|NCT05659381|Active Comparator|No HIPEC|No treatment
33257582|NCT05657288|Experimental|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
33257583|NCT05656053||Patients undergoing glioma removal surgery|Patients will undergo magnetic resonance examination before surgery, followed by rapid ultrasound acquisition of the tumor section by the surgeon during surgery and the resection of the tumor tissue for cryopreservation. After surgery, the tissue sample will be used for genetic sequencing and mass spectrometry to obtain molecular information. The data involved in the overall surgical procedure will be saved and used in this observational study.
33257584|NCT05651542|Experimental|Comprehensive Self-Management|The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.
33257585|NCT05651542|Other|Usual care group|The control group will receive standard care without the comprehensive self-management intervention.
33257588|NCT05648110|Experimental|Sentinel Safety Cohort - Subcohort 1a Gluteal - AZD5156|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33076740|NCT05425147||Post-induction hypotension group|Post-induction hypotension is defined as systolic blood pressure (SBP) <90 mmHg, mean arterial pressure (MAP) <65 mmHg, or a decrease of more than 30% of baseline within 20 minutes after induction or before incision.
33076741|NCT05425147||Stable blood pressure group|All enrolled elderly patients will undergo surgery under general anesthesia after preoperative monitoring. Those patients whose blood pressure is relatively stable after induction and does not meet the PIH criteria is classified as the stable blood pressure group.
33076742|NCT05425069||Dexmedetomidine with minimal concentration of propofol (D-P)|"Intravenous infusion with Dexmedetomidine for 10 minutes at 0.8 ug/kg/hr and so on, then induction with Propofol TCI Target 2.0 ug/ml (Schnider model) and Remifentanil TCI 4.5 ng/ml. 3 minutes after LOC Propofol will be reduced to 0.5 ug/ml. intubate using Remifentanil 4.5 ng/ml and Rocuronio 0.5 mg/kg.~Anesthesia will be dynamically adjusted to maintain SEF95 remains at minimum values at 10 Hz for the rest of the surgery. Sedline will be maintained for up to 60 min post-op. in the recovery room. Data will be retrieved via pen drive stick from SEdline"
33257589|NCT05648110|Placebo Comparator|Sentinel Safety Cohort - Subcohort 1a Gluteal - Placebo|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257590|NCT05648110|Experimental|Sentinel Safety Cohort - Subcohort 1b Thigh - AZD5156|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257591|NCT05648110|Placebo Comparator|Sentinel Safety Cohort - Subcohort 1b Thigh - Placebo|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257592|NCT05648110|Experimental|Sentinel Safety Cohort - Subcohort 2a Gluteal- AZD5156|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257593|NCT05648110|Placebo Comparator|Sentinel Safety Cohort - Subcohort 2a Gluteal - Placebo|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257594|NCT05648110|Experimental|Sentinel Safety Cohort - Subcohort 2b Thigh - AZD5156|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257595|NCT05648110|Placebo Comparator|Sentinel Safety Cohort - Subcohort 2b Thigh - Placebo|The Sentinel Safety Cohort will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
33257596|NCT05648110|Experimental|Main Cohort - AZD3152|Main Cohort will enroll approximately 3200 participants, 12 years of age or older with a minimum weight of 40 kg with conditions causing immune impairment, who are less likely to mount an adequate protective immune response after vaccination and thus are at high risk of developing severe COVID-19. Participants in the Main Cohort will be randomized 1:1 to receive AZD3152 (plus an administration of placebo to preserve the blind) or AZD7442 administered IM in the thigh on Day 1 and will receive a second dose of their original randomized study intervention 6 months after Visit 1.
33257597|NCT05648110|Active Comparator|Main Cohort - AZD7442 (EVUSHELD™)|Main Cohort will enroll approximately 3200 participants, 12 years of age or older with a minimum weight of 40 kg with conditions causing immune impairment, who are less likely to mount an adequate protective immune response after vaccination and thus are at high risk of developing severe COVID-19. Participants in the Main Cohort will be randomized 1:1 to receive AZD3152 (plus an administration of placebo to preserve the blind) or AZD7442 administered IM in the thigh on Day 1 and will receive a second dose of their original randomized study intervention 6 months after Visit 1.
33257598|NCT05644496|Experimental|Intervention|In addition to the standard-of-care arm description, single administration of Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release in the surgical site before complete wound closure.
33257599|NCT05644496|No Intervention|Standard-of-care|Usual standard of care procedure for knee replacement and pain management before, during and immediately following surgery.
33257600|NCT05643885||apixaban|patients treated with apixaban
33076743|NCT05425069||Propofol TCI fine titrated (P)|"Basal frontal EEG with eyes opened and closed (90 sec each) The previous bolus of Lidocaine in a 20 mg intravenous dose, TCI Propofol Induction (Schnider Model) is initiated starting 8 mg/kg/h until clinical unconsciousness (LOC loss of response to the call and to moderate stimulus in the shoulder) and then it is passed to TCI to keep the Ce calculated to the LOC.~After LOC, we proceed to intubate using Remifentanil 4.5 ng/ml and Rocuronio. Anesthesia will be dynamically adjusted to maintain Sedline SEF 95 value of minimum at 10Hz. Sedline will be maintained for up to 60 min post LOC in the recovery room.~Data will be retrieved via pen drive stick."
33076744|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
33076745|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
33076746|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
33257601|NCT05643885||Low molecular weight heparin (LMWH)|patients treated with low molecular weight heparin
33257602|NCT05642468|Experimental|10 mg (Arm 1)|10mg tablet A3907 administered orally once daily for 12 weeks.
33257603|NCT05642468|Experimental|30 mg (Arm 2)|30mg (3x10 mg tablets) A3907 administered orally once daily for 12 weeks.
33257604|NCT05639634|Experimental|Chlorella Supplementation and Exercise|Supplementation with Chlorella (1.5 g/d) with a physical exercise program for 12 weeks
33257605|NCT05639634|Experimental|Chlorella Supplementation|Supplementation with Chlorella (1.5 g/d) only for 12 weeks. No exercise programme
33076747|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
33076748|NCT05424913|Other|Subjects with Dunnigan's Lipodystrophy|
33076749|NCT05424913|Other|Non-lipodystrophic insulin-resistant subjects|
33076750|NCT05424913|Other|Insulin-sensitive non-lipodystrophic subjects|
33076751|NCT05424718|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile application for the first three months of the trial.
33076752|NCT05424718|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile for the first 3 months of the study and will receive access to the MyPEEPS Mobile App at the 3 month follow-up visit.
33257606|NCT05639634|Placebo Comparator|Placebo Supplementation and Exercise|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) with a physical exercise program for 12 weeks
33257607|NCT05639634|Placebo Comparator|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) only for 12 weeks. No exercise programme
33257608|NCT05637801|Experimental|Active|Treatment Group: Subjects are treated with the Active Sensory Stimulation System at home for 60 minutes daily for up to12 months.
33257609|NCT05637801|Sham Comparator|Control|Control Group: Subjects are treated with a Sham Sensory Stimulation System at home for 60 minutes daily for up to 12 months.
33257610|NCT05631938|Experimental|Group 1: Normal Renal Function|Participants with normal renal function receive a 3 mg single dose of cytisinicline.
33257611|NCT05631938|Experimental|Group 2: Mild Renal Impairment|Participants with mild renal impairment receive a 3 mg single dose of cytisinicline.
33257612|NCT05631938|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate renal impairment receive a 3 mg single dose of cytisinicline.
33257613|NCT05631938|Experimental|Group 4: Severe Renal Impairment|Participants with severe renal impairment receive a 3 mg single dose of cytisinicline.
33257614|NCT05631938|Experimental|Group 5: ESRD Participants Undergoing Dialysis|Participants with ESRD undergoing dialysis receive a 3 mg single dose of cytisinicline on 2 occasions: after and prior to a dialysis session.
33257615|NCT05630170|Experimental|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.The AI-ECG model will be used on all participants undergoing a 12-lead ECG.
33257616|NCT05627674|Active Comparator|Usual Care|Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.
33257617|NCT05627674|Experimental|RiskProfile-Clin|RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.
33257618|NCT05627674|Experimental|RiskProfile-Gen|RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.
33257619|NCT05626049|Active Comparator|Usual Medical Care|This group will consist of patients who contact clinics that have been randomized to usual medical care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
33257620|NCT05626049|Experimental|Primary Spine Provider Model|This group will consist of patients who contact clinics that have been randomized to the primary spine provider (PSP) model (intervention clinics). Patients seeking care at intervention clinics will be given the option of seeing either a DC or a PT as their first contact clinician for an initial trial of PSP care.
33257621|NCT05621317|Experimental|PVX108 50 nmol in adolescents|Twelve 4-weekly intradermal (ID) doses of PVX108 at 50 nmol in adolescents (Cohort 1)
33257622|NCT05621317|Placebo Comparator|Placebo in adolescents|Twelve 4-weekly ID doses of placebo matching PVX108 in adolescents (Cohort 1)
33076753|NCT05311969|Experimental|groups/cohort|participants will perform the various neuropsychological tests provided for in the protocol
33076754|NCT05311930|Experimental|2.5mg/d|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hetrabopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
33257623|NCT05621317|Experimental|PVX108 5 nmol in children|Twelve 4-weekly ID doses of PVX108 at 5 nmol in children (Cohort 2)
33257624|NCT05621317|Experimental|PVX108 50 nmol in children|Twelve 4-weekly ID doses of PVX108 at 50 nmol in children (Cohort 2)
33257625|NCT05621317|Placebo Comparator|Placebo in children|Twelve 4-weekly ID doses of placebo matching PVX-108 in children (Cohort 2)
33257626|NCT05621148||Full population|LLC patients with prior treatment with BTKi - Underlying tenet: these patients have been treated with a BTKi in at least one of two or more prior lines of therapy and progressed - FULL POPULATION
33257627|NCT05621148||Narrow population|LLC Patients who progressed BTKi and failed VEN (defined as patients who discontinued VEN due to disease progression, intolerability, or failure to achieve an objective response within 3 months of initiating therapy; small patient population) - Tenet: these patients have been treated with both BTKi and VEN in any one of the prior two lines of therapy and progressed
32734700|NCT04526873|Experimental|Postcard: non-telehealth, photo|This group receives a postcard that does not include telehealth information and features a stock photo
32734701|NCT04526873|Experimental|Postcard: non-telehealth, salience/humorous cartoon|This group receives a postcard that does not include telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
33076755|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
33076756|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
33076757|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
33076758|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
33257628|NCT05620407|Experimental|Arm 1: Deucravacitinib|
33257629|NCT05620407|Placebo Comparator|Arm 2: Placebo|
33076759|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
33076760|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
33257630|NCT05619003|Experimental|Single-arm|The Clinical investigation is an open-labelled, non-comparative, single-arm, prospective, multi-center obser-vational investigation
33257631|NCT05616871||Upadacitinib Alone or In Combination with Methotrexate|Participants will receive upadacitinib alone or in combination with methotrexate as prescribed by their physician according to local label in real- world practice.
33257632|NCT05616780|Other|Obtaining lung volume measurements in patients with airflow obstruction|"All patients involved in this study will be attending a pulmonary function test as part of their routine patient treatment pathway, requested by their consultant. Potential participants will be sent a patient information sheet prior to their lung function test.~The pulmonary function test begins routinely, with the pre-test questions. Spirometry will then be performed. If the patient's results are variable and the repeatability criteria are not met, the patient will not be asked to take part in the study, and no additional tests (not requested by the consultant routinely) will be carried out. If the patient has normal or obstructive results (FEV1/FVC <70%) the patient will sign the consent form and both lung volume tests will be conducted. They must be able to follow the instructions for both nitrogen washout and body plethysmography, and the results must also meet the acceptability and repeatability criteria."
33257633|NCT05613608|Active Comparator|Full-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
33257634|NCT05613608|Active Comparator|Broad-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing 0.0% THC.
33076761|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
33257635|NCT05613608|Placebo Comparator|Placebo|210mg/day of hemp seed oil with no cannabinoids present.
33257638|NCT05607498|Experimental|EMB-07|Patients will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
33257639|NCT05603416|Active Comparator|Benegut|Dietary Supplement: Perilla frutescens extract
33257640|NCT05603416|Placebo Comparator|Placebo|Dietary Supplement: Placebo, no active ingredient
33257641|NCT05603026|Active Comparator|TAVR using the self-expanding valve Evolut FX|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Medtronic Evolut FX supra-annular self-expanding valve
33257642|NCT05603026|Active Comparator|TAVR using the balloon-expandable valve Sapien 3 Ultra|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Edwards Sapien 3 Ultra valve
33076762|NCT00177177|Experimental|1|L Carnosine
33076763|NCT00177177|Placebo Comparator|2|Placebo
33257643|NCT05602883|Experimental|Experimental group|Experimental: Experimental group Pregnant women in this group will listen to a music of their choice for 30 minutes before going to bed at night.
33257644|NCT05602883|No Intervention|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
33257645|NCT05601973|Experimental|Treatment Arm|Amivantamab (fixed dose of 1750 mg (or 2100 mg, i.v. every 3 weeks, until disease progression, or intolerable toxicity) PLUS Lazertinib (240 mg, orally, once daily, until disease progression or intolerable toxicities) PLUS Bevacizumab (Zirabev® is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity).
33257646|NCT05601908|Experimental|VR Relaxation|a 5-week course of 20-min sessions of VR relaxation
33257647|NCT05598320|Experimental|TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of TransCon CNP for 52 weeks
33076764|NCT05311774|Experimental|•tramadol and duloxetine|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive duloxetine 30mg daily fixed dose in combination with tramadol. Investigators will follow up the patients for 3 months
33257648|NCT05598320|Placebo Comparator|Placebo for TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for TransCon CNP for 52 weeks
33257649|NCT05597020|Experimental|50 mg daridorexant|Daridorexant will be taken orally, once daily in the evening within approximately 30 min before going to bed.
33257650|NCT05597020|Placebo Comparator|Placebo|Matching placebo will be taken orally, once daily in the evening within approximately 30 min before going to bed.
33257653|NCT05593029|Experimental|SEP-363856 & ADT (Antidepressant Therapy)|
33257654|NCT05593029|Placebo Comparator|Placebo & ADT (Antidepressant Therapy)|
33257655|NCT05592613|Experimental|PrEP Participants|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
33257656|NCT05592613|Experimental|ART Participants|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
33076765|NCT05311774|Active Comparator|tramadol and placebo|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive placebo drug once daily in combination with tramadol. Investigators will follow up the patients for 3 months
33076766|NCT05307133|Other|Pre menopausal women undergoing sleeve gastreexctomy for morbid obesity|After the indication for sleeve gastrectomy has been retained by the multidisciplinary committee eligible patients will be contacted and offered to participate in the BARIAXYTOCINE study. At the time of the first outpatient visit (V1), body densitometry and blood sample for estradiol, leptin and oxytocin will be done. Patients will undergo surgery within one month and 6 months after surgery they will undergo the same work-up (V2).
33076767|NCT05302102|Experimental|Paretic-limb-only plyometric training group|Participants in this group performed plyometric movements/exercises unilaterally using the paretic leg.
33076768|NCT05302102|Experimental|Doule-limb plyometric training|Participants in this group performed plyometric movements/exercises bilaterally through the paretic and non-paretic legs.
33257657|NCT05592600|Experimental|Neurofeedback|Subjects will undergo one session where they will visualize real-time feedback of signals recorded from their brains.
33257658|NCT05591352|Placebo Comparator|Placebo sachet|consume 1 sachet per day
33257659|NCT05591352|Experimental|Chenopodium formosanum extracts sachet|consume 1 sachet per day
33257660|NCT05590039|Experimental|Treatment for MyEllevate Procedure|The subjects were treated with the MyEllevate procedure.
33076769|NCT05302102|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program.
33076770|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
33076771|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
32898300|NCT03126630|Experimental|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.
33076772|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
33076773|NCT05296213|Experimental|silver diamine fluoride-potassium iodide SDF-KI (riva star)|SDF-KI was applied once as a professional application over the early enamel lesions in cervical third of the buccal surface of molar teeth.
33076774|NCT05296213|Experimental|casein phosphopeptide amorphous calcium phosphate CPP-ACP(tooth mousse)|CPP-ACP cream was applied twice daily according to manufacturer's instructions over the early enamel lesions in cervical third of the buccal surface of molar teeth.
33076775|NCT05296213|Experimental|Experimental tricalcium silicate|Experimental tricalcium silicate paste was applied twice daily over the early enamel lesions in cervical third of the buccal surface of molar teeth
33076776|NCT05295004|No Intervention|No Treatment|Patient will receive no mindfulness meditation training.
33076777|NCT05295004|Experimental|Mindfulness at Pre-Op|Patient will receive a one time training at their pre-operative appointment.
33076778|NCT05295004|Experimental|Multiple Mindfulness Meditation|Mindfulness Video Training at Pre-Op, 1 Day Prior to surgery, 3 day's Post OP and 2 Weeks Post OP.
33076779|NCT05284240|Experimental|Auryon Laser Treatment Arm|Auryon Laser to be used on target lesion in the below the knee artery.
33076780|NCT05282875||kidney transplant patients returning to dialysis after graft loss|"This cohort contains kidney transplant patients returning to dialysis after graft loss in Lorraine between 1 January 2007 and 31 December 2019. They are identified by the REIN registry of the Lorraine region.~The REIN registry is a national database that contains multiple information on patients with chronic end-stage renal disease (type of nephropathy, type of replacement therapy, comorbidities)."
33076781|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
33076782|NCT05279560|Experimental|Autologous intra-ovarian PRP injection|Study group, treated with autologous intra-ovarian PRP injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
33076783|NCT05279560|Placebo Comparator|intra-ovarian saline solution (NaCL) injection|Control group, treated with intra-ovarian NaCl injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
33076784|NCT05276206|Active Comparator|NSAID|The Control group will be given nothing and only non-steroidal anti-inflammatory drugs on need
33076785|NCT05276206|Active Comparator|Nalufin|group will be given IV nalufin
33076786|NCT05276206|Active Comparator|local anesthetic group|the local anesthetic group will be given a S.C injection of local anesthetic in the wound
33076787|NCT05276206|Active Comparator|TAP block|Total abdominal plain block group will be given a TAP block
33257661|NCT05585398|Experimental|LMRC (left with micro-/right with conv- needle)|
33257662|NCT05585398|Experimental|RMLC (right with micro-/left with conv- needle)|
33257663|NCT05585398|Experimental|LCRM (left with conv-/ right with micro-needles)|
33257664|NCT05585398|Experimental|RCLM (right with conv-/left with micro-needles)|
33257665|NCT05578872|Experimental|ANV419 single agent, dose 1, Q2W|
33257666|NCT05578872|Experimental|ANV419 single agent, dose 2, Q2W|
33257667|NCT05578872|Other|ANV419 + Pembrolizumab, Q3W|
33257668|NCT05578872|Other|ANV419 + Ipilimumab, Q3W|
33257669|NCT05573243|Experimental|Etch-and-rinse|G2 Bond Universal bonded to NCCL using etch-and-rinse technique
33257670|NCT05573243|Experimental|Selective enamel etching|G2 Bond Universal bonded to NCCL using selective enamel etching technique
33257671|NCT05573243|Experimental|self-etch|G2 Bond Universal bonded to NCCL using self-etch technique
33257672|NCT05572138||Critically ill patients|
33257673|NCT05568719||Hemophilia A / giroctocogene fitelparvovec|Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study
33257674|NCT05568719||Hemophilia B / fidanacogene elaparvovec|Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study
33076788|NCT05276089|Experimental|Intervention arm|A total of 50 practices who use System 1 will be in the intervention arm to send out the video to their eligible patients.
33076789|NCT05276089|No Intervention|Control arm|50 practices who use EMIS will be in the control arm to deliver care as usual
33076790|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
33076791|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
33076792|NCT05259631|Experimental|Inhalational sedation|
33076793|NCT05259631|Active Comparator|Intravenous sedation|
33257675|NCT05567562|Experimental|COPD Cases: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
33257676|NCT05567562|Placebo Comparator|COPD Cases: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
32734702|NCT04526873|Experimental|Postcard: telehealth, photo|This group receives a postcard that does includes telehealth information and features a stock photo
32734703|NCT04526873|Experimental|Postcard: telehealth, salience/humorous cartoon|This group receives a postcard that includes telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
33076796|NCT05220163|Experimental|CAD + POC Xpert|CAD followed by Xpert in CAD-positive participants (performed at POC) employing a low-cost panel van that is staffed by three health care workers. CAD-negative participants will be followed up, while CAD-positive participants will be offered POC Xpert. Xpert-positive participants will be referred for TB treatment initiation, while Xpert-negative (but CAD-positive) participants will undergo a clinical review. Thus, the active case finding (ACF) interventional package is one of CAD + POC Xpert (only in CAD positive participants).
33076797|NCT05220163|Active Comparator|POC Xpert only|Participants who are Xpert-positive will be referred for TB treatment initiation while Xpert-negative participants will be followed up. Thus, the active case finding (ACF) standard of care package is POC Xpert.
33257677|NCT05567562|Active Comparator|Controls: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
33257678|NCT05567562|Placebo Comparator|Controls: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
33257679|NCT05566574|Experimental|RP-3500 in Combination With Standard Radiation Therapy|Patients with metastatic cancers with identified mutations in ATM will be enrolled. All patients will receive a standard palliative RT (4Gy x 5 fractions) on Days 1-5 in combination with RP-3500 on Days 1-5. In the first phase of the study, a 3+3 study design will be used to identify a safe dose of RP-3500 (starting at 80 mg QD) in combination with palliative RT.
33257680|NCT05558215|Experimental|Remote Otago Exercise Program|Individuals with dementia will participate in Otago Exercise Program in their home using video recordings and with safety oversight by their trained care partners.
32734704|NCT04526873|Experimental|Phone call|This group receives a phone call
32734705|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
32734706|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
32734707|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
33076798|NCT05205304|Experimental|Treatment group|Subjects will be treated with liquid carbon dioxide (D'oxyva) administered transdermally on the thumb after the Aortic Cross Clamp is removed
33076799|NCT05205304|No Intervention|Control group|Subject will not be treated with liquid carbon dioxide (D'oxyva)
33257681|NCT05556265|Experimental|Deucravacitinib Dose 1|
33257682|NCT05556265|Experimental|Deucravacitinib Dose 2|
33257683|NCT05556265|Placebo Comparator|Placebo, followed by Deucravacitinib Dose 1 or Dose 2.|
33257684|NCT05554978|Experimental|Landiolol|initial dose: 20mg target dose: repeated dose (20mg) possible, max. 40mg (total)
33257685|NCT05554978|Placebo Comparator|Placebo|Sodium Chlorid 0,9%
33257686|NCT05554627|Experimental|Esketamine|Intranasal spray of esketamine. Administered twice weekly for first 4 weeks, reduced to once weekly until week 12, then dosage will be determined by response and treating prescriber.
33257687|NCT05554627|Active Comparator|Aripiprazole|Participants will be randomized in a 1:1 ratio of equal allocation to either adjunctive ARI (n=470) or adjunctive IN ESK (n=470), stratified by participating site.
33257688|NCT05554380|Experimental|Treatment (paclitaxel, ipatasertib)|Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.
33257689|NCT05553444|Experimental|Self-management intervention|"The intervention is based on the 5 key skills for successful self-management which are;~Problem solving~Decision-making~Utilizing resources~Forming partnerships with healthcare providers~Taking action. It is important to keep in mind, that not all included patients will necessarily lack all 5 skills. As such, the intervention will be tailored to each participant based on the initial assessment and continuous clinical reasoning."
33257690|NCT05546866|Experimental|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
33257691|NCT05545969|Experimental|Neoadjuvant and Adjuvant Therapy|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks
33257692|NCT05543642|Active Comparator|Arm 1 (control group, sequential administration)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive sequential administration of both tdap booster and hepA vaccinations."
33076800|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
33076801|NCT05187637||Intervention|Patients on the waiting list for liver transplantation with haemoglobin less than 11.5g/dL and transferrin saturation index less than 20%, which are considered iron deficiency susceptible to respond to intravenous iron administration.
33257693|NCT05543642|Active Comparator|Arm 2 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of hepA vaccination."
33257694|NCT05543642|Active Comparator|Arm 3 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of tdap booster vaccination."
33257695|NCT05543642|No Intervention|Arm 4 (Inflammatory arthritis patients using DMARDS)|"Individuals with inflammatory arthritis patients using DMARDS, who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will only receive the standard of care COVID-19 booster vaccination."
33257696|NCT05541627|Experimental|Cohort 1|Low-dose of AB-1001
33257697|NCT05541627|Experimental|Cohort 2|High-dose of AB-1001
33257698|NCT05540457|Experimental|Non-Invasive Blood Pressure (NIPB)Monitors|"NIPB Tablo Brachial Cuff (Intermittent): Will be placed contralateral to the access arm. Blood pressure measurements will be collected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~VitalStream Monitor (Continuous):A cuff will be applied to the middlefinger ipsilateral to the accessarm. Blood pressuremeasurements will be collectedpre-dialysis, continuously duringdialysis, and post-dialysis."
33257699|NCT05539352|Experimental|Active treatment plus EUC|All caregivers are assigned to this condition and receive the treatment plus EUC.
33257700|NCT05538897|Experimental|Phase Ib (megestrol acetate, ipatasertib)|Patients receive megestrol acetate PO QD and ipatasertib PO QD throughout the trial. Patients undergo a CT or MRI during screening, on study, and during follow-up.
33257701|NCT05538897|Active Comparator|Phase II (megestrol acetate)|Arm I: Patients receive megestrol acetate PO QD throughout the trial. Patients undergo a CT or MRI during screening, on study, and during follow-up.
33257702|NCT05538897|Experimental|Phase II (megestrol acetate, ipatasertib)|Arm II: Patients receive megestrol acetate PO QD and ipatasertib PO QD throughout the trial. Patients undergo a CT or MRI during screening, on study, and during follow-up.
33257703|NCT05538273||Minimal invasive surgery|removal of urinary catheter postoperatively
33257704|NCT05538273||Laparotomy|removal of urinary catheter postoperatively
33257705|NCT05538273||Simple surgery|removal of urinary catheter postoperatively
33076802|NCT05187637||Control|Patients on the waiting list for liver transplantation in the same period of the intervention cohort, with haemoglobin less than 11.5g/dL and transferrin saturation index more than 20%, which are considered of non susceptibles for iron supplement alone.
33257706|NCT05538273||Radical surgery|removal of urinary catheter postoperatively
33257707|NCT05530343|Other|Seattle protocol, then WATS3D brushings.|Participants in the screening or surveillance population that receive the Seattle protocol, then WATS3D brushings, during the same procedure.
33076803|NCT05182099|Other|Conventional image reconstruction|Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a conventional image reconstruction algorithm. It is automatically generated from a MRI console after the examination.
33257708|NCT05530343|Other|WATS3D brushings, then Seattle Protocol.|Participants in the screening or surveillance population that receive the WATS3D brushings, then the Seattle protocol, during the same procedure.
33257709|NCT05529823|Experimental|Experimental group|The women in this group will have a warm shower during the labor process.
33257710|NCT05529823|No Intervention|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
33257711|NCT05528900|Experimental|FPEIS children|
33257712|NCT05525247|Experimental|Monotherapy|SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle
33257713|NCT05525247|Experimental|Gemcitabine combination|"SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle~Gemcitabine 1000 ㎎/㎡ Intravenous infusion over 30 minutes on day 1 and 8 of each 21-day cycle"
33257714|NCT05524428|Other|Introduction of Implementation Strategies|The investigators will determine the best intervention and strategy (and thus implementers) based on high ranking barriers/facilitators identified in focus groups. A minimum of 2 implementation strategies will be developed and implemented at each level (patient, provider, system) at each site that considers (1) implementation strategy; (2) mechanism in which the strategy impacts the identified determinant (3) the determinant; (4) moderators that may influence the impact of the strategy; (5) the preconditions necessary for successful implementation; and (6) implementation outcomes affected. Each community health center (CHC) will serve as its own separate subject, and individual strategies will be tested using single case experimental design (SCED) at each CHC using component analysis to rapidly test and optimize our strategies. In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
33257715|NCT05524428|No Intervention|Withdrawal of Implementation Strategies|In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
33257716|NCT05521776|Experimental|With first trimester preeclampsia screening|Risk assessment of developing preeclampsia between 11 and 14 WG based on maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentration. Patients at high risk of preeclampsia are treated with aspirin.
33257717|NCT05521776|No Intervention|Without first trimester preeclampsia screening|Usual prenatal care
32734708|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
32734709|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
32734710|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
33076804|NCT05182099|Active Comparator|Deep learning image reconstruction|"Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a deep learning based image reconstruction algorithm (AIRTM). It is additionally generated aside from the conventional images.~For obtaining the images, we will use the same MRI raw data which is used for conventional image reconstruction."
33076805|NCT05181904||Critically ill children ready for extubation|Children admitted to a paediatric intensive care unit, invasively ventilated and intubated, enterally fed and presenting with a clinical condition allowing for extubation. 45 children will be included.
32734711|NCT03295357||Patients with extubation while on ECLS|
33257718|NCT05516212|Active Comparator|CAFMONO supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMONO in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMONO will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
33257719|NCT05516212|Active Comparator|CAFMIPS_1 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_1 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_1 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
33257720|NCT05516212|Active Comparator|CAFMIPS_2 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_2 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_2 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
33257721|NCT05516212|Placebo Comparator|Placebo treatment|The experimental procedure for each participant assume random blind acute ingestion of placebo (PLA) at one of the study visits, which will be separated from other study visits with 7-days wash-out. The PLA preparation will be provided in the form of powder and dissolved in 200 mL of water. PLA will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
33257722|NCT05514873|Experimental|0.3 mg/kg zilucoplan (RA101495)|Study participants will be treated with subcutaneous zilucoplan (0.3mg/kg/day)
33257723|NCT05514496|Experimental|Part 1: NX-019 Dose Escalation|Patients will be treated with NX-019 in multiple ascending cohorts.
33257724|NCT05514496|Experimental|Part 2: NX-019 Dose Expansion|Patients will be treated with the MTD/RP2D of NX-019 as determined in Part 1.
32734712|NCT03295357||Patients without extubation|
32734713|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
33257725|NCT05511207|Experimental|RECOM - hBCI training|Patients in the RECOM group will receive treatment in add-on to standard rehabilitation as follows. The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
32734714|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
32734715|NCT04488835|Experimental|TENS Therapy Group|patients in this group received TENS therapy in addition to routine physical therapy
32734716|NCT04488835|Experimental|PEMFT group|patients in this group received PEMFT therapy in addition to routine physical therapy
32734717|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
32734718|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
32734719|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
32734720|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
32734721|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
32734722|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
32734723|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
32734724|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
32734725|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:~Single dose of Indoximod base formulation under fasting conditions~Single dose of Indoximod HCL (salt) formulation under fed conditions~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
32734726|NCT03372239|Experimental|Part 2: Single Ascending Dose|
32734727|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.~Each subject will undergo catheter change with novel gel instillation device procedure"
32734728|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.~Each subject will undergo catheter change with standard procedure"
33076806|NCT05175040|Experimental|Prophylactic manual rotation|Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
33076807|NCT05175040|Sham Comparator|Sham rotation|Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.
33076808|NCT05160376|Experimental|Guided Intervention Group|The participants in the guided intervention group will receive feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor, after each online self-help intervention session. The participants in the guided intervention group will also receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
33076809|NCT05160376|Experimental|Unguided Intervention Group|The participants in the unguided intervention group will not receive the aforementioned feedback calls. The participants in the unguided intervention group will only receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
33257726|NCT05511207|Active Comparator|CTRL - upper limb training with FES|Patients in the CTRL group will receive treatment in add-on to standard rehabilitation as follows. An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
33257727|NCT05509959|Placebo Comparator|Control Arm|Women assigned to the control arm (n=180) will receive one 60-minute group session facilitated by the licensed clinical therapist (LCT) on self-care and well-being as it relates to HIV, interpersonal violence, trauma, adverse mental health, and substance use. During this session, women will be provided with resources to HIV care, interpersonal violence, trauma, mental health, and substance use, through a static website created for Women SHINE. The content will include: 1) names and locations of clinics and organizations, services provided, and contact information; 2) links to support websites and hotlines and 3) testimonials from WLHA.
32734729|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
32734730|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
32734731|NCT03371927|No Intervention|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
32734732|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
32734733|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
32734734|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
32734735|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
32734736|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
32734737|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
32734738|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
32734739|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
32734740|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
32734741|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
32734742|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
32734743|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
32734744|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
32734745|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
32734746|NCT03371303||diabetology|
32734747|NCT03371303||cardiology|
32734748|NCT03371303||rheumatology|
32734749|NCT03371303||geriatrics|
32734750|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
32734751|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
32734752|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
32734753|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
32743120|NCT04938297|Experimental|Primary CNS Lymphoma，age>65|8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration
32734754|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
32734755|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
32734756|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
32734757|NCT04307329|Experimental|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
33257728|NCT05509959|Experimental|Women SHINE|Women SHINE consists of a four-month intervention that includes video-based one-on-one peer navigation and 7 weekly psycho-education support group sessions co-facilitated by a licensed clinical therapist (LCT) and peer navigator (PN). 180 women will be enrolled in the Women SHINE intervention and will remain in their assigned psycho-education support group sessions with the same members over the course of the intervention.
33257729|NCT05508464|Active Comparator|Standard of Care|Standard or care palliative radiotherapy (includes the option for no treatment)
33257730|NCT05508464|Active Comparator|SABR|SABR to all tumors 6Gy x 5 over 3 weeks
33257731|NCT05508243|Experimental|Experimental|
33257732|NCT05508230|Experimental|Experimental|
33076810|NCT05160376|No Intervention|Wait-list Control Group|The waitlist control group will not receive any online self-help intervention. Unguided intervention will be provided to the waitlist control group after both the Post-treatment Assessment Phrase are finished.
33076811|NCT05153161|Experimental|Persons with ADRD living in a residential care facility|Each consented participant will receive the current Memesto device and will be provided formal and informal training instructions. After consent and screening, a two-week training period with a Memesto device will be followed by ten weeks of data collection. An experienced research assistant will administer the baseline NPI in order to collect the agitation ratings by the family caregiver, and the professional caregiver will be collected by a trained research assistant and captured in an electronic case report form designed using REDCap.14,15 Then, participants will undergo evaluation of the NPI agitation domain at 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks. Adverse events related to the device will be collected from the family and professional caregivers. Human centered system designers will work with the operations team to enhance participant engagement and maintain high quality data collection.
33076812|NCT05140330|Experimental|Intervention|7 ALAPAGE sessions over 2 months and 1 evaluation session at 3 months
33257733|NCT05505305|Experimental|Time-restricted eating and high-intensity interval training|Seven weeks of time-restricted eating and high-intensity interval training with digital follow-up.
33257734|NCT05505305|No Intervention|Control|No intervention nor digital follow-up for seven weeks.
33257735|NCT05505019|Experimental|Parkinson's Disease with apathy - Music-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in constructing a playlist of music that they find rewarding or motivating."
33076813|NCT05140330|Other|Control|3 evaluation sessions over 2 months and 1 session at 3 months
33076814|NCT00194844|Experimental|1|Nurse Caring
33257736|NCT05505019|Experimental|Parkinson's Disease with apathy - Podcast-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in choosing a podcast that they find rewarding or motivating."
33257737|NCT05494697|Experimental|Ampligen / rintatolimod|Subjects will receive rintatolimod [intravenous (IV)], up to 400 mg twice weekly until disease progression.
33257738|NCT05494697|No Intervention|Control Group / No Treatment|Subjects will be followed / no treatment until evidence of disease progression.
33257739|NCT05494346|Other|Arm A: Patients with peak nasal flow performed|This arm is made up of major patients. Nasal flow point measurements will be performed at D0 and D3.
33257740|NCT05494346|No Intervention|Arm B: No peak nasal flow|This arm is made up of minor patients. Unlike arm A, nasal flow measurements will not be performed at D0 and D3.
33076815|NCT00194844|Experimental|2|Self Caring
33076816|NCT00194844|Experimental|3|Combined Caring
33076817|NCT00194844|No Intervention|4|This group is not treated and serves as control.
33257741|NCT05492578|Experimental|Amlitelimab|Subcutaneous injection as per protocol.
33257742|NCT05482711|Other|Time Restricted Eating intervention|Participants will be asked to stop eating by 7 PM every day and to fast for a target of 16 hours per day for 8 weeks. During the first two weeks of the intervention, participants will gradually ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 8 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Additionally, they will be asked to keep a Fasting and Sleeping diary logging their eating habits and sleep quality.
32734758|NCT04307329|Experimental|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
32734759|NCT04526483|Experimental|laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D|
32734760|NCT04526717|Other|MPT0B640|There is single Arm in this clinical trials.
32734761|NCT04295707|Experimental|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
32734762|NCT04295707|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
32743121|NCT04938297|Experimental|Recurrent/refractory primary CNS lymphoma|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
32734763|NCT04295707|Active Comparator|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
32734764|NCT04526327|Other|exercise group|Female and male patients over 70 years of age with osteoporosis and sarcopenia
32734765|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
32734766|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
33257745|NCT05481931||Safety Population|The safety population will consist of all patients who receive at least one treatment of NUCEIVA.
33257746|NCT05481931||Botulinum Toxin Naïve|Sub-population of patients that have never been treated with botulinum toxin
33257747|NCT05481931||Botulinum Toxin Exposed|Sub-population of patients that have previously been treated with botulinum toxin
33257748|NCT05481333|Experimental|IV Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
33257749|NCT05481333|Experimental|IV Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
33257750|NCT05481333|Experimental|IV Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
33257751|NCT05481333|Experimental|IV Cohort 4|Single dose REGN7999 or Placebo; randomized 3:1
32734767|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
33257752|NCT05481333|Experimental|IV Cohort 5|Single dose REGN7999 or Placebo; randomized 3:1
33257753|NCT05481333|Experimental|SC Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
32734768|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
32734769|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
33257754|NCT05481333|Experimental|SC Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
33257755|NCT05481333|Experimental|SC Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
33257756|NCT05480917|Other|IRIS|
33257757|NCT05476770|Experimental|Part 1|"Tagraxofusp -Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT)~-Days 1 and 22, +/- 3 Days"
33257758|NCT05476770|Experimental|Part 2 - Cohort A|"Tagraxofsup~-Days 4-8~Fludarabine -Days 1-5~Cytarabine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy -Days 1 and 29, +/- 3 days~CNS2/3 IT Therapy~-Days 1, 8, 15, 22, and 29, +/- 3 days"
33257759|NCT05476770|Experimental|Part 2 - Cohort B|"Tagraxofsup~-Days 8-12~Dexamethasone -Days 1-5~Vincristine~-Days 1, 8, 15, and 22~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy -Days 1 and 29, +/- 3 days~CNS2/3 IT Therapy~-Days 1, 8, 15, 22, and 29, +/- 3 days"
32734770|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
32734771|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
32734772|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
32734773|NCT03294577|Active Comparator|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
32734774|NCT03294577|Experimental|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
32734775|NCT04526015|Experimental|Ilioinguinal iliohypogastric Block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
32734776|NCT04526015|Other|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
33257760|NCT05476770|Experimental|Part 2 - Cohort C|"Tagraxofsup -Days 1-5~Azacitidine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy -Days 1 and 29, +/- 3 days~CNS2/3 IT Therapy~-Days 1, 8, 15, 22, and 29, +/- 3 days"
33257761|NCT05476289||A|children who received partially hydrolyzed formula containing synbiotics in the first 17 weeks of life in the Dragon study.
33257762|NCT05476289||B|children who received standard infant formula containing prebiotics in the first 17 weeks of life in the Dragon study.
32734777|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
33257763|NCT05476289||C|children who received full breastfeeding in the first 17 weeks of life in the Dragon study.
33257764|NCT05475678|Experimental|（Carrelizumab + TCb） regimen|The experimental group received 6 cycles of TCb+carrelizumab (docetaxel 75mg/m2 on the first day + carboplatin AUC=6, on the first day; camrelizumab 200mg on the third day) regimen neoadjuvant chemotherapy, every 21 days is a cycle.
33257765|NCT05475678|Placebo Comparator|TCb regimen|The control group received 6 cycles of TCb (docetaxel 75mg/m2 on the first day + carboplatin AUC=6 on the first day) regimen neoadjuvant chemotherapy, every 21 days as a cycle.
33257766|NCT05473962||exposed to Alex storm|"Child and/or young adult aged under 18 at the time of exposure having been assessed by the CUMPS teams during the ALEX Storm interventions of October 2020"
33257767|NCT05471947|Experimental|Treatment|Treatment of hand lentigines with 15% trichloroacetic acid + 3% glycolic acid
33257768|NCT05468320|Experimental|Caplacizumab & immunosuppressive therapy without 1st-line TPE|All participants will receive open label caplacizumab daily and immunosuppressive therapy (corticosteroid +/-anti-CD20 therapy antibody [rituximab or biosimilar]) without first line TPE
33257769|NCT05466630|Other|participant|All eligible participants will undergo 5 serological field tests for HAT and a malaria test. Those testing positive in at least 1 serological field test will undergo parasitology to confirm HAT and immunological and molecular laboratory tests
32734778|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
32734779|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
32734780|NCT04525859|Experimental|Safety|Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.
32734781|NCT04525859|Experimental|Expansion Cohort|If at most one (1) patient in the Phase 1 safety cohort experiences a DLT then a total of thirteen (13) additional patients will be enrolled into the Phase 1b Expansion Cohort. Patients in the Expansion Cohort will receive the same dose and schedule of Poly-ICLC as in the Phase 1 safety cohort. Patients will be followed for safety and tolerability, as well as efficacy. If a total of 4 or more patients experience DLTs then the study will be closed due to excessive toxicity.
32734782|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
32734783|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
32734784|NCT04526171|Experimental|Vaparshun|In intervention clusters, two full day events, with a gap of 4 weeks between the two events, were organized at cluster level. Eligible households with a government or contract tor built toilet were invited to enroll for a toilet makeover. Intervention activities, delivered at cluster level, included films on toilet improvement, comfort and convenience of toile use, addressing pit filling anxiety and celebrating proud toilet owners by providing certificates and acknowledging them during the events.
32734785|NCT04526171|No Intervention|Control Arm|No intervention was delivered to clusters in the control arm.
32734786|NCT02460367|Experimental|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
32734787|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
32734788|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
32734789|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
32734790|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
32743122|NCT04938297|Experimental|Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
32743123|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
32743124|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
32743125|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
33257770|NCT05463783|Experimental|Biktarvy|15 subjects will get Biktarvy (single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide) once daily.
33257771|NCT05463783|Experimental|Symtuza|15 subjects will get Symtuza (single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide) once daily.
33257772|NCT05462132|Experimental|Cohort 1|"HV subjects receive doses 3 × 10^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
33076818|NCT05133622|Active Comparator|Covid-19 group|"Individuals between the ages of 20-30 Individuals who were diagnosed with COVID-19 positive in the last 3-10 months and were treated with home isolation and whose last PCR test was negative Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to International Physical Activity Questionnaire-Short form (IPAQ-SF) (sedentary)"
33257773|NCT05462132|Experimental|Cohort 2|"HV subjects receive doses 3 × 10^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
33257774|NCT05462132|Experimental|Cohort 3|"HV subjects receive doses 6 × 10^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
33076819|NCT05133622|Active Comparator|Control group|Individuals between the ages of 20-30 Individuals who have not been diagnosed with COVID-19 positive Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to the IPAQ-SF (sedentary)
33257775|NCT05462132|Experimental|Cohort 4|"HV subjects receive doses 6 × 10^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
33257776|NCT05462132|Experimental|Cohort 5|"HV subjects receive doses 1 × 10^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
33257777|NCT05462132|Experimental|Cohort 6|"HV subjects receive doses 1 × 10^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
33257778|NCT05462132|Experimental|Cohort 7|"HV subjects receive doses less than or equal to 2 × 10^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
33257779|NCT05462132|Experimental|Cohort 8|"HV subjects receive doses less than or equal to 2 × 10^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
33257780|NCT05458622|Other|Stable or quiescent SLE|"Patients included in this study will undergo one assessment at the time of recruitment and at the time of the end of study (time of a flare or at least 24 months after inclusion)~The following information will be collected :~General data: date of flare.~Disease activity: BILAG; SLEDAI-2K; PhGA (0-3); PGA (0-10); LLDAS; DORIS ; CLASI for mucocutaneous involvement; 44 joint assessment; proteinuria (UPCR); serum creatinine and eGFR for lupus nephritis.~Organ damage: SLICC/ACR Damage Index.~Kidney histopathology~HRQoL: EQ-5D-5L; FACIT-F; Medical Outcomes Study 36-item Short Form health survey (SF-36); Epworth Sleepiness scale (ESS); Lupus-QoL.~Start day and current dose for current treatments~Biological samples which will be obtained twice, at baseline and at the time of the first flare documented over 24 months, or at month 24 if no flare has been documented:~Blood~Urine~Stool~Saliva~Tissue samples for organ-specific manifestations"
33257781|NCT05458401||Trastuzumab Deruxtecan (T-DXd) Cohort|Patients with advanced/metastatic HER2-positive breast cancer who are receiving treatment (or previously treated) with trastuzumab deruxtecan (T-DXd).
33257782|NCT05453500|Experimental|Treatment (DA-EPOCH+/-R, tafasitamab)|Patients receive etoposide, doxorubicin, and vincristine IV continuously over 96 hours on days 1-4 of each cycle, cyclophosphamide IV over 1 hour on day 5 of each cycle, prednisone PO BID on days 1-5 of each cycle, and tafasitamab IV weekly on days 1, 8, and 15 of each cycle. CD20 positive patients also receive rituximab IV per guidelines on days 1 or 5 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33257783|NCT05450224|Other|Telehealth Massed Imaginal Exposure Therapy|
33257784|NCT05446051|Experimental|Experimental Group|New patients and take the TRAEs Questionnaire on week.
33257785|NCT05446051|No Intervention|Control group|Control Group：Old patients and usual care.
33257786|NCT05445674|Experimental|Plasma Exchange|6 sessions of PE with human serum 5% albumin. Plasma exchange sessions will occur on days 1, 3, 8, 10, 15 and 17
33257787|NCT05445674|Sham Comparator|Sham Plasma Exchange|6 sessions of sham plasma exchange (one infusion of sterile saline solution 0.9%) on days 1, 3, 8, 10, 15 and 17.
33257788|NCT05441267|Active Comparator|Oral semaglutide|14mg daily (option to reduce to 7mg daily)
33257789|NCT05441267|Placebo Comparator|Placebo|
33257790|NCT05438888||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
33257791|NCT05438888||Apixaban cohort|Patients with NVAF treated with apixaban
33257792|NCT05430074|Other|HM Cast|
33257793|NCT05430074|Other|Fibreglass Cast|
33257794|NCT05427487|Experimental|IVX037|IVX037 administered intratumorally, 1, 2 or 3 doses q2wks, Day 1, 15 and 29 of Cycle 1.
33257795|NCT05424406|Experimental|Active light condition|Timed bright light exposure will be delivered in a controlled laboratory setting (10,000 lux) designed to delay the DLMO to 4 am or later. This would shift the circadian nadir (e.g., the period of maximal sleepiness) into the typical daytime sleep period after the nightshift (i.e., circadian nadir at ~10am). Bright light will be delivered in a controlled lab environment using a full spectrum light-box with UV filter (Sunbox Sunray II) to achieve a robust reduction of circadian misalignment. The light schedule will be tailored to each individual nightshift worker, determined by: 1) their baseline circadian phase, and 2) the human phase response curve adjusted to the individual's baseline circadian phase.
33257796|NCT05424406|Active Comparator|Control light condition|Shift workers randomized to the control condition will receive less intense light that still has a perceptible alerting effect (100 photopic lux). However, light will occur during a portion of the phase response curve with minimal phase shifts.
33257797|NCT05424406|Experimental|Cognitive Behavioral Therapy (CBT) condition|The CBT condition will probe sleep reactivity using validated CBT strategies over 6 sessions in accordance with the two-factor theory of emotion. Behavioral strategies will be used to reduce physiological arousal (e.g., relaxation training, breathing) and to strengthen behavioral cues for sleep (e.g., sleep hygiene and sleep scheduling). Sleep times will be scheduled to align with the reduced circadian misalignment (compromised phase position, i.e., maintaining a slightly delayed sleep period on offwork days). Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
33257798|NCT05424406|Active Comparator|Sleep education control condition|"This condition will use an established sleep education control protocol modified for nightshift workers based on the Plain Language about Shiftwork published by the National Institute for Occupational Safety and Health (NIOSH). Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion."
33257799|NCT05423717|Experimental|Daridorexant 10 mg|
33257800|NCT05423717|Experimental|Daridorexant 25 mg|
33257801|NCT05423717|Experimental|Daridorexant 50 mg|
33257802|NCT05423717|Placebo Comparator|Placebo|
33257803|NCT05423327|Other|Single Blood Draw|
32734791|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
32734792|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
32734793|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
32734794|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
33076820|NCT05124067|Experimental|Group A (DEXA)|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
33257804|NCT05419934|Experimental|EMDR|"Patient receiving  EMDR therapy  over 6 to 10 sessions."
33257805|NCT05419934|Sham Comparator|Routine Care|"Patient receiving the  routine care  over 6 to 10 sessions"
33257806|NCT05418972|Experimental|Neoadjuvant immunotherapy +/- Adjuvant immunotherapy|"NEOADJUVANT: All participants will receive neoadjuvant therapy with the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg x 2 doses on days 1 and 29.~SURGERY: All participants will have sentinel lymph node mapping and biopsy prior to a wide local excision of the primary melanoma between days 43 and 56.~ADJUVANT: Participants with no pathological response or partial pathological response will receive the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg for a further 11 doses."
33257807|NCT05414136|Experimental|A1/3mg/kg|Dose: 3mg/kg
33257808|NCT05414136|Experimental|A2/6mg/kg|Dose: 6mg/kg
33257809|NCT05414136|Experimental|A3/10mg/kg|Dose: 10mg/kg
33257810|NCT05414136|Experimental|A4/15mg/kg|Dose: 15mg/kg
33257811|NCT05414136|Experimental|A5/20mg/kg|Dose: 20mg/kg
33257812|NCT05414123||Breast Cancer|Subjects with Breast Cancer of all subtypes and independent of Hormone status who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
33257813|NCT05414123||Non-Small Cell Lung Cancer|Subjects with Non-Small Cell Lung Cancer of all subtypes who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
33257814|NCT05411731|Active Comparator|Conventional physical therapy treatment|Patients in this group will receive conventional physical therapy i.e. stretching, strengthening exercises, Aeroplan positioning
33257815|NCT05411731|Experimental|Constraint induced movement therapy|patients of this group will receive the same treatment along with constraint induced movement therapy
33076821|NCT05124067|Experimental|Group B (ONDAN)|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
33257818|NCT05407064|Placebo Comparator|Arm 1- Placebo|A substance that is designed to have no therapeutic value.
33257819|NCT05407064|Experimental|Arm 2- 25 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
33257820|NCT05407064|Experimental|Arm 3- 50 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
33257821|NCT05407064|Experimental|Arm 4- 100 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
33257822|NCT05407064|Experimental|Arm 5- 200 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
33257823|NCT05403541|Experimental|Batoclimab Induction Dose 1 (Period 1)|
33257824|NCT05403541|Experimental|Batoclimab Induction Dose 2 (Period 1)|
32769382|NCT04813757|Active Comparator|control group|Participants in the control group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy, posterior shoulder stretching, and mobilization-with-movement into shoulder elevation. The exercise program will include 2 exercises focusing on scapular and rotator cuff strengthening without a special emphasis on scapular upward rotation as well as one additional flexibility exercise. These exercises will be performed at home on the days on between the therapy sessions.
33257825|NCT05403541|Placebo Comparator|Placebo Induction Dose (Period 1)|
33257826|NCT05403541|Experimental|Batoclimab Maintenance Dose 1 (Period 2)|
32769383|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
32769384|NCT04813523|Experimental|Experimental: Pembrolizumab+Cisplatin+5-FU|Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 600 mg/m^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.
33257827|NCT05403541|Experimental|Batoclimab Maintenance Dose 2 (Period 2)|
33257828|NCT05403541|Placebo Comparator|Placebo Maintenance Dose (Period 2)|
33257829|NCT05399043|Experimental|Technology-based Rehabilitation Group|Patients will undergo conventional treatment and, additionally, robot-assisted therapy or virtual reality-based rehabilitation.
33257830|NCT05399043|Active Comparator|Conventional Rehabilitation Group|Patients will undergo conventional treatment exclusively.
33257831|NCT05394116|Experimental|High dose Garetosmab|Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
33257832|NCT05394116|Experimental|Low dose Garetosmab|Garetosmab is administered by IV administration Q4W
33257833|NCT05394116|Experimental|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
33257834|NCT05392504|Experimental|Core stability exercise|"The core stability training consist of three phases. The first and second phases each will last for three weeks in total, and the third phase will take place in four weeks. Each training session will begin with 10 minutes of warm-up exercises and finish with 10 minutes of cool-down exercises; both warm-up and cool-down exercises includes breathing and stretching exercises. The number of repetitions will be adjusted according to the participant's exercise tolerance.~During the first week of each phase, the number of repetitions of each exercise will be 7-10, and this will progress to 10-15 based on the patient's physical tolerance."
33257835|NCT05392504|Active Comparator|Scroth's program|The Schroth program include exercises for rotational breathing, spinal elongation, de-flexion, stretching, de-rotation, and strengthening, and these exercises are performed to improve the curvature, muscle strength, and endurance of postural muscles. During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support. The intensity of the Schroth exercises will gradually increased depending on the patient's improvement in exercise performance by decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises
33257836|NCT05388604|Experimental|Treatment|Subjects are to be treated with the RF device, followed by the microneedling device. Parameters may be adjusted throughout the treatment and will determined by the Clinician. Subjects will receive up to 4 treatments, spaced approximately 4 weeks apart.
33257837|NCT05385484|Experimental|Mobile banking account with incentives to save|Participants in the savings intervention group will be provided with basic information on the importance of saving for the future, as well as (a) lottery-based incentives to save, (b) opportunities to develop savings goals, and (c) periodic reminders about the savings incentives and goals. Participants will receive assistance in opening and using a mobile savings account and will receive an education session that emphasizes the importance of saving for the future. Participants will be told about lottery-based incentives for saving money in their account.
33257838|NCT05385484|No Intervention|Basic health and financial education|Participants in the control group will be given basic information on the importance of saving for the future. In addition, health education curriculum developed by Impact Research & Development Organization (IRDO) will be provided to participants with standard health education on places to seek services for HIV and STI prevention and treatment, including information on alcohol and transactional sex as risk factors for HIV transmission.
33257839|NCT05378529|Other|Participants with history of ASCVD|Participants with history of ASCVD with known or unknown Lp(a) values.
33076822|NCT05124067|Experimental|Group C (DEXMED)|Patients will receive dexmedetomidine (0.3 μg/kg)
33076823|NCT05124067|Placebo Comparator|Group D (CONTROL)|patients will receive normal saline
33257840|NCT05377541||PENG block|To perform the PENG block, the patient will be placed in the supine position and with the convex transducer in a transverse plane over the anteroinferior iliac spine, the probe will be aligned with the iliopectineal eminence of the pubic ramus rotating about 45º medially.
33257841|NCT05377541||Fascia iliaca compartment block|To perform the iliac fascia block, the patient is placed in the supine position and with the linear transducer placed at the junction of the middle third with the lateral third of the inguinal ligament, the needle is inserted through the fascia lata and the iliac fascia.
33257842|NCT05377112|Experimental|SYNB8802v1|Dose ramp to 1 × 1011 QD and then dose ramp to 3 × 1011 TID SYNB8802v1 live cells
33257843|NCT05377112|Placebo Comparator|Placebo|Placebo will be administered during the dose ramp such that all subjects receive IMP dosing TID
33257844|NCT05354557|Experimental|Single prior autoHCT with melphalan|"Participants have not experienced disease progression since initiation of initial systemic anti-myeloma therapy, are within 12 months of frontline autoHCT with~>/=140mg/m2 of melphalan, initiated lenalidomide maintenance at least 6 months ago, and have a very good partial response (VGPR) or less at time of enrollment. Cohort 1 will be initiated after evaluation of preliminary efficacy and safety data from Cohort 2."
32734795|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
32734796|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
32734797|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
33257845|NCT05354557|Experimental|2 to 3 prior lines of systemic anti-myeloma therapy +/- prior autoHCT|Participants have already received lenalidomide maintenance after a prior line of treatment, underwent a salvage autoHCT within the prior 2-6 months as consolidation therapy for relapsed disease after 2 to 3 prior therapies
32734798|NCT04132661|Experimental|bisacodyl|5 mg bisacodyl, one tablet once
33076824|NCT05109286|Experimental|CrossFit training|CrossFit training twice a week.
33076825|NCT05109286|No Intervention|Control arm|Exercise according to their ideas.
33257846|NCT05354362|Experimental|ATG-010 and ATG-008|ATG-010 and ATG-008 should be taken 6 hours apart on a PK sampling day
33257847|NCT05351736|Experimental|Recent-onset schizophrenia|Patients diagnosed with schizophrenia with onset in the last 5 years that will be started on lurasidone or that have been on treatment with lurasidone for less than two weeks at the time of enrollment.
32734799|NCT04132661|Placebo Comparator|placebo|placebo, one tablet once
32734800|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
32734801|NCT03369977|Other|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
32734802|NCT03376373|Experimental|active|Neurofeedback for FER
32734803|NCT03376373|No Intervention|control|waiting list
32734804|NCT03709511|No Intervention|Conventional Treatment Group|This arm will receive usual care. In accordance with current guidelines a cardiologist sees all patients 4 to 6 weeks after heart valve surgery. At the follow-up visit a clinical examination, biochemistry and echocardiography are performed. All patients are given general information on anticoagulation and endocarditis prophylaxis. During the trial period the patients will be seen by a physician at The Guangdong Provincial People's Hospital, for the follow-up visit, after 1 and 12 months. All patients are instructed to initiate their usual activities of daily living. Patients in the control group have accepted not to receive local rehabilitation at the hospital or community setting in their written consent.
32734805|NCT03709511|Active Comparator|Cardiac Rehabilitation Group|Rehabilitation starts preoperatively with education and exercise management.After screening with cardiopulmonary exercise test,the participant will receive daily preoperative exercise rehabilitation till surgery.It lasts for 20 minutes per day, starting with a 40-60% anaerobic threshold and gradually advancing to 80%.Each patient was motivated to adhere to the basic protocol, but individual adjustments were allowed in case of slower progress. Physical exercise starts 1 month postoperative after the first cardiopulmonary exercise testing, and comprises the following three elements: individual planning of the physical exercise, a specially trained physiotherapist conduction, and integrating detailed information concerning medical treatment and diet.The exercise diary and the heart rate monitor recordings are essential in monitoring during the whole intervention.
33257848|NCT05350072|Experimental|Arm A|ianalumab
32734806|NCT03700541|Active Comparator|Morphine|Morphine-based perioperative analgesia
33076826|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
33076827|NCT00194922|Placebo Comparator|A|
33257849|NCT05350072|Placebo Comparator|Arm B|placebo
33257850|NCT05345041|Experimental|Keep it Movin'|
33257851|NCT05345041|Active Comparator|Go 4 Life Self Guided Education|
32734807|NCT03700541|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
32743126|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
32743127|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
33076828|NCT05056363|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
33257852|NCT05343364|Experimental|Vonoprazan 10 mg|Participants will receive vonoprazan 10 mg once daily for 14 days.
33257853|NCT05343364|Experimental|Vonoprazan 20 mg|Participants will receive vonoprazan 20 mg once daily for 14 days.
33257854|NCT05343065|Experimental|CGM insulin bolus calculator arm|Participants will use the CGM insulin bolus calculator arm
33076829|NCT05056363|Experimental|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
33257855|NCT05342064|No Intervention|Standard of care|No intervention will be administered. Observational data regarding TPT uptake and adherence will be captured on all participants presenting for care
33076830|NCT05046535||Smokers|Individuals with MS who are current tobacco smokers: Either cigarettes, hookah pipe, E-cigarettes or other forms of tobacco. This group will perform all the assessments including surveys about nicotine dependence and smoking behavior.
33257856|NCT05342064|Experimental|TB screening and evaluation followed by TPT via a decentralized delivery system|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
33257857|NCT05337098|Active Comparator|Aspartame|Controlled feeding study. Dosage of aspartame will follow 50% of the acceptable daily intake (equivalent to 25 mg/kg for aspartame). This amount represents 1,500 mg/day of aspartame for a 60 kg adult.
33257858|NCT05337098|Active Comparator|Sucralose|Controlled feeding study. Dosage of sucralose will follow 50% of the acceptable daily intake (equivalent to 2.5 mg/kg for sucralose). This amount represents 150 mg/day of sucralose for a 60 kg adult.
33257859|NCT05337098|Sham Comparator|No NNS|Controlled feeding study with no non-nutritive sweeteners.
33257860|NCT05335928|Experimental|Abatacept plus standard of care|Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.
33257861|NCT05335928|Placebo Comparator|Placebo plus standard of care|Placebo will be administered at the same intervals.
33257862|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 1|Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
33257863|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 2|Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
33257864|NCT05325775|Experimental|ACER-801 50 mg BID|ACER-801 (osanetant) 50 mg BID (1 x 50 mg and 3 x placebo, twice daily)
33257865|NCT05325775|Experimental|ACER-801 100 mg BID|ACER-801 (osanetant) 100 mg BID (2 x 50 mg and 2 x placebo, twice daily)
33257866|NCT05325775|Experimental|ACER-801 200 mg BID|ACER-801 (osanetant) 200 mg BID (3 x 50 mg and 1 x placebo, twice daily)
33257867|NCT05325775|Placebo Comparator|Placebo|Placebo (4 x Placebo of ACER-801 twice daily)
33257868|NCT05325281|Experimental|CPI-613® (Dose level -1.0 250 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
33257869|NCT05325281|Experimental|CPI-613® (Dose level 1.0 500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
33257870|NCT05325281|Experimental|CPI-613® (Dose level 2.0 1,000 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
33257871|NCT05325281|Experimental|CPI-613® (Dose level 3.0 1,500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
33257872|NCT05325281|Experimental|CPI-613® Maximum Tolerated Dose (MTD)|MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
33257873|NCT05324293|Experimental|HMI-115 240mg|
33257874|NCT05319561|Experimental|VAST+|Sites that implement the VAST augmented by quarterly facility-level Antibiotic Use Reports (VAST+).
33257875|NCT05319561|No Intervention|VAST -|to sites that implement the VAST and do NOT receive a quarterly facility-level Antibiotic Use Reports (VAST-).
33257876|NCT05317455|Placebo Comparator|Placebo|capsule with excipient only, no active drug.
33257877|NCT05317455|Active Comparator|Dichloroacetate|sodium salt of dichloroacetate, 1000mg
33257878|NCT05310721|Experimental|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window. The first meal will be before 10 am (last meal before 18h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
33257879|NCT05310721|Experimental|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window. The first meal will be at 13h or later (last meal not before 21h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
33257880|NCT05310721|Experimental|Self-selected time-restricted eating|Participants will self-selecte an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
33076831|NCT05046535||Non-smokers|Individuals with MS who are non-smokers of any form of tobacco. This group will perform all the assessments except for the surveys related to nicotine dependence and smoking behavior.
33076832|NCT05019742|Experimental|Placebo|2 placebo tablets, 1 in the morning and 1 in the evening, daily for 8 weeks. After 8 weeks, optional randomization to 1 of 2 SPH3127 daily treatment arms for an additional 10 months
33076833|NCT05019742|Experimental|SPH3127 50 mg|"1 50 mg SPH3127 tablet in the morning and 1 placebo tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
33257881|NCT05310721|No Intervention|Usual-care group|Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
33257882|NCT05310097|Experimental|Cognitive Processing Therapy + Memory Support (CPT + MS)|CPT + MS will involve the same treatment strategies as CPT while incorporating deliberate and frequent use of memory and learning support strategies. MS strategies are designed to enhance the memory of specific treatment points, defined as any insight, skill or strategy determined to be important for the patient to remember and/or implement. MS is not designed to enhance memory functioning generally, but rather improve the encoding, consolidation and retrieval of specific components of therapeutic learning.
32734808|NCT01854775|Experimental|Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg|HIV-infected, ARV treatment-naive adolescents (12 to < 18 years of age weighing ≥ 35 kg) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
32734809|NCT01854775|Experimental|Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg|Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
32743128|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
32743129|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
33076834|NCT05019742|Experimental|SPH3127 100 mg|"1 50 mg SPH3127 tablet in the morning and 1 50 mg SPH3127 tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
33076835|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
33076836|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
33076837|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
33257883|NCT05310097|Active Comparator|Cognitive Processing Therapy (CPT)|CPT is a manualized, trauma-focused therapy for PTSD. Treatment consists of psychoeducation on the cognitive model of PTSD, identification of trauma-related stuck points (i.e. dysfunctional beliefs), and cognitive challenging techniques to help participants identify more realistic and adaptive ways of viewing their trauma, themselves, and the world.
33257884|NCT05310071|Experimental|Aducanumab|Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.
33257885|NCT05310071|Placebo Comparator|Placebo|Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.
33257886|NCT05303064|Experimental|Group 1 OLZ/SAM|Fixed dose combination of olanzapine and samidorphan
33257887|NCT05303064|Active Comparator|Group 2 Olanzapine|Fixed dose of olanzapine
33076838|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
33076839|NCT04943458||Cardiac surgery group|
32743130|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
33076840|NCT04943458||Glaucoma group|
33076841|NCT04943458||Control group|
33076842|NCT04910152|Experimental|Treatment for aGVHD (BRD4 inhibitor PLX51107)|Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33076843|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
33076844|NCT04892914|Experimental|Embr thermal device|Use of the Embr thermal device
33257888|NCT05286957|Experimental|MRD-guided adjuvant tislelizumab and chemotherapy|"MRD+: Tislelizumab 200mg Q3W + chemotherapy 1-4 cycles and followed by Tislelizumab 200mg Q3W Up to 16 cycles or until PD or intolerable toxicity or withdrawal~MRD-: Adjuvant chemotherapy and surveillance the MRD status, the patient will receive treatment for MRD+ patient when MRD detected,"
33257889|NCT05286957|Active Comparator|Non MRD-guided adjuvant tislelizumab and chemotherapy|patients in non MRD-guided arm receive adjuvant tislelizumab and chemotherapy
33257890|NCT05282108||Carcemia group|The cohort treated with Carcemia
33257891|NCT05282108||Glivec Group|The cohort treated with Glivec
33257892|NCT05277571|Experimental|UCB1381 dosing regime 1 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33257893|NCT05277571|Experimental|UCB1381 dosing regime 2 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33257894|NCT05277571|Experimental|UCB1381 dosing regime 3 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33076845|NCT04881058|Experimental|PicoSure Device|The PicoSure device will be used on the face for the treatment of pigmentation and mild to moderate wrinkles.
33076846|NCT04834765|Active Comparator|Mindfulness|Participants will be engaging in a mindfulness tasks twice per week for 5 weeks in which they will learn techniques through the use of yoga, meditation and breathwork.
33076847|NCT04834765|Active Comparator|Art Therapy|Participants will engage in art therapy with the use of clay twice per week through prompts.
33257895|NCT05277571|Experimental|UCB1381 dosing regime 4 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33076848|NCT04834765|Active Comparator|Mindfulness based Art Therapy|Participants will engage in both mindfulness activities and art therapy twice per week and will learn techniques through the use of yoga, mediation, breathwork and art.
33257896|NCT05277571|Experimental|UCB1381 dosing regime 5 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
33257897|NCT05277571|Experimental|UCB1381 dosing regime 6 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
33257898|NCT05277571|Experimental|UCB1381 dosing regime 7 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33257899|NCT05277571|Experimental|UCB1381 dosing regime 8 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
33257900|NCT05277571|Experimental|UCB1381 dosing regime 9 in Part B|Participants will be randomized to receive repeated doses UCB1381 intravenously (iv).
33076849|NCT04834765|No Intervention|Control Group|Participants will go about daily life as usual.
33076850|NCT04819399|Experimental|Catumaxomab|intravesical Catumaxomab instillation
33257901|NCT05277571|Placebo Comparator|Placebo iv Arm Part A|Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.
33257902|NCT05277571|Placebo Comparator|Placebo sc Arm Part A|Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.
33257903|NCT05277571|Placebo Comparator|Placebo iv Arm Part B|Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.
33257904|NCT05275751|Placebo Comparator|Hot injection without TRP-channel inhibition|Pain induced by an increasingly hot intradermal injection up to 52°C over 2 minutes.
32769385|NCT05032261||Group 1: surviving Patients|Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
33257905|NCT05275751|Experimental|Hot injection with TRPA1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257906|NCT05275751|Experimental|Hot injection with TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
32769386|NCT05032261||Group 2: Deceased patients|Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
33257907|NCT05275751|Experimental|Hot injection with TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257908|NCT05275751|Experimental|Hot injection with TRPA1- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257909|NCT05275751|Experimental|Hot injection with TRPA1- and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257910|NCT05275751|Experimental|Hot injection with TRPM3- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33076851|NCT04800172|Active Comparator|Roflumilast arm|
33076852|NCT04800172|Placebo Comparator|Placebo arm|
33076853|NCT04769596|Experimental|Treatment|Subject in this arm will undergo treatment with the NEUROMARK device.
33076854|NCT04769596|Sham Comparator|Sham|Subjects in this arm will undergo the procedure with a Sham device. At 3 months post treatment these subjects will cross over to Arm 1.
33257911|NCT05275751|Experimental|Hot injection with TRPA1-, TRPV1 and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPV1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257912|NCT05275751|Experimental|Hot injection with TRPA1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33076855|NCT04769518|Active Comparator|Advanced Recovery Room Care (ARRC)|Patients are provided with high acuity care from arrival in Recovery (PACU) until the morning after surgery. This includes higher than normal nursing ratios (1:2), regular frequent rounds by specialist anaesthetic staff, and access to monitoring and medicines (eg vasopressor infusions) not available on normal postoperative surgical wards.
33257913|NCT05275751|Experimental|Hot injection with TRPV1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257914|NCT05275751|Experimental|Hot injection with TRPA1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257915|NCT05275751|Experimental|Hot injection with TRPV1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257916|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
32734810|NCT01854775|Experimental|Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg|Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
32734811|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
33076856|NCT04769518|Placebo Comparator|Usual care|Patients are managed in Recovery (PACU), then normal postoperative surgical wards, as per usual care.
33257917|NCT05275751|Experimental|Hot injection with TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33076857|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
33076858|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
32734812|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
32734813|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
32734814|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
32734815|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
32734816|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
32734817|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
32743131|NCT04945551|Experimental|Diabetes|Aerobic exercise training
33076859|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
33076860|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
33076861|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
33076862|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
33076863|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
33076864|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
33076865|NCT04729933|Experimental|Treatment|V-Wave Shunt Placement
33076866|NCT04716985|Active Comparator|TREATMENT GROUP|"Water saturated with molecular hydrogen at the rate of 2 times 250 mL / day for 21 days.~80 mg of Mg metal, and safe excipients (dextrose, malic acid, L-tartaric acid, adipic acid)."
33076867|NCT04716985|Placebo Comparator|PLACEBO GROUP|Water saturated with magnesium at the rate of 2 times 250 mL / day for 21 days. 80 mg of Mg, but in ionic form.
33076868|NCT04711174||movement,high Aldrete score group (MH group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 9
33076869|NCT04711174||movement,low Aldrete score group (ML group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 7
33076870|NCT04711174||sedation,high Aldrete score group (SH group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 9
33076871|NCT04711174||sedation,low Aldrete score group (SL group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 7
33076872|NCT04705246|Experimental|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
33076873|NCT04693819||Hyperacusis|Abnormally reduced tolerance to sound
33076874|NCT04669210|Active Comparator|PTCY tacrolimus MMF|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35"
33076875|NCT04669210|Experimental|PTCY ruxolitinib|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150"
33076876|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
33076877|NCT04660045|Experimental|Acalabrutinib|Acalabrutinib 100 mg will be administered orally twice daily continuously in 28-day cycles until treatment is discontinued for any reason.
33076878|NCT04612387|Experimental|Mind-body Intervention arm|Online yoga, meditation and nutrition tips.
33076879|NCT04604743|Experimental|Intervention|2 Clinics
33076880|NCT04604743|No Intervention|Control|2 Clinics
33076881|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.~This will continue for the 6-month duration of the intervention."
33076882|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
33076883|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
33257918|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257919|NCT05275751|Experimental|Hot injection with chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while a chloride channel is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
33257920|NCT05274451|Experimental|Experimental LYL797|ROR1-targeted CAR T cells
33257921|NCT05268133|Experimental|Aronia|An aronia melanocarpa extract. Study volunteers will receive a daily oral dose of 160 mg AME for 6 weeks.
33257922|NCT05268133|Placebo Comparator|Control|Cellulose. Study volunteers will receive a daily oral dose of 160 mg cellulose for 6 weeks.
33257923|NCT05262725|Experimental|Values-based Behavioral Activation (BA)|
33257924|NCT05260008|Experimental|ATX-101 Dose A|ATX-101 Dose A
33257925|NCT05260008|Experimental|ATX-101 Dose B|ATX-101 Dose B
33257926|NCT05260008|Active Comparator|bupivacaine hydrochloride|bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block
33076884|NCT04566250|Active Comparator|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 20mg PO daily x 30 tabs (to be taken only while utilizing Naproxen). In the case of a Naproxen intolerance, a prescription for Meloxicam 15mg PO BID PRN x 60 tabs will be given.~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
33076885|NCT04566250|Other|Standard of Care|The control group is standard of care, which typically includes a prescription for an opioid.
33076886|NCT04564378||Mild Fuchs Dystrophy|
33076887|NCT04564378||Severe Fuchs Dystrophy|
33076888|NCT04548583|Experimental|remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)"
33076889|NCT04548583|Experimental|remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
33076890|NCT04548583|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
33076891|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
33401373|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
33257927|NCT05255276|Active Comparator|Group 1 Treatment A|A single-dose administration of sitravatinib malate 50 mg on Day 1. Day 12, a single dose of sitravatinib malate 50 mg will be will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
32734818|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
32734819|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
32734820|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
32734821|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
32734822|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
32734823|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
32734824|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
32734825|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
32743132|NCT04945551|Experimental|Healthy|Aerobic exercise training
32743133|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
33076892|NCT04687579|Experimental|Umbilical hernia repair|Patients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
33076893|NCT04687579|Other|Watchful waiting|Patients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
33076894|NCT04519684|Experimental|Mesenchymal stem cells|Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
33076895|NCT04519684|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s).
33076896|NCT04506190||Robotic-assisted revisional bariatric surgery|Subjects who undergo robotic-assisted revisional bariatric surgery
33076897|NCT04441840|Active Comparator|Active Probiotic Culture|Active culture of Bacillus Coagulans Dose: 1 x 10^9 colony forming units (CFU)
33076898|NCT04441840|Active Comparator|Inactive Probiotic Culture|"Inactive culture of Bacillus Coagulans (GBI-30, 6086) - Marked as StaImune Dose: 1 x 10^9 colony forming units (CFU)"
33076899|NCT04381078|Experimental|Intervention|Standardised Verbal Instructions Standardised Written Instructions Audiovisual Guide
33076900|NCT04381078|No Intervention|Control|Standardised Verbal Instructions Standardised Written Instructions
33257928|NCT05255276|Active Comparator|Group 1 Treatment B|On Days 9 to 11, itraconazole 200 mg will be administered QD in the morning. On Day 12, a single dose of sitravatinib malate 50 mg will be coadministered with itraconazole. Itraconazole QD dosing will continue on Days 13 to 18 to maintain steady state during the PK sample collection period.
33257929|NCT05255276|Active Comparator|Group 2 Treatment A|A single-dose administration of sitravatinib malate 100 mg on Day 1 will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
33257930|NCT05255276|Active Comparator|Group 2 Treatment B|On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.
33257931|NCT05254834||Cancer Group|Collect Subject Data Collect Blood Specimen
33257932|NCT05254834||Non-cancer Group|Collect Subject Data Collect Blood Specimen One Year Follow Up On Cancer Status
32734826|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
32734827|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
33257933|NCT05253833|Active Comparator|Group 1|Allopurinol once daily for 24 weeks
33257934|NCT05253833|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 22 weeks
33076901|NCT04369417|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
33076902|NCT04369417|Active Comparator|Active Comparator: Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
33257935|NCT05253833|Experimental|Group 3|AR882 Dose 1 + Allopurinol for 24 weeks
33257936|NCT05252858|Experimental|nCAP + ERAS|Participants will have the nCAP Signal Relief Patch and complete Enhanced Recovery After Surgery (ERAS) standard of care. After surgery, the subjects randomized to the intervention group will have the nCAP Signal Relief patch applied to their surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU).
33257937|NCT05252858|Active Comparator|ERAS alone|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no nCAP patch.
33257938|NCT05246579||Patients with short cervix|Patients with a short cervix identified on transvaginal ultrasound <30 mm
33257939|NCT05246579||Patients with a history of spontaneous preterm birth|Patients with a history of spontaneous preterm birth (<34 weeks)
33257940|NCT05246579||Patients with symptoms of preterm birth|Patients with preterm premature rupture of membranes or </=2 cm dilated before 34 weeks gestation.
33257941|NCT05246579||Control/Nulliparous|Nulliparous patients
33257942|NCT05246514|Experimental|T-DXd arm|Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.
33257943|NCT05243199|Experimental|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it
32734828|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
33076903|NCT00195195||1|Sirolimus
33076904|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
33076905|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
33257944|NCT05243199|Active Comparator|Irbesartan|the maximum tolerated dose of irbesartan was administered
33257945|NCT05241873|Experimental|Phase I - Part 1A Dose Escalation|BLU-451 monotherapy with dose escalation in participants with metastatic cancer with EGFR Ex20ins or other selected EGFR mutations that have progressed after prior systemic therapies.
33257946|NCT05241873|Experimental|Phase I - Part 1B Dose Escalation (US only)|BLU-451 with dose escalation in combination with carboplatin and pemetrexed in participants with metastatic NSCLC with common EGFR mutations. This arm will enroll participants only in the United States.
33257947|NCT05241873|Experimental|Phase I - Part 2 BLU-451 Monotherapy Enrichment|BLU-451 enrichment at select doses.
33257948|NCT05241873|Experimental|Phase II - Cohort 2A|EGFR Ex20ins participants who have previously received platinum-based chemotherapy and either amivantamab or mobocertinib will receive BLU-451.
33257949|NCT05241873|Experimental|Phase II - Cohort 2B|EGFR Ex20ins participants who have previously received platinum-based chemotherapy but have not received a prior EGFR Ex20ins-targeted agent will receive BLU-451.
32734829|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
33076906|NCT04299880|Other|Napabucasin monotherapy|Patients in this arm will receive napabucasin administered orally, twice daily
33076907|NCT04299880|Other|Napabucasin in combination with Gemcitabine and Nab-paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.
32734830|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
32734831|NCT02460757||Patients with COPD|
32734832|NCT02460757||Patients with interstitial lung disease|
32734833|NCT02460757||Healthy subjects|
32734834|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
33076908|NCT04299880|Other|Napabucasin in combination with Nivolumab|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.
32734835|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
32734836|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
33076909|NCT04299880|Other|Napabucasin in combination with paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.
33076910|NCT04299880|Other|Napabucasin in combination with FOLFIRI|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.
33076911|NCT04282330|Other|CEST imaging performed|CEST imaging will be performed (15 min): Axial 3D volume acquisition at 3.5 mm isotropic voxel size, 20-30 offset frequencies, plus Axial 3D T1w and T2w map at same resolution for use in CEST quantification. A routine stroke MRI protocol will also be performed (10 min): Axial T2w; Axial DWI and ADC (apparent diffusion coefficient) using accelerated multi-band sequence; Axial T2w* or SWI (susceptibility weighted imaging); and dynamic susceptibility contrast-enhanced (DSC) perfusion imaging following contrast agent administration (5 min, provided Radiology Department protocols allow DSC (e.g. no renal impairment)).
33076912|NCT04248010|Active Comparator|standard tDCS|20 min of standard 2-electrode transcranial direct current stimulation (2 mA) at a previously reported scalp location.
33076913|NCT04248010|Active Comparator|HD-tDCS - anterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to anterior language areas of the brain.
33076914|NCT04248010|Active Comparator|HD-tDCS - posterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to posterior language areas of the brain.
33076915|NCT04248010|Sham Comparator|sham tDCS|sham transcranial direct current stimulation using a brief pulse at the beginning and end of the 20 min intervention.
33076916|NCT04188067|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
33076917|NCT04122898|Experimental|Intervention Group|Three months home-based PFM training program with weekly follow-up by a physiotherapist
33076918|NCT04122898|No Intervention|Control Group|No intervention
33076919|NCT04092790|Experimental|Virtual Gate Device (VGD)|The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.
33076920|NCT04087096|Experimental|Denosumab|Denosumab 60mg subcutaneous injection every 6 months
33076921|NCT04087096|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months
33076922|NCT04687657|Experimental|cord blood transfusion|The arm that will receive the target treatment.
33076923|NCT04064593|Experimental|Polygraphy|
33076924|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
33076925|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
33076926|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
33076927|NCT04030234|Experimental|Intensive treatment group|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
33076928|NCT04030234|Active Comparator|Standard treatment group|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
33076929|NCT03962023||Patient cohort|Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse
33076930|NCT00532090|Experimental|1|
33076931|NCT00532090|Experimental|2|
33076932|NCT00532090|Experimental|3|
33076933|NCT03920176|Active Comparator|Computed tomography coronary angiography|
33076934|NCT03920176|Sham Comparator|Assign Score only|
33076935|NCT03911908|Active Comparator|ERC guided CPR (intervention/NIRS group)|CPR protocol according to current ERC guidelines (2015)
33257950|NCT05241873|Experimental|Phase II - Cohort 2C|EGFR Ex20ins participants with at least one measurable lesion in brain per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 who have previously received platinum-based chemotherapy will receive BLU-451. Previous treatment with EGFR Ex20Ins-targeted therapies is allowed but not required.
33257951|NCT05241873|Experimental|Phase II - Cohort 2D|Participants with EGFR Ex20ins who have previously received platinum-based chemotherapy and both amivantamab AND mobocertinib, OR received any investigational Ex20Ins targeted agent(s) will receive BLU-451. Participants with Ex20ins or atypical mutations enrolled in other cohorts and who have other oncogenic drivers by central testing at baseline will be moved to this arm.
33257952|NCT05241873|Experimental|Phase II - Cohort 2E|Participants with EGFR Ex20ins who have not received prior systemic therapy in metastatic setting will receive BLU-451.
33257953|NCT05241873|Experimental|Phase II - Cohort 2F|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have previously received at least one EGFR tyrosine kinase inhibitor (TKI) will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
33257954|NCT05241873|Experimental|Phase II - Cohort 2G|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have not received prior systemic therapy in metastatic setting will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
32734837|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
32734838|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
32734839|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
32734840|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
32734841|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.~No improvement: the patient will undergo ERCP and then LC."
32734842|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.~b- No improvement: the patient will undergo ERCP and then LC."
33257957|NCT05236673||Patients who have started at first time on Jardiance®|
33257958|NCT05235464|Active Comparator|Standard meal|
33257959|NCT05235464|Experimental|High animal protein meal|
33257960|NCT05235464|Experimental|High plant protein meal|
33257961|NCT05235464|Experimental|High plant protein meal with additional leucine|
33257962|NCT05229211||New Onset Atrial Fibrillation|Patients admitted to an adult intensive care unit for more than 24 hours who develop new onset atrial fibrillation during their ICU admission will be included. After discharge from ICU patients will undergo continuous ECG monitoring via VitalConnect patch for 14 days or until hospital discharge, whichever is shortest. They will undergo a further 7 days of continuous ECG monitoring via VitalConnect patch as an outpatient at 3 months post hospital discharge.
33257963|NCT05227716|Experimental|Magnesium sulphate|"Administration of intravenous MgSO4 as an adjunct to anesthesia.~Dose: 30 mg / kg of MgSO4 IV 15 minutes before induction of anesthesia and 10 mg / kg / h in continuous IV infusion during the operation"
33257964|NCT05227716|Placebo Comparator|Placebo|"Administration of intravenous physiological solution (NaCl 0.9%) as a complement to anesthesia.~Dose: equivalent to that administered in the MgSO4 group"
33257965|NCT05222555|Experimental|Treatment (Tafasitamab + Lenalidomide)|"Treatment:~Tafasitamab will be combined with lenalidomide in R/R DLBCL patients.~Dose:~Cohort 1: The dose of tafasitamab will be level 1 high dose in combination with the approved dose~Cohort 2: The dose of tafasitamab will be level 2 high dose in combination with the approved dose~Expansion Cohort: The dose of tafasitamab will be the dose that is deemed safe and tolerable as determined from cohort 1 & cohort 2~Treatment consisting of tafasitamab and lenalidomide combination will be administered until disease progression, unacceptable toxicity, or discontinuation for any other reason, whichever comes first. Lenalidomide can be given for up to 12 cycles in total, after which patients can continue with tafasitamab as monotherapy until progression or unacceptable toxicity."
33257966|NCT05218343|No Intervention|Control|No change in default dose or frequency selected for the eight targeted drugs
32734843|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
33257967|NCT05218343|Experimental|Intervention|The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
33257968|NCT05217433|Experimental|Investigational product|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
33257969|NCT05217433|Placebo Comparator|Control arm|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
33257970|NCT05201248|Experimental|Cohort 1 Part 1: Epcoritamab Monotherapy|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
33257971|NCT05201248|Experimental|Cohort 1 Part 2: Epcoritamab Expansion|Participants will receive SC epcoritamab in 28 day cycles.
33257972|NCT05201248|Experimental|Cohort 2: Epcoritamab + RCHOP|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)] in 21 day cycles followed by 28 day cycles.
33257973|NCT05201248|Experimental|Cohort 3: Epcoritamab + R2|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, and oral lenalidomide (R2)] in 28 day cycles.
33257974|NCT05199259||HCC positive Group|Multi-analyte blood test screen in participants with a recent confirmed untreated diagnosis of HCC by CT scan, MRI or biopsy.
33257975|NCT05199259||HCC negative Group: Sub-Group 1|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by CT or MRI (No lesion, LR-1 or LR-2)
33257976|NCT05199259||HCC negative Group: Sub-Group 2|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by ultrasound. Participants will be scheduled for a 6 month visit (at least 5 months but no more 9 months form enrollment) for a confirmatory ultrasound.
33257977|NCT05196737|No Intervention|Non-Intervention Week Reflex Measurements|Baseline reflex measurements will be collected during the first week of the study (Visits 1-4). No dry needling will occur during this week. The aim of this arm is to track any natural variability in nervous system excitability at the same time points as reflex measurements during the intervention week.
33257978|NCT05196737|Experimental|Dry Needling Reflex Measurements|All participants who participated in baseline reflex measurements during week 1 will continue to the second week of the study (Visits 5-7). Participants will receive dry needling to relieve spasticity in the target calf muscle (middle gastrocnemius) during Visit 5. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to DDN, immediately after DDN, 90 minutes after DDN, 24 hours after DDN, and 72 hours after DDN. These assessments will examine how you move your leg and how your nervous system responds to non-invasive nerve stimulation.
33257979|NCT05195996|Active Comparator|beta blocker|Will be given Propranolol 1mg in 10 ml distilled water intravenous every 6 hours for 48 hours
33257980|NCT05195996|Placebo Comparator|placebo|Will be given normal saline 10 ml every 6 hours for 48 hours
33257981|NCT05195814||Effectiveness of tofacitinib|Participants receiving tofacitinib will be included to assess the effectiveness of tofacitinib overall and stratified by key variables of interest
32935439|NCT05393479|Experimental|Intervention Arm: Thinking Healthy Programme|"Perinatal women identified with depression in intervention arm will be engaged in 2 modules, one during pregnancy and one during postnatal. Each module has 3 sessions each focusing on a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. Altogether 8 sessions (including 1 introductory session, 6 THP sessions, and 1 closing session) each lasting 30 minutes to 1 hour will be provided to intervention arm participants. In the third session of each module that deals with the mother's relationship with others, family members will be engaged as well. Questionnaire evaluation will be conducted at baseline, post-Module 1 (after 2 months from recruitment date) and at 3 months post delivery after completing Module 2 and closing session."
32935440|NCT05393479|No Intervention|Control Arm: Usual Care|Subjects in the control arm will receive usual care, where perinatal women identified with depression, are provided with psychoeducation about their condition and about the availability of services at the health facility and other health information. They will be then referred to the health facility where trained health workers are available.
32935441|NCT05442385||cardiac patients admitted to PICU|To describe the clinical patterns of infants and children with cardiac disease admitted to PICU and their outcome.
32935442|NCT05442307|Experimental|asthma education|The general practices in this arm will receive the education visits about asthma.
32935443|NCT05442307|Placebo Comparator|Other education|The general practices in this arm will receive an educational visit on another topic (PPI).
32935444|NCT05440513|Experimental|Renal Pelvic Denervation|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
32935445|NCT05439967|Experimental|Intervention|
32935446|NCT05439967|Active Comparator|Conventional Training|
32935447|NCT05439499|Experimental|FCN-437c+Letrozole/anastrozole ± Goserelin acetate|
32935448|NCT05439499|Placebo Comparator|Placebo+Letrozole/anastrozole ± Goserelin acetate|
32935449|NCT04036435|Experimental|BMS-986165|
32935450|NCT04018261|Experimental|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
32935451|NCT04003987|Active Comparator|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
33076936|NCT03911908|No Intervention|ERC-based CPR (control group)|modified CPR protocol based on current ERC guidelines (2015), extended by evaluation of NIRS readings and interventions to optimize CPR quality
32734844|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
32734845|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
33257982|NCT05195359|Active Comparator|Allocation to Sleep Improvement App|Participants will be instructed to engage with the Dein Schlaf. Dein Tag. smartphone app, log their behaviors in-app, and track their sleep daily for the duration of the study (12 weeks). Participants will be instructed to start the sleep tracking device via their iOS device before lying down in bed and turning off the lights to go to sleep. In the morning, participants will turn off the sleep tracking device as soon as they wake up and decide to leave the bed. At the three time points (baseline, 6 weeks, and 12 weeks), participants will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
33257983|NCT05195359|No Intervention|Allocation to Waitlist Control Group|At the three time points (baseline, 6 weeks, and 12 weeks) participants assigned to the wait-list control group will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
33257984|NCT05194397|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
33257985|NCT05194397|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
33257986|NCT05194397|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
33257987|NCT05194397|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo"
33257988|NCT05192876||Data Base of Patient Records 2000-2025|Analysis of outcomes and adverse events
33257989|NCT05190939|Active Comparator|no-dye/saline|Subjects assigned to the no-dye/saline group will have cystoscopy performed using saline as the bladder distending media and will not utilize any intravenous dye
32734846|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
32734847|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
33257990|NCT05190939|Experimental|dye/saline|Subjects assigned to the dye/saline group will have cystoscopy performed using saline as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
33257991|NCT05190939|Experimental|no-dye/water|Subjects assigned to the no-dye/water group will have cystoscopy performed using water as the bladder distending media and will not utilize any intravenous dye
32734848|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
33257992|NCT05190939|Experimental|dye/water|Subjects assigned to the dye/water group will have cystoscopy performed using water as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
33257993|NCT05187858|Experimental|LNP3794|Participants will receive LNP3794 orally once daily at different doses in 28 day cycles on a continuous basis
33257994|NCT05184231||Patient cohort|
33257995|NCT05184231||Physician cohort|
33257996|NCT05182788|Placebo Comparator|Placebo pressed candy|
33257997|NCT05182788|Experimental|CHOLESWISE pressed candy|
33257998|NCT05178862|Experimental|IV echinocandin followed by oral ibrexafungerp (SCY-078)|
33257999|NCT05178862|Active Comparator|IV echinocandin followed by oral fluconazole|
33258000|NCT05174338||AL and TTR amyloidosis|immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR)
32935452|NCT04003987|Active Comparator|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
32935453|NCT03984331|Experimental|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
32935454|NCT03984331|Active Comparator|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
32935455|NCT05368129|Experimental|POT group|A total of 24 patients are assigned to POT group after randomization schedule.
33258001|NCT05172752|Other|Citizen Science Training|Study participants in this condition will participate in training and in-home sampling for disinfection by-products.
33258002|NCT05172752|Other|Stakeholder Consultation Core Membership|Study participants in this condition will participate in quarterly meetings and deliberative activities of the project's Stakeholder Consultation Core.
33076937|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
33076938|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
33258003|NCT05169593|Other|Endoscopy-driven postoperative biological therapy|"Endoscopic recurrence at week 30~Adalimumab: 160 mg SC at week 32, 80 mg SC at week 34, 40 mg SC at week 36 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg IV at week 32, and 5 mg/kg IV at week 34; maintenance with 5 mg/kg IV at week 38, week 42 or week 46 and every eight weeks thereafter or with 120 mg SC at week 38 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg) or 390 mg (55-85kg) or 520 mg (>85kg) IV at week 32, 90 mg SC at week 40, and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at week 32, and 300 mg IV at week 34; maintenance with 300 mg IV at week 38 and every eight weeks thereafter or with 108 mg SC at week 38, week 42 or week 46 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at week 32, week 36 and week 40; maintenance with 360 mg SC at week 44 and every eight weeks thereafter."
33258004|NCT05169593|Active Comparator|Systematic postoperative prophylaxis with a biological|"Adalimumab: 160 mg subcutaneous (SC) at day 0, 80 mg SC at week 2, 40 mg SC at week 4 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg intravenous (IV) at day 0, and 5 mg/kg IV at week 2; maintenance with 5 mg/kg IV at week 6, week 10 or week 14 and every eight weeks thereafter or with 120 mg SC at week 6 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg), 390 mg (55-85kg) or 520 mg (>85kg) IV at day 0, 90 mg SC at week 8 and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at day 0, and 300 mg IV at week 2; maintenance with 300 mg IV at week 6 and every eight weeks thereafter or with 108 mg SC at week 6, week 10 or week 14 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at day 0, week 4 and week 8; maintenance with 360 mg SC at week 12 and every eight weeks thereafter."
33258008|NCT05136196|Experimental|Treatment (nivolumab and cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO BID. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans and collection of blood samples throughout the trial. Patients undergo a tumor biopsy during screening and optionally during follow-up.
33258009|NCT05134571|Experimental|Aldurazyme (laronidase)|Aldurazyme (laronidase) treatment at approved dose and regimen, administered every week as an IV infusion
33258010|NCT05130229|Experimental|Sleep Well Bee Well|Sleep program to help toddlers sleep better
33258011|NCT05130229|Placebo Comparator|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
33258012|NCT05124158||Patients with a diagnosis of COVID-19|"A directed psychiatric evaluation will be carried out and 1 evaluation instrument will be applied: Global Tool for the Evaluation of Mental Health in Primary Care (GMHAT / PC).~The Global Mental Health Assessment Tool / Primary Care (GMHAT / PC) is a computerized, semi-structured clinical interview tool developed to assess and identify mental health problems. The main diagnosis derives from the use of a hierarchical model based on ICD-10. The diagnostic program takes into account the severity of symptoms (moderate to severe). It also generates alternative diagnoses and comorbidity states based on the presence of symptoms of other disorders. In addition, it includes a suicide risk assessment."
33076939|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
33076940|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
33076941|NCT03869710|Experimental|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
33076942|NCT03852706|Experimental|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
33076943|NCT03852706|Other|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
33076944|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
33076945|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
33076946|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
32743134|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
32743135|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
33076947|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
33076948|NCT00167687|Placebo Comparator|2|
33076949|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
33076950|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
32734849|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
32734850|NCT04471805|Sham Comparator|Women Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
32734851|NCT04471805|Experimental|Women tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
32734852|NCT04471805|Sham Comparator|Women Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
32734853|NCT04471805|Experimental|Women tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
33076951|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
33076952|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
33258013|NCT05120089|Experimental|muscle energy technique|Muscle energy technique is an associate degree of osteopathic manipulation methodology. The muscles of patients were used, on request, to type a singular controlled position, in a very specific direction, and against a distinctly executed therapist-applied counterforce. Muscle energy technique could be a post-isometric relaxation, because it reduces the tone of a muscle or cluster of muscle after a brief period following an isometric contraction. The result of post-isometric relaxation is mediated by receptive input from Golgi connective tissue organ (GTO) that has associate degree repressive result on the antagonist muscles mediated by the muscle spindle receptive. The technique will be applied for three month (3 session/week)
33258014|NCT05120089|Experimental|myofacial release|The technique will be applied for three month (3 session/week). All participants underwent ipsilateral side bending in a side-lying position, with the goals being de-rotation and scoliosis reduction.
33076953|NCT02906683|Experimental|TAS-303 3mg|
33076954|NCT02906683|Experimental|TAS-303 6mg|
33076955|NCT02906683|Placebo Comparator|Placebo|
33076956|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
33076957|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
32734854|NCT04471805|Sham Comparator|Men Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
32734855|NCT04471805|Experimental|Men tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
32734856|NCT04471805|Sham Comparator|Men Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
32734857|NCT04471805|Experimental|Men tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
33076958|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
33076959|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
33076960|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
33076961|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
33277492|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
32734858|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
32734859|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
32734860|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
32734861|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
32734862|NCT04440449|Experimental|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
32734863|NCT04440449|Other|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
32734864|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
32734865|NCT04403789|Experimental|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
32734866|NCT04403789|Active Comparator|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
32734867|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
32734868|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
32734869|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
32734870|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
32734871|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
32734872|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
32734873|NCT04385537|No Intervention|Control|Participants in this group avoid all nuts for 4-weeks
32734874|NCT04385537|Experimental|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
32734875|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
32734876|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
32734877|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
32734878|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
32734879|NCT03375905|Experimental|cNEP|cNEP treatment
32734880|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
32734881|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
32734882|NCT02519543|Placebo Comparator|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
32734883|NCT02519543|Experimental|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
32734884|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
32734885|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
32734886|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
32734887|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
32734888|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
32734889|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
32734890|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
32734891|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
32743136|NCT04421937|Experimental|Neuromuscular Electrical Stimulation (NMES) with TDT|
33258017|NCT05115110|Experimental|RO7204239 + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive RO7204239 (low or high dose) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with RO7204239 + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
32734892|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
32734893|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
33258018|NCT05115110|Active Comparator|Placebo + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive placebo (low or high dose-matched) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with placebo + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
33258019|NCT05113966|Experimental|Trilaciclib + Sacituzumab Govitecan-hziy|During the Treatment Phase patients will receive trilaciclib + sacituzumab govitecan-hziy on days 1 & 8 of a 21 day cycle. Trilaciclib is administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion to be completed within 4 hours prior to the start of sacituzumab govitecan-hziy.
33258020|NCT05110326|Experimental|ERGON Technique Group|Patients in this group will receive ERGON Technique along with conventional therapy
33258021|NCT05110326|Experimental|Proprioceptive Neuromuscular Facilitation(PNF) stretching Group|Patients in this group will receive Proprioceptive Neuromuscular Facilitation (PNF) stretching along with conventional therapy
33258022|NCT05109884|Other|newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer|
33258023|NCT05109884|Other|metastatic, castration resistant prostate cancer|
32734894|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
32734895|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
32734896|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
32734897|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
32734898|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
32734899|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
33258024|NCT05109884|Other|newly diagnosed prostate cancer with planned radical prostatectomy|
33258025|NCT05109884|Other|primary bladder cancer with planned radical cystectomy|
33258026|NCT05103345|Other|Cohort|"The standard 3+3 dose escalation algorithm will be applied to explore dose limiting toxicity (DLTs) in up to 5 sequential cohorts with 3- 6 patients and identify the maximally tolerated dose (MTD).~When the cohort is completed in Part 1, the Part 2 study could be started according to the SMC evaluation (If there is no DLT, and there is the complete response [CR] or partial response [PR] observed at the cohort or at least all patients have stable disease [SD] result available for the tumor assessment)."
33258027|NCT05101564|Experimental|IC1:Alpelisib in combination with Tamoxifen|Integrative subtype IC1, Treatment (14 days, - 2 or + 7 days): Take assigned alpelisib pills, 300 mg (two 150 mg tablets) with food, once daily by mouth. Tamoxifen pills, 20 mg once daily by mouth
33258028|NCT05101564|Active Comparator|IC1:Tamoxifen|Integrative subtype 1, Treatment (14 days, -2 to +7 days): Take assigned tamoxifen pills, 20 mg once daily by mouth
33258029|NCT05101564|Experimental|IC2:Zotatifin in combination with Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
32743137|NCT04421937|Active Comparator|Traditional Dysphagia Therapy (TDT)|
32743138|NCT03246737||pregnant women|
33258030|NCT05101564|Active Comparator|IC2:Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258031|NCT05101564|Experimental|IC3:Zotatifin in combination with Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
32734900|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
32734901|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
33076962|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
33076963|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
33258032|NCT05101564|Active Comparator|IC3:Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1. on Day 1.
33258033|NCT05101564|Experimental|IC4:Zotatifin in combination with Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258034|NCT05101564|Active Comparator|IC4:Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1..
32734902|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
33258035|NCT05101564|Experimental|IC6:Zotatifin in combination with Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
32734903|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
32734904|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
32734905|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
32734906|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
32734907|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
32734908|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
32734909|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:~Adult patients (≥18 years);~Of Italian mother tongue;~Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit~The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies~Give full, written informed consent~The following exclusion criteria will be applied:~PDAC recurrence after previous diagnosis and treatment~poor performance status (ECOG ≥ 3);"
32734910|NCT04525235|Active Comparator|Rifampicin standard dose|rifampicin standard dose + phenotyping cocktail
32734911|NCT04525235|Experimental|Rifampicin high dose|rifampicin high dose + phenotyping cocktail
32734912|NCT04240639|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
32734913|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
32734914|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
32734915|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
32734916|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
32734917|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
32734918|NCT03286621||Typically Developing Children|Typically developing children
32734919|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
32734920|NCT03363737|Active Comparator|Static|
32734921|NCT03363737|Experimental|Dynamic|
32734922|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
32734923|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
32734924|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
32734925|NCT04523909||Thoracic aortic surgery patients|
32734926|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
33076964|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
33076965|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
33258036|NCT05101564|Active Comparator|IC6:Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258037|NCT05101564|Experimental|IC7:Zotatifin in combination with Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258038|NCT05101564|Active Comparator|IC7:Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258039|NCT05101564|Experimental|IC8:Zotatifin in combination with Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258040|NCT05101564|Active Comparator|IC8:Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
33258041|NCT05094505|Active Comparator|CONTROL GROUP|Exercise at sea level, normoxia. Control diet.
33258042|NCT05094505|Experimental|Ex. Hyp. GROUP|Exercise in hypoxia at 3000m altitude. Control diet.
33258043|NCT05094505|Experimental|Ex. Hyp. + LCD GROUP|Exercise in hypoxia at 3000m altitude. Low carbohydrate diet.
33258044|NCT05086796|Active Comparator|Substance Use Treatment and Recovery Team (START)|The intervention is administered to participants in this arm. Participants in this arm will work with the Substance Use Treatment and Recovery Team (START), a collaborative care team for inpatients with opioid use disorder.
33258045|NCT05086796|No Intervention|Usual Care|Usual care for people with opioid use disorder.
33258046|NCT05086380|Experimental|FND Patients Experimental|Group of patients with functional neurological disorders
32734927|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
32734928|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
32734929|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
32734930|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
32734931|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
32734932|NCT03363581||Control|Normal Weight Healthy Controls
32734933|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
32734934|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
32734935|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
32734936|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
32734937|NCT03363425|Active Comparator|Lidocaine|
32734938|NCT03363425|Active Comparator|Dexmedetomidine|
32734939|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
32734940|NCT03292783|Experimental|NOV150101 (ABL001)|
32734941|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
32734942|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
32734943|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
32734944|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
32734945|NCT03298555|No Intervention|Control|This group will only receive standard care.
32734946|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
32734947|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
32734948|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
32734949|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
32734950|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
33076966|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
33076967|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
32769387|NCT04812977|Experimental|Group A|A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
32769388|NCT04812977|Active Comparator|Group B|Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
32769389|NCT05052073||MD patients|"patients with different forms of muscle dystrophy, for example~facioscapulohumeral dystrophy~dysferlinopathy~caveolinopathy"
33076968|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
33258047|NCT05086380|Active Comparator|Organic controls|Group of patients with organic neurological disorders
32769390|NCT05052073||Controls|- healthy age- and sex-matched controls (10 men, 10 women)
32769391|NCT04813133|Experimental|Synchronized Lifestyle Modification Program|Synchronized Lifestyle Modification Program
32769392|NCT04813133|Experimental|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronized Lifestyle Modification Program and Physiotherapy
32769393|NCT04813133|Experimental|Physiotherapy|Physiotherapy included Aerobics, Resistance exercise, Flexibility exercise, and Balance exercise.
32769394|NCT04813133|No Intervention|Control Group|No intervention will be given to this Group
32769395|NCT05032027|Experimental|Probiotic group|Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention
32769396|NCT05032027|No Intervention|placebo group|placebo( one times a day)with radiotherapy and Chemotherapy Intervention
32769397|NCT05032027|No Intervention|healthy control group|healthy control group
32769398|NCT04813289||Anaesthesia type|"Inhalational anaesthesia without Remifentanil use~Inhalational anaesthesia with Remifentanil use~Total intravenous anaesthesia"
32769399|NCT04813289||Blood pressure monitoring|"Intraarterial line use~Non-invasive blood pressure monitoring"
32769400|NCT04813211|Experimental|Trial group|20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
33258048|NCT05086380|Active Comparator|Healthy controls|Group of healthy controls
33258049|NCT05086380|Active Comparator|FND Patients Comparator|Group of patients with functional neurological disorders
33258050|NCT05080491|Experimental|Determination of thyroid profile and neuropsychological assessment|
32769401|NCT04813211|Experimental|Control group|20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
32769402|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
32769403|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
32769404|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
32769405|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
32769406|NCT05619341|Placebo Comparator|inulin|20g inulin in 500ml water
32769407|NCT05619341|Active Comparator|inulin + psyllium|Inulin 20g + 20g psyllium in 500 ml water
32769408|NCT05619341|Active Comparator|inulin divided doses|2.5 g inulin in 62.5ml water given at 45 minute intervals
32769409|NCT05040919||with an arrythmia|patient suffering from STEMI and presenting an arrythmia
32769410|NCT05040919||without an arrythmia|patient suffering from STEMI and not presenting an arrythmia
32769411|NCT05040607||Primary Ciliary Dyskinesia (PCD)|"The first stage of the study:~Data of 20 PCD patients from the database recorded between 10 July 2015 and 10 January 2017.~The second stage of the study:~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent supervised inspiratory muscle training (IMT) at our research unit and airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017.~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017."
32769412|NCT05040607||Healthy Group|Data of 20 healthy subjects from the database recorded between 10 July 2015 and 10 January 2017.
32769413|NCT04818827||Ketamine group|This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
32769414|NCT04818827||Non Ketamine group|This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
32769415|NCT05040529||PLDRH|patients who underwent pure laparoscopic donor right hepatectomy
32769416|NCT05040529||ODRH|patients who underwent conventaional open donor right hepatectomy
32769417|NCT05040139||Malone procedure|The percutaneous caecal access is performed surgically
32769418|NCT05040139||Percutaneous Endoscopic Caecostomy|The percutaneous caecal acces is performed endoscopically.
32769419|NCT05031793|Experimental|Collaborative Care of TCM and Western Medicine|
32769420|NCT05031793|Active Comparator|Western medicine|
32769421|NCT05039905|Experimental|99mTc-MSA-ICG injection|"99mTc-MSA-ICG injection~1mCi of 99mTc~1mg of MSA 0.1mg of ICG Total 1cc injection volume at 2 hours before the surgery"
33258051|NCT05079347|Experimental|Healer led HIV testing|"Traditional healers will offer HIV testing to their patients. They will provide the test result to patients. If the patient is positive they will refer their patients to the health facility via referral form and/or walk them to the clinic (based on patient preference). If the patient is negative, the healer will encourage them to re-test at the health facility in 6 months during an open house event where healers will attend to try and de-stigmatize going to the health facility."
33258052|NCT05076617|Experimental|Staccato alprazolam|Participants will receive Staccato alprazolam by inhalation.
33258053|NCT05076175|Experimental|Ozanimod High Dose|
33258054|NCT05076175|Experimental|Ozanimod Low Dose|
33258055|NCT05073484|Experimental|10 mg of BAT6021|BAT6021 100mg/vial，10mg Ⅳ infusions
33258056|NCT05073484|Experimental|30 mg of BAT6021|BAT6021 100mg/vial，30mg Ⅳ infusions
33258057|NCT05073484|Experimental|100 mg of BAT6021|BAT6021 100mg/vial，100mg Ⅳ infusions
33258058|NCT05073484|Experimental|300 mg of BAT6021|BAT6021 100mg/vial，300mg Ⅳ infusions
32734951|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
32734952|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
33258059|NCT05073484|Experimental|600 mg of BAT6021|BAT6021 100mg/vial，600mg Ⅳ infusions
33258060|NCT05073484|Experimental|900 mg of BAT6021|BAT6021 100mg/vial，900mg Ⅳ infusions
32734953|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
32734954|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
32734955|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
32734956|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
32734957|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
32734958|NCT03368339|Placebo Comparator|Vehicle|Placebo
33258061|NCT05073484|Experimental|100mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
32734959|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
33258062|NCT05073484|Experimental|300mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions
33258063|NCT05073484|Experimental|600mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions
33258064|NCT05071014|Experimental|pembrolizumab followed by cryoablation|The treatment will consist of 1 cycle of pembrolizumab (200mg/flat dose) intravenously followed by cryoablation of an ablation index lesion 1-7 days prior to the start of cycle 2. Pembrolizumab will be continued for up to 24 months, until disease progression, or intolerable toxicity. Treatment beyond progression at discretion of the treating physician and Study PI. There will be a research biopsy within 1 week of cycle 5 start and an optional biopsy at end of treatment and/or progression of disease.
32734960|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
32734961|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
32734962|NCT03363269|Experimental|ID1201 100mg|
32734963|NCT03363269|Experimental|ID1201 200mg|
32734964|NCT03363269|Experimental|ID1201 400mg|
32734965|NCT03363269|Placebo Comparator|Placebo|
32734966|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
32734967|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
32734968|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
33258069|NCT05069259||Patients with active Ulcerative Colitis|
33258070|NCT05061550|Experimental|Oleclumab + Durvalumab + Platinum doublet chemotherapy|"Participants will receive Durvalumab + Oleclumab + platinum doublet chemotherapy as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
33258071|NCT05061550|Experimental|Monalizumab + Durvalumab + Platinum doublet chemotherapy|"Participants will receive Durvalumab + Monalizumab + platinum doublet chemotherapy as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
33258072|NCT05061550|Experimental|MEDI5752 + Platinum doublet chemotherapy|"Participants will receive MEDI5752 + platinum doublet chemotherapy as neoadjuvant treatment and MEDI5752 as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
32935456|NCT05368129|Active Comparator|NCB group|A total of 24 patients are assigned to NCB group after randomization schedule.
32935457|NCT05448001|Experimental|Study Group|
32935458|NCT05448001|Active Comparator|Control Group|
32935459|NCT05366257||CAR-T: Inpatient (IP) Cohort|Patients received CAR-T infusion in IP setting
32935460|NCT05366257||CAR-T: Outpatient (OP) Cohort|Patients received CAR-T infusion in OP setting
32935461|NCT05366257||Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
32935462|NCT05340673|Experimental|Arm I (Aquaphor)|Beginning on day 1 of radiation therapy, patients apply Aquaphor BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
32935463|NCT05340673|Experimental|Arm II (Miaderm)|Beginning on day 1 of radiation therapy, patients apply Miaderm BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
32734969|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
32734970|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
32734971|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
32734972|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
32734973|NCT04523987|Experimental|gemcitabine and nab-paclitaxel chemotherapy|Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
32734974|NCT03292627||mid age|mid age: 50-70 years old
32734975|NCT03292627||old age|old age: age older than 70 years old
32734976|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
32734977|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
32734978|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
32734979|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
32734980|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
32734981|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
32734982|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
32734983|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
32734984|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
32734985|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
32734986|NCT03292549||Patients|Robotic partial surgery
32734987|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
32734988|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
32734989|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
32734990|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
32734991|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
32734992|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
32734993|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
32734994|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
32734995|NCT03285841||Vulvar sites|Imaging vulvar lesions
33076969|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
33076970|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
33076971|NCT02906293||Healthy Participants|Potential participants will self-refer.
33258073|NCT05061550|Experimental|Dato-DXd + durvalumab + single agent platinum|"Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:~Carboplatin or Cisplatin"
33258074|NCT05061550|Experimental|AZD0171 + durvalumab + platinum doublet chemotherapy|"Participants will receive AZD0171 + durvalumab + platinum doublet chemotherapy as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
33076972|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
33076973|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
33258075|NCT05061316|Experimental|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
33258076|NCT05060016|Experimental|Part 1: Tarlatamab Low Dose|Participants will receive the low dose of Tarlatamab.
33258077|NCT05060016|Experimental|Part 1: Tarlatamab High Dose|Participants will receive the high dose of Tarlatamab.
33076974|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
33076975|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
33258078|NCT05060016|Experimental|Part 2: Dose Expansion|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.
33258079|NCT05060016|Experimental|Part 3: Modified Monitoring Substudy|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1 with reduced Cycle 1 monitoring requirements.
32769422|NCT05039983|Experimental|EGCG application|We have chosen a dose of 880 umol/L as the lower limit for this phase I study by referring to previous studies. Six dose levels for EGCG were defined as following: 880, 1760, 2640, 3430, and 4400 umol/L per dose. Dose escalation proceeded according to a standard phase I design with three patients initially treated on each tier. If, on any dose tier of EGCG, two of three patients or two of six patients experienced a grade III or IV toxicity due to EGCG, dose escalation of EGCG would cease. The maximally tolerated dose (MTD) was defined as the highest dose with fewer than one-third of patients experiencing a dose-limiting toxicity (DLT) due to EGCG. EGCG solution was given continuously for 8 days before anti-tumor treatment.
32769423|NCT05031403|Experimental|Stroke (Telerehabilitation)|Exercise therapy with telerehabilitation system
32769424|NCT05031403|Other|Stroke (Home Exercise)|Exercise therapy with brochure
33076976|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
33076977|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
33258080|NCT05058963|Experimental|Mantram repetition program|Weekly 90 minute virtual group therapy sessions for 8 weeks run by two faciliators and will consist of 5-8 participants.
33258081|NCT05047172|Experimental|Experimental Arm: Ticagrelor and Aspirin|Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
33258082|NCT05047172|Active Comparator|Standard of Care Arm: Clopidogrel and Aspirin|Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)
33258083|NCT05047172|Experimental|Experimental Arm: Rivaroxaban and Aspirin|Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
33076978|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
33076979|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
33076980|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
33258084|NCT05044013|Experimental|JomPrEP App Group|Participants in the JomPrEP group will be provided with full app access and will be encouraged to use all features of the app.
33258085|NCT05044013|Active Comparator|Control Group|Participants in the control group will receive the JomPrEP app with major intervention features inactivated.
33258086|NCT05038228||NVAF High GI bleed risk|NVAF patients with a high risk of gastrointestinal bleeding
33258087|NCT05038150|Experimental|Cohort|Cohorts of 3 patients will be enrolled. The first patient of each cohort in Part 1 will be admitted to an infusion unit and treated with an IV infusion of SGN1 over 2 hours. All dosed patients will be closely evaluated for DLTs for 28 days post first dose. Up to 5 cohorts will be evaluated.
33258088|NCT05036993|Experimental|Intervention|Coaching
33258089|NCT05036993|Experimental|Control|Control, Coaching later
33258090|NCT05033821|Experimental|Intervention|Participants who receive the FOY+ImPACT intervention
33258091|NCT05033821|No Intervention|Control|Participants who receive standard library programing, but not the FOY+ImPACT intervention.
33258092|NCT05026645||adult inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258093|NCT05026645||Infant inflicted by a CBRNE weapon|Part of the population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258094|NCT05026645||Women inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258095|NCT05026645||Men inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258096|NCT05026645||Elderly inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258097|NCT05026645||Diagnosed with chronic disease(s) inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
33258098|NCT05026645||Clinician (adult) whom performs his/her clinical interventions|Clinician (adult) whom performs his/her clinical interventions while integrating competences in protections and decontamination. Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician is required to ensure safety toward his/her patient while performing his/her interventions & procedures.
33258099|NCT05026645||Clinician (adult) injured by duties circumstances|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician becomes inflicted by a CBRNE weapon while intervening toward contaminated patient due to any failure in protection and decontamination.
33258100|NCT05025865|Placebo Comparator|HA35 Placebo Group|12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.
33076981|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
32734996|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
32734997|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
32769425|NCT05031403|Experimental|Multiple Sclerosis (Telerehabilitation)|Exercise therapy with telerehabilitation system
32769426|NCT05031403|Other|Multiple Sclerosis (Home Exercise)|Exercise therapy with brochure
33258101|NCT05025865|Active Comparator|HA35 Treatment Group|12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.
33258102|NCT05022290|Experimental|Single-syringe technique|Patients in this arm will receive adenosine in a single syringe, diluted with normal saline up to 20 ml. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
33258103|NCT05022290|Active Comparator|Double-synring technique|Patients in this arm will receive adenosine using a double syringe, the first syringe contains only adenosine and the second syringe contains only normal saline 20 ml. Both syringes are connected to each other, and to the patient's IV portal with a stopcock. The administration must be done by two nurses one after another, adenosine syringe is injected first, then follow by normal saline. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
33258104|NCT05017935|Experimental|Renal Denervation|
33258105|NCT05012397|Experimental|Milademetan (RAIN-32)|260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
33258106|NCT05010525|Experimental|ATG-016-20mg|20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
33258107|NCT05010525|Experimental|ATG-016-35mg|35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
33258108|NCT05010525|Experimental|ATG-016-50mg|50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
33258109|NCT05010525|Experimental|ATG-016-65mg|65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
32769427|NCT05031403|Experimental|Parkinson Disease (Telerehabilitation)|Exercise therapy with telerehabilitation system
33258111|NCT05005741|Experimental|Beinaglutide|
33076982|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
33076983|NCT00177840|Experimental|1|True acupuncture using true needles
33076984|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
33076985|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
33258112|NCT05005741|Active Comparator|Dulaglutide|
33258113|NCT05002829|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
33258114|NCT05002829|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
33258115|NCT04995029|Experimental|Induction Phase: Rapid Induction|Participants will receive 4 mg transmucosal buprenorphine on Day 1. Participants meeting eligibility requirements will then receive 300 mg extended-release buprenorphine by subcutaneous injection at least 1 hour later and a second dose on Day 8.
33258116|NCT04995029|Experimental|Induction Phase: Standard of Care Induction|Participants will receive transmucosal buprenorphine for a minimum of 7 days per applicable product labelling information. Participants meeting eligibility requirements will receive 300 mg extended-release buprenorphine by subcutaneous injection on Day 1 and a second dose on Day 8.
33258117|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 100 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 100 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
33258118|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 300 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 300 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
33258119|NCT04994990|Active Comparator|Standard Dosing Group|
33258120|NCT04994990|Experimental|Half Standard Dosing Group|
32769428|NCT05031403|Other|Parkinson Disease (Home Exercise)|Exercise therapy with brochure
33076986|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
33258121|NCT04994717|Experimental|Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy|"The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.~The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion."
33258122|NCT04994717|Experimental|Phase 3: Blinatumomab alternating with low-intensity chemotherapy|Participants will receive blinatumomab alternating with low-intensity chemotherapy.
33258123|NCT04994717|Active Comparator|Phase 3: Standard of care (SOC) chemotherapy|Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.
33258124|NCT04987229|Experimental|All subjects|All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)
33258125|NCT04984226|Experimental|Sodium bicarbonate 16 weeks|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
33258126|NCT04984226|Placebo Comparator|placebo 16 weeks|Microcrystalline cellulose
33258127|NCT04976855|Placebo Comparator|Part I: Placebo|Healthy volunteers will receive placebo either once daily or twice daily for 7 days.
32769429|NCT05039827|Experimental|MWM GROUP|Mobilization with movement with wrist extension
32734998|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
33258128|NCT04976855|Experimental|Part I: INDV-2000|Healthy volunteers will receive INDV-2000 once daily or twice daily for 7 days.
33258129|NCT04976855|Placebo Comparator|Part II: Placebo|Healthy volunteers will receive placebo twice daily for 28 days.
32734999|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
32735000|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
32735001|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
32735002|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
32735003|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
32735004|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
32735005|NCT03367481|Active Comparator|Control toothbrush|The participants will use a toothbrush with soft bristles.
32735006|NCT03367481|Experimental|Test toothbrush|The participants will use a toothbrush with medium bristles.
32735007|NCT03292159|Experimental|RAVANS|
32735008|NCT03292159|Sham Comparator|Sham stimulation|
32735009|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
32735010|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
32735011|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
32735012|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
32735013|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
32735014|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
32735015|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
32735016|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
32735017|NCT04036799||Hypertrophic Cardiomyopathy|
32735018|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
32743139|NCT04937907|Experimental|Hydroxychloroquine Cohort|Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).
32935464|NCT05301751|Experimental|Cohort 1|A single intravitreal (IVT) dose of 0.5 mg AG-73305
33258130|NCT04976855|Experimental|Part II: INDV-2000|Healthy volunteers will receive INDV-2000 twice daily for 28 days.
33258131|NCT04976855|Experimental|Part III: INDV-2000 + SUBOXONE|Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.
33258132|NCT04976634|Experimental|Arm 1: Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg (For HCC: 8 mg [body weight <60kg] or 12 mg [body weight ≥ 60 kg]). Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
33076987|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
33258133|NCT04976634|Experimental|Arm 2: Pembrolizumab + Lenvatinib|Participants with IO resistant ESCC will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
33258134|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 1|Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
33258135|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 2|
33258136|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 3|
33258137|NCT04975997|Active Comparator|Daratumumab in combination with dexamethasone and bortezomib|Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
33258138|NCT04974216|Experimental|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
33258139|NCT04972552|Active Comparator|Watermelon Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus diet high in watermelon
33258140|NCT04972552|Active Comparator|Usual Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus no watermelon in diet
33258141|NCT04972552|Placebo Comparator|Watermelon Diet & Placebo|Placebo pill plus diet high in watermelon
33258142|NCT04972552|Placebo Comparator|Usual Diet & Placebo|Placebo pill plus no watermelon in diet
33258143|NCT04957719|Experimental|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
32735019|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
33258144|NCT04957719|Placebo Comparator|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
33258145|NCT04955925||Sevoflurane group|Anesthesia is maintained with sevoflurane during the surgery.
32743140|NCT04937907|Sham Comparator|Comparator Cohort|During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
32743141|NCT03246971|Experimental|Wafermine™|
33076988|NCT04681885|Experimental|Tapered bristles A|
33258146|NCT04955925||Propofol group|Anesthesia is maintained with total venous anesthesia using propofol during the surgery.
33258147|NCT04947865|Experimental|Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
33258148|NCT04947865|Experimental|Healthy Individuals|Healthy Individuals
33258149|NCT04944862|Experimental|CDX-0159 1.5mg/kg|CDX-0159 1.5mg/kg administered once
33258150|NCT04944862|Experimental|CDX-0159 3mg/kg|CDX-0159 3.0 mg/kg administered once
33258151|NCT04944862|Placebo Comparator|Placebo|Normal saline administered once
33258152|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
33258153|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
33258154|NCT04936685|Experimental|Group 1|Participants will receive a first booster dose of MenACYW conjugate vaccine at Day 1 and a second booster dose at year 5 of study MEQ00073
33258155|NCT04936685|Experimental|Group 2|Participants will receive a single booster dose of MenACYW conjugate vaccine at year 5 of study MEQ00073
33258156|NCT04934332|Experimental|Newly hospitalized patients|Patients admitted for the first time to a post intensive care rehabilitation unit after severe neurological trauma.
33258158|NCT04924699|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
33258159|NCT04924699|Active Comparator|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection will be administrated via intravenous infusion of 3.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
33258160|NCT04920084|Experimental|Plant-based meals|Patients who will be administered a whole-foods plant-based diet for 12 weeks with nutrition counselling for 24 weeks.Participants will be asked to complete a survey via MSK Engage and a notification will be sent via email notification.
33258161|NCT04915729|Experimental|tenecteplase|Treatment Group
33258162|NCT04915729|Active Comparator|alteplase|Active control group
32743142|NCT03246971|Placebo Comparator|Placebo|
33076989|NCT04681885|Active Comparator|Tapered bristles B|
33076990|NCT04681885|Active Comparator|End rounded bristles|
33258163|NCT04910685|Experimental|(Part 1) BLU-263 Dose 1 + BSC|Patients will receive best supportive care (BSC) and Dose 1 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
33258164|NCT04910685|Experimental|(Part 1) BLU-263 Dose 2 + BSC|Patients will receive best supportive care (BSC) and Dose 2 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
33258165|NCT04910685|Experimental|(Part 1) BLU-263 Dose 3 + BSC|Patients will receive best supportive care (BSC) and Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
33258166|NCT04910685|Placebo Comparator|(Part 1) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1
33258167|NCT04910685|Experimental|(Part 2) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for approximately 24 weeks
33258168|NCT04910685|Placebo Comparator|(Part 2) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks
33076991|NCT04681924|Experimental|Low carb diet|Low carb diet (n=54)
33258169|NCT04910685|Experimental|(Part 3) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablet in an open-label fashion for up to 5 years.
33258170|NCT04910685|Experimental|(Part M) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for the duration of participation in the study.
33258171|NCT04910685|Experimental|PK Groups (Dose 2 or Dose 3)|Patients will receive best supportive care (BSC) and Dose 2 or Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally for the duration of participation in the study.
33258172|NCT04909229|Experimental|PEAR-003b PDT Intervention|Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
33258173|NCT04909229|Placebo Comparator|Control Arm|Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
33258174|NCT04907539|Experimental|Arm A: RXC004 monotherapy|"Patients will receive RXC004 (2 mg once daily [QD], orally).~Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression)."
33258175|NCT04907539|Experimental|Arm B: RXC004 + nivolumab|"Patients will receive RXC004 (1.5 mg QD, orally) in combination with nivolumab (480 mg every 4 weeks [q4w], intravenous [IV] infusion).~Arm B will be opened once a RP2D for RXC004 in combination with nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with nivolumab will be based on data from the phase 1 study (NCT03447470)."
33258176|NCT04907227|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
32735020|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
32735021|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
32935465|NCT05301751|Experimental|Cohort 2|A single IVT dose of 1 mg AG-73305
32935466|NCT05301751|Experimental|Cohort 3|A single IVT dose of 2 mg AG-73305
32935467|NCT05301751|Experimental|Cohort 4|A single IVT dose of 3 mg AG-73305
32935468|NCT05447845||Healthy|healthy volunteers with no known ocular condition
32935469|NCT05447845||Patients|Subjects with diseases of the eye or the orbit
32935470|NCT05447767|Active Comparator|intra-articular injection of BMAC|intra-articular injection of BMAC
32935471|NCT05447767|Active Comparator|intra-osseous and intra-articular injection of BMAC|intra-osseous and intra-articular injection of BMAC
32935472|NCT05447767|Active Comparator|intra-articular injection of at- SVF|intra-articular injection of at- SVF
32935473|NCT05447767|Active Comparator|intraosseous and intra-articular injection of at-SVF|intraosseous and intra-articular injection of at-SVF
33076992|NCT04681924|Experimental|Low fat diet|Low fat diet (n=40)
33258177|NCT04907227|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
33258178|NCT04907097|Other|MOF/placebo|During period 1 (4 weeks) participants will receive monomeric and oligomeric flavanols and during period 2 (4 weeks) placebo. Wash out period between two interventions will be 4 weeks. The daily dose of monomeric and oligomeric flavanols will be 200 mg (2 capsules once a day) and for placebo (2 capsules once a day).
32735022|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
33258179|NCT04907097|Other|Placebo/MOF|During period 1 (4 weeks) participants will receive placebo and during period 2 (4 weeks) monomeric and oligomeric flavanols. The wash out period between two interventions will be 4 weeks. The daily dose of placebo will be 2 capsules once a day and for monomeric and oligomeric flavanols 200 mg (2 capsules once a day).
33258180|NCT04901325|Experimental|Baricitinib for PG|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
33258181|NCT04895358|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg administered by intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W) PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle (Q4W), 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 by oral administration (PO) twice a day (BID) on Days 1-14 Q3W for up to 35 administrations.
33258182|NCT04895358|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline or dextrose) IV on Day 1 Q3W PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 Q4W, 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 PO BID on Days 1-14 Q3W for up to 35 administrations.
33258183|NCT04894682||Vaccinated Case|Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
32735023|NCT04527055|Active Comparator|The 14-day bismuth-based quadruple therapy group|The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
33258184|NCT04894682||Vaccinated Healthy Control|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
33258185|NCT04894682||Unvaccinated Case|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2
33258186|NCT04893798|Experimental|Sayana Press, Upper Arm injection|Sayana Press, administered subcutaneously into upper arm
33258187|NCT04893798|Active Comparator|Sayana Press, anterior thigh|Sayana Press, administered subcutaneously into anterior thigh
32743143|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
33076993|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
33258188|NCT04893798|Active Comparator|Sayana Press, abdomen|Sayana Press, administered subcutaneously into abdomen
33076994|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
33076995|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
33258189|NCT04892537|Active Comparator|CSR|Coronary Sinus Reducer implantation
33258190|NCT04892537|Placebo Comparator|Placebo|Placebo procedure
33258191|NCT04889911|Experimental|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a structured, 20-session group-based treatment called that combines psychoeducation, cognitive restructuring, and elements of narrative psychotherapy. NECT-YA will be modified to meet the needs of people who have experienced an FEP and may have fewer sessions or be provided in individual format or via telehealth for this study. NECT-YA will be offered to participants who are also receiving treatment within Coordinated Specialty Care programs for First Episode Psychosis.
33258192|NCT04889911|Active Comparator|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based treatment for FEP that includes multiple treatment components. The FEP programs in at the recruiting site follow the Coordinated Specialty Care model.
33258193|NCT04889209|Experimental|Cohort 1 Group 10E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
33258194|NCT04889209|Experimental|Cohort 1 Group 11E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
33258195|NCT04889209|Experimental|Cohort 1 Group 12E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA- 1273 N = 50
33076996|NCT02905513|Placebo Comparator|Control|App only
33076997|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
33076998|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS~Patient will be paired to index case by:~Hospital site~Age~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
33258196|NCT04889209|Experimental|Cohort 1 Group 13E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna-mRNA-1273 at 100mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
33258197|NCT04889209|Experimental|Cohort 1 Group 14E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
33258198|NCT04889209|Experimental|Cohort 1 Group 15E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp for one or two doses stratified with two age ranges of 18-55 years (n= 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
33258199|NCT04889209|Experimental|Cohort 1 Group 16E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
33258200|NCT04889209|Experimental|Cohort 1 Group 17E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
33258201|NCT04889209|Experimental|Cohort 1 Group 1E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
33258202|NCT04889209|Experimental|Cohort 1 Group 2E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
33258203|NCT04889209|Experimental|Cohort 1 Group 3E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n ˜ 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
32735024|NCT04527055|Active Comparator|The 10-day bismuth-based quadruple therapy group|The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
32735025|NCT04527055|No Intervention|The non-H. pylori-infected control|Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.
32735026|NCT04527055|Active Comparator|The probiotic therapy group|"The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
32735027|NCT04527055|No Intervention|The non-probiotic control group|The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.
32735028|NCT03362645||Fabry cardiomyopathy|
32735029|NCT03362645||Hypertrophic cardiomyopathy|
32735030|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
32735031|NCT03292081|Experimental|OFDI-guided PCI|
32735032|NCT03292081|Active Comparator|IVUS-guided PCI|
32735033|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
32735034|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
32735035|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
32735036|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
32735037|NCT04019093|Experimental|Jaw pain patients|Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
32735038|NCT04019093|Experimental|Healthy controls|Healthy social drinkers without jaw pain recruited as a comparison group.
32735039|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
32735040|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
32735041|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
32735042|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
32735043|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
32735044|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
33258204|NCT04889209|Experimental|Cohort 1 Group 4E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
33258205|NCT04889209|Experimental|Cohort 1 Group 5E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
33258206|NCT04889209|Experimental|Cohort 1 Group 6E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
33258207|NCT04889209|Experimental|Cohort 1 Group 7E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp stratified with two age ranges of 18-55 years (n=˜ 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
33076999|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
33258208|NCT04889209|Experimental|Cohort 1 Group 8E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
33258209|NCT04889209|Experimental|Cohort 1 Group 9E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
33258210|NCT04889209|Experimental|Cohort 2|A prospective design cohort with naïve to COVID-19 vaccine and infection participants of > / = 18 years of age to receive COVID-19 vaccine intramuscularly under Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100mcg dose at a 28 days of interval) followed by a delayed booster vaccination (50 mcg mRNA-1273) after a minimum of 12 weeks. Additional pools of subjects can be included as additional COVID-19 vaccines are awarded EUA (e.g., Janssen - Ad26.COV2.S or Novavax- NVX-CoV2373). A second booster (fourth dose) will be administered intramuscular using Moderna mRNA-1273.222 at 50 mcg at a 4-12 month interval N=250
33258211|NCT04885205|Experimental|CBT-I Initial Group|The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
33077000|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
33077001|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
32735045|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
32735046|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
32735047|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
32735048|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
32735049|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
32735050|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
32735051|NCT03298243|Experimental|Stroke Cohort - Optimize Delivery|Aim 1 intervention: Vibrotactile stimulation. An optimal location and style of vibrotactile feedback for reach and stabilization behaviors will be determined.
32735052|NCT03298243|Experimental|Stroke Cohort - Extended Training|Aim2 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching and stabilizing tasks using vibrotactile feedback to guide performance
32743144|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
32735053|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
32735054|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
32735055|NCT02460289|Experimental|Treatment|
32735056|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:~20-minute Ekso GT gait training with high swing assistance~20-minute Ekso GT gait training with neutral swing assistance~20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
32735057|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
32735058|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
32735059|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
32735060|NCT03361787|Experimental|Parentship coaching intervention|
32735061|NCT04524065|Experimental|Early intervention group|The 14 early rehabilitation sessions(10=physical therapy, 4=occupational therapy) occurred per week over a 2-week period (excluding weekends) in the early rehabilitation group for 15 minutes each.
32735062|NCT04524065|No Intervention|Control group|The control group received 2 sessions(physical therapy) per week over a 2-week period for 10 minutes each.
32735063|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
32735064|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
32735065|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
32735066|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
32735067|NCT03284905|Active Comparator|Probiotics|
32735068|NCT03284905|Placebo Comparator|Placebo|
32735069|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
32735070|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
32735071|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
32735072|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
32735073|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
32735074|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
32735075|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
32735076|NCT04523675|Experimental|EXP-NAC|Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
32735077|NCT04523675|Experimental|EXP-Pla|Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
32735078|NCT04523675|Active Comparator|CON-NAC|Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
32735079|NCT04523675|Active Comparator|CON-Pla|Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
32735080|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
32735081|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
32735082|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
32735083|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
32735084|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
32735085|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
32735086|NCT03291301|No Intervention|Wait-list Control Group|
32735087|NCT04523519|Experimental|Video directly observed therapy with contingency management|Video directly observed therapy with contingency management, in addition to Integrated Next-Step Counseling.
32735088|NCT04523519|Placebo Comparator|Integrated Next-Step Counseling|
32735089|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
32735090|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man~Aged from 18 to 50 years~Having a diabetes evolving for at least 10 years~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)~IIEF-5 score less than or equal to 10"
32735091|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
32735092|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
32735093|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
32735094|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
33258212|NCT04885205|Active Comparator|Wait List Group|The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
32769430|NCT05039827|Active Comparator|SOFT TISSUE MOBILIZATION GROUP|Parallel and perpendicular soft tissue massage at common extensor origin
33258213|NCT04884087|Experimental|EMA, 3x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
33258214|NCT04884087|Experimental|EMA, 6x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
33258215|NCT04884087|Experimental|EMA, 3x/day, prize-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
33258216|NCT04884087|Experimental|EMA, 6x/day, prized-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
33258217|NCT04877990|Experimental|Long-Term Extension Rollover Study: Deucravacitinib|
33258218|NCT04877288|Experimental|Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap|Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
33258219|NCT04877288|Active Comparator|Arm 2: Continue calcineurin inhibitor-based regimen|
33258220|NCT04873583|Experimental|Steroids + Standard of care|Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.
33258221|NCT04873583|No Intervention|Standard of care|Standard of care (including aspirin)
33258222|NCT04869670|Experimental|G-POEM|
33258223|NCT04869670|Sham Comparator|Sham procedure|
33258224|NCT04864639|Experimental|Transition of Care|Experimental: 32 participants will be discharged to a newly developed discharge/transition of care model.
33258225|NCT04858568||Hodgkin lymphoma|"Diagnoses:~Hodgkin lymphoma (classical Hodgkin lymphoma)"
33258226|NCT04858568||Aggressive B-NHL|"Diagnoses:~Aggressive B-NHL (E.g. Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, de novo transformed lymphoma, follicular lymphoma grade 3b)"
33258227|NCT04858568||Indolent B-NHL|"Diagnoses:~Indolent B-NHL (E.g.follicular lymphoma grades 1-3a, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant Hodgkin lymphoma)"
33258228|NCT04858568||Peripheral T/NK-cell|"Diagnoses:~Peripheral T/NK-cell lymphomas (any mature T/NK cell malignancy)"
32769431|NCT05040061|Experimental|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
32769432|NCT05040061|Active Comparator|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices. These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
32769433|NCT05051839|Experimental|Radiographic bone level|
32769434|NCT05051839|Experimental|Peri implant soft tissue volume|
32769435|NCT05031559|Experimental|Episodic Future Thinking|
33258229|NCT04857034|Experimental|Active Treatment: Deucravacitinib Dose 1|
33258230|NCT04857034|Experimental|Active Treatment: Deucravacitinib Dose 2|
33258231|NCT04857034|Placebo Comparator|Placebo|
33258232|NCT04854005||Breast Cancer|Patients with cT1-2cN1 HR+/HER2- tumors who are scheduled to undergo upfront surgery will undergo AUS at the enrolling institution to characterize suspicious-appearing lymph nodes, as is part of routine practice.
33258233|NCT04844749|Experimental|Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day|32mg of VERU-111 26mg of VERU-11
33258234|NCT04844749|Active Comparator|Active control alternative androgen receptor targeting agent|The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.
32769436|NCT05031559|Experimental|Compassion|
32769437|NCT05031559|Sham Comparator|Control|
32769438|NCT05039749|Experimental|Human Central Lighting (HCL) Room|This inpatient room was outfitted with lights that mimic the day/night cycle, thereby supporting circadian rhythm. Day time lights were automatically on during 0600 to 1900 and in use any time the patients would normally utilize their lights, with a goal of three hours of light exposure per day. The lights automatically transitioned to warmer toned evening lighting at 1900.
33258235|NCT04843566|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
33258236|NCT04843566|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
33258237|NCT04830709||PARPi maintenance cohort (PMC)|patients who received at least one dose of PARPi as 1L MTX after 1L platinum-based CTX
33258238|NCT04830709||Bevacizumab maintenance cohort (BMC)|patients who continue to receive at least one dose of bevacizumab after 1L platinum-based CTX and who have not received PARPi MTX treatment
33258239|NCT04830709||No maintenance cohort (NMC)|patients who never received any 1L MTX treatment (PARPi or bevacizumab)
33258240|NCT04830397|Experimental|QLS-101 0.5%|
33258241|NCT04830397|Experimental|QLS-101 1%|
33258242|NCT04830397|Experimental|QLS-101 2%|
33258243|NCT04830397|Active Comparator|Timolol Maleate 0.5% preservative free ophthalmic solution|
33258244|NCT04826341|Experimental|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
33258245|NCT04826341|Experimental|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
33258246|NCT04821960|Active Comparator|Conventional Mindfulness Program|Routine mindfulness lessons and activities.
33258247|NCT04821960|Experimental|Tailored Mindfulness Program for Fear of Memory Loss|Tailored mindfulness lessons and activities for fear of memory loss.
33258248|NCT04818762||Preterm neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
32735095|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
32735096|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
33258249|NCT04818762||Preterm neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
33258250|NCT04818762||Term neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
33258251|NCT04818762||Term neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
33258252|NCT04815876|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
33258253|NCT04815876|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
33258254|NCT04804891|Experimental|Cell Therapy|Patients will receive an infusion containing 1x106/kg CD34+ cells. No more than 104 CD34+ T cells per kg recipient weight will be included in the infusion. Cadaveric donor CD34 cell infusion will occur at any time between post-operative day 11 to day 13 following transplantation.
33258255|NCT04804891|No Intervention|Control|Patients who do not consent to receive donor CD34 cell infusion or whose donor family declines consent for research use of donor bone marrow will receive their usual standard of care.
33258256|NCT04802590|Experimental|Arm A|Ibrutinib (+ CD20Ab)
33258257|NCT04802590|Experimental|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
33258260|NCT04797260|Experimental|Gene therapy|In this arm, 10 patients will be included for gene therarpy
33258261|NCT04785521||BM patients|Adult patients carrying new diagnosed BM confirmed by MRI
33258262|NCT04785521||No BM patients|Adult patients carrying extracranial tumor without BM as confirmed by MRI
33258263|NCT04785521||Benign lesion patients|Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI
33258264|NCT04782297||Titan HD Catheter|The Titan HD Catheter is a double lumen catheter that provides 2 dedicated (arterial/venous) access lumens. Each lumen is connected through an extension line with female luer connectors. The arterial and venous catheter lumens connect to a hub to facilitate connection of extension tubes with clamps intended to prevent air/fluid communication and control fluid flow through the catheter. At the proximal end of the extension tubes are female Luer fittings to provide a needleless connection. The clamps and the sleeves are color-coded red for the arterial lumen and blue for the venous lumen. Each catheter has a cuff which is intended to be positioned underneath the skin at the skin exit to aid in securing the catheter and to provide a barrier to minimize the risk of infection. Each lumen is connected through an extension line with female Luer connectors. The transition between lumen and extension is housed within a molded hub.
33258265|NCT04782297||Hemo-Flow Catheter|The Hemo-Flow® Catheter has two lumens (one arterial lumen, one venous lumen) comprised of a biocompatible polymeric material that contains radiopaque filler to allow radiographic imaging of the distal tips to ensure proper placement into the superior vena cava. The arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment
33258266|NCT04781309|Experimental|NT-I7|480 microgram/kg IM (initial dose)
33258267|NCT04780477|Experimental|High Fiber Diet (HFD)|High Fiber Diet (HFD) will add approximately 25-30 grams of dietary fiber/d from legume dishes.
32735097|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
32735098|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
32735099|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
32735100|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
32735101|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
32735102|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
32735103|NCT03366389||Case|patients with irritable bowel syndrome
32735104|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
32735105|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
33077002|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
32735106|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
32735107|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
32735108|NCT03284593||Azacitidine group|patients treated with azacitidine
32735109|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
32735110|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
32735111|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
32735112|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
32735113|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
32735114|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
33077003|NCT04682041|Experimental|EnteraGam + standard of care|Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
32735115|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
32735116|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
32735117|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
32735118|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
32735119|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
32735120|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
32735121|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
32735122|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
32735123|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
32735124|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
32735125|NCT03366077|Active Comparator|Active|L reuteri
32735126|NCT03366077|Placebo Comparator|Placebo|Placebo
32735127|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
32735128|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
32735129|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
32735130|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
32735131|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
32735132|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
32735133|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
32735134|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
32735135|NCT04489147|Active Comparator|metformin|Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI
32735136|NCT04489147|No Intervention|No Metformin|Group B ( involve 200 patients) will not receive metformin
32735137|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
33258268|NCT04780477|Active Comparator|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat.
33258269|NCT04776993|Experimental|Methimazole|Antithyroid drugs (at individualized dosage) for 72 weeks and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
33258270|NCT04776993|Active Comparator|Thyroid ablation|Radioiodine therapy or total thyroidectomy (according to ultrasound thyroid volume) and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
33258271|NCT04771663|Experimental|Hypoxic|In this phase, participants inhale the hypoxic mixture for five minutes.
33258272|NCT04771663|Experimental|Hypoxic and Hypercapnic|In this phase, participants inhale the hypoxic and hypercapnic mixture for five minutes.
33258273|NCT04771273|Experimental|BI 456906 low dose|low dose
33258274|NCT04771273|Experimental|BI 456906 medium dose|medium dose
33258275|NCT04771273|Experimental|BI 456906 high dose|high dose
32735138|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
32735139|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
33258276|NCT04771273|Placebo Comparator|Placebo|Placebo
33258277|NCT04766723|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs."
33258278|NCT04766723|Placebo Comparator|Placebo|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs."
33258279|NCT04766138|Experimental|Fecobionics studies|Single-arm study
33258280|NCT04753658||Pediatric Neuroblastoma Patients Treated with Lorlatinib|
33258281|NCT04752891|Experimental|AOM diagnosis with app|
33258282|NCT04752891|Other|AOM diagnosis without app|
33258283|NCT04750954|Experimental|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/MRI throughout the trial and undergo collection of blood samples on study.
33258284|NCT04742400|Experimental|Tolebrutinib (Cohort A)|Tolebrutinib 60 mg/day for 48 weeks, Tolebrutinib 120 mg/day for 96 weeks
32735140|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
32735141|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
32735142|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
32735143|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
32735144|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
32935474|NCT05447611||high score CARE group|"Patient-perceived empathy was assessed using the Consultation and Relational Empathy (CARE) questionnaire that has been validated in cancer care. This is a self-reported ten-point questionnaire with a five-point Likert-type scale ranging from poor to excellent Likert-type scale. It has excellent psychometric properties with α = 0.92. High scores indicate a higher perception of the health care personnel empathy.~The three distinct empathic processes were also assessed with the CARE measure. 'Relationship' was assessed with items 1-3, 'emotional process' with items 4-6, and 'cognitive process' with items 7-10."
32935475|NCT05447611||lower score CARE group|In line with the recent literature, we considered differentiating the study population into two groups: those with a high perceived empathy (maximum CARE score) and those without.
32935476|NCT05447455|Active Comparator|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
32935477|NCT05447455|Active Comparator|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
33258285|NCT04742400|Experimental|Tolebrutinib (cohort B)|Tolebrutinib 120 mg daily
33258286|NCT04742400|Experimental|tolebrutinib (initial cohort)|Tolebrutinib 60 mg daily
33258287|NCT04741932|No Intervention|Care as usual|
33258288|NCT04741932|Experimental|Intervention|
32735145|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^4 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
32735146|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
32735147|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
33258292|NCT04729114|Experimental|Cohort 1|180 mg PRL-02 + dexamthasone or prednisone
32735148|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
32735149|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
33077004|NCT04682041|Other|Control (standard of care)|Subjects will receive standard of care for COVID-19 alone for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
33077005|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
33258293|NCT04729114|Experimental|Cohort 2|360 mg PRL-02 + dexamthasone or prednisone
33258294|NCT04729114|Experimental|Cohort 3|720 mg PRL-02 + dexamthasone or prednisone
33258295|NCT04729114|Experimental|Cohort 4|1260 mg PRL-02 + dexamthasone or prednisone
33258296|NCT04729114|Experimental|Cohort 5|1800 mg PRL-02 + dexamthasone or prednisone
33258297|NCT04729114|Experimental|Phase 1 Expansion Group D|Prior abiraterone
33077006|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
33258298|NCT04729114|Experimental|Phase 1 Expansion Group E|Prior enzalutamide
33258299|NCT04729114|Experimental|Phase 2a Dose Expansion|Dosing at recommended Phase 2 dose (RP2D)
33258300|NCT04702893||Chronic fibrosing interstitial lung disease (ILD) patients with a progressive phenotype|
33258303|NCT04699201|Experimental|Prosthesis|Firstly, a laparoscopic cholecystectomy is performed. After suturing the aponeurosis with a J needle and 0 Polydioxanone, a lightweight, large-pore mesh made of PVDF monofilament (polyvinylidene fluoride - DynaMesh-CICAT, FEC Textiltechnik, Germany) will be placed onlay, overlapping 2cm in all directions from the edge of the aponeurosis incision at the umbilical trocar site. The mesh will be fixed to the aponeurosis with cyanoacrylate glue (Glubran®, GEM, Viareggio, Italy).
33258304|NCT04699201|Active Comparator|Control|Firstly, a laparoscopic cholecystectomy is performed. Closure of the aponeurosis will be performed by standard procedure: under direct vision, suturing the aponeurosis with a J needle and 0 Polydioxanone, with a stitch interval of ≤ 5mm.
33258305|NCT04698291||Controls|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
33258306|NCT04698291||Cases|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
33258307|NCT04693520|Experimental|Active treatment|ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter
33258308|NCT04683640|Experimental|Daily Oral GABA|You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks
32735150|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
32735151|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
32735152|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
32735153|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
32735154|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
32735155|NCT03283189||Group 6|Liberal follow-up of pregnancy
32735156|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
32735157|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
33258309|NCT04683640|Placebo Comparator|Daily Placebo|You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks
33258310|NCT04680637|Placebo Comparator|Placebo + Standard of Care|
33258311|NCT04680637|Experimental|Efavaleukin Alfa Dose Level One + Standard of Care|
33258312|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Two + Standard of Care|
33258313|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Three + Standard of Care|
33258314|NCT04679961||Experimental|"Epidermal inflammations, including eczematous diseases and psoriasis~Epidermal tumors, including benign tumors and malignant tumors~Pigmented diseases, including hypopigmentation and hyperpigmentation"
33258315|NCT04679961||Control|Healthy skin
33077007|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
33077008|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
33077009|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
33258318|NCT04671875|Experimental|MIL93|
33258319|NCT04669249|Experimental|PROCare|Technology-enabled, reward-based recovery platform
33258320|NCT04669249|No Intervention|Control|Treatment-as-Usual
33258321|NCT04667702||Patient Focused Interviews|
32735158|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
32735159|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
33258322|NCT04667702||Caregiver Focused Interviews|
33258323|NCT04667702||Healthcare Provider Focused Interviews|
32735160|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
33258324|NCT04666545|Experimental|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
33258325|NCT04666545|No Intervention|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
33077010|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
33258326|NCT04664972|Placebo Comparator|TAC regimen group|The control group was treated with TAC (docetaxel 75mg/m2 + adriamycin 50mg /m2 + cyclophosphamide 500mg/m2) for 6 cycles, 21 days as a cycle.
33258327|NCT04664972|Experimental|TP regimen group|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
33258328|NCT04660344|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
33258329|NCT04660344|Placebo Comparator|Arm B: Placebo|Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
33258330|NCT04660162|Experimental|Arm-1: Laser speckle contrast imaging|(Perimed AB, Järfälla, Sweden)
33258331|NCT04660162|Experimental|Arm-2: Laser Doppler perfusion imaging|(Moor Instruments, Devon, UK)
33258332|NCT04652544|Experimental|"Low dose"|One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.
33258333|NCT04652544|Experimental|"High dose"|Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.
33258334|NCT04652544|Placebo Comparator|Placebo|Two vials with a placebo every month.
33258335|NCT04652076|Other|Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)|Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
33258336|NCT04652076|Other|Arm B: Experimental double combination [Standard Chemotherapy +NP137]|Experimental double combination [Standard Chemotherapy +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
33258337|NCT04652076|Other|Arm C: Experimental double combination [Pembrolizumab +NP137]|Experimental double combination [Pembrolizumab +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
33258338|NCT04652076|Other|Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]|Experimental triple combination [Pembrolizumab+ Standard Chemotherapy + NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
33258339|NCT04650854|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
33258340|NCT04650854|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
33258341|NCT04647253|Experimental|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
33258342|NCT04647253|Active Comparator|Commercially available, PTCA Dilation Catheter|
33077011|NCT02905123|No Intervention|Control|No Intervention Control
33077012|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
33077013|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
33258343|NCT04632069|Experimental|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
33258347|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 Dose 1|Monotherapy - Dose 1
33258348|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 Dose 2|Monotherapy - Dose 2
32735161|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
33258349|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 plus IL-2|NEO-PTC-01 in combination with a fixed dose of IL-2 (cohort will only be open in countries where IL-2 is approved)
33258350|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 plus αPD- 1 therapy|The αPD-1 therapy will be introduced, beginning 1 to 2 weeks post NEO-PTC-01, to patients who failed αPD-1/α programmed death ligand 1 (αPD-L1) therapy prior to enrollment in the NTC-001 study
33258351|NCT04625205|Experimental|Part 2 dose expansion phase: NEO-PTC-01|Patients currently receiving PD-1/PD-L1 inhibitors (as single agent or in combination with cytotoxic T-lymphocyte-associated antigen-4 [CTLA4] inhibitors) as therapy for metastatic melanoma
33258352|NCT04618913||VTE and history of cancer|VTE and history of cancer
33077014|NCT04723329|Experimental|web-based education group|Patients will be given a username and password to access the website. The change stage of the patients will be determined by the researcher with the Exercise Change Phase Short Question Form, and it will be ensured that they reach the educational content prepared according to the transtheoretic model. Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
32735162|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
32735163|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
33258353|NCT04618913||VTE and active cancer|VTE and active cancer
33258354|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
33258355|NCT04616196|Experimental|Dose Escalation of NKTR-255 with Cetuximab|Establish RP2D, of NKTR-255 with cetuximab.
33258356|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort A|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with HNSCC.
32935478|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot A|"SII-YFV Lot A:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot A will be administered concomitantly with an MMR and a Men A vaccine."
33258357|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort B|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with CRC.
33258358|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort C|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cSCC.
33258359|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort D|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with ASCC.
33258360|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort E|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cervical cancer.
33258361|NCT04613518|Experimental|BMS-986165|
33258362|NCT04613518|Placebo Comparator|Placebo|
33258363|NCT04613518|Experimental|Open label Extension, BMS-986165|
33258364|NCT04610892|Experimental|MEDI6570 Low dose|Monthly Subcutaneous administration.
33258365|NCT04610892|Experimental|MEDI6570 Medium dose|Monthly Subcutaneous administration.
33258366|NCT04610892|Experimental|MEDI6570 High dose|Monthly Subcutaneous administration.
33258367|NCT04610892|Placebo Comparator|Placebo Low dose|Monthly Subcutaneous administration.
33258368|NCT04610892|Placebo Comparator|Placebo Medium dose|Monthly Subcutaneous administration
33258369|NCT04610892|Placebo Comparator|Placebo High dose|Monthly Subcutaneous administration
33258370|NCT04607148|Experimental|Galegenimab 20 mg Q4W|Participants will receive 20 milligrams (mg) galegenimab via ITV injection every 4 weeks (Q4W).
33258371|NCT04607148|Experimental|Galegenimab 20 mg Q8W|Participants will receive 20 mg galegenimab via ITV injection every 8 weeks (Q8W).
33258372|NCT04607148|Experimental|Galegenimab 10 mg Q4W|Participants will receive 10 mg galegenimab via ITV injection Q4W.
33258373|NCT04607148|Experimental|Galegenimab 10 mg Q8W|Participants will receive 10 mg galegenimab via ITV injection Q8W.
33258374|NCT04599634|Experimental|Experimental treatment: FL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-days each, Cycles -2 and -1), then venetoclax will be added at target dose (dose determined from Arm 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax will be 6 cycles (28-days each, Cycles 1-6); further treatment will be response-adapted.
32935479|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot B|"SII-YFV Lot B:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot B will be administered concomitantly with an MMR and a Men A vaccine."
32935480|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot C|"SII-YFV Lot C:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot C will be administered concomitantly with an MMR and a Men A vaccine."
33258375|NCT04599634|Experimental|Experimental treatment: FL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax 800mg PO combination administered to 6 patients for six (6) cycles (28-days each, Cycles 1-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 600mg with magrolimab and obinutuzumab.
33258376|NCT04599634|Experimental|Experimental treatment: MZL, MCL, and CLL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax ramp-up to target dose of 400mg over 5 weeks (35 days, Cycle 1) administered to 6 patients. Triplet combination of magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for five (5) additional cycles (28-days each, Cycles 2-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 200mg with magrolimab and obinutuzumab.
33258377|NCT04599634|Experimental|Experimental treatment: mzl, MCL, CLL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-day cycles, Cycles -2 and -1), then venetoclax safety ramp-up to target dose (dose determined from Arm 2) over 5 weeks (35-days, Cycle 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for 5 additional cycles (28-days each, Cycles 2-6); further treatment will be response-adapted.
33258378|NCT04598165|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
33258379|NCT04598165|No Intervention|No SMS Control|Control receiving standard of care.
33258380|NCT04592913|Placebo Comparator|Arm B|placebo product and FLOT chemotherapy
33258381|NCT04592913|Experimental|Arm A|Durvalumab and FLOT chemotherapy
33258384|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
33258385|NCT04585815|Experimental|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
33258386|NCT04573023|Experimental|JR-141 2.0 mg/kg/week|
33258387|NCT04573023|Other|administered as the standard of care: idursulfase (ELAPRASE®)|standard of care-controlled study
33258388|NCT04573023|Other|Rescue arm|
33258389|NCT04570553|Experimental|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
33258390|NCT04570553|Active Comparator|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
33258391|NCT04547907|Experimental|nab-PHP|Albumin binding paclitaxel + trastuzumab+ patuzumab
33258392|NCT04547907|Active Comparator|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
33258393|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
33258394|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
33258395|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
33258396|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
33258397|NCT04545944|Experimental|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
33258398|NCT04533451|Experimental|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33258399|NCT04533451|Experimental|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33258400|NCT04529928|Experimental|Implanted|Subjects successfully implanted with the Carillon Mitral Contour System
33401374|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
33401375|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
32735164|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
33258401|NCT04522804|Experimental|Treatment: all patients|"Subjects will participate in a total of seven group sessions. There will be 4 or 6 subjects per group and one therapist will be assigned to each subject for a total of 4 or 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
33258402|NCT04520763|Experimental|Respiratory Muscle Exercises|Two respiratory muscle exercises
32735165|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
32735166|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
32735167|NCT03297463|Experimental|Phase II (Dose Expansion)|
33258403|NCT04520763|No Intervention|Control|The control intervention consists of quiet sitting for 15 min
33258404|NCT04503395|Experimental|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
33258405|NCT04503395|Active Comparator|FEVAR|Fenestrated EndoVascular Aneurysm Repair
32735168|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
32735169|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
32735170|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
32735171|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
32735172|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
33258406|NCT04484935|Experimental|Nirsevimab|"1st RSV season: 50mg nirsevimab~st RSV season: 100mg nirsevimab~nd RSV season: 200mg nirsevimab"
33258407|NCT04477356|Active Comparator|Swim-up technique (SU)|The SU method's principle is that the normal and highly motile sperm will move against the gravity and separate from the dead or abnormal sperms to swim up to the upper media culture layer.
33258408|NCT04477356|Active Comparator|Density gradient centrifugation technique (DG)|The DG method is based on the density in which mature and normal sperms are capable of passing through filtration layer to be isolated from dead or abnormal sperms in semen.
33258409|NCT04472351|Experimental|ASCEND-I|Computerized WM training with Rehacom will be implemented in daily 30-minute sessions that are scheduled prior to the participant's occupational therapy (OT) session as an adjunct to routine rehabilitation. Tasks are tailored to the participant's current ability level and are adaptive to performance changes. During these sessions, the study staff member will use guided questioning to help the participant anticipate challenges, reflect on performance, and link computerized exercises to the Multicontext sessions. The Multicontext treatment sessions will be delivered within the participant's OT session by an OT. The Multicontext approach helps individuals to self-discover WM-related error patterns and learn to anticipate WM performance challenges through repeated practice using functionally-relevant activities. The OT conducts guided questioning pre- and post-task to help the participant anticipate challenges and self-discover WM strategies.
33258410|NCT04472351|No Intervention|Enhanced Usual Care|The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
33401376|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
33401377|NCT05276869||group A|from 3 to 7 years included 36 patients
32743146|NCT03246659|Experimental|arm 1|111In-CP04
32743147|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
32743148|NCT04945005||Lead implantation with transesophageal echocardiography|All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance
32743149|NCT04945005||Lead implantation without transesophageal echocardiography (retrospective)|All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)
33258411|NCT04463212||Patient|Diagnosis of probable SVCR evoked, faced with a single or repeated episode of unusual thunderclap or rapidly progressive headache, and demonstration of diffuse vasospasms via sectional imaging (angiography, angio-MRI or cerebral arteriography) or an increase in transcranial doppler speeds
33258412|NCT04463212||Subject control|Subject without SVCR (current and history)
33258413|NCT04460937|Experimental|Treatment (radiation therapy, adavosertib)|Patients undergo radiation therapy QD 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive adavosertib PO QD for 2-5 days (depending on dose level) during weeks 1 and 3 of radiation therapy in the absence of disease progression or unacceptable toxicity.
32735173|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
33258414|NCT04455724|Experimental|Negative Pressure Incisional Wound Therapy|A PREVENA™ PEEL & PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
32735174|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
32735175|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
33258415|NCT04455724|Active Comparator|Standard sterile dressing|A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
32735176|NCT03283735|No Intervention|Control|This will be the control group.
32743150|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
33258416|NCT04454203|Experimental|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
33258417|NCT04454203|Placebo Comparator|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
32743151|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
32743152|NCT04944693||Cohort 1|Anterior cruciate ligament-injured patients with excessive ATS
33258418|NCT04442022|Experimental|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1, and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
33258419|NCT04442022|Experimental|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
33258420|NCT04442022|Active Comparator|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
33258421|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
33258422|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
33258423|NCT04442022|Placebo Comparator|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
33258424|NCT04441307|Active Comparator|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
33258425|NCT04441307|Experimental|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
33258426|NCT04440943|Experimental|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
33258427|NCT04439149|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33401378|NCT05276869||group B|from 8 to 16 years included 17 patients
32743153|NCT04944693||Cohort 2|Anterior cruciate ligament-injured patients with minimal ATS
32743154|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
32743155|NCT04937985||UULEX Test Group|Patients with chronic neck pain
33401379|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
32735177|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
32735178|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
32735179|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
32735180|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
32735181|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
32735182|NCT03283579||Pregnant women|
32735183|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.~After 3 months they will have a prostatectomy."
32735184|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
32735185|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
33077015|NCT04723329|No Intervention|Control Group|In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
33258428|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33258429|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32735186|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
32735187|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
33077016|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
33077017|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
33077018|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
33258430|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
33258431|NCT04431011||Participants|Healthy right-handed participants aged 18-50
33258432|NCT04429555|Experimental|MN-166 (ibudilast)|MN-166 capsules, 50 mg twice daily, for 7 days.
32735188|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
32735189|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
32735190|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
32735191|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
32735192|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
33258433|NCT04429555|Placebo Comparator|Placebo|Placebo capsules, 50 mg twice daily, for 7 days.
33077019|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
33077020|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
33258436|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
33258437|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
33258438|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
32735193|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
32735194|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
33258439|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
33258440|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
33258441|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
33258442|NCT04413461|Experimental|TENS|
33258443|NCT04413461|Placebo Comparator|TENS Sham|
33258444|NCT04409925|Experimental|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
33258445|NCT04408820||Roxadustat|Participants will receive oral dose of roxadustat.
33258446|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in antenatal clinic (ANC) at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in ANC at the site will be prospectively enrolled. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having congenital abnormalities (CAs) will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
33258447|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
33258448|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
33258449|NCT04394325|Experimental|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
33258450|NCT04394325|No Intervention|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
32735195|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
32735196|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
33258451|NCT04393285|Experimental|Abemaciclib and Letrozole|Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.
33258452|NCT04379596|Experimental|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
33258453|NCT04379596|Experimental|Arm 1B|T-DXd and capecitabine
33258454|NCT04379596|Experimental|Arm 1C|T-DXd and durvalumab
32735197|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
32735198|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
32735199|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
33258455|NCT04379596|Experimental|Arm 1D(a)|T-DXd, 5-FU, and oxaliplatin
32735200|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
33077021|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
33077022|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
33077023|NCT02904967|Experimental|patients with recurrent VTE|
33077024|NCT02904967|Active Comparator|patients with only one episode of VTE|
33258456|NCT04379596|Experimental|Arm 1D(b)|T-DXd, capecitabine, and oxaliplatin
33258457|NCT04379596|Experimental|Arm 1E(a)|T-DXd, 5-FU, and durvalumab
33258458|NCT04379596|Experimental|Arm 1E(b)|T-DXd, capecitabine, and durvalumab
33258459|NCT04379596|Active Comparator|Arm 2A|Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
32735201|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
33258460|NCT04379596|Experimental|Arm 2B|T-DXd monotherapy
33258461|NCT04379596|Experimental|Arm 2C|T-DXd, 5-FU or capecitabine, and oxaliplatin
33258462|NCT04379596|Experimental|Arm 2D|T-DXd, 5-FU or capecitabine, and pembrolizumab
33258463|NCT04379596|Experimental|Arm 2E|T-DXd and pembrolizumab
32735202|NCT04068805|Active Comparator|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
33258464|NCT04374799|Active Comparator|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
32735203|NCT04068805|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32735204|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
32735205|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
32735206|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
32735207|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
32735208|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
32735209|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
32735210|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
32735211|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
32735212|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
32769439|NCT05039749|No Intervention|Standard Hospital Lighting (SL) Room|The lighting in this room was standard florescent hospital lighting. The only changes in the lighting was the on/off settings normally associated with lighting.
33258465|NCT04374799|Active Comparator|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
33258466|NCT04374799|Placebo Comparator|Placebo|Normal saline 0.9%.
33258467|NCT04373382|Experimental|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
33077025|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
33077026|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
32769440|NCT05031013||Dialysis patients|Dialysis patients
33258468|NCT04373382|No Intervention|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
33258469|NCT04373382|Experimental|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
33258470|NCT04373382|No Intervention|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
33258471|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
33258472|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
33258473|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
33258474|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
33258475|NCT04367311|Experimental|NSC: Non-squamous cell tumors|Atezolizumab 1200mg, Pemetrexed 500 mg/m^2, Cisplatin 60-75 mg/m^2
33258476|NCT04367311|Experimental|SC: Squamous cell tumors|Atezolizumab 1200mg, Docetaxel 60-75 mg/m^2, Cisplatin 60-75 mg/m^2
33258477|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
33258478|NCT04343586|Experimental|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
33258479|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
33401380|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
33401381|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
33401382|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
33258480|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
33258481|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
33258482|NCT04333238|Active Comparator|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
33077027|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
33077028|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
33258483|NCT04333238|Experimental|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
33258484|NCT04312945|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
33258485|NCT04312945|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
33258486|NCT04312945|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
33258487|NCT04312945|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
33258488|NCT04308785|Experimental|Arm A: Atezolizumab + Tiragolumab|Participants will receive atezolizumab + tiragolumab intravenously on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and tiragolumab treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
33258489|NCT04308785|Experimental|Arm B: Atezolizumab + Placebo|Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
33258490|NCT04301076|Experimental|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients also receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity."
33258491|NCT04298723|Experimental|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
33258492|NCT04298723|No Intervention|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
33258493|NCT04288947|Other|Usual Care|Training of midwives on 4 respectful maternal care modules.
33258494|NCT04288570|Active Comparator|Bone socket formation with a punch|suture anchor socket creation with punch
33258495|NCT04288570|Active Comparator|Bone socket formation with a drill|suture anchor socket creation with drill
33258496|NCT04287192|No Intervention|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
33258497|NCT04287192|Experimental|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
33258498|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
33258499|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
33258500|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
33258501|NCT04284787|Active Comparator|Arm I (AZA, VEN)|"INDUCTION THERAPY PHASE: Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY PHASE: Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment per physician discretion.~Patients also undergo biopsy at baseline, blood specimen collection and bone marrow biopsy baseline and on study."
33401383|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
33258502|NCT04284787|Experimental|Arm II (AZA, VEN, pembrolizumab)|"INDUCTION THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment with azacitidine and venetoclax per physician discretion."
33258503|NCT04266275|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks
33258504|NCT04266275|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks
32735213|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:~a clinical examination;~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
33258505|NCT04252742|Experimental|Erenumab|"The 4-month DBTP has 2 phases:~Main double-blind treatment phase (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
33258506|NCT04252742|Experimental|Placebo|"The 4-month DBTP has 2 phases:~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
33258507|NCT04248920|Experimental|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
33258508|NCT04248920|Other|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
33258509|NCT04245449|Experimental|e learning+therapy (TEAACH)|TEAACH-Training to Empower Activity-dependent plasticity-based Arm-use habits in the Community and at Home
33258510|NCT04241185|Experimental|Pembrolizumab + Chemotherapy + Radiotherapy|Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
33258511|NCT04241185|Placebo Comparator|Placebo + Chemotherapy + Radiotherapy|Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
33258512|NCT04222790|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
33258513|NCT04222790|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
33258514|NCT04222413|Experimental|1/Arm 1|Escalating/de-escalation doses of metarrestin
33258515|NCT04222413|Experimental|2/Arm 2|MTD of metarrestin
33258516|NCT04216329|Experimental|1/Experimental therapy|Selinexor with temozolomide and radiation
33258517|NCT04212013|Experimental|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 on cycle 1.
33258518|NCT04212013|Placebo Comparator|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
33258519|NCT04210700|Active Comparator|Fascia iliaca compartment block|Participants will receive fascia iliaca compartment block before spinal anesthesia and operation
33258520|NCT04210700|Experimental|Pericapsular nerve group block group|Participants will receive pericapsular nerve group block before spinal anesthesia and operation
33258521|NCT04210115|Experimental|Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy|"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year."
33401384|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
33401385|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
33401386|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
33401387|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
33401388|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP~+ pIL-12 (500 g)"
33401389|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP~+ pIL-12 (1500 g)"
32769441|NCT05039437|Experimental|MGF-4|Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.
32769442|NCT05039437|Experimental|MGF-7|Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.
32769443|NCT05030779|Experimental|Treatment of SLE|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
33258522|NCT04210115|Placebo Comparator|Placebo+FP or FOLFOX Therapy+Radiotherapy|"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year."
33258523|NCT04207086|Experimental|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
33258524|NCT04206319|Experimental|1|Participants will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
33258525|NCT04195451|Experimental|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
33258526|NCT04195451|Experimental|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
33258527|NCT04194359|Experimental|Sintilimab (IBI308) plus Bevacizumab, Oxaliplatin and Capecitabine|Sintilimab (IBI308)：200MG, once every three weeks; Bevacizumab:7.5mg/kg, once every three weeks; oxplatin: 135 mg per square meter body surface, once every three weeks; Capecitabine : Capecitabine 1 gram per square meter body surface area, from the first day to the 14th day
33258528|NCT04192955|Active Comparator|Active|Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
33258529|NCT04192955|Placebo Comparator|Control|Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
33258530|NCT04191785|Experimental|plasmatic NGAL and MRI|
33077029|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
33077030|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
33077031|NCT02963103|Experimental|Tacrolimus group|oral
33077032|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
32769444|NCT05031091||Case: patients with confirmed leprosy|diagnosed or followed up in French Guiana between the beginning of 2006 and the end of 2022
32769445|NCT05031091||Control: patient with a dermatological condition not clinically suspicious of leprosy|Any patient, of any age, consulting for a dermatological pathology not clinically suspicious of leprosy during a dermatological consultation by a practitioner of the Cayenne Hospital
32769446|NCT05051683|Active Comparator|group (1)|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
32769447|NCT05051683|No Intervention|group (2)|surgical management of acute perforated peptic ulcer
32769448|NCT05031169|Experimental|A-PRF|Surgical treatment A-PRF membrane
32769449|NCT05031169|Active Comparator|SCTG|Surgical treatment with SCTG
33077033|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
33077034|NCT02904421||Group 1|the placebo group
33077035|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
33077036|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
33077037|NCT02904343|Experimental|Group of domestic hemodialysis machine|
33077038|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
33077039|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
32769450|NCT05051137||Infliximab initiators|Rheumatoid arthritis patients initiating infliximab after treatment with methotrexate for a minimum of 30 days.
32769451|NCT05051137||Sulfasalazine + Hydroxychloroquine initiators|Rheumatoid arthritis patients initiating sulfasalazine and hydroxychloroquine after treatment with methotrexate for a minimum of 30 days.
32769452|NCT05039125|Active Comparator|40000HZ ultrasound cavitation|group A (n=15) received 40000HZ ultrasound cavitation, Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
32769453|NCT05039125|Active Comparator|2600HZ ultrasound cavitation|group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
32769454|NCT05039203||Intervention group|Inpatients with an indwelling urinary catheter (IUC) at admission to a rehabilitation clinic for persons ≥65 years in Sweden. Intervention is removal of the IUC.
32769455|NCT05039203||Control group|Inpatients without an IUC at admission to a rehabilitation clinic for persons ≥65 years in Sweden
32769456|NCT05038969|Experimental|A test|Test drug (Stomopral) 1 capsule contains 40 mg Enteric Coated Pellets of Esomeprazole
33077040|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
33258544|NCT04172532|Experimental|Phase I (hypofractionated radiation therapy, M3814)|Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
33258545|NCT04172532|Experimental|Phase II Group I (hypofractionated radiation therapy M3814)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
33077041|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
33258546|NCT04172532|Placebo Comparator|Phase II Group II(hypofractionated radiation therapy, placebo)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
33258547|NCT04168008|Experimental|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for ART adherence and engagement in HIV care.
33077042|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
32769457|NCT05038969|Active Comparator|B reference|Reference drug (Nexium) 1 capsule contains 40 mg Esomeprazole
33077043|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
33077044|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
33077045|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
33258548|NCT04168008|Active Comparator|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
33258549|NCT04165798||Prospective NSCLC Participants|Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 3 pembrolizumab substudies.
33401390|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP~+ ID2 EP"
33077046|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
32735214|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
32735215|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
32735216|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
32735217|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
33258550|NCT04162665|Experimental|Preoperative MR-guided Radiation Therapy|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25 Gy at 5 Gy per fraction. The clinical target volume will include the entire stomach and locoregional lymph nodes. Radiation must be delivered with MR guided radiation therapy (MRgRT) and daily adaptive planning. The stomach and OARs must be redrawn each day for the adaptive plan. Plans should be adapted to meet OAR constraints or improve coverage as needed for each day's unique anatomy~Chemotherapy will be given as per standard of care. It should begin 2 to 4 weeks after completion of radiotherapy and will consist of CAPOX (capecitabine/oxaliplatin) for 5 cycles.~Standard of care gastrectomy or esophagogastrectomy within 2-4 weeks following completion of chemotherapy~All stage II-III patients should receive 3 cycles of CAPOX postoperatively for a total of 8 cycles of CAPOX. Postoperative CAPOX should start within 3 months of surgery."
32735218|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
32735219|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
32735220|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
33258551|NCT04159805|Experimental|TAK-079 Dose 1|TAK-079 dose 1 injection, subcutaneously, once weekly for 8 weeks.
33258552|NCT04159805|Experimental|TAK-079 Dose 2|TAK-079 dose 2 injection, subcutaneously, once weekly for 8 weeks.
33258553|NCT04159805|Placebo Comparator|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously, once weekly for 8 weeks.
33258554|NCT04157686|Experimental|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL.
33258555|NCT04157686|Experimental|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL.
33258556|NCT04157686|Experimental|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 will be injected into the LCL.
32735221|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
33077047|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
32735222|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
33258557|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
32735223|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
33077048|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
33077049|NCT04681495|Other|Usability of Bullying Prevention Online Application|This intervention has a single arm. It consists of conducting focus groups and usability testing of a bullying prevention online application for middle-school-aged students.
33258558|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
33258559|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
33258560|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
32735224|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
32735225|NCT03920527|Active Comparator|Six months|Six months of itraconazole
32735226|NCT03920527|Experimental|12 months|12-months of itraconazole
33258561|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
33258562|NCT04124341|Experimental|Prefrontal Cortical Stimulation (PCS)|Stereotactically implanted bilateral PCS
33258563|NCT04120493|Experimental|Cohort 1|Low dose rAAV5-miHTT (6x10^12 gc/subject).
32735227|NCT03764995|Experimental|Abdominal Massage|
32735228|NCT03764995|Placebo Comparator|Placebo Ultrasound|
33258564|NCT04120493|Experimental|Cohort 2|High dose rAAV5-miHTT (6x10^13 gc/subject).
33258565|NCT04120493|Sham Comparator|Cohorts 1, 2, 3A & 3B|Imitation (sham) surgery
33258566|NCT04120493|Experimental|Cohort 3A|High dose rAAV5-miHTT (6x10^13 gc/subject).
33258567|NCT04120493|Experimental|Cohort 3B|High dose rAAV5-miHTT (6x10^13 gc/subject).
33258568|NCT04118010|Active Comparator|Vitamin D3 and Inulin|Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks
33258569|NCT04118010|Active Comparator|Vitamin D3 and placebo Inulin|Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
33258570|NCT04118010|Active Comparator|Placebo vitamin D3 and Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks
33258571|NCT04118010|Placebo Comparator|Placebo vitamin D3 and placebo Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
33258572|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
33258573|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
33258574|NCT04113863|Active Comparator|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
33258575|NCT04113863|Experimental|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
33258576|NCT04110249|Experimental|Diagnostic (PAI, ALTENS)|"PART I: Patients undergo PAI before the start of chemoradiation therapy, weekly during 7 weeks of chemoradiation, and again 3-4 months after completion of chemoradiation therapy.~PART II (CANCER-FREE WITH XEROSTOMIA): Patients undergo PAI at baseline, up to twice during acupuncture-like transcutaneous nerve stimulation (ALTENS) therapy, once after ALTENS, and at 3-6 months follow up."
33258577|NCT04099342|Experimental|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
33258578|NCT04099342|Experimental|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
33258579|NCT04099342|Experimental|C: RC FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Configuration (RC) utilizes the same current flow as FEAST but a reversed electrode configuration.
33258580|NCT04071223|Experimental|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33258581|NCT04071223|Active Comparator|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33258582|NCT04066907|Experimental|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a heart failure educator (HFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and HFE to enable monitoring and management of HF by the participant.
33258583|NCT04066907|No Intervention|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months telephone follow-up will be conducted by the research assistant and the questionnaires will be completed.
33258584|NCT04053491|Experimental|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
33258585|NCT04053491|Experimental|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
33258586|NCT04052997|Experimental|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
33258587|NCT04041232|Experimental|PBA treatment of ATF6-/- Achromatopsia|Patients will be monitored at the baseline visit, followed by a second and third visit that will be 1 and 3 months after the initial visit. Patients will complete a standard visual functioning questionnaire and undergo a complete ophthalmic evaluation at each visit. Other visual assessments will consist of color vision testing, contrast sensitivity, retinal imaging, and macular sensitivity testing using microperimetry. Full-field electroretinogram will also be performed at the baseline visit and after 1 and 3 months of PBA use. If improvement in retinal function is observed, an additional ophthalmic evaluation will be conducted after 6 months of PBA use. A blood draw will be performed at each visit to test for any indications of adverse effects from drug use.
33258588|NCT04038541|Other|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
33258589|NCT04038541|Other|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
33258590|NCT04037501|Experimental|Intervention|
33258591|NCT04037501|No Intervention|care as usual|
33258592|NCT04036682|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.
33258593|NCT04036682|Experimental|Phase 1 Dose Escalation (Rolling Six)|CLN-081 BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.
33258594|NCT04036682|Experimental|Phase 2a Dose Expansion(s)|CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Rolling Six cohorts.
33258595|NCT04036682|Experimental|Module A Food Affect|Single-dose CLN-081 150 mg with and without high fat food intake.
33258596|NCT04036682|Experimental|Module B|CLN-081 BID in NSCLC patients with EGFR exon 20 insertion mutations that have received prior systemic therapy for locally advanced or metastatic disease.
33258597|NCT04036682|Experimental|Module C|CLN-081 BID to patients with EGFR exon 20 insertion mutant NSCLC after prior therapy with an agent approved for the treatment of ex20ins mutant NSCLC.
32735229|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures and stutter frequency are investigated in this group."
33258598|NCT04036058|Experimental|Intervention|Enact universal gloving practices
32735230|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures are investigated in this group"
32735231|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
32735232|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
32735233|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
32735234|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
32735235|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
33258599|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
33258600|NCT04030000|Other|Paclitaxel/Carboplatin and radiation|"Paclitaxel 135 mg/m2 over 3 hrs on day 1 Carboplatin IP (AUC= 6.0) on day 1 Paclitaxel 60 mg/m2 IP on Day 8 Repeat q 21 days x 6 cycles~Pelvic 6MV Photon Beam Energy, or IMRT where appropriate 1.8 Gy Dose/FX Total Dose 45 Gy~High Dose Radiation (HDR) x 3, or IMRT where appropriate 5 Gy to 0.5cm Depth from the Vaginal Cylinder Surface Total Dose 15 Gy"
33258601|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
33258602|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
32735236|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
32735237|NCT03611569|Experimental|Lu AF82422|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
33258603|NCT04010539|Experimental|Participants receiving Gepotidacin|Participants will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 10 to 12 hours after the first dose.
33258604|NCT04010539|Active Comparator|Participants receiving Ceftriaxone plus Azithromycin|Participants will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
33258605|NCT04009174|Experimental|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
32735238|NCT03611569|Placebo Comparator|Placebo|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
32735239|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
32735240|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
33258606|NCT03992781||Newly prescribed tofacitinib|patients who were newly prescribed tofacitinib at baseline and who scored at least 11 points on CUDOS scale
33258607|NCT03992404|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
33258608|NCT03992404|Placebo Comparator|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
33258609|NCT03983161|Experimental|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
33258610|NCT03983161|Experimental|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
33258611|NCT03983161|Experimental|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
33258612|NCT03983161|Experimental|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
33258613|NCT03982940|Experimental|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
33258614|NCT03972709|Experimental|Galegenimab Q4W|Participants will receive galegenimab every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label galegenimab injections.
33258615|NCT03972709|Sham Comparator|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label galegenimab injections.
32735241|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
32735242|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
32735243|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
32735244|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
32735245|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
32735246|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
32735247|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
32935481|NCT05447377|Active Comparator|STAMARIL®|"STAMARIL is a Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos.~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL.~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of STAMARIL will be administered concomitantly with an MMR and a Men A vaccine."
33258616|NCT03972709|Experimental|Galegenimab Q8W|Participants will receive galegenimab every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label galegenimab injections.
33258617|NCT03972709|Sham Comparator|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label galegenimab injections.
33258618|NCT03965676|Other|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia < 360µmol/L).
33258619|NCT03957590|Experimental|Tislelizumab + chemoradiotherapy|Tislelizumab once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
33258620|NCT03957590|Placebo Comparator|Placebo combined + chemoradiotherapy|Placebo once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
33258621|NCT03952637|Experimental|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg/kg of the gene transfer agent, and two Type II subjects will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transfer agent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
33258622|NCT03952637|Experimental|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing and assessments will be determined. If Stage 2 dosing is to proceed, it will be reflected in a protocol amendment.
33258623|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
33258624|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
33258625|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
33258626|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
33258627|NCT03924895|Experimental|Arm A: Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
33258628|NCT03924895|Active Comparator|Arm B: Surgery alone|Participants receive standard of care surgery alone.
33258629|NCT03924895|Experimental|Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
32735248|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
32735249|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
32735250|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
32735251|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
32735252|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
33258632|NCT03919955|Experimental|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
33258633|NCT03919955|Placebo Comparator|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
33258634|NCT03919799|Experimental|Group 1|20 subjects will be randomized to receive orally administered belumosudil 200 mg QD double-blinded for the first 28 weeks. Subjects will then will be unblinded and continue on the same belumosudil dose for the remaining 24 weeks.
33258635|NCT03919799|Experimental|Group 2|20 subjects will be randomized to receive orally administered belumosudil 200 mg BID double-blinded for the first 28 weeks. Subjects will then will be unblinded, and continue on the same belumosudil dose for the remaining 24 weeks.
33258636|NCT03919799|Placebo Comparator|Group 3|20 subjects will be randomized to receive orally administered matched placebo double-blinded for the first 28 weeks. Subjects will then will be unblinded and re-randomized to one of the belumosudil doses (200 mg QD or 200 mg BID) in a 1:1 fashion.
33258637|NCT03919071|Experimental|Treatment (radiation therapy, dabrafenib, trametinib)|Patients undergo standardized local RT 5 days a week (Monday-Friday) for 6-7 weeks. Four weeks after completion of RT, patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI at baseline, on day 1 of cycles 1, 3, 5, 7, 11, 14, 17, 20, and 23 while on treatment, then at time of relapse, every 3 months for year 1, every 4 months for year 2, every 6 months for year 3, and annually for years 4-5. Patients may also undergo lumbar puncture for CSF testing during treatment. Patients also undergo collection of blood on study.
33258638|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.~Patients will receive the following per 28-day (± 3 days) cycle:~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
33258639|NCT03888027|No Intervention|Control|Patients receive no intervention
33258640|NCT03888027|Active Comparator|WalkMORE group|"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~Standard of care; or~WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE volunteer two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."
33258641|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
33258642|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
33258643|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
33258644|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
33258645|NCT03864042|Experimental|Arm 1 - CYP Probe Cocktail|"Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:~25 mg losartan oral tablet~30 mg dextromethorphan oral capsule~50 mg caffeine oral liquid~20 mg omeprazole oral capsule~2 mg midazolam oral syrup~encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
33258646|NCT03864042|Experimental|Arm 2 - Rosuvastatin and Bupropion|"Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:~10 mg rosuvastatin oral tablet~75 mg bupropion immediate release (IR) oral tablet~encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
33258647|NCT03864042|Experimental|Arm 3 - Modafinil|"Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~then receive continuous treatment of modafinil on Day 15 through Day 21:~- 400 mg modafinil tablet once daily (QD)"
32735253|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
32735254|NCT03281941|Other|Patients without BT|
33401391|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
33401392|NCT04059068||NASH (non-alcoholic steatohepatitis)|Patients diagnosed with non-alcoholic steatohepatitis.
32735255|NCT03281941|Other|Post BT|
32735256|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
32735257|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
33401393|NCT04059068||NAFLD (non-alcoholic fatty liver disease)|Patients diagnosed with non-alcoholic fatty liver disease.
32735258|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
32735259|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
32735260|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
32735261|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
32735262|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
32735263|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
33258648|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
33258649|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).~Exercises will be graduated according to the patient pain tolerance."
33258650|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
33258651|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
33258652|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
33258653|NCT03846804|Experimental|Karius Test|Participants will have additional blood drawn for the purposes of analysis with the Karius test.
33258654|NCT03833167|Experimental|Pembrolizumab|Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
32735264|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
33077050|NCT04681378|Active Comparator|Classical double layer closure|a holding Vicryl 1-0 was placed in the in the left corner to stabilize and define the demarcation of the suture line. A continuous unlocked stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, including the decidual layer. The second unlocked stitch was performed by Vicryl 1-0 in a lateral -lateral (horizontal) position, adapting the first layer. Up to three additional single sutures were added for hemostasis if required.
33077051|NCT04681378|Active Comparator|Turan technique|beginning in one corner, the incision is closed using Vicryl 1-0 stitch. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously in the form of a purse string closure. With this technique, the original string is returned to the starting point and tied with a knot. Following the double layered purse-string closure, the aperture left in the middle of the uterine incision is closed with one separate figure of eight suture
33258655|NCT03833167|Placebo Comparator|Placebo|Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
33258656|NCT03779841|Experimental|AGN-151607 (250 U)|Injections of 50 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
33258657|NCT03779841|Experimental|AGN-151607 (125 U)|Injections of 25 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
33258658|NCT03779841|Placebo Comparator|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
33258659|NCT03765918|Experimental|Pembro Neoadjuvant+Pembro SOC Adjuvant|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles as a neoadjuvant prior to surgery. Following surgical resection, high risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 every 3 weeks (Q3W) for fifteen 21-day cycles plus standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 Q3W for fifteen 21-day cycles plus standard of care radiotherapy as adjuvant therapy.
33258660|NCT03765918|Active Comparator|No Neoadjuvant+SOC Adjuvant|Participants receive no neoadjuvant prior to surgery. Following surgical resection, high risk participants receive standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive standard of care radiotherapy as adjuvant therapy.
33258661|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
33258662|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
33258663|NCT03760588|Experimental|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
33258664|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
33258665|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
33258666|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
33258667|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
32735265|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
32735266|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
33258668|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
32735267|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
32735268|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
32735269|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
32735270|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
32735271|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
33258669|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
33258670|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
33258671|NCT03718260|Experimental|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258672|NCT03718260|Experimental|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258673|NCT03718260|Experimental|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258674|NCT03718260|Experimental|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258675|NCT03718260|Experimental|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258676|NCT03718260|Experimental|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
33258677|NCT03718260|Experimental|Cohort 7|[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
33258678|NCT03711032|Experimental|BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)|Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).
33258679|NCT03711032|Experimental|BCG Monotherapy: Post-induction Cohort A (Arm A-2)|Participants receive BCG monotherapy (Induction and Maintenance).
33258680|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)|Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (~1 year).
33258681|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)|Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (~1 year).
33258682|NCT03711032|Experimental|BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)|Participants receive BCG monotherapy (Induction and Maintenance).
33258683|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth or through a gastrostomy tube, once or twice a day for 16 weeks.
33258684|NCT03682068|Experimental|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
33258685|NCT03682068|Experimental|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks~Tremelimumab will be provided for 4 cycles.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
33258686|NCT03682068|Active Comparator|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
33258687|NCT03681561|Experimental|Ruxolitinib and Nivolumab|
33258688|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
33258689|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
33258690|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
33258691|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
33258692|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
33258693|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
32735272|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
32735273|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
32735274|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
32735275|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
33258694|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
33258695|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
33258696|NCT03642626||Arm E: Breyanzi for relapsed or refractory large B-cell lymphoma (RLBCL)|
33258697|NCT03642626||Arm F: Abecma for relapsed or refractory multiple myeloma|
33258698|NCT03642626||Arm G: Tecartus B-cell acute lymphoblastic leukemia (ALL)|
33258699|NCT03640481|Experimental|Arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
33258700|NCT03640481|Experimental|Arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
32735276|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
32735277|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
32735278|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
32735279|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
32735280|NCT02458573|Experimental|continuous epidural analgesia group|
32735281|NCT02458573|Active Comparator|continuous intravenous analgesia group|
32735282|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
32735283|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
32935484|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
32935485|NCT03831139|No Intervention|Control|The youth participate in school as usual.
32935486|NCT05447299||Typically developing children|Reference group of typically developing children
33258701|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
33258702|NCT03637660|Experimental|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
33258703|NCT03621982|Experimental|Part 1: Dose Escalation, ADCT-301 Monotherapy|In Part 1 (dose escalation) patients will receive escalating doses of ADCT-301 as monotherapy.
32935487|NCT05447299||Cerebral palsy group|Children with a diagnosis of cerebral palsy
33258704|NCT03621982|Experimental|Part 1: Dose Escalation, ADCT-301 Combination Therapy|In Part 1 (dose escalation) patients will receive escalating doses of ADCT-301 in combination with pembrolizamab as combination therapy.
33258705|NCT03621982|Experimental|Part 2: Dose expansion, ADCT-301 Combination Therapy|"In Part 2 (dose expansion), patients will receive ADCT-301 in combination with pembrolizamab as combination therapy at the dose identified in Part 1 (dose escalation). Patients will be split into two groups:~Group 1: One of the indications identified in Part 1, for which at least 1 response (PR [partial response] or CR [complete response]) was seen.~Group 2: A basket group of patients with advanced/metastatic solid tumors and microsatellite instability/deficient MisMatch Repair (MSI-H/dMMR) status, who have received prior regimen containing a PD-1/PD-L1 inhibitor, for which the best response was CR, PR, or SD (stable disease) ≥4 months, and then progressed while continuing on the PD-1/PD-L1 inhibitor-based regimen."
33258706|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
33258707|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
33258708|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
33258709|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
33258710|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
32735284|NCT03269929|Experimental|Music therapy|
32735285|NCT03269929|Active Comparator|Midazolam|
33258711|NCT03608163|No Intervention|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.
33077052|NCT04681378|Active Comparator|Double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
33077053|NCT04681573|Other|Single ARM|Only one arm
33077054|NCT00168233||1|No antiretroviral therapy for 12 months
33077055|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
33077056|NCT00168233||3|Initiating ARV therapy with a PI based regimen
33077057|NCT04681612||MINOCA|Patients hospitalised with MINOCA according to the recently published consensus document of ESC after cardiac MRI confirmation.
33077058|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
33401394|NCT04059068||Control|Patients with normal liver tissue.
33077059|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
33077060|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
33077061|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
33401395|NCT04059068||obese / high WAT inflammation and fibrosis|Patients who are obese with inflammed white adipose tissue and evidence of fibrosis.
33258712|NCT03608163|Experimental|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
33258713|NCT03608163|Placebo Comparator|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
32769458|NCT04434547|Experimental|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
33077062|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
33258714|NCT03608163|Experimental|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
33258715|NCT03608163|Active Comparator|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
33401396|NCT04059068||obese / low WAT inflammation and fibrosis|Patients who are obese with no evidence of inflammed white adipose tissue and no evidence of fibrosis.
33401397|NCT04059068||non- obese controls|Patients who are not obese.
33401398|NCT04051658|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the motor area (M1) of the affected hemisphere, Cathodal on the contralateral supraorbital area. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
33077063|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
33077064|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
33077065|NCT00195858|Active Comparator|Diet and Resistane Exercise|
33077066|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
33077067|NCT00195858|Other|Diet-only control group|
33077068|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
33077069|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
33077070|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
33077071|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
33077072|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
33258716|NCT03608163|Active Comparator|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
33258717|NCT03608163|Placebo Comparator|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
33258718|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
33258719|NCT03604406|Experimental|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
32769459|NCT04434547|No Intervention|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
33077073|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
33077074|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
33077075|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
33077076|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
33077077|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
33077078|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
33077079|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
33077080|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
33258720|NCT03604406|Placebo Comparator|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
33258721|NCT03604406|Experimental|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
33258722|NCT03604406|Placebo Comparator|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
33258723|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
33258724|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
33258725|NCT03598257|Experimental|Group I (olaparib, radiation therapy)|Patients receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
33258726|NCT03598257|Active Comparator|Group II (radiation therapy)|Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity
33258727|NCT03587116|Other|Standard of Care FIX replacement therapy|
33077081|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
33077082|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
33077083|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
33258728|NCT03587116|Other|Standard of Care FVIII replacement therapy|
33258729|NCT03581292|Experimental|Treatment (radiation therapy, veliparib, temozolomide)|"CHEMORADIOTHERAPY PHASE: Patients receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, patients receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
32769460|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
32769461|NCT05030389|Experimental|Adapted Physical Activity (APA)|Participants receive a web-based adapted physical activity (APA) during 12 weeks, on the basis of three at-home sessions a week
32769462|NCT05030389|Experimental|Adapted Physical Activity + Bright Light Exposure (APA + BLE)|Participants receive a web-based APA program during 12 weeks on the basis of three at-home sessions a week, supplemented by a bright light exposure (BLE) during 12 weeks, on the basis of five at-home sessions a week
32769463|NCT05030389|Experimental|Galvanic Vestibular Stimulation (GVS)|Participants receive Galvanic Vestibular Stimulation (GVS) during two weeks, on the basis of five at-home sessions a week
33258730|NCT03573700|Experimental|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.~Cells for infusion are prepared using the CliniMACS System."
33258731|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
33077084|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
33077085|NCT02903173||Women who undergo cesarean delivery|
33258732|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
33258733|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
33258734|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
33258735|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
33258736|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
33258737|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
33258738|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
33258739|NCT03530371|Experimental|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
33258740|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Cohort A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
33258741|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Cohort B: Nivolumab 240mg IV + ipilimumab 1mg/kg IV q3 weeks x 4 doses, then nivolumab 480mg IV q4 weeks x 7 doses for up to 48 total weeks of therapy.
33258742|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A)|Cohort C: Nivolumab 480 mg IV q4 weeks plus relatlimab 480 mg IV q4 weeks for up to 48 weeks.
33258743|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
33258744|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
33258745|NCT03489122|Experimental|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
33258746|NCT03489122|Active Comparator|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
33401399|NCT04051658|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the supraorbital area of the affected hemisphere, Cathodal on the primary motor area (M1) of the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
32769464|NCT05030389|Active Comparator|Health Education program (HE)|Participants receive a web-based health education program (HE) during 14 weeks, on the basis of one at-home session a week
32735286|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
32735287|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
33077086|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
33077087|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
33258752|NCT03467958|Experimental|Administration of oral Ozanimod|
33258753|NCT03464097|Experimental|Ozanimod|
33258754|NCT03464097|Placebo Comparator|Placebo|
33258755|NCT03456934|Experimental|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
33258756|NCT03456934|Active Comparator|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
33258757|NCT03456934|No Intervention|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
33258758|NCT03440385|Experimental|Administration of oral Ozanimod|
33258759|NCT03440385|Placebo Comparator|Administration of Placebo|
32735288|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
33258760|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
33258761|NCT03433417|Experimental|Treatment Side|One truSculpt treatment
33077088|NCT04723589|No Intervention|Standard Arm|Participants randomized to standard care will not receive an intervention but will participate in other study procedures, which are blood collection and data collection.
33077089|NCT04723589|Experimental|Intervention Arm|Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
33258762|NCT03433417|No Intervention|Control Side|Untreated contralateral control
33258763|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
32735289|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
32735290|NCT03269773|Placebo Comparator|Placebo|
33258764|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
33258765|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
33258766|NCT03418649|Experimental|Experimental|Eplerenone 50 Mg Tab
33258767|NCT03418649|Placebo Comparator|Control|Placebo Oral Tablet
32735291|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
32735292|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
32735293|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
33258770|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
33258771|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
33258772|NCT03395210|Experimental|PRN1008 Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
33258773|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
33258774|NCT03375307|Experimental|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33258775|NCT03375307|Experimental|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline.
33258778|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
32735294|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
33258779|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
33258780|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
33258781|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
33258782|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib
33258783|NCT03331198|Experimental|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
32735295|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
33258784|NCT03331198|Experimental|Phase 1 JCAR017 + venetoclax|Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
33258785|NCT03327441|Experimental|Almonds|
32735296|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
32735297|NCT03360383|Active Comparator|grade 2|conservative treatment
32735298|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
32735299|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
32735300|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
32735301|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
32735302|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
32735303|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
32735304|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
32735305|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
32735306|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
33077090|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
33258786|NCT03327441|Active Comparator|Omelette|
33258787|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
33258788|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
33077091|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
33077092|NCT02903056||Control-normal|Healthy people
33258789|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
33258790|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
33258791|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
33258792|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
33258793|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
33258794|NCT03292601|Experimental|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
33258795|NCT03260920|Experimental|Low Dose|
33258796|NCT03260920|Experimental|Medium Dose|
33258797|NCT03260920|Experimental|High Dose|
33258798|NCT03258593|Experimental|1/ Run In|Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 subjects
33258799|NCT03258593|Experimental|2/ Expansion|Durvalumab + Vicineum, at the MTD. Up to 24 subjects
33258801|NCT03211663|Other|Interventional : MOTO Medial® UKA|Interventional : Patients who are planned to undergo a primary medial UKA using the MOTO Medial® will be enrolled.
32735307|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
32735308|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
32735309|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
32735310|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
32735311|NCT03364985|Experimental|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
32735312|NCT04523441||Parents|man or woman
32735313|NCT04523441||Professionals|health professionals in charge of monitoring children
32735314|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
32769465|NCT05038579|Experimental|Musiquence|Dementia group was involved in a 14-session customized cognitive stimulation program, using Musiquence.
33077093|NCT00195936|Experimental|Overall Study|Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
33077094|NCT02903095|Experimental|TD-1439|Capsule formulation
33077095|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
33258806|NCT03164616|Experimental|Treatment Arm 1|durvalumab + tremelimumab combination therapy + SoC chemotherapy
32735315|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
32735316|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
33258807|NCT03164616|Experimental|Treatment Arm 2|durvalumab monotherapy + SoC chemotherapy
33258808|NCT03164616|Active Comparator|Treatment Arm 3|SoC chemotherapy alone
33258809|NCT03155620|Experimental|Subprotcol M (HRAS gene alterations)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
33258810|NCT03155620|Experimental|Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)|Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate PO or via nasogastric- or gastric-tube BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33258811|NCT03155620|Experimental|Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)|Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
32735317|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
32735318|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
32735319|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
32735320|NCT04523285|Experimental|TQB3728 tablets|TQB3728 tablets administered orally, once a week in 28-day cycle.
32735321|NCT04524923||cohort group|Ninety-seven typically developing preschool children of both genders with age ranges from three to five years will be included in this study. Visual motor integration, quality of life and cognitive function were assessed by the Peabody Developmental Motor Scale, the Pediatric Quality of Life Inventory™ and the Pediatric Quality of Life Inventory™ cognitive functioning scale respectively
32735322|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
32735323|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
32735324|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
32735325|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
32735326|NCT04524845|Experimental|Rebel Reliever|Rebel Reliever (RR) (Thuasne, Levallois Perret, France) with bilateral rigid frames and two hinges. The valgus correction was set by adjusting the medial and lateral frame lengths to a difference of two or three points as dictated by the participant's feeling and comfort. Six straps maintained the brace in place
32735327|NCT04524845|Experimental|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France) made mainly from textile. Upper and lower straps were adjusted to the participant's feeling and comfort.
32735328|NCT04524845|Active Comparator|Unloader One|Unloader One (UO) (Össur, Reykjavik, Iceland), with unilateral frame and one hinge. Upper and lower straps were adjusted to the setting recommended by the fitting instructions and confirmed by the participant's sensation.
32935488|NCT05447221||Whole slide images of gastric biopsy specimens|Whole slide images of gastric biopsy specimens
32935489|NCT05446987|Experimental|Position change and back massage group|The patients received changing of position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the patients received a simple stroke of lower back massage for 5 minutes every 2 hours
32935490|NCT05446987|Experimental|Early ambulation|The patient are allowed to ambulate after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle.
32735329|NCT04524845|No Intervention|No orthosis|Control condition without brace
32735330|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
32735331|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
32735332|NCT03364361|Other|Acupuncture|Feasibility Study
32935491|NCT05446909|Experimental|IBMT mindfulness|An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress, and improving self-control and brain plasticity related to cognitive performance. It has bodifulness and mindfulness components.
32935492|NCT05446909|Active Comparator|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
32935493|NCT05256511||SARS-CoV-2 first wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the first wave of the pandemic, starting on 01-01-2020
32735333|NCT03364205|Experimental|intervention|solution-focused interview techniques
32735334|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
32735335|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
33258812|NCT03155620|Experimental|Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)|Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33258813|NCT03155620|Experimental|Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)|Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33258814|NCT03155620|Experimental|Subprotocol E (activating MAPK pathway gene mutation)|Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33258815|NCT03155620|Experimental|Subprotocol F (ALK or ROS1 gene alteration)|Patients with an ALK or ROS1 gene alteration receive ensartinib PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
32769466|NCT05038657|Experimental|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
32769467|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
32769468|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
32769469|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
32769470|NCT05038501||Comorbidities in Oncosurgery patients|Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
32769471|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
32769472|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
32769473|NCT05038423|Active Comparator|A structured 12-week group walking program|Participants engaged in an evidence-based 12-week walking program.
32769474|NCT05038423|Experimental|A structured 12-week group walking program + 5RS|In addition to the 12-week group walking program, participants engaged in the 5R Shared Leadership Program, which implements a structure of shared leadership and strengthens the identity leadership skills of the appointed peer leaders.
32769475|NCT05038189|Experimental|Ankylosing Spondylitis|Study group
32769476|NCT05038189|Experimental|Non-radiographic Axial Spondyloarthritis|Study group
32769477|NCT05038189|Experimental|Healthy individuals|Control group
32769478|NCT05051215||Control group|40 healthy volunteers were included in the healthy control group
32769479|NCT05051215||NPM group|60 patients of NPM (30 PCM and 30 GM)were included
32769480|NCT04973059|Active Comparator|Summer Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the summer. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
32769481|NCT04973059|No Intervention|Summer Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the summer no power assist.
32769482|NCT04973059|No Intervention|Winter Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the winter no power assist
32769483|NCT04973059|Active Comparator|Winter Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the winter. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
33258816|NCT03155620|Experimental|Subprotocol G (BRAF V600 gene mutation)|Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32769484|NCT05038267||Femous patients|Adults undergoing general anesthesia for an elective cardiac surgery requiring cardiopulmonary bypass
32769485|NCT05038111||Dex|Dexmedetomidine infusion during the perioperative period
32769486|NCT05038111||Non-Dex|Did not have dexmedetomidine infusion during the perioperative period
32769487|NCT05038033|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy program adapted for the prevention of excessive weight gain. Involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
32769488|NCT05038033|Active Comparator|Cognitive-Behavioral Therapy (CBT)|The CBT program will match the delivery format and dose of the IPT program. There will be one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
32769489|NCT05029531|Experimental|intervention/treatment|
32935494|NCT05256511||SARS-CoV-2 second wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the second wave of the pandemic, starting on 10-01-2020
32935495|NCT05247541|Active Comparator|Healthy Participants|
32935496|NCT05247541|Experimental|Study participants|
32935497|NCT05446753|Experimental|Animal-based meats (ABMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with animal-based meats (ABMD group).
33258817|NCT03155620|Experimental|Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)|Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33258818|NCT03155620|Experimental|Subprotocol I (Rb positive, alterations in cell cycle genes)|Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33258819|NCT03155620|Experimental|Subprotocol J (MAPK pathway mutations)|Patients with MAPK pathway mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33258820|NCT03155620|Experimental|Subprotocol N (activating RET mutations)|Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
33258821|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
33258822|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
33258823|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
33258824|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
33258825|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
33258826|NCT03142152|Experimental|Intervention Group|Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
33077096|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
33258827|NCT03142152|Active Comparator|Control Group|Guideline Directed Heart Failure Medication
33258828|NCT03132337||Stem Cell Transplant|Serial Blood Draws
33258829|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
33077097|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
33258830|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
33258831|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
33258832|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
33258833|NCT03126916|Experimental|Arm E (lorlatinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
33258834|NCT03124355|Experimental|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
33258835|NCT03124355|Experimental|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
33258836|NCT03124355|Experimental|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
33258837|NCT03122652|Experimental|Terifunomide|
33258838|NCT03122652|Placebo Comparator|Placebo|
33258839|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
33258840|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
33258841|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
33258842|NCT03004261|Experimental|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
33258843|NCT02997228|Active Comparator|Arm I (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL)
33258844|NCT02997228|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity.
33258845|NCT02997228|Experimental|Arm III (atezolizumab, bevacizumab, mFOLFOX6)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
33258846|NCT02981628|Experimental|Cohort I (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (COMPLETE)
33258847|NCT02981628|Experimental|Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)|See Detailed Description
32769490|NCT05037643|Experimental|Pre-emptive TIPS in Cystic Fibrosis Related Liver Disease and non-cirrhotic portal hypertension|"Patients with CFLD without cirrhosis were eligible for a pre-emptive TIPS, when early (asymptomatic) signs of portal hypertension. All procedures were performed under general anaesthesia by an experienced interventional radiologist. Depending on the patient's age and physiognomy, TIPS was created following a conventional transjugular technique as for adults or by a dedicated combined percutaneous transhepatic-transjugular (PIPS) approach for small children. Routinely, an expanded polytetrafluoroethylene-covered endoprosthesis was used for shunt creation. If the sheath could not be negotiated into the main portal vein, a self-expandable, non-covered stent was placed. We did not pursue a minimum gradient reduction.~Percutaneous liver biopsy was performed during TIPS procedure to confirm the diagnosis of fibrosis or cirrhosis."
32769491|NCT05050513||interventional group|kidney graft preserved with M101
32769492|NCT05050513||control group|kident graft preserved in standard condition (without M101)
32769493|NCT05029453|Experimental|Experimental Group|apatinib combine with chemotherapy. Apatinib: initial dose: 500mg,oral,once a day, after meal ( try to take the medicine at the same time each day) Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
32769494|NCT05029453|No Intervention|Control Gtoup|chemotherapy Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
32769495|NCT04434625|No Intervention|control group|Colonoscopy was performed in the control group directly.
32769496|NCT04434625|Experimental|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group colonoscopy directly.
32769497|NCT05029765|Placebo Comparator|Healthy diet Arm|Healthy diet (WHO recommendations) + placebo
32769498|NCT05029765|Placebo Comparator|Mediterranean diet Arm|Mediterranean diet + placebo
32769499|NCT05029765|Active Comparator|"Mediterranean diet plus Arm"|Mediterranean diet + Biopolis-MIX42 (1 capsule per day containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium long).
32769500|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
32769501|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
32769502|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
32769503|NCT04471519|Experimental|BBV152A - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
32769504|NCT04471519|Experimental|BBV152B - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
32769505|NCT04471519|Experimental|BBV152C - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152C], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
32769506|NCT04471519|Active Comparator|Placebo - Phase I|0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.
32769507|NCT04471519|Experimental|BBV152A - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.
32769508|NCT04471519|Experimental|BBV152B - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28
32769509|NCT05037565|Experimental|Treatment group|One group receive PHGG following study protocol (treatment group).
32769510|NCT05037565|No Intervention|Control group|This group will not receive PHGG
33258848|NCT02968212|Experimental|clofazimine|Participants receive lamprene
33258849|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
32769511|NCT05037721|Experimental|gargling with green tea of stroke patients|Use fresh green tea (package date less than one month) sourced from the local market and serve in the form of soaked tea bags. 0.5% green tea refers to a tea bag soaked in 0.5g green tea, soaked in 100ml warm water for 5 minutes and let cool. Then, put each bottle of 15ml mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
32769512|NCT05037721|Active Comparator|gargling with water of stroke patients|Use water 15ml of mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
32769513|NCT05037253|Active Comparator|high dose|Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months.
32769514|NCT05037253|Active Comparator|Low dose:|Vitamin D therapy will prescribe for 3 months at a dosage of 2,000 IU/day.
32769515|NCT05029297|Experimental|CAPSAICIN 0.75 mg/g topical solution applicable in roll-on|CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
32769516|NCT05029297|Active Comparator|CAPSAICIN 0.075% cream|CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
32935498|NCT05446753|Experimental|Plant-based meat alternatives (PBMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with Plant-based meat alternatives (PBMD group).
32935499|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
32735336|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
32735337|NCT04524377|Experimental|DBS for Parkinsons Disease|
33258850|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33258851|NCT02960022|Experimental|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day
33258852|NCT02960022|Experimental|enzalutamide plus abiraterone acetate and prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily
33258853|NCT02956031||HIV pos|those who serologically tested positive for HIV
33258854|NCT02956031||HIV neg|those who serologically tested negative for HIV
33258855|NCT02956031||HIV unk|those with no available serological test for HIV
33258856|NCT02945774|Experimental|(18F)-FEPPA|
33258857|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
33258858|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
33258859|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
33258860|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
33258861|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
32735338|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
32735339|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
33077098|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
33258862|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
33258863|NCT02889523|Experimental|DLBCL cohort|"RCHOP + tazemetostat:~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
33258864|NCT02889523|Experimental|FL cohort|"RCHOP + tazemetostat:~Induction~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):~6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID~Maintenance~Tazemetostat : 6 months (every 8 weeks)~Rituximab : 24 months (every 8 weeks)"
33258865|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
33258866|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
33258867|NCT02784210|Experimental|Methylprednisolone|3 day course of intravenous methylprednisolone 1000 mg/day
33258868|NCT02784210|Experimental|prednisone|3-day course of oral prednisone 1250 mg/day
33258869|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
33258870|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
32735340|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
33258871|NCT02771626|Experimental|Telaglenastat 600 mg + Standard Dose Nivolumab|Telaglenastat 600 mg in combination with standard dose nivolumab in participants with advanced/metastatic clear cell renal cell carcinoma (ccRCC), melanoma, and non-small cell lung cancer (NSCLC).
33258872|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitor (TKI) but are treatment naïve to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
33258873|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Recently Treated With Nivolumab|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with stable disease for at least 24 weeks.
32735341|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
32735342|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
32735343|NCT04524299|Experimental|Concurrent chemotherapy Twice a Week|During the period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.
33258874|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
33258875|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: Melanoma With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
32735344|NCT04524299|Active Comparator|Concurrent chemotherapy Once a Week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours.
32735345|NCT03358433|Experimental|Exercise|
32735346|NCT03358433|Active Comparator|Antidepressants|
32735347|NCT03359369||Septic Patients|
33258876|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: NSCLC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
33258877|NCT02724579|Experimental|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.~MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients also undergo MRI throughout the trial."
33258878|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
33258879|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
33258880|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
32735348|NCT03359369||Non Septic Patients|
32735349|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
32735350|NCT04522583||Troponin-positive ED patients|All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter).
32735351|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
32735352|NCT03359135||group1|hEDS treated with rehabilitation only
33258881|NCT02677896|Experimental|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
33258882|NCT02628067|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
33258883|NCT02628067|Experimental|Pembrolizumab 400 mg|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).
33258884|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
33258885|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
33258886|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
32735353|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
32735354|NCT04522193|Experimental|Experimental group|All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
32735355|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
32735356|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
33258887|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
32735357|NCT04522115|Experimental|aerobic training|Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.
32735358|NCT04522115|Experimental|Resistance training|Resistance exercise training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
32735359|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
32735360|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
32735361|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
32735362|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
32735363|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
32735364|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
32735365|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
32735366|NCT02714569|Experimental|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
32735367|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
32735368|NCT02714569|Experimental|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
32735369|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
32735370|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
32735371|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
32735372|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
32735373|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
32735374|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
32735375|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
32735376|NCT04522817|Experimental|CLBS119 Active Treatment|Single administration of CLBS119
32735377|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
32735378|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
32735379|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
32735380|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
32735381|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
33258888|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.
33258889|NCT02564991||Healthy Controls|125 non-substance abusing controls (NSAC)
33077099|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
32735382|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
33258890|NCT02564991||Individuals with Alcohol Use Disorder|This group includes individuals who enrolled NIAAA alcohol treatment.
33258891|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~The investigator believes it is in the patient's interest to receive durvalumab;~The patient consents to the continued treatment;~It is clinically appropriate for the patient to continue on durvalumab treatment;~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
33258892|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
33258893|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
33258894|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
33077100|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
33077101|NCT00195975||1|Children with FD
33258895|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
33258896|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
33258897|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
32735383|NCT04521959|Active Comparator|Blood Flow Restricted Aerobic and Resistance Exercise Group|kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak
32735384|NCT04521959|Active Comparator|Normal aerobik ve direnç egzersiz grubu|Normal şartlarda aerobik ve direnç egzersizi uygulanacak
32735385|NCT04522037||interventional group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
32735386|NCT04522037||control group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
33077102|NCT00195975||4|Healthy controls
33258898|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
33258899|NCT02535702|Experimental|Attentional Bias Task|Subjects will briefly see two images side by side on a screen. Immediately after, a dot appears on the left or on the right. The subjects task is to press the left or right button, following the position of the image (left or right). Images can contain food-related items. We will also show short 1-minute food-related movies. Subjects will be asked to fast for three hours before this task begins.
33258900|NCT02535702|Experimental|Cue Reactivity Task|In this task subjects will view pictures of various items on the screen in front of them. Subjects will rate the items by how much they would like to have them. Subjects will choose how much they want the item by pressing a button.
32735387|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
32735388|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
32735389|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
32735390|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
32735391|NCT04522661|Experimental|Early Vitrectomy Group|Vitrectomy surgery plus intravitreal antibiotics
32735392|NCT04522661|Active Comparator|Control Group|Intravitreal antibiotics
32735393|NCT04445051|Active Comparator|Standard of care|SpeediCath® standard Male and Female
32735394|NCT04445051|Experimental|New intermittent catheter variation 1 for male and female|New intermittent catheter variation 1 for male and female
32735395|NCT04445051|Experimental|New intermittent catheter variation 2 for male and female|New intermittent catheter variation 2 for male and female
32735396|NCT04522349|Active Comparator|Greifer then Axon-Hook|T0 + 2 weeks: evaluation with Greifer. T1 + 2 weeks: evaluation with Axon-Hook
32735397|NCT04522349|Active Comparator|Axon-Hook then Greifer|T0 + 2 weeks: evaluation with Axon-Hook. T1 + 2 weeks: evaluation with Greifer
32735398|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
32735399|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
33077103|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
33077104|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
33258901|NCT02535702|Experimental|Delay Discounting Task|Subjects will be asked to imagine whether they would receive money now or money later (in the future). The future money option may be several days from now or as far out as 6 weeks from now. For example, a s ubject may see a $100 option in 6 weeks or a $10 option now. Subjects will not receive actual money for participation in this task
33258902|NCT02535702|Experimental|Motivational Reward Task|Subjects will make a choice among some items presented on the screen in front of them. One of the items will be the winner item. The other items will be loser items. Each time a subject is presented with various items, they will choose the item they think is the winner item. Subjects will start with bonus points at the beginning of the task, so they can add more points to this amount as they continue to choose winner items.
33258903|NCT02535702|Experimental|NSPRD Task|During the MRI scan, subjects will get small electric shocks through electrodes placed on one of their toes. The shocks feel like an elastic band snapping against the skin. Right after a shock, subjects will see a dot on the computer screen. Subejcts will press a button to rate the intensity of the shock.
33258904|NCT02535702|Experimental|Reasoning Task|Subjects will identify changes in various shapes when they are displayed on the screen in front of them. Some changes of the shapes may be that they were rotated, enlarged, or multiplied. Subjects will choose the changes in the shapes by pressing a button.
33258905|NCT02535702|Experimental|Respiratory Challenge (RC) Task|Participants will be visually instructed to take a brief deep breath (inhale) and release the breath (exhale). They will inhale and exhale one more time with visual cues at specific times (60 seconds, 120 seconds, 180 seconds, 240 seconds, etc. with successive 60 seconds intervals). A black cross will remain centered on a grey slide during the normal respiration periods. To signal the RC periods, the slide will change color to yellow READY slide, then to green BREATHE IN slide, then to blue BREATHE OUT slide. The sequence will repeat one more time to Breath In and Breath Out and then finally go back to the yellow Breathe Normally slide. The instruction words will be written on the slides. Each slide will be shown for 3 seconds. The task will take a total of 15 minutes (total of 900 seconds with 14 RC periods).
33401400|NCT04051658|Experimental|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
33077105|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
32735400|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
32735401|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
32735402|NCT03358589|Other|MESTAR|All patients will have the same scans performed
33077106|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
32735403|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
32735404|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
32735405|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
32735406|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
32735407|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
32735408|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
32735409|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
32735410|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
32735411|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
32735412|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
32735413|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
33401401|NCT04051658|Sham Comparator|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
33077107|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
33258906|NCT02535702|Experimental|Self-control Task|During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
33258907|NCT02535702|Experimental|Spinner Task and MID Task (monetary incentive delay task)|The Spinner task requires the subject to participate in a game of chance while lying in the MRI scanner. Subjects will be asked to respond by pressing a button. The MID task is a reaction time task. The MID Task tests how quickly a subject can press a button to hit a target on the screen in front of them. If the subject presses the button as soon as the target appears, the subject will score points. Subjects should try to score as many points as you can.
33258908|NCT02515370|Experimental|Friends for Life Circles (FLC)|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
33077108|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
33258909|NCT02515370|No Intervention|Standard of Care (SOC)|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
33077109|NCT02902744|Experimental|ILUVIEN 0.19 MG|
33258911|NCT02501733|Other|Medacta GMK Sphere® Knee Prosthesis|All subjects enrolled will receive the Medacta GMK Sphere® Medial Knee Prosthesis
33258912|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
33258913|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
33258914|NCT02379429||1/Participants|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
33258915|NCT02379429||2/Healthy Volunteers|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
33258916|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~cisplatin 25 mg/m^2 IV daily on Days 2-5~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
33258917|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~carboplatin daily on Days 1-3~etoposide 400 mg/m^2 daily on Days 1-3~stem cell reinfusion on day 5~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
33258918|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
33258919|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
33258920|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
33258921|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33258922|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
33258923|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
33258924|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
33258925|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
33258926|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
33258927|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
33258928|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
33258929|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
33258930|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
33258931|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
33258932|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
33258933|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
32735414|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
33258934|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
33258935|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
32735415|NCT03280927|Experimental|Jublia®|
32735416|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
33258936|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
32735417|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
32735418|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
32735419|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
32735420|NCT04522427|Experimental|Multifocal and Extended Depth-of-Focus intraocular lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
32735421|NCT04522427|Active Comparator|Monofocal intraocular Lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
32735422|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
32735423|NCT04521491|Experimental|FOLFOX4|Patients who will receive FOLFOX4 chemotherapy after liver resection
32735424|NCT04521491|No Intervention|placebo|No adjuvant therapy after liver resection
33258937|NCT02190500|Active Comparator|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
33258938|NCT02190500|No Intervention|Standard Management|Acute ischemic stroke patients receiving standard management
33258940|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
33258941|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
33258944|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
33258945|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
32735425|NCT04509635|Experimental|Arm A|Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
32735426|NCT04509635|Active Comparator|Arm B|Using treatment of chemotherapy alone. Chemotherapy: detailed regimen is determined by a multi-disciplinary team
32735427|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
32735428|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
32735429|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
32735430|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
32735431|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
32735432|NCT04521023|Experimental|A|
32735433|NCT04521023|Active Comparator|B|
32735434|NCT03269071|Experimental|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
32735435|NCT03269071|Experimental|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
32735436|NCT03269071|Experimental|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
32735437|NCT03269071|Experimental|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
32735438|NCT04521101|Other|VAST Course|
32735439|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
33401402|NCT04316182|Experimental|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
33077110|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
33077111|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
33077112|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
33077113|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
33077114|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
33077115|NCT02902393||Success of revascularisation|
33077116|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
32735440|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
32735441|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
32735442|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
33077117|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
33077118|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
33077119|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
33258946|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
33258947|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
33258948|NCT02077894||Affected participants|Participants with an eye disease.
33258949|NCT02077894||Unaffected family members|Unaffected family members.
32735443|NCT05234827|Experimental|Virtual Reality|VR sessions include a device (XBOX 360) and motion sensor (Kinect) and LED (tv screen) with speakers attached. Height of the device is 1m while tv screen is placed 2.5m away, motion sensor is placed 1.2m away from the patient, play area should be 1.8m wide and long. Instruction to play game is provided to each patient. Before starting each training session, the device was adjusted to correctly follow the movements of each patient. VR session includes games by Kinect Adventures (Microsoft games studios, Washington, US) which include minigames in which patients participated these mini games are 20000 Leaks, Curvy Creek, Rally Ball and Reflux Ridge.
32735444|NCT05234827|Active Comparator|Control|Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing
32735445|NCT04520945|Active Comparator|Active Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
33258950|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
33258951|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33258952|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
33077120|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
33077121|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
33077122|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
33077123|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
33077124|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
33258953|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
33258954|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
33258955|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
33258956|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
33258957|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
33258958|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
33258959|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
33258960|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
33258961|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
32735446|NCT04520945|Placebo Comparator|Placebo Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
32735447|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
32735448|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
32735449|NCT04509089|Experimental|Experimental|Congestive heart failure patients scheduled for pulmonary artery catheterization (Swan-Ganz)
32735450|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
32735451|NCT04509323|Experimental|Experimental：Huperzine A for Injection+Basic treatment|Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days； Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
32735452|NCT04509323|No Intervention|Control：Basic treatment|Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
32735453|NCT04520789|Sham Comparator|RD control group|Conventional Surgery for Retinal Detachment
33077125|NCT02902627|Experimental|Metastatic cancer|
33077126|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
33077127|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
33077128|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
33077129|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
33258962|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
33258964|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
33258965|NCT01802034||Native, Non-tissue Preservation Group|"Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or~Subjects with diabetes and renal disease who have not had a renal biopsy."
33258966|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
33258968|NCT01736293||Affected Participants|Participants with ABCA4-related retinopathies.
33258969|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
33258971|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
33258972|NCT01566695|Placebo Comparator|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
33258973|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
33401403|NCT04505540|Active Comparator|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
33258975|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
32769517|NCT05028907|Experimental|group one (cases with inflamatory punctal stenosis treated with steroids and antibiotics)|patients with inflammatory punctal stenosis were treated by steroids and antibiotics and evaluated by anterior segment optical coherence tomography before and after treatment
32769518|NCT05028907|Placebo Comparator|control group|patients with inflammatory punctal stenosis received only preservative free tear substitutes
33258976|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
33258977|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
33258978|NCT01524822||Unexposed|People not exposed to repeated blasts
33258979|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
33258982|NCT01464164|Experimental|Sotatercept|Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. *Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.
33258983|NCT01464164|Experimental|Sotatercept with prednisone boost|Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).
33077130|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
33258987|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
33258988|NCT01399385|Experimental|Group 1|Group 1 will consist of subjects with a 10-year total CHD risk <10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
33258989|NCT01399385|Experimental|Group 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
33258990|NCT01399385|Experimental|Group 3|Group 3 will consist of subjects with a 10-year total CHD risk >20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
33258991|NCT01399385|Experimental|Group 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
33258992|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
33258993|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
33258994|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
33258995|NCT01324206||Healthy Volunteers|Healthy Volunteers, 18 or older years
33258996|NCT01306084||1|NIH campus employees who have recently recovered from COVID-19
33258997|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
33258998|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
33258999|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
33259000|NCT01306084||5|Healthy subjects who grew up in dengue endemic areas.
33259001|NCT01306084||6|Healthy subjects with a history of viral hepatitis
33259002|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
33259003|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
33259004|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
33259005|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
33259006|NCT01174121|Experimental|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CD8+ enriched TIL + high-dose aldesleukin (CLOSED)
33259007|NCT01174121|Experimental|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin (CLOSED)
32735454|NCT04520789|Experimental|RD treatment group1|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study
33259008|NCT01174121|Experimental|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
33259009|NCT01174121|Experimental|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
33259010|NCT01174108|Experimental|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
32735455|NCT04520789|Active Comparator|RD treatment group2|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention
33259011|NCT01174108|No Intervention|2|Donor
33259012|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
32735456|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
32735457|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
32735458|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
32735459|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
32735460|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
32735461|NCT04443647|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
32735462|NCT04443647|Placebo Comparator|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
33259013|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
33259014|NCT01132885||Adults with WS or genetic abnormalities|Adults with Williams syndrome or genetic abnormalities in chromosome 7q11.23
33259015|NCT01132885||Children with WS or genetic abnormalities|children ages 5-17 with Williams Syndrome or genetic abnormalities in chromosome 7q11.23
33259016|NCT01132885||Parents|Parents of children with 7q11.23 CNV will undergo blood draws
32735463|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
33077131|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
33077132|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
33077133|NCT02901847|Other|Intervention|PAD tailored care
33259017|NCT01132885||Unaffected Siblings|Siblings of children with 7q11.23 CNV
33259018|NCT01132885||Unrelated children|Typically developing children ages ages 5-17
33259019|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
33259020|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
33259021|NCT01087294|Experimental|1A/T cell Arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body-weight
33259022|NCT01087294|Experimental|1B/T memory stem cell arm|Dose Escalation with 5 dose levels of CAR+ T memory cells based on the patients actual body-weight
33259023|NCT01087294|Other|2/Donor arm|Leukapheresis
32735464|NCT04443881|Experimental|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
32735465|NCT04443881|No Intervention|Control Arm|Standard of care
32735466|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
32735467|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
33259025|NCT00977977|Experimental|Combination of Rituximab plus cyclosporine|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months. Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued.
33259026|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
33259027|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
33259033|NCT00655096||Affected participants|Adults and children with either diagnosed or un-diagnosed ocular conditions.
33259034|NCT00655096||Disease free control|Adults and children without any ocular disorders.
33259035|NCT00655096||Unaffected relative|Unaffected first degree relative of a genetic ocular disease participant.
33259036|NCT00628745||Observational|
33259037|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
32935500|NCT05234281|Other|Low back pain|Adults with chronic low back pain and at least 4 months of decreased work participation. Intervention as for all groups but with the use of GLADRyg back rehabilitation principles.
33077134|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
33259038|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
33259039|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
33259040|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
32935501|NCT05234281|Other|Chronic Obstructive Pulmonary Disease (COPD)|Adults with COPD (FEV1<80%). Intervention as for all groups but with added pulmonary rehabilitation focus.
33259041|NCT00591175||1|Standard Care
33259042|NCT00591175||2|Standard Care with Hygienist Counseling
33259043|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
33259044|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
33259045|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
33259048|NCT00199043|Experimental|Only 1 arm|
32935502|NCT05234281|Other|Diabetes type 2|Adults with type 2 diabetes and diabetes-related challenges including dysglycaemia, diabetic complications and/or weight issues. Intervention as for all groups but with added focus on how to make useful microchoices in terms of lifestyle.
32935503|NCT05234281|Other|Mixed anxiety/depression|"Young adults (18-35 years) with mixed anxiety/depression. Intervention as for all groups but with added focus on acceptance and commitment therapy, behavioral analysis, metacognitive therapy and physical activity."
32935504|NCT05234281|Other|Post COVID-19|Adults who have persistant fatigue and/or dyspnea following infection with COVID-19.
32935505|NCT05222737|Active Comparator|test group|intra pocket diode laser application
32935506|NCT05222737|Active Comparator|control group|antibiotic adminstration
32935507|NCT05446675||eTEP|First 30 participants who meet the inclusion criteria and do not exhibit any of the exclusion criteria will be investigated. The option for endoscopic eTEP repair, if feasible, is given preoperatively as a standard for the treatment of symptomatic midline abdominal wall hernias with concomitant rectus abdominis diastasis as an alternative to open Rives-Stoppa mesh repair. The modality of operative treatment is made in cooperation with the participant.
32935508|NCT05446675||Rives-Stoppa, control|Thirty participants will be selected out of all patients who underwent an open Rives-Stoppa (midline repair with sublay mesh) in the investigators' center and who do not meet any of the exclusion criteria. Participant selection will consist of matching to participants in group 1 according to gender and age (e.g. a male participant in group 1 will be matched to a male participant (group 2) out of the investigators' records who underwent an open Rives-Stoppa repair and whose age most closely resembles the age of the matched participant in group 1).
32935509|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
32935510|NCT05217979|Active Comparator|Transcutaneous pulsed radiofrequency|After signing informed consent, patients assigned to the intervention group by randomization will receive a single treatment with transcutaneous pulsed radiofrequency.
32735468|NCT04509245|Experimental|Effects of a digitally assisted lifestyle intervention|Testing the effects of a low-calorie diet in connection with app-based digital education and behavioral change program on glucose metabolism and disease management.
33077135|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
33259053|NCT00084305||Family|Family members of patients with pulmonary fibrosis
33259054|NCT00084305||Healthy Volunteers|Healthy Volunteers
33259055|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
33259056|NCT00067821||1/Patients|Must have a brain tumor, or residual abnormality that is measurable or evaluable on standard MRI or CT
32735469|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
33259059|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
33259060|NCT00029965||Glycoprotein Disorders|Glycoprotein Disorders
33259061|NCT00029965||Lysosomal Storage Diseases|Lysosomal Storage Diseases
32735470|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
32735471|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
32735472|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
33259062|NCT00006177||Adult bipolar patients|Adult bipolar patients
33259063|NCT00006177||Adult Extended Relatives of BD probands|Adult Extended Relatives of BD probands
33259064|NCT00006177||Bipolar Children and Youth|Bipolar Children and Youth
33259065|NCT00006177||Child/Adolescent Extended Relatives of BD probands|Child/Adolescent Extended Relatives of BD probands
33259066|NCT00006177||Children with ADHD only (controls)|Children with ADHD only (controls)
33259067|NCT00006177||First degree relatives of BD patients|First degree relatives of BD patients
33259068|NCT00006177||Healthy volunteer adults (parents or not)|Healthy volunteer adults (parents or not)
32735473|NCT03354533|Other|Treatment with ORL-1F - L-fucose|
32735474|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
32769519|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
33259069|NCT00006177||Healthy volunteer children and youth|Healthy volunteer children and youth
33259073|NCT00004568||Inherited Neurological Patients|Includes individuals and families with a known or unknown inherited neurological condition.
33259074|NCT00001975||Group 1|Patients will be those already diagnosed with TSC (definite or possible)
33259075|NCT00001594||Children with OI|Children with OI
33259076|NCT00001529||Group 1|Healthy volunteers
33259077|NCT00001452||1|families with PPNAD and/or Carney complex
33259084|NCT00001205||1|Male and female subjects aged 3-75 years with likely or definite neurocysticercosis (NCC) diagnosis
33259085|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
33259086|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
33259087|NCT04098419|Experimental|Williams Implementation|
33259088|NCT04098419|Experimental|Pittsburg Implementation|
33259089|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
33401404|NCT04505540|Active Comparator|Local Waivered Physcian|Medication assisted treatment supervised by local waivered physician.
33259090|NCT04097015|Experimental|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
33259091|NCT02601365|Experimental|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
33259092|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
33259093|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
33259094|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
33259095|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
33259096|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
33259097|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
33259098|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
33259099|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
33259100|NCT00568776|Placebo Comparator|1|
33259101|NCT00568776|Active Comparator|2|
33259102|NCT00568776|Active Comparator|3|
33259103|NCT00568776|Active Comparator|4|
33259104|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
33259105|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
33259106|NCT04021511|No Intervention|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
33259107|NCT04021511|Experimental|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
33259108|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
33259109|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
33259110|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
33259111|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
33259112|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
33259113|NCT01065259|No Intervention|control|the normal control with no intervention
33259114|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
33259115|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
33259116|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
33259117|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
33259118|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
33259119|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
33259120|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
33259121|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
33259122|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
33259123|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
33259124|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
33259125|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
33259126|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
33077136|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
33259127|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
33259128|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
33259129|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
33259130|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
33259131|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
33259132|NCT00293215|Experimental|Cohort 1 (1.0 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles.
33259133|NCT00293215|Experimental|Cohort 2 (2.6 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
33259134|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
33259135|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
33259136|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
33259137|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
33259138|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
33259139|NCT04102787|Experimental|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
33259140|NCT04102787|No Intervention|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
33259141|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
33259142|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
33259143|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
33259144|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
33259145|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
33259146|NCT00819468|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
33259147|NCT00819468|Active Comparator|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
33259148|NCT04102553|Experimental|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
33259149|NCT04102553|Active Comparator|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
33259150|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
33259151|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
33259152|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
33259153|NCT00822822||A|Health History Process
33259154|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
33259155|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
33259156|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
33259157|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
33259158|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
33259159|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
33259160|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
33259161|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
33259162|NCT00293059|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
33259163|NCT00293059|Placebo Comparator|Placebo|Matching placebo to be taken orally daily
33259164|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
33259165|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
33259166|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
33259167|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
33259168|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
33259169|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
33259170|NCT00758459|Experimental|1|
33259171|NCT00758459|Placebo Comparator|2|
33259172|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
33259173|NCT05460143||Dementia with Lewy Bodies|These subjects should meet the criteria for dementia with Lewy Bodies (McKeith et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 65:1863-72.).
33259174|NCT05460143||Alzheimer's Disease|These subjects should have a clinical diagnosis of AD in accordance with the National Institute of Neurological Disorders and Stroke-Alzheimer Disease and Related Disorders criteria (McKhann, G. M., et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263-9.).
33259175|NCT05460143||Mild Cognitive Impairment - LB|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with at least one LB symptom (MCI-LB; McKeith, I. G., et al. 2020. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94(17): 743-55.).
33259176|NCT05460143||Mild Cognitive Impairment - AD|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with AD symptoms (MCI-AD; Dubois, B., et al. 2009. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci. 11(2): 135-9.).
33259177|NCT05460143||Healthy controls|These subjects should have MMSE scores above 26, no regular memory complaints, no signs/symptoms of dementia and no unstable or significant medical illness.
33259178|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
33259179|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
33259180|NCT00298831|Experimental|Sugammadex|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.
33259181|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
33259182|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
33259183|NCT00758069|Placebo Comparator|1|Placebo
33259184|NCT00758069|Experimental|2|Sitagliptin 100 mg
33259185|NCT00758069|Experimental|3|Sitagliptin 50 mg
33259186|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
33259187|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
33259188|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
33259189|NCT01067677|Placebo Comparator|Saline|Placebo
33259190|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
33259191|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
33259192|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
33259193|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
33259194|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
33259195|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
33259196|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
33259197|NCT03979573|Other|Intervention Arm|"PSA testing~Multiparametric MRI (mp-MRI)~Radiomics~MR-guided biopsy (MR-guided and systematic US-guided)~Molecular Markers (Histological analysis of biopsy cores)"
33259198|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
33259199|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
33259200|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
33259201|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
33259202|NCT01065649|Placebo Comparator|Placebo|Placebo arm
33259203|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Hypotension despite adequate fluid resuscitation:~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
33259204|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Absence of refractory hypotension"
33259205|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
33259206|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
33259207|NCT01065727|Active Comparator|natalizumab|
33259208|NCT01067833|Placebo Comparator|Placebo|Placebo
33259209|NCT01067833|Experimental|Dose 1|K201
33259210|NCT01067833|Experimental|Dose 2|K201
33259211|NCT01067833|Experimental|Dose 3|K201
33259212|NCT01065805|Experimental|1|18F-FLT PET
33259213|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
33259214|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
33259215|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
33259216|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
33259217|NCT00311623|Active Comparator|Control group|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Receive no intervention on Days 1-14. Surgery performed on Day 15."
33259218|NCT00311623|Experimental|Low-dose Rapamycin (3mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
33401405|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~detection of PUUV RNA in plasma collected at admission.~or/and detection of IgM and IgG against PUUV in serum collected at admission,~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
33401406|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
33401407|NCT05676814|Active Comparator|Pecto-intercostal Fascial Block (PIFB)|Subjects in this arm receive standard of care PIFB after surgery
33259219|NCT00311623|Experimental|High-dose Rapamycin (6mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
33259220|NCT01067989|Experimental|intervention|same treatment for all patients
33259221|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
33259222|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
33259223|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
33259224|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
33259225|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
33259226|NCT00817128|Experimental|1|PEPT after randomization
33259227|NCT00817128|Experimental|2|CBO after randomization
33259228|NCT04840888|Experimental|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
33259229|NCT04840888|Experimental|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
33259230|NCT04840888|Experimental|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
33259231|NCT04840888|Experimental|LY3484356 + Carbamazepine (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and carbamazepine administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of carbamazepine on Day 12 orally followed by single dose of carbamazepine administered orally on Days 13 to 15.
33259232|NCT05396014|Active Comparator|Treatment Period 1: Enhanced Self-Care (ESC)|"This arm includes participants who are randomized to ESC in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ESC or be randomized to augment ESC with an additional treatment during Treatment Period 2."
33259233|NCT05396014|Active Comparator|Treatment Period 1: Acceptance and Commitment Therapy (ACT)|"This arm includes participants who are randomized to ACT in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ACT, augment ACT with an additional treatment, or switch to a new treatment during Treatment Period 2."
33259234|NCT05396014|Active Comparator|Treatment Period 1: Evidence-Based Exercise and Manual Therapy (EBEM)|"This arm includes participants who are randomized to EBEM in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on EBEM, augment EBEM with an additional treatment, or switch to a new treatment during Treatment Period 2."
33259235|NCT05396014|Active Comparator|Treatment Period 1: Duloxetine|"This arm includes participants who are randomized to Duloxetine in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on Duloxetine, augment Duloxetine with an additional treatment, or switch to a new treatment during Treatment Period 2."
33259236|NCT04717336|Placebo Comparator|PERIOD 1|Participant will be instructed to take 3 pills per day for a total of 3 grams. Participant will take Sodium Chloride or placebo for a two week period.
33259237|NCT04717336|Placebo Comparator|PERIOD 2|Participant will be instructed to take 3 pills per day for a total of 3 grams. Participant will take Sodium Chloride or placebo for a two week period.
33259238|NCT04717336|No Intervention|WASHOUT OUT PERIOD|Participant will have a wash-out period for three-weeks.
32935511|NCT05217979|Sham Comparator|Sham|After signing informed consent, patients assigned to the sham group by randomization will receive a single treatment with sham, which is indistinguishable from the active treatment. This is achieved by putting the device in demo mode, which gives all the same audiovisual signals as the active mode, but no treatment. Given that the treatment is not felt by patients, this ensures blinding.
32935512|NCT05445739|Other|The effect of an online exercise course on the increase of elders' regular exercise intention|The effect of an online exercise course on the increase of elders' regular exercise intention.
32935513|NCT00368719|No Intervention|1|
32935514|NCT05445193|Experimental|Module PEaters Choice™|Using module that will be develop
32935515|NCT05445193|No Intervention|Standard nutrition information|No intervention done, just a standard information about nutrition.
32935516|NCT03647761|No Intervention|Control|Standard of care
32935517|NCT03647761|Experimental|Treatment|Tetra-grip applied
32935518|NCT05184283||Prospective Cohort|Chart review will be performed for patients who consent to inclusion in the study. Information from routine care will be reviewed and body composition assessment will be done by routine MRI with an additional 6-8 minute scan using AMRA® Profiler 4 Muscle Assessment Score (MAsS) by performing volumetric quantification of fat and water images acquired with 2-point Dixon magnetic resonance imaging (MRI).
32935519|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
32935520|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
33259239|NCT04714840|Other|Personalized exercise group (INTGroup)|Participants in this group have individually tailored exercise program with supervision, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
33259240|NCT04714840|Other|Generalized exercise group, Attention Control (AC Group)|Study participants in this group receive generalized exercise recommendations, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
33259241|NCT04944160||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2019-2020 winter epidemic"
33259242|NCT04944160||Post Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2020-2021 winter epidemic"
33259243|NCT04707976|Experimental|Navina Smart|An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
33259244|NCT04707976|Active Comparator|Standard Bowel Care|Supportive bowel care without using irrigation.
32735475|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
32735476|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
33259245|NCT00755807|Placebo Comparator|Placebo|
33259246|NCT00755807|Experimental|Duloxetine|
33259247|NCT03998644||healthy|Subjects without colorectal disorders.
33259248|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
33259249|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
33259250|NCT05372224|Experimental|Vitamin D 4000 IU|4000 IU of vitamin D were administrated once a day orally and calcium carbonate 1.2 g a day in a single dose.
32735477|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
32735478|NCT04520243|Experimental|English alphabet illiterate group|Individuals with no self-reported understanding of English alphabet and recognition of <6/10 Sloan Letters
32735479|NCT04520243|Active Comparator|English alphabet literate group|Individuals with self-reported understanding of English alphabet and recognition of ≥6/10 Sloan Letters
33259251|NCT04831606|Active Comparator|Control Arm|Patients will receive a biweekly standard treatment at home according to the International Working Group on Diabetic Foot consisting of: Debridement of the lesion, unloading with a brace up to the calf, non-removable (except for contraindications), dressing of the wound with advanced dressings in use at the specialized center and in the home care network.
32735480|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
32735481|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
32735482|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
32735483|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
33259252|NCT04831606|Experimental|EmoLED Arm|Patients on top of the standard treatment of the control arm will receive EmoLED blue light irradiation for two minutes at each biweekly medication.
33259253|NCT04638322|Experimental|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
33259254|NCT04638322|No Intervention|No intervention group|This group does not receive any treatment.
33259255|NCT04819594|Experimental|Study Group|Nurses will wear the Elequil aromatabs ® (100% pure essential oil) over a four-hour period
33259256|NCT00916019|Experimental|exercise|mild exercise training
33259257|NCT00631410|Experimental|A|
33259258|NCT00631410|Experimental|B|
33259259|NCT04097951|Experimental|Montelukast|
33259260|NCT04097951|Experimental|Bepotastine|
33259261|NCT04097951|Experimental|Montelukast + Bepotastine|
33259262|NCT05301712|Experimental|Naloxone hydrochloride 5.0mg/5ml|Naloxone hydrochloride 60mg (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
33259263|NCT05301712|Placebo Comparator|Placebo|Placebo 60ml (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
33259264|NCT04096469|Experimental|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
32735484|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
33259265|NCT04096469|Active Comparator|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
33259266|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
33259267|NCT00822978|Placebo Comparator|2|Placebo is normal saline
33259268|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
33259269|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
33259270|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
33259271|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
33259272|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
33259273|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
33259274|NCT04096235|Experimental|RAM Cannula|
33259275|NCT00823056|Placebo Comparator|1|
33259276|NCT00823056|Active Comparator|2|
33259277|NCT04096157|Experimental|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
33259278|NCT04096157|Experimental|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
33259279|NCT00819624|Other|Interactive Voice Response System|
33259280|NCT00819624|Other|Personal Digital Assisstant|
32735485|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
33259281|NCT00823368||Arbaclofen followed by Placebo|
33259282|NCT00823368||Placebo followed by Arbaclofen|
33259283|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
33259284|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
32735486|NCT04520321|Placebo Comparator|Vehicle (placebo)|Placebo weekly x 4
32735487|NCT04520321|Experimental|Low dose|TTHX1114(NM141) low-dose weekly x 4
33259285|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
33259286|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naïve|Treatment naïve Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
33259287|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
32735488|NCT04520321|Experimental|Mid-dose|TTHX1114(NM141) mid-dose weekly x 4
33259288|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
33259289|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
33259290|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
32735489|NCT04520321|Experimental|High-dose|TTHX1114(NM141) high-dose weekly x 4
32735490|NCT04520399||violence|
32735491|NCT04520399||non-violence|
32735492|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
33259291|NCT04565028|Experimental|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
33259292|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
33401408|NCT05676814|Experimental|PIFB with adjuvants|Subjects in this arm receive standard of care PIFB with additional medications after surgery
33259293|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
33259294|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
33259295|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
32769520|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
33259296|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
33259297|NCT05293912|Experimental|SG2501|SG2501 monotherapy intravenous (IV) infusion - Weekly doses
33259298|NCT04493034|Experimental|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
33259299|NCT04493034|Experimental|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
33259300|NCT04493034|No Intervention|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
33259301|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
33259302|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
33259303|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
33259304|NCT00819858|No Intervention|control|no supplement given
33259305|NCT00819936|Experimental|2|Backward walking,
33259306|NCT00819936|Active Comparator|1|Forward walking
33259307|NCT05457803||In-persom kratom users|10 subjects that use kratom an additional cross-sectional evaluation: one session day at the NIDA IRP preceded by a consent session day; 2 visits at our BRC building total.
33259308|NCT05457803||Online kratom users|240 subjects that use kratom, prospective observational cohort study in which each participant provides intensive longitudinal data on kratom use for 15 consecutive days via smartphone app
33259309|NCT00527488|Experimental|Degarelix 16+16 mg|
33259310|NCT00527488|Experimental|Degarelix 32 mg|
33259311|NCT00527488|Experimental|Degarelix 32+32 mg|
33259312|NCT00527488|Experimental|Degarelix 64 mg|
33259313|NCT00820014|Experimental|1|ESBA105 eye drops
33259314|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
33259315|NCT05440097|Other|single-arm|GINA guideline education and implementation
33259316|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
33259317|NCT00825864|Active Comparator|2dexamethasone drops|
33259318|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
33259319|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
33259320|NCT05286112|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT delivered over the course of 10, ~60 minute sessions
33259321|NCT05286112|Active Comparator|Health Education|Health education sessions delivered over the course of 10, ~60 minute sessions
33259322|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
33259323|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
33259324|NCT00823446|Experimental|Revera Wound Care|
33259325|NCT00823446|Placebo Comparator|Normal Saline|
33259326|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
33259327|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
33259328|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
33259329|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
33259330|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
33259331|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
33259332|NCT05269810|Experimental|Group 1|SA001 Low dose
33259333|NCT05269810|Experimental|Group 2|SA001 Mid dose
32769521|NCT05050357|Active Comparator|hormonal intrauterine device arm|
32769522|NCT05050357|Active Comparator|progestin arm|
32769523|NCT05050201|Experimental|Sleepio Intervention|Participants using the Sleepio application - access for 6 sessions, over 10 weeks
32769524|NCT05028985||early COPD patients|younger than 50 years with 10 or more pack-years smoking history and any of these abnormalities: 1) early airflow limitation (post-bronchodilator forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC) < lower limit of normal), 2) compatible CT abnormalities, 3) rapid decline in FEV1 (≥60 ml/yr).
33259334|NCT05269810|Experimental|Group 3|SA001 High dose
33259335|NCT05269810|Placebo Comparator|Placebo|Placebo
33259336|NCT04017156|Experimental|Test site (torque of <10 Ncm)|The test sites (<10 Ncm) will be over-prepared with drills of larger diameter
33259337|NCT04017156|Other|Control site (torque of ~30 Ncm)|the standard sites (~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
33259338|NCT05268094|Experimental|Ductal Artery Stent|Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.
33259339|NCT05268094|Experimental|Systemic-to-Pulmonary Artery Shunt|Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.
32769525|NCT05028985||Healthy people|healthy without any disabling, physical, neurological, or mental disease and were excluded living in a nursing home.
33259340|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
33259341|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
33259342|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
33259343|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
33259344|NCT04602286|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
33259345|NCT04602286|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
33259346|NCT04602286|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
33259347|NCT04602286|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
33259348|NCT00752609|Experimental|Peginesatide|
33259349|NCT03684304|No Intervention|Control / No Binder|Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
32769526|NCT05026411|Other|Orthodontic patients|Magnetic resonance images will be taken from 20 individuals with eating disorders before fixed orthodontic treatment, 12 months of orthodontic treatment and 6 months after orthodontic treatment finished
32769527|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
33259350|NCT03684304|Experimental|Abdominal binder|Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.
33259351|NCT04023539|Active Comparator|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
33259352|NCT04023539|Placebo Comparator|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
33259353|NCT05255068|Experimental|Arm1|OPTIMAL
33259354|NCT04093583|Active Comparator|Simple suture|
33259355|NCT04093583|Experimental|PRGF-Endoret|
32935521|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
32935522|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
32935523|NCT05443711||obesity|Patients with obesity attended in the High-Risk Obesity clinic of the Complejo ASistencial Universitario de León, 50-60 years-old
33259356|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
33259357|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
33259358|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
33259359|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
33259360|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
33259361|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
33259362|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
33259363|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
33259364|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
33259365|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
33259366|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
33259367|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
32935524|NCT05443711||control|control group of healthy people of the same age group without obesity or cardiovascular risk factors that will be selected among volunteers from the CAULE staff. and University of Leon
32935525|NCT05443633|Experimental|Active therapy group|Participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation difficulties, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks.
32935526|NCT05443633|Active Comparator|control group|control group will undergo standard speech-language intervention
32935527|NCT05166655|Experimental|Parkinson disease patients|Parkinson disease patients undergoing DBS Surgery of the Globus Pallidus Internus (GPi) for clinical indications
32935528|NCT03593317|Experimental|Spironolactone group|
32935529|NCT03593317|Placebo Comparator|Placebo group|
32935530|NCT05440825|Experimental|VRelax|Participants will be using Virtual Reality relaxation (VRelax) in addition to treatment as usual
32935531|NCT05440825|Active Comparator|Relaxation exercises|Participants will be using relaxation exercises in addition to treatment as usual
33077137|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.~The participants will note their tobacco and NRT consumption in a smoking diary."
33077138|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
33077139|NCT04681300||Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis|
33077140|NCT04681300||Patients with plastic surgery interventions|
33077141|NCT04681222||LFCN|Patients received LFCN + PENG blocks
33259368|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
33259369|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
33259370|NCT00526162|Experimental|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
32735493|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
32735494|NCT03356639|Experimental|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
33259371|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
33259372|NCT02600195|No Intervention|Control sites|Continue current practices
33259373|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
33259374|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
32735495|NCT03356639|Experimental|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
32735496|NCT03356639|Experimental|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
33259375|NCT03875482|Experimental|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
33259376|NCT03875482|Placebo Comparator|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
33259377|NCT04093427|Active Comparator|softSTOPP active|
33259378|NCT04093427|No Intervention|softSTOPP inactive|
33259379|NCT04095767|Experimental|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
33259380|NCT00820404|Experimental|1|BLI-489
33259381|NCT00820404|Placebo Comparator|2|Placebo
33077142|NCT04681222||Wound Infiltration|Patients received wound infiltration + PENG blocks
33077143|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
33077144|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
33077145|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
33259382|NCT02600663||acute back pain|
33077146|NCT02901808||NOMI|Patients suffering from NOMI
33077147|NCT02901808||No-NOMI|Patients not suffering from NOMI
33077148|NCT00196092|Other|1|Roll-in
33077149|NCT00196092|Other|2|Surgical
33259383|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
33259384|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
33259385|NCT05249530|Experimental|Force|Chiropractic spinal adjustment with force
33259386|NCT05249530|Active Comparator|Touch|non-force stimulation
33259387|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
33259388|NCT00754793|Placebo Comparator|2|
33259389|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
33259390|NCT00826488|Other|observational|Observational
33077150|NCT00196092|Other|3|Standard Risk
33077151|NCT00196092|Other|4|High Risk
33077152|NCT00196092|Other|5|Compassionate Use
33077153|NCT00196092|Other|6|Treatment for females.
32769528|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
32769529|NCT05025319||Taditional Grid|Patients imaged with traditional grid
33259391|NCT04102397|Experimental|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
33259392|NCT04102397|Active Comparator|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
33259393|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
33259394|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
33259395|NCT03999190||30 subjects with schizophrenia|
32769530|NCT05025319||Virtual Grid|Patients imaged with virtual grid
32769531|NCT05025553|Other|Gut mobilization|Polyethylene Glycol (PEG) at the dose of 6.9 g/d once a day for 6 months.
33259396|NCT03999190||30 healthy controls|
33259397|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
33259398|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
33259399|NCT05245162||Participants|Study participants with breast cancer
33259400|NCT05245162||Participants partner|Study participants partner
33259401|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
33259402|NCT04559464|Other|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
32769532|NCT05028127|Experimental|Bimekizumab dosage regimen 1|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
32769533|NCT05028127|Experimental|Bimekizumab dosage regimen 2|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.
33259403|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :~Upper tract location : upper endoscopy~Colorectal location : colonoscopy~Perianal location : pelvic MRI~All patients : abdominal MRI"
33259404|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
32769534|NCT05024695|Experimental|Implant Group|
33259405|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
33259406|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
32769535|NCT05049811|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
33077154|NCT00196092|Other|7|Standard Risk Continued Access
33077155|NCT00196092|Other|8|High Risk Continued Access
33077156|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
33077157|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
33077158|NCT02901652|Active Comparator|NIPPV|"noninvasive respiratory support devices~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
33077159|NCT02901652|Active Comparator|BİPAP|"noninvasive respiratory support devices~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
33077160|NCT02901691|Experimental|Deaf children|
33259407|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
33077161|NCT02901691|Placebo Comparator|healthy volonteer children|
33077162|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
33077163|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
33259408|NCT05244694|Experimental|Insulin|Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.
33259409|NCT00820638|Experimental|1|observational
33259410|NCT04023383|Placebo Comparator|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
33259411|NCT04023383|Experimental|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
33259412|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
33259413|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
33259414|NCT00626028|Experimental|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
33259415|NCT00626028|Experimental|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
33259416|NCT05244070|Experimental|BMS-986403 + Fludarabine + Cyclophosphamide|
33259417|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
33259418|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
33259419|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
33259420|NCT00820716|Experimental|CA|Exercise training with alternate load
33259421|NCT00820716|Active Comparator|CC|Exercise training with constant load
33259422|NCT05240794|Experimental|Experimental group|Participants receive active ABM-01 for the study
33259423|NCT05240794|Placebo Comparator|Placebo Control|Participants receive a digital control for the study
33259424|NCT00826644|Experimental|Belotecan plus Cisplatin|
33259425|NCT00826644|Active Comparator|Etoposide plus Cisplatin|
33259426|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.~One-time Measures:~Illness severity as measured by the SOFA score within the first 24 hours of admission.~duration of mechanical ventilation~duration of stay in the ICU~duration of stay in the hospital"
33077164|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
33259427|NCT04018560|Experimental|Intervention|
33259428|NCT04018560|No Intervention|Usual care|
33259429|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
33259430|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
33259431|NCT04925050|Active Comparator|Drug VB0004|Experimental, Single Ascending dose , Multiple Ascending dose in healthy subjects and naive patients with mild or moderate hypertension with low cardiovascular risk
33259432|NCT04925050|Placebo Comparator|Placebo|Matching Placebo for VB0004
33259433|NCT05437055|Experimental|Single Arm|Use of Penumbra System including Thunderbolt in patients with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy
33259434|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
33077165|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
33077166|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
33077167|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
33077168|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
33077169|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
33259435|NCT05198050|Active Comparator|single dose letrozole tablets|starting from the first of January, patients will receive a single dose of letrozole (20 mg) two days, before starting misoprostol administration. Placebo tables with a similar appearance to letrozole will be administered the day before misoprostol administration and on the day of misoprostol administration.
33259436|NCT05198050|Active Comparator|multiple dose letrozole tablets|starting from the first of January, patients will receive 10 mg letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
33259437|NCT05198050|Active Comparator|misoprostol tablets|starting from the first of January, patients will receive placebo tablets with a similar appearance to letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
33259438|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
33077170|NCT00196131|No Intervention|0|
33077171|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
33259439|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
33259440|NCT04516876|Experimental|Camp-based bimanual intensive training(BIT)|
33259441|NCT04044378|Experimental|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
33259442|NCT04044378|Active Comparator|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
33259443|NCT04044378|Experimental|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
33259444|NCT04512586|Experimental|Conduction System pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead or an LBB pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing or LBB pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. If failure to implant with these tools, other leads and sheaths can be used at the discretion of the operator. A standard DDD pacemaker or CRT-P device from Medtronic will be used.~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
33077172|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
33077173|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
33259445|NCT04512586|Active Comparator|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Pulsed field ablation can be used if available. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
33259446|NCT04914052||Study group|"Patients will be requested to sign an informed consent in which they will agree to have their face filmed in the post-anesthesia care unit.~The facial expressions will be filmed in 30 second segments. A pain assessment will be measured immediately following filming of each segment using two modalities:~Pain score assessed by an attending anesthesiologist assigned to the study team.~VAS assessment by the patient. Following data collection, the data will be forwarded in a coded manner, according to Clalit's data security regulations, to Third Eye systems a facial recognition software company.~Third Eye systems will analyze and process the data using AI and machine learning models and develop an algorithm that can predict pain level by watching facial expressions."
33259447|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
33077174|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
33077175|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
33259448|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
33259449|NCT04491604|Experimental|B-VEC|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
33259450|NCT04491604|Placebo Comparator|Placebo|Matching masked inactive topical gel
33259451|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
33259452|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
33259453|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
33259454|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
33259455|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
33259456|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
33259457|NCT00826878|Experimental|Tivozanib (AV-951)|
33259458|NCT00827034|Other|A|A: Warfarin alone
33259459|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
33259460|NCT00754559|Experimental|Tocilizumab|
33259461|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
33259462|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
33259463|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
32735497|NCT03356639|Experimental|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
32735498|NCT03263689|Experimental|Intervention|"ITM group were given~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~100 micrograms of preservative-free morphine."
32735499|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
32735500|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
32735501|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
33077176|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
33259464|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
33259465|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
33259466|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
33259467|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
33259468|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
33259469|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
33259470|NCT04794322||Pelvic Mass Cohort (cohort #1)|200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.
33259471|NCT04794322||BRCA1/2 Carriers Cohort (cohort #2)|50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.
33259472|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
33259473|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
33259474|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
33259475|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
33259476|NCT05160610|Experimental|Intervention group|receiving multilevel intervention, electronic monitoring and stroke registry participation
33259477|NCT05160610|No Intervention|Control group|receiving routine care , electronic monitoring and stroke registry participation
33077177|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
33259478|NCT00298363|Experimental|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
33077178|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
33077179|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
33077180|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
33077181|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
33077182|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
33077183|NCT02901106|Experimental|Patient with recurring-remitting MS|
33259479|NCT00298363|Experimental|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
33259480|NCT00298363|Experimental|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
33259481|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
33259482|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
33077184|NCT00553579||DE|All subjects will have clinically significant dry eye.
33259483|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
33259484|NCT04457778|Experimental|Part 1A: M6223 Monotherapy|
33259485|NCT04457778|Experimental|Part1B: M6223 + Bintrafusp alfa|
33259486|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
33259487|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
33259488|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
33259489|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
33259490|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
33259491|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
33259492|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
33259493|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
33259494|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
33259495|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
33259496|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
33259497|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
33259498|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
33259499|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
33259500|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
33259501|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
33259502|NCT00777101|Experimental|Neratinib|
33259503|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
33259504|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
33259505|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
33259506|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
33259507|NCT01068067|Active Comparator|standard dosing|
33259508|NCT00827190|Experimental|1|ILS-920
33259509|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
33259510|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
33259511|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
33259512|NCT00297427|Experimental|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
33259513|NCT00297427|Sham Comparator|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
33259514|NCT04904536|Experimental|Study Medication Arm|6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 18 months.
33077185|NCT04723628|Experimental|Experimental group|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
33077186|NCT04723628|No Intervention|Control group|All data forms were then completed, and the HbA1c value was taken from the medical data. No additional procedure was performed to the control group. The research data were collected again at the end of 12 weeks.
33077187|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
33259515|NCT04904536|Active Comparator|Standard Care Arm|Standard care for a period of 18 months.
33259516|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
33259517|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
33259518|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
33259519|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
33259520|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
33259521|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
33259522|NCT05062330|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days|
33259523|NCT05062330|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days|
33259524|NCT00297037|Active Comparator|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
33077188|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
33077189|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
33077190|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
33077191|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
33077192|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in teh two study units
33259525|NCT00297037|Placebo Comparator|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
33259526|NCT04093193|Experimental|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
33259527|NCT04093193|No Intervention|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
33259528|NCT00292981|Experimental|C1 Esterase Inhibitor|
33259529|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
33259530|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
33259531|NCT04095455|Active Comparator|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
33259532|NCT04095455|Active Comparator|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
33259533|NCT04095455|Active Comparator|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
33259534|NCT04095299|Active Comparator|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
33077193|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
33259535|NCT04095299|Experimental|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
33077194|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
33077195|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
33259536|NCT00296725|Experimental|fluoxetine / Imipramine|fluoxetine or Imipramine
33259537|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
33259538|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
33259539|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
33259540|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
33259541|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
33077196|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
33259542|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
33259543|NCT00296647|Active Comparator|patch|
33259544|NCT00296647|Active Comparator|nicotine lozenge|
33259545|NCT00296647|Active Comparator|bupropion|
33259546|NCT00296647|Active Comparator|patch + lozenge|
33259547|NCT00296647|Active Comparator|buproion + lozenge|
33259548|NCT00754013|Active Comparator|Donepezil|
33259549|NCT00754013|Placebo Comparator|Placebo|
33259550|NCT04094987|Experimental|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
33259551|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
33259552|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
33259553|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
33259554|NCT04094831|Active Comparator|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
33259555|NCT04094831|Active Comparator|Control|No intervention
33259556|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31-7164
33259557|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
33259558|NCT01068145|Experimental|Very low dose SCH 527123|
33259559|NCT01068145|Experimental|Low dose SCH 527123|
33259560|NCT01068145|Experimental|Medium dose SCH 527123|
33259561|NCT01068145|Experimental|High dose SCH 527123|
33259562|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
33259563|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
33259564|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
32735502|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
32735503|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
32735504|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
32735505|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
32735506|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
33077197|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
33259565|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
33259566|NCT01068145|Placebo Comparator|Placebo (Part 2)|
33259567|NCT05059132|Experimental|Tele-rehabilitation|Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.
32735507|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
32735508|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
33259568|NCT05059132|Active Comparator|Education only|Participants in the education arm will receive educational materials only, delivered through telecommunication messages.
33259569|NCT05428475|Experimental|[18F]FDG-PET Scan|Participants with unclear symptoms of cognitive impairment who will undergo the [18F]FDG-PET scan (185 MBq of [18F]FDG administered once during study).
33259570|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
33259571|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
33259572|NCT02599103|Placebo Comparator|fat-free milkshake|
33259573|NCT02599103|Active Comparator|Olive oil|
32735509|NCT03268369|Active Comparator|Control group|
32735510|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
33259574|NCT02599103|Experimental|soybean oil|
32735511|NCT03268369|Experimental|Idiopathic generalized epilepsy|
32735512|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
33259575|NCT02599103|Experimental|fried soybean oil|
33259576|NCT02599103|Experimental|palm oil|
33259577|NCT02599103|Experimental|fried palm oil|
33259578|NCT02599103|Experimental|camellia oil|
33259579|NCT02599103|Experimental|fried camellia oil|
33259580|NCT02599103|Experimental|tallow|
33259581|NCT02599103|Experimental|fried tallow|
33259582|NCT04352140|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand, ToFscan placed on non-dominant hand
33259583|NCT04352140|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand, ToFscan placed on dominant hand
33259584|NCT05049382|Experimental|Mesioangular|Classified as mesioangular according to winter classification
33259585|NCT05049382|Experimental|Vertical|Classified as vertical according to winter classification
33259586|NCT05049382|Experimental|Distoangular|Classified as distoangular according to winter classification
33259587|NCT05049382|Experimental|Horizontal|Classified as horizontal according to winter classification
33259588|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
33259589|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
33259590|NCT05049148|Other|Patients requirering brain/medullary tumors excision|All patients requirering a surgery for brain or medullar excision
32735513|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
32735514|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
33259591|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
33259592|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
33259593|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
33259594|NCT00752219|Active Comparator|Meropenem|
33259595|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
33259596|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants with NDMM, RRMM, and Non-myeloma Participants diagnosed with newly diagnosed multiple myeloma (NDMM) who have received at least one dose of ixazomib-based regimen treatment and diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
33259597|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
33259598|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
33259599|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
33259600|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
33259601|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:~Full medical assessment in all cases.~Surgical operation/Intervention where indicated.~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
32735515|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
32735516|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
32735517|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
32735518|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
33259602|NCT04774354||Abdominal surgery|POSSUM, the P-POSSUM and the Charlson comorbidity index will be calculated and compared to the outcomes obtained in our center.
33259603|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
33259604|NCT03856476||Control group|Children and adolescents without dyslipidemia
33259605|NCT02598791|Active Comparator|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
33259606|NCT02598791|Active Comparator|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
33259607|NCT02598791|Placebo Comparator|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
32735519|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
32735520|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
32735521|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
33259608|NCT02598791|Active Comparator|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
33259609|NCT02598791|Other|50 g OGTT|50 g oral glucose tolerance test (OGTT)
33259610|NCT00827346|Active Comparator|Group 1|600-mg double dose
32735522|NCT02458417|No Intervention|Control|No intervention
33259611|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
33259612|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
33259613|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
33259614|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
33259615|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
33259616|NCT02600507|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
33259617|NCT02600507|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
33259618|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
33259619|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
33259620|NCT03998956|Active Comparator|Circumferential PV isolation|Circumferential PV isolation only
33259621|NCT03998956|Experimental|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
33259622|NCT03998956|Experimental|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
33259623|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
33077198|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:~Anterior surface of the pancreas (yellow);~Posterior surface of the pancreas (orange);~Superior mesenteric/portal vein groove (blu);~Superior mesenteric artery margin (retroperitoneal margin) (red);~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
32735523|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
33077199|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
33259624|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
33259625|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
32735524|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
32735525|NCT04508387|Active Comparator|Group HH (heated-humidified) patients|Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
33259626|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
33259629|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
33077200|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
33077201|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
33077202|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
33259630|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
33259631|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
33259632|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
33259633|NCT04251052|Experimental|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery. Patients also undergo a transvaginal ultrasound during screening and blood sample collection throughout the trial.
33259634|NCT04251052|Active Comparator|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy. Patients also undergo a transvaginal ultrasound during screening and blood sample collection throughout the trial.
33259635|NCT04095065|Experimental|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
33259636|NCT04095065|Experimental|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
33259637|NCT04095065|Experimental|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
33077203|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
33259638|NCT04095065|Experimental|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
33259639|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
33259640|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
33259641|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
33259642|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
33259643|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
32735526|NCT04508387|Placebo Comparator|Group CD (cold-dry) patients|Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C). All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
32735527|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
32735528|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
33259644|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
33259645|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
33259646|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
32735529|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
32735530|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
32735531|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
33077204|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:~daily x 21 days every 28 days"
33259647|NCT04093271|Experimental|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
33259648|NCT04093271|Experimental|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
33259649|NCT04093271|Experimental|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
33259650|NCT00831402|No Intervention|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
33259651|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
33259652|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
33259653|NCT04090307|Experimental|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
33259654|NCT04090307|No Intervention|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
33259655|NCT04093115|Experimental|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
33259656|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
33259657|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
33259658|NCT04092959|Experimental|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
33259659|NCT04092959|Experimental|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
32735532|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
33259660|NCT04092959|Experimental|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
33259661|NCT00827580|Experimental|Eniluracil|
33259662|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
33259663|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
33259664|NCT04094909|Experimental|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and [nab]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
33259665|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
33259666|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
33259667|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
33259668|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
33259669|NCT00296491|Active Comparator|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
33259670|NCT00296491|Active Comparator|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
33259671|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
33259672|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
33259673|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
33259674|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
33259675|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
33259676|NCT04092725|Experimental|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
33259677|NCT04092725|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
33259678|NCT00296335|Active Comparator|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
33259679|NCT00296335|Experimental|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
33259680|NCT04094597|Placebo Comparator|placebo|saline is given orally in dose of 2 ml per day for one month
33259681|NCT04094597|Active Comparator|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
32735533|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
32735534|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
32735535|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
32735536|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
32743156|NCT04938063||Cerebral palsy children|Sample size estimation was carried out to determine the recruited number of the diplegic CP children from the outpatient clinic at the Faculty of Physical Therapy, Cairo University, Physical Therapy Department at the National Institute of Neuromotor Disorder, Abu El-Reesh Hospital, and private physiotherapy clinics. The age of patients will range from 18 months to 5 years old. Both sexes will participate in this study
32735537|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
32735538|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
32735539|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
32735540|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
32735541|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
32735542|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
32735543|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
32735544|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
32735545|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
32735546|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
33259682|NCT04093037|Experimental|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:~Time #1: LacryDiag examination without dye~Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score~Time #3: Standard Break-Up Time (SBUT)~Time #4: Schirmer test~Satisfaction questionnaire to the patient"
33259683|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
33259684|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
33259685|NCT04092881|Active Comparator|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
33259686|NCT04092881|Active Comparator|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
33259687|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
33259688|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
33259689|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
33259690|NCT04234360|Experimental|Eosinophil count > 2%; corticotherapy|Eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
33259691|NCT04234360|Experimental|Eosinophil count <= 2%; corticotherapy|Non-eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
32735547|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
32735548|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
32735549|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
32735550|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
32735551|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
32735552|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
32735553|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
32735554|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
32735555|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
32735556|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
32735557|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
32735558|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
32735559|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
32735560|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
33259692|NCT04234360|Placebo Comparator|Eosinophil count > 2%; placebo|Eosinophilic patients randomized to this arm will receive 5 days of placebo.
33259693|NCT04234360|Placebo Comparator|Eosinophil count <= 2%; placebo|Non-eosinophilic patients randomized to this arm will receive 5 days of placebo.
33259694|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
32769536|NCT05049811|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
33259695|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
33259696|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
32735561|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
32735562|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
33259697|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
33259698|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
33259699|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
33259700|NCT04092647|Experimental|ashwagandha|Ashwagandha
33259701|NCT04092647|Placebo Comparator|placebo|Placebo
33259702|NCT04219774|Experimental|Endovascular arm|Subjects meet all inclusion criteria and were randomized to intervention
33259703|NCT04219774|Active Comparator|Medical arm|Subjects meet all inclusion criteria and were randomized to best medical management
32735563|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
32735564|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
33259704|NCT04219774|Active Comparator|Non-Randomized Arm|Subject meets all inclusion criteria EXCEPT abnormal CTP. Subjects are not randomized and are eligible for only best medical management
33259705|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
33259706|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
33259707|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
33259708|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
33259709|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
33077205|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
33077206|NCT02900677|No Intervention|Control|usual care
33259710|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
33259711|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
33259712|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
33259713|NCT04187872|Experimental|Patients with Recurrent Brain Metastes|Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed SRS treatment will receive LITT per standard of care in combination with Pembrolizumab 200mg IV every 3 weeks (+/-3 days) up to 2 years.
33259714|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
33259715|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
33259716|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
33259717|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
33259718|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
33259719|NCT04999228|Experimental|Infliximab treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, infliximab will be used as first-line treatment
33259720|NCT04999228|Active Comparator|Corticosteroid treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, corticosteroids will be used as first-line treatment
33259721|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
32735565|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
32735566|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
32735567|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
32735568|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
32735569|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
32735570|NCT04516811|Experimental|Arm 1|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
32735571|NCT04516811|Placebo Comparator|Arm 2|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines.
32735572|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
32735573|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
33077207|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
33077208|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
33077209|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
33077210|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
33077211|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
33077212|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
33077213|NCT02900638|No Intervention|Wait list control|
33077214|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
33077215|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
33077216|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
33077217|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
33077218|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
33077219|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
33077220|NCT00178620|Active Comparator|I|Retavase 10 U IV Bolus
33077221|NCT00178620|Other|II|
33077222|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
33077223|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
33077224|NCT02900014|Experimental|Children with cleft|
33077225|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
33077226|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
33077227|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
33077228|NCT00169208|Experimental|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
33077229|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
33077230|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
33077231|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
33077232|NCT00178698|Other|1|Thermochemotherapy
33077233|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
32735574|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
32735575|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
33077234|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
33077235|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
33077236|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
32735576|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
32735577|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
32735578|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
32735579|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
32735580|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
33077237|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
33077238|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
33077239|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
33077240|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
33077241|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
33077242|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
33077243|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
33077244|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
33077245|NCT00178776|Experimental|Transtheoretical Model Group|
33077246|NCT00178776|Active Comparator|Education / Advice|
33077247|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
33077248|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
33077249|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
33077250|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
33077251|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
33077252|NCT02899351||Infants less than 12 months|intubated infants in ICU
33077253|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
33077254|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
33077255|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
33077256|NCT00196365|Experimental|1|
33077257|NCT00196365|Active Comparator|2|
33077258|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
33077259|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
33077260|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
33077261|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
33077262|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
33077263|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
33077264|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
33259722|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
33259723|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
33259724|NCT04866550||Connected tablet|Patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (France and Belgium).
33259725|NCT04092569|Active Comparator|Intervention group|Pre-medical consultation structured diabetes self-care education programme
33259726|NCT04092569|No Intervention|Control group|Usual care
33259727|NCT01063465|Experimental|Early weightbearing|
33259728|NCT01063465|Experimental|Control group|
33259729|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
33259730|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage: Chest tube placement~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
33259731|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
33259732|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
33259733|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
33259734|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
33259735|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
33259736|NCT04094129|Placebo Comparator|Placebo|Subjects received two placebo sachets per day
33259737|NCT04094129|Experimental|Probiotic|Subjects received two Wismemo sachets with 1x10^10 cfu/day
33259738|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
33259739|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
33259740|NCT03976921|Experimental|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis > 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR > 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis > 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
33259741|NCT03976921|Active Comparator|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
32735581|NCT04444271|Experimental|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
32735582|NCT04444271|Placebo Comparator|Placebo|Only supportive care will be given to 10 patients
33077265|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
33259742|NCT04092023|Other|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
33259743|NCT04092023|Other|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
33259744|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
33077266|NCT00196404|Experimental|1|
33077267|NCT00196404|Experimental|2|
32735583|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
32735584|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
32735585|NCT04444349|Experimental|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
32735586|NCT04444349|Sham Comparator|Control|Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
32735587|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
32735588|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
32735589|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
32735590|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
33259745|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
33259746|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
33259747|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
33259748|NCT04767958|Experimental|Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
33259749|NCT04767958|Experimental|patients undergoing cardiac testing/procedures|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
32735591|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
32735592|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
32735593|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
33259750|NCT04767958|Experimental|patients awaiting surgery|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
33259751|NCT04767958|Experimental|Health Care Workers|Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.
33259752|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
33259753|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
33259754|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
33259755|NCT02600039|Experimental|ELTGOL|
32735594|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
32735595|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
33259756|NCT02600039|Active Comparator|Acapella|
33259757|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
33259758|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
33259759|NCT04092101|Experimental|RC 1 only|Research Cigarettes #1
33259760|NCT04092101|Experimental|RC 2 only|Research Cigarettes #2
33259761|NCT04092101|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
32735596|NCT04516655|Experimental|C-R-MTX|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles
32735597|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
32735598|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
32735599|NCT04444193|Experimental|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
33259762|NCT04092101|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
33259763|NCT04091945|Active Comparator|LT3001 Drug Product|
33259764|NCT04091945|Placebo Comparator|Placebo|
33077268|NCT00196404|Placebo Comparator|3|
33259765|NCT04091789|Experimental|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
33259766|NCT04091711|Experimental|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
33259767|NCT05443919|Experimental|treatment group|The arm contains patients with acute pulmonary embolism who undergoing interventional therapy with transcatheter pulmonary embolectomy system which named 'TwiFlow-Thrombectomy Catheter System'
33259768|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
33259769|NCT04093895|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
33259770|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
33259771|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
33259772|NCT00624780|Experimental|1|
33259773|NCT00624780|Active Comparator|2|
33259774|NCT00624780|Experimental|3|
33259775|NCT00624780|Placebo Comparator|4|
33259776|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
33259777|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
33259778|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
33259779|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
33259780|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
33259781|NCT04766866|No Intervention|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
33259782|NCT04766866|Experimental|Intervention group or reveal group|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
33259783|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
33259784|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
33259785|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
33259786|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
33259787|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
33259788|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
33259789|NCT02629120|Active Comparator|1|There is only one treatment arm for this study
33259790|NCT04044612|Experimental|Medial Unloader Brace|
33259791|NCT04119934||Control - None|A retrospective chart review will assess physician/NP behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
33259792|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians/NPs (for eligible patients). Chart review will be conducted for the patient's physician/NP within a three-month window of receiving the infographic to assess outcomes.
33259793|NCT04093505|Experimental|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
33259794|NCT04093505|Placebo Comparator|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
33259795|NCT04093505|Experimental|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
33259796|NCT04093505|Placebo Comparator|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
33259797|NCT00622440|Active Comparator|1|
33259798|NCT00622440|Placebo Comparator|2|
32735600|NCT03267901|Experimental|Walnut-Control|
32735601|NCT03267901|Experimental|Control-Walnut|
33077269|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
33077270|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
33077271|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
33259799|NCT04759690|Experimental|Action observation and exercise group|Action observation group consist of 30 randomly selected participants.Action observation + conventional balance exercise group
33259800|NCT04759690|Other|Exercise group|Exercise group is the control group.Consist of 30 randomly selected participants. The participants will only do the conventional balance exercise.
33259801|NCT05417477|Experimental|chronic inflammatory rheumatism or osteoarthritis|"The experimental intervention consists in providing the patient with access to a specific version of the application ''MedicApp'' for the duration of the study.~The intervention will be limited for each patient to the entry of their data on the application at regular intervals during the study.~The interface on the rheumatologist side will contain the demographic characteristics of the patient, his history, the treatments and the pathology requiring the use of physiotherapy Then, at regular intervals, the scores of the questionnaires addressed to the patient will be available on his interface. The interface, on the physiotherapist side, will contain the summary of the patient's clinical history, his treatments and the reason for the physiotherapy sessions. Then, at regular intervals, the physiotherapist will indicate the patient's locomotor assessment, the type of intervention performed and the final summary."
33259802|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
33259803|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
33259804|NCT00831714||Group 1|
33259805|NCT00831714||Group 2|
33259806|NCT01564966||Living kidney donors|Those who donate kidneys
33259807|NCT02597699|Active Comparator|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
33259808|NCT02597699|Experimental|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
33259809|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
33259810|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
33259811|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
33259812|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
33259813|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
33259814|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
33077272|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
33077273|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
33259815|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
33259816|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
33259817|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
33259818|NCT01565044|Experimental|" AUTO  Group"|
33259819|NCT01565044|Sham Comparator|" CONTROL  Group"|
33259820|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
33259821|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
33259822|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
33259823|NCT04044300|Experimental|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
33259824|NCT04044300|Experimental|Non-operative|Continued pain management and physical therapy
33259825|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
33259826|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
32769537|NCT05049577|Placebo Comparator|Control group|To maintain blinding, in the control group, the remifentanil infusion was replaced with 50 ml of normal saline in 50 ml syringe. The remifentanil (or saline) infusion was run until the pump indicated the target Ce had been achieved. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia in all patients was induced using 2 mg/kg of 2% propofol. The attending anesthesiologist asked the patients how they felt pain to evaluate pain severity of PIP while half -dose of propofol was administered. After the rest of the propofol was administered, the attending anesthesiologists asked the same question.
32769538|NCT05049577|Experimental|Remifentanil group|Remifentanil 1 mg was diluted into 50 ml of normal saline. A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of remifentanil. The study groups received remifentanil to a target Ce of 4 ng/ ml. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia induction and the evaluation of pain were same as control group
33077274|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
33077275|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
33077276|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
33077277|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
33077278|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
33077279|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
33077280|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
33077281|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
33077282|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
33077283|NCT02898649|Experimental|IRE|The intervention group
33077284|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
33077285|NCT02898337||Methadone-induced QTc interval prolongation|
33077286|NCT02898337||Methadone-treated patients, no QT interval prolongation|
33077287|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
33077288|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
33077289|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
33077290|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
33077291|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
33077292|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
33077293|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
33077294|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
33077295|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
33077296|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
33077297|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
33077298|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
33077299|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
33077300|NCT00169559|Placebo Comparator|Arm 1|Placebo
33077301|NCT00169559|Active Comparator|Arm 2|Fenofibrate
33077302|NCT00408213|Experimental|1|
33077303|NCT00408213|Placebo Comparator|2|
33077304|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
33077305|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
33077306|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
33259827|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
33259828|NCT05413655|Experimental|1000 mg|The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
33259829|NCT05413655|Experimental|750 mg|The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
33259830|NCT05413655|Placebo Comparator|placebo|The recruited patient randomly assigned to this arm will take placebo per day
33259831|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
33259832|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
33259833|NCT04089605|Experimental|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
33259834|NCT04089605|Active Comparator|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
33259835|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
33259836|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
33259837|NCT02597621||Healthy Controls|Healthy controls.
33259838|NCT02599025|No Intervention|Supine position|Children tested while lying down
32735602|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
32735603|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
32735604|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
32735605|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
32735606|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
33259839|NCT02599025|No Intervention|Standing position|Children tested while standing
33259840|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
32735607|NCT03984955|Active Comparator|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
33259841|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
33259842|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
33259843|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
33259844|NCT03977077|Experimental|Albumin binding taxol|
33259845|NCT03981679|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
33259846|NCT01068457||PTPS|Patients with pain after VATS
33259847|NCT01068457||Pain free|Patients reporting no pain late after VAT
32735608|NCT03984955|Active Comparator|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
32735609|NCT03984955|Sham Comparator|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
32735610|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
32735611|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
32735612|NCT03946969|Experimental|Sintilimab + Liposomal Paclitaxel + Cisplatin + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
32735613|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
33077307|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
33077308|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
33077309|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
33077310|NCT02897752|Experimental|WalkAide|
33077311|NCT02897752|Active Comparator|Usual gait Training|
33077312|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
33077313|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
33077314|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
33077315|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
33077316|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
33077317|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
33077318|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
33077319|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
33077320|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
33077321|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
33077322|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
33077323|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
33077324|NCT00169676||cohort|Registry and Database
33077325|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
33077326|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
33077327|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
33077328|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
33077329|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
33077330|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
33077331|NCT04681027|Active Comparator|Pediatric Age Groups: 7 to ≤12 years|Participants expected to require ATC opioids for an extended period of time
33077332|NCT04681027|Active Comparator|Pediatric Age Groups: 13 to ≤17 years|Participants expected to require ATC opioids for an extended period of time
33077333|NCT00408330|Active Comparator|1|azelaic acid 15%
33077334|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
33077335|NCT00169715|Other|A|
33077336|NCT02897245||Patient with intentionally stop|
33077337|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
33077338|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
33077339|NCT02897167||Controls|Healthy subjects without psychotic disorder.
33077340|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
33077341|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
33077342|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
33077343|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
33077344|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
33077345|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
33259848|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
33259849|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~Body Mass Index ≤ 25~Regular menstrual cycles (occur every 24-35 days)~Fasting glucose < 100mg/dL~HDL-C ≥ 50mg/dL~Waist measurement ≤ 35 inches~Fasting triglycerides < 150mg/dL"
33259850|NCT03981601|Active Comparator|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
33259851|NCT03981601|Active Comparator|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
33259852|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
33259853|NCT00292045|Experimental|NY-ESO-1 protein + CpG 7909|Patients received immunization with intradermal injections of the NY-ESO-1 protein combined with CpG 7909.
33259854|NCT00274651|Experimental|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
33259855|NCT00274651|Experimental|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
33259856|NCT00274261|Experimental|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
33259857|NCT00274261|Active Comparator|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
33077346|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
33077347|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
33077348|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
33259858|NCT00624468|Experimental|Atacicept|
33259859|NCT00624468|Placebo Comparator|Placebo|
33077349|NCT00169754|Other|cohort|mapping and data collection
32735614|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
32735615|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
32735616|NCT03355313|Experimental|Low level light therapy 1|
33077350|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
33077351|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
33077352|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
33077353|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
32735617|NCT03355313|Experimental|Low level light therapy 2|
32735618|NCT03355313|Experimental|Low level light therapy 3|
32735619|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
32735620|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
32735621|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
32735622|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
32735623|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
32735624|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
32735625|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
33077354|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
33077355|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
33077356|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
33077357|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
33077358|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
33077359|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
33077360|NCT02897284|No Intervention|Control|waiting list
33077361|NCT02896933||patients with multiple sclerosis|recruited in a former study
33077362|NCT02896933||healthy control subjects|
33077363|NCT00169793|Other|A|
33259860|NCT03976687|Experimental|1: EYP001a Dose A|Dose A once daily morning dose
33259861|NCT03976687|Experimental|2: EYP001a Dose B|Dose B once daily morning dose
33259862|NCT03976687|Experimental|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
33259863|NCT03976297|Experimental|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
33259864|NCT03976297|No Intervention|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
33259865|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
33259866|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
33259867|NCT00827814|Experimental|Dutasteride|
33259868|NCT01069783|Experimental|A3309 low dose|
33259869|NCT01069783|Experimental|A3309 high dose|
33259870|NCT01069783|Placebo Comparator|Placebo|
33259871|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
33259872|NCT03976765||Hospital discharge at day 7|
33259873|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
33259874|NCT00827892|Experimental|1|
33259875|NCT00827892|Placebo Comparator|2|
33259876|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
33259877|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
33259878|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
32735626|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
32735627|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
32735628|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
32735629|NCT04514705|Experimental|Intervention Group|The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
32735630|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
32735631|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
32735632|NCT04508231||Hormonal treatment|The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
32735633|NCT04508231||Controls|Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study.
33259879|NCT04043676|Experimental|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL > 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
33259880|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
32735634|NCT04514627|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
33259881|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
33259882|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
33259883|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
33259884|NCT02327884||Group 1|Healthy Volunteers matched with Sjogren's Syndrome patients
33259885|NCT02327884||Group 2|Family Members, affected and unaffected
33259886|NCT02327884||Group 3|any other cause salivary gland dysfunction
33259887|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
33259888|NCT00560235|Experimental|1|
33259889|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
33259890|NCT00827970|No Intervention|2 Control|Control group receiving usual care
33259891|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
33259892|NCT00825708|Active Comparator|rTMS|rTMS session
33259893|NCT00825708|Sham Comparator|SHAM|sham session
33259894|NCT00291577|Experimental|1|
33259895|NCT00520936|Experimental|Pemetrexed|
33259896|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
33259897|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
33259898|NCT00828126||PET-CT Scan|
33259899|NCT00947037|Experimental|Extension|Open label extension, 1 arm
33259900|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
33259901|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
33259902|NCT02548104|Active Comparator|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
33259903|NCT02548104|Experimental|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
33259904|NCT00943839|Experimental|SUVEGIL|
33259905|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
33259906|NCT05280171|Experimental|Teach back|Discharge information was explained by the principal investigator. It includes pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.
33259907|NCT05280171|Active Comparator|Standard of Care|Discharge information as per the standard existing routine. Than assessed the recall and patient engagement of CLD patients in general ward regarding discharge instructions by structure questionnaires for patients recall, and PAM for patient's
33259908|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
33259909|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
33259910|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
33259911|NCT04018716|Experimental|MTA|mineral trioxide aggregate
33259912|NCT04018716|Active Comparator|Dycal|calcium hydroxide cement
33259913|NCT00837408||Cases|Individuals with Type 2 Diabetes
33259914|NCT00837408||Controls|Individuals without Type 2 Diabetes
33259915|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
33259916|NCT00828282|Experimental|1|
33259917|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
33259918|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
33259919|NCT04012125|Experimental|Prospective, single-arm trial|
33259920|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
33259921|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
33259922|NCT05300607||questionnaire|rotator cuff diseases patients will self report the items of the Arabic version of The Western Ontario Rotator Cuff Index questionnaire
33259923|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
33259924|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
33401409|NCT04054778|Experimental|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
33259925|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
32735635|NCT04514627|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
32735636|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
32735637|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
32735638|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
32735639|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
33259926|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
33259927|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
33259928|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
33259929|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
33259930|NCT00952887|Experimental|ACE-031|8 dosing groups
33259931|NCT00952887|Placebo Comparator|Placebo|
33259932|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
33259933|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
33259934|NCT00555009|Experimental|Genotropin treatment arm|
33259935|NCT00555009|Placebo Comparator|Placebo|
33259936|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
33259937|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
33259938|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
33259939|NCT04000516|No Intervention|Control|The control group was asked to continue their usual eating schedule and pattern.
33259940|NCT04000516|Experimental|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
33259941|NCT04000516|Experimental|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
33259942|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
33259943|NCT00944385|Placebo Comparator|C group|administer normal saline
33259944|NCT01529775|Experimental|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
33259945|NCT01529775|Active Comparator|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
33259946|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
33259947|NCT00953355|Experimental|Folate|Folate plus metformin
33259948|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
33259949|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
33259950|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
33259951|NCT00956397|Active Comparator|Control Participants|
33259952|NCT00956397|Active Comparator|FD Participants|
33259953|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
33259954|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
33259955|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
33259956|NCT00953511|Other|genetic|
33259957|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
32735640|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
32735641|NCT04513613||Subjects with a clinical indication for PVI|Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).
32735642|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period~An Omeprazole Treatment Period 1 (Day -15 to Day -1)~A G17DT treatment period (Day 0 to Day 85)~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
32735643|NCT03263143|No Intervention|Standard of Care|
32735644|NCT03263143|Other|Early Palliative Care Consultation|
33259958|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
33259959|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
33259960|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
33259961|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
33259962|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
33259963|NCT04011501|Experimental|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
32735645|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
32769539|NCT05028049||Sufentanil-analgesia in plain area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients.
33259964|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
33259965|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
33259966|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
33259967|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
33259968|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
33259969|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259970|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259971|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259972|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259973|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259974|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259975|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259976|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259977|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259978|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
33259979|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
33259980|NCT00947817|Experimental|patient|
33259981|NCT00947817|Other|control|
33259982|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
33259983|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
33259984|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
33259985|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
33259986|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
33259987|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
33259988|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
33259989|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
33259990|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
33259991|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
33259992|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
33259993|NCT00837564|Experimental|CBASP|CBASP psychotherapy
33259994|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
33259995|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
33259996|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
33259997|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
33259998|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
32735646|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
32735647|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
32735648|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
33077364|NCT04680754|Experimental|Experimental Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to patients in experimental group after thyroidectomy. A brochure was developed in line with the literature on head-neck stretching exercises. Since the patients came to the clinic on surgery day, the exercises were examined by the patient on the first postoperative day. The patient was asked to perform the exercises 3 times a day, in the morning, noon and evening for a month, provided that each movement was 5 times. Then, the Patient and Observer Scar Rating Scale (POSAS)  was applied.~The pain level of the patient on postoperative day 1 was evaluated using VAS. For further evaluations, the patient was called by phone at the 1st week and 1st month. Neck pain and discomfort status was evaluated with the Neck Pain and Disability Scale (NPAD), and then the scar appearances with the Patient and Observer Scar Assessment Scale by requesting neck photographs at the 1st week and 1st month."
33077365|NCT04680754|No Intervention|Control Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to the control group after thyroidectomy. Follow-up of the patients with the scales applied in the experimental group were also performed to the control group at the same intervals. After thyroidectomy, patients were called by phone in the 1st week and 1st month. Neck pain and discomfort scale and Patient and Observer Scar Rating Scale were applied again in both phone calls. Photographs of the scar appearance at the 1st week and the 1st month were requested from the patients."
32735649|NCT04512677|No Intervention|No Interventions: Control|Conventional clinical treatment and using the ventilatory weaning protocol and standard extubation with the spontaneous breathing test (SBT) with the T-piece in 30 minutes.
32735650|NCT04512677|Experimental|Experimental: Intervention|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
32735651|NCT03266731|Experimental|use of aspirin and clopidogrel|
33077366|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
33077367|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
33077368|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
32735652|NCT04507529|Experimental|Peer-mentoring|Peer-mentoring
32735653|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
32735654|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
32735655|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
33077369|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
33077370|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.~Surface EMG, MRI and PET scan will be performed at baseline."
33077371|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
33077372|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
33077373|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
33077374|NCT00169832|Experimental|Rosiglitazone (Avandia)|
33077375|NCT00169832|Placebo Comparator|Placebo|
33077376|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
33077377|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
33077378|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
33077379|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
33077380|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
33077381|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
33077382|NCT00178971|Placebo Comparator|2|placebo
32769540|NCT05028049||Remifentanil-analgesia in plain area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients.
33077383|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.~A capsule with both drugs was taken once daily in the morning for eight weeks."
33077384|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
33077385|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
33077386|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
33077387|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
33077388|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
33077389|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
33077390|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
33077391|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
33077392|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
33077393|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
33077394|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
33077395|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
33077396|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
33077397|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
33077398|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
33077399|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
33077400|NCT02896309|No Intervention|No treatment|No treatment
33077401|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
33077402|NCT02895958|Other|Administration of Zepatier|
33077403|NCT02896192|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
33077404|NCT02896192|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
33077405|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
33077406|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
33077407|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
33077408|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
33077409|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
33077410|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
33077411|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
33077412|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
33077413|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
33077414|NCT02895529|Experimental|Itraconazole|
33077415|NCT02895529|Active Comparator|Caspofungin|
33077416|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
33077417|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
33259999|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
33260000|NCT00954213|Experimental|DIR/Floortime parent intervention|
33260001|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
33260002|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
33260003|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
33260004|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
33260005|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
33260006|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
33260007|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
33260008|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
33260009|NCT00954291||Granisetron|14 mg Granisetron
33260010|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
33260011|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
33260012|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
33260013|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
33260014|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
33260015|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
33260016|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
33260017|NCT00957177|Placebo Comparator|Placebo|Placebo
33260018|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
33260019|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
33260020|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
33260021|NCT00948051|Experimental|Fructo-oligosaccharides|
33260022|NCT00948051|Placebo Comparator|Placebo|
33260023|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
33260024|NCT00828438|Experimental|Lorcaserin 10mg|
33260025|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
33260026|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
33260027|NCT04337580|Experimental|Omeprazole Plus Standard of Care for Prostate Cancer Regimen|This intervention will be given on an outpatient basis. Omeprazole, 80 mg twice daily.
33260028|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
33260029|NCT00833118||Intubation|
33260030|NCT00550407|Placebo Comparator|Placebo|
33260031|NCT00550407|Active Comparator|BW430C(lamotrigine)|
33260032|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
33260033|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
33260034|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
33260035|NCT02547558|Experimental|Indacaterol|"Drug:~-Indacaterol, inhaled, single dose, 300 mcg~Diagnostic Interventions:~Arterial blood gases~Cardiac output~Vital signs~Exhaled breath~Spirometry"
33260036|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
33260037|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
33260038|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
33260039|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
33260040|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
33260041|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
33260042|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
33260043|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
33260044|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
33260045|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
33260046|NCT00954525|Experimental|Intravenous Vitamin C|
33260047|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
33260048|NCT00957489|Experimental|Functional appliance|
33260049|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
33260050|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
33077418|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
32769541|NCT05028049||Sufentanil-analgesia in plateau area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
33260051|NCT04011345|Other|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
33260052|NCT04011345|Other|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
33260053|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
33260054|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
33260055|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
33260056|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
33260057|NCT00531934|Experimental|1|
33260058|NCT00531934|Active Comparator|2|
32769542|NCT05028049||Remifentanil-analgesia in plateau area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
33260059|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
33260060|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
33260061|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
33260062|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
33260063|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
33260064|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
33260065|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
33260066|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
33077419|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
33260067|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
33260068|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
33260069|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
33260070|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
33260071|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
33260072|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
33260073|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
32769543|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
33260074|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
33260075|NCT00833742|Experimental|1|ISTDP therapy was provided
33260076|NCT00833742|No Intervention|2|People referred but never seen
33260077|NCT04580368|Experimental|CFTR modulator or other therapies|CFTR modulator or active therapy
33260078|NCT00833820|Active Comparator|A|Patients receiving real rTMS
33260079|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
33077420|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
33260080|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
33077421|NCT02895646||Control|No specific clinical investigation for control subjects
33077422|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
32735656|NCT04511819|Experimental|Losmapimod|COVID-19 patients with PCR confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 14 days.
32735657|NCT04511819|Placebo Comparator|Placebo|COVID-19 patients with PCR confirmation will receive Placebo twice daily given as two tablets per dose by mouth; for a total of 4 tablets daily for 14 days.
32735658|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
32735659|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
33077423|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
33077424|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
32735660|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
32735661|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
33077425|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.~Donor-derived WT1-CTL and P-CTL.~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
33077426|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
33077427|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
33077428|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
33077429|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
33077430|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
33077431|NCT00553774|Placebo Comparator|Placebo|
33077432|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
33077433|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
33077434|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
33077435|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
33077436|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
33077437|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
33077438|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
33077439|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
33077440|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
33077441|NCT04680559|Experimental|MCBI Group|Training in mindfulness and compassion (MCBI) is facilitated in eight weekly sessions of 2 hours. With a didactic format, through theory, class discussions, and guided meditation practices.
33077442|NCT04680559|Active Comparator|Active-Wait List Group|Completion of a record during these 8 weeks. Active work of introspection about one's own sensations, thoughts, distractions, judgments, etc. in therapy sessions. Registered after each session.
33077443|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
33077444|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
33077445|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
33260081|NCT00272779|Active Comparator|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
33260082|NCT00272779|Active Comparator|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
33260083|NCT04036006|Experimental|Group-Based|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
33260084|NCT04036006|Active Comparator|Self-Directed|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment
33077446|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
33260085|NCT04011423|Experimental|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
33260086|NCT04011423|Active Comparator|Stable shoes|Wearing stable shoes during the whole-body vibration training
33260087|NCT00828906|Experimental|1|DuoTrav
33260088|NCT00948363|Active Comparator|Kiwi fruits|
33401410|NCT04054778|Active Comparator|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
33260089|NCT00948363|Placebo Comparator|Apple|
33260090|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
33260091|NCT01838512||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) followed up for up to 5 years
33260092|NCT01838512||Cohort 2|Participants with newly-diagnosed multiple myeloma (NDMM) followed up for up to 8 years
33260093|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
33260094|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
33260095|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
33260096|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
33260097|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
33260098|NCT00957957||2|Participants having elective gastric banding surgery (GB)
32735662|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
33260099|NCT00834054||Double-lung transplanted patients|
33260100|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
33260101|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
33260102|NCT04011033|Experimental|TACE+iNKT for unresectable HCC|TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
33260103|NCT04011033|Other|TACE for unresectable HCC|TACE will be conducted at 0th week and 4th week.
33260104|NCT00829140|Placebo Comparator|Placebo BID|
33260105|NCT00829140|Experimental|Lorcaserin 10mg BID|
33260106|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
33260107|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
33260108|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
33260109|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
33260110|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
33260111|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
33260112|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
33260113|NCT00998686|Experimental|dutogliptin/PHX1149T|
33260114|NCT00998686|Active Comparator|sitagliptin|
32735663|NCT04507607|Experimental|Pregnant women with CHB|Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
32735664|NCT04507607|Active Comparator|women with CHB|Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.
32735665|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
32735666|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
32735667|NCT03353441|No Intervention|No treatment|
33260115|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
33260116|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
33260117|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
33260118|NCT00948519|Active Comparator|Laser only|same as above, without ICG
33260119|NCT00838422||FD-OCT, ORA, USP|
32735668|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
32735669|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
33260120|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
33260121|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
33260122|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
33260123|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
33260124|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
33260125|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
33260126|NCT01068925|Experimental|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
33260127|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
33260128|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
33260129|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
33077447|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
33260130|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
33260131|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
33260132|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
32735670|NCT04511429||Kidney transplant patients|Patients submitted to kidney transplantation.
32735671|NCT04511429||Liver transplant patients|Patients submitted to liver transplantation.
32735672|NCT04511429||Oncological patients|Oncological patients submitted to chemotherapy.
33077448|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
32735673|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
33260133|NCT00958425|Experimental|Hyaluronic acid gel|
33260134|NCT00958425|Active Comparator|Saline|
33260135|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
33260136|NCT00291499|Active Comparator|Chondroitin 4&6 sulfate (Condrosulf)|
33260137|NCT00291499|Placebo Comparator|placebo|
33260138|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
33260139|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
33260140|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32735674|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
32735675|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
32735676|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
33077449|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
33077450|NCT05424445|Experimental|Cytotec®|IOL with misoprostol oral solution (Cytotec®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
33077451|NCT05424445|Active Comparator|Angusta®|IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
33077452|NCT05424211|Experimental|Music group|the group using the music therapy mobile application
33260141|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33401411|NCT05276713||Tucidinostat-based therapy|30 mg tucidinostat was given orally(as six 5 mg tablets per day) twice a week (either, Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday) for 4 consecutive weeks in a 4-week cycle.The endocrine drugs combined with tucidinostat were given based on previous treatment.Patients received tucidinostat-based treatment until disease progression or intolerable adverse events.
33260142|NCT03964636||no contraceptive intake|
33260143|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
33260144|NCT03964636||3rd/4th generation combined oral contraceptives intake|
33260145|NCT00838734||1|Pre-LASIK
33260146|NCT00838734||2|Post-LASIK
33260147|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
33260148|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
33260149|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
33260150|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
33260151|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
33260152|NCT00838812|Other|clindamicin and tretinoin gel|
33260153|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
33260154|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
33260155|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
33260156|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
33260157|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
33260158|NCT00838968|No Intervention|control|no interventions were assigned
33260159|NCT00829842|Placebo Comparator|1|Placebo
33260160|NCT00829842|Experimental|2|
33260161|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
33260162|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
33260163|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
33260164|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
33260165|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
33260166|NCT05352477|Experimental|Balneotherapy with thermal water|Daily balneotherapy with Acquabios thermal water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
33260167|NCT05352477|Placebo Comparator|Balneotherapy with tap water|Daily balneotherapy with tap water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
33260168|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
33401412|NCT04303858|Experimental|RO7284755 as a Single Agent|Part 1: Dose-escalation of RO7284755 as a single agent. RO7284755 will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
33401413|NCT04303858|Experimental|RO7284755 in Combination with Atezolizumab|Part 2: Dose-escalation of RO7284755 in combination with atezolizumab.
33401414|NCT04303858|Experimental|RO7284755 as a Single Agent and/or with Atezolizumab|Part 3: Extension of RO7284755 as a single agent and/or in combination with atezolizumab.
33401415|NCT05276635|Other|Control (EFT)|had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I)
33401416|NCT05276635|Active Comparator|Sleep Hygiene Education (SHE) intervention group|received a Sleep Hygiene Education (SHE) intervention
33401417|NCT04056182|Experimental|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
33401418|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
33401419|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
33260169|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
33077453|NCT05424211|No Intervention|control group|the group that received routine care and treatment
32769544|NCT05024461|Experimental|Patient with an indication for a COVID19 test|The persons included will be those who have an indication for a COVID 19 test and who present themselves at the Cayenne hospital and during the screening missions organised by the Red Cross and Médecin du Monde during the COVID 19 epidemic in the territory
33077454|NCT05424094|Experimental|'kinderleicht' programme|Children receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals.
33077455|NCT05423977|Experimental|Experimental:ZV0203|
33077456|NCT05423938|Experimental|Bi1 diacare hp-hc|During 6 days, patients received 2 ONS of a specific formula for diabetes, high energy (300 kcal/unit) and high protein (20%), with fiber, EPA&DHA, EVOO and a specific mix of low glycemic index of carbohydrate
33077457|NCT05423938|Active Comparator|Control|During 6 days, patients received 2 ONS of a standar formula, high energy (300 kcal/unit) and high protein (20%), without fiber, without EPA&DHA, without EVOO and without a specific mix of low glycemic index of carbohydrate
33260170|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
33260171|NCT05352165|Experimental|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
33260172|NCT05352165|Active Comparator|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
32769545|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
33260173|NCT05352165|Active Comparator|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
33260174|NCT05352165|Active Comparator|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
33260175|NCT05352165|Active Comparator|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
33260176|NCT05352165|Active Comparator|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
33260177|NCT04016688|Active Comparator|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
33260178|NCT04016688|Active Comparator|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
33077458|NCT00179205|Active Comparator|1|
33077459|NCT00179205|Placebo Comparator|2|
33260179|NCT05300061|Experimental|Personal Values Intervention|Brief personal values intervention
33260180|NCT05300061|Experimental|Prosocial Values Intervention|Brief prosocial values intervention
32769546|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
33077460|NCT05423899|Experimental|Humanoid Robot|
33077461|NCT05423899|Active Comparator|Treatment as Usual|
33077462|NCT05423704|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W,with cisplatin 40 mg/m2/W and nimorazole to suitable patients
33077463|NCT05423626|Experimental|technologies of robotic mechanotherapy with FES|"In the course of this study, each patient will be given 10 sessions using the ExoAtlet I robotic simulator. The duration of the procedure, according to the patient's condition, is up to 1 hour (taking into account the time for reconfiguring the exoskeleton and positioning the patient). Measurement of pulse, pressure and saturation in the preparatory, main and final parts. The length of stay in an upright position depends on the patient's condition. In order to study and monitor the state of the cardiovascular system during the procedure, the system of remote monitoring of ECG, breathing and movement Accordis will be connected. If necessary, a pause is made to rest in a standing or sitting position. The transition to the formation of subsequent skills is recommended after mastering the skills of the previous procedure."
33260181|NCT05300061|No Intervention|Control|No intervention control
33260182|NCT05352087|Active Comparator|early cholecystectomy|In early cholecystectomy group after antibiotherapy was started with ceftriaxone and metronidazole, laparoscopic cholecystectomy was performed in the first 7 days following the hospitalization.
33260183|NCT05352087|Active Comparator|delayed cholecystectomy|Patients who accepted delayed surgery were also given the same antibiotherapy and operated after 6 weeks following their discharge
33260184|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
33260185|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
33260186|NCT05351931|Active Comparator|SPC-flakes with or without Salovum|SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
33260187|NCT05351931|Placebo Comparator|SPC-flakes placebo with or without Salovum placebo|SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum placebo egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
33077464|NCT05423626|Experimental|biofeedback virtual reality technologies|"The group will have 10 classes on a simulator using the technology of virtual reality with biofeedback ReviVR. The total duration of the procedure is 30 minutes. Before the procedure, blood pressure and heart rate are measured, the size of the pneumatic cuffs on the feet is selected. After instructing the patient and selecting the virtual environment and the optimal speed of movement in VR, VR glasses are installed. Then rehabilitation exercises are carried out for 15 minutes. The patient moves in a virtual environment, receiving visual, auditory and tactile signals that form the correct walking pattern. At the end of the training, the VR glasses are dismantled. Then blood pressure and heart rate are measured and information about the state of health and sensations during the procedure is recorded."
33260188|NCT05351697|Experimental|BR105|BR105 infusions will be administered weekly 21 days after the initial dose
33260189|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
33260190|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
33260191|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
33260192|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
33260193|NCT05351619|Experimental|An intervention group|An intervention group: will include 41 patients who will receive the oral care bundle.
33260194|NCT05351619|No Intervention|A control group|A control group: will include 41 patients who will receive the traditional oral care.
33260195|NCT05351463|Other|one arm study|in each case one site was assigned as control site and one site was assigned as test site.
33260196|NCT04226391||RAS Partial Nephrectomy|
33260197|NCT04226391||RAS Radical Prostatectomy|
33260198|NCT00949143|Experimental|forward position|
33260199|NCT00949143|Experimental|rear position|
33260200|NCT00955071|No Intervention|Control|
33260201|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
33260202|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
33260203|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
33260204|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
33260205|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
33260206|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
33260207|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
33260208|NCT05351385||Covid +|Patients SARS-CoV-2 positive.
33260209|NCT05351385||Control|Patients with Pneumonia non-SARS-CoV-2 related
33260210|NCT05351307||POAG patients|OCT angiography will be performed
33260211|NCT05351307||Normal participants|OCT angiography will be performed
33260212|NCT04090541|No Intervention|Control|Tests were applied with any taping.
33260213|NCT04090541|Sham Comparator|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
33260214|NCT04090541|Experimental|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
33260215|NCT04090541|Experimental|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
33260216|NCT04011657|Experimental|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
33260217|NCT04011657|No Intervention|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
33260218|NCT04019951|Experimental|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
33260219|NCT04019951|Experimental|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
33260220|NCT04019951|Placebo Comparator|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
32735677|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
32735678|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
33077465|NCT05423626|Experimental|Complex application of robotic mechanotherapy technologies with FES and VR with biological feedback|The group plans to carry out comprehensive rehabilitation with the use of robotic mechanotherapy and virtual reality with BOS. In this group, patients will first practice for 30 minutes on a VR simulator with a BFB (the duct is identical to group 2), then after 2 hours on an exoskeleton with a FES (the protocol of the lesson is identical to group 1)
32735679|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
32735680|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
33077466|NCT05423626|No Intervention|Control group|control group with basic course of reabilitation
33077467|NCT05423197|Active Comparator|panitumumab 30 mg|Subjects will be given a 30mg of panitumumab
33077468|NCT05423197|Experimental|89Zr-panitumumab IV|Subjects will be given 89Zr-panitumumab IV
33077469|NCT05423002|Placebo Comparator|Control|Dim light condition as a baseline
33077470|NCT05423002|Active Comparator|Modulation|Flickering light will be added sinusoidally onto the background light.
33077471|NCT05423002|Sham Comparator|Background|Constant light with maximum half irradiance (50%) of all primaries.
33077472|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
33077473|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
33077474|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
33077475|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
33077476|NCT05422963||severe and critical COVID-19|"hospital admission time more than 24 hours~meet the standard of definition of severe and critical COVID-19 in Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
33077477|NCT05422885|Experimental|Arm 1|Dasatinib and Quercetin
33077478|NCT04680325|Placebo Comparator|Placebo juice|
33077479|NCT04680325|Active Comparator|Cranberry juice|
33077480|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
33077481|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
33077482|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
33077483|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
33077484|NCT05422846|Experimental|exercise protocol group|The group that applied progressive exercise according to the motivation of patients and healing status of ulcers.
33077485|NCT05422846|Experimental|aerobic exercise group|The group performing aerobic exercise with a bicycle ergometer
33077486|NCT05422846|Experimental|control group|The group to which standard applications of DFU treatment will be applied
33077487|NCT05422807|Active Comparator|Psychological intervention|Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
33077488|NCT05422807|No Intervention|Control group|The participants assigned to the control group will receive their standard medical care for diabetes.
33077489|NCT04679974|Experimental|MBCT treatment|Melodic-based communication treatment
33077490|NCT04680286|Placebo Comparator|Placebo|A 5 ml syringe with saline will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
33077491|NCT04680286|Experimental|Methadone|A 5 ml syringe with 1 mg/ml of methadone will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
33077492|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
33077493|NCT05420506|Experimental|NROT1|Intestinal device placement in subjects and their follow up
33077494|NCT05420389|Experimental|breast massage|The mothers who were included in the breast massage group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day state anxiety scale (SATI-I). Milk amounts are measured in ml.
33077495|NCT05420389|Experimental|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the state anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
33077496|NCT05420389|Experimental|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
33077497|NCT05420389|No Intervention|control group|The mothers who were included in the control group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were told by the researcher how to fill out the breast milk follow-up form for 4 days as long as they were in the hospital. Milk amounts are measured in ml. On the last day, the state anxiety scale has been filled.
33077498|NCT05420350|Active Comparator|Lamotrigine and Bupropion|"Lamotrigine will be taken orally for a duration of 28 weeks, consisting of a six-week titration, 20-week study period, and two-week taper. Possible doses are 25mg one a day, 50mg once a day, 50mg twice a day, 75mg twice a day during titration; 125mg twice a day for the study period; and 125mg once a day during the two-week taper. Patients who discontinue at any point of the study will have a two-week taper of lamotrigine.~Bupropion will be taken orally for the duration of 20 week at the dosage of 100mg twice a day."
33077499|NCT05420350|Placebo Comparator|Placebo|The placebo will match the lamotrigine and bupropion dosage, frequency, and duration.
33077500|NCT03097939|Experimental|Nivolumab and Ipilimumab|
33077501|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
33077502|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
33077503|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
33077504|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
33077505|NCT00170573|Experimental|Caelyx|
33077506|NCT02885272|Experimental|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
33077507|NCT02793583|Experimental|Umbralisib + Ublituximab|Umbralisib oral daily dose in combination with Ublituximab intravenous administration
33077508|NCT02793583|Experimental|Umbralisib|Umbralisib oral daily dose
33077509|NCT02793583|Experimental|Umbralisib + Ublituximab + Bendamustine|Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
33077510|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
33077511|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
33077512|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
33077513|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
33077514|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
33077515|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
33077516|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
33077517|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
33077518|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
33401420|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
33401421|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
33401422|NCT04058054|Experimental|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
33401423|NCT04058054|Experimental|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
33401424|NCT04058054|Experimental|Biafine|Wound dressing for management of partial and full thickness wounds.
32735681|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
33077519|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
32735682|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
32735683|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
32735684|NCT04086121|Experimental|Spesolimab 600 mg|"600 milligrams (mg) solution for subcutaneous (SC) injection of BI 655130 (Spesolimab) were to administered subcutaneously every 4 weeks.~All patients will return 16 weeks post the last treatment for an End of Study (EOS) visit."
32735685|NCT03353207||health Control|"No family history of RBD;~Age- and sex- matched with isolated RSWA subjects~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
33077520|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
33077521|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
33077522|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
33077523|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
33077524|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
33077525|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
33077526|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
33077527|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
33077528|NCT00170768|Experimental|1|Darifenacin
33077529|NCT00170768|Active Comparator|2|Oxybutynin
33077530|NCT00170768|Placebo Comparator|3|Placebo
33077531|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
33077532|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
33077533|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
33077534|NCT02502253|Experimental|Low dose|
33077535|NCT02502253|Experimental|moderate dose|
33077536|NCT02502253|Experimental|High dose|
33077537|NCT05414617|Experimental|Medical Device : Happyone|Hyaluronic acid associated with tranexamic acid ; 4.8 ml will be injected in one time
33077538|NCT05414617|Experimental|Medical Device : Happysoft|Hyaluronic acid associated with tranexamic acid ; 2.2 ml will be injected in three times (one injection per week)
33077539|NCT05412667|Placebo Comparator|Placebo|Pea protein without TWK10 (20g/day)
33077540|NCT05412667|Experimental|TWK10|Pea protein (20g/day) with TWK10 (10 billion CFU/day)
33077541|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
33077542|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
33077543|NCT05405959|Experimental|Kinesiotaping (KT) with EDF technique|the patients were seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side while the shoulder was adducted. I band was first fold in half and then divided into 5 lines without cutting the ends to form a web shape. Two pieces of web shaped 20-25 cm length KT were used. The end of the KT was applied to the acromion, and the spinal process of C7 vertebra without stretching, but the web on the muscle had %10-15 tension. The second web shaped band was applied using the same technique between acromion and thoracal vertebral insertion of the middle trapezius muscle. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program.
33260221|NCT05351073|Experimental|Normobaric Oxygen Inhalation Group|Participants in the intervention group will receive oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa) after randomization until adimisson to the hospital. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
33260222|NCT05351073|No Intervention|Control Group|Participants in the control group will not receive oxygen inhalation therapy during ambulance transportation. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
32735686|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;~Age 45 years or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
32735687|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;~Age- and sex- matched with isolated RSWA subjects;~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
33260223|NCT04091399|Experimental|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
33260224|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
33260225|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
33260226|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
32735688|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
32735689|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
32735690|NCT05234905|Experimental|Recombinant human adenovirus type 5+ Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×10^12vp (3 injections) on day 1, 1.0×10^12vp (2 injections) on day 4.~② Tumor maximum diameter >5cm but ≤10cm, 3.0×10^12vp (6 injections) on day 1 and 2.0×10^12vp (4 injections) on day 4.~③ Tumor maximum diameter >10cm, 4.5×10^12vp (9 injections) on day 1 and 3.0×10^12vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
32735691|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
32735692|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
32735693|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
33077544|NCT05405959|Sham Comparator|Sham Kinesiotaping|The sham group received improper KT application consisting two I strips (same material as the real application) applied with no tension on c7 spinal process as cross sign. For sham taping, the cervical spine of the participants was placed in a neutral position. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program
33260227|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
33260228|NCT00747149|Experimental|Rosuvastatin 1|titrated
33260229|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
33260230|NCT00271609|Other|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
33260231|NCT00271609|Other|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
33260232|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
33260233|NCT00949377|Experimental|Methylnaltrexone Bromide|
33260234|NCT00949377|Placebo Comparator|Normal Saline|
32735694|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
32735695|NCT04511195|Experimental|Sphaeralcea angustifolia standardized extract|Patients with diagnosis of knee osteoarthritis will be included in the experimental group and assigned the treatment consisting of a topical administration of a gel elaborated with the pharmaceutical formulation prepared with a standardized extract from S. angustifolia, which will be administered three times a day for four weeks.
32735696|NCT04511195|Active Comparator|Diclofenac 2 %|Patients with diagnosis of knee osteoarthritis will be included in the control group and assigned the treatment consisting of a topical administration of a gel elaborated with 2% diclofenac, which be administered three times a day for four weeks
33260235|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
33260236|NCT04090151||The Australian HIV Observational Database (AHOD)|
33260237|NCT04090151||CHU Saint-Pierre|
33260238|NCT04090151||University Hospital Cologne|
33401425|NCT04058054|Active Comparator|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
33077545|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
33260239|NCT04090151||The EuroSIDA cohort|
33260240|NCT04090151||Frankfurt HIV Cohort Study|
33260241|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
33260242|NCT04090151||Modena HIV Cohort|
33260243|NCT04090151||San Raffaele Scientific Institute|
33260244|NCT04090151||Swiss HIV Cohort Study (SHCS)|
33260245|NCT04090151||Royal Free HIV Cohort Study|
33260246|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
33260247|NCT04090151||Nice HIV Cohort|
33260248|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
33260249|NCT04090151||PISCIS Cohort Study|
33260250|NCT04090151||Swedish InfCare HIV Cohort|
33260251|NCT04090151||Bonn University Hospital|
33260252|NCT05350683|No Intervention|Control group|EVAR patients no ischemic preconditioning
33260253|NCT05350683|Active Comparator|Preconditioning Group|EVAR patients with remote ischemic preconditioning
33260254|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
33260255|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
33077546|NCT02447614||Surgery|Adenotonsillectomy
33260256|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
33260257|NCT00955383|Placebo Comparator|Placebo|Matching placebo
33260258|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
33260259|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
33260260|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
33260261|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
33260262|NCT05350605|Experimental|Experimental: Laid back breastfeding position education group|Breastfeeding education will be given to pregnant women in the laid-back breastfeeding position group, which includes the laid back breastfeeding position with a lactation simulation model.
33260263|NCT05350605|Experimental|Experimental: Upright breastfeeding position education group|Breastfeeding education will be given to pregnant women in the upright breastfeeding position group, which includes the upright breastfeeding position with a lactation simulation model.
33260264|NCT05350605|No Intervention|No Intervention: Control Group|Mothers in the control group will receive routine hospital care
33260265|NCT04019795|Sham Comparator|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
33260266|NCT04019795|Experimental|Active REVIAN Cap 101|(625 nm and 660 nm)
33260267|NCT04019795|Experimental|Active REVIAN Cap 102|(425 nm)
33260268|NCT04019795|Experimental|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
33260269|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
33260270|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
33260271|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
33260272|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
33260273|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
33260274|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
33260275|NCT04010799|Experimental|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
33260276|NCT04010799|Placebo Comparator|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
33260277|NCT04011579|Experimental|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
33260278|NCT04011579|No Intervention|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
33260279|NCT00749411|Experimental|Arm 1|
33260280|NCT00749411|Placebo Comparator|Arm 2|
33260281|NCT05342805|Experimental|Subtotal stomach|The vessels at the anastomosis of right and left gastric arteries were separated, then the proximal haft of lesser curvature and cardia was resected using linear staplers.
33260282|NCT05342805|Active Comparator|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler.
33260283|NCT00955539|Active Comparator|CRT group 1|
33260284|NCT00955539|Active Comparator|CRT group 2|
33260285|NCT05296161|No Intervention|Standard interval dosing|The standard group will receive ocrelizumab every 24 weeks following the current label.
33401426|NCT04058054|Sham Comparator|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
33260286|NCT05296161|Experimental|Personalized B cell tailored ocrelizumab treatment|The personalized group will start with B cell measurements 24 weeks after the last infusion (baseline). The infusion interval will never be shorter than 24 weeks. The personalized group will start the study with a possible extension of the interval. The infusion will be postponed as long as CD19 B cell count stays below 10 cells/µL (determined every 4 weeks). When CD19 B cell count exceeds or is equal to 10 cells/µL, ocrelizumab infusion will be scheduled within two weeks
33260287|NCT00949611|Experimental|FRAX + Decision Aid|
33260288|NCT00949611|No Intervention|Usual care|
33260289|NCT00949611|Experimental|FRAX estimated fracture risk|
33401427|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
32735697|NCT05075473|Experimental|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
33260290|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
33260291|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
32735698|NCT05075473|Active Comparator|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
32735699|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
32735700|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
32735701|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
33260292|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
32735702|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
32735703|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
32735704|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
32735705|NCT03262207||testicular tumours|
32735706|NCT03262207||fertile|
32735707|NCT03262207||infertile|
32735708|NCT04443725|Experimental|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
33260293|NCT05240001|Experimental|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
33260294|NCT05240001|Experimental|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
33260295|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
33260296|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
33260297|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
33260298|NCT00549549|Active Comparator|1|
33260299|NCT00549549|Experimental|2|
33260300|NCT00549549|Experimental|3|
32735709|NCT04443725|Active Comparator|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
32735710|NCT04507451|Experimental|Trained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle training. This program will be delivered 5 days a week.~Inspiratory muscle training (IMT): using a threshold IMT device with mouthpiece, 5 sets of 6 breaths, intensity is prescribed at 60% of maximal inspiratory pressure for the first set, and then increased to the highest tolerable intensity to allow completion of the 6th breath Expiratory muscle training (EMT): using a bottle filled with water, starting at 5cm and then increased to 8 cm gradually, 5 sets of 6 breaths~Training program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
33260301|NCT00549549|Experimental|4|
33260302|NCT00270205|Experimental|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
33260303|NCT00270205|Experimental|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
33260304|NCT00270205|Experimental|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
33260305|NCT00270205|Experimental|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
33401428|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder delivered via INOpulse® DS-C device
33401429|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder delivered via INOpulse® DS-C device
33401430|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
33077547|NCT02447614||Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
33077548|NCT02447614||no treatment|just regular follow-up
33077549|NCT02285725|Experimental|Augmented Microdrilling Surgery|
33401431|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
33077550|NCT05400031|No Intervention|Control|In this group, the researcher will provide the participants with routine care.
33077551|NCT05400031|Placebo Comparator|placebo group|In this group, the researcher will provide the participants with a propolis vehicle
33077552|NCT05400031|Active Comparator|propolis group|In this group, the researcher will provide the participants with a propolis solution.
32735711|NCT04507451|Placebo Comparator|Untrained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle exercises that are not planned to train muscles. This program will be delivered 5 days a week.~Inspiratory exercises: fractionated inspiration, 5 sets of 6 breaths Expiratory exercises: using a bottle filled with water (1 cm)~Exercises program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
33077553|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
33077554|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
32735712|NCT05074927|Other|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
32735713|NCT04510805|Experimental|Intervention Arm|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
32735714|NCT04510805|No Intervention|Control Arm|Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
32735715|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
32735716|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
32735717|NCT04507295|Active Comparator|volume controlled group|"15 patients in is this group will be ventilated during capnothorax using volume controlled ventilation with the following parameters:~FIO2 of 60 %.~Tidal Volume (TV) of 6-8 ml/kg.~Respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~inspiratory to expiratory ratio (I: E) 1:2.~using a minimal Positive End Expiratory Pressure (PEEP) of 2 cm H2O."
32735718|NCT04507295|Active Comparator|pressure controlled group|"15 patients in is this group will be ventilated during capnothorax using pressure controlled ventilation with the following parameters:~FIO2 60 %.~inspiratory pressure adjusted to fulfil the required TV according to the weight of the patient (6-8 ml /kg) then the insufflation pressure will be added to the driving pressure.~respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~I:E ratio of 1:1.5 .~Using a minimal PEEP of 2 cm H2O."
33077555|NCT05393674|Experimental|Experimental|"Fedratinib (Cycle 1: Run-in-Phase with 400 mg QD for 4 weeks, Cycle 2-12: 400 mg QD, Dose modifications will be allowed based on observed toxicity to a 300 mg or a 200 mg daily dose) + Nivolumab (Cycle 2-12: 240 mg, i.v., q2w)~Patients will receive study treatment until loss of response, death or study discontinuation for other reasons."
33077556|NCT05392699|Experimental|Human single chain IL-12 mRNA-single dose|Human single chain IL-12 mRNA-single dose
33077557|NCT05392699|Experimental|Human single chain IL-12 mRNA-multiple dose|Human single chain IL-12 mRNA-multiple dose
33077558|NCT05391568|Experimental|Dry Needling|One single session of DN
33077559|NCT05391568|Sham Comparator|Sham Dry Needling|One single session of Sham DN
33077560|NCT05391334||Usual Care|Contact mat (CareMat®) for bed-exit detection in combination with Qumea fall detection.
33077561|NCT05391334||Intervention|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
33077562|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
33077563|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
33077564|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
33077565|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
33077566|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
33077567|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
33077568|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
33260306|NCT00270205|Experimental|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
33260307|NCT00270205|Experimental|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
33260308|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
33260309|NCT00949767|Experimental|BMS-866949 (Panel 1)|
33077569|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
33260310|NCT00949767|Experimental|BMS-866949 (Panel 2)|
33260311|NCT00949767|Experimental|BMS-866949 (Panel 3)|
33260312|NCT00949767|Experimental|BMS-866949 (Panel 4)|
33260313|NCT00949767|Experimental|BMS-866949 (Panel 5)|
33260314|NCT00949767|Experimental|BMS-866949 (Panel 6)|
33260315|NCT00949767|Experimental|BMS-866949 (Panel 7)|
33260316|NCT05299827||Children diagnosed with lower urinary system dysfunction (LUTD Group)|Children who are between the ages of 5-18 and diagnosed with lower urinary system dysfunction by pediatric urologist.
33260317|NCT05299827||Healty Group|Healthy participants in the same age group in the control group; The siblings or cousins of the cases who applied to Tuğtepe Pediatric Urology Center but did not meet the inclusion and exclusion criteria and/or the cases who applied to the outpatient clinic were determined to be healthy after being examined by the relevant physician, and consisted of girls and boys who volunteered to participate in the study. .
33260318|NCT05206929|Experimental|Arm 1|Arm 1 will receive instruction to use pain and discomfort as the safe limits for their upper limb use during daily activities at post operative discharge.
33260319|NCT05206929|Active Comparator|Arm 2|Arm 2 will receive the standard sternal precautions at time of post operative discharge.
33260320|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
33260321|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
33260322|NCT00269113|Experimental|1|
33260323|NCT00269113|Active Comparator|2|
33260324|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
33260325|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
33260326|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
33260327|NCT00949923|No Intervention|Control|No tea capsules
33260328|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
33260329|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
33401432|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
33077570|NCT00553228|Experimental|group I|Tdap
33077571|NCT00553228|Active Comparator|group 2|Td
33077572|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
33260330|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
33260331|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
33260332|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
33260333|NCT03975205|Active Comparator|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
33260334|NCT03975205|Experimental|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
33260335|NCT01325779|Active Comparator|subcutaneous heparin|
33260336|NCT01325779|Active Comparator|subcutaneous enoxaparin|
33260337|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
33260338|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
33260339|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
33260340|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
33260341|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
33260342|NCT00291187|Placebo Comparator|Placebo|Take orally 30 minutes prior to bedtime.
33260343|NCT00291187|Experimental|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
33077573|NCT05379790|Experimental|Intraperitoneal irinotecan 50 mg + CAPOX|Intraperitoneal irinotecan, dose level 1 50 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33260344|NCT00291187|Experimental|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
33260345|NCT00291187|Experimental|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
32735719|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
32735720|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
32735721|NCT04507217|Experimental|BM without prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC~With asymptomatic untreated BM"
32735722|NCT04507217|Experimental|BM with prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC~With Clinical stable BM with prior radiotherapy"
32735723|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
32735724|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
32735725|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
33260346|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
32735726|NCT04510493|Active Comparator|active treatment arm|Treatment with Canakinumab i.v. administered over 2 hours
32735727|NCT04510493|Placebo Comparator|placebo treatment arm|placebo treatment
32735728|NCT04509869|Experimental|pre-operative and postoperative|the patients who will undergo the operation to treat the pain
33077574|NCT05379790|Experimental|Intraperitoneal irinotecan 75 mg + CAPOX|Intraperitoneal irinotecan, dose level 2 75 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33260347|NCT04016766|Experimental|Prepartying mobile app intervention|Mobile app intervention
33260348|NCT04016766|No Intervention|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
33260349|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
33260350|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
33260351|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
33260352|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
33260353|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
33260354|NCT00956319|Experimental|Zolpidem group|
33260355|NCT00956319|Active Comparator|Estazolam group|
33260356|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
33260357|NCT02547948|No Intervention|No Intervention|
33260358|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
33260359|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
33260360|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
33260361|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
33260362|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
33260363|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
33260364|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
33260365|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
33260366|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
33260367|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
33260368|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
33260369|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
33260370|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
33260371|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
33260372|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
33260373|NCT04009941|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
33260374|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
33260375|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized affected by pneumonia COVID related.
33260376|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
33260377|NCT04407897|Experimental|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
33077575|NCT05379790|Experimental|Intraperitoneal irinotecan 100 mg + CAPOX|Intraperitoneal irinotecan, dose level 3 100 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33260378|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
33260379|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
33260380|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
33260381|NCT04010877|Experimental|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
33260382|NCT00843648||preterms|mother and preterm babies
33260383|NCT00843648||term-bfing|term breastfed babies and mothers
33260384|NCT00843648||term-PIF|term non breastfed babies and mothers
33260385|NCT00843648||c-section|c-section babies and their mothers
33260386|NCT05169723|Experimental|Respiratory Activity 1|
33260387|NCT05169723|Experimental|Respiratory Activity 2|
33260388|NCT05169723|Experimental|Respiratory Activity 3|
33260389|NCT05169723|Experimental|Respiratory Activity 4|
33260390|NCT05169723|Experimental|Respiratory Activity 5|
33260391|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
33260392|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
33260393|NCT05156463|No Intervention|Control|Participants will receive standard follow-up survivorship care, an accelerometer to measure physical activity and NCCN (National Comprehensive Cancer Network) patient materials.
33260394|NCT05156463|Experimental|Treatment|Participants will receive same materials as standard of care group. In addition participants will use PAI Activity tool, Garmin activity tracker and exercise logs, and also receive periodic exercise coaching.
33260395|NCT04267731|Placebo Comparator|Placebo|Cellulose 0.75g per day
33260396|NCT04267731|Experimental|Low dose|0.25g VMK223 per day
33260397|NCT04267731|Experimental|Middle dose|0.5g VMK223 per day
33260398|NCT04267731|Experimental|High dose|0.75g VMK223 per day
33260399|NCT00836160||1|
33260400|NCT00836160||2|
33260401|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
33260402|NCT02547870|Experimental|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
33260403|NCT04251897|Active Comparator|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
33260404|NCT04251897|Experimental|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.~They will then continue with the novel support surface and turned every 4 hours for 3 days."
33260405|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
33260406|NCT04251195|Experimental|Cognitive Intervention|
33260407|NCT04251195|Active Comparator|Active Control Intervention|
33260408|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
33260409|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
33260410|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
33401433|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
33260411|NCT04016610|Experimental|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
33260412|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
33260413|NCT04010409||TD Group|Typically developmental controls,no intervention
33260414|NCT00962169|Experimental|Quality improvement program|
33260415|NCT00962169|Experimental|Electronic patient device (EPD)|
33260416|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
33260417|NCT00836394|No Intervention|Control|Will follow daily habitual activities
33077576|NCT05379790|Experimental|Intraperitoneal irinotecan 150 mg + CAPOX|Intraperitoneal irinotecan, dose level 4 150 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33260418|NCT00843960|Active Comparator|1|intervention group
33260419|NCT00843960|No Intervention|2|control group
33260420|NCT00962325|Experimental|Activity behaviors counseling|
33260421|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
33260422|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
33260423|NCT00962403|Experimental|Yoga treatment|
33260424|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
33077577|NCT05379790|Experimental|Intraperitoneal irinotecan 200 mg + CAPOX|Intraperitoneal irinotecan, dose level 5 200 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33260425|NCT00844038||1|Sick
33260426|NCT05010837|Experimental|Kinesio taping with abdominal exercises|Kinesio taping will be applied along with abdominal exercises.
33260427|NCT05010837|Active Comparator|Abdominal Exercises|Only abdominal exercises will be administered to the participants.
33260428|NCT04043754|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
33260429|NCT04043754|Active Comparator|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
33260430|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
33260431|NCT00836550|Experimental|Video|
33260432|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
33260433|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
33260434|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
33260435|NCT04010643|Active Comparator|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
33260436|NCT04010643|Experimental|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework & 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
33260437|NCT00962481|Active Comparator|Bimosiamose|
33260438|NCT00962481|Placebo Comparator|Placebo|
33260439|NCT05299437|Experimental|Optimized therapy|"Patients with ascertained metastatic differentiated thyroid cancer will be studied with FDG PET, CT, and for genetic characterization. 100 MBq of 124-I are administered for blood and PET lesion dosimetry.~According Jentzen et al, good efficacy (Tumour Control Probability > 80%) is obtained with absorbed dose higher than 80 Gy to soft tissue metastases, and > 650 Gy to bone metastases. These values ae pursued with the limit of 2 Gy to blood.~Only soft tissue lesions will be considered as target for the calculation of the complete response rate.~However, for ethical reasons, therapeutic activity will be chosen in order to be effective both on soft tissue and bone lesions. Patients with too low predicted lesion absorbed dose even administering the Maximum Tolerable Activity (2 Gy to blood) will exit the protocol to receive the standard of care."
33260440|NCT04913805|Active Comparator|Potassium Nitrate|Potassium Nitrate (KNO3) 6 mmol three times daily
33260441|NCT04913805|Active Comparator|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
33260442|NCT04913805|Placebo Comparator|Potassium Chloride|Potassium Chloride (KCl) 6 mmol three times daily
33260443|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
33260444|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
33077578|NCT05379790|Experimental|Intraperitoneal irinotecan 250 mg + CAPOX|Intraperitoneal irinotecan, dose level 6 250 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
33077579|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
33260445|NCT00548145|Experimental|1|
33260446|NCT00548145|Active Comparator|2|
33260447|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
33260448|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
33260449|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
32769547|NCT05024617||trigger finger stage 1-2-3|Volunteer patients between 35-65 years old diagnosed with Stage 1, Stage 2 and Stage 3 trigger finger based on the Froimson Classification were included in the study. Exclusion criteria include paediatric trigger finger, trigger thumb, concomitant de'Quervain tenosynovitis, carpal tunnel syndrome, or Dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers
32769548|NCT05049109|Experimental|Group X|Patients who have had stroke and high blood pressure will participate in 5 telehealth visits, which will take place over 3 months. In addition, remote BP monitoring will be given.
32769549|NCT05049109|Active Comparator|Group Y|Patients who have had stroke and high blood pressure will participate in 3 visits with primary care and stroke practitioner.
33260450|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
33260451|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
33260452|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
32769550|NCT05027659|Experimental|intervention|This study was carried out with two groups. Virtual reality glasses were used for the intervention group.
32769551|NCT05027659|No Intervention|control|No application was made to the control group, standard procedure was followed.
33077580|NCT05357521||Borderline personality disorder|female patients between 18 and 25 years old meeting DSM V criteria for borderline personality disorder
33077581|NCT05357521||Control|female participants between 18 and 25 years old, with no psychiatric history, not meeting criteria for borderline personality disorder
33260453|NCT00839280|Experimental|Arm 1|
33260454|NCT00839280|Active Comparator|Arm 2|
33260455|NCT00836628|Experimental|experimental|
33260456|NCT00962637|Experimental|1|Androxal™ 12.5 mg
33260457|NCT00962637|Experimental|2|Androxal™ 25 mg
33260458|NCT00962637|Active Comparator|3|AndroGel®
33260459|NCT00962637|Placebo Comparator|4|Placebo
33260460|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
33260461|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
33260462|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
33260463|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
33260464|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
33260465|NCT00836784|Experimental|1|
32735729|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
32735730|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
32735731|NCT04509713||infected/positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
32735732|NCT04509713||uninfected/negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
32935532|NCT05159713|Other|Treatment as Usual (TAU)|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
32935533|NCT05159713|Experimental|dCBI + Treatment as Usual|Participants randomly assigned to the intervention group (dCBI+TAU) will receive standard care and also gain access to the dCBI. The dCBI, RxWell, is a trans-Cognitive Behavioral Therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
32935534|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
32935535|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
32935536|NCT05120791|Placebo Comparator|Placebo|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
33260466|NCT00836784|Experimental|2|
33260467|NCT00836862||Arteriovenous Fistula|
33260468|NCT04886271|Experimental|HX009|
33260469|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
32735733|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
32735734|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
32735735|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.~EG-EUS will be applied in all patients."
32735736|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.~EG-EUS will be applied in all patients."
32935537|NCT05120791|Active Comparator|Microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
32935538|NCT05120791|Active Comparator|Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
32935539|NCT05120791|Active Comparator|Combi Microalgae phaeodacytlum and Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
32935540|NCT03562897|Experimental|Ocoxin-Viusid®|Ocoxin-Viusid® before, during and after the Chemotherapy treatment.
32935541|NCT03559543|Experimental|Ocoxin-Viusid®|
32935542|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
32935543|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
32935544|NCT05431309|Active Comparator|CCTA-based strategy group|Patients will be managed following the CCTA -based coronary heart disease prevention strategy for statin initiation and follow-up.
32935545|NCT05431309|Sham Comparator|Traditional strategy group|Patients will be managed following the Traditional cardiovascular disease prevention strategy based on Chinese guideline for statin initiation and follow-up.
32935546|NCT05429047||SARS-CoV-2 vaccine during pregnancy|Pregnant women who received a vaccine against SARS-CoV-2 during pregnancy and their children
32935547|NCT05429047||SARS-CoV-2 infection during pregnancy|Pregnant women who were diagnosed with a SARS-CoV-2 infection during pregnancy and their children
32935548|NCT05429047||SARS-CoV-2 vaccine or infection before pregnancy|Pregnant women who neither received a COVID-19 vaccine nor were diagnosed with COVID-19 during their pregnancy but had either a COVID-19 vaccine or infection before pregnancy and their children
32935549|NCT05429047||No exposure|Pregnant women, who were never exposed to a SARS-CoV-2 vaccine or infection until the birth and their children
33260470|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
33260471|NCT04170153|Experimental|Part A1: Monotherapy Dose Escalation|Participants will initially receive M1774 once daily under fasting conditions. Additional schedules may be evaluated if needed.
33401434|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
33401435|NCT04057430|Active Comparator|String floss|
33401436|NCT04057430|Experimental|Gumchucks floss|
33401437|NCT04498286||Amsterdam MS Cohort|
33401438|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
33077582|NCT05350267|Experimental|Treatment|HALO is a mixed-delivery intervention (online learning, digital technologies, telehealth visits) co-designed with mothers that (a) uniquely tailors intervention content to integrate post-bariatric surgery guidelines to recommendations to reduce child obesity risk, (b) teaches mothers evidence-based parenting behaviors to support intergenerational lifestyle and home food environment changes, and (c) addresses unique barriers to family-level change identified by mothers post-bariatric surgery.
33077583|NCT05350267|Active Comparator|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
33077584|NCT05349448|Active Comparator|solo group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
33401439|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
33401440|NCT05676736||Study group (S) Obese group|Patients with body mass index (BMI) range from (≥30 kg/m2)
33401441|NCT05676736||Control group (C) Normal weight group|Patients with body mass index (BMI) range from (18.5-24.9 kg/m2)
33401442|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
33401443|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
33401444|NCT04479904|Experimental|famitinib|
32735737|NCT03352973|Experimental|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
32735738|NCT03352973|Sham Comparator|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
32735739|NCT04506827|Active Comparator|Control group|patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
32735740|NCT04506827|Experimental|Test group 1|patients in the test group 1 received TCP with particle size from 250 to 1000 µm
32735741|NCT04506827|Experimental|Test group 2|patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
32735742|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
32735743|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
32735744|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
32735745|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
32735746|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
32735747|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
32735748|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
32735749|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
32735750|NCT04504643|Experimental|Technology-assisted circuit training|Multicomponent circuit training using FItLight Trainer™ as an embodied tool to perform motor task. The circuit training is composed by aerobic, muscular, coordination and balance exercises.
32735751|NCT04504643|Experimental|Conventional circuit training|Multicomponent circuit training composed by aerobic, muscular, balance and coordination exercises. Coordination exercises wll be charged of simple dual task cognitive exercises (counting backwards, or making some easy math calculations, repeating words backward, finding words of the same family).
32735752|NCT04504643|Experimental|Nordic Walking|The training sessions are performed in a natural parc, which offers pathways of different lengths and levels of difficulty that will increase over the weeks.
32735753|NCT05074147|Experimental|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
32735754|NCT05074147|Experimental|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
33077585|NCT05349448|Active Comparator|dex plus hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Dexmedetomidine 0.5mic/kg + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)+ Saline solution (2 mL)
32735755|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
33077586|NCT05347810|Experimental|Study group|All participants in the study will receive the same investigational treatment (application of prolonged repetitive forces) and provide continuous comfort ratings.
33401445|NCT03725111|Experimental|arterio venous leg ulcers|
32735756|NCT03350633|Active Comparator|Azathioprine|Imuran
32735757|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
32735758|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
32735759|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
32735760|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
32735761|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
33260472|NCT04170153|Experimental|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive M1774 at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of M1774 will be administered on Day -7 under a fed (high-fat meal) or fasted condition, followed by a 1-week washout period. After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1. Participants will be administered M1774 at a dose and schedule determined as RDE in Part A1.
33260473|NCT04170153|Experimental|Part A3 - Monotherapy Expansion|Part A3 is an expansion of Part A1 where M1774 will be administered as a single agent at the RDE established in Part A1. Participants with defined loss-of-function mutation in ARIDIA, ATRX and/or DAXX, and ATM will be enrolled.
33260474|NCT04170153|Experimental|Part B1a: Combination Therapy Dose Finding|Participants with baseline body weight less than (<) 77 kilogram (kg) or platelets <150,000 cubic per millimeter (mm^3) will receive Niraparib once daily combined with different doses of M1774.
33260475|NCT04170153|Experimental|Part B1b: Combination Therapy Dose Finding|Participants with baseline body weight greater than or equal to (>=) 77 kg and or platelets >= 150,000 mm^3 will receive Niraparib once daily combined with different doses of M1774 and schedule determined as recommended dose for expansion (RDE) in Part B1a.
33260476|NCT00836940|Placebo Comparator|1|
33260477|NCT00836940|Experimental|2|GRC 8200-25mg OD
32769552|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
33260478|NCT00836940|Experimental|3|GRC 8200-50mg OD
33260479|NCT00836940|Experimental|4|GRC 8200-50mg BD
32769553|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
32769554|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
33077587|NCT01656343||Belatacept treated kidney-only transplant recipients|
33077588|NCT01656343||CNI treated kidney-only transplant recipients|
33077589|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
33260480|NCT00836940|Experimental|5|GRC 8200-100mg OD
33260481|NCT04138953|Experimental|TMS over premotor cortex|Noninvasive brain stimulation in the premotor cortex
33260482|NCT04138953|Experimental|TMS over primary motor cortex|Noninvasive brain stimulation in the motor cortex
33077590|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
33077591|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
33077592|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33077593|NCT05331586|No Intervention|control intervention|The control group will receive the standard prenatal care in Hospital Center of São Joao (CHUSJ). The standard prenatal care will be regular appointments with obstetrician and midwife nurses, ultrasounds and nutritional appointments. The pregnant women in control group will also receive a pamphlet with the benefits of physical exercise during pregnancy and recommendations for adequate gestational weight gain. Pregnant women in control group will not be discouraged from exercising on their own.
33077594|NCT05331586|Experimental|Exercise intervention|The exercise group intervention will perform home-based remotely monitored exercise
33077595|NCT01367002|Active Comparator|Carboplatin/Paclitaxel|Chemotherapy
33077596|NCT01367002|Experimental|Trastuzumab|Monoclonal antibody
33260483|NCT04138953|Sham Comparator|Sham TMS over premotor cortex|Sham brain stimulation in the premotor cortex
33260484|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
33260485|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
33260486|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
33260487|NCT04796649|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
33260488|NCT04796649|Active Comparator|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
33260489|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
33260490|NCT00963183|Experimental|A|Drug: AZD5423
33260491|NCT00963183|Placebo Comparator|B|Drug: Placebo
33260492|NCT04042974|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
33260493|NCT04042974|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
33260494|NCT05299671|Experimental|Video consultation group|Patients starting a new oral anti-cancer drug (OACD) will receive help to identify and manage potential drug-drug interactions alongside patient's oncologist through a one-time video consultation.
33077597|NCT05331430|Experimental|Experimental group 1: Dry needling on cervical trigger point|Dry needling of the trigger point of the upper fibres of the trapezius muscle. Using the Hong technique.
33077598|NCT05331430|Experimental|Experimental group 2: Trapezius muscle stretch|Manual passive stretching of the upper trapezius muscle fibres.
33077599|NCT05331430|No Intervention|Control group: Informative talks|Informative talks on breathing techniques, relaxation techniques and posture hygiene.
33260495|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
32735762|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32735763|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33260496|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
33260497|NCT04783545|Experimental|Single Ascending Dose Cohorts 1-6|Drug: VLX-1005
33260498|NCT04783545|Placebo Comparator|Single Ascending Dose Cohorts 1-6, Placebo|Drug: Placebo
33260499|NCT04783545|Experimental|Multiple Ascending Dose Cohorts 7-9|Drug: VLX-1005
33260500|NCT04783545|Placebo Comparator|Multiple Ascending Dose Cohorts 7-9, Placebo|Drug: Placebo
33260501|NCT00844350|No Intervention|letrozole+hCG|
33260502|NCT00844350|No Intervention|letrozole+oxytocin|
33260503|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
33260504|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
33260505|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
33260506|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
32735764|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
32735765|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32735766|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
32735767|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
32735768|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
33077600|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
33077601|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
33077602|NCT00179634|No Intervention|1|Usual Care
33260507|NCT00963261|No Intervention|control group|
33260508|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
33260509|NCT00839670|Active Comparator|Modified Therapy|
33260510|NCT00839670|Active Comparator|Standard Therapy|
33260511|NCT04704609||Imaging Analysis of patients with uveitis|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
33260512|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
33260513|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
33260514|NCT01563393|Other|STAMP using|Relevant to the third part of the study. 30 Children between 1 and 17 years of age from internal medicine department will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
33260515|NCT01563393|Other|No STAMP using|Relevant to the third part of the study. Other 30 children that are not screened by dietitian and either not by STAMP
33260516|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
33260517|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
33260518|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
33260519|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
33260520|NCT00839826|Active Comparator|Arm 2|
33260521|NCT00839826|Experimental|Arm 1|
33260522|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
33401446|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
33401447|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
32735769|NCT04504409|Active Comparator|Exercise group (ExG)|The exercise program consisted of; Codman , wand, stretching and strengthening exercises [25] applied twice a day, 5 times a week and duration of 3 weeks in all groups. All exercises were performed for 10 repetitions and 3 sets. Patients performed exercises with under supervision of physiotherapist in the clinic settings. In ExG, patients received only this exercise protocol for 3-weeks.
32735770|NCT04504409|Experimental|KT application combined with exercise (KTG)|Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
32735771|NCT04504409|Active Comparator|DN combined with exercise (DNG)|The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
32735772|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
33260523|NCT04042896|Experimental|exergame group|"The exergame group performed exercise using the Exer Heart device (D&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
33260524|NCT04042896|Active Comparator|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = [Exercise Intensity × (HRmax - resting HR)] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
32735773|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
33260525|NCT04042896|No Intervention|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
33260526|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
33260527|NCT00844662|Experimental|1|
33260528|NCT00844662|Active Comparator|2|
33260529|NCT04678089||Health group|The healthy control group mainly collected patients with other chronic diseases or blood tumors who did not meet the exclusion criteria and were not diagnosed with multiple myeloma. Also，we need some healthy volunteers. Healthy volunteers refer to people without serious physical disease, immune disease and family history of mental illness.There is no distinction between age, gender and nationality.
33260530|NCT04678089||Multiple Myeloma group|In the exposure group, all patients with multiple myeloma met the inclusion and did not meet exclusion criteria, including planning for autologous stem cell transplantation or not. There is no distinction between age, gender and nationality.
33260531|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
33077603|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
33077604|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
33077605|NCT01280032|Experimental|Kypho-IORT|
33077606|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
33260532|NCT05299593|Experimental|tafluprost/timolol|Enrolled patients will be treated with one drop of the fixed combination Tafluprost-Thymol without preservative in the evening at 20.00 (+/- 1 hour). Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day.
32735774|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
32735775|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
33077607|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
33077608|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
33077609|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
32735776|NCT04506749|Experimental|Experimental group|"Consumption of antioxidant boiled ham, 100 grams daily to consume during the day.~Consumption time: 8 weeks."
33077610|NCT05330455|Experimental|Part 1 Cohort 1: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 1) + Placebo; in period 2: GSK3965193 (Dose 2) + Placebo; in period 3: GSK3965193 (Dose 3) + Placebo and in period 4: GSK3965193 (Dose 4) + Placebo. There will be a minimum of 7 days washout between dosing in each treatment period.
32735777|NCT04506749|Placebo Comparator|control group Placebo|Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
32735778|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
32735779|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
32735780|NCT04506671|Experimental|Cryoablation group|Patients with T1b renal tumor and ECOQ>20
32735781|NCT04506671|Active Comparator|Partial nephrectomy group|Patients with T1b renal tumor
33077611|NCT05330455|Experimental|Part 1 Cohort 2: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 5) + Placebo; in period 2: GSK3965193 (Dose 6) + Placebo; in period 3: GSK3965193 (Dose 7) + Placebo and in period 4: GSK3965193 (Dose 8) + Placebo. There will be a minimum of 7 days washout between dosing in each period.
33077612|NCT05330455|Experimental|Part 2A Cohort 3: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
33077613|NCT05330455|Experimental|Part 2A Cohort 4: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Y) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
33077614|NCT05330455|Experimental|Part 2A Cohort 5: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Z) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
33077615|NCT05330455|Experimental|Part 2B Cohort 6: GSK3965193|Healthy Participants will be randomized 1:1 to receive single doses of GSK3965193 (Dose A) under fasted and fed conditions in treatment period 1. In period 2, the participants who received GSK3965193 (Dose A) under fasted conditions in treatment period 1 will receive the same dose under fed conditions, and vice versa. In the third period, all participants will receive a single dose of GSK3965193 (Dose B) different strength under fasted conditions. The dose level for the third period will be selected based on the results of the first two periods. There will be a minimum of 7 days washout between dosing in each treatment period.
33077616|NCT05330455|Experimental|Part 3 Cohort 7: GSK3965193 or placebo|PLWCHB on stable nucleos(t)ide analog (NA) therapy will be randomized 3:1 to receive repeat dose of either GSK3965193 (Dose E) or placebo. This part will commence after completion of both Part 1 and Part 2.
33077617|NCT05330455|Experimental|Part 4 Cohort 8: GSK3965193 and bepirovirsen or placebo and bepirovirsen|PLWCHB participants on stable NA therapy who have not participated in Part 3 of the study will be randomized 3:1 to receive repeat dose either GSK3965193 or placebo. In addition, all participants in this cohort will also receive bepirovirsen. This part will commence after completion of Part 3, contingent on the clinical safety and efficacy data from Part 3.
33077618|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
33077619|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
33077620|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
33077621|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
33077622|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
33077623|NCT05309512|Experimental|KN052 single drug group|The 8 dose groups in the dose increasing period were intravenous administration of 0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg and 9mg/kg every two weeks, respectively. Based on the selected maximum tolerated dose of Q2W and in combination with the pharmacokinetic model, the sponsor would consider adding 1-2 Q3W treatment groups, with 6-12 patients in each dose group for DLT observation to explore the optimal dose regimen. The queue extension period is dose RP2D; Give it intravenously every two weeks or three weeks.
33077624|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
33077625|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
33077626|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks~Cisplatin will be administered intravenously on predetermined days~Stereotactic Body Radiotherapy (SBRT)"
33077627|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
33077628|NCT05276401|Experimental|Active|Dosage Form: Topical Antimicrobial Gel; Dosage: 5% Gel, 10% Gel; Frequency: BID for 28 days
33077629|NCT05276401|Placebo Comparator|Placebo|Dosage Form: Topical Gel; Dosage: Placebo; Frequency: BID for 28 days
33077630|NCT05265052|Experimental|3D1002 50 mg group (Phase IIa)|3D1002 is given 50 mg twice a day for 2 weeks.
33077631|NCT05265052|Experimental|3D1002 100 mg group (Phase IIa)|3D1002 is given 100 mg twice a day for 2 weeks.
33077632|NCT05265052|Experimental|3D1002 150 mg group (Phase IIa)|3D1002 is given 150 mg twice a day for 2 weeks.
33077633|NCT05265052|Experimental|3D1002 monotherapy group (Phase IIb)|3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.
33077634|NCT05265052|Experimental|OxyContin monotherapy group (Phase IIb)|OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.
33077635|NCT05265052|Experimental|3D1002 + OxyContin group (Phase IIb)|3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.
33260533|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
33260534|NCT00839904|No Intervention|control|no intervention
33401448|NCT04245280|Active Comparator|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
33077636|NCT05261893|Experimental|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"In this we will use myofascial stretching Elongation Longitudinaux Avec Decoaption Osteo Articulaire for knee osteoarthritis. Each patient perform half kneeling posture with homolateral foot and knee in alignment with hip while knee flex to 90° and retrovulsion of the pelvis. Chin tucked in and head towards ceiling. Patient elbow and wrist in extension and arms in external rotation. In this homolateral arm directed anteriorly and pushing arm away from body and contralateral arm directed superiorly and tibia externally rotated.~This position maintained for 1 minute with 15 secs rest. This group will receive 40 mins of session."
33401449|NCT04245280|Placebo Comparator|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
33401450|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
33401451|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
33077637|NCT05261893|Experimental|Post Facilitation Stretching|"This group will receive post facilitation stretching technique. In this all the major muscles of the lower limb (quadriceps, hamstrings ,upper and lower calf muscles) are stretched .And the physiotherapist instruct the patient how to perform stretch . When we target a muscle and perform stretch patient feels sensation of stretch .~The stretch was hold on to 60 secs and repeated 3 times on each muscle group on each leg."
32735782|NCT04982497|Experimental|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
32735783|NCT04982497|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
32735784|NCT03352739|Experimental|DBS of the fornix, power on|
32735785|NCT03352739|Experimental|DBS of the NbM, power on|
32735786|NCT03352739|Sham Comparator|DBS of the fornix, power off|
32735787|NCT03352739|Sham Comparator|DBS of the NbM, power off|
32735788|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
32735789|NCT03350399||level of placenta growth factor in IUGR|
32735790|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
32735791|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
32735792|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
32735793|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
32735794|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
32735795|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
32735796|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
32735797|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
32735798|NCT03261739|Placebo Comparator|Placebo|vehicle control
32735799|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
32735800|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
32735801|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
32735802|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
32735803|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
32735804|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
32735805|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
32735806|NCT03352505||control|healthy walking control participants
32735807|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
33077638|NCT05261854|Experimental|Deep cervical muscle training using pressure biofeedback and conventional Exercises|"The duration of preesure biofeedback includes 3 sets in a session with 10 repetitions each with 2 minutes of rest between sets and 5 days a week for 6 weeks.~Conventional exercises like Stretching and strengthening of neck flexor muscles will include 10 repetitions, each held for 10s with rest of 2 minutes between sets. The session will be conducted for 6 weeks, 5 days a week."
33077639|NCT05261854|Experimental|conventional exercises for Neck pain|Only conventional exercises like stretching and strengthening of neck flexor muscles will be given.
33077640|NCT04723290|Experimental|Serological tests|All staff at GHdC who want to know their level of antibodies against SARS CoV-2
33260535|NCT04667403|Experimental|Telemedicine|"Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access.~This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment."
33260536|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
33260537|NCT04657575|No Intervention|ASTI|ECT guided with ASTi 2-4 min
33260538|NCT04657575|Active Comparator|Narcotrend|ECT guided with ECT
33260539|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
33260540|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
33260541|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
33260542|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
33260543|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
33260544|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
33260545|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
33260546|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
33260547|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
33260548|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
33260549|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33260550|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
33260551|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
33260552|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
33260553|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
33260554|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
33260555|NCT04534023|Experimental|trial group|
33260556|NCT04534023|Placebo Comparator|control group|
33260557|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
33260558|NCT00851292|Active Comparator|End-firing|
33260559|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
33260560|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
33260561|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
33260562|NCT00844974|Other|1|
33260563|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
33260564|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
33260565|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
33260566|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
33260567|NCT04009317|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
33260568|NCT04009317|Active Comparator|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
33260569|NCT00845052||First group of house staff|First group of house staff to be surveyed
33260570|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
33260571|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
33260572|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
33260573|NCT00851370|Experimental|Omalizumab|
33260574|NCT00851370|Placebo Comparator|Placebo|
33260575|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
32735808|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
33260576|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
32735809|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
32735810|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
32735811|NCT03261895|No Intervention|control group|usual diabetes care
32735812|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
32735813|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
32735814|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
32735815|NCT04933669|Experimental|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
32735816|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
33260577|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
32735817|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
32735818|NCT04889287|Experimental|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
33260578|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
33077641|NCT05261815|Experimental|Ultrasound therapy|"Continuous ultrasound therapy for 15 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
32735819|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
32735820|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
33260579|NCT00289783|Experimental|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
33260580|NCT00289783|Experimental|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
33260581|NCT00289783|Experimental|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
33077642|NCT05261815|Experimental|High Intensity Laser Therapy|"High intensity laser for 10 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
33077643|NCT05260606||Patients with NSCLC who will have FDG PET/CT before and during ICI Tx|There is no difference from the treatment schedule performed in usual clinical setting except for an additional F-18 FDG PET/CT scan. Detailed plan of ICI treatment and patient management (dose, administration date, treatment period, and follow-up) follows the standard protocol of our institution in this study.
33260582|NCT00289783|Experimental|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
33260583|NCT00289783|Active Comparator|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
33260584|NCT00851526||Coronary bifurcation lesion|
33260585|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
33260586|NCT00851604||1|Patients with malignant neuroendocrine tumors
32735821|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
33260587|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
33260588|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
33260589|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
33260590|NCT00845208|Active Comparator|Case Management|
33260591|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
33260592|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
33260593|NCT00840606|Experimental|1|
33260594|NCT00840606|Active Comparator|2|
33260595|NCT03975127|No Intervention|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
33260596|NCT03975127|Experimental|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
33260597|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
32935550|NCT05119387||Individuals diagnosed with ALS|Individuals diagnosed with ALS that are being followed through the Norwegian health-care system. ALS patients ( probable or definite per El-Escorial criteria)
32935551|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
33260598|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
33260599|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
33260600|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
33260601|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
33260602|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
33260603|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
33260604|NCT04043052|Active Comparator|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
33260605|NCT04043052|Experimental|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
33260606|NCT00267865|Experimental|Rituximab, High-Dose Methotrexate & Leucovorin Treatment|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
33260607|NCT00851760|Experimental|1 Combined Surgery|
33260608|NCT00851760|Active Comparator|2 consecutive surgery|
32735822|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
32935552|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
32935553|NCT05069467|Experimental|Acupuncture|Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
32935554|NCT05069467|Sham Comparator|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
32935555|NCT05069467|No Intervention|Usual Care|Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
32935556|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
32935557|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
32935558|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
33260609|NCT00851838|Experimental|PD solution|
33260610|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
33260611|NCT01069237||Clear Care|Lens Care Solution for contact lenses
33260612|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
33260613|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
33260614|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
33260615|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
32735823|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
32735824|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
32735825|NCT04870255|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
33260616|NCT01582165|Active Comparator|Angina. IMR. Statin.|
33260617|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
33260618|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
33260619|NCT03975049|Active Comparator|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8
33260620|NCT03975049|Experimental|mFOLFOXIRI|mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4
33260621|NCT03975049|Experimental|mFOLFOX|mFOLFOX * 9 --- TME --- mFOLFOX * 3
32735826|NCT04870255|Active Comparator|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
32735827|NCT04870255|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
32735828|NCT04669561|Experimental|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
32735829|NCT03904927|Experimental|Experimental Arm|The arm will be treated with combined chemotherapy and local therapy such as radiation, surgery or radiofrequency ablation.
32735830|NCT03904927|Active Comparator|Control Arm|The arm will be treated with chemotherapy alone.
32735831|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
32735832|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
32735833|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
32735834|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
33077644|NCT05259358|Active Comparator|exercise|"In addition to routine treatment:~Postural evenness~Chin tuck exercise~Range of motion exercises for all angles of the cervical joint~Neck isometric exercises~Cervical stabilization exercises (with ball)~Stretching exercises of pectoralis, latissimus dorsi, trapezius upper part, levator scapula, rhomboid and scalene muscles"
33077645|NCT05259358|No Intervention|routine|only routine treatment
33260622|NCT00841074|Experimental|1|Peridex mouthwash
33260623|NCT00841074|Placebo Comparator|2|Placebo mouthwash
33260624|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
33260625|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
33260626|NCT00967707|Active Comparator|Gabapentin + donepezil|
33260627|NCT04176120|Experimental|TTAX01|TTAX01 plus standard care
33260628|NCT04176120|Other|Control|Standard Care alone
33260629|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
33260630|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
33260631|NCT00845598|Experimental|Azelastine Fluticasone|
33260632|NCT00845598|Active Comparator|Fluticasone propionate|
33260633|NCT00251719|Experimental|Dexlansoprazole MR 60 mg QD|
33260634|NCT00251719|Experimental|Dexlansoprazole MR 90 mg QD|
33260635|NCT00251719|Active Comparator|Lansoprazole 30 mg QD|
33260636|NCT02547090||CP who underwent PSF by two attendings in 2012|
33260637|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
33260638|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
33260639|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
33260640|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
33260641|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
33260642|NCT00845754|Placebo Comparator|1|Placebo
33260643|NCT00845754|Active Comparator|2|Ketorolac
33260644|NCT00851994||1|Patients having surgery
33260645|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
33260646|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
33260647|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
33260648|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
33260649|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
33077646|NCT05233228|Experimental|Automated Treatment|Consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos.
33077647|NCT05233228|Active Comparator|Standard Care|Consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of nicotine replacement therapy (transdermal patches).
33260650|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
33260651|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
33260652|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:~Chest wall movement assessment without CPAP~Breath hold assessment without CPAP~Chest wall movement assessment with CPAP~Breath hold assessment with CPAP"
33260653|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
33077648|NCT05223478|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|One drop of study medication in each eye.
33260654|NCT00841230|Experimental|Deanxit|
32735835|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
32735836|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
32735837|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
33260655|NCT00841308|Active Comparator|Usual care|
33260656|NCT00841308|Active Comparator|Home blood pressure monitoring|
33260657|NCT00852072|Active Comparator|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
32735838|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
33260658|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
32735839|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
33260659|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
33260660|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
33260661|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
33260662|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
33260663|NCT03952143|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
32735840|NCT04506203|Experimental|Air test|
32735841|NCT03352193||SOTI group|Wheat spaghetti
32735842|NCT03352193||Historical control group|No intervention
33260664|NCT03952143|Active Comparator|Insulin Lispro|Participants received 100 U/mL insulin lispro (Humalog) given SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
33260665|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
33260666|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
32735843|NCT03252769|Other|Self-sampling|Invitation to self-sample
32735844|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
33077649|NCT05223478|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop of study medication in each eye.
33260667|NCT00621192|Experimental|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
33260668|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
33260669|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
33260670|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
32735845|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
32735846|NCT05723861|Experimental|VR group|Participants will receive Virtual Reality intervention in addition to routine care during colonoscopy.
32735847|NCT05723861|No Intervention|Control group|Receive routine treatment.
33077650|NCT04710459|Active Comparator|Group 1|it included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy.
32735848|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
32735849|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
32735850|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
32735851|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
33260671|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
33260672|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
33260673|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
32735852|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
32735853|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
33260674|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
33260675|NCT00852228|Experimental|conventional HAI chemotherapy|
33260676|NCT00267007|Experimental|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
33260677|NCT00267007|Placebo Comparator|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
32735854|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
32735855|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
33260678|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
33260679|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
33260680|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
33260681|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
33260682|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
32735856|NCT04506281|Experimental|Neoadjuvant treatment|"Gemox chemotherapy:~Day1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~Lenvatinib (8mg/d) for 9 weeks of continuous use.~Toripalimab (240mg, once every 3 weeks), used 3 times. Evaluate the resectability of the operation within 2-4 weeks after the end of the neoadjuvant treatment course, and implement radical resection. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses"
32735857|NCT04506281|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients undergoing resection use capecitabine 2500mg/m2 twice a day, stopping for 1 week as a course of treatment, totaling 8 courses.
33260683|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
33260684|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
33260685|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
33260686|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
33260687|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
33260688|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
33260689|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
33260690|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
32735858|NCT04506125|Experimental|Liberal Group|transfusion of an erythrocyte concentrate in case of haemoglobin below 9.5 g/dL
33260691|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
33260692|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
33260693|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
33260694|NCT04010019|Experimental|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
33260695|NCT04010019|Active Comparator|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
33260696|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
33260697|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
33260698|NCT05299281|Other|Glaucoma patients|Patients were enrolled from outpatient clinic with glaucoma during the period between January 2020 and July 2021
33277493|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33260699|NCT04043130|Experimental|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black & Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, & utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
33077651|NCT04710459|No Intervention|Group 2|it included include 30 patients, they were subjected to chemoradiotherapy.
32735859|NCT04506125|Active Comparator|Restrictive group|transfusion of an erythrocyte concentrate in case of haemoglobin below 7.5 g/dL
33260700|NCT04043130|Active Comparator|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
33260701|NCT00968487|Experimental|Lyophilized Plasma|
33260702|NCT00968487|Active Comparator|Fresh Frozen Plasma|
33260703|NCT00848562|Experimental|Nicorandil|
33260704|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
33260705|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
33260706|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
32735860|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
32735861|NCT04503941|Experimental|Active Comparator|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
32735862|NCT04503941|Placebo Comparator|The control group|False Needle treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
32735863|NCT04488211||Prospective survey respondents|Invitations to participate in the survey will be emailed on three occasions to selected fertility specialists worldwide who are affiliated to a public or private fertility clinic.
32735864|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
32735865|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
32735866|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
32735867|NCT04504019|Experimental|USCTR Procedure|Participants will undergo the USCTR procedure with SX-One MicroKnife®
32735868|NCT04504019|Active Comparator|mOCTR Procedure|Participants will undergo the traditional mOCTR procedure.
32735869|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
32735870|NCT03349697|Experimental|Active Product then Placebo|
32735871|NCT03349697|Experimental|Placebo then Active Product|
32735872|NCT04505579||Tether|Patients who have received The Tether HUD for treatment of idiopathic scoliosis.
32735873|NCT05723627|Experimental|Remimazolam|Patient group who receives remimazolam for sedation during endoscopy
33077652|NCT05209360|Experimental|Arm 1|Testing Order: NoCDO, CDO, Lateral, Medial
33077653|NCT05209360|Experimental|Arm 2|Testing Order: NoCDO, CDO, Medial, Lateral
33260707|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
33260708|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
33260709|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
33260710|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
32735874|NCT05723627|Active Comparator|Propofol|Patient group who receives propofol for sedation during endoscopy
32735875|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
33260711|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
33260712|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
32735876|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
32735877|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
32935559|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
32935560|NCT05066737|Experimental|patients who has pelvic organ prolapse and underwent lateral suspension via V-notes surgery|
32735878|NCT03349619|Placebo Comparator|Placebo|
33260713|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
32735879|NCT04505657|Experimental|Celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
32735880|NCT04505657|Active Comparator|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
32735881|NCT04505657|Active Comparator|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
32735882|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
32735883|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
32735884|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
32735885|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
32735886|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
33260714|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
33260715|NCT00848640|Experimental|Sorafenib|
32735887|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
33260716|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
33260717|NCT04010331|Experimental|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
32735888|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32735889|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
32735890|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
32735891|NCT03258775|Active Comparator|250ml|
32735892|NCT03258775|Active Comparator|500ml|
32735893|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
32735894|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
32735895|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
33260718|NCT04010331|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
33260719|NCT00842010||HND|Patients with hyperglycemia, without previous diagnosis of diabetes
32735896|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
32735897|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
33260720|NCT00842010||DH|Patients that have previous diagnosis of Diabetes Mellitus
33260721|NCT00842010||NHND|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
33260722|NCT00965133|No Intervention|Normal daily activity|
33260723|NCT00848796|Other|Heparin|Compare two market brands of Heparin
33260724|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
33260725|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
33260726|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
33260727|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
33260728|NCT05251155||Standard vision chart.|Best corrected visual acuity measured by standard chart projector.
33260729|NCT05251155||Mobile based vision chart.|Best corrected visual acuity measured by mobile based chart with screen mirroring over 24 inch monitor.
33260730|NCT00848874|Experimental|PVGS User|
33260731|NCT00968721||IBD patients|
33260732|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
32735898|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
32735899|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
32735900|NCT03349463|Experimental|18F-Fluciclovine|
32735901|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
32735902|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
32735903|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
32735904|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
32735905|NCT03351881|Active Comparator|Opt Out|
32735906|NCT03351881|Active Comparator|Opt In|
32735907|NCT03351881|Active Comparator|Opt Neutral|
32735908|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
32735909|NCT04505501|Experimental|N-803|N-803 at 6mcg/kg every 3 weeks for 3 doses plus ART (n=10)
32735910|NCT04505501|No Intervention|Control|ART alone (n=5)
32735911|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
32735912|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
32735913|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
32735914|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
32735915|NCT03349307|Experimental|No Intervention|
32735916|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
32735917|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
32735918|NCT05550623|Experimental|Transfemoral amputation performed with tourniquet application|"Group 1:Randomized to procedure with Tourniquet application Sterile wash to groin and placement of sterile tourniquet. The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out.~The leg is lifted, and the tourniquet is inflated. The pressure is set to 250 mmHg. Starting time is noted. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed The tourniquet is deflated. Tourniquet time is noted. Rest of procedure as listed in arm2~Weight of the leg is noted. Weight of surgical swabs is noted, to estimate intraoperative blood loss."
32735919|NCT05550623|No Intervention|Transfemoral amputation performed without tourniquet application|"Group 2: Randomized to procedure without Tourniquet The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed.~The edge of the femoral bone is rasped smooth. A myodesis is performed, attaching the adductor muscle to the end of the femoral bone. Nervus Ischiadicus is dissected as proximal as possible and protected within a purse string suture to avoid development of neuroma.~Ligation of bleeding vessels. Fascia and skin is closed with sutures. A soft compression bandage is applied to the stump.~Weight of the leg is noted.~Weight of surgical swabs is noted, to estimate intraoperative blood loss."
32735920|NCT04505345|Experimental|Virtual reality cognitive training|Virtual reality cognitive training consists of a behavioral intervention of 10 sessions of training using virtual reality exercises depicting daily life activities from the Systemic Lisbon Battery aiming cognitive impairments.
33260733|NCT04042506|Experimental|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
33260734|NCT00251641|Experimental|Infliximab|
33260735|NCT00251641|Active Comparator|Methotrexate|
33260736|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(<2y), income primarily from agricultural production, poverty and climate data.~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
33077654|NCT05209360|Experimental|Arm 3|Testing Order: NoCDO, Medial, CDO, Lateral
32735921|NCT04505345|Other|Treatment-as-usual|Treatment-as-usual for alcohol use disorder (AUD) in our partner institution, a therapeutic community for rehabilitation of AUD, is conducted according to the Minnesota Model requiring alcohol abstinence.
32735922|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)~anticipated n = 500"
32735923|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)~anticipated n = 500"
33260737|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
32735924|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)~anticipated n = 150"
33260738|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
32735925|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study~anticipated n = 500"
33260739|NCT00250705|Other|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
33260740|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
33260741|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
33260742|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
32735926|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
32735927|NCT04505033|Experimental|50 mg s.c|
32735928|NCT04505033|Placebo Comparator|50 mg placebo|
32735929|NCT04505033|Experimental|150 mg s.c.|
32735930|NCT04505033|Placebo Comparator|150 mg placebo|
32735931|NCT04505033|Experimental|300 mg s.c.|
32735932|NCT04505033|Placebo Comparator|300 mg placebo|
32735933|NCT04505033|Experimental|450 mg s.c.|
32735934|NCT04505033|Placebo Comparator|450 mg placebo|
32735935|NCT03258307|Active Comparator|omentectomy|Preoperative
32735936|NCT03258307|Other|Omentectomy|Postoperative
32735937|NCT03258307|Other|No omentectomy|Preoperative post operative
33260743|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
33260744|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
33260745|NCT00842478|Experimental|Raspall|
33260746|NCT00842478|No Intervention|Control|
33260747|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
33260748|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
33260749|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
33260750|NCT00266695|Experimental|Ruboxistaurin|
32735938|NCT05550545||Parents/caregivers of RSV-infected infants|
32735939|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
32735940|NCT05545787|Experimental|Cold snare endoscopic mucosal resection (CS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by CS-EMR
32735941|NCT05545787|Experimental|Hot snare endoscopic mucosal resection (HS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by HS-EMR
32735942|NCT03252223|Active Comparator|Women with normal menses|
32735943|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
32735944|NCT05513807|Experimental|Nicotinamide|
32735945|NCT05513807|Placebo Comparator|Placebo|
32735946|NCT03251833||obese|Body mass index >30 Kilogram/m2
32735947|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
32735948|NCT02518217|Active Comparator|Apps Only|
32735949|NCT02518217|Experimental|ShapeUp Empower|
33077655|NCT05209360|Experimental|Arm 4|Testing Order: NoCDO, Medial, Lateral, CDO
33260751|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
33260752|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
33260753|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
33260754|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
33260755|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
33260756|NCT00849342||A|
33260757|NCT00842556|Active Comparator|Dapagliflozin|
33260758|NCT00842556|Active Comparator|Glimepiride|
33260759|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
33260760|NCT00842556|Active Comparator|Sitagliptin|
33260761|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
33260762|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
33260763|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
32735950|NCT02518217|Experimental|ShapeUp Empower + Incentives|
33077656|NCT05209360|Experimental|Arm 5|Testing Order: NoCDO, Lateral, Medial, CDO
33260764|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
33260765|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33260766|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33260767|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
33260768|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
33260769|NCT00849654|Experimental|PCI-32765|
33260770|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
33260771|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
33260772|NCT00849732|Placebo Comparator|3|Placebo to V520
33260773|NCT00849966|Experimental|A|Celebrex suspension
33260774|NCT00849966|Placebo Comparator|B|Placebo
33260775|NCT00853086||A|
33260776|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
33260777|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
33260778|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
33260779|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
32735951|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
33077657|NCT05209360|Experimental|Arm 6|Testing Order: NoCDO, Lateral, CDO, Medial
33077658|NCT02432326|Experimental|Arm A|
33260780|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
33260781|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
33260782|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
33260783|NCT00853398|Experimental|Minimal Invasive Surgery,|
33260784|NCT00853398|Active Comparator|Standard Surgical Technique|
33260785|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
33260786|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
33260787|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
33260788|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
33260789|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
33260790|NCT00850044|Active Comparator|1|ABT-450
33260791|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
33260792|NCT00850044|Active Comparator|3|ABT-450/ritonavir
33260793|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
33260794|NCT00266227|Experimental|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
33260795|NCT00266227|Placebo Comparator|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
33260796|NCT04233216|Experimental|Part 1, Group 1: ISL + ART|HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7 in Part 1.
33260797|NCT04233216|Experimental|Part 1, Group 2: DOR + ART|HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7 in Part 1.
33260798|NCT04233216|Experimental|Part 1, Group 3: DOR/ISL + ART|HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7 in Part 1.
33260799|NCT04233216|Placebo Comparator|Part 1, Group 4: Placebo + ART|HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7 in Part 1.
33260800|NCT04233216|Experimental|Part 2, Group 5: Open-Label DOR/ISL + OBT|HTE participants from Groups 1 to 4 with HIV-1 infection take open-label 100 mg DOR/0.75 mg ISL + OBT in Part 2 (Day 8 to Week 97).
32735952|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
32735953|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
32735954|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
33260801|NCT00968877|Active Comparator|Cholecalciferol|
33260802|NCT00968877|Placebo Comparator|Placebo|
33260803|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
32769555|NCT05023915|Active Comparator|diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasone|Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
32769556|NCT05023915|Active Comparator|High-dose dexamethasone|Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
32769557|NCT05024071|Experimental|Swiss Ball|Swiss ball practice can create an unstable environment, promote the recovery of muscle function and develop joint stability. It can train the muscle groups in chest, abdomen, back, buttocks and legs, which play an important role in maintaining body balance and improving athletes' body.
33260804|NCT00965367|Experimental|Acustimulation|
33260805|NCT00965367|No Intervention|Standard treatment group|
33260806|NCT00287365|Experimental|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
33260807|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
33260808|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
33260809|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
33260810|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
33260811|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
33260812|NCT01072279|Experimental|Burundi: T24|
33260813|NCT01072279|Experimental|Burundi: TNFP|
33260814|NCT01072279|Experimental|Burundi: T18|
33260815|NCT01072279|No Intervention|Burundi: Control|
33260816|NCT01072279|Experimental|Guatemala: PROCOMIDA|
33260817|NCT01072279|Experimental|Guatemala: no family ration|
33260818|NCT01072279|Experimental|Guatemala: LNS|
33260819|NCT01072279|Experimental|Guatemala: Sprinkles|
33260820|NCT01072279|Experimental|Guatemala: reduced family ration|
33260821|NCT01072279|No Intervention|Guatemala: control|
33260822|NCT00965445||cardiac surgery with CPB|
33260823|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
33260824|NCT05279625|Experimental|Interval exercise training|Interval exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
33260825|NCT05279625|Experimental|continuous exercise training|continuous exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
33260826|NCT05279625|Experimental|machine-assisted exercise training|machine-assisted exercise training for 6 months
33260827|NCT05279625|Active Comparator|traditional rehabilitation|traditional rehabilitation for 6 months
33260828|NCT03975985|Experimental|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
33260829|NCT03975985|Active Comparator|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
33260830|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
33260831|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
33260832|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
33260833|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
33260834|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
33260835|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
33260836|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
33260837|NCT01071109|Experimental|Therapeutic Massage|
33260838|NCT01071109|No Intervention|No therapeutic massage|
33260839|NCT04025463|Other|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
33260840|NCT00853710|Experimental|rapid PSA assay on whole blood|
33260841|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
33260842|NCT00969033|Active Comparator|irintoecan|irinotecan alone
33260843|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
33260844|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
33260845|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
33260846|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
32735955|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
32735956|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
32735957|NCT05505617||Lung diffusing capacity measurements|Participants will be randomly allocated to perform single-breath lung diffusing capacity measurements on both devises during a single study visit.
33260847|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
33260848|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
33260849|NCT00573768|Active Comparator|1|
33260850|NCT00573768|Placebo Comparator|2|
33260851|NCT00573768|Active Comparator|3|
33260852|NCT00969189||Children|between 10 and 30 kgs
33260853|NCT00969189||Infants|between 5 - 10 kg
33260854|NCT04042428|Experimental|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
33260855|NCT04042428|No Intervention|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
33260856|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
33260857|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
33260858|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
33260859|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
33260860|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
33260861|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
33260862|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
33260863|NCT00969267|Experimental|Stimulation A|with needle A stimulation
33077659|NCT05200936|Placebo Comparator|Arm 1- Placebo|A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
33260864|NCT00969267|Active Comparator|Stimulation B|with stimulation
33260865|NCT00969267|Sham Comparator|Stimulation C|without needle
33260866|NCT00850434|Experimental|modified autoset|the modified AutoSet responds to different breathing patterns than the standard AutoSet, to treat OSA. Participants in this arm will trial the modified AutoSet for one night, and the standard AutoSet for one night, in a randomised order
33260867|NCT00850434|Active Comparator|standard AutoSet|The standard autoset treat OSA by using pressure increases to overcome abnormal breathing patterns. Patients in this arm will use the standard AutoSet for one night and the modified AutoSet for one night, in a randomised order
33260868|NCT00965835||DS|Those with Down syndrome
33260869|NCT00965835||Non-DS|Healthy controls
33260870|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
33260871|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
33260872|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
33260873|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
33260874|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
33260875|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
33260876|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
33260877|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
33260878|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
33260879|NCT00853866|Experimental|1|reboxetine + tDCS verum
33260880|NCT00853866|Experimental|2|reboxetine + sham tDCS
33260881|NCT00853866|Experimental|3|placebo drug + verum tDCS
33260882|NCT00853866|Experimental|4|placebo drug + sham tDCS
33260883|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
33260884|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
33260885|NCT00965991|Active Comparator|Metformin|
33260886|NCT00965991|Active Comparator|Glyburide|
33260887|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
33260888|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
33260889|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
33260890|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
33260891|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
33260892|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
33260893|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
33260894|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
33260895|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
32735958|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
32735959|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
33260896|NCT00854178|Experimental|2|
33260897|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
33077660|NCT05200936|Experimental|Arm 2- MM-120|A total of 26 patients will receive 20 μg of MM-120 administered orally twice weekly for 6 weeks.
33077661|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32735960|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
32735961|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
33077662|NCT04723745||VTRACTS|We will target post-9/11 Veterans with TBI or blast exposure who self-report ongoing post-concussive neurobehavioral symptoms, but V-TRACTS will be open to all post-9/11 Veterans irrespective of any diagnoses.
33260898|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
33260899|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
33260900|NCT04009473|Experimental|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
33260901|NCT00850746|Placebo Comparator|A. Placebo|
32735962|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
33260902|NCT00850746|Experimental|B. Ym443 Lower Dose|
33260903|NCT00850746|Experimental|C. YM443 Higher Dose|
33260904|NCT00850746|Active Comparator|D. Moxiflocxacin|
33260905|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
33260906|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
33260907|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
33260908|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
33260909|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
33260910|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
33260911|NCT00850902|Active Comparator|Moderate Humidity (MH)|
33260912|NCT00850902|Experimental|High Humidity|
33260913|NCT04041882|Experimental|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
33260914|NCT00969813|Experimental|Normal hepatic function|
33260915|NCT00969813|Experimental|Mild hepatic impairment|
33260916|NCT00969813|Experimental|Moderate hepatic impairment|
33260917|NCT00854256|Experimental|Canaloplasty|
33260918|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
33260919|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
33260920|NCT04042662||Meropenem Failure ( Treatment failure)|
33260921|NCT04042662||Meropenem Success ( Treatment Success)|
32735963|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
32735964|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
32735965|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
32735966|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
33260922|NCT00969891||AML patients in induction treatment|
33260923|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
33260924|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
33260925|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
32735967|NCT04504877|Experimental|cannabidiol plus general clinical supportive measures|The participants will receive CBD 300mg/daily plus general measures (supporting motivational videos, fitness videos). All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as well as five collections of saliva, in a collecting tube, to assess viral load. They will also be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
32735968|NCT04504877|Other|general clinical supportive measures|The participants will receive general measures (supporting motivational videos, fitness videos) alone. All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern in a collecting tube to assess viral load. Also, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
32735969|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
32735970|NCT03251755|No Intervention|Control|Usually clinical practice
32735971|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
32735972|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
32735973|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
32735974|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
32735975|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
32735976|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
32735977|NCT05501717|Experimental|ALXN2030 Dose A|ALXN2030 will be administered as a manual subcutaneous (SC) injection.
32735978|NCT05501717|Experimental|ALXN2030 Dose B|ALXN2030 will be administered as a manual SC injection.
32735979|NCT05501717|Experimental|ALXN2030 Dose C|ALXN2030 will be administered as a manual SC injection.
32735980|NCT05501717|Experimental|ALXN2030 Dose D|ALXN2030 will be administered as a SC infusion via a syringe pump.
32735981|NCT05501717|Experimental|ALXN2030 Dose E|ALXN2030 will be administered as a SC infusion via a syringe pump.
32735982|NCT05501717|Placebo Comparator|Placebo|Placebo will be administered as a manual SC injection or as a SC infusion via a syringe pump, depending on dose.
32735983|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
32735984|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
32735985|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
32735986|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
32735987|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
32735988|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
32735989|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
32735990|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
32735991|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
32735992|NCT05462249||Vaccinated|Patients who have been vaccinated against HPV virus.
32735993|NCT05462249||Not vaccinated|Patients who have not been vaccinated against HPV virus.
32735994|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
32735995|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
32735996|NCT05452733|Experimental|Sleepwalking patient|
32735997|NCT05452733|Active Comparator|Non sleepwalking patient|
32735998|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
32769558|NCT05024071|Experimental|Balance Plate|The balance board can exercise athletes' waist explosive force and body balance ability in an unstable state.
33260926|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
33077663|NCT05159050|Experimental|Intraperitoneal paclitaxel-loaded tumor penetrating microparticles (TPM)|Paclitaxel-loaded tumor penetrating microparticles (TPM), dose escalation starting at 50 mg/m^2 instilled in the peritoneal cavity at study start and again 6-8 weeks after the first TPM treatment.
32735999|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
32736000|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis
32736001|NCT05438147|Sham Comparator|Care-as-Usual control in Patients with Multiple Sclerosis|Randomized controlled Study to Evaluate Care-as-Usual control in Patients with Multiple Sclerosis
33077664|NCT05136742|Experimental|aerobic exercise and diet program|aerobic exercise with balanced restricted diet
33077665|NCT05136742|Active Comparator|diet program|balanced restricted diet
33077666|NCT05113303||navigation assisted knee revision surgery|
33077667|NCT05113303||manual procedure|
33077668|NCT05103904|Experimental|Treatment (Lenvatinib)|Patients receive lenvatinib PO QD. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the protocol therapy
33077669|NCT05101369|Experimental|INCB086550|Participants will be administered INCB086550 orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
33077670|NCT00171821|Experimental|ICL670 (Deferasirox)|
33077671|NCT05099965|Active Comparator|Vaccine Group|60 participants will receive CMV-MVA Triplex® containing 5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections.
33077672|NCT05099965|Placebo Comparator|Placebo Group|30 participants will receive a volume of placebo (7.5% Lactose in phosphate-buffered saline [PBS]) that matches the volume of the active vaccine injection by IM deltoid injections.
33077673|NCT05098054|Experimental|Arm 1, Moderate HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with moderate HI.
33077674|NCT05098054|Experimental|Arm 2, Mild HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with mild HI.
33077675|NCT05098054|Experimental|Arm 3, Normal hepatic function: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to healthy participants.
33077676|NCT05070442|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart which replicates the traditional shopping experience of online grocery stores.
33077677|NCT05070442|Experimental|Norms Arm (Arm 2)|Participants will experience a modified version of NUSMart with norm-based messaging and peer comparison features enabled. Nutri-Score labels will be enabled and displayed on all products within the store. A floating side panel will provide a visual indicator of the participants' average weighted Nutri-Score.
33077678|NCT05070442|Experimental|Norms and Incentive Arm (Arm 3)|Same as Arm 2, except participants are notified that they have been awarded an additional $5 towards their participation reimbursement. However, this additional $5 will be forfeited if their basket average weighted Nutri-Score falls below the average of their peers'. (Financial incentive leveraging on loss aversion).
33077679|NCT05054023|Active Comparator|Piroxicam gel|50g tubes that contained 0.5% piroxicam. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
33077680|NCT05054023|Active Comparator|Soulagel®; Belpharma Tunisia|50 ml tubes that contained rosemary essential oil (Romarinus offienalus), mint essential oil, clove essential oil (Eugenda caryophyllus), harpgophytum natural extract (Harpagophytum procumbens), meadowsweet natural extract (Filipendula ulmaria), aqua, methyl salicylate, menthol, camphre, carbomer, triethanolamine, polysorbate-20, sodium polyacrylate, trideceth-6, methylchloroisothiazolinone, methylisothiazolinone , magnesim Chloride and magnesium nitrate. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
33077681|NCT00171860|Experimental|STI571|
33077682|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
33077683|NCT05038384||Observational (survey)|Participants complete a survey over 20 minutes.
33077684|NCT00171899|Experimental|STI571|
33077685|NCT05031325|Experimental|Endoscopic submucosal dissection with Purastat|To compare of the risk of bleeding after endoscopic submucosal dissection, after ESD, application of Purastat gel (not a drug but a device with CE mark) with a catheter of a gel on the resected area to cover the whole surface of mucosal resection.
33077686|NCT05031325|No Intervention|Comparative arm without Purastat|After endoscopic submucosal dissection (ESD) and hemostasis, if the patient is randomized in the comparative group, no gel will be applied on the resected area that will remain like this without intervention (common practice)
33077687|NCT05004259|Experimental|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
33077688|NCT05003050|Experimental|Meditation Based Group|8 sessions weekly for 8 weeks Each session for 1hour Sessions on line (virtual) Self-care tools and techniques, mindfulness and meditation
33077689|NCT05003050|Experimental|Energy Therapy (Pranic Healing)|8 Sessions Weekly sessions for 8 weeks Each session 1 hour Pranic Healing (Energy Therapy)
33077690|NCT05003050|No Intervention|Stanrd of Care Group|Routine medical care and appointments
33077691|NCT04981132|Experimental|Education+Exercise Group|Group 1: Patients will have 15 minutes of pain neuroscience education (PNE) and 30 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
33077692|NCT04981132|Experimental|Exercise group|Group 2: Patients will have 45 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
33077693|NCT04981132|No Intervention|Control Group|Group 3: Participants will be taken for the waiting list after evaluation with the telerehabilitation method.
33077694|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
33077695|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
33077696|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
33077697|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
33260927|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
33260928|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
33260929|NCT00619866|Placebo Comparator|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
33260930|NCT00619866|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
32736002|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with with Breast or Lung Cancer
33260931|NCT00619866|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
33260932|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
33260933|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
33260934|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
33260935|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
33260936|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
32736003|NCT05438147|Sham Comparator|Care-as-Usual control in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate Care-as-Usual control in Patients with with Breast or Lung Cancer
33260937|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
33260938|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
33260939|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
33260940|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
33260941|NCT02544828|Placebo Comparator|Control Group|placebo
33260942|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
33260943|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
32935561|NCT05023993|Active Comparator|Arm I (home exercise)|Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.
33260944|NCT01095003|Experimental|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
33260945|NCT01095003|Active Comparator|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
33260946|NCT00854568|Experimental|CEOP regimen|CEOP regimen
33260947|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
33260948|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
33260949|NCT00856362|Experimental|1|
33260950|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
33260951|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
33260952|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
33260953|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
33260954|NCT00969969|Active Comparator|Arthrodesis|Fusion
33260955|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
33260956|NCT00966381|No Intervention|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 wks postpartum), they will be given all intervention materials.
32736004|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment
32736005|NCT05438147|Sham Comparator|Care-as-Usual in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate Care-as-Usual in Patients with Mild Cognitive Impairment
32736006|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
32736007|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
33260957|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 wks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-wk exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
33260958|NCT00966459|Other|1|
33260959|NCT00958503|Placebo Comparator|Placebo|Placebo
33260960|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
33260961|NCT04119024|Experimental|Treatment (chemotherapy, IL13Ralpha2, Il-2)|Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1. Patients then receive IL13Ralpha2 CAR T cell IV on day 0. Patients may also receive recombinant interleukin-2 SC BID on days 1-7.
32736008|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
32736009|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
33260962|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
33077698|NCT04679662|Experimental|Single-arm study of PLAR Implant and Delivery System to treat severe mitral regurgitation|All enrolled patients will receive the study device
33260963|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
33260964|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
32736010|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
32736011|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
32736012|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
32736013|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
32736014|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
32736015|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
32736016|NCT03348761|Experimental|rTMS Group|"Twenty sessions of neurostimulation at the left DLPFC.~Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).~Phase II: A Neuro-MS/D Advanced Therapeutic Transcranial Magnetic Stimulator (Neurosoft, Russia) with a 100-mm cooled figure-of-eight coil and Neural Navigator navigation (Brain Science Tools, the Netherlands) are used. Stimulation parameters: triplet 50 hertz, repeated at 5 hertz, 120% resting motor threshold, 20 trains of 2 seconds with 8 seconds between trains, 600 pulses per day delivered 5 days per week (total: 12000 pulses)."
32736017|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
32736018|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
33077699|NCT04679545|Experimental|CBD|Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
33260965|NCT00970125|Experimental|Cancer subjects|
33260966|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
33260967|NCT00966615|Active Comparator|Control group|conventional PD solution
33260968|NCT00861666|Other|Forgiveness-based Writing|
33260969|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
33260970|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
33260971|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
33260972|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
33260973|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
33260974|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
33260975|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
33260976|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
33260977|NCT00856440||1|SCI
33260978|NCT00856440||2|Able-bodied
33260979|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
33077700|NCT04679545|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 28 days.
33260980|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
33260981|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
33260982|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
33260983|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
33260984|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
33260985|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
33260986|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
33260987|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
33260988|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
33260989|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
33260990|NCT00855192|Experimental|interpersonal therapy|psycho-educational
33260991|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
33260992|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
33260993|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
33260994|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
33260995|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
33260996|NCT04041960|Experimental|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
33260997|NCT04041960|Experimental|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
33260998|NCT04041960|Active Comparator|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
33260999|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
33261000|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
32736019|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
33077701|NCT04679701||Recruited Amputees|The amputee participants will be recruited over the course of 6 months. Once a patient is recruited and has given consent, they will be fitted with a prosthesis using the Confidence Socket technology and be administered an initial survey. A follow-up meeting for one month after the fitting is scheduled. At the follow-up appointment adjustments to the prosthesis are made as needed and the patient is administered another survey.
33261001|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
33261002|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
33261003|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
33261004|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
33261005|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
33261006|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
33261007|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
33261008|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
32736020|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
33261009|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
33261010|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
33261011|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
33261012|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
33261013|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
32736021|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
32736022|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
33077702|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
33077703|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
33077704|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
33077705|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
33261014|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
33261015|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
32736023|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
32736024|NCT04502303|Experimental|Crohn's disease: patients with intestinal stricture|Patients with intestinal strictures confirmed by other modalities, e.g. CT, MR, ultrasound, and endoscopy, will be recruited in the study.
32736025|NCT05350943|Experimental|HAIC+Toripalimab+Donafenib|HAIC(GEMOX)+Toripalimab+Donafenib
32736026|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk"
32736027|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
32736028|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
33261016|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
33261017|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
33261018|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
33261019|NCT00967395|No Intervention|Control|Business as usual in the third arm
33261020|NCT00970827|Active Comparator|1|Leg postconditioning
33261021|NCT00970827|Active Comparator|2|Arm postconditioning
33261022|NCT00970827|Placebo Comparator|3|Control group
33261023|NCT00970905|Experimental|Aprepitant & Ondansetron|
33261024|NCT00619476|Placebo Comparator|Placebo|placebo
33261025|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
33261026|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
33261027|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
33261028|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
33261029|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
33261030|NCT04009083|Other|Standard of Care|
33261031|NCT04009083|Experimental|18F-Fluciclovine PET Scan|
33261032|NCT00971061|Experimental|MSPI|Molteno single-plate implant
33261033|NCT00971061|Active Comparator|AVI|Ahmed valve implant
33261034|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
32736029|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
32736030|NCT04503785||Dysphagia|Patients with Esophageal dysphagia
33077706|NCT04958122|Experimental|Cefixime|Oral cefixime 400mg, taken twice a day for 10 days
33261035|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
33261036|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
33261037|NCT00861978|Placebo Comparator|1|
32736031|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
32736032|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
33261038|NCT00861978|Experimental|2|
33261039|NCT04158375|Experimental|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
33261040|NCT04158375|No Intervention|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
33261041|NCT04158375|No Intervention|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
33261042|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
32736033|NCT05329571|Experimental|Low-FODMAP Diet|Participants will be instructed to maintain their usual diet, while eliminating FODMAPs (A subgroup of carbohydrates are considered fermentable, given the lack of suitable hydrolase enzymes in the colon, required for their digestion and absorption, thus making them available for fermentation).
32736034|NCT05329571|Experimental|Gluten-Free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
32736035|NCT05329571|Other|Control|Patients of this group will be asked to adhere to their regular, daily diet.
32736036|NCT03261115|No Intervention|Control group|Topical Anesthesia
32736037|NCT03261115|Experimental|Study group|No topical anesthesia
32736038|NCT03348527|Experimental|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
32736039|NCT03348527|Experimental|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
32736040|NCT03348527|Experimental|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
32736041|NCT03348527|Experimental|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
32736042|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
33077707|NCT04958122|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
33077708|NCT02232646|Experimental|BBI503|
33261043|NCT00971139|No Intervention|Control group|Patients receiving usual care
33261044|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
33261045|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
33261046|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
33261047|NCT04040712|Experimental|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
33261048|NCT04040712|Sham Comparator|Sham FMT|Sham fecal microbiota transplantation
33261049|NCT00973713|Experimental|RAD001 10mg/d|
33261050|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
32736043|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
32736044|NCT05320133|Experimental|JWC group|Jinghua Weikang Capsule containing quadruple therapy.
32736045|NCT05320133|Active Comparator|Control group|Bismuth-containing quadruple therapy.
32736046|NCT03257293|Active Comparator|Routine Cystoscopy|
32736047|NCT03257293|Experimental|Modified Cystoscopy|
32736048|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.~Anxiety reduction workshop and take-home anxiety reduction program."
33261051|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
33261052|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
32736049|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
33261053|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
33261054|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
33077709|NCT04950673||Subjects who had COVID-19 infection and recovered at 3 months|500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
33077710|NCT04950673||Subjects who never had COVID-19 infection|500 subjects who never had a history of COVID19 infection prior to the enrollment
32736050|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
32736051|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
32736052|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
33261055|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
33261056|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
32736053|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
33261057|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
33261058|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
33261059|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
33261060|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
33077712|NCT04947319|Experimental|Tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A)|Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.
32736054|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
32736055|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
32736056|NCT03351179||AMI patients with HFpEF|
32736057|NCT03351179||AMI patients without HF|
32736058|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
32736059|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
32736060|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
33261061|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
32736061|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
32736062|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
32736063|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
32736064|NCT04503629|Experimental|Anaprazole Sodium 20mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
33261062|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
33261063|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
33261064|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
33261065|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
33261066|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
33261067|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
33261068|NCT04041492|Experimental|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
32736065|NCT04503629|Experimental|Anaprazole Sodium 40mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
32736066|NCT04503629|Active Comparator|Rabeprazole sodium 10mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
32736067|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
32736068|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
33261069|NCT04041492|Experimental|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
33261070|NCT04041492|Active Comparator|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
33261071|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
33261072|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
33261073|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
33261074|NCT00862212|No Intervention|Control Group|
33261075|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
33261076|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
33261077|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
32769559|NCT05027581|Experimental|Chondrochymal® group|Subjects will be IA injected at the target knee with 3 mL of Chondrochymal® containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.
33261078|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
33261079|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
33261080|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
33261081|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
33261082|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
33261083|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
33261084|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
33261085|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
33261086|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
32769560|NCT05027581|Active Comparator|Hya-Joint Plus Synovial Fluid Supplement|Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1.
33077713|NCT04947319|Experimental|Tirabrutinib + MTR in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 1)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + methotrexate/temozolomide/rituximab (MTR)
33261087|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
33261088|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
33261089|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
33261090|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
33261091|NCT00959517|Experimental|CQ|
33261092|NCT00959517|Experimental|CQ+PQ|
33261093|NCT00959517|Experimental|CQ + AS|
33261094|NCT00959517|Experimental|SP|
33261095|NCT00959517|Experimental|SP + PQ|
33261096|NCT00959517|Experimental|SP + AS|
33261097|NCT04008771|Experimental|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
33261098|NCT04008771|Experimental|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
33261099|NCT00959595|Experimental|EMLA cream|
33261100|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
33261101|NCT00666926|Experimental|1|
33261102|NCT00666926|Experimental|2|
33261103|NCT00666926|Experimental|3|
33261104|NCT00666926|Experimental|4|
33261105|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
33261106|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
33261107|NCT00862290||control group|normal healthy volunteers
33261108|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
33261109|NCT00974103|Experimental|Exercises|Exercise advise
33261110|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
33261111|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
33261112|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
33261113|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
33261114|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
33261115|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
33261116|NCT00857610||1|Subjects using 0.1% retinol one day per week
33261117|NCT00857610||2|Subjects using 0.1% retinol three days per week
33261118|NCT00857610||3|Subjects using 0.1% retinol seven days per week
33261119|NCT00857610||4|Subjects using 0.5% retinol one day per week
33261120|NCT00857610||5|Subjects using 0.5% retinol three days per week
33261121|NCT00857610||6|Subjects using 0.5% retinol seven times per week
33261122|NCT00971607|Active Comparator|1|Sevoflurane
33261123|NCT00971607|Placebo Comparator|2|Oxygen
33261124|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
33261125|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
33261126|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:~Prolonged capillary refill time (>3sec)~Reduced urine output (<1 mL/kg/hr)~Metabolic acidosis (Base deficit >5)"
33077714|NCT04947319|Experimental|Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 2)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + rituximab/methotrexate/procarbazine/vincristine (R-MPV)
33261127|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
33261128|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
33261129|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
33261130|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
33261131|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
33261132|NCT03861052|Experimental|5 mg Tirzepatide|Participants received 5 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 52 weeks.
33261133|NCT03861052|Experimental|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.
33261134|NCT03861052|Experimental|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.
33261135|NCT03861052|Active Comparator|0.75 mg Dulaglutide|Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks.
33261136|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
32736069|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
33077715|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
33261137|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
32736070|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
32736071|NCT05296421|Experimental|Basic science (uniformly-labeled [13C]glucose)|Patients receive uniformly-labeled [13C]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
32736072|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
32736073|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
32769561|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
33077716|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
33261138|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
33261139|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
33261140|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)~Cyclophosphamide 750mg/m^2 day 1~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)~Prednisolone 100mg/day days 1-5~Rituximab 375mg/m^2 day 1~Neulasta 6mg day 9"
33261141|NCT04018170|Experimental|JW1601|tablet formulation
33261142|NCT04018170|Placebo Comparator|Placebo|tablet formulation identified with JW1601
33261143|NCT00785252|Experimental|1|EZIO
33261144|NCT00785252|Experimental|2|Central line
33261145|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
33261146|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
33261147|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
33261148|NCT00781196|Experimental|1|Oral folic acid
33261149|NCT00781196|Placebo Comparator|2|placebo
33261150|NCT00865644|Experimental|Imiquimod|
33261151|NCT00785330|Other|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
33261152|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
33261153|NCT00974649|No Intervention|Included in questionnaire study|
33261154|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
33261155|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
33261156|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
33261157|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
33261158|NCT00790946|No Intervention|standard therapy|
33261159|NCT05263102|Experimental|Treatment Arm|Treatment duration: 8 weeks Twice treatments per week
33077717|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
33077718|NCT04941313|Experimental|Single Dose Escalation-3D229|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
33261160|NCT05179239|Experimental|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|
33261161|NCT05179239|Experimental|SHR-1701 + paclitaxel + cisplatin/carboplatin ± BP102|
33077719|NCT04941313|Placebo Comparator|Single Dose Escalation- placebo|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
33261162|NCT05179239|Placebo Comparator|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|
33261163|NCT04046666|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
33261164|NCT04046666|Other|Healthy group|This group will include 40 healthy volunteers.
33261165|NCT04046666|Other|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
33261166|NCT04527874|Experimental|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
33261167|NCT04527874|No Intervention|Control|Clusters in the control arm continue standard of care.
33261168|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
33261169|NCT00972075|Placebo Comparator|Placebo|
33261170|NCT00974727|Experimental|Gardening Program|
33261171|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
33261172|NCT00785408|Experimental|1|
33261173|NCT00785408|Experimental|2|
33261174|NCT00785408|Experimental|3|
33261175|NCT00785408|Placebo Comparator|4|
33261176|NCT00785408|Placebo Comparator|5|
33261177|NCT00785408|Placebo Comparator|6|
33261178|NCT01565122||Cohort|
33261179|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
33261180|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
33261181|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
33261182|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
33261183|NCT00960219|Experimental|DAAOI-1|
33261184|NCT00960219|Placebo Comparator|placebo|
33261185|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
33261186|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
33261187|NCT02555774|No Intervention|No intervention|This group receives no intervention.
33261188|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
33261189|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
33261190|NCT00791024|Experimental|single arm|
33261191|NCT03897244|Experimental|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
33261192|NCT03897244|Experimental|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
33261193|NCT03897244|Active Comparator|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
33261194|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
33261195|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
33261196|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
33261197|NCT04046354|Experimental|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
33261198|NCT04046354|Active Comparator|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
33261199|NCT00781430|Experimental|1|
33261200|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
33261201|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
33261202|NCT03931785|Experimental|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
33261203|NCT03931785|Experimental|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
33261204|NCT03931785|Experimental|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
33261205|NCT03931785|Placebo Comparator|Placebo|4 matching placebo oral tablets
33261206|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
32769562|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
32769563|NCT03093337|No Intervention|Control|No specific support.
32769564|NCT05027191||Sevoflurane|This group will receive sevoflurane as the maintenance inhalational anesthetic.
33261207|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
33261208|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
33261209|NCT00666458|Experimental|1|saxagliptin add-on to metformin
32769565|NCT05027191||Desflurane|This group will receive desflurane as the maintenance inhalational anesthetic.
33261210|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
33261211|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
33261212|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
32769566|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
32769567|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
33077720|NCT04941313|Experimental|Repeat Dose-3D229|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
33261213|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
33261214|NCT00511108|Experimental|1|Arm 1: drug
33261215|NCT00511108|Active Comparator|2|Arm 2: active comparator
33261216|NCT00511108|Experimental|3|Arm 3: drug + active comparator
32769568|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
32769569|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
32769570|NCT02528253|Experimental|Tanezumab 5 mg SC|
33077721|NCT04941313|Placebo Comparator|Repeat Dose-placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
33077722|NCT04934449|Experimental|Hard splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, hard occlusal splints for 2 months during sleep
33077723|NCT04934449|Experimental|Hard splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, hard occlusal splints for 2 months during sleep
33261217|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
33261218|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
33261219|NCT00781586|Experimental|Arm 1|
33261220|NCT00781586|Active Comparator|Arm 2|
33261221|NCT00781586|Placebo Comparator|Arm 3|
33261222|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
33261223|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
33261224|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
33261225|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
33261226|NCT00781664|Experimental|D|AN2718 Gel Vehicle
33261227|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
33261228|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
33261229|NCT00781664|Experimental|G|AN2718 Gel, 5%
33261230|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
33261231|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
33261232|NCT00785876|No Intervention|1|Control Sites
33261233|NCT00785876|Experimental|2|Intervention Sites
33261234|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
32769571|NCT02528253|Experimental|Tanezumab 10 mg SC|
32769572|NCT02528253|Active Comparator|Tramadol PR oral|
32769573|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
32769574|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
32769575|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
32769576|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
33261235|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
33261236|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
33261237|NCT00791570|Experimental|A|
33261238|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
33261239|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
33261240|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
33261241|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
33261242|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
33261243|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
33261244|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
32736074|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
33261245|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
33261246|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
33261247|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
33261248|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
33261249|NCT00858000||Group A|No intervention
33261250|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
33261251|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
32736075|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
32736076|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
32736077|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
32736078|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
32736079|NCT05278559||Adolescents living with HIV|- ALHIV with a viral load result of less than <1000 copies/mL and aged between 13-19 years
32736080|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
32736081|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
32736082|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
32736083|NCT05257577||Study group|Breast conserving surgery
32736084|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
32736085|NCT04504721|Experimental|Light therapy group|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
32736086|NCT04504721|No Intervention|Waiting list group|Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
32736087|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
32736088|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
33261252|NCT02544438|Experimental|Astarabine|Astarabine
33261253|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
33261254|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
32736089|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
32736090|NCT04504565|Experimental|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTC-3PRGD2, patients underwent single-photon emission computed tomography/COMPUTED tomography (SPECT/CT) examination.
32736091|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
32736092|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
32736093|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
33261255|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
33261256|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
33261257|NCT00791726||1|Patients with noninfectious uveitis and macular edema
33261258|NCT00781820|Placebo Comparator|Arm 2|
33261259|NCT00781820|Experimental|Arm 1|
33261260|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
32736094|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
33261261|NCT00781976|Placebo Comparator|1|
33261262|NCT00781976|Active Comparator|2|
33261263|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
33261264|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
33261265|NCT00791804|Experimental|Single Arm|
33261266|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
33261267|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
33261268|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
33261269|NCT00791960|Placebo Comparator|Placebo|Placebo
32769577|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
32769578|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
32769579|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
33261270|NCT00792038||1|OCD patients
33401452|NCT04220008|Experimental|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
33261271|NCT00792038||2|Normal Controls
32769581|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
33261272|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
33261273|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
33261274|NCT00792350||Group 1|
33261275|NCT04046198|Experimental|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
33261276|NCT04046198|Other|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
33261277|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
33261278|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
33261279|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
33261280|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
33261281|NCT00792740|Placebo Comparator|Placebo capsules|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)"
33261282|NCT00792740|Experimental|ITF2357|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)."
33261283|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
33261284|NCT00782366||Control|Those who will receive standard of care
33261285|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
33261286|NCT00782522|Experimental|1|Eccentric training program
33261287|NCT00782522|Active Comparator|2|Traditional training program
33261288|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
33261289|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
33261290|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
33261291|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
33261292|NCT05025020|Experimental|Standard consultation with interactive 3D visualization|Participants in this group will use the interactive 3D tool in addition to receiving the standard surgical consultation before their breast reconstruction procedure.
33261293|NCT05025020|Active Comparator|Standard consultation|Participants in this group will receive a standard surgical consultation before their breast reconstruction procedure.
33261294|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
33261295|NCT00786266|Experimental|Sleep Enhancement Training System|
33261296|NCT04093752|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
33261297|NCT04093752|Experimental|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC QW.
33261298|NCT04093752|Experimental|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC QW.
33261299|NCT04093752|Active Comparator|Insulin Glargine|Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.
33261300|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
33261301|NCT00865956|No Intervention|Usual care|Usual care
33401453|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
33401454|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
33261302|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
32736095|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
32736096|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
32736097|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
32736098|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
32736099|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
32736100|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
32736101|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
32736102|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
32736103|NCT05231603|Active Comparator|Treatment group:|Ivermectin 0.4 mg/kg/day (maximum 24 mg)
32736104|NCT05231603|Placebo Comparator|Control group|Placebo-inactive substance
32736105|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
32736106|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
32736107|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
32736108|NCT04503083||Migraine patients|"Excellent responder, a patient who experiences a >75% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~Responder, a patient who experiences a >50% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~Non responder, a patient who experiences a decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days ranging from 26 to 49% during the last 4 weeks of treatment as compared to baseline;~Full non responder, a patient who experiences a <25% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline."
32736109|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
32736110|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
32736111|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
32736112|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
32736113|NCT02914483|Other|Enhanced Usual Care (EUC)|
32736114|NCT02914483|Other|Stress Management|
32736115|NCT05196191|Experimental|Viagenex Max|VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.
32736116|NCT05196191|Active Comparator|Standard of care|Hibiclens wash will be performed.
32736117|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
32736118|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
33261303|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
32736119|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
32736120|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
32736121|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
32736122|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
32736123|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
32736124|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
32736125|NCT03467113|Experimental|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
32736126|NCT02517983||Chronic respiratory disease|
33401455|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
32736127|NCT03438331|Experimental|CBT-I|
32736128|NCT03438331|Active Comparator|CBT-D|
33401456|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
33401457|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
33401458|NCT03435458|Active Comparator|Oral misoprostol alone|
32736129|NCT03438331|No Intervention|Waiting-list control|
32736130|NCT05585489|Experimental|Persons with moderate idiopathic Parkinson's disease|
32736131|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
32736132|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
32736133|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
32736134|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
32736135|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
32736136|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
32736137|NCT02888249|Experimental|Cigarette W|"Altered composition cigarettes~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
32736138|NCT02888249|Experimental|Cigarette X|"Altered composition cigarettes~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
32736139|NCT02888249|Experimental|Cigarette Y|"Altered composition cigarettes~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
32736140|NCT02888249|Experimental|Cigarette Z|"Altered composition cigarettes~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
32736141|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
32736142|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
32736143|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
32736144|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
32736145|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
32736146|NCT05585411|Experimental|LBBAP group|In this arm, a left bundle branch area pacing(LBBAP) lead will be attempted to be placed.
32736147|NCT05585411|Active Comparator|RVP group|In this arm, a Right ventricular pacing (RVP) lead will be attempted to be placed.
32736148|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
32736149|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
32736150|NCT04503239||Prediabetes (both IGT and IFG)|Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736151|NCT04503239||Type 2 Diabetes on 1 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
33077724|NCT04934449|Experimental|Soft splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, soft occlusal splints for 2 months during sleep
32736152|NCT04503239||Type 2 Diabetes on 2 or more OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736153|NCT04503239||Type 2 Diabetes using Basal insulin with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736154|NCT04503239||Type 2 Diabetes in GLP-1 with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736155|NCT04503239||Type 2 Diabetes using intense insulin treatment-Multiple Dail|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736156|NCT04503239||Type 2 Diabetes in MDI or basal insulin plus GLP-1|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736157|NCT04503239||Type 2 Diabetes on 0 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736158|NCT04503239||High Risk to Develop Prediabetes / Type 2 Diabetes|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
32736159|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
32736160|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
32736161|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
32736162|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
32736163|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
32736164|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
32736165|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
32736166|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
32736167|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
32736168|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
32736169|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
32736170|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
33261304|NCT00866112|Experimental|1|Intervention group to promote physical activity
32736171|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.~--------------------------------------------------------------------------------"
32736172|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
32743157|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
32769582|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
33077725|NCT04934449|Experimental|Soft splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, soft occlusal splints for 2 months during sleep
33077726|NCT04682275|Other|Female Group|Females with periodontal disease (71 subjects with gingivitis, 100 subjects with periodontitis)
33261305|NCT00866112|Other|2|Minimal contact control group
33261306|NCT00862602|Experimental|1|Stepping Up to Health
33261307|NCT00862602|No Intervention|2|Usual care group
33261308|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
33261309|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
33261310|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
33261311|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
33077727|NCT04682275|No Intervention|Male Group|males with periodontal disease (72 subjects with gingivitis, 96 subjects with periodontitis)
33077728|NCT00172094|Placebo Comparator|1|PLACEBO
33077729|NCT00172094|Experimental|2|400 mg 1776 powder
33261312|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
33261313|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
33261314|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
33261315|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
33261316|NCT05227482|Active Comparator|Standard dosimetric approach for 90Y activity calculation|The radionuclide activity to be injected is calculated with standard dosimetric approach such as body surface area (BSA) method or Medical Internal Radiation Dose (MIRD) monocompartmental method.
33261317|NCT05227482|Experimental|Personalized voxel-based dosimetric method for 90Y activity calculation|The radionuclide activity to be injected is calculated with voxel-based approach based on pre-treatment simulation with the injection of 99mTc-MAA and the acquisition of SPECT/CT images.
33261318|NCT04041804|Active Comparator|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
33401459|NCT05580250|Experimental|Part A: Single Dose LY3526318|LY3526318 administered orally in three study periods.
32736173|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
32736174|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
32736175|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
32736176|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
32736177|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
32736178|NCT03255343|Experimental|IMDENDRIM|
32736179|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
32736180|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
32736181|NCT05585255||Acute ischemic stroke patients|Acute ischemic stroke patients with large vessel occlusion who received mechanical thrombectomy therapy and are successfully revascularized
32736182|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
32736183|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
32736184|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
32736185|NCT04488445|Experimental|Strength Training|The intervention group performs a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 RM) and 3 minutes of resting time between sets.
32736186|NCT04488445|Placebo Comparator|Stretching|The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
32736187|NCT04502459|Active Comparator|Cement only|The tourniquet was inﬂated just before cement application and deﬂated after its hardening
32736188|NCT04502459|Active Comparator|Skin to Cement|Inﬂation of tourniquet before skin incision and its deﬂation after hardening of cement
32736189|NCT04502459|Active Comparator|Skin to Skin|Inflate of tourniquet before incision and deflate following completion of skin closure
32736190|NCT05585177|Experimental|Growth hormone pretreatment+IVF/ICSI|After 3 months of Growth hormone treatment (2 units daily), IVF/ICSI was performed
32736191|NCT05585177|No Intervention|IVF/ICSI|IVF/ICSI was performed
32736192|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
32736193|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
32736194|NCT04501835||Cardiac implantable electronic device infections|Patients hospitalised in Nancy University Hospital for suspected cardiac implantable electronic device infections
32736195|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
32736196|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
32736197|NCT05584943||84 patients on ASA chronic treatment|A total of 84 patients on chronic treatment with low-dose ASA (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
32736198|NCT05584943||Healthy subject|9 healthy subjects, not on ASA treatment, as controls.
32736199|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
33401460|NCT05580250|Placebo Comparator|Part A: Single Dose Placebo|Placebo administered orally in three study periods.
32736200|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
32736201|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
32736202|NCT03122015|No Intervention|Standard care|
32736203|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
32736204|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
32736205|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
32736206|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
32736207|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
32736208|NCT05584865|Experimental|Group I|
32736209|NCT05584865|Active Comparator|Group II|
32736210|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
32736211|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
32736212|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
32736213|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
32736214|NCT05082779|Experimental|Cohort A1: 0.2 mg|Participants in fasted state will receive CS0159 0.2 mg or placebo once on Day 1.
32736215|NCT05082779|Experimental|Cohort A2: 0.6 mg|Participants in fasted state will receive CS0159 0.6 mg or placebo once on Day 1.
32736216|NCT05082779|Experimental|Cohort A3: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once on Day 1 followed by a 7-day washout period then given in 1 mg tablet (in fed state) on Day 8.
33401461|NCT05580250|Experimental|Part B: Multiple Dose LY3526318|LY3526318 administered orally.
32736217|NCT05082779|Experimental|Cohort A4: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once on Day 1.
32736218|NCT05082779|Experimental|Cohort A5: 4 mg|Participants in fasted state will receive CS0159 4 mg or placebo once on Day 1.
32736219|NCT05082779|Experimental|Cohort A6: 8 mg|Participants in fasted state will receive CS0159 8 mg or placebo once on Day 1.
32736220|NCT05082779|Experimental|Cohort B1: 0.4 mg|Participants in fasted state will receive CS0159 0.4 mg or placebo once daily for a consecutive 14 days.
32736221|NCT05082779|Experimental|Cohort B2: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once daily for a consecutive 14 days.
32736222|NCT05082779|Experimental|Cohort B3: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once daily for a consecutive 14 days.
32736223|NCT05082779|Experimental|Cohort B4: 4mg|Participants in fasted state will receive CS0159 4 mg or placebo once daily for a consecutive 14 days.
32736224|NCT03255265||Acute rejection|
32736225|NCT03255265||No acute rejection|
32736226|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
32736227|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
32736228|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
32736229|NCT02880319|Experimental|Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
32736230|NCT05045183|No Intervention|Treatment A: Uncovered Wound (Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as a negative control.
32736231|NCT05045183|Active Comparator|Treatment B: Standard of Care (SoC) Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, SoC adhesive bandage will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736232|NCT05045183|Experimental|Treatment C: Antibiotic Ointment|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment will be applied. This treatment will be applied daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736233|NCT05045183|Experimental|Treatment D: Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736234|NCT05045183|Experimental|Treatment E: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 0 through Day 2 and all wound sites will be uncovered after Day 3 to Day 16 for assessments.
32736235|NCT05045183|Experimental|Treatment F: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736236|NCT05045183|Experimental|Treatment G: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736237|NCT05045183|Experimental|Treatment H: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
32736238|NCT04487977||Surveyed professionals|
32736239|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
32736240|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
32736241|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
32736242|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
32736243|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
32736244|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
32736245|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
32736246|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
32736247|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
32736248|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
32736249|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
32736250|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
32736251|NCT03249571|Placebo Comparator|Placebo|Placebo
32736252|NCT05013437|Experimental|Evomela (Melphalan)|Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
32736253|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
32736254|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
32736255|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
32736256|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
32736257|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
32736258|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
32736259|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
32736260|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
32736261|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
32736262|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
32736263|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
32736264|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
32736265|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
32736266|NCT03254875|No Intervention|Control|Usual care
32736267|NCT05584787|Experimental|TPLA in patients with prostate cancer|Patients diagnosed with low- and intermediate risk unifocal prostate cancer undergo to focal laser ablation therapy.
32736268|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
32736269|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
32736270|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
32769583|NCT05047861|Experimental|Study group|patients will receive the implant in the previously preserved socket using Socket shield technique with Alloplastic graft material
33077730|NCT00172094|Experimental|3|1776 (800 mg)
32736271|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
32736272|NCT04487821|Experimental|Experimental Group|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. This contained 4 types of progressive activities. Respectively every type contains 2 to 4 tasks, performed in sets of 10 repetitions for 4 weeks.~Results were obtained by using Balance scoring system, and physical performance test for speed and agility"
32736273|NCT04487821|No Intervention|Control Group|"Control group: (Group B) Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. They were asked to perform the regular drills.~Results were obtained using Balance Error scoring system and physical performance test for speed and agility."
32736274|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
33261319|NCT04041804|Active Comparator|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
33261320|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
33261321|NCT04041648|Placebo Comparator|placebo|placebo group
32736275|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
33261322|NCT04041648|Experimental|L606 Liposomal inhalation solution|Liposomal inhalation solution
33261323|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
33261324|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
33261325|NCT03928821|Experimental|Group 1: PGT121 + VRC07-523LS|Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.
32736276|NCT04487743|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
32736277|NCT04487743|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
32736278|NCT05010629|Experimental|9-ING-41 + carboplatin|"Participants will be divided into 2 cohorts: Salivary Gland Cancer with adenoid cystic carcinoma (ACC) and Salivary Gland Cancer without adenoid cystic carcinoma (ACC) and receive:~9-ING-41 2x every 21 day study cycle on Day 1 and Day 4 up to 1 year with option to continue beyond if participant is showing benefit~Carboplatin 1x every 21 day study cycle on Day 1 up to 1 year"
32736279|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
32736280|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
32736281|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
32736282|NCT05584631|Experimental|Intravenous immune globulin G|Subjects will receive there current intravenous immune globulin dose.
32736283|NCT05584631|Experimental|Subcutaneous immune globulin G|The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).
32736284|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
33261326|NCT03928821|Experimental|Group 2: PGDM1400 + VRC07-523LS|Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.
33261327|NCT03928821|Experimental|Group 3: 10-1074 + VRC07-523LS|Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.
33261328|NCT03928821|Experimental|Group 4: PGDM1400 + PGT121 + VRC07-523LS|Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.
33261329|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
33261330|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
33261331|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
33261332|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
33261333|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
33261334|NCT00866424|Experimental|A,2, II|
33261335|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
33261336|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
33261337|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
33261338|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
33261339|NCT00975117|Placebo Comparator|Placebo|
33261340|NCT00975117|Experimental|Spermotrend|
33261341|NCT00786344|Experimental|Lifestyle Redesign|
32769584|NCT05047861|Active Comparator|Control group|patients will receive the implant in the previously preserved socket shield with Autogenous dentin graft
32769585|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
32769586|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
32769587|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
32769588|NCT05023447|Experimental|BRIDGE Intervention (+Service as Usual)|The brief, intensive assessment and integrated formulation (BRIDGE) intervention is delivered over 3-6 months and has a three-fold focus: Firstly, an intensive (post-randomisation) assessment, taking up to two sessions, including BPD symptoms, co-presenting difficulties, neurodevelopmental profile, life events history and psychosocial functional impact. Secondly, up to 16 sessions of Cognitive Analytic Therapy (CAT). Thirdly, development of a shared formulation with a multi-agency group; further development of the shared formulation with the young person, using CAT principles (Reformulation, Recognition and Revision) and, where clinically applicable, their family and service-providers.
33261342|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
33261343|NCT00858624|Active Comparator|Chronic Cough Patients|
33261344|NCT00858624|Active Comparator|Healthy Volunteers|
33261345|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
32769589|NCT05023447|Active Comparator|Service as Usual|For participants randomised to Service-As-Usual (SAU), a routine letter of their participation will be shared with their service provider(s), including the GP. SAU, likely to range from social services, mentalhealth services, forensic services to no intervention will be mapped and described for each participant. Treatment fidelity to SAU will therefore not be assessed, but the nature and intensity of SAU in different contexts will be described in detail through the qualitative process evaluation.
32769590|NCT05026255|Experimental|mechanically ventilated intensive care patients.|Observational data collected for patients in intensive care under mechanical ventilation.
32769591|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
32769592|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
32769593|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
32769594|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
32769595|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
32769596|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
32769597|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
32769598|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
32769599|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
32769600|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
32935562|NCT05023993|Experimental|Arm II (home exercise, nicotinamide riboside)|Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.
33077731|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
33261346|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
33261347|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
33261348|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
33261349|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
33261350|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
33261351|NCT00265759|Experimental|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
33261352|NCT00265759|Experimental|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
33261353|NCT00265759|Experimental|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
33261354|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
33261355|NCT00786500|Placebo Comparator|Placebo tea|
33261356|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
33261357|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
33261358|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
33261359|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
33261360|NCT00866580|Experimental|Group A|
33261361|NCT00866580|Experimental|Group B|
33261362|NCT00744263|Placebo Comparator|Placebo|
33261363|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
32736285|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
32736286|NCT04503005|Active Comparator|Effect of fasting duration|study the effect of different daily fasting duration on body composition and blood lipid and inflammatory markers in healthy adults.
32736287|NCT04503005|Other|Effect of time restricted eating protocol on chronotype|study the effect of 2 month of time restricted eating on the chronotype profile of healthy adults.
32736288|NCT04487587|Active Comparator|Active|Cediranib 20mg tablet OD (5 days out of 7) and Olaparib 300mg tablet BD (continuous) + standard of care
32736289|NCT04487587|Placebo Comparator|Placebo|Placebo Cediranib 20mg tablet OD (5 days out of 7) and Placebo Olaparib 300mg tablet BD (continuous) + standard of care
32736290|NCT05584397||Tenofovir-containing ART|Cohort 1: Tenofovir-containing ART (tenofovir disoproxil fumarate [TDF] OR tenofovir alafenamide [TAF] PLUS any other ART drugs) prescribed for daily use by participants' primary care providers.
32736291|NCT05584397||NRTI-sparing ART|Cohort 2: NRTI-sparing ART (specifically: rilpivirine PLUS dolutegravir OR rilpivirine PLUS cabotegravir) prescribed for daily use by participants' primary care providers.
32736292|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
32736293|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
32736294|NCT04833413||Continue intensive treatment group|Patients with type 2 diabetes who continued intensive treatment within 6 months after hospital discharge
32736295|NCT04833413||Premixed insulin treatment group|Patients with type 2 diabetes who changed to premixed insulin within 6 months after hospital discharge
32736296|NCT04833413||Basic insulin treatment group|Patients with type 2 diabetes who changed to basic insulin treatment within 6 months after hospital discharge
32736297|NCT04833413||Oral hypoglycemic drug treatment group|Patients with type 2 diabetes who changed to oral hypoglycemic drug treatment within 6 months after hospital discharge
32736298|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
32736299|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
32736300|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg~Efficacy, safety and effect on cognitive and behavioural function"
32736301|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
32736302|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
32736303|NCT04786613|Active Comparator|20 mg, 1.0% hyaluronic acid injection groups|In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.
32736304|NCT04786613|Active Comparator|32 mg, 1.6% hyaluronic acid injection groups|In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.
32736305|NCT04786613|Active Comparator|48 mg, 2.0% hyaluronic acid injection groups|In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
32736306|NCT04767191|Active Comparator|artemether lumefantrine|The drug is approved and in use by the Kenya Ministry of Health as the 1st line treatment for malaria. The study is to assess the continued efficacy of the drug.
32736307|NCT04767191|Active Comparator|dihydroartemisinin piperaquine|The drug is approved and in use by the Kenya Ministry of Health as the 2nd line treatment for malaria. The study is to assess the continued efficacy of the drug.
32736308|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
32736309|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
32736310|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)"
32736311|NCT04502069|Experimental|Open label opaganib|opaganib dosed at 500 mg Q12 hours
32736312|NCT03246139|Experimental|Action observation, imagery & execution|
32736313|NCT03246139|Active Comparator|Action observation|
33261364|NCT00862914||1|benign melanocytic naevi
33401462|NCT05580250|Placebo Comparator|Part B: Multiple Dose Placebo|Placebo administered orally.
33261365|NCT00862914||2|dysplastic melanocytic naevi
33077732|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
33077733|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
33077734|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
32736314|NCT03246139|Active Comparator|Control treatment|
32736315|NCT02517359|Experimental|Single dose, healthy volunteers|
32736316|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
32736317|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
32736318|NCT02517359|Experimental|14 day repeat dose, asthma patients|
33077735|NCT04682002|Experimental|OMT + multidisciplinary path|Patients in the experimental group will follow the obstetrician's and multidisciplinary path which provides osteopathic treatments, mindfulness, yoga, clinical nutrition, coaching and usual obstetric care.
33077736|NCT04682002|Other|Usual care|Patients in control group will continue the routine obstetrical care as established by international guidelines
32736319|NCT02517359|Experimental|14 day repeat dose, smokers|
32736320|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy~Surgery"
32736321|NCT02454673||Group B|"3-4 cycles of induction chemotherapy~Radiotherapy with concurrent chemotherapy for 5 weeks~Surgery"
32736322|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
33077737|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
33077738|NCT04904809|Experimental|All Registered Patients|All registered patients will have multiple access sites in a single vein closed utilizing the Perclose ProGlide Suture-Mediated Closure System and/or Perclose ProStyle Suture- Mediated Closure and Repair System.
33077739|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
33077740|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
33077741|NCT04895254||Experimental: Motorized spiral Enteroscopy|Consecutive patients with difficult colonoscopies to be enrolled to achieve total colonoscopy using the motorized spiral enteroscope.
33077742|NCT01781455|Experimental|BBI503|
33077743|NCT01765777|No Intervention|Control Group|Subjects in this arm continue with standard medical care
33077744|NCT01765777|Experimental|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
33077745|NCT01765777|Experimental|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
33077746|NCT01765777|Experimental|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
33077747|NCT04891666|Experimental|Lactobacillus plantarum DSM 33464|1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
33077748|NCT04891666|Placebo Comparator|placebo|1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
33077749|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
33077750|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
33077751|NCT00202293|Experimental|Lithium and olanzapine|
33077752|NCT00202293|Active Comparator|Lithium and chlorpormazine|
33077753|NCT04870606|Active Comparator|GT0918+ standard of care|
33077754|NCT04870606|Placebo Comparator|placebo+ standard of care|
33077755|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
33077756|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
33077757|NCT00197730|Placebo Comparator|Placebo|Placebo
33077758|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
33077759|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
33077760|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
33077761|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
33077762|NCT00172172|Experimental|2|PTH 100 mcg and placebo
33077763|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
33077764|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
33261366|NCT00862914||3|cutaneous malignant melanoma
33261367|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
33261368|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
33261369|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
32736323|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
32736324|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
32736325|NCT00700999|Other|Arm 1|Intervention-Paroxetine
32736326|NCT00700999|No Intervention|Arm 2|No Intervention
33077765|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block at the end of the surgery."
33077766|NCT04865731|Experimental|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
32736327|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
32736328|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
33077767|NCT04865731|Active Comparator|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
33077768|NCT04804774|Experimental|WW program modified for people with Type 2 diabetes|Includes weekly Virtual Workshops and use of the WW App.
32736329|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
32736330|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
33077769|NCT04799938|Active Comparator|İntevention group|Prediabetic patients with age 30-50 and overweight Standart recommendations Exercise intervention will be made.
33077770|NCT04799938|No Intervention|Control group|Prediabetic patients with age 30-50 and overweight Only Standart recommendations
32736331|NCT03248869|Active Comparator|Current Daily Survey|need description
32736332|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
33077771|NCT04799938|No Intervention|Metformin Group|Prediabetic patients who received metformin Standart recommendations
33077772|NCT04798846|Active Comparator|External fixator|patient treated by external fixator
32736333|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
32736334|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
33077773|NCT04798846|Active Comparator|Dorsal plate|patient treated by dorsal spanning plate
33077774|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
33077775|NCT02908594|No Intervention|control group|The control group received routine care
32736335|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
33077776|NCT04791280||patients with systemic sclerosis|"On the day of inclusion, the faeces collection will be carried out by the patient using adapted equipment, either at the hospital or at home. In the case of a home collection, it will be carried out on the day of a planned hospital and preserved using equipment provided and tested to maintain the quality of the collection before storage.~6 months after inclusion (+/- 2 months) a follow-up visit will be carried out and the patient will perform a second faecal sample.~At the inclusion visit and at M6 the UCLA SCTC GIT 2.0 questionnaire will be completed by the patient."
33077777|NCT04723901|Experimental|Treatment group|Dual target CAR-T cell therapy
33077778|NCT04791241|Experimental|check-list with ultrasound|check-list including lung ultrasound for the management of patients with acute respiratory failure at the emergency department during the COVID-19 era
33077779|NCT04768855|Experimental|LY3540378 (Part A)|Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
33077780|NCT04768855|Experimental|LY3540378 (Part B)|Multiple ascending doses of LY3540378 administered SC.
33077781|NCT04768855|Experimental|LY3540378 (Part C)|Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
33077782|NCT04768855|Experimental|LY3540378 (Part D)|Multiple ascending doses of LY3540378 administered SC in Chinese Participants.
33077783|NCT04768855|Placebo Comparator|Placebo (Part A, B, C & D)|Placebo administered either IV or SC.
33077784|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
33077785|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
33077786|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
33077787|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
33077788|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
33077789|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
33077790|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
32736336|NCT04502771||Antifungal treatment|Patients receiving antifungal treatment during their stay in Intensive Care Unit
32736337|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
32736338|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
33401463|NCT05580250|Experimental|Part C: Iohexol + Simvastatin + Metformin + LY3526318|Iohexol administered intravenously (IV) and simvastatin, metformin, and LY3526318 administered orally.
33401464|NCT03663374|Experimental|Odelepan|One tablet once daily
32736339|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
32736340|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
33401465|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
33401466|NCT05676580|Other|Abstention|After keratoconus diagnosis the patient won't be assigned to intervention
33401467|NCT05676580|Other|Intervention (cross-linking surgery or intra corneal ring)|After keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery
33401468|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
33401469|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
32736341|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
32736342|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
32736343|NCT04502849||"Group Bypass (A)"|50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).
33401470|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
32736344|NCT04502849||"Group Endovascular (B)"|50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).
32736345|NCT04502849||"Group Hybrid (C)"|50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).
32736346|NCT04502849||"Group Conservative (D)"|50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).
32736347|NCT04502849||"Group Healthy volunteers (E)"|50 healthy subjects.
32736348|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
32736349|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
32736350|NCT04761887|Experimental|Cool Block|Ropivacaine administered at approximately 4C, via a TAP block.
32736351|NCT04761887|Active Comparator|Room Temp Block|Ropivacaine administered at approximately 20-25C, via a TAP block.
32736352|NCT05584007|Placebo Comparator|Intervention|Flucloxacillin 500mg four times a day (QDS) for 5 days (unblinded NHS prescription) followed by blinded placebo QDS for 2 days (5 days of antibiotic)
32736353|NCT05584007|Active Comparator|Control|Flucloxacillin 500mg QDS for 5 days (unblinded NHS prescription) followed by flucloxacillin 500mg QDS (blinded) for 2 days (7 days of antibiotic)
32736354|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
32736355|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
32736356|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
32736357|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
32736358|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
32736359|NCT03245905|Experimental|Chidamide|Chidamide should be given at a fixed time with fixed dosage
32736360|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
32736361|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
32736362|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
32736363|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
32736364|NCT05583695|Experimental|mindfulness-based music therapy|
32736365|NCT05583695|Experimental|mindfulness-based therapy|
32736366|NCT05583695|Active Comparator|routine care|
32736367|NCT03254641||hypogondal men|men referred for hCG stimulation test
32769601|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
32769602|NCT05018065|Active Comparator|50 women previously diagnosed with mild - medium Covid-19 and had ambulatory care|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
32769603|NCT05018065|Active Comparator|51 women having no Covid-19 history|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
32769604|NCT05023213|Experimental|Warna-Warni Waktu intervention|Participants in this condition will be asked to view six, approximately five minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
32769605|NCT05023213|No Intervention|Waitlist control condition|These participants will no be contacted during the intervention timeframe.
32769606|NCT05047393||Coccygodynia group|51 patients with a diagnosis of coccygodynia will be included in the study.
32769607|NCT05047081|Experimental|College Workshop Arm|Intervention
32769608|NCT05047081|Placebo Comparator|Placebo|Placebo
32769609|NCT05022745|Experimental|ERAS group|Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.
32769610|NCT05022745|Active Comparator|Standard group|Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative
32769611|NCT05017987|Active Comparator|Sequence A=Reference-Test|"T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012~First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose"
32769612|NCT05017987|Active Comparator|Sequence B=Test-Reference|First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose
32769613|NCT04465435||SUN-participants|"University students enrolled in a selected university in Stockholm, studying on a full-time educational program with at least one academic year left before graduation.~There is no intervention. The exposures are repeated measures, 5 times (every three months), using web-based self-report questionnaires during one academic year. Also weekley SMS are used to measure depression, anxiety and pain intensity."
32769614|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
32769615|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
32769616|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
32769617|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
32769618|NCT05022277|Experimental|Phone-based intervention Plus SMS messages|
32769619|NCT05022277|Experimental|SMS messages only|
32769620|NCT05022277|No Intervention|Control|
32769621|NCT05022043|Active Comparator|EOS|
32769622|NCT05022043|No Intervention|NO-EOS|
32769623|NCT05021887|Experimental|Test Product|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
32769624|NCT05021887|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK
32769625|NCT05022199|Experimental|Study Arm: SPY fluorescent angiography|
32769626|NCT05022199|No Intervention|Historic Control Arm: Urinary diversion without the use of SPY|This arm consists of 215 historic controls who have undergone urinary diversion at UVA from 2015-2020 without the use of SPY fluorescent angiography
32769627|NCT05021575||2020|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2020.
32769628|NCT05021575||2019|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2019.
33077791|NCT04760899|Active Comparator|Active Group|This group will receive the active form of tDCS. The tDCS will be administered with the anode over the right lobule of the cerebellum, and the cathode over the left lobule of the cerebellum. Stimulation will be administered for a twenty minute period that does not include the 30 second ramp up at the beginning and end of the stimulation.
32769629|NCT05021419|Active Comparator|Standard Arm|"Active Comparator: Standard Arm~Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:~Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started"
32769630|NCT05021419|Experimental|Streamlined protocol arm|"Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)~Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started~Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers."
32769631|NCT05021731|Active Comparator|3-month Isoniazid plus Rifampicin|Daily isoniazid 300 mg plus rifampicin 600 mg for three months
32769632|NCT05021731|Experimental|3-month Isoniazid plus Rifapentine|Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks
32769633|NCT05021731|Experimental|4-month Rifampicin|Daily rifampicin 600 mg for four months
32736368|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
32736369|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
32736370|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
32736371|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
33261370|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
33261371|NCT00866736|Experimental|dasatinib|
33077792|NCT04760899|Sham Comparator|Sham Group|This group will receive the sham form of tDCS. The electrodes will be placed in the same montage as in the Active group, however the stimulation parameters are different. For this group, the stimulation will be ramped up to the target intensity over thirty seconds at the beginning, then immediately ramp down over thirty seconds. The stimulation will then remain off for the next twenty minutes. After twenty minutes the stimulation will ramp up to the target intensity and then back down over thirty seconds.
33261372|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
33261373|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
33261374|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
33261375|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
33261376|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
33261377|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
32736372|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
32736373|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
33261378|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
33261379|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
33261380|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
33261381|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
32736374|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
32736375|NCT04487197||Cohort 1|"Adult patients (age ≥ 18 years),~kidney or pancreas or pancreatic islets transplantation~transplanted patients (period: 01.01.2020 to 30.06.2020)"
32736376|NCT04487197||Cohort 2|"Adult patients (age ≥ 18 years),~kidney or pancreas or pancreatic islets transplantation~Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020."
32736377|NCT04663997|Experimental|177 Lu-PSMA-617|
33261382|NCT00786578||1|overweight runners (BMI>25)
33261383|NCT00786578||2|lean runners (BMI<24)
33261384|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
32736378|NCT04663997|Active Comparator|Docetaxel|
33261385|NCT01071187|Placebo Comparator|Placebo|
33261386|NCT04008693|Active Comparator|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
33261387|NCT04008693|Placebo Comparator|Placebo|Maltodextrin
33261388|NCT00792896|Experimental|1|Family conference + education materials
33261389|NCT00792896|No Intervention|2|education materials
33261390|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
33261391|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
33261392|NCT00792974||COPD by GOLD-criteria III and IV|
33261393|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
32736379|NCT03248635||Focus group|Male and female adults age 40-75
33261394|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
33261395|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
33261396|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
33261397|NCT00917345||aldosteronism, hypertension|
33261398|NCT00917345||hypertension|
33261399|NCT00793052|Experimental|A|
33261400|NCT00859092|Experimental|Thickening of feeds|
32736380|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
32736381|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
32736382|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
32736383|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
32736384|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
33261401|NCT00859092|No Intervention|Removal of thickener|
33261402|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
32736385|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
32736386|NCT05582603|Experimental|Computerized Cognitive Training|Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones.
32736387|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
32736388|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
32736389|NCT04585685|Experimental|2 week baseline, CPT + SC|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
32736390|NCT04585685|Experimental|2 week baseline, SC + CPT|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
32736391|NCT04585685|Experimental|4 week baseline, CPT + SC|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
32736392|NCT04585685|Experimental|4 week baseline, SC + CPT|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
32736393|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
32736394|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
32736395|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
32736396|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
32736397|NCT03248323||pre-con|
32736398|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
32736399|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
32736400|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
32736401|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
32736402|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
32736403|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
32736404|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
32736405|NCT04553471|Experimental|SBRT|5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
32736406|NCT04502927|Other|Stroke patients with hand spasticity (n=20)|
32736407|NCT04502927|Other|Healthy volunteers (n=10)|
32736408|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
32736409|NCT05573399||Early oral feeding|No enteral feeding tube was placed after pancreaticoduodenectomy and oral nutrition was given early. Patients were given liquid drinks on the second day after pancreaticoduodenectomy, and solid food from the fifth day.
32736410|NCT05573399||Early nasojejunal enteral nutrition|Early enteral nutrition was given early through nasojejunal tube. 5% glucose saline was given on the first day after pancreaticoduodenectomy through nasojejunal tube. Enteral nutrition was given from the second day after pancreaticoduodenectomy. When oral intake was adequate, the nasojejunal tube was removed on the sixth day.
32736411|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
32736412|NCT03253939||Control group|Cytoreductive surgery alone
32736413|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
32736414|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
32736415|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
32736416|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
32736417|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
32736418|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
32736419|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
32736420|NCT03245281|Experimental|Diuretic Suspension (DS)|
32736421|NCT03245281|Experimental|Diuretic Increase (DI)|
32736422|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
32736423|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
32736424|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
32736425|NCT03248011|Experimental|Flexibility|Stretching exercise
32736426|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
32736427|NCT03248011|Experimental|Neuromuscular|Balance exercise
32736428|NCT03248011|No Intervention|Control|No exercise
32736429|NCT03253861||control patients|patients without an infected pancreatic necrosis
32736430|NCT03253861||Case patients|patients with an infected pancreatic necrosis
32736431|NCT04487275|Experimental|Drug|MLC901 capsules three times per day over 6 months
32736432|NCT04487275|Placebo Comparator|Placebo|Placebo capsules three times per day over 6 months
32736433|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
32736434|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
32736435|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
32736436|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
32736437|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.~Step Targets for Children in CBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
32736438|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.~Step targets for children and parents in FBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
32736439|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
32736440|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
32736441|NCT05565131|Experimental|PAtients requiring pedicle screw implantation|
32736442|NCT02516267|No Intervention|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
32736443|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
32736444|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
32736445|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
32736446|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
32736447|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
32736448|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
32736449|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
32736450|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
32736451|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
32736452|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
32736453|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
32736454|NCT03253471|Experimental|AL-611|
32736455|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
32736456|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
33261403|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
33261404|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
33261405|NCT04091009|Active Comparator|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
33261406|NCT04091009|Active Comparator|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
33261407|NCT00866892|Active Comparator|irrigation|
33261408|NCT00866892|Experimental|no irrigation|
33261409|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
32769634|NCT05009953|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
33077793|NCT04760899|No Intervention|Healthy Controls|These will be age and sex-matched healthy controls who only come in for the baseline visit in order to provide comparative values with which to confirm adequate impairment in our diseased population.
33261410|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
33261411|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
33261412|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
33261413|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
33261414|NCT00866970|Experimental|1|ALD518
33261415|NCT00866970|Experimental|2|ALD518
33261416|NCT00866970|Experimental|3|ALD518
33261417|NCT00866970|Placebo Comparator|4|No ALD518
33261418|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
33261419|NCT00783380|Experimental|Virosomal influenza vaccine|
33261420|NCT00783380|Active Comparator|Subunit influenza vaccine|
33261421|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
33261422|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
33261423|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
33261424|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.
33261425|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
33261426|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
33261427|NCT04041024|Experimental|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
33261428|NCT04041024|Other|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
33261429|NCT00793286|Other|A|Mesh fixation by staples
33261430|NCT00793286|Other|B|Mesh fixation by glue
33261431|NCT00859404|Experimental|1. oglemilast|
33261432|NCT00859404|Experimental|2. oglemilast|
33261433|NCT00859404|Experimental|3. oglemilast|
33261434|NCT00859404|Placebo Comparator|4. placebo|
33261435|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
33261436|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
33261437|NCT04008381|Experimental|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
33261438|NCT00786734|Experimental|Pitavastatin Group|
33261439|NCT00786734|Other|Usual Care Group|
33261440|NCT04089995||Coats + and LCC syndrome|
33261441|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
33261442|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
33261443|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
33261444|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
33261445|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
32736457|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736458|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
33261446|NCT00263887|Experimental|Group 1|Prolastin
33261447|NCT00263887|Placebo Comparator|Group 2|
33261448|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
32736459|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736460|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736461|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736462|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736463|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
32736464|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
33261449|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
33261450|NCT00960765||Roux-En-Y Gastric Bypass|
33261451|NCT00960765||Gastric Banding|
33261452|NCT00960765||Sucessful Response to RYGB|
33261453|NCT00960765||Failed Response to RYGB|
33261454|NCT00748553|Experimental|All patients|All participants enrolled.
33261455|NCT03974815|Experimental|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
33261456|NCT03974815|Sham Comparator|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
33261457|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
33261458|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
33261459|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
33261460|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
33261461|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
33261462|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
33261463|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
33261464|NCT02597465|Experimental|SPARC1507|SPARC1507
33261465|NCT02597465|Experimental|Chemotherapy|Chemotherapy
33261466|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
33261467|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
33261468|NCT04090931|Experimental|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):~0.014-inch HANT~0.016-inch HANT"
33261469|NCT04090931|Experimental|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):~0.014-inch SENT~0.016-inch SENT"
33261470|NCT00786812|Other|CAMN107A2109 Extension Patients|
33261471|NCT00786812|Other|AMN107 Naive|
33261472|NCT04008147|Active Comparator|No GDM, non-anemic|12 women with no gestational diabetes who are not anemic
33261473|NCT04008147|Active Comparator|No GDM, anemic|12 women with no gestational diabetes who are anemic
33261474|NCT04008147|Experimental|GDM, non anemic|12 women with gestational diabetes who are not anemic
33261475|NCT04008147|Experimental|GDM, anemic|12 women with gestational diabetes who are anemic
33261476|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
33261477|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
33261478|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
33261479|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
33261480|NCT00867282|Experimental|Treatment A|
32736465|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
32736466|NCT03244813|Experimental|Adapted physical activity|
32736467|NCT03244813|No Intervention|Standard care|
32736468|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
32736469|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
32736470|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:~before fluid challenge~after fluid challenge~During each phase, the subjects will be studied at:~baseline - spontaneously breathing~head down position - spontaneously breathing~baseline - positive pressure ventilation~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
32736471|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
32736472|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
33261481|NCT00867282|Active Comparator|Treatment B|
33261482|NCT00263575|Experimental|sublingual fentanyl tablet|
33261483|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
33261484|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
33261485|NCT00748241|Experimental|Astra Tech Fixture ST|
33261486|NCT00570128|Active Comparator|Donepezil HCl|
33261487|NCT00570128|Placebo Comparator|Placebo|
33261488|NCT05108415||Cohort A|"Blood specimen collection.~Study samples must be collected prior to any treatment."
33261489|NCT05108415||Cohort B|"Blood specimen collection.~Samples must be collected prior to perform the ultrasonography."
33261490|NCT05108415||Cohort C|"Blood specimen collection.~Study samples must be collected prior to any treatment."
33261491|NCT04042194|Experimental|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
32736473|NCT03345797|Experimental|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
32736474|NCT03345797|Experimental|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
33261492|NCT04042194|Active Comparator|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
33261493|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
33261494|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
33261495|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
33261496|NCT00863382|Active Comparator|1|Standard Event Monitor
33261497|NCT00863382|Active Comparator|2|Sleuth recorder
32736475|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
32736476|NCT04500743|Active Comparator|Dienogest|
33261498|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
33261499|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
33261500|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
33261501|NCT00973089|No Intervention|Complete caries removal|Control group
33261502|NCT00973089|Other|Incomplete caries removal|Test group
33261503|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
33261504|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
33261505|NCT00262951|Experimental|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
33261506|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
33261507|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
33261508|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
33261509|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
33261510|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
33077794|NCT04756999|Experimental|Intervention|informed consent forms, nine sessions of foot reflexology massage will be given to reflex points including the solar plexus, brain, pituitary, thyroid, diaphragm, upper lymphs, lung, spinal cord and adrenal glands for 3 weeks. Then data collection tools were applied.
33077795|NCT04756999|Placebo Comparator|Control|informed consent forms, foot massage were performed. Then data collection tools were applied.
33077796|NCT02908555||no intervention|Descriptive study without groups
33261511|NCT00867438|Placebo Comparator|1|
32769635|NCT05009953|Experimental|Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
33261512|NCT00867438|Experimental|2|
32769636|NCT05009407||HOSTS|patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
33261513|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
33077797|NCT02908321|Active Comparator|CBT|
33077798|NCT02908321|No Intervention|WL|
33261514|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
33261515|NCT00786890||no treatment|observational, no treatment needed
32769637|NCT05009407||DONORS|grafts from donors that would be analyzed
33261516|NCT04089215|Experimental|JWCAR029 treatment|JWCAR029 be administrated in two dose level
33077799|NCT04743895|Active Comparator|Stainless Steel Wire Cerclage|Sternotomy closure using Stainless Steel Wire Cerclage
33261517|NCT00262873|Experimental|Bortezomib|
33261518|NCT00867516|Experimental|1|ALD518 80 mg
33261519|NCT00867516|Experimental|2|ALD518 160 mg
32769638|NCT05009641|Experimental|carnitine2|2000 mg L-carnitine per day for 24 weeks
33261520|NCT00867516|Experimental|3|ALD518 320 mg
33261521|NCT00867516|Placebo Comparator|4|No ALD518
33261522|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
33261523|NCT00975819|Experimental|Sirolimus|
33261524|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
32769639|NCT05009641|Active Comparator|carnitine|1000 mg L-carnitine per day for 24 weeks
33077800|NCT04743895|Active Comparator|FiberTape Cerclage|Sternotomy closure using FiberTape
33077801|NCT04742296|Active Comparator|Treatment group of low level laser therapy|
33077802|NCT04742296|Placebo Comparator|Sham group of low level laser therapy|
33261525|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
33261526|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
33261527|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of >30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
33401471|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
32769640|NCT05009641|No Intervention|control|no supplementation
33077803|NCT04731844|Experimental|Prostate Cancer|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
33077804|NCT04731844|Experimental|Smoldering Multiple Myeloma (SMM)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
33077805|NCT04731844|Experimental|Monoclonal Gammopathy of Unknown Significance (MGUS)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
33077806|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
33077807|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
33077808|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
33077809|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
33077810|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
33077811|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
33077812|NCT04716244||Gestational diabetes|Women who were diagnosed with gestational diabetes within the least year
33077813|NCT04716244||Pre-eclampsia|Women who were diagnosed with pre-eclampsia within the past year
33077814|NCT04710394|Active Comparator|Unimodal Olfactory Training with Conventional Odors|Participants will undergo smell training without a visual component, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
33261528|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
33261529|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
33261530|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
33261531|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
33261532|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
32736477|NCT04500743|Active Comparator|GnRH analogue|
32736478|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
33261533|NCT00859872|Active Comparator|IM group|haloperidol IM injection
33261534|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
32736479|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
32736480|NCT04500431|Experimental|spCART-269|spCART-269 administered by intravenous (IV) infusion
32736481|NCT02623699|Experimental|Single Ascending Dose|Part A: Randomized single ascending dose
32736482|NCT02623699|Experimental|Multiple Ascending Dose|Part B: Randomized multiple ascending dose
32736483|NCT02623699|Experimental|Fixed Dose|Part C: Fixed Dose
32736484|NCT04303715|Experimental|No SLNB group|The study arm - BCS without SLNB
32736485|NCT04303715|Other|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
32736486|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
32736487|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
32736488|NCT04279847|Experimental|INCB057643 Monotherapy|INCB057643 dose escalation (Part 1) and dose expansion (Part 2: treatment group A).
32736489|NCT04279847|Experimental|INCB057643 Combination with Ruxolitinib|Combination arm in dose escalation (Part 1) and dose expansion (Part 2: Treatment Group B)
32736490|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
32736491|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
32736492|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
33261535|NCT03974659|Active Comparator|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
33261536|NCT03974659|Sham Comparator|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
32736493|NCT04501991||Patients with Type 2 Diabetes|Patients with type 2 diabetes and a scheduled visit during the lockdown for COVID-19
32736494|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
32736495|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
32736496|NCT04501601|Experimental|Experimental: weight loss program kit|weight loss program kit
32736497|NCT04501445|Experimental|Rounding Summary|Surrogates who were assigned to the intervention group received a written rounding summary every day or every other day that the patient is in the ICU.
32736498|NCT04501445|No Intervention|Usual Care|
32736499|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
32736500|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
32736501|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
32736502|NCT03244657|Experimental|Q12W group|
32736503|NCT03244657|Experimental|TAE group|
32736504|NCT03346499|Experimental|NK cells and IL-2|
32736507|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
32736508|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
32736509|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
32736510|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
32736511|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
33261537|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
33261538|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
33261539|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
32736512|NCT04164563|No Intervention|Control|Standard CAM boot treatment without Even-Up device.
33261540|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
32736513|NCT04164563|Experimental|Study|CAM boot treatment with Even-Up for contralateral extremity.
33261541|NCT05147493|Experimental|Single-arm|"Eligible patients will initially receive an induction phase of six 28-day cycles of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by a maintenance phase with isatuximab and lenalidomide until disease progression, death, unacceptable adverse events (AEs), lost to follow up, or consent withdrawal, whichever occurs first.~Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.~Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Cyclophosphamide will be given at 300 mg/m2 on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.~Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards."
33261542|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
32736514|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
32736515|NCT03345641||dyads|dyads with babies and their mothers
32736516|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
32769641|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
32769642|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
33261543|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
33261544|NCT04090385|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
33261545|NCT04090385|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
33261546|NCT04090385|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
33261547|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
33261548|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
33261549|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
33261550|NCT03974425|Other|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
33261551|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
33261552|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
32769643|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
32769644|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
32769645|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
33077815|NCT04710394|Experimental|Unimodal Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training without a visual component, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
33077816|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Conventional Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
33077817|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
33077818|NCT04675255|Active Comparator|Immediate switch|Immediate switch
33077819|NCT04675255|Active Comparator|Delayed switch|Delayed switch
33077820|NCT04673539||Single group|Instrument validation in stroke patients
33077821|NCT04673266|Experimental|romiplostim|Romiplostim will be administered from the beginning of the next chemotherapy cycle with a starting dose of 3 mcg/kg subcutaneously. Dose will be titrated based on nadir of the platelet counts during the prior cycle. The maximum dose of romiplostim will be 6 mcg/kg.
33077822|NCT04632316|Experimental|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
33077823|NCT04630327||Female Cancer Patients|Female cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center or Kazakh Scientific Research Institute of Oncology and Radiology
33077824|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
33077825|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
33077826|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
33077827|NCT02908204||Traditional surgery|Patients underwent traditional surgery
33077828|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
33077829|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
33077830|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
33077831|NCT04576507|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
33077832|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
33077833|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
33077834|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
33077835|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
33077836|NCT04569877|Experimental|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
33077837|NCT04569877|Placebo Comparator|Placebo nebuliser solution|Placebo nebuliser solution
33077838|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
33077839|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
33077840|NCT04534270|Experimental|Dapagliflozin treatment|
33077841|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
33077842|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
32736517|NCT04156919|Experimental|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
33261553|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
33261554|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
32736518|NCT04156919|Experimental|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
32736519|NCT04156919|Active Comparator|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
32736520|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
32736521|NCT03239353|Active Comparator|3 mg ETV XR tablet|
32736522|NCT03239353|Active Comparator|6 mg ETV XR tablet|
32736523|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
32736524|NCT03239353|Other|0.5 mg ETV IR tablet|
32736525|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
32736526|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
32736527|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
32736528|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
32736529|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
32736530|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
32736531|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
32736532|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
33077843|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be 60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
33077844|NCT04492540|Other|The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet program|the control group will receive MIND diet program for 12 weeks
33077845|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
33077846|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
33077847|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
33077848|NCT04455334|Other|healthy|year 1 study
33077849|NCT04455334|Other|stroke|year 1 study
33077850|NCT04455334|Active Comparator|active control group|year 2 study
33077851|NCT04455334|Experimental|Error-augmented treadmill training|year 2 study
33261555|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
33261556|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
33261557|NCT05145231||grup 1|GMFCS PEDİ ABİLOCO-KİDS FMS
33077852|NCT04455334|Experimental|Error-augmented concept combined physical therapy group|year 3 study
33261558|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
33077853|NCT04455334|Active Comparator|conventional physical therapy group|year 3 study
33261559|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
33261560|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
33077854|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
33261561|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
32736533|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
32736534|NCT04486651|Experimental|HX008 plus Irinotecan|Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
32736535|NCT04486651|Placebo Comparator|Placebo plus Irinotecan|Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
32736536|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
32736537|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
32736538|NCT04088591|Experimental|Treatment arm|The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
32736539|NCT04088591|Placebo Comparator|Placebo arm|The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
32736540|NCT04501289|Experimental|Low dose magnesium sulphate|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive low dose magnesium sulphate
32736541|NCT04501289|Experimental|Magnesium sulphate Pritchard regimen|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive Pritchard regimen of magnesium sulphate
32736542|NCT03244345|Experimental|Epileptic patient|
32736543|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
32736544|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
32736545|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
32736546|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
32736547|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
32736548|NCT02453971|No Intervention|control|It is an assessment only condition.
32736549|NCT05559047|Experimental|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
32736550|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
32736551|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
32736552|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
32736553|NCT04501367|Experimental|DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
32736554|NCT04501367|Experimental|Second DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
32736555|NCT04501367|Experimental|Topical Prednisolone Acetate 1% Group|Patients undergoing vitrectomy with internal limiting membrane peel
32736556|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
32736557|NCT03347357|Experimental|tacrolimus|
32736558|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
32736559|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
32736560|NCT03346421||diet and physical activity|
32736561|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
32736562|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
32736563|NCT03952091|Experimental|TJ202, Lenalidomide and Dexamethasone|
32736564|NCT03952091|Active Comparator|Lenalidomide and Dexamethasone|
32736565|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
32736566|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
32736567|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
33261562|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
33261563|NCT04040868|Other|robot-assisted technique|
33261564|NCT04040868|Other|conventional fluoroscopy-assisted technique|
33261565|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
33261566|NCT03974269|Active Comparator|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
33261567|NCT03974269|Placebo Comparator|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
32736568|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
33077855|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
33261568|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
33261569|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
32736569|NCT05555537||Drug resistant epilepsy|failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications
33261570|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
33261571|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
33261572|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
32736570|NCT05555537||Medically controled epilepsy|seizure freedom for at least the last 6months) matched in sex and age.
32736571|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
32736572|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
33261573|NCT00793676|Other|A= Asthma|
33261574|NCT00793676|Other|B= COPD|
33261575|NCT00793676|Other|C= Control|
32736573|NCT04502537||Roxadustat|treatment with roxadustat
32736574|NCT04502537||erythropoietin|treatment with erythropoietin
33077856|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
33261576|NCT00863538|Experimental|1|
33261577|NCT00260533|Experimental|1|Atomoxetine
33261578|NCT00260533|Placebo Comparator|2|Placebo
33261579|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
33261580|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
33261581|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
33261582|NCT00973245|Experimental|Arm 1|
33261583|NCT00973245|Experimental|Arm 2|
33261584|NCT00973245|Active Comparator|Arm 4|
33261585|NCT00973245|Experimental|Arm 3|
33261586|NCT00793754|No Intervention|1|
33261587|NCT00793754|Experimental|2|Aspirin 100 mg / day
33261588|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
33261589|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
33261590|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
33261591|NCT03976141||a|
33261592|NCT00793832|Active Comparator|1|Supervised exercise.
33261593|NCT00793832|Active Comparator|2|Diet Advice
33261594|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
33261595|NCT00973323|Experimental|Arm 1|
33261596|NCT00973323|Experimental|Arm 2|
33261597|NCT00973323|Experimental|Arm 3|
33261598|NCT00973323|Active Comparator|Arm 4|
33261599|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
33261600|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
33261601|NCT00973401||Diabetic individuals|
33261602|NCT04040322|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
33261603|NCT04040322|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
33261604|NCT00787358|Active Comparator|ZT-031|
33261605|NCT00787358|Placebo Comparator|Placebo|
33261606|NCT00794066||1|TIA
32736575|NCT03246997|Other|Autumn Group|Intervention Group
33261607|NCT00794066||2|Ischemic stroke
33261608|NCT00794066||3|Hemorrhagic stroke
32736576|NCT03246997|Other|Spring Group|Delayed Intervention
32736577|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
33261609|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
32736578|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
32736579|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
32736580|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
32736581|NCT02515799|Active Comparator|Tacholiquine|Inhalation
32736582|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
32736583|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $35 credit for groceries.
32736584|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $35 credit for groceries.
33261610|NCT00784004|Other|Volunteers|Ten healthy volunteers
33261611|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
32935563|NCT05377411|Experimental|Optimized tDCS + Cognitive Training|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of up to 4.0mA direct current through two biocarbon rubber electrodes covered with at least 5mm-thick conductive electrode paste buffer, and placed over the optimized locations based on the international 10-20 system by using a combination of 10-20 EEG cap measurement and a stereotactic neuronavigation system. Stereotactic neuronavigation will be used as needed and may not be used on all participants.
32935564|NCT05377411|Sham Comparator|Sham tDCS + Cognitive Training|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of up to 4 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
32935565|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
33261612|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
32736585|NCT03802955|Experimental|ADG106 Dose escalation|
32736586|NCT03239431||Asthma group|Patients with asthma
32736587|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
32736588|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
32736589|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
32736590|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
33261613|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
33261614|NCT00787436|No Intervention|1|Standard of care with normal treatment
33261615|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
33261616|NCT03945981|Experimental|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
33077857|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
33261617|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
33261618|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
33261619|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
33261620|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
33261621|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
33261622|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
33261623|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
33261624|NCT00784160|Experimental|1|Lactic Acid
33261625|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
33261626|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
33261627|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
33261628|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
33261629|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
33261630|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
33261631|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
33261632|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
33261633|NCT00794300||Acute myocardial infarction patients|
33261634|NCT00787592||Silver Sulfadiazide (SSD)|Patients that receive SSD as the topical debriding agent
33261635|NCT00787592||Collagenase|Patients that receive collagenase as the debriding agent
33261636|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
33261637|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
33261638|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
33261639|NCT00863850|Experimental|1|
33261640|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
33261641|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
33261642|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
33261643|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
33261644|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
33261645|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
33261646|NCT00784316|Active Comparator|metoprolol|
33261647|NCT00784316|Active Comparator|amiodarone|
33261648|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
33261649|NCT00286429|Placebo Comparator|Insulin|
33261650|NCT00286429|Experimental|Alogliptin 12.5 mg QD|
33261651|NCT00286429|Experimental|Alogliptin 25 mg QD|
33261652|NCT00665444|Experimental|A|Aripiprazole
33261653|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
33261654|NCT00860418|Experimental|2 PAAL|PAAL
33261655|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
33261656|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
33261657|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
33261658|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
33261659|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
33261660|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
33261661|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
33261662|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
33261663|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
33261664|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
33261665|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
33261666|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
33077858|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
33261667|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
33261668|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
33261669|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
32769646|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
33077859|NCT02907580|Experimental|Local educational data|Local-based educational handout
33077860|NCT02907580|Experimental|National educational data|National-based educational handout
33077861|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
33261670|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
33261671|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
33261672|NCT03926169|Experimental|Risankizumab 180 mg|In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
33261673|NCT03926169|Experimental|Risankizumab 360 mg|In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
33261674|NCT03926169|Placebo Comparator|Placebo|In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
33077862|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
33077863|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
33261675|NCT03926169|Experimental|Risankizumab 180 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg every 8 weeks (q8w) at Weeks 20, 28, 36, 44, 52, and 60."
33261676|NCT03926169|Experimental|Risankizumab 360 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
33261677|NCT03926169|Placebo Comparator|Placebo / Risankizumab 360 mg|"In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded risankizumab 360 mg at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
33261678|NCT00860808|Experimental|1 AM-101|low dose
33261679|NCT00860808|Experimental|2 AM-101|high dose
33261680|NCT00860808|Placebo Comparator|3 Placebo|
33261681|NCT00285649|Experimental|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
33261682|NCT00285649|Experimental|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
33261683|NCT00285649|Active Comparator|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
33261684|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
33261685|NCT00795392||1|Patients assessed with ASA physical status scale
33261686|NCT00795392||2|Patients assessed with full-scale psychological factors
33261687|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
33261688|NCT02554370|No Intervention|Usual care|No psychoeducational programme
33261689|NCT04018404|No Intervention|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
33261690|NCT04018404|Experimental|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
33261691|NCT04936880|Experimental|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
32769647|NCT04294459|Experimental|Phase 1|Isatuximab dose level 1 or dose level minus 1 depending on predefined unacceptable toxicities observed.
33261692|NCT04936880|Active Comparator|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
33261693|NCT00979641|Experimental|chemoterapy|docetaxel/paclitaxel + bevacizumab
33261694|NCT00788060|Experimental|RAD001|
32769648|NCT04294459|Experimental|Phase 2: Cohort A|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with living donor.
32769649|NCT04294459|Experimental|Phase 2: Cohort B|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with no living donor cleared for donation.
33261695|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
33261696|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
33261697|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
33261698|NCT00788138|Placebo Comparator|2|Matching Placebo
33261699|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
32935566|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
32935567|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
33077864|NCT04682080|Active Comparator|Needle-free injection group|In needle-free injection techniques, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using the Comfort-In system. Pain intensity and anxiety levels of patients were measured.
33261700|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
33261701|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
33261702|NCT00864396|Experimental|Prevacid|
33261703|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
33261704|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
33261705|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
33261706|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
33261707|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
33261708|NCT04090073|Experimental|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
33261709|NCT04090073|Active Comparator|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
33261710|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
33261711|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
33261712|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
33261713|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
33261714|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
33261715|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
33261716|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
33261717|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
33261718|NCT00976365|Experimental|THL-P|Solution for study only.
33261719|NCT00976365|Placebo Comparator|Sugar pill|THL-p
33261720|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
33261721|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
33261722|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
33261723|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
33261724|NCT00663260|Placebo Comparator|Placebo|
33261725|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
33261726|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
32736591|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
32736592|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
32769650|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
32769651|NCT05610813|Experimental|Test intervention: VER-01|
33261727|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
33261728|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
33261729|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
33261730|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
33261731|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
33261732|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
33261733|NCT04988841|Experimental|Fecal microbiotherapy (MaaT013) associated to ipilimumab and nivolumab|Fecal microbiotherapy MaaT013 (actif arm) enemas will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
33261734|NCT04988841|Placebo Comparator|fecal microbiotherapy Placebo associated to ipilimumab and nivolumab|Placebo fecal microbiotherapy will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
33261735|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
33261736|NCT00800618|Placebo Comparator|Placebo|Placebo
33261737|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
33261738|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
33261739|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
33261740|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
33261741|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
33261742|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
33261743|NCT00980187|Active Comparator|Hydrochlorothiazide|
33261744|NCT00980187|Experimental|Indapamide SR|
33261745|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
33261746|NCT00795470|Active Comparator|Antimicrobial and catheter change|
33261747|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
33261748|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
33261749|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
33261750|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
33261751|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
33261752|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
33261753|NCT00284089|Experimental|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
33261754|NCT00284089|Experimental|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
33261755|NCT00284089|Experimental|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
33261756|NCT00284089|Experimental|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
32736593|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
32736594|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
32736595|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
33261757|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
33261758|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
33261759|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
33261760|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
33077865|NCT04682080|Active Comparator|Dental injection group|In the conventional dental-injection method, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using a 27G, 50-mm, disposable syringe with a needle. Pain intensity and anxiety levels of patients were measured.
32736596|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
32736597|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
32736598|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
33077866|NCT00407732|No Intervention|SC|standard care
33077867|NCT00407732|Experimental|INT|psychosocial intervention
32736599|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
32736600|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
32736601|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
33077868|NCT04682119|Experimental|LY3526318 (Part A)|LY3526318 administered orally as single ascending doses.
33077869|NCT04682119|Experimental|LY3526318 (Part B)|LY3526318 administered orally as multiple doses.
33077870|NCT04682119|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
33077871|NCT04682119|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
33077872|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
33077873|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
33077874|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
33077875|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
33077876|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
32736602|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
32736603|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
33077877|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
33077878|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
33077879|NCT02907424|Active Comparator|BP-100|standard treatment
33077880|NCT02907424|Experimental|Num Trey|locally produced RUTF
33077881|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
33077882|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
33077883|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
33077884|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
33077885|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
32736604|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
33077886|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
33077887|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
33077888|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
33077889|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
33077890|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
33077891|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
33077892|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
33077893|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
33077894|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
33077895|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
33077896|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
33077897|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
33077898|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
33077899|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
33077900|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
33077901|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
33077902|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
33077903|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
33077904|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
33077905|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
33077906|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
33077907|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
33077908|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
33077909|NCT04723550|Experimental|Telemedicine|Diabetes education and support by telemedicine
33077910|NCT04723550|Active Comparator|Usual care|Diabetes education and support in person
33077911|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
33077912|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
33077913|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
33077914|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
33077915|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
33077916|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
33077917|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
33077918|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
33077919|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
33077920|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
32736605|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
32736606|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
32736607|NCT03707093|Experimental|ADG106 Dose escalation|
32736608|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
32736609|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
32736610|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
32736611|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
32736612|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
32736613|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
32736614|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
32769652|NCT05610813|Active Comparator|Comparative intervention: Opioid therapy (with an authorised and marketed opioid, ATC code N02A)|
32769653|NCT05412615|Experimental|Meniscal Allograft with PRC|These patients will receive a tissue allograft with their wrist reconstruction procedure.
33077921|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
33077922|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
33077923|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
33077924|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
33077925|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
33077926|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
33077927|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
33077928|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
33077929|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
33077930|NCT04678219|Experimental|Low-Protein/Vegan/Low-Sulfur Diet|This is a specific diet that is both vegan and low in protein. The vegan diet eliminates all animal products, (including meats, eggs, dairy products) and animal by-products such as honey.
33077931|NCT04678219|Experimental|Specific Carbohydrate Diet|"The Specific Carbohydrate Diet emphasizes consumption of specific carbohydrates that require minimal digestion. Therefore, it eliminates most carbohydrates, including grains, starches, dairy and sugars.~The idea behind this diet is that it reshapes the microbiome of the intestines. The diet restricts the intake of certain carbohydrates that may increase the growth of bad bacteria possibly contributing to inflammation. By restricting the amount of these carbohydrates in the microbiome, the diet aims to reduce their activity in the gut and reduce inflammation."
33077932|NCT04677868|Experimental|MTX and corticosteroid|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
33077933|NCT00198393|Experimental|A|Gefitinib
33077934|NCT00198393|Experimental|B|Gemcitabine
33077935|NCT00198393|Experimental|C|Docetaxel
33077936|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
33077937|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
33077938|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
33077939|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
33077940|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
32736615|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
32736616|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
32736617|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
32736618|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
32736619|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
32736620|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
33077941|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
33077942|NCT00554827|Experimental|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
33077943|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
33077944|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
33077945|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
32736621|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
32736622|NCT05584553||ToggleLoc 2.9 mm soft tissue device|Patients who already received the ToggleLoc 2.9 mm soft tissue device in the shoulder. No additional surgery will be performed.
33077946|NCT04677790|Active Comparator|"Very short arm (12 months)"|Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.
33261761|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
32736623|NCT05584553||JuggerLoc soft tissue device|Patients who already received the JuggerLoc soft tissue device in the shoulder. No additional surgery will be performed.
32736624|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
32736625|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
32769654|NCT05412615|Placebo Comparator|PRC only|These patients will receive the standard proximal row carpectomy procedure.
32769655|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
33261762|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:~10mg daily"
33261763|NCT00864474||Maraviroc Tablets|Patients administered.
33261764|NCT00283387|Experimental|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
33261765|NCT00283387|Placebo Comparator|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
33261766|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
33261767|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
33261768|NCT00976833|Active Comparator|Usual Care|Usual Care
33261769|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
33261770|NCT00788294|Active Comparator|10 mg IV|
33261771|NCT00788294|Active Comparator|5 mg SC|
33261772|NCT00788294|Active Comparator|10 mg SC|
33261773|NCT00788294|Active Comparator|19 mg SC|
33261774|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
32736626|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
32736627|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
32736628|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
32736629|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
32736630|NCT03581357|Active Comparator|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
32736631|NCT03581357|Active Comparator|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
32736632|NCT03581357|Active Comparator|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
32736633|NCT03581357|Active Comparator|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
32736634|NCT03489707|Experimental|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
32736635|NCT03489707|Active Comparator|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
32736636|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
32736637|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
33261775|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
33261776|NCT00282919|Experimental|Azithromycin plus chloroquine|Single Arm, Open label study
33261777|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
33261778|NCT00984789|Experimental|Arm 1|
33261779|NCT00984789|Active Comparator|Arm 2|
33261780|NCT00864552||Group 1|
33261781|NCT03975673|Active Comparator|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique~medializing the hip center of rotation~obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
33261782|NCT03975673|Experimental|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique~restoring the acetabular center of rotation~restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.~making personalized choice for the hip component design~considering additional spine surgery based on the assessment of the individual spine-hip relation."
33261783|NCT04046822|Active Comparator|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
33261784|NCT04046822|Placebo Comparator|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
33261785|NCT04007835|Experimental|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
33261786|NCT00795626|Experimental|Lifestyle counseling|"Two groups:~control - conventional care~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
33261787|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
33261788|NCT00867984|Active Comparator|2|AV optimization only.
33261789|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
33261790|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
32736638|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
32736639|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
32736640|NCT03238573||optical enhancment endoscopy|
33261791|NCT00868062|Experimental|1|
32736641|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
32736642|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
33261792|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
33261793|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
32736643|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
33261794|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
32736644|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
32736645|NCT04486339|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
32736646|NCT03345329||Periodontal patient|
32736647|NCT03345329||Healthy person|
32736648|NCT03345329||Peri-implantitis patient|
32736649|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
32736650|NCT03243799|No Intervention|Control Group|Usual clinical care
32736651|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
32736652|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
33261795|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
33261796|NCT00860886||1|Mongolian Women
33261797|NCT00860886||2|Women in other parts of the world other than Mongolia.
32736653|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
33261798|NCT00282295|Experimental|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
33261799|NCT00282295|Experimental|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
33261800|NCT00282295|Experimental|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
33261801|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
33261802|NCT00663026|Experimental|A|5 mg/week
33261803|NCT00663026|Experimental|B|10 mg/week
33261804|NCT00663026|Experimental|C|Placebo
33261805|NCT00280735|Other|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
33261806|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
33261807|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
33261808|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
32736654|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
32736655|NCT03403361|Active Comparator|Arm A: Conventional SECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine single-energy computed tomography (SECT) or DECT scans~In Arm A, patients are treated with treatment plans optimized and calculated on the SECT data. Plan dose is re-calculated for every patient with the clinical plan in a Monte Carlo dose calculation engine for better accuracy. The investigators will use TOPAS, an extension of Geant4 simulation toolkit, as the dose calculation engine.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
32736656|NCT03403361|Experimental|Arm B1: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B1, DECT data is used to estimate the actual dose delivered using the clinical plan based on SECT data.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
32736657|NCT03403361|Experimental|Arm B2: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B2, the plan is re-optimized on DECT data with the conventional uncertainty margin of 3.5% of proton range.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
33077947|NCT04677790|Active Comparator|"Short arm (20 months)"|Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
32736658|NCT03403361|Experimental|Arm B3: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B3, the plan is re-optimized on DECT data with the SPR uncertainties derived from the patient-specific uncertainty model developed.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
32736659|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
33077948|NCT04677556|Other|Severe acute bronchiolitis|Infants under 6 months admitted in Pediatric Intensive Care Unit for a severe acute bronchiolitis needing NIV (modified Woof clinical asthma score (WCAS) >4 and/or hypercapnic acidosis (pH<7,3 and/or pCO2>50mmHg)
32736660|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
32769656|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
33261809|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
33261810|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
33261811|NCT03975283|Experimental|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
33077949|NCT04677673|Experimental|NAC PLUS SURGERY|Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.
33261812|NCT03975283|Active Comparator|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
33261813|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
33261814|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
33261815|NCT00795782|No Intervention|NoCND|No central lymph node dissection
33261816|NCT01070407|Experimental|Arm A, group 1|4 volunteers
33261817|NCT01070407|Experimental|Arm A, group 2|4 volunteers
32769657|NCT05385159|Experimental|ADSVF group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
33077950|NCT04677673|Active Comparator|SURGERY FIRST|Patients undergo curative gastrectomy without any prior chemotherapy.
33077951|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
33077952|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
33077953|NCT04677634|Other|Tolerability Arm|This is a single arm study. All subjects will receive the test material. The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily for 30 days.
33077954|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
33077955|NCT02078674|Experimental|Group A|Placebo
33077956|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
33261818|NCT01070407|Experimental|Arm A, group 3|5 volunteers
33261819|NCT01070407|Experimental|Arm B, group 5|4 volunteers
33261820|NCT01070407|Experimental|Arm B, group 6|4 volunteers
33261821|NCT01070407|Experimental|Arm B, group 7|5 volunteers
33261822|NCT01070407|Experimental|Arm C, group 9|5 volunteers
33261823|NCT01070407|Experimental|Arm C, group 10|5 volunteers
33261824|NCT01070407|Experimental|Arm C, group 11|4 volunteers
33261825|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
33261826|NCT00801086|Placebo Comparator|2|Vehicle
33261827|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
33077957|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
33077958|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
33261828|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
33261829|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
33261830|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
33077959|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
32736661|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
32736662|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
33261831|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
33261832|NCT00795860|Active Comparator|Weight loss - diet only|
33261833|NCT00795860|Experimental|Weight loss plus exercise|
33261834|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
32736663|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
32769658|NCT05385159|Placebo Comparator|Placebo group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
33261835|NCT00795938|Experimental|Experimental Tablet With Water|
33077960|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
33261836|NCT00795938|Experimental|Experimental Tablet Without Water|
33261837|NCT00260065|Experimental|1|
33261838|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
33261839|NCT01072435|Active Comparator|patient-controlled sedation|PCS
33261840|NCT01072435|Active Comparator|target-controlled infusion|TCI
33261841|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
33261842|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
33261843|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
33261844|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
33261845|NCT00796172|Active Comparator|2|Usual care
33261846|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
33261847|NCT01071655|Active Comparator|1|BVZ + XELOX
33261848|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.~Establishment of an infusion G5 500cc% in vein custody."
33261849|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
33261850|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
33261851|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
33261852|NCT04046510|Active Comparator|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
33261853|NCT04046510|Experimental|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
33261854|NCT04046510|Experimental|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
33261855|NCT00788762||Villagers in Taxiarchis|
33261856|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
33261857|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
33261858|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
33261859|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
33261860|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
33261861|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
33261862|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
33261863|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
33261864|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
32769659|NCT05009563|Experimental|Inpatients with RT-PCR proven SARS-CoV-2 infection|Inpatients with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection of the Department of Pulmonology of Semmelweis University who will undergo whole-body FDG-PET/CT
33261865|NCT00788840|Active Comparator|1. Insulatard|
33261866|NCT00788840|Active Comparator|2. Detemir|
33261867|NCT00258895|Experimental|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
33261868|NCT00258895|Experimental|Pentacel Primed|Participants received Pentacel in Study P3T06
33261869|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
33261870|NCT00801710|Experimental|BridgePoint Medial System|
33261871|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
33261872|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
33261873|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
33261874|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
33261875|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
33077961|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
33261876|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261877|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261878|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261879|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261880|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261881|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33261882|NCT00796250|Experimental|Group A|
33261883|NCT00796250|Active Comparator|Group B|
33261884|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
33261885|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
33261886|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
33261887|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
33261888|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
32769660|NCT05009563|Active Comparator|patients undergoing FDG-PET/CT for oncological indication|Age- and gender-matched group of patients undergoing FDG-PET/CT for oncological indication in the same time period
33077962|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
33077963|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
33077964|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
33261889|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
33261890|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
33261891|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
33077965|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
33261892|NCT00246805|Experimental|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
33261893|NCT00246805|No Intervention|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
33261894|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
33261895|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
33261896|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
33261897|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
33261898|NCT03973879|Experimental|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
33261899|NCT00519376|Experimental|GW642444M 25mcg|
33261900|NCT00519376|Experimental|GW642444M 50mcg|
33261901|NCT00519376|Experimental|GW642444M 100mcg|
33261902|NCT00519376|Experimental|GW642444H 100mcg|
33261903|NCT00519376|Experimental|placebo|
33261904|NCT00860964|Placebo Comparator|Placebo|
33077966|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
33077967|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
33261905|NCT00860964|Experimental|estradiol valerate|
33261906|NCT00745121|Experimental|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
33261907|NCT00745121|Experimental|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
33261908|NCT00864630|No Intervention|Wait list|
33261909|NCT00864630|Experimental|Computer-based problem solving therapy|
33261910|NCT00861042|Experimental|1|
32736664|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
32736665|NCT04486105|Placebo Comparator|control|vehicle only for one week
33261911|NCT04088903|Experimental|Daratumumab infusion|"Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.~For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
33261912|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
33261913|NCT05395871|Active Comparator|Usual Care|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the 'usual care' content that is currently sent by the London Breast Cancer Screening Programme. This includes a link to a YouTube hosted video.
33261914|NCT05395871|Experimental|Behavioural Message|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message has been informed by previous co-design work, and incorporate behavioural change techniques. This will include the same link to a YouTube hosted video, as the usual care arm.
33261915|NCT05395871|Experimental|Behavioural Message + Video|An text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the same as the Behavioural text, however the link will be replaced with a weblink to an animated video. This video has been designed through an extensive co-design process involving several behavioural change techniques designed to overcome barriers highlighted in this qualitative work.
33261916|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
32736666|NCT04486105|Experimental|40g sucrose ingestion|40g sucrose treatment on top of habitual diet for one week
32736667|NCT04486105|Experimental|80g sucrose ingestion|80g sucrose treatment on top of habitual diet for one week
32736668|NCT04486105|Experimental|120g sucrose ingestion|120g sucrose treatment on top of habitual diet for one week
32736669|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
33077968|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
33077969|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
33077970|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
33261917|NCT00864786|Experimental|Cohort 1|200 mcg
33261918|NCT00864786|Experimental|Cohort 2|600 mcg
33261919|NCT00864786|Experimental|Cohort 3|1000 mcg
33261920|NCT00864786|Experimental|Cohort 4|Dose to be decided
33261921|NCT00864786|Experimental|Cohort 5|Dose to be decided
33261922|NCT00740051|Experimental|Linagliptin|52 week treatment
33261923|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
33261924|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
33261925|NCT00864864|Experimental|Sunitinib|
33261926|NCT00868686|Active Comparator|Volar aluminum splint|
33261927|NCT00868686|Active Comparator|Dorsal aluminum splint|
33261928|NCT00868686|Active Comparator|Custom thermoplastic|
33261929|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
33261930|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
33401472|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
33261931|NCT00518986|Placebo Comparator|2|Placebo
33261932|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
32736670|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
32736671|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
32736672|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
32736673|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
32736674|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
32736675|NCT03148613|Other|18-49 year old smokers using COBSS|"Younger smokers - Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE: 18-49 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
32736676|NCT03148613|Other|≥50 year old smokers using COBSS|"Older smokers- Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE:≥50 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
32736677|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
32736678|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
33261933|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
33261934|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
33261935|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
33261936|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
33261937|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
33261938|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
33261939|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
33261940|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
33261941|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
33261942|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
33261943|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
33261944|NCT00870402|Experimental|1|
33261945|NCT00870402|Placebo Comparator|2|
33261946|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
33261947|NCT00742391|Placebo Comparator|2|Vehicle gel
33261948|NCT05227560|Experimental|Emotional Freedom Technique group|"Personal characteristics questionnaire, State Anxiety Scale (SQS) and Stress Coping Styles Scale (SST) were applied to the intervention group at the pre-test stage. Subjective discomfort level scale (ERDS) was also applied to the intervention group before EFT was applied. After four sessions of EFT, DKO, SBO, ORDS were applied to the intervention group again in the post-test phase."
33261949|NCT05227560|No Intervention|Control|Participants in the control group received no intervention throughout the study.
33261950|NCT02596139||Healthy people|
33261951|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
33261952|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
33261953|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
33261954|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
33261955|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
33261956|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
32769661|NCT05384769|Experimental|Cohort A (liquid biopsy, optional LDCT)|Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
32769662|NCT05384769|Experimental|Cohort B (LDCT, optional liquid biopsy)|Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
32769663|NCT05021341|Active Comparator|Berberine|500 mg of Berberine
32769664|NCT05021341|Active Comparator|Dihydroberberine 200|200 mg of Dihydroberberine
32769665|NCT05021341|Active Comparator|Dihydroberberine 100|100 mg of Dihydroberberine
32769666|NCT05021341|Placebo Comparator|Placebo|Maltodextrin
32769667|NCT05362071|Experimental|Remote Exercise Group|Participants will practice physical exercises twice a week, remotely and under the supervision of an exercise professional, for 12 weeks.
32769668|NCT05362071|Other|Group control|Participants will receive a booklet with recommendations for physical activity from the physical activity guide for the Brazilian population.
32769669|NCT05020561|Experimental|Arm 1 - Group and Individual|Participants in this experimental Arm 1 will receive the 3 group sessions followed by 4 to 5 individual coaching sessions via phone calls that last 60 minutes each.
32769670|NCT05020561|Experimental|Arm 2 - Group only|Arm 2 will receive only the first 3 Life coach sessions (group session).
32769671|NCT05020561|No Intervention|Arm 3 - Routine care|Arm 3 will receive routine care by the Breast clinic team for the entire course of the study.
32769672|NCT05017909|Experimental|Experimental Group 1|3-week web-based education group
32769673|NCT05017909|Experimental|Experimental Group 2|3-week face to face education group
32769674|NCT05017909|Active Comparator|Control Group|Uneducated group
32769675|NCT05384535|Experimental|Bi-parametric Screening MRI|Bi-parametric MRI to be administered to High Risk males
32769676|NCT05020639|Experimental|TQB3820 tablets|TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
32769677|NCT05384379|Experimental|Treated Group|Intubated patients treated with inhaled BZ371B will receive a dose of 12 mg of BZ371B divided in two different nebulizations per day, for three cosnecutive days
32769678|NCT05009017||Biosimilar group|
33261957|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
33261958|NCT04730362|Active Comparator|Control group|20 patients in which a Guedel oral airway will be inserted for airway management and to conduct inhalational anesthetic through face mask fixed with harness to the head and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
32769679|NCT05009017||Originator group|
32769681|NCT05017597|Experimental|Fatigue management|"Prescribed exercises by Physical Therapy Problem-Solving Sessions to resume activities that ther person needs to do, wants to do or is expected to do.~Four online educational modules: What is Cancer-Related Fatigue? Nutrition, Sleep Hygiene and Exercise"
32769682|NCT05384145|Other|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
32769683|NCT05008939|Experimental|sevoflurane|Those with 1-hour inhalation of 1% sevoflurane/30% oxygen
32769684|NCT05008939|Placebo Comparator|placebo|Those with 1-hour inhalation of 30% oxygen
32769685|NCT05361525|Active Comparator|Lipoabdominoplasty with anatomic definition|Lipoabdominoplasty with anatomic definition without over dissection on the lateral recti region
32769686|NCT05361525|Sham Comparator|traditional abdominoplasty|abdominoplasty with dissection in v- shaped pattern till coastal margin
32769687|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
32769688|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
33261959|NCT04730362|Active Comparator|supraglottic group|20 patients in which supraglottic airway laryngeal mask airway (LMA) will be used and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
33261960|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
33261961|NCT00662792|Experimental|T+S_PE/ Tio18GEL / Salm50DPI / T18GEL+S_DPI|7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)/ 18 µg Tiotropium (Tio18GEL) / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (T18GEL) plus 50 µg Salmeterol MDPI (S_DPI) BID
33261962|NCT00662792|Experimental|Tio18GEL/ T18GEL+S_DPI/ T+S_PE/ Salm50DPI|18 µg Tiotropium (Tio18GEL) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 50 µg Salmeterol MDPI (Salm50DPI)
33261963|NCT00662792|Experimental|Salm50DPI/ T+S_PE/ T18GEL+S_DPI/ Tio18GEL|50 µg Salmeterol MDPI (Salm50DPI) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 18 µg Tiotropium (Tio18GEL)
33261964|NCT00662792|Experimental|T18GEL+S_DPI/ Salm50DPI/ Tio18GEL/ T+S_PE|18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (Tio18GEL) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)
33261965|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
33261966|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
33261967|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
32736679|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
32736680|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
32736681|NCT03238261|Active Comparator|Radiotherapy|
32736682|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
32736683|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
32736684|NCT04485793|Active Comparator|Active Comparator|Dietary supplement
32736685|NCT04485793|Placebo Comparator|Placebo comparator|Placebo
32736686|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
32736687|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
32736688|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
32736689|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
32736690|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
32736691|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
32736692|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
32736693|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
32935568|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
33077971|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
33261968|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
33261969|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
33261970|NCT01009528|No Intervention|control|Control group. No special attention
33261971|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
33261972|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
33261973|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
33261974|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
33261975|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
32736694|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
33261976|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
33261977|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
33261978|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
33261979|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
32736695|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
32736696|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
32736697|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
32736698|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
32736699|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
32736700|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
32736701|NCT03234205|Experimental|MRI scan during free respiration|
32736702|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
32736703|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
32736704|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
32736705|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
32736706|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
32736707|NCT03237715||Breast fed cohort|
33261980|NCT02596295||Mothers for term infants|Lactating mothers
33261981|NCT02596295||Mothers for preterm infants|Lactating mothers
32736708|NCT03237715||Formula fed cohort|
32736709|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
33261982|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
33261983|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
33261984|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
32736710|NCT05621603|Experimental|Training|Participants receive the intervention, which is a training program.
32736711|NCT05621603|No Intervention|Control|Participants do NOT receive the intervention, which is a training program. This is a waitlist control comparison model.
32935569|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
33261985|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
33261986|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
33261987|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
33261988|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
33261989|NCT00801944|Experimental|II|Placebo
33261990|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
33261991|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
33261992|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
33261993|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
33261994|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
33261995|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
33261996|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
33261997|NCT00796484|Experimental|1|
33077972|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
33261998|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
33261999|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
33262000|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
33077973|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
33262001|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
33262002|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
33262003|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
32736712|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
33077974|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
33077975|NCT02067793|Placebo Comparator|Placebo|Placebo
33262004|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
33262005|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
32736713|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
32736714|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
32736715|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
32736716|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
32736717|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
32736718|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
32736719|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
32736720|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
32736721|NCT05600075|Active Comparator|Glycolic acid 35% group|will be subjected to microneedling with topical glycolic acid 35%.
32736722|NCT05600075|Active Comparator|topical insulin group|will be subjected to microneedling with topical human insulin solution.
32736723|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
32736724|NCT03234127|Other|Control|FH patient with atheroclerosis
32736725|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
33262006|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
33262007|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
33262008|NCT04088669|Experimental|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
33262009|NCT04088669|Active Comparator|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
32736726|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
33077976|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
33077977|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
33077978|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
33077979|NCT02066545|Placebo Comparator|Vehicle Gel|
33077980|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
33077981|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
33077982|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
33077983|NCT04723121|Other|High risk NMIBC|Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered
33077984|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
33077985|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
33077986|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
32736727|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
32736728|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
32736729|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
33077987|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
33077988|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
33262010|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
33262011|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
32736730|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
32736731|NCT03233971||Older adults|
32736732|NCT03233971||Caregivers|
32736733|NCT02512367|Experimental|Intervention|
33262012|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
33262013|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
33262014|NCT00662558|Experimental|celecoxib|
33262015|NCT00662558|Active Comparator|tramadol|
33262016|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
33262017|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
32736734|NCT02512367|Placebo Comparator|Surveillance|
32736735|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
32736736|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
32736737|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
32736738|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
32736739|NCT05597813|Active Comparator|Group A|microneedling group
32736740|NCT05597813|Active Comparator|Group B|microneedling plus timolol group
33262018|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
33262019|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
33262020|NCT00870792|Active Comparator|Received report|
33262021|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
33262022|NCT05226546|Other|control group|Patient underwent simple olfactive training for one month.
33262023|NCT05226546|Experimental|PRP injected group|Patient had one injection in each olfactory cleft.
32736741|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
33077989|NCT00554905|Active Comparator|2|RFA alone
33077990|NCT00173108|No Intervention|Term group|
33262024|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
33262025|NCT00788996|Experimental|Lifestyle counseling|Usual care
33262026|NCT00869856|Experimental|1|HX575, EPO Hexal
33262027|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
33262028|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
33077991|NCT00173108|No Intervention|Usual care program group|
33262029|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
33262030|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
33262031|NCT00802334|Experimental|1|
33262032|NCT00876564|Other|Trauma patients|Included in trauma registry
33262033|NCT00876642|Experimental|1|
33262034|NCT00876642|No Intervention|2|
33077992|NCT00173108|Experimental|Clinic-based interveniton program group|
33262035|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
33262036|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
33262037|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
33262038|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
33262039|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
33262040|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
33077993|NCT00173108|Experimental|Home-based interveniton program group|
33262041|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
32736742|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
32736743|NCT03237247||Benign|cases with benign biliary stricture
33262042|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
33262043|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
33262044|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
33262045|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
33262046|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
33262047|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33262048|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33077994|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
33262049|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
32736744|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
32736745|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
32736746|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
32736747|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
32736748|NCT04499261|Experimental|laparoscopic surgery|The laparoscopic view is caudal to cephalic, which is consistent with the direction of hepatic transection. In addition, the high-definition magnified view and ability to change perspectives with the laparoscope are conducive to subtle manipulation, and compression of the carbon dioxide pneumoperitoneum can reduce venous bleeding. Therefore, laparoscopic surgery may have certain advantages in the treatment of paracaval-originating lesions.
32736749|NCT04499261|Active Comparator|Open surgery|Open surgery is the traditional surgical method for resection of paracaval-originating lesions.
32736750|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
32736751|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
32736752|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
32736753|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
33077995|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
33077996|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
33262050|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
32736754|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
32736755|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
32736756|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
33262051|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33262052|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33262053|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33262054|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
33262055|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
33262056|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
32736757|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
33262057|NCT00789230|Active Comparator|primary suture|
32736758|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
32736759|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
33262058|NCT00789230|Active Comparator|mesh enforced closure|
33262059|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
33262060|NCT00869934|Experimental|2. Behavior Therapy|
33262061|NCT00869934|Experimental|3. Cognitive Therapy|
32736760|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
32736761|NCT04497623|Experimental|Intervention arm|Patients with indication for volume-controlled mechanical ventilation
32736762|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
33262062|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
33262063|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
33262064|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
32736763|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
32736764|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
33262065|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
33262066|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
33262067|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
33262068|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
33262069|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
32736765|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
32736766|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
32736767|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
32736768|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
32736769|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
32736770|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
32736771|NCT03242629|Active Comparator|oral group|
33262070|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
33262071|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
32736772|NCT03242629|Experimental|enema group|
33262072|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
33262073|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
33262074|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
33262075|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
33262076|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
33262077|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
33262078|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
33262079|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
33262080|NCT00870246||1|High mobility
33262081|NCT00870246||2|Lower mobility
33262082|NCT05174572|Other|IMR|IMR evaluation before and after Reducer implantation
33262083|NCT00802958||Cohort Group 1|Subjects number 1 to 30
33262084|NCT00802958||Cohort Group 2|Subjects number 31 to 56
33262085|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
33262086|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
33262087|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
33262088|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
33262089|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
33262090|NCT04898036|Experimental|Sham First, then Experimental|Participants in this group will receive the sham treatment first, then the experimental treatment.
33262091|NCT04898036|Experimental|Experimental First, then Sham|Participants in this group will receive the experimental treatment first, then the sham treatment.
33262092|NCT01565512|Placebo Comparator|saline injection|saline injection
33262093|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
32736773|NCT02452723|Experimental|ISC-hpNSC|
32736774|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
32736775|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
32736776|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
32736777|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:~CMR~EV with an inter-electrode gap (lower pair) of 5 cm~EV with an inter-electrode gap (lower pair) of 15 cm"
32736778|NCT05211895|Experimental|Arm A: Durvalumab + Domvanalimab|Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months
32736779|NCT05211895|Active Comparator|Arm B: Durvalumab + Placebo|Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months
33262094|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
33262095|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
32769689|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
32769690|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
32736780|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
32769691|NCT05361369|Experimental|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule will be administered once as a single dose during a single-period.
32769692|NCT05017519||Nuclear family type|The husband and wife with baby (aged less than 5 months) and with or without children (2-5)
33262096|NCT04895930|Experimental|Furmonertinib Plus Anlotinib|Furmonertinib (80mg) plus Anlotinib (10mg)
33262097|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
32769693|NCT05017519||Extended family type (three-generation family)|The husband and wife with baby (aged less than 5 months), children (2-5), and grandparents aged > 65 years old
33262098|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262099|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262100|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33277494|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
32736781|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
33077997|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
33077998|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
33077999|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
33262101|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262102|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262103|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33078000|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
33078001|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
33078002|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
33277495|NCT05355428|Experimental|35 Term infants|Series of 35 term infants
33277496|NCT04000724|Experimental|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
33277497|NCT04000724|Experimental|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
33078003|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
33078004|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
33078005|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
33078006|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
33078007|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
33078008|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
33078009|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
32736782|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
33078010|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
33078011|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
33078012|NCT02052778|Experimental|Phase 1 Dose escalation|Phase 1 Dose escalation portion for once daily and thrice weekly dosing of futibatinib (TAS-120) in patients with solid tumors.
33078013|NCT02052778|Experimental|Phase 1 Dose expansion|Phase 1 Dose expansion portion for once daily dosing of futibatinib (TAS-120) in patients with tumors harboring FGF/FGFR aberrations
33078014|NCT02052778|Experimental|Phase 2|Phase 2 portion for once daily dosing of futibatinib (TAS-120) in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).
33262104|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262105|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262106|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262107|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262108|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
33262109|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
33262110|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
33262111|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
33277498|NCT04000724|Experimental|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
33078015|NCT00203151|Experimental|1|
32769694|NCT05384067|Experimental|Mindfulness-based intervention|Participants in this arm will wear a sleep-monitoring device, complete questionnaires and participate in an online mindfulness component each week for the duration of this study.
32769695|NCT05384067|No Intervention|Control|Participants in this arm will only wear a sleep-monitoring device and complete questionnaires.
33078016|NCT00203151|Placebo Comparator|2|
33078017|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
33078018|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
33078019|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
33078020|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
33262112|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
33262113|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
33262114|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
33262115|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
33078021|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
33262116|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
33262117|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
33262118|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
33262119|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
33262120|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
32736783|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
32736784|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
32736785|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
32736786|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
32736787|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
33262121|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
33277499|NCT00773123||1|Primary open angle glaucoma
32736788|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
32736789|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
32736790|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
32736791|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
32736792|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
32736793|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
32736794|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
32736795|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
32736796|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
32736797|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
32736798|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
32769696|NCT05360901|Other|IntelliCare with automated motivational messaging|Digital mental health intervention with micro-randomized automated motivational messaging delivery
32769697|NCT05020093|Experimental|Injection molding|cavity design, packing technique, bonding technique
33262122|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
33262123|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
32769698|NCT05020093|Active Comparator|Incremental packing|cavity design, packing technique, bonding technique
32769699|NCT05360823|Experimental|Birth Ball Group|In the active and transitional phases, during contractions, performing exercises on the birth ball (fully rotating the hip, moving to the right/left, coming back and forth, and slightly bouncing while sitting on the birth ball) (average 25 minutes). In order to monitor the condition of the fetus, exercises on the birth ball were performed by the pregnant woman during contractions while connected to NST.
32769700|NCT05360823|Experimental|Squatting Group|In the active and transitional phase, squatting position (squatting with feet shoulder-width apart by laying a clean sheet on the floor and getting support from a bed, chair or birth ball) during contractions (average 25 minutes). In order to monitor the condition of the fetus, the squatting position was used by the pregnant woman during contractions while connected to the NST.
32769701|NCT05360823|No Intervention|Control Group|Usual routine care of the service.
32769702|NCT05017285|Other|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
32769703|NCT05017285|Experimental|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.
32769704|NCT05610501||Patient population|"All consecutive patients (> 18 years) undergoing a tru-cut biopsy at the participating centers during the study periof will be eligible for inclusion in the study.~All biopsies will be performed by trained operators in gynecologic ultrasound and tru-cut biopsies. Tissue samples will be assessed by experienced pathologists, dedicated in gynecologic oncology. Data will be collected by reviewing patients' electronic medical file including data concerning further treatment-strategy and pathology reports. Patients' level of pain and overall experience will be assessed by an independent investigator not present during biopsy. This will be performed from 0-72h after the biopsy using a numeric rating scale (0-100). Safety and complication-rate will be assessed by both using the collected data and via postprocedural assessment and by phone after six weeks. Inclusion and exclusion criteria can be found elsewhere."
32769705|NCT05008861|Experimental|FMT with anti-PD-1/PD-L1 treatment|
32769706|NCT05016739|Experimental|CADISS System|
32769707|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.~The duration of all measurement will be 60 minutes."
32769708|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
32769709|NCT04433923|Active Comparator|GROUP1|Phototherapy with aluminum foil
32769710|NCT04433923|Placebo Comparator|GROUP2|Phototherapy without aluminum foil
32769711|NCT05360589||Shoulder non-specific pain|68 adult gender-balanced subjects will be enrolled, reporting unilateral, atraumatic, and non-specific shoulder pain68 healthy subjects who regularly perform sports activities (at least one weekly session).
32769712|NCT05360589||Controls|68 healthy subjects who regularly perform sports activities (at least one time/week) without shoulder pain will be recruited.
32769713|NCT05360277|Experimental|Tislelizumab + Capecitabine|"Tislelizumab 200mg every 3 weeks, or 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
32769714|NCT05360277|Active Comparator|Best supportive care|Best supportive care was the standard care in this setting.
32769715|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
32769716|NCT05359965|Experimental|CPAP|Subjects randomized to the treatment arm, will receive continuous positive airway pressure (CPAP) while sleeping via an autoPAP device for 4-8 weeks.
32769717|NCT05359965|No Intervention|No CPAP|Subjects assigned to the no CPAP group will not have any intervention for a 4-8 week period.
32769718|NCT05016973|Experimental|RC48-ADC+ Triplizumab|RC48-ADC on days 1 every 21 days plus triplizumab on days 1 every 21 days
32769719|NCT05382819|Experimental|Part 1A Single Ascending Dose (SAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
32769720|NCT05382819|Placebo Comparator|Part 1A Single Ascending Dose (SAD) - Placebo|Matching placebo will be administered to healthy volunteers.
32769721|NCT05382819|Experimental|Part 1B Multiple Ascending Dose (MAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
32769722|NCT05382819|Placebo Comparator|Part 1B Multiple Ascending Dose (MAD) - Placebo|Matching placebo will be administered to healthy volunteers.
32769723|NCT05382819|Experimental|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Active|FRTX-02 Capsules will be administered daily for 28 days to subjects with atopic dermatitis.
33262124|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
33262125|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
33262126|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
33262127|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
33262128|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
33262129|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
33262130|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
33262131|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
33262132|NCT02553980|Experimental|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
33262133|NCT02553980|Experimental|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
33262134|NCT02553980|Placebo Comparator|Control|Participants in this group did not receive any VT treatment, and live as usual.
33262135|NCT00803192|Active Comparator|Test Drug|
33262136|NCT00803192|Active Comparator|Reference Drug|
33262137|NCT00544557||Patients with Ankylosing Spondylitis|
33262138|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
33262139|NCT02554214|Experimental|Glafkos device|
33262140|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
33262141|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
32736799|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
32736800|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
32736801|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
32736802|NCT03237091|Active Comparator|sham-control|
32736803|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
32736804|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
32736805|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
32736806|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
32736807|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
32736808|NCT04485715|Experimental|AI-aided group|
32736809|NCT04485715|No Intervention|control group|
32736810|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
32736811|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
32736812|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
32736813|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
32736814|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
33262142|NCT00789386|Experimental|Remifentanil|
33262143|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
33262144|NCT05157282|Active Comparator|Active TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, active transcutaneous electrical spinal stimulation (TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
33277500|NCT00773123||2|Normal controls
32736815|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
32736816|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
32736817|NCT04499651|No Intervention|Control|All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
32769724|NCT05382819|Placebo Comparator|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Placebo|Matching placebo will be administered daily for 28 days to healthy volunteers.
32935570|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
33262145|NCT05157282|Sham Comparator|Sham TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, sham transcutaneous electrical spinal stimulation (sham-TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
33262146|NCT05157282|Active Comparator|Active TESS + Training|Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: [1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping & reaching + training.] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
33262147|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
33262148|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
33262149|NCT00977067|Experimental|A|
33262150|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
33262151|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
33262152|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
33262153|NCT00877188|No Intervention|control|waist list control with usual care
33262154|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
33262155|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
32736818|NCT04499651|Active Comparator|Navigation|"Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format:~Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder~Session 2: Rapport Building~Session 3: Society and Self and the Role of Disclosure~Session 4: Accompaniment 1~Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit~Session 6: Accompaniment 2~Session 7: Accompaniment 3 (ONLY if needed)~Weekly check-in calls following Session 2 for six months"
33262156|NCT02593955|No Intervention|Healthy control|MRI sub-study only
33262157|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
33262158|NCT05226000|Experimental|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
33262159|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
32736819|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
33262160|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
32736820|NCT04499339|Experimental|All eligible patients|
32736821|NCT03242083||Primary atrophic AMD|
32736822|NCT03242083||Secondary atrophic AMD|
32935571|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
32935572|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
32935573|NCT05005819|Experimental|[18F]APN-1607|Participants will receive an IV bolus injection of [18F]APN-1607, followed by PET brain imaging.
32935574|NCT05359081|Experimental|SEP-363856|SEP-363856 (50 or 75 mg/day, flexible dose)
32935575|NCT04963777|Experimental|Prebiotic|Oligofructose-enriched inulin
32935576|NCT04963777|Placebo Comparator|Placebo|Maltodextrin
33262161|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
33262162|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
32736823|NCT04499885|Active Comparator|Paraffin oil gastric lavafe|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
32736824|NCT04499885|Active Comparator|Saline gastric lavage|Gastric lavage with saline and sodium bicarbonate
32736825|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
32736826|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
32736827|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
32736828|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
32736829|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
32736830|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
32736831|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
33078022|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
33078023|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
33078024|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
33078025|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
33262163|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
33262164|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
32769725|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
33262165|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
32769726|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
33262166|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
33262167|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
33262168|NCT00980733|No Intervention|Control|Non blinded group given no intervention
32769727|NCT05359575|Experimental|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 1 month follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 1 month follow-up.
32769728|NCT05359575|Experimental|Instructional flashcard with cervical-collar - 1 month follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 1 month follow-up.
32769729|NCT05359575|Experimental|In-person training with cervical-collar - 1 month follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 1 month follow-up.
33078026|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
33078027|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
33078028|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
33078029|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
33078030|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
33078031|NCT02019589|Placebo Comparator|Placebo|Placebo
33262169|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
33262170|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
33262171|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
33262172|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
33262173|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
33262174|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
33262175|NCT04039854|Active Comparator|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
33262176|NCT04039854|Active Comparator|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
33262177|NCT04045730|Experimental|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
33262178|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
32769730|NCT05359575|No Intervention|Control group with no in-person training and no access to POC instruction - 1 month follow-up|There is no in-person training or point-of-care (POC) instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 1 month follow-up.
32769731|NCT05359575|Experimental|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 2 Months follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 2 months follow-up.
33078032|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
33262179|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
33262180|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
32769732|NCT05359575|Experimental|Instructional flashcard with cervical-collar - 2 months follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 2 months follow-up.
32769733|NCT05359575|Experimental|In-person training with cervical-collar - 2 months follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 2 months follow-up.
33262181|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
33262182|NCT03721068|Experimental|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10^6 cells/kg, 1.0 x 10^6 cells/kg, 1.5 x 10^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10^6 cells/kg.
33262183|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
33262184|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
33262185|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
33078033|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
33078034|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
32769734|NCT05359575|No Intervention|Control group with no in-person training and no access to POC instruction - 2 months follow-up|There is no in-person training or POC instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 2 months follow-up.
32769735|NCT05359575|Experimental|Audio recording with instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
32769736|NCT05359575|Experimental|Instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
33078035|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
33078036|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
33078037|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
33078038|NCT01989325|Experimental|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
33078039|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
33078040|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
33262186|NCT00735371|Active Comparator|LDX 50 mg|
33262187|NCT00735371|Active Comparator|LDX 70 mg|
33262188|NCT00735371|Placebo Comparator|Placebo|
33262189|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
33078041|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
33078042|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
33262190|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
33262191|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
33262192|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
33262193|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
33262194|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
33078043|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
33078044|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
33078045|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
33078046|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
33078047|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
33078048|NCT04676893|Experimental|Reference-Test|
33078049|NCT04676893|Experimental|Test-Reference|
33078050|NCT04677361|Experimental|MILs™ in Combination with Pembrolizumab|"Each patient will have their bone marrow collected, MILs produced, and the patient will be dosed with all of the MILs produced for that individual patient. The minimum requirement for treatment is 2 x 108 cells. The MILs™ must be administered via a central catheter which could either be a PICC line, port or central line.~Subjects will be treated with MILs™ and pembrolizumab (200 mg Q3W) combination. MILs™ will be administered on Day 0 and pembrolizumab administered on Day 1. Pembrolizumab will be administered as a 30 minute IV infusion with a window of -5 minutes and +10 minutes is permitted."
33078051|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
33078052|NCT04677127|Experimental|Intervention|The intervention group was given training based on the health belief model with groups of 10-12-13 people every week for 6 weeks in the Family Health Center, followed by telephone counseling in the following 6 weeks and follow-up for 12 weeks.
33078053|NCT04677127|No Intervention|Control|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
33078054|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
33078055|NCT04677088|Experimental|HBV/ TCR T cell infusion|Autologous T cells with HBV antigen-specific TCR
33078056|NCT04676971|Experimental|100 mg hzVSF-v13 IV + SOC|100 mg hzVSF-v13 IV + SOC
33262195|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
33078057|NCT04676971|Experimental|200 mg hzVSF-v13 IV + SOC|200 mg hzVSF-v13 IV + SOC
33078058|NCT04676971|Placebo Comparator|Placebo (saline) IV + SOC|Placebo (saline) IV + SOC
33262196|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
33262197|NCT04046588|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
33262198|NCT04046588|Other|Healthy control group|This group will include 40 healthy volunteers.
33262199|NCT04046588|Experimental|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
33262200|NCT04981431|Experimental|Elinzanetant single dose step 1|Each participant will receive a single oral dose of elinzanetant or placebo.
33262201|NCT04981431|Experimental|Elinzanetant single dose step 2|Each participant will receive a single oral dose of elinzanetant or placebo.
33262202|NCT04981431|Experimental|Elinzanetant single dose step 3|Each participant will receive a single oral dose of elinzanetant or placebo.
33262203|NCT04981431|Experimental|Elinzanetant single dose step 4|Each participant will receive a single oral dose of elinzanetant or placebo.
32736832|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
32736833|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
32736834|NCT04499105|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem cell + Nacl 0.9%
32736835|NCT03236701|No Intervention|Control|usual diet
32736836|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
32736837|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
32736838|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
32736839|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
33262204|NCT04981431|Experimental|Elinzanetant single dose step 6|Each participant will receive a single oral dose of elinzanetant or placebo.
32769737|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
33262205|NCT04981431|Experimental|Elinzanetant multiple dose step 5|Each participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.
32769738|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
32769739|NCT05610423||Covid-19 vaccine associated myocarditis|No intervention
32769740|NCT05016115||physiotherapy students|Totally 120 physiotherapy students at a non-governmental university in Istanbul participated in this study.
32769741|NCT05344209|Experimental|anti-PD-1/PD-L1 treatment + UV1 vaccination|anti-PD-1/PD-L1 treatment + UV1 vaccination (and sagramostim)
32769742|NCT05344209|Other|anti-PD-1/PD-L1 treatment|anti-PD-1/PD-L1 treatment
33262206|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
32769743|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
32769744|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
32769745|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
32769746|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
32769747|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
32769748|NCT04253457|Experimental|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
32769749|NCT04253457|Active Comparator|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
32769750|NCT05380947|Experimental|Treatment sequence 1: R - T1 - T2 - T3|"Treatments:~R: TF1 fasted T1: NF fasted T2: NF fed T3: NF fasted + rabeprazole"
32769751|NCT05380947|Experimental|Treatment sequence 2: T1 - T3 - R - T2|
32769752|NCT05380947|Experimental|Treatment sequence 3: T2 - R - T3 - T1|
32769753|NCT05380947|Experimental|Treatment sequence 4: T3 - T2 - T1 - R|
32769754|NCT05008471|Experimental|Intervention group|The recommended target energy for NPC radiotherapy patients is 25-30kcal/(kg·d), in addition，the intervention group begins with an additional 50% daily energy increase during the peri-radiotherapy.
32769755|NCT05008471|No Intervention|Conventional group|Unlike the intervention group,conventional group should be treated according to the consensus of experts on standardized nutrition management.
32769756|NCT05342727|Active Comparator|tDCS group|The tDCS arm receives two real (or active) stimulation at 2 mA and 3 mA intensities and one placebo electrical stimulation for 20 minutes.
32769757|NCT05342727|Active Comparator|tACS group|The tACS arm receives two real (or active) stimulation at 8 Hz and 40 Hz frequencies and one placebo alternating electrical stimulation for 20 minutes.
33262207|NCT00803582|Experimental|Experimental|Traditional acupuncture
33262208|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
33262209|NCT00803582|No Intervention|No-treatment|no treatment
33262210|NCT01565590|Active Comparator|Propofol|
33262211|NCT01565590|Experimental|Dexmedetomidine|
33262212|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
33262213|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
33262214|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
33262217|NCT04088201|Experimental|Measuring glucose|Measuring glucose from interstitial fluid
33262218|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
33262219|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
33262220|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
32769758|NCT05357781||MS patients with IgG deficiency (serum IgG-concentration <7g/L).|
33078059|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
32769759|NCT05357781||MS patients with normal IgG serum concentration (serum IgG-concentration ≥7g/L).|
32769760|NCT03088969||patient with a chronic back pain|
33078060|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
33078061|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
32769761|NCT05008315|Experimental|deep and superficial tissue mobilization group|include deep and superficial tissue mobilization
33078062|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
33078063|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
33262221|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
33078064|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
33078065|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
33262222|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
33078066|NCT01968187|Experimental|FE 992097|
33078067|NCT01968187|Placebo Comparator|Placebo|
33262223|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
33262224|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
33078068|NCT01966549|Experimental|CNTO 6785|
33078069|NCT01966549|Placebo Comparator|Placebo|
33262225|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
33078070|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
33078071|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
33262226|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
33262227|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
33262228|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
33262229|NCT04973553|Experimental|participants with acute stroke|(a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) UL hemiparesis or hemiplegia with a ≥ trace of muscle contraction (≥grade 1 at wrist extensors measured by the MRC Scale and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)[24], (d) the age of > 18 years and (e) the ability to provide informed consent.
33262230|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
33262231|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
33262232|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
33262233|NCT04007913|Experimental|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
33262234|NCT04046432|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
33262235|NCT04046432|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
33262236|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
33262237|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
33262238|NCT04039698|Experimental|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
33262239|NCT04006821|Experimental|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
33262240|NCT00871884|Active Comparator|Treatment As Usual|
33262241|NCT00871884|Experimental|Experimental|
33277501|NCT03979352|Active Comparator|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.~Participant and research staff is blinded to arm assignment."
33078072|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
33078073|NCT00173537|Other|other|
33078074|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
33262242|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
33262243|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
33262244|NCT04007679|Experimental|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
33262245|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
33262246|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
33262247|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
33262248|NCT00981123||1|
33262249|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
33262250|NCT04087499|Sham Comparator|regular medication treatment|regular medication treatment
33262251|NCT04087499|Experimental|acupuncture and regular medication treatment|acupuncture and regular medication treatment
32769762|NCT05008315|Active Comparator|superficial tissue mobilization group|superficial tissue mobilization
32769763|NCT05008315|Placebo Comparator|control group|Sham (very light hand touch on the same location as the other two groups but without any treatment intention)
32769764|NCT05008315|Other|vaginal delivery group|education session
32769765|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
33078075|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
33262252|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
33262253|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
33262254|NCT00797264|Experimental|C|Ketamine and morphine postoperative
33262255|NCT00981201|Experimental|Celecoxib + Placebo|
33262256|NCT00981201|Experimental|Celecoxib + Celecoxib|
33078076|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
33078077|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
33262257|NCT00981201|Active Comparator|Placebo + Celecoxib|
33262258|NCT00981201|Placebo Comparator|Placebo + Placebo|
33262259|NCT04842708|No Intervention|Healthy Volunteers that are not to be vaccinated against COVID19|Healthy Volunteers that are not eligible to be vaccinated against COVID19
33262260|NCT04842708|Experimental|Healthy Volunteers that are assigned to be vaccinated against COVID19|Healthy Volunteers that are eligible to be vaccinated against COVID19
33262261|NCT00797342|Other|first of three dosing cohorts|
33262262|NCT00797342|Other|second of three dosing cohorts|
33262263|NCT00797342|Other|third of three dosing cohorts|
33262264|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
33262265|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
33262266|NCT05279391|Active Comparator|SOC|Patients included in this arm treated with the standard of care (SOC), including dexamethasone plus heparin, with or without the addition of antibiotics and remdesivir
33262267|NCT05279391|Active Comparator|TOCI|Patients included in this arm treated with the SOC plus Tocilizumab (single IV dose: 8mg/kg)
32769766|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
33078078|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
33078079|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
33078080|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
33262268|NCT05279391|Active Comparator|ANA|Patients included in this arm treated with the SOC plus Anakinra (200mg twice daily IV for 3-6 days, then 100 mg/twice daily, for up to 10 days in total)
33262269|NCT05279391|Active Comparator|COMBI|Patients included in this arm treated with the SOC plus the combination of Tocilizumab, Baricitinib and inhaled DNase (COMBI) as a rescue treatment.
33262270|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
33262271|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
33262272|NCT04087733|Experimental|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
33262273|NCT04087733|No Intervention|GROUP / CONTROL EYE|Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
33262274|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
33262275|NCT00880152|No Intervention|2|Treatment as usual
33262276|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
33262277|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
33262278|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
33078081|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
33078082|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
32769767|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
33262279|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
32769768|NCT05356299|Experimental|MagneticTape group|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
32769769|NCT05016427|Experimental|VT301(low dose)|VT301 low dose: 8.5x10^4 cells/kg
32769770|NCT05016427|Experimental|VT301(high dose)|VT301 high dose: 1.7x10^5 cells/kg
33262280|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
33262281|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
33262282|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
33262283|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
33262284|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
33262285|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
32769771|NCT05602311||Group SDB|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
32769772|NCT05602311||Group control|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
33078083|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
33078084|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
33262286|NCT04828746|No Intervention|Control|Patients who will undergo lumbar puncture without pre-procedural ultrasound-guided skin marking
33262287|NCT04828746|Experimental|Experimental|Patients who will undergo lumbar puncture after pre-procedural ultrasound-guided skin marking
33262288|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
32769773|NCT05016349|Experimental|All trans-retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral All trans-retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
33078085|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
33078086|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
33078087|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
33078088|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
33078089|NCT01908595|Experimental|M518101|Proper quantity twice daily
33078090|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
33078091|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
33078092|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
32769774|NCT05016349|Experimental|Mifepristone, Cannabidiol (Epidiolex) , All trans-retinoic acid and tamoxifen|Patients will receive oral Mifepristone daily for 4 weeks ,after which daily oral All trans-retinoic acid, tamoxifen and Cannabidiol (Epidiolex) is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
32769775|NCT05016349|Experimental|Mifepristone , All trans-retinoic acid, Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, All trans-retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
32769776|NCT05016349|Experimental|9 cis retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 9 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
33078093|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
33078094|NCT01887886|Experimental|Onartuzumab + Erlotinib|
33262289|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
33262290|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
33262291|NCT00877656|Experimental|CD4|Open label treatment arm
33078095|NCT01887886|Active Comparator|Placebo + Erlotinib|
33078096|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
33078097|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
33078098|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
32769777|NCT05016349|Experimental|Mifepristone, 13 cis retinoic acid , Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
32769778|NCT05016349|Experimental|9 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral 9 cis retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
32769779|NCT05016349|Experimental|13 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
32769780|NCT05016349|Sham Comparator|Standard therapy|Patients will receive the approved standard therapy
32769781|NCT05355675||observational group|Patients with hematologic malignancies following allogeneic hematopoietic stem cell transplantation treatment
32769782|NCT05355675||control group|health control group: healthy volunteers
32769783|NCT05016193|Experimental|Intervention Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week."
33078099|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
33078100|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
33078101|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
33078102|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
33078103|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
33078104|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
33262292|NCT00803894|Active Comparator|A|MK0752 1000 mg
33262293|NCT00803894|Active Comparator|B|MK0752 350 mg
33262294|NCT00803894|Placebo Comparator|C|Placebo
33262295|NCT05371925|Active Comparator|Sulodexide group|the participant will receive one Sulodexide capsule of 250LRU twice a day for 8 weeks
33078105|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
33262296|NCT05371925|Placebo Comparator|control group|the participant will receive on placebo capsule twice a day for 8 weeks of same appearance as IMP
33262297|NCT00985023|Active Comparator|Steel screw fixation|
33262298|NCT00985023|Experimental|Bioabsorbable screw fixation|
33262299|NCT00797420|Other|Loading Dose|Loading Dose
33262300|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
33262301|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
33262302|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
33262303|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
33262304|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
33262305|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
33262306|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
33262307|NCT00985101||diabetes no complications|
33262308|NCT00985101||diabetes with complications|
33262309|NCT00880308|Experimental|LDE225|
33262310|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
33078106|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
33078107|NCT01871428|Experimental|Aleglitazar|
33262311|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
33262312|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
33262313|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
33262314|NCT00985179|No Intervention|Waiting control group (WCG)|
33262315|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
33262316|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
32769784|NCT05016193|Active Comparator|Control Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions."
32769785|NCT05380635|Experimental|HyBryte (0.25 % Hypericin)|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 5 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 8 weeks.
32769786|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
33262317|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
33078108|NCT01871428|Placebo Comparator|Placebo|
33078109|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
33078110|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
33262318|NCT00872586|Active Comparator|2|olmesartan medoxomil
33262319|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
33262320|NCT00977925|Experimental|Fibrin Pad|
33078111|NCT01867762|Experimental|JNJ 49095397|
33262321|NCT00977925|Active Comparator|Standard of Care|
33262322|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
33262323|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
33262324|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
33262325|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
33262326|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
33262327|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
33078112|NCT01867762|Placebo Comparator|Placebo|
33078113|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
33078114|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
33262328|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
33262329|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
33078115|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
33262330|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
33262331|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
33262332|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
33262333|NCT04812366|Active Comparator|Group 1a|LHRHa plus apalutamide.
33262334|NCT04812366|Active Comparator|Group 1b|LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
33262335|NCT04812366|Active Comparator|Group 2a|LHRHa plus abiraterone acetate plus prednisone.
33262336|NCT04812366|Active Comparator|Group 2b|LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
33262337|NCT04812366|Active Comparator|Group 3|LHRHa plus abiraterone acetate plus prednisone plus niraparib
33262338|NCT04812366|Active Comparator|Group 4|LHRHa plus apalutamide plus atezolizumab
33262339|NCT04928391|Experimental|Group D|Dexmedetomidine IV at the end of surgery
33262340|NCT04928391|Experimental|Group N|Nalbuphine IV at the end of surgery
33262341|NCT04928391|Placebo Comparator|Group C|Same volume of saline placebo IV at the end of surgery
33262342|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
33262343|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
33262344|NCT00877734|Experimental|1|Baclofen
33262345|NCT00877734|Placebo Comparator|2|Placebo
33262346|NCT00981591|Experimental|Inhaled Iloprost|
33262347|NCT00981591|Placebo Comparator|Inhaled Placebo|
33262348|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
33262349|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
33262350|NCT04545216||UT4M 40|athletes participating to the 40 km mountain race.
33262351|NCT04545216||UT4M 160|athletes participating to the 160 km mountain race.
32769787|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
32769788|NCT05380323|Experimental|LY3541105 (Part A)|Single ascending doses of LY3541105 administered subcutaneously (SC).
32769789|NCT05380323|Experimental|LY3541105 (Part B)|Multiple ascending doses of LY3541105 administered SC.
32769790|NCT05380323|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
32769791|NCT05380323|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
32769792|NCT04254861|Experimental|Simplified Papilla Preservation Flap (SPPF) and PRGF|
32769793|NCT04254861|Active Comparator|Simplified Papilla Preservation Flap (SPPF) and GTR|
32769794|NCT05015959||mortality outcomes|mortality classification into preventable, potentially preventable and non-prevenatable
32769795|NCT04254393|Experimental|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
33262352|NCT04545216||UTV 55|athletes participating to the 55 km mountain race.
33262353|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
33262354|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
33262355|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
33262356|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
32769796|NCT04254393|Placebo Comparator|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
32769797|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
32769798|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
32769799|NCT05538819||Glimepiride group|509 patients aged >18 years with T2D and CHF had continuous glimepiride use (1-4 mg/day).
32769800|NCT05538819||Non-glimepiride group|509 patients aged >18 years with T2D and CHF had no glimepiride use.
32769801|NCT05015647|Experimental|LP group|LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively) supplemented with commercial protein free products (protein content <2%).
32769802|NCT05015647|Active Comparator|NP group|NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)
32769803|NCT05308641|Active Comparator|PreviousSurgery(PrevSurg)_YES/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 4000 pulse, 20 Hz
32769804|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 500 pulse, 2 Hz
32769805|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: no
32769806|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: denied
32769807|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 4000 pulse, 20 Hz
32769808|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 500 pulse, 2 Hz
32769809|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: no
32769810|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: denied
32898301|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
33262357|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
33262358|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
33262359|NCT00981903|Experimental|VTE Treatment Group|
33262360|NCT00981903|No Intervention|Control|
33262361|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32769811|NCT05354583||Acquired Interferon-gamma Autoantibody Syndrome|"Patients infected with M. abscessus at any site, who have acquired interferon-gamma autoantibody syndrome defined as one of the following features:~The M. abscessus infection site is lymph node.~The M. abscessus infection is disseminated (more than 1 organ of infection or blood culture positive for M. abscessus).~The M. abscessus infection is accompanied by one of reactive skin diseases which are Sweet's syndrome, pustular psoriasis, erythema nodosum.~History of opportunistic infection such as salmonellosis, penicillosis, histoplasmosis, cryptococcosis, melioidosis~The patients must not be infected with HIV, in-hospital M. abscessus infection, diagnosed with cancer, or receiving immunosuppressants."
33078116|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
33078117|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
33262362|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32769812|NCT05354583||Chronic Lung Disease|"Patients with one of chronic lung diseases which are COPD, chronic bronchiectasis, history of pulmonary tuberculosis and diagnosed with Pulmonary M. abscessus infection.~Pulmonary M. abscessus infection diagnosis must be met all of the following criteria:~Symptoms and signs are correlated with the pulmonary M. abscessus infection.~One of the radiological evidences:~2.1) nodular infiltration or cavitary lesion on plain chest radiography~2.2) bronchiectasis and multiple small nodules on chest computerized tomography~Mycobacterial culture from respiratory tract specimen is positive for M. abscessus"
32769813|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
32769814|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
33262363|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
33262364|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
33262365|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
33262366|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
33262367|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
33262368|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
33262369|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
33262370|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
33262371|NCT00877968|Placebo Comparator|White bread|
32769815|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
32769816|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
33262372|NCT00877968|Placebo Comparator|Boiled yellow peas|
33262373|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
32769817|NCT05019469|Experimental|Single arm of study|Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.
33262374|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
32769818|NCT03091153|No Intervention|Control|Standard care. Annual medication review
32769819|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
33262375|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
33262376|NCT04773288|Experimental|Live feedback provided on display during handwashing|
32769820|NCT05015179|No Intervention|Control|Laparoscopic partial nephrectomy is performed with an intraoperative ultrasound (US) control
32769821|NCT05015179|Experimental|Experimental|Underwent Laparoscopic partial nephrectomy with the aid of the mixed reality model
32769822|NCT05019781|Experimental|KT group|Participants were received single session therapeutic tape application for one week.
32769823|NCT05019781|Placebo Comparator|Placebo group|Participants were received single session placebo tape application for one week.
32769824|NCT05019781|No Intervention|Control group|No intervention.
33262377|NCT04773288|No Intervention|No live feedback provided during handwashing|
33262378|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
33262379|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
33262380|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
33078118|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
33078119|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
33262381|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
33262382|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
33262383|NCT05056155|Experimental|Systane Complete|First dose of Systane Complete in both eyes on Day 0, followed by Systane Complete self-administered 4 times daily for 28 days
33262384|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
33262385|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
33078120|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
33078121|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
32769825|NCT05019157|Experimental|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic under the supervision of the specialized staff for familiarization with the intervention. and then the participants will proceed with the telerehabilitation program at their homes. Participants will undergo an exercise - based program 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down, with the use of wearable sensors.
33078122|NCT01853995|No Intervention|Untreated Class II Control Group|control group
33262386|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
33262387|NCT00978237|Experimental|LPV/r and combination of analogues.|
33262388|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
33262389|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
32769826|NCT05019157|Active Comparator|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down.
32769827|NCT05019157|No Intervention|Usual care group|Patients will not undertake any exercise based intervention and will only follow their usual medication treatment .The patients will wear the accelerometer for the 12 week study duration and visit the corresponding outpatient cardiac clinic every 4 weeks to upload the recorded data. The patients will also receive educational phone videoconference sessions every week for physical activity, diet/nutritional and smoking cessation counseling.
32769828|NCT05008237|Experimental|Cisplatin plus docetaxel|"D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Treatment will be continued until disease progression or unacceptable toxic effects."
32769829|NCT05014711|Experimental|remifentanil group|After enrollment, remifentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
32769830|NCT05014711|Active Comparator|fentanil group|After enrollment, fentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
32769831|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
32769832|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
32769833|NCT05007457|Experimental|Experimental Group|telerehabilitation
32769834|NCT05007457|Active Comparator|Control group|Standard treatment
32769835|NCT05018923|Experimental|RBMD group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
32769836|NCT05018923|Active Comparator|RAMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days
32769837|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
32769838|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
32769839|NCT05019079|Experimental|electroacupuncture group|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation was stopped 30min later.
33078123|NCT00173888|Experimental|A|
33078124|NCT00173888|Active Comparator|B|
33262390|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
33262391|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
32769840|NCT05019079|No Intervention|control group|The patient underwent routine anesthesia without acupuncture treatment
33078125|NCT01853722|Experimental|DCN01|
33078126|NCT01853722|Placebo Comparator|Unisol|
33078127|NCT00554983|Placebo Comparator|2|
33078128|NCT00554983|Experimental|1|
33078129|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
33078130|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
33078131|NCT04676815||NBI PATIENT|Diagnostic Test: NBI in combination with electronic bronchoscope
33078132|NCT04676815||Non-NBI PATIENT|Diagnostic Test: Electronic bronchoscope without NBI
33262392|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
33262393|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
33262394|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
33262395|NCT00978393|Experimental|A|
33262396|NCT00978393|Experimental|B|
33262397|NCT00978393|Experimental|C|
33262398|NCT00978393|Experimental|D|
33262399|NCT00978393|Experimental|E|
33262400|NCT00978393|Experimental|F|
33262401|NCT04040010|Experimental|Postmenopausal women colostrum supplement|
33262402|NCT04040010|Experimental|Osteoporosis patients colostrum supplement|
33078133|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
32769841|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle insertion by 10-15 mm and de qi sensation~Park sham guide tubes~Low frequency electronic stimulation (30 Hz)~Retention for 20 minutes."
32769842|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle installation without penetration~Park sham guide tubes~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~Retention for 20 minutes."
32769843|NCT05019001|Other|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
32769844|NCT05019001|Other|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
32769845|NCT05019313||COVID 19 positive patients|"COVID19 positive patients with hypoxemic acute respiratory failure hospitalized in intensive care unit.~This study evaluates diaphragmatic contractility with ultrasound, blood gas analytical parameters during weaning from invasive mechanical ventilation"
32769846|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
32769847|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
32769848|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
32769849|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
32769850|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
32769851|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
32769852|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
32769853|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
32769854|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
32769855|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
32769856|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~Dose escalation phase: 6-12 patients~MTD expansion cohort: 10 patients"
32769857|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
32769858|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
32769859|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
32769860|NCT03079063|Active Comparator|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
32769861|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
32769862|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
32769863|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
32769864|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
32769865|NCT04958941|Experimental|Intervention group|The group will receive the ecological momentary intervention (CUIDA-TE APP). This intervention will allow the individual to learn and practice adaptive ways to regulate their emotions. The protocol contains the following components: Distraction, acceptation skills, re-appraisal and problem-solving skills.
32769866|NCT04958941|No Intervention|Control group|This condition is a waiting list control group with no intervention. The participants will wait for a period of 3 months. They will be offered the possibility of receiving the intervention APP (CUIDA-TE) after the waiting list period.
32769867|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
32769868|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
32769869|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
32769870|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
33078134|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
32769871|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
32769872|NCT01659255|Experimental|Tirabrutinib 400 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
32769873|NCT01659255|Experimental|Tirabrutinib 500 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
32769874|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
32769875|NCT01659255|Experimental|Tirabrutinib 300 mg Twice Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
32769876|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
32769877|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
32769878|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
32769879|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
32769880|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
32769881|NCT01659255|Experimental|Tirabrutinib 480 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
32769882|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
33262403|NCT04040010|Experimental|Osteopenia patients colostrum supplement|
33262404|NCT04040010|Placebo Comparator|Postmenopausal women placebo|
33262405|NCT04040010|Placebo Comparator|Osteoporosis patients placebo|
33262406|NCT04040010|Placebo Comparator|Osteopenia patients placebo|
33262407|NCT00878280||1|1:control(healthy subjects)
33262408|NCT00878280||2|2:case(dementia patients)
33262409|NCT00872976|Experimental|Cohort #1|
33262410|NCT00872976|Experimental|Cohort #2|
33262411|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
33262412|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
33262413|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
33262414|NCT00878358|Active Comparator|Physiotherapy|
33262415|NCT00878358|Experimental|Hydrotherapy|
33262416|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
33262417|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
33262418|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
33262419|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
33262420|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
33262421|NCT05225844|Experimental|Camrelizumab Plus Apatinib mesylate|for advanced gastric cancer with previous standard treatment failure
33262422|NCT05225844|Experimental|Camrelizumab and Apatinib mesylate|for advanced colorectal cancer with previous standard treatment failure
33262423|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
33262424|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
33262425|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
33262426|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
33262427|NCT00804440|Active Comparator|Test Product|
33078135|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
33078136|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
33078137|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
33078138|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
33078139|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
33262428|NCT00804440|Active Comparator|Reference Product|
32769883|NCT01659255|Experimental|Tirabrutinib 240 mg Twice Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
33078140|NCT04676620||CK surgery|Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation.
33078141|NCT04676620||LASIK surgery|LASIK surgery is femtosecond laser assisted conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
32769884|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
32769885|NCT03076567||control|Controls from two previously conducted studies in China
32769886|NCT05014633|Experimental|EI skills training|Individuals in the intervention group received the pertinent training. The duration of the training for the intervention group was 16 hours (four four-hour sessions). The whole training process lasted for one month. EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
32769887|NCT05014633|No Intervention|Control|Individuals in the control group did not receive any training
32769888|NCT05308485||Parkinson´s disease individuals|
32769889|NCT05308485||Individuals with recent-onset parkinsonism|
32769890|NCT05308485||Healthy individuals|
32769891|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
32769892|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
32769893|NCT05341089|Experimental|LY3502970 (Formulation 1)|LY3502970 administered orally.
32769894|NCT05341089|Experimental|LY3502970 (Formulation 2)|LY3502970 administered orally.
32769895|NCT05001529|Experimental|Group A|Subject with severe asthma, treated with anti IL5R antibodies
32769896|NCT05001529|No Intervention|Group B|Subject with severe asthma, treated with conventional therapy
32769897|NCT05307159|Experimental|bean protein supplement|The supplement will be consumed daily for 21 days in the athletes' snack, the supplement contains 7 g of bean protein mixed in 60 mL of milk and 60 mL of strawberry drinkable yogurt
32769898|NCT05001061|Active Comparator|Sublingual Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses
32769899|NCT05001061|Active Comparator|Vaginal Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses
32769900|NCT05531955|Experimental|Pirfenidone group|Drug name:Pirfenidone Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week~52th week.
32769901|NCT05531955|Placebo Comparator|Placebo group|Drug name:Placebo Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week~52th week.
33078142|NCT04676581||Aeromonas infection|
33078143|NCT04676581||No infected|
33078144|NCT04676581||bacterial infection|
33078145|NCT04676503|Experimental|Test Arm - Biovaginil 480 mg capsules|All patients will be treated with 1 capsule/day of BIOVAGINIL for two treatment cycles of 14 days each.
33078146|NCT04676269|Sham Comparator|Amnion only|Amnion bilayer as a scaffold to overlay the endometrium, with minor curettage prior to stick the scaffold.
33078147|NCT04676269|Experimental|Amnion- self endometrium stem cells (EnSC)|Amnion bilayer as a scaffold, seeded with endometrium stem cells to regenerate the thin endometrium.
33262429|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
33262430|NCT03871868||study group|In Woman With Myoma Uteri
33262431|NCT03871868||control group|In Woman Without Myoma Uteri
33262432|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
33262433|NCT00804518|Experimental|Exercise intervention|
33262434|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
33262435|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
33262436|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
33262437|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
33262438|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
33262439|NCT00543855|Placebo Comparator|Placebo|
33262440|NCT00797810|Experimental|therapy|
33262441|NCT03831048|Experimental|DCD Heart Possible|
33262442|NCT03831048|Active Comparator|Standard of Care Heart Only|
32769902|NCT05014555||Group A Non-biologic Group|Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.
32769903|NCT05014555||Group B Anti-TNF Group|Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.
32769904|NCT05014555||Group C Ustekinumab Group|Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.
32769905|NCT05014555||Group D Vedolizumab Group|Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.
32769906|NCT05340621|Experimental|OKI-179 + binimetinib|
32769907|NCT05014009|Experimental|FIFA11+ and multidirectional training (MD)|Participants in the MD group will take part in an 8-week NMT intervention known to reduce the risk of sports injury and expected to improve COD movement strategies.
32769908|NCT05014009|Active Comparator|FIFA11+ and linear sprint training (LS)|Participants in the LS group will take part in an 8-week NMT intervention, which is known to reduce the risk of sports injury but is unlikely to improve COD movement strategies and is expected to improve linear sprint performance.
32769909|NCT05339529|Experimental|Thymosin alpha 1|1.6 mg q12h for 5 days
32769910|NCT05339529|Sham Comparator|Blank control|
32769911|NCT05006911|Experimental|PBOHB|Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients
32769912|NCT05339295|Experimental|Test Group|Levomerc (Levofloxacin) tablets 500 mg
33078148|NCT04676269|Experimental|Amnion- amnion epithelial stem cells (AESC)|Amnion bilayer as a scaffold, seeded with amnion epithelial stem cells to regenerate the thin endometrium.
32769913|NCT05339295|Active Comparator|Reference Group|Tavanic (Levofloxacin) tablets 500 mg
32769914|NCT05353569|Experimental|Midtown Health Clinic|Subjects will receive a standard-of-care pneumatic otoscopy examination, followed by a research-only examination using an OCT device (PCT).
32769915|NCT05353569|No Intervention|Children's Wisconsin (Effusion in 0 or 1 ear)|Subjects will only receive a standard-of-care pneumatic otoscopy examination.
33262443|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
33262444|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
33262445|NCT00881010||Telephone Intervention|
33262446|NCT00881010||Usual Care|
33262447|NCT04921605|Experimental|Tricuspid regurgitation|Subjects received the Dragonfly system for the treatment of tricuspid regurgitation.
33078149|NCT04676269|Experimental|Amnion- co culture self EnSC - AESC|Amnion bilayer as a scaffold, seeded with co-culture of endometrium stem cells and amnion epithelial stem cells to regenerate the thin endometrium.
33078150|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
33078151|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
32769916|NCT05353569|Experimental|Children's Wisconsin (Effusion in 2 ears)|Subjects will receive standard-of-care ear and hearing examinations (pneumatic otoscopy and audiology/tympanometry), followed by research-only examinations using two OCT devices (UIUC OCT and PCT).
32769917|NCT05353491|Experimental|Technology assisted Thinking Healthy Program delivered by peers|"A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app. The bespoke android app leverages human-centered design and makes use of 2-d videos demonstrating narrative scripts delivered by culturally appropriate animated avatars representing depressed mothers, families, peers and mental health experts.~It is designed as a low intensity psychosocial multicomponent intervention based on cognitive behavioral approaches. The THP improves depression through psychoeducation, behavior activation, thought challenging, improving problem solving skills and by activating social support networks.~The intervention program comprises of 8 sessions delivered by trained peers."
32898302|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
33078152|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
33262448|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
33262449|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
33262450|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
33262451|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
33262452|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
33262453|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
33262454|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
33262455|NCT00804674|Active Comparator|1 bupivacain|
32769918|NCT05353491|Active Comparator|Standard Thinking Healthy Program delivered by community health workers|"The Thinking Healthy Programme (THP) is a CBT-based manualised paper version of the intervention targeting women with perinatal depression in low socioeconomic settings.~The CBT techniques include guided discovery using illustrated brief vignettes, behavioural activation, and problem solving. Non-specific techniques include empathic listening and promoting social support from key family members for the mother in negotiating challenges during the perinatal period. This intervention programme is paper based utilizing reference manual, health calendar and job aid as tools for delivering content.~The intervention employs these techniques to improve outcomes in three areas: maternal well-being, mother-infant interaction and relationship with significant others. The intervention consists of 8 core sessions starting in the second or third trimester of pregnancy and continuing to 3 months postnatal."
32769919|NCT05352009|Experimental|Sling exercise training group|Participants will practice core muscle exercise in different positions with sling systems (Redcord®, Norway).
32769920|NCT05352009|Active Comparator|Conventional training group|Participants will practice balance exercise, including sit-to-stand, forward reaching, postural training on the therapeutic ball, maintaining standing balance with eyes open and progress to eyes close, and tandem stance.
32769921|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
33262456|NCT00804674|Placebo Comparator|2 placebo|
33262457|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
33262458|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
32769922|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
32769923|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
32769924|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
32769925|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
32769926|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
32769927|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
32769928|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
32769929|NCT05307081||1|
32769930|NCT05306535|Experimental|occlusal reduction|Performing occlusal reduction on the experimental tooth until absence of occlusal contact is confirmed following completion of the endodontic treatment
32769931|NCT05306535|No Intervention|control|No occlusal reduction or modification of the occlusal anatomy will be performed
32769932|NCT05000827|Experimental|PSMA PET/CT based indication for ePLND:|"Node-negative PSMA PET/CT [N0] and M0: do not perform ePLND~Node-positive PSMA PET/CT [N1] and M0: perform ePLND"
32769933|NCT05000827|Active Comparator|Nomogram-based indication for ePLND (standard of care)|Nomogram-based indication for ePLND (conform current EAU guidelines)
32769934|NCT05306067||Children at low transmission health facilities|
32769935|NCT05306067||Children at medium-to-high transmission health facilities|
32769936|NCT05306067||Pregnant women at low transmission ANC|
33078153|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
33078154|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
33078155|NCT01809964|Experimental|Dose 1|ANT-1401
33078156|NCT01809964|Experimental|Dose 2|ANT-1401
33262459|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
33262460|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
33262461|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
33262462|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
33262463|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
33262464|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
33262465|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
33262466|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
32769937|NCT05306067||Pregnant women at medium-to-high transmission transmission ANC|
33078157|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
33262467|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
33262468|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
33262469|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
33262470|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
33262471|NCT00873522||Community acquired pneumonia|
33262472|NCT00873522||Health-Care-Associated pneumonia|
33262473|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
33262474|NCT04016948|Experimental|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
33262475|NCT04016948|Active Comparator|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
33262476|NCT04007211|Experimental|ABT13107|
33262477|NCT04007211|Active Comparator|Hyalobarrier|
33262478|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
33262479|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
33078158|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
32769938|NCT05350527|Experimental|Arm A: Web platform and video information support|After usual preoperative information delivered by surgeon, patients allocated to Arm will be able to access to video information support and web platform.
32769939|NCT05350527|No Intervention|Arm B: Standard Preoperative information|Patients randomized in Arm B will only receive usual preoperative information delivered by the surgeon.
33262480|NCT00881166|Experimental|3|oral MP-470 + topotecan
33262481|NCT00881166|Experimental|4|oral MP-470 + docetaxel
33262482|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
33078159|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
33078160|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
33078161|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
33078162|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
33078163|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
33078164|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
33262483|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
33078165|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
33078166|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
32769940|NCT04462705|Active Comparator|Usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1 post-surgical:~- First lift with verticalization.~- A session with the Cliniflo® in a seated position.~- Walk at least 100 m with the help of the physiotherapist.~At- D+2 and D+3 post-surgical Same session as on D+1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3"
32769941|NCT04462705|Experimental|abdominal massage and usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1post-surgical:~- First lift with verticalization.~- A session with the Cliniflo® in a seated position.~- Walk at least 100 m with the help of the physiotherapist.~At- D + 2 and D + 3 post-surgical Same session as on D + 1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3~In this experimental arm, a abdominal massage will be performed in addition to the usual physiotherapeutic intervention (respiratory and walking exercices).~The sessions take place on D+1, D+2 and D+3 post-surgical The first session is performed at least 20 hours after surgery (incision begins) Never within an hour of a meal. The session is timed."
33078167|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
33078168|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.~Initial dose will be 30/m2/day SQ for 5 days~total 10 cycles of SGI-110"
33078169|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
33078170|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
33262484|NCT05225766|Active Comparator|Group ESPB|Erector spinae plane block
33262485|NCT05225766|Active Comparator|Group RSB|Rectus sheath block
33262486|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
33262487|NCT00873678||1|Children or adult patients affected with JS/CORS
33262488|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
33262489|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
33262490|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
33262491|NCT00805922||A|
33262492|NCT00978783|Active Comparator|speaking valve|
33262493|NCT00978783|Active Comparator|Positive end expiratory pressure|
33262494|NCT00806000||Athletes|
33262495|NCT00982293|Active Comparator|Active fields|
33262496|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
33078171|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
33078172|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
33078173|NCT01781104|Active Comparator|RM-131|
33078174|NCT01781104|Placebo Comparator|Placebo|
33262497|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
33262498|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
33262499|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
32769942|NCT05338905|Experimental|Group A (quality of life questionnaire)|Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.
32769943|NCT05338905|Active Comparator|Group B (standard symptom management)|Patients receive standard symptom management QW during standard of care radiation therapy and at 1, 3, and 6 months after completing radiation therapy course.
33262500|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
33262501|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
32769944|NCT05338593||prolonged veno-venous extracorporeal membrane oxygenation|Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
32769945|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
33078175|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
33078176|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
32769946|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
33078177|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
33078178|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
33262502|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
33262503|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
33262504|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
33262505|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
33262506|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
33262507|NCT04007445|Active Comparator|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
33262508|NCT04007445|Placebo Comparator|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
33262509|NCT00881244|Experimental|1|AS1411
33262510|NCT00655928|Experimental|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
33262511|NCT00655928|Placebo Comparator|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
33262512|NCT04038762|Active Comparator|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
33262513|NCT04038762|Experimental|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
33078179|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
33078180|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
33078181|NCT01777165|Placebo Comparator|Arm 4 placebo|
33078182|NCT00203619|Experimental|1|Wireless capsule endoscopy
33078183|NCT00203619|Active Comparator|2|Standard care
33078184|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
33078185|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
33078186|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
33262514|NCT00805220|Active Comparator|1|Regular overground walking without poles
33262515|NCT00805220|Experimental|2|Nordic Walking
33262516|NCT05224908|Experimental|pregnant women with a breech fetus|pregnant women with a breech fetus performing standing and sitting EOS pelvimetry
33262517|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
33262518|NCT00873756|Experimental|A|
33078187|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
33078188|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
33078189|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
33262519|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
33262520|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
33262521|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
33078190|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
33078191|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
32769947|NCT05305989|Experimental|Arm A: belumosudil 200 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
32769948|NCT05305989|Experimental|Arm B: belumosudil 200 mg BID|The assigned arm is per the previous study KD025-213 or study KD025-208
33078192|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
33078193|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
33078194|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
32769949|NCT05305989|Experimental|Arm C: belumosudil 400 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
32769950|NCT05013697|Experimental|Experimental group 1|"Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).~Maintenance treatment: TQB2450 injection+Anlotinib."
32769951|NCT05013697|Experimental|Experimental group 2|Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.
32769952|NCT05509647||Covid-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. All patients have Covid-19 proven by PCR or nose- or airway swab. Patients admitted to the ICU from the 15th of March 2020 until January 2022.
32769953|NCT05509647||non-COVID-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. Patients admitted to the ICU between the 1st of January 2014 and the 1st of January 2020 are included.
32769954|NCT04928911||Adults receiving COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
32769955|NCT05305911|Active Comparator|Treatment Group|Treatment group will receive dapagliflozin in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
32769956|NCT05305911|Placebo Comparator|Placebo Group|Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
32769957|NCT05349591|No Intervention|Control|The Participants in this arm receive islet transplant only and no cePolyTregs.
32769958|NCT05349591|Experimental|Treatment|Participants will receive cePolyTregs (target 400-1600 million, with a minimal acceptable dose of 100 million) two weeks post islet transplant and will be followed for 1 year after cePolyTregs infusion to assess the safety and preliminary efficacy of cePolyTregs therapy.
33078195|NCT01756924|Experimental|CEM-102 plus Rifampin|
32769959|NCT05349435|Experimental|Cohort 1 Dose Level 1|Drug: Fezagepras and sodium PBA
32769960|NCT05349435|Experimental|Cohort 2 Dose Level 2|Drug: Fezagepras and sodium PBA
32769961|NCT05007223||1. Experimental: doxycycline|Given doxycycline and assessment of skin
33262522|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
33262523|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
33262524|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
33262525|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
33262526|NCT00881322|Experimental|BC-130|Active Arm
33262527|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
33262528|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
33262529|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
33262530|NCT04038918|Experimental|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
33262531|NCT04038918|Other|Control Group|Standard postoperative physiotherapy program will be applied.
33262532|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
32769962|NCT05007223||2. No Intervention: Healthy Controls|Control subjects to assess if there is baseline difference in the skin microbiome
32769963|NCT05305599|Experimental|ZED1227 (low dose) 10 mg|
32769964|NCT05305599|Experimental|ZED1227 (middle dose) 25 mg|
33078196|NCT01756924|Active Comparator|Standard of Care|
33262533|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
33078197|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
33262534|NCT00874068|Active Comparator|Standard vegetable oil formula|
32769965|NCT05305599|Experimental|ZED1227 (high dose) 50 mg|
33262535|NCT00874068|Active Comparator|InFat|
33262536|NCT00874068|No Intervention|Breast-fed|
33262537|NCT00805298|Active Comparator|methylprednisolone|
33262538|NCT00805298|Placebo Comparator|placebo|
33262539|NCT00805298|Active Comparator|lidocaine|
33262540|NCT00805298|Active Comparator|bupivacaine|
32769966|NCT05305599|Placebo Comparator|Placebo|
33262541|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
33262542|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
33262543|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
33262544|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
33262545|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
33262546|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
33262547|NCT00246571|Experimental|A|
33262548|NCT00246571|Active Comparator|B|
33262549|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
32769967|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
32769968|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
32769969|NCT05337891||Patients with suspected or diagnosed myasthenia gravis|Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form), aged 18-80, both sexes, with performed or planned determination of anti-acetylcholine receptor antibodies and muscle-specific tyrosine kinase antibodies
32769970|NCT05000281|Experimental|NSAID|Standard of care pain medication regimen with NSAIDs.
32769971|NCT05000281|No Intervention|No NSAIDs|Standard of care pain medication regiment with no NSAIDs
32769972|NCT05348889|Experimental|Dose Escalation|Open label, single arm trial where 1A46 will be administered
32769973|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
33262550|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
33262551|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
33262552|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
32769974|NCT03081949|No Intervention|Control|No treatment
32769975|NCT04999579|Active Comparator|Complete denture|Conventional complete denture without supporting devices
32769976|NCT04999579|Experimental|Ultra suction retained complete denture|Conventional complete denture with ultra suction device
33078198|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
33262553|NCT00798356|Other|1|Yoga training
33262554|NCT00734591||Previously treated with Exubera|
33262555|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
33078199|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
33078200|NCT01754935|Experimental|VX-509 100 mg qd Arm|
33262556|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
33262557|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
33262558|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
33262559|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
33262560|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
33262561|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
33262562|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
33262563|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
33262564|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
33262565|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
33262566|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
33262567|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
33078201|NCT01754935|Experimental|VX-509 200 mg qd Arm|
33262568|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
32769977|NCT05303883|Experimental|Pediatric constraint induced therapy|Constrained induced therapy for children with hemiplegic cerebral palsy. Three hours of therapy per day, for five days a week, for four weeks.
33262569|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
32769978|NCT04999813|Experimental|Comprehensive intensive intervention|On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability.
33262570|NCT00545103|Experimental|SPD476 (1.2 g)|
33262571|NCT00545103|Experimental|SPD476 (2.4 g)|
33262572|NCT00545103|Experimental|SPD476 (4.8 g)|
33262573|NCT00545103|Placebo Comparator|Placebo|
33262574|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
32769979|NCT04999813|No Intervention|Routine management|Only routine management was carried out for the subjects without special intervention.
32769980|NCT05347797|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue. The KRAS Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
33078202|NCT01754935|Experimental|VX-509 300 mg qd Arm|
33078203|NCT01754935|Placebo Comparator|Placebo Arm|
33262575|NCT00586157|Placebo Comparator|Placebo|
33262576|NCT04087421|Experimental|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
33262577|NCT04087421|Active Comparator|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
33262578|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
33262579|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
33262580|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
33078204|NCT01751152|Experimental|NNC0114-0006|
33078205|NCT01751152|Placebo Comparator|Placebo|
33078206|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
33078207|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
33262581|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
33078208|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
33078209|NCT00555178||4|Normal healthy subjects
33262582|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
33262583|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
33262584|NCT04045574|Experimental|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
33262585|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
33262586|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
33262587|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
33262588|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
33262589|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
33262590|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
33262591|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
33262592|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
33262593|NCT00809822|Placebo Comparator|2|Physiological saline
33262594|NCT04006587|Experimental|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
33262595|NCT04006587|No Intervention|control|standard care without IS intervention
33262596|NCT00246337|Placebo Comparator|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
33262597|NCT00246337|Experimental|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262598|NCT00246337|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262599|NCT00246337|Experimental|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262600|NCT00246337|Experimental|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262601|NCT00246337|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
32769981|NCT04458883|Experimental|Myocardial Infarction Group|Patients diagnosed with a myocardial infarction
33262602|NCT00246337|Experimental|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262603|NCT00246337|Experimental|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262604|NCT00246337|Active Comparator|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
33262605|NCT05370521|Experimental|Treatment with Tildacerfont|Subjects randomized in this arm will receive 4 weeks of 50mg of oral tildacerfont tablet, followed by 4 weeks of 100 mg oral tildacerfont tablet, and then 4 weeks of 200 mg oral tildacerfont tablet for a total of 12 weeks of treatment.
33262606|NCT05370521|Placebo Comparator|Placebo Control Arm|Subjects randomized in this arm will receive 12 weeks of oral matched-placebo tablet
32769982|NCT04458883|Experimental|Healthy Volunteers|Healthy Volunteers
33262607|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
32769983|NCT05347563||Group A|group A: Patient < 18 years old admitted to a continuous monitoring unit - resuscitation for acute respiratory failure regardless of the ventilation modality and benefiting from TIE monitoring
32769984|NCT05347563||Group B (reference)|Group B (reference): Patient under general anesthesia with mechanical ventilation without respiratory pathology.
32769985|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
32769986|NCT05337735|Experimental|XmAb20717|Participants will receive XmAb20717 by vein over 1 hour on Days 1 and 15 of each cycle.
32769987|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
32769988|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
32769989|NCT05336877||Device: Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
32769990|NCT05336877||Device: Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
32769991|NCT05303649|Experimental|Intermittent TBS (iTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of 200-second of iTBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
32769992|NCT05303649|Experimental|Continuous TBS (cTBS) of the right hemisphere plus behavioral aphasia therapy|15 sessions of 40 seconds of cTBS over the pars triangularis of the right inferior frontal gyrus (BA 45 homologue), preceding 45-minutes of behavioral aphasia therapy.
32769993|NCT05303649|Sham Comparator|Sham TBS (sTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of sham TBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
32769994|NCT05006755|Experimental|control group|the group of primary molar teeth that will be treated in furcal perforation with Mineral Trioxide Aggregate
32769995|NCT05006755|Experimental|experimental group|the group of primary molar teeth that will be treated in furcal perforation with Biodentine
33262608|NCT04789161||double kissing crush stenting|patients with true bifurcation lesion undergoing double kissing crush stenting
33262609|NCT04789161||double kissing culotte stenting|patients with true bifurcation lesion undergoing double kissing culotte stenting
33262610|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
33262611|NCT05012943|Experimental|ARCT-154|Each participant is planned to receive a two-dose vaccination series of ARCT-154 at a dose of 5 µg with 28 day interval in the first vaccination series.
32769996|NCT05347173|No Intervention|Bupivacaine group (B gp)|Patients will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus 0.5 ml normal saline
32769997|NCT05347173|Active Comparator|Bupivacaine-Dexmedetomidine group (BD gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 10 µg Dexmedetomidine in 0.5 mL normal saline
32769998|NCT05347173|Active Comparator|Bupivacaine-Nalbuphine group (BN gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 1 mg Nalbuphine in 0.5 mL normal saline
32769999|NCT05006287|Experimental|Non-Vitamin K Oral Anticoagulant (NOAC) Group|Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)
32770000|NCT05006287|Active Comparator|Warfarin Group|Anticoagulation with warfarin to target INR 2.5
32770001|NCT05303415|Experimental|LIFU, heat evoked fMRI signals|fMRI resting and heat evoked signals performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).
32770002|NCT05013151|Experimental|Date consumption|Consumption of 6 dates a day until 41 weeks of gestation
32770003|NCT05013151|Experimental|Castor oil consumption|One time consumption of 60 CC of Castor oil
32770004|NCT05013151|No Intervention|Control Group|
33078210|NCT01750957|Placebo Comparator|Placebo|
33078211|NCT01750957|Experimental|RO4917523 Dose A|
33078212|NCT01750957|Experimental|RO4917523 Dose B|
33078213|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
33262612|NCT05012943|Placebo Comparator|Placebo|Each participant is planned to receive a two-dose vaccination series of placebo (normal saline) with 28 day interval in the first vaccination series.
33262613|NCT05012943|Active Comparator|Astra Zeneca COVID-19 vaccine|Each participant is planned to receive a two-dose vaccination series of Astra Zeneca COVID-19 vaccine with 28 day interval in the first vaccination series.
32770005|NCT05303337||Patients switching towards a long-aging injectable treatment|
32770006|NCT05303337||Patients maintaining oral ART 2-drug regimens|
32770007|NCT05303337||Patients maintaining oral ART 3 drug regimens|
32770008|NCT05006365|Experimental|Transcranial Pulse Stimulation|Investigators will use a single-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. The first arm is the Intervention Group (Transcranial Pulse Stimulation) (TPS group)
32770009|NCT05006365|Active Comparator|Waitlist Control Group|Second arm is the waitlist control group.
32770010|NCT05302089|Experimental|One-time physiotherapy instruction|One-time physiotherapy instruction and no usual rehabilitation care
32770011|NCT05302089|Active Comparator|Usual rehabilitation care|One-time physiotherapy instruction and usual rehabilitation care
32770012|NCT05006209|Active Comparator|One visit root canal treatment with CHX|The teeth were treated in one-visit (OV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
32770013|NCT05006209|Active Comparator|Two visit root canal treatment with CH|The teeth were treated in two visit (TV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
32770014|NCT05346003|Experimental|Intervention Group|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. he BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human CPR mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a CPR mock-up in a home environment, and after blended e-learning, they will be able to perform CPR iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice CPR in a real simulation model two weeks after the blended e-learning.
32770015|NCT05346003|No Intervention|Control Group|In the pretest, all students will be given a BLS knowledge test, followed by e-learning blended with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class. Two weeks after the blended e-learning, all students will practice CPR in a real simulation model. Psychomotor skills will be recorded in the evaluation form.
32770016|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
32770017|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
32770018|NCT05335629|Active Comparator|Intervention arm|"30 patients will receive standard of care in addition to the SGLT2 Dapagliflozin 10 mg daily for 4 Weeks~Interventions:~Drug: Dapagliflozin 10 mg oral tablets Standard of care: Dual antiplatelet therapy, Statin, anticoagulation therapy"
33078214|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
33078215|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
33078216|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
33078217|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
33078218|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
33078219|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
33078220|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
33078221|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
33078222|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
33078223|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
33078224|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~Injection of Lexiscan.~Coronary catheterization:~Pressure and flow readings using Combowire~Injection of Adenosine."
33078225|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
33078226|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
33078227|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
33078228|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
33078229|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
33078230|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
32770019|NCT05335629|No Intervention|Control arm|30 patients will receive standard of care (Dual antiplatelet therapy, Statin, anticoagulation therapy) for 4 weeks
33078231|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
33401473|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
33401474|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
33401475|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
33401476|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
32770020|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
33078232|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
33078233|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
32770021|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
32770022|NCT03078673|Experimental|Control group|Only regular training
32770023|NCT03075787||patients with obstructive sleep apneas|
32770024|NCT05531253||Main cohort|Patients undergoing cardiac surgery who will have a pulmonary artery catheter in-situ at the time of admission to cardiac intensive care postoperatively.
32770025|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
32770026|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
32770027|NCT05301621||Arthritis patients|It is not planned any intervention. The patients' group will be invited to 4 visits.
32770028|NCT05301621||Healthy controls|No intervention planned. Only one visit will be conducted.
32770029|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
32770030|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
32770031|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
32770032|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
32770033|NCT05345769|Experimental|Phase I- All|Subjects with neovascular AMD
32770034|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
32770035|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
32770036|NCT05301543|Experimental|Behavioral approach 1|This includes sleep hygiene and other elements to serve as an experimental arm; subjects will receive a clinically proven therapeutic intervention.
32770037|NCT05301543|Active Comparator|Behavioral approach 2|This includes sleep hygiene and other elements to serve as an active comparator; subjects will receive a clinically proven therapeutic intervention.
33078234|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
33078235|NCT01712308|Experimental|Treatment (sotatercept)|Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
33078236|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
33078237|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
33078238|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
33401477|NCT04978168|Experimental|Implementation Core|During baseline Exploration, staff organizational surveys are collected. During Preparation, staff focus groups conduct needs assessment with system mapping of linkage points for screening, assessment, and referral, and the agencies/staff involved in these activities. During Implementation, sites use facilitated local change teams (LCT) provided with a core set implementation strategies to facilitate linkages between probation agencies and local community treatment providers. The LCTs identify barriers to change, approaches to overcome barriers, do goal selection using SMART (specific, measurable, achievable, relevant, timely) goals and evidence for medications, address stigma, and clarify needs/expectations/roles of probation officers and treatment providers, then choose and implement goals and strategies. Sustainability Phase: Facilitators work with LCTs for 12 months using a written action plan based on goal selection.
32770038|NCT05554965|Active Comparator|propofol|The control group was sedated with propofol
32770039|NCT05554965|Experimental|Remimazolam besylate|The experimental group was given remazolam besylate for sedation
33078239|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
33078240|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
33078241|NCT00174434|Experimental|A|
33078242|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
33078243|NCT01691755|Placebo Comparator|Placebo|
33078244|NCT01691755|Experimental|aleglitazar|
33078245|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
33078246|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
33078247|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
33078248|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
33078249|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
33078250|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
33078251|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
33078252|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
33078253|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
33078254|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
33078255|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
33078256|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
33078257|NCT01665391|Placebo Comparator|Placebo|
33078258|NCT01665352|Experimental|TTP054 400 mg|
33078259|NCT01665352|Experimental|TTP054 200 mg|
33078260|NCT01665352|Experimental|TTP054 800 mg|
33078261|NCT01665352|Placebo Comparator|Placebo|
33078262|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
33078263|NCT04676659|Experimental|Group 1 (rhTNK-tPA 0.10 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.10 mg/kg IV bolus over 5-10 seconds.
33078264|NCT04676659|Experimental|Group 2 (rhTNK-tPA 0.25 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.25 mg/kg IV bolus over 5-10 seconds.
33078265|NCT04676659|Experimental|Group 3 (rhTNK-tPA 0.32 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.32 mg/kg IV bolus over 5-10 seconds.
33078266|NCT04676659|Active Comparator|Group 4 (rt-PA 0.9 mg/kg)|10% of rt-PA 0.9 mg/kg administered as an initial IV bolus followed by the remaining 90% as an IV infusion over the next 1 hour.
33078267|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
33078268|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
33078269|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
33078270|NCT01655680|Placebo Comparator|Placebo|Placebo
33078271|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
33078272|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
33078273|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
33078274|NCT00174629|Experimental|1|
33078275|NCT00174629|Active Comparator|2|
33078276|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
33078277|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
33078278|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
33078279|NCT00555334|Active Comparator|2|RFA only
33078280|NCT01640080|Experimental|Esketamine (Group 1)|
33078281|NCT01640080|Experimental|Esketamine (Group 2)|
33078282|NCT01640080|Placebo Comparator|Placebo|
33078283|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
33078284|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
33078285|NCT01636843|Experimental|60 mg|
33078286|NCT01636843|Experimental|120 mg|
33078287|NCT01636843|Experimental|240 mg|
33078288|NCT01636843|Experimental|Placebo|
32770040|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
32770041|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
32770042|NCT05300217|Experimental|Intervention Group 1 - Strategies for promoting mental health|Exposure to information about strategies for promoting mental health
32770043|NCT05300217|Experimental|Intervention Group 2 - General information about depression|Exposure to general information about depression
32770044|NCT04947475|Experimental|Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program|There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.
32770045|NCT05554419|Active Comparator|ARM A (cytarabine)|Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
32770046|NCT05554419|Experimental|ARM B (cytarabine, venetoclax)|Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
32770047|NCT05554419|Experimental|ARM C (liposomal daunorubicin-cytarabine, venetoclax)|Patients receive liposome-encapsulated daunorubicin-cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
32770048|NCT05554419|Experimental|ARM D (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
32770049|NCT05554341|Experimental|Treatment (nilotinib hydrochloride monohydrate, paclitaxel)|Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening, on study, and during follow up. Patients also undergo collection of blood samples and tumor biopsy prior to starting treatment.
32770050|NCT05552469|Experimental|DFV890 low dose|DFV890 given as single agent at a low dose
32770051|NCT05552469|Experimental|DFV890 high dose|DFV890 given as single agent at a high dose
32770052|NCT05335161|Experimental|Home-based leg heat therapy|Patients will be provided with the Aquilo heat therapy device and will be instructed on how to operate the equipment. The device will be used in accordance to the manufacturers recommendations. Patients will be asked to apply the therapy daily in the home setting for 12 week (90 min/day, 7 days/week).
32770053|NCT05335083|Experimental|CPAP on condition|Participants in this arm will begin by using their CPAP as per usual for 2 weeks. Then they will undergo 2 weeks of CPAP withdrawal and stop using their CPAP machine.
32770054|NCT05335083|Experimental|CPAP off condition|Participants in this arm will withdraw from their regular CPAP use for 2 weeks. They will then resume their CPAP use for 2 weeks as usual.
32770055|NCT05333835|Experimental|HR17031 injection|
32770056|NCT05333835|Active Comparator|INS068 injection|
32770057|NCT05333835|Active Comparator|SHR20004 injection|
32770058|NCT05268471|Experimental|Positional Device (PD)|Vibrating positional device (Nightbalance, Philips) to treat positional obstructive sleep apnea
32770059|NCT05268471|Active Comparator|Continuos Positive Airway Pressure (CPAP)|Continuos Positive Airway Pressure (standard treatment) to treat obstructive sleep apnea
32770060|NCT05505825|Experimental|AK104 once every 3 weeks and Chiauranib once a day|Subjects receive AK104 once every 3 weeks plus Chiauranib once a day until intolerable toxicity, no more clinical benefit as judged by the investigator, or completion of 24 months of treatment, or meeting other criteria for termination of treatment in the protocol, whichever occurs first.
32770061|NCT05333523|Experimental|Sentinel lymph node biopsy guided selective elective neck irradiation|"FDG-PET-scan in treatment mask for radiotherapy planning~Sentinel lymph node biopsy~Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with selective elective neck irradiation guided by histopathologic status of the sentinel lymph node(s)"
32770062|NCT05333523|Active Comparator|Standard elective neck irradiation|"FDG-PET-scan in treatment mask for radiotherapy planning~Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with standard elective neck irradiation"
32770063|NCT05299749|Experimental|stg-rt-fMRI|will receive feedback from the STG
32770064|NCT05299749|Sham Comparator|sham-rt-fMRI|will receive feedback from the motor cortex
32770065|NCT05299047|Active Comparator|Group US-guided|will receive superior hypogastric plexus neurolysis by the US-guided anterior approach
32770066|NCT05299047|Active Comparator|- Group fluoroscopy-guided|will receive superior hypogastric plexus neurolysis by the fluoroscopy-guided anterior approach
32770067|NCT05333445|Experimental|Nursing intervention|The NI will be performed at 3 times: face to face between 21 and 7 days before admission, between 7 and 15 days after the date of ablation, and 6 months after the ablation procedure.
32770068|NCT05333445|Active Comparator|control group|"After hospital discharge, all patients will be referred to their primary care physician or cardiologist for follow-up.~Patients will receive standard follow-up checks by the medical team will not receive structured education from the nurse."
32770069|NCT05268003|Experimental|Ponatinib|Patients will continue to take ponatinib 30mg daily continuously daily from Day 1. On Day 1, 20mg for 1 day, 50mg for 1 day, 100mg for 1 day, 200mg for 1 day, then 400mg daily
32770070|NCT05268003|Experimental|Venetoclax|Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.
32770071|NCT05268003|Experimental|Mini-hyper-CVD|Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.
32770072|NCT05267769|Experimental|Verum|AP707 single dose oromucosal application
33078289|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
33078290|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
33078291|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
33078292|NCT01635907|Experimental|Dovitinib|
33078293|NCT01633372|Experimental|itacitinib 100 mg|itacitinib 100 mg twice a day
33401478|NCT04978168|Experimental|Randomized Trial of Peer Support Specialist Model|After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
33401479|NCT04978168|Active Comparator|Randomized to Treatment as Usual|After Core Implementation is complete, half of adult participants in probation who consent will be randomly assigned to continue with usual care.
33401480|NCT04057508|Active Comparator|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
33401481|NCT04057508|Sham Comparator|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
33401482|NCT04887077|Experimental|Kiplin intervention|Kiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
33401483|NCT04887077|Active Comparator|face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
33078294|NCT01633372|Experimental|itacitinib 200 mg|itacitinib 200 mg twice a day
33078295|NCT01633372|Experimental|itacitinib 300 mg|itacitinib 300 mg once a day
33078296|NCT01633372|Experimental|itacitinib 400 mg|itacitinib 400 mg once a day
33078297|NCT01633372|Experimental|itacitinib 600 mg|itacitinib 600 mg once a day
33078298|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
33078299|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
33078300|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
33078301|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
33078302|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
33078303|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
33078304|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
33078305|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
33078306|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
33078307|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
33078308|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
33078309|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
33078310|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
33078311|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
33078312|NCT00693238|Experimental|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
33078313|NCT00693238|Experimental|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
33078314|NCT02894359||CD patients|10 patients with a cervical dystonia
33078315|NCT02894359||control subjects|10 healthy patients
33078316|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
33078317|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
33078318|NCT00555373|Other|Sirolimus|Single arm
33078319|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
33078320|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
33078321|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
33078322|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
33078323|NCT00555490|Experimental|1|
33078324|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
33078325|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
33078326|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
33078327|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
33078328|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
33078329|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
33078330|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
33078331|NCT02894125||old subject|
33078332|NCT02894320||Parkinson's disease|
33078333|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
33078334|NCT00199290|Placebo Comparator|P|
33078335|NCT00199290|Experimental|L|low dose (0.2 %)
33078336|NCT00199290|Experimental|M|medium dose (0.3 %)
33078337|NCT00199290|Experimental|H|high dose (0.4 %)
33078338|NCT04676542|Experimental|One group taking part in 2 separate conditions|The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
33078339|NCT04676776|Experimental|Missed period pill regimen|1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3
33078340|NCT04676464||ultra- sound|ultra- sound assessment of their quadriceps muscle layer thickness (QMLT)
33078341|NCT04676230|Experimental|Experimental group|caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
33078342|NCT04676230|Active Comparator|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
33078343|NCT04676074|No Intervention|control group|the participant will not do any exercise program but just they will take the routine medication.
33078344|NCT04676074|Experimental|study group|will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.
33078345|NCT04676113||Pediatric Patients with Sickle Disease who are overweight/obese|Pediatric Patients age 10-19 years diagnosed with Sickle cell disease who have a BMI of >85%ile.
33078346|NCT04676113||Pediatric Patients with Sickle Cell Disease who are underweight/normal weight|Pediatric Patients age 10-19 years diagnosed with Sickle Cell disease who have a BMI<85%ile.
33078347|NCT04675762|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
33078348|NCT04675762|Placebo Comparator|Placebo with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with placebo.
33078349|NCT04675645|Other|HU-Go app intervention arm|Participants will use HU-Go app intervention arm for a total of 12 weeks.
33262614|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
33262615|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
33262616|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
33262617|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
33262618|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
33262619|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
33262620|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
33401484|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
33401485|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
33401486|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
33401487|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
33078350|NCT04675684|Experimental|Recovery-group|"The recovery group consists of:~Physical, mental and social health education, advice and feedback from a health investigator.~Daily self-monitoring about their mood and health in an app, Monsenso.~Intersectoral collaboration between 1) Mental Health Centre Copenhagen Rigshospitalet, IAOC 2) Centre for Research and Education in General Practice, University of Copenhagen 2) Centre for Social Medicine at Frederiksberg Hospital, 3) Competence Centre for Rehabilitation and Recovery, Mental Health Centre Ballerup, and 5) Private Practicing Psychiatrists."
33078351|NCT04675684|No Intervention|Control-group|The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
33078352|NCT00555529||1|
33078353|NCT00555529||2|
33078354|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
33078355|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
33078356|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
33078357|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
33078358|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
33078359|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
33078360|NCT00555724|Experimental|BIIB022|
33078361|NCT00555763|Active Comparator|1|
33078362|NCT04675528|Experimental|Fasting treatment|
33078363|NCT04675528|Experimental|Fed treatment|
33078364|NCT04675177|Active Comparator|Polidocanol foam sclerotherapy|Patients submitted to polidocanol foam sclerotherapy
33078365|NCT04675177|Active Comparator|Doppler-guided hemorrhoidal artery ligation|Patients submitted to doppler-guided hemorrhoidal artery ligation
33078366|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
33078367|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
33078368|NCT04675372|Experimental|Group 1|Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
33078369|NCT04675372|Active Comparator|Group 2|Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
33078370|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
33078371|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
33078372|NCT04449991|Experimental|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
33078373|NCT04449991|No Intervention|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
33078374|NCT04447768|Experimental|Venetoclax and Obinutuzumab|All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
33078375|NCT04424602|Experimental|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
33078376|NCT04424602|Active Comparator|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
33078377|NCT04395079|Experimental|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
33078378|NCT04395079|Experimental|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
33078379|NCT04389892|Experimental|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
33078380|NCT04353739|Experimental|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
32770073|NCT05267223||Individuals with Paraplegia|After screening the participants according to the inclusion/exclusion criteria, informed consent will be obtained from all the selected participants. Their demographic details will be obtained and asked for their comfortable time for the interview. Data will be collected by in-depth face to face, semi- structured interviews. Audio/video recording of the interview will be taken & it will be written in English and will be transcribed verbatim also manual notes will be prepared for their analysis after the interview is conducted
32770074|NCT05298891|Experimental|Acromegalic adult in therapy with somatostatin analogues|Patients will continue the usual medical outpatient visits cadency and will keep the same pharmacological therapy throughout the whole duration of the study. Drugs have to include somatostatin analogues. At the same time, patients will be trained by an expert dietician in the habit of an isocaloric and hypoproteic diet and will come back at 2,4,6 and 8 weeks after T0 for all the necessary study assessments and compliance checking.
32770075|NCT05298033|Experimental|Active NBUVB plus Crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical along with 6 months of treatment with active NBUVB
32770076|NCT05298033|Experimental|Active NBUVB plus PF-07038124 0.01% topical ointment|12 participants will receive 6 months of treatment with active NBUVB, to be combined with 3 months of treatment with PF-07038124 0.01% topical ointment followed by 3 months of vehicle ointment
32770077|NCT05298033|Active Comparator|Active NBUVB plus vehicle ointment|8 participants will receive 6 months of treatment with active NBUVB combined with 6 months of vehicle ointment application
32770078|NCT05298033|Experimental|Sham phototherapy plus crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical ointment combined with 6 months of sham phototherapy
32770079|NCT05298033|Experimental|Sham phototherapy plus PF-07038124 0.01% topical ointment|12 participants will receive 3 months of treatment with PF-07038124 0.01% topical ointment, followed by 3 months of vehicle ointment, along with 6 months of sham phototherapy
32770080|NCT05298033|Placebo Comparator|Sham phototherapy plus vehicle ointment|8 participants will receive 6 months of sham phototherapy combined with 6 months of vehicle ointment application
32770081|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
32770082|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
32770083|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
32770084|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
32770085|NCT05297097|Experimental|Trulacta breastmilk supplement|Once daily Trulacta supplement
32770086|NCT05266053|Experimental|Treatment Group|This group will have a PICO negative pressure wound treatment device applied to their surgical wound site.
32770087|NCT05266053|Other|Control Group|Standard Intervention. This group will have a standard wound dressing (gauze, bandage) applied to their surgical wound site.
32770088|NCT05265195||Semi-structured Interviews|"Interviews will be conducted with parents and clinicians regarding their experiences of periviable counselling conversations. The interviews aim to identify key priorities and topic themes for the pre-delivery conversation for both parents and the clinicians, as these are hypothesised to differ between the groups.~Thematic analysis of transcribed semi-structured interviews with 20 parents and 20 clinicians.~The recruited parents will encompass a mixture of parent experiences: those with a surviving periviable child, parents whose baby died in delivery room and parents whose baby died in the neonatal unit."
32770089|NCT05265195||National evaluation of current periviable management practices across the UK.|Review of periviable deliveries and antenatal management practices in the United Kingdom for infants where the decision is for active care at delivery.
32770090|NCT05265195||Recording and thematic analysis of periviable decision-making conversations|"Recruiting parents who have presented in periviable labour to Manchester Foundation Trust sites.~Aiming to audio record 20 conversations discussing management options and potential outcomes between healthcare professionals and parents.~Thematic analysis will be undertake to determine key topics and priorities for parents and clinicians (these may well differ), time taken to discuss each topic, order topics presented, management options offered or requested, and discussion of comfort care."
32770091|NCT05265195||Comparison of recorded and simulated periviable decision-making conversations|"Recruit 20 senior clinicians from mixture of obstetric and neonatal specialities.~Clinician will participate in a standardised simulated discussion with two parents (played by actors) who have presented in periviable labour.~Simulated conversations will be audio recorded and transcribed.~Analysis will be performed for structure and topics included in this simulated conversation. Comparison will be undertaken comparing the conversational architecture of the simulated conversations with the recorded real conversations (recorded in the above phase of this study)."
32770092|NCT05265195||Focus Groups with parents and clinicians|"Parent focus groups to consolidate and stratify key priority themes for periviable counselling and development of parent resources.~Clinician focus groups to discuss experiences with training in this area and preferences for future training methods/resources.~Parents will be recruited from parental advisory groups and local baby groups.~Aiming to run 5x focus groups with maximum 8 participants in each group."
32770093|NCT05265195||Parental survey of long-term outcomes|"Survey will be distributed to all parents of surviving periviable deliveries at St Mary's Manchester over the last 2 - 10 years.~Parents will be asked to complete the survey at home giving their views on their child's strengths, difficulties, development and social interactions.~The survey also asks parents for their views on what they remember they were told before they delivered and, in light of their experiences, what would they recommend clinicians include in pre-delivery periviable conversations with future parents.~The survey will be sent to all eligible parents, which equates to 220 surviving infants. All returned surveys will be analysed."
32770094|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start = T1; end= T2)"
33078381|NCT04353739|Active Comparator|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
33078382|NCT04335721|Experimental|Voxelot|Voxelotor 1500mg once a day
32770095|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:~Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
32770096|NCT04136223||RA-ILD|"Consecutive adult patients (aged >18 years) with RA* and interstitial lung disease~*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010"
32770097|NCT05501379||Cancer Patients|Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.
33078383|NCT04335721|Other|Standard of Care (SOC)|Observational while receiving SOC
33078384|NCT04314973|Active Comparator|Evaluation sessions|Patients will be evaluated while walking without wearing the robotic device, once before the intervention phase, once right after, and once a month after.
32770098|NCT05262855|Experimental|68Ga-FAPI-46 PET/CT|Patients receive [68Ga]FAPI-46 intravenously followed by PET/CT 15-25 minutes later
32770099|NCT05262777|Experimental|GP0112|GP0112 Single injection and optional touch up injection and re-treatment with GP0112
33078385|NCT04314973|Experimental|Intervention phase|Patients will walk with the robotic device, for 12 sessions of 10 min.
33078386|NCT04306393|Experimental|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg
32770100|NCT05262777|Active Comparator|Restylane Lyft Lidocaine|Restylane Lyft Lidocaine Single injection and optional touch up injection and re-treatment with Restylane Lyft Lidocaine
32770101|NCT05262075|Experimental|Mindfulness and Resiliency Program|This is an online mindfulness program that integrates resiliency factors to women
33078387|NCT04306393|No Intervention|Control Group|
32770102|NCT05261451|Experimental|Head Start Teachers|Participants will engage in three 1- hour workshops and optional consultations with an occupational therapist
32770103|NCT05260359|Active Comparator|6% BEMT HRIPT|During the challenge phase of the HRIPT portion of the study, there will be 6 patches (2 product patches, 2 vehicle controls. 1 saline control and 1 empty patch), leaving out the positive control.
32770104|NCT05260359|Active Comparator|6% BEMT Cumulative Irritation Study|During the Cumulative Irritation portion of the study there will be 7 patches (2 product patches, 2 vehicle controls, 1 positive control, 1 low-irritancy control, and 1 empty patch). The low-irritancy control patch will be a saline patch. The positive control will be a SLS patch. The negative control will be an undosed patch.
32770105|NCT05260047|Active Comparator|IMANI BREAKTHROUGH|Participants will participate in 24-week IMANI weekly groups
33078388|NCT04304092|Experimental|Low amount, low intensity|
33078389|NCT04304092|Experimental|Low amount, high intensity|
33078390|NCT04304092|Experimental|High Amount, low intensity|
33078391|NCT04304092|Experimental|High Amount, high intensity|
33078392|NCT04304092|No Intervention|Control|
33078393|NCT04297189|Experimental|Coaching Intervention|Single arm pilot study of coaching intervention
33078394|NCT04294381|Experimental|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
33078395|NCT04259710|Placebo Comparator|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
33078396|NCT04259710|Active Comparator|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
33078397|NCT04259710|Experimental|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
33078398|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
33078399|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
33078400|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
33078401|NCT04251013|Active Comparator|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
33078402|NCT04251013|Active Comparator|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
33078403|NCT04242043||AI|
33262621|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
33262622|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
33262623|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
33262624|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
33262625|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
33262626|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
33262627|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
33262628|NCT00979095||Control group|Patients without hernias
32770106|NCT05260047|Experimental|IMANI BREAKTROUGH + church-based telehealth MAT option (IMANI + CTM)|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as a church based telehealth Medication Assisted Treatment option. The church based telehealth MAT will consist of participants assigned to receive MAT from addiction treatment providers via telehealth. Telehealth sessions will be provided in the church.
33262629|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
33262630|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
33262631|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
33078404|NCT04233970|Experimental|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
33262632|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
33262633|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
33262634|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
33262635|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
33262636|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
33262637|NCT00798980||Arm 1|
33262638|NCT00243919|Active Comparator|Early Locomotor Training Program|body weight supported training program with treadmill
33262639|NCT00243919|Active Comparator|Late Locomotor Training Program|body weight supported training program with treadmill
32770107|NCT05260047|Experimental|IMANI BREAKTHROUGH + Traditional MAT plus Referral and Linkage|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as Traditional MAT services with Referral and Linkage to services. Participants in this arm will be provided a list of referrals and links to community MAT providers. They will choose their providers.
32770108|NCT05258409|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
32770109|NCT05258409|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
32770110|NCT05331027|Experimental|Desflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
32770111|NCT05331027|Active Comparator|Sevoflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
32770112|NCT05330091||Healthy Women|Once Daily Women's Probiotic Placebo
32770113|NCT05329155|Experimental|Administration of Heparin in ER|Administration of Heparin (100U/Kg body weight) with loading dose of DAPT (Aspirin 300mg and Ticagrelor 180mg) at first medical contact for STEMI patients intended to perform PPCI.
32770114|NCT05329155|Active Comparator|Administration of Heparin in Cathlab|Administration of Heparin (100U/Kg body weight) in Cathlab after insertion of artery sheath catheter.
32770115|NCT05295849|Experimental|Habit App|Habit Mobile App
33262640|NCT00243919|Active Comparator|Early Home Exercise Program|a non-specific low intensity exercise program
33262641|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
33262642|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
33262643|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
33262644|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
33262645|NCT00985803|No Intervention|Group Control|
33262646|NCT00985803|Experimental|Endurance|
33262647|NCT00985803|Experimental|Cardiovascular|
33262648|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
33262649|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
33262650|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
33262651|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
33262652|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
33262653|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.~Patients track the characteristics of migraine headaches for one month before surgery.~After this month, patients receive surgery in the operating room for migraine.~After surgery, patients track the characteristics of migraine headaches for 3 months.~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
33262654|NCT00806780|No Intervention|1|routine surgery with cholangiography
33262655|NCT00806780|Experimental|2|routine cholangiography
33262656|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
33262657|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
32770116|NCT05328063|Experimental|Control Group. Gluteus maximus strengthening specific program|
32770117|NCT05328063|Experimental|Intervention group. Specific manual therapy program for hip joint and Gluteus maximus strengthening|
33262658|NCT00874146||1|HER2-positive advanced breast cancer
32770118|NCT05257707|Experimental|intervention|
33262659|NCT00982605||non small cell lung cancer|cancer patients
33262660|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
33262661|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
33262662|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
33262663|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
33262664|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
33262665|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
33262666|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
32770119|NCT05485935|Experimental|Investigational device - intermittent catheter with micro-zone|Ready-to-use, sterile, hydrophilic coated intermittent male catheter (sizes CH12 and CH14) with a flexible tip and a micro-hole zone for urinary drainage. The investigational device is for single use.
32770120|NCT05485935|Active Comparator|Comparator device - standard intermittent catheter|Single-use, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPor Plus Pocket.
33262667|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
32770121|NCT05294835|Experimental|Ketamine Infusion|subanesthetic ketamine infusion (0.5mg/kg) over 2-3 weeks
32770122|NCT04422405|Experimental|Patients undergoing OAGB|
33262668|NCT00917813|Experimental|KD-247|
32770123|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
32770124|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
32770125|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
32770126|NCT04243785|Experimental|Phase 1a (Dose Escalation Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 20 mg (60 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
32770127|NCT04243785|Experimental|Phase 1b (Cohort Expansion Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Phase 1b will continue at the MTD or the highest dose achieved in Phase 1a.
33078405|NCT04233970|Active Comparator|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
33078406|NCT04230187|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
33262669|NCT00917813|Placebo Comparator|Placebo|
33262670|NCT00239005|Active Comparator|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
33262671|NCT00239005|Experimental|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
33262672|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
33262673|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
33262674|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
33262675|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
33262676|NCT01581697|Experimental|Oat bran|
33262677|NCT00652340|Experimental|A|
33262678|NCT00652340|Placebo Comparator|B|
33262679|NCT00257725|Experimental|ADHD Treatment Group|Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.
33262680|NCT00544869|Experimental|1|
33262681|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
33262682|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
33262683|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
33262684|NCT00874302|Experimental|25 mg|25 mg Proellex
33262685|NCT00874302|Experimental|50 mg|50 mg Proellex
32736840|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
32770128|NCT04243785|Experimental|Continued Treatment Phase|Participants who complete one cycle of BTX-A51 treatment in either Phase 1a or Phase 1b will be offered continued access to treatment for up to eight 28-day cycles if the Investigator determines that the benefit outweighs the risk. Dosing will continue at the assigned dose or may be increased (not to exceed a level already tolerated by at least one participant if Phase 1a is ongoing or the MTD/recommended Phase 2 dose if already established).
32770129|NCT05326581||PATIENTS|patients benefiting from an MRI examination as part of their care
33262686|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
33262687|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
33262688|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
33078407|NCT04230187|Active Comparator|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
32770130|NCT05326581||VOLUNTEERS|healthy volunteers among staff.
33078408|NCT00199485|Experimental|1|Angelica Sinensis
33078409|NCT00199485|Placebo Comparator|2|placebo
33078410|NCT04222309|Experimental|Laparoscopically harvested omental free flap|"Standard neurosurgical removal of recurrent GBM,~Removal of fat from the abdomen called omentum using a camera (laparoscopically),~Lining the brain tumor cavity with the piece of omentum,~Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
33262689|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
33262690|NCT05261087||Factory worker|Workers working in the TPI blade factory will be included in the study. Those working in the wind vane production at the factory are divided into departments. The 65.5 main mold workers, which will require the most attention, will be included in our work.
33262691|NCT00881556|Experimental|RIC Group|"Reduced Intensity Transplant Conditioning (RIC):~Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
33262692|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
33262693|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
33262694|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
33262695|NCT00874458|Experimental|MRI|
33262696|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
33262697|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
33262698|NCT00733499|Other|LCS Complete Duofix|102 patients
33262699|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
33262700|NCT00878748|Experimental|A|Effexor XR
33262701|NCT00878748|Other|B|Effexor XR discontinue
33262702|NCT04088045|Experimental|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
33262703|NCT00652028|Other|Group 1|Dose level 1
33262704|NCT00652028|Other|Group 2|Dose level 2
33262705|NCT00652028|Other|Group 3|Dose level 3
32770131|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
32770132|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
32770133|NCT05326347|Experimental|Rollover subjects|For rollover subjects, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation at 24 mg. From Week 1 onward, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 51 weeks.
32770134|NCT05326347|Experimental|New subjects|In medication switching period, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation 24 mg, and the dose of the other antipsychotics will be gradually reduced, finally switching to monotherapy with 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) by Week 4. In treatment period, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 52 weeks.
32770135|NCT04243551|Active Comparator|Latiglutenase|IMGX003
32935577|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
33262706|NCT00652028|Other|Group 4|Dose level 4
33262707|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
32935578|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
33262708|NCT00738101|Experimental|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
33262709|NCT00810212|Active Comparator|1|Autograft
33262710|NCT00810212|Experimental|2|Low Dose MPCs
33262711|NCT00810212|Experimental|3|Medium Dose MPCs
33262712|NCT00810212|Experimental|4|High Dose MPCs
33262713|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
33262714|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
33262715|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
33262716|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
32770136|NCT04243551|Placebo Comparator|Placebo|Placebo
32770137|NCT04243395|Experimental|Pork|1 ounce lean pork
32770138|NCT04243395|Experimental|Egg|1 large whole egg
32770139|NCT04243395|Experimental|Black beans|0.5 cups of cooked black beans
32770140|NCT04243395|Experimental|Almonds|0.5 ounce of whole almonds
32770141|NCT01672879|Experimental|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
32770142|NCT01672879|Experimental|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
32770143|NCT01672879|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
32770144|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32935579|NCT04956289|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
32935580|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
32935581|NCT04892329|Experimental|EUS AI navigation system augmentation|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
32935582|NCT04892329|No Intervention|without EUS AI navigation system augmentation|The endoscopists in the contrpl group performs the examination routinely without special prompts.
32935583|NCT05320393|Experimental|Study Drug|40U of PrabotulinumtoxinA-xvfs
33262717|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
33262718|NCT00733421|Experimental|1|"Active study drug:~Etoricoxib 90 mg once daily"
33262719|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
33262720|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
33262721|NCT00806858||A|
33262722|NCT00917891|Placebo Comparator|vehicle placebo gel|
33262723|NCT00917891|Experimental|dapivirine gel|
33262724|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
33262725|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
33262726|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
33262727|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
33262728|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
33262729|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
33262730|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
33262731|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
33262732|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
33262733|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
33262734|NCT00874692|No Intervention|BMS standard water heating|
33262735|NCT00881790||Fluoride application|
33262736|NCT05097456|Active Comparator|Laser treatment|carbon dioxide treatment
33262737|NCT05097456|Sham Comparator|Sham treatment|sham treatment
33262738|NCT00810446||rifabutin|Patients administered Rifabutin.
33262739|NCT05093868|Experimental|FIRMap™ (Abbott Laboratories, Abbott Park, IL)|A 64-pole basket mapping catheter (FIRMap™, Abbott Laboratories, Abbott Park, IL) will be used to passively acquire electrical signals
33262740|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
33262741|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
33262742|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
33262743|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
33262744|NCT00810680|Experimental|Valproic acid|
33262745|NCT00806936||A|
33262746|NCT00806936||B|
33262747|NCT00807170|Experimental|ZACTIMA TM|
33262748|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
33262749|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
33262750|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
33262751|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
33262752|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
33262753|NCT00799682|Active Comparator|Xalatan®|
33262754|NCT00799682|Active Comparator|Travatan Z®|
33262755|NCT00810758|Experimental|PF-04878691|
33262756|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
33262757|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
33262758|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33262759|NCT00810836|Active Comparator|1|BG00012 480 mg/day
33262760|NCT00810836|Active Comparator|2|BG00012 720 mg/day
33262761|NCT00810836|Placebo Comparator|3|
33262762|NCT00874926||Group 1|
33262763|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
33262764|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
33262765|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
33262766|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
33262767|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
33262768|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
33262769|NCT00737711|Experimental|Mircera|
33262770|NCT00881946|Experimental|GSK2119183|
33262771|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
33262772|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
33262773|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
33262774|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
33262775|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
33262776|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
33262777|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
33262778|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
33262779|NCT00238303|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33262780|NCT00238303|Experimental|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33262781|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
33262782|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
33262783|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
32770145|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
33262784|NCT00811460|Experimental|1|
33262785|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
32770146|NCT05012839||Complicated appendicitis|The development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
32770147|NCT05012839||Non-complicated appendicitis|No development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
33262786|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
33262787|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
33262788|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
33262789|NCT05204082|No Intervention|Standard IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have standard IV insertion
33262790|NCT05204082|Other|SU-VEID assisted IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have IV insertion using SU-VEID device
33262791|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
33262792|NCT00811538||2 (L*)|intraarterial thrombolysis
33262793|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
33262794|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
32935584|NCT05320393|Active Comparator|OnabotulinumtoxinA|20U of OnabotulinumtoxinA
32935585|NCT05320393|Active Comparator|PrabotulinumtoxinA-xvfs|20U of PrabotulinumtoxinA-xvfs
32935586|NCT05315947|Experimental|Treatment A-B|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
32935587|NCT05315947|Experimental|Treatment B-A|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
32935588|NCT05445050|Other|clinical application of mULM to support breast cancer diagnosis and therapy|"The study arm includes three parts A, B and C. In part A, the scan protocol, including the injection of the clinically approved contrast agent SonoVue® and the data acquisition time range, is optimized based on the mULM measurements of participants with primary breast cancer.~The following part B consists of 2D-mULM measurements applied to triple-negative breast cancer patients throughout their neoadjuvant chemotherapy cycles with the aim to evaluate to which degree 2D-mULM allows for an assessment of the tumor response during therapy.~In the last part C, participants with neoplasms of uncertain dignity will be investigated by 2D- and 3D-mULM measurements and the accuracy of differentiation between the lesions assessed."
33401488|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
33262795|NCT00882024|Placebo Comparator|3|Placebo
33262796|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
33262797|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
33262798|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
33262799|NCT00875316|Experimental|Cohort A|
33262800|NCT00875316|Experimental|Cohort B|
33262801|NCT00875316|Experimental|Cohort C|
33262802|NCT00875316|Experimental|Cohort D (Optional)|
33262803|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
33262804|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
33262805|NCT04038684|Experimental|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 12-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 60 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
33262806|NCT04038684|Active Comparator|Standard Behavioral Weight Control|All participants will be randomly assigned to a 12-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 12 group sessions will be approximately 60 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
33262807|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
33262808|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
33262809|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
33262810|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
33262811|NCT00799994||2|Patients who have received no intervention
32770148|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
33078411|NCT00554008|Active Comparator|1|children randomized to open appendectomy
33262812|NCT03838458||Study|Children with isolated hypospadias
33262813|NCT03838458||Control|Children with planned circumcision
33262814|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
33262815|NCT04019717|Experimental|8 weeks|
33262816|NCT04019717|Experimental|12 weeks|
33262817|NCT00879216|Placebo Comparator|Sugar pill|
33262818|NCT00879216|Experimental|VA106483|
33262819|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
33262820|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
33262821|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
33078412|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
33078413|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
33078414|NCT00554047|Active Comparator|2|General practitioner
33262822|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
33262823|NCT04938570||University-level and amateur rugby players|"University-level and amateur rugby players will be recruited and assessed (motor, visual and symptom assessment) over one season ( June 2021 to August 2022).~Participants will be stratified according to gender (males n≈100, and females n≈100). Although the number of SRC that will be observed during the season is not known, the investigators will compare a number of head injuries/SRC to the results from cohort baseline testing. Participants that do not sustain a concussion will also have follow up testing at the end of the season."
33078415|NCT04173364|Experimental|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
33262824|NCT00800306|Experimental|levosimendan|
33262825|NCT00800306|Active Comparator|Control|
33262826|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
33262827|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
33262828|NCT04039152||Pre- interventions group|Without clinical pharmacists recommendations to optimize antibiotics use
33262829|NCT04039152||Post - interventions group|interventions include clinical pharmacists recommendations to optimize antibiotics use
33262830|NCT04046276|Placebo Comparator|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
33262831|NCT04046276|Sham Comparator|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
33262832|NCT04046276|Experimental|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
33262833|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
33262834|NCT01072591|Experimental|1|
33262835|NCT01072591|Placebo Comparator|2|
33262836|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
32770149|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
32770150|NCT05012449|Experimental|Arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.
33262837|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
32770151|NCT05012449|No Intervention|No arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with open or close reduction .
32770152|NCT05012215|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
32770153|NCT05012215|Active Comparator|Caudal|Caudal block
33078416|NCT04173364|Active Comparator|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
33262838|NCT00882258|Placebo Comparator|Placebo|Placebo daily
33262839|NCT00811694||a|15 male and 15 female patients with glaucoma
33262840|NCT00811694||b|30 sex matched healthy volunteers
33262841|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
33262842|NCT04038606|Active Comparator|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
33262843|NCT04038606|Experimental|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
33262844|NCT03741595|Experimental|Single Arm|
33262845|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
33262846|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
33262847|NCT00879294|No Intervention|Control|Usual post-operative care.
33262848|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
33262849|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
33262850|NCT02594657|Experimental|pedal rate ON 50 RPM|
33262851|NCT02594657|Experimental|pedal rate on 80 RPM|
33262852|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
33262853|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
33262854|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
33262855|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
33262856|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
33262857|NCT00879372|Placebo Comparator|1|Placebo
33262858|NCT00879372|Active Comparator|2|Tianeptine
33262859|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
33262860|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
33262861|NCT00879450|Experimental|1 Booklet|
33262862|NCT00879450|Active Comparator|2 standard|
33262863|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
33262864|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
33262865|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
33262866|NCT03691350|Experimental|Group IV (usual cigarette brand, nicotine-containing SREC)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the nicotine-containing SREC for 2 weeks and use both their usual brand of cigarettes and the nicotine-containing SREC starting day 15 for 8 weeks with the intention of smoking reduction to 5 cigarettes or less per day. Participants undergo a second bronchoscopy on day 71.
33262867|NCT03691350|Experimental|Group V (NRT)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 2 days before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
33262868|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
33401489|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
33262869|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
33078417|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
33078418|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
33078419|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
33078420|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
33078421|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
33078422|NCT04138732|Experimental|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
33078423|NCT04138732|Other|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
33078424|NCT04111315|Active Comparator|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
33078425|NCT04111315|Active Comparator|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
33078426|NCT04111315|Active Comparator|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
33078427|NCT04111315|Active Comparator|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
33078428|NCT00204516|Experimental|mRNA Vacc|
33078429|NCT04105582|Experimental|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
33078430|NCT04093180|Experimental|Experimental group|Experimental group undergoing treatment course according to INRS
33078431|NCT04093180|Other|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
33078432|NCT04679584||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).
33078433|NCT04679584||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).
33078434|NCT04679584||Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).
33078435|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
33078436|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
33078437|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
33078438|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
33078439|NCT04679350|Experimental|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
33078440|NCT04679350|Placebo Comparator|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
33078441|NCT04084249|Experimental|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the FCRI questionnaire.
33262870|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
33078442|NCT04084249|No Intervention|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
33078443|NCT02962830|Experimental|Sufentanil|
32770154|NCT05012137|Experimental|SASIS-FICB|All subjects will be enrolled in the experimental group and receive an Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
32770155|NCT03080467||Suture|Wound repair with suture
33262871|NCT04589676|Active Comparator|Personal recruitment|Participants in this training condition will receive recruitment messages that appeal to their personal sense of identity (e.g., you could be a hero if you get trained with naloxone).
33262872|NCT04589676|Experimental|Online training|Participants in this training condition will receive recruitment messages that appeal to their communal sense of identity (e.g., your family and friends will thank you for getting trained with naloxone).
32770156|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
32770157|NCT05325723||Intervention group|"30 second audio phonocardiogram (PCG) recordings at each of the five standard cardiac auscultatory positions using an Apple iPhone®.~the assessment of VHD by echocardiogram, as reported by the echocardiography laboratory."
33262873|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
33262874|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
33262875|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
33262876|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
33262877|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
33262878|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
32770159|NCT05291559|Experimental|Enterade (VS001)|237 mL (8 fluid oz) per os, once daily for 14 days
32770160|NCT05291559|Placebo Comparator|Placebo|237 mL (8 fluid oz) per os, once daily for 14 days
32770161|NCT04999345|Experimental|Experimental Group|Provide resistance and aerobic exercise
32770162|NCT04999345|Placebo Comparator|Control Group|Health education and gross range of motion exercise for upper and lower extremities
32770163|NCT05325645|Experimental|Brexpiprazole QW 48mg|Brexpiprazole QW 48mg, tablet, once weekly, for seven weeks(Initial dose Brexpiprazole QW 24mg)
32770164|NCT05325645|Placebo Comparator|Placebo|
33262879|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
33262880|NCT04936386||Healthcare professionals|Healthcare professionals (medical specialists and general practitioners, medical residents, midwives, professional nurses, medical students).
32770165|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
33078444|NCT04065100|Experimental|Study group|Maternal PCOS
33078445|NCT04065100|Active Comparator|Comaprator|Non-PCOS pregnant women
33262881|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
33262882|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
33262883|NCT04038840|Experimental|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
33262884|NCT04038840|Experimental|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
33262885|NCT04087187|Experimental|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
33262886|NCT04087187|Experimental|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
33078446|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
32770166|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
32770167|NCT05325333|Experimental|Retrieval practice during word learning: expanding schedule|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) . Four nouns will be learned in an expanding spaced retrieval practice condition; four will be learned in a standard spaced retrieval practice condition. In the standard spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the expanding spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase gradually from 0 to 1 to 3 words."
32770168|NCT04999033||Inpatient|This study is a cross-sectional study and no intervention will be involved
32770169|NCT04818203|Experimental|Test Group|Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
32770170|NCT04818203|Placebo Comparator|Placebo|Participants receive 1 mL of placebo solution to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
32770171|NCT05252793|Experimental|Diabetes Education Program Based on Health Belief Model|"Experimental: Intervention Patients will be given links to training videos once or twice a week depending on the length of the training module for 6 weeks.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
32770172|NCT05252793|No Intervention|Control|"No intervention will be taken against the patients.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
32770173|NCT04827797|Experimental|birth ball|The positions and movements for birth ball in the active and latent phases: kneeling on the ground and leaning on the spherical birthing ball, sitting on the ball with front support, sitting positions on the spherical birthing ball, full rotation of hip, moving to the right/left, back and forth. Positions and movements were repeated every 30 minutes. The 30-minute intervals were interrupted in cases where the women were not feeling well.
32770174|NCT04827797|Experimental|peanut ball|The positions and movements for the pregnant women in peanut ball: upright sitting position, forward bending positions, with backward and forward movement and swaying right and left on the peanut ball
32770175|NCT04999189|Experimental|Patients using mobile applications|Patients diagnosed with type 2 diabetes will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
32770176|NCT04999189|No Intervention|Control group|Patients will receive treatment from medical staff (as usual).
32770177|NCT05290779|Active Comparator|ultrasound|selective lumbar nerve root steroid injection under ultrasound guidance.
32770178|NCT05290779|Sham Comparator|fluoroscopy|selective lumbar nerve root steroid injection under fluoroscopy guidance.
32770179|NCT05252481|Active Comparator|Active tDCS|Transcranial current direct stimulation. 8 days.
32770180|NCT05252481|Sham Comparator|Sham tDCS|Sham transcranial current direct stimulation. 8 days.
32770181|NCT04998955|Experimental|MST group|Exercise intervention, 20 supervised MST sessions
32770182|NCT04998955|No Intervention|Control group|IRD patient controls
32770183|NCT05324631|Experimental|Treatment group A|SHR0302
32770184|NCT05324631|Placebo Comparator|Treatment group B|SHR0302 Placebo
32770185|NCT05290155|Experimental|Anti-CD7 CAR T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
32770186|NCT04827563||Participants with Normal Baseline Endothelial Function|
32770187|NCT04827563||Participants with Abnormal Baseline Endothelial Function|
32770188|NCT05011747|Active Comparator|single-site VT group|Viscotrabeculotomy is performed through a superonasal triangular scleral flap.
32770189|NCT05011747|Active Comparator|two-site VT group|Viscotrabeculotomy is performed through a superonasal and an inferotemporal triangular scleral flap.
32770190|NCT04422327|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
32770191|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
32770192|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
32770193|NCT04827329||Patients with a sleep disorder|Patients with a sleep disorder recording performed in the Sleep Unit in Montpellier University Hospital.
32770194|NCT04827329||Patients with a narcolepsy|Patients with a narcolepsy (type 1 or type 2) / a idiopathic hypersomnia or a restless legs syndrome.
32770195|NCT05251467||People with CF age 12 years and over|Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
32770196|NCT04925167|Experimental|argatroban group|Patients received argatroban for anticoagulation during V-V ECMO.
33262887|NCT04087187|Experimental|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
33262888|NCT04087187|Experimental|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
33262889|NCT04087187|Experimental|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
32770197|NCT04925167|Active Comparator|UFH group|Patients received UFH for anticoagulation during V-V ECMO.
32770198|NCT04812587|Experimental|Experimental group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
32770199|NCT04812587|No Intervention|Comparison group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
32770200|NCT04998565|Experimental|Routine care|Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
32770201|NCT04998565|Experimental|Routine care plus EA|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Electrical acupuncture on body acupoints"
32770202|NCT04998565|Experimental|Routine care plus TENS|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Transcutaneous electrical nerve stimulation on breasts"
32770203|NCT04427267||Health workers|
32770204|NCT04998721|Experimental|Maternal Infant Dyadic Care|Perinatal collaborative care and Promoting First Relationships-Brief
32770205|NCT04998721|Active Comparator|Control|Perinatal collaborative care only
32770206|NCT04812431|Experimental|PSA-NCAM(+) NPC|Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
32770207|NCT05011669|Experimental|Latuda® 40mg/d|
32770208|NCT05011669|Experimental|Latuda® 80mg/d|
32770209|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
32770210|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
32770211|NCT04812353|Other|Foot and ankle arthrodesis or osteotomy|Patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
32770212|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
32770213|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
32770214|NCT05619263|No Intervention|Control|Caregivers who consent to participate, complete a baseline survey, and are assigned to the control arm will receive a four-page handout on Emergency Preparedness published by the Alzheimer's Association that provides tips on preparing for disasters and what to do during and after a disaster. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
32770215|NCT05619263|Experimental|Disaster PrepWise-Caregiver Intervention|Caregivers who consent to participate, complete a baseline survey, and are assigned to the intervention arm will receive a Disaster PrepWise-Caregiver program from a trained interventionist and receive a completed household emergency management plan. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
32770216|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
32770217|NCT04817423||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
33078447|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
33078448|NCT00199602|No Intervention|lack of drug prophylaxis|
33078449|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
33262890|NCT04087187|Experimental|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
33262891|NCT04924764|Active Comparator|Follow-up on daily basis|Patient receiving treatments on daily basis (5 days a week)
33262892|NCT04924764|Active Comparator|Follow-up on alternate days|Patients receiving treatment on alternate days (3 days a week)
33262893|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
33262894|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
33262895|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
33262896|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
33262897|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
33262898|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
33262899|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
33262900|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
33262901|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
32770218|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
32770219|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
32770220|NCT05619185|Experimental|Intervention|Those randomized to the CRAFT intervention will receive a web-based intervention
32770221|NCT05619185|Active Comparator|Control|Those randomized to CONTROL will complete a self-guided intervention
33262902|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
33262903|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
33262904|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
33262905|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
33262906|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
33262907|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
33262908|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
33262909|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
33262910|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
32770222|NCT05619185|Experimental|Phone Based CRAFT|If a member of the recruited dyad does not respond, then participants will be randomized to receive phone-based CRAFT
32770223|NCT05619185|Active Comparator|CRAFT Workbook|If a member of the recruited dyad does not respond, then participants will be randomized to receive a CRAFT workbook
32770224|NCT04998175|Experimental|iNPH cohort|The patients diagnosed of iNPH.
33262911|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
33262912|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
33262913|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
33262914|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
32770225|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
32770226|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
32935591|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
32935592|NCT05287867|Experimental|Platelet treatment|A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
32935593|NCT05287867|Sham Comparator|Sham procedure|A series of two sham procedures spaced 4 weeks apart.
32935594|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
32935595|NCT04874077||Case|
32935596|NCT04874077||Control|
32935597|NCT04862000||Endometriosis or adenomyosis|participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis
32935598|NCT05286385|Active Comparator|CP1150|CP1150 will be used as the comparator device for speech perception testing in quiet.
32935599|NCT05286385|Experimental|CP1150 (modified firmware)|CP1150 Sound Processor with modified firmware.
32770227|NCT04998253|Experimental|Group 1: Sevofruorane (Svofast)|"Experimental group: will receive sedation with sevoflurane with an infusion rate to maintain MAC of 0.7 and fentanyl 1mcg /kg/hour.~Inhalation sedation The AnaConda device (Sedana Medical, Ireland) is placed between the endotracheal tube and the ventilator circuit. The anesthetic infusion line is attached to a syringe, from where the anesthetic (sevoflurane) will be delivered to said device. The sample line will be taken to the anesthetic gas analyzer whit the Carescape B450 multiparametric monitors (General Electric, Finland) for MAC control. The anesthetic gas outlet port will be attached to the absorbent material container."
32770228|NCT04998253|Active Comparator|Group 2: Propofol (Diprivant)|"Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.~For both groups, the doses will be titrated to maintain a RASS score between -3 to -4 in both groups.~Both groups will receive cisatracurium (Nimbex) as a continuous infusion of 3 to 5mcg / kg/min for 48 hours. We will maintain sedation for both groups with the same scheme for 48 hours, after which the drugs used for sedation will be modified at the discretion of the intensive care physicians."
32770229|NCT05289999|Experimental|Using the virtual reality headset for the first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset, then the second injection following the usual conditions of care without the device
32770230|NCT05289999|Experimental|Using the virtual reality headset for the second injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus following the usual conditions of care, then the second injection using the virtual reality headset
32770231|NCT05288439|Experimental|patients|A full neurocognitive battery with quality-of-life assessment will be conducted and an rs-fcMRI sequence will be added to the brain MRI performed as standard of care follow-up between 3-5 months post-PBRT.
33262915|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
33262916|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
33262917|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
33262918|NCT00882804|Experimental|Hemin|
33262919|NCT00882804|Placebo Comparator|placebo|
33262920|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
32770232|NCT05288439|Experimental|healthy matched controls|Healthy participants will be asked to complete the MRI scan and undergo neurocognitive assessment.
32770233|NCT05324475|Placebo Comparator|Standard treatment (SC)|nutritional counselling (SC) + Placebo: These patients will receive Oral Nutrient Supplementation (ONS) and maltodextrin 4 g
32770234|NCT05324475|Experimental|Branch-chained aminoacids|In addition to the ONS these patients will receive 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1.
32770235|NCT05324475|Experimental|Micronutrients|In addition to the ONS the patients will receive a combination of micronutrients
32770236|NCT05616923|Experimental|Trametinib|Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)
32770237|NCT05616923|Placebo Comparator|Vehicle|Cheek receiving cream without active compound (topical cream lacking active ingredient)
33262921|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
33262922|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
33262923|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
33262924|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
33262925|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
33262926|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
33262927|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
33262928|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
33262929|NCT00883194|Experimental|1|PRF-108 Gel, 4% ropivacaine
33262930|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
33262931|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
33262932|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4% ropivacaine
33262933|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
33262934|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
33262935|NCT04037436|Experimental|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
33262936|NCT04037436|Other|Control|Each cluster contributes observations under both control and intervention observation periods.
33262937|NCT00888576||1|Non-intervention
33262938|NCT04038060|Experimental|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
33262939|NCT04038060|Experimental|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
33262940|NCT04038060|Experimental|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
33262941|NCT04038060|Experimental|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
33262942|NCT04038060|Experimental|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
33262943|NCT04038060|Experimental|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
33262944|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
32770238|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
32770239|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
32770240|NCT03078205|No Intervention|The control group|No Intervention
32770241|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
32770242|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
32770243|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
33401490|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
33262945|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
33401491|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
33401492|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
33401493|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
33262946|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
33262947|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
33262948|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
33262949|NCT00236899|Experimental|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
33262950|NCT00236899|Experimental|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
33262951|NCT00236899|Experimental|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
33262952|NCT00236899|Experimental|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
33401494|NCT01592968|Experimental|Arm I (SRS)|Patients undergo SRS on day 1.
32770244|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
33262953|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
33262954|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
33262955|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
33262956|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
33262957|NCT01071733||ultrasound wrist|
33262958|NCT01071733||ultrasound finger|
32935600|NCT05286385|Experimental|CP1150 + FF|CP1150 Sound Processor with ForwardFocus.
32935601|NCT05286385|Experimental|CP1110|CP1110 is a BTE Sound Processor.
33262959|NCT01071733||ultrasound ankle|
33262960|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
33262961|NCT02542176|Placebo Comparator|Grape Powder Placebo|
33262962|NCT00256243|Experimental|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
33262963|NCT04037202|Experimental|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
33401495|NCT01592968|Experimental|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
33401496|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
33401497|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
33401498|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16)."
33078450|NCT00199602|Experimental|warfarine 1mg daily|
32770245|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
32770246|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
32770247|NCT02524275|Experimental|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32770248|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
32770249|NCT03078049||Sitagliptin|Patients take sitagliptin
32770250|NCT04997551|Active Comparator|Colchicine|EC Experimental group: colchicine for 2 weeks orally added to standard treatment.
32770251|NCT04997551|Placebo Comparator|Placebo|Control group: placebo for 2 weeks added to standard treatment.
33078451|NCT00554125|Active Comparator|2, III ,intervention|
32770252|NCT04997707|Active Comparator|P group|75-100 µg/kg/min propofol
32770253|NCT04997707|Active Comparator|BA group|25ug/kg/min propofol and 0.2% below corrected-to-age- half MAC of sevoflurane
32770254|NCT04997863|Experimental|Sericin hydrogel sheet impregnated with EBN extract|Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
32770255|NCT04997863|Placebo Comparator|Placebo hydrogel sheet|Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
32770256|NCT05010889||Achalasia patients|Patients schedule to undergo POEM for treatment of symptomatic achalasia. The diagnosis of achalasia was based on high resolution manometry, barium esophagram, and upper endoscopy.
33078452|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
33078453|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
33078454|NCT03986671|Experimental|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
33078455|NCT03981640|Experimental|African American Adults|African American adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
33078456|NCT03981640|Experimental|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
33078457|NCT03973606|No Intervention|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. During the focus groups, a set of pre-prepared questions will be presented to the participants. The focus groups will be recorded and analyzed verbatim.
33078458|NCT03973606|Experimental|Health literacy workshop|Women from East-Jerusalem and other Arab communities in Israel will be invited to participate in a 4-sessions workshop designed to improve health literacy, self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
33078459|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
33078460|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
33078461|NCT03964441||professional|obstetrician, midwife, geneticist, biologist
33078462|NCT03952078|Experimental|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for >2 months or if dose determined to be unsafe.
33078463|NCT03952078|Experimental|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for > 2 months."
33078464|NCT03948139|Other|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
33078465|NCT03948139|Other|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
33078466|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
33078467|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
33078468|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
33262964|NCT04037202|No Intervention|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
33262965|NCT01325857|Experimental|Group B|Group B = Nerve block group
33262966|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
33262967|NCT01325857|Active Comparator|Group C|Group C = Control group
33262968|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
33262969|NCT00236197|Experimental|1|
33262970|NCT00236197|Placebo Comparator|2|
33262971|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
33262972|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
33262973|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
33262974|NCT00278629|Experimental|Hematopoietic Stem Cell Transplantation in CIDP|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide 200 mg/kg/intravenously(IV), rATG(thymoglobulin) 5.5 mg/kg/IV and rituximab 1000mg/IV.
33262975|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
33262976|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
33262977|NCT03973567|Experimental|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
33262978|NCT03973567|Placebo Comparator|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
33262979|NCT03973567|No Intervention|normal control|Age, sex and education matched, right-handed 30 normal people.
33262980|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
33262981|NCT03975361|Other|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
33262982|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
33262983|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
33262984|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
33262985|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
33262986|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
33262987|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
32770257|NCT05010499|Active Comparator|Femoral nerve block|Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
33262988|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
33262989|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
33262990|NCT03973411|Active Comparator|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
33262991|NCT03973411|Placebo Comparator|Control group|Patients will receive intravenous saline before spinal anesthesia
33262992|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
33262993|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
33262994|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
33262995|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
33262996|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
33262997|NCT00278473|Experimental|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
33262998|NCT00278473|Active Comparator|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
33262999|NCT04037280|Experimental|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
33401499|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
33263000|NCT04037280|Experimental|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
33263001|NCT04037280|Experimental|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
32770258|NCT05010499|Active Comparator|Fascia iliaca block|Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
32770259|NCT05010187|Experimental|Behavioral: Motivational Interview (MI)|Participants will complete a brief motivational interview focusing on determinants of women's alcohol use, including a focus on normative perceptions as well as motives for drinking.
33263002|NCT04037280|Experimental|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
33263003|NCT00278395|Experimental|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
33263004|NCT00889044|Experimental|clopidogrel by chewing|
33263005|NCT00889044|Placebo Comparator|Placebo|
33263006|NCT00889122|Experimental|Lifestyle Counseling|
32770260|NCT05010187|Active Comparator|Behavioral: Health Coaching (HC)|Participants will complete a brief health coaching interview and session focusing on educational modules.
33263007|NCT00883584|Active Comparator|1|IMD-1041
32770261|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
33078469|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .~Gefitinib will be administered daily, at a dose of 250 mg orally ."
33263008|NCT00883584|Placebo Comparator|2|
33263009|NCT00883662||Group 1|
33263010|NCT03669822||Inpatient ulcerative colitis patients|Patients hospitalized for acute severe ulcerative colitis will be invited to enroll. Participants will be treated at the discretion of their treating physicians per standard of care. We expect some participants will be treated with standard versus accelerated infliximab dosing, permitting comparison, in addition to other treatment strategies.
33263011|NCT00883818|Experimental|Antibiotics therapy|
33263012|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
33263013|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
33263014|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
33263015|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
33263016|NCT00889434|Active Comparator|Tocotrienol|
33263017|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
33263018|NCT00612534|Experimental|1|
33263019|NCT00612534|Experimental|2|
33263020|NCT00612534|Experimental|3|
33263021|NCT00612534|Placebo Comparator|4|
33263022|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
33263023|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
33263024|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
33263025|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
33263026|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
33263027|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
32770262|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
32770263|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
32770264|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
32770265|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
33078470|NCT03733210|Experimental|Lymph Node-positive Tumor|Participants whose lymph nodes are positive for cancer
33078471|NCT03733210|Experimental|Lymph Node-negative Tumor|Participants whose lymph nodes are negative for cancer
33078472|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
33263028|NCT04179396|Experimental|Arm A: Oral rucaparib and enzalutamide|
33263029|NCT04179396|Experimental|Arm B: Oral rucaparib and abiraterone|
33263030|NCT00883974|Experimental|1|
33263031|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
33263032|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
33078473|NCT00204594|Experimental|Antibody|
33078474|NCT04679779|Experimental|control group|receive occupational therapy program
33078475|NCT04679779|Experimental|study group|receive wii virtual reality
32770266|NCT04997083|Experimental|cleft lip and palate patients|Cleft patients with transverse maxillary constriction and anteroposterior deficiency
32770267|NCT04994119|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
32770268|NCT04994119|Experimental|Warfarin|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received a single dose of racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
32770269|NCT04994119|Experimental|BIA 5-1058 and Warfarin|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
32770270|NCT04996849||Observational (data collection)|Patients undergo data collection every 6 months for up to 15 years.
32770271|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
32770272|NCT03074851|Other|informational intervention|to give 1 month informational intervention
32770273|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
33078476|NCT04679077|Other|Cytocam-IDF Imaging|All patients will undergo the same interventional test.
33263033|NCT00889590|No Intervention|Control|Standard care
33263034|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
33263035|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
33263036|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
33263037|NCT04037514|Experimental|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
32770274|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
33263038|NCT04037514|Active Comparator|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
33263039|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
33263040|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
33263041|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
32770275|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
32770276|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
33078477|NCT03722953|Other|Aerobic Exercise|"Control: Cerebrovascular function and peripheral vascular function will be measured.~Aerobic Exercise: Across four separate visits, participants will perform light intensity exercise, light intensity exercise plus an additional task, vigorous intensity exercise and vigorous intensity exercise to match the energy expenditure of light intensity exercise visit."
33078478|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
33078479|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
33078480|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
33078481|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
33078482|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
33263042|NCT00884130||Open|Patients having an open colorectal resection
33263043|NCT04141878|Active Comparator|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
33401500|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
33401501|NCT03305809|Placebo Comparator|Placebo|Participants received placebo administered orally once a day (QD).
33078483|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
33263044|NCT04141878|Active Comparator|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
32770277|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
32770278|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
32770279|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
32770280|NCT04433533|Active Comparator|Rosuvastatin 20mg (Group 1)|
32770281|NCT04433533|Experimental|Rosuvamibe 10/10mg (Group 2)|
32770282|NCT04993729|Experimental|T89 low-dose group|Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
32770283|NCT04993729|Experimental|T89 high-dose group|Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
32770284|NCT04993729|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
33263045|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
33263046|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
33263047|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
33263048|NCT04034004|Experimental|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
33263049|NCT04034004|Experimental|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
33263050|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
33263051|NCT00889980||Melanoma|Patients with primary melanoma
33078484|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
33078485|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
33078486|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
33263052|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
33263053|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
33263054|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
33263055|NCT04037826|Experimental|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
33263056|NCT04037826|Placebo Comparator|Placebo|Placebo chewable tablets
33263057|NCT00886314|Active Comparator|midazolam|
33263058|NCT00886314|Active Comparator|clown doctor|
33263059|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
32770285|NCT04812275|Active Comparator|Non absorbable suture|Wound closure with non absorbale suture. Dimension and brand at the discretion of the surgeon.
32770286|NCT04812275|Experimental|Absorbable suture|Wound closure with absorbale suture. Dimension and brand at the discretion of the surgeon.
32770287|NCT04996459||Tislelizumab group|
32901851|NCT05621954|Experimental|Telehealth monitoring|"Telehealth remote monitoring provided by a specialised service with a monitoring and patient education app featuring:~Symptom, blood pressure, weight, heart rate and oxygen saturation monitoring with optional step counters~Customised algorithms with patient feedback for prehabilitation (e.g. patient self-reporting of symptoms, activities and health-related activities with positive feedback loops and recommendations for self-directed management)~Centralised weekly review and escalation to expedited surgery if deteriorations noted~Post-operative monitoring with symptom, blood pressure, weight, heart rate, oxygen saturation and photographic wound review with optional step counters"
33263060|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
33263061|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
33263062|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, applied topically to each axilla once daily for 48 weeks
33263063|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, applied topically to each axilla once daily for 48 weeks
33263064|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
33263065|NCT00884208||Group 1|Recommend assistive device
33263066|NCT00884208||Group 2|Consultation for PT assessment
33263067|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
33263068|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
33263069|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
33263070|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
33263071|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
33263072|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
33263073|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
33263074|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
33263075|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
33263076|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
33263077|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
33263078|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
33263079|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
33263080|NCT00890370|Other|1|Active cycle of breathing techniques
33263081|NCT00890370|Other|2|Autogenic drainage
33263082|NCT00890370|Other|3|R-C Cornet
33263083|NCT00890370|Other|4|Flutter
33263084|NCT00890370|Other|5|PEP
33263085|NCT00890448||Lapaquistat acetate participants|
33263086|NCT00235495|Active Comparator|Albumin (ALB)|Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
33263087|NCT00235495|Placebo Comparator|Saline|Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period
33263088|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
33263089|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
33263090|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
33263091|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
32935602|NCT04828928|Experimental|proportion of patients with neuropathy|to prospectively study patients with a wild-type amyloid cardiopathy condition to identify and describe the associated neuropathy
33263092|NCT00884364|Active Comparator|Control|
33263093|NCT00884364|Experimental|Exercise|
33263094|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
33263095|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
33263096|NCT04087031|Active Comparator|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
33263097|NCT04087031|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
33263098|NCT04087031|Experimental|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
32935603|NCT04828304|No Intervention|control group|
32935604|NCT04828304|Experimental|treatment group|
32935605|NCT04847323|Active Comparator|V-bend Bonded Retainer|"The V-bend retainer was bonded in the lingual surface of the anterior teeth. The retainer was constructed using 0.024 stainless steel wires. Differently from the conventional bonded retainers, this retainer presents V-bends in the sagittal direction, parallel to the occlusal plane in each interproximal contact point of the incisors and canines.~The retainers was bonded after adequate etching with phosphoric acid and application of adhesive with a low viscosity resin."
33263099|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
33263100|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
33263101|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
33263102|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
33263103|NCT04087265|Other|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
33263104|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
33263105|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
33263106|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
33263107|NCT05362877|Experimental|Earplug|Earplug group- using earplugs, n=30 Patients will use only earplugs
33263108|NCT05362877|Experimental|Splint|Occlusal splint group- using occlusal splints, n=30 Patients will use only occlusal splints
33263109|NCT05362877|Experimental|Physical|Exercise group- using physical therapy, n=30 Patients will do only exercise
33263110|NCT05362877|No Intervention|control group|Control group-no intervention, n=30
32770288|NCT04993105|Experimental|B (exercise + graston):|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surf and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restriction was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
32770289|NCT04993105|Active Comparator|A (exercise only)|Exercises only. Patients will be given gastrocnemius stretching, plantar fascia stretching, myofascial release and then graston will be given as sham treatment for 10 minutes after applying cream (applying graston on skin but not giving enough pressure).
32770290|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
33263111|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
33263112|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
33263113|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
33263114|NCT02594345|Experimental|Intervention group|
33263115|NCT00278161|Experimental|R-HiCy|Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.
33263116|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
33263117|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
33263118|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
33263119|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
33263120|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
33263121|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
33263122|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
33263123|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
33263124|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
33263125|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
33263126|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
33263127|NCT00890526|Experimental|3|No Counseling + Sound Therapy
33263128|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
33263129|NCT00890604|Other|1|Usual Care
33263130|NCT00890604|Experimental|2|Normothermia Protocol
33263131|NCT00255151|Experimental|Dexlansoprazole MR 60 mg QD|
33263132|NCT00255151|Experimental|Dexlansoprazole MR 90 mg QD|
32770291|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
32770292|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
32770293|NCT03077581|Active Comparator|Rectus sheath block group|
32770294|NCT03077581|Active Comparator|local infiltration group|
32770295|NCT04993573||Caregivers|Caregivers who work with older patients will be included. They will have a questionnaire
32770296|NCT04993573||Older|Older 65 people who live alone in their house will be included. They will have Individual interviews.
32906336|NCT04939272|Experimental|Treatment (copanlisib hydrochloride, venetoclax)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
33263133|NCT00255151|Placebo Comparator|Placebo|
33263134|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
33263135|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
33263136|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
33263137|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
33263138|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
33263139|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
33263140|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
33401502|NCT03305809|Experimental|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
32770297|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
32770298|NCT05005117|Experimental|Laparoscopic operation|Laparoscopic emergency colon resection
32770299|NCT05005117|Active Comparator|Open operation|Open emergency colon resection
33078487|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
33263141|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
33401503|NCT03305809|Experimental|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
32770300|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
32770301|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
32770302|NCT05287737||Referred for Total pancreatectomy with islet autotransplantation|Followed up for up for 15 years after TPIAT.
32770303|NCT04996537|Experimental|Micro-video with pressure injury(PI) education|"The experimental group's flipped education and training courses adopt a digital learning method and provide a digital learning platform. Log in according to personal account and password, and learn the curriculum units planned by the researcher in order: Prevention and management of stressful injury care as the main axis, enter the digital platform The provided video audio-visual digital teaching materials, combined with clinical situational learning, are equipped with basic knowledge learning, in-class test questions, and unit review, and can open courses for self-study anytime and anywhere, regardless of time and space constraints."
32770304|NCT04996537|Active Comparator|NIS with PI education|At the login interface of the Nursing Information System (NIS) used by the nursing staff daily, a link to the lecture notes (PDF file) of the course on prevention of stress injury is attached, and the nursing staff can view or download them according to their needs. Learn. At the same time, it provides a digital learning platform to download the self-study course handouts (PDF files) and complete the basic demography, pre-test, and post-test data on the platform.
32770305|NCT04996303|Other|Routine|Routine steroid administration group
32770306|NCT04996303|Other|Pulse|Steroid pulse therapy group
32770307|NCT05247567|Other|First year students|Students in their first year of Hairdressing School
32770308|NCT05247567|Other|Third year students|Students in their third year of Hairdressing School
32770309|NCT05287347||Prospective|Blood specimens will be obtained for the model-assigned high risk cohort at each collaborating HCO, over two years of recruitment period. Data of each participant will be electronically followed for observation of outcome measures for up to 3 years.
32770310|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
32770311|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
32770312|NCT04993417|Experimental|Mime Therapy along with EMS|MT Group: Mime Therapy along with EMS
32770313|NCT04993417|Experimental|Motor imagery technique along with EMS|MIT Group: Motor imagery technique along with EMS
32770314|NCT05246085||Steroid|Subjects who take chronic swallowed topical steroids (i.e. budesonide or fluticasone) will be enrolled in the steroid cohort.
32770315|NCT05246085||Proton pump inhibitor|Subjects who take chronic proton pump inhibitors will be enrolled in the proton pump inhibitor cohort.
32770316|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
32770317|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
32770318|NCT05518695|Experimental|A1/100mg|Drug:BAT2022 for Intravenous fluids 100mg
32770319|NCT05518695|Experimental|A2/300mg|Drug:BAT2022 for Intravenous fluids 300mg
32770320|NCT05518695|Experimental|A3/1000mg|Drug:BAT2022 for Intravenous fluids 1000mg
32770321|NCT05518695|Experimental|A4/1500mg|Drug:BAT2022 for Intravenous fluids 1500mg
32770322|NCT05285475|Experimental|Group A|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
32770323|NCT05285475|No Intervention|Group B|The participants in this group will be asked neither to do any exercise nor to change their daily basis routine.
32770324|NCT04920097|Experimental|APA Group|A self-guided smartphone application to self-administered APA
32770325|NCT04920097|Experimental|Virtual APA group|A virtual APA (vAPA): APA app+ plus secure zoom sessions for APA coaching with questions and answers
32770326|NCT04920097|Active Comparator|Usual Care Control|Wait-List Usual Care Control (UC)
32770327|NCT05285319|Experimental|Prostate Only (Arm A)|Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to a dose of 60Gy/20fractions (3 Gy per fraction)
33263142|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
33263143|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
33263144|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
32770328|NCT05285319|Experimental|Prostate and Pelvic Lymph Nodes (Arm B)|Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to a dose of 60Gy/20fractions (3 Gy per fraction)
32770329|NCT04136067|Experimental|NNC0268-0965|Participants will receive NNC0268-0965
33263145|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
33263146|NCT04037670|Experimental|SASI bypass|Patients with super obesity underwent SASI bypass
33078488|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
33078489|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
33078490|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
33263147|NCT00890994||Suspected breast cancer|
33263148|NCT03973957|Active Comparator|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
33078491|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
33263149|NCT03973957|Active Comparator|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
33263150|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
33263151|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
33263152|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33263153|NCT01072903||IBS|Subjects with IBS
33263154|NCT01072903||Healthy|Healthy Controls
33263155|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
32770330|NCT04136067|Active Comparator|Insulin glargine|Participants will receive insulin glargine
33263156|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
33263157|NCT04037046|Experimental|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
33263158|NCT04037046|Active Comparator|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
33401504|NCT03305809|Experimental|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
32770331|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
32770332|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
33263159|NCT04037046|Active Comparator|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
33263160|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
33263161|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
33263162|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
32770333|NCT05244291|Experimental|Intervention Group 1|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times in 1 weeks.
32770334|NCT05244291|Experimental|Intervention Group 2|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
32770335|NCT05244291|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
32770336|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
32770337|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
32770338|NCT05284383|Experimental|Open-label counterconditioning|Closed-label conditioning followed by open-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and open-label nocebo reduction suggestions
32770339|NCT05284383|Experimental|Closed-label counterconditioning|Closed-label conditioning followed by closed-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and closed-label nocebo reduction suggestions
32770340|NCT05284383|Active Comparator|Closed-label extinction|Closed-label conditioning followed by closed-label extinction, using moderately painful stimuli (during conditioning) and slightly-painful stimuli (during extinction), combined with closed-label nocebo suggestions during conditioning and no/neutral suggestions during extinction
32770341|NCT04995991|Experimental|RRT rhythm only|10 RRT rhythm only sessions of 60 minutes, twice a week under the supervision of a trainer
32770342|NCT04995991|Experimental|RRT rhythm + visual cue|10 RRT rhythm + visual cue sessions of 60 minutes, twice a week under the supervision of a trainer
32770343|NCT04995991|No Intervention|No intervention|5 weeks no intervention period
32770344|NCT05283135|Experimental|risankizumab subcutaneous injection 600 mg (4x dosing) at Weeks 0, 4, and 16|
32770345|NCT05283135|Experimental|risankizumab subcutaneous injection 300 mg (2x dosing) at Weeks 0, 4, and 16|
32770346|NCT04995913|Experimental|Computer-based (PC) online CBT program (Web version of the EASE Online Program)|The Web version of the EASE Online Program delivers the online CBT program through the Program website. It includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy.
32770347|NCT04995913|Experimental|Smartphone-based (App) online CBT program (App version of the EASE Online Program)|The App version of the EASE Online Program delivers the online CBT program through a smartphone application. The program content and system functions are the same as those of the Web version.
32770348|NCT04995913|Other|Waitlist control group|The Waitlist control group will receive the service of the Web version of the EASE Online Program after the two experimental groups completed the service.
32770349|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
32770350|NCT05282901|Experimental|Metastatic Uveal MElanoma patients|Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic uveal melanoma (UM)
32770351|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
32770352|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
32770353|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
32770354|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
32770355|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
32770356|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
32770357|NCT03073369|Placebo Comparator|Placebo|
32770358|NCT04995757|Experimental|MicroPort NeuroTech Stentretriever|
32770359|NCT04995757|Active Comparator|Solitaire FR|
32770360|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
32770361|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
33401505|NCT05231356||2|group 1 with positive signs group 2 with negative signs
33263163|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
32770362|NCT04995679|Other|Patient whit osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery with metaphyseal sleeves
32770363|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
32770364|NCT03077035|Experimental|glass ionomer sealant|
32770365|NCT03077035|Active Comparator|resin-based sealant|
33263164|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
33263165|NCT00800462|Active Comparator|Oxybutynin Cl|
33263166|NCT00800462|Active Comparator|Trospium Cl|
33263167|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
33263168|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
33263169|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
33263170|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
33263171|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
33263172|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
32770366|NCT04992325||Patients with type 2 diabetes mellitus|The patients with previous diagnosis of type 2 diabetes mellitus, without signs of diabetic retinopathy
33263173|NCT01326091|No Intervention|Standard Positioning|
33263174|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
33263175|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
33263176|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
33263177|NCT03973801|Experimental|Auricular acupressure|
33263178|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
33263179|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
33263180|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
33263181|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
33263182|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
33263183|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
33263184|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
33263185|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
33263186|NCT00891306|Experimental|Treatment arm|Gene Therapy
33401506|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
33401507|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
32770367|NCT04992325||Healthy subjects|Healthy subjects without actual and previous ocular diseases
32770368|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
32770369|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
32770370|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
32770371|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
32770372|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
32770373|NCT04433611|Experimental|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
32770374|NCT04433611|Placebo Comparator|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
32770375|NCT04992559|Experimental|Toripalimab Arm|Toripalimab consolidation therapy
33401508|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
33263187|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
32770376|NCT04992481|Experimental|1. professional mechanical tooth cleaning (PMTC)+fluoride varnish|This arm constituted of randomly selected 30 participants. In this group professional mechanical tooth cleaning (PMTC)+fluoride varnish were performed.
32770377|NCT04992481|Experimental|2. PMTC+fluoride varnish+gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+gaseous ozone therapy were performed.
32770378|NCT04992481|Experimental|3. PMTC+fluoride varnish+domestic octenidin mouth rinse|This arm contituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse were applied.
33078492|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33078493|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
33263188|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
33263189|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
33263190|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
33263191|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
33263192|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
33078494|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
33263193|NCT00807794|Experimental|1|MEDI-507
33263194|NCT00807794|Experimental|2|MEDI-507
33263195|NCT00807794|Experimental|3|MEDI-507
33263196|NCT00807794|Experimental|4|MEDI-507
33263197|NCT00807794|Experimental|5|MEDI-507
33263198|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
33263199|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
33263200|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
33263201|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
33263202|NCT00812162|Experimental|1|High protein diet.
33263203|NCT00812162|Experimental|2|Lower protein diet.
33263204|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
33263205|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
33263206|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
33263207|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
33263208|NCT00813644||1|uromentor training
33263209|NCT00813644||2|non uromentor training
33263210|NCT00813722|Active Comparator|phone calls|patients received phone calls
32770379|NCT04992481|Experimental|4. PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy were performed.
32770380|NCT04992481|No Intervention|Control group|Control group not subjected to any prophylactic program constituted of randomly selected 30 participants.
32770381|NCT04992091|Experimental|CONSTRUCTIVE DEBRIEFING|interventional group
33263211|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
33263212|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
33263213|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
33263214|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
33263215|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
33263216|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
33263217|NCT00812396|Active Comparator|1|Low dose testosterone
33263218|NCT00812396|Active Comparator|2|High dose testosterone
33263219|NCT00812396|Placebo Comparator|3|Placebo
33263220|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
33263221|NCT00649220|Experimental|Memantine|
33263222|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
33263223|NCT00812552||Control|No drug-eluting stent thrombosis
33263224|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
33263225|NCT00813878||Normal participants|
33263226|NCT00813878||Breast Cancer Patients|
33263227|NCT00808106||Albinism|Patients with albinism
33263228|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone~Receive the FeatForward app~Receive a Samsung smartwatch~Continue to receive medical care as usual"
33263229|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone~Receive a Samsung smartwatch~Continue to receive medical care as usual"
33263230|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
33263231|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
33263232|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
33263233|NCT00812864|Experimental|Capecitabine|
33263234|NCT00814034||1:Tamoxifen|
33263235|NCT00814034||2:Steroidal Aromatase Inhibitor|
33263236|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
33263237|NCT00808184|Active Comparator|CPT-11|
33263238|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
33263239|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
33263240|NCT00814112||1 septic shock|septic shock, ICU
33263241|NCT00814112||2 controls|matched controls
33263242|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
33263243|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
33263244|NCT00812942|Active Comparator|fobt|faecal occult blood test
33263245|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
33263246|NCT00647426|Experimental|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
33263247|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
33263248|NCT00647348|Placebo Comparator|2|Placebo
33263249|NCT00813020|Experimental|A|
33263250|NCT00813020|Experimental|B|
33263251|NCT00813020|Experimental|C|
33263252|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
33263253|NCT00647270|Active Comparator|40 mg|40 mg every other week
33263254|NCT00647270|Active Comparator|80 mg|80 mg monthly
33263255|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
33263256|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
33263257|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
33263258|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
33263259|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
33263260|NCT04708496|Experimental|Standard dose of Artemether lumefantrine|Dose comparison-concurrent control In this arm, Participants receiving Efavirenz400mg based ART will be randomized to standard dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
33263261|NCT04708496|Experimental|Double dose Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to double dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
33263262|NCT04708496|Experimental|5 day course of Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to 5 day course of Artemether Lumefantrine as opposed to the standard 3day course when treating uncomplicated malaria in HIV-malaria co-infected participants
33263263|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
33263264|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
33263265|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
33263266|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
33263267|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
33263268|NCT04692818|Experimental|Clinically indicated breast tumor biopsy|Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed
33263269|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
32770382|NCT04992091|No Intervention|traditional debriefing|noninterventional group
32770383|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
33263270|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
33263271|NCT00817544|Experimental|ORM-12741|ORM-12741
33263272|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
33263273|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
33263274|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
33263275|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
33263276|NCT00808262|Experimental|TNFa Kinoid dose 1|
33263277|NCT00808262|Experimental|TNFa Kinoid dose 2|
33263278|NCT00808262|Experimental|TNFa Kinoid dose 3|
33263279|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
32770384|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
32770385|NCT04995367|Experimental|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke|The participants will carry out tests for the evaluation of the functionality of the BCI system integrated to the T-FLEX device. The test consists of 1 session that includes four conditional experiments. Real Movement, Continuous Stationary Therapy, Motor Imagery Detection with Visual Stimulation, and Motor Imagery Detection with Tactile Stimulation.
32770386|NCT05004415|Experimental|AT-527 550 mg (R07496998)|
32770387|NCT04912843|Experimental|NR082 injection|0.5E9 viral genomes (vg), 0.05 mL eye/dose ,single-dose,only one eye per subject; 1.5E9 viral genomes (vg), 0.05 mL eye/dose single-dose,only one eye per subject; 4.5E9 viral genomes (vg) , 0.05 mL eye/dose single-dose,only one eye per subject Part 1: Dose-Finding；The recommended dose (safe and effective dose) of the Part 2 study will be determined jointly by the SRC, IDMC, sponsor and the drug regulatory authority after the interim analysis in Part 1 is completed.
32770388|NCT04912843|Sham Comparator|sham-injection|Part2.Second Stage: randomized, double-blind, sham-injection control study One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
32770389|NCT04911127|Placebo Comparator|Placebo|Participants will take capsules containing medium chain triglyceride (MCT) oil
33263280|NCT00817622|Active Comparator|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
33263281|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
32770390|NCT04911127|Experimental|200mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 200mg CBD twice daily
32770391|NCT04911127|Experimental|400 mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 400mg CBD twice daily
33263282|NCT00817622|Active Comparator|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
33263283|NCT00808418|Experimental|Cohort|
33263284|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
33263285|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
33263286|NCT04572152|Experimental|AK119/ AK104|Single-arm
33263287|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
33263288|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
33263289|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
33263290|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
33263291|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
33263292|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
33263293|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
33263294|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
33263295|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
32770392|NCT04995133|Experimental|Colistin Arm|Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes
33263296|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
33263297|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
33263298|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
33263299|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
33263300|NCT00814814||Cardiopulmonary arrest|
33263301|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
32770393|NCT04827173|Experimental|Healthy volunteers|
32770394|NCT04991857|Experimental|The technology-based family-centered empowerment program for heart failure (T-FAME-HF)|The T-FAME-HF is a 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits. The Program includes 3 four-week phases, which followed by 2 bi-weekly telephone visits. Each phase is designated with a specified goal of care to guide the disease management activities. Commenced with the home visit by the team nurse for each phase, patients' condition and self-care will be assessed. A goal-setting approach will be used to enhance disease monitoring, symptom recognition and response, and treatment compliance. A mobile apps (T-FAME) will be installed in participants' smart-phone and supports the prescribed actions for goal attainment.
32770395|NCT04991857|Active Comparator|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by another team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
32770396|NCT04362839|Experimental|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
32770397|NCT04994821|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), (Soterix Medical mini-CT tDCS stimulator)
32770398|NCT04994821|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
33263302|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
33263303|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
33263304|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
32770399|NCT04994821|Experimental|Active tDCS with Cognitive Reappraisal (CR)|Active Transcranial Direct Current Stimulation (tDCS) (Soterix Medical mini-CT tDCS stimulator), and Cognitive Reappraisal (CR)
32770400|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
33263305|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
33263306|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
32770401|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
32770402|NCT04361591||COVID-19|Liver Transplant recipients
32770403|NCT04991623|Experimental|Kinesiology taping|Apply a kinesiology taping on the abdominal muscles plus conventional physiotherapy
32770404|NCT04991623|Active Comparator|Physiotherapy Group|Apply a conventional physiotherapy
32770405|NCT04360889|Experimental|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
32770406|NCT04360889|Experimental|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
32770407|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
32770408|NCT04360889|No Intervention|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
32770409|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
32770410|NCT05616689|Experimental|Bundled hyperpolypharmacy intervention|Eligible participants with physician authorization who are randomly assigned to intervention
32770411|NCT05616689|No Intervention|Control|Eligible participants with physician authorization who are randomly assigned to usual care
32770412|NCT04994743|Experimental|Cohort 1: CORT113176 150 mg|Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.
32770413|NCT04994743|Placebo Comparator|Cohort 1: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
32906337|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
32906338|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
33263307|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
33263308|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
33263309|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
33263310|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
32770414|NCT04994743|Experimental|Cohort 2: CORT113176 300 mg|Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.
33263311|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
33263312|NCT00808574|No Intervention|Control|No risk assessment or presentation
33263313|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
33263314|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
33263315|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
32770415|NCT04994743|Placebo Comparator|Cohort 2: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
32770416|NCT04994743|Experimental|Cohort 3: CORT113176 ≥300 mg|Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.
32770417|NCT04994743|Placebo Comparator|Cohort 3: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
32770418|NCT04812041||Intensive care unit delirium|Covid-19 patients in ICU are screened for delirium and rated the severity with CAM-ICU 7 scores.
32770419|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
32770420|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
32770421|NCT04811885||child with ASD of school going age|Questionnaire complete by parent with children with ASD semi structure interview complete by parent with children
32770422|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
32770423|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
32770424|NCT04426877|Experimental|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
32770425|NCT04426877|Experimental|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
32770426|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
32906339|NCT04969770|Experimental|Neuromuscular scoliosis|Minor patients with neuromuscular scoliosis and followed at Necker Hospital
33263316|NCT00645164|Experimental|Xenaderm|Subject serves as own control
33263317|NCT00815048|Active Comparator|Remifentanil|"Atropine~Remifentanil"
33263318|NCT00815048|Placebo Comparator|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
33263319|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
33263320|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
33263321|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
33263322|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
33263323|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
33263324|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
33263325|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
33263326|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
33263327|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
33263328|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
33263329|NCT00818402||Non-small cell lung cancer patients|
33263330|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
33263331|NCT04044638|Experimental|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
33263332|NCT04044638|Experimental|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
33263333|NCT00808730|Experimental|1|fiberoptic fibroscopy
33263334|NCT00722423|Experimental|Integrated Care Model|Integrated Care
33263335|NCT00722423|Experimental|Usual Care Model|Usual Care
33263336|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
33078495|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
33078496|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
33263337|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
33263338|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
33263339|NCT00640562|Experimental|Quetiapine Extended Release|
33263340|NCT00640562|Active Comparator|Risperidone|
33078497|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
33078498|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
32770427|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
33263341|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
33263342|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
32770428|NCT04426799|No Intervention|Control group|no application
33263343|NCT04019639|Experimental|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
33263344|NCT04019639|Active Comparator|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
32770429|NCT04426799|Experimental|Experimental group|application is done
33263345|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
33263346|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
33263347|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
33263348|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
33263349|NCT00818558|Experimental|5|control groupe [tabagic subject]
33263350|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
33263351|NCT00815204||posttraumatic stress disorder|
33263352|NCT00815204||history of trauma exposure but no PTSD|
32770430|NCT04994353|Experimental|Supplementation|"Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are food grade, purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia)."
32770431|NCT04826783|Experimental|Diode laser|
33078499|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
33078500|NCT00176267|Experimental|1|
32770432|NCT04826783|Experimental|Er,Cr:YSGG laser|
32770433|NCT04826783|Experimental|Er:YAG LAser|
33263353|NCT00815204||healthy controls|
33263354|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
33263355|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
32770434|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
32770435|NCT04807829|Experimental|Nabilone|Patients in the treatment group will be administered oral Nabilone 2 mg once daily for 3 days in addition to treatment as usual according to current clinical guidelines and standard of care.
32770436|NCT04807829|Placebo Comparator|Placebo Comparator|Patients in the Placebo Comparator group will receive placebo once daily for 3 days plus treatment as usual.
32770437|NCT04994275||Patients admitted to undergo a major elective surgery|
32770438|NCT05619029||Positive|chest radiographs with the specific target radiologic findings (Atelectasis, Calcification, Cardiomegaly, Consolidation, Fibrosis, Mediastinal Widening, Nodule/Mass, Pleural Effusion, Pneumoperitoneum, Pneumothorax)
32770439|NCT05619029||Negative|chest radiographs with no target radiologic findings
32770440|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
32770441|NCT04811573|Experimental|Tfasted|T: Test Treatment fasted: under fasted conditions
32770442|NCT04811573|Experimental|R1fasted|R1: Reference 1 Treatment fasted: under fasted conditions
32770443|NCT04811573|Experimental|R2fasted|R2: Reference 2 Treatment fasted: under fasted conditions
32770444|NCT04811573|Experimental|Tfed|T: Test Treatment fed: under fed conditions
32770445|NCT04811573|Experimental|R1fed|R1: Reference 1 Treatment fed: under fed conditions
32901852|NCT05621954|No Intervention|Standard of Care|Standard of care will be no remote monitoring for patients whilst on the waiting list or after discharge from hospital. Access to tertiary services for advice, information or to report deteriorations will be through conventional existing modes such as printed or online literature provided at the time of outpatient review, telephone access to administrative staff allowing clinical information to be conveyed to the usual care team, and local primary care and emergency services for acute deteriorations. Existing standard of care remote services (e.g. wound monitoring by digital photograph reviews) will continue.
32901853|NCT05132790|Experimental|TNBC|
33078501|NCT04679116|Other|Laparoscopic|laparoscopic inguinal hernia repair, TAPP
33078502|NCT04679116|Other|Open|open inguinal hernia repair
33078503|NCT00204750|Active Comparator|1|Bougie dilation
33263356|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
33263357|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
33263358|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
33263359|NCT00653432|Experimental|Monovisc®|Injectable Hyaluronic Acid Gel
33263360|NCT00653432|Placebo Comparator|Saline|0.9% Sterile Saline
33263361|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
33263362|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice."
33263363|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
33263364|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
33263365|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
33263366|NCT03954587||Artificial (HRT) Cycles|"Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).~Embryo transfer is scheduled on the 5th full day of progesterone administration."
33078504|NCT00204750|Experimental|2|Needle-knife incision
33263367|NCT03954587||Spontaneous natural cycles:|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
32770446|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
33263368|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
33263369|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
33263370|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
32901854|NCT05132790|Experimental|HER2-/HR+BC|
32901855|NCT05621798|Active Comparator|Hearing Aid Manufacturer's Software Group|Participants' hearing aids are fitted by using manufacturer's software.
32901856|NCT05621798|Active Comparator|REM Group|Participants' hearing aids are fitted by REM (Real Ear Measurements) method.
33263371|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
33263372|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
33263373|NCT00818792|Active Comparator|Bare-metal stent Vision|
33263374|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
33263375|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
33263376|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
33263377|NCT00818870|Active Comparator|Omeprazole 20 mg|
33263378|NCT00818870|Experimental|Vecam 20/300|
33263379|NCT00818870|Experimental|Vecam 40/300|
33263380|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
33263381|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
33263382|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
33263383|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
33263384|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
33263385|NCT00254293|Placebo Comparator|Group 1 (weight < 60 kg)|
33263386|NCT00254293|Placebo Comparator|Group 2 (weight < 60 kg)|
33263387|NCT00254293|Placebo Comparator|Group 3 (weight 60-100 kg)|
33263388|NCT00254293|Placebo Comparator|Group 4 (weight > 100 kg)|
33263389|NCT00254293|Placebo Comparator|Group 5 (weight > 100 kg)|
33263390|NCT00254293|Experimental|Abatacept|Long Term
33263391|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
33263392|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
33263393|NCT00585221|Experimental|All patients|All participants enrolled in the study.
33263394|NCT02594033|Experimental|3 mm needle|
33263395|NCT02594033|Experimental|3.5 mm needle|
33263396|NCT02594033|Active Comparator|4 mm needle|
33263397|NCT00253747|Active Comparator|Osmotic-Release Methylphenidate|
33263398|NCT00253747|Placebo Comparator|Placebo|
33263399|NCT00252733|No Intervention|1|Placebo
33263400|NCT00252733|Experimental|2|candesartan cilexetil
33263401|NCT03974035|No Intervention|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
33263402|NCT03974035|Experimental|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
33078505|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
33263403|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
33263404|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
33263405|NCT00275821|Experimental|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
33263406|NCT00275821|Experimental|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
33263407|NCT00275821|Active Comparator|Ranibizumab 0.3 mg monthly|
33263408|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
33263409|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
33263410|NCT03973099|Experimental|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
33263411|NCT03973099|Experimental|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
33263412|NCT00275509|Experimental|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
33263413|NCT00275509|Experimental|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
33263414|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
33263415|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
32770447|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
32770448|NCT05616611|Active Comparator|Control group|control group received medication and traditional physiotherapy programs for stroke patients (strengthening, stretching, and balance exercise)
32770449|NCT05616611|Experimental|high-intensity laser group|The high-intensity laser (HIL) group received the same intervention as the control group in addition to high-intensity laser therapy.
32770450|NCT05616611|Experimental|shock wave group|shock wave (SW) group received the same intervention as the control group in addition to shock wave therapy.
32770451|NCT04991545|No Intervention|Group A: control group (intubation without IRD/IRRIS device)|Group A = control group (intubation without IRD/IRRIS device) (15 subjects) The first operator experienced with video-laryngoscopy intubation will do the endotracheal intubation after induction of anesthesia.
33263416|NCT01073059|Experimental|Valproic acid|
33263417|NCT00252577||Group 1|Veterans with bipolar disorder
33263418|NCT01073137||Diabetic Subjects|
33263419|NCT01073137||Non diabetic subjects|
33263420|NCT00252499|Placebo Comparator|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
33263421|NCT00252499|Experimental|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
33263422|NCT00252499|Experimental|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
33263423|NCT00252187|Active Comparator|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
33263424|NCT00252187|Placebo Comparator|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
33263425|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
33263426|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
33263427|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
33263428|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
33263429|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
33263430|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
33263431|NCT00163657|Active Comparator|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
33263432|NCT00163657|Active Comparator|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
33263433|NCT00163657|Active Comparator|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
33263434|NCT03971149|Experimental|Behavorial intervention|
33263435|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
33263436|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
32770452|NCT04991545|Experimental|Intervention group using Infrared (Active IRD/ IRRIS) device|Group B = intervention group using Infrared active IRD/IRRIS device (15 subjects) Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients. After confirming lack of discomfort during application of the IRRIS/IRD device, anesthesia will be induced
32770453|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
32770454|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
32770455|NCT04807751|Experimental|Delgocitinib cream 20 mg/g|topical occlusive administration
32770456|NCT04807751|Placebo Comparator|Delgocitinib cream vehicle|topical occlusive administration
32770457|NCT04807751|No Intervention|Untreated skin|topical occlusive administration
32770458|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
32770459|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
32770460|NCT05618951|Experimental|Group A: Lower Trapezius Strengthening Exercises|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide and~Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra and Standardized Physical Therapy treatment will be given as Hot pack at neck area, upper trapezius stretching, neck isometrics and transverse mobilization glide."
32770461|NCT05618951|No Intervention|Group B: Standardized Physical Therapy|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide~Group B given Standardized Physical therapy management"
32770462|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
33263437|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
33263438|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
32770466|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
32770467|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
32770468|NCT05618873|Experimental|flutter device therapy|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
32770469|NCT05618873|Experimental|Positive Expiratory Pressure Mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
32770470|NCT04993963|Experimental|Cycle Ergometery Training (Prehabilitation)|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown) Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale
32770471|NCT04993963|Active Comparator|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
32770472|NCT05618795|Other|aggresive gap arthoplasty|control group- aggressive gap arthroplasty(15 to 20 mm) for management of TMJ ankyosis
32770473|NCT05618795|Active Comparator|minimal gap arthoplasty|experimental group-minimal gap arthroplasty(5 to 8mm) for management of TMJ ankylosis
32770474|NCT04994041|Experimental|Pelvic floor muscle plus adductor strengthening|pelvic floor muscle plus adductor strengthening
32770475|NCT04994041|Active Comparator|Pelvic floor muscle exercises|pelvic floor muscle exercises
32770476|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
32770477|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
32770478|NCT04994197||Diagnosis group of patients with urothelial cancer|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as urothelial carcinoma in this study will be assigned to this group
32770479|NCT04994197||Diagnosis group of patients with benign urinary diseases|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as benign urinary diseases in this study will be assigned to this group
32770480|NCT04994197||Recurrence diagnosis group with urothelial cancer|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as recurrent urothelial carcinoma in this study will be assigned to this group
32770481|NCT04994197||Recurrence diagnosis group with benign urinary diseases|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as benign urinary diseases in this study will be assigned to this group
32901857|NCT01493947|Experimental|Ivermectin 1% cream|
32901858|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
33263439|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
32770482|NCT04987567|Active Comparator|Antioxidant docosahexaenoic acid (DHA)|"Antioxidant docosahexaenoic acid (Tridocosahexaenoin-AOX ® 70%) 50mg/kg/day:~50mg/kg/day so:~> = 13-17kg: 2 pearls (700mg DHA) every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls (1050mg DHA) every day, od or bd~> = 25-30kg: 4 pearls (1400mg DHA) every day, bd (2-0-2)~> = 31-36kg: 5 pearls (1750mg DHA) every day, bd (2-0-3)~> = 37-43kg: 6 pearls (2100mg DHA) every day, bd (3-0-3)~> = 44-49kg: 7 pearls (2450mg DHA) every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls (2800mg DHA) every day, td (3-2-3)."
33078506|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
33078507|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
33078508|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
33078509|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
33263440|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
33078510|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
33263441|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
33263442|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
33263443|NCT00230971|Active Comparator|A|
33263444|NCT00230971|Active Comparator|B|
33263445|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
33078511|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
33078512|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
33263446|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
33263447|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
33263448|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
33263449|NCT00211081|Experimental|Open Label|
33263450|NCT05278806|Experimental|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|After the step in which the primary care providers are randomized to receiving intervention, one group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control. One of the options will be to refer patients to a community health worker (CHW) program focused specifically on addressing hypertension.
33263451|NCT05278806|Experimental|Equity Dashboard and Population Health Coordinator Support|After the step in which the primary care providers are randomized to receiving intervention, a second group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control.
33263452|NCT05278806|No Intervention|Delayed intervention|Black, Indigenous and People of Color (BIPOC) patients and patients with limited English proficiency (LEP) before their primary care providers are randomized to receiving the intervention. (By the end of the 12 steps, all BIPOC/LEP patients will be assigned to an experimental group)
33263453|NCT05278806|No Intervention|Usual Care|Patients who are not eligible for additional clinical support (i.e. White and English speaking patients).
33263454|NCT03971227|Experimental|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
33263455|NCT03971227|Active Comparator|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
33263456|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
33263457|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
33263458|NCT02542800|Experimental|Healthy participants|
33263459|NCT04036812|Experimental|Superficial cervical plexus block group|
33263460|NCT04036812|Sham Comparator|Control group|
33263461|NCT00891384|Experimental|1|25 mg lenalidomide
33263462|NCT00891384|Experimental|2|5 mg lenalidomide
33263463|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
33263464|NCT00887328|Placebo Comparator|Placebo|
33263465|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
33263466|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
33263467|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
33263468|NCT00612066|Experimental|Rosiglitazone|
33263469|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
33263470|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
33263471|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
33263472|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
33263473|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
33263474|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
33263475|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
33263476|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
33263477|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
33263478|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
33263479|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
33263480|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
33263481|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
33263482|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
33263483|NCT04397406|Active Comparator|Group C (Control group)|pidural analgesia with levobupivacaine alone
33263484|NCT04397406|Experimental|Group D (Dexmedetomidine group)|Epidural analgesia with levobupivacaine and dexmedetomidine
33263485|NCT04397406|Experimental|Group F (Fentanyl group)|Epidural analgesia with levobupivacaine and fentanyl
33263486|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
33263487|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
33263488|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
33263489|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
33263490|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
33263491|NCT00887718|Experimental|PET scan for lymphoma assessment|
33263492|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
33263493|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
33263494|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
33263495|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
33263496|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
33263497|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
33263498|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
33263499|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
33263500|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
33263501|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
33263502|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
33263503|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
33263504|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
33263505|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
33263506|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
33263507|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
33263508|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
33263509|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
33263510|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
33263511|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
33263512|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
33263513|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
33263514|NCT00163189|Experimental|Somatropin|
33263515|NCT04036890|Experimental|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
33263516|NCT04036890|Placebo Comparator|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
33263517|NCT00887874||A|
33263518|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
32770483|NCT04987567|Placebo Comparator|Placebo|"Olive oil 50mg/kg/day so:~> = 13-17kg: 2 pearls every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls every day, od or bd~> = 25-30kg: 4 pearls every day, bd (2-0-2)~> = 31-36kg: 5 pearls every day, bd (2-0-3)~> = 37-43kg: 6 pearls every day, bd (3-0-3)~> = 44-49kg: 7 pearls every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls every day, td (3-2-3)."
33263519|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
32770484|NCT04811495|Experimental|patient with temporomandibular joint disorders|
32770485|NCT05004103|Experimental|Skin microbiome evaluation|Female healthy volunteers applied cosmetic products (cleanser and moisturizer cream), the diversity of skin microbiome will be examined before and after using the products
32770486|NCT05003869|Experimental|Intraoperative resection of intrauterine scar tissue by TCRA|Study group: patients took the bladder lithotomy position, routinely disinfected vulva and vagina, and laid sterile towel and sheet.pliers Clamp the front lip of the cervix, explore the depth of the uterine cavity, dilate the cervical canal one by one, place the endoscopy, and examine the uterine cavity.After the scar tissue contracted on one side, the scar tissue was disintegrated at the boundary between the intima and scar tissue. The scar tissue was removed with the annular electrode, and a balloon was placed after surgery to prevent re-adhesion.Complete adhesion release is defined as a return to normal shape of the uterine cavity with bilateral uterine angles exposed.
32770487|NCT05003869|No Intervention|No scar tissue resection group|During the operation, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips with needle-like electrodes, and scar tissue was not excised.
33078513|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
33263520|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
33263521|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
32770488|NCT03072199|Experimental|Rituximab|
32770489|NCT04811105|Active Comparator|steam ablation|The fistula tract which treated with steam ablation
32770490|NCT04811105|Active Comparator|control group|The fistula tract which do not take any treatment
32770491|NCT04990999|Experimental|Vestibular Root Extraction|
32770492|NCT04990999|Active Comparator|Atraumatic extractions using periotomes followed by conventional forceps|
32770493|NCT04811183||Experimental group|Adult patients hospitalized with diabetes and polymedicated. Selected to benefit from a pharmaceutical consultation before their return home.
32770494|NCT04901533|Experimental|cervical manipulation|The objective of this technique is to restore joint mobility between the joints of the occipital, first (atlas) and second cervical vertebra (axis). It is a technique performed in rotation on a vertical axis that passes through the odontoid process of the axis, without placing flexion or extension, and with very slight sidebending; it is done bilaterally.
32770495|NCT04901533|Active Comparator|Cranial Listening|Cranial palpation maneuver
32770496|NCT04825925|Experimental|DEB-BACE|
32770497|NCT05003479|Experimental|candidate vaccine|
32770498|NCT05003479|Placebo Comparator|Placebo|
32770499|NCT04806659|Experimental|SH1573 Capsules|SH1573 capsules administered orally. Multiple doses will be administered by effiacy and safety to determine the RP2D.
32770500|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 1|"Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: L"
32770501|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 2|"Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: M"
33263522|NCT00162097|Experimental|EFV600mg Participants With Mild Hepatic Impairment|
33263523|NCT00162097|Experimental|EFV600mg Participants With Moderate Hepatic Impairment|
32770502|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 3|"Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: H"
32770503|NCT04806737|Active Comparator|IMP|Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.
33078514|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
33263524|NCT00162097|Experimental|EFV600mg Participants With Severe Hepatic Impairment|
32770504|NCT04806737|Placebo Comparator|Placebo|Sham tablets
33078515|NCT03056872||Healthy Controls|Community sample
33263525|NCT00162097|Active Comparator|EFV600mg Participants With Normal Hepatic Function|
33263526|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
33263527|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
33263528|NCT04037982|Experimental|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
33263529|NCT04037982|Active Comparator|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
33263530|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
33263531|NCT00888030||2|CKD patients with normal p-cresol
33263532|NCT00888030||3|CKD patient with normal indoxyl sulfate
33263533|NCT00888030||4|CKD patients with high indoxyl sulfate
33263534|NCT00888030||1|CKD patients with high p cresol
33263535|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
33263536|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
33263537|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
33263538|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
33263539|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
33263540|NCT04036734|Active Comparator|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
33263541|NCT04036734|Experimental|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
33263542|NCT01073215|Active Comparator|Group Condition|
33263543|NCT01073215|Experimental|Self-Guided Condition|
33401509|NCT04934488|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1). The experimental group will also receive care as usual from their healthcare providers.
33401510|NCT04934488|Other|Waitlist Control|The waitlist control group will receive care from usual healthcare providers and will receive the intervention at the conclusion of the study period (T2, 12 weeks after enrollment).
33263544|NCT05278728|Experimental|Nimotuzumab and Irinotecan|Nimotuzumab： 200, 400, 600 or 800mg weekly until progression or AEs Irinotecan：180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
33263545|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
33263546|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
33263547|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
33263548|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
33401511|NCT04056806|Experimental|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
33401512|NCT04056806|Active Comparator|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
33263549|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
33263550|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
33263551|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
32770505|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
32770506|NCT04825691||cases diagnosed as prostatic acinar adenocarcinoma|
32770507|NCT04991233|Experimental|Endoscopic surgery|Endoscopic surgery group
32770508|NCT04991233|Active Comparator|Suboccipital craniotomy surgery|Suboccipital craniotomy surgery group
32770509|NCT04810637|Experimental|GX-I7|Patients randomised on experimental arm will receive GX-I7 drug
33078516|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
33263552|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
33263553|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
33263554|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
33263555|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
33263556|NCT04036656|Experimental|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
32770510|NCT04810637|Placebo Comparator|GX-I7 vehicle|Patients randomised on comparator arm will receive placebo
32770511|NCT04987411||Hemorrhagic group|Patients with bleeding confirmed with eFAST or CT.
32770512|NCT04991155|Experimental|PART 1 (400 mg BIA 5-1058)|Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3): Part 1: 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 1, 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 2, and 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 3.
32901859|NCT05067348|Experimental|Tocilizumab|Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
33263557|NCT04036656|Experimental|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
33263558|NCT04036656|Experimental|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
33263559|NCT04036656|Experimental|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
33263560|NCT04036656|Experimental|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
33263561|NCT04036656|Experimental|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
33263562|NCT04036656|Experimental|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
33263563|NCT04036656|Experimental|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
33263564|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
33263565|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
33263566|NCT04036422|Experimental|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
33263567|NCT04036422|Active Comparator|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
33263568|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
33263569|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
33263570|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
33263571|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
32770513|NCT04991155|Experimental|PART 2 (800 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 2: 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 1, 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 2, and 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 3."
32770514|NCT04991155|Experimental|PART 3 (1200 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 3: 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 1, 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 2, and 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 3."
32770515|NCT04825457|Active Comparator|Anchoring-tip EMR|AEMR, the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins.
32770516|NCT04825457|Active Comparator|Conventional EMR|After injection of normal saline solution mix, snaring was tried for CEMR.
32770517|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
32770518|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
32770519|NCT05618717||Surpoint Index Guided Ablation Group|Maximum Radiofrequency delivery duration cannot exceed Surpoint Index of 550
32770520|NCT05618717||Conventional Ablation Group|Operator determined ablation duration regardless of Surpoint Index Value
32770521|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
32770522|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
32901860|NCT05067348|Placebo Comparator|Placebo|Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
33263572|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
33263573|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
33263574|NCT04036578|Other|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I~II) and group 2(Pelvic Floor Dysfunction With POP Stage I~II)
33263575|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
33263576|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
33263577|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
33263578|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
33263579|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
33263580|NCT00888108|Experimental|docetaxel +ABT-263|
33263581|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
33263582|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
33263583|NCT00888186|Active Comparator|1. Duodopa optimal dose|
33263584|NCT00888186|Experimental|2. Duodopa 20% too high dose|
33263585|NCT00888186|Experimental|3. Duodopa 10% too low dose|
33263586|NCT00888186|Experimental|4. Duodopa 20% too low dose|
33263587|NCT00888186|Experimental|5. Duodopa 10% too high dose|
33263588|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
33078517|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
33263589|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
33263590|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
33263591|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
33263592|NCT00892554|Experimental|DHA supplementation|
33263593|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
33263594|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
33263595|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
33263596|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
33263597|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
33263598|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
33263599|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
33263600|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
33263601|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
33263602|NCT00895518|No Intervention|1|Participants will receive assessments only.
33263603|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
33263604|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
33263605|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
33263606|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
33401513|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
33263607|NCT03482778||AYA Patients - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA patients (n=36). AYA patients are eligible if they: (1) are 15 to 39 years of age, (2) were diagnosed with cancer at 15 to 39 years of age; (3) are able to read and understand English; (4) have a new cancer diagnosis and are receiving curative treatment OR are currently 0 to 5 years post-treatment. AYA patients will be excluded if they: (1) were diagnosed with basal cell skin cancer; (2) experienced a cancer recurrence; (3) are currently receiving palliative or hospice care; (4) had an infertility diagnosis prior to their cancer diagnosis, or (5) report a significant psychiatric history.
33263608|NCT03482778||AYA Providers - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA providers (n=36). Providers will be health professionals who provide supportive care for AYAs to help address financial, body image, and fertility/future parenthood concerns or needs. Psychosocial providers (e.g., social workers, patient navigators, psychologists) will all be eligible to participate. We will also include reproductive endocrinologists, nurse practitioners, and other medical professionals who have expertise in the appropriate area of health-related quality of life (HRQOL). Additional inclusion criteria will be: (1) provision of care to AYAs; (2) ≥2 years practicing; (3) English-speaking.
32770523|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - within-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS on a visual working memory task in aged HV
32770524|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - cross-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized cross-frequency fronto-parietal tACS stimulation on a visual WM task in aged HV
32901861|NCT05621720|Experimental|Intervention group|Subjects in the intervention group will receive a 3-moth community-based health-social partnership program (C-HSPP) led by a nurse case manager, and supported by social workers and community workers.
33263609|NCT03482778||Content Experts - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with content experts (n=36). Content experts are a purposive sample of scientists and clinicians who have recognized expertise in each of the three domains of interest to this project - financial burden, body image, and fertility/future parenthood.
33263610|NCT03482778||AYA Patients - AIM1B|Five forms have been created for AYA patients (n=25). Each form consists of 25 to 30 items. Forms for AYA patients include an even number of items from the body image, financial burden, and fertility domains counterbalanced in order of administration to reduce the potential for order effects. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
33263611|NCT03482778||AYA Caregivers - AIM1B|Two forms for AYA caregivers (n=10). Each form consists of 25 to 30 items. Forms for AYA caregivers only include items from the financial burden domain. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
33263612|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
33263613|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
33263614|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
33263615|NCT04036500|Experimental|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
33263616|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
32770525|NCT04986787|Experimental|Cerebellar rTMS to modify the effects of cortico-cortical, fronto-parietal tACS in HV|double-blind, randomized, sham-controlled, cross-over trial assessing the effects of cerebellar stimulation on individualized fronto-parietal tACS stimulation during a visual WM task in aged HV
33263617|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
33263618|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
32770526|NCT04986787|Experimental|Neuromodulation protocol in MCI patients (precise protocol to be chosen on results of previous arms)|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS stimulation or a combination of rTMS-tACS on a visual working memory task in MCI patients
33263619|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
33263620|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
33263621|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
33263622|NCT00895674||Group 1|
33263623|NCT00892944|Experimental|1|AZD2516
33263624|NCT04035330|Experimental|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
33078518|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
33078519|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
33263625|NCT04035330|Active Comparator|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
33263626|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
33263627|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
33263628|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
33263629|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
32770527|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
33263630|NCT04035096|Experimental|The high-dose vitamin C with very low carbohydrate diet group|"Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.~Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose~Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.~The Riordan IVC protocol (Taiwan)~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks~The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month~VLCD intervention in the first 12 weeks"
32770528|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
33263631|NCT04035096|Active Comparator|The control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
33263632|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
33263633|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
33263634|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
33263635|NCT00606294|Experimental|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
33263636|NCT00606294|Experimental|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
33263637|NCT04035018|Experimental|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
33078520|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
33078521|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
33078522|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
33263638|NCT04035018|Active Comparator|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
33078523|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
33078524|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
33263639|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
33263640|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
33263641|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
33263642|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
33263643|NCT00893100|Experimental|Diltiazem|
33263644|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
33263645|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
33263646|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
33263647|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
33263648|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
33263649|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
33263650|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
33263651|NCT03324984|Experimental|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
33263652|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
33263653|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
33263654|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
33263655|NCT00896376|Experimental|trastuzumab|
33263656|NCT00901290|Experimental|1|monophasic oral contraceptive
33263657|NCT00901290|Experimental|2|AZD7325
33263658|NCT04018014||< 30 kg/m2|patients with BMI < 30/kg/m2
33263659|NCT04018014||>30 kg/m2|patients with BMI > 30 kg/m2
33263660|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
33263661|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
33263662|NCT00605280|Sham Comparator|Sham Control|
33263663|NCT00605280|Experimental|Macugen|
33263664|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
33263665|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
33263666|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
33263667|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
33263668|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
33263669|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
33263670|NCT00893334||Control|Healthy Controls
33263671|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
33263672|NCT04034940|Other|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
33263673|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
32770529|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
32770530|NCT04462315||Everolimus Arm|Everolimus Eluting Coronary Stent System
32770531|NCT04462315||Non-drug eluting stent Arm|Cobalt chromium balloon-expandable stent
32770532|NCT04825535|Experimental|Standard psychiatry and cognitive behavioural online intervention|The online group CBT-M program combines software-based workbooks with phone-based Navigator-Coaching that coordinates software interactions (e.g., secure text messaging, Fitbit tracked walking, food monitoring via photography). Navigation coaching is supplied by students who were pursuing graduate degrees (MSc, MA, PhD) in kinesiology and health science, education, and psychology.
32770533|NCT04825535|Active Comparator|Standard psychiatry and cognitive behavioural in-person intervention|The on-site, usual-care CBT group follows the structure of the Mind Over Mood workbook in reviewing CBT concepts and procedures. A series of work sheets assist participants in differentiating moods, and in differentiating moods from thoughts and situational influences, leading to modifications of thinking, behaviour, emotion and mood. Group leaders are standard leaders in the CAMH group-CBT program who have Masters-level degrees in psychology, social work and occupational therapists.
32770534|NCT04461067|Experimental|Gastric antrum measurement|
32770535|NCT04806425|Active Comparator|IL group|receive 1.5 ml /kg intralipid 20% through Central venous line after sternotomy over 1 hour
33078525|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
33078526|NCT00204828||1.|Children with asthma
33078527|NCT00204828||2.|Children without asthma
33078528|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
33078529|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
33078530|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
33078531|NCT02606422|Experimental|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
33078532|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
33078533|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
33078534|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
33078535|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
33078536|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
33078537|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
33078538|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
33078539|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
33078540|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
33078541|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
33078542|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
33078543|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
33078544|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
33078545|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
33078546|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
33078547|NCT00554281|No Intervention|A|Run in period
33078548|NCT00554281|Experimental|B|
33078549|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
33078550|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
33078551|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
33078552|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
33078553|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
33078554|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
33078555|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
33078556|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
33078557|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
33078558|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
33078559|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
33078560|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
33263674|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
32770536|NCT04806425|Placebo Comparator|NS group|recieve 1.5 ml /kg normal saline 0.9% through central venous line after sternotomy over 1 hour
33078561|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
33078562|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
33263675|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
33263676|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
33263677|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
33263678|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
33263679|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
33078563|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
33078564|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
33078565|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
33078566|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
33078567|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
33263680|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
33263681|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
33078568|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
33263682|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
33263683|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
33263684|NCT04036344|No Intervention|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
33263685|NCT04036344|Experimental|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
33263686|NCT04036344|Experimental|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
33263687|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
33263688|NCT00893490|Experimental|AGV plus MMC|
33263689|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
33263690|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
33078569|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
33078570|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
33078571|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
33078572|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
33078573|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
33263691|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
33263692|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
33263693|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
33263694|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
33263695|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
33263696|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
33263697|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
33263698|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
33263699|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
33263700|NCT04017780|Experimental|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
33263701|NCT04017780|Experimental|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
32770537|NCT04460677|Experimental|Emotional Support Plan (ESP) + Weekly Monitoring|This will involve weekly assessments without prompting to use the plan.
33263702|NCT04017780|Experimental|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
33263703|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
33263704|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
33263705|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
33263706|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
33263707|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
33263708|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
33263709|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
33263710|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
33263711|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
33263712|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
33263713|NCT00893724|Placebo Comparator|P (Placebo)|
33263714|NCT00893724|Active Comparator|S (Supplement)|
33263715|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
33263716|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
33078574|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
33263717|NCT00893802|No Intervention|Control|
33263718|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
32770538|NCT04460677|Experimental|Emotional Support Plan (ESP) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt
33263719|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
33263720|NCT00893880|Experimental|1|(1) 30min treatment
33263721|NCT00893880|Experimental|2|(1) 60min treatment
33263722|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
32770539|NCT05618561||Nasopharyngeal specimen collection arm|Specimens collected in nasopharyngeal form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
32770540|NCT05618561||Combined nasal mid-turbinate and throat specimen collection arm|Specimens collected in combined nasal mid-turbinate form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
32770541|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
32770542|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
33263723|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
33263724|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
33263725|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
32770543|NCT04809779|Experimental|Sintilimab|
32770544|NCT04282915|Active Comparator|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
32770545|NCT04282915|Experimental|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
32770546|NCT04809935|Active Comparator|EUS-CPB|Chemical ablation of the coeliac plexus
32770547|NCT04809935|Active Comparator|EUS-CPA|Radiofrequency ablation of the coeliac plexus
32770548|NCT04255927|Experimental|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
32770549|NCT04255927|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
33078575|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
33078576|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
33078577|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
33263726|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
33263727|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
33263728|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
33263729|NCT00815750|Other|Phase I - Information Gathering|
33263730|NCT00815750|Other|Phase 2 - Decision Aid|
33263731|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
33263732|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
33263733|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
33263734|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
33263735|NCT00543387|Experimental|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263736|NCT00543387|Experimental|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263737|NCT00543387|Experimental|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263738|NCT00543387|Experimental|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263739|NCT00543387|Experimental|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263740|NCT00543387|Experimental|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
33263741|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
33263742|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
33263743|NCT00543387|Experimental|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
33263744|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
33263745|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
33263746|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
33263747|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33263748|NCT04045106|Experimental|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of~Cervical flexion with right rotation followed by extension with left rotation.~Cervical flexion with left rotation followed by extension with right rotation."
33263749|NCT04045106|Experimental|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
33263750|NCT04045106|Sham Comparator|control|Participants allocated to the control group received ineffective passive ROM.
33263751|NCT04017624|Experimental|Fresh Truck with stipend|Referral to Fresh Truck mobile market
32770550|NCT04809857|Experimental|Plyometric Exercise Group|Plyometric exercise training 3 days a week for 6 weeks
32770551|NCT04809857|Active Comparator|Isokinetic Exercise Group|Isokinetic exercise training 3 days a week for 6 weeks
32770552|NCT04809857|No Intervention|Control Group|no exercise intervention
33263752|NCT04017624|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
33263753|NCT00815828|Other|1|Group that don't do the resistance exercises
33263754|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
33263755|NCT02540304|No Intervention|Business as Usual|Business as usual
33263756|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
33263757|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
33263758|NCT00897468||breast cancer patients|
33263759|NCT00809042|Experimental|1|Hydroxyurea
33263760|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
32770553|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
32770554|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
33263761|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
33263762|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
33263763|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
33263764|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
33263765|NCT00988377|Experimental|10 g whey protein|
33263766|NCT00988377|Experimental|20 g whey protein|
32770555|NCT04986553||50 subjects, male and female, at least 18 years of age|50 subjects who are candidates for surgery using the Arthrex Clavicle Plate for treatment of clavicle fractures.
32901862|NCT05621720|Other|Control group|Subjects in the control group will receive usual community services and a monthly social control call from trained community workers.
32901863|NCT05013372|Other|Dose-escalation|Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg
32906340|NCT04969770|Other|Neuromuscular pathologies without instrumented scoliosis|Minor patients with neuromuscular pathology without instrumented scoliosis and followed at Necker Hospital
32770556|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have >30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
33263767|NCT00988377|Experimental|30 g whey protein|
33263768|NCT00988377|Experimental|40 g whey protein|
33263769|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
33263770|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
33263771|NCT02551328||Propofol|Patients with no preconditioning
33263772|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
33263773|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
32770557|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
32770558|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
32770559|NCT04809389|Experimental|Test Product|DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration
32770560|NCT04809389|Placebo Comparator|Reference Product|Matching placebo, 2 doses 4 weeks apart, intranasal administration
32770561|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
32770562|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
32770563|NCT04805723|Experimental|Patients with pulmonary nodule scheduled VATS|"Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
32901864|NCT05132556|Experimental|Nitrate-rich beetroot juice (~12.8 mmol)|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the nitrate-rich beetroot juice (~12.8 mmol).
32906341|NCT04969770|Other|Controls|Minor patients without neuromuscular pathology or scoliosis and followed at Necker Hospital
33263774|NCT00901914|Placebo Comparator|1|Placebo
33263775|NCT00901914|Experimental|2|12.5 µg rBet v 1
33263776|NCT00901914|Experimental|3|25 µg rBet v 1
33263777|NCT00901914|Experimental|4|50 µg rBet v 1
33263778|NCT00815906|Experimental|SBI-087 0.15 mg IV|
33263779|NCT00815906|Experimental|SBI-087 0.5 mg IV|
33263780|NCT00815906|Experimental|SBI-087 100 mg SC|
33263781|NCT00815906|Experimental|SBI-087 200 mg SC|
33263782|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
33263783|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
33263784|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
33263785|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
33263786|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
33263787|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
33263788|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
33263789|NCT00983151|Experimental|Active|
33263790|NCT00983151|Placebo Comparator|Placebo|
33263791|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
33263792|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
33263793|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
33263794|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
33277502|NCT03979352|Placebo Comparator|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.~Participant and research staff is blinded to arm assignment."
33263795|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~Direct evaluation of laryngeal view through CTrach~Tracheal intubation through CTrach LMA~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
33263796|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through ILMA using fibrescope~Tracheal intubation through ILMA using fibrescope.~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
33263797|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through I-gel using fibrescope~Tracheal intubation through I-gel using fibrescope~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
33263798|NCT04035876|Experimental|Camrelizumab plus apatinib|
33263799|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
33263800|NCT00635492||1|exenatide
33263801|NCT00635492||2|insulin
33263802|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
33263803|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
33277503|NCT00780767|Experimental|Thrombectomy arm|
32770564|NCT04805723|Experimental|Patients with pulmonary nodule scheduled thoracotomy|"Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
32770565|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
32770566|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
32770567|NCT04798391|Experimental|Dexamethasone with lignocaine|
32770568|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
32770569|NCT05616455|Experimental|Propionibacterium extract gel|"The Propionibacterium extract gel is a topical product that protect the skin and mucous membranes from external agents. Its film forming property on the epidermis helps reduce inflammation, itching and pain, while the adjunct of antioxidant ingredients helps promote the healing process.~Patients were instructed to squeeze out from the aluminium tubes containing the Propionibacterium extract gel, 3 grams of gel (3 cm), applying it twice a day for 40 days in the distal anal canal and perianal area."
32770570|NCT05616455|Active Comparator|0.4% glyceryl trinitrate ointment|"0.4% glyceryl trinitrate ointment is a well-known nitric oxide donor which promotes fissure healing by decreasing resting anal pressure and increasing anoderm blood flow, via the stimulation of the intracellular cyclic GMP resulting in a consequent reduction in cytosolic calcium. The success rate is variable, with 28% of patients experiencing transient headache often leading to drug discontinuation and poor compliance to treatment.~Patients were instructed to squeeze out from the aluminium tubes containing 0.4% glyceryl trinitrate ointment approximately 1.5 mg of the ointment applying it to the distal anal canal and perianal area with a gloved finger, every 12 hours for 40 days."
32770571|NCT04986319||Adequately sun-exposed healthy population|Healthy coastal fishermen of Cox's Bazar district of Bangladesh
32770572|NCT04986319||Inadequately sun-exposed healthy population|Healthcare workers of the selected hospitals of Dhaka, Bangladesh
32770573|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
32770574|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
32770575|NCT05002855||Enhanced Recovery After Surgery (ERAS)|
32770576|NCT05002855||Conventional Recovery Strategy (pre-ERAS)|
32770577|NCT04805801||Hemophilia A with FVIII inhibitors|Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
32770578|NCT04805801||Hemophilia A without FVIII inhibitors|Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
32770579|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
32770580|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
32770581|NCT04805957|Experimental|Treatment|All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
32770582|NCT04990765|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
32770583|NCT04990765|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
32770584|NCT04797923|Experimental|Intraperitoneal paclitaxel with systemic chemotherapy|
33263804|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
33263805|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
33263806|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
32770585|NCT04986475|Experimental|Music Therapy|Music therapy was applied during the non-stress test.
32770586|NCT04986475|No Intervention|Control|A routine non-stress test was performed.
32770587|NCT04798157|Experimental|Children with Hemoglobinopathies|children from 2-18 years old , diagnosed to have hemoglobinopathy disease
32770588|NCT04990453|Other|RPD frameworks fabricated from PEEK material|14 patients received extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
33263807|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
33263808|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
33263809|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
33263810|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
32770589|NCT04990453|Other|RPD frameworks fabricated from Co-Cr|14 patients received extracoronal precision attachment RPD frameworks fabricated from Co-Cr material using casting machine
32770590|NCT04805645||Non-Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit which died before or on day 28 post ICU admission
32770591|NCT04805645||Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit whom are still alive on day 28 post ICU admission
32770592|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
32770593|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
32770594|NCT04805567||Patients with polyps and adenomas|The inclusion criteria are: (i) CRC screening; (ii) post-polypectomy surveillance; (iii) diagnostic assessment (anemia, lower gastrointestinal bleeding, abdominal pain, recent change in bowel habits); and (iv) age over 50 years.
33263811|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
33263812|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
32770595|NCT04985617|Experimental|Warmed Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
32770596|NCT04985617|No Intervention|Room Temperature Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the control group was given at room temperature without heating and without intervention
33263813|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
33263814|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
33263815|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
33263816|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
33263817|NCT00988689|Experimental|Soup with no added starch|
33263818|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
32770597|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
32770598|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
33263819|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
32770599|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
33263820|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
32770600|NCT03071107|No Intervention|Control arm|Standard of care
32770601|NCT04990063|Experimental|adoptive TKC transfer combined with chemotherapy|NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
32770602|NCT04985149|Other|Grup 1; participants with fibromyalgia|Participants with fibromyalgia
32770603|NCT04985149|Other|Grup 2: patients without fibromyalgia|Patients without fibromyalgia
32770604|NCT05001997|Active Comparator|Diet A - Lactose free probiotic yogurt|Plain flavoured lactose free probiotic yogurt (contains Lactobacillus acidophilus and Bifidobacterium lactis)
32770605|NCT05001997|Placebo Comparator|Diet B - Lactose free yogurt (non-probiotic)|Plain flavoured lactose free yogurt (contains only starter cultures)
32770606|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
32770607|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
32770608|NCT05001919|Placebo Comparator|collagen membrane|10 sites treated with surgery and bone graft and collagen membrane as GTR
32770609|NCT05001919|Experimental|Concentrated growth factor membrane|10 sites treated by surgery +bone graft and concentrated growth factor membrane as GTR
32770610|NCT05001763|Placebo Comparator|Placebo|Glucose, 2mg, tablet.
32770611|NCT05001763|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment.
32770612|NCT04989985|Active Comparator|Active Comparator|"SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
32770613|NCT04989985|Experimental|Experimental|"Sinitlimab + SOX； SOX: Oxaliplatin+S-1~Sinitlimab: 200mg, ivdrip, d1, q3w;~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
32770614|NCT05242809|No Intervention|Control group|The control group receives standard care, which means the participants will receive verbal instruction on PFMT from midwives without any further supervision. For reasons of equipoise, women in the comparator group will be offered the group-based PFMT intervention at the end of the study if they wish.
33078578|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
33078579|NCT02367313|Placebo Comparator|Placebo|Placebo
33263821|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
33263822|NCT00902382||1|Infertile women who conceive spontaneously
33263823|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
33263824|NCT04006977|Placebo Comparator|Arm 1: placebo plus standard therapy|placebo plus standard therapy
33263825|NCT04006977|Experimental|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
33263826|NCT04332432|Experimental|belapectin|"Single dose of 4 mg/kg of lean body mass (LBM) belapectin solution for injection administered intravenously (infused over approximately 60 minutes).~Group 1: 16 matched healthy subjects with normal hepatic function~Group 2: 8 subjects with mild hepatic impairment (Child-Pugh Class A [4 x subjects with a score of 5 and 4 x subjects with a score of 6])~Group 3: 8 subjects with moderate hepatic impairment (Child-Pugh Class B [score of 7 to 9])~Group 4: 8 subjects with severe hepatic impairment (Child-Pugh Class C [score of 10 to 14])."
33263827|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
33263828|NCT00569582|Experimental|1|
33263829|NCT03906435|No Intervention|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
33263830|NCT03906435|Experimental|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
33263831|NCT00894192|Active Comparator|Wavefront guided lenses|
33263832|NCT00894192|Placebo Comparator|Conventional lenses|
33263833|NCT00988845|Experimental|Indole-3-carbinol|
33263834|NCT00819416|Experimental|1|5% albumin
33263835|NCT00819416|Other|2|Normal saline
33263836|NCT04005807|Experimental|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
33263837|NCT04005807|Experimental|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
33263838|NCT04005807|Experimental|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
33263839|NCT04005807|Experimental|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
33263840|NCT04005807|Experimental|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
33263841|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
33263842|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
33263843|NCT00902460|Experimental|Treatment Sequence 1|
33263844|NCT00902460|Experimental|Treatment Sequence 2|
33263845|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
32770615|NCT05242809|Experimental|Group-based PFMT group|The participants in the intervention group will receive PFMT supervision in groups. The number of women per group and the detail of the intervention will be decided through stakeholder development group meetings.The intervention will be teaching the participants to do PFMT in groups. The intervention will help women to identify their pelvic floor muscles and then guide them how to contract the pelvic floor muscle correctly (the detail of the intervention will be discussed and determined in phase 1 of this project).
32770616|NCT04269655|Experimental|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
32770617|NCT04269655|No Intervention|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
32770618|NCT05242653|Experimental|cotton swab|
32770619|NCT05242653|Active Comparator|balanced salt solution (BSS)|
32770620|NCT04989751||LGMD patients|
32770621|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-1)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
32770622|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-2)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
32770623|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-3)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
32770624|NCT05239845|Placebo Comparator|Control|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
32770625|NCT05239767|Active Comparator|Ketorolac|Ketorolac 20mg orally x 1
32770626|NCT05239767|Active Comparator|Ibuprofen|Ibuprofen 800mg orally x 1
32770627|NCT05239221|Experimental|AZP-3601|s.c. administration once daily
32770628|NCT05239221|Placebo Comparator|Placebo (Parts A and B)|s.c. administration once daily
32770629|NCT05001607|Other|Study trial|All participants will perform pulmonary blockade on an intubating manikin using 4 different methods: Endobronchial intubation with an endotracheal tube; Bronchial blocker attached to the outside of an endotracheal tube; Double lumen endotracheal tube; and Intraluminal placement of bronchial blocker.
32770630|NCT05321355||Patient with narcolepsy treated with vagus nerve stimulation|Patient with narcolepsy treated with vagus nerve stimulation
32770631|NCT05321355||Patient without narcolepsy treated with vagus nerve stimulation|Patient without narcolepsy treated with vagus nerve stimulation
32770632|NCT04989673||Exposed group (GE)|Pregnant women with symptomatic dengue fever, confirmed biologically between the presumed date of conception and the date of delivery.
32770633|NCT04989673||Unexposed group with fever (GNEF)|Pregnant women presenting a febrile syndrome not due to the dengue virus between the presumed date of conception and the date of delivery, excluding malaria, rubella, toxoplasmosis, chickenpox, listeriosis, CMV infection and primary HIV infection.
32770634|NCT04989673||Unexposed group without fever or dengue (GNES)|Pregnant women exhibiting neither febrile syndrome nor asymptomatic dengue fever between the presumed date of conception and the date of delivery.
32770639|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
32770640|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
32770641|NCT02592551|Placebo Comparator|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
32770642|NCT04989127||group 1|platelet-rich fibrin placed into the socket of the extracted tooth.+ Augmentin 1 gr tablet prescribed 3 times a day
32770643|NCT04989127||group 2|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
32770644|NCT04989127||group 3|platelet-rich fibrin placed into the socket of extracted tooth + Clin 150 mg capsule prescribed 4 times a day
32770645|NCT04989127||group 4|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
32770646|NCT04989127||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
32770647|NCT05281887||ischemic stroke|According to diagnostic criteria
32770648|NCT05281887||healthy control|without any retinal diseases
32770649|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
33078580|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
33078581|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
33078582|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
33078583|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
33078584|NCT02363491|Experimental|OPN-305|OPN-305
33078585|NCT00554359|Experimental|I5NP drug|
33078586|NCT00554359|Placebo Comparator|Placebo|
33263846|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
32770650|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
33078587|NCT00554398|Experimental|A|MK-0518 400mg twice a day
33078588|NCT00554398|No Intervention|B|No intervention
33078589|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
33078590|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
33078591|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
33078592|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
33078593|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
33078594|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
33078595|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
33078596|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
33078597|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
33078598|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
33078599|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
33078600|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
33078601|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
33078602|NCT02335918|Experimental|Varlilumab and Nivolumab|
33078603|NCT00200109|Other|Group 1|See protocol
33078604|NCT00200109|Other|Group 2|See protocol
33078605|NCT00200109|Other|Group 3|See protocol
33078606|NCT00200109|Other|Group 4|See protocol
33263847|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
33078607|NCT04679155|Experimental|eTRE|participants allocated to this group will be required to eat only between 0800h and 1600h.
33078608|NCT04679155|Active Comparator|lTRE|participants allocated to this group will be required to eat only between 1200h and 2000h
33078609|NCT04678609|Experimental|Open kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
33078610|NCT04678609|Experimental|Closed kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
33078611|NCT04678609|No Intervention|Control|The untreated control group will receive patient's usual care of local government hospital which includes information about clinical manifestations, risk factors, diagnosis, treatment and nursing care for knee OA. Control group did not receive any home exercises guidance.
33263848|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
32770651|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
32770652|NCT04294901|Experimental|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose >1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
33078612|NCT04678375||Retinal diseases diagnosed by artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
33078613|NCT04678531|Experimental|Swabs containing tea tree oil and chamomile oil|The swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
33078614|NCT04678531|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
33078615|NCT04678063|Experimental|Asthmatic subjects allergic to cat|Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
33263849|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
33263850|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
33263851|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
32770653|NCT04294901|Experimental|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
32770654|NCT04294901|Experimental|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
32770655|NCT05320185||Control group|CCTA images will be visually evaluated by physicians.
32770656|NCT05320185||Experiment group|CCTA images will be evaluated by physicians using RuiXin-CoronaryAI.
32770657|NCT05320185||Reference group|CCTA images will be visually evaluated by cardiologists with at least 10 years experiences, and the conclusions they offer will be used as golden standard.
32770658|NCT04983745|Experimental|Experimental|niraparib and dostarlimab
32770659|NCT04293653|Experimental|Care bundle|Patients above 75 years where emergency surgery is indicated and with a Clinical Frailty Scale Score of 1-6 will be included in a perioperative care-bundle. While waiting for surgery patients will be monitored and optimized if deteriorating. Antibiotics will be administered if indicated. Surgery is delivered within 2, 6 or 24 h depending on suspected abdominal pathology and clinical condition.
32770660|NCT05238753|Experimental|Intervention, stimulated|Electromagnetic stimulation of the phrenic nerve in critically ill patients.
32770661|NCT05238753|No Intervention|Control, not stimulated|Control group, no stimulation of the phrenic nerve.
32770662|NCT04984135||Enrolled patients|Patients fulfilling the study criteria were included.
32770663|NCT04797377|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
32770664|NCT05281809|Experimental|Treatment Arm|CAR -T-cell collection, infusion
32770665|NCT04989205||HAP - group|The target group was individuals who engaged in regular or daily cannabis use, and who were motivated to quit cannabis. The formal inclusion criteria was a Severity of Dependence Scale (SDS) score ≥4 and being ≥16 years old. Exclusion criteria was polydrug use where cannabis was not the predominating substance of use and psychiatric comorbidity that was perceived as too severe to handle at the community-based centers .
32770666|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
32770667|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
32770668|NCT05281731|Experimental|Sonobiopsy|"Once enrolled, participants would be prepared for surgery following the standard procedure.~The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur.~Blood will be collected before the sonobiopsy, immediately after the sonobiopsy, and then optional blood draws at 30 minutes after sonobiopsy, 60 minutes after sonobiopsy, and during the planned surgery.~A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor.~The blood, tumor, and skin (if applicable) will undergo genetic analysis."
32770669|NCT04982809|Active Comparator|Betamethasone group|
32770670|NCT04982809|Active Comparator|Dexamethasone group|
32770671|NCT04982809|Active Comparator|Prednisolone group|
32770672|NCT04808765|Experimental|VAC group|A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
32770673|NCT04808765|Active Comparator|ST group|A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
32770674|NCT05518071|Experimental|Cohort 1 - N=4 (0.05mg/kg, 2-4h before intervention)|
32770675|NCT05518071|Experimental|Cohort 2 - N=4 (0.05mg/kg, 14-24h before intervention)|
32770676|NCT05518071|Experimental|Cohort 3 - N=4 (0.10mg/kg, 2-4h before intervention)|
32770677|NCT05518071|Experimental|Cohort 4 - N=4 (0.1mg/kg, 14-24h before intervention)|
32770678|NCT05518071|Experimental|Expansion cohort - N=4 (optimal dose, optimal dose-interval)|
32770679|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
32770680|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
32770681|NCT04804865||population|"The population includes adult patients.~Patients died from refractory or relapsed diffuse large-cell lymphoma.~Patients <65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.~Patients >65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles)."
32770682|NCT05281341|Experimental|Poseidon Group 4A & 3A|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH <1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH <1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
32770683|NCT05281341|No Intervention|poseidon Group 4B & 3B|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH <1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH <1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
32770684|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
32770685|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
33277504|NCT03968900|Experimental|Sleep Restriction|4 hours time in bed (1 am to 5 am)
32770686|NCT04809155|Experimental|Girl2Girl|Girls receive text messages that address the information, motivation, and behavioral skills components need to prevent unwanted pregnancy.
33263852|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
33263853|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
33263854|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
33078616|NCT04678063|Active Comparator|Asthmatic allergic subjects not sensitized to cat|Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
33263855|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
33078617|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
33263856|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
33263857|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
33263858|NCT04006743|No Intervention|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
33263859|NCT04006743|Experimental|The swaddling group|In this group, preterm infants were given swaddling method.
33263860|NCT04006743|Experimental|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
33263861|NCT04006743|Experimental|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
32770687|NCT04809155|No Intervention|Control - Healthy lifestyle|Girls receive text messages about a 'healthy lifestyle', including healthy social media use and self-esteem.
32770688|NCT05280249|Experimental|Both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air. For 20 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 15 minutes of low-intensity (50% of the maximum repetitions) resistance exercises will be trained in the presence of a physiotherapist. resistance exercises will be performed for shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle groups. At the end of each session, 5 minutes of stretching exercises will also be trained.
33263862|NCT04006743|Experimental|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
33263863|NCT04006743|Experimental|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
32770689|NCT05280249|No Intervention|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
32770690|NCT04809077|Other|Reverse total shoulder replacement|Patients who underwent a total shoulder replacement using a reverse type implant (Delta Xtend or Zimmer TM)
33263864|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
32770691|NCT05635981|Active Comparator|Clearfil S3 Bond Plus|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA"
32770692|NCT05635981|Experimental|Clearfil S3 Bond Plus with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
33263865|NCT00894426||1|Morning Symptoms (+)
33263866|NCT00894426||2|Morning Symptoms (-)
33263867|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
33263868|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
33263869|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
33263870|NCT04017858|Experimental|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
33263871|NCT04017858|Active Comparator|Control|Patients will be submitted to total knee replacement.
33263872|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
33263873|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
33263874|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
33263875|NCT00984087|Experimental|Active rTMS treatment|
33263876|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
33263877|NCT00989313||1|
33263878|NCT04035954|Active Comparator|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
33277505|NCT03968900|Experimental|Sleep Extension|10 hours time in bed (10 pm to 8 am)
33277506|NCT00773201|Experimental|1|Healthy subjects
32770693|NCT05635981|Active Comparator|G-Premio Bond|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA"
32770694|NCT05635981|Experimental|G-Premio Bond with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
32770695|NCT05320029|Active Comparator|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|
32770696|NCT05320029|Active Comparator|Echelon Flex POWERED Articulating Endoscopic Linear Cutters|
33263879|NCT04035954|Experimental|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
32770697|NCT04797689|Experimental|Trauma Informed Yoga|Participants will receive 12 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
32770698|NCT04797689|Experimental|Trauma Informed Psychotherapy|Participants will receive 12 x 120 min group-based psychotherapy sessions, delivered synchronously over Zoom.
32770699|NCT04797689|No Intervention|Control|These participants will not receive an intervention.
32770700|NCT04988581|Experimental|Intensively Integrated Care of Microvascular Risk Factors|intensively integrated care of microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL])
33263880|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
33263881|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
32770701|NCT04988581|No Intervention|Usual Care of Microvascular Risk Factors|Usual care among patients with diabetes
32770702|NCT05516511||cases|systemic lupus erythematosus patients
32770703|NCT05516511||control|healthy individuals
32770704|NCT04796987||cervical myelopathy|MR images of patients with cervical myelopathy
32770705|NCT04796987||normal|normal section of the MRI of patients with cervical myelopathy
32770706|NCT05237895|Other|Patients with Gestational Diabetes|pregnant women who are at 24-26 weeks of gestational age with positive oral glucose tolerance screening test.
32770707|NCT05237895|Other|Healty Pregnants|pregnant women who are at 24-26 weeks of gestational age with normal oral glucose tolerance screening test.
32770708|NCT05453539|Experimental|Healthy volunteers dose level 1|0.53 mL ADx-001 / kg
32770709|NCT05453539|Experimental|Patients dose level 1|0.53 mL ADx-001 / kg
32770710|NCT05453539|Experimental|Patients dose level 2|1 mL ADx-001 / kg
32770711|NCT05453539|Experimental|Patients dose level 3|2 mL ADx-001 / kg
32770712|NCT05453539|Experimental|Patients dose level 4|4 mL ADx-001 / kg
32770713|NCT04796753||Youth basketball players who belonged to basketball developmental teams (U12, U14,U16,U17).|All participants completed the same ten-minute neuromuscular warm-up consisting of the following exercises: joint mobility exercises, dynamic stretching exercises, jumps, multidirectional displacements and changes of direction. Following, subjects were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. The performance of each test was recorded using two cameras (Iphone XS, Apple). To allow visible tracking of the different joints, participants were required to wear shorts with the hem at approximately mid-thigh. When scoring performance, each test was viewed in both planes (sagittal and frontal views).
33263882|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
32770714|NCT05237271|No Intervention|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new SomaLogic test.
32770715|NCT05237271|Experimental|Intervention Group 1|Intervention group 1 will receive educational materials on the single cardiovascular disease in type 2 diabetes risk score. They will then be forced to used the risk score for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
32770716|NCT05237271|Experimental|Intervention Group 2|Intervention group 2 will receive educational materials on the cardiovascular disease in type 2 diabetes (CVD-T2D) risk score as well as the panel of metabolic scores. They will then be forced to used the CVD-T2D score and the metabolic panel scores for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
33263883|NCT05712681|Experimental|Sequence 1|T → Washout period(7-14days) → R
33263884|NCT05712681|Experimental|Sequence 2|R → Washout period(7-14days) → T
33263885|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
33263886|NCT05712603||Prospective care path arm|"Participants who enter the care path will make up the prospective care path arm.~In patients entering the care path three diagnostic tests for liver fibrosis will be performed. FIB4-score, Vibration controlled transient elastography and Enhanced Liver Fibrosis test"
33263887|NCT05712603||Prospective arm of 'regular care'|Patients who are referred to the hepatologist in participating centers during the study period without using the care path (e.g. because of altered liver function tests for instance), will be the prospective 'regular care' arm
33263888|NCT05712603||Retrospective arm of 'regular care'|The investigators will do an data extraction of the electronic health records of patients referred to the hepatologist in the five years prior to the study. They will make up the retrospective comparative arm of regular care
33263889|NCT00898482||Healthy individuals|
33263890|NCT00898482||At risk individuals|
32770717|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
32770718|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
33078618|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
33078619|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
33263891|NCT00898482||Cancer patients|
33263892|NCT03667443|Active Comparator|Myo-inositol plus folic|
33263893|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
33263894|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
33263895|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
33263896|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
32770719|NCT05280015|Active Comparator|Microbiotherapy in addition of venlafaxin|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.
33263897|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
33263898|NCT00902772|Placebo Comparator|A|Placebo
33263899|NCT00902772|Active Comparator|B|Lorazepam
32770720|NCT05280015|Placebo Comparator|calibration arm|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.
33263900|NCT00902772|Active Comparator|C|Lorazepam
32770721|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
32770722|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
32770723|NCT05429983||Hypoglossal Nerve Stimulation Candidates|Participants will have a diagnosis of obstructive sleep apnea and have failed treatment with continuous positive airway pressure (CPAP). Participants will be those undergoing drug-induced sleep endoscopy (DISE) as part of routine clinical care for work up of hypoglossal nerve stimulation candidacy as a treatment for obstructive sleep apnea.
33263901|NCT00902772|Active Comparator|D|Lorazepam
33263902|NCT00902772|Experimental|E|AZD7325
32770726|NCT04808687|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
32770727|NCT05635825||Healthy Asian|Healthy Asian, non-vegetarian that is aged between 21 to 99, literate and numerate.
33263903|NCT00902772|Experimental|F|AZD7325
33263904|NCT00902772|Experimental|G|AZD7325
33263905|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
33263906|NCT00894660|Experimental|Amodiaquine (Pfizer)|
33263907|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
33263908|NCT02539212|Active Comparator|microwave ablation|microwave ablation
33263909|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
33263910|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
33263911|NCT00721409|Active Comparator|Arm B|letrozole
33263912|NCT05712369|Experimental|Prospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN candidate to anti-CD20 monoclonal antibodies therapy.
33263913|NCT05712369|Experimental|Retrospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN, treated with anti-CD20 monoclonal antibodies therapy.
33263914|NCT05712369|Active Comparator|Healthy volunteers cohort|Subjects not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
33263915|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
33263916|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
33263917|NCT00898716|Experimental|BMS-754807|
33263918|NCT05277948|Active Comparator|treatment group|Active thumbtack needle will be used for the treatment group
33263919|NCT05277948|Sham Comparator|control group|Sham thumbtack needle will be used for the control group
33263920|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
33263921|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
33263922|NCT00542997|Experimental|IgPro20|
33277507|NCT05355194|Experimental|Group A: Kinesiotaping with pelvic tilts|Kinesiotape will be applied to patients. In addition, patients will be instructed to perform pelvic tilts.
32770728|NCT04804397|Experimental|Sucrose|Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks
32770729|NCT04804397|Placebo Comparator|Aspartame|Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks
32770730|NCT05279703|Active Comparator|0.03 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
32770731|NCT05279703|Active Comparator|0.02 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
32770732|NCT05279703|Active Comparator|0.01 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
32770733|NCT05635747||Patients who have completed the Relizorb Trial and consented into the 90 day extension trial|Patients aged 2-18 who have completed the 90 day open label phase 3 Relizorb trial who consent to the 90 day observational Relizorb extension trial
32770734|NCT04808219||Driver|Ambulance driver who was involved in a traffic collision - video analysis of the collision records and in-depth interview aiming to find the cause of the collision.
32770735|NCT05235945|Experimental|Online exercise intervention|A four-week preoperative physical activity intervention, involving a combination of supervised and unsupervised (live or pre-recorded), online exercise sessions. These sessions will be designed to meet the National physical activity guidelines (2020) of at least 150 minutes of low-moderate or 75 minutes of vigorous physical activity per week (or a combination of the two). The intervention will involve moderate intensity activities that aim to increase or maintain muscle strength (resistance training) as well as short bouts of vigorous aerobic exercise, using major muscle groups in the lower and upper body.
32770736|NCT05235945|No Intervention|Control|Usual care
32770737|NCT04796519|Experimental|Unilateral TKA|Unilateral total knee arthroplasty group (UTKA) consisted of patients who did not undergo a second TKA within 3 months of the first TKA
32770738|NCT04796519|Experimental|Bilateral TKA|bilateral total knee arthroplasty group (BTKA) were those who had a second TKA within 12 months after initial TKA
32770739|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
32770740|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
32770741|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
33263923|NCT04035720|Experimental|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
33263924|NCT04035720|Active Comparator|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
32770742|NCT05279001|Experimental|Jaktinib|
32770743|NCT04804475|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
33263925|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
33263926|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
32770744|NCT04804475|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
33263927|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
32770745|NCT05406115|Experimental|Part A: Single Ascending Dose Cohorts|Participants in 5 cohorts will receive either AMG 786 or placebo in Single Ascending Doses.
32770746|NCT05406115|Experimental|Part A: Food Effect Cohort|Participants in the food effect cohort (FEC) will receive 1 of 2 AMG 786 in 1 of two sequences. Participants in Sequence 1 will receive a dose of AMG 786 on day 1 under fed conditions followed by a 10-day washout period and another dose of AMG 786 on day 11 under fasted conditions. Participants in Sequence 2 in the FEC cohort will receive the first dose on day 1 under fasted conditions and the second dose on day 11 under fed conditions.
32770747|NCT05406115|Experimental|Part B: Multiple Ascending Dose Cohorts|Participants in 4 cohorts will receive either AMG 786 or placebo in Multiple Ascending Doses.
32770748|NCT05235399||Preterm infants who are born before 32 weeks of gestation.|The study aims to recruit preterm infants who are born before 32 weeks of gestation.
32770749|NCT04808063|Experimental|Algorithm use for prphylactic mesh after emergency laparotomy|Patients with emergency surgery in whom algorithm for prophylactic mesh is use to help decide abdominal wall mesh reinforcement or not.
32770750|NCT03070561|Experimental|Sublingual film with peanut extract|
32770751|NCT05514951|Experimental|Blood sampling|Blood sampling
32770752|NCT04796441|Experimental|CAR--γδT|Patients will be treated with CAR--γδT cells
32770753|NCT05318781||Patients undergoing bariatric surgery|Adult patients (≥ 30y yrs.) scheduled to undergo a first bariatric surgery recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=120]
32770754|NCT05318781||Patients on the bariatric surgery waitlist|Age-, sex-, and BMI-matched waitlist control group [awaiting for bariatric surgery] recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=60]
32770755|NCT05318781||Non-bariatric eligible individuals|"Age-and sex-matched individuals who are not eligible for bariatric surgery, as an additional non-bariatric comparison group [N=60]~*The 60 age-and sex-matched non-bariatric participants will have data captured just once [at baseline] on a limited number of key assessments"
33078620|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
33263928|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
33263929|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
33263930|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
33263931|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
33263932|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
33263933|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
33263934|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
33263935|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
32770756|NCT04988737|Experimental|CDS Group|Clinicians complete tasks using the CDS prototype. Briefly, the clinician scans the barcode on the syringe label immediately prior to medication administration. The scan triggers the CDS to display a dosing window with pertinent patient-specific information and/or alert(s) when necessary to prevent a medication error (ME) prior to the medication being administered. Medication data are then sent from the CDS application to the patient's anesthesia record for automatic documentation in real-time, eliminating the need to manually document the medication in the Anesthesia Information Management System (AIMS). When necessary, the CDS application generates alerts to prevent medication errors. Upon receiving an alert, the anesthesia clinician may accept the alert and revise the action that generated the alert, or override the alert and continue with the planned action.
32770757|NCT04988737|No Intervention|Control Group|Clinicians complete tasks using the conventional medication administration and documentation workflow in anesthesia.
33263936|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
32770758|NCT05278845|Experimental|Treatment Sequence 1|SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fasted conditions.
32770759|NCT05278845|Experimental|Treatment Sequence 2|SLC SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fed conditions.
32770760|NCT05392933|Experimental|Piriformis syndrome with lumbar radiculopathy (PSWLR)|All patients (n=40) will be evaluated with detailed physical examination and special clinical tests for both lumbar radiculopathy and piriformis syndrome. If patients have lumbar magnetic resonance imaging or electromyography results, they will be recorded to confirm the diagnosis of lumbar radiculopathy. The patients who have the final diagnosis of lumbar radiculopathy and prediagnosis of piriformis syndrome will be evaluated for the pain scores (pain at resting, sitting, standing, lying, at night and during activity) using numeric rating scale. Then, an ultrasound guided piriformis muscle injection will be performed. The patients will be kept under observation for 30 minutes afterwards and the percentage of their pain relief will be recorded. The patients whose pain resolves at least 50% from the baseline after the injection will be diagnosed as piriformis syndrome and will be reevaluated one week and one month after the injection and the changes in the pain scores will be recorded.
32901865|NCT05132556|Placebo Comparator|Beetroot juice with nitrate removed|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the beetroot juice with nitrate removed.
33078621|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
33078622|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
33263937|NCT00986817|Experimental|Terlipressin|
33263938|NCT00986817|Placebo Comparator|Placebo|
33263939|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
33263940|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
33263941|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
33263942|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
33263943|NCT04747587||Patients with stroke|
33263944|NCT04747587||Controls|
33263945|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
33263946|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
33263947|NCT05712135||supine|The patient group whose cuff pressure was measured in the supine position in neurosurgery
33263948|NCT05712135||prone|The patient group whose cuff pressure was measured in the prone position in neurosurgery
33263949|NCT05712135||semi-fowler|The patient group whose cuff pressure was measured in the semi-fowler position in neurosurgery
33277508|NCT05355194|Active Comparator|Group B: Kinesiotaping without pelvic tilts|Kinesiotape will be applied to patients.
33078623|NCT02320708|Placebo Comparator|Placebo|
33078624|NCT02310802|Experimental|OBE001 dose 1|
33078625|NCT02310802|Experimental|OBE001 dose 2|
33263950|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
32770761|NCT04796675|Experimental|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10^7, 0.1×10^7, 1.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
33263951|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
33263952|NCT04086719|Experimental|BMS- 986185 + Pyrimethamine|
33263953|NCT04086719|Experimental|BMS-986185|
33263954|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
33263955|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
33263956|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
32770762|NCT05635357||Anastrozole|Exposure group
33263957|NCT00898950|Placebo Comparator|placebo|
33263958|NCT04086797|Experimental|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
32770763|NCT05635357||Exemestane/Letrozole|Reference group
32770764|NCT04954677|Experimental|Participates being subjected to capsule endoscopy (AI-box assistant)|In this group ,Participates will be subjected to magnet controlled capsule endoscopy with AI-box assistant.
32770765|NCT04954677|No Intervention|Participates being subjected to capsule endoscopy|In this group ,Participates will be subjected to magnet controlled capsule endoscopy without AI-box assistant.
32770766|NCT04348643|Experimental|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1~3 times
32770767|NCT05233839|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
32770768|NCT05233839|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
32770769|NCT04796051|Experimental|Neck orthosis group, posterior cervical weight orthosis|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull. Neck orthosis group will use a cervical orthosis (with the posterior cervical neck weight) for 10 minutes / 3 times a day, for a total of 30 minutes a day
32770770|NCT04796051|Active Comparator|Deep cervical flexors exercise|Deep cervical flexors exercise group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
32770771|NCT05233761|Experimental|Defined CBD|Defined CBD will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that contain a total of 300 mg CBD and 8 mg terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks.
32770772|NCT05233761|Placebo Comparator|Placebo|The placebo control will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that do not contain any CBD or terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks. The Placebo capsules will look and smell identical to the Defined CBD capsules.
32770773|NCT04803929|Experimental|Anti-ILT3 CAR-T cells|All subjects were intravenous administrated with anti-ILT3 CAR-T cells
32770774|NCT05232045||Automated urinary output collection system group (tight monitoring of urine output)|
33078626|NCT02310802|Experimental|OBE001 dose 3|
33078627|NCT02310802|Placebo Comparator|Placebo|
33263959|NCT04086797|Placebo Comparator|Placebo|2 capsules after 3 main meals per day
33263960|NCT04034784|Experimental|Discrete(TM)|Intraperitoneal injection
33263961|NCT04034784|Sham Comparator|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
33263962|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
33263963|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
33263964|NCT05279235|Experimental|JT001& Favipiravir Placebo|JT001 (VV116):Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days Favipiravir placebo:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
33263965|NCT05279235|Active Comparator|Favipiravir & JT001 Placebo|Favipiravir:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days JT001 (VV116) placebo:Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
33263966|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
33263967|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
33263968|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
33263969|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
33263970|NCT04035252||2. Patients with an AAA|Individuals (>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
33263971|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
33263972|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
33263973|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
33263974|NCT00229723|Placebo Comparator|1|Radiation + cisplatin; followed by placebo as maintenance therapy
33263975|NCT00229723|Experimental|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
33263976|NCT00229723|Experimental|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
32770775|NCT05232045||Manual urinary output collection system group (routine monitoring of urine output)|
32770776|NCT04796207|Experimental|Fish Oil Capsules|Participants in the treatment arm will receive 3 grams of DHA and EPA (2:1 weight ratio) 3 times a week for 25-weeks during regular football season.
32770777|NCT04796207|Placebo Comparator|Safflower Oil Capsules|Participants in the treatment arm will receive 3 grams of high-oleic safflower oil) in a 1:1 allocation ratio for 25-weeks during regular football season.
32770778|NCT05317923|Experimental|airway management and ventilation in patients with unusual placement of tracheal stenosis|Flow-controlled ventilation (FCV) in patients with unusual placement of tracheal stenosis
32770779|NCT04786925|Placebo Comparator|Control diet|A conventional diet based on the current Spanish Mediterranean dietary guidelines: Spanish Society of Community Nutrition (SENC).
32770780|NCT04786925|Experimental|Nutriprecision diet|A Mediterranean, balanced diet based on the inclusion of precision foods designed and developed within the framework of Nutriprecision project. A mobile application to empower and support the management of the dietary prescription. A digital tool for cognitive stimulation.
32770781|NCT05230875||Patients participating in the therapeutic education program|Patients participating in an educational program on Inflammatory Bowel Disease (IBD) including a specific discussion on intimacy and sexuality .
32770782|NCT05230875||Patients control (not participating in the therapeutic education program)|A control group (at the rate of two controls for one case) will be made up of IBD patients routinely followed in the gastroenterology department.Those patients will not participate in the therapeutic education program.
32770783|NCT05276037||Study group|Milan-out, up-to-7-in, PET negative (≤1.15) HCC patients
32770784|NCT05276037||Control group|Milan-in HCC patients
32770785|NCT04795973|Experimental|IF group|intermittent fasting intervention for 4 weeks
32770786|NCT05275725|Experimental|Sildenafil|
32770787|NCT04803617||Patient's group|geriatric patients with interstitial lung disease
32770788|NCT04803617||Control group|healthy volunteers selected from the geriatric population
32770789|NCT05229939||Development cohort|kidney transplant recipients in 3 centres in France: Necker, Saint-Louis and Toulouse hospitals
32770790|NCT05229939||Validation cohort 1|kidney transplant recipients from Montpellier Hospital, France
32770791|NCT05229939||Validation cohort 2|kidney transplant recipients from Lyon Hospital, France
32770792|NCT05229939||Validation cohort 3|kidney transplant recipients from Tenon Hospital, France
32770793|NCT05229939||Validation cohort 4|kidney transplant recipients from Saint-Etienne Hospital, France
32770794|NCT05229939||Validation cohort 5|kidney transplant recipients from Mayo Clinic Hospital, USA
32770795|NCT05229939||Validation cohort 6|kidney transplant recipients from Bergamo hospital, Italy
32770796|NCT05229939||Validation cohort 7|kidney transplant recipients from Zagreb hospital, Croatia
32770797|NCT04795817||Single arm|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA
32770798|NCT05275413|Experimental|family-based mHealth intervention|The expectant mothers and their family members (fathers and grandparents) in this group will receive health education and support and family support via a smartphone app.
32770799|NCT05275413|Experimental|mother-only mHealth intervention|The expectant mothers in this group will receive health education and support via a smartphone app.
32770800|NCT05275413|Active Comparator|Health education|The expectant mothers in the control group will receive health education via a smartphone app.
32770801|NCT04795349|Experimental|NAC Patients.|Breast cancer patients after NAC completion, prior to surgery
33263977|NCT00229723|Experimental|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
33263978|NCT00229723|Experimental|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
33263979|NCT00229723|Placebo Comparator|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
32770802|NCT04786535|Active Comparator|Hemodiafiltration|
32770803|NCT04786535|Experimental|Expanded hemodialysis|
32770804|NCT04786535|Experimental|Conventional high-flux hemodialysis|
32770805|NCT05272917|Experimental|head and neck cancer patients with radiotherapy AND chemotherapy|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) + chemotherapy
32770806|NCT05272917|Experimental|head and neck cancer patients with radiotherapy only|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) without chemotherapy
33263980|NCT00229723|Placebo Comparator|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
33078628|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
33078629|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
33078630|NCT02309671|Experimental|FE 999049 6 µg|
33078631|NCT02309671|Experimental|FE 999049 9 µg|
32770807|NCT05272917|Active Comparator|healthy volunteers|healthy volunteers paired with experimental patients on age (+/- 5 years), gender, tobacco status
32770808|NCT05316987|Other|Active vitiligo patients|NBUVB
32770809|NCT05315817|Experimental|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
32770810|NCT04925895|Experimental|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization (DSTM) is a soft tissue mobilization technique use to treat tight spasm using progressive muscle activation.
32770811|NCT04925895|Active Comparator|Proprioceptive neuromuscular facilitation stretching|PNF stretching technique, a type of flexibility training that is effective in improving muscle flexibility and restore functional ranges using a wide array of techniques.
32770812|NCT04803851|Experimental|Treatment group|Anlotinib plus AK105
32770813|NCT04803773|Experimental|Experimental Arm|
32770814|NCT05227755|Active Comparator|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
32770815|NCT05227755|Experimental|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
32770816|NCT04786379|Experimental|Patients with confirmed septic arthritis of the native knee|
32770817|NCT05226507|Experimental|Dose Escalation|Seven dose levels are planned, with a starting dose level of 50 mg once per day, up to a maximum planned dose of 150 mg twice per day (300 mg per day).
32770818|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 3 microgram|
32770819|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 5 microgram|
32770820|NCT05226429|Active Comparator|CoronaVac Biofarma COVID-19 Vaccine|
32770821|NCT05616377||target therapy + local therapy group vs target therapy alone group|
33078632|NCT02309671|Experimental|FE 999049 12 µg|
33078633|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
33078634|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
33078635|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
33078636|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
33078637|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
32770822|NCT05616377||local therapy before target therapy group vs local therapy after target therapy group|
32770823|NCT04785755|Active Comparator|Group I|The control group (n=15) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
33078638|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
33078639|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
33078640|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
33078641|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
33078642|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
33078643|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
33078644|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
33078645|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
33078646|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
33078647|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
33078648|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
33078649|NCT02282215|Active Comparator|G-CSF|Randomized
33078650|NCT04678687|Other|COVID-19 group|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
33078651|NCT04678102|Experimental|Cohort 1 (PHI-101 40mg/day)|In the starting dose cohort 1 subject will be administered 40mg/day PHI-101 and will be assessed for DLT ('single subject cohort'), and until an ADR ≥ [CTCAE version 5.0] grade 2 occurs, higher doses will be explored in single subject cohorts in a stepwise fashion. If an ADR ≥ [CTCAE version 5.0] grade 2 occurs, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme.
33078652|NCT04678102|Experimental|Cohort 2 (PHI-101 80mg/day)|In cohort 2, the subject will be administered 80mg/day PHI-101.
33078653|NCT04678102|Experimental|Cohort 3 (PHI-101 120mg/day)|In cohort 3, the subject will be administered 120mg/day PHI-101.
33263981|NCT04035798|Experimental|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
33263982|NCT04035798|Placebo Comparator|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
33078654|NCT04678102|Experimental|Cohort 4 (PHI-101 160mg/day)|In cohort 4, the subject will be administered 160mg/day PHI-101.
33263983|NCT04585035|Experimental|Dose escalation of D-1553 monotherapy|Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
33263984|NCT04585035|Experimental|Dose combination of D-1553 with other therapies|Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.
32770824|NCT04785755|Experimental|Group II|The hypertonic saline solution (HSS) group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the start of the study to the end of the study) with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
32770825|NCT04785755|Experimental|Group III|The etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
32770826|NCT04785755|Experimental|Group IV|The hypertonic saline solution (HSS) + Etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg100mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days, and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
32770827|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 5mcg + MF59|DoCo-Pro-RBD-1 antigen 5mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
32770828|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1)15mcg + MF59|DoCo-Pro-RBD-1 antigen 15mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
32770829|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 45mcg + MF59|DoCo-Pro-RBD-1 antigen 45mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
32770830|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 10mcg|MIPSCo-mRNA-RBD-1 antigen 10mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
32770831|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 20mcg|MIPSCo-mRNA-RBD-1 antigen 20mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
32770832|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 50mcg|MIPSCo-mRNA-RBD-1 antigen 50mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
32770833|NCT05272605|Placebo Comparator|Normal saline (0.9%)|Normal saline (0.9%) administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
32770834|NCT04351373|Experimental|Treatment|"At the time of tumor exposure, patients will be given intravenous fluorescein sodium. The timing and dose may vary. Maximum cumulative dose will not exceed 500 mg.~• Initial dosing protocol will be 1 mg/kg intravenous FS.~o If insufficient fluorescence is obtained or washout occurs, additional doses of 1 mg/kg may be administered~The surgeon will use the YELLOW 560 nm microscope filter (YE560) to assist in visualizing the tumor during the resection."
32770835|NCT04244253|Experimental|OPC-64005 20 mg|
32770836|NCT04244253|Experimental|OPC-64005 10 mg|
32770837|NCT04244253|Placebo Comparator|Placebo|
32770838|NCT04785833|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
32770839|NCT04240899|Experimental|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
32770840|NCT04240821|Experimental|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
32770841|NCT04795193|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
32770842|NCT04795193|Active Comparator|OPCABG|Patients undergoing thoracotomy OPCABG.
32770843|NCT05314179|Experimental|DOULA -AC|Four hours/week of Doula and Patient engagement.
32770844|NCT05615441|Active Comparator|ANI-guided|Patients receiving remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
32770845|NCT05615441|Experimental|Standard|Patients receiving remimazolam-based total intravenous general anesthesia based on hemodynamic variables and without ANI nociception monitoring
32770846|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
32770847|NCT05218941|Experimental|Passive robotic group|Implant surgery without flap assisted by passive robotics
33078655|NCT04678102|Experimental|Cohort 5 (PHI-101 200mg/day)|In cohort 5, the subject will be administered 200mg/day PHI-101.
33078656|NCT04678102|Experimental|Cohort 6 (PHI-101 240mg/day)|In cohort 6, the subject will be administered 240mg/day PHI-101.
33078657|NCT04677985|Experimental|Menthol based topical analgesic|Menthol based topical analgesic was applied to a variety of upper and lower body muscles and tendons.
33078658|NCT04677985|Placebo Comparator|Placebo|Placebo (cream that smelled like menthol) was applied to a variety of upper and lower body muscles and tendons.
33078659|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
33078660|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
32770848|NCT05218941|Active Comparator|Control group|Implant surgery with flap
32770849|NCT04785599|Experimental|Group EC1: Exercices, informative talk|Group EC1 carried out the conventional prevention program consisting of an informative talk and an exercise program
33078661|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
33078662|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
32770850|NCT04785599|Experimental|Group ECCP2: Exercices, informative talk, compression garment|Group ECCP2 carried out the same program but with the addition of a prophylactic compression garment
32770851|NCT05314101|Experimental|TAS-102 combined with bevacizumab and tislelizumab|TAS-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer
32770852|NCT02595749|Experimental|Placebo then Intranasal Oxytocin (40 IU)|Participants received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
32770853|NCT02595749|Experimental|Intranasal Oxytocin (40 IU) then Placebo|Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
32770854|NCT05218707||Group A|An appropriate size oropharyngeal airway (GUEDEL) will be inserted immediately after removal of LMA and time will be noted. (Size will be chosen by placing the flange at the corner of the mouth and tip at the angle of the jaw).
32770855|NCT05218707||Group B|In Group B No oropharyngeal airway (GUEDEL) will be inserted.
32906342|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
33078663|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
33078664|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
33078665|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
33078666|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
33078667|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
33078668|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
33078669|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
33078670|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
33078671|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
33078672|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
33078673|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
33078674|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
33078675|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
33078676|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
33078677|NCT00200148|Experimental|1|For patients randomized to ANH
33078678|NCT00200148|Active Comparator|2|standard intraoperative management
33078679|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
33078680|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
33078681|NCT00177086|Experimental|Alfuzosin|
33078682|NCT00177086|Placebo Comparator|Placebo|
33078683|NCT02235259|Experimental|XG-104 low dose|
33078684|NCT02235259|Experimental|XG-104 intermediate dose|
33078685|NCT02235259|Experimental|XG-104 high dose|
33078686|NCT02235259|Placebo Comparator|Placebo|Placebo
33078687|NCT00205023|Experimental|A|
33263985|NCT04585035|Experimental|Phase 2 of D-1553 monotherapy and combination therapies|The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.
33078688|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
33078689|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
32770856|NCT04794647|Experimental|cervical mobilization|'Rotation mobilization' was applied to the symptomatic segment / segments after the detailed evaluation (symptom localization tests, cervical region safety tests, joint play tests, pain provocation/alleviation tests) in accordance with the Kaltenborn-Evjenth system in cervical region. Five series of 45-s mobilizations were performed with 15 s of rest. Each patient received 6 treatment sessions over a period of 3 week.
32770857|NCT04794647|Placebo Comparator|placebo mobilization|Placebo mobilization was applied to the cervical region in the same position and the same grip with the mobilization group. The physiotherapist put her hand on a randomly selected faset without any pushing or pulling, The duration of placebo mobilization was the same as the duration of the other group. Each patient received 6 treatment sessions over a period of 3 week.
32770858|NCT04350827|Active Comparator|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
33078690|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
33263986|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
33263987|NCT01075477||Cohort|
33263988|NCT04006275|Experimental|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
33263989|NCT04006275|Experimental|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
33263990|NCT00987051|Experimental|1|Patients with endometrial cancer
33263991|NCT01075555|Active Comparator|sorafenib|sorafenib
33263992|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
33263993|NCT05517837|Experimental|BMS-986421 Under Fasted Conditions|
33263994|NCT05517837|Placebo Comparator|Placebo|
33078691|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
33078692|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
33263995|NCT03972787|Experimental|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
33263996|NCT03972787|No Intervention|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
33263997|NCT00606684|Active Comparator|GW642444|GW642444
33263998|NCT00606684|Placebo Comparator|placebo|
33263999|NCT04731441|Experimental|Exercise Group|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
33264000|NCT04731441|Active Comparator|Education Group|Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC. Results and outcomes will not be recorded.
33264001|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
33264002|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
33264003|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
33264004|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
33264005|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
32770859|NCT04350827|Active Comparator|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
32770860|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
32770861|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
32770862|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
32770863|NCT04350359|Active Comparator|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
33264006|NCT03973021|Experimental|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
33264007|NCT03973021|Experimental|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
33264008|NCT03973021|Experimental|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
33264009|NCT03973021|No Intervention|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
33264010|NCT05711589|Placebo Comparator|conventional group|cryoablation (CBA) was performed under fluoroscopic guidance
33264011|NCT05711589|Experimental|Zero-X group|CBA was performed under intracardiac echocardiography guidance without fluoroscopy
33264012|NCT05711511|Experimental|coventional obturation technique|In conventional method, paper point will be used to coat the walls of the canal with sealer, Standardized Protaper F-3 master gutta-percha cone will slid to the working length and ISO No.25 finger spreader was applied under vertical loading.The first accessory cone will slid promptly to proper length with a light coating of sealer. Compaction and accessory cone insertion will be continued;each spreader insertion will be seen to be slightly less deep than former, as mirrored by shorter and shorter accessory cone insertion. Condensation continued until the spreader reached 2-3 mm into the canal. Heat will be applied with to the root filling at or below canal orifice level, and the filling will then compacted apically with the help of a cold plugger.
33264013|NCT05711511|Active Comparator|Obtura II|The Obtura II system will be prepared ,sealer will be applied to canal wall . A 23G needle is selected and a stopper will place at 4-6 mm of the WL. The control unit of Obtura II will be on, and the display showed the required temperature of 185°C. The gun will be loaded with a fresh pellet of gutta- percha and plunger will be pushed forward.The needle will be then positioned in the canal so that it reached 3 to 5 mm of the apical preparation. 3-4 mm of the gutta-percha was passively injected without any apical pressure and will be compacted gently with a #11 endodontic plugger. Thus, the apical plug will be created in this manner. A segmental technique will be used in which 3 to 4 mm of gutta-percha will be sequentially injected and compacted. Increments will be added until gutta-percha reached top orifice level, and then compaction will be done with a cold plugger. Excess gutta-percha was severed at or below the orifice level.
33264014|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
33264015|NCT05278182|Experimental|Naoxintong Capsule|Naoxintong Capsule
33264016|NCT05278182|Placebo Comparator|Placebo|Placebo
33264017|NCT00228553|Experimental|1|Armodafinil 100 to 250 mg/day
32770864|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
32770865|NCT04785209||No complication|Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
32770866|NCT04785209||No reflow|No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
33264018|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
33264019|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
33264020|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
33264021|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
33264022|NCT00903708|Experimental|LY2275796|
33264023|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
32770867|NCT04785131|Experimental|Prune group|Oral contraceptive users will consume 50 grams prunes daily.
32770868|NCT04785131|No Intervention|Oral contraceptive users|Oral contraceptive users will be monitored throughout the study period.
33264024|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
33264025|NCT04035642|Experimental|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
33264026|NCT00895050||1|Patients diagnosed with RA
32770869|NCT04785131|No Intervention|Non oral contraceptive users|Non oral contraceptive users will be monitored throughout the study period.
32770870|NCT05222763|Experimental|Experimental: Interventional group|The web-supported interactive nursing program intervention will take 3 weeks. The first week of the training will begin with the patient's admission to the clinic. Shoulder and Arm Exercises, Lymphedema in the Arm and Prevention of Its Development, and qualitative study, the themes of misperception determined in this area will be emphasized. In the second week, they will be asked to continue their Shoulder and Arm Exercises training, to examine the Other Side Breast Examination Training and Adaptation Process to Life Activities, Skin Care and Post-Surgery Cancer Treatment and Breast Reconstruction. In the last week of the training, it will be requested to review the contents again. Correct perceptions that may emerge as a result of the qualitative study will be supported in the relevant parts of the training. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times).
32770871|NCT05222763|Active Comparator|Behavioral:|"The handbook developed within the scope of the Women's Return to Social Life After Mastectomy Project on the website of the Continuing Education, Research and Solidarity Association will be used on the website of the participants assigned to the control group."
33264027|NCT00903864||stethoscopy|
33264028|NCT00903864||BPM|blood pressure monitor
33264029|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
33264030|NCT00895206|Experimental|1|individual adapted immunosuppression
33264031|NCT00895206|Active Comparator|2|golden standard therapy
33264032|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
33264033|NCT05278026||HFrEF|heart failure with reduced ejection fraction
33264034|NCT05278026||HFpEF|heart failure with preserved ejection fraction
33264035|NCT05278026||nonfailing control|patients without heart failure
33264036|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
33264037|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
33264038|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
33264039|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
33264040|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
33264041|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
33264042|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
33264043|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
33264044|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
33264045|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
33264046|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
33264047|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
33264048|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
33264049|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
33264050|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
33264051|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
33264052|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
33264053|NCT00904176|Active Comparator|Warfarin|
33264054|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
32770872|NCT05222685|Experimental|Intervention Group|Will receive the 6 month online group coaching program from 9/1/2022-3/1/23
32770873|NCT05222685|No Intervention|Control Group|"Control group - no coaching intervention from 9/1/2022-3/1/23.~(They will receive the coaching intervention after study completion from 3/1/23-9/1/23)"
32770874|NCT04794881|Experimental|24 hours|Newborn infants in this group will undergo repeat lumbar puncture at 24 hours after a traumatic lumbar puncture
32770875|NCT04794881|Active Comparator|48 hours|Newborn infants in this group will undergo repeat lumbar puncture at 48 hours after a traumatic lumbar puncture
33078693|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
33264055|NCT00904176|Active Comparator|Digoxin|
33264056|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
33264057|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
33264058|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
33264059|NCT00895440||1|Diabetic patients without neuropathy
33264060|NCT00895440||2|Diabetic patients with painless neuropathy
33264061|NCT00895440||3|Diabetic patients with painful neuropathy
33264062|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
33264063|NCT00895440||5|Control non-diabetic subjects
33264064|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
33264065|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
33264066|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
33264067|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
33264068|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
33264069|NCT00905970||3|Patients with LTBI diagnosed time ago.
33264070|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
33264071|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
33264072|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
33264073|NCT00904410|Experimental|1|
33264074|NCT00160693|Experimental|Certolizumab Pegol|
33264075|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
33264076|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
33264077|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
33264078|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
33264079|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
33264080|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
33264081|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
33264082|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
33264083|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
33264084|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
33264085|NCT04034472|Other|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
33264086|NCT05277870|Active Comparator|control|Standard eyedrops of IOP-lowering medications
33264087|NCT05277870|Experimental|Nanodropper|Microdrops of IOP-lowering medications using Nanodropper adaptor
33264088|NCT00900744||Tamoxifen|20mg daily
33264089|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
33264090|NCT00643760|Placebo Comparator|Placebo|Placebo
33264091|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
32770876|NCT05221749|Active Comparator|Silver diamine fluoride|These active caries lesions will receive silver diamine fluoride treatment
32770877|NCT05221749|Experimental|Nanosilver fluoride|These active caries lesions will receive nanosilver fluoride treatment
32770878|NCT04426721|Experimental|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
32770879|NCT04426721|Active Comparator|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
33264092|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
33264093|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
33264094|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
33264095|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
32770880|NCT05221359|Experimental|test arm|All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.
33264096|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
33264097|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
33264098|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
33264099|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
33264100|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
32770881|NCT04803071|Experimental|Adjuvant therapy trial group|N-3pufas improved cognitive formula adjuvant therapy intervention group
32770882|NCT04803071|Active Comparator|Adjuvant treatment control group|General fish oil formula product adjuvant treatment control group
32770883|NCT04803071|Placebo Comparator|Placebo assisted treatment control group|
33264101|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
33264102|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
32770884|NCT04803071|No Intervention|Healthy group|
32770885|NCT05219955|Experimental|Active condition (SAMM Protocol)|The goal of the SAMM protocol is to increase morning activity engagement over a 6-week period. Participants in this condition will review their morning routine, and make a list of potential morning activities to add. They will choose one activity and develop a plan for doing it. Each day, participants are asked to track if they do the morning activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one.
33264103|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
33264104|NCT00904800|Experimental|1|Low dose
33264105|NCT00904800|Experimental|2|Middle dose
33264106|NCT00904800|Experimental|3|High dose
33264107|NCT00904800|Placebo Comparator|4|placebo
33264108|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
33264109|NCT00906438|Placebo Comparator|Control|
33264110|NCT00906438|Experimental|Treated|
33264111|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
33264112|NCT00819494|Sham Comparator|Healthy controls|
33264113|NCT00819494|Active Comparator|Patients with immediate reactions|
33264114|NCT02550626||Delirium|occurrence of post-operative delirium
33264115|NCT02550626||No delirium|no presence of post-operative delirium
32906343|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
33264116|NCT00603798|Active Comparator|3.75% imiquimod cream|
33264117|NCT00603798|Active Comparator|2.5% imiquimod cream|
33264118|NCT00603798|Placebo Comparator|Placebo cream|
33264119|NCT00819572|Experimental|1|DLX105 low dose
33264120|NCT00819572|Experimental|2|DLX105 high dose
33264121|NCT00819572|Placebo Comparator|3|
33264122|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
33264123|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
33264124|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
33264125|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
33264126|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
33264127|NCT03323502|No Intervention|Control|There is no study interaction with control facilities. Facility will follow usual ACP procedures.
33264128|NCT00630812|Experimental|A|active treatment
33264129|NCT00630812|Placebo Comparator|B|
33401514|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
32770886|NCT05219955|Active Comparator|Attention-matched supportive control condition|Participants in this condition will receive sessions in the same number and duration as the SAMM experimental condition. Therapists will create a comfortable environment by demonstrating interest, empathy, and acceptance without judgment. Caregivers will be encouraged to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials.
32770887|NCT04794413|Experimental|Pimavanserin|All participants will receive pimavanserin 17mg once daily for 1 week and, if the tics are deemed to be inadequately controlled then increase to 34 mg once daily, taken orally as two 17 mg tablets once daily.
33401515|NCT05549596|Experimental|Traction treatment|About 40 minutes spine traction including temperature application, Spine Scan, Pre-stroke, and Main Stroke
32770888|NCT05219565|Experimental|Attractive Targeted Sugar Bait (ATSB)|Clusters within the ATSB arm will have 2 to 3 ATSBs hung on all eligible structures in the cluster where consent from the corresponding compound has been given.
32770889|NCT05219565|No Intervention|Control|Clusters within the control arm will not receive ATSBs.
32770890|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70 years and older|All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma
32770891|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70-79 years|All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma
32770892|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 80 years and older|All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma
32770893|NCT04802993||All patients resected with pancreaticoduodenectomy, all ages|All patients in the registry resected with pancreaticoduodenectomy during the study period
32770894|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 70-79 years|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years
32770895|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 80 years and older|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older
32770896|NCT02634307|Experimental|ALKS 8700|Oral capsules taken twice daily.
32770897|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
32770898|NCT01365273|Active Comparator|Mepitel One|Device, dressing
32770899|NCT04793945|Active Comparator|light therapy twice weekly|15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light twice weekly and topical steroid twice daily the second patch will be treated by topical steroid twice daily. the third patch will be left as a control.
32770900|NCT04793945|Active Comparator|light therapy once weekly|"15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light once weekly and topical steroid twice daily.~the second patch will be treated by topical steroid twice daily. the third patch will be left as a control."
32770901|NCT05312775|Active Comparator|Single-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
32770902|NCT05312775|Active Comparator|Double-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
32770903|NCT04794257|Active Comparator|i-IONM|In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
32770904|NCT04794257|Experimental|NerveTrend|In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
32770905|NCT04794179|Other|Naida Link CROS device|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
32770906|NCT05311449|Experimental|Acupressure Group (experimental)|The experimental group will be given acupressure.
32770907|NCT05311449|Placebo Comparator|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure.
32770908|NCT05214729|Experimental|Fast to Slow Group|The Fast to Slow Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the fast UF challenge immediately after inclusion, followed by the slow UF challenge after a washout period of 24 hours.
32770909|NCT05214729|Experimental|Slow to Fast Group|The Slow to Fast Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the slow UF challenge immediately after inclusion, followed by the fast UF challenge after a washout period of 24 hours.
32770910|NCT04784741|Other|Control group|The control group was given the static hamstring muscle stretches, five sessions on alternative days according to the set protocols.
32770911|NCT04784741|Experimental|Experimental Group|Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.
32770912|NCT05635279||HCC patients who received ICIs combined with TKIs|HCC patients who received ICIs combined with TKIs regularly and periodically.
32770913|NCT05635279||HCC patients treated with TACE|HCC patients who underwent TACE as initial treatment.
32770914|NCT04802915|Other|epiretinal membrane group|Patient with epiretinal fibrosis confirmed by OCT with BCVA< 0,6 and complaints of metamorphopsies
32770915|NCT05311215|Experimental|SL-1002|SL-1002 injectable solution, single dose
32770916|NCT05311215|Placebo Comparator|Matching placebo|Matching placebo injectable solution, single dose
32770917|NCT05359861|Experimental|Lead-In|A minimum of 6 patients and up to 30 patients will be enrolled in an open-label Lead-In to assess the preliminary safety and tolerability of SRF388 with atezolizumab plus bevacizumab.
32770918|NCT05359861|Experimental|Arm A: SRF388 in Combination with atezolizumab plus bevacizumab|Patients randomized to Arm A will receive SRF388 with atezolizumab plus bevacizumab.
32770919|NCT05359861|Experimental|Arm B: Placebo in combination with atezolizumab plus bevacizumab|Patients randomized to Arm B will receive placebo with atezolizumab plus bevacizumab.
32770920|NCT05214573||Aims 1, 2B, and 3 Groups|De-identified administrative claims with linked laboratory results, electronic health record (EHR), and mortality data from the OptumLabs Data Warehouse (OLDW) and Medicare fee-for-service data (Medicare parts A, B, D) will be utilized to identify adults (≥21 years) with T2D (established using validated Healthcare Effectiveness Data and Information Set criteria) who first filled any study drug GLP-1RA, SGLT2i, DPP-4i, or SU between 1/1/2014-12/31/2021.
32770921|NCT05214573||Aim 2A Group|Adults with Type 2 diabetes treated with one or more of the study medications (GLP-1RA, SGLT2i, DPP-4i, or SU) and not treated with insulin who receive medical care at Mayo Clinic Rochester, Mayo Clinic Health System in Minnesota or Wisconsin, or Emory University/Grady Hospital.
32770922|NCT04988191|Experimental|Toripalimab combined with bevacizumab and chemotherapy|
33401516|NCT05549596|Active Comparator|Physical Therapy|About 40 minutes standard physical therapy including temperature application and traction
32770923|NCT05310201|Experimental|Be Well Care Well|
32770924|NCT05310201|No Intervention|Control|
32770925|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
32770926|NCT04784975||Preclinical Type 1 Diabetes|"Adolescents and young adults with preclinical diabetes (having at least 2 positive diabetes autoantibodies but who do not meet criteria for clinical diagnosis of type 1 diabetes).~There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health."
32770927|NCT04784975||New Onset Type 1 Diabetes|Adolescents and young adults with a diagnosis of clinical type 1 diabetes. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
32770928|NCT04784975||Long standing Type 1 Diabetes|Adolescents and young adults with type 1 diabetes for at least 2 years. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
32770929|NCT04784975||Control|Adolescents and young adults without any evidence of diabetes or hyperglycemia. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
32770930|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.~Simeprevir 150 mg orally once-daily.~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
32906344|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
33230560|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
33230561|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
33230562|NCT04111848|Experimental|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
33230563|NCT04111848|Experimental|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
33230564|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
33230565|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
33401517|NCT04056884|Active Comparator|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
32770931|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
32770932|NCT05309733||Observational Cohort 1|All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
32770933|NCT04784195||Profesional acrobatics|Profesional Acrobatic Skyedivers as the cort group
32770934|NCT04784195||General active participations|Adults with meched caracteristics with the profesional acrobatics
32770935|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
32770936|NCT05165511|Experimental|Executive Function-Enhanced Parent-Based Behavioral Treatment (PBT-EF)|PBT-EF will integrate executive function training with family-based behavioral treatment (FBT) for obesity, the gold-standard behavioral treatment for childhood obesity. PBT-EF will include self-monitoring, calorie reduction, and dietary and physical activity recommendations in addition to planning, organization, and problem-solving skills.
33401518|NCT04056884|No Intervention|Waitlist|Waitlist is 12 week of no intervention/usual care
32770937|NCT04784351||Training|A subset of patients that are used to train the machine learning algorithm.
32770938|NCT04784351||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
32770939|NCT04239651|Active Comparator|Enrolment in rTMS sessions alone|All patients will be scheduled to receive 30 sessions of rTMS treatments over a six-week period as pre-determined by Alberta Health Services' Strategic Clinical Network for Addiction and Mental Health.
32770940|NCT04239651|Active Comparator|Enrolment in iCBT Plus rTMS|Patients in the rTMS plus iCBT arm of the study, would be assisted to register on the iCBT program (Moodgym) to receive unique login information. They would be assisted to participate in 12 one-hour sessions of iCBT at the clinic prior to receiving rTMS treatments. These in-clinic iCBT sessions would be scheduled in about three days intervals (ideally Tuesdays and Thursdays) so that patients receive two iCBT sessions each week. Patients would also be encouraged to continue with iCBT treatments on their own at home outside the sessions delivered in the clinic.
32770941|NCT04095091||Control Group|"Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan."
32770942|NCT04095091||Patient Group|Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.
32770943|NCT04784273||All study patients|Device - DynaNail - Utilization of a novel dynamic compression pseudoelastic intramedullary nail
32770944|NCT05163171||patient consulting or hospitalized in addiction structure|patient consulting or hospitalized in addiction structure
32770945|NCT04426643|Experimental|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
32770946|NCT04426643|Active Comparator|control|Patients with Urinary incontinence receiving standard treatment
32770947|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
32770948|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
32770949|NCT04238949|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
32770950|NCT04238949|Experimental|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
32770951|NCT05473403|Experimental|Corticosteroid therapy|Prednisone or Prednisolone or Methylprednisolone : Patient with ASAIH will be treated in oral or intravenous (IV) with high doses ( ≥ 1mg/kg/day) of corticosteroids (Prednisone or Prednisolone or Methylprednisolone) until relapse (confirmed by blood tests and clinical status) requiring an emergency Liver Transplantation (LT) or death.
32770952|NCT05473403|No Intervention|Patient without corticosteroid therapy|Patient not treated will undergo to emergency Liver Transplantation (LT) or death.
32770953|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
32770954|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
32770955|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
32770956|NCT05109117|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Active Performance Unscented will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
32770957|NCT05109117|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
32770958|NCT04988347|Experimental|Spirulina|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
32770959|NCT04988347|Placebo Comparator|Placebo|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
32770960|NCT05473169||Patients|Patients with Vocal fold immobility
32770961|NCT05473169||Control|Normal volunteer don't have dysphagia , neurological diseases , heart burn and acid regurgitation
32770962|NCT04452097|Experimental|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
32906345|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
33401519|NCT05675410|Active Comparator|Arm A (ABVD)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive ABVD IV for an additional 2 cycles on study. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
32770963|NCT04452097|Experimental|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
32770964|NCT04452097|Experimental|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
32770965|NCT04452097|Experimental|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
32770966|NCT04452097|Placebo Comparator|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
32770967|NCT05213091|Experimental|Otago Exercise Group|Otago Exercise program wil be applied to the elderly.
32770968|NCT05213091|No Intervention|Control Group|The elderly wil be expected to continue their daily life.
32770969|NCT05473091||Experimental group|
32770970|NCT05473091||Control group|
32906346|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
32906347|NCT04969692|No Intervention|non-warming group|
33078694|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
33078695|NCT04659265|Active Comparator|No suspected diagnosis (control group)|Participants receive the information that the pre-treating physician thought that the patient is suffering from a medical emergency (no diagnosis).
33078696|NCT04659265|Active Comparator|Correct suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from an acute myocardial infarction (correct diagnosis).
33078697|NCT04659265|Active Comparator|Wrong suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from a pulmonary embolism (wrong diagnosis).
33078698|NCT04659187||All hospitalized COVID-19 patients|All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany
33078699|NCT04659187||Subgroup: Detailed cohort of 7 hospitals|Cohort of 7 hospitals with detailed data set
33078700|NCT04659187||Subgroup with cardiovascular events|Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke
33078701|NCT04659187||Subgroup with oncological patients|Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease
33078702|NCT04659187||Subgroup with critical ill COVID-19 patients|Definition: Patients hospitalized to COVID-19 with intensive care treatment
33078703|NCT04659109|Experimental|glenzocimab 1000 mg|
33078704|NCT04659109|Placebo Comparator|Placebo|
33078705|NCT04659070|Experimental|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
33078706|NCT04659070|Active Comparator|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
33078707|NCT04659070|Active Comparator|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
33078708|NCT04658875|Experimental|Spirulina maxima supplementation and exercise group|Supplementation with Spirulina maxima (4.5 g/d) with a systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
33078709|NCT04658875|Experimental|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) without exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
33078710|NCT04658875|Experimental|Exercise group|Systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
33078711|NCT04658875|Active Comparator|Control group|No systematic physical exercise program and No supplementation during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
33078712|NCT00205101||1|Triad allograft
33078713|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
33078714|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
33078715|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
33078716|NCT04658524||Chonic kidney disease stages 3, 4 and 5|Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2
33078717|NCT04658407||all patients diagnosed with a severe hepatic failure|Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)
33078718|NCT00200226|Placebo Comparator|1|Vitamin B6
32770971|NCT05634889|No Intervention|Standard|Radiotherapy to the remaining breast after breast conserving surgery or chest wall after mastectomy, and regional axillary lymph node levels I-IV. Internal mammary nodes are included in the target volume if the tumor has a central/medial localization in the breast.
32770972|NCT05634889|Experimental|Intervention|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery, while mastectomy patients do not receive any radiotherapy at all.
32770973|NCT05161845|Experimental|Experimental group|Participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at Day 0.
32770974|NCT04802369|Active Comparator|Identyfication of prognostic factors in VO2max<17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max<17 ml/kg/min
32770975|NCT04802369|Sham Comparator|Identyfication of prognostic factors in VO2max>17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max>17 ml/kg/min
32770976|NCT04988269||Patients (Cases)|"Adult consecutive patients that visited the Emergency Department of LAIKO General Hospital of Athens, Greece from May to July 2021 due to confirmed COVID-19 and related symptomatology.~Blood sampling on the day of admission (one time point) and saliva sampling at 4 different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day)."
32770977|NCT04988269||Healthy Controls|Age and gender matched healthy individuals without COVID-19. Blood sampling (at day 1) and saliva sampling at different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day-day 2).
32770978|NCT05109039|Experimental|Creatine Supplementation|
32770979|NCT05109039|Placebo Comparator|Placebo Supplementation|
32770980|NCT05473013|Active Comparator|Base BT (Skills Monitoring Off + No Micro-Interventions)|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application.
32770981|NCT05473013|Experimental|Base BT + Skills Monitoring On + No Micro-Interventions|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
32770982|NCT05473013|Experimental|Base BT + Skills Monitoring On + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
32770983|NCT05473013|Experimental|Base BT + Skills Monitoring On + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
32770984|NCT05473013|Experimental|Base BT + Skills Monitoring Off + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
32770985|NCT05473013|Experimental|Base BT + Skills Monitoring Off + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
32770986|NCT05211921|Other|Multi-Gyn ActiGel Plus|vaginal gel
32770987|NCT04802291|Experimental|Healthy HomeStyles|Online educational intervention addressing salient factors affecting school-age children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, irregular breakfast consumption, limited physical activity, and inadequate sleep as well as children's limited food preparation skills.
32770988|NCT04802291|Active Comparator|Safe HomeStyles|Online educational intervention addressing aspects of home safety issues, such as indoor air quality, mold & moisture, hazardous household products, carbon monoxide, home safety, foodborne illness, and refrigerator temperatures.
32770989|NCT05161611|Experimental|Zinc sulfate|Patients will receive 10mg/day zinc sulfate along with phototherapy after being diagnosed to have hyperbilirubinemia
32770990|NCT05161611|Placebo Comparator|Placebo|Patients will receive placebo in addition to phototherapy
32770991|NCT05634655||invasive PAs|
32770992|NCT05634655||non-invasive PAs|
32770993|NCT05161455|Experimental|A-PRF|
32770994|NCT05161455|Experimental|A-PRF+ allograft bone|
33264130|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
33264131|NCT03299478||NSCLC patients|
33264132|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
33264133|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
33264134|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
33264135|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
33264136|NCT00160615|Experimental|Levetiracetam|Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
33264137|NCT03158454|Other|Capsula Closure|
33264138|NCT03158454|Other|Non-Capsula Closure|
33264139|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
32770995|NCT05161455|Active Comparator|allograft bone+crosslinked collagen membrane|
33264140|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
33264141|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
32770996|NCT05161455|Sham Comparator|collagen plug|
33264142|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
33264143|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
32770997|NCT04802525|Experimental|Moderate-intensity aerobic exercise training without dietary control group|
32770998|NCT04802525|Experimental|Low-fat diet program without exercise intervention group|
32770999|NCT04802525|Experimental|Moderate-intensity aerobic exercise training plus a low-fat diet program group|
33264144|NCT03970759||Positive Control Dentifrice|Twice daily brushing
33264145|NCT03970759||Negative Control Dentifrice|Twice daily brushing
33264146|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
33264147|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
32771000|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
32771001|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
32771002|NCT04802213|Active Comparator|Rehabilitation exercise|1.perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
33264148|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
32771003|NCT04802213|Experimental|Rehabilitation exercise + joint mobilization device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)"
32771004|NCT04802213|Experimental|Rehabilitation exercise +joint mobilization device treatment + laser acupuncture device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)~perform laser acupuncture device treatment for patients with frozen shoulders ( three sessions per week for 8 consecutive weeks. patients in each treatment session received laser at a dosage of 4 joules/cm2 for the eight chosen position. )"
32771005|NCT05211609|Experimental|Plasmatic 3-O-Methyldopa Level|Prevalence of High Plasmatic 3-O-Methyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency (Aromatic L-Amino Acid Decarboxylase)
32771006|NCT05615987|Active Comparator|Classic injection|200iu/2ml OnabotulinumtoxinA in total to 2-4 points proximal to the gastrocnemius muscle
32771007|NCT05615987|Experimental|İnjection along the length of the muscle|A total of 200iu/2ml of onabotulinumtoxinA by spreading along the length of the gastrocnemius muscle
33264149|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
33264150|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
33264151|NCT03972631|Placebo Comparator|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
33264152|NCT03972631|Experimental|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
33264153|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
33264154|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
33264155|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
33078719|NCT00200226|Active Comparator|2|misoprostol
32771008|NCT05160675||Group 1|Group 1: 690 healthy infants and their mother followed from birth to 12 months
32771009|NCT05160675||Group 2|Group 2: 690 healthy infants and their mother followed from 6 months to 3 years of age
32771010|NCT05472545|Experimental|Neurofeedback Group|Mothers of adolescent participants will view real-time fMRI neurofeedback representing activity in their daughter's anterior insula during an emotion discussion task. Activity will be presented as a colored bar of moving height, and mothers will be instructed to attempt to downregulate the activity through what they say to their daughter.
32771011|NCT05472545|No Intervention|Control Group|The paradigm for the control condition will be identical to that of the experimental condition except that no neurofeedback will be presented. Participants in the control group will be told that we would like to see if the mother can regulate her daughter's brain activity through supportive statements.
32771012|NCT05107869|Active Comparator|High fat meal and FMD|This arm will assess the effect of increased plasma ceramide (high fat meal) on flow-mediated dilation (FMD) in the brachial artery.
32771013|NCT05107869|Placebo Comparator|High Fat Meal and peripheral microvascular function|This arm will assess the effect of increased plasma ceramide (high fat meal) on peripheral microvascular function.
32771015|NCT04346225|Experimental|Cohort A: Hyperpolarized C13 MRI at a single time point|Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
32906348|NCT04969692|Active Comparator|warming group|
33078720|NCT00408083|Experimental|1|MultiHance MRI contrast agent
33078721|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
33078722|NCT04658485|Active Comparator|Active tDCS|
33078723|NCT04658485|Placebo Comparator|Sham tDCS|
33230566|NCT05606328|Experimental|Implementation Period|ED leadership at each site will identify 5-10 delirium champions (nurse educators and managers, bedside nurses) based on their interest in delirium and commitment to program participation, including training of nurses by champions. The implementation period will take place over a period of 3 months. No data analysis will take place during the implementation period.
33230567|NCT05606328|No Intervention|Intervention Period|The intervention period will take place 3-9 months after implementation of the ED-DDP program over a 15 month period, depending on when a site is randomized to receive the ED-DDP intervention.
33230568|NCT00654940|Active Comparator|A|
33230569|NCT00654940|Placebo Comparator|B|
33230570|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
33230571|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
33230572|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
33230573|NCT00807430|Experimental|1|24 patients receiving active treatment
33230574|NCT00807430|Placebo Comparator|2|Placebo treatment
33230575|NCT04109196|Experimental|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
33230576|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
33230577|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
33230578|NCT01019785|Active Comparator|High dose Vitamin D|
33230579|NCT01019785|Sham Comparator|Low dose Vitamin D|
33230580|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
33230581|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
33230582|NCT01024543|Sham Comparator|Placebo|Placebo
33230583|NCT01024543|Experimental|Angiotensin II|Angiotensin II
33230584|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
33230585|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
33230586|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
33230587|NCT01024621|Experimental|1|confocal laser endomicroscopy
33230588|NCT01024621|Active Comparator|2|standard endoscopy
33230589|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
33230590|NCT00811330|No Intervention|2: No Atrovastatine|
33230591|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
33230592|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
33230593|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
32771016|NCT04346225|Experimental|Cohort B: Hyperpolarized C13 MRI at multiple time points|Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 12 weeks (+/- 8 weeks). Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as well.
32771017|NCT05478135|Experimental|NAVIFY Oncology Hub|We will first conduct a small number of simulation sessions (3-5) to validate study methods and data collection procedures. Study methods may then be refined before conducting simulation sessions with a larger number of participants (approx. 25). In this phase, each participant will participate in a 90-minute simulation session in which they will use NAVIFY Oncology Hub to review synthetic patient cases. Participants will be tasked with reviewing the cases as if they were preparing to see a patient in a real clinical setting.
33078724|NCT04658719|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
33078725|NCT04658719|Active Comparator|Standard Care|Foley catheter, uncoated
33078726|NCT00200265|Experimental|1|Behavioral: diet
33078727|NCT00200265|Experimental|2|Behavioral: diet
33078728|NCT00200265|Placebo Comparator|3|Behavioral: diet
33078729|NCT04658563|Experimental|Group 1: Yoga|High-density HY training; average 90-110 minutes, 2 sessions per week under the supervision of the physiotherapist, once a week as a home program, will be applied for a total of 8 weeks to the first group.
33078730|NCT04658563|No Intervention|Group 2: Control|Individuals in the second group will not included in any exercise training program
33078731|NCT04658602|Active Comparator|Direct composite restoration|Bulk-fill composite (Filtek bulk flow, 3M Espe ) will be used and covered using a nanohybrid copmosite (filtek XT, 3M Espe )
33078732|NCT04658602|Active Comparator|Preformed metal crowns|Preformed stainless-steal crowns cemented by glass ionomer lutting cement (ketac cem. 3M Espe )
33078733|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
33078734|NCT00408161|Active Comparator|2|standard case management treatment
33078735|NCT00557518|Active Comparator|1|
33078736|NCT00557518|Placebo Comparator|2|
33078737|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
33078738|NCT04657978||Substrate guided intervention arm|Participants recruited to the study will undergo High Density Wave Solution™ guided substrate mapping of the left atrium. Ablation will thereafter be performed to comprise wide area circumferential ablation of the pulmonary veins in pairs, followed by ablation of low voltage zones in the left atrium.
33078739|NCT04658134|Experimental|Glycine supplementation|Glycine supplementation
33078740|NCT04658212|Experimental|3D LCBDE group|
33078741|NCT04658212|Active Comparator|ERCP group|
33078742|NCT04658017|Experimental|GARNET device|All enrolled subjects will receive treatment with the GARNET device.
33078743|NCT04658056||WATER AQUABEAM Robotic System cohort|WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
33078744|NCT04658056||WATER TURPS cohort|WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
33078745|NCT04657744|Experimental|A test|Test drug (Sphingomod ) 1 capsule contains 0.5 mg Fingolimod
33078746|NCT04657744|Active Comparator|B reference|Reference drug (Gilenya) 1 capsule contains 0.5 mg Fingolimod
33078747|NCT04657627|Experimental|PACE plus calorie information intervention group|PACE plus calorie information intervention group will receive PACE plus calorie information of discretionary foods via social media posts.
33078748|NCT04657627|Active Comparator|Calorie-only information comparator group|Calorie-only information comparator group will receive calorie-only information of discretionary foods via social media posts.
33078749|NCT04657471|Experimental|revised HOMe-CoV|Revised HOME-CoV
33078750|NCT04657549|Active Comparator|Tonsillectomy|Patients will undergo tonsillectomy under general anesthesia within three weeks after enrollment.
33078751|NCT04657549|Active Comparator|Tonsillotomy|Patients will undergo tonsillotomy under general anesthesia within three weeks after enrollment.
33078752|NCT04657549|No Intervention|Watchful waiting|Patients will be closely monitored for the 5-6 months monitoring period.
33078753|NCT04657354|Active Comparator|Fast track|Study subjects in Fast Track arm will get an MRI done on the same day. If the MRI shows concordant findings of herniated disc, the subject will be referred to a spine surgeon to be seen within one week. If the surgeon and subject decide on discectomy, the surgery is scheduled within the same week. Total timespan from first interview to surgery will be no longer than 2 weeks.
33230594|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
33230595|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
33230596|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
33230597|NCT00807508|Experimental|1|daily leucine supplementation
33230598|NCT00807508|Placebo Comparator|2|daily placebo supplementation
33230599|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
33230600|NCT00446797|Experimental|Celecoxib|
33230601|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
33264156|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
33264157|NCT00908856|Placebo Comparator|Placebo|Placebo
33078754|NCT04657354|No Intervention|Usual care|"Study subjects in Usual Care will be treated following the Danish National Guidelines in which a conservative approach for the first 4-6 weeks with focus on pain relief by pain-relief medication, exercises and encouragement to resume normal activities as much as possible. Patients in this arm will be scheduled 2 and 4 week follow-up appointments as per national guidelines.~If the symptoms have not resolved after this period, then a referral to a multidisciplinary spine care department is made. However, if symptoms are still present at 8-12 weeks first then a referral for a spine surgeon assesment can be done."
33264158|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
33264159|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
33078755|NCT04657510||Proximal femur fracture AND COVID-19|Surgical treatment of femur fracture
33264160|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
33264161|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
33264162|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
33264163|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
33078756|NCT04657510||Proximal femur fracture NO COVID|Surgical treatment of femur fracture
33078757|NCT04657237|No Intervention|control group|all patients will receive general anesthesia and will receive intravenous paracetamol (1 g) before skin closure and then given every 6 hrs in the 1st postoperative day
33078758|NCT04657237|Active Comparator|TPVB group|Patients will receive total volume (20 ml) 0.25% bubivicaine divided equally at each level of T4 and T6 at thoracic paravertebral space then they will recive general anesthesia.
33264164|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
33264165|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
33264166|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
33078759|NCT04657042||Healthy|Healthy volunteers from the local community
33264167|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
33264168|NCT00906672|Experimental|INTEGRA®|
33264169|NCT00906672|Active Comparator|Flap technique|
33078760|NCT04657042||Liver cancer|Patients undergoing radiotherapy for liver cancer
33264170|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
33264171|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
33264172|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
33264173|NCT00909168|Experimental|Efficacy of FLAIMy|
33264174|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
33264175|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
33264176|NCT00906750|Experimental|1|
33264177|NCT00906750|Active Comparator|2|
33264178|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
33264179|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
33264180|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
33264181|NCT00819728|Experimental|Taxotere/Irinotecan|
33264182|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
33264183|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
33264184|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
33078761|NCT04657042||Lung cancer|Patients undergoing radiotherapy for lung cancer
33078762|NCT04656886|Experimental|Ketalar|0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.
33264185|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
33264186|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
33264187|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
33264188|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
33264189|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
33264190|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
33264191|NCT00909402|Experimental|All Subjects|
32906349|NCT01838096|Experimental|THA|
33264192|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
33264193|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
33264194|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
33264195|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
33264196|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
33264197|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
33264198|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
33264199|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
33264200|NCT00819884|Experimental|1|twice daily during 4 days
33264201|NCT00819884|Experimental|2|once daily during 4 days
33264202|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
33264203|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
33264204|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
33264205|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
33264206|NCT00819962|Other|TAP|ksu
33264207|NCT00927342|Active Comparator|Vivostat|
33264208|NCT00927342|Active Comparator|BioGlue|
33264209|NCT00542919|Experimental|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
33264210|NCT00542919|Experimental|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
33264211|NCT00542919|Experimental|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
33264212|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
33264213|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
33264214|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
33078763|NCT04656886|Placebo Comparator|Saline|Single, intravenous, steady state infusion over 40min.
33230602|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
33230603|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
33230604|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
33230605|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
33230606|NCT00811486|No Intervention|Usual care|Group II
33230607|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
33230608|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
33230609|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
33230610|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
33230611|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
33230612|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
33230613|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
33230614|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
33230615|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
33230616|NCT04114188|Experimental|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 & 1 post op
33230617|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
33230618|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
33230619|NCT04125017|Other|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
33230620|NCT04125017|Other|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
33230621|NCT00813826|Experimental|SLC022|300mg TID
33230622|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
33230623|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
33230624|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
33230625|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
33230626|NCT00593489|Experimental|Basal Insulin Initiation Strategy|"Basal Insulin Initiation Strategy which includes:~support by community pharmacist~support by diabetes specialist"
33230627|NCT00593489|No Intervention|Usual Practice|The physicians randomized to this group proceeded with their usual practice
33230628|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
33230629|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
33230630|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
33230631|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
33230632|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
33230633|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
33230634|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.~They were followed when possible one year after surgery."
33230635|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
33230636|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
33230637|NCT00814060|Experimental|1|40-mg tablet
33230638|NCT00814060|Experimental|2|240-mg tablet
33230639|NCT00814060|Experimental|3|80-mg capsule
33230640|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
33230641|NCT00792636|Active Comparator|sumatriptan|
33230642|NCT00792636|Active Comparator|naproxen sodium|
33230643|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
33230644|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
33230645|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
33230646|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
33230647|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
33264215|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
33264216|NCT05513157||Chronic stroke patients with knee hyperextension|Chronic stroke patients with a maximum knee extension angle of less than 0 degrees in movement analysis
33230648|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
33264217|NCT05513157||Chronic stroke patients without knee hyperextension|Chronic stroke patients with a maximum knee extension angle greater than 0 degrees in movement analysis
32771018|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
32771019|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
33264218|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
32771020|NCT05107557|Experimental|Experimental Group|The experimental group is also called the combined immunization group.260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
32771021|NCT05107557|Active Comparator|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
32771022|NCT05347927||Test group|will receive water resistante padding and a cast
32771023|NCT05347927||Control group|will receive traditional non-water resistante padding and cast
32771024|NCT02594735|Other|Open Label (One Arm)|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
32771025|NCT05315713|Experimental|Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
32771026|NCT05315713|Experimental|Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
32771027|NCT05159583|Experimental|In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
32906350|NCT05565053|Active Comparator|Bilateral Erector Spinae Plane Block|Bilateral Erector Spinae Plane Block
33230649|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
33264219|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
33264220|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
33264221|NCT05711355|Active Comparator|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Paitents treated with platelet-rich plasma injection and treated with according to guidelines
33264222|NCT05711355|Active Comparator|Control group of meningomyelocele sac repair|Paitents treated according to guidelines
33264223|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
33230650|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
33230651|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
33264224|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
33264225|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
33264226|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
33264227|NCT00816374|Other|1|Group I
33264228|NCT00816374|Other|2|Group II
33264229|NCT00906906||1|Patient to receive CPB
33264230|NCT00159913|Experimental|Sildenafil Low dose|
33264231|NCT00159913|Experimental|Sildenafil Medium dose|
33264232|NCT00159913|Experimental|Sildenafil High dose|
33264233|NCT00159913|Placebo Comparator|Placebo|
33264234|NCT05498259|Experimental|Orelabrutinib+R-CHOP-like|Orelabrutinib plus Rituximab for 21 days; Following Imaging examinations, patients with ≥25% tumor reduction, treat with orelabrutinib 150mg qd orally plus R-CHOP-like for 6 cycles; whereas, patients with <25% tumor reduction, withdraw from the study，treat with R-CHOP-like alone for 6 cycle
33264235|NCT00820274|Experimental|amniotic membranes|
33264236|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
33264237|NCT00987207|Experimental|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
33264238|NCT00987207|Other|Control|No cyclosporine A is administered before aortic cross-declamping
33264239|NCT04044326|Experimental|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring <5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
33264240|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
32771028|NCT05159583|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
32771029|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
33264241|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
33264242|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
33264243|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
33264244|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
33264245|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
32771030|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
32771031|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
33082298|NCT04619641|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
33264246|NCT00927654|Experimental|Iloprost|
33264247|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
33264248|NCT05709327|Other|Single-arm observational study|All participants in the study will be provided a smart ring to wear for the entire duration of the pregnancy.
33264249|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
33264250|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
33264251|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
33264252|NCT04423575|Experimental|Outpatients|Health care pathway: patient education, communication to liberal nurses, first-position surgical planning, bariatric surgery (bypass or sleeve) as outpatient procedure, follow-up by home nurse twice-a-day, standardized communication to surgeons, management of possible complications
33264253|NCT04423575|No Intervention|Inpatients|Standard care pathway with bariatric surgery (bypass or sleeve) as inpatient procedure (at least one night in the hospital)
33264254|NCT00227539|Experimental|Neoadjuvant therapy, PET scan and surgery|
33264255|NCT04414761|Active Comparator|Antagonist group|Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
33264256|NCT04414761|Experimental|PPOS group|Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger.
33264257|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
33264258|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
33264259|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
33264260|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
32771032|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
33264261|NCT05706519||Control Group|Six hundred volunteers. This group has to be without any type of cardiovascular Disease.
32771033|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
33078764|NCT04656808|Experimental|Guilt focused intervention|Following literature on factors associated with guilt experiences in caregivers (Gonyea et al., 2008; Gallego-Alberto et al., 2019; Losada et al., 2014; Prunty & Foli, 2019; Romero-Moreno et al., 2014; Spillers et al., 2008) and previous intervention studies testing an Acceptance and Commitment Therapy intervention for dementia family caregivers (Losada et al., 2015; Márquez-González et al., 2020), a guilt focused intervention was specifically designed for caregivers who experienced high levels of guilt and emotional distress. The program is based on CBT (Márquez-González et al., 2007) and Acceptance and Commitment Therapy (ACT) approaches (Losada et al., 2005; Márquez-González et al., 2010), combined with techniques of Compassion-Focused Therapy (CFT; Gilbert, 2009), which were adapted to work with guilt experienced by family dementia caregivers.
33264262|NCT05706519||Case Group|Six hundred volunteers. In this group, participants must present a diagnosis of ischemic heart disease at least 1 year but less than 5 years from recruitment
33264263|NCT00927966|Experimental|RAD001 in combination with figitumumab|
33264264|NCT00816608||type 2 diabetes|
33264265|NCT05705505|Experimental|Escalating daily doses of narazaciclib in combination with letrozole (2.5mg day)|"Phase 1: Initiating at 160mg per day of narazaciclib, patients will receive escalating doses of narazaciclib (oral capsules/once daily) in combination with 2.5mg of letrozole (oral tablet/once daily).~Phase 2: All patients will receive the recommended phase 2 dose (RP2D) of the combination of narazaciclib (oral capsules) and letrozole (oral tablet/QD)"
33264266|NCT00720941|Active Comparator|Sunitinib|Control arm
33082299|NCT04619758|Experimental|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
33264267|NCT00720941|Experimental|Pazopanib|Experimental arm
33264268|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
33264269|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
33264270|NCT05704335||Patients with headache during the course of influenza|Patients with influenza infection who experience new-onset headache during the course of the disease, or a two-fold worsening of a prior headache disorder, according to the International Classification of Headache Disorders
33264271|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
33264272|NCT00821756|No Intervention|2|Control arm: Treatment as usual
33264273|NCT00924222|Experimental|Sevoflurane|
33264274|NCT00924222|Experimental|Propofol|
33264275|NCT00924300||patients|children and/or adolescents with psychiatric disorder
33264276|NCT00924300||controls|typically-developing children/adolescents
33264277|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
33264278|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
33264279|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
33264280|NCT03972319|Experimental|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
33264281|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
33264282|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
33264283|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
33264284|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
33264285|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
33264286|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
33264287|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
33264288|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
33264289|NCT05702931|Active Comparator|Semaglutide treated group|Oral semaglutide once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
33264290|NCT05702931|Placebo Comparator|Placebo treated group|Oral placebo once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
33264291|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
33264292|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
33264293|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
33264294|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
33264295|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
33264296|NCT01073371|Active Comparator|3% plain prilocaine|
33264297|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
33264298|NCT05470491|Experimental|1/Recipient Arm 1|RIC+alloHCT+GVHD prophylaxis per dose levels 1, 2, and
33264299|NCT05470491|Experimental|2/Recipient Arm 2|RIC+alloHCT+GVHD prophylaxis per RP2D
33082300|NCT04619758|No Intervention|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
33264300|NCT05470491|No Intervention|3/Donor Arm|Collection of research samples on hematopoietic donors
33264301|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
33264302|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
33264303|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
33264304|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
33264305|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
33264306|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
33264307|NCT03970369|Experimental|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
33264308|NCT03970369|Active Comparator|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
33264309|NCT04034394|Experimental|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
33264310|NCT04034394|Active Comparator|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
33264311|NCT04005573|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
33264312|NCT04005573|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
33264313|NCT04005573|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
33264314|NCT04005573|Other|control group|no intervention was given
33264315|NCT03970213|Placebo Comparator|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
33264316|NCT03970213|Experimental|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
33264317|NCT00821834|Experimental|Clopidogrel|"Patients received:~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~ticlopidine matching placebo twice daily."
33264318|NCT00821834|Active Comparator|Ticlopidine|"Patients received:~ticlopidine 100 mg twice daily,~clopidogrel matching placebo once daily."
33264319|NCT00924534|Placebo Comparator|1|
33264320|NCT00924534|Experimental|2|
33264321|NCT00924534|Experimental|3|
33264322|NCT00924534|Experimental|4|
33264323|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
33264324|NCT04005417||Positive control dentifrice|Twice daily brushing
33264325|NCT04005417||Negative control dentifrice|Twice daily brushing
33264326|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
33264327|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
33264328|NCT05356715|Experimental|Group A|● Group A (n=110): will receive Ultrasound guided bilateral ESBP.
33264329|NCT05356715|Active Comparator|Group B|● Group B (n=110): will receive fentanyl IV infusion 2mic/kg/hr
33264330|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
33264331|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
33264332|NCT05698407|Experimental|Dexmedetomidine|0.4 microgram/ml dexmedetomidine plus 0.08% ropivacaine
33264333|NCT05698407|Active Comparator|Sufentanil|0.4 microgram/ml sufentanil plus 0.08% ropivacaine
33264334|NCT03743454||Men|
33264335|NCT03743454||Women|
33264336|NCT05698251|Experimental|Reducing uncertainty distress: Psychological therapy intervention|"Up to 16 sessions of psychological therapy delivered weekly either face to face or via telehealth . Based on empirically grounded models of anxiety/threat, illness uncertainty and intolerance of uncertainty.~Formulation driven and clinically responsive individualised treatment based on four intervention areas: information management, building safety, reducing overestimation of threat and tolerating uncertainty."
33264337|NCT00585533|Other|A|
33264338|NCT00924690|Experimental|1|Behavioral Message Arm
33264339|NCT00924690|Active Comparator|2|Generic Message Arm
33264340|NCT04719741||O-4PI|4 mg Ondansetron given Pre-Induction
33264341|NCT04719741||O-8PI|8 mg Ondansetron given Pre-Induction
33264342|NCT04719741||O-4PE|4 mg Ondansetron given Pre-Emergence
33264343|NCT04719741||O-8PE|8 mg Ondansetron given Pre-Emergence
33264344|NCT04719741||D-4PI|4 mg Dexamethasone given Pre-Induction
33264345|NCT04719741||D-8PI|8 mg Dexamethasone given Pre-Induction
33264346|NCT04719741||D-4PE|4 mg Dexamethasone given Pre-Emergence
33264347|NCT04719741||D-8PE|8 mg Dexamethasone given Pre-Emergence
33264348|NCT04719741||O-4PI+D-8PI|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-induction
33264349|NCT04719741||O-4PI+D-8PE|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-emergence
33264350|NCT04719741||O-4PE+D-8PI|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction
33264351|NCT04719741||O-4PE+D-8PE|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-emergence
33264352|NCT04719741||Placebo Group|2 ml Saline 0.9%
33264353|NCT04085861|Experimental|Dancers|Recruited group of professional dancers from the Norwegian University of dance
33264354|NCT04085861|No Intervention|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
33264355|NCT04085861|Experimental|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
33264356|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
33264357|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
33264358|NCT00628862|Placebo Comparator|PBO|Placebo
32771034|NCT05209425|Active Comparator|Regular Vitamin D3 1000IU|The first group receives regular Vitamin D3 1000IU
32771035|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 1000IU|The second group receives microencapsulated Vitamin D3 1000IU
32771036|NCT05209425|Active Comparator|Regular Vitamin D3 2500IU|The third group receives regular Vitamin D3 2500IU
33264359|NCT00907140|Other|Chemoradiation therapy|
33264360|NCT05420727|Experimental|Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1|Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.
33264361|NCT04085783|Experimental|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
33264362|NCT04753164|Experimental|100 mg twice daily (b.i.d.) ACT-539313|
33264363|NCT04753164|Placebo Comparator|Placebo|
33264364|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
32771037|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 2500IU|The fourth group receives microencapsulated Vitamin D3 2500IU
33264365|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
33264366|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
32771038|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
32771039|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
32771040|NCT04793243|Experimental|Intervention group|Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
32771041|NCT04793243|No Intervention|Control group|Formed by 20 patients that did not receive supplementation
32771042|NCT05158569|Experimental|Slow breathing exercise group|Slow breathing 5-6 breaths/minute, 3 sets of 5 minutes 2 times/day for 4 weeks.
32771043|NCT05158569|Experimental|Diaphragmatic breathing exercise group|Diaphragmatic breathing, 3 sets of 5 minutes 2 times/day for 4 weeks.
32771044|NCT05472467|Experimental|Immunotherapy combined with Stereotactic Body Radiation Therapy|"Camrelizumab： 200mg IV Q3W~Chemotherapy：Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.~Stereotactic Body Radiation Therapy(SBRT) for Oligometastatic the total dose 35Gy/5f(7.0Gy/f,5f per week)。"
33082301|NCT04619914|Experimental|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
32901866|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
32901867|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
33082302|NCT04619914|Experimental|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
33264367|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
33264368|NCT04086563|Experimental|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
33264369|NCT04086563|Experimental|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
33264370|NCT04086563|Active Comparator|Strength Training|Strength protocol for the dominant hand.
33264371|NCT04086563|Experimental|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
33264372|NCT00820820|Active Comparator|Rouvax|
33264373|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
33264374|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
33264375|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
33264376|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
33264377|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
33264378|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
33264379|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
33264380|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
33264381|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
33264382|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
33264383|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
33264384|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
33264385|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
33264386|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
33082303|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
33264387|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
33264388|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
33264389|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
33264390|NCT05695521|Experimental|CK0803|"CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously Dose: 100 million Treg cells (fixed dose)~Dose regimen:~Induction: one infusion every 7 days (+/-3) x 4 doses~Consolidation: one infusion every 28 days (+/-3) x 5 doses"
33264391|NCT05695521|Placebo Comparator|Placebo|Excipient
33264392|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
33264393|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
33082304|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
33264394|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
33264395|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
33264396|NCT05373537|Experimental|Home-based|home- based CBT-Insomnia intervention
33264397|NCT05373537|Experimental|web-based|web-based CBT-Insomnia intervention
33264398|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
33264399|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
33264400|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
33264401|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
33264402|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
33264403|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
33264404|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
33264405|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
33264406|NCT05690997|Other|Intensive Treatment Group|SBP target 120-129 mmHg
33264407|NCT05690997|Other|Standard Treatment Group|SBP target 130-140 mmHg
33264408|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
33264409|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
33264410|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
33264411|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
33264412|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
33264413|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
33264414|NCT05325905||Healthy|bleeding on probing (BoP) ≤ 10% of the sites, probing depth (PD) ≤ 3 mm and no indication of clinical attachment level (CAL) or radiographic bone loss
33264415|NCT05325905||Gingivitis|gingival inflammation (BoP ≥ 10% of the sites, red-blue discoloration of the gingiva and edema) PD ≤ 4 mm and no clinical attachment or radiographic bone loss
33264416|NCT05325905||Periodontitis|PD ≤ 5 mm, radiographic bone loss, and 3-4 mm CAL in at least 30% of the sites
33264417|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
33264418|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
33264419|NCT05689827|Experimental|Ethyl methyl hydroxypyridine succinate + Meldonium|Arm 1 (n=80) received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days; total number of injections for the treatment course is 10 and then orally with the dosage regimen of 2 capsules (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) twice per day for 30 days; total number of capsules for the treatment course is 120. Second group received Placebo in the same way.
33264420|NCT05689827|Placebo Comparator|Placebo|Arm 2 (n=80) received Placebo in the same way.
33264421|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
33264422|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
33264423|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
33264424|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
33264425|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
33264426|NCT00727649|Active Comparator|Arm 2|Loperamide
33264427|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
33264428|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
32901868|NCT05066724|Experimental|Centanafadine|400 mg total daily dose Centanafadine Sustained Release (SR)
32901869|NCT01495585|Placebo Comparator|Placebo|Placebo control
32901870|NCT01495585|Experimental|Group 1|lonafarnib 100mg
33264429|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
32901871|NCT01495585|Experimental|Group 2|lonafarnib 200mg
32901872|NCT04421976|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
33264430|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
33264431|NCT04006041|Experimental|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
33264432|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
33082305|NCT04619875|Other|Lactulose|
33264433|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
33264434|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
33264435|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
33264436|NCT00225277|Experimental|Pioglitazone QD|
33082306|NCT04619875|Other|KB5|
33082307|NCT04619875|Other|SG1|
33082308|NCT04619290|Experimental|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
33264437|NCT00225277|Active Comparator|Glimepiride QD|
33264438|NCT00821054|Experimental|Period 1|Treatment A, B or C
33264439|NCT00821054|Experimental|Period 2|Treatment A, B or C
33264440|NCT00821054|Experimental|Period 3|Treatment A, B or C
33264441|NCT05354453|Experimental|SRD Part|Single-rising dose (SRD)
33264442|NCT05354453|Placebo Comparator|SRD Part: Placebo|
33264443|NCT05354453|Experimental|Skin Challenge Part|
33264444|NCT05354453|Placebo Comparator|Skin Challenge Part: Placebo|
33264445|NCT04391673||Dizzy group|Patients attending the dizziness and balance exercise programme at Guy's Hospital, London. Patients data will be included if they complete at least 4 sessions.
33264446|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33264447|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33264448|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33264449|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
33264450|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
33264451|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
33264452|NCT04388319|Experimental|Combination zonisamide and bupropion with e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
33264453|NCT04085627|Experimental|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
33264454|NCT04085627|Active Comparator|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
33264455|NCT00821210|Sham Comparator|2|
33264456|NCT00821210|Active Comparator|1|
33264457|NCT03970135|Experimental|Fasting|
33264458|NCT04086173|Experimental|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
33264459|NCT04086173|Placebo Comparator|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
33264460|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
33264461|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
33264462|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
33264463|NCT00224887|Experimental|in home nutrition counseling|In-home family-based behavioral counseling using in-person and video interventions delivered by community health advisors
33264464|NCT00224887|Active Comparator|standard nutrition education curriculum|standard nutrition education curriculum consisting of video and lesson plans based on USDA Food Guide pyramid
33264465|NCT04085393|Active Comparator|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
33264466|NCT04085393|Active Comparator|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
33264467|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
33264468|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
33264469|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
33264470|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
33264471|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
33264472|NCT00148759|Active Comparator|adult male subjects|LPV/r 800/200 mg once daily
33264473|NCT00148759|Experimental|Adult female subjects|LPV/r 800/200 mg once daily
33264474|NCT00925080||A|
33264475|NCT00717275|Experimental|Temozolomide|
33264476|NCT00822068|Experimental|anodal tDCS|
33264477|NCT00822068|Active Comparator|2|cathodal tDCS
33264478|NCT00822068|Placebo Comparator|3|sham stimulation
33264479|NCT04006353|Experimental|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
33264480|NCT04006353|Experimental|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
33264481|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
33264482|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
33264483|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
33264484|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
33264485|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
33264486|NCT04515849|Experimental|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
33264487|NCT04515849|Experimental|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
33264488|NCT04515849|Experimental|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
33264489|NCT04515849|Placebo Comparator|Placebo|Placebo administered subcutaneously
33264490|NCT04515849|Active Comparator|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
33401520|NCT05675410|Experimental|Arm B (ABVD, brentuximab vedotin, nivolumab)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive brentuximab vedotin IV and nivolumab IV for 4 cycles on study. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
32906351|NCT05565053|Active Comparator|Trigger Point Injection|Trapezius muscle Trigger Point Injection
33264491|NCT04034316|Experimental|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:~25% reduction of the ongoing immunosuppressive treatment following the first administration;~50% reduction of the ongoing immunosuppressive treatment following the second administration;~interruption of the ongoing immunosuppressive treatment following the third administration.~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
33264492|NCT03972241|Experimental|Intervention|different interventions including foot insole or kinetic training
33264493|NCT03972241|No Intervention|control|No intervention
33264494|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
33264495|NCT04085159|Experimental|CART/CTL/DCvac cells to treat cancer|
33264496|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
33264497|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
33264498|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
33264499|NCT03972085|Experimental|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
33264500|NCT03972085|Active Comparator|Group 2|Patient received only electrotherapy sessions
33264501|NCT00584909|Experimental|Open Label|
33264502|NCT05672199|Placebo Comparator|Placebo|Participants who were receiving the placebo during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive the placebo.
33264503|NCT05672199|Experimental|Efavaleukin Alfa Dose 1 (Low Dose)|Participants who were receiving efavaleukin alfa dose 1 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 1.
32771047|NCT05208099||Patients with Hidradenitis suppurativa|
33264504|NCT05672199|Experimental|Efavaleukin Alfa Dose 2 (Moderate Dose)|Participants who were receiving efavaleukin alfa dose 2 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 2.
33264505|NCT05672199|Experimental|Efavaleukin Alfa Dose 3 (High Dose)|Participants who were receiving efavaleukin alfa dose 3 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 3.
33264506|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
32771048|NCT05208099||Controls (coming for abdominoplasty)|
32771049|NCT04760639||Test group|Participants who have a positive Covid-19 Test or negative Covid-19 test who provide a breath sample.
33264507|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
33264508|NCT00147823|Experimental|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
33264509|NCT00147823|Active Comparator|Vitoss Alone|vitoss alone
32771050|NCT05634421||Dermatologists|Dermatologists who have no experience with OCT.
33264510|NCT05361915|Experimental|Abivertinib - Abiraterone-naive|Abiraterone-naive: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
33264511|NCT05361915|Experimental|Abivertinib - Abiraterone-progressing|Abiraterone-progressing: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
33264512|NCT00929058|Experimental|Bevacizumab|
33264513|NCT05375669|Experimental|ISIS IOM System|Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement.
33264514|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
33264515|NCT00822146|Experimental|1|
33264516|NCT05346393|Experimental|TIPS group|TIPS implant (transjugular intrahepatic portosystemic shunt)
33264517|NCT05346393|Active Comparator|Control group|Standard medication therapy with terlipressin and albumin
32771051|NCT05634421||Residents/physicians|Residents/physicians who have no experience with OCT
32771052|NCT05634421||Medical students|Medical students who have no experience with OCT
32771053|NCT05634421||Nurses|Nurses who have no experience with OCT
32771054|NCT05157789|Experimental|Sms group|Relatives of patients who were sent SMS
32771055|NCT05157789|No Intervention|Control Group|Relatives of patients who were no intervation
33264518|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
33264519|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
33264520|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
33264521|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
33264522|NCT00987753|Experimental|infusion of L-377202|
33264523|NCT00822224|Experimental|1|Use of MEOPA during the painful care
33264524|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
33264525|NCT00907530|Active Comparator|GADOVIST|gadobutrol
33264526|NCT05331885|Experimental|AR-320 (Suvratoxumab)|Participants will receive a single intravenous (IV) dose of suvratoxumab on Day 0 of the study.
32771056|NCT04793165|Experimental|Non-hybrid closed-loop system|"To compare two types of treatments:~During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.~During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm."
32771057|NCT05634343|Experimental|Laughter Group|The laughter therapy program consists of 16 sessions, twice a week for eight weeks. Each session; It is planned to last 30-45 minutes with a maximum of 25 nurses.
32771058|NCT05634343|Experimental|Mindfulness Group|The mindfulness practice program consists of 16 sessions, twice a week for eight weeks. Each session is planned to last 45-60 minutes with a maximum of 25 nurses.
32771059|NCT05634343|No Intervention|Control Group|No intervention was made in the control group.
32771060|NCT04793399|Experimental|Bosutinib-Atezolizumab Combination|"Drugs to be administered:~Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year"
32771061|NCT05634265|Experimental|Pilot|Participants will be offered the Vijana-SMART WhatsApp group intervention
32771062|NCT05157711|Experimental|Anusol ointment|Anusol ointment (Zinc oxide [10.75g], Bismuth subgallate [2.25 g], Balsam peru [1.875 g], Bismuth oxide [0.875 g] in each 100g of ointment).
32771063|NCT05157711|Active Comparator|Benchmark|RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed
32771064|NCT05157711|Placebo Comparator|Placebo|Anusol ointment after the removal of the active ingredients
33264527|NCT05331885|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo to survatoxumab on Day 0 of the study.
33264528|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
33264529|NCT00929136|Experimental|Endotoxin|
33264530|NCT00925392|Experimental|Doripenem 500 mg|
33264531|NCT00925392|Experimental|Doripenem 1000 mg|
33264532|NCT05315271|Active Comparator|Group 1|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
33264533|NCT05315271|Active Comparator|Group 2|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
33264534|NCT00147745|Experimental|1|colesevelam 3.8g administered daily for 12 weeks
33264535|NCT00147745|Placebo Comparator|2|Colesevelam matching placebo for 12 weeks
33264536|NCT00147745|Active Comparator|3|open-label Insulin Glargine for 12 weeks
33264537|NCT04542486|Experimental|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
33264538|NCT04542486|Active Comparator|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Soft tissue trimmer."
33264539|NCT05650203|Experimental|JS009 as a monotherapy and JS009 Combine with Toripalimab and JS006|"JS009 as Monotherapy in first cycle of dose escalation and the triple combination therapy will be administered in subsequent cycles：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1200mg).~The triple combination therapy in dose expansion：1 or 2 proposed dose levels, to be determined.~The triple combination therapy in indication expansion：4 or more cohorts, to be determined."
33264540|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
33264541|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
33264542|NCT05632965||Healthy preterm infants|Thyroid function in Preterm infants not needing hospital admission will be estimated at day 3 and day 10 of life.
33264543|NCT05632965||Sick preterm infants|Thyroid function in sick preterm infants admitted to NICU will be estimated at day 3 and day 10 of life .
33264544|NCT01326169|Active Comparator|Standard care|No intervention
33264545|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
33264546|NCT00642902|Experimental|Atacicept 25 mg|
33264547|NCT00642902|Experimental|Atacicept 75 mg|
33264548|NCT00642902|Experimental|Atacicept 150 mg|
33264549|NCT00642902|Placebo Comparator|Placebo|
33264550|NCT00925470||1|
33264551|NCT05313477|Active Comparator|Supplement group|"Vitamin D2 supplement based on initial vitamin D level~≥ 20ng/mL -> vitamin D2 20,000unit/week~10-19.9ng/mL -> vitamin D2 40,000unit/week~<10ng/mL -> vitamin D2 60,000unit/week Calcium carbonate 1000mg/day"
33264552|NCT05313477|No Intervention|No supplement group|no medication supplement
33264553|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
33264554|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
33264555|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
33264556|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
33264557|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
33264558|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
33264559|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
33264560|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
33264561|NCT05307939|Experimental|Screening, active surveillance, and treatment (Arm A)|Participants who meet criteria for the treatment phase (a post-operative HPV ctDNA which rose from initial undetectable to meet HPV16 ctDNA criteria and have no clinical or radiographic evidence of gross disease) will undergo delayed standard of care adjuvant radiation (50-60 Gy administered in 1.8-2 Gy fractions) based on the patient's initial pathology. Treatment will be initiated within 4 weeks of a NavDx result. Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed.
33264562|NCT05307939|Experimental|Screening and deescalated treatment (Arm B)|"Participants who meet criteria for the de-escalated treatment phase (Arm B) will undergo adjuvant radiation (30 Gy administered in 2 Gy fractions) with concurrent chemotherapy.~They will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed and the Study calendar."
33401521|NCT05675410|Experimental|Arm C (ABVD, eBEACOPP, ISRT)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive eBEACOPP regimen IV and PO for 2 cycles and undergo ISRT on study. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
33078765|NCT04656808|Active Comparator|Cognitive behavioral therapy|Following the cognitive behavioral model adapted to caregiving (Losada et al., 2006) and considering other previous CBT intervention studies with dementia caregivers (Gallagher-Thompson et al., 2003), a CBT intervention developed and tested for dementia family caregivers (Márquez-González et al., 2007) was used for this study. Specifically, this intervention consists of different components that are described in more detail in Losada et al. (2011) and Márquez-González et al. (2007): a) a cognitive restructuring module aimed at modifying caregivers' dysfunctional thoughts about caregiving into other, more appropriate thoughts which promote the use of more adaptive coping strategies for caregivers; b) increasing pleasant activities or behavioral activation; c) asking for help skills; and d) relaxation techniques for reducing physiological activation.
33078766|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
33078767|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
33078768|NCT04656457|Active Comparator|resistance exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting) three times daily and five times per week. The 1 repetition maximum (1RM) is measured at baseline and following the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last 6 weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. Time of exercise equal time of rest
33078769|NCT04656457|Active Comparator|aerobic exercise|Aerobic training (AT) program of submaximal intensity will include a 45-minute session five times per week under the supervision of the researcher. Aerobic exercise will consist of three phases: warm-up, training and cool down. At the beginning of exercise session, subjects will have a ten-minute warm-up. The warm up protocol will be slowly running on treadmill. Then, the warm-up phase will be followed by the training phase. At baseline, the training phase will be commenced with two 30- minute running on treadmill at 50% of their maximal heart rate (MHR) in the first week and increased to 70% MHR by the final week of training. By the end of exercise session, subjects will have a five-minute cool down. The cool down protocol will be slowly running on treadmill. The vital measures such as HR and blood pressure was monitored before patient left the department (Dimeo et al.,2016), maximum heart rate will be calculated using the formula: (HR Max =220- age)
33078770|NCT04656613|Experimental|Vaccine|a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection
33078771|NCT04656613|Placebo Comparator|Placebo|a reference group of 250 subjects receiving placebo
33078772|NCT04656769||PERI group|
33078773|NCT04656769||EV group|
33078774|NCT04656574|Experimental|Experimental Group|Experimental group received the course explaining vaginal delivery for the first timethat used simulation-based training.
33078775|NCT04656574|No Intervention|Control Group|Control group received the course explaining vaginal delivery for the first time
33078776|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
33078777|NCT04656340|Active Comparator|Standard rehabilitative care (SC)|Twice weekly physical therapy, occupational therapy and pain psychoeducation
33078778|NCT04656340|Experimental|Complementary and Integrative Health (CIH) therapies in addition to Standard rehabilitate care (SC)|Twice weekly chiropractic, acupuncture, yoga and foam roller instruction, in addition to SC
33078779|NCT04655989|Experimental|Routine first|Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).
33078780|NCT04655989|Experimental|Investigational first|Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).
33078781|NCT04655989|Other|VARRM sub-study|Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
33078782|NCT04656106||Ryzodeg|Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.
33078783|NCT04656262|Experimental|Metronomic cyclophosphamide|Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
33078784|NCT04656262|Active Comparator|Doxorubicin|Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
33078785|NCT04655872|Experimental|[14C]TPN171H|
33078786|NCT04655677|Experimental|Autologous EXP039 administered by intravenous (IV) infusion|Autologous EXP039 administered by intravenous (IV) infusion
33078787|NCT04655560||Women living with HIV|
33078788|NCT02962635||Hemodialysis patients|"A total of 30 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
33078789|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
33078790|NCT04655794||had >= grade 2 adverse reactions|
33078791|NCT04655794||had <2 frade 2 adverse reactions|
33078792|NCT04655443||Control Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that maintained sinus rhythm will be assigned to Control."
33078793|NCT04655443||Afib Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that developed persistent atrial fibrillation will be assigned to Afib."
33264563|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
33264564|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
33264565|NCT00224107|Experimental|Silodosin|Silodosin 8 mg once daily with food
32771065|NCT04793321|Other|healty nulliparous females|"each participant did three conditions:~holding nothing (unloaded).~holding an infant mannequin in arms(arms).~holding an infant mannequin in the baby carrier(carriers)."
32771066|NCT05105997|Active Comparator|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision.
32771067|NCT05105997|Placebo Comparator|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
32771068|NCT05283577|Experimental|Treatment Arm|Each participant will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Each EA session will be approximately 1 hour. Participants in the treatment arm will receive EA at 13 standardized acu-points that were chosen for their therapeutic effects.
33264566|NCT00224107|Placebo Comparator|placebo|Matching Placebo capsule once daily with food
33264567|NCT04696731|Experimental|ALLO-647, ALLO-316|
33264568|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
33264569|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
33078794|NCT04655209|Experimental|M1-Seq group|
33264570|NCT04004871|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
33264571|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
33264572|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
32771069|NCT05283577|Sham Comparator|Control Arm|Each participant in the control arm will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Participants in the control arm will receive electrical stimulation at non-disease related acu-points for approximately 1 hour per session.
32771070|NCT04801433|Experimental|Boleda Supramolecular Active Zinc|Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
32771071|NCT04801433|Active Comparator|Capotetriol scalp solution|30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
32771072|NCT04801433|Placebo Comparator|Supramolecular Hydrogel|30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
33264573|NCT03972007|Experimental|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
33264574|NCT03972007|Experimental|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
33264575|NCT03972007|Sham Comparator|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
33264576|NCT03972007|Sham Comparator|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
33264577|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
32901873|NCT04421976|Experimental|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
33078795|NCT04655209|Experimental|PMC-Seq group|
33078796|NCT04655209|Sham Comparator|MT with sham tDCS|
33078797|NCT04655131|Active Comparator|Protein consumption : 0 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
33078798|NCT04655131|Experimental|Protein consumption : 12.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
33264578|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
33264579|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
33264580|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
33264581|NCT00822380|Experimental|Anemic children|
33078799|NCT04655131|Experimental|Protein consumption : 25 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
33078800|NCT04655131|Experimental|Protein consumption :37.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
33264582|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
33264583|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
33264584|NCT05621811|Experimental|Naronapride 10 mg|
33264585|NCT05621811|Experimental|Naronapride 20 mg|
33264586|NCT05621811|Experimental|Naronapride 40 mg|
33264587|NCT05621811|Placebo Comparator|Placebo|
33264588|NCT00826436||8 subjects for Cohort 1|
33264589|NCT00826436||8 subjects for Cohort 2|
33264590|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
33264591|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
33264592|NCT05619471|Experimental|Subjects with Skin conditions that are candidates for biopsy|
33264593|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
33264594|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
33264595|NCT04044950|Experimental|Arm 1|Approximately 3x10^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
33264596|NCT05616585|Experimental|Pharmacokinetic|Single Day Intervention of 10 test foods
33264597|NCT05616585|Experimental|Dose Response|Six day, 3 level (zero, medium, high dose) controlled feeding study
33264598|NCT00907608|Experimental|1|Receive Darbepoetin alfa
32771073|NCT05105607|Experimental|Cohort 1: 0.25 mg/kg D-4517.2|Participants will be administered a single dose of 0.25 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the safety review committee (SRC) will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
32771074|NCT05105607|Experimental|Cohort 2: 0.5 mg/kg D-4517.2|Participants will be administered a single dose of 0.5 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
33264599|NCT00907608|No Intervention|2|
33264600|NCT00224029|Experimental|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
33264601|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
32771075|NCT05105607|Experimental|Cohort 3: 1.0 mg/kg D-4517.2|Participants will be administered a single dose of 1.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
33264602|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
33264603|NCT04085081|Experimental|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
33264604|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
33264605|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
33264606|NCT05613309||patients with acute varicose hemorrhage in Renmin Hospital of Wuhan University in recent 10 years|In this study, patients with liver cirrhosis and acute variceal bleeding in Renmin Hospital of Wuhan University in the past 10 years will be selected as the research objects. Patients will be divided into survival and death groups according to whether they died 6 hours after admission. The differences in clinical data between the two groups will be compared and analyzed to decide the risk factors for early death and establish a mortality risk prediction model.
33264607|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
33264608|NCT03969979||healthy testis|The patients' non inflamed testis
33264609|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
33264610|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
33264611|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
33264612|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
33264613|NCT05605275||Gram negative|Patients who had at least one blood culture with a gram- isolate during hospitalisation in the surgical ICU
33264614|NCT05605275||Gram positive|Patients who had at least one blood culture with a gram+ isolate during hospitalisation in the surgical ICU
33264615|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
33264616|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
33264617|NCT03967795|Other|All patients|"Citrulline genration test before starting enteral nutrition~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
32771076|NCT05105607|Experimental|Cohort 4: 2.0 mg/kg D-4517.2|Participants will be administered a single dose of 2.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort.
32771077|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
32771078|NCT05206383|Experimental|Positive message|Group A - 30 subjects who will be told that positive message.
32771079|NCT05206383|Experimental|Negative message|Group B - 30 subjects who will be told negative message.
33264618|NCT04086251|Experimental|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
33264619|NCT00907764|Experimental|Regadenoson alone|
32771080|NCT05206383|Experimental|Neutral message|Group C - 30 people who will be told neutral message.
32771081|NCT05472155|Experimental|Oropharyngeal suctioning with a bulb syringe|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a bulb syringe
33078801|NCT04655131|Experimental|Protein consumption : 50 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
33078802|NCT04655131|Experimental|Protein consumption : 62.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
33078803|NCT04655014|Experimental|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
33078804|NCT04655599|Experimental|Olorinab, Then Placebo|Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.
33264620|NCT00907764|Experimental|Regadenoson with exercise|
33264621|NCT00907764|Experimental|Regadenoson with contrast agent|
32771082|NCT05472155|Active Comparator|Oropharyngeal suctioning with a suction catheter|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a suction catheter
33264622|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
33264623|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
33264624|NCT00987987|Experimental|1|1
32771083|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
32771084|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
32771085|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
32771086|NCT05471999|Other|Patients with SBP|
32771087|NCT05104983|Experimental|Sirolimus|Sirolimus
32771088|NCT05104983|Placebo Comparator|Placebo|Placebo
32898303|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series.
33078805|NCT04655599|Placebo Comparator|Placebo, Then Olorinab|Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.
33078806|NCT04654936|Experimental|MIND diet with support|This intervention group are to follow the MIND diet guidelines for 12 weeks with the support of a 12 week online theory driven website and resources
33078807|NCT04654936|Experimental|MIND diet no support|This group are to follow the MIND diet guidelines with no website support
33264625|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
33264626|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
33264627|NCT04504968|Experimental|Intervention group|Multimodal intervention:
33264628|NCT04504968|Placebo Comparator|Usual care group|Usual care group
33264629|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
33078808|NCT04654936|No Intervention|Control|The group follow usual diet
33264630|NCT00223795|Active Comparator|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
33078809|NCT04654858|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used after infiltration or block anaesthesia for affected molar, following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
33078810|NCT04654858|Active Comparator|Performed metal crowns|PMCs (3M Espe, Seefeld, Germany) will be placed after infiltration or block anaesthesia for affected molar, followed by removal of carious dentin and enamel, Tooth preparation for fitting the crown, The correct size of crown will be chosen, and then Cemented with glass ionomer luting cement (KetacCem, 3M Espe).
33264631|NCT00223795|No Intervention|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
32771089|NCT04801511|Experimental|Experimental|"Preoperative concurrent chemoradiotherapy and high-dose intravenous vitamin C :~The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C preoperatively. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25fraction/5weeks. If necessary. During IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C ( 24g/d，QD ) will be delivered on the day of radiotherapy from the beginning to the end of IMRT.~preoperative consolidation chemotherapy: Three additional cycles of neoadjuvant chemotherapy (mFOLFOX6) will be given after the end of IMRT.~TME （total mesorectal excision）or sphincter preserving surgery will be performed approximately the 10th-12th weeks after the end of IMRT. Whether or not to select watch and wait needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."
32771090|NCT04159675||control patients|Patients with idiopathic craniosynostosis
32771091|NCT04159675||HR patients|Patients with craniosynostosis due to HR
32771092|NCT05471765|Experimental|Moderate Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index above fifteen are classified to have moderate obstructive sleep apnea
32771093|NCT05471765|Experimental|Severe Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index with a result higher than thirty are considered to have severe obstructive sleep apnea
32771094|NCT05156229|Experimental|CDK-003|CDK-003 administered subcutaneously every 2 weeks.
33264632|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
33264633|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
33264634|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
33264635|NCT00817310||control|infants born at less than 1500g without IVH on HUS
33264636|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
33264637|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
33264638|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
33264639|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
33264640|NCT00826670|Experimental|Topical decolonization|
33264641|NCT00826670|Placebo Comparator|Placebo|
33264642|NCT05238519|Experimental|Motivational Interview|Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.
32771095|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
32771096|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
32771097|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
32771098|NCT04793009||mesh group|patients undergoing abdominoperineal resection with end colostomy and implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
32771099|NCT04793009||no-mesh group|patients undergoing abdominoperineal resection with end colostomy without implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
32771100|NCT04230759|Active Comparator|5FU+Mitomycin C|Radiochemotherapy for anal cancer
32771101|NCT04230759|Experimental|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
32771102|NCT02704117|Experimental|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
32771103|NCT05615909||Online MR-guided radiotherapy|Prostate cancer patients treated with online MR-guided radiotherapy in the Unity MR-linac.
33264643|NCT05238519|No Intervention|Usual Care|Usual care arm will receive baseline and follow up surveys only.
33264644|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
33264645|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
33264646|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
32771104|NCT05615909||CT-guided radiotherapy|Prostate cancer patients treated with CT-guided radiotherapy (VMAT) in linear accerelators.
33264647|NCT02549612|No Intervention|Control|No intervention is used in this group.
33264648|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
32771107|NCT05471687|Experimental|Patients with CAC ≥ 300 three years ago|Patients with CAC ≥ 300 three years ago with the need for repeat screening. Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score >300 AU and requiring iterative screening for IMS recommended every 3 at 5 years.
32771108|NCT05471687|Experimental|Patients with CAC between 200-299 three years ago|"Patients with CAC between 200 and 299 three years ago, with the need for a reassessment of their cardiovascular risk.~Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score that has become pathological > 300 AU during the reassessment of their cardiovascular risk."
32771109|NCT05471687|Experimental|Patients with a recent positive scintigraphy (< three months)|Patients with a recent positive scintigraphy (< three months) requiring coronary angiography Stable symptomatic diabetic adult patients, suspected of coronary insufficiency in whom the assessment included a positive scintigraphy with indication of coronary angiography in the perspective of revascularization.
32771110|NCT04230369|Experimental|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
32771111|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
32901874|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
33264649|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
33264650|NCT00907842|Experimental|mesh placement|
33264651|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
33264652|NCT00822536|Active Comparator|2|Monotherapy: aspirin
33264653|NCT04015752||diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations includes :~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
33264654|NCT04015752||non diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
33264655|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
33264656|NCT05237973||Neuromuscular disorders|Diagnosed with a neuromuscular disorder such as motor neuron disorder, myopathy or have findings consistent with a peripheral neuropathy.
33264657|NCT05237973||Normal volunteers|No known abnormal muscle or nerve disorders
33264658|NCT00826826|Active Comparator|Amiodarone|
33264659|NCT00826826|Placebo Comparator|Placebo|
33264660|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
33264661|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
33264662|NCT05217615|Experimental|ezParent+ coach|"ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation. Coaches will be trained in active and empathic listening and problem solving techniques to facilitate learning and support of parents."
33401522|NCT05675410|Experimental|Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive brentuximab vedotin IV and nivolumab IV as in arm B and undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
33264663|NCT05217615|Experimental|ezParent|ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.
33264664|NCT05217615|Active Comparator|Active Control+coach|"Active Control - The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation."
33264665|NCT05217615|Placebo Comparator|Active Control|The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks (~1 topic every 1.5 weeks) to match the dose and timing of contact that the intervention groups will receive.
33264666|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
32771112|NCT05471609|Experimental|levodopa/carbidopa oral formulation A|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/100mg LD and inner sachet contains 0mg CD /300mg LD.
32771113|NCT05471609|Experimental|levodopa/carbidopa oral formulation B|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/0mg LD and inner sachet contains 0mg CD /400mg LD.
32771114|NCT05471609|Experimental|levodopa/carbidopa oral formulation C|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 50mg CD/200mg LD and inner sachet contains 50mg CD /200mg LD.
32771115|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
32771116|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
32771117|NCT05370729|Experimental|N-acetyl cysteine (NAC)|Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
32771118|NCT05370729|No Intervention|Intra lipid emulsion (ILE)|Conservative management + ILE infusion 10 ml/hr + normal saline infusion
32771119|NCT05471531|Experimental|Combined immunization group|160 subjects received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
32771120|NCT05471531|Experimental|Non combined immunization group|There were two subgroups in non combined immunization group,and 160 subjects in each subgroup.The non combined immunization subgroup 1 received one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28.The non combined immunization subgroup 2 received one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28.
32771121|NCT05471531|Experimental|Safety group|2520 subjects were enrolled and received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
32771122|NCT04426331|No Intervention|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
32771123|NCT04426331|Experimental|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
32771124|NCT04426331|Experimental|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
32771125|NCT05615831|Experimental|Young adult (19-30 years)|Individuals aged 19-30 who are not physically active will participate in resistance training combined with blood flow restriction.
32771126|NCT05615831|Experimental|Older adults adult (aged 65 years and older)|Individuals aged 65 years and older who are not physically active will participate in resistance training combined with blood flow restriction.
32771127|NCT05104671|Active Comparator|Scapular stabilization exercises|Group I (control group) will receive scapular stabilization exercises.
32771128|NCT05104671|Experimental|Thoracic manipulation.|Group II will receive scapular stabilization exercises and thoracic manipulation.
32901875|NCT05065632||Groupe 1|[1-15[
32901876|NCT05065632||Group 2|[15- 30[
33401523|NCT05675410|Experimental|Arm E (ABVD, AVD)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive AVD regimen for 4 cycles on study. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
32771129|NCT05104671|Experimental|Myofascial release|Group III will receive scapular stabilization exercises and myofascial release by instrument assisted soft tissue mobilization techniques.
32771130|NCT04792619|Experimental|Control|
32771131|NCT04792619|Active Comparator|Study|
32771132|NCT05204667|Experimental|Methocarbamol 380 mg/paracetamol 300 mg (4 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 4 times/day up to 7 days (i.e., every 6 hours±1 hour).
32771133|NCT05204667|Active Comparator|Methocarbamol 380 mg/paracetamol 300 mg (6 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 6 times/day up to 7 days (i.e., every 4 hours±1 hour).
32771134|NCT04801199|Experimental|CPL-2009-0031 140 mg|Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
33078811|NCT04654624|Experimental|Silver Diamine Fluoride|
32771135|NCT04801199|Active Comparator|Sitagliptin 100 mg|Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
32771136|NCT05103423|Experimental|Treatment group 1|
32771137|NCT05103423|Experimental|Treatment group 2|
32771138|NCT05103423|Placebo Comparator|Placebo|
32771139|NCT05102877|Experimental|Sensory level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
32771140|NCT05102877|Experimental|Motor level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
32771141|NCT04340141|Experimental|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
32771142|NCT04340141|Active Comparator|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
32771143|NCT05154357|Experimental|Group 1|Half an hour before the first feeding hour, the infant's heart rate and oxygen saturation will be recorded. Then, he/she will be placed in the elastic sac, positioned and will be allowed to take a rest until the feeding hour for 30 minutes. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When the feeding time begins, the chronometer will be started and it will be stopped when feeding is completed. At the second feeding time, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
32771144|NCT05154357|Experimental|Group 2|Half an hour before the first feeding time of the infant, his/her heart rate and oxygen saturation will be recorded. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped. At the second feeding hour, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be placed in the elastic sac, positioned, and allowed to take a rest until the feeding hour. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
32771145|NCT05153967||Pediatric Myeloablative allo-HSCT|Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
32771146|NCT05153967||Pediatric Standard Disease-Modifying Therapy|Participants ages 4 to 17 years old with SCD who receive standard therapy.
32771147|NCT05153967||Adult Non-Myeloablative allo-HSCT|Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
32771148|NCT05153967||Adult Standard Disease-Modifying Therapy|Participants ages 18 to 65 years old with SCD who receive standard therapy.
32771149|NCT05153811|Experimental|Non-Contingent Condition|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
32771150|NCT05153811|Experimental|mHealth and CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings. Participants will also interact with a mobile health application to facilitate drinking reduction.
32771151|NCT05153811|Experimental|CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
32901877|NCT05065632||Group 3|[30-45[
32901878|NCT05065632||Group 4|[45-60[
32901879|NCT05065632||Group 5|60+
33078812|NCT04654624|Active Comparator|Atraumatic Restorative Treatment|
33078813|NCT00200577|Experimental|TIL+IL2|TIL + IL2
33401524|NCT05675410|Experimental|Arm F (ABVD, brentuximab vedotin, nivolumab)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
33264667|NCT05013996|Experimental|Intervention|Patients randomized to the experimental (MIDSA groupe) will be treated according to the usual methods of each of the centers (CMP / CRIAVS / private practitioners, etc.) completed with the Multidimensional Inventory of Development, Sex, and Aggression-MIDSA groupe Multidimensional Inventory of Development, Sex, and Aggression-inventory tool.
33264668|NCT05013996|Active Comparator|Control|Patients randomized to the control group will be treated according to the usual methods of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
33264669|NCT03762291|Experimental|CVD908ssb-TXSVN|"3 different dosing schedules will be studied (3+3 design). At the beginning, patients will start on the lowest dose (1 of 3 different levels) of TXSVN. Once that dose schedule proves safe, the next group of patients will be started at a higher dose. This process will continue until all 3 dose levels are studied. If the side-effects are too severe, the dose will be lowered or the TXSVN administrations will be stopped. Each patient will receive 2 vaccinations at the same dose, 2 weeks apart, according to the following dosing schedules: The administration will be oral.~Dose Level 1~Day 0: 2 x 10^5 cfu~Day 14: 2 x 10^5 cfu~Dose Level 2~Day 0: 2 x 10^6 cfu~Day 14: 2 x 10^6 cfu~Dose Level 3~Day 0: 2 x 10^7 cfu~Day 14: 2 x 10^7 cfu"
33264670|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
33264671|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
33264672|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
33264673|NCT04087967|Experimental|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
33264674|NCT04087967|Active Comparator|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
33264675|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
33264676|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
33264677|NCT00929448||Immunoglobulin|
33264678|NCT04087577|Experimental|experimental group|conventional physical therapy with mirror therapy
33078814|NCT00200577|No Intervention|control|Patients are not treated
33264679|NCT04087577|Active Comparator|control group|conventional physical therapy
33264680|NCT04196751|Experimental|Clinical Supervision Intervention|All the enrolled participants will be undergoing Clinical Supervision sessions with their selected supervisors for pre-identified objectives for their skill and knowledge development.
32771152|NCT05153421|Experimental|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
32771153|NCT05203575|No Intervention|Control|Control condition
32771154|NCT05203575|Experimental|Weekly nudge in Cycle 2|Weekly nudge intervention in Cycle 2
32771155|NCT05203575|Experimental|Fast-forwarding|Fast-forwarding interventions in both Cycles
32771156|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 2|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 2
32771157|NCT05203575|Experimental|Weekly nudge in Cycle 1|Weekly nudge intervention in Cycle 1
32771158|NCT05203575|Experimental|Weekly nudge|Weekly nudge interventions in both Cycles
32771159|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 1|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 1
32771160|NCT05203575|Experimental|Full intervention|All interventions applied in all Cycles
32771161|NCT05203575|Experimental|Fast-forwarding in Cycle 1|Fast-forwarding intervention in Cycle 1
33264681|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
33264682|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
33264683|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.~18FFDG is considered standard care and has been approved by Health Canada."
32771162|NCT05203575|Experimental|Full in Cycle 1|Fast-forwarding and weekly nudge interventions in Cycle 1
32771163|NCT05445791|Placebo Comparator|Placebo|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus placebo 500 mg twice daily until disease progression.
32771164|NCT05445791|Experimental|Metformin|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus metformin 500 mg twice daily until disease progression.
33078815|NCT04654585|Experimental|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
33082309|NCT04619290|Active Comparator|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
33082310|NCT04619563|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
33264684|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
33264685|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
33264686|NCT05237531|Experimental|Experimental Arm|"Patients in the experimental arm will receive standardized preoperative education in the form of a brief video, interactive quiz, and written handout.~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
33264687|NCT05237531|Active Comparator|Control Arm|"Patients in the control arm will receive education per the provider's preference (current standard of care).~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
33264688|NCT04015206|Experimental|IPT-G+UCT|10 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
33082311|NCT04619329|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
33264689|NCT04015206|Active Comparator|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
33264690|NCT04799223|Experimental|Group receiving the 4 designed foods|The experimental group consumes the 4 foods designed for the study and will follow healthy eating guidelines.
33264691|NCT04799223|Active Comparator|Group with no designed foods|The control group follows healthy eating guidelines.
33264692|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
33264693|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
33264694|NCT05280366|Other|Streamline Surgical System|Streamline Surgical System procedure administered
33264695|NCT05280366|Active Comparator|iStent Inject W|iStent Inject W implanted
33264696|NCT04765449|Experimental|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
33264697|NCT04765449|No Intervention|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
33264698|NCT00926094||1|
33264699|NCT00926094||2|
33264700|NCT00827138|Experimental|DCC-2036|This is a single arm study
33264701|NCT00907998|Experimental|APL180 (first dose level)|
33264702|NCT00907998|Experimental|APL180 (second dose level)|
33264703|NCT00907998|Placebo Comparator|Placebo|
33264704|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
33264705|NCT03907683|Experimental|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
33264706|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
33264707|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
33264708|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:~Are 18 to 85 years old at the time of enrollment;~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);~Are willing to participate in up to four study sessions."
33264709|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:~Are 18 to 85 years old at the time of study enrollment;~Can read, write, and understand English,~Are willing to participate in three planned study sessions."
33264710|NCT04173195|Experimental|Intervention arm|The CT intervention will be administered by the nurse in charge of the chemotherapy 5 min after the initiation. the CT content will be partially script.
33082312|NCT04619329|Active Comparator|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
33082313|NCT00220844|Experimental|Nortriptyline|
33264711|NCT04173195|No Intervention|No intervention arm|Patients assigned to this arm will received current care.
32771165|NCT04801277|Active Comparator|Acupuncture on PC6 and LI4|Acupuncture on bilateral acupoints, that are PC6 and LI4. The pericardium meridian PC6 point (Neiguan) is defined as follows. The patient's four fingerbreadths will be placed on the medial aspect of their forearm with the edge of the 4th finger on the wrist crease. This is then subtracted from the width of the interphalangeal joint of her thumb. The point between the tendons of extensor carpi radialis and palmaris longus was the pericardium meridian PC6 point (Neiguan). The large intestine LI4 point (Hegu) located on the dorsum of the hand, between the first and second metacarpal bones, at the midpoint of the second metacarpal bone and close to its radial border.
33264712|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
33264713|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
33264714|NCT05175885|Experimental|Experimental group|Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
33264715|NCT05175885|Active Comparator|Historical control group|Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
33264716|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
32771166|NCT04801277|Sham Comparator|Acupuncture on Sham acupoints|Acupuncture on bilateral non acupoints. In sham/placebo group, patient will have the acupuncture needles inserted at non-acupoint 2cm radial to PC6 and between 2nd and 3rd metacarpal bone bilaterally, superficial skin piercing (adequate depth to let patient feels needle is inserted)
32771167|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 1|"Starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles.~Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles"
33264717|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
33264718|NCT04015674|Experimental|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
33264719|NCT04015674|Active Comparator|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
33264720|NCT03656133|Active Comparator|Standard Fractionation|Standard Radiotherapy Fractionation
32771168|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 2|3 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
32771169|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 3|10 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
33264721|NCT03656133|Active Comparator|Hyperfractionation|Hyperfractionation
33264722|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
33264723|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
32771170|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 4|30 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
32771171|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 5|100 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
32771172|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 6|200 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
33264724|NCT04044404||Normal|without functional kidney injury
33264725|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
32771175|NCT05477277|Experimental|Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes|
32771176|NCT04792229|Experimental|Experimental Group|"Standing on WBV device (frequency of 40 Hz); 3 Minute vibration with 3 minute rest.~Three times repetition . Total 18-minute vibrational therapy protocol. 3 days session per week"
33082314|NCT00220844|Experimental|Placebo|
33082315|NCT04619212|Other|Standard of Care|Standard of Care
33082316|NCT04619212|Other|new device|new device
33082317|NCT04619251|Experimental|SRD part, active drug, poor metabolizers|
33082318|NCT04619251|Experimental|SRD part, active drug, extensive metabolizers|
33082319|NCT04619251|Placebo Comparator|SRD and MD part, placebo|
33264726|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
33264727|NCT05164575|Experimental|eRP-LOw Intensity (eRP-LO)|an 8-week intervention that includes FOUR virtual visits with a physiotherapist
33264728|NCT05164575|Experimental|eRP-HIgh Intensity (eRP-HI)|an 8-week intervention that includes EIGHT virtual visits with a physiotherapist
33264729|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
33264730|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
33264731|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
33264732|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
33264733|NCT00926250|Experimental|PS-IPC supplementation|
33264734|NCT00926250|Placebo Comparator|Placebo supplementation|
33264735|NCT03627351||Healthy Women and Men|Group of healthy women and men
33264736|NCT04582370|Experimental|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares [Stanislavsky C, 1989]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
33264737|NCT04582370|No Intervention|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
33264738|NCT00908154|Other|Cohort 1|
33264739|NCT00908154|Other|Cohort 4|
33264740|NCT00908154|Other|Cohort 3|
33264741|NCT00908154|Other|Cohort 2|
33264742|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
32771177|NCT04792229|Active Comparator|Control Group|"Stretching exercise (hip adductors ,plantar flexors, external rotators of hip & knee flexors).~Active and passive ROMS to lower extremities. Strengthening exercises (hip and knee extensors, ankle dorsiflexes) 3 Repetitions into 3 day session per week"
32771178|NCT05102175||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
32771179|NCT04800653|Experimental|Stellate ganglion block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
32771180|NCT04800653|No Intervention|Control|Do nothing
32771181|NCT05203263|Experimental|Condition 1 : Prototype (810A-v1) and Frequency of application 1|Application of the prototype (810A-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
32771182|NCT05203263|Experimental|Condition 2 :Prototype (810B-v1) and Frequency of application 1|Application of the prototype (810B-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
32771183|NCT05203263|Experimental|Condition 3 : Prototype (810A-v1) and Frequency of application 2|Application of the prototype (810A-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
32771184|NCT05203263|Experimental|Condition 4 : Prototype (810C-v1) and Frequency of application 2|Application of the prototype (810C-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
32771185|NCT05203263|Active Comparator|Condition 5 : Prototype (810C-v1) and Frequency of application 3|Application of the prototype (810C-v1) at Day 0, Day 14, Day 28, Day 42, Day 56 and Day 70.
32771186|NCT04800497||Patients resected for hepatocellular carcinoma|
32771187|NCT04800497||Patients who underwent surgery for benign diseases|
32771188|NCT05101707|Experimental|CIMT + taVNS|The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia
33264743|NCT00830648|Experimental|1|
33264744|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
33264745|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
33264746|NCT04268901|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for the medical procedure.
32771189|NCT04792307|Other|Neuromuscular electrical stimulation (NMES) to one leg|"NMES left leg, no high protein ice cream supplementation~NMES right leg, no high protein ice cream supplementation"
33264747|NCT04268901|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction.
33264748|NCT04708899|Active Comparator|Cases|cases will receive the proposed program(the arabic version of differential processing training program)
33264749|NCT04708899|Active Comparator|control|controls will receive the computer based auditory training program (CBAT)
33264750|NCT00926484||Tooth Mousse|
33264751|NCT00926484||fluoride varnish|
33264752|NCT00926484||Tooth Mousse + fluoride varnish|
33264753|NCT04371783|Other|Immediate FET group|FET will be performed in the first menstrual cycle following the stimulated IVF cycle
33264754|NCT04371783|Other|Delayed FET group|FET will be performed in the second menstrual cycle following the stimulated IVF cycle
33264755|NCT00930072|Experimental|Block|
33264756|NCT00930072|No Intervention|Standard Care|
33264757|NCT00626522|Experimental|1|
33264758|NCT00626522|Experimental|2|
33264759|NCT00626522|Experimental|3|
33264760|NCT00626522|Placebo Comparator|4|
33264761|NCT00626522|Placebo Comparator|5|
33264762|NCT00626522|Placebo Comparator|6|
33264763|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
33264764|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
33264765|NCT04366791|Experimental|Supportive care (low-dose radiation therapy)|Patients undergo 1 fraction of low-dose radiation therapy.
33264766|NCT05132673||Participants|Those who meet the Eligibility Criteria will be asked to complete online questionnaires and wear a device on your wrist for two weeks that measures your heart rate, physical activity, and sleep. A WHOOP® wrist monitor and charging equipment will be used.
32771190|NCT04792307|Other|High protein ice cream supplementation|"NMES left leg, high protein ice cream supplementation~NMES right leg, high protein ice cream supplementation"
32771191|NCT05101473|Experimental|Exercise therapy|Exercises will be performed with minimal weight bearing on foot soles, as recommended in the literature for people with diabetic peripheral neuropathy.
33264767|NCT00926640|Experimental|1|Belinostat dose escalation
33264768|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
33264769|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
33264770|NCT04656171|Experimental|Minor patients with Fanconi anemia|MRI of hands and forearm, neuropsychological and neuromotor tests
33264771|NCT04656171|Active Comparator|Minor controls|MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
33264772|NCT00830726||1|Healthy volunteers
33264773|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
32771192|NCT05101161|Experimental|Bidirectional Neurofeedback|
32771193|NCT04800419|Experimental|Acceptance and Commitment Therapy (ACT)|ACT will be conducted in a group of 10 for each session. The ACT modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
32771194|NCT04800419|Experimental|Mindfulness-based Stress Reduction (MBSR)|MBSR will be conducted in a group of 10 for each session. The MBSR modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
32771195|NCT04800419|No Intervention|Control|The subjects in the control group will be assigned in the wait-list where either ACT or MBSR will be provided after the study has been completed.
32771196|NCT05336201|Experimental|C-READY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Self-management and goal-setting cognitive remediation
32771197|NCT05336201|Other|Wait-List Control Group|Will receive the same C-READY intervention after a 4-week wait period
32771198|NCT05203185|Experimental|Post-pilot Group|Full time employed Emergency Department providers will use the new CDS tool, Pulmonary Embolism Risk Kalculator (PERK), which includes nudges to improve use and will be integrated into the electronic medical record and will be accessible for 6 months
32771199|NCT05203185|No Intervention|Pre-pilot Group|Full time employed Emergency Department providers used a CDS tool, Pulmonary Embolism Calculator (PE CALC), without nudges to improve use, to reduce unnecessary imaging in the diagnosis of pulmonary embolism (PE) in the emergency department (ED).
32771200|NCT05100537|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
32771201|NCT05100537|Active Comparator|CONTROL GROUP|no intervention
32771202|NCT04800575|Experimental|Semi-permeable film dressing|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
32771203|NCT04800575|Other|sterile gauze and tape dressing|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
32898304|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
33264774|NCT00830726||3|Patients with symptomatic aortic valve stenosis
33264775|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
33264776|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
33264777|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
33264778|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
33264779|NCT00931398|Placebo Comparator|Placebo|
33264780|NCT00827216|Placebo Comparator|Physiologic saline|
33264781|NCT00827216|Active Comparator|Erythromycine|
33264782|NCT00827294|Experimental|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
33264783|NCT03760692|Active Comparator|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
33264784|NCT03760692|Experimental|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
33264785|NCT05097729|Experimental|Stimulation Modality 1|Repetitive TMS will be applied at 100% resting motor threshold intensity to a region of interest located in the parietal cortex, that will be determined based on its connectivity with the hippocampus.
33264786|NCT05097729|Sham Comparator|Stimulation Modality 2|Parameters will be identical to the modality 1, except that the coil will be flipped over.
33264787|NCT05097729|Active Comparator|Stimulation Modality 3|The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.
33264788|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
33264789|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
33264790|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
33264791|NCT04622319|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.
33264792|NCT04622319|Active Comparator|Trastuzumab ematansine (T-DM1)|Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
33264793|NCT00926718|Experimental|Dose 1a|
33264794|NCT00926718|Experimental|Dose 2a|
33264795|NCT00926718|Experimental|Dose 3a|
33264796|NCT00926718|Experimental|Dose 1b|
33264797|NCT00926718|Experimental|Dose 2b|
33264798|NCT00926718|Experimental|Dose 3b|
33264799|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
32898305|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
32898306|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
33078816|NCT04654585|Active Comparator|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
33078817|NCT04654819|No Intervention|Control group|This group made anesthesia application on patients without training on simulators.
33078818|NCT04654819|Experimental|Study group|This group made anesthesia application on patients after training on simulators.
33264800|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
33264801|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
33264802|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
33264803|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
33264804|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
33264805|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
33264806|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
33264807|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
33264808|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
33264809|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
33264810|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
33264811|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
33264812|NCT04015284|Experimental|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
33264813|NCT04015284|Active Comparator|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
33264814|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
33264815|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
33264816|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
33264817|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
33264818|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
33264819|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
33264820|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
33264821|NCT04044092|Active Comparator|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
33264822|NCT04044092|Experimental|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
33264823|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
33264824|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
33264825|NCT03584724|Experimental|Norflo Oro|The study subject will take the entire content of one packet of Norflo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
33264826|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|The study subject will take the entire content of one packet of Placebo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
33264827|NCT00823238|Active Comparator|systemic|
33264828|NCT00823238|Active Comparator|inhaled|
33264829|NCT00931788|Experimental|Intensive pharmacist case management|
33264830|NCT00931788|Active Comparator|Usual care|
33264831|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
33264832|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
33264833|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
33264834|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
33264835|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
33264836|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
33264837|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
33264838|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
33264839|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
33264840|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
33264841|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
33264842|NCT00931866|Experimental|Diclofenac Sodium Patch|
33264843|NCT00931866|Placebo Comparator|Topical Placebo Patch|
33264844|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
32771204|NCT05203029|Experimental|Aerobic exercises|The warm-up for 5 minutes; stretching exercises include stretching the neck to the sides, stretching the muscles of the shoulder girdle, back, and legs for 10 minutes; resistance exercises for 15 minutes, which will initially be applied in a light and weight-bearing manner, and in each session, according to the patient's progress, using free lightweights; light aerobic exercise for 10 minutes standing, sitting and lying down by controlling patients' heartbeat; cool down for 5 minutes.
33264845|NCT04885452||Patients treated with casirivimab/imdevimab according to the ATU protocol|
33264846|NCT04885452||Patients treated with bamlanivimab/etesevimab according to the ATU protocol|
33264847|NCT04885452||Patients treated with Xevudy according to the authorisation for early access (AAP) protocol|
33264848|NCT04885452||Patients treated with Paxlovid according to the authorisation for early access (AAP) protocol|
33264849|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
33264850|NCT00831194|Experimental|Diet plan and PDA|
33264851|NCT04366544|Other|Time Point 1: Baseline/Pre-preparatory Samyama|"Survey link for participant~Survey link for spouse/ control~Stool collection from home~Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
33264852|NCT04366544|Other|Time point 2: Post-Preparatory/Pre-Samyama|"Online Surveys~Participant~Spouse~Stool collection from IIIS/home~Blood sample collection: on site at IIIS/home EEG and fMRI"
33264853|NCT04366544|Other|Timepoint 3: Immediate Post-Samyama|"Online survey to be completed~Survey link for participant~Survey link for spouse~Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
33264854|NCT04366544|Other|Timepoint 4: 3 months Post Samyama|"Blood draw at home by at home phlebotomist~Post program online survey follow up to be completed~Survey link for participant~Survey link for spouse: https~Stool collection from home"
32771205|NCT05203029|Experimental|Laughter yoga|Breathing techniques for 20 minutes including deep breathing, diaphragmatic breathing, tap on immune-boosting centers like thymus; laughter concert for 20 minutes such as laughter for no reason, childish movements, release the inner child; and laughter meditation for 5 minutes.
32898307|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
33264855|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
33264856|NCT00930462|Experimental|Cap-assisted colonoscopy|
33264857|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
33264858|NCT00827840|Active Comparator|2 Risperidone|
33264859|NCT05280288|No Intervention|The control group (Standard care)|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management under follow-up having usual care alone conducted by physicians and therefore not able to use the app Bone@BC in any versions (access denied).
33264860|NCT05280288|Experimental|The intervention group|Intervention: This arm will be assigned to the intervention which will be that the participants will be invited to become active users of the app Bone@BC version 4.0 combined with usual care alone.
33264861|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
33264862|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
33264863|NCT00930618|Experimental|IMN|Isosorbide mononitrate
33264864|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
33264865|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
33264866|NCT00823550|Experimental|A|entecavir 0.5 mg QD
33264867|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
33264868|NCT00937014|Active Comparator|Standard infant formula|
33264869|NCT00937014|Experimental|Test formula|
33264870|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
33264871|NCT00828152|Placebo Comparator|2|On line discussion group.
33264872|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
33264873|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
32771206|NCT05203029|Active Comparator|Yoga|Meditation and deep breathing for 10 minutes; physical posture for 15 minutes; 15 minutes relaxation exercises; and 5 minutes mindfulness practices.
32771207|NCT04349111|Other|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
33078819|NCT04654780|Experimental|tax on purchases|"exposed to high-price purchases of high in foods, including sugary drinks."
33264874|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
32771208|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
32771209|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
33264875|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
32771210|NCT04799951||Breast Surgeon|surgeons having experience in and regularly conducting breast conservation surgery and mastectomy surgeries
32771211|NCT05202639||Continuation of pregnancy|The parents who have chosen to continue pregnancy will be asked to complete a questionnaire.
32771212|NCT05202639||Medical termination of pregnancy|The parents who have chosen to terminate pregnancy will be asked to complete a questionnaire.
32771213|NCT05324579|Experimental|Neurosurgical subjects|Subjects undergoing intracranial neurosurgical procedures
32771214|NCT05148039|Active Comparator|Community cohort|Participants from the Ehlers Danlos UK society community who low diet quality
32771215|NCT05148039|Active Comparator|Clinic cohort|Participants from a Tertiary Neurogastroenterology clinic who have low die quality
32771216|NCT05147337|Experimental|Cohort 1: E2511 10 mg or Placebo|Non-Japanese adult (greater than or equal to [>=] 18 years and less than [<] 55 years old) participants will receive 10 milligram (mg) E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
33078820|NCT04654780|Experimental|subsidies on purchases|exposed to purchases with prices that consider subsidies in fruits and vegetables.
33078821|NCT04654780|Placebo Comparator|Control|It will not be subjected to any intervention and therefore will buy with current or market prices.
33264876|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
33264877|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
33264878|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
33264879|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
32771217|NCT05147337|Experimental|Cohort 2: E2511 20 mg or Placebo|Non-Japanese adult participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
32771218|NCT05147337|Experimental|Cohort 3: E2511 40 mg or Placebo|Non-Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
32771219|NCT05147337|Experimental|Cohort 4: E2511 80 mg or Placebo|Non-Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
32771220|NCT05147337|Experimental|Cohort 5: E2511 20 mg or Placebo|Japanese adult (>=20 years and <55 years old) participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
33078822|NCT04654390|Experimental|DWP16001 Amg, Dapagiflozin Bmg placebo|Tablets, Orally, Once daily
33264880|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
33264881|NCT04469556|Active Comparator|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
33264882|NCT04469556|Active Comparator|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
33264883|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
33264884|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
33264885|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
33264886|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
33264887|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
32771221|NCT05147337|Experimental|Cohort 6: E2511 40 mg or Placebo|Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
33078823|NCT04654390|Active Comparator|DWP16001 Amg placebo, Dapagliflozin Bmg|Tablets, Orally, Once daily
33078824|NCT04654741|Experimental|Progestin Primed ovarian stimulation Group|progestin 10 mg daily during ovarian stimulation
33082320|NCT04619251|Experimental|DDI part, poor metabolizers|DDI part will be initiated after SRD part
33264888|NCT03710850|Experimental|Responders|Responders in terms of fecal butyrate production after acute inulin test.
33264889|NCT03710850|Experimental|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
33264890|NCT05051241|Experimental|GFH018|"The duration of the first cycle is 31 days and the subsequent periods are 28 days.~Subjects will receive treatment with GFH018 until disease progression (clinically- or radiologically-confirmed), occurrence of intolerable toxicity, or subjects discontinue from the study treatment for other reasons."
33264891|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
32771222|NCT05147337|Experimental|Cohort 7: E2511 80 mg or Placebo|Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
32898308|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
33264892|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
33264893|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
33264894|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
33264895|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
33264896|NCT00932334|Other|Usual Care|Participants receive their usual medical care
33264897|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
33264898|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
33264899|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
33264900|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
33264901|NCT04124601|Other|Neoadjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)
33264902|NCT04124601|Experimental|Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)
33264903|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
33264904|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
33264905|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
33264906|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
33264907|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
33264908|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
33264909|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
33264910|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
33264911|NCT05046639|Experimental|Treatment group 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
33264912|NCT05046639|Placebo Comparator|Sham preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
33264913|NCT04565613|No Intervention|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
33264914|NCT04565613|Experimental|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
33264915|NCT04014036|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
33264916|NCT04014036|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
33264917|NCT05007951|Experimental|Test group (GBP510) - Cohort 1|Immunogenicity Cohort
33264918|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 1|Immunogenicity Cohort
33264919|NCT05007951|Experimental|Test group (GBP510) - Cohort 2|Safety Cohort
33264920|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 2|Safety Cohort
33264921|NCT05007951|Experimental|Test group (GBP510) - Cohort 3|Booster Subcohort
33264922|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 3|Booster Subcohort
33264923|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
33264924|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
33264925|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
33264926|NCT00932490|No Intervention|Control|
33264927|NCT04565067||1|COVID-19 recovered adult patients
33264928|NCT04521621|Experimental|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
32771223|NCT05147337|Experimental|Cohort 8: E2511 40 mg or Placebo|Non-Japanese older (>=55 years and less than or equal to [<=] 85 years old) participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
32771224|NCT04791917|Experimental|Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
32771225|NCT04791917|Sham Comparator|Sham Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
32771226|NCT04791605|Experimental|Gait analysis of cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to cemented stem
32771227|NCT04791605|Experimental|Gait analysis of non-cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to non-cemented stem
32771228|NCT05201547|Experimental|Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks|
32771229|NCT05201547|Experimental|Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles.|
32771230|NCT04791683|No Intervention|Control|Infertile couples in the control group were selected by randomization, routine protocols in the clinic were applied
32771231|NCT04791683|Experimental|Experimental|"st interview: Application of data collection tools~nd meeting: Sexual counseling (1 week after the first interview)~rd interview: Sexual counseling (1 week after the first session)~th meeting: Sexual counseling (1 week after the second session)~th interview: Telephone interview (2 months after the first assessment)~th interview: re-application of data collection tools, including the final evaluation"
32771232|NCT05145699|Experimental|Right hemispheric stroke with hemineglect|
32771233|NCT05145699|Active Comparator|Right hemispheric stroke without hemineglect|
32771234|NCT05145699|Other|Normal people|
32771235|NCT05226455|Experimental|venetoclax + azacitidine +/- donor lymphocyte infusion|"Venetoclax + azacitidine +/- donor lymphocyte infusion (maximum 12 cycles). Venetoclax: on D1 to D14 of 28 days cycle ; Phase I: 4 dose levels: 50, 100, 200, 400 mg/d, starting dose at 100 mg ; Phase II: dose defined in the phase I.~Azacitidine 75 mg/m²/d or 50 mg/m²/d (if allohematopoietic stem cell transplantation relapse < 4 months) x 5 days (on D1 to D5 of 28 days cycle)."
32771236|NCT05201313|Experimental|lidocaine spray|nebulization 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
32771237|NCT05201313|Active Comparator|mepivacaine infiltration|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
32771238|NCT05201001|Active Comparator|Standard of Care|"Carboplatin AUC = 5, IV day 1 and pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks~Total:6 cycles or until progressive disease or unacceptable toxicity."
32771239|NCT05201001|Experimental|APX005M|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy~Total:6 cycles or until progressive disease or unacceptable toxicity."
32771240|NCT05201001|Experimental|APX005M+RT|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy External beam radiation therapy; a dose of 0.5 Gy per fraction, administered as single fractions prior to APX005M administration; days 1 & 15 q4 wks x 6 cycles. Maximum 24 wks of therapy; total dose 6 Gy.~Total:6 cycles or until progressive disease or unacceptable toxicity."
32771241|NCT04888585|Experimental|Dose A of ABBV-154|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 12 weeks in the placebo-controlled period, 66 weeks in the long term extension (LTE) period 1 and 104 weeks in LTE period 2.
32771242|NCT04888585|Experimental|Dose B of ABBV-154|Participants in this group will receive dose B of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
32771243|NCT04888585|Experimental|Dose C of ABBV-154 EOW|Participants in this group will receive dose C of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
32771244|NCT04888585|Experimental|Dose C of ABBV-154 E4W|Participants in this group will receive dose C of ABBV-154 SC every 4 weeks (e4w) for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
32771245|NCT04888585|Experimental|Placebo|Participants in this group will receive placebo SC eow for 12 weeks in the placebo-controlled period and will be re-randomized in 1:1 ratio to receive ABBV-154 dose B or C respectively SC eow for 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
32771246|NCT04799561|Experimental|Teleprehabilitation cohort|Patients in this single-arm study will receive multimodal teleprehabilitation.
32771247|NCT05199519|Other|IBI345|Single arm
32771248|NCT04799639|Experimental|paclitaxel + cisplantin + Sindilimab|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,>3 hours cisplantin 70mg/m2，ivdrip，>1 hours Sindilimab 200mg，ivdrip, >0.5 hours
32771249|NCT05144763|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
32771250|NCT05144763|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
32771251|NCT05614973|Active Comparator|Conventional|Percutaneous liver biopsy is carried out through multiple punctures of liver capsule.
32771252|NCT05614973|Experimental|Coaxial/plugging|Percutaneous liver biopsy is carried out through single puncture of liver capsule using coaxial needle and subsequent needle tract plugging.
32771253|NCT04799093||Cannabis users|
32771254|NCT04799093||Normals|
32898309|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
33078825|NCT04654741|Active Comparator|GnRH antagonist|GnRH antagonist 0.25 mg daily during ovarian stimulation
33264929|NCT04521621|Experimental|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33264930|NCT04521621|Experimental|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
32898310|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
33264931|NCT04521621|Experimental|Part 2 Dose Level 1, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33264932|NCT04521621|Experimental|Part 2 Dose Level 2, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33264933|NCT04521621|Experimental|Part 2 Dose Level 3, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33082321|NCT04619251|Experimental|MD part, active drug, poor metabolizers|
33264934|NCT04521621|Experimental|Part 2, Cohort D: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33264935|NCT04521621|Experimental|Part 2, Cohort E: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
33264936|NCT00932724|Experimental|CY-503|
33264937|NCT00932724|Placebo Comparator|Placebo|
33264938|NCT04963413|Experimental|Autologous DCs derived from PBMC loaded with RNA|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
33264939|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
33264940|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
33264941|NCT00932802||Group 1|
33264942|NCT05360199|No Intervention|control group|no recall PROMs group ; without knowledge of previous PROMs scores
33264943|NCT05360199|Active Comparator|intervention group|recall PROMs group ; with knowledge of previous PROMs scores
33264944|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
33082322|NCT04619407||teacher|"Employed in a school in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
33082323|NCT04619407||pupils|"Attending school in Mecklenburg-Vorpommern~Age between 6 to 17 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
33082324|NCT04619407||childcare educators|"Employed in a kindergarten in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
33264945|NCT00937638|Experimental|Modified-DASH Diet|
33264946|NCT00937638|Experimental|BOLD diet|
33264947|NCT00937638|Experimental|BOLD-X|
33264948|NCT03401853|Experimental|Arm I (pembrolizumab, rituximab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity."
33264949|NCT03401853|Experimental|Arm II (pembrolizumab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better, who are experiencing clinical benefit in the judgment of the investigator, may receive obinutuzumab IV on day 1 of cycles 5, 9, 13, 17, 21, and 25."
33264950|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
33264951|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
33264952|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
33078826|NCT04654234||Total-body PET/CT (uExplorer)|Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment
33078827|NCT00177944||patients with funal infections|
33078828|NCT04654156||Pathological group|Patients with pulmonary embolism on thoracic CT angiography
33078829|NCT04654156||Healthy group|Patients without pulmonary embolism on thoracic CT angiography
33078830|NCT04654078|Experimental|Group 1|Group 1
33078831|NCT04654078|Experimental|Group 2|Group 2
33078832|NCT04654078|Experimental|Group 3|Group 3
33078833|NCT04654078|Experimental|Group 4|Group 4
33078834|NCT04654078|Experimental|Group 5|Group 5
33078835|NCT04654078|Experimental|Group 6|Group 6
33078836|NCT04654000|Experimental|Rheopheresis group|"In addition to the standards of care, the experimental group will carry out the rheopheresis in two stages:~Stage 1: induction treatment: 3 apheresis sessions during the first week (w0; i.e. between D1 and D7) and then 2 apheresis sessions each week for 3 weeks (from w1 to w3; i.e. between D8 and D28) ;~Step 2: maintenance treatment with 1 apheresis session per week until the 11th week (i.e. between D29 and D84)."
33264953|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
33264954|NCT04482621|Active Comparator|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
33078837|NCT04654000|Sham Comparator|Sham-apheresis group|In addition to the standards of care, the comparator group will carry out Sham-apheresis sessions according to the same scheme as the rheopheresis sessions of the experimental group.
33264955|NCT04482621|Placebo Comparator|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
32771258|NCT05144373|Experimental|Gross motor intervention|Participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.
32771259|NCT05144373|Experimental|Gross and fine motor intervention|"Besides the body-weight supported treadmill intervention as illustrated above, participants will receive additional fine motor intervention using sticky mittens from about 10 months of age for five months."
32771260|NCT05144373|No Intervention|Control|Participants will not receive specific intervention.
32898311|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
33078838|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
33078839|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
33078840|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
33078841|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
33078842|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
33078843|NCT04653727||Online survey with 3.000 participants using mobile website technology|
33078844|NCT04653532|Experimental|mHealth Technology|Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
33078845|NCT04653532|Active Comparator|Exercise Counselling|Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
33078846|NCT04653649|Experimental|HSP-CAR30 (anti-CD30 CAR T cells)|"Phase I:~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.~Phase IIa:~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."
33078847|NCT04653493|Experimental|CD19 CAR-T cells|Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)
33078848|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
33078849|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
33078850|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
33078851|NCT04653415|Active Comparator|Study Group|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
33078852|NCT04653415|Placebo Comparator|Controls group|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.
33082325|NCT04619407||preschoolers|"Attending kindergarten in Mecklenburg-Vorpommern~Age between 3 to 6 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
33082326|NCT00243399|Experimental|Oxandrolone|
33082327|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
33082328|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
33264956|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
33264957|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
32906352|NCT04201548|Active Comparator|Active Comparator|This is the constant-load Endurance Training (ET) group which will constitute the control group.
32906353|NCT04201548|Experimental|Long High Intensity Interval Training|This is the Long High Intensity Interval Training (Long-HIIT) group.
33078853|NCT04653259|Experimental|Intervention Group|The INT group will meet with their health coach over the phone or video chat. The health coach will orient them to the LyfeMD, app and ensure the participant has received a nutrition plan in the app. They will be asked to complete the app assessment tools to design a personalized nutrition, physical activity and yoga and meditation program. They will set goals in each area they are interested in implementing. The health coach will then follow-up by phone, video or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach will use the following schedule to discuss app related content: First visit nutrition content; second visit behaviour change tools; third visit Yoga, meditation and breathing plans, and; the fourth visit the physical activity plans. The health coach will also be available to answer questions when required using email. Goal attainment will be collected weekly within the app.
33078854|NCT04653259|No Intervention|Conventional Management Group|The CM group (n=22) will receive conventional care as well as a similar health coaching schedule as the intervention group. The health coach will meet the patient over the phone or video chat to outline their role over the next 3 months and to provide general nutrition guidelines using Canada's Food Guide and Alberta Health Services online resources. The health coach will then follow-up by phone, video chat or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach session topics will be the same as the intervention group. For example, the second visit will provide online resources from Alberta Health Services focused on promoting behaviour change, the third visit will orient the patient to Alberta Health Services focused online stress management tools and the final visit will share online versions of the Canadian guidelines for physical activity and sedentary time.
33078855|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
33078856|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
33078857|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
33078858|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
33078859|NCT04653376||Chronic tonsillitis|Patients with tonsil sizes grade 1 and 2, and tonsillectomy indications included frequently recurrent tonsillary infection, sore throat, and malodorous mouth problems were accepted as the chronic tonsillitis group.
33078860|NCT04653376||Tonsillar hypertrophy|Patients with tonsil size grades 3 and 4 and tonsillectomy indications included obstructive symptoms such as snoring, open mouth breathing, difficulty in breathing, and swallowing problems were accepted as the tonsillar hypertrophy group.
33078861|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
33078862|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
33078863|NCT04653025|Experimental|Test group|Test group patients received an immediate implant with provisional restoration, bone augmentation and soft tissue grafting
33078864|NCT04653025|Experimental|Control group|Patients in the control group received soft tissue grafting after tooth extraction and an implant with bone augmentation after 6 weeks of healing.
33078865|NCT04653103||Patients with obesity|Subjects with different classes of obesity
33078866|NCT04652635|Active Comparator|Nail plate removal, nail bed repair|Participants will undergo nail plate removal and nail bed repair, and follow up at clinic visits at 1 week, 3 months, and 6 months
33078867|NCT04652635|No Intervention|Observation|Participants will follow up at clinic visits at 1 week, 3 months, and 6 months
33078868|NCT04652752|Experimental|CONNETTIVINA HI TECH patch|CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management
33078869|NCT04652791||Wangbi Capsule|Patients who are taking Wangbi Capsule for the treatment.
33078870|NCT04652791||Other drugs|Patients who are not taking Wangbi Capsule for the treatment.
33078871|NCT04652284|Active Comparator|Rifabutin full dose|oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days
33078872|NCT04652284|Active Comparator|Rifabutin low dose|oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days
33078873|NCT04652284|Active Comparator|Standard of Care|Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available
33078874|NCT04652323||Control|Twenty-one empty polyethylene tubes remained empty to bewere used as in the control group.
33264958|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
33264959|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
33264960|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
33264961|NCT00624338|Experimental|Atacicept 75 mg|
33264962|NCT00624338|Experimental|Atacicept 150 mg|
33264963|NCT00624338|Placebo Comparator|Placebo|
33264964|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
33264965|NCT00933192||Group 1: young healthy patients|
33264966|NCT00933192||Group 2: old healthy patients|
33264967|NCT03977454|Experimental|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
33264968|NCT03977454|Active Comparator|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
33264969|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
33264970|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
33264971|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
33264972|NCT00831350|Experimental|ranibizumab|
33264973|NCT00933348|Active Comparator|OPAL A plus standard wound care|
33264974|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
33264975|NCT00823628|Active Comparator|iopromide|
33264976|NCT00823628|Experimental|iodixanol|
33264977|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
33264978|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
33264979|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
33264980|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
32771261|NCT04790981|Active Comparator|selected physical therapy program group|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
32771262|NCT04790981|Active Comparator|motor imaginary training and selected physical therapy program group|"The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following.~Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise"
32771263|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
32771264|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
32771265|NCT04798937|Experimental|Intervention group|Youth in this group received usual care, consisting of medical consultations, in combination with a health education program based on motivational interviewing provided by a nurse
32771266|NCT04798937|No Intervention|Control group|Youth in this group received usual care only consisting of medical consultations
33264981|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
33264982|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
33264983|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
33264984|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
33264985|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
33264986|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
33264987|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
33264988|NCT04014582|Experimental|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
33264989|NCT04014582|Active Comparator|Control|This group will participate in diabetes education and an individual intervention.
33401525|NCT05675410|Experimental|Arm G (ABVD, eBEACOPP, ISRT)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive treatment as in arm C. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
33078875|NCT04652323||ProRoot MTA|ProRoot White MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
33078876|NCT04652323||Medcem MTA|Medcem MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
33078877|NCT04652323||Medcem Pure Portland Cement|Medcem Pure Portland Cement mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
32771267|NCT05097261|Experimental|Ketamine|"Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h. Study patients weighing over 120 kg will not exceed the maximum dose of 120mg/kg of ketamine.~The study medication will be started within 6 hours after randomization. The IMP, ketamine, will be provided directly to each Participating Site by the official supplier of ketamine for Belgium (Pfizer)."
32771268|NCT05097261|Active Comparator|Placebo|The placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
32771269|NCT05629897|Experimental|Intervention|They will perform an initial test of processing speed, attentional span and executive control. After this test, they will start the training programme. It consists of 40 sessions of cognitive stimulation, distributed over 8 weeks of treatment with a frequency of five sessions per week. In the last session, a final test will be performed, the same as the initial one.
33078878|NCT04652011||Patients with chronic pelvic pain|Patients with chronic pelvic pain and a benign gynecologic disease associated, referring to our Unit, medically or surgically treated from 2010 to 2019
33078879|NCT04651933||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
33078880|NCT04651933||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
32771270|NCT05629897|No Intervention|Waiting list|"They will perform an initial test of processing speed, attentional span and executive control. In the last session, 8 weeks after the initial test, a final test will be performed, the same as the initial one.~They will have the opportunity to perform the same training as the experimental group after performing the final test. At 8 weeks, patients on the waiting list will be taught, if the wish, how to use the platform to perform the stimulation. They will be offered cognitive training with COPERIA-COG under the same conditions, periodicity, automatic reminders and calls from the psychologist as in the intervention group."
32906354|NCT04201548|Experimental|Short High Intensity Interval Training|This is the Short High Intensity Interval Training (Short-HIIT) group.
32906355|NCT01837784||Elderly patients|
33078881|NCT04652128|Experimental|zoledronate|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
33078882|NCT04652128|Placebo Comparator|saline|Subject will receive a single infusion of physiological saline 100mL intravenously.
33078883|NCT04651738|Experimental|Study group|All eligible participants consenting to participate the study.
33078884|NCT04651426|Placebo Comparator|Placebo|The Placebo is a Patch identical to the F3 and F4 patches in aesthetics but without any biomineral, therefore with no reflectance ability.
33078885|NCT04651426|Active Comparator|F3 Patch|The F3 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum 2 m x kg
33078886|NCT04651426|Active Comparator|F4 Patch|The F4 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum of 4 m x kg
33078887|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
33078888|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
33078889|NCT04651777|Experimental|Participants with poorly controlled moderate to severe asthma|Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.
33078890|NCT04651231|Active Comparator|tight flap technique group (forty patients-group A)|in this arm forty patients did tight flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap.
33078891|NCT04651231|Experimental|loose flap technique (securing sutures) group (forty patients-group B).|in this arm forty patients did loose flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B.
33078892|NCT04650958|Active Comparator|STN DBS stimulation group|In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
33078893|NCT04650958|Sham Comparator|Sham stimulation group|In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
33078894|NCT00178412|Experimental|1|Treatment group
32771271|NCT05154539|Experimental|Test Group 1 (TG1)|"TG1 participants are testing the new digital assessment routine in a private setting.~Audiology assistants in private hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The private hearing clinics also conduct hearing aid treatment for TG1 participants with simple hearing loss.~TG21 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
32771272|NCT05154539|Experimental|Test Group 2 (TG2)|"TG2 participants are testing the new digital assessment routine in a public setting.~Audiology assistants in public hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The public hearing clinics also conduct hearing aid treatment for TG2 participants with simple hearing loss.~TG2 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
32906356|NCT01837784||Patients with diabetes mellitus|
32906357|NCT01837784||Patients with heart failure|
32906358|NCT01837784||Patients with resistant hypertension|
33078895|NCT00178412|Active Comparator|2|Comparison Group
33078896|NCT04651309|Other|Ultrasound group|Labor progress assessed by US, avoiding digital exams as much as possible;
33264990|NCT04013958|Active Comparator|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
33264991|NCT04013958|Experimental|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
33078897|NCT04651309|No Intervention|Control group|Labor progress assessed according to the regular protocol
33078898|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
33078899|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
33078900|NCT00557986|Other|B|Surgery group
33078901|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
33078902|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
33264992|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
33264993|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
33264994|NCT00933660|No Intervention|Control-2|No intervention
33264995|NCT00933660|Experimental|Experimental-1|Web-based training only
33264996|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
33264997|NCT00938574|Experimental|Drug Atu027|
33264998|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
33078903|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
33264999|NCT00938730|Experimental|2. YM150, Dose X, once daily|
33265000|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
33265001|NCT00938730|Experimental|4. YM150, Dose Y once daily|
33265002|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
33265003|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
33265004|NCT00938730|Active Comparator|7. Warfarin|
33265005|NCT00933816|Experimental|Sorafenib with Low-dose FP|
33265006|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
33265007|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
33265008|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
33265009|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
33265010|NCT00990015|Experimental|PF-04308515|
33265011|NCT00990015|Placebo Comparator|Placebo|
33265012|NCT04237545|Experimental|T3 short implant|The short implants are available in lengths of 5mm and 6mm and in diameters of 5mm and 6mm. For study both configurations, T3 short without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 short with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
33265013|NCT04237545|Active Comparator|T3 standard length|The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
33265014|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
33265015|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
33265016|NCT05360121|Experimental|Muscle energy technique+ Thermotherapy +Back Strengthening exercise|
33265017|NCT05360121|Active Comparator|General stretching+ Thermotherapy +Back Strengthening exercise|
33078904|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
33265018|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
33265019|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
33265020|NCT04004715|Experimental|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
33265021|NCT04004715|Active Comparator|Whey Protein|commercially available whey protein isolate
33265022|NCT04004715|Active Comparator|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
33265023|NCT05360043|Experimental|LPNY side|1064-nm LPNY (Gentle YAG, Candela ®, USA)
33265024|NCT05360043|Experimental|NAFL side|1565-nm NAFL(ResurFX mode, M22, Lumenis ®, Yokneam, Israel)
32771273|NCT05154539|Active Comparator|Control Group 3 (CG3)|"CG3 participants will be assessed conventionally by a private practicing ENT specialist in the Region of Northern Jutland in Denmark at physical consultation in accordance with current Danish practice. CG3 participants with simple hearing loss can choose whether hearing aid treatment should be conducted in either a private or a public hearing clinic.~CG3 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
32771274|NCT04798703|Experimental|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|
33265025|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
33265026|NCT04004637|Experimental|CD7 CAR-T cells Infusion|
33265027|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
32771275|NCT04798313|Experimental|MW031|MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
33265028|NCT00538629||schizophrenic|patients with schizophrenia
32771276|NCT04798313|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.
33078905|NCT04650997|Experimental|Combined|12 weeks eccentric exercise combined with 6 sessions of extracorporeal shockwave therapy in the initial 6 weeks
33078906|NCT04650997|Sham Comparator|Exercise|12 weeks eccentric exercise combined with 6 sessions of sham extracorporeal shockwave therapy in the initial 6 weeks
33265029|NCT00538629||bipolar disorder|patients with bipolar disorder
33078907|NCT04650724|Experimental|T cell infusion agent targeting BCMA chimeric antigen receptor|
33265030|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
33265031|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
33265032|NCT04232163|Experimental|Immediate Treatment Group|Participants will receive the intervention right away
33265033|NCT04232163|No Intervention|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
33265034|NCT04188327|Sham Comparator|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
33265035|NCT04188327|Experimental|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
33265036|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
33265037|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
33265038|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
33265039|NCT04211727||Cohort 1|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
33265040|NCT04211727||Cohort 2|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
33265041|NCT03025035|Experimental|Pembrolizumab + Olaparib|This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.
33265042|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
33265043|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
33265044|NCT04003935||Control|Continuing habitual diet and lifestyle.
33265045|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
33265046|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
33265047|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
33265048|NCT04004013|Active Comparator|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
33265049|NCT04004013|Placebo Comparator|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
33265050|NCT05359497|Other|Additional sequences and extra MRI|"PSC patients, suspected for having a dominant stenosis, that undergo additional LMS sequences next to standard care MRI prior to ERCP and an additional MRI/MRCP with additional LMS sequences 8 weeks after ERCP.~MRI images will be analysed by the post-processing tool called MRCP+ and Liver Multiscan, which are performed after the MRI is performed."
33265051|NCT05279079||Group 1|Drug-associated AP: patients aged 18 or more years undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
33265052|NCT05279079||Group 2|Other cause AP: patients aged 18 or more years not undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
33265053|NCT05279079||Group 3|Chronic pancreatitis: patients aged 18 or more years with symptomatic chronic pancreatitis confirmed by CT or MRI
33265054|NCT05279079||Group 4|Pancreas cancer: patients aged 18 or more years with biopsy proven pancreas cancer
33265055|NCT05279079||Group 5|Diabetes mellitus: patients aged 18 or more years with type 1 or type 2 diabetes mellitus in receipt of insulin or oral hypoglycaemics
33265056|NCT05279079||Group 6|Healthy volunteers
33265057|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
33265058|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
33265059|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
33265060|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
33265061|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
33265062|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
33265063|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
33265064|NCT04004091|Experimental|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33265065|NCT04004091|Experimental|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33078908|NCT04650802|Experimental|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
33078909|NCT00205920|Experimental|single|BLVR Treatment
33265066|NCT04004091|Experimental|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33265067|NCT04004091|No Intervention|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33078910|NCT04651036|Experimental|Pegfilgrastim biosimilar product|QL0605 subcutaneously at a dose of 6 mg/0.6 mL.
33265068|NCT04004091|No Intervention|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33265069|NCT04004091|No Intervention|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
33265070|NCT04025229|Experimental|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
33078911|NCT04651036|Active Comparator|US Neulasta|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
33078912|NCT04650685|Experimental|The novel Salvadora persica toothbrush|The novel toothbrush is under Al-Abyad Miswak brand that will be supplied by Insight Prestige Sdn Bhd. Participants are expected to use this oral hygiene tool for 3 weeks.
33265071|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
33265072|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
33265073|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation~100 Patients after CEASE Implementation~Exit Interview and Tobacco Use Survey"
33265074|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
33265075|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
33265076|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services~100 patients in usual care~Exit Interview and Tobacco Use Survey"
33265077|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
33265078|NCT02548130||Patients before MELD score|Recipients before the MELD score
33265079|NCT02548130||Patients after the MELD score|Recipients after the MELD score
33265080|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
33265081|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
33265082|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
32771277|NCT05614661|Experimental|Mom Power|Mom Power is an evidence-based 13-session psychosocial mother-child group intervention that improves sensitive caregiving, parental stress, and depression
33265083|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
33078913|NCT04650685|Experimental|The Salvadora persica (miswak) chewing sticks|The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
33078914|NCT04650685|Other|Standard toothbrush and toothpaste (control)|Participants will be given straight-handle soft-bristle Oral-B™ standard toothbrush and Colgate® fluoride tooth. Participants are expected to use this oral hygiene tool for 3 weeks.
33265084|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
33265085|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
33265086|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
33265087|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
33265088|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
33265089|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
33265090|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
33078915|NCT04650334|Other|Perinatal Collaborative Care|Experimental: Perinatal Collaborative Care in Can Tho, Vietnam This is an active treatment arm consisting of 3 health centers receiving training in collaborative care and enrollment of a total of 100 perinatal patients into collaborative care.
33265091|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
32771278|NCT05614661|Sham Comparator|Control|Controls participants for the intervention receive 12 weekly mailings, with content relevant for the postpartum period (i.e., information on baby sleep, developmental milestones, box breathing and other self-care/coping strategies, fun games to play with a baby, and community resources), but devoid of specific attachment-based MP parenting concepts; plus 12 brief check-in phone calls verifying that material was received.
32771279|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
32771280|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
32771281|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
33078916|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
33078917|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
33078918|NCT04650412|Experimental|Intervention|Bundle of comorbidities care
33265092|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
32771282|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
32771283|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
32771284|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
32771285|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
33078919|NCT04650412|No Intervention|Control|Standard care
33078920|NCT04650373||Surgical management|Underwent bariatric surgery
32771286|NCT05615675|Experimental|Virtual Reality|Patients undergo prone pain procedure with virtual reality distraction
32771287|NCT05615675|No Intervention|Control|Patients undergo prone pain procedure without virtual reality distraction
32771288|NCT05132855|Experimental|Booster group 1 (BNT162b2 30ug)|The participants in this group will receive BNT162b2 30ug as the booster dose.
33078921|NCT04650373||Non-surgical management|Patients treated medically
33078922|NCT04650763|No Intervention|Control Group|Dental implant was placed in these patients following full protocol of immediate implant placement.
33265093|NCT00828698||Acute Myocardial Infarction patients|
33265094|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
33265095|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
33265096|NCT04044014|Active Comparator|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
33265097|NCT04044014|Active Comparator|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
33265098|NCT04044014|Active Comparator|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
33265099|NCT04044014|Active Comparator|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
33265100|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
33265101|NCT00828776|Experimental|1|Heparin Cristália
33265102|NCT00828776|Active Comparator|2|Heparin - Roche
33265103|NCT05361135|Experimental|PET/CT|Enhanced imaging with PET/CT
33265104|NCT05361135|No Intervention|Routine Imaging|Standard of Care Imaging
33265105|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
33265106|NCT02617251||neonatology patients|neonatology patients
33265107|NCT02617251||paediatric patients|paediatric patients
33265108|NCT04004247|Experimental|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
33265109|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
33265110|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
33265111|NCT04004169|Experimental|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
33265112|NCT04004169|Sham Comparator|Arm 2: Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
33265113|NCT04043858|Experimental|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
33078923|NCT04650763|Experimental|PRP Group|In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.
32743158|NCT04937673|Experimental|Camrelizumab+ Paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
33265114|NCT05359419|Experimental|Ameluz|AMELUZ® (aminolevulinic acid hydrochloride) gel, 10% with its approved light source (BF-RhodoLED® lamp, 635 nm ± 9 nm, Biofrontera, Inc., Wakefield, MA, US)
33265115|NCT05359419|Active Comparator|Levulan|LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution, 20% with its approved light source (BLU-U® Blue light photodynamic Therapy Illuminator Model 4170, 417 nm ± 5 nm, DUSA Pharmaceuticals, Wilmington MA, US)
33265116|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
33265117|NCT03922971|Other|National comparison|Ability to view center's rate compared with all others
33265118|NCT03922971|Other|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
33265119|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
33265120|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
33265121|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
33265122|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
33265123|NCT00828932|Experimental|Lorcaserin 10mg|
33265124|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
33265125|NCT00537771|Active Comparator|2|Tamoxifen
33265126|NCT00831740|Experimental|Speech Therapy|
33078924|NCT04649983|Experimental|Arm 1|Patients will be be treated with CD19 and CD22 CAR-T cells
33078925|NCT04649749||Patients - bionic hand acquired|3 adult patients who acquired a bionic hand at the Medical University of Vienna after a traumatic brachial plexus lesion.
33265127|NCT00831740|Active Comparator|ACT NoW Visitor|
33265128|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
33265129|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
33265130|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
33265131|NCT00831818||2|Mothers of healthy infants who do not breastfeed
33265132|NCT00831896|Experimental|1|TAK-701
33265133|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
33265134|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
33265135|NCT00823940|Other|Cohort B1|Glucagon challenge test
33265136|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
33265137|NCT04043546|Experimental|Exercise intervention|
33265138|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
33265139|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
33265140|NCT00829322|Experimental|Treatment group|
33265141|NCT00829322|Placebo Comparator|Control group|
33265142|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
33265143|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
33401526|NCT05675410|Experimental|Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients receive ABVD regimen IV for 2 cycles on study. Patients receive treatment as in arm D. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
33401527|NCT04057118|Experimental|SKI-O-703 100 mg|
32771289|NCT05132855|Experimental|Booster group 2 (mRNA-1273 50ug)|The participants in this group will receive mRNA-1273 50ug as the booster dose.
32771290|NCT05132855|Experimental|Booster group 3 (mRNA-1273 100ug)|The participants in this group will receive mRNA-1273 100ug as the booster dose.
33265144|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
33265145|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
33265146|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
33265147|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
33265148|NCT00829478|Placebo Comparator|1|Usual Care
32771291|NCT05132855|Experimental|Booster group 4 (MVC-COV1901 15ug)|The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
33265149|NCT00829478|Experimental|2|Intervention
33265150|NCT00991419|Experimental|A|[18F]4694
33265151|NCT00829556|Experimental|1|
33265152|NCT00829556|No Intervention|2|Standard Surgical skin preparation
33265153|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
33265154|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
32771292|NCT05197257|Experimental|Men with pathologically proven prostate adenocarcinoma|The intervention is a PET scan with the radiolabelled PSMA ligand, 68Ga-PSMA-11. The PET may be combined with a CT scan as a PET/CT or an MRI scan as PET/MRI. 68Ga-PSMA-11 PET/CT will be acquired using a modern digital GE PET/CT scanner or a modern digital PET / MRI scanner.
32771293|NCT05141799|Active Comparator|high-intensity laser therapy (HILT)|"we will apply the HILT device to the most painful area of the wrist in two phases. In both phase I and phase II, the laser will be applied using continuous circular movements.~The first three sessions (phase I) will be used to provide analgesic effects at an intermittent phase, applying a 75 sec, 8 W, 6 J/cm2 treatment for a total of 150 J of energy. The subsequent six sessions (phase II) will provide a biostimulatory effect at a continuous phase, applying a 30 sec, 6 W, 120 to 150 J/cm2 treatment. The HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks."
33265155|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
33265156|NCT00829634|Other|l-methamphetamine|
33265157|NCT05277753|Experimental|CART/CTL/DCvac cells to treat T-ALL|
33265158|NCT00991497|Active Comparator|24 hours compression bandaging|
33265159|NCT00991497|Active Comparator|5 days compression bandaging|
33265160|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
33265161|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
33265162|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
33265163|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
33265164|NCT00832052|Experimental|Cohort 4|
33265165|NCT00991575||Diabetes, type 1|
33265166|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
33265167|NCT04003467|Experimental|EBP05 1.5mg|subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
33265168|NCT04003467|Experimental|Placebo for EBP05 0.5mg (1, 2, 3 or 5)|subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
33265169|NCT04003467|Experimental|EBP05 2.5mg|subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
33265170|NCT04003467|Experimental|EBP05 0.5mg|subjects will be randomly assigned to receive 1 tablet of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
33265171|NCT04003467|Experimental|EBP05 1.0mg|subjects will be randomly assigned to receive 2 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
33265172|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
33265173|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
33265174|NCT05361057|Experimental|venetoclax pluse azacitidine arm|azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21
33265175|NCT05361057|Active Comparator|venetoclax pluse DA arm|daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
33265176|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
33265177|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
33265178|NCT00829946|Experimental|2|
33265179|NCT04016792|Placebo Comparator|Placebo|Placebo qd
33265180|NCT04016792|Experimental|SPN-812|200 mg SPN-812
33265181|NCT04044170|Experimental|Poziotinib|"Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
33265182|NCT00832364|Experimental|1|U0279 and Injectable Biologic
33265183|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
33265184|NCT00832442||Beta blocker|
33265185|NCT00832442||Placebo|
33265186|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
33265187|NCT00830414|Experimental|1|
33401528|NCT04057118|Experimental|SKI-O-703 200 mg|
33265188|NCT00830414|Active Comparator|2|DEPO-PROVERA®
33265189|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
33265190|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
33078926|NCT04649749||Patients - bionic hand not yet acquired|3 patients eligible for the bionic hand prior to a possible amputation.
33078927|NCT04649749||Control subjects|Ten control subjects will be included for comparison.
33265191|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
33078928|NCT04650139||successful CTO|
33078929|NCT04650139||non- successful CTO|
33265192|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
32771294|NCT05141799|Sham Comparator|sham HILT|We will apply the HILT device to the most painful area of the wrist by using continuous circular movements, but the laser instrument will switched off during applications. The sham HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks.
32771295|NCT05105711|Experimental|Primary care providers|Providers who treat 11-12 year old adolescent patients in participating Kaiser Permanente Washington pediatric and family medicine practices.
32771296|NCT05141175|Experimental|Hypertension patients|Patients with documented diagnosis of hypertension and their most recent office systolic BP average measured using automated office BP is ≥140 mmHg systolic or ≥90 mmHg diastolic and they are currently prescribed at least one BP-lowering medication will be recruited.
32771297|NCT04345289|Active Comparator|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
33265193|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
33265194|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
33265195|NCT00837278||2 Control|Spontaneously conceived pregnancies.
33265196|NCT00837356|Experimental|Advate®/turoctocog alfa|
33265197|NCT04472000|Experimental|Vitamin C|Patients who are assigned to the experimental treatment group will be given extended release capsules with 500 mg of ascorbic acid orally two times daily, packed in PET/PP-bottles identical as used for the licenced product.
33265198|NCT04472000|Placebo Comparator|Placebo|The control intervention of this study consists of treatment with no active substance (placebo) but in the same schedule as the experimental treatment (verum).
33265199|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
33265200|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
33265201|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
33265202|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
33078930|NCT04649827||COVID-19|Patients with confirmed COVID-19 by RT-PCR or serological test
33078931|NCT04650022||TPCIV-ABAO|TPCIV-ABAO
33078932|NCT04650061|Experimental|PIMA Group|"MEntA: Educational & Training Program~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~Identification of Care plan and Schedule next visits~Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan"
33265203|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
33265204|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
33265205|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
33265206|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
33265207|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
33265208|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
33265209|NCT00837746||1|Women taking risedronate for 5 years
33265210|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
33265211|NCT00832910||2|
33265212|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
33265213|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
33078933|NCT04650061|Active Comparator|Control|"Training program~Schedule next visits~Follow-up D21-D90-D120-D180 using the same process: visit at home or phone."
33078934|NCT04649554|Experimental|Experimental: ExAblate 4000 System|Exablate treatment on Neuropathic Pain
33078935|NCT04649437|Other|Symptomatic patients|Subjects with symptoms of atrial fibrillation i.e. AF-6 sum score 30 points or more.
33078936|NCT04649437|Other|Asymptomatic patients|Subjects with no symptoms of atrial fibrillation i.e. AF-6 sum score = 0.
33078937|NCT04649281|Other|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
33265214|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
33265215|NCT04043702||no treatment|all patients' vs no treatment ( control group).
33078938|NCT04638556||Normal|A healthy, disease-free population.
33078939|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
33265216|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
33265217|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
33265218|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
33265219|NCT00833066|Placebo Comparator|Placebo|
33265220|NCT00833066|Experimental|gpASIT 25|
33265221|NCT00833066|Experimental|gpASIT 100|
33265222|NCT00833066|Experimental|gpASIT 400|
33265223|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
33265224|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
33265225|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
33265226|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
33265227|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
33265228|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
33265229|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of nine years also by the child itself.
33265230|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography, spirometry and actigraphy.
33265231|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of 1,000 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
33265232|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
33265233|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
33265234|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
33265235|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
33265236|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
33265237|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
33265238|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
33265239|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
33265240|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
33265241|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
33265242|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
33401529|NCT04057118|Experimental|SKI-O-703 400 mg|
33230652|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
33230653|NCT04654468|Experimental|Crovalimab|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
32771298|NCT04345289|Placebo Comparator|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
32771299|NCT05141019|Experimental|Immediate panel-based pharmacogenetic genotyping|Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and have their results both entered into their electronic health record as well as provided to them within 2-4 weeks from enrollment.
32771300|NCT05141019|Other|Delayed panel-based pharmacogenetic genotyping|Subjects assigned to delayed panel-based pharmacogenetic genotyping will be tested, but their results will not be released until after their participation in the study has ended (12 months after enrollment).
32771301|NCT04343573|Experimental|Proton CSI Followed by Standard of Care (NSCLC & Breast)|Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
32771302|NCT04343573|Experimental|Standard of Care|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
32771303|NCT04343573|Other|Proton CSI Followed by Standard of Care (Other Solid Tumors)|(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization. Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
32771304|NCT05195463|Experimental|First group|Core stabilization exercises
32771305|NCT05195463|Experimental|Second group|Combination of core stabilization and abdominal corset
32771306|NCT05195463|Experimental|Third group|Only abdominal corset
33230654|NCT00699959||1|patients with heart failure
32771307|NCT05139615|Experimental|APD418 (Part A: Dose Cohort 1-5)|
32771308|NCT05139615|Experimental|APD418 (Part B: Dose Group 1 and 2)|
32771309|NCT05139615|Placebo Comparator|Placebo (Part A: Cohort 1-5 and Part B)|
32771310|NCT04343105|Sham Comparator|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
32771311|NCT04343105|Experimental|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
32771312|NCT04342793|Placebo Comparator|Placebo|Placebo
32771313|NCT04342793|Experimental|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
32771314|NCT04342793|Experimental|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
32771315|NCT05624359|Experimental|ropivacaine plus FA|5 mL FA (50 mg; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline
32771316|NCT05624359|Active Comparator|ropivacaine alone|15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline
32906359|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
33230655|NCT00699959||2|patients without heart failure
33230656|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
33230657|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
33230658|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
33230659|NCT00814216|Experimental|QAV680|
33230660|NCT00814216|Placebo Comparator|Placebo|
33230661|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
33230662|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
33230663|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
33230664|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
33230665|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
33230666|NCT00799266|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
33230667|NCT00799266|Placebo Comparator|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
33230668|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
33230669|NCT05757986||Experimental group|
33230670|NCT05757986||Control group|
33230671|NCT05231642|Experimental|Low GI|Consumption of standardised low-GI mixed-macronutrient breakfast-based meal followed by a standardised low-GI mixed-macronutrient lunch meal 4 hours later.
33230672|NCT05231642|Experimental|High GI|Consumption of a standardised high-GI mixed-macronutrient breakfast-based meal followed by a standardised high-GI mixed-macronutrient lunch meal 4 hours later.
33230673|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
33078940|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
33078941|NCT04638868|Experimental|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
33078942|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
33265243|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
33265244|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
32771317|NCT05095389|Experimental|Standard Care plus ARDCs|"All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~All patients will receive standard care for their Diabetic Foot Ulcer.~Additionally, patients randomized to the ADRC arm will receive ADRCs"
32771318|NCT05095389|Active Comparator|Standard Care plus Placebo|"All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~All patients will receive standard care for their Diabetic Foot Ulcer.~Additionally, patients randomized to the Control arm will receive Placebo"
32771319|NCT04790747|Experimental|radiotherapy and CAR-T therapy|sequential radiotherapy and CAR-T cell therapy
32771320|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
33265245|NCT00833144||1|Congestive Heart Failure
33265246|NCT00833144||2|Patients without congestive heart failure
33265247|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
33265248|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
33265249|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
33078943|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
33078944|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
33265250|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
32771321|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
33265251|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
32771322|NCT05068271|Experimental|Multi-Domain Exercise Program|"Time: 6 months, total of 150 min of exercise per week.~Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation, and social interaction."
32771323|NCT05068271|Other|Control Group|"Time: 6 months, total of 60 min of online educational course per week.~Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline."
32771324|NCT05181085|Active Comparator|NST 6179|double blind, single ascending and multiple ascending dose, sequential group design
33265252|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
33265253|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
32771325|NCT05181085|Placebo Comparator|Placebo|matched placebo arm
32771326|NCT05195385|Other|Procedure|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
32771327|NCT05056103|Other|TrachFlush|
33265254|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
33265255|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
33265256|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
33265257|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
33265258|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
33265259|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
33265260|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
33265261|NCT00838448|Experimental|Cannabis users|Cannabis users
33265262|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
33265263|NCT00510718|Experimental|1|MDV3100
33265264|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
33265265|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
33265266|NCT00833300|Active Comparator|1|Haloperidol
33265267|NCT00833300|Active Comparator|2|Olanzapine
33078945|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
33078946|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
32771328|NCT05194293|Experimental|Treatment (regorafenib, durvalumab)|Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days until surgery or up to 2 years post registration unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
32771329|NCT04336163|Experimental|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
33265268|NCT00833378|Active Comparator|Period 2|Treatment B
33265269|NCT00833378|Active Comparator|Period 1|Treatment A
33265270|NCT00833378|Active Comparator|Period 3|Treatment C
33265271|NCT05359341|Active Comparator|Sitagliptin 50 mg twice daily|sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
33265272|NCT05359341|Active Comparator|Empagliflozin 12.5 twice daily|Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
33265273|NCT05359341|Active Comparator|Sitagliptin 50 mg + empagliflozin 12.5 mg|empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.
33265274|NCT05359341|Active Comparator|Empagliflozin 12.5 + sitagliptin 50mg|sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.
32771330|NCT04336163|Other|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
32771331|NCT05139381||Treated with Mepolizumab|
32771332|NCT05614505|Active Comparator|RUTF standard|PlumpyNut
32771333|NCT05614505|Experimental|RUTF local_1|Soybean RUTF
32771334|NCT05614505|Experimental|RUTF local_2|Mungbean-thick RUTF
32771335|NCT05614505|Experimental|RUTF local_3|Mungbean-thin RUTF
32771336|NCT05614505|Experimental|RUTF local_4|Wafer RUTF
32771337|NCT05093673|Active Comparator|Cathodal Cerebellar tDCS and SFA|Cathodal cerebellar tDCS, 2 milliamp (mA) plus Semantic Feature Analysis (SFA) naming treatment for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes. SFA will be delivered by a Speech and Language Pathologist to improve naming
32771338|NCT05093673|Sham Comparator|Sham Cerebellar tDCS and SFA|Sham cerebellar tDCS plus SFA for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SFA will be delivered by a Speech and Language Pathologist to improve naming.
32771339|NCT04790591|Active Comparator|Age <80 yrs. and ASA class <3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
32771340|NCT04790591|Active Comparator|Age ≥80 yrs. and/or ASA class ≥3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
33078947|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
33078948|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
33265275|NCT05398731||patients received ACEI|patient who use ACEI ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
33265276|NCT05398731||patients received ARBs|patient who use ARBs ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
33265277|NCT05398731||other antihypertensive drugs|patient who use other antihypertensive drugs(for example ca channel blockers and Beta blockers) ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
33265278|NCT05398731||non hypertensive group|Non hypertensive persons with matched age and sex
33265279|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
33265280|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
33265281|NCT05384301|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
33265282|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
33265283|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
33277509|NCT05068505|Experimental|Community health worker delivered multicomponent intervention|The study will employ a closed cohort stepped wedge cluster randomized design. There will be a sequential crossover of clusters from the control to the intervention arms and the order of the cross over will be randomly determined. This study will be conducted in 21 clusters within Nakaseke district. Each cluster will consist of 4-5 villages. We plan to rollout the intervention in two clusters per month and one cluster in the final month.
33277510|NCT05068505|No Intervention|Control|All clusters will be observed under both the intervention and control arm through sequential crossover.
33277511|NCT03905174|Active Comparator|Standard treatment|A porous collar for either distal or proximal femoral replacements
33401530|NCT04057118|Placebo Comparator|Placebo|
33078949|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
33078950|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
33078951|NCT00559780|Experimental|1|12 weeks of resistance training
33078952|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
33265284|NCT05380089|Experimental|Experimental group|"Over a 4-day period, participants randomly assigned to the experimental group will be instructed to maintain normal solid food choices, but to increase water intake to achieve a total water intake of ≥45ml/kg/day. Prepared bottles of water with the required amount will be given to each participant every morning and collected empty the following day. Instructions to drink small amounts of water every hour be transmitted.~Adherence to instructions regarding water intake will be determined by the return of drinking bottles, analysis of daily food records, assessment of water flux (i.e., collecting urines after subjects being dosed with deuterium), and daily screening questions. These samples will be delivered on a subsequent morning during a daily laboratory visit to collect urine and saliva samples, as well as BI assessment. On the 4th day, participants will perform a neuromuscular function assessment."
32771341|NCT02633527|Placebo Comparator|Placebo|Placebo, qd, oral capsule
32771342|NCT02633527|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
33265285|NCT05380089|No Intervention|Control group|Participants randomly assigned to the control group will be instructed to maintain normal solid food choices and water intake based on their average intake reported on the food records. Adherence to instructions regarding water intake will be determined and assessments performed will occur as mentioned previously for the experimental group.
33265286|NCT03791398|Experimental|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
33265287|NCT03791398|Experimental|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
33265288|NCT03791398|Experimental|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
33265289|NCT03791398|Experimental|Nivolumab|240mg IV flat dose q 2 weeks
33265290|NCT00838838||Group 1|
33265291|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
33078953|NCT00559780|Other|3|12 weeks of standard rehabilitation
33078954|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
33265292|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
33265293|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
33265294|NCT05360979|Experimental|Neoadjuvant and adjuvant therapy|After signing the informed consent, eligible subjects who meet the inclusion criteria will receive neoadjuvant therapy comprising envafolimab combined with platinum-containing chemotherapy and recombinant human endostatin, as well as postoperative envafolimab single-agent adjuvant therapy.
33265295|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
33265296|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
32771343|NCT02633527|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
32771344|NCT02633527|Experimental|300mg SPN-812|300mg SPN-812, qd, oral capsule
32771345|NCT02633527|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
32771346|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
32771347|NCT04790669|Experimental|Daily adjustable progressive resistance exercises (DAPRE)|DAPRE technique, hot pack, stretching exercises.
32771348|NCT04790669|Experimental|Close kinetic chain exercises (CKC).|CKC exercises, hot pack, stretching exercises
32771349|NCT05092971|Other|Clinic|Tasks to be completed in OP4 clinic
32771350|NCT05092971|Other|fMRI|Tasks to be completed in fMRI
33078955|NCT00559975|Active Comparator|1|
32771351|NCT05092893||Children with Developmental Coordination Disorder|"INCLUSION:~Confirmed diagnosis of DCD~Comorbidities are allowed (f.e. ASD, ADHD, ADD,…)~EXCLUSION:~o Any other neurodevelopmental disorder which might affect motor development (f.e. CP)."
32771352|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
32771353|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
32771354|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
33078956|NCT00559975|Active Comparator|2|
33078957|NCT00559975|Experimental|3|
33078958|NCT00559975|Experimental|4|
33078959|NCT00559975|Experimental|5|
33078960|NCT04638439|Experimental|P1101 + Nivolumab + Entecavir|
33078961|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
33265297|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
33265298|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
33265299|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
33265300|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
33265301|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
33265302|NCT05356377||PKU Palynziq Group|Individuals with PKU who have previously completed baseline (pre-Palnyziq) neurocognitive and neuroimaging evaluations and have since demonstrated a significant and prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L).
33265303|NCT00833612|No Intervention|Control arm of study|
33265304|NCT05591001|Active Comparator|Ketamine-dexmedetomidine group|Dexmedetomidine( 0.4 -0.6 μg/.kg /.h r)) ketamine,( 1-2m/.kg/.hr) infusion and giving bolus of fentanyl,( 1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rates changes within 25% of the baseline.
33265305|NCT05591001|Active Comparator|propofol group|propofol (100 ug/kg/min) -giving a bolus of fentanyl, (1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rate changes within 25% of the baseline.
33265306|NCT05283369|Experimental|Videogame therapy|Participants will receive conventional physical therapy, plus 300 minutes of videogame in-home therapy a week, for 8 weeks.
33265307|NCT05283369|Active Comparator|Conventional therapy|Participants will receive conventional physical therapy, plus conventional occupational therapy, as prescribed by the doctor for 8 weeks.
33265308|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
32771355|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
32771356|NCT05192499|Other|Case|"Patients aged to 1 to 3 years with severe asthma (i.e. resistant to inhaled corticosteroid doses less than or equal to 200μg fluticasone equivalent).~Severe asthma patients (cases) are defined by poor asthma control under doses of inhaled corticosteroids ≤200μg fluticasone equivalent."
32771357|NCT05192499|Other|Control|"Patients aged to 1 to 3 years with low or moderate asthma (controlled with mild to moderate doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent).~Mild to moderate asthma patients (controls) are defined by disease control by first-line treatment in asthma, i.e. corticosteroids inhaled at mild to moderate doses of ≤200 micrograms/day of fluticasone equivalent."
32771358|NCT05092581|Experimental|casirivimab+imdevimab|
32771359|NCT04790357|Other|Reference strategy|correspond to the reference techniques according to the current guidelines in the etiological work up of ischemic strokes and TIA
32771360|NCT04790357|Other|Evaluated strategy|correspond to perform the cci-MR: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
32771361|NCT05191485||Patients of decision making need assessment|"We will conduct semi-structured interviews with target patients and patients' representatives to assess their decisional needs. Decisional needs including difficult decision type /timing, unreceptive decisional stage, decisional conflict (uncertainty), inadequate knowledge & unrealistic expectations, unclear values, inadequate support & resources, and Personal & clinical needs. All interviews will be conducted one-to-one or one-to-many (including families) and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For patients, aiming for diversity regarding age, sex, education level and annual household income. All participants should be Chinese-speaking."
32898312|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.~PEEP at 8 cmH2O.~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
32898313|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
33265309|NCT00145327|Experimental|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
33265310|NCT00145327|Placebo Comparator|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
33277512|NCT03905174|Active Comparator|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
33277513|NCT03905174|Active Comparator|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
33265311|NCT00145327|Experimental|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
33265312|NCT05408793|Experimental|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
33265313|NCT05408793|Sham Comparator|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
33265314|NCT00833768|Active Comparator|Sevelamer carbonate|
33265315|NCT00833768|Placebo Comparator|Placebo|
33265316|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
33265317|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
33265318|NCT05590611|Placebo Comparator|Brown Bread|
33265319|NCT05590611|Active Comparator|Wholemeal Sourdough Bread|
33265320|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
33265321|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
32771362|NCT05191485||Other stakeholders of decision making need assessment|"We will conduct semi-structured interviews with other stakeholders to assess their decisional needs. All interviews will be conducted one-to-one and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For other stakeholders (including thoracic surgeons, nurses, psychoanalyst, hospital administrators, molecular testing company staffs and insurance company staffs), region, seniority, position, and attitude toward both molecular testing and SDM are considered. All participants should be Chinese-speaking."
33265322|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
33265323|NCT00839150||2|Sex and age-matched control subjects : No intervention
33265324|NCT05358405|Other|Müller maneuver|Open Label with intervention Müller maneuver
33265325|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
33265326|NCT00510484|Experimental|A|
33078962|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
33078963|NCT00560014|Experimental|2|Arginine and Coromega
33078964|NCT00560014|No Intervention|3|Control
33230674|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
33230675|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
33265327|NCT00510484|Placebo Comparator|B|
33265328|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
33265329|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
33265330|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
33265331|NCT00839462|Experimental|Arm 1|
33265332|NCT00839462|Active Comparator|Arm 2|
33265333|NCT05590221|Experimental|Relmacabtagene Autoleucel|Participants will receive cyclophosphamide250 mg/m^2/day intravenously (IV) and fludarabine 25 mg/m^2/day IV conditioning chemotherapy for 3 days followed by Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day 1.
33265334|NCT01009996||Coronary bifurcation lesions|
33265335|NCT05590143|Experimental|Intervention|Dapagliflozin 10 mg
33265336|NCT05590143|Placebo Comparator|Placebo|Matching Placebo
33265337|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
33265338|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
33265339|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
33265340|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
33265341|NCT01156389|Active Comparator|Arm A Ritonavir plus Pyramax|7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by a 33 day follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
33265342|NCT01156389|Active Comparator|Arm B Pyramax|3 day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
33265343|NCT04043624|Experimental|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
33265344|NCT04043624|Placebo Comparator|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
33265345|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
33265346|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
33265347|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
33265348|NCT05589987|Experimental|Power mobility|The study will take place in the child's natural environment for 12 weeks.
33265349|NCT05589987|No Intervention|Non-power mobility|Children will perform their typical daily routine without any modification. After the study they will be invited to participate in the experimental group if positive benefits are obtained.
33265350|NCT00834158|Active Comparator|TACE|perform TACE only
33078965|NCT04638010|Experimental|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
33078966|NCT04638010|Active Comparator|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
33078967|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
33078968|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
33078969|NCT04638166|Experimental|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
33078970|NCT04638166|Active Comparator|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
33265351|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
33265352|NCT05589909||Infection Group|Both suspected and confirmed sepsis occurred ≤72 hours after delivery were counted as cases of EONS.
33078971|NCT00178880||Healthy volunteers|
33265353|NCT05589909||None Infection Group|No evidence clinical or laboratory of infection
33265354|NCT05589675|Experimental|Intervention arm|Invitation letter to the screening program with the FIT test
33265355|NCT05589675|Experimental|Intervention arm - sub study|Prior notification to the new entrants, followed by an invitation letter to the screening program with the FIT test
33265356|NCT05589675|No Intervention|Control arm|Invitation letter to visit its own GP who will deliver the FIT test
33265357|NCT03693430|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
33265358|NCT03693430|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
33265359|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
33265360|NCT05407779|Experimental|Cohort 1|"The Cohort 1 include one subject (sentinel volunteer) to receive BCD-180 at a dose 1"
33265361|NCT05407779|Experimental|Cohort 2|The Cohort 2 include 3 subjects to receive BCD-180 at a dose 2
33265362|NCT05407779|Experimental|Cohort 3|The Cohort 3 include 3 subjects to receive BCD-180 at a dose 3
33265363|NCT05407779|Experimental|Cohort 4|The Cohort 4 include 3 subjects to receive BCD-180 at a dose 4
33265364|NCT05407779|Experimental|Cohort 5|The Cohort 5 include 3 subjects to receive BCD-180 at a dose 5
33265365|NCT05407779|Experimental|Cohort 6|The Cohort 6 include 3 subjects to receive BCD-180 at a dose 6
33265366|NCT05407779|Experimental|Cohort 7|The Cohort 7 include 3 subjects to receive BCD-180 at a dose 7
33265367|NCT05407779|Experimental|Cohort 8|The Cohort 8 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
33265368|NCT05407779|Experimental|Cohort 9|The Cohort 9 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
33265369|NCT00834314|Experimental|Vacuum-pack|see Interventions
33078972|NCT00178880||Depressed patients|
33078973|NCT04637737|Experimental|Training group|
33078974|NCT04637737|Other|Control group|
33265370|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
33265371|NCT05589441|Experimental|Nebulized inhalation of salbutamol group|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
33265372|NCT05589441|Experimental|Insulin complex glucose group|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
33265373|NCT00825188|Active Comparator|eplerenone|
33265374|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
33265375|NCT05407623|Experimental|PAX Good Behavior Game|PAX Good Behavior Game (GBG) is based on its precursor programme Good Behavior Game (GBG) that trains teachers to use principles of social learning in order to maximize the childrens' task-oriented and prosocial behaviors and minimize the occurrence of disruptive and off-task behaviors.
33265376|NCT05407623|Active Comparator|Active control (choice between on of two active interventions)|"[The project has two alternative control interventions for the schools to choose between, in order to increase their engagement in the control intervention. They are hence only provided with one of these interventions, not both.]~Count On Me! is an adaptive application teaching fluency in addition and subtraction facts (i.e., math facts), equality, compose and decompose numbers and a few more basic mathematical skills taught in the first grades of schooling.~Collegial earning is based on five cyclical steps for professional learning for teachers."
33265377|NCT00834392|No Intervention|Control|
33265378|NCT00834392|Experimental|Exercise|
33265379|NCT05589363|Active Comparator|ABC block with bupivacaine and liposomal bupivacaine|The study solution used in the active arm will comprise 20 mL of liposomal bupivacaine (266 mg) admixed with 40 mL of 0.25% bupivacaine HCl. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
33401531|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
33265380|NCT05589363|Sham Comparator|ABC block with saline|The study solution used in the active arm will comprise 60 mL of 0.9% saline. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
33265381|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
33078975|NCT04637854|Experimental|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.~Each patients will be recalled for follow-up visits at 7 days."
33265382|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
33265383|NCT03997864|Active Comparator|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
33265384|NCT03997864|Placebo Comparator|Control - placebo|Participants randomized to this group will receive placebo .
33265385|NCT05407467|No Intervention|Control Group|There is no additional intervention other than subject's standard diabetes treatment
33265386|NCT05407467|Experimental|Interventional Group|This group will received additional supplementation of curcumin and virgin coconut oil aside from their standard treatment
33265387|NCT04043468|Experimental|Improved A&F intervention|Two feedback sessions and four structured focus groups
32771363|NCT05191485||Participants of cognitive debriefing/alpha tests|The purpose of Alpha test is to test the understandability of Decision Aid for Lung Cancer Molecular Testing version 1.0 (DA_LCMT 1.0). All debriefing interviews will be conducted one-on-one with structured probing questions. Participants will be encouraged to comment on DA_LCMT 1.0 and give recommendations to replace any unclear wording. At the start, the interviewer will explain the aim of the study and the procedures of the cognitive debriefing to participants. Then a paper-based DA_LCMT 1.0 will be given to participants, and sufficient time will be guaranteed to allow them to read DA_LCMT 1.0. The cognitive debriefing interview will start afterwards, and participants will answer questions probing questions asked by interviewers about DA_LCMT 1.0. Each cognitive debriefing interview will last for about 20 minutes. DA_LCMT 2.0 will be generated after the completion of the cognitive debriefing (Alpha test).
32771364|NCT05191485||Patients of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
33265388|NCT04043468|Active Comparator|Standard A&F intervention|Two feedback sessions
33265389|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
33265390|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
33078976|NCT04637854|Active Comparator|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
33078977|NCT04637854|Active Comparator|Naked Eye.|The same as above but the intervention will be performed at naked eyes
32898314|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
32898315|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
32898316|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
33265391|NCT05589285|Experimental|Treatment group|Chronic plantar fasciitis patients who will receive autologous whole blood injection.
33265392|NCT05589285|Sham Comparator|Control group|Chronic plantar fasciitis patients who will receive normal saline injection.
33265393|NCT00834548||1|WB-MRA standard protocol
33265394|NCT00834548||2|WB-MRA hybrid protocol
33265395|NCT05407233|Active Comparator|Group 1|Doesn´t reuse the syringe for insulin application
33265396|NCT05407233|Experimental|Group 2|Uses the syringe five times to insulin application
33265397|NCT05589129|Experimental|Whey Protein Supplement|Whey protein will come in powder form and will consist of 20g of protein, and 25.3g of product. We will use Optimum Nutrition Double Chocolate Whey Protein Isolate.
33265398|NCT05589129|Placebo Comparator|Carbohydrate Control|Carbohydrate control will come in powder form and will consist of 20g of carbohydrate and 21.6g of product. We will use Nesquick Chocolate Powder mix.
33265399|NCT00839774|Experimental|1|Whole yellow pea flour
33265400|NCT00839774|Experimental|2|Fractionated yellow pea flour
33265401|NCT00839774|Experimental|3|White wheat flour
33265402|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
33265403|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
33265404|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
33277514|NCT05064527||Patients|"OCD (ICD-10 F42) as the primary or secondary diagnosis, verified with a semi-structured psychopathological interview using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-PL).~CY-BOCS > 7: mild (8-15), moderate (16-23), severe (24-31), extreme (32-40)~A psychiatrist determined that the child is eligible for care within psychiatry for their primary diagnosis.~Patient is age 8 through 17 years (both inclusive)."
33078978|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
33078979|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
33078980|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
33078981|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
33078982|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
33265405|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
33265406|NCT00840008|Experimental|Educational intervention|see protocol
33078983|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
33078984|NCT00201084|No Intervention|2|Usual primary care
33078985|NCT04637503|Experimental|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
33265407|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
33265408|NCT05407155|Experimental|Experimental arm|Patients received bevacizumab plus nab-paclitaxel and platinum as second-line therapy.
33265409|NCT05358093||45|
33265410|NCT00840242|Experimental|Nicotine gum|Nicotine gum
33265411|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
33265412|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
33265413|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
33265414|NCT04894383|Experimental|Prefabricated Orthotics in shoes & indoor comfort sandals with built-in arch support|Participants from Group A will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) and an Aetrex comfort sandal with built-in arch support (https://www.aetrex.com/aetrex-flips-black-L3000M.html?lang=en_US or https://www.aetrex.com/fiji-flips-women-watermelon-L7009W.html?lang=en_US) according to participants shoe size. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the orthotic/comfort sandal wherever possible.
33265415|NCT04894383|Active Comparator|Prefabricated Orthotics in shoes only|Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
33265416|NCT00621296|Experimental|MP-424|
33265417|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
33265418|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
33265419|NCT00840398|Experimental|1|
33265420|NCT00840398|Active Comparator|2|
33265421|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
33265422|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
33265423|NCT00840554|Active Comparator|Physical Therapy|
33265424|NCT00840554|Experimental|Home Exercise|
33265425|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
33265426|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
33265427|NCT05586087|Experimental|Experimental group|Participants perform a 16-week of High-Speed Resistance Training program.
33265428|NCT05586087|No Intervention|Control group|Participantes continued their usual activity without engaging in any strength training or beginning a new exercise program during the study.
33265429|NCT00834704|Other|1|Dose determination
33265430|NCT05360433|Active Comparator|10 tablet prescription group|These participants receive 10 tablets of oxycodone 5 mg at discharge for postoperative pain.
33265431|NCT05360433|Active Comparator|20 tablet prescription group|These participants receive 20 tablets of oxycodone 5 mg at discharge for postoperative pain.
33265432|NCT00834782||IOP|Measuring IOP
33265433|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
33265434|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
32898317|NCT02825160||Ventavis|Ventavis treatment group
32906360|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
33078986|NCT00408239|Experimental|1|Dose regimen 1
33078987|NCT00408239|Active Comparator|2|
33078988|NCT00408239|Experimental|3|Dose regimen 2
33078989|NCT04637308|Experimental|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
33078990|NCT04637308|No Intervention|Control|Observation.
32771365|NCT05191485||Clinician of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
33078991|NCT04637542|Experimental|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
33230957|NCT03995953|Experimental|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
33230958|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
33230959|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
33230960|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
33230961|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
33230962|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
33230963|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
33230964|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
33230965|NCT00816478|Experimental|1|Galactose
33230966|NCT00809068|Active Comparator|1|fenofibrate and tibolone
33230967|NCT00809068|Sham Comparator|2|tibolone
33230968|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
33230969|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
33230970|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
33230971|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
33230972|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
33230973|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
33230974|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
33230975|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
33230976|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
33230977|NCT03995563|Active Comparator|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
33230978|NCT03995563|Placebo Comparator|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
33230979|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
33230980|NCT04122625|Experimental|Debio 1143 + Nivolumab|Part A: Participants will receive Debio 1143 at a starting dose of 150 milligrams (mg) orally once daily on Days 1-10 and Days 15-24 every 4 weeks (q4w) along with nivolumab at a flat dose of 240 mg intravenously (IV) on Days 1 and 15 of a 28-day cycle, participants may be switched to 480 mg IV on Day 1 q4w, exclusively upon investigator request with the sponsor agreement. Part B: Participants will receive Debio 1143 at RP2D established in Part A in combination with nivolumab as per standard care.
33265435|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
33265436|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
33265437|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
33265438|NCT04875195|Experimental|Arm 1|Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.
33265439|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
33078992|NCT04637542|Experimental|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
33078993|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
33265440|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
33265441|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
32771366|NCT04756193||Asymptomatic/Mild COVID-19 Group|50 confirmed COVID-19 patients who showed no or only mild respiratory/GI symptoms (not admitted to the hospital at all)
33265442|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
33265443|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
33078994|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
33078995|NCT04637464|Experimental|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
33078996|NCT04637464|No Intervention|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
33078997|NCT00560092|Experimental|intrathecal magnesium sulfate|
33078998|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
33078999|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
33079000|NCT04637152|No Intervention|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
33265444|NCT04696575|Experimental|Treatment (lamivudine, chemoimmunotherapy)|"INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered."
33265445|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
33265446|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
33265447|NCT04003545|Active Comparator|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
33265448|NCT04003545|Placebo Comparator|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
33265449|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
33265450|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
33265451|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
33277515|NCT05064527||Controls|"Ages 8 through 17 years (both inclusive).~Sex and age (+/- 3months) matched to an included patient."
33277516|NCT05064527||Caregivers of Patients|Parent or guardian of patient with OCD
33277517|NCT05064527||Caregivers of Controls|Parent or guardian of control participant
33079001|NCT04637152|Experimental|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
33079002|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
33079003|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
33277518|NCT05063045|Experimental|smart-cloth|Participants receive smart-cloth assisted home nursing care
33277519|NCT05063045|No Intervention|routine care|This group receive routine care
33277520|NCT05355038|Experimental|lifesyle modification|intervention group will take lifestyle modification protocol which composed of health teaching about low glycemic index diet, physical activity and self glucose monitoring
33265452|NCT05576883|Other|Emotion Regulation Intervention and Control Intervention|"Participants will be asked in the morning and in the evening at their self-selected time to evaluate their emotional state through ecological momentary assessment (EMA) and will be prompted to engage in an ER intervention (60% likelihood) or to read health information (40% likelihood). Upon completion they will evaluate the likability and helpfulness of the exercise or the article and re-evaluate their emotional state (post-EMA).~The intervention consists of 20 ER exercises and 20 health facts. The ER intervention is based on different therapeutic approaches targeting various underlying transdiagnostic factors such as rumination, self-referential thoughts etc. The 20 health facts will act as a placebo intervention with no effect on emotion regulation and keep participants engaged in the post-EMA evaluation when they are not randomized to an exercise.~The interventions and the control intervention materials were developed by the research team for the purposes of this study."
33265453|NCT05358015|Experimental|scaphoid nonunion|pedicled and free ABG for treatment of scaphoid nonunion
33265454|NCT04043780|Experimental|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
33265455|NCT04043780|Active Comparator|standard splint|The patients of this group will wear a standard splint.
33265456|NCT05558007|Active Comparator|Daily oral Tadalafil 5mg + Topical Placebo|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo
33265457|NCT05558007|Experimental|Daily oral placebo + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A
33265458|NCT05558007|Active Comparator|Daily oral Tadalafil 5mg + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A
33265459|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
33265460|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
33265461|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
33265462|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
33265463|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
33265464|NCT05549739||Control Group|Individuals without cardiac and pulmonary disease
33265465|NCT05549739||Study Group|Individuals with coronary artery disease
33265466|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
33265467|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
33265468|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
33265469|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
33265470|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
33265471|NCT01012882|Experimental|sublingual application of allergen extract|
33265472|NCT01012882|Placebo Comparator|sublingual application of placebo|
33265473|NCT00841022|Experimental|1|Information of children with comic leaflet
33265474|NCT00841022|No Intervention|2|
33265475|NCT00989469|Experimental|Sorafenib and irinotecan|
33265476|NCT04709458|Experimental|TBX-2400 treatment|Single intravenous infusion of TBX-2400
33265477|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
33265478|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
33265479|NCT00989547|Active Comparator|A|
33265480|NCT00989547|No Intervention|B|
33265481|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
33265482|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
33265483|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
33265484|NCT04002687|Experimental|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
33265485|NCT04002687|Active Comparator|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
33265486|NCT04002687|Active Comparator|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
33265487|NCT04002687|Placebo Comparator|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
33277521|NCT05355038|No Intervention|control group|routine care of the hospital
33277522|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
33277523|NCT00777413|Active Comparator|2|Minocin 100mg tablets
32771367|NCT04756193||Moderate COVID-19 Group|50 confirmed COVID-19 patients who were able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs (admitted to the hospital, but never to the ICU and no obvious cardiac complications during the stay)
32771368|NCT04756193||Severe COVID-19 Group|50 confirmed COVID-19 patients who had oxygen saturation lower than 92% at rest and PaO2/FiO2 between 200 and 300 (High-flow oxygen group, mostly in the ICU, and may have some cardiac complications)
32771369|NCT04756193||Critical COVID-19 Group|50 confirmed COVID-19 patients who had PaO2/FiO2 less than 200 or required mechanical ventilation (in the ICU, need mechanical ventilation and more likely to have cardiac complications)
32771370|NCT04756193||Control Group|50 age and sex-matched controls from our hospital admission database
32906361|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
32906362|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
33079004|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
33079005|NCT04637191|Experimental|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
33079006|NCT04637347|Other|IP-ISV|In plane infraclavicular subclavian vein catheterization
33079007|NCT04637347|Other|IP-SSV|In plane supraclavicular subclavian vein catetherization
33079008|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
33079009|NCT04637269|Experimental|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
33079010|NCT04636918|Other|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
33079011|NCT00560209|Placebo Comparator|P|
33079012|NCT00560209|Experimental|E2|
33079013|NCT00560209|Experimental|E1|
33079014|NCT04636957|Experimental|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
33079015|NCT04636957|Active Comparator|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
33079016|NCT04636996|Experimental|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
33079017|NCT04636996|Placebo Comparator|Control group|Control group
33079018|NCT04636567|Experimental|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
33079019|NCT04636606|Active Comparator|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
33079020|NCT04636606|Active Comparator|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
33079021|NCT04636606|Active Comparator|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
33079022|NCT00178997||Good blood flow|Group without ischemia to the small intestine
33079023|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
33079024|NCT04636645|Active Comparator|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
33079025|NCT04636645|Experimental|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
33401532|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
33079026|NCT04636645|Experimental|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
33079027|NCT04636489|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
33079028|NCT04636489|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
33079029|NCT04636684|Experimental|patients undergoing surgical valve replacement for degenerative aortic stenosis|
33079030|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
33079031|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
33079032|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
33079033|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
33079034|NCT00560287|Active Comparator|2|Pressure Assist mode
33079035|NCT00560326|Experimental|1|
33079036|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
33079037|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
33079038|NCT00560521|Active Comparator|1|
33079039|NCT04636450|Active Comparator|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
33079040|NCT04636450|Experimental|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
33079041|NCT04636450|Active Comparator|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
33079042|NCT04636450|Experimental|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
33079043|NCT04636372|Experimental|Intense pulsed light therapy group|
33079044|NCT04636372|Experimental|Hot compress massage group|
33079045|NCT04636372|Experimental|Intense pulsed light therapy and hot compress massage group|
33079046|NCT04636411|Experimental|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
33079047|NCT04636411|Active Comparator|Control group|This group will receive the standard care for diabetic patients
33079048|NCT00179153|Active Comparator|1|
33079049|NCT04636099|Experimental|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
33079050|NCT04636099|No Intervention|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
33079051|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
33079052|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
33079053|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
33079054|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
33079055|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
33079056|NCT00179192|No Intervention|1|control group
33079057|NCT00179192|Active Comparator|2|angioplasty intervention
33079058|NCT00179192|Active Comparator|3|surgery intervention
33079059|NCT04635982|Placebo Comparator|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
33079060|NCT04635982|Experimental|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
33079061|NCT04635982|No Intervention|Control Group|It has not done any intervention in this group.
33079062|NCT04635865|Experimental|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
33079063|NCT04635865|Active Comparator|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
33079064|NCT00201396|Active Comparator|A arm|CCRT
33079065|NCT00201396|Experimental|B arm|Induction/CCRT
33079066|NCT04635709|Experimental|behavioral therapy|applying biofeedback training on the pelvic floor muscles
33079067|NCT04635709|Experimental|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
33079068|NCT04635475|No Intervention|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
33401533|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
33401534|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
33401535|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
33265488|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
33265489|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
33079069|NCT04635475|Experimental|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
33079070|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
33079071|NCT04635358|Experimental|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
33265490|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
33265491|NCT04590417|Other|20 HIV-negative TGW|A single-arm prospective PK study of HIV-negative TGW taking FHT and daily PrEP.
33265492|NCT00825656|Experimental|1|Sinol-M
33265493|NCT00825656|Active Comparator|2|Sinol
32906363|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
33079072|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
33079073|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
33079074|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
33079075|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
33265494|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
33265495|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
33265496|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
33265497|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
33265498|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
33265499|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
33265500|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
33265501|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
33265502|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
33265503|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
33265504|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
33265505|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
33265506|NCT05360355||patients undergone total face reconstruction and intraoperative indocyanine green angiography|This clinical study enrolled 10 patients treated with total face reconstruction and intraoperative indocyanine green angiography from Jun 2018 to Jun 2021.
33265507|NCT01010542|Active Comparator|ILV-095|
33265508|NCT01010542|Placebo Comparator|placebo|
33265509|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
33265510|NCT00989703|Placebo Comparator|2|placebo for 14 days
33265511|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
33265512|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
33265513|NCT04572009|Experimental|Augmented physician|Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
33265514|NCT04572009|Placebo Comparator|Control|Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
33265515|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
33265516|NCT00625586|Experimental|RAV12 plus gemcitabine|
33265517|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
33265518|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
32771371|NCT05138991|Experimental|Screening (echo, CMR, Tonometry-based system)|Patients undergo a one time assessment of cardiac function by echo, CMR, and the Tonometry-based system system in the clinic over 4-6 hours, and will be asked to perform their home-based measurements within 1-5 days of the clinical assessment, allowing us to directly compare measurements obtained by survivors to those by research personnel. Patients also complete questionnaires at baseline.
33230981|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
33401536|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
33401537|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
33401538|NCT04916782||Observational group|
33401539|NCT04906174||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
33401540|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
33401541|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
33401542|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
33401543|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
32771372|NCT04953767|Experimental|Blue light therapy|The participants receive blue light therapy for 1 hours, between 8am to 12pm in the morning.
32771373|NCT04953767|Sham Comparator|White light|The participants receive white light for 1 hour, between 8am to 12pm in the morning.
32771374|NCT05138601|No Intervention|Usual Care with Education|The participant will be provided with educational material and a home BP monitor. Control participants will continue to see their physicians for their usual care for BP management (their BP data will not be reviewed by pharmacists and the patients will not have support from vCCC pharmacists)
32771375|NCT05138601|Experimental|Virtual Collaborative Care Clinic|Participants will partake in the virtual collaborative care clinic
33401544|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
33401545|NCT04846972||Control group|After inclusion, patients will receive standard care. Women allocated in this group will have the standard care.
32771376|NCT05614427|Active Comparator|Anterior nasal swab|Lateral flow tests performed on anterior nasal swabs compared to routinely taken nose and throat swabs with RT-PCR
32771377|NCT05614427|Active Comparator|Buccal swab|Lateral flow tests performed on buccal swabs compared to routinely taken nose and throat swabs with RT-PCR
33401546|NCT04846972||FASTRACS intervention group|Women allocated in the FASTRACS intervention group will follow a structured care pathway comprising three successive steps (end of chemotherapy interview with a nurse, transitional visit with their GP, pre-RTW visit with their OP), plus one optional step (late visit with an OP- RTW to work coordinator). Four tools will be used during the intervention (RTW guide or checklist for the patient, the GP, the OP and the employer).
33401547|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
33401548|NCT05675332|Placebo Comparator|no stress exposure|no threat stress
33401549|NCT05675332|Active Comparator|stress exposure|exposure to stress threat
33401550|NCT05675254||EP with ASMs|Epilepsy patients who administered Anti-seizure Medications(ASMs)
33401551|NCT05675254||EP without ASMs|Epilepsy patients who were not administered ASMs
32771378|NCT05137899|Experimental|Neoadjuvant Atezolizumab/Bevacizumab|• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
32771379|NCT05137899|Experimental|Neoadjuvant SBRT|• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
33230982|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
32771380|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral & Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
32771381|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral & Glenoid Components as a primary, fracture or revision total shoulder replacement
32771382|NCT04010981|Experimental|study grup-Virtual reality- Nintendo Wii Fit exercise group|in this group patients will complete 12 sessions of virtual reality exercise - Nintendo Wii Fit Plus, 30-minute training sessions with strengthening exercises for the lower extremities and upper extremities, aerobic and balance exercises, two days a week. They will do 5 minute warm-up exercises before stretching, stretching exercises and 5 minute cooling exercises at the end of the session, as well as breathing exercises and will attend a total of 50 minutes of treatment.
32906364|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
33230983|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
33230984|NCT00811070|Experimental|1|
33230985|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
33230986|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
33230987|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
33230988|NCT00642460|Experimental|1|
33230989|NCT00642460|Placebo Comparator|2|
33230990|NCT00814658|Experimental|Galantamine + Nimodipine|
33230991|NCT00814658|Experimental|Galantamine + Placebo|
33230992|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
33265519|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Reproducibility Subjects|Some of the individuals with documented cardiac amyloidosis from arm 1 will undergo a second F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) within 30 days to measure reproducibility
33265520|NCT00841334|Experimental|1|ACTION
33265521|NCT00841334|Active Comparator|2|Usual care
33265522|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
33265523|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
33265524|NCT05377047|Experimental|Experimental SABR arm|Standard first line systemic therapy + SABR.
33265525|NCT05377047|No Intervention|Control systemic therapy arm|Standard first line systemic therapy.
32771383|NCT04010981|Active Comparator|control group-home based video exercise group|Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
33079076|NCT04635202|Experimental|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
33079077|NCT04635202|Other|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
33079078|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
33265526|NCT00841490||1|Intellectually & Developmentally Disabled Adults
33265527|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
33265528|NCT05363397|Experimental|AZD6482 30mg (25% of target dose)|"Following randomisation, 30mg AZD6482 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of AZD6482 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
33265529|NCT05363397|Experimental|AZD6482 60mg (50% of target dose)|"Following randomisation, 60mg AZD6482 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of AZD6482 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
33265530|NCT05363397|Experimental|AZD6482 120mg (100% of target dose)|"Following randomisation, 120mg AZD6482 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of AZD6482 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
33265531|NCT05363397|Experimental|AZD6482 180mg (150% of target dose)|"Following randomisation, 180mg AZD6482 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of AZD6482 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
33265532|NCT00144781|Active Comparator|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
33265533|NCT00144781|Active Comparator|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
33265534|NCT00144781|Active Comparator|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
33265535|NCT00144781|Active Comparator|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
33265536|NCT00835562|Experimental|Osteosynthesis|
33265537|NCT00835562|Experimental|Non-surgical|
33265538|NCT00835562|Experimental|Hemiarthroplasty|
33265539|NCT05359107|Experimental|"The Free From Pain Exercise Book"|"Participants who consent and are randomised into Group 1 (experimental group) will be provided with the Free From Pain Exercise Book. Participants in Group 1 will be asked to independently engage in the exercises included in the book throughout the entire 6 month study period. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day.~Furthermore, it will be recommended that participants in this group read one information chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information."
33265540|NCT05359107|Active Comparator|"The Back Book"|"Participants who consent and are randomised into Group 2 (control group) will be provided with The Back Book. Participants in Group 2 will be asked to ensure that they read the book in its entirety during the 12-week intervention period and refer to relevant sections during the follow-up period for advice if required."
33265541|NCT03971695|Experimental|BI 706321|
33265542|NCT03971695|Placebo Comparator|Placebo|
33265543|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
33265544|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
33265545|NCT05357937|Active Comparator|Obese group|Received standard physiotherapy program
33265546|NCT05357937|Active Comparator|Non-Obese group|Received standard physiotherapy program
33265547|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
33265548|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
33265549|NCT05312697|Experimental|Setrusumab QM -->Setrusumab QM|"During Retreatment Period: Setrusumab will be administered via intravenous (IV) infusion once a month (QM) for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion QM for at least 12 months or until commercially available."
33265550|NCT05312697|Experimental|Setrusumab QM --> Setrusumab TBD|"During Retreatment Period: Setrusumab will be administered via IV infusion QM for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion at a dose frequency to be determined (TBD) for at least 12 months or until commercially available."
33265551|NCT04551651|Active Comparator|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
33265552|NCT04551651|Active Comparator|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
33265553|NCT00841646|Other|1|
33265554|NCT04464213|Experimental|Single dose experiments|
33265555|NCT04464213|Experimental|Multi-dose experiments|
33265556|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
33265557|NCT05357625|Experimental|Treatment group|Clients in the treatment group received the usual floating support service as described for the control group together with feedback. The support workers received feedback from the clients through the ORS and SRS scales of the feedback tool (Bargmann and Robinson 2011). The support worker evaluated the progress of the outcome for the client and the alliance between the support worker and the client from session to session.
33265558|NCT05357625|No Intervention|Control group|Clients in the control group received the usual floating support service without Feedback. Therefore, there was no systematic feedback between clients and support workers in the control group. The service was provided in the clients' homes, and there was no fixed limit of sessions for the support. The support covered any problem, including setting up tenancies, working with clients around practical things, so they could live independently, making sure that clients received all relevant benefits and helping clients with access to physical and mental health services. Some support workers saw their clients on a weekly basis, but there was a large variation in the frequency of meetings. Furthermore, the duration of the support service varied, from a few weeks to several years.
33265559|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
32771384|NCT05191017|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with enzalutamide until the recommended Phase 2 combination dose (RP2cD) is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
32771385|NCT05191017|Experimental|Phase 2|"NUV-422 will be administered orally at the RP2cD in combination with enzalutamide.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
32771386|NCT05190159||Monster Screw System|
32771387|NCT04848857|Experimental|Treatment Group|colchicine (0.5mg), one pill a day, oral intake
32771388|NCT04848857|Placebo Comparator|Control Group|placebo, one pill a day, oral intake
32771389|NCT03973385|Experimental|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
32771390|NCT03973385|Placebo Comparator|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
32771391|NCT05137431||High Flow Nasal Oxygenation-HFNO|The current will be adjusted from 50-70 liters. The patient's SpO2 value will be maintained at at least 92%. Arterial blood gas will be checked at the 1st hour
32771392|NCT05137431||Non-Invasive Ventilation-NIV|Tidal volume will be adjusted to be 6-8 ml/kg. The respiratory rate will be <30. The patient's SpO2 value will be maintained at at least 92%. The PEEP value will be 5 cmH2O. At the 1st hour, arterial blood gas will be checked.
33079079|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
33079080|NCT00201474||major depressive disorder|
33265560|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
33265561|NCT04003233|Experimental|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
33265562|NCT04003233|Experimental|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
33265563|NCT00841802|Experimental|Prednisone|Steroid medication
33265564|NCT00841802|No Intervention|No Intervention|No Intervention
33265565|NCT05300295|Experimental|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
33265566|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
33265567|NCT04446117|Experimental|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
33265568|NCT04446117|Active Comparator|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
33265569|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
33265570|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
33265571|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
33265572|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
33265573|NCT03971851||Low frailty|Frailty risk score less than 5
33265574|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
33265575|NCT03971851||High frailty|Frailty risk score 15 and above
32771393|NCT05135871|Experimental|Cohort 1: Mavacamten 15 mg|Cohort 1: 15 mg capsules × 1 on Day 1
32771394|NCT05135871|Experimental|Cohort 2: Mavacamten 25 mg|Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
32771395|NCT05135871|Experimental|Cohort 3: Mavacamten 15 mg|Cohort 3: 15 mg capsules × 1 on Day 1
32771396|NCT05135871|Experimental|Cohort 4: Mavacamten 15 mg|Cohort 4: 15 mg capsules × 1 on Day 1
32771397|NCT03909347|Experimental|PLAN (intervention)|Group 1 will receive the study intervention during the 6 months of the study, after the first baseline questionnaire. The intervention is as follows: participants will be asked to take part in a one-time, one-hour education in participants' home or any community location that is most convenient for the participants by a trained community health worker. An educational resource that participants can read at home will be provided at the end of education session. Participants' community health worker will call the participants monthly to identify barriers to dementia care and help participants and participants' elder with making an appointment or transportation to the health care facility, when participants request for assistance.
32771398|NCT03909347|Active Comparator|Standard of care (control)|Group 2 will receive a signs and treatment of dementia pamphlet by the Alzheimer's Association and will be referred to the elder's primary physician.
32771399|NCT05091957|Experimental|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
32771400|NCT05091957|Active Comparator|Usual Care|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. Based on the ethical imperative to provide some support to families who identify unmet social needs, the comparator group will receive Usual Care, defined as: Participants in both groups will receive a written summary of available resources.
32771401|NCT04338659|Experimental|Dose Escalation of IBI322|Participants will receive escalating dose levels of IBI322 to determine maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of IBI322
32771402|NCT05190003|Experimental|Study group I: The first time of patients attending single-level lumbar microdiscectomy|"Study group I:~On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises."
32771403|NCT05190003|No Intervention|Study group II: Control healthy people|"Study group II:~40 people aged 20-65 years. Including criteria: healthy persons without lumbar spine pain for at least 6 months and without lumbar spine surgery."
32771404|NCT03901001|Active Comparator|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
32771405|NCT03901001|Placebo Comparator|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
32771406|NCT05189535|Experimental|pentoxifylline 400 mg|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and pentoxifylline 400 mg twice daily for the paclitaxel treatment period.
32771407|NCT05189535|Placebo Comparator|Placebo|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and placebo twice daily for the paclitaxel treatment period..
32771409|NCT03744611|Experimental|Cortex Eucommiae(CE)|CE capsule administered orally twice daily for 12 weeks.
33401552|NCT05675254||No EP|Non-epileptic children and had never taken any ASMs
33401553|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
33401554|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
32771410|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
32771411|NCT05135169||Contrast administration|
32771412|NCT04755179||Complex appendicitis without abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis without clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
32771413|NCT04755179||Complex appendicitis with abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis with clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
32771414|NCT05187585|Sham Comparator|radiograph interpretation without the support of the RAYVOLVE app|
32771415|NCT05187585|Experimental|radiograph interpretation with the support of the RAYVOLVE app|
32771416|NCT05133999||Preterm infants|infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight
33079081|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
33401555|NCT02674750|Experimental|Group A|Group A: MYC translocation+ and/or MYC gene copy number gain by FISH
32771417|NCT04732871|Experimental|Group A|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until the study end.
33401556|NCT02674750|Experimental|Group B|Group B: MYC expression in > 40% of tumor cells by IHC
33401557|NCT02674750|Experimental|Group C|Group C: MYC translocation- by FISH, and MYC expression in < 40% of tumor cells, and no MYC gene copy number gain by FISH
32771418|NCT04732871|Experimental|Group B|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 1 revaccination dose at 24 months post-Dose 1 and are followed up until the study end.
32771419|NCT04732871|Experimental|Group C|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until the study end.
33079082|NCT04635124|Active Comparator|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
33079083|NCT04635124|Experimental|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.~Apart from the visitor, an observer is present."
33079084|NCT04635124|Active Comparator|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.~Apart from the visitor, an observer is present, but no dog is present.."
33265576|NCT03969745|Experimental|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
33265577|NCT03969745|Active Comparator|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume ~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
33265578|NCT00835952|Experimental|ATX-101|
33265579|NCT03971773|Experimental|Patient ongoing hypnosis sessions|
33079085|NCT04635085|Experimental|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
33265580|NCT05035173|Experimental|Intervention Arm|Participants will have available the services offered by the Women's Cancer Survivorship Clinic and will undertake electronic Patient Reported Outcomes at baseline, 2, 4, 6, 8, 10, 12 months (end of the study).
33265581|NCT05035173|Active Comparator|Control Arm|Participants will attend a baseline and end of the study visit (12-month time point) to the Women's Cancer Survivorship Clinic to undertake the baseline and complete end of study assessments. They will complete ePRO at baseline and at 12 months. They will have usual follow up care over the 12 month period of the study. Where participants in the control arm contact the Survivorship team for clinical or other advice, they will be referred to the usual care pathway.
33265582|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
33265583|NCT03971617|Experimental|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
33265584|NCT03971617|Placebo Comparator|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
33265585|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
33265586|NCT00504556|Experimental|2|DU-176b 60mg once daily
33265587|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
33265588|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
33265589|NCT00504556|Active Comparator|5|warfarin tablets
33265590|NCT05274009|Experimental|Extreme heat event simulation + no cooling (control)|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
33265591|NCT05274009|Experimental|Extreme heat event simulation + recommended cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
33265592|NCT05274009|Experimental|Extreme heat event simulation + hybrid cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
33265593|NCT00836030||A|
33265594|NCT00206323|Placebo Comparator|placebo/sugar pill|Placebo or sugar pill
33265595|NCT00206323|Active Comparator|Topiramate|Topiramate 25 mg to 200 mg
33265596|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
33265597|NCT04043000|Experimental|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
33265598|NCT04043000|Placebo Comparator|Placebo|" The placebo without Super 13 Pro & Prebiotics was given three times a day for four weeks."
33265599|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
33265600|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
33265601|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
33265602|NCT00205855|Experimental|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
33265603|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
33265604|NCT01013038|Experimental|Thrombus aspiration|
33265605|NCT04526704|Experimental|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
33265606|NCT04526704|Experimental|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
33265607|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
33265608|NCT00842192||A|
33277524|NCT05199974|Active Comparator|Group A: Linea alba was closed with conventional continuous technique .|Group A: 25 patients included . Linea alba will be closed with conventional continuous technique .
33265609|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33265610|NCT00842270|Experimental|2|4,5 mg/kg/day
33265611|NCT00842270|Experimental|3|6 mg/kg/day
33265612|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
33265613|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
33265614|NCT00836108|Sham Comparator|1|spontaneous
33265615|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
33265616|NCT00836108|Experimental|3|coordinating arm elevation with expiration
33265617|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with surface lesions|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
33265618|NCT04348916|Experimental|Dose expansion of ONCR-177 in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
33265619|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
33265620|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory solid tumor cancer with liver metastases
33265621|NCT04348916|Experimental|Dose expansion of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory solid tumor cancer with liver metastases
33265622|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory solid tumor cancer with liver metastases
33265623|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
33265624|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
33265625|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
33265626|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
33265627|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
33265628|NCT04946721||1.BMT Patients (Study)|Patients prior to receiving a bone marrow transplant will be recruited during their initial intake prior to their BM transplant through the PI's regularly scheduled appointment with these patients.
33265629|NCT04946721||2.Controls|Patients with no history of eye disease or cancer history
33265630|NCT01013116|Experimental|modified allergen extract of house dust mites|
33265631|NCT01013116|Placebo Comparator|Placebo|
33265632|NCT04002765|Other|New RA patients|"Adults aged 18 to 90 years-old~Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria~Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
33265633|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
33265634|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
33265635|NCT03998020|Other|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
33265636|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
33265637|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
33265638|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
33265639|NCT00843596|Experimental|vacuum device - suction cup|
33265640|NCT00842426|No Intervention|Usual Care|Usual Care
33265641|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
33265642|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
33265643|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
33265644|NCT00842504|Other|Micafungin|3 mg/kg given once
33265645|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
33265646|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
33265647|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
33265648|NCT00842660|Experimental|Gemzar,survival|
33265649|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
33277525|NCT05199974|Active Comparator|Group B: Linea alba was closed with Modified Smead Jones technique with Far-near near-far technique.|Group B:25 patients included. Linea alba will be closed with Modified Smead jones technique with Far-near near-far technique.
33277526|NCT02556671||Moderate CKD Patients Undergoing PCI|
33277527|NCT02556671||Normal renal function Patients Undergoing PCI|
32771420|NCT05133219|Experimental|Research Group|"Participants will be received Intensified sensory therapy.~Other: Occupational Therapy Activities of Daily Living Training~Intervention: Other: Occupational therapy intervention"
32771421|NCT05133219|Experimental|Control Group|"Participants will be received Occupational Therapy.~Other: Activities of Daily Living Training"
32771422|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
32771423|NCT05131659|Experimental|Executive function group therapy|
32771424|NCT04627493|No Intervention|Waitlist (Control)|Usual care
32771425|NCT04627493|Experimental|Exercise|Online exercise program
32771426|NCT05002075|No Intervention|Usual care arm|Participants in the usual control group will receive standard of care per their providers' discretion.
32771427|NCT05002075|Experimental|m-health cardiac rehabilitation intervention arm|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
32771428|NCT05090553|Active Comparator|surgical treatment|Lumbar Spinal Fusion Surgery
32771429|NCT05090553|Experimental|Bacterial culture|"Cutibacterium acnes culture in two different atmosphere:~Carbon dioxide (CO2) from 5% up to 10%~CO2 10%, H2 10% and N2 80%"
32771430|NCT05090553|Experimental|Phenotypic and genotypic characterization|Mass spectrometry and (Polimerase Chain Reaction) PCR
32771431|NCT05090553|Experimental|Multiomics analysis|"Genome sequencing~Proteomics~Metabolomics"
32771432|NCT04789811|Experimental|Exercise Group|It describes the exercise protocol that the patients will do.
32771433|NCT04789811|Experimental|Exercise plus Dry Needling Group|It describes the exercise protocol to be performed by the patients and the methodology of dry needling to be applied.
32771434|NCT05089461|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced malignant tumor will receive 20 mg/m^2 Mitoxantrone Hydrochloride Liposome by an intravenous infusion (IV) on day 1 of each treatment cycle.
32771435|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
32771436|NCT04789343|Experimental|hand files with lateral condensation technique|Previously done root canal filling removed by hand files (Hedstrom file,VDW, Munich,Germany ) and shaped with the same files and after instrumentation, all canals were filled by AH Plus sealer (Dentsply De Tray, Costanz, Germany) and lateral condensation technique of gutta-percha.
32771437|NCT04789343|Experimental|Reciproc instrument with lateral condensation technique|Previous root canal filling removed by Reciproc instrument (VDW ,Munich, Germany )using Endomotor (VDW, Munich, Germany). After removal, root canal instrumented with the same instrument and obturated using AHPlus sealer with lateral condensation technique of gutta-percha.
32771438|NCT04789343|Experimental|Reciporoc instrument with continuous warmed condensation technique|Previous root canal removed by Reciproc instrument using Endomotor, shaped and obturated by AhPlus sealer with continuous gutta-percha technique (Diadent Dia-Duo (Diadent, Chongju, Korea).
32771439|NCT05186415|Experimental|diagnostic arm|The echocardiography team will perform baseline echocardiographic views of the right ventricle without contrast. The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations. Dosages and timing of administration as well as patient size and transducer type will be recorded for each patient. The total cumulative dose of Lumason from the clinical study and the research study will not exceed the maximum recommended dose by the manufacturer, 4.8 mL. A single injection will not exceed the maximal FDA-recommended dose of 2.4 mL per single injection. These echocardiographic views of the right ventricle with ultrasound enhancing agent will be compared to the measurements made without the use of ultrasound enhancing agents, and the measurements made in MRI.
33230993|NCT00816634|Active Comparator|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
33230994|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
33230995|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
33230996|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
33230997|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
33230998|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
33230999|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
33231000|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
33231001|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
33231002|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
33231003|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
33231004|NCT00653224|Experimental|LCTZ|5 mg tablet
33231005|NCT00444925|Experimental|Fesoterodine|Tablets
33231006|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
33231007|NCT00444925|Active Comparator|Tolterodine|Capsules
33231008|NCT00641056|Experimental|1|
33231009|NCT00641056|Active Comparator|2|
33231010|NCT00814346|Active Comparator|EGb 120 mg|
33231011|NCT00814346|Placebo Comparator|Placebo|
33231012|NCT00809224||ALS|ALS group should have ALS.
33401558|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
32771440|NCT05730439|Experimental|Arm I (usual SLT, ZYN NP, Rogue NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, ZYN brand nicotine patch at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
32771441|NCT05730439|Experimental|Arm II (usual SLT, Rogue NP, ZYN NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, Rogue brand nicotine patch at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
33231013|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
33231014|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
33231015|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
33231016|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
33231017|NCT00816712|Placebo Comparator|C|Placebo - IM
33231018|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
33231019|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
33231020|NCT02610686|Other|Chloroquine|Single treatment arm
33231021|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
33231022|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
33231024|NCT03864796||cases of newly diagnosed ITP|no intervention
33231025|NCT03864796||cases of ITP after responding to treatment|no intervention
33231026|NCT03864796||healthy subjects|no intervention
33231027|NCT00818350|Experimental|SUNITINIB|
33231028|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
33231029|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
33231030|NCT05500586|Experimental|Healthy Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
33231031|NCT05500586|Experimental|Obese Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
33231032|NCT05500586|Experimental|Adults with Type 2 Diabetes|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
33231033|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
33231034|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
33231035|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
33231036|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
33231037|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
33231038|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
33231039|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
33231040|NCT00628108|Placebo Comparator|Placebo|
33231041|NCT00628108|Experimental|Levocetirizine|
33231042|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
33231043|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
33231044|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
33231045|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
33231046|NCT03864640||Colorectal cancer|Patients with colorectal cancer
33231047|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
33231048|NCT00821392|Active Comparator|1 Febuxostat 40mg|
32771442|NCT05730439|Experimental|Arm III (ZYN NP, usual SLT, Rogue NP)|Participants receive ZYN brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
32771443|NCT05730439|Experimental|Arm IV (ZYN NP, Rogue NP, usual SLT)|Participants receive ZYN brand nicotine patch at study visit 1, Rogue brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
32771444|NCT05730439|Experimental|Arm V (Rogue NP, usual SLT, ZYN NP)|Participants receive Rogue brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
32771445|NCT05730439|Experimental|Arm VI (Rogue NP, ZYN NP, usual SLT)|Participants receive Rogue brand nicotine patch at study visit 1, ZYN brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study
32771446|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
32771447|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
32771448|NCT05182125|Experimental|Part A, Group 1: AdC6-HIVgp140|Participants will receive 1 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
32771449|NCT05182125|Experimental|Part A, Group 2: AdC7-HIVgp140|Participants will receive 1 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
32771450|NCT05182125|Placebo Comparator|Part A, Group 3: Placebo|Participants will receive placebo for AdC6-HIVgp140 or AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
32771451|NCT05182125|Experimental|Part B, Group 4: AdC6-HIVgp140 + AdC7-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
32771452|NCT05182125|Experimental|Part B, Group 5: AdC7-HIVgp140 + AdC6-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
32771453|NCT05182125|Placebo Comparator|Part B, Group 6: Placebo + Placebo + Placebo|Participants will receive placebo for AdC6-HIVgp140and AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0 and 3. Placebo for CH505TF/GLA-SE (labeled as Sodium Chloride for Injection, 0.9% ) to be administered as 1 mL IM injection into either thigh at month 6.
32771454|NCT05730361|Experimental|ScTIL injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: ScTIL210 injection alone or with B lymphocytes adjuvant.
32771455|NCT04789187|Active Comparator|Arm A: Exercise intervention arm|
32771456|NCT04789187|Placebo Comparator|Arm B: Control arm|
32771457|NCT05550493|Experimental|Digital Therapeutics|The DTx group was asked to download and install a smartphone application (WonderLab Harbor) that incorporated Internet-based Cognitive Behavioral Therapy (ICBT), Approach Bias Modification (ApBM), cognitive function training, and Contingency Management (CM). During the 8-week treatment program, the participants in the DTx group were instructed to complete ICBT, cognitive trainings, and ApBM trainings. Reward points (which can be redeemed for cellphone plan credit) were rewarded following completing each task as part of the positive reinforcement following CM principles.
33231049|NCT00821392|Active Comparator|2 Febuxostat 80mg|
32771458|NCT05550493|Active Comparator|Treatment as Usual|Upon enrollment, TAU participants were informed that they would receive weekly counseling sessions from a social worker for eight weeks. The counseling covered topics including work, family, stress management, and drug craving suppression.
32771459|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo or no intervention to children 12-59 months old
33231050|NCT00821392|Active Comparator|3 Febuxostat 120mg|
32771460|NCT04224987|Active Comparator|Azithro 1-59|Biannual age, weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
32771461|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
32771462|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
32771463|NCT05532007|Active Comparator|Peanut Group|Peanuts: 2-3 ounces per day to replace 20% of daily energy intake
32771464|NCT05532007|Active Comparator|Control Group|Habitual diet abstain from eating peanuts
32771465|NCT04583969|Experimental|Remdesivir + Lenzilumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
33265650|NCT04249622|Experimental|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
33265651|NCT04249622|Active Comparator|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
33265652|NCT00509236|Experimental|Sitagliptin 25 mg|
33265653|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
33265654|NCT00836420||liver|patients with acute liver failure
33265655|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
33265656|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
33265657|NCT00842738|Other|Controls|Women with normal cervical cells
33079086|NCT04635085|No Intervention|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
33265658|NCT00842816|Experimental|1|10 mg ST101
33265659|NCT00842816|Experimental|2|60 mg ST101
33265660|NCT00842816|Experimental|3|120 mg ST101
32771466|NCT04583969|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab placebo infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
32771467|NCT05087823|Experimental|Lipid, Glucose, and Mixed Meal Challenges|Participants will take part in three different meal challenges on three separate days with approximately two weeks in between. The first meal challenge is the lipid challenge, the second meal challenge is the glucose challenge and third meal challenge is the mixed-meal challenge.
32771468|NCT05730283|Experimental|High Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 150mg followed by a daily dose of 30mg. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
32771469|NCT05730283|Experimental|Low Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 60mg capsules followed by a daily dose of 12mg capsules. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
32771470|NCT05730283|Placebo Comparator|Placebo|This arm is a daily treatment regimen of a placebo with a loading dose and a daily dose of placebo capsules to match the treatment arms. Placebo regimen will run concurrently with treatment with IV amikacin. Placebo regimen will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
33265661|NCT00842816|Placebo Comparator|4|Placebo
33265662|NCT00842894||Insulin detemir|
33265663|NCT00842894||Biphasic insulin aspart 30|
33265664|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
33265665|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
33265666|NCT04043390|Experimental|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP >10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
33265667|NCT04043390|Experimental|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP >10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
33265668|NCT04043390|No Intervention|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
33265669|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
33265670|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
33265671|NCT03896295|Experimental|M281|
33265672|NCT00508924|Experimental|ARG250|
33265673|NCT00508924|Experimental|ARG300|
33265674|NCT00508924|Experimental|ARG350|
33265675|NCT00508924|Placebo Comparator|Heparin|
33265676|NCT00836576|Experimental|1|
33265677|NCT00836576|Active Comparator|2|
33265678|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
33265679|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
33265680|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
33265681|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
33079087|NCT04634812|Experimental|[14C]-KBP-5074|
33079088|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
33079089|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
33079090|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
33079091|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
32771471|NCT05087667|Experimental|Polymer Cerclage System OrthoLoop|Patients receives Ortholoop Cerclage System
33079092|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
33079093|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
33079094|NCT04634656|Active Comparator|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
33079095|NCT04634656|Placebo Comparator|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
33079096|NCT04634500|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
33079097|NCT04634500|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
33079098|NCT04634422|Experimental|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
33079099|NCT04634422|No Intervention|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
33231051|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
33231052|NCT00821392|Placebo Comparator|5 Placebo|
33231053|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
33231054|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
33231055|NCT00591578|Active Comparator|Valsartan 320 mg QD|
33231056|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
33231057|NCT00817024|Active Comparator|Sheng Mai Capsules|
33231058|NCT00817024|Placebo Comparator|Placebo|
33231059|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
33231060|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
33231061|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
33231062|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
33231063|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
33231064|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
33231065|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
33231066|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
33231067|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
33231068|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
33231069|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
33231070|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
33231071|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
33231072|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
33231073|NCT00455533|Experimental|A|
33231074|NCT00455533|Active Comparator|B|
33231075|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
33231076|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
33231077|NCT05227742|Placebo Comparator|Placebo (0 mg psilocybin)|Participants in this arm will receive 0 mg of psilocybin once per week for 5 weeks.
33231078|NCT05227742|Experimental|1 mg psilocybin|Participants in this arm will receive 1 mg psilocybin once per week for 5 weeks.
33231079|NCT05227742|Experimental|2.5 mg psilocybin|Participants in this arm will receive 2.5 mg psilocybin once per week for 5 weeks.
33231080|NCT05227742|Experimental|5 mg psilocybin|Participants in this arm will receive 5 mg psilocybin once per week for 5 weeks.
33265682|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
33265683|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
33265684|NCT00844064|Experimental|AP 12009|
33401559|NCT03285854||Healthy age and gender matched children|"All children <18 years~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
33265685|NCT04688788|Experimental|Rituximab|Intravenous biosimilar rituximab (Ruxience®) 1000 mg given every 6th month (first 2 infusions 1000mg/1000 mg given 2 weeks apart).
33265686|NCT04688788|Active Comparator|Ocrelizumab|Intravenous ocrelizumab (Ocrevus®) 600 mg every 6th month (first 2 infusions 300 mg/300 mg given 2 weeks apart).
33079100|NCT04633954|Experimental|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
33079101|NCT04633954|No Intervention|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
33079102|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
33265687|NCT04003077|Experimental|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
33265688|NCT04003077|No Intervention|Control|A control group of participants without laser meridian massage treatment are matched by age.
33265689|NCT05221593|No Intervention|control group|will receive chemotherapy regimen with placebo
33265690|NCT05221593|Experimental|study group|"will receive chemotherapy regimen with Lithium Carbonate in controlled release formula (400mg b.i.d).~In order to avoid the potential for bone marrow stimulation at the time chemotherapy was administered, the administration of lithium was started 24 hours after the administration of chemotherapy and continued for 18 days of every 21.the lithium serum level will be measured at specific times to ensure lithium serum level between 0.4-0.8 mmol\L along the treatment course."
33265691|NCT00844142|Other|1|etanercept 25mg twice weekly
33265692|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
33265693|NCT04688554||Refractory Obsessive Compulsive Disorder|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical capsulotomy
33265694|NCT04688554||Refractory Pain|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
33265695|NCT04688554||Refractory Tremor|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical thalamotomy
33265696|NCT04688554||Refractory Depression|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
33265697|NCT04924569||Standard of Care|Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.
33265698|NCT00837044|Active Comparator|1|Treximet, cognitive testing
33265699|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
33265700|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
33401560|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
33079103|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
33079104|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
33079105|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
33079106|NCT00560872|Other|1|conventional ablation with manual catheter navigation
33079107|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
33079108|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
33079109|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
33079110|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
33079111|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
33079112|NCT04633876|Active Comparator|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
33265701|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
33265702|NCT04232085|Experimental|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
33265703|NCT04232085|Experimental|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
32771472|NCT05087667|Active Comparator|cerclages used in standard care|"Patients receives cerclages used in standard care"
33265704|NCT04678804|Experimental|Matrix Graft Group|patients treated with Porcine Derived Volume Stable Matrix
33265705|NCT04678804|Other|Autogenous ctg group|patients treated with autologous tissue
33079113|NCT04633876|Experimental|Individual coaching|These subjects receive individual counselling during the study.
33079114|NCT04633876|Experimental|Group coaching|These subjects receive individual counselling during the study.
33265706|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
33265707|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
33265708|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
33265709|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
33265710|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
33265711|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
33265712|NCT04905849|Experimental|Adaptive Cognitive Control Trainer (ACCT)|There are three modules within the game, each training a different aspect of cognitive control (attention, goal management, working memory): a visual search task for attention abilities, a spatial span task for working memory, and a task switching paradigm for goal management abilities. There are also 3 different levels of difficulty associated with each module; advancing to the next level delivers an advanced challenge that enhances the difficulty in performing the given cognitive task. Participants advance to the next level of difficulty following 6 training sessions occurring over 2 weeks, with the total training experience being 6 weeks of training (3 days/week), with each training session lasting 36 minutes (not including self-paced breaks).
32771473|NCT05613959||Veress +|The Veress+ system was used
32771474|NCT05613959||Veress conventional|The Conventional Veress needle was used
32771475|NCT05730049|Experimental|Active taVNS|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA. Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients. Stimulation will be applied for a duration of 1 hour.
32771476|NCT05730049|Sham Comparator|Sham taVNS|The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve.
33265713|NCT04905849|Active Comparator|Active Control Group|An active control application will be used for this arm. The total training experience here will also be for 6 weeks (3 days/week), with each training session lasting ~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
33265714|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
32771477|NCT04517279|Experimental|Invest in My Recovery Bank|The Invest in My Recovery Bank arm is an intervention focused on enhancing the recovery capital of individuals in early psychosis care. The intervention is provided by a peer provider, operating on the coordinated specialty care team
33079115|NCT04633720|Experimental|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
33079116|NCT00201669|Experimental|Arm I|
33079117|NCT04633798|Experimental|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
33079118|NCT04633798|Active Comparator|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
33265715|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
33265716|NCT04905537||Sick Neonates or Stillbirth|Infants and their parents enrolled through Neonatal Intensive Care Unit or stillbirths through Obstetrics Department of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/ physical exam, and the results of the genomic sequencing report.
33265717|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
33265718|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
33265719|NCT00851240|Experimental|BTT1023|
33265720|NCT00851240|Placebo Comparator|Placebo|
33265721|NCT04893291|Active Comparator|Everolimus Eluting Stent|
33265722|NCT04893291|Experimental|Magic Touch Sirolimus Coated Balloon|
33079119|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
32771478|NCT04517279|Active Comparator|Usual Care|The peer providers operating under the Usual Care condition will continue to provide peer support services to individuals within the coordinated specialty care team.
33265723|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
33265724|NCT03535324|Other|Control|There will be no intervention.
32771479|NCT05519449|Experimental|Dose Escalation|Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose.
33265725|NCT00620750|Experimental|Extended release injectable naltrexone|
33265726|NCT04884243|Placebo Comparator|CBT-006|
33265727|NCT04884243|Experimental|2.5% CBT-006|
32771480|NCT05519449|Experimental|Backfill Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable.
33265728|NCT04884243|Experimental|10% CBT-006|
33265729|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
32771481|NCT05519449|Experimental|Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).
32771482|NCT04789031|Experimental|Intervention group|Patients received oral nutritional supplementation and standard nutritional counseling for 6 months.
32771483|NCT04789031|No Intervention|Control group|Patients received standard nutritional counseling for 6 months.
32771484|NCT05506423|Experimental|CycloPen|Participant underwent intraocular pressure lowering surgery using the CycloPen Cyclodialysis System
32771485|NCT05126745||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
32771486|NCT04789421|Active Comparator|Arm 1 (interventional)|Patients with equivocal skin lesions suspicious for melanoma, randomised to adjunctive RCM evaluation, following clinical and dermoscopy evaluation.
32771487|NCT04789421|Placebo Comparator|Arm 2 (control)|Patients with equivocal skin lesions suspicious for melanoma, randomised to clinical and dermoscopy evaluation only; adjunctive RCM evaluation refused.
32771488|NCT05500417|Experimental|Group 1A|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32771489|NCT05500417|Experimental|Group 1B|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32771490|NCT05500417|Experimental|Group 2A|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32771491|NCT05500417|Experimental|Group 2B|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32935606|NCT04847323|Active Comparator|Vacuum-formed Retainer|The removable Vacuum-formed retainers were made of acetate 1mm thickness. They were made at the same appointment of debonding using plaster models. The patients were instructed to use the retainers only during nights.
32935607|NCT05282173|No Intervention|Treatment As Usual (TAU)|Monitoring of treatment as usual (i.e., routine interactions between community health workers (CHWs) and their patients).
33079120|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
33079121|NCT04633525|Experimental|Optimum Cup Orientation|
33079122|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
33265730|NCT04867707|Experimental|Zanamivir treatment|Study participants will receive 5 days of treatment with a zanamivir inhaler.
33265731|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
33265732|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
33265733|NCT04002999|Active Comparator|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
33265734|NCT04002999|Experimental|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
33265735|NCT04002999|Experimental|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
32771492|NCT05500417|Experimental|Group 3A|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32771493|NCT05500417|Experimental|Group 3B|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
32771494|NCT05126199|Experimental|Time restricted eating|"Time-restricted eating using 18:6 protocol (12 weeks)~Washout Period (4 weeks)~Crossover to Normal ad libitum diet (12 weeks)"
32771495|NCT05126199|Active Comparator|Normal ad libitum diet|"Normal ad libitum dietary patterns without defined eating window, fasting or restrictions on types of food or drink consumed (12 weeks)~Washout Period (4 weeks)~Crossover to time-restricted eating using 18:6 protocol (12 weeks)"
32771496|NCT04789265|Experimental|Combined Therapy (Instrumented Soft Tissue Mobilization)|
32771497|NCT04789265|No Intervention|Control Group (Exercise Therapy)|
32771498|NCT05493787|No Intervention|Passive control|No message
32771499|NCT05493787|Active Comparator|Active control message|A message that simply states that patients can get a flu shot at Geisinger
33265736|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
33079123|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
33079124|NCT04633330|Experimental|Study Arm|AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
33079125|NCT04633330|Placebo Comparator|Control Arm|Simulation of AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
33079126|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
33265737|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
33265738|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
33265739|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
33265740|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
33265741|NCT00844220|Active Comparator|Catheterization|Standard clinical management
33265742|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
33265743|NCT05357547|Experimental|Buspirone|
32771500|NCT05493787|Experimental|Ease message|A message emphasizing the ease of scheduling a flu shot at Geisinger
33079127|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
33265744|NCT05357547|Placebo Comparator|Control|
33265745|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
33265746|NCT00844454|Active Comparator|RFA|radiofrequency ablation
33265747|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
33265748|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
32771501|NCT05493787|Experimental|Waiting for you message|"A message that states the patient's flu shot is waiting for them at Geisinger"
33265749|NCT01011010|Other|Single Arm|Single Arm Trial
33265750|NCT05357391|Experimental|The pressure injury prediction and education model group|The experimental group will be provided a pressure injury prediction of the patient and personalized care information of pressure injury by a smart care platform. The participants (primary caregivers) will fill out the questionnaires online at admission (baseline-T0) and before the patient is discharged(T1). The questionnaires will collect the following data, including demographic information(only T0), knowledge, self-efficacy, anxiety, depression of wound care(T0&T1), and satisfaction of the smart care platform(only T1). The time to fill out the questionnaires will be about 10 minutes.
33265751|NCT05357391|No Intervention|The control group|Routine care
33265752|NCT00851708|Active Comparator|NAC|treatment
33265753|NCT00851708|No Intervention|control|
33265754|NCT05018481|Placebo Comparator|HA35 Placebo Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.
33265755|NCT05018481|Active Comparator|HA35 Treatment Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.
33265756|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
33265757|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
33265758|NCT05011851|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
33265759|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
33265760|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
32771502|NCT05493787|Experimental|Protect yourself - rare message|A message that emphasizes the rare, dangerous outcomes of getting the flu (e.g., hospitalization, pneumonia), and states that a flu shot can offer protection from those outcomes
32771503|NCT05493787|Experimental|Protect yourself - frequent message|A message that emphasizes the outcomes that frequently occur in people with the flu (e.g., fever, chills, missing important events), and states that a flu shot can offer protection from those outcomes
33079128|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
33265761|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
33265762|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
33265763|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
33265764|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
33265765|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
33265766|NCT05356143|Other|Sequence 1|Subjects will take comparator and active drug at different study periods Treatment sequence AAB
33265767|NCT05356143|Other|Sequence 2|Treatment sequence ABA
33265768|NCT05356143|Other|Sequence 3|Treatment sequence BAA
33265769|NCT04849455|Experimental|Active Treatment|This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)
32771504|NCT05613569||A group who administered KLS-2031 in the KS-GIG-001-01 Study|
32771505|NCT05180955|Other|Digital drainage system group|chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data.
32771506|NCT05180955|Other|Digital drainage system + clamping trial group|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
32771507|NCT04830163|Experimental|PCMS during brain states reflecting strong corticospinal transmission|
33079129|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
33265770|NCT04849455|Placebo Comparator|Placebo|This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
32771508|NCT04830163|Active Comparator|PCMS during random brain states|
32771509|NCT04788719|Experimental|Preoperative|Gait analysis kinematics and kinetics
32771510|NCT04788719|Experimental|Postoperative|Gait analysis kinematics and kinetics
32771511|NCT05125263|Experimental|group 1|This group receives KinesioTaping along with conventional treatment
32771512|NCT05125263|Experimental|group 2|This group receives mulligan taping along with conventional treatment
32771513|NCT05197595|Experimental|Compassion condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
32771514|NCT05197595|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extracurricular activity.
32906365|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
33265771|NCT04509076|Experimental|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
33265772|NCT04509076|Placebo Comparator|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
33265773|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
33265774|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33265775|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33265776|NCT05355909|No Intervention|controll group|Standard of care without preoperative fitness program
33265777|NCT05355909|Experimental|Interventional group|After randomisation the patients will obtain a two week personalised fitness program to improve the preoperative fitness
33265778|NCT00844688|Other|sorafenib/gemcitabine|
33079130|NCT04633018|Experimental|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
33079131|NCT04633018|Experimental|Wait list control|Control group with usual care (not using app).
33265779|NCT04541680|Experimental|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
33265780|NCT04541680|Placebo Comparator|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
33265781|NCT04815369||Guidance Clinical Pathway|Facilities will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification to a central point person within the Nursing Home (NH) facility
33265782|NCT04815369||Traditional Clinical Pathway|Facilities will employ their current standard clinical care practices for suspected UTI, including SUC, UA, and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
33265783|NCT00855530|Experimental|1|
33265784|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
33265785|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
33265786|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
33265787|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
33265788|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
33265789|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
33265790|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
33265791|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
33079132|NCT00410358|Experimental|LBQ707|
33265792|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
33079133|NCT04632979|Experimental|Backward runners|Training protocol patients
33079134|NCT04632862|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
33265793|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
33265794|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
33265795|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
33265796|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
33265797|NCT04190186|Active Comparator|Biotronik ICM-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
33079135|NCT04632862|Placebo Comparator|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
33079136|NCT04633174|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
33079137|NCT04633135|No Intervention|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
33079138|NCT04633135|Experimental|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
33079139|NCT04633135|Experimental|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
33079140|NCT04633135|Experimental|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
33265798|NCT04190186|No Intervention|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
33265799|NCT04793373|Experimental|EpiFaith® group|Study subject will have the epidural placement with an EpiFaith® syringe.
33265800|NCT04793373|Active Comparator|Conventional group|Study subject will have the epidural placement with a conventional glass syringe.
33265801|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
33265802|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
33265803|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
33079141|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
32771515|NCT04805515|Experimental|Nicotine Corrective Messages|Participants in the nicotine corrective messages condition will receive 8 brief nicotine corrective public education messages delivered online during 4 waves of the 12 week study. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.
32771516|NCT04805515|No Intervention|Delayed Message Control|Participants in the control condition will be exposed to the nicotine corrective messages after the completion of the final assessment at the end of the 12 week study.
33265804|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
33265805|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
33265806|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
33265807|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
33265808|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
32771517|NCT05124873|Experimental|Experimental Prosthetic Liner|
32771518|NCT05195177|Experimental|Study group|
33265809|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
33265810|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
32771519|NCT05729971||with NGT|In these patients, the nasogastric tube remains after surgery. It was removed after x-ray test.
33079142|NCT00410397|Placebo Comparator|B|
33079143|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
32771520|NCT05729971||noNGT|In these patients, NGT was removed at the end of surgery.
32906366|NCT01837940|Placebo Comparator|Placebo|
32906367|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
33079144|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
33079145|NCT04632745|Other|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
33079146|NCT04632745|Other|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
33079147|NCT04632823|Experimental|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
33079148|NCT04632823|No Intervention|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
33079149|NCT04632277|Placebo Comparator|Placebo|"A tap water,"
33079150|NCT04632277|Experimental|Expermental recieve low MG|Low Mg bottle water (50mg/l)
33079151|NCT04632277|Experimental|Expermental recieve high MG|high Mg bottle water (100 mg/l)
33079152|NCT04632628|Experimental|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
33079153|NCT04632472|Active Comparator|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
33079154|NCT04632472|Placebo Comparator|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
33079155|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
33265811|NCT04002531|Other|Single Visit|"General and neurological examination~Vital signs including height, weight, blood pressure, pulse, temperature~12 lead ECG~2 hour Holter monitor for heart rate variability~Echocardiogram~Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.~CBC with differential~Complete metabolic panel~Urinalysis~Urine Albumin/creatinine ratio.~Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.~Brief Pain Inventory questionnaire.~Quality of Life Questionnaires (SF36)"
33265812|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
33265813|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
33265814|NCT00852098|Active Comparator|1|dividing short gastric vessels
33265815|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
33265816|NCT05356689|Experimental|traditional physiotherapy|Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
33265817|NCT05356689|Experimental|3- 2dimensional lumbar traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed.
33265818|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
33265819|NCT05260671|Experimental|Penpulimab+cetuximab|Erbitux 500 mg/m2 without immunotherapy for 14 days prior to first cycle. Cetuximab Injection 500 mg/m2 and Penpulimab Injection 200 mg are intravenously infused on Day 1 (D1) of Cycle 1, with 14 days as one cybcle. Penpulimab for up to 96 weeks (48 cycles)
33265820|NCT00855686|Experimental|Memantine|
33265821|NCT00855686|Placebo Comparator|Placebo|
33265822|NCT04041908|Experimental|Experimental Product|Drink mix powder
33265823|NCT04001283|Experimental|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
33265824|NCT04001283|Experimental|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
33265825|NCT04001283|Placebo Comparator|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
33265826|NCT03523377|Experimental|prolonged overnight fasting|Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following the first overnight fast, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.
33265827|NCT03523377|Active Comparator|usual care|Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.
33265828|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
33265829|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
33265830|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
33265831|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
33265832|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
33265833|NCT00844922|Placebo Comparator|Placebo|
33265834|NCT05272761||Oronasal Route|Patients will sleep in the sleep lab for CPAP titration wearing a custom oronasal mask with 2 open oral and nasal compartments. The titration was split between the first half of the night and the second half. The titration will be started with the patient remaining for 90 minutes with the pressure he uses at home (supine position and in lateral decubitus), after a period of 90 minutes the patient will be titrated in order to abolish respiratory events in both positions of the body.
33265835|NCT05272761||Oral Route|"Group/Cohort Interventions Oronasal Route~Patients will sleep in the sleep lab for CPAP titration using a custom 2-compartment oronasal mask. In this titration, the nasal compartment will be closed and the patient will be titrated only through the oral route. The titration split between the first half of the night and the second half. The titration will be started with the patient staying for 90 minutes with the pressure used at home (during the supine position and lateral position), after the 90 minute period the patient will be titrated in order to abolish respiratory events in both positions of the body."
33265836|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
33265837|NCT03500757||360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
33265838|NCT00845078||1|Immediate reconstruction followed by radiation therapy
32771521|NCT05180331|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
32771522|NCT05465083|Experimental|Lungpacer AeroPace Protect System|"The PNS device used for this study will be the most recent AeroPace central venous catheter from Lungpacer Medical Inc (Vancouver, BC). It is an 8.5F 23cm triple lumen central venous catheter with 30 electrodes arranged in two arrays (distal 9 electrodes intended to capture the right phrenic nerve and the 21 proximal to capture the left phrenic nerve). It is inserted via the left internal jugular or left subclavian vein where it is placed in the proximal superior vena cava (SVC) at or above the cavo-atrial junction.~The AeroPace system monitors airway pressure to detect ventilator-triggered controlled mechanical breaths and patient-triggered assisted mechanical breaths. In response to detection of native respiratory efforts the PNS lies quiescent."
33079156|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
33265839|NCT00845078||2|Radiation therapy followed by delayed reconstruction
33265840|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
33265841|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
33265842|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
33265843|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
33265844|NCT00855998||1|With BRCA1 or BRCA2 mutations
33265845|NCT00855998||2|Without BRCA1 or BRCA2 mutations
32771523|NCT05123859||age groups|"A total of 30 participants in the 25- to 34-year age group~A total of 45 participants in the 35- to 44-year age group~A total of 50 participants in the 45- to 54-year age group~A total of 50 participants in the 55- to 64-year age group~A total of 45 participants in the 65- to 74-year age group~A total of 30 participants in the 75- to 85-year age group"
33265846|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
33265847|NCT00845156|Placebo Comparator|Placebo|Placebo
32771524|NCT05170919|Experimental|Olanzapine|
33265848|NCT04001985|Active Comparator|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
33265849|NCT04001985|Active Comparator|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
33265850|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
33265851|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
33265852|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
33265853|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
33265854|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
33265855|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
33265856|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
33265857|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
33265858|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
33265859|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
33265860|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
33265861|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap~T/Cap~T/Vino~T/Eri"
33265862|NCT00852332|Experimental|Curcumine|With curcumin capsules
33265863|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
33265864|NCT00992043|Placebo Comparator|exercise and placebo|
33265865|NCT00992043|Experimental|exercise and creatine|
33265866|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
33265867|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
33265868|NCT05246943||UTMB's Colorectal Surgical Cohort|Subjects who meet the inclusion criteria that will have colorectal surgery at UTMB
33265869|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
33265870|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
32771525|NCT05170919|Experimental|Mirtazapine|
32771526|NCT05729893|Active Comparator|resin group|obturated with resin sealer
33079157|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
33265871|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
33265872|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
33265873|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
33265874|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
33265875|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
33265876|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
33265877|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
33265878|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
33265879|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
32771527|NCT05729893|Active Comparator|bio ceramic group|obturated with bioceramic sealer
32771528|NCT05121831|Experimental|Single Ascending Dose Cohort S1|Subjects will receive a single dose of either dose level 1 of DGX-001 or placebo
32771529|NCT05121831|Experimental|Single Ascending Dose Cohort S2|Subjects will receive a single dose of either dose level 2 of DGX-001 or placebo
32771530|NCT05121831|Experimental|Single Ascending Dose Cohort S3|Subjects will receive a single dose of either dose level 3 of DGX-001 or placebo
32771531|NCT05121831|Experimental|Single Ascending Dose Cohort S4|Subjects will receive a single dose of either dose level 4 of DGX-001 or placebo
32771532|NCT05121831|Experimental|Multiple Ascending Doses Cohort M1|Subjects will receive multiple doses of either dose level 1 of DGX-001 or placebo
32771533|NCT05121831|Experimental|Multiple Ascending Doses Cohort M2|Subjects will receive multiple doses of either dose level 2 of DGX-001 or placebo
32771534|NCT05121831|Experimental|Multiple Ascending Doses Cohort M3|Subjects will receive multiple doses of either dose level 3 of DGX-001 or placebo
33079158|NCT04632550|Active Comparator|Circumferential pulmonary vein isolation(CPVI) group|
33079159|NCT04632550|Experimental|Posterior box isolation(POBI) group|
33265880|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
33265881|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
33265882|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
33265883|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
33265884|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
33265885|NCT04420299|Experimental|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
33265886|NCT04420299|Experimental|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
33265887|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
33265888|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
33265889|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
33265890|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
33265891|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
33265892|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
32771535|NCT05121831|Experimental|Stress Exposure Resilience Panel Cohort 1|Subjects will receive any of the MAD dose panel or placebo
32771536|NCT05168813|Experimental|Group 1|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 negative at baseline.
32771537|NCT05168813|Experimental|Group 2|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 positive at baseline.
33401561|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
32771538|NCT05168813|Experimental|Group 3|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in HIV negative adults who are SARS-CoV-2 negative at baseline.
32771539|NCT05168813|Experimental|Group 4|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in HIV negative adults who are SARSCoV-2 positive at baseline.
32771540|NCT05602285||Usual care group|Usual IV securement
32771541|NCT05602285||Dislodgement device group|Usual IV securement plus dislodgement device
32771542|NCT05729737||Pancreatic ductal adenocarcinoma|"Patients who planned to receive first-line chemotherapy for pathologically diagnosed PDAC were recruited.~Intervention:Diagnostic test:Contrast-enhanced ultrasound"
32771543|NCT05179629|Active Comparator|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
32771544|NCT05179629|No Intervention|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
32771545|NCT05613491|Experimental|Intranasal insulin group|Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
32771546|NCT05613491|Placebo Comparator|Saline group|Before anesthesia induction, give the equal volumes'saline nasal spray, once per hour, 20 IU each time, until the end of the operation
32771547|NCT05082207|Experimental|Remote Ischaemic preconditioning (RIPC)|The group underwent Remote Ischemic Preconditioning.
32771548|NCT05082207|Sham Comparator|Sham Group|Sham control group without remote ischemic preconditioning
32771549|NCT05597839|Experimental|Monotherapy DF9001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
32771550|NCT05597839|Experimental|Monotherapy DF9001 PK/PD Expansion|Expansion cohorts of monotherapy DF9001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
32771551|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Head and Neck Squamous Cell Carcinoma|Monotherapy expansion cohort enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
32771552|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Colorectal Cancer|Monotherapy expansion cohort enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
32771553|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Non-small Cell Lung Cancer|Monotherapy expansion cohort enrolling up to 40 patients with Non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
32771554|NCT05597839|Experimental|Combination Escalation with DF9001 and nivolumab|Combination dose escalation of DF9001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.
32771555|NCT05597839|Experimental|Combination PK/PD Expansion with DF9001 and nivolumab|Expansion cohorts of DF9001 in combination with a PD-1 checkpoint inhibitor in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
32771556|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Head and Neck Squamous Cell Carcinoma|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
32771557|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Colorectal Cancer|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33277528|NCT05189912|Experimental|Specimen retrieving bag group|Resected polyps were retrieved by specimen retrieving bag. This group was set as a experimental group.
33277529|NCT05189912|Active Comparator|Suction group|"Resected polyps were retrieved by removing the colonoscope suction valve and connecting a polyp trap to suction onto the instrument channel port.~This group was set as a control group."
32771558|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Non-Small Cell Lung Cancer|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
32771559|NCT05157425|Experimental|Experimental|Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
32771560|NCT05157425|Placebo Comparator|Placebo|Maltodextrin (E1400, qs) in HPMC capsules
33079160|NCT04632550|Experimental|POBI+Anterior linear ablation(AL) group|
33265893|NCT04041986|Experimental|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
33265894|NCT04041986|Active Comparator|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
33265895|NCT04041986|Sham Comparator|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
33265896|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
32771561|NCT05179317|Experimental|QL1706+chemotherapy±Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1706 5mg/kg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6 withor without bevacizumab 15 mg/kg)
33079163|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
33079164|NCT04632082|Experimental|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
33265897|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
33265898|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
33265899|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
33265900|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
33265901|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
33265902|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
33265903|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
33265904|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
33265905|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
33265906|NCT04042220||GK + IT|Gamma Knife and immunotherapy
33265907|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
33265908|NCT04042220||GK only|Gamma Knife without immunotherapy
33265909|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
33265910|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
33265911|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
33265912|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
33265913|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
33265914|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
33265915|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
33265916|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
33265917|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
33265918|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
33265919|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
33265920|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
33265921|NCT04042922|Experimental|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
33265922|NCT04042922|Sham Comparator|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
33265923|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
33265924|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
33079165|NCT04632082|Active Comparator|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
33265925|NCT04042454|Experimental|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
33265926|NCT04042454|Active Comparator|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
33079166|NCT04632160|Experimental|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
33079167|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
33265927|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
33265928|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
33265929|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
32771562|NCT05592379|Experimental|2-minute IV Psilocybin/Placebo Infusion - Asleep|Participants will receive 2mg of IV psilocybin over 2 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 2 minutes while asleep during another overnight visit. The order of administration will be determined by the study protocol.
32771563|NCT05592379|Experimental|2-minute IV Psilocybin/Placebo Infusion - Awake|Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 2 minutes during an overnight visit while awake.
32771564|NCT05592379|Experimental|10-minute IV Psilocybin/Placebo Infusion - Asleep|Participants will receive 2mg of IV psilocybin over 10 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 10 minutes while asleep during another overnight visit. The order of administration will be determined by the study protocol.
33079168|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
32771565|NCT05592379|Experimental|10-minute IV Psilocybin/Placebo Infusion - Awake|Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 10 minutes during an overnight visit while awake.
32771566|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
32771567|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
32771568|NCT05179083|Experimental|High-impact Exercise|
32771569|NCT05179083|Active Comparator|Low-impact Exercise|
32771570|NCT04731571||Adaptive Radiotherapy|Patients treated using adaptive radiotherapy on the Varian Ethos linear accelerator
33265930|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
33265931|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
33265932|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
33265933|NCT00618956|Experimental|1|
33265934|NCT00618956|Placebo Comparator|2|
33265935|NCT00845468||No treatment|
33265936|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
33265937|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
33265938|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
33265939|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
33265940|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
33265941|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
33265942|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
33265943|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
33265944|NCT02545478||Infected Group|subjects with suspected infection
33265945|NCT02545478||Non-infected group|subjects without any infection
33265946|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
33265947|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
33265948|NCT00857012||All patients|treated with Anastrozole as per SPC
33265949|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
33265950|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
33265951|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
33265952|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
33265953|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
32771571|NCT04731571||Conventional Radiotherapy|Patients treated using conventional, non-adaptive radiotherapy on the Varian Truebeam linear accelerator
32771572|NCT05177757|Experimental|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
32771573|NCT04410679|Experimental|injectabl PRF for treatment of internal root resorption|
32771574|NCT04788407|Experimental|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID.
32771575|NCT04788407|Placebo Comparator|Placebo|Subjects will receive placebo TID.
32771576|NCT05119335|Experimental|Phase 1 dose escalation|Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients
32771577|NCT05119335|Experimental|Phase 2 dose expansion|Phase 2 will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients
32771578|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
32771579|NCT04788485|Active Comparator|Neonates before adding smectite|neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
32771580|NCT04788485|Active Comparator|neonates after adding smectite|neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
32771581|NCT05118087|Active Comparator|Coaptation Splint|
32771582|NCT05118087|Active Comparator|Sarmiento Brace|
32771583|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
32771584|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
32771585|NCT05177133|Experimental|Capecitabine, oxaliplatin and retifanlimab|IV and PO Capecitabine 1000 mg/m2, oxaliplatin 130 mg/m2, every three weeks (up to 2 cycles) IV retifanlimab 500mg, every four weeks
32771586|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
32771587|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
32771588|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
32771589|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
32771590|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
32771591|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
32771592|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
32771593|NCT05729581|No Intervention|Control group|This group of pregnant women (24-32 SG) will not be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding. It is a control group.
32771594|NCT05729581|Experimental|Experimental group|This group of pregnant women (24-32 SG) will be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding
32771595|NCT05176821|Experimental|High-dose dual therapy group|esomeprazole 20mg qid plus amoxicillin 750mg qid were used in the high-dose dual therapy group
32771596|NCT05176821|Active Comparator|Furazolidone-based quadruple therapy|furazolidone 100mg bid + amoxicillin 1000mg bid + esomeprazole 20mg bid + bismuth potassium citrate 1000mg(220mg of bismuth) bid were used in the Furazolidone-based quadruple therapy
32771597|NCT05555641|Experimental|Nafamostat Mesylate|VV-ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
32771598|NCT05555641|Active Comparator|Unfractionated Heparin|VV-ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
32771599|NCT05116527|Experimental|High Dose THC|Participants will receive high dose THC.
32771600|NCT05116527|Experimental|Placebo THC|Participants will receive placebo THC.
33265954|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
33079169|NCT04631887|Experimental|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
32771603|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
32771604|NCT04989647|Experimental|A: Surgery only|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*. No further treatment will be administered.~*PLND can be avoided in patients with tumours < 4cm"
32771605|NCT04989647|Experimental|B: Surgery + radiothrerapy|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*, followed by adjuvant treatment.~*PLND can be avoided in patients with tumours < 4cm"
32771606|NCT05175729||Pregnant Group|First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
32771607|NCT05175729||Control group|Age-, sex-matched healthy volunteers
32771608|NCT05729425||Observational (microvessel ultrasound imaging)|Patients undergo microvessel ultrasound imaging on study.
32771609|NCT05115513|Experimental|Placebo Marijuana|Placebo Marijuana will be administered.
32771610|NCT05115513|Experimental|Medium THC Marijuana|Medium THC marijuana will be administered.
33265955|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
33265956|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
33265957|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
33265958|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
32771611|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
32771612|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
32771613|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~Up to 5,000 patients not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
32771614|NCT02622581||NSCLC, Stage I/II/III|Up to 1600 patients with NSCLC stage I, or stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy, or are receiving best supportive care
32771615|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
32771616|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
32771617|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
32771618|NCT04939259|Experimental|New Music Program|The new hearing aid contains the new music program will be worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
32771619|NCT04939259|Active Comparator|Standard Listening Program|The new hearing aid also contains the standard listening program worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
32771620|NCT05729269||Chronic liver disease|non-alcohol liver disease, alcohol liver disease, liver cirrhosis
32771621|NCT04787861|Active Comparator|Control group|Control group treatment is identical to treatment of the study group but without a motorized movement device.Childen in this group received chest physical therapy program including positioning, breathing exercises, and postural drainage in addition to incentive spirometer training for 20 minutes, 3 times/week for 12 weeks.
32771622|NCT04787861|Experimental|study group|This group received the same program given to the control group in addition to an aerobic training regimen for 25 minutes 3 times/week for 12 weeks using a motorized movement device.
32771623|NCT05522803|Other|Sequence 1|TMS followed by sham TMS
33265959|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
33265960|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
32771624|NCT05522803|Other|Sequence 2|Sham TMS followed by TMS
32771625|NCT05612087||gastrointestinal post acute COVID-19 syndrome|newly developped functional dyspepsia or irritable bowel syndrome after COVID-19 infection
32771626|NCT05114187|Experimental|Education Intervention|
32771627|NCT05114187|Active Comparator|Education Control|
32771628|NCT05729113|Experimental|Distraction technique|
32771629|NCT05729113|No Intervention|Pain monitor|
32771630|NCT05613335|Experimental|fibrin glue group|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
33079170|NCT04631887|No Intervention|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
33265961|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
32771631|NCT05613335|Experimental|sticky bone group|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
32771632|NCT05508997|Experimental|Positive End Expiatory Pressure + Reverse Trendelenburg Position|Group A received the procedures of the physiotherapy part by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), which is the patient laid supine with the head up 30 degrees higher than the feet & received the recruitment maneuver (RM) by Positive End Expiratory Pressure (PEEP) titration
32771633|NCT05508997|Active Comparator|Reverse Trendelenburg Position|"Group B received only the procedures of the physiotherapy part at the 3rd phase of operation by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), in which the patient laid supine with the head at 15-30 degrees higher than the feet to unload the weight of intra-abdominal contents from the diaphragm, this position:~Increase pulmonary compliance, functional residual capacity (FRC), and oxygenation.~Allows easier ventilation.~This position called safe apnea time allows time to secure the airway before desaturation for a 20-minute positioning time."
32771634|NCT05612009||1. Signal Expert Protection|After scoring clinically and with dental plaque imaging methods, Signal Expert Protection toothpaste was given to 10 volunteers.
32771635|NCT05612009||2. Colgate Hemp Seed Oil|After scoring clinically and with dental plaque imaging methods, Colgate Hemp Seed Oil toothpaste was given to 10 volunteers.
32771636|NCT05612009||3. Gumgumix|After scoring clinically and with dental plaque imaging methods, Gumgumix toothpaste was given to 10 volunteers.
32771637|NCT01655901|Experimental|Active video gaming|Playing Kinect
32771638|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
32771639|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
33265962|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
33265963|NCT04085003||Intact abdominal aortic aneurysm|
33265964|NCT04085003||Ruptured abdominal aortic aneurysm|
33265965|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
33265966|NCT05302895||single-group|The health monitoring data of all the resident participants are measured using traditional device and the all-in-one health monitoring device on the same day for 12 weeks
33265967|NCT03951233||K-RAS and EGFR mutated|
33265968|NCT03951233||Wild type|
32771640|NCT05504551|Active Comparator|group B|Superficial cervical plexus block (SCP) block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize superficial cervical plexus (SCP) posterior to the midpoint of sterno cleido mastoid (SCM) muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
32771641|NCT05504551|Placebo Comparator|group S|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, 10 ml of normal saline is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
32771642|NCT05173779|Experimental|Left atrial isolation arm|All the enrolled subjects will receive left atrial isolation through catheter ablation.
32771643|NCT05503693|Experimental|AP303|AP303
32771644|NCT05503693|Placebo Comparator|Placebo|Placebo
32771645|NCT05475353|Active Comparator|Asyncronized Exercise Group|- Ergonomics awareness education and exercise suggestions
32771646|NCT05475353|Experimental|Syncronized Exercise Group|- Ergonomics awareness education and than 6 weeks online supervised exercise training
32771647|NCT05113797|Active Comparator|Control Group|Subjects will perform YBT-LQ practice tests using standardized set of verbal instructions provided in the YBT-LQ online manual prior to the testing condition.
32771648|NCT05113797|Experimental|OPTIMAL Motor Learning Group|Subjects will perform the YBT-LQ with the practice period altered to implement aspects of the three pillars of the OPTIMAL motor learning theory (promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task).
32771649|NCT04450069|Experimental|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
33079171|NCT00560911|Other|1Self-management|
33079172|NCT00560911|Other|2 Routine control|
33079173|NCT04632043|Active Comparator|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will undergo intubation.
33265969|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
33265970|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
33265971|NCT04086095|Experimental|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
33265972|NCT05325827|Experimental|Group A: H-FICB under ultrasound guidance before general anesthesia|Group A was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
33265973|NCT05325827|No Intervention|Group B: FBC combined with SBC under ultrasound guidance before general anesthesia|Group B was subjected to a femoral nerve block combined with a sciatic nerve block under ultrasound guidance before general anesthesia.
33265974|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
33265975|NCT05296733|Experimental|Part A: BI 456906: Cohort 1|Healthy subjects
33265976|NCT05296733|Experimental|Part A: BI 456906: Cohort 2|Patients with cirrhosis + Child-Turcotte-Pugh (CTP) Class A
33265977|NCT05296733|Experimental|Part A: BI 456906: Cohort 3|Patients with cirrhosis + CTP Class B
33265978|NCT05296733|Experimental|Part A: BI 456906: Cohort 4|Patients with cirrhosis + CTP Class C
33265979|NCT05296733|Experimental|Part B: BI456906: Cohort 1|Patients with overweight/obesity without cirrhosis/hepatic impairment
33265980|NCT05296733|Experimental|Part B: BI456906: Cohort 2|Patients with overweight/obesity with cirrhosis + CTP Class A
33265981|NCT05296733|Experimental|Part B: BI456906: Cohort 3|Patients with overweight/obesity with cirrhosis + CTP Class B
33265982|NCT04084535|Active Comparator|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
33265983|NCT04084535|Active Comparator|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
32771650|NCT05172687||Nursing home patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in a nursing home.
32771651|NCT05172687||Nursing home patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in a nursing home.
33265984|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
33265985|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
33265986|NCT03941015||patients with renal desaturation|Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
33265987|NCT03941015||patients without renal desaturation|Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
33265988|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
33265989|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
33265990|NCT00715793|Experimental|Single Arm|
33265991|NCT04085549|Experimental|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
33265992|NCT04085549|No Intervention|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
33265993|NCT04085549|Active Comparator|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
33265994|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
33265995|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
33265996|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
33265997|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
33265998|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
33265999|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
33266000|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
33266001|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
33266002|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
33266003|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
33266004|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
33266005|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
33266006|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
33266007|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
33266008|NCT00853502|Active Comparator|testosterone cypionate|
33266009|NCT00853502|No Intervention|bone monitoring|
33266010|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
33266011|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
33266012|NCT00857168|Active Comparator|Group 1|
33266013|NCT00857168|Active Comparator|Group 2|
33266014|NCT00857168|Active Comparator|Group 3|
33266015|NCT00857168|Active Comparator|Group 4|
33266016|NCT00857168|Active Comparator|Group 5|
33266017|NCT00857168|Active Comparator|Group 6|
33266018|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
33266019|NCT04043078|Other|Exercise|Exercise and respiratory muscle training before surgery
33266020|NCT00857402|Active Comparator|Peanuts|
33266021|NCT00857402|Active Comparator|Daboqolo|
33266022|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
33266023|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
33266024|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
33266025|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
33266026|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
33266027|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
33266028|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
32771652|NCT05172687||Community-dwelling patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in the community.
32771653|NCT05172687||Community-dwelling patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in the community.
33401562|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
32771654|NCT04787081|Experimental|Sleep Care Positioning Training Program GRP1|A sleep care positioning lesson created by a University's postural-care scholars using Camtasia® video creation software with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of interactive videos embedded with learning checkpoints. All videos included narration and closed captioning. The following link contains the videos which were modified post-study to reflect some of the participant's feedback: https://stkatentpc.weebly.com/
32771655|NCT04787081|Active Comparator|Sleep Care Positioning Training Program GRP2|A sleep care positioning lesson created by a research assistant along with the principal investigator with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of primarily written summary statements and links to freely available web-based information. Most of this lesson's modules included written information that the participant would need to read with the exception of the positioning methods modules. For the positioning module, participants were provided with links to manufacturers' websites which contained video clips on how to place postural supports.
32771656|NCT05113017||SBRT group|Patients with residual lung nodules are treated with SBRT
32771657|NCT05492695|Active Comparator|Galcanezumab + BMPT|"240 mg of galcanezumab will be administered once as a loading dose at Visit 2, followed by monthly doses of 120 mg at Visits 3 and 4.~All participants will be required to continue BMPT. For consistency purposes visit 2/ randomization should be scheduled within +/- 3 days of subjects next Botox administration as part of BMPT."
32771658|NCT05492695|Placebo Comparator|Placebo + BMPT|• Galcanezumab matching placebo will be administered at Visits 2, 3 and 4.
32771659|NCT04913675|Experimental|VIR-7831 (Sotrovimab)|Main Study participants will be randomized to receive VIR-7831 by intramuscular injection or intravenous infusion
32771660|NCT04913675|Experimental|Safety Substudy VIR 7831 (Sotrovimab)|"Cohort A: Dose 1 infused IV over 60 min~Optional Cohort B1: Dose 1 infused IV over 30 min~Optional Cohort B2: Dose 1 infused IV over 15 min~Optional Cohort C: Dose 2 infused IV over 90 min"
32771661|NCT05172375|Experimental|The Shared Care model - intervention group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties. The final version of the intervention can only be determined based on the results of the research steps 1+2.
32771662|NCT05172375|No Intervention|Treatment as usual - Control group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. In the control group the patients will receive treatment as usual.
32771663|NCT04911803|Experimental|Anxiety Group|Participants will download the anxiety application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the anxiety application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the anxiety group are asked to complete daily brief exercises. For example, they will practice noticing worry thoughts and journal them down.
32771664|NCT04911803|Active Comparator|Procrastination Group|Participants will download the procrastination application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the procrastination application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the procrastination group are asked to complete daily brief exercises. For example, they will practice to reduce procrastination-related thoughts.
32771665|NCT05111925||Pilot Cohort|Active duty Service members with no recent history of musculoskeletal injury, no history of musculoskeletal related surgery, and no restrictions on physical activity participation.
32771666|NCT05111925||Uninjured Cohort - Initial Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
32771667|NCT05111925||Injured Cohort - Initial Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
32771668|NCT05111925||Uninjured Cohort - Optimized Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
32771669|NCT05111925||Injured Cohort - Optimized Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
32771670|NCT04838405|Experimental|CT-388|SC dose of CT-388
32771671|NCT04838405|Placebo Comparator|Placebo|SC dose of placebo matching CT-388 dose
32771672|NCT05111847|Active Comparator|Short-term Baseplate|
32771673|NCT05111847|Active Comparator|Long-term Baseplate|
32771674|NCT04801121||Pregestational diabetic pregnant|Cases: Women with type 1 or type 2 diabetes before start of pregnancy
32771675|NCT04801121||Non-diabetic pregnant|Controls: Women without metabolic disease before start of pregnancy
32771676|NCT05111301|Experimental|Basal Insulin Only (Group A)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
32771677|NCT05111301|Experimental|Multiple Daily Injections (Group B)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
32771678|NCT05475275|Experimental|Experimental group|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was <0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
32771679|NCT05475275|Active Comparator|Control group|"The patients in the control group were given traditional pancreaticojejunostomy"
32771680|NCT05078463|Experimental|Intervention A: Microneedle with 1 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 1 Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
32771681|NCT05078463|Experimental|Intervention B: Microneedle with 0.5 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 0.5 Finger Tip Unit (FTU) of EMLA cream containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5% (dose: approximately 0.369 g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
32771682|NCT05078463|Experimental|Intervention C: Microneedle with 1 Finger Tip Units (FTUs) EMLA for 15 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 15 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
32771683|NCT05078463|Sham Comparator|Intervention D: 1 Finger Tip Unit (FTUs) EMLA only and PVA-containing PET Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of 1 cm x 1cm size will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
32935608|NCT05282173|Experimental|Siyakhana CHW Training|The Siyakhana CHW Training is a multi-day group training that aims to reduce stigma around mental health and substance use among CHWs. It integrates psychoeducation around TB/HIV, stigma, depression, and substance use, including countering myths and stereotypes around mental health and substance use; skills for CHW self-care; evidence-based skills for working with patients living with depression and substance use, such as components of motivational interviewing and problem-solving therapy; and exposure to individuals with lived experience of mental health and substance use. The training is a combination of informative presentations, discussions, worksheets/activities, and role-plays aimed at increasing awareness of mental health and substance use, reducing stigma, and improving interactions when working with patients with HIV/TB and mental health and substance use concerns.
32935609|NCT04784234|Active Comparator|GlaucoCetin Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
32771684|NCT05077137|Experimental|Td Vaccine|The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.
32935610|NCT04784234|Placebo Comparator|Placebo Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
32935611|NCT04784234|Active Comparator|GlaucoCetin Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
32935612|NCT04784234|Placebo Comparator|Placebo Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
32935613|NCT04835935||subject who developed atopic disease|
32935614|NCT04835935||subject who did not develop atopic disease|
32935615|NCT05261503|Experimental|Homeostasis-Enrichment-Plasticity|HEP group will receive an environmental enrichment-based intervention.
32935616|NCT05261503|Experimental|Traditional Physical Therapy|TPT group will receive traditional physiotherapy intervention.
32771685|NCT05077137|Experimental|IPOL Vaccine|Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor
32771686|NCT04786769|Experimental|Iron supplementation|"Intravenous ferric carboxymaltose will be administered according to weight and hemoglobin values at randomization as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention (if determined by dose calculation, otherwise placebo) 12 weeks after valve intervention (if iron deficiency persists, otherwise placebo)"
33266029|NCT04042610|Experimental|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
33266030|NCT04042610|No Intervention|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
33079174|NCT04632043|Active Comparator|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
33079175|NCT04631614|Experimental|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - [a] passive calf muscle stretching and [b] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
32771687|NCT04786769|Placebo Comparator|Placebo|"Intravenous 0.9% NaCl (placebo) will be administered as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention 12 weeks after valve intervention"
32771688|NCT05611541|Experimental|İntervention group|"Progressive Muscle Relaxation Training Program; The training was carried out in a single session for 2 hours and a break of 10-15 minutes was given.~Pregnant women were instructed to perform PMR at least 1 hour after dinner 5 days a week."
32771689|NCT05611541|Active Comparator|Control group|"The Progressive Muscle Relaxation Training Program and the Progressive Muscle Relaxation were not applied.~The pregnant women were asked to continue their normal daily activities for 8 weeks."
32771690|NCT05170113|Active Comparator|Alpinia galanga formulation|Alpinia galanga formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
33079176|NCT04631614|Active Comparator|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
33266031|NCT04164212|Other|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
33266032|NCT00854126|Experimental|1|
33266033|NCT00857480|Experimental|Reference|No pre-treatment
33266034|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
32771691|NCT05170113|Active Comparator|Theacrine formulation|Theacrine formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
32771692|NCT05170113|Active Comparator|Caffeine formulation.|Caffeine formulation capsule: Take one (1) capsules once daily at noon with 8 oz.(240 ml) of water for a 14-day dosing period
32771693|NCT05170113|Placebo Comparator|Placebo|Placebo capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
32771694|NCT05475119|Experimental|Participants diagnosed with Obstructive Sleep Apnea|The participants will sleep three nights at the sleep lab and undergo in their first night, Polysomnography (PSG). Then at random, some of them will do CPAP titration in the second night followed by HFNC titration in the third night. While others will do HFNC titration in the second night followed by CPAP titration in the third night
32771695|NCT05110521|Experimental|Intervention (PROMPTS and MENTORS offered)|Health facilities randomized into the Intervention Arm will be offered the MENTORS program, which trains in-facility nurse-mentors to provide health workers with training and mentorship on aspects of basic and emergency obstetric and newborn care. At health facilities in the intervention arm, patients attending antenatal care clinics will be offered the PROMPTS program, which is a digital health platform that connects mothers with information, advice and referrals to care.
32771696|NCT05110521|No Intervention|Control (Routine Care/No PROMPTS or MENTORS OFFERED)|In the control arm, neither the PROMPTS program nor the MENTORS program will be offered during the study period.
33266035|NCT00857480|Experimental|T2|UDCA pre-treatment
33266036|NCT00857558|Experimental|1|OPC-262 1mg
32771697|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
33266037|NCT00857558|Experimental|2|OPC-262 2.5mg
33266038|NCT00857558|Experimental|3|OPC-262 5mg
33266039|NCT00857558|Placebo Comparator|4|
33266040|NCT00857636|Experimental|Health Literacy|
33266041|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
33266042|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
33266043|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
33266044|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
33266045|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
33266046|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
32771698|NCT05169957|Experimental|Ipilimumab + Nivolumab + Stereotactic Body Radiation Therapy (SBRT)|Liver SBRT following the second cycle of ipilimumab + nivolumab, which will then be continued up to 4 total cycles prior to subsequent maintenance nivolumab for duration of clinical benefit and tolerance (standard of care systemic therapy)
32935617|NCT04774796|Experimental|Cognitive Behavioural Therapy|Participants in this group will take part in a group CBT workshop for parents of children with food allergy. They will also have access to a self-help booklet in order to reinforce the learning that has taken place during the workshop.
33266049|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
33266050|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
33266051|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
33266052|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
33266053|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
33266054|NCT05289869|Experimental|High-dose oxytocin regimen|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
33266055|NCT05289869|Experimental|Low-dose oxytocin regimen|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
33266056|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
33266057|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
33266058|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
33266059|NCT05684861|Active Comparator|Group I patients|90 patients with acne vulgaris Patients classified according to the global acne grading system(GAGS) into moderate, severe, and very severe cases
33266060|NCT05684861|Active Comparator|Control group|60 age-sex-matched healthy subjects as a control group
33266061|NCT05684783||Group 1 interviews|Care professionals with experience of being or working with Dementia Champions, and people affected by dementia who have received care from services with Dementia Champions.
33266062|NCT05684783||Group 2 interviews|Homecare professionals working in services where there are no Dementia Champions, and people affected by dementia who have received care from services with no Dementia Champions.
32935618|NCT04774796|No Intervention|Treatment as usual|Participants in the control group will not take part in the group CBT workshop, but will have access to any treatment as usual relating to their child's food allergy. They will have access to the CBT self-help booklet after the all data collection has been finalised.
32935619|NCT05256277|Experimental|CT101a|1 dose infusion
33266063|NCT02591069|Experimental|All patients will undergo the same procedure|
32935620|NCT05444738|Experimental|oral oxytocin|oral lollipop with oxytocin (24IU)
32935621|NCT05444738|Placebo Comparator|oral lollipop with placebo|Placebo orally (identical ingredients, except the active agent)
32935622|NCT04772755|No Intervention|Usual Care|Participants will receive usual care that follows administration of a vaccine and will have a 20 minute post vaccination observation period.
32935623|NCT04772755|Experimental|Buzzy ® and Electronic Game|Buzzy® will be applied to arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants will be instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then play that game for a specified amount of time before, during and after the vaccination administration.
32935624|NCT04746638|Experimental|Prostate cancer|At least five (5) evaluable subjects with prostate cancer.
32935625|NCT04746638|Experimental|Breast cancer|At least five (5) evaluable subjects breast cancer.
32935626|NCT05253859||Cystic fibrosis registry (UK or US)|People with cystic fibrosis of any genotype registered on either the UK or US CF registry
33266064|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
33266065|NCT04042688|Experimental|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
33266066|NCT04042688|No Intervention|Control gorup|
33266067|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
33266068|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
33266069|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
33266070|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
33266071|NCT02590991||Prebiotics group|No intervention since is a follow-up study
33266072|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
33266073|NCT02590991||Control group|No intervention since is a follow-up study
33266074|NCT02590211|Other|non-poker players|(control group)
33266075|NCT02590211|Other|expert unproblematic poker players|(comparator)
33266076|NCT02590211|Other|pathological poker players|(comparator)
33266077|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
33266078|NCT00854438|No Intervention|Control|No intervention
33266079|NCT00857870|Active Comparator|Metformin|
33266080|NCT00857870|Active Comparator|Insulin glargine|
33079177|NCT04632004|Other|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
33266081|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
33266082|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
33266083|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
33266084|NCT04043156|Experimental|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
33266085|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
33266086|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
33266087|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
33266088|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
32771699|NCT05611463|Experimental|Camrelizumab Plus Docetaxel and Cisplatin|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
33266089|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
33266090|NCT00858026|Other|1|Breastfed babies
33266091|NCT00858026|Active Comparator|2|Weaning with the standard milk
32771700|NCT05110365|Experimental|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation techniques
32771701|NCT05110365|No Intervention|control|no intervention
32771702|NCT05613257|Active Comparator|Free-hand/perfect circles|Patients in this group will have interlocking screw placement using a free-hand, perfect circles technique.
32771703|NCT05613257|Experimental|Distal targeting jig|Patients in this group will have interlocking screw placement using a proximally placed distal targeting jig
33079178|NCT00560989||1|CBD cases
33079179|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
33079180|NCT00560989||3|Sarcoidosis cases
33079181|NCT00560989||4|Sarcoidosis control subjects
33266092|NCT00858026|Experimental|3|Weaning with the fermented milk
33266093|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
33266094|NCT00848666|Experimental|I|Patients with tinea pedis
33266095|NCT00858104|Active Comparator|1|Laser thermal ablation
33266096|NCT00858104|No Intervention|2|Follow-up
33266097|NCT00858182|Experimental|Group A|
33266098|NCT00858182|Experimental|Group B|
33266099|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
33266100|NCT00854984|No Intervention|Usual care|
33266101|NCT04123340|Experimental|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
33266102|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
33266103|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
33266104|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
33266105|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
33266106|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
33266107|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
33266108|NCT00848900|No Intervention|Control|
33266109|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
33266110|NCT00858416|Experimental|AB|First active then Sham
33266111|NCT00858416|Sham Comparator|BA|First sham then active
33266112|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
33266113|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
33266114|NCT00858572|Experimental|Cohort|
33266115|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
33266116|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
33266117|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
33266118|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
33266119|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
33266120|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
33079182|NCT04631653|Experimental|Verisee|Screening diabetic retinopathy using Verisee software
33079183|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
33266121|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
33266122|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
33266123|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
33266124|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
33266125|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
33266126|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
32771704|NCT05110131|Active Comparator|Needle-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with needle aspiration first, followed by forceps biopsy
32771705|NCT05110131|Active Comparator|Forceps-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with forceps first, followed by needle aspiration.
33266127|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
33266128|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
33266129|NCT00858884|No Intervention|No intevention|No intervention
33266130|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
33266131|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
33266132|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
33266133|NCT02545088|Active Comparator|1st control group|
32771706|NCT05611385||Positive for Amphetamine|Patients admitted to the burn unit that are positive for amphetamine
32771707|NCT05611385||Negative for Amphetamine|Patients admitted to the burn unit that are negative for amphetamine
32771708|NCT05076279|Experimental|Single port or reduced ports|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
32771709|NCT05475041||Minor liver resection|Minor liver resection (<3 contiguous segments) in the anterolateral segments
32771710|NCT05475041||Technically major liver resection|Minor liver resection (<3 contiguous segments) in the posterosuperior segments (Segment 1,4a,7,8)
32771711|NCT05475041||Major liver resection|Major liver resection (3 or more contiguous segments)
32906368|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
32935627|NCT04734158||Healthy control|
32935628|NCT04734158||Diabetics with macular edema|
32935629|NCT04734158||Diabetics without macular edema|
32935630|NCT05243953|Experimental|Levcromakalim|A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
32935631|NCT05243953|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
32935632|NCT04715984|Experimental|Neural recordings and stimulation|
33266134|NCT02545088|Active Comparator|2nd control group|
33266135|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
33266136|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
33266137|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
33266138|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
33266139|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
33266140|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
33266141|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
33266142|NCT00861458|Experimental|PF-00868554|
33266143|NCT00861536|Experimental|ATG Fresenius|
33266144|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
33266145|NCT00849446||Activity monitoring in CVA patients|
33266146|NCT00849446||Activity monitoring in healthy persons|
33266147|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
33266148|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
33266149|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
33266150|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
33266151|NCT00859196|Experimental|Arm 1|
33266152|NCT00859196|Placebo Comparator|Arm 2|
33266153|NCT00849602|Placebo Comparator|1|
33266154|NCT00849602|Active Comparator|2|
33266155|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
33266156|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
33266157|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
33266158|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
33266159|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
33266160|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
33266161|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
33266162|NCT00861848||12-50 with heart disease|12-50 with heart disease
33266163|NCT00861848||12-50 normal controls|12-50 normal controls
33266164|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
33266165|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
33266166|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
33266167|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
33266168|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
33266169|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
33266170|NCT04041518|Other|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
33266171|NCT00849836||Acute exacerbation|
33266172|NCT00849836||Stable disease|
33266173|NCT00849836||Healthy control|
33266174|NCT04041752|Experimental|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
33266175|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
33266176|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
33266177|NCT00849914||1|Patients with actinic keratoses of the skin
33266178|NCT00849914||2|Patients with basal cell carcinoma of the skin
33266179|NCT00849914||3|Patients with squamous cell carcinoma of the skin
33266180|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
33266181|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
33266182|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
33266183|NCT00859742|Experimental|EBUS-TBNA|
33266184|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33266185|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33266186|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33266187|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33266188|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
33266189|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
33266190|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
33266191|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
33266192|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
33266193|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
33266194|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
33266195|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
33266196|NCT00850148|Experimental|Melles|
33266197|NCT00850148|Experimental|Anwar|
33266198|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
33266199|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
33266200|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
33266201|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
33266202|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
33266203|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
33266204|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
33266205|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
33266206|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
33266207|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
33266208|NCT02544620||Total Hip arthroplasty|"Unselected primary THA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
33266209|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
33266210|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
33266211|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
33266212|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
33266213|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
33266214|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
33266215|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
33266216|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
33079184|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
33266217|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
33266218|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
33266219|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
33266220|NCT04007744|Experimental|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33266221|NCT00850304|Experimental|Arm one|
33266222|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
33266223|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
33266224|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
33266225|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
33266226|NCT02544464|Placebo Comparator|Control group|placebo
33266227|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
33266228|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
33266229|NCT00862628|Experimental|Rebamipide|
33266230|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
33266231|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
33266232|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
33266233|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
33266234|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
33266235|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
33266236|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
33266237|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
33266238|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
33266239|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
33266240|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
33266241|NCT00850616|Placebo Comparator|8|Placebo
33266242|NCT00862706|Experimental|A|
33266243|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
33266244|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
33266245|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
33266246|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
33266247|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
32771712|NCT05076123|Experimental|Experimental group-1 (M-CIMT group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) in addition to conventional therapy. M-CIMT is shorter versions of CIMT. The original CIMT devotes six or more hours for therapy and constraining of the intact arm for 90% of waking hours per day and over a period of two weeks. Researchers have observed that such a schedule of CIMT is exhaustive and possibly resulting in non-compliance. Because of this reason,s Modified shorter versions of CIMT (mCIMT) have been designed by researchers. Duration of M-CIMT interventions varies from 2 to 10 weeks and the treatment time also varies from as short as 30 minutes to three hours per day in various studies. Nevertheless both CIMT and mCIMT have shown promising success. M-CIMT emphasizes massed practice with the affected upper limb.
32935633|NCT02788045|Experimental|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
33266248|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
32935634|NCT02788045|Placebo Comparator|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
33266249|NCT00850694||1|Obese female adolescents
33079185|NCT04631341|Experimental|Melatonin Group|Take melatonin supplements
33079186|NCT04631341|No Intervention|Normal Control Group|Don't take melatonin supplements
33266250|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
33266251|NCT04041362|Active Comparator|Arm1 (Standard ART)|Standard ART
33266252|NCT04041362|Experimental|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
33266253|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
33266254|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
33266255|NCT00860678|Active Comparator|A|Training group
33266256|NCT00860678|Other|B|Controls
33266257|NCT00860756|Experimental|1|Intervention Group
33266258|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
33266259|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
33266260|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
33266261|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
33266262|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
33266263|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
33266264|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
33266265|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
33266266|NCT00860990||1|SCI or disabled
33266267|NCT00860990||2|Able-bodied
33266268|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
33266269|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
33266270|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
33079187|NCT04723238|Experimental|Duloxetine Test Product|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
33079188|NCT04723238|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
33079189|NCT04631575|Experimental|Healthy participants|Intervention: Drug: SHR6390 single dose
33079190|NCT04631575|Experimental|Mild liver impairment|Intervention: Drug: SHR6390 single dose
33079191|NCT04631575|Experimental|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
33079192|NCT04631068|Active Comparator|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
33079193|NCT04631068|Placebo Comparator|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
33079194|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
33079195|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
33079196|NCT04723433|Experimental|"Conservative O2 Supplementation"|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
33079197|NCT04723433|Active Comparator|"Liberal O2 Supplementation"|Oxygen administration will titrated to an SpO2 > 96%.
33079198|NCT04630951|Experimental|Strength training based on low loads with blood flow restriction (Experimental group I)|"Squat~Single Deadlift~Back Squat"
33079199|NCT04630951|Experimental|Strenght training based on high loads (Experimental group II)|"Squat~Single Deadlift~Back Squat"
33079200|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
33079201|NCT04630678|Experimental|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
33079202|NCT04630678|Active Comparator|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
33079203|NCT04630522|Experimental|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
33079204|NCT04630522|Experimental|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
33079205|NCT04630522|Experimental|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
33079206|NCT04630444|Experimental|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
33079207|NCT04630405|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
33079208|NCT04630405|Active Comparator|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
33079209|NCT00186810|Other|1|
33079210|NCT04630600|Other|Control|Normal waiting room
33079211|NCT04630600|Experimental|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
33079212|NCT04630600|Experimental|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
33079213|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
33266271|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
32771713|NCT05076123|Experimental|Experimental group-2 (M-CIMT+TES group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) and threshold electrical stimulation (TES) in addition to conventional therapy. TES is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes. TES provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction. TES can improve motor learning and motor performance by improving connections between sensory-motor cortical association regions in the brain.
33266272|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
33266273|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
33079214|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
33266274|NCT04040972|Experimental|Rebalance - Group Compassion Focussed Therapy|
33266275|NCT00861068|Experimental|1|
32771714|NCT05076123|No Intervention|Control group|participants in this group will be trained with conventional therapy. Conventional therapy consists of strength training, stretching exercises and functional activity training.
32771715|NCT05611307||Surgical/Surveillance|TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)
33266276|NCT00861068|Placebo Comparator|2|
33266277|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
33266278|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
33266279|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
32771716|NCT05611307||Cisplatin-based chemotherapy (CBCT)|TCS treat with one or more lines of cisplatin-based chemotherapy
32771717|NCT05611307||Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)|TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant
33266280|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
33266281|NCT00863096||Gardasil|
33266282|NCT00863174|Experimental|1|SPARC147709
33266283|NCT00863174|Active Comparator|2|Reference147709
32771718|NCT05075967|Experimental|Integrated Strategy|"Black MSM living in intervention communities will have access to the HPTN 096 integrated strategy in addition to standard HIV prevention and care services available in their communities.~The integrated strategy includes a combination of four community-, organizational-, and interpersonal-level components designed to impact individual-level outcomes."
32771719|NCT05075967|Other|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
32771720|NCT05473533|Placebo Comparator|Arm 1|Placebo
32771721|NCT05473533|Experimental|Arm 2|PRS-220
33266284|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
33266285|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
33266286|NCT00863252|Experimental|1|MMF
33266287|NCT00863252|Active Comparator|2|Control
33266288|NCT00503308|Experimental|Abbreviated Consenting|
33266289|NCT00503308|No Intervention|Standard Consenting|
33266290|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
33266291|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
33266292|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
33266293|NCT00863564|Active Comparator|Whey Isolate|
33266294|NCT00863564|Active Comparator|Caseine|
33266295|NCT00863564|Active Comparator|Cod|
33266296|NCT00863564|Active Comparator|Gluten|
33266297|NCT03893565|Experimental|GSK2831781-Double blind phase|Eligible participants will receive GSK2831781 intravenously in the double blind induction phase at different dose levels. Participants identified as Responders at Week 10 will then receive GSK2831781 subcutaneously during the double-blind ETP from Week 14 until Week 26
33266298|NCT03893565|Experimental|GSK2831781- Open label phase|Eligible participants will receive GSK2831781 intravenously in the open label induction phase. Participants identified as Non-Responders at Week 10 will receive GSK2831781 from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
33266299|NCT03893565|Placebo Comparator|Placebo matching GSK2831781- Double blind phase|Eligible participants will receive Placebo in the double blind induction phase Participants identified as Responders at Week 10 will continue to receive Placebo subcutaneously during the double-blind ETP from Week 14 until Week 26.
33266300|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
33266301|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
33266302|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
33266303|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
33079215|NCT00561028||1|ST-elevation acute myocardial infarction.
32771722|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
32771723|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
32771724|NCT04234737|Experimental|Hypnotherapy|
32771725|NCT04234737|No Intervention|Control|
32771726|NCT04998747|Experimental|AMG 701: dose exploration|Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
32771727|NCT04998747|Experimental|AMG 701: dose expansion|Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
32771728|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
32771729|NCT02631577|Experimental|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
32771730|NCT02631577|Experimental|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
32771731|NCT05074953||Adults|145184 patients with COVID-19 over 17 years of age.
32771732|NCT05074953||Children and adolescents|11950 patients with COVID-19 under 18 years of age.
32771733|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
32771734|NCT04998045|Experimental|Intervention arm|Youth aged 15-24 years Intervention: screening and brief intervention for substance use
32771735|NCT05558111||Patients with orthotopic neobladder|Patients with orthotopic neobladder who met the inclusion criteria will be enrolled.Inclusion criteria :(1) being right-handed;(2) 3 months or more after operation;(3) No contraindications to fMIR examination;(4)Does not meet the relevant exclusion criteria.
32771736|NCT05052411|Experimental|Expanded beta testing of the JomPrEP app|App usage assessments and analytics over a 1-month period.
32771737|NCT04545619|Experimental|Paroxysmal and Early Persistent AFIB|
32771738|NCT05052333||Examining the psychosocial impacts of Covid-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
32771739|NCT05052333||Examining the psychosocial impacts of Covid-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
32771740|NCT05052333||Examining the psychosocial impacts of Covid-19 in Turkey.|This is exploratory research and data will be obtained on a set of measures (N=500) using a unilingual (Turkish) survey with longitudinal assessment after 12 months of the initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
32771741|NCT05052333||Examining the psychosocial impacts of Covid-19 in Bangladesh.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Bangla) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
33079216|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
33079217|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
33079218|NCT00561028||4|blood donors without known coronary artery disease.
33079219|NCT00561067|Active Comparator|1|Methylprednisolone
33079220|NCT00561067|Experimental|2|Erythropoietin
33079221|NCT00561106|Active Comparator|1|
33079222|NCT00561106|Placebo Comparator|2|
33079223|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
33079224|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
33079225|NCT04630639|Experimental|Validation Arm|Participants will wear the Sparkle device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
33079226|NCT00561184|Experimental|1|
33079227|NCT00561184|Experimental|2|
33079228|NCT00186849|Other|1|
33079229|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
33079230|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
33079231|NCT04629859|Experimental|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
33079232|NCT04629859|Experimental|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
33079233|NCT00201981|Active Comparator|1|rebamipide 1%
33079234|NCT00201981|Active Comparator|2|Rebamipide 2%
33079235|NCT00201981|No Intervention|3|placebo
33079236|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:~Of all ages, genders, races, and ethnic groups~Living in the United States~Diagnosed with type 1 diabetes~Currently taking insulin or have had a pancreatic or islet cell transplant"
33079237|NCT04629742|Experimental|Seawater Pizza|Administration of a seawater pizza
33079238|NCT04629742|Active Comparator|Standard Pizza|Administration of a Standard pizza
33266304|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
33079239|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
33079240|NCT04629391|Active Comparator|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
33079241|NCT04629391|Experimental|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
33079242|NCT04629235|Active Comparator|24 hours of bedrest|- 24 hours of bedrest
33079243|NCT04629235|Experimental|Intervention group|- Wonder around after 8 hours of bedrest
33079244|NCT00180011|Experimental|omaluzimab|
33079245|NCT00186966|Other|FLAG|
33079246|NCT00186966|Other|FLAG and LP Dox|
33079247|NCT04629001||with Covid-19 infection|
33079248|NCT04629001||without Covid-19 infection|
33079249|NCT04629313||periodontal disease group|"Gingivitis: BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.~SI Periodontitis: interdental AL of 1-2 mm, PD≤4 mm and no tooth loss SII Periodontitis: interdental AL of 3-4 mm, PD≤5 mm and no tooth loss SIII Periodontitis: interdental AL ≥5 mm, PD≥6 mm SIV Periodontitis: interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root,"
33079250|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva
33079251|NCT04629040|Experimental|Intervention|
33079252|NCT04629040|Placebo Comparator|Control|
33079253|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
33079254|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
33079255|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
33079256|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
33079257|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
33079258|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
33079259|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
33079260|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
33079261|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
33079262|NCT00575458||1|Static Splint
33079263|NCT00575458||2|Dynamic Splint
33079264|NCT04579588||COVID-19 participants|
33079265|NCT04579588||Control participants|
33079266|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
33079267|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
33079268|NCT00575497|Experimental|C|Every other day short daily hemodialysis
33079269|NCT00575497|Experimental|D|Every other night hemodialysis
33079270|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
33079271|NCT00575497|Experimental|F|5 nights per week hemodialysis
33079272|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
33079273|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
33079274|NCT00575575|Experimental|A,2|
33079275|NCT00575614|Active Comparator|1|
33079276|NCT00575614|Placebo Comparator|2|
33079277|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
33079278|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
33079279|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
33079280|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
33079281|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
33079282|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
33079283|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
33079284|NCT00180167|Experimental|Mitoxantrone + Ara-C|
33079285|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
33079286|NCT04579354|No Intervention|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
33079287|NCT04579354|Experimental|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -> inpatient preparation for the operation -> administration of premedication -> way to the operating theater -> OP preparation (holding) -> safe surgery
33079288|NCT04579705|Experimental|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
33079289|NCT04579705|No Intervention|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
33266305|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
33266306|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
32771742|NCT05052333||Examining the psychosocial impacts of Covid-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a bilingual (Malay-English) survey. Data will be obtained longitudinally after 12 months of initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
32771743|NCT05052333||Examining the psychosocial impacts of Covid-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
33266307|NCT00870506|No Intervention|2|No intervention (control)
32771744|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somalia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Somalia-English) longitudinally. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
33079290|NCT04579705|Experimental|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
33266308|NCT00870506|Experimental|1|5-minute video on donation and transplantation
33266309|NCT00870662|Experimental|Automatic Fluid Shunt|
33266310|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
33266311|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
33266312|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
33266313|NCT05356611|Experimental|Engage Treatment|The study is a single-arm study. The single-arm will be implementation of the 9-week protocol of Engage in an older adult population with late-life depression and comorbid executive dysfunction and mild cognitive impairment.
33266314|NCT00863876||1|non-operated healthy eyes
33266315|NCT00863876||2|eyes 1 months following LASIK
33266316|NCT00863876||3|eyes 3-6 months following LASIK
33266317|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
33266318|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
33266319|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
33266320|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
33266321|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
33266322|NCT00863876||9|eyes with keratoconus
33266323|NCT00863954|Active Comparator|Output A|
33266324|NCT00863954|Active Comparator|Output B|
33266325|NCT00863954|Active Comparator|Output C|
33266326|NCT00863954|Active Comparator|Output D|
33266327|NCT00863954|Active Comparator|Output E|
32771745|NCT05474885|Experimental|BCMA-CD19 cCAR T cells|Dose escalation phase: patient's T cells will be transduced with a lentiviral vector to express a BCMA-CD19 cCAR. with an escalation approach.
32771746|NCT04334135|Experimental|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
32771747|NCT04334135|Placebo Comparator|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
32771748|NCT05728879|Experimental|CTCL participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8.
32771749|NCT04421469|Experimental|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
33079291|NCT04579705|No Intervention|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
33266328|NCT00863954|Active Comparator|Output F|
33079292|NCT00575809||Obsevational|
33079293|NCT00575848|Active Comparator|1|
33079294|NCT00575848|Placebo Comparator|2|
33266329|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
33266330|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
33266331|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
33266332|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
33266333|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
33266334|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
33266335|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
33266336|NCT05325749||unaffected|newborns without developmental features having no variations according to an inherited diseases screening;
33266337|NCT05325749||affected|newborns showing either phenotypic features or deviations according to MS screening
33266338|NCT05325749||refused families|parents refused to enroll their newborns to the study
33266339|NCT05325749||unaffected born prematurely|newborns without specific developmental features having no variations according to an inherited diseases screening, born before term
33266340|NCT05325749||unaffected wirh family history|newborns without developmental features having no variations according to an inherited diseases screening but with affected relative(s)
33266341|NCT05325749||unaffected wirh prenatal phenotype|newborns without developmental features at birth and on, having no variations according to an inherited diseases screening which had been observed to show signs of developmental features during prenatal ultrasound examination
33266342|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
33266343|NCT00918515|Experimental|AZD3043|Intravenous solution
33266344|NCT04084223|Experimental|Active RA patients group|"64 active RA patients (DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
33266345|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
33266346|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
32771750|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
32771751|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
32771752|NCT04333745|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.
33079295|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
33079296|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
33079297|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
33079298|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
33266347|NCT05271773||Mayo 0|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 0 endoscopic activity.
33266348|NCT05271773||Mayo 1|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 1 endoscopic activity.
33266349|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
33266350|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
33266351|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
33266352|NCT02589431||Patients with severe sepsis|
33266353|NCT02589431||Controls|Healthy subjects
33266354|NCT00864422|Experimental|1|
33266355|NCT00864422|Active Comparator|2|
33266356|NCT05269667|Experimental|Cohort 1: treatment-naïve NMOSD patients|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
33266357|NCT05269667|Experimental|Cohort 2: NMOSD patients who are inadequate responders to previous treatment with RTX|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
33266358|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
33266359|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
33266360|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
33266361|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
33266362|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
33266363|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
33266364|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
32771753|NCT05073861|Experimental|App-based STEM online learning group|Participants in the experimental group will receive a 2.5-month intervention with the blended STEM learning app.
32771754|NCT05073861|Active Comparator|E-book learning group|The control group receive e-book chapters about STEM for learning for the same period of 2.5-month as the experimental group.
33079299|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
33079300|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
33079301|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
33266365|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
33266366|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
33266367|NCT05179421|Experimental|saline (placebo) then oxytocin 1.3 micrograms|Participants will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms. Participants will be randomized to receive this on study visit 2 or 3.
33266368|NCT05179421|Experimental|oxytocin 0.3 micrograms then oxytocin 7 micrograms|Participants will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms. Participants will be randomized to receive this on study visit 2 or 3.
33266369|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
33266370|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
33266371|NCT04084691|Experimental|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
32771755|NCT05728801||Superagers|SuperAgers are determined by the scores of global cognitive function. This ensured that the participants are divided by a measure relevant to the current study without directly biasing the results toward the domain of interest.
32771756|NCT05728801||Normal ageing elderly|The cases with the scores of cognitive performance within 1.5 standard deviation (SD) of age and education matched normative values derived from our cohort study, of which presented with HK MoCA score greater than 26 and CDR score equal to 0
32771757|NCT05728801||Neurocognitive disorders patients|NCD patients are deﬁned as: evidence of modest decline in one or more cognitive domains, which is set as ≥ 1.5 SD below the age- and education-adjusted normative scores; no interference with independence in everyday activities; and no comorbid major psychiatric disorders.
33266372|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
33266373|NCT00864812|Active Comparator|2|tiotropium
32771758|NCT05613179|Experimental|Group1 (lever positioning manipulation)|Patients with lumbar disc herniation treated by lever positioning manipulation
32771759|NCT05613179|Active Comparator|Group2 (analgesic)|Patients with lumbar disc herniation treated by analgesic
32771760|NCT05613179|No Intervention|Group3 (healthy controls)|Healthy control group without any intervention.
33266374|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
33266375|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
33266376|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
33266377|NCT00919295|Placebo Comparator|placebo|placebo
33266378|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
33266379|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
33266380|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
33266381|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
33266382|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
33266383|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
33266384|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
33266385|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
33266386|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
33266387|NCT00866138|Experimental|1|masitinib (AB1010)
32771761|NCT04997499|Experimental|Teaching video|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by watching the teaching video and then will be asked to self inject subcutaneous depot-medroxyprogesterone as per the protocol. All participants will then be asked to answer survey questions. All health care providers that participate in the study will likewise be asked to answer survey questions.
32771762|NCT04997031||Latinx Adults 18 - 65 y|
32771763|NCT05728645|Experimental|colloid group|The participants in colloid group will received intravenous HES130/0.4 of 5ml/kg before the Induction of anesthesia.
32771764|NCT05728645|Active Comparator|crystalloid group|The participants in crystalloid group will received intravenous Lactated Ringer's solution of 5ml/kg before the Induction of anesthesia.
32906369|NCT04969224|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA fixed-dose combination (FDC) in the morning and IVA in the evening.
32906370|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
33266388|NCT00502840|Experimental|1|
33266389|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
33401563|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
33266390|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
33266391|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
33266392|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
33266393|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
32771765|NCT05611229||Population 1: BRAF+ melanoma patients treated with either TT or IO in the adjuvant setting|Included patients were aged more than or equal to 18 years, were required to have a diagnosis of melanoma (ICD-9 172.x & ICD-10 C43.x or D03.x), pathologic stage III disease, evidence of resection, adjuvant treatment with IO (e.g., nivo or pembro) or TT (e.g., dab+tram) on or after January 1, 2014, and prior to August 30,2020 (data cut-off), and any evidence of a BRAF+ result.
32771766|NCT05611229||Population 2: BRAF+ melanoma patients with LTB treated with TT or IO in the metastatic setting|Included patients were aged more than or equal to 18 years, and were required to have a diagnosis of melanoma (ICD-9 172.x & ICD-10 C43 or D03x), a pathologic stage IV diagnosis, treatment with IO (e.g. ipi, nivo, pembro, ipi+nivo) or TT (dab+tram, vem+cobi, enco+bini) on or after January 1, 2014 and prior to May 31, 2020 (data cut-off), and evidence of a BRAF+ result after therapy initiation. Patients were required to be classified as LTB at the time of stage IV diagnosis. LTB was defined as having normal LDH and <3 metastatic sites at the time of stage IV diagnosis.
33079302|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
33266394|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
33266395|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
33266396|NCT00514540|Experimental|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
33079303|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
33079304|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
33266397|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
33266398|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
33266399|NCT03121534|Experimental|Ibrutinib, Nivolumab and Blinatumomab|"2 (8week) cycles of ibrutinib, nivolumab and blinatumomab. 9 (4week) cycles ibrutinib and nivolumab. Maintenance with ibrutinib monotherapy until disease progression following completion of nivolumab.~Ibrutinib treatment will begin cycle 1, day 1 at 420mg/d. Nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.~blinatumomab continuous IV infusion, starting day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week blinatumomab treatment-free interval. Hospitalization in cycle 1 on day 15-31 (first 17 days of blinatumomab therapy). Blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28, followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days. Blinatumomab in cycle 2 will be administered at a dose of 112 mcg/day from day 1-28."
33266400|NCT03997474|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
33266401|NCT03997474|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
33266402|NCT03997474|Experimental|Cohort C|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
33266403|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
33266404|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
33266405|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
33266406|NCT01013818|Experimental|HGS1029|
33266407|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
33266408|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
32771767|NCT05073393|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
32771768|NCT05073393|Placebo Comparator|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
32771769|NCT05473507||Participant with Basal Cell Carcinoma/BCC|Participants have been diagnosed with at least 1 Basal Cell Carcinoma/BCC based on clinical, dermoscopy, RCM (reflectance confocal microscopy) and OCT (optical coherence tomography)
33266409|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
33266410|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
33266411|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
33266412|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
33079305|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
33079306|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
33266413|NCT04615624|Experimental|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
32771770|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
32771771|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
32771772|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
33266414|NCT04615624|Placebo Comparator|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
33266415|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
33079307|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
33079308|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
32771773|NCT04330781|Experimental|Intervention group|N=123
32771774|NCT04330781|Active Comparator|Control group|N=31
32771775|NCT05050149|Experimental|Experimental: PTX-022|PTX-022 QTORIN
32771776|NCT05471245|Experimental|angiographic evaluation|QCA at 9 months
32771777|NCT05557799|Active Comparator|Photobiomodulation group|Participants in this group will receive photobiomodulation with a vaginal diode laser and its introit.
32771778|NCT05557799|Placebo Comparator|Placebo group|Participants in this group will receive simulated photobiomodulation, with the laser device turned off.
32771779|NCT05613101|Active Comparator|Erector Spinae Plane Block|Erector Spina Plane Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
32771780|NCT05613101|Active Comparator|Adductor Canal Block|Adductor Canal Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
32771781|NCT05466955|Experimental|Free eye glasses for un or under-corrected myopia|Free eyeglasses for the correction of uncorrected myopia will be provided to participants at the time of enrolment into the intervention group.
32771782|NCT05466955|No Intervention|Control-No treatment|Participants in the control period will not have glasses but the SW-CRT design means that all trial participants with uncorrected myopia will receive free glasses by the trials' completion, and no participant will have glasses withheld after being diagnosed with un- or under-corrected myopia.
32771783|NCT05613023|Active Comparator|P-SBRT|Participants allocated P-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate CTV).
33079309|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
33079310|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
33266416|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
33266417|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
33266418|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
32771784|NCT05613023|Experimental|PPN-SBRT|Participants allocated PPN-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate clinical target volume (CTV)) and 25Gy in 5 fractions to pelvic nodes on alternate days.
32771785|NCT04746677|Experimental|Complex abdominal aortic aneurysm (AAA)|Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
32771786|NCT04746677|Experimental|Thoracoabdominal aortic aneurysm (TAAA)|Includes Type I, Type II, and Type III TAAA
32771787|NCT04746677|Experimental|Type B aortic dissection|
32771788|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
33079311|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
33266419|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
33266420|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
33266421|NCT00513682|Experimental|Ultrase® MT20|
32771789|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
32771790|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
33079312|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
33079313|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
32771791|NCT05474729|Experimental|minocycline|minocycline capsule 100mg per day orally
32771792|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
32771793|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
32771794|NCT04733963|Experimental|Arm A|Maintenance therapy with Fruquintinib Plus Capecitabine
32771795|NCT04733963|Active Comparator|Arm B|Maintenance therapy with Bevacizumab Plus Capecitabine
32771796|NCT04222023|Experimental|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
32771797|NCT04222023|No Intervention|Control group|
32771798|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
32771799|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
32771800|NCT04212039|Active Comparator|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
32771801|NCT04212039|Sham Comparator|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
32771802|NCT04716413|Experimental|Treatment|Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL (sublingual). If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.
32771803|NCT04716413|No Intervention|Control|Subjects will be receive routine standard of care.
32771804|NCT04488523|Experimental|Family-based Telehealth Treatment|A family-based telehealth intervention.
32771805|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
32771806|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
32771807|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
32771808|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
32771809|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
32771810|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
32771811|NCT04445701|Experimental|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
32771812|NCT04445701|Experimental|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
32771813|NCT04445701|Experimental|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
33079314|NCT00576433|Experimental|1|
33079315|NCT00576511|Active Comparator|1|Prucalopride
33079316|NCT00576511|Placebo Comparator|2|
33079317|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
33079318|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
33079319|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
33079320|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
33079321|NCT00576589|Experimental|CE-326,597|
33079322|NCT00576589|Placebo Comparator|Placebo|
33079323|NCT00576706|Experimental|1|
33079324|NCT00576706|Active Comparator|2|
33079325|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
33079326|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
33079327|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
33079328|NCT00576862|Experimental|1|
33079329|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
33079330|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
33079331|NCT00577018|Active Comparator|1|
33079332|NCT00577018|Active Comparator|2|
32771814|NCT05465161|Experimental|StingMark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
32771815|NCT05464147|Experimental|DynamX Drug-Eluting Coronary Bioadaptor System|
32771816|NCT05048667|Experimental|SWT plus PRP Group|Participants will receive weekly Shockwave Therapy (SWT) and Platelet Rich Plasma (PRP) for 5 weeks. SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. PRP will be administered on Week 1 and Week 5.
33266422|NCT05171387|Experimental|Double-blind treatment: Darolutamide in addition to Androgen deprivation therapy (ADT)|"Participants in the darolutamide arm can continue open-label darolutamide if in the opinion of the investigator the participant continues to derive benefit from treatment with darolutamide.~Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body."
32771817|NCT05048667|Placebo Comparator|Sham SWT plus Placebo Saline Group|Participants will receive weekly Sham Shockwave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 5 weeks. Sham SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. Placebo Saline ICI will be administered on Week 1 and Week 5.
32771818|NCT05459545||Patients with Significantly Higher Risk of Developing VHD based on Medical History|History of at least one of the following: hypertension, BMI ≥ 30, diabetes mellitus, hyperlipidemia, atrial fibrillation, myocardial infarction, stroke/TIA, previous coronary surgery, or previous coronary angiography.
32906371|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
33266423|NCT05171387|Placebo Comparator|Double-blind treatment: Placebo in addition to Androgen deprivation therapy (ADT)|"Participants in the control arm can cross over to open-label darolutamide treatment and will be able to continue this treatment until treatment discontinuation criteria.~Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body."
33266424|NCT05262023|Experimental|DNL593 (Healthy Participant)|
33266425|NCT05262023|Placebo Comparator|Placebo (Healthy Participant)|
33266426|NCT05262023|Experimental|DNL593 (Participants with FTD)|
33266427|NCT05262023|Placebo Comparator|Placebo (Participants with FTD)|
33266428|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
33266429|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
33266430|NCT00918593|Experimental|Electrochemotherapy|
33266431|NCT00918593|Active Comparator|radiotherapy|
33266432|NCT04084847|Active Comparator|Barberry|Daily consumption of barberry in powder form.
33266433|NCT04084847|Placebo Comparator|placebo|Daily consumption of placebo powder.
33266434|NCT04485130|Experimental|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
33266435|NCT04485130|Placebo Comparator|Placebo|This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
33266436|NCT04084457|Placebo Comparator|Placebo|Matched for macronutrients, micronutrients and fibre
33266437|NCT04084457|Active Comparator|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
33266438|NCT05163431|Experimental|Painful Hallux Valgus|
33266439|NCT04083833|Experimental|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
33266440|NCT04083833|Placebo Comparator|Control|"Treatment D:~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo~Treatment E:~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment F:~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment G:~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment H:~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment I:~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
33266441|NCT05330429|Experimental|Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive magrolimab in de-escalating doses to establish recommended Phase 2 dose (RP2D) in combination with + bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
33266442|NCT05330429|Experimental|Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
33266443|NCT05330429|Active Comparator|Randomized Cohort: Bevacizumab + FOLFIRI|Participants will receive bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
33266444|NCT05155241|Experimental|Intervention|Participants will watch an online health promotion video tailored to their current stage of change related to SIV uptake once every two weeks for four times (at week 0, 2, 4, and 6)
33266445|NCT05155241|Active Comparator|Control|Participants will watch a same online video providing general advices related to SIV at week 0, 2, 4, and 6
32906372|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
32771819|NCT05459545||Patients without Significantly Higher Risk of Developing VHD based on Medical History|No history of hypertension, BMI ≥ 30, diabetes mellitus, hyperlipidemia, atrial fibrillation, myocardial infarction, stroke/TIA, previous coronary surgery, or previous coronary angiography.
32771820|NCT04995081|Active Comparator|Allogeneic HB-adMSCs.|"Biological/Vaccine: Allogeneic HB-adMSCs~Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.~Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells."
32771821|NCT04995081|Placebo Comparator|Placebo|"Placebo will be administered intravenously to study participants who qualify.~Other Names: Sterile Saline Solution 0.9%"
32771822|NCT04433377|Experimental|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
33266446|NCT05151653|Experimental|BI 765250 arm|
33266447|NCT05151653|Placebo Comparator|Placebo arm|
32771823|NCT04433377|Experimental|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
32771824|NCT05048589|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
33266448|NCT05144477|Experimental|FAID Fear Intervention|Family members of CA patients assigned to intervention will receive the ICU diary.
33266449|NCT05144477|No Intervention|Control condition - Usual Care|Family members of CA patients assigned to usual care will not receive the ICU diary.
33266450|NCT05684315|Experimental|soft tissue flossing therapy right lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their right leg flossed while performing the fatigue protocol.
33266451|NCT05684315|Experimental|soft tissue flossing therapy left lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their left leg flossed while performing the fatigue protocol.
33266452|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
33266453|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
32771825|NCT05048589|Experimental|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
32771826|NCT05728567||Health control group|The participants without type 2 diabetes (T2DM) and mild cognitive impairment (MCI)
32771827|NCT05728567||T2DM group|The T2DM patients without MCI
33079333|NCT00577018|Placebo Comparator|3|
33079334|NCT04578847|Experimental|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
33079335|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
33266454|NCT05135663|Experimental|NS-089/NCNP-02 40 mg/kg|
33266455|NCT05135663|Experimental|NS-089/NCNP-02 80 mg/kg|
33266456|NCT05684237|Other|HiSMILE treatment option|HiSMILE treatment option
33266457|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
33266458|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
33266459|NCT05246813||Osteoporotic hip fracture patients|
33266460|NCT05246813||Hip osteoarthritis patients|
33266461|NCT05245097|Experimental|Intervention Group|"The intervention group will be assigned a Tango Belt to be worn around the waist for up to 24 hours a day (removed for bathing, charging of device and upon request) for 6 months. The Tango Belt (the Device) is a wearable belt designed to enable safer mobility of geriatric individuals (≥ 65 years of age) at risk for fall injury by mitigating major hip injuries due to falls by deploying an airbag around the hips upon sensing a serious hip-impacting fall-in-progress to protect the hips from ground impact forces."
33266462|NCT05245097|No Intervention|Control Group|The the clinical site's electronic medical record (EMR) database will be reviewed determine their long-term care patient population's initial eligibility for meeting the study inclusion criteria beginning at the time frame 6 months prior to the institutional review board (IRB) approval date. Subjects eligible for the control group must meet the requirements of the inclusion and exclusion criteria except for the waist circumference and need for consent. Eligible subjects' electronic health records will be mined for the baseline, midpoint, and final study metrics.
33266463|NCT05684705|Experimental|BV100|7 doses of BV100 (q12h)
33266464|NCT05238233|Experimental|Eye Dilation and Constriction|"Participants screened for hyperopia >+1 diopter using a phoropter, have their intraocular pressures measured using a tono pen, and have their iridocorneal angle measured with a gonio lens.~Proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens.~The following day, the participant will receive one drop of tropicamide and one drop of 1% pilocarpine in the left eye.~If the left eye has no response to the 1% pilocarpine, or if the diameter of the pupil returned to baseline size, we will ask participants to come back to the clinic on another day to have the process repeated in the right eye."
33266465|NCT05685017||Metablic syndrome vs. non-metabolic syndrome|Obese adolescents were grouped on MetS vs. non-MetS based on The International Diabetic Federation criteria
33401564|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
33401565|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
32771828|NCT05728567||DCI group|The T2DM patients with MCI
32771829|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
32771830|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
33079336|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
33079337|NCT00187005|Other|1|
32771831|NCT05072457|Experimental|Experimental|All participants in the study will have both localization and spatial hearing tested with the Roger On transmitter as well as the Roger Select transmitter.
32771832|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
32771833|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
32771834|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
32771835|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
32771836|NCT04994301||Patient with Cystic Fibrosis|Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.
32771837|NCT03065881|Active Comparator|Dilated versus Natural pupil|
32771838|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
32906373|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
33079338|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
33079339|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
33079340|NCT00577252||1|Adolescents with CF.
33079341|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
33079342|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
33079343|NCT04579003|Experimental|Mobilization|Mobilization, heat application, ultrasound, TENS
33079344|NCT04579003|Active Comparator|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
33079345|NCT04578418|Active Comparator|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
33079346|NCT04578418|Experimental|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
33079347|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
33079348|NCT00577447|Active Comparator|1|DHA supplemented group
33079349|NCT00577447|Placebo Comparator|2|Placebo group
33079350|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
33079351|NCT00577525||2|Controls (matched for age and sexe with the first group)
33079352|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
33079353|NCT00187044|Other|1|
33079354|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
33079355|NCT00577603|Active Comparator|Arm 1|standard stoma
33079356|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
33079357|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
33079358|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
33079359|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
33079360|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
33079361|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
33079362|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
33079363|NCT00577759|Placebo Comparator|Usual Care|Usual care
33079364|NCT00577798|No Intervention|Observational|Only had observational arm
33079365|NCT00187083|Experimental|1|Native asparaginase
33079366|NCT00187083|Experimental|2|PEG-asparaginase
33266466|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
32771839|NCT05047575|Experimental|REASSURE Cohort 1|Survivors who are enrolled at time of a follow-up visit and who will be offered the REASSURE intervention at the next 6 month visit (including the opportunity to replace a visit with feedback communication).
33266467|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
33266468|NCT05232851|Experimental|Arm A (PDS0101)|Patients receive PDS0101 SC on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
32771840|NCT05047575|Experimental|REASSURE Cohort 2|Survivors who are enrolled prior to a follow-up visit and who will be offered the REASSURE PRO assessment and feedback communication (but not provided the opportunity to replace a visit with feedback communication).
32771841|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
32771842|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
32771843|NCT04452721||Retrospective cohort|340 to 400 patients
32771844|NCT04452721||Validation cohort|120 patients
32771845|NCT04993365|Experimental|Experimental Group|The experimental group is also called the combined immunization group .260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
33079367|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
33079368|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
33079369|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
33079370|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
33079371|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
33079372|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
33079373|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
33079374|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
33079375|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
33079376|NCT00202098|Experimental|1|ALI/ARDS patients
33079377|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
33079378|NCT00578110|Experimental|Group 1|Glaucoma Patients
33079379|NCT00578110|Experimental|Group 2|Glaucoma suspects
33079380|NCT00578110|Active Comparator|Group 3|Controls
33079381|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
33079382|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
33079383|NCT00180635|Experimental|Healthy volunteers non smoker|Control group
33079384|NCT00180635|Experimental|Healthy volunteers smoker|More than 10 pack-years
33266469|NCT05232851|Experimental|Arm B (PDS0101, pembrolizumab)|Patients receive PDS0101 SC on day 1 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
33266470|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
33266471|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
33266472|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
33266473|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
33266474|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
33266475|NCT05318417|Other|Children and adults with unilateral hearing loss/single-sided deafness|
33266476|NCT05314439|Experimental|ION904|Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.
33266477|NCT05314439|Placebo Comparator|Placebo|Up to 4 monthly doses of placebo will be administered by SC injection.
33266478|NCT05684627|Experimental|Fast mimicking diet group|The patients in this group will be assigned to follow three cycles of a fasting mimicking diet (FMD) the same day after receiving the full-mouth non-surgical periodontal treatment.
33266479|NCT05684627|Active Comparator|Normal diet group|The patients in this group will be assigned to normal diet after receiving the full-mouth non-surgical periodontal treatment.
33079385|NCT00180635|Experimental|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
32935635|NCT02788045|Experimental|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 4 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events [SAEs]).
32935636|NCT02788045|Placebo Comparator|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
32935637|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
33266480|NCT05311475|Experimental|Mometasone + Azelastine|Mometasone + Azelastine (50 + 140 mcg per actuation)
33266481|NCT05311475|Active Comparator|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
33266482|NCT05311475|Active Comparator|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
33266483|NCT05311475|Placebo Comparator|Placebo|Placebo nasal spray
33266484|NCT00617708|Experimental|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33266485|NCT00617708|Active Comparator|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33266486|NCT05054309|Active Comparator|Probiotic|Bifidobacterium longum [BL NCC3001]
33266487|NCT05054309|Placebo Comparator|Placebo|Maltodextrin
33266488|NCT04083209|Experimental|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
33266489|NCT04083209|No Intervention|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
33266490|NCT02589119|Other|MSC-AFP|Single Treatment Group
33266491|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
33266492|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
33266493|NCT05227586||LA + RA ablation|Patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation when left atrial ablation did not terminate atrial fibrillation.
33266494|NCT05227586||LA ablation only|Patients with persistent atrial fibrillation and right atrial enlargement received left atrial ablation only
33266495|NCT05051033|Active Comparator|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
33266496|NCT05051033|Active Comparator|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
33266497|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
33266498|NCT00876044|Placebo Comparator|2|matching placebo
33266499|NCT04040114|No Intervention|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
33266500|NCT04040114|Active Comparator|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
33266501|NCT00876122|Experimental|1|
33266502|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
33266503|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
33266504|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
33266505|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
33266506|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
33266507|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
33266508|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
33266509|NCT04083521|Experimental|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
33266510|NCT04083521|No Intervention|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
33266511|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
33266512|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
33266513|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
33266514|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
33266515|NCT04083053|Experimental|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
33266516|NCT04083053|Experimental|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
33266517|NCT05227274||MFM-Play|Neuromuscular disease patients completed MFM using MFM-Play
33266518|NCT05113745|Experimental|AXS-12 (reboxetine)|"Up to 24 weeks in open-label period~Up to 4 weeks in randomized double-blind period"
32771846|NCT04993365|Active Comparator|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
32771847|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
32771848|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
32771849|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
33079386|NCT00578266|Other|No Arms|
33079387|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
33266519|NCT05113745|Placebo Comparator|Placebo|Up to 4 weeks in randomized double-blind period
33266520|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
33266521|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
33266522|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
33266523|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
33266524|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
33266525|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
33266526|NCT03894969|Experimental|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
33266527|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
33266528|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
33266529|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
33266530|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
33266531|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
33266532|NCT05355597|Experimental|Exparel Group|70 subjects will receive Exparel
33266533|NCT05355597|Experimental|Multi-Drug Cocktail Group|70 subjects will receive a Multi-drug Cocktail
33266534|NCT05684003|Experimental|Intervention group|Neuromuscular exercise based injury-prevention program
33266535|NCT05684003|No Intervention|Control group|Nonspecific warm-up including a combination of aerobic exercises and range of motion exercises.
33266536|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
33266537|NCT05355519|Active Comparator|Curriculum and Instructor-Led Course|Participants first complete an online cognitive assessment. Once complete, staff email the electronic curriculum for participants to read. On a specific day, participants will go to the designated center to participate in an instructor-led course and simulated medical scenarios and complete megapode and online cognitive assessment. After a washout period of six months, participants return to the designated center to participate in simulated medical scenarios and complete the online cognitive assessment again. After a second washout period of six months, participants will take the online cognitive assessment again.
32771850|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
32771851|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
32771852|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
32771853|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
33079388|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
33079389|NCT04578496|Experimental|Afamelanotide|
33079390|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
33266538|NCT05355519|Placebo Comparator|Placebo|On a specific day, participants will go to a designated center to complete an online cognitive assessment and participate in simulated medical scenarios. Once complete, study staff will email the electronic curriculum for participants to read. After a washout period of six months, participants will return to the designated center to participate in an instructor-led course and simulated medical scenarios and complete a megapode and online cognitive assessment. After a second washout period of six months, participants will take an online cognitive assessment again.
33266539|NCT05031767|Active Comparator|Usual care|Conventional current follow-up strategy
33266540|NCT05031767|Experimental|Remote monitoring|Remote monitoring by health professionals at the hospital
33266541|NCT05031767|Experimental|Patient-initiated care|No pre-scheduled visits or remote monitoring.
32771854|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
32771855|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
32771856|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
33266542|NCT00871598|Placebo Comparator|Placebo|
33266543|NCT00871598|Experimental|Single 0.3|
33266544|NCT00871598|Experimental|Repeat 1.0|
33266545|NCT00871598|Experimental|Repeat 2.0|
33266546|NCT00871598|Experimental|Repeat 4.0|
33266547|NCT00871598|Experimental|Repeat 8.0|
33266548|NCT04082741|Experimental|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
33266549|NCT04082741|Experimental|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
33266550|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
33266551|NCT05684549||stage I/II lung cancer patients|Patients with stage I/II lung cancer will receive radical surgery.
33266552|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
33266553|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
33266554|NCT05171972||Relapsing-remitting Multiple Sclerosis|Enrolled subjects in this group will have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and will be treated with Ofatumumab.
33266555|NCT05171972||Healthy Control Subjects|Enrolled subjects must not have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria, any other autoimmune disease, demyelinating co-morbidity, neurological disease or immune system altering disease.
33266556|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
33266557|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
32771857|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
32935638|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
32935639|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
32935640|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
32935641|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
32935642|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
32935643|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~5FU: 2400 mg/m2~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
32935644|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
32935645|NCT04738591|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
32935646|NCT04738591|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
32935647|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
32935648|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
32935649|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
32935650|NCT02636647|No Intervention|No treatment|No transplant performed
32935651|NCT05227027|Experimental|Education plus game module|Participants receive an educational intervention through the Smoke Free application with the embedded game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
32935652|NCT05227027|Active Comparator|Education module only|Participants receive an educational intervention through the Smoke Free application only (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
32935653|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
32935654|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
32935655|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
32771858|NCT04993131|Experimental|Liver transplant|The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
33079391|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
32771859|NCT05428813|Experimental|Experimental|The group to which art therapy techniques will be applied.
33079392|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
33401566|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
33401567|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
33079397|NCT00578578|Active Comparator|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
33079398|NCT00578578|Placebo Comparator|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
33079399|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
33079400|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
33266558|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
33266559|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
33266560|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
32771860|NCT05428813|No Intervention|Control|The group that will continue their routine coping habits related to premenstrual syndrome.
32771861|NCT05046561|Active Comparator|STRI Formula|STRI Formula 3 capsules by mouth twice daily for 10 days
32771862|NCT05046561|Placebo Comparator|Placebo|Placebo 3 capsules by mouth twice daily for 10 days
33266561|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
33266562|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
33266563|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
33266564|NCT05103683|Experimental|Monotherapy Dose Finding - Part 1|TORL-1-23
33266565|NCT05103683|Experimental|Expansion as Monotherapy - Part 2|TORL-1-23
33266566|NCT05356533|Active Comparator|Intervention|A total of 60 young adults will be randomized to the 4-week, web-based drinking to cope intervention.
33266567|NCT05356533|No Intervention|Assessment Control|A total of 60 young adults will be randomized to the assessment only control condition.
33266568|NCT04001361|Sham Comparator|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
32771863|NCT05419219|Active Comparator|The Multi-domain Tai Chi Digital Therapy Group|participants will be provided via a tablet or smart phone the traditional Tai Chi exercise with background music and respiratory control exercise with 18 BPM metronome, and 40 Hz sound stimulation for 4-week therapeutic session.
33079401|NCT00578890|Experimental|1|
33079402|NCT00579007||1|Women with a strong family history of breast cancer.
33079403|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
33079404|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
33079405|NCT00579046|Experimental|1|
33079406|NCT00579085|Placebo Comparator|1|
33079407|NCT00579085|Experimental|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
33266569|NCT04001361|Experimental|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
33266570|NCT04001361|Experimental|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
33266571|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
33266572|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
33266573|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
33266574|NCT00992979|Experimental|Therapeutic Massage|
32771864|NCT05419219|Placebo Comparator|The regular Tai Chi Exercise Group|participants will be provided by the same way to deliver traditional Tai Chi exercise with plain music background, but without respiratory control exercise or 40 Hz sound stimulation. All participants will receive any other routine care or treatment as usual (TAU).
33266575|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
33266576|NCT05028101|Active Comparator|Control (Standard of Care (SOC))|Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
33266577|NCT05028101|Experimental|SOC + Functional Medicine|"Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.~Perioperative nutrition and lifestyle-based interventions along with select dietary supplements."
33266578|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
33266579|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
33266580|NCT05356455|Experimental|EXPERIMENT- active|Motivational interview technique
33266581|NCT05356455|No Intervention|control passive|just watched
33266582|NCT05211947|Experimental|Patients with cognitive impairment due to schizophrenia|
33079408|NCT00579241|Experimental|1|Transcranial imaging using Doppler ultrasound
33266583|NCT05225948|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
33266584|NCT05225948|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
33266585|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
33266586|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
32771865|NCT05416801||Volleyball Group|Female Volleyball players who are currently playing in a university team and who are meeting the inclusion criteria.
32771866|NCT05416801||Control Group|Female university students who are meeting the inclusion criteria.
32771867|NCT05728333|Experimental|Tirofiban|Tirofiban will be administrated intravenously before endovascular thrombectomy.
32771868|NCT05728333|Active Comparator|Alteplase|Alteplase will be administrated intravenously before endovascular thrombectomy.
32771869|NCT04447651||Patients with SF3B1, U2AF1 or SRSF2 mutation|Metastatic solid tumor patients that have a SF3B1, U2AF1 or SRSF2 mutation
32771870|NCT05370703||Standard of Care (SOC) group|This group will continue their current lipid-lowering therapy and will not need to download any mobile application.
32771871|NCT05370703||SOC + My A:Care group:|This group will continue their current lipid-lowering therapy along with access to the mobile application My A:Care that supports medication adherence through motivational messages and challenges, health insights, and medication reminders.
33266587|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
33266588|NCT04001907|Experimental|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
32771872|NCT05370703||SOC + Smart Coach group:|"This group will continue their current lipid-lowering therapy along with access to the mobile application Smart Coach that supports medication adherence through personalized motivational messages and challenges, health insights, and medication reminders. Personalization of the messages and challenges will be based on a behavioral profiling Social, Psychological, Usage, Rational (SPUR™) questionnaire that is completed at randomization to the Smart Coach application.~Study site will guide the subjects on how to use these mobile applications. Eligibility assessment will be based on information collected at screening/baseline visit (Visit 1) and assessment of Part 1 of MARS 5VA questionnaire. Adherence at baseline (Visit 1) and after 12 weeks of observation (Visit 2), will be evaluated by the complete MARS 5VA (Part 1 and 2) questionnaire. Each subject will be followed up for approximately 12 weeks from randomization at Visit 1."
33266589|NCT04001907|Placebo Comparator|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
33266590|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
33266591|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
33266592|NCT04039646|Active Comparator|Standard postoperative care group|Patients received standard postoperative care as ususal.
33266593|NCT04039646|Experimental|ERAS group|Patients received postoperative ERAS treatment.
33266594|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
33266595|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
33266596|NCT05024045|Experimental|LOXO-338 (Monotherapy)|LOXO-338 administered orally.
33266597|NCT05024045|Experimental|LOXO-338 + Pirtobrutinib (Combination)|LOXO-338 administered orally in combination with pirtobrutinib
33266598|NCT05251311|Experimental|Social Risk Screening + Resource Map|Participants randomized to the experimental arm will receive a social risk assessment tool followed by an electronic resource map
33266599|NCT05251311|Active Comparator|Resource Map|Participants randomized to the active comparator group will receive only an electronic resource map
33266600|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
33266601|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
33266602|NCT05683925|No Intervention|baseline|Participants will receive no stimulation, the electrode will be placed in the ear in a random position and turned off. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
33266603|NCT05683925|Active Comparator|taVNS100|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
32771875|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
33266604|NCT05683925|Active Comparator|taVNS25|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
33266605|NCT05683925|Sham Comparator|sVNS|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
33266606|NCT00993369||Healthy newborns conceived naturally|
33266607|NCT00993369||Healthy newborns conceived with IVF|
32771876|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
32771877|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
32771878|NCT04990869|Experimental|COPD-NR|COPD patients receiving Nicotinamide Riboside
32771879|NCT04990869|Placebo Comparator|COPD-placebo|COPD patients receiving placebo
32771880|NCT04990869|Experimental|Control-NR|Lung-healthy controls receiving Nicotinamide Riboside
32771881|NCT04990869|Placebo Comparator|Control-placebo|Lung-healthy controls receiving placebo
33266608|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
33266609|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
33266610|NCT04141839|Other|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
33266611|NCT04141839|Experimental|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
33266612|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
32771882|NCT05728177|Experimental|STUDY GROUP|"Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools~The program of intervention took four-weeks for each patient (total eight sessions- four outpatient sessions and four home-based sessions- two sessions per week- one outpatient and one home session/week). The outpatient sessions were done once per week during the patient visit to the outpatient clinic, as the patients visited the clinic 4 times/ month."
33266613|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
32771883|NCT05728177|Active Comparator|Control group|Patients in this control group will be left without any intervention to undergo the usual outpatient routine care.
32771884|NCT05070429|Other|Conventional hearing healthcare group|The conventional hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. During Year 1, this group will receive clinic-based audiological rehabilitative service delivery and be able to use conventional options to address any unanticipated needs that arise, and then during Year 2, this group will also receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise.
33266614|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
33266615|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
33266616|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
33266617|NCT05355441||Multidisciplinar pain treatment patients|Major trauma patients with moderate, severe or incapacitating pain will be referred to consultation specialized in chronic pain and psychology. Patients will be evaluated, in terms of quality of life, before and after the treatment.
33266618|NCT05094089||SYNECOR IP Device|Hernia mesh repair with GORE® SYNECOR Intraperitoneal Biomaterial
33266619|NCT05094089||SYNECOR PRE Device|Hernia mesh repair with GORE® SYNECOR Preperitoneal Biomaterial
33266620|NCT05155436|Experimental|Fixed-Dose Combination pill of Telmisartan and Amlodipine|Fixed-Dose Combination pill of Telmisartan 40 mg and Amlodipine 5 mg, once daily for 3 months
33266621|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
33266622|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
33266623|NCT05093933|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
32771885|NCT05070429|Other|Telehealth hearing healthcare group|The telehealth hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. This group will receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise during both years of the study.
32771886|NCT04401553|Experimental|First Tier Antibiotic|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
32771887|NCT04401553|Active Comparator|Second Tier Antibiotic|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam
33266624|NCT05093933|Placebo Comparator|Placebo|Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.
32771888|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must be within 6 weeks of discharge from or current receive mental health treatment services in a VA San Diego Healthcare System psychosocial rehabilitation and recovery center (PRRC), mental health residential rehabilitation treatment program (RRTP), general mental health outpatient treatment, or recent acute mental health inpatient hospitalization.
33266625|NCT05213481|Experimental|Tepotinib then Carbamazepine|Participants will receive a single dose of tepotinib after standard breakfast on Day 1 and Day 26, along with carbamazepine twice daily at the same time each day in the morning and evening from Day 8 to Day 32.
32771889|NCT05725993||TBI Patient|
33266626|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
33266627|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
32771890|NCT05725993||Healthy Control|
33266628|NCT04075461|Experimental|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
33266629|NCT04075461|Active Comparator|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
33079409|NCT04578262|Experimental|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
33079410|NCT04578262|Sham Comparator|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
32771891|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
32771892|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
32771893|NCT05336227|Experimental|Immediate Start - Virtual Reality Exergaming|12 weeks of virtual reality active video gaming using immersive commercially available equipment, with adapted games for people to play in the seated position. Maintain normal eating/nutritional behaviors.
32771894|NCT05336227|No Intervention|Wait-list Control|Maintain habitual physical activity levels for 12 weeks, before receiving the same intervention. Maintain normal eating/nutritional behaviors.
32771895|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
32771896|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
33266630|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
33266631|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
33266632|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
33266633|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
33266634|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
33266635|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
33266636|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
33266637|NCT05132049|Experimental|Sequence A|
33266638|NCT05132049|Experimental|Sequence B|
33266639|NCT00993759|No Intervention|No treatment|
33266640|NCT00993759|Experimental|3804-250A lotion|
33266641|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
33266642|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
32743159|NCT04937673|Experimental|Camrelizumab+ Albumin bound paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
33266643|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
33266644|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
33266645|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
33266646|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32743160|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
32771897|NCT05042973|Active Comparator|Active drug (Empagliflozin)|Empagliflozin 10 mg, 1 capsule per day
32771898|NCT05042973|Placebo Comparator|Inactive drug (placebo)|Placebo, 1 capsule per day
32771899|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
32771900|NCT03065491|Placebo Comparator|Placebo|Placebo
32743161|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
32743162|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
32743163|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
32743164|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
32743165|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
32743166|NCT04958343||reconstruction group|Patients will receive pelvic reconstruction following radical cystectomy during the operation.
32743167|NCT04958343||non-reconstruction group|Patients will not receive pelvic reconstruction following radical cystectomy during the operation.
32743168|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
32743169|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
32743170|NCT04937439|Experimental|Segmental trunk training A|Children in this group will receive specially designed physical therapy program while wearing a segmental trunk support from the level of pelvis to a level just below the rib cage.
32743171|NCT04937439|Active Comparator|Segmental trunk training B|Children in this group will receive the same program given to (group A) while wearing a segmental trunk support from the level of pelvis to a level just below the inferior angle of scapula.
32743172|NCT04937439|Active Comparator|Segmental trunk training C|will receive the same program given to (group A and B) while wearing a segmental trunk support from the level of last rib to the level of the inferior angle of scapula.
32743173|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
32743174|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
32743175|NCT04944381|Experimental|SARS-Cov-2 mRNA vaccine immunization group|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd.
32743176|NCT04944381|Experimental|Inactivated SARS-Cov-2 vaccine immunization group|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
32771901|NCT04990401|Experimental|Behavioral Activation Teletherapy|All eligible participants will be assigned to receive the behavioral activation teletherapy intervention.
32935656|NCT05211739|Other|LID205255, then Biofinity Toric|Lehfilcon A toric contact lenses worn first, followed by comfilcon A toric contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
33401568|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
33401569|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
33401570|NCT04056728|Experimental|Eupenta Inj.|
33401571|NCT04800562|Experimental|PCS499 900mg BID|PCS499 900mg twice a day with food
33401572|NCT04800562|Placebo Comparator|Placebo|similar in appearance to active study drug
33401573|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
33401574|NCT04056338||Non-delirium|Patients without delirium.
33401575|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
33401576|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
33401577|NCT04056260|Experimental|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
32771902|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
32771903|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
32771904|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
32771905|NCT04989699|Active Comparator|OTX-TKI|
32771906|NCT04989699|Active Comparator|Aflibercept|
32771907|NCT05333185|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
32935657|NCT05211739|Other|Biofinity Toric, then LID205255|Comfilcon A toric contact lenses worn first, followed by lehfilcon A toric contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
33079411|NCT04577950|Experimental|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
33401578|NCT05675020|Experimental|Parent-Adolescent Dyad|"Each parent-adolescent dyad will receive the intervention (educational program delivered via a 45-minute presentation via Zoom).~The educational program will promote healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines. The educational presentation will include 5-10 minutes of education regarding recommendations versus reality for nutrition, PA, screen time, and sleep, 20-25 minutes of education regarding ways to improve healthy lifestyle knowledge and behaviors, 10 minutes for questions and discussion."
33401579|NCT05674864|Placebo Comparator|Group 1 (Control Group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Placebo 1 capsule three times daily for 14 days.
33401580|NCT05674864|Active Comparator|Group 2 (Linex ® group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Linex ® capsule (which contains Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus) 1 capsule three times daily for 14 days.
32771908|NCT05333185|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
32771909|NCT05040633|Experimental|Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by the Low Lever Laser Therapy.
33079412|NCT00579397||1|"For Objective #1:~Healthy adult volunteers"
33079413|NCT00579397||2|"For Objectives #2 & #3:~Recipients undergoing an allogeneic stem cell transplant"
33401581|NCT02391688|Experimental|Treatment A|"Oral intake of:~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
33401582|NCT02391688|Experimental|Treatment B|"Oral intake of:~fexofenadine 25 mg"
33401583|NCT02391688|Experimental|Treatment C|"Oral intake of:~bupropion 20 mg"
33401584|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
32771910|NCT05040633|Sham Comparator|Sham Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by a sham Low Level Laser Therapy (LLLT). The laser equipment will be deactivated and not switched on.
33266647|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33266648|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33266649|NCT03971409|Experimental|Arm A (avelumab, binimetinib, liposomal doxorubicin)|Patients receive a 15 day lead-in of binimetinib orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib PO BID on days 1-28, avelumab intravenously (IV) over 60 minutes on days 1 and 15, and liposomal doxorubicin IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33266650|NCT03971409|Experimental|Arm B (avelumab, sacituzumab govitecan)|Patients will receive a 15-day lead-in of sacituzumab govitecan given on day -15 and day -8, followed by sacituzumab govitecan day 8 and day 15 of Cycle (C) 1; day 1,8, and 21 of C2; day 1, 15 and 21 of C3; day 8 and 15 of C4, and schedule continues with two weeks on, one week off for 21-day cycles. Patients also receive 10mg/kg avelumab over 60 minutes on day 1 and day 15 of each 28 day cycle. Cycles repeat in the absence of disease progression or unacceptable toxicity.
32771911|NCT05040633|Active Comparator|Standard Exercise Therapy|Trial participants in this group will only receive the standard exercise therapy. The exercise therapy will consist of strengthening and stretching exercises.
32771912|NCT05711407||Peri-implantitis|Group Case
32771913|NCT05711407||Healthy|Group Control
32771914|NCT05068479|Experimental|Natural Emmetropic Presbyopes|Patients that did not undergo any vision correcting surgery or implantation of an intraocular lens but suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
32771915|NCT05068479|Experimental|Post Laser Vision Correction (LVC) Emmetropic Presbyopes|Patients that underwent laser vision correction procedure (e.g. LASIK) in the past and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
32771916|NCT05306665|Experimental|ACT intervention|Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
32771917|NCT05306665|No Intervention|Treatment As Usual|Participants assigned to this arm will receive treatment as usual.
32771918|NCT05067933|Experimental|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
32771919|NCT05067933|Experimental|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
32771920|NCT05067933|Experimental|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
32771921|NCT05067933|Experimental|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
32771922|NCT05067933|Experimental|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
33079414|NCT04578067|Experimental|Intervention|culturally tailored intervention package on changes in lifestyle-habits
33079415|NCT04578067|No Intervention|Control|
33079416|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
33079417|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
33401585|NCT05676502|Active Comparator|Nasal High Flow with Optiflow M cannula|Nasal high flow treatment 35L/min with the standard symmetric nasal cannula (Optiflow M)
33401586|NCT05676502|Active Comparator|Nasal High Flow with Optiflow Duet Cannula|Nasal high flow treatment 35L/min with the asymmetric nasal cannula (Optiflow Duet)
33401587|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
33401588|NCT02391454|Other|Group A|usual care
32771923|NCT05067933|Experimental|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
32771924|NCT05067933|Experimental|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
32771925|NCT05067933|Experimental|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
32771926|NCT05067933|Experimental|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
32771927|NCT05067933|Placebo Comparator|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
33079418|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
33079419|NCT04578184|Other|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
32771928|NCT05286229|Experimental|Cohort 1 (ABBV-383 Dose A)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 dose A in 21-day cycles.
32771929|NCT05286229|Experimental|Cohort 2 (ABBV-383 Dose B)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 dose B in 21-day cycles.
32771930|NCT05279131|Experimental|Tirbanibulin (Klisyri®)|Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of AK lesions in the treatment field (TF) until completion of the response assessment period at Day 57
32771931|NCT04426487|Placebo Comparator|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
33266651|NCT03971409|Experimental|Arm C (avelumab, liposomal doxorubicin)|Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin on Day 1 and 10mg/kg avelumab over 60 minutes on Day 1 and Day 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33266652|NCT00872144|Active Comparator|Sativex|
32771932|NCT04426487|Active Comparator|progesterone group|Intramusculer progesterone therapy before and after craniotomy
33401589|NCT02391454|Experimental|Group B|usual care + RunKeeper app
32771933|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
32771934|NCT03797937|No Intervention|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
32771935|NCT03797937|No Intervention|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
32771936|NCT03797937|No Intervention|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
32771937|NCT04242199|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
32771938|NCT04242199|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
32771939|NCT04242199|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
32771940|NCT04989465|Experimental|Experimental Group|450 Participants (including 150 subjects aged 2~17 years, 150 subjects aged18~60 years and 150 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd will be collected venous blood about 3.0~3.5 ml.
32771941|NCT04989465|Placebo Comparator|Control Group|150 Participants (including 50 subjects aged 2~17 years, 50 subjects aged18~60 years and 50 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Chengdu Institute of Biological Products will be collected venous blood about 3.0~3.5 ml.
32771942|NCT05557565|Experimental|QL1706 injection|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
33079420|NCT04578184|Other|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
32771943|NCT05067621|Experimental|Receive treatment|Semaglutide (Wegovy) pen is a subcutaneous injection
32771944|NCT05067621|Placebo Comparator|Placebo|The placebo pen is almost exactly the same as the Wegovy subcutaneous injection except it does not contain the active ingredient, Semaglutide.
32771945|NCT04685525|Experimental|Mycobiome Supporting Diet|Participants will be able to abide by the allowed and disallowed foods in MSD diet for at least four consecutive weeks prior to conditioning and up to 10 days after transplant. Participants will maintain a diary of foods they consume and any adverse effects they are experiencing and will self- collect fecal samples 28 days before transplant, 2 days before transplant and 10 days after transplant
32771946|NCT03066895|Experimental|Experimental|BabyGentleStick
32771947|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
32771948|NCT05040243|Experimental|Treatment Group|"On the basis of conventional acupuncture treatment combined with acupoint application of Yanqing Zhitong Ointment.~Acupuncture point:Weizhong,Shenshu,Dachangshu,Jaji,Ashi Acupoint application:Pain in the lumbar spine, Mingmen, Yaoyangguan, Shenshu (double), Ashi (6 points in total); Within 3 inches beside the spine on both sides of the waist, Shenshu (double), Dachangshu (double), Ashi (6 points in total); 3 inches away from the sides of the spine on both sides of the waist, Shenshu (double), Zhishi (double), Ashi (6 points in total).~Stick to each point for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Three times a week( Monday, Wednesday, and Friday). Course of treatment: each course lasts for 2 weeks, a total of 2 courses of continuous treatment."
33079421|NCT00579475|Placebo Comparator|Placebo|
33079422|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
33079423|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
33079424|NCT00579631||1|Questionnaire or Interview
33079425|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
33079426|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
33266653|NCT05355129|Experimental|Dose 1|low dose
33266654|NCT05355129|Experimental|Dose 2|Middle dose
33266655|NCT05355129|Experimental|Dose 3|High dose
33266656|NCT05355129|Placebo Comparator|Placebo|
33266657|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
33266658|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
32771949|NCT05040243|Sham Comparator|Control Group|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
32771950|NCT05697133|Experimental|SEMSTOP|It is the group to which the initiatives will be applied.
33079427|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
32771951|NCT05697133|Active Comparator|Control|It is the group to be compared to which the interventions will not be applied.
33079428|NCT00579748||1|
33079429|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
33079430|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
33079431|NCT00579865||Group A|Patients scheduled for percutaneous drainage
32771952|NCT05039151||septic shock|50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
32771953|NCT05039151||control|35 non-septic patients with oedema from another cause
32771954|NCT04221295|Experimental|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
32771955|NCT04221295|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
32771956|NCT04988217|Experimental|Part 1a: Interferon alpha 2b 2.5 MIU|Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)
32771957|NCT04988217|Experimental|Part 1b: Interferon alpha 2b 5 MIU|Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)
32771958|NCT04988217|Placebo Comparator|Part 1: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
32771959|NCT04988217|Experimental|Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)|Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)
32771960|NCT04988217|Placebo Comparator|Part 2: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
32771961|NCT05038839|Experimental|Treatment (cabozantinib, pamiparib)|Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32771962|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
32771963|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
32771964|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
32771965|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
32771966|NCT05038371||Patients with neovascular age-related macular degeneration|This will include 10 subjects with a diagnosis of age-related macular degeneration.
32771967|NCT05038371||Controls|This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.
32771968|NCT05038137|Experimental|Time restricted feeding|daily eating period of 8 hours, before 8 PM
32771969|NCT05038137|Active Comparator|Control|daily eating period ≥ 12 hours
32771970|NCT04443673|Experimental|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
32771971|NCT04443673|No Intervention|Control|Participants will receive the habitual treatment for their severe condition.
32771972|NCT05037903|Experimental|Cognitive-behavioral therapy|Cognitive-behavioral therapy, including behavioral exercises and homework assignments.
32771973|NCT05663203|Experimental|Supportive care (CRCWeb intervention)|Patients and caregivers attend a CRCweb intervention over 8 weeks. Patients and caregivers complete interviews and surveys throughout the trial.
32771974|NCT04986969|Active Comparator|real-time, face-to-face, video-conferenced CBT (vcCBT)|vcCBT is cognitive behavioral therapy that consists of eight face-to-face video-conferencing sessions via tablet computers lasting approximately 45 minutes each.
32771975|NCT04986969|Active Comparator|self-administered internet-based CBT (iCBT)|iCBT is self-directed cognitive behavioral therapy using an interactive internet program, MoodGYM, which does not include direct interactions with a therapist.
32771976|NCT04986501|Experimental|MucoPEG|Arm being compared to against Biotene
32771977|NCT04986501|Active Comparator|Biotene|Arm being compared against MucoPEG
33079432|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
33079433|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
32771978|NCT05065593|Experimental|Face-to-Face Training Group|"After completing all assessments, the intervention group will participate in face-to-face exercise training with a physiotherapist for 3 days for 4 months.~In the first week, patients will be taught body awareness; parameters of correct loading on the muscle will be explained and the limits of safe exercise will be drawn. At the beginning and end of all exercises, there will be short-term active stretching and relaxation exercises performed by the patient as a warm-up and cool-down period. In the first 4 weeks, it is planned to increase the physical fitness levels of individuals with progressive resistance exercises and to make them suitable for aerobic loading. For each patient, the PRE, resistance will be increased from 60% to 80% for as long as the person can. At the end of the 1st month, the time allocated to resistance exercise training will be reduced and until the end of the 4th month, an increasing intensity aerobic exercise training will be given on the stationary bike."
32771979|NCT05065593|Active Comparator|Home-Based Control Group|After the patients assigned to the control group are evaluated by the physiotherapist with field tests and scales for physical functions, the patients will be informed about the importance of lifestyle changes in disease management, gait training will be given to increase their physical activity level and participants will be asked to follow a 45-minute walking program every day within their own means. All patients in the control group will be followed up regularly and their activity levels will be questioned in interim evaluations by asking them to keep a weekly physical activity diary.
32771980|NCT05036577|Experimental|ORMD (Orelabrutinib, Rituximab, Methotrexate and Dexamethasone)|Patients were treated for 6-8 cycles of induction therapy with 21 days per cycle, receiving rituximab (375mg/m2 on day 1), dexamethasone (10-15mg on d1-d4), MTX (d2, 3.5g/m2 or 5g/m2), and orelabrutinib (once daily, after MTX clearance, 150mg/d, or 200mg/d), followed by orelabrutinib maintenance up to one year among CR/CRu patients or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). The primary objective was to determine the maximum tolerated dose (MTD) of the combination of orelabrutinib and MTX with R and D and investigate the safety and tolerability of this regimen using Bayesian Optimal Interval (BOIN) waterfall design to determine rule of dose escalation and movement among dose combination matrix to identify MTD contour.
32771981|NCT04985799|Active Comparator|Gynecare TVT Exact sling|Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
32771982|NCT04985799|Active Comparator|Neomedic KIM sling|Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.
32771983|NCT04982367|Experimental|Sirolimus-eluting balloon angioplasty|Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
32771984|NCT04982367|Active Comparator|Paclitaxel-eluting balloon angioplasty|Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
32771985|NCT05034627|Experimental|Treatment (calaspargase pegol-mknl, cobimetinib)|Patients receive calaspargase pegol-mknl IV over 1 hour on day 1 and cobimetinib PO QD on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32771986|NCT05033145|Experimental|AZVUDINE|"Experimental:~AZVUDINE 1mg tablet~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days"
32771987|NCT05033145|Placebo Comparator|AZVUDINE placebo|"Control:~AZVUDINE placebo~Intervention:~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days"
32771988|NCT05031975|Experimental|TEMIRI|"Irinotecan intravenous infusion (IV) given every 14 days in combination with oral (PO) temozolomide over days 1-5 every 28 days.~The treatment will consist of six 28-days cycles of TEMIRI."
32771989|NCT05031273|Experimental|Residents moving into a congregate-living development with more features that support healthy living|Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
32771990|NCT05031273|No Intervention|Residents living in a standard congregate-living development|Residents living in a standard community-based congregate-living development designed for older adults.
32771991|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
32771992|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
32771993|NCT04218825|Experimental|Adult patients with early stage MF-CTCL (stage IA-IB)|Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.
32771994|NCT04217811||Late neutropenia|Neutrophil count < 1500
32771995|NCT04217811||No late neutropenia|Neutrophil count > 1500
32771996|NCT04137757|Experimental|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
32771997|NCT04137757|Sham Comparator|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
32771998|NCT04217343||non-complement mediated pAMR(H+)|
32771999|NCT04217343||complement mediated pAMR(I+)|
32772000|NCT05660161|Experimental|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
32772001|NCT04216797|Active Comparator|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
32772002|NCT04216797|Active Comparator|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
32772003|NCT05029401|Experimental|Single dose IMP (DMX-1002)|"Stage 1 (single blind, placebo controlled): initial dose of placebo, followed by treatment at one of 4 ascending dose levels of IMP (3, 6, 9 or 12 mg/kg)~Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)"
32772004|NCT05029401|Placebo Comparator|Matching Placebo|Placebo using capsules identical to the IMP (DMX-1002)
32772005|NCT05194267|Experimental|Active tDCS|Will be receiving active intensive tDCS treatment
32772006|NCT05029011||Patients of the Sleep Disorders Laboratory|Monitoring vital signs
33079434|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
33079435|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
32772012|NCT05028855||sCAS patients|Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
32772013|NCT05641207|Experimental|Experimental device RheOx™ with the RheOx™ Catheter was only used in the trial|All of participants who signed the ICF and meet all of inclution and exclution criterias will be enrolled to experimental arm.
32772014|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
32772015|NCT04040569|Experimental|Single-fraction stereotactic partial breast radiotherapy|The primary objective is to escalate the dose of 1 fraction stereotactic partial breast radiotherapy utilizing the MR Linac,Gammapod or Cyberknife system to an ablative dose in the pre-operative setting to the primary tumor without exceeding the maximum tolerated dose in patients with early stage breast cancer.
32772016|NCT05025813|Experimental|Arm A|"Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:~If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if >10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W"
32772017|NCT04033237|Experimental|Very low nicotine content cigarettes|
32772018|NCT04033237|No Intervention|Usual Brand|
32772019|NCT05064501||Asthma and COVID19 infection|Asthma and COVID19 infection
32772020|NCT05064501||Asthma without COVID19 infection|Asthma and COVID19 infection
32772021|NCT05627089||Patients with Rheumatoid Arthritis and/or Myositis|"All patients 18 years or older who have been diagnosed with Rheumatoid Arthritis according to the 2010 ACR/EULAR Classification Criteria.~All patients 18 years or older who have been diagnosed with Myositis according to the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies Classification Criteria."
32772022|NCT05064345|Active Comparator|HB0034 dose group 1|HB0034 single dose
32772023|NCT05064345|Active Comparator|HB0034 dose group 2|HB0034 single dose
32772024|NCT05064345|Active Comparator|HB0034 dose group 3|HB0034 single dose
32772025|NCT05064345|Active Comparator|HB0034 dose group 4|HB0034 single dose
32772026|NCT05064345|Active Comparator|HB0034 dose group 5|HB0034 single dose
32772027|NCT05064345|Active Comparator|HB0034 dose group 6|HB0034 single dose
32772028|NCT05064345|Active Comparator|HB0034 dose group 7|HB0034 single dose
33079436|NCT00580021||1|Patients with breast and pancreas cancer.
33079437|NCT00202176|Experimental|1|Ipratropium Bromide
33079438|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
32772029|NCT05064345|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
32772030|NCT03939169|Other|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
32772031|NCT03939169|Other|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
33079439|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
33079440|NCT00580099|Active Comparator|2|cuddle for 20 minutes
33079441|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
33079442|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
33079443|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
33079444|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
33079445|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
33079446|NCT04578145|Other|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
33079447|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
33079448|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
33079449|NCT00580450|No Intervention|2|
33079450|NCT00580450|Experimental|1|
33079451|NCT00580528|Experimental|1|
33079452|NCT00580528|Experimental|2|
33079453|NCT00580528|No Intervention|3|
33079454|NCT00580567||1|Pathological Gamblers
33079455|NCT00580567||2|Non-Pathological Gamblers
33266659|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
32772032|NCT03939169|Other|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
32772033|NCT03939169|Other|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
32772034|NCT05063331|Active Comparator|Sacrocolpopexy|Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP)
33266660|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
33266661|NCT00877526||A|
33266662|NCT05018585|Experimental|Diamyd|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
33266663|NCT05018585|Placebo Comparator|Placebo|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
33266664|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
32772035|NCT05063331|Active Comparator|Uterosacral Ligament Suspension|Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
32935658|NCT04697264|Experimental|Patients with endometrial cancer|"Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy."
32935659|NCT04700761|Experimental|Group OFA (Opioid-free anesthesia)|Not using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (except a single dose of alfentanil for endotracheal intubation)
33266665|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
33266666|NCT00993837|Experimental|conversion|
33266667|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
32935660|NCT04700761|Active Comparator|Group OUA (Opioid-using anesthesia)|Using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (continuous infusion of remifentanil)
33266668|NCT05093543|Experimental|Intervention|"The experimental group is based on a telematic multidisciplinary approach for CnsLBP. Scheduled and periodic telematic sessions will be performed. The multidisciplinary approach (to be carried out by telematic means) consists of a biopsychosocial rehabilitation program for patients with CnsLBP that includes physical rehabilitation/physiotherapy and psychosocial group sessions (performed by psychologists, social workers), which will be offered as part of the integrated program.~Patients assigned to the experimental group will receive a Google Meet® link by email, so that they may join the weekly 2-hour group sessions (every Tuesday at 9 a.m.). Google Meet® is a free real-time meeting app by Google that does not require download, has no session time limit, and neither limits the number of users per session. Patients assigned to the experimental group will receive a single-use link by email to access each online group session."
32935661|NCT05206201|Experimental|ZY19489 Capsule|Experimental study drug
32772036|NCT05623735|Experimental|Instrument Assisted Soft Tissue Mobilization (IASTM) Group While Lying Prone|"The application will take a total of 6 sessions, with two sessions per week for 3 weeks.~While individuals are lying in the prone position, the IASTM protocol will be applied bilaterally on the erector spinae and then on the hamstrings. The application will take approximately 17 minutes."
32772037|NCT05623735|Experimental|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"While standing in the extended child pose (utthita balasana) stance, the IASTM protocol will be applied bilaterally on the lumbar erector spines, with the hands on them and moving back to the old position. Then, the IASTM protocol will be applied bilaterally on the hamstrings by making consecutive knee flexion-extension up to 90 degrees while the individuals are lying prone.~The application will take approximately 17 minutes."
32935662|NCT05206201|Placebo Comparator|Placebo|Matching placebo
32935663|NCT04689776|Experimental|High Frequency Dual-Task Training (HF)|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-120 minutes of training.
32935664|NCT04689776|Experimental|Low Frequency Dual-Task Training (LF)|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-120 minutes of training.
32935665|NCT05194033|Experimental|Probiotics|The intervention group consumes oral probiotics 1 time/day for 7 consecutive days.
32935666|NCT05194033|Placebo Comparator|Placebos|The placebo group consumes oral placebo 1 time/day for 7 consecutive days.
33266669|NCT05093543|No Intervention|Control|Explanation for choice of comparators {6b} The telematics multidisciplinary approach (experimental group) will be compared to Standard of Care (SoC) (control group). SoC consists of a patient's follow up according to the usual clinical practice. In Bellvitge University Hospital's setting, the treatment protocol for CnsLBP indicates physical rehabilitation/physiotherapy as the first treatment step, and Pain Clinic evaluation as a second step for those who did not improve. For patients who did not improve with the previous steps and that still demand a solution for their CnsLBP, a third step would be to refer the patient for surgical evaluation - a spine surgeon would, then, evaluate, alongside with the patient, whether a surgical approach would be appropriate for his/her case. If the surgery is ruled out by the spine surgeon, the patient may be referred, once more, to physical rehabilitation/physiotherapy and/or to the Pain Clinic, at the surgeon's discretion.
33266670|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
33266671|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
33266672|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
33266673|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
32772038|NCT04421547|Experimental|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
32772039|NCT04421547|Active Comparator|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
32772040|NCT04987489|Experimental|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
32772041|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
33266674|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
33079456|NCT04577872|Experimental|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
33266675|NCT00993993||"group early intervention"|
33266676|NCT00993993||"group late intervention"|
33266677|NCT05014841|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 20-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
33266678|NCT04039958|Experimental|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
33266679|NCT04039958|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
33266680|NCT04039958|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
33266681|NCT05007821|Experimental|Arm A|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.~Weeks 1-26: LZD 600 mg once daily (QD)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
33266682|NCT05007821|Experimental|Arm B|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.~Weeks 1-4: LZD 1200 mg once daily (QD)~Weeks 5-26: LZD 1200 mg three times per week (TIW)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
32772042|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
32772043|NCT03910075|Experimental|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
32772044|NCT03910075|Experimental|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
33266683|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
33266684|NCT00534105||2|Normal pregnant women without gestational diabetes
32772045|NCT03910075|Active Comparator|Usual & Customary Treatment|Usual & Customary Treatment
32935667|NCT04668391|Experimental|Quadratus lumborum block|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament.
32935668|NCT04668391|Active Comparator|Thoracic epidural analgesia|Thoracic epidural analgesia at the level of T7-10.
33266685|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
33266686|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
33266687|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
33266688|NCT05084885|Experimental|Online treatment|The participants will receive counseling over the internet.
33266689|NCT05084885|No Intervention|Non-treatment|Participants who did not participant in the group were asked to complete the 12ve month followup questionnaire (but not the post treatment questionnaire).
33266690|NCT05226351|Active Comparator|Dronabinol PTSD|Donabinol before cognitve testing - PTSD patients
32935669|NCT04658888|Experimental|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
33266691|NCT05226351|Active Comparator|Dronabinol healthy controls|Donabinol before cognitve testing - healthy controls
33266692|NCT05226351|Placebo Comparator|Placebo PTSD|Placebo before cognitve testing - PTSD patients
33266693|NCT05226351|Placebo Comparator|Placebo healthy controls|Placebo before cognitve testing - healthy controls
33401590|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
32772046|NCT05061771|Active Comparator|nomacopan (rVA576)|"PART A:~High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd~or~Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS~PART B:~Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd"
32772047|NCT05061771|Placebo Comparator|Placebo|"PART A:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~or~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~PART B:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd"
32772048|NCT05061069|Experimental|Infants with permanent hearing loss|Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.
32772049|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
32772050|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
32772051|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
32772052|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
32772053|NCT05060913|Experimental|5% EMLA Cream|EMLA cream will be applied over buccal mucosa of one side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
32772054|NCT05060913|Active Comparator|20% Benzocaine gel|Benzocaine gel will be applied over buccal mucosa on another side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
32772055|NCT03870763|Experimental|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
32772056|NCT03870763|Experimental|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
32772057|NCT03870763|Placebo Comparator|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
32772058|NCT05060367|Experimental|Liposomal multivitamin/mineral condition|Ingestion of novel, liposomal multivitamin/mineral.
33079457|NCT04577872|Experimental|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
33079458|NCT04577872|No Intervention|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
33079459|NCT00580684|Active Comparator|G1|G1: prevenar
33079460|NCT00580684|Active Comparator|G2|G2: pneumo 23
33079461|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
33079462|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
33079463|NCT00209040|Experimental|1|Subjects with posttraumatic stress disorder
33079464|NCT00209040|Active Comparator|2|Healthy controls
33079465|NCT00209040|Active Comparator|3|Combat controls
33079466|NCT00580918||1|Mild Traumatic Brain Injury group
33079467|NCT00580918||2|Normal healthy control group
33079468|NCT00581035|Experimental|1|Prevenar and Meningitec
33079469|NCT00581035|Experimental|2|Prevenar
33079470|NCT00581035|Experimental|3|Meningitec
33079471|NCT00187317|Experimental|PERT|Perturbation-based balance training.
33079472|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
33079473|NCT04577560|Experimental|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 [PB1] (36-42 hours post trigger injection) and if fertilization occurred on day 1 [PB2] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
33079474|NCT04577560|Experimental|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
33079475|NCT00581074|Active Comparator|G|grapefruit
33079476|NCT00581074|Active Comparator|J|Juice
33079477|NCT00581074|Placebo Comparator|W|placebo
33079478|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
33079479|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
33079480|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
33079481|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
33079482|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
33079483|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
33079484|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
33079485|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
32772059|NCT05060367|Active Comparator|Standard multivitamin/mineral condition|Ingestion of standard multivitamin/mineral.
32772060|NCT05060289||Modeling group|The data of modeling group is used to construct a predictive model of DILI endpoint events.
32772061|NCT05060289||Validation group|Validation group is used to validate the predictive model externally.
32772062|NCT05168839|Experimental|FLUO+|"Experimental arm = surgery with IOFA.~In the experimental arm, cancer resection and anastomosis will be performed after assessment of descending colon perfusion using intravenous injection of indocyanine green 0.1ml/kg."
32772063|NCT05168839|No Intervention|FLUO-|"Control arm = Surgery without IOFA.~In the control arm, cancer resection and anastomosis will be performed without intraoperative fluorescence angiography."
32772064|NCT05059821|Experimental|Experimental Personalized Cancer Vaccine|Patients with recurrent HCC after surgical resection and refractory to available line of treatment will receive Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes
32772065|NCT05165251|Experimental|Amlodipine/atorvastatin|amlodipine/atorvastatin (5mg/10mg QD)
32772066|NCT05165251|Active Comparator|Amlodipine|amlodipine (5mg QD)
32772067|NCT05165251|Other|Lifestyle intervention|
32772068|NCT04209075|Experimental|Placebo then Prebiotic|Participant will take Placebo during Period 1 and Prebiotic during Period 2
32772069|NCT04209075|Experimental|Prebiotic then Placebo|Participant will take Prebiotic during Period 1 and Placebo during Period 2
32772070|NCT05151991|Active Comparator|Groups MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
32772071|NCT05151991|Active Comparator|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
32772072|NCT04980495|Experimental|efgartigimod IV - I|Patients receiving efgartigimod IV treatment (Continuous regimen: efgartigimod 10 mg/kg q2w)
32772073|NCT04980495|Experimental|efgartigimod IV - II|Patients receiving efgartigimod IV treatment (Cyclic regimen: efgartigimod 10 mg/kg q7d for a total of 4 infusions per TP for 2 TPs with a fixed 4-week IP between each TP)
32772074|NCT05151601|Experimental|HMOs + Probiotics|"Dosing: A total daily dose of 2 x sachets (6g/day)~Product Comprised of:~2.5g of a proprietary blend of human milk oligosaccharides combined with~20 billion CFUs of a mixture of Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium animalis spp. lactis, and Bifidobacterium longum.~Mode of administration: oral."
32772075|NCT05151601|Placebo Comparator|Placebo|Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
32772076|NCT04433221|Experimental|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
32772077|NCT05138419|Active Comparator|Case Management Model (CMM)|CMM includes 3 visits of pharmacist initiated discussion of workbook content (including AP [action plan] and CKD web-based sites) and AP reinforcement. Pre-testing is done on Visit 1 (V1) and Post testing and program evaluation on V3. Subjects are asked to read 1 chapter a week, write down questions and take tests at the end of chapters. On V1 pharmacist introduces the Workbook System highlighting chapters 1-4 and assist with AP goal selection. On V2, the pharmacist answers questions, provides chapter 4-8 highlights and reviews AP goal progress and food label exercise. On V3, pharmacist answers questions, expands on workbook content and reviews AP goals progress and program evaluation including modality and transplant questions from pre/posttests, identification and ranking of peer cluster leader teaching style and effectiveness, identification of AP goals selected and ranking of helpfulness is completed. Pharmacists track time spent at each visit to compare cost and outcomes.
32772078|NCT05138419|Active Comparator|Self Study (SS)|SS includes 2 visits. Subjects receive the workbook, paper copies of AP and food label exercise. Pre-testing will be done on V1 and Post testing on V2, eight weeks later. Subjects will be asked to read 1 chapter a week for the next 8 weeks. The pharmacist will provide a brief introduction of the workbook (5-10 minutes) and the AP. Only subject initiated questions will be answered. On V2, the pharmacist will answer subject initiated questions and ask about progress in the AP goal attainment and the program evaluation will be completed, as described in arm 1.Pharmacists track time spent at each visit to compare cost and outcomes.
32772079|NCT05138419|Sham Comparator|Control (Ctrl)|Ctrl includes 2 visits. Subjects receive a list of web-based CKD sites, a food label exercise and a copy of the AP with no additional intervention, other than answering subject initiated questions, on V1. Pre-testing will be done on V1 and Post testing on V2 and program evaluation will be done eight weeks later. On V2, the pharmacist will ask about AP goals and answer subject initiated questions. Pharmacists track time spent at each visit to compare cost and outcomes.
32772080|NCT05125939||Screening indication|Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.
32772081|NCT05125939||Surveillance indication|Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.
32772082|NCT05125939||Diagnostic indication|Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.
32772083|NCT05125939||Positive fecal immunochemical test|FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.
32772084|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape~Resistance to femoral head rotation and cut-out~Active compression through linear motion without rotation~Single subtrochanteric lag screw option for stable fractures below lesser trochanter~Preloaded cannulated set screw converts construct to fixed angle device~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~Clothespin tip for stress modulation in femoral shaft~Potential for improved patient mobility and recovery~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
32935670|NCT04658888|No Intervention|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
32772085|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
32772086|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
32772087|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
32772088|NCT05058729||Cohort 1|Participants with multiple sclerosis (MS) or clinically isolated syndrome (CIS) who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution.
32772089|NCT05023473|Active Comparator|PENG block+ morhine|the participants will receive PENG block before being attached to morphine PCA
32772090|NCT05023473|Active Comparator|MORPHINE|The participants will be given morphine PCA without PENG block
32772091|NCT04978779|Experimental|Dose escalation of VIP152 Escalation|Investigating VIP152 in a dose escalation cohort in patients with CLL
32772092|NCT04978779|Experimental|Dose expansion of VIP152 Expansion|Investigating VIP152 in a dose expansion cohort in patients with CLL and Richter Syndrome.
32772093|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
33266694|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
33266695|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
33266696|NCT05084417||Cohort 1: Alopecia Areata|Cohort 1 is limited to patients clinically diagnosed with Alopecia Areata. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional AA-specific measures throughout the length of the study.
33266697|NCT05084417||Cohort 2: Atopic Dermatitis|Cohort 2 is comprised of patients that have been clinically diagnosed with Atopic Dermatitis. Patients in this cohort will receive the universal PROs and ClinROs, but will also receive additional AD-specific measures throughout the length of the study.
32772094|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
32772095|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
32772096|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
32772097|NCT05022147|Experimental|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
32772098|NCT05021679|Experimental|AMP Implementation|
32772099|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
33266698|NCT05084417||Cohort 3: Hidradenitis Suppurativa|Cohort 3 is limited to patients clinically diagnosed with Hidradenitis Suppurativa. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional HS-specific measures throughout the length of the study.
33266699|NCT05084417||Cohort 4: Psoriasis|Cohort 4 is limited to patients clinically diagnosed with Psoriasis. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional PsO-specific measures throughout the length of the study.
33266700|NCT05084417||Cohort 5: Vitiligo|Cohort 5 is limited to patients clinically diagnosed with Vitiligo. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional VL-specific measures throughout the length of the study.
33266701|NCT00573248|Experimental|4|
32772100|NCT03712657|No Intervention|conservative group|normal treatment
33266702|NCT00994227|Experimental|surgery|
33266703|NCT05206565|Experimental|Autologous with TRAM/DIEP flaps, with neurotization|Autologous with TRAM/DIEP flaps, with neurotization
32772103|NCT05105503||Adults with AVFs currently in the process of maturing|Adults with ESRD who currently have a maturing AVF that has not yet been cannulated
32772104|NCT05104567|Experimental|Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32772105|NCT05104567|Experimental|Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
33079486|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
33079487|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
33079488|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
33079489|NCT00581269|Active Comparator|2|dietary restriction group
33079490|NCT00581269|No Intervention|3|control group
33079491|NCT00581425|Experimental|Treated|
33266704|NCT05206565|No Intervention|Autologous with TRAM/DIEP flaps, without neurotization|Autologous with TRAM/DIEP flaps, without neurotization
33266706|NCT04039880|Experimental|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
33266707|NCT04039880|Experimental|Cohort B (biliary evaluation)|evaluation of biliary elimination
33266708|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
33266709|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
33266710|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
33266711|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
33266712|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
33266713|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
33266714|NCT04083911|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
32772106|NCT05104567|Experimental|Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32772107|NCT05104567|Experimental|Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
33079492|NCT04577092|Active Comparator|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
32772108|NCT05104567|Experimental|Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32772109|NCT05104567|Experimental|Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32772110|NCT05104567|Experimental|Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type|SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
32772111|NCT05057793|No Intervention|Standard of care|Multilayer, multicomponent compression intended for the treatment of VLU
33266715|NCT05354895|Experimental|Intervention: Transcranial Infrared Laser Stimulation (TILS)|Participants receive 10 minutes of TILS treatment to the right prefrontal cortex once a week for 6 weeks. TILS will use an FDA-cleared 1064-nm laser (CG-5000, Cell Gen Therapeutics, LLC, Dallas, TX). The irradiance will be 0.25 W/cm2, and fluence, 60 J/cm2.
33266716|NCT04998851|Experimental|Women with CIS or MS|Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
33266717|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
33266718|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
33266719|NCT00867542||past IUGR|3-4 y old children with past IUGR
33266720|NCT00867542||control|3-4 y old healthy children
33266721|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
33266722|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
33266723|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
33266724|NCT00872612|Experimental|A|Endosonography arm
33266725|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
33266726|NCT05198765|Experimental|BMI-CDS|Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.
33266727|NCT05198765|No Intervention|Control|Clinicians and their patients assigned to control clinics will engage in the usual standard of care with no access to shared decision support tools.
33266728|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
33266729|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
33266730|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
33266731|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
33266732|NCT00867620||1|case group: patients with urothelial carcinoma
33231138|NCT04882982|Experimental|Caria app|"The Caria app is publically available on the Apple app store. It is an interactive native app that provides education on menopause as well as symptom tracking/feedback features, social support as well as cognitive behavioral and relaxation techniques. Participants will be given an unlocked version with all content available at no charge. The app sends out occasional automated emails to users to remind of features of the app and to encourage them to return to the app. Users can opt out of reminder features."
33231139|NCT04882982|Active Comparator|Menopause education|Participants will receive educational material about menopause from the North American Menopause Society, a well respected menopause organization.
32772112|NCT05057793|Active Comparator|Standard of care + geko 12h|Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
32772113|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol + Polmacoxib capsule
32772114|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib
32772115|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl)
32772116|NCT04978311|Experimental|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
32772117|NCT04978311|Active Comparator|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
32772118|NCT04978311|Active Comparator|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
32772119|NCT04976205|Experimental|TMI/TMLI|"The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI.~CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure.~The treatment will be performed the day before the BMT."
32772121|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
32772122|NCT05056623|Experimental|Dyadic pain management program|The DPM is an 8-week group-based program. The DPM included 4 weeks of center-based, face-to-face activities and 4 weeks digital-based activities delivered via a WhatsApp group.
32772123|NCT05056623|Other|Usual care and pain management pamphlet|The participants in the control group will receive the usual care and a pain management pamphlet.
32772124|NCT05055609|Experimental|Open Label|In the dose escalation portion, it is estimated that approximately 12-24 subjects will be enrolled in four dose cohorts. The dose expansion portion will enroll 6-12 subjects.
32772125|NCT04940065||Kesimpta|Patients treated with Kesimpta
32772126|NCT05019885|Experimental|IV Ketamine Hydrochloride|dose 0.5mg/kg of IV Ketamine Hydrochloride over 40 min
32772127|NCT05019105|Placebo Comparator|Placebo|Placebo administered orally
32772128|NCT05019105|Active Comparator|ALKS 1140|Up to 8 single ascending doses of ALKS 1140 and 4 multiple ascending doses administered orally
32772129|NCT04933747|Experimental|Group 1: Participants with severe Renal Impairment (RI)|Severe Renal Impairment (RI), as defined by an eGFR < 30 mL/min/1.73 m2 and not requiring dialysis, at screening
32772130|NCT04933747|Experimental|Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)|Kidney failure participants on intermittent hemodialysis (IHD)
32772131|NCT04933747|Experimental|Group 3: Participants with normal renal function|Normal renal function, as defined by a creatinine clearance (Clcr) > 90 mL/min estimated using the Cockcroft-Gault (C-G) equation, at screening.
32772132|NCT05018325|Active Comparator|Arm 1: Colonoscopy 6 minute withdrawal time|-Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
33231140|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
33231141|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
33231142|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
33231143|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
33231144|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
33231145|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
33231146|NCT00627016|Placebo Comparator|Placebo|
33231147|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
33231148|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
33231149|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.~Intervention: Clown therapy"
33231150|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
33231151|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
33231152|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
33231153|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
33401591|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
33401592|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
32772133|NCT05018325|Experimental|Arm 2: Colonoscopy 9 minute withdrawal time|-Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
32772134|NCT05018325|Experimental|Arm 3: Colonoscopy 12 minute withdrawal time|-Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time
32772135|NCT04208919|Experimental|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
32772136|NCT03064945|Sham Comparator|Shame device|
32772137|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
32772138|NCT05016609|Experimental|POC HCV antibody group (Arm A)|This group will receive POC HCV antibody testing via fingerprick using the OraQuick HCV antibody test (OraSure) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
32772139|NCT05016609|Experimental|POC HCV RNA group (Arm B)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will receive POC HCV viral load testing via fingerstick using the Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
32772140|NCT05016609|Experimental|Test and treat group (ArmC)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will be provided a starter pack of HCV treatment (epclusa). POC tests results will be confirmed through standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. HCV RNA positive participants will continue treatment. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
32772141|NCT05016609|No Intervention|Control|This group will receive the standard of care for HCV testing and treatment. Participants in this group will fill out a short behavioural questionnaire and a clinical questionnaire.
32772142|NCT05016141|No Intervention|no intervention|Participants will be observed for 12 months. Participants will use the Health in Motion app to set goals and keep track of their health and health events, including falls. These participants will NOT receive the education modules or the exercise program.
32772143|NCT05016141|Experimental|digital fall prevention program|Participants will complete the Health in Motion digital fall prevention program for 12 months. This program consists of education modules (modified from the Matter of Balance Program) and exercises based on a digital translation of the Otago Exercise Program.
32772144|NCT05055063|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
32772145|NCT05024929||Prospective Cohort|Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
32772146|NCT05024929||Data Sharing Cohort|Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing
32772147|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
32772148|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
32772149|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
33401593|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
33231154|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
33231155|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
33231156|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
33079493|NCT04577092|Active Comparator|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
33079494|NCT04577170||Fabry disease|
33079495|NCT04577170||Healthy|age and sex matched
33079496|NCT04577053|Experimental|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
33266733|NCT00867620||2|control group: those without previous history of any malignancy
33266734|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
33266735|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
33401594|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
32772162|NCT05054361||recent onset patients|patients with recently diagnosed type 1 diabetes
32772163|NCT05054361||at risk patients|patients with a high genetic risk type 1 diabetes
32772164|NCT05054361||control subjects|control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
32772165|NCT05054361||control subjects for endoscopy|patients without type 1 diabetes requiring UGI endoscopy for any medical reason
32772166|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
32772167|NCT03066973|No Intervention|Control group|control group that received standard care service.
32772168|NCT05015283|Experimental|Laparoscopic One-anastomosis gastric bypass|In this group, the bariatric procedure is laparoscopic one-anastomosis gastric bypass, all operations follow the same standard operating procedure.
32772169|NCT05015283|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass, all operations follow the same standard operating procedure.
32772170|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
32772171|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
32772172|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
32772173|NCT03066349||Patients with PCOS undergoing IVM|
32772174|NCT04972305|Experimental|Exercise group|12 weeks exercise programme, 3 days a week Bicycle ergonomics will be applied.
32772175|NCT04972305|Experimental|Ergonomics group|Bicycle ergonomics will be applied.
32772176|NCT04972305|No Intervention|Control group|No Intervention
32772177|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
33079497|NCT04577053|No Intervention|Control|Control group will not receive treatment.
33079498|NCT00581464|Active Comparator|1|
33079499|NCT00581464|Active Comparator|2|
33266736|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
33266737|NCT00532935|Active Comparator|2|pioglitazone
33266738|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
33266739|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
33266740|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
33266741|NCT04001751|Experimental|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
33266742|NCT00878306|Active Comparator|Disulfiram|Disulfiram
33266743|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
33266744|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
33266745|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
33266746|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
33266747|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
33266748|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
33266749|NCT04082975|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
33266750|NCT04082975|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
33266751|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
32772178|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
32772179|NCT04972227|Experimental|CY6463|CY6463 once-daily (QD) for 14 days
33266752|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
32772180|NCT04972227|Placebo Comparator|Placebo|placebo QD for 14 days
32772181|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
32772182|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
32772183|NCT04970355|Experimental|Erenumab|Double-Blind Treatment Phase: Participants receive erenumab 280 mg subcutaneous (SC) injections (loading dose, week 0) followed by erenumab 140 mg s.c. in week 4.
33266753|NCT05196269|Experimental|Artificial Intelligence and Digital Health Arm|Using an Artificial Intelligence approach integrated in a cloud-based healthcare platform CANKADO to give the patient complete information about the proposed type of locoregional treatment and access to photographs and data of patients with similar characteristics previously treated with the same technique (using AI). All interaction will be through the CANKADO Platform
32772184|NCT04970355|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Participants receive placebo subcutaneous (SC) injections in week 0 and week 4.
32772185|NCT04906213|Active Comparator|Arm I: With Type II Diabetes|Kidney Transplant recipient with Type II diabetes, randomized to either Empagliflozin or a placebo.
33079500|NCT04577131|Experimental|With check-ins|Daily blood pressure monitoring with weekly check-ins
33079501|NCT04577131|No Intervention|Without check-ins|Daily blood pressure monitoring without weekly check-ins
33079502|NCT00209079|Active Comparator|1|
33079503|NCT04576975|Experimental|Ketamine|This group will receive a bolus dose of Ketamine [Ketamine HCL - Sterop, Belgium] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
33266754|NCT05196269|Other|Control Comparator|The standard approach of proposing patients for locoregional treatment with or without printed or digital materials and hypothetic visualization of results
33266755|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
32772186|NCT04906213|Active Comparator|Arm 2: Without Diabetes|Kidney Transplant recipient without Type II diabetes, randomized to either Empagliflozin or a placebo
32772187|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
32772188|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
32772189|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
32772190|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
32772191|NCT04431895|Experimental|tofacitinib 5mg twice a day|
32772192|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
32772193|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
32772194|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
32772195|NCT04950465|Experimental|Test Dentifrice|Apply a full ribbon of toothpaste on the head of the toothbrush provided. Brush teeth for 1*-timed minute, followed by brushing of the qualifying sensitive teeth. Following brushing rinse once with 10 milliliter (ml) of water from the rinsing cup provided.
33266756|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
33266757|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
33266758|NCT04971161|Experimental|allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)|Application of IMP on patients wound
32772196|NCT04950465|Active Comparator|Negative Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
32772197|NCT04950465|Active Comparator|Positive Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
32772198|NCT04877821|Experimental|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, those who exhibited residual disease were treated with capecitabine (1000-1250 mg/m2) given two-times a day for 1-14 days and cycled every 21 days for a total of 6-8 cycles.
33266759|NCT04971161|Placebo Comparator|Placebo|Application of IMP on patients wound
32772200|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
32772201|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
32772202|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
32772203|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
32772204|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
32772205|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
33079504|NCT04576975|Experimental|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine [Precedex® -Hospira, USA] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
33079505|NCT04576975|Placebo Comparator|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
33079506|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
33266760|NCT04971161|Experimental|allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)|Application of IMP on patients wound
33266761|NCT04971161|Experimental|allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)|Application of IMP on patients wound
33266762|NCT05066477|Active Comparator|CalGo (Salmon bone meal)|4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains ~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.
32772206|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
32772207|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
32772208|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
32772209|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
32772210|NCT04969341||Screening (survey, medical record review)|Patients complete survey over 20 minutes consisting of validated and piloted items related to cost and convenience barriers in lung cancer screening, personal financial and lung cancer risk perception questions, and the Telehealth Satisfaction and Usefulness questionnaire. Patients also have their medical records reviewed retrospectively.
32772211|NCT04840615|Experimental|1/Intratumoral LMB-100 Administration|Those with pleural or peritoneal mesothelioma receiving intratumoral administration of LMB-100 + ipilimumab for up to 4 cycles
32772212|NCT05011383|Experimental|ATM|Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
32772213|NCT05011383|Experimental|CDK12|Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
32772214|NCT05011383|Experimental|CHEK2|Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
33266763|NCT05066477|Placebo Comparator|Maltodextrin|4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.
33266764|NCT05684393|Experimental|Anatomy based fitting|
33266765|NCT05684393|Active Comparator|Standard fitting|
33266766|NCT04968743|Experimental|Participants With Unilateral Stroke|"Participants with self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold."
32772215|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
32772216|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
32772217|NCT05010603||Families with a history of Alzheimer's Disease|Families with two or more family members affected with Alzheimer's Disease
32772218|NCT05010603||Un-related, non-demented controls|Un-related, non-demented healthy controls over age 55
32772219|NCT05010603||Individuals with Dementia (Alzheimer's Disease)|Individuals with dementia over the age of 65
32772220|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
32772221|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
32772222|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
32772223|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
32772224|NCT01697527|Experimental|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
32772225|NCT04613843|Active Comparator|Water stirring|
32772226|NCT04613843|Experimental|No water stirring|
32772227|NCT04457453|Active Comparator|control group|intubation with direct laryngoscope in sniffing position
32772228|NCT04457453|Experimental|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
32772229|NCT04457453|Experimental|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
33266767|NCT04968743|Experimental|Participants Without Unilateral Stroke|"Participants without self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere."
33266768|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
33266769|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
33266770|NCT05061953||EDSS 0-2.0|Confirmed diagnosis of MS with an EDSS score between 0 and 2.0.
33266771|NCT05061953||EDSS 2.5-4.0|Confirmed diagnosis of MS with an EDSS score between 2.5 and 4.0.
33266772|NCT05061953||EDSS 4.5-6.0|Confirmed diagnosis of MS with an EDSS score between 4.5 and 6.0.
32772230|NCT04969185||Group 1: Children eligible to receive SMC diagnosed with uncomplicated Plasmodium falciparum malaria|Children eligible to receive SMC (6-59 months of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility.
32772231|NCT04969185||Group 2: Children eligible to receive SMC presenting at health facility without malaria parasitemia|Group 2 will be defined as children eligible to receive SMC (6-59 months of age) who presented at the health facility and tested negative for malaria parasitemia.This group will serve as the control group to Group 1 Cases to compare the SP-AQ drug levels between children who did and did not get malaria.
32772232|NCT04969185||Group 3: Children 5-10 years of age diagnosed with uncomplicated Plasmodium falciparum malaria|Group 3 will be defined as children ineligible to receive SMC (5-10 years of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility. This group will serve as the control group to Group 1 Cases to compare the prevalence of SP and AQ resistance markers.
32772233|NCT04826965|Active Comparator|Wound vac application|Wound vac application for open upper/lower extremity open wound
32772234|NCT04826965|Active Comparator|Wound vac application including irrigation|Wound vac application WITH irrigation for upper/lower extremity open wound
32772235|NCT04426409|No Intervention|control group|
32772236|NCT04426409|Experimental|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
32772237|NCT04966923||Breast Cancer and documented pathogenic variant TP53|Documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and localized breast cancer diagnosis by histological confirmation. All patients met Revised Chompret criteria or Li Fraumeni like syndrome or family member of carrier TP53
32772238|NCT04966923||Breast Cancer and no documented pathogenic variants in genetic test|Control group with localized breast cancer and no pathogenic variants documented in a genetic test
32772239|NCT01411345|Other|Phase 3 - Arm I: Standard Salvage Radiation Treatment (SSRT)|"Phase 3 total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.~this arm is closed"
32935671|NCT05192551||Plenvu|A new type of low-volume bowel-prep recently approved and introduced in the Swedish market. The dose is 500 ml x 2, The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
33266773|NCT05061953||EDSS 6.5-8.0|Confirmed diagnosis of MS with an EDSS score between 6.5 and 8.0.
33266774|NCT05061953||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
33266775|NCT05059223|Experimental|AXS-12 (reboxetine)|Up to 5 weeks
33266776|NCT05059223|Placebo Comparator|Placebo|Up to 5 weeks
33266777|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
32772240|NCT01411345|Experimental|Phase 3 - Arm II: Mapped Tumor Salvage RT (MTSRT)|"Phase 3 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).~this arm was continues as single arm phase 2"
32772241|NCT01411345|Experimental|Phase 2: Mapped Tumor Salvage RT (MTSRT)|Phase 2 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
32772242|NCT05557097||Group ultrasound + vaginal examination|Patients submitted to instrumental delivery by clinicians who routinely perform intrapartum sonography as an adjunct to clinical examination prior to vacuum delivery
32772243|NCT05557097||Group vaginal examination|Patients submitted to instrumental delivery by clinicians not performing intrapartum sonography prior to vacuum delivery
32772244|NCT04421157|Experimental|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
32772245|NCT04421157|Experimental|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
33266778|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
33266779|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
33266780|NCT05188391|Other|Positive Group (Rupture and Gap Sign are both positive)|Rupture and Gap Sign are both positive
33266781|NCT05188391|Other|Rupture Positive Group (Rupture positive but Gap Sign is negative)|Rupture positive but Gap Sign is negative
32772246|NCT04432753|Experimental|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
32772247|NCT04432753|Active Comparator|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
32772248|NCT05473793|Experimental|Highest fiber dose|This arm receives the highest dose of the intervention product, which is 15g dried vegetable per day divided into two portions of each 7.5g, which are consumed during the course of the day in the food of choice.
32772249|NCT05473793|Experimental|Medium fiber dose|This arm receives the highest dose of the intervention product, which is 10g dried vegetable per day divided into two portions of each 5.0g, which are consumed during the course of the day in the food of choice.
32772250|NCT05473793|Experimental|Lowest fiber dose|This arm receives the highest dose of the intervention product, which is 5g dried vegetable per day divided into two portions of each 2.5g, which are consumed during the course of the day in the food of choice.
32772251|NCT05473793|Placebo Comparator|Control|This arm is the control arm receiving as placebo rice puff particles each day, whose amount corresponds iso-calorically to the medium fiber dosage (~ 21 kcal/day).
32772252|NCT01362595|Other|Leucine|No alternative treatment arm
32772253|NCT04421391|Experimental|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
32772254|NCT05556941|Experimental|Metacognitive Group Intervention|Meta cognitive intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored to individuals with schizophrenia.
32772255|NCT05556941|Active Comparator|Occupational therapy standard care|Standard care of occupational therapy in mental health, focused on work occupations.
32772256|NCT05556863|Experimental|Part 1: Single Ascending Dose|"Cohort 1 Single dose: 0.001 mg/kg IV~Cohorts 2 - 11 Single dose: dose level and route (IV or SC) to be determined~Japanese Cohort Single dose: dose level and route (IV or SC) to be determined"
32772257|NCT05556863|Experimental|Part 2: Multiple Ascending Dose|Cohort 1 - 3 Multi-dose: dose level, route (IV or SC) and frequency to be determined
33266782|NCT05188391|Other|Gap Sign Positive Group (No rupture exists but Gap Sign is positive)|No rupture exists but Gap Sign is positive
33266783|NCT05188391|Other|Negative Group (Rupture and Gap sign are both negative)|Rupture and Gap sign are both negative
32772258|NCT04949139|Active Comparator|Rapid intermittent bolus group|"A : males < 65 ; B : females < 65 or males ≥ 65 ; C : females ≥ 65 yrs~<During the first 3 h>~Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg~If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h~<At 3-24 h> Modify protocol based on sNa at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion"
32935672|NCT05192551||Laxabon|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
33079507|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
33266784|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
33266785|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
33266786|NCT05187611|Experimental|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing was allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
33266787|NCT05187611|Active Comparator|Biventricular pacing|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
32772259|NCT04949139|Active Comparator|Slow continuous infusion group|"Participants will be divided into three groups same as above~<During the first 3 h>~Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h~Modify protocol as described below based on sNa measurement at 3 h~undercorrection: maintain the infusion rate~target correction: stop the infusion~<At 3-24 h> Modify protocol based on sNa measurement at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa measurement at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion"
33266788|NCT05187221||Control Group|The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains.
33266789|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
33266790|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
32772260|NCT03064399|Experimental|lateral ligament repairment|
33079508|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
33079509|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
33079510|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
33079511|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
33079512|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
33079513|NCT03453073||Younger|Age<65 years at follow-up baseline
33079514|NCT03453073||Older|Age>=65 years at follow-up baseline
33079515|NCT00581620|Active Comparator|G1|G1: HIV+
33266791|NCT01014364|Placebo Comparator|Control|isotonic saline
33266792|NCT04082351|Active Comparator|Magnalife|the group of patients receiving the nanotechnology structured water
33266793|NCT04082351|Placebo Comparator|Ordinary water|the group of patients receiving ordinary water
33266794|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
33266795|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
33079516|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
33266796|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
33266797|NCT04848389|Experimental|Skin adhesive|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
33266798|NCT04848389|Other|Standard suture|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed with the same thread with a subcutaneous stitch.
33266799|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
33079517|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
33266800|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
33266801|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
33266802|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
33266803|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
33266804|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
33266805|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
33266806|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
33266807|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
33266808|NCT04082273|Experimental|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
33079518|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
33079519|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
33079520|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
33079521|NCT00581815|Experimental|1|
33079522|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
33079523|NCT00582049||1|Cases: retinoblastoma patients
33079524|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
33079525|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
32772261|NCT03064399|Experimental|without lateral ligament repairment|
32772262|NCT04948983|Active Comparator|Intervention group|"The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records.~The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?"
32772263|NCT04948983|Placebo Comparator|Control group|"The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system.~The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records."
32772264|NCT04426097|Experimental|Cervical Vagal Blockade|
32772265|NCT04426097|Placebo Comparator|Without Blockade|
33266809|NCT04082273|Active Comparator|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
33266810|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
33266811|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
33266812|NCT04826003|Experimental|Part I: Dose-escalation of RO7122290|The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
32772266|NCT04203381|Other|Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
32772267|NCT04203381|No Intervention|Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
32772268|NCT05556551|Other|Hybrid resin ceramic restoration|Dental restoration
32772269|NCT05556551|Other|Full ceramic restoration|Dental restoration
32772270|NCT04411173|Active Comparator|Rice Protein|Rice Protein - 24 grams, chocolate, powder
32772271|NCT04411173|Active Comparator|Whey Protein|Whey Protein - 24 grams, chocolate, powder
32772272|NCT05556317|Experimental|Group A|Receive advices to reduce insomnia
32772273|NCT05556317|Active Comparator|Group B|Receive advices and resistive exercise
32772274|NCT04411407|Other|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
32772275|NCT04411407|Other|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
32772276|NCT05556083|Active Comparator|sofenacine recievers group A|Group (A) will receive sildenafil 50mg tablet form as additive therapy to dapoxetine 30 mg tablet form on demand for 8 weeks.
32772277|NCT05556083|Placebo Comparator|palcebo recievers group B|Group (B) will continue on dapoxetine 30mg tablet form with placebo tablet form of the same shap and colour of sildinafile on demand for 8 weeks.
32772278|NCT05556005|Experimental|Group 1|Patients will receive 35 mg of Trimetazidine modified release tablet twice daily in addition to their standard treatment for three months.
32772279|NCT05556005|Placebo Comparator|Group 2|Patients will receive Placebo tablet twice daily in addition to their standard treatment for three months.
33266813|NCT04826003|Experimental|Part II: Dose-expansion of RO7122290|Part II of this study will evaluate selected dose levels of RO7122290 from Part I (a QW RO712290 administration in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment) in a Q3W regimen in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment.
33266814|NCT04823663||BSC Product Use|"Subject fulfilling one of the following conditions:~a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products/components or BSC Capital Equipment products/components or ii.the BSC CRM product implant."
32772280|NCT05008809|Experimental|Treatment|Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
32772281|NCT05008809|No Intervention|Control|Structured Follow-up for up to five years after randomization
32772282|NCT04374461|Experimental|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm A:~Transfer out of the critical-care unit~Extubation~Toxicity~Death"
32772283|NCT04374461|Experimental|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm B:~Discharge from hospital~Admission to a critical-care unit~Intubation~Toxicity~Death"
33266815|NCT04082195|Experimental|Fooya mobile game|An arm that receives a mobile-app-based treatment.
33266816|NCT04082195|Active Comparator|Uno board game|An arm that receives a non mobile-app-based treatment.
33266817|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
33266818|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
33266819|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
32772284|NCT04373603|Experimental|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
32772285|NCT04373603|Placebo Comparator|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
32772286|NCT04301531|Experimental|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
33266820|NCT04795427|Experimental|asciminb arm|Patients will receive asciminib (40 mg BID continuous)
33266821|NCT04795427|Experimental|best available treatment arm|Patients will receive best available therapy chosen by investigator
32772287|NCT04301531|Other|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
32772288|NCT05611073||Distance with Minimal Intermediate Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLs. And defined by BCDVA of 0.1 logMAR or better but a DCIVA of 0.4 logMAR or worse.
32772289|NCT05611073||Distance with Enhanced Intermediate/Near Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLS. And defined by BCDVA of 0.1 logMAR or better and a DCIVA of 0.3 logMAR or better.
32772290|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
32772291|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
32772292|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
32772293|NCT05610995|Experimental|SENSIUM Group|Patients in the experimental group will be discharged with the device after an assessment on Day 1.
32772294|NCT05610995|No Intervention|ERAS standard Group|Patients in the control group will receive the usual ERAS (conventional hospitalization for clinicobiological monitoring).
32772295|NCT05610917|Experimental|case group,|Patients in case group will be treated with CBRM program
33266822|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
32772296|NCT05610917|Other|control group|the control group patients will be treated routinely as usual.
32772297|NCT04278755|Experimental|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
32772298|NCT04277975|Active Comparator|A: liberal post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + liberal opioid prescription provided prior to surgery (standard prescription for opioid prescribed prior to surgery)
32772299|NCT04277975|Experimental|B: restricted post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + opioid prescribed only 'as needed' after discharge
32772300|NCT05610839|Experimental|AEBT website with check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) and will receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
32772301|NCT05610839|Active Comparator|AEBT website without check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) but will not receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
32772302|NCT04105751|Experimental|Use of Device with post-use interview/questionnaire|All patients will be asked to utilize device and will then be asked to provide feedback on their experiences. This may be done by interview or a questionnaire. There could be up to three sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, session could last up to one hour.
32772303|NCT04093349|Experimental|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
32772304|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
32772305|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
33266823|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
33266824|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
33266825|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
33266826|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
32772307|NCT05473637||Genetic group|Patients who have positive DNA results by NGS screening of the following 5 genes: NOTCH3 (19q13.12), HTRA1 (10q26.13), GLA (Xq22.1), TREX1 (3p1.31) and COL4A1 (13q34).
32772308|NCT05473637||Nongenetic group|Patients who have negative DNA results by NGS screening .
33266827|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
33266828|NCT04082039|Active Comparator|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
33266829|NCT04082039|Experimental|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
33266830|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
33266831|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
33266832|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
32772309|NCT05555927|Experimental|active tDCS|tDCS devices (Neuroelectrics, Starstim 8, USA) are used. The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed.
33266833|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
33266834|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
33266835|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
33266836|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
32772310|NCT05555927|Sham Comparator|sham tDCS|The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed. For sham, the current rapidly ramp up to 2mA over the first 30s and rapidly ramped down to 0mA over the next 30s automatically to allow participants to feel typical initial sensations of active tDCS.
32772311|NCT05555849||Study group, Newly retired elite athletes|Elite athletes at the time of retirement of professional career. Reinvestigated after three months and thereafter yearly.
32772312|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
32772313|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
32772314|NCT04330079|Experimental|Dapagliflozin|
32772315|NCT04330079|Other|Lifestyle modification|
32772316|NCT05612945|Experimental|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. This protocol will elicits moderate-to-severe claudication pain during exertion. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test."
32772317|NCT05612945|Experimental|Low-to-moderate intensity training group (LowMod group)|Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.
32772318|NCT03911687|No Intervention|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
32772319|NCT03911687|Experimental|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
32772320|NCT05555693||Patients in the control group were followed up without POCD postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
32772321|NCT05555693||Patients in the case group were followed up with POCD postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time
32772322|NCT00660673|Experimental|Levodopa-Carbidopa Intestinal Gel|"Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL.~Participants will receive LCIG until it is commercially available."
33079526|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
33079527|NCT00582127||1|Mild-moderate Alzheimer's Disease
33079528|NCT00582127||2|Age-matched Controls
33079529|NCT00582244|Experimental|1|CBT and relaxation.
33079530|NCT00582244|Experimental|2|Physical activity
33079531|NCT00582244|Experimental|3|CBT and physical activity
33079532|NCT00582244|No Intervention|4|Control group
33079533|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
33266837|NCT05578547|Experimental|combined Kndell and McKenzie group|patients receivee combined Kndell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
33266838|NCT05578547|Active Comparator|Conventional therapy group|patients receive ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
33266839|NCT04680065|Experimental|Active Treatment|
33266840|NCT04680065|Sham Comparator|Placebo Surgery|
32772323|NCT05612867||PO Vitamin C|Patients who got PO vitamin C
32772324|NCT05612867||IV Vitamin C|Patients who got IV vitamin C
32772325|NCT05473559|Active Comparator|Adductor canal block with Ipack block|
32772326|NCT05473559|Active Comparator|Adductor canal block with selective tibial nerve block|
32772327|NCT05555459|Experimental|CompressOn group|125 participant patients undergoing bone fixation surgical operation specified in the study description. All bone fixation surgeries are performed using Inion CompressOn screws.
32772328|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
32772329|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
32772330|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
32772331|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
32772332|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months~ConM SOSIP Administered at 12 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
32772333|NCT04048759|Other|Remote Low|
32772334|NCT04048759|Other|Remote High|
32772335|NCT04048759|Other|Personal Coach|
32772336|NCT05470907||EBP|ICU COVID-19 patients treated with hemoperfusion/hemadsorption
32772337|NCT05470907||non-EBP|ICU COVID-19 patients not treated with hemoperfusion/hemadsorption
32772338|NCT04810975|Other|The effect of exercise A on musculoskeletal health|
32772339|NCT04810975|Other|The effect of exercise B on musculoskeletal health|
32772340|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
32772341|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
32772342|NCT05612711|Experimental|Dronabinol First|Participants will take Dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week. They will then undergo a 3-week washout period, followed by placebo capsules twice daily for 8 weeks.
33079534|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
33079535|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
33079536|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
33266841|NCT00491608|Experimental|1|rThrombin
33266842|NCT04081415||Group with FPIES|Not yet healed children with FPIES
33266843|NCT01018888|Experimental|Keratoprosthesis|
33266844|NCT04678583|Experimental|A - Anatomical resection|removal of the entire, tumor-bearing liver segment(s)
33266845|NCT04678583|Active Comparator|B - Non-anatomical resection|metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
33266846|NCT03996928|Experimental|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
32772343|NCT05612711|Experimental|Placebo First|Participants will take matching placebo capsules twice daily for 8 weeks, followed by a three week washout period. They will then begin taking dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week.
32772344|NCT04807309|Placebo Comparator|Placebo|Placebo comparison
32772345|NCT04807309|Active Comparator|Danazol Pill|Danazol 200mg orally twice a day
32772346|NCT04744649|Active Comparator|Control group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to control group(N=40), will receive the neoadjuvant regime of XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
32772347|NCT04744649|Experimental|Experimental group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to experimental group(N=40), will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
33079537|NCT04576624|Experimental|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
33266847|NCT03996928|Active Comparator|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
33266848|NCT04677647|Experimental|OurChild|
33079538|NCT04576624|Sham Comparator|Social Activities|Social Activities Group will receive twenty-two group sessions
32772348|NCT04744649|Other|Exploratory group|"All the patients of Epstein-Barr virus-positive (EBV(+)) [N=15]or mismatch repair-deficient (dMMR)/ microsatellite instability-high (MSI-H)[N=15] , will be assigned to exploratory group, and will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
32906374|NCT05564897|Experimental|Combination of H101 with Camrelizumab treatment|Patients receive a combination therapy of PD-1 inhibitor Camrelizumab with oncolytic adenovirus H101 for up to 1 years. Camrelizumab are administered at dose of 200 mg i.v. every 3 weeks. H101 are instilled intravesically with a dose of 5×10*11 Vp in a 50 mL normal saline solution via a catheter, and dwell time is 1 to 2 hours,. Intravesical H101 is instilled weekly for 6 weeks for both induction and maintenance treatments.
33079539|NCT04576624|No Intervention|Passive Control|Control group will receive patient education materials with each assessment
33079540|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
33079541|NCT04723407||Exposed patients|Those who had the management strategy implemented by the service during confinement
33079542|NCT04723407||Unexposed patients|Those who could not benefit from this strategy
33079543|NCT00582673|Experimental|1|
33079544|NCT00582673|Placebo Comparator|2|
33079545|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
33079546|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
33079547|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
33079548|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
33079549|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
33079550|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
33079551|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
33079552|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
33079553|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
33079554|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
33079555|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
33079556|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
33079557|NCT00181181|Placebo Comparator|Placebo|
33079558|NCT00583024|Experimental|Arm A|
33079559|NCT04576468|Experimental|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
33079560|NCT04576468|Experimental|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
33079561|NCT04576468|Experimental|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
33079562|NCT04576468|Experimental|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
33079563|NCT04576351||1|"Sub cohort 1:~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
33079564|NCT04576351||2|"Sub cohort 2:~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
33079565|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
33079566|NCT00187590|No Intervention|Control|No phone call after an ER visit.
33079567|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
33079568|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
33079569|NCT04576312|Experimental|Cohort 1|Single dose of UNI911 inhalation (4 mL 0.1% ~ 3,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
33079570|NCT04576312|Experimental|Cohort 2|Single dose of UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
33079571|NCT04576312|Experimental|Cohort 3|Single dose of UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
33079572|NCT04576312|Experimental|Cohort 4|Single dose of UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
32772349|NCT04801225|Experimental|VItalFlow Stimulation Treatment|"Enrolled subjects shall receive a VitalFlow stimulation after other standard-of-care treatments are initiated. VitalFlow treatment is initiated by powering on the System and positioning the two (Left and Right) VItalFlow coils on each side of the head (by the ear).~The operator controls the VItalFlow Stimulation through the accompanying console with simple button operation. Once treatment is initiated, the VitalFlow provides continuous, biphasic pulses at a preset power cycle with the total treatment time under 5 min (fixed time). After treatment is completed, the coils are removed and replaced on the VitalFlow System."
32772350|NCT05612633|Other|Oral zelavespib 100 mg|Oral zelavespib 100 mg will be administered once daily
32772351|NCT04793893|Experimental|Treatment of residual hypermetropia refraction after LASIK|"The main problem at young patients post - LASIK after one year is residual hypermetropic refractive errors (especially accommodation problem) The method used in Eye Hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50D) taken from myopic patients in post - LASIK patients with residual hypermetropic refractive error (min. +1.0D).~The flap of LASIk is lifted,cleaned and then the lenticule gently inserted.The lenticule was positioned according the K2 values when is astigmatism residual refractive error.In cases where is not astigmatism the lenticule was positioned in central position under the flap."
32772352|NCT05701007||Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)|
33266849|NCT04675775|Experimental|Medically-tailored meals|Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than 2000 grams a day).
33266850|NCT05557721|Experimental|Sub-tenon lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, sub-tenon anaesthesia with 2 ml lidocaine 1% will be performed. After 10 minutes of waiting time, MP-TLT will be performed.
33266851|NCT05557721|Experimental|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage. Thereafter, MP-TLT will be performed.
33266852|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
33266853|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
33266854|NCT04932785|Active Comparator|Regular Diet|Patient randomized to regular diet will begin with a regular diet.
33266855|NCT04932785|Active Comparator|Clear Liquid Diet|Patient randomized to clear liquid diet will begin with a clear liquid diet.
33266856|NCT04778189|Placebo Comparator|normal saline group (NS)|patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
32772353|NCT05701007||Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)|
32772354|NCT04002661|Active Comparator|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
32772355|NCT04002661|Placebo Comparator|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
32772356|NCT05458583|Other|Direct bonding with conventional adhesive|The fixed retainer was applied with direct bonding technique using two-step (conventional) adhesive
32772357|NCT05458583|Other|Direct bonding with one-step adhesive|The fixed retainer was applied with direct bonding technique using one-step adhesive
32772358|NCT05458583|Other|Indirect bonding with conventional adhesive|The fixed retainer was applied with indirect bonding technique using two-step (conventional) adhesive
32772359|NCT05458583|Other|Indirect bonding with one-step adhesive|The fixed retainer was applied with indirect bonding technique using one-step adhesive
33266857|NCT04778189|Active Comparator|dexamethasone group (SD)|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia
33266858|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
33266859|NCT04777721|Experimental|Group 1: 1 x 10^4 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^4 cfu aerosol inhaled BCG. All Group 1 volunteers will have a bronchoscopy 14 days post challenge.
33266860|NCT04777721|Experimental|Group 2: 1 x 10^5 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^5 cfu aerosol inhaled BCG. All Group 2 volunteers will have a bronchoscopy 14 days post challenge.
33266861|NCT04777721|Experimental|Group 3: 1 x 10^6 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^6 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
32772360|NCT03998605|Experimental|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
32772361|NCT03998605|Active Comparator|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
32772362|NCT04983277||Diabetes|patients with diagnosed Diabetes Mellitus
33266862|NCT04777721|Experimental|Group 4: 1 x 10^7 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
33266863|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
33266864|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
33266865|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
33266866|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
33266867|NCT04040270|Experimental|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
33266868|NCT04040270|Experimental|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
33266869|NCT04040270|No Intervention|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
33266870|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
33266871|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
33266872|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
33266873|NCT05136248|Experimental|intraarticular injection|intra-articular steroid injection with the ultrasound guidance technique,
33266874|NCT05136248|Active Comparator|peng block|Ultrasound guided drug injection between to iliopubic eminentia and psoas tendon
33266875|NCT00878540|Experimental|mirtazapine|
33266876|NCT04039334|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
33266877|NCT04039334|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
33266878|NCT04018274|Experimental|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
33266879|NCT04018274|Experimental|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
33266880|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
32772363|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
32772364|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
32772365|NCT04763161||Experimental group|"Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.~Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral"
32772366|NCT04763161||Control group|"Patients not suffering from AIC, hospitalised in neurosurgery for another reason,~Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach."
33266881|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
32772367|NCT04426955|Experimental|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
32772368|NCT04426955|Placebo Comparator|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
33266882|NCT00491530|Experimental|ABT-335 + simvastatin|
33266883|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
33266884|NCT04313062|Experimental|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
32772369|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
32772370|NCT05700695|Experimental|Experiential Arm|Drug: iv Branch Chain Amino Acid + Lactulose Intravenous Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
32772371|NCT05700695|Active Comparator|Comparator Arm|Drug: Lactulose + Placebo
32772372|NCT05445557|Active Comparator|RZL-012 50mg/ml|Subjects flanks treated with RZL-012 (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal doses 412.5 mg. Each injection point will be dosed with 7.5 mg for in a volume of 0.15 mL/injection site.
32772373|NCT05445557|Placebo Comparator|Placebo|Subjects flanks treated with placebo (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal volume of 8.25mL. Each injection point will be dosed with 0.15 mL/injection site.
32772374|NCT04982341||HFNC/prone|awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position
32772375|NCT04426019|Experimental|CLS intervention|
32772376|NCT04426019|Active Comparator|No CLS intervention|
33079573|NCT04576312|Experimental|Cohort 5|UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 2,5 days.
32772377|NCT04432987|Experimental|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
32772378|NCT04432987|Experimental|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
32772379|NCT05428085||Caregivers whose children are currently receiving early treatment|Individual caregivers were interviewed through paper questionnaires to assess children's and families' digital media usage habits, children's activity levels, and parental stress. Pearson's Chi-Square test and liner regression was used for analysis.
32772380|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
32772381|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
32772382|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
32772383|NCT05412329|Experimental|GC012F treatment|R/R multiple myeloma patients be treated with a single dose of GC012F cells.
32906375|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
32906376|NCT01838252|Sham Comparator|Saline|
33079574|NCT04576312|Experimental|Cohort 6|UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
33079575|NCT04576312|Experimental|Cohort 7|UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
33079576|NCT04576312|Placebo Comparator|Placebo (applicable for cohorts 1-5)|Placebo, administered in a double-blinded fashion (except for the first subjects of cohorts 1-4) at the same dose and frequency as UNI911 inhalation and intranasal spray.
33079577|NCT04576234|Experimental|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
33079578|NCT04576234|Experimental|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
33079579|NCT00209391|Experimental|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
33079580|NCT00181298|Active Comparator|1|
33079581|NCT00181298|Placebo Comparator|2|
33079582|NCT04576273||Non-parasitic|
33079583|NCT04576273||Parasitic|
33079584|NCT00583180||A|Capsaicin treated patients
33079585|NCT00583180||P|Placebo treated patients
33079586|NCT00583258|Experimental|A|
33079587|NCT00583258|Placebo Comparator|B|
33079588|NCT04576039|Experimental|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
33079589|NCT00187629|Experimental|1|dietary phosphorus
33079590|NCT00187629|Active Comparator|2|other
33079591|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
33079592|NCT00583336|Experimental|Diagnostic|
33079593|NCT04576390|Active Comparator|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
33079594|NCT04576390|Active Comparator|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
33079595|NCT00583570|Experimental|A|
33079596|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
33079597|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
33079598|NCT00181571|Active Comparator|1|Concerta
33079599|NCT00181571|Placebo Comparator|2|Placebo
33079600|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
33079601|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
33401595|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
32772384|NCT05555381|Experimental|Intervention group (pilot study)|"needs detection by means of survey and interviews (mixed-methods)~6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
32772385|NCT05397743|Experimental|Questionnaires|Questionnaires for global, psychological and visual Quality of Life (QoL)
33079602|NCT00583726|Experimental|2|This arm also receives telephone counseling.
32772387|NCT05555225||Patients with amelia|Patients with severe hypoplasia or agenesia of at least two limbs who gave their consent for the research and for whom a DNA sample is available in our laboratory
32772388|NCT05555225||Patients with Femur-Fibula-Ulna Syndrome|Patients with anomaly of at least one femur, one fibula and with oligodactyly who gave their consent for the research and for whom a DNA sample is available in our laboratory.
33079603|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
33079604|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
33079605|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
33079606|NCT00181649|Experimental|Recombinant human prolactin|
33079607|NCT04575805|Experimental|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
33079608|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
33079609|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
33079610|NCT04575805|No Intervention|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
33079611|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
33079612|NCT04575454|Other|Comatose or post-comatose patients|
33079613|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
33079614|NCT00583882|Other|2|New site every 6 days
33079615|NCT00583882|Other|3|New site every 12 days
33079616|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
33079617|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
33079618|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
33079619|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
33079620|NCT03452956||FTD Cohort|No intervention-observation only
33079621|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
33079622|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
33079623|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
33079624|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
33079625|NCT00583999||A|bariatric surgery
33079626|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
33079627|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
33079628|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
33079629|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
33079630|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
33079631|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
33079632|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
33266885|NCT04313062|No Intervention|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
32772389|NCT05555225||Healthy subjects|Healthy subjects used as controls, who gave their consent for the research and for whom a DNA sample is available in our laboratory.
33266886|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
33401596|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
33401597|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
32772390|NCT05555147|Experimental|Nerve Block Group|Thirty minutes prior to surgery the patients received bilateral infraorbital and infratrochlear nerve block. Infraorbital nerve block was performed while using an extraoral approach. A 25 gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 mL of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed Infratrochlear nerve block. After negative aspiration of blood, 1 mL of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
33266887|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
33266888|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
33266889|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
33266890|NCT04670549|Other|Pre and post implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase patients with hip and knee OA will receive OA care more in line with the treatment recommendations."
32772391|NCT05555147|Sham Comparator|Control Group|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
32772392|NCT02587247|Experimental|TF2 antibody/68Ga-IMP-288|TF2 antibody/68Ga-IMP-288
32772393|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
32772394|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
32772395|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
33266891|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
32772396|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
32772397|NCT05612477|Experimental|Autotransfusion|patients in this arm will receive their salvaged and washed RBCs via transfusion
32772398|NCT05612477|No Intervention|No Autotransfusion|patients in this arm will have their salvaged and washed RBCs discarded.
33266892|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
32772399|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
32772400|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
32772401|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
32772402|NCT04334525|No Intervention|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
32906377|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
32906378|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
33266893|NCT04775927|Experimental|education group|marriage preparation training
33266894|NCT04775927|No Intervention|control group|No intervention
33266895|NCT04918355||Provider Group 1: no alert|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
33266896|NCT04918355||Provider Group 2: Mandated alert|Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.
32772403|NCT04334525|Experimental|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
32772404|NCT02174159|Experimental|Panel A: MK-8507 600 mg|Single oral dose of MK-8507 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
32772405|NCT02174159|Experimental|Panel B: MK-8507 150 mg|Single oral dose of MK-8507 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
32772406|NCT02174159|Experimental|Panel C: MK-8507 <=600 mg|Single oral dose of MK-8507 <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
33079633|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
33079634|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
33079635|NCT00182039|Experimental|A|metoprolol
33079636|NCT00182039|Placebo Comparator|B|placebo
33266897|NCT04918355||Provider Group 3: PDMP alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid naïve patients.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
33266898|NCT04918355||Provider Group 4: PDMP + EHR alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
33266899|NCT04039490|No Intervention|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
33266900|NCT04039490|Experimental|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
33266901|NCT05676593|Active Comparator|People living with diabete standard TPE|HBA1c at 3 and 6 months Therapeutic education Auto questionnary on Aviitam plateform at 3 and 6 months
33266902|NCT05676593|Experimental|People living with diabete standard TPE + FSL 28 days|"Continuous mesure of glucose (FSL2) during 28 days at enrollment Therapeutic education HBA1c at 3 and 6 months Auto questionnary on Aviitam plateform at 3 and 6 months~Auto questionnary on Aviitam plateform at 3 and 6 months"
33266903|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
33266904|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
33079637|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
33079638|NCT00584389|Other|2|Dietary intervention
33079639|NCT00584428|Experimental|1|
33079640|NCT00216372|Experimental|1|
33079641|NCT00216372|Placebo Comparator|2|
33266905|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
33266906|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
33266907|NCT05676281|Other|Healthy Together (includes Streetwyze) (Control/Standardized Care)|Control - standardized Healthy Together program: The Healthy Together Program is not standard of care at Family Health Centers (FHC). Instead, it was originally developed by FHC clinicians interested in addressing childhood obesity and has been implemented by a limited number of clinicians at FHC. UCSD has been working in partnership with FHC to create standardized protocols and to incorporate additional research-oriented tools into this standardized protocol, which will be used as our experimental control.
33277530|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
33079642|NCT00584584|Experimental|1|
33079643|NCT00584584|Placebo Comparator|2|
33079644|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
33079645|NCT00182156||1|conventional HD
33079646|NCT00182156||2|short daily HD
33079647|NCT00182156||3|PD
33079648|NCT00584779|Experimental|1|
33079649|NCT00584779|Experimental|2|
33079650|NCT00584779|Experimental|3|
33079651|NCT00584779|Experimental|4|
33079652|NCT00216411|Experimental|Dysport|
33079653|NCT00216411|Placebo Comparator|Placebo|
33079654|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
33079655|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
33079656|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
33401598|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
33401599|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
33401600|NCT03662594|Other|ECMO tube|
33401601|NCT04056572|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
33401602|NCT04056650|Active Comparator|Single caffeinated beverage/supplement|
33401603|NCT04056650|Active Comparator|Combination caffeine and L-theanine|
32772407|NCT02078141|Experimental|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG)
32772408|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
32772409|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
32772410|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
32772411|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
32772412|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
33079657|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
33079658|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
33079659|NCT00585364||healthy control|healthy non-CF
33079660|NCT00585403||Children|Early and late pubertal girls and boys
33079661|NCT00585442|Experimental|Calcitriol|
33079662|NCT00585442|Placebo Comparator|Placebo|
33079663|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
33079664|NCT00585520|Active Comparator|PG|
33079665|NCT00585520|Placebo Comparator|PLA|
33079666|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
33079667|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
33079668|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
33079669|NCT00585676||Diabetic|Patients with Diabetes
33079670|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
33079671|NCT00585676||Control|Non-diabetic (normal glucose screening)
33079672|NCT00585754|Active Comparator|Guanfacine|
33079673|NCT00585754|Placebo Comparator|PLA|
33079674|NCT00585793||PEPFAR 1|
33079675|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
33079676|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
33079677|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
33079678|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
33079679|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
33079680|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
33079681|NCT00585988|Other|1|
33079682|NCT00585988|Other|2|
33079683|NCT04722393|Experimental|Pulmonary Rehabilitation Group|An 8-week comprehensive outpatient PR program including respiratory exercises, aerobic and strengthening training
33079684|NCT04722393|Other|Control Group|Respiratory exercises
33079685|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
33079686|NCT04722861||Primary Glaucoma|Patients with primary glaucoma diagnosed by glaucoma professionals
33079687|NCT04722861||Glaucoma Suspect Controls|Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
33079688|NCT03452722||Study group|Applied rtPA
33079689|NCT03452722||Control study|rtPA not applied
33079690|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
33079691|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
33079692|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
33079693|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
33079694|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
33079695|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
33079696|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
32772413|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32772414|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32901880|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
33079697|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
33079698|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
33079699|NCT00586222|Placebo Comparator|2|
33079700|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
33079701|NCT00586222|Experimental|1|
33079702|NCT00586300|Active Comparator|1|Physical training program
33079703|NCT00586300|Active Comparator|2|Self-management training program
33079704|NCT00586300|Active Comparator|3|Physical and self-management training programs
33079705|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
33079706|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
33079707|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
33079708|NCT00586807|Other|Infliximab|Subjects on infliximab
33079709|NCT00586885|Experimental|1|Single arm, active treatment
33079710|NCT00587002|Active Comparator|1|Gender comparison
33079711|NCT04575493|Experimental|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
33079712|NCT04575493|Active Comparator|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
33079713|NCT00587119|Experimental|1|Single arm, active treatment
33079714|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
33079715|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
33079716|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
33079717|NCT00587470|Experimental|1|Atacand treatment.
33079718|NCT00587470|Placebo Comparator|2|Placebo
33079719|NCT04575103|Active Comparator|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
33079720|NCT04575103|No Intervention|Control|Healthy controls, not treated with antipsychotics.
33079721|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
33079722|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
33079723|NCT00587665|Experimental|1|Low dose ketamine given
33079724|NCT00587665|Placebo Comparator|2|Saline given as control
33079725|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
33079726|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
33079727|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
33266908|NCT05676281|Active Comparator|Healthy Together + Promotora support|In addition to the basic program described above, those randomized to this intervention will receive Promotora support. Families assigned to a promotora will receive 30-60 minutes of phone-based support weekly, with more frequent interactions that will taper starting at month 3 of the intervention. Promotoras may also provide home-visit support up to 4 times during the 6 months, based on family interest and needs. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families. For families in this condition, they will be asked to engage in at least 30 minutes of additional sessions per week with the promotora beyond the 1- hour allotted time working with FHC professionals.
32772415|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32772416|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32901881|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
33266909|NCT05676281|Active Comparator|Healthy Together + Parenting training|In addition to the basic program described above, those randomized to this intervention will attend Parenting Training sessions with the mental health provider at FHC. Families assigned to parenting training will receive 10-12 sessions. Sessions will focus on topics like strategies to support the child's physical, social, and emotional growth. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.
33266910|NCT05676281|Active Comparator|Healthy Togethers + Parenting Training + Promotora support|Those randomized to this intervention will receive all components described above including the Healthy Together Program, Parenting Training and Promotora support. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.. Families in this group will also be asked to engage in at least 30-60 minutes of additional sessions per week including up to 4 home visits.
33266911|NCT05102942|Experimental|Group A: a gamified AACTP smartphone application + treatment as usual (TAU)|
33266912|NCT05102942|Placebo Comparator|Group B: a gamified AACTP sham-control application + TAU|
33266913|NCT05102942|No Intervention|Group C: only TAU|
33079728|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
33266914|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
33266915|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
33266916|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
32906379|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
33079729|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
33079730|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
33079731|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
33266917|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
33266918|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
33266919|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
33266920|NCT04039724|Experimental|Sequence A|"Period 1 : HCP0605+HGP0816~Period 2 : HCP1305"
33266921|NCT04039724|Experimental|Sequence B|"Period 1 : HCP1305~Period 2 : HCP0605+HGP0816"
33266922|NCT00878696||Tinnitus|Tinnitus patients
33266923|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
33266924|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
33266925|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
33266926|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
33266927|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
33266928|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
33266929|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
33266930|NCT05683301|Experimental|Arm 1|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Perindopril 4 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Perindopril 8 mg once daily, orally
33266931|NCT05683301|Experimental|Arm 2|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Perindopril 4 mg and Indapamide 1.25 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Perindopril 8 mg and Indapamide 2.5 mg once daily, orally
33266932|NCT05683301|Experimental|Arm 3|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Indapamide 1.5 mg sustained release once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Indapamide 1.5 mg sustained release once daily, orally
33266933|NCT05081648|Experimental|Intervention group: Multiple Single Cannulation Technique (MuST)|
33266934|NCT05081648|Other|Control group: Rope-ladder cannulation technique (RL)|
33266935|NCT04770623|Experimental|Chemotherapy|"Second line treatment will be as follows~Docetaxel at 30 mg/m2 over 500 cc normal saline over 1 hour infusion~Irinotecan at 185 mg/m2 with a maximum of 300 mg given over 500 cc normal saline over 2 hours infusion~The whole regimen is to be cycled every 2 weeks for a maximum of 6 months with interim and end of treatment evaluation"
33266936|NCT05068856|Experimental|HRS2543|
33266937|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
33266938|NCT04770467|Placebo Comparator|Placebo in adult subjects with severe COVID-19|
33266939|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
33266940|NCT04770467|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
33266941|NCT00873314|Experimental|Bed rest|
33266942|NCT00873314|Placebo Comparator|Activity restriction|
33266943|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
33266944|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
33266945|NCT05226806||Healthy adults|"Inclusion criteria: both, mals and female, age 45 years and older. Exclusion criteria: Medical contraindications for a maximum stress test and endurance test by the attending physician~Pathologies in the context of the preliminary examinations:~Acute and chronic cardiovascular diseases except arterial hypertension (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg in untreated and drug-treated participants) and minor valve insufficiency~Acute and chronic lung diseases~Liver and kidney diseases~diabetes mellitus~Alcohol (> 30g / day) or drug abuse~Obesity from grade 2 (body mass index> 35 kg / m²)~Orthopedic diseases with reduced physical performance~Existing pregnancy"
33266946|NCT05671367||Artery without microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR<2.5 mmHg*s/cm is defined as no microvascular resistance.
33266947|NCT05671367||Single artery with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. There is only one of three major coronary arteries in 3 that meets this condition.
33266948|NCT05671367||Multiple arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. Two of the three major coronary arteries meet this condition.
33266949|NCT05671367||Three arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. All three major coronary arteries meet this condition.
33266950|NCT05671367||Significant microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. The sum of AMR of the three main arteries is greater than 7.5mmHg*s/cm
33266951|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
33266952|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
33266953|NCT05653661|Experimental|Treatment (AP160-complex)|Patients receive AP160-complex IV on study. Patients in the dose-escalation cohort undergo computed tomography/magnetic resonance imaging (MRI) scans, tissue biopsies, and collection of blood samples throughout the trial. Patients in the dose-expansion cohort undergo MRI scan during screening, collection of blood samples during screening and on study, and tissue biopsies throughout the trial.
33266954|NCT00873392|Experimental|1|Experimental drug
33266955|NCT00873392|Active Comparator|2|Usual treatment
33266956|NCT04876391|Experimental|Participants from parent trial (1368-0052) who were on placebo or active medication|
33266957|NCT04039256|Experimental|PVR implantation group|Patients enrolled receive PVR intervention
33266958|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
33266959|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
33266960|NCT04040036|Experimental|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
32772417|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32772418|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
32772419|NCT05700929|Experimental|Communication skills training|The intervention is a one-day face-to-face training to foster patient-centered communication skills of nursing professionals at the University Medical Center Hamburg-Eppendorf, Germany. The training is developed based on results of a previously conducted needs assessment with nurses, medical assistants and nursing service managers as well as literature research and will be rolled out after baseline assessment and randomization.
32772420|NCT05700929|No Intervention|Waitlist-control group|Participants of the waitlist-control group receive no specific study related intervention. Participants of this group will be offered a communication skills training after complete data collection of all participants of the RCT has been finished.
32772421|NCT05554991|Experimental|Liquid oral supplement comprising HMO|
32772422|NCT05554991|Placebo Comparator|Placebo|
32772423|NCT05554913|Experimental|QL0911|The study in a 2:1 randomization ratio(40 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
32772424|NCT05554913|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio(20 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
32772425|NCT05554835||Mitochondrial patients|Patients with a suspected or confirmed mitochondrial disease.
32772426|NCT05554757|Experimental|conventional rubber dam system|in the first 30 patients, the conventional rubber dam was used prior to the OptraDam For the first 30 patients, on the day of the first appointment, the stopwatch was set for recording the time taken for the application of the conventional rubber dam . Following this, the required dental treatment was carried out. Radiographs were taken as & when necessary . At the end of the appointment, the questionnaires were filled by the patient as well as the operator regarding their experience of the conventional rubber dam
32772427|NCT05554757|Active Comparator|OPTRADAM|In second appoinment the optradam was applied. The stopwatch was set for the recording the time of application of the OptraDam. The required dental treatment was carried out. Radiographs were taken. At the end of the appointment, the questionnaires were again filled by the patient as well as the operator regarding their experience of the OptraDam.
33266961|NCT04040036|Experimental|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
32772428|NCT05612321|Active Comparator|Traditional supine position|Participants enrolled in the Control Group undergo vacuum-assisted delivery in traditional supine position (supine with 90 degrees bended legs on footrests)
32772429|NCT05612321|Experimental|All-fours position|Participants enrolled in Experimental Group experience vacuum application in all-fours position.
32772430|NCT05317247||Discovery Cohort|An anticipated number of 473 participants will be recruited in Cape Town, South Africa. Data (cough audio) will be collected and used to train a machine learning algorithm. The cough audio signal specific for TB will be refined. During the discovery phase, the ground truth obtained through biological testing of sputum specimens will be used to inform the machine learning.
32772431|NCT05317247||Validation Cohort|In the validation phase, the cough audio signature will have its sensitivity and specificity measured in new patients in Cape Town, South Africa (n=511) and Kampala, Uganda (n=767). The data will be used to evaluate the performance of the algorithm.
32772432|NCT05554523||Vitiligo|
32772433|NCT05554523||Fitzpatrick Type 1|
32772434|NCT05554523||Fitzpatrick Type 2|
32772435|NCT05554523||Fitzpatrick Type 3|
32772436|NCT05554523||Fitzpatrick Type 4|
32772437|NCT05554523||Fitzpatrick Type 5|
32772438|NCT05554523||Fitzpatrick Type 6|
32772439|NCT04426565|Other|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
32906380|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
33266962|NCT04040036|No Intervention|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
33266963|NCT00879008||Group 1|
33266964|NCT04081181|Experimental|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
33266965|NCT04658147|Experimental|Arm A - Nivolumab|Participants receive Nivolumab only.
33266966|NCT04658147|Experimental|Arm B - Nivolumab and Relatlimab|Participants receive Nivolumab and Relatlimab.
33266967|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
33266968|NCT00873548||PFNA_Asia treated|
33266969|NCT02586935|Active Comparator|Tideglusib|
33266970|NCT02586935|Placebo Comparator|Placebo|
32772440|NCT04426565|Other|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
33079732|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
32772441|NCT04426565|Other|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
32772442|NCT04426565|Other|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
33079733|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
32772443|NCT04328831|Other|IBI322|Single arm
32772444|NCT05558813|Experimental|DMD-CMP cohort|Minor (≥ 6 years) and major patients with genetically proven Duchenne myopathy
32772445|NCT05558735||case group|The case group is composed of Adult male with a positive biopsy (Gleason score greater than or equal to 7)
32772446|NCT05558735||control group|The control group is made up of adult men performing a biopsy whose Gleason score is less than or equal to 6.
32772447|NCT05558657|Experimental|Intervention group|The intervention group will receive acupressure, and then they will receive nursing intervention.
33079734|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
33079735|NCT00587977||1|Aortic aneurysm repair
33079736|NCT00587977||2|Aortic aneurysm growth
33079737|NCT00587977||3|Aortic aneurysm growth stable.
33079738|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
33079739|NCT00588133|Experimental|1|New drug dosing schedule
33079740|NCT00588133|Active Comparator|2|Standard drug dosing schedule
33079741|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
33079742|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
33079743|NCT00209742|Experimental|2|
33079744|NCT00209742|Experimental|3|
33079745|NCT00209742|Active Comparator|1|
33079746|NCT00588250|Experimental|A|
33079747|NCT00588250|No Intervention|B|
33079748|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
33079749|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
33079750|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
33079751|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
33079752|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
33079753|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
33079754|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
33079755|NCT00588328|Experimental|1|
33079756|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
33079757|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
33079758|NCT00588367||3|Autoimmune pancreatitis.
33079759|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
33079760|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
33079761|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
33079762|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
33079763|NCT00588718||Cases|Infants who meet the entry criteria
33079764|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
33079765|NCT00588757|Active Comparator|1|Optease filter
33079766|NCT00588757|Active Comparator|2|Tulip filter
32772448|NCT05558657|Active Comparator|Control group: caregiver-led sham group , acupressure combined with nursing interventions|The control group will receive sham acupressure as a placebo and then they will receive nursing intervention.
32772449|NCT05700851|Other|Immuno-nutrition|"Participants will be advised to take daily one sachet (74 g) of the immuno-nutrition supplement (Oral Impact®, Nestle) dissolved in 125 ml of water and will be followed-up for 6 weeks.~Participants will receive individualised (to patient needs and food preferences) dietetic advice formulated and delivered by an experienced renal dietitian under an honorary NHS research contract, who is a member of the research team and will be supervised by an NHS renal dietitian, aiming to achieve estimated nutritional requirements for people on haemodialysis (i.e., energy: 30-35 kcal/kg/day, and protein intake: 1.0-1.2 g/kg/day). Each dietetic advice provided to participants will also be reviewed by the NHS clinical renal dietitians who are members of the participants' usual clinical care team."
32772450|NCT05554211|Experimental|Experimental Breast|Participants will receive 50 ml of TxA and gentamicin to the assigned experimental breast.
33266971|NCT00868400|Experimental|1|High-carbohydrate
33079767|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33266972|NCT00868400|Placebo Comparator|2|Placebo
33266973|NCT00868400|No Intervention|3|Control
32772451|NCT05554211|Placebo Comparator|Control Breast|Participants will receive a standard irrigation of 50 ml of 0.9% NS and gentamicin to the assigned control breast.
32772452|NCT05225363|Experimental|Treatment (TAG72-CAR T cells)|Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
33266974|NCT05647811|Experimental|Cohort 1|6 subjects will receive NM8074 at 5 mg/kg weekly.
33266975|NCT05647811|Experimental|Cohort 2|6 subjects will receive NM8074 at 10 mg/kg every 2 weeks.
33266976|NCT05647811|Experimental|Cohort 3|6 subjects will receive NM8074 at 20 mg/kg every 2 weeks.
33266977|NCT04079699|Experimental|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
33266978|NCT04079699|Other|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
32772453|NCT05554133|Experimental|The Active Biopsy Guidance System|This imaging scanning device is made up of 2 parts: the optical mapping scope and the high-resolution microendoscope (HRME):
32772454|NCT05612165|Experimental|tDCS group|
33266979|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
33266980|NCT04657289|Experimental|Arm A [Q36W] 36-weeks between refill-exchange procedures|Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
33266981|NCT04657289|Active Comparator|Arm B [Q24W] 24-weeks between refill-exchange procedures|Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
33079768|NCT00588796||Healthy Volunteers|Healthy Volunteers
32772455|NCT05612165|Sham Comparator|Control group|
32772456|NCT05558345|Experimental|Contingency Management for Methamphetamine Reduction|8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests
32772457|NCT05558345|No Intervention|Non-substance-using Control|Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine.
32772458|NCT05543291||healthy controls|
32772459|NCT05543291||mild CKD|
33079769|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
32772460|NCT05543291||Moderate CKD|
32772461|NCT05543291||ESRD|
33079770|NCT00588796||Trauma patients|Patients who have undergone trauma
33079771|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
33079772|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
33079773|NCT00588874||1|men 50 yrs of age or older
33079774|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
33079775|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
33079776|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
33079777|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
33266982|NCT04603001|Experimental|Dose Escalation Arm A (Monotherapy)|Patients not requiring a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
33266983|NCT04603001|Experimental|Dose Escalation Arm B (Monotherapy)|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
33266984|NCT04603001|Experimental|Dose Escalation Arm C (LY3410738, Venetoclax, and Azacitidine)|Patients with no prior venetoclax therapy and not requiring a strong CYP3A4 inhibitor for active treatment within 7 days of starting LY3410738.
33266985|NCT04603001|Experimental|Cohort 1|Patients with relapsed/refractory (R/R) AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
33266986|NCT04603001|Experimental|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
33266987|NCT04603001|Experimental|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation.
33266988|NCT04603001|Experimental|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
32772462|NCT05549921|Experimental|NY-ESO-1 TCR Specific T cell Therapy|This research is divided into two stages, Stage 1 and Stage 2, respectively. In Stage 1, 14 patients with advanced soft tissue sarcoma with positive expression of tumor antigen NY-ESO-1 and HLA-A*02:01 genotype were enrolled. A further 42 patients will be enrolled in Stage 2, where the primary efficacy analysis will be performed at 3 months after the completion of cell reinfusion in the last subject, with a target ORR of 25%.
32772463|NCT05549843|Experimental|Hemophilia group|"Intervention protocol:~Preparatory work: active mobilizations with the patient supine.~Global passive mobilization of the forefoot and midfoot.~Calcaneocuboid mobilization, functional and structural work of said joint.~Astragaloscaphoid mobilization, functional and structural work of said joint.~Talar manipulation dorsally.~Manipulation-tibial displacement:~Tibiotarsal decompression: 2 very gentle high-speed and short-course tibial-tarsal manipulations.~Plantar fascia induction for foot captors of the plantar fascia.~Tibiotarsal sustained traction technique (unwinding)~Sural triceps induction technique:"
32772464|NCT05553899|Experimental|Diagnostic (PET-MRI)|Patients will undergo PET-MRI
32772465|NCT05553821|Active Comparator|Manual pressure group|A sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
32772466|NCT05553821|Experimental|Cold pressure group|A cold sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
32772467|NCT04327115|Other|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
33266989|NCT04603001|Experimental|Cohort 5|Patients with newly diagnosed AML, R/R AML, or other advanced hematologic malignancy harboring IDH1 and/or IDH2 mutations with no prior venetoclax therapy. Strong CYP3A4 inhibitor allowed but not required.
33266990|NCT04738487|Experimental|Pembrolizumab/Vibostolimab|Participants will receive pembrolizumab/vibostolimab as a coformulation (MK-7684A).
32772468|NCT04327115|Other|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
32772469|NCT04327115|Other|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
32772470|NCT05543213|No Intervention|Control group|Videos of nature will be shown to them, and exercises similar to those in the intervention group will be practiced with them.
32772471|NCT05543213|Active Comparator|Action Observation group|In the intervention group, the same exercises related to balance and walking are practiced after watching videos of the exercises
33266991|NCT04738487|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab (MK-3475) alone.
33266992|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
33266993|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
33266994|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.~4, can except other similar clinical manifestations of lesions."
33266995|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
33266996|NCT04081883|Experimental|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
33266997|NCT05487599|Experimental|Low Dose LY3884961|
33266998|NCT05487599|Experimental|Medium Dose LY3884961|
32772472|NCT05543135||cases|patients with asymmetrical hearing loss
32906381|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
33266999|NCT05487599|Experimental|High Dose LY3884961|
33267000|NCT05487599|Experimental|Expansion cohort|LY3884961 dose to be determined
32906382|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
33267001|NCT05620823|Experimental|Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 54 weeks.
33267002|NCT05620823|Experimental|Povorcitinib Dose B|Participants will receive Povorcitinib Dose B for 54 weeks.
33267003|NCT05620823|Placebo Comparator|Placebo|Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
33267004|NCT04079543|Other|Strict NPO|NPO after midnight. No solids or liquids after midnight.
33267005|NCT04079543|Other|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
33267006|NCT04593251|Experimental|CALY-002|
33267007|NCT04593251|Placebo Comparator|Placebo|
33267008|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
33267009|NCT00920543|Active Comparator|Fluticasone propionate|
33267010|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
33267011|NCT04731155|Active Comparator|standard group|
33267012|NCT04731155|Experimental|experiment group|
33267013|NCT04080011|Experimental|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
33267014|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
32772473|NCT05549687|Experimental|Group I (Pack Health Program)|Patients participate in the Pack Health Program which includes up to 60 scheduled touch points via phone, text, email and a mobile application and weekly interaction with a health coach over 3 months. They also have access to standard of care support services at MD Anderson including a telephone triage line 5 days a week between 8 a.m. and 5 p.m.
33267015|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
33267016|NCT04729049|Experimental|Erector spinae plane block + patient controlled analgesia (PCA) with intravenous morphine|"Preoperative bilateral ESP block with ropivacaine 0,4% + dexamethasone 4 mg, 20 mL per side, at the median spinal level of intervention.~End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
33267017|NCT04729049|Active Comparator|Patient controlled analgesia (PCA) with intravenous morphine|"End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
33267018|NCT04723823|Experimental|fMRI w/ motor or sensory imagery|Individuals will be asked to imagine movements or sensations while fMRI is used to measure brain activity.
33267019|NCT04722107|Experimental|Single arm|All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye
33267020|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
33267021|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
33267022|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
33267023|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
33267024|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
33267025|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
33267026|NCT04080401|Experimental|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
33267027|NCT04080401|Active Comparator|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
33267028|NCT04576091|Experimental|Treatment (pembrolizumab, BAY 1895344, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or positron emission tomography PET-CT scan during screening and follow-up. Patients also undergo blood sample collection throughout the trial.
33267029|NCT04634669|Experimental|AXS-05 (dextromethorphan-bupropion)|
33267030|NCT04575311|Active Comparator|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 will be random.
32772474|NCT05549687|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services with a telephone triage line available 5 days a week between 8 a.m. and 5 p.m.
32772475|NCT05549375|Experimental|Neurorehabilitation of the Hand|
32772476|NCT05700617|Active Comparator|1:1 Randomization to Milrinone or Dobutamine|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min. Patients may be randomized to dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min.
32935673|NCT05192551||Vistaprep|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
32935674|NCT05192551||Movprep|A standard median volume bowel-prep, used for a long time in Sweden. The dose is 1000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
32935675|NCT05192395|Experimental|Group A|fed state: period 1) DWJ15251, period 2) DWP16001 and DWC2021011 fased state: period 3) DWJ15251, period 4) DWP16001 and DWC2021011
32935676|NCT05192395|Experimental|Group B|fed state: period 1) DWP16001 and DWC2021011, period 2) DWJ15251 fased state: period 3) DWP16001 and DWC2021011, period 4) DWJ15251
32935677|NCT04651088|Placebo Comparator|Metabolic diet|Controlled metabolic diet arm.
32772477|NCT05700617|Active Comparator|1:1 Randomization to Dobutamine or Milrinone|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase, and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min.
33267031|NCT04575311|Placebo Comparator|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive matching placebo will be random.
33267032|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
33267033|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
33267034|NCT04691297|Experimental|Escape|The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
33267035|NCT04691297|Experimental|Standard Care|The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
33267036|NCT04572893|Experimental|MYK-491|Primary DCM due to MYH7 or TTN Variant or due to other causalities not related to MYH7 or TTN variants
33267037|NCT04572503|Experimental|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
33267038|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
33267039|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
33267040|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
33267041|NCT04565795|Experimental|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
33267042|NCT04080713|Experimental|Budesonide|
32772478|NCT05700461|Experimental|Implantable microdevice (IMD) + Biopsy + Standard of Care Treatment|"Participants with confirmed or suspected metastatic Renal Cell Carcinoma (RCC) and who are candidates for standard of care metastatectomy or debulking/consolidative nephrectomy will be selected for study participation and will undergo study procedures as outlined:~Placement of 1-6 microdevice(s) 72 +/- 24 hours prior to scheduled, standard of care surgery. The number of microdevices implanted into a tumor will be made on a case-by-case basis based on tumor and participant factors before and during the procedure.~At the time of standard of care surgery, surgical removal of microdevice(s) along with surrounding tumor tissue.~Monitoring for safety endpoints during inpatient stay and at a follow-up clinic visit."
32772479|NCT05542979|Experimental|HH-003 Group|
32772480|NCT05542979|Placebo Comparator|Placebo Group|
32772481|NCT05542745|Active Comparator|palatal retractor|palatal retraction
32772482|NCT05542745|Active Comparator|buccal retractor|buccal retraction
33267043|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
33267044|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
33267045|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
33267046|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
33267047|NCT05610683|Experimental|SHFVE-HD group|Hemodialysis sessions using the VieX™ (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan).
33267048|NCT05610683|Experimental|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg).
33267049|NCT05598827|Experimental|Watch the Tik Tok|Unlimited Tik Tok viewing was encouraged from 24 hours before chemotherapy until the seventh day after chemotherapy.
33267050|NCT05598827|No Intervention|Tik Tok is not allowed|Viewing of Tik Tok was prohibited from 24 hours before chemotherapy until the seventh day after chemotherapy.
33267051|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
33267052|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
32772483|NCT05553743||Main Study|The purpose of this project is to collect and store breast milk samples and health information about moms and their babies in a Human Milk Biorepository at UCSD. Through these studies, researchers hope to understand more about the benefits of breast milk, and how it prevents or treats child health problems.
32935678|NCT04651088|Active Comparator|Potassium citrate|
32935679|NCT04651088|Active Comparator|Sodium Bicarbonate|
32935680|NCT04651088|Active Comparator|Litholyte arm|
32935681|NCT04651088|Active Comparator|Crystal Lite|
32935682|NCT04651088|Active Comparator|Potassium Bicarbonate|
32935683|NCT04614571|Other|Gluten Challenge|
32935684|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
32772484|NCT05553743||Sub-study 100: COVID-19 Exposure|The purpose of this substudy is to learn how exposures to COVID-19 and breastfeeding may affect the development of the child. Women who contact the UCSD Human Milk Biorepository will be screened for possible COVID-19 infection or exposure. Women will be eligible to enroll in the COVID-19 sub-study if they are confirmed positive, are presumptive positive, are symptomatic but not tested, or have confirmed exposure but are asymptomatic.
32772485|NCT05553743||Sub-study 101: Antibiotic Exposure|The purpose of this substudy is to learn more about maternal use of antibiotics in women who do or do not breastfeed, and how this may influence infant and child health. Women who contact or are referred to the UCSD Human Milk Biorepository will be screened to participate in the Antibiotic Exposure sub-study. Women will be eligible to enroll in the Antibiotic Exposure sub-study if they are 18 years of age or older, have a singleton infant who is <3 months of age at the time of recruitment, and agree to all requirements of the study.
32772486|NCT05553665|Other|transudative pleural effusion|Subjects with undiagnosed transudative pleural effusion will undergo medical thoracoscopy as per studies protocols.
33267053|NCT04081805|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
33267054|NCT04081805|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
33267055|NCT04081805|Active Comparator|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
33267056|NCT04079309|No Intervention|No Intervention|No mist will be diffused into the environment.
33267057|NCT04079309|Active Comparator|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
33267058|NCT04079309|Active Comparator|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
33267059|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
33267060|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
33267061|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
33267062|NCT05546723|Experimental|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
33267063|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
33267064|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
33267065|NCT04550039|Experimental|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
32772487|NCT05553665|Other|exudative pleural effusion|Subjects with undiagnosed exudative pleural effusion will undergo medical thoracoscopy as per studies protocols.
33267066|NCT04550039|Experimental|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
33267067|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
33267068|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
33267069|NCT02585297||Control- semen|Semen of fertile men
33267070|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
33267071|NCT02585297||Case-semen|Semen of infertile men
33267072|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
33267073|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
33267074|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
33267075|NCT00501046|Placebo Comparator|Placebo|
33267076|NCT00501046|Experimental|AST-120|
32772488|NCT05553587|Experimental|Amara Drops|Phytopharmaceutical / therapeutic intervention
32935685|NCT02350699||Control|Nautilus BrainPulse
32935686|NCT04595617|Experimental|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
32772489|NCT05553509||ANGIOPLASTY GROUP|All patients undergoing PTA are going to be classified according to GLASS staging system
32772490|NCT05553509||DEBRIDEMENT GROUP|The most commonly used technique for diabetic foot ulcers is sharp or surgical debridement using a scalpel, tissue forceps or similar instruments. It should be sufficiently extensive to remove all infected and necrotic tissue;
33079778|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
33401604|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
33401605|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
33231157|NCT05757752|Other|Intervention|Participants meeting eligibility criteria will participate in the Mind Body Program for Vascular Disease, working in-person or via telehealth with a study interventionist for an hour weekly in 6-8 week cycles learning problem-solving techniques targeting mood/distress and enhancing disease management strategies. Participants will be assessed at baseline, 3-months, and 6-months.
33401606|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
33401607|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
33401608|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
33401609|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
33401610|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
32772491|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
32772492|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
33231158|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
33231159|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
33231160|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
33231161|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
33231162|NCT05753930|Experimental|Imlifidase|Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation.
33231163|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
33231164|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
33231165|NCT04832360|Experimental|Control (CTL)|Participants do not receive financial incentive intervention
33231166|NCT04832360|Experimental|Single Target (ST)|One member of each dyadic-smoking couple will receive financial incentive intervention
33231167|NCT04832360|Experimental|Dyadic Target (DT)|Both members of each dyadic-smoking couple will receive financial incentive intervention
33231168|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
33231169|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
33231170|NCT04107714|Experimental|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.~Fidelity to manual is rated in each session by study staff."
32772493|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
32901882|NCT04214886|Experimental|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
33267077|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
33267078|NCT04468607|Experimental|Dose-Escalation Stage|Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).
33267079|NCT04468607|Experimental|Dose-Expansion Stage|Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.
33267080|NCT04460885|Experimental|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
33267081|NCT04460885|Active Comparator|Insulin glargine|Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
33267082|NCT01018966|Experimental|Ixabepilone|
33267083|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
33267084|NCT04546061|Experimental|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
33267085|NCT04078685|Active Comparator|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
33267086|NCT04078685|Experimental|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
33267087|NCT05519189|Active Comparator|Peri-anal infiltration of Ropivacaine|
33267088|NCT05519189|Experimental|Failure to perform peri-anal ropivacaine infiltration|
33267089|NCT04080323|Experimental|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
33267090|NCT04080323|Placebo Comparator|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
33267091|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
33267092|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
33267093|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
33267094|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
33267095|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
33267096|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
33267097|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
33267098|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
33267099|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
33267100|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
33267101|NCT05472077|Experimental|Participants with COVID-19 Symptom(s)|Participants 4 years old or older with at least one COVID-19 symptom being tested for the virus
33267102|NCT05514353|Experimental|PBI-100 Topical Cream|"SAD: 4 cohorts of subjects are planned to receive a single dose of PBI-100 topical cream in one of three dosage strengths, administered once or twice daily~MAD: 3 cohorts of subjects are planned to receive one of three dosage strengths of PBI-100 administered once or twice daily for periods of 14 consecutive days"
33401611|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
32772494|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
33079779|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
33267103|NCT05514353|Placebo Comparator|Vehicle|
33267104|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
33267105|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
33267106|NCT05409833||Group 1|Patients aged ≥ 60 years old with symptomatic carpal tunnel syndrome submitted to surgery
32772495|NCT05548985|Placebo Comparator|control group|oral metoclopramide 10 mg, Metoclopramide tablet was chosen as a placebo because it has the same appearance of midodrine tablet with no cardiovascular effects
33267107|NCT05409833||Group 2|Patients aged ≥ 60 years old without symptomatic carpal tunnel syndrome submitted to hand surgery
33267108|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
33267109|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
33267110|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
33267111|NCT04543097|No Intervention|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
33267112|NCT04543097|Experimental|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
33267113|NCT04079231|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
33267114|NCT04079231|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
33267115|NCT04428281|Experimental|Cohort A1 RO7248824|Participants 5-12 Years
32772496|NCT05548985|Active Comparator|Midodrine group|oral midodrine tablet (5 mg)
33267116|NCT04428281|Experimental|Cohort A2 RO7248824|Participants 5-12 Years
33267117|NCT04428281|Experimental|Cohort A3 RO7248824|Participants 5-12 Years
33267118|NCT04428281|Experimental|Cohort A4 RO7248824|Participants 5-12 Years
33267119|NCT04428281|Experimental|Cohort A5 RO7248824|Participants 5-12 Years
33267120|NCT04428281|Experimental|Cohort B1 RO7248824|Participants 1-4 Years
33267121|NCT04428281|Experimental|Cohort B2 RO7248824|Participants 1-4 Years
33267122|NCT04428281|Experimental|Cohort B3 RO7248824|Participants 1-4 Years
33267123|NCT04428281|Experimental|Cohort B4 RO7248824|Participants 1-4 Years
33267124|NCT04428281|Experimental|Cohort B5 RO7248824|Participants 1-4 Years
33267125|NCT04428281|Experimental|Cohort EA1 RO7248824|New participants (age 5-12) enrolling directly in the LTE part
33267126|NCT04428281|Experimental|Cohort EA2 RO7248824|Participants continuing from MAD cohorts A1 and A2
33267127|NCT04428281|Experimental|Cohort EA3 RO7248824|Participants continuing from MAD cohorts A3 and A4
33267128|NCT04428281|Experimental|Cohort EA4 RO7248824|Participants continuing from MAD Cohort A5
33267129|NCT04428281|Experimental|Cohort EB1 RO7248824|New participants (age 1-4) enrolling directly into the LTE
33267130|NCT04428281|Experimental|Cohort EB2 RO7248824|Participants continuing from MAD cohorts B1 and B2
33267131|NCT04428281|Experimental|Cohort EB3 RO7248824|Participants continuing from MAD cohorts B3 and B4
33267132|NCT04428281|Experimental|Cohort EB4 RO7248824|Participants continuing from MAD Cohort B5
33267133|NCT05350293|Active Comparator|Molded abutment|A plastic abutment that is provided by the implant manufacturer will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture. A plastic abutment that the implant manufacturer provides will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture.
33267134|NCT05350293|Experimental|3D printed abutment|The customised abutment will be made using a laser printer with a Cr-Co mixture after being designed using a special computer program.
33267135|NCT05349123|Experimental|Intervention|Home-based pulmonary rehabilitation that includes health coaching with mindful breathing module
33267136|NCT05349123|Active Comparator|Control|Home-based pulmonary rehabilitation that includes health coaching
33267137|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).~Secondary transabdominal approach :~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
33079780|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
32772497|NCT05548829||Non-hospitalised Covid-19 patients (mild infection)|COVRES1, retrospective recuitment from public advertisment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772498|NCT05548829||Hospitalised Covid-19 patients (severe infection)|COVRES1, retrospective recuitment from secondary care, attended wards. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772499|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772500|NCT05548829||Hospitalised Covid-19 patients (severe infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772501|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772502|NCT05548829||Hospitalised Covid-19 patients (severe infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
32772503|NCT05698979|Experimental|drug administration|Botox Injection
32772504|NCT05553431|Experimental|No EP system Group|Patients were performed left bundle branch pacing without EP system.
32772505|NCT05553353|Experimental|Active rTMS|Active repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling.
33079781|NCT00589225||1|Genetic Analysis
33079782|NCT00589264|Experimental|1|iron + copper + zinc
33079783|NCT00589264|Active Comparator|2|iron + copper only
33079784|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
33079785|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
32772506|NCT05553353|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling, but a sham treatment coil will be used; thus, no active treatment will be administered.
32772507|NCT05553197|Experimental|Cognitive Behavior Therapy + Ecological Momentary Assessment (CBT + EMA)|Cognitive Behavior Therapy + Ecological Momentary Assessment
32772508|NCT05553197|Active Comparator|Treatment as Usual (TAU)|Cognitive Behavioural Therapy (Treatment as Usual)
32772509|NCT05553119||Home-based Pulmonary Rehabilitation and Health Coaching|Subjects with symptomatic bronchiectasis (CAT score ≥10) will receive a 12-week intervention with home-based pulmonary rehab (PR).
32772510|NCT05552885||Stroke patients|General cognitive level will be evaluated with the Standardized Mini Mental Test to determine the eligibility of the participants for the study. The American National Institutes of Health Stroke Scale will be applied to determine the stroke severity and functional status of the participants. The reliability and validity of the eight-shape gait test and the double-task octagonal gait test will be examined. The reliability of the tests will be evaluated by calculating the test-retest method, standard error measurement and minimum detectable change values. The initial test and retest will be evaluated two days apart. The concurrent validity of the tests will be evaluated by the correlation between the timed get-and-go test, the 10-meter walk test, and the modified four-square step test.
33079786|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
33079787|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
33079788|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
33079789|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
33079790|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
33079791|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
33079792|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
33079793|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
33079794|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
33079795|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
33079796|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~Ispahgula husk 1 Tsf daily after dinner for six weeks."
33079797|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.~Ispaghula husk 1 Tsf daily after dinner for six weeks"
33079798|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
33079799|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
33079800|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
33079801|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
33079802|NCT00589966|Experimental|Coping Skills Training|
33079803|NCT00589966|Active Comparator|Prostate Cancer Education|
33267138|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
33267139|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
32772511|NCT04982263||Mild cases|Patients with confirmed COVID-19 and with mild disease
32772512|NCT04982263||Severe cases|Patients with confirmed COVID-19 and with severe disease
32772513|NCT05548673|Experimental|Experimental Group|Stress management training was applied to the experimental group for eight weeks in sessions of 60-90 minutes once a week.
32772514|NCT05548673|No Intervention|Control group.|No action was taken on the students in the control group.
33267140|NCT04521803|No Intervention|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
33277531|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
33277532|NCT05162690|Active Comparator|The Drug Arm|"Dapagliflozin 10 milligram Once a day~1 year"
32772515|NCT04727359||FIT64b model project|Patients being treated in FIT64b model project at UKT
32772516|NCT04727359||Standard care|Patients being treated in standard care (control hospitals)
32772517|NCT05548595|Experimental|Investigational|"Active ingredients (per tablet):~• NeumentixTM Phenolic~Complex K110-42:~450 mg Spearmint extract (Mentha spicata)~100 mg Alpha-Glyceryl Phosphoryl Choline~50 mg Phosphatidylserine (Sharp PS®)~10 mg Pyrroloquinoline quinone~Inactive ingredients (per tablet):~Microcrystalline cellulose~Maltodextrin~Hardened rapeseed fat~Magnesium salts from fatty acids (palm oil free)~Silicon dioxide~Glycerin~Hydroxypropyl methylcellulose"
32772518|NCT05548595|Placebo Comparator|Placebo|"Active ingredients (per tablet):~N/A~Inactive ingredients (per tablet):~Lactose monohydrate~Magnesium stearate~Microcrystalline cellulose"
32772519|NCT04981951|Experimental|Dexmedetomidine and Bupivacaine|Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine
32772520|NCT04981951|No Intervention|Bupivacaine alone|patients will be given Bupivacaine alone
32772521|NCT04982185||Deep block|Deep neuromuscular block before initial (V1) vagal stimulation.
32772522|NCT04982185||Moderate block|Moderate neuromuscular block before initial (V1) vagal stimulation.
32772523|NCT05548361|Experimental|Active Chx|This group will receive active chlorhexidine and placebo probiotics
32772524|NCT05548361|Experimental|Active probiotics|This group will receive placeo chlorhexidine and active probiotics
32772525|NCT05548361|Experimental|Active Chx & probiotics|This group will receive active chlorhexidine and active probiotics
33079804|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
33079805|NCT00590356|Active Comparator|A2|AngioSeal®
33079806|NCT00590356|Experimental|A1|StarClose®
33079807|NCT04574791|No Intervention|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol.
33079808|NCT04574791|Experimental|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
32772526|NCT05548283|Other|β-lactam Only (Non-AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam as selected by their treating physician. Treatment must not include an IV aminoglycoside.
32772527|NCT05548283|Other|β-lactam and Aminoglycoside (AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam and aminoglycoside selected by their treating physician.
32772528|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
32772529|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
32772530|NCT05698901||Group A|"18 years or older~Male or female with Fabry disease diagnosed~Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~ERT Treatment naïve Fabry patients"
32772531|NCT05698901||Group B|"18 years or older~Male or female with Fabry disease diagnosed~Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~Agalsidase beta (ERT) exposed or treated Fabry patients"
32772532|NCT05552807|Experimental|Cohort 1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed consent, death, or loss of visit
33079809|NCT00183014|Experimental|1|discussion session and exercise class
33079810|NCT00183014|Active Comparator|2|exercise class only
32772533|NCT05552807|Experimental|Cohort 2-1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
32772534|NCT05552807|Experimental|Cohort 2-2 SCT200+paclitaxel/docetaxel|SCT200+paclitaxel/docetaxel was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; paclitaxel was 80mg/m^2/QW by intravenous infusion; docetaxel was 75mg/m^2/Q3W. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
32772535|NCT05552807|Experimental|Cohort 3 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who have not received prior systemic chemotherapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
33079811|NCT04574674|Experimental|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
33079812|NCT04574674|Experimental|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
33079813|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
33079814|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
33079815|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
33079816|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
33079817|NCT00590512|Active Comparator|High Sodium|High sodium
33079818|NCT00590512|Active Comparator|Low sodium|Low sodium
33079819|NCT03452332|Experimental|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33079820|NCT00590551|Experimental|1-6|
33079821|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
33079822|NCT00590785|Experimental|1|
33079823|NCT00590785|Experimental|2|
33079824|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
33079825|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
33079826|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
33079827|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
33079828|NCT00477295|Active Comparator|Zonisamide|
33079829|NCT00477295|Active Comparator|Carbamazepine|
33079830|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
33079831|NCT00183365|Active Comparator|2|Participants will receive parent training alone
33079832|NCT04571788||FCB group|FCB group received FCB implantation
33079833|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
33079834|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
33079835|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
33079836|NCT00210132|Experimental|Ropivacaine|
33079837|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
33079838|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
33079839|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
33079840|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
33079841|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
33079842|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
33079843|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
33079844|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
33079845|NCT00183599|Experimental|1|
33079846|NCT00183599|Experimental|2|
33079847|NCT00183599|Experimental|3|
33079848|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
33079849|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
32772536|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
32772537|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
32772538|NCT05698745||Cohort A (preclinical IBD)|asymptomatic patients with a new diagnosis of IBD during the colorectal cancer screening programme meeting all inclusion and none of the exclusion criteria (n=350).
32772539|NCT05698745||Cohort B (control)|new-onset symptomatic IBD (n=20) - patients with a symptomatic debut of IBD in the last 3 months, naïve to immunosuppressants and biologic agents.
32772540|NCT05698745||Cohort C (control)|healthy controls (n=20): patients with a normal screening colonoscopy, with no signs of IBD after a detailed evaluation of the ileum and colon, will be included.
32772541|NCT04701619|Other|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
32772542|NCT05552729|Active Comparator|High dose group|A 2000IU vitamin D3 supplement was started the next day after surgery.
32772543|NCT05552729|Active Comparator|Low dose group|A 400IU vitamin D3 supplement was started the next day after surgery.
32772544|NCT05552729|No Intervention|The control group.|No vitamin D3 supplement was started the next day after surgery.
32772545|NCT05548049|Experimental|Piezosurgery Group|In the experimental group, a piezosurgical device was used to harvest the bone block from the ramus area.
32772546|NCT05548049|Active Comparator|Conventional Group|In the experimental group, a conventional burr was used to harvest the bone block from the ramus area.
32772547|NCT04436107|Experimental|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
33079850|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
33079851|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
33079852|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
33079853|NCT00183716|Active Comparator|2|Participants will receive usual care
33079854|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
33079855|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
33079856|NCT04722705|Experimental|combined IPL/fractional Er:YAG laser treatment site|"At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed all laser treatments including IPL and 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
33079857|NCT04722705|Active Comparator|fractional Er:YAG laser treatment alone site|"At baseline, three lesions were randomized to fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
33079858|NCT04722705|No Intervention|untreated control site|At baseline, three lesions were randomized to untreated control site. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The evaluation of scar site was conducted 3 months later after last treatment.
33079859|NCT00183755||1|Control participants
33079860|NCT00183755||2|Participants with MDD
33079861|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
33079862|NCT00412035|Placebo Comparator|Placebo|saline injection
33079863|NCT00183833|Experimental|A|Xeloda plus gleevec
33079864|NCT02963402||Tocilizumab treated|
33079865|NCT02963402||Anti-TNF treated|
33079866|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
33079867|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
33079868|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
33079869|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
33079870|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
33079871|NCT00412230||no treatment|
33079872|NCT00412230||2|
33079873|NCT00408785|Experimental|A|Injection
33079874|NCT00408785|Placebo Comparator|B|Injection
33079875|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
33079876|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
33079877|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
33079878|NCT00475657|Experimental|A|
33079879|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
33079880|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
32772548|NCT04436107|Experimental|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
32772549|NCT05547971||Radiation Encephalopathy Group|Patients with radioactive encephalopathy during follow-up
32772550|NCT05547971||No Radiation Encephalopathy Group|Patients without radioactive encephalopathy during follow-up
32772551|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
32772552|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
33079881|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
33079882|NCT02963480||SIRS|Patients, who developed postoperative SIRS
32772553|NCT05547893|No Intervention|control group|workshop discussing the clinical ethical case scenario
32772554|NCT05547893|Experimental|Intervention group|a simulated clinical ethical situation with simulation patients
33079883|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
33079884|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
32772555|NCT04981561|Experimental|100 microgram GATE-251|GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up
32772556|NCT04981561|Experimental|1 mg GATE-251|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up
32772557|NCT04981561|Experimental|3 mg GATE-251|GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up
32772558|NCT04981561|Experimental|10 mg GATE-251|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up
33079885|NCT00475423|Experimental|1|
33079886|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
33079887|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
33079888|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
33079889|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
33079890|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
33079891|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
33079892|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
33079893|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
33079894|NCT04722237|Experimental|Immediate Acceptance and Commitment Therapy|Receiving 6-to-12 weekly sessions of Acceptance and Commitment Therapy immediately after allocation. Each session will be up to one hour in length.
33079895|NCT04722237|No Intervention|Waitlist Control|Receiving no intervention during a 12-week wait, though no restrictions will be placed on the use of other services. After the wait participants will receive 6-to-12 weekly sessions of Acceptance and Commitment Therapy. Each session will be up to one hour in length.
33079896|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
33079897|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
33079898|NCT00217308|Experimental|Lactobacillus|
33079899|NCT00217308|Placebo Comparator|Placebo capsules|
33079900|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
33079901|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
33079902|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
33079903|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
33079904|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
33079905|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
33079906|NCT00184223|Other|control group|treatment as usual
33079907|NCT00184262|Active Comparator|ERP cognitive therapy|
33079908|NCT00184262|Experimental|ERP behavioral therapy|
33079909|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
33079910|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
33079911|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
33079912|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
33079913|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
32772559|NCT04981561|Experimental|25 mg GATE-251|GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up
32772560|NCT04981561|Experimental|50 mg GATE-251|GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up
32772561|NCT04981561|Experimental|100 mg GATE-251|GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up
32772562|NCT04981561|Experimental|1 mg GATE-251 with CSF collection|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
32772563|NCT04981561|Experimental|10 mg GATE-251 with CSF collection|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
32772564|NCT04981561|Placebo Comparator|Placebo|Placebo tablet, PO, Single Dose with 28 day follow up
33277533|NCT05162690|Placebo Comparator|The Placebo Arm|Metformin 1gram Per Oral Twice a day Glimepiride 2 milligram oral twice a day Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors)
32772566|NCT05698589|Experimental|Compassion Focused Therapy|
32772567|NCT05698589|Active Comparator|Ending Self Stigma|
32772568|NCT05698589|No Intervention|Treatment As Usual|
32772569|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
32772570|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
33079914|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
32772571|NCT05699993|Other|IBI351+ itraconazole|Enrolled subjects were treated with IBI351 on an empty stomach on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 3 to Day 6. IBI351 and itraconazole were administered simultaneously on an empty stomach on Day 7. On Day 8, itraconazole was orally administered once after a standard meal.
32772572|NCT05699993|Other|IBI351+ dextromethorphan|Enrolled subjects were orally administered dextromethorphan on an empty stomach on Day 1. IBI351 and dextromethorphan were orally administered simultaneously on an empty stomach on Day 3, followed by IBI351 12 hours later.
32772573|NCT05552651|Experimental|Envafolimab plus chemotherapy|
32772574|NCT04981483|Experimental|Any age and parity with placenta accreta spectrum|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
32772575|NCT05542199|Active Comparator|+MCNS+WL|This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.
32772576|NCT05542199|Placebo Comparator|-MCNS+WL|This group receives the placebo nutrition supplement and the behavioral weight loss intervention.
32772577|NCT05542199|Active Comparator|+MCNS-WL|This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).
32772578|NCT05542199|No Intervention|-MCNS-WL|This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)
32772579|NCT04981327|Experimental|Experimental|After a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID during 3 months.
32772580|NCT04981327|Active Comparator|Standard|After a conventional course of 7 days of Apixaban 10 mg BID, Apixaban 5 mg BID during 3 months.
33079915|NCT00210678||Group: 1|Men with premature ejaculation (PE)
33277534|NCT00773435|Active Comparator|1. Echinacea purpurea|
32772581|NCT05699837|Experimental|hBET 1|Rhythmic stimulation (2 weeks) followed by non-rhythmic stimulation (2 weeks)
32772582|NCT05699837|Experimental|hBET 2|Non-rhythmic stimulation (2 weeks) followed by rhythmic stimulation (2 weeks)
32772583|NCT05547815|Experimental|experimental arm|5 doses of rabies vaccine
32772584|NCT05541965|Experimental|Median score distributions of the reflexology groups, ICIQ-SF, IQOL and ISI|
32772585|NCT05541965|Active Comparator|Median score distributions of the kegel groups, ICIQ-SF, IQOL and ISI|
32772586|NCT05541965|Active Comparator|Median score distributions of the control groups, ICIQ-SF, IQOL and ISI|
32772587|NCT05547659|Active Comparator|multimodal|pregabalin/ acetaminophen/ celecoxib
32772588|NCT05547659|Active Comparator|unimodal|Pregabalin
32772589|NCT05547659|No Intervention|control|
33079916|NCT00210678||Group: 2|Men without PE
33079917|NCT00184418||All patients admitted to a psychiatric acute ward|
33079918|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
33079919|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
33079920|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
33277535|NCT00773435|Placebo Comparator|2. placebo|
33277536|NCT00777569|Experimental|Extra-low nicotine cigarettes|
33277537|NCT00777569|Experimental|Nicotine-free cigarettes|
33277538|NCT00777569|Active Comparator|Medicinal Nicotine|
33079921|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
33079922|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
33277539|NCT05119868|Experimental|Group 1|Group 1 will receive standard obstetrical and gynecological follow-up and nutritional intervention based on Mediterranean Diet provided by certified dietitians
33277540|NCT05119868|No Intervention|Group 2|Group 2 will receive standard obstetrical and gynecological follow-up alone
32772590|NCT05552417|No Intervention|control group|Conventional control group(C) (n=--) where --- children will not receive any intervention.
32772591|NCT05552417|Active Comparator|Pectointercostal|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
32772592|NCT04426175|Experimental|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
32772593|NCT04426175|Experimental|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
32772594|NCT05552183|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7-9 will receive 14 days of 200 mg BID pacritinib.
32772595|NCT05552183|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10-15 will receive 14 days of 200 mg BID pacritinib.
32772596|NCT05552183|Experimental|Normal Hepatic Function|Healthy subjects who have normal hepatic function with age (± 10 years; ≥ 18 years old and ≤ 85 years old), BMI (±20%), and sex, matching with the moderate and severe hepatic impairment cohorts will receive 14 days of 200 mg BID pacritinib.
32772597|NCT05552105|Other|Cohort|
32772598|NCT05541809|Experimental|Peppermint group|This group will receive peppermint oil aroma
32772599|NCT05541809|Placebo Comparator|Water group|This group will receive water as an aroma oil
32772600|NCT05547503|Placebo Comparator|Placebo Control|Double blind placebo control
32772601|NCT05547503|Experimental|AFA-281|"Part 1: AFA-281 administered as an oral capsule at tentative 20, 40, 80, 160 or 300 mg (total daily dose) for one day.~Part 2: AFA-281 administered as an oral capsule at 3 dose levels twice daily for 14 consecutive days. Doses will be determined after completion of Part 1."
33277541|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
32772602|NCT05541575|Experimental|Intervention|Experimental: offered 3 films of VR course of BPSD for 30 mins to each participants.
32772603|NCT05541575|No Intervention|No intervention|NO films of VR course of BPSD to any participants.
32772604|NCT05551715|Other|Untreated eyes|Participants in the untreated arm will undergo an ophthalmic examination only once.
32772605|NCT05551715|Other|Refractive surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For refractive surgery participants, refractive surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
32772606|NCT05551715|Other|Cataract surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For cataract surgery participants, cataract surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
32772607|NCT05541419|Experimental|Maximum clinical treatment + Budesonide diluted|"The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.~In this study, the investigator wishes to add to the maximum clinical treatment a daily wash with high volume diluted budesonide."
32772608|NCT05541419|Placebo Comparator|Maximum clinical treatment + Placebo|To compare the efficacy of adding diluted budesonide lavage to maximal clinical treatment, the placebo group is used. The placebo formula is composed of 1% glycerin diluted in water.
32772609|NCT05551637|No Intervention|control group|(n=300): Children eat usual dietary (not using Oral Nutritional Supplementation) for 3 months. After that, they will use the product in 3 months
32772610|NCT05551637|Experimental|specific intervention group|"(n=300): Children eat usual dietary and using 2 glasses (49,2 gr powdered milk x 180 ml boil water/time x 2 times/day) of the Oral Nutritional Supplementation as the side meals. The product provides GOS, Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.~The product will be provided for subjects at school in 5 days per week (From Monday to Friday) and at home on weekend."
32772611|NCT05547113||Cochlear implant patients|The group of patients will consist of 40 adult patients indicated for cochlear implantation at the Department of ENT and Head and Neck Surgery, 1st Faculty of Medicine and FN Motol. Patients who meet the indication criteria for implantation also meet the conditions for inclusion in the study, another criterias are absence of diseases of the bearing joints, absence of diseases peripheral nervous system or muscle disease and absence of disease vision that would prevent visual fixation.
32772612|NCT05547035|Experimental|Wearable monitor collected phydiological measurements|This is a single arm study with a wearable monitor that collects physiological measures (falling in the categories physical activity, heart rate, heart rate variability, breathing rate and sleep) 24/7 in ambulatory.
33277542|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
32772617|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
33079923|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
33267141|NCT04521803|Experimental|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
33267142|NCT00920465|Experimental|one-visit|
33267143|NCT00920465|Active Comparator|two-visit|
33267145|NCT03890367|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
33267146|NCT03890367|Active Comparator|Group 2: Nimenrix® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
33267147|NCT03890367|Active Comparator|Group 3: NeisVac-C® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of NeisVac-C® vaccine on Day 0.
32772618|NCT04321109|Experimental|Collagen cone|Collagen matrix
32772619|NCT04321109|Active Comparator|Allograft|mineralized corticocancellous allograft
32772620|NCT05551559|Experimental|Bariatric surgery|
32772621|NCT05541263|Experimental|MBSR group|The MBSR group participants will receive an Mindfulness Based Stress Reduction training programme over 2 months.
32772622|NCT05541263|No Intervention|Wait-list group|The wait-list control group participants will wait while the experimental group is participating in the Mindfulness Based Stress Reduction training. This group will follow the training at the end of the study (7 months after baseline), after all relevant measurements are concluded.
32772623|NCT05700383|Experimental|GetActive with Steps!|GetActive with Steps! is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive with Steps! sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
32772624|NCT05700383|Active Comparator|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive with Steps! program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
32772625|NCT04980937||Patients with perineal nerve damage after ski injury|Retrospectively aquired patients from insight in medical records. All patients with perineal nerve damage after ski injury in the time period of question were enrolled. Inclusion required operative management of the injury interns of microsurgical reconstruction of peroneal nerve.
32772626|NCT05551481|Experimental|In Group A,(Variolink II, Ivoclar Vivadent).|In Group A, the onlays and overlays were luted adhesively with etch and rinse, dual cure resin cement (Variolink II, Ivoclar Vivadent).
32772627|NCT05551481|Active Comparator|In Group B, (Relyx U200, 3M ESPE).|In Group B the onlays and overlays were luted using a self-adhesive resin cement (Relyx U200, 3M ESPE).
32772628|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
32772629|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
32772630|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
32772631|NCT05546879|Experimental|Experimental|NP137+Atezolizumab-Bevacizumab
32772632|NCT05541185|Experimental|Nigella sativa oil group|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
32772633|NCT05541185|Experimental|Naproxen and lidocaine gel group|1 ml of naproxen and lidocaine gel was applied to both knee areas of the naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
32772634|NCT05541185|Placebo Comparator|Massage group|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
32898318|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
33267148|NCT04078919|Active Comparator|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
33267149|NCT04078919|Placebo Comparator|Low calorie diet|Low calorie diet
33267150|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
33267151|NCT00994773|Experimental|Simvastatin|Simvastatin orally
33267152|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
33267153|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
33267154|NCT05405543|Experimental|Arm 1|
33267155|NCT05405543|Experimental|Arm 2|
33267156|NCT05405543|Experimental|Arm 3|
32772635|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
33267157|NCT05405543|Experimental|Arm 4|
33267158|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
33267159|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
33267160|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
33267161|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
33267162|NCT05402345|Experimental|GlcNAc|GlcNAc eye drops
33267163|NCT05402345|Placebo Comparator|Placebo|Placebo eye drops
32772636|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Part B of the study."
32772637|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
32772638|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
32772639|NCT05541107|Experimental|MAT2203 Induction / MAT2203 Consolidation|2 days IV Amphotericin B (AMB) + flucytosine (5FC) followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by MAT2203 +fluconazole for 4 weeks of consolidation therapy
32772640|NCT05541107|Experimental|MAT2203 Induction / SOC Consolidation|2 days IV AMB + 5FC followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by 4 weeks of standard of care consolidation therapy
32772641|NCT05541107|Active Comparator|SOC Induction / SOC Consolidation|Standard of care induction therapy (IV AMB + 5FC) followed by 4 weeks of standard of care consolidation therapy (fluconazole)
32772642|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
32772643|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
32772644|NCT05540951|Experimental|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
32772645|NCT05540951|Active Comparator|BEV|Bevacizumab Plus Chemotherapy
32772646|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
32772647|NCT04966455|No Intervention|Control group|No intervention
33079924|NCT04722471||400 mg|Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.
33079925|NCT04722471||200 mg|Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.
33267164|NCT00995787|Experimental|AZD1656|
33267165|NCT00995787|Placebo Comparator|Placebo|
33267166|NCT04079153|Active Comparator|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
33267167|NCT04079153|Active Comparator|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
33267168|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
33267169|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
33267170|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
33267171|NCT04001127|Experimental|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
33267172|NCT04078607|Experimental|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
33267173|NCT04078607|Placebo Comparator|Control|No distraction during eating
33267174|NCT05198505|Experimental|TQB2868 Injection|The drug was administered once every 3 weeks (administration time window: ± 3 days), the dose of each administration was 1.5-600 mg, and 3 weeks was a treatment cycle until the disease progressed or the investigator judged that it was not suitable to continue the drug use.
33267175|NCT04078841|Active Comparator|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
33267176|NCT04078841|Placebo Comparator|Inert Brown Powder|"Brown powder~Inert brown powder to look similar to RLP"
33267177|NCT04078841|No Intervention|Control|Control
33267178|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
33267179|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
33267180|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
33267181|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
33267182|NCT04000893|Experimental|Resistance exercise session|Acute isometric session, about 20 minutes.
33267183|NCT04000893|Active Comparator|Aerobic exercise session|Acute aerobic session, about 20 minutes.
33277543|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
33277544|NCT00777647|Placebo Comparator|Water|0kJ/100mL
32772648|NCT04966455|Experimental|Experimental group|Supplementation of 50 g daily of rainsins for 3 months
32772649|NCT04948827|Experimental|Part A - Single-Dose (Active)|In Part A, cohorts of healthy nonsmokers will be randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
32772650|NCT04948827|Placebo Comparator|Part A - Single-Dose (Placebo)|In Part A, cohorts of healthy nonsmokers will be randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
32772651|NCT04948827|Experimental|Part A - Single-Dose Food-Effect (Active)|In this two-period food-effect cohort, each healthy nonsmoker subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
32772652|NCT04948827|Placebo Comparator|Part A - Single-Dose Food-Effect (Placebo)|In this two-period food-effect cohort, each healthy nonsmoker subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
32772653|NCT04948827|Experimental|Part B - Multiple-Dose (Active)|In Part B, cohorts of healthy nonsmokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
32772654|NCT04948827|Placebo Comparator|Part B - Multiple-Dose (Placebo)|In Part B, cohorts of healthy nonsmokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
32772655|NCT04948827|Experimental|Part C - Smoker Phase (Active)|In Part C, cohorts of healthy smokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
32772656|NCT04948827|Placebo Comparator|Part C - Smoker Phase (Placebo)|In Part C, cohorts of healthy smokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
32772657|NCT05551325|No Intervention|Control|Usual ICU care.
32772658|NCT05551325|Experimental|Chronobundle|The chronobundle will include bright daytime light, time-restricted intermittent feeding, enhanced mobility, and overnight sleep promotion.
32772659|NCT04964505|Experimental|Treatment (uproleselan, azacitidine, venetoclax)|Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
33079926|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
33079927|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
33079928|NCT00217893|Active Comparator|2|Usual education program
33231171|NCT04107714|No Intervention|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
33231172|NCT05753852|Experimental|Active treatment|
33231173|NCT00847613|Experimental|Sequence 1|
33231174|NCT00847613|Experimental|Sequence 2|
33231175|NCT00847613|Placebo Comparator|Sequence 3|
33231176|NCT00847613|Placebo Comparator|Sequence 4|
33231177|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
33231178|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
33231179|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
33231180|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
33231181|NCT00821938|Active Comparator|CRT-ICD|
33231182|NCT00821938|Placebo Comparator|DDD-ICD|
33231183|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
33231184|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
33231185|NCT00794118||1.0|As per routinary clinical practice
33231186|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
33231187|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
33231188|NCT04112550|Active Comparator|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
33401612|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
33401613|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
32772660|NCT05540639|Experimental|Intervention with modified Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, by a video, in a leaflet and at a website. The practice is described as spending 15 minutes every day from gestational week 28+0 to get to know the fetal movement pattern. The fetus must be awake when practicing Mindfetalness and the woman is suggested to lay on her left side when she observes fetal movements. In the leaflet the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek healthcare without unnecessary delay.
32772661|NCT05540639|No Intervention|Routine care|Historical comparison of the maternal clinics before the intervention. No activities have been taken place.
33231189|NCT04112550|Active Comparator|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
32772662|NCT04981093|Experimental|Group Dexamethasone|"Group dexamethasone patients received intravenous injection after anesthesia induction~Injection 0.15mg/kg dexamethasone (2ml）"
32772663|NCT04981093|Placebo Comparator|Group Saline|Group Control patients were also given 2ml of normal saline intravenously after induction of anesthesia
32772664|NCT05699681||Study cohort|Children aged below 12 years undergoing elective cardiac surgery for congenital heart disease with left to right shunt with prior evidence of pulmonary arterial hypertension on preoperative echocardiography
32772665|NCT05004831|Experimental|fruquintinib plus TAS-102|fruquintinib plus TAS-102, orally given, Q4W
32772666|NCT05546489|Experimental|Lymfit intervention|Participants will receive a Fitbit wearable tracker, expert guidance, and a personalized exercise prescription to optimize physical activities among lymphoma survivors. The intervention is 12 weeks long, participants are meeting with a kinesiologist every 2 weeks.
32772667|NCT04642729|Other|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
33231190|NCT00640042|Experimental|1|
33231191|NCT00807014|Experimental|Duac Gel|Duac Gel
33231192|NCT00807014|Active Comparator|Differin gel|Differin gel
33231193|NCT00847535|Other|1|Transurethral dose escalation
33231194|NCT00847535|Other|2|Periurethral dose escalation
33231195|NCT04830566|Experimental|Myofascial release technique group|
33231196|NCT04830566|Sham Comparator|Simulated myofascial release technique group|
33231197|NCT04809272|Experimental|ParentChat for parents of children ages 2-17|The ePLH parent support groups will be delivered over a 8 week period (i.e., 7-8 short online interactive group sessions, two per week). ePLH facilitators will moderate discussions around the parenting theme, support parents on an individual basis, and encourage them to apply the parenting skills at home. The facilitators will begin the next group engagement with a brief voice summary of the feedback and address possible solutions to 2-3 key challenges. Facilitators will also be provided with weekly supervision by an ePLH coach or trainer. A designated research assistant will provide parent support groups with needed technical support during the implementation - including IT-related support. Data bundles will be provided for internet access and to incentivise engagement.
33231198|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
33231199|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
33231200|NCT05753774|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
33231201|NCT05757674||Patients|Patients
33231202|NCT05757674||Control|Control
33231206|NCT04116125|Placebo Comparator|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
33231207|NCT04116125|Experimental|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
33231208|NCT04805918|Experimental|VIPP-SD (Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline).|The VIPP-SD includes seven sessions of 1½-2 hours each with an 2-4 weeks interval VIPP-SD is delivered by a VIPP-SD trained pedagogue and takes place in the family home and the targeted parent and child are videotaped during daily interactions. The intervener studies the video and prepares feedback. During the sessions, the intervener and parent review the video together and the intervener provides their feedback according to the VIPP-SD protocol.
33231209|NCT04805918|Active Comparator|Care as ususl|The existing standard practices for parents of 2-6 year old children identified to be at risk for developing externalizing problems in the participating municipalities will be the active control condition. These vary in content and duration in the municipalities. Likewise, CAU may change during the project period. The exact content and duration of CAU interventions as well as participants' adherence to treatment will be described as precisely as possible.
33231210|NCT05755256|Experimental|Probiotic|The product contains the probiotic strain and no other ingredients.
33231211|NCT05755256|Placebo Comparator|Placebo|The control product is a placebo with the same characteristics of appearance and packaging as the tested product.
33231212|NCT05757596|Active Comparator|VSA001 injection|A single dose of active drug (VSA001, low or high dose) will be administered by subcutaneous injection on Day 1.
33231213|NCT05757596|Placebo Comparator|Placebo|The placebo is normal saline (0.9%) administered subcutaneously; volume matched to the corresponding VSA001 dose volume.
33231214|NCT00791388|Placebo Comparator|placebo|placebo capsule
33231215|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
33231216|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
33231217|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
33231218|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
33267184|NCT04078217|Experimental|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
33267185|NCT04078217|Active Comparator|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
32772668|NCT04642729|Other|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
32772669|NCT05003817|Experimental|LV-unloading|Participants in the elective unloading (intervention) group will have a percutaneous left ventricular unloading device (pLVAD) inserted at the start of the procedure, before the coronary intervention. Maximal support will be provided throughout the procedure, following which support will be weaned and the device removed should the patient remain haemodynamically stable.
33079929|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
33079930|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
32772670|NCT05003817|No Intervention|Standard of Care|Participants in the control arm will receive the planned high-risk percutaneous coronary intervention as is the current standard of care without elective left ventricular unloading. Alternative mechanical circulatory support devices (such as the intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) will only be permitted in case of complications.
32772671|NCT04981015||Women with lower urinary tract symptoms|Women with lower urinary tract symptoms without cystocele were included.
32772672|NCT05551247|Experimental|Envafolimab plus recombinant human endostatin (endostatin)|Envafolimab:300mg,sc,d3,Q3W; endostatin:210mg,civ,d1-3,Q3W.
32772673|NCT05003505||Women with cervical cytology (TCT) abnormalities|In the enrollment, women who have undergone cervical cytology (TCT) examination for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months, 12 months and 24 months.
32772674|NCT05540561||Subjects consuming nitrous oxide with clinical outcomes|Subjects who consume nitrous oxide and who have been hospitalized in this context and who present clinical signs determined during a neurological evaluation according to the PND (Peripheral Neuropathy Disability) score or who have had a thrombotic accident related to the consumption of nitrous oxide.
32772675|NCT05540561||Subjects consuming nitrous oxide without clinical outcomes|Subjects who consume nitrous oxide who do not present clinical signs related to this consumption and recruited during a routine medical consultation.
32772676|NCT05540483|Experimental|Experimental arm|Disitamab Vedotin combined with Zimberelizumab
32772677|NCT04963803|Experimental|Active transcranial direct current stimulation (tDCS) paired with speech-language therapy|Active transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
32772678|NCT04963803|Sham Comparator|Sham transcranial direct current stimulation (tDCS) paired with speech-language therapy|Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
32772679|NCT05551169||Patients with stable COPD in Stage1|no intervention
32772680|NCT05551169||Patients with stable COPD in Stage2|no intervention
32772681|NCT05551169||Non-COPD subjects in Stage2|no intervention
32772682|NCT04945707|Active Comparator|Arm 1|Ferric derisomaltose (Monoferric®) 1000 mg X 1 (for subject <50 kg, 20 mg/kg X1)
32772683|NCT04945707|Placebo Comparator|Arm 2|Normal Saline
33079931|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
33267186|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
33267187|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
33267188|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
33079932|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
33079933|NCT00218049|Experimental|1|50 mg of GBR 12909
33079934|NCT00218049|Experimental|2|75 mg of GBR 12909
33079935|NCT00218049|Experimental|3|100 mg of GBR 12909
33079936|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
33267189|NCT05347329|Placebo Comparator|Control Arm 1|Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient), administered orally once daily on empty stomach with plenty of water.
33079937|NCT00185159|Experimental|1|olmesartan medoxomil
33079938|NCT00185159|Placebo Comparator|2|placebo
33079939|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
33079940|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
33079941|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
33079942|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
33079943|NCT00185198|Active Comparator|Arm 1|
33079944|NCT00185198|Placebo Comparator|Arm 2|
33079945|NCT04722198|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
33079946|NCT00185237|Experimental|Arm 1|
33079947|NCT00185237|Placebo Comparator|Arm 2|
33079948|NCT00185276|Experimental|Arm 1|
33079949|NCT00185276|Experimental|Arm 2|
33079950|NCT00218166|No Intervention|A|Within subject design
33079951|NCT00185315|Experimental|Arm 1|
33079952|NCT00185354|Experimental|Arm 1|
33079953|NCT00185354|Active Comparator|Arm 2|
33079954|NCT00185393|Experimental|Arm 1|
33267190|NCT05347329|Experimental|400 mg Tongkat Ali+ 200 mg Maca (Experimental Arm 2)|The content of 2 capsules of Tongkat Ali Maca (600 mg of active ingredient), Plus is equally distributed and inserted into 3 capsules size 1 (low dose), administered orally once daily with plenty of water.
33267191|NCT05347329|Experimental|600 mg Tongkat Ali+ 300 mg Maca ( Experimental Arm 3)|The content of 3 capsules of Tongkat Ali Maca Plus (900 mg of active ingredient), is equally distributed and inserted into 3 capsules size 1 (high dose), administered orally once daily with plenty of water.
33267192|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
33267193|NCT02582567|No Intervention|Control group|Usual care (control) group
33267194|NCT05347017|Experimental|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using HCL acid as demineralized dentin block graft and inserted in the extraction socket
33267195|NCT05347017|Active Comparator|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non-restorable teeth, then autogenous bone block will be harvested from the maxillary tuberosity and reshaped and inserted in the extraction socket
33267196|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
33079955|NCT00185393|Other|Arm 2|
33267197|NCT04403009||the severe Coronavirus Disease 2019 Patients|
33267198|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
33267199|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
33267200|NCT04621643|Experimental|digital cognitive behavioral therapy (dCBT-I)|
33079956|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
33079957|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
33079958|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
33079959|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
33079960|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
33079961|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
33079962|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
33079963|NCT00211263|Experimental|Enhanced Clinical Intervention|
33079964|NCT00211263|Active Comparator|Clinical Intervention|
33079965|NCT00185510|Experimental|Arm 1|
33079966|NCT00185510|Placebo Comparator|Arm 2|
33079967|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
33079968|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
33079969|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
33267201|NCT04621643|Active Comparator|Patient education about sleep (PE)|
33267202|NCT03084237|Experimental|HLX02+docetaxel|
33267203|NCT03084237|Active Comparator|Herceptin®+docetaxel|
33267204|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
33267205|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
33267206|NCT04620629||control group|Late premature and term babies without any disease
33267207|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
33267208|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
33267209|NCT04615715|Experimental|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
33267210|NCT04615715|Placebo Comparator|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
33267211|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
33079970|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
33079971|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
33079972|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
33079973|NCT00218322|Experimental|2|
33079974|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
33267212|NCT04614779|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.~The dosage form is tablets."
33267213|NCT00996099|Active Comparator|CGM-eMPC|
33267214|NCT00996099|Other|Control|
33267215|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
32772684|NCT05698511|Experimental|Psilocybin|Healthy volunteers will receive up to four doses of psilocybin separated from each other by at least one week. The first dosing session will involve 10 mg psilocybin, the remaining three dosing sessions will receive up to 25mg psilocybin.
32772685|NCT05002257|Experimental|Experimental Arm|
32772686|NCT05002257|Active Comparator|Control arm|
32772687|NCT05546255|Experimental|Eribulin Combined With Lobaplatin|Eribulin 1.4mg/m2 d1 Lobaplatin 25g/m2 d1 / q14d
32772688|NCT05546177|Experimental|instrumented assisted soft tissue mobilization|the patients will receive instrumented assisted soft tissue mobilization three times a week for eight weeks
32772689|NCT05546177|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for eight weeks
33079975|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
33267216|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
33267217|NCT05345301|Experimental|Measuring neural activity|While completing hand opening/closing, individuals will have the following measured (1) Neural activity (specifically sensorimotor rhythms) using a EEG cap; (2) muscle activity (specifically finger flexors and extensors) using EMG sensors.
33079976|NCT00218517|Experimental|1|
33267218|NCT04515329|Experimental|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
33267219|NCT04515329|Other|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
33267220|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
33267221|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
33267222|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
33267223|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
32772690|NCT05551091|Experimental|GMP 25 mg BID|Investigators will conduct a pilot cross-over study in which 13 obese participants undergo measures of study outcomes: satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota at baseline and after 7 days of consuming the supplement. On day one participants will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements twice a day (BID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
33267224|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
32772691|NCT05551091|Experimental|GMP 25 mg TID|After a washout period, the same 13 participants will undergo repeated measures of study outcomes (satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota). On day one subjects will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements thrice a day (TID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
33079977|NCT00218517|Placebo Comparator|2|
33079978|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
33079979|NCT00218556|No Intervention|Control|Treatment as usual.
33079980|NCT00218595|Experimental|DBT|
33079981|NCT00218595|Active Comparator|I/GDC|
33267225|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
33267226|NCT00999219|Experimental|FK199B-first group|
33267227|NCT00999219|Experimental|Zolpidem-first group|
33401614|NCT04055402|Experimental|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
33267228|NCT02583971||Patients with AF|"Split into 3:~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
33267229|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
32901883|NCT04214886|Experimental|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
33079982|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
33267230|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
33267231|NCT04079933|No Intervention|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
33267232|NCT04079933|Experimental|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint) also under ad libitum conditions
33267233|NCT00996255|Experimental|Dose-Escalation|
33267234|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
33267235|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
33267236|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
33267237|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
33267238|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
33267239|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
33267240|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
33267241|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
33267242|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
33267243|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
33267244|NCT05388695|Experimental|19+22 CART and 19+20 CART|Eligible patients will be treated with 19+22 CAR-T and 19+20 CAR-T.
33267245|NCT04078451|Experimental|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
33267246|NCT04078451|No Intervention|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
33267247|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
33267248|NCT05371223|Experimental|Interventional|"Eligible patients affected by pancreatic cancer PM will be enrolled according to in-/exclusion criteria.~Each patient will be scheduled for three treatment combined courses for a total of six cycles of endovenous Nabpaclitaxel-Gemcitabine chemotherapy and three of Nabpaclitaxel-PIPAC."
33267249|NCT04079075|Experimental|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
33267250|NCT05370443|Experimental|Life Skills intervention group|The participants in the intervention group will receive eight sessions of the online life skills educational program via the zoom platform for eight weeks. Each session will last for 1-hour. All the participants will receive a short reminder SMS for enrolling in the online session. The assessment for all students will be done at baseline, immediate and 3-months post-intervention.
33267251|NCT05370443|No Intervention|control group|Participants in the control group will receive no intervention during the study period. However, they will receive the same educational activities after finishing study. They will answer the same questionnaires at baseline, immediately following the intervention, and three months later.
33267252|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
33267253|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
33267254|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
33267255|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
33267256|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
33267257|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
33267258|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
33267259|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
33267260|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
33267261|NCT04489355||CABG|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG)
33267262|NCT04489355||CABG with SVR|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR)
33267263|NCT04489355||CABG with mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with and mitral repair (MR)
33267264|NCT04489355||CABG with SVR and mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
33267265|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
33267266|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
33267267|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
33267268|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
33267269|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
33267270|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
33079983|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
32772692|NCT04962711|Experimental|Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)|"Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.~Exercise intervention: Individualized training program provided by an exercise physiologist."
32772693|NCT04962711|Active Comparator|Usual care|Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.
33267271|NCT04078763|Experimental|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
33267272|NCT04078763|Experimental|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
33267273|NCT04001673|Active Comparator|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
32772694|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
33267274|NCT04001673|No Intervention|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
33267275|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
33267276|NCT00996411|Experimental|Salvinorin A|
32772695|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
33079984|NCT00218673|Experimental|experimental|social network
33079985|NCT00218673|No Intervention|control|testing and counseling
33267277|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
33267278|NCT00996567|Experimental|Cetuximab (Erbitux)|
33079986|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
33079987|NCT00218712|Active Comparator|2|Participants will receive standard counseling
33079988|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
33267279|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
33267280|NCT04120805|Experimental|Group 1 (Hemostatic Agents Plus +)|
33267281|NCT04120805|Active Comparator|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
33267282|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
33401615|NCT04055402|Active Comparator|Control group|Participate in the baseline survey,and a 1-month follow-up survey
33079989|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
33079990|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
33079991|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
33079992|NCT00218868||skin scrape|
33079993|NCT00186914|Other|1|
33079994|NCT00186953|Other|1|
33079995|NCT00187031|Other|1|
33079996|NCT00187070|Other|1|
33079997|NCT00187148|Other|1|
33079998|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
32772696|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
32772697|NCT04999995||HFrEF|Patients admitted with acutely decompensated HFrEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
32772698|NCT04999995||HFpEF|Patients admitted with acutely decompensated HFpEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
32772699|NCT04999995||Non-HF Dyspnea|Patients admitted with acute dyspnea without evidence of HF and without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
32772700|NCT04945473|Experimental|Revision|"BMI≥30 or total weight loss (TBWL) < 10% and relaxation of gastric tubulisation at 6 months after ESG.~Additional stitches will be placed during the follow-up gastroscopy at 6 months."
32772701|NCT04945473|No Intervention|Without revision|The control gastroscopy will be performed without any additional procedure (no additional stitches).
32772702|NCT04317989|Experimental|Practice Facilitation|All enrolled practices will receive practice facilitation for the duration of the intervention period.
32772703|NCT04959279|Experimental|ED-TREAT|EHR-embedded clinical decision support (CDS) tool designed to overcome the challenges to risk assessment and suggest pre-emptive use of behavioral techniques in the emergency setting.
32772704|NCT04959279|No Intervention|Usual Care|
32772705|NCT05540249|Experimental|Group CHO|Patients in Group CHO will orally consume CHO 355ml containing 50 g of carbohydrates 8-12 hours before operation (20:00 -24:00 the evening before operation).
32772706|NCT05540249|No Intervention|Group CTRL|Patients in Group CTRL will consume no food or drink 12 hours before operation (20:00 the evening before operation).
32772707|NCT05461287|Experimental|QLS31904|Qls31904 is a bi-specific recombinant protein construct containing 2 humanized antibody derived binding domains.
32772708|NCT05546021|Active Comparator|NOL monitor|Patients will receive opioids as per the guidance of a nociception level monitor (NOL)
32772709|NCT05546021|No Intervention|Standard care|Patients will be treated as per the department´s standard protocol.
32772710|NCT04958733|Active Comparator|Autologous Bone Grafting|Excess bone obtained from graft preparation and the coring reamer will be used to fill the patellar and tibial donor sites.
33079999|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
33080000|NCT02962479||TNF blocker-naïve nrSpA patients|
33080001|NCT02962479||TNF blocker-exposed nrSpA patients|
33080002|NCT02962479||Healthy Participants|
33080003|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
33080004|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
33080005|NCT00412386||BAV|patients with BAV
33080006|NCT00412386||Normal control|normal patients
33080007|NCT00211926|Experimental|StaphVAX|
33080008|NCT00211926|Placebo Comparator|Placebo|
33080009|NCT00218946|No Intervention|control|no fluid, no pacifier
33080010|NCT00218946|Experimental|water|water, no pacifier
33080011|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
33080012|NCT00218946|Experimental|pacifier|No fluid, pacifier
33080013|NCT00218946|Experimental|water and pacifier|water, pacifier
33080014|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
33080015|NCT00218985|Experimental|exercise training|
33080016|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
33080017|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
33267283|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
33267284|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
33267285|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
33267286|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
33267287|NCT05335551||Patients monitored with TruGraf/TRAC Liver testing|"Subjects in the biomarker arm will have TruGraf Liver and TRAC Liver testing at study enrollment (1-2 months post-liver transplant) and thereafter every month for 6 months. Subjects will also have Trugraf Liver and TRAC Liver testing at months 9 and 12 following transplantation (7-8 and 10-11 months postbaseline)~The TruGraf and TRAC Liver results will be used in the biomarker arm in conjunction with all other clinical parameters available to guide decisions of the Principal Investigator and Sub-Investigators related to immunosuppression management.~changes."
33401616|NCT04055480|Active Comparator|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
33401617|NCT04055480|Experimental|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
33080018|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
33401618|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
33401619|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
33080019|NCT00211965|Experimental|vaccine|single dose
33080020|NCT00211965|Placebo Comparator|placebo|single dose
33080021|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
33080022|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
33080023|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
33080024|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
32772711|NCT04958733|Placebo Comparator|Control|The control group will have their patellar and tibial defects remain unfilled.
32772712|NCT05540015|Active Comparator|Group with impacted third molar, extracted by cutting and rotary tools|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction. Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
32772713|NCT05540015|Active Comparator|Group with impacted third molar, extracted by erbium laser 2.94 nm|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction.Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
32772714|NCT05545709||remote group|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
32772715|NCT05545709||local group|Local orthopedic robot-assisted spine surgeries were performed according to the guidelines for thoracolumbar pedicle screw placement assisted by orthopedic surgical robots.
32772716|NCT05545631||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
33080025|NCT00187538|Active Comparator|1|
33080026|NCT00187538|Active Comparator|2|
33080027|NCT00187538|Active Comparator|3|
32772717|NCT05545631||Conception negative|serum human chorionic gonadotropin <10 mIU/mL
33080028|NCT00187538|Active Comparator|4|
33080029|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
32772718|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
32772719|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
33080030|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
33080031|NCT00187733||Fasting|Other: Fasting blood and urine collection
33080032|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
33080033|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
33080034|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
33080035|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
33080036|NCT00187850|Experimental|PP|Partial pulpotomy
33080037|NCT00187850|Other|DPC|Direct pulp capping
33080038|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
33080039|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
33401620|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
33401621|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
33401622|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
33401623|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
33401624|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
33401625|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
32772724|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
32772725|NCT04980859|Experimental|Zebutinib Combined With CIT arm|Zebutinib Combined With FCR( under 60 years of age) or BR (over 60 years of age )
33401626|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
33401627|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
32772726|NCT04432519|Experimental|Group CA|Customized healing abutment inserted in immediate implant placement.
32772727|NCT04432519|Active Comparator|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
32772728|NCT05545475||Anticoagulation group|1 mg/kg of nadroparin calcium or enoxaparin every 12 h, 5000 IU of low molecular weight heparin (LMWH) every 12 h, 20 mg of rivaroxaban once daily, or warfarin adjusted by an increase or decrease of 0.75 mg until the target international normalized ratio (INR) of 2-3 was reached.
32772729|NCT05545475||Control group|No anticoagulation group.
33080040|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
33267288|NCT05335551||Patients not monitored with TruGraf/TRAC Liver testing|Patients in control/ stamdard of care arm will have immusuppresion reduction based on the clinical judgement and management of the Principal Investigator and Sub-Investigators.
33401628|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
33401629|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
32772733|NCT05539703|Experimental|Intervention groups: Invitation to get 2nd booster|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
32772734|NCT05539703|No Intervention|Control group: No invitation to get 2nd booster|The control group will receive no intervention.
32772735|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
32901884|NCT04214886|Experimental|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
33267289|NCT04358237|Experimental|Experimental: lurbinectedin (PM01183) + pembrolizumab|"During the phase I stage, patients will start receiving pembrolizumab at a fixed dose of 200 mg as a 30-min intravenous (IV) infusion followed by lurbinectedin at a starting dose of 2.4 mg/m2 as a 1-h IV infusion on Day 1, both every 3 weeks (Q3W). Lurbinectedin dose will be escalated from the starting dose in successive cohorts of patients, with a pre-established fixed dose increase (in mg/m2) of approximately 30%.~During the phase II stage, patients will receive pembrolizumab at a fixed dose of 200 mg as a 30-min IV infusion followed by lurbinectedin as a 1-h IV infusion on Day 1 Q3W at the redommended dose (RD) determined during the phase I stage. A cycle is defined as an interval of 3 weeks. No dose escalation will be allowed during the phase II stage."
33267290|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
33267291|NCT04293562|Experimental|Arm A High Risk Group|Arm A High Risk Group: See Detailed Description.
33267292|NCT04293562|Experimental|Arm A Low Risk Group 1|Arm A Low Risk Group 1: See Detailed Description.
33267293|NCT04293562|Experimental|Arm A Low Risk Group 2|Arm A Low Risk Group 2: See Detailed Description.
33267294|NCT04293562|Experimental|Arm AC High Risk Group|Arm AC High Risk Group: See Detailed Description.
33267295|NCT04293562|Experimental|Arm AC Low Risk Group 2|Arm AC Low Risk Group 2: See Detailed Description.
32772736|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
32772737|NCT05545397||The propofol group|Patients undergoing painless gastroenteroscopy under general anesthesia
32772738|NCT04952727|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
32772739|NCT04952727|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
33267296|NCT04293562|Experimental|Arm AD High Risk Group|Arm AD High Risk Group: See Detailed Description.
33267297|NCT04293562|Experimental|Arm AD Low Risk Group 2|Arm AD Low Risk Group 2: See Detailed Description.
33267298|NCT04293562|Experimental|Arm B High Risk Group|Arm B High Risk Group: See Detailed Description.
33267299|NCT04293562|Experimental|Arm B Low Risk Group 1|Arm B Low Risk Group 1: See Detailed Description.
33267300|NCT04293562|Experimental|Arm B Low Risk Group 2|Arm B Low Risk Group 2: See Detailed Description.
33267301|NCT04293562|Experimental|Arm BC High Risk Group|Arm BC High Risk Group: See Detailed Description.
33267302|NCT04293562|Experimental|Arm BC Low Risk Group 2|Arm BC Low Risk Group 2: See Detailed Description.
33267303|NCT04293562|Experimental|Arm BD High Risk Group|Arm BD High Risk Group: See Detailed Description.
32772740|NCT04952727|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months
32772741|NCT04952727|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
33267304|NCT04293562|Experimental|Arm BD Low Risk Group 2|Arm BD Low Risk Group 2: See Detailed Description.
33267305|NCT04358159|Experimental|Ventralex|Repair with Ventralex patch in sublay position
33267306|NCT04358159|Active Comparator|Progrip|Repair with Progrip in Onlay position
33267307|NCT05313347||Healty Participants with varying BMI|30 healthy participants with a body mass index ranging from 17.5 to 35kg/m2.
33267308|NCT05312801|Experimental|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
33267309|NCT05304533|Experimental|Arm 1: MYK-224|
33267310|NCT05304533|Experimental|Arm 2: MYK-224 + Itraconazole|
33267311|NCT05304533|Experimental|Arm 3: MYK-224 + Verapamil|
33267312|NCT04338269|Experimental|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
33267313|NCT04338269|Active Comparator|Cabozantinib|Participants will receive cabozantinib every day.
33267314|NCT05674487|Experimental|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
33267315|NCT05674487|Active Comparator|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
33267316|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
33267317|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
33267318|NCT04077827|Experimental|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)~Recommended dosage:~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
33267319|NCT04077827|Experimental|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)~Recommended dosage:~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
33267320|NCT00999375|Experimental|Group A|
33267321|NCT00999375|Active Comparator|Group B|
33267322|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
33267323|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
33267324|NCT00996723|Other|1|
33267325|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
33080041|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
33080042|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
33267326|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
33267327|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
33267328|NCT04354025|Experimental|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
33267329|NCT04354025|Other|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
33267330|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
33267331|NCT05332587|Experimental|Rituximab Treated|rituximab
33401630|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
32772742|NCT05539625|Active Comparator|MitoQ|Once daily dosing of two capsules for 40mg/d (or one capsule for 20mg/d if weight <30kgs)
32772743|NCT05539625|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
33080043|NCT00188279|Experimental|MnDCT|
32772744|NCT05699369|Experimental|Intervention arm|A comprehensive package of digital health interventions to connect patients, patient champions and public health providers to improve the management of non-communicable diseases (NCDs) during the pandemic will be implemented, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Patient champions are experienced patients who can provide peer support.
33080044|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
33080045|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
32772745|NCT05699369|No Intervention|Control arm|Usual care, which is routine hypertension and diabetes diagnosis and treatment under the World Diabetes Foundation (WDF) project will be implemented. The WDF project provides initial Zoom-based training of NCD care to rural health center (RHC) staff, but no tele-mentorship is offered. Under the usual care, patients with hypertension or diabetes are required to visit RHCs every month to renew their medications and measure their blood pressure. No other interventional components will be implemented in the control arm.
32772746|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
32772747|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
33080046|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
33080047|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
33080048|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
33080049|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
33080050|NCT00411606||1|Subjects with no allergies
33080051|NCT00411723|Experimental|1|
33267332|NCT04078529|Experimental|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
33267333|NCT04078529|Active Comparator|Comparison group[|This group will complete the home exercise programme only.
33267334|NCT01015690||unexplained infertility|patients with unexplained infertility
33267335|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
32772748|NCT05539547|Sham Comparator|Control Group|Patients shall receive the usual physiotherapy care, including chest and mobility physiotherapy on quadriceps strength and endurance during hospital admission on patients with severe acute exacerbation COPD.
33080052|NCT00411723|Placebo Comparator|2|
33080053|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
33080054|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
33080055|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
33080056|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
33267336|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
33267337|NCT00996879|Experimental|Midazolam + BMS-791325|
33267338|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
33267339|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
33267340|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
33080057|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
33080058|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
33080059|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
33267341|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
32772749|NCT05539547|Experimental|Experimental Group|Patients shall receive the investigated modality, NMES on quadriceps strength and endurance as an adjunct to usual physiotherapy care (chest physiotherapy and mobility) during hospital admission in patients with severe acute exacerbation COPD.
33267342|NCT02582177|Experimental|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
33267343|NCT02582177|Experimental|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
33267344|NCT00999531|Experimental|1|GS-9411 9.6 mg
33267345|NCT00999531|Experimental|2|GS-9411 4.8 mg
33267346|NCT00999531|Experimental|3|GS-9411 2.4 mg
32772750|NCT05545241|Experimental|Neurofeedback and BART-EEG assessment|Healthy subjects realized 10 sessions of emotional neurofeedback. Before (Baseline, Day 0), and after (at the study completion (after 10 neurofeedback sessions, Week 5)) neurofeedback sessions, the BART, assessing risk-taking behavior, coupled with an EEG record is realized by the subjects.
32772751|NCT05545241|Sham Comparator|BART-EEG assessment without neurofeedback|At the same times (Baseline, Day 0), and at the study completion (after 10 neurofeedback sessions, Week 5), healthy subjects realized the BART, assessing risk-taking behavior, coupled with an EEG record.
32772752|NCT04941183|Experimental|NTR-441|Single Ascending Dose; Multiple Ascending Dose.
32772753|NCT04941183|Placebo Comparator|Placebo|Single Ascending Dose; Multiple Ascending Dose.
32772754|NCT05698433||high Blood pressure variability team|The group with excessive blood pressure fluctuation during operation is high Blood pressure variability team
32772755|NCT05539235|Experimental|2 week group|Drug injection adjustment interval is 2 weeks
32772756|NCT05539235|Experimental|4 week group|Drug injection adjustment interval is 4 weeks
32772757|NCT04940403|Active Comparator|Unimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will only train their hemiparetic arm (unimanual tasks only).
32772758|NCT04940403|Experimental|Bimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will train their hemiparetic arm as well as interacting with the contralateral arm for bimanual tasks (unimanual + bimanual tasks).
33267347|NCT00999531|Placebo Comparator|4|Saline Placebo
33267348|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
32772759|NCT05545163|No Intervention|I-gel with standard insertion technique|in this arm, trainees performed the standard I-gel insertion technique
32772760|NCT05545163|Experimental|Modified jaw thrust I-gel insertion technique|in this arm, trainees performed modified jaw thrust insertion technique
32772761|NCT04433143|Experimental|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
32772762|NCT04433143|Experimental|Intense Pulsed Light single filter|Intense pulsed Acne filter
32772763|NCT04433143|Experimental|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
33267349|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)~Trade Name (generic name)"
33267350|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)~Trade Name (generic name)"
33267351|NCT05325177|Active Comparator|Group 1 infants|(n=15) will receive three doses of standard-dose Ibuprofen. (10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
33267352|NCT05325177|Active Comparator|Group 2 infants|(n = 15) will receive three doses of high-dose Ibuprofen Motrin. (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
32772764|NCT02477553|Experimental|Quantitative|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
32772765|NCT02477553|Active Comparator|Verbal|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
32772766|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
32772767|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
32772768|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
32772769|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
32772770|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
32772771|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
32772772|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
32772773|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
32772774|NCT04620733|Experimental|Seladelpar 10 mg|
32772775|NCT04620733|Placebo Comparator|Placebo|
32772776|NCT04620733|Experimental|Seladelpar 5 mg|
32772777|NCT05538923||Patients with IBD|Patients with inflammatory bowel disease on remission period
32772778|NCT05538923||Control|Age- and gender- matched healthy population
33267353|NCT04099667|Experimental|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
33267354|NCT04099667|Experimental|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
33267355|NCT04099667|Placebo Comparator|Phase 2; Placebo|Volume-matched placebo is a single treatment
33267356|NCT04099667|Experimental|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
33267357|NCT04099667|Placebo Comparator|Phase 3; Placebo|Volume-matched placebo is a single treatment
33267358|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
33267359|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
33267360|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
33267361|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
33267362|NCT05315739|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the gammaCore device (electroCore)
33267363|NCT05315739|Sham Comparator|Sham treatment|Inactive sham vagus nerve stimulation applied by the gammaCore sham device (electroCore)
33267364|NCT05294081|Experimental|Exposure (EXP)|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
33401631|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
32772779|NCT05544851|Experimental|Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
33401632|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
33401633|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.~Review a 15-20 minute educational tool on a tablet about kidney health~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
33401634|NCT04061044|Experimental|Treatment|
33401635|NCT04056910|Experimental|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
33401636|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
33401637|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
33401638|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
33401639|NCT04040296|No Intervention|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
33401640|NCT04040296|Experimental|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
32772780|NCT05544851|Experimental|Non-Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
33401641|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
32772781|NCT05550155|Sham Comparator|sham rTMS|"The sham treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial sham rTMS phase will consist of four sham stimulation sessions (20 Hz sham) within two consecutive days. One sham rTMS maintenance phase will consist of two sham stimulation sessions on one day every week for one month and then every two weeks for three months.~Clinical data will be assessed by an investigator blind to group assignment until the end of the study. Patients will also be blind to stimulation. A questionnaire will assess the investigator physician and patient beliefs about what group the patient was involved in (placebo group or active group) at the end of the treatment initial phase and at the end of the treatment maintenance phase"
32772782|NCT05550155|Experimental|active rTMS|The active treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial active rTMS phase will consist of four stimulation sessions (20 Hz) within two consecutive days. One active rTMS maintenance phase will consist of two active stimulation sessions on one day every week for one month and then every two weeks for three months.
32901885|NCT04214886|Experimental|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
33401642|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
33401643|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
33401644|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
33401645|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
33401646|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
33401647|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
33401648|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
33401649|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
33401650|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
33401651|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
33401652|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
33401653|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
33267365|NCT05294081|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
32772783|NCT04429009|Experimental|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:~The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.~A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.~The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
33267366|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
33267367|NCT00997269|Experimental|CoQ-10 supplementation|
33267368|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
33267369|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
33267370|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
33267371|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
33267372|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
32772784|NCT04429009|Active Comparator|Control Group|Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
32772785|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
32772786|NCT05550077||Optical Coherence Tomography (OCT)|OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
32772787|NCT05550077||Non-Optical Coherence Tomography (N-OCT)|Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
32772788|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
32772789|NCT04428307|Experimental|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
32772790|NCT04428307|Experimental|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
32772791|NCT05538845||Screw|Screw fixation
32772792|NCT05538845||Suture button|Suture button
33267373|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
33267374|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
33267375|NCT04345601|Experimental|Mesenchymal stromal cells|Patients will receive up to 2 infusions of mesenchymal stem cells.
33267376|NCT04345601|Other|Control Group|Patients will receive supportive care or treatment designated by their treating doctor.
33267377|NCT04001439|Other|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
33267378|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
33267379|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
33267380|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
33267381|NCT05301153||Myasthenia Gravis cases|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39.~Autoantibodies detection:~Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA according to the manufacturer's protocol."
32772793|NCT04618705|No Intervention|control group|Participants who have not smoked for at least 10 years
32772794|NCT04618705|No Intervention|smoking group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years.
32772795|NCT04618705|Experimental|smoking cessation group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years and who are planning to quit smoking.
32772796|NCT05535725|Experimental|expose|A group of patients receiving 1g of powdered vancomycin in the operative wound before its closure, and another group not receiving it
32772797|NCT05535725|No Intervention|non expose|A group of patients not receiving 1g of powdered vancomycin in the operative wound before its closure
32772798|NCT05698355|Experimental|Telerehabilitation group|"Multimodal self-treatment-based telerehabilitation will be implemented with a video conference method. For telerehabilitation, at each session, manual therapy techniques, (i.e., stretching, myofascial release, and tissue desensitization), sex education, and pelvic floor muscle relaxation massages with a pelvic wand (i.e., relaxation, stretching) using small intra-vaginal wand were used. Women were also asked to perform home exercises resembling those performed under supervision five times per week as well as auto-insertion exercises with a pelvic wand in addition to desensitization techniques three times per week.~Sessions consist of 60 minutes. Telerehabilitation will take place 2 days a week for 12 weeks."
32772799|NCT05698355|No Intervention|Education group|60 minutes of video recording training will be given about pelvic pain relaxation exercises.
32772800|NCT05535647|Experimental|Regorafenib and HAIC|Regorafenib HAIC with FOLFOX
32772801|NCT05535647|Active Comparator|FOLFOX|FOLFOX
32772802|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
32772803|NCT03064321|Other|Information Control|General health information website
32772804|NCT05535569|Experimental|Experimental|
32772805|NCT04980079|Active Comparator|group A -undergo primary ureteroscopy URS|Thirty children with calicular anuria will undergo primary ureteroscopy URS
32772806|NCT04980079|Active Comparator|the group B(30 patients) will undergo deferred ureteroscopy URS|group B (30) patients will be admitted to do urinary drainage through the insertion of a double-J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done
32772807|NCT05538455|Experimental|Experimental group, use of PC4L solutions|Participants who will use the PC4L solutions for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will receive recommendations in the PC4L app
33267382|NCT05301153||Healthy Control|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39."
32772808|NCT05538455|No Intervention|Control group, no use of PC4L solutions|Participants who will be monitored for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will only receive written recommendations
32772809|NCT04980313|Experimental|Xenogenic collagen matrix|Volumetrically stable xenogenic collagen matrix
32772810|NCT04980313|Active Comparator|Autogenous connective tissue graft|Autogenous connective tissue graft obtained from the tuberosity area
32772811|NCT05544539|Experimental|drug arm|In the study group the (0.5 ml) of Ozone oil (perio3®, Hoffmann, German) was placed inside the socket of the extracted tooth filling it completely following suturing of the flap
32772812|NCT05544539|Placebo Comparator|placebo arm|the ozone oil syringe was placed inside the patient mouth without applying the oil.
32772813|NCT04979689|Experimental|Intensive physical therapy|Intensive session
32772814|NCT04979689|Other|Non intensive physical therapy|Non intensive session
32772815|NCT05538377|Experimental|Focal Vibration|
32772816|NCT05538377|Active Comparator|Control Group|
32772817|NCT03822871|Experimental|Cohort A-J|Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled.
32772818|NCT03822871|Experimental|Cohort K - at Recommended Phase 2 Dose|Cohort F: Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled at the recommended phase 2 dose.
32772819|NCT05544383|Experimental|Intervention group|Interdisciplinary Pain Education Program and conventional physical therapy treatment
32772820|NCT05544383|Active Comparator|Comparison group|Conventional physical therapy treatment
32772821|NCT05544305|Experimental|Digitised Home Based Care pathway|The investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), that delivers self-management support and clinical expertise to the patient's home, supported by digitally-enabled remote monitoring with a wrist-worn sensor, the Parkinson's Kinetograph, and digitally-delivered questionnaires, to replace the current pen-and-paper processes.
32772822|NCT04425551|Active Comparator|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
32772823|NCT04425551|No Intervention|Untreated|The lateral eye was observed as control.
32772824|NCT03818035|Experimental|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
32901886|NCT05621642|Experimental|Online Group|Trainings will be given to the intervention group patients by the researchers. Respiratory, balance and strengthening exercises suitable for the patients will be applied over an online platform under the supervision of a physiotherapist.
32772825|NCT03818035|Experimental|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder [SRe]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score >5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
32772826|NCT03818035|Experimental|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
32772827|NCT03818035|Experimental|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score <3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 116 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to [>=] 3) at week 68 or PASI >5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
32772828|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
32772829|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
32772830|NCT05544149|Experimental|TRT|Patients with es-SCLC after first line treatment with immune checkpoint inhibitors will be treated with thoracic radiotherapy.
32772831|NCT05535491|Experimental|GROUP 1|BREATHING EXERCISE GROUP
32772832|NCT05535491|No Intervention|GROUP 2|CONTROL GROUP
32772833|NCT05535413|Experimental|UDT1 combined with capecitabine|
32772834|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate"
32772835|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate"
32772836|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate"
32772837|NCT05537909|Experimental|Patients|adult patients with aseptic abscess syndrome
32772838|NCT05537909|Experimental|control|control An adult person living in the same environment as the case.
32772839|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
32772840|NCT05699135||Canadian Patients with Advanced Urothelial Carcinoma|Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks
32772841|NCT03791593|Experimental|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
32772842|NCT03791593|No Intervention|Control group|The patient will continue guideline-driven medical treatment
32772843|NCT04732715|Experimental|CaRE Course|Black American caregivers of PLWD will participate in the CaRE Course.
32772844|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
32772845|NCT05537831|Active Comparator|Study Intervention Group (Ultrasound)|The ultrasound probe will be used for real-time needle and hematoma localization using the linear probe. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
32772846|NCT05537831|No Intervention|Study Control Group (Landmark)|The ultrasound probe will be in place on the patient's arm to maintain single blinding of the study. The ultrasound machine will not be used for needle and hematoma localization. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
32772847|NCT05543993||COVID-19 booster in pregnancy|Pregnant singletons who have received COVID-19 booster in pregnancy
32772848|NCT05543993||COVID-19 booster in breastfeeding|Breastfeeding individuals who have received COVID-19 booster while breastfeeding
32772849|NCT03765619|Experimental|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
32772850|NCT03765619|No Intervention|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
33401654|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
33401655|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
32772851|NCT05698043|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3tablets under fasting condition~Period 4: CKD-386(5)- A single oral dose of 1 tablet under fasting condition"
32772852|NCT05698043|Experimental|Sequence 2|"Period 1: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
32772853|NCT05537675||20 patients with meningioma|20 meningioma patients will be included in this study, 10 of whom will have been treated with Lutathera®.
32772854|NCT05537675||10 patients will have been treated with Lutathera®.|10 patients of the 20 will have been treated with Lutathera®.
32772857|NCT04979845|Experimental|Telerehabilitation|
32772858|NCT04979845|Active Comparator|Video exercise|
32772859|NCT05543759||Cases|Children aged 6-59 months of both sexes from households established permanently in the catchment area of the selected health posts or health centers, meeting the SAM or MAM acute malnutrition case definitions described below with no medical complications and disability, and whose caregiver has granted consent to participate.
32772860|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
32772861|NCT03062215|No Intervention|Control Group|Waiting list
32772862|NCT05543603|Experimental|Chlorhexidine 0,12%|15 ml 0,12% Chlorhexidine, one minute rinse.
32772863|NCT05543603|Experimental|Chlorhexidine 0,20%|15 ml 0,20% Chlorhexidine, one minute rinse.
32772864|NCT05543603|Experimental|Gingilacer Encias Delicadas|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse.
32772865|NCT05543603|Placebo Comparator|Distilled Water|15 ml Distilled Water, one minute rinse.
33267383|NCT05183139|Experimental|Cohort A: Ixazomib 4 mg + Pomalidomide 4 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with pomalidomide 4 mg, capsules, orally from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of pomalidomide or dexamethasone can start at that dose level in the study.
33267384|NCT05183139|Experimental|Cohort B: Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with lenalidomide 25 mg capsules, orally, from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally, on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of lenalidomide or dexamethasone can start at that dose level in the study.
32772866|NCT04979923|Experimental|Lidocaine group|
32772867|NCT04979923|Placebo Comparator|Salbutamol group|
32772868|NCT04979923|Active Comparator|Beclomethasone plus salbutamol|
32772869|NCT05543525||Male Athletes|Athletes who underwent a pre-participation medical evaluation in the Nancy University Hospital between January 1st, 2013, and January 1st, 2020.
32772870|NCT05543525||Control Group|A subgroup of 161 participants in a population-based cohort (STANISLAS Cohort) restricted by age and sex to create a control group in the current analysis.
32772871|NCT04979767||Sepsis|I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days
32772872|NCT04979767||Control|I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days
32772873|NCT04434937|Experimental|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
32772874|NCT04519411|Experimental|Intubated pediatric patients with COVID-19 respiratory failure|
32772875|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
32772876|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
32772877|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
32772878|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
32772879|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
32772880|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
32772881|NCT04979221|Experimental|Cyproheptadine and usual care|"Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.~Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution."
32772882|NCT04979221|No Intervention|Usual care|Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.
32772883|NCT04503109|Other|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
32772884|NCT05697887|Experimental|The feasibility of the ketogenic diet|The purpose of this study was to verify the feasibility of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered feasible if he (or she) did not have the contra-indication for the ketogenic diet
33267385|NCT00999765||Bipolar Disorder - stable|
33267386|NCT03830567||Pharmacist prescription|
33267387|NCT03830567||Clinician prescription|
32772885|NCT05697887|Experimental|the tolerability of the ketogenic diet|The purpose of this study was to verify the tolerability of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered tolerant if he (or she) did not have any side effects caused by the ketogenic diet
32772886|NCT05697887|Experimental|the efficacy of the ketogenic diet|The purpose of this study was to verify the efficacy of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. Patients were considered responders when a 50% seizure frequency was reached.
32772887|NCT05697809|Experimental|A1: OXU-001 / Mid dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
32772888|NCT05697809|Experimental|A2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied.
33267388|NCT00997659|Experimental|chromium picolinate|
32772889|NCT05697809|Experimental|B1: OXU-001 / Mid Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
32772890|NCT05697809|Experimental|B2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied. This dose may be adpated based on the outcome of a Week 6 data review of Part A
32772891|NCT05697809|Active Comparator|B3: Ozurdex®|A single treatment with intravitreal Ozurdex®
32772892|NCT01671085|Experimental|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
32772893|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
32772894|NCT05537363|No Intervention|Healthy adults|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
32772895|NCT05537363|No Intervention|Healthy elderly and mild cognitive impairment elderly|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
32772896|NCT05537363|Active Comparator|Mild cognitive impairment elderly with health education|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
32772897|NCT05537363|Experimental|Mild cognitive impairment elderly with multicomponent training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
32772898|NCT05537363|Experimental|Mild cognitive impairment elderly with agility training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
33267389|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
33267390|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
33267391|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:~Serum albumin level < 30g/L.~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
33267392|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
33267393|NCT05300919|Experimental|MBC for depressive and manic symptoms|"Measurement-based care (MBC) is a clinical strategy involving consistent assessment of clinical status and using those findings to drive clinical decision making. MBC involves clinic staff providing the measure to the patient at each visit which the patient completes and returns, staff enters results into the electronic medical record, clinician reviews current results and compares to past results, and discusses with the patient.~The experimental condition patients will receive MBC for manic and depressive symptoms."
33267394|NCT05300919|Active Comparator|MBC for depressive symptoms only|The active comparator arm patients will receive MBC for depressive symptoms.
33267395|NCT03827213|Experimental|Single shot Interscalene Nerve Block|This group will receive an interscalene nerve block. This will be administered as a single 20mL injection consisting of a mixture of 10mL of Exparel and 10mL of 0.5% bupivacaine hydrochloride.
33267396|NCT03827213|Active Comparator|Indwelling Interscalene Catheter|"This group will receive an indwelling interscalene catheter placed posterior to C5-C6 nerve roots (between the shoulders) and administered 15 mL of 0.5% ropivacaine plain for the block with no superficial cervical block. The On-Q pump will be set at a rate of 4 mL/hr."
33267397|NCT00999999|Active Comparator|Standard|Standard dural closure
33267398|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
32772899|NCT05537363|Active Comparator|Healthy elderly with health education|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
32772900|NCT05537363|Experimental|Healthy elderly with multicomponent training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
32772901|NCT05537363|Experimental|Healthy elderly with agility training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
32772902|NCT03063931|Experimental|magnesium|
32772903|NCT03063931|Placebo Comparator|placebo|
33267399|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
33267400|NCT00997815|Placebo Comparator|Placebo|Using normal saline
33267401|NCT04078139|Experimental|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
33267402|NCT04078139|Active Comparator|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
33267403|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
33267404|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
32772904|NCT03980483|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and more than or equal to (>=)5 mg/week folic (or folinic) acid as standard of care (SoC).
33267405|NCT04077983|Experimental|combined therapy using nab-paclitaxel and gemcitabine chemo|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
33267406|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
32772905|NCT03980483|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
32772906|NCT03980483|Active Comparator|Tofacitinib|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
33267408|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
33080060|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
32772907|NCT03980483|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
33267409|NCT03823469|Active Comparator|Intervention: Nutritional counseling + CCTP|Nutritional counseling + Culinary Coaching Telemedicine Program (CCTP)
32772908|NCT03980483|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
32772909|NCT03980483|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
32772910|NCT04979455||Exertional heat illness|Participants who experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
32772911|NCT04979455||Control|Participants who do not experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
33267410|NCT03823469|Active Comparator|Control: Nutritional counseling only|Two 30-minute nutritional counseling sessions
33080061|NCT00409253|Active Comparator|Urapidil|
32772912|NCT03621631|Experimental|optimized Tai Chi intervention|optimized Tai Chi intervention
32772913|NCT03621631|Active Comparator|traditional Tai Chi intervention|traditional Tai Chi intervention
32772914|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
32772915|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
33267411|NCT04000191|Active Comparator|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
33267412|NCT04000191|Experimental|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
33267413|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
33080062|NCT00409253|Active Comparator|Nicardipine|
33080063|NCT00212550||TB diagnosis|
33080064|NCT00188825|Experimental|basiliximab|
33267414|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
33267415|NCT01000233|Placebo Comparator|Placebo|
33080065|NCT00188825|Placebo Comparator|placebo|
33080066|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
33080067|NCT00219882|Experimental|1|standardized turmeric root extract
33267416|NCT04075955|Experimental|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
33267417|NCT04075955|Active Comparator|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
33080068|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
33080069|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
33080070|NCT00189020|No Intervention|Control|Control group
33080071|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
33080072|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
33080073|NCT00189176|Experimental|Tetrathiomolybdate|
33080074|NCT00212862||Patients with chemotherapy induced anemia|
33080075|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
32772916|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
32772917|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
32772918|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
32772919|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
32772920|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
32772921|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
33080076|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
33080077|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
32772922|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
32772923|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
32772924|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
32772925|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
32772926|NCT03063775|No Intervention|5. Spongostan®|
32772927|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
33080078|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
33080079|NCT00219999||normal|normal, healthy volunteers
33080080|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
33080081|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
33080082|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
33080083|NCT00212979||non intervention study|
33080084|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
33080085|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
33080086|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
33080087|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
33080088|NCT00189839|Active Comparator|1|
33080089|NCT00189839|Experimental|2|
33080090|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
33080091|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
33080092|NCT00220311|Experimental|Arm 1|
32772928|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
32772929|NCT04978753|Experimental|treatment|Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)
32772930|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
32772931|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977* height-4.2423"
32772932|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
32772933|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
33080093|NCT00189917|Experimental|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
33080094|NCT00189917|Experimental|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
33080095|NCT00189917|Experimental|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
33080096|NCT00189917|Experimental|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
33080097|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
33080098|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
33080099|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
33080100|NCT00213252|Experimental|1|
33080101|NCT00213252|Active Comparator|2|
33080102|NCT00213291|Experimental|1|
33080103|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
33080104|NCT04722770||Pediatric patients with possible ear infections|Pediatric patients presenting with otitis media (acute otitis media or otitis media with effusion) will be imaged with the PhotoniCare OtoSight.
33080105|NCT00412620|Placebo Comparator|Sugar Pill|
33080106|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
33080107|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
33080108|NCT00412620|Experimental|Group 2 - ABT-925|
33080109|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
32772934|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
32772935|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
33080110|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
33080111|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
33080112|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
33080113|NCT00190229|Experimental|1|Cyclophosphamide
33080114|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
33080115|NCT00190307|Experimental|1|Aspirin:KARDEGIC
33080116|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
33080117|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
33080118|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
33080119|NCT00190385|Active Comparator|A|
33080120|NCT00190424|No Intervention|control|
33267418|NCT04076033|Experimental|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
33267419|NCT04076033|Experimental|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
33267420|NCT03814187|Experimental|Inclisiran|"Inclisiran sodium 300 milligrams (mg) will be administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990.~*Subjects who received blinded placebo in the feeder study will receive blinded inclisiran and subjects who received blinded inclisiran in the feeder study will receive blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study will not receive any injection of study drug on Day 1. Their first dose of study medication will be at day 90"
33267421|NCT04066283||Older transgender women|This cohort will consist of transgender women aged 50-75 years old who have taken estradiol and spironolactone for at least one year.
33267422|NCT04066283||Younger transgender women|This cohort will consist of transgender women aged 18-40 years old who have taken estradiol and spironolactone for at least one year.
33080121|NCT00190424|Experimental|CpG-ODN|
33080122|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
33080123|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
33080124|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
33080125|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
33080126|NCT00190580|Experimental|1|
33080127|NCT00190580|Experimental|2|
32901887|NCT05621642|Active Comparator|Offline Group|The exercises will be video recorded gradually every two weeks and the exercise program of each week will be sent to the patient. The patient will do respiratory, balance and strengthening exercises accompanied by video.
33080128|NCT00220584|Experimental|Open donepezil|open donepezil
33080129|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
33080130|NCT00122993|No Intervention|2|Control group
33080131|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
33080132|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
33080133|NCT00213759|Active Comparator|groupe filigrastin|
33080134|NCT00213759|Placebo Comparator|groupe placebo|
33080135|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
33080136|NCT00123032|No Intervention|2|A control group will not receive any intervention.
33080137|NCT00221013|Experimental|Higher intensity CRRT regimen|
33080138|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
33080139|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
33080140|NCT00213954|Other|axillary block|Locoregional anesthesia selection
33080141|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
33080142|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
33080143|NCT00191126|Other|A|
33080144|NCT00191126|Experimental|B|
33080145|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
33080146|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
33080147|NCT00191243|Experimental|A|
33080148|NCT00191243|Experimental|B|
33080149|NCT00214032|Experimental|1|pycnogenol daily
33080150|NCT00214032|Placebo Comparator|2|placebo daily
33080151|NCT00123266|Experimental|Active|
33080152|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
33080153|NCT00123305|Experimental|1|
33080154|NCT00123305|Experimental|2|
33080155|NCT00123305|Experimental|3|
33080156|NCT00123305|Placebo Comparator|4|
33080157|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
33080158|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
33080159|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
33080160|NCT04722965|Active Comparator|Fistulotomy with marsupialization|40 patients with a simple low transsphincteric anal fistula. A fistulotomy with marsupialization is performed.
33080161|NCT04722965|Active Comparator|Fistulotomy with open wound|40 patients with a simple low transsphincteric anal fistula. A fistulotomy leaving the wound open is performed.
33080162|NCT00221325|Experimental|Rituximab Plus MTX|
33267423|NCT04075799|Experimental|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
32772936|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
32772937|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
32772938|NCT04978597|Experimental|Opicapone|OPC will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
33267424|NCT00484198|Placebo Comparator|1|
33267425|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
33267426|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
32772939|NCT04978597|Placebo Comparator|Matching placebo|Matching placebo will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
32772940|NCT04978441||Type 1 diabetes mellitus (T1DM)|"Males or females above 18 years old~Patients with a prior medical history diagnosis of T1DM~Patients who are using a continuous glucose monitor (CGM or FGM)"
32772941|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
32772942|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
32772943|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
33267427|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
33267428|NCT04077905|Experimental|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
33267429|NCT04076501|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
33267430|NCT04076501|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
32772944|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
32772945|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
32772946|NCT03467191|Placebo Comparator|Placebo Beverage|
32772947|NCT04328779|Experimental|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
32772948|NCT04328779|Active Comparator|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
33267431|NCT04077749|Experimental|Probiotic|
32772949|NCT04328779|Active Comparator|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
32772950|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
32772951|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
32772952|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
33267432|NCT04077749|Placebo Comparator|Placebo|
33267433|NCT04282187|Experimental|Treatment (decitabine, ruxolitinib, fedratinib)|Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID or fedratinib PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33080163|NCT00123500|Active Comparator|1|Worksite Intervention
33267434|NCT01015846|Experimental|Intervention|
33267435|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
33267436|NCT04471246|Experimental|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
33267437|NCT04471246|Active Comparator|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
33267438|NCT04278521|Other|Unipolar Depression|Patients diagnosed with unipolar depression.
33267439|NCT04166110|Active Comparator|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
33267440|NCT04166110|Experimental|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).~Minimum of duration of antibiotic treatment: 3 days."
33080164|NCT00123500|Placebo Comparator|2|Control Group
33267441|NCT04276259|Experimental|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
33267442|NCT04276259|Experimental|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
33267443|NCT04276259|Experimental|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
33267444|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
33267445|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
33267446|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
33267447|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
33267448|NCT05062109|Experimental|Multimodal geriatric prehabilitation|
32772953|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
32772954|NCT04977973|Experimental|Intervention group: Body Image|Participants will complete a 9-day self-guided programme on body image delivered via a mobile phone application with daily exercises informed by cognitive-behavioural and self-compassion principles.
32772955|NCT04977973|Active Comparator|Control group|Participants will complete a 9-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
32772956|NCT04285879|Experimental|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR [18]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
32772957|NCT04285879|No Intervention|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
32772958|NCT04977661|Active Comparator|Group1|Group I (n = 34) received 400 IU Vitamin E (Vitamin E 400 IU®, MEPACO Pharmaceutical Company, Sharqia, Egypt) twice daily for 3 month
32772959|NCT04977661|Active Comparator|Group2|Group II (n =34) received 250 mg Ursodeoxycholic acid (Ursofalk 250 mg®, MINAPHARM Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
32772960|NCT04977661|Active Comparator|Group3|Group III (n = 34) received 400 mg sustained release (SR) Film-Coated Tablets of pentoxifylline (Trental 400 mg®, SANOFI Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
33080165|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
33267449|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
33267450|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
33267451|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
33267452|NCT05057117|Active Comparator|Botulinum toxin A|One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla
33267453|NCT05057117|Active Comparator|Microwave thermolysis|One standard treatment (energy level 5) with microwave thermolysis in one axilla
33267454|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
33267455|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
33080166|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
33267456|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
33267457|NCT01014520|Experimental|Gabapentin|Neurontin
33267458|NCT01014520|Experimental|Amitriptyline|Elavil
33267459|NCT04040699|Experimental|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
33267460|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
33267461|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
33267462|NCT04267367|Experimental|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
33267463|NCT04267367|No Intervention|Usual care|The usual care arm will be only provided general education.
33267464|NCT04266574|Experimental|Near Infrared Spectroscopy (NIRS)|
33267465|NCT04266574|Active Comparator|Standard Care|
33267466|NCT04035005|Experimental|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
33267467|NCT04035005|Placebo Comparator|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
33267468|NCT01016002|Experimental|Intervention|
33267469|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
33267470|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
32772961|NCT04977427|Active Comparator|Prednisolone Arm|Standard post-cataract surgery therapy arm; acts as control in each patient.
32772962|NCT04977427|Active Comparator|Dextenza Arm|Investigational arm to compare the effectiveness of the Dextenza insert to standard therapy.
32772963|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 4 weeks prior to and during the testing period.
32772964|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 4 weeks prior to and during the testing period.
32772965|NCT04275895|Experimental|Prematurely born Children|"Evaluation of different attention or/and postural activities :~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
32772966|NCT04275895|Active Comparator|Term born Children|"Evaluation of different attention or/and postural activities~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
33080167|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
33080168|NCT00221442|Placebo Comparator|Sugar pill|fake pill
33080169|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
33080170|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
33080171|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
33267471|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
33267472|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
33267473|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
33267474|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.~They will also undergo a whole body DXA (intervention) during the study day."
33267475|NCT04265261|Placebo Comparator|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
33267476|NCT04265261|Experimental|Group B|Participants will receive a low oral dose of RG7774 QD
33267477|NCT04265261|Experimental|Group C|Participants will receive a high oral dose of RG7774 QD
32772967|NCT03063697||patients who check the safety data after taking Dilatrend SR|
32772968|NCT04977505||Pushlock|Patients with recurrent shoulder dislocation received surgery fixed by pushlock
32772969|NCT04977505||Gryphon|Patients with recurrent shoulder dislocation received surgery fixed by Gryphon
32772970|NCT04261855|Experimental|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
33267478|NCT05325671|Experimental|transarticular multimodal drug infiltration|infiltration the mixture into intraarticular by catheter guided approach
33267479|NCT05325671|Active Comparator|periarticular multimodal drug infiltration|"3 location of infiltration~hip capsule~gluteus medius and short external rotator~gluteus maximus"
33267480|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
32772971|NCT04261855|Experimental|Arm B|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
32772972|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
33267481|NCT03778229|Placebo Comparator|placebo + savolitinib|placebo + savolitinib
33267482|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33267483|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
33267484|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
33267485|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
32772973|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
32772974|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
33080172|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
33080173|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
33080174|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
33080175|NCT00123656|Active Comparator|1|fluticasone
32772975|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
32772976|NCT04235257|Experimental|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
32772977|NCT04235257|Experimental|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
33080176|NCT00123656|Active Comparator|2|esomeprazole
33080177|NCT00221715|Experimental|1|bypass by autologous saphenous vein
33080178|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
33080179|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
33080180|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
32772978|NCT04977193|Experimental|Treatment group|
33267486|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
33080181|NCT00214773||Observational|No intervention. This is an observational program.
33080182|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
33267487|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
33267488|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
33080183|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
33080184|NCT02962440|Experimental|Somapacitan|
33080185|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
33080186|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
33080187|NCT00412698|Experimental|1|
33080188|NCT00412698|Placebo Comparator|2|
33080189|NCT00123929|Active Comparator|1|doxorubicin
33080190|NCT00123929|Other|2|docetaxel
33080191|NCT00475033|Experimental|1|
33080192|NCT00475033|Active Comparator|2|
33080193|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
33080194|NCT00412776|No Intervention|2|Best Supportive Care
33267489|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
33267490|NCT03775421|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
33267491|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
33267492|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
33267493|NCT01014676|Active Comparator|Probiotic milk|
33267494|NCT01014676|Placebo Comparator|Standard milk|
33080195|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
33080196|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
33267495|NCT05325437|Experimental|Experimental Group|Laparoscopic splenectomy and azygoportal disconnection
33267496|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
33267497|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
33267498|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
33267499|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
33267500|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
33267501|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
33267502|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
33080197|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
33267503|NCT01019746|Experimental|control propofol administration|
33267504|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
33267505|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
33267506|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
33267507|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
33267508|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
33267509|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
33080198|NCT00192140|Active Comparator|1|FluMist
33267510|NCT03764033|Experimental|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
33267511|NCT03764033|Active Comparator|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
33267512|NCT00205777|Active Comparator|A|
33267513|NCT00205777|Placebo Comparator|B|
33267514|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
33267515|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
33267516|NCT01004055|Experimental|Procellera™ Wound Dressing|
33267517|NCT01004055|Active Comparator|ACTICOAT™|
33267518|NCT01004055|Active Comparator|Mepilex® Ag|
33267519|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
33267520|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
33267521|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
33267522|NCT00483652|Placebo Comparator|Placebo|Placebo control
33267523|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
33267524|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
33267525|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
33267526|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
33267527|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
33267528|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
33267529|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
33267530|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
33267531|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
33267532|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
33267533|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
33080199|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
33267534|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
33267535|NCT03996473|Experimental|Phase 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
33267536|NCT03996473|Experimental|Phase 2 Cohort 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
33267537|NCT03996473|Active Comparator|Phase 2 Cohort 1: Pembrolizumab alone|Participants will receive pembrolizumab every 3 weeks
33267538|NCT03996473|Experimental|Phase 2 Cohort 2: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
33267539|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
32772979|NCT04977115|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
33080200|NCT00124046|Active Comparator|Surgical|
33267540|NCT04075565|Active Comparator|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
33267541|NCT04075565|Experimental|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
33267542|NCT04075565|No Intervention|Control|the participants are exposed to a normoxic and normobaric environment.
33267543|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
32772980|NCT04977115|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
32772981|NCT04224415|Other|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
32901888|NCT05011266|Experimental|Buprenorphine-naloxone|Buprenorphine/naloxone 5.7 mg /1.4 mg/day sub-lingual tablets
32901889|NCT05011266|Placebo Comparator|Placebo|placebo sub-lingual tablet
33080201|NCT00124046|Active Comparator|Medical Treatment|
33267544|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
33080202|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
33267545|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
33267546|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
33267547|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
33267548|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
33267549|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time~Esophagus~Skin near to temporal artery~Skin near to carotid artery"
33267550|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
33267551|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
33267552|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
33267553|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
33267554|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
33267555|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
33267556|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
33267557|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
33267558|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
33267559|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
33267560|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
33267561|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
33267562|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
33267563|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
33267564|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
33080203|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
33080204|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
33267565|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
32772982|NCT04869085|Experimental|e-PainSupport Condition|e-PainSupport is a self-administered, digital pain application. Over the course of the two weeks, caregivers and patients will record the severity of patient's pain and how much pain medicine they use to control patient's pain in the e-PainSupport application.
33080205|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
33080206|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
33080207|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
33080208|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
33080209|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
33080210|NCT00124124|Experimental|2|KLH, peptides plus Montanide
33267566|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
33267567|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
33267568|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.~Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.~This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
33267569|NCT03954509||questionnaires|"From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:~to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;~reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.~Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
33267570|NCT03996772|Experimental|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:~Direct thrombin inhibitor: Dabigatran~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
33267571|NCT03996772|No Intervention|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
33267572|NCT05251181|Active Comparator|Normal saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
33267573|NCT05251181|Experimental|Centhaquine|Hypovolemic shock patients will be provided the standard of care. Following randomization centhaquine (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
33080211|NCT00474253|Experimental|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
33080212|NCT00474253|Active Comparator|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
33080213|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
33080214|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
32772983|NCT04869085|No Intervention|Standard Care Condition|Patients and caregivers will be given a paper copy of the same list of resources for pain management included in the Education Module of the e-PainSupport condition at baseline.
33267574|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
33267575|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
33267576|NCT04228367|Experimental|Meniscal repair|Patients in need of meniscal repair
33267577|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
33267578|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
32772984|NCT04223401|Experimental|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
33267579|NCT04075643|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
33267580|NCT04075643|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
33267581|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
33267582|NCT01004445|Experimental|Arm 1|
33267583|NCT01004445|Experimental|Arm 2|
33080215|NCT00192218|Experimental|1|FluMist
33267584|NCT01004445|Placebo Comparator|Arm 3|
33080216|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
33267585|NCT03739931|Experimental|Arm A: mRNA-2752|Participants will be administered mRNA-2752 at an applicable dose as monotherapy.
33267586|NCT03739931|Experimental|Arm B: mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab.
33267587|NCT03739931|Experimental|Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab.
33267588|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
33267589|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
33267590|NCT04075019|Experimental|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
33267591|NCT04075019|Experimental|late intervention|students in intervention classrooms in grades 5 and 6 only
33267592|NCT04075019|Experimental|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
33267593|NCT04075019|No Intervention|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
33267594|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
32772985|NCT04223401|No Intervention|Control group|Patients in the control group will not undergo prehabilitation.
32772986|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
33267595|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
32772987|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
33080217|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
33080218|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
33267596|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
33267597|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
33267598|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
33267599|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
33267600|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
33267601|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
33267602|NCT04077203|Sham Comparator|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
33267603|NCT04077203|Experimental|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
33267604|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
33267605|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
33267606|NCT03944915|Experimental|ARM 1|Induction Therapy
33267607|NCT03944915|Experimental|ARM 2|Radiation therapy with chemotherapy
33267608|NCT05674019|Experimental|Neurodevelopmental Group|The volunteer presents at least 2 of 12 neurodevelopmental crieria
33267609|NCT05674019|Active Comparator|Non-neurodevelopmental Group|The volunteer does not present any of the 12 neurodevelopmental crieria
32772988|NCT03239899|Experimental|Pembrolizumab arm|Pembrolizumab 200mg will be administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
32772989|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
32772990|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
33267610|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
32772991|NCT04976569|Experimental|DBS Regulation Group|All participants will receive STN-DBS sleep regulation.
32772992|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
32772993|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
32772994|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
33080219|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
33080220|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
33080221|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
33267611|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
33080222|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
33080223|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
33267612|NCT05228249|Experimental|Treatment (loncastuximab tesirine, BEAM chemotherapy)|"PART I (CONDITIONING): Patients receive loncastuximab tesirine IV on day -7, carmustine IV over 2 hours on day -7, etoposide IV over 1-2 hours BID days -6, -5, -4, and -3, cytarabine IV over 1 hour BID on days -6, -5, -4, and -3, and melphalan IV over 15-20 minutes on day -2. Patients undergo peripheral blood ASCT per standard practice on day 0.~PART II (MAINTENANCE): Beginning 30-90 days after ASCT, patients receive loncastuximab tesirine IV Q3V for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
33267613|NCT03935321|Active Comparator|Patients with acute cervical spinal cord injury: NG-101|
33267614|NCT03935321|Placebo Comparator|Patients with acute cervical spinal cord injury: Placebo|
33267615|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When both needles were positioned inadequately for a facet joint."
33267616|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~when one of the needles for a facet joint medial branch was placed inadequately."
33267617|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When all needles were placed adequately.'"
33267618|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
33267619|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
33267620|NCT04076267||Patients with cancer|
33267621|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
33267622|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
33267623|NCT04218695|Experimental|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
33267624|NCT04218695|Placebo Comparator|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
33267625|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
33267626|NCT01000935|No Intervention|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
33267627|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
33267628|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
33267629|NCT05674331|Active Comparator|socket seal group|After tooth extraction a soft tissue pounch is sutured above the extraction socket.
33267630|NCT05674331|Experimental|XSD+ socket seal group|After tooth extraction for the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
33267631|NCT05674331|Experimental|XSD+ ATB+socket seal group|After tooth extraction, the tooth will be grinded and after the sterilization procedure it will be filled back to the extraction socket. For the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
33267632|NCT00998673|Experimental|Arm 1|
33267633|NCT00998673|Other|Arm 2|
33267634|NCT03967561|Experimental|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
33267635|NCT03967561|Experimental|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
33267636|NCT04214249|Experimental|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
33267637|NCT04214249|Active Comparator|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
33267638|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
32772995|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
32772996|NCT02510001|Experimental|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
33080224|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
33080225|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
32772997|NCT02510001|Experimental|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
33267639|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
33267640|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
33267641|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
33267642|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
33267643|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
33267644|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
33267645|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
33267646|NCT02580929|Experimental|radiation|
33267647|NCT02580929|No Intervention|no radiation|
33267648|NCT01016470|Placebo Comparator|B|Placebo
33267649|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
33267650|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
33080226|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
33267651|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
33267652|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
33267653|NCT04460326|Active Comparator|Group 1 insulin glargine and Novolog|Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal BG is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
33267654|NCT04460326|Experimental|Group 2 insulin glargine and Fiasp|Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
33267655|NCT00998829||Study population|The group comprises the entire study population
33267656|NCT04205357|Other|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
33267657|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
33267658|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
33267659|NCT02580773|Other|Prophylactic anticoagulation|
33267660|NCT02580773|Experimental|Curative anticoagulation|
33267661|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
33267662|NCT05032937|Experimental|ECMR|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.
33267663|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
33267664|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
33267665|NCT03634397|Experimental|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
33267666|NCT03634397|Sham Comparator|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
33267667|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
33267668|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
33267669|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
33267670|NCT05089695|Experimental|Helmet Noninvasive ventilation (NIV)|"Patients in helmet noninvasive ventilation group will receive continuous helmet pressure support ventilation for at least 16 hours/day in the first 2 calendar days. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Each patient will be connected to a mechanical ventilator ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV-NIV mode, with the following suggested settings [34-38]:~initial pressure support=12 cmH2O and adequate to permit a peak inspiratory flow of 100 l/min;~positive end-expiratory pressure=12 cmH2O.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Inspiratory flow trigger = 2 l/min or according to the practice of each institution;~fastest pressurization time;~expiratory trigger: 10-50% of the maximum inspiratory flow, eventually modified to avoid double triggering;~maximum inspiratory time 1.2 second."
33267671|NCT05089695|Experimental|Helmet continuous airway pressure (CPAP)|"Patients in CPAP group will receive continuous helmet CPAP for at least 16 hours/day in the first 2 calendar days. Continuous CPAP without interruptions will be strongly encouraged in the first 48 hours of treatment. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~Continuous air flow>45 l/min.~Bi-tube circuit with no humidification, Y-piece with heat and moisture exchanger, or active heating and humidification with humidification chamber temperature set at 31 °C, 34 °C or 37 °C according to patients' comfort.~Expiratory positive end-expiratory pressure valve set to achieve PEEP=12 cmH2O.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%."
33267672|NCT05089695|Active Comparator|High-flow nasal oxygen|"Initial set flow will be 50-60 l/min and flows will be decreased. in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber will be set at 31 °C, 34 °C or 37 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Weaning the patient from high-flow will be considered only after 48 hours from enrolment and will be discouraged until the patients is considered for ICU discharge."
33267673|NCT05674565|Experimental|Loading dose only|Those receiving only the loading dose of magnesium sulphate 4 gm infusion over 20 minutes therapy within one hour before delivery without the maintenance dose
32772998|NCT02510001|Experimental|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
32772999|NCT02510001|Experimental|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
32773000|NCT02510001|Experimental|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
33080227|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
32773001|NCT02510001|Experimental|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
32773002|NCT02510001|Experimental|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
32773003|NCT02510001|Experimental|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
32773004|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
32773005|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
32773006|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
32773007|NCT04925505||BPB success|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the SUCCESS (or failure) of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
32773008|NCT04925505||BPB failure|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the (success or) FAILURE of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
33080228|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
33080229|NCT04571437|Active Comparator|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
33267674|NCT05674565|Experimental|Loading plus maintenance dose|Receiving magnesium sulphate loading 4 gm infusion over 20 minutes, followed by maintenance therapy 1gm per hour infusion until delivery or completion of 24 hours, the sooner.
33267675|NCT05674565|No Intervention|Control|comparable number of women who did not receive magnesium sulphate neuroprotection for any reason
33267676|NCT01001481||001|
33267677|NCT03927053||HIV infected youth who use marijuana only|
33267678|NCT03927053||HIV infected youth who use tobacco only|
32773009|NCT02475369|Other|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
32773010|NCT02475369|Other|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
33267679|NCT03927053||HIV infected youth who use tobacco and marijuana|
33267680|NCT03927053||HIV infected youth with no substance use|
33080230|NCT04571437|Active Comparator|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
33267681|NCT03999645|Active Comparator|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
33080231|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
33080232|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
33267682|NCT03999645|Active Comparator|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
33267683|NCT05195801||Group with local anesthesia|The group that did not apply general anesthesia
33267684|NCT05195801||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
33267685|NCT05195801||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
33080233|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
33080234|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
33267686|NCT01001637|Active Comparator|curcumin|
33267687|NCT01001637|Placebo Comparator|Placebo|
32773011|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
33267688|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
32773012|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
33267689|NCT01005069|Experimental|Treatment I|
33267690|NCT01005069|Experimental|Treatment II|
33267691|NCT01005069|Experimental|Treatment III|
33267692|NCT01005069|Experimental|Treatment IV|
33267693|NCT01005069|Placebo Comparator|Placebo|
33267694|NCT01009125|Experimental|$2 cash incentive|
33267695|NCT01009125|Experimental|$5 cash incentive|
33267696|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
33267697|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
33267698|NCT01005147|Experimental|Tranexamic acid arm|
33267699|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
33267700|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
33267701|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
33267702|NCT01009359|Experimental|Arm 1|
33267703|NCT01009359|Experimental|Arm 2|
33267704|NCT01009359|Experimental|Arm 3|
33267705|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
33267706|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
33267707|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
33267708|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
33267709|NCT02580071|No Intervention|Control|Control group will receive standard of care
33267710|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
32773013|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
32773014|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
33267711|NCT05673941|Experimental|Creative movement|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
33267712|NCT05673941|No Intervention|Control group|The control group receives standard medical care and gets access to the intervention in digital form after the study has ended.
33267713|NCT01001949|Experimental|Wheat Bran Extract|
33267714|NCT01001949|Placebo Comparator|placebo|
33267715|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
33267716|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
33267717|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
33267718|NCT01005303|Placebo Comparator|Placebo|
33267719|NCT01005303|Active Comparator|Micronutrient|
33267720|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
33267721|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
33267722|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
32773015|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
32773016|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
32773017|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33267723|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
33267724|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
33267725|NCT05080335|Active Comparator|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
33267726|NCT05080335|Active Comparator|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
33267727|NCT05080335|Active Comparator|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth [until AFTER completion of the POST outcome measures]; lesson is led by a CIS-gender woman with extensive experience as an educator on transgender health
32773018|NCT05592431|Experimental|High Frequency Oscillatory Ventilation with Volume Guarantee (HFOV-VG )|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV-VG ) will be assessed by doppler cerebral blood flow velocity measurements
32773019|NCT05592431|Active Comparator|High Frequency Oscillatory Ventilation (HFOV)|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV) will be assessed by doppler cerebral blood flow velocity measurements
33267728|NCT05080335|No Intervention|No intervention control|Subjects randomized to this arm will complete the baseline assessment and the post assessment thirty days later, but just *before* receiving the intervention (TV).
33267729|NCT01002183|No Intervention|single arm|Fos-clin/Arte
33267730|NCT05734209|Experimental|Virtual, then real meal|Participant first had two lunch sessions eating virtual food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating real food (meal), with a wash-out period of three days.
33267731|NCT05734209|Experimental|Real, then virtual meal|Participant first had two lunch sessions eating real food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating virtual food (meal), with a wash-out period of three days.
32773020|NCT05537285|Experimental|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|Patients will receive individualized unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions. The target for stimulation will be individualized using the participant's fMRI scans by finding the region of the DLPFC most anti-correlated with the subgenual anterior cingulate cortex (sgACC). This target will be determined using e-field modeling and theta-gamma coupling.
33080235|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
33267732|NCT05154279|Active Comparator|intramyometrial Terlipressin|intramyometrial injection of Terlipressin in women undergoing laparoscopic myomectomy procedure
33267733|NCT05154279|Active Comparator|intramyometrial carbitocin|intramyometrial injection of Carbetocin in women undergoing laparoscopic myomectomy procedure
33267734|NCT05154279|Placebo Comparator|intramyometrial saline|intramyometrial injection of saline in women undergoing laparoscopic myomectomy procedure
33267735|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
33267736|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
33267737|NCT05734053||Nilotinib|patients prescribed with nilotinib in routine medical practice
33267738|NCT05733975|Other|Use of Decision Making Tool|Single Arm design, study team will deliver the tool to be used by the parent(s) to help guide them in discussion with their infant's clinicians.
33267739|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
32773021|NCT05537285|Active Comparator|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
32773022|NCT05537285|Sham Comparator|Sham Accelerated Intermittent Theta Burst Stimulation (sham)|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
33267740|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
33267741|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
33267742|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
33267743|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
33267744|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
32773023|NCT05537207|Experimental|study group|low level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs
32773024|NCT05537207|Experimental|control group|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will be described by their gynecologist.
32773025|NCT05537129|Experimental|Laparoscopic Total Gastrectomy|
32773026|NCT05537129|Active Comparator|Open Total Gastrectomy|
32773027|NCT05696171|Active Comparator|Manual insertion|Manual insertion of the cochlear implant
32773028|NCT05696171|Experimental|Robotized insertion|Robotic insertion of the cochlear implant
32773029|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
32773030|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
32773031|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
32773032|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
32773033|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
32773034|NCT04939311|Experimental|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
32773035|NCT04939311|Placebo Comparator|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
32773036|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
32773037|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
32773038|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
33267745|NCT05733741|Experimental|Preservative-free topical anesthetics group|Patients in this group will have the standard post-PRK treatment regimen in addition to the prescription of preservative-free topical anesthetics for pain control following single-step transepithelial PRK surgery in one eye.
33267746|NCT05733741|Placebo Comparator|Preservative-free artificial tears group|Patients in this group will have the standard post-PRK treatment regimen in addition to the prescription of preservative-free artificial tears as a placebo following single-step transepithelial PRK surgery in the other eye.
33267747|NCT01005771|Experimental|GF-001001-00 2%|
33267748|NCT01005771|Experimental|GF-001001-00 1%|
33267749|NCT01005771|Experimental|GF-001001-00 0.25%|
33267750|NCT01005771|Placebo Comparator|Placebo|
33267751|NCT01005849|Experimental|Protecflor|
33267752|NCT01005849|Placebo Comparator|Placebo|
33267753|NCT05733663||Adult patients diagnosed with coeliac disease|A group of paediatric or adult patients diagnosed with CD and started on a strict GFD, with baseline and a follow-up intestinal biopsy to assess histological and intraepithelial lymphogram at least 1-year after starting the GFD, and with increased γδ+ T-cells at baseline.
33267754|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
33267755|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
33267756|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
33267757|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
33267758|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
33267759|NCT01002651|Placebo Comparator|placebo|
33267760|NCT05733429|Experimental|eye cervical re-education|patients will receive eye cervical re-education three times a week for four weeks
33267761|NCT05733429|Experimental|motor imagery therapy|patients will receive motor imagery therapy three times a week for four weeks
33267762|NCT05733429|Active Comparator|conventional physical therapy|patients will receive conventional physical therapy three times a week for four weeks
33267763|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
33267764|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
33267765|NCT01002807|Other|dapagliflozin and Glucophage® XR|
32773039|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
32773040|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
33267766|NCT05733351|Experimental|Cohort A (Vudalimab, Abiraterone)|Patients receive vudalimab IV on days 1 and 15 plus abiraterone PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
33267767|NCT05733351|Experimental|Cohort B (Vudalimab, Enzalutamide)|Patients receive vudalimab IV on days 1 and 15 plus enzalutamide PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
33267768|NCT05733351|Experimental|Cohort C (Vudalimab, Docetaxel, Abiraterone)|Patients receive vudalimab IV on days 1 and 15, docetaxel IV on days 1 and 22 plus abiraterone PO QD of 6-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
33267769|NCT05215197|Experimental|intracochlear prf administration group|intracochlear prf administration group
33267770|NCT05733273|Active Comparator|Nordic Hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
33267771|NCT05733273|Experimental|Single leg hamstring bridge exercise program|The single-leg hamstring bridge is performed with the athlete lying on the ground with one heel supported by their partner, the hip in approximately 45° and the knee in approximately 20° of flexion. The participants cross their arms across the chest and push down through the heel to lift their buttocks off the ground. The participant should allow their buttocks to touch the ground momentarily and then the hip should be extended to 0°.
33267772|NCT05733273|Placebo Comparator|Control group, hamstring flexibility|Participant will lie supine and bend one knee towards their chest by flexing their hip. They will hold their hip in this position and then slowly straighten their knee until they feel a gentle stretch in their hamstring muscle. They will hold this for 30 seconds before repeating on the other side.
32773041|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
33080236|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
33267773|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
33267774|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
33267775|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
33267776|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
33267777|NCT05057637||Complete cohort|In all patients included in the study subsequent optical coherence tomography (OCT) measurements will be performed pre and post stent placement.
33267778|NCT01002963|Experimental|PF-04418948 30 mg|
33267779|NCT01002963|Experimental|PF-04418948 100 mg|
33267780|NCT01002963|Experimental|PF-04418948 300 mg|
33267781|NCT01002963|Experimental|PF-04418948 1000 mg|
33267782|NCT01002963|Experimental|PF-04418948 3000 mg|
33267783|NCT01002963|Experimental|PF-04418948 4500 mg|
33267784|NCT01002963|Experimental|PF-04418948 6000 mg|
33267785|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
33267786|NCT01006161|Experimental|Low dose SCH 527123|
33267787|NCT01006161|Experimental|Medium dose SCH 527123|
33267788|NCT01006161|Experimental|High dose SCH 527123|
33267789|NCT01006161|Placebo Comparator|Placebo|
33267790|NCT05733195||Women with GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At four time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery, and 6 weeks after delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. In the GDM group, blood samples were collected at the same time during routine visit 6 weeks after delivery. The relevant broad metabolomics and targeted vitamin profiles were also detected.
33267791|NCT05733195||Women with no-GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At three time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. The relevant broad metabolomics and targeted vitamin profiles were also detected.
33267792|NCT05733117|Active Comparator|NanoVitD|Oral nano form of the calciferol
33267793|NCT05733117|Active Comparator|ConvVitD|Conventional oral calciferol
33267794|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
33267795|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
32773042|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
32773043|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
32773044|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
32773045|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
32773046|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
32773047|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
32773048|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
32773049|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
33267796|NCT01003197||complication group < III|
33267797|NCT01003197||complication group >= III|
33267798|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
33267799|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
33267800|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
33267801|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
33080237|NCT04727294||MGUS, SMM, MM Patients or their Caregivers|"Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.~The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.~Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete."
33267802|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
33267803|NCT05732961|Experimental|Participants with gene mutations other than SF3B1|Participants with lower risk MDS or non-proliferative MDS/MPN with somatic splicing gene mutations other than SF3B1
32773050|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
32773051|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
32773052|NCT02506101|No Intervention|no intervention|untreated
32773053|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
32773054|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
33080238|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
33080239|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
33080240|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
33080241|NCT00192491|Active Comparator|2|FluMist
33267804|NCT05732961|Experimental|Participants with SF3B1 mutation|Participants with lower risk MDS or non-proliferative MDS/MPN with SF3B1 mutation who had received hypomethylating agents and or lenalidomide.
33080242|NCT00192491|Placebo Comparator|3|Placebo
33080243|NCT00192491|Active Comparator|1|FluMist with other solution
33267805|NCT01006395|Active Comparator|zoledronic acid|intervention
33267806|NCT01006395|Placebo Comparator|Placebo|
33267807|NCT03999801||All|All subjects that previously received RGX-314 in a parent study are enrolled into this arm.
33267808|NCT03999957|Other|Interventional Arm|Telehealth conferencing
33267809|NCT05732805|Experimental|BCD-217 (nurulimab + prolgolimab)|BCD-217 followed by prolgolimab 1 mg/kg monotherapy.
33267810|NCT05732805|Active Comparator|BCD-100 (prolgolimab)|Prolgolimab monotherapy.
33267811|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
33267812|NCT00615056|Experimental|C|AG-013736 (axitinib)
33267813|NCT00615056|Experimental|A|AG-013736 (axitinib)
33267814|NCT00615056|Active Comparator|D|bevacizumab (avastin)
33267815|NCT01003431|Experimental|1|RotaTeq™ + DTwP
33267816|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
33267817|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
32773055|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
32773056|NCT02505867|No Intervention|Control|No device provided
33267818|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
33267819|NCT01006473|No Intervention|Inactive control group|No intervention
33267820|NCT01006551|Experimental|Ziprasidone|
33267821|NCT05732727|Experimental|Experimental group|Antihypertensive algorithm based on diuretics agents : the clinicians will adjust the drug therapy according to the antihypertensive algorithm based on diuretics agents.
33267822|NCT05732727|Active Comparator|Control group|Standard of care : the clinicians will adapt the antihypertensive strategy according to his own standard of care which can be pharmacological or non-pharmacological therapies.
33267823|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
33267824|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
33267825|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
32773057|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
32773058|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
33267826|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
32773059|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
32773060|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
32773061|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
33267827|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
33267828|NCT00868556||1 episodic migraine sufferers|
33267829|NCT00868556||2 chronic migraine sufferers|
33267830|NCT00868556||3 non migraine sufferers (controls)|
33267831|NCT05732493|Experimental|short-course radiotherapy and immunotherapy|A total of 60 patients will receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the surgery.
33267832|NCT05732493|Active Comparator|chemotherapy|A total of 60 patients will receive 4 cycles of CAPOX chemotherapy ,then receive the surgery.
33267833|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
33267834|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
33267835|NCT01003587|Experimental|District health information package|
33267836|NCT01003587|No Intervention|No Intervention|
33267837|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
33267838|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
33267839|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
33267840|NCT00879320||1|Adults with ADHD
33267841|NCT00879320||2|Healthy adults without ADHD
33267842|NCT05232357|Experimental|Endoscopic nerve staining|Methylene blue (MB) solution was used as nerve staining agent. Routine endoscopic submucosal injection of MB solution for mucosal nerve staining was used to identify and evaluate the neural architecture and special morphology of normal gastrointestinal mucosa, adenoma and malignant lesions.
33267843|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
33267844|NCT05020275||Blood samples|Blood samples for further assays
33267845|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
33267846|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
33267847|NCT00873938||1-supervised|
33267848|NCT00873938||2 -unsupervised|
33267849|NCT05732337|Other|Poxclin Coolmousse|A cooling mousse for application to the skin supplied in a 100 mL plastic bottle with a pump (a foamer)
33267850|NCT05732259|Active Comparator|Percussion therapy group|"Group A would be given Conventional treatment along with percussion therapy with Theragun PRO (1750-2400 rpm).~•Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest"
33267851|NCT05732259|Active Comparator|Manual Myofascial Release technique group|Group B would be given Conventional treatment along with manual myofascial release technique for 90 sec continuous.
33267852|NCT04925102||GMFCS level I|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level I will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
33267853|NCT04925102||GMFCS level II|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level II will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
33267854|NCT04925102||GMFCS level III|Goal specific treatment protocol with respect to the problem enlisted in GMFCS level III will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
33267855|NCT04925102||GMFCS level IV|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level IV will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
33267856|NCT04925102||GMFCS level V|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level V will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
33267857|NCT00879554|Experimental|1|
32773062|NCT03194971||TTField at Recurrence|
32773063|NCT03194971||TTField at New Diagnosis|
32773064|NCT04213885|Experimental|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
32773065|NCT04213885|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
32773066|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle~One cycle is 28 days."
32773067|NCT03117751|Experimental|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
32773068|NCT03117751|Experimental|B-ALL and B-LLy, Standard-risk|"Induction (6wks), Early Intensification (4wks), Consolidation (8wks) and Continuation (120 wks). Remission Induction: Prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib: given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib: given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin"
32773069|NCT03117751|Experimental|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
33080244|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
33080245|NCT00222066|No Intervention|2|Expectative
33080246|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
33080247|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
33080248|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
33267858|NCT00879632||1|TREATMENT AS USUAL
33267859|NCT00879632||2|CONTROLS
33267860|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
33267861|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
33267862|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
33267863|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
33267864|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
33267865|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
33267866|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
33267867|NCT03595553|Experimental|ridinilazole|ridinilazole 200mg bid
33267868|NCT03595553|Active Comparator|vancomycin|vancomycin 125 mg qid
33267869|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
33267870|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
33267871|NCT04119154|Experimental|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
33267872|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
33401656|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
33401657|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
32743177|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
32743178|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
32743179|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
32743180|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
32743181|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
32743182|NCT04944537||ICU management for patients with severe trauma|Group to investigate the current status of ICU management for patients with severe trauma
32743183|NCT04937283|Experimental|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy. When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
32743184|NCT04937283|Active Comparator|Lobectomy with systemic lymph node dissection|"lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.~The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery."
32743185|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
32743186|NCT04933305||RYGB patients|Patients that already received RYGB one year prior commencement of their participation in the study
32743187|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
32743188|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
32743189|NCT04937049|Experimental|EMAeHealth digital tool|This team has designed a digital tool called EMAeHealth involving healthcare professionals. It is organized into 4 areas: 1) an Information area, 2) a Communication area, 3) a Health Self-management area, 4) a Clinical data area, The tool is conceived as a complement that can reinforce maternal health education with resources that facilitate its accessibility, and rapid remote response, which will also improve its results. It will be incorporated into the Osakidetza-Basque Health Service corporate Website.
32743190|NCT04937049|No Intervention|No EMAeHealth digital tool|Usual care. This group, like experimental group, receives the usual care, which includes traditional maternal education, but does not receive the EMAeHealth intervention
32743191|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
32743192|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
32743193|NCT04932993|No Intervention|Standard care|Will not write down goals their goals for their medical care (usual care).
33080249|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
33080250|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
33080251|NCT00222144|Experimental|1|Gleevec and Taxotere
33080252|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
33267873|NCT04861298|Active Comparator|Standard of care (SOC)|This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
33267874|NCT04861298|Experimental|Quercetin|This arm will receive standard of care + oral Quercetin for two weeks
33267875|NCT00869102|Experimental|GLP-1|
33267876|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
33267877|NCT03582917|No Intervention|No treatment|
33267878|NCT05226728|Experimental|pharmacokinetic-guided pembrolizumab cohort|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression.
33267879|NCT00869180|Experimental|Diclofenac Sodium Patch|
33267880|NCT00869180|Placebo Comparator|Topical Placebo Patch|
32773070|NCT03117751|Experimental|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
32773071|NCT03117751|Experimental|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
32773072|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine after Continuation Week 1. Patients in low- risk will complete vincristine in Week 49 and those in standard/high-risk will complete in Week 101.~Intervention: vincristine."
32901892|NCT05128422|Experimental|NBO+EVT group|Normobaric hyperoxia Combined with Endovascular therapy group were given 100% oxygen via a face mask initiated before vascular recanalization (10L/min for 4h) . In addition, the patient will be given endovascular therapy surgery.
32901893|NCT05128422|No Intervention|EVT group|The Endovascular therapy group were given room air. And the patient will also be given endovascular therapy surgery.
32901894|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
33267881|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
33267882|NCT00879866|Experimental|1|
33267883|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
33267884|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
33080253|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
33080254|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
33080255|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
33080256|NCT00411996|Other|1|IDV/r 600/100 mg + rifampicin
33080257|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
33080258|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
33080259|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
33080260|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
33080261|NCT00222417||Otosclerosis|Patients subject to stapes surgery
33080262|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
33080263|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
33267885|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
33267886|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
33267887|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
33267888|NCT04840628|Experimental|neural respiratory drive|neural respiratory drive assessed by EMGdi recorded from a multipair esophageal electrode
33267889|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
32773073|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment. Patients at low-risk will complete vincristine in Week 49.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
32773074|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
32773075|NCT04924257|Experimental|Intranasal Esketamine|
33267890|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
33267891|NCT04038866|Experimental|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
33267892|NCT04038866|Active Comparator|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.~The objectives and walking exercises were the same as those performed in the experimental group."
33080264|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
33267893|NCT00529659|Experimental|MK-0773|MK-0773
33267894|NCT00529659|Placebo Comparator|Placebo|Placebo
33267895|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
33080265|NCT00215826|Active Comparator|1|650 IU
32773076|NCT04924257|Active Comparator|ECT|
32773077|NCT04924179|Experimental|Tislelizumab plus Fruquintinib and SBRT|
32773078|NCT04975945|Experimental|Local|Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)
32773079|NCT04975945|Active Comparator|Parenteral|Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol
32901895|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
32901896|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
33080266|NCT00215826|Active Comparator|2|1300 IU
33080267|NCT00215904|Placebo Comparator|1|
33080268|NCT00215904|Experimental|2|
33267896|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
33267897|NCT03569891|Active Comparator|FIX replacement (Lead-in Period)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
33080269|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
33080270|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
33080271|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
33080272|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
33267898|NCT05726565||LNNB-S >=10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S >=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S >=10.
33267899|NCT05726565||LNNB-S <10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S >=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S >=10.
33267900|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
33267901|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
33267902|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
33267903|NCT04076969|Experimental|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
33267904|NCT04076969|Other|Routine follow up|Routine follow up
33267905|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
33267906|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
33080273|NCT00409604|No Intervention|2|Standard PCI procedure
33080274|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
33267907|NCT04077125||Controls|Healhty subjects
33267908|NCT05716893|Experimental|Adaptive Aerobic Training/AT Dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
33267909|NCT05716893|Active Comparator|Standard (fixed) Aerobic Training/AT dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
33267910|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
33267911|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
33267912|NCT05710965|Active Comparator|FRx-001|FRx-001 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and scheduled assistive messaging.
33080275|NCT00473746|Experimental|Phase I Dose Escalation|
33080276|NCT00473746|Experimental|Phase II Dose Treatment|
33267913|NCT05710965|Active Comparator|FRx-003|FRx-003 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and may include periodic assistive messaging.
33080277|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
33080278|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
33080279|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
33080280|NCT04722497||Physicians and nurses|All physicians, nurses, involved in a cesarean births are included in the cohort.
33080281|NCT04722497||Patients undergoing cesarean births|All patients undergoing cesarean births
33080282|NCT00409721|Experimental|Memantine Low Dose|
33080283|NCT00409721|Experimental|Memantine High Dose|
33080284|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
33267914|NCT05710965|Active Comparator|FRx-004|FRx-004 is a wearable digital intervention that displays periodic therapeutic assistive messaging.
33267915|NCT04076891|Active Comparator|Cohort 1 - Dercum's disease|Nodule size - diameter (cm) 2-2.9 3-3.9 4-8 Total Dose of RZL-012 (mg) 10 15 20 Dose per NOAEL* 1/25th 1/18.75th 1/12.5th Number of Injections 2 3 4
33267916|NCT04076891|Active Comparator|Cohort 2 - Lipedema|Total Dose RZL-012 (mg) 60 80 Dose per NOAEL* 1/4.688 1/3.125 Number of Injections 12 16
33267917|NCT05707689|Experimental|Gaming|Gaming intervention with entertainment video games will be run in small groups (6-10 players) closely monitored by trained gaming facilitators. Pre-scheduled gaming sessions, about 60 minutes each, will be run twice a week over 10 weeks (totally 20 hours).
33267918|NCT05707689|No Intervention|Treatment as usual (TAU)|Participants will join usual practices as planned in community services. No specific activities will be organized to them by the research team.
33267919|NCT05172401|Experimental|Active Treatment - Oxulumis® - Triesence®|"The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization~Interventions:~Device: Oxulumis® suprachoroidal microcatheterization device~Drug: Triesence® (Triamcinolone acetonide)"
33267920|NCT05167877||Control group|Participants without CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices.
33267921|NCT05167877||Active group|Participants with CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices. Self-reported measures of pain and type of activity for 7 days using electronic dairy.
33267922|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
33267923|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
33267924|NCT00143455|Experimental|B|
33267925|NCT00143455|Experimental|A|
32901897|NCT05062980|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with Reqorsa intravenously on Day 1 in addition to pembrolizumab 200 mg fixed dose infusion every 21 days until progression or unacceptable toxicity.~The first group will receive Reqorsa IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third group will receive 0.12 mg/kg. Once the RP2D is determined, an additional group of patients will be enrolled at the RP2D."
32743194|NCT04932993|Experimental|Writing down goals|Will write down goals their goals for their medical care.
33231219|NCT00794040|Active Comparator|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
33231220|NCT00794040|Placebo Comparator|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
33231221|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
33231222|NCT04109742|Active Comparator|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
33231223|NCT04109742|Active Comparator|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
33231224|NCT04109742|Placebo Comparator|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
33231225|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
32743195|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~1 injection every 2 weeks~1 injection every 3 weeks~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
32743196|NCT04409145|Experimental|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
32743197|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
32743198|NCT04958187|Experimental|ANG-3777|Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
32743199|NCT03244319|Experimental|Edoxaban|
32743200|NCT03244319|Active Comparator|Warfarin|
32743201|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
32743202|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
32743203|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
33231226|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
33231227|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
33231228|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
33231229|NCT02603874|No Intervention|Control|Without target tape in the procedure
33231230|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
33231231|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
33231232|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
33231233|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
33231234|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
33231235|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
33231236|NCT00587964|Experimental|Treatment|
33231237|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
33231238|NCT05640336|Active Comparator|Single DAIR Surgery Arm|Subjects will undergo a single Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
33231239|NCT05640336|Active Comparator|Double DAIR Surgery Arm|Subjects will undergo planned double Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
33267926|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
33267927|NCT05016765|Experimental|Active MNS|Active, self-directed electrical stimulation of the right median nerve
33267928|NCT05166551|Experimental|Experimental Group|"Acupressure will be applied to the infants in this group by the researcher in accordance with the technique for 1 minute on the GB31 acupuncture point on the leg where the vaccine will be administered.The considerations before, during and after acupressure application are as follows:~The hands will be washed to warm them up to body temperature.~The acupressure will be applied using the thumb to the GB31 acupuncture point for 1 minute before the vaccine is administered to the infants in the experimental group.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
33267929|NCT05166551|Placebo Comparator|Placebo Group|"Pressure will be applied by the researcher on a placebo point at least 2 cun above the GB31 acupuncture point, on the leg to be vaccinated, for 1 minute. The considerations before, during and after pressure are as follows:~The hands will be washed to warm them up to body temperature.~For the infants in the placebo group, pressure will be applied using the thumb for 1 minute to a placebo point that does not coincide with any acupuncture point at least 2 cun above the acupuncture point before the vaccine is administered.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
33267930|NCT05166551|No Intervention|Control Group|"The considerations before, during and after are as follows:~Without any intervention, the infants in this group pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
33267931|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
32901898|NCT05062980|Experimental|Phase 2 Combination|Patients will receive the RP2D of Reqorsa intravenously on Day 1 in addition to pembrolizumab 200 mg fixed dose infusion every 21 days until progression or unacceptable toxicity.
32901899|NCT05062980|Active Comparator|Phase 2|Patients will receive docetaxel 75 mg/m2 infusion with or without ramucirumab 10 mg/kg infusion every 21 days until progression or unacceptable toxicity.
33080285|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
33267932|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
33267933|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
33267934|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
33267935|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
32901900|NCT00514592||All|All patients enter the same group
33267936|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
33267937|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
33080286|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
33080287|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
33080288|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
33267938|NCT05688189|Experimental|37 degree centigrade|The 37°C arm implies the setting of the temperature immediately at 37°C.
33267939|NCT05688189|Experimental|34-37 degree centigrade|The 34-37°C arm implies the setting of the temperature at 34°C and after 15 minutes at 37°C.
33267940|NCT05688189|Experimental|31-34-37 degree centigrade|The 31-34-37°C arm implies setting the temperature initially at 31°C, after 15 minutes at 34°C and after another 15 minutes at 37°C.
33267941|NCT03967093|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
33080289|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
33080290|NCT00223353||Lower Limb Amputee|
33080291|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
33080292|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
33080293|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
33267942|NCT03967093|Experimental|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
33267943|NCT03967093|Experimental|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
32773080|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
33267944|NCT03967093|Experimental|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
33267945|NCT03967093|Experimental|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
33267946|NCT01006941|Experimental|Trichuris suis ova|
33267947|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
33267948|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
33267949|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
32773081|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
32773082|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
32773083|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of 200 g Nutri-jelly with 20 mg PEITC per day, five days per week for 3 months.
33080294|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
33080295|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
33080296|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
33080297|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
33080298|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
33080299|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
33080300|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
33080301|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
33080302|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
33080303|NCT00223587|Experimental|A|1 week of treatment discontinuation
33080304|NCT00193934||1|Cervical Cancer Patients
33080305|NCT00223626|Experimental|Topiramate|
33080306|NCT00223626|Placebo Comparator|Placebo|
33080307|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
33080308|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
33080309|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
33080310|NCT00193973|Active Comparator|1|
33080311|NCT00223782|Other|1|
33080312|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
33080313|NCT00223860|Other|1|
33080314|NCT00125255|Experimental|S-Caine Peel|
33080315|NCT00125255|Placebo Comparator|Placebo Peel|
33080316|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
33080317|NCT00223938|Active Comparator|1|Oral Iron
33080318|NCT00223938|Experimental|2|sodium ferric gluconate
33080319|NCT00223938|Experimental|3|sodium ferric gluconate
33080320|NCT00206466|Active Comparator|One|Taxotere
33080321|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
32773084|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of 200 g Nutri-jelly per day, five days per week for 3 months.
32773085|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
32773086|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
32773087|NCT03063307|Experimental|Silver Diamine Fluoride|
33267950|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
33267951|NCT04075175|Experimental|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
33267952|NCT04075175|Placebo Comparator|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
32773088|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
33267953|NCT05550051|Active Comparator|lignocaine nebulization before awake nasal fiberoptic intubation|Patients will have lignocaine nebulization by using 3 ml of lignocaine 2%, with O2 flow rate 10 l/min to deliver 60 mg lignocaine, of which about 25% is absorbed, and patients were encouraged to inhale deeply to facilitate further delivery of the anesthetic in their airway. After finishing the nebulization setting the patient will be asked about facial, nasal, and oral numbness if no numbness, the patient will have another nebulization setting.
33267954|NCT05550051|Active Comparator|Upper airway block before awake nasal fiberoptic intubation|"Upper airway block by using about lignocaine 2%, the block will be performed by:~Bilateral superior laryngeal nerve block and will be performed by slight neck extension to identify the hyoid bone. Insert the needle laterally aiming at the greater cornu, and after hitting the bone, it will slide inferiorly, and 2 mL of 2% lignocaine will be injected blocking both the internal and the external branches of the superior laryngeal nerve.~Trans tracheal instillation for recurrent laryngeal nerve block and will be performed by extending the neck to identify the midline and palpate the cricoid cartilage. The cricothyroid membrane lies above the cricoid cartilage. A needle will be inserted in the cricothyroid membrane while aspirating and once air bubbles appears, 5ml of 4% lignocaine will be injected resulting in cough and dispersing of the LA, blocking the nerve."
33080322|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
33267955|NCT03967015|Experimental|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
33267956|NCT03967015|No Intervention|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
33267957|NCT05012007|No Intervention|Control arm: No Reminder|Usual care
33267958|NCT05012007|Experimental|Automated phone reminder|Standard reminder via phone (audiocare)
33267959|NCT05012007|Experimental|Text reminder|Standard reminder via text (VEText)
33267960|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
33267961|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
33267962|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
33267963|NCT05682495|Experimental|ARM A：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
33267964|NCT05682495|Experimental|ARM B：HR20031 FDC 10/100/1000 mg|
33267965|NCT05682495|Experimental|ARM C：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
33267966|NCT05682495|Experimental|ARM D：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
33267967|NCT05682495|Experimental|ARM E：HR20031 FDC 5/50/750 mg*2|
32773089|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
32773090|NCT04434313|Experimental|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
33080323|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
33080324|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
33080325|NCT00206544|Placebo Comparator|3|Placebo daily
33080326|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
33080327|NCT00125450|Active Comparator|B|Aspiration
33080328|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
33080329|NCT00224211||I|Stable premature infants
33080330|NCT00206622|Active Comparator|Arm 1|
33080331|NCT00206622|Active Comparator|Arm 2|
33080332|NCT00206622|Placebo Comparator|Arm 3|
33267968|NCT05682495|Experimental|ARM F：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
33080333|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
33267969|NCT05541393|Experimental|COVID-19 Education Group|Participants randomized to the intervention will be engaged over a three-week period in discussions by their health ministries; any identified concerns or barriers around the initial vaccination series and/or booster vaccinations will be addressed and the importance of continued COVID-19 testing will be emphasized. Evidence-based vaccine strategies that focus on positive framing will be employed
33267970|NCT05541393|No Intervention|Delayed Control Group|Participants in the delayed intervention control group will not receive any outreach during the three-week control period. Subsequent to completing the follow-up questionnaire, they will then be invited to join the intervention for the next three weeks. A follow-up questionnaire will be administered following their intervention period to be used in later analyses.
33267971|NCT00142909|Experimental|Drug: Lofexidine|"Lofexidine: Study medication~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
33267972|NCT00142909|Placebo Comparator|Drug: Placebo|"Placebo pill.~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
32773091|NCT04877431||De Nova Participants|De nova participants who had received teduglutide after marketing authorization will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
32773092|NCT04877431||Legacy Participants|Legacy participants who received teduglutide treatment prior to marketing authorization under expanded access type of program will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
32773093|NCT04975711|Experimental|Sequence 1|Period 1: RLD2104 Period 2: HIP2105
32773094|NCT04975711|Experimental|Sequence 2|Period 1: HIP2105 Period 2: RLD2104
32773095|NCT04874935|Active Comparator|Lansoprazole arm|33 patients who will receive neoadjuvant chemotherapy and lansoprazole 60 mg twice daily four days before starting chemotherapy regimen and then the same dose will be used during chemotherapy cycles
32773096|NCT04874935|Placebo Comparator|Placebo arm|33 patients who will receive neoadjuvant chemotherapy and placebo capsules.
32773097|NCT04975477||Training cohort|A cohort was used to develop the novel score for predicting liver decompensation
32773098|NCT04975477||Validation cohort|A cohort was used to validate the performance of novel score for predicting liver decompensation
32773099|NCT04975477||Exploratory cohort|A cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension
32773101|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
32773102|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
32773103|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
32773104|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
32773105|NCT04974229||acute non-specific low back pain|patients with acute low back pain of (< 6 weeks) were consecutively included with or without radiating pain, aged 18 to 60 years with a pain-free episode for at least 3 months before the onset of their current back pain. They were also required to be able to read and understand the Dutch language.
33080334|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
33080335|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
33080336|NCT00206661|Experimental|Arm 1|
33080337|NCT00206661|Experimental|Arm 2|
33080338|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
33080339|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
32773106|NCT04974931|Active Comparator|Patients applied with PREVENA system|This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.
33080340|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
33267973|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
33267974|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
33267975|NCT01007019|Experimental|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267976|NCT01007019|Experimental|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267977|NCT01007019|Experimental|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267978|NCT01007019|Experimental|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267979|NCT01007019|Experimental|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267980|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
32743204|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
32935687|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
33267981|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
32935688|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
33267982|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267983|NCT01007019|Experimental|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267984|NCT01007019|Experimental|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
33267985|NCT01007019|Placebo Comparator|Placebo|
33267986|NCT01007019|Active Comparator|Esomeprazole 40mg|
33267987|NCT05673863|Experimental|Psychological resilience training program|Children in the intervention group participated in a psychological resilience program organized as a group activity.
33267988|NCT05673863|No Intervention|control group|Children in the control group did not receive any intervention. There was also no intervention for the family members accompanying the children.
33267989|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
33267990|NCT05633979|Experimental|Group 1|Participants will receive the same drugs at the same schedule, and the same dose of trastuzumab deruxtecan
32935689|NCT02108899|Experimental|Patients with schizophrenia|
33267991|NCT05633979|Experimental|Group 2|Participants will only receive 1 dose level of valemetostat.
33267992|NCT04075097|Experimental|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
33267993|NCT04075097|Experimental|Yoga|44 minutes of Iyengar yoga.
32935690|NCT02108899|Active Comparator|Healthy subjects|
32935691|NCT05176873|Experimental|Single dose of DZD8586|Single dose of DZD8586
32935692|NCT05176873|Placebo Comparator|Single dose of Placebo|Single dose of Placebo
32935693|NCT05444270|Active Comparator|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
32935694|NCT05444270|Experimental|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
32935695|NCT05172817|Experimental|Advixa|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
32935696|NCT05172817|Active Comparator|Humira|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
33267994|NCT01007175|Experimental|Cohort 1|
33267995|NCT01007175|Experimental|Cohort 2|
33267996|NCT01007175|Experimental|Cohort 3|
32935697|NCT04600622|Experimental|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
32935698|NCT04600622|Active Comparator|Active Comparator|Participants will receive diabetes education materials.
32935699|NCT05145907|Experimental|TJ107+Pembrolizumab|TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W
33267997|NCT01007175|Experimental|Cohort 4|
33267998|NCT01007175|Experimental|Cohort 5|
33267999|NCT04076189|Experimental|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
33268000|NCT04076189|Active Comparator|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
33268001|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
33268002|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
33268003|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
33268004|NCT00205699|Active Comparator|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
33268005|NCT00205699|Active Comparator|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
33268006|NCT00205699|Active Comparator|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
32773107|NCT04974931|No Intervention|Patients applied with conventional dressings|This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy
33080341|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
33080342|NCT00125567|Active Comparator|2|Levodopa/carbidopa
33080343|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
33080344|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
33080345|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
32773108|NCT04975165|Experimental|Staged total knee arthroplasty|Staged replacement of both knees in two separate surgeries.
32773109|NCT04975165|Experimental|Simultaneous total knee arthroplasty|Simultaneous replacement of both knees in a single surgery.
32773110|NCT04974073|No Intervention|control group|with traditional western medicine treatment based on underlined disease
33080346|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
33080347|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
33080348|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
33080349|NCT00472420|Experimental|1|
33080350|NCT00194519|Active Comparator|Acyclovir|
33080351|NCT00194519|Placebo Comparator|Placebo|
33080352|NCT00206700|Experimental|Arm 1|
33268007|NCT03503513|Experimental|Gentamicin sulfate|Participants initiate Gentamicin instillations every night for a period of 6 months. After baseline and consented they are instructed on how to do the instillations through a catheter, once they receive the drug and aid equipment (i.e. syringes) to do installations. Remaining drug is to be disposed after each use. Participants use their own catheters.
32773111|NCT04974073|Experimental|PHY606|PHY606 7.5gm BID for 3 months
33268008|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
33268009|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
33268010|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
32773112|NCT04974073|Other|Healthy group|PHY606 7.5gm BID for 2 days
32773113|NCT04975087||Patients group|Individuals with primary Sjögren's syndrome
32773114|NCT04973995||Patients with shoulder pain who received ER lag sign|
32773115|NCT04973995||Patients with shoulder pain who received External rotation resistence strength test|
32773116|NCT04973995||Patients with shoulder pain who received Patte's test|
32773117|NCT04973995||Patients with shoulder pain who received Errsair test|
32773118|NCT04973995||Patients with shoulder pain who received speed test|
32773119|NCT04973995||Patients with shoulder pain who received Yergason test|
32773120|NCT04973995||Patients with shoulder pain who received backward traction test|
32773121|NCT04973995||Patients with shoulder pain who received Cui's test|
32773122|NCT04974853|Experimental|Ayurveda Formulation|Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement
33080353|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
33080354|NCT00125723|No Intervention|No Intervention|
33080355|NCT00125723|Other|Intervention|PI Discretion
32773123|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
33080356|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
33080357|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
32773124|NCT04973839|Experimental|Video optimizing expectations before PMR (unguided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided)
32773125|NCT04973839|Experimental|Video optimizing expectations before PMR (guided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided)
32773126|NCT04973839|Active Comparator|Neutral video before PMR (unguided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided),
32773127|NCT04973839|Active Comparator|Neutral video before PMR (guided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided)
32773128|NCT04839601|Experimental|Evaluation Group (stimulation ON)|Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
33080358|NCT00125879|Experimental|1|
33080359|NCT00125918|Placebo Comparator|1|Placebo
33080360|NCT00125918|Active Comparator|2|2.5 mg tadalafil
33080361|NCT00125918|Active Comparator|3|10 mg tadalafil
32773129|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
32773130|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~PM01183 predetermined dose daily via IV per cycle~Doxorubicin predetermined dose daily via IV per cycle"
33080362|NCT00125918|Active Comparator|4|20 mg tadalafil
33080363|NCT00125918|Active Comparator|5|40 mg tadalafil
33080364|NCT00224523|Experimental|Arm 1|
33080365|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
33231240|NCT05753696|Experimental|azilsartan group|the initial dose of azilsartan is 20mg/day, if not reached the goal of blood pressure, azilsartan was adjust to 40mg/day
33231241|NCT05753696|Active Comparator|losartan group|the initial dose of losartan is 40mg/day, if not reached the goal of blood pressure, losartan was adjust to 80mg/day
33231242|NCT04109898|No Intervention|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
33231243|NCT04109898|Experimental|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
33231244|NCT04788992|Experimental|Intervention group|receive dementia care training
33231245|NCT04788992|Active Comparator|Control group|receive dementia care training without virtual reality activity
33231246|NCT04107480|Experimental|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
33231247|NCT04107480|Active Comparator|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
33231248|NCT05753618|Active Comparator|Receive G-CSF|Receive G-CSF injections (either filgrastim or pegfilgrastim) after each cycle of paclitaxel chemotherapy.
33231249|NCT05753618|Experimental|Omission of G-CSF|Omission of G-CSF injections after each cycle of paclitaxel chemotherapy.
33231250|NCT05564130|Experimental|Sodium bicarbonate|50 ml of 1 mmol/ml sodium bicarbonate given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 ml of 1 mmol/ml sodium bicarbonate will be administered after the second dose of adrenaline dose for a maximum of two doses.
33231251|NCT05564130|Placebo Comparator|Placebo|"50 mL of 9 mg/mL NaCl (normal saline) given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 mL of 9 mg/mL NaCl will be administered after the second dose of adrenaline dose for a maximum of two doses."
33231252|NCT04024202||Patients|"Patients with a positive DAT, a positive eluate and signs of hemolysis~Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
33231253|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
33231254|NCT00915408|Experimental|CRD|
33231255|NCT05573724|Experimental|Treatment Arm|"Part A:~The participants will receive a single oral dose of AZD5305 on Day 1, followed by a 2-day washout. Then Itraconazole will be dosed for 3 days [BD] on Day 4 and [OD] on Days 5 and 6, then a single oral dose of AZD5305 administered concurrently with Itraconazole on Day 7 and only Itraconazole on Days 8 to 12.~Part B:~Patients proceeding to Part B after completing Part A of the study will receive AZD5305 OD as monotherapy."
33231256|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
33231257|NCT04030286||Control|Healthy patients
33231258|NCT04030286||Periodontitis|Patients with periodontal disease
33231259|NCT04030286||Cardiovascular|Patients with cardiovascular disease
33231260|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
33231261|NCT05753540|Experimental|Laser therapy|Multiwave locked system laser therapy
33231262|NCT05753540|Placebo Comparator|Sham laser therapy|Sham laser therapy
33231263|NCT02602548||Open Shoulder Surgery|Culture
32773131|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~PM01183 predetermined dose given twice via IV per cycle~Gemcitabine predetermined dose given twice via IV per cycle"
33268011|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
33268012|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
33268013|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
33268014|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
33268015|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
32773132|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
32773133|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
33268016|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
33268017|NCT03971539|Experimental|Single Rising Dose|
33268018|NCT03971539|Experimental|Multiple Rising Dose|
33268019|NCT03880227|Experimental|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
32773134|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
32773135|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
32773136|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
32773137|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
33268020|NCT03880227|Active Comparator|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
32773138|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
32773139|NCT04836247|Experimental|Disclosure Intervention Arm|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
32773140|NCT04836247|Active Comparator|Control Arm|Participants will be able to choose from several guided meditations to promote mindfulness.
33268021|NCT03880227|Experimental|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
33268022|NCT03880227|Active Comparator|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
33268023|NCT04000113|Experimental|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
33268024|NCT04000113|Sham Comparator|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
33268025|NCT03850691|Experimental|Cohort 1: Nivolumab|
33268026|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
33268027|NCT03999567|Experimental|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
33268028|NCT05629767||Patients with ASCVD|Patients with ASCVD on statins and LDL-C more than 70 mg/dl
33268029|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
33268030|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
33268031|NCT05628831|Placebo Comparator|Traditional surgery|This group of patients will be treated with standard technique (vaginal hysterectomy with anterior and/or posterior vaginal repair) for pelvic organ prolapse .
33268032|NCT05628831|Active Comparator|vNOTES PREFAP|This group of patients will be treated with vNOTES aproach using autologous graft isolated from posterior rectus fascia for pelvic organ prolapse.
33268033|NCT05502159|Active Comparator|Group M-TAPA = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
33268034|NCT05502159|Active Comparator|Group EOB = EOB group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
33268035|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
33268036|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
33268037|NCT05618925|Experimental|Arm A|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab
33268038|NCT05618925|Experimental|Arm B|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab (cohort A) or in combination with rituximab and N-803 (cohort B).
33268039|NCT04996017|Experimental|Arm A|atezolizumab 1200mg every 21 days
33268040|NCT04996017|Placebo Comparator|Arm B|Placebo will be supplied by the sponsor and will be identical in appearance to atezolizumab and will comprise the same excipients but without atezolizumab every 21 days
33268041|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
33268042|NCT03483935|No Intervention|Control|No treatment will be given.
32773141|NCT02504151|Experimental|Cannabidiol, then Placebo|The subject will receive treatment with cannabidiol (CBD)(800mg/day) for four weeks, followed by a two week washout period, followed by four weeks of placebo.
32773142|NCT02504151|Experimental|Placebo, then Cannabidiol|The subject will receive placebo for four weeks, followed by a two week washout period, followed by four weeks of treatment with cannabidiol (CBD)(800mg/day).
33268043|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
33268044|NCT00530439|No Intervention|Control|
33268045|NCT03481829||Children|Children of mothers enrolled in the study
33268046|NCT03481829||Pregnant women and mothers|Pregnant women/mothers
33268047|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
32773143|NCT03060109||Suspected traumatic brain injury|
33268048|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
33268049|NCT04994223|Experimental|Group A(combined anticoagulation plus antithrombotic therapy group)|group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
33268050|NCT04994223|Active Comparator|Group B( antithrombotic therapy alone group)|group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
33080366|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
33268051|NCT04076423|Experimental|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
33268052|NCT04076423|Active Comparator|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
33268053|NCT04962633|Experimental|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
33268054|NCT04962633|Active Comparator|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
33268055|NCT04126031|Experimental|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
33268056|NCT04126031|Experimental|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
33268057|NCT01007565|Experimental|periarticular injection, pain level|
33268058|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
33268059|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
33268060|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
33268061|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
33268062|NCT05229003|Experimental|cohort A|"Anlotinib + Irinotecan:~Anlotinib, 10mg, oral, once daily, D1-10, q2W; Irinotecan, 180mg/m2, iv drip, d6, q2w."
33080367|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
33080368|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
33268063|NCT05229003|Experimental|cohort B|"Anlotinib + Penpulimab + Irinotecan:~Anlotinib, 8mg, oral, once daily, d1-10, q2w; Penpulimab 200mg, i.v. d6, q2w; Irinotecan, 180mg/m2, iv infusion, d6, q2w."
32773144|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
32773145|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
32773146|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
32773147|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
32773148|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
32773149|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
32773150|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
32773151|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
32773152|NCT05697731||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
32773153|NCT05697731||non-obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
32773154|NCT04317755|Experimental|Intervention|Comic-based body image programme
32773155|NCT04317755|No Intervention|Control|Schools lessons as usual
32773156|NCT05696093|Experimental|cotrimoxazole|Use of cotrimoxazole for enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
32773157|NCT05696093|Active Comparator|standard antibiotic therapy|Use of standard antibiotic therapy enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
33080369|NCT00194870|Other|Digital EEG|Digital EEG
33080370|NCT00206934|Placebo Comparator|1|
33080371|NCT00206934|Placebo Comparator|2|
33080372|NCT00224640|Experimental|1|Iron chelating intervention
33231264|NCT02602548||Arthroscopic Shoulder Surgery|Culture
33231265|NCT04064840|Active Comparator|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
33231266|NCT04064840|Placebo Comparator|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
33231267|NCT04064840|Active Comparator|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
33231268|NCT04064840|Placebo Comparator|FET: control|On the day of FET, normal saline will be injected subcutaneously.
33231269|NCT00791076|Placebo Comparator|Saline Placebo|Saline
33231270|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
33231271|NCT05757518|Experimental|Experimental group|Cryo-stimulation using cryosauna after fatigue-induced exercise.
33231272|NCT05757518|No Intervention|Control group|Without any intervention after fatigue-induced exercise.
33231273|NCT04785560|Active Comparator|Shunt setting 4 (=110 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 4 (110 mm H20), our standard setting.
33231274|NCT04785560|Active Comparator|Shunt setting 8 (=400 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 8 (400 mm H20 a k a virtual off), in practice a closed non-functional shunt.
33231275|NCT05538312|Experimental|ARV-471 with and without itraconazole|ARV-471 administered as a single dose in Period 1 and Period 2. Itraconazole administered once a day for 11 days in Period 2.
33231276|NCT05537766|Experimental|Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2 × 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg.
33231277|NCT05537766|Experimental|Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2×10^6 anti-CD19 CAR T cells/kg.
33231278|NCT05537766|Experimental|Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2x10^6 anti-CD19 CAR T cells/kg.
33231279|NCT05537766|Experimental|Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2 × 10^6 anti-CD19 CAR T cells/kg.
33231280|NCT05757440|Experimental|Icon resin|Low-viscosity Icon resin infiltration
33231281|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
33231282|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
33231283|NCT04107402|Experimental|Septic shock|Septic shock Patients admitted to the ICU
33268064|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
33268065|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
33268066|NCT01019824|Experimental|Low Dose|160 mg dose
32773158|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
32773159|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
33268067|NCT01019824|Experimental|High Dose|320 mg dose
33268068|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
32773160|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
32773161|NCT05536739|Experimental|Powered Hip Exoskeleton for Stroke Assistance|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
33268069|NCT01016626|Experimental|CKD-4101 tablet|
33268070|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
33268071|NCT01016704|No Intervention|Control|
33268072|NCT01016704|Experimental|Incentive|
33268073|NCT04935879|Experimental|inclacumab, 30 mg/kg|Participants will receive inclacumab 30 mg/kg administered IV every 12 weeks
33268074|NCT04935879|Placebo Comparator|placebo|Participants will receive placebo administered IV every 12 weeks.
33268075|NCT04436926|Experimental|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
33268076|NCT04436926|Sham Comparator|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
33268077|NCT04108000|Experimental|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
33268078|NCT04108000|Active Comparator|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
33268079|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine [Tdap](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine [Tdap](GSK776423).
32773162|NCT05536661|Experimental|Study group|Preservative free Hyaluronic acid 0.15% artificial tear instilled in both eyes 4 times daily for 3 days
32773163|NCT05536661|No Intervention|Control group|No artificial tear instilation
32773164|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
33080373|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
33268080|NCT00489970|Active Comparator|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine [Tdap](GSK776423).
33268081|NCT00489970|Active Comparator|Control group|Subjects received the first dose of Boostrix vaccine [Tdap](GSK776423) in this study at Year 9.
32773165|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
33080374|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
33080375|NCT00207051|Experimental|1|
33080376|NCT00402467|Experimental|Arm 6|
33268082|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
32773166|NCT05536583|Experimental|PCOS group|Obese Patients with PCOS underwent LSG
33080377|NCT00402467|Experimental|Arm 1|
33080378|NCT00402467|Experimental|Arm 2|
33080379|NCT00402467|Experimental|Arm 3|
32773167|NCT05536583|Active Comparator|Control group|Sample obese patients without PCOS underwent LSG
32773168|NCT05536505|Experimental|MRD Positivity Post Operation|If MRD confirmed Positivity at either of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive icotinib until MRD turned Negativity. During MRD monitoring, icotinib would rechallenge
33080380|NCT00402467|Experimental|Arm 4|
33080381|NCT00402467|Experimental|Arm 5|
33080382|NCT00224718|Active Comparator|1|surgery - open repair
33080383|NCT00224718|Experimental|2|endovascular procedure
33080384|NCT00207129|Experimental|A|
33268083|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
33268084|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
33268085|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
33268086|NCT03443765||Patients with Pityriasis alba|
33268087|NCT03443765||Healthy participants (control group)|
33268088|NCT03441893|Active Comparator|Patients with ulcerative colitis|Patients with ulcerative colitis in this group will take nitazoxanide per os
33268089|NCT03441893|No Intervention|Participants (control group)|only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
33268090|NCT03441893|Active Comparator|UC patients (cohort 1)|Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
33268091|NCT03441893|Placebo Comparator|UC patients (cohort 2)|Patients with ulcerative colitis in this group will take placebo tabletes
33268092|NCT03441893|Active Comparator|UC patients (cohort 3)|Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide
33268093|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
33268094|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
32773169|NCT05536505|No Intervention|MRD Negativity Post Operation|If MRD confirmed negativity at both of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive ctDNA MRD monitoring.
33268095|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
32773170|NCT05695937|Placebo Comparator|DICA-HF + placebo|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus placebo of both phytosterol and krill oil during 120 days.
32773171|NCT05695937|Experimental|DICA-HF + phytosterol|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
32773172|NCT05695937|Experimental|DICA-HF + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
33080385|NCT00207129|Experimental|B|
33268096|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
33268097|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
33268098|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
32773173|NCT05695937|Experimental|DICA-HF + phytosterol + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
32773174|NCT05536271|Experimental|Acute coronary syndrome patients|Acute coronary syndrome patients prescribed with bisoprolol
33268099|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
33268100|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
33268101|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
33268102|NCT02758847|Other|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
33268103|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
33268104|NCT04075877|Experimental|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
33080386|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
33080387|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
33080388|NCT04722159||Treatment resistent hypertensives, treated with renal denervation|Patients having undergone renal denervation and fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
33268105|NCT04075877|No Intervention|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
33268106|NCT00874484|Experimental|1|
33268107|NCT00874484|Placebo Comparator|2|
32773175|NCT03157115|Experimental|Impaired left ventricular ejection fraction|Patients with reduced left ventricular ejection fraction (< 50 %)
33268108|NCT03414905||Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
33268109|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
32773176|NCT03157115|Active Comparator|Control|Patients with a normal left ventricular ejection fraction (≥ 50 %), without heart failure. The patients from the reduced left ventricular ejection fraction group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
33268110|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
32773177|NCT05697653|Experimental|intervention group (skin-to-skin contact group)|skin-to-skin contact: It is the laying of the newborn in the prone position on the mother's bare chest area with only a diaper on.
33268111|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
33268112|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
33268113|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
33268114|NCT05325359||Multiple sclerosis|. Inclusion criteria for volunteers; Individuals with relapsing-remitting type MS, who are between 18-65, EDSS scores between 1 ≤ and ≤ 5.5, individuals who score 24 and above in Mini Mental State Examination and who can walk a minimum of 20 m independently will be included. In addition, exclusion criteria for volunteers; Severe spasticity of the lower extremities (Ashworth score 3 or 4), having an acute MS attack or a history of an attack in the last 1 month, having an orthopedic or systemic problem that would prevent participation in the tests, having another neuromuscular disorder other than MS, visual involvement or diplopia, and is that he has a cardio-pulmonary problem that will prevent him from participating in the tests.
33268115|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
32773178|NCT05697653|No Intervention|control group|The routine applications of the hospital were applied to the pregnant women in the control group.
33268116|NCT05072795|Experimental|Stress Induction|
33268117|NCT05127304||Chronic obstructive pulmonary disease (COPD) patients treated with Tiotropium Bromide/Olodaterol|COPD patients who initiated treatment with Tiotropium Bromide/Olodaterol between 01 June 2015 and 30 November 2019
32773179|NCT05536193|Experimental|Topical Metformin Emulgel and salicylic acid|
32773180|NCT05535881|Experimental|Experimental Group|
32773181|NCT05535881|No Intervention|Waitlist Control Group|
32773182|NCT04425707|Experimental|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
32773183|NCT04425707|Experimental|B standard care alone|standard care will be administarted alone
32773184|NCT04425707|Active Comparator|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
32773185|NCT05697185|Experimental|the evolocumab plus statin therapy|Patients with AIS are treated with atorvastatin (40mg) daily and evolocumab (420 mg) every months throughout the study period
32773186|NCT05697185|No Intervention|the statin alone therapy|Patients with AIS are treated with atorvastatin (40mg) daily throughout the study period.
32773187|NCT05695781|Active Comparator|BRM421 Ophthalmic Solution|
32773188|NCT05695781|Placebo Comparator|Vehicle|
32773189|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
33268118|NCT05127304||COPD patients initiated treatment with Furoate/Umeclidinium/Vilanterol|COPD patients who initiated treatment with Furoate/Umeclidinium/Vilanterol between 01 June 2015 and 30 November 2019
33268119|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
33268120|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
33268121|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
33268122|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
33268123|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
33268124|NCT03412643|Experimental|Arm 1|"Celcuity CELx HSF Test on tumor material obtained from research core biopsy to select patients with abnormal HER2 signaling tumors~Doxorubicin + cyclophosphamide followed by Weekly Paclitaxel +Trastuzumab+Pertuzumab"
33268125|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
32773190|NCT04316663|Experimental|Well-Being and Sleep Hygiene|Participants in the experimental group will receive an intervention focused on both principles of psychological well-being and sleep hygiene education.
32773191|NCT04316663|Active Comparator|Sleep Hygiene (Control)|Participants in the control group will receive sleep hygiene education alone.
32773192|NCT05535803|Experimental|Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment and mesenchymal stem cells
32773193|NCT05535803|Active Comparator|Patients with tracheal/laryngeal stenosis receiving standard treatment|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment
32773194|NCT05559671|Experimental|HZ/su Vaccine, then Placebo|During the initial 24-week period (Period 1), participants will receive HZ/su injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive placebo saline injection at week 24 and week 32.
32773195|NCT05559671|Experimental|Placebo, then HZ/su Vaccine|During the initial 24-week period (Period 1), participants will receive placebo saline injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive HZ/su injection at week 24 and week 32.
32773196|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
32773197|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
32773198|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
32773199|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
32773200|NCT04725149|Placebo Comparator|0 ml tart cherry concentrate|Still cherry-flavored beverage, similar in appearance, taste, aroma and calories to the 30 ml and 60 ml tart cherry concentrate beverages
32773201|NCT04725149|Experimental|30 ml tart cherry concentrate|"Low dose tart cherry concentrate beverage"
32773202|NCT04725149|Experimental|60 ml tart cherry concentrate|"High dose tart cherry concentrate beverage"
32773203|NCT05511233|No Intervention|CONTROL GROUP|Control Group: Electronic health records of the newborns who do not receive breast milk in the first 48 hours of the postoperative period will be in the control group.
32773204|NCT05511233|Experimental|ERAS GROUP|ERAS Group: Electronic health records of the newborns who had breastmilk within the first 48 hours in the postoperative period will be in the ERAS group.
33231284|NCT04107402|Other|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
33231285|NCT04107402|Experimental|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 < 200
33231286|NCT05757362|Other|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation|Participants will be asked to complete the questionnaire developed.
33231287|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
33231288|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
33231289|NCT02610062|Experimental|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
33231290|NCT02610062|Experimental|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
33231291|NCT02610062|Experimental|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
33231292|NCT02610062|Experimental|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
33231293|NCT02610062|Experimental|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
33231294|NCT05757284||patients with unilateral or bilateral, primary or secundary LLL|
33231295|NCT05757284||healthy controls|
33231296|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
33231297|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
33231298|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
33231299|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
33231300|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants receive single-agent sorafenib at the same dose and schedule as in their original clinical trials.
33231301|NCT05753384|Experimental|continued treatment with TKI at 50% dose reduction|continued treatment with TKI at 50% dose reduction compared to dosing received at randomization and then stopped treatment 12 months after randomization
33231302|NCT05753384|Active Comparator|continuation of TKI treatment without dose change|continued treatment with TKI at same dose compared to dosing received at randomization and then stopped treatment 12 months after randomization
33231303|NCT00822250|Other|1|cutting hair, skin phenotype description
32773205|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
32773206|NCT05591417|Active Comparator|Intravenous morphine|Patients will receive intravenous morphine 0.1 mg/kg
33268126|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
33268127|NCT01017094|Experimental|dry dressing|local application
33268128|NCT04074239|Experimental|Video triage|The sick child will be triaged on video by the operator.
33268129|NCT04074239|No Intervention|Telephone triage|The sick child will be triaged solely on telephone by the operator.
32773207|NCT05591417|Experimental|Bilevel erector spinae plane block|Patients will receive erector spinae plane block at 2 levels
32773208|NCT05591417|Experimental|Bilevel erector spinae plane block with dexamethasone|Patients will receive erector spinae plane block at 2 levels with dexamethasone
32773209|NCT05591417|Experimental|Bilevel erector spinae plane block with dexmedetomidine|Patients will receive erector spinae plane block at 2 levels with dexmedetomidine
32773210|NCT05535179|Experimental|treatment group|
32773211|NCT05535179|No Intervention|control group|
32773213|NCT05462405|Experimental|Experimental group|All subjects enrolled will be in the same experimental group.
32773214|NCT05679167|Active Comparator|Supervised digital training: core stability|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 1 the patients will attend supervised digital training with focus on core stability
32773215|NCT05679167|Active Comparator|Supervised digital training: aerobic exercise|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 2 the patients will attend supervised digital training with focus on aerobic exercise
32773216|NCT05679167|Active Comparator|Non-supervised daily physical activity|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 3 will start a daily physical activity program, with regular support from a physiotherapist.
32773217|NCT05679089||Cancer Arm|Participants with newly diagnosed intracranial malignant tumors, from whom blood samples will be collected.
32773218|NCT05679089||Benign Arm|Participants with newly diagnosed benign central nervous system disorders, from whom blood samples will be collected.
33268130|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
33268131|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
33268132|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
33268133|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
33268134|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
33080389|NCT04722159||Treatment resistent hypertensives, conservatively treated|Patients fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
33080390|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
33268135|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
33268136|NCT04919993|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Group intervention; topics include psychoeducation about sleep, sleep restriction, stimulus control, relaxation strategies, and cognitive restructuring.
33268137|NCT00565812|Active Comparator|200 mg|High dose active comparator
33268138|NCT00565812|Active Comparator|50 mg|Low dose active comparator
33268139|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
33268140|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
33268141|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33268142|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33268143|NCT03970824|Active Comparator|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33268144|NCT00933972|Experimental|1 (normal)|
33268145|NCT00933972|Experimental|2 (mild)|
33268146|NCT00933972|Experimental|3 (moderate)|
33268147|NCT00933972|Experimental|4 (severe)|
33268148|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
33268149|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
33268150|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
33268151|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
33268152|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
33268153|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
33268154|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
33268155|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
33268156|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
33268157|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
33268158|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
33268159|NCT00480532|Experimental|Doxycycline 100bid x5 days|
32773219|NCT05679089||Healthy arm|Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
32773220|NCT05591261|Experimental|ePREP condition|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
32773221|NCT05688527|Experimental|5 Step Skin Care Regimen|The subject uses 5 facial products in the regimen; a cleansing balm, a toner, a serum, a moisturizer and an eye cream.
32773222|NCT05591027|Experimental|Centella asiatica water extract product (CAP) 4g|A sachet of containing 4g dried hot water extract (CAW) of Centella asiatica combined with inactive ingredients will be dissolved in water and orally consumed daily as a drink for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
32773223|NCT05591027|Placebo Comparator|Placebo|A sachet of inactive ingredients (excipients) identical in composition to those found in the active arm will be be dissolved in water and orally consumed daily for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
32773224|NCT05589857|Experimental|Group 1 (Spellbound)|Participants will play SpellBound using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
32773225|NCT05589857|Experimental|Group 2 (Spellbound)|Participants will play the game using augmented reality.
32773226|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
32773227|NCT05589545|Experimental|Intervention|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
33268160|NCT00480532|Placebo Comparator|placebo bid x 5 days|
33268161|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
33268162|NCT00480532|Placebo Comparator|placebo daily|
32773228|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
33080391|NCT00224835|Experimental|2|Cardiac Education Class
33080392|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
33268163|NCT04013880|Experimental|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33268164|NCT01017328||surgery with general anesthesia|
33268165|NCT00939432||Gender|male/female
33268166|NCT00939432||Age|18-100 years
33268167|NCT00939432||Educational level|primary school, secondary school, university
33268168|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
33268169|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
33268170|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
33268171|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
33268172|NCT00934752|Experimental|Lutonix Catheter|
33268173|NCT01020292|Experimental|NFV and Concurrent ChemoRads|
33268174|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
33268175|NCT04014426|Other|Exposed|Healthcare workers participating at two PIPAC
33268176|NCT04014426|Other|Non-exposed|Healthy volunteers unexposed to chemotherapy
33268177|NCT01020370||Alemtuzumab Group|
33268178|NCT01020370||Interferon Beta-1a SC Group|
33268179|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
33268180|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
33268181|NCT00934830|Active Comparator|Antibiotic|
33268182|NCT00934830|Experimental|Therapeutic ultrasound|
33268183|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
33268184|NCT00934908|Active Comparator|2|Green Tea Capsules
33268185|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
33268186|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
33268187|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
33268188|NCT02575404|Experimental|4 mg/kg GR-MD-02 17 Cycles Maximum|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment up to a maximum of 17 cycles.
32773229|NCT05695703|Experimental|Core Strength Training Group|The participants of core strength training group will perform core strength training for 6 weeks (3 days per week).
32773230|NCT05695703|Active Comparator|Conventional Training Group|The participants of conventional training group will perform conventional exercises for 6 weeks (3 days per week).
33268189|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
33268190|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
33268191|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
33268192|NCT04013724|Experimental|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18~The topics that were explored during the group sessions include:~Introduction to the Program and Reasons to Quit~Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting~Withdrawal Symptoms and Social Support~Dealing with Stress and Anxiety and Coping with Depression~Assertiveness Training and Anger Management~Tobacco-Free Lifestyle and Dealing with High Risk Situations"
33268193|NCT04013724|No Intervention|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
32773231|NCT05685485||Standard Implantation|Standard Implantation
32773232|NCT05685485||Tied off Tube|Tied off Tube
32773233|NCT05695625|Active Comparator|Group ESPB|Spinal anesthesia + bilateral ESPB (total of 40 ml, %0.5 bupivacaine)
32773234|NCT05695625|Active Comparator|Group SA|Only spinal anesthesia
32773235|NCT05695547|No Intervention|Standard education|Patients will be educated about the procedure in a standard way by a doctor and a nurse
32773236|NCT05695547|Experimental|VR Education|Patients will be educated with the use of virtual reality
32773237|NCT05684159|Experimental|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at every two weeks for a total of 7 doses
33268194|NCT04013412|Experimental|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
33268195|NCT04013412|No Intervention|Control|Ad libitum diet for four days immediately before surgery
33268196|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
33080393|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
33080394|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
33268197|NCT04014192|Experimental|Dapagliflozin Group|10mg/d for one week
33268198|NCT04014192|Experimental|Empagliflozin Group|10mg/d for one week
33268199|NCT04014192|Experimental|Canagliflozin Group|100mg/d for one week
33268200|NCT04014192|No Intervention|Normal Glucose Tolerance Group|
32773238|NCT05684159|Experimental|Cohort 2|6 subjects will receive weekly doses of 10 mg/kg for a total of 4 doses followed by biweekly doses at 20 mg/kg for a total of 5 doses
32773239|NCT05589077|Experimental|Knowledge Assessment and Educational Intervention|All participants will be asked to complete the pre-intervention survey assessing knowledge and confidence of female athlete nutritional concerns. Then participants will engage in an educational intervention on these same topics. Following the intervention, participants will repeat the same survey.
32773240|NCT05415371|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
32773241|NCT05415371|Experimental|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care plus incentives for completing counseling calls and abstinence.
32773242|NCT05586737|Experimental|rituximab|Controlled ovarian hyperstimulation will be performed before and four months after two infusions of 1-gram rituximab (Mabthera®).
32773243|NCT05678933|Experimental|AC-CHOP|Azacitidine administered IV at day 1-5 and Chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)
32773244|NCT05678933|Active Comparator|CHOP|CHOP administered every 3 weeks for 6 cycles.
33080395|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
33080396|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
33080397|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
33268201|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
33268202|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
33268203|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
33268204|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
33268205|NCT00935610|Placebo Comparator|Casein|20g of Casein
33268206|NCT04013646|Experimental|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
33268207|NCT04013646|Experimental|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
32773245|NCT05678855|No Intervention|control group|Control Group: The topics of the course were prepared by the researcher using PowerPoint. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the control group with the traditional education method on a weekly basis.
32773246|NCT05678855|Experimental|experimental group|a) Experimental Group: First, the topics of the course were prepared by the researcher using multimedia tools. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the experimental group in an interactive way on a weekly basis.
32773247|NCT05357495|Experimental|frustration and control fMRI tasks|all subjects complete one scanning session with frustration induction and one scanning session with the control task.
32773248|NCT05678699|Other|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) Only|The investigators will employ a quasi-experimental study design to test two hypotheses: H1: SMM rates among Black people will decline after the interventions (equity payment and obstetric bundled payment), relative to people of other race groups within Pennsylvania (PA); and H2: Racial inequities in SMM will decline among those exposed to the interventions in PA, relative to those in similar states. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare interventions on beneficiaries' experiences.
32773249|NCT05678699|Other|Doula Only|The investigators will test two hypotheses: H1: SMM rates among Black people will decline more after the addition of doula care in PA, relative to healthcare quality interventions alone. H2: Racial inequities in SMM will decline more among those exposed to both healthcare quality and doula care interventions in PA, relative to states implementing doula care only. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare and service interventions on beneficiaries' experiences.
32773250|NCT05678699|Other|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) + Doula|
32773251|NCT05678699|No Intervention|Standard Care|
32773252|NCT05678621|Experimental|ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics|"Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.~Duration: 12 months. Route: PO"
32935700|NCT04563325|Active Comparator|Experimental|"< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~=/> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
32935701|NCT04563325|Active Comparator|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:~< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
33268208|NCT04013646|Placebo Comparator|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
33268209|NCT03381287|Experimental|HTD1801 250 mg BID|Subjects received 500 mg/day HTD1801
33268210|NCT03381287|Experimental|HTD1801 500 mg BID|Subjects received 1000 mg/day HTD1801
33268211|NCT03381287|Experimental|HTD1801 1000 mg BID|Subjects received 2000 mg/day HTD1801
33268212|NCT03381287|Placebo Comparator|Placebo|
33268213|NCT04074473|Placebo Comparator|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
33268214|NCT04074473|Active Comparator|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
33268215|NCT04074473|Experimental|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
33268216|NCT04074473|No Intervention|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
32773253|NCT05678621|Experimental|ARM B: Stop immunoglobulin (without prophylactic antibiotics)|"Participants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.~Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.~Duration: 12 months. Route: PO"
32935702|NCT05142163|Active Comparator|Stroke Volume Variation Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain SVV <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
33268217|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
33268218|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
33268219|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
33080398|NCT00413127|Experimental|1|Lidocaine i.v
33268220|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
32935703|NCT05142163|Active Comparator|Plethysmography Variability Index Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain PVI <10%, for values >10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
32935704|NCT04559737|No Intervention|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
33268221|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268222|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268223|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268224|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33080399|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
33080400|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
33080401|NCT00413127|Active Comparator|4|lidocaine epidural
33080402|NCT00413127|Placebo Comparator|5|placebo i.v.
33268225|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268226|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268227|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268228|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268229|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
33268230|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
33268231|NCT03345563|Active Comparator|Body Training (BT)|Body training only
33268232|NCT03345563|Other|Usual care (UC):|Control
33080403|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
33080404|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
33401658|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
33401659|NCT04743466||Observational (biobank review)|Patients' records from institutional or national biobanks are reviewed.
33401660|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
33401661|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
33080405|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
33401662|NCT03998566|Experimental|TraceIT Tissue Spacer|
33401663|NCT04740736|Experimental|Saline Infusion|
33401664|NCT04740736|Sham Comparator|Sham Infusion|
33401665|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
33401666|NCT05672758||Sprint-Trained Athletes|Highly trained track sprinters at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
33080406|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
33080407|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
33231304|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
33231305|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
33231306|NCT00806624|Experimental|2|DU-176b tablets: high-dose
33231307|NCT00806624|Active Comparator|3|Warfarin tablets
33231308|NCT00806624|Experimental|1|DU-176b tablets: low-dose
33231309|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
33231310|NCT05753228|Active Comparator|COVID fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
33231311|NCT05753228|Active Comparator|Cancer fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
33231312|NCT05753228|Active Comparator|Healthy patients as controls|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
33231313|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
33231314|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
33231315|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
33231316|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
33231317|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
33231318|NCT04029662|Experimental|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
33231319|NCT04029662|No Intervention|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
33231320|NCT05753150||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 U/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to chloroquine, the standard blood schizonticidal drug.
33231321|NCT05753150||Daily primaquine (PQ) for 14 days|Patients aged ≥16 years, G6PD activity ≥ 4.1 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
33231322|NCT05753150||Weekly primaquine (PQ) for 8 weeks|Patients aged ≥16 years, G6PD activity ≤ 4.0 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
33231323|NCT00826774|Active Comparator|Ususal Care|
33231324|NCT00826774|Experimental|Breif Lifestyle Counseling|
33231325|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
33231326|NCT05757128|Experimental|treatment arm|The single treatment arm will be administered optimal health program (OHP) intervention.
33231327|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
33268233|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
33080408|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
33268234|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
33268235|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
33268236|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
33268237|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
33268238|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
33268239|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
33268240|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
33268241|NCT00869648|Active Comparator|Extension|Head placed in extension
33268242|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
33268243|NCT03325985|Experimental|Nurse-led telephonic case management|"Telephonic nurses will contact patients within 72 hours of enrollment~Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
33401667|NCT05672758||Endurance-Trained Athletes|Highly trained long-distance runners and triathletes at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
33080409|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
33080410|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
33080411|NCT00225069|Experimental|1|T2 sympathectomy
33268244|NCT03325985|Active Comparator|Facilitated, outpatient specialty palliative care|"Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.~Clinic visits will be scheduled the same day as other specialty appointments if possible"
33080412|NCT00225069|Experimental|2|T2-T3 sympathectomy
33080413|NCT00207441|Experimental|Arthritis self management program|
33080414|NCT00207441|Experimental|Chronic Disease Self Management Program|
33268245|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
33268246|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
33268247|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
33268248|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
33268249|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
33268250|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
33268251|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
33268252|NCT00203047|Active Comparator|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
33268253|NCT00203047|Experimental|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
33268254|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
33268255|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
33268256|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
33268257|NCT04074551|Experimental|Experimental|HCP1701
33268258|NCT04074551|Active Comparator|Active Comparator 1|HGP0904, HGP0608
33268259|NCT04074551|Active Comparator|Active Comparator 2|HGP0608, HCP1306
33268260|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
33268261|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
33268262|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
33268263|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
33268264|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
33268265|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
33268266|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
33268267|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
33268268|NCT00142519|Active Comparator|1|methadone
33268269|NCT00142519|Experimental|2|methadone and morphine
33268270|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously (SC) once weekly for up to 6 weeks and an additional loading dose on Day 3.
33268271|NCT03714776|Experimental|ISIS 757456 80 mg|ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3.
33268272|NCT03713294|Experimental|Treatment (dexamethasone, elotuzumab, pomalidomide)|Patients receive dexamethasone IV on days 1, 8, 15, and 22 of cycles 1-2 and IV on day 1 and PO on days 8, 15, and 22 of subsequent cycles and elotuzumab IV on days 1, 8, 15, and 22 of cycles 1-2 and day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33268273|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
33268274|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
33080415|NCT00225186|Experimental|Arm 1|
33080416|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
33080417|NCT00225225|Placebo Comparator|Control (no diet change)|
33268275|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
33268276|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
33268277|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
33268278|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
33268279|NCT03967171|Experimental|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
33268280|NCT03967171|Active Comparator|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
33268281|NCT03971383|Experimental|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
33268282|NCT03971383|Placebo Comparator|Placebo|3 tablets one time, 3 times a day(tid)
33268283|NCT01077349|Experimental|high volume hemofiltration|
33268284|NCT01077349|Active Comparator|standard care|
33268285|NCT03966937|Experimental|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
33268286|NCT03966937|Active Comparator|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
33268287|NCT00880646|Experimental|1|
33268288|NCT00880646|Placebo Comparator|2|
33268289|NCT00880724|No Intervention|Medical management|
33268290|NCT03967327|Active Comparator|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
33268291|NCT03967327|Experimental|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
33268292|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
33268293|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
33268294|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
33268295|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
33268296|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
33268297|NCT00874640||Group 1|
33268298|NCT00882830|Experimental|EMS group|
33268299|NCT00882830|No Intervention|control group|
33268300|NCT00874718|Active Comparator|Action group|
33268301|NCT00874718|Other|Control group|Non-specific educational program for general health.
33268302|NCT00201643|Active Comparator|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
33268303|NCT00201643|Placebo Comparator|2 - Control|Placebo group = received placebo course
33268304|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
33268305|NCT00882986||1|Men with high fitness (above VO2max of 60)
33268306|NCT00882986||2|Men with average fitness (below VO2max of 50)
33268307|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
33268308|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
33268309|NCT05204654|Experimental|In-office fabricated appliance|A customized in-office fabricated appliance using the printed digital model of the subject will be used for AP correction. AP correction will be completed following CMA protocol (see model description)
33268310|NCT05204654|Active Comparator|Carriere Motion Appliance|The appropriate length appliance will be placed as directed in the CMA handbook on the maxillary first molar and canine. AP correction will be completed following CMA protocol (see model description)
33268311|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
33268312|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
33268313|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
33268314|NCT00883142||Group 1|
33268315|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
33268316|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
33268317|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
33268318|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
33268319|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
33268320|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
33268321|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
33268322|NCT01076257|Experimental|Constraint-induced Movement Therapy|
33080418|NCT00225264|Experimental|Pioglitazone QD|
33268323|NCT01076257|Other|Transditional rehabilitation|
33268324|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
33268325|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
33268326|NCT05204264|Experimental|Acceptance and Commitment Therapy (ACT)|Intervention based on Acceptance and Commitment Therapy that promotes the acceptance and defusion of unwanted internal experiences and commitment to values of the personal life project.
33268327|NCT05204264|Experimental|Mindfulness-based Emotional Regulation (MER)|Intervention inspired in the Mindfulness-Based Stress Reduction program that fosters the development of a behavioral pattern made up of conscious responses in order to decrease reactivity to stressors.
33268328|NCT04017884|Experimental|Remin Pro Forte.|intervention
33268329|NCT04017884|Active Comparator|Remin pro.|comparator
33268330|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
33268331|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
33268332|NCT00880958|Experimental|1|
33268333|NCT00880958|Placebo Comparator|2|
33268334|NCT04489628|Active Comparator|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
33268335|NCT04489628|Placebo Comparator|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
33268336|NCT00130039|Experimental|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
33268337|NCT00130039|Active Comparator|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
33268338|NCT00875030|Experimental|1.0|
33268339|NCT00875030|Active Comparator|2.0|
33268340|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
33080419|NCT00225264|Active Comparator|Glimepiride QD|
33080420|NCT00470704|Other|Cohort 1|"This cohort is made up of participants without prior trastuzumab for MBC. Adjuvant or neoadjuvant trastuzumab was allowed, if the interval from trastuzumab completion to recurrence exceeded 1 year.~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
33080421|NCT00470704|Other|Cohort 2|"This cohort is made up of participants with one to two lines of chemotherapy for metastatic disease with at least one trastuzumab-containing regimen or patients who recurred within 12 months of adjuvant or neoadjuvant trastuzumab with up to one line of metastatic trastuzumab-based therapy~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
33080422|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
33268341|NCT03969277|Experimental|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
33268342|NCT03969277|Active Comparator|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
33268343|NCT04038788|Active Comparator|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
33268344|NCT04038788|Sham Comparator|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
33268345|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
33268346|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
33268347|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
33268348|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
33268349|NCT04687436||Foley catheter group|mechanical cervical ripening
33268350|NCT04687436||Double-balloon group|mechanical cervical ripening
33268351|NCT04687436||Cook cervical ripening balloon|mechanical cervical ripening
33268352|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
33080423|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
33080424|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
33268353|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
32773254|NCT05678621|Active Comparator|ARM C: Continue immunoglobulin|"Participants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg)~IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG <4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion.~SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.~Duration: 12 months."
32773255|NCT05338073||Cancer patients|Patients who have primary solid cancer that is being surgically resected, biopsied, or drained (via malignant pleural effusion) and are 18 years of age or older.
33268354|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
32773256|NCT05334953|Experimental|Experimental: ESWT(Extracorporeal Shock Wave Therapy)|Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program
32773257|NCT05334953|Experimental|Phonophoresis|Group 2 ( n=17) will be given five times a week, total 10 sessions of diclofenac phonophoresis + home exercise program
32773258|NCT05334953|Experimental|Ultrasound therapy|Group 2 (n=17) will be given five times a week, total 10 sessions of ultrasound therapy+ home exercise program
32773259|NCT05334953|Other|Control goup|Group 4 ( n=17) will be given home exercise program
32773260|NCT05678543||Mothers|Pregnant women with pre existing diabetes.
32773261|NCT05678543||Partners|Partners to pregnant women with pre existing diabetes.
32773262|NCT05678543||Offspring|Offspring born to women with pre existing diabetes
32773263|NCT05697029|Experimental|tetrandrine group|Tetrandrine 60mg TID for 28 days
33080425|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
33080426|NCT00225381||metabolic gas exchange and cardiac output|
33080427|NCT00225381||mass spectrometer and anaerobic metabolism|
32773264|NCT05697029|Placebo Comparator|placebo group|placebo TID for 28 days
32773265|NCT05240729|Active Comparator|Retroclavicular|Retroclavicular approach to the infraclavicular region, the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will then be inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip will be constantly seen, until it will be positioned posterior to the axillary artery.
32773266|NCT05240729|Active Comparator|Costoclavicular|A new approach to the infraclavicular block The ultrasound transducer will be placed parallel and inferior to the clavicle and angled cephalad to optimize the ultrasound view. The block needle will be inserted in-plane from a lateral to medial direction into the costoclavicular space and the entire drug will be deposited in this location
33080428|NCT00225381||metaboic gas exchange and type of anesthesia induction|
33080429|NCT00225381||metabolic gas exchange and PEEP|
33080430|NCT00225381||metabolic gas exchange and trendelenburg position|
33080431|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
33268355|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
33268356|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
33268357|NCT00141271|Active Comparator|20-40mg BID arm|
33268358|NCT00141271|Active Comparator|60-80mg bid arm|
33268359|NCT00141271|Placebo Comparator|Placebo|
33268360|NCT01017562||condition of joint implant|
33268361|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
33268362|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33268363|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
33268364|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
33268365|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
33268366|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
33268367|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
33268368|NCT05014646|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33268369|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
33268370|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
33268371|NCT00495820|Experimental|Arm 1|Methylphenidate
33268372|NCT00495820|Placebo Comparator|Arm 2|Placebo
33268373|NCT00883376||1|OSAS patients
33268374|NCT00883376||2|no OSAS patients
33080432|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
32773267|NCT05240729|Active Comparator|Classic|Infraclavicular brachial plexus block (ICPB) ultrasound probe will be placed near the lower edge of the clavicle, and a transverse view of the subclavian artery and vein will be visualized. Using a needle guide, the needle will be advanced under real-time ultrasound guidance, and local anaesthetic will be injected near the subclavian artery, 15 mm medially and 15 mm laterally to the artery. The extent of sensory and motor block will be evaluated at 30 minutes after the injection
33080433|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
33080434|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
33080435|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
33080436|NCT00470158|Experimental|iron alone|Iron
33268375|NCT04387240|Experimental|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
33268376|NCT04387240|Placebo Comparator|placibo|this group will receive a placebo of the same shape and picture of the study drug
33080437|NCT00470158|Experimental|zinc alone|Zinc
33080438|NCT00470158|Placebo Comparator|placebo|
33080439|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
33080440|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
33268377|NCT05203328|Experimental|High flow nasal cannula oxygen|High flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
33268378|NCT05203328|Active Comparator|Regular nasal cannula|Regular nasal cannula oxygen will be provided during the procedure
33268379|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
33268380|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
33268381|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
33268382|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
33268383|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
33268384|NCT05200754|Experimental|Convalescent/Vaccine-boosted Plasma|Infusion of plasma on day 1 and 2 (238 - 337 ml anti-SARS-Cov-2 CP/PVP each)
33268385|NCT05200754|No Intervention|Standard of Care|No intervention - standard therapy
33268386|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
33268387|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
33268388|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
33268389|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
33080441|NCT00472186|Experimental|1|Post-operative administration of Lansoprazole
33080442|NCT00472186|Placebo Comparator|2|Placebo
33080443|NCT00202358|Placebo Comparator|placebo|
33080444|NCT00202358|Experimental|atenolol|
33080445|NCT00479713|Experimental|1|Arm 1: drug
33080446|NCT00479713|Active Comparator|2|Arm 2: active comparator
33080447|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
33080448|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
33080449|NCT00479635|Experimental|TPI 287|
33080450|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
33268390|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
33080451|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
33080452|NCT00477529|Experimental|ABI-008|
33080453|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
33080454|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
33080455|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
33268391|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
33268392|NCT00883766|Active Comparator|Long agonist protocol|
33268393|NCT00883766|Experimental|Antagonist protocol|
33268394|NCT04262258|Experimental|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
33268395|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
33268396|NCT00875654|No Intervention|1|Control group without intervention nor placebo
33268397|NCT00875654|Experimental|2|First dose of stem cells
33268398|NCT00875654|Experimental|3|Second dose of stem cells
33268399|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
33080456|NCT00202436|Active Comparator|1|Phlebotomy
33080457|NCT00202436|Active Comparator|2|Erythrocytapheresis
33268400|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
33268401|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
33268402|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
33268403|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
32935705|NCT04559737|Active Comparator|Case Management|Patients will undergo the same follow-up process as described in the Usual Care Pathway. A population CM dashboard (Somnoware, Inc.) will be used to automatically identify PAP strugglers (defined as <70% nights with ≥4 hours use during the preceding month) for 1 year. Video encounters will be triggered for these select patients for troubleshooting. Additionally, throughout this 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the case manager convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year.
32935706|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
32935707|NCT01689740|Placebo Comparator|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
32935708|NCT01689740|Experimental|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
32935709|NCT04545151|Experimental|Verapamil SR|Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
32935710|NCT04545151|Placebo Comparator|Placebo|"Eligible participants will be randomised into the placebo arm and receive instructions on frequency of administration (daily intake).~40 participants on the control arm are expected to complete the trial."
32935711|NCT01438034|Experimental|kisspeptin|intravenous administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
32935712|NCT05443958||Seizure free group|
32935713|NCT05443958||Not seizure free group|
32935714|NCT04543903|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
32935717|NCT04562792|Experimental|Patients with relapsed/refractory ALL and AML|Patients in this arm will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
33080458|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
33231328|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
33231329|NCT04734392||Cohort A|Historical cohort 2019 + 2020
33231330|NCT04734392||Cohort B|Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)
33231331|NCT05156840||Telehealth|Patients/Caregivers who received a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
33231332|NCT05156840||Usual Care|Patients/Caregivers who did not receive a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
33231333|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
33231334|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
33231335|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
33231336|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
33231337|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
33231338|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
33231339|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
33231340|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
33231341|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
33231342|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
33231343|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
33231344|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
33231345|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
33231346|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
33231347|NCT04723784|Experimental|Person with disability|"Initial assessment.~Implementation of AT in the daily life of participants~Application of outcome measures and analysis of the data"
33231348|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
33231349|NCT05123768||Patients with cerebral palsy|In Slovenia, all children with cerebral palsy born in 1996 or later are included in the Slovenian National Registry of Cerebral Palsy. All patients from the Registry will be invited to participate in the study.
33231350|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
33231351|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
33231352|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
33231353|NCT04704986|Active Comparator|PVI using the Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
33080459|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
33268404|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
33268405|NCT00875732|Experimental|1|Biventricular Pacing
33268406|NCT00875732|Active Comparator|2|Right Ventricular Pacing
33268407|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
33268408|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
33268409|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
33268410|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
33268411|NCT00875888|Active Comparator|control|conventional high-flux filters
33268412|NCT00881972|Experimental|exercise|
33268413|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
33268414|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
33268415|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
33268416|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
33268417|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
33268418|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
33268419|NCT04142294|Experimental|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
33268420|NCT04142294|Experimental|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
33268421|NCT04142294|Experimental|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
33268422|NCT04142294|Experimental|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
33268423|NCT00141037|Active Comparator|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40kg and 1.5 mg/kg/day in subjects weighing >40 kg) and proceed with a prednisone taper according to the trial's protocol.
33268424|NCT00141037|Experimental|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
33268425|NCT04612946|Experimental|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
33268426|NCT04612946|Active Comparator|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
33268427|NCT04602884|Experimental|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
33268428|NCT04602884|Other|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
33268429|NCT00140413|Experimental|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
33268430|NCT00140413|No Intervention|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
33268431|NCT04039178|Active Comparator|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
33268432|NCT04039178|Sham Comparator|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
33268433|NCT03966781|Active Comparator|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
33268434|NCT03966781|Sham Comparator|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
33268435|NCT04038398|Other|FiO2 : 100% - 50% - 21%|see above
33401668|NCT05672758||Amateur/Recreational Athletes (Controls)|Individuals participating in amateur non-professional sport aged 18-35 years with activity experience 5-10 years; unstructured non-periodized training
33268436|NCT04038398|Other|FiO2: 21% - 50% - 100%|see above
33268437|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
33401669|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
33401670|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
33401671|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
33401672|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
32773268|NCT05530577|Experimental|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (0.25mg to 1.0mg) over 9 weeks.
32773269|NCT05530577|Sham Comparator|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
32773270|NCT04722263|Experimental|Radiotherapy for patients with nonresectable keloids|Patients will be seen by a treating radiation oncologist and treatment with the assigned dose schedule will be planned using either EBRT with electrons or high dose-rate radiotherapy (HDR) brachytherapy as deemed appropriate by the treating radiation oncologist. The treatment dose of 15 Gy in 3 fractions will be prescribed to the 90% isodose line.
32773271|NCT05695469|Experimental|ResuGlove group|Participants in the ResuGlove group will be guided by the audio feedback from the smart resuscitation glove.
32773272|NCT05695469|Active Comparator|Traditional CPR group|Participants in the traditional CPR group will perform chest compressions without guidance from the smart resuscitation glove.
32773273|NCT04718909|Experimental|Regorafenib + sintilimab|Regorafenib combined with sintilimab.
32773274|NCT04718909|Active Comparator|Regorafenib|Regorafenib alone.
33080460|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
33080461|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
33080462|NCT00202475|Active Comparator|1|
33080463|NCT00202475|Active Comparator|2|
33080464|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
33080465|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
33080466|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
33080467|NCT00207831|Active Comparator|radiotherapy|
33080468|NCT00202670||1|SPECT
33080469|NCT00202670||2|dobutamine echocardiography
33080470|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
33080471|NCT00202709|No Intervention|Wait list control|
33080472|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
33080473|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
33080474|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
33080475|NCT00202787|Active Comparator|2|FOLFOX-4
33080476|NCT00202865|Experimental|1|
33080477|NCT00202865|Placebo Comparator|2|
33080478|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
33080479|NCT00196352|Experimental|1|
33080480|NCT00226044|No Intervention|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
33080481|NCT00226044|Active Comparator|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
33080482|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
33080483|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
33080484|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
33080485|NCT00196391|Experimental|1|
33080486|NCT00196391|Experimental|2|
33080487|NCT00196391|Experimental|3|
33080488|NCT00196391|Experimental|4|
33080489|NCT00196391|Experimental|5|
33080490|NCT00196391|Placebo Comparator|6|
33080491|NCT00203060|Experimental|A|Rasagiline treatment
33080492|NCT00203060|Placebo Comparator|B|placebo arm
33080493|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
33080494|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
33080495|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
33080496|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
33080497|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
33080498|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
33080499|NCT00226317|Experimental|Aripiprazole in depression treatment|
33080500|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
33080501|NCT04722458||Patients with Lower urinary tract sypmtoms|Patients with Lower urinary tract sypmtoms over 18 years old will be included to this study
33080502|NCT00226434|Experimental|1|
33080503|NCT00226434|Active Comparator|2|
33080504|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
33080505|NCT00208260|Active Comparator|A|FOLFIRI
33080506|NCT00208260|Active Comparator|B|FOLFOX-4
33080507|NCT00208260|Experimental|C|FOLFIRI-HD
33080508|NCT00208260|Experimental|D|FOLFOX-7
33080509|NCT00208260|Experimental|E|FOLFIRINOX
33080510|NCT00208299|Experimental|1|Regadenoson
33268438|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
33080511|NCT00208299|Active Comparator|2|Adenoscan
33080512|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
33268439|NCT00882128||1|
33268440|NCT00139477|Experimental|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
33080513|NCT00208338|Active Comparator|2|Standard rotator cuff repair
33268441|NCT00139477|Active Comparator|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
33268442|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
33268443|NCT00884000|Active Comparator|1|
33268444|NCT00884000|Experimental|2|
33268445|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
32743516|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C|"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation. 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)~Lenalidomide: 25 mg per day orally from day 1 to day 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
33080514|NCT00413322|Experimental|Single-arm dose escalation|
32743517|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D|tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
32743518|NCT04431531|Active Comparator|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
33080515|NCT00196781|Experimental|the Information + Decision Aid group|
33080516|NCT00196781|Active Comparator|Information Only group|
33080517|NCT00413361|Placebo Comparator|A|placebo
33080518|NCT00413361|Experimental|B|versus hydroxychloroquine
33080519|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
33080520|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
33080521|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
33080522|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
33080523|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
33080524|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
33080525|NCT00409799|Experimental|1|Experimental - high dose
32743519|NCT04431531|Active Comparator|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
32743520|NCT04929561|Experimental|Video-conferencing group|The mothers in the video-conferencing group were counseled via video-conferencing a total of six times (three times a week, at equal intervals) during the first 2 weeks after birth. Each interview was approximately 15-20 minutes. In video-conferencing sessions, the breastfeeding position, the mother's grasping the breast, the baby's latch-on, and sucking duration were observed. Mothers' questions were answered and solutions were offered for breastfeeding problems (sore nipple, engorgement, etc.).
32743521|NCT04929561|No Intervention|Control group|The mothers in the control group were given usual care before discharge and no intervention was made after discharge.
32743522|NCT04934241|Experimental|Self-Acupressure|Self-Acupressure Each application to the acupressure points (HT 7, CV17,PC 6, LI4,SP 6) will be done in 2 minutes and right and left)
32743523|NCT04934241|No Intervention|Control group|Routine maintenance will be applied
32743524|NCT04929093|Experimental|Novel dose adjustment schedule|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with novel dose adjustment schedule.
32743525|NCT04929093|Active Comparator|Conventional dose adjustment|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with conventional dose adjustment schedule.
33080526|NCT00409799|Experimental|2|Experimental - low dose
33080527|NCT00409799|Active Comparator|3|Autograft
32743526|NCT04929093|Active Comparator|Continuous cluster SCIT schedule|The subjects had a routine cluster SCIT schedule without interrupted period.
32743527|NCT04408209|Experimental|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
32743528|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
32743529|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
32743530|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
32743531|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
32743532|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
32743533|NCT04929327|Active Comparator|Self-etch resin based sealant|Self-etch resin based sealant (prevent seal) without prior sandblasting.
32743534|NCT04929327|Active Comparator|Prior Sandblasting|Self-etch resin based sealant prevent seal) with prior sandblasting.
32743535|NCT04929327|Active Comparator|Total-etch resin based sealant|Total-etch resin based sealant (ultraseal XT) (Ultradent Pro. Inc., USA)
33268446|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
33268447|NCT00885716|Experimental|communication skills training|group training in shared decision making.
33268448|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
33268449|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
33268450|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
33268451|NCT02543684|Experimental|ready to eat mixed meal 1|
33268452|NCT02543684|Experimental|ready to eat mixed meal 2|
33268453|NCT02543684|Experimental|ready to eat mixed meal 3|
33268454|NCT02543684|Experimental|oral glucose load|
33268455|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
33268456|NCT04562714|Experimental|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
32773275|NCT05678387||Healthy participants|Participants without chronic pain and depression
33268457|NCT04562714|Other|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
32773276|NCT05678387||Chronic Widespread Pain participants|Participants with Chronic Widespread Pain
32773277|NCT04315571|Active Comparator|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
32773278|NCT04315571|Active Comparator|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
32773279|NCT05216549|Experimental|Water-based exercise|The water-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
32773280|NCT05216549|Experimental|Land-based exercise|The land-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
32773281|NCT05216549|No Intervention|Control|The control group will be asked not to change their physical activity for 8 weeks. After that period and post-test the control group will receive the exercise.
32773282|NCT05214989|Experimental|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
32773283|NCT04708613||Former Professional Football Players|Former professional football players who played in at least 3 professional seasons, with at least 3 games each season.
32773284|NCT04708613||Control Groups|Friends and brothers of the Former Professional Football Player group.
32773285|NCT05674175|Experimental|Dose Finding Arm|Phase 1 will evaluate the safety of co-administration of CART22-65s with huCART19 in patients who experienced a disease relapse after prior CAR T cell therapy. There is no planned dose escalation but a dose-deescalation will be made based on the incidence of Dose Limiting Toxicities
32901901|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
33268458|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
33268459|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
32773286|NCT05674175|Experimental|Expansion Arm|If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) & Cohort B (prior treatment with a prior CAR T cell product).
33268460|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
33268461|NCT00882674|Experimental|1|
32773289|NCT05678075|Active Comparator|Whole food plant-based nutrition education|Providers will receive an educational intervention on whole food plant based nutrition that will last 6 weeks.
32773290|NCT05678075|No Intervention|Delayed intervention|Providers will receive a educational intervention on whole food plant based nutrition that will last 6 weeks.
32773291|NCT05379881|No Intervention|Waiting list control (WLC)|Participants who are assigned to the control condition will complete the baseline questionnaires and assessments at weeks 2, 4, and 8. After the last assessment, they will be given access to COMET.
32773292|NCT05379881|Experimental|Common Elements Toolbox (COMET)|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities."
32773293|NCT05373719||0-2 Years of Age|Patients from birth to 2 years of age at time of study entry
32773294|NCT05373719||3-5 Years of Age|Patients aged 3 to 5 years at time of study entry
32773295|NCT05373719||6-12 Years of Age|Patients aged 6 to 12 years at time of study entry
32773296|NCT05373719||13-55 Years of Age|Patients aged 13 to 55 years at time of study entry
32773297|NCT05177393||Participants with Esophageal Cancer|Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
32773298|NCT05671523|Experimental|Dry needling|The patients will receive ten sessions, twice a week, for five weeks of dry needling in addition to their conventional physical therapy program (splinting and ultrasound therapy.)
32773299|NCT05671523|Active Comparator|conventional treatment|The patients will receive conventional treatment (splinting and ultrasound therapy) for 5 weeks
33268462|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
33268463|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
32773302|NCT04315337|Experimental|Virtual Training Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
32773303|NCT04315337|No Intervention|Control Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
33080528|NCT00208416|Active Comparator|1|DePuy MI System
33080529|NCT00208416|Active Comparator|2|Conventional surgical technique
33268464|NCT04038242|Experimental|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
33268465|NCT04038242|No Intervention|Treatment as usual|Treatment as usual for subjects in the control group.
33268466|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
32773304|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
32773305|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
32773306|NCT04133363|Experimental|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
32773307|NCT05160155|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. The block will be terminated.
32901902|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
32901903|NCT05127876|Experimental|Group E|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group E: were administered intravenous ephedrine 10 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
32901904|NCT05127876|Experimental|Group OL|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OL: were administered intravenous ondansetron 4 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
33268467|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
33268468|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
33268469|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
33268470|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
33268471|NCT00888602|Sham Comparator|Meal Only|meal only
33268472|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
33268473|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
33268474|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
33268475|NCT00888758|Experimental|1|
33268476|NCT00888758|Active Comparator|2|
33268477|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
33268478|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
33268479|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
33268480|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
33268481|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
33268482|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
33268483|NCT00888992|Experimental|Group B|
33268484|NCT00888992|Experimental|Group C|
33268485|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
33268486|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
33268487|NCT00563706|Experimental|1|
32773308|NCT05160155|Active Comparator|Intercostal Block|The USG probe will be placed at the level of the posterior axillary line and the broken ribs. The ribs, external intercostal muscle, and internal intercostal muscle structures will be imaged. 3 ml of 0.25% bupivacaine will be injected into the subcostal area. This 3 ml 0.25% bupivacaine injection will be administered for each broken rib. The block will be terminated.
32773309|NCT05695391|Experimental|Coagulation Factor VIIa (Recombinant)|
32773310|NCT02627677|Experimental|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily (QD) until achievement of major molecular response (MMR) up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 42 months.
32773311|NCT02627677|Experimental|Cohort B: Ponatinib 15 mg|Ponatinib 15 mg, tablets, orally, QD until achievement of MMR up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 45 months.
32935718|NCT04523701|Experimental|Experimental Intervention (treatment)|"Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).~SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the white test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution."
32935719|NCT04523701|No Intervention|Control Intervention|Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
33080530|NCT00410735|Placebo Comparator|P|
33268488|NCT00563706|Active Comparator|2|4mg/day
33268489|NCT00563706|Placebo Comparator|3|matching placebo
33268490|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
33268491|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
32773312|NCT02627677|Active Comparator|Cohort C: Nilotinib 400 mg|Nilotinib 400 mg, tablets, orally, twice daily up to approximately 42 months.
32773313|NCT05677841|Experimental|Exercise group|Exercise group will be given spinal stabilization exercises focusing on the pelvic floor and lifestyle reccommendations
33080531|NCT00410735|Experimental|E|
33268492|NCT04038632|Experimental|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
33268493|NCT04038632|Experimental|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
32773314|NCT05677841|Active Comparator|Control group|Control group will be given lifestyle recommendations
32773315|NCT05660603|Placebo Comparator|control group|patients will be operated on under general anesthesia
33268494|NCT00935844|Experimental|TAK-901 Arm|
33268495|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
33268496|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
33268497|NCT00939588|Experimental|Aliskiren and Valsartan|
33268498|NCT00939588|Active Comparator|Telmisartan and Ramipril|
33268499|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
33268500|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
33268501|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
33268502|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
33268503|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
33268504|NCT00936000|Active Comparator|protandim therapy for 7 days|
33268505|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
33268506|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
33268507|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
32773316|NCT05660603|Active Comparator|LSP group (lumbar and sacral plexus block)|patients will receive ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of 0.25% of bupivacaine.
32773317|NCT05660603|Active Comparator|CP group (circum-psoas block)|patients will receive ultrasound-guided circum-psoas blocks with 40 ml of 0.25% of bupivacaine.
32773318|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
32773319|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
32773320|NCT05677685|Active Comparator|Investigational Device|
32773321|NCT05677685|Placebo Comparator|Placebo|
32773322|NCT04964479|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
33268508|NCT00889148|Placebo Comparator|Placebo|
33268509|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
32773323|NCT04964479|Active Comparator|Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules|"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
32773324|NCT05261867||Diabetic patients treated with SGLT2-I|Diabetic patients treated with SGLT2-I alone or in combination with other oral anti-diabetic (OAD) agents. Patients were considered in the SGLT2-I group if it was started at least 1 month prior to index hospitalization.
32773325|NCT05261867||Diabetic patients treated with other oral anti-diabetic (OAD) agents|Diabetic patients treated with other oral anti-diabetic agents alone.
33080532|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
33268510|NCT00129961|Experimental|1|Conversion to a sirolimus-based regimen
32773326|NCT04964401|Active Comparator|Thoracic Paravertebral Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the thoracic 5 spinous process, the US-compatible needle will be advanced to the paravertebral area with in-plane technique, and 20 ml of 0.25% bupivacaine hydrochloride will be injected into this area.
32773327|NCT04964401|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
32773328|NCT05224505|Experimental|GNT0006 - Stage 1|6 patients treated with GNT0006 in Stage 1 (open label) 2 dose cohorts : Cohort 1: single intravenous injection 9.0E+12 vg/Kg Cohort 2: single intravenous injection 2.7E+13 vg/Kg
32773329|NCT05224505|Experimental|GNT0006 - Stage 2|"22 patients randomized in single intravenous GNT0006 arm at selected dose in Stage 2 (double blind).~The patients will receive placebo one year after to maintain the blind"
32773330|NCT05224505|Placebo Comparator|Placebo - Stage 2|11 patients randomized in placebo arm in Stage 2 (double blind). The patients will receive single intravenous GNT0006 at selected dose one year after to maintain the blind
32773331|NCT04964245|Experimental|Respiration monitoring group|The respiration is simultaneously measured by accelerometer, thermographic camera, Impedance Tomography, and mattress sensor.
32773332|NCT05110001|Placebo Comparator|Standard Therapy|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
33080533|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
33080534|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
33268511|NCT00129961|Active Comparator|2|Continuation of a CNI-based regimen
33268512|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
33268513|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
33268514|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
33268515|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
33268516|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
33268517|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
33268518|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
33268519|NCT00889304||A|HTO cohort
33268520|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
33268521|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
33268522|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
32773333|NCT05110001|Experimental|Cross-Linking with rose Bengal (RB-PDT)|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT
32773334|NCT04964167|Placebo Comparator|Group I (Standard Root Planning)|
32773335|NCT04964167|Active Comparator|Group II (Standard Root Planning + Photodynamic Therapy)|
32935720|NCT05443646|Experimental|HLX10 (Serplulimab) Consolidation After Chemotherapy Concurrent Hypofractionated Radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) concurrently with Hypofractionated Radiotherapy, followed by HLX10 300 mg every 3 weeks (Q3W) with maximum 1 years or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
33268523|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
33268524|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
33080535|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
33268525|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
33268526|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
33268527|NCT00936546|Experimental|Rituximab|
33268528|NCT00889460|Placebo Comparator|1|Placebo group
33268529|NCT00889460|Experimental|2|rBet v 1 tablets
33268530|NCT00936624|Experimental|SOTB07 100mg|
33268531|NCT00936624|Experimental|SOTB07 200mg|
33268532|NCT00936624|Placebo Comparator|Placebo|
33268533|NCT00936624|Active Comparator|Montelukast 10mg|
33268534|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
33268535|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
33268536|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
33268537|NCT04012476|Experimental|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
33268538|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
32773336|NCT04964167|Experimental|Group III (Standard Root Planning + Aloe Vera)|
32773337|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
32773338|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
32773339|NCT05182073|Experimental|Regimen A|FT576 single dose monotherapy in subjects with r/r MM
32935721|NCT04338373|Experimental|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
33080536|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
33268539|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
33268540|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
33268541|NCT04012788|Active Comparator|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
33268542|NCT04012788|Placebo Comparator|placebo arm|placebo powder, 15 g
33268543|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
33268544|NCT04038164|Experimental|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
33268545|NCT04038164|Active Comparator|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
33268546|NCT04013490|Placebo Comparator|Placebo capsule|Subject receive the Placebo product for 4 weeks.
33268547|NCT04013490|Active Comparator|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
33268548|NCT04013490|Active Comparator|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
33268549|NCT04037306|Active Comparator|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
33268550|NCT04037306|Active Comparator|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
32773340|NCT05182073|Experimental|Regimen A1|FT576 multiple dose monotherapy in subjects with r/r MM
32773341|NCT05182073|Experimental|Regimen B|FT576 single dose in combination with daratumumab in subjects with r/r MM
32935722|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
33401673|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
33401674|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
33080537|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
33080538|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
33080539|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
33080540|NCT00203450|Experimental|Zonegran|Zonegran
33080541|NCT00203450|Placebo Comparator|Placebo|Placebo pill
33080542|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
33401675|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
33401676|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
33401677|NCT02391064|Experimental|Control|healthy subject
33401678|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
33401679|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
33401680|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
32773342|NCT05182073|Experimental|Regimen B1|FT576 multiple dose in combination with daratumumab in subjects with r/r MM
32773343|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
32773344|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
32773345|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
32773346|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
32773347|NCT04432129|Experimental|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
32935723|NCT00368953|Experimental|1|
32935724|NCT00368953|Active Comparator|2|
32935725|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
32935726|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
32935727|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
32935728|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
32935729|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
32935730|NCT05452382||Partial colectomy|Patients with appendiceal cancer who underwent segmental resection of appendiceal adenocarcinoma
33080543|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
33080544|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
32935731|NCT05452382||Hemicolectomy|Patients with appendiceal cancer who underwent formal right hemicolectomy of appendiceal adenocarcinoma
33080545|NCT00203567|Active Comparator|Equetro|Equetro
33080546|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
33080547|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
33080548|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
33080549|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
33080550|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
33080551|NCT00203645|Active Comparator|Workbook only|Workbook only
33080552|NCT00203645|No Intervention|Waitlist|Six week waitlist
33080553|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
33080554|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
33080555|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
33080556|NCT00208845||adult ED patients|
33231354|NCT04704986|Active Comparator|PVI using the PolarX Cryoballoon (Boston Scientific)|Pulmonary vein isolation using the PolarX Cryoballoon (Boston Scientific)
32935732|NCT05443178|Experimental|Cohort 1|100 mg Nivaquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
32773348|NCT04432129|Active Comparator|Service As Usual|Standard vocational rehabilitation and treatment
32773349|NCT04964011|Experimental|Board game group|The Board game group was led by an occupational therapist who has been working for six years. The intervention comprised 1 week of board game instruction and 11 weeks of board game tasks (combined with daily tasks), for a total of 12 weeks, once a week for 2 hours, for a total of 24 hours of intervention.
32935733|NCT05443178|Experimental|Cohort 2|200 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
33268551|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
33268552|NCT00939744||EAU2|Women who will have a c-section at the CHUS
33268553|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
33268554|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
33268555|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
33268556|NCT04970277|Experimental|drinking water group|Patients in this group drink colorless water after capsule ingestion.
33268557|NCT04970277|Other|control group|Patients in this group don't drink colorless water after capsule ingestion.
33268558|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
33268559|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
33268560|NCT05444049|Experimental|Treatment|The NEURESCUE device will be used as an adjunct to ACLS.
33268561|NCT00886106|Experimental|1|Remifentanil
33268562|NCT00886106|Active Comparator|2|Midazolam
33268563|NCT00939978|Active Comparator|Venoferrum|
33268564|NCT00939978|Placebo Comparator|saline|
33268565|NCT04012320||Pamidronate therapy|
33268566|NCT04012320||Zoledronate therapy|
33268567|NCT05278910|Placebo Comparator|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour.
33268568|NCT05278910|Experimental|Fish oil + Roasted wheat flour|Assign fish oil capsule and roasted wheat flour.
33268569|NCT05278910|Experimental|Soybean oil + Vegetable and fruit extracts|Assign soybean oil capsule and Vegetable and fruit extracts.
33268570|NCT05278910|Experimental|Fish oil + Vegetable and fruit extracts|Assign fish oil capsule and Vegetable and fruit extracts.
33231355|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
33231356|NCT00822484|Placebo Comparator|Placebo|Placebo
32935734|NCT05443178|Experimental|Cohort 3|300 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
33231357|NCT00633880|Experimental|Droxidopa|Double-blind
33268571|NCT04701203|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
33268572|NCT04701203|Placebo Comparator|Placebo|Placebo for TransCon PTH delivered once daily by subcutaneous injection
32935735|NCT05443178|Experimental|Dose extension group|Dose escalation: XX mg Chloroquine (depending on results) and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
33268573|NCT00940212|Experimental|A|AZD2423
33268574|NCT00940212|Experimental|B|Placebo
33268575|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
33268576|NCT04421664|Experimental|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
33268577|NCT04421664|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
33268578|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
32935736|NCT05064319|Experimental|Group A - Gabapentin|
32935737|NCT05064319|Placebo Comparator|Group B - Placebo|
33231358|NCT00633880|Placebo Comparator|Placebo|Double-blind
33231359|NCT04029428|Active Comparator|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
33268579|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
33268580|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
33268581|NCT04037384|Active Comparator|Eye Yoga group|Eye yoga exercises
33268582|NCT04037384|Placebo Comparator|Reading Group|Passive reading
33268583|NCT04895709|Experimental|Part 1A: BMS-986340 Dose Escalation|
33268584|NCT04895709|Experimental|Part 2A: BMS-986340 Dose Expansion|
33268585|NCT04895709|Experimental|Part 1B: BMS-986340 + Nivolumab Dose Escalation|
33268586|NCT04895709|Experimental|Part 2B: BMS-986340 + Nivolumab Dose Expansion|
33268587|NCT04895709|Experimental|Part 1C: BMS-986340 + Docetaxel Dose Escalation|
33268588|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
33268589|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
33268590|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
33268591|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
33268592|NCT00940056|Active Comparator|Rate control|
33268593|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
33268594|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
33080557|NCT04722588|No Intervention|Control period|The control period is represented by standard care procedures, which are similar in all three EDs: Patients cared for in the EDs receive treatment from ED physicians and nurses, and no pharmacists are involved in any of the EDs.
32773350|NCT04964011|Active Comparator|Health promotion group|MCI seniors in the health promotion group received general health promotion and were led by instructors from the long-term care facility for 12 weeks, including 4 weeks of physical activities, 4 weeks of singing activities, and 4 weeks of art activities, once a week for 2 hours, for a total of 24 hours.
33080558|NCT04722588|Experimental|Intervention period|"During the intervention period, clinical pharmacists will be present in the EDs from 08.00 - 19.00 Monday to Friday.~The ED pharmacists will collaborate with the interdisciplinary team and perform the following tasks as appropriately as possible and by prioritized need; medication history taking, medication reconciliation, medication review, drug therapy recommendations, guidance on drug administration, medication information and counseling to patients/next of kin and health care personnel and communication about medications and changes in medication regimes. Standardized procedures, like the integrated medicines management (IMM) methodology, will be applied where possible. How, when and which task will be performed for each patient cannot be predetermined, but must be performed according to patient's needs and eventual time constraints."
33268595|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
33268596|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
33268597|NCT04074317|Experimental|PRAM9|Xeris pramlintide + insulin co-formulation
33268598|NCT04074317|Experimental|Regular Insulin + Pramlintide|Humulin® + Symlin® pen as separate injections
33268599|NCT04074317|Active Comparator|Regular Insulin|Humulin®
33268600|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
32773351|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
32773352|NCT04963621|Experimental|Intervention|Child-Adolescent Emotion and Stress Intervention Program
32773353|NCT04963621|Active Comparator|waiting|treat as usual
32901905|NCT05127876|Experimental|Group OH|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OH: were administered intravenous ondansetron 8 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
33080559|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
33080560|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
33268601|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
33268602|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
33080561|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
33080562|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
33268603|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
33268604|NCT04073849|Active Comparator|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
33268605|NCT04073849|Sham Comparator|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
33268606|NCT05280210|Experimental|Neoadjuvant therapy based on PTC drug screening|Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.
33080563|NCT00208962|Active Comparator|1|
33268607|NCT05280210|No Intervention|Neoadjuvant therapy based on clinical experience|Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.
33268608|NCT05221203|Experimental|Training|Participants in this arm will perform seven bodyweight training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
33268609|NCT05221203|No Intervention|Control|Participants in this arm will receive no intervention.
33268610|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33268611|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
33268612|NCT00609674|Experimental|fluticasone furoate nasal spray|
33268613|NCT00609674|Placebo Comparator|Placebo|
33268614|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
33268615|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
33268616|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
33268617|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
33268618|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
33268619|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
33268620|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
33268621|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33268622|NCT00137839|Experimental|Erlotinib|Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.
33268623|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
33080564|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
33080565|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
33080566|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
33080567|NCT00209001|Active Comparator|Acupuncture|Acupuncture
33080568|NCT00209001|No Intervention|Observation|Observation
33080569|NCT00197444|Experimental|1|Chemoradiotherapy
33080570|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
33080571|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
33080572|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
33080573|NCT00197561|Placebo Comparator|Placebo|Placebo
33401681|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
33080574|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
33401682|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
33080575|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
33080576|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
33080577|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
33080578|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
33080579|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
33080580|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
33080581|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
33080582|NCT00204308|Experimental|combination tenofovir-emtricitabine|
33080583|NCT00204308|No Intervention|control arm|
33080584|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
33080585|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
33080586|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
33080587|NCT00230763|Experimental|Active|
33080588|NCT00230763|Other|Procedure|
33080589|NCT04721964|Experimental|Intervention|All 24 participants will daily consume 6 mg iron/kg body weight for 13 weeks to correct their anaemia and increase their iron stores.
33080590|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
33080591|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
33080592|NCT00204425|Experimental|1|exercise/soy isoflavone
33080593|NCT00204425|Experimental|2|exercise/isoflavone placebo
33080594|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
33080595|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
33080596|NCT00230880|Experimental|Treatment|follow-up phone counseling
33080597|NCT00230880|No Intervention|Control|Usual care
33080598|NCT04721847|Experimental|Pain Neuroscience Education|Pain Neuroscience Education (PNE) sessions. Additionally, treated with Transcutaneous Electrical Nerve Stimulation (TENS), Stretching and Strengthening exercises similar as in control group
33080599|NCT04721847|Active Comparator|Conventional Physical therapy|Control group will be treated by TENS, stretching and strengthening exercises.
33080600|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
33080601|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
33080602|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
33080603|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
33080604|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
33080605|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
33268624|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
33268625|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
32773354|NCT05696951|Active Comparator|The effectiveness of Tranexamic acid use of sleeve gastrectomy|In this study, it was determined which treatment package would be received by opening the closed envelopes of patients who had at least one point or more bleeding during the operation and had hemostasis with clips. In the intervention group, at the end of the surgery, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) saline.
32773355|NCT05696951|Placebo Comparator|Plasebo grup|The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
32773356|NCT05696951|Active Comparator|Sham grup|Patients with no bleeding to be treated were not enveloped and were excluded from the intervention or placebo group.
32773357|NCT05695313|Placebo Comparator|Placebo|Standard chemotherapy PACLITAXEL + placebo dietary supplement
32773358|NCT05695313|Experimental|OnLife®|Standard chemotherapy + OnLife® dietary supplement
32773359|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
32773360|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
32773361|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
32773362|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
32773363|NCT01439269|Active Comparator|Phase 2: Effectiveness|All participants receiving FNI
32773364|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
32773365|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
32773366|NCT04973761|Other|Strip composite crowns|
32935738|NCT05061901|Other|Sequence TR|19 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32935739|NCT05061901|Other|Sequence RT|19 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32935740|NCT04398056|Experimental|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
32935741|NCT05054803|Experimental|WJ-MSC (XCEL-UMC-BETA)|Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.
32935742|NCT05054803|Placebo Comparator|Placebo|Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin
33268626|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
33268627|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.~Subjects randomized to EVT will receive the following:~imaging-guided iliac vein stent placement, and~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
33268628|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
33268629|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
32773367|NCT04973761|Experimental|Zirconium crowns|
32773368|NCT05677451|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 3 cycles of 24 weeks.
32773369|NCT05677451|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally b.i.d. for 12 weeks (randomized in a 2:1 ratio arm 1: arm 2), followed by LOU064 (open-label) taken orally b.i.d. for 12 weeks
32773370|NCT04973371|Experimental|Home-based GeneXpert TB test|Screening household contacts + home-based GeneXpert® MTB/RIF TB testing for those with TB symptoms + immediate referral for clinic-based treatment initiation.
32773371|NCT04973371|No Intervention|Standard home-based TB symptom screening with immediate referral|Screening household contacts + immediate referral for clinic-based TB testing
32773372|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
32773373|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
32773374|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
32773375|NCT04432363|Active Comparator|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
32773376|NCT04432363|Active Comparator|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
33268630|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
33268631|NCT04013178|Experimental|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
33268632|NCT04013178|Active Comparator|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
33268633|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
33268634|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
33268635|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
33268636|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
33268637|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
33080606|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
33080607|NCT00413556|Active Comparator|1|
33268638|NCT02542670||control group|Genetic: Whole genome Sequencing
33268639|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
33268640|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
33080608|NCT00413556|Placebo Comparator|2|
33080609|NCT00204698|Active Comparator|1|All subjects will be given active drug.
33080610|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
33268641|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
33268642|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
33268643|NCT04037774|Active Comparator|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
33268644|NCT04037774|Active Comparator|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
33268645|NCT04037774|Placebo Comparator|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
33268646|NCT00890474|Experimental|Moxibustion|
33268647|NCT00890474|No Intervention|Control|
33268648|NCT01529736|Experimental|High torque insertion|High torque insertion
33268649|NCT01529736|Active Comparator|Low torque insertion|Low torque insertion
33268650|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
33268651|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
33080611|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
33080612|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
33080613|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
33080614|NCT00204737|Placebo Comparator|placebo|placebo
33080615|NCT00198380|Experimental|1|
33080616|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
33080617|NCT00228306|Experimental|1|
33080618|NCT00228306|No Intervention|2|Control Group
33080619|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
33080620|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
33080621|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
33080622|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
33080623|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
33080624|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
33080625|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
33080626|NCT00231582|Experimental|1|1
33268652|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
33268653|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
33268654|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
33268655|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
33268656|NCT04037540|Experimental|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
33268657|NCT04037540|Experimental|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
33268658|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
33268659|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
33268660|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
33268661|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
33268662|NCT03178487|Experimental|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
33268663|NCT03178487|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
33268664|NCT02542826|Experimental|Pulmonary Rehabilitation|
32773377|NCT04432363|Sham Comparator|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
32773378|NCT02500719|Experimental|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
32773379|NCT02500719|Experimental|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
33268665|NCT04430036|Experimental|Safety Run-In|The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there will be a pause in enrollment until all three complete the DLT period. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If > 2 DLTs are experienced in the initial 3 patients, the study will be terminated.
33268666|NCT04430036|Experimental|Phase II, Stage 1|In the first stage of phase II of this study, 17 patients will be enrolled. Patients will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. They will be evaluated with each cycle of therapy, with radiographic restaging assessment after 2 cycles of therapy and prior to the third cycle of treatment. If no disease progression is identified, patients will receive a third and fourth cycle of therapy. Following this neoadjuvant regimen, they will proceed to planned surgery following preoperative clearance within 10 weeks of the last dose of neoadjuvant therapy.
33268667|NCT04430036|Experimental|Phase II, Stage 2|If criteria are met to continue to the second stage of the Phase II portion of the study, 19 more patients will be enrolled for a total of 36 evaluable patients. Patients will be treated and endpoints evaluated.
33268668|NCT00528957|Experimental|Tenofovir DF|
33268669|NCT00528957|Active Comparator|stavudine or zidovudine|
33268670|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
33268671|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
33268672|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
33268673|NCT00890708|Experimental|TDM of voriconazole|
33268674|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
33268675|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
33268676|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
33268677|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
33268678|NCT05127759|Experimental|HLX208|Participants receive HLX208 450mg bid po
33268679|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
32773380|NCT05677373|Experimental|Treatment (PLX2853, trametinib)|Patients receive PLX2853 PO in combination with trametinib PO throughout the study. Patients also undergo collection of blood at screening and on study. Patients also undergo CT or MRI with contrast and collection of blood at screening and on study.
32773381|NCT04963855|Active Comparator|CT300|GT300 capsule given once daily
32773382|NCT04963855|Placebo Comparator|Placebo|Microcrystalline cellulose capsule given once daily
32773383|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
32773384|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
33268680|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
33268681|NCT00890942|Experimental|naloxone|
33268682|NCT00890942|Placebo Comparator|normal saline|
33268683|NCT05119959|Experimental|Arm 1- CHEU + ECD intervention|Participants randomized to this arm will receive a bi-weekly community health worker-delivered ECD intervention for CHEUs
33268684|NCT05119959|Active Comparator|Arm 2- CHEU without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
33268685|NCT05119959|Active Comparator|Arm 3- HIV Unexposed (HUU) without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
33268686|NCT04037852|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
33268687|NCT04037852|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
33268688|NCT04037852|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
33268689|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
33268690|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
33268691|NCT04963179|Experimental|Womed Leaf|IUA prevention: The novel intrauterine barrier film (Womed Leaf) is inserted immediately after completion of the hysteroscopic adhesiolysis
33268692|NCT04963179|No Intervention|Control|No IUA prevention - no placebo after adhesiolysis
33268693|NCT04938986|Experimental|IMMUNOSCORE®|
33268694|NCT00942006|Active Comparator|LNB-doxycycline|
33080627|NCT04721574|Active Comparator|Bright light therapy|Daily exposure to a high brightness LED light box for 30 minutes as soon as possible after awakening, preferably between 7 and 8 AM in the patient's hospital room The device emits 10,000 lux of cool-white fluorescent light at 50-75 cm from the screen to the cornea with an ultraviolet filter
33080628|NCT04721574|Sham Comparator|Sham Therapy|Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
33268695|NCT00942006|Active Comparator|LNB-ceftriaxone|
33268696|NCT04887519||All Participants|Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.
33268697|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
33268698|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
33268699|NCT00942240|Experimental|ACU-4429 tablet|
33268700|NCT00942240|Placebo Comparator|matching placebo tablet|
33268701|NCT05398185|No Intervention|Control|The control includes standard health services offered at each site (e.g., mental health services, case-management, referral to clinical care) and a brief adherence educational session.
33268702|NCT05398185|Experimental|Intervention|WiseApp that delivers medication adherence reminders
33080629|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
33080630|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268703|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
33268704|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
33268705|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
33268706|NCT04880031|Experimental|Cohort A1: BOS-580 Dose 1 or placebo (PBO)|
33268707|NCT04880031|Experimental|Cohort A2: BOS-580 Dose 2 or PBO|
33268708|NCT04880031|Experimental|Cohort A3: BOS-580 Dose 3 or PBO|
33268709|NCT04880031|Experimental|Cohort A4: BOS-580 Dose 4 or PBO|
33268710|NCT04880031|Experimental|Cohort A5: BOS-580 Dose 5 or PBO|
33268711|NCT04880031|Experimental|Cohort B1: BOS-580 Dose 6 or PBO|
33268712|NCT04880031|Experimental|Cohort B2: BOS-580 Dose 7 or PBO|
33268713|NCT04037618|Experimental|[14C]-EYP001a|[14C]-EYP001a dose A containing 100 μCi radioactivity
33268714|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
33268715|NCT00891098|Active Comparator|Imaginal exposure|
33268716|NCT00891098|Experimental|Imagery rescripting|
33268717|NCT04819269|Active Comparator|Tivanisiran sodium ophthalmic solution|
33268718|NCT04819269|Placebo Comparator|Vehicle ophthalmic solution|
33268719|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
33268720|NCT05280054|Experimental|AV-101|AV-101 360 mg oral capsules single dose
33268721|NCT05280054|Experimental|AV-101 + Probenecid|AV-101 360 mg oral capsules + 1000 mg Probenecid
33268722|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
33268723|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
33268724|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
33268725|NCT03999099|Placebo Comparator|Placebo|
33268726|NCT03999099|Experimental|Suvorexant 10mg|Suvorexant 10mg oral dose
33268727|NCT03999099|Experimental|Suvorexant 20mg|Suvorexant 20mg oral dose
33268728|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
33268729|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
33268730|NCT05362773|Experimental|Dose Escalation|Escalating doses of MGD024 will be assigned based on safety and tolerability of the previous dose level.
33080631|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268731|NCT05323695|Other|Depression Screening Intervention|All eligible participants will be screened using the Patient Health Questionnaire-2 (PHQ-2) for depression. If screened positive, participants will be further screened with Patient Health Questionnaire-9 (PHQ-9).
33268732|NCT05310279|Experimental|Active video gaming|Participants will engage in 6 weeks of active video gaming (AVG), 2x/week
33268733|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
33268734|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
32773385|NCT05695235||Traditional call|In the traditional overnight on-call system, each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning)
32773386|NCT05695235||Float call|In the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month
32773387|NCT04954729||Experimental Group|The experimental group underwent neuropsychological testing, 18F-FDG PET/CT, 3T resting state fMRI examinations.
32773388|NCT04954729||MRI Control Group|The MRI control group underwent neuropsychological testing and 3T resting state fMRI examinations
32773389|NCT04954729||PET Control Group|The PET control group underwent 18F-FDG PET/CT examination
33268735|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
33268736|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
33268737|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
33268738|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
33268739|NCT01007877|No Intervention|No break|
33268740|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
32773390|NCT05051579|Experimental|LY3502970 Dose 1|Participants will receive LY3502970 administered orally
32773391|NCT05051579|Experimental|LY3502970 Dose 2|Participants will receive LY3502970 administered orally
33268741|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
33268742|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
33268743|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
33268744|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
33268745|NCT01008033|Experimental|IDP-108|
33268746|NCT01008033|Placebo Comparator|Vehicle|
32773392|NCT05051579|Experimental|LY3502970 Dose 3|Participants will receive LY3502970 administered orally
32773393|NCT05051579|Experimental|LY3502970 Dose 4|Participants will receive LY3502970 administered orally
32773394|NCT05051579|Placebo Comparator|Placebo|Placebo administered orally
32773395|NCT04973215||work package 1|all participants in Norwegian introduction program and their family relations
32773396|NCT04973215||work package 2|strategic sample of refugees with health problems currently participating in the introduction program
32773397|NCT04973215||work package 3|3-6 families from which one or more participate in the introduction program and one or more have health problems
32773398|NCT04150939|Experimental|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
32773399|NCT05695001||No Intervention: Baseline therapy|Basic therapy is the routine practice of an institution for the treatment of patients with acute pancreatitis without signs of infection
33080632|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268747|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
33268748|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
33268749|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
33268750|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
33268751|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
33268752|NCT05272293|Experimental|expanded haploidentical NK cell immunotherapy|After a cycle of chemotherapy a patient receive three intravenous infusions of expanded haploidentical NK cells.
33268753|NCT00891332|Experimental|1|S-1 plus LV
33268754|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
33268755|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
33268756|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
33268757|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
33268758|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
33268759|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
33268760|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
33080633|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
32773400|NCT05695001||Experimental: Basic therapy + Efferon CT|Basic therapy is a routine practice of the institution for the treatment of patients with acute uninfected pancreatitis in combination with extracorporeal hemoperfusion (Efferon CT)
32773401|NCT04963465||Before rupture of membranes|Vaginal swab collection prior to iatrogenic rupture of membranes
33268761|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
33268762|NCT00884936||Group 1|Young age: 20 to 30 years old
33268763|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
33268764|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
33268765|NCT04038008|Other|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
33268766|NCT04038008|Other|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
33268767|NCT05278832|Experimental|QLS31905|QLS31905 injection
33268768|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
33268769|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
33268770|NCT00891488||Fit|
33268771|NCT00891488||Unfit|
32773402|NCT04963465||After rupture of membranes|Vaginal swab collection after iatrogenic rupture of membranes
32773403|NCT05041907|Active Comparator|Positive control: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|
32773404|NCT05041907|Experimental|AZD7442 (EVUSHELD™)|
32773405|NCT05041907|Experimental|Fluoxetine|
33268772|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
33268773|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
33268774|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
33268775|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
33268776|NCT00611858|Experimental|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
33268777|NCT00137449|Experimental|A|
33268778|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
33268779|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
32773406|NCT05041907|Experimental|Molnupiravir|
32773407|NCT05041907|Experimental|Nitazoxanide|
33080634|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268780|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
33268781|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
33268782|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
33268783|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
33080635|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268784|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
33268785|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
33268786|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
33268787|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
33080636|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268788|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
33268789|NCT04036760||Standard of Care transitional care coordination|
33268790|NCT04036760||Research transitional care coordination|
33268791|NCT04036916|Experimental|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
33268792|NCT04036916|No Intervention|No Virtual Reality Training (Control)|True control.
33268793|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
33268794|NCT00886964|Active Comparator|1|HBV ID
33268795|NCT00886964|Active Comparator|2|HBV IM
33268796|NCT00887042|Experimental|Fludarabine|
33268797|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
33268798|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
33268799|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
33268800|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
33268801|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
33268802|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
33268803|NCT00887276|Active Comparator|Moxifloxacin|
33268804|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
33268805|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
33268806|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
33268807|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
33268808|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
33268809|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
33268810|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
33268811|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
33268812|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
33268813|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~CTX+G-SCF mobilization to collecetd PBSC~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
33268814|NCT00892424|Experimental|Sorafenib + RT|
33268815|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
33268816|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
33401683|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
32773408|NCT05041907|Other|Negative control group|
33268817|NCT00557856|Experimental|1|
33268818|NCT04757649|Experimental|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
33080637|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
33268819|NCT00892502|Active Comparator|1|Bismuth tablets
33268820|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
32773409|NCT05041907|Experimental|Ensitrelvir|
33268821|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
33268822|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
33268823|NCT00885404|Other|Intravenous fluids|
33268824|NCT04753359|Experimental|Med-A|"Med-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of the intervention. For subjects randomized to Med-A the study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized MedDiet exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to maintain weight. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 8 months.~The Med-A group will be asked to maintain their usual physical activity."
33268825|NCT04753359|Experimental|WL-A|"WL-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the intervention. For WL-A, the focus will be on daily calorie restriction (-500-750 kcal/day) to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months in the context of the subject's typical diet pattern. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 8 months.~The WL-A group will be prescribed an activity program. Physical activity will be monitored via FitBit."
32773410|NCT05041907|Experimental|Molnupiravir and Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|
32935743|NCT05443100|Experimental|Rehabilitation|Multidisciplinary rehabilitation program consisting of diet and physical exercise for 4 weeks.
32935744|NCT05443100|Experimental|Whole-Body Cryotherapy|Rehabilitation program consisting of 10 WBC sessions over two weeks.
32935745|NCT05452603||Study group|Thirty consecutive patients with GERD symptoms and an acid exposure time (AET) measured by impedance measurement/pH between 4 and 6% will be included.
32935746|NCT05451992|Placebo Comparator|Placebo|Control group that will consume a placebo product
32935747|NCT05451992|Experimental|SuperFood|The superfood group will have to consume the superfood product (vegetable smoothie)
32935748|NCT05443022|Active Comparator|Photobiomodulation group|Participants in this group will have their larger salivary glands irradiated with diode laser.
32935749|NCT05443022|Placebo Comparator|Placebo group|Participants in this group will be subjected to a simulation, where the application protocol will be repeated, but with the laser turned off.
32773411|NCT05041907|Experimental|Sotrovimab [Pending addition]|
32773412|NCT05041907|Active Comparator|Positive control (REGN-COV2) [This arm is now closed to recruitment]|
32935750|NCT04338919|Experimental|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
32935751|NCT04338919|Active Comparator|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
33080638|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080639|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
32773413|NCT05041907|Experimental|Favipiravir [This arm is now closed to recruitment]|
32773414|NCT05041907|Experimental|Ivermectin [This arm is now closed to recruitment]|
32773415|NCT05041907|Experimental|Remdesivir [This arm is now closed to recruitment]|
32773416|NCT04963309||OR-EX|the group with endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
33268826|NCT04753359|Experimental|WL-Med|"WL-Med will attend a one-hour, in-person session with a registered dietitian (RD) prior to the intervention. The RD will instruct on an eating pattern consistent with a MedDiet using an individualized exchange list. Exchanges are based on individual caloric needs to lose weight (WL-Med, calorie restriction to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months). We will not ask subjects to abstain from alcohol despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 26 group sessions (1-hour, held approximately weekly).~The WL-Med group will be prescribed an activity program. Physical activity will be monitored via FitBit."
32773417|NCT04963309||NOR-EX|the group without endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
32773418|NCT05019209|Experimental|Exposure to saline-dissolved house dust mite allergen and allergen-free air|Subjects are blinded to the sequence of interventions in the allergen challenge chamber (ACC). Overall, subjects will be in the ACC 4 times during the study. Of those, exposure to allergen-free air and HDM is allocated in a 2:2 ratio.
32773419|NCT04963387|Experimental|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session. The duration of vibration exposure was preset with the automatic set time intervals in the vibration machine Prior to each vibration bout. When the predefined time was reached the machine automatically turned off . Based on previous researches the total exposure of four minutes per session interval was selected. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
32773420|NCT04963387|Active Comparator|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
33268827|NCT04753359|No Intervention|Control|The study RD will meet individually with the Control group subjects in-person for 1-hour at the start of the 8-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 8 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-4 and post-intervention (month-8) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-4 assessment, weight will be checked and those with >2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 8-month intervention.
33268828|NCT04743765|Experimental|Accelerated medical clearance and surgery|Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
33080640|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080641|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080642|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080643|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33268829|NCT04743765|No Intervention|Standard surgical care|Hip fracture repair and surgical care according to treating institution guidelines.
33268830|NCT00191113|No Intervention|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
33268831|NCT00191113|Experimental|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
33268832|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
33268833|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
33268834|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
33268835|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
33268836|NCT05265117||HIPEC|HIPEC is given after primary debulking surgery or interval debulking.
33268837|NCT05265117||CONTROL|No HIPEC
33268838|NCT03964974|Experimental|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|
33268839|NCT03964974|Placebo Comparator|Sleep Hygiene Education (SHE)|
33268840|NCT00892658|Experimental|Sorafenib + RT|
33268841|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
33268842|NCT03966235|Experimental|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
33268843|NCT03966235|Placebo Comparator|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
33268844|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
33268845|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
33080644|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080645|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080646|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
33080647|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
33080648|NCT04722081|Experimental|Control Group|children received selected physical therapy exercises
33080649|NCT04722081|Experimental|Study Group|children received selected physical therapy exercises plus virtual reality training
33080650|NCT00478738|Other|GSK961081|GSK961081
33080651|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
33268846|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
33080652|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33268847|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
33080653|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
33080654|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
33268848|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
32773421|NCT05694299|Experimental|Nasal bridle|Nasal bridle fixation after nasoenteral feeding tube placement.
32773422|NCT05694299|Active Comparator|Nasal patch|Nasal patch fixation after nasoenteral feeding tube placement.
32773423|NCT04962763||Heart Failure|
33080655|NCT00477412|Experimental|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
33080656|NCT00410852|Experimental|A|
32773424|NCT04962763||Control|
32773425|NCT05674253|Active Comparator|Dexmedetomidine + Hydrocortisone group|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours .
32773426|NCT05674253|No Intervention|Standard group|Patients will not receive dexmedetomidine nor Hydrocortisone and will receive the standard management
32773427|NCT04954417||MSCT image|Scanning of the vertebral body using MSCT
32773428|NCT04954417||micro-CT image|Scanning of the vertebral body using micro-CT
33080657|NCT00410852|Experimental|B|
33080658|NCT00410852|Active Comparator|C|
33080659|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
33080660|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
33080661|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
33268849|NCT00606320|Experimental|Aripiprazole|
33268850|NCT03966079|Experimental|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
33268851|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
33268852|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
33268853|NCT03966859|Placebo Comparator|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
33080662|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
33080663|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
33080664|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
33080665|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
33080666|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
33268854|NCT03966859|Experimental|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
33268855|NCT00528411|Active Comparator|1|Aspirin + Placebo
33268856|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
33268857|NCT00528411|Experimental|3|Aspirin + Ticagrelor
33268858|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
33268859|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
33268860|NCT00136357|Experimental|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
32743536|NCT04955145|Active Comparator|Ruta C 60 group|Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg Dosage:2 tablets three times daily for 4 months
33080667|NCT00204893|Experimental|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
33080668|NCT00232011|Experimental|1|
33080669|NCT00204971|Experimental|1|Nutritional supplement
33080670|NCT00204971|Placebo Comparator|2|placebo
33080671|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
33080672|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
33268861|NCT00136357|No Intervention|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
33268862|NCT00895700|Experimental|Web-based behavioral intervention|
33268863|NCT00895700|No Intervention|Usual care|
33268864|NCT00129649|No Intervention|control group|This group received usual care and did not receive a telephone reminder
33080673|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
33080674|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
33080675|NCT00205361||1|well-nourished
33080676|NCT00205361||2|malnourished
33080677|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
33080678|NCT00232245|No Intervention|Control|No fish oil exposure
33268865|NCT00129649|Active Comparator|telephone reminder group|This group received a telephone reminder for their clinic appointment
33268866|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
33268867|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
33268868|NCT00895856||Old-aged people|
33268869|NCT04927533|Experimental|Older adults with psychiatric problems|The target group is a group of older adults with psychiatric problems (≥60 years old) admitted to a residential psychogeriatric department of the Psychiatric Clinic of the Alexians Care Group Tienen. The following exclusion criteria apply: a score of less than 21 on the MMSE (excluding dementia or other moderate to severe cognitive disorders), a mother tongue other than Dutch and having undergone surgery and/or chemotherapy in the last 3 months.
33268870|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
33268871|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
33268872|NCT00187135|Active Comparator|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
33268873|NCT00187135|Active Comparator|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
33268874|NCT00187135|Placebo Comparator|3|normal saline
33268875|NCT00896324|Active Comparator|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
33268876|NCT00896324|Active Comparator|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
33268877|NCT00896324|Sham Comparator|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
33268878|NCT00528021|Active Comparator|1|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
33268879|NCT00528021|Active Comparator|2|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
33268880|NCT00528021|Active Comparator|3|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
33268881|NCT00528021|Placebo Comparator|4|
33268882|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
33268883|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
33268884|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
33268885|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
33268886|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
33268887|NCT04037696|Experimental|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
33080679|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
33080680|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
33268888|NCT04037696|Other|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
32743537|NCT04955145|Active Comparator|C- Retard group|Ascorbic acid 500mg capsule dosage: 1 capsule two times daily for 4 months
33080681|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
33268889|NCT00944736|Active Comparator|VSL#3|
32743538|NCT04955145|No Intervention|Control group|No intervention
33080682|NCT00205556|Other|1: low flux hemodialysis|standard treatment
33268890|NCT00944736|Placebo Comparator|Placebo|
33268891|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
32743539|NCT04933461|Other|Simulation of skin pricking by using Medlance Plus|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
33268892|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
33268893|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
33268894|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
33268895|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
33268896|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
33268897|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
33268898|NCT00893048|Experimental|Placebo|
33268899|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
32743540|NCT04933461|Other|Simulation of skin pricking by using myLance|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
32743541|NCT04955301|No Intervention|Control message group|Participants will not receive the priming manipulation.
32743542|NCT04955301|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
32743543|NCT04955301|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
32743544|NCT04955301|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
32743545|NCT04955067||Normal control group-Grade 0|Arthroscopic examination of the ankle joint was normal, and the ligament was intact without injury or tear.
32743546|NCT04955067||Ligament injury -Grade 1|Arthroscopic examination of the ankle joint showed ligament degeneration or injury, but no local or complete tear.
32743547|NCT04955067||Ligament tear-Grade 2|Arthroscopy of the ankle joint revealed partial or complete loss of ligaments.
32743548|NCT04929171||Patients with myofascial pain having centralized pain features|Adult patients with myofascial pain having centralized pain features who will be undergoing physical therapy
32743549|NCT04928937||bariatric surgery|consisting of gastric bypass surgery: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)
32743550|NCT04928937||conservative therapy|consisting of medical visits, nutritional counseling, physiotherapy, anti-obesogenic medication and psychological coaching
32743551|NCT04928469||P.1|Patients infected with the P.1 SARS-CoV-2 variant
32743552|NCT04928469||Other variants|Patients infected with SARS-CoV-2 variants other than P.1
32743553|NCT04922151|Experimental|group I|601 1.25mg
32743554|NCT04922151|Active Comparator|group II|Ranibizuman 0.5 mg
32743555|NCT04928859||the albumin group|The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group.
33080683|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
33080684|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
33268900|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
33268901|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
33268902|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
33268903|NCT00557076|Experimental|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
33080685|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
33080686|NCT00229437|Experimental|TAK-128 5 mg QD|
33080687|NCT00229437|Experimental|TAK-128 50 mg QD|
33268904|NCT00557076|Sham Comparator|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
33268905|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
33268906|NCT04036448||Lenalidomide in Refractory/relapsed rrMC/ Follicular lymphoma population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. For the Follicular lymphoma (FL), the recommended starting dose of rituximab is 375 mg/m2 intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for Cycles 2 through 5.
33080688|NCT00229437|Experimental|TAK-128 100 mg QD|
32773429|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
32773430|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
33080689|NCT00229437|Placebo Comparator|Placebo QD|
33268907|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
32773431|NCT05662553|Experimental|Ablation|After randomization, the enrolled patients in this arm should be performed path simulation under ENB with preoperative CT. On the operation day, single-cavity intubation will be carried out first, and the secondary lesion will be reached through the planned path. After that，the biopsy tissue of the lesion will be sent to ROSE for detection. If malignant，the ablation will be performed，and the location, energy and ablation time will be adjusted according to intraoperative CT. After ablation, radical surgery will be performed on the primary lesion.
33080690|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
33080691|NCT00205907|Experimental|single|BLVR treatment
33080692|NCT00205946|Placebo Comparator|Placebo|
33080693|NCT00205946|Active Comparator|Bupropion|
33080694|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
33080695|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
33268908|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
33268909|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
33268910|NCT04017728|Active Comparator|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
33268911|NCT04017728|Experimental|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
33080696|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
33080697|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
33080698|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
33080699|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
33080700|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
33080701|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
32773432|NCT05662553|Active Comparator|Surgery|The control group will undergo VATS treatment on the primary lesion on the day of operation, and will be re-admitted to the hospital after discharge and recovery (3-4 months) for contralateral secondary lesion surgery.
33080702|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
32773433|NCT04973293|Experimental|Neoadjuvant treatment|"Participants will receive 4 doses of sintilimab (200 mg, IV) and bevacizumab (15 mg/kg, IV) every 3 weeks (Q3W). Participants will also receive 4 doses of carboplatin (AUC=5, IV) and pemetrexed (500 mg/m2, IV) Q3W.~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.~After the second dose of sintilimab, bevacizumab and chemotherapy, contrast-enhanced chest CT will be performed. Patients with progression disease will receive surgery without the last 2 doses of treatment."
32773434|NCT05657249|Experimental|US & MRI|All participants undergo biannual US (as a part of standard-of-care) and annual non-contrast focused MRI.
32773435|NCT04972903||Group 1.HIV+/SAM+|Group 1. HIV-infected with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV+/SAM+)
32773436|NCT04972903||Group 2. HIV+/SAM-|Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)
32773437|NCT04972903||Group 3. HIV-/SAM+|Group 3. HIV-negative with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV-/SAM+)
32773438|NCT04972903||Group 4. HIV-/SAM-|Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)
32773439|NCT04962997||Transgender women|Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022
32773440|NCT05067569|Experimental|Digital brief behavioural therapy for insomnia|Participants randomised to the digital brief behavioural therapy for insomnia (SleepFix app) will be provided an unique access code to download the app. The intervention uses sleep retraining therapy to reduce excess time spent in bed and retrain sleep by matching time in bed (minimum of five and a half hours) to total sleep time. All participants in the intervention arm will also be provided a sleep-tracking wearable device (Fitbit) which will synchronised bed times (going to bed and rising) and are synchronised with the SleepFix app. Participants wil complete a daily sleep diary, rate sleep quality and mood. The intervention is provided for 6 weeks.
33080703|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
32773441|NCT05067569|Active Comparator|Sleep Health Education wait-list control|"Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are three modules provided bi-weekly with information about sleep health and broad details about managing sleep disturbances. Participants will receive a link to this information as each module is made available.~Upon completion of the study (week 26), the control group will receive free access to the SleepFix mobile application."
33268912|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
33268913|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
32773442|NCT04972669|Sham Comparator|control group|sham electroaupuncture
32773443|NCT04972669|Experimental|experimental group|Electroaupuncture
32773444|NCT05061173|Experimental|Aerobic exercise training Group|
32773445|NCT05061173|Experimental|Resistance Exercise Training Group|
32773446|NCT05061173|Experimental|Combined Exercise Training Group|
32773447|NCT04962451|Experimental|Intervention group|
32773448|NCT04962451|Placebo Comparator|Placebo group|
33080704|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
32773449|NCT05059925|Experimental|Structured gym activities|Planned and structured activities such as Strength training for 4 weeks
32773450|NCT05059925|Active Comparator|Traditional aerobic activities|Activities performed such as Treadmill , Cycle ergometer , Elliptical exercises for 4 weeks
32773451|NCT04962295||Cerebral Small Vessel Diseases group|CSVD patients
32773452|NCT05010083|Experimental|diet and lifestyle program|
32773453|NCT04953715||1 - This is a multicenter microbiome and pharmacokinetic study.|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied. To assess the relationship between kidney graft outcomes and stool, oral, nasal and urine microbiome diversity. To assess the relationship between transplant graft outcomes and urinary transcriptome.
32773454|NCT04980833|Experimental|Alpelisib|All participants will receive alpelisib once a day
33080705|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
33080706|NCT00229671|Experimental|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
33268914|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
33268915|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
33268916|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
33268917|NCT00943176|Placebo Comparator|Sugar Pill|
32773455|NCT04972591||CHB Group|Patients with CHB
32773456|NCT04972591||Compared Group|Healthy people
33080707|NCT00229671|Experimental|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
33080708|NCT00411203|Active Comparator|Tamoxifen Citrate|
33268918|NCT00943176|Experimental|Modafinil|
33268919|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
33268920|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
33268921|NCT00896636||Menopause|Women who have entered menopause.
33401684|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
33401685|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
33401686|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
33080709|NCT00411203|Placebo Comparator|Placebo|
33080710|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
33401687|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
33401688|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
33080711|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
33401689|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
33401690|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
33401691|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
33401692|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
33401693|NCT04479202|Experimental|berberine group (B group)|Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.
33401694|NCT04479202|Sham Comparator|control group (C group)|Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.
33401695|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
33401696|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
33401697|NCT05511064|Experimental|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT)
32743205|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
32743206|NCT04957875||urgent endoscopy group|endoscopy <6h after admission
32743207|NCT04957875||early endoscopy group|endoscopy 6-24h after admission
32743208|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
32743209|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
32743210|NCT04932837||migrant worker residents|The target population will be the 124 residents in the 2 migrant worker residences who were included in the previous seroprevalence study and those who arrived at the 2 residences since September 1st, 2020
33080712|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
33080713|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
33080714|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
33080715|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
33080716|NCT00206648|Experimental|Arm 1|
33080717|NCT00206648|Active Comparator|Arm 2|
33080718|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
33080719|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
33080720|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
33080721|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
33080722|NCT00424710|Other|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
33080723|NCT00206843|Experimental|Results available|
33080724|NCT00206843|No Intervention|Results blinded|
33080725|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
33080726|NCT00232830|Active Comparator|2|Bare-metal stent
33080727|NCT00206960|Active Comparator|1|
33080728|NCT00206960|Active Comparator|2|
33080729|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
33080730|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
33080731|NCT00206999|Experimental|1|
33080732|NCT00207077|Experimental|A|
33401698|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
32773457|NCT04916249|Experimental|Tibetree pain relieving plaster|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
32773458|NCT04916249|Placebo Comparator|Placebo plaster groups|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
32773459|NCT04953793|Experimental|TAY SUCCESS intervention|This intervention group received the TAY SUCCESS intervention over the course of 1 school year approximately 30 sessions.
33401699|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
33401700|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
33401701|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
33080733|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
33401702|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
33080734|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
32773460|NCT04953793|Active Comparator|Usual Care|This usual care group received typical High school or transition program curriculum over the course of 1 school year.
32773461|NCT04953871|Experimental|Spondyloarthritis|Spondyloarthritis patients who was initiated TNF alfa blocker
32773462|NCT04866719|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
33401703|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
32773463|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
32773464|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
32773465|NCT04980599|Active Comparator|K56 very high dose -E1|Probiotic drink (lactobacillus paracasei K56 10^11CFU) 350ml/d , for 60days
32773466|NCT04980599|Placebo Comparator|control -E2|maltodextrin , for 60days
32773467|NCT04980599|Active Comparator|K56 high dose-E3|Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10^10cfu) , for 60days
32773468|NCT04980599|Active Comparator|K56 middle dose-E5|Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10^9cfu) , for 60days
32773469|NCT04980599|Active Comparator|K56 low dose -E7|probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10^7cfu) , for 60days
32773470|NCT04980599|Active Comparator|K56 middle dose-E9|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^9cfu) ,for 60days
32773471|NCT04980599|Active Comparator|K56 high dose-E1K|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^10cfu), for 60days
32773472|NCT04980599|Active Comparator|K56 very high dose-E11|probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10^11cfu) ,for 60days
32773473|NCT04972435|Experimental|Multifocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with multifocal intraocular lens implantation.
32773474|NCT04972435|Sham Comparator|Monofocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with monofocal intraocular lens implantation which are the standard IOL.
32773475|NCT05653271|Experimental|Treatment Group A (ACE1831)|ACE1831 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE1831.
33080735|NCT00207116|Experimental|A|
32773476|NCT05653271|Experimental|Treatment Group B (ACE1831 and obinutuzumab)|ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.
32773477|NCT04972357||Standard RYGB|
32773478|NCT04972357||Banded RYGB|
33080736|NCT00232908|Experimental|1|
33080737|NCT00207155|Experimental|A|
33080738|NCT00413673|Experimental|1|PRK
33080739|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
33080740|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
33080741|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
33080742|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
33080743|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
33080744|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
32773479|NCT04972357||Extended pouch RYGB|
33080745|NCT04721496|Experimental|Trained|Athletes who had at least 2 years of continuous strength training experience, and at least 6 months of training with unstable situations and device
33080746|NCT04721496|Experimental|Untrained|Athletes who had at least 2 years of continuous strength training experience, but no training experience with unstable situations and devices
33268922|NCT00129259|Experimental|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 [Cycle 1] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)[Cycle 2]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
33080747|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
33080748|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
33080749|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
33268923|NCT00129259|Active Comparator|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
33268924|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
33268925|NCT00896714|Experimental|Closed loop anesthesia|
33268926|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
33268927|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
32743211|NCT04937205||Cohort 2|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on February 13, 2019.
32743212|NCT04937205||Cohort 3|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on November 5, 2019.
32743213|NCT04937205||Cohort 4|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on October 22, 2020.
33080750|NCT00233142|Experimental|Expressive writing|Expressive writing
33080751|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
33080752|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
33080753|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
33268928|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
33268929|NCT04017572|Active Comparator|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
33268930|NCT04017572|Active Comparator|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
32743214|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
33080754|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
33080755|NCT00233220|Active Comparator|2|Patients will receive usual care.
33080756|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
33080757|NCT00233259|Placebo Comparator|2|Control group
33080758|NCT00207857||With and Without PFTs|
33080759|NCT00411320|Active Comparator|Group 1|Smokers with asthma
33080760|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
33080761|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
33080762|NCT00411320|No Intervention|Group 4|Non smokers without asthma
33080763|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
33080764|NCT01089556|Experimental|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
33080765|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
33080766|NCT01089556|Experimental|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
33268931|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
33268932|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
33268933|NCT00186901|Placebo Comparator|1A|Nutritional counseling + placebo
33268934|NCT00186901|Experimental|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
33268935|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
33268936|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
32773480|NCT05651945|Experimental|Cardiac rehabilitation group|Traditional medically supervised center-based cardiac rehabilitation program; including 36 sessions (30-50 minutes) of a progressive exercise program and educational sessions for cardiovascular disease (CVD) risk factors.
33080767|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
32743215|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
32743216|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
33268937|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
33268938|NCT00943332||spica casting|
33268939|NCT00943332||intramedullary nailing|
32743217|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
32773481|NCT05651945|No Intervention|Standard of care|Depending on functional deficits, conventional rehabilitation therapies can include physical therapy, occupational therapy, and/or speech therapy sessions with 2-3 visits per week. Participants will receive their standard of care therapies as prescribed by their treating physicians.
33080768|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
33080769|NCT00411359|No Intervention|Monitoring|Carry on life as normal
33268940|NCT00943332||submuscualr plating|
33268941|NCT04036370|Active Comparator|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
33268942|NCT04036370|Sham Comparator|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
33268943|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
33268944|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
33268945|NCT00186121|Experimental|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
33268946|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
33268947|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
33268948|NCT04392440|Experimental|intervention|
33268949|NCT04392440|Other|control|Usual care
33268950|NCT00186043|Experimental|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
33268951|NCT00186043|Placebo Comparator|Placebo|Placebo
33268952|NCT00897260|Experimental|1|
33268953|NCT00185965|Experimental|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
33268954|NCT00185965|Experimental|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
33268955|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
33268956|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
33268957|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
33268958|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
33268959|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
33268960|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
33268961|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
33268962|NCT00127933|Experimental|HER2-NEU Positive|
33268963|NCT00127933|Experimental|HER2-NEU Negative|
33268964|NCT03875313|Experimental|600 mg CB-839 + 1 mg Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with advanced or metastatic solid tumors.
33268965|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: ccRCC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received ≥ 2 prior systemic regimens including ≥ 1 vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy.
33268966|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: TNBC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic triple-negative breast cancer (TNBC) estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative who received ≥ 1 prior line of cytotoxic chemotherapy with no prior poly adenosine diphosphate ribose polymerase (PARP) inhibitor therapy for TNBC or platinum-based chemotherapy for metastatic TNBC.
33268967|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: CRC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with with incurable/locally advanced or metastatic colorectal cancer (CRC) who received appropriate oxaliplatin or irinotecan- and fluorouracil (5-FU)-based chemotherapy with or without bevacizumab.
33268968|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: Other Histology|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with other tumor types (prostate, urinary bladder, pancreas, and stomach).
33268969|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
33268970|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
32743556|NCT04928859||the control group|The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group.
32743557|NCT04928001|Other|Youth Thrive iCBT program|Youth Thrive iCBT online program
33080770|NCT00237159|Experimental|ZOL446|
33268971|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
33268972|NCT01008345|Placebo Comparator|placebo|
33268973|NCT04675515|No Intervention|Usual Tobacco Treatment|All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals
33268974|NCT04675515|Experimental|Intensive Tobacco Treatment|"Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ).~These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months."
33268975|NCT03999255|Experimental|Patients undergoing intrarenal surgery|
33268976|NCT05239533|Experimental|Safety lead-in Phase: Participants with Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. The protocol will start with a safety-lead in phase using a 3+3 design to establish the maximal tolerated dose (MTD) of 177Lu-labeled-girentuximab in combination with standard-dose nivolumab. The initial starting dose of 177Lu-labeled-girentuximab is 1804 MBq/m2 which is 75% of the single agent dose established in prior studies and will proceed as shown in the schema below. Once the MTD is established, a Simon two-stage optimal design will commence. 10 patients will be enrolled in the first stage and if no responses are observed, the study will be terminated. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
33268977|NCT05239533|Experimental|Phase 2 Participants|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
33268978|NCT04828083|Active Comparator|Ultrasound-guided adductor canal block with local anesthetic|Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
32743558|NCT04928547||U.S.|
32743559|NCT04928547||MRI|
32743560|NCT04928625|Experimental|SHR-A1904|
32743561|NCT04920747||S group|platin-5FU + trastuzumab
32743562|NCT04920747||T group|taxanes + platin-5FU + trastuzumab
32743563|NCT04927767|Experimental|Denture adhesives|Participants will be shown to apply the adhesive following the manufacturer's instructions. The denture is pressed firmly into place, then held firmly as the participant bites down to secure it. Participants will be instructed to apply the adhesive twice daily with an 8-hour interval.
32743564|NCT04927611||Gastroenteropancreatic neuroendocrine neoplasms|Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
32743565|NCT04927611||Pancreatic ductal adenocarcinoma|Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
32743566|NCT04927299|Experimental|Group A: Losartan + chlorthalidone|Administered orally, one tablet a day, for 2 months.
32743567|NCT04927299|Active Comparator|Group B: Losartan + hydrochlorothiazide|Administered orally, one tablet a day, for 2 months.
32743568|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
32743569|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
32743570|NCT03056547|Experimental|Induced dyspnea|
32743571|NCT04913181||Sepsis prediction model|This group of people was used for the clinician's decision, and the sepsis prediction model was used simultaneously for the prediction, but the model was not involved in the decision, and was only used for verification
32743572|NCT04913181||Daily clinical judgment of doctors|This group of people was used for the clinician's decision without sepsis prediction model.
32743573|NCT04913103|Experimental|single arm, open-label|combination of polatuzumab-vedotin, bendamustine and rituximab
33268979|NCT04828083|Sham Comparator|Ultrasound-guided adductor canal block with saline|Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
33268980|NCT05225961|Experimental|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 10 ml (500 micrograms) of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters).
33268981|NCT05225961|Active Comparator|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. One vial of ASPIRINA ® in not more than 250 ml in 0.9% sodium chloride solution, 5% and 10% glucose solution, Ringer's solution or lactated Ringer's. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial.
33268982|NCT00556998|Experimental|1|
33268983|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
33268984|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
33268985|NCT01564563|Placebo Comparator|Placebo|
33268986|NCT01564563|Experimental|Low dose|
33268987|NCT01564563|Experimental|High dose|
33268988|NCT00945204|Experimental|access to intermediate care clinics|
33268989|NCT00945204|No Intervention|usual care|
33268990|NCT05188521|Experimental|Cutaneous LP|Subjects with a diagnosis of cutaneous LP will receive Baricitinib (LY3009104) for a 16 weeks treatment period
33268991|NCT05188521|Experimental|Dose Escalation Extension Group|Subject that demonstrate a response to the 16 weeks of treatment with 2 mg of Baricitinib (LY3009104), but have not achieved a PGA 0 will receive 4 mg of Baricitinib (LY3009104) for 16 weeks
33268992|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
33268993|NCT05178927|Sham Comparator|Standard of Care-Group 1|"During treatments 1-5, radiation therapists will position the participant for treatment using the standard of care method.~During treatments 6-10, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method."
33268994|NCT05178927|Experimental|Mixed-reality guided patient setup-Group 2|"During treatments 1-5, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method.~During treatments 6-10, radiation therapists will position the participant for treatment using the standard of care method."
33268995|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
33268996|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
33268997|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
33268998|NCT01008657|Active Comparator|intranodular multipolar RFA|
33268999|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
33269000|NCT00940680|Active Comparator|losartan 100mg|
33269001|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
33269002|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
33269003|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
33269004|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
33269005|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
33269006|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
33269007|NCT00940758|Experimental|PEP02|
33269008|NCT01792752|Experimental|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
33269009|NCT01792752|No Intervention|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
33269010|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
33269011|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
33269012|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
33269013|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
33269014|NCT00527397|Experimental|A|Type 1 DM
33269015|NCT00943956|Experimental|Everolimus|Everolimus + radiation
33269016|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
32743574|NCT04913259|Other|Remote monitoring for elderly patients with cancer|
32743575|NCT04912635|No Intervention|Control|
33269017|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
33080771|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
33269018|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
33269019|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
32773482|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
32773483|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
33269020|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
32773484|NCT05619575|Experimental|CP1170 sound processor|Take home use of CP1170 Sound processor for 2 weeks followed by in booth testing of the investigational device.
33269021|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
33269022|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
33269023|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
33269024|NCT04012086|Experimental|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
33269025|NCT04012086|No Intervention|No physical therapy (CT)|Subjects in CT group received only standard medication.
33269026|NCT01529814|Experimental|New abutment connection implant|Implant with new abutment connection
33269027|NCT01529814|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
33269028|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
32743576|NCT04912635|Experimental|Intervention|
32743577|NCT04920669|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
33269029|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
33269030|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
33269031|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
33269032|NCT00944268|Experimental|Liquid and solid|
33269033|NCT00527319|No Intervention|Group A, control group|Supportive care only
33269034|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
33269035|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
33269036|NCT04597125|Experimental|Arm A|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive radium-223 dichloride
33269037|NCT04597125|Active Comparator|Arm B|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive second novel anti-hormonal therapy (NAH)
32743578|NCT04920669|Experimental|erector spinae block + dexmedetomidine|erector spinae block with 19 ml bupivacaine + dexmedetomidine
32743579|NCT04920669|No Intervention|control group|standard general anesthesia without any block
32743580|NCT04912947|Active Comparator|Dietary supplement|One cp/day of the IMMUSYSTEM food supplement for 3 months
32743581|NCT04912947|Placebo Comparator|Placebo|One cp/day of Placebo for 3 months
32743582|NCT04926753|Experimental|Experimental|5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1
33269038|NCT04115319|Experimental|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
33269039|NCT04115319|Active Comparator|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
33269040|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
33269041|NCT00562302|No Intervention|Control Group|Control group with no intervention
33269042|NCT04758195|Experimental|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
32743583|NCT04920357||Post-COVID-19|Persons with a verified previous COVID-19 infection
32743584|NCT04920357||COVID-19 naive|Persons that have no history of COVID-19
32743585|NCT04402437|Active Comparator|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
33269043|NCT04758195|Active Comparator|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
33269044|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
33269045|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
33080772|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
33269046|NCT04012632||cases|Early puberty cases of Han Chinese
33269047|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
33269048|NCT00134719|Experimental|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
33269049|NCT00134719|Active Comparator|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
32773485|NCT05619575|Active Comparator|CP1150 sound processor|In booth testing of CP1150 sound processor.
32773486|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
33269050|NCT00134719|Active Comparator|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
33269051|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
32773487|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
33080773|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
33269052|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
33269053|NCT03999177|Experimental|Kinect-TOLF prototype|
33269054|NCT05104827|Experimental|Healthcare providers|Healthcare providers employed in COVID-19 departments are referred to integrative oncology-trained practitioners for an evaluation of their two main concerns, followed by a 30-minute individually tailored integrative care.
33269055|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
32773488|NCT05617391||Pediatric Childhood Cancer Survivors|The comparison of two ECGs in terms of predictive risk.
32773489|NCT04972045|Experimental|CuminUP60®,then Curcumin capsules|Participants first received CuminUP60® 1600mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 1600mg on the eighth day in a fasting state.
33269056|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
33269057|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
33269058|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
33269059|NCT04591353|Experimental|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
33269060|NCT04591353|Active Comparator|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
33269061|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
33269062|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
33080774|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
33080775|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
33080776|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
32773490|NCT04972045|Experimental|Curcumin capsules,then CuminUP60®|Participants first received curcumin capsules 1600mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP60® 1600mg on the eighth day in a fasting state.
33080777|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
32773491|NCT05614115|Experimental|Empagliflozin 10mg|Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
32773492|NCT05614115|Experimental|Empagliflozin 25mg|Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability. At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.
32773493|NCT05614115|Placebo Comparator|Placebo|Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
33269063|NCT04754295|Experimental|STANDARD|In this arm standard monitoring of vital signs will be used during operation.
33269064|NCT04754295|Experimental|GDT|A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.
33269065|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
32773494|NCT04953481||Amyotrophic lateral sclerosis group|Patients with amyotrophic lateral sclerosis undergoing home care.
32773495|NCT04953481||Caregiver group|Caregivers
32773496|NCT04956887|Experimental|Intervention|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
32773497|NCT04956887|Placebo Comparator|Placebo|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning.
33080778|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
33080779|NCT00233532|Other|1|
32773498|NCT04953949|Experimental|NU-MAX®|Topical Hemostat
32773499|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
32773500|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
33269066|NCT04803825|Experimental|Heavy Slow Exercise|One dedicated physiotherapist will supervise and instruct the exercise program on an individual basis. If the patient doesn't have access to a dumbbell, it will be offered free rental from the physiotherapy ward. Follow-up on the exercises will be scheduled as needed and tele rehabilitation will be offered as an option. Additionally to HSR exercises, participants will be instructed to perform daily stretches of the forearm.
32773501|NCT05691413|Experimental|Product X facial cleanser|Participants will used Product X facial cleanser twice daily for 5 weeks
33080780|NCT00233532|Other|2|
33080781|NCT00233532|Other|3|
33080782|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
33080783|NCT00237198|Experimental|Letrozole|
33269067|NCT04803825|Active Comparator|Extracorporeal Shock wave therapy|The patients will receive rESWT (SwissDolodClast/EMS) once a week for three sessions. The treatment will be given by a physiotherapist trained in using rESWT. The rESWT is given on the ECRB tendon insertion area.
33269068|NCT04803825|Active Comparator|Information and advice|The information and advice group are given a single face-to-face session with a physiotherapist, lasting up to 60 minutes.
33269069|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
33269070|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
33080784|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
33269071|NCT04115007|Experimental|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
33269072|NCT04115007|Active Comparator|Arm B|Standard of care
33269073|NCT04012866|Experimental|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
32773502|NCT04971421||Benign ovarian tumors|All histological proven benign ovarian tumors
33269074|NCT04012866|Experimental|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
33269075|NCT04012866|Active Comparator|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
33269076|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
33269077|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
33269078|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
33269079|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
33269080|NCT05068791|Experimental|Psilocybin|Participants in the Psilocybin condition will receive .36 mg/kg of psilocybin.
33269081|NCT05068791|Active Comparator|Active Placebo|Participants in the Active Placebo condition will receive 2.6 mg/kg of dextromethorphan (DXM).
33269082|NCT04529577|Experimental|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
33269083|NCT04529577|Experimental|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
33269084|NCT00950196|Experimental|amantadine (PKMERZ)|
33269085|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
33269086|NCT04012554|Experimental|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
33269087|NCT04012554|Other|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
33269088|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
32773503|NCT04971421||Malignant ovarian tumors|All histological proven malignant ovarian tumors
32773504|NCT04971421||Borderline ovarian tumors|All histological proven borderline ovarian tumors
32773505|NCT05691335|Other|Standard CXL|Patients treated according to Dresden Protocol with epithelium-off CXL.
32773506|NCT05691335|Experimental|Accelerated CXL|Patients treated according to accelerated Protocol with epithelium-off CXL.
32773507|NCT05691335|Experimental|Transepithelial CXL|Patients treated according to transepithelial Protocol with epithelium-on CXL.
32773508|NCT04772885|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
32773509|NCT04772885|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
32773510|NCT04772885|Experimental|Food Effect Cohort in healthy subjects|Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.
33269089|NCT04521699|Experimental|CalmioGo + Standard of care|Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation
33269090|NCT04521699|No Intervention|Standard of Care|Stand of care alone with 12 weeks of Cardiac rehabilitation
33269091|NCT00526071|Experimental|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
33269092|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
33269093|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
33269094|NCT03143153|Experimental|Nivolumab + Ipilimumab|
33269095|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
33269096|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
33269097|NCT05191329||study group|40 patients with non surgical presbyopic correction e.g. glasses and 80 patients that underwent pseudophakic presbyopic correction with multifocal or trifocal IOLs
33269098|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
33269099|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
33269100|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
33269101|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
33269102|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is a patient safety checklist (two parts) for patients to be performed on paper or electronically: a) before admission to hospital, and b) under hospital stay (discharge)
33269103|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
33080785|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
33269104|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
33269105|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
33269106|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
33269107|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
33269108|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
33269109|NCT04887701|Experimental|Non-hormonal device therapy|Daily non-hormonal device therapy
33269110|NCT04887701|Sham Comparator|Sham Therapy|Daily non-hormonal sham device therapy
33269111|NCT00134563|Experimental|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
33269112|NCT00134563|Experimental|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
33269113|NCT00134563|Placebo Comparator|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
33269114|NCT04019171|Experimental|interval exercise training|
33269115|NCT04019171|No Intervention|waiting list|
33269116|NCT03966547|Experimental|Local anesthetic|
33269117|NCT03966547|Placebo Comparator|Isotonic NaCl|
33269118|NCT05189379|Experimental|Olfaction First|Participants assigned to this arm will undergo the experiment in the following order: Odour based Cue Reactivity Task, Monetary Incentive Delay Task, Image based Cue Reactivity Task
33269119|NCT05189379|Experimental|Image First|Participants assigned to this arm will undergo the experiment in the following order: Image based Cue Reactivity Task, Monetary Incentive Delay Task, Odour based Cue Reactivity Task
33269120|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
33269121|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
33269122|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
33269123|NCT02408861|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection throughout the study. Patients undergo PET and CT scan during screening and on study. Patients undergo bone marrow biopsy on screening and may undergo it during follow up.
32773511|NCT04772885|Experimental|Multiple dose cohort in HS and AD patients|A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.
33269124|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
33269125|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
33269126|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
33269127|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
33269128|NCT00185731|Experimental|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
33269129|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
32773512|NCT04772885|Experimental|Multiple dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.
32773513|NCT04962061|Experimental|Multidomain intervention|The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
33269130|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
33269131|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
33269132|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
32773514|NCT04962061|Experimental|Physical exercise intervention|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
33269133|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
32773515|NCT04962061|Active Comparator|Active control intervention|The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
32773516|NCT04755413|Experimental|Optimization Group|Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C<70 mg/dL, hemoglobin A1c <7%, blood pressure <130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index <30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.
33269134|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
33269135|NCT02390453|Active Comparator|Active Control|This consists of 45 minutes of group discussion of health and successful aging, 2 days a week for 12 weeks (24 sessions).
33269136|NCT04074707|Experimental|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (daily dosing, alternate-day dosing, every third-day dosing)
33269137|NCT04679051|Experimental|8 hours time in bed|Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
33269138|NCT04679051|Experimental|11 hours time in bed|Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.
33080786|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
33080787|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
33269139|NCT03075917|Experimental|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
32773517|NCT04755413|Active Comparator|Usual Care Group|Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.
32773518|NCT04755413|Other|Registry Group|Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.
32773519|NCT04938245||Observed Cohort|Participants with chronic pain scheduled to undergo externalized trial for assessment of spinal cord stimulation will undergo intraoperative stimulation and up to three postoperative visits where already externalized electrodes (used clinically for stimulation) will be used to record and stimulate using evoked complex action potentials (ECAPs) while also measuring other electrophysiological responses.
32773520|NCT04971577|Placebo Comparator|Control arm|
32773521|NCT04971577|Experimental|Treatment arm|
32773522|NCT04961983|Experimental|Intervention group|Tour guides who will receive a comprehensive travel health education model.
33269140|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
33269141|NCT03873987|Experimental|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
33269142|NCT03018587|Experimental|All subjects|All subjects will receive 1 truSculpt radiofrequency treatment in desired area.
33269143|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
33269144|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
33269145|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
33269146|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
33269147|NCT04072913|Other|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
33269148|NCT04072913|Other|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
33269149|NCT04072913|Other|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
33269150|NCT04072913|Other|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
33269151|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
33269152|NCT04072679|Experimental|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
33269153|NCT04975503||Young Women|Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
33269154|NCT04975503||Older Women|Older women, aged >50 years, with documented atherosclerotic cardiovascular disease
33269155|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
33269156|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
33269157|NCT00474760|Experimental|1|
33269158|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
33269159|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
33269160|NCT02911103|Experimental|Active|single arm study
33269161|NCT04072757|Active Comparator|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
33269162|NCT04072757|Placebo Comparator|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
33269163|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
33269164|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
33269165|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
33269166|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
33269167|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
33269168|NCT04073693|Active Comparator|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
33269169|NCT04073693|Placebo Comparator|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
33269170|NCT04097145|Experimental|Edwards PASCAL System & OMT|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
33080788|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
33080789|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
33269171|NCT04097145|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
33269172|NCT04097145|Experimental|Single-Arm Registry|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
33269173|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
33269174|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
33269175|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
33269176|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
33269177|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
33401704|NCT04528069|Experimental|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
32773523|NCT04961983|No Intervention|Control group|Tour guides who will receive no intervention.
32773524|NCT04961749|Experimental|Vibration group|This group will receive vibration stimulation while standing on a side-alternating vibration platform. Vibration sessions will occur three times per week over four-weeks. Each session will include three-minutes of vibration followed by three-minutes rest, completing this sequence three times per session
32773525|NCT04961749|No Intervention|Control group|This group will not receive vibration, but will rather hear a recording of the vibration, while still standing on the vibration platform. Still, this group will receive this training three times per week over four-weeks with a similar three-minute rotation as the vibration group.
33269178|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
33269179|NCT05001646|Experimental|In-home EMF protection device|
32901906|NCT05127876|Placebo Comparator|Group P|"Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group P: was a control group who received 0.9% saline 10 mL over 1 minute as a placebo.~Then under aseptic precautions, spinal anesthesia was administered."
33269180|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
33269181|NCT04073537|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
33269182|NCT04073537|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
33269183|NCT03998631|Placebo Comparator|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
33269184|NCT03998631|Experimental|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
33269185|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
33269186|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
33269187|NCT01020916|Experimental|Target Temperature 33°C|
33269188|NCT01020916|Active Comparator|Target Temperature 36°C|
33269189|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
33269190|NCT01020994|Experimental|LAS41003|
32901907|NCT05010174||Observational, long-term safety follow-up of patients who have received MDR product|Only patients who have received treatment with MDR product will be eligible for this study.
33269191|NCT01020994|Active Comparator|LAS189962|
33269192|NCT01020994|Active Comparator|LAS189961|
33269193|NCT00494026|Experimental|Pemetrexed + Carboplatin|
32901908|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
32901909|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
33269194|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
33269195|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
33269198|NCT04074837|Placebo Comparator|Placebo|Placebo liquid suspension.
33269199|NCT04074837|Active Comparator|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
33269200|NCT04074837|Active Comparator|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
33269201|NCT04074837|Active Comparator|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
33269202|NCT04074837|Active Comparator|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
33269203|NCT04074837|Active Comparator|NNI-362, 240 mg|NNI-362 at 240 mg in liquid suspension
32901910|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
33269204|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
33269205|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
32901911|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
32773526|NCT04953247||Methylprednisolone|"As there was no consensus on the use of steroids in the early stage of the COVID-19 pandemic, all steroid therapies were initiated at the time of admission at the discretion of attending physicians on the basis of clinical symptoms and CT images. According to our previous experience, intravenous methylprednisolone at a dose of 1.0-1.5 mg/kg every 12 h was initiated for 5 days or until oxygen saturation improved, followed by gradual tapering by 0.5 mg/kg every 3-5 days.~Standard care such as the use of antibiotics, ventilation, laboratory testing, and hemodynamic management were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China."
32773527|NCT04953247||Standard care|Standard care were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China.
33269206|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
33269207|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
33269208|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
33269209|NCT00127855|Experimental|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
33269210|NCT00127855|Experimental|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
32773528|NCT04953013||sodium bicarbonate group|Sodium bicarbonate was initiated within 48 hours after ICU admission.
32773529|NCT04953013||non-sodium bicarbonate group|Patients were not infused with sodium bicarbonate.
32773530|NCT04953169|Other|Video|The video is information regarding biobanking
33269211|NCT00127855|Experimental|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
33269212|NCT00127855|Active Comparator|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
32773531|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
32773532|NCT04425655|Experimental|Fludarabine and CPX351|"Induction 1:~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses~Induction 2 (residual leukemia after Induction 1):~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses~Optional consolidation, up to 2 cycles:~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
33269213|NCT00127855|Active Comparator|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
33269214|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
33269215|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
33269216|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
32773533|NCT04970719|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
32773534|NCT04970719|Active Comparator|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5 -day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
32773535|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
32773536|NCT04970797||Conventional treatment group|Western medicine treatment
32773537|NCT04970797||Combination treatment group|Xinglouchengqi decoction combined with western medicine treatment
33269217|NCT04207060|Experimental|Oral indomethacin 50 mg po BID|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed NSAID. Commercially available indomethacin will be utilized in this study. One capsule orally BID for 28 days. Those in the indomethacin arm will receive indomethacin 50 mg BID. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication.
33269218|NCT04207060|Placebo Comparator|Placebo po BID|"Participants in both study arms will receive study medication, one capsule orally BID for 28 days. Those in the placebo arm will receive placebo capsules BID.~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
33269219|NCT03996382|Other|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
33269220|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
32773538|NCT04970485|Experimental|Talking Matters intervention|Talking Matters is a group-level, two-pronged intervention for Black and African American 14 to 19 year old adolescents recruited from school- and community-based settings in Philadelphia, PA. Goals are to reduce teens' risk for unplanned pregnancy, sexually transmitted infections, and HIV, and to strengthen protective factors to improve health. The two prongs include (1) an adolescent-focused five-session, group-level intervention called We Get to Choose (WGTC) covering sexual and reproductive health (SRH) knowledge and skills, decision making and self-worth, healthy relationships, substance use and mental health; and (2) an adult-focused three-session, group-level training called Let's Talk Real Talk (LTRT) to build SRH knowledge and skills to communicate with teens about SRH. An opportunity to connect WGTC participants to trusted adults who completed LTRT is provided during one facilitated session conducted each quarter. LTRT participants are not human subjects of the study.
32773539|NCT04970485|No Intervention|Control Group|Business as usual
33269221|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
33269222|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
33269223|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
33269224|NCT03965767|Placebo Comparator|control|
33269225|NCT03965767|Active Comparator|local group|
33269226|NCT03965767|Active Comparator|systemic group|
33080790|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
33269227|NCT03965767|Active Comparator|combined local and systemic|
33269228|NCT00470626|Experimental|1|Vena Cava Filter
33269229|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
32773540|NCT04431817||Left transtibial|Left below knee amputation- 25
32773541|NCT04431817||Right transtibial|Right below knee amputation- 25
32773542|NCT04431817||Left transfemoral|Left above knee amputation- 25
32773543|NCT04431817||Right transfemoral|Right above knee amputation- 25
33269230|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
33269231|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
33269232|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
33269233|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
33269234|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
32773544|NCT04431817||Provider|Provider- 15
32901912|NCT05009862|Placebo Comparator|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
32901913|NCT05009862|Experimental|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
33080791|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
33269235|NCT00133705|Experimental|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
33269236|NCT00133705|Placebo Comparator|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
33269237|NCT00132769|Experimental|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
33269238|NCT00132769|Placebo Comparator|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
33269239|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
33269240|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
33269241|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
33269242|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
33269243|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
33080792|NCT00233688|Active Comparator|2|Surgical intervention
33269244|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
33269245|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
33269246|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
33269247|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
33269248|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
33269249|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
33269250|NCT02478255|Active Comparator|Healthy volunteers|
33269251|NCT00132691|Active Comparator|1|Immunosuppressant medication implant
33080793|NCT01085812|Experimental|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
33080794|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
33080795|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
33080796|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
33269252|NCT00132691|Active Comparator|2|Systemic corticosteroids with immunosuppressant drugs as needed
33269253|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
32773545|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
32773546|NCT04960969|Experimental|Time-restricted Feeding Group|Participants will apply time-restricted feeding (8 hours/day) for 28 days.
32773547|NCT04960969|No Intervention|Control Group|No intervention will be applied.
33269254|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
33269255|NCT02390427|Experimental|Arm A|"Arm A~- Taselisib with Trastuzumab emtansine (also called T-DM1)~Taselisib administered orally, daily in each treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
33269256|NCT02390427|Experimental|Arm B|"Arm B~-Taselisib with T-DM1 and Pertuzumab~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
33269257|NCT02390427|Experimental|Arm C|"Arm C:~Taselisib with Pertuzumab and Trastuzumab~Cohort C will not open without additional authorization from Genentech~Taselisib is administered oral, daily in each treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
33269258|NCT02390427|Experimental|Arm D|"Arm D~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel~Cohort will not be opened without additional authorization from Genentech~Taselisib- administered oral, daily in each treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
32773548|NCT04972201||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected.
32773549|NCT04972201||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.
32773550|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
32773551|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
32773552|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
33269259|NCT00125359|Experimental|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
33269260|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
33269261|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
33269262|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
33269263|NCT03966703|Experimental|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
33269264|NCT03966703|Experimental|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
33269265|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
33269266|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
33269267|NCT01076803|Experimental|Lanreotide (acetate)|
32901914|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
33080797|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
33269268|NCT01076881|Experimental|combined aerobic and resistance training|
33269269|NCT01076881|Active Comparator|resistance training alone|
33269270|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
33269271|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
33269272|NCT03998865|Experimental|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
32773553|NCT04936191|Experimental|DynamX Bioadaptor|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
32773554|NCT04936191|Active Comparator|DESyne Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
32773555|NCT04201353|Experimental|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
32773556|NCT04201353|No Intervention|Control|Participants attending control clinics will receive the standard of care.
33269273|NCT03998865|Active Comparator|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
33269274|NCT04028115|Experimental|Interventional|Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. In this, study no randomisation will occur. All patients will receive the same treatment.
33269275|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
33269276|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
33269277|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
33269278|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
33269279|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
33269280|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
33269281|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
33269282|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
33269283|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
33269284|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
33269285|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
33269286|NCT00132301|Active Comparator|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
33269287|NCT00132301|No Intervention|Arm 2: Standard of care|Standard of care
33269288|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
33269289|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
33269290|NCT03684057|Experimental|TAU + App-Delivered Mindfulness Training (MT)|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
33269291|NCT03684057|Other|Treatment as Usual (TAU)|Individuals in the TAU group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control period)
33269292|NCT03864627|Placebo Comparator|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
33269293|NCT03864627|Experimental|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
33269294|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
33269295|NCT04303845|Experimental|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
33269296|NCT03995667|Experimental|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
33269297|NCT03964623||smokers|
32901915|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
33269298|NCT03964623||vapers|
33269299|NCT03964623||non smokers/non vapers|
33269300|NCT01634607||HIV uninfected|HIV negative patients
33269301|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
33269302|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
33080798|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
33080799|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
33269303|NCT04269915|Experimental|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
33269304|NCT04187703|Experimental|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.~Treatments will include:~5-azacytidine (50mg/m^2) Day 1 every week~Decitabine (5mg/m^2) Day 4 every week~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
33269305|NCT00131911|Experimental|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
33269306|NCT00131911|Experimental|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
33269307|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
33269308|NCT01077037|No Intervention|Control|Patient receives usual care.
33080800|NCT00208403|Active Comparator|1|Acryloc™ GHV
33269309|NCT03968887||Case group|Patients with postoperative delirium.
33269310|NCT03968887||Control group|Patients who have not had postoperative delirium.
33269311|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
33269312|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
33269313|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
33269314|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
33080801|NCT00208403|Active Comparator|2|Palacos R
33080802|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
33080803|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
33080804|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
33080805|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
33080806|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
33269315|NCT03968575|Experimental|Laser|
33269316|NCT00184093|Experimental|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
33269317|NCT01074619|Experimental|1|Memantine
33269318|NCT01074619|Placebo Comparator|2|Placebo
33269319|NCT00183625|Active Comparator|Risperidone Plus Supported Employment|
33269320|NCT00183625|Active Comparator|Olanzapine Plus Supported Employment|
33269321|NCT00183625|Active Comparator|Risperidone+Supported Employment+Skills|
33269322|NCT00183625|Active Comparator|Olanzapine+Supported Employment+Skills|
33269323|NCT00511875|Experimental|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
33269324|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
33269325|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
33269326|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
33269327|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
33269328|NCT00183391|Active Comparator|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
33269329|NCT00183391|Active Comparator|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
33269330|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
33269331|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
33269332|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
33269333|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
33269334|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
33269335|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
33269336|NCT03997006|Active Comparator|Group A (n=30)|Aminophylline group
33269337|NCT03997006|Active Comparator|Group NA (n=30)|Neostigmine/Atropine group
33269338|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
33269339|NCT01015144||Atorvastatin|
33269340|NCT01015144||No statin|
33269341|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
33269342|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
33269343|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
33269344|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
33269345|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
33269346|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
33269347|NCT04072367|Other|Active Treatment Group|NeVa Stent Retrievers
33269348|NCT04072367|Other|Control Device|Solitare Stent Retrievers
33269349|NCT03996538|Experimental|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
33269350|NCT03996538|Placebo Comparator|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
33269351|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
33269352|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
33269353|NCT03998475|Experimental|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
33269354|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
33269355|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
33269356|NCT00182689|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33269357|NCT04156191|Experimental|ARQ-151 cream 0.15% or 0.05%|Open-label study of 0.15% or 0.05% active concentration
33269358|NCT01326247|No Intervention|0.9% NaCl solution|
33269359|NCT03860259|Placebo Comparator|Auriculotherapy without nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
33269360|NCT03860259|Active Comparator|Auriculotherapy with nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
33269361|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
33269362|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
33269363|NCT04071509|Experimental|Percutaneous Lung Biopsy|
33269364|NCT00131365|Experimental|ExAblate MRgFUS|Treatment with the ExAblate 2000 system Version 4.1
33269365|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
33269366|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
33269367|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
33269368|NCT01077115|Experimental|Laparoscopic cholecystectomy|
33269369|NCT01077115|Active Comparator|Open cholecystectomy|
33269370|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
33080807|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
33080808|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
33269371|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
33269372|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
33269373|NCT03998085|Experimental|anlotinib|
33269374|NCT00579579||1|Patients Undergoing Surgery for Rectal Cancer
33269375|NCT02224391|Experimental|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
33269376|NCT02224391|Sham Comparator|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
33269377|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
33080809|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
33080810|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
33269378|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
33269379|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
33080811|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
33269380|NCT01021384|Other|Problem Solving Education|
33269381|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
33269382|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
33269383|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
33269384|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
33269385|NCT04770675||Treatment group|Any subject who is scheduled to undergo bronchoscopy as per routine clinical practice
33269386|NCT03816345|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue, blood, and cerebral spinal fluid (CSF) on study.
33080812|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
33080813|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
33269387|NCT04202692|Experimental|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
33080814|NCT00237393|Experimental|1|Quetiapine
33080815|NCT00237393|Placebo Comparator|2|
33080816|NCT00208559|Other|1 Open Label|Open Label
33080817|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
33080818|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
33269388|NCT04202692|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
33269389|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
33269390|NCT03998787||Healthy Subjects|Healthy subjects
33269391|NCT01721291|Experimental|COPD 1|COPD patients
33269392|NCT01721291|Experimental|Healthy|Healthy participants
33269393|NCT01721291|Experimental|COPD 2|Second group of COPD patients
33269394|NCT01721291|Active Comparator|Asthmatics|Asthmatics patients
33269395|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
33269396|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
33269397|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
33269398|NCT02579369|Experimental|ALLO-ASC-DFU|
33269399|NCT02579369|Active Comparator|Conventional Therapy|
33269400|NCT04840511|Experimental|lidocaine group|The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy
33080819|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
33269401|NCT04840511|Placebo Comparator|control group|The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy
33269402|NCT04072133|Experimental|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
33269403|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
33269404|NCT05007275|Experimental|Single arm, dose escalation|Experimental: Healthy Volunteers Biological/Vaccine: AZD1222 (1x10^9 vp, 5x10^9 vp and 1x10^10 vp)
33269405|NCT04196062|Experimental|Robotic ESD|Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system
33269406|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33269407|NCT01021696|No Intervention|Treatment as usual|Control group
33269408|NCT01021696|Active Comparator|Paracetamol|Intervention group
33269409|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
33269410|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
33269411|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
33269412|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
33269413|NCT04669301|Active Comparator|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
33269414|NCT04669301|Experimental|MAAT-G intervention|The MAAT-G intervention will be delivered by a trained psychology fellow at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPPA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPPA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study
33269415|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
33269416|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
33269417|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
33269418|NCT04827407|Experimental|Basic therapy + Efferon LPS|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
33269419|NCT04827407|No Intervention|Baseline therapy|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.
33269420|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
33080820|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
33080821|NCT01083316|Experimental|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
33080822|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
33080823|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
33269421|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
33269422|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
33269423|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
33080824|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
33269424|NCT04073459|Experimental|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
33269425|NCT04073459|Experimental|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
33269426|NCT04073459|Experimental|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
33269427|NCT04073459|Active Comparator|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
33269428|NCT01018576|Experimental|Delayed cord clamping|
33269429|NCT02577341|Experimental|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
33269430|NCT02577341|Active Comparator|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
33269431|NCT03998800|Experimental|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
33269432|NCT03998800|Experimental|L-arginine|10 days of supplementation with 3 g of L-arginine per day
33269433|NCT03998800|Placebo Comparator|Placebo (corn-starch)|10 days of supplementation with corn-starch
33269434|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
33269435|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
33269436|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
33269437|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
33269438|NCT01021774|Active Comparator|Advancement flap surgery|
33080825|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
33269439|NCT01021774|Active Comparator|Collagen plug|
33269440|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
33269441|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
33269442|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
33269443|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
33269444|NCT02577419|Experimental|Target Fortification|
33269445|NCT02577419|Experimental|Higher Initial Concentration|
33269446|NCT02577419|Active Comparator|Portagen Growth Reference|
33269447|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
33080826|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
33080827|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
33269448|NCT04071665|Experimental|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
33269449|NCT04071665|Active Comparator|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
33269450|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
33269451|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
33269452|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
33269453|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
33269454|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
33269455|NCT04779827|Experimental|Egalitarian Networks of Homogeneous Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
33269456|NCT04779827|Experimental|Egalitarian Networks of Diverse Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
33269457|NCT04779827|Experimental|Centralized Networks of Homogeneous Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices."
33269458|NCT04779827|Experimental|Centralized Networks of Diverse Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices."
33269459|NCT04779827|Experimental|Independent Control of Homogeneous Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
33269460|NCT04779827|Experimental|Independent Control of Diverse Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
33269461|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
33269463|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
33269464|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
33269465|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
33269466|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
33269467|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
33269468|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
33269469|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
33269470|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
33269471|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
33269472|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
33269473|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
33269474|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
33269475|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
33269476|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
33269477|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
33269478|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
33269479|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
33269480|NCT03987022|Experimental|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive~ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.~Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
33269481|NCT03987022|Active Comparator|Standard of care|"Regimen #2 STANDARD Postoperative Regimen~Once out of the PACU patients will receive Standard postoperative regimen~Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain~Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain~Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain~Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
33269482|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
33269483|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
33269484|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
33269485|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
33269486|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
33269487|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
33269488|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
33269489|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
33269490|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
33269491|NCT04073381|Experimental|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
33269492|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
33269493|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
33269494|NCT01025206|Experimental|BI-505|
33269495|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
33269496|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
33269497|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
33269498|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
33269499|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
33269500|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
33269502|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
33269503|NCT05673317|Experimental|Experiment Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the breastfeeding application at admission to labor and delivery or in the immediate postpartum period. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
33269504|NCT05673317|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
33269505|NCT05212857|Experimental|systemic treatment combined with radical treatment and radiotherapy|"All recruited participants would receive long-term and unified systemic treatment. Systemic treatment is defined as chemical castration plus new-generation anti-androgen therapy.~For the primary lesion:~The preferred local treatment for primary lesion is radical prostatectomy. Patients who refuse surgery or whose tumors cannot be surgically resected after 3 months' systemic treatment could receive radical radiotherapy.~For the metastatic lesion:~Radiotherapy for metastatic lesions would be performed between 4 weeks and 24 weeks after the local treatment for primary lesion. Stereotactic body radiation therapy (SBRT) is preferred, which could treat all the detected lesions at once or in stages."
33269506|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
33269507|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
33269508|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
33269509|NCT00468676|Active Comparator|B|Treatment as usual
33269510|NCT00468676|Experimental|A|Case management intervention
33080828|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
33080829|NCT00208793|Placebo Comparator|Placebo|
33080830|NCT00233883|Experimental|1|
33080831|NCT00233883|Active Comparator|2|
33269511|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).~A total of 40 participants will be enrolled."
33269512|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).~A total of 20 participants will be enrolled."
33269513|NCT01969643|Experimental|LV Dose Escalation|
33080832|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
33080833|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
33269514|NCT01969643|Experimental|LV + Trastuzumab|
33269515|NCT01969643|Experimental|LV Monotherapy|LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
33269516|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
33269517|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
33269518|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
33269519|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
33080834|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
33269520|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
33269521|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
33269522|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
33269523|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
33269524|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
33269525|NCT03995758|Active Comparator|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
33269526|NCT03995758|Active Comparator|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
33269527|NCT00129389|Active Comparator|Arm A: FAC|FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.
33269528|NCT00129389|Experimental|Arm B: FAC-wP|FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)
33269529|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
33269530|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
33269531|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
33269532|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
33269533|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
33269534|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
33269535|NCT04712981|Experimental|Intervention|HOPE intervention peer-led online community
33269536|NCT04712981|No Intervention|Control|Online community without HOPE intervention psychological components
33269537|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
33269538|NCT04071743|Active Comparator|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
33269539|NCT04071743|Sham Comparator|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
33269540|NCT02578667|No Intervention|Gorbly Compression not needed|
33269541|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
33269542|NCT04711343|Experimental|BAT2306 injection|150mg /1ml; subcutaneous injection
33269543|NCT04711343|Active Comparator|Cosentyx (US-licensed)|150mg /1ml; subcutaneous injection
33269544|NCT04711343|Active Comparator|Cosentyx (EU-licensed)|150mg /1ml; subcutaneous injection
33269545|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
33269546|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
33269547|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
33269548|NCT04609553|Active Comparator|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
33269549|NCT04609553|Experimental|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
33269550|NCT04609553|Experimental|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
33269551|NCT04071431|No Intervention|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
33269552|NCT04071431|Experimental|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
33269553|NCT04073927|Active Comparator|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
33269554|NCT04073927|Placebo Comparator|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
33269555|NCT00124657|Experimental|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and <26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
33269556|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
33269557|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
33269558|NCT02578589|Active Comparator|surgery|
33269559|NCT02578589|Active Comparator|Conservative treatment|
33269560|NCT01079845|Experimental|Low-glycemic Load Diet|
33269561|NCT01079845|Active Comparator|Low-fat Diet|
32773557|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
32773558|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
33269562|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
33269563|NCT04071197|Experimental|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
33269564|NCT04071197|Experimental|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
33269565|NCT00555906|Experimental|1|
33269566|NCT03817879|Experimental|VivaSight double-lumen tube|
33269567|NCT03817879|Active Comparator|Conventional double-lumen tube|
33269568|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
33269569|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
33269570|NCT03968497|Other|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
33269571|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
32773559|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
33269572|NCT01078129|Sham Comparator|non-CRT|no intervention
33269573|NCT04071899||Patients|patients with RBD
33269574|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
33269575|NCT01078285||Control|
33269576|NCT01078285||Intervention Arm|
33269577|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
33269578|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
33269579|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
33269580|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
32773560|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
32773561|NCT04961125||colorectal polyposis|
32773562|NCT04201197|Active Comparator|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
32773563|NCT04201197|Experimental|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC
32773564|NCT04201197|Experimental|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC and 640mg CBD
33080835|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
33080836|NCT04710186||Male patients with PAD|The cohort was built to collect information about the role of androgen receptor, insulin receptor and Insulin-like Growth Factor 1 Receptor (IGF-IR) expression in patients with peripheral artery disease referred to Vascular Surgeon Specialist.
33269581|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
33269582|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
33269583|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
33269584|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
33269585|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
32773565|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
33269588|NCT04071275|Active Comparator|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
33269589|NCT04071275|Sham Comparator|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
33080837|NCT00234000|Experimental|Arm 1|see description in intervention
33080838|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
33080839|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
33080840|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
33080841|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
33269590|NCT04071275|Experimental|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
33269591|NCT00709475||A|
33269592|NCT04071041|Experimental|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
33269593|NCT04071041|No Intervention|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
33269596|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).~Experimental procedures consist in:~Fibroscan measure, preceded by tracking sonography.~liver MRI (for substudy about MRI comparison, in step 2)~a blood test for biological assessment of liver functions"
33269597|NCT00555672|Experimental|A|
33269598|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
33269599|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
33269600|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
33269601|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
33269602|NCT04652375|Experimental|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
33269603|NCT04652375|Experimental|Lactated Ringer's Solution|Participants will receive lactated Ringer's for fluid resuscitation post-surgery
33269604|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
33080842|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
33080843|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
33080844|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
33269605|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
33269606|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
33269607|NCT03958656|Experimental|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
33269608|NCT03958656|Experimental|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
33080845|NCT00209261|Active Comparator|1|
33080846|NCT00209261|Active Comparator|2|
33269609|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
33269610|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
33269611|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
33269612|NCT00950274|Placebo Comparator|Placebo|
33269613|NCT03777306|Experimental|ARM A EARLY INTERVENTION GROUP|In Arm A, the intervention group, the participants will start on the program immediately. The participants will receive MPI educational program, implemented in parallel with standard of care treatment. The MPI is implemented at the time of enrollment x 12 weeks
33269614|NCT03777306|Experimental|ARM B DELAYED INTERVENTION GROUP|Arm B, is a wait-list control group that will serve as the control. The wait-list control group will be observed for an initial 12 week period while receiving usual care and then have the educational intervention implemented from week 12-24 in parallel with standard of care
33269615|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
33269616|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
33269617|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
33080847|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
33080848|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
33269618|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
33269619|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
33269620|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
33269621|NCT00463684|Experimental|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
33269622|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
33080849|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
33269623|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
33269624|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
33269625|NCT03996070|Active Comparator|Treatment arm|Therapeutic dose regime
33269626|NCT03996070|Placebo Comparator|Sham arm|Sub-therapeutic dose regime
33269627|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
33269628|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
33269629|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
33269630|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
33269631|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
33269632|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
32773566|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
32773567|NCT04970329|Experimental|Systane|Instill one drop three times a day for one month.
32773568|NCT04970329|Experimental|Tears Naturale 2|Instill one drop three times a day for one month.
32773569|NCT04970329|Placebo Comparator|Placebo|Instill one drop three times a day for one month.
32773570|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
32773571|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
32773572|NCT04970095|Experimental|cleft lip and palate patient|Clefts patient with transverse maxillary constriction and anteroposterior deficiency
32773573|NCT04960657|Active Comparator|PACAP38 and glibenclamide|Participants will receive glibenclamide after PACAP38 infusion
32773574|NCT04960657|Active Comparator|PACAP38 and placebo|Participants will receive placebo after PACAP38 infusion
32773575|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
32773576|NCT04960501||New tension band system|
32773577|NCT04960501||Patella reduction band system|
32773578|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
32773579|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
32773580|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
32773581|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
32773582|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
32773583|NCT04960345||The traditional group|The traditional group underwent prosthesis placement using traditional intramedullary positioning method.
32773584|NCT04960345||The navigation group|The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping.
32773585|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
32773586|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
32773587|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
32773588|NCT04960189|Experimental|Acupuncture|GB34 acupuncture will be applied every day. Patients will receive standard medical treatment
32773589|NCT04960189|No Intervention|Controls|Patients will only receive standard medical treatment
32773590|NCT04935255||Single Arm|The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.
32773591|NCT04960267|Experimental|Use of pre-peritoneal drainage after rTAPP|"Use of pre-peritoneal drainage after rTAPP~Outcomes will be compared with retrospective cohort from our previous experiments"
33269633|NCT00950508|Placebo Comparator|Standard medical treatment|
33269634|NCT00950586|Experimental|Cohort 1|14 days dosing
33269635|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
33269636|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
33269637|NCT00174187|Experimental|Somatropin|
32773592|NCT04960033||Osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
33269638|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
33269639|NCT01011335|Placebo Comparator|Placebo with Alum|
33269640|NCT01011335|Placebo Comparator|Saline Placebo|
33269641|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
33269642|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
32773593|NCT04960033||women without osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was <20% or the 10-year probability of HF was <3%.
33269643|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
33269644|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
33269645|NCT00579059|Other|2|Maxim® Regular Tibia
33269646|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
33269647|NCT00467818|Active Comparator|Omega 3 fatty Acids, drug|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
33269648|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
33269649|NCT00001373||Affected|Patients with auto-inflammatory disorders
33269650|NCT00001373||Family Members|Family members of patients
33269651|NCT00001373||Healthy Volunteers|Healthy Volunteers
33269652|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
33269653|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
33269654|NCT00709709|Experimental|1|Scan
33269655|NCT00709787||Hypertensive Subjects undergoing primary prevention|
33269656|NCT04069949|Experimental|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
33269657|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
33269658|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
33269659|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
33269660|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
33269661|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
32773594|NCT04952935|Experimental|True Acupuncture|
32773595|NCT04952935|Sham Comparator|Sham Acupuncture|
32773596|NCT04895111||Patients with suspected sarcoidosis|Consecutive patients with clinical and radiological (CT scan +/- PET) suspect of sarcoidosis
32898319|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
33269662|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
33269663|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride (CPC)|1.5mg CPC will be taken daily for four weeks.
33269664|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride (CPC)|4.5mg CPC will be taken daily for four weeks.
33269665|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
33269666|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
33269667|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
33269668|NCT00710099|Experimental|1|
33269669|NCT00710099|Active Comparator|2|SNP iontophoresis
33269670|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
33269671|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
33269672|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
33269673|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
33269674|NCT03944044|Other|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
33269675|NCT03944044|Other|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
33269676|NCT00553254|Experimental|1|
33269677|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
33269678|NCT05673239|Experimental|Test group|The patients in the test group were injected with levocarnitine on each dialysis day, and other conventional treatment drugs such as hemodialysis drugs were maintained in the original scheme and recorded in detail on the CRF form.
33269679|NCT05673239|No Intervention|Control group|The patients in the control group were the same as those in the test group, except that they were not treated with L-carnitine.
33269680|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
33269681|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
33269682|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
33269683|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
33269684|NCT00714701||High Risk Group 5|both parents affected
33269685|NCT00714701||Control 1|negative controls
33269686|NCT00714701||Control 2|chronic pancreatitis
33269687|NCT00714701||Control 3|pancreatic cancer
33269688|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
33269689|NCT01025518|Experimental|resistance training and dietary supplement|
32935752|NCT04379414|Experimental|Newly Diagnosed Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
33269690|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
32935753|NCT04379414|Experimental|Newly Diagnosed Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
32935754|NCT04379414|Experimental|Metastatic Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
32935755|NCT04379414|Experimental|Metastatic Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
33269691|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
33269692|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
33269693|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
33269694|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
32935756|NCT05049187||Group 1 COVISHIELD|Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
33269695|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
33269696|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
33269697|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
33269698|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
33269699|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
33269700|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
33269701|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
33269702|NCT00168805|Experimental|dabigatran etexilate 220 mg|220 mg once daily
33269703|NCT00168805|Experimental|dabigatran etexilate 150 mg|150 mg once daily
33269704|NCT00168805|Active Comparator|enoxaparin|40 mg once daily
33269705|NCT00950976|Experimental|Citrulline|
33269706|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
33269707|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
33269708|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
33269709|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
32773597|NCT05600465|Experimental|BA+OT intervention|Following baseline assessment, the PI, a BA-trained, licensed occupational therapist will deliver a 10-session manualized program in the participants' homes to ensure optimal uptake of the active ingredients and integration into daily life routines. This intervention occurs over 10 weeks. The intervention manual will include educational materials for the 4-step approach, and worksheets for goal setting and developing daily routines. In the 1st BA-OT session, the PI will collect baseline assessments and use Canadian Occupational Performance Measure (COPM) data to facilitate goal setting. The top 5 participant-selected goals chosen will be the subject of the 4-step process in sessions 2 - 10. At least one goal must be related to improving physical activity routines; each participant will receive a Fitbit Charge 5 to self-monitor fitness progress. The unbiased evaluator will carry out follow-up assessments at 10 weeks and 22 weeks with participants in both conditions.
32773598|NCT05600465|Placebo Comparator|Enhanced Usual Care|The enhanced usual care control group will receive the same assessment battery, a Fitbit Charge 5 with 1 hour training, and a handout about living with chronic conditions.
32773599|NCT04969393|Experimental|Group A (High Intensity Laser therapy + Conventional Physical Therapy)|Patients in group (A) received conventional physical therapy program along with HILT. Patients received pulsed Nd: YAG laser treatment, produced by EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2).
32901916|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
33269710|NCT04521725|No Intervention|Group1: ECG+SpO2 only|Traditional ECG (heart rate) and SpO2 (pulse oximetry) monitoring for resuscitation only.
33269711|NCT04521725|Active Comparator|Group 2: ECG+SpO2+RFM|Addition of Respiratory Function Monitor to ECG and SpO2 during resuscitation.
33269712|NCT04521725|Active Comparator|Group 3: ECG+SpO2+RFM+NIRS|Addition of cerebral NIRS and Respiratory Function Monitor to ECG and SpO2 during resuscitation.
33269713|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
33269714|NCT02574611|Experimental|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
33269715|NCT02574611|Experimental|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
33269716|NCT02574611|Active Comparator|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
33269717|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
33269718|NCT01025596|Experimental|CYT107|
33269719|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
33269720|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
33269721|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
33269722|NCT00714779|Active Comparator|1|Fluoxetine
33269723|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
33269724|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
33269725|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
33269726|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
33269727|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
33269728|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
33269729|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
33269730|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
33269731|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
33269732|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
33269733|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
33269734|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
32773600|NCT04969393|Active Comparator|Group B (Conventional Physical Therapy)|Patients in this group received the conventional physical therapy program in the form of splinting, tendon and neural gliding exercises. Patients were instructed to wear a neutral custom volar splint at night and while performing strenuous activities during the day for 5 weeks.Also, the patients performed nerve-and tendon-gliding exercise under direct supervision of the therapist during the treatment sessions. Each exercise was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
32773601|NCT05595083|Experimental|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
33269735|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
33269736|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
33269737|NCT00168103|Experimental|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
33269738|NCT00168103|Experimental|C1-INH 20 U/kg bw|20 U/kg bw dose
33269739|NCT00168103|Placebo Comparator|Placebo|
33269740|NCT04011228||Type 2 diabetic patients|
33269741|NCT04011228||Prediabetic patients|
33269742|NCT04011228||Women with gestational diabetes|
33269743|NCT04011228||Healthy control subjects|
33269744|NCT04011228||Pregnant women without gestational diabetes|
33269745|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
33269746|NCT03964753|Experimental|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.~Surgery:~4-6weeks after Neo-adjuvant chemotherapy"
33269747|NCT03964753|Active Comparator|Surgery alone|Surgery alone
33269748|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
33269749|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
33269750|NCT00710333|Placebo Comparator|1|500ng dose
33269751|NCT00710333|Experimental|2|
33269752|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
33269753|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
33269754|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
32773602|NCT05595083|Experimental|intravenous dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
32773603|NCT04960111|Experimental|knee arthroplasty with radiostereometry tecnique|patient underwent total knee arthroplasty with insertion of microsphere in tantallium for radiostereometry tecnique.
32901917|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
32901918|NCT05062434|Experimental|Intervention Arm|VA cardiac electrophysiologists receiving the intervention
32935757|NCT05049187||Group 2 COVAXIN|Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
33269755|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
33269756|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
33269757|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
33269758|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
33269759|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
33269760|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
33269761|NCT05300958|Experimental|Treatment arm|Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy
33269762|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
33269763|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
33269764|NCT04070729|Placebo Comparator|Negative control|Placebo gel
33269765|NCT04070729|Experimental|Test group 1|Hyaluronic acid gel
33269766|NCT04070729|Experimental|Test group 2|injectable prf
33269767|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
33269768|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
33269769|NCT00462904|Experimental|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
33269770|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
33269771|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
33269772|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
33269773|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg intravenous (IV) every 24 hours for at least 7-14 days, depending on the type of bacteria.
33269774|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
33269775|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
33269776|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
33269777|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
33269778|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:~11C Donepezil PET/CT scan~3D-Transit~3D-Transit during treatment with pyridostigmine~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
33269779|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:~11C Donepezil PET/CT scan~3D-Transit"
33269780|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
33269781|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
33269782|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
33269783|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
33269784|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
33269785|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
33269786|NCT04011306|Experimental|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
33269787|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
33269788|NCT00714935|No Intervention|1|
33269789|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
33269790|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33269791|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
33269792|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33269793|NCT00718601|Experimental|1|3+3 cohort dose escalation
33269794|NCT00951522|Experimental|1|GS-9411 2.4 mg
33269795|NCT00951522|Experimental|2|GS-9411 4.8 mg
33269796|NCT00951522|Experimental|3|GS-9411 7.2 mg
33269797|NCT00951522|Experimental|4|GS-9411 9.6 mg
33269798|NCT00951522|Placebo Comparator|5|Placebo
33269799|NCT00718679|Experimental|1|Study drug
33269800|NCT00718679|Placebo Comparator|2|Placebo
33269801|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
33269802|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
33269803|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
33269804|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
33269805|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
33269806|NCT00710723|Experimental|1|vitrification
33269807|NCT00710723|No Intervention|2|Slow freezing
33269808|NCT04323839||Pregnant Women|Women who are currently pregnant and are suspected or diagnosed COVID-19 positive.
33269809|NCT04323839||Post-partum women|Women who have been pregnant in the past 6 weeks and are suspected or diagnosed COVID-19 positive.
33269810|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
33269811|NCT00957216|Placebo Comparator|sugar pill|
33269812|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
33401705|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
33269813|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
33269814|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
32773604|NCT04888169|Experimental|Attention Bias Modification - Word Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
32773605|NCT04888169|Active Comparator|Attention Bias Modification - Face Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
32901919|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
33269815|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
33269816|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
33269817|NCT00718757|Experimental|1|
33269818|NCT00947466|Experimental|Patch|
33269819|NCT04069013|Active Comparator|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
33269820|NCT04069013|Active Comparator|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
33269821|NCT00951756|Other|High Fat Low Fiber Diet|
33269822|NCT00951756|Other|Low Fat High Fiber Diet|
33269823|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
33269824|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
33269825|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
33269826|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
33269827|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
33269828|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
33269829|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
33269830|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
33269831|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
32901920|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
33269832|NCT00718913|Experimental|1|TCX ->RT -> TCX
33269833|NCT04011930|Active Comparator|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)~other name D-rise"
33269834|NCT04011930|Placebo Comparator|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene~,magnesium stearate~other name D-rise"
33269835|NCT04068857|Experimental|rTMS|
33269836|NCT04068857|Sham Comparator|Sham|
33269837|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
33269838|NCT00715169|Active Comparator|1|
33269839|NCT00715169|Placebo Comparator|2|
33269840|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
33269841|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
33269842|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
33269843|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
32773606|NCT04888169|Experimental|Attention Control Training - Word Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
32773607|NCT04888169|Active Comparator|Attention Control Training - Face Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
32773608|NCT04888169|Placebo Comparator|Placebo Attention Training - Word Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
33269844|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
33269845|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
33269846|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
33269847|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
33269848|NCT00551616|Experimental|CDB-2914|
33269849|NCT00551616|Active Comparator|Levonorgestrel|
33269850|NCT00715325|Experimental|A|
33269851|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
33269852|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
33269853|NCT00719147||1|
33269854|NCT02572349|Experimental|IW-1701|Single Dose
33269855|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
33269856|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
33269857|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
33269858|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
33269859|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
33269860|NCT00549198|Experimental|ABC/3TC + EFV|
33269861|NCT00549198|Active Comparator|TDF/FTC + EFV|
33269862|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
33269863|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
33269864|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
33269865|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
33269866|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
33269867|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
33269868|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
33269869|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
33269870|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
32901921|NCT05126550||Immunogenicity|Group 1 constitutes the immunogenicity group which will be evaluated regarding immunogenicity, safety, and effectiveness of the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm
33269871|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
33269872|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
33269873|NCT04036526|Experimental|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
33269874|NCT04036526|Experimental|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
33269875|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
33269876|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
33269877|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
33269878|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
33269879|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
33269880|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
33269881|NCT04036604|Experimental|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
33269882|NCT04036604|No Intervention|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
33269883|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
33269884|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
33269885|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
33269886|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
33269887|NCT02572115|No Intervention|Control|This arm does not get the intervention.
33269888|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
33269889|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
33269890|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
33269891|NCT00452452|Experimental|A|
33269892|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
33269893|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~ER+, HER2-~ER+, HER2+~ER-, HER2+~ER-, PR+, HER2-~ER-, PR-, HER2-"
33269894|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
33269895|NCT04322435|Other|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
33269896|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
33269897|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
33269898|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
33269899|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
33269900|NCT04575051|Active Comparator|Residents|Residents will be exposed to the Consult Model and then the Engage Model. Hearing Specific Quality of Life and Satisfaction with Social Participation are the outcome measures. Hearing Specific Quality of Life is measured using the HHIE with a range of scores from 0-40 with a lower score revealing less handicap. Satisfaction with Social Participation is measured using the Satisfaction with Participation in Discretionary Social Activities Short form 7a with a range of scores from 7-35 with a higher score meaning higher satisfaction.
33269901|NCT04575051|Active Comparator|Family|Families will be surveyed related to burden during the Consult and Engage Model of Care. Family Burden will be measured using the Zarit Burden scale with a range of scores from 0-16 and a lower scoring revealing less burden.
33269902|NCT04575051|Active Comparator|Staff|Staff of the Assisted Living/Personal Care Facilities will be surveyed related to work satisfaction during the Consult and Engage Model of Care. Staff work satisfaction will be measured with the Michigan Organizational Assessment Questionnaire (MOAQ) with a range of scores from 3-18 and a lower score revealing higher satisfaction.
33269903|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
33269904|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
33269905|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
33269906|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
33269907|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
33269908|NCT05673161||anemia, treatment|anemic patients who had iron therapy
33269909|NCT05673161||anemia, no treatment|anemic patients who had no therapy
33269910|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
33269911|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
33269912|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
33269913|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
33269914|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
33269915|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
33269916|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
33269917|NCT03783442|Experimental|Tislelizumab + chemotherapy|"Tislelizumab administered with chemotherapy doublet:~Doublet A: Cisplatin or Oxaliplatin plus Fluorouracil (5-FU); Doublet B: Cisplatin or Oxaliplatin plus Capecitabine; Doublet C: Cisplatin or Oxaliplatin plus Paclitaxel"
33269918|NCT03783442|Active Comparator|Placebo + chemotherapy|"Placebo administered with chemotherapy doublet:~Doublet A: Cisplatin or Oxaliplatin plus Fluorouracil (5-FU); Doublet B: Cisplatin or Oxaliplatin plus Capecitabine; Doublet C: Cisplatin or Oxaliplatin plus Paclitaxel"
33269919|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
33269920|NCT05300646|Experimental|Intervention|The prenatal MBSR program is an adaptation of MBSR. Details on the adaptation process is described in Skovbjerg S et al. Pilot and feasibility studies, 2021 Jun 3; 7 (1):118. Prenatal MBSR include nine weekly two-hour classes and is delivered in a combination between physical attendance and live-online teaching. The recommended time for daily mindfulness training between sessions is 15 minutes a day with options for longer practice. Audio recordings with guided meditations and a video with yoga programs for pregnancy is provided for home practice.
33269921|NCT05300646|No Intervention|Treatment as usual|Standard clinical practice, usual care (TAU), consists of an average of six routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Routine pregnancy visits involves primarily preventive counselling by midwifes, and in some cases consultations with a physician or social worker throughout pregnancy and the early post-partum period. In some cases, usual care may include consultations with a psychologist, although usually limited to a few sessions, and in more severe cases referral to psychiatric treatment.
33269922|NCT04319237||All Participants|
33269923|NCT00518973|Placebo Comparator|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
33269924|NCT00518973|Experimental|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
33269925|NCT00897806||Genetic Markers|
33269926|NCT03905525|Experimental|Cohort 1 /Arm A|CFZ533 dose 1
33269927|NCT03905525|Experimental|Cohort 1/Arm B|CFZ533 dose 2
33269928|NCT03905525|Experimental|Cohort 1/Arm C|CFZ533 dose 3
33269929|NCT03905525|Placebo Comparator|Cohort 1/Arm D|Placebo dose (up to week 24)
33269930|NCT03905525|Experimental|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
33269931|NCT03905525|Experimental|Cohort 2/Arm E|CFZ533 dose 1
33269932|NCT03905525|Placebo Comparator|Cohort 2/Arm F|Placebo dose (up to week 24)
33269933|NCT03905525|Experimental|Cohort 2/Arm F1|CFZ533 dose 2 (from week 24)
33269934|NCT00958152|Experimental|Cohort 1|
33269935|NCT00958152|Experimental|Cohort 2|
33269936|NCT00958152|Experimental|Cohort 3|
33269937|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
33269938|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
33269939|NCT01022164|Other|fibrin glue|
33269940|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
33269941|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
33269942|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
33269943|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
33269944|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
33269945|NCT05300178||multiple vessel disease|patients with coronary artery disease will be revascularized by using different bypass configuration.
33269946|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
33269947|NCT04317287|Experimental|Cardio formulation|Tomato-based formulation with dietary supplement
33269948|NCT04317287|Placebo Comparator|Placebo|Placebo softgels
33269949|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
33269950|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
33269951|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
33269952|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
33269953|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
33269954|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
33269955|NCT00462670|Placebo Comparator|1|0mg
33269956|NCT00462670|Experimental|2|15mg OPC-41061
33269957|NCT01009593|Experimental|ABT-869|
33269958|NCT01009593|Active Comparator|Sorafenib|
33269959|NCT00719459|Experimental|1|Hospira Iron Sucrose
33269960|NCT00719459|Active Comparator|2|Venofer
33269961|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
33269962|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
33269963|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
33269964|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
33269965|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
33269966|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
33269967|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
33269968|NCT00958386|Experimental|1|Panitumumab+irinotecan
33269969|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
33269970|NCT04035512|Experimental|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
33269971|NCT04035512|No Intervention|Control group|Any intervention
33269972|NCT05352438|Experimental|Manual Therapy Group|Manual Therapy combined with education and home exercises
33269973|NCT05352438|Experimental|Splint Therapy Group|Splint Therapy combined with education and home exercises
33269974|NCT04069871|Active Comparator|TENS|
33269975|NCT04069871|Sham Comparator|Control|
33269976|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
33269977|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
33269978|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
33269979|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
33269980|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
33269981|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
33269982|NCT04068701|Experimental|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
33269983|NCT04068701|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
33269984|NCT05352360|Experimental|Pilates Exercises with kinesiotaping|
33269985|NCT05352360|Experimental|Muscle energy technique with kinesiotaping|
32773609|NCT04888169|Placebo Comparator|Placebo Attention Training - Face Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
32773610|NCT04888169|Sham Comparator|Control - Questions|The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.
32773611|NCT04968691|Experimental|Telerehabilitation group|The group to which a structured exercise program supported by telerehabilitation will be treated.
32773612|NCT04968691|Active Comparator|Control group|The group to which the home exercise program will be treated.
32773613|NCT05589701||Stereotactic Radiotherapy (SBRT)|Standard of care stereotactic radiotherapy.
32773614|NCT05589701||Conventional Radiotherapy (CRT)|Standard of care conventional radiotherapy.
33269986|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
33269987|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
33269988|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
33269989|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
33269990|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
33269991|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
33269992|NCT01009749|Experimental|MESA|
33269993|NCT01009749|Active Comparator|MESH|
33269994|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
33269995|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
33269996|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
33269997|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
33269998|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
33269999|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
33270000|NCT00948402|Experimental|metformin|
33270001|NCT00948402|Active Comparator|oral contraceptive|
33270002|NCT04068467|Experimental|Active|Instructed to download the app and use the app daily for 30 days.
33270003|NCT04068467|Active Comparator|Waitlist Control|Waitlist control.
33270004|NCT05352126|Experimental|Puressentiel Purifying spray|"Puressentiel Air Purifying Spray with 41 essential oils~Capacity: 200 ml~BIOCIDE Product type 2: Disinfectants used in the private and public health sector~Composition: Ethanol (CAS no. 64-17-5) 75% m/m and 41 essential oils"
33270005|NCT05352126|Placebo Comparator|Placebo|Saline spray in the similar device as Puressentiel Purifying spray
33270006|NCT00719927|Experimental|1|Comadre Treatment
33270007|NCT00719927|Active Comparator|2|Non Support Partner Treatment
33270008|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care (SOC) nucleos(t)ide (NrtI)-suppressed and HBeAg-negative will receive both ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.
33270009|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|"Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.~Subjects with insufficient virologic response will discontinue ABI-H0731 only and continue on SOC NrtI alone and followed-up for 12 weeks."
33277545|NCT05119400||COVID-19 group|"COVID-19 group will be made up of 30 patients that have a past diagnosis of COVID-19 with confirmed positive SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) PCR (polymerase chain reaction) test in their electronic medical record and were previously hospitalized at NYP/WCM (NewYork Presbyterian/ Weill Cornell Medicine) between March 1 and December 31, 2020 for a minimum of three days.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
32773615|NCT04959955||AECOPD group|
32773616|NCT04959955||CAP group|
32773617|NCT04951843|Experimental|Black soybean koji product|Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
32901922|NCT05126550||Non-Immunogenicity|Group 2 that constitutes the non-immunogenicity group which will be evaluated regarding only safety and effectiveness of the aforementioned vaccine
32901923|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
32901924|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
32901925|NCT05061576|Active Comparator|Standard of care|Oral advice on exercise from a physician.
33270010|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148.~Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up for up to 3 years. Subjects with insufficient virologic response at Week 148, will discontinue ABI-H0731 only and continue on SOC NrtI alone for up to 12 weeks.~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731only and continue on SOC NrtI alone and enter follow-up for up to 12 weeks."
33270011|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
33270012|NCT05351970||Monofilament closure|Patients with midline emergency laparotomy, which closure was performed with monofilament suture
32773618|NCT04968769|Experimental|ischemic compression and exercise|"Individuals were positioned in a comfortable position in a chair with back support. By palpating the UT muscle, first the taut band and then the active TP on the muscle were determined. Before starting the treatment, , a statement was made to the individual that you will soon feel a high level of pain with pressure, and at the same time, you may feel pain, tingling, pricking in additional areas (head-neck-shoulder-arm), after a while the pain will decrease and disappear. In this process, try to stay as steady as possible and breathe regularly and calmly.'' The highest level of pressure that the patient could tolerate was applied to the determined TP with the thumb. Pressure time will be in the range of at least 10-20 seconds and at most 60 seconds; It was terminated after the therapist felt complete relaxation in the tissue under his thumb or after the patient received the return of pain completely disappeared"
32773619|NCT04968769|Experimental|kinesio taping and exercise|While performing KT, the individual was seated in a comfortable and upright position in a chair with back support. The subject was asked to bring his hand to his back in internal rotation of the shoulder of the taped side and to bring his head to the contralateral lateral flexion and contralateral rotation so that the UT muscle was in a tense position. KT was applied using 'muscle inhibition technique' to ensure correct contraction of the muscle with muscle length/tension optimization, to target the reduction of excessive muscle tension, and to increase circulation with the effects of the tape on the skin. In this technique, to inhibit the muscle, the tape direction is from the muscle insertion to the origin. KT was performed 5 cm below the acromion to the protuberantia occipitalis with 10% tension
32773620|NCT04968769|Active Comparator|exercise|In order for all the exercises to be done correctly and not to cause any pain, the individuals were asked to perform the movements in front of the mirror. Posture exercises given the individuals for scapular retraction. During the posture exercises individual was positioned in a chair without back support. By counting 5 it was requested to do 10 repetitions of each exercise. For the UT muscle stretching, individuals were asked to hold their right ear with their left hand over their head while sitting on a back-supported chair with their hips and back fully resting on the chair, and to bring their left ear closer to their left shoulder with the help of their hand and count to 20 from the outside.
32773621|NCT04952155|Experimental|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
32773622|NCT04884971|Experimental|Microbiota Treatment Arm|Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.
33270013|NCT05351970||Barbed closure|Patients with midline emergency laparotomy, which closure was performed with barbed suture
33270014|NCT05351814|Active Comparator|Control group|Control group; traditional patellofemoral pain syndrome exercises; isometric exercises 3 sets of 10 repetitions in one session, balance exercise 30/45 sec, one leg balance exercise 45/60 sec , stretching exercises 4 sets 5 repetitions 20 sec duration, off kinetic chain (CHC) AND open kinetic chain (ACZ) exercises were planned as 3 sets for 4 weeks and 3 days a week.
33270015|NCT05351814|Experimental|Core Stability group|Core stability group; In addition to traditional patellofemoral pain syndrome exercises; hip muscle strengthening exercises are 3 sets of 10 repetitions in each session, and (core) stabilization exercises are 1st and 2nd weeks 2 sets 15 repetitions 3rd and 4th weeks 2 sets 5 repetition was planned for 4 weeks and 3 days a week.
33270016|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
33270017|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score < 7.
33270018|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score > 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
32773623|NCT04959721|Experimental|Injection group|Patients in the injection group will be injected 10 mg (0.25 mL) of triamcinolone acetonide, mixed with 0.25 mL of 0.125% bupivacaine and 0.5 mL of normal saline.
33270019|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
33270020|NCT03753555|Experimental|high-dose statin or PCSK9 inhibitor group|"high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.~PCSK9 inhibitor group will receive the subcutaneous injection of Evolocumab (140mg, 2 / month) for one year."
33270021|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
33270022|NCT00606086|Active Comparator|2|Standard of care alone
33401706|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
33401707|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
33270023|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
33270024|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
33270025|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
33270026|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
33270027|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
33270028|NCT01012791|Experimental|Zumba exercise group|
33270029|NCT01012791|No Intervention|Non-Zumba exercise group|
33270030|NCT05278052|Active Comparator|ARM A: Standard maintenance therapy alone|Maintenance systemic therapy/ observation
33270031|NCT05278052|Experimental|ARM B: Local consolidative radiation therapy (LCRT)|Radiation therapy to all oligometastatic sites including primary loco-regional disease
33270032|NCT00953004|Experimental|fiber drink|
33270033|NCT00953004|Experimental|fiber bread|
33270034|NCT00953004|Experimental|placebo|
33270035|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
33270036|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
33270037|NCT00898274||Healthy participants|Aged matched healthy participants
33270038|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
33270039|NCT05300490||Knee infiltration|Patients requiring prednisolone knee infiltration as part of routine medical management
33270040|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
33270041|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
33270042|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
33270043|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
33270044|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
33270045|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
33270046|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
33270047|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
33270048|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
33270049|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
33270050|NCT05351502|Experimental|Cohort 1|Subjects will receive 25,000 ppm NO
33270051|NCT05351502|Experimental|Cohort 2|Subjects will receive 50,000 ppm NO
33270052|NCT05351502|Experimental|Cohort 3|Subjects will receive 100,000 ppm NO
33270053|NCT05351502|Experimental|expansion|Subjects will receive the selected dose of NO
33270054|NCT00888368|Experimental|Transpatellar Approach|
33270055|NCT00888368|Active Comparator|Suprapatellar Approach|
33270056|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
33270057|NCT04010916|Active Comparator|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
33270058|NCT04010916|Active Comparator|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
33270059|NCT04010916|Active Comparator|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
33270060|NCT00893672||1|Routine strategy of chest radiograph prescription
33270061|NCT00893672||2|On-demand strategy of chest radiograph prescription
33270062|NCT00711815||UA|HPV positive
32773624|NCT04717739||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
32773625|NCT04959565|Experimental|16 online lectures in sports nutrition + 8 individual consultations for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
33270063|NCT00948714|Experimental|Case|
33270064|NCT00948714|Active Comparator|Control|
33270065|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
33270066|NCT00898508||Invasive breast cancer|
33270067|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
32773626|NCT04959565|No Intervention|Control|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing).~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation."
32935758|NCT05442944|Experimental|A study group with physiotherapeutic intervention.|The study group - 30 people - participated in the three-week physiotherapy program.
33270068|NCT00720239|No Intervention|0|
33270069|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
33270070|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
33270071|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
33270072|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
33270073|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
33270074|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
33270075|NCT02572193|Experimental|Active case|POEM procedure
33270076|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0 + 6"
33270077|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0+12"
33270078|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+6"
33270079|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+12"
33270080|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+6"
33270081|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+12"
33270082|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of <1/8~Dosage level 3 x 10^12 DRP~Month 0+6"
33270083|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
33270084|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
33270085|NCT02540174|Experimental|Arm A|integrated addiction treatment program
33270086|NCT02540174|Other|Arm B|standard of care
33270087|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
33270088|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
33270089|NCT04035824|Active Comparator|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
33270090|NCT04035824|Placebo Comparator|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
33270091|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
33270092|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
33270093|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
33270094|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
33270095|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
33270096|NCT00893750|Experimental|NET Truth Education|
33270097|NCT00893750|Experimental|Conflict Resolution Trainings|
33270098|NCT00893750|Experimental|Traditional Methods|
33270099|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
33270100|NCT00712049|Active Comparator|2|Simvastatin
33270101|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
33270102|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
33270103|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
33270104|NCT00898742||head and neck cancer patients|
33270105|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
33270106|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
33270107|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
33270108|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
33270109|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
33270110|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
33270111|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
33270112|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
33270113|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
33270114|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
33270115|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
33270116|NCT04162691||Malignant thymoma|
33270117|NCT04162691||Benign thymoma|
33270118|NCT00712283|Placebo Comparator|D|healthy volunteers
33270119|NCT00712283|Active Comparator|C|healthy volunteers
33270120|NCT00712283|Active Comparator|B|healthy volunteers
33270121|NCT00712283|Active Comparator|A|healthy volunteers
32901926|NCT05061576|Experimental|Active intervention|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
33270122|NCT04070495|Experimental|Clarithromycin|
33270123|NCT04070495|Experimental|Rifampicin|
33270124|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
33270125|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
33270126|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
33270127|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
33270128|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
33270129|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
33270130|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
33270131|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
33270132|NCT00712439|Experimental|1|
33270133|NCT00712439|Placebo Comparator|2|
33270134|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
33270135|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
33270136|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
33270137|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
33270138|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
33270139|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
33270140|NCT03995446|Experimental|low-level laser therapy|808nM wavelength, power density of 300mW
33270141|NCT03995446|Sham Comparator|Sham laser acupuncture treatment|received the same manner except for joule.
33270142|NCT04069559|Experimental|Intervention Group|Intervention contain education and application about refugees health.
33270143|NCT04069559|No Intervention|Control Group|Students of control group performed routine public health nursing practices.
33270144|NCT04070417|Experimental|Treatment Group|Lifestyle Medicine Group
33270145|NCT04070417|No Intervention|CAU Group|Care-As-Usual Group
33270146|NCT03996226|Experimental|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
33270147|NCT03996226|Experimental|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
33270148|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
33270149|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
33270150|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
33270151|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
33270152|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
33270153|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
33270154|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
33270155|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
33270156|NCT00115765|Active Comparator|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
33270157|NCT00115765|Experimental|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
33270158|NCT00115765|Active Comparator|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
33270159|NCT00115765|Experimental|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
33270160|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
33270161|NCT00721019|Experimental|5-hour bedtime|
33270162|NCT00721019|Experimental|8.5-hour bedtime|
33270163|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
33270164|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
33270165|NCT04068233|Experimental|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
33270166|NCT04068233|Experimental|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
32901927|NCT05621486|Experimental|B4T2-001 CAR T cells|Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD. Treatment follows a lymphodepleting chemotherapy regimen
33270167|NCT04035122|Experimental|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
33270168|NCT04035122|Active Comparator|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
33270169|NCT00461812|Experimental|Mometasone|
33270170|NCT00461812|Experimental|Advair|
33270171|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
33270172|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
33270173|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
33270174|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
33270175|NCT00721331|Experimental|0.1% nortriptyline HCl|
33270176|NCT00721331|Active Comparator|0.1% mometasone furoate|
33270177|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
33270178|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
33270179|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
33270180|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
33270181|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
33270182|NCT00123955|Experimental|1|Spironolactone
33270183|NCT00123955|Placebo Comparator|2|Placebo
33270184|NCT04372121|Experimental|Linzagolix 75 mg|
33270185|NCT04372121|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
33270186|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
33270187|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
33270188|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
33270189|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
33270190|NCT02539784|Experimental|Spinal Cord Stimulation|
33270191|NCT04069481|Experimental|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
33270192|NCT04069481|Active Comparator|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
33270193|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
33270194|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
33270195|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
33270196|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
33270197|NCT05667545|Active Comparator|Negative control group (A1)|A1: cavities will be sealed directly by restorative material (conventional glass ionomer) without any treatment.
32935759|NCT05442944|No Intervention|A Control group without physiotherapeutic intervention|The control group - 30 people - did not participate in the program.
33080850|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
33270198|NCT05667545|Active Comparator|Treatment group (A2)|A2: cavities will be treated by Self-Assembling peptide P11-4 then sealed by conventional glass ionomer.
33270199|NCT01025986||Noninfectious Uveitis|
33270200|NCT00115063|Experimental|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
33270201|NCT00115063|Active Comparator|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
33270202|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
33270203|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
33270204|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
33270205|NCT05659745|Placebo Comparator|Vaginal Suppository Capsule|In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.
33080851|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
33080852|NCT00237627|Experimental|Part 1|Doxil + PS-341
33270206|NCT05659745|Experimental|Vaginal Suppository Capsule Active|In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.
33270207|NCT05659745|Experimental|Vaginal Suppository Tablet Active|In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.
33270208|NCT05659745|Experimental|Oral Capsule Active|In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.
33270209|NCT05659745|Other|Commercial Oral Vaginal Probiotic Competitor|In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.
33270210|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
33270211|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
33270212|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
33270213|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
33270214|NCT00167245|Experimental|Topiramate|topiramate capsules dose titrated up to 300 mg daily
33270215|NCT00167245|Placebo Comparator|Placebo|placebo capsules identical in appearance to the topiramate capsules
33270216|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
33270217|NCT00716339|Active Comparator|1|motivated
33270218|NCT00716339|No Intervention|2|control
33270219|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
32773627|NCT04959565|Experimental|16 online lectures in sports nutrition for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
32773628|NCT04968613|Experimental|Madopar monotherapy group|Patients in this group received Madopar monotherapy
32773629|NCT04968613|Active Comparator|senfrol monotherapy group|Patients in this group were treated with senfrol (D2 receptor agonist) alone
32773630|NCT04968613|Placebo Comparator|placebo group|Patients in this group were treated with selegiline alone
33270220|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
33270221|NCT00894062|Active Comparator|2|EES (Xience®)
33270222|NCT00721565|Experimental|1|behavior change intervention
33270223|NCT00721565|No Intervention|2|written materials
33270224|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
33270225|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
33270226|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
32773631|NCT04968535|Experimental|Therapy|Patients receiving suprathreshold electrotherapy in weekly intervals for a Duration of 30 min each. Device calibration with determination of the individual threshold was performed prior to the application of electrical current.
32773632|NCT04968535|Sham Comparator|Control|Patients receiving device calibration without consequent electrotherapy.
33080853|NCT00237627|Experimental|Part 2|Doxil + Velcade
33270227|NCT04098341|Other|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
33270228|NCT00922454|Experimental|Talent Stent-Graft|
33270229|NCT00922454|Experimental|Cook Zenith Stent-Graft|
33270230|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
33270231|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
33270232|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
33080854|NCT00209495|Placebo Comparator|A|
33270233|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
33270234|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
33270235|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
33270236|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
33270237|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
33270238|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
33270239|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
33270240|NCT01022710||Group 1|Veterans with sensorineural hearing loss
33270241|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
33270242|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
33270243|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
33270244|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
33270245|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
33270246|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
33270247|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
33270248|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
33270249|NCT00712907|Placebo Comparator|2|Placebo
33270250|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
33270251|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
33270252|NCT05003141|Experimental|Single-arm, escalating dose levels|3 + 3 Phase 1 dose escalation design; sequential ascending dose levels.
33270253|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
33270254|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
33270255|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
33270256|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
33270257|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
33270258|NCT03671213|Experimental|Calypso|Calypso Knee System
33270259|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
33270260|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
33270261|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
32773633|NCT04968535|No Intervention|Control of control|Patients lay on the mat without receiving device calibration nor electrotherapy.
33270262|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
33270263|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
33270264|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
33270265|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
33270266|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
33270267|NCT03742570||CBBDQ|A Questionnaire
33270268|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
33270269|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
33270270|NCT01022788|No Intervention|Standard care through existing health system|
33270271|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
33270272|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
33270273|NCT00900458|Other|3|Healthy controls
33270274|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
33270275|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
33270276|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells.
33270277|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
32773634|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
33080855|NCT00209495|Experimental|B|Pregabalin
33080856|NCT00209495|Experimental|C|Pregabalin + dexamethasone
33080857|NCT00414141|Experimental|1|Grass MATA MPL
33080858|NCT00414141|Placebo Comparator|2|
33270278|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
33270279|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
33270280|NCT00722033|Other|A|< 30 weeks of gestation
33270281|NCT00894296||1|schizophrenia patients
33270282|NCT00894296||2|healthy control
33080859|NCT01081678|Placebo Comparator|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
33080860|NCT01081678|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
33270283|NCT01027936||Normal Healthy Volunteers|
33270284|NCT00894374|Experimental|Artesunate (Pfizer)|
33270285|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
33270286|NCT04920149|Experimental|Mesalamine|Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
33270287|NCT04920149|Placebo Comparator|Placebo|Placebo for Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
33270288|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
33270289|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
33270290|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
33270291|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
33270292|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
33270293|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
33270294|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
33270295|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
33270296|NCT00901550|Active Comparator|Infliximab|for RA treatment
33270297|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
33270298|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
33270299|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
33080861|NCT01081678|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
33270300|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
33270301|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
33080862|NCT01081678|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
33080863|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
33270302|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
33270303|NCT00716729||Pateints with longstanding hip and/groin pain|
33270304|NCT00713141||1|Early breast cancer
33270305|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
33270306|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
33270307|NCT00722189||A|All patients treated
33080864|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
33270308|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
33270309|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
33270310|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
33270311|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
33270312|NCT00900848||8|8 patients
33270313|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
33270314|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
33270315|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
33270316|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
33270317|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
33270318|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
33270319|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
33080865|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
33080866|NCT00209651|Experimental|1|Irinotecan and S-1
33270320|NCT04035980|No Intervention|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
33270321|NCT04035980|Active Comparator|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
33270322|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
33270323|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
33270324|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~Dyspnoe NYHA class III and IV~Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~Renal failure (creatinine >1.70 mg/dl)~Signs of infection or inflammation"
33270325|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
33270326|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
33270327|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
33270328|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
33270329|NCT00722345|Placebo Comparator|1|
33270330|NCT00722345|Experimental|2|
33270331|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
33270332|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
33277546|NCT05119400||Comparison group|"The subjects in comparison group will be 30 patients previously hospitalized at NYP/WCM between March 1 and December 31, 2020 for a minimum of three days. The recruited subjects would have undergone hospitalization secondary to a medical diagnosis that was not COVID-19.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
33277547|NCT00777725||1|Chronic stable left sided HF patients
33270333|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
33270334|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
33270335|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
33270336|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
33270337|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
33270338|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
33270339|NCT00717119||1|Patients with sprain of ankle treated with NSAID
33270340|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
33270341|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
33270342|NCT00713297||Observation|Those who will use the new CPOE system
33270343|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
33270344|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
33270345|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
33270346|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
33270347|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
33270348|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
33270349|NCT00906308|Placebo Comparator|Placebo|
33270350|NCT00906308|Experimental|MF101 5 g/day|
33270351|NCT00906308|Experimental|MF101 10 g/day|
33270352|NCT00906386|Experimental|1|
33270353|NCT00906386|Placebo Comparator|placebo|
32773635|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
32773636|NCT04676555||Ocrelizumab|Ocrelizumab is administered intravenously (IV) under the guidance of a specialized physician and followed by one-hour observation after the infusion. It requires a corticosteroid pre-medication and some antipyretics may also be administered.
32773637|NCT04676555||Ofatumumab|Ofatumumab is administered through a subcutaneous injection and allows self-administration after training.
32773638|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
32773639|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
32773640|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
32773641|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
32773642|NCT04314167|Experimental|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
32773643|NCT04968301||hip developmental dysplasia group|patients with developmental dysplasia of hip
32773644|NCT04968301||femoroacetabular impingement group|patients with femoroacetabular impingement
32773645|NCT04968301||control group|healthy volunteers
33270354|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
33270355|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
33270356|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
33270357|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
33270358|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
33270359|NCT04067687|No Intervention|Control|No palliative home visit intervention
33270360|NCT04067687|Experimental|Intervention|Palliative home visit intervention
32773646|NCT05575427|Experimental|Combination therapy with minocycline|"Minocycline oral 50 mg per capsule~4 capsules oral stat then 2 capsules oral every 12 hours~duration 7-28 days"
32773647|NCT05575427|Active Comparator|Monotherapy plus placebo|Patients were treated Stenotrophomonas maltophilia infection with standard monotherapy either levofloxacin or Trimethoprim/sulfamethoxazole plus placebo
32773648|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
33080867|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
33270361|NCT04035902|Experimental|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
33270362|NCT04035902|Active Comparator|control|Ferric carboxymaltose is not administered
33270363|NCT04069169|Experimental|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
33270364|NCT04069169|Placebo Comparator|Intravenous saline control|0.9% sodium chloride, also known as normal saline
33270365|NCT00894842|Active Comparator|Pregnenolone|
32773649|NCT04959253|Experimental|Psilocybin 25mg PO|
32773650|NCT04959253|Placebo Comparator|Placebo PO|
32773651|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
32773652|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
32773653|NCT04706273||GORE® VIABAHN® Endoprosthesis|Participants with symptomatic peripheral arterial disease in superficial femoral artery lesions.
32773654|NCT04968223||Patient Group|Patients with Schizophrenia
32773655|NCT04968223||Relatives Group|Healthy first-degree relatives of persons with schizophrenia
32773656|NCT04968223||Control Group|Healthy subjects without family history of psychotic illness
32773657|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
32773658|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
32773659|NCT04968145|No Intervention|Control Group|Participants in the control group receive routine follow up care which consists of (i) written instructions regarding potential complications and the contact information of their treating surgeon, (ii) a follow up telephone call 4 weeks following discharge by a member of the health care team and (iii) an in-person follow up visit in clinic with the treating surgeon 4-6 weeks following discharge.
32773660|NCT04968145|Experimental|Intervention Group|The participants in the intrevention group receive the same routine care as the control group in addition to post discharge monitoring with the Home to Stay app
32773661|NCT02445573|Active Comparator|EA group|
32773662|NCT02445573|Placebo Comparator|Sham EA group|
32773663|NCT05645705|Experimental|Arm 1: Brush/ LISTERINE Cool Mint Antiseptic Mouthwash|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
32773664|NCT05645705|Experimental|Arm 2: Brush / Listerine Advanced Gum Alcohol|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
32773665|NCT05645705|Experimental|Arm 3: Brush / Listerine Advanced Gum Zero|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
33270366|NCT00894842|Placebo Comparator|Sugar pill|
32773666|NCT05645705|Experimental|Arm 4: Brush / LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
32773667|NCT05645705|Other|Arm 5: Brush Only|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
32773668|NCT04951687|Experimental|Active: Ecologic Barrier©|"Dietary supplement: Ecologic Barrier©~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58).~Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
33270367|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
33270368|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
33270369|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
33270370|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
33270371|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
33270372|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
32773669|NCT04951687|Placebo Comparator|Placebo|"Dietary supplement: placebo powder~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate.~As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
32773670|NCT04968067|Experimental|App group|In addition to the usual care, the participant will receive a health talk , a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
32773671|NCT04968067|Active Comparator|Nursing telephone advice (NTA) group|In addition to the above usual care, the participant will receive a health talk , three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages.
33270373|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
32773672|NCT05644613|Active Comparator|GROUP A|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercise on land in form of walking on the treadmill for 20 min 3 times per week for 3 months.
32773673|NCT05644613|Active Comparator|GROUP B|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercises in water in form of walking on the treadmill for 20 min 3 times per week for 3 months
32773674|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
33270374|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
32773675|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
32773676|NCT04704635||Ischemic stroke/TIA|Patients with ischemic stroke or transient ischemic attack
33270375|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
33270376|NCT00717353||1|Lung cancer
33270377|NCT00902408|Experimental|Lutein|Lutein enriched eggs
33080868|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
33270378|NCT00902408|Placebo Comparator|Placebo|Non enriched
32773677|NCT04699877|Experimental|Part 1: Participants with Severe Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1
32773678|NCT04699877|Experimental|Part 1: Participants with Normal Renal Function|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1
33080869|NCT00209690|Experimental|1|
33080870|NCT01081132|Experimental|Extended-release Guanfacine HCl|
33080871|NCT01081132|Placebo Comparator|Placebo|
33080872|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
33270379|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
33270380|NCT02539550|Placebo Comparator|Placebo|Placebo
33270381|NCT02539550|Experimental|PF-06266047|PF-06266047
33270382|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
33270383|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
33270384|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33270385|NCT04353791|Active Comparator|Experimental arm OST-122|24 subjects will be randomized to receive OST-122 orally daily for 28 days
33270386|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
33270387|NCT00894920|Placebo Comparator|placebo|
33270388|NCT00894920|Active Comparator|biotin|
33270389|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
33270390|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
33270391|NCT00902642|No Intervention|control group|
33270392|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
33270393|NCT00717509||clozapine group|"chronic schizophrenia~have been taking clozapine at leaset one year~without diabetes, pulmonary tuberculosis"
33270394|NCT04067531|Other|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
33270395|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
33270396|NCT00713765|Experimental|A|AZD3480 + Donepezil
33270397|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
33277548|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
33277549|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
33277550|NCT00777725||4|Control subjects with no evidence of heart disease.
33270398|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
33270399|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
33270400|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
33270401|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
33080873|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
33080874|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
33080875|NCT00209729|Experimental|1|Docetaxel plus S-1
33080876|NCT01089790|Experimental|1|
33270402|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
33270403|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
33270404|NCT00906854||Group I|practice of weight training exercises
33270405|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
33270406|NCT00906854||Group III|swimming (crawl mode)
33270407|NCT00717665|Experimental|A, 1, I|
33270408|NCT00717665|Active Comparator|A, 2, I|
33270409|NCT03218384|Experimental|Ferric Carboxymaltose|HF patients with functional iron deficiency assigned to receive one-time dose of Ferric Carboxymaltose 750 mg. Participants will undergo serial assessment before and 4 weeks after study drug administration
33270410|NCT03218384|Active Comparator|Placebo|HF patients with functional iron deficiency assigned to receive one-time dose of Placebo (saline injection). Participants will undergo serial assessment before and 4 weeks after study drug administration.
33270411|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
33270412|NCT00717743||1|Patients diagnosed with RCC.
33270413|NCT05658263|Active Comparator|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
33080877|NCT01089790|Active Comparator|2|
33080878|NCT01089010|Experimental|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33270414|NCT05658263|Experimental|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
33270415|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
33270416|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
33270417|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
32773679|NCT04699877|Experimental|Part 2: Participants with Mild Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
33080879|NCT01089010|Experimental|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33080880|NCT01089010|Experimental|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33080881|NCT01089010|Experimental|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33270418|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
33270419|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
33270420|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
33270421|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
33270422|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
33270423|NCT04072601|Experimental|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
33270424|NCT04072601|Placebo Comparator|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
33270425|NCT00717821|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
33270426|NCT00717821|Active Comparator|Epoetin Beta or Darbepoetin Alfa|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
33270427|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
33080882|NCT01089010|Experimental|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33080883|NCT01089010|Experimental|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
33270428|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
33270429|NCT00722891|Active Comparator|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
33270430|NCT00722891|Active Comparator|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
33270431|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
33080884|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
33080885|NCT01084330|Experimental|AUY922|
32773680|NCT04699877|Experimental|Part 2: Participants with Moderate Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
33080886|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
33270432|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
33270433|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
33270434|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
33270435|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
33080887|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
33080888|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
33270436|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
32773681|NCT04699877|Experimental|Part 2: Participants with Normal Renal Function|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
32773682|NCT04951531|Experimental|BPTB double-bundle allograft group|The patient underwent arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
33080889|NCT00209807|Other|3|Healthy volonteers
33080890|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
33080891|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
33270437|NCT04067297|No Intervention|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
33277551|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
33270438|NCT04067297|Experimental|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
33270439|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
33080892|NCT04571476|Experimental|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
33270440|NCT00714155||2|Questionnaires, retrospective chart review
33080893|NCT04571476|Active Comparator|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
33080894|NCT04571476|Active Comparator|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
33270441|NCT00714155||3|Retrospective chart review
33270442|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
33270443|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
33270444|NCT00722969|Experimental|A|
33270445|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (~.05mg/kg and 0.5mg/kg) or placebo.~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
33270446|NCT04069325|Experimental|simiaowan 6g + febuxostat 40mg|
33270447|NCT04069325|Placebo Comparator|placebo 6g + febuxostat 40mg|
33270448|NCT00723047|Experimental|1|
33270449|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
33270450|NCT03444779|Active Comparator|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
33270451|NCT03444779|Experimental|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
33270452|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
33270453|NCT04069403|Experimental|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
33270454|NCT04069403|No Intervention|Control Arm: Usual clinical education and feedback|Receive no reports
33080895|NCT04571593|Experimental|Digital Yoga Nidra|"Participants will voluntarily complete a ~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
33270455|NCT05373797||experimental and control group|experimental: 26 control group:26
33270456|NCT05373641|Experimental|Experimental group|Documentation audit and educational feedback
33270457|NCT05373641|Active Comparator|Control group|Documentation audit
33270458|NCT05373251|Experimental|Whole genomic DNA/RNA tumour sequencing|All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.
33270459|NCT05373173|Experimental|Tele-assessment + In-person assessment|All families will receive an in-person tele-assessment appointment and an in-person evaluation.
33270460|NCT04066985|Experimental|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
33270461|NCT04066985|Experimental|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
33270462|NCT04066985|Active Comparator|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
33270463|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
33270464|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
33270465|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
33270466|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0,3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
33270467|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0.3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
33270468|NCT01026688|Experimental|Intervention|
33270469|NCT01026688|Other|Control|
33270470|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
33270471|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
33270472|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
33270473|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
33270474|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
32773683|NCT04951531|Active Comparator|BPTB single-bundle allograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
33080896|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
33270475|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
33270476|NCT00723671|Experimental|metabolic peaks|
33270477|NCT04067219|Experimental|Single arm|HIV-1 infected patients
33270478|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
33270479|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
33270480|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
33270481|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
33270482|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
33270483|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
33270484|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
33270485|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
33270486|NCT00450658|Active Comparator|2|Ibuprofen 800mg
33270487|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
33270488|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
33270489|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
33270490|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
33270491|NCT00718133|Experimental|1|Children at school age from Haifa bay region
33270492|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
33270493|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
33270494|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
32773684|NCT04951531|Active Comparator|BPTB single-bundle autograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
32773685|NCT04934787|Experimental|ENMS-BSF assisted gait training|The participants will receive the full assistance of the ENMS-BSF during a 20-session gait rehabilitation.
33270495|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
33270496|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
33270497|NCT00517881|Experimental|C.E.R.A.|
33270498|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
33270499|NCT01009905||A|
32773686|NCT04934787|Active Comparator|Partial ENMS-BSF assisted gait training|The participants will receive a partial assistance of the ENMS-BSF during a 20-session gait rehabilitation.
32773687|NCT04934787|Sham Comparator|Sham ENMS-BSF assisted gait training|The participants will only wear the device without assistance during a 20-session gait rehabilitation.
33270500|NCT05372081||Patients who will receive digital assistant|Patients will receive digital assistance (in a few words text format) for any symptoms/adverse events they will include in their profile in the digital platform.
33270501|NCT05372081||Patients who will not receive digital assistant|Patients will just include any symptoms/adverse events in their profile in the digital platform.
33270502|NCT01565577|Experimental|Bras A|
33270503|NCT00724217|Experimental|Normal weight|BMI < 26
33270504|NCT00724217|Experimental|Overweight|BMI >= 26
33270505|NCT00724295||Arm 1|Overall study population
33270506|NCT05366621||Used osteoporosis medication|Patients who had used osteoporosis medication after osteoporotic fractures.
33270507|NCT05366621||Did not use osteoporosis medication|Patients who didn't use osteoporosis medication after osteoporotic fractures.
33270508|NCT05366075|Experimental|Intervention 1 (simple exercise program)|The intervention will include up to four sessions per day. It consists of sit-to stand exercises and walking along the corridor of the ward (for those who can walk).
33270509|NCT05366075|Experimental|Intervention 2 (comprehensive exercise program)|This intervention consists of two daily sessions (morning and afternoon). The morning session includes individualized supervised progressive resistance, balance, and walking training exercises, tailored to each participant's capacity. The resistance training includes using weight cuffs, involving mainly lower-extremity muscles. Balance and gait exercises includes different exercises such as line walking, stepping practice, and walking with small obstacles. The evening session consists of functional exercises using light loads, such as knee extension and flexion, hand training with a ball, and daily walking exercises (for those who can walk).
32773688|NCT04951765|Experimental|Arm A|Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal
32773689|NCT04951765|Experimental|Arm B|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting
32773690|NCT04951765|Experimental|Arm C|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal
32773691|NCT04951765|Experimental|Arm D|Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal
33080897|NCT01082068|Experimental|Arm 2|XL765 + letrozole
33270510|NCT05366075|No Intervention|Control group|The control group will receive usual care, which may include physical rehabilitation when needed.
33270511|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
33270512|NCT00718289|Active Comparator|Acetate|Acetate dialysate
33270513|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
33270514|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
33270515|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
33270516|NCT03525886|Experimental|Cohort 1 (50 mg QHS)|NBI-74788 50 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
33270517|NCT03525886|Experimental|Cohort 2 (100 mg QHS)|NBI-74788 100 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
33270518|NCT03525886|Experimental|Cohort 3 (100 mg QPM)|NBI-74788 100 mg once daily in the evening (QPM) administered orally for 14 consecutive days.
33270519|NCT03525886|Experimental|Cohort 4 (100 mg BID)|NBI-74788 100 mg twice daily (BID) administered orally for 14 consecutive days.
33270520|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
33270521|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
33270522|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
33270523|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
33270524|NCT05363345|Experimental|Vortic Catch V basket catheter|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter following endoscopic papillary large balloon dilation.
33270525|NCT05363345|Active Comparator|ordinary basket catheter|Common bile duct stones (≧ 10 mm) are removed by using ordinary basket catheter following endoscopic papillary large balloon dilation.
33270526|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
33270527|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
33270528|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~Patients seen in the Department of Neurology at Drexel University College of Medicine"
33270529|NCT03690999|Placebo Comparator|Placebo group|Placebo product
33270530|NCT03690999|Experimental|Prebiotic Supplement, low dose|
33270531|NCT03690999|Experimental|Prebiotic Supplement, high dose|
33270532|NCT05361785|Active Comparator|FMT form healthy donor|FMT from healthy donor
33270533|NCT05361785|Placebo Comparator|FMT plasebo|FMT plasebo
33270534|NCT03709342|Experimental|All Patients|
33270535|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
33270536|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
33270537|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
33270538|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
33270539|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
33270540|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
33270541|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
33270542|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
33270543|NCT02570945|No Intervention|Control|
33270544|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
33270545|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
33270546|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
33270547|NCT00604214|Experimental|Drotrecogin alfa (activated)|
33270548|NCT00604214|Placebo Comparator|Placebo|
33270549|NCT01010529|Experimental|occupational therapy|
33270550|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
33270551|NCT05325203|Experimental|JS002 150mg Q2W for 24 weeks|40 patients will be enrolled in this arm
33270552|NCT05325203|Placebo Comparator|placebo 150mg Q2W for 24 weeks|20 patients will be enrolled in this arm
33270553|NCT05325203|Experimental|JS002 450mg Q4W for 24 weeks|40 patients will be enrolled in this arm
33270554|NCT05325203|Placebo Comparator|placebo 450mg Q4W for 24 weeks|20 patients will be enrolled in this arm
33270555|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
33270556|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
33270557|NCT00724685|Placebo Comparator|Placebo|
33270558|NCT00724685|Experimental|Active|
33270559|NCT00123487|Experimental|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
33270560|NCT00123487|Experimental|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
33270561|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
32773692|NCT04951765|Experimental|Arm E|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal
33270562|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
33270563|NCT00724763|Experimental|1|Treatment group.
33270564|NCT00724763|Sham Comparator|2|control group
33270568|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
33270569|NCT05319041|Experimental|Active herbal capsules|"Wei's Qi Ju Gan Lu Formula is a herbal formulation initiated by the senior TCM collaborator, Prof Wei QP. This TCM formulation is prescribed to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
33270570|NCT05319041|Placebo Comparator|Placebo capsules|Placebo capsule which contains 0.5g maltodextrin without any herbs medicine.
33270571|NCT05287685|Experimental|Screen media adapted School Readiness Parenting Program|Screen media adapted School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
33270572|NCT05287685|Active Comparator|Original School Readiness Parenting Program|Original School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
33270573|NCT05277974|Active Comparator|Group B.|group B will receive Inj Bupivicain only in Erector Spinae Plane Block.
33270574|NCT05277974|Active Comparator|Group D|group D will receive Inj Bupivicain plus Dexamethasone in Erector Spinae Plane Block.
33270575|NCT00504777|Experimental|1|
33270576|NCT03351803||Participants with Ashkenazi ancestry|
33277552|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
33270577|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
33270578|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
33270579|NCT00724919||1|
33270580|NCT03968263|Active Comparator|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
33270581|NCT03968263|Active Comparator|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
32773693|NCT04951765|Experimental|Arm F|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting
33270582|NCT03968263|Active Comparator|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
33270583|NCT03968263|Active Comparator|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
33270584|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
33080898|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
33080899|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
33270585|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
33270586|NCT03164447|Experimental|Multi-Drug Resistant|
33270587|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
33270588|NCT00906932||See above|See above
33270589|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
33270590|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
33270591|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
33270592|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
33270593|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
33270594|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
33270595|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
33270596|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
33270597|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
33270598|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
33270599|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
33270600|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
33270601|NCT05206877|Experimental|Low dose topical insulin|Group 1; N=6: 100 U/ml; 4 units of insulin per application, 1 drop done in clinic daily for 5 days
33270602|NCT05206877|Experimental|High dose topical insulin|Group 2; N=6: 500 U/ml; 20 units of insulin per application, 1 drop done in clinic daily for 5 days
33270603|NCT05206877|Experimental|Longer-term topical insulin|Group 3 randomized; N=20: 10 subjects will receive the highest tolerated dose (e.g. from group 1 or group 2), 1 drop per day at home for 1 month, full testing pre- and post-treatment, and 10 subjects will receive 1/5 of the highest tolerated dose (either the lower dose, or if needed will dilute) 1 drop per day at home for 1 month, full testing pre- and post-treatment.
33270604|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
33270605|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
33270606|NCT00902876|Experimental|CAF|Coronally advanced flap (CAF) alone
33270607|NCT02977715|Experimental|Intervention|Up to 1600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation [n=1000 subjects] or lyophilized formulation [n=600 subjects]) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
33270608|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
33270609|NCT01074697|Placebo Comparator|Saline water|
33270610|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
33270611|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
33270612|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
33270613|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
33270614|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
33270615|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
33270616|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
33270617|NCT05124275|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
33270618|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
32773694|NCT04701437|Experimental|Peer-enhanced intervention|Those randomized to the peer-enhanced intervention group will be contacted by a peer mentor within 72 hours of enrollment to discuss the early release period, readiness for HCV treatment, and identify ancillary needs. Individuals randomized to this arm will be provided a study cell phone.
33270619|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
33270620|NCT03997695|Active Comparator|Core stabilization exercise group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
33270621|NCT03997695|Experimental|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.~Kinesio Taping:~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
33270622|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
33270623|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
33270624|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
33270625|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
33270626|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
33270627|NCT01080079|Active Comparator|Group E|Terbinafine HCl
33270628|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
33270629|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
33270630|NCT04682223|Experimental|Aphasia Remote Therapy (ART)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done remotely with a speech-language pathologist through an online platform using therapy applications. Participants will be provided with teletherapy kits (including an Internet hotspot if needed) to complete the therapy tasks."
33270631|NCT04682223|Active Comparator|In-Clinic Therapy (I-CT)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done in person with a speech-language pathologist at the UofSC Aphasia Lab."
33270632|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
33270633|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
33270634|NCT02539238|Active Comparator|control|Annual BLS training
33270635|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
33270636|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
33270637|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
33270638|NCT00114127|Placebo Comparator|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
33270639|NCT00114127|Active Comparator|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
33270640|NCT00114127|Active Comparator|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
33270641|NCT05158179|Experimental|Spasmodic Dysphonia Patients|
33270642|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
33270643|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
33270644|NCT02570009|Active Comparator|TEAMS|
33270645|NCT02570009|Active Comparator|TEAMS+|
33270646|NCT04034966|Active Comparator|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
33270647|NCT04034966|No Intervention|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
33270648|NCT05077553|Placebo Comparator|Placebo sachet|
33270649|NCT05077553|Experimental|TCI999 probiotic sachet|
33270650|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
33270651|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
33270652|NCT05060705|Experimental|Efesovir|The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
33270653|NCT05060705|Active Comparator|Remdesivir|"The patients are treated with the antiviral drug Remdesivir in dose 200 mg intravenously on the 1st day, then by 100 mg intravenously daily for 5 - 10 days, depending on the severity of the disease."
33270654|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
33270655|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
33270656|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
33270657|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
33270658|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
33270659|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
33270660|NCT02703545||Peutz-Jeghers syndrome|
33270661|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family~first degree relative and 1 second degree relative(1st degree link) or~first degree relatives or~1 first degree relative and 2 or more second degree relatives"
33080900|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
33270662|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
33270663|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
33270664|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
33270665|NCT00122317|Experimental|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
33080901|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
33270666|NCT00895388|Other|Structured Rehabilitation program|
33270667|NCT00895388|No Intervention|Controls|
33270668|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
33270669|NCT03964675|Experimental|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
33270670|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
33270671|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
33270672|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
33270673|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.~During surgery the study group will undergo intra-operative tracking and pressure measurements."
33270674|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.~The control group will undergo gait analysis and electromyography."
33270675|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
33270676|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
33270677|NCT03964519|Experimental|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
33270678|NCT03964519|Experimental|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
33270679|NCT03964519|Placebo Comparator|Control group|This group will be just tested as a control group.
33270680|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
33270681|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
33270682|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
33270683|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
33270684|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
33270685|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
33270686|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
33270687|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
33270688|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
33270689|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
33270690|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
33270691|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
33270692|NCT00908492|Active Comparator|Education Control|
32773695|NCT04701437|Placebo Comparator|Standard of care|If randomized to the standard of care intervention, the participant will only receive passive referral to HCV-care.
33270693|NCT00908492|Experimental|Environmental Skill Building|
33270694|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
33270695|NCT04880291|Active Comparator|GFB-024 SAD Active|Single ascending dose arm of GFB-024 treatment
33270696|NCT04880291|Placebo Comparator|SAD Placebo|Single ascending dose arm of placebo treatment
33270697|NCT04880291|Active Comparator|GFB-024 Repeat-dose Active|Repeat-dose arm of GFB-024 treatment
33270698|NCT04880291|Placebo Comparator|Repeat-dose Placebo|Repeat-dose arm of placebo treatment
33270699|NCT00908570|Experimental|1Topical estriol cream|
33270700|NCT00908570|Placebo Comparator|2Placebo cream|
33270701|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
32773696|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
32773697|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
33270702|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
33270703|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
33270704|NCT00725777|Experimental|A|
33270705|NCT00165841|Placebo Comparator|Placebo|
33270706|NCT00165841|Experimental|Rabeprazole 20 mg|
33270707|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
33270708|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
33270709|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
33270710|NCT00725855|Experimental|1|1 mg dose
33270711|NCT00725855|Experimental|2|5 mg dose
33270712|NCT00725855|Experimental|3|15 mg dose
33270713|NCT00725855|Experimental|4|50 mg dose
33270714|NCT00725855|Placebo Comparator|5|Placebo dose
32773698|NCT04959409||Exposed Cohort|Children receiving topical analgesia
32773699|NCT04959409||Control / Unexposed Cohort|Children who do not receive topical analgesia
32773700|NCT05571059|Experimental|Ifetroban Sodium|Drug: Ifetroban Oral capsule, 250 mg, once daily for 12 months
32773701|NCT05571059|Placebo Comparator|Placebo|Drug: Placebo Matching placebo, oral capsule, once daily for 12 months
32773702|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
32773703|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
33270715|NCT01326637|Experimental|intervention|Received the intervention: previsit planning phone call with filled out patient overview document & clinician huddle
33270716|NCT01326637|No Intervention|observation|Received usual care
33270717|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
33270718|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
33270719|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
33270720|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
33270721|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
33270722|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
33270723|NCT04984811|Experimental|NT-I7 and atezolizumab|Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.
33270724|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
33270725|NCT05277662|Experimental|Precision diagnostics profiling|The study will involve subjects with endoscopically, laboratory and clinically confirmed diagnoses of organic and functional intestinal pathology or none of the above (healthy volunteers). All diagnoses are defined in accordance with the validated criteria presented in the clinical guidelines for the diagnosis and treatment of functional bowel pathology (Irritable Bowel Syndrome), 2020, Crohn's Disease (approved by the Ministry of Health of the Russian Federation, 2020), Ulcerative Colitis (approved by the Ministry of Health of the Russian Federation, 2020), in accordance with international criteria of ECCO-ESGAR Guidelines, 2018, 2019. After the initial screening and inclusion in the study, intestinal biopsy samples are taken in accordance with the applied endoscopic examination technique during the endoscopic examination. These biopsy samples will be further used for molecular and immunological diagnostics.
33270726|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
33270727|NCT00460798||Non-Interventional Study|
33270728|NCT03965455||conventional group|
33270729|NCT03965455||diode laser group|
33270730|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
33270731|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
33270732|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
33270733|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
33270734|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
33270735|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
33270736|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
33270737|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
33270738|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
33270739|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
33270740|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
33270741|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
33270742|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
33270743|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
33270744|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
33270745|NCT04880837|Experimental|Prevention (educational session, handout, survey)|Participants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
33270746|NCT00603980|Other|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270747|NCT00603980|Other|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270748|NCT00603980|Other|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270749|NCT00603980|Other|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270750|NCT00603980|Other|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270751|NCT00603980|Other|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270752|NCT00603980|Other|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270753|NCT00603980|Other|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270754|NCT00603980|Other|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270755|NCT00603980|Other|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270756|NCT00603980|Other|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270757|NCT00603980|Other|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270758|NCT00603980|Other|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270759|NCT00603980|Other|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
33270760|NCT01026766||Non obese/ Warming blankets|
33270761|NCT01026766||Non obese/ Warming intravenous fluids|
33270762|NCT01026766||Obese/ Warming intravenous fluids|
33270763|NCT01026766||Obese/ Warming blankets|
33270764|NCT04880603|Active Comparator|A - Standard of Care|
33270765|NCT04880603|Experimental|B - Restrata Graft|
33270766|NCT01028404|Experimental|Trial part 1|
32773704|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
33270767|NCT01028404|Experimental|Trial part 2|
33270768|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
32773705|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
32773706|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
33080902|NCT04996966|Placebo Comparator|control|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
33270769|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
33270770|NCT00450190|Experimental|Saizen® E-Device|
33270771|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
33270772|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
33277553|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
33277554|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
33277555|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
33277556|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
33277557|NCT00535730|Placebo Comparator|1|Placebo Comparator
33277558|NCT00535730|Experimental|2|vaccine
33277559|NCT00780923|Experimental|CPAP|
33277560|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
33270773|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
33270774|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
33270775|NCT00907322|Experimental|Dimbeon 20 mg|
33270776|NCT00907322|Experimental|Dimebon 40 mg|
33270777|NCT00907322|Experimental|Dimebon 60 mg|
33270778|NCT00907322|Experimental|Placebo|
32773707|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
33270779|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
33270780|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
33270781|NCT00726245|Experimental|1|PRGF
33270782|NCT00726245|Placebo Comparator|2|physiological saline
33270783|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
33270784|NCT00908726|Experimental|Microemulsion propofol|
33270785|NCT00908726|Active Comparator|Lipid emulsion propofol|
33270786|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
33270787|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
33270788|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
33270789|NCT00726401|Active Comparator|1|
33270790|NCT00726401|Placebo Comparator|2|
33270791|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
33270792|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
33270793|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
33270794|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
33270795|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
33270796|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
33270797|NCT00449956|Active Comparator|3|timolol maleate
33270798|NCT00908804|Active Comparator|open appendectomy|
33270799|NCT00908804|Active Comparator|laparoscopic appendectomy|
33270800|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
33270801|NCT00903422|Placebo Comparator|Placebo|Placebo
33270802|NCT01323088|Other|Control|Standard care control (no-exercise)
33270803|NCT01323088|Active Comparator|Aerobic Exercise|
33270804|NCT01323088|Active Comparator|Resistance Exercise|
33270805|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
33270806|NCT00907400|Experimental|1|PN400
33270807|NCT00907400|Active Comparator|2|Naprosyn E
33270808|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
33270809|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
33270810|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
33270811|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
33270812|NCT04034732|Experimental|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
32773708|NCT04515875|Experimental|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
32773709|NCT04515875|Placebo Comparator|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
33270813|NCT04034732|Active Comparator|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
33270816|NCT03995602|Experimental|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
33270817|NCT03995602|Experimental|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
33270818|NCT05277506|Experimental|smile arc protection bonding strategy group|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
33270819|NCT05277506|Active Comparator|MBT placement guide group|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide
33270820|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
33270821|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
33270822|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
33270823|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.~Wean off in 4 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
33270824|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.~Wean off in 4-6 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
33270825|NCT00727727||Parkinsonian patients|
33270826|NCT00907712|No Intervention|cardiovascular|cardiac echo
33270827|NCT04720079|Active Comparator|Intercostobrachial nerve Infiltration|Preoperative infiltration of intercostobrachial nerve with 10ml of ropivacaine 0.5%
33270828|NCT04720079|Active Comparator|Ultrasound guided T2 paravertebral block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of ropivacaine 0.5%
33270829|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
33270830|NCT00729989|No Intervention|1|
32773710|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
32773711|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
33270831|NCT00729989|Experimental|2|
33270832|NCT00903578||Kidney transplant recipients|
33270833|NCT00903656|Experimental|Caelyx/Lapatinib|
33270834|NCT02687243|Experimental|Interactive Virtual Application|Online application
33270835|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
33270836|NCT00730067|Experimental|1|Sildenafil treatment
33270837|NCT00730067|Placebo Comparator|2|placebo
33270838|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
33270839|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
33270840|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
33270841|NCT00509145|Placebo Comparator|Placebo|Matching placebo
33270842|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS~--------------------------------------------------------------------------------"
33270843|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
33270844|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
33270845|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
33270846|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
33270847|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
33270848|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
33270849|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
33270850|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
33270851|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
33270852|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
33270853|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
33270854|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
33270855|NCT04603079|Experimental|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
33270856|NCT04603079|No Intervention|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
33270857|NCT00903812||A|No intervention - observational study
33270858|NCT04589273|Experimental|Alginate capsule|The participants of this arm will be give the alginate capsules
33270859|NCT04589273|Placebo Comparator|Placebo|The participants of this arm will be give the placebo capsules
33270860|NCT00907946|Experimental|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
33270861|NCT00907946|No Intervention|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
33270862|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
33270863|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
33270864|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
33270865|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
33270866|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
33270867|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
33270868|NCT04504487|Experimental|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
33270869|NCT04504487|Placebo Comparator|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
33270870|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
33270871|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
33270872|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
33270873|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
33270874|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
32773712|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
33401708|NCT04526509|Experimental|Substudy 1: Cohort 1 - GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as intravenous (IV) infusion after completing lymphodepleting chemotherapy.
33401709|NCT04526509|Experimental|Substudy 1: Cohort 2 - GSK3901961 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as IV infusion after completing lymphodepleting chemotherapy.
33401710|NCT04526509|Experimental|Substudy 2: GSK3845097 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as IV infusion after completing lymphodepleting chemotherapy.
33401711|NCT04526509|Experimental|Substudy 3: GSK4427296 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.
33401712|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
33401713|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
32773713|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
32773714|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
32773715|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
32773716|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
32773717|NCT04958629||non-FH Group|
32773718|NCT04958629||FH Group|
32773719|NCT04958863|No Intervention|No Mask|Runners do not use mask while running
32773720|NCT04958863|Experimental|Surgical Mask|Runners use surgical mask while running
32773721|NCT04958863|Experimental|Polyester Reusable Mask|Runners use polyester reusable mask while running
32773722|NCT04445519|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes (initial phase of trial)
32773723|NCT04445519|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (initial phase of trial)
32773724|NCT04445519|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (initial phase of trial)
32773725|NCT04445519|Experimental|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (chosen dose of NCX 470 to continue in remainder of trial)
32773726|NCT04445519|Active Comparator|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (active comparator for remainder of trial)
32773727|NCT04416841|Experimental|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
32773728|NCT04416841|Active Comparator|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
33401714|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
33401715|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
33401716|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
33401717|NCT03303469|Experimental|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
33401718|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
33401719|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
33401720|NCT04521127|Active Comparator|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
33401721|NCT04521127|Active Comparator|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
33401722|NCT04521127|No Intervention|Control Group|Control group will not receive any additional intervention
32773729|NCT04416841|Other|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
32773730|NCT05696639||Undeveloped venous group|patients with undeveloped cerebral venous
32773731|NCT05696639||Well Developed venous group|patients with well-developed cerebral venous
32773732|NCT04967911|Experimental|Rhythmic stabilization exercises|baseline physical therapy conventional treatment along Rhythmic stabilization exercises
32773733|NCT04967911|Other|Conventional treatment|Baseline physical therapy conventional treatment
32773734|NCT04291079|Experimental|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
32773735|NCT04291079|Experimental|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
32773736|NCT04291079|Experimental|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-small cell lung cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous melanoma (MEL), clear cell Renal cell carcinoma (ccRCC) or other advanced or metastatic solid tumor type that is not NSCLC, UC, MEL, or ccRCC will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
33080903|NCT04996966|Experimental|MSCs injection|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
33401723|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
33401724|NCT03660254|No Intervention|no intervention|no intervention
33401725|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
33401726|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
33270875|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
33270876|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
33270877|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
33270878|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
33270879|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
33270880|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
33270881|NCT00730145|Experimental|PD-0332334|
33270882|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
33270883|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
33270884|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
33270885|NCT00508755|Experimental|Arm 1|stroke
33270886|NCT04065815|Experimental|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
33270887|NCT04065815|Experimental|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
33270888|NCT04065815|Experimental|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
33270889|NCT04065815|Experimental|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
33270890|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
33270891|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
33270892|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
33270893|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
33270894|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
33270895|NCT03870243|Active Comparator|Bubble CPAP|6 hospitals will be selected randomly for this arm
33270896|NCT03870243|Active Comparator|Low flow oxygen|6 hospitals will be selected for low flow oxygen therapy
33270897|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
33270898|NCT04480463|Experimental|SCD411|
33270899|NCT04480463|Active Comparator|Aflibercept|
33270900|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
33270901|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
33270902|NCT00904124|Placebo Comparator|Control|No regular flour replaced
33270903|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
33270904|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
33270905|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
33270906|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
33270907|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
33270908|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
33270909|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
33270910|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
33270911|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
33270912|NCT00909506|Placebo Comparator|Placebo|Placebo
33270913|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
33270914|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
33270915|NCT03997539|Experimental|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
33270916|NCT03997539|Experimental|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
33270917|NCT03997539|Experimental|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
33270918|NCT03997539|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
33270919|NCT04422899|Experimental|AIV007 Treatment Dose 1|Intravitreal, Dose 1
33270920|NCT04422899|Experimental|AIV007 Treatment Dose 2|Intravitreal, Dose 2
33270921|NCT04422899|Experimental|AIV007 Treatment Dose 3|Intravitreal, Dose 3
33270922|NCT04034108|Experimental|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
33270923|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
33270924|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
33270925|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
33270926|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
33270927|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
33270928|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
33270929|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
33270930|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
33270931|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
33270932|NCT00927212|Experimental|Group 1|2% AS101 ointment
33270933|NCT00927212|Experimental|Group 2|4% AS101 ointment
33270934|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
33270935|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
33270936|NCT04015466||Control|Patients with confirmed absent of GC
33270937|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
33270938|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
33270939|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
33270940|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
33270941|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
33270942|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
33270943|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
33270944|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
33270945|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
33270946|NCT04390217|Experimental|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
33270947|NCT04390217|Placebo Comparator|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
33270948|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
33270949|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
33270950|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
33270951|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
33270952|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
33270953|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
33270954|NCT00927602|Experimental|fondaparinux|
33270955|NCT04286867|Experimental|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
33270956|NCT04286867|Active Comparator|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
33270957|NCT00927680||Colorectal cancer cases|
33270958|NCT00927680||Controls|
33270959|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
33270960|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
33270961|NCT00730535|Experimental|Tolterodine 1|
33270962|NCT00730535|Experimental|Toterodine 3|
32773737|NCT04291079|Experimental|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:~Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.~Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.~Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
32773738|NCT04950985||Participants|Adults undergoing a CT scan to investigate possible NOE.
32773739|NCT04951141|Experimental|anti-GPC3 CAR-T|
32773740|NCT04283045|Active Comparator|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will continue to do JASPER daily, 5 times a week, for the remaining 18 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
32773741|NCT04283045|Active Comparator|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 60 minutes with TA, 5 times a week, for the remaining 12 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
33080904|NCT04999735||Patients with FSHD|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
33270963|NCT00730535|Experimental|Tolterodine 6|
33270964|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
33270965|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
33270966|NCT05602649|Placebo Comparator|Placebo Gummy|Participants will self-administer a gummy containing 0mg THC
33270967|NCT05602649|Experimental|Low Dose Gummy|Participants will self-administer a gummy containing 10mg THC
33270968|NCT05602649|Experimental|High Dose Gummy|Participants will self-administer a gummy containing 25mg THC
33270969|NCT05602649|Placebo Comparator|Placebo Chocolate|Participants will self-administer chocolate containing 0mg THC
33270970|NCT05602649|Experimental|Low Dose Chocolate|Participants will self-administer chocolate containing 10mg THC
33270971|NCT05602649|Experimental|High Dose Chocolate|Participants will self-administer chocolate containing 25mg THC
33270972|NCT05602649|Placebo Comparator|Placebo Beverage|Participants will self-administer a beverage containing 0mg THC
33270973|NCT05602649|Experimental|Low Dose Beverage|Participants will self-administer a beverage containing 10mg THC
33270974|NCT05602649|Experimental|High Dose Beverage|Participants will self-administer a beverage containing 25mg THC
33270975|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
33270976|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
33270977|NCT00728429|Experimental|exercise program|
33270978|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
33270979|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
33270980|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
33270981|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
33270982|NCT04066595|Experimental|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
33270983|NCT00927836|Experimental|AX200|
33270984|NCT00927836|Placebo Comparator|Placebo|
33270985|NCT04066517|Experimental|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
33270986|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
33270987|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
33270988|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
33270989|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
33270990|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
33270991|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
33270992|NCT00904280|Experimental|Oxymorphone ER|
33270993|NCT04237103|Experimental|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
33270994|NCT04237103|Placebo Comparator|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
33270995|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
33270996|NCT04236479|Experimental|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
33080905|NCT04999735||Healthy controls|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
33080906|NCT04996693|Other|Scanner 1|Imaging performed on scanner 1: Photon-Counting Detector CT
33270997|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
33270998|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
33270999|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
33271000|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
33271001|NCT00928148|Placebo Comparator|Placebo|
33271002|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
33271003|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
33271004|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
33271005|NCT00904436|No Intervention|2|Controls
33271006|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
33271007|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
33271008|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
33271009|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
33271010|NCT04200287|Experimental|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
33271011|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
33271012|NCT04139993|Experimental|Treatment (RBX7455)|Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
33271013|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33271014|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33401727|NCT04056026|Experimental|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
33080907|NCT04996693|Other|Scanner 2|Imaging performed on scanner 2: Energy-Integrating Detector CT (128-slice)
33080908|NCT04996693|Other|Scanner 3|Imaging performed on scanner 3: Energy-Integrating Detector CT (20-slice)
33271015|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33271016|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33271017|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33271018|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
33271019|NCT04124705|Experimental|Armour® Thyroid|Participants were randomized to receive Armour Thyroid at a dose corresponding to their pre-randomized dose of synthetic T4. During the first 18 to 36 weeks (titration period) the dose of Armour Thyroid could be titrated based on levels of thyroid stimulating hormone (TSH), in order to achieve TSH levels within the normal reference range (0.45 - 4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of Armour Thyroid for an additional 12 weeks (stabilization period).
33271020|NCT04124705|Active Comparator|Levothyroxine|Participants were randomized to receive levothyroxine at their pre-randomized dose. During the first 18 to 36 weeks (titration period) the dose of levothyroxine could be titrated based on levels of TSH in order to achieve TSH levels within the normal reference range (0.45-4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of levothyroxine for an additional 12 weeks (stabilization period).
33271021|NCT03110861|Experimental|Pulsta® Transcatheter Pulmonary Valve|Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
33080909|NCT00234546|Experimental|1|Dysport
33080910|NCT00234546|Placebo Comparator|2|Placebo
33080911|NCT04994002|Experimental|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
33271022|NCT00731003|Experimental|I|ATD procedure
33271023|NCT00731003|Experimental|II|Oxitriptan
33271024|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
33080912|NCT04994002|Experimental|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
33080914|NCT04991077||patients group|patients with malignant hypertension
33080915|NCT04991077||Control group|patients with severe hypertension (Grade 2 or 3 hypertension)
33080916|NCT04990336|Experimental|DDC(Dachaihu decoction compound) Group|Treated with Dachaihu decoction compound and regular therapies
33080917|NCT04990336|Active Comparator|RSM(rhubarb single medicine) Group|Treated with rhubarb single medicine and regular therapies
33271025|NCT00731003|Placebo Comparator|IV|Placebo capsule
33271026|NCT00928226|Experimental|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
33271027|NCT00928226|Experimental|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
33271028|NCT00928226|Experimental|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
33271029|NCT00928226|Experimental|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
33271030|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
33271031|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
33271032|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
33271033|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
32773742|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
32773743|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
33271034|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
33271035|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
33271036|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
33271037|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
33271038|NCT00728975||9|Providence Health Marion Hospice inpatients
33271039|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
33271040|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
33271041|NCT00728975||12|Fraser Health Mission Hospice inpatients
33271042|NCT00728975||13|Fraser Health Langley Hospice inpatients
33271043|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
33271044|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
33271045|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
32773744|NCT04578041|Experimental|Arm 1: TRPMS + Aerobic Physical Activity Program|
33271046|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
33271047|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
33271048|NCT04095611|Experimental|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
33271049|NCT04095611|Active Comparator|LATERAL|hemiarthroplasty surgery, the standard lateral approach
33271050|NCT04056455|Experimental|Severe Renal Impairment (RI): Mobocertinib 80 mg|Mobocertinib 80 milligram (mg), capsule, orally, a single dose on Day 1.
33271051|NCT04056455|Experimental|Normal Renal Function: Mobocertinib 80 mg|Mobocertinib 80 mg, capsule, orally, a single dose on Day 1.
33271052|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
33271053|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
32773745|NCT04578041|Active Comparator|Arm 2: TRPMS + Adaptive Cognitive Training|
33271054|NCT00729209|Placebo Comparator|Placebo|
32773746|NCT04950829|Active Comparator|Conventional brackets|Patients will receive an orthodontic treatment using conventional brackets until achieving appropriate alignment of the upper anterior teeth.
32773747|NCT04950829|Experimental|Self-ligating brackets|Patients will receive an orthodontic treatment using self-ligating brackets until achieving appropriate alignment of the upper anterior teeth.
33271055|NCT04026347|Experimental|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
33271056|NCT04026347|Sham Comparator|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
33271057|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
32773748|NCT04950829|Experimental|3- Self-Ligating brackets with fapless corticotomy|Patients will receive an orthodontic treatment using self-ligating brackets with corticotomy until achieving appropriate alignment of the upper anterior teeth.
32773749|NCT05564195||Patients undergoing elective surgery with a duration of > 60 minutes|Participants included will be patients undergoing planned non-cardiac surgery with general anesthesia that are >60 years of age, have a Mini-mental state examination score of >24, are able to speak Swedish and does not suffer from uncorrected severe visual or auditory disorder, disease of the central nervous system, psychiatric diseases including alcoholism or drug dependence, current motor impairment in dominant hand, or colour-blindness.
33271058|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
33271059|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
33271060|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
33271061|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
32773750|NCT04951219|Experimental|Single-blind 80 mg Daily|Single-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
33271062|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
33271063|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
33271064|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
33271065|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
33271066|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
33271067|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
33271068|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
33271069|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
33271070|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
33271071|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
33271072|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
33271073|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
32773751|NCT04951219|Experimental|Single-blind 100 mg Daily|Single-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
32773752|NCT04951219|Experimental|Open-label 100 mg Daily|Open-label resmetirom 100 mg for an additional 52 weeks
33271074|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
33271075|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
33271076|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
33271077|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
33271078|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
33271079|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
33271080|NCT00729443|Experimental|1|
32773753|NCT05563649|Experimental|Online Guided Self-Help-Family-based Treatment (GSH-FBT)|"GSH-FBT consists of 10 20-minute parent-only sessions over 9 months. The guidance portion is manualized and will be delivered by a clinician familiar with both the online modules and FBT, who acts as a coach. Sessions follow an online curriculum containing a total of 65 short videos. Each lecture series is comprised of a written introduction orienting the viewer to the videos, 5-9 short videos (< 7 minutes each), and assigned reading from the parent education manual, Help Your Teenager Beat an Eating Disorder. In line with GSH approaches, coaches direct parents to watch or re-watch specific videos contained in the online platform related to their questions."
33080918|NCT04990336|Other|N Group|Treated with regular therapies and without traditional Chinese medicine
33271081|NCT00729443|Placebo Comparator|2|
33271082|NCT00731627|Placebo Comparator|1|placebo
33271083|NCT00731627|Active Comparator|11|simvastatin
33271084|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
33271085|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
33271086|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
33271087|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
33271088|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
33271089|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
33271090|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
33271091|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
33271092|NCT00924248||Group 1|
33271093|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
33271094|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
33271095|NCT04726514|Experimental|SleepFlex Treatment|
33271096|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
33271097|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
33271098|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
33271099|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
33271100|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
33271101|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
32773754|NCT05563649|Active Comparator|FBT via Videoconferencing (FBT-V)|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
33080919|NCT04990726||Observational (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline, 1, 3, 6, 12, 18, and 24 months.
33271102|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
33271103|NCT00460564|Active Comparator|High-Dose BTX|
33271104|NCT00460564|Placebo Comparator|High-Dose Placebo|
33271105|NCT00460564|Active Comparator|Low-Dose BTX|
33271106|NCT00460564|Active Comparator|Low-Dose Placebo|
33271107|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
33271108|NCT04015076|Experimental|Single Ascending Dose|Inzomelid or Placebo
33271109|NCT04015076|Experimental|Multiple Ascending Dose|Inzomelid or Placebo
33271110|NCT04015076|Experimental|Patients with CAPS|Inzomelid Open Label
33080920|NCT04990726||Treatment (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline (prior to C1 infusion), 2, 4, 7 infusion, at end of treatment, and 18 and 24 months after completion of treatment.
33080921|NCT04995601|No Intervention|Standard of Care|Participants will receive DVT prophylaxis using standard intermittent pneumatic compression during postoperative care after total joint replacement.
33080922|NCT04995601|Experimental|Recovery Force MAC|Participants will receive DVT prophylaxis using the RF Health MAC during postoperative care after total joint replacement.
33080923|NCT04991272|Active Comparator|warming group|Warming group patients are applied prewarming with bair-hugger (43'C)(warm touch, COVIDIEN, full body blanket) for 10 minutes in the preanesthetic unit prior to induction of anesthesia. During operation, prewarmed intravenous fluid which was stored in the warming cabinet for more than 8 hours is connected and infused. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
33080924|NCT04991272|No Intervention|no warming group|No warming group patients are not applied prewarming devices. Intravenous fluid stored in room air is connected and infused during the operation. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
33080925|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
33271111|NCT03843125|Experimental|Baricitinib High Dose|Baricitinib administered orally.
33271112|NCT03843125|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
33271113|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
33271114|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
33271115|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33271116|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
33271117|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
33271118|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~Qi ming granula, Usage: 4.5g，po，tid."
33271119|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
33271120|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
33271121|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
33271122|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
33271123|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
33271124|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
33271125|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
33271126|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
33271127|NCT00731861|Experimental|1|Paclitaxel plus PTK787
32773755|NCT04177433|Experimental|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
32773756|NCT04177433|Placebo Comparator|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
32773757|NCT04373993||Nordlandssykehuset HF|
32773758|NCT04373993||Akershus universitetsssykehus|
33271128|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
33271129|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
33271130|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
33271131|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
33271132|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
33271133|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
33271134|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
33271135|NCT04065737|Experimental|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
33271136|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
33271137|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
33271138|NCT02735252|Experimental|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
32773759|NCT04373993||Helgelandssykehuset|
33271139|NCT02735252|Experimental|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271140|NCT02735252|Experimental|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
32773760|NCT04373993||Basel University Hospital|
32773761|NCT04344665|Experimental|Virtual Care and Remote Automated Monitoring|
32773762|NCT04344665|No Intervention|Standard Care|
33080926|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
33271141|NCT02735252|Experimental|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271142|NCT02735252|Experimental|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271143|NCT02735252|Experimental|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33401728|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
33271144|NCT02735252|Experimental|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271145|NCT02735252|Experimental|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271146|NCT02735252|Experimental|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271147|NCT02735252|Experimental|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
33271148|NCT04018703|Experimental|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
33271149|NCT04018703|Experimental|Midazolam|Midazolam will be used for perioperative sedation.
33271150|NCT04629872|Experimental|endovascular treatment with fingolimod|
33271151|NCT04629872|No Intervention|endovascular treatment without fingolimod|
33271152|NCT04065581|Experimental|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
33271153|NCT04065581|Experimental|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
33271154|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
33271155|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
33271156|NCT05585645|Experimental|Stimus|"NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
33271157|NCT05585645|Active Comparator|Aranesp|"Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
33271158|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
33271159|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
33271160|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
33271161|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
33271162|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
33271163|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
33271164|NCT00733889|Experimental|1|
33271165|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
33271166|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
33271167|NCT05153655|Experimental|Ischemic post-conditioning group|The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.
33271168|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
33271169|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
33271170|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
33271171|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
33271172|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
33271173|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
33271174|NCT00732095|Experimental|Experimental|Immediate Ad
33271175|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
33271176|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
33271177|NCT04650243|Experimental|ursodeoxycholic acid 250mg bid|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally twice a day.
33271178|NCT04650243|Experimental|ursodeoxycholic acid 250mg qd|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally once a day.
33271179|NCT04650243|Active Comparator|ursodeoxycholic acid standard dosage|Patients will receive standard dosage of ursodeoxycholic acid 250mg orally three times a day.
33271180|NCT00738569|Experimental|Raltegravir|
33271181|NCT04646811|Experimental|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
33271182|NCT04646811|Other|Best medical treatment|
33271183|NCT00732329|Experimental|A|"optimized home based occupational therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
33271184|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
33271185|NCT04644627|Experimental|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
33271186|NCT00734045||1|Subjects with diagnosed congestive heart failure
32773763|NCT04967755|Experimental|Jing-Si-Herbal-Tea(JSHT)|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians.
32773764|NCT04950907|Experimental|treatment|Uniportal VATS biopsy
33271187|NCT00734045||2|Subjects not diagnosed with congestive heart failure
33271188|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
32773765|NCT04950907|Active Comparator|control|CT-guided fine needle biopsy
32901928|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
33271189|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
33080927|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
33080928|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
33080929|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
33080930|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
33080931|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
33080932|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
33080933|NCT04990804|Active Comparator|Standard Perioperative Pain Regimen|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
33271190|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
33271191|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
33271192|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
33271193|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
33271194|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
33271195|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
33271196|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
33271197|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
32773766|NCT04692233|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (follow-up; 8 hours). The sessions will be supervised by an experienced qigong master. Throughout the intervention period, participants will be asked to self-practice BQ for 30 minutes twice a week from weeks 1 to 8, and then three times a week from weeks 9 to 16 (20 hours).
33271198|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
33271199|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
33271200|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
33271201|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
33271202|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
33271203|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
33271204|NCT03490240|Experimental|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
32901929|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
33271205|NCT03490240|Active Comparator|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
33271206|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
33271207|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
33271208|NCT00732485|Active Comparator|Fenofibrate|
33271209|NCT00732485|Placebo Comparator|Placebo|
33271210|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
33271211|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
33271212|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
33271213|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
33271214|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
33271215|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
33271216|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
33271217|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
33271218|NCT03449667|Active Comparator|Cryoneurolysis first, then optional sham crossover treatment|"Initial treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.~Optional sham crossover treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis."
33271219|NCT03449667|Sham Comparator|Sham Comparator first, then optional cryoneurolysis treatment|"Initial treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.~Optional cryoneurolysis treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis."
33271220|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
33271221|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
33271222|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
33271223|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
33271224|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
33271225|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
33271226|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
33271227|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
33271228|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
33271229|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
33271230|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
33271231|NCT03410043|Experimental|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33271232|NCT03410043|Experimental|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33271233|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
33271234|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
33271235|NCT00738725||1|Survey only
33271236|NCT00738725||2|Imaging group
33271237|NCT00738725||3|Non-imaging group
33271238|NCT04065503|Experimental|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
33271239|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
33271240|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
33271241|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
33271242|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
33271243|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
33271244|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
33271245|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
33271246|NCT01010997||Dry AMD|Intermediate AMD subjects
33271247|NCT01010997||Wet - treated AMD|AMD subjects under treatments
33271248|NCT00738803|Experimental|1|Leg Length and offset measurement arm
33271249|NCT01013259|Placebo Comparator|Placebo|
33271250|NCT01013259|Experimental|Mutaflor|
33271251|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
33271252|NCT00732953|Active Comparator|2|Genous stent implantation
33271253|NCT03374085|Experimental|Administration of CC-92480 in combination with dexamethasone|Part 1: Escalating doses of CC-92480 plus a fixed dose of dexamethasone Part 2: RP2D of CC-92480 in combination with dexamethasone
33271254|NCT03374085|Experimental|Administration of CC-92480 monotherapy|Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
32901930|NCT00450242|Placebo Comparator|Placebo cream|
32901931|NCT05009238|Experimental|Group (A)|Group (A): will receive lumbar stabilization exercises
32901932|NCT05009238|No Intervention|Group (B)|Group (B): will be control group.
33271255|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
33271256|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
33271257|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
33271258|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
33271259|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
33271260|NCT04514679||Healthy Lifestyles Program|Usual care in the Healthy Lifestyles Program.
33271261|NCT04514679||Obesity Medicine Program|Usual care in the Obesity Medicine program.
33271262|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
33271263|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
33271264|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
33271265|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
33271266|NCT00734513|Active Comparator|2|Cancer Education
33271267|NCT01327781|Experimental|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33271268|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
33271269|NCT00738959|Experimental|1|
33271270|NCT00113269|Experimental|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
33271271|NCT00113269|Active Comparator|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
33271272|NCT00113269|Experimental|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
33271273|NCT00113269|Active Comparator|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
33271274|NCT04065269|Experimental|1A: AZD6738|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
33271275|NCT04065269|Experimental|1B: AZD6738 + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
33271276|NCT04065269|Experimental|2: AZD6738 + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
33271277|NCT04065269|Experimental|3: AZD6738 + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
33271278|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
33271279|NCT00733109|Active Comparator|excision of the lesion|
33271280|NCT00733109|No Intervention|espontaneous regression|
33271281|NCT00733187|Experimental|1|
33271282|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
32773767|NCT04692233|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise without any abdominal breathing and meditation techniques. The duration and frequency of supervised sessions and self-practice will be identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
33271283|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
33271284|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
33271285|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
33271286|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
33271287|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
33271288|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
33271289|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
32773768|NCT04950595|Experimental|Beef mince group|The test meal provided at lunch will be made up of 45% beef mince, with all remaining ingredients the same as the other arm.
33271290|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
33271291|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
33271292|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
33271293|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
33271294|NCT00733265|Experimental|AZD6140|
33271295|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
33271296|NCT03462628|Active Comparator|Control Group|PVI only
33271297|NCT00112489|Experimental|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
32773769|NCT04950595|Experimental|Plant-based mince group|The test meal provided at lunch will be made up of 45% plant-based mince, with all remaining ingredients the same as the other arm.
32773770|NCT05696561|Experimental|Treatment with a Canaloplasty Device|Canaloplasty Device
32773771|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
32773772|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
32773773|NCT04411589|Experimental|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
32773774|NCT04411589|Active Comparator|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
32773775|NCT04958395||Myocardial bridge|Measure FFR and d-FFR
32773776|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
32773777|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
32773778|NCT04958317|Placebo Comparator|Early exercise|Participants will exercise for 30 minutes prior to an evening meal
32773779|NCT04958317|Experimental|Late exercise|Participants will exercise for 30 minutes after an evening meal
32773780|NCT04692077|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or may be offered the opportunity to join an open label CAB study instead, if such a study is being implemented in their area at the time.
32773781|NCT04950751|Experimental|SCB-2020S Standard Dose|Day 1 and 22: standard dose SCB-2020S with CpG 1018/alum adjuvant
32773782|NCT04950751|Experimental|SCB-2020S Low Antigen Dose|Day 1 and 22: low dose SCB-2020S with CpG 1018/alum adjuvant
32773783|NCT04950751|Experimental|SCB-2020S Low Adjuvant Dose|Day 1 and 22: standard dose SCB-2020S with low dose CpG 1018/alum adjuvant
32773784|NCT04950751|Experimental|SCB-2020S Mixed Series|Day 1 (Dose 1) standard dose SCB-2020S with CpG 1018/alum adjuvant and Day 22 Dose 2) standard dose SCB-2020S with alum adjuvant
32773785|NCT04950751|Active Comparator|SCB-2019|Day 1 and 22: standard dose SCB-2019 with CpG 1018/alum adjuvant
32773786|NCT05632757|Experimental|Psychological assessments|
33271298|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
33271299|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
33271300|NCT01023100|Experimental|Open label|
33271301|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
33271302|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
33271303|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
33271304|NCT01078831||ARDS / ALI patients|
33271305|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
33271306|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
33271307|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
33271308|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
33271309|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
33271310|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
33271311|NCT00739037|Placebo Comparator|A|
33271312|NCT00739037|Experimental|B|
33271313|NCT01080157||Volunteers 18+, at risk for diabetes|
33271314|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
33401729|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
33401730|NCT03660020|Sham Comparator|local anaesthetic group|
33271315|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
32773787|NCT04950517||Wave 1 participants|The study consists of three work packages. Wave 1 participants will be included in all work packages.
33271316|NCT00734825|Active Comparator|1|IV contrast
33271317|NCT00734825|Active Comparator|2|IV contrast and oral contrast
33271318|NCT01080313||Patients with head and neck cancer|
33271319|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
33271320|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
33271321|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
33271322|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
33271323|NCT00739193|Placebo Comparator|Placebo|Placebo Control
33271324|NCT00739193|Experimental|PM101|PM101
33271325|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
33271326|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
33271327|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
33271328|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
33271329|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
33271330|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
33271331|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
32773788|NCT04950517||Wave 2 participants|The study consists of three work packages. Wave 2 participants will only be recruited for work package 2.
33271332|NCT03997461|Experimental|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
33271333|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
33271334|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
33271335|NCT04513977|No Intervention|Usual care|For older adults with cancer with G8 score 14 or less. Randomized to usual oncology care.
33271336|NCT04513977|Experimental|Geriatric Oncology Supportive Clinic|For older adults with cancer with G8 score 14 or less. Randomized to attend Geriatric Oncology Supportive Clinic
33271337|NCT01013493||myopic|
32773789|NCT04528199|Experimental|[18F]FLOR (FC303)|[18F]FLOR (FC303) PET/CT imaging.
33271338|NCT01013493||non myope-healthy|
33271339|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
33271340|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
33271341|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
33271342|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
33271343|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
33271344|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
33271345|NCT04064255|Active Comparator|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
33271346|NCT04064255|No Intervention|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
33271347|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
33271348|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
33271349|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
33271350|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
33271351|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
33401731|NCT03660020|Active Comparator|hyalorounidase group|
33401732|NCT03661112||All of Us Research Program (AoURP) consortium members|
33401733|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
33401734|NCT03659864|Sham Comparator|Exposure 1|filtered air
33401735|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
33401736|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
33401737|NCT04055792|Experimental|Sintilimab combine with Anlotinib|Sintilimab 200mg intravenously on day 1 and Anlotinib 12mg per os on day 1-14 of each 3-week cycle
33401738|NCT04055792|Active Comparator|Anlotinib|Anlotinib 12mg per os on day 1-14 of each 3-week cycle
33401739|NCT04055714|Experimental|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
33080934|NCT04990804|Experimental|Opioid-Free Perioperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
33080935|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
33080936|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
33080937|NCT04991662|Experimental|metaraminol group|During the cesarean section, metaraminol 2ug/kg/min is preventively infused after anesthesia to prevent and treat hypotension.
33080938|NCT04991662|Experimental|phenylephrine group|During cesarean section, preventive infusion of phenylephrine 0.54ug/kg/min after anesthesia to prevent and treat hypotension.
33080939|NCT04991662|Experimental|norepinephrine group|During cesarean section, preventive infusion of norepinephrine 0.08ug/kg/min after anesthesia to prevent and treat hypotension.
33080940|NCT04997941|Experimental|Tamoxifen 40mg|Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
33080941|NCT04997941|Active Comparator|Tamoxifen 20mg|Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
33080942|NCT00413790|Experimental|1|Darifenacin
33080943|NCT00413790|Active Comparator|2|Tolterodine
33080944|NCT00413790|Placebo Comparator|3|Placebo
33080945|NCT04994665|Active Comparator|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
33080946|NCT04994665|Experimental|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
33080947|NCT04571710|Experimental|Treatment group|Intervention: Drug: SHR1258 400mg
33080948|NCT04993612||No pulmonary Hypertension|
33080949|NCT04993612||pulmonary Hypertension Group 1|
33080950|NCT04993612||pulmonary Hypertension Group 2|
33080951|NCT04993612||pulmonary Hypertension Group 3|
33080952|NCT04993612||pulmonary Hypertension Group 4|
33080953|NCT04993612||pulmonary Hypertension Group 5|
33080954|NCT04999774||School-age children|"Each SAC will be asked to supply fecal and blood samples for testing with:~Stool microscopy~Baermann method~Real-time PCR for S. stercoralis~Lateral flow rapid test~ELISA serology (NIE/SsIR and IgG Ratti)"
33080955|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
33080956|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
33080957|NCT04992754||Pregnant women over 18 years old coming to consult at the gynecology department|Pregnant women over 18 years old coming to consult at the gynecology department in the Montpellier's hospital
33080958|NCT04990180|Experimental|Shared Decision Making Intervention|The intervention is a shared decision making consultation supported by a patient decision aid and decision coaching for healthcare professionals.
33080959|NCT04571203|Experimental|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
33080960|NCT04571164|Experimental|LY03003|
33080961|NCT04571164|Placebo Comparator|Placebo|
33080962|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
33080963|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
33080964|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
33080965|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
33080966|NCT04993885|Experimental|Treatment group|Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
33080967|NCT04998916|Experimental|Real TBS to the mPFC|For continuous theta burst stimulation (cTBS), participants will receive 3 sessions of stimulation per visit over the left medial prefrontal cortex (mPFC) (each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec, 600 pulses/session, 60 sec intertrain interval; 120% RMT, MagPro; 10-15 min inter session interval) using a figure 8 coil (Coil Cool-B65 A/P).
33080968|NCT04998916|Sham Comparator|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
33401740|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
33401741|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
33271352|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
33271353|NCT00920777|Experimental|8 weeks CBT|
32773790|NCT05617079||Medicine physicians|Anesthesiologists, intensive care specialists, heads of departments of anesthesiology and intensive care, deputy chief physicians for anesthesiology and intensive care (heads of centers), employees of the department of anesthesiology and intensive care, pulmonologists working in medical organizations that use nebulizer therapy.
32773791|NCT04967131||PNF group|Proprioceptive Neuromuscular Fascilitation exercises were given this group
33271354|NCT00920777|Active Comparator|Control group|
33271355|NCT00920777|Experimental|16 weeks CBT|
33271356|NCT05741333|Experimental|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is a disposable surgical tool designed to deliver a tympanostomy tube into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure.
33271357|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
33271358|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
33271359|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
33271360|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
33271361|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
33271362|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
33271363|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
33271364|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
33271365|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
33271366|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
33271367|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
33271368|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
33271369|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
32773792|NCT05546957|Experimental|Arm 1: Aspirin QD|Randomized 1:1:1
32773793|NCT05546957|Experimental|Arm 2: Aspirin QD + rivaroxaban BID|Randomized 1:1:1
32773794|NCT05546957|Experimental|Arm 3: Aspirin QD + rivaroxaban QD|Randomized 1:1:1
32773795|NCT04950205|Experimental|Sevoflurane post conditioning group（S1）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery ,1% sevoflurane plus after open Carotid artery until the end of surgery
32773796|NCT04950205|No Intervention|The control group（P）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery without sevoflurane
32773797|NCT05544461|Experimental|Intervention group|Those in the intervention group will receive eNutri PN advice after completing the eNutri FFQ at baseline only. At weeks 1 and 3 of the study, participants will also receive coaching emails which includes reminders of their PN advice, questions asking them to reflect on their goal progress (if any), and tips and recipes to help them follow the PN advice.
33271370|NCT05741255|Experimental|STUDY GROUP|After random sampling and dividing patients into two groups of study and control. Patients from the study and control groups will be interviewed individually by the researcher to apply the study tools. Acceptance and Commitment Therapy will be carried out for patients in the study group
33271371|NCT05741255|Active Comparator|Control group|Those in the control group will be left without any intervention to undergo the usual unit routine care.
33271372|NCT05741177||bronchiolitis|children with bronchiolitis
33271373|NCT05741099|Experimental|MSCs group|Patient in Mscs group will receive MSCs implantation by intravenous injection Within 10-15 days of infection
33271374|NCT05741099|Placebo Comparator|comparator|Patients in comparator group will receive placebo treatment Within 10-15 days of infection
33271375|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
33271376|NCT00739895||Athletes|high performing athletes
33271377|NCT04560647||Psoriasis|Subjects diagnosed with psoriasis.
33271378|NCT04560647||Control|Subjects who do not have psoriasis.
33271379|NCT05740943|Experimental|Treatment Arm|Patients will receive 12-week induction Lorlatinib followed by radical surgery or local radiotherapy or continue Lorlatinib through MDT and consolidation lorlatinib for up to 2 years.
33271380|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
33271381|NCT00735683|Placebo Comparator|1|
33271382|NCT00735683|Experimental|2|
33271383|NCT00735683|Experimental|3|
33271384|NCT00735683|Experimental|4|
33271385|NCT00735683|Experimental|5|
33271386|NCT00735683|Experimental|6|
33271387|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
33271388|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
33271389|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
33271390|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
33271391|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
33271392|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
33271393|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
33271394|NCT00740285|Experimental|1|
33271395|NCT00740285|Placebo Comparator|2|
33271396|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
33271397|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
33271398|NCT01011621|Experimental|0.5% prednisolone acetate cream|
33271399|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
33271400|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
33271401|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
33271402|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
33271403|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
33271404|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
33271405|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
33271406|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
33271407|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33271408|NCT05740787||Patient|No intervention
33271409|NCT05740709||AKI patients|Patients who suffered from AKI whilst in ICU and are awaiting discharge from hospital
33271410|NCT00735995|Experimental|A|Individual CBT
33271411|NCT00735995|Experimental|B|Group CBT
33271412|NCT00735995|No Intervention|C|Waiting-list control
33271413|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
33271414|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
32773798|NCT05544461|No Intervention|Control group|Those in the control group will not receive any PN advice from eNutri and hence, will not receive any coaching emails. They will only record their diet using the eNutri FFQ.
32773799|NCT04415047|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Trilogy Heart Valve System Intervention Device: JenaValve Trilogy Heart Valve System
32773800|NCT05540093|Experimental|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy twice a week for four weeks
32773801|NCT05540093|Active Comparator|traditional therapy|the patients will receive traditional therapy twice a week for four weeks
33271415|NCT05740631|Experimental|Obeticholic acid|"FXR agonist, orally administration (10 mg)~Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days."
33271416|NCT05740631|Placebo Comparator|Placebo|Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days.
33271417|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
32773802|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
32935760|NCT05451758|Experimental|Natural outdoor environment|The park is a well-managed green space containing trees, shrubs, flower beds, lawns and a lake, and includes facilities such as benches, wooden bridges, a bandstand and monuments. The experiment was carried out in a location defined by planted areas containing shrubs and small trees, with some distant views.
33271418|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
33271419|NCT04065035|Active Comparator|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
33271420|NCT04065035|Placebo Comparator|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
33271421|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
33271422|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
33271423|NCT04065191|Experimental|High-intensity interval training|High-intensity interval training
33271424|NCT04649177|Other|study group|There is only one study group in this study. All subjects will receive the OCT scanning and PROSE lens fitting.
33271425|NCT03444844|Experimental|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for ~ 60 min (~150 min for first 10 patients/dosimetry) starting immediately after injection.~A contrast CT scan follows PET scan."
33271426|NCT03444844|Experimental|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for ~ 50 min.
33271427|NCT00740441|Experimental|A|AS1411 treatment
33271428|NCT00740519||A|
33271429|NCT03397342|No Intervention|standard breath hold|"Breath-hold CT and 4D-CT without CPAP~Breath-hold MRI and 4D-MRI without CPAP a) T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
33401742|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
33401743|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
33401744|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
33401745|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
33401746|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
33271430|NCT03397342|Experimental|CPAP intervention|"Breath-hold CT without CPAP~4D-CT with and without CPAP~4D-MRI with CPAP~T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
33271431|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:~Discharge medication reconciliation screen.~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
33271432|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
33271433|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
33271434|NCT05740475|Experimental|9MW3811 injection|single dose escalation for experimental drug
33271435|NCT05740475|Placebo Comparator|placebo|matching placebo administration for control
33271436|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
33271437|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
32773803|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
33271438|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
33271439|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
33271440|NCT00711425|Experimental|A|
33271441|NCT05740397|Other|Standard MAP|Control group: MAP values between 50-60 mmHg
33271442|NCT05740397|Other|High MAP|First Comparator group: MAP values between 70-80 mmHg
33401747|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
33401748|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
33401749|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
33401750|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
33401751|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
33271443|NCT05740397|Other|Patient-tailored MAP|"Second Comparator group: MAP comparable to the patient's pre-operative MAP. This one will be calculated by performing 3 blood pressure measurement in three different moments of the day before surgery (at 8 am, at 3 pm, and at 9 pm), and will be calculated using the standard formula Diastolic AP + 0,33 x (systolic AP - Diastolic AP). The preoperative MAP value obtained will be target during CPB, within a range of ± 10 mmHg"
33271444|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
33271445|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
32773804|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
32773805|NCT04109027|Experimental|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
33271446|NCT00740909|No Intervention|MAC|Minimal Attention Control
33271447|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
33271448|NCT05740319|Experimental|FMT|Participants will be given FMT through oral capsules or nasojejunal tube once a month for three months.
33271449|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
33271450|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
33271451|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
33271452|NCT04064645|Experimental|Respiratory rate accuracy measurement|
33271453|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
33271454|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
33271455|NCT05737823|Experimental|Carers-ID online support programme|Participants in this arm will receive access to the Carers-ID online programme. Participants will be able to access the online programme for 2 weeks.
33271456|NCT05737823|Other|Wait-list Control|Wait-list control arm
33271457|NCT00503997|Experimental|drug therapy|
33271458|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
33271459|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
33271460|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271461|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271462|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271463|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271464|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271465|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
33271466|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
33271467|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
33271468|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
33271469|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
33271470|NCT00736541|Experimental|2|
33271471|NCT00096265|Active Comparator|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
33271472|NCT00096265|Experimental|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33271473|NCT00096265|Experimental|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
33271474|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
33271475|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
33271476|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
33271477|NCT01078987|No Intervention|Group 3|No intervention taken
33271478|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
33271479|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
33271480|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
33271481|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
33271482|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
33271483|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
33271484|NCT00711191|Experimental|single arm|
33271485|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
33271486|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~Cetuximab 250 mg/m2 weekly IV X 7 weeks~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
33271487|NCT04557761|Experimental|Closure with microMend® Arm|The microMend® wound closure product will be used to close the Subject's laceration. The wound will be covered with a non-stick dressing.
33271488|NCT04557761|Active Comparator|Closure with Sutures Arm|The Subject's laceration will be closed with sutures. The standard method for suture closed wounds will be followed in accordance with regular institutional policies and procedures.
33271489|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
33271490|NCT05742269||PD-L1 positive disease (on PET and/or IHC)|"Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.~The patients with a PD-L1+ tumour, according to IHC with the SP142 antibody (≥ 1% on immune cells) and/or 89Zr-atezolizumab tracer uptake on PET-imaging, will receive atezolizumab at a dose of 840 mg, administered intravenously, on days 1 and 15."
33271491|NCT05742269||PD-L1 negative disease (on PET and IHC)|Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.
32773806|NCT04109027|Active Comparator|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
33271492|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
33271493|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
33271494|NCT00706511|Experimental|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
33271495|NCT00706511|No Intervention|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
33271496|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
33271497|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
33271498|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
33271499|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
33271500|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
33271501|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
33271502|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
33271503|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
33271504|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
33271505|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
33271506|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
33271507|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
33271508|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
33271509|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
33271510|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
33271511|NCT00924872|Experimental|intervention|receive wheelchair skills training
33271512|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
33271513|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
33271514|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
33271515|NCT00905138|Experimental|1|single ascending doses
33271516|NCT00905138|Placebo Comparator|2|single dose placebo
33271517|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
33271518|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
33271519|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
33271520|NCT00905216|Active Comparator|Comparator|Heparin APP
33401752|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
33401753|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
33401754|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
33401755|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
33401756|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
33401757|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
33401758|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
33401759|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
33401760|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
32898320|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care. Protocol-specific interventions during homebound care will continue until patient has achieved neutrophil engraftment. Post engraftment, standard of care practice will resume. Once discharged from homebound care, the patient will complete routine post-HSCT follow-up visits in the clinic setting.
33080969|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
33080970|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
33080971|NCT04996771|Experimental|Surufatinib Combined With Toripalimab and Chemotherapy|
33080972|NCT04996771|Experimental|Surufatinib Combined With Chemotherapy|
33080973|NCT04996615||high risk population|women at high risk of breast cancer undergoing enhanced MRI
33080974|NCT00210314|Active Comparator|High-dose methotrexate alone|
33080975|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
33080976|NCT04990024|Experimental|Mediterranean Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on Mediterranean diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
33080977|NCT04990024|Experimental|High protein/Low Carbohydrate Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on HP/LC diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
33080978|NCT04990024|Active Comparator|Low Fat Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on low fat diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
33080979|NCT04999501|Experimental|65 - 75 years|All volunteers aged 65 - 75 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
33080980|NCT04999501|Experimental|85 years and over|All volunteers over the age of 85 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
33080981|NCT04990882||Low Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of less than 30 studies.
33080982|NCT04990882||Intermediate Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 30 studies and less than 300 studies.
33080983|NCT04990882||High Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 300 studies.
33080984|NCT04998487|Experimental|LY3471851 (Abdomen)|LY3471851 administered subcutaneously (SC) into the abdomen.
33080985|NCT04998487|Experimental|LY3471851 (Thigh)|LY3471851 administered SC into the thigh.
33080986|NCT04993183|Experimental|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
33080987|NCT00413829|Other|1|
33080988|NCT04999267|Experimental|INVEST Intervention|
33080989|NCT04993534|Experimental|Psychological First Aid + Stepped-care intervention (DWM/PM+)|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~The treatment group will receive the stepped-care program consisting of DWM (step 1) and Problem Management Plus (PM+).~The DWM program has been developed by WHO and collaborators working in the humanitarian field. DWM was designed to be relevant for large segments of adversity-affected populations: it is intended to be transdiagnostic, and easily adaptable to different cultures and languages.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques that are empirically supported."
33080990|NCT04993534|Other|Psychological First Aid + usual care|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~In addition, both the groups will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation."
33401761|NCT03660956|Experimental|Exercise and back counselling group|
33401762|NCT03660956|Active Comparator|Back counselling group|
33401763|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
33401764|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
33401765|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
33401766|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
33080991|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
33080992|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
33080993|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
33080994|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
33080995|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
33080996|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
33080997|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
33080998|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
33080999|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
33081000|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
33081001|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
33081002|NCT00234702|Experimental|1|
33081003|NCT00234702|Placebo Comparator|2|
33081004|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
33081005|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
33081006|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
33081007|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
33081008|NCT04570735||patients with obesity, no diabetes and no kidney disease|
33081009|NCT04570813|Experimental|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
33081010|NCT04570813|No Intervention|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
33081011|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
33081012|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9.
33081013|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
33081014|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2>45mmHg as measured by arterialized capillary blood gas analysis.
33081015|NCT04570462|Experimental|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
33081016|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
33081017|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
33081018|NCT04570345|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
33081019|NCT04570345|Active Comparator|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
33081020|NCT04570228|Active Comparator|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
33081021|NCT04570228|Sham Comparator|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
33081022|NCT04570072|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.
33081023|NCT04570072|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
33081024|NCT04570150|Active Comparator|Sugammadex|
33081025|NCT04570150|Placebo Comparator|Neostigmine|
33271521|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
33271522|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
33271523|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
33271524|NCT03800654|Other|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
33271525|NCT03800654|Active Comparator|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
33271526|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
32773807|NCT05602493|Experimental|test group (n=30) Soludronate® 0.7 mg/ml|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit, 91 days later (-/+ 2 day) the follow-up 2 will take place. A CBCT scan and intraoral photos will be required."
33271527|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
33271528|NCT00925106|Experimental|D1|Test formulation D1
33271529|NCT00925106|Experimental|D2|Test formulation D2
33271530|NCT00925106|Experimental|D3|Test formulation D3
33271531|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
32773808|NCT05602493|Placebo Comparator|control group (n=30) sterile saline|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit will be 1,5 months after the intervention and will be optional for those cases showing redness, swelling or pain during the first follow up, 3,5 months later (-/+ 1 week) the end visit will take place. A CBCT scan and intraoral photos will be required at the end visit."
32935761|NCT05451758|Experimental|Built outdoor environment|A courtyard on the university campus was chosen as a built outdoor environment. The courtyard was surrounded by concrete and brick built settings, with no visible vegetation.
33271532|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
33271533|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
33271534|NCT00706355|Experimental|1|
33271535|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
33271536|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
33271537|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
33271538|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
33271539|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
33271540|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
33271541|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
33271542|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
33271543|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
33271544|NCT00925340|Active Comparator|2 - Psychoeducation|
33271545|NCT00736697|Experimental|1|
33271546|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
33271547|NCT00711113|Experimental|A|
33271548|NCT03796598|Placebo Comparator|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
33271549|NCT03796598|Active Comparator|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
33271550|NCT03796598|Active Comparator|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
33271551|NCT03796598|Experimental|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
33271552|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
33271553|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
33271554|NCT03784898|Other|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
33271555|NCT05727137|Experimental|Single shot adductor canal block|
33271556|NCT05727137|Active Comparator|Continuous adductor canal block|
33271557|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
33271558|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
33271559|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
33271560|NCT05717621|Experimental|Test Arm|VTD-101 ointment
33271561|NCT00905684||Group 1|
33401767|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
32773809|NCT05696327|Experimental|Experimental Group|tyler twist wrist extensor strengthening exercises Treatment protocol will be followed for thrice a week for 4 weeks. The session will be of approximately 20 minutes. The initial Conventional therapy program will be the same as discussed in the control group except strengthening exercise which is excluded in experimental group because of Tyler twist exercise which is being used as a strengthening protocol.
32773810|NCT05696327|Active Comparator|Control Group|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.) The treatment will continue for 4 weeks and 3 sessions/ week i.e. thrice a week. The session will be of approximately 20 minutes.
33271562|NCT00905684||Group 2|
33271563|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
32773811|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
32773812|NCT05592041|Experimental|Treatment group (Group I)|
32773813|NCT05592041|No Intervention|Control group (Group II)|
33271564|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
33271565|NCT05742191||Established Clinic Patients at OSF INI with Episodic Migraine diagnosis.|Study subjects will be established clinic patients at OSF HealthCare INI neurological institute with a diagnosis of Episodic Migraine.
32773814|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
33271566|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
33271567|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
33271568|NCT05742113|Experimental|Triage status red|the relationship between the perfusion index and the emergency triage classification in patients admitted to the emergency department with dyspnea.
33271569|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
33271570|NCT05706623|Experimental|Moderate hepatic impairment|Child-Pugh B
33271571|NCT05706623|Experimental|Normal hepatic function|
33271572|NCT05706623|Experimental|Mild hepatic impairment|Child-Pugh A
33271573|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
33271574|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
33271575|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
33271576|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
33271577|NCT02568137|No Intervention|Usual background care|Standard care
33271578|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
33271579|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
33271580|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
33271581|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
33271582|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
33271583|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
33271584|NCT05704985|Experimental|DK210 (EGFR) Monotherapy (Dose escalation and expansion)|DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity, disease progression, or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.
33271585|NCT05704985|Experimental|DK210 (EGFR) + chemotherapy|In patients with good tolerance of first line systemic therapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity, disease progression, or withdrawal of consent
33271586|NCT05704985|Experimental|DK210 (EGFR) + radiation|In patients with need of palliative radiation, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity, disease progression, or withdrawal of consent
33271587|NCT05704985|Experimental|DK210 (EGFR) + immunotherapy|In patients with good tolerance of first line immunotherapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity, disease progression, or withdrawal of consent
32773815|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
32773816|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
32773817|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
33271588|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
33271589|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
33271590|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
33271591|NCT02568839|Active Comparator|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
33271592|NCT02568839|Experimental|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
33271593|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
32773818|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
33081026|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
33271594|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
33271595|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
33271596|NCT05742035|Experimental|Hereditary hemochromatosis|Individual with ferritin >500 ng/mL and documented homozygous or compound heterozygous HFE-gen mutation.
33271597|NCT05742035|Experimental|secondary hyperferritinemia|Individual with ferritin >500 ng/mL, not fulfilling the criteria for hereditary hemochromatosis.
33271598|NCT05742035|Other|healthy blood donor with normal ferritin value.|Healthy comparator.
33271599|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
33271600|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
33271601|NCT00930488||Group 1|
33271602|NCT04063943|Experimental|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
33271603|NCT05694533|Experimental|INDV-2000 BID + Midazolam|Participants will receive a single oral dose of 5 mg midazolam on Day 1. Participants will receive 400 mg INDV-2000 twice a day (BID) from Days 2 to 15. On Day 15 participants will also receive a single oral dose of 5 mg midazolam co-administered with the INDV-2000 morning dose.
33271604|NCT05690789||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
33271605|NCT05690789||Health Care Professionals (HCPs)|HCPs treating people who have obesity
33271606|NCT05690789||Employers|Single-selection response from defined list
33271607|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
33271608|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
33271609|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
33271610|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
33271611|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
33271612|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
33271613|NCT05741879|Experimental|Gamified online exercise in a family environment|Strength training Resistance training Flexibility training Basic motor skills training Executive function training
33271614|NCT05741879|Active Comparator|Standard care Non-supervised daily routines/activities|Non-supervised daily routines/activities
33271615|NCT05669339|Experimental|Irinotecan, Sonidegib, and Sorafenib|Subjects will be assigned to a dose of each drug following a 3 + 3 design
33271616|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
33401768|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
33401769|NCT01068626|Active Comparator|Rosuvastatin|
33401770|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
33401771|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
33401772|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
33401773|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
33401774|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
33401775|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
33401776|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
33401777|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
33081027|NCT04570033|Experimental|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
33081028|NCT04569721|Experimental|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
33081029|NCT00234858|Active Comparator|1|
33081030|NCT00234858|Active Comparator|2|
33081031|NCT04569838|Experimental|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
33081032|NCT04569916|Experimental|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
33081033|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
33081034|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
33081035|NCT04569760|Experimental|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
33081036|NCT04569760|Placebo Comparator|Placebo Oil - Oral Preparation|"MCT Oil~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
33081037|NCT04569565|Experimental|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
33081038|NCT04569292||Cancer patients|"confirmation of COVID-19 in the laboratory (RT-PCR techniques);~suspected cases of COVID-19; clinically diagnosed based on symptoms (fever> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;~asymptomatic cases; diagnosed based on positive swab results but without symptoms"
33081039|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
33081040|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
33081041|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
33081042|NCT04569214|Placebo Comparator|A - Placebo Control|4 tablets of placebo
33081043|NCT04569214|Experimental|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
33081044|NCT04569214|Experimental|C - PAZ320 High Dose|4 tablet of PAZ320
33081045|NCT04569409|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
33081046|NCT04569409|Placebo Comparator|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
33081047|NCT00237978|Active Comparator|1|VIS and wIRA
33081048|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
33081049|NCT00237978|Active Comparator|3|Adapalen
33081050|NCT04568941|Experimental|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
33081051|NCT04568941|Experimental|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
33081052|NCT04568941|Experimental|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
33271617|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
33271618|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
33271619|NCT05547347||Observational (twinkle marker placement)|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker throughout the trial. Patients undergo a breast ultrasound during screening, on study, and as clinically indicated. Patient also undergoes a mammogram on study and as clinically indicated as well as a MRI as clinically indicated.
33271620|NCT00920933|Experimental|AIN457|
33271621|NCT00920933|Placebo Comparator|Placebo|
33271622|NCT00920933|Active Comparator|oral corticosteroid|
33271623|NCT00930566|Experimental|Extracorporal Photopheresis|
33271624|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
33271625|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
33271626|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
32773819|NCT03779711|Experimental|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
33271627|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
33271628|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
33271629|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
33271630|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
33271631|NCT00713219|Experimental|1|CHEMORADIATION
33271632|NCT03699644||Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
33271633|NCT03699644||Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
33271634|NCT03699644||Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
33271635|NCT00931580|Placebo Comparator|Placebo|placebo tablet
33271636|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
33271637|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
33271638|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
33271639|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
33271640|NCT05665751|Experimental|TLC-3595 Dose 1|Subjects will receive 12.5 mg of TLC-3595 once daily for 28 days
33271641|NCT05665751|Experimental|TLC-3595 Dose 2|Subjects will receive 25 mg of TLC-3595 once daily for 28 days
33271642|NCT05665751|Placebo Comparator|Placebo|Subjects will receive placebo-to-match TLC-3595 once daily for 28 days
33271643|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
33271644|NCT05661461|Experimental|Experimental|nab-Sirolimus
33271645|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
33271646|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
33271647|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
33271648|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
33271649|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
33271650|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
33271651|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
33271652|NCT05651711|Experimental|Rocatinlimab|Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
33271653|NCT05651711|Placebo Comparator|Placebo|Placebo Q4W for 24 weeks with a loading dose at Week 2.
33271654|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
33271655|NCT05651555|Experimental|N arm|
33271656|NCT05651555|Active Comparator|Control group|
33271657|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
33271658|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
33271659|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
33271660|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
33271661|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
33271662|NCT00931034|Active Comparator|ADA Diabetes meal plan|
33271663|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
32935762|NCT05451758|Experimental|Indoor environment|The indoor setting was a seminar room: a white painted room without windows in the basement of a university building. It contained chairs, a neutral coloured picture and no vegetation.
33271664|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
33271665|NCT00931814|Other|exercise|
33271666|NCT05741567||transobturator cystocele repair by vaginal plastron|patients who underwent surgery using the transobturator repair by vaginal plastron for correction of anterior prolapse
33271667|NCT00931112|Other|exercise|
33271668|NCT05741489|Experimental|ESKD with Burnt-out Diabetes|Participants with ESKD and burnt-out diabetes wearing a CGM for 10 days.
33271669|NCT05741489|Experimental|ESKD without Diabetes|Non-diabetic participants with ESKD wearing a CGM for 10 days.
33271670|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
33271671|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
33271672|NCT00932048|No Intervention|Control|
33271673|NCT00932048|Experimental|Atorvastatin|
33271674|NCT04015778|Experimental|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
33271675|NCT04015778|Experimental|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
33271676|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
33271677|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
33271678|NCT05546099|Experimental|Self-management|Patients monitor their home BP and self manage their BP medications based on a predesigned titration protocol and under the guidance of the clinical pharmacist.
33271679|NCT05546099|Active Comparator|Self-monitoring|Patients monitor their home BP and contact their provider if the BP is above the goal.
33271680|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
33271681|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
33271682|NCT05540873|Experimental|IL13Rα2 targeted CAR-T|
33271683|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
33271684|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
33271685|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
33271686|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
33271687|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
33271688|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
33271689|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
33271690|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
33271691|NCT05741411|Experimental|Concussed youth at risk for prolonged symptoms|
33271692|NCT05518877|Active Comparator|Ketamine 15 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 15 minutes.
33271693|NCT05518877|Experimental|Ketamine 30 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 30 minutes.
33271694|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
33271695|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
33271696|NCT05612789|Experimental|Cohort A (Prehab)|Pre-frail and frail subjects will attend at least twice weekly exercise sessions with a physical therapist and be given an exercise program to complete at home prior to admission for HCT. Patients enrolled in this cohort can continue on to Cohort B.
33271697|NCT05612789|Experimental|Cohort B (Rehab)|All patients 60 years and older upon discharge from their initial hospital stay for HCT will attend at least weekly exercise sessions with a physical therapist and be given an exercise program to complete at home with sessions continued through Day +100 after HCT.
33271698|NCT05611619|No Intervention|Control|Single study night with no noise exposure, to determine normal baseline sleep
33271699|NCT05611619|Experimental|Study 1: High level continuous flow tyre noise (A1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by high level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
33271700|NCT05611619|Experimental|Study 1: Medium level continuous flow tyre noise (B1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
33271701|NCT05611619|Experimental|Study 1: High level, discrete traffic tyre noise (A2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by high level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
33271702|NCT05611619|Experimental|Study 1: Medium level, discrete traffic tyre noise (B2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by moderate level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
33271703|NCT05611619|Experimental|Study 2: Medium level composite wheel tyre noise (A1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of composite wheel types.
33271704|NCT05611619|Experimental|Study 2: Low level composite wheel tyre noise (B1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of composite wheel types.
33271705|NCT05611619|Experimental|Study 2: Medium level air-filled tyre noise (A2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of traditional air-filled wheel types.
33271706|NCT05611619|Experimental|Study 2: Low level air-filled tyre noise (B2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of traditional air-filled wheel types.
33271707|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
33271708|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
33271709|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
33271710|NCT05595161|Experimental|Intervention|Bright Bodies
33271711|NCT05556473|Experimental|[18F]FETrp PET radiotracer|All participants will receive the tracer to evaluate the uptake of [18F]FETrp PET/CT on intra- and extracranial cancers.
33271712|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
33271713|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
33271714|NCT05097599|Other|Lorbrena® (lorlatinib)|
33271715|NCT05097599|Other|Braftovi® (encorafenib) + Mektovi® (binimetinib)|
33271716|NCT05097599|Other|Talzenna® (talazoparib)|
33271717|NCT05097599|Other|Enhertu® (fam-trastuzumab deruxtecan-nxki)|
33271718|NCT05097599|Other|Padcev® (enfortumab-vedotin)|
33271719|NCT05095259|Experimental|Participants with Type 1 Diabetes Mellitus|Participants with Type 1 Diabetes Mellitus
33271720|NCT05095259|Active Comparator|Healthy Controls|Healthy Controls
33271721|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
33271722|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
33271723|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
33271724|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
33271725|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
33271726|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
33271727|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
33271728|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
33271729|NCT00936650|Experimental|cinacalcet|
33271730|NCT00936650|Placebo Comparator|placebo|
33271731|NCT00442546|Experimental|1|
33271732|NCT00442546|Experimental|2|
33271733|NCT00442546|Placebo Comparator|3|
33271734|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
33271735|NCT00936806||Control group|Subjects without intracranial pathology
33271736|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
33271737|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
33271738|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
33271739|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
33271740|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
33271741|NCT04501328|Experimental|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
33271742|NCT04501328|Active Comparator|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
33271743|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
32935763|NCT04351009|Experimental|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa or subserosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
33271744|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
33271745|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
33271746|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
33271747|NCT00514683|Placebo Comparator|placebo|placebo
33271748|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
33271749|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
33271750|NCT00937196|Experimental|Placebo globuli|
33271751|NCT00937196|No Intervention|No treatment|
33271752|NCT04013984|Experimental|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
33271753|NCT04013984|No Intervention|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
33271754|NCT00937274|Experimental|Test product|
33271755|NCT00937274|Active Comparator|Commercial product|
33271756|NCT00937274|Placebo Comparator|Standard care|
33271757|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
33271758|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
33271759|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
33271760|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
33271761|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
33271762|NCT04014686|Sham Comparator|Control group|No exercise intervention
33271763|NCT04014686|Experimental|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
33271764|NCT00926900|Active Comparator|D-cycloserine|
33271765|NCT00926900|Placebo Comparator|Placebo|
33271766|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
33271767|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
33271768|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
33271769|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
33271770|NCT00937508|Experimental|Smoking counseling, Varenicline|
33271771|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
33271772|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
33271773|NCT03743324||BR group|Breast reconstruction without radiation therapy
33271774|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
33271775|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
33271776|NCT00937820|Experimental|YM150 group|
33271777|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
33271778|NCT00932516|Active Comparator|South Beach Diet™ alone|
33271779|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
33271780|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
33271781|NCT03376126||MI-ILP|
33271782|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
33271783|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
33271784|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
33271785|NCT00937976|Other|Control-delayed periodontal therapy|
33271786|NCT00937976|Other|Intensive Periodontal Therapy|
33271787|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
33271788|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
33271789|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
33271790|NCT00506883|Placebo Comparator|Placebo|
33271791|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
33271792|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
33271793|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
33271794|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
32773820|NCT03779711|Active Comparator|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
32773821|NCT04958083|Experimental|aortopathy patient|Patients who have proximal aortic conditions and are referred to the aortic team in Royal Brompton and Harefield Hospitals will be screened for eligibility. For this pilot study and in view of the volume of aortic surgery in the Trust (approx. 100 cases per year), 30 patients will be recruited in the first year of this project to be followed for at least one year for clinical outcomes.
32773822|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
32773823|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
32773824|NCT04958473|Experimental|Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
32773825|NCT04957927|Experimental|Intranasal Fluticasone Propionate Group|Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly
32773826|NCT04957927|Experimental|Montelukast Group|Montelukast 4mg oral granule formulation 24 hourly
32898321|NCT02667587|Experimental|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
33271795|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
33271796|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
33271797|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
33271798|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
33271799|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
33271800|NCT00938132|Experimental|Fimasartan|
33271801|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
33271802|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
33271803|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value >140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values > 6.5% prior to admission.
33271804|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
33271805|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
33271806|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
33271807|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
33271808|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
33271809|NCT00932750|Placebo Comparator|MOS Weight maintenance|
33401778|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
33401779|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
33401780|NCT03658382|No Intervention|Telephone Results Disclosure|
33401781|NCT03658382|Experimental|Virtual Visit Results Disclosure|
33401782|NCT04401566|Experimental|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
33081053|NCT04568668|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
33401783|NCT04401566|Experimental|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
33401784|NCT04401566|Other|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
33401785|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
33401786|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
33081054|NCT04568668|No Intervention|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
32736841|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thoracic vertebral posteroanterior mobilization~Thrust dorsal~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
32736842|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
32736843|NCT03242239|Experimental|ALT02|
32736844|NCT03242239|Active Comparator|EU-licensed Herceptin|
32736845|NCT03242239|Active Comparator|US-licensed Herceptin|
33081055|NCT04568746|Other|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
33081056|NCT04568746|Other|patients with qSOFA <2|adult patients with a qSOFA score < 2 at the screening in the emergency department, will be referred to the box
33081057|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
33081058|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
33081059|NCT04568785|Experimental|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
33081060|NCT04568785|Active Comparator|Control group|the control group intervention was the normal advice that professionals used to give their patients
33081061|NCT04568863|Experimental|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
33081062|NCT04568863|Placebo Comparator|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
33081063|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
33081064|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
33081065|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
33081066|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
33081067|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
33081068|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
33081069|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
33081070|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
33271810|NCT00932750|Placebo Comparator|MOS weight loss|
33271811|NCT00938288|Other|1|Single group
33271812|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
33271813|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
33271814|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
33271815|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
33271816|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
33271817|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
33271818|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
33271819|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
33271820|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
33271821|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
33271822|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
33271823|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
33271824|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
32898322|NCT02667587|Placebo Comparator|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
33271825|NCT00938522|Experimental|Cilostazol loading|
33271826|NCT00938522|Placebo Comparator|Placebo|
33271827|NCT00938600|Experimental|A1 - non-pregnant single-dose|
33271828|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
33271829|NCT00938600|Experimental|B1 - pregnant; single-dose|
33271830|NCT00938600|Experimental|B2 - pregnant; weekly dose|
33271831|NCT00938600|Active Comparator|C1 - active control; pregnant women|
33271832|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
33271833|NCT00938678|Experimental|Treatment Group 1|
33271834|NCT00938678|Active Comparator|Treatment Group 2|
33271835|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
33271836|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
33271837|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
33271838|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
33271840|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
33271841|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
33271842|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
33271843|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
33401787|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
33401788|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
33401789|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
33401790|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
33401791|NCT04387916|Experimental|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
33401792|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
33401793|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
33401794|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
33401795|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
33401796|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
33401797|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
32898323|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
33401798|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
32898324|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions~TGR-1202: Fixed oral daily dose"
33081071|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
33081072|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
33081073|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
33081074|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
33081075|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
33081076|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
33081077|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
33081078|NCT02210494|Experimental|Secretrol|
33081079|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
33081080|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
33081081|NCT04568707|Experimental|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
33081082|NCT04568512|Placebo Comparator|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
33081083|NCT04568512|Active Comparator|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
33081084|NCT04568473|Experimental|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
33081085|NCT04568473|Experimental|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
33081086|NCT04568473|Active Comparator|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
33081087|NCT04568278|Experimental|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
33081088|NCT04568278|No Intervention|Controlled Group|Usual care
33081089|NCT04568317|Experimental|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
33081090|NCT04568317|Active Comparator|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
33081091|NCT04568161|Experimental|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
33081092|NCT04567966|Experimental|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
33081093|NCT04567966|Active Comparator|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
33401799|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
33401800|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
33401801|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
33401802|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
32773827|NCT04957849|Active Comparator|Trans-frontal keyhole approach|After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.
32773828|NCT04957849|Active Comparator|Trans-occipital keyhole approach|After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.
33081094|NCT02962011|Experimental|Knotless barbed suture|
33081095|NCT02962011|Active Comparator|polyglactin 910|Vicryl
33081096|NCT04568356|Experimental|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
33081097|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
33081098|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
33081099|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
33081100|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
33081101|NCT04567459|No Intervention|control group: chemotherapy|No intervention
33081102|NCT04567459|Experimental|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
33081103|NCT04567147|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
33081104|NCT04567147|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
33081105|NCT04722380|Experimental|test group|10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
33081106|NCT04722380|Placebo Comparator|control group|10 infrabony defects treated surgically with xenograft alone
33081107|NCT04566952|Experimental|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
33081108|NCT04567069|Experimental|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
33081109|NCT04567069|Experimental|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
33081110|NCT04567069|Experimental|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
33081111|NCT04566874|Other|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
33081112|NCT04566874|Active Comparator|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
33081113|NCT04566796|Active Comparator|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
33081114|NCT04566796|Experimental|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
33081115|NCT04566913|Experimental|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .~> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .~Post operative instructions include :~Analgesics (Prufen 400 mg ) three times for three days~Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
32773829|NCT04688801|Active Comparator|Chemotherapy± Radiotherapy Group|Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
32773830|NCT04688801|Experimental|Chemotherapy + Immunotherapy ± Radiotherapy Group|Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
32773831|NCT04957771|Experimental|Regular exercise group|
33271844|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
33271845|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
33271846|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
33271847|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
33271848|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
33271849|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
32773832|NCT04957771|No Intervention|non-regurlar exercise group|
32773833|NCT00912041|Other|BrainGate|BrainGate Neural Interface System
33271850|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
33271851|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
33271852|NCT00933218|Placebo Comparator|beverage without polyphenols|
33271853|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
33271854|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
33271855|NCT00737945||2|
32773834|NCT04966975||Histologically confirmed bladder cancer treated with NAC|
32773835|NCT04957693|Experimental|treatment arm|vegan diet and lifestyle change
32773836|NCT04682561|Experimental|Supportive Trauma Exposure Preparation (STEP) Program|Nurses or personal support workers at Unity Health Toronto - Providence Healthcare will undergo the STEP Program Psychotherapy
33271856|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
33271857|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
33271858|NCT05465291|No Intervention|Conventional care|Control Group
33271859|NCT05465291|Experimental|Exercise Group|Passive/active range of motion exercises group
33271860|NCT05465291|Experimental|Neuromuscular Electrical Muscle Stimulation group|Neuromuscular Electrical Muscle Stimulation group
33271861|NCT05465291|Experimental|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise)|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise).
33271862|NCT02536755|Experimental|Eliglustat|Participants who completed one of the Phase 2 (GZGD00304 [NCT00358150]) or Phase 3 studies (GZGD02507 [NCT00891202], GZGD02607 [NCT00943111], or GZGD03109 [NCT01074944]) were enrolled in this current (EFC13781) study. Participants who were cytochrome P450 (CYP) 2D6 intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizers (URM) received eliglustat 84 milligrams (mg) twice daily and participants who were CYP2D6 poor metabolizer (PM) received eliglustat 84 mg once daily, for duration of minimum 2 years (unless early discontinuation occurred) and up to 4 years, or until commercial eliglustat was available to participants through reimbursement or through the compassionate use (expanded access) program.
33271863|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
33271864|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
33277561|NCT05354960||Validation of LIMB-Q questionnaire|We plan to validate the questionnaires for quality of life and functional impairment in a mixed study population. In addition, CROMs, specifically the active range of motion, the 2 PD, compara-tive circumference measurements, AOFAS and MFS will be collected. In addition, photo documen-tation of the operated lower extremity will be performed. The results obtained will be correlated with each other.
33277562|NCT00781001|Placebo Comparator|1|Placebo cannabis
33277563|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
33277564|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
32773837|NCT04950049|Active Comparator|2 ml dexamethasone (5 mg/ml)|50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.
32773838|NCT04950049|Experimental|5 ml dexamethasone (2mg/ml)|50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
32773839|NCT04950049|Experimental|10 ml dexamethasone (1mg/ml)|50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
33271865|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
33271866|NCT05460689|Experimental|Smartphone Application|mHealth App provided to caregivers of children undergoing tonsillectomy and/or adenoidectomy
33271867|NCT05460689|Sham Comparator|standard support|Information provided by nurses and physician orally or through printed booklets.
33271868|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
32773840|NCT04950049|Experimental|20 ml dexamethasone (0.5mg/ml)|50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
32773841|NCT05438927|Experimental|Nutritional Support|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing data with a dietician
32773842|NCT04966897|Experimental|GBNS + PERT placebo|GBNS + PERT placebo (drink volume sufficient to supply 0.5 g of MAG per kg of body weight plus PERT placebo capsules according to patient body weight.
32773843|NCT04966897|Active Comparator|Standard Nutritional Supplement + PERT|Standard nutritional supplement + PERT (drink volume sufficient to supply 0.5 g of TAG per kg of body weight plus PERT capsules according to body weight).
33271869|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
33271870|NCT04013594|Experimental|carbohydrate group(CHO group)|
33271871|NCT04013594|No Intervention|control group|
33271872|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
33271873|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
33271874|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
33271875|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
33271876|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
33271877|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
33271878|NCT03263325||AKI Group|Patients developing AKI after surgery
33271879|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
33271880|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
33271881|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
33271882|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
33271883|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
33271884|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
33277565|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
33277566|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
33401803|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
32773844|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
32773845|NCT03730259|Experimental|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
32773846|NCT03730259|No Intervention|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
32773847|NCT05587673|Experimental|Methylprednisolone|Participants who have failed first line therapy and are still experiencing flare symptoms.
32773848|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
32773849|NCT04957381||low to moderate CRF with low MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and low muscular fitness (MF).
32773850|NCT04957381||low to moderate CRF with moderate MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and moderate muscular fitness (MF).
32773851|NCT04957381||low to moderate CRF with high MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and high muscular fitness (MF).
32773852|NCT04957381||high CRF with low to moderate MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and low to moderate muscular fitness (MF).
32773853|NCT04957381||high CRF and high MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and high muscular fitness (MF).
32773854|NCT04957069||Avulsion fracture|avulsion fracture of the Achilles tendon
33081116|NCT04566835|Experimental|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
33081117|NCT04566835|Other|Control Group|Taking standart care
33081118|NCT04567030|Experimental|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
33081119|NCT04567030|Experimental|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
33081120|NCT04567030|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
33081121|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33081122|NCT04566757|Experimental|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
33081123|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
33081124|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
33081125|NCT04566679|Experimental|Butyrate|oral butyrate (500mg) once or twice per day
33081126|NCT04566679|Placebo Comparator|Placebo|oral placebo once or twice per day
33081127|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
33081128|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
33081129|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
33081130|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
33081131|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
33081132|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
33081133|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
33081134|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
33081135|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
33081136|NCT00238290|Experimental|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
33401804|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
32773855|NCT04957069||Rupture|Achilles tendon rupture
32773856|NCT04966429|Active Comparator|Maraviroc 150 mg per day|
32773857|NCT04966429|Active Comparator|Maraviroc 600 mg per day|
32773858|NCT04966429|Placebo Comparator|Placebo|
32773859|NCT04956913||Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
32773860|NCT04956913||Machintosh|Patients of this group were intubated using the classic Macintosh laryngscoscope
32773861|NCT04956991||CDAI≤220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group A (CDAI≤220)
32773862|NCT04956991||CDAI>220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group B (CDAI>220)
32773863|NCT04949659|Experimental|Low pressure pneumoperitoneum|Use of low pressure pneumoperitoneum during laparoscopic appendectomy
32773864|NCT04949659|Experimental|Medium pressure pneumoperitoneum|Use of medium pressure pneumoperitoneum during laparoscopic appendectomy
33081137|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
32773865|NCT04949581|Experimental|bioelectric therapy|patients will receive micro-current electrical stimulation three times/week for four weeks
32773866|NCT04949581|Active Comparator|cardiac rehabilitation programe|patients will receive a cardiac rehabilitation program three times/week for four weeks
32773867|NCT04949971||High volume group|The tidal volume of the exposed group was 10ml/kg ideal body weight.
32773868|NCT04949971||Low volume group|The tidal volume of the non-exposed group was 6ml/kg ideal body weight
33081138|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
33081139|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
33081140|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
33081141|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
33081142|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
33081143|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
33081144|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
33081145|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
33081146|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
33081147|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
33081148|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
33081149|NCT02894827||EMS|
33081150|NCT02894827||Control|
33081151|NCT02894788||ICU|patients postoperatively admitted to ICU
33081152|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
33081153|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
33081154|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
33081155|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
33081156|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
33081157|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
33081158|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
33081159|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
33081160|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
33081161|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
33081162|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
33081163|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
33081164|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
33271885|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
32773869|NCT04966195|Other|radiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
32773870|NCT04965883|Experimental|Early Excision and Grafting|"The early excision will be done surgically within 4-10 days post burn by whatson knife by tangential excision of burned tissue until capillary bleeding appears to make a good bed to be covered with grafts split thickness grafts STG at the same time.~The first dressing will be in the fifth day post operative."
33271886|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
33277567|NCT05252234||Group 1|Patients undergoing elective surgeries with past history of COVID-19 infection during the past six months
33277568|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
32773871|NCT04965883|Experimental|Dressing and Delayed Grafting|• Dressing will be done for the second group every other day until spontanous eschar seperation or after surgiacl debridrment of adherent eschar then for delayed grafting more than 10 days post burn.
32773872|NCT04949347||Glycerin-preserved, human-donor, cornescleral patch grafts|Consecutive glaucoma patients who had undergone glaucoma drainage device implantation using glycerin-preserved, human-donor, cornescleral patch grafts
32773873|NCT04956367|Experimental|CO2 laser with PRP|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, PRP will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
32773874|NCT04956367|Placebo Comparator|CO2 laser with placebo|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, pNSS will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
32773875|NCT04956601|Experimental|VBT|CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
32773876|NCT04956601|Active Comparator|EBRT|Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
33277569|NCT00773591|Placebo Comparator|Placebo|
32773877|NCT04965961|Experimental|Recombinant human erythropoietin treatment|Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
32773878|NCT04965961|Placebo Comparator|Control group|Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.
33277570|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
32773879|NCT04966039||monochorionic twin pregnancies with demise of one fetus|Twin pregnancy was diagnosed and one fetus died in utero, 20 pregnant women
32773880|NCT04966039||Twin control group|Twin pregnancy with one abnormal fetus, 20 pregnant women
32773881|NCT04966039||Singleton control group|Singleton pregnancy with abnormalities outside the fetal brain, 20 pregnant women
32773882|NCT04956055|Experimental|Experiment group|Experimental group to be applied hand reflexology
32773883|NCT04956055|No Intervention|Control group|experimental group for which hand reflexology will not be applied
33277571|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
32773884|NCT04955977|Experimental|G1: People with a diagnosis of COPD stratified in GOLD 1-2.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1-2, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
32898325|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
32898326|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
32898327|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
32898328|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
33277572|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
33277573|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
33271887|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
33271888|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
33271889|NCT00447694|Experimental|deferasirox every day for 77 weeks|Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.
33271890|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
33271891|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
33271892|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
33271893|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
33271894|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
33271895|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
33271896|NCT04013906|Experimental|Rotational atherectomy|Patients will undergo rotational atherectomy
32898329|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
32898330|NCT02583113||Total and Unicompartment Knee Replacement|
32898331|NCT02552511||Exposure|Perinatal factors exposure
33271897|NCT04013906|Experimental|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
33271898|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
33271899|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
33271900|NCT00933920|Active Comparator|Fed Group|
33271901|NCT00933920|Active Comparator|Fasted group|
33271902|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
33271903|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
33271904|NCT00938990|Active Comparator|Midazolam|
33271905|NCT00938990|Experimental|Etomidate|
33271906|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
33271907|NCT00447226|Experimental|Lapatinib Oral Tablets|
33271908|NCT00447226|Placebo Comparator|Placebo Control|
33271909|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
33271910|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
33271911|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
33271912|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
33271913|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
33271914|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
33271915|NCT00577031|Experimental|1|
33271916|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
33271917|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
32898332|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
33271918|NCT01012011||Group 1|
33271919|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
33271920|NCT04495803|Experimental|Experimental|After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
33271921|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
33271922|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
33271923|NCT00934154|Experimental|Thalidomide|MPT
33271924|NCT00934154|Active Comparator|Control|MP
33271925|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
33271926|NCT05078255|Placebo Comparator|placebo injections + placebo infusion|
33271927|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + GIP infusion|
33271928|NCT05078255|Experimental|placebo injections + GIP infusion|
33271929|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + placebo infusion|
33271930|NCT05077943|Active Comparator|No Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time, in 3 months without being supervised
33271931|NCT05077943|Experimental|With Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time and breathing and chest mobilization exercise for 3 times per week. They will be supervised through online meetings.
33271932|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
33271933|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
33271934|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
33271935|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
33271936|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
33271937|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
33271938|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
33271939|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
33271940|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
33271941|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
33271942|NCT04061837|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
33271943|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
33271944|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
33271945|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
33271946|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
33271947|NCT05325125||Children who have completed treatment for Tuberculosis|Children < 18 years, who had drug sensitive pulmonary tuberculosis, either bacteriologically confirmed or not and who have completed treatment within the preceding 1 month before enrolment
33271948|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
33271949|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
33271950|NCT04061759|Active Comparator|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:~Soft Tissue Mobilization;~Pretzel Maneuvers;~Pelvis Backward-Distraction;~Trunk Rotation;~Multifidus Mobilization; and~Piriformis Transverse Friction Massage"
33271951|NCT04061759|Active Comparator|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
33271952|NCT04061759|Active Comparator|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
33271953|NCT04061759|Active Comparator|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
33271954|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
33271955|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
33271956|NCT00738179|Active Comparator|2|Standard care alone
33271957|NCT00492921|Experimental|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
33271958|NCT00492921|Experimental|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
33271959|NCT00492921|Experimental|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
33271960|NCT00738257|Experimental|Parmidronate|
33271961|NCT00502671|Experimental|1|
33271962|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
33271963|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
33271964|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
33271965|NCT03996915|Experimental|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
33271966|NCT03996915|Active Comparator|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
33271967|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
33271968|NCT04409795|Other|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
33271969|NCT04409795|Other|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
33271970|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
33271971|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
33271972|NCT04334603|Experimental|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
33271973|NCT04334603|Active Comparator|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
33271974|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
33271975|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
33271976|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
33277574|NCT05354570|Experimental|Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.
33271977|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
33271978|NCT00111475|Experimental|Part A: Romiplostim 0.2 µg/kg|Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
33271979|NCT00111475|Experimental|Part A: Romiplostim 0.5 µg/kg|Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
33271980|NCT00111475|Experimental|Part A: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
33271981|NCT00111475|Experimental|Part A: Romiplostim 3 µg/kg|Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
33271982|NCT00111475|Experimental|Part A: Romiplostim 6 µg/kg|Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
33271983|NCT00111475|Experimental|Part A: Romiplostim 10 µg/kg|Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
32736846|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
32736847|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
32736848|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
33271984|NCT00111475|Placebo Comparator|Part B: Placebo|Participants received placebo subcutaneously once a week for 6 weeks.
33271985|NCT00111475|Experimental|Part B: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
33271986|NCT00111475|Experimental|Part B: Romiplostim 3.0 µg/kg|Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
33271987|NCT00111475|Experimental|Part B: Romiplostim 6.0 µg/kg|Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
33271988|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
33271989|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
33271990|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
33271991|NCT04948463|Experimental|Early Stopping|Stopping empiric FN antibiotics after resolution of fever for 48 hours, irrespective of absolute neutrophil count (ANC)
33271992|NCT04948463|Active Comparator|Standard of care|Continuing empiric FN antibiotics until resolution of fever for 48 hours and recovery of ANC as defined by the treating clinician but usually to ≥200-500/mm3
32736849|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
32736850|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
33271993|NCT04945421|Experimental|Sintilimab and IBI310 (single arm)|The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
33271994|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
33271995|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
32736851|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
32736852|NCT03232879|Experimental|Experimental 1|Motor Imagery
33271996|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
33271997|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
33271998|NCT04930991|Experimental|Arm A (High Dose)|Omeprazole, 80 mg, PO, BID for 2 weeks prior to surgical therapy of pancreatectomy. All 30 subjects in Arm A to be enrolled prior to Arm B cohort enrollment.
33271999|NCT04930991|Placebo Comparator|Arm B (Normal Dose)|Omeprazole, 20 mg, PO, QD for 2 weeks prior to surgical therapy of pancreatectomy.
32736853|NCT03232879|Experimental|Experimental 2|Action Observation
32736854|NCT03232879|No Intervention|Control Group|No intervention
32736855|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
32736856|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
32736857|NCT03241849|Other|Modified surgical technique for placenta accreta|
33272000|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
32773885|NCT04955977|Experimental|G2: People with a diagnosis of COPD stratified in GOLD 3-4.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 3-4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
32773886|NCT04955977|Active Comparator|G3: Control - People without a COPD diagnosis.|Healthy people, over 40 years old. No history of cigarette smoking or exposure to wood smoke. Who do not present diagnoses of musculoskeletal injuries and who are residents at 2600 meters above sea level for more than 14 months. With affiliation to a mandatory health plan and signature of informed consent.
33272001|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
33272002|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
33272003|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
32935764|NCT05451680|Experimental|Negative-pressure treatment|A negative pressure wound dressing is placed over the skin graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
33272004|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
33272005|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
33272006|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
33272007|NCT04608435||Male Group|
33272008|NCT04608435||Female Group|
33272009|NCT03997227|Active Comparator|Block group|
33272010|NCT03997227|No Intervention|control group|
33272011|NCT00697073|Experimental|1|high dose Idebenone
33272012|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
33272013|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
33272014|NCT04061681|Experimental|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
33272015|NCT04061681|No Intervention|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
33272016|NCT04835129|Experimental|Safety Run-in|Six subjects will be enrolled. Isatuximab (10 mg/kg) intravenous (IV) on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) by mouth (PO) days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
33272017|NCT04835129|Experimental|Expansion|"Forty-seven subjects with relapsed and/or refractory multiple myeloma will be enrolled.~Isatuximab (10 mg/kg) IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) PO days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle."
33272018|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
33272019|NCT00934388|Active Comparator|No mesh placed|
33272020|NCT00939224||Cohort Phase 1|Cardiac Catheterization
33272021|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
33272022|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
33272023|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
33272024|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
33272025|NCT04816643|Experimental|Mid-Dose, ≥5 to <12 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
33272026|NCT04816643|Experimental|High-Dose, ≥5 to <12 Years|High-Dose (30mcg), 2 doses 21 days apart
33272027|NCT04816643|Experimental|Low/Mid-Dose, ≥2 to < 5 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
33272028|NCT04816643|Experimental|Mid-Dose, ≥2 to <5 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
33272029|NCT04816643|Experimental|High-Dose, ≥2 to <5 Years|High-Dose, (30mcg), 2 doses 21 days apart
33272030|NCT04816643|Experimental|Low/Mid-Dose, ≥6 Months to <2 Years|Low/Mid-Dose, (10mcg), 2 doses 21 days apart
33272031|NCT04816643|Experimental|Mid-Dose, ≥6 Months to <2 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
32773887|NCT04956211|Experimental|Non-surgical periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
33272032|NCT04816643|Experimental|High-Dose, ≥6 Months to <2 Years|High-Dose, (30mcg), 2 doses 21 days apart
33272033|NCT04816643|Experimental|Low/Mid-Dose, 16 to <18 Years (21 day schedule)|Low/Mid-Dose (10mcg), 2 doses 21 days apart
32773888|NCT04956211|Active Comparator|Conventional periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
33272034|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years|
32773889|NCT04949035||COVID-19 survivors|
33272035|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years|
33272036|NCT04816643|Placebo Comparator|Placebo, ≥5 to <12 Years|
33272037|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years|Low-Dose (3mcg), 2 doses 21 doses apart
33272038|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years|Low-Dose (3mcg), 2 doses 21 days apart
33272039|NCT04816643|Experimental|Low/Mid-Dose, 12 to <16 Years (21 day schedule)|Low/Mid-Dose (10mcg), 2 doses 21 days apart
33272040|NCT04816643|Experimental|High-Dose, 12 to <16 Years (Troponin I Testing)|High-Dose (30mcg), 3 doses
33272041|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)|Low/Mid-Dose (10mcg), 3 doses
33272042|NCT04816643|Experimental|Placebo, ≥5 to <12 Years (Troponin I Testing)|
33272043|NCT04816643|Experimental|Low/Mid-Dose, 12 to <16 Years (8 week schedule)|Low/Mid-Dose (10mcg), 2 doses 8 weeks apart
33272044|NCT04816643|Experimental|Low/Mid-Dose, 16 to <18 Years (8 week schedule)|Low/Mid-Dose (10mcg), 2 doses 8 weeks apart
33272045|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
33272046|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
33272047|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years (3-dose regimen)|
33272048|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years (3-dose regimen)|
33272049|NCT04013516|No Intervention|Pure Control|Respondents received New Incentives' normal program.
33272050|NCT04013516|Placebo Comparator|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
33272051|NCT04013516|Experimental|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
33272052|NCT04013516|Experimental|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
33272053|NCT04014452|Experimental|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
33272054|NCT04014452|Active Comparator|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
33272055|NCT04013750|Experimental|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
33272056|NCT04013750|Experimental|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
33272057|NCT04013750|No Intervention|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
33272058|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
33272059|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
33272060|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
33272061|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
33272062|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
33272063|NCT00921089||Control group|Normotensive healthy controls
33272064|NCT00934466|Experimental|1|MK2637 120 mg
33272065|NCT00934466|Experimental|2|MK2637 50 mg
33272066|NCT00934466|Placebo Comparator|3|Placebo
33272067|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
33272068|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
33272069|NCT00921245||Group 1|
33272070|NCT00563186|Experimental|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
33272071|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms [80%], shared bathrooms, curtains present)
33272072|NCT00699413|Active Comparator|1 - nutrition education plus active supplement|nutrition education plus active supplement
33272073|NCT00699413|Placebo Comparator|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
33272074|NCT01028872|Sham Comparator|Sensar IOL|
33272075|NCT01028872|Active Comparator|Tecnis IOL|
33272076|NCT01028872|Active Comparator|AcrySof IQ|
33272077|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
33272078|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
33272079|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant >50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
33272080|NCT04808609|Experimental|Intervention|The Intervention group receives standard smoking cessation counseling and nicotine replacement therapy AND access to the Lumme app that tracks smoking behaviors and provides cessation support.
33272081|NCT04808609|Other|Control|The Control group receives standard smoking cessation counseling and nicotine replacement therapy
32773890|NCT04948879||Vascular reconstruction|Patients who have undergone resection with or without reconstruction of a major blood vessel in the context of surgery for a locally advanced pelvic malignancy. This will mostly refer to patients who have had resection/reconstruction of their internal iliac vessels, or less likely common iliacs.
32773891|NCT04948957||esmolol (Group E)|
32773892|NCT04948957||nitroglycerin (Group N)|
32935765|NCT05451680|Active Comparator|Conventional treatment|A conventional antimicrobial wound dressing is placed on top of the graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
33272082|NCT00940160|Active Comparator|QAX576 1 mg/kg|
32935766|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
32935767|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
33272083|NCT00940160|Active Comparator|QAX576 3 mg/kg|
33272084|NCT00940160|Active Comparator|QAX576 10 mg/kg|
33272085|NCT00940160|Placebo Comparator|Placebo|
33272086|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
32935768|NCT05442476|Experimental|kinesiotaping|
33272087|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
33272088|NCT04013438|Experimental|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
33272089|NCT04013438|Active Comparator|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
32773893|NCT04948801||genotype 3a HCV|genotype 3a hepatitis C
32773894|NCT04948801||genotype 6 HCV|genotype 6 hepatitis C
32935769|NCT05442476|Other|Muscle Energy Technique|
32935770|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
32935771|NCT05451290|Experimental|treatment arm|
32935772|NCT05452135||Healty Adults|aged between 20 - 30 years right dominant being a volunteer to participate in the study
32935773|NCT04357964||obese and lean individuals|obese and lean individuals
32935774|NCT04284865|Experimental|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
32935775|NCT04344860|Active Comparator|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
32935776|NCT04344860|Active Comparator|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
33272090|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
33272091|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
33272092|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
33272093|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
33272094|NCT00934778|Experimental|Bronchoscopy|
33272095|NCT00111007|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
33272096|NCT00111007|Active Comparator|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
33272097|NCT03975920|No Intervention|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
33272098|NCT03975920|Experimental|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
32773895|NCT04948801||genotype 3b HCV|genotype 3b hepatitis C
32773896|NCT04948255||Healthcare Workers at the Gill Medical Centre|Clinical and non-clinical staff at the Gill Medical Centre will complete a validated stress questionnaire during the Covid-19 pandemic. A baseline was established in May, 2019.
33272099|NCT01082887|Experimental|TIL-Ad-INFg|
33272100|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
33272101|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
33272102|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
33272103|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
33272104|NCT03962881|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
33272105|NCT03962881|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
33272106|NCT03962881|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
33272107|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
32773897|NCT04965415|Active Comparator|Lagged|Businesses in the lagged arm participated in Health Links for one year from their baseline assessment to their first follow-up assessment one year later. They were eligible to participate in the Leadership Training after both assessments were completed.
32773898|NCT04965415|Experimental|Early|Businesses in this arm participated in Health Links + Leadership Training for one year from their baseline assessment to their first follow-up assessment one year later.
32773899|NCT04948567|Experimental|split-dose of Magnesium Sulfate solution|Those assigned to MSS group were instructed to take 30ml of 50% magnesium sulfate solution and then drink 600ml water on the evening before colonoscopy. 70ml of 50% MMS and then 1500ml water was taken at least 4 hours before procedure on the colonoscopy day.
32773900|NCT04948567|Placebo Comparator|split-dose of PEG|Patients in PEG group were instructed to take first dose of 1.5L PEG on the evening before colonoscopy and take the second dose of 1.5L PEG at least 4 hours before the colonoscopy procedure on the morning.
32773901|NCT04955665||Bone block procedure|patients with recurrent peroneal tendon dislocation underwent the bone block procedure
33272108|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
32773902|NCT04955665||Reattachment of the superior peroneal retinaculum|patients with recurrent peroneal tendon dislocation underwent reattachment of the superior peroneal retinaculum
32773903|NCT04965571||WD-seizures|Chinese WD patients with generalized epilepsy
32773904|NCT04955509||Training|random splitting based on random sequences generated by engineers to train and optimize a machine learning model
32773905|NCT04955509||Testing|random splitting based on random sequences generated by engineers to evaluate the performance of the model
32773906|NCT04948177||Group A|Group A: Individuals who had normal pyloric orifice structure;
33272109|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
33272110|NCT01083043||Type 2 Diabetes Mellitus|
33272111|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
33272112|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
33272113|NCT04013360|Active Comparator|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
33272114|NCT04013360|Active Comparator|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
33272115|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
33272116|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
33272117|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
33272118|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
33272119|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
33272120|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
33081165|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
33272121|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
33272122|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
33272123|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
33272124|NCT00935480|No Intervention|HAART|
33272125|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
33272126|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
33272127|NCT04013048|Experimental|[14C]-Fluzoparib|Patients will receive single dose of [14C]- Fluzoparib.
33272128|NCT04014218|Experimental|Inhalation sedation|
33272129|NCT04014218|Active Comparator|Propofol|
32773907|NCT04948177||Group B|Group B: Individuals who have abnormal pyloric orifice structure
32773908|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
32773909|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
32773910|NCT04419181|Experimental|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP [docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
33272130|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
33272131|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
32773911|NCT04419181|Experimental|Residual Disease|Participants will receive four cycles of TCHP [docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
33272132|NCT05280236|Active Comparator|Propofol|Patients receiving general anesthesia with propofol-based total intravenous anesthesia
33272133|NCT05280236|Experimental|Remimazolam|Patients receiving general anesthesia with remimazolam-based total intravenous anesthesia
32773912|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
32773913|NCT04955353|Experimental|AVC-H2|Participants received Avicenna Hydrolyzed Chicken Collagen Type II (AVC-H2), 2.5g daily, for 8 weeks.
32773914|NCT04955353|Placebo Comparator|Placebo|Participants received placebo of matching amount to that of AVC-H2 daily for 8 weeks.
32773915|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
32773916|NCT04955119|Experimental|Fusion imaging contrast-enhanced ultrasound LI-RADS|"Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
32773917|NCT04965103|Active Comparator|Bridging|Tendon repair with graft interposition
32773918|NCT04965103|Experimental|SCR|Superior Capsule reconstruction
32773919|NCT04954963||conventional examination|patients undergo conventional examination
32773920|NCT04954963||Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
32773921|NCT04964869|Experimental|Epinephrine solution injection group|In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.
32773922|NCT04964869|No Intervention|non-injection group|In non injection group, the saline epinephrine solution is not given
32773923|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
32773924|NCT04955041||mild CSM|preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
33081166|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
33272134|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
33272135|NCT00940472|Active Comparator|Metformin|Metformin + Diet
33272136|NCT04013204|Experimental|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
33272137|NCT04013204|No Intervention|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
33272138|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
33272139|NCT00940550|Active Comparator|Temazepam 20 mg|
33272140|NCT00940550|Active Comparator|Zolpidem 10 mg|
33272141|NCT00940550|Placebo Comparator|Placebo|
33272142|NCT00935714|Active Comparator|Muscle Group|Exercise
33272143|NCT00935714|Active Comparator|Sequence|Exercise
33272144|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
33272145|NCT00935870||B|BENIGN BONE TUMOR
33272146|NCT00935870||C|SPINAL FUSION
33272147|NCT00935948|Active Comparator|Imescard ointment|
33272148|NCT00935948|Placebo Comparator|Placebo|
33272149|NCT00940628|Experimental|1|
33272150|NCT00940628|Other|2|
32773925|NCT04955041||moderate CSM|preoperative mJOA score 13~14
33272151|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
33272152|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
32773926|NCT04955041||severe CSM|preoperative mJOA score ≤12
33272153|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
33272154|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
33272155|NCT05294471||Healthy participants|70 healthy participants will be recruited, across substudies 1, 2, 4, and 5
32773927|NCT04954885||Ancillary-correlative (biospecimen, questionnaire, testing)|Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
32773928|NCT04965805|Experimental|Cold plasma jet|The treatment scheme of the cold plasma jet will be applied in the following manner, quantity and frequency: Cold plasma is always applicated for 30 seconds/ cm^2 wound size. Wounds will be treated three times in the first week, twice in the second week and once per week in the following observation period. In case of locally infected ulcers, treatment will be performed 1x per day during the first week and afterwards in the same manner as in non-infected ulcers. After application of cold plasma, the wound will be covered with Adaptic perforated gauze and a non-active dressing.
32773929|NCT04965805|Active Comparator|Best Practice wound dressings|Immediately after dressing removal, the wound will be cleaned with a physiological saline solution soaked swab. In case of locally infected wounds, an antiseptic will be used instead of the physiological saline solution. Subsequently, a wound phase-adapted primary dressing will be applied according to the experience of the practitioner and, if necessary, the wound will be covered with a secondary dressing according to the experience of the practitioner as well. In case of locally infected wounds, silver dressings can be applied. The dressing will be changed at least every 2nd day and on weekends every 3rd day; in case of locally infected wounds, dressings will be changed daily. Dressing changes beyond visits can also be performed by the general practitioner, a nursing service, or by the participant him- or herself.
32773930|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
32773931|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
32773932|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
33272156|NCT05294471||Participants with known or suspected iron overload|30 Participants with known or suspected iron overload will be recruited, to substudy 3
32773933|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
32773934|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
33272157|NCT05294471||Participants with elevated levels of liver fat|30 participants with elevated levels of liver fat will be recruited, to substudy 3
32773935|NCT04430179|Active Comparator|Active drug|Dupilumab 300 mg every other week for 24 weeks
33272158|NCT05294471||Participants referred for clinical abdominal MRI|60 participants referred for clinical abdominal MRI will be recruited, to substudy 6
32773936|NCT04430179|Placebo Comparator|Placebo|Placebo
32773937|NCT04946929|Experimental|Ticagrelor, 2-3mg/kg, 12h|2-3mg/kg, q12h, p.o. for 2w
32773938|NCT04946929|Active Comparator|low molecular weight heparin|half amount low molecular weight heparin
32773939|NCT04933045||Syndesmotic Fixation Group|Cohort of patients treated with anatomic ATFL reconstruction for syndesmotic ankle injury.
32773940|NCT03058159|Other|Subjects with a high dream recall frequency|
32773941|NCT03058159|Other|Subjects with a law dream recall frequency|
33272159|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
33272160|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
33272161|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
32773942|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
32773943|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
33272162|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
33272163|NCT00936182|Experimental|Fluconazole|
33272164|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
32773944|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
32773945|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
32773946|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
32773947|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
33272165|NCT00940082||youth control group|healthy people which ages from 30 to 59
33272166|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
33272167|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
33272168|NCT00940082||elderly control group|healthy people which ages from 60 to 90
33272169|NCT00936260|Experimental|alendronate 6 years|
33272170|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
33272171|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
33272172|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
33272173|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
32773948|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
33081167|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
33081168|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
33272174|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
33272175|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
33272176|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
33272177|NCT00445978|Experimental|Sapropterin dihydrochloride|2.5, 5, 10, 20 mg/kg/day of sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
33272178|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
33272179|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
33272180|NCT00936338|Active Comparator|splint|
33272181|NCT00936338|Active Comparator|joint mobilization self exercise|
33272182|NCT05281991||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
33272183|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
32773949|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
32773950|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
32773951|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
33272184|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
33272185|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
33272186|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
33272187|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
33272188|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
33272189|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
32773952|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
33272190|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
33272191|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
33272192|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
33272193|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
33272194|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
33272195|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
32773953|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
33081169|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
33272196|NCT01028950|Experimental|YM150 group|
33272197|NCT05265923|Experimental|CM310|CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)
33272198|NCT05265923|Placebo Comparator|Placebo|"Double blind treatment period : Placebo~Maintenance treatment period : CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)"
33272199|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
33272200|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
33272201|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
33272202|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
33272203|NCT01023490|Placebo Comparator|Placebo|
33272204|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
33272205|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
33272206|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
33272207|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
33272208|NCT01027156|Experimental|High Intensity Exercise|
33272209|NCT05264831|Active Comparator|PVI procedure alone|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 1: PVI procedure alone in accordance with ESC recommendations"
33272210|NCT05264831|Experimental|PVI procedure combined with substrate modulation|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 2: PVI procedure associated with substrate modulation"
33272211|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
33272212|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
33272213|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
33272214|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
32773954|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
32773955|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
32773956|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
33272215|NCT04648631|Experimental|ABWG|The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.
33272216|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
33272217|NCT04012658||Asymptomatic Wilson's Disease carriers|
33272218|NCT04012658||Relatives of Wilson's Disease patients or carriers|
33272219|NCT04012658||Unrelated healthy controls|
33272220|NCT00944606|Active Comparator|Vitamin D|
33272221|NCT00944606|Placebo Comparator|Placebo|
33272222|NCT05257655|Other|Intervention|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius;
33272223|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
33272224|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
33272225|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
33272226|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
33272227|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
33401805|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
33272228|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
33272229|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
33272230|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
33272231|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
33272232|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
33272233|NCT04061057|Experimental|IV lidocaine|Perioperative IV lidocaine infusion
33272234|NCT04061057|Placebo Comparator|Normal saline|Perioperative IV normal saline infusion
33272235|NCT04635059|Experimental|Pacritinib|Pacritinib is an oral drug.
33272236|NCT00921167|Experimental|Bevacizumab/Irinotecan|
33272237|NCT04061447|Experimental|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
33272238|NCT04061447|Active Comparator|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
33272239|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
33272240|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
33272241|NCT05472779|Active Comparator|Intravaginal Estrogen Application|Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months
33272242|NCT05472779|Experimental|Periurethral Estrogen Application|Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months
33272243|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
33272244|NCT02567591|No Intervention|B: conventional management|conventional management
33272245|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
33272246|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
33272247|NCT05462951|Other|Radiochemotherapy followed by brachytherapy|Standard daily radiotherapy plus weekly cisplatin followed by brachytherapy
33272248|NCT00562718|Experimental|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
33272249|NCT05222165|Experimental|Infigratinib (BGJ398)|"Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules.~Phase 1b Three dose levels escalation until RP2D is determined.~Phase 2~Pediatric patients: dose defined in the phase 1b (RP2D);~Adults: 125 mg.~Frequency: once daily for 21 days in each 28-day treatment cycle.~Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur."
33272250|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
33272251|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
33272252|NCT04555811|Experimental|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
33272253|NCT04555811|Experimental|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
33272254|NCT04555811|Experimental|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
33272255|NCT04546217|Experimental|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
33272256|NCT04546217|Active Comparator|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
33272257|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
32773957|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
32773958|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
32773959|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
32773960|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
32773961|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
32773962|NCT04947241|Experimental|Neoadjuvant therapy|Patients included are going to receive neoadjuvant therapy, surgery and adjuvamt therapy post surgery. Before surgery, patients will receive therapy as follows: PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
32773963|NCT04946539||Spondyloarthritis|
32773964|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
32773965|NCT04944511|Experimental|PD-1 antibody for mixed chimerism|PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT
32773966|NCT04944043|Experimental|TQ05105 Tablet|TQ05105 tablet 10mg given orally, twice daily in 28-cycle.
32773967|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
32773968|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
32773969|NCT04410991|Experimental|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
32773970|NCT04410991|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
32773971|NCT04933279|Experimental|Potassium iodide group|administrated the subjects with 150 ml - 200 ml iodine-containing spareribs soup delivering ≈ 600 µg or 1200 µg iodine
32773972|NCT04933279|Experimental|Natural kelp group|administrated the subjects with a bowl of 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine in natural kelp).
32773973|NCT04932655|Other|Fasted|Phase 3 simufilam 100 mg tablet dosed under fasted conditions.
32773974|NCT04932655|Other|High Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a high-fat meal.
32773975|NCT04932655|Other|Low Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a low-fat meal.
32773976|NCT04932655|Other|Phase 2 tablet|Phase 2 simufilam 100 mg tablet dosed under fasted conditions.
32773977|NCT04943809||POD 26P AY FT|26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT
32773978|NCT04943809||POD 26P AY F|26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F
32773979|NCT04946461||group 1; lisdex - dex|subjects are assigned to group 1 based on the type of medication prescribed by the practitioner. Subjects which started with lisdexamphetamine are assigned to group 1.
32773980|NCT04946461||group 2; dex - lisdex|subjects are assigned to group 2 based on the type of medication prescribed by the practitioner. Subjects which started with dexamphetamine are assigned to group 1.
32773981|NCT04946695|Experimental|Telefisio India|Feasibility and efficacy of the use of Telephysiotherapy for improving functional independence and quality of life in children and young people with lower limb fracture in a low resource setting in Anantapur (India).
33272258|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
33272259|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
33272260|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
33272261|NCT05324891|Active Comparator|Fentanyl|Neonates received fentanyl infusion during postoperative phase.
33272262|NCT05324891|Active Comparator|Dexmedetomidine|Neonates received dexmedetomidine infusion during postoperative phase.
33272263|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score <3 between M0 and M6) contributing to the test-retest
33272264|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
33272265|NCT04494113|Experimental|Treatment (triapine, surgical resection)|Patients receive triapine IV over 2 hours on day 1 in the absence of unacceptable toxicity. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.
33272266|NCT04482803|Experimental|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
33272267|NCT05451329|Active Comparator|VVN539 Ophthalmic Solution 0.02%|VVN539 Ophthalmic Solution 0.02%
33272268|NCT05451329|Active Comparator|VVN539 Ophthalmic Solution 0.04%|VVN539 Ophthalmic Solution 0.04%
33272269|NCT05451329|Placebo Comparator|VVN539 Ophthalmic Solution Vehicle|VVN539 Ophthalmic Solution Vehicle
33272270|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
33272271|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
33272272|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
33272273|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
33272274|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
33272275|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
33272276|NCT00696137|Experimental|BEMA Fentanyl|BEMA Fentanyl
33401806|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
33401807|NCT04505839|Experimental|STP1002|
33401808|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
33401809|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
33401810|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
33401811|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
33401812|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
33401813|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
33401814|NCT04745143|Experimental|NMDAE|An NMDA enhancer
32773982|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
33272277|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
33272278|NCT04036721|Experimental|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
33272279|NCT04036721|Active Comparator|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
33272280|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
33401815|NCT04745143|Placebo Comparator|Placebo|Placebo
33401816|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
33401817|NCT03657524|Experimental|Resuscitation patients|
33401818|NCT03657524|Active Comparator|healthy volunteers|
33401819|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
33272281|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
33272282|NCT05208281|Experimental|Adult: GNR-055|GNR-055: 1.0-2.0-3.0 mg/kg
33272283|NCT05208281|Experimental|Paediatric: GNR-055 2.0 mg/kg|GNR-055 2.0 mg/kg
33272284|NCT05208281|Experimental|Paediatric: GNR-055 3.0 mg/kg|GNR-055 3.0 mg/kg
33272285|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
33272286|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
33272287|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
32773983|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
32773984|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
32773985|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
33272288|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
33272289|NCT04025021|No Intervention|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
33272290|NCT04025021|Experimental|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
33272291|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
33272292|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
33272293|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
33272294|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
33272295|NCT04060979|Experimental|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
33272296|NCT04060979|Experimental|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
33272297|NCT04060979|Other|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
33272298|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
33272299|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
33272300|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.~Dose level : Target Number LeY CART cells infused *~-1 (if needed): 1 x 10e8~2 x 10e8~5 x 10e8~1 x 10e9~5 x 10e9~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
33272301|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
33272302|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
33272303|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
33272304|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
32773986|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
33272305|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
33272306|NCT03847480|Experimental|Dose painting|Dose painting
33272307|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
33272308|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
33272309|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
33272310|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
33272311|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
33272312|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
33272313|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
33081170|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
33272314|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
33272315|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
33272316|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
33272317|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
33272318|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
33272319|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
33272320|NCT01027234|Experimental|1|
33272321|NCT01027234|Placebo Comparator|2|
33272322|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
33272323|NCT01027312||Control Group|Aged matched people with no eye diseases.
33272324|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
33272325|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
33272326|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
33272327|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
33272328|NCT01027390|No Intervention|reference|no training
33272329|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
33272330|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
33272331|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
33272332|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
33272333|NCT04839562|Experimental|solriamfetol|Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
33272334|NCT04839562|Placebo Comparator|placebo|Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
32773987|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
32773988|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
33272335|NCT04888624|Experimental|DrySee® dressing with moisture detection|DrySee® dressing with moisture detection
33272336|NCT04888624|Active Comparator|Tegaderm® + Pad transparent film dressing|Tegaderm® + Pad transparent film dressing
33272337|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
32773989|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
33272338|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
33272339|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
33272340|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
33272341|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
33272342|NCT03316222|Experimental|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
32773990|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
33272343|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
33272344|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
33272345|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
33272346|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
33272347|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
33272348|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
33272349|NCT03962738|Experimental|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
33272350|NCT03962738|Experimental|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
33272351|NCT03962738|Experimental|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
33272352|NCT03962738|Placebo Comparator|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
33272353|NCT05280002|Experimental|Adipose Tissue derived Total-Stromal-Cells (TOST)|Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.
33272354|NCT05280002|No Intervention|Control|Standard Conventional Treatment
33272355|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
33272356|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
33272357|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
33272358|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
33272359|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
33272360|NCT00562484|Experimental|1|
33272361|NCT00562484|Other|2|
33272362|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
33272363|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
33272364|NCT04012892|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
33272365|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
33272366|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
33272367|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
33272368|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
33272369|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
33272370|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
32773991|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
33272371|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
33272372|NCT04012580|Experimental|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
33272373|NCT04012580|No Intervention|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
33272374|NCT03937661|Experimental|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
33272375|NCT03937661|Placebo Comparator|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
33272376|NCT04012502|Active Comparator|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
33272377|NCT04012502|Experimental|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
33272378|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
33272379|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
33272380|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
33272381|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
33272382|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
33272383|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
33272384|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
33272385|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
33272386|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
33272387|NCT01307306|Experimental|Metformin|
33272388|NCT01307306|Experimental|Insulin|
33272389|NCT01307306|No Intervention|Control|
33272390|NCT04012424|Experimental|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
32773992|NCT04946773||Malignancy Cohort|Patients with hepatic or hepatobiliary malignancy at enrolment
32773993|NCT04946773||Control Cohort|Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
33272391|NCT04012424|Placebo Comparator|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
33272392|NCT00562094||Pantoprazole|
33272393|NCT03817853|Experimental|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone [CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone [CVP - 21-day cycle]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
33272394|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
33272395|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
32773994|NCT04932889||Change|the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)
32773995|NCT04932889||No change|the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)
32773996|NCT04946617||H group|healthy periodontium, BOP at \20 % of the sites and no sites with probing depth (PD) [3 mm and clinical attachment level (CAL) [2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38
33272396|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
33272397|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
33272398|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
33272399|NCT02914067|Experimental|Cohort 1|"Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.~Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
33272400|NCT02914067|Experimental|Cohort 2|"Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.~Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
33272401|NCT02914067|Experimental|Cohort 3|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient."
33272402|NCT02914067|Experimental|Cohort 4 Arm A|"Undergo the following MRI images: RSFC MRI, T2/T1 MRI, and DTI.~Will complete cognitive testing using the NIH Toolbox Cognitive Battery~All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age."
33272403|NCT02914067|Experimental|Cohort 4 Arm B|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~Will complete cognitive testing using the NIH Toolbox Cognitive Battery~All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age."
32773997|NCT04946617||G group|gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL [3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);
33272404|NCT02565095|Other|Carotid Baroreflex measurements|
33272405|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.~Colonoscopy will be performed in case of a positive FIT."
33272406|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
33272407|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
33272408|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
33272409|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
33272410|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
33272411|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
33272412|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
33272413|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
33272414|NCT00944918|Experimental|1|fulvestrant and anastrozole
33272415|NCT00944918|Experimental|2|fulvestrant and placebo
33272416|NCT00944918|Active Comparator|3|exemestane alone
33272417|NCT04012268|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.
33272418|NCT04012268|Other|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists.
33272419|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
33272420|NCT00553280|Experimental|pregabalin|
33272421|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
33272422|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
33272423|NCT00944996|Active Comparator|antidepressant|
33272424|NCT00944996|No Intervention|Healthy volunteers|
33272425|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
33272426|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
33272427|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
33272428|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
33272429|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
33272430|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
33272431|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
33272432|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
33272433|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
33272434|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
33272435|NCT00945074|Experimental|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
33272436|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
33272437|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
33272438|NCT03994744|Experimental|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
33272439|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
33272440|NCT01031290|Experimental|Group A|Active TMS
33272441|NCT01031290|Sham Comparator|Group B|Sham TMS
33272442|NCT05301530|Experimental|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
32773998|NCT04946617||CP group|chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at [≥80 % of the proximal sites and radiographic evidence of interproximal bone loss
32773999|NCT04946383|Experimental|Quercetin and Dasatinib supplements|500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.
33272443|NCT05301530|Active Comparator|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
33272444|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
33272445|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
33272446|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
33272447|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
33272448|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
33272449|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
33272450|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
33272451|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
33272452|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
32774000|NCT04943653|Experimental|Intraperitoneal paclitaxel + XELOX|"Intraperitoneal paclitaxel Day1, Day8 + *XELOX~*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks"
32774001|NCT04942951||Pregnant women with the diagnosis of urinary incontinence (Study group)|The pregnant women who were diagnosed with the urinary incontinence (n=80) with category 0 or category 1 Pelvic Organ Prolapse Quantification (POP-Q) score in physical examination.
32774002|NCT04942951||Healthy pregnant women (Control group)|Control group consisted of healthy women with uncomplicated pregnancies (n=80). They had no complaint of urinary incontinence and their gynecological examination did not reveal any finding of pelvic organ prolapse.
32774003|NCT04943029|Experimental|PD-1+Chemo+surgery+PD-1|Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.
33272453|NCT00440518|Placebo Comparator|Placebo|Placebo
33272454|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
33272455|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
33272456|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
33272457|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
33272458|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
33272459|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
33272460|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
33272461|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
33272462|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
33272463|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
33272464|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
33272465|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
33272466|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
33272467|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
33272468|NCT00950768|Active Comparator|Mel100|
33272469|NCT00950768|Experimental|Mel200|
33272470|NCT03172936|Experimental|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
33272471|NCT03172936|Experimental|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
32774010|NCT05236283||Bern ICU|
32774011|NCT05236283||Lausanne ICU|
33272472|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
32774012|NCT04932499|Active Comparator|Control group|Standard of care
33272473|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
33272474|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
33272475|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
33272476|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
33272477|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
33272478|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
33272479|NCT00941408||Diagnostic tumor core biopsy|
33272480|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
33272481|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
33272482|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
32774013|NCT04932499|Experimental|Mindfulness Meditation|Mindfulness meditation in addition to standard of care
32774014|NCT05535101|Experimental|theta burst stimulation|Those participants to receive 1-3 sessions in a single day at an interval of 15 minutes(at least), and 5 high-frequency iTBS sessions per week in total four weeks. Each session: 600-900 pulses with 120-100% resting motor threshold.
32774015|NCT05535101|Sham Comparator|Sham arm|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
32774016|NCT04932421|Experimental|Experimental group (UP-C intervention)|UP-C intervention 15 weekly sessions, for children and parents
32774017|NCT04932421|Active Comparator|Control group (ABC of emotions intervention)|ABC of emotions - a psychoeducational intervention 5 sessions every 3 weeks for children
32774018|NCT05535023|Experimental|SAR444245 plus Cemiplimab|Participants will receive SAR444245 and Cemiplimab by vein on Day 1 of Cycles 1 and 2. Each drug's infusion should take about 30 minutes.
32774019|NCT04943107||healthy control|adults without glaucoma history or hypertension history
33081171|NCT05428189|Experimental|Guided Biofilm Therapy (GBT)|The subjects receive professional oral hygiene guided by plaque a disclosing agent, using air-polishing and a ultrasonic device
33272483|NCT01030120|Placebo Comparator|placebo|matching placebo
33272484|NCT04012112|Experimental|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
33272485|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
33272486|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
33272487|NCT00941564|Active Comparator|Commercially available infant formula B|
33272488|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
33272489|NCT00951236|Active Comparator|One injection|
33272490|NCT00951236|Active Comparator|Two Injections|
33272491|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
33272492|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
33272493|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
33272494|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
33272495|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
33272496|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
33272497|NCT00951392|Experimental|Problematic aging|
33272498|NCT00951392|Experimental|successful aging|
33272499|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
33401820|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 1|Subjects will receive 3 single ascending oral doses (SAD) of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 1 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
33272500|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
32774020|NCT04943107||glaucoma patients|adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
33272501|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
33272502|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
33272503|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
33272504|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
33272505|NCT01030276|Experimental|Bright light|
33272506|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
33272507|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
33272508|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
33272509|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
33272510|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
32774021|NCT04943107||hypertension patients|adults with primary hypertension history; without glaucoma history
33272511|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
33272512|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
33272513|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
33272514|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
33272515|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
33272516|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
32774022|NCT04943107||glaucoma+hypertension|adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
32774023|NCT03660059|Experimental|ASP015K 100 mg|Participants will receive 100 milligrams (mg) of ASP015K once daily after breakfast for 52 weeks.
32774024|NCT03660059|Experimental|ASP015K 150 mg|Participants will receive 150 mg of ASP015K once daily after breakfast for 52 weeks.
32774025|NCT03660059|Placebo Comparator|Placebo/ASP015K|Participants will receive placebo for 24 weeks, then either 100 mg or 150 mg of ASP015K for 28 weeks as determined randomly at Week 0 in advance.
32774026|NCT04943263|Experimental|Tracheal Temperature|Intubation done with a temperature sensor located on the cuff surface of the endotracheal tube
33272517|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
33272518|NCT00951548|Placebo Comparator|placebo|Corn Starch
33272519|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
33272520|NCT03994666|Experimental|simple dose|
33272521|NCT03994666|Experimental|double dose|
33272522|NCT03994666|Placebo Comparator|placebo|
33272523|NCT00951704||Cardiac arrest|
33272524|NCT03994588|Active Comparator|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
33272525|NCT03994588|Active Comparator|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
33272526|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
33272527|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
33272528|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
32774027|NCT05519969||6-4-2 group|- Cases from centres implementing the rule of a minimum of 6 hours of fasting for solids, 4 hours for breast milk and 2 hours for clear fluids before anesthesia.
32774028|NCT05519969||6-4-1 group|- Cases from centres implementing the 1 hour fasting rule for clear fluids recommended by ESAIC and specified in the guideline Preoperative fasting in children
33272529|NCT00951782|Sham Comparator|Sham TMS - no cue|
33272530|NCT00951782|Active Comparator|High frequency TMS - no cue|
33272531|NCT00951782|Active Comparator|Low frequency - no cue|
33272532|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
33272533|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
33272534|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272535|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272536|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272537|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272538|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272539|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
33272540|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
32774029|NCT05519969||6-4-0 group|"- Cases from centres implementing the zero hour clear fasting rule, which means that children are allowed intake of clear fluids until they are called to the operating room"
32774030|NCT04943185|Other|Ab interno technique|Ab Interno is traditional method of stent XEN implantation, where the device will injected through a small corneal incision that closes with the preloaded XEN injector.
32774031|NCT04943185|Other|Ab externo technique|The ab externo approach does this without any incision, less invasive, and the implant is directly injected through the conjunctiva into the anterior chamber of the eye. Both methods create a new way out through the subconjunctival space, which is the traditional target of trabeculectomy.
32774032|NCT03657251||CureCloud Direct to Patient|
32774033|NCT04942873||dabigatran group|NVAF patients who taking dabigatran capsule 110mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
32774034|NCT04942873||Rivaroxaban group|NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
33272541|NCT01565824|No Intervention|Usual care|
33272542|NCT04222634|Other|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:~radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)~metastasectomy~salvage lymphadenectomy~salvage prostatectomy in case of local recurrence or untreated primary tumor"
32774035|NCT04942873||wafarin group|NVAF patients who taking wafarin tablet during 2016.2-2021.1，the duration of continuous medication was more than 3 months， the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
33272543|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
33272544|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
33272545|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
33272546|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
33272547|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
33272548|NCT04813822|Active Comparator|Gyno-Daktarin® Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
33272549|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
32774036|NCT04946227|Experimental|Single Arm|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor.
32774037|NCT04945525|Experimental|Care Continuity Program + Education|Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
33272550|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
33272551|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
33272552|NCT00945776|Active Comparator|Usual care|
33272553|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
33272554|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
33272555|NCT00941954|Experimental|Lifestyle counseling|A group-based structured educational programme.
33272556|NCT00941954|Active Comparator|Control|Written Information (booklet).
33272557|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
32774038|NCT04945525|No Intervention|Education Alone|Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.
32774039|NCT04932187|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
32774040|NCT04931719|Active Comparator|the PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
32774041|NCT04931719|Experimental|the PRP+HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
32774042|NCT04945681|Experimental|Mass vaccination|Mass vaccination of children aged 6 weeks to 14 years old with pneumococcal conjugate vaccine. Children 6 weeks to 11 months old receive two doses, spaced 4 weeks apart. All other children receive a single dose. Vaccination is simultaneous, as per a campaign delivery strategy.
32774043|NCT04945291|Experimental|research built JA Method mobile application + Counting method using the hands|The participant will watch a video that explains a new counting method using the hands and use the research built mobile application to log and track the calories
32774044|NCT04945291|Active Comparator|FitnessPal mobile application (or Arabic alternative) + Counting method using the hands|the participants will watch a video that explains a new counting method using the hands and they will be asked to use a commercial mobile app to log and track the calories
32774045|NCT04945291|Active Comparator|Fitness Pal Mobile Application (or Arabi alternative)|The participants will watch a generic video about the mobile app and they will be asked to use a commercial mobile app to log and track the calories
32774046|NCT04942795||Mechanical thrombectomy|Patients who underwent mechanical thrombectomy for large vessel occlusion of the anterior circulation
32774047|NCT04931173|Active Comparator|Group A: IV and Oral antibiotics (IVA+OA)|Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery. Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure. Following surgery, no further IVA will be given for SSI prophylaxis. In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery. Following this, they will not receive any further OAs for SSI prophylaxis.
33272558|NCT00945932|Experimental|28 day repeat dose|
33272559|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
33272560|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
33272561|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
33272562|NCT05300828||Genexol PM|Genexol PM/carboplatin combination treatment is performed as an adjuvant treatment after cytoreductive surgery for newly diagnosed ovarian cancer.
33272563|NCT05300750|Experimental|Oral Fluid|The oral fluid intake was in form of peppermint or anise
33272564|NCT05300750|Experimental|Chewing Gum|Free sugar gum
33272565|NCT05300750|No Intervention|Standard hospital care|Control group
33272566|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
33272567|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
33272568|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
33272569|NCT00942110|Experimental|CPAP|
33272570|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
33272571|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
33272572|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
33272573|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
33272574|NCT00952406||Survey of Women PFDs|Women with PFDs
33272575|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
33272576|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
33272577|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
33272578|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
33272579|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
33272580|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
33272581|NCT00952562|Placebo Comparator|placebo|
33272582|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
33272583|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
33272584|NCT00942500|Experimental|Post-conditioning|
33272585|NCT00942500|No Intervention|Conventional primary PCI|
33272586|NCT00946244||Term infants|Healthy term infants
33272587|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
33272588|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
33272589|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
33272590|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
33272591|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
33272592|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
33272593|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
33272594|NCT00953030|No Intervention|light health education control|
33272595|NCT00953108|Experimental|quetiapine|
33272596|NCT00953108|Active Comparator|escitalopram|
33272597|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
33272598|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
33272599|NCT00953264|Experimental|life style intervention|
33272600|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
33272601|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
33272602|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
33272603|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
33272604|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
33272605|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
33272606|NCT00943046|Experimental|Siello pacemaker lead|Patients with Siello Pacemaker lead
33272607|NCT04012034|Experimental|Radiofrequency A|Treatment with radiofrequency
33272608|NCT04012034|Placebo Comparator|Placebo|Treatment with radiofrequency without energy
33272609|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
33272610|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
33272611|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
33272612|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
33272613|NCT05301296|No Intervention|Control Arm|Standard of Care.
32774048|NCT04931173|Active Comparator|Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)|Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
33081172|NCT05428189|Active Comparator|Air Polishing and Ultrasonic Debridment|The subject receive professional oral hygiene using air-polishing and a ultrasonic device
33272614|NCT05301296|Active Comparator|Intervention Arm|Clinical examination of the breast for early detection of Cancer.
33272615|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
33272616|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
33272617|NCT00120289|Experimental|Combination Therapy|Extended release niacin plus simvastatin
33272618|NCT00120289|Active Comparator|Monotherapy|Simvastatin alone
33272619|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
33272620|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
33272621|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
33272622|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
33272623|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
33272624|NCT00953732||1|
33272625|NCT04011488|No Intervention|Standard patient information data sheet|
33272626|NCT04011488|Experimental|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
33272627|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
33272628|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
33272629|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
33272630|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
33272631|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
33272632|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
33272633|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
33272634|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
33272635|NCT00953888|Experimental|Active|AZD5069 oral solution
33272636|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
33272637|NCT00953966|Other|Starch 1|Starch 1
33272638|NCT00953966|Other|Starch 2|Starch 2
33272639|NCT00953966|Other|Starch 3|Starch 3
33272640|NCT00953966|Other|Starch 4|Starch 4
33272641|NCT00953966|Other|Starch 5|Starch 5
33272642|NCT00953966|Other|Starch 6|Starch 6
33272643|NCT00953966|Other|Starch 7|Starch 7
33272644|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
33272645|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
33272646|NCT00954200|Placebo Comparator|Placebo|
33272647|NCT00954200|Active Comparator|ibuprofen|
33272648|NCT00954278|Experimental|sorafenib|
33272649|NCT00550446|Active Comparator|1|
33272650|NCT00550446|Experimental|2|
33272651|NCT00550446|Experimental|3|
33272652|NCT00550446|Experimental|4|
33272653|NCT00550446|Experimental|5|
33272654|NCT00550446|Experimental|6|
33272655|NCT00550446|Placebo Comparator|7|
33272656|NCT05279820|Active Comparator|Partial Pulpotomy|After pulp exposure 2-3 mm of the pulp tissue will be amputated, a calcium silicate based material will be placed over the pulp and the tooth will be restored.
33272657|NCT05279820|Active Comparator|Full Pulpotomy|After pulp exposure the entire coronal pulp to the level of canal orifices will be amputated , calcium silicate based material will be placed over the pulp and the tooth will be restored.
33272658|NCT00953550|Experimental|Rocuronium-Sugammadex|
32774049|NCT04942561|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for PIVC placement (i.e., a topical numbing spray and Buzzy® Bee, a vibrating device placed near the PIVC site for pain distraction).
33272659|NCT00953550|Active Comparator|Succinylcholine|
33272660|NCT00948870|Experimental|Shugan Decoction|
33272661|NCT00948870|Placebo Comparator|low does of Shugan decoction|
33272662|NCT05350956|Experimental|Herombopag monotherapy|
33272663|NCT05350956|Experimental|Herombopag is treated in combination with rhTPO(Recombinant human thrombopoietin)|
33272664|NCT05350878|Experimental|Implementation Intervention|Through virtual and in-person meetings, the internal/external facilitation team will support sites in utilizing the multi-component implementation strategy for 7 months
33272665|NCT05350878|No Intervention|Implementation as Usual|In control 'implementation as usual' sites, no facilitation or implementation strategies will be provided. Controls will receive 1) an informational session on the text intervention during grand rounds/staff meetings and 2) flyers to provide patients with intervention enrollment information.
33272666|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
33272667|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
33272668|NCT00949026|Experimental|A|
33272669|NCT00953784|No Intervention|1|Standard management
33272670|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
33272671|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
33272672|NCT00949104|Placebo Comparator|Placebo|Double distilled water
33272673|NCT00953940|Experimental|Isotonic saline|Isotonic saline
33272674|NCT00953940|No Intervention|No treatment|Habitual therapy
33272675|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
33272676|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
33272677|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
33272678|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
33272679|NCT03995836||Obstructive Sleep Apnea|
33272680|NCT03995836||Non Obstructive Sleep Apnea|
33272681|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
33272682|NCT01024660|Placebo Comparator|2|
33272683|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
33272684|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
33272685|NCT01751126|Experimental|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
33272686|NCT01751126|Experimental|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
33272687|NCT01751126|Placebo Comparator|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
33272688|NCT01570010|Experimental|Intervention group|The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. Both groups are offered equal general advice of physical activity.
33272689|NCT01570010|Other|Control group|The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups are offered equal general advice of physical activity.
33272690|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
33272691|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
33272692|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
33272693|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
33272694|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
33272695|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
33272696|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
33272697|NCT00954434|No Intervention|total abstention from alcohol|
33272698|NCT04011878|Experimental|isolated trabeculodysgensis|etiology of primary congenital glaucoma
33272699|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
33272700|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
33272701|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
33272702|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
33272703|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
33272704|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
33272705|NCT00954252|Experimental|Test Article|
33272706|NCT00954252|Placebo Comparator|Placebo|
33272707|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
33272708|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
33272709|NCT00110617|Experimental|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
33272710|NCT00110617|Experimental|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
33272711|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
33272712|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
33272713|NCT00949494|Active Comparator|Synvisc|
33272714|NCT00949494|Placebo Comparator|Placebo|
33272715|NCT04011462|Experimental|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
33272716|NCT04011462|Experimental|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
33272717|NCT04011462|No Intervention|Standard care|warming with cotton sheet and blanket for 20 minutes.
33272718|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
33272719|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
32774050|NCT04942561|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction. Patients began gameplay <5 minutes before their PIVC placement and concluded after successful vascular access.
32774051|NCT04942171|Experimental|Atrial fibrillation catheter ablation group|catheter ablation
32774052|NCT04942171|Active Comparator|Medical therapy group|standard treatment include anti-arrhythmic drug
32774053|NCT04945135||liver donors|
33272720|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
33272721|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
33272722|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
33272723|NCT03956862|Experimental|GB001|GB001 40 mg once per day (QD) for 16 weeks
33272724|NCT03956862|Placebo Comparator|Placebo|Placebo QD for 16 weeks
32774054|NCT04944979|Experimental|Experimental: Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
32774055|NCT04944823||Patients with COVID 19 infection who develop bacterial coinfection.|Follow-up for 24 months
33272725|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
33081173|NCT05428111|Active Comparator|control|healthy control individuals
33272726|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
33272727|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
33272728|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
33272729|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
33272730|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
33272731|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
33272732|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
33272733|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
33081174|NCT05428111|Active Comparator|case|Newly diagnosed and under treatment cases of acute lymphoblastic leukemic
33081175|NCT05428072|Experimental|sugar test|Participants will undergo 3 sugar tests followed by
33272734|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
33272735|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
33272736|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
33272737|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
33272738|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
33272739|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
33272740|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
33272741|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
33272742|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
33272743|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
33272744|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
33272745|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
33272746|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
33272747|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
33272748|NCT04012346|Active Comparator|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
33272749|NCT04012346|Sham Comparator|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
33272750|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
33272751|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
33272752|NCT00949728|Other|Fibrin glue|
33272753|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
33272754|NCT05229666|Other|Cognitive Challenge|
33272755|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
33272756|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
33272757|NCT00954902|Experimental|Spice, no stress|
33272758|NCT00954902|Experimental|Spice and Stress|
33272759|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
33272760|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
33272761|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
33272762|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
33272763|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
33272764|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
33272765|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
33272766|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
33272767|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
33272768|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
33272769|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
33272770|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
33272771|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
33272772|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
32774056|NCT04944823||Patients with COVID 19 infection who do not develop bacterial coinfection.|Follow-up for 24 months
33272773|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
33272774|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
33272775|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
33272776|NCT05190510||Patient with atheromatous stenosis of the internal carotid artery|
33272777|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
33272778|NCT00954642|Experimental|A|
33272779|NCT00954642|Experimental|B|
33272780|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
33272781|NCT00955058|Experimental|oral contraceptive pill|Treatment
33272782|NCT01024816|Experimental|Restorative yoga intervention|
33272783|NCT01024816|Active Comparator|Stretching group|
33272784|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
33272785|NCT04359186|Experimental|Treatment Interruption Arm|
33272786|NCT01024894|Experimental|CYT107|
33272787|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
33272788|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
33272789|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
33272790|NCT00110305|Experimental|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
33272791|NCT00110305|Experimental|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
33272792|NCT00110305|Experimental|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
33272793|NCT00110305|Active Comparator|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
33272794|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
33272795|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
33272796|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
33272797|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
33272798|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
33272799|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
33272800|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
33272801|NCT01083355||Mechanical ventilation|Critical care patients
33272802|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
33272803|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
33272804|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
33272805|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
33272806|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
33272807|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
33272808|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
33272809|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
33272810|NCT05100654|No Intervention|No post-operative oral antibiotics|Patients will only receive 24hr of IV peri-operative antibiotics
33272811|NCT05100654|Active Comparator|6 days of oral antibiotics|Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics
33272812|NCT05098548||patients with Chronic limb threatening ischemia|"All patients with Chronic limb threatening ischemia present with one or more of the following:~Rest pain (Rutherford category 4)~Minor tissue loss (Rutherford category 5) admitted to the department of Vascular surgery for Endovascular Intervention with provided written informed consent."
33272813|NCT00096031|Experimental|Cetuximab|250 mg/m^2 on days 1, 8, 15, and 22 of every 28-day cycle.
33272814|NCT04010526|Experimental|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
33272815|NCT04010526|Placebo Comparator|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
33272816|NCT05043324|Experimental|AIDS, HIV, HBV, HCV, co-infections.|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
33272817|NCT05043324|Experimental|"stable cancer, acquired or congenital immunodeficiency."|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
32774057|NCT04930939|Experimental|Heart rate variability-guided training group|Patients allocated to heart rate variability-guided training group trained 3 days a week for 6 weeks. These patients carried out moderate continuous traininig sessions or high intensity interval training sessions based on their daily heart rate variability assessments follwing a decision schema.
33272818|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
33272819|NCT04010604||SMA type I|
33272820|NCT04010604||SMA type II|
33272821|NCT04010604||SMA type III|
33272822|NCT04010604||Asymptomatic carriers of SMA|
32774058|NCT04930939|Active Comparator|Predefined training group|Patients allocated to predefined training group also trained 3 days a week for 6 weeks. Nonetheless, these patients performed a predefined training program regarless of their parasympathetic modulation status.
33272823|NCT04010604||Relatives of SMA patients and carriers|
33272824|NCT04010604||Unrelated healthy controls|
33272825|NCT04303728|Experimental|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
33272826|NCT00118417|Experimental|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
33272827|NCT00118417|Experimental|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
32774059|NCT03597347|Experimental|Group 1|Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.
32774060|NCT03597347|Experimental|Group 2|Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.
33272828|NCT04293744|Experimental|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
33272829|NCT04293744|Active Comparator|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
32774061|NCT03597347|Experimental|Group 3|Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).
33272830|NCT01080703|Experimental|Lower extremity strengthening|
33272831|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
33272832|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
33272833|NCT04271436|Experimental|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
33272834|NCT01079455|Active Comparator|HA|Coxarthrosis
33272835|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
33272836|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
33272837|NCT04270422|Experimental|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial, twice a week, 12 sessions
33272838|NCT04270422|Active Comparator|Usual physiotherapy|Usual evidence based physiotherapy, twice a week, 12 sessions
33272839|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
33272840|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
33272841|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
33272842|NCT05005962||Acute ischemic patients suffering with stroke|Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
33272843|NCT01080859||BAS|Patient's receiving BAS
33272844|NCT01080859||EES|Patients receiving EES
33272845|NCT04258332|Other|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
33272846|NCT04258332|Other|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
33272847|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
33272848|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
33272849|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
33272850|NCT05299788|No Intervention|The routine analgesia group|The routine analgesia and warming protocol was applied to patients in the control group.The routine postoperative analgesic treatment protocol at the unit comprises the administration of 75 mg IM (Intramuscular) Diclofenac Sodium before the patient wakes up, 30 mg intravenous (IV) Tramadol if the patient complains of pain when awake (maximum dose of 100 mg/day), and 10 mg/day Morphine Sulfate. In addition to, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for warming.
32774062|NCT04942015|Experimental|Honghuaruyi Wan|Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
33272851|NCT05299788|Experimental|The routine analgesia+active external warming+ice application group|In addition to the routine analgesia protocol, the study group was administered non-pharmacological pain control interventions.
33272852|NCT01083745||IVF patients - 1|Poor responders
33272853|NCT01083745||IVF patients - 2|Good responders
33272854|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
33272855|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
33272856|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
33272857|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
33272858|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
33272859|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
33272860|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
33272861|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
32774063|NCT04942015|Placebo Comparator|Placebo|Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
32774064|NCT04941859|Experimental|experimental group|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
33272862|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
33272863|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
33272864|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
33272865|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
33272866|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
33272867|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
32774065|NCT04941859|No Intervention|control group|The treatment plan of control group was carried out according to the diagnosis and treatment standard of acute poisoning.
32774066|NCT04942249||Symptomatic|167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
33272868|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
33272869|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
33272870|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
33272871|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
33272872|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
33272873|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
33272874|NCT04010994|Other|rtACS|repetitive transorbital ACS
33272875|NCT05299710||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation.Pre-surgery assessment will be done while your child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove your child's ovary is called laparoscopy. It is not required for the treatment of your child's cancer. Laparoscopic surgery is done under general anesthesia (your child will be asleep during the surgery) in the operating room.
33272876|NCT04857996|Experimental|UBX1325|
33272877|NCT04857996|Sham Comparator|Sham Control|
33272878|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
33272879|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
33401821|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 2|Subjects will receive 3 SAD of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 2 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
32774067|NCT04942249||Asymptomatic|167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
33272880|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
33272881|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
33272882|NCT04850196|Experimental|TEAS group|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
32774068|NCT04942249||No evidence of infection|167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)
33272883|NCT04850196|Sham Comparator|Control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS.
33272884|NCT04846374||PowerPort Subjects|This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
33272885|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
33272886|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
33272887|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
33272888|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
33272889|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
33272890|NCT02494570|Experimental|ABI-009|
33272891|NCT04839588||Usability study, healthy volunteers and those with cognitive impairments following chemotherapy|"2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be~Female Either healthy or breast cancer survivor;~Age 20 to 65 years;~Have st least 12 years of formal education;~Be English speakers;"
32774069|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Escalation|
32774070|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Expansion|
32774071|NCT04431427|Active Comparator|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
33272892|NCT03994198|Experimental|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
33272893|NCT03994198|Active Comparator|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
33277575|NCT05352074|Active Comparator|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
33401822|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 in Cohort 3|Subjects will receive GSK3186899 orally, under fasted condition and fed conditions on Day 1 of cohort 3 in each of the two treatment periods. There will be a wash out period of at least 10 days between each treatment period. A dose level will be determined based on the effect of food on the safety, tolerability and PK of a single dose of GSK3186899, with dose level selected from Cohorts 1 and 2.
33401823|NCT03874234|Experimental|Part B: Subjects receiving GSK3186899|Subjects will receive GSK3186899, orally, twice daily (BID) on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
32736858|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
32736859|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
32736860|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
32736861|NCT05560841|Experimental|Nailner 2 in 1|"Nailner Brush 2-in-1 (5ml)~Liquid solution in glass bottle with a brush applicator Topical application twice a day during 4 weeks then once a day until 6 months"
32736862|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
32736863|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
33081176|NCT05427916|Experimental|Negative Pressure Wound Therapy|Negative pressure to the incision site and managing exudate generated by the incision.
33081177|NCT05427916|Active Comparator|Optifoam|This foam is standard of care and is currently stocked by the operating rooms at Mount Sinai hospital and indicated for use in high risk wounds
33081178|NCT05427877|Experimental|Heating Device Application|Heating devices will be applied to the trunk and extremities of the body.
33081179|NCT00211562|Active Comparator|Olanzapine|
33081180|NCT00211562|Active Comparator|Omega 3|
33081181|NCT00211562|Active Comparator|Vitamin E +C|
33081182|NCT05427799|Experimental|Honey|"Treatment with honey will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption.~During the six months intervention, a daily dose of 0.5 g/kg body weight of honey will be consumed by each participant. Participants will be provided with Mixed flora honey that will be obtained from local producers. The daily dose of treatments will be divided into two doses to simulate a natural pattern of consumption.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
33081183|NCT05427799|Placebo Comparator|Other carbohydrate alternatives|"Treatment with simple sugar alternatives (other carbohydrates, such as jell-o) will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption, and during the study periods.~A daily dose of 0.5 g/kg body weight of jell-O will be consumed by each participant and will be divided into two doses to simulate a natural pattern of consumption. Jell-O was selected as a source of sucrose with negligible phenolic capacity, which will serve as a control.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
33081184|NCT05427721|Experimental|Group A|Thymol
33081185|NCT05427721|Placebo Comparator|Group B|Calcined magnesia
33081186|NCT05427682|Experimental|Group A (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
33081187|NCT05427682|Experimental|Group B (mild liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
33081188|NCT05427682|Experimental|Group C (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
33081189|NCT05427682|Experimental|Group D (moderate liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
33081190|NCT05427604|Other|Sequential intervention|"single ingestion of olive oil for assessement of monounsaturated fatty acids peak time in blood (3g)~single ingestion of olive oil for collection of blood sample at peak time (3g)~single ingestion of DHA-rich oil for assessement of polyunsaturated fatty acids peak time in blood (3g)~single ingestion of DHA-rich oil for collection of blood sample at peak time (3g)"
33081191|NCT05427409|Active Comparator|Beta-alanine supplementation|Beta-alanine (4.8 grams) pills (Crown Nutrition, Haro, Spain) in four doses each day during a 4-week supplementation period.
33081192|NCT05427409|Placebo Comparator|Placebo supplementation|Placebo (4.8 grams) pills (Crown Nutrition, Haro, Spain) contain fructose (300mg) and excipients (1200 mg) such as cellulose, calcium phosphate, silicon dioxide and magnesium stearate in four doses each day during a 4-week supplementation period.
33081193|NCT05427331|Experimental|FMT capsule treatment group|drugs use generic name: FMT capsule dosage form: capsule dosage, frequency: 16 capsules once a week duration: 4 weeks
33081194|NCT05427331|Placebo Comparator|Placebo treatment group|drugs use generic name: Placebo dosage form:capsule dosage,frequency:16 capsules once a week duration:4 weeks
33081195|NCT05427175|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
33081196|NCT05427175|Active Comparator|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
33081197|NCT05427175|No Intervention|healthy individuals as control group|
33272894|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
33272895|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
32736864|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
32736865|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
32736866|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
32736867|NCT05234515||Patients with intestinal failure or an enterocutaneous fistula undergoing elective surgery.|Adult patients with a diagnosis of intestinal failure (IF) or an enterocutaneous fistula (ECF) undergoing planned surgery in our unit.
33272896|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
33272897|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
32736868|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
32736869|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
32736870|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
32736871|NCT03236233|Experimental|Single dose - healthy subjects|
33272898|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
33272899|NCT04768686|Experimental|FLX475 and pembrolizumab combination therapy|"Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer~Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer"
33272900|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
32736872|NCT03236233|Experimental|Repeat dose - healthy subjects|
33272901|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
32736873|NCT03236233|Experimental|Single dose - subjects with asthma|
32736874|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
33272902|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
33272903|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
33272904|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
33272905|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
33272906|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
33272907|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
33272908|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
33272909|NCT00956124||uveitic patients|
33272910|NCT00956124||patients with diabetes|
33272911|NCT04717284|Experimental|Self-compassion intervention (SCI)|Self-compassion prompt.
33272912|NCT04717284|Other|Control condition|Neutral prompt during the initial administration and no intervention during the two-week follow-up.
33272913|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
33272914|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
33272915|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
33272916|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
33272917|NCT01563276||Healthy Control|
33272918|NCT04711512||Single Arm (All Participants)|Within this arm, participants are randomized to one of the interventions described below at each of 4 times per day.
33272919|NCT04010838|No Intervention|Conventional treatment|
33272920|NCT04010838|Experimental|Spinal cord stimulation and conventional treatment|
33272921|NCT04012164|Experimental|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
33272922|NCT04674618|Experimental|US-assisted nusinersen administration|A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
33272923|NCT04674618|No Intervention|landmark based nusinersen administration|The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
33272924|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
33272925|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
33272926|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
33272927|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
33272928|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
33272929|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
33272930|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
33272931|NCT00956358||Control|Healthy HSCT donors
33272932|NCT04009590|Experimental|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
33272933|NCT04009590|Active Comparator|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
33272934|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
33272935|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
33272936|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
33272937|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
33272938|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
33272939|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
33272940|NCT05112731||First Ischemic Cardiac Event|Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up
33272941|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
33272942|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
33272943|NCT02768363|Active Comparator|CAN-2409|Patients randomized to the active arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir
33272944|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
33272945|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
33272946|NCT00548262|Experimental|1|
33272947|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
33272948|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
33272949|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
33272950|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
33272951|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
33272952|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
32736875|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
32736876|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
33272953|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
33272954|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
33272955|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
33272956|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
33272957|NCT02730923|Active Comparator|Arm B: anastrozole alone|
33272958|NCT04619082|Experimental|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
33272959|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
33272960|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
32736877|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
33272961|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
33272962|NCT04060667|Experimental|Intervention|
33272963|NCT04060667|No Intervention|control|
33272964|NCT03717623|Experimental|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
33272965|NCT00742703|Experimental|1|
33272966|NCT00742703|Active Comparator|2|
33272967|NCT00095173|Active Comparator|Abatacept|Double Blind Period
33272968|NCT00095173|Placebo Comparator|Placebo|Double Blind Period
33272969|NCT00095173|Experimental|Abatacept - Open Label|
33272970|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
33272971|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
33272972|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
33272973|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
32743218|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
33081198|NCT05427058|Active Comparator|group 1: superior hypogastric plexus block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
33081199|NCT05427058|Experimental|group 2: ganglion impar block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
33272974|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
33272975|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
33272976|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
33272977|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
33272978|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
33272979|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
33272980|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
33272981|NCT03954834|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
33272982|NCT03954834|Experimental|10 mg Tirzepatide|Participants received 10mg of tirzepatide as subcutaneous injection once a week.
33272983|NCT03954834|Experimental|15 mg Tirzepatide|Participants received 15mg of tirzepatide as subcutaneous injection once a week.
33272984|NCT03954834|Placebo Comparator|Placebo|Participants received placebo as subcutaneous injection once a week.
32774072|NCT04431427|Active Comparator|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
32774073|NCT04930627|Experimental|oral administration of Empagliflozin|
32774074|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
32774075|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
32774076|NCT05508269||Control subjects|control cases who were diagonosed as healthy subjects after diagnostic catheterization
32774077|NCT05508269||Stable coronary artery disease|patients with stable coronary artery disease undergoing elective PCI who were diagnozed with coronary lesion/s and underwent stent implantation without previous history of myocardial infarction
32774078|NCT05508269||Myocardial infarction patients|patients with history of myocardial infarction or with acute myocardial infarction undergoing primary PCI
32774079|NCT05508269||Ischaemic cardiomyopathy patients|patients with ischaemic cardiomyopathy diagnosed by ejection fraction less than 35% with history of coronary artery disease or myocardial infarction or those with acute myocardial infarction with reduced ejection fraction.
32774080|NCT05531045||Cohort|FDG PET/CT assessed after 2 cycles of chemotherapy
32774081|NCT04633577|Experimental|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
32774082|NCT04633577|Placebo Comparator|Group Control|2020 eligible patients are received equal 0.9% normal saline.
32774083|NCT04941625||non-AKI|patients do not have post-HIPEC AKI
33081200|NCT04680091|Experimental|Efavirenz 600 mg + Pyrotinib 400 mg|
33081201|NCT04680091|Active Comparator|Pyrotinib 400 mg|
33081202|NCT04680364|Experimental|participants|to analyze the effects of 6-month ballroom dance (3 times/wk) on physical fitness and reaction time in twenty-four experienced older adults
33081203|NCT04680247|Active Comparator|VA-LCP|Osteosynthesis with a VA-LCP system
33081204|NCT04680247|Active Comparator|NCB-PT|Osteosynthesis with a NCB-PT system
33081205|NCT04680169|Active Comparator|Group A: Bronchoscopic intubation using AuraGain LMA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain
33081206|NCT04680169|Active Comparator|Group B: Bronchoscopic intubation with I-gel SGA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
33081207|NCT04680208||Planned ICU admission|Cases who were planned for postoperative ICU admission at the time of preanesthetic check up
33081208|NCT04680208||Unplanned ICU admission|Cases who got admitted to ICU postoperatively without anticipation
33081209|NCT05426824|Experimental|P-GOD|P-GOD (peasparaginase + gemcitabine + oxaliplatin + dexamethasone) ;
33081210|NCT05426824|Experimental|PEMD|PEMD (peaspargase + etocytidine + methotrexate + dexamethasone)
33081211|NCT05426629|Experimental|Treatment|"4 sessions of treatment at 1-week interval for first 4 weeks 3 sessions of treatment each 4 weeks apart, at week 8, week 12 and week 16~1 Follow-up visit: Follow up 4 weeks after the last treatment at week 20"
33081212|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
33081213|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
33081214|NCT05426590|Active Comparator|Diabetic patient|Patient with diabetes will undergo cataract surgery
33081215|NCT05426590|Active Comparator|Non diabetic patients|Healthy non diabetic patients will undergo cataract surgery
33081216|NCT05426551|Experimental|Bolus-spi|The volunteers will consume the test-meal as a bolus in one time at t = 0, with 13C-spirulina as the reference protein
33081217|NCT05426551|Experimental|Plateau-spi|The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-spirulina as the reference protein
33081218|NCT05426551|Experimental|Plateau-AA|"The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-free AA mixture as the reference protein"
33081219|NCT05426512||Primary Hyperparthyroidism|
33081220|NCT05426512||Postmenopausal women|
33081221|NCT05426317|Other|Metastatic solid tumor treated with first line therapeutic of Immune Checkpoint Inhibitor|"The determinations of soluble PDL1 and serum B2M will be taken by blood sample at diagnosis and then every 3 months for 1 year, during a consultation or treatment in an outpatient hospital.~The measurement of the tumor PDL1 level at diagnosis will be carried out by immunohistochemistry in the anatomopathology department of Clermont Ferrand University Hospital on the tumor sample that allowed the diagnosis, which does not add an additional sample for the patient.~Clinical and imaging examinations will be those conventionally carried out in the context of patient monitoring, the data will only be recorded in the patients' medical files."
33081222|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
33081223|NCT00211874|No Intervention|Usual Care|Usual care as control group
33081224|NCT05426278|Other|FAW and Bair Hugger Group|Group B, the intervention group (with FAW and Bair Hugger).
33081225|NCT05426278|No Intervention|Control group|Group A, the control group (No FAW or Bair Hugger)
33081226|NCT05426239||Cohort 1|Participants initiating first-line systemic therapy to treat advanced melanoma.
33081227|NCT05426044|Placebo Comparator|Patients will receive oral metformin|twice daily, oral metformin 750mg (i.e. 1500mg/day)
33272985|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
33272986|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
33272987|NCT00693017|Active Comparator|Zonisamide|
33272988|NCT00693017|Placebo Comparator|Placebo|
32774084|NCT04941625||AKI|patients have post-HIPEC AKI
33272989|NCT05299554|Experimental|Chronocort (hydrocortisone modified-release capsule)|Chronocort (hydrocortisone modified-release capsules) supplied as 5 mg and 10 mg per capsule for oral administration.
33272990|NCT03965065|Experimental|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
33272991|NCT03965065|Active Comparator|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
33272992|NCT00692237|Active Comparator|1|Sildenafil 100 mg
33272993|NCT00692237|Placebo Comparator|2|Placebo 100 mg
33272994|NCT00110149|Experimental|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
33272995|NCT03964285|Active Comparator|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
33272996|NCT03964285|Experimental|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
33272997|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
32774085|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.~Duvelisib will be administered orally twice daily~Venetoclax will be administered orally daily~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
32774086|NCT04944589|Experimental|single visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in single visit including access cavity, chemo-mechanical preparation and obturation, all were done in one visit
32774087|NCT04944589|Experimental|Multiple visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in multiple visit including access cavity, chemo-mechanical preparation and obturation, all were done in two or three visits
33272998|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
33272999|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33273000|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33273001|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
33273002|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
33273003|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
33273004|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
33273005|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
33273006|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
33273007|NCT00117949|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
33273008|NCT00117949|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
33273009|NCT00117949|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
33273010|NCT00117949|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
33273011|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
33273012|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
33273013|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
33401824|NCT03874234|Placebo Comparator|Part B: Subjects receiving placebo|Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
33401825|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
33401826|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
33401827|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
32774088|NCT04922125|Experimental|Pulse flour|Puree produced from pulse flours and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
32774089|NCT04922125|Experimental|Pre-processed pulse flour|Puree produced from pre-processed pulse flour with different structural aspects and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
33401828|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
32774090|NCT04922203|No Intervention|Control group|Anesthesiology residents do not receive any in situ simulation sessions during the observation period
32774091|NCT04922203|Experimental|Simulation group|Anesthesiology residents receive in situ simulations sessions during the observation period
33081228|NCT05426044|Experimental|Patients will receive oral placebo.|twice daily, oral metformin 750mg (i.e. 1500mg/day)
33081229|NCT05425966|Experimental|CLS-R-FUERTE|Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
33081230|NCT05425693|Experimental|Hybrid warm-up intervention|
33081231|NCT05425693|Experimental|Dynamic warm-up intervention|
33081232|NCT05425693|Experimental|Stretching warm-up intervention|
33081233|NCT05425693|No Intervention|No warm-up intervention|
33081234|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
33081235|NCT05425654|Experimental|RL-MPV + BBC/auto-HCT+ nivolumab|Rituximab, methotrexate (MTX), procarbazine, vincristine and lenalidomide (RL-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed after 2nd cycle of RL-MPV. High dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. 3 months after auto-HSCT, maintenance therapy with nivolumab 3 mg/kg is started for 6 months every 2 weeks
33081236|NCT05425576|Experimental|Drug OT-101 plus pembrolizumab|"OT-101 will be administered at a RP2D dose/m2/day for 4 days continuously and 10 days off every two weeks via a portable infusion pump.~Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks."
33081237|NCT05425537||Fatal drowning accident|Fatal drowning accident where the patient died because of the drowning process or as a consequence of his/her injuries.
33081238|NCT05425537||Non-fatal drowning accident|Non-fatal drowning accident where the patient was drowning and can be ascertained to have been experiencing either mild, moderate, or severe respiratory impairment immediately after the drowning process ended but did not die.
33081239|NCT05425381|Experimental|Enhanced version of Interconnected Systems Framework (ISFE)|The ISFE addresses limitations of positive behavioral interventions and supports (PBIS) and school mental health (SMH) and improves the quality of services within the three tiers of multi-tiered systems of support (MTSS) by providing specific guidance on their systematic interconnection. Meaningful interconnection requires effective interdisciplinary collaboration, well-functioning teams, data-based decision making, and effective selection and implementation of evidence-based practices. The original interconnected systems framework (ISF) capitalizes on PBIS' strong implementation infrastructure and universal prevention strategies and combines these elements with SMH enhancements to Tiers 2 and 3 to achieve a comprehensive continuum of evidence-based practices. The ISFE leverages the strengths of PBIS and SMH to create one integrated system of care that achieves synergy and economies of scale.
33081240|NCT05425381|Active Comparator|Positive Behavioral Interventions and Supports with Co-located School Mental Health (PBIS+SMH)|Mental health clinicians will be assigned and can work with MTSS teams (or not). Otherwise, there will be no special guidance. We expect this condition to mimic typical practices in schools, where PBIS and SMH efforts are co-located, but not meaningfully interconnected. In other words, we expect parallel functioning (Splett et al., 2014).
33081241|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
33081242|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
33081243|NCT05425342|Experimental|ECG single group|Patients will be instructed how to record an ECG on a smartwatch using the front camera of an iPad. In a second step, a standard ECG will be recorded by medical staff. The ECGs will then be compared by two board certified cardiologists
33081244|NCT05425225|Experimental|Low level LASER therapy|low level laser therapy in continues wave at a wavelength in the near infrared of 830nm. Power density will be 670 mW/cm2. The treatment time per point will be 30 seconds. Probe head will be placed with light pressure on the calf muscles. Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds
33081245|NCT05425225|Active Comparator|Conventional physical therapy|sustained stretching (10 seconds hold), strengthening exercise, balance training and gait training
33081246|NCT04668976|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
33081247|NCT00238953|Experimental|EC MPS|
33081248|NCT04669366||Patients in Sweden with metastatic renal cell carcinoma|The cohort of patients with metastatic renal cell carcinoma in Sweden
33401829|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
32774092|NCT04922047|Experimental|Experimental: Intravenous tislelizumab / Intravesical BCG|"Drug: tislelizumab / BCG~Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).~Other Name: BGB-A317"
33081249|NCT04668703|Experimental|combined cataract surgery and intravitreal Conbercept injection|Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.
33401830|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
33401831|NCT05276323|Experimental|Medihoney Derma Cream|Intervention group: Medihoney Derma Cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
33401832|NCT05276323|Active Comparator|Hydrocortisone 1% cream|control group: Hydrocortisone 1% cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
33401833|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
33401834|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
32774093|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
32774094|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
32774095|NCT04407013|Experimental|A|Experimental group with application of the standardized care pathways and symptom management education
32774096|NCT04407013|Other|B|Control group with usual care (symptom monitoring only)
32774097|NCT04941235|Active Comparator|NU group|Bth nerve stimulator and ultrasound guided interscalene brachial plexus block
32774098|NCT04941235|Active Comparator|U group|Ultrasound guided interscalene brachial plexus block
32774099|NCT04941235|Active Comparator|N group|Nerve stimulator guided interscalene brachial plexus block
32774100|NCT04941235|No Intervention|C group|No block only IV analgesics
32774101|NCT04921891|Active Comparator|Blocked arm|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
32774102|NCT04921891|Active Comparator|Unblocked arm|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
33081250|NCT04668703|No Intervention|cataract surgery alone|Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.
33081251|NCT04669327||Normal|normal subjects
33081252|NCT04669327||Scoliosis|subjects with moderate idiopathic scoliosis
33081253|NCT04721301|Experimental|Combination immunotherapy|Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment
33081254|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2019|
33081255|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2020|
33081256|NCT04668625|Experimental|Experimental group|Participate in a massive musical event
33081257|NCT04668625|No Intervention|Control Group|Not participate in a massive musical event
33081258|NCT04668508|Experimental|anlotinib combined with radiation|
33081259|NCT04668430|Other|patients|"Patients for whom orthopedic surgery is indicated and planned among :~Tibial valgus osteotomy~Supra-malleolar osteotomy~Hallux osteotomy for hallux valgus~Total knee arthroplasty~Total ankle arthroplasty~Ankle arthrodesis~Hallux arthrodesis~Rear foot torque arthrodesis~Inverted shoulder prosthesis~Anterior lumbar interbody arthrodesis"
33081260|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
33081261|NCT00556465|No Intervention|B,2, III|
33081262|NCT04668469|Experimental|Ivermectin plus standard care in Mild/Moderate COVID-19 (Group I)|100 patients with Mild/Moderate COVID-19 (Coronavirus disease) infection received a 4-days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard of care as issued by Egyptian protocol of COVID-19 treatment.
33081263|NCT04668469|Active Comparator|hydroxychlorquine plus standard care in Mild/Moderate COVID-19 (Group II)|100 patients with mild/moderate COVID-19 infection received hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care.
33081264|NCT04668469|Experimental|Ivermectin plus standard care and steroids in Sever COIVD-19 (Group III)|100 patients with severe COVID-19 infection received a 4 days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard care and steroids
33081265|NCT04668469|Active Comparator|hydroxychlorquine plus standard care and steroids in Sever COVID-19 (Group IV)|100 patients with Severe COVID-19 infection received hydroxychlorquine (400 mg every 12 hours for one day followed by 200 mg every 12 hours for 9days) plus standard care and steroids
33081266|NCT04668469|Experimental|Ivermectin plus personal protective measures in COVID-19 prophylaxis (Group V)|100 health care and or household contacts received a prophylactic dose of ivermectin 400 micrograms/kg single oral dose before breakfast to be repeated after one week in addition to Personal Protective Measures ( (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
33081267|NCT04668469|Active Comparator|Personal protective measures in COVID-19 prophylaxis (Group VI)|100 health care and or household contacts received only Personal Protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
33081268|NCT04668547|Experimental|Interventional arm|Single arm, no comparison
33081269|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
33081270|NCT00211913|Placebo Comparator|placebo|single dose
33081271|NCT00239031|Experimental|1|
33081272|NCT00212030|Active Comparator|1|
33081273|NCT00212030|Placebo Comparator|2|
33081274|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
33273014|NCT04517994|Experimental|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
33273015|NCT04517994|Active Comparator|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
33081275|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
33273016|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
33273017|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
33273018|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
33273019|NCT04478136||Non-major bleeders (NMB)|
33273020|NCT00117793|Active Comparator|Arm 1|Current clinical practice
33273021|NCT00117793|Experimental|Arm 2|Novel socket system
33273022|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
33081276|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
33081277|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
33081278|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
33081279|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
33081280|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
33273023|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
33273024|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
33081281|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
33081282|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
33273025|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
33273026|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
33273027|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
33273028|NCT03671369||Cervarix Group|The study group comprised of 9-25 year-old male and female subjects who were administered with 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects were vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose was administered before 5 months after the first dose, the third dose vaccination was required. In the 3 doses schedule, if the vaccination schedule required flexibility, the second dose was administered between 1 and 2.5 months and the third dose was administered between 5 and 12 months after the first dose.
33273029|NCT04060745|Experimental|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
33273030|NCT04060745|Experimental|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
33273031|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
33273032|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
33273033|NCT00692003|Active Comparator|Zonisamide|
33273034|NCT00692003|Placebo Comparator|Placebo|
33273035|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33081283|NCT00212342|Placebo Comparator|Sugar pill|
33081284|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
33081285|NCT00414375|Experimental|2|appendectomy on presentation
33081286|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
33081287|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
33081288|NCT00414414|Active Comparator|prednisone|
33081289|NCT00414414|Placebo Comparator|placebo|
33081290|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
33081291|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
32774103|NCT04406389|Active Comparator|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:~Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min~Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min~If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.~Fondaparinux (if history of heparin-inducted thrombocytopenia [HIT]) 2.5 mg daily subcutaneously"
33273036|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273037|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
32774104|NCT04406389|Experimental|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:~Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).~Enoxaparin 1 mg/kg subcutaneously every 12 hours~Argatroban (if heparin-induced thrombocytopenia [HIT]), dosed according to institutional protocol.~Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:~≥100 kg: 10 mg daily~<100 kg but ≥50 kg: 7.5 mg daily~<50 kg: 5 mg daily"
32774105|NCT04941079||Immune-related Myopathy Patient (myasthenia gravis and inflammatory myopathy)|
32774106|NCT04941079||Health Control|
33273038|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273039|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273040|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273041|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273042|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
33273043|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:~Phase 2: Preparation Phase Control Treatment~Phase 3: No Treatment"
33273044|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
33273045|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
33273046|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
33273047|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
33273048|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
33273049|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
33273050|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
32774107|NCT03057457||Kidney Injury|
33273051|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
33273052|NCT02564939|Active Comparator|ramelteon|receive ramelteon
33273053|NCT02564939|Placebo Comparator|placebo|receive placebo
33401835|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
32774108|NCT04921579|Experimental|En masse retraction|six anterior teeth are retracted by en masse technique using a crimpable hook distal to upper lateral incisor and a power chain.
33273054|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~Disease onset as metastatic or unresectable disease.~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
33273055|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
33273056|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
33273057|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
33273058|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
33273059|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
33273060|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
33273061|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
33273062|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
33273063|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
33273064|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
33273065|NCT00427648|Active Comparator|1|xylocaine
33273066|NCT00427648|Placebo Comparator|2|normal saline
33273067|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
33273068|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
33273069|NCT00743327||1|Participants receiving ADT and pioglitazone
33273070|NCT00743327||2|Participants receiving ADT only
33273071|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
33273072|NCT01032460|Active Comparator|macintosh|
33273073|NCT01032460|Active Comparator|C-MAC|
33273074|NCT01032460|Active Comparator|Airtraq|
33273075|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
33273076|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
33273077|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
33273078|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
33273079|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
33273080|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
33273081|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
33273082|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
33273083|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
33273084|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
33273085|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
33273086|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
33273087|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
33273088|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
33273089|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
33273090|NCT02564081|No Intervention|Ctrl|No intervention
33273091|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
33273092|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
33273093|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
33273094|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~Mini-Mental State Exam score between 26-30~CDR score = 0~flortaucipir (18F-AV-1451) PET scanning"
33273095|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
33273096|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
33273097|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
33273098|NCT03502733|Experimental|Cohort I (Doublet) (copanlisib, nivolumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study.
33273099|NCT03502733|Experimental|Cohort II (Triplet) (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Beginning cycle 2, patients also receive ipilimumab IV over 90 minutes on day 1 for a total of 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study.
33273100|NCT00555620|Experimental|A|
33273101|NCT00555620|Experimental|B|
33273102|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~reduced rates of major bleeding events at 30 days~similar rates of major adverse ischemic cardiac events at 30 days~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
33273103|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~reduced rates of target lesion revascularization for ischemia at 1 year~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~lower rates of analysis segment binary angiographic restenosis at 13 months"
33273104|NCT00743561|Other|1|
33273105|NCT00743639|Other|1|Interventional
33273106|NCT03463265|Experimental|nab-sirolimus|nab-sirolimus (ABI-009, nab-rapamycin, albumin-bound rapamycin) will be administered at 100 mg/m2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle. Two dose reduction levels will be allowed for toxicities: 75 mg/m2 and 60 mg/m2.
33273107|NCT03463265|Experimental|nab-sirolimus + bevacizumab|"ABI-009 will be administered intravenously at 60 mg/m 2 as a 30-minute infusion on Days 1, 8, and 15 of every 28-day cycle. If ABI-009 is well tolerated at 60 mg/m2 in the first 3 patients in the cohort, the dose may be increased to 75 mg/m2. Three dose reduction levels will be allowed: 45, 30, and 20 mg/m2.~Bevacizumab will be administered as an IV infusion (90 minutes 1st dose, 60 minutes 2nd dose, and 30 minutes afterward assuming tolerability) at a fixed dose of 5 mg/kg on Days 1 and 15 of every 28-day cycle. Bevacizumab will be administered approximately 10 minutes after the end of the ABI-009."
33273108|NCT03463265|Experimental|nab-sirolimus + temozolomide|ABI-009 will be administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. If ABI-009 is well tolerated at 60 mg/m2 in the first 3 patients in the cohort, the dose may be increased to 75 mg/m2. Three dose reduction levels will be allowed: 45, 30, and 20 mg/m2. Temozolomide will be administered PO at 50 mg/m2 daily.
33273109|NCT03463265|Experimental|nab-sirolimus + lomustine|ABI-009 will be administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle. If ABI-009 is well tolerated at 60 mg/m2 in the first 3 patients in the cohort, the dose may be increased to 75 mg/m2. Three dose reduction levels will be allowed: 45, 30, and 20 mg/m2. Lomustine (CCNU) will be administered PO at 90 mg/m2 on Day 1 of each odd 21-day cycle (ie, every 6 weeks).
33273110|NCT03463265|Experimental|nab-sirolimus + temozolomide + radiotherapy|Concomitant Treatment will start 1 week after the completion of Induction Treatment and will last for 6 weeks (2 cycles). ABI-009 will be administered IV at 60 mg/m2 as a 30-minute IV infusion on Days 8 and 15 of every 21-day cycle. Three dose reduction levels will be allowed: 45, 30, and 20 mg/m2. Temozolomide will be administered at 75 mg/m2 PO daily for 6 weeks. Focal RT will be given daily at 30 x 200 cGy, 5 days/week for a total dose of 60 Gy (or equivalent regimens as per RTOG guidelines).
33273111|NCT03463265|Experimental|nab-sirolimus + marizomib (MRZ)|"ABI-009 will be administered at 60 mg/m 2 as a 30-minute IV infusion on Days~1, 8, and 15 of every 28-day cycle. If ABI-009 is well tolerated at 60 mg/m2 in the first 3 patients in the cohort, the dose may be increased to 75 mg/m2. Three dose reduction levels will be allowed for toxicities: 45, 30, and 20 mg/m2. MRZ will be administered at 0.8 mg/m 2 as a 10-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ will be administered approximately 10 minutes after the end of the ABI-009 infusion."
33273112|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
33273113|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
33273114|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
33273115|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
33273116|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
33273117|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
33273118|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
33273119|NCT00955292|Experimental|Quarfloxin|
33273120|NCT00956462|Experimental|NSAID|
33273121|NCT00956462|Active Comparator|Steroids|
33273122|NCT04011254||Healthy Control|Healthy control
33273123|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG >4%
33273124|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG <4%
33273125|NCT00956696||Topiramte|single arm, flexible dosing
33273126|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
32774109|NCT04921579|Experimental|two step retraction|six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to upper lateral incisor and a power chain.
33273127|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
33273128|NCT03952650|Experimental|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
32774110|NCT04921657||Patients treated with statin.|Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.
33273129|NCT03952650|Experimental|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
33273130|NCT03952650|Experimental|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
33273131|NCT03952650|Experimental|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
33273132|NCT03952650|Experimental|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
33273133|NCT03952650|Experimental|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
33273134|NCT03952650|Placebo Comparator|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
33273135|NCT03952650|Placebo Comparator|4b|Receiving normal saline with 75 mg pyrimethamine days 2&amp;3 post injection
33273136|NCT03952650|Placebo Comparator|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
33273137|NCT03952650|Experimental|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
33273138|NCT03952650|Experimental|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
33273139|NCT03952650|Experimental|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
33273140|NCT03952650|Experimental|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
33273141|NCT00955526|Experimental|Istradefylline 20mg|
33273142|NCT00955526|Experimental|Istradefylline 40mg|
33273143|NCT00955526|Placebo Comparator|Placebo|
33273144|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
33273145|NCT00955604||Group R|At least 2 months of rasagiline
33273146|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
33273147|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
33273148|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
33273149|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
33273150|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
33273151|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
33273152|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
33273153|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
33273154|NCT04010448|Experimental|TV P2-VP8|
33273155|NCT04010448|Active Comparator|Rotarix®|
33273156|NCT00955838|Experimental|Manus|
33273157|NCT00955838|Experimental|BCI_Manus|
33273158|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
33273159|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
33273160|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
33273161|NCT05277480|Experimental|Apatinib+IE group|IE: Ifosfamide Plus Etoposide
33273162|NCT05277480|Active Comparator|IE group|IE: Ifosfamide Plus Etoposide
33273163|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
33273164|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
33273165|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
33273166|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
33273167|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
33273168|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
33273169|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
33273170|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
33273171|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
33273172|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
33273173|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
33273174|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
33273175|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
33273176|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
33273177|NCT03477708||Study group|TCCO2 monitoring
33273178|NCT03477708||Control group|Routine monitoring
33273179|NCT00956150|Active Comparator|60 GWS Rifaximin|
33273180|NCT00956150|Placebo Comparator|60 GWS Placebo|
33273181|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
33273182|NCT02564393||T|Control
33273183|NCT02564393||A|Adult with cystic fibrosis
33273184|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
33273185|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
33273186|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
33273187|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
33273188|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
33273189|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
33273190|NCT03284502|Experimental|Stage 1|Dose-escalation
33273191|NCT03284502|Experimental|Stage 1b|Dose-escalation
33273192|NCT03284502|Experimental|Stage 2 (Cohort I and II)|Dose-expansion
33273193|NCT03284502|Experimental|Stage 2 (Cohort III)|Dose-expansion
33273194|NCT00743873|Placebo Comparator|2|saline
33273195|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
33273196|NCT04011098|Active Comparator|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
33273197|NCT04011098|Experimental|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
33273198|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
33273199|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
33273200|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
33273201|NCT00956306|Experimental|Child-Pugh A|
33273202|NCT00956306|Experimental|Child-Pugh B|
33273203|NCT00956306|Experimental|Healthy Volunteers|
33273204|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
33273205|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
33273206|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
33273207|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
33273208|NCT05228340|Experimental|Intervention|Flexor tenotomy
33273209|NCT05228340|No Intervention|Controle|Usual-care
33273210|NCT00775229|Active Comparator|1|Naltrexone
33273211|NCT00775229|Placebo Comparator|2|Placebo
33273212|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
33273213|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
33273214|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
33273215|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
33273216|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
33273217|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
33273218|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
33273219|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
33273220|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
33273221|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
33273222|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
33273223|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
33273224|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
33273225|NCT00962676||immunocompromised group|
33273226|NCT00962676||non-immunocompromised group|
33273227|NCT04316078|Experimental|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
33273228|NCT04316078|No Intervention|control group|The control group will not be registered to the PEP nor receive any PEVs.
33273229|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
33273230|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
33273231|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
33273232|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
33273233|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
33273234|NCT00948272|Experimental|VRVg Group|
33273235|NCT00948272|Active Comparator|Verorab Group|
33273236|NCT00968136||a short-term trial of the ketogenic diet|
33273237|NCT00968136||long-term trial of the ketogenic diet.|
33273238|NCT05319509|Experimental|gameChange|
33273239|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
33273240|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
33273241|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
33273242|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
33273243|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
33273244|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
33273245|NCT00744029|No Intervention|Control group|No intervention was performed
33273246|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
33273247|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
33273248|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
33273249|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
33273250|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
33273251|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
33273252|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
33273253|NCT00957710|Other|langauge therapy|Naming therapy
33273254|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
32774111|NCT04930471||Metformin (all participants)|Patients with a new indication for Metformin (standard dosage as assigned by the treating physician) therapy. Samples will be collected before and after 12 weeks of Metformin treatment.
33273255|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
33273256|NCT00117637|Experimental|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis.
33273257|NCT00117637|Active Comparator|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median]).
33273258|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
33273259|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
33273260|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
33273261|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
32774112|NCT04921813|Experimental|Schroth method + brace|3-dimensional scoliosis exercise program according to Schroth method + brace.
32774113|NCT04921813|Experimental|Schroth + balance-coordination exercises + brace.|3-dimensional scoliosis exercise program according to Schroth + balance-coordination exercises + brace.
32774114|NCT04921813|Experimental|Brace|Only brace treatment.
33273262|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
33273263|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
33273264|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
33273265|NCT00744185|Placebo Comparator|2|30-days placebo treatment
33273266|NCT00744185|Experimental|1|30-days propranolol treatment
33273267|NCT02897778|Active Comparator|Entinostat|Participants received a single oral supratherapeutic dose of 15 mg entinostat under fasted conditions.
33273268|NCT02897778|Placebo Comparator|Placebo|Participants received a single dose of placebo-matching entinostat under fasted conditions.
32774115|NCT04921813|No Intervention|healthy individuals|Age-matched control group
33081292|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
33081293|NCT00411827|Active Comparator|1|PRK
33273269|NCT00746291|Experimental|A|Traumatic brain injury
33273270|NCT00746291|Experimental|B|Cerebral palsy
33273271|NCT00746291|Experimental|C|Controls
33273272|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
33273273|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
32774116|NCT04418401|Experimental|Experimental group|Treatment with Donafenib 100mg PO BID，and anti-PD-1 antibody 3mg/kg ivgtt Q2W. Treatment will last 6 months, unless the tumor recurrence.
32774117|NCT04930393|Active Comparator|PECS II Block|This group will receive an interscalene block in addition to a pectoral nerve block under ultrasound guidance with local anesthetic injected in the plane between the pectoralis minor and serratus anterior muscles
32774118|NCT04930393|Active Comparator|Axillary Ring Block|This group will receive an interscalene block in addition to a ring block with local anesthetic injected subcutaneously along the axilla from anterior to posterior direction.
32774119|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
32774120|NCT04940923||Patients|Patients within 4 weeks of a whiplash injury.
32774121|NCT04940923||Healthy controls|Age and gender matched healthy controls
32906383|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
33081294|NCT00411827|Active Comparator|2|LASIK
33273274|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
33273275|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
33273276|NCT00963066|Active Comparator|Pressure Support ventilation|
33273277|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
33273278|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
33273279|NCT01081093|Experimental|Biventricular pacing|
33273280|NCT00744341|Experimental|1|
33273281|NCT00744341|Experimental|2|
33273282|NCT00744341|Experimental|3|
33273283|NCT00744341|Experimental|4|
33273284|NCT00744341|Placebo Comparator|5|
33273285|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
33273286|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
33273287|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
33273288|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
33273289|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
32898412|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
33273290|NCT00968448|Sham Comparator|sham training|training with low resistance
33273291|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
33273292|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
33273293|NCT05317403|Other|AML without Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
33273294|NCT05317403|Other|AML with Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
33273295|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
33273296|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
33273297|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
33273298|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
33273299|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
33273300|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
33273301|NCT00690755||Group 1|type 2 diabetic individuals
33273302|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
33273303|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
33273304|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
33273305|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
33273306|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
33273307|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
33273308|NCT00746369|No Intervention|2|
33273309|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
33273310|NCT00746447|Experimental|3.0g OD|
33273311|NCT00746447|Experimental|1.5g OD|
33273312|NCT00746447|Active Comparator|0.5g TID|
33273313|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
33273314|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
33273315|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
33273316|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.~Patients in this group will have morning hypertension that is classified into two types:~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
33273317|NCT00742157|No Intervention|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
33273318|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
33273319|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
33273320|NCT00957788|Experimental|Cohort 0|
33273321|NCT00957788|Experimental|Cohort 1|
33273322|NCT00957788|Experimental|Cohort 2|
33273323|NCT00957788|Experimental|Cohort 3|
33273324|NCT04230278|Experimental|START-Play Intervention|Sitting Together And Reaching to Play is an intervention designed to work on motor-based problem-solving. Thus the activities keep thinking skills at the forefront while also working on advancing motor skills. When initially developed to work with children who were emerging sitters the motor tasks focused on sitting and reaching resulting in the name.
33273325|NCT04230278|Active Comparator|Movement, Orientation, Repetition, and Exercise (MORE-PT) - Usual Care Physical Therapy|This intervention was based on the observations of usual care from a previous study. Key principles included the use of Movement, Orientation, Repetition, and Exercise thus the intervention name was changed to MORE-PT before enrollment started. This reduced bias as the therapists and families were not informed this was usual care which could have biased them.
33273326|NCT04225130|Experimental|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
33273327|NCT04225130|Active Comparator|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
33273328|NCT05299424|Experimental|Phase 1, Dose escalation|There are 14 dose groups in dose escalation part ( Phase 1 study).
33081295|NCT00212498||TB diagnosis|
33273329|NCT05299424|Experimental|Phase 2, Dose expansion|Based on the data of phase 1, the dose level recommended for the phase 2 study (RP2D) will be evaluated.
33273330|NCT04277858|Experimental|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.~Carboplatin may be used instead of Cisplatin."
33273331|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
33273332|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation >48h
33273333|NCT03961724||ESRD group|
33273334|NCT03961724||Control group|
33273335|NCT03898856|Experimental|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
33273336|NCT00117325|Experimental|GW685698X|GW685698X
33273337|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
33273338|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
33273339|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
33273340|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
33273341|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
33273342|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
33273343|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
33273344|NCT00948662|Experimental|1|active arm/healthy young
33273345|NCT00948662|Placebo Comparator|2|placebo arm
33273346|NCT00948662|Other|3|ketoconazole interaction evaluation
33273347|NCT03748472|Experimental|Bolus feeding|
33273348|NCT03748472|Experimental|continuous gavage feeding|
33273349|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
33273350|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
33273351|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
32774122|NCT04940689|Active Comparator|Standard arm|"General anesthesia strategy with morphine:~Within 10 minutes before the induction of general anesthesia: administration of a placebo of 50 mL of 0.9% NaCl by slow IV~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with IV curare and remifentanil (morphine derivative) IV for a concentration target of 3-6 ng / mL.~Maintenance of anesthesia will be carried out with propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qs bispectral index 40-60) and remifentanil (target concentration 1-10 ng / mL). The administration of curare will be carried out as needed. In order to anticipate the sudden end of the analgesia, an administration of morphine 0.15 mg / kg IV will be carried out 30 minutes before the end of the intervention as recommended"
32774123|NCT04940689|Experimental|OFA arm|"General anesthesia strategy without morphine~Within 10 minutes before the induction of general anesthesia: pre-induction dose of dexmedetomidine 0.5 g / kg and lidocaine 1.5 mg / kg by slow IV.~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with an IV curare~The maintenance of the anesthesia will be carried out by propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qsp bispectral index 40-60), dexmedetomidine 0.5-1.0 g / kg / h, lidocaine 2 mg / kg / h. The administration of curare will be carried out as needed."
33273352|NCT04010084|Placebo Comparator|Control group|
33273353|NCT04010084|Active Comparator|Laser group|
33273354|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
33273355|NCT05300126|Experimental|Hypnosis|
33273356|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
33273357|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
33273358|NCT05352308|Experimental|Common Sense Model Guided Narrative Video Group|The narrative videos is guided by the CSM and designed to provide a comprehensive resource for college students. The narrative video addresses illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers. The format of the narrative video includes (1) a direct testimonial of a college woman (in her dorm room) telling a story to her roommates about what motivated her to get vaccinated, and (2) a conversation among the roommates where information about the HPV vaccine is discussed.
33273359|NCT05352308|No Intervention|Standard of Care Group|"Participants in the standard of care group will receive the Centers for Disease Control and Prevention's Vaccine Information Statement (VIS; https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf). The VIS contains information about HPV, the HPV vaccine, and the benefits and risks of the vaccine.~The VIS will be utilized because healthcare providers are required to distribute the VIS to patients before receiving each dose of the HPV vaccine, it is easy to understand, and it is publicly available information."
33273360|NCT05352308|No Intervention|Time & Attention Group|Participants in the time and attention video group will receive a Centers for Disease Control and Prevention video on binge drinking (https://youtu.be/I9hdkDTaQWU; 4:22 minutes). The video contains information on the health risks of binge drinking including unintended pregnancy, sexually transmitted diseases, injury, car accidents, violence, and HIV/AIDS
33273361|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
33273362|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
32774124|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
32774125|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
32774126|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
32774127|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
32774128|NCT04921501|Experimental|Proven or suspected arrhythmias group|
32774129|NCT04921267|Experimental|trained group|group receives training with sounds that correspond to simulated hearing protection
32774130|NCT04921267|No Intervention|Control|group receives no training
33273363|NCT04010006|Experimental|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
33273364|NCT04010006|Active Comparator|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
33273365|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
33273366|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
33273367|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
33273368|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
33273369|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
33273370|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
33273371|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
33273372|NCT00116779|Experimental|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
33273373|NCT00116779|Experimental|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
33273374|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
33273375|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
33273376|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
33273377|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
33273378|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
33273379|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
33273380|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
33273381|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
33273382|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
33273383|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
33273384|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
33273385|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
33273386|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
33273387|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
33273388|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
33273389|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
33273390|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
33273391|NCT00108355|Active Comparator|Albumin (Control group)|"After LVP, patients in this group received:~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
33273392|NCT00108355|Experimental|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
33273393|NCT05351996|Active Comparator|Kinesiotape|The participants received kinesiotape to the rectus femoris muscle.
33273394|NCT05351996|Sham Comparator|Sham-kinesiotape|Non-specific taping was applied.
33273395|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
33273396|NCT05351606|Experimental|Brief Intervention|Participants will receive one time tobacco use cessation counseling and quitline number.
33273397|NCT05351606|Experimental|Intensive Intervention|Participants will receive intensive behavioral counseling spread over 12 sessions, Nicotine Replacement Therapy and Bupropion, and the quitline number.
32774131|NCT05530811|Active Comparator|with dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
32774132|NCT05530811|Placebo Comparator|without dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline.
33273398|NCT02435472|Experimental|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
33273399|NCT02435472|No Intervention|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
33273400|NCT02435472|Active Comparator|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
33273401|NCT02435472|Active Comparator|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
33273402|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
32774133|NCT04940845|Experimental|HS-20090-2|
33273403|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
33273404|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
32774134|NCT04940845|Active Comparator|Prolia®|
32774135|NCT05507567|Experimental|Neumifil multiple dose prophylactic treatment|Neumifil intranasal spray administered as 3 single daily doses prior to viral challenge
33273405|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
33273406|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
33273407|NCT05297474||SSc patiant|We recruited 95 patients with systemic sclerosis
33273408|NCT05297474||health control|We recruited 95 healthy people for control
33273409|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
33273410|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
33273411|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
33273412|NCT04010292|Experimental|Patient education card|
33273413|NCT04010292|No Intervention|Control|
33273414|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
33273415|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
33273416|NCT02575976|Other|wait list control|no cardiac rehabilitation
33273417|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
32774136|NCT05507567|Experimental|Neumifil single dose prophylactic treatment|Neumifil intranasal spray administered as a single dose and blinded by placebo administered as two single daily doses. All administrations completed prior to viral challenge
33273418|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
33273419|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
33273420|NCT02573324|Experimental|ABT-414, Radiation and Radiation/Temozolomide (TMZ)|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
33273421|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
32774137|NCT05507567|Placebo Comparator|Placebo|Intranasal spray administered as 3 single daily doses prior to viral challenge
32906384|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
33273422|NCT04009980|Experimental|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
33273423|NCT04009980|Placebo Comparator|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
33273424|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
33273425|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
33273426|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
33273427|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
33273428|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
33401836|NCT05276245|Experimental|Program Group|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
33401837|NCT05276245|No Intervention|Waitlist control group|Participants who were randomly assigned to the waitlist control group were instructed to spend their usual half-hour lunch break in the office for consecutive 10 weekdays. Also, the waitlist control group was told to wait for at least three months before they took part in the structured protocol of nature contact.
32774138|NCT04921111|Experimental|Healthy Women Aged 18 to 26 Years|120 healthy women aged18 to 26 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil®9 : placebo =3:1:1.
32774139|NCT04921111|Experimental|Healthy Women Aged 27 to 45 Years|120 healthy women aged 27 to 45 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil® : placebo =3:1:1.
32906385|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
33081296|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
33081297|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
33081298|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
33081299|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
33081300|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
33081301|NCT00212615|Active Comparator|A|Standard XELOX
33081302|NCT00212615|Active Comparator|B|Chronomodulated XELOX
33081303|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
33081304|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
33081305|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
33081306|NCT04709406||obese patients|obese patients underwent bariatric surgery
33081307|NCT00213278|Experimental|1|
33081308|NCT00222846|Active Comparator|A|Attention control
33081309|NCT00222846|Experimental|B|Intervention
33081310|NCT00223002|Experimental|1|PI
33081311|NCT00223002|Experimental|2|Chlorohex
33081312|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
33081313|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
33081314|NCT00240006|Experimental|1|Shared Solutions®
33081315|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
33081316|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
33081317|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
33081318|NCT00213629|Other|no arm|no arm
33081319|NCT00240045|Experimental|1|
33081320|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
33081321|NCT00243789|Active Comparator|1|Pentoxifylline
33081322|NCT00243789|No Intervention|2|Placebo
33081323|NCT00214175||patients|patients who will receive XRT
33081324|NCT00214175||matched volunteers|Spouse or sibling
33081325|NCT00214253|Experimental|1|Thiazolidinedione therapy
33081326|NCT00214253|No Intervention|2|
33081327|NCT00214331||1|ciprofloxacin
33081328|NCT00214331||2|azithromycin
33081329|NCT00214331||3|gentamicin
33081330|NCT00244023|Experimental|1|Testosterone gel (intervention)
33081331|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
33401838|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)|Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
33401839|NCT05275777|Experimental|ADG106 combined with Paclitaxel (Phase Ib)|Intravenous ADG106 + weekly paclitaxel
33273429|NCT00968916|Experimental|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
33273430|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
33273431|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
33273432|NCT00969072|Experimental|GI198745|
33273433|NCT00094861|Placebo Comparator|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
33273434|NCT00094861|Experimental|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
33273435|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
33273436|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
33273437|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
33081332|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
33273438|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
33273439|NCT01079767|Other|Temsirolimus|Temsirolimus
33273440|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
33273441|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
33273442|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
33273443|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
33273444|NCT05260710|Experimental|Telemedicine intervention|Tele-critical care + continuing education activities
33273445|NCT05260710|No Intervention|Usual Care|Usual Care
33273446|NCT01109238||Process Feasibility|
33273447|NCT00958464||1|MRI protocol on 2 separate occasions
33273448|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
33273449|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
33273450|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
33273451|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
33273452|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
33273453|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
33401840|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)|Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
33401841|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
32774140|NCT05530733|Other|Pacifier only|Participants in the pacifier-only group will get a pacifier five minutes prior to tube feeding. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the volume of gastric residue will be controlled.
33273454|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
33273455|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
32774141|NCT05530733|Other|Pacifier with breast milk|Five minutes prior to tube feeding, participants in the pacifier with breast milk group will get their own breast milk dripping pacifier. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
33273456|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
33273457|NCT00969462|No Intervention|Doxorubicin|Single arm
32774142|NCT05530733|No Intervention|standard care (no pacifier)|The premature babies in the standard care (no pacifier) will get standard care while being fed through an orogastric tube. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
33273458|NCT00963846|Placebo Comparator|placebo|
33273459|NCT00963846|Experimental|huperzine 0.2 mg BID|
33273460|NCT00963846|Experimental|huperzine 0.4 mg BID|
33273461|NCT00963846|Experimental|huperzine 0.8 mg BID|
33273462|NCT00958620|Active Comparator|Active ESWT|
33273463|NCT00958620|Sham Comparator|Sham ESWT|
33273464|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
33273465|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
33273466|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
33273467|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
33273468|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
33273469|NCT04009278|Experimental|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
32774143|NCT03387917|Experimental|TLD-1|"Duration of treatment~1 cycle: 21 days~1 cycle: 28 days (only comparative PK part, in cycle 1 or 2)~until progression or occurrence of unacceptable toxicity or withdrawal, but~maximum 9 cycles for patients previously not treated with anthracyclines~maximum 6 cycles for patients previously treated with anthracyclines.~Dose: i.v., according to DL on day 1 of each cycle or tentative MTD"
33273470|NCT04009278|No Intervention|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
33273471|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
33273472|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
33273473|NCT00958932|Active Comparator|Speech recognition (Usual care)|
32774144|NCT03387917|Experimental|Caelyx (only for comparative PK part)|"Duration of treatment~1 cycle: 28 days~Caelyx is given only in one cycle (cycle 1 or 2)~Dose: i.v., 40mg/m2"
32774145|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
33273474|NCT00969852|Experimental|Sertraline|Single Arm
33273475|NCT04170738|Experimental|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
33273476|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
33273477|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
33273478|NCT04009434|Other|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
33273479|NCT04009434|Experimental|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
33273480|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
33273481|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
33273482|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
33273483|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
33273484|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
33273485|NCT00969930||healthy controls|
33273486|NCT00969930||BD type I patients|
33273487|NCT00107653|Experimental|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
33273488|NCT00107653|Experimental|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
33273489|NCT03994354||1,2|"J-P drain group~Penrose drain group"
32774146|NCT05421065|Experimental|Psilocybin Group (Arm 1)|receives individual psychotherapy sessions plus a (25 mg) psilocybin session.
32774147|NCT05421065|Active Comparator|Ketamine Group (Arm 2)|receives individual psychotherapy sessions plus a (300 mg) ketamine session with open-label access option at the end of their study involvement.
33273490|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
33273491|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
33273492|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
32774148|NCT04921423|Experimental|situational simulation teaching|Clinical case role play and empathy skill practice
32774149|NCT04921423|No Intervention|Clinical Case (Problem Based Learning)|Clinical Case discuss (Problem Based Learning)
33273493|NCT03950856|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
33273494|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
33273495|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
33273496|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
32774150|NCT04425005|No Intervention|Control group|
32774151|NCT04425005|Experimental|Exercise training group|
32774152|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
32774153|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
32774154|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
32774155|NCT04940455|Experimental|Educational digital platforms|"Nursing students from the Experimental Group (GE), will participate in educational activities made available on digital platforms on nursing care for patients with signs and symptoms of sepsis"
32774156|NCT04940455|Active Comparator|High-Fidelity Simulation|Nursing students in the Control Group (GC) will be exposed to high-fidelity simulation in the intensive care setting, where they must solve situations and procedures related to the nurse's performance in recognizing the signs and symptoms of sepsis.
32906386|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
33273497|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
33273498|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
33273499|NCT05281146|Active Comparator|chickpea and peanuts biscuits dependent group|children aged 8- 12 years attending the village school. This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months.
33273500|NCT05281146|Active Comparator|The chickpea and crushed peanut biscuits non-dependent group|Matched age and sex children attending the same village school. This group did not receive the fortified biscuits but received their ordinary usual breakfasts or snacks for four months.
33273501|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
33273502|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
33273503|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
33273504|NCT00689351|Experimental|1|13vPnC
33273505|NCT00689351|Active Comparator|2|7vPnC
33401842|NCT04744714||GDM group|questionnaire survey and clinical follow-up
33401843|NCT04744714||non-GDM group|questionnaire survey and clinical follow-up
33401844|NCT05275699|Experimental|68Ga-FAPI-04 PET/CT and 68Ga-RGD PET/CT|All patients diagnosed with keloid underwent 68Ga-FAPI PET/CT and 68Ga-RGD PET/CT.
33273506|NCT05448287|Experimental|Intervention|Suaahara interventions span health and family planning; nutrition; agriculture/homestead food production; and water, sanitation and hygiene (WASH). Diverse social and behavior change communication interventions are used, primarily to generate demand for access to improved services and to motivate households to adopt optimal health, nutrition, and WASH practices. All Suaahara interventions are supported by a crosscutting theme of gender equality and social inclusion (GESI), in part by targeting women and disadvantaged groups and conducting activities that address GESI-related barriers to optimal health, nutrition, and WASH behaviors.
33273507|NCT05448287|No Intervention|Comparison|Usual care.
33273508|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
33273509|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
33273510|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
33273511|NCT03950622|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
32774157|NCT05411237|Active Comparator|Pegylated Liposomal Doxorubicin|Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.
32774158|NCT05411237|Active Comparator|Paclitaxel|Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.
33273512|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
33273513|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
32774159|NCT04920877|Experimental|Central catheter-related bloodstream infection rates in intensive care units|
32774160|NCT03234881|Active Comparator|MOVE!|Weight management delivered as Treatment-as-Usual
32774161|NCT03234881|Experimental|MOVE!+CBT|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
33273514|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273515|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273516|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273517|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273518|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273519|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
33273520|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
33273521|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
33273522|NCT00746681|Placebo Comparator|C|Placebo
33273523|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
33273524|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
33273525|NCT00746759||Standard of Care|
33273526|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
33273527|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
33273528|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
33273529|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
33273530|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
33273531|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
33273532|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
33273533|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
33273534|NCT00749177|Active Comparator|1|Treatment as usual
33273535|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
33273536|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
33273537|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
33273538|NCT04059419|Experimental|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
33273539|NCT04059419|Active Comparator|Control|Should remain under geriatric care after randomization.
33273540|NCT00959400|Experimental|Fentanyl Transdermal|
33273541|NCT02563769|Experimental|Treatment Arm 1|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
33273542|NCT02563769|Experimental|Treatment Arm 2|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
33273543|NCT02563769|Experimental|Treatment Arm 3|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
33273544|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
33273545|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
33273546|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
33273547|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
33273548|NCT00744575||1|Chronic Back Pain
33273549|NCT00744575||2|Healthy Sex & Age Matched Controls
33273550|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~Fast Facts about Carbon Monoxide Educational Tool~Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
33273551|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
33273552|NCT03937908|Experimental|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
33273553|NCT03937908|Experimental|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
32774162|NCT04930003|Experimental|Experimental: Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
33273554|NCT00689273|Experimental|PF-04136309|
33273555|NCT00689273|Placebo Comparator|Placebo|
33273556|NCT00959634|Experimental|1|Dose 1 BID
33273557|NCT00959634|Experimental|2|Dose 2 BID
33273558|NCT00959634|Placebo Comparator|3|Placebo BID
33273559|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
33273560|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
33273561|NCT00970554|Active Comparator|Patching only|
33273562|NCT00970554|Experimental|Patching plus telescope group|
33273563|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
33273564|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
33273565|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
33273566|NCT04059575|Experimental|PERFORMANCE PLUS|performance plus better than GOLD TEX
33273567|NCT04059575|Active Comparator|GOLD TEX|GOLD TEX better than performance plus
33273568|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
33273569|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
33273570|NCT00749333|Experimental|1|
33273571|NCT00749333|Placebo Comparator|2|
33273572|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
33273573|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
33273574|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
33273575|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
33273576|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
33273577|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
33273578|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
33273579|NCT00746993|No Intervention|2|Routine care.
33273580|NCT04060433|Experimental|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
33273581|NCT04060043|Experimental|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
33273582|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
33273583|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
33273584|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
33273585|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
33273586|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
33273587|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
33273588|NCT00749489|No Intervention|No Intervention|No intervention
33273589|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
33273590|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
33273591|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
33273592|NCT00688181||Subjects treated with the Prefyx PPS System|All patients presenting to the institution for treatment of female Stress Urinary Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
33273593|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
33273594|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
33273595|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
33273596|NCT04010942|Active Comparator|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
33273597|NCT04010942|Placebo Comparator|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
33273598|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
33273599|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
33273600|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
33273601|NCT05351216||Cases|Individuals diagnosed with KHE and treated with sirolimus. After immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice. （Sirolimus Rapamycin 0.8mg/m2 bid po）
33273602|NCT05351216||Controls|Healthy children with no immunodeficiency disease, vaccinated according to the National Immunization Program. Particpants should be age-matched with the case group.
33273603|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
33273604|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
33273605|NCT00689117|Experimental|1|CT Gel
33273606|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
33273607|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
33273608|NCT00689117|Placebo Comparator|4|Vehicle Gel
33273609|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
33273610|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
33273611|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
33273612|NCT00949442|Experimental|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
33273613|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
33273614|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~maintenance therapy with oral trofosfamide, etoposide"
33273615|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
33273616|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
33273617|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
33273618|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
33273619|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
33273620|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
33273621|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
33273622|NCT00749801|Placebo Comparator|C|Placebo
32774163|NCT04930003|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
32774164|NCT04930003|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
33273623|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
33273624|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
33273625|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
33273626|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
33273627|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
33273628|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
33273629|NCT00547248|Active Comparator|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
33273630|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
33273631|NCT00547248|Active Comparator|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
33273632|NCT02562833|Experimental|Self-Management and exercise|
33273633|NCT02562833|Active Comparator|Educational|
33273634|NCT05351060|Experimental|3D model splinting intervention group|The researcher will scan the participant's forearm, wrist, and hand with an iPhone camera through the Comb O&P Scan App. Scans will be completed individually to maintain privacy. The entire Comb O&P platform is HIPAA compliant. The data is de-identified encrypted when it moves from the iPhone app to the computer through the cloud. Precision Valve Automation (PVA) will use the de-identified scans to print the 3D models which are a precise replica of the participant's hand. Once the researcher obtains the 3D models, resting hand splints will be fabricated on the 3D models to provide custom-made hand splint(s) to each participant. The participants will receive the splint(s) to wear during the hours of sleep for six weeks.
33273635|NCT05350982||Hospital Arm|Participants will be recruited to use the SalivaBio +/- SaliPac in a hospital setting. They will be provided with collecting instructions and will be guided by a member of the research team.
33273636|NCT05350982||Stimulated Home Arm|10 participants will be randomly selected by a random number generator. This arm will also be conducted in the Hospital, and the collection using a SalivaBio +/- SaliPac will still be observed by a member of the research team. These participants will receive the same information as those in the Hospital Arm, but will receive minimal input. This is to establish whether the collection instructions provided would be suitable to use in the home environment.
33273637|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
32774165|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
33273638|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
33273639|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
33273640|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
33273641|NCT00964704|Experimental|Single Arm|
33273642|NCT00949676||Heart Failure|
33273643|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
33273644|NCT00747071|Experimental|2|Close hospital contacts of each index case
33273645|NCT05350670|Experimental|perineal massage and cold compress group|
33273646|NCT05350670|No Intervention|no intervention group|
33273647|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
33273648|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~Distribution of educational materials~Case manager~Reminders~Practical training"
33273649|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
33273650|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
33273651|NCT00686855|Experimental|Dexamethasone|
33273652|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
33273653|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
33273654|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
33273655|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
33273656|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
33273657|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
33273658|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
33273659|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
32774166|NCT04930003|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
32774167|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
32774168|NCT04940143|Experimental|Botulinum toxin-A|Botulinum toxin-A (Onabotulinum toxin type-A) injection with electrical stimulation guidance will be administered to spastic ankle plantar flexor muscles. After the injection, the patients will be included in the comprehensive physiotherapy program.
32774169|NCT04920955||G1, CRC Relapse|Patients with an actual relapse of CRC, within 5 years from primary surgery. A single blood sample is collected at relapse diagnosis.
33273660|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
33273661|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
33273662|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
33273663|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
33273664|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
33273665|NCT00970788|Experimental|Video group|Video decision aid.
32774170|NCT04920955||G2, CRC Disease-free|Patients previously diagnosed with CRC and declared disease-free for at least 36 months but less than 5 years. A single blood sample is collected at standard monitoring visit.
33273666|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
33273667|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
32774171|NCT04920955||G3, CRC Disease-free (longitudinal)|Patients declared disease-free for at least 3 months but less than 18 months. Longitudinal blood samples will be collected during standard monitoring visits up to relapse, or for a maximum of 4 time points.
32774172|NCT04920955||G4, Primary CRC (longitudinal)|Patients with an actual diagnosis of CRC who are eligible for a treatment with curative intent. Blood samples will be collected pre and post-surgery (~6 weeks) and, eventually, at relapse.
32774173|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
32774174|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
32774175|NCT04929613|Experimental|Mindfulness-Based Resilience Training|Designed to train participants in a number of experiential exercises evoking qualities of mindfulness: mental focus, sustained attention and personal and situational awareness. These exercises include versions of the body scan (body awareness exercise), sitting meditation, mindful movement, walking meditation, eating meditation, mindful martial arts exercises and other elements of mindfulness.
32774176|NCT04920409|Experimental|FAWGT Diet|Composed of fruit, avocado, whole grains and trout
32774177|NCT04920409|Active Comparator|Usual diet (UD)|Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
32774178|NCT04920721||Allergic|suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests
32774179|NCT04920721||Non allergic|suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests
32774180|NCT04939675|Experimental|Anti-seizure medication|The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
33273668|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
33273669|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
33273670|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
33273671|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
33273672|NCT00959426|Experimental|PF-04620110|
33273673|NCT00959426|Placebo Comparator|Placebo Comparator|
33273674|NCT05328050||Achondroplasia|
33273675|NCT05328050||Hypochondroplasia|
33273676|NCT05297162|Experimental|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"Single-arm case-control imaging trial designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy (experimental test) with mpMRI/TRUS fusion prostate biopsy (standard test) in men suspected for PCa after at least one negative biopsy."
33273677|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
33273678|NCT04009772|Active Comparator|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
33273679|NCT04009772|Active Comparator|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
33273680|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
33273681|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
33273682|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
33273683|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
33273684|NCT00962156|Experimental|HES 130/0.4|Volume expansion
33273685|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
33273686|NCT00959738|Other|A|diverting loop ileostomy with rod
33273687|NCT00959738|Other|B|diverting loop ileostomy without rod
32743219|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th ~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
33273688|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
33273689|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
33273690|NCT00959816|Experimental|Single Dose (Part 1)|
33273691|NCT00959816|Experimental|Multiple Dose (Part 2)|
33273692|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
33273693|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
33273694|NCT05254106||Paclitaxel drug-eluting devices|Patients treated by at least one paclitaxel drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
33273695|NCT05254106||Non-drug-eluting devices|Patients exclusively treated by a non-drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
33273696|NCT00747383|Active Comparator|1|
33273697|NCT00747383|Active Comparator|2|
33273698|NCT00106639|Experimental|CP-690,550 15 mg BID|
33273699|NCT00106639|Experimental|CP-690,550 30 mg BID|
33273700|NCT00106639|Active Comparator|tacrolimus|
33273701|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
33273702|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
33273703|NCT00745433||A|Repaglinide add-on to metformin.
33273704|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
33273705|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
33273706|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
33273707|NCT04059653|Experimental|Electrical stimulation|Neuromuscular electrical stimulation treatment
33273708|NCT04059653|Active Comparator|Treatment As Usual|Usual GP treatment
33273709|NCT04009616|Experimental|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
33273710|NCT04009616|Experimental|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
33273711|NCT04009616|Placebo Comparator|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
33273712|NCT00750035|Experimental|1|total abdominal hysterectomy and
33273713|NCT00750035|Experimental|2|Subtotal hysterectomy
33273714|NCT00106249|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
33273715|NCT00106249|Sham Comparator|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
33273716|NCT00960128||A|Adult cohort
33273717|NCT00960128||B|Paediatric cohort
33273718|NCT01086943|Experimental|device arm|
33273719|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
33273720|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
33273721|NCT00105469|Experimental|AzaSite|1.0% azithromycin in DuraSite
33273722|NCT00105469|Active Comparator|Tobramycin|0.3% tobramycin
33273723|NCT05192408|Experimental|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone.~Initial sessions will last around 30 minutes and subsequent sessions will last 15 to 30 minutes."
33273724|NCT05192408|Other|Usual Care|"Patient Education Materials (PEMs) on:~Exercise in older adults (Stay Active, Stay Strong and Stay Steady) - 3 different levels tailored to frailty level and for progression~Falls prevention~FoF"
33401845|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
33401846|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
33273725|NCT04009694|Experimental|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.~Participants will be assessed at weeks 0 / 4 / 10 & 16 and the outcome measures will be recorded at week 0 & week 16.~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
33273726|NCT00960362|Placebo Comparator|A|
33273727|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
33273728|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
32743220|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
32743221|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
32743222|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
32743223|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
32743224|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
32774181|NCT04939675|No Intervention|Observation|The participants will be followed every 4 weeks without anti-seizure medication.
33273729|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
33273730|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
33273731|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
33273732|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
33273733|NCT00962312|Experimental|Capecitabine and Lapatinib|
33273734|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
33273735|NCT00962468|No Intervention|Usual care|Usual care will be provided.
33273736|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
33273737|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
33273738|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
33273739|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
33273740|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
33273741|NCT05299814|Experimental|Behavior Therapy|8 sessions of an evidence based parenting program to address oppositional behaviors and ADHD symptoms at home. All participants are in this arm.
33273742|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
33273743|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
33273744|NCT05069948|Experimental|HeadOn intervention|Participants are given access to HeadOn - a web application that delivers a CBT programme to patients following concussion.
33273745|NCT00960830|Placebo Comparator|mirtazapine|
33273746|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
33273747|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
33273748|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
33273749|NCT05037266|Experimental|55 - 64 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
33273750|NCT05037266|Experimental|At least 65 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
33273751|NCT05033990||Healthy Controls|Participants with no smoking history (< 100 cigarettes in lifetime); post-bronchodilator FEV1/FVC > 0.70; post-bronchodilator FEV1 > 80% predicted; and post-bronchodilator FVC > 80% predicted.
33273752|NCT05033990||Gold 0|"Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 > 80% predicted.~GOLD stands for the Global initiative for Chronic Obstructive Lung Disease."
33273753|NCT05033990||Preserved Ratio Impaired Spirometry (PRISm)|Participants with with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 < 80% predicted.
33273754|NCT05033990||Gold 1 - 2|Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-80% predicted.
33273755|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
32774182|NCT04939285|Experimental|PEEP=5cmH2O|In PSV mode,PS = 8 cmH2O,PEEP= 5 cmH2O, and FiO2 level was consistent with that before SBT
32774183|NCT04939285|Experimental|PEEP=0cmH2O|In PSV mode,PS = 8 cmH2O,PEEP=0 cmH2O, and FiO2 level was consistent with that before SBT
32774184|NCT04929691|Experimental|CPAP- Helmet Users|Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet
33273756|NCT00105235|Experimental|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
33273757|NCT03962803|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
33273758|NCT03962803|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
33273759|NCT03962803|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
33273760|NCT00547118|Experimental|1|Rimonabant
33273761|NCT00547118|Placebo Comparator|2|Placebo
33273762|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
33273763|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
33273764|NCT01084525|Placebo Comparator|Placebo|
33273765|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
33273766|NCT00962936|Experimental|CT-011|
33273767|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273768|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273769|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273770|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
32774185|NCT04929691|Active Comparator|Non-CPAP helmet users|Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet
32774186|NCT04939441|Experimental|TAF group|TAF [Vemlidy® 25mg QD] monotherapy
32774187|NCT04938583|Experimental|oregovomab, bevacizumab, paclitaxel and carboplatin|Combination of anti-angiogenesis and Chemo-immunotherapy
32774188|NCT04938739|Experimental|Cognitive Behavioral therapy|to modify any erroneous beliefs about pain and disability and to promote coping strategies and self-efficacy through a graded activity.
33273771|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273772|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
32774189|NCT04938739|Active Comparator|Home program exercises|Patients in both groups carried out exercise therapy for six weeks. There will be an educational session for each patient to make sure the exercises will be done successfully and supervision once per week.
32774190|NCT04929145||MICROMS|No intervention will be administered. Stool, hair, and blood samples will be collected at baseline and three months post baseline. Clinical follow-up will occur at year 1, 2, and 4.5 (neurological consultation) and in-between visits (regular follow-up).
32774191|NCT04938349|Experimental|Single session dual task perturbation training-OAwMCI|Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
33273773|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273774|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273775|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273776|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273777|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273778|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
33273779|NCT01087099|Experimental|Albendazole|Treatment with albendazole
32774192|NCT04938349|Experimental|Multiple session dual task perturbation training-OAwMCI|All participants will undergo stance and walking perturbation training for 4 weeks. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
32774193|NCT04938349|Active Comparator|Single session dual task perturbation training-CIOA|All participants will receive only one training session of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
33273780|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
33273781|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
33273782|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
33273783|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
33273784|NCT04009538|Experimental|COPD patients participated PR program|COPD patients participated first and second PR program
33273785|NCT02561741|Experimental|COV155|
33273786|NCT04010708||IOMUM|Pregnant women
33273787|NCT00750113|Experimental|Arm 1|
33273788|NCT00750113|Experimental|Arm 2|
33273789|NCT00750113|Experimental|Arm 3|
33273790|NCT04971590||Participants with Lupus Nephritis|
33273791|NCT05412953|Experimental|Supportive care (tonation breathing techniques, questionnaire)|Patients participate in tonation breathing techniques twice daily (or more if pain occurs) for 2 weeks. Patients also complete questionnaire at baseline and at 2 weeks.
32774194|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
32774195|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
32774196|NCT04929301|Experimental|AME Hand-Expression|Participants in the antenatal milk expression (AME) group will learn hand-expression from a certified lactation consultant beginning at 37 weeks of pregnancy. At the same visit, the PI or RA will also provide oral and written instructions for AME at home, specifically instructing participants to do AME 1-2 times per day for no longer than 10 minutes.
32774197|NCT04929301|Active Comparator|Education|Participants in the education group will receive a weekly educational hand-out on varying breastfeeding topics (e.g., latch).
32774198|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
32774199|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
33273792|NCT00745511|Active Comparator|1|
33273793|NCT00745511|Active Comparator|2|
33273794|NCT00745511|Placebo Comparator|3|
33273795|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
33273796|NCT00961376|Experimental|Cohort B|CD25 depletion
33273797|NCT00545688|Experimental|1|
33273798|NCT00545688|Experimental|2|
33273799|NCT00545688|Experimental|3|
33273800|NCT00545688|Experimental|4|
33273801|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
33273802|NCT01563380|No Intervention|Control Arm|
33273803|NCT00961610||Internet support group Intervention|
33273804|NCT00961610||Control group|
33273805|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
33273806|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
33401847|NCT05275621|Experimental|Subjects requiring PICC|Subjects requiring a PICC. Positioning is first tried under Virtual Reality distraction. If failure (movements or discomfort) standard procedural sedation is applied. No kind of physical restraint is allowed.
33273807|NCT04903028|Sham Comparator|Sham rTMS|Participants will be fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device with adjustable output amplitude and powered by a 9-V battery. We will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses or 1 Hz over mOFC total 900 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
33273808|NCT04903028|Active Comparator|Active rTMS 10 Hz DLPFC|A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
33273809|NCT04903028|Active Comparator|Active rTMS 1 Hz mOFC|A stimulation frequency of 1Hz, E-field-modeling to determine TMS intensity and coil orientation, session time of 15 minutes, and 900-total pulses per day, will be the same for all subjects (both active and sham). TMS will be delivered over the left mOFC.
33273810|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
33273811|NCT04900298|Experimental|Intervention Arm|Use of SafeHaven hand hygiene system in the operating room
33273812|NCT04900298|No Intervention|Control Arm|Standard of care hand hygiene
33273813|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
33273814|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
33273815|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
33273816|NCT04819256|Experimental|Intervention arm|Providers use PACE-It mobile application as a care co-ordination platform
33273817|NCT04819256|No Intervention|Usual care|Providers use usual modes of communication (e.g., phone calls, emails)
33273818|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
33273819|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
32774200|NCT04928443||Scar dressing group|Patients planning to treat surgical scar with scar dressing
33273820|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
33273821|NCT00967772|Experimental|Naftopidil|
33273822|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
33273823|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
33273824|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
32736878|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
33273825|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
33273826|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
33273827|NCT04009928|Experimental|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
33273828|NCT04009928|Sham Comparator|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
33273829|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
33273830|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
33273831|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
33273832|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
33273833|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
33273834|NCT00971022||Low-income Populations|
33273835|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
33273836|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
33273837|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
33273838|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
33273839|NCT00971100|Experimental|high dose of antigen|
32774201|NCT04928443||Regular care group|Patients treated with adhesive tapes or strips or did not take care of surgical scar.
32906387|NCT03213158|Experimental|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
33273840|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
33273841|NCT00968162|Experimental|Dose de-escalation|
33273842|NCT05207462|Experimental|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
33273843|NCT00501969|Experimental|Rotigotine|Rotigotine
33273844|NCT03942042|Experimental|Ixekizumab|"Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
33273845|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
33273846|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
33273847|NCT04008732|Experimental|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
32774202|NCT04920019|Experimental|Thoracic continuous epidural analgesia|"Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).~Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.~Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)"
32774203|NCT04920019|Active Comparator|intravenous opioid|IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)
33273848|NCT04008732|Experimental|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
33273849|NCT04008732|Experimental|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
33273850|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
33273851|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
33273852|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
32774204|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
33273853|NCT04008732|Active Comparator|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
32774205|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
32774206|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
32774207|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
32774208|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
32774209|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
32774210|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
32774211|NCT03057379|No Intervention|Control arm|Usual source of care
32774212|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
32774213|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
32774214|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
33273854|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
33273855|NCT04699604|Active Comparator|Levocetirizine (LTZ)|Participants will take Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) in addition to their current asthma regimen.
33273856|NCT04699604|Placebo Comparator|Placebo|Participants will take a placebo solution previously developed by the Children's Mercy Investigational Pharmacy to match the color, flavor, and consistency of the active drug in addition to their current asthma regimen.
33273857|NCT01013727|Experimental|Postural Reconstruction|
33273858|NCT01013727|Active Comparator|muscular stretching|
33273859|NCT00960180|Experimental|1|
33273860|NCT00960180|Placebo Comparator|2|
33273861|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
33273862|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
33273863|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
32774215|NCT04928365|Other|Advanced melanoma patients|
33273864|NCT04593290|Experimental|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
33273865|NCT04593290|Active Comparator|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
32774216|NCT04928365|Other|Stage III and IV melanoma patients after radical surgery|
32774217|NCT04938037|Experimental|SSNB through the spinoglenoid notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
32774218|NCT04938037|Active Comparator|SSNB through the suprascapular notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
33273866|NCT00971490|Experimental|Group 1|
33273867|NCT00971490|Placebo Comparator|Group 2|
33273868|NCT00971490|Sham Comparator|Group 3|
33273869|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
33273870|NCT05299580|Experimental|single arm|Patients will be treated with Dabrafenib 150 mg bid and Trametinib 2mg qd. Each cycle is 28 days and the treatment will be continued until documented disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons.
33273871|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
33273872|NCT04491045|Experimental|Community-Engaged Learning Collaborative (CELC)|The CELC arm is an integration of community engagement and learning collaborative approach which involves province-wide collaborative meetings for commune health stations (6 CHSs for each province) randomized into the CELC implementation condition. CELC CHSs will meet monthly initially for 3 months, followed by bi-monthly meetings for 12 months to engage in continuous quality improvement process, track implementation goals, problem solve implementation barriers, and engage in cross-site learning. This is in addition to usual implementation condition (supervision, workshops, technical assistance, and evidence-based toolkit)
33273873|NCT04491045|Experimental|Enhanced Supervision (ES)|This is an evidence-based training approach which involves 6-9 months of ongoing group supervision support from psychiatric hospital mental health specialist (psychiatrist, psychiatric nurse, or psychologist) for each community health station randomized to the ES condition. Supervision approach is structured and involves observation of sessions, feedback on fidelity and quality. Supervision support will be provided biweekly initially and monthly after completion of one practice case. This is in addition to usual implementation condition (workshops, technical assistance, and evidence-based toolkit)
32774219|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
32774220|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
32774221|NCT04919785|Experimental|Deep brain stimulation|Deep brain stimulation in the bed nucleus of stria terminalis
32774222|NCT04928833|Experimental|Pilates Group|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks.
32774223|NCT04928833|Active Comparator|Control Group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
32774224|NCT04928833|No Intervention|Evaluation of 'Core' Stability|"Core stability was evaluated with two important dimensions, core strength and endurance tests."
32774225|NCT04928833|No Intervention|Ultrasound Examination of M. Transversus Abdominus and M. Multifidus|M. transversus abdominus (TrA) and m. multifidus (MF) muscles were visualized by ultrasonography and the evaluations were performed by an experienced radiologist who was blind to the case groups.
32774226|NCT04928833|No Intervention|Evaluation of Lower Extremity Functional Strength|Lower extremity functional strength was evaluated with the 5-Times Sit-and-Stand Test.
32774227|NCT04928833|No Intervention|Evaluation of Balance|Balance was evaluated using the Berg Balance Scale (BBS).
32774228|NCT04928833|No Intervention|Evaluation of Functional Mobility|Functional mobility was evaluated using the Timed Up and Go Test (TUG).
33273874|NCT04491045|Active Comparator|Usual Implementation (UI)|"Usual Implementation (UI) Control intervention that will be enhanced usual implementation and includes hybrid training workshops on basic implementation and training supports for Multicomponent Collaborative Care for Depression program, which is an evidence-based stepped collaborative care intervention for integrating depression care into primary care settings. It consists of six components: routine screening, diagnostic assessment, psychoeducation, antidepressant medication, adherence management, behavior activation therapy.~This implementation and training supports includes a series of online training modules, weekly webinars, and 3 one-day in-person workshops on collaborative care for depression (MCCD), limited technical assistance, and toolkit."
33273875|NCT00104299|Experimental|Rituximab|
33273876|NCT00104299|Active Comparator|Control Group|
33273877|NCT03939312|Experimental|Atogepant 60 mg|Participants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.
33273878|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
33273879|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
33273880|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
33273881|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
33273882|NCT05196308|Experimental|Xeomin® receivers|Patients will receive Xeomin®.
33273883|NCT05196308|Placebo Comparator|Placebo receivers|Patients will receive placebo injection instead of Xeomin®.
33273884|NCT01563432|Experimental|febuxostat (TR)|
33273885|NCT01563432|Experimental|febuxostat (RT)|
33273886|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
33273887|NCT00960258|Experimental|Arm 1|
33401848|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
33273888|NCT04566926|Experimental|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
33273889|NCT04566926|Experimental|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
32774229|NCT04928833|No Intervention|Evaluation of Functional Exercise Capacity|Functional exercise capacity was evaluated using the 6 Minute Walking Test (6-MWT).
32774230|NCT04928833|No Intervention|Activities of Daily Living and Evaluation of Motor Impairment|Activities of daily living and motor impairment were evaluated with activities of daily living (II) and motor impairment (III) sub-dimensions of the Unified Parkinson's Disease Rating Scale (UPDRS).
33273890|NCT04566926|Experimental|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
33273891|NCT04566926|Experimental|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
33273892|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
33273893|NCT00082381|Experimental|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
33273894|NCT00082381|Active Comparator|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
33273895|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
32774231|NCT04928833|No Intervention|Evaluation of Freezing|The Freezing of Gait Questionnaire (FOGQ) was used to identify and evaluate the subjective perception of Parkinson's patients regarding the severity and effect of freezing on gait performance.
32774232|NCT04928833|No Intervention|Evaluation of Fatigue|Fatigue, one of the non-motor findings associated with Parkinson's, was evaluated with the Parkinson's Fatigue Scale-16 (PFS-16).
32774233|NCT04928833|No Intervention|Evaluation of Quality of Life|Quality of Life was evaluated with Parkinson's Disease Questionnaire-39 (PDQ-39).
32774234|NCT04919473|Experimental|vMCO-I High dose|Participants received 3.5E11vg/eye of vMCO-I
32774235|NCT04919473|Experimental|vMCO-I Low Dose|Participants received 1.75E11vg/eye of vMCO-I
32774236|NCT04937569|Active Comparator|Group 1: Ivermectin + standard treatment|Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
32774237|NCT04937569|Other|Group-2: Standard treatment only|This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.
32774238|NCT04937257|Active Comparator|Virtual Reality|"Participants randomized to the immersive virtual reality study arm, considered the intervention group received training on donning and doffing PPE using a program developed by Axon Park Inc. (California, USA)"
32774239|NCT04937257|Placebo Comparator|E-module|"Participants randomized to the e-module study arm, considered the control group received training on donning and doffing PPE using an e-module containing a video and slide show."
32774240|NCT04937335||Non-hemorrhage group|Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
32774241|NCT04937335||Hemorrhage group|Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation
32774242|NCT04919005|Experimental|Healthy elderly people|Twelve healthy elderly people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
33273896|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
33273897|NCT00960336|Experimental|single arm|
33273898|NCT04557176|Experimental|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
32774243|NCT04919005|Experimental|Elderly people with Alzheimer's in the initial phase|Seven elderly people with Alzheimer's in the initial phase. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
32774244|NCT04919005|Experimental|Healthy young people|Fifteen healthy young people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
32774245|NCT04927507|No Intervention|Control group|The control group was given routine nursing.
32774246|NCT04927507|Experimental|Observation group|The observation group was given the Internet plus nursing home rehabilitation mode.
32774247|NCT04918849||Community Sample|We plan to recruit a community sample of 1000 from the Indian Population.
32774248|NCT04937101|Experimental|Antihistamine treatment group|Chlorpheniramine, the concentration is 10mg/ml per unit point, the highest dose is 1ml
32774249|NCT04937101|No Intervention|Control group|
32774250|NCT04937023|Experimental|UDCA gel will be injected using a syringe with blunt cannula into the defect site|In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth ≥3mm after performing SRP.
32774251|NCT04937023|Placebo Comparator|placebo gel will be injected in to the defect site using a syringe with blunt cannula.|In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.
32774252|NCT04937179|Sham Comparator|Ischemic Conditioning Low|Blood flow restriction with low compression
32774253|NCT04937179|Active Comparator|Ischemic Conditioning High|Blood flow restriction with high compression
32906388|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
32906389|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
32906390|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
32906391|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
32906392|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
32906393|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
32906394|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
33081333|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
33081334|NCT04720950|Experimental|Morning exercise|1 hour of exercise completed between 0800-1000
33081335|NCT04720950|Experimental|Evening exercise|1 hour of exercise completed between 1800-2000
32906395|NCT04201704|Active Comparator|Liberal IV Fluid|"Maintenance fluid rate calculated by 4-2-1 formula for patients <110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg >20kg~Patients >110kg maintenance 150 mL/hr~Bolus Criteria: change in 1 of: >20% decrease in systolic blood pressure 50th percentile for age and sex, >20% increase in heart rate over 50th percentile for age, base excess > -5mmol/L, blood lactate >2mmol/L, AND urine output (UO) <1 mL/kg/hr if <50kg or <50 mL/hr if >50kg~If criteria met: bolus 20 mL/kg if <50kg or 1 L if ≥50 kg~For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If >25kg give 250 mL.~Diuresis- after minimum 24hrs: if UO <2 mL/kg/hr (or <100 mL/hr if >50 kg) continue maintenance rate and bolus per initial phase. If UO >2 mL/kg/hr (or >100 mL/hr if >50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
32906491|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
33081336|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
33081337|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
33081338|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
33081339|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
33401849|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
33401850|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
33401851|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
33401852|NCT05672212|Experimental|ANI (Analgesia/Nociception Index) monitoring|
33401853|NCT05672212|Active Comparator|Standard monitoring|
33081340|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
33081341|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
33081342|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
33401854|NCT05275309|Experimental|Children <= 1 years old|Pediatric patients <= 1 years old of age scheduled for surgery in the prone position
33401855|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
33401856|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
33401857|NCT05275153|Experimental|Home based cognitive rehabilitation program|The intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
33081343|NCT00214760|Experimental|PGET|
33401858|NCT05275153|No Intervention|No intervention|In the control group, natural cognitive changes with the passage of time were observed.
33401859|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
33401860|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
33401861|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
33401862|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
33401863|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
32906492|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
33081344|NCT00214760|Active Comparator|PMMA|
33081345|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
33081346|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
33081347|NCT00240630|Placebo Comparator|Arm 1|placebo to match
33081348|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
33081349|NCT00244218|Experimental|Treatment Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
33081350|NCT00244218|Placebo Comparator|Control Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
33081351|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
33081352|NCT00244257|Experimental|1|Cohort 1
33081353|NCT00244257|Experimental|2|Cohort 2
33081354|NCT00244257|Experimental|3|Cohort 3
33081355|NCT00244257|Experimental|4|Cohort 4
33081356|NCT00244257|Experimental|5|Cohort 5
33081357|NCT00244335||1|PTSD Subjects
33081358|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
33081359|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
33081360|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
33081361|NCT04709523|Experimental|i-PRF enriched bovine-derived xenograft|Patients treated with i-PRF-enriched bovine-derived xenograft + resorbable membrane
33081362|NCT04709523|Experimental|bovine-derived xenograft|Patients treated with bovine-derived xenograft + resorbable membrane
33081363|NCT04668352|Experimental|Dactolisib 10mg once daily|
33081364|NCT04668352|Placebo Comparator|Placebo|
33081365|NCT04668196||High-flow nasal cannula treatment|
33081366|NCT04668196||Continuous positive airway pressure (CPAP) treatment|
33081367|NCT04668196||Noninvasive ventilation treatment|
33081368|NCT04668079|Experimental|Modified cross body stretch|modified cross body stretch
33081369|NCT04668079|Experimental|Modified sleeper stretch|modified sleeper stretch
33081370|NCT00215501|Experimental|Group A|Oral capecitabine
33081371|NCT00215501|Experimental|Group B|5-fluorouracil
32774254|NCT04936711|Experimental|Back Massager Device + Standard Pain Treatment|"Resteck Shiatsu Neck and Back Massager (brand name), with recommended use for at least every 2 hours for at least 15 minutes on the first post-operative day and then every 4 hours for 2 days and then as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
32774255|NCT04936711|Active Comparator|Marcaine spray + Standard Pain Treatment|"30cc of 0.25% Marcaine spray on the diaphragm at the end of surgery.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
32774256|NCT04936711|No Intervention|Standard Pain Treatment|"will receive standard pain treatment include local anesthetic agent at the incision sites + oral Tylenol and oral or IV opioid as breakthrough pain treatment postoperatively as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
32774257|NCT04927117||high myopic group (group1:AL≥26.0 mm)|axial length≥26.0 mm)
32774258|NCT04927117||age-matched control group|axial length<26.0mm
32774259|NCT04936945|Active Comparator|arthroscopy plus platelet rich plasma.|Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
32774260|NCT04936945|Active Comparator|arthroscopy plus hyaluronic acid.|Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
32774261|NCT04936789|Experimental|Single arm|Single arm. All subjects will receive the intervention. Comparator device will be subjects' own prosthesis at baseline.
32774262|NCT04936555|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
32774263|NCT04936555|No Intervention|No Intervention|Control group Routine maintenance will be applied
32774264|NCT04918615|Experimental|Sirolimus coated balloon catheter|Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.
32774265|NCT04918615|Active Comparator|Paclitaxel coated balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd
32774266|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
32774267|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
32774268|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
32774269|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
32774270|NCT03056677|Experimental|Control|No Whey Protein
32774271|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
32774272|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
32774273|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
32774274|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
32774275|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
32774276|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.~Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.~Headteachers and physical education teachers will be administered questionnaires."
32774277|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
32774278|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
33273899|NCT04557176|No Intervention|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
33273900|NCT00971646||OAB|Patients with overactive bladder syndrome
33273901|NCT00971646||Osteoporosis|Patients with osteoporosis
33273902|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
33273903|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
33273904|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
32774279|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
32774280|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
33273905|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
33273906|NCT04505852|Experimental|EMBRACE USERS|Embrace wristband users
33273907|NCT00960414|Experimental|SHINE A|
32774281|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
32774282|NCT04926883|Active Comparator|Sonic fill|
32774283|NCT04926883|Active Comparator|X-tra fill|
32774284|NCT04926805|Experimental|Mask A|Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
32774285|NCT04926805|Active Comparator|Mask B|Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.
33273908|NCT00960414|Active Comparator|SHINE B|
33273909|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
33273910|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
32774286|NCT04936087|Other|WHO 8-steps|Single group intervention and described in the Intervention section.
32774287|NCT04936165|Experimental|Healthy experimental participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min intervention, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
32774288|NCT04936165|No Intervention|Healthy controlled participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min rest, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
32774289|NCT04926727||Pregnant women|"600 Pregnant women between the 18th and 22nd week.~200 from Northern Italy;~200 from Central Italy;~200 from Southern Italy and the Islands."
32774290|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
32774291|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
32774292|NCT04927039|Placebo Comparator|Control group|
32774293|NCT04927039|Experimental|Iloprost group|
32774294|NCT04926493||BIOPAVIR Cohort|Critically ill patient > 18 years of age with mechanical ventilation for >2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
32774295|NCT04918303|Experimental|SKNA group|
32774296|NCT04917679|Experimental|Combination group|Eltrombopag plus diacerein
32774297|NCT04917679|Placebo Comparator|Monotherapy group|Eltrombopag monotherapy
32774298|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
32774299|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
32774300|NCT04926649|Sham Comparator|Conventional ventilation group|Conventional SLV and complementary with DLV when necessary. When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. The right lung was totally collapsed. If the SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted.
32774301|NCT04926649|Active Comparator|CPAP group|"SLV of left lung and CPAP of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, CPAP was started with the pressure less than 8 cmH2O. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
32774302|NCT04926649|Experimental|HFLVV group|"SLV of left lung and HFLVV of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, HFLVV was started with tidal volume of 2ml/kg, respiratory rate of 60 bpm. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
32774303|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
33273911|NCT03962413|Active Comparator|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.~Using a through-cutting forceps, the ostium will be enlarged."
32774304|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
32774305|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
32774306|NCT02443155|Experimental|NNC0114-0006 + Placebo|
33273912|NCT03962413|Active Comparator|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
32774307|NCT02443155|Active Comparator|Liraglutide + Placebo|
33273913|NCT03962413|Active Comparator|The canine fossa approach.|"It will be done either transnasally or transorally:~** The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.~** The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
33273914|NCT00545844|Experimental|1|montelukast sodium
32774308|NCT02443155|Placebo Comparator|Placebo|
32774309|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
32774310|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
32774311|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
32774312|NCT04935541|Active Comparator|Dexmedetomidine infusion|Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
33273915|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
33273916|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
33273917|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
33273918|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
33273919|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
33273920|NCT04008654|Active Comparator|ERAS group|This groups will receive ERAS protocol
33273921|NCT04008654|Placebo Comparator|Conventional care|This group will not receive the ERAS protocol.
33273922|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
32774313|NCT04935541|Active Comparator|Remifentanil infusion|Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.
32774314|NCT04925791|Experimental|The IPC group|subjects will get a standardized pre-conditioning treatment 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of occlusion alternating with 5 minutes of reperfusion while seated.
32774315|NCT04925791|Other|The CON group|subjects will get a controlled treatment of 20% of limb occlusion pressure 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of minimal occlusion alternating with 5 minutes of reperfusion while seated.
32774316|NCT04935151|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
32774317|NCT04935151|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
32774318|NCT04935073|Experimental|Traditional Chinese Medicine herbs treatment group|the treatment group will receive treatment with the Chinese herbal formula on the 5th day of the menstrual cycle and lasts to 14 days after IVF-ET.
32774319|NCT04935073|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
32774320|NCT04934761|Experimental|capacity shock|2ml/kg succinylateol gelatin
32774321|NCT04934761|Other|routine management|conventional strategy
32774322|NCT04934059|Experimental|Yuxuebi tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
32774323|NCT04934059|Placebo Comparator|Placebo tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
32774324|NCT04917835|Experimental|treatment with argon- and nitrogen-NTAPP|PLADUO (argon- and nitrogen- non-thermal, atmospheric-pressure plasma) treatment
32774325|NCT04917991|Experimental|Extra Virgin Olive Oil Group|Subjects will consume 100 grams of Extra Virgin Olive Oil-enriched chocolate spread for 14 days.
32774326|NCT04917991|Active Comparator|Palm oil Group|Subjects will consume 100 grams of palm oil enriched chocolate spread for 14 days.
32774327|NCT04917289|Experimental|Treatment Arm|Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.
33273923|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
33273924|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
33273925|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
33273926|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
33273927|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
32774328|NCT04917289|No Intervention|Control Arm|Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.
32774329|NCT04917913|Experimental|Intervention|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
32774330|NCT04917913|Placebo Comparator|Placebo|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
32774331|NCT04925869||The hospitals of Besançon|Adult patients with MRI-confirmed CVA admitted to the hospitals of Besançon
33273928|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
33273929|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
33273930|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
32774332|NCT04925869||the hospitals of Cayenne|Adult patients with MRI-confirmed CVA admitted to the hospitals of Cayenne.
32774333|NCT04925869||the hospitals of Tours|Adult patients with MRI-confirmed CVA admitted to the hospitals of Tours.
32774334|NCT04925635||experimental group|The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group.
32774335|NCT04925635||control group|Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given.
32774336|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
32774337|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
32774338|NCT04916899||Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral
32774339|NCT04933981||interventional nursing home (INH).|regular, twice to three times weekly, and voluntary, i.e. non-mandatory, on-site testing for SARS-CoV-2 of HCW and visitors (INH)
32774340|NCT04933981||control nursing home (CNH)|routine setting without frequent regular testing for SARS-CoV-2 (control nursing homes; CNH). Testing only performed by local health authorities upon medical indication, i.e. non-surveillance testing
32774341|NCT04925245|Experimental|Clinical Reminder|
32774342|NCT04925245|No Intervention|No Reminder|
32774343|NCT04933357|Experimental|Dose escalation|
32774344|NCT04933357|Active Comparator|Standard dose|
32774345|NCT04916821|Experimental|water extract of propolis|Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week
32774346|NCT04916821|Experimental|olive oil extract of propolis including perga|Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week
32774347|NCT04916821|No Intervention|control|control group (patients not given any investigational product)
32774348|NCT04933201|Experimental|Music group|Perioperative music intervention
32774349|NCT04933201|Active Comparator|Control group|No perioperative music
32774350|NCT04925323|Experimental|a plastic or repair surgery indication generating surgical waste|
32774351|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
32774352|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
32774353|NCT04925011|Other|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
32774354|NCT04913155|Other|Reporting group (coronary calcium score and emphysema score)|Coronary calcium score and emphysema score are reported to subjects
32774355|NCT04913155|Other|Reporting group (coronary calcium score only)|Only coronary calcium score is reported to subjects
32774356|NCT04913155|Other|Reporting group (emphysema score only)|Only emphysema score is reported to subjects
32774357|NCT04913155|Other|Non-reporting group|Coronary calcium score and emphysema score are not reported to subjects
32774358|NCT04913155|No Intervention|Low-risk group|No CT screening, collection of health data only
32774359|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
32774360|NCT04916509||Palbociclib plus an aromatase inhibitor|"Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.~Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
32774361|NCT04916509||palbociclib plus fulvestrant|"Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
32774362|NCT04916353|Experimental|20% hypertonic dextrose water injection group|echo guide 20% dextrose water 3ml was injection in lesion site
33273931|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
33273932|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
33273933|NCT04331301|Active Comparator|vapoenucleation group|Group A
33273934|NCT04331301|Active Comparator|needlescopic enucleation|group B
33273935|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
33273936|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
33273937|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
33273938|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
33273939|NCT05181813|Experimental|Group 1: Ginge-Cal group:|primary molars were filled by creamy mixture pulpectomy paste of Gingerols and Calcium Hydroxide.
33273940|NCT05181813|Active Comparator|Group 2: Metapex group|primary molars were filled by a ready-made injectable creamy mixture pulpectomy paste of Metapex
33273941|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
33273942|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
33273943|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
33273944|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
33273945|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
33273946|NCT00971958|Active Comparator|Mogen Clamp|
33273947|NCT00971958|Active Comparator|Plastibell|
33273948|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
32774363|NCT04916353|Active Comparator|Steroid injection group|Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group
32774364|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
33273949|NCT00093145|Experimental|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
33273950|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
32774365|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
33273951|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
33273952|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
33273953|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
33273954|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
32774366|NCT04924465||Anti-Jo1|Patients with anti-Jo1 antibodies
32774367|NCT04924465||Anti-PL7|Patients with anti-PL7 antibodies
32774368|NCT04924465||Anti-PL12|Patients with anti-PL12 antibodies
32774369|NCT04924465||Anti-EJ|Patients with anti-EJ antibodies
32774370|NCT04924465||Anti-OJ|Patients with anti-OJ antibodies
32774371|NCT04916275||Staff working in a nursing home in Occitanie|
32774372|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
32774373|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
32774374|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
32774375|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
32774376|NCT04915885|Other|Control arm|routine contraceptive counseling and care and a range of family planning methods that are routinely available at field level
32774377|NCT04915885|Experimental|Intervention package|contraceptive counseling package but still with a range of family planning methods that are routinely available at field level
32774378|NCT04915885|Experimental|Intervention package & expanded methods|contraceptive counseling package but with an expanded range of family planning methods that are recommended by national guidance
32774379|NCT04915963|Experimental|vitamin D group|170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube
32774380|NCT04915963|Sham Comparator|Placebo group|170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube
32774381|NCT04915807||Prospective population|The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
33273955|NCT01014039|No Intervention|Control arm|No intervention (no screening)
33273956|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
33273957|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
33273958|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
33273959|NCT00960726|Experimental|NOV-002|
33273960|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
33273961|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
33273962|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
33273963|NCT00960882|Experimental|DMMET-01|
33273964|NCT05181735|Experimental|Arm A (Luspatercept alone)|Patients will receive Luspatercept 1mg/kg (every 3 weeks) with titration up to max of 1.75mg/kg, subcutaneously on day 1 of each 21 day cycle (every three weeks).
33273965|NCT05181735|Experimental|Arm B (Luspatercept + EPREX)|"Patients will receive Luspatercept (at the selected dose according to part A) subcutaneously on day 1 of each 21 day cycle (every three weeks) AND Epoetin alfa: At the selected dose (in part A) per week, subcutaneously, every week~Doses schedules Part A :~Level 1 : Luspatercept 0.8 mg/kg + EPREX 30000 UI~Level 2 : Luspatercept 1.33 mg/kg + EPREX 30000 UI~Level 3 : Luspatercept 1.75mg/kg + EPREX 30000 UI~Level 4 : Luspatercept 1.75mg/kg + EPREX 60000 UI"
32774382|NCT04915807||Historical retrospective population|The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.
33273966|NCT05163678||patient group|"All adolescents or young adults presenting for a consultation in the FSEF Relais systems.~They will be assessed upon entry into the device (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6)."
33273967|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
32774383|NCT04915651|Experimental|Gallbladder Cryoablation|High-risk patients who undergo gallbladder cryoablation
32774384|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
32774385|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
32774386|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
32774387|NCT04924309||Patients undergoing assisted reproductive technology with donor sperm|
32774388|NCT04924309||Patients undergoing assisted reproductive technology with husband's semen due to male factor|
32774389|NCT04915573||patients with Cirrhosis|Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease
32774390|NCT04912375|Experimental|Low EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
32774391|NCT04912375|No Intervention|Low EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a similar puzzle task but the statements they searched are neutral.
32774392|NCT04912375|Experimental|High EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
32774393|NCT04912375|No Intervention|High EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a similar puzzle task but the statements they searched are neutral.
32774394|NCT04923685||MDD with elevated CM and suicidality scores|Major Depressive Disorder with elevator childhood maltreatment and suicidality scores.
32774395|NCT04923685||MDD with CM history but lower suicidality|Major Depressive disorder with childhood maltreatment history but lower suicidality scores.
32774396|NCT04923685||MDD without CM but with elevated suicidality|Major Depressive Disorder without childhood maltreatment, but with elevated suicidality scores.
32774397|NCT04923685||MDD without CM but with lower suicidality|Major Depressive Disorder without childhood maltreatment but with lower suicidality scores.
32774398|NCT04923685||Healthy controls with CM history|Healthy controls with childhood maltreatment history,
32774399|NCT04923685||Healthy controls without CM history|Healthy controls without childhood maltreatment history.
32774400|NCT04912219|Experimental|Treatment|
32774401|NCT04912219|No Intervention|Control|
32774402|NCT04915339|Experimental|Group 1: physical activity then cognitive training|Using an online-computerized application, physical activities will be prescribed for one month. After a 15 days break, cognitive training activities will be prescribed the same way. A feedback by the patient will be asked fallowing each activity to control the observance.
33273968|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
33273969|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
33273970|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
33273971|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
33273972|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
32774403|NCT04915339|Experimental|Group 2: Cognitive training then physical activity|Contrary to the first group, the second one starts with cognitive training intervention then engages in physical activity in same way as the first group. A feedback by the patient will also be asked fallowing each activity to control the observance
32774404|NCT04915339|Experimental|Group 3 : resonance frequency breathing then combined physical activity and cognitive training|The third group takes part in a 1 month breathing exercise program. After a 15 days break (as the groups 1 and 2), a combined physical activity and cognitive training program is administrated for 1 month. As the others arms, a feedback by the patient will be asked fallowing each activity to control the observance
32774405|NCT04923373|Experimental|telerehabilitation|physiotherapeutic programme brochure exercises 7/week controlled by phone every week (5x in total)
32774406|NCT04923373|Active Comparator|standard physiotherapy|"Supervised physical therapy 3/ week,~+ physiotherapeutic programme brochure 4/week"
32774407|NCT04915417|Experimental|Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|10 Resectable PDAC patients will receive a hybrid PET/MRI before SABR and DCE-CT before SABR, 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
32774408|NCT04915417|Experimental|Borderline Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|20 Borderline Resectable PDAC patients will receive a DCE-CT scan prior to neoadjuvant chemotherapy, a PET/MRI and DCE-CT after neoadjuvant chemotherapy and before SABR, DCE-CT at 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
32774409|NCT04912297||PCV10 2+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 2+1 schedule (two vaccinations with minimum 8-week intervals followed by a booster dose at least 4 months after the last primary dose).
32774410|NCT04912297||PCV10 3+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 3+1 schedule (three vaccinations with minimum 4-week intervals, followed by a booster dose at least 4 months after the last primary dose).
32898413|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
32898414|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
33273973|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
32898415|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
33273974|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273975|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
33273976|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273977|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273978|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273979|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273980|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
33273981|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
32774411|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
32774412|NCT04923607|Experimental|TQC2731 injection(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 ."
32774413|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg)."
32774414|NCT04923607|Experimental|TQC2731 injection(SAD,iv.)|Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
32774415|NCT04923607|Placebo Comparator|Matching Placebo(SAD,iv.)|Healthy subjects received 210mg matching placebo intravenously (iv.) once.
32774416|NCT04923607|Experimental|TQC2731 injection(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .
32774417|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .
32774418|NCT04911985||ICU Patients with PAC|All patients admitted to the Medical ICU of the University Hospital Zürich, complying with the inclusion criteria and monitored by a pilmonary artery catheter
32774419|NCT04912141|Placebo Comparator|Conestat alfa 50 U/kg - Placebo|50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
32774420|NCT04912141|Active Comparator|Conestat alfa 50 U/kg - Conestat alfa 50 U/kg|50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
32774421|NCT04912141|Active Comparator|Conestat alfa 100 U/kg - Conestat alfa 50 U/kg|100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
33273982|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
32774422|NCT04912141|Placebo Comparator|Placebo - Placebo|Placebo pre-angiography and 3 hours after the first dose
33273983|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
33273984|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
33273985|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
32774423|NCT04915105|Experimental|Prescreen on psoriasis and psoriatic arthritis treatment|Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients.
32898416|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
33273986|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
33273987|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
33273988|NCT00972270|Experimental|IMPELLA LP 2.5|
33273989|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
33273990|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
33273991|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
33273992|NCT04307277|Other|Control arm|
33273993|NCT04307277|Experimental|Experimental arm|
33273994|NCT00961038|Experimental|Arm 1|
33273995|NCT00961038|Experimental|Arm 2|
33273996|NCT00961038|Placebo Comparator|Arm 3|
33273997|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
33273998|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
33273999|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
33274000|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
33274001|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
33274002|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
33274003|NCT02665923||Newborn (gastric emptying)|A total of 100 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
32774424|NCT04923451|Active Comparator|Patient with sexual addiction - active stimulation|25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days
32774425|NCT04923451|Sham Comparator|Patient with sexual addiction - sham stimulation (placebo)|25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days
32774426|NCT04922385|Experimental|CBT|Individual 4-week CBT protocol
33274004|NCT02665923||Infants (4-6mons)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
32774427|NCT04923061|Experimental|Acupressure group|The experimental group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
32774428|NCT04923061|Sham Comparator|Sham acupressure group|The sham group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
32774429|NCT04932759|No Intervention|control group|In the control group there will be no music listening
32774430|NCT04932759|Experimental|experimental group|In this group patients will listen to music while their dental treatments are being made.
32774431|NCT04911907|Experimental|Squamous cell carcinoma of head and neck: Utidelone Injection|Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy
32774432|NCT04911907|Experimental|Esophageal cancer: Utidelone injection|Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.
32774433|NCT04911907|Experimental|Stomach cancer: Utidelone injection|Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.
32774434|NCT04911907|Experimental|Pancreatic cancer: Utidelone Injection|Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
33274005|NCT02665923||Infants (9-12 months)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
32774435|NCT04911907|Experimental|Ovarian cancer: Utidelone Injection|Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
33274006|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
33274007|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
32774436|NCT04911907|Experimental|Cholangiocarcinoma: Utidelone|Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy
32774437|NCT04911907|Experimental|Other solid tumors: Utidelone Injection|Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy
33274008|NCT03929562|Active Comparator|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
33274009|NCT03929562|Experimental|Health coaching|Two health coaching sessions, resource brochure, standard of care
33274010|NCT05279586|Active Comparator|patients that will receive lactulose|Cirrhotic patients who were recovered from HE will be randomized into lactulose group receiving 30-60 ml of lactulose orally in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
32774438|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
32774439|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
32774440|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
32774441|NCT03056287|Sham Comparator|Sham|Sham rTMS
32774442|NCT04911829|Active Comparator|Inpatient treatment|High intensity high dosage inpatient short-term psychodynamic psychotherapy
32774443|NCT04911829|Experimental|Outpatient treatment|Low dosage outpatient short-term psychodynamic psychotherapy
32774444|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
33274011|NCT05279586|Active Comparator|patients that will receive colistin|colistin group receiving colistin sulfate 1.5 million I.U. tablet orally twice
33274012|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
32774445|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
32774446|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
33274013|NCT00415636|Experimental|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
33274014|NCT00415636|Experimental|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m^2 [4.5-hour infusion]), the LY2603618 40 mg/m^2 dose in Cohort 2 (LY2603618 40 mg/m^2 [1-hour infusion]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
33274015|NCT00415636|Experimental|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m^2), dose modifications were allowed. LY2603618 70 mg/m^2 was administered over the course of 1 hour.
33274016|NCT00415636|Experimental|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m^2 administered over the duration of 1 hour.
33274017|NCT00415636|Experimental|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m^2 administered over the duration of 1 hour.
33274018|NCT00415636|Experimental|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m^2 administered over the duration of 1 hour.
33274019|NCT00961272||HIV-infected, pre-menopausal women|
33274020|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
33274021|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
33274022|NCT00965874|Placebo Comparator|placebo|serum salin
33274023|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
33274024|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
33274025|NCT00972582|Experimental|Leucine|
33274026|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
33274027|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
33274028|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
33274029|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
33274030|NCT04008966|Active Comparator|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
33274031|NCT04008966|Active Comparator|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
33274032|NCT00425854|Experimental|BIBW 2992|high dose once daily
33274033|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
33274034|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
33274035|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
33274036|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
33274037|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
33274038|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
33274039|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
33274040|NCT00966030|Experimental|1|MK0974 Tablet
33274041|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
33274042|NCT01037530|Experimental|Ramipril|
33274043|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
33274044|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
33274045|NCT05238246|Sham Comparator|Standard treatment group|Dental treatment was carried out with tell-show-do technique as a behavioural guidance technique.
33274046|NCT05238246|Experimental|Robot group|The robot group (RG) were treated with the robot accompaniment
33274047|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
33274048|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
33274049|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
33274050|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
33274051|NCT00966108||Healthy subjects|
33274052|NCT00966108||Glaucoma patients|
33274053|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
33274054|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
33274055|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
33274056|NCT00966420|Experimental|mucosa resection|
33401864|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
33401865|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
33401866|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
33401867|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
33401868|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
32774447|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
32774448|NCT04914715|Experimental|Non-invasive High Frequency Oscillatory Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirefment more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option."
32898417|NCT00004984|Experimental|Parenteral Insulin|High risk participants randomized to intervention
32898418|NCT00004984|Active Comparator|Close Observation|High risk participants randomized to observation
32898419|NCT00004984|Experimental|Oral Insulin|Intermediate risk participants randomized to intervention
32898420|NCT00004984|Placebo Comparator|Placebo|Intermediate risk participants randomized to placebo
32898421|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
32898422|NCT01284517|Placebo Comparator|Placebo|
32898423|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
32898424|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
32898425|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
32898426|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
33081372|NCT04667728|Experimental|intervention group (IGr)|The IGr participants wore a professional continuous glucose monitoring (CGM) sensor (iPro™2) during the first six days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received a personalized diet plan from a dietitian. After three months, the IGr participants again wore the CGM sensor for one week. These participants also followed the regular institutional Comprehensive Diabetes Care program care plan.
33081373|NCT04667728|No Intervention|control group (CGr)|The control group followed the regular institutional Comprehensive Diabetes Care program care plan.
33081374|NCT04668040|Experimental|Muscle energy technique|Muscle energy technique applied in the lower cross syndrome muscle pattern.
33081375|NCT04668040|Active Comparator|Stretching|Stretching technique applied in the lower cross syndrome muscle pattern.
33081376|NCT04667611||Mild|
33081377|NCT04667611||Moderate|
33081378|NCT04667611||Severe|
33081379|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
33081380|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
33081381|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
33081382|NCT00556660|Experimental|1|SPECT imaging
33081383|NCT00556699|Experimental|1|
33081384|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
33081385|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
33081386|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
33081387|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
33081388|NCT04667455|No Intervention|Control subjects|Infants and Children with no evidence of congenital heart disease based on echocardiography and standard ECG assessment
33081389|NCT04667455|Active Comparator|Congenital heart disease subjects|Infants and Children with evidence of predefined congenital heart disease lesions based on echocardiography and standard ECG assessment
33081390|NCT04667182||Combined Diabetes Management Data|Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
33081391|NCT04667221|Experimental|Anodal transcranial direct current stimulation|Patients will be bilaterally stimulated with anodal tDCS at the parietal cortex (Broadman Area 7).
33081392|NCT04667221|Experimental|Cathodal transcranial direct current stimulation|Patients will be bilaterally stimulated with cathodal tDCS at the parietal cortex (Broadman Area 7).
33081393|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for anodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
33081394|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for cathodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
33081395|NCT04667299|Experimental|BMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days
33274057|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
33274058|NCT00973986|Active Comparator|CYP3A4*1/*1|
33274059|NCT00973986|Active Comparator|CYP3A4*1/*1G|
33274060|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
33274061|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
33274062|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
32774449|NCT04914715|Active Comparator|Conventional Invasive Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirement more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to invasive ventilation through endotracheal tube, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40."
33274063|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
32774450|NCT04914871|Experimental|The experimental protocol UN Lifeguard Kids in the Tunja version|Group to which the experimental protocol will be offered.
32774451|NCT04914871|Placebo Comparator|Educational session, accident prevention and wound management.|The control group will be offered the Educational session.
32774452|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
32774453|NCT04914481||Classical Low-Flow, Low-Gradient Aortic Stenosis|Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction <50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
32774454|NCT04914481||Paradoxical Low-Flow, Low-Gradient Aortic Stenosis|Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
32774455|NCT04914481||High-Gradient Aortic Stenosis (Control group)|High-Gradient Aortic Stenosis is defined as valve area <1 cm2 and mean gradient >40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
32774456|NCT04914481||Conservative treatment (Control group)|The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.
32774457|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
32774458|NCT03056131|No Intervention|Control Group|
32774459|NCT03056209|Experimental|KL1333 25mg|Group 1
32774460|NCT03056209|Experimental|KL1333 50mg|Group 2
32774461|NCT03056209|Experimental|KL1333 100mg|Group 3
32774462|NCT03056209|Experimental|KL1333 200mg|Group 4
32774463|NCT03056209|Experimental|KL1333 400mg|Group 5
32774464|NCT03056209|Experimental|KL1333 600mg|Group 6
32774465|NCT03056209|Experimental|KL1333 800mg|Group 7
32774466|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
32774467|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
32774468|NCT04914325|Experimental|Intervention arm :copings veneered with CAD/CAM composite resin|
32774469|NCT04914325|Active Comparator|Control arm : copings veneered with manual layering|
32774470|NCT04943211|Other|R1|
32774471|NCT04922905|Other|NEURO +|"Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations"
32774472|NCT04922905|Other|NEURO -|"Patients neuro - are those with a CASE score < 2"
32774473|NCT04914559|Active Comparator|Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
33401869|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
33401870|NCT02390596|Experimental|Anakinra|
33401871|NCT04438382|Experimental|Arm A (infliximab)|Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
33401872|NCT04438382|Experimental|Arm B (intravenous immunoglobulin therapy)|Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
33401873|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
33401874|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
33401875|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
33401876|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
33081396|NCT04667299|Active Comparator|BMQ group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days
33081397|NCT04720794|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
33081398|NCT04666792|Other|PrEP for HIV-1 uninfected for women accessing family planning|Women accessing family planning will be assessed for HIV risk and PrEP eligibility. If eligible and willing to initiate PrEP, they will be provided PrEP in accordance with national guidelines as part of their standard of care at the family planning clinic.
33081399|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR|
33081400|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR|
33081401|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR|
33081402|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR|
33081403|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR|
33081404|NCT04666870||axis length|1007 healthy students with moderate to high myopia (SE ≤ -4.00D) and 894 without myopia (-0.50D ≤ spherical power ≤ +2.00D) were enrolled.
33081405|NCT04666870||gender|male were 54.29% (N=1032), and female were 45.71% (N=869)
33081406|NCT04666753||ImmunoFormulation cohort|"Patients treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
33081407|NCT04666753||Control cohort|"Control cohort: patients not treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
33081408|NCT00240825|Experimental|001|Acetaminophen
33081409|NCT00240825|Experimental|002|Ibuprofen
33081410|NCT00240825|Placebo Comparator|003|Placebo
33081411|NCT04666597||Modified CariesCare International management intervention group|
33081412|NCT04666675|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A once daily (QD).
33081413|NCT04666675|Experimental|Upadacitinib Dose B|Participants will receive Upadacitinib Dose B QD.
33081414|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose A|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.
33081415|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose B|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.
33081416|NCT04666480|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
33081417|NCT04666363|Experimental|Lavender oil|On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
33081418|NCT04666363|No Intervention|Control group|The patients will not smell lavender oil.
33081419|NCT00240864|Experimental|001|acetaminophen
33081420|NCT00240864|Experimental|002|ibuprofen
33081421|NCT00240864|Placebo Comparator|003|placebo
33081422|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
33081423|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
33081424|NCT00556855|Experimental|A|applied on one hand
33081425|NCT00556855|Placebo Comparator|B|applied on the other hand
33081426|NCT00557011|Experimental|1|NRP104
33081427|NCT00557011|Active Comparator|2|Adderall XR
33081428|NCT00557011|Placebo Comparator|3|Placebo
33081429|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
33081430|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
33081431|NCT04666324|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
33274064|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
33274065|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
33274066|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
33274067|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
32774474|NCT04914559|Active Comparator|Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
32774475|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
33274068|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
33274069|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
32774476|NCT04911205|Experimental|Intervention Group|Patients who were randomly allocated to intervention group (N=44) completed a 6-week preoperative training program, 5 days per week prior to surgery
32774477|NCT04911205|No Intervention|Control Group|Patients who were randomly allocated to control group (N=44), they continued to live as usual, prior to surgery
32898427|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
32898428|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
32898429|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
32898430|NCT01285843|Active Comparator|Quadra Group|
33274070|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
32898431|NCT01285843|Active Comparator|AMIStem Group|
32898432|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
33274071|NCT04008888|Experimental|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
33274072|NCT04008888|Experimental|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
33274073|NCT04008888|Experimental|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
33274074|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
33274075|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
33274076|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
33274077|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
33274078|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
33274079|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
33274080|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
33274081|NCT00979680|Active Comparator|High-dose Radiotherapy|
33274082|NCT00979680|Active Comparator|Chemo-radiotherapy|
33274083|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
33274084|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
33274085|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
33274086|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
33274087|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
33274088|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
33274089|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
33401877|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
33401878|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
33401879|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
32774478|NCT04922307|Experimental|Blood Sparing Protocol|The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (>1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.
32898433|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
32898434|NCT01264705|Experimental|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
32898435|NCT01264705|Experimental|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
32898436|NCT01264705|Experimental|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
33081432|NCT04666324|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
33081433|NCT04720833|Experimental|dried plum (100 g dried plum)|Participants will receive 100 g dried plum daily plus 500 mg calcium and 300 IU vitamin D daily
33081434|NCT04720833|Placebo Comparator|Calcium and vitamin D|Participants will receive 500 mg calcium and 300 IU vitamin D daily
33081435|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
33081436|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
33081437|NCT04666168|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
33081438|NCT04666090|Experimental|Carillizumab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
33081439|NCT04665895|Experimental|Test Product|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
33081440|NCT04665895|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
33081441|NCT04665895|Placebo Comparator|Placebo|Placebo
33081442|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
33081443|NCT04665661|Experimental|High-intensity aerobic training (HIAT)|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
33081444|NCT04665661|Active Comparator|Wait-list control (WLC)|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
33081445|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
33081446|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
33081447|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
33081448|NCT04665505|Experimental|ICU Staff|The study group is composed of ICU care providers at the Ottawa Hospital Civic campus and the Montfort Hospital, including intensivists, fellows, nurses and allied health professionals. The study site participant breakdown is approximately 58 TOH staff respondents and 15 Montfort respondents.
33081449|NCT04665778||high risk of hospitalization|
33081450|NCT04665778||not high risk of hospitalization|
33081451|NCT04665466||Group A|QFR≤0.80 vessels with PCI strategy and low PPG index
33081452|NCT04665466||Group B|QFR≤0.80 vessels with PCI strategy and high PPG index
33081453|NCT04665466||Group C|QFR≤0.80 vessels with conservative strategy
33274090|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
33274091|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
33274092|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
33274093|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
33274094|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
33274095|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
33274096|NCT01672060|Active Comparator|Existing services|
33274097|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
33274098|NCT00979836|Experimental|Calcium Dobesilate|
32774479|NCT04922307|Active Comparator|Standard Blood Replacement|The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.
32774480|NCT04910971||Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine|
32774481|NCT04910971||Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine|
32774482|NCT04911283||MCs type 1 patients (study group; n=37)|
32774483|NCT04911283||MCs type 2 patients (comparator group; n=44)|
32774484|NCT04911283||healthy controls (n=37)|
32774485|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
32774486|NCT04922359|Experimental|Experimental: Lidocaine group|
32774487|NCT04922359|Placebo Comparator|Placebo Comparator: comparator group|
32774488|NCT02495883|Other|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
32774489|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers will receive no interventions.
32774490|NCT04910893|Experimental|Cytokine Adsorption Arm|Intervention with CytoSorb
32774491|NCT04910893|Other|Historical Comparison|Patients extracted from a septic shock population treated at the same institution between 2010 and 2018 and matched to the intervention group.
32898437|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
32898438|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
33274099|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
33274100|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
33274101|NCT01588912|Active Comparator|Entecavir|
33274102|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
33274103|NCT01589068|Active Comparator|Male Smokers|
33274104|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
33274105|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
33274106|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
32898439|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
32898440|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
33274107|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
33274108|NCT04008498|Experimental|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
33274109|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33274110|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33274111|NCT00966966|Experimental|1|SAM-531_gemfibrozil
33274112|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
33274113|NCT00979914|No Intervention|Control|Patients randomized to control group
33274114|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
33274115|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
33274116|NCT00980070|Experimental|Positioning Device|use of positioning device
33274117|NCT00980070|Active Comparator|Control|institutional standard of care
33081454|NCT04665544|Experimental|Early-stage endometrial cancer patients|"Histologically proven endometrial cancer (any tumour type).~Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.~Performance status ECOG: 0-1.~Age ≥18, ≤85.~History of second primary cancer only if more than 5 years with no evidence of disease.~Approved and signed informed consent"
33081455|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
33081456|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
33081457|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
33081458|NCT04665427|Other|Patient in whom a bilioenteric anastomosis is performed for any etiology.|Patient in whom a bilioenteric anastomosis is performed for any etiology..
33081459|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
33081460|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
33081461|NCT04665349|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
33081462|NCT04665349|No Intervention|Control|No intervention
33081463|NCT04665232||Patients affected by autoimmune diseases|Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone
33081464|NCT04665076|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
33081465|NCT04665193|Experimental|Abbott Panbio test device|WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device
33081466|NCT00241020|Experimental|Octreotide|
33081467|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
33081468|NCT04665310|Active Comparator|Group 1 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
33081469|NCT04665310|Active Comparator|Group 1 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
33081470|NCT04665310|Active Comparator|Group 1 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
33081471|NCT04665310|Active Comparator|Group 2 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
33081472|NCT04665310|Active Comparator|Group 2 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
33401880|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
33274118|NCT00432172|Active Comparator|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
33274119|NCT00432172|Experimental|Group 1 (Luminal A) Selective treatment|"Selective treatment:~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
33274120|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
32774492|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
32774493|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
32774494|NCT04910659|Active Comparator|acupuncture|Group1, laser acupuncture was applied to each of the previously described P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds
32774495|NCT04910659|Sham Comparator|false acupuncture|P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds while laser acupuncture closed
32774496|NCT04910347|Experimental|Single Arm|Nivolumab
32774497|NCT04914169||Indoor cycling training|8 subjects were asked to complete indoor cycling training, 3 times a week for 4 weeks. Each session of training consisted of 30-minute stationary biking (5 minutes of warm-up, 20 minutes of training and 5 minutes of cooldown).
32774498|NCT02439957|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
32774499|NCT02439957|Active Comparator|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
32774500|NCT04913857|Experimental|24-week SUDOKU Training Programme|"The SUDOKU training program include a 12-week face-to-face training session and a 12-week facilitated self-practice. The 12-week (60-minute sessions) training program will be evenly divided into 3 modules of increasing difficulty for the suboptimal cognitive function of the participants with MCI. As the use of T-code in solving the SUDOKU allows communicating the way a number is assigned to a box, participants are grouped into a small team of 3, so that they will work together during the tutorial practice.~Facilitated self-practice will last for another 12 weeks immediately after the group training session. The instructor will give them a workbook with 12 SUDOKU puzzles of increasing level of difficulty for completion. The instructor will encourage and facilitate their accomplishment by giving them guidance on the taught method through regular phone call. Solutions of the assigned puzzle and the T-code will be provided in the following week."
32774501|NCT04913857|Active Comparator|wait-list|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
32774502|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
32774503|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
32774504|NCT03054415|Other|Healthy Subjects|
32774505|NCT04922437||Enterocystoplasty (EC)|Patients who had an implantation of the catheterizable continent channel by seromuscular plicature on the anterior wall of the bladder augmentation.
32774506|NCT04922437||Detrusor (D)|Patients who had an implantation of the catheterizable continent channel in the detruosr of their native bladder (Lich-Gregoir or Cohen).
32774507|NCT04913545||normal group|participants with out any systemic medical problemes or oral lesions. we will only take saliva sample.
32774508|NCT04913545||potientially malignant group|participants with suspicious oral lesions without any medical diseases. we will take saliva sample and take a biopsy sample .
32774509|NCT04913545||malignant group|participants with already diagnosed oral malignant lesions without receiving any treatment yett
32774510|NCT04913935||TMC OA|women who were diagnosed with TMC OA
32774511|NCT04913935||Control|healty volunteer women
32898441|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
32898442|NCT00016718|Experimental|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
32898443|NCT00016718|Experimental|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
33274121|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
33274122|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
33274123|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
33274124|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
33274125|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
33274126|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
33274127|NCT00415168|Experimental|Pemetrexed + Cisplatin|
33274128|NCT03921528|Experimental|Cohort 1|Ambulatory Type 3 SMA
33274129|NCT03921528|Experimental|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
33081473|NCT04665310|Active Comparator|Group 2 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
33081474|NCT04664920||Intervention|Exergame intervention arm.
33081475|NCT00241059|Experimental|EC-MPS arm|
33081476|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
33081477|NCT04664803|Experimental|Cefecin Tab.|Cefecin Tab./Placebo to Omnicef Cap.
33081478|NCT04664803|Active Comparator|Omnicef Cap.|Omnicef Cap./Placebo to Cefecin Tab.
33081479|NCT04664725|Experimental|SHR3680+ Repaglinide, Bupropion|"Experimental: Repaglinide, Bupropion and SHR3680~Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26"
33081480|NCT04664764|Active Comparator|degludec arm|Group A received insulin degludec,
33081481|NCT04664764|Active Comparator|glargine arm|group B received insulin glargine
33081482|NCT04664764|Active Comparator|NPH group|Group C received NPH insulin
33081483|NCT00244803||HIV Positive FRAM 1 Participant|
33081484|NCT04664686|Active Comparator|AF catheter ablation|
33081485|NCT04664686|Active Comparator|AV node ablation|
33081486|NCT04664374||Mood Disorder|Based on screening questions administered on-line as part of the enrollment process, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.
33081487|NCT04664374||Other|see above
33081488|NCT04664647||Patients with CCPD|"Inclusion criteria：~Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.~Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.~Exclusion criterion:~Secondary demyelinating diseases or changes."
33081489|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
33081490|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
33081491|NCT04664296||Children|Hospitalized children, 0 to 17 years of age, 25 subjects, consecutive sample survey
33081492|NCT04664296||Adults|Hospitalized adults, 18 years and above, 50 matched subjects
33081493|NCT04664842|Experimental|Manual Therapy Group|
33081494|NCT04664842|Sham Comparator|Manual Control Group|
33081495|NCT04664842|Experimental|Breathing Training Group|
33081496|NCT04664842|Sham Comparator|General Exercise Control Group|
33081497|NCT04664842|Experimental|Manual Therapy Combined Breathing Training Group|
33081498|NCT04664491|Experimental|Standardized management|Patients will be managed according to recommendations in GOLD guideline and China's guidelines for COPD care.
33081499|NCT04664491|Other|Usual care|Patients will undergo usual care according to current clinical practice in study sites.
33081500|NCT04664530|Placebo Comparator|Control group|
33081501|NCT04664530|Experimental|Treatment group|
33081502|NCT04664218|Experimental|patients with Peritoneal carcinomatosis|Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy.
33081503|NCT04663906||Isotretinoin|Test population, prescribed oral isotretinoin between March and October 2020.
33081504|NCT04663906||Control|Background age-matched population, not prescribed oral isotretinoin during March to October 2020
33081505|NCT04663789|Experimental|Staple line plus reinforcement|In this experimental group, a lock stitch will be placed after transecting the pancreas with stapler.
33081506|NCT04663789|Other|staple line with no reinforcement|In this control group, no additional reinforcement is used after transecting the pancreas with stapler.
33081507|NCT04663360|Experimental|Intervention|Intervention to be administered: Adverse Drug Reactions (ADRe) Profile. asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
33081508|NCT04663360|No Intervention|Control|Usual clinical care.
33081509|NCT04663477||Trained nurse-completed CRS|
33081510|NCT04663477||Patient-completed CRS|
33081511|NCT04663438||Arm A|200/Atezolizumab combined with EC regimen Atezolizumab:1200 mg Q3w
33081512|NCT04663438||Arm B|100/Atezolizumab combined with chemotherapy Atezolizumab:1200mg Q3w
33081513|NCT04663516|Experimental|experimental|exercise through video game (Wii)
33081514|NCT04663516|No Intervention|control|children in this group will be given advice about the importance of exercising
33081515|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
33081516|NCT04663672|Experimental|Exposure Therapy + Exposure Scent Cue During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
33274130|NCT03921528|Experimental|Cohort 3|Type 2 SMA
33274131|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
33274132|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
33274133|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
33274134|NCT00967122|No Intervention|No Arm|
33274135|NCT05140590||Participants with a diagnosis of hypertension admitted to the emergency department|"Direct questioning about general data, medical history and about the pharmacological scheme for the treatment of hypertension.~Review of clinical records to obtain data about the admission diagnosis, drugs administered during their hospital stay, and blood pressure figures at admission, during hospital stay and at discharge.~Analysis and classification of theoretical drug interactions using the IBM Micromedex Drug Interactions and iDoctus clinical decision support systems."
33274136|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
33274137|NCT00974610||Breast|
33274138|NCT00974610||Lung|
33274139|NCT00974610||Melanoma|
33274140|NCT00974610||Pancreatic|
33274141|NCT00974610||Colorectal|
33274142|NCT00974688|Active Comparator|Group 1|
33274143|NCT00974688|Active Comparator|Group 2|
33274144|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
33274145|NCT00967356|Experimental|A|AZD5985
33274146|NCT00967356|Placebo Comparator|B|Placebo
33274147|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
33274148|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
33274149|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
33274150|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
33274151|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
33274152|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
33274153|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
33274154|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
33274155|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
33274156|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
33274157|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
33274158|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
33274159|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
33274160|NCT04082910|Experimental|Conditional therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was initially given from the day of CRS diagnosis confirmation post CAR T cell infusions till CRS remission in patients without bulky tumor burden. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
33274161|NCT04082910|Experimental|Prophylactic therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was given starting from the day before CAR T infusion till CRS remission in patients with bulky disease. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
33274162|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
33274163|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
33274164|NCT00967590|Experimental|1|
33274165|NCT00967590|Placebo Comparator|2|
33274166|NCT00975078|Experimental|adrenal insufficiency|
33274167|NCT00984516|Experimental|Intradermal Juvidex|
33274168|NCT00984516|Placebo Comparator|Placebo (vehicle)|
33274169|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
33274170|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
33274171|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
33274172|NCT00980616|No Intervention|No infiltration|B: no infiltration
33274173|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
33274174|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
33274175|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
33274176|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
33274177|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
33274178|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
33274179|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
33274180|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
33274181|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
33274182|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
33274183|NCT00984750|Placebo Comparator|2|Statin and placebo
33274184|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
33274185|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
33274186|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
33274187|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
33274188|NCT00984906|Other|Empty Easyhaler type A|
33274189|NCT00984906|Other|Empty Easyhaler type B|
33274190|NCT00984906|Other|Empty Turbohaler|
33274191|NCT04974996|Experimental|Part 1: Dose Escalation|Participants will receive escalating doses of loncastuximab tesirine (initial dose of 60 μg/kg and highest dose possibly tested of 150 µg/kg) in combination with R-CHOP (rituximab 375 mg/m^2, cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, and prednisone 100 mg/day) according to a standard 3+3 dose escalation design. The dose escalation part will be completed once the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) has been identified.
33274192|NCT04974996|Experimental|Part 2: Dose Expansion|Participants will receive the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as determined in Part 1.
33274193|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
33274194|NCT00975390|Experimental|1|Carbohydrate ingestion
33274195|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
33274196|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
33274197|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
33274198|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
33274199|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
33274200|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
33274201|NCT00984984|Experimental|methylprednisolone PO|
33274202|NCT00984984|Active Comparator|methylprednisolone IV|
33274203|NCT04818138|Active Comparator|Narrowband UVB|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
33274204|NCT04818138|Active Comparator|Broadband UVB|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
33274208|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
33274209|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
33274210|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
33274211|NCT05115786||Cohort A|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
33274212|NCT05115786||Cohort B|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
33274213|NCT05115786||Cohort C|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
33274214|NCT05115786||Cohort D|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
33274215|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
33274216|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
33274217|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
33274218|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
33274219|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
33274220|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
33274221|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
33274222|NCT04006860|Experimental|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
33274223|NCT04006860|Experimental|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
33401881|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
33401882|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
33401883|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
32898444|NCT00016718|Experimental|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
32898445|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
33081517|NCT04663672|Placebo Comparator|Exposure Therapy + Novel Scent During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
33081518|NCT04663672|Sham Comparator|Exposure Therapy + No-Scent Control During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
33081519|NCT04663048|Experimental|Protocol A|PiXL treatment with pulsed UV illumination (1.0 sec on /0.8 sec off) in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 10 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
33081520|NCT04663048|Active Comparator|Protocol B|PiXL treatment with pulsed (0.5 sec on / 1 sec off) UV illumination in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 16:40 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
33081521|NCT04663009||Mechanical chest compression|Patients recieving LDB CPR
33081522|NCT04663009||Manual chest compressions|Patients recieving manual CPR
33081523|NCT04663165|Other|Flap surgery alone|Access flap
33081524|NCT04663165|Other|Flap surgery with adjunctive EMD|Access flap and adjunctive enamel matrix derivative
33081525|NCT04663243|Experimental|Quasi experimental study|Before intervention and after intervention comparison
33081526|NCT00241254|Experimental|1|Cyclophosphamide
33081527|NCT00241254|Active Comparator|2|Methylprednisolone
33081528|NCT04662775|Experimental|Intervention group|This group received the multi-component physical activity intervention (physical activity programme, weekly behaviour change support calls, non-reply text messages)
33081529|NCT04662775|No Intervention|Waitlist control|Participants in the wait-list control group were asked to continue their usual PA habits and received no additional contact from the research team outside of data collection points. Following post-intervention data collection, control group participants were invited to participate in the same intervention as described above.
33081530|NCT04662814|Experimental|shock wave|shock wave for primary dysmenorrhea for study group along side to dietary modification
33081531|NCT04662814|Active Comparator|dietary modification|dietary modification for primary dysmenorrhea for control group
33081532|NCT04662736||patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|
33081533|NCT04662853||Patients with positive results in the fecal occult blood test.|Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
33081534|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
33081535|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
33081536|NCT04662541|Experimental|Mobile Integrated Health (MIH)|Patients with urgent medical needs are seen and treated in the home by trained community paramedics. The community paramedics perform a standardized assessment, including a physical examination, vital signs, home safety evaluation, and medication reconciliation. During the MIH encounter, the emergency medicine physician at each site is contacted via telemedicine. Physicians can access clinical notes, discharge summaries, and medication lists via the institutional EHR. Adjustments to outpatient medications can be e-prescribed and follow-up appointments can be scheduled with primary care clinicians.
33081537|NCT04662541|Active Comparator|Transitions of care coordinator (TOCC)|Patients receive a follow-up phone calls for a nurse coordinator within 48-72 hours of hospital discharge. Phone calls include clinical/social needs assessment with escalation to primary care team, emergency care, or social work as needed; patient education; and reminder about follow-up appointments.
33081538|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
33081539|NCT04662658|Other|Visit 1 UVA|"Visit 1 will last approximately 4 hours, and will include consenting, collection of data, questionnaires, and procedures as follows:~Informed consent~Demographic data~Smoking history~Medical history review~Medication review~Limited physical exam~6-minute walk test~St. George's Respiratory Questionnaire (SGRQ)~Baseline dyspnea index (BDI)~Chronic respiratory questionnaire (CRQ)~PFTs including:~Pre-bronchodilator spirometry/ post bronchodilator spirometry.~Body plethysmography (static lung volumes)~Carbon monoxide diffusion capacity (DLCO)~Collection of peripheral blood (20mL), exhaled breath condensate (EBC), and urine~Hyperpolarized xenon-129 MRI (HXeMRI) if all eligibility criteria are met"
33401884|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
33401885|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
32898446|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
33081540|NCT04662658|Other|Visit 2 Duke University|"Visit 2 will last about 3 hours, and will occur within 2-12 weeks of Visit 1. The purpose of this study visit is to obtain a measure of basic test-retest variability on 6 e-cigarette users and 6 control subjects. Participants will be selected based on age and sex matching needs at the time of enrollment.~During Visit 2, changes in health since Visit 1 will be assessed. In addition, the following will be done in accordance with the parent protocol:~The standard MR compatibility screening form will be completed.~Spirometry will be performed before and after MR imaging.~A limited physical exam~Female subjects who could be pregnant will take a urine pregnancy test prior to imaging.~Xenon MRI will be performed~In addition to the above, the following will be completed:~Carbon monoxide diffusion capacity (DLCO)~Peripheral blood (20mL) and urine"
33081541|NCT04662424|Experimental|MUSIC|music in labor
33081542|NCT04662424|No Intervention|control|no music during labor
33081543|NCT04662346|Other|patients undergoing robotic pancreatoduodenectomy|patients have pancreatic neoplasm and undergoing robotic pancreatoduodenectomy
33081544|NCT04662385|Experimental|aloe vera toothpaste group|a recently available aloe vera toothpaste for gingival care, offers a completely improved approach for treatment of gingivitis. aloe vera toothpaste was certified as an antibacterial .This innovative toothgel is made using stabilized aloe vera gel from Forever's own plantations and can help you fight plaque as part of a regular brushing routine.
33081545|NCT04662385|Active Comparator|colegate total toothpaste group|Active Ingredient: Stannous fluoride 0.454% (0.15% w/v fluoride ion) Purposes: Anticavity, Antigingivitis, Antisensitivity. Inactive ingredients: Zinc phosphate, Water, Sorbitol, Hydrated silica, Glycerin, PEG-12, Tetras
33081546|NCT04662229|Experimental|Experimental: 10 hz stimulatión|Eco-guided percutaneous electrical stimulation application of low frequency electrical current at 10 hz, 240 microsecond, over the median and ulnar nerve in the arm, for 1 minute on each nerve. The intensity of the current will reach the excitomotor threshold, causing visible but comfortable contractions.
33081547|NCT04662229|Sham Comparator|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and a sound will be applied.
33081548|NCT00557206|Experimental|1|This is a single arm trial.
33081549|NCT04661917|Experimental|BAY2327949|Participants will receive 60 mg of BAY2327949 (2 tablets of 30 mg) once daily for 28 days.
33081550|NCT04661917|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 28 days.
33081551|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
33081552|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
33081553|NCT04661800|Other|Test de bâton de Sniff|Cohorte
33081554|NCT04661644|Experimental|Test Group 1 (Low Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.
33081555|NCT04661644|Experimental|Test Group 2 (High Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia.
33081556|NCT04661527|Experimental|Sarilumab arm|
33081557|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
33081558|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
33081559|NCT04661488||Children and adolescence|
33081560|NCT00216983||1|"Fasting condition to measure:~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
33081561|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
33081562|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
33081563|NCT04661449|Experimental|Lifestyle Intervention|every 3 months within 1 year.
33081564|NCT04661449|No Intervention|control group|Regular follow-up every 6 months within 1 year.
33274224|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
33274225|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
33274226|NCT04007718|Experimental|Active|
32898447|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
33274227|NCT04007718|Sham Comparator|Control|
33274228|NCT03920670|Experimental|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
33274229|NCT03920670|Active Comparator|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
33274230|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
33274231|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
33274232|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
33274233|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
33274234|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
33274235|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
33274236|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
33274237|NCT05077722|Experimental|AI Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.
33274238|NCT05077722|Sham Comparator|Sham Biometric - Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.
32898448|NCT04613414|Experimental|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
32898449|NCT04613414|No Intervention|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
33274239|NCT04007484|Experimental|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
33274240|NCT04007484|No Intervention|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
33274241|NCT04928352|Experimental|Group B1|Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
33274242|NCT04928352|Experimental|Group B2|Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
33274243|NCT04928352|Placebo Comparator|Group C|Same volume of nebulized saline placebo
33274244|NCT00981864|Experimental|Concurrent Boost RT|
33274245|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
33274246|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
33274247|NCT00985296||Ragweed + Dust Mite - CAC|
33274248|NCT00985374|Experimental|1|
33274249|NCT05072730|Experimental|Super high-pressure balloon (OPN NC)|Patients will be treated with a Super High Pressure percutaneous transluminal coronary angioplasty (PTCA) Balloon (OPN NC).
33274250|NCT05072730|Experimental|Intravascular lithotripsy (IVL)|Patients will be treated with intravascular lithotripsy (IVL).
33274251|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
33274252|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
33274253|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
33274254|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
33274255|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
33274256|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
33274257|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
33274258|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
33274259|NCT04006782|Other|Narrow dental implants in multiple fixed prosthesis|
33274260|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
33274261|NCT04006470||Positive control dentifrice|Twice daily use
33274262|NCT04006470||Negative control dentifrice|Twice daily use
33274263|NCT01323712|Placebo Comparator|Placebo|
33274264|NCT04911036||Mothers and/or fathers with an antenatal diagnosis|
33274265|NCT04911036||Mothers and/or fathers with a postnatal diagnosis|
33274266|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
33274267|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
33274268|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
32743225|NCT04936503|Experimental|High-level athletes|"High level athletes are rugby players, intervention unit agents of the National Police, sports students.~Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.~The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects."
33274269|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
33274270|NCT03927144|Experimental|AMG334 70 mg/140 mg|"Participants were randomized to receive 70 mg or 140 mg of AMG334 as a subcutaneous injection once per month for 52 weeks in the Core Phase.~Participants were permitted to switch to an approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
33274271|NCT03927144|Active Comparator|Oral Prophylactic|"Participants were randomized to receive a standard of care (SOC) locally approved oral prophylactic migraine medication once per day for 52 weeks in the Core Phase, as prescribed per local country labels.~Participants were permitted to switch to a different approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
33274272|NCT00976170|Experimental|1|
33274273|NCT00982176||1|
33274274|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
33274275|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
33274276|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
33274277|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
33274278|NCT00985764||placental previa|
33274279|NCT00976326|Experimental|A: Healthy volunteers|
33274280|NCT00976326|Experimental|B: Subjects with mild liver impairment|
33274281|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
33274282|NCT00976326|Experimental|D: Subjects with severe liver impairment|
33274283|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
33274284|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
33274285|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
33274286|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
33274287|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
33274288|NCT04007328|Experimental|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
33274289|NCT04007328|Placebo Comparator|Placebo|normal saline IV Q12H for 5 days
33274290|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
33274291|NCT04007172|Experimental|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
33274292|NCT04007172|Experimental|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
33274293|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
33274294|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
32743226|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
33274295|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
33274296|NCT04780230|Experimental|real tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
33274297|NCT04780230|Sham Comparator|sham tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
33274298|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
32743227|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
32743228|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
32743229|NCT03243617|Placebo Comparator|Placebo|Placebo
32743230|NCT04932525|Experimental|solid tumor or hematological malignancy|
32743231|NCT04936659|Experimental|Treatment group|
32743232|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
32743233|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
32743234|NCT04957797|Other|ROT-Group|reamed with round tunnel
33081565|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
33274299|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
33274300|NCT00985998|Experimental|Nimotuzumab|
33274301|NCT04008186|Experimental|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
33274302|NCT04008186|Experimental|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
33274303|NCT04008186|Experimental|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
32743235|NCT04957797|Experimental|FLT-Group|reamed with flat tunnel
32743236|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
32743237|NCT04936347|Experimental|Cold knife|The interference of the experimental group is to perform intrauterine adhesiolysis with scissors
33081566|NCT04661098|Experimental|Postpubertal patients with imperforate hymen|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
33274304|NCT04008186|Experimental|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
33274305|NCT00982566|Experimental|Sequence I|
33274306|NCT00982566|Experimental|Sequence II|
33274307|NCT00982566|Experimental|Sequence III|
33274308|NCT00982566|Experimental|Sequence IV|
33274309|NCT00982566|Experimental|Sequence V|
33274310|NCT00982566|Experimental|Sequence VI|
33274311|NCT00982566|Experimental|Sequence VII|
33274312|NCT00982566|Experimental|Sequence VIII|
33274313|NCT00982566|Experimental|Sequence IX|
33274314|NCT00982566|Experimental|Sequence X|
33274315|NCT00982566|Experimental|Sequence XI|
33274316|NCT00982566|Experimental|Sequence XII|
33274317|NCT00982566|Experimental|Sequence XIII|
33274318|NCT00982566|Experimental|Sequence XIV|
33274319|NCT00982566|Experimental|Sequence XVI|
33274320|NCT00982566|Experimental|Sequence XV|
33274321|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
33274322|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
33274323|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
33274324|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
33274325|NCT04006938|Experimental|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
33274326|NCT04006938|Experimental|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
33274327|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
33274328|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
33277576|NCT05352074|Experimental|subtotal colectomy with cecal-rectal anastomosis|After a complete mobilization of the colon, a resection 2-3cm distal to the ileocecal junction and at the upper part of the rectal ampulla are conducted; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
32743238|NCT04936347|Other|Hot knife|The interference of the control group is to perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.
32743239|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
32743240|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
32743241|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
32743242|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
32743243|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
32743244|NCT04957563|Experimental|experimental rehabilitation|recived olfactory rehabilitation
32743245|NCT04957563|No Intervention|control|withouth olfactory rehabilitation
32743246|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
32743247|NCT04957407||non-atrophic gastritis|OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)
32774512|NCT04910191|Experimental|Open Label|"Up to 200 patients will participate in this open study. Before each examination with the study device, data from each patient (Current medical condition, medical history and demographic data) will be inserted to a computer and added to the database of the study for further processing in conjunction with the study device results.~The study device electronic stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. At the end of each examination the data will be transferred to a computer and stored in the patient's file. Each patient will be requested to attend the examination once."
32774513|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
32774514|NCT04913779|Active Comparator|Anti-SARS-CoV-2|Administration of 10 ml of a concentrated equine hyperimmune serum solution with neutralizing activity of SARS-CoV-2 not less than1/5120, administered in slow intravenous infusion (10 ml diluted in100 ml of physiological solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
32774515|NCT04913779|Placebo Comparator|Placebo|Administration of 10 ml of a control-solution with no-neutralizing activity of SARS-CoV-2, administered in slow intravenous infusion (10ml diluted in 100 ml of physiological solution, administered over 50 to60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0when incorporated into the study -initial dose- and at 48 hours -second dose-).
32774516|NCT04904497|Experimental|Early Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
33277577|NCT00992888|Experimental|albumin liver dialysis|
33081568|NCT04661371|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
33081569|NCT04661371|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
33081570|NCT04661020|Experimental|Administration of CD19 CAR T-cells|
33081571|NCT04660630|Experimental|Precision group|The subjects were tested for gene, and the corresponding therapeutic drugs were selected according to the results of gene detection. Regular follow-up was conducted according to the study design to evaluate the efficacy and adverse reactions.
33081572|NCT04660630|Active Comparator|Experience group|The subjects were treated with drugs selected by doctors according to their experience. Follow up was performed at the same frequency as the precision group to evaluate the efficacy and adverse reactions.
33081573|NCT04660630|No Intervention|Observation group|The subjects did not accept any intervention, including follow-up, especially regular evaluation of efficacy and adverse reactions.
33081574|NCT04660786|Active Comparator|intralesional injection of triamcinolone acetonide|5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions
33081575|NCT04660786|Active Comparator|intralesional injection of vitamin D|(2.5 mg/mL) every 4 weeks for 3 sessions
33081576|NCT00217100|Active Comparator|Multi Vitamin Formulation|
33081577|NCT00217100|Placebo Comparator|Sugar pill|
33081578|NCT04660981|Experimental|İntervention Group|"The women in the intervention group were individually provided with Training Program on Fear of Childbirth Based on Motivational Interview Method once a week, four sessions in total."
33081579|NCT04660981|No Intervention|Control Group|No interventions were made for those in the control group other than routine hospital practices.
33081580|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
33081581|NCT00241410|Placebo Comparator|2|4 consecutive groups
33081582|NCT04660825|Experimental|High intensity resistance band exercise|Randomly assigned as exercise group, exercise intervention. This will be a progressive exercise programme with the aim being to participate three times per week, one in a group session and two in-home sessions.
33081583|NCT04660825|Experimental|Non resistance band exercise|Randomly assigned non-exercise group
33081584|NCT04660942||Control|Healthy child
33081585|NCT04660942||Experimental|Patients with developmental delay
33081586|NCT04660513||Morbid obesity|BMI 32.5 kg/m2 and above
33081587|NCT04660513||Non-obese healthy controls|BMI below 25 kg/m2
33081588|NCT04660591|Active Comparator|standard femoral stem|standard length femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
33081589|NCT04660591|Active Comparator|long femoral stem|long femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
33081590|NCT04660552|Experimental|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
33081591|NCT04660552|Placebo Comparator|Placebo condition|During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
33081592|NCT04660318|Experimental|Experimental: remote photoplethysmography for physiological parameters Monitor Readings|
33081593|NCT04660318|Other|Control: rstandard acquisition system for physiological parameters Monitor Readings|
33081594|NCT00241449|Active Comparator|1|Tamoxifen
33081595|NCT00241449|Experimental|2|Fulvestrant
33277578|NCT00992888|No Intervention|Standard medial care without dialysis|
33277579|NCT05351372|Experimental|ULD protocol|ultra-low dose protocol in cone-beam computed tomography with a field of view including the cleft area
32774517|NCT04904497|No Intervention|Standard|"The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.~Occupational Therapy interventions for control group will be allowed for this group only before 1 week after the first day on light sedation"
32774518|NCT04913701||1 - Health workers|A total number of 200-300 healthcare workers, exposed to close contact with patients, will be asked to participate to the study and will be asked to sign the informed consent.
32774519|NCT04913701||2 - Patients|A total number of 100-200 patients admitted to the rehabilitation facility, referred from other healthcare facilities or from their own home, will be asked to participate to the study.
32774520|NCT04913701||3 - Real life participants|A total number of 100 real-life participants, will be represented by volunteers (other employees, staff not in contact with patients
32774521|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in cemented THA|
32774522|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in non cemented THA|
32774523|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
32774524|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
32774525|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
32774526|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
32774527|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
32774528|NCT04910035|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
32774529|NCT04910035|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
32774530|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~Decortication of the bone bed to increase the blood supply to the onlay graft.~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~Periosteal incisions are usually needed to allow tension free sutures.~Vicryl 3/0 sutures for closer.~augmentin 1g twice daily for 5 days.~catflam 50g twice daily for 3 days"
32774531|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~Drilling of pilot drill and first drill only.~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~splitting osteotomes are used and mallet to complete the splitting of the bony segment.~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~Drilling through the bony segment and the block graft.~Immediate implant placement~chin graft block dental implants"
32774532|NCT04909879|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
32774533|NCT04909879|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
32774534|NCT04894513|Experimental|study group|the study group received the conventional selected program in addition to Kabat motor control re-education
32774535|NCT04894513|Experimental|control group|the control group received the conventional selected program
32774536|NCT04921137|Experimental|Omission of endocrine therapy|Omission of endocrine therapy
33081596|NCT04660474||Early reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT<24 hours were assigned to Early reperfusion group.
33081597|NCT04660474||Intermediate reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT ranging from 24 hours to 7days were assigned to Intermediate reperfusion group.
33081598|NCT04660474||Late reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT>7days were assigned to Late reperfusion group.
33081599|NCT04659889||Patients with clinical features of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are currently displaying symptoms of long Covid
33081600|NCT04659889||Patients with no symptoms of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are not displaying symptoms of long Covid
33081601|NCT04659733|Experimental|Anlotinib hydrochloride|
33081602|NCT04660006||Control|Patients undergoing uneventful cataract surgery with no retinal vascular disease.
33081603|NCT04660006||Diabetic Retinopathy (DR)|Patients with non-proliferative diabetic retinopathy with no diabetic macular edema treatment in the 6 months prior to uneventful cataract surgery.
33401886|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
32743248|NCT04957407||mild-moderate atrophic gastritis|OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)
32743249|NCT04957407||severe atrophic gastritis|OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)
33081604|NCT04660006||Diabetic Macular Edema (DME)|Patients with diabetic macular edema undergoing active Anti-VEGF treatment (within the last 3 months) undergoing uneventful cataract surgery.
33081605|NCT04659850|Other|Group 1|Group 1 participants in the young 18 - 30 age group
33081606|NCT04659850|Other|Group 2|Group 2 participants in the older 55 - 75 age group
33081607|NCT04659460|Experimental|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
33081608|NCT04659460|Sham Comparator|Sham Remote Ischemic Conditioning|RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
33081609|NCT04659343||Cohort 1|Patients treated for metastatic renal cell carcinoma in Denmark over a 2-year period.
33081610|NCT04659694|Other|Single arm study|This study only contains one arm
33081611|NCT04659499|Experimental|Nab-paclitaxel in combination with pyrotinib treatment group|Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year
33081612|NCT00245349||FLT|Study group receiving FLT for imaging
33081613|NCT04659304|Active Comparator|Cohort 1|Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells
33081614|NCT04659304|Active Comparator|Cohort 2|Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells
32743250|NCT04957407||gastric cancer|gastric cancer
32743251|NCT04487093|Experimental|neoantigen vaccine + EGFR-TKI|
32743252|NCT04487093|Experimental|neoantigen vaccine + anti-angioge|
32743253|NCT04936269||Group 1|Children under five years old
32743254|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
32743255|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
32743256|NCT04936971|Experimental|Everolimus|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS) as per local practice."
32743257|NCT04936971|Active Comparator|Mycophenolate Mofetil|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Mycofenolate Mofetil (MMF) 500mg/bid and Corticosteroids (CS) as per local practice."
32743258|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
32743259|NCT03242681|Active Comparator|Simple Probing|Simple Probing
32743260|NCT04419909|Experimental|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
32743261|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
32743262|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
32743263|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
32743264|NCT04931433|Experimental|Lignocaine|This arm will receive intravenous Lignocaine bolus and infusion
32743265|NCT04931433|Placebo Comparator|Placebo|This arm will receive Normal saline 0.9% bolus and infusion
32743266|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
32743267|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
32743268|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
32743269|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
32743270|NCT03242291|Active Comparator|conventional resin-based flowable composite|
32743271|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
32743272|NCT04931355|Experimental|Acupuncture treatment group|Method: Acupuncture at Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi. The acupuncture treatment starts on the 5th day of the menstrual cycle and lasts to the days before IVF-ET
32743273|NCT04931355|Active Comparator|Western medicine group|The western medicine group will be treated with conventional western medicine
32743274|NCT04486937|Experimental|SC10914|400mg TID，oral admination on an fasting state
32743275|NCT03242213|No Intervention|Usual Care|Standard of Care
32743276|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
32743277|NCT04931121||Osteoarthritic patients|Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
32743278|NCT03241979||laryngeal microsurgery|
32743279|NCT04931277|Other|stepped cataract surgery|
32743280|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
32743281|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
32774537|NCT04921137|Active Comparator|Administration of endocrine therapy for at least 5 years|Administration of endocrine therapy for at least 5 years
32774538|NCT04894201||All patients with relevant dental findings|
32774539|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
32774540|NCT04893889|Experimental|Fabry disease patients|Patients diagnosed with Fabry disease. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
32774541|NCT04893889|Active Comparator|Amyloidosis transthyretin with cardiac commitment|Patients diagnosed with amyloidosis who present cardiac commitment. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
32774542|NCT04893889|Placebo Comparator|Healthy subjects|Healthy patients. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test.
32774543|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
32774544|NCT04909411|Other|Exposed arm|child infected with chikungunya virus during childbirth
32774545|NCT04909411|Other|Non-exposed arm|child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
32774546|NCT04399603||COVID critically unwell patients|
32774547|NCT04399603||Non-Covid critically unwell Patietns|
33081615|NCT04659304|Active Comparator|Cohort 3|Two IV doses of Allocetra-OTS with 10x10^9 cells in each dose
33081616|NCT04659655|Other|surgical aortic valve replacement|n=20 patients with aortic valve pathology and indication for surgical aortic valve replacement
33081617|NCT04659655|Other|surgical mitral valve replacement|n=10 patients with mitral valve pathology and indication for surgical mitral valve replacement
33081618|NCT04649320||cancer patients|adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
33081619|NCT04649086|Experimental|Eccentric group|The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
33081620|NCT04649086|Active Comparator|Concentric group|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
33081621|NCT04648735|Experimental|Drivers with cognitive impairments|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
33081622|NCT04648735|Active Comparator|drivers with normal cognition|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
33081623|NCT04648657||acute hypoxemic respiratory failure patients|Mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) with P/F ratio < 300 with at least PEEP 5 cmH2O)
33081624|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
33081625|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
33081626|NCT04648813|Experimental|tiotropium bromide monohydrate (Spiriva Respimat)|
33081627|NCT04648813|Placebo Comparator|matching placebo|
33081628|NCT04648384|Experimental|Protein Supplementation and Resistance exercise|Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
33401887|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
32774548|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
32774549|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
32774550|NCT04903561|Experimental|Intervention|In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
32774551|NCT04903561|No Intervention|control|Women in the control group will receive an oral recommendation given by the GP with a reminder of the current screening policy to have a cervical sample taken by a physician chosen by the woman. This clinician-taken cervical sample will be sent to a laboratory for processing with the usual screening test. Today the usual screening test still is cytology, but this will change in the future (date to be defined) to an HPV test.
32774552|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
32774553|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
32774554|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
32774555|NCT04893733|Experimental|Vitamin B complex|Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours. They will also received the Institution standard of care for AKI.
32774556|NCT04893733|Placebo Comparator|Placebo|Randomized patients with AKI to this arm will received during 5 consecutive days IV placebo each 12 hours. They will also received the Institution standard of care for AKI.
32774557|NCT04893421|No Intervention|Standard of Care WGS or RSL|Patients will undergo the institutional standard of care approach (WGS or RSL) for BCS. For WGL, a hooked wire will be implanted to mark the center or outer edges of the lesion under imaging guidance. For RSL, patients will be implanted with a radioactive seed using an impregnated needle under imaging guidance. A special handheld probe will be used to find the radioactive seed during the lumpectomy surgery.
32774558|NCT04893421|Experimental|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
32774559|NCT04903483|Other|target-controlled infusion (propofol) with depth of anesthesia monitoring|In this group, propofol dosing is adjusted with bispectral index monitoring.
32774560|NCT04903483|Other|target-controlled infusion (propofol) without depth of anesthesia monitoring|In this group, propofol dosing is adjusted without bispectral index monitoring.
32774561|NCT04903405||Sepsis|
32774562|NCT04903639||obese COPD|COPD patient with BMI more than 30
32774563|NCT04903639||non obese COPD|COPD patient with BMI less than 30
32774564|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
33081629|NCT04648384|Placebo Comparator|Placebo Supplementation|Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
33081630|NCT04648384|Experimental|Resistance Training|Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.
33081631|NCT04648423|Experimental|sodium oxybate|Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
33081632|NCT04648423|Placebo Comparator|placebo|Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
33081633|NCT00558181|Experimental|Rituximab, Methylprednisolone|
33081634|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
33081635|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
33081636|NCT04648618||OSA + DME +|Patients with OSA and DME
33081637|NCT04648618||OSA - DME +|Patients with DME, but no evidence of OSA
33081638|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
33081639|NCT04648345|Experimental|Erector spinal plane block group (ESPB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block will be performed in the ESPB group.
33081640|NCT04648345|Active Comparator|Vertebral side block group (VSB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral vertebral side block will be performed in the VSB group.
33274329|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
33274330|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
33274331|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
33274332|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
33274333|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
33274334|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
33274335|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
33274336|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
33274337|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
32774565|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
32774566|NCT03053323|Experimental|Lifestyle Intervention|
32774567|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
32774568|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
32774569|NCT04903171|No Intervention|GROUP ONE|The participants do not receive incentive to visit any gardens
32774570|NCT04903171|Placebo Comparator|GROUP TWO|The participants receive incentives by carers to visit regularly a conventional sensory garden
32774571|NCT04903171|Experimental|GROUP THREE|The participants receive incentives by carers to visit regularly an enriched garden
32774572|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
32774573|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
32774574|NCT04909489||PDR group|Phlegm-Dampness Retention syndrome group
32774575|NCT04909489||SKYD group|Spleen and Kidney Yang Deficiency syndrome group
32774576|NCT04909489||NC group|Normal Control group
32774577|NCT04893031||Tocilizumab treatment group|Symptoms of hypoxia and systemic inflammation (SpO2 <90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
32774578|NCT04893031||Standard treatment group|Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.
32774579|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
33274338|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
33274339|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
33274340|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
33274341|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
33274342|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
33274343|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
33274344|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
32774580|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
32774581|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
32774582|NCT04892485||CF patients|
32774583|NCT04892485||Controls|
32774584|NCT04147585|Experimental|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
33274345|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
33274346|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
33274347|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
33274348|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
33274349|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
33274350|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
33274351|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
33274352|NCT00983112|Experimental|Evicel|
33274353|NCT00983112|Placebo Comparator|Placebo|
33274354|NCT04006704|Experimental|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
33274355|NCT04006704|Experimental|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
33274356|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
33274357|NCT00986466|Active Comparator|exercise with placebo|
33274358|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
33274359|NCT00986466|Placebo Comparator|no exercise with placebo|
33274360|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
33274361|NCT00983190|Other|Single Group Assignment|
33274362|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
33274363|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
32774585|NCT04147585|No Intervention|Control Arm|Regular Diet
32774586|NCT04892563|Experimental|ESPB Block|Patients with rib fracture randomized to block group
32774587|NCT04892563|Active Comparator|Standard Care|Patients with rib fracture receiving IV analgesia/standard care
32774588|NCT04892251|Experimental|MORE+KAP|8 weeks of Mindfulness-Oriented Recovery Enhancement plus two ketamine assisted psychotherapy sessions
32774589|NCT04892251|Active Comparator|MORE|8 weeks of Mindfulness-Oriented Recovery Enhancement
32774590|NCT04909255|Active Comparator|Antimuscarinic|oxybutynin, tolterodine, solifenacin
32774591|NCT04909255|Experimental|B3-agonist|mirabegron
32774592|NCT04908553|Other|low dose group|Remimazolam Tosilate for Injection 0.1mg/kg at induction
32774593|NCT04908553|Other|medium dose group|Remimazolam Tosilate for Injection 0.15mg/kg at induction
32774594|NCT04908553|Other|high dose group|Remimazolam Tosilate for Injection 0.2mg/kg at induction
32774595|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
32774596|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
32774597|NCT04149457|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
32774598|NCT04149457|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
32774599|NCT04891939|Experimental|The intervention Arm|This arm will receive the novel intervention package for a period of three months to prevent smoking initiation and increase quit rate. The intervention will consist of 4 lessons which will be taught for about one hour each day. This will be segmented into two broad areas as knowledge and skill development. Under the knowledge-based program, participants will be taught, the global challenge of tobacco and tobacco products, correcting the erroneous impression about tobacco, the media and advertisement, and the harmful effects of smoking. The skill development program teaches about refusal skills (self-esteem, interpersonal relationship skills, and problem-solving skills). The participants will understand the tobacco advertising and marketing strategies; peer influence, and skills for resisting influences to smoke.
32774600|NCT04891939|Active Comparator|The Control Arm|The control arm will not receive novel intervention program but will continue with the usual School Health and Education program (SHEP) however, at the end of the intervention, all the materials will be sent to the control arm to also benefit from the lessons.
32774601|NCT04892095||Study participants|Adult subjects (men and women) aged 18 years or more, living in 12 European countries
32774602|NCT04891861|Active Comparator|1 week restart|restart DOAC at 1 week post injury at label dose and frequency
33274364|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
32774603|NCT04891861|Active Comparator|4 week restart|restart DOAC at 4 weeks post injury at label dose and frequency
32774604|NCT04902313|Experimental|Cancer patients|Youths (10-18 y) with newly diagnosed cancer, as well as their family members.
32774605|NCT04902313|Active Comparator|Pediatric patients|Youths (10-18 y) with a chronic somatic disease receiving care at a pediatric outpatient facility.
33081641|NCT04648345|Placebo Comparator|Local block group （LB group）|Local block will be performed at the surgical incisions after the surgery under general anesthesia.
33274365|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
33274366|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
33274367|NCT00977730|Active Comparator|Protandim|
33274368|NCT00977730|Placebo Comparator|Sugar pill|
33274369|NCT00983268|Experimental|Treatment Arm|
33274370|NCT03957252||Training Cohort|1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than or equal to than 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
33277580|NCT05351372|Active Comparator|Standard dose protocol|Standard dose protocol in cone-beam computed tomography with a field of view including the cleft area
33277581|NCT00666965|Placebo Comparator|1|inactive placebo
33274371|NCT03957252||Validation Cohort|Up to 1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than or equal to 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
33274372|NCT03811236|Experimental|Cold exposure|
33274373|NCT03811236|No Intervention|Room temperature|
33274374|NCT00977886|Placebo Comparator|Placebo|
33274375|NCT00977886|Experimental|ELB353|
32774606|NCT04891783||50 patients diagnosed as AS|50 patients diagnosed as AS according to 1984 modified New York criteria of AS .including radiographic and non-radiographic AS according to ASAS criteria these patients will undergo carotid ultrasound examination
32774607|NCT04891783||30 patients with psoriatic arthritis|30 patients with psoriatic arthritis who will be diagnosed according to the Classification Criteria of Psoriatic Arthritis (CASPAR) study these patients will undergo carotid ultrasound examination
33274376|NCT00977964|Experimental|Milk Based Protein Formula Process A|
33274377|NCT00977964|Experimental|Milk Based Protein Formula Process B|
33274378|NCT00977964|Experimental|Milk Based Protein Formula Process C|
33274379|NCT00977964|Experimental|Milk Based Protein Formula Process D|
33274380|NCT00977964|Experimental|Milk Based Protein Formula Process E|
33274381|NCT00977964|Experimental|Milk Based Protein Formula Process F|
33274382|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
33274383|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
33274384|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
33274385|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
32774608|NCT04891783||40 healthy controls|healthy controls will undergo carotid ultrasound examination
33274386|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
33274387|NCT00978198|Experimental|Part 1|single administration
33274388|NCT00978198|Experimental|Part 2|multiple administration
33274389|NCT00983658|Experimental|huMAb OX40L|
33274390|NCT00983658|Placebo Comparator|Placebo|
33274391|NCT00983736|Experimental|Active|
33274392|NCT00983736|Placebo Comparator|Placebo|
33274393|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
33274394|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
33274395|NCT00986700|Other|different types of bad time food|Different types of bad time food
33274396|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
33274397|NCT00986778|Active Comparator|Entecavir|
33274398|NCT00986778|Experimental|Entecavir plus Adefovir|
33274399|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
33274400|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
33274401|NCT04758468|Experimental|Telerehabilitation-based pelvic floor muscle training|
33274402|NCT04758468|Active Comparator|Home-based pelvic floor muscle training|
33274403|NCT04758468|No Intervention|Control (no specific intervention)|
33274404|NCT04008342|Experimental|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
33274405|NCT04008342|No Intervention|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
33274406|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
33274407|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
33274408|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
33274409|NCT00987012|Experimental|Pomegranate juice|
33274410|NCT00987012|Placebo Comparator|Placebo drink|
33274411|NCT00984360|Experimental|A118G|
33274412|NCT00984360|Experimental|Wild-type|
33274413|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
33274414|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
33274415|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
33274416|NCT00978588|Experimental|HES 130/0.4|
33274417|NCT00978588|Active Comparator|5% albumin|
33274418|NCT04006080|Experimental|Vedolizumab|
33274419|NCT01034722||Western Diet|Volunteer mothers with western diet.
33274420|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
33274421|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
33274422|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
32774609|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
32774610|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
32774611|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
32774612|NCT04901923|Experimental|Part 1 Cohort 1|Participants will receive ACP-196 2.5 mg capsule orally BID on Day 1.
32774613|NCT04901923|Experimental|Part 1 Cohort 2|Participants will receive ACP-196 5 mg (2 x 2.5 mg capsules) orally BID on Day 1.
32774614|NCT04901923|Experimental|Part 1 Cohort 3|Participants will receive ACP-196 25 mg capsule orally BID on Day 1.
32774615|NCT04901923|Experimental|Part 1 Cohort 4|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally BID on Day 1.
32774616|NCT04901923|Experimental|Part 1 Cohort 5|Participants will receive ACP-196 100 mg (4 x 25 mg capsules) orally QD on Day 1.
32774617|NCT04901923|Experimental|Part 2 Cohort 6|Participants will receive ACP-196 75 mg (3 x 25 mg capsules) orally QD on Day 1 and Day 8.
32774618|NCT04901923|Experimental|Part 3 Cohort 7|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally QD on Day 1, itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then ACP-196 50 mg (2 x 25 mg capsules) along with itraconazole 200 mg capsule QD on Day 9 under fasting state.
32774619|NCT04901845||Patients applying to Primary Healthcare Consultation|Consequent patients applying to the Primary healthcare to consult for any reason during 2 week period
32774620|NCT04901845||Patients applying to Specialized Healthcare Consultation|Consequent patients applying to the Specialized healthcare to consult for any reason during 2 week period
32774621|NCT04908007||Professional qualitative group|Qualitative analysis of crisis management by interviewing professionals most involved during the crisis in each university hospital.
33274423|NCT00978666||Healthy controls|Healthy comparison adolescent females
33274424|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
33274425|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
33274426|NCT03920280|Experimental|LID015385|LID015385 contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
33274427|NCT03920280|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
33274428|NCT00424372|Experimental|pregabalin|
33274429|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
33274430|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
33274431|NCT04006236|Experimental|Experimental Infant Formula|extensively hydrolyzed casein protein
32774622|NCT04908007||Professional quantitative group|Quantitative analysis of crisis management using the WHO grid adapted sent to the target persons identified within the establishments
32774623|NCT04908007||Patient quantitative group|Quantitative analysis of crisis management using a questionnaire sent to patients hospitalized in the first wave asking them about their perception of crisis and post-crisis management.
32774624|NCT04908007||Tools development|Development of tools to prepare for situations of uncertainty
33274432|NCT04006236|Active Comparator|Control Infant Formula|extensively hydrolyzed casein protein
32774625|NCT04907929|Experimental|post-implantation care|
32774626|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
32774627|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
33274433|NCT04676178|Experimental|SAD Cohorts 1-6 Experimental Arm|Subjects will receive single intravenous doses of PRA023 in a dose escalation format
32774628|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
33274434|NCT04676178|Placebo Comparator|SAD Cohorts 1-6 Placebo Arm|Subjects will receive intravenous doses of placebo
33274435|NCT04676178|Experimental|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three intravenous doses of PRA023, one dose every 2 weeks, in a dose escalation format
33274436|NCT04676178|Placebo Comparator|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three intravenous doses of placebo, one dose every 2 weeks,
33274437|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
33274438|NCT00988104|Active Comparator|Supportive Counseling|
33274439|NCT00978900|Active Comparator|Acesulfame K|
33274440|NCT00978900|Active Comparator|Sucralose|
33274441|NCT00978900|Active Comparator|Aspartame|
33274442|NCT00978900|Active Comparator|Glucose|
33274443|NCT00978900|Active Comparator|Fructose|
33274444|NCT00978900|Placebo Comparator|Water|
33274445|NCT00988182|Experimental|whey protein, 5g|
33274446|NCT00988182|Experimental|whey protein, 10g|
33274447|NCT00988182|Experimental|whey protein, 20g|
33274448|NCT00988182|Experimental|whey protein, 40g|
33274449|NCT00988182|Experimental|water control|
33274450|NCT00987168|Experimental|Sandostatine LP|
33274451|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
33274452|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
33274453|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
33274454|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
33274455|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
33274456|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
33274457|NCT03726294|Experimental|NBM-BMX|
33274458|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
33274459|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
32774629|NCT04891159||Shared decision making|During the first consultation (V1), the doctor will present the patient on the therapeutic treatment information related to diabetes according to the shared decision making (options, benefits, risks) with the assistance of decision support tools. The decision-making visit will take place after a reflection period of 8 to 15 days after V1. A discussion based on the feedback from this period of reflection will take place between the two actors and either there is a common agreement on the decision taken (shared decision-making), or the decision is taken by the patient, or the decision is made by the physician at the request of the patient. A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing. After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires: SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire
33274460|NCT00987246|Experimental|LAS41005|
33274461|NCT00987246|Active Comparator|LAS106521|
33274462|NCT00987246|Placebo Comparator|Placebo|
33274463|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
33274464|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
33274465|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
33274466|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
33274467|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
32774630|NCT04891159||Control group|"Decision-making for insulin therapy is based on the usual practice defined in each Cystic Fibrosis Centers Competences with decision-making procedures specific to each center and doctor. The decision-making process is generally carried out in two consultations.~A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing.~After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires (SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire)."
32774631|NCT04900909||Aortic valve replacement with mechanical valves|
32774632|NCT04900909||Aortic valve replacement with bioprostheses|
33274468|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
33274469|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
33274470|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
33274471|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
33274472|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
33274473|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
33274474|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
33274475|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
33274476|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
33274477|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
33274478|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
33274479|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
33274480|NCT04006158|Experimental|LightStim LED Bed|Full body LED bed device.
33274481|NCT00988338||Trinity Evolution|
33274482|NCT01033396|Experimental|PF-03654764 + Allegra|
33274483|NCT01033396|Experimental|PF-03654764|
33274484|NCT01033396|Active Comparator|Allegra-D|
33274485|NCT01033396|Placebo Comparator|Placebo|
33274486|NCT01033474||donor eggs|
33274487|NCT01033474||infertile patients|
33274488|NCT00979056|Experimental|Rifaximin|
33274489|NCT00979056|Placebo Comparator|Lactose|
33274490|NCT04006314|Other|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
33274491|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
33274492|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
33274493|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
33274494|NCT00979290||Separate anti-TB drugs|
33274495|NCT00979290||Fix-dosed combination anti-TB drugs|
33274496|NCT00988494|Experimental|High concentration|DE-105 high concentration
33274497|NCT00988494|Experimental|Low concentration|DE-105 low concentration
32774633|NCT04891003||Patients Diagnosed with Endometriosis (or endometrioma alone)|Nulliparous patients who had diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
32774634|NCT04891003||Patients With No Gynecological Pathology|Nulliparous patients who had not diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
32774635|NCT04907461|Experimental|Laparoscopic guided TAP block|"The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called Doyle's bulge sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin."
32774636|NCT04907461|Active Comparator|Ultrasound guided TAP block|The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
32774637|NCT04907617|Experimental|G1|After the induction of anaesthesia, the first group will be heated with only forced-air warming device.
32774638|NCT04907617|Experimental|G2|After the induction of anaesthesia, the second group will receive only warmed IV and irrigation fluids.
32774639|NCT04907617|Experimental|G3|After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the third group
32774640|NCT04907617|Experimental|G4|After the induction of anaesthesia, the fourth group will be the control group without any intervention.
32774641|NCT04890925|No Intervention|Control group|Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)
33274498|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
33274499|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
33274500|NCT00092677|Experimental|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
33274501|NCT00092677|Placebo Comparator|Placebo|
33274502|NCT03702270|Experimental|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
33274503|NCT03702270|No Intervention|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
32774642|NCT04890925|Experimental|Community Support Network (CSN) intervention group|The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.
32774643|NCT04890925|Active Comparator|Usual care|Participants in this group will receive dose-equivalent usual care
32774644|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
32774645|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
32774646|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
33274504|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
33274505|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
33274506|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
33274507|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
33274508|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
33274509|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
33274510|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
33274511|NCT04651920||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
33274512|NCT04651920||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
33274513|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
33274514|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
33274515|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
32774647|NCT04901065|Experimental|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle.
32774648|NCT04901065|Sham Comparator|Control|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery.
32774649|NCT04430803|Experimental|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)~8 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
32774650|NCT04430803|Placebo Comparator|Control water|"Tap water~0 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
32774651|NCT04891081||Patients with cyanotic Congenital Heart Disease|
32774652|NCT04891081||Patients with acyanotic Congenital Heart Disease|
32774653|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
32774654|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
32774655|NCT04412005||Magude|Pregnant women attending the Magude Health Center
32774656|NCT04890847||human-machine collaboration group|healthcare professionals and machine collaboration for annotation and AI model development
32774657|NCT04890847||pure mannual group|healthcare professionals for pure manual annotation and AI model development
32774658|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
32774659|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
32774660|NCT04890691|Experimental|BLT-1|Light therapy (wavelengths between 470nm and 525nm), 30 minutes/day for 4 weeks.
32774661|NCT04890691|Placebo Comparator|BLT-2|Placebo light (wavelength between 620nm and 750 nm), 30 minutes/day for 4 weeks.
32774662|NCT04890457|Experimental|Tragus then earlobe stimulation|
32774663|NCT04890457|Experimental|Earlobe then tragus stimulation|
32774664|NCT04890223|Experimental|Intervention group|The participants in the intervention group will be asked to identify an unfavourable behaviour that they wish to change when filling out the baseline questionnaire. The research nurse will conduct the individual face-to-face brief MI interviews for this purpose, which will last for approximately five to ten minutes. After the face-to-face brief MI interviews, the participants in the intervention group will receive brief MI messages individually by means of mobile instant messaging for six months from the baseline. After six months, the brief MI messages will cease to be delivered to the participants in the intervention group, with whom the research team will then maintain only minimal contact until the 12-month follow-up.
33081642|NCT04648072|Experimental|Periarticular Injection + Adductor Canal Block (Local Anesthestic)|"The experimental arm with receive both the periarticular injection and the adductor canal block.~The periarticular injection will be performed by the surgeon and will consist of 100 mL of injectate being distributed in the following manner: 30 mL to the posterior capsule, 10 mL to the medial collateral ligament, 10mL to the lateral collateral ligament (ensuring not to infiltrate common peroneal nerve), 20mL to the quadriceps and anterior capsule, and 30 mL to the subcutaneous tissue. The periarticular injection will consist of 250 mg of ropivacaine, 30 mg of ketorolac, and 0.5 mg of epinephrine.~The adductor canal block will be completed by the anesthesiologist after spinal anesthesia has been initiated, but before the surgery commences. The block will be completed using an aseptic technique under dynamic, in-plane US guidance. 20 mL of injectate consisting of 100mg of ropivicaine and 50 mcg of epinephrine will be injected around the hyperechoic saphenous nerve."
33081643|NCT04648072|Placebo Comparator|Periarticular Injection + Adductor Canal Block (Normal Saline)|"The control arm with receive a periarticular injection and a sham adductor canal block.~The periarticular injection will be carried out in the same manner as described for the experimental group. The technical aspects of the sham adductor canal block will be the same as for the experimental arm; however, the injectate will consist of 20 mL of normal saline."
33081644|NCT04648267|Active Comparator|Control group|Patients who have the cast and bolster on for standard 5 days after their radial forearm free flap and 7 days after their fibula free falp
33081645|NCT04648267|Experimental|Experimental group|Patients who have the cast and bolster on for 10-14 days
33081646|NCT00245427|Other|1 All macrolide antibiotics|
33081647|NCT00245427|Other|2 All beta lactam antibiotics|
33081648|NCT04647955|Experimental|Itopride|Oral dose of itopride 100 mg three times daily before the meal for 8 weeks
33081649|NCT04647955|Placebo Comparator|Placebo|Oral dose of placebo three times daily before the meal for 8 weeks
33081650|NCT04647799||forward head position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes in forward head position while Children will sit on chair with their feet on the ground without any tension, the upper limbs are rested in a table then, the angle between the line passing horizontally from the spinous process of C7 and the line passing between the tragus and spinous process of C7 will be measured by goniometer and goniometer pro application to evaluate the craniovertebral angle recording, we will fix the craniovertebral angle between 40.7° and 43.2°(severe FHP )
33081651|NCT04647799||neutral position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes while Children will sit on chair with their feet on the ground with head in anatomical position, the upper are rested in a table and used both hand on touch screen of mobile phone
33081652|NCT04647877|Experimental|Phenytoin 10 percent cream|Phenytoin 10 percent cream, 2 to 4 times daily application, 2 weeks long
33081653|NCT04647877|Experimental|Phenytoin 20 percent cream|Phenytoin 20 percent cream, 2 to 4 times daily application, 2 weeks long
33081654|NCT04647877|Placebo Comparator|Placebo cream|Placebo cream, 2 to 4 times daily application, 2 weeks long
33081655|NCT04647838|Experimental|NSCLC|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
33274516|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
33274517|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
33274518|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
33274519|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
33274520|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
33274521|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
33274522|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
33274523|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
33274524|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
33274525|NCT00979446|Experimental|Guided|
33274526|NCT00979446|Active Comparator|Self-directed|
32774665|NCT04890223|Placebo Comparator|Control group|Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
32774666|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
32774667|NCT04907149|Experimental|Absolute Bioavailability - Period 1|Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of [14C]GLPG3970 on Day 1.
32774668|NCT04907149|Experimental|Mass Balance - Period 2|Participants will receive [14C]GLPG397 under fasted conditions on Day 1.
32774669|NCT04431037|Experimental|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
32774670|NCT04431037|No Intervention|Traditional postoperative care group(B)|Patients in this group were managed traditionally
32774671|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
32774672|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
32774673|NCT04906681|Experimental|Arthroplasty, hip or knee|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
32774674|NCT04906681|Experimental|Neurology: stroke or Parkinson disease|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
32774675|NCT04906915|Experimental|Ketamine|The experimental group was continuously pumped with remifentanil + ketamine for analgesia, and the control group was continuously pumped with remifentanil + placebo (normal saline) for analgesia. RASS and CPOT scores were performed to evaluate the pain degree of the patients.
32774676|NCT04890379|Experimental|standard management plus Dimethyl Fumarate|
32774677|NCT04890379|Placebo Comparator|standard management plus placebo|
32774678|NCT04900285|Other|Dental Device Arm|Subjects in this single arm study serve as their own control by recording snoring on the SnoreLab device for five days and completing the Snore Outcomes survey. After five nights with now device, the lower dental device is used for five nights and snoring is recorded in the SnoreLab app. At the end of the five nights the subjects complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. If the lower device was tolerated well, the process is repeated with the upper dental device used with the lower device.
33081656|NCT04647838|Experimental|Other cancers|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
33274527|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
33274528|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
33274529|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
33274530|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
33274531|NCT05587998|Experimental|AZD4041 and morphine|Participants will receive an IV dose of morphine on Days 1 and 15. From Days 2 to 15, participants will receive an oral dose of AZD4041 once daily.
33274532|NCT05587998|Placebo Comparator|Placebo and morphine|Participants will receive an IV dose of morphine on Days 1 and 15. From Days 2 to 15, participants will receive an oral dose of placebo once daily.
33274533|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
33274534|NCT00988728|Placebo Comparator|Placebo|
33274535|NCT00988728|Active Comparator|Olanzapine|
33274536|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
33274537|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
33274538|NCT04005768|Experimental|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
33274539|NCT04005768|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
33274540|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
33274541|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
33274542|NCT00987792||Group 1|
33274543|NCT04459260|Experimental|Cognitive Behavior Therapy|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
32774679|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
32774680|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
32774681|NCT04906291|Experimental|H.A.F. toothpaste (1000 ppm F-)|The children were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
32774682|NCT04906291|Active Comparator|Fluoridated toothpaste (1000 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
32774683|NCT04906291|Experimental|H.A.F. toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
32774684|NCT04906291|Active Comparator|Fluoridated toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
32774685|NCT04900129|Experimental|Study Group|This group inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg. These drugs have no systemic and local side effects in these small doses, though it may cause slight eye irritation.
32774686|NCT04900129|No Intervention|Control Group|This group inhaled plain aquatic vapor in addition to conventional treatment.
32774688|NCT04929483|Experimental|BIO89-100 - 15 mg QW|
32774689|NCT04929483|Experimental|Experimental: BIO89-100 - 30 mg QW|
32774690|NCT04929483|Experimental|Experimental: BIO89-100 - 44 mg Q2W|
32774691|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo QW|
32774692|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo Q2W|
33274544|NCT04459260|Active Comparator|Unified Protocol|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on a transdiagnostic approach derived from cognitive behavior therapy called Unified Protocol, focusing on the shared emotional aspects underlying depression and anxiety disorders. The treatment was manualized by Ellard et al. (2010) and has been tested in several clinical trials, but so far not over the Internet.
33274545|NCT00987870|Experimental|BFH772 cream 1%|
33274546|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
33274547|NCT00987870|Experimental|BFH772 ointment 1%|
33274548|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
33274549|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
33274550|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
33274551|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
33274552|NCT00988962|No Intervention|High-Risk No Treatment|
33274553|NCT00988962|Experimental|High-Risk Treatment|
33274554|NCT00988962|No Intervention|Low-Risk|
32774693|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
33274555|NCT05578170||Pembro Neoadjuvant + SOC Adjuvant|
33274556|NCT00989118|Experimental|Laser treatment|
33274557|NCT00989118|Active Comparator|Endometrioma cystectomy|
33274558|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
33274559|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
33274560|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
33274561|NCT04888494|Experimental|Hippocampus-stimulation|Active high-frequency rTMS (20 Hz pulse trains)
33274562|NCT04888494|Experimental|Sham-stimulation|Sham rTMS
33274563|NCT04852302|Experimental|Arm 1|Remote CALM therapy for participants with newly or recurrent PCNST
33081657|NCT04647448||Healthy volunteers|Participants with no known cardiovascular disease
33274564|NCT04442490|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days. The dose may be decreased based on safety and tolerability.
33274565|NCT04442490|Placebo Comparator|SAGE-217 Matched Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
33274566|NCT04812522|Other|Clean Cut intervention - Cluster 1|"Cluster 1 will receive the Clean Cut infection prevention intervention at random time point A"
32774694|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
32774695|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
32774696|NCT04927845|Experimental|Immediate Intervention Condition|Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
32774697|NCT04927845|No Intervention|Waitlist Condition|Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.
32774698|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
32774699|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
32774700|NCT04920279||The patients with diabetes mellitus|When patients with diabetes mellitus admitted to our outpatient clinic if they have inclusion criteria, we have used the ABC questionnaire. And we have done perform Time Up And Go Test twice respectively.
32774701|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
32774702|NCT04906603|Experimental|TBS Headache|
32774703|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
32774704|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
32774705|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
32774706|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
32774707|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
32774708|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
32774709|NCT04393207|Active Comparator|Control group (Bupivacaine)|Patient will receive intrathecal morphine and TAP block with plain bupivacaine.
33081658|NCT04647448||Chest pain|Patients with symptoms of chest pain, undergoing elective coronary artery CT
33081659|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
33081660|NCT04647370|Active Comparator|Remote ischemic preconditioning|
33081661|NCT04647370|Sham Comparator|Sham remote ischemic preconditioning|
33081662|NCT04646980|Experimental|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
33081663|NCT04646980|Placebo Comparator|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
33081664|NCT04646863|Experimental|group A|consists of 20 patients received a multiwave locked system laser
33081665|NCT04646863|Experimental|group B|consists of 20 patients received Pilates exercises
33081666|NCT04646863|Experimental|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
33081667|NCT04647292|Experimental|Target systolic blood pressure 115-125 mmHg|Recommended target SBP 115-125 millimetres of mercury (mmHg).
32774710|NCT04393207|Experimental|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
32774711|NCT04393207|Active Comparator|Bupivacaine + dexamethasone and methylprednisolone|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
32774712|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
32774713|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
32774714|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
32774715|NCT04817917|Experimental|3JEV-I (Group 1)|"Retrospective: 3 doses of JE vaccines. 2 doses of Inactivated JE Vaccine (JEV-I, 7-10 days apart) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
32774716|NCT04817917|Experimental|JEV-L+JEV-I (Group 2)|"Retrospective: 2 doses of JE vaccines.~1 dose of JE attenuated live vaccine (JEV-L) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
32774717|NCT04817917|Experimental|JEV-L+2JEV-I (Group 3)|"Retrospective: 3 doses of JE vaccines.~1 dose of JEV-L at 8 months of age and 2 dose (7-10 days apart) of JEV-I at 2 years old."
32774718|NCT04817917|Experimental|2JEV-I+JEV-L (Group 4)|Retrospective: 3 doses of JE vaccines. 2 doses of JEV-I (7-10 days apart) at 8 months of age and 1 dose of JEV-L at 2 years old.
32774719|NCT04817917|Experimental|2JEV-L (Group 5)|Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
32774720|NCT04412161||Extra-Malatya|Liver transplant patients with MTD>6 cm of HCC
32774721|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
32774722|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
32774723|NCT04815499|Experimental|Food supplement|One tablet a day, during 12 months
32774724|NCT04815499|Placebo Comparator|Placebo|One tablet a day, during 12 months
32774725|NCT04398901||Colombia ZIKV-exposed|Seventy children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
33274567|NCT04812522|Other|Clean Cut intervention - Cluster 2|"Cluster 2 will receive the Clean Cut infection prevention intervention at random time point B"
33274568|NCT04812522|Other|Clean Cut intervention - Cluster 3|"Cluster 3 will receive the Clean Cut infection prevention intervention at random time point C"
33274569|NCT04812522|Other|Clean Cut intervention - Cluster 4|"Cluster 4 will receive the Clean Cut infection prevention intervention at random time point D"
33274570|NCT04812522|Other|Clean Cut intervention - Cluster 5|"Cluster 5 will receive the Clean Cut infection prevention intervention at random time point E"
33274571|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
33274572|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
33274573|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
33274574|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
33274575|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-623|Participants with Relapsed/Refractory (R/R) B-cell malignancies will receive escalating doses of ABBV-623.
32774726|NCT04398901||Colombia Non-ZIKV exposed control|The investigators will enroll 70 non-ZIKV exposed children, age 4 to 5 years, in Department of Atlántico, Colombia with birth dates prior to March 31, 2016. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure in the first half of gestation and unlikely during any of the pregnancy.
33274576|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-992|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-992.
33274577|NCT04804254|Experimental|Combination in Dose Escalation|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-623 and ABBV-992.
33274578|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-623|Participants with R/R B-cell malignancies will receive ABBV-623 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
33274579|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-992|Participants with R/R B-cell malignancies will receive ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
33274580|NCT04804254|Experimental|Combination in Dose Expansion|Participants with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) will receive ABBV-623 and ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
32774727|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
32774728|NCT04398901||United States Non-ZIKV exposed control|The investigators will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
32774729|NCT04814875|Experimental|Part 1 - ACD (Safety)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
33274581|NCT04776720|Experimental|Yoga Program|The 3-month yoga intervention provides instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
32774730|NCT04814875|Experimental|Part 2 - ACD (Efficacy)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
32774731|NCT04812535|Experimental|Arm A: IFX-1 monotherapy|IFX-1 monotherapy
32774732|NCT04812535|Experimental|Arm B: IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
33274582|NCT04776720|Active Comparator|Physical Conditioning Program|The 3-month physical conditioning program provides instruction and practice in a variety of exercises and stretches that have been designed by the study physical therapist.
33274583|NCT05712642|Experimental|Group A recieved 0.3125mg intravitreal bevacizumab in both eyes|9 infants in group A with type 1 ROP , received 0.3125mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
33274584|NCT05712642|Active Comparator|Group B received 0.625mg intravitreal bevacizumab in both eyes|10 infants in group B with type 1 ROP , received 0.625mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
33274585|NCT00092521|Experimental|1|V501
33274586|NCT00092521|Placebo Comparator|2|Placebo
33274587|NCT00092521|Experimental|3|HPV 16 Monovalent Vaccine
33274588|NCT05712564||MFS_cohort|Adult patients with Marfan syndrome
33274589|NCT05712564||EDS_cohort|Adult patients with Ehlers-Danlos syndrome
33274590|NCT05712486|Experimental|Lateral distraction group|High force lateral distraction of affected hip.
33274591|NCT05712486|Sham Comparator|Placebo distraction group|Placebo lateral traction of affected hip.
33274592|NCT05492682|Experimental|open label non-randomized|All patients will follow the same treatment schedule.
33274593|NCT05712408|Experimental|Diet Intervention|8 week non-restrictive diet program
33274594|NCT03908970|Experimental|1% OPA-15406|Twice daily
33274595|NCT03908970|Placebo Comparator|Placebo|Twice daily
33274596|NCT05487924|Experimental|SVV-GDHT|SVV ≤12% and CI of at least 2.5 L•min-1•m-2 were required. 500 mL of crystalloids was infused during induction, followed by a 2 ml•kg-1•h-1continuous infusion. If SVV was higher than 12% for over 5 minutes, a 250 mL bolus of crystalloid was given. Another 250 ml bolus of colloid was administrated if SVV was still higher than 12% or SVV decreased over 10%. If CI value was below 2.5 L•min-1•m-2, inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If SVV and CI were within the target range but MAP was below 65 mmHg, norepinephrine was started. After the initial assessment, patients were reassessed every 5 minutes intraoperatively to maintain values according to the study algorithm
33274597|NCT05487924|Experimental|O2ER-GDHT|the goal of O2ER is assessed every one hour to keep O2ER<27% which calculated by the following equation:(SaO2 - SvO2)/SaO2, when O2ER is greated than 27%, CVP lower than 10mmHg, 250ml colloid is given, otherwise, inotropes is given as CVP≥10mmHg.
33274598|NCT05487924|Active Comparator|conventional care|MAP was kept between 65 and 90 mmHg, CVP between 8 and 12 mmHg and urinary output more than 0.5 ml•kg-1•h-1. 500 ml of crystalloids was infused during induction, followed by a continuous infusion of crystalloids (4 ml•kg-1•h-1). If the MAP decreased below 65 mmHg, or if the CVP decreased below 8 mmHg, a 250 mL bolus of colloid was given after waiting 5 minutes if any one of the criteria was met. If the MAP decreased below 65 mmHg and remained unresponsive to fluids, norepinephrine or inotropes was given to maintain the MAP above 65 mmHg.
33274599|NCT05712330|Experimental|non invasive ventilation|SMA patients with NIV
33274602|NCT00092443|Experimental|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart."
33274603|NCT00092443|Placebo Comparator|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
33274604|NCT05712174|Experimental|[18]F-PSMA-1007 PET/CT or PET/MRI|All participants will undergo a single [18]F-PSMA-1007 PET/CT or PET/MRI scan. Intravenous bolus injection of 4 MBq/kg +/- 10% of [18]F-PSMA-1007, up to a maximum of 400 MBq.
33274605|NCT04005924|No Intervention|Control|Bread and sugar-free blackberry jam breakfast
33274606|NCT04005924|Experimental|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
33274607|NCT04005924|Experimental|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
33274608|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
33274609|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
33274610|NCT04691622|Experimental|Norovirus -specific T-cell (NST) therapy for chronic norovirus infection|"This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study:~Arm A: Participants who receive donor-derived NST therapy after HSCT~Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:~Participants with PID who have not undergone HSCT~Participants who undergo HSCT but do not have available donor derived NSTs~Participants who have donors from whom NSTs cannot be generated due to norovirus seronegativity"
33274611|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
33274612|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
33274613|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
33274614|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
33274615|NCT05430906|Experimental|AK104+chemotherapy|Participants received 3-4 neo-adjuvant cycles of standard 3 weekly AK104 10mg/kg then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)]; followed by surgery
33274616|NCT04005612|Experimental|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
33274617|NCT04005612|Experimental|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
33274618|NCT04005612|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
33274619|NCT04005612|No Intervention|Control group|NO INTERVENTION
33081668|NCT04647292|Active Comparator|Target systolic blood pressure 130-139 mmHg|Target SBP 130-139 mmHg (per American Stroke Association, European Stroke Organisation guidelines).
33081669|NCT04647097|Active Comparator|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
33274620|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
33274621|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
33274622|NCT03993964|Experimental|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
33274623|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
33274624|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
33274625|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
33274626|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
33274627|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
33081670|NCT04647097|Active Comparator|Standard intervention only|Patients randomized to the standard intervention only arm
33081671|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
33274628|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
33081672|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
33081673|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
33081674|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
33081675|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
33081676|NCT04646824|Experimental|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
33081677|NCT04646707|Experimental|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
33081678|NCT04646707|Placebo Comparator|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
33081679|NCT04646629|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
33081680|NCT04646629|Sham Comparator|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
33081681|NCT04646668|Active Comparator|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
33081682|NCT04646668|Active Comparator|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
33081683|NCT04646512|Active Comparator|Taurine group and exercise|Intervention with taurine supplementation and physical training.
33081684|NCT04646512|Placebo Comparator|Placebo group and exercise|Intervention with placebo supplementation and physical training.
33081685|NCT04646785|Experimental|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
33081686|NCT04646785|Active Comparator|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
33081687|NCT04646317|Experimental|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
33081688|NCT04646317|Placebo Comparator|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
33081689|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
33274629|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
33274630|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
33274631|NCT00091819|Experimental|Telavancin|
33274632|NCT00091819|Active Comparator|Vancomycin|
33274633|NCT01085227||Patients carrier of a LRRK2 mutation|
33274634|NCT01085227||Asymptomatic relatives of LRRK2 patients|
33274635|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
33274636|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
33274637|NCT01081327||Patients receiving Warfarin|
33274638|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
33274639|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
33274640|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
33274641|NCT03964129|Experimental|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
33274642|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33274643|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33274644|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33274645|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33274646|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33274647|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
33274648|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
33274649|NCT04620174|Other|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
33274650|NCT04620174|Other|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
33274651|NCT04620174|Other|Control Group|Twenty intact contralateral teeth will be evaluated as the controls (10 molars will be the controls for custom-made ZrCs and 10 molars will be the controls for prefabricated ZrCs).
33274652|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
33274653|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
33274654|NCT05711940|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
33274655|NCT05711940|Experimental|10 mg COMP360 Psilocybin|10 mg COMP360 Psilocybin
33274656|NCT05711940|Active Comparator|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin, active comparator
33274657|NCT05372094|Experimental|Phonak Hearing Aid|The study hearing aid is commercially available Receiver-in-Canal model.
33274658|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
33274659|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
33274660|NCT05367882||critically ill COVUD-19 patients in ICU|critically ill COVID-19 patients who are recommended to receive IL-6R antagonist as tocilizumab at the dosage of 8 mg/kg with a second dose 12 hours after the first dosage, or sarilumab at the dosage of 200 mg subcutaneously or 200 to 800 mg intravenously.
33274661|NCT05347290|Experimental|Lead Apron + Rampart IC, M1128|Consented providers will perform catherization procedures utilizing both lead apron and Rampart system. Radiation will be measured by dosimeters worn by the providers.
33274662|NCT05347290|Experimental|Rampart M1128 IC, Only|Consented providers will perform catherization procedures utilizing only the Rampart system. Radiation will be measured by dosimeters worn by the providers.
33274663|NCT05347290|Active Comparator|Lead Apron Only|This is the control group. Consented providers will perform catherization procedures utilizing only the lead apron and ancillary shields (lead skirt, vest, thyroid collar (all at least 0.5mm Pb) with use of under table lead per lab operating policy and mobile suspended lead-acrylic shield and lead glasses). Radiation will be measured by dosimeters worn by the providers.
33274664|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
33274665|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
33274666|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
33274667|NCT04508790|Experimental|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33274668|NCT05711706|Experimental|Su Jok Application|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
33274669|NCT05711706|No Intervention|Standard care|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
33274670|NCT04004676|Active Comparator|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
33274671|NCT04004676|Experimental|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
32774733|NCT04413097|Active Comparator|DCC and Low Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
33274672|NCT05711550|Experimental|Healthy Subjects: Study 1|This arm corresponds to study 1 (Real Neurofeedback uses only normal frequency band signals ranging from 1 to 35 Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
32774734|NCT04413097|Experimental|DCC and High Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
32774735|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
32774736|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
32774737|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
32774738|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
32774739|NCT04899817|Active Comparator|Group G|will receive granisteron 1mg after induction of general anesthesia
32774740|NCT04899817|Placebo Comparator|Group C|Will receive metoclopramide 10 mg after induction of general anesthesia
33274673|NCT05711550|Experimental|Healthy Subjects: Study 2|This arm corresponds to study 2 (Real Neurofeedback uses only infra-low frequencies below 0.1Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
32774741|NCT04905667|Experimental|GB221 group|6 mg/kg, single dose, intravenous infusion, 90-100 min
32774742|NCT04905667|Active Comparator|Herceptin group|6 mg/kg, single dose, intravenous infusion, 90-100 min
32774743|NCT03151811|Experimental|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
32774744|NCT03151811|Active Comparator|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
32774745|NCT03050749|Other|Princess® VOLUME|
32774746|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
32774747|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
32774748|NCT04889677|Experimental|Group 1: 200 mg|All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.
32774749|NCT04889677|Experimental|Group 2: 600 mg|All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.
32774750|NCT04889677|Experimental|Group 3: 1200 mg|All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
33081690|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
33274674|NCT05711550|Experimental|Healthy Subjects: Study 3|This arm corresponds to study 3 (normal frequency band & infra-low frequencies are used in Real Neurofeedback). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
33274675|NCT04564560||Patients treated with Zenith Alpha Spiral-Z®|Patients that from January 2017 until December 2019 received endovascular aortic repair with the Zenith Alpha Spiral-Z® at St. Olavs Hospital
33274676|NCT04005222|Other|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
33274677|NCT04005222|Other|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
33277582|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
33277583|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
33277584|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
33274678|NCT05711472|Experimental|Experimental|"Intervention Group Three different ball sizes, 55, 65 and 75 cm in diameter, were provided to the pregnant women, and the appropriate ball size was determined according to the height of the participant. In order for the pregnant woman to continue the balance exercises, they were allowed to sit on the round birth ball with their knees and hips at an angle of approximately 90°, with an upright spine. A birth ball of 55 cm was used for women between 150 and 160 cm in height, 65 cm for women between 160 and 170 cm, and 75 cm for women between 170 and 185 cm in height. Exercises with the round birth ball were guided by the researcher and the pregnant women performed the exercises in line with the guide.~These are the movements performed with the round birth ball in 3 different positions: sitting (pelvic rocking movement, forward-backward and right-to-left rocking, forward supported sitting, and springing motion), kneeling, and squatting (ball hugging and pelvic rocking motion)."
33274679|NCT05711472|No Intervention|No Intervention|"Control Group~The followings were administered to the pregnant women in the Control Group after they were admitted to the hospital for delivery:~Information was given about the research,~Written consent was obtained,~Routine practices and care were provided in the delivery room (taking anamnesis, taking vital signs, demonstrating correct breathing techniques, ensuring freedom of movement)~Cervical changes were recorded on the partograph by vaginal examination,~EFM (Electronic Fetal Monitoring) was applied based on doctor's orders,~Fetal Heart Sound (FHS) was listened to every half hour and recorded on the partograph."
33274680|NCT04441710||Caregivers|Staff of university hospitals
33274681|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
33274682|NCT04441710||Patients|
33274683|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
33274684|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
33274685|NCT05314374|Experimental|Bile Acid Supplement Group|Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements
33274686|NCT05314374|Placebo Comparator|Placebo Group|Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
32774751|NCT04889677|Experimental|Group 4: 2400 mg|All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.
33274687|NCT05298306|Experimental|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion on separate days at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, LAT8881 will be given as a single intravenous infusion. The dose will be determined from the results of Part A."
33274688|NCT05298306|Placebo Comparator|Placebo|Matching placebo will be given as a single intravenous infusion in Part A and Part B
32774752|NCT04889677|Experimental|Group 5: 1200 mg|All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
32774753|NCT04397107|Experimental|Recombinant Human Interleukin-2|Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.
32774754|NCT04397107|No Intervention|Traditional therapy|Patients were treated with glucocorticoid and/or immunosuppressor.
32774755|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
32774756|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
32774757|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
32774758|NCT04905823||Type 1 diabetes patients|Patients with type 1 diabetes
32774759|NCT04905823||Non-diabetic subjects|Subjects in whom diabetes has not been diagnosed
32774760|NCT04905823||Type 2 diabetes patients|Patients with type 2 diabetes
32774761|NCT04430647|Experimental|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before [18]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
32774762|NCT04430647|Active Comparator|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
32774763|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
32774764|NCT04889365||COVID-19 positive, asymptomatic|COVID-19 positive, asymptomatic (i.e. no current symptoms of COVID-19, confirmed PCR positive for COVID-19)
32774765|NCT04889365||COVID-19 positive, symptomatic|COVID-19 positive, symptomatic (i.e. current symptoms of COVID-19, confirmed PCR positive for COVID-19)
32774766|NCT04889365||COVID-19 negative|COVID-19 negative (i.e. no current or previous symptoms of COVID-19, confirmed PCR negative for COVID-19)
32774767|NCT04889131|Experimental|Yoga Program|12-week yoga program begins immediately
32774768|NCT04889131|Active Comparator|Wait-list Control|Wait-listed to take the Yoga Program in 12-weeks time
33274689|NCT04403802|Experimental|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
32774769|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
32774770|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
33274690|NCT04403802|Experimental|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
33274691|NCT05710536|Experimental|Formulation X|Participants will use the formulation once every 72 hour for 5 weeks
32774771|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
32774772|NCT04889053||D2M, Vascular calcification-free|Meet the inclusion criteria, there is no calcification detected by low dose prospectively triggered sequential dual-source CT coronary angiography
32774773|NCT04889053||D2M with vascular calcification|Meet the inclusion criteria, and have coronary artery calcification ( be confirmed by low dose prospectively triggered sequential dual-source CT coronary angiography)
32774774|NCT05530265|Experimental|Smart watch group|The user of the smart watch and Samsung Health app
32774775|NCT05530265|No Intervention|Usual care|No use of both the smart watch and Samsung Health app
32774776|NCT04888663|Experimental|Study treatment|(Phase Ib part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel 80 or 70 mg/m2 IV (according to dose level) (Phase II part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel at RP2D (80 or 70 mg/m2 IV)
32774777|NCT04662905|Experimental|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
32774778|NCT04899427|Experimental|orelabrutinib combined with PD-1 inhibitor|"The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.~The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment."
32774779|NCT02453685|Experimental|BIAsp|
32774780|NCT02453685|Active Comparator|IGlar + IAsp|
33274692|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
33274693|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 & 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
33274694|NCT05268744|Experimental|Micronutrient|In this open-label trial, all subjects will receive the daily dose of micronutrient, in the form of one lightning stick per day, which contains 2.9 grams of micronutrients per stick. It will be delivered in a powder form taken sublingually.
33274695|NCT02531191|Experimental|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
33274696|NCT02531191|Experimental|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
33274697|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
33274698|NCT01081639|Experimental|Gonal-f|
33274699|NCT01081639|Active Comparator|Puregon|
32774781|NCT04658771|Experimental|All patients|"Patients will undergo MR-HIFU ablation procedure of OO under general anesthesia. Patients will be monitored for disease status and adverse events for 12 months following procedure. Patients with incomplete or partial response at 28 days after MR-HIFU will be permitted a second MR-HIFU procedure.~If there is still incomplete pain relief without medication use by 28 days following the second MR-HIFU treatment, patients will be offered standard of care treatment with RFA and followed for one year."
32774782|NCT04888975|Experimental|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery
32774783|NCT04655963|Experimental|Dose 1|All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span. A single session=600 pulses at 120% rMT, iTBS triplets at 50 Hz for 2 s and repeated every 10 s for a total of 190 s to left dlPFC. Total pulses=14,400.
32774784|NCT04899739|Experimental|Peripancreatic and distant lymph node assessment|All patients programmed for an endoscopic ultrasound in the context of a pancreatic cancer
32774785|NCT04918797|Experimental|Study vaccine|SARS-COV2 vaccine
32774786|NCT05530187|No Intervention|Control|
32774787|NCT05530187|Experimental|Intervention|
33274700|NCT01081717||001|golimumab as prescribed
33274701|NCT01081717||002|anti-TNF biologics as prescribed
32774788|NCT04905355|Active Comparator|Virtual Reality (VR)|Patient with VR experience during the ambulatory orthopedic surgery
33274702|NCT01081717||003|non-anti-TNF biologics as prescribed
33274703|NCT01081717||004|systemic non-biological treatments as prescribed
33274704|NCT01081717||005|general population non-treated cohort
33274705|NCT03963973|Experimental|RDN-929|low, medium and high dose of RDN-929 capsules
33274706|NCT03963973|Placebo Comparator|Placebo|Matching placebo capsules
33274707|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
33274708|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
32774789|NCT04905355|No Intervention|NO VR|Patient without any VR experience during the ambulatory orthopedic surgery
32774790|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
32774791|NCT04905043|Experimental|SmartPill® + Acalabrutinib|Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.
32774792|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
32774793|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
32774794|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
32774795|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
32774796|NCT04888741|Active Comparator|Control Arm Thymoglobulin + Cyclosporine + MMF|"Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
32774797|NCT04888741|Experimental|Experimental arm (PTCy + Cyclosporine + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
33274709|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
33274710|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
33274711|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
33274712|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
32774798|NCT04888741|Experimental|Experimental arm (PTCy + Sirolimus + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Sirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.~MMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
32774799|NCT04888819|Experimental|fed state group|just after a meal
32774800|NCT04888819|Experimental|fasted state group|before a meal
33274713|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
33274714|NCT01087411|Experimental|Motivational interviewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
33274715|NCT01087411|Experimental|Control and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
32774801|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
32774802|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
33274716|NCT01087411|Placebo Comparator|Control and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
33274717|NCT00485589|Placebo Comparator|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
32774803|NCT04927065|Experimental|Part A.1: mRNA-1273.211 50 μg|Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211 on Day 1.
33274718|NCT00485589|Experimental|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
33274719|NCT00485589|Experimental|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
33274720|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
32774804|NCT04927065|Experimental|Part A.1: mRNA-1273.211 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.
33274721|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
33274722|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
33274723|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
33274724|NCT00490971|Experimental|Paliperidone ER|
33274725|NCT00490971|Placebo Comparator|Placebo|
33274726|NCT00490971|Active Comparator|Olanzapine|
33274727|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
33274728|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
33274729|NCT04284267|No Intervention|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
33274730|NCT04284267|Experimental|Bipolar Group|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses) and sham TMS.
33274731|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
33274732|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
33274733|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
33274734|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
33274735|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
33274736|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
33274737|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
33274738|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
33274739|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
32774805|NCT04927065|Experimental|Part B: mRNA-1273 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
32774806|NCT04927065|Experimental|Part C: mRNA-1273.617.2 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
33274740|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
33274741|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
33274742|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
33274743|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
33274744|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
32774807|NCT04927065|Experimental|Part C: mRNA-1273.617.2 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
32774808|NCT04927065|Experimental|Part D: mRNA-1273.213 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.
33274745|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
33274746|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
32774809|NCT04927065|Experimental|Part D: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
32774810|NCT04927065|Experimental|Part E: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
32774811|NCT04927065|Experimental|Part F Cohort 1: mRNA-1273.529 50 μg|Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.
33274747|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
33274748|NCT00745589|Active Comparator|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
33274749|NCT00745589|Active Comparator|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
33274750|NCT05417867||Observational (survey, biospecimen collection)|Patients undergo collection of stool samples over 10 minutes and complete questionnaires over 60 minutes at baseline and 3-5 days following initiation of standard of care chemotherapy.
33274751|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
33274752|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
33274753|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
33274754|NCT00745667|Active Comparator|1|laparoscopic
33274755|NCT00745667|Active Comparator|2|open correction
33274756|NCT00745745|Active Comparator|1|Apical ICD lead placement
33274757|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
33274758|NCT00750659|Experimental|1|Nilotinib treatment
32774812|NCT04927065|Experimental|Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529 (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
32774813|NCT04927065|Experimental|Part G: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular second booster dose of mRNA-1273.214 50 μg on Day 1.
33274759|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
33277585|NCT05350358||Patients who have undergone surgical treatment with LeMaitre Cardial Dialine II|Subject who has undergone surgical treatment for the replacement or bypass in aneurysmal and/or occlusive diseases and for arterial reconstruction in patients requiring systemic heparinization with LeMaitre Cardial Dialine II.
32774814|NCT04927065|Experimental|Part A.2: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214 on Day 1.
32774815|NCT04927065|Experimental|Part H: mRNA-1273.222 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222 on Day 1.
32774816|NCT03051685|Experimental|DFN-15 Dose 1|
32774817|NCT03051685|Experimental|DFN-15 Dose 2|
32774818|NCT03051685|Experimental|DFN-15 Dose 3|
32774819|NCT03051685|Active Comparator|Active Comparator|
33277586|NCT00781157|Experimental|1|
33274760|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
33274761|NCT00098293|Experimental|1|
32774820|NCT04918173|Experimental|Atenativ treatment|Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients
33274762|NCT00098293|Active Comparator|3|
32774821|NCT04410523|Experimental|CSJ117 0.5 mg|0.5 mg
32774822|NCT04410523|Experimental|CSJ117 1 mg|1 mg
32774823|NCT04410523|Experimental|CSJ117 2 mg|2 mg
33274763|NCT00098293|Experimental|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
33274764|NCT04056065|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
33274765|NCT04056065|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
33274766|NCT04055285|Experimental|Sympathetic Renal Denervation|Sympathetic Renal Denervation
33274767|NCT04055285|Active Comparator|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
32774824|NCT04410523|Experimental|CSJ117 4 mg|4 mg
32774825|NCT04410523|Experimental|CSJ117 8 mg|8 mg
32774826|NCT04410523|Placebo Comparator|Placebo|0 mg
32774827|NCT04888351||Mastectomies with IBR|Every women>18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020
32774828|NCT04888351||Mastectomies without IBR|Every women>18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse
32774829|NCT04888117||Laparoscopic cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a laparoscopic cholecystectomy.
33274768|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
33274769|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
33274770|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
33274771|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
33274772|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
33274773|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
33274774|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
33274775|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
33274776|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
33274777|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
33274778|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
33274779|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
33274780|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
33274781|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
33274782|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
33274783|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
33277587|NCT00995462|No Intervention|Control|
32774830|NCT04888117||Robotic-assisted cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a robotic-assisted cholecystectomy.
32774831|NCT04904887|Other|Assessment of intermediate vision, defocus curve|"Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.~he binocular defocus curve: The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps."
32774832|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
32774833|NCT04898881|Active Comparator|Breast Milk|2 ml of Breast milk given one time, two minutes prior to the heel lance
33274784|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
33274785|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
33274786|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
33274787|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
33274788|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
32774834|NCT04898881|Other|24 %Sucrose|0.5 ml sucrose to be given once, two minutes prior to the heel lance
33274789|NCT00751049|Experimental|PhXA41|
33274790|NCT00751049|Active Comparator|timolol|
32774835|NCT04904185|Other|Part A|Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
32774836|NCT04904185|Other|Part B|Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.
33274791|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
33274792|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
33274793|NCT00751985|Placebo Comparator|3|Control
33274794|NCT03857841|Experimental|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
32774837|NCT04898725|Experimental|Vit D Group (randomized)|Subjects will be randomly assigned to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks
32774838|NCT04898725|No Intervention|Control Group (randomized)|Subjects will be randomly assigned to receive a placebo for 8 weeks.
32774839|NCT04898725|Experimental|Preference Vit D Group (non-randomized)|Subjects with a strong preference to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks.
32774840|NCT04898725|No Intervention|Preference no Vit D Group (non-randomized)|Subjects with a strong preference to receive usual care (not receiving vitamin D supplements) for 8 weeks.
32774841|NCT04884607|Experimental|Study group|Study group will receive subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes.
33274795|NCT03857841|Experimental|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
33274796|NCT03857841|Experimental|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
33274797|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
33274798|NCT01014429|Experimental|1|
33274799|NCT00500331|Experimental|Arm 1|GSK189075
33274800|NCT00500331|Placebo Comparator|Arm 2|Placebo
33274801|NCT00500331|Other|Arm 3|pioglitazone (active control)
33274802|NCT01015755|Experimental|thirst intervention|
32774842|NCT04887961|Experimental|Single Arm|PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.
32774843|NCT04887883||Males|10 young healthy biological males aged 18 - 30 y
32774844|NCT04887883||Females|10 young healthy biological females aged 18 - 30 y
33274803|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
33274804|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
33274805|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
33274806|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
33274807|NCT04475835|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during PCI
33274808|NCT04475835|Active Comparator|Heparin|Heparin 100U/kg
33274809|NCT01014507|Active Comparator|A|
33274810|NCT01014507|Experimental|B|
33274811|NCT00484185||1|
33274812|NCT00097981|Active Comparator|Thalidomide + dexamethasone|
32774845|NCT04887649|Placebo Comparator|Placebo|Patients en treatment whit placebo, salIne solution in peridural cateter
32774846|NCT04887649|Active Comparator|Morphine|Epidural Catheter morphine 2mg
32774847|NCT04887649|Active Comparator|morphine|Epidurla cateter morphine 3 mg
33274813|NCT00097981|Experimental|Thalidomide + dexamethasone + DOXIL|
33274814|NCT01015911|Experimental|1|SGN-75
33274815|NCT03997149|Experimental|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
33274816|NCT03997149|Placebo Comparator|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
33274817|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
33277588|NCT00995462|Experimental|Small-group seminar for 2 years|
33274818|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
33274819|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
33274820|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
33274821|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
33274822|NCT01016223|Placebo Comparator|Matched inhaler|
33274823|NCT01087645|Experimental|Trial part 1|
33274824|NCT01087645|Experimental|Trial part 2|
33274825|NCT04151121|Experimental|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
32774848|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
32774849|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
32774850|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
32774851|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
32774852|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
33274826|NCT04151121|No Intervention|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
32774853|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
32774854|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
32774855|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
32774856|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
33274827|NCT04151017|Experimental|Autologous fibrin glue|
33274828|NCT04151017|Active Comparator|Sutures|
33274829|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
33274830|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
32774857|NCT04898569|Experimental|Ferinject®|
32774858|NCT04898569|Placebo Comparator|Normal saline|
32774859|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
32774860|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF >50%; Elevated levels of natriuretic peptides (NT-pro BNP > 300 pg/ml in sinus rhythm, >600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
32774861|NCT04391491||Microvascular angina|Patients of both sexes and > 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (>1 mm down-sloping or rectilinear ST-segment depression in >2 leads)); No fixed stenosis (>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
32774862|NCT04391491||Pulmonary hypertension|Patients of both sexes and > 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
32774863|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
32774864|NCT02489799|Active Comparator|Intervention|Advance care planning video
32774865|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
32774866|NCT04401319|Sham Comparator|Sham Stimulation Group for Crossover Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the crossover study.
32774867|NCT04401319|Active Comparator|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
33274831|NCT01085617|Active Comparator|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
33274832|NCT01085617|Experimental|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
33274833|NCT01085617|Active Comparator|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
33274834|NCT01085617|Experimental|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
33274835|NCT01085617|Active Comparator|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
33274836|NCT01085617|Experimental|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
33274837|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
33274838|NCT03963661|Experimental|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
33081691|NCT04645888|Active Comparator|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
33274839|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
33274840|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
33274841|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
33274842|NCT01019421|Experimental|Lu AE58054|
33274843|NCT01019421|Placebo Comparator|Placebo|
33274844|NCT01085695|Experimental|1|
33274845|NCT01085695|Experimental|2|
33274846|NCT01085695|Experimental|3|
33274847|NCT01085695|Active Comparator|4|
33274848|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
32774868|NCT04401319|Active Comparator|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
33081692|NCT04645888|Active Comparator|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
33274849|NCT01088035|Experimental|Carboplatin|
33081693|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
33081694|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
33081695|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
32774869|NCT04401319|Sham Comparator|Sham Stimulation Group for Parallel Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
32774870|NCT04401319|Active Comparator|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
32774871|NCT04401319|Active Comparator|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
32774872|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
32774873|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
32774874|NCT05457699|Experimental|SABR consolidation|
32774875|NCT05457699|Active Comparator|Control - no SABR consolidation|
33081696|NCT00558337|Active Comparator|A|
32774876|NCT04391257|Other|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
32774877|NCT04917861|Experimental|mRNA-1893 Low Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
32774878|NCT04917861|Experimental|mRNA-1893 High Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
32774879|NCT04917861|Experimental|mRNA-1893 High Dose (1-Dose Regimen)|Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.
33081697|NCT00558337|Active Comparator|B|
33081698|NCT04646278|Experimental|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
33081699|NCT04645849||"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
33081700|NCT04645849||"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
33274850|NCT03961477|Active Comparator|IF group|Interferential therpapy
32774880|NCT04917861|Placebo Comparator|Placebo|Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
32774881|NCT04884841||Patients with postoperative complications|Patients with postoperative complications
33274851|NCT03961477|No Intervention|Placebo|No intervention
33274852|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
33274853|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
33274854|NCT00751127|Active Comparator|Timolol|
33274855|NCT00751127|Experimental|PhXA41|
33274856|NCT00751205|Experimental|Arm 1|
33274857|NCT00751205|Placebo Comparator|Arm 2|
33274858|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
33274859|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
33274860|NCT00751283|Experimental|1|GRST Peripheral Catheter System
33274861|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
33274862|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
33274863|NCT00751361|No Intervention|2|No treatment control group
33274864|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
33274865|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
32774882|NCT04884841||Patients without postoperative complications|Patients without postoperative complications
32774883|NCT04884529|Experimental|Chair Yoga Treatment Group|The chair-yoga session will occur for 8-weeks (60 minutes/week) on Zoom. The chair-yoga intervention will include gentle seated postures, relaxation using breathing techniques, and a mindfulness component.
33081701|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
32774884|NCT04884529|No Intervention|Waitlist Control Group|These participants will be on a waitlist to receive the chair yoga program after data collection has been completed (e.g., after 8-weeks).
32774885|NCT04884217|Active Comparator|Pro-ocular™|Pro-ocular™ Topical Gel
32774886|NCT04884217|Placebo Comparator|Placebo|Placebo Topical Gel
32774887|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
32774888|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
32774889|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
32774890|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
32774891|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
32774892|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
32774893|NCT04898335||Tendyne|all patients treated with a Tendyne Mitral Valve System
32774894|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
32774895|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
32774896|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~Cycle 1: cytarabine, HPC-A donor infusion~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
32774897|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
32774898|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
33081702|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
33081703|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
33081704|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
33081705|NCT00558454|Placebo Comparator|1|Placebo
33081706|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
33081707|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
33081708|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
33081709|NCT04645615|Experimental|CURE AF|
33081710|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
33081711|NCT04645459|Experimental|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
33081712|NCT04645459|Placebo Comparator|control group|The boiling method did not process for the control meals.
33081713|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
33081714|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
33081715|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
33081716|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
33081717|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
33081718|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
33081719|NCT00558805|Other|2|Usual Care
33081720|NCT04645303|Experimental|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
33081721|NCT04645303|Active Comparator|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
33274866|NCT00752141|Experimental|1|oral oxybutynin
33274867|NCT00752141|Experimental|2|oxybutynin topical gel
33274868|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
33274869|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
32774899|NCT04914195|Experimental|Leuprolide acetate 3.75 mg Depot (Luprodex)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
32774900|NCT04914195|Active Comparator|Leuprolide acetate 3.75 mg Depot (Lucrin)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
33081722|NCT04644835|Experimental|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
32774901|NCT04913025|Active Comparator|Standard interval|Standard of care regimen Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 4 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 6 weeks
32774902|NCT04913025|Experimental|Extended interval|Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 8 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 12 weeks
32774903|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
32774904|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
32774905|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
32774906|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
32774907|NCT02487771|Placebo Comparator|Placebo Capsule|
32774908|NCT02487771|Experimental|DHA Capsule|
32774909|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
32774910|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
32774911|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
32774912|NCT04898101|Experimental|Cohort 1|Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (<10 μg; <=1 μCi) [14C]ACP-196 as a 5 mL IV push over 2 minutes.
32774913|NCT04898101|Experimental|Cohort 2|Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (<10 μg; <=1 μCi) of [14C]ACP-196.
33081723|NCT04644835|Sham Comparator|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
33081724|NCT04644757|Experimental|Treatment|
33081725|NCT04644718|Experimental|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
33081726|NCT04644718|Sham Comparator|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
33081727|NCT04644562|Experimental|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
33081728|NCT04644484|Experimental|Experimental Group: SYN023+Rabies Vaccine|"SYN023:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid, Dosage: 0.3 mg/kg of SYN023 Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
33081729|NCT04644484|Active Comparator|Control Group: HRIG+Rabie Vaccine|"HRIG:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid, Dosage: 20 IU/kg Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
33274870|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
33274871|NCT00751517|Active Comparator|A|Cyclophosphamide
33274872|NCT00751517|Experimental|B|Methotrexate
33274873|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
33274874|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
33274875|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
33274876|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
33274877|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
33274878|NCT02561117|Experimental|q24h|Metronidazole given once daily
33274879|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
33274880|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
33274881|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
32736879|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
32736880|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
32736881|NCT03241693|Other|control group|Physiotherapy students
33274882|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
33274883|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
32736882|NCT03241693|Experimental|experimental group|Physiotherapy students
33274884|NCT00490815|Experimental|1|
33274885|NCT00490815|Experimental|2|
33274886|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
33274887|NCT01016301|No Intervention|Control|Usual care
32736883|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
33274888|NCT01014663|Active Comparator|Therapeutic Exercise|
33274889|NCT01014663|Active Comparator|Non-Contact Boxing Training|
33274890|NCT04150263|Other|Traditional IOL repositioning|Intraocular lens (IOL) ab externo scleral suture fixation
33274891|NCT04150263|Other|Modification of traditional IOL repositioning|Modified intraocular lens (IOL) ab externo scleral suture fixation
33274892|NCT01019499|Active Comparator|berry products|Berry products
33274893|NCT01019499|Placebo Comparator|control products|Control products
33274894|NCT04453137|Active Comparator|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
33274895|NCT04453137|Active Comparator|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
33277589|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
32736884|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
32736885|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
32736886|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
32736887|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
32736888|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
33277590|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
33277591|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
32736889|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
32736890|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
32736891|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
33277592|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
33277593|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
33277594|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
33277595|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
33277596|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
33277597|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
33277598|NCT05187650|Experimental|Ekso and FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton combined with gait-synchronized FES using the FES RehaMove2.
33277599|NCT05187650|Active Comparator|Ekso without FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton without applying FES.
33277600|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
33277601|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
33274896|NCT04453137|Experimental|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:~Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),~Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),~Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
33274897|NCT04453137|Experimental|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
33274898|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
32736892|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
32736893|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
33274899|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
33274900|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
33274901|NCT03853551|Experimental|Single|Single arm
33274902|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
32736894|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
32736895|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
33274903|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
33274904|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
33274905|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
33274906|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
33274907|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
33274908|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
33274909|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
33274910|NCT03996759||Critically ill patients|Patients admitted in ICU
33274911|NCT01019577|Experimental|Ixabepilone|
33274912|NCT05072535|Experimental|Part 1-Group A|Subjects will receive 200 mg HA121-28 tablet A on Day 1 of the first cycle, followed by tablet B on Day 36 of the second cycle, in the fasted state.
33274913|NCT05072535|Experimental|Part 1-Group B|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle, followed by tablet A on Day 36 of the second cycle, in the fasted state.
33274914|NCT05072535|Experimental|Part 2-Group C|Subjects will receive 200 mg HA121-28 tablet B on Day1 of the first cycle in fasted state, followed by tablet B on Day 36 of the second cycle in the fed state.
33274915|NCT05072535|Experimental|Part 2-Group D|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle in the fed state, followed by tablet B on Day 36 of the second cycle in fasted state.
33277602|NCT05186948||Breast cancer patients (stages I-IIIA)|200 patients with an initial diagnosis of breast cancer stages I-IIIA and scheduled chemotherapy, fulfilling the eligibility criteria
33277603|NCT05186948||healthy control|Group of 30 healthy control participants, matched for age and sex, with no evidence or history of significant neurodegenerative disorder affecting brain function.
32736896|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
32736897|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
32736898|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
32736899|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
32736900|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
32736901|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
33274916|NCT03996837|Experimental|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
33274917|NCT03996837|No Intervention|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
33274918|NCT03996837|Experimental|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
33274919|NCT03996837|No Intervention|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
33274920|NCT03996681|Experimental|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
33274921|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
33274922|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
33274923|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
33274924|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
33274925|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
33274926|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
33274927|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
33274928|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
33274929|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
32736902|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
32736903|NCT03241147|Experimental|Healthy subjects (Group B)|
32736904|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
32736905|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
32736906|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
32736907|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
32736908|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
32736909|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
32736910|NCT04499417|Experimental|Experimental-Condition|"8 weeks x weekly 20 minutes whole-body-workouts with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
32736911|NCT04499417|Sham Comparator|Sham-Condition|"8 weeks x weekly 20 minutes whole-body-workouts without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are not actually stimulated by EMS."
32736912|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
32736913|NCT03235921|Other|control group|no drug given to the patients in control group
32736914|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
32736915|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
32736916|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
32736917|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
32736918|NCT04499183|Experimental|non-digestible carbohydrates|fructo- and galacto-oligosaccharides
32736919|NCT04499183|Placebo Comparator|placebo|maltodextrin
33274930|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
32774914|NCT04884451|Experimental|Intervention|Participants will receive nutritional counselling from the researcher based on Stage-Based, Nutrition Education Package for Childhood Obesity (ST-NEPCO). Nutritional advice and educational tools will be provided according to participants' stages of change.
33274931|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
33274932|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
33274933|NCT00483405|Other|Single Arm Trial|Single Arm Trial
32774915|NCT04884451|No Intervention|Control|Participants will receive counseling from dietitians based on the routine care for the management of childhood obesity.
33274934|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
32774916|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
32774917|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
32774918|NCT04887727|Experimental|Healthy, recreationally-active adult males - Muscle Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine and L-ring-[2H5]phenylalanine with a primed-constant infusion of L-[555-2H3]leucine to assess myofibrillar protein synthesis rates
32774919|NCT04887727|Experimental|Healthy, recreationally-active adult males - Whole Body Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine with a primed-constant infusion of L-[555-2H3]leucine to whole-body protein turnover, amino acid oxidation, and net protein balance
33081730|NCT04644250|Experimental|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
33081731|NCT04644211|Experimental|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
33274935|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
33274936|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
33274937|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
33274938|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
33274939|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
33274940|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
33274941|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
33274942|NCT00752531|Experimental|HAT|
33274943|NCT00752531|No Intervention|Control|
33274944|NCT04055987|Experimental|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
33274945|NCT04055987|Experimental|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
33274946|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
33274947|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
33274948|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
33274949|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
33274950|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
33274951|NCT02561507||American College of Surgeons members|Survey participants
33274952|NCT00751907|Experimental|Atorvastatin|40mg Atorvastatin nightly for 4 months
33274953|NCT00751907|Placebo Comparator|Placebo|matching placebo nightly for 4 months
33274954|NCT00752843|Experimental|1|
33274955|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
33274956|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
33274957|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
33274958|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
33277604|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
33274959|NCT04051541|Other|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
33274960|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
33274961|NCT00683657|Placebo Comparator|Placebo + Metformin|
33274962|NCT00755963|Experimental|1|
32774920|NCT04887493|Experimental|Sublingual misoprostol|Sublingual misoprostol group will receive misoprostol 25µg by sublingual routes; the dose will be given repeatedly every 4 hours by sublingual route till there is labour pain or contraction or to a maximum of 6 dosages.
32774921|NCT04887493|Experimental|Vaginal misoprostol|Vaginal misoprostol group will receive misoprostol 25µg by per vaginal routes; the dose will be given repeatedly every 4 hours by per vaginal route till there is labour pain or contraction or to a maximum of 6 dosages.
33274963|NCT00755963|Experimental|2|
33274964|NCT00755963|Placebo Comparator|3|Placebo
33274965|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
32774922|NCT04898257|Other|Lactibiane Tolerance®|30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
32774923|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
32774924|NCT04897633|Experimental|Patients ON|Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)
32774925|NCT04897633|Experimental|Patients OFF|Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)
32774926|NCT04897633|Experimental|Healthy volunteers|Healthy volunteers will performed Simon's task with tDCS active or sham
32774927|NCT04887103|Experimental|hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
32774928|NCT04887103|No Intervention|Control group|There will be no intervention other than routine follow-up and maintenance.
33274966|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
33274967|NCT00756041|Experimental|TAK-128 100 mg QD|
33274968|NCT05388851|Experimental|Prevention (Educational training)|Participants complete an educational training module and complete questionnaire at baseline (before educational training module) and 3 months after completing educational training.
32774929|NCT04887181|Active Comparator|Teethmate Desensitizer|Tetracalcium phosphate and dicalcium phosphate containing desensitizer
32774930|NCT04887181|Active Comparator|Gluma Desensitizer|%35 hydroxyethyl methacrylate and %5 glutaraldehyde containing desensitizer
33274969|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
32774931|NCT04887181|Active Comparator|Hybrid Bond|Self-etch adhesive resin
32774932|NCT04883515|Experimental|Oral glutamine supplementation|patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
32774933|NCT04883515|Active Comparator|Oral protein powder supplementation|patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
32774934|NCT04883593|Experimental|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
33274970|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
33274971|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
33274972|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
33274973|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
33274974|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
33274975|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
33274976|NCT00756587|Experimental|II|Group 2 received all feeding by cup
33274977|NCT00756743|Experimental|PF-04802540|
33274978|NCT00756743|Placebo Comparator|Placebo|
33274979|NCT00753389||1|
33274980|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
33274981|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
33274982|NCT00680771||1|Primary Insomnia
33274983|NCT00680771||2|Good Sleepers
33274984|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
33274985|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
33274986|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
33274987|NCT00482703|Experimental|A|
33274988|NCT00482703|Experimental|B|
33274989|NCT00756899||Obese|Chilren with BMI of >95th percentile
33274990|NCT00756899||Non-obese|Children with BMI of <85th percentile
33274991|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
33274992|NCT00757055|Placebo Comparator|2|No therapy given
33274993|NCT04052867|Experimental|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
33274994|NCT04052867|Active Comparator|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
33274995|NCT00757133|Experimental|1|Conventional laparotomy closure
33274996|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
32774935|NCT04883593|Placebo Comparator|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
32774936|NCT04883203|Active Comparator|VITD|A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,
32774937|NCT04883203|Placebo Comparator|Placebo|A single vial of physiological salin Oral form
32774938|NCT04897789||children/pregnant women|children/pregnant women (2,310)
33274997|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
33274998|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
33274999|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
33275000|NCT00757289|Experimental|1|PRP injection
33275001|NCT00757289|Active Comparator|2|Corticosteroid Injection
33275002|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
33275003|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
33275004|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
32774939|NCT04897789||parents|parents (2,310)
33275005|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
33275006|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
32774940|NCT04897789||classrooms/teachers|classrooms/teachers (840)
32774941|NCT04897789||home visitors|home visitors (630)
32774942|NCT04897789||center directors|center directors (493)
33275007|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
33275008|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
33275009|NCT00757679|Experimental|Milnacipran|
33275010|NCT00757679|Placebo Comparator|Placebo|
33275011|NCT00754091|Experimental|1|
33275012|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
32774943|NCT04897789||program directors|program directors (140)
32774944|NCT04883047|Experimental|experiment|"Women in the experimental group will be given care at the first stage of labor (will start in the latent phase) using Integrated Birth Support Strategies created in line with the Algorithm for Coping with Birth Pain.~Among the interventions made into a checklist, the interventions applied to the woman will be marked by the midwives and nurses working in the delivery room. The Scale for Coping with Birth Pain (DABS), which will be applied once in each phase (latent phase, active phase and transition phase), will guide the delivery of care; Care practices will differ depending on the woman's ability to cope with labor pain.At least 3 of each sub-heading of the physical comfort parameter, at least 1 of each sub-heading of the parameter of providing emotional comfort, at least 2 of each sub-heading of informative support and advocacy sub-parameters will be applied to pregnant women by midwives / nurses working in the delivery room."
32774945|NCT04883047|No Intervention|control|Pregnant women assigned to the control group will be followed up with the routine care applied in the delivery room.
32774946|NCT04897555|Experimental|LLLT Active Treatment|LLLT Therapy will be administered to the treatment site.
32774947|NCT04897555|No Intervention|No LLLT Comparator|No LLLT Therapy will be administered to the comparator site.
33275013|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
33275014|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
33275015|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
33275016|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
33275017|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
33275018|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
33275019|NCT00757913|Experimental|1|n-3 enriched nutrition
33275020|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
33275021|NCT01038154|No Intervention|control|Not Receive pravastatin
33275022|NCT01038154|Experimental|Pravastatin|
33275023|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
33275024|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
33275025|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
33275026|NCT04052321|Experimental|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
33275027|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
33275028|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
33275029|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
33275030|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
33275031|NCT04052165|Experimental|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
33275032|NCT04052009|Experimental|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
33275033|NCT04052009|Active Comparator|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
33275034|NCT04052009|Active Comparator|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
33275035|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
33275036|NCT00754403|Active Comparator|Metformin 1000 mg QD|
33275037|NCT00754481|Active Comparator|1|
33275038|NCT00754481|Experimental|2|
33275039|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
32774948|NCT04882969|Experimental|Fractionated Thulium Laser and KeraFactor|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied KeraFactor every 2 weeks for 12 week period.
32774949|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
32774950|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
32774951|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
32774952|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
32774953|NCT02418819|Placebo Comparator|Placebo|Placebo BID
32774954|NCT04886869|Experimental|Coffee|Oral consumption of 3 cups of coffee containing 240 mg caffeine
32774955|NCT04886869|Experimental|Energy drink|Oral consumption of 750 mL of a commercial energy drink containing 240 mg caffeine
32774956|NCT04886869|Placebo Comparator|Placebo|Oral consumption of 750 mL water
32774957|NCT04886947|Experimental|stem cell intervention|"Arm A patients who will have surgery with stem cell added.~Arm B only surgery with no stem cell added."
33275040|NCT00758225|Experimental|only one arm|
33275041|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
33275042|NCT00754715|Experimental|AZD2516|
33275043|NCT00754715|Placebo Comparator|Placebo|
33275044|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
33275045|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
33275046|NCT00422734|Placebo Comparator|1|Placebo
33275047|NCT00422734|Active Comparator|2|5 mg tadalafil
33275048|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
33275049|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
33275050|NCT03916198|Experimental|PDRN(polydeoxyribonucleotide)|polydeoxyribonucleotide 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
33275051|NCT03916198|Placebo Comparator|CONTROL(normal saline)|normal saline 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
33275052|NCT00422422|Experimental|Brivaracetam|
33275053|NCT00413374|Other|Enoxaparin|
33275054|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
33275055|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
33275056|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
33275057|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
33275058|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
33275059|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
32774958|NCT04897477|Experimental|combination of Azacytidine, Bendamustine and Piamprizumab|combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days
32774959|NCT04886713||Obese HFpEF|Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²
33275060|NCT05436119||GrowBaby|All pregnant women presenting at < 19 weeks EGA for prenatal care covered by Molina Health of Nevada MCO will be offered the GrowBaby group nutrition and lifestyle program. Primary and secondary outcomes of those who opt out of the program will be compared to those who opt in. Additionally, all women who develop primary or secondary outcomes in the GrowBaby arm will be compared to those who do not develop primary or secondary outcomes (nested case-control). Outcomes will be compared locally, regionally and nationally within the Medicaid population, as well.
33275061|NCT00754871|Experimental|Arm 1|
33275062|NCT00754871|Experimental|Arm 2|
32774960|NCT04886713||Obese controls|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI ≥ 30kg/m²
32774961|NCT04886713||Lean control|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI < 30kg/m²
33275063|NCT00754871|Experimental|Arm 3|
33275064|NCT00754871|Experimental|Arm 4|
32774962|NCT04882813||Dapagliflozin|Exposure group
33275065|NCT05435807|Experimental|intervention group|Clinical Pilates Exercises+TNE
33275066|NCT05435807|Experimental|control group|Clinical Pilates Exercises
33275067|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
32774963|NCT04882813||Sitagliptin|Reference group
32774964|NCT04882891|Experimental|MS patients|Ambulant patients with multiple sclerosis
32774965|NCT04897243||Multidisciplinary model of care|The Chronic Viral Illness Service at the Glen hospital of the MUHC will provide care with a multidisciplinary assessment, according to local current standard practice. Each newly-referred patient at the CVIS will be first received by a dedicated nurse, who then orients referral to a physician and/or a social worker and/or a pharmacist.
33275068|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
33275069|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.~Treatment continues until progression or unacceptable toxicity."
33275070|NCT05435729|Experimental|DSP-9632P 27.5 mg in Periods 3 of Part A|Single dose of DSP-9632P 27.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
33275071|NCT05435729|Experimental|DSP-9632P 82.5 mg in Periods 4 of Part A|Single dose of DSP-9632P 82.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
33275072|NCT05435729|Experimental|DSP-9632P 55.0 mg in Period 1 or 2 of Part B|Multiple dose of DSP-9632P 55.0 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
33275073|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33275074|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
33275075|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
33275076|NCT05435495||Participants undergoing 177Lu-PSMA-617 treatment|Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
33275077|NCT05435183|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high-frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
33275078|NCT05435183|Active Comparator|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
33275079|NCT04050059|Active Comparator|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
33275080|NCT04050059|Active Comparator|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
33275081|NCT05435105|Experimental|Virtual Reality Group|Watching the cartoon by wearing virtual reality glass to the child during the peripheral intravenous catheterization
33275082|NCT05435105|Experimental|Local Cold-Vibration Group|The local cold-vibration device is placed 5 cm above the area just before peripheral intravenous catheterization
33275083|NCT05435105|No Intervention|Control Group|Routine Care
32774966|NCT04897243||Physician-only model of care|The Jewish General Hospital will provide care as per current local standard practice. Each newly-referred patient will be assessed by a clinician. Blood tests will be performed by central laboratory nurses who are not part of the HIV clinic.
33275084|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
33275085|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
33275086|NCT05434949||Effect of food intake on C4|Blood tests to analyse serum C4 pre, and 2 and 4 hours post a standardised meal, and the same 10 patients to analyse serum C4 at 0, 2 and 4 hours, all fasting.
33275087|NCT05434949||Effect of Lipid-lowering therapy on C4|Spare sample collected from patients before and after starting on lipid-lowering therapy will be used to measure C4 before and after lipid-lowering therapy.
33275088|NCT02150967|Experimental|BGJ398 (infigratinib)|To estimate the anti-tumor activity of BGJ398 (infigratinib)
32774967|NCT04886557||DDS fixation|Adult patients with degenerative spondylolisthesis over L4-L5 received DDS with a minimum of 2-year follow-up were reviewed. Surgical indications were patients who failed to respond to conservative treatment for at least 6 months. The exclusion criteria were: (1) presence of degenerative scoliosis or spinal deformity, (2) prior spine surgery, (3) lost to follow-up, or (4) failure to complete the questionnaires or radiographic examinations.
32774968|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
32774969|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
32774970|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
32774971|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
32774972|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
32774973|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
32774974|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
32774975|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
32774976|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
32774977|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
32774978|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
32774979|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
32774980|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
32774981|NCT04896853|Experimental|Treatment|Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells.
32774982|NCT05530031|Experimental|pediatric glaucoma patients either primary or secondary|All Cases with pediatric glaucoma prepared for trabeculotomy including Primary congenital glaucoma and secondary glaucoma as : glaucoma following cataract surgery and traumatic glaucoma
32774983|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|
33275089|NCT02560103||Single group|No treatment
33275090|NCT05434871|Experimental|Yoga Group|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
33275091|NCT05434871|Active Comparator|Control Group|The routine physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
33275092|NCT00482001|Experimental|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
33275093|NCT00482001|Placebo Comparator|placebo|placebo (cornstarch), capsule, once daily for 14 days
33275094|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
33275095|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
33275096|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
33401888|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
32774984|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|
32774985|NCT04897165|No Intervention|Waitlist controls|
32774986|NCT05529875|Active Comparator|Group PRO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and propofol in TCI effect compartment concentration 4-6ug/kg.~Anesthesia was maintained with propofol in TCI effect compartment concentration 3-4ug/kg."
32774987|NCT05529875|Active Comparator|Group SEVO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and sevoflurane in the method of vital capacity with inspired-limb drug concentration measured upon 6%.~Anesthesia was then maintained with sevoflurane in vaporizer concentration 1.5-2%."
33081732|NCT04644211|Experimental|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.~In stage 2, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
33081733|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
33081734|NCT00217919|No Intervention|2|Usual care
33081735|NCT04644445|No Intervention|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
33081736|NCT04644445|Experimental|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
33081737|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
33081738|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
33081739|NCT04643938||Two spontaneous abortions|No intervention
33081740|NCT04643938||three spontaneous abortions|No intervention
33081741|NCT04643938||Four or more spontaneous abortions|No intervention
33081742|NCT04643977|Experimental|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
33081743|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
33081744|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
33081745|NCT04643821|Experimental|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
33081746|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
33081747|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
33081748|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
33081749|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
33081750|NCT04643236|Experimental|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
33081751|NCT04643236|Active Comparator|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
33081752|NCT00559000|No Intervention|Waitinglist Control|
33081753|NCT00559000|Experimental|KIDNET|
33081754|NCT00414570|Experimental|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.
33081755|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
33081756|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
33081757|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
33081758|NCT00559117|Experimental|Cohort|
33081759|NCT04643275|Experimental|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
33081760|NCT04643041|Experimental|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
33081761|NCT04642924|Experimental|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
32774988|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
33275097|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
33275098|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
33275099|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
33275100|NCT01016535||Children, Health Professionals|
33275101|NCT00404248|Active Comparator|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
33275102|NCT00404248|Active Comparator|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
33275103|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
32774989|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
33275104|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
33275105|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
32774990|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
32774991|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
32774992|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
33275106|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
33275107|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
32774993|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
32774994|NCT05529719|Other|Control group|Patients assigned to the control group were given theoretical training and a brochure containing MBA information. The control group patients participating in the evaluation session were recommended to be included in the same clinical Pilates training conducted by the intervention group after the study was completed.
32774995|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
33275108|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
33275109|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
33275110|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
33275111|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
33275112|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
33275113|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
33275114|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
33275115|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
33275116|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
33275117|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
33275118|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
33275119|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
33275120|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
33275121|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
33275122|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
33275123|NCT04261491|Experimental|postmenopausal women with chronic periodontitis|postmenopausal women with chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers IL-6
33275124|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
33275125|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
33275126|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
33275127|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
33275128|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
32774996|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
33275129|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
33275130|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
33275131|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
33275132|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
32774997|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
32774998|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
32774999|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
32775000|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
32775001|NCT04885933||COPD exacerbation|
32775002|NCT05529641|Experimental|Combined diaphragmatic resistance training and cervical stabilization exercise group|Participants in this group will receive supervised cervical stabilization exercise and diaphragmatic resistance training as home grogram.
32775003|NCT05529641|Active Comparator|Cervical stabilization exercise group|Participants in this group will only receive supervised cervical stabilization exercise.
33275133|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
33275134|NCT00420628|Placebo Comparator|Vehicle|Vehicle
32775004|NCT04883125|Active Comparator|Interventional no|Patients treated with both drugs ( imatinib and pioglitazone)
32775005|NCT04883125|No Intervention|Control|Historical control (treated with imatinib only)
32775006|NCT04882423|Experimental|Test meal 1 - grilled hamburger (7 oz) with no vegetables|Randomly assigned participants are given grilled hamburger (7 oz) with no vegetables
33081762|NCT04642924|Experimental|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
33277605|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
33277606|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
33277607|NCT00773825||1|Pregnancy after ICSI or IVF
33277608|NCT00773825||2|Pregnancy after ovarian stimulation
33277609|NCT00773825||3|natural pregnancy
32775007|NCT04882423|Experimental|Test meal 2 - grilled hamburger with steamed broccoli and Brussels sprouts|Randomly assigned participants are given grilled hamburger with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
32775008|NCT04882423|Experimental|Test meal 3 - grilled hamburger with steamed parsnips, fresh parsley, and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
32775009|NCT04882423|Experimental|Test meal 4- grilled hamburger with broccoli, Brussels sprouts, parsnips, parsley and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
32775010|NCT05529563||obesity without AN (OB group) and obesity with AN (AN group)|LSG
33081763|NCT04643119|Active Comparator|Cruciate-Retaining Insert|
33081764|NCT04643119|Experimental|Medial-Congruent Insert|
33081765|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
33275135|NCT03993808|Experimental|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
33275136|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
33275137|NCT00489255|Placebo Comparator|Inactive substance|
33275138|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
33275139|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
33275140|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33275141|NCT03994042|Experimental|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
33275142|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
33275143|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
33275144|NCT03993886|Other|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
33275145|NCT03993886|Other|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
33275146|NCT03993886|Other|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
33275147|NCT03993886|Other|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
33275148|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
33275149|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
33275150|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
33275151|NCT00420238|Experimental|A|
33275152|NCT00420238|Placebo Comparator|B|
33275153|NCT01016925|No Intervention|Control|
32775011|NCT04882267|No Intervention|Determination of attitudes and perceived barriers to exercise|Adults with CF will take part in a quantitative modified Exercise Benefits/Barriers Scale (EB/BS) survey to identify universal and unique benefits and barriers to regular exercise activity. Subjects will be surveyed on potential ways to engage in exercise, including perceptions and prior use of smart device exercise technology. Qualitative input will be incorporated to better understand potential solutions to barriers, and develop more personalized plans for exercise engagement.
32775012|NCT04882267|No Intervention|Determination of baseline exercise activity (Baseline Period)|Adults with CF who identify as 'willing to use technology' and own compatible smart phones/tablets will undergo the Short General Health Questionnaires (GHQ 12) to establish baseline levels of general and mental health. Subjects will be fitted with wrist actigraphy and monitored for four weeks to establish baseline levels of exercise activity at home. Anticipated outcomes: Access to actigraphy will encourage personal accountability, and physical activity will increase during the first two weeks before reaching a plateau.
33081766|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
33275154|NCT01016925|Experimental|femoral tunnelized perineural catheter|
33275155|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
33081767|NCT04643197|Experimental|Experimental arm|Abdominal fascia will be closed with barbed suture.
33275156|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
33275157|NCT04362657|Experimental|Computer aided diagnosis|Using CAD to assist in completeness of the examination during OGD
33275158|NCT04081545|Active Comparator|Control Goup A- Opioid-based regimen|"Preop - Multimodals unless contraindicated~Induction~Fentanyl (50mcg IV)~Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Maintenance~Sevoflurane~Neuromuscular blockade at discretion of anesthesiology team~May use fentanyl to treat SBP or HR > 20% of baseline~Emergence~Neuromuscular reversal, dosed according to Virginia Mason protocol~May titrate fentanyl per anesthesiology team throughout the case.~Patient extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
33277610|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
33275159|NCT04081545|Experimental|Experimental Group B- Opioid-free regimen|"Preop - Multimodals unless contraindicated~Induction~Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW~Lidocaine 1.5mg/kg IV bolus using IBW~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Ketamine 0.5mg/kg IV bolus (based on IBW)~Maintenance~Sevoflurane~Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)~Lidocaine 2mg/kg/hr IV infusion using IBW~May use esmolol as needed to treat SBP or HR > 20% of baseline~Neuromuscular blockade at the discretion of anesthesiology team~Emergence~Dexmedetomidine infusion turned off during laparoscopic desufflation~Lidocaine infusion turned off at skin closure~Neuromuscular reversal, dosed according to VM protocol~Pt extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
33275160|NCT04073745|Experimental|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
33275161|NCT03994432|Experimental|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
33275162|NCT03994432|No Intervention|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
32775013|NCT04882267|Experimental|Engagement in home self-directed exercise incorporating Team and Technology (Intervention Period)|"Subjects will take part in a live demonstration of three subscription-based AI-learning home exercise apps, and one self-directed exercise website designed by a CF patient partner. Subjects will be surveyed on willingness to use technology, and provide feedback on exercise options. They will be given free full access to the apps and website (Technology), and receive a phone call once a week from their CF specialty team offering encouragement and positive reinforcement (Team). App and website usage, actigraphy, EB/BS and GHQ 12 scores will be measured at the end of four weeks. Anticipated outcomes: Activity will increase significantly during the Team and Technology intervention period, barriers on the EB/BS score will decrease, and GHQ 12 scores will increase."
33081768|NCT04643197|Active Comparator|Control|Abdominal fascia will be closed with non-barbed suture.
33275163|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
33275164|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
33275165|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
33275166|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
33275167|NCT00494481|Experimental|2|Vandetanib + Docetaxel
33275168|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
33275169|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
33275170|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
33275171|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
33275172|NCT00097591|Experimental|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
33275173|NCT00097591|Active Comparator|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
33275174|NCT01082029|Experimental|Lansoprazole|
33275175|NCT01082029|Placebo Comparator|Placebo|
33275176|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
33275177|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
33275178|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
33275179|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
33275180|NCT01040572||Obesity recidivism after gastric bypass|
33275181|NCT00419770|Experimental|B|Deferasirox
33275182|NCT00419770|Placebo Comparator|A|
33275183|NCT00080119|Experimental|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
33275184|NCT00080119|Placebo Comparator|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
33275185|NCT00080119|Experimental|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
33275186|NCT00080119|Placebo Comparator|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
33275187|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
33275188|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
33275189|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
32775014|NCT04882267|Active Comparator|Determination of sustainability (Sustainability Period)|Phone calls will cease, but subjects will maintain access to apps, websites, and actigraphy. After four weeks, EB/BS and GHQ 12 scores, physical activity, app and website use will be reassessed. Anticipated outcomes: Activity will decrease during the sustainability period, but will remain significantly greater than the pre-intervention period. Overall GHQ 12 and EB/BS scores will improve.
32775015|NCT05534633|Other|Participants requesting test(s) for HIV, HCV, and/or syphilis|
32775016|NCT05481125|Experimental|Clareon/Clareon Toric|Phacoemulsification surgery, followed by implantation with Alcon Clareon Aspheric Hydrophobic Acrylic IOL or Alcon Clareon Aspheric Hydrophobic Acrylic Toric IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
32775017|NCT05481125|Active Comparator|Eyhance/Eyhance Toric|Phacoemulsification surgery, followed by implantation with TECNIS Eyhance IOL or TECNIS Eyhance Toric II IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
33275190|NCT03961633|Experimental|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
33275191|NCT01040650||Normal Controls|Normal Controls
33275192|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
33275193|NCT01082107|Other|Solar disinfection of drinking water|
33275194|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
33275195|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
33275196|NCT03961399|Active Comparator|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
33275197|NCT03961399|Experimental|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
33275198|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
33275199|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
33275200|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
33275201|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
33275202|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
33275203|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
33275204|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
33275205|NCT01088113||Qigong|Healthy subjects with Qigong practice
33275206|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
33275207|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:~negative: watchful waiting including confirmatory ultrasound~positive: diagnostic thyroid surgery as planned"
33275208|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
33275209|NCT00494091|Experimental|A.|
33275210|NCT00494091|Experimental|B.|
33275211|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
33275212|NCT01017159|Placebo Comparator|Saline|
33275213|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
33275214|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
33275215|NCT00079339|Experimental|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
33275216|NCT01020201||PONV group|patients with postoperative nausea and vomiting
33275217|NCT01020201||Control group|patients without postoperative nausea and vomiting
33275218|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
33275219|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
33275220|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
33275221|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
33275222|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
33275223|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
33275224|NCT01017315|Experimental|No application of baby talcum|control
33275225|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A:~Schedule B:~Expansion Phase~Schedule A:~Schedule B:"
33275226|NCT01082419|Other|Group A|healthy volunteers
33275227|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
33275228|NCT01082419|Other|Group D|patients with cirrhosis
33275229|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
33275230|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
33275231|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
33275232|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
33275233|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
33275234|NCT01088269||AF|Hypertensive patients in AF
33275235|NCT01088269||Non-AF|Hypertensive Patients
33275236|NCT04070781|Experimental|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:~Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level~Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
33275237|NCT04070781|Experimental|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
33275238|NCT00090493|Experimental|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
33275239|NCT01088347|Experimental|Advanced cervical cancer patients|
33275240|NCT05257824|Active Comparator|short-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 6 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling
33275241|NCT05257824|Experimental|long-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 12 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling.
33275242|NCT04329702|Experimental|coping skills training plus therapist input|Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
33275243|NCT04329702|Experimental|coping skills training without therapist input|Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
33275244|NCT04329702|No Intervention|usual care control|Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.
33275245|NCT05220930|Experimental|Foot bath for heel warming group|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap. Before piercing the heel, the heel will be wiped with a blanket and dried. After the intervention, blood collection from the heel will be performed by following the standard procedure steps that are routinely applied in the service.
33275246|NCT05220930|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
33275247|NCT04302558|Experimental|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
33275248|NCT04302558|Sham Comparator|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
33275249|NCT04268004|No Intervention|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
33277611|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
33277612|NCT00778193|Placebo Comparator|Placebo|
33277613|NCT00778193|Active Comparator|Naproxen|
33275250|NCT04268004|Experimental|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
33275251|NCT04251702||Healthy Low-Risk Nulliparous Women in Spontaneous Labor|Healthy Nulliparous women with a Singleton Term fetus in the Vertex position in spontaneous labor.
33275252|NCT04226898|Experimental|Synbiotic Supplement|The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
33275253|NCT04226898|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the synbiotic supplement. In this arm, the participant will take 1 powder stick of the placebo daily for 12 weeks after a 2 week placebo run-in.
33275254|NCT05692440|Other|Basivertebral Nerve Ablation|Intraosseous radiofrequency basivertebral nerve ablation
33275255|NCT04221828|Experimental|NanoPac|Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.
33275256|NCT05138328|Experimental|Treatment of basal cell carcinoma with Nd:YAG laser|All enrolled patients will be treated with the Nd:YAG laser for this study as part of the intentional intervention for this study.
33275257|NCT04221750|Experimental|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
33275258|NCT04221750|Placebo Comparator|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
32775018|NCT04430413|No Intervention|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
33275259|NCT04221750|Active Comparator|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1 gm bid
33275260|NCT04221438|Experimental|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
33275261|NCT04198428|Experimental|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
33275262|NCT04198428|No Intervention|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
33275263|NCT04182126|Placebo Comparator|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
33275264|NCT04182126|Experimental|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
32775019|NCT04430413|Active Comparator|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
32775020|NCT04882345|Experimental|Almonertinib group|Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
32775021|NCT04882033|Experimental|Concurrent chemoradiotherapy plus anlotinib|Concurrent chemoradiotherapy plus anlotinib for 4-6 cycles This study will include a sequential evaluation of 3 subjects per dose group. Low-dose groups: anlotinib 8mg per day with concurrent chemoradiotherapy. Middle-dose groups: anlotinib 10mg per day with concurrent chemoradiotherapy. High-dose groups: anlotinib 12mg per day with concurrent chemoradiotherapy.
32775022|NCT05474183|Active Comparator|Group (K)|Group (K): (n=30) will receive ketamine infusion 1-2 μg/kg/min (0.12 mg/kg/h) titrated to desired level of sedation.
32775023|NCT05474183|Active Comparator|Group (D)|Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation.
33277614|NCT00778193|Experimental|Aspirin|
33277615|NCT00778193|Experimental|Clopidogrel|
33277616|NCT00778193|Experimental|Celecoxib|
33277617|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
33277618|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
33277619|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
33277620|NCT00778271|Experimental|1|Gabapentin 400mg capsules
33277621|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
33277622|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
33277623|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
33277624|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
33277625|NCT00995618|Experimental|Tranilast|Tranilast tablets
33277626|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
33277627|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
33277628|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
33275265|NCT04182126|Experimental|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including both physical and chemical methods by physical filling or removal of temporary larval habitats and larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. We will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
33275266|NCT04182126|Experimental|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2. The enhanced intervention is determined by machine learning method.
33275267|NCT04182126|Experimental|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the recommended frequency of once a year.
33275268|NCT04182126|Experimental|LLIN+IRS+LSM|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. LSM will be added on these clusters at Stage 2 interventions. LSM at Stage 2 will be the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
33275269|NCT04182126|Experimental|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is determined by machine learning method.
32775024|NCT05474183|Placebo Comparator|Group (C)|Group (C): (n=30) will receive fentanyl only.
32775025|NCT04885777|Active Comparator|Lidocaine group|One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
32775026|NCT04885777|Placebo Comparator|Placebo group|The Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril).
32775027|NCT05529407|Experimental|Simple Vaginal Tampon|Dilation exercises will be performed with tampon
32775028|NCT05529407|Experimental|Glass Vaginal Dilator|Dilation exercises will be performed with vaginal dilator
32775029|NCT04885855|Experimental|8-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.
32775030|NCT04885855|Active Comparator|12-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.
32775031|NCT05380505|Experimental|Condition 1: Race Congruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
32775032|NCT05380505|Experimental|Condition 2: Race Incongruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
32775033|NCT04886011|Placebo Comparator|placebo gel|Methylcellulose gel was applied to the ulcer till complete healing
32775034|NCT04886011|Experimental|camel whey protein gel|camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing
32775035|NCT05196659|No Intervention|CONTROL Group|"Regular current system of care~Treating physicians provided current cardiovascular disease management guidelines~Patients provided a leaflet (printed information) on healthy lifestyle"
32775036|NCT05196659|Active Comparator|INTERVENTION Group|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
32775037|NCT04895683|Active Comparator|Arm 1 - Control SMS|Control (current practice) text message invitation
32775038|NCT04895683|Experimental|Arm 2 - Behavioural Science informed SMS content|Experimental text message invitation
32775039|NCT04895683|Experimental|Arm 3 - Pre-alert and behavioural science informed SMS content|Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
32775040|NCT05534555|Other|Febridx|Undergo FebriDx testing
32775041|NCT04885621||underserved patients with diabetes mellitus|patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled
32775042|NCT05534399|Experimental|Sparing antibiotic strategy|No antibiotic therapy will be administered during the peri-operative period
32775043|NCT05534399|Sham Comparator|Peri-operative antibiotic strategy|"Recommendations - An antibiotic therapy will be administered during the peri-operative period.~The antibiotic will be selected according to the type of bacteria isolated and the antibiotic susceptibility testing, and started two days before and pursued until two days following intra-vesical BoNTA injections"
32775044|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
32775045|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
33275270|NCT04145466|Experimental|Fat responders (1)|receiving high-fat diet
33275271|NCT04145466|Experimental|Carbohydrate responders (1)|receiving high-fat diet
33275272|NCT04145466|Experimental|Fat responders (2)|receiving high-carbohydrate diet
33275273|NCT04145466|Experimental|Carbohydrate responders (2)|receiving high-carbohydrate diet
33275274|NCT04113018|Experimental|1|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
33275275|NCT05681442|Experimental|continuous infusion dosing of a pivotal AND AG infusion for 5 days|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
33275276|NCT05681442|Experimental|intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 days|intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
33275277|NCT05681442|Experimental|continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )
33275278|NCT05681442|Experimental|intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
33275279|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
33275280|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275281|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275282|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275283|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
32775046|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
32775047|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
32775048|NCT04379401|Other|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
32775049|NCT04379401|Other|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
32775050|NCT02632721|Experimental|Phase I: Dose Escalation|Combination treatment of decitabine with escalating doses of BI 836858
32775051|NCT02632721|Experimental|Phase I: Extension|Cohort A treated with BI 836858 plus intensive decitabine treatment schedule. Followed by Cohort B treated with BI 836858 plus standard decitabine treatment schedule.
32775052|NCT02632721|Experimental|Phase II: Arm 1|Combination treatment of decitabine with BI 836858
32775053|NCT02632721|Other|Phase II: Arm 2|Monotherapy treatment with decitabine (standard of care treatment)
32775054|NCT05529095|Experimental|Sublingual Apomorphine (Kynmobi)|Sublingual apomorphine to be titrated after initial dose of 10 mg. Titration is dependent on subjects response.
32775055|NCT05529095|Placebo Comparator|Placebo|At week 4, subjects will be given randomization packet including 2 drug doses and 2 placebos.
32775056|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
32898450|NCT00019682|Experimental|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
33275284|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275285|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275286|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
33275287|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
33275288|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
33275289|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
33275290|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
33275291|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
33275292|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
33275293|NCT05434793|Experimental|The meridian effect of sham testing from mechanical stimulation|The effects of sham acupuncture at Tsu San Li (St-36) were examined by analyzing noninvasive 30-sec. recordings of the radial arterial pulses for 3 groups of patients treated with different probes (blunt, sharp, and patch) on the superficial skin of the acupuncture point. The 3 groups were then treated with the sharp probe for 3 different periods (16, 30, and 50 seconds). Then we compared the harmonics of the radial arterial pulse after Fourier transformation before and after the treatment.
33277629|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
33277630|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
32775057|NCT05534321|Active Comparator|Standard of Care Systemic Therapy or Surveillance|Patients randomized to arm 1 will undergo appropriate systemic therapy as determined by their oncology team. These patients will either continue the current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to arm 1, these patients may also undergo palliative radiation therapy for progressive or painful lesions (a skeletal related event as defined in the study) at the time of symptom development*(not upfront palliative radiation therapy)
33275294|NCT05434715|Active Comparator|conventional technique of thyroidectomy|"A standard transverse skin incision will be done two fingers above supra-sternal notch extend from the medial head of sternomastoid muscle at one side to the other one at the opposite side, incision of platysma along the whole length of skin incision.~Dissection of the thyroid gland will begin with securing the middle thyroid vein using ligation, bipolar diathermy, or harmonic scalpel.~Dissection of the upper pole with securing the superior thyroid vessel preserving the superior parathyroid glands and the external laryngeal nerve.~Severing the Berry's ligament with ligation of its artery and vein. The contralateral lobe of the thyroid gland will then be approached in a similar fashioon."
33275295|NCT05434715|Active Comparator|Minimal invasive technique|"The procedure will start by placing a small incision 2.5-3cm at the upper border of the cricoid cartilage at one of the natural creases of the neck, followed by an incision of the platysma along the length of the skin incision.~Identification of the midline of the neck and division of the strap muscles, followed by dissection of the plane between the muscles and the anterior surface of the thyroid gland.~Dissection of the lateral surface of the thyroid lobe with identification Cutting of sternothyroid muscle at its superior portion. Individual ligaton of branches of superior thyroid artery and vein near to the gland using haemostatic techniques (Harmonic or LigaSure scalpel), guarding the superior parathyroid glands.~Appropriate dissection will then be done. Dissection of the inferior pole and vessel securing using Harmonic or LigaSure scalpel will take place, then dissection of the undersurface of the thyroid gland will be done to separate the gland from its bed."
33275296|NCT05434637|Experimental|Individualized Physiotherapy|Individuals randomized to this group will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
33275297|NCT05434637|Active Comparator|Sound-based Therapy|Individuals randomized to this group will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
32775058|NCT05534321|Experimental|Prophylactic Radiation Therapy|"Patients randomized to Arm 2 of the study will undergo upfront prophylactic radiotherapy to ≤ 5 highest risk bone metastases followed by standard of care, as defined by:~Bulkiest sites of disease ≥ 2cm (can include paraspinal disease extension)~Disease in junctional spine (Occ-C2, C7-T1, T12-L1, L5-S1)~Disease with posterior element involvement (facet(s), interspinous)~Compression Deformity > 50%"
32775059|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
32775060|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
32775061|NCT05529017||non/injured players|rink hockey players participating in senior leagues
32775062|NCT04895059|Experimental|Group A: Rosuvastatin / Ezetimibe fixed dose|In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
32775063|NCT04895059|Active Comparator|Group B: Rosuvastatin (Crestor®)|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
32775064|NCT04895059|Active Comparator|Group C: Ezetimibe (Ezetrol®)|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
32775065|NCT05534243|Active Comparator|Before group|Mechanically ventilated emergency department patients receiving standard neuromuscular blockers prior to an educational initiative on the importance of ED-based targeted shorter acting neuromuscular blocker.
32775066|NCT05534243|Experimental|After group|Mechanically ventilated emergency department patients receiving neuromuscular blockers after an educational initiative aimed at improving use of shorter acting neuromuscular blocker practices in the ED.
32775067|NCT04391413|Experimental|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
32775068|NCT04391413|No Intervention|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
32775069|NCT05467475|Experimental|esomeprazole + BI 1819479 (Test (T))/ BI 1819479 (Reference (R))|
32775070|NCT05467475|Experimental|BI 1819479 (R)/ esomeprazole + BI 1819479 (T)|
32775071|NCT05528705|Experimental|LAENNEC|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
32775072|NCT05528705|Active Comparator|0.9% Normal saline|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
32775073|NCT04430491||Training dataset|No interventions
32775074|NCT04430491||Validation dataset|No interventions
32775075|NCT05534165|Experimental|Tecovirimat|Tecovirimat (TPOXX®) Capsules, 200 mg (as tecovirimat monohydrate) administered as 600 mg (three 200 mg capsules) taken twice daily orally, every 12 hours, within 30 minutes after a full meal of moderate or high fat (approximately 25 g of fat) for 14 days
32775076|NCT05534165|Placebo Comparator|Placebo|Identical placebo supplied by SIGA Technologies Inc.
33275298|NCT05434637|Experimental|Combination Therapy|Individuals randomized to this group will receive both individualized physical therapy and sound-based therapy.
33275299|NCT05434403|Placebo Comparator|Sham stimulation group|
33275300|NCT05434403|Experimental|stimulation group|
32775077|NCT04881019||Type 2 Diabetes|Individuals who have been diagnosed with Type 2 diabetes.
33275301|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
33275302|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
33275303|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
33275304|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
33275305|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
32775078|NCT04881019||Non type 2 diabetes|Individuals who have not been diagnosed with Type 2 diabetes.
33275306|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
33275307|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
33275308|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
33275309|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
32775079|NCT05195489|Experimental|Active Intervention|Family members participate in Connectors by phone and receive a packet of resources
32775080|NCT05195489|No Intervention|Comparison|Family members receive a pack of resources
32775081|NCT04895137|Experimental|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colon and upper rectum cancer
32775082|NCT02332577|Experimental|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
32775083|NCT02332577|Active Comparator|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
32775084|NCT04885387|Other|Standard protocol using chest CT|
32775085|NCT04885387|Experimental|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|
32775086|NCT04885309|Active Comparator|Obturator Nerve Block + Spinal Anaesthesia|Patients who underwent obturator nerve block with spinal anesthesia prior to TURBT
32775087|NCT04885309|Sham Comparator|Spinal Anaesthesia|Patients who underwent spinal anesthesia prior to TURBT
32775088|NCT04880941|Experimental|Progressive Relaxation Exercise|The Progressive Relaxation Exercise will be held 7 days for 4 weeks, a total of twenty eight sessions. Each session is set as fifty minutes
32775089|NCT04880941|No Intervention|Control group|Routine maintenance will be applied
32775090|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
32775091|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
32775092|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
32775093|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
33275310|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
33275311|NCT05677620||Group A - Pharyngeal Computed Tomography Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo pharyngeal CT with cephalometry and with registration in maximum comfortable protrusion (MCP)
33275312|NCT05677620||Group B - Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
33275313|NCT05677620||Group C - Pharyngeal Computed Tomography and Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo a pharyngeal computed tomography + Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
33275314|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
33275315|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
33275316|NCT04525950|Experimental|Navio|Using the new technology during surgery
33275317|NCT04525950|Active Comparator|Conventional|Using the conventional surgical instruments
33275318|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
33275319|NCT05669586|Experimental|Organoid-Guided Antitumor therapy|Non-small cell lung cancer specimens are obtained from lung tumor surgery or biopsy and are used to grow organoids. Then organoids are used for drug sensitivity tests to obtain the sensitivity to drugs. Patients will receive a relatively sensitive antitumor regimen based on the test results.
33275320|NCT05669586|No Intervention|Physician-decided Antitumor therapy|According to the National Comprehensive Cancer Network's (NCCN) Guidelines for non-small cell lung Cancer, physicians will determine antitumor protocols. They're also not sure what the drug susceptibility test says.
33275321|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
33275322|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
33275323|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
32775094|NCT04880551||COPD patients with a recent Spirometry|Patients that have a diagnosis of COPD and have completed a recent Pulmonary Function Test - Spirometry.
33081769|NCT04643314|Experimental|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
33275324|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
32775095|NCT05528627|Other|Pectoral Nerve (PECS) block|Pectoral Nerve (PECs) block was performed at the surgical side 30 min before the procedure
32775096|NCT04880005|Experimental|The intervention group|The three core elements of the intervention are: 1) individualized data-driven recommendations to GPs on how to treat each individual T2D patient, as well as 2) individualized digital coaching of T2D patients, and 3) on-line presentation of patient registered outcomes (PRO) to GPs.
32775097|NCT04880005|No Intervention|Control group|Usual care
33275325|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
32775098|NCT05528471|Experimental|Intervention group|Iso-caloric and low fructose /low HFCS diet (~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) (n=35)
33275326|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
33275327|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
33275328|NCT04503252||Study population: patients with CSAI caused by MSSA|Inpatients with CSAI caused by MSSA treated or intended to receive cefazolin within the next 24-48 hours (at least 10 (maximum of 20) critically-ill patients, at least 10 (maximum of 20) patients with an estimated glomerular filtration rate of <60ml/min, at least 10 patients with BSI).
33275329|NCT04503252||Sub-study: Torque Teno virus (TTV) viremia|TTV viral load may indicate the immunological status of the host. The TTV sub-study is to to describe the viral kinetics of TTV in CSAI patients.
33275330|NCT04503252||Sub-study: cefazolin concentrations in sweat|Out of the study population (patients with CSAI) a total of 15 CSAI patients will be included for the substudy investigating cefazolin concentrations in sweat as a non-invasive therapeutic drug monitoring.
33275331|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
32775099|NCT05528471|No Intervention|Control group|Iso-caloric with higher fructose diet (~10% of TEI; HFCS max 20-30% of total fructose intake) (n=35)
33081770|NCT04643314|No Intervention|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
33081771|NCT04643080|No Intervention|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
33081772|NCT04643080|Experimental|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
33275332|NCT05112432|No Intervention|Treatment as Usual|Participants will be treated as usual and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
33081773|NCT04642846|Experimental|one application of SDF|
33275333|NCT05112432|Experimental|Cognitive Training plus Personalized Real-Time Motivational Enhancement App (PRIME)|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks in addition to PRIME. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
33275334|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
33275335|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
33081774|NCT04642846|Experimental|two application of SDF one month apart|
33081775|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
33081776|NCT04642768|Experimental|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
33081777|NCT04642768|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
33081778|NCT00241917|Experimental|Video|
33081779|NCT00241917|No Intervention|Control|
33081780|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
33081781|NCT04642456|Other|Control group|"Healthy subjects or volunteers~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
33275336|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
32775100|NCT05377697|Experimental|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
32775101|NCT05377697|No Intervention|Control group|Participants in the control group will not receive any intervention.
32775102|NCT05528393||GDM and Non-GDM|
32775103|NCT05528393||Pregnant group and non-pregnant group|
32775104|NCT01595581|Experimental|Testosterone|Weekly injection of testosterone enanthate 200mg
33275337|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
33275338|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
33275339|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
32775105|NCT01595581|Placebo Comparator|Placebo|Weekly injection of saline as the placebo
32775106|NCT05534009||Heath care workers (HCW)|Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
33275340|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
33275341|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
33275342|NCT05091918|Other|Motionsense Wearable Group|Using Motionsense from pre-op to 90 days post-op during the recovery after primary TKA
33275343|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
33275344|NCT00973544||study|drains will be removed on post operative day (POD) 10
32775107|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
32775108|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
32775109|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
32775110|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
32775111|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
32775112|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
32775113|NCT04885153|Experimental|Intervention Group|Subjects who were given simvastatin 10 mg and fenofibrate 200 mg.
32775114|NCT04885153|Placebo Comparator|Control Group|Subjects who were given simvastatin 10 mg and placebo (lactic acid) 200 mg.
32775115|NCT04302311|Active Comparator|Standard of Care|Holter monitoring
32775116|NCT04302311|Active Comparator|Enhanced Monitoring|Kardia/AliveCor monitoring with additional Holter monitoring as needed
32775117|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
33275345|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
33275346|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
33275347|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
33275348|NCT00755495|Placebo Comparator|Placebo|
33275349|NCT00964184|Experimental|Drug|1 gm metformin per day
33275350|NCT00964184|Other|control|lifestyle intervention
33275351|NCT04005300|Experimental|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
33275352|NCT04005300|Active Comparator|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
33275353|NCT04005300|No Intervention|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of >0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
33275354|NCT04005300|No Intervention|nRFS group|It is not up to the RFS definition
33275355|NCT00969644|Active Comparator|GH|
33275356|NCT00969644|Active Comparator|Pegvisomant|
33275357|NCT05646420|Experimental|ADPKD patients|"The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test.~Specifically, five groups of patients will be identified according to KDIGO classification:~18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage~18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage~18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage~18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage~18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage."
32775118|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
32775119|NCT05528315|Experimental|Single dose, ABX-002|Single Dose (solution) dose escalating
32775120|NCT05528315|Experimental|Multiple dose, ABX-002|Multiple Dose (solution) dose escalating
33275358|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
33275359|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
33275360|NCT04079634|Experimental|Treatment|Placement of study device (EnsoETM) for temperature management
33275361|NCT04079634|Active Comparator|Control|Placement of standard temperature probe
33275362|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
33275363|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
33275364|NCT05061888|Active Comparator|Food Waste Intervention Group|This group will receive an intervention on food waste management and fruit and vegetable replacement to increase diet quality while avoiding an increase in calories. Both groups will obtain free fruit and vegetable boxes and will use the FoodImage app to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
33275365|NCT05061888|Placebo Comparator|Stress Management Control Group|This group will receive an intervention on Stress Management and will be intensity matched to the treatment group. Both groups will obtain free fruit and vegetable boxes and will use FoodImage to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
33275366|NCT04008914||readmission at 30 days|
33275367|NCT04008914||readmission at 90 days|
33275368|NCT04073394|Active Comparator|Standard Lifestyle Intervention|Participants in this group will be instructed to follow a standard low calorie diet, recommended to have 30 minutes of physical activity 3-5 days per week, and will be followed by a wellness couch weekly.
33275369|NCT04073394|Experimental|Modified Lifestyle Intervention|Participants in this group will have a tailored diet, exercise, and behavioral plan according to their obesity phenotype.
33275370|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
33275371|NCT05623410|Experimental|Botulinum toxin type A(ATGC-110)|ATGC-110 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
33275372|NCT05623410|Active Comparator|Incobotulinumtoxin A (Xeomin®)|Xeomin® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
33275373|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
33275374|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
33275375|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
33275376|NCT04004598|Experimental|golf training|12-week golf training program
33275377|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
33275378|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
33275379|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
33275380|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
33275381|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
33275382|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
33275383|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
33275384|NCT00964418|Experimental|IDeg|
33275385|NCT00964418|Active Comparator|IGlar|
33275386|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
33275387|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
33275388|NCT04009226||Participants with GNE|
33275389|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
33275390|NCT04008680|Other|Low response burden|Participants will be assigned to complete only the EQ-5D-5L questionnaire.
33275391|NCT04008680|Other|Low to medium response burden|Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.
33275392|NCT04008680|Other|Medium to high response burden|Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.
33275393|NCT04008680|Other|High response burden|Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.
33275394|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
33275395|NCT03937778|Experimental|Tourniquet block to left upper arm|Participants underwent ~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
33275396|NCT03935126||All patients|
33275397|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
33275398|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
33275399|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
33275400|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
33275401|NCT04009304|Experimental|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
33275402|NCT04009304|Experimental|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
33275403|NCT04009304|No Intervention|Control|
33275404|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
33275405|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter [mg/m^2] as intravenous [IV] infusion on Day 0 of Cycle 1 and 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m^2 on Days 1-3) and cyclophosphamide (250 mg/m^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
33275406|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
33275407|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
33275408|NCT00964730|Experimental|Talampanel|
33275409|NCT00964730|Placebo Comparator|Placebo|
33275410|NCT00964730|Other|Moxifloxacin|
33275411|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
33275412|NCT00539838|Experimental|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
33275413|NCT00539838|Experimental|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
33275414|NCT00539838|Placebo Comparator|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
33275415|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
33275416|NCT00964808|Experimental|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
33275417|NCT05011890|Other|Single-arm|Participants will be assigned to the single-arm involving weekly monitoring of their patient-reported outcomes using Moovcare®.
33275418|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
33275419|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
33275420|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
33275421|NCT05258084|Experimental|initiative group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will be applied to this group
33275422|NCT05258084|No Intervention|control group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will not be applied to this group
33275423|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
33275424|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
33275425|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
33275426|NCT05257772|Active Comparator|Optimum Right Ventricular Pacing On|AV Delay Optimised RV Pacing. Subjects will remain in this arm for 3 months before being crossed-over.
33275427|NCT05257772|No Intervention|Optimum Right Ventricular Pacing Off|Subjects will remain in this arm for 3 months before being crossed-over. The pacemaker will be programmed to minimum ventricular pacing & dynamic AV delay will be programmed off.
33275428|NCT04004988|Experimental|Tirzepatide Test|Tirzepatide administered subcutaneously (SC) to healthy participants via an autoinjector (AI) in one of two study periods.
33275429|NCT04004988|Experimental|Tirzepatide Reference|Tirzepatide administered SC to healthy participants via a prefilled syringe (PFS) in one of two study periods.
33275430|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (>5 years duration)
33275431|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
33275432|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
33275433|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
33275434|NCT00971126|Experimental|Single Group Assignment|
33275435|NCT04001946|Other|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
33275436|NCT04001946|No Intervention|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
33275437|NCT00971360||Conversion disorder|
33275438|NCT00971360||Healthy control|
33275439|NCT02759094|Experimental|Treatment with RefluxStop device|All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention
33275440|NCT00964964|Experimental|SIBA 3W|
33275441|NCT00964964|Experimental|SIBA OD|
33275442|NCT04183998|Experimental|tsES|trans-spinal Electrical Stimulation (tsES)
33275443|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
33275444|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
33275445|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
33275446|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
33275447|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
33275448|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
33275449|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
33275450|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
33275451|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
33275452|NCT03657888|Experimental|Family Club Denmark (FCD)|Participation in FCD
33275453|NCT03657888|Other|Wait-list|Wait-list control
32775121|NCT05528315|Experimental|Formulation Comparison Solution or Capsule|ABX-002 Single Dose TBD - Solution ABX-002 Single Dose TBD - Capsule
33275454|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
33275455|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
33275456|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
33275457|NCT00971516|Active Comparator|Implants|Compare implant healing phases
32775122|NCT04884997|Active Comparator|Arm A|toripalimab 3mg/kg, Q2w;
32775123|NCT04884997|Experimental|Arm B|toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w
32775124|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
32775125|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
32775126|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
32775127|NCT04879771||Morning GIE|
32775128|NCT04879771||Afternoon GIE|
32775129|NCT03048565|No Intervention|Usual care|No intervention
33275458|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
33275459|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
33275460|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
33275461|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
33275462|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
33275463|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
33275464|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
33275465|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
33275466|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
33275467|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
33275468|NCT00755573|Placebo Comparator|Placebo|Placebo arm
33275469|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
33275470|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
33275471|NCT00971906|Experimental|high dose of antigen|
33275472|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
33275473|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
33275474|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
33275475|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
33275476|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
33275477|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
33275478|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
33275479|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
33275480|NCT00975026|No Intervention|No Intervention|
33275481|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
33275482|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
33275483|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
33275484|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
33275485|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
33275486|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
33275487|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
33275488|NCT00975104|Placebo Comparator|Placebo|Placebo
32775130|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
32775131|NCT04879693|Experimental|Hospitalized Patients|To assess performance of CGM compared to comparator measurement.
32775132|NCT04885075|Other|Intravenous Diazepam|Intravenous diazepam (0.2mg/kg/dose) single dose stat
32775133|NCT04885075|Other|Intranasal Midazolam|Intranasal midazolam (0.2mg/kg/dose) single dose stat
32775134|NCT05179369|No Intervention|Standard Care|Participants randomized to standard care will be offered prenatal and postpartum care in accordance with site-specific procedures based on AAP and ACOG Guidelines for Perinatal Care. The initial intake appointment, involving a comprehensive visit with physical exam, medical and psychosocial history, laboratory testing, and education would optimally occur in the 1st trimester. Subsequent prenatal visits, per ACOG, is monthly for the first 28 weeks, biweekly for weeks 28-36, and weekly after 36 weeks. More frequent visits may be offered to women at high risk. In addition, some sites may offer supports such as nutritional counseling, childbirth education, and case management. A comprehensive postpartum care visit would typically occur within the first 6 weeks of birth, involving a physical examination, lab tests, and immunizations.
32775135|NCT05179369|Experimental|Standard Care with Well-Mama Intervention|Participants will receive standard perinatal care plus the Well Mama intervention, including the Well Mama Checklist, assistance from a Community Doula Navigator, and virtual support groups.
32775136|NCT01610687|Experimental|GW-1000-02|Active treatment
32775137|NCT04884919|Placebo Comparator|Regular Gauze Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a regular gauze made of traditional cotton yarn. The regular gauze is applied on the half side of the wound.
33275489|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
33275490|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
33275491|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
32775138|NCT04884919|Experimental|Chitosan Dressing Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a chitosan dressing made of chitosan material. The chitosan dressing is applied on another half side of the wound.
32775139|NCT04879303|Experimental|Robot-assisted social skill intervention|Social robotics will be used by the instructor to conduct the social skill training activities.
33275492|NCT04008290|Experimental|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
32775140|NCT04879303|Active Comparator|Human-only instruction program on social skill training|The children will receive only the human-delivered social skill training.
32775141|NCT04879303|No Intervention|Control|There will be no intervention conducted during the tested period
32775142|NCT05533931|Experimental|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
33275493|NCT04008290|Placebo Comparator|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
33275494|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
33275495|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
33275496|NCT00975182|Experimental|A|
33275497|NCT05271071|Active Comparator|Gluteus Maximus Group|30 patients in the gluteus maximus group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for gluteus maximus muscle is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the piriformis muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
33275498|NCT05271071|Active Comparator|Piriformis Muscle group|30 patients in the piriformis muscle group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for piriformis muscle (piriformis syndrome) is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the gluteus Maximus muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
33275499|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
33275500|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
33275501|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
33275502|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
33277631|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
33277632|NCT03889886|Placebo Comparator|Vehicle|Vehicle
33277633|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
33275503|NCT05261945|Experimental|Routine Physical Therapy|"Electrotherapy~Exercises.~Electrotherapy Hot pack Patients will be in prone position and for relaxation pillow will place beneath the abdomen. Then to reduce muscle spasm and to induce vasodilation hot pack will use for 15 minutes. Treatment with hot pack helps in improving and relaxing the muscle spasm and soft tissue elasticity.~TENS TENS will be of 50 Hz, duration of pulse will be<150 microseconds, for 15 minutes to reduce pain.~TENS and Hot Pack will use at the same time for 15 minutes.~Ultrasound Ultrasound's gel will be applied on outer surface of skin with 2-3 mm thickness. Then ultrasound which frequency will be 1MHz applied for 5 min.~• Exercises Passive Range of Motion exercises for 10 minutes~Neck Flexion~Neck Side bending~Neck Rotation~Isometric neck flexion~Isometric neck extension~Isometric neck side bending~These exercises will repeat 3 times within the treatment program."
33275504|NCT05261945|Experimental|Manual Therapy And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 mins, TENS and hot pack for 15 mins, ultrasound for 5 mins.~Manual therapy~Natural Apophyseal Glides The natural apophyseal glides, which will be applied between C2 and C7, will be the Manual Muscle Testings first action. Patients may request to sit and lean on a chair. The oscillatory motions will reapply the mobilization.~Sustained Natural Apophyseal Glides Sustained Natural Apophyseal Glides will be a mixture of mobilization and active gestures/movements.~5 repetitions for 10 minutes of each."
33275505|NCT05261945|Experimental|Stretching Exercises And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 minutes, TENS and hot pack is applied for 15 minutes at the same time, then ultrasound will applied for 5 minutes.~Stretching exercises will be done in the following order;~For trapezius: Stretching into lateral flexion for the upper part, For scalene: rotation and ipsilateral flexion For the extensor muscles: flexion will be performed.~Performing each action for 30 seconds with 5 repetitions for 10 minutes Finally, by retruding the jaw, a neck straightening exercise can be performed."
33275506|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
33275507|NCT05230901|Other|Control group|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care
33275508|NCT05230901|Experimental|Spironolactone|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.)
33275509|NCT05230901|Experimental|Spironolactone + Dihydralazine|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.) + Dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg / d p.o. in fast acethylators, confirmed by genetic testing)
33275510|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
33275511|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
33275512|NCT00972296||Persons with hemophilia with ankle pain|
33275513|NCT03908099|Experimental|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
33275514|NCT03908099|Active Comparator|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
33275515|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
33275516|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
33275517|NCT00965432|Placebo Comparator|Placebo|
33275518|NCT00965432|Active Comparator|STX107|
33275519|NCT03827993|No Intervention|Routine surveillance|"Routine surveillance consists of attending gynecologic oncology office visits and being provided with an educational pamphlet discussing common sexual health concerns in gynecologic cancer patients, describing vaginal dilators, moisturizers, and lubrication. Resources for psychosocial counseling, physical therapy, and the sexual health clinic will be provided as well.~Participants will have follow up at baseline, 3, 6, 9, and 12 months. Baseline visit consists of the initial visit where the Female Sexual Function Index (FSFI) screen was performed. Subsequent follow up visits will consist of FSFI, Female Sexual Distress Scale (FSDS), Kessler 10 surveys, and clinical assessment with Vaginal Assessment Scale and Vulvar Assessment Scale (VAS and VuAS)."
33275520|NCT03827993|Experimental|Dedicated sexual health clinic appointment|"Dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This will consist of the provider performing a focused history and physical, who will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.~The participants will follow up at 3, 6, 9, and 12 months after initial visit, either with the sexual health focused provider or their primary gynecologic oncologist, as determined by the needs of the participant per the provider."
33275521|NCT00972452|Experimental|Exercise|5-10d exercise training
33275522|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
33275523|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
33275524|NCT02559089||anti-NMDA receptor encephalitis|
33275525|NCT02559089||other autoimmune encephlitis|
33275526|NCT02559089||other encephalopathy|
33277634|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
33275527|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
33275528|NCT00921869|Experimental|1|
33275529|NCT00965588|Experimental|Vaccine (UB 311)|
33275530|NCT04972955||Pregnant women diagnosed with gestational diabetes|Pregnant women who have been diagnosed with gestational diabetes during the current pregnancy
33275531|NCT00972764||Control|
33275532|NCT00972764||Laryngomalacia Cases|
33275533|NCT05279534|Experimental|Probiotic|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS) status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
33275534|NCT05279534|Placebo Comparator|Control|The control study product is identical in packaging and formulation except that none of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485 and Pediococcus acidilactici CECT7483 (probiotic bacteria) are present. The Control product contains maltodextrin (E1400, qs) only, in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
33275535|NCT04008992|Experimental|Part A SAD - A1 Cohort|Single Ascending Dose
33275536|NCT04008992|Experimental|Part A SAD - A2 Cohort|Single Ascending dose
33275537|NCT04008992|Experimental|Part A SAD- A3 Cohort|Single Ascending dose
33275538|NCT04008992|Experimental|Part A SAD- A4 Cohort|Single Ascending dose
33275539|NCT04008992|Experimental|Part A SAD - A5 Cohort|Single Ascending dose
33275540|NCT04008992|Experimental|Part A SAD- A6 Cohort|Single Ascending dose
33275541|NCT04008992|Experimental|Part B MAD- B1 Cohort|Multiple Ascending Dose
33275542|NCT04008992|Experimental|Part B MAD - B2 Cohort|Multiple Ascending Dose
33275543|NCT04008992|Experimental|Part B MAD - B3 Cohort|Multiple Ascending Dose
33275544|NCT04008992|Experimental|Part B MAD - B4 Cohort|Multiple Ascending Dose
33275545|NCT04008992|Experimental|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
33275546|NCT04008992|Experimental|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
33275547|NCT04008992|Experimental|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
33275548|NCT05248490|Experimental|Patients with pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization.
33275549|NCT05248490|No Intervention|Patients without pharmaceutical interview|Control group without interview
33275550|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
33275551|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
33275552|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
33275553|NCT00975494|Placebo Comparator|Placebo|Placebo
33275554|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
33275555|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
33275556|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
33275557|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
33275558|NCT00975572|Placebo Comparator|Placebo control|
33275559|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
33275560|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
33275561|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
33275562|NCT00972998|Experimental|Healthy individuals|
33275563|NCT00965666|Experimental|Open Label|
33275564|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
33275565|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
33275566|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
33275567|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
33275568|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
33275569|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
33275570|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
33275571|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
33275572|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
33277635|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
33277636|NCT00781469||Naive patients|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
33275573|NCT04919057|Experimental|Robotic perineal radical prostatectomy|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
33275574|NCT05248178|Experimental|CO-OP and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned CO-OP.
33275575|NCT05248178|Active Comparator|CO-OP and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned CO-OP.
32775143|NCT05533931|Active Comparator|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
33275576|NCT05248178|Active Comparator|Computer cognitive training and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned computer cognitive training.
33275577|NCT05248178|Active Comparator|Computer cognitive training and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned computer cognitive training.
33275578|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
33275579|NCT04049747|Experimental|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
33275580|NCT04049747|Experimental|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
33275581|NCT04049747|Experimental|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
33275582|NCT04049747|Experimental|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
33275583|NCT04049747|Experimental|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
33275584|NCT00973154|Active Comparator|Prednisone|Drug
33275585|NCT00973154|Placebo Comparator|Placebo|
33275586|NCT00965822|Active Comparator|1|
33275587|NCT00965822|Placebo Comparator|2|
33275588|NCT04822025|Experimental|High Dose|High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33275589|NCT04822025|Experimental|Mid Dose|Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33275590|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
33275591|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
33275592|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
33275593|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
33275594|NCT00973232|Experimental|Part A, Arm A|
33275595|NCT00973232|Experimental|Part A, Arm B|
33275596|NCT00973232|Active Comparator|Part A, Arm C|
32775144|NCT04879381||Cystic Fibrosis patients|Sputum samples
32775145|NCT05528237|Experimental|HPV self-sampling|Participants will be offered self-collection kits for HPV-based cervical cancer screening.
32775146|NCT04879537|No Intervention|Control|Participants in this group are routinely treated.
32775147|NCT04879537|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
32775148|NCT05533853|Active Comparator|Traditional exercise|The exercise group will receive a posture corrective exercise program in the form of two strengthening(deep cervical flexors and shoulder retractors)and two stretching (cervical extensors and pectoral muscles) exercises. The exercise program will be done according to Harman et al.'s protocol and based on Kendall et al.'s approach.
32906432|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
33275597|NCT00973232|Active Comparator|Part A, Arm D|
33275598|NCT00973232|Experimental|Part B, Arm E|
33275599|NCT00973232|Active Comparator|Part B, Arm F|
33275600|NCT00973232|Active Comparator|Part B, Arm G|
33275601|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
33401889|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
33401890|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
33401891|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
33081782|NCT04642456|Other|ASD group|"Patient group with ASD~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
33081783|NCT04642339|Experimental|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
33081784|NCT04642339|Placebo Comparator|Placebo|Placebo
33081785|NCT04642300|Active Comparator|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
33081786|NCT04642300|Active Comparator|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
33081787|NCT04642066|Experimental|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
33081788|NCT04642066|Sham Comparator|Sham control|Control without CWI exposition
33081789|NCT00245895|Active Comparator|1|Aranesp
33081790|NCT04642222|Experimental|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
33081791|NCT04642222|Active Comparator|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
33081792|NCT04642144|Experimental|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
33081793|NCT04642144|Active Comparator|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
33081794|NCT04642144|Active Comparator|Carbohydrate and water|Carbohydrate meal consumption and water intake.
33081795|NCT00218231|Experimental|1|300 mg/day bupropion-sr
33081796|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
33081797|NCT04641754|Experimental|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
33081798|NCT04641676|Other|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
33081799|NCT04641676|Other|Foundation Medicine NGS|The patient will have only FMI NGS test.
33081800|NCT04641676|Experimental|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
33081801|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
33081802|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
33081803|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
33081804|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
33081805|NCT04641793|Experimental|SCI|
33081806|NCT04641793|Experimental|STROKE|
33081807|NCT04641793|Experimental|UNIMPAIRED|
33081808|NCT04641598|Experimental|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
33081809|NCT04641598|Sham Comparator|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
33081810|NCT04641364|Placebo Comparator|Control: placebo|Subjects received 0.9% sodium chloride injection.
33081811|NCT04641364|Active Comparator|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
33277637|NCT00781469||Patients in remission|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
32775149|NCT05533853|Experimental|Denneroll extension traction|Denneroll extension traction. Participants in the intervention group will receive the Denneroll cervical orthotic . In the current study, Denneroll cervical traction will be used to restore the normal cervical alignment. . We will follow previously published protocols and procedures for application of this orthotic. The Denneroll orthotic will be performed in the physiotherapy clinic setting. The participants will be instructed to lie supine on the floor, in a straightened position, with their arms gently folded across their stomach.
32775150|NCT03048409||Enteral tube fed adults|Enteral formula
32775151|NCT05528081||Persons with migraine disease|Persons diagnosed with migraine based on the third edition of the International Classification of Headache Disorders (ICHD-3) and underwent baseline 3-tesla MRI
32775152|NCT05528081||Persons with medication-overuse headache|Persons diagnosed with MOH based on the ICHD-3 and underwent baseline 3-tesla MRI
32775153|NCT05528081||Healthy controls|Healthy individuals with no history of primary or secondary headache based on the ICHD-3 and underwent baseline 3-tesla MRI
32775154|NCT04129931|Experimental|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
32775155|NCT04129931|Experimental|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
32775156|NCT04129931|Experimental|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
32775157|NCT04129931|Experimental|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
32775158|NCT04129931|Experimental|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
32775159|NCT04879147||Syncope|Subjects admitted immediately after syncopation.
32775160|NCT04879147||Seizre|Subject admitted immediately after cerebarl seizure
33081812|NCT04641364|Experimental|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
33081813|NCT04641481|Experimental|Study vaccine|BBV152B (6µg-Algel-IMDG)
33081814|NCT04641481|Placebo Comparator|Placebo|Phosphate buffered saline with Alum (without antigen)
33081815|NCT04720638|Experimental|Short fiber reinforced flowable resin composite restorations|(everX Flow, GC Europe) + (Gaenial posterior, GC Europe
33081816|NCT04720638|Active Comparator|Conventional resin composite restoration.|(Gaenial posterior, GC Europe)
33081817|NCT04641013||People with HIV over the age of 55 years|
33081818|NCT04641013||People without HIV over the age of 55 years|
33081819|NCT04641130|Experimental|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
33081820|NCT04641325|Experimental|Exercise Intervention Group|Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
33081821|NCT00246051|Other|Sleep Hygiene Education|
33081822|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
33081823|NCT00246051|Other|Online Sleep Disorders Screening|
33081824|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
33081825|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
33081826|NCT00559351|Active Comparator|S|esophagectomy
33081827|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
33081828|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
33081829|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
33081830|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
33081831|NCT00559429|Active Comparator|C1|
33081832|NCT00559429|Active Comparator|C2|
33081833|NCT00559429|Active Comparator|C3|
33081834|NCT00559429|Active Comparator|C4|
33081835|NCT04641403|No Intervention|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
33081836|NCT04641403|Active Comparator|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
32775161|NCT04879069||Intermediate-high risk PE|Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
32775162|NCT04879069||High-risk PE|"Confirmed PE causing hemodynamic instability:~Cardiac arrest (need for cardiopulmonary resuscitation) or,~Obstructive shock (systolic blood pressure < 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or~Persistent hypotension (systolic blood pressure < 90 mmHg for at least 15 minutes)"
33275602|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
33275603|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
33275604|NCT04762823|Experimental|PD-ctDCS|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
33401892|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
32775163|NCT04878835|No Intervention|Control group|No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
33275605|NCT04762823|Sham Comparator|PD-sham|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
33275606|NCT04762823|Active Comparator|NH-ctDCS|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
33275607|NCT04762823|Sham Comparator|NH-sham|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
33275608|NCT05103722|Experimental|Supportive Care|Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy
33275609|NCT04728815|Experimental|CAMS to Maintenance|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
33275610|NCT04728815|Experimental|CAMS to CAMS|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
33275611|NCT04728815|Experimental|CAMS to DBT|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
33275612|NCT04728815|Experimental|TAU to Maintenance|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
33275613|NCT04728815|Experimental|TAU to CAMS|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
33275614|NCT04728815|Experimental|TAU to DBT|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
33275615|NCT04728815|Experimental|DBT Only|Subject Assigned to DBT for Phase 1, continuing up to 16 weeks.
33275616|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
33275617|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
33275618|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
33275619|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
33275620|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
33275621|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
33275622|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
33275623|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
33275624|NCT04008212||EVAR aneurysm|
33275625|NCT04008212||Stenosis|
33275626|NCT03523728|Placebo Comparator|Stage 1- Placebo|Participants from Stage 1 were randomized to receive 2 capsules of placebo matched to venglustat once daily for treatment period of 24 months.
33275627|NCT03523728|Experimental|Stage 1- Venglustat 8 mg|Participants from Stage 1 were randomized to receive venglustat 8 milligrams (mg) (i.e., 2 capsules of 4 mg) once daily for treatment period of 24 months.
33275628|NCT03523728|Experimental|Stage 1- Venglustat 15 mg|Participants from Stage 1 were randomized to receive 1 capsule of venglustat 15 mg and 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
33275629|NCT03523728|Placebo Comparator|Stage 2- Placebo|Participants from Stage 2 were randomized to receive 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
33275630|NCT03523728|Experimental|Stage 2- Venglustat 15 mg|Participants from Stage 2 were randomized to receive 1 capsule of venglustat 15 mg once daily for treatment period of 24 months.
33275631|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
33275632|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
33275633|NCT00979784|Active Comparator|1|
33275634|NCT00979784|Experimental|2|
33275635|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
33275636|NCT00966134||probands|
33275637|NCT00976118|Placebo Comparator|placebo|
33275638|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
33275639|NCT00966212|No Intervention|health promotion materials|
33275640|NCT00966212|Active Comparator|print parent education|
33275641|NCT00980252|Experimental|CBT|UK-based intervention
33275642|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
33275643|NCT00966290|Active Comparator|UC group|Usual care group
33275644|NCT04004052|Active Comparator|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
33275645|NCT04004052|Active Comparator|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
33275646|NCT04004052|Sham Comparator|Group 3|Sham TENS was applied to the group 3 with the same protocol.
33275647|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant"
33275648|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
33275649|NCT00966368|Experimental|IDeg E|
33275650|NCT00966368|Experimental|IDeg M|
33275651|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
33275652|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
33275653|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
33275654|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
33275655|NCT00980408|Active Comparator|D-Cycloserine behavioral|
33275656|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
33275657|NCT00980408|Active Comparator|Memantine, behavioral|
33275658|NCT00980408|Active Comparator|Memantine, fMRI|
33275659|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
33275660|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
33275661|NCT00980486||BMI <30|BMI <30
33275662|NCT00980486||BMI 30-39|BMI 30-39
33275663|NCT00980486||BMI >40|BMI >40
33275664|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
33275665|NCT04007978|Experimental|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
33275666|NCT03970590|Experimental|CTC|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
33275667|NCT03970590|Active Comparator|Control|6-month HTN management assessment text messages without narrative component
33275668|NCT00980876|Active Comparator|Cipro HC|Reference product
33275669|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
33275670|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
33277638|NCT00781469||Patients still have active disease|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
33275671|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
33275672|NCT03902184|Experimental|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
33275673|NCT03902184|Experimental|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
33275674|NCT03902184|Experimental|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed)|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
33275675|NCT03902184|Experimental|Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
33275676|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
33275677|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
33275678|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
33275679|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
33275680|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
33275681|NCT05279040||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis who will be initiating Trikafta treatment
33275682|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
33275683|NCT00976742|Experimental|Endurance Exercise Training|
33275684|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
33275685|NCT03813654|No Intervention|Control (Group A)|During the intervention block of the Field Trial, at the end of the first night shift, the participant will be told about their randomization group. In the control group (Group A), participants will not be given any instructions about the timing or duration of their sleep, but will be instructed to follow their usual night shift sleep routine.
33275686|NCT03813654|Experimental|8-h Afternoon-Evening Sleep (Group B)|In the 8-h afternoon-evening sleep intervention group (Group B), participants will be instructed to go to bed between 13:00 and 14:00 (depending on their individual commute time) and to remain in bed attempting to sleep for 8 hours (until 21:00-22:00) before the next two night shifts.
33275687|NCT03813654|Experimental|8-h Free Sleep (Group C)|In the 8-h free sleep group (Group C), participants will be instructed to remain in bed for 8 continuous hours before the next two night shifts, but will not be given any instruction regarding which 8 hours they should sleep.
33275688|NCT04931862|Experimental|WVE-004 (Dose A) or placebo|
33275689|NCT04931862|Experimental|WVE-004 (Dose B) or placebo|
33275690|NCT04931862|Experimental|WVE-004 (Dose C) or placebo|
33275691|NCT04931862|Experimental|WVE-004 (Dose D) or placebo|
33275692|NCT05360160|Experimental|SNDX-5613|Capsules by mouth 2 times every day (about 12 hours apart).
33275693|NCT05360160|Experimental|Venetoclax|Tablets by mouth on Days 1-14 of each cycle.
33275694|NCT05360160|Experimental|ASTX727|Tablets by mouth on Days 1-5 of each cycle.
33275695|NCT04930536|Experimental|Acalabrutinib Capsule|Single-arm study
33275696|NCT04328532|Experimental|Pregnancy with risk factors for PPA|
33275698|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
33275699|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
33275700|NCT04313868|Experimental|Phase 1A.1: Peripheral IV|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
33275701|NCT04313868|Experimental|Phase IA.2: Hepatic Artery Infusion|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
33275702|NCT04313868|Experimental|Phase IA.3: Intratumoral Injection|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
33277639|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
33401893|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
33081837|NCT04641403|Experimental|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
33081838|NCT04641403|Experimental|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
33081839|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
33081840|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
33081841|NCT04641169|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
33081842|NCT04640740|Experimental|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
33081843|NCT04640740|Experimental|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
33081844|NCT00218660|Experimental|1|Nal + BRENDA
33081845|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
33081846|NCT00218660|Experimental|3|Nal + CBT
33081847|NCT00218660|Placebo Comparator|4|Placebo + CBT
33081848|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
33081849|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
33081850|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
33081851|NCT04640233|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
33081852|NCT04640233|Placebo Comparator|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
33081853|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
33081854|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
33081855|NCT04640116|Experimental|TIPS combined with microwave ablation|
33081856|NCT00242112|Other|MRI - pathology|
33081857|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
33081858|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
33081859|NCT04639921|Experimental|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
33081860|NCT04639921|Placebo Comparator|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
33081861|NCT04639882|Experimental|Control-Remote-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
33081862|NCT04639882|Experimental|Control-Remote-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
33081863|NCT04639882|Experimental|Control-InPerson-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
33081864|NCT04639882|Experimental|Control-InPerson-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
33081865|NCT04639882|Experimental|PNF-Remote-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
33081866|NCT04639882|Experimental|PNF-Remote-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
33081867|NCT04639882|Experimental|PNF-Inperson-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
33081868|NCT04639882|Experimental|PNF-Inperson-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
33081869|NCT00218816|Experimental|1|
33081870|NCT00218816|Other|2|
33081871|NCT04639804|Active Comparator|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
33081872|NCT04639804|Active Comparator|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
33081873|NCT04639804|Active Comparator|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
33081874|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
33081875|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
33081876|NCT04639570|Experimental|KneuroKnits group|Participants in the KneuroKnits group
33081877|NCT04639687|Experimental|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
33275703|NCT05400954||Reconstruction with silicone breast implant|The cohort will be composed of women who underwent surgery for first invasive breast cancer or ductal carcinoma in situ (DCIS) in the years 2000 to 2015 in the collaborating centres. Eligible for inclusion in the exposed group are all women who underwent (i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant
33275704|NCT05400954||Breast cancer surgery without silicone breast implant|. Eligible for inclusion in the comparison group are women who underwent (i) simple mastectomy without reconstruction, (ii) autologous reconstruction and (iii) breast conserving surgery. From the latter group a frequency-matched sample will be selected based on age at breast cancer diagnosis and calendar year of diagnosis.
33275705|NCT05400954||cosmetic breast augmentation|. Women who underwent cosmetic augmentation in the years 2000 to 2015 constitute a second comparison group. From this group a frequency-matched sample will be selected based on age and year of surgery.
33275706|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
33275707|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
33275708|NCT00990054|Experimental|plerixafor|
33275709|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
33275710|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
33275711|NCT05361564|Experimental|Brigatinib|
33275712|NCT03388632|Experimental|lead-in doublet A|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
33275713|NCT03388632|Experimental|lead-in doublet B|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
33275714|NCT03388632|Experimental|triplet|triplet combination
33275715|NCT05399472||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar fasciopathy, metatarsalgias, etc);~athletes who have undergone surgery on their lower limb."
33275716|NCT05360004|Experimental|CHM+Vc|Participants in CHM+VC group are required to consume vitamin C 1000mg/day and 1 sachet (9 g) of granules daily (1 hour after meal by dissolving 1 sachet of 9g granules in 150 ml of hot water and drink it orally) .
33275717|NCT05360004|Placebo Comparator|Vc|Participants will receive vitamin C 1000mg/day for 14 days
33275718|NCT05359926|Experimental|Early Urethral Catheter Removal|Removal of the urethral catheter in the operating room at the conclusion of surgery
33275719|NCT05359926|Active Comparator|Delayed Urethral Catheter Removal|Removal of the urethral catheter in next morning after surgery
33275720|NCT05361408|Active Comparator|Denosumab short-term user|Denosumab injection less than 5 times
33275721|NCT05361408|Active Comparator|Denosumab long-term user|Denosumab injection more than 5 times
33275722|NCT05590806|Experimental|Arm 1|Restoration
33275723|NCT05590806|Experimental|Arm 2|Evaluate
33275724|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
33275725|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
33275726|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
33275727|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
33275728|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
33275729|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
33275730|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
33275731|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
33275732|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
33275733|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
33275734|NCT05590572|Active Comparator|Etoposide plus Ifosfamide group|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
33275735|NCT05590572|Experimental|Etoposide plus Ifosfamide Combined With Sulfatinib|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
33275736|NCT05359614|Experimental|GROUP A=CoolSculpting Elite and CoolTone|Group A: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area 6 weeks prior to four EMMS treatment sessions during the study.
33275737|NCT05359614|Active Comparator|GROUP B CoolSculpting Elite alone|Group B: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area.
33275738|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
33275739|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
33275740|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
33275741|NCT05590416||adalimumab group|The initial dose of glucocorticoid is 1 mg/kg/day, and gradually stops within 90-180 days. Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
33275742|NCT05590416||traditional therapy group|Acute VKH patients treatment with only glucocorticosteroid or glucocorticosteroid combined with immunosuppressive agents.
33275743|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
33275744|NCT02910414|Sham Comparator|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
32775164|NCT04878835|Experimental|Intervention group|The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
32775165|NCT05528003||Handmade single-access port device|The homemade single-access device was composed of a wound protector, sterile surgical glove, and three trocars inserted into and secured over three digits of the glove
32775166|NCT05528003||Commercialized single-access port devices|Commercialized single-access port devices including GelPOINT® (Applied Medical, Rancho Santa Margarita, CA, USA) and LAGIPORT® (LAGIS, Taichung, Taiwan)
32775167|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
33275745|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
33275746|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
33275747|NCT00990522|Experimental|debridement|monthly vs weekly debridement
33275748|NCT05590338|Experimental|Part A: GSK1070806|Participants in Part A will receive single dose of GSK1070806 intravenous (IV) infusion
33275749|NCT05590338|Experimental|Part B: GSK1070806|Participants in Part B will receive single dose of GSK1070806 IV bolus
33275750|NCT05590338|Placebo Comparator|Part A: Placebo|Participants in Part A will receive single dose of placebo
33275751|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
33275752|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
33275753|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
33275754|NCT05590260|Experimental|IV iron arm|Which will result in receipt of a single-dose IV iron infusion between 6 and 48 hours after delivery and prior to discharge from the facility; folate tablets per local guidelines.
32775168|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
32775169|NCT05114057|Other|PICU Patients|Prospectively enrolled patients admitted to the PICU will be assessed by the RAI calibration for sepsis in the PICU and including additional risk factors.
33275755|NCT05590260|Active Comparator|Oral iron comparator arm|Oral iron tablets (containing 60 mg of elemental iron (± folate as per local guidelines)) to be taken at a treatment dose of twice daily for 6 weeks.
33275756|NCT02797548|Experimental|Aspirin only|
33275757|NCT02797548|Active Comparator|No antiplatelet therapy|
33275758|NCT05590182|Active Comparator|CO2 first/ iodine CM second|CO2-enhanced angiography
33275759|NCT05590182|Active Comparator|iodine CM first/ CO2 second|iodine contrast media-enhanced angiography
33275760|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
33275761|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
33275762|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
33275763|NCT05265468|Experimental|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
32775170|NCT05114057|Other|CICU Patients|Prospectively enrolled patients admitted to the CICU will be assessed by the RAI calibration specific to the CICU, especially post cardiac bypass
32775171|NCT05114057|Other|NICU Patients|Prospectively enrolled patients admitted to the NICU will be assessed by the RAI calibration for neonatal patients with sepsis or post abdominal surgeries
33275764|NCT05265468|Active Comparator|Lewit Group|Lewit Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques
33275765|NCT05265468|Active Comparator|Chaitow Group|Chaitow Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques and deep diaphragmatic respiration
33275766|NCT05265468|Placebo Comparator|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
33275767|NCT05359458|Experimental|Emotional Freedom Liberation Technique Applied to Laparoscopic Cholecystectomy Patients|The intervention group is the group in which the investigators applied Emotional Freedom Liberation Technique Intervention: Behavioral: Emotional Freedom Liberation Technique
33275768|NCT05359458|No Intervention|Standard Clinical Care Applied to Laparoscopic Cholecystectomy Patients|The control group is the group that receives standard clinical care
33277640|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
32775172|NCT04878523|Placebo Comparator|Placebo drink|
32775173|NCT04878523|Experimental|multi berries juice|
33277641|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
33277642|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
32775174|NCT05112809|Experimental|Normal hearing subjects|Subjects with normal hearing will have a standard hearing test utilizing the cochlear stimulation system.
32775175|NCT05112809|Experimental|Bilateral hearing impaired|Subjects with bilateral hearing impairment will have a standard hearing test utilizing the cochlear stimulation system.
32775176|NCT05112809|Experimental|Asymmetrical hearing-impaired|Subjects with asymmetrical hearing-impairment will have a standard hearing test utilizing the cochlear stimulation system.
32775177|NCT04390009|Other|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
32775178|NCT04390009|Other|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
32775179|NCT05527925||Congenital cataracts children (0~3 years)|Children with congenital cataracts between the ages of 0 and 3 years
32775180|NCT05527925||Normal children (0~3 years)|Children without congenital cataracts between the ages of 0 and 3 years
32775181|NCT05527925||Congenital cataracts children (6~18 years)|Children with congenital cataracts between the ages of 6 and 18 years
32775182|NCT05527925||Normal children (6~18 years)|Children without congenital cataracts between the ages of 6 and 18 years
32775183|NCT04872283|Active Comparator|Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
32775184|NCT04872283|Active Comparator|No Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain
33081878|NCT04639687|Other|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
33081879|NCT00218855|Placebo Comparator|A|
33081880|NCT00218855|Active Comparator|B|
33081881|NCT04639609|Experimental|Group 1 : Patients|
33081882|NCT04639609|Other|Group 2 : healthy volunteers|
33081883|NCT04639726|Active Comparator|Whey Protein|
33081884|NCT04639726|Placebo Comparator|Placebo|
33081885|NCT04639765|No Intervention|No video|This condition involves no video presentation.
33081886|NCT04639765|Experimental|CBT without Personalization|Video provides information about cognitive behavioral therapy.
33081887|NCT04639765|Experimental|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
33081888|NCT04639765|Experimental|ADM without Personalization|Video provides information about antidepressant medications.
33081889|NCT04639765|Experimental|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
33081890|NCT04639765|Experimental|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
33081891|NCT04639765|Experimental|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
33081892|NCT00218894||post cataract surgery|
33081893|NCT04639375|Experimental|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
33081894|NCT04639492|Experimental|MBS oral solution|fermented soybean extract-MBS
33081895|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
33081896|NCT00218933|Active Comparator|moderate exercise training|
33081897|NCT00218933|Experimental|high intensity exercise training|
33081898|NCT00218933|No Intervention|controls|
33081899|NCT04639180|Experimental|Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))|Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
33081900|NCT04639180|No Intervention|Control group (Active surveillance)|
33081901|NCT04638985|Experimental|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
33081902|NCT04638985|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
33081903|NCT04638985|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
33081904|NCT04638985|Active Comparator|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
33081905|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
33081906|NCT04709718||churgery of geant liver hemangioma|
33081907|NCT04628884|Active Comparator|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
33081908|NCT04628884|Experimental|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
33081909|NCT04629157|Experimental|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
33081910|NCT00561301|No Intervention|1|
33275769|NCT05590104|Experimental|Hysteroscopic CS scar defect repair|"Patient who is randomized to the hysteroscopic repair of CS scar defect will be prepared to have the surgery postmenstrual.~The surgery will be under general anasthesia. The participants will be placed in the lithotomy position. The cervix will be visualized using a Sims speculum and grasped using a single-toothed tenaculum, and the cervix, fornix, and vagina will be cleaned.~Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis. After that the patient will be prepared for another euoploid embryo transfer."
32775185|NCT05182385|Experimental|hematological relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy~Untreated first relapse of BCP-ALL with first remission duration < 12 months or~Second or greater relapse of BCP-ALL or refractory relapse or~Relapse of BCP-ALL any time after allogeneic HSCT"
32775186|NCT05182385|Experimental|molecular relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~-Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.01% if in first or second remission of BCP-ALL"
32775187|NCT04871581|Active Comparator|Device|Subjects receiving the FDA-cleared device
32775188|NCT04871581|Placebo Comparator|Placebo|Subjects receiving the sham device
32775189|NCT05533619||AKI Group|
32775190|NCT05533619||Non-AKI Group|
32775191|NCT04871347|Experimental|Dose Escalation Cohort|Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.
32775192|NCT04871347|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
32775193|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
32775194|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
33081911|NCT04720755|Experimental|Treatment|Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)
32775195|NCT05527769||pre-pectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using a pre-pectoral technique
32775196|NCT05527769||retropectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using the retropectoral technique
32775197|NCT05524805|Experimental|BTL-785-7 Treatment|Treatment with the BTL-785-7 applicator to the BTL-785F system.
32775198|NCT04466761|Experimental|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
32775199|NCT04466761|Placebo Comparator|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
32775200|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
32775201|NCT04425083||control|non- Polycystic Ovary Syndrome women
32775202|NCT04871269|Experimental|Drug: Dronabinol before the trauma film paradigm|
32775203|NCT04871269|Experimental|Drug: Dronabinol after the trauma film paradigm|
32775204|NCT04871269|Placebo Comparator|Placebo before and after the trauma film paradigm|
32775205|NCT05527613|Experimental|Conventional bracket bonding with instructions by WhatsApp|will receive the WhatsApp application, through which oral hygiene reminders will be sent through images and videos with the necessary information, and at the same time they will receive verbal oral hygiene instructions
32775206|NCT05527613|Active Comparator|Conventional bracket bonding without instructions by whatsapp|receive verbal instructions on oral hygiene
32775207|NCT04871035||Immunoadsorption|
32775208|NCT04871035||Plasma Exchange|
32775209|NCT05524649|Experimental|Experimental 1|Probiotic single strain formulation comprising Bifidobacterium longum CECT7894 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
32775210|NCT05524649|Experimental|Experimental 2|Probiotic single strain formulation comprising Pediococcus pentosaceus CECT8330 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
32775211|NCT05524649|Placebo Comparator|Placebo|Sunflower oil
32775212|NCT04878445||Cohort A: 10 participants with no COPD|"Control patients Have no physician diagnosis of COPD Have no other significant chronic lung disease (asthma, fibrotic diseases) or ongoing lung infection other than the suspected cancer for which they have been referred for surgery.~Lifelong never-smokers or ex-smokers (< 10 pack years). (1 pack year= 20 cigarettes/day for 1 year)."
32775213|NCT04878445||Cohort B: 10 participants with COPD - chronic bronchitis|Have a physician diagnosis of COPD with primarily a chronic bronchitis presentation (determined via CT, spirometry, histopathology, GOLD COPD classification).
33081912|NCT00412334|Experimental|1|
33081913|NCT00412334|Experimental|2|
33081914|NCT00412334|Experimental|3|
33081915|NCT00412334|Experimental|4|
33081916|NCT00561379|Active Comparator|1|
33081917|NCT00561379|Active Comparator|2|
33081918|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
32775214|NCT04878445||Cohort C: 10 participants with COPD emphysema|Have a physician diagnosis of COPD with primarily a emphysema presentation (determined via CT, spirometry, histopathology, GOLD COPD classification) .
33275770|NCT05590104|No Intervention|Expectant management|Patient who is randomized to the expectant management will be prepared for another embryo transfer for euoploid embryo.
33275771|NCT00990756|Experimental|PF-03526299 1.396 mg|
33275772|NCT00990756|Experimental|PF-03526299 4mg|
33275773|NCT05589870||Clinical pharmacists group|A group of patient files that were evaluated by the clinical pharmacists, Insights Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
33275774|NCT05589870||MDI system group|A group of patient files that were evaluated by the MDI system. Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
33275775|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
32775215|NCT04878133|Experimental|Exsperimental Arm|
32775216|NCT04878133|No Intervention|Control Arm|
32775217|NCT05527535||AI screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by AI
32775218|NCT05527535||Manual screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by health care personnel
32775219|NCT05533385|Experimental|Extract J. oxycedrus + extract C. arizonica + positive control + negative control|"There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10 mg/mL) and the negative control, with prick test.~Juniperus oxycedrus: 300, 60 and 12 µg/mL Cupressus arizonica: 100, 20 and 4 µg/mL"
32775220|NCT05524493||Healthy participants|
32775221|NCT05524493||Patients with migraine|
32775222|NCT05524493||Patients with drug resistent epilepsy|
32775223|NCT04389073|Experimental|Arm 1 (PD-1+NVB)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])."
32775224|NCT04389073|Experimental|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Bevacizumab (5 mg/kg every 3 weeks, intravenously [IV])."
32775225|NCT04389073|Experimental|Arm 3 (PD-1+NVB+DDP)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cisplatin (50mg/m2 every 3 weeks, intravenously [IV])."
32775226|NCT04389073|Experimental|Arm 4 (PD-1+VEX)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cyclophosphamide (50 mg/day, qd, per os)~Capecitabine (500 mg, tid, per os)"
32775227|NCT04389073|Active Comparator|Arm 5 (NVB)|• Vinorelbine (40 mg/day, tiw, per os)
32775228|NCT05175443|Experimental|Exercise Intervention|"Wall Angels:Stretching tight anterior shoulder musculature Participants will assume this position and slide their arms up and down the wall for 2 minutes.~Cervical Spine Mobility: will be accomplished by having the participant stabilize their shoulders and side bend their head in various positions to stretch each side of their next for 2 minutes with 10-15 second holds in each position.~Posterior shoulder strengthening: will be performed with shoulder externally rotating and squeezing the scapular with 5 second holds for 2 minutes.~Thoracic Spinal mobility: to improve thoracic extension participants will use a strap or tennis ball and perform thoracic extension with 10 second holds for 2 minutes."
32775229|NCT04371445|Experimental|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
32775230|NCT04371445|Active Comparator|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
33275776|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
33275777|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
33275778|NCT05589636|Experimental|Bergamot juice|Consumption of 400 cc/die of Bergamot juice (35% in water sweetened with stevia) for 12 weeks
33275779|NCT05589636|No Intervention|Free diet|Free diet
33275780|NCT00990990|Experimental|Cohort 1|
33275781|NCT00990990|Experimental|Cohort 2|
33275782|NCT00990990|Experimental|Cohort 3|
33275783|NCT00990990|Experimental|Cohort 4|
33275784|NCT00990990|Experimental|Cohort 5|
33275785|NCT00990990|Experimental|Cohort 6 (optional)|
33275786|NCT00990990|Experimental|Linezolid Cohort|
33275787|NCT05361096|Experimental|Educational approach (Flipped learning) group|The teaching of the patient safety subject was performed with the flipped learning to the intervention group (n=45).
33275788|NCT05361096|No Intervention|Traditional education group|The teaching of the patient safety subject was performed with the traditional educational to the control group (n=44).
33275789|NCT05589558|Experimental|Patients with suspected prostate cancer underwent 4 biopsy methods|Patients with suspected prostate cancer consequently underwent TRUS-guided, cognitive, fusion and transperineal template mapping biopsy
33275790|NCT05589480||postoperative recurrence|
33275791|NCT05589480||postoperative non-recurrence|
33277643|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
33277644|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
33275792|NCT05589402|Experimental|Lidocaine Cream 5%|"A topical anesthetic will be used to deliver temporary inactivation of muscle sensation. Specifically, due to its high safety profile, Lidocaine Cream 5% will be used in the current sub-study. Lidocaine cream (5%) is FDA-approved and available over-the-counter. The investigators will apply the lidocaine cream 5% following FDA guidelines and previously published protocol methodology. A test will be utilized to evaluate if the approach provides complete and temporary inactivation of sensation from the biceps. The von Frey filament test will be used with filaments ranging in size (1,65 to 6,65) to be placed on the biceps muscle every 15 minutes after lidocaine application.~Based on published work, and the current investigators' pilot data, it is anticipated that all sensations from the biceps should be blocked approximately 30 to 60 minutes after lidocaine application. Complete temporary inactivation will be defined at the point when all baseline sensation can no longer be achieved."
33275793|NCT05589402|Other|Rehabilitation Movement Training|"During temporary deafferentation, subjects will perform movement training. Similar to other single-session studies, the current investigators chose to pair the paradigm with movement training to bolster the effects of the approach.~A reaching task that is commonly performed in rehabilitation will be used. Task practice will be performed for 1 hour, with breaks given every 10 minutes. Past experiments in the current investigators' lab have adopted a similar protocol for task practice in SCI and found no adverse events. Movement training will also be assisted by the Bionik InMotion Arm/Hand robot, which has been studied in clinical and rehabilitative practices for over 20 years.~Movement training at 1 hour will be ceased due to issues with fatigue, as has been noted in previous SCI clinical studies. In addition, published work suggests that lidocaine has a half-life of one 1 hour. Thus, maximum benefits should be achieved at the 1-hour mark after application."
33275794|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
33275795|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
33275796|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
33275797|NCT05359380||SG1 - Trifocal Group|Patients implanted bilaterally with trifocal diffractive IOLs
33275798|NCT05359380||SG2 - Bifocal Group|Patients implanted bilaterally with bifocal hybrid (diffractive - refractive) IOLs
33275799|NCT05359380||SG3 - Monofocal Group|Patients implanted bilaterally with monofocal IOLs
33275800|NCT00991146|Experimental|canakinumab|
33275801|NCT05589324||3D-printed writing aids group|Thirty subjects were recruited from outpatient rehabilitation of neurologically injured patients with limited hand function. Their basic information was recorded, including basic abilities and pen-holding posture, etc. Using three different angles of 3D printing writing aids, the writing efficiency and the satisfaction of the aids are evaluated by the writing task and the Satisfaction with Assistive Technology.
33275802|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
32736920|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
32736921|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
32736922|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
32736923|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
32736924|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
32736925|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
32736926|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
32736927|NCT04486183|Experimental|Intervention|The data were collected by the researcher at the waiting room of the blood collection unit at a close distance to the lavatory. The capillary first and second blood drop values taken from the patients after fasting and at two hours following OGTT and capillary and venous blood glucose values were compared.
32736928|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
32736929|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
33081919|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
32775231|NCT05524337|Experimental|White noise group|"In the white noise group, it will be explained to the mother of the baby that the white noise sound to be used in the research will be used for pain relief. Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db. The loudspeaker will be placed on the tip of the foot, approximately 30 cm from the newborns ear, five minutes before the procedure, and will be played to the baby during the procedure. 5 minutes without taking heel blood. Before, during the procedure and 5 minutes after the end of the procedure, this sound will be played to the baby and the data will be recorded by the observer."
32775232|NCT05524337|Experimental|therapeutic touch group|"Therapeutic touch steps:~Before the application, explaining the study and the intervention to be applied to the mother, obtaining the consent of the mother to participate in the study, and filling the introductory information form will be done at this stage.~Immobile touching: Hands will be washed and warmed so that they do not disturb the baby. The researcher will support the babys back and hips with one hand, while holding the baby's chest and abdomen with the other hand. In the meantime, the nurse who will take the heel blood will start the process and continue to touch.~Compassionate touch: While the practitioners hands are in the same position; He would caress for 1 minute, rest his hands for 30 seconds, then caress again for 1 minute, rest his hands for 30 seconds, and finally continued to caress for 2 minutes. The caressing process was completed by touching it with circular movements of 1 cm diameter in a clockwise direction every 10 seconds."
33275803|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
33275804|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
32775233|NCT05524337|Experimental|therapeutic touch and white noise group|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time. Meanwhile, the data will be recorded on the form by the observer.
32775234|NCT05524337|No Intervention|Control group|Non-pharmacological intervention will not be made for the baby in the control group,
32775235|NCT05364905||Cohort 1|Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
32775236|NCT05364905||Cohort 2|Patients in second line treatment (after one prior systemic chemotherapy) in 2019
33081920|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
33275805|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
33275806|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
33275807|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
33275808|NCT00991380|Experimental|Lifestyle counselling|
33275809|NCT00991380|Active Comparator|Usual Care|
33275810|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
33275811|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
33275812|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
33275813|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
33275814|NCT02211768|Experimental|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
33275815|NCT02211768|Other|2/FDG-PET scan|Subjects will undergo FDG-PET scan
33275816|NCT05589246|No Intervention|control|intraoperative cryoanalgesia of intercostal nerves with multimodal analgesia
33275817|NCT05589246|Experimental|intervention|regional analgesia (ESP block) with intraoperative cryoanalgesia of intercostal nerves and multimodal analgesia
33275818|NCT05589168|Experimental|Triage Nurse|Triage nurse
33275819|NCT05589168|Active Comparator|No Triage Nurse|No triage nurse
33275820|NCT01017471|Experimental|control|carpal tunnel release using standard incision
33275821|NCT05589090|Experimental|Intervention group|Super Skills for Life intervention
33275822|NCT05589090|No Intervention|Wait-list group|Children in this group did not receive any phycological (public or private) intervention during the eight-week duration of the SSL program. They were informed that children in this group will receive the intervention once the follow-up visit is completed.
33275823|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 1 and once weekly at weeks 13, 21, 29, and 37.
33275824|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
33275825|NCT05589012||Human placentas and trophoblasts (biological waste) from uncomplicated pregnancies.|"The placentas will be collected following a birth by caesarean section after oral and written information by delivery of the information note for women who have had a normal singleton pregnancy at term.~Similarly, trophoblasts are collected following endo-uterine aspiration in the context of voluntary termination of pregnancy.~Cell line and virus~Infection of human placental culture explants~Determination of viral load in tissues by qRT-PCR"
32775237|NCT04230577|Active Comparator|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
32775238|NCT04230577|Sham Comparator|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
32775239|NCT05533307||nulliparous women with normal birth (not needed mediolateral episitomy)/1|group without mediolateral episiotomy
32775240|NCT05533307||nulliparous women with normal birth (with mediaolateral episiotomy)/2|group with mediolateral episiotomy
32775241|NCT03049267|Experimental|Apremilast|N=15
32775242|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
32775243|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed."
32775244|NCT05524259|Active Comparator|Myo-inositol and routinely recommended folic acid|Myo-inositol is a naturally occurring substance, with a structure quite similar to glucose, which forms an essential component of the cell membrane and is known to support several cellular processes in all living organisms. It is present in nature in high abundance and can be found in many food products. Myo-inositol was historically considered part of the vitamin-B complex and can safely be used as a dietary supplement. In humans, it is synthesized de novo from glucose-6-phosphate in many tissues, mainly in the kidney. Under normal circumstances, the kidneys produce large quantities of myo-inositol, estimated at about 4 grams of endogenous production per day. Myo-inositol has been shown to have a physiological role in supporting the effects of insulin in all living beings. It fulfils a second messenger role in the insulin signalling pathway by enhancing the translocation of GLUT-4 receptors on the plasma membrane and thereby facilitates the intra-cellular uptake of glucose.
32775245|NCT05524259|Placebo Comparator|Routinely recommended folic acid|Folic acid supplements are part of routine pregnancy care and frequently used as background supplements in previous trials on myo-inositol supplementation in pregnancy.
32775246|NCT03047317|Experimental|MABp1|
32775247|NCT05533151|Experimental|Bronchial asthma|This group envolves parients suffering from bronchial asthma.
32775248|NCT05533151|Experimental|Interstitial lung diseases|This group envolves parients suffering from interstitial lung disease.
32775249|NCT05533151|Experimental|Lung transplantation|This group envolves parients after lung transplantation done for a pulmonary disease.
32775250|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
32775251|NCT05171777|Experimental|Treatment A|Participants will receive atezolizumab SC followed by atezolizumab IV.
32775252|NCT05171777|Experimental|Treatment B|Participants will receive atezolizumab IV followed by atezolizumab SC.
32775253|NCT04112095|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
32775254|NCT04052971|Experimental|Escalation phase|"Drug: ABN401~Route of Administration: Oral~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
32775255|NCT04052971|Experimental|Expansion phase|"Drug: ABN401~Route of Administration: Oral~Once the maximum tolerated dose (MTD) or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to Recommended Phase 2 dose (RP2D) will be determined. Up to 40 patients with Non-Small Cell Lung Cancer Harboring c-MET Dysregulation will be recruited."
32775256|NCT05524181|Experimental|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, 6, 9, and 12 months.
32775257|NCT05524181|No Intervention|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, 6, 9 and 12 months.
32775258|NCT05527379|Experimental|CIP procedure under virtual reality|CIP procedure under virtual reality
32775259|NCT05257993|Experimental|Arm A (mFOLFIRINOX)|JPI-547 and Combination Chemotherapy(mFOLFIRINOX) The study is conducted in a 3+3 dose escalation method.
32775260|NCT05257993|Experimental|Arm B (GemAbraxane)|JPI-547 and Combination Chemotherapy (Gemcitabine-nab-paclitaxel) The study is conducted in a 3+3 dose escalation method.
32775261|NCT05533073|Experimental|Group A: Etoricoxib/Tramadol FDC|Pharmaceutical Form: Sachet with granules to dilute in 100 mL of water Formula: Each sachet contains Etoricoxib 90 mg / Tramadol 50 mg Dosage: 100 mL Administration way: oral
32775262|NCT05533073|Active Comparator|Group B: Etoricoxib|Pharmaceutical Form: Tablet Formula: Tablet containing Etoricoxib 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
33275826|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
33275827|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
33275828|NCT05588232|Experimental|Patient with virtual reality|The virtual reality sedation-analgesia solution developed by Deepsen combines 3D environment content with medical hypnosis techniques. The technology includes a wearable visual headset that contains head movement sensors, enabling patient interaction in the virtual environment, as well as isolating headphones.
33275829|NCT05588232|Active Comparator|Patient with pharmacological sedation|
33275830|NCT00991614||EVOLUTION® Duodenal Stent|
33275831|NCT05358054|Experimental|GROUP A|GROUP A
33275832|NCT05358054|Experimental|GROUP B|GROUP B
33275833|NCT01287936|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
33275834|NCT01287936|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
32775263|NCT05533073|Active Comparator|Group C: Tramadol|Pharmaceutical Form: Capsule Formula: Each capsule contains 50mg of Tramadol Dosage:1 capsule of 50 mg Administration way: oral
33275835|NCT01287936|Experimental|SB623 Implant (10.0M)|10 million SB623 cells
33275836|NCT05586984||Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
33275837|NCT05586984||Transvaginal sacrospinous fixation|Uterus-preserving transvaginal sacrospinous fixation for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
33275838|NCT00848328|Experimental|Lenalidomide and Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
33275839|NCT00991692|Experimental|Treatment dosage levels examined|
32775264|NCT04050553|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) in one of two study periods.
32775265|NCT04050553|Placebo Comparator|Placebo|Placebo administered SC in one of two study periods.
32775266|NCT05527301|Experimental|HEM1036 (Lactobacillus fermentum)|Daily dose of 1 × 10^10 colony-forming units divided in 2 equal doses as a powder for BID oral administration
32775267|NCT05527301|Placebo Comparator|Placebo|2g Powder for BID oral administration
32775268|NCT03946891|Experimental|Arm A|
32775269|NCT03946891|Experimental|Arm B|
32775270|NCT05524103|Experimental|ALMB-0166|Two-thirds of patients will be randomized to receive a single dose of ALMB-0166 within 72 hours after spinal cord injury.
32775271|NCT05524103|Placebo Comparator|Placebo|One-third of patients will be randomized to receive a single dose of placebo within 72 hours after spinal cord injury.
32775272|NCT05257915||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
32775273|NCT04300049|Experimental|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
32775274|NCT05257837|Experimental|Gun safety vid x Movie clip - guns present|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
32775275|NCT05257837|Active Comparator|Gun safety vid x Movie clip - guns absent|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure with the guns edited out.
33081921|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
32775276|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns present|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
32775277|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns absent|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
32775278|NCT05166629|Other|Usual Care|Usual care in the POWER Kids weight management program includes a nutrition assessment and education by a registered dietician nutritionist (RD). This includes taking a detailed dietary history, and providing individualized counseling, motivational interviewing, and nutrition education handouts/ web-based resources.
32775279|NCT05166629|Experimental|Eatable Alphabet|The intervention group will receive usual care, as described above, plus a set of Eatable Alphabet cards, which will be utilized during the visit for counseling and education, and given to the family to take home and use as they wish.
33081922|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
33081923|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
33275840|NCT05571150|Experimental|Experimental intervention group|The dyad-focused strategy training intervention will be delivered to the treatment group. The intervention protocols of the dyad-focused strategy training were developed based on the strategy training guideline outlined by Skidmore et al, Bodenmann's framework of dyadic coping, and the self-efficacy theory.
33275841|NCT05571150|Active Comparator|Control intervention group|Participants in the control group will receive a dose-matched stroke education provided by a trained research therapist as an attention-control intervention. The therapist will provide in-person education to the dyad using an illustrated manual developed based on the stroke rehabilitation guidelines suggested by the American Heart Association/American Stroke Association .
33275842|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
33275843|NCT00991770|Active Comparator|Control|Empathic support conversation
33275844|NCT04003428|Experimental|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
33275845|NCT05408988||Patients with subarachnoid haemorrhage|Patients aged 18 or older hospitalized in the Intensive Care Unit with Subarachnoid Haemorrhage.
33275846|NCT05566626|Experimental|Camera test group|The Principal Investigator will take a hyperspectral image of all subjects, both healthy volunteers and patients.
33275847|NCT05549544|Experimental|LBBAP group|Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.
33275848|NCT05549544|Active Comparator|BiVP group|Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.
33081924|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
33081925|NCT00561535|Placebo Comparator|B|Placebo
33081926|NCT03454672|Experimental|Tixel|Tixel Treatment.
33081927|NCT03454672|Active Comparator|Laser|Laser Treatment.
32736930|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
32736931|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
32736932|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
32736933|NCT02509871|Other|Body composition measurement|DXA, impedance
32736934|NCT02510105|Experimental|ARDS patients|
32736935|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
32736936|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
32736937|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
32736938|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
32736939|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
32736940|NCT03344783||mother-children pairs|
32736941|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
32736942|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
32736943|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
32736944|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
32736945|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
32736946|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
32736947|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
32736948|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
32736949|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
32736950|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
32736951|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
32736952|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
32736953|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
32736954|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
32736955|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
32736956|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
32736957|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
32736958|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
32736959|NCT00707993|Experimental|Alogliptin 25 mg QD|
32736960|NCT00707993|Active Comparator|Glipizide 5 mg QD|
32775280|NCT04870723|Experimental|Immediate|Behavioral: Motivational interviewing (MI)-based peer counseling: MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness.
32775281|NCT04870723|Other|Waitlist|"Behavioral: Motivational interviewing (MI)-based peer counseling: After the immediate group completes the intervention, the waitlist group will receive the intervention.~MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness."
32775282|NCT05527145|Active Comparator|surgery|Oper or minimally invasive surgery
32775283|NCT05527145|Active Comparator|percutaneous|percutaneous non-surgical insertion of interspinous device
32775284|NCT04870879|Experimental|Study arm|Liver transplant
32775285|NCT04870879|Other|Parallel arm|Chemotherapy
32775286|NCT05524025||Control Cohort: Adult Male Without HPV-positive throat cancer|Participants will receive 1x Salivary TTMV-HPV DNA Test. If test is negative there will not be follow up, if test is positive participants will have repeat Salivary TTMV-HPV DNA Test, a blood test and head and neck exam.
32775287|NCT05524025||Case Cohort: Any Adult With HPV-positive throat cancer|Participants will receive 1x Salivary and Blood TTMV-HPV DNA Test(s).
32775288|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
32775289|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
32775290|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~Fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
32775291|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
32775292|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
32775293|NCT05532917||Gupta group|Cardiology consultation requested using Gupta score
32775294|NCT05532917||Non-Gupta group|Number of cardiology consultations requested without using Gupta score
32775295|NCT05257369|Experimental|1.Blue-Green LED wide band phototherapy|"For experimental group was used Malysh phototherapeutic device (Luzar ltd, Belarus); it includes of eighteen blue- green super bright LEDs (12 blue (λmax 476 ) and 6 green (505 nm)."
32775296|NCT05257369|Active Comparator|2.Blue LED narrow band phototherapy|For control group was used blue LED BILI-THERAPY (Atom Medical Inc., Tokyo, Japan) in high-mode which have a 20 μW/cm2 with peak wavelength between (λmax 480 nm).
32775297|NCT04632329|Experimental|Negative Pressure|
32775298|NCT04632329|No Intervention|Control Eye|
32775299|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
32775300|NCT05523791|Experimental|WPS|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus a whey protein-based oral formula twice a day
32775301|NCT05523791|Active Comparator|Mg|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus 2.250g of magnesium pidolate twice a day
32775302|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
32775303|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
32775304|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
32775305|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
32775306|NCT05526911|Active Comparator|Group 1|The pharmacokinetics of midazolam, a CYP3A4 substrate, and digoxin, a P-gp substrate, will be studied before and after dosing with TBAJ-876.
32775307|NCT05526911|Active Comparator|Group 2|The pharmacokinetics of antiretroviral regimen TLD will be studied before and after dosing with TBAJ-876.
32898451|NCT00019682|Experimental|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
32775308|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
32775309|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
32775310|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
32775311|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
32775312|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
32775313|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
32775314|NCT04870489|Active Comparator|Isotretinoin + Co2 ablative laser|Isotretinoin treatment while being treated with CO2 laser
32775315|NCT04870489|Active Comparator|Co2 ablative laser|6 months to 1 year without isotretinoin treatments to start second side of face with CO2 ablative laser only
32775316|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
32775317|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
32775318|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
32775319|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
32775320|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
32775321|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
32775322|NCT05526833|Experimental|Non-responders undergo rTMS of the right superior temporal sulcus (STS)|Non-responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the right superior temporal sulcus (STS). The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
32775323|NCT05526833|Experimental|Partial responders undergo rTMS of the left temporo-parietal junction (TPJ)|Partial responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the original left temporo-parietal junction (TPJ) target. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
32775324|NCT05526833|No Intervention|Complete responders undergo four follow-up clinical assessments|Complete responders to protocol #8116 will be offered followup clinical assessments at 1, 2, 4, and 8 weeks to assess sustainability of their response.
32775325|NCT05526677||dynamic navigation group or static guide group|"Every patient has 2 missing in one jaw The missing tooth will be restored with one-visit single implant immediate loading.~One implant placed is assisted with dynamic navigation system, and the other one is assisted with static surgical guide."
32775326|NCT05523245||complete response|Patients receiving neoadjuvant therapy achieved pathological complete response before LARC.
32775327|NCT05523245||non complete response|Patients receiving neoadjuvant therapy did not achieve pathological complete response before LARC.
32775328|NCT05349227|Experimental|Intervention Group|In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
32775329|NCT05349227|Other|Wait List Control Group|In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
32775330|NCT05532761||diffuse lare B cells lymphoma|Diffuse large B cells lymphoma patients eligibles for CAR-T cells therapy
32775331|NCT04301453|Experimental|Maternal Scent Group|Infants in this group will be exposed to a breast pad worn by their mothers to extract maternal scent. This exposure will last 24 hours.
32775332|NCT04301453|No Intervention|Control Group|Infants in this group will receive standard of care.
32775333|NCT05344859|Experimental|Arm 1|Adaptive Rewards + Weekly automated coaching
32775334|NCT05344859|Experimental|Arm 2|Adaptive Rewards + Weekly human coaching
32775335|NCT05344859|Experimental|Arm 3|Fixed Reward + Weekly automated coaching
32775336|NCT05344859|Experimental|Arm 4|Fixed Reward + Weekly human coaching
33081928|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
33275849|NCT05357976|Active Comparator|Patients with a BMI of 18-24.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
33275850|NCT05357976|Active Comparator|Patients with a BMI of 25-29.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
33275851|NCT05357976|Active Comparator|Patients with a BMI of 30-40 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
33275852|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
33275853|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
33275854|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
33275855|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
33275856|NCT05408442||Prone|ARDS patients during mechanical ventilation in prone position
33275857|NCT05408364|Placebo Comparator|Natural yoghurt|SRP+nature yogurt (Danone® yogurt, Luleburgaz, Türkiye)
32736961|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
32736962|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
33275858|NCT05408364|Experimental|Probiotic yoghurt|SRP+probiotic containing yogurt (Danone Activia® Plain, Luleburgaz, Türkiye)
33275859|NCT05492448|Placebo Comparator|Placebo|
32736963|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
32736964|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
33275860|NCT05492448|Experimental|L. salivarius and L. reuteri|
33275861|NCT05492448|Experimental|L. reuteri|
33275862|NCT05408286||inclusion criteria|All patients aged ≥18 years admitted for COVID-19 pneumonia treated with NIV/CPAP, discharged to their home with a negative molecular swab and signed informed consent were included in the study.
32736965|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
32736966|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
32736967|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
33275863|NCT05360394|Active Comparator|PCB Only|Cephalic arch stenosis is first treated with conventional plain balloon angioplasty. Once treated adequately (<30% residual stenosis), CAS will be treated with PCB angioplasty.
33275864|NCT05360394|Experimental|Stent Graft and PCB angioplasty of stent edges|CAS is first treated with conventional plain balloon angioplasty. Once treated adequately (<30% residual stenosis), CAS will be treated with PCB first to avoid geographical miss. After which, stent graft will be deployed. Length of PCB shall be long enough to cover stent edges.
32736968|NCT04495361|Experimental|Online learning portal|Final year medical students will use an online learning portal in which three case scenarios of under five pneumonia patients will be displayed each month. Based on history and examination, the user will diagnose and manage the patient.
32736969|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
32775337|NCT05336123|Experimental|Hatha Yoga|Participants will be invited to attend one 60-75 minute yoga class for 10 weeks in the prison facility where they reside. Each class will consist of: breathing exercises, brief guided centering meditation, warm-ups, standing postures, floor postures, an inversion, relaxation, and between-class practice assignments. Classes will emphasize mindfulness, including noticing emotions, thoughts, and physical sensations related to anger, and moderate physical activity. Classes will include some teaching of a relevant yoga theme, such as nonviolence (ahimsa).
32775338|NCT05336123|Active Comparator|Health Education|To match for attention, the control condition will be a 10-week program that consists of weekly 60-75 minute group classes. In classes, instructors will provide information about general health topics through a variety of means such as slides and handouts. There will be an emphasis on group discussion of relevant topics; instructors do not just lecture. The core rationale for this course is that good physical health is important for good mental health. Instructors will provide information and encourage questions but avoid psychotherapeutic techniques or personalized goal-setting. Instructors will give participants readings to explore on their own.
32775339|NCT05523089|Placebo Comparator|Placebo (Arm 1)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of placebo, administered by subcutaneous (SQ) injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 1, to receive a single dose of placebo by SQ injection prior to viral challenge.
32775340|NCT05523089|Experimental|CD388 High Dose (Arm 2)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 150 milligrams (mg) CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 2, to receive a single dose of 150 mg CD388 by SQ injection prior to viral challenge.
32775341|NCT05523089|Experimental|CD388 Low Dose 1 (Arm 3)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 50 mg CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 3, to receive a single dose of 50mg CD388 by SQ injection prior to viral challenge.
33081929|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
33275865|NCT00090259|Experimental|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
33275866|NCT00090259|Experimental|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
33275867|NCT01082497|Experimental|Mindfulness|
33275868|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
33275869|NCT03961711|Experimental|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
33275870|NCT03961711|Active Comparator|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
33275871|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
33275872|NCT00079183|Experimental|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
33275873|NCT03961243|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
33275874|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
33275875|NCT01086085|Experimental|A|
33275876|NCT01086085|Experimental|B|
33275877|NCT01086085|Experimental|C|
33275878|NCT01086085|Experimental|D|
33275879|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
33275880|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
33275881|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
33275882|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~survived first-time AMI more than 12 months ago~stable medical treatment during the last 3 months (except removal of Plavix)~Ethnicity: Caucasians~Males, 50 - 60 yrs~non-diabetics~excluded are those who eat more than one meal of fish / week~excluded are those who take omega-3 supplements of any sorts"
33275883|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
33275884|NCT00676403|Placebo Comparator|1|Placebo
33275885|NCT00676403|Experimental|2|investigational treatment
33275886|NCT00676403|Experimental|3|investigational treatment
33275887|NCT00676403|Experimental|4|investigational treatment
32775342|NCT05523089|Experimental|CD388 Low Dose 2 (Optional Arm 4)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 4, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
32775343|NCT05523089|Experimental|CD388 Low Dose 3 (Optional Arm 5)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 5, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
32775344|NCT05523089|Experimental|CD388 Low Dose 4 (Optional Arm 6)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 6, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
32775345|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
32775346|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
32775347|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
32775348|NCT05523011|Experimental|Exosome Ointment|The subjects will apply exosome ointment along with Vesiderm liposome cream (TID per day, 20 days). Each day (from Day 1 to 20), the study product will be applied with a gap of 4 hours between three doses to a healthy area (one hand area) on the forearm using 1 fingertip unit (FTU). The Vesiderm liposome cream is meant to keep the application site moisturized.
32775349|NCT05522933|Experimental|Musculoskeletal Health|The intervention group will receive the 4 weekly workshops
32775350|NCT05334485|Experimental|Pyridostigmine|Patients randomized to this group will be given 60mg of pyridostigmine bromide orally, every 12 hours. Pyridostigmine will be administered from the time of diagnosis of postoperative ileus until the return of bowel function, or for a maximum of 48 hours.
32775351|NCT05334485|Placebo Comparator|Placebo|Patients randomized to this group will be given starch orally, every 12 hours for a maximum of 48 hours.
32775352|NCT05526209||1 with using longitudinal relaxing incision|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
33275888|NCT00676403|Experimental|5|investigational treatment
32775353|NCT05526209||2 without using longitudinal relaxing incision|without using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
33275889|NCT00676403|Experimental|6|investigational treatment
33275890|NCT00078949|Experimental|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
33275891|NCT00078949|Experimental|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
33275892|NCT00078949|Experimental|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
33275893|NCT00078949|No Intervention|Maintenance arm II|Patients undergo observation only.
33275894|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
33275895|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
33275896|NCT00078325|Experimental|1|Armodafinil 250 mg/day
33275897|NCT00078325|Experimental|2|Armodafinil 150 mg/day
33275898|NCT00078325|Placebo Comparator|3|Placebo
33275899|NCT01086319||Patients exposed to saxagliptin|
33275900|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
33275901|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"Unexplained polymorphic VT and/or VF patients.~Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.~The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
33275902|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
33275903|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
33275904|NCT03963193|Experimental|Etoposide plus Cisplatin|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
33275905|NCT03963193|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
33275906|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
33275907|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
33275908|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
33275909|NCT03961867|Experimental|DS|D2 resection -- S1 * 1 cycle + DS * 6 cycles + S1 * 9 cycles
33275910|NCT03961867|Active Comparator|SOX|D2 resection -- SOX * 8 cycles + S1 * 8 cycles
33275911|NCT04626245|Experimental|Mindfulness training|Phone-delivered mindfulness training
33275912|NCT04626245|Other|Treatment as usual|Prenatal care
33275913|NCT03962179|Experimental|VACStent Group|Patient s who received a VACStent
33275914|NCT00077857|Experimental|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
33275915|NCT00077857|Experimental|825 mg/m^2 capecitabine + docetaxel|825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
32775356|NCT04870567|Active Comparator|High dose rate brachytherapy|After spinal anesthesia steel or plastic needle placement performed under TRUS guidance. Pre- and post-insertion ultrasound based planning is obligatory in all cases. Two fractions of 13Gy are delivered with 2 separate implantations and 2-3 weeks interval. The CTV was defined as the prostate capsule with 1mm (low-risk) - 3 mm (intermediate risk) expansion plus proximal 1/3 of seminal vesicles. The PTV was equal to CTV. The rectum, bladder and urethra are contoured as organs at risk. The dosimetry plan objectives are the following: prostate D90 - above 104% and V100% - above 92%; urethra D10 < 110% , rectum D2cc<75% (below 75Gy EQD2).
33275916|NCT01086397||1|
33275917|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
33275918|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
33275919|NCT03963115|Active Comparator|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
33275920|NCT03963115|Placebo Comparator|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
33275921|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
33275922|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
32775357|NCT04870567|Experimental|Stereotactic ablative radiotherapy|"Before SBRT three fiducial markers are obligatory inserted into the prostate.Planning MRI on diagnostic table with subsequent fusing with simulation CT is obligatory. CTV to planning target volume (PTV) expansion was 3-5 mm in all direction except posteriorly (in the direction of the rectum) where it is 1-3 mm. Dose must be delivered as 5 fraction of 7.25Gy. V100% for PTV ≥ 95%. Main dose constraints are as follows: D 2cm³ ≤ 36Gy for rectum (below 75Gy EQD2)., V 37.5 Gy <5 cm³ for bladder, V 20 Gy <10 cm³ for femoral heads. Androgen deprivation therapy is not permitted.~All treatments must be performed on conventional linear accelerators with cone beam CT guidance before each fraction, intrafractional motion monitoring is optional."
32775358|NCT05526131|Active Comparator|Patients with type 2 Diabetes Mellitus and depression|This arm includes patients with type 2 diabetes mellitus that were diagnosed with depression using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
32775359|NCT05526131|Active Comparator|Patients with type 2 Diabetes Mellitus and no depression|This arm includes patients with type 2 diabetes mellitus where depression was ruled out using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
32775360|NCT04870645|Experimental|Diagnostic (advanced MRI)|Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart.
32775361|NCT05256433|Experimental|IASTM|
32775362|NCT05256433|Active Comparator|Transverse friction massage|
32775363|NCT05522621|Experimental|TJAOA102|Once enrolled, participants will be administrated TJAOA102 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
32775364|NCT05256043||Target Population|Adult patients age ≥ 18 admitted to the Stamford Hospital ICU between 9/14/11 and 11/30/19 with HbA1c available on admission and at least 4 blood glucose (BG) tests during ICU stay. Two groups were created; patients with previously undiagnosed diabetes (NDDM) compared to those with known diabetes (KDM) at the time of admission to the intensive care unit (ICU).
32775365|NCT05532527|Experimental|Study group|Microwave ablation combined with Camrelizumab and chemotherapy
33275923|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
33275924|NCT00976976|Experimental|DXP|
33275925|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
33275926|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
33275927|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
33275928|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
33275929|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
33275930|NCT00977210|Experimental|OXi4503|
33275931|NCT00545792|Experimental|Avastin|Avastin
33275932|NCT00977288|Experimental|1|MK0859 10 mg + placebo
32775366|NCT05231941|Experimental|Lidocaine Group|After induction of anaesthesia, a bolus of 2mg/kg intravenous lidocaine will be given followed by Lidocaine infusion at the rate of 1.5 mg/kg/hour which will be stopped at the end of surgery.
32775367|NCT05231941|Experimental|TAP group|After completion of procedure and before extubation, bilateral ultrasound guided subcoastal transversus abdominis plane (TAP) block will be performed by the primary anaesthetist. After taking aseptic measures, with patient in supine position a high frequency (6-13 MHz) linear ultrasound probe will be placed obliquely just inferior to the costal margin over the anterior abdominal wall. With the help of a 21G or 22G, 100 mm needle, 20 ml of 0.375% Ropivacaine will be injected between rectus sheath and fascia of transversus abdominis muscle, bilaterally.
32775368|NCT05231941|No Intervention|Control group|No additional intervention will be given to this group
32775369|NCT05217745|Experimental|Treatment|MLCT oil (provided through ready to eat meals and snacks)
32775370|NCT05217745|Placebo Comparator|Control|Corn oil (provided through ready to eat meals and snacks)
32775371|NCT05216575||Almitrine treated patients|Administration of Almitrine in spontaneoulsy breathing COVID-19 patients with moderate to severe ARDS treated by high-flow nasal canula oxygen therapy as first-line ventilatory support with persitent severe hypoxemia after awake prone positioning.
32775372|NCT05522543|Experimental|Conventional treatment with manual segmental lumber traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
33275933|NCT00977288|Experimental|2|MK0859 40 mg + placebo
33275934|NCT00977288|Experimental|3|MK0859 100 mg + placebo
33275935|NCT00977288|Experimental|4|MK0859 300 mg + placebo
33275936|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
33275937|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
33275938|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
33275939|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
33275940|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
33275941|NCT00977288|Placebo Comparator|10|Placebo
33275942|NCT00966602|Experimental|Treatment Period 1|
33275943|NCT00966602|Experimental|Treatment Period 2|
33275944|NCT00966602|Experimental|Treatment Period 3|
33275945|NCT00977366|Active Comparator|Hydrochloric acid infusion|
33275946|NCT00977366|Placebo Comparator|Saline|
33275947|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
33275948|NCT00977444|Experimental|kondrium|intraarticular injections once month
33275949|NCT00977444|Experimental|kondrium f|
33275950|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
33275951|NCT04093934|Experimental|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
33275952|NCT04093934|No Intervention|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
33275953|NCT00966758|Other|1|
33275954|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
33275955|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
33275956|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
33275957|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
33275958|NCT00966836|Experimental|Pre-emptive everolimus|
33275959|NCT00966836|Experimental|Prophylaxis mycophenolate|
33275960|NCT00966836|Experimental|Prophylaxis Everolimus|
33275961|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
33275962|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
33275963|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
33275964|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
33275965|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
33275966|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
33275967|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
33275968|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
33275969|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
33275970|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
33275971|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
33275972|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
33275973|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
33275974|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
33275975|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
33275976|NCT00977834||Group 1|Patients with lymphoma or lung cancer
33275977|NCT00977834||Group 2|Caregivers
33275978|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 & Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
33275979|NCT03938870||Experimental: Group 2|Group 30 CDR > 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
33275980|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
33275981|NCT04938206|Experimental|management reduction strategy|Patients classified as low risk by the DRC who will have a reduction in the management of their post-chemotherapy NF.
33275982|NCT04938206|Active Comparator|standard management|Patients classified as low risk by the DRC who will have standard management of post-chemotherapy NF.
33275983|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
33275984|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
33275985|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
33275986|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
33275987|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
33275988|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
33275989|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
33275990|NCT04007588|Experimental|Nivolumab+BMS-986205|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~BMS-986205 will be administered orally on a daily basis"
33275991|NCT04007588|Experimental|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
33275992|NCT04007588|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~Ipilimumab will be administered intravenously every 6 weeks"
33275993|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
33275994|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
33275995|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
33275996|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
33275997|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
33275998|NCT04928300|Experimental|Group D|Dexmedetomidine infusion IV for 5 days.
33275999|NCT04928300|Experimental|Group K|Ketamine infusion 2.5 µ/kg/min for 5 days.
33276000|NCT04928300|Placebo Comparator|Group C|The same dose and duration of normal saline will be given.
33276001|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
33276002|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
33276003|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
33276004|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
33276005|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
33276006|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
33276007|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
33276008|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
32775373|NCT05522543|Active Comparator|Conventional treatment with passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
32775374|NCT05522387|Experimental|Experimental: 1.0 mg/kg XPro1595|Patients will receive XPro1595.
32775375|NCT05532449|No Intervention|control|
32775376|NCT05532449|Experimental|Dezocine|intravenous dezocine (0.03mg/kg diluted to 5 ml)
32775377|NCT05532371|Experimental|Aerobic exercise training combined with lower limb strengthening group (AG)|Aerobic exercise training combined with lower limb strengthening.
32775378|NCT05532371|Experimental|Dual-task training combined with lower limb strengthening group (DG)|Dual-task training combined with lower limb strengthening.
32775379|NCT05532371|Experimental|Aerobic exercise training combined with dual-task training and lower limb strengthening group (ADG)|Aerobic exercise training combined with dual-task training and lower limb strengthening.
32775380|NCT05532371|Active Comparator|Only lower limb strengthening group (CG)|Only lower limb strengthening.
32775381|NCT05146739|Experimental|Treatment (uproleselan, fludarabine, cytarabine)|Patients receive uproleselan IV QD over 20 minutes on day 1 and IV over 20 minutes BID on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Patients also receive cytarabine IT on day 0 then weekly starting on day 7-28 or ITT on day 0 then weekly starting on day 7-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients (with down syndrome only) receive leuvoorine PO or IV BID on days 1, 8, 15, 22, and 29.
32775382|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
32775383|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
32775384|NCT05146037|Active Comparator|Saline flushing|TAVI valves will be prepared according to instruction for use(IFU) with saline flushing only.
32775385|NCT05146037|Experimental|CO2 and saline flushing|TAVI valves will be flushed with CO2 and then saline as per IFU
32775386|NCT04870021|Experimental|Intervention Arm|"After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy."
32775387|NCT04870021|Other|Control Arm|"In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan."
32775388|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
32775389|NCT04144387|Experimental|Test group|Each patient included in the study will be followed for 5 years
32775390|NCT05142215|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).
32775391|NCT05142215|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo procedure for chronic total occlusion (CTO).
32775392|NCT05525897|Experimental|Life skills course|Participants will take part in the psychoeducational course
32775393|NCT05525897|No Intervention|Waitlist|
33276009|NCT04007354|No Intervention|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
33276010|NCT04007354|Experimental|Non-intubated|The patients were oxygenated via facial mask with O2 5~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
33276011|NCT00982202|Experimental|PGZ|
33276012|NCT00982202|Placebo Comparator|Placebo|
33276013|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
33276014|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
32775394|NCT05522231|Experimental|Investigational arm|Fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; Sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
32775395|NCT05522231|Active Comparator|Control arm (comparator)|Axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion ;Everolimus, 10 mg, QD, PO, 3 weeks/cycle.
32775396|NCT05522231|Other|Fruquintinib monotherapy factorial study|Fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
32775397|NCT04877509||Over 50 year's COVID-19 patients hospitalized at HCL from 1st March to 29th May 2020.|
32775398|NCT05525819|Experimental|Control group|Cases will be subjected to spinal anesthesia with hyperbaric bupivacaine 10 mg.
32775399|NCT05525819|Experimental|Intrathecal group|Cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg.
32775400|NCT05525819|Experimental|Intravenous group|Cases will receive hyperbaric bupivacaine (10 mg), in addition to IV dexmedetomidine (1 μg/kg loading dose, followed by 0.4 μg/kg/h maintenance dose).
32775401|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
32775402|NCT05522153|Experimental|Arista group|this group of randomized patients will receive 5 grams of arista hemostatic powder intra-operatively in their wound in addition to 1 gram of IV transexemic acid prior to incision
32775403|NCT05522153|No Intervention|control group|this group of randomized patients will receive just the 1 gram of IV transexemic acid prior to incision
32775404|NCT05532293|Experimental|MSP008-22|"MSP008-22 is a New Chemical Entity (NCE) that has demonstrated positive outcomes during in vitro and in vivo studies for COVID19.~Formulated as tablets intended for oral dosing to trial participants."
32775405|NCT05532293|Placebo Comparator|Placebo|placebo will be identical in smell, taste, and appearance to the tablets of MSP008-22
32775406|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
32775407|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
33276015|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
32775408|NCT05525429|Active Comparator|Nutrition Education|Households in this arm will participate in a multidimensional nutrition education intervention, including (1) didactic training on family nutrition (mothers, fathers, adolescent girls), (2) participatory learning activities (mothers, fathers, adolescent girls), (3) model kitchens (mothers, adolescent girls), and (4) Nutrition Club (adolescent girls).
32775409|NCT05525429|No Intervention|Control|No intervention will be provided. After the research period is complete, the Control group will receive all inputs described above, but no data will be collected during this time period.
32775410|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
32775411|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
32775412|NCT05532215|Experimental|Misoprostol|400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
32775413|NCT05532215|Placebo Comparator|Placebo|Two sublingual placebo tablets similar to the misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
32775414|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
32775415|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
32935777|NCT05452057|Experimental|Prehabilitation|"This will include an individualized, light to moderate intensity resistance training and aerobic exercise components. Each prescribed session will include: a minute warm-up, aerobic exercise, resistance training, and a cool-down, but may be modified to accommodate the participants exercise ability.~A registered dietitian will provide an individualized nutrition assessment and counselling session within the first week of prehabilitation and again in the week prior to surgery.~A staff psychologist or psychology resident will deliver a ~60-minute psychoeducation session that focuses on stress management via relaxation, mindfulness, goal setting, and strategies to overcoming barriers to practice. In the week prior to surgery, participants will be offered a second consultation with the psychology team member to review their stress management experiences and provide further support for the acute perioperative period."
33276016|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
33276017|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
33276018|NCT00978302|Placebo Comparator|Placebo (vehicle)|
32775416|NCT05521997|Active Comparator|Control Arm: Standard of Care Chemoradiation|-Participants will receive 7 weeks of standard of care chemoradiation.
32775417|NCT05521997|Experimental|Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation|-Participants will receive 2 weeks of telaglenastat and 7 weeks of standard of care chemoradiation plus telaglenastat.
33276019|NCT00978302|Experimental|Avotermin|
33276020|NCT00978536|Other|group 1|MS with cortical cognitive troubles
33276021|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
33276022|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
32775418|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
33276023|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
33276024|NCT00982358|Placebo Comparator|Placebo|
32775419|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
32775420|NCT04877353|Experimental|Group N|50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
32775421|NCT04877353|No Intervention|group C|50 patients recieved conventional oxygen therpy.
32775422|NCT05521841|Experimental|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
32775423|NCT05521841|Active Comparator|Transversus abdominis plane block|Bilateral Ultrasound-guided bilateral Transversus abdominis plane block
33276025|NCT00982358|Active Comparator|Valsartan|
33276026|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
33276027|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
33276028|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
33276029|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
33276030|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
33276031|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
33276032|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
33276033|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
32775424|NCT05525351||NI-VATS (Non-intubated video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
32775425|NCT05525351||VATS (video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
32775426|NCT04869865|Experimental|Intervention|Detoxification cleanse
32775427|NCT04869475|Experimental|Experimental|arsenic trioxide 7mg/m2 ivgtt d1-14, q3w
33276034|NCT00982826|Experimental|2|Placebo tablet
33276035|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
33276036|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
33276037|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
33276038|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
33276039|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
33276040|NCT00984854|Experimental|Intradermal Juvidex|
33276041|NCT00984854|Placebo Comparator|Placebo (vehicle)|
33276042|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
33276043|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
33276044|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
33276045|NCT00982904|Experimental|Fexinidazole|
33276046|NCT00982904|Placebo Comparator|Placebo|
33276047|NCT04869020|Other|Otoband efficacy versus Sham A|Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Sham Device A is an OtoBand in which the transducer is modified so that the vibrations do not target the vestibular system. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham or effective).
33276048|NCT04869020|Other|Otoband efficacy versus Sham B|Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. Sham Device B is an OtoBand that operates at settings found to be non-therapeutic in motion sickness studies. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham, or effective).
33276049|NCT00984932|Experimental|Rosuvastatin|
33276050|NCT00983138|Experimental|recombinant asparaginase|
33276051|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
33276052|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
33276053|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
33276054|NCT05015270||Less disease group|"Patients with coronary artery diameter stenosis <70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
32775428|NCT05521763|Experimental|Intervention package with the availability of vaccine supply only|"The investigators will work with the supplier to make that vaccine available at the hospital premises. Then a vaccination booth will be set up at the hospital premises and will administer the vaccine at the MRP.~All HCWs will be notified about only vaccine availability information by the hospital director and respective heads.~A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number. The study staff will ensure receipt of vaccination cards for all participants.~A short message (SMS) will be delivered over the mobile phone number to all participants, e.g. vaccination program duration, venue, time, vaccine price, to cascade vaccination information to participants.~Posters with only vaccine delivery information (i.e. vaccination duration, vaccination venue, vaccine price) will be displayed at key hospital locations."
32775429|NCT05521763|Experimental|Intervention package with vaccinationation awareness only|"The hospital director and respective heads will notify all HCWs about participating in the vaccination awareness program facilitated by the study team.~The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~Posters containing messages on the importance of influenza vaccination will be displayed at key hospital locations, e.g., the main entrance of the hospital, nursing station, vaccine delivery point/place, doctors' room, nurses' room, intern doctors' room, common room canteen etc."
32775430|NCT05521763|Experimental|Intervention package with a combination of vaccine availability and awareness|"The investigators will work with the study hospital authority, Influenza vaccine manufacturer, and supplier company to set up a vaccination booth at the hospital premises to administer the vaccine at the market-rated price (MRP) by hospital nurses.~The hospital director and respective department heads will notify all HCWs to receive the offered influenza vaccine.~A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number.~The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~A short message (SMS) will be delivered over the mobile phone number to all participants.~Posters with key messages will be displayed at key hospital locations,"
32775431|NCT05521763|No Intervention|No intervention|In the control facility, we will not intervene in the existing knowledge and practice about influenza vaccination of the HCWs.
32775432|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
32775433|NCT05117255|Experimental|Experimental: Computer-delivered cognitive behavioral therapy hybrid for comorbidity|Four, approximately 60 minute each, computerized therapy sessions delivered on an interactive computerized platform. All participants are undergoing a standard 28 day residential alcohol treatment program.
32775434|NCT05117255|Active Comparator|Control: Progressive Muscle Relaxation Training (PMRT)|Four, one-hour computerized segments delivered on an interactive computerized platform teaching Progressive Muscle Relaxation Training (PMRT). All participants are undergoing a standard 28 day residential alcohol treatment program.
32775435|NCT05117255|No Intervention|Treatment as Usual (TAU)|Participants are undergoing a standard 28 day residential alcohol treatment program. No study intervention.
32775436|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
32775437|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
32775438|NCT05100251|Experimental|WBC100|WBC100
32775439|NCT05100017|Active Comparator|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
32775440|NCT05100017|Active Comparator|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
32775441|NCT04366531|No Intervention|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
32775442|NCT04366531|Active Comparator|Reentry Program|Veterans will receive the START-VET reentry program
32775443|NCT04865575||controlled asthmatics|moderate-to-severe asthmatic children with good asthma control
33276055|NCT05015270||Severe disease group|"Patients with coronary artery stenosis ≥70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
32775444|NCT04865575||uncontrolled asthmatics|moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations
32775445|NCT04876885|Other|General public|The individuals recruited to the study will include those who are age 16 and older. Due to recruitment feasibility we will focus efforts on individuals living in Ontario. We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
32775446|NCT04876885|Other|Healthcare professionals and public health professionals|The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks. Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers. Public health units will disseminate surveys to their workforce.
32775447|NCT05532137|No Intervention|Control group|This arm uses the 'non-feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index.
32775448|NCT05532137|Experimental|Intervention group|This arm uses the 'feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet.
32775449|NCT04865185|Active Comparator|Xylocaine spray 100mg/ml|Topical application
32775450|NCT04865185|Placebo Comparator|Ethanol|Topical application
32775451|NCT04865107|Experimental|MSCs Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
32775452|NCT04865107|Placebo Comparator|Placebo Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
32775453|NCT05531903|Experimental|Patients with atrioventricular node reentrant tachycardia|Patient with documented AVNRT and fragmented/slow conduction zones observed in a 3D high density mapping
32775454|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
32775455|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
32775456|NCT05521373|Active Comparator|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
32775457|NCT05521373|Active Comparator|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
32775458|NCT05521295||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
32775459|NCT05521295||Conception negative|serum human chorionic gonadotropin <10 mIU/mL
32935778|NCT05452057|No Intervention|Usual care|Usual care group will be asked to resume your typical lifestyle behaviours until the date of the surgery and will be provided with publicly available resources on physical activity, diet, and stress management.
33276056|NCT04810364||All HIV-positive patients with chronic coronary syndrome|The Group includes all HIV-positive patients with stable chest pain. The progression of atherosclerosis will be quantitatively characterized by the parameters of the lesions (e.g. plaque burden, cap thickness, arterial remodeling, presence of erosions or rupture, malaposition of the stent, a vessel injury score, etc.). The imaging data will be handled with expert-level post-processing software.
33276057|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
33276058|NCT00979316|Experimental|BMS-708163 (800 mg)|
33276059|NCT00979316|Experimental|BMS-708163 (200 mg)|
33276060|NCT00979316|Placebo Comparator|Placebo|
33276061|NCT00979316|Active Comparator|Moxifloxacin|
33276062|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
33276063|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
33276064|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
33276065|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
33276066|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
33276067|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
32775460|NCT04876807|Experimental|Part 1 (Acidic formulation)|In Part 1 of the study, the participants will receive Dose 1 of ACP-196 (reference or acidic formulation as applicable) with 240 mL water in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
33276068|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
33276069|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
33276070|NCT00983762||Heathly knee subjects|Persons with healthy knees
33276071|NCT00983840|Experimental|Family Eats|8-session program on health eating
33276072|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
33276073|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
33276074|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
33276075|NCT00979394||Patients with type 2 diabetes|
33276076|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
33276077|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
33276078|NCT00979472|Experimental|with urgency|
33276079|NCT00979472|Experimental|without urgency|
33276080|NCT04007120|Experimental|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
33276081|NCT04007120|Experimental|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
33276082|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
33276083|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
33276084|NCT00985322|Experimental|ACE inhibitor Ramipril|
33276085|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
33276086|NCT00984230|No Intervention|Breastfeeding (Reference)|
33276087|NCT00984230|Active Comparator|Basic starter formula: BSF|
33276088|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
33276089|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
33276090|NCT00984386|Experimental|Intradermal Zesteem|
33276091|NCT00984386|Placebo Comparator|Placebo|
33276092|NCT00985478|Experimental|A|SLV342 suspension or capsule
33276093|NCT00985478|Placebo Comparator|B|matching placebo
33231360|NCT04029428|Experimental|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
33231361|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
32775461|NCT04876807|Experimental|Part 2 (Orange drink)|In Part 2 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or acidic beverage as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
32775462|NCT04876807|Experimental|Part 3 (Grapefruit juice)|In Part 3 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or grapefruit as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
32775463|NCT05518409|Experimental|AD group|20 subjects who met the diagnostic criteria and exclusion criteria of AD were included in the discovery cohort.
33231362|NCT00827086||1|Patients with non-infectious Uveitis
33231363|NCT00827086||2|Patients with scleritis
33231364|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
33231365|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
33231366|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
33231367|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
33231368|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
33231369|NCT05755178|Experimental|Musical group intervention|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
33231370|NCT05755100|Other|Pilot study of I MOVE!+UP among Veterans with PTSD and BMI of 30 or greater.|Single arm pilot trial.
33231371|NCT04029740|Other|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
33231372|NCT04029740|Experimental|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
33231373|NCT00631696|Experimental|1|
33231374|NCT00631696|Placebo Comparator|2|
33231375|NCT05752994|Active Comparator|Home program group|The guardians will receive the education about autistic spectrum disorder and home program training.
33231376|NCT05752994|Experimental|Multisensory room group|The guardians in this group will receiver the educational program the same as the home program group plus the training in multisensory room.
33231377|NCT04430140||1|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
33231378|NCT05326100|Active Comparator|Conventional Therapy (CPT) Group|Each session will include vestibular exercises, customized to address the participant's symptoms of vestibular dysfunction and functional ability.
33231379|NCT05326100|Active Comparator|CAREN Group|The CAREN group will undergo vestibular physical therapy that will include virtual environment (VE) applications on the CAREN.
33231380|NCT05326100|Experimental|Augmented Reality (AR) Group|The AR group will undergo vestibular physical therapy that will include VE applications on the AR HMD.
33231381|NCT00822562|Active Comparator|Procedure/Surgery|surgery
33231382|NCT00822562|Experimental|Procedure|PRFA or PMCT
33231383|NCT05749172|Experimental|Group A|This group would be provided with Strength training along with parkour routine training.
33231384|NCT05749172|Active Comparator|Group B|The control group will be provided with parkour routine training
33231385|NCT00631540|Experimental|1|renal artery stenting
33231386|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
33231387|NCT00630916|No Intervention|A|
33231388|NCT04375384|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
33231389|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
33231390|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
33231391|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
33231392|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
33231393|NCT02549404|Experimental|KHK7580|
33231394|NCT00819598||SUSPECTED ARTERIAL DISEASE|
33276094|NCT00988286|Experimental|CEP|
33276095|NCT05593796|Active Comparator|treatment-as-usual (TAU)|
33276096|NCT05593796|Active Comparator|Clinician-delivered CBT with tratment as usual|
33276097|NCT05593250|Experimental|Cohort A|dose 1
33276098|NCT05593250|Experimental|Cohort B|dose 2
32775464|NCT05518409|Experimental|DLB group|Of the 30 subjects who met the DLB diagnostic criteria and exclusion criteria, 20 were included in the discovery cohort and 10 in the validation cohort.
32775465|NCT05518409|Experimental|Healthy control group|Among the 30 subjects who met the diagnostic and exclusion criteria of the healthy control group, 20 were included in the discovery cohort and 10 in the validation cohort.
32775466|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
32775467|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
32775468|NCT05531825||Normal control group|Patients with no disease in the main organs, with well-developed body shape, and with good physiological functions, physical activity abilities and labor abilities.
32775469|NCT05531825||Newly established arteriovenous fistula group|Chronic kidney disease stage 5 (CKD5) non-dialysis patients planning to undergo internal arteriovenous fistula surgery.
33276099|NCT05593250|Experimental|Cohort C|dose 3
33276100|NCT05593250|Placebo Comparator|Placebo|
33276101|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
33276102|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
33276103|NCT05572424|Experimental|Adaptated Physical Activity + pedometer watch|Follow an Adapted Physical Activity program during 12 weeks and wear a pedometer watch during 1 year
33276104|NCT05572424|No Intervention|Control group|Usual care
33276105|NCT04780490|Active Comparator|liberal fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).~Standard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.~In patients with MAP <65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.~If the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times."
33276106|NCT04780490|Active Comparator|restrictive fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.~In patients with MAP<65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.~If the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given."
33276107|NCT05542160|Placebo Comparator|Placebo|Placebo capsule
33276108|NCT05542160|Experimental|Treatment|IRK-19 capsule
33276109|NCT05537402|Experimental|Arm A: Atezolizumab and bevacizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.~Atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing."
33276110|NCT05537402|Active Comparator|Arm B: Locoregional therapy with TACE or TARE|"Patients will undergo locoregional therapy with TACE or TARE per investigator preference.~TACE will be administered every 8 +/- 4 weeks; TARE will be administered every 12 +/- 4 weeks. Proportion of patients being treated with TARE will be capped at 50% of cohort at a protocol level. After 50% cap is reached, patients randomized to Arm B will be treated with TACE."
33276111|NCT04445246|Experimental|Inhaled Iloprost therapy|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
33276112|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
33276113|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
33276114|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
33276115|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
33276116|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
33276117|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
33276118|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
33276119|NCT00988676||colonoscopy|
33276120|NCT05498090|No Intervention|Arm 1 (Cross-sectional, Cases v. Controls)|Cases (those with Klinefelter) vs. controls (those without Klinefelter)
33276121|NCT05498090|Experimental|Arm 2 (Interventional with cases)|Cases (those with Klinefelter); Comparison of outcomes pre and post fenofibrate intervention, 145mg PO daily for 4 weeks
32775470|NCT05531825||reconstructed arteriovenous fistula group|Patients with maintenance hemodialysis who need to reconstruct the internal arteriovenous fistula on account of dissatisfaction with blood flow.
32775471|NCT05531825||Long-term maintenance hemodialysis group|Patients undergoing hemodialysis with long-term fixed internal arteriovenous fistula.
32775472|NCT05518331|Experimental|Avatrombopag in RAA|"After the patients met the above-mentioned inclusion conditions and signed informed consent, they began to be included in this program.~The main research objectives are to take avatrombopag conversion therapy for at least 3 months, to monitor hematological indicators, biochemical indicators and bone marrow related tests, to determine hematological responses, and to evaluate the safety of the drug.~In the 6th and 12th months after treatment, comprehensive review of bone marrow and peripheral blood was performed to evaluate the recovery of hematopoiesis, determine the curative effect, evaluate adverse events, and whether there was clonal transformation.~After the patients completed the main study observation, they were followed up for at least 3 months, that is, from the time the patients were enrolled, for a total of at least 6 months of follow-up."
32775473|NCT04876573|Experimental|Cyproheptadine|
32775474|NCT05521139||CRKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-resistant Klebsiella pneumoniae.
32775475|NCT05521139||CSKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-sensitive Klebsiella pneumoniae.
32775476|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
32775477|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
32775478|NCT05521061|Experimental|1.5 g/day 2-fucosyllactose|1.5 g/day of human milk oligosaccharides will be supplemented in the first intervention group.
32775479|NCT05521061|Experimental|3 g/day 2-fucosyllactose|3 g/day of human milk oligosaccharides will be supplemented in the second intervention group.
32775480|NCT05521061|Placebo Comparator|Maltodextrine|The placebo group will receive maltodextrin as a placebo at a dose with no effect on metabolic control.
32775481|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
32775482|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
32775483|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
33231395|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
33276122|NCT00077623|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
32775484|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
33231396|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
33231397|NCT00630292|Experimental|1|
33231398|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
33231399|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
33231400|NCT00819676||subjects with asthma|
33231401|NCT00819676||healthy subjects|
33231402|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
33231403|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
33231404|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
33231405|NCT04563520|Experimental|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
33231406|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
33231407|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
33231408|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
33231409|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
33231410|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
33231411|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
33231412|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
33231413|NCT00822874|Experimental|in-vitro maturation of oocytes|
33276123|NCT00077623|Experimental|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
33276124|NCT00077623|Active Comparator|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
33276125|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33276126|NCT00986024|Experimental|aerobic exercise|
33276127|NCT00986024|Experimental|strength training|
33276128|NCT00986024|No Intervention|control group|
33276129|NCT05488652|No Intervention|Control|no intervention
33276130|NCT05488652|Experimental|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
33276131|NCT01090375|Experimental|Exercise|
33276132|NCT01090375|Placebo Comparator|Non Exercise|
33276133|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
33276134|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
33276135|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
33276136|NCT05470400|Experimental|Dose Escalation - Group 1|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
32736970|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
32736971|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
32736972|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
32736973|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
32736974|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
32736975|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
32736976|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
32736977|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
32736978|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
32736979|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
32736980|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
32736981|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
32736982|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
32736983|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
32736984|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
32736985|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
32736986|NCT04498637||Physiotherapy students|Students enrolled in the Physiotherapy Bachelor´s Degree of the University of Cadiz, Spain
32736987|NCT04498637||Nursing students|Students enrolled in the Nursing Bachelor´s Degree of the University of Cadiz, Spain
32736988|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
32736989|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
32736990|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
32736991|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
32743282|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~tablet for 5-14kg;~tablets for 15-24 kg;~tables for 25 - 34kg and~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
33276137|NCT05470400|Experimental|Dose Escalation - Group 2|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
32775485|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
32775486|NCT05092451|Experimental|Cyclophosphamide|Cyclophosphamide is dosed per adjusted body weight for patients weighing > 20% above their ideal body weight using the calculation.
32775487|NCT05092451|Experimental|CAR.70/IL15-transduced CB-NK cells|Patients will receive a single flat dose of CAR-NK.
32775488|NCT05092451|Experimental|Fludarabine phosphate|Fludarabine is dosed using actual body weight.
33276138|NCT05470400|Experimental|Dose Escalation - Group 3|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
33276139|NCT05470400|Experimental|Dose Escalation - Group 4|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
33276140|NCT05470400|Experimental|Dose Escalation - Group 5|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
33276141|NCT05470400|Experimental|Prime Boost Regimen - Group 6|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
33276142|NCT05470400|Experimental|Prime Boost Regimen - Group 7|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
33276143|NCT05470400|Experimental|Prime Boost Regimen - Group 8|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
33276144|NCT05462210|No Intervention|Control group|The first mobilization of patients undergoing surgical treatment for lumbar disc herniation and lumbar spine stenosis in the clinics where the study will be conducted is routinely performed within the first 24 hours after surgery. When the data collection process of the control group is completed, the data will be integrated with the mobilization protocol assisted with simulated clinical immersion videos created for the research.
33276145|NCT05462210|Experimental|Intervention group|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
33276146|NCT05450900|Active Comparator|Cohort 1|hCG plus biotin supplement
33276147|NCT05450900|Placebo Comparator|Cohort 2|hCG plus placebo supplement
33276148|NCT04004858|Active Comparator|Standard margin|Patient cohort planned with the current standard PTV margin
33276149|NCT04004858|Experimental|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
33276150|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
33276151|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
33276152|NCT00988910||Group 1|
33276153|NCT00988910||Group 2|
33276154|NCT04768244||COVID19|- Women with SARS-CoV-2 infections
33276155|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
33276156|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
33276157|NCT00988988|Active Comparator|placebo|inactive cream
33276158|NCT00986336|Experimental|001|
33276159|NCT00986336|Experimental|002|
32775489|NCT05316701|Experimental|Orca-T|For patients randomized to the Orca-T arm, Orca-T will be administered after myeloablative conditioning regimen. Single-agent GVHD prophylaxis with tacrolimus will be administered following Tcon infusion (generally Day +3).
32775490|NCT05316701|Active Comparator|Standard of Care alloHCT Control|For patients randomized to the standard-of-care control arm, an unmanipulated allograft derived from the peripheral blood of a matched donor will be administered after a myeloablative conditioning regimen. Dual-agent prophylaxis consisting of tacrolimus plus methotrexate will be administered starting on Day -3.
33276160|NCT00986336|Experimental|003|
33276161|NCT00986336|Experimental|004|
33276162|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
33276163|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
33276164|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
33276165|NCT00989300|Placebo Comparator|Placebo group|
33276166|NCT05413850|Experimental|Phase 1, Cohort A|Subjects with PSMA positive disease will receive 5.55GBq of 177Lu-rhPSMA-10.1 (maximum of 3 cycles).
32775491|NCT04876183|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Binge Eating Disorder)
32775492|NCT04876183|No Intervention|Waitlist Control Group|12-week waiting period
32775493|NCT04864873|Active Comparator|Standard diagnostic pathway|Part of each patient sample will be tested using current standard microbiological techniques.
32775494|NCT04864873|Experimental|mNGS pathway|Part of each sample will be testing using mNGS methodology, which will be compared to the standard diagnostic pathway.
32775495|NCT05518253|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
32775496|NCT05518253|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
32775497|NCT04864717|Active Comparator|Doxycycline|Doxycycline 100mg po once daily x 6 months
32775498|NCT04864717|Active Comparator|Isotretinoin|Isotretinoin 40mg po once daily x 6 months
32775499|NCT05518175|Active Comparator|Route A: Traditional laparoscopy|
32775500|NCT05518175|Experimental|Route B: Single site laparoscopy|
32775501|NCT05518175|Experimental|"Route C:V-Notes surgery"|
32775502|NCT04876495|Active Comparator|Whey protein|Whey protein isolate (45.5g total protein content)
32775503|NCT04876495|Active Comparator|Potato protein|Potato protein isolate (45.3g total protein content)
32775504|NCT04876495|Active Comparator|Rice protein|Rice protein isolate (45.5g total protein content)
32775505|NCT04876261|Active Comparator|Group A|Group A will receive Oliphenolia® bitter on intervention visit 1 followed by Oliphenolia® on intervention visit 2 and followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on the third and final intervention visit
32775506|NCT04876261|Active Comparator|Group B|Group B will receive Oliphenolia® on intervention visit 1 followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 2 and followed by Oliphenolia® bitter on the third and final intervention visit
32775507|NCT04876261|Active Comparator|Group C|Group C will receive La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 1 followed by Oliphenolia® bitter on intervention visit 2 and followed by Oliphenolia® on the third and final intervention visit
32775508|NCT05518097||Conventional Physical Therapy Program|Patients with knee osteoarthritis underwent a conventional physical therapy program including hotpack, US, TENS and exercise.
32775509|NCT05518019|Experimental|"Prima CBD The Daily Supplement"|Participants are provided with the dietary supplement (1 capsule per day). Participants are to take the supplement at the same time every day Participants will take a weekly well-being survey Participants are to complete the well-being questionnaire after the 4th week
32775510|NCT05517785||Medicated|Assessment of motor function will be performed 1 hour after taking the usual stimulant ADHD medication.
32775511|NCT05517785||Unmedicated|Participants will remain unmedicated for the duration of the assessment, and will delay taking their usual stimulant ADHD medication until all the motor function assessments are completed.
32775512|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
32775513|NCT05531747|Experimental|Physiopathologic exploration|A non randomised study with one arm, addind experimental acts to standard of care (skin biopsy and biological sample ) in order to explore Hidradenitis Suppurativa physiopathology
32775514|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
32775515|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) < 15 % by volume expansion in fluid responders
32775516|NCT04875949|Experimental|Anti-AChRs Abs positive patients|Immunoabsorption
32775517|NCT05520671|Experimental|TESLA-G|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
32775518|NCT05520671|Active Comparator|Control|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
32775519|NCT04869709|Active Comparator|Late Preterm Steroids 2 Days|
32775520|NCT04869709|Active Comparator|Late Preterm Steroids 7 Days|
32775521|NCT04869631||Aortic valve stenosis undergoing aortic valve replacement|Aortic valve stenosis undergoing aortic valve replacement.
32775522|NCT05021081|Experimental|TEST/CONTROL|For Phase 2, eligible subjects that are enrolled will be randomized to the Test/Control contralateral sequence.
32775523|NCT05021081|Experimental|CONTROL/TEST|For Phase 2, eligible subjects that are enrolled will be randomized to the Control/Test contralateral sequence.
32775524|NCT04864327|No Intervention|control|Usual care
32775525|NCT04864327|Other|intervention|5 minutes brief smoking cessation advise
32775526|NCT05520515|Experimental|Aquatic training plus health education group|Aerobic exercise training program in the aquatic environment twice a week plus health education program once a week
32775527|NCT05520515|Experimental|Land training plus health education group|Aerobic exercise training program in the land environment twice a week plus health education program once a week
33276167|NCT05413850|Experimental|Phase 1, Cohort B|Subjects with PSMA positive disease will receive 7.4GBq of 177Lu-rhPSMA-10.1 (maximum of 2 cycles).
32775528|NCT05520515|Active Comparator|Health education group|Health education program once a week
32775529|NCT05520437|Experimental|Physically active males|Half of the study population will consist of long-distance runners with 2-5 years of experience in running and similar times in covering the half-marathon distance.
32775530|NCT05520437|Experimental|Physically inactive males|The other half of the study population will consist of age-matched individuals involved in no regular physical activity.
32775531|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
32775532|NCT04622735|Experimental|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
32775533|NCT04622735|Active Comparator|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
32775534|NCT04622735|Active Comparator|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
32906433|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
33231414|NCT00847379|Experimental|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
33231415|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
33231416|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
32736992|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
32736993|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
32736994|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
32736995|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
32736996|NCT02508155|Experimental|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
32736997|NCT02508155|Placebo Comparator|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
32736998|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
32736999|NCT02508155|Placebo Comparator|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
32737000|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
32737001|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
32737002|NCT04498793|Experimental|PD-1 group|"Participants receive tislelizumab every 3 weeks (Q3W) + nab-paclitaxel weekly x 4 cycles, followed by tislelizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 14 cycles of tislelizumab Q3W plus capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
32737003|NCT04498793|Active Comparator|Control group|"Participants receive nab-paclitaxel weekly x 4 cycles followed by (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
32737004|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
32737005|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
32737006|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
33231417|NCT00820144|Experimental|1|voie nasale 0.25 mg
33231418|NCT00820144|Experimental|2|0.5mg of CTB by oral way
33231419|NCT00820144|Experimental|3|1mg of dukoral by oral way
33231420|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
33231421|NCT00820144|Experimental|5|1mg of CTB by sublingual way
33231422|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
33231423|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
33231424|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
33231425|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
33231426|NCT00847301||Renal Impairment|
33231427|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
33231428|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
33231429|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
33231430|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
33231431|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
33231432|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
33231433|NCT04118075|Experimental|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
33401894|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
32737007|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
32737008|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
32737009|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
32737010|NCT04498325|Experimental|NT-I7 (Phase I)|"In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant~NT-I7 will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
32737011|NCT04498325|Experimental|NT-I7 (Pilot)|"NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
32737012|NCT04498325|Placebo Comparator|Placebo (Pilot)|"Placebo will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
32737013|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
32737014|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
32737015|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
32737016|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
32737017|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
32737018|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
32737019|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
32737020|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
32737021|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
32737022|NCT04498091||A|Type 2 MI with COVID-19
32737023|NCT04498091||B|Type 2 without COVID-19
32737024|NCT04498091||C|Type 2 MI with pneumonia without COVID-19
32737025|NCT04498091||D|Type 2 MI without pneumonia and without COVID-19
32737026|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
32737027|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
32737028|NCT04495205|Experimental|Non-eugenol containing periodontal packs with PRF|Non-eugenol containing periodontal packs with PRF after gingival de-pigmentation
32737029|NCT04495205|Placebo Comparator|Non-eugenol containing periodontal packs|Non-eugenol containing periodontal packs after gingival de-pigmentation
32737030|NCT02499809|Experimental|Passive|Passive recovery
32737031|NCT02499809|Experimental|Vibration|Vibration recovery
32737032|NCT04498013|Experimental|Treatment group|Patients will be treated with Cyclodynon 1 tablet per day 6 month in addition to lifestyle modification
32737033|NCT04498013|Other|Control group|Lifestyle modification only
32737034|NCT04497935||1LPEG|Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
32737035|NCT04497935||2LPEG|Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.
32737036|NCT02507531|Experimental|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
33276168|NCT05413850|Experimental|Phase 2, Cohort 1, post-chemotherapy mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose [RP2D]
33276169|NCT05413850|Experimental|Phase 2, Cohort 2, Taxane-naïve mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose [RP2D] .
33276170|NCT05378672|Experimental|Dasiglucagon 0.6 mg|Participants will receive a single dose of dasiglucagon.
33276171|NCT04005014|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
33276172|NCT04005014|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
33276173|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
33276174|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
33276175|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
33276176|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
33276177|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
33276178|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
33276179|NCT04005950||medical doctors|
33276180|NCT04005950||paramedics|
33276181|NCT00986414|Experimental|AFQ056-10mg|
33276182|NCT00986414|Experimental|AFQ056-25mg|
33276183|NCT00986414|Experimental|AFQ056-50mg|
33276184|NCT00986414|Experimental|AFQ056-75mg|
33276185|NCT00986414|Experimental|AFQ056-100mg|
33276186|NCT00986414|Placebo Comparator|Placebo|
32737037|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
33276187|NCT05712668|Active Comparator|Standard Pre-operative Counseling|Participants will receive standard counseling.
33276188|NCT05712668|Experimental|Standard Pre-operative Counseling plus Asynchronous Telemedicine|Participants will receive standard counseling plus access to a 5 minute video reviewing their in-office counseling.
33276189|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
33276190|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
33276191|NCT05712590||Vegans|In this group women aged 30-45 years that follow vegan diet for at least 3 years will be included.
33276192|NCT05712590||Vegetarians|In this group women aged 30-45 years that follow vegetarian (lacto-ovo/lacto/ovo) diet for at least 3 years will be included.
33276193|NCT05712590||Omnivores|In this group women aged 30-45 years that follow omnivorous diet for at least 3 years will be included.
33276194|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
33276195|NCT05265026|Experimental|Exercise Intervention Arm|The high intensity interval exercise sessions per week of 38 minutes. Exercise will be performed on ergometerbikes.
33276196|NCT05265026|No Intervention|No Intervention|No lifestyle changes
33276197|NCT00543062|Other|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
33276198|NCT00543062|Other|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
33276199|NCT00543062|Other|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
33276200|NCT00543062|Other|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
33276201|NCT05235074|Experimental|Dose escalation and dose expansion|The dose-escalating phase of the phase I trial of OH2 injection is divided into two dose groups (10^6 CCID50/mL and 10^7 CCID50/mL).It will be administered by Ommaya reservoir injection, and the total amount of each dose in each dose group should not exceed 2ml according to the size of the tumor cavity.
33276202|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
33276203|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
33276204|NCT05222594|Other|Epileptic participants undergoing intracranial monitoring|Patients with pharmaco-resistant epilepsy undergoing intracranial monitoring involving the left cerebral hemisphere.
33276205|NCT05221580||Real-world adult population of Chinese patients with T2DM|Ryzodec as per local clinical practise
33276206|NCT05712512||Infant siblings of children with autism spectrum disorder|
32737038|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
33276207|NCT04005092|Active Comparator|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
32737039|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
33276208|NCT04005092|Active Comparator|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
33276209|NCT04004624|Active Comparator|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
33276210|NCT04004624|No Intervention|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
33276211|NCT04006574|Experimental|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
33276212|NCT04006574|Active Comparator|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
33276213|NCT05195606|No Intervention|Control group|There is no standard sensory stimulation program for comatose patients with head trauma in the hospitals where the research will be conducted. Therefore, the control group will receive routine practice.
33276214|NCT05195606|Experimental|Auditory stimulus (Intervention A)|Auditory stimulus for patients in this group
33276215|NCT05195606|Experimental|Tactile stimulus (Intervention B)|Tactile stimulus for patients in this group
33276216|NCT05192720|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 100 ml/day orally for 1 month. The intervention solution is given in a neutral plastic container
33276217|NCT05192720|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 100 ml/day orally for 1 month. The placebo solution is given in a neutral plastic container (same as for intervention/experimental solution).
33276218|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
33276219|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
33276220|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
33276221|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
33276222|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
33276223|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
33276224|NCT05712122|Experimental|stellat gagnliyon blockadge|Ultrasound-guided stellate ganglion blockade and for blockage, the solution was prepared by adding 8 mg dexamethasone, 40 mg lidocaine, and 10 mg bupivacaine to 10 mL with physiological saline.
33276225|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
33276226|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
33276227|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
33276228|NCT04542161|Active Comparator|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
33276229|NCT04542161|Active Comparator|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
32737040|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
32737041|NCT05504057||Patients with chronic treatment with antihistamines or amantadine|The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.
32737042|NCT05504057||Other population of the THC|The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups.
32737043|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
32737044|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
32737045|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
32737046|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
32737047|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
32743283|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
32775535|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
32775536|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
32775537|NCT04615559|Experimental|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
32775538|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
33276230|NCT04542161|Placebo Comparator|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
33276231|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
33276232|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
33276233|NCT00812201||1|
33276234|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
33276235|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
33276236|NCT04331561|Experimental|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
33276237|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
33276238|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
32775539|NCT05517629||All the time|Students who wore face masks all the time when outside
33276239|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
33276240|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
33276241|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
33276242|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
33276243|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
33276244|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
33276245|NCT04249427|Active Comparator|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
33276246|NCT04249427|Placebo Comparator|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
33276247|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33276248|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33276249|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
33276250|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
33276251|NCT04003350|Active Comparator|Opioid Regimen|"Weeks 1-4~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
33276252|NCT04003350|Experimental|Multimodal pain regimen with PRN opioids|"Weeks 1-4~Tylenol 1000 mg q8h (standing)~Meloxicam 15 mg qD (standing).~Gabapentin 200 mg BID (with morning and evening Tylenol dose)~Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)~Esomeprazole 20mg daily if not already on another H2 blocker or PPI~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
33276253|NCT00748007|Experimental|A|
33276254|NCT00748007|Placebo Comparator|Placebo|Placebo
33276255|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
33276256|NCT00748319|Other|1|Detection of KIR receptor
33276257|NCT00748397|Experimental|A|
33276258|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
33276259|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
33276260|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
33276261|NCT00748475|Experimental|Neurofeedback|
33276262|NCT00758537||Patients with chronic kidney disease stage 3|
33276263|NCT00758537||patients with chronic kidney disease stage 4|
33276264|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
33276265|NCT00758537||Controls (no kidney disease)|
32775540|NCT05517629||Most of the time|Students who wore face masks most of the time when outside
32775541|NCT05517629||Only when told to|Students who wore face masks only when they were told to when outside
32775542|NCT05517629||Not At All|Students who did not wear face masks at all when outside
32775543|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
32775544|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
33401895|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
33401896|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
32935779|NCT04322162|Experimental|Active implementation - Wave 1 (First and Second Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 1 corresponds to Wave 1."
33231434|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
33231435|NCT04122209|Experimental|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
33231436|NCT04122209|Experimental|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
33231437|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
33231438|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
32775545|NCT05075135|Experimental|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
32775546|NCT05075135|Active Comparator|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
32775547|NCT04875559||Breast cancer surgery patients.|Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.
32775548|NCT04875637|Other|MEMR Diagnostic Evaluation|Middle Ear Muscle Reflex using wideband acoustic reflectance to assess hearing status.
33231439|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
33231440|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
33231441|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
33231442|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
33231443|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
33231444|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
33231445|NCT02613143||Surgery|
33231446|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
33231447|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
33231448|NCT04117529|Experimental|Experimental Arm|Pemphigus or other autoimmune diseases.
33231449|NCT02612987|Experimental|iCBT|
33231450|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
33231451|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
33276266|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
33276267|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
33276268|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
33276269|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
33276270|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
33276271|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
33276272|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
33276273|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
33276274|NCT00989742|Active Comparator|Doxycycline|
33276275|NCT00989742|Placebo Comparator|Placebo|
33276276|NCT05408208|Active Comparator|Methotrexate|Intralesional injection of methotrexate
33276277|NCT05408208|Active Comparator|Triamcinolone Acetonid|Intralesional injection of trimethinolone acetonide
32737048|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
32737049|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
32737050|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
32737051|NCT05472701|Experimental|Whole Food Plant-Based (WFPB)|2 meals/day of traditional plant proteins (tofu, quinoa, black beans) and minimized intake of processed food, eggs, and dairy
32737052|NCT05472701|Experimental|Plant-Based Meat Alternatives (PBMA)|2 servings/day of plant-based meat alternatives (Beyond Beef, Impossible Burger, Gardein Chick'n)
32737053|NCT05472701|Experimental|Animal|2 servings/day of traditional meat products (beef burger, pork, chicken)
32737054|NCT03232255|Experimental|Treatment Group|
33276278|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
33276279|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
33276280|NCT02559245|No Intervention|controled|participants will follow their usual diet
33276281|NCT05358756|Experimental|Treatment A :Fasted|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours.
33276282|NCT05358756|Experimental|Treatment B: Fed|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
33276283|NCT05358756|Active Comparator|Treatment C: Fed|Adminstartion of Edurant, 150 mg (6 × 25 mg rilpivirine, oral tablets), after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
33276284|NCT00758615|Experimental|I|Walking School Bus Intervention
33276285|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
33276286|NCT00758693|Experimental|1|Bendamustine + Rituximab
33276287|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
33276288|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
33276289|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
33276290|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
33276291|NCT05092646|Placebo Comparator|Control Group|Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
33401897|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
32775549|NCT05520359|Experimental|Neurologic Disorders|Evaluation of individual and combined effects of mobility devices and spinal stimulation for individuals with neurologic disorders.
32775550|NCT05070923|Experimental|HealthyLifetime Group|"HL is an 8-week, personalized health coaching program that includes a comprehensive assessment made through a survey and a virtual' home visit (via video), a goal-directed strengthening action plan developed by the participant with the guidance of the nurse, a tailored daily planning guide to enhance action steps and goal attainment, and six weekly 30 minute nurse coaching sessions with participants the Healthie application technology via their personal home computer, Tablet or Smartphone device. If a participant does not use a personal device or the device cannot support the Healthie platform, the HL program will provide a Tablet to them for their use during the program. All video sessions ( ie, home visit, strengthening plan, and weekly coaching sessions will use a two-way video but only the audio portions of the sessions will be recorded. The HL program, tailored to each participant's need for strong and resilient function, encompasses the following key elements:"
32775551|NCT05070923|No Intervention|Usual Care Group|Participants randomized to the usual care group will be given information about when to expect reminders on the Healthie platform to complete future surveys at the end of week 8, and after three months that will be available on the Healthie Platform for them to fill out and save on the platform. They will also be reminded how to contact the study coordinator if they should have questions. Participants in this group will have the view to other functions on the platform turned off. They will only be able to view documents as the reminders appear for them to complete.
32775552|NCT05531669|Experimental|Study group|the study group will receive 12 months of Play Project + Parental Education intervention
32775553|NCT05531669|Active Comparator|control group|the control group will receive Parental Education intervention in the first 6 months, and then receive Play Project + Parental Education intervention in the next 6 months
32775554|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
32775555|NCT04864015|Placebo Comparator|Conventional mouthpiece|Patients undergoing standard EGD using a conventional mouthpiece
32775556|NCT04864015|Active Comparator|Droplet reduction mouthpiece|Patients undergoing standard EGD using a new droplet reduction mouthpiece
32775557|NCT05298917|Other|extended contact lens wear|subjects wear silicone hydrogel contact lenses continuously for 7+/- 1 days - corneal sensitivity will be measured and compared at baseline versus after extended contact lens wear
32775558|NCT04385251||SARS-CoV-2 infection/COVID-19|Adults who present for SARS-CoV-2 testing will be consented for this study. Participants who are enrolled will be informed that if they have SARS-CoV-2 infection/COVID-19, they will be followed for 28 days in an observational cohort study, and that if they do not have SARS-CoV-2 infection, there will be no further follow-up.
32775559|NCT05293067||carotid endarterectomy|High-sensitive troponin would be measured in patients undergoing carotid endarterectomy (CEA). Patients would be followed during the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
32775560|NCT05293067||carotid artery stenting|High-sensitive troponin would be measured in patients undergoing carotid artery stenting (CAS). Patients would be followed in the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
32775561|NCT05531591|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
32775562|NCT05531591|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
32775563|NCT05531591|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
32775564|NCT05531591|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 mEq/L (milliequivalents/liter).
33231452|NCT00912977||Group 1|Groups are defined by another study
33231453|NCT00912977||Group 2|Groups are defined by another study
33231454|NCT00912977||Group 3|Groups are defined by another study
33231455|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
33231456|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
33231457|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
33231458|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
33231459|NCT00698945|Active Comparator|2|Alphagan
33231460|NCT00698945|Active Comparator|1|Istalol and Optive
33231461|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
33231462|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
33231463|NCT00790842|Experimental|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
33231464|NCT00790842|Experimental|Group B, CrCl < 30 mL/min|Creatinine clearance < 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
33231465|NCT00790842|Experimental|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance < 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
33231466|NCT04107012|Experimental|Clear Aligner|Group 1 treated with clear aligners
33231467|NCT04107012|Active Comparator|Fixed appliance|Group 2 treated with conventional fixed appliances
33276292|NCT05092646|Experimental|Investigational Group|"Biological/Vaccine: Axolotl Ambient~Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.~Other Names:~• CA20"
33276293|NCT04041479|Active Comparator|Standard of Care|FDA-cleared, standard-of-care iTBS repetitive Transcranial Magnetic Stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
33276294|NCT04041479|Experimental|Targeted Side Arm|iTBS rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
33276295|NCT04041479|Active Comparator|Opposite Side Arm|iTBS rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
33276296|NCT05407896|No Intervention|Comparison arm|Patients and caregivers in this arm will receive existing counselling by trained counsellors.
33276297|NCT05407896|Experimental|Intervention arm|Patients and caregivers in this arm will receive counselling with the newly developed web-based decision aid (myKIDNEY) by trained counsellors.
33276298|NCT05078450|Experimental|Graduate Student Program|This is the graduate student version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
33276299|NCT05078450|Experimental|Young Professional Program|This is the young professional version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
33276300|NCT05078450|No Intervention|Waitlist|This is the waitlist. Participants may be randomly assigned here first. After the typical period fo the intervention on the waitlist (12 weeks), these participants will be invited to join the arm which they are most appropriate for (i.e., graduate student or young professional).
33276301|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
33276302|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
33276303|NCT00748631|Experimental|1|balloon Kyphoplasty
33276304|NCT04742114|Sham Comparator|the face mask without EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The face mask without the application of EPAP will be used.
33276305|NCT04742114|Experimental|the face mask with EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The application of EPAP (15cmH2O) via face mask will be used.
32737055|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
32737056|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
32737057|NCT03232177|Experimental|Anagre Cap.|twice a day
33276306|NCT00758849|Placebo Comparator|1|
32737058|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
32737059|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
33276307|NCT00758849|Active Comparator|2|
33276308|NCT05334186|Experimental|Telehealth Reasoning Training|Telehealth-delivered inductive reasoning training will focus on improving the ability to solve problems that require linear thinking and that follow a serial pattern or sequence. Participants will be taught strategies to identify patterns to solve problems. These problems involve identifying the pattern in series of numbers and letters, or recognizing patterns in everyday activities, like dosing for medications. Training will consist of ten training sessions, over 5 weeks, and will be conducted over Zoom. Each training session is 60-75 minutes long and typically consists of (a) 10 minutes of introductory training exercises for basic mental abilities, such as finding patterns in schedules, (b) training exercises for everyday tasks, such as filling out medication charts, recycling charts, and understanding medicine bottle labels, and (c) a 20-question practice assessment.
33276309|NCT05070884||non respondants of neo treatment|those patients with no response or partial response when administered with Chemotherapy prior to sugery
33276310|NCT05357820|Experimental|Itraconazole cohort|
33276311|NCT05357820|Experimental|Rifampicin cohort|
33276312|NCT00748787|Experimental|1|
33276313|NCT00748787|Placebo Comparator|2|
33276314|NCT05712044|No Intervention|Basal|Samples will be taken to participants.
33276315|NCT05712044|Experimental|15 days folate suplementation|5mg tablets of folic acid will be given to participants every 8 hours for a period of 15 days, then samples are to be taken in duplicate for each individual.
33276316|NCT05712044|Experimental|30 days folate suplementatio|5mg tablets of folic acid will be given to participants every 8 hours fora a period of 30 days, then samples are to be taken in duplicate for each individual.
33276317|NCT05360316|Placebo Comparator|ESWT|Patients assigned to the ESWT group received ESWT over the plantar fascia, three days/week, for six weeks. In addition patients participated additional in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
33276318|NCT05360316|No Intervention|Placebo|Routine therapy Patients participated in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
33276319|NCT04059731|Experimental|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
33276320|NCT04059731|Active Comparator|Atempero® or Impact®|Inmunonutrition
33276321|NCT00986960|Active Comparator|Adrenocorticotropin hormone|Patients receive the hormone
33276322|NCT00986960|Placebo Comparator|Placebo|Patients receive placebo only
33276323|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
33276324|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
33276325|NCT05711966|Experimental|IN-REC-SUR-E|INRECSURE infants will receive preintubation medications and HFOV starting at MAP 8 cmH2O; frequency 15 Hz, with volume-guarantee (1.5-1.7 mL/kg). The I:E will be 1:1. An oxygenation guid-ed lung recruitment procedure will be performed using stepwise increments then decrements in MAP. The starting MAP will be increased stepwise as long as SpO2 improves reducing the FiO2 keeping SpO2 within the target range (90-94 %) until the oxygenation no longer improves or the FiO2 is equal to or less than 0.25 (opening MAP). Next, the MAP will be reduced stepwise until the SpO2 deterio-rates (closing MAP). After a second recruitment maneuver at the opening pressure, the optimal MAP will be set 2 cmH2O above the closing MAP. Then 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) via a closed administration system will administrate. Infants with sufficient res-piratory drive will be extubated within 30 minutes after surfactant administration starting nCPAP (7-9 cm H2O) or NIPPV.
33276326|NCT05711966|Active Comparator|Less Invasive Surfactant Administration|By contrast, infants allocated to the LISA group will receive 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) according to the following protocol: during nasal CPAP with a pressure of 7-8 cm H2O, surfactant will be administered over 0.5-3 min using the SurfCath™ tracheal instillation catheter (VYGON S.A. - Ecouen, France), or a 4- 6 F end-hole catheter, according to local protocols. After the same pre-procedural medications, the catheters will be positioned during laryngoscopy with or without Magill forceps. The catheter will be connected to a syringe pre-filled with the surfactant, and the surfactant is instilled slowly. The infant's mouth will be closed. In cases of apnoea or bradycardia, positive pressure ventilation will be performed until recovery. After surfactant administration, CPAP (7-9 cm H2O) therapy (16) or NIPPV will be continued.
33276327|NCT05407506|Experimental|THYROID AI|
33276328|NCT00759005|Experimental|A, 4|
33276329|NCT05357586|Experimental|Transdiagnostic cognitive behavioral therapy|Transdiagnostic cognitive behavioral therapy
33276330|NCT04360070|Experimental|Ketamine Arm|Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
33276331|NCT04360070|No Intervention|Control Arm|Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
33276332|NCT04354688|Experimental|T3 Certain Tapered implant with DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
33276333|NCT04354688|Active Comparator|T3 Certain Tapered implant without DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
33276334|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
33276335|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
33276336|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
33276337|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
33276338|NCT04733846||corneal trauma sutured with Vicryl 10-0 monofilament|corneal trauma sutured with Vicryl 10-0 monofilament will be included. They will have data collection of medical records.
33276339|NCT05407350||Crohns disease patients|Adult patients with moderately to severely active CD
33276340|NCT04048889|Experimental|Popliteal plexus block and continuous femoral nerve block|
33276341|NCT04048889|Active Comparator|continuous femoral nerve block|
33276342|NCT04005560|Other|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
33276343|NCT04901442|Active Comparator|Running with an Orthotic|Group A will receive an L700 Speed Orthotic (https://www.aetrex.com/running-orthotic/?lang=en_US) according to participants shoe size and will run with this Orthotic in the participants normal running shoes. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to run as normal over the 8-week trial period
33276344|NCT04901442|No Intervention|Running without an Orthotic|Group B will not be provided with the Orthotic and will run in the participants normal running shoes during the course of the study. The group will be asked to run as normal over the 8-week trial period. At the end of the study and following collection of data participants in Group B will also be provided with an L700 Speed Orthotic.
33276345|NCT00987038|Other|PF-04171327 and Midazolam|
33276346|NCT00761033|Experimental|music|children will listen to music during procedure
33276347|NCT00761033|Other|Standard care|Standard care
33401898|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
33401899|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
33401900|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
33401901|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
33401902|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
32775565|NCT05531591|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
32775566|NCT04384705||caregivers|caregivers
32775567|NCT05517551||normal flow anesthesia|A fresh gas flow of 3 L/min will be applied continuously
32775568|NCT05517551||low flow anesthesia|A fresh gas flow of 3 L/min will be applied for the first 20 minutes after intubation , and then it will be reduced to 1 L/min.
32775569|NCT05067647|Experimental|Thoracic, Urologic, Ear, Nose and Throat (ENT) Procedures|Any thoracic, urologic, or ENT procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use. Participants will be considered enrolled when the ENSEAL X1 device has been attempted to be used for a vessel transection during thoracic, urologic, or ENT procedures.
33081930|NCT04628923|Experimental|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
33081931|NCT04628611|Active Comparator|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
33231468|NCT04104204|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
33231469|NCT04104204|Experimental|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
33401903|NCT05671978|Placebo Comparator|neutral position|intubation was performed in the neutral position
33401904|NCT05671978|Experimental|back-up head elevated position|he trachea was intubated in the back-up head elevated position
33401905|NCT05671510|Experimental|Arm 1: ONC-392 6 mg/kg with 2 loading doses of 10 mg/kg, Q3W|ONC-392 will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
33401906|NCT05671510|Experimental|Arm 2: ONC-392 3 mg/kg Q3W|ONC-392 will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
33401907|NCT05671510|Active Comparator|Arm 3: Docetaxel 75 mg/m2, Q3W|Docetaxel will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
32775570|NCT05520125|Experimental|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles
33401908|NCT05667454|Active Comparator|Low dose atropine|Atropine 0.05% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
33401909|NCT05667454|Active Comparator|High dose atropine|Atropine 0.5% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
33401910|NCT05457478|Active Comparator|Cohort 2 (no weighing)|"Patients do not weigh themselves using the Smart scale during standard radiation therapy."
33401911|NCT05457478|Experimental|"Cohort I ('Smart scale weighing)"|"Patients weigh themselves daily using the Smart scale over 5-8 weeks during standard radiation therapy."
33401912|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
33401913|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
33401914|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
33401915|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
33401916|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
33401917|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
33401918|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
33401919|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
33231470|NCT04107324|Other|PVE (Portal vein embolisation)|Standard of care when FLR is small.
32775571|NCT05520125|Active Comparator|Patients with bone defects receiving standard treatment|Patients with bone defects receiving standard surgical treatment
32775572|NCT04297319|Experimental|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
32775573|NCT04297319|Placebo Comparator|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
32775574|NCT05067491|Experimental|Intervention|The experimental group will go through an exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable.
32775575|NCT05067491|No Intervention|Non-intervention|The control group will not go through an exposure therapy session using an augmented reality headset device. This will be a no-intervention control group that can have some form of exposure therapy following the conclusion of the treatment/research period.
32775576|NCT05517395|Experimental|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
32775577|NCT05517395|Active Comparator|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
33231471|NCT04107324|Experimental|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
33231472|NCT05572476|Experimental|Experimental Arm A: treatment by lurbinectedin and durvalumab|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of lurbinectedin and durvalumab
33231473|NCT05572476|Other|Standard Arm B: treatment by carboplatin and etoposide|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of carboplatin and etoposide
33231474|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
33231475|NCT00915486|Experimental|GSoC + vehicle|Twice per week
33231476|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
33231477|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
33231478|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
33231479|NCT05533866|Experimental|EB participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8, followed by a visit without use of the APR-TD011 for 4 weeks (week 12) for microbiome assessment off of therapy.
33231480|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
33231481|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
33231482|NCT00574288|Experimental|Dose Escalation: Daratumumab|
33231483|NCT00574288|Experimental|Dose Expansion: Daratumumab|
33231484|NCT02603562|Experimental|ATYR1940|Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.
33231485|NCT02603562|Placebo Comparator|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
33231488|NCT05568654|Active Comparator|Rapid diagnostic testing (RDT)|Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.
33231489|NCT05568654|Active Comparator|Pharmacist-led de-escalation|Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for > 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
33231490|NCT05568654|Active Comparator|Rapid diagnostic testing (RDT) and Pharmacist-led de-escalation|"Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.~Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for >48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page."
33231491|NCT05568654|No Intervention|Usual care (no intervention)|Usual care
33231492|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
33231493|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
33231494|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
32775578|NCT05060549|Experimental|Cariprazine 1.5 mg|Participants will receive 1.5 mg daily of cariprazine (Vraylar) for six weeks
32775579|NCT05060549|Experimental|Cariprazine 3 mg|Participants will receive 3 mg daily of cariprazine (Vraylar) for six weeks
32775580|NCT05048615|Experimental|Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine|Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.
32775581|NCT05531435|Experimental|SleeperOne|SleeperOne S4 (Revello S.p.A., Verona, Italy) appliance will be used for the administration of local anesthetic.
32775582|NCT05531435|Active Comparator|Traditional anesthesia|Local anesthesia will be performed with a traditional syringe (0480-1, ASA Dental, Massarosa, LU, Italy).
32775583|NCT05517317|Experimental|Autologous BMMC infusion|One administration of autologous bone marrow mononuclear cells via the hepatic artery
32775584|NCT05517239|Experimental|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
32775585|NCT05517161||Individuals with TBI|
32775586|NCT05517161||Individuals without neurological diagnoses|
32775587|NCT05519813|Experimental|Use Metformin for 3 months to treat PCOS|Active Comparator: Metformin (BMI<24) Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
32775588|NCT05519813|Experimental|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS|Active Comparator: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets (BMI<24) Subjects: PCOS patients whoseBMI<24 Drug: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Generic name: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Dosage form: 15mg/500mg Dosage: 2 tablets/day Frequency: one tablet twice a day Duration: 3 months
32775589|NCT05519735|Other|Multimodal imaging|Multimodal imaging approach. This includes a CXCR4 targeted PET/CT ([68Ga]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.
32775590|NCT05285345||Pre-Guideline Implementation|Participants in this group will be recruited during the first 3 months of the study and the time will be used for baseline data collection with existing standards of care around discharge practices of infants with BPD
32775591|NCT05285345||Post-Guideline Implementation|After 3 months, the discharge bundle developed from consensus from the Delphi process will be introduced to both NICUs using Quality Improvement principles. Participants will be recruited after the introduction of the discharge bundle.
32775592|NCT05517005|Experimental|Hype Bites Supplement|Participants will take the 2 chocolates each day, complete surveys at baseline, midpoint, and study conclusion, and take blood biomarker samples at baseline and conclusion
32775593|NCT05519657||postoperative pulmonary complications group|Postoperative pulmonary complications group no intervention
32775594|NCT05519657||non-postoperative pulmonary complications group|Non-postoperative pulmonary complications group no intervention
32775595|NCT05519579|Experimental|Intrathecal chemotherapy before blinatumomab|
32775596|NCT05012111||Cohort 1|Severe Aplastic Anemia(SAA): Age 2 and older; Previous diagnosis of bone marrow failure
32775597|NCT05012111||Cohort 2|Other Marrow Failure: Age 2 and older; Previous diagnosis of bone marrow failure;
32775598|NCT05012111||Cohort 3|Telomere Biology Disorders(TBD): Age 2 and older; Previous diagnosis of bone marrow failure
32775599|NCT05012111||Cohort 4|Inherited Bone Marrow Failure(IBMF)Syndromes: Age 2 and older; Previous diagnosis of bone marrow failure
32775600|NCT05012111||Cohort 5|Family Screening: Age 2 and older; First degree family member with a known or suspected inherited bone marrow failure syndrome
32775601|NCT05516849|Experimental|Oxandrolone|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
32775602|NCT05516849|Placebo Comparator|Placebo|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
32898452|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
32906434|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
33081932|NCT04628611|Active Comparator|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
33081933|NCT04628845|Placebo Comparator|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
33081934|NCT04628845|Active Comparator|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
33081935|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
33081936|NCT04628689|Active Comparator|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
33081937|NCT04628689|Active Comparator|Group 0.375% bupivacaine|0.375% bupivacaine
32775603|NCT05082311||Patients with Pheochromocytoma/Paraganglioma (secretory, extra adrenal pheochromocytoma)|"Patients included in this cohort (n=50) are those who are diagnosed of Pheochromocytoma / Paraganglioma, willing to consent for the study and not on α-blockade at the time of recruitment into study, while can be on any other anti hypertensives~Patients in this group, besides the usual evaluation of Pheochromocytoma / Paraganglioma, will also undergo detailed cardiac and vascular evaluation, which will be done at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision The cardiovascular evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses"
32775604|NCT05082311||Essential Hypertensive Groups|This is a contemporary age- and gender-matched control group This group includes 10 newly detected (within 3 months) Essential Hypertensive patients, who will undergo treatment with standard anti- HT medications Cardiac evaluation will be done at baseline and after 3 months of anti hypertensive medications
32775605|NCT05082311||Healthy Individuals|This is a contemporary age- and gender-matched control group This group includes 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer Cardiac evaluation will be done at the start of study and after 6 months
32775606|NCT05519501|Experimental|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
32775607|NCT05519501|Other|Standard of Care|Offloading
32775608|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
32775609|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
32775610|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
32775611|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
32775612|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
32775613|NCT05531279|Experimental|PEG-rhG-CSF group A|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected,after monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
32775614|NCT05531279|Experimental|PEG-rhG-CSF group B|PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected,after monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
32775615|NCT05531279|Experimental|rhG-CSF group(short-acting )|rhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.After monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
32775616|NCT05003531|Experimental|IBI112 dose 1|Participants will receive IBI112 dose 1 subcutaneous injection(SC)
32775617|NCT05003531|Experimental|IBI112 dose 4|Participants will receive IBI112 dose 4 subcutaneous injection(SC)
32775618|NCT05003531|Experimental|IBI112 dose 2|Participants will receive IBI112 dose 2 subcutaneous injection(SC)
32775619|NCT05003531|Experimental|IBI112 dose 3|Participants will receive IBI112 dose 3 subcutaneous injection(SC)
32775620|NCT05003531|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection(SC)
32775621|NCT04875403|Experimental|Respiratory muscle training group|Inspiratory muscle training with linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).The resistance training protocol will consist of the exercises of the front pull, the extension chair and the vertical bench press, covering large muscle groups in the dorsal region of the quadriceps and chest, respectively. Each year consist of three sets of 10 repetitions with a load equivalent to 60% of a test Repetition Maximum (1RM), which will be changed every week (1 to week 60%, 2 to week 65%;. 3 the . week 70%, 4 to week. 75%, 5 to week 80%).
32775622|NCT04875403|Active Comparator|Aerobic exercise group|Exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate, training has to be equivalent to 40% to 60%% target intensity.
32775623|NCT05267093|Experimental|Acupuncture group|Participants in acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
32775624|NCT05267093|Placebo Comparator|Sham acupuncture group|Participants in sham acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The sham acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
32775625|NCT04356391|Active Comparator|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
33081938|NCT04628455|Other|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
32775626|NCT04356391|Experimental|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
32775627|NCT05519267|Experimental|MBSWSC programme|The Experimental group will take part in the Mindfulness Based Social Work and Self Care (MBSWSC) programme (6 sessions). MBSWSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
32775628|NCT05519267|Active Comparator|MBSC Programme|The Active comparator group will take part in the Mindfulness and Self-compassion (MBSC) programme (3 sessions). MBSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
32775629|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
32775630|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
32775631|NCT04863937|Experimental|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
32775632|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
32775633|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
33276348|NCT05711810|Experimental|Experiment Participant|"COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night.~Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding."
33276349|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
33276350|NCT04864236|Experimental|Intervention group|This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
33276351|NCT04864236|No Intervention|Control group|
33276352|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
33276353|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
33276354|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
33276355|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
33276356|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
33276357|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
33276358|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
33276359|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
33276360|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
33276361|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
32775634|NCT04874701|Experimental|Capsimax|
33276362|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
32775635|NCT04874701|Placebo Comparator|Placebo|Placebo, 2 capsules per day, for 12 weeks
32775636|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
32775637|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
33276363|NCT05305950||Healthcare administrators|Healthcare administrators at MD Anderson Cancer Center and the sister institutions
33276364|NCT05305950||Physicians/referring providers|Physicians/referring providers and the occupational therapy (OT) and physical therapy (PT) therapists at MD Anderson Cancer Center and the sister institutions
33276365|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
33276366|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
33276367|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
32775638|NCT05516693|Experimental|Intervention group (MOG)|Patients in the experimental group (MOG) will undergo a myofunctional training protocol.
32775639|NCT05516693|No Intervention|Control group (COG)|Patients in the control group (COG) will not undergo any intervention, being only evaluated at the beginning and at the end of the protocol.
32775640|NCT04874779||Acute kidney injury (AKI) group|Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)
32775641|NCT04874779||NON-Acute kidney injury (non-AKI) group|NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)
32775642|NCT05002127|Experimental|Phase 2 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
32775643|NCT05002127|Active Comparator|Phase 2 - Arm B|Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
32775644|NCT05002127|Experimental|Phase 3 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
32775645|NCT05002127|Active Comparator|Phase 3 - Arm B|Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
32775646|NCT03045757||Healthy Newborn|Healthy Newborn
32775647|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
32775648|NCT04863547||Exposed|Patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1
32775649|NCT04863547||Non exposed|Patients hospitalized for COVID-19 to SARS-CoV-2 corresponding to wild type 20A variants. EU1 or 20A. EU2
32775650|NCT05264129|Experimental|Atogepant + Ubrogepant|Participants will receive atogepant for 12 weeks followed by atogepant + ubrogepant for 12 weeks.
33081939|NCT00246363|Experimental|Silymarin|Silymarin
33081940|NCT00246363|Placebo Comparator|Placebo|Placebo
33231495|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
33231496|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
33231497|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
33231498|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
33231499|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
33231500|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
33231501|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
33231502|NCT02550496|Experimental|tinea capitis|
33231503|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
33231504|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
33231505|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
33231506|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
33231507|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
33231508|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
33231509|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
33231510|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
33231511|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
33231512|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
33231513|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33231514|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33231515|NCT00823420|Experimental|in-vitro maturation of oocytes|
33231516|NCT00820768|Experimental|ABI-010|
33231517|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
33231518|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
32775651|NCT04874389||Recreationally active males and females|"Subjects to be considered recreationally must regularly engage in >150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named concussion) within the last 12 months."
32775652|NCT04874389||Athletes or performing artists with reported history of concussion|Participants will be considered if they are recreationally active or considered an athletic performer (i.e.,history of participation in athletics at the university, amateur, elite or professional levels, or a military veteran), or a performing artist (i.e., stunt actors, circus artists, dancers or acrobats) with reported history of concussion incident(s), with most recent incident occurring >1 month and less than five years from the study testing dates.
32775653|NCT05531201|Experimental|Interventional|Trainig of GP and physiotherapist at collaborative coordinated care pathway
32775654|NCT05531201|No Intervention|Control|without modification of the usual follow-up
32775655|NCT05519111|Experimental|Dronabinol|BID for 8 weeks. Dosage will be individualized per patient. In days 1-4 of the study each patient will be titrated from 5mg bid to a minimum dose of 2.5 mg bid to a maximum dose of 10 mg bid depending on patient preference.
32775656|NCT05519111|Placebo Comparator|Placebo|A placebo comparator
32775657|NCT04869163|Active Comparator|red meat consumers|Consumes red meat 3 times a week
32775658|NCT04869163|Experimental|non-red meat consumers|Consumes a non-red meat comparison product 3 times a week
32775659|NCT04873921|Experimental|Group 1: Sterile Kinesio tape application|Sterile Kinesio Taping application will be applied with Sterile Web Cut Kinesio Tape (Sterile Kinesio Tex Tape, Alberquerque, USA) without tension.
32775660|NCT04873921|No Intervention|Group 2: Control group|Group 2 will not receive any taping
32775661|NCT04869241|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
32775662|NCT05531123|Experimental|Arm1(cCR=cT0, cTa)|
32775663|NCT05531123|Experimental|Arm2 (non-cCR)|
32775664|NCT04429867|Experimental|Hydroxychloroquine|
32775665|NCT04429867|Placebo Comparator|Placebo|
32775666|NCT04604561||Participants receiving SmartClip|Participants will undergo a preoperative physical exam and at least one preoperative ultrasound demonstrating the mass for resection. The SmartClip will be placed under ultrasound guidance. Post-placement mammogram will be obtained after placement of the clip. The SmartClip can be placed up to 30 days prior to the planned surgical resection. At the time of definitive surgery, the Envisio system will be used to identify the clip and the targeted lesion for resection. Intraoperatively, a specimen radiograph will be performed to confirm the presence of the SmartClip and the targeted lesion in the surgical specimen. The breast surgical specimen will be sent for gross examination, including measurements of the tumor in 3 axes. Immediately post-procedure, the performing surgeon will fill out a questionnaire to determine the ability of localizing in-breast lesions using the Envisio Navigation and SmartClip system in surgery.
32775667|NCT04604561||Radiologist Placing SmartClip|Radiologist will place SmartClip under ultrasound guidance. A Post-placement mammogram will be obtained after placement of the SmartClip. Immediately post-procedure, the performing radiologist will fill out a questionnaire.
32775668|NCT04604561||Surgeon|The surgeon will use the EnVisio™ Navigation System to identify the SmartClip and the targeted lesion for resection. Immediately post-procedure, the performing surgeon will fill out a questionnaire
32775669|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
32775670|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
32775671|NCT05038709|Experimental|Pink Pad|Hip arthroscopy using The Pink Pad Hip Kit Patient Positioning System (Xodus Medical, New Kensington, PA). The pad is placed between the patient and the traction table, using a perineal post.
32775672|NCT05038709|No Intervention|Control (No pad)|Hip arthroscopy in the usual fashion, no pad, using traction table with perineal post.
32775673|NCT03047941||All patients|All patients included in the present study
32775674|NCT05032313||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders.
32775675|NCT04863391||early/none vs.|For identification of early/none (i.e., non-referral level) Age Related Macular Degeneration (ARMD)
32775676|NCT04863391||intermediate/late AMD|intermediate/late (i.e., referral level) Age Related Macular Degeneration (ARMD)
32775677|NCT05516459||Three doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment
32775678|NCT05516459||Four doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment and decided to receive another dose at time of recruitment or followup
32775679|NCT04869007||Patients with a history of cesarean section and a hysterosonographically diagnosed isthmocoele|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
32775680|NCT04869007||Patients with a history of cesarean section without isthmocoele hysterosonographically diagnosed|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
32775681|NCT05029427|Experimental|Study period 1: β-glucan Oat ; Study period 2: Wheat|For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
33276368|NCT05357274||Respiratory|Patients attending primary care, non-specialist respiratory clinics and advanced nurse practitioner clinics with undiagnosed persisting respiratory symptoms that have been attributed to asthma by a physician.
33276369|NCT05407116|Experimental|Experimental|Patients receiving standard or hypofractionated radiotherapy for curative intent to a pelvic malignancy with an intended total dose of 25-60 Gy.
33276370|NCT04003194|Experimental|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
33276371|NCT04003194|Active Comparator|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
33276372|NCT05232864|Experimental|Secukinumab|Secukinumab 300 mg solution for s.c. injection in a 2mL Pre-Filled Syringe (PFS)
33276373|NCT05406960|Experimental|Tea infusion|The aerial parts of each plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. the powder of the mixture was added to 100 ml of boiling water and the tea infusion was taken three times a day for three consecutive days and it was repeated for three consecutive months
33276374|NCT05406882|Experimental|combination therapy group|From the first day of chemoradiotherapy, live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
33276375|NCT05406882|No Intervention|control group|After the start of chemoradiotherapy, the control group don't take the experimental drug orally . When patients have radiation proctitis of grade ≥2, they would be crossed over to the combined treatment group：live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
33276376|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
33276377|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
33276378|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
33276379|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
33276380|NCT05357196|Other|PT-112 in Combination with Gemcitabine Injection|PT-112 in combination with Gemcitabine injection for the treatment of patients with advanced solid tumors
33276381|NCT04684524|Experimental|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
33276382|NCT04684524|Placebo Comparator|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
33276383|NCT05357118|Experimental|One arm|The study is an one-arm pre- and post-design.
33276384|NCT05232630|Experimental|- Group 1A.|Patients with genetic testing showing a pathogenic or likely pathogenic variant in main synaptopathy genes (SYNGAP1 and STXBP1)
33276385|NCT05232630|Experimental|Group 1B.|Patients with genetic testing showing a pathogenic or likely pathogenic inverted duplication of chromosome 15 [inv-dup (15)].
33276386|NCT05232630|Experimental|Group 1C.|Patients with neuroimaging showing multifocal or bilateral malformations of cortical development.
33276387|NCT05232630|Experimental|Group 2.|Electroclinical diagnosis of Continuous Spikes and Waves during Sleep (CSWS) syndrome, with baseline video-EEG monitoring showing epileptiform activity occupying at least 50% of slow sleep tracing, after failing at least 3 antiseizure medications
33276388|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
33276389|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
33276390|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
33276391|NCT04874454|Experimental|vocal cord movement among the stroke patients|
33276392|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
33276393|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
33276394|NCT04584294|Experimental|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
33276395|NCT04584294|No Intervention|Uusal Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
33276396|NCT05189262||Cardiac Sugery Patients Requiring Cardiopulmonary >1hour|Patients admitted for a complex cardiac surgery, heart valve replacement and/or CABG surgery requiring CPB >1hour
33276397|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
33276398|NCT05356026|Experimental|Online follow up group|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
33276399|NCT05356026|No Intervention|Routine follow up group|The women in the control group received the routine follow-up and care provided by the hospital.
33276400|NCT04002804|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
33276401|NCT05355948|Experimental|MEMO Patch PLUS ECG monitoring for One-day|
33276402|NCT05355948|Experimental|MEMO Patch PLUS ECG monitoring for More than 8-days|
33276403|NCT04824066||Cardiothoracic Surgery Cohort|Adults patients who are scheduled to undergo cardiothoracic surgery and meet the inclusion and exclusion criteria.
33276404|NCT04302818|Experimental|Social skills group training SKOLKONTAKT|Manualised social skills group training.
33276405|NCT04302818|Active Comparator|Active control comparison group|Social activities in a group setting.
33276406|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
33276407|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
32737060|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
32737061|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
33276408|NCT04866680|Experimental|Personalized Circulating DNA follow-up|FFPE tissue sample + blood sample (20ml)
33276409|NCT04853810||Major diabetic subjects having used a system with adhesives|Major diabetic subjects, whatever the etiology of diabetes, using or having used in the last 10 years a system with skin adhesives, i.e. insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. MINIMED 640G®, YpsoPump®) or continuous glucose measurement system (Free Style®, DexCom® sensors, Enlite® sensors).
33276410|NCT04006340|Placebo Comparator|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
33276411|NCT04006340|Active Comparator|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
33276412|NCT04282304|Other|Usual Care|The patients in this arm will have usual care during preoperative period, bariatric surgery and follow-up.
33276413|NCT04282304|Experimental|UGECAM|During the preoperative period, the patients in this arm will have usual care and a 4 weeks intensive, comprehensive behavioral lifestyle intervention. They will then have usual bariatric surgery and follow-up.
33276414|NCT05711654|Experimental|Health coaching group|"The patients in the health coaching group will first be given data collection tools, and then the COPD patient information training created by the researcher will be given.~For the first eight weeks after the training, face-to-face meetings will be held with patients once a week.~Data collection tools will be applied to the patients again in the fourth week and 12 weeks after the interviews are over."
33276415|NCT05711654|No Intervention|Control group|"Data collection tools will be applied to the patients in the control group first, and then the COPD patient information training created by the researcher will be given.~After the training, there will be no interviews with the patients, and data collection tools will be applied again in the 12th and 20th weeks."
33276416|NCT05711576|Placebo Comparator|SRP and no chlorhexidine|Patients received a one-stage full-mouth scaling without chlorhexidine performed in one session of full mouth scaling and root planing.
33276417|NCT05711576|Active Comparator|SRP plus 0.12% chlorhexidine|Patients received a one-stage full-mouth scaling with 0.12% chlorhexidine performed in one session of full mouth scaling and root planing.
33276418|NCT04005326|Experimental|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
33276419|NCT04005326|Experimental|FIB Group|this group will receive suprainguinal fascia iliaca block
33276420|NCT04004702|Experimental|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
33276421|NCT04767854|Experimental|OA school + Virtual Training mobile health application|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The intervention group will receive an individually tailored exercise program through the Virtual Training mobile health application. After each exercise the patient score his/her execution of the exercise on a Likert-scale of 1 to 5, judging their effort from very poor to very good. After the session, patients rate their pain on a Numeric Rating Scale from 0 to 10. The patients in the intervention group will be instructed to exercise 3 times per week for 6 weeks. If the patients want to exercise more than 3 times per week, the exercise program will be available in the app once every day."
33276422|NCT04767854|Active Comparator|OA school + usual care|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The control group will receive individually tailored supervised exercise therapy by a physiotherapist individually or in a group setting, twice a week for 6 weeks. Additionally, the patients will be motivated to perform one session of home exercise a week, a total of 3 sessions per week"
33276423|NCT00542828|Experimental|Thymoglobulin|
33276424|NCT04731974|Placebo Comparator|Placebo|Liquid Placebo
33276425|NCT04731974|Active Comparator|Melatonin|Liquid Melatonin
33276426|NCT04533074|Experimental|Single-visit regeneration protocol|
33276427|NCT04533074|Active Comparator|Multiple-visits regeneration protocol|
33276428|NCT04722692|Experimental|Delayed SLND (SPIO-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, SPIO is the primary detection tracer."
33276429|NCT04722692|Active Comparator|Late SLND (RI-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, Tc is the primary detection tracer."
33276430|NCT05711420|Experimental|Gamification method group|"The group to be trained by gamification method; A gamification application was made every week. Points are given in the table prepared for those who are successful in weekly participation in gamification, coming to the lesson with their homework done, participating in the discussions in the lesson, and in the evaluation at the end of the lesson. Every week, the winner was given a gift. At the end of the lesson, the points in the headings of Leaderboard, Badge and Status, which are the elements of the gamification method, were added weekly. And in the last week, a meeting was held with the students according to all scores and a post-test was applied."
33276431|NCT05711420|Experimental|Flipped learning group|"Before the study, videos were found each week that lecture on the relevant subject, videos were shot on the subject, and the videos were transferred to the students via a platform. At the end of each video, they were told to complete the homework on the subject and come to the lesson.~In the lesson, the lesson was processed with activities according to the videos."
33276432|NCT05711420|No Intervention|Control group|Lessons were taught with traditional learning method.
33276433|NCT05711342|Active Comparator|Treatment as usual (TAU)|In this control condition, participants receive in-person aggression treatment as usual (TAU). No changes to the way treatment is provided as usual are made. In general, this refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient in a one-on-one setting. The main focus of treatment as usual should lie on aggression regulation. Additionally, patients should receive individual, one-on-one treatment and should not participate in group treatment of aggression during data collection.
33276434|NCT05711342|Experimental|Treatment as usual (TAU) +Internet-based intervention Aggression|In the experimental condition, participants receive TAU, and additionally work on the 10-week internet-based intervention 'Aggression', on which they can work in their own time, i.e. outside of treatment sessions. Consequenlty, the intervention is used in a blended way. The intervention is focused on three main objectives: (1) increasing the motivation to change, (2) acquiring skills for dealing with conflict, and (3) breaking the cycle of aggression by providing knowledge on situational, emotional, cognitive and physical triggers. The module consists of 10 lessons:
33276435|NCT05710796||All population|The total population reported to Cardiology department during enrollment period
33276436|NCT05710796||COVID recovered|Patient having history of COVID 19 disease
33276437|NCT05710796||No history of COVID|Population those who never exposed to COVID 19 disease and never suffers
33276438|NCT04266470|Experimental|Lara Device Scan|This imaging study will be obtained strictly for the research purposes of mid-treatment assessment of blood flow and uptake kinetics analysis
33276439|NCT04621448|Experimental|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
33276440|NCT04621448|Experimental|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
33276441|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
33276442|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
33276443|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
33276444|NCT00987428|Active Comparator|Groupe 2|usual procedure
33276445|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
33276446|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
33276447|NCT05708612|Experimental|Implantation of SimplyFI|Long-term non-active implant
33276448|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
33276449|NCT04582916|Other|One Arm|All subject receive the same tests
33276450|NCT04567082||Cancer group|
33276451|NCT04567082||Control group|
33276452|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
33276453|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
33276454|NCT05698784||"Group a inappropriate"|"In the inappropriate , we placed prescriptions with no indication, 123I-FP-CIT SPECT"
33276455|NCT05698784||"Group b uncertain"|"In the uncertain, we did not have sufficient data to determine with certainty whether this was an inappropriate or relevant indication."
33276456|NCT05698784||"Group c relevant"|"In the relevant , the prescriptions concerned the differential diagnosis between neurodegenerative parkinsonism and secondary parkinsonian syndromes"
33276457|NCT00987740|Experimental|Hemolung Respiratory Assist System|
33276458|NCT04482374||Transgender females|Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months
33276459|NCT04482374||Cisgender males|Cisgender male controls
33276460|NCT04430426|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
33276461|NCT00987818|Experimental|PCT guided antibiotic therapy|
33276462|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
33276463|NCT05690126|Active Comparator|Saffron extract|"Daily, two dietary supplements (Saffron extract) will be taken orally with water, the first one at breakfast and the second one at dinner.~Dietary supplements in capsule form"
33276464|NCT05690126|Placebo Comparator|Placebo|"Daily, two dietary supplements (Maltodextrin) will be taken orally with water, the first one at breakfast and the second at dinner.~Dietary supplements in capsule form"
33276465|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
33276466|NCT00090103|Active Comparator|dutasteride|dutasteride 0.5mg once daily
33276467|NCT00090103|Experimental|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
33276468|NCT00090103|Active Comparator|tamsulosin|tamsulosin 0.4mg once daily
33276469|NCT01088659|Experimental|1|
33276470|NCT01088659|Experimental|2|
33276471|NCT03962257|No Intervention|Conventional|This group will have standard of care infertility counseling and consent processes.
33276472|NCT03962257|Experimental|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
32775682|NCT05029427|Experimental|Study period 1: Wheat ; Study period 2: β-glucan Oat|For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
32775683|NCT04429789|Experimental|Active-Alert Hypnosis|
32775684|NCT04429789|Experimental|Traditional Hypnosis|
32775685|NCT04429789|No Intervention|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
33081941|NCT04628533|Experimental|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
33276473|NCT00087607|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) [Pegasys] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin [Copegus] 1000 or 1200 milligram (mg)/day), orally, [according to body weight, lesser than or greater than/equal to (< or >/=) 75 kilogram (kg), respectively] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
33276474|NCT00087607|Active Comparator|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin [Rebetol] 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
33276475|NCT00069823|Experimental|Esomeprazole|Proton pump inhibitor of gastric acid
33276476|NCT00069823|Placebo Comparator|Placebo for esomeprazoe|Placebo
33276477|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
33276478|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
33276479|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
33276480|NCT00086515|Experimental|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
33276481|NCT00086515|Placebo Comparator|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
33276482|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
33276483|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
33276484|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
33276485|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
33276486|NCT04384952|Experimental|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeated reading with feedback from the parent and time control.
33276487|NCT04384952|Active Comparator|Dyslexic's Holliday Workbook.|Use of a special Dys holiday book, no parent-guided training.
33276488|NCT04378868|Active Comparator|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
33276489|NCT04378868|Experimental|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
33276490|NCT04378868|Experimental|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
32775686|NCT05518955|Experimental|Virtual reality combine with sleep promotion routine|Participants will receive virtual reality for 30 minutes before bedtime then will be placed on an eye mask and combine with the sleep promotion routine. The intervention duration need continues for two days or until discharge from ICU.
32775687|NCT05518955|No Intervention|control group|Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
32775688|NCT05516381|Other|Restricted Invers Kinematic Knee Alignment Technique|Restricted Invers Kinematic Knee Alignment Technique
33276491|NCT04378868|Experimental|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
32775689|NCT05516381|Other|Mechanical Knee Alignment Technique|Mechanical Knee Alignment Technique
33276492|NCT04334174|Experimental|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
33276493|NCT04333706|Experimental|Experimental: Phase I|A dose finding study of sarilumab plus capecitabine in patients with metastatic TNBC and metastatic HER2/neu-negative and hormone resistant breast cancer.
33276494|NCT04333706|Experimental|Phase 2 single arm study|Study of adjuvant sarilumab plus capecitabine in stage I to III TNBC with less than a pCR
33276495|NCT04333706|Other|Parallel Baseline Arm|Study of standard adjuvant capecitabine in stage I to III TNBC with less than a pCR. This Arm will be open in parallel with both Phases 1 and 2. Blood samples will be obtained during the course of the study. Bone marrow samples are optional.
33276496|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
33276497|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
33276498|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
33276499|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
33276500|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
33276501|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
33276502|NCT04324580|Active Comparator|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
33276503|NCT04324580|Active Comparator|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
33276504|NCT05279144|Experimental|Experimental|Ventrogluteal region IM injection will be applied to the children in the intervention group, which is recommended by the literatureIn order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
33401920|NCT04703647||Patients with CRPS type 1: prospective group|"Ambulatory patients of the Clinique romande de réadaptation (CRR) which have a CRPS type 1 of a limb.~Five measurement times (first visit (T0) and then after 3 (T1), 6 (T2), 12 (T3) and 24 (T4) months). At every time point, following data will be collected: physical examination, monitoring of the health and professional status with the physician, and self-administrated questionnaires. Blood sampling will be performed at T0, T1,T2 and T3.~Eight different self-administrated questionnaires will be used, in their French or Portuguese version. Each participants will answer seven questionnaires each time, depending if he/she suffers of arm or leg injury.~We will assess, in blood samples, the expression levels of specific molecules (miRNAs and a selection of cytokines) in patients diagnosed with acute CRPS. In a second time, miRNAs and cytokines profiles will be compared between acute and chronic (CRPS still diagnosed 6 months after the first diagnosis) CRPS patients."
33401921|NCT04703647||control group for blood analysis|"For the blood analysis, we will recruit 30 healthy controls who did not report any kind of pain. They will be recruited via posters that will be posted on the billboards of the Hôpital de Sion (employees and visitors) and on the visitor's billboards of the CRR. If this is not enough, we will expand the recruitment perimeter with other locations. The healthy control will be adjusted for age, sex and BMI with the CRPS groups. They will be informed about the study and procedure. The procedure for the blood samples will be the same as for patients.The screening for miRNAs of interest will be performed using a decision tree-based ensemble method (Random Forest). For this step, miRNAs profile of 30 control patients will be compared to the same number of CRPS patients.~The control group will have just one blood analysis."
33401922|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
33401923|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
33401924|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
33401925|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
33401926|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
33401927|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
33401928|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
33401929|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
33401930|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
33401931|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
33401932|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
33276505|NCT05279144|No Intervention|No Intervention|Vastus Lateralis IM injection, which is the routine practice of the clinic, will be applied to the children in the control group of the study. In order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
33276506|NCT04229888|Experimental|Subject Treatment|All subjects will receive light based (sham) treatment, then all subjects will receive LipiFlow treatment.
33276507|NCT04004546|Experimental|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
33276508|NCT04004546|No Intervention|Control group|Usual care
33276509|NCT04236284|Experimental|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
33276510|NCT04005248|Other|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
33276511|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
33276512|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
33276513|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
33276514|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
33276515|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276516|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276517|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276518|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276519|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276520|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276521|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
32737062|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
33276522|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276523|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33276524|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
33401933|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
32737063|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
32737064|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
32737065|NCT05467163|Active Comparator|Biventricular pacing + AV node ablation|Implantation of biventricular pacemaker with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
33276525|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
32775690|NCT04863235|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week, and set a physical activity goal. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Monitoring Physical Activity Session 4: Action and Coping Planning. Session 5: Self-Efficacy (master and vicarious experiences). Session 6: Self-Efficacy (modeling experiences, verbal persuasion). Session 7: Physical Activity Enjoyment and Barriers. Session 8: Making long-term Change. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, blood pressure, cholesterol, benefits of water, benefits of vitamin D, the Infodemic).
32898453|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
32898454|NCT00022490|Experimental|Cytarabine/ Imatinib Mesylate|
33276526|NCT05659316||Healthy volunteers|Healthy volunteers without any patellar injury
33276527|NCT03907280|Experimental|T1-T2-R-T3|
33276528|NCT03907280|Experimental|R-T1-T2-T3|
33276529|NCT03907280|Experimental|T2-R-T1-T3|
33276530|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
33276531|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
33276532|NCT04004468|Active Comparator|Standard Periodization Training|Utilization of traditional periodization strength training model
33276533|NCT04004468|Active Comparator|Conjugate Training|Utilization of conjugate strength model
33276534|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
33276535|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
32898455|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
33276536|NCT04120376|Experimental|Counseling Intervention|All participants will receive contraception counseling by study Advanced Practice Providers (APPs)
33276537|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
33276538|NCT04108130|No Intervention|Usual Care|Participants in this arm will receive usual anesthetic and postoperative care as provided in each site.
33276539|NCT04108130|Experimental|Intervention|This arm will receive the bundle of interventions.
33276540|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
33276541|NCT04499300||Covid positive|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.
33276542|NCT04499300||Sub-group: deceased patients|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.
33276543|NCT04499300||Sub-group: patients who survived|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.
33276544|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
33276545|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
33276546|NCT05613374|Active Comparator|Control Group|"Participants in the control group will receive conventional functional training (conventional physical therapy program) for one hour as the following.~Part (1) Postural reactions exercises. (for 30 minutes)~Rest for 15 minutes between the first part and the second part.~Part (2) Indoor open environment gait training exercises (over-ground gait training exercises.). (for 30 minutes)"
33277645|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
33277646|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
33276547|NCT05613374|Experimental|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~There will be 15 minutes rest between parts one and two of the training program~The second part (conventional training program) (30 minutes) will include:~Postural reactions exercises. ( 20 minutes)~Indoor open environment gait training exercises (over-ground gait training exercises.). (10 minutes)"
33276548|NCT05611580|No Intervention|Control|The participant in the control group receive usual care.
33276549|NCT05611580|Experimental|Intervention|The participants in the intervention group received the chronic disease risk reduction intervention.
33276550|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
33276551|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
33276552|NCT04004156|Experimental|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
33276553|NCT04038476|Other|Standard monitoring|"When assigned to the group Standard monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
33276554|NCT04038476|Other|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
33276555|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
33276556|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
33276557|NCT04126538|Experimental|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
33276558|NCT04126538|Experimental|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
33276559|NCT04004234|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
33276560|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
33276561|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
33276562|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
33276563|NCT00990002||Control|A children's milk-based beverage
33276564|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
33276565|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
33276566|NCT04095416|Experimental|Intervention|Bilateral lower extremity ACE compression wraps in addition to standard medical care
33276567|NCT04095416|No Intervention|Control|Standard medical care
33276568|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
33276569|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
33276570|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
33276571|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
33276572|NCT02736344||BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
33276573|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
33276574|NCT05279066||Patients scheduled to undergo an elective cardiac ultrasound|All cardiac patients undergoing an elective cardiac ultrasound as an outpatient at UCLA may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented prior to their scheduled ultrasound.
32737066|NCT05467163|Experimental|Conduction system pacing + AV node ablation|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
33276575|NCT05279066||Patients with a pulmonary arterial catheterization scheduled or completed|All patients hospitalized in the cardiac ICU at UCLA with a pulmonary arterial catheterization scheduled or completed may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented during their hospital stay.
33276576|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
33276577|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
33276578|NCT00412984|Active Comparator|1|
33276579|NCT00412984|Experimental|2|
32737067|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
32737068|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
32737069|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
32737070|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
33276580|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
33276581|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
33276582|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
33276583|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
33276584|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
33276585|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
33276586|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
33276587|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
33276588|NCT04003376|Active Comparator|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
32737071|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
33231519|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
33276589|NCT04003376|Experimental|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
33231520|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
33231521|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
33276590|NCT04003376|Experimental|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
33276591|NCT04003376|Experimental|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
33276592|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
33276593|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
33276594|NCT04086212|Experimental|IXC Peritoneal dialysis solution|IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution
33276595|NCT04086212|Active Comparator|Icodextrin|Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution
33276596|NCT05404490|Experimental|Bupivacaine|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
33276597|NCT05404490|Placebo Comparator|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
33276598|NCT05359874|Experimental|treatment arm|
33276599|NCT05359796||long-term T1D|Subjects who has the T1D duration ≥10 years, with or without diabetic complications.
33276600|NCT03391466|Experimental|Axicabtagene Ciloleucel Treatment|
33276601|NCT03391466|Active Comparator|Standard of Care Therapy|
33276602|NCT05359640||quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
33276603|NCT05359640||consumption of analgesics|The consumption of analgetics, VAS score and improvement of quality of life will be monitored.
33276604|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
33276605|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
33277647|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
33276606|NCT05385536||Guidance clinical pathway|Sites will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification.
33081942|NCT04628533|Active Comparator|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
33081943|NCT04628299|Placebo Comparator|Sham Laser|A non-emission laser will be applied in plantar fascia
33276607|NCT05385536||Traditional clinical pathway|Sites will employ their current standard clinical care practices for suspected UTI, including Standard Urine Culture (SUC), Urine Analysis (UA), and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
33276608|NCT05590988|Experimental|Tablet|The intervention group trained bimanual coordination once a day for about 31 minutes on a total of ten days using a tablet game. A ball is to be moved on a circular line.
33276609|NCT05590988|Active Comparator|Aximo|"The patients in the control group receive an ergotherapeutic therapy unit once a day for the same length of time (approx. 31 minutes) for a total of ten days, in which they train unilaterally. In this therapy unit, the control group uses the Aximo. This is a comb stand and so-called rolls with which plugging tasks can be practiced. The patients should push the rolls into the stand fields with the affected hand. With the plug-in game, the patients can complete different tasks that challenge and train their hand-eye coordination, their fine motor skills and their ability to grasp things (e.g. following a specific pattern based on a template or putting colors in a specific order)."
33276610|NCT05590910|Experimental|Music Intervention Group|The music intervention group will receive a 15-minute music intervention and variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
33276611|NCT05590910|No Intervention|Non-Music Control Group|Variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
33276612|NCT05590832|Experimental|İnitiative group|"All pregnant women participating in the study were divided into intervention and control groups by applying randomization. Pre-test data of both groups will be collected before 18th gestational week, and post-test data will be collected after 37th gestational week.~Pregnant women assigned to the initiative group were added to a group established via Whatsapp. Information messages will be sent via Whatsapp on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks. When necessary, individual messages will be sent to the pregnant women and special directions will be given according to their weight gain rates."
33276613|NCT05590832|No Intervention|Control group|In the same way, a Whatsapp group will be set up to the control group and messages will be sent once a month about the subjects included in antenatal care up to 37 weeks. Topics included in routine maintenance will be included.
33276614|NCT03367754|Experimental|1|single dose of 200 mg (IV) infusion
33276615|NCT03367754|Placebo Comparator|2|single dose (IV infusion)
33276616|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
33276617|NCT03335072|Experimental|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
33276618|NCT03335072|Experimental|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
33276619|NCT03335072|Experimental|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
33276620|NCT01563926|Experimental|Somatropin|
33276621|NCT05590520|Experimental|Botulinum group|The internal anal sphincter to be palpated and injected with a 27-gauge needle while the patient lying on his or her left side. Each patient will receive 0.4 ml of solution containing botulinum toxin (for a total of 20 U), administered as two injections of equal volume (0.2 ml), one on each side of the anterior midline of the internal anal sphincter. No sedation or local anesthesia to be used during the procedure)
33276622|NCT05590520|Active Comparator|GTN group|0.2 percent nitroglycerin ointment applied twice daily for six weeks.
33276623|NCT05590442||Training cohort|The patients will be divided into the training and validation cohorts with a ratio of 7:3. The training cohort will be used to screen variables and construct the model.
33276624|NCT05590442||Validation cohort|The validation cohort will be used to validate the results obtained using the training cohort.
33276625|NCT05361356|Experimental|Experimental group, all volunteer will be scanned.|
33276626|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
33276627|NCT05590130|Experimental|Nonin oximeter with a 90% SpO2 target|During this periods , oxygen will be administered in an automated titration with the FreeO2 device to reach 90% of SpO2.
33276628|NCT05590130|Experimental|Philips oximeter with a 90% SpO2 target|During this periods, oxygen will be adjusted manually, to reach 90% of SpO2.
33276629|NCT05590130|Experimental|Nonin oximeter with a 94% SpO2 target|During this periods , oxygen will be administered in an automated titration with the FreeO2 device to reach 94% of SpO2.
33276630|NCT05590130|Experimental|Philips oximeter with a 94% SpO2 target|During this periods, oxygen will be adjusted manually, to reach 94% of SpO2.
33276631|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
33276632|NCT05590052|Active Comparator|Bipolar Electrosurgery group (n=60)|Group A
33276633|NCT05590052|Active Comparator|Thermocautery group (n=60)|Group B
33276634|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
33276635|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
33276636|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
32737072|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
32737073|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
32775691|NCT04863235|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week and set a physical activity goal. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Introduction to self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Mindfulness and Resistance. Session 6: Meeting Difficult Emotions. Session 7: Embracing the Good. Session 8: Applying Self-compassion to Physical Activity and Moving Forward.
32775692|NCT05518799|Other|Patients with prostate cancer|
32775693|NCT05518799|Other|Male patients with other types of solid tumours|
32775694|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
32775695|NCT05512403|Experimental|Patients with Low Grade Glioma (LGG) without any MRI contrast enhancement|"Patients presenting with brain lesions that lack contrast enhancement on MRI, that are suspected to be LGGs and that are referred for biopsy or surgery within the following 6 months will be eligible for the study. The initial MRI should be performed a maximum of 3 weeks before patient inclusion and should at least include the conventional morphological sequences (T1, T1 sequences with injection of contrast product and T2 FLAIR).~Patients will be selected in a neuro-oncological multidisciplinary consultation meeting."
32775696|NCT05516303||Case|MS patients treated with fingolimod who experienced liver enzymes elevation
32775697|NCT05516303||Control|MS patients treated with fingolimod not experiencing elevated liver enzymes
32775698|NCT04863079|Experimental|Pembrolizumab for Postoperative Adjuvant Treatment of ESCC|Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.
32775699|NCT05512325||Gene evolution of glioma in vivo|Group A: gene evolution with relapsed. From the first day after the operation, the ctDNA was extracted from TISF before concurrent chemoradiotherapy as the baseline, and then the ctDNA was detected again after concurrent chemoradiotherapy. For the third time, ctDNA was detected in intensive chemotherapy with temozolomide. The image showed that the tumor progress was detected for the fourth time, and the ctDNA was detected for the fifth time when the tumor recurred. Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) * 150mg/m2/day BSA(Body Surface Area)=[weight (kg)* height (cm)/3600]2,
32775700|NCT05512325||Gene evolution and molecular response under Bevacizumab treatment|After the recurrence, temozolomide combined with bevacizumab was used for chemotherapy, After bevacizumab was applied after six week , ctDNA is tested every six weeks. temozolomide combined with bevacizumab (600mg) in the course of tumor progression once a month.
32775701|NCT04868383|Experimental|Single pilot arm|In this single arm pilot study, all participants will receive access to a novel smartphone app designed to support PrEP uptake and adherence for a 6 month period.
32775702|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
32775703|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
32775704|NCT04868227|Experimental|INTERVENTION STUDY|TREATED WITH 3200IU FULTIUM VITAMIN D3
32775705|NCT03048019||Tirofiban Therapy|
32775706|NCT03048019||Cangrelor Therapy|
32775707|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
32775708|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
32775709|NCT04868149|Experimental|Laparoscopic ALPPS|Laparoscopic ALPPS procedure
32775710|NCT04868149|Active Comparator|Open ALPPS|Open ALPPS procedure
32775711|NCT04873531|Experimental|Neostigmine|"For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
32775712|NCT04873531|Placebo Comparator|Normal saline|"For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
32775713|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
32775714|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
32775715|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
32775716|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
32775717|NCT04862845|Active Comparator|Patients in group I (PD group)|
32775718|NCT04862845|Active Comparator|patients in group II (P group)|
32775719|NCT04862845|Sham Comparator|patients in group III (C groups)|
32775720|NCT04873687|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)
32775721|NCT04873687|No Intervention|Control|Eligible stable angina pectoris patients in the control arm will receive no intervention therapy
32775722|NCT04873609|No Intervention|No primary care provider (PCP) appointment, No patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
32737074|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
32737075|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
32737076|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
32737077|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
32775723|NCT04873609|Active Comparator|No PCP appointment, Patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
32775724|NCT04873609|No Intervention|PCP appointment, No patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
32775725|NCT04873609|Active Comparator|PCP appointment, Patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
32775726|NCT04873141||Case Group|All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.
32775727|NCT04862377|Active Comparator|Standard treatment group|"Infants randomised to the standard treatment arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.~In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP)."
32775728|NCT04862377|Experimental|Interventional treatment group|"Infants randomised to the interventional treatment arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the standard treatment arm, will be decided using the calculator."
32775729|NCT04862377|No Intervention|Control group|Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
32775730|NCT05516225|Experimental|PBCLN-003, 1.8 g daily in 3 divided oral doses for 7 days|
32775731|NCT05516225|Experimental|PBCLN-003, 3.6 g daily in 3 divided oral doses for 7 days|
32775732|NCT05516225|Experimental|PBCLN-003, 9 g daily in 3 divided oral doses for 7 days|
32775733|NCT05516225|Experimental|PBCLN-003, 18 g daily in 3 divided oral doses for 7 days|
32775734|NCT04867993|Active Comparator|asphyxiated neonates treated with amikacin and hypothermia|Amikacin (Likacin®; 500 mg/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
32775735|NCT04867993|Placebo Comparator|asphyxiated neonates treated with amikacin|Amikacin (Likacin®; 500m g/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
32775736|NCT05507723|Experimental|Treat-to-target|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. All Participants in the treat-to-target group will be provided with a BeneCheck hand-held device and taught to perform urate finger prick self-testing. Participants will be prompted to submit urate readings by the GoutSMART app and if urate levels remain above target their allopurinol will be increased incrementally up to the pre-specified maximum dose of allopurinol.
32775737|NCT05507723|Active Comparator|Treat-to-flare|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. Participants in the treat-to-flare arm of the study will be reviewed every 4 months and allopurinol dose escalated incrementally if they have sustained a gout flare in the preceding 4 months, up to the maximum pre-specified allopurinol dose.
32775738|NCT04873219|Active Comparator|CAD/CAM milled complete denture|the dentures were milled out of a block of pre-polymerized PMMA resin (Avadent, Global dental Science, Netherlands)
32775739|NCT04873219|Experimental|CAD/CAM rapid prototyped complete denture|the dentures will be 3D-printed from a liquid PMMA, including the teeth (NexDent, Netherlands)
32775740|NCT04988009||Observational (survey, medical chart review)|Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
32775741|NCT04872985|Experimental|Arm 1: Pyrotinib+ AC/EC followed by T|400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
32775742|NCT04872985|Placebo Comparator|Arm 2: Placebo+ AC/EC followed by T|400 mg placebo orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
32775743|NCT04872907|Experimental|adhesive system + flowable composite|Side of the mouth randomlly assigned to this arm will receive self etch adhesive system and flowable composite combination on temporary molars and self etch adhesive system on anterior temporary teeth at baseline, M6, M12, M18
32775744|NCT04872907|Active Comparator|Fluoride varnish|Side of the mouth randomly assigned to this arm will receive the fluride varnish at baseline, M6, M12, M18 on the temporary teeth
32775745|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
32775746|NCT04868071|Experimental|High-Speed Resistance Training|Participants performed exercises 8 times (sets) with 3-5 repetitions at 70%-75% of the maximal strength.
32775747|NCT04868071|Experimental|Low-Speed Resistance Training|Participants performed exercises 4 times (sets) with 8-10 repetitions at 70%-75% of the maximal strength.
32775748|NCT04868071|No Intervention|Control Group|No activities
32775749|NCT04861909||AT LISA tri 839MP|Patients implanted with AT LISA tri 839MP
32775750|NCT03047707|Experimental|S-Shearwave and TE|
32775751|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
32775752|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
33276637|NCT05589974||Acute|Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.
33276638|NCT05589974||Chronic|Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.
33276639|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
33276640|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
33276641|NCT00990626||1|Schizophrenic outpatients
33276642|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
32898456|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
33276643|NCT05589896|Experimental|Regimen A (MAC)|"Pre-transplant conditioning treatment with Busulfan and Fludarabine~Bone Marrow Transplant with Ossium HPC, Marrow~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
33276644|NCT05589896|Experimental|Regimen B (MAC)|"Pre-transplant conditioning treatment with Fludarabine and Total Body Irradiation~Bone Marrow Transplant with Ossium HPC, Marrow~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
33276645|NCT05589896|Experimental|Regimen C (RIC)|"Pre-transplant conditioning treatment with Fludarabine, Cyclophosphamide, and Total Body Irradiation~Bone Marrow Transplant with Ossium HPC, Marrow~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
33276646|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
32737078|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
33276647|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
33276648|NCT05589740|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
33276649|NCT05589740|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
33276650|NCT04003844|Experimental|Experimental|Investigational product (IP)
33276651|NCT05589584|Experimental|intervention|NAC and weight reduction program
33276652|NCT05589584|No Intervention|control|weight reduction program only
33276653|NCT05359484|Experimental|detrusor underactivity|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
33276654|NCT05359484|Experimental|bladder out flow obstruction|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
33276655|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
33276656|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
32737079|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
33276657|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
33276658|NCT05361278|Experimental|Chlorhexidine irrigation solution|CHx 2% solution will be used.
32737080|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
33276659|NCT05361278|Experimental|Activated chlorhexidine irrigation solution|CHx 2% solution will be used with ultrasonic activation.
33276660|NCT05361278|Experimental|Chlorhexidine irrigation gel|CHx 2% gel will be used.
33276661|NCT05361278|Experimental|Activated chlorhexidine irrigation gel|CHx 2% gel will be used with ultrasonic activation.
33276662|NCT05361278|Other|Sodium hypochlorite irrigation solution|NaOCl 5,25% solution will be used.
33276663|NCT00764855||1|Patients undergoing a surgery with general anesthesia
33276664|NCT02161900|Active Comparator|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
33276665|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
33276666|NCT05589506|Experimental|Removable partial denture PEEK|Removable partial denture using PEEK-acrylic resin
33276667|NCT00759317|Active Comparator|1|venlafaxine
33276668|NCT00759317|Placebo Comparator|2|
33276669|NCT02148796|Active Comparator|Broncho-Vaxom (BV)|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
32775753|NCT04861753||Reiki|"The modern-day Reiki (pronounced ray-kee) practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an energy healing therapy, is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being."
32775754|NCT04861753||Back massage|Massage therapy involves the manipulation of the soft tissues of the body by touch. It consists of gentle movements such as effleurage, petrissage and percussion.
32775755|NCT04861753||Control|Routine postoperative care was given to the control group without any intervention
32775756|NCT04861675||Prospective follow up cohort study|Assessment of Changes in Oral Health-related Quality of Life , Oral Hygiene status and Body Growth in Egyptian Children with Special Health Care Needs following Dental Treatment under General Anaesthesia
32775757|NCT04901039||Decompensated heart failure|Previously diagnosed heart failure presenting with decompensation to the emergency department
32775758|NCT04861519||adult subjects who underwent a clinically indicated invasive coronary angiography|adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
33276670|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
32775759|NCT04769765|Experimental|All patients on the basic diabetic program, eligible for an individualized care pathway.|This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.
32775760|NCT03045523|Experimental|GLPG2222 Dose 1|
32775761|NCT03045523|Experimental|GLPG2222 Dose 2|
32775762|NCT03045523|Placebo Comparator|Placebo|
32775763|NCT04984967|Experimental|Insertion of peripheral venous catheter with micro-guide|
32775764|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|
32775765|NCT04872829||multifocal IOL group|patients with unilateral and bilateral multifocal IOL
32775766|NCT04872829||monofocal IOL group|patients with unilateral and bilateral monofocal IOL
32775768|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
32775769|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
32775770|NCT05515991|Experimental|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|Feasibility of SUPPORT-Dialysis at Toronto General Hospital
33276671|NCT00764933|Experimental|1|Structured information
32775771|NCT05515991|Experimental|SUPPORT-DIALYSIS Only|Usual Treatment at Humber River Hospital
32775772|NCT04872361|Placebo Comparator|Low PEEP|Low positive end-expiratory pressure (PEEP) and no recruitment maneuver (RM)
32775773|NCT04872361|Active Comparator|High PEEP|High positive end-expiratory pressure (PEEP)
33276672|NCT00764933|Sham Comparator|2|Unspecific conversation
33276673|NCT00076999|Experimental|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
32775774|NCT04872361|Active Comparator|High PEEP/RM|High positive end-expiratory pressure (PEEP) and recruitment maneuver (RM)
32775775|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
32775776|NCT04763681|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
32775777|NCT04763681|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
32898457|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
33081944|NCT04628299|Experimental|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
33081945|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
33276674|NCT00076999|Experimental|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
33276675|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
33276676|NCT00765011|Other|Grupo B|Surgery
33276677|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
33081946|NCT00561613|Active Comparator|2|SILCS with N-9
33276678|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
33276679|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
33276680|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
32775778|NCT04861129|Experimental|Bowen therapy group|The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black & Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
32775779|NCT04861129|Sham Comparator|Sham Bowen Therapy group|The control group will receive a sham Bowen therapy with the same number of treatment session, treatment time and rest time, that received in the experimental group. However, it consists of gently placing the hands over the areas just enough to maintain contact for the desired time as required by Bowen Therapy, without applying Bowen movement, which is considered the active principle of this technique.
32775780|NCT05507489|Experimental|treatment group|Jinzhen oral liquid(for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day)
32775781|NCT05507489|Active Comparator|control group|The usage and dosage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition and recorded truthfully
32775782|NCT04761341|Experimental|AMD|
32775783|NCT04761341|Active Comparator|healthy control|
32775784|NCT05507411|Other|CCR-Watch and Wait|
32775785|NCT05507411|Other|CCR-Surgery|
32775786|NCT05507411|Other|Non-CCR|
32775787|NCT05507333|Other|Gedea pessary|Gedea pessary administration
32775788|NCT05515913||ASD ( autistic spectrum disorder)|Children already diagnosed with autistic spectrum disorder
32775789|NCT05515913||TDC (typically developing children)|Children within the typically development
32775790|NCT04603625|Experimental|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
32775791|NCT04603625|Active Comparator|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
33276681|NCT03770650|Experimental|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index >0.8.~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be >0.8."
33276682|NCT03770650|Active Comparator|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of ≥Type B dissection.
33276683|NCT00765167|Placebo Comparator|A|
33276684|NCT00765167|Active Comparator|B|
33276685|NCT00765167|Active Comparator|C|
33276686|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
33276687|NCT00759551|Experimental|Azilsartan 5 mg QD|
33276688|NCT00759551|Experimental|Azilsartan 10 mg QD|
33276689|NCT00759551|Experimental|Azilsartan 20 mg QD|
33276690|NCT00759551|Experimental|Azilsartan 40 mg QD|
33276691|NCT00759551|Placebo Comparator|Placebo QD|
32775792|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
32775793|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
32775794|NCT05512013|Experimental|Ibuprofen|Participants will consume a single dose of ibuprofen prior to a plyometric exercise bout
32775795|NCT05512013|Experimental|Celecoxib|Participants will consume a single dose of celecoxib prior to a plyometric exercise bout
32775796|NCT05512013|Experimental|Flurbiprofen|Participants will consume a single dose of flurbiprofen prior to a plyometric exercise bout
32775797|NCT05512013|Placebo Comparator|Placebo|Participants will consume a single dose of an inert placebo prior to a plyometric exercise bout
32898458|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
32898459|NCT00097448|Other|1|Nineteen days of oral prednisone
32898460|NCT00097448|Experimental|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
33276692|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
33276693|NCT03905096|Experimental|Part 1|
33276694|NCT03905096|Experimental|Part 2|
33276695|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
33276696|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
33276697|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
33276698|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
33276699|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
33276700|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
33276701|NCT03957967||acute pain|Patient with acute pain
33276702|NCT00761501|Experimental|1|
33276703|NCT00761501|Active Comparator|2|
33276704|NCT00761501|Active Comparator|3|
33276705|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
33276706|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
33276707|NCT01088893|No Intervention|observation|
32775798|NCT04894643|Other|Preoperative, proton- radiotherapy combined with chemotherapy|Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery
32775799|NCT04893083||LRRK2 Mutant PD|Patients with a G2019S mutation
32775800|NCT04893083||LRRK2 Wild Type PD Low burden|Patients with a low burden of genetic modifiers
32775801|NCT04893083||LRRK2 Wild Type High burden|Patients with a high burden of genetic modifiers
32775802|NCT05511857|Experimental|The effect of a self-distanced view on pain perception.|The participant will exert self-distanced, third-person self-talk following a cue-card while induced with experimental pain.
32775803|NCT05511857|Experimental|The effect of a self-immersed view on pain perception.|The participant will exert self-immersed, first-person self-talk following a cue-card while induced with experimental pain.
32775804|NCT05511857|Experimental|The effect of non-view, self-talk on pain perception.|The participant will exert self-talk following a cue-card while induced with experimental pain.
32775805|NCT05511857|No Intervention|Pain perception in induced, experimental pain.|Control group. This group will be induced with experimental pain, but will receive no specific task to exert.
32775806|NCT05511623|Experimental|tislelizumab|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks. In addition, patients also receive tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
32775807|NCT05511623|Active Comparator|concurrent chemoradiotherapy|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
33276708|NCT01088893|Experimental|Everolimus|
33276709|NCT03026036||MDD|Patients with current Major Depressive Disorder
33276710|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
33276711|NCT03026036||HC|Healthy control participants
33276712|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
33276713|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
33276714|NCT01088971|Active Comparator|Duolac 7S|
33276715|NCT01088971|Placebo Comparator|starch capsule|
33276716|NCT00990860|Experimental|Sorafenib|
33276717|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
33276718|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
33276719|NCT01035190|Experimental|inhaled Budesonide|
33276720|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
33276721|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
33276722|NCT03022682||IDEO Cohort|"Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required.~Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma.~Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed.~Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits."
33276723|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
32898461|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
32898462|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
32898463|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
32898464|NCT00423280|Placebo Comparator|3|Placebo
32898465|NCT00028262|Experimental|Drug: Cystagon and N-acetylcysteine|
32898466|NCT04771286|Experimental|BI 1015550 (C-14)|
33081947|NCT00561769||A|poor responder
33276724|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
32898467|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
32898468|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
32898469|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
33276725|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
33276726|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
32775808|NCT05511545|Experimental|Patient Education Booklet|"One day before surgery:~The patients in the training group were informed about the study one day before the operation and their verbal and written consents were obtained. Afterwards, the Descriptive Information Form, the State-Trait Anxiety Inventory, and the Surgery-Specific Anxiety Inventory were administered. A training booklet was prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. The training took an average of 25-30 minutes. Afterwards, the questions of the patients were answered and the training booklet was given to the patient.The scales were reapplied on the morning of the surgery.~Before discharge, the State Anxiety Scale and the Readiness to Discharge Scale-Patient Self-Assessment Form were administered. Then, the Adult Patient Discharge Readiness Scale-Nurse Evaluation Short Form was filled by the clinical nurse caring for the patient."
33276727|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
33276728|NCT01041196||perforated ulcer after gastric bypass|
32775811|NCT04752137|Other|ICG Dye and use of SPY-PHI Imaging|ICG will be administered in the pre-operative unit via IV injection at the time that they present to the pre-operative unit, which is approximately 4 hours before surgery. ICG Angiography (SPY PHI) will be performed to detect any residual signal
32775812|NCT05506865|Experimental|Indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once daily, with dry powder inhaler device.
32775813|NCT05506865|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once daily, with dry powder inhaler device
32775814|NCT05506787|Experimental|Esketamine Group|The patients in S-ketamine group received 0.25 mg/kg intravenous S-ketamine (Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) drip under general anesthesia induction, followed by continuous infusion of S-ketamine with 0.12 mg/kg/h for more than 30 minutes through target-controlled infusion. Drug A: S-ketamine, diluted to 1mg/ml with normal saline, total 50ml).
32775815|NCT05506787|Placebo Comparator|Placebo Group|Patients in Placebo group received intravenous infusion of 0.9% saline during anesthesia induction and were maintained through the infusion pump of drug B (50 ml 0.9% saline) for more than 30 minutes.
32775816|NCT05506709|Experimental|Test|Subjects receive only the test product (medical device/nasal pump containing moderately hypertonic solution produced based on 100% natural sea water rich of marine trace elements with added manganese and calcium)
32775817|NCT05506631|Experimental|Outpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in outpatient setting
32775818|NCT05506631|Active Comparator|Inpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in inpatient setting
32775819|NCT05506553|Active Comparator|Control arm|Bilateral insertion of Alcon IQ Toric IOL in micro-monovision
32775820|NCT05506553|Experimental|Intervention arm|Bilateral insertion of Eyhance Toric II IOL
32775821|NCT05506397|Experimental|Acupressure (intervention group)|Acupressure was applied to individuals in the acupressure group every day for 12 days.
32775822|NCT05506397|Placebo Comparator|control group|Placebo acupressure was applied to the individuals in the placebo acupressure group in accordance with the same protocol.
32775823|NCT04140773|Experimental|D-serine group|Oral administration of 2g D-serine per day, for 6 weeks.
32775824|NCT04140773|Placebo Comparator|Placebo group|Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.
32775825|NCT05506319|Experimental|norepinephrine group|Initial suspension of norepinephrine.
32775826|NCT05506319|Experimental|vasopressin group|Initial suspension of vasopressin.
32775827|NCT05506241|Experimental|Repetitive Visual Scanning Training|Participants will receive 30 minutes of their usual occupational therapy treatment and a 30 minute session of the Dynavision for 10 sessions for short stay inpatients (~ 3 weeks) and 20 sessions for clients with longer 5-6 week stay.
32775828|NCT05506241|No Intervention|Usual Treatment|Participants will receive the standard 60 minutes of occupational therapy treatment.
32775829|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
32775830|NCT05511467|Experimental|stroke group|
32775831|NCT05511467|Experimental|control group|
32775832|NCT04976621|Experimental|Behavioral Activation (BA) intervention group|Participants in the BA group will receive BA treatment and treatment as usual. BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
32775833|NCT04976621|Other|Treatment as Usual Control Group|Participants in the Control group receive treatment as usual (TAU), which is usual care provided by the VA medical center.
32775834|NCT05506007|Experimental|[Part A] DA-5216|
32775835|NCT05506007|Experimental|[Part A] DA-5216-R|
32775836|NCT05506007|Experimental|[Part B] DA-5216(Fasting)|
32775837|NCT05506007|Experimental|[Part B] DA-5216(Fed)|
32775838|NCT05515757|Other|Mobile app-based contingency management|All participants will be enrolled into an 8-week mobile app-based contingency management intervention starting during a prolonged hospitalization.
32775840|NCT04975139||IDH-mutant astrocytoma or oligodendroglioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
32898470|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
33276730|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
32775841|NCT04975139||IDH-wildtype astrocytoma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
32775842|NCT04975139||Benign Brain Tumor|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
32775843|NCT04594187|Experimental|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
32775844|NCT04594187|Active Comparator|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
32775845|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
33081948|NCT04628143|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
33081949|NCT04628143|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
33276731|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
33276732|NCT01035268|Experimental|surgery by fatty tissue transfer|
33276733|NCT01035268|No Intervention|simple supervision|
33276734|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
33276735|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
33276736|NCT03742934|Other|Control group|regular liquid diet
33276737|NCT00084799|Experimental|hu3S193 10 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 10 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
32775846|NCT05515133||Observation group of newly diagnosed glioblastoma patients with high-level psychological stress|The patients had high threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
32775847|NCT05515133||Observation group of newly diagnosed glioblastoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
33276738|NCT00084799|Experimental|hu3S193 20 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 20 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
33276739|NCT00991016|Experimental|PF-04805712|
33276740|NCT03993652|Experimental|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
33081950|NCT04627792|Other|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
33081951|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
33276741|NCT03993652|Experimental|Screen-time only|Aim: to reduce screen-time only
33276742|NCT03993652|Experimental|Snacking only|Aim: to reduce unhealthy snacking only
33276743|NCT03993652|No Intervention|Control|Control
33276744|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
33276745|NCT02558777|No Intervention|Control Group|Usual care
33276746|NCT01089049|Experimental|Pre-Menopausal|
33276747|NCT01089049|Experimental|Post-Menopausal|
33276748|NCT01038934|Experimental|buccal cytobrhsh|healthy young
33276749|NCT00765557|Active Comparator|MiraLAX|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to MiraLAX versus placebo.
33276750|NCT00765557|Placebo Comparator|Placebos|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to placebo versus MiraLAX.
33276751|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
33276752|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
33276753|NCT01086553|Experimental|A|9mg budesonide OD
33276754|NCT01086553|Active Comparator|B|3mg budesonide TID
33276755|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
33276756|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
33276757|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
33276758|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
33276759|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
33276760|NCT05585918|Active Comparator|SEL Only|"SEL Only Condition supports include:~School wide support for implementation of Second Step curriculum (e.g., technical assistance professional development, facilitated professional learning communities)~Support to Positive Behavioral Intervention and Supports (PBIS) and Multi Tiered System of Supports (MTSS) and equity teams with alignment of initiatives~Individualized technical assistance with Second Step SEL implementation"
33401934|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
32775848|NCT04725071|Experimental|Immunonutrition|Participants will consume a 6oz immunonutrition drink 2 times daily for 7 days and then once a day for remaining hospital stay.
32775849|NCT04725071|Active Comparator|Conventional Supplement|Participants will consume a 6oz conventional supplement drink 3 times daily for 7 days and then once a day for remaining hospital stay.
32775850|NCT05505851|Active Comparator|A: Control|Corrective Exercises Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
32775851|NCT05505851|Experimental|B: Sequential Core Stability Corrective Exercise Approach|"Corrective Exercises~Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~Core Stability exercises~Beginning~Progressing~Advanced"
32775852|NCT04969445||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
32775853|NCT04969445||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
32775854|NCT05505695|Experimental|"Brace&Exercise Group"|The patients who were the rigid brace and performed the SSE therapy in the specified constituted the Brace & Exercise. Experimental group patients wore full-time rigid brace and Schroth exercises for 60 minutes 5 days a week by the physician.
32775855|NCT05505695|Active Comparator|"Brace Group"|The patients who wore full-time rigid braces but did not perform exercise constituted the Brace group. Comparator group patients wore full-time brace only, did not perform Schroth exercises.
32775856|NCT04960787|Active Comparator|Group I (usual care)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
32775857|NCT04960787|Experimental|Group II (financial navigation intervention)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also meet with CENTS counselor and PAF case manager over approximately 1 hour every month for 6 months (with each group). Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
32775858|NCT04945187|No Intervention|Standard care|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management before each cycle of chemotherapy conducted by physicians.
32775859|NCT04945187|Experimental|Intervention group|Intervention: This arm will be assigned to the intervention which will be nurse-led consultations based on electronic patient-reported outcomes. The patients will report ePRO weekly during chemotherapy and the answers will be used proactively in the nurse-led consultations. Nurses will conduct the clinical assessment regarding side effects and management before each cycle of chemotherapy.
32775860|NCT05505539|Experimental|5-fluorouracil|Participants will receive up to 3 intralesional 5-fluorouracil injections (0.25 mL of a 50mg/mL solution) once every 2 weeks into an oral leukoplakia lesion.
32775861|NCT04588103|No Intervention|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
32775862|NCT04588103|Experimental|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
32775863|NCT04588103|Experimental|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (~40-59% VO2 reserve) 3 times per week for 8 weeks.
32775864|NCT04588103|Experimental|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
32775865|NCT04943315|Experimental|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia crowns
32775866|NCT04943315|Active Comparator|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic crowns
32775867|NCT04292717|Active Comparator|Deficit-oriented training group|
32775868|NCT04292717|Active Comparator|Non-specific, standardised walking training group|
32775869|NCT05514977|Active Comparator|L group|Patients are given 20 ml of 2 % lidocaine for ESPB
32775870|NCT05514977|Active Comparator|H group|Patients are given 40 ml of 1 % lidocaine for ESPB
32775871|NCT04140539|Experimental|Gene Therapy|Infusion OTL-101
32775872|NCT05514821|Experimental|Experimental condition 1|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (~400mg dietary nitrate)
33276761|NCT05585918|Experimental|SEL + Equity|"SEL + Equity (Second Step + Equity) supports include supports from the SEL Only condition plus:~Training and implementation support for teachers to deliver 6 equity literacy lessons tailored to each grade level (4th and 5th for elementary schools; 6th - 8th for middle schools) and aligned with Second Step core content~Five 45-minute school-wide equity focused Professional Development (PD) sessions to complement AACPS Equity PD~Individualized teacher coaching to support implementing equity practices and equity-focused classroom lessons"
32775873|NCT05514821|Experimental|Experimental condition 2|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (~400mg dietary nitrate)
33276762|NCT04049513|Experimental|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
33276763|NCT02810990|Experimental|Bosutinib treatment|
33276764|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
32775874|NCT05514821|Placebo Comparator|Control condition 1|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (~0mg dietary nitrate)
33276765|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
33276766|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
32775875|NCT05514821|Placebo Comparator|Control condition 2|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (~0mg dietary nitrate)
32775876|NCT05505461|Experimental|Neoadjuvant therpy|Neoadjuvant chemoradiation plus SOX and PD-1 antibody
32775877|NCT05505383|Experimental|Backward walking training group|This group will participate in a backward walking training program (8-week, 3 times weekly, and 30-min each time) and conventional gait training program (8-week, 3 times weekly, and 45-min each time).
32775878|NCT05505383|Active Comparator|Conventional gait training|This group will participate in a conventional gait training program (8-week, 3 times weekly, and 45-min each time).
32775879|NCT05514743|Active Comparator|Heart rate|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout."
32775880|NCT05514743|Active Comparator|Blood pressure|It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day &in the 21st.day.) It will be used as a training tool as well as an assessment tool.
32775881|NCT05511311|Active Comparator|Control|12-week of Standard Therapy using elastic-band
33276767|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
33276768|NCT01041508|Active Comparator|A|Stratum A are those patients with related stem cell donors.
33276769|NCT01041508|Active Comparator|B|Stratum B are those patients with unrelated stem cell donors.
33276770|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
33276771|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
33276772|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
33276773|NCT05580380|Active Comparator|Limited Patient-Clinician Relationship Group|
33276774|NCT05580380|Experimental|Enhanced Patient-Clinician Relationship Group|
33276775|NCT00766025|Experimental|Rosuvastatin Calcium|
33276776|NCT01039012|Other|Tai Chi plus Standard Care|
32775882|NCT05511311|Experimental|Intervention|12-week of Resistance Training developed by RSCM using sand-bag
32775883|NCT05514665||Neonates with perinatal hypoxic-ischemic brain injury|Neonates who are admitted to the Level III Neonatal Intensive Care Unit with a diagnosis of hypoxic ischemic encephalopathy will undergo diffuse optical tomography measurements prior to discharge from Neonatal Intensive Care Unit . Their developmental assessment will be performed at 6 months and 12 months postmenstrual age.
32775884|NCT05514275|Experimental|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin and Capecitabine
32775885|NCT04877249|Experimental|Gait training for stroke|
32775886|NCT04877249|Active Comparator|Gait training for healthy|
32775887|NCT05510999|Placebo Comparator|Placebo|Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
32775888|NCT05510999|Experimental|Water soluble pollen extract fraction|The experimental product contains 180mg (360mg/day) of water soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
33081952|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
33276777|NCT01039012|Other|Standard Care|
33276778|NCT02789228|Experimental|Group A|"Group A includes patients who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) as part of their prior therapy.~Group A patients (post allogeneic HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first."
33276779|NCT02789228|Experimental|Group B|"Group B includes patients who have undergone conventional (standard) therapy which does not include an allogeneic HSCT. Within group B, a cohort of patients with relapsed or refractory Wilms tumor will be enrolled and receive a lymphodepleting chemotherapy regimen followed by TAA-T.~Group B patients (no prior allogeneic HSCT): TAA-T will be infused any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. Patients receiving lymphodepletion will be >2 weeks from most recent course of conventional therapy and have nadired and recovered before beginning protocol therapy."
33276780|NCT04049357|Experimental|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
33276781|NCT04049357|No Intervention|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
33277648|NCT00532844|Experimental|Sapropterin dihydrochloride|Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
32775889|NCT05510999|Experimental|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|The experimental product is a combination of 9 mg lipid soluble pollen extract fraction (18mg/day) and 180 mg water soluble pollen extract fraction (360mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
32775890|NCT05510999|Experimental|Lipid soluble pollen extract fraction|The experimental product contains 9mg (18mg/day) of lipid soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
32775891|NCT05510999|Experimental|Water soluble pollen extract fraction + cranberry powder|The experimental product is a combination of 42 mg water soluble pollen extract fraction (84 mg/day) and 125 mg cranberry powder (250 mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
32775892|NCT05505149|Active Comparator|0 to 6 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
32775893|NCT05505149|Active Comparator|7 to 12 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
32775894|NCT05505149|Active Comparator|13 to 18 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
32775895|NCT05505071|Experimental|DANTE SPACE MRI Sequence|Participants will receive an additional DANTE SPACE sequence with their clinical MRI
32775896|NCT05504993||High comorbidity group|CCI equal or higher than 2 COTE equal or higher than 4 COMCOLD equal or higher than 4
32775897|NCT05504993||Low comorbidity group|CCI lower than 2 COTE lower than 4 COMCOLD lower than 4
32775898|NCT05504915||Participants with IBD|Participants diagnosed with IBD (UC or CD) who switched from vedolizumab IV to vedolizumab SC treatment during routine clinical practice, will be observed prospectively for up to 12 months from switch.
32775899|NCT05504837|Experimental|Cohort 1 (open label)|A single administration of KB407
32775900|NCT05504837|Experimental|Cohort 2 (open label)|Two administrations of KB407
32775901|NCT05504837|Experimental|Cohort 3 (randomized, placebo-controlled)|Four administrations of KB407 or placebo
32775902|NCT05514119|Experimental|Recipients of DCD liver transplants|Subjects that have undergone transplant of a liver donation after circulatory death (DCD) in the last 21-35 days will receive a 12 week fenofibrate (Lofibra) for a duration of 12 weeks
32775903|NCT05514041|Experimental|OC-01 (varenicline solution) nasal spray 0.03 mg|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
32775904|NCT05514041|Placebo Comparator|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
32775905|NCT04691531|Experimental|group C|After induction of general anesthesia, patients will undergo caudal block by classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
32775906|NCT04691531|Experimental|Group S|After induction of general anesthesia, patients will undergo caudal block by Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
32775907|NCT05513963|Experimental|Treatment|Participants will complete a Clairity session between their regular therapy visits. The Clairity interview is between 4-11 minutes where a clinical research coordinator will ask participants questions about hope, secrets, anger, fear, and emotional pain.
32775908|NCT05513963|No Intervention|Control|Participants will submit demographics and medical records and will only complete standard of care.
32775909|NCT04924907||Dysbiosis microbiota|microbiota with proinflammatory pattern or dysbiosis
32775910|NCT04924907||Normal microbiota|microbiota with antiinflammatory pattern or normal
32775911|NCT04667663|Experimental|CPD-DARA|"Drug: Daratumumab Other Name: Darzalex~Drug: Cyclophosphamide~Drug: Pomalidomide Other Name: Pomalyst/ Imnovid~Drug: Dexamethasone"
32775912|NCT04666259|Experimental|Cohort A|40 mg asciminib orally twice daily (BID)
32775913|NCT04666259|Experimental|Cohort B|80 mg asciminib orally once daily (QD)
32775914|NCT04666259|Experimental|Cohort C|200 mg asciminib orally twice daily (BID)
32775915|NCT05510765|Experimental|Study arm|Low resource, high risk individuals with limited transportation options as a social determinant of health.
32775916|NCT05504759|Experimental|Group 1|2 weeks rest protocol + standardized exercise program
32775917|NCT05504759|Experimental|Group 2|local steroid injection + 2 weeks rest protocol + standardized exercise program
32775918|NCT05504759|Experimental|Group 3|dry needling of forearm extensor muscles + 2 weeks rest protocol + standardized exercise program
33081953|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
33081954|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
33081955|NCT04627519|No Intervention|SoC alone|Standard of Care alone (days 1 to 9)
33231522|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
33276782|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
32775919|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
32775920|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
32775921|NCT05513729||Canagliflozin treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive canagliflozin on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group.
32775922|NCT05513729||Pioglitazone treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive pioglitazone on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group. as placebo comparator group.
32775923|NCT05504603|Experimental|zanubrutinib(80mg), rituximab(100mg), ASCT|"Phase I(Combined Immunotherapy Phase):~Part A(Induction Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1,8,15,22.~Part B(Consolidation Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for 4 cycles.~Phase II(ASCT): BEAM pretreatment. Patients receive semustine on day1, etoposide on days 2-5, cytarabine on days 2-5 and melphalan on day 6.~Phase III(maintenance): Zanubrutinib"
32775924|NCT05510609|Other|Thyroidectomy|Patients set for total thyroidectomy incl. functional total thyroidectomies.
32775925|NCT05510531|Experimental|Treatment Diabetes Survival Skills (DSS)Training|Participants in the treatment group received a 6-session 1-hour weekly literacy tailored DSS education intervention.
32775926|NCT05510531|No Intervention|Control No intervention|Participants in the Control facility received the intervention upon completion of week twelve measurements.
32775927|NCT05513573|Experimental|HLX07+HLX10+chemotherapy|
32775928|NCT05513573|Experimental|Placebo+HLX10+chemotherapy|
32775929|NCT04863131|Experimental|EXG-5003|
32775930|NCT04863131|Placebo Comparator|Placebo|
32775931|NCT05504447|Experimental|"Rong-Yang Zhengyifang tea bag"|"Inclusion criteria:~Aged over 20 years old, according to the guidelines of the Epidemic Command Center, during home isolation and self-epidemic prevention or home quarantine, use a household novel coronavirus antigen rapid screening reagent to test positive, and after the medical staff confirms the relevant symptoms or the PCR test is positive, it is determined to be mild. Those who were diagnosed with severe disease and who did not use antiviral drugs were given tea immediately.~Exclusion criteria:~(1)Patient characteristics: excluded under 20 years of age, incapacity, pregnancy or lactation women (2)Disease characteristics: Western medicine has clearly diagnosed mental diseases (3)Environmental characteristics: Other conditions that prevent the patient from cooperating. If you feel unwell after screening not to sign the subject's consent form, etc."
32775932|NCT05504447|Placebo Comparator|placebo tea bag|The appearance is exactly the same as the Zhengyifang tea bag, and the ingredient is oolong tea
33276783|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
33276784|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
33276785|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
33276786|NCT00766103|Other|crossover: hypo- and hypercarbia|
32775933|NCT05504369|Active Comparator|Magnetic tape arm|Tape application bilaterally in the lumbar spine
32775934|NCT05504369|Sham Comparator|Placebo tape arm|Tape application bilaterally in the lumbar spine
32775935|NCT05513495|Active Comparator|Drip Group|Each infant received the same amount of feed via continuous administration for 3 hours, and subsequent feeding resumed 1 hour after the end of continuous feeding. All of the infants were fed through an orogastric tube that was attached to a syringe infusion pump for continuous feeding. Once a full enteral feed of 120 mL/kg/day was achieved, the drip feeding was stopped.
32775936|NCT05513495|Active Comparator|Intermittent Group|Every 3 hours (×8/day), each infant received a 10-minute gravity bolus of milk/preterm formula via orogastric tube.
32775937|NCT05513417||Intervention|These programs will cover participants with pelvic floor conditions which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these conditions.
32775938|NCT04662047||Adults and children living in the 11 principal cities of Cataluña, Spain.|Adults and children living in the 11 principal cities of Cataluña, Spain: Barcelona, Hospitalet de Llobregat, Tarrasa, Badalona, Sabadell, Lérida, Tarragona, Mataró, Santa Coloma de Gramanet, Reus, Girona.
32775939|NCT05504213|Experimental|Cohort 1: Endocrine therapy-resistant (Stage 1)|Participants who are endocrine therapy pre-treated will be administrated at escalating doses orally of HS-10352 in combination with fulvestrant (500 mg, intramuscular).
33276787|NCT05577572|Experimental|Probiotics packets|Probiotics contains 450 billion colony-forming units per packet. The compositions are maltose, lactic acid bacteria and bifidobacteria blend, cornstarch, silicon dioxide.
33276788|NCT05577572|Placebo Comparator|Placebo packets|The compositions are maltodextrin, silicon dioxide, sucralose
33276789|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
33276790|NCT00766181||1: Lifestyle|Observatonal
33276791|NCT00766181||2: Lifestyle|Observational
33276792|NCT05358002|Active Comparator|Frontalis sling|Connecting the frontalis muscle action with the tarsus of the upper eyelid with synthetic material PTFE ( gore-tex )
32775940|NCT05504213|Experimental|Cohort 2: Endocrine therapy-resistant (Stage 2)|Participants who are endocrine therapy-resistant will be treated with HS-10352 orally at the MTD/MAD identified in Stage 1 or/and lower dose in combination with fulvestrant (500 mg, intramuscular)
32775941|NCT05504213|Experimental|Cohort 3: Endocrine therapy-sensitive or endocrine-naïve (Stage 2)|Participants who are endocrine therapy-sensitive or naïve will be treated with HS-10352 orally at MTD/MAD or/and lower dose identified in Stage 1 in combination with fulvestrant (500 mg, intramuscular)
32775942|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
32775943|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775944|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775945|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775946|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775947|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775948|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775949|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
32775950|NCT04661813|Experimental|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
32775951|NCT05513339||Cardiology Fellows|Cardiology fellows at Thomas Jefferson University Hospital (PGY4-PGY6)
32775952|NCT05513183||Arm I (Severe neutropnia group),|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had absolute neutrophil count (ANC) < 1000/mm3 during the postoperative period are assigned as experimental group (Arm I, severe neutropnia group).
32775953|NCT05513183||Arm II (No severe neutropenia group)|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had ANC ≥ 1000/mm3 during the postoperative period are assigned as the control group (Arm II: no severe neutropenia group).
32775954|NCT05510453|Experimental|Intervention|
32775955|NCT05510453|Other|Wait-list control|
32775956|NCT05510375|Active Comparator|Cocoa extract + multivitamin|Two capsules/day for 600 mg/day of cocoa flavanols One tablet/day of multivitamin
32775957|NCT05510375|Active Comparator|Cocoa extract + multivitamin placebo|Two capsules/day for 600 mg/day of cocoa flavanols Multivitamin placebo
32775958|NCT05510375|Active Comparator|Cocoa extract placebo + multivitamin|Cocoa extract placebo One tablet/day of multivitamin
32775959|NCT05510375|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo Multivitamin placebo
32775960|NCT05512871|Experimental|Group 1 (Intervention group)|Group 1 (Intervention group) :Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App)
32775961|NCT05512871|Other|Group 2 (Control group)|Group 2 (Control group) : Oura ring with Oura App alone (without lifestyle interventions)
32775962|NCT05512715|Active Comparator|Lithium|Tablet Lithium Carbonate 300mg daily for 2 months
32775963|NCT05512715|Active Comparator|Carbimazole|Tablet Carbimazole 10mg daily for 2 months
32775964|NCT05510219|Experimental|Intravenous rapid infusion of obinutuzumab|Patients with B-cell non-Hodgkin's lymphoma were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
33276793|NCT05358002|Experimental|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
32775965|NCT05503745|Active Comparator|CBT-E|Participants in the CBT-E condition will receive a total of 20 CBT-E sessions over 20 weeks. CBT-E treatment will consist of four stages. In particular, CBT aims to inform patients about the importance of self-control, the dangers of some restrictive behaviors such as self-induced vomiting. Moreover, CBT provides strategies to patients in order to monitor their usually dysfunctional behaviors and so increasing their awareness (i.e. food diary method) while reducing the availability of food and encourages activities that are incompatible with overeating. Patients will be trained in problem solving in order to change these feelings, as well as in increasing their self-awareness in order to recognize irrational thoughts about their body weight and shape. Additionally, they will be gradually exposed to foods that they had been avoiding.
32898471|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
33081956|NCT04627519|Experimental|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
33081957|NCT04627636|Experimental|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
33276794|NCT04048577|Experimental|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
33276795|NCT04048577|No Intervention|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
33401935|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
33081958|NCT04627636|Experimental|control group|which treated with conventional physical therapy program
32775966|NCT05503745|Experimental|CBT-F+MIT|"Participants in the CBT-F+MIT condition will receive a total of 20 sessions over 20 weeks. Specifically, 2 sessions will be based on CBT-F as usual only. During these sessions participants will receive psychoeducational training on eating behaviors and an introduction to the protocol tools, namely the monitoring form, weight chart, transdiagnostic formulation and Eating Problem Check List (EPCL).~These elements will be used at the beginning of the remaining 18 sessions, in order to monitor the regulations of eating behaviors as well eliciting narrative episodes. These materials will form the basis for the MIT-part of the session, in which therapists will seek to form with the patient a shared understanding of the psychological reasons underlying their ED symptoms and their maladaptive interpersonal functioning. MIT sessions will be integrated within the CBT-F protocol which will provide psycho-educational, nutritional re-education and management for ED."
32775967|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
32775968|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
32775969|NCT02564471|Experimental|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
32775970|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
32775971|NCT05503667|Experimental|Furmonertinib Plus Bevacizumab|Furmonertinib Plus Bevacizumab
32775972|NCT05503667|Active Comparator|Furmonertinib|Furmonertinib monotherapy
32775973|NCT04411979|No Intervention|treatment-as-usual|
32775974|NCT04411979|Experimental|treatment-as-usual plus aerobic walking|
32775975|NCT05512637||neurodevelopmental disorders|"Step 1 - Screening: the targeted sample is the siblings of the autistic children, these siblings being at risk of neurodevelopmental disorders.~Step 2 - Clinical interview: All the children with a positive screening."
32775976|NCT05512481|Experimental|Neoadjuvant/adjuvant therapy|"Drug: Camrelizumab~Drug: Apatinib mesylate~Drug: Temozolomide Injection"
32775977|NCT05503589||student group|have taken the professional practice/internship lecture and be practicing in the hospital
32775978|NCT05503589||control group|who routinely work during the pandemic
32775979|NCT02563067|Experimental|QAW039 150 mg|QAW039 150 mg once daily
32775980|NCT02563067|Experimental|QAW039 450 mg|QAW039 450 mg once daily
32775981|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
32775982|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
32775983|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
32775984|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
32775985|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and <60 mL/min/1.73m2) during the observation period
32775986|NCT05502731|Experimental|Add-on filgotinib|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and filgotinib p.o. (200 mg once daily) for 24 weeks
32775987|NCT05502731|Active Comparator|Add-on adalimumab|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and adalimumab s.c. (40 mg biweekly) for 24 weeks
32775988|NCT04842773|Experimental|US measurement of sarcopenia|
32775989|NCT04635917|Experimental|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
32775990|NCT04635917|Experimental|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
32775991|NCT04635917|Other|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
32775992|NCT04635917|Other|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
32775993|NCT04633811|Experimental|Controlled Diet and Weight Loss Program|Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.
32775994|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment~Platinum drugs~Taxanes~Vinca alkaloids~Epothilones~Proteasome inhibitors~Thalidomide~Vedotin-based drugs~checkpoint inhibitors~Any combination of the aforementioned drugs"
32775995|NCT05502497|Other|Control Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
32775996|NCT05502497|Experimental|IASTM Treatment Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
32775997|NCT04287413|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
32775998|NCT04287413|Active Comparator|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
32775999|NCT05503277|Active Comparator|Superglottic airway device LTSD|measuring seal pressure
32776000|NCT05503277|Active Comparator|Superglottic airway device i-gel|measuring seal pressure
32776001|NCT05510141|Experimental|Virtual Reality Gaming|
32776002|NCT05510141|Active Comparator|Nitrous Oxide|Standard procedure
32776003|NCT05502419|Active Comparator|conventional physical therapy|
32776004|NCT05502419|Experimental|conventional physical therapy with slump stretching|
32776005|NCT05503199|Experimental|Combined suture- and plug-based VCD strategy|1 ProGlide or ProStyle + 1 Angio-Seal
32776006|NCT05503199|Experimental|Pure suture-based VCD strategy|2 ProGlides or ProStyles
32776007|NCT05502263||moderate/high risk|FEV and/or DLCO <80% And VO2peak <20ml/kg.min or <75% predicted value
32776008|NCT05502263||Control|FEV and DLCO >80% and VO2peak > 20ml/kg.min or >75% predicted value
32776009|NCT05503121||Study Group|"The volunteer group planned to be included in the study will consist of individuals diagnosed with Nonspecific Low Back Pain who applied to Istinye University Physiotherapy and Rehabilitation Application and Research Center (Isu Fizyotem).~21 volunteers with low back pain will be included in the study."
32776010|NCT05503121||Contol Group|The control group will consist of healthy individuals. 21 healty volunteers will be included in the study.
32776011|NCT04823039|Other|Vaccination in patient with sepsis|
32776012|NCT05503043|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
32776013|NCT05503043|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
32776014|NCT05502185||healthy volunteers|no intervention
32776015|NCT05502185||Atopic Dermatitis patients|no intervention
32776016|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative, as defined by a review of at least 3 year or more years of culture data and at least 3 NTM negative cultures with one of those negative cultures being within the last 3 years and no known history of previous positive cultures for pathogenic NTM by chart review.
32776017|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
32776018|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
32776019|NCT01663727|Experimental|B|Paclitaxel + Placebo
32776020|NCT04607135|Experimental|Acoustic radiation force impulse (ARFI)|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
32776021|NCT04607135|Active Comparator|MR-ultrasound fusion|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
32776022|NCT05509985|Experimental|ASKG315|Single or multiple ascending dose of ASKG315
32776023|NCT05509829|Experimental|NPWT group|Patients who receive NPWT after surgery.
32776024|NCT05509829|No Intervention|Control group|Retrospective cohort who did not receive NPWT.
32776025|NCT02614261|Placebo Comparator|Placebo|"Double-blind treatment phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they receive 240 milligram (mg) galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
32776026|NCT02614261|Experimental|Galcanezumab 120 mg|"Double-blind treatment phase: Participants received loading dose of 240 mg of galcanezumab at first dosing visit followed 120 mg galcanezumab once a month by SC injection for 2 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
33081959|NCT04627480|Experimental|Experiment Arm|Active Fisher Wallace device for full 8 weeks
33081960|NCT04627480|Sham Comparator|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
32776027|NCT02614261|Experimental|Galcanezumab 240 mg|"Double-blind treatment phase: Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 3 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
32776028|NCT02614261|Experimental|Israel Addendum|Eligible participants from main study were enrolled in Israel addendum. Participants received 120mg or 240mg galcanezumab SC once a month, at the discretion of the investigator, for up to 3 years or until Israel's Ministry of Health's conditions for continued access cease to be met, whichever occurs first.
32776029|NCT04859023|Experimental|mass screening SARS-COV-19|"20 0000 participant will be included during mass screening SARS-COV-19 of the population of the city of Saint-Etienne.~They will have two strategies both based on self-samples: (i) a saliva sample combined to an anterior nare self-swabbing tested by antigenic test versus (ii) a saliva sample tested by RT-PCR."
33231523|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
33231524|NCT00823498||African American Parents|
33231525|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
33231526|NCT04044430|Experimental|Treatment (encorafenib, binimetinib, nivolumab)|"Participants in Phase 1 receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.~The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
33231527|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
33231528|NCT00821158|Experimental|2|Placebo tablet and intervention iv
33231529|NCT00821158|Experimental|3|Intervention tablet and placebo iv
33231530|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
33231531|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
33231532|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
33231533|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
33231534|NCT04018456|Experimental|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
33231535|NCT04018456|Active Comparator|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
33231536|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
33231537|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
33231538|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
33231539|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
33231540|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
33231541|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
33231542|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
33231543|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
33231544|NCT00828724|Experimental|Lorcaserin 10mg|
33231545|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
33231546|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
33231547|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
33231548|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
33231549|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
33231550|NCT00823810|Experimental|Colorectal cancer|
33231551|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
33231552|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
33231553|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
33231554|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
33231555|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
33231556|NCT00828880||DRX9000|
33231557|NCT02548390|Experimental|RXDX-107|
33231558|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
33231559|NCT04105101|Experimental|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
33231560|NCT04105101|Experimental|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
33231561|NCT04105101|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
33231562|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
33231563|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
32776030|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
32776031|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
32776032|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
32776033|NCT04867681|Experimental|Administration of a short psycho-education programme|
32776034|NCT04867681|No Intervention|Control group|
32776035|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
32776036|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
32776037|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
32776038|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
32776039|NCT01594333|Experimental|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
32776040|NCT01594333|Placebo Comparator|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
32776041|NCT04342039|Placebo Comparator|Placebo|Participants will use a placebo nasal spray before being exposed to a series of allergen and pollution challenges.
32776042|NCT04342039|Active Comparator|Budesonide nasal|Participants will use budesonide nasal spray before being exposed to a series of allergen and pollution challenges.
32776043|NCT04860895|Other|Nasopharyngeal swabs|Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
32776044|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
32776045|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
32776046|NCT04338529||Group Alendronate 6m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 6 months and then followed for another 6 months without medication. In case serum P1NP levels are > 35μg/L and/or serum CTX levels are > 280 ng/L at 9 months (3 months following alendronate discontinuation) the patients would be strongly advised to restart alendronate treatment.
32776047|NCT04338529||Group Alendronate 12m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 12 months.
32776048|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
32776049|NCT04858633|Active Comparator|PEP group|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg)
32776050|NCT04858633|Placebo Comparator|Control group|Placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
32776051|NCT04867291|Experimental|Pizza|Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
32776052|NCT04867291|Experimental|Seaweed Sheets|Consumption of a portion of Itsu Crispy Seaweed Thins equivalent to 200 µg of iodine (10g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
32776053|NCT04867291|Experimental|Seaweed Powder|Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
32776054|NCT04867291|Experimental|Potassium Iodide Supplement|Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
32776055|NCT04867447||Case-Immigrants psychotic patients|"Individuals who have presented at least one non-affective psychotic episode with an immigrant status, defined as a person who migrates to another country, usually for permanent residence"
32776056|NCT04867447||Control-Non immigrants psychotic patients|Individuals who have presented at least one non-affective psychotic episode who do not have an immigrant status.
32776057|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
32776058|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
33276796|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
32776059|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
32776060|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
33276797|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~Temodal® (temozolomide)~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
33276798|NCT00762047|Experimental|Durasphere|
32776061|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
32776062|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
32776063|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
32776064|NCT03043027|Experimental|Liposomal bupivicaine|
32776065|NCT03043027|Active Comparator|bupivicaine|
32776066|NCT03043027|Placebo Comparator|saline|
32776067|NCT04861207|Experimental|Cladribine|
32776068|NCT04858477|Other|Colonoscopy Patients + their Gastroenterology Fellows|Inpatient and outpatient colonoscopies performed by fellows at NYU Langone Health, NYU Langone Hospital Brooklyn, Bellevue Hospital Center, and Manhattan VA Medical Center from October 2020 - March 2021. These will include all colonoscopies with polyps done in adults age 45 and above.
33081961|NCT04627363|Experimental|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
33081962|NCT04627207|Experimental|Reference-Reference-Test|Sequence 1
33081963|NCT04627207|Experimental|Reference-Test-Reference|Sequence 2
33276799|NCT00762047|Sham Comparator|Sham|
33276800|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
33276801|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
33276802|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
33276803|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
33276804|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
33276805|NCT00762125|Experimental|Exposure therapy (ET)|
33276806|NCT00762125|Experimental|Combination (COMB) treatment|
33276807|NCT00762125|Active Comparator|Attention control (AC) treatment|
33276808|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
33276809|NCT02719106||Ultimaster stent|
33276810|NCT00760175|Active Comparator|intradermal|
33276811|NCT00760175|Active Comparator|intramuscular|
33276812|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
33276813|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
33276814|NCT00762437|Experimental|1|
33276815|NCT05361122|Experimental|Xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
33276816|NCT05361122|Active Comparator|Non xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
33276817|NCT05361122|Experimental|Xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
33276818|NCT05361122|Active Comparator|Non xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
33276819|NCT02557763|Experimental|Severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
33276820|NCT02557763|Experimental|non severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
33276821|NCT00991484||control group|
32776069|NCT04858165|No Intervention|CONTROL|without MY GERYFS
32776070|NCT04858165|Other|INTERVENTION|with MY GERYFS
33081964|NCT04627207|Experimental|Test-Reference-Reference|Sequence 3
33276822|NCT00991484||individuals from hernia-family|
33276823|NCT00766259||1|Hemodialysis
33276824|NCT00766259||2|Intensive care
33276825|NCT00766259||3|vascular patients with open wounds
33276826|NCT00766259||4|nursing home
33276827|NCT00766259||5|skin infections
33276828|NCT00766259||6|control- ambulatory care clinic patients with no infections
33276829|NCT05394818|Experimental|SHR-A2009|
33276830|NCT00766337|Experimental|Dose Group 1|
33276831|NCT00766337|Experimental|Dose Group 2|
33276832|NCT00766337|Placebo Comparator|Dose Group 3|
33276833|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
33276834|NCT00760253||1|pure propofol by TCI pump with titration.
33276835|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
33276836|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
33276837|NCT05381792||Known colorectal advanced neoplasia group|Subjects with known colorectal advanced neoplasia and requiring endoscopic resection
33276838|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
33276839|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
33276840|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
33276841|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
33276842|NCT00762671|Placebo Comparator|2|Placebo
33276843|NCT00762671|Active Comparator|1|Ebselen
33276844|NCT05306483|Active Comparator|Ventricular septal defect closure surgery|Surgical closure would be done under general anesthesia, hypothermic cardiopulmonary bypass and cardioplegic arrest. Chest would be opened through standard median sternotomy Surgical techniques would be determined according to the nature of every defect and includes direct closure, patch closure which involves the use of autologous pericardium; however, polyethylene terephthalate (Dacron; C.R Bard, Haverhill, MA) and expanded polytetrafluoroethylene (Gore-Tex; W.L. Gore & Associates, Inc.,AZ) may be occasionally used. These patches are held with continuous or interrupted sutures. Direct closure (without a patch may be done for the very small defects.Most VSDs would be repaired through right atriotomy to avoid the the undesirable effects of the trans ventricular approach.
33276845|NCT05306483|Active Comparator|catheter closure of ventricular septal defect|"Under general anesthesia, patients will be fully heparinized (100IU/Kg) with follow up by activated clotting time. IntraoperativeTEE will be done for more detailed assessment of the defect size, relation to the surrounding structures especially the distance from the tricuspid and the aortic valve to guide the procedure and for proper assessment after device positioning yet before its release.~Left ventricular angiogram will be done in LAO 60, cranial 30 projection to define location and size of the defect. Accordingly, proper selection of the device siz."
33276846|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.~A slit lamp examination and indirect ophthalmoscopy will be performed.~Experimental:~The subject's eye will be held open with an eye speculum during the exam.~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.~Intraocular Pressure will be measured.~An Optic Coherence Tomography (OCT) will be performed.~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.~Optional:~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
33276847|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
33276848|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
33276849|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
33276850|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
33276851|NCT00766961|Active Comparator|Surgery group|Surgery
33276852|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
33276853|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
33276854|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
33276855|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
33276856|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
33276857|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
33276858|NCT00760565|Experimental|1|
33276859|NCT00760565|Placebo Comparator|10|
33276860|NCT00760565|Experimental|11|
33276861|NCT00760565|Placebo Comparator|12|
33276862|NCT00760565|Placebo Comparator|2|
33276863|NCT00760565|Experimental|3|
33276864|NCT00760565|Placebo Comparator|4|
33276865|NCT00760565|Experimental|5|
33276866|NCT00760565|Placebo Comparator|6|
33276867|NCT00760565|Experimental|7|
33276868|NCT00760565|Placebo Comparator|8|
33276869|NCT00760565|Experimental|9|
33276870|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
33276871|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
33276872|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
33276873|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
33276874|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
33276875|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
33276876|NCT00762905|Active Comparator|2|Dermabond
33276877|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
32776071|NCT04858321|Experimental|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
32776072|NCT04858087||All students|All participating students were screened for Pf infection using malaria rapid diagnostic tests (mRDTs) and treated if positive. All were followed 1, 2, and 6 weeks after screening-and-treatment.
32776073|NCT04860427|Active Comparator|Trapezoidal condylar plate|Trapezoidal condylar plate open reduction and internal fixation of subcondylar fractures
32776074|NCT04860427|Active Comparator|two miniplates|two miniplates open reduction and internal fixation of subcondylar fractures
32776075|NCT04867057|Experimental|Experimental: Trichomylin for SAD|6 out of 8 subjects will be randomized to receive Trichomylin in a single dose.
32776076|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for SAD|2 out of 8 subjects will be randomized to receive placebo in a single dose.
32776077|NCT04867057|Experimental|Experimental: Trichomylin for MAD|6 out of 8 subjects will be randomized to receive Trichomylin in multiple doses.
32776078|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for MAD|2 out of 8 subjects will be randomized to receive Placebo in multiple doses.
32776079|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
32776080|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
32776081|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
32776082|NCT04857853|Experimental|Exercise Without Rest Breaks|Exercise Without Rest Breaks
32776083|NCT04857853|Experimental|Exercise With Rest Break|Exercise With Rest Break
32776084|NCT04857853|Experimental|Rest Break|Rest Break
32776085|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
32776086|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
32776087|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
32776088|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
32776089|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
32776090|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
32776091|NCT04866667||antidiabetic drugs including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs
32776092|NCT04866667||antidiabetic drugs not including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin
32776093|NCT04857463|Experimental|Nutritional supplement drink|Nutritional supplement, this group receives a nutritional supplement for a period of 12 weeks.
32776094|NCT04857463|Placebo Comparator|Nutritional education|Qualified clinical dietitians provide regular nutrition education and ensure the effectiveness of nutrition education
32776095|NCT04866745|Experimental|Magnetotherapy plus exercise|"The patients will receive a total of 12 sessions, 3 sessions per week of magnetotherapy. The duration of treatment will be 20 minutes with a magnetic field frequency of 50Hz and a power of 100 Gauss.~After the magnetotherapy treatment, the patient will have to perform 12 sessions, 3 sessions per week of a program of therapeutic exercise with a duration of 25 minutes. This exercise program will be the same in the microwave and sham groups."
32776096|NCT04866745|Placebo Comparator|Sham Magnetotherapy plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
33081965|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
33276878|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
33276879|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
33276880|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
33081966|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
33276881|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
32737081|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
32737082|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
33276882|NCT05200871||Adult patients|Adult patients (at least 18 years old) with FSGS or IgAN located in each of the six countries
32737083|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
33276883|NCT05200871||Adult patient care-partners of adult patients|Adult care-partners (paired with adult patients) (at least 18 years old) of adult patients with FSGS or IgAN located in each of the six countries
33276884|NCT05200871||Adult patient care-partners of pediatric/adolescent patients|Adult parents/care-partners (paired with adult patients) (at least 18 years old) of pediatric/ adolescent patients with FSGS or IgAN located in each of the six countries
33276885|NCT00767429|Experimental|1|subjects with fall risk
33276886|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
33276887|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
33276888|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
33276889|NCT01039090|Active Comparator|Per os dopaminergic treatment|
33276890|NCT01039090|Experimental|Continuous Apomorphine infusion|
33276891|NCT04049201|Experimental|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
33276892|NCT04049201|Active Comparator|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
33276893|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
33276894|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
33276895|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
33276896|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
33276897|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
33276898|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
33276899|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
33276900|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
33276901|NCT00767663|Experimental|1|dipyridamole
33276902|NCT00767663|Placebo Comparator|2|placebo
33276903|NCT00767741|Experimental|with treatment|
33276904|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
33276905|NCT00763295||HIV infection|
33276906|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
33276907|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
33276908|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
33276909|NCT04049045|Active Comparator|Verum arm|25 mg tablet of empagliflozin once daily for five days
33276910|NCT04049045|Placebo Comparator|Placebo arm|one tablet of the matching Placebo once daily for five days
33276911|NCT00763373||1|Observation group
33276912|NCT00763373||2|Intervention group
33276913|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
33276914|NCT00760799|Experimental|2|Standard Discectomy with anular repair
33276915|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
33276916|NCT03993730|Other|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF <45% and LGE on CMR.
33276917|NCT03993730|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF <45% and no LGE on CMR.
33276918|NCT01041586|Experimental|BTVA|
33276919|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
33276920|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
33276921|NCT00671879|Placebo Comparator|Placebo|Placebo
33276922|NCT00402298|Experimental|Full dose (125 mg) MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long therapy sessions.
33276923|NCT00402298|Active Comparator|Active Comparator (25 mg) MDMA-assisted therapy|Participants will receive an initial dose of 25 mg MDMA followed 2.5 hours later by a supplemental dose of 12.5 mg MDMA during the course of two day-long therapy sessions.
33276924|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
33276925|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
33081967|NCT04627324|Experimental|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
33276926|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
33276927|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
33276928|NCT03994276|Placebo Comparator|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
33276929|NCT03994276|Active Comparator|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
33276930|NCT03994276|Experimental|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
33276931|NCT03994276|Active Comparator|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
33276932|NCT03994276|Experimental|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
33276933|NCT03994276|Experimental|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
32737084|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
32737085|NCT04497701|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24~72 hours after the end of chemotherapy, 100µg/kg, once in each chemotherapy cycle.
33276934|NCT01036048||cabg disease|pts with saphenous vein graft disease
33276935|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
33276936|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
33276937|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
33276938|NCT00767897||Healthy|Girls and Boys age 9-18
33276939|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
33276940|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
33276941|NCT00768131|Experimental|A1 FISH (+)|
33276942|NCT00768131|Active Comparator|B1 FISH (+)|
33276943|NCT00768131|Experimental|A2 FISH (-)|
32737086|NCT04497701|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24~72 hours after the end of chemotherapy, 100µg/kg/d, and stop using it until the ANC value exceeds the lowest value for 2 consecutive days> 0.5×10^9/L.
32737087|NCT02496065|Experimental|BLZ-100|
32737088|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
32737089|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
33276944|NCT00768131|Active Comparator|B2 FISH (-)|
33276945|NCT00401830|Placebo Comparator|Placebo|
33276946|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
33276947|NCT00768209|Experimental|Treatment A|
33276948|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
33276949|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
33276950|NCT02471144|Placebo Comparator|Placebo|Placebo
33276951|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
33276952|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
33276953|NCT00768365||group 1|patients with adrenal incidentaloma
33276954|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
33401936|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
32737090|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
32737091|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
32737092|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
32737093|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
32737094|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
32737095|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
32737096|NCT02495597||Control Group|age- and sex matched to subject-group
32737097|NCT03341897|Experimental|Surgical varicocelectomy|
32737098|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
32737099|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
32737100|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
33081968|NCT04627324|Active Comparator|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
32776097|NCT04866745|Active Comparator|Microwave plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of microwave therapy. The duration of the session will be 20 minutes, 10 minutes on the anterior side and 10 minutes on the posterior side of the joint in case of unilateral knee osteoarthritis. In the case of bilateral knee osteoarthritis, the MW will be applied 20 minutes over the anterosuperior side of both knees. After the microwave session, the patient will have to perform a program of therapeutic exercise.
32776098|NCT04867213||SARS-CoV-2 Positive|Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
32776099|NCT04867213||SARS-CoV-2 Negative|Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
32776100|NCT04860115|Experimental|Block group|Patients in a Block group will be anesthetized and receive PECS II+PIFB with dexmetomidine prior to their surgery.
32776101|NCT04860115|No Intervention|Control group|Patients in a Control group will receive a standard general anesthesia the same way as patients in the interventional group but without regional anesthesia.
32776102|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
32776103|NCT04856995||working in the operating|operating room workers exposed to surgical smoke
32776104|NCT04856995||working in internal units|Internal unit workers not exposed to surgical smoke
32776105|NCT04859881||Barotrauma/cases|Cases were defined as patients with barotrauma consulted with the Surgery Department
32776106|NCT04859881||No braotruma/Controls|Controls were selected from a random sample of the COVID-19-ARDS cohort.
32776107|NCT04429711|Placebo Comparator|IVERMECTIN|
32776108|NCT04429711|Active Comparator|PLACEBO|
32776109|NCT04429633|Active Comparator|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
32776110|NCT04429633|Active Comparator|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
32776111|NCT04856839||syringomyelia group|
32776112|NCT04856839||Other neurodegenerative diseases|such as hydrocephalus
32776113|NCT04856839||Normal group|
32776114|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
32776115|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
32776116|NCT04859569|Experimental|LY01011|Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.
32776117|NCT04859569|Active Comparator|Xgeva®+LY01011|After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.
32776118|NCT04859413||the young group|healthy participants age between 20 and 40
32776119|NCT04859413||the elder group|healthy participants age over 60
32776120|NCT04859959|Experimental|68Ga-Pentixafor PET/CT scan|Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.
32776121|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
32776122|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
32776123|NCT04856371|Experimental|CYH33 + fulvestrant|Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.
32776124|NCT04856371|Experimental|CYH33 + fulvestrant + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).
32776125|NCT04856371|Experimental|CYH33 + letrozole + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)
32776126|NCT04866277|Experimental|Intervention|"Women who present at least one of the four risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will be eligible to receive the intervention. The intervention will be the activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study. All pregnant women referred by the STOP LBW project would have access to consultations or other health activities, such as counselling and group meetings, within a maximum of seven days, in reference services available in each metropolitan area. The activation of the fast-track referral will be the responsibility of the doctor/nurse who applies the questionnaires to identify the risk factors. The intervention ends with childbirth, abortion or if the participant decides to abandon the study."
32776127|NCT04866277|No Intervention|Standard of care|Women who present at least one of the risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will receive the standard of care currently existing in each PHCU. The standard of care varies across the various PHCU and may include several approaches: routine screening with care by the antenatal care provider; routine screening with referral to other health professional in the same health unit; and routine screening with referral to other health services, with the time elapsed for consultation depending on the health resources available in each area. In each PHCU, different standards of care may exist for each of the four risk factors.
32776128|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
32776129|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
32776130|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
32776131|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
33081969|NCT04627402|Experimental|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
33081970|NCT04627402|Active Comparator|Injection single agent|Intravitreous injection of conbercept only.
33276955|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
33276956|NCT04048967|Experimental|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
33276957|NCT04048967|No Intervention|Control|Staffs receive no professional development and children will receive standard care.
33276958|NCT00770471|Experimental|Dose Escalation|
33276959|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
33276960|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
33276961|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
33276962|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
33276963|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
33276964|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
33276965|NCT00770627|Placebo Comparator|Placebo caps|
33276966|NCT00770627|Active Comparator|Omega 3 caps|
33276967|NCT00417976|Experimental|Bevacizumab|
33276968|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
33276969|NCT00770705|Other|2|Historical control
33276970|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
33276971|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
33276972|NCT00991718|Experimental|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
33276973|NCT00991718|Experimental|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
33276974|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
33276975|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
33276976|NCT04048733|Experimental|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
33401937|NCT05222620|Other|Arm A (single fraction SRS)|Patients undergo single fraction SRS.
32737101|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
32737102|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
32737103|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
32737104|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
32737105|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
32737106|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
32737107|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
32737108|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
32737109|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
32737110|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
32737111|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
32737112|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
32737113|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
32737114|NCT02495051||single group-study|
32776132|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
32776133|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
32776134|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
32776135|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
32776136|NCT04859335|Other|Schwannomas patients needing gammaknife radiosurgery|"Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery.~This is a before/after analysis needing only one arm: the before data will serve as control to the after data"
32776137|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
32776138|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
33276977|NCT04048733|No Intervention|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
33276978|NCT05359250||Patients with evidence of myocardial injury related to vaccination with a SARS-CoV-2 mRNA vaccine|Patients who present with new symptoms of chest pain within 2-10 days following SARS-CoV-2 mRNA vaccination will be recruited up to 180 days following diagnosis. Patients will be screened using multiple methods and then provided informed consent. If patients are unable to consent, health care decision makers of patients who meet initial inclusion criteria will be approached for consent. Following informed consent, a cardiac MRI will be performed (if not performed prior) to assess myocardial function and potential damage. Patients will qualify on the basis of the presence of late-gadolinium enhancement and/or abnormal T1 mapping on MRI. The patient will then be taken to the cardiac catheterization lab where he/she will undergo endomyocardial biopsy and right heart catheterization (RHC) for candidate gene analysis. A blood sample will be collected to analyze circulating biomarkers associated with myocardial injury.
33276979|NCT01036360||physical activity|
33276980|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
33276981|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
32776139|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
32776140|NCT04808011|Experimental|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
32776141|NCT04866355|Experimental|Lumbar spine manipulation|Application of lumbar spine manipulation by a physical therapist.
32776142|NCT04866355|Active Comparator|Lumbar spine manipulation plus pharmacological therapy|Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
32776143|NCT04866355|Active Comparator|Pharmacological therapy|Application of pharmacological therapy
33081971|NCT04627051|Experimental|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
33081972|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
33276982|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
33276983|NCT05357768||retrospective cohort|"Patients with undifferentiated round cell sarcomas treated from 01 January 1983 to April 2019 will be included.~For retrospective analysis, it is expected to include about 200 patients."
33276984|NCT05357768||prospective cohort|prospective patients with undifferentiated round cell sarcomas will be included in the study. For prospective study, it is expect to include 60 patients.
33276985|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
33276986|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
33276987|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
33276988|NCT05290610|Other|Research IESM|Functional mapping for research application
33276989|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
33276990|NCT00763685|Placebo Comparator|2|Placebo
33276991|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
33276992|NCT01039402||1|Adults ≥ 50 years old
33276993|NCT05281874|Placebo Comparator|Control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
33276994|NCT05281874|Experimental|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
33276995|NCT05281874|Experimental|Positive Change (+Change) Plus Booster|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation. It is provided at baseline and a booster at 6 months.
33276996|NCT04048655|Other|Study group|Single arm and everyone gets the same treatment according the protocol
33276997|NCT04002986|Experimental|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
33276998|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
33276999|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
33277000|NCT02557997||ART-controlled|ART-controlled HIV infected adults
33277001|NCT02557997||ART-failing|ART-failing HIV infected adults
33277002|NCT05273918|Experimental|Therapy cognitivo-comportmental|"Each child will participate in a structured cognitive behavioral therapy program entitled better manage your anger and frustration. 15 workshops is planned."
33277003|NCT05273918|Active Comparator|Body mediation|Each child will participate in sports, artistic or fun activities involving the body (physical, emotional and communicative dimensions)
33277004|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
32776144|NCT04866121|No Intervention|Standard Treatment|Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
32776145|NCT04866121|Active Comparator|Single point (P6) Acupuncture|"Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.~Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia."
33277005|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
33277006|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
33277007|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
33277008|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
33277009|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
33277010|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
32776146|NCT04866121|Experimental|Double point (P6+ST36) Acupuncture|Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
32776147|NCT04849819||never receive systemic medications|
32776148|NCT04849819||ever user of systemic medications|
32776149|NCT04849819||current user of systemic medications|
32776150|NCT02607865|Experimental|Semaglutide 3 mg|
33277011|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
33277012|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
33277013|NCT04048187|Experimental|Phone Application|
33277014|NCT05408858|Experimental|LGBTQ-affirmative cognitive behavioral group therapy|LGBTQ-affirmative cognitive behavioral group therapy consists of 10 weekly, 90-minute group therapy sessions, delivered remotely via Zoom. Intervention sessions and associated home practice will cover the following topics: Building and keeping motivation; Introduction to LGBTQ-related stress; Getting to know your emotions; Introduction to emotional behaviors and behavioral experiments; Awareness of physical sensations and introduction to flexible thinking; Being flexible in your thinking; Awareness of emotional experiences; Assertiveness; Situational exposures; Reviewing accomplishments and looking ahead. Participants will be taught intervention content through a range of teaching modalities including use of the Zoom whiteboard feature, videos, interactive activities, worksheets, and group discussion.
33277015|NCT01041742|Experimental|OPCAB|
33277016|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
33277017|NCT04003298|Experimental|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
33277018|NCT04003298|Active Comparator|Electric toothbrush|Electric toothbrush
33277019|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
33277020|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
33277021|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
33277022|NCT00763841|Sham Comparator|2|
33277023|NCT05408702||Autoimmune Myasthenia Gravis|
33277024|NCT05408702||Congenital Myasthenic Syndrome|
33277025|NCT05408702||Lambert Eaton Syndrome|
33277026|NCT01037140|Active Comparator|cholecalciferol|
33277027|NCT01037140|Placebo Comparator|placebo|
33277649|NCT00532844|Experimental|Sapropterin dihydrochloride+Vitamin C|Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
33277650|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
33277651|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
32776151|NCT02607865|Experimental|Semaglutide 7 mg|
32776152|NCT02607865|Experimental|Semaglutide 14 mg|
32776153|NCT02607865|Active Comparator|Sitagliptin 100 mg|
32776154|NCT04856137|Experimental|single arm|ruxolitinib, paclitaxel, and rituximab
32776155|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
33081973|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
33277028|NCT05357456||autonomous cortisol secretion|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then ACS patients are diagnosed based on the serum cortisol ≥ 50 nmol/L following the 1 mg dexamethasone suppression test and without any other signs or symptoms of cortisol excess.Patients with ACS will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline and 12 months after their surgery or conservative treatment.
33277029|NCT05357456||non-functioning adrenal adenomas|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then non-functioning adrenal adenomas patients are diagnosed based on the serum cortisol < 50 nmol/L following the 1 mg dexamethasone suppression test .Patients with non-functioning adrenal adenomas will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline.
33277030|NCT00069121|Active Comparator|5-Fluorouracil/Leucovorin (5-FU/LV)|Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
33277031|NCT00069121|Experimental|Capecitabine in Combination with Oxaliplatin (XELOX)|Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
33277032|NCT00768911|Experimental|1|
33277033|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
33277034|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
33277035|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
32776156|NCT04849195||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
33277036|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
33277037|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
33277038|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
33277039|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
33277040|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
33277041|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
33277042|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
33277043|NCT03900728|Active Comparator|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
32776157|NCT04849351|Experimental|Relapsed/Refractory MZL and FL|Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
32776158|NCT04849039||Mechanicaly ventilated adult patients for non-pulmonary conditions|
32776159|NCT03044899||Adult surgical patients|All surgeries in adult patients
33081974|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
33277044|NCT03900728|Active Comparator|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
33277045|NCT03900728|Sham Comparator|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
33277046|NCT00763997|Experimental|1|Dipyrone
33277047|NCT00763997|Active Comparator|2|Ibuprofen
33277048|NCT00763997|Active Comparator|3|Acetaminophen
33277049|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
33277050|NCT00771095|Active Comparator|Control (available) podcast|
33277051|NCT00771095|Experimental|Enhanced podcast|
33277053|NCT00771251|Experimental|CNTO 148 50 mg|
33277054|NCT00771251|Experimental|CNTO 148 100 mg|
33277055|NCT00771251|Experimental|Placebo|
33277056|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
33277057|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
33277058|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
33277059|NCT03960853|Experimental|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
33277060|NCT03960853|Placebo Comparator|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
33081975|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
33277061|NCT05088356|Experimental|Arm A: Matched related/matched unrelated donor transplantation|Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/unrelated donor transplant. All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus. Fludarabine (160 mg/m2)/ Melphalan (50 mg/m2)/TBI (4Gy)
33277062|NCT05088356|Experimental|Arm B: Haploidentical transplantation|Subjects without an identified matched related or matched unrelated donor will receive a haploidentical transplantation with reduced intensity preparative conditioning. Patients will receive GVHD prophylaxis with post-transplant cyclophosphamide and tacrolimus. Fludarabine (160 mg/m2)/ Melphalan (100 mg/m2)/TBI (4Gy)
33277063|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
33277064|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
33277065|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
33277066|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
33277067|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
33277068|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
33277069|NCT01039558|Placebo Comparator|lansoprazole + placebo|
33277070|NCT04994912|Experimental|EI-001|IV infusion
33277071|NCT04994912|Placebo Comparator|Placebo|IV infusion
33277072|NCT00769301||1|Not hospitalized cancer patients under active treatment
33277073|NCT00769301||2|Caregivers of these cancer patients
33277074|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
33277075|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
33277076|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
33277077|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
33277078|NCT05408546|Placebo Comparator|Placebo|Placebo + standard of care (SOC) anticoagulation
33277079|NCT05408546|Experimental|Low dose TS23|TS23 low dose + SOC anticoagulation
33277080|NCT05408546|Experimental|Intermediate dose TS23|TS23 medium dose + SOC anticoagulation
33277081|NCT05408546|Experimental|Higher dose TS23|TS23 highest dose + SOC anticoagulation
33277082|NCT01037296|Other|manual ablation|
33277083|NCT01037296|Experimental|robotic ablation|
33277084|NCT05120999||Dominant hand|Application of either TetraGraph or TOFScan device on dominant hand
33277085|NCT05120999||Non-Dominant hand|Application of either TetraGraph or TOFScan device on non-dominant hand
33277086|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33277087|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33277088|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33277089|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33277090|NCT01415882|Experimental|Arm E (ixazomib citrate, cyclophosphamide, daratumumab)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33277091|NCT00068419|Experimental|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
33277092|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
33277093|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
33277094|NCT01039714||Total Thyroidectomy|
33277095|NCT01037374|Experimental|Difficult Airway Assessment Form|
33277096|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
33277097|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
32776160|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
32776161|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
32776162|NCT04855903|Experimental|Arm 1 (early phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 3 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 5 weeks"
32776163|NCT04855903|Experimental|Arm 2 (mid phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 4 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 4 weeks"
32776164|NCT04855903|Experimental|Arm 3 (late phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 5 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 3 weeks"
32776165|NCT04849117||Systemic analgesia|Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically. Morphine was administered if necessary, according to our institutional pain management protocol.
32776166|NCT04849117||Bilateral TTMP block + systemic analgesia|Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
32898472|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
32906435|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
33277098|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
33277099|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
33277100|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
33277101|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
33277102|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
33277103|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
33277104|NCT01757626|Experimental|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123^I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
33277105|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
33277106|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
33277107|NCT05408234|Experimental|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
33277108|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
33277109|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
33277110|NCT00068107|Experimental|Relagal|All participants received Relagal administered weekly
33277111|NCT04048811|Experimental|HSK3486|HSK3486 induction + maintenance group
33277112|NCT04048811|Active Comparator|Propofol|Propofol induction + maintenance group
33277113|NCT04048811|Other|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
33277652|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
32776167|NCT04848493||HEMATOLOGICAL MALIGNANCIES|"1a. Newly diagnosed patients with ANY haematological malignancy requiring treatment (No.=100).~1b. Patients with ongoing treatments or with treatments completed within 6 months (chemotherapy and target therapies) other than antibodies. More specifically: patients with ongoing or completed chemotherapy (No.=50) or patients with ongoing or completed Ibrutinib (No.=50) or patients with ongoing or completed ruxolitinib (No.=50)~1c. Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy OR patients receiving CAR-T cells: patients treated anti-B-cell (No.=50) or patients treated anti-CD30 (No.=50) or patients treated anti-PD1 (No.=50).~1d. Patients at three months after autologous or allogeneic transplantation without active immune suppressive therapy: after autologous transplantation (No.=50) or after allogenic transplantation (No.=50)."
32776168|NCT04848493||SOLID TUMORS|"2a. Chemotherapy in adjuvant therapy. All patients with a diagnosis of solid tumors apart resected basal-cell or squamous-cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, and carcinoma in situ of the Breast. Under curative surgery (stage II-III) for the solid tumor or hemotherapy alone or in combination with target therapies or radiotherapy (No.=100).~2b. Chemotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing chemotherapy alone or in combination with immunotherapy or target therapy (No.=100).~2c. Immunotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing immunotherapy alone (No.=100).~2d. Target therapies in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), Undergoing target therapy alone (No.=100)"
32776169|NCT04848493||IMMUNORHEUMATOLOGICAL DISEASES|3a. Patients with ANCA-associated vasculitis classified according to Chapel Hill Consensus Conference nomenclature, treated with immunodepressants agents with/without glucocorticoids (No.=50) or treated with RTX with/without glucocorticoids (No.=50) 3b. Interstitial Lung Disease in Autoimmune Conditions. Patients with a diagnosis of a specific CTD, myositis or rheumatoid arthritis based on validated classification criteria, and clinically significant ILD defined as disease treated with traditional immunodepressants or rituximab and fibrotic and/or inflammatory changes on chest CT not attributable to infection, and no evidence of obstructive lung disease. Patients treated with traditional immunodepressive agents with/without glucocorticoidspatients (No.=50) or patients treated with rituximab with/without glucocorticoids (No.=50)
32776170|NCT04848493||NEUROLOGICAL DISEASES|"4a. Patients with a diagnosis of multiple sclerosis, age < 60 years with relapsing-remitting MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50) or with secondary/primary progressive MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50).~4b. Generalized Myasthenia Gravis, on immunosuppressive polytherapies or on B-cell targeted biological treatments, with lymphocytes count < 1 cell/microliter, or with thymoma (No.=100)"
32776171|NCT04855591|Experimental|SHR-1703 Dose Level 1|Dose level 1 SHR-1703
32776172|NCT04855591|Experimental|SHR-1703 Dose Level 2|Dose level 2 SHR-1703
32776173|NCT04855591|Experimental|SHR-1703 Dose Level 3|Dose level 3 SHR-1703
32776174|NCT04855591|Experimental|SHR-1703 Dose Level 4 (optional)|Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
32776175|NCT04848649|Experimental|Arm 1|
32776176|NCT04855279|Placebo Comparator|Control|
32776177|NCT04855279|Active Comparator|Topical neutral sodium fluoride|
32776178|NCT04855279|Active Comparator|ACP-CCP gel|
32776179|NCT04855279|Active Comparator|nano-hydroxyapatite solution|
32776180|NCT04848259|Placebo Comparator|Control|No drug given before surgery
32776181|NCT04848259|Active Comparator|Dexamethason|Dexamethason will be given IV before surgery
33277114|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
33277115|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
32776182|NCT04848259|Active Comparator|Natural honey|Honey will be placed locally after impaction removal
32776183|NCT04848259|Active Comparator|Dexamethason and natural honey|Dexamethason will be given IV before surgery and Honey will be placed locally after impaction removal
33277116|NCT00764387|Experimental|Arm 1|
33277117|NCT00764387|Active Comparator|Arm 2|
33277118|NCT03957889||Student|
33277119|NCT03957889||Trainers|
32776184|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
32776185|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
32776186|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
32776187|NCT04848571|Placebo Comparator|control group|Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling
33277120|NCT00769691||Group A|Adult patients undergoing cardiac surgery
33277121|NCT04909502|Experimental|EHP-101 Once a day (OD)|
33277122|NCT04909502|Experimental|EHP-101 Twice a day (BID)|
33277123|NCT00769769|Experimental|Telephone-based psychotherapy|
33277124|NCT00769769|Active Comparator|Face-to-face psychotherapy|
33277125|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
33277126|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
33277127|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
33277128|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
33277129|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
33277130|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
33277131|NCT04048265|Experimental|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
33277132|NCT04048265|Sham Comparator|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
33277653|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
32776188|NCT04848571|Experimental|medicine group|Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy
32776189|NCT04840537|Active Comparator|cytological brushing followed by cholangioscopy in case of failure|
32776190|NCT04840537|Experimental|cholangioscopy from the start|
32776191|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
32776192|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
32776193|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
32776194|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
32776195|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.~Other Names:~• Decapeptyl 0.1 mg"
33277133|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
33277134|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
33277135|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
33277136|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
33277137|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
33277138|NCT00770003|Experimental|1|
33277139|NCT00770003|Placebo Comparator|2|
33277140|NCT00771329|Experimental|1|BIIB023
33277141|NCT00771329|Placebo Comparator|2|
33277142|NCT04837820|Experimental|Acupuncture|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
33277143|NCT04837820|Placebo Comparator|Sham Acupuncture (SA)|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
33277144|NCT04837820|Experimental|Wait-List Control|During the 26-week waiting period, the CRC will contact patients in the WLC group at the same frequency as the acupuncture groups with respect to data collection. Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians. WLC patients will be compensated with real acupuncture treatments after Week 26 (end of study).
33277145|NCT00771485|Experimental|1|
33277146|NCT00771485|Other|2|
33277147|NCT04002752|Experimental|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
32776196|NCT03039049|No Intervention|Control|No intervention
33277148|NCT04002752|Experimental|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
33277149|NCT04002752|Experimental|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
33277150|NCT00770159|Experimental|1|MK0822
33277151|NCT00770159|Placebo Comparator|2|Placebo to MK0822
33277152|NCT00399490|Experimental|1|
33277153|NCT00716066|Experimental|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
33277154|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
33277155|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
33277156|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
32776197|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
32776198|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
32776199|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
32776200|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
32776201|NCT04848181|Active Comparator|cyproterone acetate|20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP
33277157|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
33277158|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
33277159|NCT00398866|Experimental|3|Synvisc
33277160|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
33277161|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
33277162|NCT04780802|Other|Ballloon catheter|Balloon-assisted transarterial therapy will be performed in the first treatment session only
33277163|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
33277164|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
33277165|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
33277166|NCT03993418|Experimental|Stevia arm|stevia drops
33277167|NCT03993418|No Intervention|Control arm|No change in diet
33277654|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
33401938|NCT05222620|Other|Arm B (fractionated SRS)|Patients undergo fractionated SRS.
33081976|NCT04626895|Other|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
32776202|NCT04848181|Active Comparator|finasteride group|20 patients received finasteride 5 mg once per day for two weeks before TURP
32776203|NCT04848181|Placebo Comparator|control group|20 patients received no treatment before TURP
32776204|NCT04847791|Experimental|Group A|Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
32776205|NCT04847791|Placebo Comparator|Group B|Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
32776206|NCT04848103|Experimental|Radial extracorporeal shockwave therapy|
32776207|NCT04847869|Experimental|NIR laser treatment 200mW/cm2 dose|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
32776208|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
32776209|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
32776210|NCT04847713||Fabry's disease|children and adults male or female between 6 and 70 years old, patients with diagnosis of FD, treated and non-treated
32776211|NCT04847713||Healthy controls|age and sex-matched group of healthy subjects with a negative family history for lysosomal storage disorders and no clinical signs of FD.
32776212|NCT04376593|Experimental|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
32776213|NCT03041155|Experimental|treatment|Muscle respiratory training
32776214|NCT03041155|No Intervention|control|No intervention
32776215|NCT04375813|Active Comparator|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
32776216|NCT04375813|Placebo Comparator|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
32776217|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
32776218|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
32776219|NCT04847245|Active Comparator|Pregabalin group|Pregabalin capsules were administered orally (75 mg, tid), combined administration of duloxetine.
32776220|NCT04847245|Experimental|0.125 mg/kg esketamine group|Intravenous administration of esketamine 0.125 mg/kg，and duloxetine is co- administered orally.
32776221|NCT04847245|Experimental|0.25 mg/kg esketamine group|Intravenous administration of esketamine 0.25mg/kg，and duloxetine is co- administered orally.
32776222|NCT04847245|Experimental|0.50 mg/kg esketamine group|Intravenous administration of esketamine 0.50 mg/kg，and duloxetine is co- administered orally.
32776223|NCT04799899|Experimental|Virtual MBCT Intervention|Participants will participate in 8 weekly virtual group sessions of MBCT. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
32776224|NCT04799899|Experimental|Virtual Health Enhancement Control|Participants will participate in 8 weekly virtual group sessions that focus on cardiac health and depression education. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
32776225|NCT04840303|Experimental|Hub user group|This group receives community-based mental wellness youth hub services for young people to enhance personal strengths and overall mental well-being.
32776226|NCT04840303|No Intervention|non-hub user active control group|This group does not receive the community-based mental wellness youth hub services but other generic youth services in the community.
32776227|NCT04840303|No Intervention|non-hub user community control group|This group does not receive any youth services in the community.
32776228|NCT04854733||Referees|There will be no interventions. Motor and cognitive assessments will be conducted.
33081977|NCT04626895|No Intervention|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
33081978|NCT04626817|Active Comparator|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
33081979|NCT04626817|Placebo Comparator|Local treatment receiving group|Local treatment receiving group for acne vulgaris
32776229|NCT04854733||Athletes|There will be no interventions. Motor and cognitive assessments will be conducted.
32776230|NCT04840225||Endocarditis|100 patients diagnosed with infectious endocarditis according to DUKE criteria. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 6 months after discharge.
32776231|NCT04840225||TAVI/TEVAR patietns|30 patients undergoing elektive TAVI/TEVAR procedures. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to procedure and followed undtill 3 months after discharge.
32776232|NCT04840225||Patients with bacterial infections without endocarditis|30 patients diagnosed with with bacterial infections, without endocarditis. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 3 months after discharge.
32776233|NCT04840225||Healthy blood donors|Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to blood donation and approximately 1 week after blood donations
33277168|NCT04048031|Active Comparator|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
33277169|NCT04048031|Placebo Comparator|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
33081980|NCT04626739|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
33081981|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
33081982|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
33277170|NCT04048031|Other|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
33081983|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
33081984|NCT04627129|Experimental|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
33277171|NCT04734548|Active Comparator|Phase Ib ApTOLL|ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
33277172|NCT04734548|Placebo Comparator|Phase Ib Placebo|Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
33277173|NCT04734548|Active Comparator|Phase IIa ApTOLL|ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
33277174|NCT04734548|Placebo Comparator|Phase IIa Placebo|Placebo is administered intravenously in one arm which includes 49 patients.
33277175|NCT01589146|No Intervention|short heparin|
33277176|NCT01589146|Experimental|extended heparin|
33277177|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
33277178|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
33277179|NCT04694300|Experimental|Naproxen sodium|Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
33277180|NCT04694300|Active Comparator|Acetaminophen|Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
33277181|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
33277182|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
33277183|NCT01589224||Healthy people|
33277184|NCT04002596|Experimental|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
33277185|NCT00764621|Experimental|Arm 1|
33277186|NCT00764621|Active Comparator|Arm 2|
33277187|NCT00764621|Active Comparator|Arm 3|
33277188|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
33277189|NCT01043770|No Intervention|Routine care|Routine care
33277190|NCT04642820|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
33277191|NCT04642820|Experimental|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
33277192|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
33277193|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
33277194|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
32776234|NCT04839835|No Intervention|standard waiting room|standard chemoterapy waiting room
32776235|NCT04839835|Experimental|waiting room enriched with art objects|waiting room enriched with music, paintings and artificial plants
32776236|NCT04847401||Group 1|patients with Irritable Bowel Syndrome
32776237|NCT04847401||Group 2|normal
32776238|NCT04846699||group 1|bulls eye localization
32776239|NCT04846699||group 2|stone targeted technique renal access
32776240|NCT04846699||group 3|triangulation renal access technique
32776241|NCT04847089|Experimental|Motor Imagery BCI training|Complete intervention with motor imagery BCI training. Patients recruited by physiotherapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
33081985|NCT04626856|Experimental|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
33081986|NCT04626856|Experimental|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
33081987|NCT04626856|Experimental|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
33081988|NCT04626856|Experimental|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
33277195|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
33277196|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
33277197|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
33277198|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
33277199|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
33277200|NCT05408078|Experimental|Intervention group - Treatment as Usual (TAU) + SLEEPexpert|"SLEEPexpert is a behavioral programme for insomnia.~The TAU + SLEEPexpert group will receive a specific treatment for insomnia. This treatment will consist of the following three phases:~a face-to-face treatment initiation (kick-off) guided by a medical doctor/ psychologist in a group format~self-managed implementation of behavioral changes supported by the nursing team (individual brief contact during the week)~self-management by the patients, potentially assisted by the Webapplication after discharge from the hospital."
33277201|NCT05408078|Other|Control group - TAU + sleep monitoring|"In addition to TAU, patients in the control group (TAU + sleep monitoring) receive a smartphone app (sleep monitoring). No further interventions will be provided through this app.~TAU comprises standard clinical care, including intensive daily contacts with health care providers on the wards, medical treatment, pharmacotherapy, psychotherapy in individual and group setting, nurse support, additional therapies such as music or ergotherapy and social support, informed by current guidelines for the respective disorder and adapted to individual needs. Of note, no change to any aspects of TAU will be made. Sleep monitoring will consist of daily sleep diary entries with the help of a smartphone app."
33277202|NCT05408000|Active Comparator|ketofol|patient given titrated dose of ketofol
33277203|NCT05408000|Active Comparator|propofol|patient given titrated dose of propofol
33277204|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
33277205|NCT05407922||Laparoscopy Group|The laparoscopy group included every pregnant woman having laparoscopic intervention because of acute abdominal pain during any trimester of her pregnancy.
33277206|NCT05407922||Non-laparoscopy Group|Non-laparoscopy Group included every pregnant woman having treatment approach other than the laparoscopic approach because of acute abdominal pain.
33277207|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
33277208|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
33277209|NCT00673361|Experimental|"Chemo-Switch Regimen"|
33081989|NCT04626856|Experimental|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
33081990|NCT04626856|Experimental|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
33081991|NCT04626856|Experimental|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
33081992|NCT04626856|Experimental|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
33081993|NCT04626856|Experimental|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
33081994|NCT04626856|Experimental|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
33081995|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
33277210|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
32776242|NCT04846621|Other|group Nicorandil|women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
32776243|NCT04846621|Other|group Nifedipine|Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
33277211|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
32776244|NCT04846777|Experimental|Mindfulness ecological momentary intervention|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
32906436|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
32776245|NCT04846777|Placebo Comparator|Self-monitoring placebo|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
33277212|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
33277213|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
33277214|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
33277215|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
33277216|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
32776246|NCT04846543|Other|MRI scan 1st and 2nd year|Additionally to routinely follow up, there will be an MRI scan of enrolled patients after one and two years in some of the study sites
33277217|NCT00670007|Experimental|Zemaira®|
33277218|NCT05407688||ADHD group|Adolescents with ADHD
33277219|NCT05407688||Health group|Adolescents without ADHD
33277220|NCT05407610|Active Comparator|Conventional Radiofrequency of the genicular nerves|In the conventional radiofrequency group a intervention of 80°C at the tip is applied during 90 seconds at each nerve (superolateral, superomedial and inferomedial genicular nerves). The probe stays in place for 150 seconds at each nerve so that the time needed for each procedure is similar.
33277221|NCT05407610|Active Comparator|Cooled Radiofrequency of the genicular nerves|In the cooled radiofrequency group a intervention of 60°C measured at the tip and on average 80°C in the targeted tissue is applied for 150 seconds using the Cooled RF system at each nerve (superolateral, superomedial and inferomedial genicular nerves).
33277222|NCT05407610|Sham Comparator|Sham procedure|In the sham group a 18 gauge introducer and probe will be placed but no RF intervention will be applied. The generator will be turned on without connection to the probe for 150 seconds and the sound of the generator will be mimicked with a recording. The position of the needle will not be checked by fluoroscopy; however, the intervention team will position the fluoroscopy arm and mention the acquisition of the fluoroscopic image to the patient. This way no unnecessary radiation is used.
33277223|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
33277224|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
33277225|NCT05407298||CBD users|
33277226|NCT05407298||CBD non-users|
33277227|NCT00775385|Active Comparator|A|Standard chemotherapy
33277228|NCT00775385|Experimental|B|Customized treatment
33277229|NCT05407220|Experimental|group1|Period1: HCP1904-1
33277230|NCT05407220|Experimental|group2|Period1: HCP1904-3
33277231|NCT04003688|Placebo Comparator|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
33277232|NCT04003688|Experimental|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
33277233|NCT04003688|Experimental|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
33277234|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
33277235|NCT05406986|Experimental|the group to which the care bundle will be applied|"Patients with a score of 13 or higher on the Braden QD medical instrument risk assessment scale.~Patients with attached nasogastric tube, intubation tube and saturation probe."
33277236|NCT05406986|No Intervention|group not to be interfered with|Patients with attached nasogastric tube, intubation tube and saturation probe.
33277237|NCT00764777|Experimental|Stenting|
33277238|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
33277239|NCT00779207|Experimental|1|weight loss
33277240|NCT00779207|Experimental|2|Weight loss and exercise
33277241|NCT00779363|Experimental|Implanted Device|
33277242|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
33277243|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
33277244|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
33277245|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
33277246|NCT00772187|Experimental|1|General anesthesia + I.V pca
33277247|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
33277248|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
33277249|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
33277250|NCT04002128|Placebo Comparator|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
33277251|NCT04002128|Active Comparator|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
33277252|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
33277253|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
33277254|NCT00989378||control|normal healthy men and women
33277255|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
32776247|NCT04854655|Active Comparator|Control|Conventional resin composite
32776248|NCT04854655|Experimental|Intervention 1|Activa Presto
32776249|NCT04854655|Experimental|Intervention 2|Giomer
32776250|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
32776251|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
32776252|NCT04854421||healthy adults|Community dwelling and have no life-threatening conditions or diseases that would alter body composition from what is typical for their age, sex, ethnicity, and BMI.
32776253|NCT04846153|Other|Human-based Quantification|No intervention. No support tool will be used for quantifying airway stenosis from the bronchoscopic images collected previously.
32776254|NCT04846153|Active Comparator|Computer-based Quantifiction|Computer based support tool will quantifying airway stenosis from the bronchoscopic images collected previously.
32776255|NCT04854577|Experimental|"Intervention group: Opioid Free Anesthesia with a pecto-intercostal fascial plane block"|Patients to whom a standardized opioid free anesthesia consisting of esketamine, lidocaine and dexmedetomidine will be administered with a pre-incisional pecto-intercostal fascial plane block.
32776256|NCT04854577|Active Comparator|"Control group: Traditional Opioid-based Anesthetic Regimen"|Patients who will receive a traditional opioid based anesthetic regimen. The administered dose of opioids is at the discretion of the attending anesthesiologist.
32776257|NCT04846465||male|normal Sohag healthy male (≥18 & ≤ 60 years)
32776258|NCT04846465||female|normal Sohag healthy female (≥18 & ≤ 60 years)
32776259|NCT04846075||Ramadan Group|Diurnal fasting and spiritual practices. Operationally assessed by the level of compliance to Sawm, Salat, and Zakat.
32776260|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
32776261|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
32776262|NCT04839445|Active Comparator|General anesthesia + TAP block|Induction: remifentanil in total intravenous anesthesia (TIVA), Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Transversus abdominis plane (TAP) block: 20 minutes before surgery. Ropivacaine 0.37% 20ml + dexamethasone 2mg per side. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the bispectral index system (BIS) values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and train of four (TOF) monitoring. Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev. Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev.
32776263|NCT04839445|Active Comparator|General anesthesia + ESP block|"Erector spinae plane (ESP) block: 20 minutes before surgery. T8 level bilaterally, ropivacaine 0.37% 20ml + dexamethasone 2mg per side.~Induction: Remifentanil in TIVA, Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the BIS values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and TOF monitoring.~Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev.~Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev."
32776264|NCT04845841|Experimental|Participants receive study medication on time point 1|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
32776265|NCT04845841|Experimental|Participants receive study medication on time point 2|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
32776266|NCT04845607|Experimental|Prophylactic amiodarone|
32776267|NCT04845607|No Intervention|Conventional management|
32776268|NCT04845763||Intervention|Each patient complete the french version of the QoR-15 score (FQoR-15) at 3 times (before surgery, on Day 1, on Day 2).
32776269|NCT04853797|Active Comparator|Ivabradine|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of ivabradine (15 mg orally).
32776270|NCT04853797|Placebo Comparator|Placebo|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of placebo.
32776271|NCT04845529|Experimental|1 tDCS Parietal|Anodal tDCS applied to the right inferior parietal cortex
32776272|NCT04845529|Experimental|2 tDCS Frontal|Anodal tDCS applied to the medial frontal cortex
32776273|NCT04845529|Sham Comparator|3 Sham|Sham tDCS (control, no stimulation delivered). Following a standard sham protocol, in this condition the tDCS will be active the first 30seconds and the last 30seconds of the session, but silent during the other 19minutes
32776274|NCT04853719|Experimental|Vascular dose|Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
32776275|NCT04853719|Active Comparator|Aspirin|Aspirin 100 mg OD for 6 months
32776276|NCT04845295|Experimental|Fast Tempo|Performed training intervention with a tempo of 1 second for eccentric and 1 second for concentric phase
32776277|NCT04845295|Experimental|Slow Tempo|Performed training intervention with a tempo of 4 seconds for eccentric and 1 second for concentric phase
32776278|NCT04845373|Experimental|Mediterrenean diet|Mediterranean diet:Target macronutrient energy contributions were 40% from carbohydrate, 35%-40% from fat (with <10% of energy as saturated fat), and 20% of energy as protein.Participant in this group were trained to consume fish, legumes at least 2-3 times a week, walnuts and olive oil every day in accordance with the Mediterranean diet model.
32776279|NCT04845373|Active Comparator|Low fat diet|Low fat diet:Target macronutrient energy contributions for the low fat diet diet were 50-60% from carbohydrate, <30% from fat (with <10% of energy as saturated fat), and 20% from protein.Participants in this group were especially recommended to consume low-fat foods.
32776280|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
32776281|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will take one tablet containing 70mg alendronate."
32776282|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
32776283|NCT03040375|No Intervention|Non peer counselling|Usual health messages
32776284|NCT04839055|Experimental|Experimental: Coenzyme A 200U|Coenzyme A 200U per day
32776285|NCT04839055|Placebo Comparator|Placebo Comparator: Placebo|Abiraterone without coenzyme A
32776286|NCT04838821|Experimental|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
32776287|NCT04838821|Experimental|Placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
32776288|NCT04853485|Active Comparator|Active TMS targeting both cerebellum and right dorsolateral prefrontal cortex.|Subjects identified as with prominent negative symptoms will be randomized into active group, who will receive active rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
32776289|NCT04853485|Sham Comparator|Sham TMS targeting both cerebellum and right dorsolateral prefrontal cortex|Subjects identified as with prominent negative symptoms will be randomized into sham group, who will receive sham rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
32776290|NCT04853485|Active Comparator|Active TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into active group, who will receive active rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
32776291|NCT04853485|Placebo Comparator|Sham TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into sham group, who will receive sham rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
33277256|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
33277257|NCT04946006|Experimental|Oxytocin infusion rate 2 IU/h|The maintenance infusion rate of oxytocin will be 2 IU/h.
33277258|NCT04946006|Experimental|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
33277259|NCT04946006|Experimental|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
33277260|NCT04946006|Experimental|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
33277261|NCT04946006|Experimental|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
33277262|NCT04946006|Experimental|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
33277263|NCT04946006|Experimental|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
32776292|NCT04853485|Active Comparator|Active deep TMS using Brainways H7 coil targeting ACC|Subjects identified as with positive symptoms will be randomized into active group, who will receive active deep rTMS over ACC using H7 coil.
33277264|NCT04946006|Experimental|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
33277265|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
33277266|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
33277267|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
33277268|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|"Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.~*High grade arm enrollment complete, no additional spots"
33277269|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
33277270|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
33277271|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
33277272|NCT05357066|Active Comparator|Treatment; Nitrous Oxide 50%|A single 60-minute session of inhaled 50% nitrous oxide.
33277273|NCT05357066|Placebo Comparator|Control; Oxygen-air mixture|A single 60-minute session of inhaled Oxygen-air mixture
33277274|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
32776293|NCT04853485|Placebo Comparator|Sham deep TMS using Brainways H7 coil targeting ACC|Subjects identified with positive symptoms will be randomized into sham group, who will receive sham deep rTMS over ACC using H7 coil.
32776294|NCT04838665|Active Comparator|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)|20 infants were enrolled in Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)
33277275|NCT00775775||TBI|Patients with moderate to severe TBI
33277276|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
33277277|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
33277278|NCT00539006|Active Comparator|FFNS, FPNS|active compound
33277279|NCT00539006|Active Comparator|FPNS, FFNS|active compound
33277280|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
33277281|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
33277282|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
32776295|NCT04838665|Experimental|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)
32776296|NCT04838665|Experimental|1 instillation of 0.5% tropicamide +0.5% phenylephrine w/a cotton wick placed in the inferior fornix|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick placed in the inferior fornix (SIW)
32776297|NCT03038659||Penile Duplex|Measuring intima media thickness
32776298|NCT04845061|Placebo Comparator|nebivolol then placebo|Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks
32776299|NCT04845061|Active Comparator|placebo then nebivolol|Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks
32776300|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
32776301|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
32776302|NCT04853953||COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
32776303|NCT04853953||Non-COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
32776304|NCT04844203||Patients with unsteadiness|Patients with unsteadiness referred for an ENMG
32776305|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
32776306|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
32776307|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
32776308|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
32776309|NCT04852939|Experimental|Bowen's Technique|Bowen's Technique
32776310|NCT04852939|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy including stretching and strengthening exercises
32776311|NCT03040219|Active Comparator|Treatment group|
32776312|NCT03040219|Placebo Comparator|Control|
32776313|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
32776314|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
32776315|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
32776316|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
32776317|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
32776318|NCT04852549|No Intervention|No intervention group|The control group continued with routine training after evaluations.
32776319|NCT04852549|Experimental|Oculomotor exercise group|After the evaluation, the intervention group performed oculo-motor exercises for 4 weeks, 6 days a week, morning and evening, twice a day for 10 minutes, in addition to normal ball training. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
32776320|NCT04142125|Experimental|Experimental (riva + ASA)|Rivaroxaban 2.5mg bid + aspirin 81mg qd
32776321|NCT04142125|Active Comparator|Control (ASA alone)|Aspirin 81 mg qd
32776322|NCT04852393||Block|Patients undergoing ultrasound-guided cervical medial branch blocks as part of their usual care
32776323|NCT04852705|Experimental|candidate vaccine|
32776324|NCT04852705|Placebo Comparator|Placebo|
32776325|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
32776326|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
32776327|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
32776328|NCT04852315|Experimental|Caffeine supplementation|Acute caffeine supplementation
32776329|NCT04852315|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
32776330|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
32776331|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
32776332|NCT04852237||Pregnancies from ICSI-TESE cycles for obstructive azoospermia.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI-TESE cycles for obstructive azoospermia.
32776333|NCT04852237||Pregnancies from ICSI cycles with ejaculated sperm.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI cycles with ejaculated sperm.
32906437|NCT00910208|Experimental|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
33081996|NCT04626856|Experimental|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
33081997|NCT04626856|Experimental|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
32776334|NCT04844047|Active Comparator|FAST|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in the community. Participants attended a 30-minute fall prevention education session once per week. FAST followed the same principles as Standard, with the addition of the following goals: 1) Increase UE strength (shoulder girdle/arm) utilizing both concentric and eccentric contractions, 2) Improve trunk and neck postural control during slow and fast body motions, 3) Optimize forward descent strategies via practice of quick response reaching, landing and controlled descent with hands on the wall or on the floor as able. Training progression for strength and body control included increasing the distance standing from the wall, progressing to one arm descents, increasing reps and speed and moving to greater gravity and body weight resistance such as hands and knees position on the floor as able. Quick movement practice targeted unexpected reaching activities, balloon and ball toss
32776335|NCT04844047|Placebo Comparator|Standard|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
32776336|NCT04843969|Experimental|Stress task and smoking cue|Exposure to a psychosocial stress task followed by smoking video cues
32776337|NCT04843969|Experimental|Stress task and neutral cue|Exposure to a psychosocial stress task followed by neutral video cues
32776338|NCT04843969|Active Comparator|Control task and smoking cue|Exposure to a control task followed by smoking video cues
32776339|NCT04843969|Active Comparator|Control task and neutral cue|Exposure to a control task followed by neutral video cues
32776340|NCT04851769|Experimental|alirocumab plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
32776341|NCT04851769|Active Comparator|standard statin therapy|Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target <100 mg/dL.
32776342|NCT04843813|Experimental|Lutein|
32776343|NCT04843813|Placebo Comparator|Safflower Oil|
32776344|NCT04843189||Da Vinci Robotic Surgery Group|Da Vinci Robotic Surgery Group
32776345|NCT04843189||Laparoscopy-assisted surgery group|Laparoscopy-assisted surgery group
32776346|NCT04838899|Experimental|Treatment Arm|All metastases that fulfill the definition of oligoprogression seen on conventional imaging will be treated with standard SABR dose fractionation schemes routinely used at Sunnybrook Odette Cancer Centre. The prostate (if present and not previously treated) will be treated to a dose of 35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Spine metastases will be treated to a dose of 24 Gy in 2-3 fractions or 30-40 Gy in 5 fractions. Involved lymphadenopathy will be treated to a dose of 30-40 Gy in 5 fractions. Similarly, brain, lung, liver, and adrenal metastases will be treated with standard Sunnybrook SABR doses. Patients will remain on abiraterone during and after SABR treatments.
32776347|NCT03037957||Group A Strep Assay|
32776348|NCT04852081||patients with HR+, HER2- advanced or metastatic breast cancer|patients with HR+, HER2- advanced or metastatic breast cancer
32776349|NCT04851457|Experimental|Intervention group|The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS
32776350|NCT04851457|No Intervention|Control group|Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.
32776351|NCT04851067|Active Comparator|Dry Needling and Therapeutic Exercises (DNTEx)|"Dry Needling - A fine needle, of 5-10 mm, will be used to penetrate the skin, subcutaneous tissues, and muscle with the intent to stimulate Myofascial Trigger Point (MTrP) or mechanically disrupt tissue without the use of an anesthetic.~Therapeutic Exercises - Are exercises will be performed to achieve a specific physical benefit, including increasing and maintaining range of motion, strengthening weak muscles, increasing joint flexibility, or improving cardiovascular and respiratory function."
32776352|NCT04851067|Active Comparator|Manual Therapy and Therapeutic Exercises (MTTEx)|"Joint Mobilization - A manual therapy technique comprising of a continuum of skilled passive movements to the joint complex will be applied at varying speeds and amplitudes. It will include a low-grades/velocity (grades I and II), high grades (grades III and IV), and small- or large-amplitude passive movement techniques within the patient's physiological range of motion and within the patient's control with the intent to restore optimal motion, function, and/ or to reduce pain.~Joint Manipulation - A passive, high velocity, low amplitude thrust will be applied to a localized joint segment/s within its anatomical limit with the intent to restore optimal motion, function, and/ or to reduce pain."
32776353|NCT04838509||Patients with elevated creatine kinase|
32776354|NCT04142047||HIV|Participants (ages 60 and above) with HIV
32776355|NCT04142047||Control|Participants (ages 60 and above) without HIV
33277283|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
33277284|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
32776358|NCT04843033|Experimental|Daily oral administration of SH3809 tablet|
32776359|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
32776360|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
33081998|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
32776361|NCT04842877|Experimental|Experimental arm|Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
32776362|NCT04842565|Experimental|TACE+Sintilimab|
32776363|NCT04850755|Experimental|patients with advanced solid malignancies|Patients will be dosed with selinexor once a week continuously in a 6 week cycle. Nivolumab will be administered on biweekly of each cycle . Ipilimumab will be dosed only on D1 of each cycle . Ipilimumab will continue for a maximum of 4 cycles. Nivolumab and selinexor will continue for up to 24 months or until discontinuation criteria is met.
32776364|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
32776365|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
32776366|NCT03037801|No Intervention|Control|
32776367|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
32776368|NCT04850131|Active Comparator|Desarda|Forty-one patients who were randomly assigned to the Desarda group underwent the Desarda repair for their problem. Patients were followed for various data point values during operation, immediately after the operation, and for a period of one year post-operatively.
32776369|NCT04850131|Active Comparator|Lichtenstein|Forty-one patients randomly assigned to the Lichtenstein group underwent the standard mesh repair and were followed for the same data point values and variables for the same specified period of time.
32776370|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
32776371|NCT04838275|Experimental|Exercise Arm|antifibrotic therapy + mHealth monitoring + 12-wk mHealth home exercise prescription
32776372|NCT04838275|No Intervention|Non-Exercise Arm|antifibrotic therapy + mHealth monitoring
32776373|NCT04842487|Experimental|Treatment arm|"Lenalidomide：25mg po QN,D1-10~Rituximab: 375mg/m2, ivdrip, D1~CTX: 750mg/m2, iv or ivdrip, D1~THP: 50mg/m2, iv or ivdrip, D1~VCR： 1.4 mg/m2 , iv（max：2mg）, D1~Pred: 60mg/m2, po, D1-5"
33401939|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
32776374|NCT04842331|Experimental|RESP301 + Standard of Care (SOC)|
32776375|NCT04842331|Active Comparator|Standard of Care (SOC)|
32776376|NCT04833751||Anesthesia for cardio/neurovascular surgery or procedure|Patients undergoing anesthesia in an operating room or hybrid room for cardio/neurovascular surgery or procedure.
32776377|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
32776378|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
32776379|NCT04841941|Experimental|single arm|G4 Multifocal soft contact lens with a 54% water content for presbyopia
32776380|NCT04841863|Active Comparator|Drug Code Active Patient o DCAP|"Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
32776381|NCT04841863|Placebo Comparator|Standard care|"Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
32776382|NCT04838119||Patients with a preoperative asymptomatic COVID screening test|
32776383|NCT04833673|Experimental|PMR|"The PMR intervention involving tensing and relaxing the body muscles accompanied with deep breathing. The researchers told each~participant to sit in a soundless and breathable room and in a comfortable position before each session at their home. The participants performed tensing and relaxing for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed with deep breathing. The participants were instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Moreover, throughout this exercise, the participants imagined a wave of relaxation flowing over their body."
32776384|NCT04833673|Experimental|BRT|Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
32776385|NCT04833673|No Intervention|CG|"Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on Living with MS; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care."
32776386|NCT04837885|Experimental|68Ga-DOTA-peptides PET/CT|68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
32776387|NCT04837885|Experimental|LUTATHERA® by intra-arterial hepatic injection (IAH)|One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations
32776388|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
32776389|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
32776390|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
32776391|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
32776392|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
32776393|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
32776394|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
32776395|NCT03037879|Experimental|SPT|Speed of Processing Training
32776396|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
32776397|NCT03037879|Experimental|mSMT|Story Memory Technique
32776398|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
32776399|NCT04833595|Experimental|Mindfulness Arm|"A recommendation on healthy food intake will be sent to participants. At the end of each week, participants will be required 1) to submit THREE photos of the meals that they are most satisfied with in terms of healthiness and 2) using the photos to answer a questionnaire about their diet. The photos and completed questionnaire must be submitted to the research investigator each week for a total of 8 weeks. After 8 weeks, participants will be required to get tested for your fasting total cholesterol and blood glucose level in the appointed pharmacy for the second time. It is estimated to require 15-30 minutes of their time weekly.~The questionnaire used for experimental group contains reflective questions as part of the mindfulness intervention."
32776400|NCT04833595|Active Comparator|Non-mindfulness Arm|Everything is similar to the experimental arm. However, the questionnaire used for control group does not contain reflective questions to serve as control group.
32776401|NCT04833205|Experimental|Leptomeningeal metastases received EGFR-TKI and Nimotuzumab|The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI
32776402|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
32776403|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
32776404|NCT03036631||General Anesthesia|
32776405|NCT04371913|Other|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
32776406|NCT04370665|Experimental|Open label single arm|Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
32776407|NCT04312243|Experimental|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
32776408|NCT04312243|No Intervention|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
32776409|NCT04841551|Other|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
32776410|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
32776411|NCT04833049|Experimental|TAK-994 Dose 1 + [14C]TAK-994 Dose 2 + [14C]TAK-994 Dose 3|TAK-994 Dose 1, tablet, orally, on Day 1, followed by [14C]TAK-994 Dose 2, infusion, intravenously, on Day 1 of Part A, followed by a washout period of at least 8 days, further followed by [14C]TAK-994 Dose 3, suspension, orally, on Day 1 of Part B.
32776412|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
32776413|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
32776414|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
32776415|NCT04841161|Other|Healthy subjects|The healthy adults who have not any neurological, musculoskeletal or rhematogical disease, a history of orthopedic surgery on spine or lower extremity. Their age should be ranged between 20 - 75 years.
32776416|NCT04841161|Experimental|Stroke subjects|Stroke patients were included if they were: (1) diagnosed with unilateral ischemic or hemorrhagic stroke; (2) a minimum of six months post stroke ; (2) able to stand without support for 1 minutes; (3) able to understand and follow verbal instructions. and (4) medically stable with physician release.
32776417|NCT04841239|Experimental|Herbal topical formulation|
32776418|NCT04841239|No Intervention|Control|
32776419|NCT04841395||PE|Premature ejaculation group
32776420|NCT04841395||CG|Control group (Healthy subjects)
32776421|NCT03036241|Experimental|Drug-eluting balloon|
32776422|NCT03036241|Active Comparator|Conventional angioplasty|
32776423|NCT03037333|Other|fluoroscopy|
32776424|NCT03037333|Other|ECG/ECHO|
32776425|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
32776426|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
32776427|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
33277285|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
32776428|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
32776429|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
32776430|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
32776431|NCT04832893|Active Comparator|Use of FFP2 respirator|Using of FFP2 respirator during the 30 minutes test
32776432|NCT04832893|Active Comparator|Use of surgical mask|Using of surgical mask during the 30 minutes test
32776433|NCT04832893|Sham Comparator|no mask|The 30 minutes test will be carried out without mask
33277286|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
32776434|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
32776435|NCT04837651||Ocrelizumab Treated Multiple Sclerosis Patients|
32776436|NCT04837651||Natalizumab Treated Multiple Sclerosis Patients|
32776437|NCT04832581|Experimental|Experimental Group|The experimental group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. Both groups were informed that the study was concluded.
32776438|NCT04832581|No Intervention|Control Group|The control group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. After the research was completed, information was given in order to avoid bias and the brochure was delivered. Both groups were informed that the study was concluded.
32776439|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
32776440|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
33277287|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
33277288|NCT04521374|Experimental|Standard Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 16g protein.
33277289|NCT04521374|Experimental|Standard Protein Fortified Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 25g protein.
33277290|NCT04521374|Experimental|Texture Modified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 340kcal, 16g protein.
33277291|NCT04521374|Experimental|Texture Modified Protein Fortified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 350kcal, 25g protein.
33277292|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
33277293|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
32776441|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
32776442|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
33277294|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
33277295|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
33277296|NCT02557295||Remsima™|Patients who are taking Remsima™ for the treatment
33277297|NCT02557295||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
33277298|NCT02557295||Biologic naive patients|Biologic naive patients (in Korea only)
33277299|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
33277300|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
33277301|NCT04494698|Active Comparator|DuoTherm VibraCool Back Device|A low back pain relief device incorporating multiple speeds and patterns of vibration and optional heat, cold, or pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice daily for 20 minutes.
33277302|NCT04494698|Active Comparator|Multimodal TENS Unit|LG SMART TENS stimulator is a portable electrotherapy device featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
33277303|NCT00776243||wDM|Early diabetes
33277304|NCT00776243||pDM|Poorly controlled diabetic patients
33277305|NCT04857398|Experimental|Insulin icodec|The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
33277306|NCT00776321|Placebo Comparator|1|
33277307|NCT00776321|Experimental|Eprotirome dose 1|
33082331|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
33082332|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
33277681|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
33277682|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
33082333|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
33277683|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
33277684|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
33277685|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
33277686|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
33277687|NCT00774605|Experimental|Varenicline free base solution|
33277688|NCT00774605|Experimental|Varenicline transdermal delivery system|
33277689|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
32830707|NCT03285204||Healthy control|
32830708|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
33082334|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
33082335|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
33082336|NCT04618939|Experimental|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
33277690|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
33082337|NCT04618939|Active Comparator|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
33082338|NCT00562900|Active Comparator|A, robotic|
33082339|NCT00562900|Active Comparator|B, laparoscopic|
33277691|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
33277692|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
33277693|NCT00782015|Active Comparator|almonds|3 oz/d almonds
33277694|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
33277695|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
33277696|NCT00784433|Experimental|alcohol 1|
33277697|NCT00784433|Experimental|alcohol 2|
33277698|NCT00784433|Placebo Comparator|control|
33277699|NCT00774917|Experimental|Numen|
33277700|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
33277701|NCT00784511|Placebo Comparator|2|placebo
33277702|NCT00784589|Experimental|Rituximab|
33277703|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
33277704|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
33277705|NCT05022641|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
33082340|NCT04618900|Experimental|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
33082341|NCT04618900|Placebo Comparator|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
33082342|NCT04619134|Experimental|NCSR Program|Non Pain Contingent Spinal Rehabilitation
33082343|NCT04619134|Active Comparator|Conventional Physical therapy|Conventional Physical Therapy
33082344|NCT00243477|Active Comparator|Treatment|Escitalopram given
33082345|NCT00243477|Placebo Comparator|Placebo|Placebo given
33082346|NCT04619173|Experimental|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
33082347|NCT04619173|Active Comparator|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
33082348|NCT04618783|Experimental|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
33082349|NCT04618783|Experimental|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
33277706|NCT05022641|No Intervention|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
33277707|NCT00784745|Experimental|Dexamethasone|
33277708|NCT00534638|Experimental|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
33277709|NCT00534638|Experimental|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
33277710|NCT00534638|Active Comparator|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
33277711|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
33277712|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
33277713|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
33277714|NCT00996086||CRT device-recipients|
33277715|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
33277716|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
33318122|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
33082350|NCT04618783|Experimental|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
33082351|NCT04618783|Active Comparator|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
33082352|NCT04618783|Active Comparator|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
33082353|NCT04618666|Experimental|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
33082354|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
33082355|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
33405342|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
33082356|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
33082357|NCT04618510|Experimental|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
33082358|NCT04618510|Sham Comparator|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
33082359|NCT04618549|Active Comparator|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
33082360|NCT04618549|Active Comparator|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
33277717|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
33277718|NCT00996242|Experimental|L-lysine|
33277719|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
33277720|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
33277721|NCT05346224|Experimental|Treatment group|HLX11 combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
33277722|NCT05346224|Active Comparator|Control group|Perjeta combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 or Perjeta combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
33277723|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
33277724|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
33277725|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
33277726|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
33277727|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg as the high dose group.
33277728|NCT00785057||1|Hypertension patients with history of stroke
33277729|NCT00785057||2|Hypertension patients without history of stroke
33277730|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
33277731|NCT00782405|Experimental|1|quetiapine
33277732|NCT00782405|Active Comparator|2|mirtazapine
33277733|NCT04000646|Other|standard care|Standard care non-pharmacologic interventions during anesthesia induction
33277734|NCT04000646|Experimental|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
33277735|NCT05250362|Experimental|Treatment|
33277736|NCT00790283|Experimental|Numen|
33277737|NCT00790283|Active Comparator|Vision/MiniVision|
33277738|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
33277739|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
33277740|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
33277741|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
33277742|NCT00785135|Active Comparator|Standard (Treatment)|
33277743|NCT00785135|Sham Comparator|Placebo (control)|
33277744|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
33277745|NCT00993902|Active Comparator|Double IUI|
33277746|NCT02555735||Solid Tumor Cancer|Participants with solid tumor cancer treated with physician-choice standard of care chemotherapy.
33277747|NCT05343260|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
33277748|NCT05343260|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
33277749|NCT05014295|No Intervention|Control Group|Survey questions at baseline and at one week. The control group will have had one week to reflect on the questions, and investigators anticipate some influence of this on responses.
33277750|NCT05014295|Active Comparator|Intervention Group|The intervention group will be prompted about accessing their medical records from the major local health systems online, with links to directions provided by each hospital system. They will then be asked to fill out the same questionnaire.
33277751|NCT05340686|Experimental|Braining high intensity|Moderate to vigorous physical exercise, supervised by psychiatric staff 3 times per week
33277752|NCT05340686|Active Comparator|Braining relaxing exercise|Relaxation, light yoga or stretching exercise, supervised by psychiatric staff 3 times per week
33277753|NCT05340686|Active Comparator|Information about physical exercise|Written and oral information about health benefits from physical exercise, provided by researcher on one occasion.
33082361|NCT04618549|Active Comparator|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
33082362|NCT04618588|Experimental|"Sinus elevation using Low Window Sinus Lift technique"|
33082363|NCT04618159|Other|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
33082364|NCT04618120|Experimental|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
33102307|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
33277754|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
33277755|NCT04001660|Experimental|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
33277756|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
33277757|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
33277758|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
33277759|NCT01564550||type 2 diabetes|
32830341|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
32830342|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
32830343|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
32830344|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
33102308|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
33102309|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
33277760|NCT01564550||healthy subjects|
33277761|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
33277762|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
33277763|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
33277764|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
33277765|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
33277766|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
33277767|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
33277768|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
33277769|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
33277770|NCT00785837|No Intervention|Before Hidrotherapy|
33277771|NCT00785837|Experimental|Hidrotherapy|
33277772|NCT00785915|Experimental|1|
33277773|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
33277774|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
33277775|NCT00785993|Experimental|Group I|vitrified donor oocytes
33277776|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
33277777|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
33277778|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
33277779|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
33082365|NCT04618120|Experimental|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
33082366|NCT04618120|No Intervention|Control Group|Only patient education on general considerations.
33082367|NCT04618276|Experimental|Arm A (MAL group)|"Skin swab for culture in the groin for baseline~PDT with 5% topical methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX~Skin swab for culture~Skin antisepsis~Skin swab for culture"
33082368|NCT04618276|Experimental|Arm B (Methylene Blue group)|"Skin swab for culture in the groin for baseline~PDT with 0.01% methylene blue based photosensitizer (NF-031)~Skin swab for culture~Skin antisepsis~Skin swab for culture"
33082369|NCT04618276|No Intervention|Control group|"Skin swab for culture in the groin for baseline~NO PDT~Skin antisepsis~Skin swab for culture"
33082370|NCT04618042|Experimental|FX06|
33082371|NCT04618042|Placebo Comparator|Placebo|
33082372|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
33082373|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
33082374|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
33082375|NCT04617691|Experimental|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
33082376|NCT04617691|Experimental|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
33082377|NCT04617613|Active Comparator|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
33082378|NCT04617613|Experimental|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
33082379|NCT04617652|Active Comparator|Group M|Magnesium group
33082380|NCT04617652|Placebo Comparator|Group C|Control group
33277780|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
33277781|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
33277782|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
33277783|NCT04047017|Experimental|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
33082381|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
33082382|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
33277784|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
33277785|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
33277786|NCT00786149|Active Comparator|2|Varenicline plus brief advice
33277787|NCT00997100|Other|ABR-215757|
33277788|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
33277789|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
33277790|NCT04001738|Active Comparator|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
33277791|NCT04001738|No Intervention|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
33277792|NCT00993980|Experimental|1|qigong
33277793|NCT00993980|Active Comparator|2|exercise therapy
33277794|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
33277795|NCT02725814|Experimental|Sucrose|
33277796|NCT00782873||obese subjects|BMI > 35
33277797|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg~1 arm for maintenance period (ABA ~10 mg/kg)"
33277798|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period~1 arm for maintenance period"
33082383|NCT04617730|Active Comparator|Control arm|
33082384|NCT04617730|Experimental|Interventional arm|
33082385|NCT04617223|Other|Treatment|
33082386|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
33082387|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
33082388|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
33082389|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
33082390|NCT04616989|Experimental|Psycho-education intervention arm|Participants will receive psycho-education materials
33082391|NCT04616989|Active Comparator|Comparator arm|Participants will receive COVID-19 leaflets
33082392|NCT04617106|Active Comparator|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
33082393|NCT04617106|Active Comparator|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
33277799|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
33277800|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
33277801|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
33277802|NCT00782951|Experimental|Org 28611|
33277803|NCT00782951|Active Comparator|morphine sulfate|
33102310|NCT02919605|Experimental|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
33277804|NCT00782951|Placebo Comparator|Placebo|
33277805|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
33277806|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
33277807|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
33277808|NCT00994058|Experimental|Intevention with Inhibitor|
33277809|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
33277810|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
33277811|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
33277812|NCT04047407||Fibromyalgia|
33277813|NCT04047407||Healthy volunteers|
33277814|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
33277815|NCT00997490|Placebo Comparator|Placebo|
33277816|NCT00783107|Experimental|Cyclosporine|
33277817|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
33277818|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
33277819|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
33277820|NCT00783185|Active Comparator|CG|Control group
33277821|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
33277822|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
33277823|NCT00783341|Experimental|GAP-134|
33277824|NCT00783341|Placebo Comparator|placebo|
33277825|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
33277826|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
33277827|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
33277828|NCT00783497||1|Caucasian Americans
33277829|NCT00783497||2|African Americans
33277830|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
33277831|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
33277832|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
33082394|NCT04617145|Active Comparator|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
33102311|NCT02919605|Experimental|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
33277833|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
33277834|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
33277835|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
33277836|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
33277837|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
33277838|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
33277839|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
33277840|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
33277841|NCT03705910|Active Comparator|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
33277842|NCT03705910|Active Comparator|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
33277843|NCT03705910|No Intervention|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
33277844|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
33277845|NCT00790517|No Intervention|2|Usual care
33277846|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
33277847|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
33277848|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
33277849|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
33277850|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
33277851|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
33277852|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
33277853|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
33277854|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
33277855|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
33277856|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
32830709|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
32830710|NCT00149487|Experimental|Experimental: Tailored Problem Solving Intervention|Participants will be randomized to follow a tailored problem solving intervention for the child.
32830711|NCT00149487|Active Comparator|Control: Family Education Intervention|Participants will be randomized to follow a family education intervention.
32830712|NCT00136695|Experimental|anastrozole|anastrozole
32830713|NCT00136695|Placebo Comparator|placebo|placebo
32830714|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
32830715|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
32900131|NCT05265884|Experimental|Group A (Kinesio taping group)(Experimental group):|This group includes 30 patients who will receive Kinesiotaping, in additional to traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
33277857|NCT00783731|Experimental|Low dose midazolam|
33277858|NCT00409708|Active Comparator|1|
33277859|NCT00409708|Other|2|
33277860|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
33277861|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
33277862|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
33277863|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
33277864|NCT01324336||4-17 years, receiving 6-MP|
33277865|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
33277866|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
32776452|NCT04428697|Experimental|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
32776453|NCT04428697|Active Comparator|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
32776454|NCT04831489||deep sedation|Anesthesia will be induced using titrated doses of propofol (0.5-1.5 mg/kg) and fentanyl (25-50 μg) initially to carefully maintain spontaneous breathing yet maintaining airway patency. Once adequate jaw relaxation is achieved, the endoscopy probe will be inserted. Maintenance of sedation will be carried out using propofol infusion between 80-120 mcg/kg/min. Additional dose 25-50 mg propofol will be given to the patient if spontaneous movement occurs
32776455|NCT04831489||Genral anesthesia|"After mask pre-oxygenation, anesthesia will be induced with (2 mg/kg) propofol and (1 μg /kg) fentanyl. The neuromuscular blockade will be achieved with (0.5 mg/kg) atracurium followed by tracheal intubation. Anesthesia will be maintained to keep the end-tidal anesthetic concentrations within 1 MAC for sevoflurane.~The neuromuscular blockade will be maintained with intermittent doses of atracurium (0.1mg/kg). Mechanical ventilation is adjusted with fresh gas flow oxygen in air 30-40% at a rate of 2 L/min to maintain end-tidal carbon dioxide of 35-40 mm Hg. Reversal of neuromuscular blockade will be achieved by intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg."
32776456|NCT04831879|Experimental|Group A AMPS - sham|Treatment phase 1: AMPS Treatment phase 2: sham
32776457|NCT04831879|Experimental|Group B sham - AMPS|Treatment phase 1: sham Treatment phase 2: AMPS
32776458|NCT04824937|Experimental|Telaglenastat + Talazoparib|"During 28 day study cycles, participants will receive:~Telaglenastat 2x daily at a predetermined dose~Talazoparib 1x daily at a predetermined dose"
32776459|NCT04824937|Experimental|Telaglenastat + Talazoparib Staggered|If a beneficial response is seen with the Arm 1 Telaglenastat + Talazoparib combination, participants will receive telaglenastat alone 2x daily at a predetermined dose with the addition of talazoparib at 1x daily at a predetermined dose if the disease gets worse.
32776460|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
32776461|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
32776462|NCT04836949|Experimental|Shear Wave Elastography Group|
32776463|NCT04836949|Active Comparator|Conventional ultrasonography Group|
32776464|NCT04836793||Patients with cancer|"Patients with active treatment in adjuvant/induction setting,~Patients with active treatment in metastatic/relapse setting,~Patients without active treatment (last treatment above 6 months)."
32776465|NCT04836793||Patients without cancer but aged above 70 years|
32776466|NCT04836793||Healthy person|
32776467|NCT04428073|Experimental|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
32776468|NCT04428073|Experimental|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
33082395|NCT04617145|Active Comparator|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
33082396|NCT04616911|Active Comparator|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
32776469|NCT04824313||COVID-CAVA PE|Patients with RT-PCR proven COVID-19 disease and CTA proven pulmonary embolism
32776470|NCT04824313||COVID-CAVA non-PE|Patients with RT-PCR proven COVID-19 disease and no evidence of pulmonary embolism on CT
32776471|NCT04824235|Experimental|Amnoitic Chorion Membrane and xenograft|extraction sockets where ridge preservation will be performed using Chorion Membrane with Xenograft
32776472|NCT04824235|Active Comparator|Amnoitic Chorion Membrane only|extraction sockets where ridge preservation will be performed using Chorion Membrane Alone
32776473|NCT04824001||STEMI|ST-segment elevation myocardial infarction (STEMI) is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial necrosis.
32776474|NCT04824001||NSTEMI|If there is elevation of the blood markers suggesting heart damage, but no ST elevation seen on the EKG tracing, this is known as a non ST-elevation myocardial infarction (NSTEMI).
32776475|NCT04823689|Sham Comparator|Dorsal decubitus|The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.
32776476|NCT04823689|Experimental|Ventral decubitus|The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
33082397|NCT04616911|Active Comparator|LIFT|Ligation of the intersphincteric fistula tract
33082398|NCT04616638|Experimental|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
32776477|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
32776478|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
32776479|NCT05618431|Other|pregnant women|Pregnant woman 18 and 50 years oldbetween 10 and 40 weeks of pregnancy
32776480|NCT04823767|Experimental|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
33277867|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
33277868|NCT03993340||1|Rescue stenting group
32776481|NCT04836871|Experimental|Double filtration plasmapheresis (DFPP) combined with chemotherapy|
32776482|NCT04836715||Parkinson's Disease|Individuals with idiopathic Parkinson's Disease and no other neurological disease
32776483|NCT04836715||Other Neurological Disorders|Individuals with one neurological disorder other than Parkinson's Disease (e.g. Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Parkinsonism)
32776484|NCT04836715||Healthy|Individuals without any neurological disorder
32776485|NCT04836481||LEV8|Levetiracetam 1000 mg every 8 hours
32776486|NCT04836481||LEV12|Levetiracetam 1000 mg every 12 hours
32776487|NCT04831333||Active CMVR|The UWF images of cytomegalovirus retinitis (CMVR) included various patterns: hemorrhagic necrotizing lesion, granular lesion, frosted branch angiitis, and optic neuropathy lesion. Active CMVR lesion was defined as obvious opacity (mild, moderate, severe, very severe)
32776488|NCT04831333||Inactive CMVR|Inactive CMVR lesion was defined as a lack of opacity or questionable/equivocal activity.
32776489|NCT04831333||Non-CMVR|The non-CMVR images included normal retina and other retinopathies such as HIV-related microvascular retinopathy, diabetic retinopathy, retinal detachment, vitreous hemorrhage.
32776490|NCT04831255|Experimental|ZILRETTA|Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.
32776491|NCT04831177|Active Comparator|Patients planned to undergo Femtosecond laser FS assisted LASIK|In FS group, Allegretto WaveLight FS-200 femtosecond laser was used to create flaps with flap thickness planned to be 100 um.
33277869|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
32776492|NCT04831177|Active Comparator|Patients planned to undergo Microkeratome MK assisted LASIK|In MK group, Moria 2 Microkeratome was used to create flaps with flap thickness planned to be 100 um.
32776493|NCT02432235|Experimental|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
32776494|NCT02432235|Experimental|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
32776495|NCT02432235|Experimental|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
32776496|NCT02432235|Experimental|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
33082399|NCT04616638|Active Comparator|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
33082400|NCT04616872|Experimental|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
33277870|NCT04047173|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
33277871|NCT04047173|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
33277872|NCT01324492|Experimental|RAD001|
33277873|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
33277874|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
33277875|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
33277876|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
33277877|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
32776497|NCT02432235|Experimental|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
32776498|NCT02432235|Experimental|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
33082401|NCT04616872|Placebo Comparator|Placebo-LDE|Lipid nanoparticle (LDE)
33082402|NCT04616755|Active Comparator|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
33082403|NCT04616755|Active Comparator|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
33082404|NCT04616755|Active Comparator|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
33082405|NCT04616716|Experimental|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
33082406|NCT04616716|Experimental|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
33082407|NCT04616716|Experimental|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
33082408|NCT04616716|Experimental|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
33082409|NCT04616716|Experimental|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
33082410|NCT04616716|Experimental|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
33082411|NCT04616521|Experimental|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
33082412|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
33082413|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
33277878|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
33277879|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
33277880|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
33277881|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
33277882|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
33277883|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
33277884|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
33277885|NCT00994136|No Intervention|Heparin lock|
33277886|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
33277887|NCT00997802|Other|CT colonography and optical colonoscopy|
33277888|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
33277889|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
33277890|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
33277891|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
33277892|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
33277893|NCT03628846||Traumatically Injured Adolescent|
33277894|NCT03628846||Not Traumatically Injured Adolescent|
33277895|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
33277896|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
33277897|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
33277898|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
33277899|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
33277900|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
33277901|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
33277902|NCT05309876|Experimental|Usage of tool|Participants get access to the tool and use it regularly
33277903|NCT05309876|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease is followed via clinical registries.
32776499|NCT02432235|Experimental|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
32776500|NCT02432235|Experimental|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
32776501|NCT02432235|Experimental|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
32776502|NCT02432235|Experimental|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
32776503|NCT02432235|Experimental|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
32776504|NCT02432235|Experimental|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
32776505|NCT04916535|Experimental|diagnostic flow|all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit
32776506|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
32776507|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
33082414|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
33082415|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
33082416|NCT00563173|Other|1|Low dose
33082417|NCT00563173|Other|2|Medium dose
33082418|NCT00563173|Other|3|High dose
33082419|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
33082420|NCT00563212|Experimental|A1|
33082421|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
33082422|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
33082423|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
33082424|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
33082425|NCT00221507|No Intervention|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
33082426|NCT00221507|Active Comparator|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
33401961|NCT05255341|Experimental|roll pedicle connective tissue graft with bovine bone|"sulcular incisions were performed on the buccal and lingual aspects of the teeth to be extracted~Atraumatic extraction was made by periotome.~After tooth extraction the soft tissue was reflected at least 4 mm beyond the alveolar crest margin and the socket was filled with bovine derived xenograft and covered with roll pedicle connective tissue graft as a barrier membrane.~This pedicle is rolled under the buccal mucosa.The palatal connective tissue pedicle graft was outlined by full thickness incision along the oblique incision line, and parallel incision given from the mesial line angle of target place and reflected coronally up to the crest of the ridge defect. then a partial thickness incision was made extending beyond the line angles of adjacent incisors and mucogingival junction, leaving the periosteum on the bone.~the pedicle graft was rolled from the apical end and secured with interrupted sutures to the labial flap."
32776508|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
32776509|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
32776510|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
32776511|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
32776512|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
32776513|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
32776514|NCT04942353|Experimental|Home-based Exercise Rehabilitation|
32776515|NCT04942353|Active Comparator|Usual Care|
32776516|NCT04942275|Experimental|Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification|"All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:~The standard functional assessment recommended before performing an SBRT.~A perfusion PET/CT scan~The treatment planning will be carried out in 2 stages:~First, an anatomical planning will be carried out, blinded to the PET results.~Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new functional lung volume constraint defined by pulmonary PET, will then be carried out.~A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months"
33277904|NCT05254808|Active Comparator|Fosfomycin in a single dose of 3000mg on day 1|Fosfomycin-trometamol Single dose scheme: 3000mg taken orally once (arm A)
33277905|NCT05254808|Experimental|Extended dosing of 3000mg fosfomycin on day 1 and 3|Fosfomycin-trometamol Extended dosing scheme: 3000mg taken orally on day 1 and day 3 (arm B)
33277906|NCT05254808|Active Comparator|Nitrofurantoin 100mg bid (slow release) for 5 days|Nitrofurantoin 100mg b.i.d. in slow release form (Furabid) taken orally for 5 days (arm C)
32776517|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
33277907|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
33277908|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
33277909|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
33277910|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
33277911|NCT00998270|Active Comparator|Autologous arm|
33277912|NCT00998270|Experimental|Allogeneic arm|
33277913|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
33277914|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
33277915|NCT00994526|Placebo Comparator|Ham|
33277916|NCT00994526|Experimental|Ham + calcium|
33277917|NCT00994526|Experimental|Ham + vitamin E|
33277918|NCT00998504|Placebo Comparator|placebo|starch pill
33277919|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
33277920|NCT00788684|Experimental|ABT-263 + rituximab|
33277921|NCT00454220|Placebo Comparator|Placebo|
33277922|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
33277923|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
33277924|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
33277925|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
33277926|NCT05219552|Experimental|Intervention group- lactation support and unconditional cash transfers|Women in this arm will receive personal lactation support from a professional lactation specialist at 5 time points: pregnancy and at 2-weeks, 4-weeks, 6-weeks and 3-months postpartum. Women in the intervention group will also receive monthly unconditional cash transfers of 10,000 Kenyan shillings sent directly to a a mobile phone-based money transfer service accounts associated with their personal cell phone.
33277927|NCT05219552|No Intervention|Control group- standard care|The women enrolled in the control arm will receive standard care at a clinic similar to, but distinct from, the intervention site.
33277928|NCT00998972|No Intervention|control|control arm without any specific intervention
33277929|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
33277930|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
33277931|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
33277932|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
33277933|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
33277934|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
33277935|NCT05219084|Placebo Comparator|placebo group|5ml of normal; saline-injected subcutaneously
33277936|NCT05219084|Active Comparator|Hip denervatiopn|Hip denervation with lidocaine 2% to each genicular branch, 2ml at each point
33277937|NCT05219084|Active Comparator|Inra-articular hydration|10 ml of normal saline injected inside the hip under ultrasound guidance
33277938|NCT05219084|Active Comparator|compined group|hip denervation and intra-articular hydration were conducted together in this group
32776518|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
33277939|NCT05133908|Active Comparator|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
33277940|NCT05133908|Experimental|dCBTi-ADHD|Participants assigned to this condition will receive a 7-module digital cognitive behavioral therapy for insomnia (dCBTi) tailored for adults with ADHD
33277941|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
33277942|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
33277943|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
33318123|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
33318124|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
32776519|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32935877|NCT05447858|Experimental|Neck-specific exercise in addition to SWEA|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control [15, 30]. To ensure that the exercises are learned and performed correctly, the participant will meet with a physiotherapist a total of four times, once during weeks 2, 3, 4, and 7 (week 1=first visit for a clinical examination due to law) for instruction, guidance, and support. In addition to photos, videos, and text regarding the exercises, the digital support (web-based program at the support and treatment platform Inera via 1177 managed by the County Councils) also contains information about why it is important to exercise the neck muscles, factors that may cause neck pain, how relapses can be handled, ergonomic advice related to the neck, and an exercise diary.
33277944|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
33277945|NCT05239754|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
33277946|NCT00999128|Experimental|Part 1|
33277947|NCT00999128|Experimental|Part 2|
32935878|NCT04934995||Study Population|Adult women undergoing cesarean delivery at The Ohio State University Wexner Medical Center under spinal anesthesia, ASA physical status I-III with a BMI during pregnancy ≥ 35 kg/m2 and singleton pregnancy.
32935879|NCT05447780|Experimental|General anesthesia|induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg maintenance anesthesia: sevoflurane, doses of the inhalation agent according to bispectral index (BIS) monitor ( target BIS level 40-60) and fentanyl 1-5 mcg\kg\h.
33277948|NCT00999206|Experimental|1|
33277949|NCT00999206|Experimental|2|
33277950|NCT00999206|Experimental|3|
33277951|NCT00999206|Active Comparator|4|
33277952|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
33277953|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
33277954|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
33277955|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
33277956|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
33277957|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
33277958|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
33277959|NCT01043302||Chemotherapy|Only treated with chemotherapy
33277960|NCT01043380|Experimental|LZ group|
33277961|NCT01043380|Active Comparator|L group|
33277962|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
32935880|NCT05447780|Experimental|Combined anesthesia: general anesthesia and Erector spinae plane block (ESP block)|"induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg ESP- block with US control with single shot of local anesthetic ( bupivacaine 0.375% or 0.25% 20-30 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\kg\h."
32935881|NCT05447780|Experimental|Combined anesthesia: General anesthesia and Thoraco-lumbar interfacial plane block (TLIP block)|"induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg TLIP- block with US control with single shot of local anesthetic ( bupivacaine 0.25% 15 ml or mixed bupivacaine 0.25% 7.5 ml and lidocaine 2% 7.5 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\kg\h."
32935882|NCT04928989|Active Comparator|Convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
32935883|NCT04928989|Experimental|Neck-specific exercise in addition to convergence dialogue meeting|Neck-specific exercise with digital web-based support and four visits to a physiotherapist. Neck-specific exercise will be performed based on a well-structured framework of neck-specific exercise for facilitation of deep neck muscles, increased muscle coordination, improved neck posture and increased neck muscle endurance. Plus additional convergence dialogue meeting as treatment arm no 1.
32935884|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
32935885|NCT05447702|Experimental|Camrelizumab + Apatinib + Chemotherapy|Participants received neoadjuvant therapy with four 4-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and nab-paclitaxel (125 mg/m2, qw), followed by four 2-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and epirubicin (90 mg/m2, q2w) + cyclophosphamide (600 mg/m2, q2w).
32935886|NCT04927819||short-length implant (<6.5 mm)|
33277963|NCT01044316|Active Comparator|Arm 1|
33277964|NCT01044316|Active Comparator|Arm 2|
33277965|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
33277966|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
33401962|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
32776520|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32776521|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
33401963|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
32776522|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32776523|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
32776524|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
32935887|NCT04927819||non-short length implant (≥6.5 mm)|
32935888|NCT05447546|Active Comparator|1 mg HT-6184 QD|Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1
32935889|NCT05447546|Placebo Comparator|1 mg Placebo QD|Cohort 1 - 2 subjects x placebo, QD on Day 1
33401964|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
33401965|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
33401966|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
33401967|NCT02157662||No coronary disease and risk factors >=3|
33401968|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
33401969|NCT02157662||No coronary disease and risk factors 0-1|
32776525|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
32776526|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
32776527|NCT04911465||Pediatric Trauma Patients|All pediatric patients >31 days who meet criteria for highest level trauma activation (Level Red or Level 1) at the Children's Hospital Colorado.
32776528|NCT05370573||Patients with central nervous system infections admitted to intensive care|
32935890|NCT05447546|Active Comparator|2 mg HT-6184 QD|Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1
32935891|NCT05447546|Placebo Comparator|2 mg Placebo QD|Cohort 2 - 2 subjects x placebo, QD on Day 1
32935892|NCT05447546|Active Comparator|3 mg HT-6184 QD|Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1
32935893|NCT05447546|Placebo Comparator|3 mg Placebo QD|Cohort 3 - 2 subjects x placebo, QD on Day 1
32935894|NCT05447546|Active Comparator|4 mg HT-6184 QD|Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1
32935895|NCT05447546|Placebo Comparator|4 mg Placebo QD|Cohort 4 - 2 subjects x placebo, QD on Day 1
32935896|NCT04616287|Experimental|dementia with Lewy bodies|
32935897|NCT04616287|Active Comparator|Alzheimer disease|
32935898|NCT04616287|Sham Comparator|healthy elderly subjects|
32935899|NCT05447468|Experimental|scapular muscles strengthning group|Patients in this group A will receive scapular muscles (lower trapezius, middle trapezius and serratus anterior) strengthening along with conventional physiotherapy (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) for 6 weeks.
32935900|NCT05447468|Active Comparator|conventional physiotherapy group|Patients in this group B will receive conventional physiotherapy only (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) 3 sessions per week for 6 weeks.
32935901|NCT04604431|Experimental|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
32935902|NCT04604431|No Intervention|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
32935903|NCT05449730||Yoga instructor|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f)practice yoga three to six days per week and at least ten years of experience in yoga
32935904|NCT05449730||Healthy adult control|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f) no experience with yoga training; (g)participated in regular exercise 2 or 3 times a week
32935905|NCT04587739|Experimental|Experimental group|
32935906|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
33401970|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
33401971|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
33401972|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
33405343|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
32935907|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current), typically but not always supported by a positive PCR test for viral RNA
32935908|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavy or extensive COVID-19 exposure in the workplace or home environment
32935909|NCT05449574||people with MS|People with MS with relapsing-remitting form
32935910|NCT05449574||healthy people|people from the age of 30-45 years old
32935911|NCT04579159|Other|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
32935912|NCT05447390|Active Comparator|Pulmonary Hypertension|
32935913|NCT05447390|Active Comparator|Healthy Control|
32935914|NCT04577287|Experimental|Cathodal tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Cathode on the on the motor area (M1) of the affected hemisphere, anode on the supraorbital area of the unaffect hemisphere.Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
33401973|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
32776529|NCT02412735|Experimental|Rexlemestrocel-L|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).
32776530|NCT02412735|Experimental|Rexlemestrocel-L + HA|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).
32776531|NCT02412735|Placebo Comparator|Placebo|Participants received saline solution as matching-placebo on Day 0 (Visit 2).
32776532|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
32776533|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
32776534|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
32776535|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
32776536|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
32776537|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
32776538|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
32776539|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
32776540|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
32776541|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
32776542|NCT04910841|Experimental|Connect|
32776543|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
32776544|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
32935915|NCT04577287|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anode on the motor are (M1) of the affected hemisphere, and cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
33405344|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
32935918|NCT04903015|Experimental|professional Soccer players|
32935919|NCT04903015|Active Comparator|athletes not exposed to head injuries.|
32935920|NCT05449184|Experimental|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|
32935921|NCT05449184|Other|Tympanostomy Tube Insertion|
32935922|NCT04569175|Experimental|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product)
32776545|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
32776546|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
32776547|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
33277967|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
32776548|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
32776549|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
32776550|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
32776551|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
32776552|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
33277968|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
32776553|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
32776554|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
32776555|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
32776556|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
32776557|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
32776558|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
32776559|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
32776560|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
32776561|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
32776562|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
32935923|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
32935924|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
33277969|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
33277970|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
33277971|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
33277972|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
33277973|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
32935925|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
32956039|NCT05764967|Active Comparator|Temporary Felt Insoles|other will be given temporary shoe insoles. A temporary orthosis will be fabricated from 7-mm orthopedic felt. The orthosis consist of two parts, a medial longitudinal buttress and a navicular/sustentaculum tali pad. The medial longitudinal buttress will extend from the posterior calcaneus to the first metatarsal head and from the medial border of the foot to the bisection of the calcaneus and calcaneal recess will be cut out. A navicular/sustentaculum tali pad will extend from the sustentaculum tali to the cuneiform.
33102312|NCT02919605|Experimental|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
33277974|NCT01043458|Experimental|1|ABT-126 Low Dose
33082427|NCT00221507|Active Comparator|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
33277975|NCT01043458|Experimental|2|ABT-126 High Dose
33277976|NCT01043458|Experimental|3|Placebo for ABT-126
33277977|NCT00530894|Experimental|1|Cohort A: Sapien Valve
33277978|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
33277979|NCT00530894|Experimental|3|Cohort B: Sapien Valve
33277980|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
32830345|NCT03773484|Experimental|Clinical Decision Support|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
32830346|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
33277981|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
33277982|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
33277983|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
32830347|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
33277984|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
33277985|NCT01040182||ischemic stroke patients|
33277986|NCT01040182||healthy subjects without cerebrovascular disease|
33277987|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
33277988|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
33277989|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
33277990|NCT01004120|Placebo Comparator|MDn|
33277991|NCT01004120|Active Comparator|B-GOS|
33277992|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
32830348|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
33277993|NCT01004198|Experimental|MP4OX - 250|250 mL dose
32830349|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
32830350|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
33277994|NCT01004198|Experimental|MP4OX - 500|500 mL dose
33277995|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
32830351|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
32830352|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
33277996|NCT01004276|Experimental|Improved module|
33277997|NCT01004276|No Intervention|Standard module|
33277998|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
33277999|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
33278000|NCT01004588|Experimental|Protein drink|protein drink
33278001|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
33278002|NCT00056407|Placebo Comparator|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
33278003|NCT00056407|Experimental|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
33278004|NCT00388726|Experimental|1|
33278005|NCT00388726|Active Comparator|2|
33278006|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
33278007|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
33318125|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
32830353|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
32830354|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
33318126|NCT04519658|Experimental|CIN-107 Dose 1|
33318127|NCT04519658|Experimental|CIN-107 Dose 2|
32935926|NCT05449951|Experimental|Dry needling|This intervention was for three weeks in which there are 2 sessions per week. Sterile, disposable dry needles brand of JIAJAN with size of 0.30x40mm were used. Intervention was initiated after palpation of muscles(flexor carpi radials and flexor carpi ulnaris).First cleaning the area through alcohol swabs. There is a point for FCR in medial forearm, to that point 4 cm below and 1 cm medial to the midpoint of crease of elbow was needled. There is a point for FCU at the center of the proximal third segment of a line from the medial epicondyle to the ulnar styloid process was needled.Then, in swift in-and-out motions around 5mm vertical motions without rotation the needle was manipulated .About 1 minute Dry needling was executed for each targeted area, in respect to the patient's level of tolerance. This was monitored by the physiotherapist throughout the session by asking for regular verbal feedback
33278008|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
33278009|NCT03957655|Experimental|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
33278010|NCT03957655|No Intervention|Control|Standard medication for viral hepatitis and cirrhosis
32935927|NCT05449951|Other|Sustained stretching|The second group received sustained stretching protocol along with conventional therapy. Participants undergone the overall treatment sessions for three weeks (3weeks) and 2 sessions per week. The targeted muscles are wrist flexors (flexor carpi radials and flexor carpi ulnaris). Participants received 10 repetition with 30 seconds hold in each session for 10 minutes. Pre and post data in each session was measured through outcome measure tools
33278011|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
33278012|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
33278013|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
33278014|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
33278015|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
33278016|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
33278017|NCT00073021|Active Comparator|Asacol 2.4 g/day|Asacol (2.4 g/day)
33278018|NCT00073021|Experimental|Asacol 4.8 g/day|Asacol (4.8 g/day)
32776563|NCT04830319|Experimental|Test-control group (TCG)|The test-control group (TCG) will initiate the protocol with exercises of the Pilates method, which includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. The TCG group will then conduct 20 task-oriented training sessions
32935928|NCT02198664|Experimental|ARC001 placebo group|Subjects who received placebo in study ARC001.
32935929|NCT02198664|Experimental|ARC001 AR101 group|Subjects who received AR101 and tolerated up to 300 mg peanut protein (443 mg cumulative) in the DBPCFC at the end of study ARC001.
32935930|NCT05449028|Experimental|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
32935931|NCT05449028|Experimental|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
32935932|NCT05449028|Experimental|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
32935933|NCT05449028|Experimental|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
32935934|NCT05449028|Experimental|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
33082428|NCT00221507|Active Comparator|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
33082429|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
33082430|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
33278019|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
33082431|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
33082432|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
33278020|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
33278021|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
33278022|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
33082433|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
33278023|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
33278024|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
33278025|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
33278026|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
33278027|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
33278028|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
33278029|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
33278030|NCT01094587|Active Comparator|Sutured closure|
33278031|NCT01094587|Active Comparator|Sutureless closure|
33278032|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
33278033|NCT01089673||no treatment|retrospective data analysis
33082434|NCT00251082|Experimental|A|
33082435|NCT00251082|Active Comparator|B|
33082436|NCT00251082|Placebo Comparator|C|
33082437|NCT00221546|Active Comparator|DHA-rich supplement|
33278034|NCT00531752|Experimental|Flexible Dose|
33278035|NCT00531752|Placebo Comparator|Placebo|
33278036|NCT00531752|Experimental|Fixed Dose|
33278037|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
33278038|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
33278039|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
33278040|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
33278041|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
33278042|NCT00994838|No Intervention|standard diet|
33082438|NCT00221546|Placebo Comparator|Placebo|
33082439|NCT04616092|Experimental|FERINJECT Group|Patients with FERINJECT injection
33082440|NCT04616092|No Intervention|Observation Group|Patients without FERINJECT injection
33082441|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
33082442|NCT04616209|Experimental|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10^9，Cohort 2:1×10^9 or Cohort 3: 1.5×10^9 cells
33082443|NCT04616404|Active Comparator|Intervention Group|
33082444|NCT04616404|Placebo Comparator|Control Group|
33082445|NCT04720482||Comatose survivors of cardiac arrest|Adult (>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
33082446|NCT04616053|Experimental|Intervention group|IMPACT intervention
33278043|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
33278044|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
33278045|NCT00055471|Experimental|ZD4054 10 mg|1 x 10 mg oral tablets once daily
33278046|NCT00055471|Experimental|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
33278047|NCT00055471|Experimental|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
33278048|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
33318128|NCT04519658|Experimental|CIN-107 Dose 3|
33082447|NCT04616053|No Intervention|Control group|Usual care
33082448|NCT04615975|Experimental|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
33082449|NCT04615897|Experimental|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
33082450|NCT04615897|No Intervention|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
33082451|NCT04615741|Experimental|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
32776564|NCT04830319|Active Comparator|Control-test group (CTG)|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
32776565|NCT05618353|Active Comparator|Colchicine|One day before surgery: Colchicine 1.2 mg with 0.6 mg PO one hour later. This load will be followed by colchicine 0.6 mg twice daily for a total of 14 days.
32776566|NCT05618353|Placebo Comparator|Placebo|Matching placebo at same time points as active comparator
32776567|NCT04836403||Rhinosinusitis without treatment group|children aged 2 and 12 years with rhinosinusitis not receiving treatment
32776568|NCT04836403||Rhinosinusitis with treatment group|children aged 2 and 12 years with rhinosinusitis receiving treatment
32776569|NCT04836403||healthy volunteers|children aged 2 and 12 years without rhinosinusitis
32776570|NCT04836091|Experimental|Immediate intervention|From baseline to 2-month post-test, participants in the intervention arm will have access to the OurPlan program app.
32776571|NCT04836091|Experimental|Waitlist-delayed intervention|Participants in this study arm will not have access to the OurPlan program in the app from baseline to day 30 (month 1) of the trial. From day 31 to day 60, participants in this study arm will be given access to the OurPlan program in the app.
32776572|NCT04836169|Experimental|InCaveo EOA System|InCaveo EOA System (including integrated CBT but without tapering) group
32776573|NCT04836169|No Intervention|Control Group-usual care with pill bottles|UCPB group-usual care with pill bottles
32776574|NCT04836013|Experimental|Probiotic group|Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1,6 g with a concentration of probiotic of 2x100bilion colony forming unit (CFU) per stick.
32776575|NCT04836013|Placebo Comparator|Placebo group|The placebo will contain 1.6 g per stick of sucralose and isomalt
32776576|NCT04822909|Experimental|Apremilast group|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids."
32776577|NCT04831099|Experimental|Testosterone|Testosterone gel (20 mg/day) for 8 weeks per period.
32776578|NCT04831099|Placebo Comparator|Placebo|Placebo gel (20 mg/day) for 8 weeks per period.
32776579|NCT04830085|Experimental|Patients with adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was diagnosed with histopathological assessment.
32776580|NCT04830085|Active Comparator|Patients without adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was excluded with histopathological assessment.
32776581|NCT04822831|Experimental|Long-term Ventilator-dependent Patients with intervention|45 Degree Semi-recumbent Position With Upper Limb Exercise Training on Long-term Ventilator-dependent Patients
32776582|NCT04822831|Experimental|Long-term Ventilator-dependent Patients without intervention|There is no intervention on Long-term Ventilator-dependent Patients ,and just keep routine treatment.
32776583|NCT04829851||Health Care Professionals|Registered health care professional, such as a General Practitioner/ Dietitian/ Nutritionist/ Registered Exercise Professional (REPs) etc. who sees clients for assistance with weight management and / or iron deficiency or diet quality.
32776584|NCT04829851||Adults who are Overweight|Adults (> 18 years) who are considered to be overweight (25 - 30 kg/m2) but are otherwise in good physical health and a regular android smart phone/ tablet user.
32776585|NCT04829851||Adults with Iron Deficiency Anaemia|Adults (> 18 years) who have been diagnosed with Iron deficiency anaemia but are otherwise in good physical health and a regular android smart phone/ tablet user.
32776586|NCT04829851||Adults with Low- Fruit/ Vegetable Intake|Adults ( > 18 years) with a low fruit and vegetable intake (2-3 portions/ d) but are otherwise in good physical health and a regular android smart phone/ tablet user.
33278049|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
33278050|NCT01004666||Women with dense breast|Women with dense breast
33082452|NCT04615741|Experimental|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
33082453|NCT04615741|No Intervention|Control|These participants will not receive an intervention.
33082454|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
33082455|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
33082456|NCT04615780|Experimental|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
33082457|NCT04615780|Placebo Comparator|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
33278051|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
33278052|NCT01004900|Active Comparator|Trabeculoplasty|
32935935|NCT04543825|Experimental|CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
33278053|NCT01004900|Active Comparator|Control (Medication)|
33278054|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
32776591|NCT04302337|Active Comparator|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
32776592|NCT04302337|Experimental|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
32776593|NCT04296097|Experimental|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
32776594|NCT04296097|Other|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
32776595|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
32935936|NCT04338841|No Intervention|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
32956040|NCT05764954|Experimental|NovoTTF-200T System Tumor-Treating Fields (TTFields)|Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
32956041|NCT05764928|Experimental|Phase I: 1.5 mg/kg BLEX404|Oral administration BID
32956042|NCT05764928|Experimental|Phase I: 3.0 mg/kg BLEX404|Oral administration BID
32956043|NCT05764928|Experimental|Phase I: 6.0 mg/kg BLEX404|Oral administration BID
33278055|NCT01583491|Placebo Comparator|control group|
33278056|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 610|
33278057|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
33278058|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 430|
33278059|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 520|
33278060|NCT03956251|Experimental|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
33278061|NCT03956251|Active Comparator|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
32776596|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
32776597|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
32776598|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
32776599|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
32776600|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
32776601|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
32776602|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
32956044|NCT05764928|Experimental|Phase II: RDL of BLEX 404|Oral administration BID
33278062|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
33278063|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
33278064|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
33278065|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
33278066|NCT03956017|Experimental|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
33278067|NCT03956017|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
33278068|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
33278069|NCT05192954|Experimental|Vessel sealing device|Vessel sealing device to be utilized for vaginal hysterectomy
33278070|NCT05192954|No Intervention|Conventional clamping and suturing method|Vaginal hysterectomy will be performed utilizing conventional Heaney clamps, scissors, and suturing material.
33278071|NCT00054691|Experimental|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
33278072|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
33278073|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Lansoprazole-Dose range 15mg per day- 30mg twice a day~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.~Rantidine may be used in combination with any of the above"
33318129|NCT04519658|Placebo Comparator|Placebo|
32776603|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
33082458|NCT04720092|Experimental|Treatment A-B|Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
33082459|NCT04720092|Experimental|Treatment B-A|Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
32776604|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
32776605|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
32776606|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
32776607|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
32776608|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
32776609|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
32776610|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
32776611|NCT04835389|Experimental|AlloGen Liquid|A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.
32776612|NCT04835389|Placebo Comparator|Saline|A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.
32776613|NCT04367935|Active Comparator|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
32776614|NCT04367935|No Intervention|Control|Control Group receiving placebo tablets three times daily for 2 months
32776615|NCT04829773|Experimental|PK Cohort 1|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence A-B-C: Subjects received a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
32776616|NCT04829773|Experimental|PK Cohort 2|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence B-C-A: Subjects received a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast)."
32776617|NCT04829773|Experimental|PK Cohort 3|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence C-A-B: Subjects received a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); and then followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
32776618|NCT04829773|Experimental|Drug-Drug interaction (DDI) Cohort|On the morning of Day 1, subjects received a single dose of midazolam 30 minutes after the start of a standardized breakfast. On Day 2 (after the 24-hour midazolam blood draw) through Day 15, subjects received a daily, single dose of palovarotene in the morning 30 minutes after the start of a standardized breakfast. A second dose of midazolam was administered on Day 15 in the morning (immediately following the palovarotene dose) 30 minutes after the start of a standardized breakfast.
32776619|NCT04822285|Experimental|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
33401974|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
32776620|NCT04822285|Active Comparator|Routine Psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
32776621|NCT04829695|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
32776622|NCT04829695|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
33082460|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
33082461|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
32776623|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
32776624|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
32776625|NCT04821973|Active Comparator|Control Respiratory Monitoring Group|
32776626|NCT04821973|Experimental|Experimental Respiratory Monitoring Group|
32776627|NCT04822207|Experimental|Acupuncture group|In the acupuncture group, those patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
32776628|NCT04822207|No Intervention|Control group|In the control group, these patients do not receive any treatments during embryo transfer cycle. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
32776629|NCT04835233|Experimental|methyldopa|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
33278074|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
33278075|NCT03957421|Experimental|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
33278076|NCT03957499|Placebo Comparator|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
33278077|NCT03957499|Active Comparator|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
33278078|NCT03957499|Active Comparator|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
33278079|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
33278080|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
33278081|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
33278082|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
33278083|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
33278084|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
33278085|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
33278086|NCT01089829||CKD Stage 4|eGFR <30
33401975|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
33401976|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
33278087|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
33278088|NCT00066703|Active Comparator|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
33401977|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
32776630|NCT04835233|Active Comparator|captopril|postpartum exchange methyldopa for captopril 25 mg 01 tablet every 8 hours, doubling the dose depending on pressure levels, up to 15 days postpartum
33278089|NCT00066703|Experimental|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
33278090|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
33278091|NCT03955939|Experimental|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
33278092|NCT03955939|Experimental|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
33278093|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
33278094|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
33401978|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
33401979|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
32776631|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
32776632|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
32776633|NCT04822051|Experimental|Psychoeducation Group|"Uncertainty Management Psychoeducation Program was given."
33401980|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
33401981|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
33401982|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
33278095|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
33278096|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
33278097|NCT01091623|Active Comparator|strength training|
33278098|NCT01091623|Active Comparator|endurance training|
33278099|NCT01091623|Active Comparator|combined training|
33278100|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
33278101|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
33278102|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
33278103|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
33278104|NCT00072475|Experimental|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
33278105|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
33278106|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
33278107|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
33278108|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
33278109|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
33278110|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
33278111|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
33278112|NCT01091701|Placebo Comparator|Plasmalyte-A|
33278113|NCT01091779||Hypertensive and normotensive|
33278114|NCT03960229|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
33278115|NCT03960229|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
33278116|NCT01091857|Experimental|Exercise intervention (STRIDE)|
33278117|NCT01091857|Active Comparator|Health and Wellness Control|
33278118|NCT00066469|Experimental|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
33278119|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~June 15 to August 21, 2009~October 15-Dec 22,2009"
33278120|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
33278121|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
33278122|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
33278123|NCT01095055|Experimental|Group 1|AdCh63 AMA1
33278124|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
33278125|NCT01095133|Experimental|Amiloride|
33278126|NCT01095133|Placebo Comparator|Placebo|
33278127|NCT01092013|Active Comparator|Operating room training|
33278128|NCT01092013|Active Comparator|Skills lab training|
33278129|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
33278130|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
33278131|NCT00070291|Experimental|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
33278132|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
33278133|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
33278134|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
33278135|NCT00053365|Experimental|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
33278136|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
33278137|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
33278138|NCT01092169||Sickle cell beta|
33278139|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
33278140|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
33278141|NCT00386776|Experimental|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
33278142|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
33278143|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
33278144|NCT00065065|Experimental|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
32776634|NCT04822051|No Intervention|Control Group|No attempt was made by the researcher during the study. Only data collection was carried out.
32776635|NCT04821427|Experimental|Brief mHealth Intervention + mobile messaging|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages
33082462|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
33082463|NCT04615585|Experimental|Aloe Vera + Scaling and root planing|
33082464|NCT04615585|Active Comparator|Scaling and root planing|
33082465|NCT04615468|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
33082466|NCT04615546|Experimental|Remote Phase: PBH Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
33082467|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. May include participants from the Remote Phase or newly enrolled participants.
33082468|NCT04615546|No Intervention|In-Clinic Phase: Surgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
32776636|NCT04821427|No Intervention|Assessment Only|This is an assessment only condition. No intervention following completion of baseline surveys will be administered.
32776637|NCT05619445|Experimental|Whole Liquid Egg|Whole Liquid Eggs
32776638|NCT05619445|Experimental|Plant-Based Egg Substitute|Plant-Based Egg Substitute
32776639|NCT04821583|Experimental|Hydrocortisone|Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.
32776640|NCT04821583|Placebo Comparator|Placebo|Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
32776641|NCT04834921|Experimental|MCO-CVVHD|CVVHD with MCO filter for 24 hours
32776642|NCT04834921|Active Comparator|HFF-CVVHDF|CVVHDF with high flux filter for 24 hours
32776643|NCT04829149||Statin therapy group (No interventional)|Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)
32776644|NCT04829149||Rosuzet tablet group (No interventional)|Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg
32776645|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
33082469|NCT04615546|No Intervention|In-Clinic Phase: Nonsurgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
33082470|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
33082471|NCT04615858|Active Comparator|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
33278145|NCT00065065|Placebo Comparator|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
33278146|NCT00386308|Experimental|1|
33278147|NCT00386308|Placebo Comparator|2|
33318130|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
32776646|NCT01668355|No Intervention|Usual Care|Usual Primary Care
32776647|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
32776648|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
32776649|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
32776650|NCT05618119|Active Comparator|Male|5 male participants will undergo a [18F]MC225 PET scan
32776651|NCT05618119|Active Comparator|Female|5 female participants will undergo a [18F]MC225 PET scan
32830355|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
32900132|NCT05265884|Active Comparator|Group B (control group)|This group includes 30 patients who will receive traditional treatment only (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for 1 month.
32900133|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
32900134|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
32900135|NCT05261360|Experimental|SF-MSC-EX Treatment Group (Experimental group's left knees)|The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.
32900136|NCT05261360|Experimental|SF-MSC Treatment Group (Experimental group's right knees)|The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.
32900137|NCT05261360|No Intervention|Control Group|Participants who received no treatment were defined as the control group.
33278148|NCT00064987|Experimental|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
32776652|NCT04828759|Experimental|VR-treatment, then Treatment as usual|Participants will receive 8 weeks of VR-treatment. Participants are allowed to practice as much as they wish during the VR-intervention. However, they are given a recommendation of the amount of practice (5 h / week). Before the VR-intervention, the participants will receive a guidance for using the VR-devices (i.e. orientation period) by the SLT. Participants will be able to contact the SLT freely during the 8 weeks VR-intervention period. After the orientation period, the participants will be practicing at their homes independently. However, they will receive remote guidance by the SLT. The guidance includes weekly remote guidance sessions by SLT (8 x 45 min) to ensure that training is fluent and unproblematic. Additionally, the content of exercises can be modified during these sessions. The SLT is also able to monitor the training of participants with the system. Devices: VR headset and controller, Tablet computer.
32900138|NCT05242094|Active Comparator|Group 1|Traditional Pulmonary Rehabilitation
32900139|NCT05242094|Experimental|Group 2|Pulmonary Rehabilitation in Virtual Reality
33278149|NCT00064987|Active Comparator|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
33278150|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
33278151|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
32900140|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
32900141|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
32900142|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
33278152|NCT00064753|Experimental|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
33278153|NCT00064753|Active Comparator|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
33278154|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
33278155|NCT00665561||Maraviroc exposed|
33278156|NCT00665561||Maraviroc unexposed|
33278157|NCT04064086|Active Comparator|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
33278158|NCT04064086|Active Comparator|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
33278159|NCT03955705|Experimental|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
33278160|NCT03955705|Placebo Comparator|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
33278161|NCT03154138|Experimental|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
33278162|NCT03154138|Placebo Comparator|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
32900143|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
33278163|NCT01095289||Total Laryngectomized|
33278164|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
33278165|NCT01090297|Active Comparator|Fixed pressure|
33278166|NCT01090297|Active Comparator|Auto-adjusting pressure|
33318131|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
32900144|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
32900145|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
32900146|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
32900147|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
32900148|NCT04346030|Experimental|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
32900149|NCT04346030|Active Comparator|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
32900150|NCT05095844||Vaccinated|All individuals who have received a vaccine dose.
33082472|NCT04615858|Active Comparator|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
33278167|NCT03955549|Experimental|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
33278168|NCT03955549|Experimental|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz & Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
33278169|NCT03955549|Active Comparator|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
33278170|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
33278171|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
33278172|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
33278173|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
33278174|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
33278175|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
33278176|NCT00786929|Experimental|drainage|
33278177|NCT00786929|Active Comparator|2|Conservative treatment
33278178|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
33278179|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
33278180|NCT00787007|Experimental|1|10 mg
33278181|NCT00787007|Experimental|2|20 mg, fasted and fed
33278182|NCT00787007|Experimental|3|40 mg
33278183|NCT00787007|Experimental|4|80 mg
33278184|NCT00787007|Experimental|5|160 mg
33278185|NCT00787007|Experimental|6|320 mg
33278186|NCT00787007|Placebo Comparator|7|placebo capsule
33278187|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
33278188|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
33278189|NCT00787163|Experimental|1|amnioinfusion
33278190|NCT00787163|No Intervention|2|expectant management
33082473|NCT04615351|Active Comparator|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
33278191|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
33278192|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
33082474|NCT04615351|No Intervention|Routine Care|Discharge information about maintaining a healthy diet
33082475|NCT04615156|Experimental|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
33082476|NCT04615312|Experimental|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
33082477|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
33278193|NCT00784355|No Intervention|2:controls|non-surgical control group
33278194|NCT00795119|Experimental|NIRS|Children who undergo NIRS
33278195|NCT00795197||Screening Group|Screening Group
33278196|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
33278197|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
33278198|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
33278199|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
33082478|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
33082479|NCT04614883|Other|Asymptomatic patients or Healthy volunteers|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
33278200|NCT04046393|Experimental|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
33278201|NCT04046393|Placebo Comparator|Saline control group|nasal irrigation with saline isotonic solution
33278202|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
33278203|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
33278204|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
33278205|NCT00787475|Experimental|1|CHW intervention
33278206|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
33278207|NCT00787553|Active Comparator|cefazolin|
33278208|NCT00787553|Active Comparator|tinidazole|
32776653|NCT04828759|Experimental|Treatment as usual, then VR-treatment|Wait list control group: During the waitlist period the participants will receive the traditional speech and language therapy rehabilitation offered by (if offered) the general health care system in their own home municipality. The amount of rehabilitation is not controlled during the wait list period. However, the amount of received traditional speech and language rehabilitation in waitlist period will be documented. The waitlist control group will receive the same VR intervention period after the 8 weeks waitlist period.
32776654|NCT04828525|Experimental|Experimental|participants will be given corticosteroids in addition to conventional treatment
32776655|NCT04828525|Placebo Comparator|Placebo|participants will be given normal saline in addition to conventional treatment
32776656|NCT04821505|Experimental|Meditation|The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
32776657|NCT04821505|Active Comparator|Health Education|Health education program matched to the experimental intervention for time, attention, and other non-specific factors.
33082480|NCT04614883|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
33082481|NCT04614883|Other|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
32776658|NCT04835155|Experimental|experimental group|The researcher applied Premature Infant Oral Motor Intervention to the experimental group for 5 minutes per day for 14 consecutive days, 15-20 minutes before a sheduled feeding at either the 09:00 or 12:00 feeding. On the first day, the baseline sucking capacity of babies in experimental group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials. Growth measures were collected on the 1st and 14th days and the day of disharge.
32776659|NCT04835155|No Intervention|control grup|The researcher did not apply any intervention. On the first day, the baseline sucking capacity of babies in control group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials.
32776660|NCT04828915||Training cohort|Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset
32776661|NCT04828915||Validation cohort|Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
32776662|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
32776663|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
32776664|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
32776665|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
32776666|NCT04427683|Experimental|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
32776667|NCT04427683|Other|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
32776668|NCT04828213|Experimental|Tooth-borne RME appliance (Hyrax)|"In the Tooth-borne RME expander group, bands were placed to the maxillary right and left upper 1st premolar and 1st molar teeth. The impression of the upper jaw was obtained with the bands in mouth by using alginate impression material. In the laboratory process, a hyrax (Forestadent, Pforzheim, Germany; Forestadent USA, St Louis, Missouri, USA) expansion appliance with an expansion screw in the middle was prepared on the models by the same technician under standard conditions.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
32830356|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
32830357|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
32830358|NCT04318704|Other|Single Arm Active|Ifenprodil
33082482|NCT04614727|Experimental|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
33082483|NCT04614727|Other|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
33082484|NCT04614415|Experimental|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
33082485|NCT04614415|Placebo Comparator|control group|group 2 treated with placebo (isotonic saline solution).
33082486|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
32830359|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
32830360|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
33082487|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
33278209|NCT00787553|Active Comparator|cefazolin plus tinidazole|
33278210|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
33278211|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
33082488|NCT04614688|Experimental|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
33082489|NCT04614688|No Intervention|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
33082490|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
33082491|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
33082492|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
33082493|NCT04614298|Experimental|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
33082494|NCT04614298|Placebo Comparator|Placebo SC|Single SC administration
33082495|NCT04613986|No Intervention|Standard|Standard of care according to our current in house SOP
33082496|NCT04613986|Experimental|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
33082497|NCT04614259|Experimental|intravenous analgesia|
33082498|NCT04614259|Experimental|infraorbital nerve block|
33082499|NCT00251160|Active Comparator|ETAC|
33082500|NCT00251160|Active Comparator|Open ICS|
33082501|NCT04613908|Active Comparator|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
33082502|NCT04613908|Experimental|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
33278212|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
33278213|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
33278214|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
33278215|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
33278216|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
33082503|NCT04613908|Experimental|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
33082504|NCT04614181|Experimental|Carbohydrate and protein loading|Nestle Resource drink
33082505|NCT04614181|Active Comparator|Usual care|Usual fracture care as determined by clinical team
33082506|NCT04613635|Experimental|Stratafix|
33082507|NCT04613635|Active Comparator|Vicryl|
33278217|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
33278218|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33278219|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
33278220|NCT01045876|Experimental|Dexamethasone|
33082508|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
33082509|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
33082510|NCT00563524|Placebo Comparator|1|
33082511|NCT04613869|Experimental|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
33082512|NCT04613869|Experimental|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
33082513|NCT04613869|Placebo Comparator|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
33082514|NCT04613557|Experimental|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
33082515|NCT00251355|Experimental|5-FU/gemcitabine/RT|
33278221|NCT01045876|Placebo Comparator|Placebo|
33278222|NCT01040416||Bleeding marginal ulcer after RYGB|
33278223|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
33278224|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
32935937|NCT04338841|Experimental|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
32935938|NCT05448950|Experimental|VIG Continued Access|"Patients referred for AVG implant should be screened for study eligibility. A member of the Research Team will evaluate the patient for eligibility. If all initial inclusion criteria are met and no exclusion criteria are present, a member of the Research Team should inform the patient about the study's purpose and should obtain written informed consent.~Final enrollment eligibility is determined at the time of surgery, after the physician has confirmed the final inclusion criterion is met. Enrolled subjects will be assigned a unique study subject identification number."
33278225|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
33318132|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
32776669|NCT04828213|Experimental|Hybrid hyrax RME appliance|"Rapid Maxillary Expansion Treatment. In the Hybrid hyrax RME appliance group, mini-screws of 2 mm diameter and 9 mm length (Benefit mini-implants; PSM Medical Solutions; Tuttlingen, Germany) were placed 3 mm posterior and 1 to 5 mm paramedian to the incisive foramina.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
32776670|NCT04821193|Experimental|Experimental Group 1|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 5% NaHCO3 water solution group Grup number: 20
32776671|NCT04821193|Experimental|Experimental Group 2|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 2% Chlorhexidine Gluconate solution group Grup number: 21
32776672|NCT04821193|No Intervention|Control Group|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 70% Alcohol solution group Grup number: 21
32776673|NCT04821037|Experimental|ACT|"A digitally-based ACT program will be conducted in two half-day workshops via meeting software (e.g. Zoom) consisting of:~mindfulness exercises, for stress reduction and to guide nurses to observe their painful thoughts and feelings that they are attempting to avoid;~ACT-metaphors, to let nurses realize the cost of struggling with psychological distress often create more distress;~experiential exercises, to guide nurses to notice their own experiences in providing nursing care throughout their nursing career and explore any special qualities;~explore the nurses' values with respect to different areas in their lives."
32776674|NCT04820725|Experimental|Study group|Patients whose BASMI score is 2 will be included in the study
32776675|NCT04820725|Experimental|Control group|Patients whose BASMI score is 0 and 1 will be included in the study
32776676|NCT04828291|Experimental|Online Mindfulness Intervention (OMI)|Before beginning the daily practices, this group will be introduced to the OMI via an online platform and answer any questions about the practice. Then, each day, this group will be guided through a series of mindfulness practices offered online (www.bemindfulonline.com) delivered on their smartphones or laptops.
32830361|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
32935939|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.
32935940|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.
32935941|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1021|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021. This was the third model evaluated in the study.
32935942|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1012|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1012. This is the fourth model currently being evaluated in the study.
32935943|NCT04338464|Experimental|Treatment Group|
32935944|NCT04495699||Observation|Patients who elect to have observation of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
32935945|NCT04495699||Stone treated|Patients who elect to have intervention of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
32935946|NCT05448794|Experimental|evaluation prolotherapy for frozen shoulder|This pilot study highlighted that prospective studies are required to prove its clinical application for FS and other conditions.
32935947|NCT05448638|Experimental|transversus thoracic muscle plane block+pectoral nerves block|the combination of transversus thoracic muscle plane and pectoral nerves blocks
32776677|NCT04828291|Experimental|OMI paired with peer support (OMI+)|Before beginning the daily OMI, in addition to being briefed, this group will be paired with a peer to be in touch with and guide and support each other in this process. Then they will start the OMI program and will follow parallel instructions as the OMI group. The peer support will include five brief (30-minute) weekly meetings to support and encourage each other to continue practicing mindfulness and to complete the online intervention. Each week we will provide prompts and topics for participants to discuss and at the end of each meeting, participants will then complete a short, 5-10 minute post-meeting survey to assess the well-being and attitudes of their partner (see additional materials for meeting prompts and post-meeting survey questions). The first of these meetings will occur on Day 8, and subsequent weekly meetings during the intervention period will be scheduled based on the shared availability of both participants in each pair.
32776678|NCT04828291|Active Comparator|Active control receiving cognitive exercises|Instead of the OMI, this group will be receiving cognitive exercises in the intervention period.
32776679|NCT04820803|Experimental|Cetylpyridinium Chloride (CPC) 0,07%|patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds
32776680|NCT04820803|Placebo Comparator|Placebo: Distilled water with the same flavor and coloring as the product to be evaluated|patients who rinse with distilled water mouthwash for 60 seconds
32776681|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
32776682|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
32776683|NCT04827511||cohort group|80 children with disabilities like autism, ADHD, Down syndrome, deafness, phocomelia, dyslexia, different motor problems
32776684|NCT04827511||control group|81 healthy children, not known or diagnosed with a chronic disease of any kind
32776685|NCT04827667||Patients with lung cancer|In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
32776686|NCT04827667||Patients wiht interstitial lung disease|In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
32776687|NCT04827667||Patients with asthma|In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
32776688|NCT04834609|Experimental|Injection with adipose tissue|Injection of freshly collected autologous adipose tissue
32776689|NCT04834531|Experimental|Zhuli capsule|Base on the standard medical treatment, the patients in this group will be used Zhuli capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
33082516|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
33082517|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.~Maximum dose 25 mg BID."
33082518|NCT04613167|Experimental|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
33082519|NCT04613167|Experimental|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
33082520|NCT04613167|Experimental|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
33082521|NCT04613245||Patient with asthma|
33082522|NCT04613284|Experimental|Endostar combined Radiation|
33082523|NCT04613401||VAD-patients with Telemonitoring|
33082524|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
33082525|NCT00563602|Experimental|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
33082526|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
33082527|NCT00563641|Active Comparator|2|NCPAP alone
32776690|NCT04834531|Placebo Comparator|Placebo|Base on the standard medical treatment, the patients in this group will be used placebo capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
32776691|NCT04360135|Experimental|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
32776692|NCT04360135|Placebo Comparator|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
32776693|NCT05617885|Experimental|Phase 1 Lead In in CRPC|Standard 3+3 dose escalation scheme with 3 dose levels of abemaciclib and a constant dose of darolutamide, per protocol, for 6, 28-day cycles
32776694|NCT05617885|Experimental|Phase 2 - Neoadjuvant Darolutamide and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
32776695|NCT05617885|Experimental|Phase 2 - Neoadjuvant Darolutamide, Ademaciclib, and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
32776696|NCT04827823||Group 1- Amalgam restorations|Multi-surface amalgam restorations performed by dental students and are in function for about 5 years.
32776697|NCT04827823||Group 2- Composite restorations|Multi-surface composite restorations performed by dental students and are in function for about 5 years.
32776698|NCT04827589|Experimental|Tirabrutinib|Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
33082528|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
33082529|NCT00248118|Placebo Comparator|Placebo|Placebo pill
33082530|NCT00221897||Healthy individuals|healthy controls with or without myopia
33082531|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
33082532|NCT04612972|Experimental|Investigational vaccine 1. Wuhan|Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
33082533|NCT04612972|Experimental|Investigational vaccine 2. Beijing|Inactivated SARS-CoV-2 vaccine (Vero cell); 4μg/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
33278226|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
33278227|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
33278228|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
33278229|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
33278230|NCT00661661|Experimental|CP-690,550|
33278231|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
33405345|NCT05167071|Experimental|HBM4003 and Toripalimab|HBM4003 combined with Toripalimab in patients with advanced NEN and other solid tumors
33278232|NCT00038467|Active Comparator|B|
33278233|NCT00038467|Experimental|A|
33278234|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
33278235|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
33278236|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
33278237|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
33278238|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
33278239|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
33278240|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
33278241|NCT00050167|Experimental|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
33278242|NCT00050167|Experimental|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
33278243|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
33278244|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
33278245|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
33278246|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
33278247|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
33278248|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
33278249|NCT03957265|Experimental|Syncone|Tapered abutment connection
33278250|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
33278251|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
33278252|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
33278253|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
33278254|NCT03953521|Experimental|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
33278255|NCT03953521|Active Comparator|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
33278256|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
33278257|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
33278258|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
33278259|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
32776699|NCT04827589|Placebo Comparator|Placebo|Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
32776700|NCT04827589|Experimental|Tirabrutinib, Open Label Extension|At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
32776701|NCT04834687|Experimental|Rope-skipping group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
32776702|NCT04834687|Experimental|Diet intervention group|Participants would be required to take part in a diet plan , including a high-fiber diet and time-restricted eating.
32776703|NCT04834687|Experimental|Combined intervention group|Participants will receive both rope-skipping and diet interventions at the same time.
32776704|NCT04834687|No Intervention|Control group|Participants would be required to maintain existing diet patterns and physical activity levels.
32776705|NCT04827277|Active Comparator|Reverse total shoulder replacement|Participants will receive a reverse total shoulder arthroplasty
32776706|NCT04827277|Active Comparator|Anatomic total shoulder replacement|Participants will receive an anatomic total shoulder arthroplasty
32935948|NCT05448638|Active Comparator|pectoral nerves block|the pectoral nerves block only
32935949|NCT04845685|Experimental|CGM Patients|Subjects with diabetes mellitus or medication induced diabetes that have been admitted to the hospital after a surgery for organ transplantation or scheduled for organ transplant surgery will be fitted with a CGM monitor to monitor glucose levels during hospitalization
32935950|NCT05446922|Other|MRI imaging of 10 healthy volunteers|10 healthy volunteers will proceed at an brain MRI imaging
32935951|NCT04845139|Experimental|Nivolumab administration|Nivolumab administration Q2W by intraventricular injection through Ommaya reservoir
32935952|NCT05446844|Experimental|A protocol group|A protocol group received a nurse caring behavior protocol by the researcher
32935953|NCT05446844|Active Comparator|A control group|A control group received routine nursing care by the staff nurse
32935954|NCT04738669|No Intervention|Control Arm|No intervention is being conducted in this arm. Routine care is being given to these patients. The patients will be followed up for any readmissions during the intervention period.
32935955|NCT04738669|Experimental|mHealth Arm|"This arm will receive first receive weekly telephone call followed by the SMS in Urdu regarding medication adherence according to the discharge instructions.~The calls and SMS will be sent on 7, 14, 21 and 30th day post-index discharge. The patients will be followed up for any readmissions during the intervention period."
32935956|NCT04738669|Experimental|Teach back arm|"The trained doctors thoroughly explained the discharge instructions, medication schedule and any other self-care instructions to these participants and asked them to repeat what they have understood from the doctor verbal counselling.~If the instructions were not clearly comprehended by the patients, then the same would be repeated by the consultant doctor.~The patients will be followed up for any readmissions during the intervention period."
32935957|NCT05446688|Experimental|6MW3211|6MW3211 injection, 45mg/kg, Q2W
32935958|NCT04563806|Experimental|Device feasibility (MRI-guided surgery)|Patients undergo standard of care spine surgery with MRI-based image guidance.
32935959|NCT04489771|Experimental|Dose A (standard dose)|Participants receive Dose A (standard dose) of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
32935960|NCT04489771|Experimental|Dose B (higher dose)|Participants receive Dose B (higher dose) of belzutifan by oral administration, QD, until disease progression or discontinuation.
32935961|NCT04738526|Active Comparator|natural tooth|
32776707|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
32776708|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
32776709|NCT05619133|No Intervention|placebo|No PBM will be emitted from the device; dose: 0 J.cm-2
32776710|NCT05619133|Experimental|PBM High standard|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
32776711|NCT05619133|Experimental|PBM High wavelength|A PBM high dose of 6.5 J.cm-2 with a wavelength of 940 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
32776712|NCT05619133|Experimental|PBM High pulse|A PBM high dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 100 Hz and 1.2 ms and duty factor of 12%
32935962|NCT04738526|Experimental|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate (IPS e-max) ceramic crown for crowns in esthetic zone
32935963|NCT04738526|Experimental|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|
32935964|NCT05446376|Experimental|68Ga-citrate PET/CT|
32935965|NCT04488055|Experimental|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
32935966|NCT04488055|Active Comparator|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
32935967|NCT05449483|Experimental|tislelizumab+ Paclitaxel+Cisplatin|Paclitaxel 135mg/m2 , D1; Cisplatin 80mg/m2, D1; tislelizumab 200mg D2 ; totally 2-4 cycles
32935968|NCT05448482|Experimental|Hybrid transobturator tape|"Anterior rectus fascia will be exposed and an approximately 8-10 cm × 1 cm strip of rectus fascia will be marked out. The sling will be harvested using sharp dissection. Thereafter, a Polyprolene monofilamentous mesh of 15 cm x 1 cm will be sutured to each edge of the rectus fascia sling that had been harvested.~Then, a 2-cm midline incision over the anterior vaginal wall at the level of mid-urethra. A combination of blunt and sharp dissection will be carried out to the obturator foramen bilaterally.~Next, a stab incision will be made at a point approximately 2.5 cm infero-lateral to the pubic tubercle bilaterally, corresponding to the level of clitoris. A trocar will be passed through each obturator foramen (outside-in) and the edge of the mesh will be retracted through the incision. Next, the retraction of both meshes will continue until the rectus fascia sling remain flushed with the urethra."
33082534|NCT04612972|Placebo Comparator|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine; Active Ingredient: None; Virus Contents: None; Adjuvant: aluminum hydroxide; Specification: 0.5 mL/ dose, 0.5mL for per human use; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
33082535|NCT04612894|Experimental|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
33082536|NCT04612777|Experimental|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
33278260|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
33278261|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
33278262|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
33278263|NCT00062647|Experimental|Telavancin|
33278264|NCT00062647|Active Comparator|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
33278265|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
33278266|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
33278267|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
33278268|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
33278269|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
33278270|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
33278271|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
33278272|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
33278273|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
33278274|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
33278275|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
33278276|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
33278277|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
33278278|NCT04047095|Experimental|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.~8 a.m. - normal meal plus one sachet immune nutrients~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
33278279|NCT04047095|Active Comparator|Control|"Normal daily meals. 8 a.m. - normal meal~1 p.m. - normal meal 6 p.m. - normal meal"
33278280|NCT00788333|Experimental|A|Combination
33278281|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
33278282|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
33278283|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
33278284|NCT00795977|Experimental|dendritic cells|
33278285|NCT00796055|Experimental|1|MEDI-547
33278286|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
33278287|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
33278288|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
33278289|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
33278290|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
33278291|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
33278292|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
33278293|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
33278294|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
33278295|NCT00788567|Experimental|1|
33278296|NCT00792311|Experimental|Tsui test|Tsui test administration.
33278297|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
33278298|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
33278299|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
33278300|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
33278301|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
33082537|NCT04612777|Active Comparator|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
33278302|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
33278303|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
33278304|NCT00788723|Experimental|3|Healthy volunteers
33278305|NCT00788801|Experimental|Baseline|
33278306|NCT00788801|Experimental|ABT-614 Low Dose|
33278307|NCT00788801|Experimental|ABT-614 High Dose|
33278308|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
33278309|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
33278310|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
33278311|NCT00050011|Experimental|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
33278312|NCT00050011|Experimental|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
33278313|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
33278314|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
33278315|NCT00049543|Experimental|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
33278316|NCT00049543|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
33278317|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
33278318|NCT04080427|Placebo Comparator|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
33278319|NCT04080427|Experimental|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
33278320|NCT00048997|Experimental|Prophylactic cranial irradiation (PCI)|Radiation therapy
33278321|NCT00048997|Other|Observation|Observation
33278322|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
33278323|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
33278324|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
33278325|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
33278326|NCT03955315|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
33278327|NCT03955315|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
33278328|NCT03955315|Sham Comparator|Sham|Sham needle puncture (outside disc)
33278329|NCT00035815|Active Comparator|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
33278330|NCT00035815|Placebo Comparator|Placebo|Placebo arm
33278331|NCT00662831|Experimental|Active|Active study treatment
33278332|NCT00662831|Placebo Comparator|Placebo|Placebo
33278333|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
33278334|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
33278335|NCT00796601|Experimental|Esreboxetine|
33278336|NCT00796601|Placebo Comparator|Placebo|
33278337|NCT00796679|Experimental|1|paricalcitol
32935969|NCT05448482|Active Comparator|Conventional transobturator tape|The conventional mesh using mid urethral sling through the trans obturator route
32935970|NCT04457401|Experimental|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10^9 colony forming units/capsule of a Bifidobacterium strain
32935971|NCT04457401|Placebo Comparator|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
32935972|NCT05448404|Experimental|18F-PSMA-1007 and 18F-FDG PET/CT scan|Patients of multiple myeloma PET/CT imaging: Within one week each patient underwent a PET/CT scan 60-min after intravenous administration of 18F-PSMA-1007 and 18F-FDG, respectively.
33278338|NCT00796679|Placebo Comparator|2|placebo
33278339|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Soccer training, 3 times a week, during 12 weeks"
33278340|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Running training, 3 times a week, during 12 weeks"
33278341|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
33278342|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
33278343|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
33278344|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
33278345|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
33278346|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
33278347|NCT04887155|Active Comparator|Cognitive behavioral therapy (CBT)_no app|
33278348|NCT04887155|Experimental|Cognitive behavioral therapy (CBT) with mobile app|
33278349|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
32935973|NCT05449093||Stage 3 Grade C Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that clinical attachment loss was caused by periodontal causes. These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. If this value was higher than 1.0, the patients were assigned to grade C.
33278350|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
33278351|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
33278352|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
33278353|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
33278354|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
33278355|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
33278356|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
33278357|NCT00789269|Experimental|1|rhubarb
33278358|NCT00789269|Placebo Comparator|2|
33278359|NCT00789347||1|Healthy volunteers
33278360|NCT00789347||2|Patient with neuropathic pain
33278361|NCT00789347||3|patients without neuropathic pain
33278362|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
33278363|NCT00793013|Experimental|APRV Ventilation|
33278364|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
33278365|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
33278366|NCT00793091|Active Comparator|1|
33278367|NCT00793091|Placebo Comparator|2|
33278368|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
33278369|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
33278370|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
33278371|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
33278372|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
33278373|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
33278374|NCT00800579|Experimental|1|GS-9411 0.6 mg
33278375|NCT00800579|Experimental|2|GS-9411 1.2 mg
33278376|NCT00800579|Experimental|3|GS-9411 2.4 mg
33278377|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
33278378|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
33278379|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
33278380|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
33278381|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
33278382|NCT00797381||1|
33278383|NCT00797381||2|
33278384|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33401983|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
33082538|NCT04612543|Active Comparator|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
33082539|NCT04612543|Active Comparator|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
32776713|NCT05619133|Experimental|PBM High skin only|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%, but in this case the participants will wear filtering googles which will not allow PBM from entering the eyes
32776714|NCT04819789|Experimental|Fermotein™ dry|Fermotein™ powder presented in the form of a porridge.
32776715|NCT04819789|Experimental|Fermotein™ wet|Fermotein™ wet presented in the form of a porridge.
32776716|NCT04819789|Experimental|Fermotein™ modified wet|Fermotein™ modified wet presented in the form of a porridge.
32776717|NCT04819789|Active Comparator|Mycoprotein|This mycoprotein product presented in the form of a porridge.
32776718|NCT04834375|No Intervention|Standard dexamethasone dose|Dexamethasone 6 mg IV daily for 10 days
32776719|NCT04834375|Experimental|Weight-based dexamethasone dose|Dexamethasone 0.2 mg/kg/day IV (maximum 20 mg daily) for 10 days
32776720|NCT04833985|Experimental|transesophageal echocardiography guidance|
32776721|NCT04833985|Experimental|intracardiac echocardiography guidance|
32776722|NCT04833985|Experimental|fluoroscopy only guidance|
32776723|NCT04827121|Active Comparator|Fascial iliac compartment block group|Patients in this group will recieve supra-inguinal fascial iliac compartment block after anesthesia induction.
32776724|NCT04827121|Active Comparator|Quadratus lumborum block group|Patients in this group will recieve quadratus lumborum block after anesthesia induction.
32776725|NCT04820101|Experimental|Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy|Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.
32776726|NCT04826887||Solep Arm|Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
32776727|NCT04826887||Control Arm|Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
32776728|NCT04328311|Experimental|Active|Watermelon juice
32776729|NCT04328311|Other|Control|Low nitrate water.
33082540|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
33082541|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
33082542|NCT04612465|Experimental|ASC (test arm)|(Autologous Adipose-derived Mesenchymal Stem Cells)
33082543|NCT04612465|Placebo Comparator|Fibringlue|Standard comparator
33401984|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
32776730|NCT04428463|Active Comparator|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
32776731|NCT04428463|Experimental|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
32776732|NCT04327609|Experimental|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
32776733|NCT04327609|Active Comparator|Control Treatment|POBA
32776734|NCT04819633||Study Group|30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
32776735|NCT04819633||Control Group|30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
32776736|NCT04819867|Experimental|propolis|propolis will be applied to the affected teeth
32776737|NCT04819867|Active Comparator|gluma desensitizer|Gluma desensitizer will be applied to the affected teeth
32776738|NCT04827043|Experimental|Quadratus lumborum block|QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg & 3mg/Kg with epinephrine), single injection sonar guided.
32776739|NCT04827043|Experimental|Thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
32776740|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
32776741|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
33401985|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
33278385|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33278386|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
33278387|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
33278388|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
33278389|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
33082544|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
33082545|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
33278390|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
33278391|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
33278392|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
33278393|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
33082546|NCT04612582|Experimental|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
33082547|NCT04612582|Experimental|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
33082548|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
33082549|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
33082550|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
33082551|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
33082552|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
33082553|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
33278394|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
33278395|NCT00800969|Other|all patients|all patients with Adenocarcinoma
33278396|NCT00801047|Experimental|1|Epidural group
33278397|NCT00801047|Active Comparator|2|Remifentanil iv PCA
33278398|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
33278399|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
33278400|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
33278401|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
33278402|NCT00801359|Active Comparator|BSSplus|
33278403|NCT00801359|Experimental|Ringer|
33278404|NCT00801437||Xalacom treatment|patients with primary glaucoma
33278405|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
33278406|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
33278407|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
33278408|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
33278409|NCT00797771|Experimental|A|"Adi insulin pump users"
33278410|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
33278411|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
33278412|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
33278413|NCT00793559|Experimental|terlipressin drip|
33278414|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
33278415|NCT00797927|No Intervention|2. conventional antipsychotics|
33278416|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
33278417|NCT00801593||Children with JIA|
33278418|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
33278419|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
33401986|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
33082554|NCT04612426|Experimental|Brain-computer Interface-Pedaling Training System|
33278420|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
33278421|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
33082555|NCT04612426|Sham Comparator|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
33082556|NCT04612504|Experimental|SynOV1.1 Injection|
33082557|NCT04612270|Experimental|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
33278422|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
33278423|NCT00801671|Active Comparator|1|
33278424|NCT00801671|Sham Comparator|2|
33278425|NCT04045925|Experimental|Taïso practice|6 months of biweekly practice Taïso
33278426|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
33278427|NCT00794027|Other|Yoga group|Patients with heart failure
33278428|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
33278429|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
33278430|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
33278431|NCT00798395|Experimental|Treatment 1|
33278432|NCT00798395|Experimental|Treatment 2|
33278433|NCT00798395|Placebo Comparator|Treatment 3|
33278434|NCT00798395|Active Comparator|Treatment 4|
33278435|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
33278436|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
33278437|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
33278438|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
33278439|NCT00048061|Active Comparator|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
33278440|NCT00048061|Experimental|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
33278441|NCT00048061|Experimental|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
33278442|NCT00048061|Experimental|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
33278443|NCT00802139|Experimental|venoferrum group|
33278444|NCT00802139|Active Comparator|Bolgre group|
33278445|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
33082558|NCT00222053|No Intervention|1|No specific intervention
33082559|NCT00222053|Active Comparator|2|Biphosphonates
33082560|NCT00222053|Experimental|3|Thalidomide
33082561|NCT04612192|Experimental|Active light|active blue-enriched bright light
33082562|NCT04612192|Placebo Comparator|Placebo light|dim red placebo light
33082563|NCT04611958|Experimental|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
33082564|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
33082565|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
33082566|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
33082567|NCT04611997|Experimental|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
33082568|NCT04611997|Placebo Comparator|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
33082569|NCT04611646|Experimental|Heat-suit training|Low-intensity endurance training with heat suit
33278446|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
33278447|NCT04808141|Experimental|Digital Rehabilitation|Home-based rehabilitation with a digital biofeedback system
33278448|NCT04808141|Active Comparator|Conventional rehabilitation at an outpatient clinic|
33278449|NCT05213741|Experimental|Magnetic-assisted colonoscopy group|Participants in this group will recieve magnetic-assisted colonoscopic examination
33278450|NCT03955159|Experimental|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
33278451|NCT03955159|Placebo Comparator|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
33278452|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
33278453|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
32935974|NCT05449093||Stage 3 Grade B Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that CAL was caused by periodontal causes.These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. When this value was between 0.25 and 1.0, patients were included in grade B.
33278454|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
33278455|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
32935975|NCT05449093||Gingivitis|Gingivitis patients showed probing depth ≤ 3 mm with bleeding on probing ≥ 30 % in the entire mouth as well as no interproximal clinical attachment loss or radiographic bone loss.
32935976|NCT05449093||Periodontal Health|Periodontally healthy individuals in the control group had an intact periodontium or a reduced periodontium (without detectable interproximal clinical attachment loss or radiographic bone loss) in a non-periodontitis patient. In this group, probing depth was ≤ 3 mm and bleeding on probing was < 10 % in the whole mouth.
33278456|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
33278457|NCT00802373|Experimental|II|Tolterodine 4mg
33278458|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
33278459|NCT01092715|Active Comparator|Massage|Neck massage and exercises
33278460|NCT03957109|Other|general anesthesia|general anesthesia
33278461|NCT03957109|Other|spinal anesthesia|spinal anesthesia
33278462|NCT03952975|Other|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as <15 adjusted days, group A).
33278463|NCT03952975|Other|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) [14]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
33278464|NCT00802451|Active Comparator|Test Drug|
33278465|NCT00802451|Active Comparator|Reference Drug|
33278466|NCT03956953|Experimental|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
33278467|NCT03956953|Experimental|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
33278468|NCT03956953|Placebo Comparator|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
33278469|NCT03956953|Placebo Comparator|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
33278470|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
33278471|NCT00798473|Placebo Comparator|2|IV saline infusion
33278472|NCT01583881|Experimental|Renal denervation|Renal denervation
33278473|NCT01583881|No Intervention|control|No intervention
33278474|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
33278475|NCT00794105||Normal ears|
33278476|NCT00794105||Otitis media ears.|
33278477|NCT03955003|Experimental|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
33278478|NCT03955003|Other|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
32935977|NCT05448326||Work package 1 (WP1)|Patients without a diagnosis who consulted for a developmental anomaly in 2012 and 2022 and agree to resume a diagnostic approach
32935978|NCT05448326||Work package 2 (WP2)|Part 1 (Lab): Patients with developmental abnormalities with or without neurodevelopmental disorders who have had a CNV (Copy Number Variation) rendering that remained of unknown significance or classified as (probably) benign Part 2 (Clinical part): Patients who agree to resume the diagnostic process following a CNV report of unknown significance or classified as (probably) benign
32935979|NCT05448326||Work package 3 (WP3)|Patients with an established clinical diagnosis belonging to the characteristic syndromes of the AnDDI-Rares network (known gene(s) but negative molecular diagnosis)
32935980|NCT04806919|No Intervention|Control group: Amelgen ® 400 mg BID|Continue daily dose progesteron
32935981|NCT04806919|Experimental|Intervention group: Amelgen ® 400 mg TID|Increase daily progesteron dose
32935982|NCT04338308||SVG PCI|
32935983|NCT04438759|Experimental|investigational group|Virtual Reality
32935984|NCT04438759|No Intervention|reference group|standard of care
33278479|NCT03955237|Active Comparator|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
33278480|NCT03955237|Active Comparator|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
33278481|NCT03955237|Active Comparator|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
33278482|NCT04045769|Experimental|Study Treatment 1|Saroglitazar magnesium 4 mg
33278483|NCT04045769|Experimental|Study treatment 2|Saroglitazar magnesium 20 mg
33278484|NCT04045769|Placebo Comparator|Placebo|Placebo
33278485|NCT04045769|Active Comparator|Active Control|Moxifloxacin 400 mg
33278486|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
33278487|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
33278488|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
33278489|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
33278490|NCT03953365|No Intervention|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
33278491|NCT03953365|Other|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
33278492|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
33278493|NCT04046705|Experimental|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
32935985|NCT04793659|Experimental|Oral Fasudil 90 mg/day|Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
33278494|NCT04046705|Other|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
33278495|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
33278496|NCT01097473|No Intervention|Control|Control group receives no intervention
33278497|NCT00802763||vaginitis|
33278498|NCT01095679|Experimental|Baclofen|
32935986|NCT04793659|Experimental|Oral Fasudil 180 mg/day|If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
32935987|NCT04793659|Placebo Comparator|Oral Placebo|Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
33278499|NCT01095679|Placebo Comparator|Placebo|Placebo
32935988|NCT04539626|Experimental|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
32935989|NCT04539626|No Intervention|Control Group|Patients who will receive conventional COVID-19 treatment
32935990|NCT05445206||Health Adult|The target population is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
32935991|NCT05448937|Experimental|3 MIX|Lesion sterilization and tissue repair; preparation of modified triple antibiotic paste tap: the chemotherapeutic agents used are metronidazole tablets 500 mg (flagyl®, sanofi, egypt), ciprofloxacin tablets 500 mg (ciproxcin®,. Epico, egypt,), and doxycycline capsules 100 mg (doxymycin™ dt, el-nile pharmaceuticals, egypt).
32935992|NCT05448937|Active Comparator|Zinc oxide and Eugenol Pulpectomy|zinc oxide and eugenol (prevestdent pro™, egypt).
32935995|NCT00370279|Active Comparator|1|scleral buckling
32935996|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
32935997|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
32935998|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
32935999|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
32936000|NCT03217058||Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
32936001|NCT05448859||3-4 hours denudation|oocytes with 3-4 hours denudation time
32936002|NCT05448859||4-5 hours denudation|oocytes with 4-5 hours denudation time
32936003|NCT05448859||5-6 hours denudation time|oocytes with 5-6 hours denudation time
32936004|NCT05448859||6-7 hours denudation time|oocytes with 6-7 hours denudation time
32936005|NCT05448859||more than 7 hours denudation time|oocytes with more than 7 hours denudation time
33082570|NCT04611646|Other|Non-heat-suit training|Low-intensity endurance training without heat suit
33278500|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
33278501|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
33278502|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
33278503|NCT01092793|Active Comparator|Krill|
33278504|NCT01092793|Active Comparator|Fish oil|
33278505|NCT01092793|No Intervention|Control|
32776742|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
32776743|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
32776744|NCT02423343|Experimental|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32776745|NCT02423343|Experimental|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32776746|NCT04909515|Experimental|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
32776747|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
32776748|NCT05617729|Placebo Comparator|Saline|this treatment consists of sterile saline that is applied to the nares using a swab
32776749|NCT05617729|Active Comparator|Povidone-iodine based gel|this treatment consists of a Povidone-Iodine based gel that is applied to the nares using a swab
33401987|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
33401988|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
32776752|NCT04317859|Experimental|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
32776753|NCT04317859|No Intervention|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
32776754|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|All 190-202 study subjects administered BMN 190 300 mg by continuous Intracerebroventricular (ICV) infusion at a rate of 2.5 mL/hour for approximately 4 hours) every 14 days.
32776755|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
32776756|NCT05619055||neonate with necrotizing enterocolitis|premature infants diagnosed as necrotizing enterocolitis
32776757|NCT05619055||neonate without necrotizing enterocolitis|premature infants without necrotizing enterocolitis
32776758|NCT04818931|Experimental|Antibiotics|Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
32776759|NCT04818931|No Intervention|No antibiotics|
32936006|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
32936007|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
32776760|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
32936008|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
32936009|NCT05448781|Experimental|endostatin combined with PD-1 antibody and platinum-containing two-drug chemotherapy|"Recombinant human vascular endostatin (Endu): 210 mg (14 PCS), administered by continuous intravenous pumping for 72h every three weeks on the first day of each cycle.Pemetrexed: 500mg/m2, administered intravenously every three weeks on the first day of each cycle.Paclitaxel:175mg/ m2, administered intravenously every three weeks on the first day of each cycle.Albumin paclitaxel:260mg/ m2, administered intravenously every three weeks on the first day of each cycle.~Carboplatin:5/AUC, maximum dose limited to 600mg, or 75 mg/m2 cisplatin, is administered intravenously every three weeks on the first day of each cycle Tirelizumab: a recommended dose of 200mg/ time, administered every three weeks on the first day of each cycle until disease progression or unacceptable toxicity is developed."
32936010|NCT05448625||High Ischemic Group|"Acute myocardial infarction (AMI)~≥ 2 stents implanted~bifurcation lesion~Left main lesion~Lesion treated with rotational atherectomy~Chronic total occlusion (CTO) lesion"
32936011|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
32936012|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
33401989|NCT02388958||Women with GDM|
33278506|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
33278507|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
32776761|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
32776762|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32776764|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
32776765|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
32776766|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
32776767|NCT04421001|Experimental|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
32776768|NCT04421001|Active Comparator|Insulin Pen Injections|Patients will administer insulin via injections as usual
32776769|NCT04420767|Experimental|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
32776770|NCT04420767|Sham Comparator|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
32776771|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
32776772|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
32776773|NCT02485353|Other|Vosaroxin and Cytarabine|
32776774|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
32830716|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
32830717|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
32936013|NCT05448079|Experimental|Sexual counseling intervention group according to the PLISSIT model|Sexual counseling according to the PLISSIT model, randomized pretest-posttest
32936014|NCT05448079|Experimental|control|Non-counseling group
32830718|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
32936015|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
32936016|NCT04506008|Experimental|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy followed by immediate surgical resection
32936017|NCT04502966|Experimental|Grazax® +Dupixent®|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of Grazax® sublingual immunotherapy and~Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
32936018|NCT04502966|Experimental|Grazax® + Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of Grazax® sublingual immunotherapy and~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
33401990|NCT02388958||Women without GDM|
33401991|NCT02386930|Experimental|Behavrioal Lifestyle modification|
33401992|NCT02386930|No Intervention|Control|
32776775|NCT02603107|Experimental|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
32776776|NCT04826263|Experimental|ESWT Group|The patients in the ESWT group will receive ESWT treatment and a home exercise program.
32776777|NCT04826263|Experimental|LLLT Group|The patients in the LLLT Group will receive LLLT treatment and a home exercise program.
32776778|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
32776779|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
32776780|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
32776781|NCT04941729|Experimental|Study Arm (dual mobility)|OR3O™ Dual Mobility in subjects who undergo Primary THA.
32776782|NCT04941729|Active Comparator|Controlled Arm (conventional)|A conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
32776783|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
32776784|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
32936019|NCT04502966|Placebo Comparator|Grazax® Placebo +Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of placebo for Grazax® sublingual immunotherapy and~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
32936020|NCT03219697|Experimental|Parenting education program|"8 weeks of group parenting education sessions followed by two optional booster sessions.~2 public health nurse home/virtual visits and 4 coaching calls over a period of 6 months."
32936021|NCT03219697|No Intervention|Control|Receive regular health care
32776785|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
32936022|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
32936023|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
32936024|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
32776786|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
32776787|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
32776788|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
32936025|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
32936026|NCT05442788|Experimental|HB0017 150mg|10 subjects is randomly assigned to receive HB0017 150mg or matching placebo at a ratio of 4:1.
32936027|NCT05442788|Experimental|HB0017 300mg|10 subjects is randomly assigned to receive HB0017 300mg or matching placebo at a ratio of 4:1.
32776789|NCT04819087|Experimental|Patients|Patients with Pelvic Floor Dysfunction Related Temporamandibular Joint Problems and Tinnitus
32776790|NCT04819165||COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with confirmed COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
32776791|NCT04819165||non COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with negative COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
32776792|NCT04819321|Experimental|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
32776793|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.~(iii) duration of symptoms: more than 3 months."
32776794|NCT04834141||Kyphotic Group|"Participants with kyphosis angle ≥ 40 degrees joined the kyphosis group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
32776795|NCT04834141||Control Group|"Participants with kyphosis angle < 40 degrees for the control group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
32936028|NCT05442788|Experimental|HB0017 450mg|10 subjects is randomly assigned to receive HB0017 450mg or matching placebo at a ratio of 4:1.
32936029|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
33401993|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
33401994|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
32776796|NCT04826497|Experimental|Nicorandil|Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
32936030|NCT04498598|Experimental|A/Z Airway|Patients under general anesthesia for surgical procedures who need airway management for ventilation.
32776797|NCT04826497|Placebo Comparator|Placebo （normal saline）|Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention
32776798|NCT04834219||On-pump CABG|Patients with an on-pump indication by the cardiovascular surgery department will be included in the study.
32776799|NCT04834219||Off-pump CABG|Patients with an off-pump indication by the cardiovascular surgery department will be included in the study.
32776800|NCT04819243|Experimental|Atezolizumab+Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment~Talazoparib 1mg po~Atezolizumab 1200mg IV (3week)"
32776801|NCT04819243|Experimental|Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment - Talazoparib 1mg po"
32776802|NCT05618821|Experimental|ICG|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
32776803|NCT05618821|Active Comparator|Non-ICG|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
32776804|NCT04818619||chronic myeloid leukemia patients|
32936031|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
32776805|NCT04818619||Healthy individuals|
32776806|NCT04818697||Patients with heart rhythm disorders|Having been diagnosed with heart rhythm disorders such as atrial fibrillation, atrial tachycardia, ventricular tachycardia, and ventricular extrasystole
32776807|NCT04818697||Healthy individuals|Healthy individuals without chronic disease
32936032|NCT05442164||Before-group|Patients undergoing major emergency surgery before a supportive network is established
32936033|NCT05442164||After-group|Patients undergoing major emergency surgery after a supportive network is established
32936034|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
32936035|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
32936036|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
32936037|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
32936038|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
32936039|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
32936040|NCT04417465|Experimental|Monotherapy Dose Escalation|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
32936041|NCT04417465|Experimental|Combination Dose Escalation with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
32936042|NCT04417465|Experimental|Backfill Cohorts with Monotherapy|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
32936043|NCT04417465|Experimental|Backfill Cohorts in Combination with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
32936044|NCT04417465|Experimental|Combination Expansion with PD-1|ABBV-CLS-579 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), microsatellite instability-high (MSI-H) tumors, and advanced clear cell renal cell carcinoma (ccRCC)
32776808|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
32936045|NCT04417465|Experimental|Combination Expansion with VEGFR TKI|ABBV-CLS-579 will be administered at the determined recommended dose in combination with Vascular Endothelial Growth (VEGFR) Factor Receptor Tyrosine Kinase Inhibitor (TKI) in subjects with advanced ccRCC.
32936046|NCT04360213||Children with Asthma|"Patients ages 1 to 17 years old~Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
32936047|NCT04360213||Children with allergy|"Patients ages 1 to 17 years old~Patients scheduled to do an oral food challenge"
32776809|NCT05618743|No Intervention|Control Group|Periodontally and systemically healthy participants (Control group)
32776810|NCT05618743|Experimental|Periodontitis without Cardiovascular disease|Periodontitis participants without cardiovascular disease
32776811|NCT05618743|Experimental|Periodontitis with cardiovascular disease|Periodontitis participants with cardiovascular disease
32776812|NCT04826107|Experimental|Part 1: Dose-finding stage|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.
32776813|NCT04826107|Experimental|Part 2: Cohort A|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.
32776814|NCT04826107|Experimental|Part 2: Cohort B|Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.
32776815|NCT04826107|Experimental|Part 2: Cohort C|Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.
32776816|NCT04826107|Experimental|Part 2: Cohort D|Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.
32776817|NCT05617417|Other|The women with stress urinary incontinence administered injectable platelet-rich fibrin|Injectable platelet-rich fibrin was prepared by centrifuging venous blood samples from women with stress urinary incontinence. The obtained autologous material was injected into the anterior vaginal wall, approximately 1.5 cm below the urethral meatus, without applying a local anesthetic. The procedure was repeated for the same patient three times with an interval of one month. The severity of urinary incontinence was evaluated by filling out questionnaires before and after the procedure.
32776818|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
32776819|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
32776820|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
32776821|NCT04825249|Experimental|The traditional suture bridge technique group|For the TSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
32776822|NCT04825249|Experimental|The modified suture bridge technique group|For the MSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
32776823|NCT04356859|No Intervention|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
32776824|NCT04356859|Active Comparator|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
32776825|NCT04818307|Experimental|Macquarie Injury Management group|
32776826|NCT04818307|Active Comparator|Mulligan Mobilization with Movement|
32776827|NCT02601001|Placebo Comparator|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
32776828|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
33401995|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
32776829|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
32936048|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
32936049|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
32776830|NCT04825405|Active Comparator|The use of the active Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the active TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
32936050|NCT04475822|Experimental|Intermittent fasting|During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
32936051|NCT04475822|Experimental|Low carb diet|According to the definition of low carbon diet given by R. D. Feinman et al. (Nutrition, 2015), the daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
32936052|NCT04475822|Experimental|Low carbon diet and intermittent fasting group|Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
32936053|NCT04338451|Active Comparator|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
32936054|NCT04338451|Active Comparator|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
32936055|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
32936056|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
33278508|NCT03953287|Experimental|Pharmacokinetic Study of Paracetamol.|"Detailed Description:~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
32936057|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
33278509|NCT02554565|Other|Tumor biopsies and blood sampling|
33278510|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
33278511|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
33278512|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
33278513|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
33278514|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
33278515|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
33278516|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
33278517|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
33278518|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
33278519|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
32936058|NCT02966756|Experimental|Cohort 1: Venetoclax|Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
32936059|NCT02966756|Experimental|Cohort 2: Venetoclax|Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
33278520|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
33278521|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
33278522|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
33278523|NCT03953209|Experimental|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
33278524|NCT03953209|Experimental|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
33278525|NCT03953209|Experimental|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
33278526|NCT00794651||OA|moderate to severe osteoarthritis of the knee
33278527|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
33278528|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
32936060|NCT04298593|Other|ECG monitoring|All patient will be under telemetry
32936061|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
32936062|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
32936063|NCT05440604|Experimental|Fortified milk group|2 daily servings of the investigational fortified milk for 16 weeks
32936064|NCT05440604|No Intervention|Observational group|will be asked to consume beverages in accordance with their habitual pattern of intake
32936065|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
32936066|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
32936067|NCT05439044||Patients who have received an anti-SARS-CoV-2 monoclonal antibody|Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.
32936068|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
32936069|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
32936070|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure <80 mmHg twice and for> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
32936071|NCT04475432|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
32776831|NCT04825405|Placebo Comparator|The use of the passive Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the passive TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
32776832|NCT05618665|Experimental|Intervention Group - Children and parents|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
32776833|NCT05618665|Experimental|Intervention Group - Children|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
32776834|NCT05618665|No Intervention|Control group|No intervention was applied to the control group.
32776835|NCT04818151||ESRD patients with VTE treated with warfarin|Warfarin as primary treatment of VTE
32776836|NCT04818151||ESRD patients with VTE treated with apixaban|Apixaban as primary treatment of VTE
32776837|NCT04817527|Experimental|Edaravone Dexborneol|
32776838|NCT04817527|No Intervention|conventional therapy|conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy
32776839|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
32776840|NCT04357795|Experimental|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
32776841|NCT05617339|Experimental|"Personalised internet-based treatment I am."|Need-based internet-based treatment
32776842|NCT05617339|No Intervention|Treatment As Usual|Control group, Treatment in primary care which is medical treatment
33082571|NCT04611724|Experimental|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
33082572|NCT00563836|Experimental|1|
33082573|NCT04611685|Experimental|NSAIDs|Parecoxib (iv.) for once & Loxoprofen (po.) for routine use during the first 3 postop. days.
32776843|NCT04816279||First Audit cycle|
32776844|NCT04816279||Second Audit cycle|
33082574|NCT04611685|Active Comparator|Tramadol|Tramadol (im.) for once & Tramcontin (po.) for routine use during the first 3 postop. days.
33082575|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
33082576|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
32776845|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
32776846|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
32776847|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
32776848|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
32776849|NCT04807699||Total participants|3500 participants that will have their medical forms checked
32776850|NCT04817215|Experimental|Patients who are Drug naïve or diet controlled|
33082577|NCT00222248|Experimental|Pelvic floor muscle training|Weekly group session of education and exercise to music incorporating pelvic floor muscle training incorporating motor control, strength, endurance, power and functional training in a variety of different positions.
33082578|NCT00222248|Active Comparator|Bladder training|Weekly group session of education regarding deferral techniques, timed voiding parameters and gentle exercise to music.
33082579|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
33278529|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
33278530|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
33278531|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
33278532|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
33401996|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
32776851|NCT04817215|Experimental|Patients on Metformin only|
32776852|NCT04817215|Experimental|Patients on two or three oral glucose-lowering agents|
32776853|NCT04817059|Experimental|Head mold on|
32776854|NCT04817059|No Intervention|Head mold off|
32776855|NCT04816903|Experimental|Symptomatic vaginitis patients|All participants will be enrolled according to their complaints, All will be tested by the Gyni system, Only in the second group the physician will be unblinded to the Gyni results.
32776856|NCT04816045|Active Comparator|Intervention|Electrochemotherapy with bleomycin
32776857|NCT04816045|Active Comparator|Control|Electroporation with saline
33082580|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
33082581|NCT00563914|Experimental|1|
33082582|NCT00563914|Active Comparator|2|
33278533|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
33278534|NCT00803465||Cohort Group 1|Subjects number 1 to 24
33278535|NCT00803465||Cohort Group 2|Subjects number 25 to 44
33278536|NCT00803465||Cohort Group 3|Subjects number 45 to 68
33278537|NCT00803465||Cohort Group 4|Subjects number 69 to 91
33278538|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
33278539|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
33278540|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
33278541|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
32776858|NCT04816123|Experimental|[14C]Donafenib|
32776859|NCT04807465|Other|G-Premio universal adhesive used in smoker participants|Participants who smoke at least 10 cigarettes per day
33278542|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
33278543|NCT03952741|Experimental|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
33278544|NCT03952741|Active Comparator|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
33278545|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
33278546|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
33278547|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
33278548|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
33278549|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
33278550|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
33278551|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
33278552|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
33278553|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
33278554|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
33278555|NCT00798941|No Intervention|control|
33278556|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
33278557|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
33278558|NCT00794807|Experimental|Alefacept|
33278559|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
33278560|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
33278561|NCT04950725|Experimental|Low respiratory muscle training|Low dose of RMT and fewer repetitions and use of RMT device per week
33278562|NCT04950725|Experimental|Respiratory muscle training for strengthening|Higher number of sets with a slightly lower number of repetitions per set
33278563|NCT04950725|Experimental|Respiratory muscle training for strengthening and nasal breathing|Higher number of sets with a slightly lower number of repetitions per set RMT accompanied with sets of nasal breathing
33278564|NCT04950725|Experimental|Respiratory muscle training for endurance|One set of RMT with a higher number of repetitions
33278565|NCT04950725|Experimental|Respiratory muscle training for endurance and nasal breathing|One set of RMT with a higher number of repetitions accompanied with sets of nasal breathing
33278566|NCT00795041||1|10 women with indication for ART with ICSI or IVF
33278567|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
33278568|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
33278569|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
33278570|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
33278571|NCT00804011|Active Comparator|2|Pressure support alone
33278572|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
33278573|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
33278574|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
33278575|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
33278576|NCT00799331|Experimental|A|AZD5985
33278577|NCT00799331|Experimental|B|placebo
33278578|NCT00804089|Experimental|1|Traditional needle acupuncture
33278579|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
33278580|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
33278581|NCT00656513|Active Comparator|Pilocarpine: Phase III|
33278582|NCT00656513|Experimental|ALTENS: Phase III|
33278583|NCT00656513|Experimental|ALTENS: Phase II|
33278584|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
32776860|NCT04807465|Other|G-Premio universal adhesive used in non-smoker participants|participants who non-smoke have never smoked before
32776861|NCT04807621|Active Comparator|Platelets|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.
32776862|NCT04807621|Experimental|Fibrinogen|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.
32776863|NCT04807543|Active Comparator|study group|17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection
32776864|NCT04807543|Placebo Comparator|control group|castor oil, 1 mL total volume intramuscular injection
32776865|NCT05616559||Patient cohort (n=800)|All participants included will contribute with basic clinical, cognitive, psychometric, genetic and biochemical data.
32776866|NCT05616559||Subcohort I (n=600)|Patients in Subcohort I undergo MRI and EEG in addition to expanded clinical, cognitive, psychometric, and biological data.
32776867|NCT05616559||Subcohort II - drug naive PET subgroup (n=60)|A subgroup of Subcohort I, including only patients who at inclusion do not receive any pharmacological treatment for their depression, undergo in addition Positron Emission Tomography imaging with [11C]-UCB-J for measurement of cerebral synaptic density.
32776868|NCT04815889|No Intervention|Control group|Recruitment of the control group is done through the county parts that have not yet been included in the clinical trial of new methods. This means that children / families are not withheld from treatment they would otherwise receive.
32776869|NCT04815889|Active Comparator|PRIMUS parent training group and preschool teacher training group|The parents have undergone PRIMUS Group-based parent support program for 5 half days This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The preschool teachers may participate for half a day in education together with the parents as a practical implementation in the child's everyday life.
32776870|NCT04815889|Other|Demand-driven intervention|"The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted parent training group: toilet, sleep, food, everyday structure, handle behavioural problems~Web Courses Each individual intervention is evaluated afterwards with the study questionnaire."
32776871|NCT04815811|Experimental|Children suffering from acute inflammatory processes.|"The study population will consist of male and female children, aged from 6 months to 7 years old, admitted to the hospital for one of the three following types of acute inflammatory processes:~Urinary tract infection caused by Escherichia coli~Pneumonia with pleural effusion caused by Streptococcus pneumoniae~Sepsis"
32776872|NCT04815811|Other|Control group|Male and female children, aged from 6 months to 7 years old, admitted to the hospital for a scheduled operation for a non-inflammatory pathology.
32936072|NCT04475432|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
32936073|NCT04450316|Active Comparator|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
32936074|NCT04450316|Placebo Comparator|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
32936075|NCT04171921|Active Comparator|Robotic ventral hernia repair|
32936076|NCT04171921|Active Comparator|Open ventral hernia repair|
32936077|NCT05431010|Experimental|electroacupuncture and rehabilitation training|Participants in this group will received electroacupuncture（EA） combined with Otago exercise program(OEP). Acupuncture will be executed with size 0.30×40mm needle. EA will be performed with electronic acupuncture instruments
32936078|NCT05431010|Active Comparator|rehabilitation training only|The rehabilitation group will be only treated with the Otago exercise program(OEP). The Otago Exercise is a program developed by the research group of fall prevention in the elderly led by Campbell of Otago Medical University in the 1990s. It is a home exercise program aimed at strengthening lower extremity muscle, balance and preventing falls in the elderly. Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia (details are as follows).
32936079|NCT05428046|Experimental|MHL intervention|Mental health literacy intervention for eating disorder
32936080|NCT05428046|Other|Waiting list|The waiting list group received MHL intervention at the end of 12 weeks follow-up assessment.
32936081|NCT04040101|No Intervention|Healthy Adult|balance assessment
32936082|NCT04040101|No Intervention|Stroke|balance assessment
32936083|NCT04040101|Experimental|Stroke smartphone training|smartphone balance training
32936084|NCT04040101|Active Comparator|Stroke traditional training|traditional physical therapy training
32936085|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
32936086|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
32936087|NCT05419778||Group A (Osteogen plug®)|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to receive treatment with a type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)(Osteogen) ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
33278585|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
33278586|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
33278587|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
33278588|NCT00805883|Experimental|1|
33278589|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
33278590|NCT04045847|Experimental|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
33278591|NCT00804401|Active Comparator|Test Product|
33278592|NCT00804401|Active Comparator|Reference Product|
33278593|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
33278594|NCT00655889|Experimental|Active|
33278595|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
33278596|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
33278597|NCT00806039|Other|1|Early renal involvement
33278598|NCT00806039|No Intervention|2|control
33278599|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
33278600|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
33278601|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
33278602|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
33278603|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
32830719|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
32830720|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
32830721|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
33278604|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
33278605|NCT00804869||1|PalmScan biometric group
33278606|NCT00804869||2|A-mode ultrasonography biometric group
33278607|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
33278608|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
33278609|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
33278610|NCT00804947|Experimental|Intravenous busulfan and melphalan|
33278611|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
32830722|NCT04756167|Active Comparator|Conventional Group|The treatment of 21 individuals in the conventional group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes) and exercise(passive and active range of motion) approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week.
32830723|NCT04756167|Active Comparator|Myofascial Release Group|Treatment of 21 individuals in the Myofascial Release group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes),exercise(passive and active range of motion) and myofascial release to subscapularis and serratus anterior muscles approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week. Myofascial release will be done in the first five sessions of treatment programs.
32830724|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
32830725|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
32830726|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
32830727|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
32830728|NCT04756011||Group A (insulin pump)|30 patients who are on insulin pump.
32830729|NCT04756011||Group B (MDI)|30 patients who are on multiple daily injection.
32830730|NCT01896063|Experimental|Electroacupuncture preconditioning|
32830731|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
32830732|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
32900157|NCT05087264|Experimental|Indocyanine green injection|43 cases received preoperative intravenous injection of indocyanine green and radical resection of q-mc1 cervical cancer under pelvic autonomic nerve fluorescence development
32776873|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
32776874|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
32776875|NCT04798105|Sham Comparator|tDCS sham|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in sham mode.
32776876|NCT04798105|Active Comparator|tDCS anodal|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in anodal/excitatory mode.
32776877|NCT04798183||Healthy participants|
32776878|NCT04798183||Amyotrophic Lateral Sclerosis with bulbar involvement patients|
32776879|NCT04815733|Active Comparator|Mandatory ventilation|deep neuromuscular block and mandatory ventilation (PCV-VG);
32776880|NCT04815733|Experimental|Pressure support ventilation|partial neuromuscular block and pressure support ventilation (PSVpro).
32776881|NCT04806763|Experimental|Menicon Z Night|The experimental group is allocated to wear Menicon Z Night orthokeratology contact lenses for two years
32776882|NCT04806763|Active Comparator|Glasses|The active comparator includes a group that was allocated to wear distance, single-vision glasses for two years
32776883|NCT04815577||CHD group|The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
32776884|NCT04815577||Controle|The controle Group consisted of children referred for nonsevere functional symptom linked to exercise (murmur, palpitations or dyspnea) or for a medical sports certificate. We included controlled children from 2015 to 2020 period who will be added to the controlled patients of the initial study. These patients only had one CPET.
32776885|NCT04797949|Active Comparator|Randomized to USPSTF Criteria|Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
32776886|NCT04797949|Active Comparator|Randomized to Universal aspirin receipt|Women randomized to receiving low dose aspirin without knowing their risk status.
32776887|NCT04797793|Experimental|Adapalene gel 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32776888|NCT04797793|Active Comparator|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32776889|NCT04797793|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32776890|NCT04806529|Experimental|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|The experimental group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
32776891|NCT04806529|Placebo Comparator|The Comparator Group - Placebo|The comparator group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
32776892|NCT04796857|Experimental|Tislelizumab in Combination With Lenalidomide|On the day of tislelizumab infusion, lenalidomide should be taken 30 minutes after the end of tislelizumab infusion
32776893|NCT04796623|Experimental|TQB3616 capsules combined with fulvestrant injection|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
32776894|NCT04815421|Experimental|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The therapy duration was 6 days.
32776895|NCT04815421|Experimental|the meridian group|Patients in the meridian group were treated with dredging the same side Hand yang meridian techniques
32776896|NCT04815265|Experimental|Experimental group|Participants in the experimental group received remimazolam for sedation
32776897|NCT04815265|Active Comparator|Control group|participants in the control group received dexmedetomidine for sedation
32776898|NCT04796389|Experimental|Recorded music|Recorded music intervention
32776899|NCT04796389|No Intervention|Control|Standard of care
32776900|NCT04806841|Experimental|Intervention group|Participants will have access to 4 weekly supervised training sessions for 3 months. The intervention group will also take part in 3 group meetings (behavioral intervention) and will receive follow-up phone calls from month 4 to 6.
32776901|NCT04806841|Experimental|Control group|Participants will have access to 4 weekly supervised training sessions for 3 months without any behavioral intervention.
32776902|NCT04815187|Experimental|Montelukast 10 mg|Subjects will be instructed to take one pill at night for 90 days
32776903|NCT04815187|Placebo Comparator|Placebo|Subjects will be instructed to take one pill at night for 90 days
32776904|NCT05616481|Active Comparator|Laparoscopic Burch|The original procedure will be performed
33082583|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
33082584|NCT00563992|Experimental|1|Participants will take lithium for 12 months
33082585|NCT00563992|Experimental|2|Participants will take valproate for 12 months
33082586|NCT04611373|Experimental|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
33082587|NCT04611256|Experimental|MSC transfusion|
33082588|NCT04611256|Active Comparator|Control|
33082589|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
33082590|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
33082591|NCT04610983|Experimental|Control|Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
33278612|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
33278613|NCT02553005|No Intervention|Control|
33278614|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
33082592|NCT04610983|Experimental|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
33082593|NCT04610983|Experimental|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
33082594|NCT04611178||CIV-ABAO|CIV-ABAO
33082595|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
33082596|NCT00222326|No Intervention|Usual care|Usual care as provided by the surgeon and hospital staff
33278615|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
33278616|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
33082597|NCT00564031|Placebo Comparator|1|
33082598|NCT00564031|Experimental|2|
33082599|NCT00564031|Experimental|3|
33082600|NCT00564031|Experimental|4|
33082601|NCT04610437|Active Comparator|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
33082602|NCT04610437|Placebo Comparator|K-wire|Arthrodesis interphalangeal with kirschner wire
33082603|NCT02961426|Experimental|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
33082604|NCT04610359|Experimental|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
33082605|NCT04610281|No Intervention|Control|"Wards without the Inner Garden biofeedback tool"
33082606|NCT04610281|Experimental|Inner Garden|"Wards with the Inner Garden biofeedback tool"
33278617|NCT00805181||Acute uncomplicated pyelonephritis|
33278618|NCT00655733|Experimental|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
33278619|NCT00655733|Placebo Comparator|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
33278620|NCT00806429|Experimental|1|transvaginal appendectomy
33278621|NCT00806429|No Intervention|2|
33278622|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
33278623|NCT00805259|Active Comparator|1. Atomistic|payment for own work
33278624|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
33278625|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
33278626|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
33278627|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
33278628|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
33278629|NCT00806663|Experimental|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
33278630|NCT00805415|Experimental|Arm 1|
33278631|NCT00805415|Experimental|Arm 2|
33278632|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
33278633|NCT02553863|Other|Control group|Standard care
33278634|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
33278635|NCT00799565|Experimental|2|Healthy Volunteers
33278636|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
33278637|NCT00806741|Active Comparator|2|Phenylephrine
33278638|NCT00806741|Placebo Comparator|3|Physiological saline solution
33278639|NCT00799721||1|VLBW infants with erythropoietin therapy
33278640|NCT00799721||2|VLBW infants without erythropoietin therapy.
33278641|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
33278642|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
33278643|NCT00806897||A|
33278644|NCT00805649|Experimental|1|eyes with predominately classic lesions
33278645|NCT00805649|Experimental|2|eyes with occult lesions
33278646|NCT00799799|Experimental|NK|patient treated as per protocol
33278647|NCT00806975|Other|usability and preference|
33278648|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
33082607|NCT04610320|Experimental|Daratumumab-SC Injection|"Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
33082608|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
33278649|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
33278650|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
33278651|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
33401997|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
33278652|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
33278653|NCT00807053|Placebo Comparator|4|Placebo
33278654|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
33278655|NCT00809393|Experimental|high dose|
33278656|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
33278657|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
33278658|NCT00807131|Experimental|1|Patient follow-up
33278659|NCT00807131|Experimental|2|Counseling
33278660|NCT00807131|Experimental|3|Drug dispensing
33278661|NCT00807131|Active Comparator|4|pharmacy usual care
33278662|NCT00658775|Experimental|1|
32738778|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
33278663|NCT00658775|Active Comparator|2|
32776905|NCT05616481|Active Comparator|Laparoscopic modefied Burch procedur (TOT-like)|Sutures on the pubocervical fascia are placed at the level of the attachment of the arcus tendinous fascia pelvis and the pubourethral ligament.
33278664|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
33278665|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
33278666|NCT00800033|Experimental|Aerobic exercise training|
33278667|NCT00800033|Placebo Comparator|Resistance exercise training|
33278668|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
33278669|NCT00800033|No Intervention|Regular diet|
33278670|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
33278671|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
33278672|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
32738779|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
33278673|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
33278674|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
32738780|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
32738781|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
32738782|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
33082609|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
33082610|NCT04610164|Experimental|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
33082611|NCT04610164|No Intervention|Group 2: Control Group|Patient will not receive TXA prior to surgery
33278675|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
33278676|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
33278677|NCT00809549|Placebo Comparator|Normal Saline|
33278678|NCT00809549|Experimental|Filgrastim|
33278679|NCT00809627|Experimental|1|IV caffeine with saline and opiate
32738783|NCT04992897||REN-Medication combinations|"all evaluable treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
32776906|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
33278680|NCT00809627|Placebo Comparator|2|IV saline with opiate
33278681|NCT00809705|Experimental|1|
33278682|NCT00809705|Experimental|2|
33278683|NCT00809705|Placebo Comparator|3|
33278684|NCT00655499|Experimental|Panitumumab + CPT11 (irinotecan hydrochloride)|1 cycle every 14 days (J1= J15)
33278685|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
33278686|NCT00809861|Active Comparator|2|
33278687|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
33278688|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
33278689|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
33278690|NCT00800267|Active Comparator|latanoprost 0.005%|
33278691|NCT00800267|Active Comparator|Timolol - 0.5%|
33278692|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
33278693|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
33278694|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
33278695|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
33278696|NCT00807443|Experimental|Raltegravir|
33278697|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
33278698|NCT00807521|Placebo Comparator|2|Placebo control
33278699|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
33278700|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
33278701|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
33278702|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
33278703|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
33278704|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
33278705|NCT00800501|Experimental|sNN0029|
33278706|NCT00800501|Placebo Comparator|Placebo|
33278707|NCT00807677|Experimental|1|TAK-901
33082612|NCT04610086||False positive FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
33082613|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
33082614|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
33082615|NCT04610203|Placebo Comparator|Glucose|Glucose - 50 g
33082616|NCT04610203|Experimental|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
33082617|NCT04610203|Experimental|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
33278708|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
33278709|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
33401998|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
32936088|NCT05419778||Group B ( MInerOss® )|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to a cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
33278710|NCT02552381||Group I|"Patients without LMWH treatment.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays~Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
33278711|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
33278712|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
33278713|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
33278714|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
33278715|NCT00810251||MatrixRIB|
33278716|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
33278717|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
33278718|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
33278719|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
32936089|NCT05417282|Experimental|Part A: Open Label|10 subjects will receive MW151 in an open label evaluation.
32936090|NCT05417282|Experimental|Part B: Randomized, placebo-controlled|30 subjects will be randomly assigned to MW151 or placebo in a 1:1 ratio.
32936091|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
32936092|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
32936093|NCT02808962|Other|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
32936094|NCT05398094|Experimental|Experimental: Induction treatment + Post-Induction Phase|"Patients enrolled in the study will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment postinduction phase.~Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death."
32936095|NCT04359446|Other|Stent under-expansion with NC Balloon|
32936096|NCT04359446|Other|Stent under-expansion with Laser Excimer + NC Balloon|
32936097|NCT05394428||Patients with female sexual organs treated with pelvic radiotherapy|Patients with female sexual organs treated with pelvic radiotherapy.
32936098|NCT05377424|Experimental|AIH + istradefylline (AIH+IST)|Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
32936099|NCT05377424|Active Comparator|Sham-AIH + istradefylline (sham+IST)|This is a sham counterpart to the low oxygen. Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
33082618|NCT04610398|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
33082619|NCT04610398|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
33278720|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
33278721|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
33278722|NCT00810329||2|The healthy control group
33278723|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
33278724|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
33278725|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
33278726|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
33278727|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
33278728|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
33278729|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
33278730|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
33278731|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
33278732|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
33278733|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
33278734|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
33278735|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
33278736|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
33278737|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
33278738|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
33278739|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
32776907|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
33278740|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
32776908|NCT04796545|Experimental|Tsert SI System model NG SI IMT 3X|All participants will be implanted with the Tsert SI System model NG SI IMT 3X.
32776909|NCT04796077|Experimental|Pop-Up Book|Patients read an interactive pop-up book about general anesthesia induction in addition to standard consultation with an anesthesia provider.
33278741|NCT00811031|Experimental|Taxotere + Prednisone|
33278742|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
33278743|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
33278744|NCT04668599||Patient with chronic lung or cardiac diseases|"This study will focus on patients with obstructive or restrictive lung diseases eligible for pulmonary rehabilitation.~Patient with cardiac disease such as heart failure, coronary artery disease or cardiomyopathies who are eligible for cardiac rehabilitation will also be included."
33278745|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
33278746|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
33278747|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
33278748|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
33278749|NCT00808223|Experimental|1. alefacept|
33278750|NCT00811343|Experimental|1|
33278751|NCT04045535|Experimental|Intervention group|Intervention with nurse and patients
33278752|NCT04045535|Active Comparator|Usual care|Usual clinical care based on current clinical practice guidelines.
33278753|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
33278754|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
33278755|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
33278756|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
33278757|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
33278758|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
33401999|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
33278759|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
33278760|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
33402000|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
33278761|NCT00808457||patients with suspected pneumonia|
33278762|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
33278763|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
33278764|NCT00808535||diabetics|
33278765|NCT00808535||healthy controls|
33278766|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
33278767|NCT00811811|Experimental|1|Behavioral neurocardiac training
33278768|NCT00811811|Active Comparator|2|Autogenic relaxation training
33278769|NCT00569231|Experimental|Candida Antigen|
33278770|NCT00654095|Experimental|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
33278771|NCT04016831|Other|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
33402001|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:~Apnea;~Spontaneous regular breathing;~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;~Hyperventilation."
32776910|NCT04796077|No Intervention|Standard Care|Patients received standard consultation with an anesthesia provider (standard care).
32776911|NCT04806061|Experimental|sodium bicarbonate|iv sodium bicarbonate 8.4%
32776912|NCT04806061|Experimental|control|standard care
32776913|NCT04805749|Experimental|Osteopathic manipulation|Spinal Mobilisation / Cranial Osteopathy therapy / Circulatory Techniques / Visceral osteopathic therapy
32776914|NCT04814797||"CF children with gas trapping"|"CF children with gas trapping will be defined by a ratio between the difference of functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of >10%"
32776915|NCT04814797||"CF children without gas trapping"|"CF children without gas trapping will be defined by a ratio between the difference of the functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of ≤10%"
32776916|NCT04814641||Infants with hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days
32776917|NCT04814641||Infants without hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia
32776918|NCT04814719|Experimental|Pentosan Polysulfate Sodium|Pentosan Polysulfate Sodium (PPS) at Dose and frequency selected in Stage 1 of Parent Study for 6 weeks
32776919|NCT04814719|Placebo Comparator|Placebo|Placebo for 6 weeks
32900158|NCT05087264|No Intervention|Not Indocyanine green injection|43 cases underwent routine surgery，not indocyanine green injection
33278772|NCT04016831|Experimental|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
33278773|NCT00808691||1|Patients with sepsis
33278774|NCT00808691||2|Patient admitted for postoperative care
33278775|NCT00808691||3|Patients with ARDS
33278776|NCT00808691||4|Patients with ARF
33278777|NCT00808691||5|Patients who receive liver support treatment
33278778|NCT00808691||6|Patients wiht brain death
33278779|NCT00811967|Experimental|Treatment Arm|
33278780|NCT00811967|No Intervention|Control Arm|
33278781|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
33278782|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
33402002|NCT05366764|Experimental|SAR443765|Single dose administration of SAR443765
33402003|NCT05366764|Placebo Comparator|Placebo|Placebo to match SAR443765
33402004|NCT05358964|Experimental|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
33278783|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
33278784|NCT00812045|Experimental|1|
33278785|NCT00812045|Placebo Comparator|2|
33278786|NCT04046159|Active Comparator|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
33278787|NCT04046159|Experimental|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
33278788|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
33278789|NCT00650585|Experimental|Treatment group|Received Project ALERT
32900159|NCT05075330|Experimental|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
33278790|NCT02552069||Tritanium® cup|
33278791|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
33278792|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
33278793|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
33278794|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
33278795|NCT00808925|Experimental|research arm|
33278796|NCT00809003||Sjogren's group|
33278797|NCT00809003||Dry eye|
33278798|NCT00809003||Normals|
33278799|NCT00809081|Other|1|1. Enteral Feeding
33278800|NCT00809081|No Intervention|2|Total Parental support
33278801|NCT00646451|Active Comparator|Pregabalin (Lyrica)|Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid
33278802|NCT00646451|Placebo Comparator|Placebo|Placebo to 4 capsules bid
33278803|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
33278804|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
33278805|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
33278806|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
33278807|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
33278808|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
33278809|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
33278810|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
33278811|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
33278812|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
33278813|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
33278814|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
33278815|NCT00817505|Active Comparator|1|AZD1656 tablet + food
33278816|NCT00817505|Active Comparator|2|AZD1656 susp. without food
33278817|NCT00817505|Active Comparator|3|AZD1656 tablet
33278818|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
33278819|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
33278820|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
33278821|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
33278822|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
33278823|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
33278824|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
33278825|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
33278826|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
33278827|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
33278828|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
33278829|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
33278830|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
33278831|NCT02551679|Active Comparator|ACP-01|Injection into lower extremity
33278832|NCT02551679|Placebo Comparator|Placebo|Injection into lower extremity
33278833|NCT00817661|Experimental|1|Vitamin A group
33278834|NCT00817661|Placebo Comparator|2|Placebo group
33278835|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
33278836|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
33278837|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
32936100|NCT05377424|Active Comparator|AIH + placebo (AIH+CON)|This is a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
32936101|NCT05377424|Active Comparator|Sham-AIH + placebo (sham+CON)|This is a sham counterpart to low oxygen, and a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
32936102|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
32936103|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
32936104|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
32936105|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
32936106|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
32936107|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
32936108|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
32936109|NCT02535247|Active Comparator|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
32936110|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
32936111|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
32936112|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
32936113|NCT02509897|Active Comparator|Hypoxic training|Endurance training
32936114|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
32936115|NCT04337996|Experimental|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
33278838|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
33278839|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
33278840|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
33278841|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
33278842|NCT00814151||Standard of Care|Blood Culture positive specimens.
33278843|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
33402005|NCT05358964|Active Comparator|Genetic Alliance: Does it run in the family|The Genetic Alliance Does it run in the family is an existing family health history tool kit generalized to all racial groups. This tool is widely available via the internet.
33402006|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
32776920|NCT04795609|Active Comparator|Interventional group|Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training or to standard rehabilitation care
32776921|NCT04795609|No Intervention|Control group|Bed restriction strategy for 5 days
33278844|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
33278845|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
33278846|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
33278847|NCT00817895|Experimental|control|
33278848|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
33278849|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
33278850|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
33278851|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
33278852|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
33278853|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
33278854|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
33278855|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
33278856|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
32776922|NCT04805905||Skin graft|
32776923|NCT04805905||Local flap|
33278857|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
33278858|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
33278859|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
33278860|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
33278861|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
33278862|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
33278863|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
33278864|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
33278865|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
33278866|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
33278867|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
33278868|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
33278869|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
33278870|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
33278871|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
33278872|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
33278873|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
33278874|NCT04044911|Active Comparator|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
33278875|NCT04044911|Active Comparator|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
33278876|NCT04045379|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
33082620|NCT04609969|Experimental|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
33082621|NCT04610125|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
33082622|NCT04610242|Experimental|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
33082623|NCT00564148|Experimental|A,1, II|
33278877|NCT04045379|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
33278878|NCT04045379|Active Comparator|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
33278879|NCT04045457|Other|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
33278880|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
33278881|NCT00061945|Experimental|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
33278882|NCT00817973|Active Comparator|Casein|
33278883|NCT00817973|Active Comparator|Whey|
33278884|NCT00817973|Active Comparator|Cod|
33278885|NCT00817973|Active Comparator|Gluten|
33278886|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
33278887|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
33278888|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
33278889|NCT01097941|Active Comparator|LAIV/LAIV|
33278890|NCT01097941|Active Comparator|IIV/IIV|
33278891|NCT01097941|Active Comparator|IIV/LAIV|
33278892|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
33278893|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
33278894|NCT00818129|Experimental|1|
33278895|NCT00818129|Placebo Comparator|2|
33278896|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
33278897|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
33278898|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
33278899|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
33278900|NCT03992326|Experimental|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
33082624|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
33278901|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
33278902|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
33278903|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
33278904|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
33278905|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
33278906|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
33278907|NCT00061633|Experimental|Telavancin|
33278908|NCT00061633|Active Comparator|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
33278909|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
32776924|NCT04805827|Experimental|Gabapentin|1 tablet contains 600 mg Gabapentin
32936116|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
33278910|NCT01044940||Blood transfusion|Babies who receives blood transfusion
33278911|NCT01044940||Heart Surgery|Babies who need heart surgery
33278912|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
32776925|NCT04805827|Active Comparator|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
32776926|NCT04795687||Ischemic stroke patients|
33278913|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
33278914|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
33278915|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
32776927|NCT04795687||Control|
33278916|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
33278917|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
32900160|NCT05075330|No Intervention|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
33278918|NCT03957031||Control|Patients with confirmed absent of GC
33278919|NCT02550977|Experimental|Gestodene/EE Patch|
33278920|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
33278921|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
33278922|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
33278923|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
33278924|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
33278925|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
33278926|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
33278927|NCT00267904|Experimental|Healthy Volunteer for Banana|Ingestion of a single banana
33278928|NCT00267904|Experimental|Healthy Volunteer for Coffee|Ingestion of caffeinated coffee on one day and decaffeinated coffee on another day
33278929|NCT00267904|Experimental|Healthy Volunteer for Olive|Ingestion of olives
33278930|NCT00267904|No Intervention|Healthy Volunteer for Quality Control Plasma|Arm venous blood is drawn via an indwelling i.v. catheter from HVs to obtain quality control plasma
33278931|NCT00267904|Experimental|Healthy Volunteer for Temp. Manip.|Manipulation of temperature at skin of the back
33278932|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
33278933|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
33278934|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
33278935|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
33278936|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
33278937|NCT01046266|Experimental|A|
33278938|NCT01046266|Active Comparator|B|
33278939|NCT00046891|Experimental|Ginkgo Biloba|120 mg per day (60 mg BID)
33278940|NCT00046891|Placebo Comparator|Placebo|1 tablet BID
33278941|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
33278942|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
33278943|NCT00365794|Experimental|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
33278944|NCT03954457|Experimental|A-CWS Intervention|Participants received A-CWS Intervention.
33278945|NCT03954457|Active Comparator|Standard Care Control|Participants received standard care.
33278946|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
33278947|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
33278948|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
33278949|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
33278950|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
33278951|NCT03956641|Experimental|experimental: observational cohort|Evaluation of the physical condition and the quality of life
33278952|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
33278953|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
33278954|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
33082625|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
32776928|NCT04805359|Experimental|Normoxic exercise (NE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 21%O2 in air (NE) for 30 minutes per day, 5 days per week for 6 weeks
32776929|NCT04805359|Experimental|Hypoxic exercise (HE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 15%O2 in air (HE) for 30 minutes per day, 5 days per week for 6 weeks
32776930|NCT04805359|No Intervention|Normoxic control|Without any exercise training
32776931|NCT04814329||effective group|After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
32776932|NCT04814329||stable group|After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
32776933|NCT04814329||Early progressed group|After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
32776934|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
32776935|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
32776936|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
32776937|NCT04805281|Active Comparator|Lithium Disilicate IPS e.max crowns in posterior teeth|
32776938|NCT04805281|Experimental|Monolithic Zirconia (5Y-TZP/3-YTZP) crowns in posterior teeth|
32776939|NCT05616403||Textbook outcome group|Achieving textbook outcome after laparoscopic pancreaticoduodenectomy
33082626|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
32776940|NCT05616403||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic pancreaticoduodenectomy
32776941|NCT04814485|Experimental|SHR-1020 combined with albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel
32776942|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
32776943|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
32776944|NCT04280887|Experimental|Intervention|Participants will wear the device for the specified test period (3 months)
32776945|NCT04280029|Experimental|SELUTION SLR™ DEB|
33082627|NCT04609462|Active Comparator|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
33082628|NCT04609462|Experimental|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
33082629|NCT04609267|Experimental|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
32776946|NCT04280029|Active Comparator|Control Treatment|"For subjects randomized to the control group (SOC) the treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. The decision should be based on the treating physicians' assessment of the best treatment option for the individual patient. However, it is expected that patients with one prior stent will receive DES and patients with two prior stents will receive POBA. Treating physicians may deviate from this if it is determined to be in the best interest of the patient, but the justification for the treatment decision must be recorded in eCRF.~Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices."
32776947|NCT04262401|Active Comparator|Standard health coaching|Standard health coaching to increase health behaviors
32776948|NCT04262401|Experimental|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
32776949|NCT04795063|Experimental|Total Robotic Distal Gastrectomy|After exploration and randomization, patients received total robotic distal gastrectomy
32776950|NCT04795063|Active Comparator|Robotic-Assisted Distal Gastrectomy|After exploration and randomization, patients received robotic-assisted distal gastrectomy.
32776951|NCT04804501|Experimental|Blue Light Glasses (experimental)|These subjects will wear the device (glasses) while performing a reading task.
32776952|NCT04804501|Other|No Glasses (control)|These subjects will not wear the device (glasses) while performing a reading task.
32776953|NCT04795297||recurrent BCC|recurrent BCC
32776954|NCT04795297||resected BCC|resected BCC
33082630|NCT04609267|Experimental|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
33082631|NCT04609189|Experimental|Pearlium®/EffectiCal®|
33278955|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
32936117|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
33278956|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
33278957|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
33278958|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
33278959|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
33278960|NCT01049620|Experimental|Xelox+RAD001|
33278961|NCT00059839|Experimental|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
33405346|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
32776955|NCT04814017|Experimental|Radial shock-wave group|Group I (15 subjects) received radial shock-wave application one times a week for six weeks and home based stretching exercises.
32936118|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
32936119|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
32936120|NCT04417920|Active Comparator|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
32936121|NCT04417920|Active Comparator|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
32936122|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
32936123|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
32936124|NCT03853759||Patients with Heart Failure|
32936125|NCT03853759||Healthy İndividuals|
32936126|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
32936127|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
32936128|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
32936129|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
33082632|NCT04609189|Active Comparator|Calcium Carbonate/Vitamin D3|
33082633|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
33082634|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
33082635|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
33278962|NCT00059839|Experimental|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
33278963|NCT00059215|Experimental|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
33278964|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
33278965|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
33278966|NCT00059215|Active Comparator|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
33278967|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
33278968|NCT00058825|Experimental|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
33278969|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
33278970|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
33278971|NCT01098409|Experimental|sodium nitrite 24 hours before|
33278972|NCT01098409|Experimental|sodium nitrite during surgery|
33278973|NCT01098409|Placebo Comparator|0.9% sodium chloride|
33278974|NCT03956719|Experimental|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
33278975|NCT02535208|Experimental|Restrictive transfusion group|
33278976|NCT02535208|Active Comparator|Liberal transfusion group|
33278977|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
33278978|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
33278979|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
33278980|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
33278981|NCT03741205|Experimental|Treatment Group|SPEAC System
33278982|NCT03741205|No Intervention|Standard of Care|Standard of Care
33278983|NCT03953989|Experimental|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
33278984|NCT01096225||vaccinated group|
33278985|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
33278986|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
33278987|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
33278988|NCT02535130|Active Comparator|Nebulization|Control arm
33278989|NCT03803059|Experimental|Wrinkles of the Neck|Microneedle treatment neck areas.
33278990|NCT01046500|Active Comparator|metformin|
33278991|NCT01046500|Active Comparator|myo-inositol|
33278992|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
33278993|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
33278994|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
33082636|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
33082637|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
33402007|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
33402008|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
33402009|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
33402010|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
33402011|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
33402012|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
32776956|NCT04814017|Experimental|Control|Group II (15 subjects) received home based stretching exercises for six weeks.
32776957|NCT04804657|Active Comparator|Sage extract|Two hours before the endurance test, participants were asked to absorb two capsules of sage extracts (600mg each - cognivia™)
32776958|NCT04804657|Placebo Comparator|placebo|Two hours before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance than active comparator).
32776959|NCT04804423|Active Comparator|Fluoride varnish (Duraphat®)|Fluoride varnish application is recommended by the German National Health System for managing hypersensitivity and dental caries. Sodium fluoride varnish (Duraphat®) will be applied on hypersensitive active carious lesions (ICDAS 5).
33082638|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
33082639|NCT00564460|Placebo Comparator|2|Placebo
33082640|NCT04609033|Active Comparator|bupivacaine group|
33082641|NCT04609033|Active Comparator|bupivacaine + morphine|
33082642|NCT04609033|Active Comparator|bupivacaine + morphine + ketamine|
33082643|NCT04609033|Placebo Comparator|isotonic saline|
33082644|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
33082645|NCT00222716|No Intervention|Usual Care|Control arm
33082646|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
33082647|NCT04608565|Other|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device & multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
33082648|NCT04608604|Active Comparator|Physiotherapy 1|
33082649|NCT04608604|Active Comparator|Physiotherapy 2|
33082650|NCT00222755|Experimental|1|Behavioral Care Management
33082651|NCT00222755|No Intervention|2|Usual Care
33082652|NCT04608760|Active Comparator|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
33082653|NCT04608760|Active Comparator|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
33082654|NCT04608760|Active Comparator|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
33082655|NCT04608760|Active Comparator|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
33082656|NCT04608370|Experimental|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
33082657|NCT04608370|Active Comparator|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
33082658|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
33082659|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
33082660|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
33082661|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
33082662|NCT04608214|Experimental|Alisporivir|Administration of alisporivir and standard of care (SOC)
32936130|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
32936131|NCT04338139|Experimental|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
33278995|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
33278996|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
33278997|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
33278998|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
33278999|NCT01098565|Experimental|Study device arm|
33279000|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
33279001|NCT03956875|Active Comparator|yoga|Yoga treatment
33279002|NCT03956875|Placebo Comparator|massage|massage
33279003|NCT01096381||Will receive bevacizumab|
33279004|NCT01096381||Will not receive bevacizumab|
33279005|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
33279006|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
33279007|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
33279008|NCT03952507|Experimental|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
32936132|NCT03758989|Experimental|Baseline PET|R-CHOP
32936133|NCT05359562|Active Comparator|Active Comparator|Male participants will receive a brief EX/RP protocol within a 10-day window.
32936134|NCT05359562|Experimental|Experimental 1|Half of female participants will be randomized to receive a brief EX/RP protocol within the first 10 days after the start of menstruation (early follicular phase).
32936135|NCT05359562|Experimental|Experimental 2|Half of female participants will be randomized to receive a brief EX/RP protocol in days 12-22 of the menstrual cycle (late follicular, early luteal phase).
32936136|NCT05359328|Other|Controled Hypoxia - Healthy Volunteers|
32936137|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
32936138|NCT05354414|Experimental|VR followed by SOC|Participants will receive a 20-minute (min) VR session at the first nusinersen IT (IT1), followed by SOC (local anesthesia - lidocaine or intravenous sedation) at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
32936139|NCT05354414|Experimental|SOC followed by VR|Participants will receive SOC (local anesthesia - lidocaine or intravenous sedation) at nusinersen IT1, followed by a 20-min VR session at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
33279009|NCT03952507|Experimental|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
33279010|NCT03952507|Experimental|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
33279011|NCT03952507|Experimental|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
33279012|NCT03952507|Experimental|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
33279013|NCT03952507|Experimental|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
33279014|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
33279015|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
33279016|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
33279017|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
33279018|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
33279019|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
32936140|NCT04122001|Experimental|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
33279020|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
32936141|NCT04122001|Experimental|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
32936142|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
33279021|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
33279022|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
33279023|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
33279024|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
33279025|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT & MR-proADM using the Samsung IB10 point of care assay.
33279026|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
33279027|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
33279028|NCT01093807|Placebo Comparator|Placebo|
33279029|NCT01093807|Experimental|Lercanidipine 10 mg|
33279030|NCT01093807|Experimental|Lercanidipine 20 mg|
33279031|NCT01093807|Experimental|Enalapril 10 mg|
33279032|NCT01093807|Experimental|Enalapril 20 mg|
33279033|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
33279034|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
33279035|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
33279036|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
33279037|NCT01046734||Adult Community|
33279038|NCT01046734||Adult Hospital|
33279039|NCT01046734||Children Hospital|
33279040|NCT01046734||Children Community|
33279041|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
33279042|NCT01098799||Control|Healthy controls
33279043|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
33279044|NCT01098799||Kidney Transplant|Kidney transplants
33279045|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
33279046|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
33279047|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
33279048|NCT01046968|Experimental|Lepticore|
33279049|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
33279050|NCT01098877|Placebo Comparator|Placebo|
33279051|NCT01098877|Experimental|Cohort 1, 1mg|
33279052|NCT01098877|Experimental|Cohort 1, 3mg|
33279053|NCT01098877|Experimental|Cohort 1, 10mg|
33279054|NCT01098877|Experimental|Cohort 2, 30mg|
33279055|NCT01098877|Experimental|Cohort 2, 100mg|
33279056|NCT01098877|Experimental|Cohort 2, 300mg|
33279057|NCT01098877|Experimental|Cohort 3, 600mg|
33279058|NCT01098877|Experimental|Cohort 3, 900mg|
33279059|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
33279060|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
33279061|NCT00044083|Placebo Comparator|Placebo Arm|Placebo one week
33279062|NCT00044083|Active Comparator|Tolcapone Arm|Tolcapone one week
33279063|NCT00058123|Experimental|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)~Intramuscular injection~Drug Poly-ICLC"
33279064|NCT03952273|Active Comparator|Combo|PCI with COMBO stent
33279065|NCT03952273|Active Comparator|BioMatrix Alpha|PCI with BioMatrix Alpha stent
33279066|NCT00022633|Experimental|gemcitabine, paclitaxel|
33279067|NCT00021541|Experimental|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33279068|NCT00021541|Placebo Comparator|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
33279069|NCT01100827||EGFR mutation status in patients|
33279070|NCT00021229|Experimental|Imatinib mesylate|
33279071|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
33279072|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
33279073|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
33279074|NCT00372112|Placebo Comparator|placebo|Twice daily
33279075|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
33279076|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
33279077|NCT02688790|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
33279078|NCT02688790|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
33279079|NCT02688790|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
33279080|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
33279081|NCT01047124|No Intervention|Treatment as usual|
33279082|NCT00488475||Patients with Rheumatoid Arthritis|
33279083|NCT01782027|Experimental|3H-cholesterol|
33279084|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
33279085|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
33279086|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
32776960|NCT04804423|Experimental|Silver fluoride and potassium iodide (Riva Star®)|Silver fluoride and potassium iodide (Riva Star®) is primarily indicated for relieving hypersensitivity will be applied on hypersensitive active carious lesions (ICDAS 5) following isolation of the affected teeth and according to manufacturer's instructions.
33279087|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
33279088|NCT01020357|Active Comparator|caffeine|
33279089|NCT01020357|Placebo Comparator|placebo|
33279090|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
33279091|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
33279092|NCT00042991|Experimental|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
32776961|NCT04804111|Placebo Comparator|Placebo|maintain the initial dose, without increasing the dose.
32776962|NCT04804111|Active Comparator|URC102 3mg|Administer 3 mg of URC102 for 12 weeks
33279093|NCT01022385|No Intervention|12-hour fast|
33279094|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
33279095|NCT01017783|Other|Healthy Choices|
33279096|NCT01017783|Experimental|Diet Substitution A|
32936143|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
32936144|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
33279097|NCT01017783|Experimental|Diet Substitution B|
33279098|NCT00466167|Other|Pramipexole ER|
33279099|NCT00466167|Other|Pramipexole IR|
33279100|NCT00466167|Placebo Comparator|Placebo|
33279101|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
33279102|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
33279103|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
33279104|NCT01017861||Non pregnant women|Non pregnant women
33279105|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
33279106|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
33279107|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
33279108|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
33279109|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
33279110|NCT01022463|Placebo Comparator|Atenolol|
33279111|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
33082663|NCT04608214|Active Comparator|Standard of care (SOC)|Locally accepted regimen protocols for patient care
33279112|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
32936145|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
32936146|NCT05353400|Experimental|(Intervention group): self-removal of transurethral catheter on POD 1|Subjects will self-remove transurethral catheter at home on postop day 1
33279113|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
33279114|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
33279115|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
33279116|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
33279117|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
33279118|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
33279119|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
33279120|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
33279121|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
33279122|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
33279123|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
33279124|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
33279125|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
33279126|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
32936147|NCT05353400|Active Comparator|(Standard practice group): self-removal of transurethral catheter on POD 3|Subjects will self-remove transurethral catheter at home on postop day 3
32936148|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
33279127|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
33279128|NCT04199247|Experimental|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
33279129|NCT04199247|No Intervention|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
32936149|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
32936150|NCT05353322|Experimental|Sedentary Break Condition > Control Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
33102313|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
32936151|NCT05353322|Experimental|Control Condition > Sedentary Break Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
32936152|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
32936153|NCT04287608||Patients with qualifying conjunctivitis events|
32936154|NCT04287608||Patients with no clinical signs of eye inflammation|
32936155|NCT02171845||Foetus|
33279130|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
33279131|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
33279132|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
33279133|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
33279134|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
33279135|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
33279136|NCT00486603|Experimental|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~Other: pharmacological study (PK)~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2~Radiation (RT)"
33279137|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
33279138|NCT00486291|Placebo Comparator|2|Matched placebo
32936156|NCT05340296|Experimental|Acute Youth Connect + TAU|Subjects will receive 12 weeks of post-discharge Acute Youth Connect intervention, in addition to regular post-discharge treatment as usual.
32936157|NCT05306756|Active Comparator|Fetal Blood Sampling (FBS)|"Fetal capillary blood samples will be collected in heparinised tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample, or the lowest reliable sample if multiple samples are tested, will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver."
32936158|NCT05306756|Active Comparator|digital Fetal Scalp Stimulation (dFSS)|"The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30-60 seconds.The CTG will be observed over a 5-10 minutes interval after the dFSS and if a fetal heart rate acceleration (>15 bpm for 15 seconds) is observed the test will be considered normal. If there is an episode of normal variability (5-25 bpm) but there is no clear acceleration, the test will be considered borderline. If there is no FHR acceleration and no episode of normal variability with ongoing abnormal features, the test should be interpreted as abnormal in the same way as an abnormal FBS result.~FHR acceleration normal, if indicated repeat in 60 min; Uncertain acceleration/ normal variability borderline, repeat in 30 minutes; No Acceleration/ongoing abnormal features abnormal, deliver."
32936159|NCT04109599|Experimental|PlaySmart Full Game|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents.
32936160|NCT04109599|Experimental|Trading Wisdom Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player receives an opioid prescription from their dentist. This storyline includes information about safe use of opioids and the difference between use and misuse.
33279139|NCT04194723|Experimental|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
33279140|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
33279141|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
33279142|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
33279143|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
33279144|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
32936161|NCT04109599|Experimental|Lean on Me Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player is offered opioids at a party. This storyline includes information about different forms of opioids and their effects.
33279145|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
33279146|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
33279147|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
33279148|NCT03996603|Experimental|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
33279149|NCT03996603|No Intervention|Control Cohort|No intervention will be given.
33279150|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
33279151|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
33279152|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
33279153|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
33279154|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
33279155|NCT01018719||Left side breast cancer|
33279156|NCT01018719||Right side breast cancer|
33279157|NCT00383188|Placebo Comparator|1|
33279158|NCT00383188|Experimental|2|
32936162|NCT04109599|Experimental|Tough Love Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player navigates supporting their partner struggling with opioid misuse. This storyline includes information about treatment and recovery resources for opioid misuse & Opioid Use Disorder.
32936163|NCT04109599|Experimental|Grandma's Pills Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player witnesses the sharing of an opioid prescription within their family. This storyline includes information about medication safety and opioid overdose identification and response.
32936164|NCT04109599|Experimental|A Friend in Need Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player interacts with a friend that is in distress. This storyline includes information about how to navigate peer-to-peer support.
32936165|NCT04109599|Experimental|A New Direction Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player seeks out therapy as an option to manage stress. This storyline includes information about how to seek professional help for mental health.
32936166|NCT04109599|Experimental|Risk Sense All Levels|Adolescents, boys and girls, aged 16-19 participated in beta testing all levels of this PlaySmart mini game intended to increase perceived risk of harm of opioid misuse.
32936167|NCT04109599|Experimental|PlaySmart Full Game: Focus on Character Development|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents. Participants in this arm focused on beta testing character development aspects throughout the game.
32936168|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
32936169|NCT04273802|Experimental|Cohort A - First line treatment|Untreated patients
32936170|NCT04273802|Experimental|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
32936171|NCT03657043|Experimental|Safety Run-In (3Q4W Schedule)|28-day, 3 dose cycle
32936172|NCT03657043|Experimental|Part A: Tisotumab Vedotin|21-day, single dose cycle
32936173|NCT03657043|Experimental|Part A: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
33279159|NCT00383188|Experimental|3|
33279160|NCT00383188|Experimental|4|
33279161|NCT00383188|Experimental|5|
33082664|NCT04608175|Experimental|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
33082665|NCT04608175|No Intervention|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
33082666|NCT04608097|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
33082667|NCT04608097|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
33279162|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
33279163|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
33279164|NCT01025115|Experimental|A|Diamel
33279165|NCT01025115|Placebo Comparator|B|Placebo
33279166|NCT01022541|Other|This is a single arm study|This is a single arm study
33279167|NCT01045408|Placebo Comparator|Berry|
33279168|NCT01045408|Placebo Comparator|Placebo|
33279169|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
33279170|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
33279171|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
33279172|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
33279173|NCT01047280|Experimental|Clarinol G-80®|
33279174|NCT01047280|Experimental|G-c9, t11|
33279175|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
33402013|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
33402014|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
33279176|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
33279177|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
33279178|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
33279179|NCT01047592|Active Comparator|sarcosine|
33279180|NCT01047592|Active Comparator|sarcosine+ BE|
33279181|NCT01047592|Placebo Comparator|Placebo|
33279182|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
33279183|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
33279184|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
33279185|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
33279186|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
33279187|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
33279188|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
33279189|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
33279190|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
33279191|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
33279192|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
33279193|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
33279194|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
33279195|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
33279196|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
33279197|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
33279198|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
33279199|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
33082668|NCT04607902|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
33402015|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
33402016|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
32738784|NCT04992897||Consistent efficacy|"all users that performed at least 2 evaluable treatments. In order to isolate the effect of REN treatments, this dataset considered only treatments where REN was used as a standalone treatment.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
32738785|NCT04992897||Treatment intensity distribution|"all treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes)."
32738786|NCT04992897||Safety|all reported treatment/device-related adverse events (AEs) within the time period.
32738787|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
32738788|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
32738789|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
32738790|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
32738791|NCT04492787|Experimental|Changkang Granules|Changkang Granules
32738792|NCT04492787|Placebo Comparator|Changkang Placebo Granules|Changkang Placebo Granules
32738793|NCT04992741|Experimental|Experimental|Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
32738794|NCT04992741|No Intervention|other|The control group will remain subject to the routine process without any intervention.
32738795|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
32738796|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
32738797|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
32738798|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
32738799|NCT02452099|Other|5% DMSO|
32738800|NCT02452099|Other|7.5% DMSO|
32738801|NCT02452099|Other|10% DMSO|
32738802|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
32738803|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
32738804|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
32738805|NCT03317717|Experimental|botulinum toxin 2U|
32738806|NCT03317717|Experimental|botulinum toxin 5U|
32738807|NCT03317717|Experimental|botulinum toxin 10U|
32738808|NCT03317717|Experimental|botulinum toxin 20U|
32738809|NCT03317717|Experimental|botulinum toxin 30U|
32738810|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
32738811|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
32738812|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
32738813|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
32738814|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
32738815|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
32738816|NCT05004597|Experimental|infants longitudinally received three dimensional photo|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months
33082669|NCT04607902|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
33082670|NCT04607902|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
33082671|NCT00251628|Active Comparator|Group A|
33082672|NCT00251628|Active Comparator|Group B|
33082673|NCT00251628|Experimental|Group C|
33279200|NCT03995745|Experimental|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
33279201|NCT03995745|No Intervention|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
33279202|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
33279203|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
33279204|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
33279205|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
33279206|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
33279207|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
33279208|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
33279209|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
33279210|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
33279211|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
33279212|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
33279213|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
33279214|NCT01022697|Active Comparator|A|Glucose drink
33279215|NCT01022697|No Intervention|B|Fasting
33279216|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
33279217|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
33279218|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
33279219|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
33279220|NCT00453063|Experimental|MFNS 200 mcg QD|
33279221|NCT00453063|Placebo Comparator|Placebo|
33279222|NCT00371566|Experimental|Lapatinib|
33279223|NCT00371566|Placebo Comparator|Placebo|
33279224|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
33279225|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
33279226|NCT00371254|Experimental|1|
33279227|NCT00371254|Experimental|2|
33279228|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
33279229|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
33279230|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
33279231|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
33279232|NCT01021449||Control|Healthy subjects
32936174|NCT03657043|Experimental|Part B: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
33279233|NCT01021449||Schizophrenia|Schizophrenic patients
33279234|NCT00461253||1|Breast Cancer Cases
33279235|NCT00461253||2|Matched Controls for Breast Cancer Cases
33279236|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
33279237|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
33279238|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
33279239|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
33279240|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
33279241|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
33279242|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
33279243|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
33279244|NCT00641537|No Intervention|Placebo/No Treatment|
33279245|NCT00641537|No Intervention|Cladribine 3.5 mg/kg/No Treatment|Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
33279246|NCT00641537|No Intervention|Cladribine 5.25 mg/kg/No Treatment|Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
33279247|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
33279248|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
33279249|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
33279250|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
33279251|NCT00461175||1|Mirena®
33279252|NCT00461175||2|Copper IUD
33279253|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
33279254|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
33279255|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
33279256|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
33279257|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
33279258|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
33279259|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
33279260|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
33279261|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
33279262|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
33279263|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
33279264|NCT01023009||eye occlusion|
33279265|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
33279266|NCT04006665||Lung Ultrasonography prior to docking Robotic arms|Base line Lung ultrasonography will be performed in three basal zones for Right and Left lung -Post intubation and prior to docking robotic arms .
33279267|NCT04006665||Lung Ultrasonography after removal of robotic arms|Lung Ultrasonography will be performed to assess degree of atelectasis after removal of robotic arms and before extubation in three basal zones for Right and Left lung .
33279268|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
33279269|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
33279270|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
32776963|NCT04804111|Active Comparator|URC102 6mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.
32776964|NCT04804111|Active Comparator|URC102 9mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose
32776965|NCT04804111|Other|Febuxostat 80 mg|maintain the initial dose, without increasing the dose.
32776966|NCT04794673||Left damage|Have the brain damage and the location of the damage in the left brain
32776967|NCT04794673||Right damage|Have the brain damage and the location of the damage in the right brain
32776968|NCT04794673||Nomal control|Not have the brain damage
32776969|NCT04804189|No Intervention|Control Group|25 4-H Shooting Sport Clubs that will not receive The Reframe intervention.
32776970|NCT04804189|Experimental|Intervention Group|25 Randomized 4-H Shooting Sport Clubs that will receive The Reframe intervention.
32776971|NCT04794049|Experimental|Experiment cohort|4-6 hours before colonoscopy, patients in experiment cohort began to drink the first 150ml lactulose and half hour later, drink other 150ml lactulose dissolved in 1.5 L of water at a rate of 250ml every 15 minutes.
32776972|NCT04794049|Active Comparator|Control cohort|The participants in control cohort began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
32776973|NCT04794127|Experimental|Trabectedin in combination with Pioglitazone|Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
33279271|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
32776976|NCT04804267|Experimental|Experimental|Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
32776977|NCT04804267|Active Comparator|Active Comparator|LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
32776978|NCT04804267|Placebo Comparator|Placebo Comparator|Placebo Drug: Placebo orally once daily
32776979|NCT04427059|Experimental|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (TPA).
32776980|NCT04427059|Active Comparator|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (PSI).
32776981|NCT04793971||postoperative cases|patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
32776982|NCT04794439|Active Comparator|Toothpaste 1 with Stannous Fluoride|Toothpaste with Stannous Fluoride
32776983|NCT04794439|Active Comparator|Toothpaste 1 with Sodium Fluoride and sodium bicarbonate|Toothpaste with Sodium Fluoride and sodium bicarbonate
32776984|NCT04794439|Active Comparator|Toothpaste 2 with Stannous Fluoride|Toothpaste with Stannous Fluoride
32776985|NCT04794439|Active Comparator|Toothpaste 2 with sodium Fluoride and sodium bicarbonate|Toothpaste with sodium Fluoride and sodium bicarbonate
32776986|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
32776987|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
32776988|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
32776989|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
32776990|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
32936175|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
32936176|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
32936177|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
32776992|NCT04793503|Active Comparator|conventional complete denture|the patients receive conventional complete denture constructed from heat cure acrylic resin
32936178|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
32936179|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
32776993|NCT04793503|Active Comparator|CADCAM 3D printed denture|the patients receiveCADCAM 3D printed denture constructed by using printing machine
32776994|NCT04793503|Active Comparator|CAD/CAM milled denture|the patients receiveCADCAM 3D printed denture constructed by using milling machine
32776995|NCT04803565|Experimental|Custom-Made Insole|"This Group will receive a custom-made shoe insole designed on the foot shape of the subjects.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
32776996|NCT04803565|Sham Comparator|Sham Insole|"This group will receive a Sham shoe insole without any specific custom-made design.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
32776997|NCT04793113|Experimental|Intervention|Low carbohydrate, high protein meals
33279272|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
33279273|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
33279274|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
33279275|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
33279276|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
33279277|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
32776998|NCT04348123|Experimental|Outreach educational program|"Participants will be given a survey to elucidate beliefs and barriers around breast health and mammography.~A brief, culturally-appropriate educational session about breast health and mammography will follow and will be delivered by a female public health educator.~After education, eligible women will be offered a free on-site mammogram"
32776999|NCT04813471|Experimental|Endothelial Dysfunction Protocol|"Experimental: Endothelial Dysfunction Protocol~Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex) in critically Ill patients already on optimal medical therapy for the treatment of COVID-19 virus. Protocol will be given for a total of 14 days or until discharge from the hospital~Patients already on home statin will continue their medication or if the are eligible for statins they will recieve 40 mg tablet to be given PO once daily.~Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days~Folic Acid Folic Acid 5 mg po once daily~L-Arginine L-Arginine 1 g po TID~Vitamin B complex (Becozyme) 1 ampoule IV daily"
32777000|NCT04813471|No Intervention|Standard of care|Standard of Care
32777001|NCT04813393||Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire Group|The CPHP-Q was administered as a caregiver-report questionnaire. It aims to measure home program adherence of parents of children with CP. Parents applied this instrument in the study.
32777002|NCT05616247|Experimental|ECALC|Cognitive Behavioral Program to Change Expectancy Processes
32777003|NCT05616247|Experimental|ECALC Plus Weekly Boosters|Cognitive Behavioral Program to Change Expectancy Processes with Weekly Booster Content Delivered by Mobile Device
33279278|NCT01021605|Experimental|Hemolung Respiratory Assist System|
33279279|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
33279280|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
33279281|NCT03839355|Active Comparator|Eliquis|
33279282|NCT03839355|Active Comparator|Warfarin|
33279283|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
33279284|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
33279285|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
32777004|NCT05616247|No Intervention|Control|Control Group Presentation on Body Image
32777005|NCT04803175||Sacubitril/valsartan|Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
32777006|NCT04803175||Valsartan|Patients undergoing continued treatment with valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
32777007|NCT04793347|Experimental|shock waves|group of patients with anal fissure will be treated with shock waves
32777008|NCT04793425|No Intervention|Standard care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI.
33279286|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
33279287|NCT03838731|Experimental|REGN1908-1909|
33279288|NCT03838731|Placebo Comparator|Placebo|
33279289|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
33279290|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
33279291|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
33279292|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
33279293|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
33279294|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
33279295|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
33279296|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
33279297|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
33279298|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
33279299|NCT00814931|Experimental|1|Treatment Group
33279300|NCT00814931|Placebo Comparator|2|
33279301|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
33279302|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
32777009|NCT04793425|Experimental|Mobile app care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI. On top of that every patient will be given an access to mobile application, which will support rehab process. The application stands as a educational and coordination tool.
32777010|NCT04351087|Active Comparator|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
32777011|NCT04351087|Active Comparator|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
32777012|NCT04803253|Experimental|Participants using the ORTHOPUS set of prosthetic solution|
32777013|NCT04792723|Experimental|Healthy volunteer|Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
32777014|NCT04813081|Active Comparator|Free gingival graft around dental implant patients|Test Group (TG) consists of patients have free gingival graft around dental implant patients
32777015|NCT04813081|Active Comparator|Free gingival graft around the teeth|Control Group (CG) consists of patients have free gingival graft around the teeth.
32777016|NCT04427215|Experimental|A - Music Therapy|Two section a week of music therapy
32777017|NCT04427215|Experimental|B - Art Therapy|Two section a week of Art therapy
32777018|NCT04427215|Experimental|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
32777019|NCT04427215|Experimental|D - Bibliotherapy|Two section a week of Bibliotherapy
32777020|NCT04427215|Experimental|E - Physical Activity|Two section a week of systematized physical activity
32777021|NCT04427449|Experimental|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
32777022|NCT04803487|Experimental|the Micro Hand S robot group|41 patients were randomly allocated in the Micro Hand S robot group and cholecystectomy was performed using the Micro Hand S robot.
32777023|NCT04803487|Other|the da Vinci robot group|41 patients were randomly allocated in the da Vinci robot group and cholecystectomy was performed using the da Vinci robot.
32777024|NCT04803097||pediatric cataract group|Children who underwent cataract surgery and primary IOL implantation at the Eye Hospital of Wenzhou Medical University (Hangzhou, China) between 2016 and 2019 were included in the study. Every surgery included posterior capsulorhexis or capsulotomy and anterior vitrectomy. Patients accept slit-lamp-adapted anterior segmental photography at 1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
32777025|NCT04812769|Experimental|Intervention|Two nursing homes will receive the eCARE-ID intervention
32777026|NCT04812769|Placebo Comparator|Control|One control nursing home will receive infectious disease consultations and antibiotic stewardship services per routine practice.
32777027|NCT04812691|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in 1 x 10^8 CAR+T cells dose level
32777028|NCT04792333|Experimental|Treatment|500 mg (2 capsules of 250 mg)
32777029|NCT04803019|Active Comparator|DEB-TACE or chemoembolization with microspheres|The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F)
32936180|NCT05284058|Experimental|Cardiac Magnetic Resonance Imaging|All patients who are candidates for surgical mitral valve repair through minimally-invasive access according to the standard of care will be considered for inclusion in this clinical study. All patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
32936181|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
32936182|NCT04267874|Experimental|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
32936183|NCT04267874|Experimental|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
33279303|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
32777030|NCT04803019|Active Comparator|TAE or embolization with microspheres|The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F)
33279304|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
33279305|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
33279306|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
33279307|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
33279308|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
33279309|NCT00818675|Experimental|Ridaforolimus|
33405347|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
32830733|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
33279310|NCT00818675|Placebo Comparator|Placebo|
33279311|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
33279312|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
33279313|NCT00452361|Experimental|1|Sirolimus therapy
33279314|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
33279315|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
33279316|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
33279317|NCT00640289|Experimental|A|Treatment
33279318|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
33279319|NCT00818909|Experimental|Systane|Systane ocular product
33279320|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
33279321|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
33279322|NCT00818987|No Intervention|Non Operative|Placebo arm
33279323|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
33279324|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
33279325|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
33279326|NCT01047670|Placebo Comparator|2|placebo
33279327|NCT04903353|Active Comparator|Treatment with Risperidone|Patients prescribed Risperidone
32830734|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
33279328|NCT04903353|Active Comparator|Treatment with Aripiprazole|Patients prescribed Aripiprazole
33279329|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
33279330|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
33279331|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
33279332|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
33279333|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
33279334|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
33279335|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
33279336|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
33279337|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
33279338|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
33279339|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
33279340|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
33279341|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
33279342|NCT03850509|Experimental|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
33279343|NCT03850509|Experimental|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
33279344|NCT03850509|Experimental|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
33405348|NCT05165355|Experimental|Experimental group|Furmonertinib (80 mg orally, once daily) for 3 years.
32777031|NCT04812613|Other|Phase 2 Intervention|This study will utilize a mixed methods CBPAR approach. A peer-driven recruitment strategy will be implemented to enroll 20 at-risk youth who attend alternative schooling and drop-in activities at OCH. The investigators will select with the help of OCH staff, youth peer researchers that will be rigorously trained, similar to the PROMPT project. Peer researchers will be paid honoraria ($15/hr) to compensate for the time spent on research activities. Qualitative data through focus groups will also be collected from youth and key informants at OCH. This information will be used to design an individualized and focused social support intervention for youth. All youth in this arm will also have option to meet with a licensed mental health and substance use nurse to discuss treatment options. Youth's progress in the intervention will be followed with monthly interviews. The involvement of the research team will be limited to referring interested youth to said licensed health professional.
32777032|NCT04802785|Experimental|The study Group|"Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.~30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.~30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os."
32777033|NCT04802785|Active Comparator|Control group|Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
32777034|NCT04802785|No Intervention|Explanatory group:|12 participants without any intervention.
32777035|NCT04802941|Experimental|Neoadjuvant Chemotherapy by CDSS|
32777036|NCT04802941|Active Comparator|Neoadjuvant Chemotherapy in General practice|
32777037|NCT04802317||Control|Health people without any respiratory diseases
32777038|NCT04802317||Bronchial asthma|Patients with asthma
32777039|NCT04802317||COPD|Patients with chronic obstructive pulmonary disease
32777040|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
32777041|NCT04791397|Experimental|Group trial|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
32777042|NCT04791397|Experimental|Group control|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
32777043|NCT04802239|Active Comparator|calm waking group|calm waking state group
32777044|NCT04802239|Experimental|hypnosis session|hypnosis session group
32777045|NCT04802551|Experimental|Intervention group|
33082674|NCT04608058|Experimental|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
33082675|NCT04608058|Experimental|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
32777046|NCT04802551|No Intervention|Control group|
32777047|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
32777048|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
32777049|NCT04791007|Experimental|Single dose administration (Part 1)|the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
32777050|NCT04791007|Experimental|Multidose administration (Part 2)|the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
32777051|NCT04791085||general surgeons|General surgeons who work at general or private hospitals in Greece
33279345|NCT03850509|Placebo Comparator|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
33279346|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
32777054|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
32777055|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
33082676|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
32777056|NCT05616949|Active Comparator|Arm 1 Title: Treatment as Usual (TAU)|Arm 1: Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
33082677|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
33082678|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
33082679|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
33082680|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
33082681|NCT04607863||Low back pain|Patients with low back pain
33082682|NCT04607863||No low back pain|No low back pain patients
33279347|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
33279348|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
33279349|NCT03866421||Kidney transplanted patients|"Number of patients: 16~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).~Same interventions as in the control Group.~Including/ Exclusion criteria are listed under the section Eligibility"
32830735|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
32830736|NCT04802343|Experimental|BAY1817080 dose escalation|Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.
33279350|NCT03866421||Control group|"Number of patients: 16~Participants in this group are matched on age and BMI according to the kidney transplanted patients.~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.~Furthermore, participants have to have normal kidney function.~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
33279351|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
33279352|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
33279353|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
33279354|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
33279355|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
33279356|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
33279357|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
33279358|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
33279359|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
33279360|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
33279361|NCT01023321|Experimental|1|single ascending doses
32830737|NCT04802343|Placebo Comparator|Placebo|Healthy male subjects will received corresponding placebo.
32830738|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
32830739|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
33279362|NCT01023321|Placebo Comparator|2|single dose placebo
33279363|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
33279364|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
33279365|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
33279366|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
33279367|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
33279368|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
33279369|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
33279370|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
33279371|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
33279372|NCT00635219|Placebo Comparator|Placebo|
33279373|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
33279374|NCT00635219|Experimental|Vortioxetine: 5 mg|
33279375|NCT00635219|Experimental|Vortioxetine: 10 mg|
33279376|NCT00635219|Other|Duloxetine: 60 mg|Active reference
33405349|NCT05070663||Participants with severe asthma|Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study.
33405350|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
33082683|NCT04607785|Active Comparator|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
33082684|NCT04607785|Other|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
33279377|NCT03987477|Experimental|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
33279378|NCT03987477|Other|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
33279379|NCT00363766|Experimental|LY573636|
33279380|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
33279381|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
33279382|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
32830740|NCT04114227|Active Comparator|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
33279383|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
33279384|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
33279385|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
33279386|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
33279387|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
33279388|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
33279389|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
33279390|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
33279391|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
33082685|NCT04607629|Experimental|Genolar® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
33082686|NCT04607629|Active Comparator|Xolair® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
33279392|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
33279393|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
33279394|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
33279395|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
33279396|NCT01026519|Experimental|Dose 1|Active dose
33279397|NCT01026519|Experimental|Dose 2|Active dose
33279398|NCT01026519|Experimental|Dose 3|Active 3
33082687|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
33279399|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
33279400|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
33279401|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
33279402|NCT00451035|Experimental|Panobinostat (LBH589)|Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
33279403|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
33279404|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
32936184|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
32936185|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
33279405|NCT03946449|Experimental|ARO-AAT Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
33279406|NCT03946449|Experimental|ARO-AAT Cohort 1b|"Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
33279407|NCT03946449|Experimental|ARO-AAT Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
33279408|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
33279409|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
33279410|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
33279411|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
33279412|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
33279413|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
33279414|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
33279415|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
33279416|NCT01023555|No Intervention|0.5cc 2 Bottles|
33279417|NCT01023555|Active Comparator|1cc single bottle|
33279418|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
33279419|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
33279420|NCT01026675||Pregnant women 6-13 weeks|
33279421|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
33279422|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
33279423|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
33279424|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
33279425|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
33279426|NCT03996213|No Intervention|supine group|induction of anesthesia will be initiated while patient in supine position
32936186|NCT02014675||SD01 ICD lead|
33279427|NCT03996213|Active Comparator|head down|induction of anesthesia will be initiated while patient in head down position
33279428|NCT03996213|Active Comparator|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
33279429|NCT04889157|Experimental|PF-06882961|Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
33279430|NCT04889157|Placebo Comparator|Placebo|Placebo
33279431|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
33279432|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
33279433|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
33279434|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
33279435|NCT00633893|Experimental|1|2.5 mg
33279436|NCT00633893|Experimental|2|5.0 mg
32936187|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
32936188|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
32936189|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
32936190|NCT04248686|No Intervention|Control|Referral to standard care - student health center on campus.
32936191|NCT04248686|Active Comparator|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
33279437|NCT00633893|Active Comparator|3|0 mg
33279438|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
33405351|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
32777057|NCT05616949|Experimental|Arm 2 Title: Peer Recovery Support Services (PRSS) + TAU|Arm 2: Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services (TAU+PRSS) vs. an active comparator composed of treatment as usual services without the PRSS intervention (i.e., TAU-alone). Follow ups will be conducted at weeks 2, 4, 8, 12, 16, 20, 24 (end of intervention), 36, and 52 to collect data on the primary outcome of MOUD retention and other outcomes.
32777058|NCT04790929|Experimental|Regular Muse Meditation System - No Coaching|Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
32777059|NCT04790929|Experimental|Regular Muse Meditation System - Additional Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
32777060|NCT04790929|No Intervention|Controls|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
32777061|NCT04345393|Experimental|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
32777062|NCT04345393|Active Comparator|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
32777063|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
32777064|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
32777065|NCT04802005|Experimental|Aerobic interval|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure ~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
32777066|NCT04802005|No Intervention|Control group|Participants in the control group will not participate in the training programs.
32830741|NCT04114227|Active Comparator|Supportive Psychotherapy|Participants will talk about their experiences to date.
32830742|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
33082688|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
33082689|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
33082690|NCT04607473|Experimental|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
33082691|NCT05558852|Experimental|Meshless Approach|Laparoscopic Sacrocolpopexy in central or anterior compartment prolapse.
33082692|NCT04607512|Experimental|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
33082693|NCT04607512|Placebo Comparator|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
33082694|NCT04607512|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
33082695|NCT04607239|Experimental|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
33082696|NCT04607239|Other|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician."
33082697|NCT04607395||pre-operative radiographs of deep carious lesion|
33082698|NCT05558189|Experimental|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
33082699|NCT04607278|Experimental|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
33082700|NCT04607278|Active Comparator|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
33082701|NCT04607278|Placebo Comparator|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
33279439|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
33279440|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
33279441|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
33279442|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
33279443|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
33279444|NCT00819611|Experimental|Working memory training|
33279445|NCT00819611|Sham Comparator|Control version of working memory training|
33279446|NCT04044677|Experimental|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).~This group will perform the tDCS-sham after one-month washout."
33279447|NCT04044677|Sham Comparator|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.~This group will perform the tDCS-active after one-month washout."
33279448|NCT00819845|Experimental|Ramipril|
33279449|NCT00819845|Experimental|Carvedilol|
33279450|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
33279451|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
33279452|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
33279453|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
33279454|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
33279455|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
33279456|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
33279457|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
33279458|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
33279459|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
33279460|NCT00820157|Experimental|TACE|TACE alone
33279461|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
33405352|NCT05164809||Tungsten/Teflon +|Dissection with novel electrodes (Tungsten needle electrode + Teflon coated Spatula electrode)
33405353|NCT05164809||Tungsten/Teflon -|Dissection without novel electrodes (Scalpel + Steel Spatula Electrode)
33082702|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
33082703|NCT04719975|Experimental|Mental Fatigue (Stroop) - Chair task|Participants will be performing the Chair Task (150 submaximal dynamic knee extensions at 50% of their maximal voluntary contraction (MVC)) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
33082704|NCT04719975|Placebo Comparator|Control Task (Documentary) - Chair Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Chair Task, During the whole trial EEG will be measured.
33082705|NCT04719975|Experimental|Mental Fatigue (Stroop) - Bike Task|Participants will be performing the Bike Task (a 9 min cycling task performed at 45 rpm with intensity being constant and will be 10% below VT) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
33082706|NCT04719975|Placebo Comparator|Control task (Documentary) - Bike Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Bike Task, During the whole trial EEG will be measured.
33082707|NCT05556356|Placebo Comparator|Control Group|Preoperative multivitamin and postoperative standardized pain management regimen
33279462|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
33279463|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
33279464|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
33279465|NCT04044599|Experimental|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
33279466|NCT04044599|No Intervention|Control|Control group
33279467|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
33279468|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
33279469|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
33279470|NCT00820391|Experimental|Meditation/Relaxation|
33279471|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
33279472|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
33279473|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
33279474|NCT00820469|Experimental|1|Patients treated by rituximab
33279475|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
32830743|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
33279476|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
33279477|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
33279478|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
33279479|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
33279480|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
33279481|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
33279482|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
33279483|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
33279484|NCT00815399|Experimental|1|
33279485|NCT00815399|Active Comparator|2|
33279486|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
33279487|NCT00644969|Active Comparator|Treatment Arm|
33279488|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
33279489|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
33279490|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
33279491|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
33405354|NCT05101083|Experimental|Hearing Aid 1|New Receiver-in-Canal device, successor of previous device generation
33082708|NCT05556356|Experimental|Test Group|: Preoperative acetaminophen and postoperative standardized pain management regimen
33082709|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
33279492|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
33279493|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
33279494|NCT04016909|Experimental|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
33279495|NCT04016909|No Intervention|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
33279496|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
33279497|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
33279498|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
33279499|NCT00812357||1|Patients treated with Symbicort basic treatment
33279500|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
33279501|NCT04046081|Other|Dichloroacetate|Open label study
33279502|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
33279503|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
33279504|NCT00812747||1|
33279505|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
33279506|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
33279507|NCT00815867|No Intervention|B|
33279508|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
33082710|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
33082711|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
33279509|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
33279510|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
33279511|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
33279512|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
33279513|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
33279514|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
33279515|NCT00644423|Placebo Comparator|2|Placebo
33279516|NCT00820859|Experimental|1|
33279517|NCT00820859|Active Comparator|2|
33279518|NCT04644497||Transphyseal drilling technique|
33279519|NCT04644497||Physeal sparing drilling technique|
33279520|NCT00812825|Experimental|PF-04173127|
33279521|NCT00812825|Active Comparator|Prednisolone|
33279522|NCT00812825|Placebo Comparator|Placebo|
33082712|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
33082713|NCT04719546||NEC Group|All Premature Neonates born in Nancy and Lyon over 10 years and presenting with Necrotizing Enterocolitis
33279523|NCT00812825|Sham Comparator|Solution Placebo|
33279524|NCT00812825|Experimental|PF-04171327 Tablet|
33279525|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
33279526|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
33279527|NCT00627497|Experimental|DIAM Group1|
33279528|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
33279529|NCT00627497|Experimental|DIAM Group2|
33279530|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
32830744|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
32830745|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
33279531|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
33279532|NCT00812903|No Intervention|Control|Control group
33279533|NCT00812903|Experimental|Exercise|Intervention group
33279534|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
33279535|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
32830746|NCT04782375|Experimental|Treatment Arm A|discontinue antiviral treatment
33279536|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
33279537|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
33279538|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
33279539|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
33279540|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
33279541|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
33279542|NCT00813059|Experimental|1|
33279543|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
33279544|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
33279545|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
33279546|NCT00467649|Experimental|Group A|
33279547|NCT00467649|Active Comparator|Group B|
33279548|NCT01023945|Experimental|ASP1941 high dose group|oral
33279549|NCT01023945|Experimental|ASP1941 low dose group|oral
33279550|NCT01023945|Placebo Comparator|Placebo group|oral
33279551|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
33279552|NCT00450333|Active Comparator|2|EPO-naive QW
33279553|NCT00450333|Active Comparator|3|EPO QW
33279554|NCT00450333|Active Comparator|4|EPO Q2W
33279555|NCT00643565|Experimental|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
33279556|NCT00643565|Active Comparator|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
33279557|NCT00643487||1|observation of the behavior of the infrapatellar plica
33279558|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
33279559|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
33279560|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
33279561|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
33279562|NCT00450177|Experimental|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
33279563|NCT00450177|Placebo Comparator|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
33279564|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
33279565|NCT00813137|Experimental|Folfox4 plus Endostar|
33279566|NCT03840993|Experimental|MT-2990|MT-2990, IV, over 16 weeks
33279567|NCT03840993|Placebo Comparator|Placebo|Placebo, IV, over 16 weeks
33279568|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
33279569|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
33279570|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
33279571|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
33279572|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
33279573|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
33405355|NCT05101083|Active Comparator|Hearing Aid 2|Legacy Receiver-in-Canal device that is currently available on the market
33279574|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
33279575|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
33279576|NCT00816647|Active Comparator|2|Medial reefing
33279577|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
33279578|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )~Lipid-rich plaque ( ≥2 quadrants )"
33279579|NCT00821483|Placebo Comparator|1: placebo|
33279580|NCT00821483|Active Comparator|2 Frovatriptan|
33279581|NCT01021995|Experimental|echinacea|
33279582|NCT01021995|Placebo Comparator|placebo|
33279583|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
33279584|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
33279585|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
33279586|NCT00813371|Active Comparator|2|ARDSnet protocol
33279587|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
33279588|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
33279589|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
33279590|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
33279591|NCT04612049|Experimental|Children with hemiplegia|40 children with hemiplegia, 7-16 years-old at Gross Motor Function Classification System (GMFCS) Levels I-III and Manual Ability Classification System (MACS) Levels I-II will be recruited as participants. This age range was chosen based on our preliminary research in which children under the age of 7 had difficulty attending to repetitive task practice. Individuals will be recruited without regard to race or ethnicity. Our goal is to have a study sample that is 50% male and 50% female, and approximates the population of the Greater Boston, MA region.
33279592|NCT04612049|Experimental|Typically developing children|40 typically developing children, 7-16 years-old.
33279593|NCT00816725|Experimental|Self-help course and information|
33279594|NCT00821717|Experimental|1:|
33279595|NCT00821717|Placebo Comparator|2|
33279596|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
33279597|NCT00822029|Placebo Comparator|2|PLACEBO
33279598|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
33279599|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
33279600|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
33279601|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
33279602|NCT00816881|Experimental|1|flutter mucus clearance device
33279603|NCT00816881|No Intervention|2|Observation
33279604|NCT01022151|Placebo Comparator|Placebo [group P]|
33279605|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
33279606|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
33279607|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
33279608|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
33279609|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
33279610|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
33279611|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
33279612|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
33279613|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
33279614|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
33279615|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
33279616|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
33279617|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
33279618|NCT00449865|Placebo Comparator|Placebo|
33279619|NCT00449865|Active Comparator|creatine|
33279620|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
33279621|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
33279622|NCT01566201|Active Comparator|anakinra|
33279623|NCT01566201|Placebo Comparator|placebo|
33279624|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
33279625|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
33279626|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
32777067|NCT04801303|Experimental|Friedreich's Ataxia patients|"Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.~During the clinical trial:~The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.~The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment."
32777068|NCT04790383|Experimental|Advanced Self-Adhesive resin composite hybrid restorations|(Surefil one (Dentsply Sirona)).
33279627|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
32777069|NCT04790383|Active Comparator|Conventional resin composite restoration.|Sphere Tec, (Dentsply Sirona)
32777070|NCT04790461|Experimental|1. experimental group: face to face education+PMR exercise|The education and PMR exercises prepared in line with the face-to-face Roy adaptation model will be applied. In groups of 8-10 people, the first 4 sessions in rehabilitation centers will last for the first 4 sessions, and then PMR exercises will be taught and applied (between the 2nd and the 5th weeks, they will be encouraged to do PGE twice at home). The next 4 weeks will be provided with PMR consultancy (3 times a week application / total 24 sessions of PMR application). PMR exercises will be given a follow-up schedule and the caregivers will be followed up by the caregivers themselves and the researchers.
32777071|NCT04790461|Experimental|2. experimental group: mobile health education + PMR exercise|Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
32777072|NCT04790461|Experimental|3rd experimental group: face to face and mobile health education + PMR exercise|4 sessions prepared in line with the Roy adaptation model face to face and held in rehabilitation centers, training in groups of 8-10 people, teaching PMR exercises and installing phone applications that can be accessed for 8 weeks), 8-week intervention including training (enabling them to do progressive relaxation exercises and access to training content) will be provided. . The PMR exercises will be uploaded to the system / given as a printout according to the caregiver's preference, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers watch the participant.
32777073|NCT04790461|Other|Control group|Without applying any intervention, the post-test YBYKA, ASÖ and SBÇYA scales will be applied in the 10th week of the study. After all the tests for the study are measured and finished, they will be provided with training and relaxation exercises.
32777074|NCT04801381|Active Comparator|Aquablation therapy|Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).
32777075|NCT04801381|Active Comparator|Transurethral laser enucleation|Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).
32777076|NCT05615779|Placebo Comparator|Randomized pectin diet|
32777077|NCT05615779|Placebo Comparator|Randomized B-fructan diet|
32777078|NCT05615779|Experimental|Personalized pectin diet|
32777079|NCT05615779|Experimental|Personalized B-fructan diet|
32777080|NCT04790539|Experimental|SHR-1210+Paclitaxel-albumin+Carboplatin|SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first day of each cycle, with intravenous drip.
32777081|NCT04790149|Sham Comparator|Conventional Group|Conventional usual Rehabilitation is administered to a group of patients without any effect on their recovery
32777082|NCT04790149|Experimental|NEUROM|participants received the new protocol of a method called NEUROM consisting of 3 phases of treatment : Motor Imagery training, active rehabilitation and functional rehabilitation
32777083|NCT04790149|Experimental|NEUROM combined with tDCS|same as the second arm of NEUROM combined with transcranial direct stimulation
32777084|NCT04812301||Group 1|Egg-white sandwich is added with 1 mCi Tc-99m sodium phytate, then Abbott Vital® added with 1 mCi Tc-99m sodium phytate
32777085|NCT04812301||Group 2|Abbott Vital® is added with 1 mCi Tc-99m sodium phytate, then egg-white sandwich added with 1 mCi Tc-99m sodium phytate
32777086|NCT04427371||survivors|Improve or under treatment
32777087|NCT04427371||nonsurvivors|all-cause 28-day mortality
32777088|NCT04801069|Experimental|Auto-Adaptative Servo-Ventilation|
32777089|NCT04801069|No Intervention|Control|
32777090|NCT04426903|Experimental|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
32777091|NCT04426903|Experimental|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
33279628|NCT00448539|Experimental|Rufinamide (Rufinamide During Core Study)|
33279629|NCT00448539|Experimental|Rufinamide (Placebo During Core Study)|
33279630|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
33279631|NCT01024257|Active Comparator|conjunctival autograft|
33279632|NCT00457665|Active Comparator|Nelfinavir (Viracept)|
33279633|NCT00457665|Active Comparator|Efavirenz (Sustiva)|
33279634|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
33279635|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
33279636|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
32777092|NCT04426903|Experimental|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
32777093|NCT04812223|Active Comparator|Delayed Clamping|In this group, the umbilical cord will be clamped 60 seconds after the baby is born.
33279637|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
33279638|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
33279639|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
33279640|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
33279641|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
33279642|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
33279643|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
33279644|NCT01027611|Experimental|proparacaine HCL 0.5%|
33279645|NCT01027611|Experimental|proparacaine + lidocaine|
33279646|NCT01027611|Experimental|lidocaine gel|
33279647|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
33279648|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
33279649|NCT03577587|Experimental|Verum|Silitidil for 21 days
32777094|NCT04812223|Active Comparator|Early Clamping|In this group, the umbilical cord will be clamped 15 seconds after the baby is born.
32777095|NCT04812223|Active Comparator|Milking Clamping|In this group in which the umbilical cord will be milked, the cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
32777096|NCT04356469|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
32777097|NCT04790071|Active Comparator|Conventional therapy|It covers the classical physical therapy modalities that patients will take for shoulder pain.
32777098|NCT04790071|Active Comparator|Conventional therapy plus dry needling|It covers the classical physical therapy modalities that patients will take for shoulder pain. It also refers to the dry needling treatment to be applied.
32936192|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
32936193|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
33279650|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
33279651|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
32777099|NCT04789759|Experimental|Socket Preservation Alloplastic Material|"10 Consecutive Patients with hopeless teeth and 1/3 or more buccal bone resorption will be placed in a therapy go bone regeneration called socket preservation technique.~The surgery will include placement of 2/3 biphasic calcium sulfate cement matrix's with hydroxyapatite (HA granules) to fill the alveolar defects, and place a resorbable membrane sutured to adjacent tissue, to avoid material leakage.~No flap retraction. 3 Month later an implant will be placed, and a bone biopsy of the healed socket harvested. 2 Month later a final Zirconia ceramic crown screw retained to the osseointegrated implant.~Primary (T0) and Secondary (T1) stability measured with ISQ values.~Intraoral Scanner and an STL File will be taken at T0 , T1 and T2 for volumetric alteration evaluation."
32936194|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
32936195|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
32936196|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
32936197|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
32936198|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
32936199|NCT04093531|Experimental|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
32936200|NCT05272670|Experimental|Experimental group|A 4-week digital foot self-management program will be provided to the participants in experimental group.
32936201|NCT05272670|No Intervention|Control group|The control group received routine care that are required to attend the education sessions in the diabetes clinic according to their scheduled appointments. Routine care included routine check-ups and foot care education.
32936202|NCT04065841|Experimental|Arm A: combination therapy|tropifexor + licogliflozin
33279652|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
33279653|NCT00446511|Active Comparator|CKD patients: Enalapril|
33279654|NCT00446511|Experimental|Non-CKD patients: Valsartan|
33279655|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
33279656|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
33279657|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
33279658|NCT01024491|Experimental|placebo|placebo
33279659|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
33279660|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
32777100|NCT04789759|Active Comparator|Extraction Socket Spontaneous Healing|10 Consecutive patients with a tooth extraction without the aim of placing a future implant and without Biomaterial filler placed in the socket. Spontaneous healing
32777101|NCT04789915|Active Comparator|Memantine + amisulpride|"Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment).~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
32777102|NCT04789915|Placebo Comparator|Placebo + amisulpride|"Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment).~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
32777103|NCT04789525|Experimental|Group A (high-intensity aerobic training with high protein diet )|
32777104|NCT04789525|Experimental|Group B(regular physical activities and taken regular diet)|
32777105|NCT04801147|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
32777106|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
32777107|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
32777108|NCT04789447||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT
32777109|NCT04811599||deep learning algorithm group|Before patients going through colonoscopy or gastroscopy ,taking them tongue images and collecting basic information by mobile phone with Anymed.After examination,endoscopic report and histology analysis is collected .Categorizing the images by gastrointestinal diseases，developing and validating a deep learning algorithm for the diagnosis of digestive tract diseases depending on tongue images.Extracting tougue coating,gastric mucosa and stool DNA by high-throughput sequencing,and analyzing their composation,adundance and diversity.
32777110|NCT04800679|Active Comparator|intravitreal bevacizumab injections and then rescue|
32777111|NCT04800679|Active Comparator|PRP group|
32777112|NCT04800679|Active Comparator|IVB injections and a modified laser|
32777113|NCT04811911|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
32777114|NCT04811911|Active Comparator|Methotrexate group|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
32777115|NCT04811911|No Intervention|healthy individuals as control group|
33279661|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
33279662|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
32777116|NCT04789291|Experimental|Fed state (Test, T) - Fasted state (Reference, R)|
32777117|NCT04789291|Experimental|Fasted state (Reference, R) - Fed state (Test, T)|
32777118|NCT04789603|Active Comparator|Without Mask Group|Patients who will perform the 6-min walk test without mask
32777119|NCT04789603|Active Comparator|Surgical Mask|Patients who will perform the 6-min walk test with surgical mask
32777120|NCT04789603|Experimental|Fpp2 Mask|Patients who will perform the 6-min walk test with Fpp2 mask
32777121|NCT04789135|Experimental|Ozone Therapy|Administration of intravesical ozone gas in patients with Interstitial cystitis/bladder pain sydrome
32777122|NCT04348669|Experimental|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
32777123|NCT04800445||Case group of fullterm neonates with neonatal sepsis|
32777124|NCT04800445||Healthy fullterm neonates|
32777125|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
32777126|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
32777127|NCT04811209||single group, open labelled observational study with no blinding.|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
32936203|NCT04065841|Experimental|Arm B: tropifexor monotherapy|tropifexor (+ licogliflozin placebo)
32936204|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|licogliflozin (+ tropifexor placebo)
32936205|NCT04065841|Placebo Comparator|Arm D: Placebo|licogliflozin placebo + tropifexor placebo
32936206|NCT05269316|Experimental|IMP9064 Monotherapy|Dose-escalation IMP9064 administered orally on empty stomach once/twice daily
32936207|NCT04186520|Experimental|8/12 Day Production of CAR-T for NHL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
32936208|NCT04186520|Experimental|8/12 Day Production of CAR-T for CLL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with CLL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
32936209|NCT04186520|Experimental|8/12 Flexible Manufacturing with Mandated Cryopreservation|8/12 flexible manufacturing with mandated cryopreservation prior to infusion of LV20.19 CAR T-cells.
32936210|NCT04186520|Experimental|12-Day Production of Car-T Cells for NHL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
32777128|NCT04800211|No Intervention|Control|Continue smoking under ad libitum use of subjects' own brand of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
32777129|NCT04800211|Experimental|Test 1|"Exclusive ad libitum use of test e-Vapor Product NuMark LLC, MarkTen® XL Bold CLASSIC* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
32777130|NCT04800211|Experimental|Test 2|"Exclusive ad libitum use of test e-Vapor Product Nu Mark LLC, MarkTen® XL Bold MENTHOL* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
32777131|NCT04811443||Patients with solid tumors who have received myelosupressive therapy|
33279663|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
33279664|NCT01027689|Experimental|Alprazolam test sublingual tablet|
32777132|NCT04810897||Parkinson's disease|The neurologists will inform the individuals with PD that we are doing this research and we will attach the research advertisement at Movement Disorder Clinic, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Only individuals with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. The researcher will inform participants about the purpose, procedure, and advantage of the study prior to participation in the study. Individuals with PD will be asked to sign an informed consent if they agree to participate in the study.
32777133|NCT04788745|Experimental|Experimental|Trimetazidine 35mg
32777134|NCT04788433||ROCCO-A (A-symptomatic)|Patients with documented COVID-19 infection and NO symptoms
32777135|NCT04788433||ROCCO-P (Pauci-symptomatic)|Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)
32777136|NCT04788433||ROCCO-L (mild)|Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT
32777137|NCT04788433||ROCCO-M (moderate)|Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities
32777138|NCT04788433||ROCCO-S(severe)|Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION
32777139|NCT04788355|Active Comparator|Control Group standard treatment|Patients will be treated only with standard hospital treatment
32936211|NCT04186520|Experimental|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|Single-stage Phase II design with three-month CR as the target endpoint.
32777140|NCT04788355|Experimental|Group Hydroxychloroquine|Patients will be treated with Hydroxychloroquine associated with standard hospital treatment
32777141|NCT04788355|Experimental|Group Hydroxychloroquine e Apixaban|Patients will be treated with Hydroxychloroquine associated with apixaban and standard hospital treatment
32777142|NCT04788355|Experimental|Group Apixabana|Patients will be treated with apixaban associated with standard hospital treatment
32777143|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
32936212|NCT04172948|Experimental|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing. This arm will be sent home with the virtual reality equipment and practice this breathing technique through the virtual reality module for 8 weeks.
32936213|NCT04172948|Placebo Comparator|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only. They will practice this breathing technique with a paper handout of diaphragmatic breathing technique instructions for 8 weeks.
32936214|NCT04059757|Experimental|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.~aGVHD will be treated as per standard of care."
32936215|NCT04164680||Patients with disorders of consciousness|
33279665|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
32936217|NCT05208944|Experimental|Part A|"Safety lead-in, modified 3+3 design. Part A:~Cohort 1: THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2 (pending emerging data from Cohort 1): THIO total 180 mg per cycle (60 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5"
32936218|NCT05208944|Experimental|Part B|Cohort 1: THIO total 60 mg per cycle (20 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2: THIO total 180 mg per cycle (60 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 3 (pending emerging data from Part A): THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5
32936219|NCT05208944|Experimental|Optional Part C|THIO total 540 mg per cycle (180 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5
32936220|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
32936221|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
32936222|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
32936223|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
32936224|NCT04140110|Experimental|Intervention group|Achieving SBP level of <120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
32936225|NCT04140110|No Intervention|Control group|Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.
32936226|NCT01666808|Experimental|FACBC PET scan|A trial group in which anti-3-[18F]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
32936227|NCT01666808|Active Comparator|Radiation therapy|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
32936228|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
32936229|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
32936230|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
33082714|NCT04719546||Control Group|All Premature Neonates born in Nancy and Lyon over 10 years without Necrotizing Enterocolitis throughout the neonatal period
33279666|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
33279667|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
33279668|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
33279669|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
33279670|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
32936231|NCT04046575|Experimental|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
33279671|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
32936232|NCT05202158|Active Comparator|Irrigation + Genta|Patients treated with gentamicin in irrigation fluid during RIRS
33279672|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
32936233|NCT05202158|Sham Comparator|Irrigation|Patients treated only irrigation fluid during RIRS
33279673|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
33279674|NCT01565733||NovoMix® 30 users|
33279675|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
33279676|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
33279677|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
33279678|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
33279679|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
33279680|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
33279681|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
33279682|NCT03846453|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57
32936234|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
32936235|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
32936236|NCT04033159|Experimental|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
32936237|NCT04033159|Experimental|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
32936238|NCT04033159|Experimental|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
32936239|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
32936240|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
32936241|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
32936242|NCT04096040|Experimental|Device Data Engagement Assessment|This arm will assess the endpoints of investigator engagement with the device data.
32936243|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
32936244|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
32936245|NCT01107613|Experimental|Intervention Arm|Opinion leader educational letter
32936246|NCT01107613|No Intervention|Control/Standard Care|Regular care
33279683|NCT03846453|Placebo Comparator|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
33279684|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
33279685|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
33279686|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
33279687|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
33279688|NCT00444795||2|patients diagnosed as advanced RCC
33279689|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
32777144|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
32777145|NCT04799977||COVID19 infection with olfaction disorder|Patients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
32777146|NCT04799977||COVID19 infection without olfaction disorder|Patients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders
32777147|NCT04799743|Experimental|Resveratrol group|Resveratrol group (treatment group) will be instructed to consume with capsules (1.0 g, orally once a day) for six months.
32777148|NCT04799743|Placebo Comparator|Placebo group|Placebo group (control group) will be instructed to orally take placebo (edible paraffin, 1.0) once a day.
32777149|NCT04788199||Non-closure group|Group in which mesenteric defects were not closed after laparoscopic Roux-en-Y gastric bypass.
32777150|NCT04788199||Closure group|Group in which mesenteric defects were closed using cyano-acrylate glue after laparoscopic Roux-en-Y gastric bypass.
32777151|NCT04788121|Active Comparator|Treatment/Tranexamic Acid Group|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS.
32777152|NCT04788121|Placebo Comparator|Control Group|The control group will receive injection 100 ml NS over 15 minutes infusion, followed by injection 500 ml NS over 12 hours infusion.
32777153|NCT04811053|Experimental|Treatment group A|
32777154|NCT04811053|Placebo Comparator|Treatment group B|
33082715|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which caecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment~patients undergoing urgent colonoscopy."
33082718|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
33082719|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
33082720|NCT04606615||Adults: NC|Adults: Normal Control
33082721|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
33279690|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
32777155|NCT04810819|Experimental|Experimental group|
32777156|NCT04810819|Placebo Comparator|control group|
33402017|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
33082722|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
33082723|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
33279691|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
33279692|NCT03846219|Experimental|IMU-838 (30 mg/day)|"IMU-838 tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets IMU-838.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 9.5 years for the main trial)."
32777159|NCT04810507|Experimental|Anagliptin arm|Anagliptin 100 mg twice a day
32777160|NCT04810507|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg once a day
32777161|NCT04810585|Experimental|Treatment|
32777162|NCT04787887|Active Comparator|Abcertin|Abcertin 60IU/kg
32777163|NCT04787887|Active Comparator|Cerezyme|EU-sourced Cerezyme
32777164|NCT04799041|Active Comparator|GTX 2/3|Dose level administered of GTX 2/3 was 80 mcg. Dose was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of GTX 2/3 was injected. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 40 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
32777165|NCT04799041|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of placebo was injected.
32777166|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
33082724|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
33082725|NCT04606615||Children: NC|Normal Control
33082726|NCT04606849|Other|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
32777167|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
32777168|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
32777169|NCT04798807||Hospitalized non-critical services patients|"Patients, who were hospitalized in the clinics (hematology, neurology, gastroenterology, nephrology, endocrine, pulmonary disease and cardiology) of Malatya Training and Research Hospital, were screened both Nutritional Risk Screening 2002 (NRS-2002) and Subjective Global Assessment (SGA) tools within the first days of admission to the patients.~The nutritional status of patients categorized according the screening tools.~Nutritional Risk Screening 2002 (NRS-2002) : The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score < 3 according to NRS 2002 results.~Subjective Global Assessment (SGA) The SGA screening provides three alternative categories for nutritional classification: well nourished (A); mild-to-moderately malnourished (B); or severely malnourished (C)."
32777170|NCT04798963|Other|On-clamp partial nephrectomy|Patients who are assigned to on-clamp partial nephrectomy.
32777171|NCT04798963|Other|Off-clamp partial nephrectomy|Patients who are assigned to off-clamp partial nephrectomy.
33402018|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
32777172|NCT04787575|Experimental|Arm A|Oxygen-ozone therapy plus antibiotic therapy
32936247|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
32936248|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
32777173|NCT04787575|Other|Arm B|Antibiotic therapy
32777174|NCT04787497|Experimental|Experimental Group|
32777175|NCT04787497|No Intervention|Control Group|
32777176|NCT04787263|Experimental|CD19-CAR_Lenti|Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose. The product will be infused fresh, at the end of manufacturing.
32777177|NCT04810039||doctor working in neuro-intensive unite care|doctor predicting the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
32777178|NCT04809727|Experimental|Biopsy|four quadrant biopsy
32777179|NCT04798417|Experimental|Probiotic|
32777180|NCT04798417|Experimental|Prebiotic|
32777181|NCT04798417|Placebo Comparator|Maltodextrin|
32777182|NCT05615545||Cryoablation|Cryoablation of selected tumor lesions
32777183|NCT04809649|Experimental|SUBA-itraconazole|Drug: SUBA-itraconazole Dosage Form: 65 mg capsules Dosage: 260 mg/day Frequency: 130 mg twice daily (BID) Duration: Up to 180 days
32777184|NCT04354831|Experimental|ICU Cohort|Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
32777185|NCT04354831|Experimental|Non-ICU Cohort|Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
32777186|NCT04786639||Surgical Fixation Group|Open reduction with deltopectoral incision and humeral osteosynthesis with anatomic plates and screws will be performed for surgical fixation.
32777187|NCT04786639||Non-Operative Group|Non-surgical treatment will be performed with sling immobilization.
32777188|NCT04786795|Experimental|Compound Azintamide Enteric-coated Tablets|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the experimental group takes Compound Azintamide Enteric-coated Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
32777189|NCT04786795|Placebo Comparator|Oryz-aspergillus Enzyme|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
32777190|NCT04375189|No Intervention|Standard Care|
32936249|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
32936250|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
32936251|NCT05179382|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol.
32936252|NCT05179382|Experimental|Hydration protocol|This intervention will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery.
32936253|NCT03236935|Experimental|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
32936254|NCT04087538||Patients treated using troponin T|
32777191|NCT04375189|Experimental|Complex Clinic Arm|
32777192|NCT04809337|Experimental|Stabilization Exercise Group|
32777193|NCT04809337|Experimental|Therapeutic Exercise Group|
32777194|NCT04808869|Sham Comparator|Control|Cycling at 70 rpm 3 times/week without any blood flow restriction cuffs
32777195|NCT04808869|Experimental|BRF 60% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in one leg.
32777196|NCT04808869|Experimental|BFR 80% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in one leg.
33279693|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838."
33279694|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.~Duration: until the end of the main treatment period (24 weeks). The placebo is not applicable in the optional extended treatment period, in which participants who were receiving placebo in the main treatment period were re-randomized to IMU-838 for the extended treatment period."
33279695|NCT03846219|Experimental|IMU-838 (10 mg/day) - Cohort 2|"Cohort 2 sub-trial: additional sub-trial with a small double-blind, placebo-controlled, randomized, parallel-group assessment of a low IMU-838 dose (i.e. 10 mg/day) to provide additional data for pharmacodynamic modelling.~Tablet containing 5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 10 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 8.5 years for the cohort 2 sub-trial)."
33279696|NCT00455325|Placebo Comparator|First Intervention (3 weeks)|Cohort 1: Chloroquine placebo one tablet daily for 3 weeks, followed by 5-7 week rest period.
33279697|NCT00455325|Active Comparator|Second Intervention (3 weeks)|Cohort 2: 80mg chloroquine or placebo tablet once daily for Weeks 3, followed by 5-7 week rest period.
33279698|NCT00455325|Active Comparator|Third Intervention (3 weeks)|Cohort 3: 80mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
33279699|NCT00455325|Active Comparator|Fourth Intervention (3 weeks)|Cohort 4: 250mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
33279700|NCT01028079|Active Comparator|Arm 2|
33279701|NCT01028079|Placebo Comparator|Arm 3|
33279702|NCT01028079|Experimental|Arm 1|
33279703|NCT01028157|Placebo Comparator|General Health Control|
33279704|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
33279705|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
33279706|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
33279707|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
33279708|NCT00443781|Other|PD and F.A.D. diagnostic testing|
33279709|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
33279710|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
33279711|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
33279712|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
33279713|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
33279714|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
33279715|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
33279716|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
33279717|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
33279718|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
33279719|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
32936255|NCT04087538||Patients treated using troponin I|
32936256|NCT02197416|Experimental|dabigatran etexilate|
32936257|NCT00370591|Experimental|Arm 1|
32936258|NCT05166044||Safety group|All of the participants(N=12500) received one dose of EV71 vaccine and one of other vaccines(such as MMR vaccine,encephalitis vaccine,mumps vaccine,inactivated poliomyelitis vaccine,influenza vaccine and so on ) at the same time.
32936259|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
32936260|NCT00598988|Experimental|Acupuncture|Traditional Chinese acupuncture in conjunction with standard medical care
32936261|NCT00598988|Active Comparator|Standard medical care|standard medical care
32936262|NCT03956173||Clamp group|24 patients with type 1 diabetes.
32936263|NCT04057820|Active Comparator|Usual care, Finnegan Neonatal Abstinence Scoring Tool|Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
32936264|NCT04057820|Active Comparator|Eat, Sleep, Console care tool|New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool
32777197|NCT04808869|Experimental|BFR Bilateral 60%|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in both legs.
32777198|NCT04808869|Experimental|BFR 80% Bilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in both legs.
32777199|NCT04808635||general surgery residents|
32777200|NCT04808635||orthopedic surgery residents|
32777201|NCT04808635||urology residents|
32777202|NCT04808635||OBGYN residents|
32777203|NCT05614219|Experimental|Biochemistry interpretive comment on LDL-C levels|"The general practitioners and hospital wards will be allocated in cluster according to their providing lab, and stepwise implement the comment on LDL-C > 4 mmol/L in persons under the age of 40 and over 5 mmol/L in persons over the age of 40 years. Raising awareness on familial hypercholesterolemia an encouraging to referral.~Cluster 1. Will from the 01.12.2022 implement comment on LDL-C Cluster 2. Will from the 01.03.2023 implement comment on LDL-C Cluster 3. Will from the 01.06.2023 implement comment on LDL-C Cluster 4.Will from the 01.09.2023 implement comment on LDL-C"
32777204|NCT05614219|No Intervention|Control|"The clusters will act as their own controls, due to the stepwise implementation of the comment.~Cluster 2: Will not implement the comment before the 01.03.2023 Cluster 3: Will not implement the comment before the 01.06.2023 Cluster 4: Will not implement the comment before the 01.09.2023"
32777205|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
32777206|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
32777207|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
32777208|NCT04241575|Experimental|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
32777209|NCT04241575|No Intervention|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
32777210|NCT04767685||All patients|Consenting patients undergoing non-emergency surgery with anesthesia
32777211|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
32777212|NCT04761523|Active Comparator|Reduced fat arm|Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
32777213|NCT04761523|Active Comparator|Standard healthy diet arm|Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
32777214|NCT04786483|Experimental|Laughter Therapy group|All students enrolled in the laughter therapy group will receive a total of 10 sessions of laughter therapy, 60 minutes, 2 days a week.
33082727|NCT04606849|Other|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
33082728|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
32777215|NCT04786483|No Intervention|Control|No attempt will be made to students in this group.
33082729|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
33082730|NCT05542121|Placebo Comparator|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks;-- Standard therapy - consisting of PT, OT and SLP. Clinical Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2).
33082731|NCT05542121|Experimental|Robot-Assisted Therapy with Rehab CARES system|"60 min sessions; 3 sessions per week; for 4 weeks;----of Upper Limb therapy using 1 or more affordable robots that replace the OT portion of standard of care plus standard of care PT and SLP. Robot sessions can be group play and/or single play.~Robot Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2)"
33082732|NCT04606810|Active Comparator|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
33082733|NCT04606810|Other|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
33279720|NCT00535236|Experimental|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279721|NCT00535236|Placebo Comparator|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
32777216|NCT04786327|Placebo Comparator|treated by using Minimally invasive flap only.|7 sites treated with Minimally invasive flap only
32777217|NCT04786327|Experimental|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft
32777218|NCT04786327|Experimental|MIST with root conditioning (EDTA) and GEM 21S .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S
32777219|NCT05614141||Study Group|
32777220|NCT05614141||Control Group|
32777221|NCT04808713|Experimental|Treatment condition|
32777222|NCT04808713|No Intervention|Waitlist condition|
32777223|NCT04153435|Experimental|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
32777224|NCT04153435|Placebo Comparator|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
32777225|NCT04121845|Active Comparator|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
32777226|NCT04121845|Sham Comparator|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
32777227|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
32777228|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
32777229|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
33082734|NCT04606888|Experimental|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan [PC6], Yintang [GV 29], Zusanli [ST36]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
32777230|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
32777231|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
32777232|NCT01667419|Experimental|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
33082735|NCT04606888|No Intervention|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
33082736|NCT04606537|Experimental|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
32777233|NCT01667419|Placebo Comparator|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
32777234|NCT01667419|Experimental|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
32777235|NCT01667419|Placebo Comparator|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
32777236|NCT04089709|Experimental|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
32777237|NCT04089709|No Intervention|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
32777238|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
32777239|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
33082737|NCT04606537|Experimental|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
33082738|NCT04606654|Experimental|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
33279722|NCT00535236|Experimental|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
32777240|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
32777241|NCT04808791|Experimental|Single Arm iTTO treatment|"Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses;~Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1~Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1~TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days."
32777242|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
32777243|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
32777244|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
32777245|NCT04808557|Active Comparator|Trial Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
32777246|NCT04808557|Active Comparator|Control Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Sensodyne Repair & Protect for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
33279723|NCT00535236|Placebo Comparator|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279724|NCT00535236|Experimental|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279725|NCT00535236|Placebo Comparator|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279726|NCT00535236|Experimental|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279727|NCT00535236|Placebo Comparator|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279728|NCT00535236|Experimental|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279729|NCT00535236|Placebo Comparator|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
33279730|NCT05357430|Experimental|group D1(obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
33279731|NCT05357430|Experimental|group D2(non-obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
33279732|NCT05357430|Experimental|group R|Administration of 0.3μg/kg of remifentanil in advance, then the calculated dose of remimazolam, according to calculated results from group D1 and D2
33279733|NCT05357430|Experimental|group C|Administration of 0.3μg/kg of remifentanil in advance, then 1.5-2mg/kg propofol.
33279734|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
33279735|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
33279736|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
32936265|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
32936266|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
32936267|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
32936268|NCT03941743|Experimental|Prevention (fingolimod hydrochloride)|Patients receive fingolimod hydrochloride PO QD starting the day before chemotherapy, the day of chemotherapy, and 1 day after chemotherapy for 12 weeks.
32936269|NCT03908593|Active Comparator|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
32936270|NCT03908593|Experimental|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
32936271|NCT05143658|Active Comparator|Laparoscopic Lateral Suspension Group (LLS)|Anterior and apical prolapse repair via LLS
32936272|NCT05143658|Experimental|Laparoscopic Pectopexy (LP)|Anterior and apical prolapse repair via LP
32936273|NCT04027322|Active Comparator|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.~Frequency: Stat Dose Route: Nebulization"
32936274|NCT04027322|Active Comparator|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.~Frequency: Stat Dose Route: Nebulization"
32936275|NCT04027322|Placebo Comparator|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
32936276|NCT00371215|Experimental|1|rThrombin
32936277|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
32936278|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
32936279|NCT05138588|Experimental|VERUM|"In the verum experimental condition, participants will receive the experimental rTMS stimulation sessions, meaning the rTMS sessions targeting the insular cortex, taking into account the insular hypoperfusion (through MRI images) of each patient."
32936280|NCT05138588|Sham Comparator|CONTROL|"In the control experimental condition, participants will receive the control rTMS stimulation sessions, meaning the rTMS sessions will target the occipital cortex."
32936281|NCT05454475||Low temperature group|The temperature is 6℃-10℃.
32936282|NCT05454475||room temperature group|The temperature is 20℃-24℃.
32936283|NCT05454475||Core temperature group|The temperature is 35℃-39℃.
32936284|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
32936285|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
32936286|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
32936287|NCT00370448|Active Comparator|2|
32936288|NCT00370448|No Intervention|3|
32936289|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
32936290|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
32936291|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
32936292|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
32936293|NCT05454644|No Intervention|Usual Pharmaceutical Care|Patients in the control arm receive usual pharmaceutical care in hospital. Reconciliation of the medication at hospital admission and a validation of the treatment modifications during the hospitalisation is carried out.
32936294|NCT05454644|Experimental|Person-Centred Prescription Model|An interdisciplinary medicine-optimisation strategy is implemented in people at the end of life (EOL) based on the person-centred prescription (PCP).
32936295|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
32936296|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
32936297|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
33279737|NCT00537030|Experimental|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
33279738|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
33279739|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
32936298|NCT05118698|Experimental|High-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 12% saponin, 2 g each time, 3 times a day for 3 months.
32936299|NCT05118698|Experimental|Low-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 8% saponin, 2 g each time, 3 times a day for 3 months.
32936300|NCT05118698|Placebo Comparator|Placebo group|Participants will be allowed to drink a placebo of spinach powder with almost no saponin content, 2 g each time, 3 times a day for 3 months.
32936301|NCT03825835|Active Comparator|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
33279740|NCT04678752|Active Comparator|Standard of Care|Each primary care provider will administer weight loss care per their standard practice.
33279741|NCT04678752|Experimental|PATHWEIGH|A weight management care path that support primary care both through the EHR and training for the clinicians.
33279742|NCT05044026||JAK inhibitor naive|JAK-inhibitor-naive patients
33279743|NCT05044026||Pretreated patients|Patients pretreated for at least 8 weeks with one or more JAK-inhibitors (Jakavi® or otherwise)
33279744|NCT04639596|Experimental|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
33279745|NCT04639596|Experimental|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
33279746|NCT04446468|Experimental|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
33279747|NCT04446468|Experimental|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
33279748|NCT05356962|Experimental|Interventional group|The surgeons will undergo a multi-module training on how to use the StOP?-protocol and perform the StOP?-protocol during all their operations during a 4-month period.
33279749|NCT05356962|No Intervention|Control group|Surgeons in the control group will not be trained to the StOP?-protocol and will communicate as usual during their operations.
33279750|NCT04410900|Experimental|Experimental (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
32777247|NCT04808089|Experimental|Health Lung App. +ezOxygen|"Health Lung App. (AstraZeneca Pharmaceuticals LP) is the application for mobile phone to help asthma care and is available freely in Google Play. Health Lung can be connected to the mobile spirometry, ezOxygen (Genius Holding Co.,Ltd Taiwan Branch).~The functions of Health Lung App. include asthma control monitor, lung function monitor, controller and reliver inhaler reminder and recording, asthma educational topics in brief and information of air quality~Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~he physicians in charge will get the information about control status score by ACT, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
32777248|NCT04808089|Active Comparator|Usual care|The research assistant assess/ teach inhaler technique, offering the asthma education as the regular clinical service.
32777249|NCT04785937|Experimental|Imaging and Biopsy|All patients undergo both liver biopsy and liver imaging (US and MR) to assess the diagnostic performance of imaging compared to histopathological examination in the diagnosis of NASH and fibrosis.
32777250|NCT04785703||oral lichen planus group|patients with chronic bollus erosive lichen planus
32777251|NCT04785547|Experimental|Blincyto|Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
32777252|NCT03938389|Active Comparator|Valsartan|Valsartan 160 mg twice daily for 26 weeks
33279751|NCT04410900|Active Comparator|Control (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
32777253|NCT03938389|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
32777254|NCT03938389|Placebo Comparator|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
32777255|NCT04785157||severe COVID-19 patients with delirium|i) SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) ii) systemic and central immune response characterization, associated to the assessment of CNS damage biomarkers (peripheral blood and CSF) iii) in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia) iv) structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity) v) multi-domains neurocognitive assessment.
32777256|NCT04785313||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) placed because of temporary contraindication to curative anticoagulation and that was been removed by the radiology department at the University Hospital of Saint-Etienne, between January 1, 2010 and December 31, 2014. All the Inferior Vena Cava Filters (IVCF) were been sent for histological examination.
32777257|NCT03892915|Experimental|Depression Care|Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
32777258|NCT03892915|No Intervention|Usual care|Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
32777259|NCT04785235||ACS|Group ACS: Acute Coronary Syndrome
33279752|NCT04400994|Active Comparator|Rituximab only|"Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)~Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)~A total of 12 doses of rituximab will be given in 55 weeks"
32777260|NCT04785235||Periodontitis|Group P :Periodontitis
32777261|NCT04807855|Experimental|the experimental arm|All subjects, the ptosis group and the normal group receive the same intervention.
32777262|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
32777263|NCT05108623|Experimental|Part 1: Monotherapy with agenT-797|3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.
32777264|NCT05108623|Experimental|Part 2: agenT-797 in Combination with approved ICIs|Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
32777265|NCT04784689||Prospective - Cancer Patients that have received COVID-19 Vaccination|
32777266|NCT04784923||Instrumentation patients|Instrumentation patients
32777267|NCT04784767|Experimental|1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.|Up to 20 participants will receive 25 µg of SpFN_1B-06-PL vaccine with 0.5 mL ALFQ adjuvant in a total 1.0 mL injection volume.
33279753|NCT04400994|Experimental|Rituximab and IVIG|"Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);~Week 4: Rituximab + IVIG 2g per kg~Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);~Week 8: Rituximab + IVIG 2g/kg~In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG~Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG~If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76~A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
33279754|NCT04991142||Persons with Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c greater than or equal to 6.5%
33279755|NCT04991142||Persons with Pre-diabetes|Venous blood draw of fasting HbA1c greater than or equal to 5.7% and less than 6.5%
33279756|NCT04991142||Persons without Pre-diabetes or Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c less than 5.7%
33279757|NCT05355714|Experimental|Sofwave|
33082739|NCT04606654|Active Comparator|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
33279758|NCT05355714|Other|Ultherapy|
33279759|NCT05260476||Reablement group|"The home reablement program will be implemented by a physical therapist according to Long-term Care Reablement Operational Guidelines announced by the Ministry of Health and Welfare of Taiwanese government"
33279760|NCT05260476||Non-reablement group|This group will only receive general home care service without the reablement program.
33279761|NCT04928820|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
33279762|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
33279763|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
33279764|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
33279765|NCT04430946|Experimental|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
33279766|NCT04430946|Experimental|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
33279767|NCT04430946|Active Comparator|Lean healthy control subjects|Test meal consumed within 10 minutes
33279768|NCT04430946|Active Comparator|Obese healthy control subjects|Test meal consumed within 10 minutes
33279769|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
33279770|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
33279771|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
32936302|NCT03825835|Experimental|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
32936303|NCT03999164|Experimental|Moderate to Severe Traumatic Brain Injury|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
32936304|NCT05454397||case group|Patients with acute stroke with nutritional risk
33279772|NCT00924456|Placebo Comparator|Wait list control|student subjects on wait list control
33279773|NCT04429152|Experimental|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
33279774|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
32936305|NCT05454332|Experimental|Early Caffeine Group|Group administering caffeine in the first 2 hours of life. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
32936306|NCT05454332|Active Comparator|Control Group|Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
32936307|NCT03977714|Experimental|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
32936308|NCT03977714|Experimental|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
32936309|NCT03977714|Experimental|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
32777268|NCT04784767|Placebo Comparator|1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
32777269|NCT04784767|Experimental|2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.|Up to 20 participants will receive 3 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
32777270|NCT04784767|Placebo Comparator|2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
32777271|NCT04784767|Experimental|3A: 50 µg of SpFN + ALFQ on Days 1 and 181.|Up to 20 participants will receive 2 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
32777272|NCT04784767|Placebo Comparator|3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1 and 181.
32777273|NCT04784611|Experimental|Group 1 - OP-ENS Intervention|Participants will be matched with a peer health navigator. As part of this complex behavioral intervention, participants and peer health navigators will engage in a systematic process of barrier and strength identification, goal setting and action planning related to issues of healthcare access and quality. Participants and peers will meet at least monthly over the course of the 12-month study period (but frequency is determined by participant need). Given the nature of the disability and healthcare experience, we anticipate the needs and therefore frequency will fluctuate over the duration of the study period. Beginning in month 10, participants and peers will engage in a period of transition planning to ensure that participants have the strategies and supports in place to assume the role of their own health navigator.
32777274|NCT04784611|No Intervention|Group 2 - Usual Care|Participants randomized to the usual care group will continue with their usual health and healthcare routines. Participants in the usual care group will receive a monthly newsletter with general interest information relevant to the disability community.
32777275|NCT04337749|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
32777276|NCT04337749|Active Comparator|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
32777277|NCT04337749|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
32777278|NCT04337749|Placebo Comparator|Placebo|Placebo socks were given to participants for 2 weeks
32777279|NCT05054179|Experimental|Intervention Group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h for 48 hours.
32777280|NCT05054179|Placebo Comparator|Placebo group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h of normal saline for 48 hours.
32777281|NCT04337515|Experimental|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).~The target dose of CD34+ cells is ≥20x10^6/kg, but a minimum of~≥2.5x10^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10^5/kg."
32777282|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
32777283|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
32777284|NCT05612113|Active Comparator|Baseline - Session Goal Formulation|"In the baseline phase, the therapist will formulate two session goals, see under descriptions of primary outcome measure.~In this SCED-study, the baseline phase will be of randomized length (5-9 sessions) for each therapist.~The reason for defining this as an active comparator is that we the behavior of formulating two session goals before each session should be considered an intervention, stimulating the therapist to reflect on the upcoming session goals, on defining concrete behaviors to reach the session goal, and to reflect upon his/her session behaviors afterwards. Thus, regarding the baselinephase as a no intervention would be misleading."
32777285|NCT05612113|Experimental|Live Supervision with Bug-in-the-Ear (BITEar) as method|"LS with the Bug-in-the-Ear (BITEar) is a video based supervision format where the supervisor watches the therapy session live through a webcam in the therapy room. During the therapy session, the supervisor provide verbal feedback and guidance to the therapist who wears wireless in-ear headphones.~In this SCED-study, the intervention phase consist of 5 to 9 BITEar supervision sessions (number of supervision sessions is randomized between therapists)~The BITEar supervision will consist of three phases:~Pre-supervision (15 minutes): Discussion of the therapists session goals, how the therapist wants the supervisor's help and agreement on prompts and cues from supervisor~Live supervision during the therapy session (≈ 45-60 minutes): Supervisor gives real time feedback and guidance focusing on helping the therapist achieve session goals~Post-supervision (15 minutes): Reflection about the session, session goals and the supervision."
32777286|NCT05018611|Experimental|LifeSkills Mobile|Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
32777287|NCT05018611|No Intervention|Standard of Care|HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.
32777288|NCT05014477||Patients experiencing device embolization after left atrial appendage occlusion|Device embolization following either surgical or interventional left atrial appendage occlusion
32777289|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
33082740|NCT04606147|Experimental|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
33082741|NCT04606147|Experimental|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
33082742|NCT04606225|Experimental|Losartan group|Drug: Losartan
33082743|NCT04606225|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
33082744|NCT05528549|Experimental|Dynamic Exercise|The investigators will look at leg blood flow during a seated leg-kicking test that is similar to biking. Leg blood flow will be measured in both the active and inactive legs. These measurements will be taken to examine how blood is directed (or controlled) during exercise.
33279775|NCT04257552|Active Comparator|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers.
33279776|NCT04257552|Active Comparator|Pre-Scheduled Postpartum Visit:|If randomized the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care.
33279777|NCT04257552|Experimental|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history. The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a printout that includes the date and time of her appointment, a copy of the commitment statement.
33279778|NCT04001400|Experimental|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
33279779|NCT04001400|Active Comparator|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
33279780|NCT04219566|Active Comparator|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
33279781|NCT04219566|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
33279782|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
33279783|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
33279784|NCT04384770||Group I (CT-SBRT)|Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
33279785|NCT04384770||Group II (MRI-SBRT)|Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
33402019|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
33279786|NCT05355636|Experimental|experiment group|patient receiving counseling
33279787|NCT05355636|No Intervention|control group|patient without counseling
33279788|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
33279789|NCT01047982|Active Comparator|myo-inositol|
33279790|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
33279791|NCT05355558|Experimental|[18F]FLT-PET/MRI body scan|
33279792|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
33279793|NCT04275102|Experimental|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
33279794|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
33279795|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
33279796|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
33279797|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
33279798|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
33279799|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
33279800|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
33279801|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
33279802|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
33279803|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
33279804|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
33279805|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
33279806|NCT05281068|Experimental|Iguratimod and Danazol|Iguratimod is given at a dose of 25 mg bid. Danazol is given at 200mg bid for 12 weeks.
32777290|NCT04972825|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
32777291|NCT04972825|Active Comparator|Implementation as Usual (IAU)|The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.
33279807|NCT05281068|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
33279808|NCT05276700||case with hcv|
33279809|NCT05276700||control without hcv|
33279810|NCT00380068|Experimental|Ambrisentan|
33279811|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
33279812|NCT04088370||Healthy Controls|No intervention- blood draw only
32777292|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
32777293|NCT05472805||CIMT ≥1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT ≥1mm
32777294|NCT05472805||CIMT <1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT <1mm
32777295|NCT05472727||Case group (mild cognitive impairment)|geriatric population with mild cognitive impairment
32777296|NCT05472727||Control Group (healthy elderly)|healthy older adults without cognitive impairment
32777297|NCT05472571|Experimental|Forest bathing|
32777298|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
32777299|NCT05472493|Experimental|CETO|The consented participants will receive the [18-F] CETO through the IV and a PET/CT scan afterwards.
32777300|NCT02588833|Experimental|Cohort 1|180 mg pegcetacoplan/day
32777301|NCT02588833|Experimental|Cohort 2|270 mg pegcetacoplan/day
32777302|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
32777303|NCT05611879|Experimental|Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery|Participants will receive neoadjuvant Tislelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection.
32777304|NCT05472415|Experimental|experimental group|cognicise training with insole intervention
32777305|NCT05472415|Active Comparator|control group|cognicise training
32777306|NCT05613751|Experimental|Pregnant women-COVID-19 vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine
32777307|NCT05613751|No Intervention|Pregnant women-COVID-19 vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine. They will receive normal care at the hospital.
32777308|NCT05613751|Experimental|Pregnant women-influenza vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine
32777309|NCT05613751|No Intervention|Pregnant women-influenza vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine. They will receive normal care at the hospital.
32777310|NCT05613751|Experimental|Medically at risk children-COVID-19 vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine
32777311|NCT05613751|No Intervention|Medically at risk children-COVID-19 vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine. They will receive normal care at the hospital.
33279813|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
33279814|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
33279815|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
33279816|NCT04230954|Experimental|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
33279817|NCT05265702|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
33279818|NCT04127838|Experimental|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
33279819|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
33279820|NCT03981432|Experimental|Constitutional leanness|Constitutional leanness
33279821|NCT03981432|Experimental|Normal weight|Normal weight women
33279822|NCT03981432|Experimental|Anorexia nevrosa|women presenting Anorexia nevrosa
33279823|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
33279824|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
33279825|NCT00370396|Experimental|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
33279826|NCT00370396|Active Comparator|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
33279827|NCT00370396|Experimental|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
33279828|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
33279829|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
33279830|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
33279831|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
33279832|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
33279833|NCT00992082|Active Comparator|Group M|Intrathecal morphine
33279834|NCT04029168||Pelvic floor surgery|The group will consist of females with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence) qualified for pelvic floor surgery
33279835|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
33279836|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
33279837|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
33279838|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
33279839|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
33279840|NCT05261412|Active Comparator|Standard Consent (Control)|Standard consent (written patient information leaflet (PIL) + verbal discussion with the responsible surgeon) for EVTA followed by signing of consent.
33279841|NCT05261412|Experimental|Digital health education tool (dHET)|dHET for EVTA + verbal discussion with the responsible surgeon followed by signing of consent.
33279842|NCT05254548|Experimental|ACT-539313 with or without a standard combination (probe substrate)|Treatment arm has 4 in-house treatment periods. In Treatment Period 1, participants will receive a single oral dose of the standardized combination (probe substrate: containing flurbiprofen [50 mg], midazolam [2 mg] and omeprazole 20 [mg]) on Day 1. Participants will be discharged from the study site on Day 2 and will be re-admitted on Day 7. In Treatment Period 2 (morning of Day 8) a first oral dose of 100 mg ACT-539313 will be administered. One hour later a single oral dose of the probe substrate will be administered. In the evening of Day 8, a second oral dose of 100 mg ACT-539313 will be administered. During Treatment Period 3 (morning of Day 9, ending on the evening of Day 14) oral doses of 100 mg ACT-539313 will be administered in the morning and evening. In Treatment Period 4 (Day 15), a single oral dose of 100 mg ACT-539313 together with the probe substrate will be administered. The participants will receive the last dose of ACT-539313 in the evening of Day 15.
33279843|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
33279844|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
33279845|NCT05246982|Experimental|Arm A|HER2 negative and PD-L1 CPS≥5, as first-line therapy
33279846|NCT05246982|Experimental|Arm B|As third-line or above therapy
33279847|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
33279848|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
33279849|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
33279850|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
33279851|NCT04002492|Experimental|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
33279852|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
33279853|NCT05243004|Experimental|Phone Nurse Consultation|Patients will benefit, in addition to the usual care, including a reminder by the secretary of the PORU the day before the operation, a phone call from nurse no later than 72 hours before surgery to explain and remind them of the instructions for preoperative preparation and answer any questions they may have.
33279854|NCT05243004|No Intervention|Standard care|Patients in this group will follow the usual preparation schedule including a reminder by the secretary of the PORU the day before the operation.
33279855|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
33279856|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
33279857|NCT04002024|Active Comparator|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
33279858|NCT04002024|Active Comparator|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
33279859|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
33279860|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
33279861|NCT05355324||anemia|patients with anemia
33279862|NCT05355324||non-anemia|patients without anemia
33279863|NCT01028313|Experimental|1|Systemic Therapy
33279864|NCT04001712|Experimental|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
33279865|NCT04001712|Active Comparator|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
33279866|NCT05355246|Experimental|assisted sit-up exercises Group|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and a maximum of 10 repetitions, two times a day and two days a week.
33279867|NCT05355246|Active Comparator|swiss ball pikes exercises Group|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend their hips and try to pull their feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups.
33279868|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
33279869|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
33279870|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
33279871|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
33279872|NCT00992160|Placebo Comparator|Placebo|Placebo
33279873|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
33279874|NCT00379912|Experimental|Investigational Arm B|Azacitidine
33279875|NCT05239650|Experimental|A：1L treatment|HLX07 * 1000 mg+HLX10* 200mg +mFOLFOX6, IV, Q2W
33279876|NCT05239650|Experimental|B：≥2L treatment|HLX07 *1000 mg monotherapy,IV, Q2W
33279877|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
33279878|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
33279879|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
33279880|NCT04001322|Experimental|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
33279881|NCT04001322|Other|7 Control LGAs|This arm will not receive any SMS messages on immunization
33279882|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
33279883|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
33279884|NCT00379210|Active Comparator|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
33279885|NCT05355090|Experimental|Protein Pacing|During the 8 week trial, the Protein Pacing (PP) group will consume 3 daily servings of whey protein powder mixed with water at timed intervals: morning (0600-0800), afternoon (1000-1400), and evening (2000-2200) in addition to their normal food intake.
33279886|NCT05355090|No Intervention|Standard Diet|The participants in the CON will continue with their usual habitual dietary intake over the 8-week study and receive no intervention.
33279887|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
33279888|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
33279889|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
33279890|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
33279891|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
33279892|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
33279893|NCT05356650|Experimental|Mulligan Mobilization|Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
33279894|NCT05356650|Experimental|PNF Technique|Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.
33279895|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
33279896|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
33279897|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
33279898|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
33279899|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
33279900|NCT01045720|Placebo Comparator|Placebo Comparator|
33279901|NCT01045720|Experimental|ChinesMed|
33279902|NCT03405792|Experimental|Optune System combined with Temozolomide (TMZ) + Pembrolizumab|Patients with newly-diagnosed GBM who undergo maximal safe resection (biopsy alone is eligible) followed by chemoradiation consisting of concomitant TMZ daily and radiation therapy (RT) with minimal RT will be eligible for this trial. Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ. Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years. Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
33279903|NCT03405792|Other|Historical Control|Historical control data of patients treated with Optune System combined with Temozolomide alone will be compared with the Optune System combined with Temozolomide (TMZ) + Pembrolizumab arm.
33279904|NCT05354934||People living with HIV|"The questionnaire includes the following modules~Demography and socio-economic conditions~Screening and modalities of discovery and announcement of HIV infection~Time and modalities of introduction of antiretroviral drugs after diagnosis~Knowledge of HIV infection~The perception of follow-up in the health care service~Experiences of stigma~Barriers to accessing care~Periods of loss of sight and reasons for this~Perceived health status, mental health (PHQ4), chronic illness, functional limitations~Addictions~Social network and support~Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
33279905|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
33279906|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
33279907|NCT03709446|Experimental|Leflunomide|Women with metastatic triple negative breast cancer. Leflunomide tablet orally daily
33279908|NCT05354700|Experimental|HLX07+HLX10+Chemotherapy|HLX07+HLX 10+Chemotherapy (Carboplatin-Etoposide)
33279909|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
33279910|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
33279911|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
33279912|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
33279913|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
33279914|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
33279915|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
33279916|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
33279917|NCT00378508|Placebo Comparator|2|Normal saline infusion
33082745|NCT05528549|Experimental|Static Exercise|The investigators will look at blood pressure responses to a sustained leg kick. Blood pressure should increase during the sustained contraction for people without Down syndrome.
33082746|NCT04606108|Experimental|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
33279918|NCT03212976|Other|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
33279919|NCT03212976|Other|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
33279920|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
33279921|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
33279922|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
33279923|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
33279924|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
33279925|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
33279926|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~Partial meniscectomy~Lavage~Debridement~Loose body removal~Synovectomy~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
33279927|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
33279928|NCT01580956|Other|STANDARD-PSV ventilatory mode|
33279929|NCT03025308|Experimental|Blinded Phase: Filgotinib 200 mg|Filgotinib 200 mg plus placebo to match (PTM) filgotinib 100 mg for up to 6 years
33279930|NCT03025308|Experimental|Blinded Phase: Filgotinib 100 mg|Filgotinib 100 mg plus PTM filgotinib 200 mg for up to 6 years
33279931|NCT03025308|Experimental|Open Label Phase: Filgotinib 200 mg|Filgotinib 200 mg for up to 6 years
33279932|NCT03025308|Experimental|Open Label Phase: Filgotinib 100 mg|Filgotinib 100 mg for up to 6 years
33279933|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
33279934|NCT00454779|Other|Arm 2|control
33279935|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
33279936|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
33279937|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
33279938|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
33279939|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
33279940|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
33279941|NCT05350254|Experimental|Stratified Maintenance Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~Participants in the Stratified Maintenance Care group will be classified based on the MAINTAIN instrument into: not a candidate, good candidate, and very good candidate for maintenance care:~Participants showing a good response to the initial care and classified as not a candidate or a good candidate for maintenance care will be given home exercise recommendations. Return for further manual treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-guided care).~Participants classified as having a good response to the initial care and very good candidates for maintenance care, will have visits with tapering manual treatments and home exercise recommendations. They will then be recommended maintenance care with pre-planned visits at 4-12 week intervals (aiming at increasing the interval as soon as possible)."
33279942|NCT05350254|Active Comparator|Standard Chiropractic Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~In the Standard chiropractic care group, participating patients will receive a standard (pragmatic) chiropractic care in which treatment will be provided based on the clinician's judgement and home exercise recommendations. This may or may not include maintenance care depending on the clinicians' standard operating procedures. All treatments provided will be recorded. Return for further treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-based)."
33279943|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
33279944|NCT05350176|Experimental|Experimental group|Probiotic intake containing 10 billions of Colony Forming Units of Lactobacillus plantarum (1 capsule per day)
33279945|NCT05350176|Placebo Comparator|Placebo group|Placebo intake. Placebo capsules will contain dextrose (1 capsule per day)
33279946|NCT00993096|Experimental|IDegAsp low|
33279947|NCT00993096|Experimental|IDegAsp middle|
33279948|NCT00993096|Experimental|IDegAsp high|
33279949|NCT00993096|Experimental|BIAsp 30 low|
33279950|NCT00993096|Experimental|BIAsp 30 middle|
33279951|NCT00993096|Experimental|BIAsp 30 high|
33279952|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
33279953|NCT00443079|Experimental|Siliphos/Placebo|Received study medication first followed by placebo
33279954|NCT00443079|Experimental|Placebo/Siliphos|Received placebo first followed by study medicaiton
33082747|NCT04606303|Experimental|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
33279955|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
33082748|NCT04719507|Experimental|erector spinae arm|ultrasound guided erector spinae block
33279956|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
33279957|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
33279958|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
33279959|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
33082749|NCT04719507|Experimental|thoracic paravertebral arm|ultrasound guided thoracic paravertebral block.
33279960|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
33279961|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
33279962|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
33279963|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
33279964|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
33279965|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
33279966|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
33279967|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, & Ascent."
33279968|NCT05348616||pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2013-2020 winter epidemic"
33279969|NCT05348616||Per-Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, 2023-2024 and 2024-2025 epidemics. The need for continuation of the study will be reassessed after each season."
33279970|NCT00993330||1|20 healthy subjects between 18 and 40 years
33279971|NCT00993330||2|20 healthy subjects between 41 and 50 years
33279972|NCT00993330||3|20 healthy subjects between 51 and 60 years
33082750|NCT04719507|Active Comparator|drug arm|pethidine (1 mg/kg ) once
33082751|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
33082752|NCT04605835||Main group|484 children with congenital obstructive uropathies
33082753|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
33279973|NCT00993330||4|20 healthy subjects between 61 and 70 years
33279974|NCT00993330||5|20 healthy subjects between 71 and 80 years
33279975|NCT00993330||6|20 healthy subjects between 81 and 90 years
33279976|NCT03190278|Experimental|Part 1: Dose Escalation|"Several tested doses of UCART123v1.2 with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART123v1.2 administered at the selected dose determined from the dose escalation phase"
33279977|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
33279978|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
33279979|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
33279980|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
33279981|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
33279982|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
33279983|NCT04001868|Experimental|Experimental Group|Application of the sub occipital inhibition technique.
33279984|NCT04001868|Placebo Comparator|Placebo Group|Hand contact in the sub occipital region without executing any technique.
33082754|NCT04605640|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
33082755|NCT04605562|Experimental|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
33082756|NCT04605562|Experimental|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
33082757|NCT04605562|Experimental|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
33082758|NCT00248586|Experimental|Standard CBT (S-CBT)|
33082759|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
33082760|NCT00248586|No Intervention|Control|
33082761|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
33279985|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
33279986|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
33279987|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
33279988|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
33279989|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
33279990|NCT01031199|Experimental|Arm 1|
33279991|NCT01031199|Experimental|Arm 2|
33279992|NCT03994107|Experimental|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.~Second phase~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
33279993|NCT03119766|Experimental|Kolofort|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
33279994|NCT03119766|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
33279995|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
32777312|NCT05613751|Experimental|Medically at risk children-influenza vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine
33082762|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
33082763|NCT04605523||Patients with Ataxia Telangiectasia|
33082764|NCT04605523||Healthy controls|
33082765|NCT04605601|Experimental|Study Group|
33082766|NCT04605601|Other|Control Group|
33082767|NCT04605367|Experimental|100% PP, a-TDCS|"After the pre-test:~repetition of the correct sequence as many times as possible (12 blocks of 30s).~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
33082768|NCT04605367|Experimental|100% PP, sham TDCS|"After the pre-test :~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
33279996|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
33279997|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
33279998|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
33279999|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
33280000|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
33280001|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
33280002|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
33280003|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
33280004|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
33280005|NCT05346042||Confirmed Covid-19|All adult COVID-19 patients and health care workers tested positive in the 7 participating hospitals identified between the end of February 2020 and December 2021.
33280006|NCT00993642|Experimental|All Participants|
32777313|NCT05613751|No Intervention|Medically at risk children-influenza vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine. They will receive normal care at the hospital.
33280007|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
33280008|NCT01028547|Active Comparator|dexamethasone 8mg|
33280009|NCT01028547|Placebo Comparator|normal saline|
33280010|NCT04001790|Experimental|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
33280011|NCT04001790|No Intervention|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
33280012|NCT01031355|Experimental|Arm 1|
33280013|NCT01031355|Active Comparator|Arm 2|
33280014|NCT01031355|Active Comparator|Arm 3|
33280015|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
33280016|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
33280017|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
33280018|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
33280019|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
33280020|NCT00427011|Experimental|1|
33280021|NCT05269992|Experimental|Real food products|The study products are 1) a 1kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed; 2) a 1.5kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed, and 3) a 1.5kcal/ml oral nutritional supplement provided in a 200ml ready to drink format. This study is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period aiming to recruit 60 in paediatric patients. During the intervention period, patients will receive one of the three study products (or more if deemed appropriate) for 28 days as a sole source of nutrition or alongside any additional routine nutritional management as required. As such, randomisation was not deemed suitable for this study. The appropriate study product and volume prescribed will be recommended by the investigating dietitian/nurse and agreed with the patient/parent/carer based on their clinical and nutritional requirements.
33280022|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
33280023|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
33280024|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
33280025|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
33280026|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
33280027|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
33280028|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
33280029|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
33280030|NCT03449589||Smokers|RA patients currently smoking
33280031|NCT03449589||Former smokers|RA patients who previously smoked
33280032|NCT03449589||Non smokers|Non smoking RA patients
33280033|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
33280034|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
33280035|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
33280036|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
33280037|NCT01031511|Experimental|Treatment Group - CBT|
33280038|NCT01031511|No Intervention|Control Group|
33280039|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
33280040|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
32777314|NCT04915495|Experimental|Singe-arm Study|Experimental device being evaluated for sensitivity and specificity.
32777315|NCT04884373||Fasted adult patients for elective surgery|"Age ≥ 18 years~Fasted according to national guidelines~Elective surgery~ASA physical status I-II~Ability to assume both supine and right lateral decubitus position.~Able to understand and to sign informed consent"
32777316|NCT05472103|Experimental|treatment|administration of Surgical ergonomics workshop
32777317|NCT05472103|No Intervention|control|no intervention
32777318|NCT05613595|Active Comparator|Positive Psychotherapy Group|In this phase of the study, the caregivers of CP having moderate to high scores on mental health issues on three scales (Depression, Burnout & Caregiver burden) will receive positive Psychotherapy sessions for a period of four months, divided over different weekly sessions. For Psychotherapy treatment group participants will be given both counseling as well as Positive psychotherapy based interventions. . Each session will be based upon individual session and duration of the session will be 40 minutes. Before starting every session feedback will be taken about the previous session and home based assignments will also be discussed
33280041|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
33280042|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
33280043|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
33280044|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
32777319|NCT05613595|Active Comparator|Counseling Group|10 participants will be included in in control group (N=10), for control group caregivers will be given regular counseling as a part of treatment of their child (psychoeducation). Each session will be based upon individual session and duration of the session will be 40 minutes.
32777320|NCT05613439||Day-surgery group|Patients having hip or knee replacement as day-surgery with successful discharge to own home on day of surgery
32777321|NCT05613439||High-risk patients|Patients evaluated to be at increased risk of postoperative complications. These patients will receive relevant additional attention based on type of comorbidity. I.e. preoperative evaluation of iron status and i.v. iron treatment in case of preoperative anaemia, increased focus on avoidance of NSAIDs and adequate fluid therapy in patients with renal disease etc.
32777322|NCT05613439||Main group|"Patients who are not scheduled for day-surgery and without comorbidities qualifying as high-risk. These patients go through a standard fast-track procedure with discharge to own home when fulfilling functional discharge criteria."
32777323|NCT05471713||PD with AutD|Parkinson's disease with autonomic dysfunction
32777324|NCT05471713||PD without AutD|Parkinson's disease without autonomic dysfunction
32936310|NCT03977714|Active Comparator|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
32936311|NCT03977714|Experimental|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
32936312|NCT03821857|Experimental|Women|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
32936313|NCT05454254|Active Comparator|Adults with Fontan circulation|Individualised muscle strengthening exercise training protocol.
32936314|NCT05454254|Active Comparator|Healthy controls|Individualised muscle strengthening exercise training protocol.
32936315|NCT03924518|Experimental|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
32936316|NCT03924518|Placebo Comparator|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
33280045|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
33082769|NCT04605367|Experimental|100% MP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
33280046|NCT00426231|Active Comparator|Information control|Information control
32936317|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
32936318|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
33280047|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
33280048|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
33280049|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
33280050|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
33280051|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
33280052|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
33280053|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
33280054|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
33280055|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
33280056|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
33280057|NCT00425373|Active Comparator|Valsartan 40 mg|
33280058|NCT00425373|Active Comparator|Valsartan 80 mg|
33280059|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
33280060|NCT00425373|Active Comparator|Amlodipine 5 mg|
33280061|NCT00425373|Placebo Comparator|Placebo|
33280062|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
33402020|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
33402021|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
33280063|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
33280064|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
33402022|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
33402023|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
32936319|NCT05454241|Experimental|anti-CD7 UCAR-T cells|
32936320|NCT05454020|Experimental|A (XG004)|XG004 in two dose level (5% or 10%) will be applied to the targeted knee
33402024|NCT02386384||Control|Normal fertile
33402025|NCT02386384||Implantation Failure|Failure to conceive
32936321|NCT05454020|Placebo Comparator|B (Placebo)|Placebo in all cohorts will be applied to the targeted knee.
32936322|NCT05454163||Exposed patients|
32936323|NCT05454163||Non exposed patients|
32936324|NCT05037344|Experimental|Internet-based psychotherapy|16 weeks of internet-based cognitive behavioral therapy
33280065|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
33402026|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
33402027|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
33280066|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
33280067|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
33280068|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
32936325|NCT05037344|Active Comparator|Internet-based psychotherapy waiting group|16 weeks of internet-based cognitive bahavioral therapy after waiting of 16 weeks
33280069|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
33280070|NCT05356260|Active Comparator|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
32936326|NCT05454085|Other|pregnancies with neural tube defects|patients with pre-diagnosis of neural tube defects (47 patients).
33280071|NCT05356260|Experimental|Online self-management intervention|"Participants in the intervention group will be given access to an online self-management program that will be personalized. This program was developed based on the results of a literature search, the opinions of expert Dutch GPs and urologists, and a pilot study in secondary care, with further preliminary testing in primary care. The program consists of nine components: information, pelvic floor exercises, bladder training, sitting voiding position, urethral milking, fluid management, caffeine avoidance, alcohol avoidance, and physical activity increase. Information is presented as text with supportive figures, plus audio (a read aloud function for all text) and video fragments to facilitate engagement by men with low literacy levels."
33280072|NCT04002336|Active Comparator|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
33280073|NCT04002336|Experimental|App Group|Voice therapy using a smartphone app.
33280074|NCT05129358|Experimental|Dehydration A|The subject is brought to light dehydration (loss of 1.5% of body weight) through physical exercise.
33280075|NCT05129358|Experimental|Dehydration B|The subject is brought to light dehydration (loss of 1.5% of body weight) through i.v. injection of up to 40ug Furosemide
33280076|NCT05332626|Experimental|Probiotic group|The probiotic group will receive a supplement diet capsule consisting of Lactobacillus acidophilus UALa-01™ with a dose of 1x10^9 CFU for 12 weeks
33280077|NCT05332626|Placebo Comparator|Placebo group|The placebo group will receive a capsule that consists of the excipient (maize starch and maltodextrins) for 12 weeks
33280078|NCT05236296|Experimental|EASE-CG Intervention|"Participants will be offered one EASE-CG therapy session every week for up to 12 weeks. Each session will last for approximately 30-60 minutes, delivered by a trained therapist at our center. Frequency and/or length of sessions may vary to accommodate the needs and availability of each participant.~Outcomes will be assessed at baseline, 1, 3, 6, 9, and 12 months. Participants may be invited to brief, semi-structured interviews."
33280079|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
33280080|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
33280081|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
33280082|NCT05088018|Experimental|Active Cannabigerol|25 mg daily swallowable Cannabigerol tablets for 2 weeks, immediately followed by 50 mg daily swallowable Cannabigerol tablets for 2 weeks
33280083|NCT05088018|Placebo Comparator|Placebo|25 mg daily swallowable placebo tablets for 2 weeks, immediately followed by 50 mg daily swallowable placebo tablets for 2 weeks
33280084|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
32936327|NCT05454085|Other|pregnancies without neural tube defects|patients with abnormal maternal serum screening test or prenatal diagnosis test, patients with abnormal ultrasonography findings (45 patients)
32936328|NCT05032976||BNT162b2|Subjects aged 5 years and older who are scheduled for BNT162b2 vaccination
33280085|NCT00994032|Active Comparator|vertebroplasty|
33280086|NCT00994032|Active Comparator|Medical Treatment|
33280087|NCT05252286|Experimental|video watching|In the video-watching group, a patient will follow the exercise instructions from watching the video. The exercise content in video are set during the patient conducting the rehabilitation program. Then, the therapist will select 3 to 5 groups of movements pattern needed to be enhanced catching from the video for the patient to practice when returning the bedside after the rehabilitation programs.
32936329|NCT05453786|Experimental|Sequence A|Period 1: SID1903-R1, SID1903-R2 / Period 2: SID1903
32936330|NCT05453786|Experimental|Sequence B|- Period 1: SID1903 / Period 2: SID1903-R1, SID1903-R2
32936331|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will receive levcromakalim infusion after glibenclamide administration
32936332|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive placebo infusion after glibenclamide administration
32936333|NCT03886922|Sham Comparator|Placebo|Participants will receive placebo infusion after placebo administration.
32936334|NCT03886922|Active Comparator|Levcromakalim and Glibenclamide|Participants will receive levcromakalim infusion before glibenclamide administration.
32936335|NCT03886922|Active Comparator|Levcromakalim and Placebo|Participants will receive levcromakalim infusion before placebo administration.
33082770|NCT04605367|Experimental|100% MP, sham TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
32936336|NCT04738370||Pregnancy of unknown location|Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
32936337|NCT04738370||Ectopic Pregnancy|Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
32936338|NCT05453552|Experimental|G-CSF+DAC+BF|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
32936339|NCT05453552|Active Comparator|G-CSF+DAC+BUCY|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
32936340|NCT05453474|Experimental|WGA|DNA from the cells are amplified by whole genome amplification prior to genetic testing.
33280088|NCT05252286|Active Comparator|paper sheet|For the paper sheet group, the therapist will prepare the exercise leaflet, suitable for the patients, in advance, and select three to five groups of movement exercises on the leaflet that his/her therapist deem the patients needed to be enhanced. When the patients ends his/her rehabilitation program, they can practice following the instructions on the leaflet for them-self in bedside.
33280089|NCT05252286|Placebo Comparator|oral health education group|In the oral health education group, the program is similar to the paper sheet group without providing any exercise paper sheet the patient but oral education.
33280090|NCT05325996|Experimental|Moderate Glaucoma|"Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period.~All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period."
33280091|NCT05229120|Experimental|Episodic Future Thinking|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant events with their children. After the intervention session, parents will receive a daily postcard over the course of two weeks including a reminder cue generated as part of the episodic future thinking (EFT) intervention and a prompt to remember these episodes in vivid detail.
33280092|NCT05315544|Experimental|CSI pVAD|
33280093|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
33280094|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
33280095|NCT05225376|Experimental|Establishment of physical activity sessions for pregnant women|All the women will receive the studied intervention
33280096|NCT05224518|Experimental|home-based elastic band training group|The interventional group received 12 weeks of home-based elastic band training, three days a week, with progressive, medium-intensity exercise.
33280097|NCT05224518|Active Comparator|stretching exercises group|The control group received home stretching exercises three days a week for 12 weeks.
33280098|NCT00994266|Experimental|A|Diamel
33280099|NCT00994266|Placebo Comparator|B|Placebo
33280100|NCT05302674|Experimental|Hot Dry|The participant will complete four hours of work at a 45:15 work rest cycle in a 98°F (36.7°C) and 20% relative humidity environment.
33280101|NCT01646814|Experimental|PL2200|Investigational product, PL2200
33280102|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
33280103|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
33280104|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
33280105|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32936341|NCT05453474|No Intervention|No-WGA|DNA from the cells are tested directly without whole genome amplification
32936342|NCT05453318|Experimental|Thermal ablation Arm|Treatment of cervical neoplasia by thermal ablation
33280106|NCT01416636|Active Comparator|Treprostinil sodium low dose - Arm I|"Arm I (low dose):~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
33280107|NCT01416636|Experimental|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
33280108|NCT00995358|Experimental|vaccination|
32777325|NCT04789057|Experimental|Statins|Atorvastatin 40 mg treatment, p.o., QD
32936343|NCT05018624|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
32936344|NCT05018624|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
32936345|NCT03851120|Experimental|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
32936346|NCT03851120|Placebo Comparator|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
32936347|NCT05011838|Experimental|A multi-component intervention to improve hypertension care and control|The intervention will be implemented in Commune 2. It will integrate activities related to 1) Health services redesign, 2) Clinical staff training and 3) Patient and community engagement. The intervention activities will be implemented by health services staff with technical assistance from the investigation team.
32936348|NCT05011838|No Intervention|Routine Care|The Commune 6 was selected as control area, where routine care will be delivered.
33280109|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
33280110|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
33280111|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
33280112|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
33280113|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
33280114|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
33280115|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
33280116|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
33280117|NCT00999024||Healthy subjects|20 healthy subjects will be included
33280118|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
33280119|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
33280120|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
33280121|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
33280122|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
33280123|NCT05280132|Experimental|Personalized strategy|"Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.~A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion.~After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7.~This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using:~The appearance of sputum (clinical approach);~PCT values and kinetics (biological approach);~Results of mPCR FA-PPP (microbiological approach)."
33280124|NCT05280132|Other|Usual strategy|"Usual antibiotic treatment~Left at the discretion of the physician as in usual practice"
33280125|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
33280126|NCT00999258|No Intervention|tacrolimus|
32777326|NCT04789057|Placebo Comparator|Placebo|Placebo tablet, p.o., QD
32936349|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
32936350|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
32936351|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
33280127|NCT00994734|No Intervention|clinic administration of mifepristone|
33280128|NCT00994734|Experimental|home administration of mifepristone|
33280129|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
33280130|NCT00999336|Experimental|Group A|Patients with mild renal impairment
33280131|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
33280132|NCT00999336|Experimental|Group C|Patients with severe renal impairment
33280133|NCT00995826|Placebo Comparator|placebo|
33280134|NCT00995826|Experimental|CS-8958 DPI|
33280135|NCT00994812|Experimental|Metformin|
32777327|NCT05611723||Healthy older Adults|Healthy older Adults: older adults without disability indicators
32777328|NCT05611723||Disability Older Adults|Disability Older Adults: older adults with disability indicators
32777329|NCT05613361|Experimental|Group 1|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours.
32777330|NCT05613361|Active Comparator|Group 2|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours and curcumin will be administered as orally or through nasogastric tube at a dose of 2 capsules every 6 hours (1 gm/6 hour)
32777331|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
32777332|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
32777333|NCT05611645|Experimental|HSRT+Low-dose Bevacizumab|HSRT with low-dose bevacizumab every 2 weeks
32777334|NCT05611645|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
32777335|NCT05611567|Experimental|POSE2.0|This is the arm that got the POSE2.0 procedure. The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA). This device is registered and commercially available in the United Arab Emirates for the management of obesity.
32777336|NCT05611567|Active Comparator|Life style and behavioral intervention|This is the comparator arm that received lifestyle modification alone for weight loss and NAFLD management (representing the comparative control group). This group underwent the same lifestyle program and clinical follow-up as the POSE2.0, but under a parallel standard clinical care pathway, which is the standard clinical pathway in the hospital this study was conducted in.
32777337|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
32777338|NCT05611489|Other|Single port Lap appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision.
32777339|NCT05611489|Other|Conventional lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic).
32777340|NCT05467735|Experimental|Interventional: Compression Arm|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
32777341|NCT05467735|No Intervention|Control Arm|The inflatable sleeves of a sequential compression device would be placed in bilateral lower extremities of patients, but the device would not be turned on, thus no external pressure would be applied.
32777342|NCT03167671|Active Comparator|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
32777343|NCT03167671|Experimental|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
32777344|NCT04426513|Active Comparator|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
32777345|NCT04426513|Experimental|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
32777346|NCT04426513|Experimental|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
32777347|NCT02977195|Experimental|Dose escalation part, biological cohort and expansion Parts|Dose Escalation and Biological Cohort: NP137 was administrated in patients with locally advanced or metastatic solid tumors Expansion Parts: NP137 was administrated in patients with locally advanced or metastatic solid tumors (Expansion part 1) and in patients with RH+ endometrial cancers (Expansion part 2)
32777348|NCT04340167|Experimental|Autologous humanized anti-CD22 CAR-T treatment|
32777349|NCT05611333|Experimental|Physician-Led Remote Exercise Program Intervention|Participants randomized to the intervention arm will attend three 45-minute walking sessions over Zoom per week for 4 weeks. Additionally, 10 people in this group will be asked to participate in brief interviews after the program for feedback on the program. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
32777350|NCT05611333|No Intervention|Control|Participants in the control group will continue with usual care. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
32777351|NCT05611255|Experimental|Systematic Intermittent Catheterization (SIC)|A bladder catheter will be placed in the operating room, at the end of the operation, in a patient still under general anesthesia. Once the urine has been drained and quantified, the bladder catheter will be removed before the patient is discharged and extubated.
32777352|NCT05611255|Active Comparator|Bladder Scan Guided Catheterization (BSGC)|No systematic catheterization will be performed, the indication for catheterization will be guided by bladder-scan volume monitoring.
32777353|NCT04339543|Other|Longitudinal assessment|
32830747|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
32936352|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
33280136|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
33280137|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
33280138|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
33280139|NCT00996138|Other|Arm 1|Dose ranging
32936353|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
32936354|NCT03811964|Other|group control|healthy subject
32936355|NCT04976972|Experimental|Robotic-Total Knee Replacement (R-TKR)|NAVIO/CORI Surgical System
32936356|NCT04976972|Active Comparator|Conventional-Total Knee Replacement (C-TKR)|Non-robotic conventional instrumentation
32936357|NCT04976738|Experimental|Treatment arm: Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
32936358|NCT04967222|Experimental|Cognitive Reappraisal-by-Distancing (CRD)|Subjects will be coached to use cognitive reappraisal-by-distancing to downregulate their negative reactions to aversive emotional pictures usng practice pictures.
32936359|NCT04967222|Active Comparator|Control Downregulate Condition (CD)|Subjects will be coached to practice their customary emotion regulatory techniques in a treatment occurring twice a week for 6 weeks.
32936360|NCT04951934|Experimental|EmoLED Group|The EmoLED Group will undergo treatment with EmoLED twice a week for 5 consecutive weeks. The therapy, in this case, in addition to the standard treatment, will also include a treatment with the EmoLED device.
32936361|NCT04951934|Active Comparator|Control Group|The Control Group will follow the standard treatment indicated.
32936362|NCT05453084|Experimental|Intervention Arm|"The exercise intervention tool will be Fitwalking, which is structured, organized, supervised and administered through a Walking Group"
33280140|NCT00996138|Other|Arm 2|Dose ranging
33280141|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
33280142|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
33280143|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
33280144|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
33280145|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
33280146|NCT04001010|Experimental|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
33280147|NCT04001010|Placebo Comparator|Placebo|Placebo inhalation with mighty medic device
33280148|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
33280149|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
33280150|NCT01003860||0.5% Ropivicaine (150 mg)|
33280151|NCT01003860||0.75% Ropivicaine (225 mg)|
33280152|NCT04000542|Experimental|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
33280153|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
33280154|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
33280155|NCT04000698|Experimental|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
33280156|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
33280157|NCT05272956|No Intervention|control group|Enteral feeding is carried out with a syringe pump
33280158|NCT05272956|Experimental|intervention group|the first enteral feeding is pushed with a syringe by the nurse. Following enteral feeding attempts are pushed with a syringe by the parents. Bolus feeding speed is at the discretion of the person pushing the syringe (nurse or parent) and is adjusted to the child's signs of discomfort. When the parents are absent, enteral feeding is carried out with a syringe pump
33280159|NCT05172336||Assisted reproductive technology (Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
33280160|NCT05172336||Assisted reproductive technology (Non-Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
33280161|NCT05172336||Spontaneous conception (SC)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
33280162|NCT01004016|Placebo Comparator|Placebo|
32936363|NCT04950296|Active Comparator|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
32936364|NCT04950296|Active Comparator|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
32936365|NCT04950296|Placebo Comparator|Microcrystalline Cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
32936366|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
32936367|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
33280163|NCT01004016|Experimental|KPS-0373|
33280164|NCT05181696||COVID-19 pneumonia patients|Patients treated at the University Hospital Osijek Respiratory Center with pneumonia caused by SARS-CoV-2
33082771|NCT04605367|Experimental|50% MP and 50% PP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
33082772|NCT04605367|Experimental|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
33082773|NCT04605367|No Intervention|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
33082774|NCT05518721|Active Comparator|Synthetic Cartilage Implant|
33280165|NCT04000932|Experimental|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
33280166|NCT04000932|Active Comparator|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
33280167|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
33280168|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
33280169|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
33280170|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
33280171|NCT00999882|Experimental|AZD8055|Dose escalation
33082775|NCT05518721|Active Comparator|Dermal Interposition Arthroplasty|
33082776|NCT04605289|Experimental|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
33082777|NCT04605289|Placebo Comparator|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
33082778|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
33082779|NCT05517278|Experimental|Treatment Group|The treatment group will receive SurgX™ Antimicrobial Wound Gel™ applied over incision after closure and then re-applied at first dressing change on day of discharge in addition to standard of care.
33280172|NCT00996528|Experimental|Philani Intervention Program|
33280173|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
33280174|NCT05170230|Active Comparator|intracapsular myomectomy Terlipressin injection|intracapsular myomectomy Terlipressin injection in women undergoing laparoscopic myomectomy procedure
33082780|NCT05517278|Other|Control Group|The control group will receive standard of care.
33280175|NCT05170230|Active Comparator|intracapsular myomectomy Carbetocin injection|intracapsular myomectomy Carbetocin injection in women undergoing laparoscopic myomectomy procedure
33280176|NCT05170230|Placebo Comparator|intramyometrial saline|intracapsular myomectomy saline injection in women undergoing laparoscopic myomectomy procedure
33280177|NCT00999960|Active Comparator|1: without simulator|without simulator
33280178|NCT00999960|Experimental|2: with simulator|with simulator
33280179|NCT01004328|Experimental|Intervention Group 1|All participants
33280180|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
33280181|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
33280182|NCT01000116|Active Comparator|Fibrin glue|
33280183|NCT01000116|Active Comparator|Tacks|
33280184|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
33280185|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
33280186|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
33280187|NCT05162196|Experimental|SBRT combined with Niraparib and Toripalimab|"Induction therapy (cyc1: D1-D28): Niraparib 200mg QD + SBRT 8Gy✖️3 QD, D4-D6 + Toripalimab 240mg iv drip D7~Maintenance (cyc2+): Niraparib 200mg QD, D1-D21 + Toripalimab 240mg iv drip D1, until disease progression or intolerable toxicity"
33280188|NCT04000464|Experimental|Single Arm|24 Week Lifestyle Modification intervention
33280189|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
33280190|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
33280191|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
33280192|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
32777354|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
32777355|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
32777356|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
32777357|NCT02835079|Other|open label study|one arm open label study
32777358|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
32777359|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
32777360|NCT05455567||patients with pre perimetric open angle glaucoma|
32777361|NCT05455567||patients with perimetric open angle glaucoma|
32777362|NCT05455567||healthy patients|
32777363|NCT05446285||Treated|Patients initiating disease modifying treatment within the first year of diagnosis
32777364|NCT05446285||Untreated|Patients who do not initiate disease modifying treatment within the first year of diagnosis
32777365|NCT05436145|Experimental|Within-participant micro-randomization|"Each day in the study, with probability .5 for each, a participant is randomized to receive a notification that day or no notification that day.~If a participant is assigned to receive a notification that day, 1 message set will be randomly selected from a pool of 60 message sets. There are 2 types of message sets: 1) Support and 2) Consequences.~If a participant is assigned to receive a Support message set, they will be randomized to receive either the Emotional or Practical Support version. If a participant is assigned to receive a Consequences message set, they will be randomized to receive either the Gain Framed or Loss Framed version."
32777366|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
32777367|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
32777368|NCT04412239|Experimental|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
32777369|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
32777370|NCT05381779|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
32777371|NCT05381779|Experimental|High Intensity Interval Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
32777372|NCT05381779|Sham Comparator|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
33082781|NCT04605250|Other|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
32777373|NCT04411615|Experimental|Omega|Omega-3 re-esterified triglyceride form
32777374|NCT02405221|Experimental|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
32777375|NCT02405221|Experimental|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
33082782|NCT00564772|Experimental|single arm|all subjects dosed the same
33082783|NCT00564811|No Intervention|G1|
33082784|NCT00564811|Experimental|G2|
33082785|NCT00564967|Experimental|1|CBT via the Internet
33082786|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
33082787|NCT03454243|Experimental|RXDX-106|
33082788|NCT05506163||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
33082789|NCT05506163||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
32777376|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
32777377|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
32777378|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
33082790|NCT04604977|Other|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
33280193|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
33082791|NCT04605016|Experimental|Hydrophilic surface implants|
33082792|NCT04605016|Active Comparator|Hydrophobic surface implants|
33082793|NCT04604938|Experimental|Losartan group|Drug: Losartan
33280194|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
33280195|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
33280196|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
33280197|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
33280198|NCT00997308|Placebo Comparator|Placebo|
33280199|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
33280200|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
33280201|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
33280202|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
33280203|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
33280204|NCT05249712|Experimental|ADT with Darolutamide|"Pathological response rate after radical prostatectomy with dalotamide combined with androgen deprivation therapy (ADT) in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer.~Duration of treatment: 28-day cycle of darotamide treatment and 6 cycles of neoadjuvant therapy. ADT treatment continued during neoadjuvant therapy and was discontinued after surgery.~Adjusted dosing: When the serum testosterone concentration cannot be maintained at <50 ng/dL, the dose and type of ADT can be adjusted. Investigators can adjust the dose of darostatide according to the situation."
33280205|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
33280206|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
33280207|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
33280208|NCT00425061|Experimental|1|
33280209|NCT00425061|Experimental|2|
33280210|NCT00425061|Placebo Comparator|3|
33280211|NCT04000308|Experimental|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
33280212|NCT04000308|Active Comparator|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
33280213|NCT01005186|Experimental|Active|Active
33280214|NCT01005186|Experimental|Active 2|Active
33280215|NCT00997542|Active Comparator|Allopurinol|
33280216|NCT00997542|Placebo Comparator|Placebo|
33280217|NCT05271630||Single Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving single maintenance therapy with an immunomodulatory drug after Autologous Stem Cell Transplant for Multiple Myeloma
33280218|NCT05271630||Double Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving double maintenance therapy with the combination of an immunomodulatory drug and a proteasome inhibitor after Autologous Stem Cell Transplant for Multiple Myeloma.
33280219|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
33280220|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
33280221|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
33280222|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
33280223|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
33280224|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
33280225|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
33280226|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
33280227|NCT01001364|Experimental|Formoterol/Budesonide|
33280228|NCT01001364|Active Comparator|Foraseq|
33280229|NCT03994185|Experimental|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
33280230|NCT03885726|Active Comparator|Treatment as Usual|
33280231|NCT03885726|Experimental|High Velocity Nasal Insufflation|
32777379|NCT04685551|Experimental|Survivorship Management among African American and Latinx Cancer Dyads|"This arm will implement a one group pre-test and posttest design to improve health outcomes of African American and Latinx cancer survivors and caregivers in collaboration with health professional students trained as Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs)."
32777380|NCT04638673|Experimental|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1&2 of stimulation and active stimulation during weeks 3&4 of stimulation of study participation.
33082794|NCT04604938|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
33082795|NCT05473520|Experimental|Doxycycline + standard anti-tuberculous treatment|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
33082796|NCT05473520|Placebo Comparator|Placebo + standard anti-tuberculous treatment|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15-20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician.
33082797|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI> 35 kg / m² for adults and Z BMI score> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
33082798|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
33082799|NCT04604587|Experimental|amyloid PET、T807 PET|PET/CT
33082800|NCT00565123|Experimental|Group A|Experimental dosage
32777381|NCT04638673|Sham Comparator|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1&2 of stimulation and active stimulation for weeks 3&4 of stimulation of study participation.
32777382|NCT04589611|Experimental|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
32777383|NCT04589611|Active Comparator|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
32777384|NCT04589611|Placebo Comparator|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
32777385|NCT04589611|Active Comparator|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
32777386|NCT04589611|Placebo Comparator|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
32777387|NCT04535479|Experimental|Individuals with spasticity resulting from stroke|This is an experimental intervention in which individuals will receive dry needling to relieve spasticity in the target muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
32777388|NCT04535479|Experimental|Individuals with no known neurological injury|This is an experimental intervention in which individuals will receive dry needling of an arm or leg muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
32777389|NCT05269849|Experimental|Oral sirolimus tablets|Sirolimus starting dose of 2 mg once daily, orally adjusted as need to maintain drug blood levels of 6-10 ng/ ml The first dose will be given at the week 12 visit and participants will be observed for 30 min
32777390|NCT05256199|Experimental|high-intensity group|The high intensity group receives a personalized, supervised intervention consisting of group meetings and individual sessions.
32777391|NCT05256199|No Intervention|low-intensity group|The low-intensity arm receives online access to general lifestyle-related health information.
32777392|NCT05240131|Experimental|Part A - GB1211 200 mg and 400 mg BID in combination with atezolizumab.|Part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg and 400 mg BID in combination with atezolizumab.
33082801|NCT00565123|Active Comparator|Group B|Classical dosage
33082802|NCT04604509|Experimental|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
33082803|NCT04604509|Experimental|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
33082804|NCT04604509|Experimental|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
33082805|NCT04604509|Experimental|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
33082806|NCT04604509|Experimental|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
32777393|NCT05240131|Experimental|Part B - GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|Part B of the study, GB1211 (200 or 400 mg BID to be selected from part A) in addition to atezolizumab, for 12 weeks
32777394|NCT05240131|Experimental|Part C - Extension of GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|"Extension of GB1211 in addition to atezolizumab until part B has been unblinded.~Extension of placebo in addition to atezolizumab until part B has been unblinded"
32777395|NCT05615233|Experimental|Intervention Group|Patient will use TACAD and the Alzheimer's Association Website
32777396|NCT05615233|Active Comparator|Active Control Group|Patient will use only the Alzheimer's Association Website
32777397|NCT05220943|Other|Video|All participants are invited to complete a pre survey, watch a five minute video, and then complete a post survey.
32777398|NCT05475145|Experimental|Child|Each patient receives treatment of dental caries in two primary molars using two diffferent methods - Resin based sealing [RBS] or Glassionomer cement [GIC].
32777399|NCT05615155|Experimental|i-PRF|The sides of the mouth that will be injected with injectable-Platelets Rich Fibrin
32777400|NCT05615155|Experimental|C-PRF|The sides of the mouth that will be injected with Concentrated-Platelets Rich Fibrin
32777401|NCT05614999|Active Comparator|Training group|Participants in this group will do the pre-training test, practicing eight-sessions (each session is approximately 15minutes) and then do the post-training test.
32777402|NCT05614999|No Intervention|Non-training group|Participants in this group will do the pre-training test, and then do the post-training test after the pre-test 4-6weeks.
32777403|NCT05188339|Experimental|4% sodium citrate group|Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.
32777404|NCT05188339|Active Comparator|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
32777405|NCT05169385|Experimental|Parent SMART|Parent SMART is a technology-assisted parenting intervention combining an off-the-shelf computer program (Parenting Wisely), up to four telehealth coaching sessions, and access to an app-based networking forum.
32777406|NCT05169385|Active Comparator|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
32777407|NCT04393909|Active Comparator|Control group|Patients do not have access to the Patient Dx Questionnaire.
32777408|NCT04393909|Active Comparator|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
32777409|NCT05474989|Experimental|Verum|Subjects in the treatment arm will receive 150 μg LSD (first session) and 150 or 250 μg LSD (second session).
32777410|NCT05474989|Active Comparator|Active placebo|Subjects in the control arm will receive 10 µg LSD at the first session and 10 µg LSD at the second session.
32777411|NCT05474911|Active Comparator|Conventional care|
32777412|NCT05474911|Experimental|Negative pressure therapy|
32777413|NCT05614843|Experimental|PBM group|Energy density 7.5 J / cm2
32777414|NCT05614843|Placebo Comparator|Control group|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective goggles) using the same laser device to imitate a real irradiation; however, the device will be turned off and recording of the emission sounds will be used to give the patient the hearing sensation of the PBM therapy.
33082807|NCT04604509|Experimental|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
33082808|NCT04604509|Experimental|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
33280232|NCT03995277|Other|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
33280233|NCT03995277|Other|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
32777415|NCT05613205|Experimental|Step 1a low dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04A Low Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
32777416|NCT05613205|Active Comparator|Step 1a control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
32777417|NCT05613205|Experimental|Step 1b low dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03A Low Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
32777418|NCT05613205|Active Comparator|Step 1b control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
32777419|NCT05613205|Experimental|Step 2 full dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04B Full Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
32777420|NCT05613205|Experimental|Step 2 full dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03B Full Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
33082809|NCT05467943|Experimental|Cohort 1 based on the EZH2 mutations|MT patients with R/R FL; planned enrollment number: 19;
33082810|NCT05467943|Experimental|Cohort 2 based on the EZH2 mutations,|WT patients with R/R FL; planned enrollment number: 20;
33082811|NCT04604392|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
33082812|NCT04604392|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
33082813|NCT04604392|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
33082814|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
33280234|NCT03995277|Other|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
33280235|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
33280236|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
33280237|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
33280238|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
33280239|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
33280240|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
33280241|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
32777421|NCT05613205|Active Comparator|Step 2 control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
33280242|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
33280243|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
33280244|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
33280245|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
33280246|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
33280247|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
33280248|NCT04000386|Experimental|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
33280249|NCT04000386|Placebo Comparator|placebo|62 patients with placebo socks
33280250|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously~Dosage to be determine by physician"
33280251|NCT00998088|Experimental|Erythropoietin|
33280252|NCT00998088|No Intervention|Control arm|
33280253|NCT00998088|Experimental|cell saver|
32777422|NCT05614765||Treatment group|statin+ezetimibe compound
32777423|NCT05611021|Experimental|Walking Condition|In the walking condition, the patients will perform fifteen bouts of two minutes of treadmill walking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
33280254|NCT00998088|Experimental|drain|
32936368|NCT05451524|Experimental|Insomnia prevention program|"The preventive program has been developed and modified as based on the evidence-based CBT-I insomnia treatment.~Active intervention group will be conducted in group size with 6-8 subjects who are from the same education level (i.e. secondary vs university). Youths in the intervention group will receive 4 weekly insomnia prevention program conducted by the sleep therapists who has received training in conducting CBT-I under close supervision of sleep experts. Each session will last for about 60-90 mins."
33082815|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy~Radiotherapy combined immunotherapy"
33082816|NCT05439707|Experimental|Experimental group|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
33280255|NCT00998088|Experimental|Erythropoietin and cell saver|
33280256|NCT00998088|Experimental|Erythropoietin and drain|
33280257|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
33280258|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
33280259|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
33280260|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
33082817|NCT05439707|Sham Comparator|Control group|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
33082818|NCT04604041||Relapsing-remmitting MS group treated with corticosteroids|"Clinical testing~Neurophysiological examination (TMS, EMNG)~Psychomotor examination~Neuropsychological evaluation~Flow cytometry~ELISA"
33082819|NCT04604041||Relapsing-remmitting MS group treated with immunomodulation|1. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry
33082820|NCT04604041||Healthy control group|5. Flow cytometry
33082821|NCT04603885|Experimental|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
33280261|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
33280262|NCT01031745|Experimental|Contingency|
33280263|NCT01031745|Active Comparator|Control|
33280264|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
33280265|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
33280266|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
33280267|NCT03246022||Group l|SBP index was less than 30% of AHI
33280268|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
33280269|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
33280270|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
33280271|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
33280272|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
33280273|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
33280274|NCT01324648|Experimental|TG + GP TAU|
33280275|NCT01324648|Experimental|UG + GP TAU|
33280276|NCT01324648|Active Comparator|GP TAU|
33280277|NCT00424515|Experimental|Treatment Arm|Imatinib
33280278|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
33280279|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
33280280|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
33280281|NCT01028703||Controls|"110 controls"
33280282|NCT05131204|Experimental|Pozelimab and Cemdisiran|Randomized 1:1
33280283|NCT05131204|Experimental|Anti-C5 standard-of-care|Randomized 1:1
33280284|NCT04619745|Experimental|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
33280285|NCT04619745|Experimental|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
33280286|NCT03994263|Experimental|iTind arm|ITind device implant
33280287|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
33280288|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
33280289|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
33280290|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
33280291|NCT05127148||Adolescents and young adults Ph-negative ALL patients in first-line|Adolescents and young adults patients (18-40 years old) with recent diagnosis of Ph-negative acute lymphoblastic leukemia who receive argentinian pediatric-like treatment depending on risk category.
33280292|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
33280293|NCT01048372||Control|Healthy adults without HIV infection.
33280294|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
33280295|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32936369|NCT05451524|Active Comparator|General health education|In order to control for placebo effect and other non-specific factors such as contact time, youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group. Modules will contain information about general well-being, diet, nutrition, and activity. It is expected that this health education will be an active control group to account for most of the non-specific effects including time, attention, therapist, and peer support.
32936370|NCT03738098|Active Comparator|Traditional Genetic Counseling|Standard of care genetic counseling session
32936371|NCT03738098|Experimental|GUÍA|Standard of care genetic counseling session with Genomic Understanding, Information and Awareness (GUÍA).
32936372|NCT05451134||patients with dysglycemia|Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma
33280296|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
33280297|NCT02910999||NSCLC patients with squamous tumor histology|
33280298|NCT02910999||NSCLC patients with non-squamous tumor histology|
33280299|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
33280300|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
33280301|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
33280302|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
33280303|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
33280304|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
33280305|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
33280306|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
33280307|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
33280308|NCT00376246|Other|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
33280309|NCT00376246|Other|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
33280310|NCT00368836|Experimental|BreathScreen PE + D-dimer|CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.
33280311|NCT03992716|Experimental|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
33280312|NCT03992716|Active Comparator|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
33280313|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
32936373|NCT05451134||patients without dysglycemia|Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
32936374|NCT05449886|Experimental|Tidal volume challenge|
32936375|NCT04945304||Magnetic bariatric surgery|Bariatric procedure performed in a human using magnetic assistance in the steps of the surgery
32936376|NCT04937504|Active Comparator|STAIR-PC Group|Participants in the Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) group will complete five (30 minute each) therapist-led sessions in-person or via Telehealth for up to 12 weeks.
33280314|NCT01050088|Experimental|Sucrose|5cc sucrose solution
33280315|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
33280316|NCT00376168|Experimental|prGCD 30 Units/kg|
33280317|NCT00376168|Experimental|prGCD 60 Units/kg|
33280318|NCT00375934|Experimental|1|
33280319|NCT00375934|Placebo Comparator|2|
33280320|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
33280321|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
33280322|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
33280323|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
33280324|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
33280325|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
33280326|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
33280327|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
33280328|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
33280329|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
33280330|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
33280331|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
33280332|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
33280333|NCT03990844|Placebo Comparator|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
33280334|NCT03990844|Experimental|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
33280335|NCT03990844|Experimental|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
33280336|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
33280337|NCT00642941|Experimental|Cohort 1: Ewings Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
33280338|NCT00642941|Experimental|Cohort 2: Ewings Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
33280339|NCT00642941|Experimental|Cohort 3: Ewings Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
33280340|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
33280341|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
33280342|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
33280343|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
32936377|NCT04937504|Experimental|WebSTAIR Group|Participants in the WebSTAIR group will complete 10 self-guided, web-based modules for up to 12 weeks.
32936378|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
32936379|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
32936380|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
32936381|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
32936382|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])
32936383|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
32936384|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
32936385|NCT04891718|Experimental|MVC-101 and Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumour resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline and solution stabilizer), a pre-cleaved/pre-activated drug control (cMVC-101), MVC-101 (the prodrug), or nivolumab as single agents or as combinations. Each drug will be delivered in subtherapeutic microdoses, and each microdose is simultaneously injected in a columnar fashion through each of 3, 5, or 8 needles (in a device configuration determined by tumour dimensions) into a single solid tumour or effaced metastatic lymph node.
33280344|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
33280345|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
33280346|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
33280347|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
33280348|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
33280349|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
33280350|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
33280351|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
33280352|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
33280353|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
33280354|NCT00816959|Active Comparator|Arm II: ABVD|
32777424|NCT05611021|Active Comparator|Arm-Cranking Condition|In the arm-cranking condition, the patients will perform fifteen bouts of two minutes of arm-cranking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
32936386|NCT03770689|Experimental|Peposertib 50 mg + RT + Capecitabine|Participants received peposertib 50 milligram (mg) once daily in combination with capecitabine 825 milligram per square meter (mg/m^2) twice daily 5 days per week and radiotherapy (RT) of 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
32936387|NCT03770689|Experimental|Peposertib 100 mg + RT + Capecitabine|Participants received peposertib 100 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
33280355|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
33280356|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
33280357|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
33280358|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
33280359|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
33280360|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
33280361|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
33280362|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
33280363|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
33280364|NCT04446611|Experimental|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
33280365|NCT04446611|Experimental|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
33280366|NCT04446611|No Intervention|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
33280367|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
33280368|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
33280369|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
33280370|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
33280371|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
33280372|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
33280373|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
33280374|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
32936388|NCT03770689|Experimental|Peposertib 150 mg + RT + Capecitabine|Participants received peposertib 150 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
33082822|NCT04603885|Placebo Comparator|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
33280375|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD)
33082823|NCT04603768|Experimental|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
33280376|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
33280377|NCT03990922|Experimental|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
33280378|NCT03990922|Placebo Comparator|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
33280379|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
33280380|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
33280381|NCT01005342|Experimental|Rye bran|Single intake of rye bran
33280382|NCT01005342|Experimental|Oat bran|Single intake of oat bran
33280383|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
33280384|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
33280385|NCT00822263|Placebo Comparator|2|control
33280386|NCT00822263|Experimental|1|Active medicine
33280387|NCT03992170|Experimental|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
33280388|NCT04044755|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
33280389|NCT04044755|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
33280390|NCT05154474||Standard|Standard follow-up MNA, IPAQ, SARC-F and SarQOL questionnaire
33280391|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
33280392|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
33280393|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
33280394|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
33280395|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
33280396|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
33280397|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
33280398|NCT04044833||intervention|(n=63)
33280399|NCT04044833||control|(n=65)
33280400|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
33280401|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
33280402|NCT01002222|Experimental|MCS-2|
33280403|NCT04018625|Experimental|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
33280404|NCT04018625|Active Comparator|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
33280405|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
33280406|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
33280407|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
33280408|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
33280409|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
33280410|NCT01002378|Experimental|Arm 1|
33280411|NCT01002378|Experimental|Arm 2|
33280412|NCT01002378|Experimental|Arm 3|
33280413|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
33280414|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
33082824|NCT04603768|Experimental|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
33280415|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
33280416|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
33280417|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
33280418|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
33280419|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
33082825|NCT04603768|Experimental|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
33280420|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
33280421|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
33280422|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
33280423|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
33082826|NCT05389553||Patients at term of pregnancy|"We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth.~Pregnant women with antepartum hemorrhage, fetal growth restriction, stillbirths, multiple gestations, or congenital abnormalities were excluded."
33280424|NCT01002534|No Intervention|baseline|visit 1
33280425|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
33280426|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
33280427|NCT01324804||CABG - subjects|only one group
33280428|NCT00817271|Experimental|1|
33280429|NCT00817271|Experimental|2|
33280430|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
33280431|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
33280432|NCT00822497|Experimental|1|Music-Based Imagery
33280433|NCT00822497|Experimental|2|Music Alternate Engagement
33280434|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
33280435|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
33280436|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
33280437|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
33280438|NCT01002768|Experimental|IDeg|
33280439|NCT01002768|Experimental|IGlar|
33280440|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
33280441|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
33280442|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
33280443|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
33280444|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
33280445|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
33280446|NCT00998478|Experimental|Activity prescription|
33280447|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
33280448|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
33280449|NCT00822575|Active Comparator|A|
33280450|NCT00822575|Sham Comparator|B|
33280451|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
33280452|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
33280453|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
32777425|NCT05611021|Sham Comparator|Control Condition|The control condition will consist of resting in the standing position for thirty minutes. The patients will be instructed to rest in the sitting position for two minutes at periods equivalent to the intervals from the exercise conditions, totalling sixty minutes of duration.
32777426|NCT05613127|Experimental|Test group|Inactivated Hepatitis A vaccine
32777427|NCT05613127|Active Comparator|Control group|Inactivated Hepatitis A vaccine
32777428|NCT05474599|Experimental|Dry cupping therapy|For pain and severity of symptoms in primary dysmenorrhea.
32777429|NCT05474599|Other|Conventional physical therapy|For management of pain and severity of symptoms
32777430|NCT05610865|Active Comparator|Control; Standard-of-care management|Saline dressing will be done as a routine care management.
32777431|NCT05610865|Experimental|Only PRP injection|Only PRP will be injected at the wound site.
32936389|NCT03770689|Experimental|Peposertib 250 mg + RT + Capecitabine|Participants received peposertib 250 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
32777432|NCT05610865|Experimental|PRP + SVF injection|SVF pellet mixed with PRP will be injected at the wound site after adjusting number of cells.
32777433|NCT05610865|Experimental|PRP + ASCs injection|Cultured ASCs mixed with PRP will be injected at the wound site after adjusting number of cells.
32777434|NCT05134051|Experimental|Single arm|single arm intervention with IVL in calcified de novo coronary stenoses with indication of plaque modification technique during PCI
32777435|NCT05114005|Experimental|Tango|The intervention will consist of 16 Argentine Tango (Tango) sessions, adapted for neurorehabilitation per Hackney and Earhart (2010). Delivered over 8 weeks at a frequency of 2x per week and duration of 1 hour per session, this program teaches the basics steps of partnered Tango dance.
32777436|NCT05114005|Active Comparator|Home Exercise (HEX)|The control group will consist of an evidence-based, structured home exercise program (HEX) based on the 8 week intervention described by Zimmer et al (2018) and recommended by physical therapists specializing in BC within our organization. This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
32777437|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
32777438|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
32777439|NCT05474521|Experimental|Participant 1|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777440|NCT05474521|Experimental|Participant 2|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777441|NCT05474521|Experimental|Participant 3|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32936390|NCT00371384|Experimental|2|structural massage
32777442|NCT05474521|Experimental|Participant 4|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777443|NCT05474521|Experimental|Participant 5|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777444|NCT05474521|Experimental|Participant 6|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777445|NCT05474521|Experimental|Participant 7|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777446|NCT05474521|Experimental|Participant 8|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777447|NCT05474521|Experimental|Participant 9|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32936391|NCT00371384|Experimental|1|relaxation massage
32936392|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
32936393|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
32936394|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
32936395|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
32936396|NCT03620474|Experimental|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr~Administration method:~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
32777448|NCT05474521|Experimental|Participant 10|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777449|NCT05474521|Experimental|Participant 11|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777450|NCT05474521|Experimental|Participant 12|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777451|NCT05474521|Experimental|Participant 13|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
33280454|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
33280455|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
33280456|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
33280457|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
33280458|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
33280459|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
33280460|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
33280461|NCT00998634|Placebo Comparator|PLACEBO|
32936397|NCT04337905|Experimental|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
32936398|NCT04337905|Active Comparator|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
33280462|NCT04044989|Experimental|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
33280463|NCT04044989|Experimental|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
33280464|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
33280465|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
33280466|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
33280467|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
33280468|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
33280469|NCT01008774|Experimental|A|
33280470|NCT01008774|Active Comparator|B|
33280471|NCT01008774|No Intervention|C|
32936399|NCT03582566|Experimental|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
32936400|NCT03582566|Experimental|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
32936401|NCT03582566|Experimental|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
32936402|NCT03582566|Active Comparator|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
33280472|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
33280473|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
33280474|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
33280475|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
33280476|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
33280477|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
33280478|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
32936403|NCT03566264||Participants hospitalized with ADHF|
32936404|NCT05453929|Experimental|Deep NMB|A TOF count of 0, and a PTC of 1 to 3 will be maintained, as close to 2 twitches as possible
32936405|NCT05453929|Active Comparator|Moderate NMB|A TOF count of 1 to 3 will be maintained, as close to 2 twitches as possible
32936406|NCT00370760|Active Comparator|1|
32936407|NCT00370760|Placebo Comparator|2|
32936408|NCT05227508|Experimental|Brizo SC012|A capsule containing 400 mg. SC012 (unique soy extract) TWICE A DAY : MORNING , EVENING.
32936409|NCT05227508|Placebo Comparator|PLACEBO|A capsule containing 400 mg OF PLACEBO, TWICE A DAY: MORNING , EVENING.
32936410|NCT03737461|Experimental|Allogenic BM-MSCs Injection|Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.
32936411|NCT03737461|Sham Comparator|Sham Procedure|anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment
32936412|NCT05203562|Active Comparator|Control group I|Patients with complete mole treated by evacuation of using suction curettage followed by conservative follow up
32936413|NCT05203562|Experimental|Prophylactic letrozole group II|Patients with complete mole treated by evacuation of using suction curettage followed by 5mg daily letrozole for 10 days followed by conservative follow up
33280479|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
32936414|NCT05453851|Experimental|Treatment (pancreatectomy, autologous islet cell transplant)|Patients undergo total pancreatectomy and autologous islet cell transplant IV over 15-60 minutes on day 1.
32936415|NCT05145374||Stressful Stimuli|Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli.
33280480|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
33280481|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
33280482|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
33280483|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
32777452|NCT05474521|Experimental|Participant 14|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
33082827|NCT04603963|No Intervention|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
33082828|NCT04603963|Experimental|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
33082829|NCT04604002|Experimental|Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
33082830|NCT04604002|Experimental|Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
33082831|NCT04603729|Active Comparator|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
33082832|NCT04603729|Active Comparator|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
33280484|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
33280485|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
33280486|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
33280487|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
33280488|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
33280489|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
33280490|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
33280491|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
33280492|NCT01006278||Group 2|volunteer group
33280493|NCT01003314|Experimental|Group 1|
33280494|NCT01003314|Experimental|Group 2|
33280495|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
33280496|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
33280497|NCT01003392||Diabetes|Diabetic patients.
32777453|NCT05474521|Experimental|Participant 15|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
33082833|NCT05372003|Experimental|Subjects on Dupilumab|"individuals with atopic dermatitis placed on dupilumab for more than 6 months will be eligible to this study. Their metabolic profile will be compared to the group of Subjects on Phototherapy"
33082834|NCT05372003|Active Comparator|Subjects on Phototherapy|"individuals with atopic dermatitis placed on phototherapy for more than 6 months will be eligible to this study to serve as an active comparator to the Subjects with Dupilumab"
33082835|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
33082836|NCT04603924|Experimental|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
33082837|NCT04603924|Placebo Comparator|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
33082838|NCT04603534|Experimental|Intervention group|
33280498|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
33280499|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
33280500|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
32777454|NCT05474521|Experimental|Participant 16|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777455|NCT05474521|Experimental|Participant 17|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777456|NCT05474521|Experimental|Participant 18|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777457|NCT05474521|Experimental|Participant 19|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777458|NCT05474521|Experimental|Participant 20|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777459|NCT05474521|Experimental|Participant 21|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777460|NCT05474521|Experimental|Participant 22|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777461|NCT05474521|Experimental|Participant 23|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777462|NCT05474521|Experimental|Participant 24|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777463|NCT05474521|Experimental|Participant 25|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
33280501|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
33280502|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
33280503|NCT01003470|Experimental|acupuncture|
33280504|NCT01003470|Active Comparator|rehabilitation|
32936416|NCT05453773|Experimental|Tobacco flavor preparation; High Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
32777464|NCT05474521|Experimental|Participant 26|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777465|NCT05474521|Experimental|Participant 27|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777466|NCT05474521|Experimental|Participant 28|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777467|NCT05474521|Experimental|Participant 29|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777468|NCT05474521|Experimental|Participant 30|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
32777469|NCT05614531|Experimental|Dose escalation- Cohort 1|dose 1 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3~6)
32777470|NCT05614531|Experimental|Dose escalation-Cohort 2|dose 2 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=6~12)
32777471|NCT05614531|Experimental|Dose escalation-Cohort 3|dose 3 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3~6)
32777472|NCT04134325|Experimental|Arm 1: Relapse After Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
32936417|NCT05453773|Experimental|Tobacco flavor preparation; High Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
32936418|NCT05453773|Experimental|Tobacco flavor preparation; Medium Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
32936419|NCT05453773|Experimental|Tobacco flavor preparation; Medium Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
32936420|NCT05087888||Observational (MRI, questionnaire, blood collection)|Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy.
32936421|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
32936422|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
32936423|NCT04844138|Experimental|Online Self-Directed Program|Participants in this condition will complete our six-week online self-directed program as soon as it's available.
32936424|NCT04844138|Other|Waitlist|Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
32936425|NCT05453383|Experimental|Anlotinib and Toripalimab treatment|Anlotinib Hydrochloride and Toripalimab Injection
32936426|NCT04830488|Experimental|Body Image after Head and Neck Cancer Treatment|
32936427|NCT05453305|Active Comparator|Control group: Traditional venipuncture, on the stretcher.|the companion will place the child on the stretcher in the supine position with the limb to be punctured in decline. At all times, during the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture while another colleague will help with tasks of holding and/or collecting samples.
33082839|NCT05364125|Experimental|Treatment arm|Olfactory training by neurological chemosensory stimulation using aromatic substances delivered via diffusers. Four aromatic substances will be used. Each substance will be given for 20 seconds sequentially, providing a total of 80 seconds of olfactory stimulation three times per day for 3 months.
33280505|NCT01003470|Active Comparator|acupuncture and rehabilitation|
33280506|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
33280507|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
33280508|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
33280509|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
33280510|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
33280511|NCT01003704||General Anesthesia only|
33280512|NCT01003704||Peripheral nerve block|
33280513|NCT01003704||spinal|
33280514|NCT04000230|Experimental|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
33280515|NCT04000230|Active Comparator|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
33280516|NCT05085288|Active Comparator|Intermittent electrical stimulation system (IES) treatment Group|Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10 seconds every 10 minutes.
33280517|NCT05085288|Active Comparator|Standard of care Group|Turning the patient every two hours as per standard inpatient nursing practice and any other wound care or plastic surgery treatments deemed appropriate as per usual care.
33280518|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
33280519|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
33280520|NCT03742674||Cohort patients post stroke|
33280521|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
33280522|NCT01028859|Experimental|CKD-516 inj|
33280523|NCT05734248|Experimental|Intervention group|"This test region (right or left cheek) will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFL) with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a operator- and subject- blinded fashion. A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: AFL Device: AFL Drug: anesthetic mixture cream"
33280524|NCT05734248|Placebo Comparator|Control|"A pass with the same fractional carbon dioxide laser with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to the test region on the other to the intervention cheek (sham AFL) at t0 in a operator- and subject-blinded fashion.~A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: sham AFL Device: sham AFL Drug: anesthetic mixture cream"
33280525|NCT05602974|Experimental|adjuvant stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy after hepatectomy with narrow margin
33280526|NCT05602974|Active Comparator|regular follow-up|regular follow-up after hepatectomy with narrow margin
33280527|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
33280528|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
33280529|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
33280530|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
33280531|NCT05139186|Experimental|WL+AI|Colonoscopy in white light and artificial intelligence
33280532|NCT05139186|Experimental|WL|Colonoscopy in white light
33280533|NCT03992248|Experimental|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
33280534|NCT03992248|Other|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
33280535|NCT05734170|Other|Cheerio breakfast|Patient consumes 1 serving of cheerios for breakfast every day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
33280536|NCT05734170|Other|Instant Oatmeal Breakfast|Patient consumes 1 package instant oatmeal for breakfast each day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
33280537|NCT05734170|Experimental|Chia Seeds and Instant Oatmeal breakfast.|Patient consumes 1 package instant oatmeal with 2 tbsp chia seeds everyday for breakfast for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
33280538|NCT01006824|Experimental|1|Capsule Endoscopy
33280539|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
33280540|NCT05734092|Active Comparator|Control group|The strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage
33280541|NCT05734092|Experimental|Low-Level Laser Therapy group|In the experimental group (LLLT), where a (Ga-Al-As) diode laser, will be used with 808 nm wavelength in continuous mode, 250 milli-Watt power output, 4 Joules/point energy density, 16 s per point. In addition to adjusting the force gauge every 4 weeks until the end of the intrusion stage and reaching normal coverage
33280542|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
33280543|NCT05586360|Experimental|Simvastatin|Patients randomized to the statin group will receive 40 mg oral simvastatin QD for eight weeks prior to prostatectomy, including the day of surgery.
33280544|NCT05586360|No Intervention|Control|Patients randomized to the control group receive no intervention prior to prostatectomy.
33280545|NCT05570916|Experimental|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
33280546|NCT05570916|Other|Reference Group|Will not be comparative against the test article, but will be performed for reference and safety.
33280547|NCT05734014|Experimental|Intervention Group|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
33280548|NCT04000074|Experimental|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
33280549|NCT04000074|No Intervention|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
33280550|NCT04000074|Experimental|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
33280551|NCT04000074|No Intervention|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
33280552|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
33280553|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
32777473|NCT04134325|Experimental|Arm 2: Relapse with no Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have not received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
33280554|NCT05733936|Experimental|criterion-based rehabilitation protocol|It's a three phases rehabilitation protocol with a goal-based progression which include a three criterion based postoperative phases: (1) impairment phase, (2) sport-specific training phase and (3) return to play phase. Patients can start with the next phase only if specific goals of the previous phase are achieved
33280555|NCT05733936|Active Comparator|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
33280556|NCT05733858|Experimental|tRNS with digital MT|
33280557|NCT05733858|Experimental|tDCS with digital MT|
33280558|NCT05733858|Sham Comparator|sham stimulation with digital MT|
33280559|NCT00626795|Experimental|1|
33280560|NCT00626795|Experimental|2|
33280561|NCT00626795|Active Comparator|3|
33280562|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
33280563|NCT05534880|Active Comparator|Virtual Reality|Condition 01 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video, lasting 10 minutes, there will be 05 sessions on alternate days with a 24-hour interval between each session, before and after each session will be applied the SSQ questionnaire subjective assessment and EEG objective assessment.
33280564|NCT05534880|Experimental|Virtual reality and binaural beats|Condition 02 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video associated with audio with binaural beat, lasting 10 minutes, there will be 05 sessions on alternate days with a 24-hour interval between each session, before and after each session, the SSQ subjective assessment questionnaire and the objective assessment EEG will be applied.
33280565|NCT00826553|Experimental|GABA agonist|
33280566|NCT00826553|Experimental|Alpha 2 agonist|
33280567|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
33280568|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
33280569|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
33280570|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
33280571|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
33280572|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
33280573|NCT00826631|No Intervention|2|Control group, parallel
33280574|NCT03880266|Active Comparator|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
33280575|NCT03880266|Placebo Comparator|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
33280576|NCT03880266|Active Comparator|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
33280577|NCT03880266|Placebo Comparator|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
33280578|NCT03880266|Active Comparator|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
33280579|NCT03880266|Placebo Comparator|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
32936428|NCT05453305|Experimental|Experimental group: DAK method venipuncture, simulating a hug.|the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture while another colleague helped with the tasks of holding and/or collecting samples.
33280580|NCT03880266|Active Comparator|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
33280581|NCT03880266|Placebo Comparator|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
33280582|NCT00423891|Experimental|Arm 1: Entecavir|
33280583|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
33280584|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
33280585|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
33280586|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
33280587|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
33280588|NCT05530512|Experimental|Anti-inflammatory EA (AI-EA)|Anti-inflammatory electroacupuncture therapy
33280589|NCT05530512|Experimental|Sympathoinhibitory EA (SI-EA)|sympatho-inhibitory electroacupuncture therapy
32936429|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
32936430|NCT04766762|Experimental|Acupuncture combined with placebo group|Patients in this group will receive acupuncture combined with placebo.
33280590|NCT05530512|Experimental|Combined EA (cEA)|combination of SI-EA and AI-EA
33280591|NCT05530512|Experimental|Control EA (Sham-EA)|Sham electroacupuncture
32936431|NCT04766762|Other|Sham acupuncture combined with medication group|Participants in this group will receive sham acupuncture plus flunarizine hydrochloride.
32936432|NCT04330040|Experimental|Single Arm|Intervention: Drug: Olaparib
32936433|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
32936434|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
33280592|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
33280593|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~Tracheal intubation through the LMA-Fastrach~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
33280594|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~Tracheal intubation through the I-gel~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
33280595|NCT05518032|Experimental|Treatment (pembrolizumab, autologous dendritic cells)|Patients receive pembrolizumab IV on days 8, 29, 50, and 71, and autologous dendritic cells intratumorally on days 1 and 8 in the absence of disease progression or unacceptable toxicity. Patients may also receive an autologous dendritic cells intratumorally on day 50.
33280596|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
33280597|NCT02549651|Experimental|MEDI4736|
33280598|NCT02549651|Experimental|MEDI4736 and tremelimumab|
33280599|NCT02549651|Experimental|MEDI4736 and AZD9150|
33280600|NCT03999762|Active Comparator|Density gradient sample prep|Standard density gradient sample preparation
33280601|NCT03999762|Experimental|Automated sample prep|Automated experimental sample preparation
33280602|NCT03999372|Experimental|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
33280603|NCT03999372|Active Comparator|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
33280604|NCT00826709|Experimental|Arm 1|2 Nasal swabs
33280605|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
33280606|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
33280607|NCT05733546|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
33280608|NCT05733546|Active Comparator|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin
33280609|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
33280610|NCT05733468|Experimental|Theracal LC Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
33280611|NCT05733468|Active Comparator|MTA Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
33280612|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
33280613|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
33280614|NCT05733312|Experimental|Focused Ultrasound|Subjects with known or suspected glioma (≥3cm) undergoing routine planned neurosurgical resection will undergo a focused ultrasound prior to the surgery with the InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
33280615|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
33280616|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
33280617|NCT00423813|Placebo Comparator|1|
33280618|NCT00423813|Experimental|2|
33280619|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
33280620|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
33280621|NCT03687372|Experimental|A-101|topical solution
33280622|NCT03687372|Other|Vehicle|topical solution
33280623|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
33280624|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
33280625|NCT05454306|Experimental|Anser Clavicle Pin|Patients treated with Anser Clavicle Pin in the setting of a displaced midshaft clavicle fracture
33280626|NCT05733234|Experimental|Test|Laser-assisted surgical treatment of peri-implantitis
33280627|NCT05733234|Active Comparator|Control|Surgical treatment of peri-implantitis - No laser
33280628|NCT05733156|Experimental|SBRT + LDRT|
33280629|NCT01007682|No Intervention|Screening for working memory capacity|
33280630|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
33280631|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
33280632|NCT00358150|Experimental|Eliglustat tartrate|
33280633|NCT05446740|Experimental|YA GSK4382276A Dose level 1 Group|Eligible young adults (YA) participants receive dose level 1 of GSK4382276A study intervention administered at Day 1.
33280634|NCT05446740|Experimental|YA GSK4382276A Dose level 2 Group|Eligible young adults (YA) participants receive dose level 2 of GSK4382276A study intervention administered at Day 1.
33280635|NCT05446740|Experimental|YA GSK4382276A Dose level 3 Group|Eligible young adults (YA) participants receive dose level 3 GSK4382276A study intervention administered at Day 1.
33280636|NCT05446740|Experimental|YA GSK4382276A Dose level 4 Group|Eligible young adults (YA) participants receive dose level 4 of GSK4382276A study intervention administered at Day 1.
33280637|NCT05446740|Experimental|YA GSK4382276A Dose level 6 Group|Eligible YA participants receive dose level 6 of GSK4382276A study intervention administered at Day 1.
33280638|NCT05446740|Experimental|YA GSK4382276A Dose level 7 Group|Eligible YA participants receive dose level 7 of GSK4382276A study intervention administered at Day 1.
33280639|NCT05446740|Active Comparator|YA Control Group|Eligible YA participants receive single dose of FDQ21A-NH administered at Day 1.
33280640|NCT05446740|Experimental|OA GSK4382276A Group|Eligible OA participants receive single dose of GSK4382276A study intervention at 1 dose level selected from the first 3 dose levels in YAs, administered at Day 1.
32777474|NCT04131439||"cochlear implantation group"|"cochlear implantation group: patients undergoing cochlear implantation between December 2019 and December 2021in the ENT department of Assiut university hospital."
32777475|NCT05474443|Experimental|Myofascial gun with Conventional therapy|• Myofascial gun was applied over the Upper Trapezius muscle for 5 minutes. In the first two sessions frequency was set to 1-2 then increased to next two sessions 3-4 and so on.
32777476|NCT05474443|Active Comparator|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool moved over the skin on upper trapezius muscle from its origin to insertion at 45 degree. conventional therapy applied with Thermotherapy, upper trapezius, levator scapulae and pectoralis major stretching and cryotherapy at the end
32777477|NCT04116697|Experimental|Acupuncture with Anti-Emetics|
32777478|NCT04116697|Experimental|Aromatherapy with Anti-Emetics|
32777479|NCT04116697|No Intervention|Control Group|
32777480|NCT05474365|Experimental|Medical students|
32777481|NCT05474365|Experimental|Surgical trainees|
32777482|NCT05474365|No Intervention|Attending Surgeons|
32777483|NCT05474209|Active Comparator|exercise patients with multiple sclerosis|"a group that undergoes a tai-chi intervention - a special program for patients with multiple sclerosis - once a week with a Tai Chi instructor lasting 90 minutes. At V0, each patient will receive an accurate instructional video for a separate home exercise tai-chi at an intensity of twice a week."
32777484|NCT05474209|No Intervention|non-exercising patients with multiple sclerosis|the group will be a control group, patients with multiple sclerosis undergo a whole battery of examinations and scales, they will not undergo exercise.
33280641|NCT05446740|Active Comparator|OA Control Group|Eligible OA participants receive single dose of FDQ21A-NH administered at Day 1.
32777485|NCT04105543|Experimental|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
32777486|NCT05474053|Experimental|Brilique group|volunteers in the Brilique group received a loading dose of 180 mg brand Brilique® (AstraZeneca , Sweden) then 90 mg twice daily regimen for 4 days
32777487|NCT05474053|Experimental|Ticaloguard group|volunteers in the Ticaloguard group received the Egyptian made generic ticalogaurd in a loading dose of 180 mg then 90 mg twice daily regimen for 4 day
32777488|NCT04027465|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
32777489|NCT04027465|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
32777490|NCT04988035|Experimental|Remdesivir + Danicopan (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
32777491|NCT04988035|Experimental|Remdesivir + Danicopan (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
32936435|NCT05055050|Experimental|UGN-201 Pre Radical Cystectomy|UGN-201 200 mg/50ml
32936436|NCT05007548|Experimental|Ga68-Dolacga Injection|Ga68-Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
32936437|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
32936438|NCT04994834|Experimental|Intervention|Probiotics
32936439|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
32936440|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
32936441|NCT04992494|Experimental|MBCT-T (Mindfulness-Based Cognitive Therapy - Telephone)|Mindfulness-based cognitive therapy delivered by Telephone
32936442|NCT04992494|Experimental|MBCT-V (Mindfulness-Based Cognitive Therapy - Video)|Mindfulness-based cognitive therapy delivered by Video
32936443|NCT05453227|Experimental|vaginal topical containing zinc sulfat|25 cases will be undergo treatment with active ingredient
32936444|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
32936445|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
33280642|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
33280643|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
33280644|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
33280645|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
33280646|NCT00831077|Active Comparator|14C-ORM-14540|
33280647|NCT00831077|Active Comparator|14C-ORM-12741|
33280648|NCT01007760|Placebo Comparator|Room air|
33280649|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
33280650|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
33280651|NCT00823355|Experimental|BCX1777|
33280652|NCT03999450|Experimental|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
33280653|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
33280654|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
33280655|NCT05435586|Experimental|Web Based Breastfeeding Education and Counseling with Digital Game Support|"During pregnancy;~Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~Program will be applied to 30 women at 35-37 gestational weeks.~Breastfeeding Self-Efficacy Scale (Antenatal form) will be applied to at the end of 37th gestational week.~In the postpartum period;~The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~Program will be applied to 30 women during the first 2 weeks postpartum.~At the end of the postpartum 2nd week, Breastfeeding Behavior and Breast Problems Evaluation Form will be administered.~Breastfeeding Self-Efficacy Scale (Postpartum form) and Breast Problems Evaluation form will be administered at postpartum 8th week."
33280656|NCT05435586|No Intervention|Standardized breastfeeding education|"During pregnancy;~Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~30 women will receive the routine care applied during pregnancy in the hospital.~At the end of the 37th week, the Breastfeeding Self-Efficacy Scale (Antenatal form) will be administered to the women in the control group.~In the postpartum period;~30 women will receive the standard breastfeeding training in the hospital.~The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~At the end of the postpartum 2nd week, the Breastfeeding Behavior and Breast Problems Evaluation Form will be applied.~Breastfeeding Self-Efficacy Scale (Postpartum form) and Breastfeeding Behavior and Breast Problems Evaluation Form will be administered at the postpartum 8th week."
33280657|NCT01049074|Experimental|Verus acupuncture|
33280658|NCT01049074|Sham Comparator|Sham acupuncture|
33280659|NCT05427630|Experimental|THC ~2.5%|Inhalation of cannabis flower containing THC ~2.5%
33280660|NCT05427630|Experimental|THC ~5%|Inhalation of cannabis flower containing THC ~5%
33280661|NCT05427630|Experimental|THC ~10%|Inhalation of cannabis flower containing THC ~10%
33280662|NCT05427630|Sham Comparator|Sham Cannabis|Inhalation of cannabis flower from which the THC and CBD have been extracted
33280663|NCT01050556|Placebo Comparator|Placebo|Placebo daily
33280664|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
33280665|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
33280666|NCT01050556|Experimental|Creatine|creatine daily
33280667|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
33280668|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
33280669|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
33280670|NCT00626327|Active Comparator|MMRV|
33280671|NCT00626327|Experimental|MenACWY-CRM|
33280672|NCT01032213|Placebo Comparator|group C|control group
33280673|NCT01032213|Experimental|group M|magnesium group
33280674|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
33280675|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
33280676|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
33280677|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
33280678|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
33280679|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
33280680|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
33280681|NCT00827021|Experimental|ESAs 1 low dose|
33280682|NCT00827021|Active Comparator|ESAs 2 high dose|
33280683|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
33280684|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
33280685|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
33280686|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
33280687|NCT01029015||Group 3 - Normal|Normal Subjects
33280688|NCT04491617|Active Comparator|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
33280689|NCT04491617|Experimental|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
33280690|NCT01050712|Experimental|Carbon Monoxide|
33280691|NCT01050712|Placebo Comparator|Synthetic Air|
33280692|NCT02407509|Experimental|Part I - Twice weekly (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours.
33280693|NCT02407509|Experimental|Part I - Three times weekly (COMPLETED)|VS-6766 will be administered three times weekly in 4 week cycles in patients with solid tumours.
33280694|NCT02407509|Experimental|Part IIA (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway.
33280695|NCT02407509|Experimental|Part IIB|VS-6766 will be administered twice weekly in 4 week cycles in patients with multiple myeloma with a mutation in KRAS, NRAS or BRAF. In order to accommodate steroid use for patients with multiple myeloma, patients will be administered for 3 weeks followed by a week interruption.
33280696|NCT02407509|Experimental|Part IIC (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. Upon occurrence of specified G2 toxicity, dosing intensity will be reduced to 3 weeks followed by a week interruption in a 4 week cycle.
33280697|NCT02407509|Experimental|Part IID - Once weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered once weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
33280698|NCT02407509|Experimental|Part IID - Twice weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
33280699|NCT02407509|Experimental|Part IID - Dose expansion|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with KRAS-mutant lung cancer. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
33280700|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
33280701|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
33280702|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
33280703|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
33280704|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
33280705|NCT00823511||Female Partners|Female partners of HIM Study participants
33280706|NCT00823589|Experimental|pathological group|pathological group
33280707|NCT00823589|Experimental|healthy aged|healthy aged
33280708|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
33280709|NCT01086670|Other|1|Subjects will be randomly assigned to use one of two novel lower extremity exercise devices: a motor-assisted cycle or an elliptical trainer.
33280710|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
33280711|NCT01050868|Experimental|Single Arm|
33280712|NCT00623363|Active Comparator|piclozotan|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of piclozotan administered at a plasma level of 30 ng/mL over 2 inpatient days.
33280713|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of 0.9 % sodium chloride (normal saline) administered at a plasma level of 30 ng/mL over 2 inpatient days.
33280714|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
33280715|NCT00823667|Active Comparator|Phase 1 Usual care|
33280716|NCT00823667|Active Comparator|Phase 2 Intervention|
33280717|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
33280718|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
33280719|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
33280720|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
33280721|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
33280722|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
33280723|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
33280724|NCT00823745|Experimental|1|[14C]-PF-00868554
33280727|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
33280728|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33280729|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
32777492|NCT04988035|Active Comparator|Remdesivir + Placebo (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan matching placebo, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
33280730|NCT04396535|Experimental|Arm I (docetaxel, bintrafusp alfa)|Patients receive docetaxel IV over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33280731|NCT04396535|Active Comparator|Arm II (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.
33280732|NCT04018391|Experimental|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
33280733|NCT04018391|Active Comparator|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
33280734|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
33280735|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
33280736|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
33280737|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
33280738|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
33280739|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
33280740|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
33280741|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
33280742|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
33280743|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
33280744|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
33280745|NCT00824057|Experimental|1|
33280746|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
33280747|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
33280748|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
33280749|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
33280750|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
33280751|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
33280752|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
33280753|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
33280754|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
33280755|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
33280756|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
33082840|NCT05364125|Placebo Comparator|Control arm|Same diffuser will be given to control group. All of the four essential oils will be replaced by normal saline using the same packing. Same treatment regime of 20 seconds for each diffuser three times per day for 3 months will be instructed to control group patients.
33082841|NCT04603378|Other|KB195|
33280757|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
33280758|NCT03991858|Other|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
33082842|NCT04603378|Other|Polydextrose|
33082843|NCT04603378|Other|Pullulan|
33280759|NCT03991858|Experimental|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
33280760|NCT00831545|Experimental|Subjects with melanoma|
33280761|NCT00831545|Experimental|Subjects with breast cancer|
33280762|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
33280763|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
33280764|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
33280765|NCT01051024|Experimental|A|Diamel
33082844|NCT04603378|Other|Maltodextrin|
33082845|NCT04603573|Experimental|(intervention)|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
33280766|NCT01051024|Placebo Comparator|B|Placebo
33280767|NCT02549417|Experimental|KHK7580|
33280768|NCT00824135|Experimental|1|
33280769|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
33280770|NCT00827333|No Intervention|Phase I-Usual Care|
33082846|NCT04603573|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
33082847|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
33280771|NCT00827333|Active Comparator|Phase 2 - Intervention|
33280772|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
33280773|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
33280774|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
33280775|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
33280776|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
33280777|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
33280778|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
33280779|NCT01029171|Active Comparator|2|CON (control; usual care)
33280780|NCT00441129|Active Comparator|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
33280781|NCT00441129|Experimental|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
33280782|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
33280783|NCT00622505|Experimental|Zoledronic acid|Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to [≥] 50 nanomoles per millimoles [nmol/mmol] creatinine or <50 nmol/mmol creatinine, respectively).
33280784|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
33280785|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
33280786|NCT02550275|Other|controls|unaffected patient with Huntington's disease
33280787|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
33280788|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
33280789|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
33280790|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
33280791|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
33280792|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
33280793|NCT00827489|Experimental|HTC-867|
33280794|NCT00827489|Placebo Comparator|Placebo|
33280795|NCT00831857||Group A|Treatment with sunitinib.
33280796|NCT00831857||Group B|Treatment with bevacizumab and interferon
33280797|NCT04467515|Experimental|Dose Escalation and Expansion|"The dose escalation phase of the study will be an open label 3 + 3 design, where at least 3 patients are treated at each dose level. Dose escalation will be done via increases of the nominal activity of CAM-H2 in cohorts of 3 to 6 patients.~In the dose expansion phase of the study, the patients will be given the RDP2 determined in the dose escalation phase. Similar to the dose escalation phase, all patients will receive at least 1 cycle of CAM-H2."
33280798|NCT00824447|Placebo Comparator|Placebo control|Placebo control
33280799|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
33280800|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
33280801|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
32936446|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
33280802|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
33280803|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
33280804|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
33280805|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
33280806|NCT00824603||primary care provider|attending insulin CME Training
32936447|NCT04941092||patients with ARDS induced by SARS CoV 2|
33280807|NCT04043429|Experimental|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
33280808|NCT04043429|Active Comparator|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
33280809|NCT04043819|Experimental|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
33280810|NCT04016987|Experimental|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
33280811|NCT04016987|No Intervention|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
33280812|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
33280813|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
33280814|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
32936448|NCT04941092||patients with ARDS induced by influenza|
32936449|NCT05453149|Experimental|Persons with Neurological Conditions|
33280815|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
32936450|NCT04902404|Experimental|First Pathways Group|Parents in the First Pathways Game group will be instructed to log into the First Pathways website daily and play First Pathways games with their child. They will receive daily reminders for the first month after randomization but will not receive reminders for the second month.
32936451|NCT04902404|No Intervention|Wait-list Control|Parents in the wait-list control group will receive access to the First Pathways game after completing their final two-month study assessment.
33280816|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
33280817|NCT00824759|Placebo Comparator|placebo|
33280818|NCT00824759|Active Comparator|oxygen|
33280819|NCT00832169|Experimental|1|
33280820|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
33280821|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
33280822|NCT00824837|Experimental|A|New larger pore membrane
33280823|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
33280824|NCT00832403||polytetrafluoroethylene|
33280825|NCT02550041|Other|Cystic fibrosis|
33280826|NCT00832481|Active Comparator|Repaglinide,tablet|
32936452|NCT04338217|Experimental|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
32936453|NCT04338217|Active Comparator|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
32936454|NCT04885322|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
32936455|NCT04885322|Experimental|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
32936456|NCT04885322|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
32936457|NCT05452993|Experimental|1 - Retinophotography for diabetic retinopathy screening|Patients who accepted to participate to this study and had retinophotography for diabetic retinopathy screening.
33082848|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
33082849|NCT05361824|Experimental|Ketorolac|Ketorolac 30mg 8 hourly for 48 hours post-operatively
33082850|NCT05361824|Active Comparator|Paracetamol|Paracetamol 1gm 6 hourly for 48 hours post-operatively
33082851|NCT04603612|Other|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
33082852|NCT04603222|Experimental|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
33082853|NCT04603222|Active Comparator|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
33280827|NCT00832481|Active Comparator|Metformin, tablet|
33280828|NCT00350272|Experimental|Elvucitabine, Efavirenz,Tenofovir|"Elvucitabine (blinded) 10 mg/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
33280829|NCT00350272|Active Comparator|Lamivudine,Efavirenz,Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
33280830|NCT04044287|Active Comparator|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
33280831|NCT04044287|Placebo Comparator|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
33280832|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
32777493|NCT04988035|Active Comparator|Remdesivir + Placebo (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) of loading dose danicopan matching placebo followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
33280833|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
33280834|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
32777494|NCT04983511|Experimental|Electrical Epidural Stimulation Test (EST)|Postpartum women are given EST to predict epidural catheter reactivation for their subsequent procedures (i.e. tubal ligation).
32777495|NCT04019197|Experimental|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
32777496|NCT04019197|Placebo Comparator|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
33082854|NCT04603339|Experimental|Intervention Arm|Single arm trial, all participants will receive the intervention
33082855|NCT05314829||Study group|Data will be collected from 2 child advocacy centers
33280835|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
33280836|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
33280837|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
33280838|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
33280839|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
33280840|NCT00832559|Experimental|CVA21|CVA21
33280841|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
33280842|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
33280843|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
33280844|NCT00357370|Experimental|Cohort 1|20 mg
32777497|NCT05473897|Experimental|Catalyst Cryohelmet intervention with symptomatic care|The treatment arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects.
32777498|NCT05473897|No Intervention|Control: symptomatic care arm|The control arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg). They will not wear any helmets.
32777499|NCT05473819|Experimental|Buffered Anaesthetic solution|8.4% sodium bicarbonate will be added to the 4% articaine HCL with 1:1000000 epinephrine carpule in ratio 19:1 the Articaine to the Sodium bicarbonate
32777500|NCT05473819|Active Comparator|Conventional Anaesthetic solution|4% Articaine HCL with 1:1000000 epinephrine Anaesthetic carpule
32777501|NCT04330729|Experimental|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
32777502|NCT05473741||SGA-LAI|Outpatients with schizophrenia treated with second generation long-acting injectable antipsychotics whose psychotic symptoms have remitted.
32777503|NCT04842721|Active Comparator|Hypertonic Saturated Saline Mouth Rinse Active Arm|The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
32777504|NCT04842721|Placebo Comparator|Plain Water Control Arm|The Control Rinse is a 25 ml of Plain Tap Water.
32777505|NCT05614375||soft tissue sarcoma with endoscopic surgery|patients with soft tissue sarcoma accept endoscopic surgery
32777506|NCT05612893||Influenza upper respiratory infection|This cohort aims to descirbe the nasal mucosal immune response in influenza patients. We will collect nasal mucosal cells from influenza patients using Nasal Cytology Curettes. Blood samples will also be obtained from the patient. All samples will be used for single cell sequencing.
32777507|NCT05612893||Viral Sepsis and Viral pneumonia|The purpose of this cohort is to characterize the immune pattern of patients with viral sepsis and find specific target for the treatment of viral sepsis. Blood samples will be obtained from the viral sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
32777508|NCT05612893||Bacterial Sepsis and Bacterial pneumonia|This cohort served as a control for the viral sepsis/pneumonia cohort.Blood samples will be obtained from the bacterial sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
32777509|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
32777510|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
32777511|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:~Aseptic necrosis of the humeral head~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis~Failed previous total shoulder replacement, resurfacing or other procedure"
32777512|NCT04803799|Experimental|Experimental Arm|Training programme using Exergame as a support over a 12 week period
32936458|NCT05452993|No Intervention|2 - No screening|Patients who did not meet inclusion criteria and/or refused the retinophotographies screening.
32777513|NCT04800601|Experimental|Experimental group|
32777514|NCT04800601|Active Comparator|Control group|
32777515|NCT04762771|Active Comparator|Active|Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
32777516|NCT04762771|No Intervention|Control|Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.
32777517|NCT04339465|Experimental|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
32936459|NCT04852484|Active Comparator|local anesthetic and morphine group|paravertebral block with local anesthetic and morphine, followed by a continuous infusion of local anesthetic and morphine in the paravertebral space
32936460|NCT04852484|Active Comparator|local anesthetic and ketamine group|paravertebral block with local anesthetic and ketamine, followed by a continuous infusion of local anesthetic and ketamine in the paravertebral space
32936461|NCT04852484|Active Comparator|local anesthetic group|paravertebral block with local anesthetic only, followed by a continuous infusion of local anesthetic only in the paravertebral space
32936462|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~History of liver transplant"
32936463|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~No history of liver transplant, managed medically"
32936464|NCT04809662||Main cohort|This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.
32936465|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
32936466|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
32936467|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
32936468|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
32936469|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
32936470|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
32777518|NCT04339465|Experimental|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform. The 12 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
32777519|NCT04339465|Experimental|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
33082856|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
33280845|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
33280846|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
33280847|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
33280848|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
33280849|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
33280850|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
33280851|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
33280852|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
33280853|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
33280854|NCT03987724|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
33280855|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
33280856|NCT00574847|Placebo Comparator|Placebo|Placebo
33280857|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
33280858|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
33280859|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
33082857|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
33280860|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33280861|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33280862|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33280863|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33280864|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33082858|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
33082859|NCT04603456|Experimental|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
33280865|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
33280866|NCT00825383|Active Comparator|1|High Fiber Diet
33280867|NCT00825383|Active Comparator|2|Moderate Fiber Diet
33280868|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
33280869|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
33402028|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
33402029|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
33280870|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
33280871|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
33402030|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
33402031|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
33280872|NCT00828269|No Intervention|1|Liver tissue biopsy
33280873|NCT00825461||1|Anorexia with tube feeding
32936471|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
32936472|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
33280874|NCT00825461||2|Anorexia without tube feeding
33280875|NCT00825461||3|Control
33402032|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
33402033|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
33402034|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
33402035|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
32936473|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
32936474|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
32936475|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
32936476|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
32936477|NCT04790474|Experimental|ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment|Prospective study of ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment for patients with relapsed and refractory multiple myeloma (RRMM) previously treated with daratumumab, lenalidomide and bortezomib
32936478|NCT05450419|Active Comparator|Vitamin D3|Patient received enteral supplementation of 576,000 IU vitamin D3 on week 1, then enteral supplementation of 72,000 IU vitamin D3 on week 2, week 3 & week 4.
32936479|NCT05450419|Placebo Comparator|Placebo|Patient received enteral supplementation of placebo on week 1, then enteral supplementation of placebo on week 2, week 3 & week 4.
32936480|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
32936481|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
33082860|NCT04603456|Experimental|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
33280876|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
33280877|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
33280878|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
32936482|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure.
32936483|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.~An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure."
32936484|NCT03507049|Other|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
33280879|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
32936485|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
32936486|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
33280880|NCT00624377||COPD patients|
33280881|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
33280882|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
33280883|NCT00624065|Experimental|carvedilol CR + lisinopril|
32936487|NCT05443009|Active Comparator|Lidocaine|"Forty-eight (48) children will receive conventional infiltration anesthesia (buccal infiltration injection followed by complementary injections on the palatal region) with 2% lidocaine and 1:100,000 epinephrine at a dose previously calculated by weight. Two-thirds of the anesthetic will be injected into the buccal area and 1/3 into the palatal area.~Other Names: Control Group"
33280884|NCT00624065|Active Comparator|lisinopril + placebo|
33280885|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
32936488|NCT05443009|Experimental|Articaine|"Forty-eight (48) children will receive a single buccal infiltration injection with 4% articaine and 1:100,000 epinephrine at a dose previously calculated by weight.~Other Names: Test Group"
32936489|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
32936490|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
32936491|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
32936492|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
33280886|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
32936493|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
32936494|NCT05421793|Experimental|Gut barrier function treatments|Stressor, fibre, combination of treatments.
32936496|NCT05413369|Experimental|iGlarLixi|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning in the hour (0 to 60 minutes) before the first meal on top of metformin ± SGLT-2 inhibitor for 24 weeks
33280887|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
33280888|NCT00833339|Experimental|1|mifepristone
33280889|NCT00833339|Placebo Comparator|2|
33280890|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
33280891|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
33280892|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
33280893|NCT00825695|Active Comparator|flavanol-rich cocoa|
33280894|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
33280895|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
33280896|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
33280897|NCT00360334|Experimental|1|
33280898|NCT00360334|Active Comparator|2|
32777520|NCT04339465|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
32777521|NCT05614297||Patients with ACL injuries|Patients who have sustained an ACL injury, surgically or non-surgically treated.
32777522|NCT04754737|Other|Prophylactic antibiotic|These patients will receive the current standard of care, which is to receive a single dose of prophylactic antibiotics just prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy. The specific prophylactic antibiotics will vary depending on patient's prior urine culture sensitivities and patient medication allergies/sensitivities and medical comorbidities.
32777523|NCT04754737|Experimental|No antibiotics|These patients will receive no prophylactic antibiotics prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy.
32777524|NCT04717141|Experimental|Biomecanical evaluation of the selective nerve block effects|"D0 :~Information, collection of consent, inclusion,~Clinical and instrumental evaluation,~Realization of the selective nerve block,~Post-selective nerve block clinical and instrumental re-evaluation,~Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
32777525|NCT04705363|Experimental|Interaction with a VHA with voice|A virtual health assistant computer-generated doctor who will have a conversation with you.
32777526|NCT04705363|Active Comparator|Interaction with a VHA without voice|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
32777527|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
32777528|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
32777529|NCT05612737|Experimental|"Sticky bone and tenting screw"|
32777530|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
32777531|NCT04680715|Experimental|Per-Operative Radiotherapy technique by Papillon +TM|Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
32777532|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
32777533|NCT04426357|Experimental|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment [optional], severe renal impairment, and end stage renal disease [ESRD] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
32777534|NCT04426357|Active Comparator|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
32777535|NCT04603417|Other|Patients|Patients with CRPS diagnosis
32777536|NCT04603417|Other|Controls|Healthy controls with known Neurological Disorders
33082861|NCT04603456|Experimental|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
33082862|NCT04603066|Experimental|Ondansetron + Tariquidar|
33082863|NCT04603066|Placebo Comparator|Ondansetron + Placebo|
33082864|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
33082865|NCT05285813|Experimental|AML MRD cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
33082866|NCT05285813|Experimental|MDS post-HMA failure cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
33402036|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
32777537|NCT05612659|Experimental|Transcranial Electrical stimulation|Subjects will receive transcranial electrical stimulation.
32777538|NCT05612659|Experimental|Transcutaneous direct current stimulation|Subjects will receive Transcutaneous direct current stimulation
32830748|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
32900161|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
32900162|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
32777539|NCT05421481|Experimental|intervention group|"In the first interview, the mobile phone contact information of the elderly will be obtained and planning will be made for the first home visit when appropriate. Physical activity education and health promotion during home visit brochure will be provided. A brochure containing healthy lifestyle habits, health responsibility, exercise, nutrition, oral hygiene and social support behaviors will be provided for general health promotion awareness. The Google Fit application, which is a mobile application, will be downloaded to the phones of the people and installed together, how to use the application will be explained and the application will be made. The group walk to be done. A reminder message will be sent by phone. Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be. Groups of five will be formed for the group walking, and it will be completed within seven days."
32936497|NCT05413369|Active Comparator|IDegAsp|IDegAsp will be self-administered subcutaneously once daily prior to the largest meal of the day according to the locally approved label on top of metformin ± SGLT-2 inhibitor for 24 weeks
33280899|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
33280900|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
33280901|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
33280902|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
32936498|NCT03254576||Children at high-risk for obesity|Healthy-weight children (5th-75thBMI%) with two overweight/obese parents (BMI>25)
32936499|NCT03254576||Children at low-risk for obesity|Healthy-weight children (5th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
32936500|NCT05378971|Experimental|experimental group|Primary MM patients started maintenance therapy after 3 months of ASCT or after maximum efficacy was achieved with induction and consolidation therapy. All patients will receive pomalidomide 1 mg daily on days 1 through 21 of each 28-day cycle.
32936501|NCT04337450|Active Comparator|SOC|Standard-of-care (SOC)
32936502|NCT04337450|Experimental|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
33280903|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
33280904|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
32936503|NCT05349344|Experimental|Aerobic Circuit Training|Each session consists of 5 minutes of warming up,20 minutes of aerobic exercises with brief resting periods, followed by 5 minutes to cool down.
33280905|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
33280906|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
33280907|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
33280908|NCT01051102|Experimental|IDegAsp|
33280909|NCT01051102|Active Comparator|BIAsp 30|
33280910|NCT01053364|Experimental|Implant|
33280911|NCT01029327||Healthy subjects|
33280912|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
33280913|NCT00434967|No Intervention|4|Placebo
33280914|NCT00434967|Active Comparator|2|Candesartan cilexetil
33280915|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
32777540|NCT05421481|No Intervention|control group|There is no health-related practice in the pensioners' club. No intervention will be made in the control group. After the experimental group's attempts are completed, a home visit is planned for the control group, and it is planned to make physical activity training, brochure, google fit application installation attempts.
32777541|NCT04580563|Experimental|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
32777542|NCT04580563|Placebo Comparator|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
32777543|NCT04577209|Experimental|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
32777544|NCT04481035|Experimental|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
32777545|NCT04481035|Placebo Comparator|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
32777546|NCT04471207|Experimental|Intelligent Biometrics - Prolonged Exposure (Therapist Guided).|In the therapist-guided group, Study Therapists will virtually accompany patients during IVEs and use actionable biometric and subjective data during IVEs (e.g., HR, GSR, SUDS) to modify the assignments in real-time.
32777547|NCT04471207|Active Comparator|Intelligent Biometrics - Prolonged Exposure (Record Only).|In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.
32777548|NCT04427137|Experimental|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
32777549|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
32777550|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
32777551|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
32777552|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
32777553|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
32777554|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
32777555|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
32777556|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
32777557|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle~Pembrolizumab will be administered prior to T-DM1 administration~Pembrolizumab will be given at a predetermine dose~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle~T-DM1 will be given at a predetermine dose"
32777558|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
32777559|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
32777560|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
32936504|NCT05349344|Active Comparator|outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
32936505|NCT02740543|Active Comparator|Allergic Asthma (AA)|
32936506|NCT02740543|No Intervention|Control|
33280916|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
33280917|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
33280918|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
33280919|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
33280920|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
33280921|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
33280922|NCT00833729|Experimental|etanercept|Single armed study
33280923|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
33280924|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
33280925|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
33280926|NCT00833885|Other|1|Control
33280927|NCT00833885|Other|2|Masks
33280928|NCT00833885|Other|3|Masks and Hygiene
33280929|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
33280930|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
33280931|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
33280932|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
33280933|NCT00828425||1|Diabetic patients with retinopathy
33280934|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
33280935|NCT04043897|Experimental|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
33280936|NCT00356590|Other|1|
33280937|NCT04043663|Experimental|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
33280938|NCT04043663|Active Comparator|control group|standard perioperative care without virtual reality program
33280939|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
33280940|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
33280941|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
33280942|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
33280943|NCT03987334|Experimental|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
33280944|NCT03987334|Active Comparator|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
33280945|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
33280946|NCT02548871|No Intervention|Comparison|Business as usual
33280947|NCT03987256|Experimental|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with PRP"
33280948|NCT03987256|Active Comparator|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with Saline solution"
33280949|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
33280950|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
33280951|NCT00828581|Experimental|Lorcaserin|
33280952|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
33280953|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
32936507|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
32936508|NCT05349266|Experimental|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10^6 cells/kg of ThisCART19A
33280954|NCT03990376|Other|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
33280955|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
33280956|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
33280957|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
33280958|NCT01051180||Non doppler patients|those with no doppler guidance
33280959|NCT04322825|Experimental|intervention|24 weeks of TENS
33280960|NCT03990142|Experimental|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
33280961|NCT03990142|Experimental|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
33280962|NCT00834665|Experimental|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
32936509|NCT05349266|Experimental|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10^6 cells/kg of ThisCART19A
32936510|NCT05349266|Experimental|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10^6 cells/kg of ThisCART19A
33280963|NCT00834665|Experimental|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
32936511|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
33280964|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
33280965|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
33280966|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
33280967|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
33280968|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
33280969|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
32936512|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
32936513|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
32936514|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
32936515|NCT05368909|Experimental|Arm 1 before Cross Over|Participants were randomized and divided into two groups: Supplement Group and Placebo Group. In this Arm 1, participants first go through a 1-week washout period, and then take either Supplement or Placebo as assigned for 2 week.
32936516|NCT05368909|Experimental|Arm 2 after Cross Over|In Arm 2, Supplement Group and Placebo Group cross over. After a 1-week washout period, and both group will take whatever product they did not take in Arm 2, for 2 week.
32936517|NCT03454555|Active Comparator|Arm 1|Arm 1 participants will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision Making (SDM) intervention during their opioid management visits.
33280970|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
33280971|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
33280972|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
33280973|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
33280974|NCT00837863|Experimental|1|ALTU-238
33280975|NCT00837863|Experimental|2|ALTU-238
33280976|NCT00837863|Experimental|3|ALTU-238
33280977|NCT00837863|Active Comparator|4|Nutropin AQ
33280978|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
33280979|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
33280980|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
33280981|NCT03991780|Experimental|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
33280982|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
33280983|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
33280984|NCT01051336|Experimental|TARIS Placebo|
33280985|NCT01051336|Sham Comparator|Sham Procedure|
33280986|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
33280987|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
33280988|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
33280989|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
33082867|NCT04602676|Experimental|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
33280990|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
33280991|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
33280992|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
33280993|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
33280994|NCT00828659|Placebo Comparator|Placebo|
33280995|NCT00828659|Active Comparator|Active Comparator #1|
33280996|NCT00828659|Active Comparator|Active Comparator #2|
33280997|NCT00828659|Active Comparator|Active Comparator #3|
33280998|NCT00828659|Experimental|Lorcaserin Dose #1|
33280999|NCT00828659|Experimental|Lorcaserin Dose #2|
33281000|NCT00828659|Experimental|Lorcaserin Dose #3|
33281001|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
33281002|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
33281003|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
33281004|NCT04044053|Experimental|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
33281005|NCT04044053|Experimental|Fasted State|Comparison of 400 mg MR in fed and fasted states
33281006|NCT00835289|Placebo Comparator|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
33281007|NCT00835289|Experimental|PUFA (Omax3)|Omax3[TM] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
33281008|NCT00838019|Experimental|Cord blood|
33281009|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
33281010|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
33281011|NCT00828737|Experimental|Arm 1|
33281012|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
33281013|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
33281014|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
33281015|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
33281016|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
33281017|NCT03989908|Experimental|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
33281018|NCT03989908|Experimental|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
33281019|NCT03989908|Placebo Comparator|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
33281020|NCT01053520|Experimental|Sequence I|
33281021|NCT01053520|Experimental|Sequence II|
33281022|NCT01053520|Experimental|Sequence III|
33281023|NCT00835445||1|Asthmatics with polyps
33281024|NCT00835445||2|Non-asthmatics with polyps
33281025|NCT00838253|Experimental|1|
33281026|NCT00838253|Experimental|2|
33281027|NCT00838253|Experimental|3|
33281028|NCT00838253|Placebo Comparator|4|
33281029|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
33281030|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
33281031|NCT00835523||OHSS risk|
33281032|NCT03990688|Experimental|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
33281033|NCT03990688|Experimental|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
33281034|NCT03990688|Experimental|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
33281035|NCT03990688|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
33281036|NCT00838409||1|
33281037|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
33281038|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
33281039|NCT00835757||1|Diabetic peripheral neuropathy
33281040|NCT00835757||2|Healthy controls
33281041|NCT02547701|Experimental|P-3058|
33281042|NCT00828971|Experimental|Arm 1|
33281043|NCT00828971|Active Comparator|Arm 2|
33281044|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
33281045|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
33281046|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
33281047|NCT00528996|Placebo Comparator|Placebo|Matching Placebo
33281048|NCT00528996|Experimental|BEA 2180 BR low dose|Low dose
33281049|NCT00528996|Experimental|BEA 2180 BR medium dose|Medium dose
32777561|NCT05388175|Experimental|Less invasive surfactant administration (LISA) with a rigid catheter|Participants will simulate the procedure of surfactant administration by using a rigid catheter
32936518|NCT03454555|Active Comparator|Arm 2|Arm 2 participants will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) Intervention.
33281050|NCT00528996|Experimental|BEA 2180 BR high dose|High dose
33281051|NCT00528996|Experimental|Tiotropium Bromide|Tiotropium Bromide
32936519|NCT04104542|Experimental|Mindfulness MTHM|online mindfulness based stress reduction training
32936520|NCT04104542|Experimental|Mindfulness JBSA|online mindfulness based stress reduction training
33281052|NCT00838487|Active Comparator|condroflex and exercise|assent arm
33281053|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
33281054|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
33281055|NCT00838877|Experimental|1|
32936521|NCT04104542|Sham Comparator|Healthy Lifestyle MTHM|online healthy lifestyle training
32936522|NCT04104542|Sham Comparator|Healthy Lifestyle JBSA|online healthy lifestyle training
33281056|NCT00836147|Placebo Comparator|1|250 ng dose
33281057|NCT00836147|Active Comparator|2|250 ng dose
33281058|NCT04365569|Experimental|Individualized, nutrition and physical activity intervention|Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
33281059|NCT05416476|Experimental|Anisodine Hydrobromide|Participants in this group took oral Anisodine Hydrobromide tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
33281060|NCT05416476|Placebo Comparator|Anisodine Hydrobromide Placebo|Participants in this group took oral Anisodine Hydrobromide placebo tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
33281061|NCT05732922|No Intervention|Control|Participants will be receiving their standard medical care.
33281062|NCT05732922|Active Comparator|Intervention|Participants will be receiving the intervention on top of their standard medical care.
32936523|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
33281063|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
33281064|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
33281065|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
33281066|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
33281067|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
33281068|NCT03987490|Experimental|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
33281069|NCT03987490|Experimental|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
33281070|NCT01008072||without buprenorphine preparation|
32936524|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
32936525|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
32936526|NCT00371371|Placebo Comparator|Placebo|Placebo
32936527|NCT04738058|Experimental|Preterm infants diagnosed as feeding intolerance will receive bovine lactoferrin|they will receive bovine lactoferrin 100mg/day with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
32936528|NCT04738058|Placebo Comparator|Preterm infants diagnosed with feeding intolerance will receive placebo|they will receive the placebo with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
32936529|NCT04092452|Experimental|Cohort 1|PF-06650833
32936530|NCT04092452|Experimental|Cohort 2|PF-6700841
32936531|NCT04092452|Experimental|Cohort 3|PF-06826647
32936532|NCT04092452|Placebo Comparator|Cohort placebo|placebo
33281071|NCT01008072||with buprenorphine preparation|
33281072|NCT00623597|Experimental|1|
33281073|NCT05732844|Experimental|Intervention group with Enna pelvic ball|This group will receive instructions on how to carry out PFMT daily at home, and indications for the placement of Enna pelvic ball vaginal spheres daily.
32936533|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
32936534|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
33281074|NCT05732844|Active Comparator|Control group|This group will receive instructions on how to carry out PFMT daily at home.
33281075|NCT01053676|Experimental|Arm 1|
33281076|NCT01053676|Active Comparator|Arm 2|
33281077|NCT05732766|Experimental|Group-I (Age: ≥18)|Group-I (Age: ≥18) In this group, a total of 600 participants aged ≥18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
33281078|NCT05732766|Experimental|Group-II (Age: ≥5 to <18)|Group-II (Age: ≥5 to <18): In this group, a total of 600 participants aged ≥5 to <18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
33281079|NCT05732766|Experimental|Group-III (Age: ≥1 to <5)|Group-III (Age: ≥1 to <5): In this group, a total of 600 participants aged ≥1 to <5 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14
33281080|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
33281081|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
33281082|NCT05732688|Experimental|Pharmacoscopy|Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds
33281083|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
33281084|NCT00347776|Active Comparator|Control|topical tetracycline
33281085|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
33281086|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
33281087|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
32936535|NCT05336383|Experimental|Radiation Therapy|Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy
32936536|NCT05291299|Other|Standard of Care (Control Group)|Physicians will follow standard of care and instruct participants in the control group to follow a Mediterranean diet higher in vegetables and fruits[19]. Patients will be provided with a handout detailing the basics of the Mediterranean diet. At follow up visits, physicians will ask participants about how they have been eating and if they have been following the guidelines.
32936537|NCT05291299|Experimental|Anti-inflammatory Diet (Intervention Group)|"An 8-week nutrition program consisting of an individualized elimination diet and systematic food reintroduction implemented and supervised by a Registered Dietitian. Clinical trials have shown some benefit from elimination diets for individuals with autoimmune disease [18].~The specifics of the elimination diet including duration and foods included will be individual and up to the RDs discretion based on the patient's medical and diet history, willingness, current diet, preferences, goals, and ability. The initial diet instruction with a Registered Dietitian will be a one-hour, individual secure video call, with nutrition evaluation/assessment and education on elimination diet protocol. Follow up visits will be approximately 20-30 minutes for the subsequent 7 weeks."
33281088|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
33281089|NCT04961814||gastric ultrasound|Patients will be asked to fast not less than 6 hours and preoperative bedside gastric ultrasound will be done
33281090|NCT00829127|Experimental|1|
33281091|NCT00829127|Placebo Comparator|2|
33281092|NCT04948476|Experimental|Standardized Dialysis and Structured Discontinuation (S2D2)|Prescription to minimize dialysis-induced ischemia and standardize dialysis discontinuation
33281093|NCT04948476|Active Comparator|Usual Care|Dialysis prescription ordered by their primary nephrologist/intensivist.
33281094|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
33281095|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
33281096|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
33281097|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
33281098|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
33281099|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
33281100|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
33281101|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
33281102|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
33281103|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
33281104|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
33281105|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
33281106|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
33402037|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
33281107|NCT04944888|Experimental|Experimental Arm A|"Eliglustat 84mg will be administered once daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be daily administered every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
32777562|NCT05388175|Active Comparator|Less invasive surfactant administration (LISA) with a soft catheter|Participants will simulate the procedure of surfactant administration by using a soft catheter
32936538|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
33281108|NCT04944888|Experimental|Experimental Arm B|"Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs), or in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
33281109|NCT03987178|Experimental|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
33281110|NCT03987178|Placebo Comparator|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
33281111|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
33281112|NCT05375760|Other|Arm A|600 mg AZD7442 following 300 mg AZD7442 every 3 months (5 doses totally)
33281113|NCT05375760|Other|Arm B|1200mg AZD7442 following 600 mg AZD7442 every 6 months (3 doses totally)
33281114|NCT01053832|Other|Ventricular Pace Suppression- ON|
33281115|NCT01053832|Other|Ventricular Pace Suppression- OFF|
33281116|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
33281117|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
33281118|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
33281119|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
33281120|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
33281121|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
33281122|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
33281123|NCT02533336|No Intervention|LLINs|LLINs only
33281124|NCT00836459|No Intervention|Control|
33281125|NCT00836459|Experimental|Mini Booster|
33281126|NCT00836459|Experimental|Full Booster|
33281127|NCT03991390|Experimental|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
33281128|NCT03991390|Active Comparator|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
33281129|NCT05367960|Other|Study Drug (BPN14770)|25mg BID Study Drug BPN14770
33281130|NCT00829361|Other|Telemedicine|
33281131|NCT03829228|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
33281132|NCT00836537|Experimental|1|
33281133|NCT00836537|Active Comparator|2|
33281134|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
33281135|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
33281136|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
33281137|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
33281138|NCT03987412|Experimental|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
33281139|NCT03987412|No Intervention|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
33281140|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
33281141|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
33281142|NCT05729724||Change treatment|Deprescribing (patients on hypotensive medications): withdrawal or reduction of one or more medications among cardiovascular and psychoactive drugs with known hypotensive effects (Table) Prescription of vasoactive medications (patients with constitutional hypotension): prescription of Fludrocortisone or other drugs that actively increase blood pressure.
33281143|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
33281144|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
33281145|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
33281146|NCT01008384|No Intervention|placebo|
33281147|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
33281148|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
33281149|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
33281150|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
33281151|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
33281152|NCT00836771|Other|Human milk|Human Milk
33281153|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
33281154|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
33281155|NCT00836849|Experimental|1|
33281156|NCT00836849|Active Comparator|2|
33281157|NCT03999294|No Intervention|Control Group|
33281158|NCT03999294|Experimental|Experimental Group|
33281159|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
33082868|NCT04602676|Experimental|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
33082869|NCT04602832|Experimental|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
33082870|NCT04602832|No Intervention|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
33082871|NCT05285501|Experimental|Virtual Therapeutic Garden|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of VRTierOne therapy (20 minutes each)"
33082872|NCT05285501|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of group relaxation and psychoeducation (20 minutes each)"
33281160|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
33281162|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
33281163|NCT04859712||Trial group: 45 patients with lumbar disc herniation|"The Pulse Detection System of Sound Waves  was used to collect three parts and five layers of pulsed sound waves from the hands of 45 patients with lumbar disc herniation."
33281164|NCT04859712||Control group :45 relatively healthy people|"The Pulse Detection System of Sound Waves  was used to collect the three-parts and five-layers pulse sound waves of the hands of 45 relatively healthy people."
33281165|NCT00837005||1|Patients with suspected CAD
33281166|NCT00837005||2|Patients with known CAD and suspected ischemia.
33281167|NCT05704062||Diagnostic (multi-parametric MRI)|Patients undergo an MRI exam that includes standard anatomic scans, DCE-MRI, and DW-MRI at baseline, after first treatment cycle, at mid-point of treatment course, and after completion of neoadjuvant chemotherapy.
33281168|NCT00839579|Experimental|4x4min|4x4minutes interval group
33281169|NCT00839579|Experimental|1x4min|
33281170|NCT00829907|Experimental|1|Orm-12741
33281171|NCT00529542|Experimental|Atorvastatin|
33281172|NCT00529542|Placebo Comparator|Placebo|
33281173|NCT04043741|Experimental|Dry Needling|Dry needling (04 Sessions) and exercises
33281174|NCT04043741|Active Comparator|Sustain Pressure|sustained pressure and Exercises
33281175|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
33281176|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
33281177|NCT05702736|Experimental|Intervention group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a pre-test. Inaddition to the Standard treatment, the intervention group received a logotherapy-based intervention. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a post test and follow up test.
32777563|NCT05700955|Experimental|temozolomide|Participants will take Temozolomide pills at home at a dose determined by body weight. They will take the pills for five days every 3 weeks. It will be dispensed by the pharmacy and must be stored in a closed container at room temperature, away from heat, moisture, and direct light and kept from freezing. It will be kept out of the reach of children. Outdated medicine or medicine no longer needed will be returned to the Brown Cancer Center pharmacy for disposal.
32777564|NCT05700955|Experimental|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg as an IV infusion through a freely flowing IV. The diluted solution will be administered intravenously over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. Other drugs will not be co-administered through the same infusion line. Pembrolizumab doses will be repeated every three weeks.
32777565|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
32777566|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
32777567|NCT04335487|Experimental|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
33082873|NCT04602910|Experimental|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
33082874|NCT00248976|No Intervention|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
33082875|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
32777568|NCT04335487|Experimental|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
32777569|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
33082876|NCT04602715|Experimental|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
33082877|NCT04602715|Placebo Comparator|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
33082878|NCT04602403|Placebo Comparator|placebo group|people who given placebo to become agroup of comparison with the other group
33082879|NCT04602403|Active Comparator|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
33082880|NCT05268809|Experimental|Ketogenic Diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
33082881|NCT05268809|No Intervention|Diet as usual|The Diet As Usual (DAU) participants will be asked to maintain their current dietary habits and will be discouraged from starting new diets during the 4-week study.
33082882|NCT00565240|Experimental|Oral Contraceptive|
33082883|NCT00565240|Experimental|Contraceptive Ring|
32777570|NCT05612503|Sham Comparator|Traditional physical therapy program|For 15 minutes, each child in both groups perform the following specific respiratory exercises: resistance-based diaphragm strengthening exercises, breathing exercises.
32777571|NCT05612503|Experimental|Virtual reality-based exercises|Following a session of traditional physical therapy, the children in study group toke 30 minutes rest then they joined in a 30-minute VR exercise session using Nintendo Wii systems.
32777572|NCT05557981|Experimental|Trainees - treatment|"Residents and fellows paired with a faculty coach from the faculty - treatment arm to participate in up to 4 coaching meetings"
32777573|NCT05557981|No Intervention|Trainees - control|Residents and fellows randomized to the control arm. They are not paired with a faculty coach and instead continue to receive standard mentorship as part of their training program.
32777574|NCT05557981|Experimental|Faculty - treatment|"Faculty members randomized to receive coaching training and are paired with a resident/fellow from the trainees - treatment arm to conduct up to 4 coaching sessions over the course of the academic year."
32777575|NCT05557981|No Intervention|Faculty - control|Faculty members randomized to control arm. They are not paired with a trainee from this study and instead continue to provide mentorship as they typically would, as part of their role at an academic medical center
32777576|NCT02347527|Experimental|Active Implicit Priming (MRI sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
33281178|NCT05702736|No Intervention|Control group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a pre-test. The control group received only standard treatment. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a post test and follow up test.
33281179|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
33281180|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
33281181|NCT05262270|Experimental|Drug intervention (XR-NTX+XR-BUP)|"The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4).~Drug: XR-NTX XR-NTX: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Extended Release Injectable Naltrexone Arm: Experimental~Drug: XR-BUP XR-BUP: 2 subcutaneous injections administered Week 0, 4. Other Names: Extended Release Injectable Buprenorphine Arm: Experimental"
33281182|NCT05262270|Placebo Comparator|Placebo|"Matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).~Drug: Placebo (PLB) Injectable Placebo: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Injectable matching (to XR-NTX) placebo Arm: Placebo Comparator - matched Placebo (PLB)~Drug: Placebo (PLB) Injectable Placebo: 2 subcutaneous injections administered Week 0, 4. Other Names: Injectable matching (to XR-BUP) placebo Arm: Placebo Comparator - matched Placebo (PLB)"
33281183|NCT00839735||COPD|Chronic obstructive pulmonary disease
33082884|NCT00565240|Experimental|Aromatase Inhibitors|
33082885|NCT00565240|No Intervention|Control|
33281184|NCT00839735||Asthma|
33281185|NCT00839735||Healthy controls|
33281186|NCT05261568|Experimental|experimental group|"The first application is carried out by a researcher close to the polyclinic with care and demonstration.~The application will be suggested by hanging it from side to side in sitting position. They will be informed about the same application conditions in their own practice at home.~The program, which will last for 6 weeks, will continue from the home environment after a video surveillance observed by the beneficiary.~Periods of entry and exit times thanks to the mobile program. It will be done over the phone by the people who will come for 6 weeks. history book, lack of tools, etc. a website will be searched. Adhering to application products through study. A total of 42 sessions for 6 weeks, 7 days a week. About 30min. It is used to benefit from training to benefit from sustained progression. Apart from that, he can enjoy wearing it by dressing casually and casually."
33281187|NCT05261568|No Intervention|control gruop|"The control group did not receive any intervention other than their own treatment during the study.~will not be applied. Progressive relaxation exercise application to the individuals included in the control group personal information form, Pittsburgh sleep quality index, fatigue severity scale will be applied as test-post-test."
33281188|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
33281189|NCT03999528||study group|RA Patients
33281190|NCT03999528||control group|normal control
33281191|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
33281192|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
33281193|NCT05259696|Experimental|Dose Escalation - Monotherapy|"Subjects will receive E-602 as monotherapy.~Planned monotherapy dose levels: 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg."
33281194|NCT05259696|Experimental|Dose Escalation - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy.~Cemiplimab dose: 350 mg."
33281195|NCT05259696|Experimental|Expansion - Monotherapy|Subjects will receive E-602 as monotherapy at the recommended Phase 2 dose determined in Phase 1.
33281196|NCT05259696|Experimental|Expansion - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with cemiplimab.~Cemiplimab dose: 350 mg."
33281197|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
33281198|NCT00830141||1|50 children with GH deficiency
33281199|NCT00830141||2|50 children with ISS
33281200|NCT00830141||3|50 children with FTT
33281201|NCT00830141||4|50 children with obesity
33281202|NCT00830141||5|50 children without short stature or obesity will serve as controls
33281203|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
33281204|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
33281205|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
33281206|NCT00830297|Active Comparator|2 Conventional treatment|
33281207|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
33281208|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
33281209|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
33281210|NCT00840125|Experimental|1|docetaxel + erlotinib
33281211|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
33281212|NCT00840359|Experimental|1 PDT|Leishmania lesion
33281213|NCT00840359|Active Comparator|Cryo|Leishmania lesion
33281214|NCT00830453|Experimental|Hyperbaric oxygen|Hyperbaric oxygen, 1.5 atmospheres absolute, 60 minutes door-to-door, 60 daily sessions.
33281215|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
33281216|NCT00528606|Experimental|AA4500 0.58 mg|
33281217|NCT00528606|Placebo Comparator|Placebo|
33281218|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
33281219|NCT04855656|Experimental|Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study|Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
33082886|NCT04719780|Active Comparator|Waitlist Control Group (CBT)|Individuals in this arm (n=44) are provided with a transdiagnostic cognitive-behavioural treatment for depression and anxiety (MoodGym) that has been empirically validated after their 15-week wait period is complete.
33082887|NCT04719780|Experimental|EFIT Group|Individuals in the EFIT Group (n=44) will receive 12-15 sessions of EFIT in order to treat their symptoms of depression and anxiety.
33082888|NCT00565279|Experimental|ASF1057|
33082889|NCT00565279|Placebo Comparator|ASF1057 placebo|
33082890|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
33281220|NCT04855656|Experimental|Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study|Patients receive RP-6306 with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
33281221|NCT00840515||Emulsion|
33281222|NCT05699226|Experimental|Variable amplitude|Individualized amplitude
33281223|NCT05699226|Active Comparator|Fixed amplitude|Fixed (800 milliamperes) amplitude
33281224|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
33082891|NCT04602637||P1|
33082892|NCT04602637||P2|
33082893|NCT04602637||P3|
33082894|NCT05234879|Experimental|Frame Running intervention|Participants will be invited to 12 Frame Running training sessions
33281225|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
33281226|NCT05014542|Experimental|Acupuncture Group|Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
33281227|NCT05014542|Active Comparator|Control Group|Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
33281228|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
33281229|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
33281230|NCT04925622||Control|No symptoms of neurological condition
33281231|NCT04925622||Parkinson's disease|Parkinson's disease diagnosis
33281232|NCT04925622||Non-PD Movement disorder|Non-PD with other movement disorder such as progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, vascular Parkinsonism, or Parkinsonian syndromes
33281233|NCT04926324|Experimental|Cohort 1 (starting)|niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
33281234|NCT04926324|Experimental|Cohort 2|niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
33281235|NCT05219994|Experimental|Oral Glucose Tolerance Test|Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
33281236|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
33281237|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
33281238|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
33281239|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
33281240|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
33281241|NCT00528840|Experimental|AA4500 0.58 mg|
33082895|NCT04602442|Experimental|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
33082896|NCT04602442|Experimental|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
33082897|NCT04602442|Placebo Comparator|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
33082898|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
33082899|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
33082900|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
33082901|NCT04602247|Experimental|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
33281242|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
32777577|NCT02347527|Placebo Comparator|Control Implicit Priming (MRI sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
33281243|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
33281244|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
33281245|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
33281246|NCT05013138|Active Comparator|Standard of Care Arm|During the study period, standard of care providers will continue to provide standard of care treatment(s); however, families receiving care from the standard of care providers will complete all study surveys. Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination. However, standard of care providers will still be able to provide resources to the families as part of standard of care.
33281247|NCT05013138|Experimental|Intervention Arm|Intervention providers will undergo training for ACEs screening and discussion. Eligible families will be enrolled into the study at the intake of their child's 4-month, 6-month, 9-month, 15-month, or 18-month well child check. Caregivers will complete the intake surveys including demographics, caregiver ACEs, resilience, warmth, PTSD, and depression. The providers will lead a discussion regarding the impact of caregiver ACEs. Patients will be contacted 1-week, 6-months, and 18-months following their enrollment to obtain repeat measures of the survey instruments. At the 18-month time point, the electronic medical record (EMR) will be queried to obtain outcome measures.
33281248|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
33281249|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
33281250|NCT05691114|Experimental|hAESCs treatment|"hAESCs will be administration through Ommaya reservoir implanted into the lateral ventricle.~The tolerability, safety, and efficacy will be examined of 4 monthly doses of hAESCs for 3 months followed by 2 doses every 3 months in dose escalation through 3 cohorts.~Dose A (5×10^7 cells/dose)~Dose B (1.0×10^8 cells/dose)~Dose C (1.5×10^8 cells/dose)."
33281251|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
33281252|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
33281253|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
33281254|NCT05686590|Experimental|Augmented Reality Enhanced Simulation (Treatment group)|Each simulation will have between two and five participants. After consent, demographic data will be collected. Then, a study RA will fit a Magic Leap One (ML1) headsets (Magic Leap Inc., Plantation, FL) to participants. Following a scripted briefing, the instructor will also orient the participants to the ML1 headset for those in that group. After orienting the participant to the use of the headsets, the instructor will remain in a room separate from the participants, who will conduct the scenario outside. This will enable assessment of the feasibility of providing simulation instruction remotely. Prior to starting the scenario, the simulation instructor will conduct an orientation to review the core tenets of effective communication skills during prehospital care.
33281255|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
33281256|NCT00851201|Active Comparator|Standard Intervention|
33281257|NCT00851201|Experimental|Intensive lifestyle|
33281258|NCT04920864|Experimental|Active 10 Hz dlPFC rTMS|10 Hz dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
33281259|NCT04920864|Sham Comparator|Sham dlPFC rTMS|inactive dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
33281260|NCT04920864|Experimental|Active 1 Hz mPFC rTMS|1 Hz medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
33281261|NCT04920864|Sham Comparator|Sham mPFC|inactive medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
33281262|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
33281263|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
33281264|NCT05219760|Active Comparator|LIVIA 1|LIVIA 1 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy.
33281265|NCT05219760|Experimental|LIVIA 2.0|LIVIA 2.0 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy but also from positive psychology and cognitive psychopathology frame.
33281266|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
33082902|NCT04602247|Experimental|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
33082903|NCT04602247|Active Comparator|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
33082904|NCT04602247|Active Comparator|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
33082905|NCT04602247|Experimental|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
33082906|NCT04602247|Experimental|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
33281267|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
33281268|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
33281269|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
33281270|NCT05205720|Experimental|NB group|"Celiac plexus block (CPB) was added to the postoperative analgesia plan.~CPB: the target nerve is located in the retroperitoneal space, embedded in the fat in front of the aorta, and distributed in a network along the anterolateral wall of the aorta, just at the beginning of the celiac trunk. During direct vision (anterior) block, first expose the upper edge of the pancreas, palpate the abdominal aorta and abdominal trunk, and palpate the pulsation of the common hepatic artery and splenic artery at the level of the abdominal trunk. Use a 25g 6cm puncture needle with an extension tube and a syringe pumped back by an assistant to form a negative pressure, then the needle is inserted into the fat on both sides of the abdominal aorta. If there is no blood or fluid outflow, slowly inject 10ml of 0.5% ropivacaine each side. After pulling out the needle, observe whether there is damage and bleeding. If necessary, use low-energy electrocoagulation to stop bleeding."
33281271|NCT05205720|No Intervention|GC group|The same analgesic plan as the experimental group, except that CPB is not performed.
33281272|NCT04043195|Experimental|Nivolumab + Oxaliplatin|Cohort 1
33281273|NCT04043195|Experimental|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 2
33281274|NCT00844103|Experimental|1|
33281275|NCT00844103|Placebo Comparator|2|
33281276|NCT04907526|Experimental|Treatment Arm|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.
33281277|NCT04907526|No Intervention|Control Arm|Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.
33281278|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
33281279|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
33281280|NCT03999060|Experimental|Electric Stimulation|
33281281|NCT00844181||0|white women
33281282|NCT00844181||1|Black women
33281283|NCT04042805|Experimental|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33281284|NCT05643846|Active Comparator|(Group 1) will receive the intervention 'Bupivacaine at concentration of 0.125%, dose of 0.2 ml/kg'.|(Group 1) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at concentration of 0.125% concentration, at a dose of 0.2 ml/kg'.
33281285|NCT05643846|Active Comparator|(Group 2) will receive the intervention 'Bupivacaine concentration of 0.25%, dose of 0.2 ml/kg'.|(Group 2) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at a concentration of 0.25% concentration, at a dose of 0.2 ml/kg'.
33281286|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
33082907|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
33281287|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
33281288|NCT00841217|Placebo Comparator|1|placebo group
33281289|NCT00841217|Active Comparator|2|GW501516, 2.5mg
33082908|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
33281290|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
33281291|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
33281292|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
33281293|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
33281294|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
33281295|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
33281296|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
33281297|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
33281298|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
33281299|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
33281300|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
33082909|NCT04602130|Experimental|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
33082910|NCT04602130|Experimental|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
33082911|NCT04602130|Experimental|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
33082912|NCT04602130|No Intervention|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
33082913|NCT04602052|Active Comparator|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
33082914|NCT04602052|Experimental|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
33082915|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
33281301|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
33281302|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
33281303|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
33281304|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
32777578|NCT02347527|Experimental|Active Implicit Priming (Behavioral-only sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
32777579|NCT02347527|Placebo Comparator|Control Implicit Priming (Behavioral-only sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
32777580|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
32777581|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
32777582|NCT05612347|Active Comparator|FIT|FIT (annual)
32777583|NCT05612347|Active Comparator|Colonoscopy|Surveillance colonoscopy (one time)
32777584|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
33281305|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
32777585|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
32777586|NCT05557903|Experimental|Treatment Group of anti-CD52 monoclonal antibody|safety and tolerability, pharmacokinetic characteristics and preliminary efficacy in the treatment of relapsed and refractory nhl (including cll/sll, pll, ptcl, diffuse large b-cell lymphoma, follicular cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma) and initially treated t-pll of recombinant humanized anti-cd52 monoclonal antibody injection
32777587|NCT04335097|Active Comparator|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
33281306|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
33281307|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
33281308|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
33281309|NCT00844571||control group|
32777588|NCT04335097|Active Comparator|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
33402038|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
32777589|NCT02386839|Experimental|Antecedent Standard of Care|Participants who were treated with standard neonatal care in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
32777590|NCT02386839|Experimental|Antecedent rhIGF-1/rhIGFBP-3|Participants who were treated with rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
32777591|NCT05557825||Radiodermatitis Case Group|04 patients with grade 2 or grade 3 radiodermatitis after radiotherapy for the treatment of head and neck cancer submitted to a PBM therapy protocol
33281310|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
33281311|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
32777594|NCT05557747|Experimental|Group A:cervicothoracic junction mobilization|Group A: patients will receive cervicothoracic junction mobilization and conventional physical therapy program for 3 sessions/week over 4 weeks periods
33082916|NCT04602013|Experimental|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy~Sintilimab Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.~Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)~Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
33082917|NCT04601701|Experimental|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
33082918|NCT04601701|Active Comparator|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
33082919|NCT05233748|Experimental|Stochastic Resonance (SR)|During this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
33082920|NCT05233748|No Intervention|No Stochastic Resonance (noSR)|During this condition, participants will walk on the treadmill while receiving no SR stimulation (noSR) with and without visual perturbations.
33082921|NCT04601662|Experimental|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
33082922|NCT04601662|Active Comparator|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
33082923|NCT04601545|Experimental|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
33082924|NCT04601545|Active Comparator|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
33082925|NCT00565318|Active Comparator|A|
33082926|NCT00565318|Placebo Comparator|B|
33082927|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
33082928|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
33082929|NCT00565357|Experimental|E|
33082930|NCT00565357|No Intervention|C|
33082935|NCT05201144|Active Comparator|Sildenafil citrate|Sildenafil citrate 1mg/kg every 8 hours (PO or NG) for up to 14 days
33082936|NCT05201144|Placebo Comparator|Placebo|Equivalent volume of Ora-sweet©/Ora-plus© every 8 hours (PO or NG) for up to 14 days
33082937|NCT04601389|Experimental|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
33082938|NCT04601389|Active Comparator|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
33082939|NCT04600843|Experimental|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
33082940|NCT04600843|Experimental|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
33082941|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
33082942|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
33082943|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
33082944|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
33281312|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
33281313|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
33281314|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
33281315|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
33281316|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
33281317|NCT04214327|Active Comparator|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
33281318|NCT04214327|Active Comparator|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
33281319|NCT04214327|Active Comparator|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 11 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 11 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
33281320|NCT04214327|No Intervention|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
33281321|NCT00851981|Placebo Comparator|1|
33281322|NCT00851981|Active Comparator|SAMe|
33281323|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
33281324|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
33281325|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
33281326|NCT00844727|Placebo Comparator|2|Placebo
33281327|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
33281328|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
33281329|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
33281330|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
33281331|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
33281332|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
33281333|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
33281334|NCT00620555|Experimental|gabapentin|
33281335|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
33281336|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
33281337|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
33281338|NCT00529386|Experimental|Botox|300 IU botox
33281339|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
33281340|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
33281341|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
33281342|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
33281343|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
33281344|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
33281345|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
33281346|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
33281347|NCT05213286|Other|Patients referred for assessment of ASD, non-ASD psychiatric patients and control group|All three groups will be tested with RAADS-R-DK and ZAQ. The results from these diagnostic tests will be compared to gold standard clinical assessments in specialized multidisciplinary teams
33281348|NCT00845585|Active Comparator|Owniflow II|
33281349|NCT00845585|Active Comparator|PTFE|
33281350|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
33281351|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
33281352|NCT04841226|Active Comparator|Silq ClearTract™ 100% Silicone 2-Way Foley Catheter|Up to 82 subjects
33281353|NCT04841226|Active Comparator|Silver-coated Latex 2-Way Foley Catheter|Up to 82 subjects
33281354|NCT04841226|Active Comparator|Silicone-coated Latex 2-Way Foley catheter|Up to 82 subjects
33281355|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
33281356|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
33281357|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
33281358|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
33281359|NCT05136144|Experimental|SM-020|Topical Akt Inhibitor SM-020 Gel
33281360|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
33281361|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
33281362|NCT00529308|Active Comparator|Active|
33281363|NCT00529308|Sham Comparator|Sham|
33281364|NCT03999840|Experimental|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
33281365|NCT03999840|Placebo Comparator|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
33281366|NCT04791540||Patients with trachestomy|Patients, attending a respiratory rehabilitation program, who underwent tracheostomy decannulation
33281367|NCT05000424|Experimental|Intervention|Participants in this group will receive a fragrant plant based massage oil with the addition of clary sage essential oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
33281368|NCT05000424|Placebo Comparator|Control|Participants in this group will receive a fragrant plant based massage oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
33082945|NCT04600765|Active Comparator|Diet Before|Typical diet contaminated with Bisphenol A. Patient assigned to this arm will consume a typical American diet as defined by USDA.
33082946|NCT04600765|Active Comparator|Diet After|Bisphenol A reduced. Patient assigned to this arm will consume a diet analogous to atypical American diet as defined by USDA, but with known Bisphenol A sources reduced or eliminated.
33281369|NCT05122650|Experimental|10 milligram (mg) JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.
33281370|NCT05122650|Experimental|20 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.
33281371|NCT05122650|Experimental|30 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.
33281372|NCT05122650|Placebo Comparator|Placebo|Participants will receive placebo from Day 1.
33281373|NCT03875508|Experimental|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
33281374|NCT03998982|Active Comparator|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
33281375|NCT03998982|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
33281376|NCT04782180|Experimental|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
33281377|NCT04991766|Experimental|[¹⁴C]-LY3484356 (Part 1)|Single dose of [¹⁴C]-LY3484356 administered orally.
33082947|NCT05197790|Other|Assess device prototype functionality|Everyone will be in the same arm
33281378|NCT04991766|Experimental|LY3484356 + [¹⁴C]-LY3484356 (Part 2)|Single dose of LY3484356 administered orally followed by Single dose of [¹⁴C]-LY3484356 administered intravenously (IV).
33082948|NCT04601116|Active Comparator|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
33281379|NCT04766814||Patient Group|10 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
33281380|NCT04766814||Control Group 1|10 healthy women subjects between the ages of 50-80 year
33281381|NCT04766814||Control Group 2|10 healthy women subjects between the ages of 20-30 years
33281382|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
33281383|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
33281384|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
33281385|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
33082949|NCT04601116|Placebo Comparator|Placebo|Placebo tablets 1 per day for 2 years.
33082950|NCT04600687|Experimental|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
33082951|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
33082952|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
33082953|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
33281386|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
33281387|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
33281388|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
33281389|NCT00852215|Active Comparator|1|Taxus stent group
33281390|NCT00852215|Active Comparator|2|Vision stent group
33281391|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
33281392|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
33281393|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
33281394|NCT00842465||1|benign breast diseases
33281395|NCT00842465||2|breast cancer
33281396|NCT00842465||3|control
33281397|NCT00848627||Males|60 years of age or older Smokers or history of smoking
33281398|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
33281399|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
33281400|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
33082954|NCT05174624||FAMILY Cohort|This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong. The Cohort has an excellent (99.8%) coverage of the neighbourhoods in Hong Kong and represents roughly 1% of all households, which enables detailed studies linking the social environment to physical and mental health.
33082955|NCT04600648|Active Comparator|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
33281401|NCT04042883|Active Comparator|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
33281402|NCT04042883|No Intervention|Control|No intervention
33281403|NCT00848705|Active Comparator|Measurement Only|
33281404|NCT00848705|Experimental|Internet Intervention|
33281405|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
33281406|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
33281407|NCT00848861|Active Comparator|1 propofol|
33281408|NCT00848861|Active Comparator|2 midazolam plus meperidine|
33281409|NCT00852371|Active Comparator|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
33281410|NCT00852371|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
33281411|NCT00852371|Placebo Comparator|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
33281412|NCT00852371|Active Comparator|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
33281413|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
33281414|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
33281415|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
33281416|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
33281417|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
33281418|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
33281419|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
33281420|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
33281421|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
33281422|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
33281423|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
33281424|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
33281425|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
33281426|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
33281427|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
33281428|NCT01564836|Experimental|Imatinib treatment discontinuing|
33281429|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
33281430|NCT00527982|No Intervention|No treatment|
33281431|NCT04121286|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
33281432|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
33281433|NCT00619619|Experimental|A|
33281434|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
33281435|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
33281436|NCT00848939|Experimental|treprostinil diethanolamine|
33281437|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
33281438|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
33281439|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
33281440|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
33281441|NCT00527826|Active Comparator|arm 1|
33281442|NCT00527826|Active Comparator|arm 2|
33281443|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
33281444|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
33281445|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
33281446|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
33281447|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
33281448|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
33281449|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
33281450|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
33281451|NCT00843089|No Intervention|1|Standard care
33281452|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
33281453|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
33281454|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
33281455|NCT03998670|Experimental|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
33281456|NCT03998670|Placebo Comparator|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
33281457|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
33281458|NCT00849407||1|melanoma patients
33281459|NCT00849407||2|controls
33281460|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
33281461|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
33281462|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
33281463|NCT05027178|Experimental|Chiropractic care for Ischemic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
33281464|NCT05027178|Experimental|Chiropractic care for Hemorrhagic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
33281465|NCT04840212|Experimental|Study Group|Patients currently hospitalized in multiple service lines (surgical intensive care unite [SICU], surgical progressive care unit [SPCU], burns, trauma, plastics, general surgery, orthopedics, surgical specialties, and inpatient rehabilitation) will be included. Lavender-Sandalwood scented aromatherapy sticker will be used throughout the patient hospital stay.
33281466|NCT04840212|No Intervention|Control Group|The historical control group will be comprised of hospitalized patients in multiple service lines from the previous year with the same time period, demographic characteristics, service line, and relevant clinical information.
33281467|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
33281468|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
33281469|NCT00849641||3|healthy control group
33281470|NCT01564992||Parkinson disease|Identification of genes
33281471|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
33281472|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
33281473|NCT04838262|Experimental|Assessment of Daily Stress Processes|Subjects will report cumulative exposure, perceived severity, and emotional responsiveness to commonly occurring everyday psychosocial stressors utilizing an ecological momentary assessment approach for 8 consecutive days.
33281474|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
33281475|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
33281476|NCT04832256||High Flow anesthesia|administered 4 L/min fresh gas flow during general anesthesia
33281477|NCT04832256||Low Flow Anesthesia|administered 1 L/min fresh gas flow during general anesthesia
33281478|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
33281479|NCT01565070|Active Comparator|Biofreeze|
33281480|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
33281481|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
33281482|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
33281483|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
33281484|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
33281485|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
33281486|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
33281487|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
33281488|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
33281489|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
33281490|NCT00852683|Active Comparator|A|
33281491|NCT00852683|Placebo Comparator|B|
33281492|NCT04116671|Experimental|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
33281493|NCT04103879|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
33281494|NCT04103255|Experimental|High frequency and intensive prevention|"High frequency and intensive prevention program~Tai Chi~CogniFit (cognitive training)~SpeechCare (speech training)"
33281495|NCT04103255|Active Comparator|Control group (CogniPlus)|Computer-assisted cognitive training program
33281496|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
33281497|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
33281498|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
33281499|NCT00923897|Experimental|RT for Liver Mets and HCC|
33281500|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
33281501|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
33281502|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
33281503|NCT00619229|Experimental|Alprostadil|Alprostadil
33281504|NCT00619229|Placebo Comparator|Placebo|Placebo
33281505|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
33281506|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
33281507|NCT02544971|Active Comparator|Control group|Treatment as usual
33281508|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
33281509|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
33281510|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
33281511|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
33281512|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
33281513|NCT02546297|Active Comparator|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
33281514|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
33281515|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
33281516|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
33281517|NCT00618995|Placebo Comparator|D|Arm D: Placebo
32777595|NCT05557747|Experimental|Group B:autogenic muscle Energy Technique|Group B: will receive autogenic muscle Energy Technique and conventional physical therapy program for 3 sessions/week over 4 weeks periods.
33281518|NCT03685344|Experimental|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
33281519|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
33281520|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 weeks.
33281521|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 weeks.
32777596|NCT05557747|Active Comparator|Group C:conventional physical therapy|Group C: will receive conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods.
32777597|NCT01718041|Experimental|VRS-317|Active treatment arm
32777598|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
32777599|NCT05352451|Experimental|Intervention Arm - coaching sessions|Intervention group, will be asked to complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member
32900163|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
33281522|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 30 mg|Participants on Dexlansoprazole 60 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
33281523|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 15 mg|Participants on Dexlansoprazole 30 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
33281524|NCT00850811|Experimental|1|
33281525|NCT00856115||African American Female|
33281526|NCT00856115||African American Male|
33281527|NCT00856115||Caucasian Female|
33281528|NCT00856115||Caucasian Male|
33281529|NCT00856271|Experimental|1|olmesartan medoxomil
33281530|NCT00856271|Active Comparator|2|losartan potassium
33281531|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
33281532|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
33281533|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
33281534|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
33281535|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
33281536|NCT02546063|Other|GoCARB app|Smartphone app
33281537|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
33281538|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
33281539|NCT00520572|Experimental|2|50mg oral, once daily
33281540|NCT00520572|Experimental|3|100 mg oral, once daily
33281541|NCT00520572|Experimental|4|200 mg oral, once daily
33082956|NCT04600648|Active Comparator|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
33082957|NCT04600453|Experimental|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
33082958|NCT04600453|No Intervention|Usual care group|Usual care
33082959|NCT04600297|Experimental|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
33082960|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
33082961|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
33082962|NCT04600414|Active Comparator|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
33082963|NCT04600414|Experimental|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
33082964|NCT05154461|Experimental|GLP-1 in relation to the 2 major BHB release sites|The magnitude of plasma GLP-1 following an OGTT (75g glucose per os) when beta-hydroxybutyrate (BHB) is released either at an upper gastrointestinal site (alginate encapsulation), or at distal gastrointestinal site (pea-protein encapsulation). BHB is given per-os in a single dose of 18g, plus 2 g encapsulation material; totally 20 g.
33281542|NCT00520572|Experimental|5|400mg once, daily
33281543|NCT00520572|Placebo Comparator|6|oral, once daily
32738817|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
33082965|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
33281544|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
33082966|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
33082967|NCT04599907|Experimental|Roll-In Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
33082968|NCT04599907|Experimental|Randomized Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
33281545|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
33281546|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
33281547|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
33281548|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
33281549|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
33082969|NCT04599907|Sham Comparator|Randomized Cohort: Sham Patch|Subjects will undergo identical procedure with an inactive sham device
33082970|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
33082971|NCT04600492|Active Comparator|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
33082972|NCT04600492|Placebo Comparator|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
33281550|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
33281551|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
33281552|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
33281553|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
33281554|NCT04041635|Experimental|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
33281555|NCT04041635|Active Comparator|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
33281556|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
33281557|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
33281558|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
33281559|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
33281560|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
33281561|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
33281562|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
33281563|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
33281564|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
33281565|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
33281566|NCT00527514|Experimental|1|
33281567|NCT00861497|Experimental|Bifeprunox|
33281568|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
33281569|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
33281570|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
33281571|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
33281572|NCT03998826|Experimental|Piroxicam drug|20 mg piroxicam
33281573|NCT03998826|Placebo Comparator|Placebo|placebo
33281574|NCT04035486|Active Comparator|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.~All patients randomized into this will only receive Osimertinib 80mg.~Dose may be reduced to allow for the management of IP related toxicity."
33281575|NCT04035486|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.~Dose may be reduced to allow for the management of IP related toxicity."
33281576|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
33281577|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
33281578|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
33281579|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
33281580|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
33281581|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
33281582|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
33281583|NCT04607538||Patellar dislocation, but no trochlear dysplasia|This group consist of patients in age from 15-20 years old in the Faroe Islands, who experience patellar dislocation, but do not have femoral trochlear dysplasia measured on MRI or X-ray
33281584|NCT04607538||Patiens with patellar dislocation and trochlear dysplasia|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have experience one or more patellar dislocations and have femoral trochlear dysplasia measured on MRI or X-ray
33281585|NCT04607538||Patients with other knee injury|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have had an ACL-rupture or an meniscus injury.
33281586|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
33281587|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
33281588|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
33281589|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
33281590|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
33281591|NCT00854009|Experimental|1|BLI-489
33281592|NCT00854009|Placebo Comparator|2|Placebo
33281593|NCT03998592|Experimental|Low-dose vaccine|
33281594|NCT03998592|Experimental|Mid-dose vaccine|
33281595|NCT03998592|Experimental|High-dose vaccine|
33281596|NCT03998592|Placebo Comparator|Placebo|
33281597|NCT00861731|Active Comparator|1|hypolipidemic treatment
33281598|NCT00861731|Sham Comparator|2|hypolipidemic treatment
33281599|NCT00861731|Sham Comparator|3|hypolipidemic treatment
33281600|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
33281601|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
33281602|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
33281603|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
32777600|NCT05352451|Active Comparator|Control Arm - interview|"Will be asked to complete the same surveys at appropriate time after meeting with the research assistant. Be asked to complete brief questionnaire about the understanding of the illness.~All individual interviews, patient and caregiver coaching, and caregiver support sessions will be audio recorded. The recorders are password protected and the audio files will be saved securely. Only authorized study team members can access the recordings to evaluate how well the answers to survey questions are logged and how well the coaching/support content is delivered by the study team member."
32777601|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:~1 x 10^4 T cells/kg~1 x 10^5 T cells/kg~5 x 10^5 T cells/kg~1 x 10^6 T cells/kg~5 x 10^6 T cells/kg~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
32777602|NCT05557669|Experimental|Investigation Group|Patients undergoing laparoscopic cholecystectomy for cholelithiasis
33281604|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
33281605|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
33281606|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
33281607|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
33281608|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
33281609|NCT00857597|Experimental|EsophyX|
33281610|NCT00857597|Active Comparator|Proton Pump Inhibitors|
33281611|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
33281612|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
33281613|NCT00861965|Experimental|Treatment|AlloStim-8
33281614|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
33281615|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
33281616|NCT00854321||patients with active RA|drug, follow-up
32936539|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
33281617|NCT03684642|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
33281618|NCT03684642|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
33281619|NCT03684642|Active Comparator|Dulaglutide 1.5 mg|Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.
33281620|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
32777603|NCT05557669|No Intervention|Control group|Patients with gallstone disease who are not planned for laparoscopic cholecystectomy in upcoming 3 months
32936540|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
32936541|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
33281621|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
33281622|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
32936542|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
33281623|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
33281624|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
33281625|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
33281626|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
33281627|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
33281628|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
33281629|NCT00857909|Placebo Comparator|Placebo|calcium tablet
33281630|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
33281631|NCT00857987|Placebo Comparator|2|Vehicle
33281632|NCT03998514|Experimental|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
33281633|NCT03998514|Experimental|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
33281634|NCT03998514|Experimental|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
33082973|NCT04600063|Other|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
33082974|NCT04600063|Experimental|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
33082975|NCT04599985|Experimental|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
33082976|NCT04599985|Active Comparator|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
33082977|NCT00414648|Experimental|1|Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
33082978|NCT00414648|Placebo Comparator|2|Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
33082979|NCT05099978||NGS analysis of ctDNA|"This study consists of 6 cohorts; cervical cancer(n=100), ovarian clear cell cancer(n=50), nasopharyngeal cancer(n=96), ovarian cancer(n=100), breast cancer(n=100), endometrial cancer(n=60).~In each cohort, the blood samples will be collected within 2weeks after registration. ctDNA will be extracted from blood samples and somatic gene abnormalities will be analyzed using NGS, PCR, and Sanger sequencing. In addition, the analysis of DNA methylation and RNA sequencing may be performed to obtain information related to gene expression."
33082980|NCT04599673|Experimental|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
33082981|NCT04599673|Placebo Comparator|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
33082982|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
33082983|NCT00565513|Other|A|cord blood and maternal milk tests
33082984|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
33082985|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass > 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
33082986|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass < 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
33082987|NCT00414687|Experimental|Arm 1|
33082988|NCT04599244|Experimental|emergency pulpotomy|intervention arm
33082989|NCT04599244|Active Comparator|complete pulp extirpation|control arm
33082990|NCT04599283|Active Comparator|Symptomatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
33082991|NCT04599283|Active Comparator|Asymptmatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
33082992|NCT05092919|Other|Flavor|Either a sweet-flavored or a non-flavored cigarillo
33082993|NCT04599322|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
33082994|NCT04599205|Experimental|Microneedling group A|"Patients will be subjected to the following:~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
33082995|NCT04599205|Experimental|Laser group B|"Patients will be subjected to the following:~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.~Laser (power=3.6 mJ) only on the left one."
33082996|NCT04599205|Experimental|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
33082997|NCT04599127|Experimental|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
33082998|NCT04599127|Placebo Comparator|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
33082999|NCT05070260|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
33281635|NCT03998514|Experimental|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
33281636|NCT03998514|Experimental|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
33281637|NCT03998514|Experimental|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
33281638|NCT03998514|Experimental|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
33281639|NCT03998514|Experimental|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
33281640|NCT03998514|Experimental|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
33281641|NCT03998514|Experimental|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
33281642|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
33281643|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
33281644|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
33281645|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
33281646|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
33281647|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
33281648|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
33281649|NCT00854633|Experimental|1|Talactoferrin
33281650|NCT00854633|Placebo Comparator|2|Placebo
33281651|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
33281652|NCT00858299|Experimental|valsartan|
33281653|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
33281654|NCT04041167|Active Comparator|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
33281655|NCT04041167|Placebo Comparator|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
33281656|NCT03998124|Experimental|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
33281657|NCT03998124|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
33281658|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
33281659|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
33281660|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
33281661|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
33281662|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
33281663|NCT00854711|Placebo Comparator|standart of care|no intervention
33281664|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
33281665|NCT00862355|Experimental|1|SPARC147609
33281666|NCT00862355|Active Comparator|2|Reference147609
33281667|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
33281668|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
33281669|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
33281670|NCT00526656|Experimental|sunitinib malate|Drug
33281671|NCT04042649|No Intervention|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
33281672|NCT04042649|Experimental|post-intervention|After providing environmental intervention for critically ill patients
33281673|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
33281674|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
33083000|NCT05070260|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
33083001|NCT04598737|Experimental|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
33402039|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
33402040|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
33083002|NCT04598737|Experimental|Lithium disilicate|Lithium disilicate laminate veneer treatment
33083003|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
33083004|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
33083005|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
33083006|NCT05055128|Experimental|X842 25 mg BID|Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
33083007|NCT05055128|Experimental|X842 50 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
33083008|NCT05055128|Experimental|X842 75 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 25 mg) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
33083009|NCT05055128|Experimental|X842 100 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
33083010|NCT05055128|Active Comparator|Lansoprazole|Patients will receive 2 tablets (X842 dummy×2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
33083011|NCT04598854|Experimental|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
33083012|NCT04598854|Sham Comparator|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
33083013|NCT00565591|Placebo Comparator|Dose escalation|
33083014|NCT00565630|Experimental|1|Vigamox via the experiemntal device
33083015|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
33083016|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
33083017|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
33083018|NCT05011526|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33083019|NCT05011526|Experimental|AZD1222|ChAdOx1 nCoV-19 vaccine
33083020|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
33083021|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
33083022|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
33083023|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
33083024|NCT04598542|Experimental|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
33083025|NCT04598542|Experimental|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
33083026|NCT04995263|No Intervention|Pre-intervention, control group|A basal measurement of primary and secondary outcomes of the target population, prior to the implementation the intervention. Estimated duration 3 months, n = 30.
33083027|NCT04995263|Experimental|Post-intervention, SUEÑA half bundle, active group 1|"Post-intervention, environmental and behavioral modifications in patient care interventions.~Implementation of components 1 through 4 of SUEÑA intervention in the entire PICU unit. All participants will be exposed to the intervention. Estimated duration: 3 months, n = 30."
33281675|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
33281676|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
33281677|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
33281678|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
33281679|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
33281680|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
33281681|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
33281682|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
33281683|NCT04565730|Active Comparator|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
33281684|NCT04565730|Active Comparator|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
33281685|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
33281686|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
33281687|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
33281688|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
33281689|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
33281690|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
33281691|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
33281692|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~Peripheral blood stem cell mobilization:Etoposide~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
33281693|NCT03889548|Experimental|Mental Imagery|
33281694|NCT03889548|No Intervention|Control|
33281695|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
33281696|NCT04130633|Placebo Comparator|Placebo|Placebo (5mL distilled water)
33281697|NCT04130633|Experimental|Vaporized high THC alone|25mg of vaporized pure THC
33281698|NCT04130633|Experimental|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
33281699|NCT04130633|Experimental|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
33281700|NCT04130633|Experimental|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
33281701|NCT04130633|Experimental|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
33281702|NCT04130633|Experimental|Vaporized low THC alone|10mg of vaporized pure THC
33281703|NCT04130633|Experimental|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
33281704|NCT04130633|Experimental|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
33281705|NCT00859157||Group 1|Patients undergo standard mastectomy.
33281706|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
33281707|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
33281708|NCT00859235|Active Comparator|1|
33281709|NCT00859235|Placebo Comparator|2. Plain water|
33281710|NCT04523688|Experimental|Experimental treatment|"Induction phase: 4 weekly doses of dendritic cell vaccine (10x10exp6 cells) intradermally administered (weeks 1-4).~Maintenance phase: 28 days cycles with vaccine administration (start on week 7) and adjuvant temozolomide (150-200mg/m2/day) assumed orally from day 1 to 5 q28 (start on week 5). The combined maintenance treatment will continue until disease progression, unacceptable toxicity or withdrawal of consent by the patient, or up to a maximum of 1 year of treatments.~After disease progression or the end of maintenance phase, is foreseen a one-year follow-up phase for each subject."
32777604|NCT05347459||New Antidiabetic|Type 2 diabetic patients receiving SGLT2 inhibitors and/or DPP-4 inhibitors with metformin
32777605|NCT05347459||Traditional Antidiabetic|Type 2 diabetic patients treated with metformin
32777606|NCT05347459||Control|Healthy non-diabetic patients
32777607|NCT05346445|Active Comparator|Fluoxetine group|Participants received fluoxetine, 20 mg tablets, once a day for six months.
32777608|NCT05346445|Experimental|Citalopram group|Participants received citalopram, 20 mg tablets, once a day for six months.
32777609|NCT05334121|Experimental|Product - Beta Alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
32777610|NCT05334121|Placebo Comparator|Control group - Placebo|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
32777611|NCT05557201||Miscarriage|Patients with at least 3 recurrent early miscarriages (before 14 weeks of gestation)
32777612|NCT05557123|Experimental|MEDI-app|conventional treatment with MEDI-app feedback
32777613|NCT05557123|Active Comparator|conventional treatment|conventional treatment
32936543|NCT03402607|Active Comparator|Percutaneous Local Ablation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
32936544|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
32936545|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
32936546|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
32936547|NCT05277727|Experimental|Fucoidan|"Fucoidan in Capsule~Intervention: Dietary Supplement: Probiotic"
32936548|NCT05277727|Placebo Comparator|Placebo|"Non active ingredients in a capsule~Intervention: Other: Placebo"
32936549|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
33083028|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA half bundle plus, active group 2|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment.~Participants will be randomized to receive SUEÑA components 1 through 5 Estimated duration: 6 months, n = 30"
33083029|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA full bundle, active group 3|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment and personalized psychoeducation.~. Participants will be randomized to receive SUEÑA components 1 through 6. Estimated duration: 6 months, n = 30"
33083030|NCT04598581|Active Comparator|Low Dose Radiation Therapy (LD-RT)|
33083031|NCT04598581|Sham Comparator|Sham irradiation|
33083032|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
33083033|NCT04598503||control|newborns without congenital anomalies
33083034|NCT04598191|Placebo Comparator|Control group|Participants in this group are administered inhaled normal saline.
33083035|NCT04598191|Experimental|iloprost group|Participants in this group are administered inhaled iloprost.
33083036|NCT04598113|Active Comparator|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
33083037|NCT04598113|Sham Comparator|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
33083038|NCT04956848|No Intervention|Embryo selection supported by KIDScore™ D5|Each embryo reaching at least developmental stage of 3BB will annotated by an embryologist using the parameters required by the KIDScore™ D5. The embryo with the highest KIDScore™ will be selected proposed for transfer.
33083039|NCT04956848|Experimental|Embryo selection supported by iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed selected for transfer.
33083040|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
33083041|NCT04598230|Active Comparator|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
33083042|NCT04598230|Active Comparator|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
33083043|NCT04955366|Active Comparator|Belatacept group (Control Group)|"Participants will receive the following:~Belatacept: 5 mg/kg i.v. monthly~Blood draws for PD studies at baseline/Month 0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) every 3 months per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at Screening visit~BK and CMV testing at 6, 12, and 24 months"
33281711|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
33281712|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
33281713|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
33083044|NCT04955366|Experimental|Abatacept Group (Conversion Group)|"Participants will receive the following:~Abatacept 125 mg s.c. weekly~Safety labs every 2 weeks (months 0-3) then monthly (months 4-12)~Blood draws forPK atMonth 6, Month 12, and two random time points in between Month 6 and Month 12 for a total of four time points.~Blood draws for PD studies at baseline/Month0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) at each study visit per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at screening~BK and CMV testing at 6, 12, and 24 months"
33281714|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
33281715|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
33281716|NCT02544347|Other|Control group|gingival crevicular fluid was collected
33281717|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
33281718|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
33281719|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
33281720|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
33281721|NCT04041713|Active Comparator|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
33281722|NCT04041713|Placebo Comparator|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
33281723|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
33281724|NCT00859625|No Intervention|2|usual colonoscopy practice
33281725|NCT00511836|Experimental|VIVITROL 380 mg|
33281726|NCT00511836|Placebo Comparator|Placebo|
33281727|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
33281728|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
33281729|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
33281730|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
33281731|NCT03998436|Active Comparator|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
33281732|NCT03998436|Sham Comparator|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
33281733|NCT03998436|Placebo Comparator|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
33281734|NCT00855101|Experimental|voriconazole|
33281735|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33281736|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33281737|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
33281738|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
33281739|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
33281740|NCT00860093|Experimental|1|MPC-5971
33281741|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
33281742|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
33281743|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
33281744|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
33281745|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
33281746|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
33281747|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
33281748|NCT00855257|Experimental|1|treatment by acid nicotinique
33281749|NCT00855257|Placebo Comparator|2|Treatment by placebo
33281750|NCT04077437|Experimental|Experimental: MDMA-assisted psychotherapy|Administration of 80 to 120 mg MDMA in combination with psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.
33281751|NCT04077437|Placebo Comparator|Placebo Comparator: Placebo|Administration of inactive placebo in combination with psychotherapy.
33281752|NCT03861936|Experimental|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
33281753|NCT03861936|Experimental|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
33281754|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
33281755|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
33281756|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
33281757|NCT04046471|Other|Individual In-Person|
33281758|NCT04046471|Other|Group Remote|
33281759|NCT00434577|Experimental|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
33281760|NCT00434577|Experimental|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
33281761|NCT00434577|Experimental|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
33281762|NCT00434577|Placebo Comparator|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
33281763|NCT00434577|Active Comparator|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
33281764|NCT04042181|Placebo Comparator|Placebo|
33281765|NCT04042181|Active Comparator|Bifidobacterium longum|
33281766|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
33281767|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
33281768|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
33281769|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
33281770|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
33281771|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
33281772|NCT00421707|Experimental|GW876008|GW876008
33281773|NCT00421707|Placebo Comparator|Placebo|Placebo
33281774|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
33281775|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
33281776|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
33281777|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
33281778|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
33281779|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.~The weekly plan includes three categories of content;~information/education~recommended daily number of steps~recommended strength and flexibility exercises"
33281780|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
33281781|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
33281782|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
33281783|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
33281784|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
33281785|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
33281786|NCT00518622|Experimental|6|125 mg q.d. MK7009
33281787|NCT00518622|Experimental|7|600 mg q.d. MK7009
33281788|NCT00518622|Experimental|8|Placebo
33281789|NCT04732182|Experimental|Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training|Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
33281790|NCT04732182|Other|Standard of care medication for early Alzheimer's disease|Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
33281791|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
33281792|NCT04718220|Placebo Comparator|Unexposed (SARS-CoV-2 negative) cohort|Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
33281793|NCT04718220|Active Comparator|Exposed (SARS-CoV-2 positive) cohort|Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
33281794|NCT01009476||001|
33281795|NCT01009476||002|
33281796|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
33281797|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
33281798|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
33281799|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
33281800|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
33281801|NCT01565304|No Intervention|Usual services|No intervention
33281802|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
33281803|NCT04711200|Experimental|Adipose derived stromal cells intravenously injected|
33281804|NCT04414722|Placebo Comparator|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
33281805|NCT04414722|Placebo Comparator|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
33281806|NCT04414722|Active Comparator|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
33281807|NCT04414722|Active Comparator|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
33281808|NCT04414722|Other|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
33281809|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
33281810|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
32777614|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
32777615|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
33281811|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
33281812|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
33281813|NCT04018157|Active Comparator|ketodex|ketamine dexmedetomidine mixture
33281814|NCT04018157|Active Comparator|ketofol|ketamine propofol mixture
33281815|NCT04018157|Placebo Comparator|placebo|normal saline
33281816|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
33281817|NCT03682848|Experimental|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
33281818|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
33281819|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
33281820|NCT00863213|Experimental|Atrial Fibrillation Ablation|
33281821|NCT00863213|Active Comparator|Drug therapy|
33281822|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
33281823|NCT00860639|No Intervention|without Mylotarg|
33281824|NCT01565226||Open|open, observational study
33281825|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
33281826|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
33281827|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
33281828|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
33281829|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
33281830|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
33281831|NCT04689282|Experimental|Intranasal M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
33281832|NCT00860873|Experimental|Test 1|Oral Powder EMS
33281833|NCT00860873|Experimental|Test 2|Hard Capsules EMS
33281834|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
33281835|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
32777616|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
32936550|NCT04054232|Experimental|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
33281836|NCT03648450||Propeller Smart Inhaler EMD|All enrolled participants will be given the Propeller Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
33281837|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
33281838|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
33281839|NCT03639714|Experimental|Phase 1|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
33281840|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
33281841|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
33281842|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
33281843|NCT04557540|Experimental|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
33281844|NCT04557540|Experimental|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
33281845|NCT00865397||A|
33281846|NCT00510510|Experimental|NVA237 100 µg|
33281847|NCT00510510|Experimental|NVA237 200 µg|
33281848|NCT00510510|Placebo Comparator|Placebo|
33281849|NCT00863525|Experimental|1|Odanacatib
33281850|NCT00863525|Placebo Comparator|2|Placebo
33281851|NCT01009632|Experimental|Voice rest|
33281852|NCT01009632|Experimental|Resonant voice exercise|
33281853|NCT01009632|Experimental|Spontaneous speech|
33281854|NCT04040855|Experimental|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
33281855|NCT04040855|No Intervention|Control|Patients were treated according to the usual routine.
33281856|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
33281857|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
33281858|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
33281859|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
33281860|NCT04685694|No Intervention|Expectant|No medication is assigned.
33281861|NCT04685694|Experimental|Medical|SL 800 mcg Misoprostol
33281862|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
33281863|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
33281864|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
33281865|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
33281866|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
33281867|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
33281868|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
33281869|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
33281870|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
33281871|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
33281872|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
33281873|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
33281874|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
32936551|NCT04054232|No Intervention|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
33281875|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
33281876|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
33281877|NCT01009944|Experimental|Lisinopril, Atenolol|
33281878|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
33281879|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
32936552|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
33281880|NCT04672746|Experimental|Brief MI interaction via instant communication|The interaction communication using brief motivational interviewing will be applied via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
33281881|NCT04672746|Placebo Comparator|General health information|"The subjects will receive general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
33281882|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
33281883|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
33281884|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
33281885|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
32936553|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
32936554|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
33281886|NCT04264026|Experimental|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
33281887|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
33281888|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
33281889|NCT01010100|Experimental|Arm 1|
33281890|NCT01010100|Placebo Comparator|Arm 2|
33281891|NCT00865787||Olive Oil A|
33281892|NCT00865787||Olive Oil B|
33281893|NCT00870779|Experimental|5-aminolevulinic acid|
33281894|NCT04201470|Experimental|MS patients|Patients with atypical MS identified in our cohort
33281895|NCT04201470|Active Comparator|Controls|
33281896|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
33281897|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
32936555|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
32936556|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
32936557|NCT05177029|Experimental|Part A: Lu AG06466 or Placebo|Participants will receive single dose of Lu AG06466 capsule or matching placebo orally on Day 1.
32936558|NCT05177029|Experimental|Part B: Lu AG06466 or Placebo|Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
32936559|NCT05169307||CPX-351|Adult patients with newly diagnosed, therapy related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who were treated in routine practice with Vyxeos liposomal in the UK.
32936560|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
32936561|NCT05349032|Other|Meriva|120 mg of curcumin in Meriva.
32936562|NCT05349032|Other|Longvida|120 mg of curcumin Longvida.
32936563|NCT05349032|Other|NovaSol|120 mg of curcumin NovaSol
32936564|NCT05349032|Other|CurcElite|120 mg of curcumin CurcElite
32936565|NCT05349032|Other|UltaCur|120 mg of curcumin Ultracur
33281898|NCT03998904|Experimental|Muscle preservation|Muscle preservation for hamsting graft
33281899|NCT03998904|Active Comparator|None preservation|No muscle preservation for hamstring graft
33281900|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
33281901|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
33281902|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
33281903|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
33281904|NCT04643418|Experimental|MPB-1734, single arm, dose escalation|intravenous, once per 3 weeks, starting at 10 mg/m˄2
32777617|NCT05556889|Experimental|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
32777618|NCT05556889|Other|Traditional auriculotemporal nerve blockade|The traditional method of auriculotemporal nerve block is to inject the needle 1~1.5 cm vertically at the level of tragus and posterior of superficial temporal artery, and inject 2-3 ml of local anesthetics after pumping back without blood
32777619|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
32777620|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
32777621|NCT04901715|Active Comparator|Genotypes associated mild phenotype|Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
32777622|NCT04901715|Active Comparator|Genotypes associated with severe phenotype|Subjects with 2 confirmed mutations in DNAH5, Dynein Axonemal Intermediate Chain 1 (DNAI1), Coiled-Coil Domain Containing 39 (CCDC39), or Coiled-Coil Domain Containing 40 (CCDC40). This group may also include subjects with mutations in newly identified genes that are associated with a more severe clinical phenotype.
32777623|NCT04901715|Active Comparator|Healthy Control|Healthy subjects with no pre-existing lung disease.
32777624|NCT05700877|Experimental|CAC-based treatment|"Patients randomized to CAC-based treatment, will be stratified into low- or high-risk patients (defined by CAC score=0 or ≥ 100), and hence, allocated to two parallel l clinical studies.~High-risk patients (CAC≥ 100) in the CAC-based treatment group will be included in a study in which they will receive information on CAC-score, mandatory treatment with dapagliflozin and semaglutide (both study drugs), and advise on further multifactorial treatment of blood lipid levels, blood pressure and antithrombotic therapy.~Low-risk patients (CAC=0) will be included in a study in which they will receive information on CAC-score and advise on how multifactorial treatment may be de-intensified."
32777625|NCT05700877|Other|Standard treatment|Patients randomized to standard treatment and their primary physician are not informed about the screening findings. Patients are encouraged to follow contemporary diabetes guidelines at the time of inclusion. This information will be given in a written letter within a week of randomization.
32777626|NCT05558917|Active Comparator|PECS BLOCK 2|PECS 2 (or modified PECS) is a block that involves the administration of local anesthetic under ultrasound guidance between the great pectoral and small pectoral and between the small pectoral and serratus anterior.
32777627|NCT05558917|Experimental|ESP BLOCK|ESP block is a block that involves injection of local anesthetic below the elevator muscles of the spine.
32777628|NCT05370105||Stroke patients|80 post-stroke patients will be asked to undergo three samples of biological material (10 ml of blood): the first collection on the second day of hospitalization at IRCCS S. Maria Nascente (Milano) or at IRCCS Don Gnocchi (Florence) of Fondazioen Don Gnocchi (t0) and a second withdrawal at discharge (t1), or approximately 2 months after the first withdrawal. Where possible, a third sampling (t2 - follow up) will be performed 6 months after the event.
32777629|NCT05370105||Healthy Controls|The healthy controls will be volunteers recruited at Fondazione Don Gnocchi, who are not affected by neurodegenerative and cardiovascular diseases and who have not taken anti-inflammatory drugs in the week prior to recruitment.
32777630|NCT05558839|Experimental|exercise training|Physiotherapists prescribed and delivered interventions in the exercise arm. Each exercise session began with a 5-minute warm up and stretching, followed by 15-minute Aerobic exercises, 15-minute of resistance training, 10-minute of agility and balance training, and 5-minute of cooling down.
32777631|NCT05558839|Experimental|cognitive training|"Board game teachers who have more than 5 years of community teaching experience prescribed and delivered interventions in the cognitive arm.~Each cognitive session uses different board games to strengthen training for different cognitive aspects."
33083045|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
33083046|NCT04598464|Experimental|Exercise group|The home-based training program
33083047|NCT04598464|No Intervention|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
33083048|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
33083049|NCT04952519|Experimental|Amantadine|
33083050|NCT04952519|Placebo Comparator|Placebo|
32777632|NCT04892199|Active Comparator|Semaglutide injection once-weekly|
33083051|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
33083052|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
33083053|NCT00414921|Active Comparator|1|clonidine
33083054|NCT00414921|Active Comparator|2|methylphenidate
33083055|NCT00414921|Active Comparator|3|methylphenidate and clonidine
33083056|NCT00414921|Placebo Comparator|4|
33281905|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
33281906|NCT04143516|Experimental|Patients with Colon Cancer Liver Metastases|The standard of care thermal ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
33281907|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
33281908|NCT00865865|Other|1|Conventional total knee arthroplasty
33281909|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
33281910|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
33281911|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
33281912|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
33281913|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
33281914|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
33281915|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
33281916|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
33281917|NCT00510276|Experimental|Atomoxetine|
33281918|NCT00510276|Placebo Comparator|Placebo|
33281919|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
33281920|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
33281921|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
33281922|NCT04018313|Experimental|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
33281923|NCT04018313|Active Comparator|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
33281924|NCT04018313|Experimental|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
33281925|NCT04018313|Active Comparator|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
33281926|NCT04018313|Active Comparator|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
33281927|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
33281928|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
33281929|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
33281930|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
33281931|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
33281932|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
33281933|NCT04545762|Experimental|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices~CAR-T cell manufacturing (estimated ~13-14 days)~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
33281934|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
33281935|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
33281936|NCT03859193|No Intervention|Standard care|Participants will receive standard nutrition counseling
33281937|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their first high risk visit. Participants will also receive standard nutrition counseling
33281938|NCT04137900|Experimental|TAB004 0.3 mg/kg repeat dose every 21 days up to 2 years|
33281939|NCT04137900|Experimental|TAB004 1 mg/kg repeat dose every 21days up to 2 years|
33281940|NCT04137900|Experimental|TAB004 3 mg/kg repeat dose every 21 days up to 2 years|
33281941|NCT04137900|Experimental|TAB004 10 mg/kg repeat dose every 21 days up to 2 years|
33281942|NCT04137900|Experimental|TAB004 200mg repeat dose every 21 days up to 2 years|
33281943|NCT04137900|Experimental|TAB004 20mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
33281944|NCT04137900|Experimental|TAB004 70mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
33281945|NCT04137900|Experimental|TAB004 200mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
33281946|NCT04137900|Experimental|TAB004 500mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
33281947|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
33281948|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
33281949|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
33083057|NCT04597762|Experimental|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
33281950|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
33281951|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
33281952|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
33281953|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
33281954|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
32777633|NCT04892199|Placebo Comparator|Semaglutide-Placebo injection once-weekly|
32777634|NCT05280145|Experimental|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating.
32777635|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
33281955|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
33281956|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
33281957|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
32777636|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
32777637|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
32777638|NCT05558683|Active Comparator|Vojta Reflex Locomotion Therapy|The Vojta Method or Vojta Reflex Locomotion Therapy (TLRV) is a rehabilitative method for neuromusculoskeletal pathologies widely used in Europe. Its development is based on the concept of motor ontogenesis and tries to trigger innate motor reactions (reflex locomotion patterns) in the trunk and limbs from defined tactile and proprioceptive stimuli, starting from certain postures. This therapy presents differential elements with respect to other existing therapies, both for neurophysiological principles and for methodological principles. It is an active therapy, in which great concentration is required on the part of the patient, that is, both therapist and patient are the central axes of the treatment.
32777639|NCT05558683|Active Comparator|Bobath Method|Within physiotherapy, the Bobath concept is a valid and recognized option in the treatment of patients with neurological disorders, and therefore, of those diagnosed with MS. It was developed by Karel and Berta Bobath. The Bobath concept is defined as a problem-solving approach in the assessment and treatment of people with impaired neuromotor function, becoming a valid tool as part of the comprehensive treatment of people with MS
32777640|NCT05558527|Experimental|Social support from a romantic partner|Participants will hold the hand of their romantic partner
32777641|NCT05558527|Active Comparator|Social support from a stranger|Participants will hold the hand of a stranger
32777642|NCT05558527|No Intervention|No social support|Participants will hold a stress ball
32777643|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
32777644|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
32777645|NCT05556655|Experimental|Active TMS|Repetitive TMS for the brain delivered between 1 and 20 Hz.
32777646|NCT05556655|Placebo Comparator|Sham TMS|Scalp stimulation that does not affect the brain.
32777647|NCT05254093|No Intervention|group A|
32777648|NCT05254093|Active Comparator|group B|
33083058|NCT04597762|Experimental|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
33281958|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
33281959|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
33281960|NCT00510198|Active Comparator|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
33281961|NCT00510198|Active Comparator|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
33281962|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
32777649|NCT05254093|Active Comparator|group C|
32936566|NCT05057689|Experimental|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.
33281963|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
33281964|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
33281965|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
33281966|NCT04127604|Experimental|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
33281967|NCT04127604|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
33281968|NCT05227859|Experimental|Piezocision therapy|In this group of patients, the canine will be retracted in association with piezocision.
33281969|NCT05227859|Experimental|Low-level laser therapy|In this group of patients, the canine will be retracted in association with LLLT.
33281970|NCT05227859|Active Comparator|Conventional treatment|In this group of patients, the canine will be retracted conventionally without any acceleration intervention.
33281971|NCT05227781|Experimental|L-Citrulline|L-Citrulline: 10 grams/day
33281972|NCT05227781|Placebo Comparator|Placebo|Maltodextrin: 10 grams/day
33281973|NCT05227469|Experimental|Skeletal class II twinblock + myofunctional therapy|Myofunctional exercises will be prescribed in addition to the standart twin block therapy. Movements will be taught to this group, for which we have prescribed the exercises. It will be ensured that the exercises are done more properly and regularly by taking video recordings every other day from the group that does the exercises twice a day. Incorrect exercises will be corrected by providing feedback.
33281974|NCT05227469|No Intervention|Control|Standard twin block therapy will be used for Class II patients. Patients will be informed that they are involved in a study that follows growth and development, and they will receive feedback on whether they use their devices properly, but no myofunctional exercise.
33281975|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
33281976|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
33281977|NCT04039997|Experimental|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
33281978|NCT04039997|Experimental|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
33281979|NCT00871637||Group One|Healthy non-smoking controls
32936567|NCT05057689|Experimental|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.
32936568|NCT05057689|Experimental|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg
32936569|NCT05348954|Experimental|Sexual dysfunction of women|Sexual dysfunction of women
32936570|NCT05348954|Experimental|Quality of sexual life|Quality of sexual life
32936571|NCT05032183|Experimental|Treatment (tagraxofusp, chemotherapy)|See Detailed Description
32936572|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
32936573|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
32936574|NCT04737980|Experimental|Experimental Group: Interscalene block with liposomal bupivacaine combined with bupivacaine|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 10 ml of liposomal bupivacaine 1.3% (133 mg) combined with 10 ml of 0.5% bupivacaine hydrochloride.
32936575|NCT04737980|Active Comparator|Control Group: Interscalene block with ropivacaine combined with dexamethasone|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 30ml of 0.5% ropivacaine combined with a 2 ml volume of 8mg of dexamethasone.
32936576|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
33281980|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
33281981|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
33281982|NCT05227625|Experimental|Body dissatisfaction management group|ACT-inspired group for the management of body dissatisfaction
33281983|NCT05227625|Active Comparator|relaxation group|standardized relaxation program
33281984|NCT00864929||1|Appropriate antimicrobial treatment
33281985|NCT00864929||2|Inappropriate antimicrobial treatment
33281986|NCT00871793|Active Comparator|1|Occupational therapy
33281987|NCT00871793|No Intervention|2|watchful waiting
33281988|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
33281989|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
33281990|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
33281991|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
33281992|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
33281993|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
33281994|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
33281995|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
32936577|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
32936578|NCT03559868|Placebo Comparator|Placebo|oral placebo
32936579|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
32936580|NCT05348798||Ultra endurance athletes|Individual participating in ultra endurance sports (events exceeding 6 hours) including running, cycling, triathlon, swimming and Nordic skiing. Participants are above 18 years of age and volunteer to participate in this web-based survey.
32936581|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
32936582|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
32936583|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
32936584|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
32936585|NCT04335422|Experimental|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
32936586|NCT04335422|Active Comparator|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
32936587|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
32936588|NCT04937491||Healthy volunteers|Adult healthy volunteers (students). Intervention 1: Intake of water (2% of body weight) Intervention 2: Intake of sports drink (2% of body weight) Intervention 3: Intake of soya saus (salt): 10 ml (equal to 8 g salt) Intervention 4: Intake of 90 g sugar (jelly figures)
32936589|NCT04917523|Experimental|Aged 3-6 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
32936590|NCT04917523|Experimental|Aged 7-12 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
32936591|NCT04917523|Experimental|Aged 13-17 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
32936592|NCT04917523|Active Comparator|Aged ≥18 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
32936593|NCT04852471|Active Comparator|Standard Post-Operative Counseling + FACT-G (Control Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. Patients will complete the Functional Assessment of Cancer Therapy - General (FACT-G).
32936594|NCT04852471|Experimental|Standard Post-Operative Counseling + PROM survey + FACT-G (Intervention Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. The intervention arm will receive and complete the Patient-Reported Outcome Measure (PROM) survey via the SMS text messaging service on a set schedule. Patients will complete the FACT-G.
32936595|NCT04850521||Remote monitoring|Remote monitoring software + connected devices
32936596|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
32936597|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
32936598|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
32936599|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
32936600|NCT02973932|Experimental|Internet-based psychotherapy|
32936601|NCT04777669|Experimental|Experiment|Subjects will be tested for their ability to understand speech with and without noise reduction
32936602|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
32936603|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
32936604|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
32936605|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
32936606|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
32936607|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
32936608|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
32777650|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
32777651|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
32777652|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
32777653|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
32777654|NCT05549947|Experimental|Treatment group A：SHR-1819|
32777655|NCT05549947|Experimental|Treatment group B：SHR-1819|
32777656|NCT05549947|Experimental|Treatment group C：SHR-1819|
32777657|NCT05549947|Placebo Comparator|Treatment group D：placebo|
32777658|NCT05556421||case group|dislocated intrauterine device
32777659|NCT05556421||control group|normal intrauterine device position
32777660|NCT04328623|Active Comparator|Infiltration|Ultrasound-guided hand infiltration
32777661|NCT04328623|Experimental|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
32777662|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
32777663|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
32777664|NCT05549869|Active Comparator|group A|obese with vitligo
32777665|NCT05549869|Active Comparator|group b|obese without vitligo
33281996|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
33281997|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
33281998|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
32777666|NCT05549869|Active Comparator|group C|non obese with vitiligo
32936609|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
32777667|NCT05549869|Active Comparator|group D|non obese without vitiligo
32777668|NCT05556109||Epileptic seizure|patients diagnosed as epileptic seizure are aged >12 years
32777669|NCT05556109||Psychogenic non-epileptic seizure|patients diagnosed as psychogenic non-epileptic seizure are aged >12 years
32777670|NCT05556109||Normal healthy control|Heathy control are aged >12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw
32777671|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
32777672|NCT05543395||The group accepting to report|
32777673|NCT05543395||The group refusing to report|
32777674|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
32777675|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
32777676|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
32936610|NCT04759885|Experimental|Phase II: NTC015 low dose (Mannitol 50 g)|One day single dose preparation same day of colonoscopy
32936611|NCT04759885|Experimental|Phase II: NTC015 medium dose (Mannitol 100 g)|One day single dose preparation same day of colonoscopy
32936612|NCT04759885|Experimental|Phase II: NTC015 high dose (Mannitol 150 g)|One day single dose preparation same day of colonoscopy
32777677|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
32777678|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
32936613|NCT04759885|Experimental|Phase III: NTC015 selected dose|One day single dose preparation same day of colonoscopy
32936614|NCT04759885|Active Comparator|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC) (Moviprep®)|Two litres of Moviprep® taken according to split-dose regimen (to commence in the evening before colonoscopy)
32936615|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
32936616|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
32936617|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
33281999|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
33282000|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
32777679|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
32777680|NCT04420377|Placebo Comparator|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
32936618|NCT05348720||COVID-19 ICU survivor|COVID-19 patients admitted to ICU between the 1st of March 2020 and the 30rd of May 2021, who survived ICU stay and still alive 18 months after ICU discharge.
32936619|NCT05348720||Relatives|Relative of those COVID-19 patients enrolled in the 'COVID-19 ICU survivor' cohort
33282001|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
33282002|NCT00876083||Group 1|
33282003|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
33282004|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
33282005|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
33282006|NCT00866567||3|Term newborns
33282007|NCT00866567||4|Adults
33282008|NCT05225909||Patients who Undergo ERCP procedure with aScope|This will be patients who undergo ERCP procedure using aScope.
33282009|NCT00876161|Experimental|DAS181|
32936620|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
32936621|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
32936622|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
33282010|NCT00876161|Placebo Comparator|Lactose|
32936623|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
32936624|NCT04728295|Experimental|Exablate Pallidothalamic Tractotomy|Exablate treatment for Advanced Idiopathic Parkinson's Disease
32936625|NCT04738045|Placebo Comparator|control|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.
33282011|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
33282012|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
33282013|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
33282014|NCT00872573|Other|C-Stem™ AMT Femoral Component|
33282015|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
33282016|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
33282017|NCT00866645|Experimental|1|Intramuscular Levosulpiride
33282018|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
33282019|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
33282020|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
33282021|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
33282022|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
33282023|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
33282024|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
33282025|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
33282026|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
33282027|NCT00876473||1|Acute Respiratory Failure patients
33282028|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
33282029|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
33282030|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
33282031|NCT05193539|Experimental|Augmented reality and virtual reality rehabilitation|This group underwent augmented reality and virtual reality rehabilitation for 60 minutes per session, 5 days per week for 2 weeks.
33282032|NCT05193539|Active Comparator|Conventional occupational therapy|This group underwent conventional occutational therapy for 60 minutes per session, 5 days per week for 2 weeks.
32936626|NCT04738045|Experimental|interventional|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
32956045|NCT05764915|Experimental|RGT-264 monotherapy|The study is composed of dose escalation stage and dose expansion stage. RGT-264 will be administered orally daily alone as monotherapy in both stages. In the dose escalation stage, the subjects will receive once daily of RGT-264 monotherapy across approximately 6 ascending dose levels. The starting dose is 10 mg/day. In the dose expansion stage, the subjects will receive RGT-264 treatment at the recommended dose from dose escalation part.
32956046|NCT05764902|No Intervention|Control|Patients will receive standard of care.
33282033|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
33282034|NCT05168501|Experimental|Lead-In|Multiple rebreathing procedures using methodology developed by Duffin (referred to as Duffin's rebreathing procedure) will be conducted under hyperoxic and hypoxic conditions over the course of a day to confirm feasibility and gather reproducibility data using the procedure.
33282035|NCT04039685|Experimental|Aerobic exercise group|
33282036|NCT04039685|Experimental|Resistance exercise group|
33282037|NCT04039685|Experimental|Combined (aerobic+resistance) exercise group|
33282038|NCT04039685|No Intervention|Non-exercise group|
33282039|NCT00876707|Active Comparator|Tecnis|
33282040|NCT00876707|Active Comparator|ReSTOR|
33282041|NCT00876707|Active Comparator|ReZoom|
33282042|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
33282043|NCT00876785|Experimental|2|Rye bread breakfast
33282044|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
33282045|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
33282046|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
33282047|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
33282048|NCT04040543|Experimental|Daily|Daily supplementation with product containing markers
33282049|NCT04040543|Experimental|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
33282050|NCT04040543|Placebo Comparator|Control|Daily supplementation with product not containing markers
33282051|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
33282052|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
33282053|NCT00876941|Experimental|Standard Brief Intervention|
33282054|NCT00876941|Experimental|Enhanced Brief Intervention|
33282055|NCT00876941|Active Comparator|Control|
33282056|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
33282057|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
33282058|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
33282059|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
33282060|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
33282061|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
33282062|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
33282063|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
33282064|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
33282065|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
33282066|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
33282067|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
33282068|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
33282069|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
32777681|NCT04420377|Experimental|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
32777682|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
32777683|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
32777684|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
32777685|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
32777686|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
32777687|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
32777688|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
32777689|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
32777690|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
32777691|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
32777692|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~Trevo Retriever~Solitaire™ FR Revascularization Device~Penumbra thrombectomy system~Covidien MindFrame Capture Revascularization Device"
32777693|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
32777694|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
32777695|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
32777696|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
32777697|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
32777698|NCT05556031||REDUCE|Standard care
32777699|NCT05549791||General anesthesia cohort|
32777700|NCT05549791||Bronchoscopy sedation cohort|
32777701|NCT05549713||Blepharoplasty group|As a single arm study, all examinees will undergo upper blepharoplasty. Data regarding corneal topography, tear film quality and contrast sensitivity will be obtained before the surgery, seven days and one month postoperatively
32936627|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~Walking exercises - 4 Meter Gait Speed (4MGS) Test~Walking Exercises - Five Times Sit to Stand (FTSTS) Test~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
32936628|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
32936629|NCT04670263|Experimental|Dry Eye Disease|Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis
32936630|NCT04670263|Active Comparator|Healthy|Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis
32936631|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
32777702|NCT05549635||Patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP)|"The overall inclusion criteria of patients in the HP cohort are:~Diagnosis of HP at an MDT conference according to the current international guidelines~Age of 18 years or older~The patients must be capable of giving informed consent"
32777703|NCT02382939|Experimental|somapacitan|
32777704|NCT02382939|Active Comparator|hGH (somatropin)|
32777705|NCT05549557|Experimental|IMM40H|IMM40H is a monoclonal antibody with target CD70.
32777706|NCT05543005|Experimental|experimental group|maternal voice
32777707|NCT05543005|No Intervention|control group|no maternal voice
32936632|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
32936633|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
32936634|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
32936635|NCT04587973|Active Comparator|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
32936636|NCT04587973|Active Comparator|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
33282070|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
33282071|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
33282072|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
33282073|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
32936637|NCT04587973|Placebo Comparator|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
33282074|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
33282075|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
33282076|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
33282077|NCT05225831|Experimental|SL19+22 CAR-T|Eligible patients will be treated with SL19+22 CAR-T.
33282078|NCT00873509|Experimental|1|Buspirone 2.5 mg
33282079|NCT00873509|Experimental|2|Buspirone 5.0 mg
33282080|NCT00873509|Placebo Comparator|3|Placebo match
32936638|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
32936639|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
33282081|NCT00873587|Other|Inspiration|
33282082|NCT00873587|Other|Expiration|
32936640|NCT04766580|Experimental|Children with ADHD group|The same protocol is used for both groups
32936641|NCT04766580|Active Comparator|Children with no ADHD group|The same protocol is used for both groups
32936642|NCT04558177|Experimental|Stimulation Group|Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
32936643|NCT04558177|Sham Comparator|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
32936644|NCT04516915|Experimental|IMU-838 + Oseltamivir|Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
33282083|NCT00867425|Experimental|Intervention|
33282084|NCT00877253|Experimental|Dose Level One|
33282085|NCT00877253|Experimental|Dose Level Two|
33282086|NCT00877253|Experimental|Dose Level Three|
33282087|NCT05225753||patients treated with Affixus Zimmer-Biomet|
33282088|NCT05225753||patients treated with EBA2 Citieffe|
33282089|NCT05225753||patients treated with Proximal Femoral Nail Antirotation Synthes|
32936645|NCT04516915|Active Comparator|Oseltamivir|Oseltamivir (75mg BID) for 14 days
32956047|NCT05764902|Experimental|Intervention|The intervention group will be given an additional questionnaire assessing individual needs and preferences. CICU staff will provide patient-tailored interventions based on the expressed needs and preferences of those in the intervention group.
32956048|NCT05764876|Active Comparator|Azithromycin|Participants in the control arm will receive standard treatment for yaws which azithromycin .
33282090|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
33282091|NCT00877331|No Intervention|2|Enhanced care as usual.
33282092|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
33282093|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
33282094|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
33282095|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
33282096|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
33282097|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
33282098|NCT00877409|Active Comparator|Acnase|
33282099|NCT00877409|Placebo Comparator|Vehicle|
33282100|NCT00873743||1|60 women after elective cesarian section
33282101|NCT00873743||2|60 women after elective cesarian section
33282102|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
32777708|NCT05542927||Critically ill Acute kidney injury patients|"AKI is defined as any of the following: Increase in SCr by ≥0.3 mg/dl (≥ 26.5 μmol/l) within 48 hours; OR increase in SCr to≥1.5 times baseline, which is known or presumed to have occurred within prior 7 days; OR Urine volume <0.5 ml/kg/h for 6 hour)~Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in ICU~Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality.~Serum creatinine will be requested every 24 hours in ICU.~Monitoring of Urinary Output every 24 hours.~Daily SOFA score."
32956049|NCT05764876|Experimental|Linezolid|Participants in the experimental arm will receive oral linezolid treatment.
33282103|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
33282104|NCT00873977|Active Comparator|C-flex|
33282105|NCT00873977|Active Comparator|A-flex|
33282106|NCT00873977|No Intervention|Auto-CPAP|
33282107|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
33282108|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
33282109|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
33282110|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
33282111|NCT04551677|Experimental|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
33282112|NCT04551677|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to <9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
33282113|NCT04551677|Experimental|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged >=65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
33282114|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
33282115|NCT00877643|Experimental|Upstream rhythm control|
33282116|NCT00877643|Active Comparator|Conventional rhythm control|
32777709|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
33282117|NCT00874289||Acute heart failure patients|
33282118|NCT00874289||Chronic heart failure patients|
33282119|NCT04040465|Active Comparator|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
33282120|NCT04040465|Active Comparator|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
33282121|NCT04040465|Active Comparator|Normal Weight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
33282122|NCT04040465|Active Comparator|Overweight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
33282123|NCT04040465|Active Comparator|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
33282124|NCT04040465|Active Comparator|Overweight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
33282125|NCT04040465|Active Comparator|Obese/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
33282126|NCT04040465|Active Comparator|Obese/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
33282127|NCT04040465|Active Comparator|Obese/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
33282128|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
33282129|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
33282130|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
33282131|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
33282132|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
33282133|NCT00877721|Experimental|balance treatment|
33282134|NCT00874523|Active Comparator|Arm A|
33282135|NCT00874523|Active Comparator|Arm B|
33282136|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
33282137|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
33282138|NCT00874679||Group 1|
33282139|NCT00420381|Experimental|A|
33282140|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
33282141|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
33282142|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
33282143|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
33282144|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
33282145|NCT00617201|Experimental|1|Atomoxetine
33282146|NCT00617201|Placebo Comparator|2|Matched Placebo
33282147|NCT00420303|Experimental|A|
33282148|NCT00420303|Placebo Comparator|B|
33282149|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
33282150|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
33282151|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
33282152|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
32936646|NCT02757326|Experimental|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
33282153|NCT00877955|Experimental|alprazolam sublingual tablet test|
32936647|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
33282154|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
33282155|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
33282156|NCT00874913|Experimental|Laser Doppler Flowmetry|
33282157|NCT00878033||1|Diabetic Dialysis Patients
33282158|NCT00878033||2|Non-Diabetic Dialysis Patients
33282159|NCT00878033||3|Healthy Controls
33282160|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
33282161|NCT00867971||RGH treated|
32936648|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
32936649|NCT05348408|Active Comparator|platelet rich plasma|patients will be injected perineural platelet rich plasmawith 1.5 to 3 ml around each affected nerve
32936650|NCT05348408|Sham Comparator|contact group|only medical treatment in form of opioid and NSAIDs will be used
32936651|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
32936652|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
32936653|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
32936654|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
32936655|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
32936656|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
32936657|NCT05349253|Experimental|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
32936658|NCT05349253|Placebo Comparator|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
32936659|NCT04337528|Experimental|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
32936660|NCT04337528|Active Comparator|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
32936661|NCT04337528|Placebo Comparator|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
32936662|NCT04337437|Experimental|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
33282162|NCT00867971||Starting treatment with RGH|
33282163|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
33282164|NCT00875069|Experimental|ethanol|
33282165|NCT00875069|Placebo Comparator|placebo|
33282166|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
33282167|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
33282168|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
33282169|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
33282170|NCT01566513|No Intervention|Treatment as usual|
33282171|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
33282172|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
33083059|NCT04597645|Experimental|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
33083060|NCT04597645|No Intervention|Control group (CG)|Control group participants will receive usual care.
33282173|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
33282174|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the therapist|
33282175|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the patient|
33282176|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
33282177|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
33282178|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
33282179|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
33282180|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
33282181|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
33282182|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
33282183|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
33282184|NCT03240237|Experimental|CCM therapy|Optimizer SMART
33282185|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
33282186|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
33282187|NCT01035177||Control|Women without hip fracture, matched on age to the cases
33282188|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
33282189|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
33282190|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
33282191|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
33282192|NCT00868049||1|Obese subjects
33282193|NCT00868049||2|Normal-weight subjects
33282194|NCT00875303|Placebo Comparator|Control|Routine primary care.
33083061|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
33282195|NCT00875303|Experimental|Multimedia intervention|
33282196|NCT05226767|Active Comparator|Active Arm|Patients who receive treatment with the NLC-V research product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization
33282197|NCT05226767|Placebo Comparator|Placebo|Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as NLC-V
33282198|NCT00878267||Interview|
33282199|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
33282200|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
33282201|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
33282202|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
33282203|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
33282204|NCT03726671|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
33083062|NCT04597957|Experimental|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
33083063|NCT04597957|Active Comparator|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
33083064|NCT04597723|Experimental|80% oxygen|80% oxygen given group
33083065|NCT04597723|Experimental|60% oxygen|60% oxygen given group
33083066|NCT04597723|No Intervention|routine hospital care|The patients in this group received routine hospital care.
32777710|NCT05555563|No Intervention|Control|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in Control group was applied with 5 ml of 17% EDTA solution and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
32777711|NCT05555563|Experimental|MTAD irrigation|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in MTAD group was applied 5 ml MTAD (n=50) and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
32777712|NCT04426435|Experimental|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
32777713|NCT04426435|Placebo Comparator|Placebo|Group B: patients receiving placebo, 10 cc three times daily
32777714|NCT05549401|Experimental|Sequence 1|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
32777715|NCT05549401|Experimental|Sequence 2|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
32777716|NCT05549401|Experimental|Sequence 3|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
32777717|NCT05549401|Experimental|Sequence 4|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
32777718|NCT05549401|Experimental|Sequence 5|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
32777719|NCT05549401|Experimental|Sequence 6|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
32777720|NCT05549245|Experimental|High-flow Nasal Cannula Oxygen Therapy group|
32777721|NCT05549245|Other|Continues Positive Airway Pressure group|
32777722|NCT05699005|Experimental|Individulised transfusion strategy group|Patients will recieve red blood cells transfusion in case of a drop of ScVO2 <65% after an assessment for the optimisation of SaO2 normalisation (SaO2>94%), volume optimisation, ECMO output increase, Fever (body temperature 38°3 C°), Anxiety and Pain
33083067|NCT04597567|Active Comparator|Metal removal|
33083068|NCT04597567|No Intervention|Metal retention|
33083069|NCT04597216|Other|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
33083070|NCT04597255|Experimental|Holographic optical coherence tomography|Healthy phakic participants
32777723|NCT05699005|Active Comparator|Conventionnal transfusion strategy group|Transfusion will be performed in case of a hemoglobin drop <9 g/dL
32777724|NCT05549167|Experimental|intervention/treatment|
32777725|NCT05542693|Experimental|RNA MCTI CIMATEC HDT 5µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 5 µg of single-dose administration on day 1.
33083071|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
33083072|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
33083073|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with ACS."
33083074|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with CCS."
33083075|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
32936663|NCT04337437|Placebo Comparator|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
32936664|NCT05348096|Experimental|Low-dose ibrutinib|Patients will receive ibrutinib 140mg/day PO in combination with oral itraconazole (100mg/day) continuously for six months.
32936665|NCT04337606|Experimental|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
32936666|NCT04337606|Experimental|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
32936667|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
32936668|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
32936669|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
32936670|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
32936671|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
33282205|NCT03726671|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
32777726|NCT05542693|Experimental|RNA MCTI CIMATEC HDT 10µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 10 µg of single-dose administration on day 1.
32777727|NCT05542693|Active Comparator|Covishield® - AstraZeneca|Intramuscular injections of vaccine Covishield® - AstraZeneca at a usual dose of single-dose administration on day 1.
32936672|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
32936673|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
32936674|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
32936675|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
32777728|NCT05542693|Active Comparator|Comirnaty® - Pfizer|Intramuscular injections of vaccine Comirnaty® - Pfizer at a usual dose of single-dose administration on day 1.
32777729|NCT05549089|Experimental|CAD/CAM Insignia™ brackets|The result from this group (10 patients) considered as a gold standard for other two groups through assessing the treatment outcomes using American Board of Orthodontics (ABO) scoring.
32936676|NCT05343962||Parkinson's Disease (PD)|Subjects with a medical diagnosis and currently cursing with Parkinson's Disease (PD)
32936677|NCT05343962||Diabetes Mellitus type I and II (DM I/II)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
32777730|NCT05549089|Experimental|Software-driven indirect bonding tray|The first comparison group (10 patients): digital setup, virtual bracket placement and creation of 3D printing indirect bounding tray by using Maestro® 3D Ortho Studio software.
32777731|NCT05549089|Experimental|Manual-driven indirect bonding tray|the second comparison group (10 patients): digital setup by using Maestro® 3D Ortho Studio software, but the bracket positioning done manually by using Ray Set® device. in this group using double-layer vacuum-formed thermoplastic indirect bonding tray.
32777732|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
32777733|NCT05542615|Experimental|Patient|Sixty patients with chronic Viral C hepatitis, who have been treated with direct-acting antivirals, with a sustained viral response and who still have advanced fibrosis (F3-F4).
32777734|NCT05700721|Experimental|Monotherapy|
32777735|NCT04323397|Experimental|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
32777736|NCT04323397|Experimental|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
32777737|NCT04134559|Experimental|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
32777738|NCT04425967|Active Comparator|25x2Gy|the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
32777739|NCT04425967|Experimental|14x3Gy|the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
32777740|NCT05542537|Experimental|BB Produce Distribution + BB Nutrition Education + CHF Weekly Wellness Groups + CHF Web-Based Module|BB is Brighter Bites. CHF is Create Healthy Futures.
32777741|NCT05542537|Active Comparator|CHF Web-Based Module|CHF is Create Healthy Futures.
32777742|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
32777743|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
32777744|NCT05698927||Intrathecal Morphine Group|"Prosedure/Surgery: Regional block and Intrathecal Morphine Comparison~Comparing postoperative pain and opioid consumption in groups"
33282206|NCT03726671|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
33282207|NCT03726671|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
33282208|NCT03726671|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
33282209|NCT03726671|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
33282210|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
33282211|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
33282212|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
33282213|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
33282214|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
33282215|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
33282216|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
33282217|NCT05203601|Experimental|SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection)|"Stage 1: dose escalation stage Injection, first dose 2mg/kg, then 5mg/kg until the dose are no longer met the requirements of continuing the trial or up to 40 mg/kg.~Stage 2: joint extension stage:~① Group of advanced head and neck squamous cell carcinoma ：SIBP-03 & Cetuximab 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW 10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW~② Group of breast cancer：SIBP-03 & Trastuzumab & Docetaxel 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w.~10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w."
33282218|NCT05202197||Experimental|Alzheimer´s patients
33282219|NCT00868283|Experimental|Cerebrolysin|
33282220|NCT00868283|Placebo Comparator|0.9% Saline Solution|
33282221|NCT05195879|Experimental|XTR004|Single dose 6.0-8.0 mCi intravenous injection of XTR004 and investigation of XTR004 (MPI radiotracer).
33282222|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
33282223|NCT04039373|Experimental|Treatment Arm|
32936678|NCT05343962||SARS Covid-19 Infection (COVID-19)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
32936679|NCT05343962||Chronic obstructive pulmonary disease (COPD)|Subjects with a medical diagnosis and currently cursing with Chronic obstructive pulmonary disease (COPD).
33282224|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
33282225|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
33282226|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
33282227|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
33282228|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
33282229|NCT00878579|Experimental|PDS System|
33282230|NCT00878579|Active Comparator|Fusion|
32936680|NCT05343962||Stroke (ST)|Subjects with a medical diagnosis and who have cursed at some point with Stroke, either ischemic or hemorrhagic (ST)
32936681|NCT05343962||Healthy population (HP)|Healthy population (HP). No chronic or acute conditions declared.
32936682|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
32936683|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
32936684|NCT05336006|Experimental|High-intensity aerobic training with high protein diet - Group A|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
32936685|NCT05336006|Placebo Comparator|Control group - Group B|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
32936686|NCT05320718|Experimental|erector spinae plane block|A needle is inserted until the tip contacted the T5 transverse process under ultrasound guidance. After confirming the needle tip position, 20 ml of 0.5% ropivacaine was injected in the plane between the erector spinae muscles and transverse process. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
33282231|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
33282232|NCT00875849|Experimental|Cetuximab|
33083076|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
33282233|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
33282234|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
33282235|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
33282236|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
33282237|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
33282238|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
33083077|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
33282239|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
33282240|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
33282241|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
33282242|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
33282243|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
33282244|NCT00879593|Experimental|PtcCO2|
33282245|NCT00879671|Active Comparator|1|Lutamax
33282246|NCT00879671|Placebo Comparator|2|Placebo
33282247|NCT00868829|Experimental|Firebird2|
33282248|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
33282249|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
33282250|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
33282251|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
33282252|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
33282253|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
33282254|NCT00869063|Experimental|Diclofenac Sodium Patch|
33282255|NCT00869063|Placebo Comparator|Placebo Patch|
33282256|NCT00869219|Active Comparator|Nevanac|
33282257|NCT00869219|Active Comparator|Acular LS|
33282258|NCT00878735|Experimental|1|Zen meditation
33282259|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
33282260|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
33282261|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
33282262|NCT00878813||3|All consecutive stroke patients treated conservatively
33282263|NCT00878813||4|All consecutive TIA patients
33282264|NCT05100095|Experimental|Radiation therapy|Patients receive radiation therapy in 10 daily fractions (M-F) over 2 weeks.
33282265|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
33282266|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
33282267|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
33282268|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
33282269|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
33282270|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
33282271|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
33282272|NCT03995043|Experimental|Control Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH"
33282273|NCT03995043|Experimental|Case Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH~Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
33282274|NCT03994965|Experimental|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand [¹¹C]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.~(Full description will be updated on approval)."
32777745|NCT05698927||Bilateral Erector Spinae Plane Block Group|"Prosedure/Surgery: Regional block and Intrathecal Morphine Comparison~Comparing postoperative pain and opioid consumption in groups"
33282275|NCT04648059||Lupus nephritis +ve|This group consists of patients with Lupus nephritis
32777746|NCT05548933||HP|Chronic periodontitis (stage III/IV) patients with hyperlipidemia
32777747|NCT05548933||CP|Chronic periodontitis(stage III/IV) patients without hyperlipidemia
32777748|NCT05542459||Non-IBD control group|A control group in which patients are not diagnosed as inflammatory bowel disease.
32777749|NCT05542459||CD group|A group in which patients are diagnosed as crohn's disease
32777750|NCT05542459||UC group|A group in which patients are diagnosed as ulcerative colitis
33282276|NCT04648059||Lupus nephritis -ve|This group consist of patients with SLE without Lupus nephritis
33282277|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
33282278|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
33282279|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
33282280|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
33282281|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
33282282|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
33282283|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282284|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282285|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
32777751|NCT05542381|Experimental|Loteprednol|1 drop of Loteprednol is administered immediately after the intravitreal injection in this treatment arm.
32777752|NCT05542381|Active Comparator|Nepafenac (NSAID Comparison)|1 drop of Nepafenac is administered immediately after the intravitreal injection in this treatment arm. This is used as an NSAID comparison based on previous studies.
32777753|NCT05542381|Placebo Comparator|Artificial tears|1 drop of artificial tears is administered immediately after the intravitreal injection in this treatment arm. This arm acts as a negative control.
32777754|NCT05548855||Heart Transplant or Cardiac Assist Device|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 For living patients who underwent heart transplantation or placement of a cardiac assist device, and for deceased patients, at least 1 MRI or echo assessment prior to heart transplantation/cardiac assist device placement or death.
32777755|NCT05548855||No Intervention|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 for living patients (who have not undergone heart transplantation or placement of a cardiac assist device), availability of at least 6-month cardiology follow-up data
32777756|NCT05698849|Placebo Comparator|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
32777757|NCT05698849|Experimental|Commercially Available Sports Drink B|A commercially available flavored carbohydrate-electrolyte solution, PepsiCo
32777758|NCT05698849|Experimental|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids.
32777759|NCT05555017|Active Comparator|Arm A: ADT|Patients in arm A will receive standard 6 months of ADT according to current clinical guidelines.
32777760|NCT05555017|Experimental|Arm B: ADT + PSMA radioguided surgery|Patients in arm B will receive standard 6 months of ADT according to current clinical guidelines, and will undergo 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.
32777761|NCT05698615|Experimental|Chess training group|group receiving additional chess training
32777762|NCT05698615|No Intervention|control group|group receiving standard therapy only
33282286|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
32936687|NCT05320718|Active Comparator|thoracic paravertebral block|A needle is inserted into the paravertebral space. After confirming the needle tip position, 20 ml of 0.5% ropivacaine is injected in the paravertebral space. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery.
32936688|NCT05314166|Experimental|"focused attention group"|"focused attention group: adult subjects practicing face-to-face focused attention meditation."
33282287|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282288|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
32936689|NCT05314166|Active Comparator|"contemplation group"|"contemplation group: adult subjects practicing face-to-face contemplation meditation."
33282289|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282290|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282291|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282292|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282293|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
32936690|NCT05308238|Experimental|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
32936691|NCT05308238|Active Comparator|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
33282294|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282295|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282296|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282297|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282298|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
32936692|NCT05302544|Experimental|"with mixed reality training group"|2 Mixed Reality sessions per week for 8 weeks in addition to motor activities usually performed
32777763|NCT05548543|Experimental|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
32777764|NCT05548543|Experimental|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
32777765|NCT05542225|Experimental|conventional physical therapy with strength training|TENS with a frequency of 2-125Hz for about 30mins in prone position. FITT guidelines for strength training: frequency: 2-3 times perweek, time: 3o mins for the whole session, intensity: 8-15 repetitions and type : major muscles( shoulder flexors and extensors, hip and knee flexors, hip abductors and adductors, foot plantar flexors and dorsiflexors using resistance bands)
32777766|NCT05542225|Active Comparator|conventional physical therapy with flexibility training|TENS with a frequency of 2-125 Hz for 30 minutes. FITT guidelines for flexibility; frequency: 5 times per week, intensity: stop before it becomes painful, time: 10-15 minutes,hold for 15 secs and type: major muscle groups( latissmus dorsi, trapezius, gluteus maximus, gluteus medius, gatrocnemius, soleus, hamstringsand paraspinals( errector spinae and multifidus through static stretching technique.
32777767|NCT05554705|Experimental|experimental|standard of care + lifestyle intervention
32777768|NCT05554705|No Intervention|control|no intervention (control group)
32777769|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
32777770|NCT04426045|Experimental|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
32777771|NCT04426045|Active Comparator|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
32777772|NCT05542147|Experimental|Fenofibrate|1 tablet per day per 12 weeks
32777773|NCT05542147|Placebo Comparator|Placebo|1 tablet per day per 12 weeks
32777774|NCT05548465|Experimental|Long-term-opioid-free anesthesia group.|
32777775|NCT05548465|Active Comparator|Long-term-opioid anesthesia group.|
32777776|NCT04882735|Experimental|Acoramidis HCI 800 mg (two 400mg tablets)|TTR stabilizer administered orally twice daily (BID)
32777777|NCT05548387|Experimental|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
32777778|NCT05548387|Experimental|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
32777779|NCT05554549||UK Biobank|UK Biobank. There are no interventions in this observational cohort study.
32777780|NCT05548309|Active Comparator|High flow nasal cannula|High flow nasal cannula (HFNC) was inserted through nasal prongs (Fisher & Paykel Healthcare, Auckland, New Zealand) . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher & Paykel Healthcare, Auckland, New Zealand) .
32936693|NCT05302544|Active Comparator|"without mixed reality training group"|group: only motor activities usually performed
32936694|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
32936695|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
32936696|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
32936697|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
32936698|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
32936699|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
32936700|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
32936701|NCT05284760|Experimental|Part A, Sequence 1: Treatment B + Treatment A + Treatment C|Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936702|NCT05284760|Experimental|Part A, Sequence 2: Treatment A + Treatment C + Treatment B|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936703|NCT05284760|Experimental|Part A, Sequence 3: Treatment C + Treatment B + Treatment A|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
33083078|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
32777781|NCT05548309|Active Comparator|oxygen face mask|Simple oxygen face mask was applied to patients starting with flow rate 6L/min .
32777782|NCT05554471|Experimental|Mynx Control Venous Closure|204 (2:1 randomized - 136 VCD:68 manual compression)
32777783|NCT05554471|Active Comparator|Manual Compression|204 (2:1 randomized - 136 VCD:68 manual compression)
32777784|NCT05541991|Experimental|Single dose product|A single dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
32777785|NCT05541991|Experimental|Double dose product|A double dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
32777786|NCT05541991|Placebo Comparator|placebo product|A placebo coated tablet without active is administrated daily in the evening during 30days
32777787|NCT05541913|No Intervention|Control Grup|After acceptance of the child's admission to the ward, parents will be asked to complete the Beck Anxiety Scale. Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again after the discharge training given routinely in the service. Control grup will be called on the postoperative 4th day after discharge and asked to fill in the Beck Anxiety Scale and Health Care Satisfaction Scale.
32777788|NCT05541913|Experimental|Intervention Grup|After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
32777789|NCT05700097|Experimental|Low Dose Arm|Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.
32777790|NCT05700097|Experimental|High Dose Arm|Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
32777791|NCT05700097|Placebo Comparator|Placebo Arm|Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
32777792|NCT05554159|Experimental|Actigraph|A device worn on the waist that measures physical activity (such as the number of steps participants walk each day, how long participants spend standing, and how long partticipants spend laying down). Participants should wear the ActiGraph at least 10 hours a day for 7 days.
32777793|NCT05554081|Placebo Comparator|Clean catch BMI < 30|Standard of care urine collection
32777794|NCT05554081|Placebo Comparator|Clean catch BMI > 30|Standard of care urine collection
32777795|NCT05554081|Experimental|PEEZy collection BMI < 30|PEEZY device for urine collection
32777796|NCT05554081|Experimental|PEEZY collection BMI > 30|PEEZY device for urine collection
32936704|NCT05284760|Experimental|Part A, Sequence 4: Treatment B + Treatment C + Treatment A|Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
33102314|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
32777797|NCT05548075||Fibromyalgia Cohort|*As diagnosed by an appropriate medical professional according to the ACR diagnostic criteria
32777798|NCT05700643|Experimental|Intervention|500 mg cherry supplement
32777799|NCT05700643|Placebo Comparator|Control|Placebo
32777800|NCT05554003|Experimental|Metronomic Temozolomide|Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs) Dosage and schedule: 60 mg/die continuosly
32777801|NCT05541757||control group|five healthy adults
32777802|NCT05541757||Study group|Twenty-five patients using the direct oral factor Xa inhibitor rivaroxaban
32777803|NCT05541601||Pearl Cohort|All 3000 patients recruited to the Pearl study
32777804|NCT05547997|Experimental|two way traction|The study group will receive 3-point bending cervical extension traction following the protocol of Harrison et al. The duration of each session will starte at approximately three minutes and increased one minute per session until reaching the goal of 20 minutes per session
32777805|NCT05547997|Active Comparator|traditional treatment|Stretching exercises: Patients will perform the stretching program 3 times a week; with a single session taking about 10 minutes to perform.
32777806|NCT05547919|Experimental|Gastrointestinal tumors histologically positive for PSMA|Tumor biopsy at baseline to establish diagnosis and to identify PSMA expression in an ex-vivo setting. Patients with ex-vivo PSMA expression receive a multimodal imaging approach: This includes a PSMA-targeted PET/CT (18F-PSMA) at baseline and conventional imaging.
32777807|NCT04326283|Experimental|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
32956050|NCT05764863|Experimental|young healthy adults|Participants need to complete three experimental conditions associated with fMRI recording of brain activity. In condition A (Visual Spatial), participants will see the sequences presented from left to right; in condition B (Visual No Spatial), participants will see sequences of items presented in the middle of the screen; and in condition C (Auditory), the sequences will be presented in an auditory format.
32956051|NCT05764850||Case|100 patients followed in pediatric diabetology at the university hospital of Geneva: a cohort
32956052|NCT05764850||Control|50 control patients
32777808|NCT04326283|Experimental|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
32777809|NCT04326283|Active Comparator|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
32777810|NCT05699941|Experimental|treatment arm|"Ectoin® Containing Inhalation Solution (EIL07) (Class-IIa MDD legacy medical device).~Taken twice daily over the period of 3 weeks (treatment) Inhalation of the content of EIL07 single dose (2.5 mL) by using a mesh nebulizer device."
32777811|NCT05700565||Steroid-refractory or dependent immune-related adverse events|Immune-related adverse events (irAE) after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade) refractory to therapy with corticosteroids or inability to taper corticosteroids to prednisone equivalent <= 5mg
32777812|NCT05698537||People living with epilepsy (PwE)|Study participants with epilepsy
32777813|NCT05698537||Control subjects|Study participants without epilepsy
32777814|NCT05541523|Experimental|cognitive behavioural therapy|
32777815|NCT05541523|Experimental|mindfulness-based therapy|
32777816|NCT05541445|Experimental|Experimental arm|Immunotherapy combined with chemotherapy and radiotherapy
32777817|NCT05699863|Experimental|Metabolically unhealthy obese (Intervention group)|Obese (BMI: 30.0 - 39.9) participants with non-alcoholic fatty liver disease and metabolic syndrome.
32777818|NCT05699863|No Intervention|Metabolically healthy obese (Comparison group 1)|Obese individuals considered metabolically healthy based on them not presenting non-alcoholic fatty liver disease or metabolic syndrome.
32777819|NCT05699863|No Intervention|Healthy normal weight (Comparison group 2)|Normal weight individuals without non-alcoholic fatty liver disease or metabolic syndrome.
32777820|NCT04325503|Experimental|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
32777821|NCT05699785|Experimental|patients on antiretroviral therapy with second generation anti-integrase drugs in triple therapy|
32777822|NCT05699785|Experimental|patients on antiretroviral therapy with second generation anti-integrase drugs in dual therapy|
32777823|NCT05541211|Active Comparator|CPN|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
32777824|NCT05541211|Experimental|SNN|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
32777825|NCT05547763|Experimental|resorbable plates, test group|after a surgical procedure under general anesthesia , resorbable plates will be placed on the fracture site of the mandibule in 20 patients out of 40 total sample size and will be compared with the titanium plates in the control group
32777826|NCT05547763|Experimental|titatnium plates, control group|after a surgical procedure under general anesthesia , titanium plates will be placed on the fracturte site in the mandible in 20 patients out of 40 total sample size and will be compared to the test group containing resorbable plates
32777827|NCT05540977|Experimental|Donepezil|Patients were randomly divided into experimental group and control group. The experimental group received routine postoperative treatment and took donepezil 5mg orally before going to bed every night from the first day after surgery.
32777828|NCT05540977|Other|Usual care|Usual care
32777829|NCT05553535||cases|cases of rotator cuff calcific tendinosis on imaging studies
32777830|NCT05553535||witnesses|differential diagnosis or normal cases
32777831|NCT05547685|Experimental|Methylene blue intradermal injection|Methylene blue intradermal injection
32936705|NCT05284760|Experimental|Part A, Sequence 5: Treatment A + Treatment B + Treatment C|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936706|NCT05284760|Experimental|Part A, Sequence 6: Treatment C + Treatment A + Treatment B|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936707|NCT05284760|Experimental|Part B, Sequence 1: Treatment E + Treatment D + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
33102315|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
33102316|NCT04687605|Experimental|Optimum duration of hypercapnia|Daily serial measurement of 2 hours under target hypercapnia of pCO2 50 - 55 mmHg by changes of respirator settings once per day
32777832|NCT05553379||Children 7 to 17|Children with asthma
32777833|NCT05553379||Adults 18 to 80|Adults with asthma
32777834|NCT05540821||conventional transvaginal ultrasound group|
32777835|NCT05540821||double contrast-enhanced ultrasound group|perfromed hysterosalpingo-contrast sonography and sonoPODography examination
32777836|NCT05547607||definite or high suspicion endocarditis|All consecutive patients referred for an echocardiography (transthoracic or transesophageal approach) with a high suspicion of endocarditis and those with a confirmed diagnosis of endocarditis independently by the request will be eligible for the study.
32777837|NCT05547607||negative examination with low suspicion of endocarditis|For patients with no evidence of endocarditis on their echocardiogram, data on the following will be collected: i) risk factors for endocarditis; i) size, type and position of valve prosthesis or other devices if present; iii) Duke criteria verification.
33102317|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
33282299|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
33282300|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
33282301|NCT01005446||RSP Device|Post Market Study
33282302|NCT00531206||All participants|
33282303|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
33282304|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
33282305|NCT04000022||Non-Treatment Resistant Patients|
33102318|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
33102319|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
33282306|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
33282307|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
33282308|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
33282309|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
33282310|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
33282311|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
33282312|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
33282313|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
33282314|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
33102320|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
33102321|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
33282315|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
33282316|NCT05152472|Experimental|Imatinib + Atezolizumab|Imatinib per os 400 mg daily continuously associated with intravenous administrations of atezolizumab at the fixed dose of 1 200 mg every 3 weeks (up to 12 months)
33282317|NCT05152472|Active Comparator|Imatinib alone|Imatinib alone, per os 400 mg daily continuously (up to 12 months)
33282318|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
33282319|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
33282320|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
33282321|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
33282322|NCT05092802|Experimental|HLX208|
33282323|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
33282324|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
32777838|NCT05547451||Trial population|Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.
33282325|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
33282326|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
33282327|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
33282328|NCT00615017|Placebo Comparator|Placebo|Placebo
33282329|NCT05236244|Experimental|İntervention group|Diaphragmatic breathing exercises: First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks of diaphragmatic breathing exercises +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
33282330|NCT05236244|No Intervention|Control Group|First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks break +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
33282331|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
33282332|NCT01006226|Experimental|64Cu-ATSM PET|
33282333|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
33102322|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
32777839|NCT05540587|Experimental|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~CrCl 15-50mL/min~Body weight ≤ 60kg~Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
33102323|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
32777840|NCT05540587|Active Comparator|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
32777841|NCT05540509|Experimental|Community-based intervention|This program consisted of 12 group exercise sessions over a three-month period that were offered in Spanish and English. Each two-hour session consisted of 90 minutes of flexibility, cardiovascular, and strength exercises to meet physical activity recommendations and 30 minutes of group discussions that focused on topics related to the adoption and maintenance of physical activity.
32936708|NCT05284760|Experimental|Part B, Sequence 2: Treatment D + Treatment F + Treatment E|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32777842|NCT05540509|Active Comparator|Home-based intervention|Mothers randomized to the HBI group participated in a three-month program where they were given print-based materials (offered in Spanish or English) at each monthly assessment time point. The print-based materials provided information on multiple cardiovascular, strength training, and flexibility exercises that they could do at home.
32777843|NCT05540431|Other|Activated charcoal|"1st group~Oral activated charcoal~20 to 25 patient with CKD will receive standard care plus Activated charcoal capsule (charconut) three times dialy for six weeks."
32777844|NCT05540431|Other|Probiotic|"2nd group~Oral probiotic~20 to 25 patient with CKD will receive standard care plus Probiotic tablet twice dialy for six weeks."
32777845|NCT05540431|Other|Control group|"3rd group~Control group~20 to 25 patient with CKD will receive standard care only for six weeks."
32777846|NCT05700409|Experimental|Telemedicine|The telemedicine arm will include 30, mostly video, consultations for each participant: 3 physician appointments, 7 exercise consultations by our exercise physiologist, 10 dietary consultations by our pediatric dietitian, and 10 psychologist consultations to assist with goal setting and overall well-being. Three visits will be conducted in-office, for physician assessment, smartphone technical assistance and physical measurements (baseline, at 3 months and at the end of the 6-month period). Participants randomized to the telemedicine arm will have a step-counting rewarding app installed on their smartphone by our staff.
32936709|NCT05284760|Experimental|Part B, Sequence 3: Treatment F + Treatment E + Treatment D|Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936710|NCT05284760|Experimental|Part B, Sequence 4: Treatment E + Treatment F + Treatment D|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936711|NCT05284760|Experimental|Part B, Sequence 5: Treatment D + Treatment E + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936712|NCT05284760|Experimental|Part B, Sequence 6: Treatment F + Treatment D + Treatment E|Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
32936713|NCT04336904|Experimental|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
32936714|NCT04336904|Placebo Comparator|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
32936715|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
32777847|NCT05700409|Active Comparator|On-site|The on-site arm will have 6 monthly visits during the study period, with two consultations performed in each visit - one by the physician or exercise physiologist, and one by our pediatric dietitian.
32777848|NCT05547217|Experimental|Neurorehabilitation of the Hand|Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
32777849|NCT04319809|Experimental|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
32777850|NCT05547139|No Intervention|Usual care group|Infants randomized to this group will receive the present standard of care for weaning respiratory support. This means the attending provider will decide when each infant is ready to be changed from CPAP to nasal cannula and the nasal cannula will be weaned according to an existing unit protocol.
32777851|NCT05547139|Active Comparator|Protocol care group|Infants randomized to this group will remain on CPAP until they are at least 32 weeks corrected gestational age or 1250g. At that point, if they meet a set of criteria, they will be transitioned to either 2L nasal cannula if they require supplemental oxygen or room air.
32777852|NCT05547061|Experimental|Phase 1 Part A(Healthy/Disease group)|Subjects are administered intravenously a single dose of 2MBq/kg of Ga-68-NGUL.
32777853|NCT05547061|Experimental|Phase 1 : Part B(Low dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with low dose of Lu-177-DGUL.
32777854|NCT05547061|Experimental|Phase 1 : Part B(High dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with high dose of Lu-177-DGUL.
32777855|NCT05547061|Experimental|Phase 2|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with Lu-177-DGUL with the determined RP2D.
32777856|NCT04318327|Experimental|PHE885|Patients will receive PHE885
32777857|NCT04318249|Experimental|Assisted Relaxation Therapy|This group will be receiving an assisted relaxation therapy intervention
32777858|NCT04318249|Experimental|Modified Assisted Relaxation Therapy|This group will be receiving a modified version of an assisted relaxation therapy intervention
32936716|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
32936717|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
32936718|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
32936719|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
32936720|NCT05263232|Experimental|Natural office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with wide transparent windows under natural daylight.
32936721|NCT05263232|Experimental|Artificial office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with shielded windows under artificial light.
32936722|NCT05257850|Active Comparator|Fan first|Patients use the fan first and high-flow nasal therapy thereafter
32936723|NCT05257850|Active Comparator|High-flow nasal therapy first|Patients use high-flow nasal therapy first and the fan thereafter
32936724|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
32936725|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
32936726|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
32936727|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
32936728|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
32936729|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
32936730|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
32936731|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
32936732|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
32936733|NCT04738136|No Intervention|Standard of Care (SOC)|Subjects will only receive standard of care treatment for moderate severity COVID19 bronchiolitis/pneumonia.
32936734|NCT04738136|Experimental|Standard of Care(SOC) + S-1226 at either 4% 8% or 12% CO2|Subjects will receive SOC plus the highest tolerated dose of S-1226 at either 4% 8% or 12% CO2 twice daily for up to 5 consecutive days.
32936735|NCT02772302|Experimental|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
32936736|NCT02772302|Experimental|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
32936737|NCT05200598||Mild psoriasis|
32936738|NCT05200598||Moderate psoriasis|
32936739|NCT05200598||Severe psoriasis not receiving systemic therapy|
32777859|NCT05540275|Experimental|Cohort 1|Patients with bevacizumab-refractory recurrent glioma with PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
32777860|NCT05540275|Experimental|Cohort 2|Patients with bevacizumab-refractory recurrent glioma without PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
32777861|NCT05540197||Autologous islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at baseline after mixed meal tolerance test (MMTT), performed separately at day -1 or 0, day 1, day 3, day 7 and 3 months, and also at 3 months after MMTT.
32777862|NCT05540197||Allogeneic islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at day -1 or 0, day 1, day 3, day 7, 3 months and at 3 months after MMTT.
32777863|NCT05540119||SWEGASS|Gastric cancer patients.
32777864|NCT05540119||SESS|Oesophageal cancer patients.
32777865|NCT05552677|No Intervention|Control Group (CG)|Patients will recieve no intervention for the period of 12 weeks
32777866|NCT05552677|Experimental|Exercise Group (EG)|Patients will undergo a 12 week multicomponent training program
32777867|NCT05546827|Experimental|Surgical resection|Patients will have surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
32777868|NCT05539885|Active Comparator|Pre-incisional PIFB|Group P (ultrasound guided parasternal; PIFP block): patients will be injected with 0.4 mL/kg 0.25 bupivacaine in the fascial plane between the pectoralis major and internal intercostal muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
32777869|NCT05539885|Active Comparator|Post-incisional PIFB|"Group S: After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
32777870|NCT05699707|Experimental|Ketone monoester|0.75 g/kg body mass of ketone monoester to be consumed within 5 minutes with venous blood samples obtained pre-ingestion, and 30-, 60- and 90-minutes post-ingestion.
32777871|NCT05539807|Experimental|Intervention|All participants receive the intervention
32777872|NCT05552599|Experimental|woolen blanket|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was admitted for the operation. Body temperature was measured before the patient wore surgical gown. Before leaving the room, patient's body was covered with a woolen blanket. The temperature of the operating room was recorded. Body temperature was stabilized under normothermic conditions with a woolen blanket until the operation began. Body temperature was measured before anesthesia was given. Body temperature was measured in the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
32777873|NCT05552599|No Intervention|standard of care|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was taken to the operation. Body temperature was measured before the patient wore surgical clothes. The temperature of the operating room was recorded. Body temperature was measured before anesthesia was givenBody temperature was measured at the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
32777874|NCT04426123|Active Comparator|Botulinum toxin|Botulinum toxin type A
32777875|NCT04426123|Placebo Comparator|Saline solution|NaCl
32777876|NCT05539651|Experimental|RBD5044 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD5044 on Day 1.
32777877|NCT05539651|Experimental|RBD5044 MAD experimental group|Subjects in MAD experimental groups will receive one subcutaneous injection of RBD5044 on Day 1 and another subcutaneous injection of RBD5044 on Day 29.
32777878|NCT05539651|Placebo Comparator|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
32777879|NCT05539651|Placebo Comparator|Placebo MAD group|Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 1 and another subcutaneous injection of placebo on Day 29.
32777880|NCT04425811|No Intervention|No tape applied|Walking parameters were evaluated without any intervention.
32777881|NCT04425811|Experimental|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
32777882|NCT04425811|Sham Comparator|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
32777883|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
32777884|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
32777885|NCT05546437||Subjects with Ion Endoluminal dye marking of pulmonary nodule for resection|Subjects in which a pulmonary lesion dye marking procedure was attempted or performed with the Ion Endoluminal System in anticipation of resection of the lesion
32777886|NCT05699395||Aortic Dissection|
33282334|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
32777887|NCT05699395||Non Aortic Dissection|
33102324|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33282335|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
33282336|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
32777888|NCT05539339|Experimental|Arm 1|This arm includes patients with ctDNA-level-relapse glioblastoma before imaging recurrence.
33083079|NCT04870151|Experimental|Anterolateral approach|"The minimally invasive anterolateral approach (Watson-Jones approach) is performed with the patient in supine position. An oblique incision is made from just dorsal to the anterior superior iliac spine, and extended distally to the greater trochanter. After the fascia is incised, deep dissection continues in the plane between the tensor fasciae latae and the gluteus medius muscles. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the fascia, subcutis and skin is closed in separate layers with sutures."
33083080|NCT04870151|Active Comparator|Direct lateral approach|"The direct lateral approach (Hardinge approach) is performed with the patient in a lateral decubitus position. A straight or curved longitudinal incision is made over the greater trochanter, and the fascia is incised longitudinally. The anterior aspect of the gluteus medius and minimus muscles are separated from the greater trochanter. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the gluteus medius and minimus muscles are reinserted using osteosutures. The fascia, subcutis and skin is closed in separate layers with sutures."
33083081|NCT04597177|Active Comparator|ST-IMRT|standard parotid sparing IMRT
32777889|NCT05539261||HVD|Heart Valve Disease
33282337|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
33282338|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
33282339|NCT04884113||Experimental: Motorized Spiral Enteroscopy|"Procedure: Motorized Spiral Enteroscopy:~PowerSpiral enteroscope will be inserted and advanced with the assistance of motorized spiral rotation, After reaching the point of maximum insertion, cecum or if no further advancement of the enteroscope can be achieved, the enteroscope will be withdrawn using motorized counter-clockwise spiral rotation. When no total enteroscopy is reached, submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde enteroscopy is then performed in the same session or at second session"
33282340|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
33282341|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
33282342|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
32777890|NCT05539261||HC|Healthy controls
33282343|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
33282344|NCT00879749|Placebo Comparator|Saline|
33282345|NCT00879749|Experimental|Nexvax2|
33282346|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
33282347|NCT00869297|Active Comparator|Control|
33282348|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
33282349|NCT00999986|No Intervention|placebo|
33282350|NCT00999986|Active Comparator|cyclophosphamide|
33282351|NCT05226611|Experimental|Tender point treatment with Counterstrain|A tender point was located in the upper trapezius region of the test subject and treated with counterstrain. The side with the highest initial pain level was used as the treatment side. Pain level was measured before and after treatment. The MyotonPRO was also used to measure physiologic parameters of the muscle before and after treatment.
33282352|NCT05181644|Active Comparator|Control Group|To the Control Group is administered the current standard therapy for 16 weeks.
33282353|NCT05181644|Experimental|EmoLED Group|The treatment with EmoLED will be carried out once a week in correspondence with the dressing change of the lesion, for sixteen consecutive weeks, for a total of 16 treatments.
33282354|NCT05178758|Experimental|Virtual Reality (VR) Rehabilitation Training|Patients in the VR group will receive VR rehabilitation training in the hospital. The content of the training is the same as the control group. The only difference is that participants in the intervention group will use VR as a training platform. The VR system will include the training materials and tasks required for the patients to perform in the 3D environment. Demographic, clinical data and treatment costs will be collected before and after the rehabilitation training.
33282355|NCT05178758|No Intervention|Control - Conventional Rehabilitation Training|Patients in the control group will receive conventional rehabilitation training currently provided in the hospital. An instructor will assign each participant for training. Demographic, clinical data, and treatment costs will be collected before and after completing the rehabilitation training
33282356|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
33282357|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
33405356|NCT02354703|Experimental|ondansetron-responsive genotype|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
32777891|NCT05539183|Experimental|Solid cancer patients with malignant pleural effusion|Solid cancer patients that have to undergo pleural evacuation because of diagnosed malignant pleural effusion mediated discomfort.
32777892|NCT05546359|Active Comparator|Stage 1 - Group 1: IV ondansetron + IV dexamethasone|Stage 1 - Group 1: IV ondansetron + IV dexamethasone
32936740|NCT05200598||Severe psoriasis receiving systemic therapy with genetic-engineering biological drugs|
32936741|NCT05200598||Patients without psoriasis|
32936742|NCT05196776|Experimental|Portable, Handheld Device|Patients will receive a point-of-care ultrasound using a handheld, portable ultrasound device.
32936743|NCT05196776|Active Comparator|Traditional, Cart-based Ultrasound|Patients will receive a point-of-care ultrasound using a traditional, cart-based ultrasound machine.
32936744|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
32777893|NCT05546359|Experimental|Stage 1 - Group 2: IV amisulpride 0.035 mg/kg + IV dexamethasone|Stage 1 - Group 2: IV amisulpride 0.035 mg/kg + IV dexamethasone
32936745|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
32936746|NCT05180786|Experimental|Stroke Participants|Single intervention session
32936747|NCT05180318|Placebo Comparator|0.9% saline preadministration group|0.9% saline will be given intravenously 24-36 hours before operation and immediately after operation
32936748|NCT05180318|Experimental|Esketamine preadministration group|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
32936749|NCT05173532|Experimental|Balance Training|Static and dynamic balance and gait stability training exercises are performed with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
33083082|NCT04597177|Experimental|SW-IMRT|swallowing sparing IMRT
32777894|NCT05546359|Experimental|Stage 1 - Group 3: IV amisulpride 0.07 mg/kg + IV dexamethasone|Stage 1 - Group 3: IV amisulpride 0.07 mg/kg + IV dexamethasone
32777895|NCT05539105||Double tract reconstruction|Double tract reconstruction would be applied after proximal gastrectomy
32777896|NCT05539105||Gastric conduit reconstruction|Gastric conduit reconstruction would be applied after proximal gastrectomy
32777897|NCT05539105||Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after proximal gastrectomy
32777898|NCT05546203|Experimental|Ischemic compression (IC) group|Ischemic compression group received ischemic compression and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
32777899|NCT05546203|Experimental|Low-level laser therapy (LLLT) group|Low-level laser therapy group received Low-level laser therapy and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
32777900|NCT05538871||Degenerative scoliosis|"Inclusion criteria for the degenerative scoliosis group :~Diagnosis of degenerative (De novo) scoliosis,~age ⩾45 years old,~curve severity over 10°, and~fluent in English.~Exclusion criteria for the scoliosis groups :~History of spine surgery or~history of diseases affecting the torso or lower extremity function,~surgery or trauma,~secondary scoliosis,~unable to fill out the questionnaires or attend physical examination,~pregnant or gave birth between 0 and 2 years ago."
32777901|NCT05538871||Adult idiopathic scoliosis|"Inclusion criteria for the idiopathic scoliosis group :~Diagnosis of idiopathic scoliosis,~age ⩾18 years old,~curve severity over 10°, and~fluent in English.~Exclusion criteria for the scoliosis groups :~History of spine surgery or~history of diseases affecting the torso or lower extremity function,~surgery or trauma,~secondary scoliosis,~unable to fill out the questionnaires or attend physical examination,~pregnant or gave birth between 0 and 2 years ago."
32777902|NCT05538871||Population sample matched to the degenerative scoliosis|"Inclusion criteria~Age ⩾ 18 years,~matched for age/height/weight (+/-5 years; +/- 10 lbs; +/- 10cm) to a degenerative scoliosis participant,~and fluent in English.~Exclusion criteria~Serious systemic pathology,~spine deformity,~spine surgery,~pregnant or gave birth between 0 and 2 years ago.~unable to fill out the questionnaires or attend physical examination~Received treatments for the spine/the lower limbs within the last year."
32777903|NCT05538871||Population sample matched to the idiopathic scoliosis|"Inclusion criteria~Age ⩾ 18 years,~matched for age/height/weight (+/-5 years; +/- 10 lbs; +/- 10cm) to an idiopathic scoliosis participant,~and fluent in English.~Exclusion criteria~Serious systemic pathology,~spine deformity,~spine surgery,~pregnant or gave birth between 0 and 2 years ago.~unable to fill out the questionnaires or attend physical examination~Received treatments for the spine/the lower limbs within the last year."
32777904|NCT05551507|Experimental|IN10018 in combination with PLD|IN10018 in combination with PLD in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma subjects.
32777905|NCT05538715|Experimental|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
32777906|NCT05538715|Experimental|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
32777907|NCT05538559|Experimental|Test|
32777908|NCT05538559|Active Comparator|Control|
32777909|NCT05545579|Experimental|circuit training|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes.
32777910|NCT05545579|Experimental|Trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
32777911|NCT05538325||Group A|9 participants were exposed to cesarean delivery with midline epidural anesthesia
32777912|NCT05538325||Group B|22 participants were exposed to cesarean delivery with midline spinal anesthesia
32777913|NCT05538325||Group C|10 participants were exposed to cesarean delivery with general anesthesia
32777914|NCT05538325||Group D|22 participants who were in the control group, they did not experience previous pregnancy or anesthesia
32777915|NCT05698303|Experimental|CT103A in patients with RRMM|After lymphodepletion, CT103A will be administered as a single infusion.
32777916|NCT05551351||Coronary CT|The single cohort consists of all patients enrolled in the study. All participants performs cardiac CT and coronary angiography as part of routine care.
32777917|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
32777918|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
32777919|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
32777920|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
33083083|NCT04596904|Experimental|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
32777921|NCT05545501|Placebo Comparator|No Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
32777922|NCT05545501|Active Comparator|High Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
32777923|NCT05545501|Experimental|High Salt, High β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
32777924|NCT05545423|Experimental|instrumented assisted soft tissue mobilization|patients will receive IASTM three times a week for eight weeks
32777925|NCT05545423|Active Comparator|traditional therapy|patients will receive traditional therapy three times a week for eight weeks
32777926|NCT05538169|Experimental|Laser therapy group|There will be 2 weekly applications of a low-level laser diode (Pioon Laser) for a 4-week active treatment period. Thus, a total of 8 therapeutic sessions will be conducted
32777927|NCT05545345|Active Comparator|TT|Participants only receive tympanostomy tube placement.
32777928|NCT05545345|Experimental|Ad+TT|Participants will receive tympanostomy tube placement and concurrent adenoidectomy.
32777929|NCT05550961||Retrospective Cohort|About 1000 patients with NSCLC pre-treated with innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
32777930|NCT05550961||Prospective Cohort|About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
32777931|NCT05550883|Experimental|Group A (aerobic exercise group)|aerobic exercise training for 45 minutes, three sessions per week for 6 weeks.
32777932|NCT05550883|Active Comparator|Group B (Medications group)|The patients in this group did not receive treatment program. just received their medical treatment tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers over the period of 6 weeks.
32777933|NCT05545189||colonoscopy group1|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients.
32777934|NCT05545189||colonoscopy group 2|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
32777935|NCT05545189||colonoscopy group 3|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
32777936|NCT05545189||colonoscopy group 4|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
32777937|NCT05545189||colonoscopy group 5|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
32777938|NCT05545189||colonoscopy group 6|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
32777939|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
32777940|NCT05698225|Experimental|Inoculation with Streptococcus pneumoniae serotype 6B|Participants will be inoculation with a controlled concentration of full sequenced, fully antibiotic sensitive Streptococcus pneumonia serotype 6B
32777941|NCT04736017|Experimental|Verum|The device records EEG and other biosignals throughout the night and scans these signals for slow waves associated with deep Non-Rapid Eye Movement (NREM) sleep. Upon recognition of such slow waves and fulfilment of other criteria, a tone is played via the headphones to stimulate and enhance slow waves without waking up the patient.
32777942|NCT04736017|Sham Comparator|Sham|Playing no tones during NREM sleep but wearing the device and recording the biosignals over a period of 2 weeks, every night.
32777943|NCT05545033|Experimental|Virtual reality intervention|Comparison of pain and anxiety levels before and after VR intervention within the same patient.
33083084|NCT04596904|Placebo Comparator|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
33083085|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
32936750|NCT05173532|Active Comparator|Breathing and Stretching Exercises|Patients perform static stretches for all major muscle groups while performing diaphragmatic breathing with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
32936751|NCT05162144|Experimental|Proximal Medial Gastrocnemius Recession Surgery|All patients included in the Cohort Study will recieve this PMGR-surgery
32936752|NCT05149352|Active Comparator|Treatment as usual (TAU)|Participants will receive an evidence-based psychotherapeutic intervention combined with/or pharmacotherapy (TAU)
33282358|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
33282359|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
33282360|NCT01000142|No Intervention|Treatment as Usual Control Group|
33282361|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
33282362|NCT01000142|Experimental|Standard OMT Group|
33282363|NCT01000220|Active Comparator|Omeprazole|
33282364|NCT01000220|Placebo Comparator|placebo|
33282365|NCT01006460|Experimental|Adapt 232|
33282366|NCT01006460|Experimental|Arctic root group|
33282367|NCT01006460|Active Comparator|Ginseng group|
33282368|NCT01006460|Placebo Comparator|Placebo group|
33282369|NCT05147558|Experimental|Pembrolizumab With Lenvatinib|Lenvatinib (20mg once daily orally) in combination with Pembrolizumab (200mg every 3 weeks, intravenously)
33282370|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
33282371|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
33282372|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
33282373|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
33282374|NCT04000100|Placebo Comparator|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
33282375|NCT04000100|Active Comparator|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
33282376|NCT01000298|Placebo Comparator|Placebo|
33282377|NCT01000298|Experimental|Amoxicillin|
33282378|NCT01000298|Experimental|cefdinir|cefdinir
33282379|NCT00614939|Experimental|Saxa|Saxagliptin
33282380|NCT00614939|No Intervention|Placebo|Placebo to match
33282381|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
33282382|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
33282383|NCT05176964||HFRT with concurrent chemotherapy and immunotherapy|CAPOX chemotherapy plus tislelizumab treatment plus split-course HFRT
33282384|NCT01006928||Mothers|Mother of infants in NICU
32936753|NCT05149352|Experimental|Treatment as usual (TAU) + Trauma-focused therapy (TFT)|Participants will receive 6 to 10, 60-90 minute TFT sessions delivered over a period of 12 weeks, in addition to TAU.
32936754|NCT05457296|Experimental|capsule hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in capsule form (15mg), one intake/ one day test.
32936755|NCT05457296|Active Comparator|tablet hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in tablet form (15mg), one intake/ one day test.
32936756|NCT05457296|No Intervention|healthy controls|healthy non treated controls, one day test.
32936757|NCT04336514|Experimental|Experimental Arm|
32936758|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
32936759|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
32936760|NCT04338230|Experimental|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
33282385|NCT00869453||1|Healthy volunteers
33282386|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
33282387|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
33282388|NCT00879827|Experimental|Single Group|
33282389|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
33282390|NCT05734352||Intervention|Completion of questionnaire
33282391|NCT01007084|Experimental|Propranolol|
33282392|NCT01007084|Placebo Comparator|Sugar pill|
33282393|NCT04992845|Experimental|Intervention|Vertebral Body Tethering surgery
33282394|NCT01000532||Pacemaker therapy|
33282395|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
33282396|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
33282397|NCT00879281|No Intervention|1 Care as usual|Regular care
33282398|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
32777944|NCT05550649|Experimental|Prophylic Embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
32777945|NCT05550649|Sham Comparator|Sham Embolization|After the angiography was completed, no embolization was performed, the catheter was withdrawn, the vascular sheath was removed, and symptomatic and supportive treatments such as acid suppression, hemostasis, blood transfusion, and fluid replacement were given.
32777946|NCT05544955|Experimental|Protein ingestion immediately prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
32777947|NCT05544955|Experimental|Protein ingestion 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
32777948|NCT05537545|Active Comparator|Immediate soft tissue grafting|A connective tissue graft is immediately harvested and inserted in the buccal mucosa at the moment of implant placement
32777949|NCT05537545|Experimental|Delayed soft tissue grafting|Three months after implant placement, a connective tissue graft is harvested and inserted in the buccal mucosa
33405357|NCT02354703|Experimental|ondansetron--non-responsive genotype|ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
32777952|NCT05544877|Experimental|Brain2Business (B2B)|"The Brain2Business (B2B) technique aims to improve creative thinking. It is a game-based conceptual combination method that is performed by the participant with support of one trained B2B administrator in a laboratory session and without support in 5 at-home sessions. In this technique, thirty-six different images are randomly selected on a board by throwing two dices. Inspired by these images, participants are asked to create new ideas regarding three questions for a total of at least 39 minutes over a period of 5 days. One question is from a standardized creativity test and two questions are part of psychotherapeutic techniques (idea generation for pleasurable activities within behavioral activation (PA-BA) and for a gratefulness exercise (GE)). The B2B technique is based on the principles of solo brainstorming (SBS). A trained B2B administrator is documenting the answers of the participant, and mentioning the principles of SBS (see SBS group)."
32777953|NCT05544877|Active Comparator|Solo Brainstorming (SBS)|Solo brain storming (SBS) is the active control condition. The technique aims to improve creative thinking through the principles of SBS. SBS principles include i) idea quantity goes before quality, ii) no criticism and evaluation of ideas during idea generation, iii) original ideas are encouraged. The principles are provided to participants in the same way, with the same questions to be answered, and over the same time period as in the B2B group. A trained SBS administrator is documenting the answers of the participant, and mentioning the principles of SBS.
32777954|NCT05550415|Experimental|Simvastatin|The group received standard treatment with simvastatin 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
32777955|NCT05550415|Placebo Comparator|Placebo|The group received standard treatment with placebo 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
32777956|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
32777957|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
32777958|NCT05537311|Experimental|Social engagement using VR|Patients will receive social engagement with emphasize on meaningful conversation, cognitive engagement, and emotional support provided by trained research assistant using virtual reality as a vehicle for delivery. Subjects will receive 15-45 minutes of treatment per day for 5 days initiated after respiratory support (Intubation via mask or tube, high-flow nasal cannula) have been weaned to nasal cannula. Experimental group will also receive standard of care
32777959|NCT05537311|No Intervention|Control|Control will receive standard of care
32777960|NCT05699161|Experimental|Single group assignment.|"Bilateral treatment.~Subdermal plane injection of SVF cells into the submuscular aponeurotic fascia of the face."
32777961|NCT05537155|Experimental|Buccal acupuncture|Buccal acupuncture will be performed in addition to routine care.
32777962|NCT05537155|Active Comparator|Routine care|Routine care will be provided.
32777963|NCT05550259|No Intervention|control period|the control period corresponds to usual care of centers
32777964|NCT05550259|Experimental|protocolized period|the protocolized period corresponds to a protocolized use of HFNO or NIV after extubation
32777965|NCT05537077|Active Comparator|Group 1|%5 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 1.
32777966|NCT05537077|Active Comparator|Group 2|%10 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 2.
32777967|NCT05537077|Active Comparator|Group 3|%20 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 3.
32777968|NCT05537077|Active Comparator|Group 4|Hotpack therapy and home based exercise program was applied to group 4.
32900164|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
32777969|NCT05544643|Experimental|A - M30IS vs. EM30IS. First phase Mio 30, second phase Extended Mio 30.|"Subjects will be randomized to a group who will be using the Mio 30 infusion set (M30IS) for the Phase 1. All patients will be retrained on the use of the M30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS).~At day 12 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the Extended Mio 30 infusion set (EM30IS), entering Phase 2. All patients will be trained at this visit on the use of the EM30IS by site staff and demonstrate proficiency in the use of the EM30IS. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS). After 28 days or after using 4 sets, the patients will return all the extracted catheters sets."
32777970|NCT05544643|Experimental|B - EM30IS vs. M30IS. First phase Extended Mio 30, second phase Mio 30|"Subjects will be randomized to a group who will be using the EM30IS for the initial Phase. All patients will be trained on the use of the EM30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS).~At day 28 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the M30IS, entering Phase 2. All patients will then be retrained on the use of the M30IS by site staff and demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS). After 12 days or after using 4 sets, the patients will all the extracted catheters sets."
32777971|NCT05550025|Experimental|TACE combined with Apatinib and Camrelizumab|TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab
32777972|NCT05544409|Experimental|MAKv1|The MAKv1 group will receive 1 hour of MAKv1 rehabilitation, thrice per week during 1 month
32777973|NCT05700253|Experimental|Cooled Radiofrequency Ablation|Relieves pain by blocking pain signals via the deactivation of nerve structures using radiofrequency energy.
32777974|NCT05700253|Active Comparator|Hyaluronic Acid Injection|Injection of hyaluronic acid into the affected knee provides lubrication and shock absorption.
32777975|NCT05536765||Patients with impacted tooth|
32777976|NCT05536687|Other|Healthy|
32777977|NCT05544331|Experimental|Written exercise group|The exercise program will consist of core stabilization exercises, which target various trunk muscles to optimize segmental control, spinal stability, spinal stiffness, orientation and the interoperability of these features. The exercise program will be in writing form, which is a common home exercise program type.
32777978|NCT05544331|Experimental|Video based exercise group|The exercise program will consist of core stabilization exercises, which provide segmental control optimization, spinal stabilization, spinal stiffness, orientation and the interoperability of these features. The exercise program will be given patients as video records, which provide visual and auditory feedbacks.
32777979|NCT05544331|No Intervention|Control group|The patients, who are referred and will wait for the exercise program in their routine daily life. Measurements will be performed at the same time frame in experimental group. After the 12 weeks of follow up period, they will join the exercise program.
32777980|NCT05535673|Experimental|ThisCART19A cell injection|In this study, allogeneic anti-CD19 CART cell (This CART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
32777981|NCT05544253|Experimental|HIPEC group|
32777982|NCT05544253|No Intervention|non-HIPEC group|
32777983|NCT05535517||Group 1|"KP Scoring Day Participants~Participants who attend the one-day scoring session in August 2022."
32936761|NCT04338230|No Intervention|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
32936762|NCT04336436|Experimental|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
32936763|NCT05457062||large amount of bleeding|large amount of upper GI bleeding after EGD identified
32936764|NCT05457062||no bleeding|no upper GI bleeding after EGD identified
32936765|NCT05457062||small amount of bleeding|small amount of upper GI bleeding after EGD identified
32936766|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~Oxford Grades 1 & 2 - intra-rectal intussusception~Oxford Grades 3 & 4 - intra-anal intussusception~Oxford grade 5 - Overt Rectal Prolapse"
32936767|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
32936768|NCT04336358|No Intervention|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
32936769|NCT04336358|Experimental|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age <9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
32936770|NCT04335266|Experimental|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
32936771|NCT04335266|Experimental|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
32936772|NCT05456438|Experimental|COCONUT OİL|"After feeding, wash hands and apply 2 drops of oil, COCONUT OİL in the 1st intervention group to the index finger and spread on the areola and nipple,~Continue this application for 10 days"
32936773|NCT05456438|No Intervention|Control group|They were told that no intervention would be performed, and that they should not use any application like herbal or chemical oils, creams, medications, etc. on the nipples during the first 10 days postpartum.
32936774|NCT05456438|Experimental|TEA TREE OİL|"After feeding, wash hands and apply 2 drops of oil, TEA TREE OİL in the 2nd intervention group, to the index finger and spread on the areola and nipple,~Continue this application for 10 days."
32777984|NCT05535517||Group 2|"KP Follow-up Scoring (September)~Participants who attended the scoring day in August will be invited to attend a follow-up scoring session in September - October 2022. The purpose of this scoring session is to see how stable their condition is and take baseline photographs of their skin to monitor their condition.~Four assessors will score the participants in 5-minute intervals with the proposed scoring system KPAI and the KP-IGA. Participants will be offered free samples of Cerave Salicylic Acid Smoothing Cleanser and Cream to try."
32777985|NCT05535517||Group 3|"KP Follow-up Scoring (November)~Participants who attend the September scoring session will be invited to return for another rescoring in November - December 2022 to see if there is any improvement in their KP and if the score is responsive to change.~Participants will be given free samples of Propaira 30% Urea exfoliating emollient and Propaira 20% Lactic acid exfoliating lotion to try."
32777986|NCT05535517||Group 4|"KP Follow-up Scoring (December)~Participants who attend the November scoring session will be invited to return for another rescoring in December 2022 to monitor their progress, and see if there is any improvement in their KP and if the score is responsive to change."
32777987|NCT05698069||Patients with chronic pain|Patients with non-cancer pain of more than 3 months duration.
32777988|NCT05535439|Experimental|19 G EBUS-TBNA Needle|Mediastinal or Hilar Lymphadenopathy will be sampled by using 19 G EBUS-TBNA Needle
32777989|NCT05535439|Experimental|22 G EBUS-FNB Device|Mediastinal or Hilar Lymphadenopathy will be sampled by using 22 G EBUS-FNB Device
32777990|NCT05535361|Experimental|Eclipse XL1 Coil Treatment Group|All subjects will be assigned to the XL1 Coil treatment group.
32777991|NCT05536609|Experimental|Epineural suture|The injured digital nerve is exposed during a surgical intervention and sutured with 2 or three epineural sutures 8.0 or 9.0 synthetic monofilament non-resorbable suture. Postoperative treatment includes 3 weeks in a plaster cast followed by rehabilitation.
32777992|NCT05536609|Active Comparator|Non-operative treatment|The injured digital nerve is not surgically exposed. The skin is closed over the injury site and the finger is protected in a plaster cast for three weeks followed by rehabilitation.
32777993|NCT05536531|Experimental|NMES group|NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.
32777994|NCT05536531|No Intervention|Control|Sham NMES will not be provided. Standard care won´t be altered and passive mobilization will be performed according to routine ICU procedures.
32777995|NCT05536063|Experimental|group A|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) for each side
32777996|NCT05536063|Experimental|Group B|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) + dexamethasone 0.1 mg/kg for each side
32777997|NCT05536063|No Intervention|Group C|control group will receive the standard analgesic regimen only
33083086|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
32777998|NCT05535985|Experimental|acupuncture group|In the acupuncture group, acupoints of Baihui, Shenting, Sishencong will be selected for acupuncture stimulation be anesthesia. The needle will be kept for 30 minutes, during which the needle will be performed once every 10 minutes for 10 seconds each time, 4 times in total. The therapist will give the subject verbal cues before and during the needle manipulation.
32936775|NCT04737824|Experimental|Experimental group A|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise."
32936776|NCT04737824|No Intervention|Control group A|No intervention was applied.
32936777|NCT04737824|Experimental|Experimental group B|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home."
33083087|NCT04596748|Placebo Comparator|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
33083088|NCT04596748|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
33083089|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
33083090|NCT00403013|Active Comparator|2|standard position during axillary plexus block
33083091|NCT04597060|Experimental|Split Keloid - first side|
33083092|NCT04597060|Experimental|Split Keloid - second side|
33083093|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
33083094|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
33083095|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
33083096|NCT00566332|Active Comparator|2|Fludarabine
33083097|NCT00403052|Experimental|1|Low dose of 1018 ISS
33083098|NCT00403052|Experimental|2|Middle dose of 1018 ISS
33083099|NCT00403052|Experimental|3|High dose of 1018 ISS
33083100|NCT04596709|Active Comparator|Vitalose|dissolved in water
33083101|NCT04596709|Active Comparator|isomaltulose|dissolved in water
33083102|NCT04596709|Placebo Comparator|sucrose|dissolved in water
33083103|NCT04596709|Placebo Comparator|glucose|dissolved in water
33083104|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
33083105|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
33083106|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
33083107|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
33402041|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
33083110|NCT04596553|Active Comparator|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
33083111|NCT04596553|Active Comparator|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
33083112|NCT04596553|Placebo Comparator|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
33083113|NCT04825769|Experimental|Intervention|Red light irradiation was conducted at school from Monday to Friday and at home everyday in summer and winter holiday twice a day for 3 minutes per time, with an interval of 4 hours
33083114|NCT04825769|No Intervention|Control|No intervention
33083115|NCT04596397|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
32936778|NCT04737824|No Intervention|Control group B|No intervention was applied.
32936779|NCT02743442|Experimental|Transoral surgery|
32936780|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
32936781|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
32936782|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
32936783|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
32936784|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
32936785|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
32936786|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
32936787|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
32936788|NCT04335565|No Intervention|Water|250 ml of water mixed with 1g of citric acid.
32936789|NCT04335565|Active Comparator|Sugar|65g of sugar dissolved in 250ml of water
32936790|NCT04335565|Experimental|Stevia|5g of stevia dissolved in 250ml of water
32936791|NCT04335409|Experimental|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
32936792|NCT04337125|Other|ADHD group|ADHD children with their parents
32936793|NCT04337125|Other|Control group|Children with typical development and their parents
33083116|NCT04596397|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
33083117|NCT00252915|Experimental|Verum|GM-CSF therapy
33083118|NCT04596280||Hinchey Classification|
33083119|NCT04596280||AAST classification|
33083120|NCT04596280||WSES classfication|
33083121|NCT04595929|Experimental|PIPAC group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².~Adjuvant chemotherapy according to indications."
33083122|NCT04595929|Active Comparator|Control group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Adjuvant chemotherapy according to indications."
33083123|NCT04802564|Experimental|Multisensory-based music treatment|Using a multisensory-based music treatment synchronizing with vibrotactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
33083124|NCT04802564|Active Comparator|Traditional sensory reeducation intervention|Using constant and moving tactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
33083125|NCT04596085|Active Comparator|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
33083126|NCT04596085|Placebo Comparator|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
32777999|NCT05535985|Placebo Comparator|placebo acupuncture group|The patients will be treated with consolation needle. Choose treatment of points that near but without going through the acupoints(upper arm deltoid muscle). Use the Park needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time and number of needles will be the same as those in the acupuncture group. The therapist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.
32778000|NCT05535985|No Intervention|control group|The patients will undergoing routine anesthesia without acupuncture treatment.
32778001|NCT05535829||Patients with FH-deficient RCC|Laboratory analysis of samples
32778002|NCT03932773|Sham Comparator|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
32778003|NCT03932773|Active Comparator|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
32778004|NCT03932773|Active Comparator|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
32778005|NCT05592535||FFR below 0.80|Patients with significant coronary hyperemic gradient
32778006|NCT05592535||FFR above 0.80|Patients without significant coronary hyperemic gradient
32778007|NCT05699083|Other|Patients with BMI between 30-34.5 kg/m2|Patients with BMI between 30-34.5 kg/m2 will be administered a body image/self-esteem questionnaire pre-operatively and at 1 month, 3 months, 6 months and 12 months post-operatively.
32778008|NCT05696197|Experimental|Experimental group|Practicing the Swipe Slide Pattern task in ST and DT conditions, offered in a random order over a period of 2 weeks, 5 days a week, approximately 10 minutes per training session. Training will be performed independently at home.
32778009|NCT05696197|No Intervention|Control group|Participants in the control group will receive no intervention during the study period. They are given the opportunity to perform the SSP-training after the study period to ensure motivation in this group.
32778010|NCT04733053|Experimental|Diet plus exercise|The initial physiotherapy consultation for participants in this group will last 75 minutes, with 30 minutes for the exercise component and 45 minutes for the diet component. Thereafter, consultations will last 50 minutes, with 20 minutes for the exercise component and 30 minutes for the diet component. The exercise component will be the same as that described for the exercise alone group.
32778011|NCT04733053|Active Comparator|Exercise|Physiotherapy consultations for participants in this group will last 30 minutes initially and then 20 minutes thereafter, consistent with clinical practice. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate and a personalised physical activity plan.
32778012|NCT05697913|Experimental|MRDI-driven treatment|Patients continue treatment until complete remission with negative MRD and Image is achieved, changing the therapeutic line if this is not achieved with the prescribed treatment. In this group of patients, treatment is suspended only when this degree of profound response is reached, in any phase of treatment.
32778013|NCT05697913|No Intervention|Conventional treatment|The patients of the conventional treatment group (control group) received six cycles of the induction traetment, bone marrow auto-transplantation, and consolidation treatment after transplantation if complete remission had not been achieved.
33083127|NCT04758533|Experimental|AloCELYVIR|Patients will received weekly infusion of AloCELYVIR during 8 weeks.
33083128|NCT04596007|Experimental|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
33083129|NCT04596007|Placebo Comparator|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
33083130|NCT00252954|Placebo Comparator|1|
33083131|NCT04595812|Active Comparator|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
33083132|NCT04595812|Active Comparator|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
33083133|NCT04595812|Experimental|Carbetocin group|receive 100 μg IV Carbetocin (1ml) [Pabal, Ferring (UK)] in 5 ml saline over 1 minute just before skin incision
33083134|NCT04595812|Active Comparator|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
33083135|NCT04596046|Active Comparator|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
33083136|NCT04596046|Experimental|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
33083137|NCT04724018|Experimental|Dose Escalation Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV),|Participants will be given the study drugs Enfortumab Vedotin and then Sacituzumab Govitecan on Days 1 and 8 of a 21-day study cycle. Dose escalation and de-escalation for the Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) combination will be guided using the Bayesian optimal interval (BOIN) design with up to 4 dose level escalations.
33083138|NCT04595890|Experimental|Intervention Group|Injection of Autologous Nucleated Cells
33083139|NCT04595500||GERD|
33083140|NCT04595500||Control|
33102325|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
32936794|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
32936795|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
32936796|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
32778014|NCT05543941|Experimental|XPERIENCE Advanced Surgical Irrigation|Patients will receive the XPERIENCE Advanced Surgical Irrigation prior to wound closure.
32778015|NCT05543941|Active Comparator|Dilute Betadine|Patients will receive Dilute Betadine solution prior to wound closure.
32778016|NCT05697835|Experimental|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
32778017|NCT05697835|Other|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
32778018|NCT04425733|Experimental|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
32778019|NCT04425733|Placebo Comparator|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
32778020|NCT04425733|Experimental|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
32778021|NCT04425733|Placebo Comparator|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
32778022|NCT04425733|Experimental|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
32778023|NCT04425733|Placebo Comparator|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
32778024|NCT05543473|Experimental|patients|patients with brain radiological findings that affect balance functions
32778025|NCT05696041|Experimental|The exercise group (WSE)|"Initial static strength training program for the wrist, which could progress to a higher weight in kilos alternatively to a dynamic strength training program~Information about HSD/hEDS~Daily exercise~Training schedule~3-4 return visits to the OT"
32778026|NCT05696041|No Intervention|Conventional intervention (HO)|"Prescribed the wrist´s with plastic or metal orthoses~Information about HSD/hEDS~Use the orthosis in specific activities; carrying, vacuuming, doing laundry, driving, bicycling~Training schedule~3-4 return visits to the OT"
32778027|NCT05697757|Experimental|Placebo Condition followed by Dynamic Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
32778028|NCT05697757|Experimental|Dynamic Condition followed by Placebo Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
32778029|NCT05557279|Other|Intervention Group|All participants will receive 500 mg NDS-446 daily for 12 weeks
32778030|NCT05592301|Active Comparator|PFO positive|Patent Foramen Ovale positive patients
32778031|NCT05592301|Active Comparator|PFO negative|Patent Foramen Ovale negative patients
32778032|NCT05695963|Experimental|Restless Legs Syndrome|
32778033|NCT05592067|Active Comparator|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
32778034|NCT05592067|Active Comparator|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
32778035|NCT05592067|Other|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
32778036|NCT05498701|Experimental|Test tablet (fasted) followed by Reference capsule (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
32778037|NCT05498701|Experimental|Reference capsule (fasted) followed by Test tablet (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
32778038|NCT05695807|Experimental|Carboxytherapy|Device
32778039|NCT05695807|Active Comparator|Fractional CO2 laser|Device
32778040|NCT05695807|Active Comparator|Platelet rich plasma|platelet rich plasma
32936797|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
32936798|NCT05456282|Experimental|AMPS first, then SHAM|Participants will receive first one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold. Then, after a 2-week washout, they will receive one session of a simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold.
32936799|NCT05456282|Sham Comparator|SHAM first, then AMPS|Participants will receive first one session of simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold. Then, after a 2-week washout, they will receive one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold.
32936800|NCT05350046|Experimental|Physically active adults|A cohort of physically-active adults will use ear-worn prototype devices and established gold standard and comparator devices during rest periods, physical activity, and various activities of daily living.
32737509|NCT05051319||Elderly participants living at home|Participants over the age of 65, living at home, not having mental and communication problems that would prevent the evaluations, and volunteering to participate in the study. The sociodemographic information of the participants such as gender, duration of education, living environment and people with whom they live were recorded. In addition, information about the medical condition of geriatric individuals, such as body mass indexes and the number of drugs used, was also recorded in the form. In order to evaluate the cognitive status of the participants, the Standardized or Standardized Mini-Mental Test for the Uneducated was used according to their educational status. The Center for Disease Control Health-Related Quality of Life-4 Scale (CDC HRQoL-4) was used to assess quality of life, and the Geriatric Depression Scale was used to assess emotional status. In addition, the presence of pain and pain levels according to body regions were determined with a 6-point Likert-type scale.
32936801|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
33282399|NCT04040309|Experimental|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
33282400|NCT04040309|Active Comparator|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
33282401|NCT05734274|Experimental|Probiotics Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
33282402|NCT05734274|Sham Comparator|Negative control Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
32936802|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
33282403|NCT00869531|Experimental|WW|wholegrain wheat
33282404|NCT00869531|Active Comparator|RW|refined wheat
33282405|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
33282406|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
33282407|NCT00879905|Experimental|once weekly dosing schedule|
33282408|NCT00879905|Experimental|twice weekly dosing schedule|
32936803|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
33282409|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
33282410|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
33282411|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
33282412|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
33282413|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
33282414|NCT00869687|Other|Poly-L-Lactic Acid Injection|
33282415|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
33282416|NCT00530504|Experimental|Device|Device
33282417|NCT00869843|Other|Single group|
33282418|NCT03999632|Experimental|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
33282419|NCT03999632|No Intervention|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
33282420|NCT01000766||Acute drug-induced liver injury|
33282421|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
33282422|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
33282423|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
33282424|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
33282425|NCT05076110|Active Comparator|Standard of Care Group|Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure
33282426|NCT05076110|Experimental|Non-Opiate Pain Control Group|Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.
33282427|NCT00880295|Active Comparator|endoscopic surgery|
33282428|NCT00880295|Active Comparator|open surgery|
33282429|NCT05734196|Experimental|INZ-701|"The first two infant subjects will receive a single dose of 0.2 mg/kg on Day 1 and start at Dose Level A (0.2 mg/kg twice weekly) on Day 8. After the second subject completes Day 32, the Data Review Committee (DRC) will perform a cumulative review of safety and PK/PD data and will make dosing recommendations, for example, modifying the dose of the ongoing subjects and/or changing the starting dose for future subjects to Dose Levels B, C, or D. Each subject's safety and PK/PD data will also be reviewed by the DRC during its quarterly review, based upon which, the subject's dose may be modified to Dose Levels B, C, or D, as specified in the protocol.~Dose Level A: 0.2 mg/kg twice weekly~Dose Level B: 0.6 mg/kg twice weekly~Dose Level C: 0.2 mg/kg once weekly~Dose Level D: 0.6 mg/kg once weekly"
33282430|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
33282431|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
33282432|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
33282433|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
33282434|NCT00870077|Experimental|1|
33282435|NCT05734118|Experimental|Intraoperative perfusion assessment using ICG-FA|Surgical procedure within standard of care. Intraoperatively, the vitality of the bowel will be assessed visually (the conventional method). Afterwards, participants will be administered indocyanine green intravenously.
33282436|NCT04782401|Active Comparator|Genicular Nerve Block|
33282437|NCT04782401|Active Comparator|Physical Therapy|
33282438|NCT01007708|Experimental|IDP-108|
33282439|NCT01007708|Placebo Comparator|Vehicle|
33282440|NCT00885443|Active Comparator|1|
33282441|NCT00885443|Active Comparator|2|
32737510|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
32737511|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
33282442|NCT00882947||Group 1|
33282443|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
33282444|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
33282445|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
33282446|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
32737512|NCT05051163|Experimental|Ceftriaxone|Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
32737513|NCT05051163|Active Comparator|Ampicillin and Gentamicin|"Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly~Gentamicin will be administered intravenously at a dose 5mg/kg once daily"
32737514|NCT03337295||Low-MGD|
32737515|NCT03337295||High-MGD|
32936804|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
33402042|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
33402043|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
32936805|NCT05456048||VAH group|Patients assigned to this group received one to two cycles of VAH regimen as salvage therapy of RR-AML.
32936806|NCT05456048||VEN+HMA group|Patients assigned to this group received one to two cycles of venetoclax plus HMA regimen as salvage therapy of RR-AML.
32936807|NCT05348707||Pre Covid 19 cohort|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020."
32936808|NCT05348707||Per Covid 19 cohort year 1|"Infant hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available."
32936809|NCT05348707||Per Covid 19 cohort, year 2|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed."
32936810|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
32936811|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
32936812|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
32936813|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
32936814|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
32936815|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
32936816|NCT04337918|No Intervention|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
32778041|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
32778042|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
32778043|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
32778044|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
32778045|NCT05591833|Active Comparator|SASI|
32936817|NCT04337918|Experimental|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
33402044|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
33402045|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
33402046|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
32778046|NCT05591833|Experimental|SAS-J|
32778047|NCT05424679|Experimental|Intervention group|Individuals randomized to the intervention group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, information on and facilitated referrals to community support services (e.g., tribal behavioral health), and up to seven culturally responsive caring messages (i.e. Caring Contacts) from the research team over a period of three months.
32778048|NCT05424679|Active Comparator|Control group|Individuals randomized to the control group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, and information on and facilitated referrals to community support services (e.g., tribal behavioral health) from the research team over a period of three months.
32778049|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
32778050|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
32778051|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
32778052|NCT05688163|Active Comparator|traditional cognitive stimulation|The control group will carry out the programme based on traditional cognitive stimulation. Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
32936818|NCT04337918|Other|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
33282447|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
32737516|NCT03337217|Experimental|Prone Position|Position during colonoscopy
32936819|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
32936820|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
32737517|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
32737518|NCT05029791|Other|Metastatic melanoma|Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy
32737519|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
32737520|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
32737521|NCT05029323|Active Comparator|Conventional HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to conventional HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray."
32737522|NCT05029323|Experimental|Fast HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to fast HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray."
32737523|NCT03335969|Experimental|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
32737524|NCT05040477|Experimental|Experimental Group (1): Muscle energy techniques,Moist Hot pack and TENS.|"Experimental group included Moist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45C.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle.These pre and post intervention values were mentioned in questionnaire. The participants were administered with muscle energy technique (PIR) and data was collected again 2 and 4 weeks after the interventions."
32737525|NCT05040477|Experimental|Experimental Group (2): Facets joint mobilizations, Moist Hot pack and TENS.|"Experimental group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Facet joint mobilization (UPA & SNAGS) and data was collected again 2 and 4 weeks after the interventions."
32737526|NCT05040477|Active Comparator|Control Group:Conventional Therapy (Stretching, strengthening , Moist Hot pack and TENS)|"Control group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Conventional (sustained stretching and isometric strengthening) physical therapy and data was collected again 2 and 4 weeks after the interventions."
32737527|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
32737528|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
32737529|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
32737530|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
32737531|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
32737532|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
32737533|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
32737534|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
32737535|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
32936821|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
32936822|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
32936823|NCT05349968|Experimental|Dose 5 mg|
33282448|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
33282449|NCT05231018|Experimental|Psychotherapy|The population of interest includes COVID-19 patients previously or currently hospitalized at the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, according to inclusion and exclusion criteria.
33282450|NCT00530348|Experimental|Alemtuzumab|
33282451|NCT00530348|Active Comparator|Interferon Beta-1a|
33282452|NCT05733962|Experimental|Use of the device DBL-4pen|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection), the patient will start a 42-day treatment period with the DBL-4pen system followed by an optional 42-day extension period.
33282453|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
33282454|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
33282455|NCT03886220|Experimental|Elagolix 150 mg|Elagolix 150 mg once daily (QD)
33282456|NCT03886220|Experimental|Placebo|Placebo QD
32936824|NCT05349968|Experimental|Dose 20 mg|
32936825|NCT05349968|Experimental|Dose 40 mg|
33282457|NCT01007864|Experimental|piribedil|
33282458|NCT01007864|Active Comparator|pramipexole or ropinirole|
33282459|NCT05111366|Experimental|TQB2450 injection combined with Anlotinib hydrochloride capsules|
33282460|NCT01008020|No Intervention|Dietary supplement: placebo|
33282461|NCT01008020|Active Comparator|Tea catechin extracts|
33282462|NCT01008098|Experimental|PTSD group|
33282463|NCT05733728||Uveal Melanoma|
33282464|NCT00530270|Active Comparator|Dexamethasone|
33282465|NCT00530270|Placebo Comparator|Placebo|
33282466|NCT01008254|Experimental|Musical prompt|
33282467|NCT01008254|Active Comparator|Delayed musical prompt|
33282468|NCT01008254|No Intervention|No musical prompt|
32936826|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
33282469|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
33282470|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
33282471|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
33282472|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
33282473|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
33282474|NCT01008488|Active Comparator|Antibiotic|
33282475|NCT01008488|No Intervention|No antibiotic|
33282476|NCT01001468|Experimental|VB-201 20 mg|
33282477|NCT01001468|Experimental|VB-201 80 mg|
33282478|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
33282479|NCT01001624|Experimental|A|Melanil facial cream
33282480|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
33282481|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
33282482|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
33282483|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
33282484|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
33282485|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33282486|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
33282487|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
32936827|NCT04335344||Control|Healthy patients
32936828|NCT04335344||Periodontitis|Patients with periodontitis
32936829|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
32936830|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
32936831|NCT04336046|Sham Comparator|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
33282488|NCT05733494||Patients with neurodegenerative disease|Patients with neurodegenerative disease
33282489|NCT05601362|Active Comparator|Gamified Attention Bias Modification|Digital therapeutic intervention based on Attention Bias Modification Training (ABMT) designed to decrease negative attention bias.
33282490|NCT05601362|Sham Comparator|Gamified Placebo Training|Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias
33282491|NCT05601128|Experimental|HIV + severe renal impairment|CAB LA + RPV LA administered to HIV virologically suppressed participants with CKD stage 4/5 (CrCl < 30 mL/min) with (n = 6) or without (n = 6) hemodialysis receiving CABENUVA monthly for 6 months followed by every 2 months for 6 months.
33282492|NCT05593406|Experimental|Vibration Group|The intervention-vibration group, in addition to the conventional physical therapy- NDT they received, were also included in mechanical vibration.
33282493|NCT05593406|Active Comparator|Control Group|The Control group received only conventional physical therapy- NDT.
33282494|NCT01001936|Experimental|1|
33282495|NCT03885596|Experimental|CA-008 Cohort 1|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block."
33282496|NCT03885596|Experimental|CA-008 Cohort 2|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
33282497|NCT03885596|Experimental|CA-008 Cohort 3|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
33282498|NCT03885596|Active Comparator|Exparel|"106 mg [8 mL of the 133 mg/10 mL suspension] only~All subjects received monitored anesthesia care (MAC) and a Mayo block."
33282499|NCT05733338|Active Comparator|IH group|Participants will receive 10 times intermittent hypoxia (oxygen concentration: 13%) intervention before exposure to acute hypoxia environment.
33282500|NCT05733338|Sham Comparator|Control group|Participants will receive 10 times sham-hypoxia (oxygen concentration: 21%) intervention in 5 days before exposure to acute hypoxia environment.
33282501|NCT01002092|Active Comparator|Chemotherapy|
33282502|NCT01002092|Experimental|Endostar plus Chemotherapy|
33282503|NCT05569772|Active Comparator|semaglutide|semaglutide SC once weekly, up titration over 2 month period to 1mg/week (0.25mg once weekly, after 4 weeks 0.5mg once weekly and after 8 weeks the maintenance dose of 1mg once weekly), treatment duration of max. 3 years
33282504|NCT05569772|Placebo Comparator|placebo|placebo SC once weekly, the same dose-escalation regimen, using matching injections, treatment duration of max. 3 years
33282505|NCT05567510|Experimental|BMS-986369|
33282506|NCT03999866|Active Comparator|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
33282507|NCT03999866|Active Comparator|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
33282508|NCT03999866|Active Comparator|duration of view|duration of the visualization the vocal cords was recorded
33282509|NCT05547386|Experimental|Observational (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and then undergo a PSMA PET/CT scan throughout the trial.
33282510|NCT05515406|Experimental|Dose Escalation Phase (Part 1)|Up to 4 dose levels will be evaluated. Eligible patients will be assigned to a dose level cohort according to a traditional 3+3 dose escalation design.
33282511|NCT05515406|Experimental|Dose Expansion Phase (Part 2)|Eligible patients will be assigned to the recommended dose level(s) selected from Part 1.
33282512|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
33282513|NCT05733182|Active Comparator|3000K|Participants will receive a reading lamp of colour temperature 3000K.
33282514|NCT05733182|Active Comparator|4500K|Participants will receive a reading lamp of colour temperature 4500K.
33282515|NCT05733182|Active Comparator|6500K|Participants will receive a reading lamp of colour temperature 6500K.
33282516|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
33282517|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
33282518|NCT01002560||Malignant melanoma tumour tissue|
33282519|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
33282520|NCT05733026||1|Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment
33282521|NCT05733026||2|Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment
33282522|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
33282523|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
33282524|NCT05467280|Experimental|Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars, and challenges.
33282525|NCT05467280|No Intervention|Control|They will not carry out any type of intervention, they will only be monitored during the 6 months
33282526|NCT04976660|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
33282527|NCT01002638|Experimental|Occlusive Dressing|
33282528|NCT01002638|Active Comparator|Surgery|
33282529|NCT05732948|Experimental|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells PD-1 silent targeted to PSMA/PSMA administered one day after pretreatment with cyclophosphamide.
33282530|NCT03878108|Active Comparator|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
32778053|NCT05688163|Experimental|programme based on everyday cognition|The experimental group, on the other hand, will carry out a programme based on everyday cognition, i.e. the use of cognitive functions to solve real everyday problems that occur in our daily lives and that allow us to be autonomous in our homes, such as preparing food, taking care of the house, using transport, shopping, using the telephone, medication, financial management and access to information and current affairs. As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above.
32778054|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
32778055|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
32778056|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
32778057|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
32778058|NCT05697679|Experimental|Usual management group|The intervention group is intervened with the RELE-W-1 plan
32778059|NCT05697679|Active Comparator|Goal-attainment-theory-based self-management group|The group is intervened with the RELE-W-2 plan
32778060|NCT05697601||Suspect of Ovarian Cancer|The participant with high suspicion of ovarian cancer and undergo gynaecology and pathology assessment
32778061|NCT05697601||Suspect of Endometrial Cancer|The participant with high suspicion of Endometrial cancer (and or endometrial hyperplasia) and undergo gynaecology and pathology assessment
32778062|NCT05697601||Normal Cohort|The participant with lower suspicion of both types of cancer and undergo gynaecology and pathology assessment
32778063|NCT05697523||Patient group|people with mild RRMS
32778064|NCT05697523||Healthy group|healthy people
32778065|NCT04425499|Placebo Comparator|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
32778066|NCT04425499|Experimental|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
32778067|NCT04425499|Experimental|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
32778068|NCT04425499|Experimental|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
32778069|NCT01905631|No Intervention|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
32778070|NCT01905631|Active Comparator|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
32778071|NCT05679115|Experimental|Lifestyle intervention|Participants get access to the tool and use it regularly
32778072|NCT05679115|No Intervention|Controls on standard care|Participants who get randomized to control cannot access the tool.
32778073|NCT05380219|Experimental|dual task strength training|The participants of this group will perform their training following the dual task described.
32778074|NCT05380219|Active Comparator|strength training|The participants of this group will perform the work of strengthening the upper limb in a conventional way.
32778075|NCT05316571|Active Comparator|One 5-Minute Walking Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
32936832|NCT04336046|Experimental|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
32936833|NCT05348239|Experimental|Oral Chlorophyllin arm|Participants will receive oral Sodium Copper Chlorophyllin at a dose of 750mg once daily (OD) on an empty stomach.
33282531|NCT03878108|Active Comparator|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
33282532|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
33282533|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
33282534|NCT01002872|Active Comparator|Lanthanum Carbonate|
32778076|NCT05316571|Active Comparator|One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
33282535|NCT01002872|Placebo Comparator|Placebo|
33282536|NCT05388812|Experimental|Individual Placement and Support|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
32936834|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
32936835|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
33102326|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33282537|NCT05388812|Active Comparator|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
33282538|NCT05386238|Experimental|Tailored treatment|6-months of group-based behavioral weight loss treatment tailored to men working in blue-collar occupations.
33282539|NCT05386238|Active Comparator|Standard of care treatment|6-months of group-based behavioral weight loss treatment following the Diabetes Prevention Program Group Lifestyle balance.
33282540|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
33282541|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
33282542|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
33282543|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
33282544|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
33282545|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
33282546|NCT05021900|Experimental|Tenalisib 800 mg BID|
33282547|NCT05021900|Experimental|Tenalisib 1200 mg BID|
33282548|NCT05305586|Active Comparator|Packable Composite|Packable composite material was selected for splinting of luxated teeth
33282549|NCT05305586|Active Comparator|Bulkfill composite|Bulkfill composite material was selected for the splinting of luxated teeth
33282550|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
33282551|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
33282552|NCT04928456|Experimental|OMT Intervention Arm|"OMT will include:~Myofascial release of the thoracic inlet: gentle pressure applied to shoulders and neck to move the tissue in different directions with a gentle motion.~Pectoral traction: The armpit will be contacted with the finger pads of the doctor and each side will be gently grasped and have a slow pulling force applied towards the shoulders.~Diaphragm release with MFR: The doctor will touch below the ribs on each side and will apply gentle pressure and move the tissue from side to side.~Splenic pump: below the ribs on the left hand-side, the doctor will apply pressure and release pressure several times to create a vibration over the area just below the ribs.~Thoracic pump: The doctor will place their hands over the chest wall on each side and will apply pressure and release pressure several times to generate a pumping action of about 100 times in one minute.~Treatment will last 5 minutes with each technique lasting 1 minute."
33282553|NCT04928456|No Intervention|Control|Participants in the control group will undergo the same assessments as the OMT intervention arm and will receive their vaccinations, but will not receive any OMT.
33282554|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
33282555|NCT05730920|Active Comparator|Intravenous (IV) Methadone|Subjects will receive IV methadone 0.2 mg/kg (maximum dose 20mg) via an infusion pump over 15 minutes while undergoing continuous monitoring. Additional IV methadone may be given during the case per the anesthesiologist's discretion, but the total dose may not exceed 20mg.
33282556|NCT05730920|Experimental|Liposomal Bupivacaine (LB, Exparel)|Subjects will receive four-point ESPB with an admixture of LB and 0.25% bupivacaine hydrochloride. The total LB dose will be 4mg/kg, max dose of 266mg, while the total dose of bupivacaine hydrochloride will be 2mg/kg.
33282557|NCT03999008|Active Comparator|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:~< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to <15 kg: 500 mcg BID in 5 ml apple sauce >15 kg: 1000 mcg BID in 5 ml apple sauce"
33282558|NCT03999008|Placebo Comparator|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
33282559|NCT05140148|Placebo Comparator|Placebo|placebo pill, twice daily
33282560|NCT05140148|Active Comparator|Amantadine|100 mg amantadine twice daily, or if 65 years or older once daily
33282561|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
33282562|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
33282563|NCT01003652||Harmonic Focus /conventional haemostasis|
33282564|NCT01003652||Harmonic Focus|
33282565|NCT01003652||new surgical device|
32936836|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
32936837|NCT05455580|Experimental|N-TORM Intervention|This is a non-randomized, non-blinded, quasi-experimental, pre- and post-test phase I feasibility design pilot study.
32936838|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
32936839|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
32936840|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
32936841|NCT05348161|Other|Anti-HER2 & Immunotherapy|Advancd gastric cancer patients received anti-HER2 & immunotherapy ± chemotherapy
33282566|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
33282567|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
33282568|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
32936842|NCT05348161|Other|Anti-HER2|Advancd gastric cancer patients received anti-HER2 ± chemotherapy.
32936843|NCT05349578|Other|Tissue|conventional RUT using biopsied tissue
33282569|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
33282570|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
33282571|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
33282572|NCT04932746|Experimental|The dexmedetomidine group:|"An initial dose of 1 mcg / kg 1 dexmedetomidine will be given 10 minutes after the start of anesthesia infusion within 10 minutes, after which the dexmedetomidine infusion is maintained at a dose of 0.4 mcg / kg / hour.~The injection will be stopped before the skin is closed."
33282573|NCT04932746|Experimental|The Placebo group (the control group):|After the same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol.
32936844|NCT05349578|Experimental|Swab|RUT using swab
33282574|NCT04929158|Experimental|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Intravascular ultrasound guided surgery
33282575|NCT04929158|No Intervention|Angiography-Guided Primary Percutaneous Intervention (PCI)|Angiography-Guided guided surgery
33282576|NCT05729204|Experimental|Hypertonic seawater group|Patients that will receive nasal irrigations with hypertonic (2.3% NaCl) seawater solution containing brown algae (Undaria pinnatifida) and blue-green algae (Spirulina platensis) as well as essential oils of Eucalyptus globulus and Mentha spicata, and Thymus vulgaris extract (Sinomarin® Plus Algae Cold & Flu Relief, Gerolymatos International SA, Krioneri, Greece)
33282577|NCT05729204|No Intervention|control group|Patients that will not perform nasal irrigations
33282578|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
33282579|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
33282580|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
33282581|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
33282582|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
33282583|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
33282584|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
33282585|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
33282586|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
33282587|NCT00883025||1|OSAS patients
32936845|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
32936846|NCT04335734|Active Comparator|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
32936847|NCT04335734|Active Comparator|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
32936848|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
33282588|NCT00883025||2|no OSAS Patient
33282589|NCT04731779|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
33282590|NCT04731779|Experimental|25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
33282591|NCT04731779|Experimental|50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
33282592|NCT04731779|Experimental|200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
33282593|NCT00880841||no treatment|phase 1a study for healthy normals
33282594|NCT04503863|Experimental|Experimental 1|Single administration of middle dose NPC-22
33282595|NCT04503863|Experimental|Experimental 2|Single administration of high dose NPC-22
33282596|NCT04503863|Placebo Comparator|Experimental 3|Single administration of placebo dose NPC-22
32936849|NCT04114604||Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher).
32936850|NCT04337593|Experimental|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
33282597|NCT00883259|Experimental|Experimental|Metformin treatment
33282598|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
32936851|NCT04790864|Experimental|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|
33282599|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
33282600|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
33282601|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
33282602|NCT00885599|Placebo Comparator|placebo|colored water
33282603|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
33282604|NCT04366115|Active Comparator|AVM0703 COVID-19 ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
33282605|NCT04366115|Placebo Comparator|Placebo COVID-19 ARDS - placebo|Matching placebo
33282606|NCT04366115|Active Comparator|AVM0703 Influenza ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
33282607|NCT04366115|Placebo Comparator|AVM0703 Influenza ARDS - placebo|Matching placebo
33282608|NCT04712747||Cases - patients with stroke|Ophthalmological examinations : At the inclusion visit and 3 months after their stroke Blood pressure measurement at rest : At the inclusion visit
33282609|NCT04712747||Controls - Individuals with no history of stroke|Ophthalmological examinations : At the inclusion visit Blood pressure measurement at rest : At the inclusion visit
33282610|NCT04038125|Other|Ozurdex Implant|Intravitreal injection of Ozurdex implant
33282611|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
33282612|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
33282613|NCT00885833|Experimental|Fludarabine|
33282614|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
33282615|NCT04038749|Experimental|Pharmaceutical method- Bromocriptine|
32936852|NCT04790864|Active Comparator|Online large-group one-session treatment with post-treatment control exercise|
32936853|NCT04737902||VATS with ESPB|Study subjects underwent anaesthesia and VATS without a change in their routine care. At the end of the surgery, an erector spinae plane block was performed for acute pain control following our institutional protocol for perioperative care.
32936854|NCT04336813|Experimental|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
32936855|NCT04336813|Active Comparator|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
33282616|NCT04038749|Experimental|Pharmaceutical method- Cabergoline|
33282617|NCT04038749|Other|Without medications that inhibit lactation|
33282618|NCT00883571|Active Comparator|house advancement flap|house advancement flap
33282619|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
33282620|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
33282621|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
33282622|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
33282623|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
33282624|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
33282625|NCT00881309|Experimental|immunosuppressor|
33282626|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
33282627|NCT00883649|Placebo Comparator|1|
33282628|NCT00883649|Active Comparator|2|
33282629|NCT00883727|Experimental|stem cells|
33282630|NCT00883727|Placebo Comparator|Placebo|
33282631|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
33282632|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
33282633|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
33282634|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
33282635|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
33083141|NCT04595539|Experimental|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
33083142|NCT04595539|Experimental|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
33282636|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
33282637|NCT00883961|Experimental|Supervised exercise|
33282638|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
33282639|NCT00885989|Experimental|1|
33282640|NCT00885989|Placebo Comparator|2|
33282641|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
33282642|NCT00886067|Experimental|AZD1446|Single oral administration
33282643|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
33282644|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
33282645|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
33282646|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
33282647|NCT04638569|Active Comparator|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
33282648|NCT04638569|Active Comparator|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
33282649|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
33282650|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
33282651|NCT04124861|Experimental|Drug free|"Arm A: Drug free Glucocorticoid（GC）is tapered and stopped in 8 weeks(GCs at a dose of ≤ 2.5 mg of prednisone or equivalent for treatment of adrenal insufficiency) .~Immunosuppressant is also tapered and discontinues in 8 weeks."
33282652|NCT04124861|Experimental|IS monotherapy|Arm B: Immunosuppressant only Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(<= 1g/d) or Leflunomide (<=20mg/d) or Methotrexate (<=15mg/w) or Azathioprine (<=100mg/d)
33282653|NCT04124861|Experimental|GC combined with IS|Arm C: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
33282654|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
33282655|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
33282656|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
33282657|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
33282658|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
33282659|NCT04015115|Experimental|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
33282660|NCT00881933|Experimental|Fludarabine|
33282661|NCT03940547|Experimental|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
33282662|NCT03940547|Active Comparator|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
33282663|NCT04459637||Asymptomatic group|Definition of asymptomatic disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
33282664|NCT04459637||Mild group|Definition of mild disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
33282665|NCT04459637||general-type group|Definition of general-type disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
32778077|NCT05316571|Active Comparator|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout and one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
33282666|NCT04459637||severe group|Definition of severe disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
33282667|NCT04459637||critical group|Definition of critical disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
32778078|NCT05316571|Active Comparator|Uninterrupted Sitting|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~This uninterrupted sedentary bout will serve as a control. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
32936856|NCT04707638||Parkinson's disease or dystonia patients|Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
32936857|NCT04337671|Experimental|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
33282668|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
33282669|NCT00884195|Experimental|1|Gratitude Journaling
33282670|NCT00884195|Placebo Comparator|2|Neutral Journaling
33282671|NCT00886223|Experimental|1|
33282672|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
33282673|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
33282674|NCT02543645|Experimental|Varlilumab and Atezolizumab|
33282675|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
33282676|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
33282677|NCT02543489|Other|Flex IM Rod|
33282678|NCT00882167||1|Patients with laparotomy in history
33282679|NCT00882245|Placebo Comparator|Vehicle ointment|
33282680|NCT00882245|Experimental|SRD441 Ointment|
33282681|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
33282682|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
33282683|NCT00882323|Experimental|Fludarabine|
33282684|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
33282685|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
33282686|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
33282687|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
33282688|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
33282689|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
33282690|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
33282691|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
33282692|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
33282693|NCT04038671|Experimental|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
33282694|NCT04038671|Active Comparator|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
33282695|NCT04038671|Active Comparator|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
33282696|NCT02543177|Experimental|group A|direct coronary angiography
33282697|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
33282698|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
33282699|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
33282700|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
33282701|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
33282702|NCT00882635|Experimental|Enoxaparin|
33282703|NCT00882635|Active Comparator|Unfractionated heparin|
33282704|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
33282705|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
33282706|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
33282707|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
33282708|NCT00886847|Experimental|EBUS FNA vs FNC|
33282709|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
33083143|NCT04595539|Experimental|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
33083144|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
33402047|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
33282710|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
33282711|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
32778079|NCT05591443||Heart failure patients|Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.
32778080|NCT05591365|Experimental|Structured In-patient and Home plan|Structured In-patient and Home plan
32778081|NCT05591365|Placebo Comparator|Conventional therapy|Conventional protocol as per guidelines
32778082|NCT05535205|Active Comparator|Face-to-face preoperative assessment group|The face-to-face screening consist of two 20-minute consecutive consultations with a nurse and subsequently an anesthesiologist or PA. The nurse obtains basic patient health information, provides information on the upcoming hospital admission, and gives advice in lifestyle procedures around the surgery. The physician assesses the patient's health status based on co-morbidities, medication use, previous surgery, and lifestyle habits to predict preoperative risks and determine the optimal anesthetic technique. Additional diagnostics, such as blood tests or electrocardiogram, can be ordered and optional anesthetic techniques will subsequently be presented and discussed with the patient, after which informed consent will be obtained.
32778083|NCT05535205|Active Comparator|Digital preoperative assessment group|Patients in the digital preoperative assessment group are asked to complete an electronic screening questionnaire through the digital patient portal of the hospital. The questionnaire was designed by the anesthetic department physicians and consisted of 50 health related questions. Through the same digital patient portal, patients have access to animated instructional videos that provides information on anesthetic techniques, preoperative lifestyle advises and procedures around the upcoming surgery. The videos can be reviewed at any desired moment in time. A telephone appointment is scheduled solemnly to decide on the anesthesia technique and obtain informed consent since this process was technically not available in the electronic portal. Physicians were thoroughly instructed not to provide more information or answer questions. Patients are instructed to complete the electronic screening questionnaire and assess the animated videos before the scheduled appointment with the physician.
32778084|NCT05275075||Pancreatic Cancer Cohort|All eligible adenocarcinoma pancreatic cancer patients with operable cancer.
32778085|NCT05679037|Placebo Comparator|Placebo group who received insulin only plus placebo tablets|(Placebo group; n=22) which will receive insulin plus placebo tablets once daily for 6 months.
32778086|NCT05679037|Active Comparator|ALA group who received Alpha lipoic acid plus insulin|(alpha-lipoic acid group; n=22) which will receive insulin plus ALA 600mg once daily for 6 months.
32778087|NCT05588401|Experimental|GenPHSat safety injection and GenPHSat efficacy injection|Initial intervention with six injections into the left biceps. A second intervention with 36 injections into the right biceps.
32778088|NCT05587465|Experimental|Treatment|Lobster device implantation
32778089|NCT05243329|Experimental|Psilocybin treatment for treatment-resistant PTSD|"Experimental Treatment:~Experimental: Psilocybin~10mg (low dose) on Day 7~25mg (high dose) on Day 14~Treatment Description:~Drug: Psilocybin drug product suspension~Psilocybin is manufactured as a bulk API powder. The psilocybin drug product suspension is prepared by a compounding pharmacist at the clinic site. The psilocybin drug product suspension will be mixed in a glass with water to produce the psilocybin solution for oral consumption. Subjects will be instructed to orally consume the study medication in the glass in its entirety.~Psilocybin will be administered in the following doses and at the following time points for this study:~1 mL of 10mg/mL (low dose) on Day 7 (10 mg)~2.5 mL of 10 mg/mL (high dose) on Day 14 (25 mg)"
32778090|NCT05573737|Experimental|Group Receiving Umbilical Cord Training|Oral umbilical care training will be given to the primiparous mothers who gave birth on odd days of the week and met the research criteria, and the training brochure will be printed out and given to the mothers. The training will be given face-to-face during the postpartum period when the mother is stabilized. In order to increase the effectiveness of the training, the content of the training will be reinforced by making mutual questions and answers.
32778091|NCT05573737|No Intervention|Group Without Umbilical Cord Training|The routine operation of the clinic will be carried out without any intervention for primiparous mothers who gave birth on even days of the week and met the research criteria.
32778092|NCT05695729|Experimental|PLYOMETRIC EXERCISE PROGRAM GROUP|"The Plyometric exercise group will receive 8 weeks of upper body plyometric exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
33083147|NCT04595695|Experimental|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
33282712|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
33282713|NCT00529568|Experimental|eltrombopag|active treatment arm
33282714|NCT00529568|Placebo Comparator|placebo|placebo control arm
33282715|NCT00888719|Experimental|CWP-0403 50mg|
33083148|NCT04595695|Active Comparator|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
33083149|NCT04595578|Active Comparator|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
33102327|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33102328|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33102329|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33282716|NCT00888719|Experimental|CWP-0403 100mg|
33282717|NCT00888719|Placebo Comparator|placebo|
33282718|NCT04037111|Experimental|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
33282719|NCT04037111|Sham Comparator|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
33282720|NCT04037111|Other|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
33282721|NCT00886925|Active Comparator|Albumin|
33282722|NCT00886925|Placebo Comparator|Saline|
33282723|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
33282724|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
33282725|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
33282726|NCT00888797|Placebo Comparator|2|Placebo
33282727|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
33282728|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
33282729|NCT00884663|Experimental|1 Candesartan|
33282730|NCT00884663|Active Comparator|2 propranolol|
33282731|NCT00884663|Placebo Comparator|3 Placebo|
33282732|NCT04867616|Experimental|Dose level 1 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 1) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
33282733|NCT04867616|Experimental|Dose level 2 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 2) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
33282734|NCT04867616|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive Placebo to maintain the blinding during the Double-blind Treatment Period and will re-randomized during the Open-label Extension Period to receive pre-specified doses of bepranemab.
33282735|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
33282736|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
33282737|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
33282738|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
33282739|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
33282740|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
33282741|NCT03998696|Active Comparator|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
33282742|NCT03998696|Experimental|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
33282743|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
33282744|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
33282745|NCT04867460|Experimental|Ultrasound guided venous access|Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
33282746|NCT04867460|No Intervention|Standard of care|Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.
33282747|NCT00889031||No Treatment|
33282748|NCT05710952|Other|Braces|Patients will receive an orthodontic treatment with fixed braces for 12 to 24 months
33282749|NCT04017923||20-29 age group|
33282750|NCT04017923||30-39 age group|
33282751|NCT04017923||40-64 age group|
33282752|NCT04017923||65 and older age group|
33083150|NCT04595578|Sham Comparator|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
33083151|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
33083152|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
33083153|NCT04595461|Placebo Comparator|Control|Standard of care patient education with verbal and written education
33083154|NCT04595461|Experimental|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
33083155|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
33083156|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) > 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
33083157|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
33083158|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
33083159|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
33083160|NCT04635683|Experimental|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
33083161|NCT04595383|No Intervention|Control|Usual care and usual communication with health professional
33083162|NCT04595383|Experimental|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
33083163|NCT04595071|No Intervention|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
33083164|NCT04595071|Experimental|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
33083165|NCT04595344|Active Comparator|Diagnostic cystoscopy , Binaural beat group|patients listened to binaural beats
33282753|NCT05019950|Experimental|LABP-104 250mg|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
33282754|NCT05019950|Placebo Comparator|Placebo|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
33282755|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
33282756|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
33083166|NCT04595344|Active Comparator|Diagnostic cystoscopy, Classical music group|patients listened to classical music
33083167|NCT04595344|Placebo Comparator|Diagnostic cystoscopy , Placebo group|patients no audio only headphones
33282757|NCT04847882||Cystic fibrosis, children from 6 to 17.|This group is made up of children with cystic fibrosis followed at the Strasbourg pediatrics CRCM, aged from 6 to 17 years old, not hospitalized at the time of inclusion, without any other criterion prejudging the seriousness of the pathology.
33083168|NCT04595344|Active Comparator|Ureteral stent removal, Binaural beat group|patients listened to binaural beats
33083169|NCT04595344|Active Comparator|Ureteral stent removal ,Classical music group|patients listened to classical music
33083170|NCT04595344|Placebo Comparator|Ureteral stent removal, Placebo group|patients no audio only headphones
33282758|NCT04847882||Control group, children from 6 to 17.|"This group is the control group. It is made up of children consulting in pediatric surgical emergencies, aged 6 to 17 years. Surgical emergencies were chosen because it is a point of consultation, rather accidental, where sleep has often not been impacted in the previous months and where the frequency of chronic pathology is not higher than the general population.~An other criteria is that these children are accompanied by at least one of their parents and that they can read and understand French well."
33282759|NCT05124080|Experimental|Deucravacitinib 6 mg Daily|All participants will receive 6 mg of deucravacitinib daily.
33282760|NCT05120648||Immediate enrollment|
33282761|NCT05120648||Wait-list controls|
33282762|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
33083171|NCT00403091|Experimental|Intervention|
33083172|NCT00403091|Active Comparator|Control|
33083173|NCT00566605|Active Comparator|Group 1|
33282763|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
33282764|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
33282765|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
33282766|NCT05695352|Placebo Comparator|Placebo Comparator in Normal Ovulatory Women|The two arm placebo comparator study will use each participant as her own control with a placebo arm in the first menstrual cycle consisting of two placebo tablets taken at the time of the ovarian follicle measuring 17 mm in diameter and a second dose of two tablets 48 hours later.
33282767|NCT05695352|Active Comparator|Active intervention in Normal Ovulatory Women|The second menstrual cycle for each participant is an active intervention arm. Levonorgestrel 1.5 mg plus meloxicam 15 mg will be taken when the ovarian follicle reaches 17 mm in largest diameter. The two medications will be repeated 48 hours later.
33282768|NCT04901546|Experimental|Infants with Esophageal Atresia|Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.
33282769|NCT04901546|No Intervention|Comparison Infants without Esophageal Atresia|Infants do not have EA and thus can swallow their own saliva.
33282770|NCT00889109||1|Open Capsular Shift
33282771|NCT00889109||2|Arthroscopic Bankart Repair
33282772|NCT00889109||3|Healthy controls
33282773|NCT04895306|Experimental|Testosterone|Weekly intramuscular administration at a dose of 3 mg
33282774|NCT04895306|Placebo Comparator|Placebo|Weekly intramuscular administration of placebo
33282775|NCT02542241|Experimental|Sodium Chloride [3%]|
33282776|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
33282777|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF/PLIF stabilized with pedicle screws and meet all of the eligibility criteria.
33282778|NCT04037891|Experimental|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
33282779|NCT04037891|Placebo Comparator|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
33282780|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
33282781|NCT05692934|Experimental|HR20031 FDC 10/100/1000 mg in the fast state|
33282782|NCT05692934|Experimental|HR20031 FDC 10/100/1000 mg in the fed state|
33282783|NCT05692934|Experimental|HR20031 FDC 5/50/750 mg*2 in the fast state|
33282784|NCT05692934|Experimental|HR20031 FDC 5/50/750 mg*2 in the fed state|
33282785|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
33083174|NCT00566605|Active Comparator|Group 2|
33083175|NCT04594954|Experimental|Diet + Exercise + FMT|
33083176|NCT04594954|Active Comparator|Diet+Exercise|
33083177|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
33083178|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
33282786|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
33282787|NCT05007158||pocket infection|Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.
33083179|NCT04626674|Experimental|SRP-9001|Participants will receive a single intravenous (IV) infusion of SRP-9001 on Day 1.
33083180|NCT04594876|Other|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
33083181|NCT04594876|Other|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
32778093|NCT05695729|Active Comparator|CONVENTIONAL EXERCISE PROGRAM GROUP|"The conventional group will receive 8 weeks of upper body strength exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
33282788|NCT05007158||CIED systemic infection|Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.
33282789|NCT05007158||Lead-associated infective endocarditis|Patients with infective endocarditis, diagnosed according to modified Duke criteria
33282790|NCT05007158||control group|CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls
33282791|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
33282792|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
33282793|NCT00889343|Experimental|1|
33282794|NCT00889343|Placebo Comparator|2|
33282795|NCT05014568|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
33282796|NCT05014568|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
33282797|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
32778094|NCT05197621||Vaccine Arm|Pregnant women who are planning to receive an mRNA COVID vaccine (Pfizer of Moderna), and/or a third booster vaccine, who consent to maternal blood collection before receipt of the vaccine and at 6 time points after receiving the vaccine and/or booster.
32778095|NCT05197621||Sample Collection at Delivery Arm|Pregnant patients who have tested positive for COVID during their pregnancy or have a positive COVID test at the time of admission to Labor & Delivery, who consent to collection of maternal blood, cord blood, placenta, and breast milk samples, as well as neonatal blood and stool samples. Patients testing negative for COVID at the time of admission to Labor & Delivery can be enrolled in the study as controls.
33282798|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
33282799|NCT04974398|Experimental|Group A|Group A (study group): Penpulimab plus cisplatin and gemcitabine
33282800|NCT04974398|Placebo Comparator|Group B|Group B (control group): Placebo plus cisplatin and gemcitabine
33282801|NCT05658458|Experimental|Vericiguat therapy|Adult participants with chronic HFrEF who are naïve to vericiguat and will be prescribed vericiguat as per local label by their treating physician (cardiologists).
33282802|NCT05229302|Experimental|Intervention|Secondary students with suicidal ideation participating in the intervention (Reframe-IT). The students will be referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment
33282803|NCT05229302|Active Comparator|Control|Secondary students referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment.
33282804|NCT04846946|No Intervention|Control|Time attention control condition.
33083182|NCT00249405|Experimental|1|citalopram
33083183|NCT00249405|Placebo Comparator|2|Placebo
33282805|NCT04846946|Experimental|Intervention, Module 1 - Knowledge|20-minute module that aims to improve HIV prevention knowledge.
33282806|NCT04846946|Experimental|Intervention, Module 1 - Stigma|20-minute module that aims to reduce SGM- and HIV- related stigma.
33282807|NCT04846946|Experimental|Intervention, Module 1 - Prevention|20-minute module that aims to promote HIV prevention strategies including testing and PrEP.
33282808|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
33282809|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
33083184|NCT04625660|Experimental|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
33083185|NCT04594447|Other|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
32778096|NCT05678959|Experimental|Ligelizumab 120 mg|120 mg
32778097|NCT05678959|Experimental|Ligelizumab 240 mg|240 mg
32778098|NCT05678881|Experimental|High dose RLS103|8 mg CBD inhaled dry powder
32778099|NCT05678881|Placebo Comparator|Placebo|placebo inhaled dry powder
33083186|NCT04594447|Other|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
33083187|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
33083188|NCT04594330|Active Comparator|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
33083189|NCT04594330|Placebo Comparator|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
33083190|NCT04618133|Experimental|Early time-restricted eating|Duration: 12 weeks
33083191|NCT04618133|Experimental|Late time-restricted eating|Duration: 12 weeks
33083192|NCT04618133|Active Comparator|Active control|Duration: 12 weeks
33083193|NCT04594057|Active Comparator|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
32778100|NCT05678881|Experimental|Low dose RLS103|4 mg CBD inhaled dry powder (open label)
33083194|NCT04594057|Experimental|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
33282810|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
33282811|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
33282812|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
33282813|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
33282814|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
33083195|NCT04594135|Experimental|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
33282815|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
33282816|NCT04702880|Experimental|Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012|
33282817|NCT04702880|Experimental|Arm B: Carboplatin + Etoposide + Nivolumab|
33282818|NCT00889499|Placebo Comparator|Crossover study|Crossover study
33282819|NCT00889499|Placebo Comparator|2|Crossover Study
33282820|NCT00889499|Placebo Comparator|3|Crossover Study
33282821|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
33282822|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
33083196|NCT00253110|Active Comparator|risperidone|
33282823|NCT05002946|Experimental|A: SP-104 Fasting|Oral administration of SP-104 under fasting conditions
33282824|NCT05002946|Experimental|B: SP-104 Under Fed Conditions|Oral administration of SP-104 under fed conditions
33083197|NCT00253110|Active Comparator|haloperidol|
33083198|NCT04594252|Experimental|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
32778101|NCT04134091|Experimental|Treatment A|LPCN 1144 Formulation A
32778102|NCT04134091|Experimental|Treatment B|LPCN 1144 Formulation B
32778103|NCT04134091|Placebo Comparator|Treatment C|Placebo
32778104|NCT05672407|Experimental|Tranexamic Acid Group|Participants undergoing standard of care periorbital procedures will be randomized to receive tranexamic acid with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
32778105|NCT05672407|Placebo Comparator|Placebo Group|Participants undergoing standard of care periorbital procedures will be randomized to receive balanced salt solution with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
33083199|NCT04594174||Responders|
33083200|NCT04594174||Non responders|
33083201|NCT04598672|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
33083202|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
33083203|NCT00566683|Active Comparator|2|Propofol- Alfentanil
33083204|NCT04593589|Experimental|Transplantation|Submandibular Gland Stem Cell Transplantation
33083205|NCT04593706|Active Comparator|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
33083206|NCT04593706|Active Comparator|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
33083207|NCT04593667|Other|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
33083208|NCT04593667|Other|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
33282825|NCT05002946|Active Comparator|Naltrexone Hydrochloride Tablets Fasting|Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting
33282826|NCT04641338|Experimental|Intervention group|
33282827|NCT04641338|Active Comparator|Control group|
33282828|NCT04635098|Experimental|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am
33282829|NCT04635098|Placebo Comparator|saline|the same rate as dexmedetomidine
33282830|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
33282831|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
33282832|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
32778106|NCT05678725|Active Comparator|Transcranial Alternating Current Stimulation|the alternating current stimulation lasted 20 mins and was delivered at 2mA (peak to peak) at 20Hz during the Simple Reaction Task(SRT), targeting the primary motor cortex. EEG should be acquired before and after the stimulation session.
32778107|NCT05678725|Active Comparator|Transcranial Direct Current Stimulation|the direct current stimulation lasted 20 minutes and was delivered at 2mA during the SRT, targeting at the primary motor cortex. EEG should be acquired before and after the stimulation session.
32778108|NCT05678725|Sham Comparator|Sham Group with No Actual Stimulation|the procedure of this protocol lasted 20 minutes and was delivered at 0mA during the SRT. EEG should be acquired before and after the stimulation session.
32778109|NCT05159869|Experimental|Experimental|After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
32778110|NCT05159869|Active Comparator|Wait-List Control|"After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., mild dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time."
32778111|NCT05678647|Experimental|Oral sucrosomial Iron (SiderAl Forte®)|Oral sucrosomial Iron (SiderAl Forte®) is given to blood donors after blood donation
32778112|NCT05678647|Active Comparator|Oral iron sulphate (Duroferon®)|Oral iron sulphate (Duroferon®) is given to blood donors after blood donation
32778113|NCT05678569||High Risk Group|Group identified by machine learning model as being at high risk of developing osteoporosis.
32778114|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
32778115|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
32936858|NCT04337671|No Intervention|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
33282833|NCT03998852|Experimental|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
32778116|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
32778117|NCT05695495|Experimental|Randomized|Subjects will be administered intravenous DMT in 4 different bolus doses or placebo in randomized, counter-balanced order. The bolus applications will be separated by one hour.
32778118|NCT05695495|Experimental|Dose ecalation|Subjects will be administered a placebo and a maximum of 5 DMT bolus doses in an escalating dose order. The bolus applications will be separated by one hour.
32778119|NCT05678491|Experimental|Endoscopic mucosal band ligation|All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference.
32778120|NCT05461261|Experimental|Docetaxel plus platinum|Docetaxel combined with platinum-based drugs will be applied every 3 weeks for 6 cycles.
32778121|NCT05461261|Active Comparator|Docetaxel alone|Docetaxel alone will be applied every 3 weeks for 6 cycles.
32778122|NCT05456035|Experimental|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy with depressed adolescents using modules from the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, therapists will teach teens explicitly about theory of mind and social perspective taking during each session and will use examples from the teen's own life to help them learn the skills.
32936859|NCT04337047||Vik sein|Vik sein users
32936860|NCT04337047||Vik asthme|Vik asthme users
32936861|NCT04337047||Vik migraine|Vik migraine users
32936862|NCT04337047||Vik depression|Vik depression users
32936863|NCT05339581|Experimental|IMRT combined with PD-1 Blockade and Lenvatinib|"Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.~Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk."
32936864|NCT05339581|Active Comparator|PD-1 Blockade and Lenvatinib|Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
32936865|NCT04766918|Experimental|High molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with high molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
32936866|NCT04766918|Active Comparator|Low molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with low molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
32778123|NCT05456035|Active Comparator|Cognitive behavioral therapy (CBT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. Therapists will conduct individual therapy sessions with depressed adolescents using modules from the Coping with Stress manual. Social cognitive training will not be provided to teens in this condition.
32778124|NCT05453617|Experimental|The TRE group|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
32778125|NCT05453617|Experimental|The 5:2 diet group|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
32778126|NCT05453617|No Intervention|Control|Participants in the control group will receive a general lifestyle counseling.
32778127|NCT05410561|Experimental|TeleTx intervention|The evidence-based manualized psychosocial program is via telehealth and uses adaptations of cognitive behavioral therapy and motivational interviewing.
32778128|NCT05410561|Active Comparator|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation about AUD and resources for treatment.
32778129|NCT05407051|Active Comparator|Treatment as Usual|In the Treatment as Usual condition, parents will simply be given a list of mental health referrals and crisis numbers.
32778130|NCT05407051|Experimental|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
32778131|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
32778132|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
33282834|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
33282835|NCT04063748|Other|Placebo|CI-users: Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, and the fifth session is an in-training test session (DTT and phoneme discrimination).
33282836|NCT04063748|Placebo Comparator|Passive Control|HA users: Participants do not receive an intervention.
33402048|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
32778133|NCT05383729|Experimental|new training|"In this new learning-curve-based training modality, after participants complete 16 procedures on a high-fidelity simulator, an individual learning curve will be generated using the previously validated equation:~ln⁡(γ)=γ_0 e^(-kn)+γ_∞ where γ is procedure time, n is previous experiences.[2] Other parameters and their 95% Confidence Interval (CI) can be obtained after curve fitting. And e^(γ_∞ ) is the asymptote of this curve. Then the trainees will continue the training. If the following procedure time falls into the 95% CI of the asymptote for three consecutive times,[6] the individual training goal is considered achieved.[2]"
32936867|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
32936868|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
32936869|NCT05441774|Sham Comparator|Sham stimulation plus sham imagery|Double sham group: Stimulator electrodes will be applied to earlobe (sham stimulation); imagery task will involve a 'draw-a-face-in-imagination' (sham imagery) task.
32936870|NCT05441774|Other|Active stimulation plus sham imagery|Single (imagery) sham group: Stimulator electrodes will be applied to the tragus (active stimulation); 'draw-a-face-in-imagination' (sham imagery) task.
32936871|NCT05441774|Other|Sham stimulation plus active self-compassion imagery|Single (stimulation) sham group: earlobe (sham) stimulation; imagery task will involve directing compassion to the self (self-compassion, active imagery).
32936872|NCT05441774|Active Comparator|Active stimulation plus active self-compassion imagery|Double active group: tragus (active) stimulation; self-compassion (active imagery)
32936873|NCT04064684|Experimental|Budesonide administered by nebulizer|
32936874|NCT04064684|Placebo Comparator|Placebo administered by nebulizer|
32936877|NCT05334199|Experimental|Biodegradable stent treatment group|Biodegradable stent treatment group
32936878|NCT05325385||OHCA attended by ambulance service|All adults attended by ambulance service where time of collapse and initial rhythm is known.
32778134|NCT05383729|Active Comparator|reference training|In this reference fixed-training-time training modality, participants will receive training with a high-fidelity simulator for 1h.
32778135|NCT05339815||36 mm CoCrMo glenospheres|
32778136|NCT05339815||40 mm cross-linked UHMWPE glenospheres|
32936879|NCT04715906|Experimental|UP-Caregiver Group|Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
33083209|NCT04593667|Other|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
33083210|NCT04587830|Experimental|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection)~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
33083211|NCT04593355||HCV|
33402049|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
32778137|NCT05285761|Experimental|paper brochure + smartphone application|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. They will also receive the new recommendations relating to complementary feeding through an educational device in the form of a smartphone application. This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd month until the 36th month of the child. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
32778138|NCT05285761|Active Comparator|paper brochure|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
32778139|NCT05204875||Functional lung imaging|Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
32778140|NCT05177263|Placebo Comparator|Supportive Positions+Sterile Water+Non-Nutritive Sucking|The enrolled premature infants will be administered 1ml of the sterile water a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of sterile water a second time.
32778141|NCT05177263|Active Comparator|Supportive Positions+10% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 10% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 10% oral dextrose solution a second time.~(%10 oral dextrose solution: osmolarity= 550 mOsm/L, pH= 3.5-6.5, calorie=400 kcal/L)"
32778142|NCT05177263|Active Comparator|Supportive Positions+20% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 20% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 20% oral dextrose solution a second time.~(%20 oral dextrose solution: osmolarity= 1010 mOsm/L, pH= 3.2-6.5, calorie= 680 kcal/L)"
32778143|NCT05177263|Active Comparator|Supportive Positions+30% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 30% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 30% oral dextrose solution a second time.~(%30 oral dextrose solution: osmolarity= 1515 mOsm/L, pH= 3.2-6.5, calorie= 1020 kcal/L)"
32778144|NCT05678413|Active Comparator|DVIU with paclitaxel|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
32778145|NCT05678413|Active Comparator|DVIU|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue.
32778146|NCT05123365|Experimental|Dose Level 1 (DL1)|"Patients take N-Acetylcysteince 600 mg orally twice daily.~This is the starting dose level for the study."
32778147|NCT05123365|Experimental|Dose Level 2 (DL2)|"Patients take N-Acetylcysteince 1200 mg orally twice daily.~If DL1 is well tolerated, the next cohort will progress to this dose level."
32778148|NCT05123365|Experimental|Dose Level 3 (DL3)|"Patients take N-Acetylcysteince 1800 mg orally twice daily.~If DL2 is well tolerated, the next cohort will progress to this dose level."
32778149|NCT05678335|Placebo Comparator|Hydroxychloroquine monotherapy|Oral hydroxychloroquine 200mg twice daily for 12 weeks.
32778150|NCT05678335|Experimental|Tacrolimus monotherapy|Oral tacrolimus 1-2mg twice daily for 12 weeks.
32778151|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
32778152|NCT04714567||Patients with severe asthma|Patients of all ages with severe asthma included in the RAG.
32778153|NCT05696977|Active Comparator|Obese nephrotic patients with BMI>25 kg/m2|"Nephrotic obese patients receive Cyclosporine capsule initially according to weight-based dose then modifying the dose according to targeted therapeutic level.~To determine the best weight can be used to get the targeted therapeutic level. Correlate with the lipid profile, fat percentage and other anthropometric measures."
32778154|NCT05696977|Other|Non obese nephrotic patients with BMI<25 kg/m2|Nephrotic non-obese patients receive Cyclosporine capsule initially according to weight-based dose then modified dose according to targeted therapeutic level.
32778155|NCT05696899|Experimental|Aromatherapy|Patients will be given STILL QuickTAB Medipack blended scent aromatherapy in addition to standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
33083212|NCT04593238|Experimental|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
33083213|NCT04593238|Active Comparator|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
33083214|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
33083215|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
32778156|NCT05696899|No Intervention|Control Group|Participants will be offered standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
32778157|NCT05051449|Experimental|Ketamine|
32778158|NCT05154721|Experimental|EXPE Group|The experimental group (EXPE Group) will receive the Mila-Learn game.
33282837|NCT04060784|Experimental|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
33282838|NCT04060784|Experimental|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
33282839|NCT04053764|Experimental|crizanlizumab + standard of care|5 mg/kg by intravenous (i.v.) infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
32936880|NCT04007900|Experimental|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
32936881|NCT04007900|No Intervention|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
33282840|NCT04053764|Active Comparator|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
33282841|NCT04996394||NMBAs|
32778159|NCT05154721|Placebo Comparator|CONT Group|The control group (CONT Group) will receive the Mila-Placebo game.
32778160|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
32778161|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
32778162|NCT04706923|Experimental|BCV 0.2mg/kg BIW|BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
32778163|NCT04706923|Experimental|BCV 0.3mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
32778164|NCT04706923|Experimental|BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
32778165|NCT04706923|Experimental|BCV 0.4 mg/kg QW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.
32778166|NCT05678257|Experimental|NUFIRI-bev on a Q1W NUC-3373 schedule|"Arm A: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1, 8, 15, and 22.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~NUC-3373 1500 mg/m2 over 120 minutes on Days 1, 8, 15, and 22."
32778167|NCT05678257|Experimental|NUFIRI-bev on a Q2W NUC-3373 schedule|"Arm B: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~NUC-3373 1500 mg/m2 over 120 minutes on Days 1 and 15."
32936882|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
32936883|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
32936884|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
32936885|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
32936886|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
32936887|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
32936888|NCT03911726|Other|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
32936889|NCT03911726|Experimental|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
32936890|NCT03911726|Experimental|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
32936891|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
32936892|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
32778168|NCT05678257|Active Comparator|FOLFIRI-bev on a Q2W schedule|"Arm C: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~5-FU 400 mg/m2 bolus on Days 1 and 15.~5-FU 2400 mg/m2 infusion over 46 hours on Days 1 and 15."
32778169|NCT05032495||Heart patients who experienced a cardiac arrhythmia while in hospital|Heart patients who experienced a cardiac arrhythmia while in hospital
32778170|NCT05032495||Heart patients who did not experience a cardiac arrhythmia while in hospital|Heart patients who did not experience a cardiac arrhythmia while in hospital
32778171|NCT05032495||Heart patients with an upcoming procedure that have not had a cardiac arrhythmia|Heart patients with an upcoming procedure that have not had a cardiac arrhythmia
32778172|NCT05032495||Members of the general public|Members of the general public
32778173|NCT05078671|Active Comparator|Standard olaparib|Olaparib 300mg twice daily
32778174|NCT05078671|Experimental|Boosted olaparib|Olaparib 100mg twice daily + cobicistat 150mg twice daily
32778175|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
32778176|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
32778177|NCT05053555|Experimental|Group A (Prospective cohort )|20 patients, will undergo initial diagnostic workup, staging and treatment per institutional standard of care. Intervention: High dose rate brachytherapy (HDRBT)
32778178|NCT05053555|Experimental|Group B( Retrospective chart review )|40 patients who meet same eligibility criteria, but did not receive HDRBT between 1/1/2000 and 1/1/2021.
32778179|NCT05028517|Experimental|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
32778180|NCT05028517|Experimental|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
32778181|NCT05028517|No Intervention|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
33282842|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
32778182|NCT05040763|Experimental|COVID-19 Swab Collection|All participants will receive standard of care COVID-19 testing in addition to buccal swab COVID-19 testing
32778183|NCT05678023|Active Comparator|Contrast media 2 hours|Patients will receive contrast media after 2 hours of nasogastric decompression
32778184|NCT05678023|Active Comparator|Contrast media 24 hours|Patients will receive contrast media after 24 hours of nasogastric decompression
32778185|NCT05677945|Experimental|(Group I Experimental Group):Simvastatin mixed with modified triple antibiotic (3Mixtatin)|"Patients will then be allocated into either one of the groups alternatively after access cavity preparation depending on the mix to be used as follows:~for this group:~2mg of pure Simvastatin powder will be added to the 1:1:1 3Mix powder and will be stored together in an air tight porcelain container to avoid the exposure to moisture and light.~Upon clinical application the 3Mixtatin powder will be mixed with normal saline to form a paste and is then applied in the same manner as the Modified 3Mix-MP paste."
32778186|NCT05677945|Active Comparator|Group II Control group Modified triple antibiotic mix in propylene glycol (3Mix)|"Removal of enteric coating/capsule of the three antibiotic tablets using a surgical blade.~500 mg Metronidazole tab~500 mg Ciprofloxacin tab~200 mg Cefixime caps~Pulverization of each of the drug, will be done using a pestle & mortar, stored in an air tight porcelain container to avoid the exposure to moisture & light.~Pulverized powders will be stored at a temperature of 16°C.Powder should be allowed to be cooled to the room temperature before initiating the preparation of 3Mix-MP paste.~Powders will be mixed in the proportion of: 1:1:1 by volume (Hoshino et al., 1988).~Vehicle that will be used is Systane eye drops (Kharadly et al., 2022) it contains the two main components propylene Glycol (Macrogol) & polyethylene glycol.~The prepared antibiotic powder is mixed with the prepared vehicle in the ratio of 7:1 by volume. The two steps above are done after access cavity preparation to obtain a fresh mix."
32778187|NCT05038735|Experimental|Alpelisib plus fulvestrant|Alpelisib 300 mg orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15, and on Day 1 on every Cycle thereafter, in a 28 days cycle.
32778188|NCT05038735|Placebo Comparator|Alpelisib-matching placebo plus fulvestrant|Alpelisib-matching placebo orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15 and on Day 1 on every Cycle thereafter, in a 28 days cycle. Participants who have disease progression per RECIST v1.1 as assessed by BIRC will have the option to crossover to be treated with alpelisib plus fulvestrant
32778189|NCT05003323||High Knee Pain with Osteoarthritis|Adults 45-80 years old who have moderately severe knee osteoarthritis and rate their daily knee pain at >=6 on a 0-10 numeric rating scale
32778190|NCT05003323||Low Knee Pain with Osteoarthritis|Adults 45-80 who have moderately severe knee osteoarthritis and rate their daily knee pain at <=5 on a 0-10 numeric rating scale
32778191|NCT05003323||Healthy Controls|Age matched, BMI matched adults who do not have knee osteoarthritis or chronic pain
32936893|NCT04334798|Experimental|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
33282843|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
33282844|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
33282845|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
32778192|NCT05650177|Experimental|Receiving intervention.|Patients with persistent depression who are receiving the intervention.
32778193|NCT04964947|Experimental|Tobramycin Treatment Group|Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.
32778194|NCT04964947|No Intervention|Standard of Care Treatment Group|Participants in this group receive standard of care treatment.
32778195|NCT04317547|No Intervention|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
32778196|NCT04317547|Experimental|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
32778197|NCT05677789||Participants The patient's CORMB score is 0 to 2|Participants The patient's CORMB score is 0 to 2
32778198|NCT05677789||Participants The patient's CORMB score is 3 to 4|Participants The patient's CORMB score is 3 to 4
32778199|NCT05677789||Participants The patient's CORMB score is 5 or above|Participants The patient's CORMB score is 5 or above
32778200|NCT05677711||Ultimaster|Ultimaster stent
32778201|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
32778202|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
32778203|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
32778204|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
32778205|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
32778206|NCT05677633|Experimental|Leukine Treatment|48 week regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
32778207|NCT05677555|Experimental|colchicine group|Treatment with colchicine 0.5 mg
32778208|NCT05677555|Placebo Comparator|placebo group|Treatment with matched placebo
32778209|NCT04832971|Experimental|ARO-ANG3|Two doses of ARO-ANG3 by subcutaneous (sc) injection during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
32778210|NCT04832971|Placebo Comparator|Placebo|Calculated volume to match active treatment by sc injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
32936894|NCT04334798|Experimental|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
33083216|NCT04593433|Experimental|Intervention|Group with the virtual museum guided tours
33083217|NCT04593511|Experimental|Formulation 1|a single dose of LY03009 F1
33083218|NCT04593511|Experimental|Formulation 2|a single dose of LY03009 F2
33282846|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
33083219|NCT04593511|Experimental|Formulation 3|a single dose of LY03009 F3
33083220|NCT04593511|Experimental|Formulation 4|a single dose of LY03009 F4
33083221|NCT00566839|Experimental|1|
33083222|NCT00566839|Active Comparator|2|
33083223|NCT04593160|Experimental|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
33083224|NCT04593160|Experimental|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
33282847|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
33282848|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
33083225|NCT04593160|Placebo Comparator|Placebo|Preoperative single dose of placebo
33083226|NCT04592965|Experimental|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
33083227|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
32936895|NCT04334798|Experimental|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
32936896|NCT04334798|Experimental|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
32936897|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
32936898|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
32778211|NCT05696821|Other|Cluster 1|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 3 months unexposed and 18 months exposed outcomes."
32778212|NCT05696821|Other|Cluster 2|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 4 months unexposed and 17 months exposed outcomes."
32936899|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
32936900|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
32778213|NCT05696821|Other|Cluster 3|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 5 months unexposed and 16 months exposed outcomes."
32778214|NCT05696821|Other|Cluster 4|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 6 months unexposed and 15 months exposed outcomes."
32778215|NCT05696821|Other|Cluster 5|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 8 months unexposed and 13 months exposed outcomes."
32778216|NCT05696821|Other|Cluster 6|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 10 months unexposed and 11 months exposed outcomes."
32778217|NCT05696821|Other|Cluster 7|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 12 months unexposed and 9 months exposed outcomes."
32778218|NCT05696821|Other|Cluster 8|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 13 months unexposed and 8 months exposed outcomes."
32778219|NCT05696821|Other|Cluster 9|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 14 months unexposed and 7 months exposed outcomes."
32778220|NCT05696821|Other|Cluster 10|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 15 months unexposed and 6 months exposed outcomes."
32778221|NCT04906759|Experimental|Meals plus exercise|
32778222|NCT04906759|Experimental|Meals only|
32778223|NCT04893265|Active Comparator|Text Messaging Only|Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
32778224|NCT04893265|Experimental|INFORMED|"Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing as described in the Text Messaging Only. In addition, participants will receive a Lay Health Worker (LHW) Educational Outreach Program, which includes 2 group sessions via video calls like Zoom or another video conferencing platform and 2 follow-up contacts via telephone, text or other media assignment."
32778225|NCT04874857|Experimental|Intervention group (Aromatherapy group)|With a mixture of Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L. essential oils, the foot and lower leg will be massaged for three sessions a week for 30 minutes in each session for four weeks.
32778226|NCT04874857|Experimental|Placebo group|The foot and lower leg will be massaged with baby oil for four weeks, three sessions a week, 30 minutes in each session.
32778227|NCT04874857|No Intervention|Control group|No application will be made in addition to standard HD treatment.
32936901|NCT02224638|Active Comparator|TheraHoney HD|Honey product
32778228|NCT05677477|Experimental|Intervention/Treatment|In the implementation process of the research, knowledge tests will be applied as pre-test and post-test, and training will be given to the mother who has a baby with physiological jaundice. In the study, the scenario of the mother with a baby with jaundice will be implemented only with the intervention group
32778229|NCT05677477|No Intervention|Control|During the application process of the research, knowledge tests will be applied as pre-test and post-test.
32778230|NCT04855357|Experimental|Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention|Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
32778231|NCT04855357|Other|Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention|The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
32778232|NCT05677399|Experimental|Treatment Group|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
32778233|NCT05677399|No Intervention|Control Group|Control group continued to use their usual medical treatment.
32778234|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2A|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2A arm will enrol patients with PSMA+ solid tumours. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
32778235|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2B|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2B arm will enrol patients with PSMA+ metastatic, castration resistant prostate cancer patients with mutations of sponsor interest. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
32778236|NCT04671901|Experimental|Pediatric Participants|Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.
32778237|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
32936902|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
32936903|NCT05390528|Experimental|Experimental Group(phase Ia)|Phase 1a uses accelerated titration design and Bayesian optimal interval (BOIN) design to investigate the safety of HLX301 and determine MTD.Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20mg/kg are planned for dose finding.
32936904|NCT04756362||Prospective cohort|A minimum of 294 patients will be included in the evaluation of 0 and 1 hour protocol (prospective evaluation).
32936905|NCT04756362||Retrospective cohort|A minimum of 1,000 patients will be included in the evaluation of prognostic value of high sensitive cardiac troponin < 5 ng/L(retrospective evaluation).
32936906|NCT05388734|No Intervention|Before group|Patients in the before group are recruited during the first 4 months of the study and will not benefit from the alternative medicine education consultation
32936907|NCT05388734|Active Comparator|After Group|Patients in the front group are recruited from the 5th month of the study and will benefit from the alternative medicine education consultation
32936908|NCT04334642|Experimental|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
32936909|NCT04695860|Experimental|Open label Burosumab|Burosumab Q4W, 1mg/kg body weight s.c.
32936910|NCT04690868|Experimental|ARM 1|Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
32936911|NCT04690868|Experimental|ARM 2|Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
32936912|NCT04654988|Experimental|Immunsuppression|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and Azathioprine: 2 mg/kg daily for 12 months
32936913|NCT04654988|Placebo Comparator|Placebo|placebo matching prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and placebo matching azathioprine: 2 mg/kg daily for 12 months
32936914|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
32936915|NCT04631432||Study participation|All participants will complete the same protocol
32936916|NCT04628858||Primary group|
32936917|NCT04609280|Experimental|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
33083228|NCT04592965|Experimental|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
33083229|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
33083230|NCT04580459|Experimental|CARE Parenting Group Treatment|Participants receive the CARE mentalizing-focused group parenting intervention.
33083231|NCT04580459|Other|Treatment as Usual (TAU)|Participants continue to receive treatment as usual in the outpatient child mental health clinic.
33083232|NCT04592926|Experimental|Accuro ultrasound|
33083233|NCT04592926|Sham Comparator|Control|
33083234|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
32900165|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
33282849|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
33282850|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
33282851|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
33282852|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
33282853|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
33282854|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
33282855|NCT00885053|Experimental|Fish oil|
33282856|NCT00885053|Placebo Comparator|Olive oil|
33282857|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
33282858|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
33282859|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
33282860|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
33282861|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
33282862|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
33282863|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
33083235|NCT00566917|Experimental|2|Anterior PROLIFT
33083236|NCT04539236|Experimental|Luspatercept + Lenalidomide Group|"Phase 1B: Luspatercept will be administered at starting dose 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered in a dose escalation design between 3 cohorts to determine MTD (2.5 mg, 5 mg and 10 mg daily dose on a 21-day cycle). MTD will be defined as the dose level with 0 or 1 DLT out of 6 participants. MTD will be declared as the RP2D for the Phase II portion of the study.~Phase II: Luspatercept will be administered at 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered with the RP2D daily for 21 days on a 21 day cycle.~Treatment with combination of Lenalidomide and Luspatercept will continue as long as a participant is deriving clinical benefit, in the opinion of the treating physician, for up to 5 years or until disease progression or treatment intolerance."
33083237|NCT00249483|Placebo Comparator|Placebo|Placebo
33083238|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
33083239|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
33083240|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
33083241|NCT00567034|Active Comparator|1|taking naltrexone
33083242|NCT00567034|Placebo Comparator|2|taking placebo
33282864|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
33282865|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
33282866|NCT00887705|No Intervention|1: Standard rehabilitation programme|
33282867|NCT00887705|Experimental|2. Additional ADL training|
33282868|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
33282869|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
33282870|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
33282871|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
33282872|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
33083243|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
33083244|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
33083245|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
33282873|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
33282874|NCT00923429|Active Comparator|S-A|
33282875|NCT00923429|Active Comparator|S-A+stretch|
33282876|NCT00923429|Experimental|S-A+stretch+manther|
33282877|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
33282878|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
33282879|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
33282880|NCT00887861|Experimental|BGG492|
33282881|NCT00887861|Placebo Comparator|Placebo|
33282882|NCT04037267|Experimental|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
33282883|NCT04037267|Active Comparator|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
33282884|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
33282885|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
33282886|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
33282887|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
33282888|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
33282889|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
33282890|NCT04037735|Experimental|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
33282891|NCT04037735|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
33282892|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
33282893|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
33282894|NCT00890357||Triptan User|
33282895|NCT00890357||Triptan Discontinued|
33282896|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
33282897|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
33282898|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
33282899|NCT02541383|No Intervention|Arm A Part 2|Observation
33282900|NCT02541383|Experimental|Arm B Part 2|daratumumab
33282901|NCT04036643|Experimental|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
33282902|NCT04036487|Experimental|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
33083246|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
33083247|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
33083248|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
32778238|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
32778239|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
33282903|NCT04036487|Active Comparator|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
32778240|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
32936918|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
32936919|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
32936920|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
32936921|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936922|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936923|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936924|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936925|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936926|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
32936927|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
32936928|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
32936929|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
32936930|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
33083249|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
32778241|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
32778242|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
32778243|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
32778244|NCT02343549|Experimental|Planned RT + TMZ + BEV + NovoTTF100A Device|Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.
32778245|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
32778246|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
32778247|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
32778248|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
32778249|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
32778250|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
32778251|NCT04778527|Experimental|Over-encapsulated DPP|A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)
32778252|NCT04778527|Experimental|Two Separate Tablets|Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles
32778253|NCT04778059|Experimental|USB002|
32778254|NCT04778059|Placebo Comparator|Placebo|
32778255|NCT04743583||Endosonography group|Patients with known or suspected lung cancer or intrathoracic malignancy with indication to endosonography for diagnosis or staging of intrathoracic lymph nodes according to currently accepted international guidelines
32778256|NCT05696665|Active Comparator|Group A|conventional therapy only
32778257|NCT05696665|Experimental|Group B|conventional therapy +500 mg chamomile 15 mg saffron twice daily
32778258|NCT05696665|Experimental|Group C|conventional therapy +500mgApigenin +30mg Crocin once daily
32778259|NCT04697563|Active Comparator|Laser|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions."
32778260|NCT04697563|Placebo Comparator|Placebo Laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
32778261|NCT04465201|Experimental|Subjects receiving the Impella/Impella® Hemodynamics platform|
32778262|NCT04403347|Experimental|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
32778263|NCT04403347|Active Comparator|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
32778264|NCT04403347|No Intervention|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
32778265|NCT05677009|Other|BUFEO vs Standard Condition|In the BUFEO vs Standard Condition arm, the patient will receive both treatments. The order in which the subject receives the treatment will be randomized.
32778266|NCT05675761||Combined bacterial and fungal infection|Combined bacterial and fungal infection
32778267|NCT05675761||No bacterial and fungal infection|No bacterial and fungal infection
32900166|NCT05005286||Group A|Lactating women with vaginal infection during pregnancy as confirmed by past medical records
32900167|NCT05005286||Group B|Lactating women without any vaginal infection during pregnancy
33102330|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33282904|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
33282905|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
33282906|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
33282907|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
33282908|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
33282909|NCT05278793|Experimental|Intermittent|This group will receive ferrous fumarate 200mg intermittent three times a week on alternate days.
33282910|NCT05278793|Active Comparator|Daily|This group will receive ferrous fumarate 200mg once daily.
32778268|NCT05674357|Experimental|Individualized Evidence-Based Therapy in Cancer (Patients)|"This arm will enroll patient participants receiving evidence-based therapy as part of the protocol.~Participants will complete:~6-16 sessions of therapy 1x/week. Sessions are virtual or in-person at the Massachusetts General Hospital Cancer Center.~Surveys and questionnaires pre- and post-treatment.~At the discretion of the therapist and the supervising therapist, the participant may receive up to 4 booster sessions after completion of the specific treatment protocol."
32778269|NCT05674357|Experimental|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|This arm will enroll therapist participants as part of the protocol. Therapists participants will enroll in the study and receive training in delivering evidence-based therapy to patients in the cancer center. Therapists will complete pre and post-measures of therapist self-efficacy and competence, as well as a semi-structured exit interview.
32778270|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
32778271|NCT04372615|Active Comparator|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
32778272|NCT04372615|Placebo Comparator|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
32778273|NCT05673655|Active Comparator|transcutaneous injection|
32778274|NCT05673655|Active Comparator|intraoral injection|
32778275|NCT05640193|Experimental|Participants with Melanoma Brain Metastases|Participants have melanoma brain metastases who will undergo surgical excision to generate LN-144.
32778276|NCT05692297|Experimental|Denosumab group|Fifty-one patients were randomly assigned to the denosumab group, which received subcutaneous injection of denosumab 60mg once every 6 months. Serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA and qCT were measured before medication. Serum calcium, phosphorus and iPTH were examined at day 1, 7 and 14, alkaline phosphatase, tPINP and 25(OH)VitD at day 7 and 14, and electrocardiogram at day 1 and 7 after treatment. Intravenous calcium supplementation was required if muscle spasms and QT prolongation occurred. Six months after medication, subcutaneous injections of denosumab 60mg were repeated. The protocol was repeated every 6 months, totally 24 months. Bone mineral density, clinical parameters and adverse events were evaluated at 24 months.
32778277|NCT05692297|Active Comparator|Non-denosumab group|The other 51 patients did not use denosumab and used other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc. At the same time, calcium and vitamin D were supplemented. The baseline serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA, and qCT were measured. The above parameters were rechecked every 6 months, and the medications was recorded, totally 24 months.
32778278|NCT05696587|Experimental|CRPS|Participants meeting inclusion and exclusion criteria undergoing 4-week multimodal rehabilitation, undergoing assessment at baseline and at 4 weeks.
32778279|NCT05696587|No Intervention|Healthy Control|Participants matched according to sex, age and education to experimental arm, undergoing psychological assessment at baseline and at 4 weeks.
32778280|NCT05696509|Other|Propofol|Anesthetic
32778281|NCT05696509|Other|Isofluran|Anesthetic
32778282|NCT05696509|Other|Sevofluran|Anesthetic
32778283|NCT04574167|Experimental|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
32778284|NCT04574167|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
32778285|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
32778286|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
32778287|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
32778288|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
32778289|NCT05654935||Cohort A|Includes 26 healthy volunteers >18 years of age without history of stroke or transient ischemic attack, coronary artery disease (prior myocardial infarction, typical angina, prior percutaneous coronary revascularization, and prior coronary bypass graft surgery), and peripheral arterial disease (claudication, peripheral arterial revascularization stenting of bypass surgery). Subjects will be recruited using advertisement flyers and emails.
33102331|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33282911|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
33282912|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
33282913|NCT05278325|Experimental|Telephone Intervention|Two planned phone call by health care professionals after 8 and 16 weeks adjusting acute and preventive treatment
33282914|NCT05278325|No Intervention|Business as usual|No planned phone calls
32778290|NCT05654935||Cohort B|Includes 100 subjects ≥ 60 years of age without known carotid artery disease. These subjects will be recruited from patients scheduled to receive a clinically indicated cardiac stress test or echocardiogram in the noninvasive cardiac testing area at Rush University Medical Center (Chicago, IL).
32778291|NCT05651893|Experimental|Second forward view examination group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. Then the left colon, including the splenic curvature to the anus, is examined twice in the forward view.
32778292|NCT05651893|Experimental|Extended withdrawal time group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. The colonoscope was withdrawn to the anus directly with withdrawal time extended to the double routine withdrawal time of the left colon.
32778293|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
32778294|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
32778295|NCT04523857|Experimental|A (Abema)|Abemaciclib (150 mg BID)
33402050|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
32778296|NCT04523857|Experimental|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)~*Abemaciclib dose will be determined by safety cohort"
32778297|NCT02581345|Experimental|M923|Participants assigned to receive M923
32778298|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
32778299|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
32778300|NCT05599321||Historical Controls Cohort|Lung cancer patients who have previously undergone a clinical bronchoscopy. This group represents the current state-of-the-art bronchoscopy practice.
32778301|NCT05599321||Consented Clinical Bronchoscopy Cohort|Lung cancer patients, scheduled for bronchoscopy, who are consented for bronchoscopy assisted by the Virtual Navigator.
32778302|NCT05590507|Experimental|Group A/Intervention|Subjects will use mindfulness audio recordings along with their physical activity, and will receive a weekly health coaching phone call along with supplemental educational materials.
32778303|NCT05590507|No Intervention|Group B/Control|Subjects will receive education materials on healthy habits for increasing physical activity based on the National Institutes of Health, and bi-weekly check-in phone call.
32778304|NCT05579509|Experimental|High Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
32778305|NCT05579509|Experimental|Low Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
32778306|NCT04314661|Experimental|Arthroscopy + Booster|After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
32778307|NCT04314661|Experimental|Arthroscopy + Pre-Conditioning|After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
32778308|NCT04314661|Experimental|Non Arthroscopy + Booster|Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
32778309|NCT04314661|Experimental|Non Arthroscopy + Pre-Conditioning|Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
32778310|NCT04029337|Experimental|Single|
32778311|NCT05696431|Placebo Comparator|Universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a universal adhesive as control group.
32936931|NCT04737889|Experimental|RL-MT|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen: Methotrexate, 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle, Temozolomide, 150mg/m2/d oral administration on day 1 to 10.~Consolidation Treatment: Autologous hematopoietic stem cell transplantation or reduced whole brain radiotherapy after high-dose chemotherapy.~Maintenance Treatment: Lenalidomide, 10mg oral administration on day 1 to 21 of each 4-week cycle for 12 months."
32936932|NCT05214716|Active Comparator|Intervention|Respiratory specimens from the subjects are tested by the FilmArray Pneumonia panel and the results are reported via an electronic health record system. Treating physicians may adjust empirical antibiotic regimens with assistance from the guidelines formulated by the study investigators. Other microbiologic tests, including cultures, are performed as per routine practice.
32936933|NCT05214716|No Intervention|Control|Microbiologic tests, including cultures, are performed as per routine practice. No intervention is made on the antimicrobial treatment in the control arm.
32936934|NCT05144828|Experimental|Intercostal Nerve Cryoablation plus Standard of Care (SOC) Pain Control|Intercostal nerve cryoablation using the CryoICE® CRYOS-L cryoablation probe and an intercostal nerve block of nerves 4-9 performed using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
32936935|NCT05144828|Active Comparator|Standard of Care (SOC) Pain Control|Intercostal nerve block of nerves 4-9 using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
32936936|NCT05455255|Experimental|Experimental Group|FL will be applied to the intervention group. In this model, short videos of the course will be delivered to students via WhatsApp one week in advance. At the beginning of the lesson, students' deficiencies will be corrected by making kahoot. Afterwards, group work, case scenario, role-play scenario and conceptual map methods will be applied in the course.
32936937|NCT05455255|No Intervention|Control Group|The subject of the nursing process will be transferred to the control group with powerpoint presentations by the educator. The activities in the other group will be presented by the trainer as an example.
32936938|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
32936939|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
32936940|NCT04336501|Experimental|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
33102332|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
32778312|NCT05696431|Active Comparator|Fluoride-releasing universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a Fluoride-releasing universal adhesive.
32778313|NCT05696431|Active Comparator|Universal adhesive with bioactive properties|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used.This group will receive a universal adhesive with bioactive properties.
32778314|NCT05696353|No Intervention|Control Group|The Control Group will have an in-vehicle device installed in the teen's car, but all feedback features will be disabled. Parents assigned into this group will receive no communication training on how to motivate their teen to adopt safe driving habits.
32778315|NCT05696353|Experimental|Feedback and Expert-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app downloaded on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a teen driving safety communication expert. A second booster session will occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
32778316|NCT05696353|Experimental|Feedback and Peer-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app download on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a peer trainer who is a parent of teen with a traffic violation and who has received the Expert-delivered Intervention and met the defined peer trainer criteria. A second booster session delivered by the peer trainer will also occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
32778317|NCT05696275|Experimental|exercise|combine walking and elastic band exercise
32778318|NCT05696275|No Intervention|usual care|as usual care
32778319|NCT05578885|Placebo Comparator|Group A|will receive Lidocaine
32778320|NCT05578885|Active Comparator|Group B|will receive Lidocaine Plus fentanyl
32778321|NCT05578885|Active Comparator|Group C|will receive lidocaine Plus dexamethasone
32778322|NCT05575453|Active Comparator|Kvatchii Portal|The intervention group will be given access to the Kvatchii portal and home blood pressure monitor
32778323|NCT05575453|No Intervention|Usual Care|The control group will not have access to the portal but will be provided with home blood pressure monitor
32778324|NCT05628883|Experimental|Infusion of TBio-4101 TIL|"TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product: participants tumor tissue is surgically removed and immune T-cells are taken out of the tumor and multiplied, or grown, in the laboratory. TIL product infused intravenously over 20 to 30 minutes within 2 to 4 days after the last dose of fludarabine~Participants will also receive:~Cyclophosphamide dose 60 mg/kg/day for 2 days administered IV in 250 mL dextrose 5% in water infused simultaneously with Mesna 15 mg/kg/day delivered over 1 hour per day for 2 days. Fludarabine 25 mg/m2/day is delivered by intravenous piggyback daily over 15-30 minutes for 5 days.~Interleukin-2 (IL-2)- will be given to participants through IV after they receive the infusion of the TIL. IL-2 is administered at a dose of 600,000 IU/kg (based on actual body weight) IV every 8-12 hours beginning within 24 hours of TIL infusion for a maximum of 6 doses."
32778325|NCT05575219|Active Comparator|Usual care (without protocolized clonidine initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
32778326|NCT05575219|Experimental|Intervention (protocolized clonidine initiation)|A protocol for clonidine initiation will be implemented based on the time on dexmedetomidine and the average hourly dose of dexmedetomidine.
32778327|NCT05610319|Experimental|Treat and Extend|Participants randomized to the T&E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100.
32778328|NCT05610319|Other|Control/Usual Care Arm|Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100.
32778329|NCT04341571|Experimental|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
32778330|NCT04341571|Experimental|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
32778331|NCT04341259|Experimental|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
32778332|NCT05568745|Experimental|Balloon+oxytocin|Mecanical cervical ripening will be done by transcervical balloon (Teleflex French Dufour catheter CH20 reference 174000). Oxytocin will be started 6 hours after balloon insertion. At H12 balloon will be removed and induction continued by oxytocin alone.
32778333|NCT05568745|Active Comparator|Oral misoprostol|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations. (Oxytocin can be started at least 4 hours after the last misoprostol administration if patient remains not in labour.)
33102333|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33402051|NCT04439500|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
32778334|NCT04314895|Experimental|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
32778335|NCT04302493|Experimental|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
32778336|NCT04302493|Active Comparator|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
32778337|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
32778338|NCT05569681|Active Comparator|Bemiparin 3500 IU|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
32778339|NCT05569681|Active Comparator|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group patients and 30 days in very high-risk group surgical patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
32778340|NCT04443907|Experimental|OTQ923|Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.
32778341|NCT05603923|Active Comparator|Group 1: Lumen Coached Group|Participants in this group will attend an Intervention Orientation session to receive the Coach Lumen tutorial, a study iPad, and a Lumen Intervention Workbook. They will complete 8 PST sessions with Coach Lumen using their study assigned iPad at home over 12 weeks. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminders on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions through the iPad. Participants will work with Coach Lumen to learn problem-solving skills to address current life challenges, plan activities, and complete home activities. Participants will also complete surveys before and after each PST session: a mood assessment survey before and a user experience survey after. At the end of study, Participants may be invited to provide their perspective regarding their Lumen use experience.
32778342|NCT05603923|Active Comparator|Group 2: Human Coached Group|Participants in this group will receive a study iPad and Human-Coached Intervention Workbook and will complete the first of 8 PST sessions in person with a trained health coach. Participants' first PST session will be in person for approximately 1 hour. Participants will complete the remaining sessions remotely via Zoom (or by phone, if necessary) using their study iPad. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminder notifications on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions with their coach. Participants will also complete a mood assessment survey at the beginning of each PST session. Participants will work with their health coach to learn problem-solving skills to address current life challenges, plan activities, and complete home activities.
32778343|NCT05603923|Placebo Comparator|Group 3: Optional (Delayed) Lumen Coached Group|Participants assigned to this group can choose to attend a Lumen Orientation session to receive training and a study iPad to complete 8 PST sessions with Coach Lumen after their follow-up assessment at 18 weeks. They will receive 8 Sunday mood assessment surveys to complete (4 every Sunday and then 4 every other Sunday).
32778344|NCT05601661|Experimental|Treatment group|Participants in the treatment group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired VNS over six weeks. Followed by 90 days home exercise program.
32778345|NCT05601661|Sham Comparator|Control Group|Participants in the control group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with sham VNS over six weeks. Followed by 90 days home exercise program.
32778346|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
32778347|NCT05535127|Active Comparator|"Palpation with  laryngeal handshake technique "|"With the non-dominant hand, the larynx is stabilized, the hyoid bone is identified with the thumb and index finger by palpation of the greater horns with a horizontal movement from side to side, move thumb and fingers inferiorly to locate thyroid cartilage,Once identified, its location is maintained with the middle finger and thumb, and the index finger travels towards the midline.~The index finger, already in the midline, makes a longitudinal movement downwards to determine the small depression between the cricoid and thyroid cartilage that corresponds to the cricothyroid membrane."
32778348|NCT05535127|Experimental|Palpation strategy plus sequential ultrasound|Palpation is performed with the previously described laryngeal handshake technique If the participant is unable to identify the location of the cricothyroid membrane with certainty, the mixed ultrasound protocol is continued. as decribed in Identification of the cricothyroid membrane with ultrasound
32778349|NCT05535127|Active Comparator|Identification of the cricothyroid membrane with routine ultrasound|"With the patient on a supine stretcher position, neck extended, with a linear transducer and ultrasound gel, a cross-sectional evaluation of the airway is performed, identifying the cartilaginous referents of the airway. In this case, the midline referent will be the union of the laminae of the thyroid cartilage. The midpoint of the hyperechoic image is located between both referents (MCT).~Next, tracheal rings are identified, the transducer is moved laterally and a 90° turn is performed for axial evaluation of the MCT. The aim is to preserve the same anatomical landmarks already identified in the transverse plane, the cephalocaudal distance between the thyroid cartilage and the cricoid is evaluated, locating the midpoint with the help of the acoustic shadow generated by a yelco without a needle. Based on these 2 measurements, the topographical location of the MCT will be marked with a visible ink marker under UV light, which will serve as a benchmark for comparison."
33402052|NCT04439500|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
32778350|NCT05601115|Experimental|Robot Assisted Therapy Group|In addition to the conventional treatment for 60 minutes in the Robot asisted therapy (RAT) group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience. For the purpose of conventional therapy, an exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) accompanied by a physiotherapist experienced in stroke rehabilitation for at least 5 years, and neuromuscular therapy for the upper and lower extremities for 15 minutes.Electrical stimulation (NMES) application was planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
32936941|NCT05041400|Other|Healthy subjects|"Evaluation carried out on a BIODEX S4 Pro isokinetic dynamometer after a standardised 10-minute warm-up on this same dynamometer .~The measurement range will be from 0° (full extension) to 90° of flexion for each knee, providing 91 degrees of measurement."
33282915|NCT04037657|Experimental|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
33282916|NCT04037657|Active Comparator|Propofol|2.5 mg propofol
33282917|NCT04037345|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33282918|NCT04037345|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33282919|NCT04037345|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33282920|NCT00893009|Placebo Comparator|Placebo|
33282921|NCT00893009|Active Comparator|Theophylline|100 twice a day
33282922|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
33282923|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
33282924|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33282925|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
33282926|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
33282927|NCT00891059||Placebo Diskus Inhaler|
33282928|NCT00888251||Comprehensive weight management program|
33282929|NCT00893087|Active Comparator|1|Flow triggering
33282930|NCT00893087|Active Comparator|2|Pressure triggering
33282931|NCT00893087|Active Comparator|3|NAVA triggering
33282932|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
33282933|NCT02541305|Experimental|Experimental|Propioceptive program
33282934|NCT04017845|Active Comparator|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
33282935|NCT04017845|Active Comparator|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
33282936|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
33282937|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
33282938|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
33282939|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
33282940|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
33282941|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
33282942|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
33282943|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
33282944|NCT05616182||LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
33282945|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
33282946|NCT03998384|Active Comparator|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
33282947|NCT03998384|Placebo Comparator|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
33282948|NCT03941600|Active Comparator|Community-based Exercise Intervention group (CBEI)|A group performing a 12-week guided exercise program at an accessible community health and wellness center
32778351|NCT05601115|Active Comparator|Conventional Therapy Group|45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological studies were performed in the presence of a physiotherapist experienced in stroke rehabilitation for at least 5 years.An exercise program consisting of exercises (Brunstroom exercises) and 15 minutes of NMES were planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
32778352|NCT05595655|No Intervention|control group|The dyads will receive traditional educational treatment only and will complete the questionnaires after 3, 6, 9 and 12 months follow-up post-intervention. Enrolled dyads will be monitored by the research team responsible for recruitment and follow-up.
32778353|NCT05595655|Other|First interventional arm|MI intervention will be administered to patients only and caregivers will receive standard education. The intervention will last approximately 30 minutes. Thereafter, the nurse who performed the MI will contact the patients over the phone 3 times during the first 2 months after MI, to strengthen the intervention. Then, the intervention will be employed again after 3, 6, 9 and 12 months from enrolment. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention
32778354|NCT05595655|Experimental|Second interventional arm|MI intervention will be administered both to patients and caregivers. The intervention will be administered to the dyad in one session and patients and their caregivers will receive the reinforcing educational treatment calibrated on the specific lacking areas of patients' self-care behaviours. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention.
32778355|NCT04425265|Experimental|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
32778356|NCT04425265|Active Comparator|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
32778357|NCT05594641|Experimental|T (Treatment)|Remote ischaemic preconditioning (RIPC) will be performed before the start of liver resection and the associated Pringle maneuver
32778358|NCT05594641|Other|C (Control)|RIPC will be not performed
32778359|NCT05535049|No Intervention|Periodontally healthy group|24 participants were included in this group.
32778360|NCT05535049|Active Comparator|Periodontitis group|24 participants were included in this group.
32778361|NCT04686253||PFO patients with CS or/and TIA|PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).
32778362|NCT04686253||PFO patients with migraine|PFO patients with migraine (transcatheter closure of PFO was performed).
32778363|NCT04686253||PFO patients without symptom|PFO patients without symptom (5-year follow-up).
32778364|NCT05551039||Physicians treating patients with mCRC|Physicians provide case histories of mCRC patients
32778365|NCT04084717|Experimental|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
32778366|NCT04084717|Experimental|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
32778367|NCT04084717|Experimental|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
32778368|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours.
32778369|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours. Infusion started at wake-up time supplemented with an oral IR LD/CD tablet.
32778370|NCT04685941|Other|Drug-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to at least 200 mcg of intracoronary nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes
32936942|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~oral prednisolone 40 mg/day for 5 days;~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
32936943|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
33282949|NCT03941600|Placebo Comparator|Exercise Education Control group (EEG)|A group receiving educational information about physical activity and exercise at home and then self-direction a 12-week exercise program on their own.
33282950|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
33282951|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
33282952|NCT04622072|Experimental|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
32936944|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
33282953|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
32778371|NCT04685941|Experimental|Flow-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to controlled saline intracoronary infusion by a dedicated microcatheter (RayFlow) at 20 ml/min during 2 minutes
32778372|NCT05587309|Experimental|Healing Phase - BLI5100|During the Healing Phase, patients will take BLI5100 once daily, orally, for up to 8 weeks.
32778373|NCT05587309|Active Comparator|Healing Phase - PPI Control|During the Healing Phase, patients will take a PPI control once daily, orally, for up to 8 weeks.
32778374|NCT05587309|Experimental|Maintenance Phase - BLI5100 Low Dose|During the Maintenance Phase, patients will take BLI5100 low dose once daily, orally, for 24 weeks.
32778375|NCT05587309|Experimental|Maintenance Phase - BLI5100 High Dose|During the Maintenance Phase, patients will take BLI5100 high dose once daily, orally, for 24 weeks.
32778376|NCT05587309|Active Comparator|Maintenance Phase - PPI Control|During the Maintenance Phase, patients will take a PPI control once daily, orally, for 24 weeks.
32778377|NCT04076059|Experimental|Double-blind treatment: Enzalutamide plus androgen deprivatio|Participants will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC ) and provided by the site's pharmacy stock.
32778378|NCT04076059|Placebo Comparator|Double-blind treatment: Placebo plus androgen deprivation ther|Participants will receive placebo once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) will be maintained during study treatment as per SOC and provided by the site's pharmacy stock.
32778379|NCT04076059|Experimental|Open-Label Phase: Enzalutamide|Participants who will receive placebo in double-blind phase and remain on study treatment until confirmed radiographic disease progression will receive enzalutamide in open-label phase.
32778380|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
32778381|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
32778382|NCT04421755|Experimental|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
32778383|NCT04421755|Experimental|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
32936945|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
33282954|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
33282955|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
33282956|NCT00526994|No Intervention|Control|no screen and no referral
32778384|NCT04421755|No Intervention|Control|Control group with no cooking classes or groceries
32778385|NCT05428345||Participants With UC or CD|Participants diagnosed with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist and have initiated treatment with vedolizumab in a routine clinical practical setting in South Korea, will be observed prospectively for 52 weeks.
32936946|NCT05454865|Experimental|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack (15 ml) oral use twice daily for two cycles (1 cycle = 3 wks)
32936947|NCT05454865|Placebo Comparator|Placebo group|Mimic Tea 1 pack (15ml) oral use twice daily in the first cycle, using Jin Si Herbal Tea in the 2nd cycle
32936948|NCT04507646|Experimental|True auricular acupuncture|Effective auricular acupuncture
32936949|NCT04507646|Sham Comparator|Sham auricular acupuncture|Ineffective auricular acupuncture
32778386|NCT04397185|Experimental|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
32778387|NCT04397185|Active Comparator|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
32778388|NCT05548777||Patients hospitalized for an anticoagulation-related major bleed|
32778389|NCT05213845|Other|Patients with chronic low back pain|
32778390|NCT04028401|Experimental|5 % benzoyl peroxide topical treatment|Application of 5% benzoyl peroxide
32778391|NCT04028401|No Intervention|No topical treatment|No intervention
32936950|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
32936951|NCT04191096|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
32936952|NCT04191096|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
32936953|NCT04507022|Experimental|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
32778392|NCT04016389|Experimental|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
32778393|NCT04130893|Experimental|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
32778394|NCT04130893|Experimental|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
32778395|NCT03908437|Experimental|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
32778396|NCT03908437|Active Comparator|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
32778397|NCT03906565|Experimental|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
33282957|NCT04743128|No Intervention|Control group|The control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
33282958|NCT04743128|Experimental|Exercise group|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
32778400|NCT05412511|Experimental|Training|Participants in this arm will perform seven medicine ball training exercises (acute bout per exercise) at two different conditions [Throwing a ball (TB) and no Throwing a ball (NTB)].
32778401|NCT05412511|No Intervention|Control|Participants in this arm will receive no intervention.
32778402|NCT05409235|Experimental|OTT166 Cohort 1|Participants will receive OTT166 low dose for 24 weeks
32778403|NCT05409235|Experimental|OTT166 Cohort 2|Participants will receive OTT166 high dose for 24 weeks
32778404|NCT05409235|Placebo Comparator|Vehicle control Cohort 1|Participants will receive vehicle control for 24 weeks
32778405|NCT05409235|Placebo Comparator|Vehicle control Cohort 2|Participants will receive vehicle control for 24 weeks
32778406|NCT05530993||Have considered use of PrEP|
32778407|NCT05530993||Have not considered use of PrEP|
32778408|NCT05534659||Programmable valve(PV) group|Adult patients with hydrocephalus who received programmable ventricular CSF shunts operation.
32778409|NCT05534659||Non-programmable valve(NPV) group|Adult patients with hydrocephalus who received non-programmable ventricular CSF shunts operation.
32936954|NCT04507022|Active Comparator|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
32778410|NCT05530681|Experimental|Participants|
32778411|NCT04304599|Experimental|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
32778412|NCT04130737|Experimental|TORUS Stent Graft System|The TORUS Stent Graft System (SGS) is comprised of a Stent Graft (SG) and a Stent Graft Delivery System (SGDS).
32778413|NCT05530525||Test-retest reliability and responsiveness group (All of the data was collected from medical record)|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture).
32778414|NCT04425187|Active Comparator|gefitinib|
32778415|NCT04425187|Experimental|gefitinib&bevacizumab|
32936955|NCT05272579|Experimental|FFT treatment|Treatment with fecal filtrate transfer in saline solution administered by nasogastric tube
32936956|NCT05272579|Placebo Comparator|Placebo Treatment|Treatment with saline solution administered by nasogastric tube
32936957|NCT00372788|Active Comparator|1|Pemetrexed
32936958|NCT00372788|Experimental|2|AZD6244
32936959|NCT04957316|No Intervention|Control group|Conventional treatment of severe septic shock.
32936960|NCT04957316|Experimental|Blood purification group|Conventional treatment of severe septic shock and blood purification.
32936961|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
32936962|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
32936963|NCT04334018|Placebo Comparator|conventional CRT|
32936964|NCT04334018|Experimental|MPP CRT|
32936965|NCT05253001|Experimental|study group|use mobile chatbot approach to improve prenatal education
32936966|NCT05253001|Placebo Comparator|controp group|a traditional approach to prenatal education
32778416|NCT03806803|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
32778417|NCT03806803|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
32778418|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
32778419|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
32936967|NCT05441293||debridements group|During study peroid, the patient who received debridement surgery for pressure injury
33282959|NCT04740242||Cohort of exposed patients (Group 1)|All patients admitted for decompensated HF and presenting MA at the time of admission
32936968|NCT05441293||flap reconstructions group|During study peroid, the patient who received flap reconstruction surgery for pressure injury
33282960|NCT04740242||Cohort of unexposed patients (Group 2)|All patients admitted for decompensated HF and who do NOT present MA at the time of admission
33282961|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
33282962|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months~1 Tablet, BID (morning and evening) for 6 months"
33282963|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
33282964|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
33282965|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
33282966|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
33282967|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
33282968|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
33282969|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
33282970|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
33282971|NCT00519194|Experimental|Epicor Cardiac Ablation|
33282972|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
33282973|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
33282974|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
33282975|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
33282976|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
33282977|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
33282978|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
33282979|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
33282980|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
33282981|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
33282982|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
33282983|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
33282984|NCT01035567|Active Comparator|Hybrid revascularization|
33282985|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
33282986|NCT00430989|Other|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
33282987|NCT00430989|Other|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
33282988|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
33282989|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
33282990|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
33282991|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
33282992|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
33282993|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
33102334|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
33102335|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
33282994|NCT04587674|Other|Spinal Cord Stimulation|
33282995|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
33282996|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
33083250|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
33083251|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
33282997|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
33282998|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
33282999|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
33283000|NCT00525902|Experimental|Adalimumab|
33283001|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
33283002|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
33283003|NCT00525590|Experimental|1|
33283004|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
33283005|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
33283006|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
33283007|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
33283008|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
33283009|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
33283010|NCT01035801|Experimental|IN105|Prandial Oral Insulin
33283011|NCT01035801|Active Comparator|Insulin Lispro Injection|
33283012|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
33283013|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
33283014|NCT03998306|Experimental|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
33283015|NCT03998306|Sham Comparator|CONTROL|no intervention
33283016|NCT05199662|Placebo Comparator|Control group|Placebo administered as a single bolus injection over 5 seconds
33283017|NCT05199662|Experimental|Intravenous tenecteplase (TNK)|Intravenous thrombolysis with Tenecteplase (TNK) at a dose of 0.25 mg/Kg (maximum 25mg, administered as a bolus over 5 seconds)
33283018|NCT04504526|Experimental|68Ga-Pentixafor, PET/CT|PET/CT perform after injecting 68Ga-Pentixafor
33283019|NCT04501406|Active Comparator|Pioglitazone|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving pioglitazone 15mg/day.
33283020|NCT04501406|Placebo Comparator|Placebo|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving placebo.
33283021|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
33283022|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
33283023|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
33283024|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
33283025|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
33283026|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
33283027|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
33283028|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
33283029|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
33283030|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
33283031|NCT03683576|Placebo Comparator|Placebo|Placebo once per day (QD) for 24 weeks
33283032|NCT03683576|Experimental|GB001 20 mg|GB001 20 mg QD for 24 weeks
33283033|NCT03683576|Experimental|GB001 40 mg|GB001 40 mg QD for 24 weeks
33283034|NCT03683576|Experimental|GB001 60 mg|GB001 60 mg QD for 24 weeks
33283035|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
33283036|NCT03998150|Active Comparator|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
32778420|NCT04425109|Experimental|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
32778421|NCT04425109|Experimental|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
32778422|NCT05523505|Sham Comparator|Sham stimulation|Participants receiving sham stimulation.
32778423|NCT05523505|Experimental|Reading and Language Network (RLN)|Participants receiving real stimulation to the left angular gyrus and left temporal pole.
33283037|NCT03998150|Active Comparator|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
32778424|NCT05523505|Experimental|Cognitive Control Network (CCN)|Participants receiving real stimulation to the bilateral dorsolateral prefrontal cortices.
32778425|NCT05523505|Experimental|RLN and CCN|Participants receiving real stimulation to the left dorsolateral prefrontal cortex and left angular gyrus.
33283038|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.~Initial titration:~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
33283039|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
33283040|NCT00430521|Experimental|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
33283041|NCT00430521|Experimental|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
33283042|NCT00430521|Experimental|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
33283043|NCT00430521|Experimental|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
33283044|NCT00430521|Experimental|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
33283045|NCT00430521|Experimental|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
33283046|NCT00430521|Experimental|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
33283047|NCT00430521|Experimental|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
33283048|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
33283049|NCT01036035|Active Comparator|Treatment B|Study drug
33283050|NCT01036035|Active Comparator|Treatment D|Study drug
33283051|NCT01036035|Placebo Comparator|Treatment E|Placebo
33283052|NCT01036035|Active Comparator|Treatment A|Study Drug
33283053|NCT01036035|Active Comparator|Treatment C|Study Drug
33283054|NCT01323699|Experimental|Behavioral Therapy|
33283055|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
33283056|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
33283057|NCT01036659|No Intervention|Historical Evaluation|
33283058|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
33283059|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
33283060|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
33283061|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
32778426|NCT05530135|Placebo Comparator|Control Group|Takotsubo patients receiving standard care
32778427|NCT05530135|Active Comparator|Exercise Group|Takotsubo patients who will undergo an exercise program in addition to standard care
32778428|NCT05530135|Active Comparator|CBT Group|Takotsubo patients who will receive cognitive behavioural therapy in addition to standard care
32778429|NCT03730207|Experimental|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
33283062|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
33283063|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
33283064|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
33283065|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
33283066|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
33283067|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
32778430|NCT03730207|Active Comparator|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
32778431|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
32778432|NCT05534113|Experimental|sequential Envafolimab therapy after Almonertinib treatment|Sequential Envafolimab therapy after patients with ctDNA EGFR mutation clearance and achieve stable radiographically deep response after treatment with Almonertinib
32778433|NCT05534035|Experimental|PTX-COVID19-B|
32778434|NCT05534035|Active Comparator|Vaxzevria®|
32778435|NCT05530057|Experimental|Eribulin + SB3|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.
32778436|NCT05530057|Active Comparator|Eribulin monotherapy|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.
32778437|NCT05533957|Experimental|Oxygen therapy administration|Three different dosages of oxygen therapy will be administered to Chronic Obstructive Pulmonary Disease (COPD) with Chronic Respiratory Failure (CRF) and Long Oxygen Therapy (LTOT)
32778438|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
32778439|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
32778440|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
32936969|NCT04759794|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
32936970|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga~60 minutes once weekly for 8 weeks"
32936971|NCT03515564|No Intervention|No Intervention|No Intervention
32936972|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
32778441|NCT04310917|Other|Lipoprotein a level|blood lipoprotein (a) test
32936973|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
32778442|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
32778443|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
32936974|NCT04759716|Experimental|Health Literacy-based Weight Control Intervention arm|intervention arm will receive weight control program
32936975|NCT04759716|No Intervention|control arm|routine care
32778444|NCT05519839|Experimental|Group A (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
32778445|NCT05519839|Experimental|Group B (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
32936976|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
32936977|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
32936978|NCT05211505|Experimental|WO 2707|Formulation containing WO 2707 for intravaginal application
32936979|NCT00372151|Experimental|L-Theanine|
32936980|NCT00372151|Placebo Comparator|Placebo|
32936981|NCT04336267|Experimental|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
32936982|NCT04336267|Sham Comparator|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
32936983|NCT00372476|Experimental|Imatinib + Vinorelbine|
32936984|NCT04457492|Experimental|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
32936985|NCT04457492|Experimental|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
32936986|NCT04457492|No Intervention|Standard of Care Group|"No FES~Assessments will be taken at the same intervals as the interventions group."
32936987|NCT05450029|Experimental|Chemoradiotherapy and PD1 inhibitor|
33102336|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
32778446|NCT05519839|Experimental|Group C (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 3. 1 dose on Days 0.
32778447|NCT05519839|Experimental|Group D (Part 1)|CIC Vaccine Formulation1 doses of Formulation 4. 1 dose on Days 0.
32778448|NCT05519839|Experimental|Group E (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 5. 1 dose on Days 0.
32778449|NCT05519839|Experimental|Group F (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 6. 1 dose on Days 0.
32778450|NCT05519839|Experimental|Group G (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 7. 1 dose on Days 0.
32778451|NCT05519839|Experimental|Group H (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 8. 1 dose on Days 0.
32778452|NCT05519839|Experimental|Group I (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 9. 1 dose on Days 0.
32778453|NCT05519839|Experimental|Group J (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 10. 1 dose on Days 0.
32778454|NCT05519839|Experimental|Group K (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 11. 1 dose on Days 0.
33083252|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
33083253|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
33083254|NCT04484909|Experimental|Treatment (NBTXR3, radiation therapy)|Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.
33083255|NCT04593043||Warfarin|Reference group
33083256|NCT04593043||Dabigatran|Exposure group
32778455|NCT05519839|Experimental|Group L (Part 1)|qNIV Vaccine Formulation 1 doses of Formulation 12. 1 dose on Days 0.
32778456|NCT05519839|Experimental|Group M (Part 1)|qNIV Vaccine Formulation 1 doses of Formulation 13. 1 dose on Days 0.
32778457|NCT05519839|Experimental|Group N (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 14. 1 dose on Days 0.
32778458|NCT05519839|Experimental|Group O (Part 1)|SARS-CoV-2 rS Vaccine Formulation 1 doses of Formulation 15. 1 dose on Days 0.
32778459|NCT05519839|Experimental|Group P (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 16. 1 dose on Days 0.
32778460|NCT05519839|Experimental|Group Q (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 17. 1 dose on Days 0.
32778461|NCT05519839|Experimental|Group R (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 18. 1 dose on Days 0.
32778462|NCT05519839|Experimental|Group S (Part 1)|Comparator Influenza Vaccine Formulation 1 doses of Formulation 19. 1 dose on Days 0.
32778463|NCT05519839|Experimental|Group T (Part 1)|Comparator Influenza Vaccine Formulation 1 doses of Formulation 20. 1 dose on Days 0.
32778464|NCT05519839|Experimental|Group U (Part 2)|CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
32778465|NCT05519839|Experimental|Group V (Part 2)|CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
32778466|NCT03648073|Experimental|Patients with Radiographic Evidence of HCC on CT or MRI|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
32778467|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
32778468|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
32778469|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
32778470|NCT05533879|Experimental|Yoga group|Women with having received a minimum of 17 points from the kinesiophobia questionnaire, have chronic low back pain and aged between 25-65
32778471|NCT05529745|Experimental|Treatment in cerebellar lesioned patient|Group of patients with a lesion of the cerebellum gaining a neurorehabilitation intervention
32778472|NCT05529745|Active Comparator|Treatment in supratentorial lesioned patient|Group of patients with a lesion of the supratentorial area gaining a neurorehabilitation intervention
32778473|NCT05533723||Percutaneous epidural neuroplasty (PEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received PEN in patients who did not respond to medication and epidural nerve block treatment.
32778474|NCT05533723||Endoscopic epidural neuroplasty (EEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received EEN in patients who did not respond to medication and epidural nerve block treatment.
32900168|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
33083257|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
33083258|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
33083259|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
33083260|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
33083261|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
33083262|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
33083263|NCT04592146|Active Comparator|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
32778475|NCT05529667|Experimental|Experimental|"phase>~INCB054828 begins with oral administration of 13.5 mg once a day.~Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression.~phase>~INCB54828 is dosed at the dose specified in phase 1.~Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression"
32778476|NCT05533645|Experimental|Experimental group|patients with high blood pressure or chronic kidney diseases stages 4-5
32778477|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
32778478|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
32778479|NCT05197387||Cases|Women with intrahepatic cholestasis of pregnancy
32778480|NCT05197387||Controls|Women without intrahepatic cholestasis of pregnancy
32778481|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
32778482|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
32778483|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
32778484|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
33083264|NCT04592146|Experimental|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
33083265|NCT04592380|Experimental|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
32778485|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
32778486|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
32778487|NCT05365477|Active Comparator|Empiric Therapy|Diet intervention and drug intervention not based on 24 hour urine results
32778488|NCT05365477|Experimental|Selective Therapy|Diet intervention and drug intervention based on 24 hour urine results
32778489|NCT05529511||Phase 1 - Preoperative|"Interviews to be completed with approximately 12 participants at three time points:~Prior to anterior cruciate ligament surgery~3-month after anterior cruciate ligament surgery~12-months anterior cruciate ligament surgery"
32778490|NCT05529511||Phase 2 - Nominal Group Technique panel|Consensus meeting with up to 12 participants (clinicians, patients and stakeholders) to develop the prehabilitation intervention
32778491|NCT05529433|Active Comparator|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is a simple technique based on preservation of sound tooth structure and minimal patient's discomfort.
32778492|NCT05529433|Experimental|Smart Burs|Smart Burs are minimally invasive technique which selectively removes the infected carious dentin leaving the affected intact dentin.
32778493|NCT05529433|Experimental|Chemo-Mechanical Caries Removal (CMCR)|A chemical agent which selectively removes the carious dentin by breaking the denatured collagen fibers making them soft and preserving the healthy dentin without drilling.
32778494|NCT05533255|Experimental|Preheated Resin Composites|Preheated resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on either one quadrant of the maxillary arch.
32778495|NCT05533255|Active Comparator|Conventional Resin Composites|Conventional resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on the other quadrant of the maxillary arch.
32778496|NCT05533177||Schizophrenia, schizotypal and delusional disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F20-F29 Schizophrenia、schizotypal and delusional disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
33102337|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
33083266|NCT04592380|Placebo Comparator|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
33102338|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
33283068|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
33283069|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
33283070|NCT01325116|Active Comparator|Control|Usual post-STEMI care
33283071|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
33283072|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
33283073|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
33283074|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
33283075|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
33283076|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
33283077|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
33283078|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
33283079|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
33283080|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
33283081|NCT03989752|Experimental|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
33283082|NCT00417885|Experimental|A|sunitinib + exemestane
33283083|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
33283084|NCT03989596|Experimental|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
33283085|NCT01036893|No Intervention|oral contraceptives without prucalopride|
33283086|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
33283087|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
33283088|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
33283089|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
33283090|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
33283091|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
33283092|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
33283093|NCT04488770|Experimental|Part 1 (SAD) Cohort 1:Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
33283094|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 1:Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
33283095|NCT04488770|Experimental|Part 1 (SAD),Cohort 2: Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 500 mg, 15 mg and 900 mg orally on Day 1 of period 1, 3 and 2 respectively.
33283096|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 2: Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 3 and 2.
32778497|NCT05533177||Mood disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F30-F39 Mood disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
32778498|NCT05533177||Neurotic, stress-related and somatoform disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F40-F48 Neurotic、stress-related and somatoform disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
32778499|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
32778500|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
32778501|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
32778502|NCT03445585||Control group 2|Patients without liver disease.
32778503|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:~Tumour tissue samples~Blood samples~Ascites samples~Other fluids requiring drainage"
32778504|NCT05529355|Experimental|Envafolimab plus Endostar and S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
32778505|NCT05529355|Active Comparator|Envafolimab plus Endostar|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles),
32778506|NCT05529355|Active Comparator|Envafolimab plus S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
32778507|NCT05529277||Dyad of person with cognitive impairment and caregiver|Households identified in routine care receiving a home-based Dementia Care Management.
32778508|NCT05533021|Experimental|intervention group|Training and consultancy
32778509|NCT05533021|No Intervention|control group|Standard postpartum care
33283097|NCT04488770|Experimental|Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg|In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
32778511|NCT05507437|Experimental|TIN816|Administered as an intravenous dose
32778512|NCT05507437|Placebo Comparator|Placebo|0.9% sterile sodium chloride solution administered as an intravenous dose
32936988|NCT04334096|Experimental|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
32778513|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
32936989|NCT04737967|Experimental|Venlafaxine Treated Arm|
32936990|NCT04737967|Experimental|Memantine Treated Arm|
32936991|NCT04441892|Experimental|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
32936992|NCT04441892|Experimental|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
32936993|NCT05350111|Other|group supported through group education and telemedicine tools|the group of this pilot study will be compared to conventional obesity clinic
32936994|NCT03464630|Experimental|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
32936995|NCT03464630|Active Comparator|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
32936996|NCT04334629|No Intervention|Standard of care|
32936997|NCT04334629|Experimental|Standard of care plus lipid ibuprofen|
32936998|NCT04334564|Active Comparator|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
32936999|NCT04334564|Placebo Comparator|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
32937000|NCT04334551|Experimental|switch from etravirine to doravirine|switches to doravirine,
32937001|NCT04334785|Experimental|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
33102339|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
33102340|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
33283098|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 3: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
33283099|NCT04488770|Experimental|Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg|GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
33283100|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 4: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
33283101|NCT04488770|Experimental|Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg|GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
33283102|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 5: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
33283103|NCT04488770|Experimental|Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg|GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
33283104|NCT04488770|Placebo Comparator|Part 2(MAD),Cohort 6: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
33283105|NCT04586894||Patients|
33283106|NCT00525044|Placebo Comparator|Control|
33283107|NCT00525044|Experimental|Ambroxol|
33283108|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
33283109|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
33283110|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
33283111|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
33283112|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
33283113|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
32778514|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
33283114|NCT01051882|Experimental|MSC-NTF cells IM|Intramuscular administration in early stage patients
33283115|NCT01051882|Experimental|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
33283116|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
33283117|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
33283118|NCT03989674|No Intervention|White bread|
33283119|NCT03989674|Experimental|Anthocyanin-fortified bread (2% w/w)|
33283120|NCT03989674|Experimental|Anthocyanin-fortified bread (4% w/w)|
33283121|NCT04678232|Experimental|receive PATH therapy|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
33283122|NCT03986788|Other|Weightlessness|Weightlessness measurements during flight
33283123|NCT03989830|Experimental|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
33283124|NCT03989518|Experimental|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
33283125|NCT03989518|Experimental|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
33283126|NCT03989284|Experimental|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
33283127|NCT03989284|Experimental|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
33283128|NCT03989284|Experimental|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
33283129|NCT03989284|No Intervention|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
33283130|NCT00355264|Experimental|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
33283131|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
33283132|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
33083267|NCT04592380|Experimental|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
33083268|NCT04592380|Active Comparator|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
33283133|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
33083269|NCT04471220|Active Comparator|Low FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 10 L/min).
33283134|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
33283135|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
33283136|NCT01056874|Active Comparator|Digoxin|
33283137|NCT01056874|Experimental|Digoxin + Maraviroc|
33283138|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
33283139|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
33283140|NCT00355030|Experimental|1|
33283141|NCT00355030|Experimental|2|
33283142|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
33283143|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
33283144|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
33283145|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
33283146|NCT03991546|Experimental|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
33283147|NCT03991546|No Intervention|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
33283148|NCT03986632|Experimental|Tundra gifts program|
33283149|NCT03986632|No Intervention|Comparison|
33283150|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
33283151|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
33283152|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
33283153|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
33283154|NCT01057108|Placebo Comparator|CKD Matching Placebo|
33283155|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
33283156|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
33283157|NCT03986476|Experimental|Lactobacillus reuteri strain 1|Probiotic compound
33283158|NCT03986476|Experimental|Lactobacillus reuteri strain 2|Probiotic compound
33283159|NCT03986476|Placebo Comparator|Placebo|Placebo
33283160|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
33283161|NCT03991312|Experimental|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
33283162|NCT03991312|Experimental|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
33283163|NCT03988972|Experimental|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
33283164|NCT03988972|Active Comparator|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
33283165|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
33283166|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
33283167|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
33283168|NCT01054690|Experimental|Silver alloyed urinary catheter|
33283169|NCT01054690|Placebo Comparator|Silicone urinary catheter|
33283170|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
33283171|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
33283172|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
33083270|NCT04471220|Active Comparator|Low FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min).
33083271|NCT04471220|Active Comparator|High FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min).
33283173|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
32778515|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
32778516|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
33283174|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
32778517|NCT05528965|Experimental|Perpendicular Group|Perpendicular genicular radiofrequency application
32778518|NCT05528965|Active Comparator|Parallel Group|Parallel genicular radiofrequency application
33283175|NCT01057576|Placebo Comparator|Placebo|Placebo
33283176|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
33283177|NCT03986242|Experimental|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
32778519|NCT05532943|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.
32778520|NCT05532943|Sham Comparator|Placebo|For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn.
32778521|NCT05528887|Experimental|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
32778522|NCT05532865||Adults with systemic sclerosis|It is a descriptive cohort of systemic sclerosis patients
32778523|NCT05501821|Experimental|Part A, dose escalation monotherapy|KBA1412 monotherapy, given intravenously, Q3W, multiple dose levels
32778524|NCT05501821|Experimental|Part B, expansion monotherapy|KBA1412 monotherapy, given intravenously, Q3W, at fixed dose as defined in dose-escalation phase (Part A)
33083272|NCT04471220|Active Comparator|High FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min).
33083273|NCT04592497|Experimental|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
33083274|NCT04592497|Active Comparator|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
32778525|NCT05501821|Experimental|Part C, expansion combination therapy|KBA1412 in combination with pembrolizumab, given intravenously, Q3W, KBA1412 at fixed dose as defined in dose-escalation phase (Part A), Pembrolizumab at fixed dose
32778526|NCT05528653|Other|Open Label Descovy|Descovy for PrEP
33083275|NCT04591990|Experimental|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
33083276|NCT04591990|Experimental|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
33083277|NCT04591990|Experimental|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
33083278|NCT04591990|Experimental|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
32778527|NCT03016975|Experimental|Randomized - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
32778528|NCT03016975|Active Comparator|Randomized - Control|Guideline directed medical therapy (GDMT)
32778529|NCT03016975|Experimental|Roll-In - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
32778530|NCT05532787||Chest pain|Patients >18 years of age presenting to ED with chief complaint of chest pain or cardiac symptoms suggestive of acute coronary syndrome with at least one troponin ordered, without evidence of ST-segment elevation myocardial infarction on ECG
32778531|NCT05528497|Experimental|VR+|For patients in the experimental group, using the virtual reality headset, the caregiver will place the headset on the patient as she is laid on the surgical table. The caregiver will ensure that the patient can see and hear the sequence that is being performed. The caregiver can then proceed to the different stages of ovocyte retrieval. Once the procedure is finished, the caregiver tells the patient that she can remove the headset
33083279|NCT04438265||quadratus lumborum|analgesic technique. The evaluation of the patient will consist of 2 stages. The first of these will consist of the evaluation consultation (clinical history, EVN evaluation, WOMAC) and initial treatment (QL2 block). In the second stage, the patient will be followed up with interviews at 3 weeks, 3 and 6 months.
33083280|NCT04438265||Control|Current analgesia , no QL block apply
33083281|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
33083282|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
33283178|NCT03986242|Experimental|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
33283179|NCT03986242|Experimental|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
33283180|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
32778532|NCT05528497|No Intervention|Control|For patients in the control group, without a headset, the oocyte retrieval procedure will not be modified.
33283181|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
33283182|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
33283183|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
33283184|NCT03988816|Experimental|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
33283185|NCT03988816|Placebo Comparator|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
33283186|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
33283187|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
33283188|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
33283189|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
33283190|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
33283191|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
33283192|NCT03988894|No Intervention|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
33283193|NCT03988894|Active Comparator|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
33283194|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
33283195|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
32778533|NCT05345899|Other|chronic rheumatism|Population of patients followed for chronic inflammatory rheumatism in remission or lupus in low activity, with chronic residual pain
32778534|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
33083283|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
33083284|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
33083285|NCT04591873||Critical patients in the emergency department|
33083286|NCT04591756|Active Comparator|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
33283196|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
33283197|NCT04782518||Participants with PD|Adults with Parkinson Disease. This is an observational study without an intervention.
33283198|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
33283199|NCT01565252|No Intervention|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
33283200|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
33283201|NCT04462796|Experimental|Magnesium Citrate|Magnesium Citrate given orally taken once daily for 8 weeks
33283202|NCT00524030|Experimental|1|
33283203|NCT00524030|Experimental|2|
33283204|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
32778535|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
33083287|NCT04591756|Active Comparator|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
33083288|NCT04423757|Experimental|BI 1358894|
33283205|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
33283206|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
33283207|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33283208|NCT00345358|Active Comparator|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
33283209|NCT00345358|Experimental|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
33283210|NCT00345358|Experimental|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
33283211|NCT00345358|Experimental|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
33283212|NCT03869684|Experimental|MT-0814 High dose|
33283213|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
33283214|NCT03869684|Placebo Comparator|Placebo|
33283215|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
33283216|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
33283217|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
33283218|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
33283219|NCT01054924||U.S. CRC screening population|
33283220|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
33283221|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
33283222|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
33283223|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
33283224|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
33283225|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
33283226|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
33283227|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
33283228|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
32778536|NCT04425343|Experimental|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
33283229|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
33283230|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
33283231|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
33283232|NCT01004978|Experimental|Arm A (sorafenib and TACE)|Patients receive sorafenib tosylate at 400mg PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (this option may only be utilized for patients registered prior to addendum #3); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising LC bead and doxorubicin. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33083289|NCT04423757|Placebo Comparator|Placebo|
33083290|NCT04591795|Experimental|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
33083291|NCT04591795|Experimental|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
33083292|NCT04591639|Other|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
33083293|NCT04591639|Other|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
33083294|NCT04719585|Experimental|Experimental: Duloxetine group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
33083295|NCT04719585|Active Comparator|Active comparator: Opioid group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
33283233|NCT01004978|Active Comparator|Arm B (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm A.
33083296|NCT04592029|Experimental|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
33283234|NCT00522626||Observational|Opioid exposed pregnancies
33283235|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
33283236|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
33283237|NCT00511472|Experimental|MK-0941|
33283238|NCT00511472|Placebo Comparator|Placebo|
33283239|NCT01033305|Placebo Comparator|Placebo|
33283240|NCT01033305|Experimental|CyCol™|
33283241|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
33283242|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
33283243|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33283244|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
33283245|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
33283246|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
33283247|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
33283248|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
33283249|NCT04384328|Experimental|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
33283250|NCT04384328|No Intervention|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
33283251|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
33283252|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
33283253|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
33283254|NCT04378790|Active Comparator|Sequential treatment|full-time spectacle correction first, with subsequent patching for 2 hours per day/7 days per week only if needed (no improvement (stable/worsening) and residual)
33283255|NCT04378790|Experimental|Simultaneous treatment|full-time spectacle correction and part-time patching for 2 hours per day/7 days per week
33283256|NCT00440037|Experimental|AMG 531|
33283257|NCT04316546|Experimental|MK-7075 (miransertib)|This is a single-arm study. All study participants will be taking the experimental drug, MK-7075 (miransertib).
33283258|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
33083297|NCT04409873|Placebo Comparator|Control (Distilled Water)|Over the counter: Distilled water
33083298|NCT04409873|Experimental|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
33083299|NCT04409873|Experimental|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
33283259|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
33283260|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
33283261|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
33283262|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
33283263|NCT01033461|Experimental|calcium and probiotic|intervention
33283264|NCT01033461|Experimental|probiotic|intervention
33283265|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
33283266|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
33283267|NCT01786785||Controls|Age and Gender Matched Controls
33283268|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
33283269|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
33283270|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
33283271|NCT01037439|Active Comparator|Conventional ASV|Current adaptive servoventilation therapy algorithm for non invasive ventilation treatment of Cheyne-Stokes Respiration.
33283272|NCT01037439|Experimental|Modified ASV|Modified adaptive servoventilation algorithm for improved treatment of nocturnal breathing disorders
33283273|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
33283274|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
33283275|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
33283276|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
33283277|NCT03067467||Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
33283278|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
33283279|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
33283280|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
33283281|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
33283282|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
33083300|NCT04409873|Experimental|CloSYS (ClO2) mouthwash|Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
33083301|NCT04409873|Experimental|Listerine Mouthwash|Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
33283283|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
33283284|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
33283285|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
33283286|NCT03993483|Experimental|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
33283287|NCT03993483|Experimental|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
32778537|NCT04425343|Experimental|Metgenomic analysis|Analysis for whole bacterial count
32778538|NCT05340751||Anesthesia|hemoglobin
33102341|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
32778539|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
32778540|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
32778541|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
32778542|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
32778543|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
32778544|NCT04302727|Experimental|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
32778545|NCT04302727|Active Comparator|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
32778546|NCT05334589|Experimental|Experimental: Intervention group|Patients in the intervention group will be prewarming with a hot air blowing system for 30 minutes before the operation. The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
32778547|NCT05334589|No Intervention|Control group|The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
32778548|NCT05532553||Group 1|Patient with T2DM and fatty liver.
32778549|NCT05532553||Group 2|patients with fatty liver only ( control group).
32778550|NCT02813785|Experimental|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
32937002|NCT04391114|Active Comparator|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
32778551|NCT02813785|Active Comparator|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
32937003|NCT04391114|Active Comparator|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence [8]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) [9]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
32937004|NCT05179447|Experimental|Molecular profile based treatment|Determination of the integrated genomic-pathologic profile to determine adjuvant treatment: observation for POLE-mutated profile; vaginal brachytherapy for intermediate profile; chemo-radiotherapy for p53-abnormal profile.
32937005|NCT05179447|Active Comparator|Radiotherapy|Adjuvant vaginal brachytherapy for intermediate risk (stage I A with G3 or stage I B with G1-2) and external beam pelvic radiotherapy for high-intermediate risk (stage I B with G3, or stage II) (standard treatment)
32937006|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
32937007|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
32937008|NCT05158153|Experimental|ORKID Bundled Intervention|
32937009|NCT04367090|Experimental|Pyrotinib and docetaxel plus trastuzumab|
32937010|NCT05131399|Experimental|Self-comparison|"Patients will be fitted with 2 types of ankle foot orthoses, alternately, divided into 4 phases, in the following order:~Phase A1: Standard Plastic ankle foot orthosis Phase B1: carbon medical device ankle foot orthosis Phase A2: Standard Plastic ankle foot orthosis Phase B2: carbon medical device ankle foot orthosis Each patient is his own comparator. For all patients, the total duration of the study will be the same, and will correspond to 12 weeks."
33283288|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
33283289|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
33283290|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
33283291|NCT03928665||Control group|
33283292|NCT03928665||Sleep apnea using CEPAP|
33283293|NCT03928665||Sleep apnea not using CEPAP|
33283294|NCT03928665||Glaucoma control group|
33283295|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
33283296|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
33283297|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
33283298|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
33283299|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
33283300|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
33283301|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
33283302|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
33283303|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
33283304|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
32937011|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
32937012|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
32937013|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
32937014|NCT05107609|Experimental|Self-Compassion Intervention|Participants will be guided through an acute, 30-minute self-compassion intervention consisting of psychoeducation, guided loving-kindness meditation, compassionate imagery and a compassionate writing activity.
32937015|NCT05107609|No Intervention|Resting Control Intervention|Participants will be asked to sit quietly and independently for 30 minutes. They can read neutral magazines provided or their own reading/writing material, but will be asked not to use outside electronic devices or communicate with anyone external.
32937016|NCT04328558|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
32937017|NCT04328558|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
32937018|NCT05350033|Experimental|Active-Active|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h) and in Phase 2 (5 sessions, intersession time-24h).
32937019|NCT05350033|Experimental|Active-Sham|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
32937020|NCT05350033|Experimental|Sham-Active|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and active-tDCS at 2 mA during 20 min in Phase 2 (5 sessions, intersession time-24h).
32937021|NCT05350033|Sham Comparator|Sham-Sham|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
32778552|NCT05491915|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 leads placed in the back of their neck, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
32778553|NCT04302181|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
32778554|NCT05528341|Experimental|NKG2D-CAR-NK92 cells immunotherapy|Preparation of NKG2D-CAR-NK92 cells suspended in saline solution.
32778555|NCT05528185|Experimental|Intervention|The intervention consists of family participation in morning interdisciplinary team rounds in the cardiac ICU. Family participation will consist of orientation, engagement, summary, questions, and communication follow-up by the care team.
32778556|NCT05528185|No Intervention|Usual care|Usual care consists of interdisciplinary team rounds that occur outside the patient's room each morning without a family member present.
32778557|NCT05532475||cases|patient with retinal vein occlusion
32778558|NCT05532475||control|cataract patient undergoing cataract surgery
32778559|NCT05527951|Experimental|Enhanced MBC Implementation(eMBC)|The eMBC implementation arm use our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
32778560|NCT05527951|Active Comparator|Standard MBC Implementation|The standard MBC implementation arm use paper and pencil questionnaires.
32778561|NCT05532397|Experimental|QPOP-guided chemotherapy|Subjects enrolled in the study will be administered combination of chemotherapy derived from QPOP analysis based on in vitro drug screening panels which comprises anti-cancer agents which have previously been evaluated in recurrent high grade astrocytic glioma.
32778562|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
32778563|NCT05527795||Non-mutated|Non mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
32778564|NCT05527795||BRAF-mutated|BRAF-mutated stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
32778565|NCT05527795||NRAS-mutated|NRAS-mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
32778566|NCT04128553|Experimental|Intervention motivational interview group|"Face-to-face motivational interviews lasted for an average of 30 minutes. After the MI, the exercise information guideline prepared by the researcher and the TTM-based MI guideline according to the stages were given to the older adults. During the MI, a form prepared by the researcher was used to note the content of the interview. At the end of MI, the next appointment was planned. In addition, the older adults were given a chart prepared by the researcher to note their walk.~On the other hand, the phone-based motivation interviews lasted an average of five to seven minutes. Before the telephone interview, it was determined which stage of change the older adult was in. Then a motivational interview was held according to the stage."
32778567|NCT04128553|No Intervention|Control|The Control Group (CG) was only followed up at the beginning and end of the study, no intervention was made. The CG received standard care. Although the family health staff do not give routine and standard training about the benefits of exercising in the FHC to the elderly, they give information when necessary.
32778568|NCT05527639|Other|intervention group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats. They had all completed a program of Kegel exercise prior.
32778569|NCT05527639|Other|control group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats
32778570|NCT05527561|Experimental|Latin Dance-Rumba|Rumba dance training was shown for the 1-6 weeks.
32778571|NCT05527561|Experimental|Latin Dance-Cha Cha Cha|Cha Cha Cha dance training for the 7-12 weeks.
32778572|NCT05532241|Experimental|metal + OH|fixed metal orthodontic appliance with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
33102342|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
32778573|NCT05532241|Experimental|metal + CHX|fixed metal orthodontic appliance with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
32778574|NCT05532241|Placebo Comparator|non-metal + OH|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
32778575|NCT05532241|Active Comparator|non-metal + CHX|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
32778576|NCT05467111|Experimental|Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines) 24-48 hours prior to each cycle of anthracyclines.
33102343|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
32778577|NCT05467111|No Intervention|Control|Patients will receive standard treatment for each type of tumor proposed by the hospital. This group of patients will be provided with the international recommendations on physical exercise for cancer patients.
32778578|NCT05453461|Experimental|new COMs for non ambulant FSHD patients|
32778579|NCT05176639|Experimental|Phase 1/2 MAD (HV and TED)|Healthy participants and participants with TED will be randomized to receive two intravenous infusions of VRDN-001 or placebo with an interval of 3 weeks.
32778580|NCT05176639|Experimental|Phase 2/3 extension study|Participants with TED will be randomized to one of two VRDN-001 dosing regimens or placebo. The dosing regimens may include doses up to 20 mg/kg with the dosing interval and duration to be defined based on the results of the MAD study part.
32778581|NCT02431897|Experimental|Estrogen Cream|Conjugated Estrogens cream
32778582|NCT02431897|Placebo Comparator|Placebo Cream|Placebo cream
33102344|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
33102345|NCT03708809|Experimental|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
32778583|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
32778584|NCT05532163|Experimental|Natalizumab|Participants will receive natalizumab 300 milligrams (mg) (2*150 mg), SC injection, once every 4 weeks (Q4W) up to Week 24.
32778585|NCT05527249|Experimental|Dietary supplement group|20g of protein powder + 1 tablet of pomegranate extracts / day for 21 days of the dietary supplement, to be taken every day before lunch time.
32778586|NCT05527249|Placebo Comparator|Placebo group|20g of protein powder + 1 tablet of maltodextrin / day for 21 days of the dietary supplement, to be taken every day before lunch time.
32937022|NCT04853888|Other|Intervention group|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal."
32778587|NCT05532085||Group: Medical abortion without analgesic protocol|All women over the age of 15, benefiting from a medical abortion between June and October 2020, including oral French.
32778588|NCT05532085||Group: Medical abortion with analgesic protocol|All women over the age of 15, benefiting from a medical abortion between October 2020 and February 2021, including spoken French.
32778589|NCT05532085||Group: Abortion by aspiration under local anesthesia without analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between June and October 2020, including oral French.
32778590|NCT05532085||Group: Abortion by aspiration under local anesthesia with analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between October 2020 and February 2021, including oral French.
32778591|NCT05318287|Experimental|PeriGrief|A brief four-module intervention delivered via computer or mobile device. Modules utilize mindfulness and cognitive behavioral therapy strategies to reduce distress following perinatal loss.
32778592|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
32778593|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
32778594|NCT02303119|Experimental|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
32778595|NCT02006251|Active Comparator|Standard Total Hip Arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
32778596|NCT02006251|Experimental|Real-time Instrumentation|Pre-operative planning through 3D software with design of real-time instrument intraoperatively using bone cement and surrogate bone model for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
32778597|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
32778598|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
32778599|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
32778600|NCT01712659|Experimental|Original Phase II Standard Ruxolitinib dose cohort|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
32778601|NCT01712659|Experimental|2- Phase 1 Dose Escalation cohorts|"Dose level 1: Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 2: Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 3: Ruxolitinib: Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity."
32778602|NCT01712659|Experimental|3- Phase 1 Dose Expansion Cohort|Ruxolitinib at the maximum tolerated dose (MTD) or the maximum administered dose (MAD) defined in the phase 1 dose escalation cohorts. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
32778603|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
32778604|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
32778605|NCT05531851|Experimental|Experiment group.|İnstrument-assisted soft tissue mobilization will be applied after the delayed onset muscle soreness induction protocol
32778606|NCT05531851|No Intervention|Control Group|Delayed onset muscle soreness generation protocol will be applied
32778607|NCT01610713|Experimental|GW-1000-02|Active treatment.
32778608|NCT05163301|Experimental|Computer delivered RPI|2 session computer delivered counseling to prevent relapse to hazardous drinking
32778609|NCT05163301|Experimental|Person delivered RPI|2 session counselor delivered counseling to prevent relapse to hazardous drinking
32778610|NCT05163301|No Intervention|Treatment as Usual|Counseling for alcohol use available in clinic as treatment as usual
32778611|NCT05162755|Experimental|Dose escalation 1a: S95029|
32937023|NCT05457127|Experimental|Automatic Positive Airway Pressure (APAP) device|
32937024|NCT04336111|No Intervention|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
33083302|NCT04591951|Active Comparator|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
33083303|NCT04591951|Placebo Comparator|Control Group|"The caregivers in the control group will receive usual care."
33283305|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
33283306|NCT03993795|Experimental|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33283307|NCT03993795|Experimental|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33283308|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
33283309|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
33283310|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
33283311|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
33283312|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
33283313|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
33283314|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
33283315|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
33283316|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283317|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283318|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283319|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283320|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283321|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283322|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
33283323|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283324|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283325|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
33283326|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
33283327|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
32937025|NCT04336111|Experimental|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
33283328|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
33283329|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
33283330|NCT03997734|Experimental|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
33283331|NCT03997734|Experimental|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
33283332|NCT03997734|Active Comparator|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
33283333|NCT03997734|Placebo Comparator|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
33283334|NCT03997734|Placebo Comparator|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
32778612|NCT05162755|Experimental|Dose escalation 1b: S95029 and Sym021|
32937026|NCT05456971|Experimental|Art filler Volume|To confirm the capacity of the VOLUME filler to restore a midface volume 3 weeks after the first injection or after 6 weeks if a touch up was performed at 3 weeks.
33283335|NCT03997890|Experimental|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
33283336|NCT03997344|Experimental|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
33283337|NCT03997344|Active Comparator|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
33283338|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
33283339|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
33283340|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
33283341|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
33283342|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
33283343|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
33283344|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
33283345|NCT03034785|No Intervention|Group 1|Term
33283346|NCT03034785|No Intervention|Group 2|Preterm
32937027|NCT05456971|Experimental|Art Filler Lips|To confirm the capacity of the LIPS filler to restored volume of the treated lip 3 weeks after the first injection or at 6 weeks if a top up at 3 weeks is performed.
32937028|NCT04737590|Active Comparator|Bioactive glass|20 bone cysts (in 20 patients) are filled with bioactive glass
33283347|NCT03034785|Experimental|Group 3|Term
33283348|NCT03034785|Experimental|Group 4|Preterm
33283349|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
33283350|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
33283351|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.~The intervention will be done twice weekly for 8 weeks."
33283352|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
33283353|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
32937029|NCT04737590|Active Comparator|Allogenic bone|20 bone cysts (in 20 patients) are filled with allogenic bone
32937030|NCT04737434|Experimental|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave
32937031|NCT04737434|Placebo Comparator|electromagnetic field with no wave|electromagnetic field with no wave
32937032|NCT05349877|Experimental|Expressive writing|Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.
32937033|NCT05349877|Experimental|Self-affirmation|Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.
33283354|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
33283355|NCT03906279||Myopic participants|
33283356|NCT03906279||Emmetropic participants|
33283357|NCT03906279||Hyperopic participants|
33283358|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
33283359|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
33283360|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
33283361|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
33283362|NCT00404547|Active Comparator|Usual Care|
32778613|NCT05162755|Experimental|Dose expansion 2a: S095029 and Sym021 and anti-HER2 therapy|
32778614|NCT05162755|Experimental|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|
32778615|NCT05527093|Experimental|Patients with focal temporal lobe epilepsy for at least one year, drug-resistant|
32778616|NCT01606189|Experimental|GW-1000-02|Active treatment.
32778617|NCT01606189|Experimental|GW-2000-02|Active treatment.
32778618|NCT01606189|Placebo Comparator|Placebo|Placebo control.
33283365|NCT01588977||All-Inside TightRope technique|
32778619|NCT05526859|Experimental|Group 1|Hyperactive muscle correction for wrist extensors: Kinesiotape was applied to facilitate wrist extensor muscles from proximal to distal with 15-35% tension in therapeutic zone and no tension at anchor and end.
32778620|NCT05526859|Experimental|Group 2|Hypoactive muscle correction for wrist flexors: Wrist flexors muscles were inhibited by applying tape from distal to proximal with 15-25% tension in therapeutic zone and no tension at anchor and end.
32900169|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
32900170|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
32900171|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
32900172|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
32900173|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
33102346|NCT03708809|Experimental|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
33102347|NCT03708809|Other|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
33102348|NCT00532428|Active Comparator|1|
33102349|NCT00532428|Active Comparator|2|
33283366|NCT01588977||ACL reconstruction with TLS system|
32900174|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
32900175|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
33283367|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
33283368|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
33283369|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
33283370|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
33283371|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
33283372|NCT04635774|Active Comparator|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
33283373|NCT04635774|Placebo Comparator|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
33283374|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
33283375|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
33283376|NCT04632030|Active Comparator|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
33283377|NCT04632030|Experimental|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
33283378|NCT04632030|Experimental|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
32778621|NCT05441449|Experimental|Arm 1: Cooling Vest|Phase 1: After satisfying bench testing criteria, AB participants will wear the wet cooling vest at maximal settings for 2 hours in the seated position in a warm thermal chamber (35°C), to determine: (1) minimum skin temperatures beneath the cooling vest and (2) subjective thermal sensation of their skin beneath the cooling vest.
32778622|NCT05441449|Experimental|Arm 2: Cooling Vest|Phase 2: Participants with Hi-SCI will wear the wet vest (experimental condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
32778623|NCT05441449|No Intervention|Arm 3: No Vest|Phase 2: Participants with Hi-SCI will wear no vest (control condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
32778624|NCT05525065||Patients with autoimmune bullous disease currently receiving glucocorticoids|Patients with autoimmune bullous disease currently receiving glucocorticoids for their condition, as independently assessed by an appropriately qualified medical professional/dermatologist.
32778625|NCT05525065||Patients with autoimmune bullous disease not currently receiving glucocorticoids|Patients with autoimmune bullous disease who have received glucocorticoids for their condition in the past, but are not currently on steroids.
32778626|NCT05524987|Experimental|INTERVENTION|"Participants in the ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits and a text messaging program for 12 consecutive months. Implementation package delivery will end after month 12, at which time intervention participants will be advised to obtain standard care from their local healthcare facility. ANDES is an adaptation of the World Health Organization (WHO) HEARTS package and consists of the following components:~A. Health agent-managed home care~BP monitoring~Health coaching~Health system navigation~Medication delivery assistance B. Text message-based health coaching Specifically, the ANDES strategy is aligned with four WHO HEARTS technical package components."
32778627|NCT05524987|No Intervention|CONTROL|Participants in the usual care group will be referred to their local healthcare facility for evaluation and/or to receive medical therapy per typical standard of care and at the discretion of the treating physician for the entirety of the ANDES study.
32778628|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
32778629|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
32778630|NCT05111353|Experimental|Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery. Day 1 should begin approximately 1 month after surgery."
32778631|NCT05111353|Experimental|Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively. Optimal timing for Day 1 is 1 week after end of chemotherapy, but Day 1 may be given up to 3 weeks after end of chemotherapy."
32937034|NCT05349877|Placebo Comparator|Placebo|Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.
32937035|NCT05456893||UC patients|All patients with an established ulcerative colitis
32937036|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
32937037|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
32937038|NCT05441137|Active Comparator|A ROC with a Standing Posture for Toddlers with Mild Motor Delays (ROC-Stand(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each week the research team will help the participant wear a wireless, head-mounted eye-tracker (46g) for recording the first 20-minute of both driving and natural play sessions in a 2-hour training session. The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary according to the previous ROC-related studies. The natural play session can be divided into two 20-to-25-minute sessions depending on the participant's condition. The head-mounted cameras worn by the participants and caregivers will record the visual and manual behaviors for 40 minutes/per week during intervention. All programs will be discussed by the family, the treating therapist and the research team.
33102350|NCT00532428|Placebo Comparator|3|
33402053|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
33102351|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
33402054|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
33402055|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
33402056|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
33402057|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
33283379|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
33102352|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
33283380|NCT00404079|Experimental|Glucosamine Sulphate|
33283381|NCT00404079|Placebo Comparator|Placebo|
33283382|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
33283383|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
33283384|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
33283385|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
33283386|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
33283387|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
33283388|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~Schedule C: 72 mg/m2 on Days 1 and 4, or~Schedule C: 90 mg/m2 on Days 1 and 4"
33283389|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
33102353|NCT02919527|No Intervention|Control|No Intervention
33283390|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
33283391|NCT03997656|Experimental|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
33283392|NCT03997656|Other|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
33283393|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
33283394|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
33283395|NCT00344968|Experimental|1|
33283396|NCT00344968|Experimental|2|
33283397|NCT00344968|Sham Comparator|3|
33283398|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
33283399|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
33283400|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
33283401|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
33283402|NCT00893243||1Tears Again/Control|
33283403|NCT00893243||2Opticol/Control|
33283404|NCT00893243||3Optive/Control|
33102354|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
33083304|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
33083305|NCT04591444|Active Comparator|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
33102355|NCT05465733|Experimental|Envafolimab|
33102356|NCT02919488|Experimental|Exercise Condition|
33283405|NCT00893243||4Tears Again/Opticol|
33283406|NCT00893243||5Tears Again/Optive|
33283407|NCT00893243||6Opticol/Optive|
33283408|NCT01055080|Placebo Comparator|Cow's milk formula|
33283409|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
33283410|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
33283411|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
33283412|NCT01012752|Active Comparator|modified allergen extract|
33283413|NCT01012752|Placebo Comparator|Placebo|
33283414|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
33283415|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
33283416|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
33283417|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
33283418|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
33283419|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
33283420|NCT00344500|No Intervention|Usual Care|Usual Care
33283421|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
33283422|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
33283423|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
33283424|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
33283425|NCT01057732||controls|subjects without primary hyperparathyroidism
33402058|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
33283426|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
32778632|NCT05526781||Clareon® monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
32778633|NCT05531773||COVID-19 patients|patients recovered from an acute COVID-19 episode
32900176|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
33283427|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
33283428|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
33283429|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
33283430|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
33283431|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
33283432|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
33283433|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
33283434|NCT00888485|Active Comparator|Standard treatment|
33283435|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
33083306|NCT04591444|Active Comparator|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
33083307|NCT04591444|Placebo Comparator|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
33083308|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 and also IL-4, IL-6 and IL-10"
33083309|NCT04404335||Periodontitis (test group)|"30 Periodontal patients (subdivided in 2 groups of 15, depending of the severity of their disease):~15 patients with Stage I-II periodontitis (mild/moderate)~15 patients with Stage III-IV periodontitis (severe).~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
33283436|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
33283437|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
33283438|NCT03988738|Experimental|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
33283439|NCT03988738|Sham Comparator|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
33283440|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
33283441|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
33283442|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
33102357|NCT02919488|Active Comparator|Control Condition|
33102358|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
33283443|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
33283444|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
33283445|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
33283446|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
33283447|NCT03233724|Experimental|1/Dose Escalation|DAC-THU + pembrolizumab at escalating doses
33283448|NCT03233724|Experimental|2/Dose Expansion|DAC-THU + pembrolizumab at the dose established in Arm 1
33283449|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
33283450|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
33283451|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
33283452|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
33283453|NCT01010724|Placebo Comparator|Placebo|
33283454|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
33283455|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
33283456|NCT04036253|Active Comparator|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
33402059|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
33083310|NCT04591522|Experimental|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
33083311|NCT04591522|No Intervention|control group|
33283457|NCT04036253|Experimental|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
33283458|NCT00343642|Experimental|Active Fructo-oligosaccharide|"Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.~The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily."
33283459|NCT00343642|Placebo Comparator|Placebo Fructo-oligosaccharide|Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.
33283460|NCT00343642|Active Comparator|Dietary Therapy|Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.
32778634|NCT05155111|Experimental|Telemedicine arm|Neonates will have telemedicine consultation to evaluate symptoms of neonatal encephalopathy
33283461|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
33283462|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
33283463|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
32778635|NCT05305651|Other|Cohort receiving Sotrovimab|Immunocompromised non-hospitalized participants will receive sotrovimab as standard of clinical care for COVID-19 in sentinel sites
32778636|NCT05524909|No Intervention|Control Group|The control group will receive a Fitbit device
33283464|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
33283465|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
33283466|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
33283467|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
33283468|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
33283469|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
33283470|NCT03988660||Healthy controls|Healthy individuals
33283471|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
33283472|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
33283473|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
33283474|NCT03986320|Experimental|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
33283475|NCT03986398|Experimental|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
33283476|NCT03988348|Experimental|study group|infraumbilical transverse incision will be done
33283477|NCT03988348|Active Comparator|control group|Direct intraumbilical transverse incision will be done
33283478|NCT03986164|Active Comparator|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
33283479|NCT03986164|Active Comparator|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
33283480|NCT03988582|Experimental|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
33283481|NCT03988582|Experimental|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
32778637|NCT05524909|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk and e-leaflet of type 2 diabetes in addition to the Fitbit .
32778638|NCT05524909|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
32778639|NCT05524831|Experimental|groupA(Kinesiotape)|kinesio tape on orbicularis oris muscle for 45 minute /3times per week for 2 successive months
33102359|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
33102360|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
33102361|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
33283482|NCT03988582|Experimental|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
32778640|NCT05524831|Experimental|group B(oromotor training)|oromotor training for 45 minute/ 3 times per week for 2 successive months
32778641|NCT05531695|Experimental|Aerobic Exercise|Graduated supervised moderate intensity aerobic exercise
33083312|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
33283483|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
33083313|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
33083314|NCT04591327||general anesthesia|
33083315|NCT04591327||spinal anesthesia|
33283484|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
33283485|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
33283486|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
32778642|NCT05531695|Active Comparator|Flexibility Exercise|Home based self-supervised flexibility exercises
32778643|NCT05526469|Active Comparator|Group serratus anterior plane (SAP)|patients will receive ultrasound guided single shot serratus anterior plane block with 0.5 ml/kg bupivacaine 0.25%
32778644|NCT05526469|Active Comparator|Group erector spinae plane (ESP)|patients will receive ultrasound guided single shot erector spinae plane block with 0.5 ml/kg bupivacaine 0.25%
33283487|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
32778645|NCT05531617|Active Comparator|M group|Group Intubated with Macintosh laryngoscope is labelled as M group
32778646|NCT05531617|Active Comparator|V group|Group Intubated with C-Mac video laryngoscope is labelled as V group
33283488|NCT01055158|Active Comparator|Control|Enhanced Usual Care
33283489|NCT01055236|Placebo Comparator|hydroxyzine|
33283490|NCT01055236|Placebo Comparator|placebo|starch tablet
33283491|NCT04036955|Experimental|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
32900177|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
33283492|NCT04036955|No Intervention|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
33283493|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
33283494|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
33283495|NCT00896129||Study population|
33283496|NCT00606281|Experimental|1|
33283497|NCT00606281|Placebo Comparator|2|
33283498|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
33283499|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
33283500|NCT00891605|Experimental|Paclitaxel and ABT-263|
33283501|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
33283502|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
33283503|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
33283504|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
33283505|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
33283506|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
33283507|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
33283508|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
33283509|NCT00514020|Experimental|Treatment|
33083316|NCT04396730|Placebo Comparator|Placebo followed by cannabidiol|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
33083317|NCT04396730|Experimental|Cannabidiol follow Placebo|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily for cycle 1. During cycle 3. placebo will be taken once daily along with OCPs.
33083318|NCT04591132|Experimental|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
33083319|NCT00253266|Experimental|Verum|Quetiapine augmentation
33283510|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
33283511|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
33283512|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
33283513|NCT03560531|Experimental|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
33283514|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
33283515|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
33283516|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
33283517|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
33283518|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
33283519|NCT03075696|Experimental|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
33283520|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
33283521|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
33283522|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
33283523|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
33283524|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
33283525|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
33283526|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
33283527|NCT00896285|Active Comparator|1|
33283528|NCT00896285|Active Comparator|2|
33283529|NCT00896285|Active Comparator|3|
33283530|NCT00896285|Active Comparator|4|
32900178|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
33083320|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
33083321|NCT00567073||Pregnant women with confirmed diagnosis of pompe Disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Pompe disease that are participating in the Pompe Registry (NCT00231400) and consented to participate in the Pompe Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglusidase alfa) and irrespective of the commercial product with which she may be treated.
33083322|NCT00567073||Pregnant women receiving no treatment for pompe disease|Pregnant women with pompe disease enrolled in the pompe disease registry (NCT00231400) who are not receiving treatment
33083323|NCT00567073||Infants born to mothers receiving treatment for pompe disease|The infants of mothers with pompe disease enrolled in the pompe disease registry (NCT00231400) where the mothers are receiving treatment of alglucosidase alpha (Myozyme)
33083324|NCT00567073||Infants born to mothers receiving no treatment for pompe disease|The infants of mothers with pompe disease enrolled in the Pompe Disease Registry (NCT00231400) where the mothers are not receiving Treatment
33083325|NCT04591288|Experimental|FES + Treadmill|Functional Electrical stimulation walking group.
33083326|NCT04591288|Active Comparator|Treadmill only|Treadmill walking group (no electrical stimulation).
33083327|NCT04591288|No Intervention|Control|"Control group.~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
33083328|NCT04591600|Experimental|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
33083329|NCT04591600|Active Comparator|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
33083330|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
33083331|NCT04591405|Placebo Comparator|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
32900179|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
33083332|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
33083333|NCT04591405|Placebo Comparator|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
33083334|NCT04590742|Placebo Comparator|Group 1|Placebo Tablet
33083335|NCT04590742|Active Comparator|Group 2|Melatonin (6mg)
33083336|NCT04590859||Penile block|Patients undergoing procedure with penile block
33283531|NCT03067272|Experimental|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
33283532|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
33402060|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
33402061|NCT02377024|Experimental|TF 600mg|TF 600mg/day
32900180|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
32900181|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
32900182|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
32900183|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
32900184|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
32900185|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
32900186|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
32900187|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
32900188|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
32900189|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
32900190|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
32900191|NCT01183559|Other|Vandetanib|Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.
32900192|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
32900193|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
32900194|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
32900195|NCT01221857|Experimental|NiCord|
32900196|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
33083337|NCT04590859||caudal block|Patients undergoing procedure with caudal block
33083338|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
33083339|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
33083340|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
33083341|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
33283533|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
33083342|NCT04316117|Experimental|Diagnostic (FDG-PET/CT)|Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
33083343|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
33083344|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
33083345|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
33083346|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
33083347|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
33083348|NCT04590937|Experimental|Reference|
33083349|NCT04590937|Experimental|BI 730357|
33083350|NCT04590625|Experimental|Group1|"Neoadjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.~Adjuvant therapy:~After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.~Adjuvant therapy is 3 cycles~maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
33283534|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
33283535|NCT04036175|Other|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
33283536|NCT04036175|Other|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
33283537|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
33283538|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
33283539|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
33283540|NCT00891917|Placebo Comparator|Syrup|identical placebo formulation to be administered twice a day.
33283541|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
33283542|NCT00893867|Experimental|DP-b99|
33283543|NCT00893867|Placebo Comparator|Mannitol|
33283544|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
32778647|NCT05155033|Experimental|1 - Pembro and IL-2|Course 1: pembrolizumab (200 mg IV) on Day 1 of each cycle with aldesleukin (600,000 IU/kg intravenous bolus every eight hours) continuing for up to 4 days (maximum 10 doses) for 2 cycles (each 21 days). Course 2: pembrolizumab (200 mg IV) on Day 1 of each cycle for 2 cycles (each 21 days).
33083351|NCT04590625|Experimental|Group2|"1.Adjuvant therapy:~After primary cytoreductive surgery,patients will received adjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
33083352|NCT04590469|Experimental|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
33083353|NCT04590469|No Intervention|Treatment as Usual|Usual Best practice
33083354|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
33102362|NCT04838925|Experimental|Mobile Neurofeedback|Participants engage in the use of a mobile neurofeedback intervention, which involves using a mobile app paired with an EEG headset, to achieve a calm, relaxed state. Participants will be instructed to use the intervention at a minimum of 10 minutes a day, 4 times a week for a total of 12 weeks.
33283545|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
33283546|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
33283547|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
33283548|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
33283549|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
33283550|NCT01011036|Other|1|
33283551|NCT01011036|Other|2|
33283552|NCT01011036|Other|3|
33402062|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
33083355|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
33283553|NCT03601637|Experimental|Part A: LUM/IVA|Participants weighing 7 to less than (<)10 kilograms (kg) at screening received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 10 to <14 kg at screening received LUM 100 mg/IVA 125 mg q12h for 15 days. Participants weighing greater than or equal to (>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 15 days.
33283554|NCT03601637|Experimental|Part B: LUM/IVA|Participants weighing 7 to <9 kg at screening received LUM 75 mg/IVA 94 mg FDC q12h and those weighing 9 to <14 kg received LUM 100 mg/IVA 125 mg q12h for 24 weeks. Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 24 weeks. Doses were adjusted upwards for changes in weight.
33283555|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
33283556|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
33283557|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
33283558|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
33283559|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
33083356|NCT04590313|Active Comparator|Arthrodesis|MTPJ I Arthrodesis
33283560|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
33283561|NCT00894101|Experimental|[F-18] FLT and FDG|
33283562|NCT00896753||patients with metastatic colon cancer|
33283563|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
33283564|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
33283565|NCT04017689||Verbal Information Group|Verbal Information
33283566|NCT04017689||Photo Group|Information by photos
33283567|NCT04017689||Video Group|Information by video
33283568|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
33283569|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
33283570|NCT00896987|Experimental|1|lamotrigine
33283571|NCT00896987|Active Comparator|2|carbamazepine
33283572|NCT04035863|Experimental|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
33283573|NCT04035863|Sham Comparator|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
33283574|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
33283575|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
33283576|NCT00894257||HCV/HIV infected pregnant women|
33283577|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
33283578|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
33283579|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
33283580|NCT00894335||1|Pheochromocytoma
33283581|NCT00894335||2|Conn-Syndrome
33283582|NCT00894335||3|Cushing disease
33283583|NCT00894335||4|Metastasis
33283584|NCT00894335||5|Non-functional tumor
33283585|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
33083357|NCT04590313|No Intervention|Watchful waiting|No intervention, patient information leaflet
33102363|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
33283586|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
33283587|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
33283588|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
32778648|NCT05524519|Active Comparator|WT group|This group will include 30 patients with MDD. Patients in this group will not receive IA treatment during the study period. When the study is over, they will receive 6 weeks of the same IA treatment as in the CCA group.
32778649|NCT05524519|Experimental|CCA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. LR3, PC6, SP6, and HT7 will be selected for IA.
32778650|NCT05524519|Experimental|TSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. TSA selected in the first part of the study will be stimulated.
32778651|NCT05524519|Experimental|PSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. PSA selected in the first part of the study will be stimulated.
33083358|NCT04590352||Index case and household contacts|"nasophryngeal and throat swab at day 0.~collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.~fingerprick at day 28 (optional).~daily record of symptoms from day 0-28."
33083359|NCT04590391|Other|Visual and Auditory Breathing-swallowing Coordinated Training device|
33083360|NCT04244552|Experimental|ATRC-101 Q3W|
32778652|NCT05524441||Airline 1|2 conditions; 18 participants per condition (n = 36)
32778653|NCT05524441||Airline 2|2 conditions; 18 participants per condition (n = 36)
32778654|NCT05524441||Airline 3|2 conditions; 18 participants per condition (n = 36)
32778655|NCT05524441||Airline 4|2 conditions; 18 participants per condition (n = 36)
32778656|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
32778657|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
32778658|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
32778659|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
32778660|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
32778661|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
32778662|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
32778663|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
32778664|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
32778665|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
32778666|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
32778667|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
32778668|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
32778669|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
32900197|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
33083361|NCT04244552|Experimental|ATRC-101 Q2W|
33083362|NCT04244552|Experimental|ATRC-101 Q3W + Pembrolizumab|Pembrolizumab 200mg IV Q3W or 400mg IV Q6W
33083363|NCT04244552|Experimental|ATRC-101 Q2W + Pegylated liposomal doxorubicin (PLD)|PLD 40mg/m^2 IV Run-in period of 28 days, and then 40mg/m^2 IV Q4W
33083364|NCT04590196|Experimental|treatment|
33083365|NCT04590196|Placebo Comparator|control|
33083366|NCT04590157|Experimental|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
33083367|NCT04590157|Experimental|control group|received pelvic floor muscle training
33083368|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
33083369|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
33083370|NCT04589884||Parathyroid disease|
33083371|NCT04589884||Thyroid disease|
33083372|NCT04589884||Liver tumors and metastases|
33083373|NCT04589884||Digestive tumors|
33083374|NCT04589884||Digestive perfusion|
33083375|NCT04589806|Experimental|2-stage ridge splitting with simultaneous implant placement|
33083376|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
33083377|NCT00567697|Sham Comparator|B|
33083378|NCT04589416|Active Comparator|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
33283589|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
33283590|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
33283591|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
33283592|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
33283593|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
33283594|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
33283595|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
33283596|NCT04036019|Experimental|C-CAR066|Autologous C-CAR066 administered by intravenous (IV) infusion
33283597|NCT00505284|Placebo Comparator|Placebo|
33083379|NCT04589416|Active Comparator|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
33083380|NCT04589416|Active Comparator|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
33083381|NCT04589455|Experimental|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
33083382|NCT04589455|Experimental|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
33083383|NCT04589494|Active Comparator|tramadol group|tramadol hydrochloride 100 mg three times daily
33083384|NCT04589494|Active Comparator|morphine group|morphine 30 mg twise times daily
33083385|NCT04589299|Active Comparator|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
33083386|NCT04589299|Active Comparator|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
33083387|NCT00253500|Experimental|Epirubicin|
33083388|NCT04213469|Experimental|PD1-CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of PD1-CD19-CART will be infused on day 0.
33083389|NCT04589026|Active Comparator|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
33083390|NCT04589026|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
33083391|NCT04589143|Experimental|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
33083392|NCT04589143|Placebo Comparator|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
33083393|NCT04589182|Experimental|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 45-65 dB, maximum 80 dB) targetted to the up-phase of sleep slow waves.
33083394|NCT04589182|Sham Comparator|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
33083395|NCT04588987|Experimental|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
33083396|NCT04588987|Experimental|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
33283598|NCT00505284|Active Comparator|Perampanel 2mg|
33402063|NCT02377024|Placebo Comparator|placebo|placebo
32778670|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
32937039|NCT05441137|Active Comparator|A ROC with a 25-minute Standing Posture for Children with Moderate Motor Delays (ROC-Stand25(Mod))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a 25-minute standing and 45-mnute sitting posture for driving. The participants will also wear the head-mounted eye tracker in one training session every week.
32937040|NCT05441137|Active Comparator|A ROC with a Sitting Posture for Children with Severe Motor Delays (ROC-Sit(Sev))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a sitting posture for driving. The participants will wear the head-mounted eye tracker in one training session every week.
33083397|NCT04589104|Experimental|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
33083398|NCT04588558|Experimental|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
33083399|NCT04588558|Active Comparator|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.~All participants received home exercise for 8 weeks."
33283599|NCT00505284|Active Comparator|Perampanel 4mg|
33283600|NCT00505284|Active Comparator|Perampanel 6mg|
33283601|NCT00505284|Active Comparator|Perampanel 8mg|
33283602|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
33283603|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
33283604|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
32937041|NCT05441137|Placebo Comparator|Conventional Therapy for Children with Mild Motor Delays (Control(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each participant will have the opportunity to walk on certain public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker in one training session every week.
32937042|NCT05441137|Placebo Comparator|Conventional Therapy for Toddlers with Moderate Motor Delays (Control(Mod))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants will wear the head-mounted eye-tracker in one training session every week.
32937043|NCT05441137|Placebo Comparator|Conventional Therapy for Toddlers with Severe Motor Delays (Control(Sev))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants and caregivers will also head-mounted eye-tracker in one training session every week.
32937044|NCT04233476|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg frequency:single dose
32937045|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
32937046|NCT04767074|Experimental|Non-pharmacological Cough control therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme.~Session 1 General assessment Prescription of cough technique~Session 2 Cough principles of cough Cough control~Session 3 Breathing pattern retraining and laryngeal hygiene~Session 4 Reinforcement of cough control therapies"
32937047|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
32937048|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
32778671|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
32778672|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
32778673|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
32778674|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
32778675|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
32778676|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
32778677|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
32778678|NCT04900701|Experimental|Hypocaloric|Participants placed in energy restriction.
32778679|NCT04900701|Experimental|Energy Balance|Participants placed in energy balance.
32778680|NCT04900701|Experimental|Hypercaloric|Participants placed in energy surplus.
32778681|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
32937049|NCT04193306|Experimental|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
32937050|NCT04193306|Placebo Comparator|Placebo|placebo s.c. every 2 weeks, for 48 weeks
32937051|NCT05456737||Unilateral Group|"Participants with a diagnosis of unilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
32778682|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
32778683|NCT04904913|Experimental|IBI362 high dose|high dose IBI362 administered subcutaneously (SC) once a week.
32937052|NCT05456737||Bilateral Group|"Participants with a diagnosis of bilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
32937053|NCT05456737||Healty Group (Control)|"Healthy participants with normal development were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
32937054|NCT05379439|Experimental|Intervention|Intervention families will participate in the Structured Family Deliberation that includes a clinician-led review of a web-based decisional aid.
32937055|NCT05379439|No Intervention|Control|Control families will undergo the standard decisional process for home ventilation and will also review the web-based decisional aid independently.
32937056|NCT04333940|Experimental|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
32778684|NCT04904913|Experimental|IBI362 low dose|Low dose IBI362 administered subcutaneously (SC) once a week.
32778685|NCT04904913|Placebo Comparator|placebo|placebo administered subcutaneously (SC) once a week.
32778686|NCT04904913|Experimental|IBI362 moderate dose|moderate dose IBI362 administered subcutaneously (SC) once a week.
32778687|NCT04904913|Experimental|IBI362 extra high dose|extra high dose IBI362 administered subcutaneously (SC) once a week.
32778688|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
32778689|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
32778690|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
32778691|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
32778692|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
32937057|NCT04333940|Active Comparator|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
32937058|NCT04335877|Experimental|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
32937059|NCT04335877|No Intervention|Control|Current standard of care + standard BCC
32937060|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
32937061|NCT05297539|No Intervention|Control Group|Control group who will do usual rehabilitation + visualization of videos representing monuments + a 3-meter round-trip walk
32937062|NCT05297539|Experimental|Experimental group 1|Experimental group 1 who will do usual rehabilitation + visualization of non focused point-light human actions + a 3-meter round-trip walk
32937063|NCT05297539|Experimental|Experimental group 2|Experimental group 2 who will do usual rehabilitation + visualization of focused point-light human actions + a 3-meter round-trip walk
32937064|NCT05284903|Other|Experimental: Phonak device with activated feature|The clinical investigation is designed to evaluate clinical performances in terms of speech intelligibility and listening effort. The expected benefit is based on clinical relevant differences. This clinical investigation is divided in three parts including Beamformer benefit, Speech Enhancer benefit and Hearing aid benefit (this part will be performed aided).
32937065|NCT05284903|Other|Comparator: Phonak device with deactivated feature|The comparative testings should be used as reference. The measures will be performed by the same participant group and the same three parts will be evaluated including Beamformer (BF) benefit, Speech Enhancer benefit and Hearing aid benefit. The reference will be performed without these features or with different settings of these features. In case of the Hearing aid benefit, the reference is an unaided fitting.
32937066|NCT04137133|Experimental|collection of expectoration, stools and blood|
32937067|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
33402064|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
33402065|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
33402066|NCT04364048|Experimental|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
32778693|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
32778694|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
32937068|NCT05455957|Experimental|Neuromuscular Training|The neuromuscular exercise training group includes single-leg stance, single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.The neuromuscular group included supervised, strength, balance and hop stabilization exercises on the different surfaces that focus on the restoring of static and dynamic balance. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
32937069|NCT05455957|Experimental|Vestibulo-Ocular Reflex Training|The vestibulo ocular reflex training group includes head and gaze stability exercises in addition to single le stance,single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.In the vestibulo- ocular exercise program, individuals tried to maintain their balance with head and eye movements in addition to balance and hop stabilization activities. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
32778695|NCT05531539|Experimental|Outpatient Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
32778696|NCT05531539|Experimental|Hospitalized Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
32778697|NCT05531539|Experimental|Critically ill Respiratory patients|They were examined with manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which the vest recorded the breathing provided by the mechanical ventilator.
32778698|NCT05526235|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will first receive Psychological First Aid (PFA). PFA consists of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.~Afterwards participants will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2). Step 2 will only be provided if the participant still has elevated levels of psychological distress (i.e. during the second quantitative assessment at 2 weeks after DWM).~Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Interventions:~Behavioral: Doing What Matters (DWM) Behavioral: Problem Management Plus (PM+) Behavioral: Psychological First Aid (PFA)"
32778699|NCT05526235|Active Comparator|Psychological First Aid (PFA)|"Participants allocated to the control arm will also receive PFA. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Intervention: Behavioral: Psychological First Aid (PFA)"
32778700|NCT05531383|No Intervention|Control group (group 1)|Patients in the control group (group 1) No memantine administration
32778701|NCT05531383|Active Comparator|Treatment group (group 2)|in addition to the standard treatment, they will receive memantine (30 mg) twice daily, either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital. The memantine dose administered in our study was based on the maximum dose of 60 mg/day reported in prior human studies
32778702|NCT05524207||Vulnerable plaque group|Patients with preoperative contrast-enhanced intra-plaque contrast agent were classified as vulnerable plaque group
32778703|NCT05524207||Stable plaque group|The patients with no contrast agent enhancement in the plaque showed preoperative contrast-enhanced ultrasound were classified as stable plaque group
32937070|NCT04061785|Active Comparator|Participants in 12 week Judo Inspired Exercise program|"The subjects will participate in a 12 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.~The subjects will be tested before and after the 12 week period"
33402067|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
33402068|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
32778704|NCT05526079|Experimental|Watchful Waiting|"Six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) will be administered every two weeks according to protocol. After a 3 week recovery period, this will be followed by conventional concurrent radiation and 5FU/capecitabine.~Patients will be re-staged two to three weeks after completion of induction FOLFOX therapy to ensure no disease progression. The patients will be re-staged again at least 7-11 weeks post completion of nCRT. Patients with restaging results showing either complete or near complete response, will be allocated to watchful waiting."
32778705|NCT05287945|Experimental|Orellanine 0.05-4.9 mg/kg single intravenous administration following hemodialysis|
32778706|NCT02392611|Experimental|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
33083400|NCT04588558|Active Comparator|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
33083401|NCT04588831|Experimental|Pre-fabricated|
33083402|NCT04588831|Experimental|Mouth-formed|
33083403|NCT04588831|Experimental|Custom-fitted|
33083404|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
33083405|NCT00567736|Placebo Comparator|2|placebo solution
32778707|NCT02392611|Experimental|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
32778708|NCT02392611|Experimental|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
32778709|NCT02392611|Experimental|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
32778710|NCT02392611|Experimental|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
32778711|NCT02392611|Experimental|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
32778712|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
32778713|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
32778714|NCT02392611|Experimental|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
32778715|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
32778716|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
32778717|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
33083406|NCT00567736|No Intervention|3|waiting list group
33083407|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
33083408|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
33083409|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
33402069|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
32778718|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
32778719|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
32778720|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
32778721|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
32778722|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
32778723|NCT02574481|Experimental|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
32778724|NCT02574481|Active Comparator|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
32778725|NCT05526001|Experimental|ELIXCYTE|Subjects will be intra-articular (IA) injected with 4 mL of ELIXCYTE (containing 32×10^6 ADSCs) at the target knee once
32778726|NCT05526001|Placebo Comparator|Placebo control (Saline)|Subjects will be intra-articular (IA) injected with 4 mL of saline at the target knee once
32778727|NCT05145829|Experimental|Melanoma patients|All patients will undergo lymphatic mapping with SPIO, 99mTc and PB.
32778728|NCT05140525|Active Comparator|participants with inoperable CTEPH|subject with inoperable Chronic thromboembolic Pulmonary Hypertension
32778729|NCT05140525|Active Comparator|post PTE residual CTEPH|Subject with post pulmonary endarterectomy (PTE) residual Chronic Thromboembolic Pulmonary Hypertension
33283605|NCT00892385|Experimental|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
33283606|NCT00892385|Experimental|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
33283607|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
33283608|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
33283609|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
33283610|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
33402070|NCT04341298|Experimental|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
32937071|NCT04061785|No Intervention|Control Group|The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
33283611|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
33283612|NCT00606905|Placebo Comparator|2|normal saline
33283613|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
33283614|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
32937072|NCT05455801|Experimental|negative wound therapy group|those who receive negative pressure therapy
32937073|NCT05455801|No Intervention|conventional dressing group|those patients who heal with conventional dressing, therefore negative pressure therapy is not applied
32937074|NCT04061330|Experimental|Ketamine Group|
32937075|NCT04061330|Active Comparator|Opioid group|
32937076|NCT00372632|Placebo Comparator|placebo|
32937077|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
32937078|NCT05455723|Active Comparator|Inflation-Deflation Group|
32937079|NCT05455723|Active Comparator|Magill Forceps Group|
33102364|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
33283615|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
33283616|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
33402071|NCT04341298|Sham Comparator|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
33405358|NCT02354703|Placebo Comparator|placebo--responsive genotype|"placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
33102365|NCT05465694|Active Comparator|2-minute-time interval of per oral 24% sucrose|For infants in the 2-minute-time interval of per oral 24% sucrose was given prior to the heel lance intervention.
33102366|NCT05465694|Active Comparator|no time interval of per oral 24% sucrose|In no time interval of sucrose was given immediately prior to heel lance intervention.
33283617|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
33283618|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
33283619|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
33283620|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: Arm D is closed for future enrollment"
33283621|NCT03985228|Experimental|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
33283622|NCT03985228|Placebo Comparator|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
33283623|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~Group 1: No additional ablation~Group 2: Additional ablation until elimination of dormant conduction."
33283624|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
33283625|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
32900198|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
32900199|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
33283626|NCT00894725|Active Comparator|Open|open left colonic resection
33283627|NCT05278637|Active Comparator|Aspirin 81mg/day, Aspirin 325mg/day, Aspirin washout, Ticagrelor 90mg BID|
33283628|NCT05278637|Active Comparator|Aspirin 325mg/day, Aspirin 81mg/day, Aspirin washout, Ticagrelor 90mg BID|
33283629|NCT05278637|Active Comparator|Ticagrelor 90mg BID|
33283630|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
33283631|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
33283632|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
33283633|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
32900200|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
32900201|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
33283634|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
33283635|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
33283636|NCT04017377|Experimental|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
32900202|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
32937080|NCT05455645|Experimental|Targeted intrinsic foot muscles exercise regimen|4 targeted intrinsic foot exercise will be performed at least 5 times per week, once in the laboratory, and four times at home. The participants will be followed up weekly at the laboratory visit. The real-time ultrasound imaging of intrinsic foot muscles will be used as guided visual biofeedback to instruct all participants to execute all exercise movement in a correct manner. If the participant misses a session, he/she is expected to replace the lost session within the same week.
33283637|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
33283638|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
33283639|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
32937081|NCT05455645|No Intervention|Control|continue normal physical activity,
32937082|NCT03964454|Experimental|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
32937083|NCT03964454|Active Comparator|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
33283640|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
33283641|NCT00894881||1 group|patients before colonoscopy
33283642|NCT00901277|No Intervention|Control|Usual Care
33283643|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
33283644|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
33283645|NCT04035785|Experimental|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
33283646|NCT04035785|Placebo Comparator|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
33283647|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
33283648|NCT04931615|Placebo Comparator|without ARTISS|Surgery performed without active comparative
33283649|NCT04931615|Active Comparator|with ARTISS|Surgery performed with active comparative
33283650|NCT04035707|Experimental|anaesthesia with rocuronium|rocuronium is used during anaesthesia
33283651|NCT04035707|Experimental|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
33283652|NCT00901433||A|Usability study of the Personal Wheezometer
33283653|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
33283654|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
33283655|NCT00901511|Experimental|WLL/GM-CSF|Whole lung lavage followed by inhaled GM-CSF
33283656|NCT00901511|Active Comparator|WLL alone|
33283657|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
33283658|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
33283659|NCT04035395|Experimental|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
33405359|NCT02354703|Placebo Comparator|placebo--non-responsive genotype|placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
33405360|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
33083410|NCT04180163|Experimental|Lanadelumab 300 mg q2w or q4w|Lanadelumab 300 mg solution, subcutaneously (SC), once every 2 weeks (q2w) for 26 weeks in Treatment Period A. This was followed by Treatment Period B (additional 26 weeks, total of 52 weeks including Treatment Period A) during which participants remained on Treatment Period A regimen or received 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well-controlled (attack-free) for 26 consecutive weeks with lanadelumab treatment. The dose frequency change was based on the Investigator's discretion and approval by the Sponsor's Medical Monitor.
33083411|NCT04588636|Active Comparator|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
33402072|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
33083412|NCT04588636|Active Comparator|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
32778730|NCT05531071|Active Comparator|Biofeedback electrical stimulation|Use the PHENIX USB4 Pelvic Floor Rehabilitation Therapy Apparatus to enter the Stress Urinary Incontinence Treatment Module. The frequency of electrical stimulation was 50Hz, the pulse width was 250μs, and the current intensity increased from 0mA, generally not exceeding 50mA. For the 1st to 3rd treatments, intermittent bioelectrical stimulation mode was given.For the 4th to 10th treatments, the biofeedback mode with intermittent bioelectrical stimulation was given, and for the 11th to 15th treatments, the simple biofeedback mode was given. 3 times a week, 30 minutes each time, a total of 15 treatments. Instruct the patient to go home to perform pelvic floor muscle training, focusing on anal contractions. Each anal contraction takes 3-5s and relaxes for 5-10s. so repeatedly. 20 minutes each time, 3 times a day in the morning, noon and evening, 5 days a week, until the end of the treatment.
32778731|NCT05531071|Active Comparator|Acupuncture|A single-use sterile needle of Changchun Aikang brand was selected, with a size of 0.30 mm × 40 mm. Ding points: Guanyuan point, Qihai point, Zhongji point, Zusanli point, Sanyinjiao point, Yinlingquan point. Routine disinfection of the patient's skin is performed, and Guanyuan, Qihai, and Zhongji points are punctured obliquely downward, and the needle is inserted 1-1.2 cun; evenly lift, insert and twist to get qi. At the same time, the moxa column was ignited and placed in the moxibustion box, and the moxibustion box was placed above the three points of Guanyuan, Qihai, and Zhongji in the patient's abdomen, and the moxibustion was performed until the skin was red and the deep tissue was heated. 1 time a day, every Monday to Friday, 30 minutes each time, 10 times as a course of treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
32778732|NCT05531071|Experimental|Acupuncture combined with biofeedback electrical stimulation|Biofeedback electrical stimulation therapy combined with acupuncture and moxibustion were given to the patients. After 10 sessions of acupuncture, continue the unfinished biofeedback electrical stimulation treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
32778733|NCT05518591|Experimental|CFT & BPR|6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining.
32778734|NCT05518591|No Intervention|Treatment As Usual|Those in the treatment as usual arm are not being asked to engage in anything additional to their regular treatment plan. They will, however, be given the option to participate in the psychological intervention after the study has ended, if they elect to do so.
33402073|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
33402074|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
33405361|NCT00384111|Experimental|1|Participants will receive standard R-CVP followed by Zevalin Therapeutic Regimen (Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin).
32778735|NCT05518513|Experimental|Continuous infusion|adductor canal block with continuous infusion of 0.25% bupivacaine 3.5 ml per hour for 2 days postoperatively
32778736|NCT05518513|Active Comparator|12hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 12 hours for 2 days postoperatively
32778737|NCT05518513|Experimental|6hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 6 hours for 2 days postoperatively
32778738|NCT05518279|Active Comparator|Tranexamic Acid Treatment Group|The intervention for the treatment group is as follows: participants in this treatment arm will given 1950mg of oral tranexamic acid pills (3 tablets, 650mg each) in the emergency department following diagnosis of hip fracture.
32778739|NCT05518279|Placebo Comparator|Oral Placebo Control Group|The intervention for the control group is as follows: participants in this treatment arm will given 3 tablets of oral placebo pills in the emergency department following diagnosis of hip fracture.
32778740|NCT05523817|Experimental|DLPFC Salience network target|iTBS delivered four times daily to an individually defined salience network representation in left dorsolateral prefrontal cortex (DLPFC).
32778741|NCT05523817|Experimental|DLPFC Control network target|iTBS delivered four times daily to an individually defined control network representation in left dorsolateral prefrontal cortex (DLPFC).
32778742|NCT05523817|Experimental|DLPFC Default network A target|iTBS delivered four times daily to an individually defined default network A representation in left dorsolateral prefrontal cortex (DLPFC).
32778743|NCT05523817|Experimental|dmPFC Default network B target|iTBS delivered four times daily to an individually defined default network B representation in left dorsomedial prefrontal cortex (DMPFC).
32778744|NCT05523817|Experimental|vmPFC limbic-reward network target|iTBS delivered four times daily to an individually defined reward network representation in left ventromedial prefrontal cortex (vMPFC).
32778745|NCT05523817|Sham Comparator|SHAM stimulation|SHAM iTBS delivered four times daily to an individually defined SHAM region in left dorsolateral prefrontal cortex (DLPFC).
32778746|NCT05523661|Experimental|Dasatinib plus anti-CD19/CD22 CAR-T cells|Administration with oral Dasatinib plus anti-CD19/ CD22 CAR-T cells in the elderly Ph-positive ALL patients.
32778747|NCT05523583||Patients newly diagnosed with lung cancer or head & neck cancer|Patients newly diagnosed with lung cancer or head & neck cancer (International Classification of Diseases 10: C76, C34) who undergo front-line treatment and who had at least one episode of smoking within the past 30 days before diagnosis
32778748|NCT04424953|Active Comparator|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
32778749|NCT04424953|Active Comparator|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
32778750|NCT05523193||Treatment group|"Treatment group (Formal treatment model group): Patients who agree and accept the surgical treatment recommendation (including medical and surgical treatment) enter the formal treatment model group.~Those who have received any of the following treatments (including but not limited to) as recommended by the standardized treatment process are considered to have received the standardized treatment, otherwise, they have not.~Surgical procedures: valve repair or replacement, left auricular ligation, left auricular clip.~Internal surgery: transcatheter valve replacement, radiofrequency ablation of atrial fibrillation, and left heart ear occlusion."
32778751|NCT05523193||Control group|Control group（Conventional treatment model group）:Patients who do not agree to enter the Formal treatment model group will automatically enter the Conventional treatment model group.
32778752|NCT05523037||Group S|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane was administered"
32937084|NCT04525352|Experimental|Experimental - RP-L401|RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene
32937085|NCT03991195|Experimental|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
32937086|NCT03991195|Placebo Comparator|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
32937087|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
32937088|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
32937089|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
32937090|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
33405362|NCT00384111|Active Comparator|2|Participants will receive standard R-CVP.
32778753|NCT05523037||Group R|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, 1-2 mg/kg/h of remimazolam was continuously infused."
32937091|NCT05125237||Amiloride|Exposure group
32937092|NCT05125237||Triamterene|Reference group
32937093|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
32937094|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
32937095|NCT04821115|Experimental|Low intensity choc waves therapy (Experimental group)|The patients will use the device with a real applicator.
32937096|NCT04821115|Sham Comparator|Sham group|The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted
32937097|NCT04820881||Case Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
32937098|NCT04820881||Control Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
32937099|NCT04333693||Cases|Adults (age>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
32937100|NCT04809883||observational study of gastric and pyloric motor function measured with Endoflip|observational study of gastric and pyloric motor function measured with Endoflip during fasting and postprandial periods There is NO intervention
32937101|NCT04792021|Active Comparator|N-acetylcysteine (NAC)|Patients receiving N-acetylcysteine (NAC)
32937102|NCT04792021|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
32937103|NCT05093413|Experimental|Fully slept first; Sleep deprived second|Participants will be fully slept during the first experimental visit and sleep deprived during the second experimental visit
32937104|NCT05093413|Experimental|Sleep deprived first; Fully slept second|Participants will be sleep deprived during the first experimental visit and fully slept during the second experimental visit
32937105|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
33283660|NCT04035395|No Intervention|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
33283661|NCT00901589|Active Comparator|Premenopausal women-fishoil|
33283662|NCT00901589|Placebo Comparator|Premenopausal-placebo|
33283663|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
33283664|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
33283665|NCT04035083|Experimental|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
33283666|NCT04035083|Active Comparator|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
32778754|NCT04625647|Experimental|Treatment (AMG 510)|Patients receive AMG 510 PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32778755|NCT05122741||Acute Myocardial Infarction|40 patients with clinical presentation of acute myocardial infarction undergoing primary percutaneous coronary intervention and eligible for dual antiplatelet therapy (DAPT) with either prasugrel or ticagrelor on top of aspirin.
32778756|NCT05122741||Chronic Coronary Syndrome|10 patients with stable coronary artery disease with an indication, according to current guidelines, to percutaneous coronary intervention and subsequent DAPT with aspirin and clopidogrel.
32778757|NCT05525767|Experimental|Assigned Interventions|Bevacizumab 10mg/Kg d1, 1/21d
32778758|NCT05517811||Cancer|new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma
32778759|NCT05517811||Control|Patients undergoing major surgery
32778760|NCT05121493|Active Comparator|Platelet Poor Plasma Tear|
32778761|NCT05121493|Experimental|Platelet Rich Plasma Tears|
32778762|NCT05525689|Experimental|Technology Enabled Service|
32778763|NCT05525689|Active Comparator|eTreatment as Usual|Current care plus access to a website that will provide content specific to perinatal depression
32778764|NCT05522725|Experimental|Intervention phase|Single-use wipes installed at the bedside
32778765|NCT05522725|No Intervention|Non-intervention phase|Standard practice according to Israeli ministry of health (MOH)
32778766|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
32778767|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
32778768|NCT05525377|Experimental|Intervention|Subjects in the intervention group receive access to an online training and educational phenotype-specific programme on how to support their relative with non-memory-led dementia. The online course consists on 6 modules to complete in 7 weeks. A course facilitator is available throughout the duration of the intervention to support participants.
32778769|NCT05525377|No Intervention|Treatment as usual (TAU)|"The treatment as usual group does not receive access to the educational programme."
32778770|NCT05025085|Experimental|Monotherapy with AGEN1777|3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days [3 weeks]).
32778771|NCT05025085|Experimental|AGEN1777 in combination with a PD-1 inhibitor|3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days.
32778772|NCT05525299|Experimental|Intervention|A brief reminiscence-based life review with six themes to recall subjects' memory through the life review reminiscence intervention will be given. A total of six reminiscence chatting sessions (30-60 minutes per session) covering these themes will be conducted weekly.
32778773|NCT05525299|No Intervention|Control|The subjects allocated in the Control group will not receive any intervention.
32778774|NCT05522491|Experimental|Olapalib|Olaparib Oral 300mg 2/day; 4 weeks (28 days) as a treatment cycle.
32778775|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
32778776|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
32778777|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
32778778|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
32900203|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
32900204|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
32900205|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
32778779|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
32778780|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
32778781|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
32778782|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
32778783|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
32778784|NCT04904289||Sepsis with MODS|Patients with sepsis occurred MODS.
32778785|NCT04904289||Sepsis without MODS|Patients with sepsis did not occur MODS.
32778786|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
32778787|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
32778788|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
32778789|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
32778790|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
32778791|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
32778792|NCT04903899|Experimental|177Lu-DOTATATE|A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
32778793|NCT05517733|Experimental|Platelet Rich Fibrin (PRF)|
32778794|NCT05517733|Experimental|Diode laser|
32778795|NCT05517655|Experimental|Pre Trikafta|129Xe MRI
32778796|NCT05517655|Experimental|Post Trikafta|129Xe MRI
32778797|NCT05522413||Health Status|normal examination in recent six months and not fit inclusion criteria of suboptimal health status.
32778798|NCT05522413||Suboptimal health Status|(A) Sub-Health Questionnaire (SHSQ-25) ≧35 points (B) Resting blood pressure 120-139/80-89 mmHg measured more than 3 times a week (C) The PSQI score of the sleep questionnaire on the first test is greater than 5 points (D) Body mass index (BMI): 24~29 Kg/m2
32778799|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
32778800|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
33083413|NCT04588636|Active Comparator|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
33083414|NCT04588636|Placebo Comparator|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
33083415|NCT04720365|Experimental|play-based rehabilitation|"Patients randomized in the play-based rehabilitation group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months."
33083416|NCT04720365|No Intervention|routine care|"Patients randomized in the usual care group will have their usual rehabilitation care provided by their physiotherapist."
33083417|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
32778801|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
33083418|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
33083419|NCT00567814|Placebo Comparator|3|
33083420|NCT04588441|Experimental|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
33083421|NCT04588753|Active Comparator|Active Isolated Stretch|active isolated stretching, strengthening exercises
33083422|NCT04588753|Active Comparator|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
33083423|NCT04588090|Experimental|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
32778802|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
33083424|NCT04588090|Placebo Comparator|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
32778803|NCT05119309||patient group|Renal biopsy diagnosis of MGRS or disease linked to multiple myeloma and B cell lymphoma
32778804|NCT05119309||control patient group|Renal biopsy diagnosis of nephropathy linked to onco-haematological pathology with full clinical expression (Multiple Myeloma, B-cell Lymphoma)
32778805|NCT04903665||Cancer Arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
32778806|NCT04903665||Benign Arm|Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
32778807|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
33283667|NCT03516617|Experimental|Arm A (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
33283668|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
33283669|NCT03516617|Active Comparator|Arm C (observation)|Patients will be observed every 6 months for up to 2 years.
33283670|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
33283671|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
33283672|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
32778808|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
33283673|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
32778809|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
32778810|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
33083425|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33283674|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
33283675|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
33283676|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
33283677|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
33283678|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
33283679|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
33283680|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
33283681|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
33283682|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
33283683|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
33083426|NCT04588285|Experimental|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
33283684|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283685|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283686|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283687|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283688|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283689|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283690|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283691|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283692|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283693|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
33283694|NCT00902057|Active Comparator|desmopressin 1.5|
33283695|NCT00902057|Active Comparator|desmopressin 3|
33283696|NCT00902057|Active Comparator|desmopressin 15|
33283697|NCT00902057|Placebo Comparator|placebo|
33283698|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
33283699|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
33283700|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
33283701|NCT04035941|Experimental|Feasibility|The cycle training intervention group
33283702|NCT00902135||Group 1|
33283703|NCT00902135||Group 2|
33283704|NCT00902135||Group 3|
32778811|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
33283705|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
33283706|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
33283707|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
33283708|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
33283709|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
33283710|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
33283711|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
33283712|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
33283713|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
33283714|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
33283715|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
33283716|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
33283717|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
33283718|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
33283719|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
33283720|NCT00902213|Active Comparator|Physical Therapy|
33283721|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
33283722|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
33283723|NCT00902369|Experimental|AK106-001616|
33283724|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
33283725|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
33283726|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
32900206|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
33283727|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
33283728|NCT00905879||Group 1|
33283729|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
33283730|NCT00605267|Active Comparator|1|Tamoxifen
33283731|NCT00605267|Experimental|2|Anastrazole (Arimidex)
33283732|NCT00898781||Metastatic Breast Cancer|
33283733|NCT00898781||Metastatic Ovarian Cancer|
33283734|NCT00898781||Metastatic Pancreatic Cancer|
33283735|NCT00898781||Metastatic Colon Cancer|
33283736|NCT00898781||Stage 3 Ovarian Cancer|
33283737|NCT00898781||Locally Advanced Pancreatic Cancer|
33283738|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
33283739|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
33283740|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
33283741|NCT00898859||1|Healthy, non-smoking
33283742|NCT00898859||2|healthy, ex-smoking
33283743|NCT00898859||3|healthy, current-smokers
33283744|NCT00898859||4|COPD, ex-smokers
33283745|NCT00898859||5|COPD, smokers
33283746|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
33283747|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
33283748|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
33283749|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
33283750|NCT00906191|Experimental|1|Single oral dose
33283751|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
33283752|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
33283753|NCT04035317|Experimental|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
33283754|NCT04035317|Placebo Comparator|Placebo|Patients will receive placebo
33283755|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
33283756|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
33283757|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
33283758|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
33283759|NCT00906269|Active Comparator|1|
33283760|NCT00906269|Sham Comparator|2|
33283761|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
33283762|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
33283763|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
33283764|NCT02538575|Experimental|6-minute walk test|
33283765|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
33283766|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
33283767|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
33283768|NCT00902993|Placebo Comparator|2|
33283769|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
33283770|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33283771|NCT04034771|Experimental|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
33283772|NCT04034771|Active Comparator|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
33283773|NCT00906581|Experimental|Behavioral|Behavioral
33283774|NCT00906581|No Intervention|Waitlist control|Waitlist control
33283775|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
33283776|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
33283777|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
33283778|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
33283779|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
33283780|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
33283781|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
33283782|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
33283783|NCT00903071|No Intervention|Control|No intervention -control group
33283784|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
33283785|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
32778812|NCT05522335|Active Comparator|BBV154 Lot-1|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
32778813|NCT05522335|Active Comparator|BBV154 Lot-2|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
32778814|NCT05522335|Active Comparator|BBV154 Lot-3|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
32778815|NCT05522335|Active Comparator|COVAXIN®|Immunogenicity Group :In this group, 160 participants will be recruited, receive Covaxin vaccine (0.5 mL each dose) on day 0 and day 28 via intramuscular route and assess for the Immunogenicity.
32778816|NCT05512429||Stage-IV non small cell lung cancer (NSCLC)|Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) /computed tomography (FDG PET/CT) from June 2012 to February 2019
32778817|NCT05522257|Other|Advanced soft tissue sarcoma (n=60) and advanced urothelial cell carcinoma (n=60)|The study population comprises sixty adult patients with diagnosis of advanced (locally irresectable or metastasized) soft tissue sarcoma (cohort 1) and sixty adult patients with diagnosis of advanced (muscle invasive or metastasized) urothelial cell carcinoma (cohort 2).
32778818|NCT04903509|Experimental|BI 1820237|Part 1 and part 2 of the trial.
32778819|NCT04903509|Placebo Comparator|Placebo|Part 1 and part 2 of the trial.
32778820|NCT04903509|Experimental|BI 1820237 + liraglutide|Part 3 of the trial.
32778821|NCT04903509|Placebo Comparator|Placebo + liraglutide|Part 3 of the trial.
32778822|NCT05522179|Experimental|NutraHeal|NutraHeal™ is a nutritional supplement that contains 7.5 micrograms (300 IU) of Vitamin D3, 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, and 45 mg of Bromelain.
32778823|NCT05522179|Experimental|NutraHeal Plus|NutraHeal Plus™ is a nutritional supplement that contains 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, 45 mg of Bromelain, and 7.5 mg of reduced Nicotinamide Adenine Dinucleotide (NADH).
32778824|NCT05522179|No Intervention|Standard of Care|Receive standard of care for 1 week prior to surgery and 3 weeks after foot surgery.
32778825|NCT04903431|Active Comparator|Clinician-administered Crisis Response Plan|Clinicians will administer the Crisis Response Plan to 75 military veterans.
32778826|NCT04903431|Experimental|Self-administered Crisis Response Plan|Participants will complete a self-guided version of the Crisis Response plan online.
32778827|NCT05517499|Experimental|Group A (Dexamethasone Group),|Group A (Case Group) was given dexamethasone i.e., 0.2 mg per kg per day every 12 hours for 7 days intravenously. All treatment strategies were same in both groups but steroid was given to group A
33283786|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
32778828|NCT05517499|No Intervention|Group B (Control Group)|Group B (Control group), received routine treatment.No dexamethasone
32778829|NCT05012371|Experimental|Arm A (lenvatinib, everolimus)|Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
32778830|NCT05012371|Active Comparator|Arm B (cabozantinib)|Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
32778831|NCT05450211|Active Comparator|Group SFI (Suprainguinal fascia iliaca block)|"In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with an 85 mm needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic into this space.~When the patient whose block procedure is successful, is taken to the recovery room, controlled analgesia will be applied to the patient and he will be transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA."
32937106|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
32937107|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
33283787|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
33283788|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
33283789|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
33402075|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
32778832|NCT05450211|Active Comparator|Group PCA (patient controlled analgesia)|No block attempt will be made to the patients in this group, and when the patient is taken to the recovery room after surgery, controlled analgesia will be administered and transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA.
32778833|NCT05512351|Experimental|Cohort 1|Subjects with ctDNA-level-relapse Oligodendroglioma before clinical relapse, determined according to the dynamics of TISF ctDNA.
32778834|NCT05512351|Experimental|Cohort 2|Subjects with clinical-relapse Oligodendroglioma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
33283790|NCT04034849|Experimental|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
32778835|NCT05512351|No Intervention|Cohort 3|Subjects without ctDNA-level-relapse and clinical-relapse Oligodendroglioma.
32778836|NCT04898985||500 patients in the LLS COVID-19 Registry with no/limited antibody response|Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in this Research Study.
32778837|NCT04898985||500 patients also participating in the LLS COVID-19 Registry with antibody response|500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled in this Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
32778838|NCT05517343|No Intervention|Ordinary care (OC)|The participants of this arm received the endoscopic optical diagnosis, histological diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule at next scheduled clinic visit (around 1 to 2 weeks later).
32778839|NCT05517343|Experimental|Real-time notification (RTN)|The participants of this arm received the endoscopic optical diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule right after the sedated colonoscopy. Histological diagnosis will be informed at next scheduled clinic visit (around 1 to 2 weeks later).
32778840|NCT05517187|Placebo Comparator|Blood Clot BC (Control arm)|Regenerative endodontic treatment with induced Blood Clot in root canal space as a secondary treatment for failed root canal treated incisors
32778841|NCT05517187|Experimental|Platelets Rich Fibrin PRF (Intervention)|Regenerative endodontic treatment with Platelet- rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
33283791|NCT04034849|Placebo Comparator|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
33283792|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
33283793|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
33283794|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
33283795|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
32778842|NCT05522023|Experimental|Experimental group (group treated with aromatic solution)|"Informed consent form will be signed by the patients selected by randomization and a personal information form will be filled.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they lie normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with the verbal descriptive scale VDS will be evaluated. After the data are collected, the aromatic solution will be shaken and applied to the oral cavity and throat as a spray 4 times. After the aromatic solution application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
32900207|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
32900208|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
32900209|NCT05412810||Oxygen exposures|mechanically ventilated patients with atleast 1.5 hours of FiO2 exposure of 50% or more
32900210|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
32900211|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
32900212|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
32900213|NCT05399082|Experimental|Standard forceps biopsy then research cryoprobe biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using forceps first followed by cryoprobe.
32900214|NCT05399082|Experimental|Research cryoprobe biopsy then standard forceps biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using the cryoprobe first followed by forceps.
32900215|NCT05412654|Experimental|High potassium water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The intervention group will receive high potassium water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
32937108|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
33083427|NCT04588285|Experimental|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
33083428|NCT04153565|Experimental|Pembrolizumab + Cisplatin + Pemetrexed|Pembrolizumab 200 mg IV every 3 weeks (Q3W) in combination with Cisplatin 75 mg/m^2 IV, and Pemetrexed 500 mg/m^2 IV for 4-6 cycles followed by monotherapy of Pembrolizumab up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years).
33283796|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
33283797|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
33283798|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
33283799|NCT00899951||Cohort 1|receiving fentaly citrate
33283800|NCT05278013|Experimental|Glue Group (GG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
33283801|NCT05278013|No Intervention|No Glue Group (NG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
33083429|NCT04588324|Experimental|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
33083430|NCT04588324|Experimental|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
33283802|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
33283803|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
33283804|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
33283805|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
33283806|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
33283807|NCT00906893|Experimental|1|
33283808|NCT05277701|Experimental|Lazertinib|
33283809|NCT00900653|Experimental|Gynoflor|
33283810|NCT00900653|No Intervention|Control|
33283811|NCT04034693|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
33283812|NCT04034693|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
33283813|NCT00605345|Experimental|CERA Treatment Once Monthly|
33283814|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
33283815|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
33283816|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
33283817|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
33283818|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
33283819|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
33283820|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
33283821|NCT00904085|Active Comparator|Oxymorphone|
33283822|NCT00904085|Placebo Comparator|Placebo|
33283823|NCT00908453|Experimental|15mg/kg of loading dose|
33283824|NCT00908453|Experimental|18mg/kg of loading dose|
33283825|NCT00908453|Experimental|22.5mg/kg of loading dose|
33283826|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
33283827|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
33283828|NCT02538497|Other|Routine care|
33283829|NCT04034537|Experimental|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
33283830|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
33283831|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
33283832|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
33283833|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment
33283834|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
32778843|NCT05522023|Placebo Comparator|Placebo group (group treated with drinking water)|"Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they sleep normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. Nausea and vomiting will be evaluated with a verbal descriptive scale. After the data are collected, drinking water will be applied to the oral cavity and throat in the form of a spray 4 times. After the drinking water application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
33283835|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
33283836|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
33283837|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
32778844|NCT05522023|No Intervention|Control Group|"Patients in the control group were planned to be followed according to their clinical procedures. Since there were no procedures or interventions in the clinical procedures, it was decided to follow up only the patient, and the control group patients to be followed up at the same times with the same forms.~Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form. Hour 0: Patients will be transferred from the recovery unit to the clinic. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with a verbal descriptive scale will be evaluated. 2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
32778845|NCT05512273|Experimental|Study|
32778846|NCT05512273|Active Comparator|Control|
32778847|NCT05521789|Experimental|Standard of Care + ESB Thoracic|Patients randomized to this group will receive an erector spinae block in addition to the standard of care treatment
32778848|NCT05521789|No Intervention|Standard of Care|Patients randomized to this group will receive standard of care treatment and NO erector spinae block
32778849|NCT05521711|Experimental|Active low dose oral immunotherapy and Placebo sublingual immunotherapy|
32778850|NCT05521711|Experimental|Placebo low dose oral immunotherapy and Active sublingual immunotherapy|
32778851|NCT05521711|Experimental|Placebo low dose oral immunotherapy and Placebo sublingual immunotherapy|
32778852|NCT05517109|No Intervention|Control group. Standart care|Standart hemodynamic goals: systolic blood pressure 160-185 mmHg in first 24 hours after intravenous thrombolysis
32778853|NCT05517109|Experimental|Systolic blood pressure ≤ 160 mmHg|Lower hemodynamic goals: systolic blood pressure ≤ 160 mmHg in first 24 hours after intravenous thrombolysis
32778854|NCT05516875|Experimental|High dose|JM-010 fixed combination drug (Group A) will be administered orally.
32778855|NCT05516875|Experimental|Low dose|JM-010 fixed combination drug (Group B) will be administered orally.
32778856|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32778857|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32778858|NCT01649427|Experimental|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
32778859|NCT01649427|Experimental|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
32778860|NCT05521633|Active Comparator|Metformin Group|Group-A; every participant took 500 mg of metformin daily
33283838|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
33283839|NCT00904319|Experimental|Aquatic|Aquatic Power Training
33283840|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
33283841|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
33283842|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
33283843|NCT00605189|Active Comparator|VAC NPWT|
33283844|NCT00605189|Active Comparator|Gauze-Based NPWT|
33283845|NCT00605189|Active Comparator|Moist Wound Therapy|
33283846|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
33283847|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
33283848|NCT02538887||Radio Frequency Surgical Detection|
33283849|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
33283850|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
33283851|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
32778861|NCT05521633|Active Comparator|Pioglitazone Group|Group-B; every participant took 30 mg of pioglitazone daily
33283852|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
32778862|NCT05512195|Experimental|New delineation approach （NDA）group|use a new method for clinical target volume delineation by referencing the nerve fiber bundles
33283853|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
33283854|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
32778863|NCT04898829|Experimental|PKU Explore|PKU Explore will be prescribed by the study dietitian based on the patient's individual requirement.
33283855|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
33283856|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
33283857|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
33283858|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
33283859|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
33283860|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
33283861|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
33283862|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
33283863|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
33283864|NCT05277389|Sham Comparator|Control|Individuals in this group will practice object manipulation tasks without the START (Startle Adjuvant Rehabilitation Therapy) intervention
33283865|NCT05277389|Experimental|START|Individuals in this group with practice object manipulation tasks with the START condition (startling acoustic stimuli applied during 33% of trials)
33283866|NCT00340834|Experimental|Fingolimod 1.25 mg|
33283867|NCT00340834|Experimental|Fingolimod 0.5 mg|
33283868|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
33283869|NCT03986554|Other|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
32778864|NCT05512117|Experimental|Midline Catheter|Midline catheter insertion
32778865|NCT05512117|No Intervention|Peripheral intravenous cannulation (PIVC)|Peripheral intravenous cannulation (PIVC)
32778866|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
32778867|NCT04411693|Active Comparator|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
32778868|NCT04411693|Active Comparator|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
32778869|NCT05521555||total knee arthroplasty under 55|Patient who had total knee arthroplasty before 55 between January 2010 and December 2019
33283870|NCT03986554|Other|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
33283871|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
33283872|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
33283873|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
33283874|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
33283875|NCT01058122||Patients on the ward|
33283876|NCT00603941|Experimental|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
32778870|NCT02336607|Experimental|Felodipine tablet (Plendil)|
33283877|NCT00603941|Experimental|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
33283878|NCT00603941|Experimental|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
33283879|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
33283880|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
33283881|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
33283882|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
33283883|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
33283884|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
33283885|NCT00904787|Experimental|1|
33283886|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
33283887|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
33283888|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
33283889|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
33283890|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
33283891|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
33283892|NCT05277311|Experimental|LongShengZhi capsule|Experimental group
33283893|NCT05277311|Placebo Comparator|LongShengZhi capsule placebo|Placebo group
33283894|NCT03986008|Experimental|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
33283895|NCT03986008|Active Comparator|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
33283896|NCT00909233||Group 1|
33283897|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
33283898|NCT00904865|Other|1|SPA cholecystectomy
33283899|NCT00904865|Other|2|laparoscopic cholecystectomy
33283900|NCT03986086|Experimental|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
33283901|NCT03986086|Placebo Comparator|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
33283902|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
33283903|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
33283904|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
33283905|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
33283906|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
33283907|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
33283908|NCT00909311|Active Comparator|1|Non-fasting
33283909|NCT00909311|Active Comparator|2|Fasting
33283910|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
33283911|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
33283912|NCT00907673|Active Comparator|Patient condition pre-implant|
33283913|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
33283914|NCT00909467||myeloproliferative, -dysplastic disease|
33283915|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
33283916|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
33283917|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
33283918|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
33283919|NCT00905411|No Intervention|Attention Control / Usual Care|
33283920|NCT00905411|Experimental|Intervention|
33283921|NCT00336544|Experimental|Cethromycin|
33283922|NCT00336544|Active Comparator|Clarithromycin|
33283923|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
33283924|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
33283925|NCT01059058|Placebo Comparator|Control Group|
33083431|NCT04587895|Experimental|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
33083432|NCT04587895|Active Comparator|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
33283926|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
33283927|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
33283928|NCT03988114|Experimental|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
33283929|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
33283930|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
33283931|NCT00905645|Experimental|Revison|Silimed Gel-Filled Mammary Implant
33283932|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
33283933|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
33283934|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
33283935|NCT04034069|Experimental|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
33283936|NCT04034069|Active Comparator|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
33283937|NCT04034069|Sham Comparator|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
33283938|NCT03987646|Experimental|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
33283939|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
33283940|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
33283941|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
33283942|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
33402076|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
33402077|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
33283943|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
33402078|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
32778871|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
33283944|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
33283945|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
33283946|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
32778872|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
33283947|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
33283948|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
33283949|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
33283950|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
33283951|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
33283952|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
33283953|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
33283954|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
33283955|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
33283956|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
33283957|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
33283958|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
33283959|NCT01055548||Parents of babies born before 33 weeks gestation|
33283960|NCT03987880|Active Comparator|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
33283961|NCT03987880|Experimental|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
33283962|NCT01325194|Experimental|CNS prophylaxis|
33283963|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
33283964|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
33283965|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
33283966|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
33283967|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
33283968|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
33283969|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
33283970|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Subject will stand up and walk around, and then lay back down~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
33283971|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
33283972|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
33283973|NCT00927173|Sham Comparator|Sham|Sham treatment
33283974|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
33283975|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
33283976|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
33283977|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
33283978|NCT00927329|Experimental|dust mite|
33283979|NCT00931541|Experimental|A|AZD6088 oral solution
32778873|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
33283980|NCT00931541|Experimental|B|Placebo oral solution
33283981|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
33283982|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
33283983|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
33283984|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
33283985|NCT03743519|Placebo Comparator|Placebo|
33283986|NCT03743519|Experimental|Cherry juice|
33283987|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
33283988|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
33283989|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
33283990|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
33283991|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
33283992|NCT00931697|Experimental|AD 452 (+) mefloquine|
33283993|NCT00931697|Active Comparator|Racemic mefloquine|
33283994|NCT00931697|Placebo Comparator|Placebo|
33283995|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
33283996|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
33283997|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
33283998|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
33283999|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
33284000|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
33284001|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
33284002|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
33284003|NCT00927875|Experimental|All Subjects|
33284004|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
33284005|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
33284006|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
33284007|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
33284008|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
33402079|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
32778874|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
32937109|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
33284009|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
33284010|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
33284011|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
33402080|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
32778875|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
33284012|NCT00568061|Experimental|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
33284013|NCT00568061|Placebo Comparator|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
33284014|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
32937110|NCT04978285||Postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. Anaemia will be defined according to the World Health Organisation definition (males Hb <130 g/L, and female Hb <120 g/L).
33284015|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
33284016|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
33284017|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
33402081|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
32937111|NCT04978285||No postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. No anaemia will be defined according to the World Health Organisation definition (males Hb ≥130 g/L, and females Hb ≥120 g/L).
33284018|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
33284019|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
33284020|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
33284021|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
33284022|NCT00932087||type 2 diabetics with metabolic syndrome|
33284023|NCT00932087||metabolic syndrome without diabetes|
33284024|NCT00932087||type 1 diabetes|
32937112|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
33284025|NCT00932087||control|
32937113|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
32937114|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
32937115|NCT04701073|No Intervention|"Control group usual care"|Promotion of physical activity and taking usual medicines for pain relief
32937116|NCT04701073|Experimental|Intervention group : lumbar belt|wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief).
32937117|NCT04697407|Experimental|MS Patients|Patients with MS at any stage and for any type of MS : MS at the onset of the disease, Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)
32937118|NCT04697407|Active Comparator|non MS Patients|Patients with a neurological and immunological disease except MS.
32937119|NCT04697407|Active Comparator|Healthy volunteers|
32937120|NCT04634773|Experimental|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
32937121|NCT04634773|Active Comparator|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
32937122|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
32937123|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
32778876|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
32778877|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
32778878|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
33284026|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
33284027|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
33284028|NCT00928343|Experimental|GLPG0187|Single dose
33284029|NCT00928343|Placebo Comparator|Placebo|
33284030|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
33284031|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
33284032|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
33284033|NCT03038100|Experimental|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
33284034|NCT03038100|Placebo Comparator|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
33284035|NCT00338728|Experimental|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
33284036|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
33284037|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
33284038|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
33284039|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
33284040|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
33284041|NCT03985618|Active Comparator|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
33284042|NCT03985618|Active Comparator|Randomized Induction of Labour|Randomized to planned induction of labour
33284043|NCT03985618|Active Comparator|Preference Caesarean section|Preference for planned pre-labour Caesarean section
33284044|NCT03985618|Active Comparator|Preference Induction of Labour|Preference for planned Induction of Labour
33284045|NCT03983278|Experimental|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
33284046|NCT03983278|Experimental|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
33284047|NCT03983278|Experimental|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
33284048|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
33284049|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
33402082|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
33284050|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
33284051|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
33284052|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.~No changes in service-directed plan of care for patients."
32778879|NCT05521477|Experimental|participant procedure|"each participant will go through 3 phases of identical protocol. In each phases blood and stools will be collected at specific days, as well as cardiometabolic measures, transit time, cognitive tests and food consumption.~Each phase last 2 weeks with a washout period of 1 month in between. In the first phase, no treatment will be provided, in the second phase a low dose of probiotic (once a day for five days) will be given and in the third phase high dose of probiotic (twice a day for five days) will be administered."
32937124|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
33284053|NCT02997462||Healthy Control|Healthy, age-matched controls.
33284054|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
33284055|NCT00504894|Active Comparator|Propofol|Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
32937125|NCT04926961|Experimental|Sham stimulation first, then real stimulation|Participants will first be delivered sham TMS stimulation. Then on a separate day, participants will be delivered real TMS stimulation.
32937126|NCT04926961|Experimental|Real stimulation first, then sham stimulation|Participants will first be delivered real TMS stimulation. Then on a separate day, participants will be delivered sham TMS stimulation.
33284056|NCT00504894|Active Comparator|Thiopental|Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.
33284057|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
33284058|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
33284059|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
32937127|NCT03612193||Study A: Chronic >1 year|
32937128|NCT03612193||Study A: Acute <1 year|
32937129|NCT03612193||Study A: Household Control|
33284060|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
33284061|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
33284062|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
32937130|NCT03612193||Study B: Newly Diagnosed <6 months|
32937131|NCT03612193||Study B: Household Controls|
32937132|NCT04737811||Study group|The group consists of Parkinson's disease patients with dysphagia complaints. The participants will be given the Turkish version of the Swallow Disturbance Questionnaire (SDQ-T), which consisted of 15 questions and two scales evaluated with the fiberoptic endoscopic evaluation of swallowing. After two weeks, all participants will be given the SDQ-T for sampling.
32937133|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
32937134|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
32937135|NCT04540003|Experimental|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
33284063|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
33284064|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
33284065|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
33284066|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
33284067|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
33284068|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
33284069|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
33284070|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
33284071|NCT00504582|Experimental|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
33284072|NCT00504582|No Intervention|No Fibrin Sealant|
33284073|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
33284074|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
33083433|NCT04587895|Experimental|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
33284075|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
33284076|NCT01011426|Active Comparator|Bisacodyl|
33284077|NCT01011426|Placebo Comparator|empty opague capsule|
33284078|NCT00925067|Experimental|lightweight TiMesh|
33284079|NCT00925067|Experimental|lightweight VyproII|
33284080|NCT00925067|Experimental|Heavyweight Marlex|
33284081|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
33284082|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
33284083|NCT00932555||Group 1|
33284084|NCT05163288|Experimental|N-acetyl-L-leucine (IB1001)|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
33284085|NCT05163288|Placebo Comparator|Placebo comparator|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
32778880|NCT05521399||Aim#1 Development|Developing dedicated multiparametric cardiac MRI protocols that account for a wide range of body sizes and patient physiology (e.g., heart rates, breathing patterns) of heart transplant recipients, is critical for the wide age range in HTx from pediatric to adult. Second, to facilitate clinical translation and multi-site portability of the often time-consuming data analysis. Methodology, to be employed and developed artificial intelligence (AI) deep learning concepts to enable automated cardiac MRI analysis across large cohorts. The hypothesis to be tested is that automated AI analysis can detect altered cardiac MRI metrics with improved efficiency and reduced inter-rater variability
33284086|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
33284087|NCT00928733|Other|Ethanol|
32778881|NCT05521399||Aim#2 Cardiac MRI in Pediatric HTx & Donor-Recipient Mismatch|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children. The anticipated enrollment of n=80 (20 per year) pediatric HTx patients (<21 years) in years 2-5 at Lurie Children's Hospital. Inclusion criteria include a clinically indicated routine cardiac MRI for HTx graft surveillance. The hypothesis to be tested is that cardiac MRI measures can inform pediatric donor selection by providing important new data on the impact of donor-recipient mismatch (e.g. age, sex, heart size, etc.) on changes in tissue and function of the transplanted heart.
32900216|NCT05412654|Placebo Comparator|Low potassium control water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The control group will receive regular bottled mineral water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
33284088|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
32900217|NCT05412420|Experimental|Patient Self-Reporting of Symptoms|
32900218|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
32900219|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
32900220|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
32900221|NCT05379426||Screening tests and semi-structured interview|Battery of screening tests with semi-structured interview First, the Mini-Mental State Examination will be administered to participants to assess whether they meet the inclusion criteria and an identification code will be assigned to eligible participants. Posteriorly, a clinical psychologist will administer the Frontal Assessment Battery, Center for Epidemiologic Studies Depression Scale, Geriatric Anxiety Inventory, Loneliness Scale 3 Portuguese version, Quality of Life - Alzheimer's Disease, and will conduct a semi-structured interview about the difficulties experienced by the older adult during the pandemic period.
32900222|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
32900223|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
32900224|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
33284089|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
33284090|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
33284091|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
33284092|NCT04014959|Experimental|All Participants|All participants follow the same procedures.
33284093|NCT01012986||2nd Grade|students of 2nd grade
32900225|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
32900226|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
32900227|NCT05598294|No Intervention|Control Group|Standard treatment and mobilization recommendations will be given to this group.
32900228|NCT05598294|Experimental|Mobilization Group|Mobilization of patients will be encouraged.
32900229|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
32900230|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
32900231|NCT05398926|Experimental|Experimental group 1 (3-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (3-month interval）.
32900232|NCT05398926|Experimental|Experimental group 2 (4-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (4-month interval）.
33284094|NCT01012986||4th Grade|students of 4th Grade
33284095|NCT04722575|Experimental|ARM A|"Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):~Vemurafenib 960 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
33284096|NCT04722575|Experimental|ARM B|"Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):~Vemurafenib 720 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
33284097|NCT04722575|Experimental|ARM C|"Arm C BRAF WT patients. Over a period of six weeks (1) + (2):~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
33284098|NCT01011582||Novel H1N1 influenza|
33284099|NCT01011582||Seasonal influenza|
33284100|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
33284101|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
33284102|NCT00925145||1|
33284103|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
33284104|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
33284105|NCT00932867||Group 1|
33284106|NCT00928967||Group 1|
33284107|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
33284108|NCT00504426|Placebo Comparator|1|
33284109|NCT00504426|Active Comparator|2|
33284110|NCT00504426|Active Comparator|3|
33284111|NCT00504426|Active Comparator|4|
33284112|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
33284113|NCT00933023|Experimental|Potent Steroid|
33284114|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
33284115|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
33284116|NCT00933179|Experimental|Arm 1|
33284117|NCT00933179|Active Comparator|Arm 2|
33284118|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
33284119|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
33284120|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
33284121|NCT00929045|Experimental|Growth Hormone|
33284122|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
33284123|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
33284124|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
33284125|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
33284126|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
33284127|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
33284128|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
33284129|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
33284130|NCT04522674|Experimental|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
33284131|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
33284132|NCT04015271|Experimental|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
33318133|NCT03457948|Experimental|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity and pembrolizumab for up to 35 cycles.
33402083|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
33284133|NCT04015271|Placebo Comparator|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
33284134|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
33284135|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
33284136|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
33284137|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
33284138|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
33284139|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
33284140|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
33284141|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
33284142|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
33284143|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
33284144|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
33284145|NCT03981562|Experimental|1000 IU Vitamin D|
33284146|NCT03981562|Experimental|4000 IU Vitamin D|
33284147|NCT03981562|Placebo Comparator|Placebo|
33284148|NCT03981484|Experimental|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
33284149|NCT03981484|Active Comparator|Standard of Care|standard resuscitation methods only
33284150|NCT03983200|Sham Comparator|Control group|Mecobalamine 0.5mg, tid
33284151|NCT03983200|Experimental|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
32900233|NCT05398926|Experimental|Experimental group 3 (5-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (5-month interval）.
33284152|NCT00567359|Experimental|Erlotinib|
33284153|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
33284154|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
33284155|NCT04014725|Experimental|Eligible patients for AI test|
33284156|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
33284157|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
33284158|NCT00925691|Active Comparator|APICAL|implantation at the apex
33284159|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
33284160|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
33284161|NCT00925847|Experimental|1|
33284162|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
33284163|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
33284164|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
33284165|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
33284166|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
33284167|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
33284168|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
33284169|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
33284170|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
33284171|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
33284172|NCT00492648|Experimental|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
33284173|NCT00492648|Experimental|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
33284174|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
32778882|NCT05521399||Aim#3 Longitudinal patient outcome study|"The study will research the diagnostic value of cardiac MRI to improve the monitoring of heart transplant recipients for the major complications of acute cardiac rejection (ACR) and cardiac allograft vasculopathy (CAV). The anticipated follow-up enrollment of a total of 80 HTx patients during years 2-5 with a minimum of 5-year follow-up (20 HTx patients/year returning for HTx surveillance, baseline MRI scan was performed during the initial funding period. To clarify, our aim isn't to perfectly match donor-recipient but rather to study the clinical implications of mismatch and to help define the threshold for too much mismatch. In other words, today human beings sometimes don't accept a heart if the mismatch will be too great, this is sometimes hard to do and literature is scarce, especially in terms of functional rather than anatomic implications. Our goal is that this study could better inform these decisions."
33284175|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
32778883|NCT05516719||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
32778884|NCT05516719||Idiopathic Parkinson's Disease|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
32778885|NCT05516719||Healthy Control|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD patholog
32778886|NCT05516641|Experimental|Prebiotic|Soluble Corn Fiber
32778887|NCT05516641|Placebo Comparator|Control|Maltodextrin
32778888|NCT05511961|Experimental|Intervention arm|Immediate referral to local budget and debt counselling service and a copy of 'Your child, your money', a financial guidance book for new parents
32937136|NCT04540003|No Intervention|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
32937137|NCT04333927|Experimental|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
33284176|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
33284177|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
33284178|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
33284179|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
33284180|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
33284181|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
32937138|NCT04333927|Placebo Comparator|Observation|Patients in observation group will not receive any anti-cancer therapy.
33284182|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
33284183|NCT03997500|Placebo Comparator|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
33284184|NCT03997500|Experimental|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
33284185|NCT00933881||Gestational Diabetes Mellitus (GDM)|
33284186|NCT01013064|Experimental|Cohort1|
33284187|NCT01013064|Experimental|Cohort2|
33284188|NCT01013064|Experimental|Cohort3|
33284189|NCT01013064|Experimental|Cohort4|
33284190|NCT01013064|Experimental|Cohort5|
33284191|NCT01013064|Experimental|Cohort6|
33284192|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~The patient will discover the underlying cause of the insomnia.~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~The patient will learn how to reduce daytime stress.~The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
33284193|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
33284194|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
33284195|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
33284196|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
33284197|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
33284198|NCT04014881|Experimental|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
32778889|NCT05511961|Active Comparator|Waitlist-control arm|Immediately given a copy of 'Your child, your money' book, and referral to local budget and debt counselling service after a period of 3 months
33284199|NCT04517604|Experimental|iTBS+yoga|Participants will receive 6 sessions of intermittent theta burst stimulation (iTBS) and the LoveYourBrain Yoga program. The LoveYourBrain Yoga program was specifically designed for people with TBI.
33284200|NCT04015505|Experimental|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
32778890|NCT04999969|Experimental|AZD0171 + Durvalumab + chemotherapy|Participants will receive AZD0171 (intravenous [IV]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
33284201|NCT01015248|Experimental|Rituximab and Bendamustine|
33284202|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
33284203|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
33284204|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
33284205|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
33284206|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
33284207|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
33284208|NCT01013142|Experimental|MN-221|
33284209|NCT01013142|Placebo Comparator|MN-221 Placebo|
33284210|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
33284211|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
33284212|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
33284213|NCT04014569|Experimental|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
33284214|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
33284215|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:~Whether the patient has been prescribed inotropic support~Wound infection by assessing use of antibiotics.~Length of stay in hospital >1 week~Reduced renal function assessed by having any AKI alert during hospital stay~Cardiac event within 31 days following surgery~Death within 31 days following surgery"
33284216|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
33284217|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
32937139|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
33284218|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
33284219|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
33284220|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
33284221|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
33284222|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
33284223|NCT00934193|Active Comparator|Gabapentin|
33284224|NCT00934193|Placebo Comparator|Placebo|
33284225|NCT01013376|Experimental|Active|Topical administration of MC-1101
33284226|NCT01013376|Placebo Comparator|Vehicle|Vehicle
33284227|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
33284228|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
33284229|NCT04014491|Experimental|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
33284230|NCT04014491|Experimental|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
33284231|NCT04014491|Other|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
33284232|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
33284233|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
33284234|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
33284235|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
33284236|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
33284237|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
33284238|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
33284239|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
32778891|NCT05521165|Experimental|group A|The patients in group (A) (n=29) will receive an American physical therapy association (APTA) guided program consisting of stretching exercises for global trunk, back muscles, and hamstring muscles, strengthening exercises for abdominal and back muscles, and stabilizing exercises for trunk and pelvic muscles.
32778892|NCT05521165|Experimental|group B|The patients in group (B) (n=29) will receive treatment as in group (A) in addition to selected G Med strengthening exercises.
32778893|NCT05511727|Active Comparator|single Foley's catheter group|
32778894|NCT05511727|Active Comparator|Double Foley's catheter group|
33284240|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
32778895|NCT05516407|Experimental|FEN164|"Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (FEN164)~Stage 1: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each) Stage 2: 20mg/kg (8 weeks), 15mg/kg, 10mg/kg, 5mg/kg (1 week each)"
33284241|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
33284242|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
33284243|NCT00934427|Active Comparator|Vascana|
33284244|NCT00934427|Placebo Comparator|Vehicle|
33284245|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
33284246|NCT01013454|Experimental|Varenicline transdermal delivery system|
33284247|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
33284248|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
33284249|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
33284250|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
33284251|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
33284252|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
33284253|NCT04015037|Experimental|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
33284254|NCT04015037|Experimental|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
33284255|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
33284256|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
33284257|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
33284258|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
33284259|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
33284260|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
33284261|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
33284262|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
33284263|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
33284264|NCT01015482|Active Comparator|Midazolam|Active Placebo
33284265|NCT03760679|Active Comparator|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
33284266|NCT03760679|Experimental|i-gel|Device: i-gel
33284267|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
33284268|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
33284269|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
33284270|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
33284271|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
33284272|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
33284273|NCT00934895|Experimental|Phase I / Phase II|"Phase I:~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
33284274|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
33284275|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
33284276|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
32937140|NCT04334005|Active Comparator|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
32937141|NCT04334005|Experimental|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
32937142|NCT04486261|Experimental|High-intensity strength training|"16 weeks of high-intensity strength training two times per week.~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)~Interventions:~Other: high-intensity strength training Drug: Usual care"
32937143|NCT04486261|No Intervention|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).~Intervention:~Drug: Usual care"
33284277|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
33284278|NCT00930449|Experimental|Cogmed Working Memory Training Program|
33284279|NCT00930449|Active Comparator|Academy of Math® program|
33284280|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
33284281|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
33284282|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
33284283|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
32937144|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
32937145|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
33284284|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 analogue) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
33284285|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
33284286|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
33284287|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
33284288|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
33284289|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
33284290|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
33284291|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
32937146|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
32937147|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
33284292|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
33284293|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
33284294|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
33284295|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
33284296|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
33284297|NCT00485472|Placebo Comparator|Placebo|Placebo
33284298|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
33284299|NCT01018836|Experimental|Riluzole; Radiation Therapy|
33284300|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
33284301|NCT04015661|Experimental|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
33284302|NCT04015661|Active Comparator|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
33284303|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
33284304|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
32937148|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
32937149|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
32937150|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
33318134|NCT03457948|Experimental|Group II [pembrolizumab, TAE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
32937151|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
32937152|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
33402084|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
33284305|NCT04015583|Experimental|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D&J Humancare, Busan, South Korea) composed of a running/jumping mat [730(W) × 730(D) × 130(H)] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
33284306|NCT04015583|Active Comparator|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
33284307|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
33284308|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
33284309|NCT00930683|Other|1|MEDI-546
33284310|NCT00930683|Other|2|MEDI-546
33284311|NCT00930683|Other|3|MEDI-546
32937153|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
32937154|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
33284312|NCT00930683|Other|4|MEDI-546
33284313|NCT00930683|Other|5|MEDI-546
33284314|NCT00930683|Other|6|MEDI-546
33284315|NCT00930683|Other|7|MEDI-546
33284316|NCT00930683|Other|8|MEDI-546
33284317|NCT00930683|Other|9|MEDI-546
33284318|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
32937155|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
33284319|NCT04314570|Experimental|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
33284320|NCT04314570|Placebo Comparator|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
33284321|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
33284322|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
33284323|NCT04297332|Experimental|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
33284324|NCT04297332|Experimental|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
33284325|NCT04297332|Experimental|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
32937156|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
32937157|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
32937158|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
32937159|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
32937160|NCT04431674|Experimental|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
32937161|NCT04430959|Experimental|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
32937162|NCT04430959|Placebo Comparator|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
32937163|NCT03821870||Standard treatment|Standard first line treatment
32778896|NCT05511649||Post-MI NOAF with low AF burden|Patients with post-MI NOAF who had a AF burden<10.87%. The cut-off value of AF burden of 10.87% was identified based on our previous work.
32778897|NCT05511649||Post-MI NOAF with high AF burden|Patients with post-MI NOAF who had a AF burden≥10.87%.
32778898|NCT05520931||Hospitalization group|Previously hospitalized Covid-19 survivors who have been admittet to the hospital with or because of SARS-CoV-2 infection. Time from infection date start is > 6 months. The group is anticipated to encompass 2.182 privously hospitalized adult patients.
32778899|NCT05520931||PCR+ group|Non-hospitalized Covid-19 survivors that has previously testet positive in an Polymerase chain reaction test without being admittet to the hospital. Time from infection data start is > 6 months. The group will include almost the total population of adults who have tested positive in a Polymerase Chain Reaction test. Those with secret adresses and those without access to digital mail (information channel of the questionnaire) will be excluded being approcimatelyh 7% of 650.000 possible participants. The group encompasses 593.741 participants.
32778900|NCT05511571|Experimental|TENS group|Transcutaneous electrical neural stimulation (TENS)
32778901|NCT05511571|Experimental|PRE group|Progressive relaxation exercises (PRE)
32778902|NCT05511571|Experimental|TENS+PRE group|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)
32778903|NCT05511571|No Intervention|Control group|
32778904|NCT02573311|Experimental|men|
32778905|NCT05520853|Experimental|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
32778906|NCT05516329|Experimental|18F-Thretide Injection|7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
32778907|NCT05511493|Experimental|fractional(Er: YAG) laser with platelet-rich plasma|"Subjected to fractional erbium: yttrium-aluminum-garnet (Er: YAG) laser (FotonaXs~Dynamis, Slovenia) with the energy of 1400 mJ in short pulse mode (SP) with spot size of 7 mm diameter, frequency of 3 Hz, and pixel 1. PRP is applied over the treated areas.This procedure will be repeated every two weeks for six months"
32778908|NCT05511493|Experimental|Microneedling with platelet-rich plasma|"Subjected to microneedling using electronic dermapen device (Dr Pen Derma Pen Ultima A6®) which has a disposable head that personalized for each patient and sterilized after each session. The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern from the perilesional areas toward the depigmented center until pinpoint bleeding appears then the PRP is applied over the treated areas.~- This procedure will be repeated every two weeks for six months."
32778909|NCT05516251|Active Comparator|Topiramate|
32778910|NCT05516251|Experimental|Transcutaneous Supraorbital Nerve Stimulator|
32778911|NCT04292743|Experimental|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
32778912|NCT04990687|Experimental|Intervention Group|Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
32778913|NCT05520697|Active Comparator|Control|Nutritional treatment with caloric restriction and mental exercise
32778914|NCT05520697|Experimental|Intervention|Nutritional treatment with caloric restriction, mental exercise, and physical training program.
32900234|NCT05398926|Experimental|Experimental group 4 (6-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (6-month interval）.
33083434|NCT04587895|Active Comparator|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
33083435|NCT04588168|Experimental|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
33083436|NCT04588168|Experimental|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
33083437|NCT04146545|Experimental|Cases|"Community Rx-Dementia CRxD Caregiver Resources"
33083438|NCT04146545|No Intervention|Control|Usual Standard Care
32900235|NCT05398848|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, Adjuvant (BFA03)
33284326|NCT04297332|Active Comparator|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
33284327|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
32778915|NCT05086393|Experimental|Duloxetine|Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally (per os [PO]) daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage.
32778916|NCT05086393|Placebo Comparator|Control|Patients randomized to the control arm will receive PO-matched placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing TKA at Rush University Medical Center.
33284328|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
33284329|NCT01013610|Active Comparator|Multiple Dose|
32778917|NCT04886791|Experimental|VANH hysterectomy|Access to the peritoneal cavity will be performed similar to vaginal surgery by a circular incision around the cervix, anterior and posterior colpotomy and transsecting the sacro-uterine ligaments. The vNOTES port will be placed to get access to the abdominal cavity and a pneumoperitoneum will be created. After positioning in 20o degree Trendelenburg laparoscopic instruments will be introduced. The peritoneal cavity and ureters are inspected. The hysterectomy is performed by dissecting from caudally to cranially. The fallopian tubes will be removed elective after counselling in the outpatient clinic and the ovaries will be removed on indication only. Haemostasis is checked and the vNOTES port and the uterus are removed trans-vaginally and the pneumoperitoneum is deflated. The vaginal cuff will be closed using a running Vicryl-1 suture. The urinary bladder catheter will be removed directly postoperative.
32778918|NCT04886791|Active Comparator|Vaginal hysterectomy|A circumferential incision is made around the cervix. Access to the peritoneal cavity will be performed through anterior and posterior colpotomy. The sacro-uterine ligaments, ligamenta cardinalia uterine arteries will be clamped and dissected. Finally, the ovarian ligament, round ligament and fallopian tubes will be dissected and tied. The uterus will be removed and the vagina will be closed. The urinary bladder catheter will be removed directly postoperative.
33284330|NCT01013610|Placebo Comparator|Placebo|
33284331|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
33284332|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
32778919|NCT05516173||Ambulatory patients|"Patient with a high blood pressure during regular visit will undertake an ambulatory blood pressure monitoring. Before wearing the device , they will be asked to answer to the questionnaire and the investigators will gather their demographic,clinical characteristics and dietary habits data.~Ethical considerations will be undertaken and respected."
32778920|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
33284333|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
33284334|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
33284335|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
33284336|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
33284337|NCT03997032|Experimental|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
33284338|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
32778921|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
32778922|NCT05520463|Experimental|Ultrasound guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under ultrasound guidance.
33284339|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
33284340|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
33284341|NCT01015794|Experimental|Adrenergic agonist|
33284342|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
33284343|NCT00935363|Experimental|glyburide + fluconazole|
33284344|NCT00935363|Experimental|glyburide + rifampin|
33284345|NCT00935363|Active Comparator|glyburide|
33284346|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
33284347|NCT04267302|Other|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
33284348|NCT04267302|Other|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
33284349|NCT04267302|Other|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
33284350|NCT04267302|Other|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
33284351|NCT00930995|Active Comparator|A|
33284352|NCT00930995|Placebo Comparator|B|
33284353|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
33284354|NCT00935441|Active Comparator|Usual case management|Case management
33284355|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
33284356|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
33284357|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
32778923|NCT05520463|Active Comparator|Fluoroscopy guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under fluoroscopy guidance.
33083439|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
33083440|NCT04587778|Experimental|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
33284358|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
33284359|NCT00931073|Experimental|Period 1|
33284360|NCT00931073|Experimental|Period 2|
33284361|NCT00931073|Experimental|Period 3|
33083441|NCT04587778|Experimental|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
33083442|NCT04139564|Experimental|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
33083443|NCT04139564|Active Comparator|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
33083444|NCT04587505|Active Comparator|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
33083445|NCT04587505|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
33083446|NCT04587544|Experimental|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
33083447|NCT04587544|No Intervention|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
33083448|NCT04128683|Experimental|Healthy Controls|Healthy Control Subjects
33083449|NCT04128683|Experimental|Anorexia Nervosa|Anorexia Nervosa Subjects
33083450|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
33083451|NCT00249756|Active Comparator|Parole Supervision and Case Management|
33083452|NCT04105634|Experimental|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
33083453|NCT04105634|Experimental|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
33083454|NCT04587349|Active Comparator|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
33083455|NCT04587349|Active Comparator|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
33083456|NCT04587349|Active Comparator|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
33083457|NCT04587349|No Intervention|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
33083458|NCT04586998|Experimental|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
33083459|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
33083460|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
33083461|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
33083462|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
33083463|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
33083464|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
33083465|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
33083466|NCT04587115|Placebo Comparator|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
33083467|NCT04587115|Experimental|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
33083468|NCT04587115|Experimental|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
33083469|NCT00403247|Experimental|A|vitamin capsule
33083470|NCT00403247|Placebo Comparator|B|placebo capsule
33083471|NCT04587037|Experimental|Fascia lata group|
33083472|NCT04587037|Experimental|Dermal allograft group|
33083473|NCT04586725|Active Comparator|Encouragement every minute|Patients will be randomised to six tests at one week apart
33083474|NCT04586725|Active Comparator|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
33284362|NCT01016028||Questionnaire + Sensory Tests + Interview|
33284363|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
33083475|NCT04586686|Other|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
32778924|NCT04597801|Experimental|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
32778925|NCT04885465|Experimental|Intervention group|Study participants will receive a web-based support program
32778926|NCT04885465|No Intervention|Control group waiting list|Study participants in the control group waiting list will receive standard support from health care and municipalities. After study termination they will receive access to the same web-based program as the experimental group
33284364|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
33284365|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone|In Phase 1b, Abiraterone/prednisone will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2
33284366|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Enzalutamide|In Phase 1b, Enzalutamide will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2
33284367|NCT04179864|Experimental|Phase 2: Tazemetostat in Combination with Enzalutamide|In Phase 2, Enzalutamide and Tazemetostat will be administered on cycle 1 day 1
33284368|NCT04179864|Active Comparator|Phase 2: Enzalutamide only|In Phase 2, Enzalutamide will be administered on cycle 1 day 1
33284369|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
33284370|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
33284371|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
33083476|NCT04586686|Other|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
33083477|NCT00403286|Experimental|C 10/1|
33083478|NCT00403286|Experimental|C 5/2|
33083479|NCT00403286|Experimental|C 5/1|
33083480|NCT00403286|Experimental|FP 1000|
33083481|NCT00403286|Experimental|FF 20|
33083482|NCT00403286|Active Comparator|AD 250/50|
33083483|NCT00403286|Placebo Comparator|Plc|
33083484|NCT00403286|Experimental|C 10/2|
33083485|NCT04586803|Experimental|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083486|NCT04586803|Experimental|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083487|NCT04586803|Experimental|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083488|NCT04586803|Experimental|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083489|NCT04586803|Experimental|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083490|NCT04586803|Experimental|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
33083491|NCT04586608|Active Comparator|active comparator|
33083492|NCT04586608|Other|soybean oil-based IVFE|soybean oil-based IVFE
33083493|NCT04586491|Experimental|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
33083494|NCT04586491|Experimental|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
33083495|NCT04719429|Experimental|Cricket-derived protein beverage|Ingestion of a cricket-derived protein beverage
33083496|NCT04719429|Experimental|Beef-derived protein beverage|Ingestion of a beef-derived protein beverage
33083497|NCT04586218|Active Comparator|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
33083498|NCT04586218|Experimental|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
33284372|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
33083499|NCT04586257|Experimental|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
32900236|NCT05398848|Placebo Comparator|Placebo|Adjuvant (BFA03)
33083500|NCT04586257|Experimental|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
33083501|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
33083502|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
33284373|NCT00936689|Active Comparator|TACE with microsphere|
33284374|NCT01018914|Active Comparator|Prograf with Myfortic|
33284375|NCT01018914|Experimental|Advagraf with Myfortic|
33083503|NCT04585867|Active Comparator|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
33284376|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
33284377|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
33284378|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
33083504|NCT04585867|Active Comparator|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
33083505|NCT04585828|Experimental|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
33284379|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
33083506|NCT04585828|Active Comparator|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
33083507|NCT04585672|Other|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
33083508|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay.
33083509|NCT04585282|Experimental|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
33083510|NCT04585282|Active Comparator|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
33083511|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
33083512|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
33083513|NCT00249912|Active Comparator|Rosuvastatin|
33083514|NCT04585438|Experimental|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
33083515|NCT04585438|Placebo Comparator|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
33083516|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
33083517|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33083518|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
33083519|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
33083520|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
33284380|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
33284381|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
33284382|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
33284383|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
33284384|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
33284385|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
33284386|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
33284387|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
33284388|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
33284389|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
33284390|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
33284391|NCT01019382|Experimental|All patients|All patients entering the trial
33284392|NCT04014023|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
33284393|NCT04014023|Experimental|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
33284394|NCT04014023|Experimental|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
33284395|NCT04014023|Placebo Comparator|Placebo|Placebo, Tablets, Orally, Once daily
33284396|NCT03997188|Experimental|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
33284397|NCT03997188|Placebo Comparator|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
33284398|NCT00935675|Active Comparator|Antidepressant treatment|
33284399|NCT00935675|Placebo Comparator|Placebo|
32778927|NCT05516095|Active Comparator|Active iTBS|iTBS will be delivered with 120% of resting motor threshold, triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays). Each patient will start treatment at the same time between 9 am and 3 pm during the 10-day treatment period.
33284400|NCT01016184|Active Comparator|vitamin D|
33284401|NCT01016184|Active Comparator|placebo|
33284402|NCT00502320|Experimental|Ramelteon|8 mg
33284403|NCT00502320|Placebo Comparator|Placebo|
33284404|NCT02567825|Active Comparator|Surgical Management|Tympanostomy Tube Placement Topical antimicrobial treatment of acute otitis media episodes with ofloxacin drops
33284405|NCT02567825|Other|Non-Surgical Management|Antimicrobial treatment of acute otitis media episodes with amoxicillin-clavulanate and/or ceftriaxone
33284406|NCT00490776|Experimental|Panobinostat 20 mg|Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.
33284407|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
33284408|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
33284409|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
33284410|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
33284411|NCT00566735|Placebo Comparator|1|
33284412|NCT00566735|Active Comparator|2, Galantamine|
33284413|NCT03653273|Experimental|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
33284414|NCT03653273|Active Comparator|DMT continuation|The previously established therapy will be continued at the same dose during two years.
33284415|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
33284416|NCT04013633|Experimental|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
33284417|NCT04013633|Active Comparator|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
33284418|NCT00566111|Active Comparator|A|
33284419|NCT00566111|Placebo Comparator|P|
33284420|NCT00937313||Champagne wine|
33284421|NCT00937313||Placebo|alcohol with sparkling mineral water
33284422|NCT00514046|Experimental|Vandetanib|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m^2/day.
33284423|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
33284424|NCT00937469|Active Comparator|Standard treatment|
33284425|NCT04014101|Experimental|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
33284426|NCT04014257|Experimental|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
33284427|NCT04618250|Experimental|Coordinated, co-produced health care|
33284428|NCT04618250|No Intervention|Care as usual|Care as usual
33284429|NCT04264052||CBE & MRI|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging (MRI-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
33284430|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
33284431|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
33284432|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
33284433|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
33284434|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
33284435|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
33284436|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
33284437|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
33284438|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
33284439|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
33284440|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
33284441|NCT00939419|Other|Health worker TB care group|
33284442|NCT00939419|Other|Community health worker TB care group|
33284443|NCT00939419|Other|Self-administered treatment group|
33284444|NCT04013243|Active Comparator|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
33284445|NCT04013243|Placebo Comparator|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
33284446|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
33284447|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
33284448|NCT03160547|Active Comparator|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
33284449|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
33284450|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
33284451|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
33284452|NCT04013711|Experimental|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
33284453|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
33284454|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
33284455|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
33284456|NCT00938249|Placebo Comparator|Placebo|
33284457|NCT05280275|Experimental|Part 1: Dose Finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~Cohort 1: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Cohort 2: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Administration schedule for daratumumab 1800mg SC (fixed dose):~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years"
33284458|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
33284459|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
33284460|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
33284461|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
33284462|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
33284463|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
33284464|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
33284465|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
33284466|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
33284467|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
33284468|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
32937164|NCT04430101|Active Comparator|Negative WB radiographs and stress fluoroscopy|"Cohort 1~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Negative stress fluoroscopy: the midfoot is tested stable"
32937165|NCT04430101|Active Comparator|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Positive stress fluoroscopy: manual testing reveals midfoot instability"
32937166|NCT04430101|Other|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
32937167|NCT04415372||Cognitive Impairment|Adults diagnosed with MS that have evidence of cognitive decline.
32937168|NCT04415372||No Cognitive Impairment|Adults diagnosed with MS that have no evidence of cognitive decline.
33284469|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
32937169|NCT04415372||Healthy Controls|Healthy adult volunteers will form a control group matched for age, gender, education, handedness
33284470|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
33284471|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
33284472|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
33284473|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
33284474|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
33284475|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
33284476|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
33284477|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
33284478|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
33284479|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
33284480|NCT04492254|Experimental|Enoxaparin|(40 mg o/d if < 100 kg, 40 mg b/d if ≥ 100 kg)
33284481|NCT04492254|No Intervention|Current standard of care (no enoxaparin)|Standard of care
33284482|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
33284483|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
33284484|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
32937170|NCT04820413|Experimental|FMT|
32937171|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
32937172|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
32937173|NCT05083130|No Intervention|standard care|Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites
32937174|NCT05083130|Experimental|prone position|prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day
33083521|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
33284485|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
33284486|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
33284487|NCT03970733|Experimental|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
33284488|NCT03970733|Experimental|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
33284489|NCT03970733|Placebo Comparator|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
33284490|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
33284491|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
33284492|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
33284493|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
33284494|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
33284495|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
33284496|NCT04013165|Active Comparator|Active control|Usual care of the Community Mental Health Service
33284497|NCT04013165|Experimental|Village-based intervention|Individual-based case management + group-based program
33284498|NCT04013477|Experimental|Cohort1|"drug : DA-5207 80mg/40cm²~placebo : 40cm²"
32778928|NCT05516095|Placebo Comparator|Sham iTBS|The sham system has an identical look, weight and sound compared to the true coil, and delivers electrical stimulation that can be felt at the skin but without penetrating the skull and thus not inducing any treatment effect. The sham stimulation will be given with the same procedure as the active stimulation; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s.
32778929|NCT04296955|Experimental|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
32778930|NCT04296955|No Intervention|Standard care|Standard care
32778931|NCT04979533|Experimental|Oxygen Insufflation|Oxygen insufflation via oxygen tubing at 15 L/min
32778932|NCT05520307||HF|Patients with heart failure.
32778933|NCT05520307||IHD|Patients with ischemic heart disease.
32778934|NCT05511259|Experimental|Intervention|Square stepping exercise
32778935|NCT05511259|No Intervention|Control|Passive control group
32778936|NCT05520151|Experimental|ORAL impact group|This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.
32778937|NCT05520151|Other|control|a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
32778938|NCT05519995||Sensate II Users|Users will be adults (18+ years of age) who have been using the Sensate II device for stress management for a minimum of 30-days or 1-month
32778939|NCT04297423|Experimental|Plenvu|Plenvu split dose
32778940|NCT04297423|Active Comparator|Citrafleet|citrafleet in split dose
32778941|NCT05515939||InPen|Patients who will begin using the InPen device as per standard of care
32778942|NCT05515861|Experimental|EUS group|The EUS group uses endoscopic ultrasound to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect.
32778943|NCT05515861|No Intervention|Control group|The control group doesn't perform endoscopic ultrasound after endoscopic cyanoacrylate injection for gastric varices.
32778944|NCT04295941||Trazodone once-a-day treated patients|Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.
32778945|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
32778946|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
32778947|NCT05510869|Experimental|B-MICS 1.4 mm|bimanual 1.4 mm cataract surgery (B-MICS)
33402085|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
32937175|NCT04737655|Active Comparator|TRIMBOW + Standard of care|"Inclusion~Maintenance therapy (LAMA or LABA) for COPD~Age >18~Admission for AE of COPD~Signed Inform consent (see protocol attached)~Admitted in ICU >24h and less than 72h~Exclusion~No CI for studied medication~Not treated with studied medication for at least 3 months~Admitted in ICU for AE of COPD within the past 3 months~Intolerance to studied medication~Hospitalized since >6 days~ARDS condition (PAFI <200)~Admitted in ICU >72H~Patient with severe asthma~The use of high dose of ICS as baseline therapy~Right/left heart failure~Immunocompromized~Acute myocardial infaction~Left heart insufficiency (LVEF<35%)~Stroke <6 months prior to hospital admission~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1."
32937176|NCT04737655|No Intervention|standard of care|
32937177|NCT05063396|Active Comparator|opioid free anesthesia|opioid free anesthesia
32937178|NCT05063396|Placebo Comparator|Opioid-sparing anesthesia|Opioid-sparing anesthesia
32937179|NCT04737499|Experimental|CASCADe Intervention|Intervention consisted of eight weekly sessions of health education and diabetes management. Topics covered include recognition of diabetes and its complications, risk factors, nutrition knowledge, dietary practices, exercise, behavioral self-monitoring, medication adherence, and stress management. Intervention also included a home visit for training of monitoring devices use, WeChat app and acquiring family support, and weekly WeChat follow-up on education tips, monitoring data summary, and group discussion. The monitoring system used a smartphone to coordinate cloud data transmission from a set of wireless devices to capture daily monitoring data on physical activity, body weight, blood pressure and blood glucose levels.
32937180|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
32937181|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
32937182|NCT04378699|Experimental|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
32937183|NCT04378699|Experimental|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
32778948|NCT05510869|Active Comparator|C-MICS 1.8 mm|coaxial 1.8 mm cataract surgery (C-MICS)
32778949|NCT05510869|Active Comparator|C-SICS 2.4 mm|coaxial 2.4 mm small incision cataract surgery (C-SICS)
32778950|NCT05515783|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|PET imaging will begin at 30s (30s/bed), 15min (1min/bed), 30min (2 min/bed), 60min (2 min/bed) and 120min (2 min/bed) after injection
32778951|NCT05515783|Experimental|Part II: diagnostic efficacy|Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-RGD and another agent (68Ga-FAPI-02 or 18F-FDG).
32778952|NCT05515705|Experimental|EUS-NS +|EUS with the navigation system first on, then off
32778953|NCT05515705|Experimental|EUS-NS -|EUS with the navigation system first off, then on
32778954|NCT05515705|No Intervention|EUS group|EUS alone
32778955|NCT05515549||Venous thrombosis group|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
32778956|NCT05515549||Group without venous thrombosis|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
32778957|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
32778958|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
32778959|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
32778960|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
32778961|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
32778962|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
32778963|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
32778964|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
32778965|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
32778966|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
32778967|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
32778968|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
32778969|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
32778970|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
32778971|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
32937184|NCT05055752|Other|PL-ASA capsule, then IR-ASA tablet|One PL-ASA 325 mg capsule, 14 day washout then one IR-ASA 325 mg tablet
32778972|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
32778973|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
32778974|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
32937185|NCT05055752|Other|IR-ASA tablet, then PL-ASA capsule|One IR-ASA 325 mg tablet, 14 day washout, then one PL-ASA 325 mg capsule,
32937186|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
32937187|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
32937188|NCT05042492|No Intervention|Group 1: SC (moveUP)|In group 1: moveUP (class 1, CE-marked, medical device) is being used as the rehabilitation solution after TKA. It has become a valid digital rehabilitation solution and is recognised by the Belgian government as mobile health application in rehabilitation of hip and knee arthroplasty surgeries. It's a full service with daily personalized and individualized follow up by certified physical therapists and certified health care providers. The use of tele-rehabilitation for TKA patients has been internationally recognized with the 2018 John N. Insall Award during the American Knee Society Meeting
32937189|NCT05042492|Experimental|Group 2: SC (moveUP) with 10 days of geko|In group 2: Next to SC (moveUP), the application of a single gekoTM device is used on the operated leg after surgery (day 0). This device will be worn for 24 hours and at least 8 hours from day 1 until day 10.
32937190|NCT04336189|Active Comparator|SP + DP placebo every 4 weeks|
32937191|NCT04336189|Active Comparator|DP + SP placebo every 4 weeks|
32937192|NCT04336189|Active Comparator|SP + DP given every 4 weeks|
32937193|NCT05037032|Active Comparator|Study drug naltrexone hydrochloride|50 mg Naltrexone PO
32937194|NCT05037032|Placebo Comparator|Matching placebo for naltrexone hydrochloride|Matching placebo for Study Drug Naltrexone
32937195|NCT05441059||Patients treated with mepolizumab|Patients treated with mepolizumab
32778975|NCT05045755||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
32778976|NCT05045755||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
32778977|NCT05510791|Experimental|Nuun Sport|Citric Acid, Dextrose, Sodium Carbonate, Potassium Bicarbonate, Sodium Bicarbonate, Natural Flavors, Potassium Chloride, Magnesium Oxide, Calcium Carbonate, Stevia Leaf Extract, Avocado Oil, Riboflavin (for color).
32778978|NCT05510791|Sham Comparator|Control|Water
32778979|NCT05515471|Experimental|Treatment group A: SHR8058 eye drops|
32778980|NCT05515471|Placebo Comparator|Treatment group B: saline eye drops|
32937196|NCT00373100|Experimental|Zinc|Zinc acetate
32937197|NCT00373100|Placebo Comparator|Placebo|Placebo
32937198|NCT04223323|Experimental|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
32937199|NCT04223323|Placebo Comparator|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
32937200|NCT04960748|Experimental|intervention|7-sesson group intervention that uses dyadic instruction, role playing and group sharing and discussion to reduce internalized stigma, improve disclosure decision making and healthy living, and teach advocacy skills
32937201|NCT04960748|No Intervention|wait-list control|Participants will not receive the intervention until all follow-up data has been collected.
32937202|NCT04181515|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
32778981|NCT05515393|Experimental|XY03-EA Tablet (300mg group)|XY03-EA 150 mg/tablet, 2 tablets，three times a day； XY03-EA Placebo 150 mg/tablet, 2 tablets，three times a day； For 90 days, continuous administration Other Name: low dose
33083522|NCT04585321|Other|T-R|"Part 1 (QD) and part 2 (BID):~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
33083523|NCT04585321|Other|R-T|"Part 1 (QD) and part 2 (BID):~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
33083524|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
33284499|NCT04013477|Experimental|Cohort2|"drug : DA-5207 120mg/60cm²~placebo : 60cm²"
33083525|NCT00412997|Experimental|LBH589|
33083526|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
33083527|NCT04585048|No Intervention|waiting list|waiting list
33083528|NCT04585048|Experimental|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
33284500|NCT04013477|Experimental|Cohort3|"drug : DA-5207 160mg/80cm²~placebo : 80cm²"
33284501|NCT04013477|Active Comparator|Cohort4|drug : Aricept
33284502|NCT00511238|Experimental|carfilzomib (A0)|
33284503|NCT00511238|Experimental|carfilzomib (A1)|
33284504|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
33284505|NCT00940667|Active Comparator|amlodipine 5mg|
33284506|NCT04013087|Experimental|Test Formula|Feihe Stage 1 infant formula
33284507|NCT04013087|Active Comparator|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
33284508|NCT04013087|Other|Breast feeding|Breast fed of human milk
33284509|NCT04013321|Experimental|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
33284510|NCT04013321|Active Comparator|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
33284511|NCT04013321|No Intervention|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
33284512|NCT04013321|No Intervention|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
33284513|NCT01019772|Experimental|LBVH0101|
33284514|NCT01019772|Active Comparator|Hiberix|
33284515|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
33284516|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
33284517|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
33284518|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
33284519|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
33284520|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
32778982|NCT05515393|Experimental|XY03-EA Tablet (600mg group)|XY03-EA 150 mg/tablet, 4 tablets ,three times a day, For 90 days, continuous administration Other Name:high dose
33083529|NCT04584931|Experimental|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
33284521|NCT04607408|Experimental|Part A, Group 1: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 2.5 mcg GLA-SE, to be administered as a 0.25 mL intramuscular (IM) injection into either thigh at Weeks 0, 8, 16, 32, and 54.
33284522|NCT04607408|Placebo Comparator|Part A, Group 2: Placebo|Participants will receive Placebo to be administered as a 0.25 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
33284523|NCT04607408|Experimental|Part B, Group 3: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
33284524|NCT04607408|Placebo Comparator|Part B, Group 4: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
33284525|NCT04607408|Experimental|Part C, Group 5: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
33284526|NCT04607408|Placebo Comparator|Part C, Group 6: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
33284527|NCT04607408|Experimental|Part C, Group 7: CH505TF gp120 + GLA-SE|Participants will receive 5 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
33284528|NCT04607408|Placebo Comparator|Part C, Group 8: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
32778983|NCT05515393|Placebo Comparator|XY03-EA Placebo Tablet|XY03-EA Placebo Tablet 150 mg/tablet, 4 tablets,three times a day, For 90 days, continuous administration Other Name: placebo
33083530|NCT04584931|Active Comparator|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
33083531|NCT04585126|No Intervention|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
33083532|NCT04585126|Active Comparator|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
33083533|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
33284529|NCT03969719|Placebo Comparator|Placebo|Palacebo
33284530|NCT03969719|Experimental|Low Dose|150 mg
33284531|NCT03969719|Experimental|High Dose|300 mg
33284532|NCT04247282|Experimental|A/arm A|M7824 (Days 1, 15)
33284533|NCT04247282|Experimental|B/arm B|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Days 1)
33284534|NCT04247282|Experimental|C/arm C|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
33284535|NCT03998072|Experimental|Intervention|
33284536|NCT03998072|No Intervention|Treatment as usual (waiting list control)|
32778984|NCT05515315|Experimental|Tislelizumab combined with chemothapy|
33284537|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
33284538|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
32778985|NCT04869787|Other|SCD Treatment|Pediatric patients receiving SCD + CRRT for up to 10 days
32778986|NCT05510713|No Intervention|the treatment-as-usual group|we used the single-cannula in femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
32778987|NCT05510713|Experimental|intervention group|we used the dual-cannula in jugular-femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
32778988|NCT05515159||ECT group|patients undergoing electroconvulsive therapy for depression
32778989|NCT05515159||control group|healthy controls; patients undergoing electroconversion for atrial fibrillation
32778990|NCT05519605||PTBD after failed ERCP|Patients with a distal malignant obstruction undergoing placement of a percutaneous transhepatic biliary drain after failed ERCP.
32778991|NCT05519605||EUS-BD after failed ERCP|Patients with a distal malignant obstruction undergoing EUS-guided biliary drainage after failed ERCP.
32778992|NCT05519371|Experimental|remimazolam group|For induction of anesthesia, rimazolam benzoate was pumped at a rate of 12 mg/kg/h; for maintenance of anesthesia, 1.0-2.0 mg/kg/h rimazolam was given as a continuous pump.
32778993|NCT05519371|Active Comparator|propoful group|For induction of anesthesia, propofol medium-length chain fatty milk injection 2 mg/kg was given by intravenous push; for maintenance of anesthesia, 6-8 mg/kg/h propofol medium-length chain fatty milk injection was given by continuous pumping.
32778994|NCT05515081|Other|vaccinated healthy subject|Procedure/Surgery: blood sample collection at regular intervals
33284539|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
33284540|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
33083534|NCT04584775|Experimental|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
33083535|NCT04584775|Other|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
33284541|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
33284542|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
33284543|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
33284544|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
33284545|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
33284546|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
33284547|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
33284548|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
33083536|NCT00568165|Experimental|1|Mobile Team
33284549|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
33083537|NCT00568165|Active Comparator|2|Standard care
33083538|NCT04584580|Active Comparator|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
33083539|NCT04584580|Experimental|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH~D-Dimer level Body Weight LMWH dose~<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD~1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD~>3 mg/ dl Enoxaparin 80mg BD"
33083540|NCT04584697|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
33083541|NCT04584697|Placebo Comparator|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
33083542|NCT04584736|Experimental|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
33083543|NCT04584736|Active Comparator|Livalo 2mg|Pitavastatin 2mg
33083544|NCT04584736|Experimental|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
33083545|NCT04584736|Active Comparator|Livalo 4mg|Pitavastatin 4mg
33083546|NCT04584268|Experimental|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
33083547|NCT04584268|Active Comparator|control|standard medical resident education
33083548|NCT04584307|Experimental|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
33083549|NCT04584151|No Intervention|standard of care|Peri operative analgesia by opioid
33083550|NCT04584151|Experimental|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
33284550|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
33284551|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
33284552|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
33284553|NCT00939887|Experimental|Treatment|
33284554|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
33284555|NCT04012541|Experimental|treatment group|"post-myocardial infarction management~basic periodontal examinations~active dental procedure"
32778999|NCT04855201|Experimental|ASP0367|Participants will receive ASP0367 once daily in the morning for 6 weeks.
32779000|NCT04855201|Placebo Comparator|Placebo|Participants will receive placebo once daily in the morning for 6 weeks.
32779001|NCT04948645|Active Comparator|ABBV-CLS-7262 LOW DOSE|
32779002|NCT04948645|Active Comparator|ABBV-CLS-7262 MEDIUM DOSE|
32779003|NCT04948645|Active Comparator|ABBV-CLS-7262 HIGH DOSE|
32779004|NCT04948645|Placebo Comparator|PLACEBO|
32779005|NCT05515003|Experimental|Education group|Individualized patient education
32779006|NCT05515003|No Intervention|Control group|No training will be provided
32779007|NCT04847947|Experimental|Interventional group|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.
32779008|NCT04847947|Placebo Comparator|Control Group|Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.
32779009|NCT05519137|Active Comparator|Active lighting intervention then Control lighting condition|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
32779010|NCT05519137|Active Comparator|Control lighting condition then Active light intervention|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
32779011|NCT05510479||OdySight vs Standardized methods|All patients perform Visual Acuity testing through OdySight and according to standard practice
33083551|NCT04720521|Experimental|OE+white light|Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.
33083552|NCT04720521|No Intervention|White light|Using White light to observe from esophagus to duodenum.
33083553|NCT04584034|Active Comparator|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
33083554|NCT04584034|Placebo Comparator|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
33083555|NCT04584229||question not suitable for study|question not suitable for study
33083556|NCT04584073|Active Comparator|Adenoidectomy|Adenoidectomy
33083557|NCT04584073|Active Comparator|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
33083558|NCT04584073|Active Comparator|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
33284556|NCT04012541|Active Comparator|control group|"post-myocardial infarction management~basic periodontal examinations"
33284557|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
33284558|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
33083559|NCT04583722|Other|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
33083560|NCT04583722|Experimental|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
33284559|NCT02877134|Experimental|Part II : Placebo|"Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ- 64304500. Participants receiving placebo during the LTE will stop receiving placebo."
33284560|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|"JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
33284561|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|"JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
33284562|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|"JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
33284563|NCT02877134|Experimental|Part II : Ustekinumab|"Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving Ustekinumab during the LTE will stop receiving study drug and will have a final safety follow-up visit after the last dose of study drug. However, participants receiving Ustekinumab in countries where Ustekinumab is not commercially available or approved for adult Crohn's disease were continued to receive Ustekinumab in the LTE."
33284564|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
33284565|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
33284566|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
33284567|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
33284568|NCT00512798|Experimental|Phase I|
32779012|NCT05514925|Active Comparator|Preoperative Anti-VEGF Intravitreal Injection|Three to five days before vitrectomy, each participant received one intravitreal Bevacizumab injection (1.25 mg,0.05 ml).
33083561|NCT04583683|Active Comparator|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
33284569|NCT00512798|Experimental|Phase II|
33284570|NCT03998930|Experimental|brain injuried patients|"Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),~15-minute break between the two evaluations.~Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
33284571|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
33284572|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
33284573|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
33284574|NCT00940121|Experimental|1. mirabegron, low dose|Oral mirabegron 25 mg
33284575|NCT00940121|Experimental|2. mirabegron, middle dose|Oral mirabegron 50 mg
33083562|NCT04583683|Active Comparator|Metabolic Surgery|Patients will undergo metabolic surgery
33284576|NCT00940121|Experimental|3. mirabegron, higher dose|Oral mirabegron 100 mg
33284577|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
33284578|NCT00940979|No Intervention|No use of integuseal|
32779013|NCT05514925|Experimental|Peripheral Retinal Cryoapplication|Four to six weeks before vitrectomy, each participant underwent peripheral retinal cryoapplication.
33284579|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
33284580|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
33284581|NCT04012619|Experimental|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
33284582|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
33284583|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
33284584|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
32779014|NCT05514847|No Intervention|1 Control Group|Control Group (Group 1): These patients will be screened negative for both the ACOG screening test and the FMF preeclampsia screen. These women will receive no aspirin.
32937203|NCT04181515|Active Comparator|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
33284585|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
33284586|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
33284587|NCT00941057|Active Comparator|Levomefolate|Treatment C
33284588|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
33284589|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
33284590|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
33284591|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
33284592|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
33284593|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
33284594|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
33284595|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
33284596|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
33284597|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
33284598|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
33284599|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
33284600|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
32937204|NCT04181515|Active Comparator|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
32937205|NCT04181515|Active Comparator|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
32937206|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
32937207|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
32937208|NCT04180969|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
32937209|NCT04180969|Experimental|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
32937210|NCT04180969|Experimental|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
32937211|NCT04180969|Experimental|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
33284601|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
33284602|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
33284603|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
33284604|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
33083563|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
33083564|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
33083565|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
33083566|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
33083567|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
33083568|NCT04583410|Experimental|Nicotine patch|
33083569|NCT04583410|Placebo Comparator|Placebo patch|
33083570|NCT04583449|Experimental|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
33083571|NCT04583449|Experimental|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
33083572|NCT04583449|Experimental|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
33083573|NCT04583449|No Intervention|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
33083574|NCT04583098||carbapenem-resistant Enterobacteriaceae|
33083575|NCT04583098||vancomycin-resistant Enterococci|
33083576|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
33083577|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
33083578|NCT04583371|No Intervention|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
33083579|NCT04583371|Active Comparator|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
33083580|NCT04583332|Other|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
33083581|NCT04583137|Experimental|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
33083582|NCT04583137|Experimental|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
33083583|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
33083584|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
33083585|NCT04583020|Experimental|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
33083586|NCT04583059|Experimental|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
32937212|NCT04943510|Experimental|Physical exercices arm|three randomizations will be used to determine the order of the tests that will be proposed to the subjects: on the one hand for the exercise modalities (match, anaerobic, aerobic) and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear
33284605|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
33284606|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
33284607|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
33284608|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
33284609|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
33284610|NCT01061320|Active Comparator|alpha tocopherol|
32937213|NCT04115527|Active Comparator|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
32937214|NCT04115527|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
32937215|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
32937216|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
33284611|NCT01061320|Placebo Comparator|placebo|
33284612|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
33284613|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
33284614|NCT01565408|Experimental|NNC0114-0006|
33284615|NCT01565408|Placebo Comparator|Placebo|
33284616|NCT03985306|Experimental|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
33284617|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
33284618|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
33284619|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
32937217|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
32937218|NCT04101877|Experimental|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
32937219|NCT04101877|Active Comparator|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
32937220|NCT04209140||bipolar I disorders who initiate lithium treatment|
32937221|NCT04334486|Experimental|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
32937222|NCT04334486|No Intervention|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
32937223|NCT04334473|Other|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
32937224|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
32937225|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
32937226|NCT04762381|Active Comparator|Dexamethasone|24 mg dexamethasone as single dose intravenously peroperatively
32937227|NCT04762381|Placebo Comparator|Placebo|saline infusion intravenously in a single dose
32937228|NCT01547468|Active Comparator|Intravenous Opioids|
32937229|NCT01547468|Experimental|Femoral Nerve Catheterization|
33284620|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
33284621|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
33284622|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
33284623|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
33284624|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
33284625|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
33284626|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
33284627|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
33284628|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
33284629|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
32937230|NCT04749433|Experimental|Participants with diagnosis of ALS|Participants with a diagnosis of ALS will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
33284630|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
33284631|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
33284632|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
33284633|NCT00309166|Experimental|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
33318135|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
32937231|NCT04749433|Experimental|Healthy Participants without a diagnosis of ALS|Healthy participants (without a diagnosis of ALS) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
32937232|NCT04900220|Active Comparator|Betamethasone|betamethasone
32937233|NCT04900220|Active Comparator|Methylprednisolone|methylprednisolone
32937234|NCT04717687|Experimental|Electrodes|Electrodes
32937235|NCT04333628|Experimental|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
32937236|NCT04333628|Experimental|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
32937237|NCT04333628|Other|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
32937238|NCT04696315||SCD subjects with positive amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with positive amyloid show the evidence of amyloid deposition in brain. They have higher risk of conversion to mild cognitive impairment and dementia compared with SCD with negative amyloid. They are also considered as preclinical AD.
32937239|NCT04696315||SCD subjects with negative amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with negative amyloid do not show the evidence of amyloid deposition in brain. They have lower risk of conversion to mild cognitive impairment and dementia compared with SCD with positive amyloid.
32937240|NCT04333771|Placebo Comparator|Placebo|
32937241|NCT04333771|Experimental|SHR0302 dose1|
32937242|NCT04333771|Experimental|SHR0302 dose2|
32937243|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
32937244|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
32937245|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
32937246|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
32937247|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
32937248|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
32937249|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
33284634|NCT00309166|Active Comparator|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
33284635|NCT01063816|Experimental|Arm 1|
32937250|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
33284636|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284637|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284638|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284639|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284640|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284641|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
33284642|NCT03981250|No Intervention|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
33284643|NCT03981250|Experimental|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
33284644|NCT03985462|Experimental|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
33284645|NCT03985462|Experimental|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
33284646|NCT03985462|Experimental|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
33284647|NCT03985462|No Intervention|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
32937251|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
32937252|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
33284648|NCT03983122|Experimental|Study group|Patients who undergo laparoscopic sleeve gastrectomy
32937253|NCT04611451|Experimental|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
32937254|NCT04611451|Active Comparator|exercise|The second group (control) only received classical lumbar home exercise program.
32937255|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
32937256|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
32937257|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.~Avelumab will be administered intravenously every 2 weeks starting on day 1."
32937258|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
32937259|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
32937260|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
32937261|NCT00813566|Experimental|All Participants|All participants will receive multi-tracer PET scans at up to 3 time points: baseline, at the conclusion of standard of care chemoradiation, and at the time of documented recurrence within two years.
32937262|NCT03908359|Active Comparator|traditional cataract surgery|Central anterior continuous capsulorhexis opening (5-6 mm)+ lens irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit)
32937263|NCT03908359|Experimental|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+lens irrigation/aspiration
33284649|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
33318136|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
33318137|NCT01205750|Experimental|Glucose clamp|
32779015|NCT05514847|Active Comparator|2 Randomized Group 1|Group 2: These patients will be screened negative for the ACOG screening test but positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
32779016|NCT05514847|Other|3 Standard of Care Group|Group 3: These patients will be screened positive for the ACOG screening test but negative for the FMF preeclampsia screen. These women will be offered 81 mg aspirin, which is the standard of care.
32937264|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
32937265|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
32937266|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.~Will receive the intervention from Sept. 2019 - June 2020."
32937267|NCT05051527||Legalon®|Legalon® 140 mg
32937268|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
32937269|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
32937270|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
32937271|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
32937272|NCT05013073|Experimental|Experimental Arm|All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.
32937273|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
32937274|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
32937275|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
32937276|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
33318138|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
32937277|NCT05008627||Doffing PPE with verbal instructions and monitor|The subject will remove the PPE according to verbal instructions by a monitor
32937278|NCT05008627||Doffing PPE without verbal instructions|The subject will remove the PPE independently without a monitor
32937279|NCT05005663|Active Comparator|group A|patients younger than 2 years
32937280|NCT05005663|Active Comparator|group B|patients older than 2 years
32937281|NCT00372853|Experimental|Arm A|
32937282|NCT00372853|Experimental|Arm B|
32937283|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
32937284|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
32937285|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
32937286|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
32937287|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
32937288|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
32937289|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
32937290|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
32937291|NCT02879630||Obese Patients|Obese patients (patients whose weight is >190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
32937292|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
32937293|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
32937294|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
32937295|NCT02892110|Experimental|Varenicline|2 mg daily
32937296|NCT02892110|Placebo Comparator|Placebo|2 mg daily
32937297|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
32937298|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
32937299|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
32937300|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
33083587|NCT04583059|Experimental|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
33083588|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
33083589|NCT00568204|Experimental|1|Mexyn-A
33083590|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
33083591|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
33083592|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
33083593|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
33083594|NCT04582630||Control (standart)|Standart medical nutrition therapy
33284650|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
33284651|NCT03982966|Experimental|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
33284652|NCT03982966|No Intervention|Control|20 patients will not take omega 3 fatty acids.
33284653|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
33284654|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
33284655|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
33284656|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
33284657|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
33284658|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
33284659|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
33284660|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
33284661|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
33284662|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
33284663|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
33284664|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
33284665|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
33284666|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
33284667|NCT00501228|Experimental|Filgrastim Injections|
33284668|NCT00308620|Experimental|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
33284669|NCT00308620|Placebo Comparator|Placebo|Placebo once daily for 8 weeks
33284670|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
33284671|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
33284672|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
33284673|NCT01016496|Active Comparator|repetition only|repetition of gestures
33284674|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
33284675|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
33284676|NCT01016574|Other|women with stage I or II breast cancer|
33284677|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
33284678|NCT01009658|Active Comparator|MSG first|
33284679|NCT01009658|Placebo Comparator|NaCl first|
32779017|NCT05514847|Active Comparator|Group 4 Randomized Group 2|Group 4: These patients will be screened negative for the ACOG screening test and positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
32779018|NCT05510401|Other|SECURIDRAP® SELFIA®|Use of a SECURIDRAP® SELFIA® restraint system Monitoring with passage of an independent assessor
32779019|NCT05035771|Experimental|Pressure wire measurements|
32779020|NCT05510323|Active Comparator|CS|low-dose corticosteroids monotherapy
32779021|NCT05510323|Active Comparator|CS+CTX|low-dose corticosteroids combined with cyclophosphamide
32779022|NCT05032339||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders
32779023|NCT05514691|Active Comparator|Anterior nasal swab sample tested on iStatis Covid-19 Antigen Testing diagnostic device|An anterior nasal swab was collected using the swab provided with the iStatis test kit and will be used for the iStatis Covid-19 Antigen Testing at the site.
32779024|NCT05514691|Active Comparator|Anterior nasal swab sample tested with RT-PCR|Another anterior nasal swab sample was collected to be tested with RT-PCR at the central research laboratory.
32779025|NCT05514613||Group G|Group G is a tracheostomy group opened using the anatomical sign technique (Griggs technique).
32779026|NCT05514613||Group U|Group U; Ultrasound-guided is used during tracheostomy technique.
32779027|NCT05510167|Active Comparator|Study|Complete abstinence or ≤2 drinks/week in group 1 during the study period
32779028|NCT05510167|Active Comparator|Control|Allowed to continue their pre-ablation drinking habit
33083595|NCT04582786|Active Comparator|Standard group|Standard treatment (morphine) administered according to usual practice
32779029|NCT05514379|Experimental|Group cognitive training|The experimental group will undergo 60 minutes long cognitive training group sessions twice a week for 12 weeks focused on executive function, attention and working memory.
32779030|NCT05514379|Active Comparator|Home-based cognitive training|The control group will perform executive function, attention and working memory training similar to the experimental group but at home as instructed by their therapist using specialized software for cognitive training (Rehacom). This training will be dose matched to the experimental group, i.e. it will be performed four times a week for 30 minutes for 12 weeks. In this group, therapists will only provide coaching once a month.
32779031|NCT04128397|Experimental|traditional stimulation site continuous theta burst stimulation (cTBS)|arm: experimental: performing cTBS to tic patients for continuous 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. Determination of stimulation target is a common method of determination in previous studies. For example the vertex (Cz) was measured for each patient and the SMA defined at 15% of the distance between inion and nasion anterior to Cz on the sagittal midline.
32779032|NCT04128397|Experimental|precise stimulation site cTBS|arm: experimental: performing cTBS to tic patients for 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. The stimulation target is determined by the resting-state functional connectivity, which is robust functional connectivity with the GPi or Thalamus.
32779033|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
32779034|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
32779035|NCT04843579|Experimental|Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)|"Selinexor~• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.~Dexamethasone~Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.~Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).~Clarithromycin~Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.~Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.~Pomalidomide~Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.~Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle."
32779036|NCT05507671|Active Comparator|BCG vaccine|BCG (Bacillus Calmette-Guérin) vaccine - 0,1ml intradermal
32779037|NCT05507671|Placebo Comparator|Placebo|Solvent of BCG vaccine - 0,1ml intradermal
32779038|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
33083596|NCT04582786|Experimental|Test group: Infusion with bolus|STR-324 or morphine HCl infusion started with a initial bolus
33083597|NCT04582786|Experimental|Test group: Infusion without bolus|STR-324 or morphine HCl infusion started without a initial bolus
33083598|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
33083599|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
32779039|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
33083600|NCT04582474|Experimental|Dengue module and rapid diagnostic tests|
33083601|NCT04582123|Other|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
33284680|NCT05113706||Bystander not emotional distressed|If caller is not emotional distressed the first minute of the call
32779040|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
32779041|NCT02566525|No Intervention|Control|Standard of care
33083602|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
33083603|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
33083604|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
33083605|NCT00223847|Other|1|
33083606|NCT04582162|Experimental|Unsplinted implants|
32779042|NCT04764253|Experimental|Modified Sodium Watcher Program + Digital Self-Monitoring|
32779043|NCT04764253|Active Comparator|Usual care + Digital Self-Monitoring|
33284681|NCT05113706||Bystander emotional distressed|If caller is emotional distressed the first minute of the call
33284682|NCT00308308|Experimental|1|Technosphere Insulin
33284683|NCT00308308|Active Comparator|2|Rapid-acting analogue insulin plus basal insulin glargine
33284684|NCT00505934|Experimental|Levetiracetam|
33284685|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
33284686|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
33284687|NCT03981406|Experimental|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
33284688|NCT03981406|Placebo Comparator|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
33284689|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
33284690|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
33284691|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
32779044|NCT05514145|Active Comparator|Nance space maintainer|Conventional space maintainer for the maxillary arch as control
33284692|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
33284693|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
33284694|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
33284695|NCT01063894|Placebo Comparator|water|water
33284696|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
33284697|NCT01064050|No Intervention|control|
33284698|NCT00308074|Experimental|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
33284699|NCT01059838|Experimental|single subject|
33284700|NCT03997058|No Intervention|Control group|
33284701|NCT03997058|Experimental|Auricular acupoint pressing group|
33284702|NCT03997058|Active Comparator|Oral estazolam group|
33284703|NCT03997058|Active Comparator|Combined treatment group|
33284704|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
33284705|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
33284706|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
33284707|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
33284708|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
33284709|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
33284710|NCT03851094|No Intervention|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
33284711|NCT03851094|Experimental|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
33284712|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
32779045|NCT05514145|Experimental|Nance/Transpalatal arch space maintainer|New design of a space maintainer for the maxillary arch
32937301|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
32937302|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
33284713|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
33284714|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
33284715|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
33284716|NCT04482894|Experimental|Palliative Care Intervention|Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
33284717|NCT04482894|No Intervention|Standard Clinical Care|Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.
33284718|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
33284719|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
33284720|NCT04334330|Experimental|Treatment group|
33284721|NCT01015196|Active Comparator|Idarubicine|
33284722|NCT01015196|Experimental|Daunorubicine|
33284723|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
33284724|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
33284725|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
32779046|NCT05514067|Experimental|Electro-acupuncture (EA) arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery randomized to receive EA before surgery.
32779047|NCT05514067|No Intervention|Standard Care arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery.
32779048|NCT05513989|Active Comparator|modified Magill forceps group|One hundred and ten patients for whom modified pediatric Magill forceps was used to assist nasotracheal intubation
32779049|NCT05513989|Active Comparator|Magill forceps group|One hundred and ten patients for whom Magill forceps was used to assist nasotracheal intubation.
32779050|NCT05513911|Experimental|Acute intermittent Hypoxia Therapy|This group will receive the acute intermittent hypoxia therapy (9% O2) for 30 minutes. Before and after the intervention the participant will perform flexion of the elbow at various levels of intensity
32779051|NCT05513833|Other|Sequence 1|"Standard School Screening: All counties in Sequence 1 will receive standard hearing screening in the control period, Year 1~Standard Referral: All counties in Sequence 1 will receive standard referral in control period, Years 1 and 2.~Enhanced mHealth screening component: Counties randomized to Sequence 1 will receive the enhanced mHealth screening in Years 2, 3, and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 1 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Years 3 and 4."
32779052|NCT05513833|Other|Sequence 2|"Standard Hearing Screening: All counties in Sequence 2 will receive standard hearing screening in the control period, Years 1 and 2~Standard Referral: All counties in Sequence 2 will receive standard referral in control period, Years 1, 2 and 3.~Enhanced mHealth screening component: Counties randomized to Sequence 2 will receive the enhanced mHealth screening in Years 3 and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 2 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Year 4."
32779053|NCT05513755|Experimental|Cardioneuroablation|
32937303|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
32937304|NCT02898740|Experimental|Exercise|Structured exercise
32937305|NCT02898740|Active Comparator|Health Education|Health education
32779054|NCT05513755|No Intervention|Conventional treatment (counter-pressurre maneuver, drugs or pacemaker)|
32779055|NCT05513677|Active Comparator|Standard of Care|Standard of Care
32779056|NCT05513677|Experimental|M4D coated catheter|Experimental
32779057|NCT05507593|Experimental|Group A|Patients of group A will be received 1x10^7 DLL3-CAR-NK cells infusion treatment.
32779058|NCT05507593|Experimental|Group B|Patients of group B will be received 1x10^8 DLL3-CAR-NK cells infusion treatment.
32779059|NCT05507593|Experimental|Group C|Patients of group C will be received 1x10^9 DLL3-CAR-NK cells infusion treatment.
32779060|NCT05507515|Experimental|Part A: Cohort A1 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
32779061|NCT05507515|Experimental|Part A: Cohort A2 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
32779062|NCT05507515|Experimental|Part A: Cohort A3 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
32779063|NCT05507515|Experimental|Part A: Cohort A4 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
32779064|NCT05507515|Experimental|Part A: Cohort A5 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
32779065|NCT05507515|Experimental|Part A: Cohort A6 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
32937306|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
32937307|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
32937308|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
32937309|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
32937310|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
32937311|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
32937312|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
32937313|NCT04400227|Experimental|Youth-Parent Dyads|Participants will receive the Family Talk intervention and followup.
32937314|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
32937315|NCT04866589|Experimental|Distribution of free face masks|Face masks will be handed out for free to all customers entering the grocery stores.
32937316|NCT04866589|No Intervention|Control|Business as usual.
32937317|NCT04333550|Experimental|Experimental: Desferal addition to standard treatment|
32937318|NCT04333550|Experimental|Experimental: standard treatment|
32937319|NCT04737733|Other|The dementia friendly hospital program|The dementia-friendly hospital program comprised three parts; 1) Educational program for health practitioners to increase the staff's knowledge and awareness of patients with cognitive impairment and/or delirium; 2) Screening, for early identification of cognitive impairment and delirium, using the Four Assessment Test (4AT); 3) Delirium risk factor modification and management for patients defined with potential cognitive impairment and risk of delirium, implying that risk factor modifications should be implemented in the patient's care plan. For patients with suspected delirium, the program promoted an additional delirium management plan.
32937320|NCT04863625|Experimental|Experimental group|748 students from two secondary schools for the intervention group will be selected and participated in a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).
32937321|NCT04863625|No Intervention|Control group|748 students from two secondary schools for the control group will selected and receive t their school's regular curriculum.
33083607|NCT04582162|Active Comparator|Splinted implants|
32779066|NCT05507515|Experimental|Part B: Cohort B1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
32779067|NCT05507515|Experimental|Part B: Cohort B2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
32779068|NCT05507515|Experimental|Part B: Cohort B3 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
32779069|NCT05507515|Experimental|Part B: Cohort B4 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
32779070|NCT05507515|Experimental|Part B: Cohort B5 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
32779071|NCT05507515|Experimental|Part C: Cohort C1 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
32779072|NCT05507515|Experimental|Part C: Cohort C2 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
32779073|NCT05507515|Experimental|Part D: Cohort D1 ONO-2020 or Placebo|Single dose of ONO-2020 orally in elderly healthy volunteers
32779074|NCT05507515|Experimental|Part E: Cohort E1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
32779075|NCT05507515|Experimental|Part E: Cohort E2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
32779076|NCT05507281|Sham Comparator|Control group|Patients received general anesthesia alone.
32779077|NCT05507281|Experimental|Ultrasound-guided Erector Spinae Plane Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced until contact is made with the transverse process. The local anesthetic agent will be injected between the transverse process and the erector spinae muscle using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
32779078|NCT05507281|Experimental|Retrolaminar Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina. The local anesthetic agent will be injected on the lamina using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
32779079|NCT05507047|Experimental|Transcrestal Sinus Lifting with Emdogain|Osteotome sinus floor elevation with enamel matrix derivated
32779080|NCT05507047|Active Comparator|Transcrestal Sinus Lifting|Osteotome sinus floor elevation
32779081|NCT04757857|Active Comparator|Rivaroxaban 10 mg|Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).
32779082|NCT04757857|No Intervention|Best locally standardized care|According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.
32779083|NCT04755283|Experimental|Abelacimab (MAA868)|"Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly~Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly"
32779084|NCT04755283|Active Comparator|Rivaroxaban|"Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal~Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily."
32779085|NCT05506969|Experimental|Part 1 Group 1:rF1V vaccine and CpG 1018® adjuvant co-administered|rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
32779086|NCT05506969|Experimental|Part 1 Group 2:rF1V vaccine and CpG 1018® adjuvant bedside mix|Bedside mix of rF1V vaccine and CpG 1018® adjuvant and placebo will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
32937322|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
32937323|NCT04846933||HGSOC patients treated with Neoadjuvant chemotherapy (NACT)|"Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET/CT. IDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines).~Digital H&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations/ascites drainages. Patients are followed with longitudinal ctDNA sampling."
32937324|NCT04846933||HGSOC patients treated with primary debulking surgery (PDS)|PDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines). Digital H&E slides and WGS, RNAseq obtained from PDS and possible relapse operations/ascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.
32937325|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
32937326|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
32937327|NCT02758184|Other|Control Group|Patients who are randomized not to receive ROTEM
32937328|NCT03099733|Experimental|concussion|patients who present to ED with concussion
33284726|NCT00307684|Experimental|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
33284727|NCT00307684|Experimental|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
32937331|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
32937332|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
32937333|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
32937334|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
32937335|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
33284728|NCT00307684|Placebo Comparator|003|double blind placebo matching placebo tablets once daily for 4 weeks
33284729|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
33284730|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
33284731|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
33284732|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
32737536|NCT05040165|Experimental|Failure time analysis|"The primary objective is to evaluate the durability of the investigational device over its intended use lifetime (i.e. warranty period), specifically relating to any defect in the TPE material. Additionally, to gather information on the rate of side-effects, i.e. skin rashes, sores, etc.~Secondary objectives relate to gather information on how amputees use the liner, specifically:~Intensity of use (days/week and hours/day)~Alternation; i.e. switching every other day between liners~Use of personal hygiene or cosmetic products~The following performance and safety aspects are to be verified:~• The ICEFORM line of devices are durable over their intended use lifetime."
32937336|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
32937337|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
32779087|NCT05506969|Active Comparator|Part 1 Group 3: rF1V vaccine and placebo|rF1V vaccine and placebo will be administered on Days 1, 29, and 183
32937338|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
32937339|NCT04233229|Experimental|closed-loop and home care services|automated insulin delivery system (Closed-loop) with tailored Home Healthcare Provider (HHP) services
32937340|NCT04233229|Active Comparator|usual care|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
32937341|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
32937342|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
32937343|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
32937344|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
32937345|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
32937346|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
32737537|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
32737538|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
32937347|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
32937348|NCT04208347|Experimental|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
32937349|NCT04208347|Experimental|Apatinib and S-1 and Oxaliplatin|
32937350|NCT04208347|Active Comparator|S-1 and Oxaliplatin|
32937351|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
32937352|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
32937353|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
32937354|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
32737539|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
32737540|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
32737541|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
33284733|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
32937355|NCT02785172|Experimental|IDP-118 Lotion|Lotion
32937356|NCT02785172|Active Comparator|Ultravate Cream|Cream
32937357|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
32937358|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
32937359|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
33284734|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
33284735|NCT00307294|Experimental|thalidomide and doxil|Combination of Thalidomide and Doxil
33284736|NCT03981094|Experimental|BMS-986278|
33284737|NCT03981094|Experimental|Pirfenidone|
33284738|NCT03981094|Experimental|BMS-986278 + Pirfenidone|
33284739|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
33284740|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
32937360|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32937361|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
32779088|NCT05506969|Experimental|Part 2 Group 1 & 3, OR Group 2 & 3|"Group 1 & 3 (if selected): Group 1: rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183. Group 3: rF1V vaccine and placebo will be administered on Days 1, 29, and 183~OR~Group 2 & 3 (if selected): Group 2: Bedside mix of rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29; placebo will be administered on Day 183. Group 3: rF1V vaccine will be administered on Days 1, 29, and 183"
32779089|NCT05509621|Experimental|Supine position|To determine the effect of supine position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
32779090|NCT05509621|Experimental|Prone position|To determine the effect of prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
32779091|NCT05509621|Experimental|Left lateral position|To determine the effect of left lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
32779092|NCT05509621|Experimental|Right lateral position|To determine the effect of right lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
33284741|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
33284742|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
32779093|NCT05509621|Experimental|Quarter prone position|To determine the effect of quarter prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
32779094|NCT04291885|Experimental|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
32779095|NCT04291885|Placebo Comparator|Placebo|6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
32779096|NCT04754191|Experimental|Treatment: all patients|Enfortumab will be administered in monotherapy on days 1, 8, and 15 as part of a 28-day cycle at 1.25 mg/kg up to 125 mg.
32779097|NCT04747327|Experimental|specific vaccine policy 1|Those in this arm will learn about a specific financial incentive or mandate policy.
32779098|NCT04747327|Experimental|specific vaccine policy 2|Those in this arm will learn about a specific financial incentive or mandate policy.
32937362|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
32937363|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
32779099|NCT04747327|Experimental|specific vaccine policy 3|Those in this arm will learn about a specific financial incentive or mandate policy.
32937364|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
32937365|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
32937366|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
32937367|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
32937368|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
32937369|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
32937370|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
32937371|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
32937372|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
32779100|NCT04747327|Experimental|Specific vaccine policy 4|Those in this arm will learn about a specific financial incentive or mandate policy.
32779101|NCT04747327|Experimental|specific vaccine policy 5|Those in this arm will learn about a specific financial incentive or mandate policy.
32779102|NCT04747327|Experimental|specific vaccine policy 6|Those in this arm will learn about a specific financial incentive or mandate policy.
32779103|NCT04747327|Experimental|specific vaccine policy 7|Those in this arm will learn about a specific financial incentive or mandate policy.
32779104|NCT04747327|Experimental|specific vaccine policy 8|Those in this arm will learn about a specific financial incentive or mandate policy.
32779105|NCT04747327|Experimental|specific vaccine policy 9|Those in this arm will learn about a specific financial incentive or mandate policy.
32779106|NCT04747327|Experimental|specific vaccine policy 10|Those in this arm will learn about a specific financial incentive or mandate policy.
32779107|NCT04747327|Experimental|sleep financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their sleep.
32779108|NCT04747327|Experimental|sleep social incentive|Those in this arm will invite adults to join an RCT that uses social (gamification) incentives to reward those who increase their sleep.
32779109|NCT04747327|Experimental|exercise financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their exercise.
32779110|NCT04747327|Experimental|exercise social incentive|Those in this arm will invite adults to join an RCT that uses social incentives to reward those who increase their exercise.
32779113|NCT05513287||Spinal anethesia|group number one which recive spinal anethesia in cesarean section in 2020 and 2021
32779114|NCT05513287||General anesthesia|Group number 2 which recive general anathesia in cesarean section in 2020 snd 2021
32779115|NCT05513209|Active Comparator|opioid based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
32779116|NCT05513209|Active Comparator|opioid free pterygopalatine ganglion block based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
32779117|NCT05513131|Experimental|Venetoclax combined with Azacitidine and Harringtonine|Venetoclax 100mg d1，200mg d2，400mg d3~d14； Azacitidine 75mg/m2/d，d1~d7； Homoharringtonine 2mg/d d1~d7
32779118|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
32779119|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
32779120|NCT05509465|Experimental|Ergonomic chinrest used with low shoulder rest (EC+)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC+) for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC+.
32937373|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
32937374|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
32937375|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
32937376|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
32937377|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
32937378|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
32937379|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
32937380|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
32937381|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
32937382|NCT00374036|Experimental|1|ECC
32937383|NCT00374036|Experimental|2|FOLFIRI
32937384|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
32937385|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
32937386|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
32937387|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
32937388|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
32937389|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
32779121|NCT05509465|Experimental|Ergonomic chinrest used without shoulder rest (EC-)|Participants will play the violin using the ergonomic chinrest without a shoulder rest for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC-.
32779122|NCT05506657|Other|State Counselor-Coordinated Services|In this program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services (NJDVRS), a state-based agency that assists people with disabilities who are interested in pursuing employment. While the participant is in inpatient rehabilitation or soon after their discharge, a member of the research team will assist them in completing the necessary documentation to apply for services from this agency. Services for which they are eligible will be provided directly through NJDVRS.
32779123|NCT05506657|Other|Center Facilitator-Coordinated Services|In this program, services are coordinated by a facilitator who is employed by Kessler Institute for Rehabilitation and works cooperatively with NJDVRS. The facilitator will begin working with the participant during inpatient rehabilitation, or soon after discharge, depending on when they enroll in the study. Some services for which they are eligible will be provided through NJDVRS and others will be provided to them by the facilitator.
32937390|NCT02910674|Other|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
32937391|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
32937392|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
33284743|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
33284744|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
33284745|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
33284746|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
33284747|NCT04410965|Experimental|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
33284748|NCT04012775|Active Comparator|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
32937393|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
32937394|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
32937395|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
32937396|NCT01929902||Surgical Patients|
32937397|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
32937398|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
32937399|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
32937400|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
32937401|NCT03001778|Experimental|Usability Testing|Prototype testing
32937402|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
32937403|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
32937404|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
32937405|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
32937406|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
32779124|NCT05512975|Experimental|Control Porridge arm|Control/ regular protein porridge recipe, not containing any additional protein fortification.
32779125|NCT05512975|Experimental|Dairy Protein Porridge arm|Porridge containing regular protein ingredients with dairy protein fortification (delical- a whey protein powder)
32779126|NCT05512975|Experimental|Plant Protein Porridge arm|Porridge containing regular protein ingredients with plant protein fortification (extruded soy and soya milk)
32779127|NCT05512897|No Intervention|standard care|standard analgesic treatment
33284749|NCT04012775|Experimental|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
33284750|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
33284751|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
33284752|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
33284753|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
33318139|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
33318140|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
32779128|NCT05512897|Experimental|standard care + ESP block|intraoperativeESP block + standard analgesic treatment
32779129|NCT05512741||Group Ileus|"Patients that experience POI after colorectal surgery. POI is defined by the presence of 2 of the 5 criteria of Vather from the first postoperative day.~The first 10 consecutive patients experiencing POI will be included in the study."
32779130|NCT05512741||No POI group|Patients that do not experience POI. The 10 patients having the fastest recovery of gastro-intestinal functions after surgery during the period of inclusion will be included in the study
32779131|NCT05509387|Experimental|4mA Stimulation|
32779132|NCT05509387|Active Comparator|2mA Stimulation|
32779133|NCT05509387|Sham Comparator|SHAM|
32779134|NCT05506501|Active Comparator|Unilateral epidural anesthesia group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
32779135|NCT05506501|Active Comparator|Ultrasound guided femoro/ sciatic nerve block group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
32937407|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
32937408|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
32937409|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
32937410|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
32937411|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
32937412|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
32937413|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
32937414|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
32937415|NCT01821781|Experimental|Preparative|
32937416|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
32779136|NCT05509309|Experimental|Experimental group|"In the experimental group, in-service training on autism, program quality, and APERS will be provided to participating staff. Furthermore, APERS-rating to assess the program quality for students with ASD/SCC will be conducted. Pertaining feedback on program areas of strength and improvement will be provided by the APERS-raters to the classroom teachers.~Subsequently, assigned coaches (already employed at the school as special educators or equivalent) will based on the APERS-ratings develop an action plan to improve program quality for students with ASD and SCC, in collaboration with classroom teachers. Subsequently, the coach will provide weekly or bi-weekly coaching to promote program quality during the course of two school semesters (approximately 8-9 months)."
32779137|NCT05509309|No Intervention|Comparison group|The classrooms in the comparison group will also be rated with the APERS, and feedback will provided to classroom teachers. However, no further support will be provided in transforming APERS-ratings with pertaining feedback into best practice.
32937417|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
32937418|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
32937419|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
32937420|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
32937421|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
32937422|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
32937423|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
32937424|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
32937425|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
33284754|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
33284755|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
33284756|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
33284757|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
33284758|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
33284759|NCT00306670|Experimental|Rituximab|Patients will receive rituximab.
33284760|NCT00306670|Active Comparator|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
33284761|NCT00306592|Experimental|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
33284762|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
33284763|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
33284764|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
33284765|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
33284766|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
33284767|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
33284768|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
33284769|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
33284770|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
33284771|NCT03982654|Experimental|Bloomlife|
33284772|NCT00403767|Experimental|Rivaroxaban|
33284773|NCT00403767|Active Comparator|Warfarin|
33284774|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
33284775|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
33284776|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
33284777|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
33284778|NCT01015274||Healthy control male|
32937426|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
32937427|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
32937428|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
32937429|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
33284779|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
33284780|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
33284781|NCT01009970|Experimental|1|R-COMP
33284782|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
33284783|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
33284784|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
33284785|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
33284786|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
33284787|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
33284788|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
33284789|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
33284790|NCT05102162|Active Comparator|Continuous Antibiotic Dose Over 24 hours Arm|Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
33284791|NCT05102162|Active Comparator|Intermittent Antibiotic Dose Over 30 minutes|Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.
33284792|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
33284793|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
33284794|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
32779138|NCT05512663|Experimental|Irreversible Electroporation (IRE) treatment|Focal Irreversible Electroporation (IRE) delivered by NanoKnife System is composed of the NanoKnife Generator and NanoKnife Single Electrode Probes.With the NanoKnife System, electrical current is delivered between pairs of probes in a series of pulses. The waveform of the current is adjustable as determined by clinician chosen parameters. Up to six probes may be placed in an array within the tissue. The probes of the array are matched as pairs by the system. When probes are activated via a foot pedal, the scheduled current is delivered to tissue between subsequent pairs of probes. Soft tissue between the probes is ablated.
32779139|NCT05502913|Experimental|standard of care (SoC) (IO±CTX) + FMT|"Subjects assigned to Arm 1 will be required to swallow FMT capsules in a regimen of ten capsules in the morning and ten capsules in the afternoon on day 1 of the first (chemo-)immunotherapy cycle, and then every three weeks.~abbreviation: Immuno-Oncology (IO) Chemotherapy (CTX)"
32779140|NCT05502913|Placebo Comparator|SoC + Placebo|Subjects assigned to Arm 2 will be required to swallow placebo capsules on day 1 of the first (chemo-)immunotherapy cycle, and then every three weeks.
32779141|NCT05509153|Experimental|NAC|1g N-Acetylcysteine capsules, taken orally twice a day.
32779142|NCT05509153|Placebo Comparator|Placebo|Coated Placebo capsules, taken orally twice a day
32779143|NCT05506189||Breast cancer survivors with over-weight or obesity|Breast cancer survivors with 25 and more than 25 of BMI will be supported with 6 months life style modification program using mobile application including human coach for reducing BMI.
32779144|NCT04799197|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
32779145|NCT05506033|No Intervention|Standard GCs taper group|After a complete response (PLT ≥100x10^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
33318141|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
33318142|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
32779146|NCT05506033|Experimental|rapid GCs taper group|After a complete response (PLT ≥100x10^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be cut in half (25mg/d for weight less than 50kg, 30mg/d for weight 50-75kg , 40mg/d for weight more than 75kg ). After that, the dose would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
33318143|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
32779147|NCT04594837|Experimental|PTR (Physical Therapy while wearing Robot group) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
32779148|NCT04594837|Active Comparator|PT (Physical Therapy Only) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
32779149|NCT04594837|Experimental|X-PTR, Cross over group for Physical Therapy n Sub-Acute group.|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
32779150|NCT04594837|Experimental|C-PTR, Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
33318144|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
33284795|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
33284796|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
32937430|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
33284797|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
33284798|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
33284799|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
33284800|NCT01589055|Active Comparator|Male Smokers|
33284801|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
33284802|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
33284803|NCT01013168|Experimental|OncoSorb® column|
33284804|NCT01013246|Experimental|Video game play|
33284805|NCT00414765|Experimental|Aldesleukin|All participants were treated with aldesleukin 600,000 international units per kilogram [IU/kg] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.
33284806|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
33284807|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
33284808|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
33284809|NCT01013480|Active Comparator|STX209|
33284810|NCT00500682|Placebo Comparator|Placebo|
33284811|NCT00500682|Experimental|AST-120|
33284812|NCT00500370|Experimental|Group A|
33284813|NCT00500370|Placebo Comparator|Group B|
33284814|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
33284815|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
33284816|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
33284817|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
33284818|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
33284819|NCT03996798|Experimental|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
33284820|NCT03996798|No Intervention|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
33284821|NCT03996486|Experimental|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
33284822|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
33284823|NCT01064206||Control group|200 atheromatous arteritis patients
33284824|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
33284825|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
33284826|NCT03980782|Experimental|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
33284827|NCT03980782|No Intervention|Care as usual|Each participant will receive care as usual.
33284828|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
33284829|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
33284830|NCT03981016|Experimental|Biological collection|"For the patients include in the study :~blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
33284831|NCT03996564|Active Comparator|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
33318145|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
32779151|NCT05509075||nutraceuticals and neurological disorders|evaluation of nutraceuticals in subjects with memory disorders
32779152|NCT05509075||nutraceuticals and skin disorders|evaluation of nutraceuticals in clinical conditions requiring topical treatment for skin diseases
32779153|NCT05509075||nutraceuticals and gastrointestinal diseases|evaluation of nutraceuticals in clinical conditions requiring systemic treatment for gastrointestinal diseases
32779154|NCT05509075||nutraceuticals and urological diseases|evaluation of nutraceuticals in the management of patients with prostate diseases or with lower tract infectious diseases requiring systemic or local treatment
32779155|NCT05509075||nutraceuticals and immunomediate diseases|evaluation of nutraceuticals in the management of patients with immunomediate disorders
32779156|NCT05509075||nutraceuticals and pain|evaluation of nutraceuticals in the management of patients with acute or chronic pain
32779157|NCT05508919|Experimental|Biofeedback Group|"The training consists of a total of 8 sessions for every individual with 2 sessions per week over the duration of 4 weeks. Each session will be approximately of 1 to 1.30 hour.~Subjects will be given clear instructions to not to use chocolate, coffee, tea and cocoa drinks at least 3 hours before the training session.~Since it is suggested that Anxiety tends to change with time so we might consider a one-month pretreatment measure as well as a just before treatment measure. That way we can be sure if our baseline is stable or not.~Baseline session: Subject will be asked to sit quietly for 15 minutes and their breathing rate, skin temperature and muscle tension using EMG will be measure without giving any intervention.~Subjects will then be given biofeedback training gradually to control their breathing rate, relaxed their muscle activity and temperature through RESP biofeedback, assisted EMG biofeedback and TEMP biofeedback, from the 1st session till their 8th Session."
32779158|NCT05508919|Active Comparator|Active Control Group|Active Control: Writing Sessions The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week. For example, in Session 1, we may ask the Subjects to write about how they will use their time. Similarly, we will ask the subject to give more detail and write briefly about the given control condition in session 2 and session 3. At the end of three writing session, we will measure their EMG, RESP and TEMP to compare with the Biofeedback training group.
32779159|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.|
32779160|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.|
32779161|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.|
32779162|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.|
33083608|NCT04582396|Experimental|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
33083609|NCT04582396|Placebo Comparator|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
33083610|NCT04581772|Experimental|Cohort A|
33083611|NCT04581772|Experimental|Cohort B|
32779163|NCT04730791||Chronic Pain Patients|Adult patients 18-65 years, with chronic pain lasting for 3 or more months, with a pain intensity of at least 3 on a 0-10 numerical pain rating scale on most days.
32779164|NCT04730791||Control Group|Free pain participants
32779165|NCT05508841|Experimental|4mA Stimulation|
32779166|NCT05508841|Active Comparator|2mA Stimulation|
32779167|NCT05508841|Sham Comparator|SHAM|
32779168|NCT05502523|Active Comparator|Group I (pulmonary vein first approach procedure)|Patients undergo pulmonary vein first approach surgical procedure on day of surgery.
32779169|NCT05502523|Active Comparator|Group II (pulmonary artery first surgical procedure)|Patients undergo pulmonary artery first approach surgical procedure on day of surgery.
32779170|NCT05508763||PGx-guided dosing|This group will be genotyped for 14 pharmacogenes at the start of the study.
32779171|NCT05508763||Standard of care|This group will be genotyped for 14 pharmacogenes at the end of the study.
32779172|NCT04584853|Active Comparator|Endocrine Therapy only|Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen
32779173|NCT04584853|Experimental|Endocrine Therapy with abemaciclib|"Abemaciclib administered at dose of 150mg twice daily (provided as 50mg tablets), for 2 years or until evidence of disease recurrence or other discontinuation criteria are met.~Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen"
33083612|NCT04581772|Experimental|Cohort C|
33083613|NCT04581616|Active Comparator|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
33083614|NCT04581616|Experimental|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
33083615|NCT00223925|Placebo Comparator|Placebo|
33083616|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
33083617|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
33083618|NCT00223925|Experimental|Maribavir (400 mg once daily)|
33083619|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
33083620|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
33083621|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
33402086|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
32937431|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
32779174|NCT05502445|No Intervention|Control Group|"This group will follow the hospital's standard nutritional assessment and monitoring flow:~24-hour recall: patients will be interviewed to report about one day of their usual diet.~Application of a questionnaire: to assess the knowledge about the importance of protein intake in the prevention of sarcopenia and functionality, and whether the participant regularly performs physical activity.~Energy and protein needs: estimated according to the clinical status and patient associated pathologies. The protocol of the Clinical Nutrition Service will be followed.~Calculation of the Body Mass Index (BMI)~Nutritional risk was determined using the Mini Nutritional Assessment-Short Form~Screening for sarcopenia: SARC-F ,Calf Circumference and Hand Grip Strength"
32779175|NCT05502445|Active Comparator|Intervention Group|"In this group, the steps below are added:~On the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance.~On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements (ONS)."
32779176|NCT05505877|Experimental|BR790+Tislelizumab dose escalation|Dose escalation part
32779177|NCT05505877|Experimental|BR790+Tislelizumab dose expansion|Dose expansion part
32779178|NCT04725721|Experimental|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
32779179|NCT04725721|Active Comparator|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
32779180|NCT04712851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
32779181|NCT05508685|Experimental|HIIT and Cognitive Reassessment|The experimental group will receive high-intensity interval training associated with cognitive reassessment
32779182|NCT05508685|Active Comparator|HIIT Group|The HITT group will receive only the exercise without cognitive reassessment
32779183|NCT05508685|Active Comparator|Emotional regulation strategy group|This group will receive only cognitive reassessment strategy
32779184|NCT05508685|Placebo Comparator|Group No exercise and cognitive reassessment|This group will only be evaluated in pre and post, without intervention.
32779185|NCT05505799|Active Comparator|Preintervention|Normal clinician intubation process
32779186|NCT05505799|Experimental|Postintervention|Clinician intubation process after implementation and clinician education with a procedural checklist
32779187|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
32779188|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
32937432|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
32937433|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
32937434|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
32937435|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
32937436|NCT03005054|Experimental|StrataGraft skin tissue|
32937437|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
32937438|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
32937439|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
33083622|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
33083623|NCT00223964|Experimental|dose level 1|1.5 mg/kg
33083624|NCT00223964|Experimental|dose level 2|3 mg/kg
33083625|NCT04581694|Experimental|TAVI without contrast|
32779189|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
33083626|NCT04581304|Experimental|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
33083627|NCT04581304|Active Comparator|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
33284832|NCT03996564|Active Comparator|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
33284833|NCT00565409|Active Comparator|1|
33284834|NCT00565409|Active Comparator|2|
33284835|NCT00565409|Placebo Comparator|3|
33284836|NCT03980860|Active Comparator|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
33284837|NCT03980860|Active Comparator|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
33284838|NCT03980860|No Intervention|Control|No exercise program intervention (usual care)
33284839|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
33284840|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
33284841|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
33284842|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
33284843|NCT03980704|Active Comparator|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
33284844|NCT03980704|Experimental|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
33284845|NCT03980548||CABG patients|
33284846|NCT03980548||PAD patients|
33284847|NCT03980548||Healthy volunteers|
33284848|NCT03980548||Patients with CAD|
33284849|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
33284850|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
33284851|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
33284852|NCT00305110|Experimental|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
33284853|NCT03984760|Experimental|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion & BF Biotech Inc.
33284854|NCT03984760|Active Comparator|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
33284855|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
33284856|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
33284857|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
33284858|NCT03984604|Active Comparator|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
33284859|NCT03984604|Placebo Comparator|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
33284860|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
33284861|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
33083628|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
33083629|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
32779190|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
32779191|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
32937440|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
32937441|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
33284862|NCT04326452|Experimental|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
33284863|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
33284864|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
33284865|NCT01015508|Other|High predisposition|High predisposition for weight regain
33284866|NCT01015508|Other|low predisposition|low predisposition for weight regain
33284867|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
33284868|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
33284869|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
33284870|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
33284871|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
33284872|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
33284873|NCT01013558|Active Comparator|remifentanil|
33284874|NCT01013558|Placebo Comparator|saline|
33284875|NCT01013636||Anaplasma|
33284876|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
33284877|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
33284878|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
33284879|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
33284880|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
33284881|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
33284882|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
33284883|NCT01020084||Control|Subjects with normal salivary flow rate
33284884|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
33284885|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
33284886|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
33284887|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
33284888|NCT01016886|Experimental|1|
33284889|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
33284890|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
33284891|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
33284892|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
33284893|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
32937442|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
32937443|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
32937444|NCT03003793||Control group|Healthy control subjects
32937445|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
32937446|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
32937447|NCT02785159|Experimental|IDP-118 Lotion|Lotion
32937448|NCT02785159|Active Comparator|Tazorac Cream|Cream
32937449|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
32779192|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
32779193|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
32779194|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
32779195|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
32779196|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
32779197|NCT01648101|Placebo Comparator|Placebo|Placebo
32779198|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
32779199|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
32779200|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
32779201|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
32779202|NCT02566993|Experimental|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
32779203|NCT02566993|Active Comparator|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
32779204|NCT02566993|Active Comparator|Control Arm 2|Topotecan
32779205|NCT05508607||Pre-Implementation|
32779206|NCT05508607||Post-Implementation|
32779207|NCT05508529|Active Comparator|Chaga Mushroom|Chaga mushroom extract (1 capsule daily) Active ingredients: 480mg chaga mushroom extract Inactive ingredients: none
32779208|NCT05508529|Active Comparator|Algae Extract|Algae Concentrate (2 tablets daily) Active ingredients: 8mg algae concentrate Inactive ingredients: none
32779209|NCT05508529|Active Comparator|Black Cumin Seed Oil|Black cumin seed oil (1 softgel daily) Active ingredients: 500mg black cumin seed oil Inactive ingredients: medium chain triglyceride (MCT) oil
32779210|NCT05508529|Active Comparator|Black Cumin Seed Oil + Astaxanthin|Black Cumin Seed Oil + Astaxanthin (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 8mg astaxanthin oleoresin Inactive ingredients: medium chain triglyceride (MCT) oil
32779211|NCT05508529|Active Comparator|Black Cumin Seed Oil + Omega 3|Black Cumin Seed Oil + Omega 3 (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 1200mg omega3 from 1500mg fish oil Inactive ingredients: none
32779212|NCT05508529|Placebo Comparator|Placebo|Placebo (1 capsule daily) Inactive ingredients: 500 mg Cornstarch/Maltodextrin
33402087|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
33083630|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
32779214|NCT05505487|No Intervention|control group|Implement routine nursing such as: routine oral nursing, tracheostomy, dressing change, sputum suction nursing, oral education, etc.
32779215|NCT05505487|Experimental|intervention group|Implement comprehensive nursing models such as: admission risk assessment, personalized oral care based on beck oral score, aspiration prevention, airway care, diversified health education
32779216|NCT05508451|Active Comparator|paracetamol|
32779217|NCT05508451|Active Comparator|tenoxicam|
32779218|NCT05508451|Active Comparator|tenoxicam+paracetamol|
32779219|NCT05508451|Placebo Comparator|placebo|
32779220|NCT05508373|Experimental|Dose Escalation: dose level：0.3mg/kg|Dose Escalation: 0.3mg/kg, IV infusion, every 3 weeks (q3w).
32779221|NCT05508373|Experimental|Dose Escalation: dose level：1 mg/kg|Dose Escalation: 1 mg/kg IV infusion, every 3 weeks (q3w).
32779222|NCT05508373|Experimental|Dose Escalation: dose level：3 mg/kg|Dose Escalation: 3 mg/kg IV infusion, every 3 weeks (q3w).
32779223|NCT05508373|Experimental|Dose Escalation: dose level：10 mg/kg|Dose Escalation: 10 mg/kg IV infusion, every 3 weeks (q3w).
32779224|NCT04565899|Experimental|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
32779225|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
33083631|NCT04581421|Experimental|High Carb first|
33083632|NCT04581421|Experimental|Low Carb first|
33083633|NCT00224081|Experimental|Ferric gluconate|
33083634|NCT00224081|No Intervention|standard of care|
32779226|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
32937450|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
33083635|NCT04581265|Experimental|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
33284894|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
33284895|NCT04250064|Experimental|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
33284896|NCT04250064|Experimental|Ultra-low-dose RT|Ultra-low-dose RT
33284897|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
33284898|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
33284899|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
33284900|NCT01013948||N/A (Survey study)|
33284901|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
33284902|NCT01017276|Experimental|ASP group|
33284903|NCT00393939|Experimental|A|
33284904|NCT00393939|Active Comparator|B|
33284905|NCT00488982|Experimental|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
33284906|NCT00488982|Experimental|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
33284907|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
33284908|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
33284909|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
33284910|NCT00393861|Experimental|oxaliplatin & bevacizumab|
32937451|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
32937452|NCT03003949|Placebo Comparator|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
32937453|NCT03003949|Active Comparator|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
33284911|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
33284912|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
33284913|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
33284914|NCT03993639|Experimental|KRN125|Single SC administration
33284915|NCT04941222|Experimental|"With robotic seal PARO"|The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
33284916|NCT04941222|No Intervention|"Without robotic seal PARO"|The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.
33284917|NCT01040481||Malabsorptive distal gastric bypass|
33284918|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
33284919|NCT03996954|Active Comparator|Normal ECGs|Patients with normal ECGs
33284920|NCT03996954|Active Comparator|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
33284921|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
33284922|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
33284923|NCT01014702|Experimental|Laser Treatment|
33284924|NCT01014702|Active Comparator|Phacoemulsifcation|
33284925|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
33284926|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
33284927|NCT04935606|Experimental|Usual Care|Usual Care participants will receive their standard medical care as usual (no provider advice or telephone coaching sessions) and all screening and study assessments. To reduce biases, Usual Care arm patients will be given a cancer screening booklet and will be shown a cancer screening Video Doctor. They will also receive 2 re-contact telephone sessions at weeks 2 and 6 corresponding to the timing of the coaching sessions for the QUIT and QUIT-Mobile arms. All participants will also receive re-contact calls monthly from 7-weeks to 12-months. The re-contact calls (5 min) provide attention control for the Usual Care arm, motivate continued trial participation by reminding them of the next research assessment, but do not provide an active intervention. At study end, the Usual Care arm will receive the QUIT video doctor and drug use reduction booklet brochure materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
33284928|NCT04935606|Experimental|QUIT|The QUIT brief intervention protocol will consist of 5 steps corresponding to the 5A's approach for assisting behavior change in the clinic setting (Ask, Advise, Assess, Assist, and Arrange) that will focus on patients' HSD (highest scoring drug on the baseline ASSIST) use in the past 30 days.
33083636|NCT04580875|Active Comparator|Minimally invasive surgery (laparoscopy, laparoscopic-assisted procedures)|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity & Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by stable penetrating abdominal trauma with significant clinical/radiologic findings, in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
33083637|NCT04580875|Active Comparator|Conservative management|patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma with imsignificant findings will be managed conservatively.
33284929|NCT04935606|Experimental|QUIT-Mobile|"QUIT-Mobile will include a mobile platform with self-monitoring surveys and feedback message and robust data transfer protocols across three mobile technology platforms to meet diverse patient's preferences and needs regardless of literacy and phone type: a mobile-optimized web-app (using any smart phone's web-browser, not native apps), SMS (text-messaging), and IVR (automated voice calls for low literacy patients). Data collected during this study on patient platform preferences and exploratory analyses on intervention efficacy across platform types will inform the development of future effectiveness trials that can evaluate effectiveness of different mobile platforms."
33284930|NCT00488592|Experimental|PR1/WT1 Vaccine Response in Participants With Low-Risk Myeloid Cancers|"Subjects were given 6 subcutaneous injects of PR1:169-177 in Montanide adjuvant and 6 subcutaneous injections of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
33284931|NCT04244760|Active Comparator|Verbal Patients|
33284932|NCT04244760|Active Comparator|Non-verbal Patients|
33284933|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
33083638|NCT04581109|Experimental|Patients with metastatic prostate cancer|
33284934|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
33284935|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
33284936|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
33284937|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
33284938|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
33284939|NCT03984682|Experimental|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
33284940|NCT03984682|No Intervention|Control group|Patients will benefit from regular care
33284941|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
33284942|NCT00333970|Experimental|cognitive remediation|cognitive remediation
33284943|NCT00333970|No Intervention|treatment as usual|treatment as usual
33284944|NCT01017588|Experimental|back exercise|strengthening back exercise
33284945|NCT03984526|Placebo Comparator|Control group|intravenous normal saline pretreatment
33284946|NCT03984526|Experimental|Atropine group|intravenous atropine 0.5mg pretreatment
33284947|NCT03984526|Experimental|Ephedrine group|intravenous ephedrine 8mg pretreatment
33284948|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
33284949|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
33284950|NCT03984370|Experimental|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
33284951|NCT03984370|Experimental|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
33284952|NCT03984370|Placebo Comparator|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
33284953|NCT03984292|Experimental|Mass Learning|Single teaching session of 3 hours shall be provided
33284954|NCT03984292|Experimental|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
33284955|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
33318146|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
32779227|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
32779228|NCT02565511|Experimental|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
32779229|NCT02565511|Placebo Comparator|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
32779230|NCT02565511|Experimental|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
32779231|NCT02565511|Placebo Comparator|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
32779232|NCT05508295||COVID positive case with mAb treatment|
32779233|NCT05508295||COVID positive case having not received mAb treatment|
32779234|NCT05508295||COVID negative cases|
32779235|NCT02561455|Experimental|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
32779236|NCT02561455|Experimental|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
32779237|NCT02561455|Experimental|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
32779238|NCT02561455|Experimental|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
32779239|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
32779240|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
32779241|NCT04549051|Experimental|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
32779242|NCT04549051|Other|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
32779243|NCT04547413|No Intervention|Control Arm|"Control Arm will will complete a total of three visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
33083639|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
33083640|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
32779244|NCT04547413|Active Comparator|Intervention Arm|"Intervention Arm will will complete a total of four visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Visit 2 (Day 2-30): Group Intervention Session, Feedback form, and post-intervention knowledge assessment (for intervention arm only)~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
32779245|NCT05505253|Active Comparator|Alfacalcidol|Alfacalcidol 0.5 mcg orally given for 3 months
33083641|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
32779246|NCT05505253|Placebo Comparator|Control|Placebo given orally for 3 months
32779247|NCT05505175||Breast Cancer Patients|Eligible patients including patients with a potential follow-up period of 6 months following the index date
32779248|NCT05505097|Other|ABCD-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence A-B-C-D during the corresponding study periods 1, 2, 3, and 4
32779249|NCT05505097|Other|BCDA-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence B-C-D-A during the corresponding study periods 1, 2, 3, and 4
32779250|NCT05505097|Other|CDAB-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence C-D-A-B during the corresponding study periods 1, 2, 3, and 4
32779251|NCT05505097|Other|DABC-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence D-A-B-C during the corresponding study periods 1, 2, 3, and 4
32779252|NCT05501977||patients with chronic pain after thoracotomy|patients with chronic pain after thoracotomy
32779253|NCT05501977||patients without chronic pain after thoracotomy|patients without chronic pain after thoracotomy
32779254|NCT04784377|Experimental|High laser group|
32779255|NCT04784377|Experimental|low laser group|
32779256|NCT04784377|Other|control group|
32779257|NCT04541095|Experimental|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
32779258|NCT04541095|Active Comparator|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
32779259|NCT04541095|No Intervention|HM group|Infants will receive human milk (HM).
33284956|NCT03980392|Experimental|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
33284957|NCT03980392|Experimental|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
33284958|NCT03980392|No Intervention|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
33284959|NCT03980236|Experimental|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
33284960|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
32937454|NCT02896075|Experimental|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
32779260|NCT04697719|Experimental|Aspirin 81mg, Then Aspirin 325mg|After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.
32779261|NCT04697719|Experimental|Aspirin 325mg, Then Aspirin 81mg|After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.
32779262|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779263|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779264|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779265|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779266|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779267|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
32779268|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
32779269|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
32937455|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
32937456|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
32937457|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
32937458|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
32937459|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
32779270|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
32779271|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
32779272|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
32779273|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
33083642|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
32779274|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
32779275|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
32779276|NCT05504863||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
32779277|NCT05504863||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
32779278|NCT05504863||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
32779279|NCT04782349|Experimental|high intensity laser group|
32779280|NCT04782349|Experimental|low intensity laser group|
32779281|NCT04782349|Other|control group|
32779282|NCT05507983|Experimental|Tranexamic acid arm|"Tranexamic acid 1500 mg dissolved in 100 ml sodium chloride, once, directly after anesthetizing the participant.~In participants with renal insufficiency (creatinine >120 umol/L) the dose will be reduced to 1000 mg."
33083643|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
33083644|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
33083645|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
32779283|NCT05507983|Placebo Comparator|Placebo arm|100ml sodium chloride 0.9%, once, directly after anesthetizing the participant.
32779284|NCT05501587||Participants with CF|
32779285|NCT05501587||Participants with other Respiratory Disease|
32779286|NCT05501587||Healthy Participants|
32779287|NCT05501509|Active Comparator|Restoring Vertical and horizontal stability of the acromioclavicular joint|
32779288|NCT05501509|Experimental|Restoring Vertical stability of the acromioclavicular joint|
32779289|NCT05501431||Progressive Supranuclear Palsy (PSP)|Participants with possible or probable PSP, wearing the Verily Study Watch for 1 year.
32779290|NCT05501431||Healthy Controls (HC)|Participants without a neurological condition, age and gender matched to the PSP cohort, , wearing the Verily Study Watch for 1 year.
32779291|NCT05490355|Active Comparator|Perineural Steroid Injections Alone|"Participants assigned to this study arm will receive only Perineural Steroid Injections per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
33083646|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
33083647|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
33083648|NCT04580797|Experimental|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
32779292|NCT05490355|Experimental|Perineural Steroid Injections Plus Radiofrequency Ablation|"Participants assigned to this study arm will receive Perineural Steroid Injections plus Radiofrequency Ablation per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
32779293|NCT05501275|Experimental|With Psychoeducation|interventional group will receive psychoeducation.
33083649|NCT04580797|Experimental|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
33083650|NCT04580797|Experimental|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
33083651|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
32937460|NCT02898103|Experimental|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
32937461|NCT02898103|Active Comparator|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
32937462|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
32937463|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
32779294|NCT05501275|No Intervention|Basic Therapy Only|this group will receive only basic therapy
32937464|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
32937465|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
32937466|NCT02799290|No Intervention|CONTROL|No intervention
32937467|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
32779295|NCT05328037||Acute diarrhea cases|Children with acute diarrhea defined as at least 3 loose or watery stools per day for at least 3 consecutive days and up to 10 consecutive days
33284961|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
33284962|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
33284963|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
33284964|NCT00304954|Active Comparator|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
33284965|NCT00304954|Active Comparator|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
33284966|NCT00304954|Active Comparator|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
33284967|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
33284968|NCT00475176|Experimental|S-Adenosyl Methionine|
33284969|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
33284970|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
33284971|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
33284972|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
33284973|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
33284974|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
32937468|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
32937469|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
32937470|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
32937471|NCT02800148|Experimental|Azelaic acid foam|
32937472|NCT02800148|Active Comparator|Finacea Foam|
32937473|NCT02800148|Placebo Comparator|Placebo Foam|
32937474|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
32937475|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
32937476|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
32937477|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
32779296|NCT05328037||Chronic diarrhea cases|Children with chronic diarrhea defined as 3 or more loose or liquid stools per day for at least 4 weeks
32937478|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
32937479|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
33284975|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
33284976|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
33284977|NCT00303628|Active Comparator|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
33284978|NCT00303628|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
33284979|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
33284980|NCT01040715|Experimental|TNFa Kinoid dose 1|
33284981|NCT01040715|Experimental|TNFa Kinoid dose 2|
33284982|NCT01040715|Experimental|TNFa Kinoid dose 3|
32937480|NCT02791399|No Intervention|Control|Treatment as usual
33284983|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
33284984|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
33284985|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
33284986|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
33284987|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
33284988|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
33284989|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
33284990|NCT00332488|Experimental|1|Technosphere Insulin
33284991|NCT00332488|Active Comparator|2|Metformin & Secretagogues
33284992|NCT00332488|Experimental|3|Technosphere & Metformin
33284993|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
33284994|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
32779297|NCT05328037||Controls|Children without fever or signs of infection or ongoing diarrhea
32937481|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
32937482|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
32937483|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
32937484|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
32937485|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
32937486|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
32937487|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
32937488|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
32937489|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
32937490|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
32937491|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
32937492|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
32937493|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
32937494|NCT00374192|Experimental|1|Eszopiclone
32937495|NCT00374192|Placebo Comparator|2|Placebo
32937496|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
32937497|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
32937498|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
32937499|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
32937500|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
32937501|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
32937502|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
32937503|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
32937504|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
32937505|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
32937506|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
32937507|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
32937508|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
32937509|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
32937510|NCT02933450|No Intervention|Standard of Care group|Standard of Care
32937511|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
32937512|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
32937513|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
32937514|NCT04333303|Experimental|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
32937515|NCT04333303|No Intervention|Care as usual|
32937516|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
32937517|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
33083652|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
33083653|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
33083654|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
33083655|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
33083656|NCT00568477|Experimental|Arm 1|Treatment with rituximab
33083657|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
32937518|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
33083658|NCT04580836|Experimental|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
33083659|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
32779298|NCT05504785|Active Comparator|Control Group|Twenty type 2 diabetic patients in the Control Group will be managed according to standard-of-care methods at TJUH using finger-stick blood glucose measurements in an attempt to maintain the patient's blood glucose levels in the desired target range (80 to 180 mg/dL). Three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
32779299|NCT05504785|Active Comparator|Investigational Group|Forty type 2 diabetic patients in the Investigational Group will be managed by the orthopedic floor nurses using the real-time DexCom G6 CGM trend data to determine the appropriate therapy to maintain the patient's glucose levels in the desired target range (80 to 180 mg/dL). In addition, three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
32779300|NCT05504629|Experimental|Endurance Training (ET) plus Resistance Training (RT)|Concurrent training of Endurance Training plus Resistance Training order.
33083660|NCT00415077|Active Comparator|3|Mitomycin C PRK
33083661|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
33083662|NCT00568516|Experimental|1.Low dose group|
33083663|NCT00568516|Experimental|2.High dose group|
33083664|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
33083665|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
33284995|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
33284996|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
32779301|NCT05504629|Active Comparator|Resistance Training (RT) plus Endurance Training (ET)|Concurrent training of Resistance Training plus Endurance Training order.
32779302|NCT05501197|Active Comparator|Synchronous Telerehabilitation Group|Synchronous Telerehabilitation Group will receive exercise therapy via video conference.
32779303|NCT05501197|Experimental|Asynchronous Telerehabilitation Group|Asynchronous Telerehabilitation Group will receive exercise therapy via mobile application.
33284997|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
33284998|NCT03979846|Experimental|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
33284999|NCT03979846|Experimental|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
33285000|NCT00474786|Experimental|1|
32779306|NCT05504473|Experimental|Patients with facial nerve palsy and lagophthalmus|There is only one arm in this study. The investigators examine if the medical device can achieve a painless blinking in patients with facial nerve palsy and lagophthalmus.
32779307|NCT05504317|Experimental|AK111 regimen|
32779308|NCT05504317|Placebo Comparator|Placebo|
32779309|NCT04582669|Placebo Comparator|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
33083666|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
33083667|NCT04580758|Active Comparator|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
33083668|NCT04580758|Active Comparator|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
33083669|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
33083670|NCT00568750|Experimental|Dasatinib|
33285001|NCT00474786|Experimental|2|
32779310|NCT04582669|Active Comparator|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
32779311|NCT04582669|Experimental|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
32937519|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
32937520|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
32779312|NCT04582669|Experimental|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
32779313|NCT05504239|Experimental|Teneligliptin 20 mg|Once daily for 24 weeks
32779314|NCT05504239|Placebo Comparator|Teneligliptin placebo|Once daily for 24 weeks
32779315|NCT04587661|Active Comparator|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
32779316|NCT04587661|Experimental|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
32779317|NCT04578925|Experimental|Happy, Healthy, Loved|"Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week (still breastfeeding? Text Y for yes, N for no). Once a no response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding."
32779318|NCT04578925|No Intervention|Control|Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
32779319|NCT05504161||Endometrial cancer group|Patients pathologically diagnosed with endometrial cancer
32779320|NCT05504161||Control group|Patients with benign endometrial pathology and interepithelial neoplasia
32937521|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
32937522|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
32937523|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
32937524|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
32937525|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
32937526|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
32937527|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
32937528|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
32937529|NCT03015961|Placebo Comparator|Bupivacaine HCl|Bupivacaine HCl
32937530|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
33285002|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
32779321|NCT05282797|Experimental|Part A - 100 mg of ANEB-001|Subjects receive 21 mg of THC and 100 mg of ANEB-001
32779322|NCT05282797|Experimental|Part A - 50 mg of ANEB-001|Subjects receive 21 mg of THC and 50 mg of ANEB-001
32779323|NCT05282797|Placebo Comparator|Part A - Placebo|Subjects receive 21 mg of THC and a placebo
32779324|NCT05282797|Experimental|Part B - Cohort 1 - ANEB-001|Subjects receive 21 mg of THC and 30 mg of ANEB-001
33083671|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
32779325|NCT05282797|Placebo Comparator|Part B - Cohort 1 - Placebo|Subjects receive 21 mg of THC and a placebo
33083672|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
33083673|NCT00568945|Experimental|Arm 1|
33083674|NCT00569023|Experimental|A,1,I|
33083675|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
33083676|NCT00569140|No Intervention|1|E10030
33083677|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
33083678|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
32779326|NCT05282797|Experimental|Part B - Cohort 2 - ANEB-001|Subjects receive 21 mg of THC and 10 mg of ANEB-001
32779327|NCT05282797|Placebo Comparator|Part B - Cohort 2 - Placebo|Subjects receive 21 mg of THC and a placebo
32779328|NCT05282797|Experimental|Part B - Cohort 3 - ANEB-001|Subjects receive 21 mg of THC and 1 hour later, 30 mg of ANEB-001
32779329|NCT05282797|Placebo Comparator|Part B - Cohort 3 - Placebo|Subjects receive21 mg of THC and 1 hour later, placebo
32779330|NCT05282797|Experimental|Part B - Cohort 4 - ANEB-001|Subjects receive a dose of THC (to be determined) and a dose of ANEB-001 (to be determined)
32779331|NCT05282797|Placebo Comparator|Part B - Cohort 4 - Placebo|Subjects receive a dose of THC (to be determined) and a placebo
33083679|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
33083680|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
33083681|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
33083682|NCT00569452|Experimental|A|
33083683|NCT00569452|Experimental|B|
33083684|NCT00569569|Experimental|1|Patients treated with Retaane
33083685|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
33083686|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
33083687|NCT00569647|Experimental|v|Use of VRH headset
33083688|NCT00569647|Placebo Comparator|c|
32779332|NCT05282797|Experimental|Part B - Cohort 5 - ANEB-001|Subjects receive a dose of THC (to be determined) and a dose of ANEB-001 (to be determined)
32779333|NCT05282797|Placebo Comparator|Part B - Cohort 5 - Placebo|Subjects receive a dose of THC (to be determined) and a placebo
32779334|NCT05282797|Experimental|Part B - Cohort 6 - ANEB-001|Subjects receive a dose of THC (to be determined) and a dose of ANEB-001 (to be determined)
32779335|NCT05282797|Placebo Comparator|Part B - Cohort 6 - Placebo|Subjects receive a dose of THC (to be determined) and a placebo
32779336|NCT04651699|Experimental|Active Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes at 2 milli amps.
32779337|NCT04651699|Sham Comparator|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.
33083689|NCT00569686|Active Comparator|1|treatment with lovaza
33083690|NCT00569686|Placebo Comparator|2|
33083691|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
33083692|NCT00569842||observational|
33083693|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
33083694|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
33083695|NCT00224471|Experimental|Group A|
33083696|NCT00224471|Experimental|Group B|
33083697|NCT00224471|Experimental|Group C|
33083698|NCT00569920|Placebo Comparator|1|Placebo
33083699|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
33083700|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
33083701|NCT00569959|Other|Fasting|
33083702|NCT00569959|Other|Non-fasting|
33083703|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
33083704|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
33083705|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
33083706|NCT00570271|Experimental|1|
33083707|NCT00570271|Experimental|2|
33083708|NCT00570271|Experimental|3|
33083709|NCT00570271|Experimental|4|
33083710|NCT00570271|No Intervention|5|
33083711|NCT00570271|No Intervention|6|
33083712|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
33083713|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
33083714|NCT00570427|Experimental|1.|All participants
33285003|NCT01041105||Gastric bypass after previous Nissen|
33285004|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
33285005|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
33285006|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
32937531|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
32937532|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
32779338|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
32779339|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
33285007|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
32779340|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
32779341|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
32779342|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
32779343|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
32779344|NCT04640311|Experimental|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
32779345|NCT04640311|Experimental|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
32779346|NCT04640311|Experimental|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
32937533|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~Peripheral blood hematopoietic cell transplantation~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~Growth factor support: G-CSF"
32937534|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
32937535|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
32937536|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
32937537|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
32937538|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
33083715|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
33285008|NCT01041261|Experimental|Treatment arm|Medical food
33285009|NCT03764943|Experimental|Immunonutrition Intervention|Participants will consume 3 'Impact Advanced Recovery' shakes daily for 5 days prior to surgery 2 hours prior to surgery.
33285010|NCT00319696|Experimental|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
33285011|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
33285012|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
33285013|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
32779347|NCT04640311|Experimental|Part B: Daprodustat Process 1/ Process 2|
32779348|NCT04640311|Experimental|Part B: Daprodustat Process 2/ Process 1|
32779349|NCT02311335||1|Dyslipidemia patients
32779350|NCT05500963|Experimental|Effective dose|• The effective dose of TENS will be set at an intensity to elicit slight contractions in each target muscle, as we have done previously. It will be delivered as 5-Hz bursts (7 pulses at 100 Hz/burst) and applied during the light exercises. The applied current (<20 mA) will differ slightly for each of the four muscle groups and will be determined while the person is standing. The current will be set at the beginning of every treatment session for both groups of participants.
32937539|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
33083716|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
33083717|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
33083718|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
33285014|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
32779351|NCT05500963|Sham Comparator|Sham dose|• The current intensity for the sham dose will be set at sensory threshold, which will be less than that used for the effective dose. After beginning each exercise set, the current for the sham dose will decay to 0 mA within 30 s. In a preliminary study that included a sham dose of TENS, we found that only two of the experienced dancers in the sham group detected the gradual decline in TENS current from its initial value slightly above motor threshold when performing prescribed exercises.
32779352|NCT05274529|Experimental|Study group|All the participants will be in the same group and have the same intervention programmes options to choose from.
33285015|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
33285016|NCT01041339||controls|asymptomatic patients
33083719|NCT04580329|Experimental|NMES group|
33083720|NCT04580329|Experimental|control group|
33083721|NCT00254436|Experimental|Epoetin Alfa|
33285017|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
33285018|NCT01043835|Active Comparator|Open gastrectomy|
33285019|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
33285020|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
33285021|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
33285022|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
33285023|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
33285024|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
33285025|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
33285026|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
33285027|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
33285028|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
33285029|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
33285030|NCT00497874|No Intervention|Usual care|Usual primary care treatment
33083722|NCT04580524|Active Comparator|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
33083723|NCT04580524|Active Comparator|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
33083724|NCT00570583||Depressed|Older individuals with major depression
33083725|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
33083726|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
33083727|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
33285031|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
33285032|NCT01043991|Placebo Comparator|Placebo|NaCl
33285033|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
33285034|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
33285035|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
33285036|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
33285037|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
32779353|NCT05264623|Experimental|TENEO 317 Model 2 excimer laser|
33285038|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
32779354|NCT04578691|Experimental|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
33285039|NCT04923282|Active Comparator|Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo|single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
32779355|NCT04578691|Active Comparator|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
32779356|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
32779357|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
32779358|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
32779359|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
32779360|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
32779361|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
32779362|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
32779363|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
32779364|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
33285040|NCT04923282|Active Comparator|Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo|single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
33285041|NCT04923282|Active Comparator|Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo|single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
33285042|NCT04923282|Active Comparator|Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3|1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
33285043|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
33285044|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
33285045|NCT03996408|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33285046|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
32779365|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
32779366|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
33083728|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
33285047|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
33285048|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
33285049|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
33285050|NCT04485728|Experimental|Sleep Improvement Intervention|
33285051|NCT04485728|No Intervention|Standard of Care (Control)|
33285052|NCT04485026|Experimental|Local Consolidative Radiation Therapy Arm|Definitive external beam radiation therapy will be delivered to all sites of progressive disease for all patients. The technique used to deliver radiation therapy will be determined by the treating radiation oncologist.
33285053|NCT04485026|Active Comparator|Standard of Care - Control Arm|Second line systemic therapy is at the discretion of the treating medical oncologist.
33285054|NCT01014104|Experimental|Case|Administration of Methylprednisolone
33285055|NCT01014104|Sham Comparator|Control|
33285056|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
33285057|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
33285058|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
32937540|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
33285059|NCT00402987|Experimental|celecoxib 100 mg/placebo|
33285060|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
33285061|NCT00402987|Placebo Comparator|Placebo|
33285062|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
33285063|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
33285064|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
33285065|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
33285066|NCT03997214|No Intervention|Control group|as usual care
33285067|NCT03997214|Experimental|experimental group|The intervention of inspiratory muscle strength training
32937541|NCT03019939|Experimental|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then Once a day (QD) or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
32937542|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
33285068|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
33285069|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
33285070|NCT01014260|Placebo Comparator|Placebo|placebo
33285071|NCT01014260|Active Comparator|Doxycycline|Doxycycline
33285072|NCT01010672|Experimental|Ridaforolimus 40 mg|
33285073|NCT01014338|Active Comparator|ACE-inhibitor|
32937543|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
32937544|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
32937545|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
32937546|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
32937547|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
32937548|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
32937549|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
32937550|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
32937551|NCT03019796|Experimental|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
32937552|NCT03019796|Experimental|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
32937553|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
32937554|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
32937555|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
32937556|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
32937557|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
32937558|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
33285074|NCT01014338|Placebo Comparator|Sugar Pill|
33285075|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
33285076|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
33285077|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
33285078|NCT00497796|Experimental|1|
33285079|NCT00497796|Active Comparator|2|
33285080|NCT04449822|Active Comparator|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
33285081|NCT04449822|Active Comparator|Colonic stenting|The colonic stent placement
33285082|NCT00496782|Other|Single|
33285083|NCT01020708|Active Comparator|Comparator|Mesalamine enema
33285084|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
33285085|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
33285086|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
33285087|NCT01020942|Experimental|Pretreatment|
33285088|NCT01020942|No Intervention|Control|
33285089|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
33285090|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
33285091|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
33285092|NCT04428372|Experimental|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
32937559|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
32937560|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
33285093|NCT04428372|Placebo Comparator|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
33285094|NCT03996642|Other|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
33285095|NCT01038141|Active Comparator|Milligan Morgan|
32937561|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
32937562|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
32937563|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
32937564|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
32937565|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
32937566|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
32937567|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
32937568|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
32937569|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
32937570|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
32937571|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
32937572|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
32937573|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
32937574|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
32937575|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
32937576|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
32937577|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
33285096|NCT01038141|Active Comparator|Recto Anal Repair|
33285097|NCT03993561|Experimental|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
33285098|NCT04056624|Experimental|Low dose|1 x 6 ounces of carotenoid-containing juice (6 mg carotenoids/6 oz)
33285099|NCT04056624|Experimental|High dose|2 x 6 ounces of carotenoid-containing juice (12 mg carotenoids/12 oz)
33285100|NCT04056624|Placebo Comparator|Placebo|12 ounces of apple juice (negligible carotenoids 0.06 mg/12 oz)
33285101|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
33285102|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
33285103|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
33285104|NCT04054050|Experimental|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
33285105|NCT00496626|Experimental|1|V501 (Gardasil®)
33285106|NCT00496626|Placebo Comparator|2|Placebo
32937578|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
33285107|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
33285108|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
33285109|NCT01018212|Experimental|A|Cicatrix cream
33285110|NCT01015014|Active Comparator|AN3365|
33285111|NCT01015014|Placebo Comparator|Saline|
33285112|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
32937579|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
33285113|NCT04213014|Experimental|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities;5 (2) Three parent-adolescent meetings (1st meeting at each school [Zoom option if needed]; 2nd and 3rd meetings via Zoom): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior wk.
33285114|NCT04213014|No Intervention|Control|Received usual school activities.
33285115|NCT04052958|Active Comparator|Group 1: Strength Training|Respiratory muscle strength training
33285116|NCT04052958|Active Comparator|Group 2: Endurance Training|Respiratory muscle endurance training
33285117|NCT04052958|No Intervention|Group 3: Control group|no training of respiratory muscles
32937580|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
32937581|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
32937582|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
32937583|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
32937584|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
32937585|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
32937586|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
32937587|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
32937588|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
32937589|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
32937590|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
32937591|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
32937592|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
33285118|NCT00471276|Experimental|1|
33285119|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
32937593|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
32937594|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
33285120|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
33285121|NCT04034862|Experimental|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
32779367|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
32779368|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
33285122|NCT04034862|No Intervention|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
33285123|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
33285124|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
33285125|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
33285126|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
33285127|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
33285128|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
33285129|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
33285130|NCT01018368|Experimental|VX-770|
32937595|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
33285131|NCT01018368|Experimental|Rifampin|
33285132|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
33285133|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
33285134|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
33285135|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
33285136|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
33285137|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
33285138|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
33285139|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
33285140|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
33285141|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
33285142|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
33285143|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 & 8"
33285144|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 & 8"
33285145|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
33285146|NCT03997682|Experimental|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
33285147|NCT03997682|No Intervention|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
32779369|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
33285148|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
33285149|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
32937596|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
33285150|NCT00500318|Experimental|Aclidinium|
32937597|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
33285151|NCT00500318|Placebo Comparator|Placebo|
33285152|NCT00508820|Experimental|1|Romiplostim
33285153|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
32779370|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
32779371|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
32779372|NCT05504083|Experimental|D-0120 group 1|take D-0120 dose 1 orally during the treatment period.
32779373|NCT05504083|Experimental|D-0120 group 2|take D-0120 dose 2 orally during the treatment period.
32779374|NCT05504083|Active Comparator|Benzbromarone|take benzbromarone orally during the treatment period.
32937598|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
32937599|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
32937600|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
32937601|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
32937602|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
32779375|NCT05504005|Experimental|Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection|Enrolled subjects will perform oral glucose tolerance test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
32779376|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
32937603|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
32937604|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
32779377|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
32779378|NCT04517929|No Intervention|control group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia.
32779379|NCT04517929|Experimental|intervention group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia and group psychotherapy.
32779380|NCT04577443|Active Comparator|Adenosine|
32779381|NCT04577443|Placebo Comparator|Saline|
32937605|NCT03031795|Placebo Comparator|placebo|look alike placebo
32937606|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
32937607|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
32779382|NCT04572763|Experimental|Dose Escalation Copanlisib + Venetoclax|"Phase 1~Dose escalation will occur using a 3+3 design~Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle~Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
32779383|NCT04572763|Experimental|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
33083729|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
32779384|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
32779385|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
32779386|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
32779387|NCT05503849|Experimental|Proactive management during pregnancy|A combination of dietary, physical activity and lifestyle modification.
32779388|NCT05503849|No Intervention|Standard Care|No additional intervention beyond standard care procedure.
32779389|NCT05093959|Active Comparator|Metformin|20 weeks of metformin 1500 mg daily. Metformin is a widely used medication with an excellent safety profile. Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks. An extended release formulation will be used which improves compliance and reduces GI side effects.
32779390|NCT05093959|Placebo Comparator|Placebo|20 weeks of placebo 1500 mg daily. Placebo is a biologically inert substance placed in capsules to match appearance of active intervention (metformin). Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks.
32779391|NCT05500729||Female CrossFitters|Crossfit practitioners born as female
32779392|NCT05500729||Male CrossFitters|Crossfit practitioners born as male
32779393|NCT04411537|Experimental|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
32779394|NCT05500573|Experimental|Sperm sorting|Selection of gender specific spermatozoa using a multilayer density gradient
32779395|NCT05500495||prolonged mechanical ventilation group|patients had 96 hours or more (PMV group).
32779396|NCT05500495||control group|patients had less than 96 hours of mechanical ventilation (control group)
32779397|NCT05503615|Other|Control Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
33285154|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
32779398|NCT05503615|Experimental|IASTM Treatment Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
32779399|NCT05503537|Active Comparator|Basic Cardiac Rehabilitation protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes.
32779400|NCT05503537|Experimental|post-isometric relaxation technique with basic cardiac protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Post-isometric relaxation technique: contraction time 10 second using 20% of strength with 15 second rest period in between contractions + 4 repetitions.
32779401|NCT05503537|Experimental|static stretching with basic cardiac protocol|Ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Static stretching: 5 repetitions with 15 sec hold time of stretch.
32779402|NCT04440163|Experimental|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
32779403|NCT04440163|Experimental|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
32779404|NCT04440163|Experimental|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
32779405|NCT04440163|Experimental|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
33285155|NCT01014494|No Intervention|Standard Care|No different treatment to normal
33285156|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
33285157|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
33285158|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
33285159|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
32779406|NCT04440163|Experimental|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
33285160|NCT04197180|Experimental|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
33285161|NCT00486720|Experimental|1|vorinostat 400 mg
33285162|NCT00486720|Experimental|2|vorinostat 200 mg
33285163|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
33285164|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
33285165|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
33285166|NCT01021644|Experimental|aerobic exercise-training|
33285167|NCT01021644|Active Comparator|stretch exercise|
33285168|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
33285169|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
33285170|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
33285171|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
33285172|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
33285173|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
33285174|NCT01021800|Experimental|Cell infusion|
33285175|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
33285176|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
33285177|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
33285178|NCT00493974|Placebo Comparator|Placebo|Placebo
33285179|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
33285180|NCT01018524|Active Comparator|small hernias - suture repair|
33285181|NCT01018524|Active Comparator|small hernias - mesh repair|
33285182|NCT01018524|Active Comparator|large hernias - sublay mesh|
33285183|NCT01018524|Active Comparator|large hernias - onlay mesh|
33285184|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
33285185|NCT01018602|Active Comparator|vildagliptin|
33285186|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
33285187|NCT01018758|Experimental|palonosetron|
33285188|NCT00469092|Experimental|BIAsp 30|
33285189|NCT00469092|Active Comparator|Glargine|
33285190|NCT03997110|Active Comparator|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
33285191|NCT03997110|Experimental|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
33285192|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
33285193|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
33318147|NCT05119036|No Intervention|Observation|If patients have negative margins and have all negative nodes or only a single positive node, patients will be placed in the observation arm and will not receive further adjuvant treatment, only postoperative follow-up visits and a surveillance visit 3 months after surgery with a CT or PET-CT.
33402088|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
32779407|NCT04440163|Experimental|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
32779408|NCT04440163|Experimental|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
32779409|NCT04440163|Experimental|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
32937608|NCT02825966|Other|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
32779410|NCT04636723||HNC Patients w/ CSS|HNC survivor patients presenting high chronic systemic symptoms
32779411|NCT04636723||Healthy Controls|Non-clinical controls
32779412|NCT04636723||HNC Patients wo/ CSS|Patient Control - HNC survivor patients presenting no/low chronic systemic symptoms
32779413|NCT05503459|Experimental|Bicycle learning|The protocol for this intervention group was a 2-week bicycle training program consisting of 10 sessions (five sessions per week, 60 mins per session) in a hall/gymnasium of each participating school and the Education University of Hong Kong. Each intervention session was conducted by a professional cycling instructor assisted by student helpers. The staff-to-participant ratio was 1:1.
32779414|NCT05503459|Experimental|Stationary cycling group|Participants were asked to ride on a stationary bicycle in the same format as that in the learning to bicycle group.
32779415|NCT05503459|No Intervention|Active control group|Participants were asked to walk with their major caregivers for 20 minutes every day during the study period. After the study, they were taught how to ride a bicycle to recognize their contribution as controls.
32937609|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
32937610|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
32937611|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
32937612|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
32937613|NCT04333394|Active Comparator|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
32937614|NCT04333394|Placebo Comparator|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
32937615|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
32937616|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
32937617|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
32937618|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
32937619|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
32937620|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
32937621|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
32937622|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
32937623|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
33285194|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
32937624|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
33285195|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
33285196|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
33402089|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
33402090|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
33285197|NCT01016210|No Intervention|control|no treatment
33285198|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
33285199|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
32779418|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
32779419|NCT04510129||non-small-cell lung cancer (NSCLC)|
32779420|NCT04510129||small cell lung cancer (SCLC)|
32779421|NCT04510129||urothelial carcinoma (UCC)|
32779422|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
33285200|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
33285201|NCT00402363|Experimental|omega-3-acid ethyl esters|
33285202|NCT00402363|Placebo Comparator|Placebo|
32779423|NCT04510129||cervical cancer|
33285203|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 30 mg/m^2 intravenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily; Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
33285204|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
33285205|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
33285206|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
33285207|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
33285208|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
33285209|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
33285210|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
33285211|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
33285212|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
32779424|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
32779425|NCT04510129||triple-negative breast cancer (TNBC)|
32937625|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
32937626|NCT02948426|Experimental|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
33083730|NCT00570856|Experimental|1|Folic acid supplementation
32779426|NCT04510129||hepatocellular carcinoma (HCC)|
32779427|NCT04510129||renal cell carcinoma (RCC)|
32779428|NCT04510129||colorectal cancer (CRC)|
33083731|NCT00570856|Placebo Comparator|2|
33285213|NCT00392223|Experimental|Treatment Group A|
33285214|NCT00392223|Experimental|Treatment Group B|
33285215|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
33285216|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
33285217|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
33285218|NCT01038375||Adherence counseling|
33285219|NCT01038375||Usual care|
33318148|NCT05119036|Experimental|Adjuvant Radiation 44 Gray|If patients have 4 or fewer positive nodes and 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 44 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
33402091|NCT04282018|Experimental|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
33402092|NCT04282018|Experimental|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at the latest cleared dose of BGB-10188 monotherapy (Part A) in combination with zanubrutinib 160mg (2*80mg capsules) administered orally twice daily (BID)
33285220|NCT03747159|Experimental|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L."
32779429|NCT04504435|Experimental|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
32779430|NCT04504435|Experimental|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
32779431|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
32779432|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
32779433|NCT04781491|Experimental|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
32779434|NCT04781491|No Intervention|Waiting list|Subjects don't receive any therapy but are offered the same treatment after trial is finished.
32779435|NCT05500183|Experimental|PA + CA|a cognitively enriched walking program (Physical Activity (PA)+Cognitive Activity (CA)
32779436|NCT05500183|Active Comparator|PA only|a walking program without cognitive enrichment (Physical Activity (PA) only)
33285221|NCT03747159|No Intervention|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
32937627|NCT02948426|Experimental|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
32937628|NCT02948426|Experimental|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
33285222|NCT01324479|Experimental|INC280|
33402093|NCT04282018|Experimental|Part C: BGB-10188 + Zanubrutinib Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part B in combination with zanubrutinib 160mg (2*80mg capsules) administered orally BID
32779437|NCT05500183|No Intervention|control|a passive control group (CG). The passive CG will receive no intervention program.
32779439|NCT05500027||Pancreatic cancer|All TNM stages of pancreatic cancer, before/after surgery, before/after chemotherapy, before/after bile drainage
32779440|NCT05500027||Low malignant grade of pancreatic neoplasms|IPMN, MCN, PNEN, and SPN
32937629|NCT02948426|Experimental|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
32937630|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
32937631|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
32937632|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
32937633|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
32937634|NCT02949518|No Intervention|Usual Care|
32937635|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
32937636|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
32937637|NCT02949674|No Intervention|Control|No application of anesthetic
32937638|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
32937639|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
32779441|NCT05500027||Pancreatitis|acute, chronic, and auto-immune pancreatitis
32779442|NCT05500027||Auto-immune diseases|SLE, RA, et al
32779443|NCT05500027||Pancreatic-biliary infections|cholecystitis, cholangitis, et al
32779444|NCT04630171|Experimental|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
32779445|NCT04630171|Active Comparator|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
32779446|NCT04630171|Active Comparator|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
32779447|NCT04630171|Experimental|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
32779448|NCT04630171|Active Comparator|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
32779449|NCT04630171|Active Comparator|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
32779450|NCT05503381|Experimental|Natural Orifice Specimen Extraction Surgery Group|The patient underwent laparoscopic lower rectal cancer surgery with transanal specimen collection
32779451|NCT05503381|No Intervention|Traditional laparoscopic surgery|The patient underwent conventional laparoscopic lower rectal cancer surgery
32779452|NCT05503147|Experimental|Sativex first (blinded) (3 dose of spray)|Trial day 1: Sativex (3 dose of spray x 2) Trial day 2: Placebo (3 dose of spray x 2) Trial day 3: Voluntary
32779453|NCT05503147|Experimental|Placebo first (blinded) (3 dose of spray)|Trial day 1: Placebo (3 dose of spray x 2) Trial day 2: Sativex (3 dose of spray x 2) Trial day 3: Voluntary
32779454|NCT04619095|Experimental|Psyllium|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
32779455|NCT04619095|Placebo Comparator|Placebo|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
32779456|NCT05499949||FONS group|Patients with morbid obesity enrolled for bariatric surgery in the Franciscus Gasthuis, Rotterdam, the Netherland
32779457|NCT04495153|Other|Cohorts|"Cohort 1 - persistent but stable disease at least 18 weeks after starting ICI treatment~Cohort 2 - radiographic progressive disease at least 18 weeks after starting ICI treatment~Cohort 3 - refractory disease defined as progressed by imaging at least 9 weeks after starting ICI treatment (CLOSED TO ENROLLMENT)"
32779458|NCT04490005||Acute brain injury|"Intensive care unit (ICU) admission after ABI, including traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH)~• Age 18 years old."
32779459|NCT04482595|Experimental|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
32937640|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
32779460|NCT04482595|Placebo Comparator|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
32937641|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
32937642|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
32937643|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
32937644|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
32937645|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
32937646|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
32937647|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
32937648|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
32937649|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.~All subjects will undergo the same procedures and interventions."
32937650|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
32937651|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
32937652|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
32937653|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
32937654|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
32937655|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
32937656|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
32937657|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
33285223|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
33285224|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
32779461|NCT04479943|No Intervention|Pre-intervention/control|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months prior to implementation of the unit-based MOVIN intervention.
33402094|NCT04282018|Experimental|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in up to 6 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
33285225|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
33402095|NCT04282018|Experimental|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part D in combination with tislelizumab 200mg IV infusion administered Q3W
32937658|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
32937659|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
33402096|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
33402097|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
33402098|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
33402099|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
33402100|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
33402101|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
33402102|NCT03656900|Experimental|BA9/BA46|
33402103|NCT03656900|Experimental|BA46/BA9|
32937660|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
32937661|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
32937662|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
32937663|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
32937664|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
32937665|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
32937666|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
32937667|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
32937668|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
32937669|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
32937670|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
32937671|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
32937672|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
32937673|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
33083732|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
33402104|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
33083733|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
33083734|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
33083735|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
33083736|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
33083737|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
33083738|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
33083739|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
33285226|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
33285227|NCT00402051|Experimental|Pemetrexed + Cisplatin|
33285228|NCT00402051|Experimental|Pemetrexed + Carboplatin|
33285229|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
33285230|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
33285231|NCT00468858|Placebo Comparator|Placebo|Control
33285232|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
33285233|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
33285234|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
33285235|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
33285236|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
33083740|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
33083741|NCT00571051|Experimental|1|MBSR 8 week course
33083742|NCT00571051|No Intervention|2|8 weeks of natural history
33083743|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
33083744|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
33083745|NCT00254553|Placebo Comparator|Arm 2|Placebo
33083746|NCT00571129|Active Comparator|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
33083747|NCT00571129|Active Comparator|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
33083748|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
33083749|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
33083750|NCT00571207||I|Drivers suspected of driving under the influence of drugs
33083751|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
33083752|NCT00571246|Experimental|Topiramate|Participants will be randomized to topiramate (250mg)
33083753|NCT00571246|Experimental|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
33083754|NCT00571246|Placebo Comparator|Placebo|Participants will be randomized placebo
33083755|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
33083756|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
33285237|NCT01038453|Placebo Comparator|placebo|
33285238|NCT00401193|Experimental|1|
33285239|NCT00401193|Experimental|2|
33285240|NCT00401193|Placebo Comparator|3|
33285241|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
33285242|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
33285243|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
33285244|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
33285245|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
33285246|NCT00413049|Active Comparator|Amlodipine 5 mg|
33285247|NCT03732495|Experimental|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met."
33285248|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
33285249|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
33285250|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
32779462|NCT04479943|Experimental|Post-intervention|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months after MOVIN has been implemented on the unit.
32779463|NCT04631185|Active Comparator|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
32779464|NCT04631185|Experimental|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
32779465|NCT05499871|Experimental|Minimalist footwear|Transition toward a minimalist footwear.
32779466|NCT05499871|Experimental|Footstrike pattern|Transition toward a forefootstrike pattern.
32779467|NCT05499871|No Intervention|Control|No intervention
32779468|NCT05499793|Experimental|Treatment group (Ginger)|"All the participants were given Zingiber Officinale powder (500 mg) capsules twice daily for twelve weeks.~Zingiber Officinale capsules were purchased from Pure Mountain Botanicals, 1712 Pioneer Ave # 1139 Cheyenne Wyoming 82001 (USA)"
32779469|NCT05499793|Placebo Comparator|Control group (Placebo)|All the participants were given starch powder (50 mg) capsules twice daily for twelve weeks.
32779470|NCT05499715|Experimental|ScTIL injection|In the dose escalation of the study, starting with the dose of injection of 5x10^9. If there is no DLT, followed by the second dose of 1.0x10^10 until the third dose of 2.0x10^10.
32779471|NCT04557553|Experimental|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
32779472|NCT05503069|No Intervention|Group A - Control|The control group will receive standard of care, which include basic training by lactation educators.
32779473|NCT05503069|Experimental|Group B - Intervention|"Women in the intervention arm will receive standard of care, which includes basic training in breastfeeding by lactation educators, and the action items related to the intervention.~The intervention will include the following~Providing a breast milk pumping machine to the mother,~Facilitating training session to improve dietary literacy for lactating mothers,~Distribution of educational material describing the benefits of continuing breastfeeding infants up to 12 months of age to family members, employers, day care managers/caregivers."
33285251|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33285252|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33285253|NCT00412971|Active Comparator|Hexvix cystoscopy group|
32779474|NCT05502991|Experimental|Cohort 1|Subjects with ctDNA-level-relapse glioblastoma before clinical relapse, determined according to the dynamics of TISF ctDNA.
32779475|NCT05502991|Experimental|Cohort 2|Subjects with clinical-relapse glioblastoma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
32779476|NCT04417621|Experimental|LXH254 + LTT462|
33285254|NCT00412971|Other|White light|Standard White light cystoscopy
33285255|NCT00303472|Experimental|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
33285256|NCT00303472|Experimental|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
33285257|NCT00303472|Experimental|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
33285258|NCT00303472|Experimental|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
33285259|NCT00303472|Experimental|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
32779477|NCT04417621|Experimental|LXH254 + trametinib|
32779478|NCT04417621|Experimental|LXH254 + ribociclib|
32779479|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
32779480|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
32779481|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
32779482|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
32937674|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
32937675|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
32937676|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
32937677|NCT02831660|Experimental|idarucizumab|
32937678|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
32937679|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
32937680|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
32937681|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
33285260|NCT00303472|Experimental|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
32937682|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
32779483|NCT02563561|Experimental|1 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
32937683|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
33285261|NCT00303472|Experimental|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
33285262|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
33285263|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
33285264|NCT00303316|Experimental|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
33285265|NCT00303316|Active Comparator|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
33285266|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
33285267|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
33285268|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
33285269|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
33285270|NCT03980002|Experimental|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
33285271|NCT03938688|Other|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
32937684|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
33083757|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
33285272|NCT03938688|No Intervention|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
33285273|NCT03938220||fluid responders|fluid responder if stroke volume increases by > 10% after the fluid challenge
33285274|NCT03938220||fluid non responders|fluid responder if stroke volume increases by <= 10% after the fluid challenge
33285275|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
33285276|NCT03984136|Experimental|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
33285277|NCT03984136|Active Comparator|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
33285278|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33285279|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
33285280|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
33285281|NCT03983746|Experimental|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
33285282|NCT03980080|Experimental|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
33285283|NCT03980080|Placebo Comparator|Placebo: Part 1 (SAD), Cohort A & Cohort B|
32937685|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
32937686|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
32937687|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
33083758|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
33083759|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
32779484|NCT02563561|Experimental|2 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
32779485|NCT02563561|Placebo Comparator|Placebo|Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
32779486|NCT05498233|Other|RT-sequence|Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2
32779487|NCT05498233|Other|TR-sequence|Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.
32779488|NCT05499481|Active Comparator|Long Antibiotic Arm|"Without implant material in place:~6 weeks of systemic post-surgical antibiotic therapy~With mateial in place 12 weeks of systemic post-surgical antibiotic therapy"
32937688|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
32779489|NCT05499481|Experimental|Short Antibiotic Arm|"Without implant material in place:~3 weeks of systemic post-surgical antibiotic therapy~With mateial in place 6 weeks of systemic post-surgical antibiotic therapy"
32779490|NCT05564689||Patients with or in need of CRT, left bundle branch block, without ischemic heart disease|
32779491|NCT05564533|Experimental|Heart-Smile Training Intensive Introductory Program (HST-IIP) Group|The HST-IIP group will complete the Heart-Smile Training Intensive Introductory Program during weeks 1 through 4 of the study.
32779492|NCT05564533|No Intervention|Waitlist Control Group|The waitlist arm will not complete any intervention during their time in the study. They will continue their treatment as usual without any change in their therapy session or medication. After their post study visits are complete, they will have the opportunity to participate in Mindfulness-Based Intervention courses through the Cambridge Health Alliance Center for Mindfulness and Compassion.
32779493|NCT05498077|Experimental|10 minute body scan meditation|Participants will be taken through a 10 minute body scan meditation by a physical therapist
32937689|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
32937690|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
32779494|NCT05497843|Experimental|Chiauranib capsule|Patients take chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression
32937691|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
32779495|NCT04140955|Experimental|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
32779496|NCT04140955|No Intervention|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
32937692|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
32779497|NCT05497765|Experimental|Compound silymarin|Dietary supplement: 4 tablets of compound silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin, mixed power of pueraria, schisandra and salvia miltiorrhiza
32937693|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
32937694|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
32937695|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
32937696|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
32937697|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
32937698|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
32937699|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
32937700|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
32937701|NCT03035318|Active Comparator|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
33083760|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
32779498|NCT05497765|Active Comparator|Silymarin|Dietary supplement: 4 tablets of silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin
32779499|NCT05497765|Placebo Comparator|Placebo|Dietary supplement: 4 tablet of placebo twice a day for 12 weeks Placebo Composition: corn dextrin
32779500|NCT05497687|Experimental|12-week strength-building intervention|Participants in the intervention group will participate in a 12-week strength-building intervention comprising of face-to-face/remote sessions with telephone follow-ups.
33285284|NCT03980080|Experimental|OSE-127: Part 2 (MAD)|
33285285|NCT03980080|Placebo Comparator|Placebo: Part 2 (MAD)|
32779501|NCT05497687|No Intervention|Routine care that they currently receiving provided by their primary healthcare providers|The control group will receive routine care that they currently receiving provided by their primary healthcare providers, which include unstructured patient education on lifestyle modification. The usual care does not include structured exercise training.
32779502|NCT05564143|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|All EUS-GE procedures were performed under general anesthesia with endotracheal intubation. A forward-viewing gastroscope or side-viewing duodenoscope is first inserted into the site of the obstruction and a 0.025- or 0.035-inch stiff GW is placed down-stream of the jejunum beyond the obstruction as far as possible. Then, oral enteral tube is placed where the jejunum intended for stent placement under fluoroscopic guidance. After exchanging to EUS endoscope, the target jejunum is visualized by EUS after continuously injection of mixed saline and contrast medium. Finally, the gastrojejunostomy stent is directly advanced from the gastric wall into the target jejunum by AXIOS-EC delivery system.
32779503|NCT05564143|Active Comparator|Laparoscopic gastroenterostomy (LGE)|All LGE were performed in the operation room with patients under general anesthesia. After CO2 insufflation, 4 to 5 trocars were introduced. Next, the Treitz ligament was identified. An anterior, dorsal laterolateral, or side- to-side isoperistaltic gastroenteric anastomosis was constructed. The exact location of the gastroenteric anastomosis, with regard to the Treitz ligament, varied from 30 to 60 cm.
32779504|NCT05564065|Active Comparator|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
32779505|NCT05564065|Active Comparator|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
32779506|NCT05497531|Experimental|ctDNA collection from draining and peripheral veins|Patient with suspected primary hepatobiliary or pancreatic cancer undergoing a diagnostic work-up with a percutaneous or trans-jugular biopsy (standard of care) and will undergo a sampling of the cancer draining vein during their biopsy procedure with a collection of an additional 10mL of blood.
32779507|NCT04047511|Experimental|Virtual Reality|"Twice a week, for a 4 consecutive weeks:~8 sessions of VRTierOne therapy ( 20 minutes each)~8 sessions of general fitness training (40 minutes each)"
32937702|NCT03035318|Experimental|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
32779508|NCT04047511|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of group psychoeducation and relaxation (20 minutes each)~8 sessions of general fitness training (40 minutes each)"
32779509|NCT04424875|Experimental|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
32779510|NCT04424875|Placebo Comparator|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
32937703|NCT03035318|Experimental|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
32937704|NCT03035318|Experimental|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
32937705|NCT03035318|Experimental|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
32937706|NCT02802241|Experimental|open-label placebo|
32779511|NCT04396795|Experimental|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
32779512|NCT04396795|Placebo Comparator|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
32779513|NCT05563519|Active Comparator|I-PRF + collagen|I-PRF will be applied with type 1 collagen to the extraction socket after the wisdom tooth operation.
32937707|NCT02802241|Experimental|double-blind placebo|
32937708|NCT02802241|Experimental|double-blind peppermint oil|
32937709|NCT02802241|No Intervention|no additional treatment|
32937710|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
32937711|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
32937712|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
32937713|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
32937714|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
32937715|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
33285286|NCT04320628|Experimental|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
32779514|NCT05563519|Active Comparator|L-PRF|Only L-PRF will be applied to the extraction socket after the wisdom tooth operation
33083761|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
32779515|NCT05563363|Experimental|Home treatment|Home visits by care staff at the same frequency as in hospital
33083762|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
32779516|NCT05563363|Active Comparator|Standard inpatient treatment|Inpatient treatment on hospital ward
33083763|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
32779517|NCT03961555|Experimental|SYN023+Rabies vaccine|"SYN023:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid,~Dosage: 0.3 mg/kg of SYN023~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
32779518|NCT03961555|Active Comparator|HRIG+Rabies vaccine|"HRIG:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~Dosage form: 150 IU/mL or 300 IU/mL, liquid,~Dosage: 20 IU/kg of HyperRab (HRIG)~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
33285287|NCT04320628|Placebo Comparator|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
33285288|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
33285289|NCT03983902|Active Comparator|Delayed cord clamping|Delayed cord clamping
32937716|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
32937717|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
33285290|NCT03983902|Active Comparator|Umbilical cord milking|Umbilical cord clamping
33285291|NCT03983902|Active Comparator|Immediate cord clamping|Immediate cord clamping
33285292|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
33285293|NCT00302458|Experimental|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
33285294|NCT00302458|Experimental|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
33285295|NCT00302458|Placebo Comparator|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
33285296|NCT00302458|Experimental|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
33285297|NCT00302458|Experimental|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
32937718|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
33285298|NCT03982264|Active Comparator|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
33285299|NCT03982264|Experimental|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
33285300|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
33285301|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
33285302|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
33285303|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
33285304|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
33285305|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
33285306|NCT00317044|Placebo Comparator|Placebo|
33285307|NCT00301834|Experimental|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m*2 on day +1, 10 mg/m*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
33285308|NCT00301366|Experimental|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
33285309|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
33285310|NCT01062334|Experimental|Microdialysis|
33285311|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
33402105|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
33083764|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
33083765|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
33285312|NCT00466440|Placebo Comparator|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
33285313|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
33285314|NCT00465972|Placebo Comparator|Placebo|Placebo
33285315|NCT00465972|Active Comparator|2|Doxepin
33285316|NCT00465972|Active Comparator|3|Temazepam
33285317|NCT03926754|Active Comparator|Mirabegron|Active treatment arm (mirabegron)
33285318|NCT03926754|Placebo Comparator|Placebo|Placebo
33285319|NCT00465894|Active Comparator|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
33285320|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
33402106|NCT03655496|No Intervention|Control group|Subject to standard care.
32779519|NCT04277845|Experimental|Group 1|"Group 1: 1 cycle will be repeated every 4 weeks~Bortezomib 1.3mg/m2 SC D1, 8, 15 - Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15~Lenalidomide 25mg/d D1-21~- Dose adjustment for more than 75 : 15mg/d D1-21~Dexamethasone 40mg D1, 8, 15, 22 - Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.~<for patients with old age or frail>~Bortezomib 1.0mg/m2 SC D1, 8, 15~: Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15 Lenalidomide 15mg/d D1-21 Dexamethasone 20mg D1, 8, 15, 22"
33285321|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
33285322|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
33285323|NCT03979768|Experimental|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
33285324|NCT03979768|Experimental|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
33285325|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
33285326|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
32779520|NCT04277845|Active Comparator|Group 2|"Group 2: 1 cycle will be repeated every 4 weeks~Lenalidomide 25mg/d D1-21~Dose adjustment for more than 75: 15mg Dexamethasone 40mg D1, 8, 15, 22~Dose adjustment for more than 75: 20mg~<for patients with old age or frail>~Lenalidomide 15mg/d D1-21~Dexamethasone 20mg D1, 8, 15, 22"
33285327|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
33285328|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
33285329|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
33285330|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
33285331|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
33285332|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
33285333|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
32779521|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
32779522|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
32779523|NCT04072315|Experimental|PLN-74809 Dose Level 1|PLN-74809 Dose Level 1
32779524|NCT04072315|Experimental|PLN-74809 Dose Level 2|PLN-74809 Dose Level 2
32779525|NCT04072315|Experimental|PLN-74809 Dose Level 3|PLN-74809 Dose Level 3
32779526|NCT04072315|Experimental|PLN-74809 Dose Level 4|PLN-74809 Dose Level 4
32779527|NCT05497141|Experimental|tricuspid valve edge-to edge Repair group|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm
32779528|NCT04277689|Experimental|Brain signal data collection|Collection of brain data during deep brain stimulation
32779529|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
33083766|NCT00571480|Other|3|standard of care
33083767|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
33285334|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
33285335|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
33285336|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
33285337|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
33285338|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
33285339|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
33285340|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
33285341|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
33285342|NCT03849300|No Intervention|Control Group|No exercise intervention
33285343|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
33285344|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
33285345|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
33402107|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
33402108|NCT05023486|Experimental|NP-G2-044 Monotherapy|NP-G2-044 capsule PO QD for each 28-day cycle
32937719|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
32937720|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
32937721|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
32937722|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
32937723|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
32937724|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
32937725|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
32937726|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
32937727|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
32937728|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
32937729|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
32937730|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
32937731|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
32937732|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
32937733|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
32937734|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
32937735|NCT02917603|No Intervention|Control|These family and residents will receive usual care
32937736|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
33285346|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
33285347|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
33285348|NCT00412737|Experimental|Oseltamivir|
33285349|NCT00412737|Placebo Comparator|Placebo|
33285350|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
33285351|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
33285352|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
33285353|NCT01041963|Active Comparator|Enalapril|
33285354|NCT01041963|Active Comparator|Enalapril plus Losartan|
33285355|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
33285356|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
33285357|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
33285358|NCT00848757|Experimental|Intensive Life-Style Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the Diabetes Prevention Program (DPP) Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
33285359|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
33285360|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
33285361|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
33285362|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
33285363|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
32779530|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
33285364|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
33285365|NCT01038999||A HIV1-infected naive patients|
33285366|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
32937737|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937738|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
33285367|NCT01038999||C= control Non infected HIV volunters|
33285368|NCT05142566|Experimental|Ultrasound Closure|Open label, single arm study using ultrasound guidance during MANTA device deployment.
33285369|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
33285370|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
33285371|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
33285372|NCT01010828|Active Comparator|Tri-Vector Approach|
33285373|NCT01010828|Experimental|Mini Mid-Vastus Approach|
33285374|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
33285375|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
33285376|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
32779531|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
32779532|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
32779533|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
32779534|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
32779535|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
32779536|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
32779537|NCT04476043|Experimental|INCB054707 15 mg|Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
32779538|NCT04476043|Experimental|INCB054707 45 mg|Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
32779539|NCT04476043|Experimental|INCB054707 75 mg|Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
33083768|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
33083769|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
33083770|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
33083771|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
33083772|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
33083773|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
33083774|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
33083775|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
33083776|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
33083777|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
33083778|NCT00571714|Active Comparator|1|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
33083779|NCT00571714|Active Comparator|2|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
33083780|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
33083781|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
33083782|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
32779540|NCT04476043|Placebo Comparator|Placebo followed by INCB054707 75 mg|Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
32779541|NCT04471597|Placebo Comparator|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
32779542|NCT04471597|Active Comparator|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
32779543|NCT04470349||LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
32779544|NCT04470349||Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
32779545|NCT05563207|Experimental|control group|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff. Among them, patients in the control group were given intervention for TCM health education standard path. During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
32779546|NCT05563207|Active Comparator|observation group|The patients in the observation group were given TCM health education standard path intervention. The contents of the health intervention mainly included: ① Graphic and text education;②Language education;③ Psychological education; ④Dietary education; ⑤ Complication education
32779547|NCT05563129|No Intervention|No first aid training|
32779548|NCT05563129|Experimental|First aid training|
32779549|NCT03806179|Experimental|Betalutin with rituximab treatment|Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
32779550|NCT05562739|Experimental|Active|Arm receiving investigational product (postbiotic)
32779551|NCT05562739|Placebo Comparator|Placebo|Arm receiving placebo
32779552|NCT05562661||M89PF/standard skin care|use of M89PF on one side of the face standard skin care products on the other side of the face
32779553|NCT05497063|Experimental|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine|Two dispersible tablets of Sulfadoxine/Pyrimethamine (250 mg sulfadoxine / 12.5 mg pyrimethamine to be given as single dose once under fasting condition
32779554|NCT05497063|Active Comparator|G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
32779555|NCT05496985|Experimental|Patients in coma|Patients in coma were assessed by the SECONDs and CRS-R for five days.
32779556|NCT05496985|Experimental|Patients in unresponsive wakefulness syndrome|Patients in unresponsive wakefulness syndrome were assessed by the SECONDs and CRS-R for five days.
33285377|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
33285378|NCT04466150|Active Comparator|Ocrelizumab treated|Participants age 18-50 with a first clinical presentation of MS or high-risk CIS diagnosed within 90 days of screening will be treated with ocrelizumab (300 mg IV x 2 doses given 2 weeks apart) at disease origin and with maintenance ocrelizumab 600 mg every 6 months through 30 months with a final study visit at 3 years
33285379|NCT04466150|No Intervention|Observational study cohort|Subjects enrolled into an observational study matched for the same disease duration and who are either untreated or treated with alternate MS disease modifying therapies will serve as a parallel reference group
32937739|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937740|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937741|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937742|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937743|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
32937744|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
32937745|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
32937746|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
32937747|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
32937748|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
32937749|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
32937750|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
32937751|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
32937752|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
32937753|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
32937754|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
32937755|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
32937756|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone~Qualitative interviews~Feedback from 5-10 caregivers to refine the intervention."
32937757|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
33285380|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
33285381|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
33285382|NCT01014650|Experimental|SC GLYX-13|Single SC dose
33285383|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
33285384|NCT00411645|Experimental|A|
33285385|NCT00411645|Placebo Comparator|B|
33083783|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
32779557|NCT05496985|Experimental|Patients in minimally conscious state|Patients in minimally conscious state were assessed by the SECONDs and CRS-R for five days.
32779558|NCT05496985|Experimental|Patients in emerge from the minimally conscious state|Patients in emerge from the minimally conscious state were assessed by the SECONDs and CRS-R for five days.
32779559|NCT05496829|Experimental|Adherence Intervention|Multicomponent Adherence Intervention
32779560|NCT05496829|Other|Usual Care|Usual Care from treating providers
32779561|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
32779562|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
32779563|NCT04424719|Other|Patients with uveal melanoma|
32779564|NCT04277611|Active Comparator|QLB|The patient is in the prone position, an ultrasound probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
32779565|NCT04277611|Active Comparator|ESPB|Using aseptic technique, an ultrasound probe is placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
32779566|NCT05562583|Experimental|Intervention (single arm)|5 session self-guided online delivered positive emotion regulation intervention with social components.
32779567|NCT05561881|Other|IPACK group|visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to a lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
32779568|NCT05561881|Experimental|genicular group|US transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, and A 20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming the placing of the needle next to each genicular artery a total amount of 20 ml of local anesthetic in equal increments at multiple sites
32779569|NCT05561803||Radiodermatitis Case Group|60 patients with grade 2 or grade 3 radiodermatitis after radiotherapy for the treatment of breast cancer submitted to a PBM therapy protocol
32779570|NCT05561413|Experimental|Mindfulness and exercise|This group will undertake exercise and mindfulness for 8 weeks. The home based walking and strengthening intervention is individually tailored for each participant. All exercise demonstrations, information, reporting of activity and setting of goals will take place in the app that participants will download. Additionally this group will receive a hard copy of the goal setting diary. All mindfulness information and practices are available in the app. New content will be released each week as the participants progress through the program. Participants will be phoned weekly over the 8 weeks to monitor progress.
32779571|NCT05561413|Active Comparator|Mindfulness|This group will undertake mindfulness only over 8 weeks. The mindfulness program is based on mindfulness-based stress reduction (MBSR). All information, practices and logging of the mindfulness practice will be done via the app that participants will download. Participants will be phoned weekly over the 8 weeks to monitor progress. New content will be released each week as participants progress through the program.
32779572|NCT05560945|Active Comparator|0.32% Sodium Fluoride Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
32779573|NCT05560945|Experimental|1.5% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
32779574|NCT05560945|Experimental|8.0% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
32779575|NCT05559463|Experimental|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
32779576|NCT05559385|Experimental|Robotic Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward, and push-ups with a Swiss Ball. This group received a robotic rehabilitation program for the upper extremity with a Houston Bionics ExoRehab X brand/model device. This device has no motor force of repulsion or attraction. Patients initiate and maintain their movements during the exercise. The device supports the patient's active movement and allows extensive movement repetition.~Before starting robotic rehabilitation, the patient was seated upright on the platform. The games were projected onto a 43-inch television screen. The exercise program was planned to include upper extremity movements in all directions."
32937758|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
32937759|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
32937760|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
32779577|NCT05559385|Active Comparator|Conventional Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. During this period, lower extremity rehabilitation was added if needed in addition to trunk rehabilitation. Exercises for the lower extremities were applied according to the patient's individual needs. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward and sideways, and push-ups with a Swiss Ball.~CR applied after the ITR program consisted of an individualized rehabilitation program for the upper extremities. These rehabilitation programs generally included activities for functional purposes (dressing, object manipulation, reaching, cup holding, range of motion, strengthening, weight-bearing, etc.). The treatment program was applied five days a week for six weeks, with the session duration limited to 60 minutes."
32779578|NCT05496751|Experimental|Low amount, low intensity exercise|exercise dose (amount and intensity) will be controlled.
33083784|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
33083785|NCT00571792||1|Individuals with normal lung function who do not smoke
33083786|NCT00571792||2|Individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
33083787|NCT00571792||3|Individuals who smoke that demonstrate symptoms of COPD
33083788|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
33083789|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
33083790|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
33083791|NCT04580173||SYNTAX score>=33|High SYNTAX group
33083792|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
33285386|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
33285387|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
33285388|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
33285389|NCT01042197|Active Comparator|2|Body surface area: 12 %
33285390|NCT01042197|Active Comparator|1|Body surface area: 6 %
33285391|NCT01042197|Active Comparator|3|Body surface area: 24 %
33285392|NCT01042197|Active Comparator|4|Body surface area: 6 %
33285393|NCT01042197|Active Comparator|5|Body surface area: 12 %
33285394|NCT01042197|Active Comparator|6|Body surface area: 24 %
32779579|NCT05496751|Experimental|Low amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
33285395|NCT01042197|Active Comparator|7|Body surface area: 6 %
33285396|NCT01042197|Active Comparator|8|Body surface area: 12 %
33285397|NCT01042197|Active Comparator|9|Body surface area: 24 %
32779580|NCT05496751|No Intervention|Control|no exercise intervention
32779581|NCT05496751|Experimental|High amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
32779582|NCT04047277|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
32779583|NCT04047277|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
32779584|NCT04224961|Experimental|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
32779585|NCT04224961|Experimental|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
32779586|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
33083793|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
33083794|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
33083795|NCT00254748|Placebo Comparator|1|Placebo
33083796|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
33083797|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
33083798|NCT00572026|Experimental|1|Daytrana
33083799|NCT00572026|No Intervention|2|No treatment for ADHD
33083800|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
33083801|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
33083802|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
33083803|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
33083804|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP's
33285398|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
33285399|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
32779587|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
32779588|NCT04044937|Experimental|Diagnostic FET PET|All participants receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
32779589|NCT04038151|Experimental|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
32779590|NCT04038151|Other|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
33083805|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
32779591|NCT04222387|Experimental|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
32779592|NCT05491525|Experimental|Cohort 1: Vibegron Adolescents (12 to < 18 years)|"Part A: Participants aged 12 to < 18 years will receive vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
32779593|NCT05491525|Experimental|Cohort 2: Vibegron Children (2 to < 12 years)|"Part A: Participants aged 2 to < 12 years will receive vibegron based on their weight, after DSMB review of Cohort 1, Part A data, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a DSMB-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
32779594|NCT05496361|Experimental|Tianyi Revascularization Device|
32779595|NCT05496361|Active Comparator|Solitaire FR Revascularization Device|
32779596|NCT05496283|Experimental|Corega|Complete denture patients given Corega denture adhesive.
32779597|NCT05496283|Experimental|OlivaFix|Complete denture patients given OlivaFix denture adhesive.
32779598|NCT05496283|Experimental|Sea.Bond|Complete denture patients given Sea.Bond denture adhesive.
32779599|NCT05496205|Experimental|iN1011-N17, Oral capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
32779600|NCT05496205|Experimental|iN1011-N17, Oral Suspension, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
32779601|NCT05496205|Experimental|iN1011-N17, Nanoparticle Capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
32779602|NCT05496205|Placebo Comparator|Placebo|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
32779603|NCT05496127|Experimental|Sensorimotor Exercise Group|Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
33083806|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
32779604|NCT05496127|Experimental|Yoga Exercise Group|Yoga group will be given yoga exercises including 14 poses. These exercises are: bridge pose, corpse pose, bharadvaja's twist, downward facing dog, downward facing hero, extended side angle, extended triangle, mountain pose, prosperous pose, reclining big toe, standing half forward bend, thunderbolt pose, upward hand pose, warrior pose II.
32779605|NCT05496049|Experimental|Triburter|The intervention group will receive a triburter device for training, the patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day.
32779606|NCT05496049|Active Comparator|Incentive spirometry|For the control group (incentive spirometry) they will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks.
32779607|NCT04380649|Experimental|ALS people with severe disability|
32779608|NCT05495893|Experimental|Cyclophosphamide|Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
32779609|NCT05495893|Experimental|Mycophenolate mofetil|Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
32779610|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
32779611|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
33083807|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
33083808|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
33083809|NCT00572338||patients with myeloma/related diseases|
33083810|NCT00572377|Active Comparator|FemLife Gel|
32937761|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
33285400|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33285401|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
33285402|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
33285403|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
32779612|NCT04201639|Experimental|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
32779613|NCT04201015|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
33285404|NCT01042275||TOT|transobturator sling, outside-in (TOT)
33285405|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
33285406|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
33285407|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
33285408|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
33285409|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
33285410|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
33285411|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
33285412|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
33285413|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
33285414|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
33285415|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
33285416|NCT04558827|Experimental|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
33285417|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
33285418|NCT03992937|Experimental|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
33285419|NCT03992937|Active Comparator|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
33285420|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
33285421|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
33285422|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
33285423|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
33285424|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
33285425|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
32779614|NCT04201015|Active Comparator|Rate-response settings off|Patients allocated to deactivated rate-response settings.
32779615|NCT04201015|Experimental|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
32779616|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
32779617|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
32779618|NCT04191967|Experimental|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive participants will be performed by a trained, non-physician clinician. Thermocoagulation will last approximately 20 seconds and will be performed using the Liger Thermocoagulator device
32779619|NCT05491291|Other|Patients with chronic wound of the lower limbs|Passing of the scale when the patient will come at the hospital for his routine health care visit in M@diCICAT center
32779620|NCT04191733|Experimental|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
32779621|NCT04191733|Active Comparator|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
33083811|NCT00572377|Placebo Comparator|Placebo|
33083812|NCT00413075|Experimental|oral belinostat|
32779622|NCT02556307||Peginterferon alfa-2a + Ribavirin|
32779623|NCT05495425|Experimental|NPC-12Y gel|NPC-12Y gel is containing 0.2% Sirolimus
33083813|NCT00572416|Experimental|1|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, phychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
32779624|NCT05495425|Placebo Comparator|NPC-12Y placebo gel|Placebo gel matched NPC-12Y gel
32779625|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
32779626|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
33083814|NCT00572416|Placebo Comparator|2|Equal time and attention, information about healthy eating and general conversation
33083815|NCT00572494|Experimental|1|Stenting with AMS
33083816|NCT00572494|Active Comparator|2|PTA alone
33083817|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
33083818|NCT00572650|Active Comparator|1|
32779627|NCT05495347||Registry of patients|
32779628|NCT05491135|Experimental|HMB002|All patients will receive HMB002 infusion into the peritoneal cavity.
32779629|NCT04185337|Experimental|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
32779630|NCT02232997|Active Comparator|Standard Hydration|Standard long-term hydration, i.e. hydrated with normal saline 12 hours before and 12 hours after coronary intervention at a rate of 1 ml/kg/h
32779631|NCT02232997|Active Comparator|Simplified Hydration|Rapid short-term hydration, i.e. hydrated with normal saline from 1 hour before to 4 hours after coronary intervention at a rate of 3 ml/kg/h
32779632|NCT05491057||Neratinib extended ajuvant treatmeng for 1 year|
32779633|NCT05490901||Patients with Unexplained Dyspnea|Patients with dyspnea on exertion
32779634|NCT05495191||Grouped as the favorable outcome|<3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
32779635|NCT05495191||Grouped as the unfavorable outcome|≥3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
32779636|NCT05495113|Sham Comparator|Sham Stimulation|Sham Stimulation
32779637|NCT05495113|Experimental|Real Stimulation (Active)|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 26 weeks
32779638|NCT04364737|Active Comparator|Convalescent donor plasma|
32779639|NCT04364737|Placebo Comparator|Lactated ringer's solution or sterile saline solution|
32779640|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
32779641|NCT05494957|Experimental|New treatment regimen including bedaquiline|Treatment regimens that include bedaquiline, linezolid, clofazimine, and other optional drugs.
32779642|NCT05494879|Experimental|microkinesitherapy treatment|"The study group received a single therapy session of microkinesitherapy. The entire procedure lasted about 10 minutes. Microkinesitherapy is based on locating information in the patient's body about previous traumas/traumas that have been experienced physically and emotionally, which the body could not eliminate. This information is interpreted on the body by sensitive tensions and called body scars and does not necessarily remain in the brain."
32779643|NCT04015921||Inpatients|Patients admitted with various psychiatric disorders
32779644|NCT04015921||Age-matched control group|
32779645|NCT04003363||Participants with Myotonic Dystrophy|
32779646|NCT04352101|Experimental|Bupropion|Participants randomized to take bupropion for 8 weeks.
32779647|NCT04352101|Active Comparator|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
32779648|NCT05490823|Experimental|Eligible patients for app-based anemia screening|Device: A smartphone app for anemia screening This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
32779649|NCT04424485|Active Comparator|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)~Standard TT+CLND procedure only"
32779650|NCT04424485|Experimental|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).~TT+CLND with NIR fluorescence ICG"
33083819|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
33083820|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
33083821|NCT00572767|Experimental|1|
33083822|NCT00572767|Placebo Comparator|2|
33083823|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
33402109|NCT05023486|Experimental|NP-G2-044 Combination Therapy With Anti-PD-1 Therapy|NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
33402110|NCT04439422|Experimental|SAINT|
33083824|NCT00572923||1|"Inclusion criteria~Histological or cytological proven SCLC~UICC stage I-III, limited disease~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
33083825|NCT00573001|Experimental|1|
33083826|NCT00573001|Experimental|2|
33083827|NCT00573001|Experimental|3|
32779651|NCT05490745|Experimental|Immediate Intervention Group (IIG)|Participants receive initially one session for psychological assessment. At the end of the session, the second session is scheduled for the following week, where feedback about the assessment will be provided. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
32779652|NCT05490745|Other|Delayed Intervention Group (DIG)|Waiting-list Comparator (nocebo): Participants initially receive one session for psychological assessment. At the end of the session, participants are informed that they will be contacted to schedule the second session, where feedback about the assessment will be provided. Participants are contacted during the same week, to schedule the second session 8 weeks after the first session. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
32779653|NCT05494645|Active Comparator|Peripheral Nerve Block Without Exparel|Lower extremity peripheral nerve block without Exparel: 0.25-0.5% bupivacaine
32779654|NCT05494645|Experimental|Peripheral Nerve Block with Exparel|Liposomal bupivicaine administered for peripheral nerve block: mixed with 0.25-0.5% bupivacaine
33083828|NCT00573001|Active Comparator|4|
33083829|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
33083830|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
33083831|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
33083832|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
33083833|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
33083834|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
33083835|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
33083836|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
33083837|NCT00573040||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~Stage IV~Performance status 3 or more~FeV 1 or DLCO < 30% of the age-predicted value"
33083838|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
33083839|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~Gemcitabine 1250 mg/m2 IV w 13,15,17,19~Vinorelbine 25 mg/m2 IV w 13,15,17,19~Prednisone 40 mg/m2 PO qod w 1-10, taper"
33083840|NCT00234975|Active Comparator|HCV +|
33083841|NCT00234975|Active Comparator|HCV -|
33083842|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
33083843|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
33083844|NCT00573196|Experimental|1|
33083845|NCT00573274||1|Elective cesarean section patients
33083846|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
33083847|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
33083848|NCT00235014|Placebo Comparator|A-3|
33083849|NCT00235014|Active Comparator|A-4|
33083850|NCT00573352|Other|1|Far infrared radiation
33083851|NCT00573586|Other|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to <0.5ng/ml.~Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)~Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
33285426|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
33083852|NCT00573664|Active Comparator|1|Gabapentin
33083853|NCT00573664|Placebo Comparator|2|Placebo
33083854|NCT00573703|Active Comparator|Group A|
33285427|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
33285428|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
33285429|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
33285430|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
33285431|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
33285432|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
33285433|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
33083855|NCT00573703|Experimental|Group B|
33083856|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
33083857|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
33285434|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
33285435|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
33285436|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
33083858|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
33285437|NCT04383587|Other|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
33285438|NCT00859781|Experimental|1. 177Lu-J591+Ketoconzole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
33083859|NCT00573820|Other|1|
33083860|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
33083861|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
33285439|NCT00859781|Placebo Comparator|2. 111In-J591 + ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
33285440|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
33285441|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
33285442|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
33285443|NCT00945347|No Intervention|Baseline|Visit 1
33285444|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
33285445|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
33285446|NCT00945425|Experimental|1|Low dose or placebo, twice daily
33285447|NCT00945425|Experimental|2|Low dose or placebo, once daily
33285448|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
33285449|NCT00945425|Experimental|4|High dose or placebo, once daily
33285450|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
33285451|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
33285452|NCT00945581|Experimental|AN777|Powder twice a day
33285453|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
33285454|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
33285455|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
33285456|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
33285457|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
33285458|NCT01042353|Experimental|E test|
33285459|NCT01042353|Active Comparator|standard culture method|
33285460|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
33083862|NCT04579861||High human development|Countries classified as very high and high human development as per the United Nations development programme.
33083863|NCT04579861||Low and medium human development|Countries classified as low and medium human development as per the United Nations development programme.
33285461|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
33285462|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
32779655|NCT05494645|Experimental|Local Infiltration of Exparel|Liposomal bupivicaine administered by surgeon intra-operatively in field block, mix with 0.25% bupivacaine
32779656|NCT05494567|Active Comparator|Tadalafil / solifenacin combination therapy|Patients will be treated by combination of Tadalafil 5 mg + solifenacin 10 mg once daily for 12 weeks
33285463|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
33285464|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
33285465|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
32779657|NCT05494567|Active Comparator|Tamsulosin / solifenacin combination therapy|Patients will be treated by combination of Tamsulosin 0.4 mg + solifenacin 10 mg once daily for 12 weeks
32779658|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
32779659|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
32779660|NCT05490667|Experimental|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
33285466|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
33285467|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Total dose = 30% total tumor volume
33083864|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
33083865|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
33285468|NCT03742401|Active Comparator|Surgery|Surgery
33285469|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
33083866|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
33083867|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
33083868|NCT04719468|Experimental|Intervention|
33083869|NCT04719468|No Intervention|Usual Treatment|usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely
33083870|NCT00574015|Active Comparator|oral|administration of oral analgesia
33285470|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
33285471|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
33285472|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
33285473|NCT00945737|Active Comparator|Soy protein|
33285474|NCT00945737|Placebo Comparator|Milk protein|
33285475|NCT04012307|Other|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33402111|NCT04439422|Active Comparator|Self-help material|
32900237|NCT05398068|Experimental|Training (Exercises and Diet) Group|"Training (Exercises and Diet) Group; Patients will follow a regular diet program for 10 weeks.~Aerobic exercises will be planned for patients 2 days a week under the supervision of a physiotherapist, and 3 days a week as home exercises.~Strengthening exercises will be planned for patients 1 days a week under the supervision of a physiotherapist, and 2 days a week as home exercises."
32900238|NCT05398068|Active Comparator|Control (Diet) Group|Control (Diet) Group; Patients will follow a regular diet program for 10 weeks.
33083871|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
33083872|NCT00574054|Other|1|
33083873|NCT00255021|Experimental|1|
33083874|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
33083875|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
32937762|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
32937763|NCT03043885|Experimental|PRF|
33402112|NCT02381470|Experimental|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
33402113|NCT02381470|Experimental|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
33402114|NCT02381470|Active Comparator|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
33402115|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
33402116|NCT04241536|Other|No arm|This is an epidemiologic study. No arms are considered.
33402117|NCT05018416|Experimental|2 REACT injections|Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
33402118|NCT05018416|Experimental|1 REACT Injection|Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.
33402119|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
32937764|NCT03043885|Experimental|PRF+FDBA|
32937765|NCT03043885|Active Comparator|FDBA|
33402120|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
33402121|NCT04190056|Experimental|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
33402122|NCT04190056|Experimental|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
32937766|NCT03043885|Active Comparator|Blood Clot|
32937767|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days < 90 days"
32937768|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days ≥ 90 days"
32937769|NCT02961062|Experimental|Treatment Sequence 1|
33402123|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
33402124|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
33402125|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
33402126|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
33402127|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
32937770|NCT02961062|Placebo Comparator|Treatment Sequence 2|
32937771|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
32937772|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
32937773|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
32937774|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
32937775|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
32937776|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
32937777|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
32937778|NCT02812771|Experimental|Efinaconazole|Efinaconazole
33083876|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
33083877|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
33083878|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
33083879|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
33285476|NCT04012307|Other|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33285477|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
33285478|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
32830362|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
32937779|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
33285479|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
33285480|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
33285481|NCT00387465|Experimental|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
33285482|NCT00387465|Experimental|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
33285483|NCT00387465|Experimental|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33285484|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
33285485|NCT00941291||vitrectomy in pseudophakic eyes|
33285486|NCT00941291||vitrectomy and cataract:combined procedure|
33285487|NCT00941291||vitrectomy followed by cataract extraction|
33285488|NCT00941291||vitrectomy on phakic eyes|
33285489|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
33285490|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
33285491|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
33285492|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
33285493|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
33285494|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
33285495|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
33285496|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
33285497|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
33285498|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
33285499|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
33285500|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
33285501|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
33285502|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
33285503|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
33285504|NCT00946049|Experimental|Vicryl Plus|
33285505|NCT00946049|Active Comparator|Vicryl|
33285506|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
33285507|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
33285508|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
33285509|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
33285510|NCT00950027|Experimental|povidone iodine|Povidone iodine
33285511|NCT00950027|Placebo Comparator|placebo|
33083880|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
33083881|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
32830363|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
33083882|NCT00574483|Experimental|1|Unblinded treatment arm
33083883|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
33285512|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.~Subjects with ocular hypertension and~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
33285513|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
33285514|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
33285515|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
33285516|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
33285517|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
33285518|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
33285519|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
33285520|NCT03993405|Active Comparator|Control group:young|Sixty older subjects will be evaluated in this study.
33285521|NCT03993405|Active Comparator|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
33083884|NCT00225563|Active Comparator|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
33083885|NCT00225563|No Intervention|Paper-based prescriptions|providers who used paper based prescriptions
33083886|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
33285522|NCT03993405|Experimental|Experimental group:older|Sixty older subjects will be evaluated in this study.
33285523|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
33285524|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
33285525|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
33285526|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
33285527|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to <36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33285528|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to <9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
32779661|NCT04331587|Experimental|Bronchoscopy|"Following airway inspection, the radial endobronchial ultrasound probe will be inserted through the working channel of the 4mm bronchoscope and will be advanced into the targeted bronchial segment towards the targeted lesion. Bronchoscopy will be performed using monoplanar fluoroscopic guidance until the peripheral lesion is located and confirmed using radial probe EBUS.~a. If a concentric view is obtained, biopsy will proceed using conventional instruments (TBNA) through the 4mm bronchoscope.~b. If an eccentric view is obtained, the 4mm bronchoscope will be withdrawn and the 3mm bronchoscope with the radial ultrasound probe will be advanced to the target lesion. Attempts will be made using the 3mm bronchoscope to obtain concentric views and ability to do so will be recorded. Biopsies will be obtained using conventional instruments (TBNA)through the 3mm bronchoscope regardless of the final ultrasound image (concentric or eccentric)."
32779662|NCT05494489|Experimental|EsoGLOVE with Trigno Biofeedback (EMG sensors) group|The subjects will receive the intervention (EsoGLOVE with Trigno Biofeedback (EMG sensors) treatment with Trigno Biofeedback (EMG sensors) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day, in addition to intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation.
33285529|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
33285530|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
32779663|NCT05494489|Active Comparator|GRASP group|Graded Repetitive Arm Supplementary Program (GRASP) following the GRASP protocolwhile wearing a neoprene wrist support) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day, in addition to intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation.
32779664|NCT00609115|Experimental|Test-Phase 1|The Test Group receives 18 half-hour AMES (Assisted Movement with Enhanced Sensation) treatments with the AMES device (Test) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
32779665|NCT00609115|Sham Comparator|Control-Phase 1|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) programed to provide placebo therapy. Each treatment session consisting of 30 minutes of sham therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
32779666|NCT00609115|Active Comparator|Crossover-Phase 2|Original Control Group receives 18 half-hour crossover treatments with the AMES device (Crossover) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
32779667|NCT05490589|Experimental|EQUIPE Program|
32779668|NCT04085887|Experimental|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
32779669|NCT04085887|Experimental|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
32779670|NCT04085887|Experimental|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
32779671|NCT04085887|Experimental|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
33285531|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged >=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
33285532|NCT00409617|Experimental|Open Label|
33285533|NCT00300274|Experimental|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
32779673|NCT05494333||2|NO INTERVENTION
33285534|NCT00300274|Experimental|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
32779674|NCT04080895|Experimental|group A|
32779675|NCT04080895|Experimental|group B|
32779676|NCT04265209|Other|SPECT and PET|[123I]-FP-CIT SPECT imaging procedure first, then [18F] LBT-999 PET Imaging procedure
32779677|NCT04265209|Other|PET and SPECT|[18F] LBT-999 PET imaging procedure first, then [123I]-FP-CIT SPECT imaging procedure
32779678|NCT05490433|Experimental|robot assisted nipple sparing mastectomy(RNSM)|Robotic papillary preservation mastectomy, robotic mastectomy, robotic papillary preservation mastectomy, hybrid robotic papillary preservation mastectomy, robotic papillary mammary complex, and skin preservation mastectomy robot papillary preservation mastectomy
32779679|NCT05490433|Active Comparator|Conventional nipple sparing mastectomy(CNSM)|Total mastectomy, mastectomy, papillary preservation mastectomy, skin preservation mastectomy, papillary preservation breast resection, open papillary preservation, open nipple sparing mastectomy) mastectomy, general papillary preservation Mammastectomy, an open-window papillary preservation
32779680|NCT04077619|Experimental|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
32779681|NCT04077619|Active Comparator|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
32779682|NCT04251169|Experimental|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
32779683|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
32779684|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
32779685|NCT04279951|Experimental|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
32779686|NCT04279951|Placebo Comparator|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
32937780|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
32779687|NCT04279951|No Intervention|Control|No intervention
32779688|NCT05494177||Premium monovision|Patients will undergo to implantation of an extended depth of field intraocular lens in the dominant eye and a trifocal diffractive intraocular lens in the non-dominant eye.
32779689|NCT05494177||Bilateral trifocal diffractive implantation|Patients will undergo to bilateral implantation of trifocal diffractive lenses.
32779690|NCT05494099||Group A (1st 25 patients)|The middle meatal mega-antrostomy approach.
32779691|NCT05494099||Group B (2nd 25 patients)|The endoscopic modified medial maxillectomy approach.
32779692|NCT05494099||Group C (3rd 25 patients)|The endoscopic prelacrimal recess approach.
32779693|NCT04165837|Experimental|Active|
32779694|NCT04165837|Placebo Comparator|Placebo|
32779695|NCT04163341|Experimental|CETA protocol|
32779696|NCT04163341|No Intervention|Enhanced Usual Care|
32779697|NCT04279561|Experimental|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
32779698|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
32779699|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
32779700|NCT05499169||16 patients with CAA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. CAA-related ICH is defined as an ICH that meets the criteria for definite or probable CAA according to the Modified Boston Criteria.
32779701|NCT05499169||16 patients with HA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. HA-related ICH is defined as ICH located in the basal ganglia, thalamus, or the deep white matter and the presence of hypertension defined as: on treatment for hypertension, or known with high blood pressure (two measurements systolic blood pressure (SBP) >140 or diastolic blood pressure (DBP) >90 mmHg) but not treated for hypertension.
32779702|NCT05490121|Active Comparator|Facilitator-Led VEGA|"Facilitator-led VEGA uses a group-based approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content as a virtual or face-to-face workshop. In this study, all workshops will be virtual to prevent social gathering during COVID-19.~If a participant is randomized to this arm, the active control (AC) arm, they will be informed that they need to attend a facilitator-led VEGA session via virtual workshop format. The AC intervention will be facilitated via Zoom technology, by two trained facilitators with between 10 to 20 participants in each workshop (keeping the recommended 10:1 participant-to-facilitator ratio) and will last approximately 3 hours. The workshop approach is delivered by trained facilitators and is standardized via the use of a flexibly structured facilitator's guide. Facilitator-led VEGA will deliver material didactically with synchronous lecturing, use case-based role play, and include group-based polling."
32779703|NCT05490121|Experimental|Self-Directed VEGA|"Self-directed VEGA uses an approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content online as a self-directed educational activity, at their own pace in a series of modules. Individuals will register to access the VEGA Educational Resources site. Participants have the option of completing the self-directed VEGA arm in either English or French as the VEGA Educational Resources site offers the content in French and English.~If a participant is randomized to the experimental arm, they will be asked to complete the self-directed VEGA at their convenience, within one week of when they are informed they have been asked to complete the self-directed VEGA program. It will take approximately 3 hours for participants to complete all modules.~Participants will read didactic material, complete case-based animated simulations, and complete individual multiple-choice questions with response feedback."
32779704|NCT04159987|Experimental|Spinal muscular atrophy patient|
32779705|NCT05494021|Experimental|Whole-process management strategy|"High-risk individuls are provided with whole-process management strategy, including lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.~LDCT was performed at baseline + 2 biennial repeated LDCT rounds."
32779706|NCT05494021|Active Comparator|Rountine screening strategy|LDCT was performed at baseline + 2 biennial repeated LDCT rounds.
32779707|NCT05493943|Active Comparator|PEMF low power|PEMF therapy using a device with low pulse intensity.
32779708|NCT05493943|Active Comparator|PEMF medium power|PEMF therapy using a medium pulse intensity.
32937781|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
32937782|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
32937783|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
33083887|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
32937784|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
32937785|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
33083888|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
33083889|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
33083890|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
32937786|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
33083891|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
33083892|NCT00574678|No Intervention|1|
32937787|NCT02970422||Quartile 1 [Mild]|
32937788|NCT02970422||Quartile 2 [Moderate]|
32937789|NCT02970422||Quartile 3 [Severe]|
32937790|NCT02970422||Quartile 4 [Very Severe]|
32937791|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
32937792|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
32937793|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
32937794|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
32937795|NCT03050203|Experimental|custom pack|
32937796|NCT03050203|Active Comparator|standard care|
33083893|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
33083894|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
33083895|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
33083896|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
33083897|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
33083898|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
33083899|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
33083900|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
33083901|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
33083902|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
33083903|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
33083904|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
33083905|NCT00575068|Experimental|1|
33083906|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
33083907|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
33083908|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
33083909|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
33083910|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
33083911|NCT00575263||Normal Teeth|Normal molar teeth
33083912|NCT00575263||painful teeth|Painful molar teeth
33083913|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
33083914|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
32779709|NCT05493943|Sham Comparator|PEMF Sham control|Control arm using a sham PEMF device.
32779710|NCT04322383|Experimental|Arm 1/Experimental therapy|Treatment with binimetinib
32779711|NCT05493865|Experimental|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|The PC-SMILE integrates the growth mindsets of intelligence, failure and negative emotions. The interventions for both students and parents consist of five components: (a) an introduction to brain functions regarding the potential of neuroplasticity and the possibility of changes in intelligence and emotions; (b) stories and testimonials from high-school-aged youths who describe their beliefs-in-change; (c) short videos with stories of improving intelligence and emotions and of failure-is-enhancing; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to young students/others about the growth mindsets. The interventions for parents and students are different in terms of narrative and content. A total of 10 weekly booster messages with core intervention content will be sent to the intervention group between the two-week post-test and the three-month follow-up survey.
32779712|NCT05493865|No Intervention|Waitlist control group|The waitlist control group will continue with normal education activities and do the pre- and post- intervention surveys at the same timeframe as the intervention group. Participants in waitlist group will be invited to complete the PC-SMILE after the three-month post-intervention survey.
32779713|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
33083915|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
33083916|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
33285535|NCT00300274|Active Comparator|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
33285536|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
33285537|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
33285538|NCT01043367|Experimental|A|Deprexil
33285539|NCT01043367|Placebo Comparator|B|Placebo
33285540|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
33285541|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
33285542|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
33285543|NCT00299728|Experimental|Arm A; 100 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|100 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
33402128|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
33285544|NCT00299728|Experimental|Arm B; 400 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|400 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
33285545|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
33285546|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
33285547|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
33285548|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
33285549|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
33285550|NCT01325272||preterm newborn|
33285551|NCT01325272||term newborn|
33285552|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
33285553|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
33285554|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
33285555|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
33083917|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
32779714|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
33083918|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
33083919|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
33083920|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
33083921|NCT00591097||pediatric|
33083922|NCT00591136|Experimental|Single Arm|
33083923|NCT00591292|Experimental|Single Arm|
33083924|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
33083925|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
33083926|NCT00591331|Placebo Comparator|3|Blank patch
32779715|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
32779716|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
33083927|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
33083928|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
32779717|NCT05499091|Experimental|Study Arm|"Specific interventions:~Blood samples, skin biopsy, urine collection or operational waste qualified as research sample."
32779718|NCT05493709|Experimental|FP-001 42 mg|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
33083929|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
33083930|NCT03452215|Experimental|Study|
33083931|NCT03452215|Sham Comparator|Control|
33083932|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
33083933|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
33083934|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:~Tyto Thermometer~Standard of Care thermometer~Predicate IR thermometer"
33083935|NCT03451981|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
33083936|NCT03451981|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
33083937|NCT03451981|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant surface.
33083938|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
33083939|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
33083940|NCT00255372|Experimental|1|
33083941|NCT00255372|Active Comparator|2|
33083942|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
33083943|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
33083944|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
33083945|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
33083946|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
33083947|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
33083948|NCT03451747||postmenopausal hypertensive women|
33083949|NCT03451747||mached hypertensive men|
33083950|NCT03451669||Shunt suspected to be functioning|
33083951|NCT03451669||Shunt suspected to not be functioning|
33083952|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
33083953|NCT00235248|Active Comparator|Warfarin|Warfarin
33083954|NCT04574323|Experimental|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
33083955|NCT04574323|Other|Standard diet group|This group is on a standard diet while receiving radiotherapy.
33083956|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
33083957|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
33083958|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
33083959|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
33083960|NCT04574596||3GCR ceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
32779719|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
32779720|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
32779721|NCT04148989|No Intervention|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
32779722|NCT04148989|Experimental|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
32779723|NCT04148989|No Intervention|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
32779724|NCT04148989|No Intervention|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
32779725|NCT04147195|Experimental|LYS006|LYS006 20 mg was administered orally twice per day (b.i.d) for 12 weeks
33083961|NCT04574596||3GCS ceftriaxone-susceptible-E. coli|Positive blood culture for above susceptible e coli. Observational there will be no intervention
33083962|NCT04575064|Other|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
33083963|NCT04575064|Experimental|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
33083964|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
33083965|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
33402129|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
33402130|NCT04724824|Experimental|Brain-Computer Interface controlled robotic feedback|
32779726|NCT04147195|Experimental|LYS006 + LJN452|LYS006 20 mg was administered orally twice per day (b.i.d) in addition to LJN452 200ug administered orally once daily for 12 weeks
32779727|NCT05498935||CPB time ≥ 90 minutes|No intervention, regular therapy
32779728|NCT05498935||CPB time < 90 minutes|No intervention, regular therapy
32779729|NCT05489887|Experimental|Subjects with ALK Wildtype or Unknown|"5 cycles of standard of care induction + naxitimab~Naxitimab on Days 1, 3, and 5 of each cycle"
32779730|NCT05489887|Experimental|Subjects with ALK aberration|"5 cycles of standard of care induction + naxitimab + ceritinib~Naxitimab on Days 1, 3, and 5 of each cycle Ceritinib once daily on every day of study"
32779731|NCT05489809|Experimental|Endotracheal extubation with suctioning|Suctioning is applied to the endotracheal tube while removing it.
32779732|NCT05489809|Experimental|Endotracheal extubation with positive pressure|Positive pressure is applied to the endotracheal tube while removing it.
32779733|NCT05493631|Active Comparator|Cohort 1 (2.0 mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with 2.0 mg/kg once weekly in cohort 1."
32779734|NCT05493631|Active Comparator|Cohort 2 (A mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with A mg/kg once weekly in cohort 2.~The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1)."
33083966|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
33083967|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
33083968|NCT03451240|Experimental|Intervention|
33083969|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
32779735|NCT05493631|Active Comparator|Cohort 3 (B mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with B mg/kg once weekly in cohort 3.~The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2)."
32779736|NCT05498857|Active Comparator|Ephedrine group|Patients will receive intramuscular ephedrine 0,5 mg/kg before spinal anesthesia
32779737|NCT05498857|Placebo Comparator|Placebo group|Patients will receive intramuscular saline before spinal anesthesia
32779738|NCT04424329|Experimental|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
32779739|NCT04424329|No Intervention|No intervention|No intervention
32779740|NCT05489731|Experimental|Dose escalation phase-Dose group 1 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
32779741|NCT05489731|Experimental|Dose escalation stage - Dose group 2 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
33083970|NCT04574284|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
33083971|NCT04574284|Experimental|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
33083972|NCT04574284|Experimental|Anlotinib|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32779742|NCT05489731|Experimental|Dose expansion phase VIC-1911 Tablets with Osimertinib Mesylate Tablets|Cohort 1: NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation positive; Cohort 2: NSCLC patients who experienced third-generation EGFR-TKI failure
32779743|NCT05489653|Experimental|mixed music group|If assigned to the mixed music group, in order to synchronize active daytime music and passive music at bedtime, active daytime music will require patients to perform physical music activities once a week and watch a recorded music intervention video three times a week during the study period (The content is the same as the physical music activities) and follow the activities, and the intervention content before going to bed is the same as the intervention content of the pure passive music group.
32779744|NCT05489653|Active Comparator|pure passive music group|If assigned to the pure passive music group, they are required to listen to soft and low-pitched music at about 60 beats per minute 30 minutes before bed every day for four weeks.
32779745|NCT05489653|No Intervention|conventional treatment|Conventional treatment group maintained their original lifestyle and were post-tested with the assistance of a single-blind study evaluator.
32779746|NCT05498545|Experimental|LUCAR-B68 cells product|Each subject will receive LUCAR-B68 cells
32779747|NCT05489419|Experimental|Prehabilitation|Patients undergo prehabilitation during 3-4 weeks before undergoing pancreatic surgery.
32779748|NCT05493319|Experimental|Hypopresive, strength and resistance exercises|Participants will perform 3 types of hypopresive exercises in the end of strength and resistance exercises intervention.
32779749|NCT05493319|Active Comparator|Strength and resistance exercises|Participants will perform strength and resistance exercises intervention.
32779750|NCT05498467|Active Comparator|Anakinra|
32779751|NCT05498467|Placebo Comparator|Placebo|
32779752|NCT05493241|Other|Open trial|In Aim 2, all 10 participants will receive the ACTIVaTE intervention.
32779753|NCT05493241|Experimental|ACTIVaTE intervention|In Aim 3, 24 participants will be randomized to receive the ACTIVaTE intervention.
32779754|NCT05493241|Active Comparator|Attention control|In Aim 3, 24 participants will be randomized to an attention control arm.
32779755|NCT05498311|Experimental|Intraoperative Radiotherapy (IORT)|Patients with diagnosis of invasive breast cancer (IBC) will be treated with conservative surgery (with or without oncoplastic surgery) and 20 Gy IORT followed by hypofractionated radiotherapy.
32779756|NCT05493007|Experimental|Sandbag motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
32779757|NCT05493007|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
32779758|NCT05489341||Public Training and Development Set (1500 cases)|Available for all participants and researchers, to train and develop AI models. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021. All data is fully anonymized and made available under a non-commercial CC BY-NC 4.0 license. Includes 328 cases from the PROSTATEx challenge (prostatex.grand-challenge.org). Imaging data has been released via: zenodo.org/record/6624726 (DOI: 10.5281/zenodo.6624726). Lesion annotations of csPCa have been released and are maintained via: github.com/DIAGNijmegen/picai_labels.
32779759|NCT05489341||Private Training Set (7500-9500 cases)|Used exclusively by the organizers to retrain the top-ranking 5 AI algorithms, with large-scale data. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021.
32779760|NCT05489341||Hidden Validation and Tuning Cohort (100 cases)|Used for a live, public leaderboard that enables AI model selection and tuning throughout the open development phase of the challenge. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021, that remain fully hidden throughout the course of the challenge.
32779761|NCT05489341||Hidden Testing Cohort (1000 cases)|Used to benchmark AI, radiologists, and test all hypotheses at the end of the PI-CAI challenge. A subset of 400 cases from this cohort is used to facilitate the PI-CAI: Reader Study. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) internal testing data (unseen prostate bpMRI cases from three seen Dutch centers {Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen}) and external testing data (unseen prostate bpMRI cases from one unseen Norwegian center {Norwegian University of Science and Technology}), acquired between 2012-2021.
32779762|NCT05489263||AKI|AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
33083973|NCT04574050|Experimental|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
33083974|NCT04574050|No Intervention|Control|standard / currently available NHS care
32779763|NCT05489263||No-AKI|No-AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
33083975|NCT04574128|Experimental|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
33402131|NCT04724824|Sham Comparator|Sham Brain-Computer Interface controlled robotic feedback|
33402132|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
33083976|NCT04574128|No Intervention|No retransfusion of cardiotomy blood|
33083977|NCT00226031|Active Comparator|1|Usual care.
32779764|NCT05486221||Cryptogenic stroke patients|Patients with an acute ischemic stroke of cryptogenic origin with a previous negative work-up that includes: blood analysis, brain CT / MRI, angio-TC / angio-MRI, brain vessel ultrasound, ECG, 24h ECG-holter, echocardiography).
32779765|NCT05489185|Placebo Comparator|Extracapsular fracture with intravenous contraindication (control).|Physiological saline
32779766|NCT05489185|Experimental|Extracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
33285556|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
33285557|NCT00498602|Experimental|1|ACC-001
33285558|NCT00498602|Other|2|QS-21
32779767|NCT05489185|Placebo Comparator|Extracapsular fracture without intravenous contraindication (control).|Physiological saline
32779768|NCT05489185|Experimental|Extracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
32937797|NCT02970812|Experimental|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
32937798|NCT02970812|Placebo Comparator|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
33285559|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
33285560|NCT00498602|Experimental|4|ACC-001
33285561|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
33285562|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
32937799|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
32937800|NCT02921737|Experimental|Treatment Arm|TAS-102
32937801|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
32937802|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
33285563|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
33285564|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
33285565|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
33285566|NCT04460066|Experimental|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
33285567|NCT04460066|Placebo Comparator|placebo group|All patients will receive 4 cycles of placebo ( IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
33285568|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
33285569|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
32937803|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32937804|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
32937805|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
32937806|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
32779769|NCT05489185|Placebo Comparator|Intracapsular fracture with intravenous contraindication (control).|Physiological saline
32779770|NCT05489185|Experimental|Intracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
32779771|NCT05489185|Active Comparator|Intracapsular fracture without intravenous contraindication (control).|Physiological saline
32779772|NCT05489185|Experimental|Intracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
32779773|NCT05492929|Experimental|The deep breathing group|The deep breathing group was administered the nightly state and trait anxiety scale and SAAQ before the operation, and then they were informed about the deep breathing exercise. Between the 1st and 6th hours of the postoperative period, deep breathing exercise was performed, with 10 breaths per hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
32900275|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
32900276|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
32937807|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
33083978|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
33285570|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
33285571|NCT00497198|Experimental|MCI-196|
33285572|NCT00497198|Placebo Comparator|Placebo|
33285573|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
33285574|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
32779774|NCT05492929|Experimental|4-7-8 breathing technique Group|The nightly state and trait anxiety scale and the PSSQ were applied to the 4-7-8 breathing group before the operation, and then they were given information about the 4-7-8 breathing technique. Between the 1st and 6th hours postoperatively, the 4-7-8 breathing technique was applied for 1 set (4 breaths) every hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
32779775|NCT05492929|No Intervention|control group|In the control group, the nightly state and trait anxiety scale and PSSQ were applied before the operation. At the end of the 6th hour postoperatively, without any application, the state anxiety scale and PSSQ were applied.
33285575|NCT04448366|Experimental|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
33285576|NCT04448366|No Intervention|Usual care|Patients in this group will undergo usual care only.
33285577|NCT05076578|Experimental|Evaluate the harvesting of micografts in healthy and patients with chronic wounds|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
33285578|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
33285579|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
33285580|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
33285581|NCT01016366|Experimental|Lu AA24493|
33285582|NCT01016366|Placebo Comparator|Placebo|
33285583|NCT03996980|Experimental|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
33285584|NCT03996980|Placebo Comparator|Placebo|a flat insole for a period of 4 weeks
33285585|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
33285586|NCT04431830|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
32779776|NCT04235101|Experimental|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
32779777|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
32779778|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
32779779|NCT05485909|Experimental|Regorafenib and Toripalimab Combined with RFA|
32937808|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
33285587|NCT04431830|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
32937809|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
32937810|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
32937811|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
32937812|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
32937813|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
33285588|NCT04420364|Experimental|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
33285589|NCT04420364|Active Comparator|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
33285590|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
33285591|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
33285592|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
32937814|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
33285593|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
33285594|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
33285595|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
32937815|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
33285596|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
32937816|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
32937817|NCT05440903|Experimental|Mindfulness|Participants in the experimental arm are asked to use a mindfulness smartphone application called Headspace. Headspace offers pre-recorded introductory mindfulness meditation audio instructions guided by experienced meditation teachers. Study participants are instructed to voluntarily complete 10 minutes of Headspace twice per day for 14 days, a total recommended dose of 280 minutes. Mindfulness practice begins the day after the baseline interview (i.e., intervention day 1). Participants are encouraged to listen at two separate times each day to support habit formation and to maximize daily exposure with low time burden. As participants have minimal prior experience with mindfulness attributed to the study eligibility criteria, all recommended trainings are at the beginner level. Participants have access to all sessions offered and are not restricted to a particular sequence.
33285597|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
33285598|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
32937818|NCT05440903|Placebo Comparator|Psychoeducation|"Participants in the psychoeducation arm listen to TEDTalks audio recordings by experts on field-specific topics. Study participants are instructed to complete 10 minutes of TEDTalks twice per day for 14 days. Sessions were selected by the study team to be of interest to the public yet not include content on meditation, smoking, or content appearing to cue behavior change associated with smoking. Like the Mindfulness condition, participants in the Psychoeducation condition begin the practice the day after the baseline interview. Participants are told to listen at two separate times each day to maximize daily exposure with low time burden. Additionally, participants are instructed to listen with full mindful attention and return attention to the audio when attention drifts to match the Mindfulness instruction and emphasize the importance of sustaining attention for each 10-minute period. Participants have access to all sessions offered and are not restricted to a particular sequence."
32937819|NCT02860988|Experimental|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
32937820|NCT02860988|No Intervention|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
32937821|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
32937822|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
32937823|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
32937824|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
32937825|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
32937826|NCT04333316|Other|large head group|study the postoperative patient's satisfaction
32937827|NCT04333316|Other|dual mobility group|study the postoperative patient's satisfaction
32937828|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
32937829|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
32937830|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
32937831|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
32937832|NCT03054805|No Intervention|Healthy Children|Healthy Children
32937833|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
32937834|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
32937835|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~Fever >39~Lower respiratory tract infection~Acute otitis media~Serious extra-pulmonary manifestations (myositis, encephalitis)"
32937836|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
33285599|NCT05058248|Active Comparator|Pudendal block|Ultrasound-guided bilateral pudendal block at the start of surgery, in gynecological position: injection of 15 mL of 0.475% Naropein in each ischiorectal fossa.
33285600|NCT05058248|Other|the standard method|Operated and anesthetized patients according to the standard method within the department
33285601|NCT05049980|Experimental|Medical treatment|Patients choosing medical treatment with Mifégyne® and MisoOne®
33285602|NCT05049980|Active Comparator|Surgical treatment|Patients choosing surgical treatment by endo-uterine aspiration.
32779780|NCT05492851|Active Comparator|Zilretta|"Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis pain of the knee.~5mL suspension of 32 mg of triamsinolone administered as a 1 dose parapatellar intra-articular injection."
32779781|NCT05492851|Active Comparator|Synvisc One|"Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B hydrated gel in a buffered physiological sodium chloride solution, pH 7.2.~Each 10 mL syringe of Synvisc-One combines the three 2-mL doses (16 mg each) of a complete SYNVISC treatment regimen (48 mg). Synvisc-One belongs to a class of drugs called Intra-Articular Agents; Rheumatologics, Other.~10mL of Hylan G-F 20 administered as a 1 dose parapatellar intra-articular injection."
32779782|NCT05492851|Active Comparator|Monovisc|"Generic Name: Hyaluronan The Monovisc™ device is a proprietary high molecular weight hyaluronic acid (HA) viscosupplementation intended for the treatment of pain in patients with moderate osteoarthritis (OA) of the knee who have failed conservative non-pharmacological therapy and simple analgesics. The device is administered by a single injection via the para-patellar approach under sterile conditions.~4mL injection of Hyaluronan administered as a 1 dose parapatellar intra-articular injection."
32779783|NCT04139395|Experimental|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
32779784|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
32779785|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
32779786|NCT05489029||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
33402133|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
32779787|NCT05489029||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
32779788|NCT04122235|Experimental|Intervention arm|New follow-up model
32779789|NCT04122235|No Intervention|Control arm|Usual care
32779790|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
32779791|NCT05485597|Experimental|Study Group: Neurological inpatients with Gait disorders|The group participates in the study intervention (they will undergo the Myosuit-based gait training)
32779792|NCT05485519|Experimental|Dexmedetomidine (D)|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
32937837|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
32937838|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
32779793|NCT05485519|Active Comparator|Midazolam (M)|1 mcg/kg/minute. Up to a maximum of 5 mcg/kg/minute.
32779794|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
32779795|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
32779796|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
32779797|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
32779798|NCT04107181|Experimental|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
32937839|NCT04737421||Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)|Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
32937840|NCT04737421||Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)|Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
32937841|NCT04737421||Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
32937842|NCT04737421||Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
32937843|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
32937844|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
32937845|NCT04736953|Active Comparator|Sirolimus|Sirolimus 1 to 2 mg bid
32937846|NCT04736953|Placebo Comparator|Placebo|Placebo 1 to 2 mg bid
32937847|NCT03055897|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
32937848|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
32779799|NCT04107181|Experimental|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
32779800|NCT05485441|Experimental|Students|The students
32779801|NCT05485441|Experimental|Parents|The parents
32779802|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
32779803|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
32779804|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
32779805|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
32779806|NCT05485363|Experimental|optic nerve sheath diameter by using ocular sonography|
32779807|NCT04102423||CCUS|All participants meeting the criteria for CCUS
32779808|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
32779809|NCT04080739|Experimental|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
33083979|NCT04573855|Experimental|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
33083980|NCT04573855|No Intervention|Control|
33285603|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
33285604|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
33285605|NCT05176418|Active Comparator|delivery rate for nicotine dose 1mg/70kg|delivery rate 50,35, 16.6 and 12.5 ug per second
33285606|NCT05176418|Active Comparator|Delivery rate for nicotine dose 0.2mg/70kg|delivery rate 10,5, 3.3 and 2.5
33285607|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
33285608|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
32937849|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
32937850|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
33285609|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
32779810|NCT04080739|No Intervention|Control Group|No regional anesthetic of any kind during the surgical procedure.
33285610|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
33285611|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
33285612|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
32779811|NCT05491993|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study. One arm was for obtaining data on the Rapid Antigen Test for Covid-19. The comparator arm was to obtain data from the RT-PCR.
32937851|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
32937852|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
32937853|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
32937854|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
32937855|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
32937856|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
32937857|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
32937858|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
32937859|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
32937860|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
33285613|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
33285614|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
32937861|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
33285615|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
33285616|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
33285617|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
32937862|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
32937863|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
33285618|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
33285619|NCT01011296|Experimental|Single IV Dose 1|
33285620|NCT01011296|Experimental|Single IV Dose 2|
33285621|NCT01011296|Experimental|Single IV Dose 3|
33285622|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
33285623|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
33285624|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
33285625|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate Otago and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
33402134|NCT04694248|Experimental|Anticoagulant plus antiplatelet therapy|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
32937864|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
32937865|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
32937866|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
32937867|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
32937868|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
32937869|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
32937870|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
32937871|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
32937872|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
32937873|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
32937874|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
32937875|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
32937876|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
32937877|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
33083981|NCT04574206|Experimental|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
33285626|NCT03853148|Experimental|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
33285627|NCT04369976|Experimental|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
33285628|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
33285629|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
33285630|NCT01043601|Placebo Comparator|Inhaled Placebo|
33285631|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
33285632|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
33285633|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
33285634|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
33285635|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
33285636|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
33285637|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
33285638|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
33285639|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
33285640|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
33402135|NCT04724980|Experimental|Adjuvant PRGN-2012|Four PRGN-2012 administrations (on days 1, 15, 43, and 85) via subcutaneous injection.
32779812|NCT03986749|Experimental|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
32779813|NCT04074733||Patients with fractures|
32779814|NCT04071457|No Intervention|Study Entry / Screening|Study entry/screening to follow patient until Maintenance.
32779815|NCT04071457|Active Comparator|Arm 1: Lenalidomide|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.
32779816|NCT04071457|Experimental|Arm 2: Lenalidomide + Daratumumab/rHuPH20|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.
32779817|NCT04071457|Active Comparator|Arm 1a: Continue Lenalidomide|MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.
32779818|NCT04071457|No Intervention|Arm 1b: Stop Lenalidomide|MRD- and randomized to Arm 1b: Discontinue protocol therapy.
32779819|NCT04071457|Active Comparator|Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20|MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.
32779820|NCT04071457|No Intervention|Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20|MRD- and randomized to Arm 2b: Discontinue protocol therapy.
32779821|NCT05485285||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
32779822|NCT05485285||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
32779823|NCT05488717|Experimental|Application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
32779824|NCT05491681|Experimental|Low dose|Experimental: Cohort 1 Low dose, 20M cells, 3 patients
32779825|NCT05491681|Experimental|Medium dose|Experimental: Cohort 2 Med dose, 100M cells, 3 patients
33402136|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
32937878|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
32937879|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
32937880|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
32937881|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
32937882|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
32937883|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
32937884|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
32937885|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
32937886|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
32937887|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
32937888|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
32937889|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
32937890|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
32937891|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
32937892|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
32937893|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
32937894|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
32937895|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
32937896|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
32937897|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
32937898|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
32937899|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
32937900|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
32937901|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
32937902|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
32937903|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
32937904|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
32937905|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
32937906|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
32937907|NCT02862080|Experimental|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
33083982|NCT04574206|Sham Comparator|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
33285641|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
33285642|NCT00441987|Experimental|Single Dose of GSI-953|
33285643|NCT00395343|Experimental|1|sitagliptin
33285644|NCT00395343|Placebo Comparator|2|Placebo
33285645|NCT00560573|Experimental|1|
33285646|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
33285647|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
33285648|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
33285649|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
33285650|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
33285651|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
33285652|NCT00946361||Diagnostic|
33285653|NCT05301257|Experimental|Experimental Group SOSteniamoci|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
33285654|NCT05301257|No Intervention|Control Group SOSteniamoci|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
33285655|NCT00941837|Experimental|Olive Oil|
33285656|NCT00941837|Experimental|Coconut oil|
33285657|NCT00941837|Experimental|Palm Olein|
33285658|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
33285659|NCT00946517||Child|Type 1 diabetics
32937908|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
32937909|NCT02862080|Experimental|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
32937910|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
32937911|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
32937912|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
32937913|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
32937914|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
32937915|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
33083983|NCT04574011|Experimental|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
33285660|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
33285661|NCT05280197|Experimental|liposomal bupivacaine plus free bupivacaine|
33285662|NCT05280197|Placebo Comparator|normal saline|
33285663|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
33285664|NCT00946595|Experimental|lopinavir/ritonavir|
33285665|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
33285666|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
33285667|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
33285668|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
33285669|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
33285670|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
33285671|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
33285672|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
33285673|NCT01011452|Placebo Comparator|Placebo|
33083984|NCT04574011|Experimental|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
33083985|NCT04721379|Experimental|Heartfulness Meditation Group|Participants will be guided through relaxation and meditation session with a Heartfulness trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
33083986|NCT04721379|Active Comparator|Control Group with Self Meditation|Participants will be self-guided through relaxation and meditation session without a trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
33083987|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
33083988|NCT04573543||Controls|40 healthy controls
33083989|NCT00226109|Active Comparator|A|
33083990|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
33083991|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
33083992|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
33083993|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
33083994|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
33083995|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
33083996|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
33083997|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
32779826|NCT05491681|Experimental|High dose|Experimental: Cohort 3 High dose, 200M cells, 3 patients
33285674|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
33285675|NCT00490022|Placebo Comparator|2|Placebo gel for one month
33285676|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
33285677|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
33285678|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
33285679|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
33285680|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
33285681|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
33285682|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
33285683|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
32779827|NCT05485207|Experimental|Transvaginal Botulinum Toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
32779828|NCT03897907|Experimental|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
33285684|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
33285685|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
32779829|NCT03897907|Placebo Comparator|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
32779830|NCT05488639||Football players at the FIFA U-20 Women's World Cup 2022.|"Upper age limit: all players must be a maximum of 20 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2002).~Lower age limit: all players must be at least 16 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2006)."
32779831|NCT05488639||Football players at the FIFA U-17 Women's World Cup 2022.|"Upper age limit: all players must be a maximum of 17 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2005).~Lower age limit: all players must be at least 15 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2007)."
33083998|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
33083999|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
33084000|NCT04573621|Active Comparator|Pelvic drain|Placement of a pelvic drain
33084001|NCT04573621|Experimental|No pelvic drain|No pelvic drain placed
33084002|NCT04573465|Experimental|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
33084003|NCT04573465|Experimental|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
33084004|NCT04573465|Active Comparator|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
33084005|NCT04573153|Experimental|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
32779832|NCT03879109|Experimental|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
32779833|NCT03879109|Active Comparator|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
32779834|NCT05485129|Experimental|Intervention|
32779835|NCT03871543|Other|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
32779836|NCT03871543|Other|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
32779837|NCT04032535|Experimental|SAD|"Single Ascending Dose of 2 cohorts:~Cohort A will be administered three ascending dose levels: 0.2 mg (dose 1), 2 mg (anticipated dose 3), 8 mg (anticipated dose 5) or placebo; Cohort B will be administered three ascending dose levels: 1 mg (anticipated dose 2), 4 mg (anticipated dose 4), 14 mg (anticipated dose 6, maximum dose) or placebo."
32779838|NCT04032535|Experimental|MAD|"Multiple Ascending Dose of 4 cohorts:~Cohort A will be administered with 2 mg (anticipated dose 1) or placebo; Cohort B will be administered with 4 mg (anticipated dose 2) or placebo; Cohort C will be administered with 8 mg (anticipated dose 3) or placebo; Cohort D will be administered with 12 mg (anticipated dose 4) or placebo;"
32779839|NCT04032535|Experimental|2way crossover|Two 28-day treatment periods (Period 1 and Period 2), separated each by 32 days (up to 40 days) wash-out period, in crossover design. The treatment period will consist in repeated administrations of CHF 6523 at one dose level or placebo.
32779840|NCT03866239|Experimental|Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab|Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).
32779841|NCT05488327|Experimental|Intervention with lenalidomide|All subjects will be treated with lenalidomide 5mg/day.
32779842|NCT04023487|Experimental|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
32779843|NCT04023487|No Intervention|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
32779844|NCT05488171|Experimental|Methylone|Methylone (3,4-methylenedioxy-N-methylcathinone) 200 mg, single dose, oral administration
32779845|NCT05488171|Active Comparator|3,4-methylenedioxymethamphetamine (MDMA)|MDMA (3,4-methylenedioxymethamphetamine) 100 mg, single dose, oral administration
32779846|NCT05488171|Placebo Comparator|Maltodextrin|Placebo, single dose, oral administration
32779847|NCT05480137|Other|plain balloon|plain balloon is used in BPA
32779848|NCT05480137|Other|NSE scoring balloon|NSE scoring balloon is used in BPA
32779849|NCT05485051|Experimental|Chlorhexidine baths|All patients in the cluster randomized to the intervention arm will receive baths using a 2% chlorhexidine digluconate solution with surface-active agents during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
32779850|NCT05485051|Active Comparator|Usual baths|All patients in the cluster randomized to the intervention arm will receive baths using soap and water according to the current practice in each center during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
32779851|NCT05484973|Experimental|All patients will use AMMA|Device: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
32779852|NCT05479903|Experimental|acupuncture stroke group|
32779853|NCT05479903|Sham Comparator|sham acupuncture stroke group|
32779854|NCT05479903|Placebo Comparator|no acupuncture stroke group|
32779855|NCT05479903|Placebo Comparator|acupuncture healthy group|
32779856|NCT05479903|Experimental|computerized cognitive training group|
33084006|NCT04573153|Placebo Comparator|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
32779857|NCT05479903|Placebo Comparator|tranditional cognitive training group|
32779858|NCT05479903|Experimental|aerobics group|
32779859|NCT05488093|Experimental|total knee replacement surgery group|"The study will be conducted in 4 visits:~a pre-inclusion visit during a routine care consultation where the patient will be informed about the study~a V1 inclusion visit (pre-surgery of the knee) during which informed consent, clinical examination, VAS, self-questionnaires, DXA, X-SENS sensor, MRI, isokinetism will be collected~a V2 visit during the operation, during which biological samples will be taken (muscle biopsy and collection of osteoarticular parts)~a V3 visit at 12 months with a clinical examination, EVA, self-questionnaires, DXA, isokinetics, X-SENS sensor, and collection of adverse events."
32900277|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
33285686|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
33285687|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
33285688|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
33285689|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
33285690|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
33084007|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
33084008|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
33084009|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
33084010|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
33084011|NCT04573192|Experimental|Phase 1 part: Dose Finding|"Phase I part:~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.~The RD will be confirmed following a traditional 3+3 design.~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
33084012|NCT04573192|Experimental|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.~Treatment Arm 1: L19TNF plus Lomustine~Treatment Arm 2: Lomustine"
33084013|NCT04573270|Experimental|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
33084014|NCT04573270|Placebo Comparator|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
33084015|NCT04573270|Experimental|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
33084016|NCT04573270|Placebo Comparator|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
33084017|NCT04572919|Active Comparator|group A|Patients were randomly assigned to undergo lateral advancement flap
33084018|NCT04572919|Active Comparator|group B|Patients were randomly assigned to undergo classic Limberg flap
32900278|NCT04934696|Experimental|BMS-986166 + Oral contraceptive|
33285691|NCT00950417|Experimental|Esophageal Cancer|
33084019|NCT04572685|Experimental|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
33285692|NCT03996902|Experimental|Tailored intervention|Brief Motivational Smoking Intervention
33285693|NCT03996902|Experimental|Control|Intervention consistent with standard clinical practice (Control)
33285694|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
33084020|NCT04572685|Experimental|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
33084021|NCT04572685|Experimental|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
33285695|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
32779860|NCT05484817||Normal cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the normal cardiac function groups are defined as GLS < -18%.
33285696|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
33285697|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
33285698|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
32900279|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
33285699|NCT00485732|Experimental|Cervarix Group|
32900280|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
32900281|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
33285700|NCT00485732|Placebo Comparator|Placebo Group|
33285701|NCT01043055||Breast Cancer Patients|
33285702|NCT01043055||Healthy Control Group|
32900282|NCT04924400|Active Comparator|CHIP Program|GHP members randomized to the intervention arm will participate in the CHIP Program.
32900283|NCT04924400|Active Comparator|Usual Diabetes Care|GHP members assigned to the control arm will receive the routine standard of care for GHP members.
33285703|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
33285704|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
33285705|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
33285706|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
33285707|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
33285708|NCT00560417|Active Comparator|Glargine|Insulin Glargine
33285709|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
33285710|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
33285711|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
33285712|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
33285713|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
32900284|NCT04919954|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 7 doses of tebipenem, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours following the last dose.
32900285|NCT04919954|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
32900286|NCT04892186|Experimental|Myo-inositol|30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g, orally, twice a day for 6 months.
32900287|NCT04892186|Active Comparator|Metformin|30 women with resistance insulin or glucose intolerance will receive metformin, orally, three times a day for 6 months
32900288|NCT01684904|Experimental|Proton radiation|Proton radiation
32900289|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
32900290|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
32900291|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
32900292|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
32900293|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
32900294|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
32900295|NCT01283555|Experimental|User-Filled Applicator|
32900296|NCT01283555|Other|Prefilled applicator|
32900297|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
32900298|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
32900299|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
32900300|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
32900301|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
32900302|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
32900303|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
33285714|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
33285715|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
33285716|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
33285717|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
33285718|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
33285719|NCT00946907|Active Comparator|aspirin|
33285720|NCT00946907|Placebo Comparator|placebo|
33285721|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
32937916|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
33285722|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
33285723|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
33285724|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
33285725|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
33285726|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
32937917|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
32937918|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
32937919|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
32937920|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
32937921|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
32937922|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
32937923|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
32937924|NCT04333381|Active Comparator|Common Practice|Patients included in the phase I will receive common practice.
32937925|NCT04333381|Experimental|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
32937926|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
32937927|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
32937928|NCT02936479|Experimental|Berinert treatment|
33285727|NCT00950573||kidney transplantation|patients treated with renal transplantation
33285728|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
33285729|NCT00345345|Experimental|Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
33285730|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
33285731|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
33285732|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
33285733|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
33285734|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:~Start treatment when 2 consecutive levels CMV PCR >200copies / ml~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
33285735|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~Stop treatment when 2 levels CMV PCR <3,000 copies / ml~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
33285736|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
33285737|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
33285738|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
33285739|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
33285740|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
33285741|NCT03965351|Experimental|Probenecid|the study medication (probenecid) as well as a placebo.
33285742|NCT03965351|Placebo Comparator|Placebo|placebo compared to probenecid
33285743|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
32937929|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
32937930|NCT00374881|Active Comparator|1|Morphine High Dose
32937931|NCT00374881|Placebo Comparator|2|Morphine Low Dose
32937932|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
32937933|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
32937934|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
32937935|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937936|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937937|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937938|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
33285744|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
32744344|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
32744345|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
32744346|NCT04870671|Experimental|High Adherence|TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills
32744347|NCT04870671|Experimental|Low Adherence|TDF/FTC (300/2200 mg), 3 pills/week. Total of 6 pills
32744348|NCT04388241|Experimental|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
32744349|NCT04876911|No Intervention|Control/Usual Care|No intervention delivered and care is provided as usual.
32744350|NCT04876911|Experimental|Simulated Presence Therapy (SPT)|Participants begin to receive the SPT.
32744351|NCT04876833||HC，healthy control|18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.
32744352|NCT04876833||HG，high-risk COPD group|18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.
32744353|NCT04876833||EG，early COPD group|"18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：~Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;~Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；~FEV1 decline (≥60 mL per year)."
32744354|NCT04876833||MG，mild and moderate COPD group|18-65 years old，FEV1/FVC<70%，FEV1%predicted ≥50%.
32744355|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
32744356|NCT03046485|No Intervention|Wait list control|Wait list control
32744357|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
32744358|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
32744359|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
32744360|NCT04865757|Experimental|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
32744361|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
32744362|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
32744363|NCT04146207|Experimental|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
32744364|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
32744365|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
32744366|NCT03046641|Experimental|continuous training group|With the continuous training program
32744367|NCT03046641|Experimental|interval training group|With the interval training program
32779861|NCT05484817||Impaired cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the impaired cardiac function groups are defined as GLS ≥ -18%.
32779862|NCT05479825|Experimental|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
32779863|NCT05484583|Experimental|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin
32779864|NCT05479747|Active Comparator|Ibuprofen (Brufen)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
32779865|NCT05479747|Experimental|Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
32779866|NCT05479747|Active Comparator|Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
33285745|NCT00942695|Other|base|average American diet without pistachios
32779867|NCT05479747|Placebo Comparator|Placebo pills (Sugar pills)|Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics & industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.
32779868|NCT05487937||Toleriane Ultra|Participants are asked to apply the study product twice daily (morning and evening) at home for 28 days.
32779869|NCT05487781|Experimental|Group 1|Tyrphostin AG-17 content 10 mg with 700 mg of L-Carnitine tartrate
32779870|NCT05487781|Experimental|Group 2|Tyrphostin AG-17 content 3.3 mg with 700 mg of L-Carnitine tartrate
32779871|NCT05487781|Experimental|Group 3|Tyrphostin AG-17 content 1 mg with 700 mg of L-Carnitine tartrate
32779872|NCT05487469|Experimental|Thymosin alpha 1|
32779873|NCT05487469|Sham Comparator|Blank control|
32779874|NCT05484427|Experimental|Telemedicine arm|Participants in this arm will be follow up by telemedicine control (via emails) instead of regular controls. They will upload the data from their devices (pump, CGM) to cloud system on their own. All instructions what to change they will recive by email only.
32779875|NCT05484427|No Intervention|Outpatient clinic meetings arm|Participants in this arm will normally come for the regular meetings with their diabetologist to the outpatient clinic.
32779876|NCT05484349|Experimental|group A|Tizanidine Hydrochloride 1 mg Tid
32779877|NCT05484349|Experimental|group B|Tizanidine Hydrochloride 2 mg Tid
32779878|NCT05484349|Placebo Comparator|group C|placebo 1 tablet Tid
32779879|NCT05484271||Leaf-like and Cord-like type|Under arthroscopy, the anatomy of middle glenohumeral ligament was leaf-like or cord-like.
32779880|NCT05484271||Absent type|Under arthroscopy, the anatomy of middle glenohumeral ligament was absent.
32779881|NCT05484271||Burford complex type|Under arthroscopy, the anatomy of middle glenohumeral ligament manifested the burford complex.
32779882|NCT05479435|Experimental|Blue Prescription Group|Participants will get an exercise program, which is designed by their needs, desires and abilities. They will perform a desired exercise program 3 days a week and they will make an interview for motivation and/or modifying the program one day a week. They will write an activity diary.
32779883|NCT05479435|Active Comparator|Video Based Home Exercise Group|Participants will get videos by different ways (closed link youtube, whatsapp, flash driver etc.). They will perform exercises 3 days a week. İnvestigator will phone them to ask whether they do the program or not. They will write an activity diary.
32779884|NCT05479435|Active Comparator|Supervised Exercise Group|Participants will perform an exercise program 3 days a week with a physiotherapist. The group will be held maximum 10 people.
32779885|NCT05479357|Active Comparator|Oxytocin|the control group will be given 10 iu intravenously.
32779886|NCT05479357|Active Comparator|Carbetocin|the treatment group will be given 100 microgram intravenously.
32779887|NCT05487391|Experimental|QL1706 plus Platinum-based chemotherapy|QL1706(5mg/kg Q3W IV) plus Platinum-based chemotherapy
32779888|NCT05487391|Placebo Comparator|Placebo plus Platinum-based chemotherapy|Placebo(5mg/kg Q3W IV) plus Platinum-based chemotherapy
32779889|NCT05484193|Experimental|GnRH-agonist group|In the GnRH-a group, LPS was initiated on the evening after the OPU, using Nafareline (Synarel nasal spray 200mg used once), followed by twice daily (total 400mg/day) until the day of serum β-hCG pregnancy test, and then stopped, regardless of the test results
32900304|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
32900305|NCT00345332|Placebo Comparator|1|Placebo
32900306|NCT00345332|Experimental|2|Botox
32900307|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
32900308|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
32900309|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
32900310|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
32900311|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
32900312|NCT00305084|Experimental|A|
32900313|NCT00305162|Experimental|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
32937939|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937940|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937941|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937942|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937943|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
32937944|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
33285746|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
33285747|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
33285748|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
32744368|NCT04876755|Experimental|Cohort 1|Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.
32744369|NCT04876755|Experimental|Cohort 2|Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
32744370|NCT04876755|Experimental|Cohort 3|Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
32744371|NCT04876755|Experimental|Cohort 4|Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
32744372|NCT04876755|Experimental|Cohort5|Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
32744373|NCT04876755|Experimental|Cohort 6|Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
32744374|NCT04876287||patients treated by 1.1 GBq|
32744375|NCT04876287||patients treated by 3.7 GBq|
32744376|NCT04876521|Experimental|Amisulpride Group|The patients will receive low dose Amisulpride at 100-300 mg/day.
32744377|NCT04876521|Active Comparator|Olanzapine-Fluoxetine Group|the patients will receive Olanzapine-Fluoxetine Combinations at 5/10-5/20 mg/day.
32744378|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
32744379|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
32744380|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
32744381|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
32744382|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
32744383|NCT04753138|Experimental|SCT with BC sealer|The teeth will be obturated with the single cone technique and BC sealer
32744384|NCT04753138|Active Comparator|WVC with AH+ sealer|The teeth will be obturated with warm vertical compaction and AH+ sealer
32744385|NCT02181556|Experimental|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
32744386|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
32744387|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
32744388|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
32744389|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
32744390|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
32744391|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
32744392|NCT04429815||Active smokers.|Active smokers since October 2019.
32744393|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
32744394|NCT04429815||Non-smoking.|Person who's never smoked before.
32744395|NCT03044769||Patient with CLA with surgery|
32744396|NCT03044769||Patient with CLA without surgery|
32744397|NCT04876443||Alcohol-related liver disease|
32744398|NCT04870437|Experimental|Extracorporeal phototherapy|
32744399|NCT04865991|Experimental|TCI propofol group|Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
32744400|NCT04865991|Active Comparator|sevoflurane group|Subjects in the sevoflurane group received sevoflurane 2 volume%, which were titrated up/down every 5 minutes to get a targeted BIS score of 40-60.
32779890|NCT05484193|Active Comparator|Progesterone group|In the progesterone group, LPS was initiated on the morning after OPU, using micronized progesterone ( PV Utrogestan 300mg, 3 times daily), until serum β-hCG pregnancy tests results were available. If a β-hCG pregnancy was confirmed, LPS was continued until the end of the 8th gestational week
32779891|NCT05479279|Experimental|Neck Stabilization Training Program|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release postural re-education cranio-cervical isometrics training of intrascapular, shoulder and upper extremity musculature resistance training with theraband
32779892|NCT05479279|Active Comparator|Conventional physical therapy|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release
32779893|NCT05484115|Active Comparator|Standard endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|
32779894|NCT05484115|Active Comparator|Endosuture aneurysm repair (ESAR) with the Endurant II/IIs in conjunction with Endoanchors|
32779895|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
32779896|NCT05487157||Actively employed social workers in Hungary|"Eligibility criteria: Social workers in Hungary, who are actively employed, 18 years of age or older, working in the field of elderly care.~Exclusion criteria: people, who do not have an active employment; currently have no job; working online; non-professional staff working in social care (eg. cleaning, maintenance)"
32779897|NCT05484037|Experimental|Intervention group|Intervention group/telehealth Arm: will be provided access to their electronic asthma action plan (eAAP) via a web Uniform Resource Locator (URL), receive weekly short message service (SMS) check-ins for one year, and be able to communicate with the site's research coordinator (RC) and Certified Respiratory Educator (CRE) via an integrated and interactive (two-way) SMS feature to manage their asthma
32779898|NCT05484037|Active Comparator|Control group|Control group/standard care Arm: will receive their written Asthma Action Plan (wAAP) and information on how to use it by the site's Certified Respiratory Educator to manage their asthma
33084022|NCT04572724|Experimental|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
33084023|NCT04572724|Active Comparator|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
33084024|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
33084025|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
32779899|NCT05487079||Diabetic|"Diabetes will be defined as below (any or combination):~2h-OGTT: ≥ 11.1 mmol/L~FPG (fasting plasma glucose): ≥ 7.0 mmol/L~HbA1c; ≥ 48 mmol/mol (6.5%)"
32779900|NCT05487079||Pre-Diabetic|"Prediabetes will be defined as as below (any or combination)~2h-OGTT is between 140 and 199 mg/dL (7.8-11.0 mmol/L)~FPG values is between 100 and 125 mg/dL (5.6-6.9 mmol/L)~HbA1c is between 42 and 47 mmol/mol (6.0 - 6.4%)"
32779901|NCT05487079||Non-Diabetics|"Normal glucose tolerance (NGT)~2h-OGTT; < 140 mg/dL (7.8 mmol/L).~FPG; < 100 mg/dL (5.6 mmol/L) and~HbA1c; < 42 mmol/mol"
32779902|NCT04274335|Experimental|Intravenous tranexamic acid|
32779903|NCT04274335|Experimental|Intramuscular tranexamic acid|
32779904|NCT04274335|Experimental|Oral liquid tranexamic acid|
32779905|NCT04274335|No Intervention|No tranexamic acid|
32779906|NCT04274179|Experimental|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
32779907|NCT04274179|Active Comparator|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual.
32779908|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
32779909|NCT05479201||Children 4-8 years of age|
32779910|NCT05479123|Experimental|ter in die (TID)three times a day|
32779911|NCT05479123|Experimental|bis in die (BID)twice a day|
32779912|NCT05479123|Active Comparator|Control|
32779913|NCT05478967|Experimental|IVA group|Received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
32779914|NCT05478967|No Intervention|control group|Did not receive IVA injection before vitrectomy
32779915|NCT05483959|Experimental|BIPAP group|Mechanically ventilated ARDS patients on BIPAP mode of ventilation
32779916|NCT05483959|Experimental|SIMV PC group|Mechanically ventilated ARDS patients on SIMV PC mode of ventilation
32779917|NCT04268641|Experimental|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
32779918|NCT04268641|Experimental|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
32779919|NCT04268641|Experimental|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
33084026|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
33084027|NCT04572607|No Intervention|Control group 1|
33084028|NCT04572607|No Intervention|Control group 2|
33084029|NCT04572607|No Intervention|Control group 3|
33084030|NCT04572607|No Intervention|Control group 4|
33084031|NCT04572607|No Intervention|Control group 5|
33084032|NCT04572607|No Intervention|Control group 6|
33402137|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
33402138|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
33402139|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
32779920|NCT04268641|Experimental|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
32779921|NCT04268641|Experimental|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
32779922|NCT04268641|Experimental|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
33084033|NCT04572607|No Intervention|Control group 7|
32779923|NCT04268407|Experimental|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
32779924|NCT04268407|Other|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
32779925|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
32779926|NCT05487001|Experimental|dexamethasone group|a iliopsoas plane block before surgery
32779927|NCT05487001|Sham Comparator|sham group|sham block before surgery
32779928|NCT05483725||First booster dose group|
32779929|NCT05486845|Experimental|adults|People who use the lower back pillow.
32779930|NCT05478889||Minimally invasive pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following minimally invasive approach (laparoscopic or robotic). Hybrid (hand assisted) precedures will be included in the minimally invasive cohort.
33084034|NCT04572607|Experimental|Honey group 1|
33084035|NCT04572607|Experimental|Honey group 2|
33084036|NCT04572607|Experimental|Honey group 3|
33084037|NCT04572607|Experimental|Honey group 4|
33084038|NCT04572607|Experimental|Honey group 5|
33084039|NCT04572607|Experimental|Honey group 6|
33084040|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
33084041|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
33084042|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
33084043|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
33084044|NCT00235365|Active Comparator|waiting list|waiting list control
33084045|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
33084046|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
33084047|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
33084048|NCT04572334|Other|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
33084049|NCT04572334|Other|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
33084050|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33084051|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33084052|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
33084053|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
33084054|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
33084055|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
33084056|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
33084057|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
33084058|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
33084059|NCT00235404|Experimental|Intermediate community hospital|
32779931|NCT05478889||Open pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following open (laparotomy) approach.
32779932|NCT05478811|Active Comparator|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigation
32779933|NCT05478811|Active Comparator|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method.
32779934|NCT04009291|Experimental|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
33084060|NCT00235404|Active Comparator|Usual care|
33084061|NCT01580839|Experimental|intravenous tissue plasminogen activator|
33084062|NCT01580839|Placebo Comparator|Placebo|
33084063|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
33084064|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
33084065|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
33084066|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
33084067|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
33084068|NCT03450226|No Intervention|control|patients will be controlled
33084069|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction >50 mL/time), and chylous ascites.~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
32779935|NCT04009291|Experimental|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
32779936|NCT04009291|Experimental|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
32779937|NCT04009291|Placebo Comparator|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
32779938|NCT04009291|Experimental|Open-Label Extension Period|Subjects who complete the four-week blinded period are assigned to open-label treatment with TransCon PTH for up to 210 weeks, with up to an initial 14 weeks of TransCon PTH titration and standard of care optimization, followed by approximately 196 weeks of individualized dosing
32779939|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
32779940|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
32779941|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
32779942|NCT05486767||Community cohort|SIRIUS study team will travel to pre-determined sociomes and perform transient elastography and other examinations
32779943|NCT05486767||Outpatient cohort|Patients recruited during the elective / preventive examinations at the primary-care clinics or at other outpatient-clinics will have performed Hep-calculator for FIB-4 w/wo transient elastography
32779944|NCT05486689|Experimental|Standard Program|Pulmonary Rehabilitation
32779945|NCT05478655||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation In all patients, the assessment of anesthetic risk was carried out according to the ASA scale.The basic tool for pain intensity research was a visual analog scale.The study of the neuropathic component of pain was carried out using the diagnostic questionnaire for the detection of neuropathic pain Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. The presence of post-traumatic stress disorders was studied using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with the results of treatment was studied using the Chaban Quality of Life Scale.
32779946|NCT05478655||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception was the study period during treatment at the military medical clinical center: here it was 14 days."
32900314|NCT00305162|Active Comparator|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus & infusion (to match) + placebo capsules (to match) post infusion
33084070|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
33084071|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
33084072|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
33084073|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
33084074|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
33084075|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
33084076|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
33084077|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
33084078|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
33084079|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
33084080|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
33084081|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
33084082|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
33084083|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
33084084|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
33285749|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
33285750|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
32744401|NCT04870203|Experimental|baricitinib + adalimumab|
32744402|NCT04870203|Placebo Comparator|baricitinib + placebo|
32744403|NCT04865523|Experimental|Manual Lymphatic Drainage|
32744404|NCT04865523|No Intervention|No intervention|
32744405|NCT04875897|Experimental|treatment with keepMED PAP device|Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
32744406|NCT04381143|Active Comparator|Aspirin|Aspirin tablet 100mg daily
32744407|NCT04381143|Placebo Comparator|Matching Placebo|Placebo tablet 1 pill daily
32744408|NCT04865211|Experimental|Liposomal Bupivicaine|Administration of a combination of lioposomal bupivicane 20ml/266mg mixed with 20mL of 0.375% bupivicaine
32744409|NCT04865211|Active Comparator|Bupivicane|Administration of 40 ml of 0.375% Bupivicaine with epinephrine 1:400,000
32744410|NCT04865211|Placebo Comparator|Placebo|Saline injection with 40mL preservative-free saline
32744411|NCT04865445|Experimental|AT-527 550 mg + midazolam (simultaneous)|n=12
32744412|NCT04865445|Experimental|AT-527 mg + midazolam (staggered)|n=12
32744413|NCT04875819|Experimental|Menveo + Bexsero|
32744414|NCT04875819|Experimental|Prevenar13 + Pneumovax23|
32744415|NCT04875663|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
32744416|NCT04875663|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
32744417|NCT04875663|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
32744418|NCT04869423|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. Assessments will be conducted before and after the 7wk program but patients in this group will not take part in it
32744419|NCT04869423|Experimental|Experimental group|Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
32744420|NCT04875741|Active Comparator|Neural mobilization|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
32744421|NCT04875741|Experimental|Muscle energy technique|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Muscle energy technique will be applied to the subjects in addition to conventional treatment.
33084085|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
33084086|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
33084087|NCT00413387|Experimental|1|chf1535
33084088|NCT00413387|Active Comparator|2|Symbicort
33084089|NCT03451786|Experimental|Treatment group|
33084090|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
33285751|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
32779947|NCT03981445|Experimental|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitis C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
33285752|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
33285753|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
33285754|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
33285755|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
33285756|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
32779948|NCT03981445|Experimental|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
32779949|NCT05483647|Active Comparator|G1|Intravenous sedation with infiltrative local anaesthesia
32779950|NCT05483647|Experimental|G2|Intravenous sedation with bilateral Erector Spine Plane Block
33285757|NCT00947687|Experimental|PUR003|
33285758|NCT00947687|Placebo Comparator|Placebo|
33285759|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
33285760|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
33285761|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
32779954|NCT05486377|Experimental|Remimazolam|General anesthesia with remimazolam-remifentanil TIVA.
32779955|NCT05486377|No Intervention|Desflurane|General anesthesia with maintaining with desflurane (induction:PPF, remifentanil CIV)
32779956|NCT05486299|Experimental|Single-port Endoscopic Surgical System|A novel robotic surgical system that can be configured for multi-port, single-port, or hybrid-port procedures. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen.
32779957|NCT05478421|No Intervention|Control group|Patients in control group will be treated by cyst enucleation.
33084091|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
33084092|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
33084093|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
33084094|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
33285762|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
33285763|NCT04279769|Experimental|Cohort 1|CB-280 twice daily at 50 mg for 14 days
33285764|NCT04279769|Experimental|Cohort 2|CB-280 twice daily at 100 mg for 14 days
33285765|NCT04279769|Experimental|Cohort 3|CB-280 twice daily at 200 mg for 14 days
33285766|NCT04279769|Experimental|Cohort 4|CB-280 twice daily at 400 mg for 14 days
33285767|NCT04279769|Placebo Comparator|Placebo|Placebo twice daily for 14 days
33285768|NCT04364555|Active Comparator|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
33402140|NCT02385448|Experimental|Dienogest|
33402141|NCT02385448|Active Comparator|Combined oral contraceptive pills|
32779958|NCT05478421|Experimental|Collagen sponge group|Cystic lesions in collagen sponge group will be filled by collagen sponge.
32779959|NCT05478421|Experimental|GBR group|Cystic lesions in GBR group will be filled by deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
32779960|NCT05478421|Experimental|CS/GBR group|Cystic lesions in GBR group will be filled by collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
32779961|NCT05483569|Other|Complex Decongestive Physiotherapy|CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, the Placebo Facial Release technique will be performed by keeping the physiotherapist's hand in contact with the patient's abdominal region without applying any pressure and tension during the breathing exercises. Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes.
32779962|NCT05483569|Experimental|Multidimensional Diaphragmatic Breathing Exercises and Facial Release Technique|"CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, Multidimensional Diaphragmatic Breathing Exercises and Facial Release technique will be applied. These two treatments consist of these sub-exercises. These; Mechanical nose opening techniques, Intermittent Sniffing exercise, Diaphragm Awareness and Exercise Short Protocol, Thorax mobilization exercises, Myofascial diaphragm release techniques, Myofascial release exercises and postures and, Pelvic floor myofascial release postures.~Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes."
32779963|NCT05478343|Experimental|IM21 CAR-T cells|
33285769|NCT04364555|Active Comparator|Placebo/active|The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
32779964|NCT05478187|Experimental|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
32779965|NCT05478187|Active Comparator|Control Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of traditional visual cues consisting of stripes on the floor
32779966|NCT05478109|Experimental|[14C]XZP-3287|Eligible healthy male subjects received a single oral 360 mg (radioactivity of 50µCi) dose of [14C]XZP-3287
32779967|NCT05475613|Experimental|HAIC combined with targeted therapy and immunotherapy as down-stage therapy of LT|HAIC combined with targeted therapy and immunotherapy as down-stage therapy before liver transplantation of hepatocellular carcinoma patients beyond Milan criteria
32779968|NCT05475535|Active Comparator|Active Control|
32779969|NCT05475535|Experimental|Cognitive Behavioural Therapy (CBT)|
32779970|NCT05475535|Experimental|Self-Compassion (SC)|
32779971|NCT05475535|Experimental|Cognitive Behavioural Therapy and Self-Compassion (CBT+SC)|
32779972|NCT05475457||Oregon County 1|First cohort to be trained and monitored with coaching in the R3 model.
32779973|NCT05475457||Oregon County 2|Second cohort to be trained and monitored with coaching in the R3 model.
33285770|NCT04364555|Placebo Comparator|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
33285771|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
32779977|NCT05475379|Experimental|Test vaccine group|"300 participants will receive Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)~Trade name: Typhocon®, Incepta Vaccine Ltd."
32779978|NCT05475379|Active Comparator|Reference vaccine group|"300 participants will receive Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV)~Trade name: Typbar-TCV®, Bharat-Biotech International Limited."
33084095|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32779979|NCT05475223|Other|Prospective|Standard of Care for Diagnosis and management of neonatal jaundice + End Tidal Carbon Monoxide measurement value
32779980|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
32779981|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
32779982|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
32779983|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
32779984|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
32779985|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
32779986|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
32779987|NCT03678025|Active Comparator|Arm I (SST)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.
32779988|NCT03678025|Experimental|Arm II (SST, prostatectomy or radiation therapy)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.
32779989|NCT03678025|Active Comparator|Step 1 (pre-randomization)|Standard treatment data collection prior to randomization
32779990|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
32779991|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
32779992|NCT03937921||Group 1 - Dotarem|Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
32779993|NCT03937921||Group 2 - Gadavist|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
32779994|NCT04542733|Active Comparator|mTORi with reduced-dose tacrolimus|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
32779995|NCT04542733|Active Comparator|reduced-dose tacrolimus|Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.
32779996|NCT05474755|Experimental|GP681 40mg|Patients in the GP681 40mg group will receive a single oral dose of GP681 tablet 40mg with 240mL water.
32779997|NCT05474755|Placebo Comparator|placebo group|Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with 240mL water.
32779998|NCT05474677|Experimental|intervention group|intervention group with the abdomen will be closed with continuous PDS 2\0 sutures
32779999|NCT05474677|Experimental|control group|the abdomen will be closed with continuous sutures size zero
32780000|NCT03937219|Experimental|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
33084096|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
33084097|NCT03455998||post surgery|Patienst consultation Questionnaires
33084098|NCT03455998||pre and post surgery|Patient consultation Questionnaires
33084099|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
33084100|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
33285772|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
33285773|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
33285774|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
33285775|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
33285776|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
33285777|NCT01045785||aspirin responsive|PFA Col/EPI normal
32780001|NCT03937219|Active Comparator|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
32780002|NCT04424017||Healthcare workers (HCWs)|
32780003|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
32780004|NCT04424017||Convalescents|
32780005|NCT05477797|Experimental|Ixazomib DX|Id: Ixazomib 4mg po d1,8,15; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
32780006|NCT05477797|Placebo Comparator|Lenalidomide DX|Rd: Lenalidomide 25mg qd d1-21; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
32780007|NCT05483179||Patients with colorectal cancer Patients with colorectal cancer who underwent elective surgery.|Diagnostic Test: Preoperative cardiopulmonary exercise tetsing Patients underwent a cardiopulmonary exercise test prior to surgery.
33084101|NCT00195052||Epilepsy Patients|
33285778|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
33285779|NCT01045083|Experimental|1|
33285780|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
33285781|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
33285782|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
33285783|NCT01045239|Active Comparator|532 nm green diode laser|
33285784|NCT01045317|Experimental|intravenous or oral administration|
33285785|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
33285786|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
33285787|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
33285788|NCT03081585||Healthy Controls|Normal weight, healthy female participants
33285789|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
33285790|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
33285791|NCT00553787|Placebo Comparator|Placebo|Placebo
33285792|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
33285793|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
33285794|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
33285795|NCT00943475|Active Comparator|anaesthesia, circumcision|
32780008|NCT05483101||alternative units|In alternative birth units : personalized follow-up with a midwife from the beginning of pregnancy, birth and parenthood preparation classes and delivery (birth room).
32780009|NCT05483101||conventional units|In standard maternity care, most full time midwives are rostered to work. They follow women during their pregnancy but not through labour. All low-risk pregnant women benefit from 5 prenatal consultations with a general practitioner, a midwife or an obstetrician, then 2 consultations with a midwife in maternity hospital of delivery. Couples have got the option to elaborate a birth project if desired
32780010|NCT04267315|Active Comparator|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
32780011|NCT04267315|Sham Comparator|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
32780012|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
32780013|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
32780014|NCT05473663|Active Comparator|Radiofrequency Ablation|Patient undergoing genicular nerve radiofrequency ablation.
32780015|NCT05473663|Sham Comparator|Sham|Patient undergoing sham.
32780016|NCT05482945|Experimental|Intervention|Patients will be ventilated with a mixture of Ar 70%/O2 30% for 4 hours
32780017|NCT05482945|No Intervention|Control-standard|Ventilation with a FiO2 of 30% in room air is continued for 4 hours.
33084102|NCT04572178|Experimental|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
33084103|NCT00199888|Experimental|124I-cG250|Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.
33084104|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part1|JAB-3068+JS001 dose escalation
32780018|NCT05473351||Thirst|Patients undergoing invasive mechanical ventilation for at least 24 hours in one of the participating centers
32780019|NCT05473117||Patient Group|A single cohort consisting of 160 patients referred for Coronary CT Angiography (CCTA) at risk of coronary artery disease. All patients will undergo both CCTA and CMRA
32780020|NCT05477641|Active Comparator|pericapsular nerve group block and lateral femoral cutaneous nerve block|Nerve blocks
32780021|NCT05477641|Active Comparator|fascia iliaca compartment block|Nerve block
33084105|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part2|JAB-3068+JS001 dose expansion
33084106|NCT04710498|Experimental|Atezolizumab|Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
33285796|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
33285797|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
33285798|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
32780022|NCT05482633|Experimental|Intervention Group|Experimental group is going to perform inspiratory muscle training exercises everyday for 8 weeks.
32780023|NCT05482633|No Intervention|Control Group|No new interventions will be given to control group.
32780024|NCT05477407|Experimental|Pathogenesis study|This pathogenesis study aimed to evaluate potential changes in adipose tissue after switching from an INSTI-based regimen (RAL or DTG or BIC) to TDF/FTC/DOR.
32780025|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
32780026|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
32780027|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
32780028|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).~For the Phase 2:~Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study."
32780029|NCT05472337|Experimental|Colchicine|Subjects allocated to the intervention group will receive colchicine + standard of care for 6 weeks.
32780030|NCT05472337|No Intervention|Standard of Care - Control|Subjects allocated to the control group will receive only standard of care for 6 weeks.
32900315|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
32780031|NCT05472259|Active Comparator|Arm A NALIRI|"Cycle length: 14 days~Day 1:~Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours~Liposomal irinotecan (FBE): 70 mg/m² IV* - Dilute in 500 mL DSW and administer over 90 min~5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.~Patients who are known to be homozygous for UGT1A1*28 should start treatment with 50 mg/m2 ONIVYDE. If they do not encounter drug related toxicities during the first cycle of therapy (started at a reduced dose of 50 mg/m2), they may have the dose of ONIVYDE increased to a dose of 70 mg/m2 in subsequent cycles based on individual patient tolerance."
32780032|NCT05472259|Experimental|Arm B NALIRINOX|"Cycle length: 14 days~Day 1:~Oxaliplatin 60 mg IV - Dilute in 500 mL D5W and administer over two hours (prior to leucovorin). Shorter oxaliplatin administration schedules (eg. 1mg/m2 per minute) appear to be safe.~Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours (after oxaliplatin)~Nanoliposomal irinotecan (FBE): 50 mg/m² IV - Dilute in 500 mL D5W and administer over 90 min~5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS."
32780033|NCT05482477|Experimental|preoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before anesthesia.
32780034|NCT05482477|Experimental|Intraoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 30 min before anesthesia to the end of surgery
32780035|NCT05482477|Experimental|Postoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, once a day, 30 minutes each time for 7 consecutive days after operation
32780036|NCT05482477|Experimental|Pre-and post-operative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 1 day before operation to 7 days after operation, once a day, 30 minutes each time.
32780037|NCT05482477|Experimental|Perioperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before the induction of anesthesia to the end of the surgery, 1 day before operation, and on the 1st, 2nd and 3rd days after surgery, 30 min once a day.
32780038|NCT05482477|Sham Comparator|Sham TEAS group|the electrodes were placed at the same time as the perioperative TEAS group, but the electronic stimulation was not applied and they were told that the TEAS treatment have no feeling
32780039|NCT05482477|No Intervention|Control group|receive standardised perioperative management such as preoperative health education, optimize anaesthesia scheme, intraoperative heat preservation, and reduce surgical trauma.
32780040|NCT04266145|Active Comparator|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
33084107|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
33084108|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
33084109|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
33084110|NCT04710264||recombinant hFSH|Patient stimulated with recombinant hFSH
33084111|NCT04710264||recombinant hFSH : r-hLH|Patient stimulated with recombinant hFSH : r-hLH ratio 2:1
33084112|NCT00199849|Experimental|Cohort 1|"4 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device. The 4 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 4 X 1 µg PMEDs in close proximity.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
33285799|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
33285800|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
32780041|NCT04266145|Active Comparator|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
32780042|NCT05477329|Experimental|Myopia control design spectacle lens|Test lenses
32780043|NCT05477329|Other|Single Vision design spectacle lens|Control lenses
32780044|NCT05477251|Experimental|microwave ablation|
33285801|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
33285802|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
32780045|NCT05477251|Active Comparator|lobectomy|
32780046|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
33285803|NCT00407745|Placebo Comparator|matched placebo|
33285804|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
33402142|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.~AKI recovery in less than 72 hours after AKI identification.~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
32780047|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
33402143|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.~AKI persistence 72 hours after AKI identification.~Normal or increased renal blood flow measured by TEE."
32780050|NCT04570969|No Intervention|standard of care|Peri-operative analgesia by opioids
32937945|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
32937946|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
32937947|NCT00375037|Active Comparator|Usual care|usual care
32937948|NCT02841397|Experimental|Test group|All subjects will be enrolled into the test group and will receive Masimo Pulse CO-Oximeter for measurement of various physiological parameters.
32937949|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
32937950|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
32937951|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
32780051|NCT04570969|Experimental|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
32780052|NCT05471635||Countries worldwide|Every country in the world for which vaccination data were available and variables of interest were accessible.
32937952|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
32937953|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
32937954|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
32937955|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
32937956|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
32937957|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
32937958|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32937959|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
32937960|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
32937961|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
32937962|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
32937963|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
32780053|NCT05482399|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
32780054|NCT05482399|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
32780055|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
32780056|NCT05482321||Group 1|SOP (healthy) subjects. Part I oF study (optimizing protocol).
32780057|NCT05482321||Group 2|Control (healthy) subjects. Part II of study (cross-sectional study)
32780058|NCT05482321||Group 3|T1D subjects. Part II of study (cross-sectional study)
32780059|NCT02554279|Experimental|menotropin|menotropins for injection
32780060|NCT02554279|Active Comparator|recombinant FSH|
32937964|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
32780061|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
32780062|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
32780063|NCT05476861||Having omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they intentionally forgot their insulin.
32780064|NCT05476861||Not intentionally omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they did not intentionally omit their insulin, but they did omit it.
32780065|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
32780066|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
32780067|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
32780068|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
32780069|NCT03337399|Experimental|Stepped PC|"Patients will receive Stepped PC~During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment~Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol~Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
32780070|NCT03337399|Experimental|Early Integrated PC|"Patients will receive Early Integrated PC~Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
32780071|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
32780072|NCT03328195|Active Comparator|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
32780073|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
32780074|NCT03328195|Active Comparator|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
32780075|NCT05482087|Experimental|XZP-3621|XZP-3621 single agent,500 mg oral tables，QD，continuously
32780076|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
32780077|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
32780078|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
33084113|NCT00199849|Experimental|Cohort 2|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 8 X 1 µg PMEDs.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
33084114|NCT00199849|Experimental|Cohort 3|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as a cluster dosage of 4 doses (day 1, 3, 5, 8) as 2 X 1 µg PMEDs per day.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
33084115|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
32780079|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
32780080|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
32780081|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
32780082|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
32780083|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
32780084|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
33285805|NCT00948233||Intervention|Educational video game
32780085|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
32780086|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
32780087|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
32937965|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
32780088|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
32780089|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
32780090|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
32780091|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
32780092|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
32780093|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
32780094|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
32780095|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
32780096|NCT02307513|Experimental|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
32937966|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
32937967|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
32937968|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
32937969|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
32937970|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
32937971|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
32937972|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
32937973|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
32937974|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
32937975|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
32937976|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
32937977|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
32937978|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
32937979|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
33285806|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
33084116|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
33084117|NCT00226733|Experimental|A|Interval exercise training with high intensity
33084118|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
33084119|NCT00415155|Experimental|A|
33084120|NCT04710225|Active Comparator|Group 1 (General anesthesia group)|"Upper limb fracture surgery will be performed with the aid of pneumatic tourniquet. General anesthesia will be induced with intravenous (IV) thiopental sodium and fentanyl.~Rocuronium will be used as the neuromuscular blocking agent. Endotracheal tube will be placed and anesthesia will be maintained with sevoflurane and IV fentanyl while the lungs were ventilated with O2-N2O (50-50%) to achieve an EtCO2 at 30-35 mm Hg."
33084121|NCT04710225|Active Comparator|Group 2 (Multiple injection axillary block group)|Multiple injection axillary block will be performed with the aid of a nerve stimulator. When the slight twitching of the motor response from the relevant muscles is achieved (at 0.4 mA, 2Hz, 0.1 ms) % 18-20 ml of Bupivacaine 0.5 (90-100 mg) will be injected.
32780097|NCT02307513|Experimental|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
32780098|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored CBT-based text-message program"
32780099|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
32780100|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
32780101|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
33084122|NCT04709913|Active Comparator|Active Treatment: HU6 Planned doses of HU6; N = 32|Drug = HU6 HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
33084123|NCT04709913|Placebo Comparator|Placebo Comparator Non-active study drug N = 8|Placebo Comparator, non-active study drug.
33084124|NCT00199381|Experimental|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
33084125|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
33084126|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
33084127|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
33084128|NCT04710069|No Intervention|Control/Usual Care|standard treatment of postoperative pain, which involves automatic prescription of a narcotic pain medication regimen after surgery,
33084129|NCT04710069|Experimental|Opt-in/POINT|An opt-in program (POINT), which requires the patient to consent to receiving a prescription for narcotics
33084130|NCT04709991||Procedures with EndoNaut|
33084131|NCT04709991||Procedures without Endonaut|
33084132|NCT04709952|Active Comparator|High real stimulation group|2mA tDCS stimulation daily (42 times) for 6 weeks
33084133|NCT04709952|Active Comparator|Low real stimulation group|1mA tDCS stimulation daily (42 times) for 6 weeks
32780102|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
32780103|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
32780104|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
32780105|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
32780106|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
32780107|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
32780108|NCT04896567|Experimental|Intervention|Patients will have kidney biopsy designated for cell isolation and culture.
32780109|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
32780110|NCT02329431|Active Comparator|support group|Parent-directed support group
32780111|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
32900316|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
33084134|NCT04709952|Sham Comparator|Sham stimulation group|sham stimulation daily (42 times) for 6 weeks
33084135|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
33084136|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
33084137|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
33285807|NCT00948467|Experimental|TAK-733|
33084138|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
33084139|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
33084140|NCT00227162|Active Comparator|Group 1|Positive affect
33084141|NCT00227162|Active Comparator|Group 2|Self-Affirmation
33285808|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
33285809|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
33285810|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
32900317|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
33285811|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
33285812|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285813|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285814|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285815|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285816|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285817|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
32900318|NCT00305942|Experimental|1|"Topotecan 4mg/m2 IV on days 1, 8.~Carboplatin AUC=5 IV day 1 only .~- Cycles are repeated every 21 days for > 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
32900319|NCT04737668|Other|Usual care|Pump refill will be performed as usual.
33285818|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285819|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285820|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285821|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285822|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
33285823|NCT00951197||elderly subjects retired from agriculture|
33285824|NCT00951353||Pediatric Renal Transplant Recipients|
33285825|NCT00951431|Experimental|PPI|
32900320|NCT04737668|Other|Virtual Reality|Children will play a commercially available VR game during pump refill
32900321|NCT04737668|Other|Distraction|Children will watch a commercial 360° music video on YouTube during pump refill
32900322|NCT02527200|Experimental|Liraglutide|
32900323|NCT02527200|Placebo Comparator|Placebo|
32900324|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
32900325|NCT00306488|Experimental|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
32900326|NCT04751006|Experimental|Gaze Group|Participants performed balance training with gaze stabilization exercises
32900327|NCT04751006|Other|Control Group|Participants performed balance training with saccade eye exercises
32900328|NCT05378334|Experimental|Combination Group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~HGXJT decoction: 1 dose daily, until tumor progression or accumulation for 1 year."
32900329|NCT05378334|Placebo Comparator|Control group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~Placebo: 1 dose daily, until tumor progression or accumulation for 1 year."
32900330|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
32900331|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
32900332|NCT05345418|Experimental|Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)|"Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.~- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation"
32900333|NCT05345418|Active Comparator|Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)|Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10
32900334|NCT00308282|Experimental|A|
32900335|NCT00308282|Placebo Comparator|B|
32900336|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
32900337|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
32780112|NCT04896021|Experimental|Intervention|On referral to Tasmanian pathology services for blood cholesterol, intervention participants will have their blood pressure measured and collated with other cardiovascular disease risk factors. An absolute cardiovascular disease risk score is calculated, interpreted according to guideline recommendations and reported to referring doctors via the established pathology system. High risk is highlighted in red as per usual practice for pathology tests outside of normal range, and advice provided regarding appropriate action according to National Vascular Disease Prevention Alliance guidelines.
32780113|NCT04896021|Active Comparator|Control|On referral to Tasmanian pathology services for blood cholesterol, control participants will have their blood pressure measured and collated with other cardiovascular disease risk factors as per the intervention arm. However, only the results relating to blood cholesterol are reported to the referring doctor, as per usual practice.
32780114|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
32780115|NCT02305797|Placebo Comparator|Placebo|Placebo
32780116|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
32780117|NCT01646073|Placebo Comparator|Placebo|placebo
32780118|NCT05438199|Experimental|apparatus use|"All participants will use the apparatus following the same procedures. They will weigh themselves on a scale located in the bathroom, use the apparatus with or without hats (hats refer to a plastic container used to catch stool/urine that needs to be placed between the toilet rim and the toilet seat and discarded after each use) and weigh themselves after using the toilet."
32780119|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
32780120|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
32780121|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
32780122|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
32900338|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
32900339|NCT00309140|Experimental|Enzastaurin|
32900340|NCT05397912||Women undergoing euploid, single frozen embryo transfer|Women age 18yo-45yo undergoing euploid, single, frozen embryo transfer with sonographically normal appearing uterus without uterine factor infertility
32900341|NCT05395806|Experimental|Health App|"This group will have access to a gamified App to help them to control their cardiovascular risk factors and to improve their adherence to medication therapy.~Half of the participants will be allocated to the App group. They will be stratified by age and cardiovascular risk level according to national standards based on the Framingham risk factors level."
32900342|NCT05395806|Active Comparator|Usual Care|This group will not have access to the gamified App and will receive their usual care at the primary care clinic. In addition, they will receive extra information on cardiovascular risk factors control. Both groups will have the same access to clinical checks and medications at the clinic.
32900343|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
32900344|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
32900345|NCT05597046||Healthcare Professionals|Planning Phase Interviews
32900346|NCT05595486|No Intervention|Usual Care|As a pragmatic trial, usual care will be defined by contemporary clinical standards. For maternal care, this includes a comprehensive medical visit between 4-12 weeks postpartum. This visit includes utilization of a validated screen for postpartum depression and, if that screen is positive, a clinical assessment and initiation of treatment (e.g. pharmacotherapy or referral for psychotherapy). In addition, this visit includes a discussion of contraception as well as supportive education on breastfeeding. For paternal care, clinical standards are gleaned from the AAP, ACOG, and USPSTF reports outlining mental health screening, reproductive health, and vaccine uptake. For infant care, standard pediatric care from the AAP and Bright Futures periodicity timeline and guidelines will be used. In addition, assignment in this arm will be given surveys at baseline, 1M, 2M, 4M, 6M, and 12M.
32900347|NCT05595486|Experimental|Baby2Home Intervention|Families randomized to the intervention arm will receive the B2H services. B2H is a novel digitized CC-based intervention delivered via a smartphone app available on iOS or Android phones, built by combining two successful programs: NICU2Home+ app and CC services. Using the UCD methodologies, AI-based communication within the app will include education for mothers and fathers on the standard of care regarding self-care and newborn care after hospital discharge as well as education, reminders and scheduling for recommended preventative healthcare services for themselves and their new infant.
32900348|NCT05376774||Critically ill patients|Patients admitted to intensive care units
33084142|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
32900349|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
32900350|NCT05540028|Experimental|Adult Cohort Group 1|Participants will receive a single 0.5mL dose of IVT PCV-25 administered by intramuscular injection on Day 1
32900351|NCT05540028|Active Comparator|Adult Cohort Group 2|Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1
32900352|NCT05540028|Experimental|Young Children Cohort Group 1|Participants will receive a single 0.5mL dose of IVT PCV-25 administered by intramuscular injection on Day 1
32900353|NCT05540028|Active Comparator|Young Children Cohort Group 2|Participants will receive a single 0.5mL dose of PCV 13 administered by intramuscular injection on Day 1
32900354|NCT05540028|Experimental|Infant Cohort Group 1|Participants will receive a 0.5mL dose of IVT PCV-25 administered by intramuscular injection at Day 1, Day 57, Day 113, and 12 months of age
32900355|NCT05540028|Active Comparator|Infant Cohort Group 2|Participants will receive a 0.5mL dose of PCV 13 administered by intramuscular injection at Day 1, Day 57, Day 113, and 12 months of age
32900356|NCT05344716|Experimental|Laser|Intraurethral and vaginal laser treatment
32780123|NCT05471323|Experimental|RC1012 injection (allo-DNT Cells)|Experimental: RC1012 injection (allo-DNT Cells) The trial is divided into two parts: Part A1 is a single- dose escalation trial with three dose groups (5×10^7 cells/kg, 1.5×10^8 cells/kg, 4.5×10^8 cells/kg), with 9-18 patients planned to be enrolled. Part A2 is a multiple-dose escalation trial consisting of 2 dose groups (1.5×10^8 cells/kg and 4.5×10^8 cells/ kg at day 0, day 7 and day 14), with 9-12 patients planned to be enrolled. Part B is a multiple-dose extension trial in which the Safety Review Committee evaluates whether to extend an additional 3-6 patients to receive the multiple cell infusions based on available PK and safety data.
32780124|NCT03315871|Experimental|1/combination therapy [close December 2018]|Combination immunotherapy
32937980|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
32780125|NCT03315871|Experimental|2/combination therapy + surveillance [closed]|Surveillance followed by Prostvac + CV301 then Prostvac + CV301 + MSB0011359C
32780126|NCT03315871|Experimental|3/combination vaccine therapy + surveillance|Surveillance followed by Prostvac + CV301 then Prostvac + CV301
32780127|NCT05482009||Strong exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment reaches more than 80% of the total course of treatment
32780128|NCT05482009||Moderate Chinese medicine exposure group|received Chinese medicine treatment + western medicine basic treatment, the cumulative time of Chinese medicine treatment reached 30%-79% of the total course of treatment
32780129|NCT05482009||Weak exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment is less than 30% of the total course of treatment
32780130|NCT05482009||Western medicine group|receive basic western medicine treatment only
32780131|NCT03570619|Experimental|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
32780132|NCT03570619|Experimental|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
32780133|NCT03570619|Experimental|Metastatic CRPC with Monotherapy|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort C once enrollment to cohort A has been completed.
32937981|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
32937982|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
32937983|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
32937984|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
32937985|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
32937986|NCT03079375|Sham Comparator|basic intervention|Medication review
32937987|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
32937988|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
32937989|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
32937990|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
32937991|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
32937992|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
32937993|NCT02871440|Experimental|Eye drop 1|Omega 3
32937994|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
32937995|NCT02871440|Active Comparator|Eye drop 3|Optive
32937996|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
32937997|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
32937998|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
32937999|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
32938000|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
32938001|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
32938002|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
32938003|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32938004|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33084143|NCT00227162|No Intervention|Group 4|Control group
33285826|NCT00951431|Placebo Comparator|Control|
33285827|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
33285828|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
33285829|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
33285830|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
33285831|NCT00943553|Experimental|1|
32938005|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32938006|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
32938007|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
32938008|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
32938009|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
32938010|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
32938011|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
32938012|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
32938013|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
32938014|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
32938015|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
32938016|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
32938017|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
32938018|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
32938019|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
32938020|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
32938021|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
32938022|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
32938023|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
32938024|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
32938025|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
32938026|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
32938027|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
32938028|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
32938029|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
32938030|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
32938031|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
32938032|NCT05405972|Experimental|Group Receiving Intervention|"The intervention group receives a link each week connecting them to the videos for both parents and children as well as a communicating/connecting activity. The intervention is self-paced over a 4 week period.~The intervention was titled the Connected Family Series - For Foster Families (CFS-FF) (further referred to as the intervention) and was created/adapted in partnership from the Connected Family Series (CFS) by psychologists at the Karyn Purvis Institute of Childhood Development (KPICD). A letter of support from the KPICD is available in Appendix D. Adaptation was needed as the original intervention was geared toward adoptive families and excluded foster families. This process was done with the original creator (Dr. Jana Hunsley) with members of the research team and fostering community."
33285832|NCT00943553|Experimental|2|
33285833|NCT04011917||Caseload group|
33285834|NCT04011917||Prediction group|
33285835|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
32938033|NCT05405972|No Intervention|Control Group|Families in the control group receive no video links during the 4 week period. Families assigned to the control do have the opportunity to participate in the intervention post-data collection and analysis and outside of the research protocol.
32938034|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
33285836|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
33285837|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
32780134|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.5. .
33285838|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
33285839|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
33285840|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
33285841|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
33285842|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
32780135|NCT03557905|Active Comparator|Group II|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.3.
32780136|NCT04539379|Active Comparator|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
32938035|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
32938036|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
32780137|NCT04539379|Active Comparator|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
32780138|NCT04537429|Experimental|Eptinezumab|
32780139|NCT04535323|Experimental|Treatment of GSM (platelet rich plasma)|Patients receive platelet rich plasma via injection into the vaginal area.
32780140|NCT04529473|Placebo Comparator|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
32780141|NCT04529473|Experimental|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
32780142|NCT05470153|Active Comparator|Asthma with Obstructive Sleep Apnea on treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization Continuous Positive Airway Pressure (CPAP) compliance: where acceptable compliance is defined as minimum of CPAP use of >/= 4 hrs/70% nights (if applicable), In one month, 3month, 6 month duration Apnea/Hypopnea Index as per CPAP reading (if applicable)"
32938037|NCT04736498|No Intervention|Control arm|Control group will follow the standard procedure in our centre and will not undergo USG assessment before spinal anaesthesia. The spinal anaesthesia procedure will be standardized. Under strict aseptic precautions spinal anesthesia will be performed at L3-L4 inter-space using a 25 Gauge Quincke spinal needle (B. Braun Medical SA, Melsungen, Germany) in sitting position. 3 ml of hyperbaric bupivacaine 0.5% (15 mg) will be injected with the needle orifice oriented cranially. After injection, patients will be immediately positioned supine. Meanwhile, the non-invasive blood pressure will be measured and recorded every 3 minute for 30 min and then every 5 min throughout surgery and anesthesia.
32938038|NCT04736498|Experimental|USG arm|In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
32938039|NCT05405348|No Intervention|Control|The control group received routine care (T0)
32938040|NCT05405348|Experimental|Intervention|Same patients, one week after T0, T1 was applied in middialysis. In T1, patients did not consume food at least half an hour before coming to hemodialysis. They also did not consume any food during hemodialysis.
32938041|NCT05405270||Primary cHSIL|Women with a first diagnosis of cHSIL (e.g. CIN 2 or CIN 3) who prefer treatment with imiquimod.
33084144|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
33084145|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
33084146|NCT00227279|Experimental|1|
33084147|NCT00227279|Placebo Comparator|2|
33084148|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
33084149|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
33084150|NCT00198133|Experimental|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
33084151|NCT00197236|Active Comparator|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
33084152|NCT00197236|Experimental|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
33084153|NCT00197236|Active Comparator|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
33084154|NCT00256152|No Intervention|AF Suppression OFF|
33084155|NCT00256152|Experimental|AF Suppression ON|
33084156|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
32780143|NCT05470153|No Intervention|Asthma with Obstructive Sleep Apnea whom refused treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
33084157|NCT04709445|Experimental|ICG-NIRF Imaging and objective perfusion rate|Intraoperatively, ICG-NIRF imaging is used to visualize the blood supply and the rate of tissue perfusion in the area of the anastomotic site. Postoperatively, an additional ingress and egress analysis at specific regions of interest is performed.
32780144|NCT05470153|No Intervention|Asthma without Obstructive Sleep Apnea|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
32780145|NCT05470075|Experimental|Experimental A: HR18042 175mg|
33084158|NCT00256230|Experimental|Disulfiram|
33084159|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
33084160|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
33084161|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
32780146|NCT05470075|Experimental|Experimental B: HR18042 225mg|
32780147|NCT05470075|Experimental|Experimental C: HR18042 275mg|
32780148|NCT05470075|Active Comparator|Active Drug Comparator：Tramadol hydrochloride SR Tablets 100mg|
32780149|NCT05470075|Placebo Comparator|Placebo Comparator: Placebos match to HR18042 and Tramadol hydrochloride SR Tablets|
33285843|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
33285844|NCT00464178|Experimental|Bortezomib and bevacizumab|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
33285845|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
32780150|NCT05481697|Experimental|UWL and GRAIL Galleri Testing|"Enrolled participants will have an initial blood sample taken and record their weights weekly on a FitBit Aria scale for three years to detect for UWL~Those who unintentionally lost lost ≥5% from their baseline weight will be identified and have a GRAIL Galleri blood test, physical examination, imaging, and cancer screenings to test for malignancy"
32780151|NCT05476627||Hypertension Group|
32780152|NCT05476627||Diabetes Group|
32780153|NCT05476627||Hyperuricemia|
32780154|NCT05476627||Obesity|
32780155|NCT05481619|Active Comparator|Group of UC patients treated with vedolizumab|Generic Name：vedolizumab Specification：300mg/bottle Dosage and Method of Administration：Usual adult dose for ulcerative colitis.300 mg IV every 30 minutes at weeks 0, 2, and 6, then every 8 weeks
32780156|NCT05481619|No Intervention|Normal control group|On the basis of the exclusion criteria, there are no significant intestinal inflammatory, autoimmune or neoplastic disorders.
33285846|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
33285847|NCT00467610|Experimental|Panhematin|
33285848|NCT00316186|Experimental|Single arm, open label|
32900357|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
33084162|NCT00197002|Active Comparator|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
33084163|NCT00197002|Experimental|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
32780160|NCT03276559|Experimental|Randomized controlled trial EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
32780161|NCT03276559|Placebo Comparator|Randomized controlled trial Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
32780162|NCT03276559|Experimental|Open-trial phase arm|The open-trial phase arm includes 10 participants who all received EMPOWER. Data from the open trial of 10 surrogate decision-makers will identify tactical and measurement issues involved in the delivery and outcomes measurements used in EMPOWER.
32780163|NCT03276559|No Intervention|Manual refinement phase arm|This phase involves obtaining feedback about the EMPOWER intervention manual using qualitative analysis from 15 stakeholders.
32780164|NCT03276559|Experimental|Open trial COVID-19 phase arm|The COVID-19 open trial phase arm did not include randomization or control arm. All participants received the EMPOWER intervention. Assessments will occur pre-intervention, immediately post-intervention, and then 1-month and 3-months from post-intervention assessment.
32780165|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
32780166|NCT05481463|Experimental|surufatinib combined with TAS-102|
32780167|NCT04510597|Active Comparator|Arm 1: Continued Systemic Therapy Only|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
32780168|NCT04510597|Experimental|Arm 2: Nephrectomy and Continued Systemic Therapy|"Continued systemic therapy as above, plus:~Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization."
32780169|NCT05476471|Experimental|intervention arm|The intervention consisted of one 60-minutes group exercise session once a week in first 8 weeks, and self-management in next 8 weeks
32780170|NCT05476471|No Intervention|control arm|The control arm received an education leaflet.
32780171|NCT05481385|Experimental|Test preparation|Ezetimibe tablets: specification: 10mg; Package specification: 7 pieces / plate, 1 plate / box; Produced and provided by Changzhou Pharmaceutical Factory Co., Ltd.
32780172|NCT05481385|Active Comparator|Reference preparation|Ezetimibe Tablets Ezetrol ®; Specification: 10mg, packaging specification: 10 pieces / plate, 1 plate / box; Licensee: MSD Pharma (Singapore) PTE. Ltd
32780173|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
32780174|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
32780175|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
32780176|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
32780177|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
32780178|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
32780179|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
32780180|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
32780181|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
32780182|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
32780183|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
32780184|NCT04507009|Active Comparator|Control|Traditional treatment group which alvogyl applied to the socket after irrigation
32780185|NCT04507009|Experimental|Ozone|Ozone group which Ozone (O3) applied after irrigation of the socket
32780186|NCT04507009|Experimental|CGF +Ozone|CGF + Ozone group which concentrated growth factor (CGF) after Ozone (O3) applied followed by irrigation of the socket.
33084164|NCT00197002|Active Comparator|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
33084165|NCT00196105|Experimental|6 mm Zilver|6 mm Nitinol Zilver Stent
33084166|NCT00196105|Experimental|10 mm Zilver|10 mm Nitinol Zilver Stent
33084167|NCT00196105|Active Comparator|10 mm Wallstent|10 mm Stainless Steel Wallstent
32938042|NCT05405270||Recurrent/residual cHSIL (rrcHSIL)|Women who were treated for cHSIL before, but who have a residual or recurrent lesion and prefer treatment with imiquimod.
32938043|NCT05405270||CIN 2 observational group|Women with primary CIN 2 who prefer expectant management to await the potential of spontaneous regression.
32938044|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
33285849|NCT04011761|Active Comparator|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
33285850|NCT04011761|No Intervention|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
33285851|NCT00948623|Experimental|1|
33285852|NCT00948623|Sham Comparator|2|
33285853|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate~estradiol~alpha-5-reductase-inhibitor"
33285854|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate~lynestrenol"
33285855|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
33285856|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
33285857|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
33285858|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
33285859|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
33285860|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
33285861|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
33285862|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
33285863|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
33285864|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
33285865|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
33285866|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
33285867|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
32938045|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
32938046|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
32938047|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
32938048|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
32938049|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
32938050|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
32938051|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
33285868|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
33285869|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
33285870|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
33285871|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
33285872|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
33285873|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
33285874|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
33285875|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
33285876|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
33285877|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
33285878|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
33285879|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
33285880|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
32780187|NCT04468789||Comparison group|Patients eligible for six-month dispensing receiving care at comparison sites.
32780188|NCT04468789||Intervention group|Patients eligible for six-month dispensing receiving care at intervention sites.
33285881|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
32780189|NCT05481307|Experimental|Fixed Sequence|Period 1: RLD2202, Period 2 : RLD2203 -> RLD2202+RLD2203
32780190|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
32780191|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
32780192|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
33285882|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
33285883|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
33285884|NCT00299182|Experimental|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33285885|NCT00299182|Experimental|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33285886|NCT00299182|Experimental|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33285887|NCT00299182|Placebo Comparator|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy~Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33084168|NCT04722068|Experimental|Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial|
33285888|NCT00299182|Experimental|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
32780193|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
32780194|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
32780195|NCT04270591|Other|SCC244 300mg|Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD
32780196|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
32780197|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
32780198|NCT05469451|Experimental|Group 1: irradiated with low power laser (940nm)|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
32780199|NCT05469451|Placebo Comparator|Group 2: Simulated that they were irradiated.|Group 2: it was simulated that they were irradiated.
32780200|NCT04505527|Active Comparator|Recurrent fallers - control group|In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
32780201|NCT04505527|Experimental|Recurrent fallers - intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
32780202|NCT04505527|Experimental|Older non-fallers intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
32780203|NCT04505527|Active Comparator|Younger adult control group|Outcome measures from a young healthy group will also be measured as a reference. Will be used to compare outcome measured between older and young adults. Young adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
32780204|NCT02553265|Placebo Comparator|Placebo|Matching placebo
32780205|NCT02553265|Experimental|Low-Dose Carbidopa|
32780206|NCT02553265|Active Comparator|High-Dose Carbidopa|
32780207|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
32780208|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
33084169|NCT00227747|Experimental|Radiothérapie + Xelox|
33084170|NCT00227747|Active Comparator|Radiothérapie + Capécitabine|
32938052|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
32938053|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
32938054|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
32780209|NCT05480839|Experimental|Manual Immediately Sequential Bilateral Cataract Surgery (MCS)|
32780210|NCT05480839|Experimental|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Early|
32780211|NCT05480839|Experimental|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Standard|
32780212|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
32780213|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
32780214|NCT04567615|Experimental|Arm A : Nivolumab|
32780215|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
32780216|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
33084171|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
33084172|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
33084173|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
33084174|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
33084175|NCT04721990|Experimental|Automatic Sound Management 3.0|Current SONNETEAS listeners, who meet the eligibility criteria, will be tested with their current listening configuration and also fit with a SONNET2EAS, programmed with Automatic Sound Management 3.0 (under the Investigational Device Exemption).
33285889|NCT00299182|Experimental|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33084176|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
33084177|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
33285890|NCT00299182|Experimental|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
33285891|NCT00467142|Experimental|Folfiri and Bevacizumab|"Premedication = Dexchlorpheniramine, 5 mg in slow Direct IntraVeinous (DIV) on D1.~FOLFIRI (simplified LV5FU2 + irinotecan):~Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.~LV5FU2, in its so-called simplified version, will be administered as follows L-folinic acid, as a 2-hour intravenous infusion, at a dose of 200 mg/m², on Day 1, in 500 mL of 5% glucose solution, concomitantly with the irinotecan infusion via a Y-tube, followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m² from D1 to D3, either in 1000 mL of 5% glucose solution, or in an electric syringe or pump dispenser~Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30 minutes for subsequent infusions if tolerated."
33285892|NCT00951977||Subjects who have formerly donated a kidney|
33285893|NCT00951977||Matched community control Subjects|
33285894|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
33285895|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
33084178|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
33084179|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
33285896|NCT05300789||pT4 colon cancer patients after curative resection|
33285897|NCT00949091|Experimental|1|
33084180|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
33084181|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
33285898|NCT00553475|Placebo Comparator|Placebo|
33285899|NCT00553475|Experimental|Pregabalin 300 mg/day|
33285900|NCT00553475|Experimental|Pregabalin 600 mg/day|
33285901|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
33285902|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
33285903|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
33285904|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
33285905|NCT01065610|Placebo Comparator|Placebo|
33285906|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
33285907|NCT01062646|Active Comparator|community treatment as usual|
33285908|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
33285909|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
33285910|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
33285911|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
33285912|NCT00551135|Experimental|3|
33084182|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
33084183|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
33084184|NCT00413543|No Intervention|control|"standard care"
33285913|NCT00551135|Placebo Comparator|4|
33285914|NCT00551135|Experimental|2|
33285915|NCT00551135|Experimental|1|
33285916|NCT00944255||RA with drug|
33285917|NCT00944255||RA without drug|
33285918|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
33285919|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
33285920|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
33285921|NCT01529801|Experimental|Roughness group A|Osseotite Certain Tapered Group A
33285922|NCT01529801|Experimental|Roughness Group B|Osseotite Certain Tapered Group B
33285923|NCT01529801|Experimental|Roughness Group C|Osseotite Certain Tapered Group C
33285924|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
33285925|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
32938055|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
32938056|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
32938057|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
32938058|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
33285926|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
33285927|NCT04012385|No Intervention|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
33285928|NCT04012385|Experimental|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
32938059|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
32938060|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
32938061|NCT05404334||Breast Cancer|Patients with histologically proven breast cancer
32938062|NCT05404334||Benign breast disease|Patients with benign breast diseases undergoing surgical resection
32938063|NCT00374972||combined contraceptives|combined contraceptives
32938064|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
32938065|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
32938066|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
32938067|NCT03127358|Experimental|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
32938068|NCT03127358|No Intervention|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
32938069|NCT03127358|Active Comparator|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
32938070|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
32938071|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
32938072|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
32938073|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
32938074|NCT03127514|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
32938075|NCT03127514|Experimental|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
32938076|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
32938077|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
32938078|NCT00375050|Experimental|Riluzole|
32938079|NCT00375050|Placebo Comparator|Placebo|
32938080|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
32938081|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
33285929|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
33285930|NCT00956423|Experimental|moderate-intensity exercise training|
33285931|NCT00956423|Active Comparator|low-intensity stretching|
33285932|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
32938082|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
33285933|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
33285934|NCT00299104|Experimental|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
33285935|NCT00299104|Experimental|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
32938083|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
32938084|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
32938085|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
32938086|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
32938087|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
32938088|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
32938089|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
32938090|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
32938091|NCT05247164|Experimental|PDAC Patients|Patients undergoing EUS for characterization of a PDAC lesion will receive EUS-guided portal blood sampling.
32938092|NCT05172206|Active Comparator|Symptom-focused Rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
32938093|NCT05172206|Other|Usual Care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
32938094|NCT05098886|Experimental|Sequence A|
32938095|NCT05098886|Experimental|Sequence B|
32938096|NCT03093025|Experimental|TS-121 10mg|
32938097|NCT03093025|Experimental|TS-121 50mg|
32938098|NCT03093025|Placebo Comparator|Placebo|
32938099|NCT05098262|Experimental|Sequence A|
32938100|NCT05098262|Experimental|Sequence B|
32938101|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
32938102|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
32938103|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
32938104|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
32938105|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
32938106|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
32938107|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
32938108|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
32938109|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
32938110|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
32938111|NCT05057858|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
32938112|NCT05057858|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
32938113|NCT05057858|Experimental|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
33084185|NCT00228215|No Intervention|Usual care|
33084186|NCT00228215|Experimental|TIPS Intervention|
33285936|NCT00299104|Placebo Comparator|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
33285937|NCT03979690|Experimental|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
33285938|NCT03979456|Active Comparator|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
33285939|NCT03979456|Experimental|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
33285940|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
33285941|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
33285942|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
33285943|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
33285944|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
33285945|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
32938114|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
32938115|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
33285946|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
33285947|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
33285948|NCT00550745|Experimental|1|Arm 1: vaccine
33285949|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
33285950|NCT05300633|Experimental|Intervention arm|Family member/concerned significant other
32780217|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
32938116|NCT02951143|Experimental|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
32938117|NCT02951143|Experimental|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
32938118|NCT02951143|Experimental|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
32938119|NCT02951143|Experimental|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
32938120|NCT05040152|Experimental|Arm I (telephone-based intervention)|Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.
32938121|NCT05040152|Active Comparator|Arm II (education brochures)|Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.
32938122|NCT04707404||PEEK|Cranioplasty patients with PEEK.
32938123|NCT04707404||Titanium|Cranioplasty patients with titanium mesh.
32938124|NCT04707092|Experimental|Antibiotic at induction|Patients will receive one single dose of Antibiotic at induction
32938125|NCT04707092|Experimental|Antibiotic one week|Patients will receive one single dose of Antibiotic at induction, plus a 7 day treatment with oral Antibiotic
32938126|NCT04707014|Placebo Comparator|Attention-Distraction techniques|A high-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure.
32938127|NCT04707014|Experimental|HIPNOSIS GROUP|A technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to the child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.
32938128|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
32938129|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
32938130|NCT04985708||Patient with AMICS are likely to benefit from MCS|later
32938131|NCT04985708||Develop and maintain a patient registry of AMICS|later
32938132|NCT04985708||Classify patients based on shock severity.|later
32938133|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
33084187|NCT00195676|Other|Adalimumab|
33285951|NCT00956579||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study"
33084188|NCT00194077|Active Comparator|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
33084189|NCT00194077|Placebo Comparator|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
33084190|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
33084191|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
33084192|NCT00193609|Experimental|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
33084193|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
33084194|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
33084195|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
33084196|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
33084197|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
33285952|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
33285953|NCT00949793|Experimental|All patients|
33285954|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
33285955|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
33285956|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
33285957|NCT04216043|Experimental|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
33285958|NCT04216043|Experimental|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
33285959|NCT04216043|Experimental|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
33285960|NCT04216043|Experimental|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
33285961|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
33285962|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
32780218|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
32780219|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
32780220|NCT05480683|Experimental|Targeted CT of pelvis with specific penile anatomical positioning for Peyronie Disease|Subject presenting with Peyronie disease signs or symptoms to Mayo Clinic Florida Department of Urology will undergo a targeted noncontrast CT of the pelvis with specific penile anatomical positioning
32780221|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
32780222|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
32780223|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
32780224|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
32780225|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
32780226|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
32780227|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
32900358|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
33084198|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
33084199|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
33285963|NCT00952679|Experimental|experimental arm|
32780228|NCT05509751|Active Comparator|Intervention group|geriatric assessment (GAM) and remote exercise and education prior to and during curative/adjuvant or first/second line palliative chemotherapy /immunotherapy or targeted therapy
32780229|NCT05509751|No Intervention|Waitlist control group|Wait list, receiving standard of care and option to receive intervention after treatment.
32780230|NCT05442203|Other|AF Cohort|Will be comprised of 500 participants predicted to be increased risk for Atrial Fibrillation (AF) will receive a 2-week ECG patch monitor to wear (up to 3 times over 12 months),
32780231|NCT05442203|Other|SHD Cohort|Will be comprised 500 participants at increased risk for Structural Heart Disease (SHD) will be referred for a single echocardiogram.
32780232|NCT04558775||Observational Cohort|
32780233|NCT05390723|Experimental|video 1|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
32780234|NCT05390723|Experimental|video 2|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
32780235|NCT05390723|Experimental|video 3|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
33084200|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
33084201|NCT00193180|Experimental|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
33084202|NCT00193063|Experimental|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
33084203|NCT00191854|Experimental|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
32780236|NCT05390723|Experimental|video 4|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
32780237|NCT05389163|Experimental|Giomer based injectable resin composite|Beautifil Flow plus X F03, SHOFU, USA
32780238|NCT05389163|Active Comparator|Resin modified glass ionomer|Fuji II LC, GC
32780239|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
32780240|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
32780241|NCT05509673|Experimental|Intervention group|The intervention group received a fat grafting under the wound bed and into the wound edges.
32780242|NCT05509673|No Intervention|Control group|The control group received an injection of saline solution (0.9%) under the wound bed and into the wound edges.
32780243|NCT05501951|Experimental|right DLPFC tDCS|Participants in this group will receive 10 sessions of right DLPFC tDCS
32780244|NCT05501951|Experimental|right OFC tDCS|Participants in this group will receive 10 sessions of right OFC tDCS
32780245|NCT05501951|Sham Comparator|Control group|Participants in this group will receive 10 sessions of sham stimulation
32780246|NCT04810559|Experimental|Investigational Device|
32780247|NCT05303753|Other|Single group|During a 3-week baseline period, participants with self-reported GI complaints consume their own protein supplement that they use for recovery purposes after exercise, followed by a 3-week intervention period in which they maintain usage of their own product, but replace a part of this product with a fermented dairy protein with prebiotic fiber. An additional reference group of athletes without self-reported GI complaints will also be followed during a 3-week period in which they consume their own protein supplement that they use for recovery purposes after exercise.
32780248|NCT04540211|Experimental|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
32780249|NCT04540211|Placebo Comparator|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
32780250|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
32780251|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
32780252|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
32780253|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
32780254|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
33084204|NCT00191854|Experimental|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
33084205|NCT00191854|Experimental|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
33084206|NCT00191815|Experimental|Gemcitabine + Cisplatin|
32938134|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
32938135|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32938136|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
32938137|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
32938138|NCT04938752|Experimental|Sequence I|
33285964|NCT04417127|Experimental|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
33285965|NCT04417127|Active Comparator|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
33285966|NCT04417127|No Intervention|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
33285967|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
33285968|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
33285969|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
33285970|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
33285971|NCT00952835||asthma and rhinitis control|
33285972|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~If complete response this treatment continues for 4 cycles, totally 6 cycles.~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~If progressive disease after the first 2 cycles individualized treatment."
33285973|NCT04327583|Experimental|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
33285974|NCT04327583|No Intervention|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
33285975|NCT04295837|Experimental|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
33285976|NCT04295837|Active Comparator|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
33285977|NCT00957203|Experimental|Istradefylline|
33285978|NCT00952913|Experimental|1|Bosutinib
33285979|NCT00952913|Experimental|2|bosutinib + lansoprazole
33285980|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
33285981|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
33285982|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
33285983|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
33285984|NCT00957749|Experimental|cPMP|
33285985|NCT00953303|Experimental|glucocorticoid|
33285986|NCT00953303|Active Comparator|Standard care|
33285987|NCT05300555|Experimental|Rivaroxaban group|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
33285988|NCT05300555|Experimental|Warfarin group|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
32938139|NCT04938752|Experimental|Sequence II|
32938140|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
32938141|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
32938142|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
33285989|NCT04010669|Active Comparator|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
33285990|NCT04010669|Placebo Comparator|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
33285991|NCT04010591||UDS group|All enrolled patients with urodynamic study
33285992|NCT04263311|Experimental|Community Health Workers (CHW) treatment group|There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
33084207|NCT00191386|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
33084208|NCT00191308|Experimental|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs~Cisplatin: 75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs"
33084209|NCT00191269|Experimental|A|Dose Level 1 - 1000 mg/m2
33285993|NCT04263311|No Intervention|Control group|There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
33285994|NCT00957983|Active Comparator|BGC20-1531 200mg|
33285995|NCT00957983|Placebo Comparator|sugar pill|
33285996|NCT00957983|Active Comparator|BGC20-1531 400mg|
33285997|NCT05299463|Other|Exercise|
33285998|NCT04243577|Experimental|Experimental Sensors|This arm will include the use of the experimental wearable sensors we are developing.
33285999|NCT04243577|Active Comparator|Conventional Sensors|This arm will include the use of the conventional sensors: regular snap on sEMG electrodes and IOPI device bulb.
33286000|NCT04214093|Experimental|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
32780255|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
33286001|NCT04214093|Experimental|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
33286002|NCT00452790|Experimental|A|
33286003|NCT00452790|Active Comparator|B|
33286004|NCT00953381|Experimental|5 mg ilaprazole|
33286005|NCT00953381|Experimental|10 mg ilaprazole|
33286006|NCT00953381|Experimental|20 mg ilaprazole|
32780256|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
32780257|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
32780258|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
32780259|NCT05509517|Experimental|Rhythm monitoring group|Patients randomized to the rhythm monitoring arm will assess their heart rhythm with a photoplethismography (PPG) based smartphone application (FibriCheck™). Measurements are performed three times daily and while experiencing symptoms. The patients start measuring immediately after discharge and continues until the scheduled postoperative consultation with the cardiologist or cardiac surgeon at 21-91days after discharge.
32780260|NCT05509517|No Intervention|Usual care|Patients randomized to the rhythm monitoring arm will be discharged without protocol mandated rhythm monitoring. A postoperative consultation is scheduled with the cardiologist or cardiac surgeon at 21-91days after discharge.
32780261|NCT05501639||tiotropium + inhaled corticosteroids (ICS) group|
32780262|NCT05501639||long-acting β2-agonists (LABA) + inhaled corticosteroids (ICS) group|
32780263|NCT05284643|Experimental|Cohort A: sMRI-Guided RT at 35 Gy in 10 fractions|"Participants will receive a total dose of 3500 centigrays (cGY) (35Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 350 cGy (3.5 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
32780264|NCT05284643|Experimental|Cohort B: sMRI-Guided RT at 40 Gy in 10 fractions|"Participants will receive a total dose of 4000 cGY (40Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 400 cGy (4 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
32780265|NCT05501405|Experimental|Schizophrenic patients|Electroencephalogram and eye-tracking recordings Behavorial tests
32780266|NCT05501405|Experimental|Autism Spectrum Disorder (ASD) patients|Electroencephalogram and eye-tracking recordings
32780267|NCT05501405|Experimental|22q11.2 DS patients|Electroencephalogram and eye-tracking recordings Behavorial tests
32780268|NCT05501405|Experimental|Williams syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
32780269|NCT05501405|Experimental|Präder Willi syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
33084210|NCT00191269|Experimental|B|Dose Level 2 - 1250 mg/m2
33286007|NCT00953381|Active Comparator|20 mg omeprazole|
33286008|NCT05300477|Experimental|Acetazolamide|Acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
33286009|NCT05300477|Experimental|Erythropoietin and Acetazolamide|Erythropoietin (subcutaneously) 50 IU /kg three times a week for 4 weeks. After the 4 week Erythropoietin, acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
33286010|NCT00953537|Other|capecitabine|
33286011|NCT00463788|Experimental|cisplatin and cetuximab|
33286012|NCT00463788|Active Comparator|cisplatin|
33286013|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
33286014|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
33286015|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
33286016|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
33286017|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
32780270|NCT05501405|Active Comparator|Control participants|Electroencephalogram and eye-tracking recordings Behavorial tests
32780271|NCT05509361|Experimental|AK101 135mg|"Subjects who have completed AK101-302 receive AK101 135mg injection subcutaneously every 12 weeks.~Subjects newly enrolled receive AK101 135mg injection subcutaneously at Week 0, 4 and then every 12 weeks."
32780272|NCT05501327|Experimental|Cohort A|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure:~Formulation buffer (control)~3.75 mg SLI-F06 total dose per wound (1X)~7.5 mg SLI-F06 total dose per wound (2X)~15 mg SLI-F06 total dose per wound (4X)"
32780273|NCT05501327|Experimental|Cohort B|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and on Days 1, 2, 3, 4:~Formulation buffer (control)~3.75 mg SLI-F06 total dose per wound (1X)~7.5 mg SLI-F06 total dose per wound (2X)~15 mg SLI-F06 total dose per wound (4X)"
32780274|NCT05501327|Experimental|Cohort C|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure:~Formulation buffer (control)~3.75 mg SLI-F06 total dose per wound (1X)~15 mg SLI-F06 total dose per wound (4X)~30 mg SLI-F06 total dose per wound (8X)"
32780275|NCT05501171|Experimental|DREAMLAND|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad.~Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
32780276|NCT05501171|Active Comparator|CERENA|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad.~Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
32780277|NCT04577963|Experimental|Part 1|Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period
32780278|NCT04577963|Experimental|Part 2|"Patients will be enrolled to one of the following expansion cohorts:~Cohort A: TNBC (immuno-oncology [IO]-treated in the metastatic setting)~Cohort B: TNBC (IO-Naïve in the metastatic setting)~Cohort C: EC~Cohort D: MSS CRC"
32780279|NCT05145335|Experimental|Autoregulated cuff|two sessions in which an autoregulated cuff will be used to adapt the pressure in order to keep the total pressure given constant. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
32780280|NCT05145335|Active Comparator|non-autoregulated cuff|two sessions in which an non-autoregulated cuff will be used. In these two sessions, the pressure will not be adapted. Consequently, during each muscle contraction the pressure will rise because the cuff is not autoregulated. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
32780281|NCT04286243|Active Comparator|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
32780282|NCT04286243|Experimental|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
32780283|NCT05092373|Experimental|Cohort 1 (TTF, cabozantinib)|Patients receive TTF continuously for at least 18 hours per day on days 1-21 of each cycle. Patients also receive cabozantinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780284|NCT05092373|Experimental|Cohort 2 (TFF, atezolizumab, nab-paclitaxel)|Patients receive TTF continuously for at least 18 hours per day on days 1-28 of each cycle. Patients also receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each cycle and atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32780285|NCT05509205||Patients with stroke|In this study 130 patients with stroke who are treating with stroke rehabilitation programs, will be included.
32780286|NCT04285697|Experimental|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
32938143|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
32938144|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
32938145|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
32938146|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
32938147|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
32938148|NCT04861844|Experimental|Mindfulness training|
32938149|NCT04861844|Active Comparator|Active listening|
32938150|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
32938151|NCT03092024|Experimental|SPIN-HAND program|
32938152|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
33084211|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
33084212|NCT04709640|Experimental|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
33084213|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
33084214|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
33084215|NCT00191191|Experimental|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
33084216|NCT00191191|Experimental|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
33084217|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
33084218|NCT00229151|Active Comparator|usual treatment|
33084219|NCT00229229|Other|1|Low glycemic load diet
33084220|NCT00229229|Other|2|Canada Food Guide Diet
33084221|NCT00229229|Other|3|Low glycemic index diet
33084222|NCT00229229|Other|4|Low carbohydrate diet
33084223|NCT00414102|Experimental|Ramelteon 8 mg QD|
33084224|NCT00414102|Placebo Comparator|Placebo QD|
33084225|NCT00229307|Active Comparator|1|
33084226|NCT00229307|Active Comparator|2|
33084227|NCT00229385|Active Comparator|1|
33084228|NCT00229385|Active Comparator|2|
33286018|NCT00463476|Experimental|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
33286019|NCT00463476|Experimental|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
33286020|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
32780287|NCT04285697|No Intervention|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
32780288|NCT05501015|No Intervention|Group A - Standard Dysphagia Treatment|Group A will serve as the control group. This group will receive oral hygiene followed by traditional dysphagia exercises, including effortful swallow, Masako Maneuver, and Tongue Press.
32900359|NCT05344404|Experimental|Nicotinamide Riboside|Nicotinamide riboside 3000mg daily for the duration of the trial (4 weeks). Administered in tablet form in doses of 1500mg twice daily.
33084229|NCT00236223|Experimental|1|
33084230|NCT00236223|Placebo Comparator|2|
33084231|NCT00229424|Experimental|1|Lafutidine group
33084232|NCT00229424|Active Comparator|2|Famotidine group
33084233|NCT00229424|Placebo Comparator|3|Placebo group
33286021|NCT01025466|Active Comparator|Combination therapy with memantine|
33286022|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
33084234|NCT00256932|Placebo Comparator|Placebo|
33084235|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
33084236|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
33084237|NCT00229502||1|Subjects receiving Avonex
33084238|NCT00229502||2|Subjects receiving Rebif
33084239|NCT00229502||3|Subjects receiving Copaxone
33084240|NCT00229502||4|Healthy controls
33084241|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
33084242|NCT00229541|No Intervention|KG|control group, receives usual care
33084243|NCT00191152|Experimental|Gemcitabine + Docetaxel|
33084244|NCT00191152|Active Comparator|Capecitabine + Docetaxel|
33084245|NCT00229580|Experimental|1|Motivational feedback
33084246|NCT00229580|Active Comparator|2|treatment as usual
33084247|NCT01059188|Experimental|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
33084248|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
33084249|NCT00236301|Active Comparator|2|CLIMASTON
33084250|NCT00236301|Placebo Comparator|3|placebo
33084251|NCT00229697|Experimental|1|ZD1839 + Nolvadex
33084252|NCT00229697|Other|2|Nolvadex + placebo
33084253|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
33084254|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
33084255|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
33084256|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
33084257|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
33084258|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
33286023|NCT03910296||Acceptance & Commitment Therapy|"Acceptance & Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.~Each subject will participate for 6 sessions of Acceptance & Commitment Therapy (ACT).~ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
33084259|NCT00190684|Experimental|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
33084260|NCT04721834|Active Comparator|Low-intensity ESWT|Patient would be positioned in a supine position. Shockwaves would be delivered to the stretched penis at proximal, mid and distal penile shaft and bilateral crura of penis. (Energy: 0.1-0.25 mJ/mm2; 3000pulses per session; Frequency 3Hz) Treatment consists of 6 sessions over 5 weeks in total. It would be a twice-weekly treatment with one-week interval of resting period. Patient would be discharged home after each treatment session.
33084261|NCT04721834|Sham Comparator|Sham ESWT|Sham therapy would be given with a modified probe which no shockwave would be emitted. A working noise would still be generated which mimicked active treatment.
33286024|NCT04857918|Experimental|Social identity informed virtual running group|Participants will join running groups of six people (males and females) for eight weeks. Each running group will be given the group goal/challenge to collectively run/brisk walk the distance across the province of British Columbia (940 km) over the course of the eight week intervention (Estabrooks et al., 2008), and encouraged to complete 150 minutes of moderate-to-vigorous exercise per week. Participants can record other moderate-to-vigorous exercise to contribute to the group goal. Running groups will be created on the fitness application Strava, and participants will record/post their runs on the Strava app so that members of their running group can provide 'kudos' and words of encouragement. Running groups will have a weekly a coffee chat (via Zoom) to socialize and discuss their experiences running/exercising and progress and challenges associated with meeting the group goal. Participants will also be provided running tip videos, phone armbands, and t-shirts with the study logo.
33286025|NCT04857918|Active Comparator|Attention control group|This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.
33286026|NCT01025544|Active Comparator|Arm 1|
32780289|NCT05501015|Experimental|Group B - Ice Chip Treatment|Group B will serve as the experimental group. In place of traditional dysphagia exercises, participants in Group B will receive oral hygiene and will consume small amounts of ice chips with supervision, three times a day. The ice chip protocol is based on the same findings as the Frazier Free Water Protocol, in that small amounts of clean water or ice chips are not harmful to the lungs and relatively benign if aspirated. Ice chips provide additional advantages in rehabilitating dysphagia as they are a cohesive bolus that are easier for patients with severe dysphagia to control in their mouth and swallow.
32780290|NCT04535531|Experimental|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
32780291|NCT04535531|Placebo Comparator|vehicle gel|Vehicle gel topically once daily
32780292|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
33084262|NCT00193219|Experimental|Intervention|"Bevacizumab 5 mg/kg IV~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)~Leucovorin 350 mg IV~Oxaliplatin 85 mg/m2 IV"
33084263|NCT00196339|Experimental|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
33084264|NCT00196339|Experimental|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
33084265|NCT00196339|Experimental|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
33084266|NCT00196339|Placebo Comparator|Placebo|1 tablet daily
33084267|NCT00177268||CTCL, atopic dermatitis, eczema|Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
33084268|NCT00179959|Active Comparator|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
33084269|NCT00179959|Placebo Comparator|Placebo|Intranasal petrolatum ointment treatment and plain water baths
33084270|NCT02961933|Experimental|Apneic oxygenation|
33084271|NCT02961933|Active Comparator|non-apneic oxygenation|
33084272|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
33084273|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
33084274|NCT00257439||CKD|Elevated se-creatinine + proteinuria
33084275|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
33084276|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
33084277|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
33084278|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
33084279|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
33084280|NCT04721340||Test Group|people with multiple sclerosis
33084281|NCT04721340||Control Group|healthy volunteers
33084282|NCT04709172|Experimental|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
33084283|NCT00415311|Other|0 mg/kg|
33084284|NCT00415311|Other|0.5 mg/kg|
33084285|NCT00415311|Other|1.0 mg/kg|
33084286|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
33084287|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
33084288|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
33084289|NCT00257673|Experimental|A|Active 30 mg MEM 1003
33084290|NCT00257673|Experimental|B|90 mg MEM 1003
33084291|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
33084292|NCT00410306||Group 1|
33084293|NCT00257712|Experimental|1|
32780293|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
33084294|NCT00257712|Placebo Comparator|2|
33084295|NCT00179647|Other|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
33084296|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
33084297|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
33084298|NCT00179413|Active Comparator|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
33084299|NCT00179413|Active Comparator|Colchicine|0.6mg twice a day
33084300|NCT00200135||1|Treated and released from ED (minor injuries)
33084301|NCT00200135||2|Trauma, admitted to the hospital (injured)
33286027|NCT01025544|Active Comparator|Arm 2|
33286028|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.
33286029|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.
33286030|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
33286031|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
32780294|NCT05500937|Active Comparator|UDCA 500mg per day|This group of participants receive UDCA 500mg per day.
33084302|NCT00200135||3|Fatalities reported by the coroner (deaths)
33286032|NCT03905928|Experimental|18mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a tobacco flavor.
33084303|NCT00200135||4|Reported by the police (No medical treatment)
33084304|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
33084305|NCT04571866|Experimental|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
33084306|NCT04571866|Sham Comparator|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
33286033|NCT03905928|Placebo Comparator|0mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a tobacco flavor.
33084307|NCT00178399|Experimental|Stereotactic body radiation therapy|
33084308|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
33084309|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
33084310|NCT00178126|Active Comparator|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
33084311|NCT00178126|Experimental|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
33084312|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
33084313|NCT00236925|Placebo Comparator|Placebo|Placebo
33084314|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
33084315|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
33084316|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
33084317|NCT00177307|Experimental|Oxaliplatin, Capecitabine, and Bevacizumab|
33084318|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
33084319|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
33286034|NCT03905928|Experimental|18mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a strawberry vanilla flavor.
33286035|NCT03905928|Placebo Comparator|0mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a strawberry vanilla flavor.
33286036|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
33286037|NCT01027494||Healthy|No intervention
33286038|NCT01025700|Experimental|Cesemat|
33084320|NCT00176644|Experimental|Transdermal estradiol|
33286039|NCT01025700|No Intervention|Placebo|
33286040|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
33286041|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
33286042|NCT00462462|Experimental|1|Ethanol gel
33286043|NCT00462462|Active Comparator|2|Ethanol solution
32780295|NCT05500937|Placebo Comparator|Placebo|This group of participants receive placebo.
32780296|NCT05509049|Experimental|Treatment|Behavioral science and reinforcement learning-driven hyper-personalized messages
32780297|NCT05509049|Active Comparator|Control|Standard of care message
32780298|NCT04810247|Experimental|Body Project intervention|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised.
32780299|NCT04744025|Experimental|Microfluidics|Half of participants eggs will be injected with sperm processed using a microfluidics chamber.
32780300|NCT04744025|Active Comparator|Density gradient centrifugation|Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).
32780301|NCT05500781|Experimental|Coaching HER|Participants in the interventional condition will take part in an online program consisting of 6 modules over 2 weeks
32780302|NCT05500781|No Intervention|Waitlist Control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
32780303|NCT04524455|Experimental|Blinatumomab and AMG 404|
32780304|NCT04420949|Experimental|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
32780305|NCT04420949|Experimental|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
33084321|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
33084322|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
33084323|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
33084324|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
33084325|NCT00176605|Experimental|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
33084326|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
33084327|NCT00200408||smokers|college students who smoke
33084328|NCT00200408||non smokers|college students who don't smoke
32780306|NCT04692155|Experimental|phase 1b and phase 2|"for phase 1 B portion, Ublitixumab will be given IV at dosage 900mg from Cycle 1 Day1 till cycle 6. If investigator decides to continue the treatment as maintenance, Ublitixumab will be given IV every 8 weeks for 24 months Umbralisib (800mg) will be given orally once a day within 30 minutes of a meal from Cycle 1 Day1 till cycle 6.If investigator decides to continue the treatment as maintenance,• Umbralisib will be given at orally daily for 24 months.~Chemotherapy combination of CHOP-cyclophosphamide IV 750mg/m2 for Age <70 years, 500 mg/m2 for Age>70 years doxorubicin IV 50mg/m2for Age <70 years, 25 mg/m2 for Age>70 years , and vincristine IV 1mg/m2 (max 2mg)) are administered on Cycle 1 day 1 till Cycle 6. Prednisone 50-100mg will be given orally on days 1 through 5 of every cycle.~For Phase II portion- Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agrees."
32780307|NCT05508893|Other|CT Angiography|Coronary CT Angiography will be performed on all individuals
32780308|NCT05508893|Other|Exercise stress test|An bicycle exercise stress test will be performed on all individuals
32780309|NCT05500625|Experimental|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|
32780310|NCT05500625|Experimental|Ballon-occluded retrograde transvenous obliteration|
32780311|NCT04789889|Experimental|IORT|intraoperative radiotherapy(IORT) in BCS.
32780312|NCT04789889|Active Comparator|PORT|traditional postoperative radiotherapy following BCS.
32900360|NCT05344404|Placebo Comparator|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (4 weeks).
33084329|NCT00176254|Experimental|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
33084330|NCT00175825|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
33084331|NCT00175825|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
33084332|NCT00175825|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
33084333|NCT00175825|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
33084334|NCT04710329||C Vit|The patients who were admitted to the intensive care unit and received a high dose intravenous vitamin C protocol constituted the treatment group
33084335|NCT04710329||non-C Vit|The patients who were admitted to the intensive care unit but did not receive the vitamin C protocol constituted the control group
33084336|NCT00174967|Placebo Comparator|Placebo QD|
33084337|NCT00174967|Experimental|Febuxostat 40 mg QD|
33084338|NCT00174967|Experimental|Febuxostat 80 mg QD|
33084339|NCT00174967|Experimental|Febuxostat 120 mg QD|
33084340|NCT00174265|Experimental|asenapine|
33084341|NCT00174265|Active Comparator|olanzapine|
33286044|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
33286045|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
32938153|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
33286046|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
33286047|NCT01027728|Experimental|CCX354-C|
33286048|NCT03776370||Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
33286049|NCT03776370||The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
33286050|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
33286051|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
33286052|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
33286053|NCT03576300||control|subjects without dry eye and diabetes
33286054|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
33286055|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
33286056|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
33286057|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
33286058|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
33286059|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
33286060|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
33286061|NCT03898986|Experimental|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
33286062|NCT03898986|Experimental|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
33286063|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
33286064|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
33286065|NCT01022658|Active Comparator|detemir and aspart|
33286066|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
33286067|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
33286068|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
33286069|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
33286070|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
33286071|NCT01022814||Pregnant woman|
33286072|NCT01025934|Active Comparator|7 days|
33286073|NCT01025934|Active Comparator|20 days|
33286074|NCT01025934|Sham Comparator|sham|
33286075|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
33286076|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
32938154|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
32938155|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
32938156|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
33084342|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
33084343|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
33084344|NCT00265356|Experimental|1|PET diagnostic imaging
33084345|NCT00265356|No Intervention|2|No PET
33084346|NCT00200876|Active Comparator|pain challenge|
33084347|NCT00200876|Sham Comparator|non-painful control|
33084348|NCT00200954|Placebo Comparator|placebo|placebo group
33084349|NCT00200954|Active Comparator|2|Probiotic bacteria group
33084350|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
33084351|NCT00265434|Placebo Comparator|isotonic saline|
33084352|NCT00172042|Experimental|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
33084353|NCT00172042|Other|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
33084354|NCT00201071||South Bronx, Harlem, Lower East Side|
33084355|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
33084356|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
33084357|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
33084358|NCT00201149|No Intervention|3|The control group will provide usual care
33084359|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
33084360|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
33084361|NCT00201188|No Intervention|2|Participants will receive usual care.
33084362|NCT00171925|Experimental|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
33084363|NCT00171925|No Intervention|Control|No treatment with study medication.
33084364|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
33286077|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
32780313|NCT04640519|Experimental|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
32780314|NCT04640519|Active Comparator|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
32780315|NCT04411901|Experimental|vitamin D 3|oral vitamin D3 drops and tablets
32780316|NCT05508815|Experimental|Guizhi Shaoyao Zhimu Decoction Combined with Methotrexate|
32780317|NCT05508815|Active Comparator|Methotrexate|
32780318|NCT05500547|Experimental|Universal single shade resin composite restorative material|Dental restorative material
32780319|NCT05500547|Active Comparator|Nano-hybrid multi-shade resin composite restorative material|Dental restorative material
32780320|NCT05508737|Experimental|Single arm, Pembrolizumab, trifluridine/tipiracil|
32780321|NCT05500235|Experimental|Smart phone based training|Smartphone-based training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
32780322|NCT05500235|Experimental|In person training|In person training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
32780323|NCT04333511|Experimental|Sequence 1|TPS first with crossover to Sham-TPS
32780324|NCT04333511|Experimental|Sequence 2|Sham-TPS first with crossover to TPS
32780325|NCT04324619|Experimental|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
32780326|NCT04324619|Experimental|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
33084365|NCT00201227|No Intervention|Control|Usual care
33084366|NCT00201266||Exacerbation resistant asthma|Control group
33084367|NCT00201266||Exacerbation prone asthma|Cases
33084368|NCT00265629|Experimental|1|RF ablation
33084369|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
33084370|NCT00201461|Active Comparator|1|Best medical therapy
33084371|NCT00201461|Experimental|2|STARFlex arm
33084372|NCT00201500||preeclampsia|women with preeclampsia
33084373|NCT00201500||controls|healthy pregnant women
33084374|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
33084375|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
33084376|NCT04709055|Experimental|Co-management arm (geriatric and surgical)|
33084377|NCT04709055|Active Comparator|Usual care|
33084378|NCT00201617||1|normal hearing sensitivity
33084379|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
33084380|NCT04709328|Experimental|SCTA01 low dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
33084381|NCT04709328|Experimental|SCTA01 middle dose+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
33084382|NCT04709328|Experimental|SCTA01 High dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
33286078|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
33286079|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
32938157|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
32938158|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
33286080|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
33286081|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
33286082|NCT01028040|Experimental|AZD3043|
32938159|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
32938160|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
32938161|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
32938162|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
32938163|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily~Docetaxel will be administered every 3 weeks intravenously~Prednisone will be taken orally twice daily~Leuprolide Acetate will be administered at the specification of the physician"
32938164|NCT03093662|Experimental|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
32938165|NCT03093662|Active Comparator|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
32938166|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
32938167|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
32938168|NCT04700150|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
32938169|NCT04700150|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
32938170|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
32938171|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
32938172|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
32938173|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
32938174|NCT04695236|Experimental|Study group|Study Group: Intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
32938175|NCT04695236|Placebo Comparator|Control group|"Control group: Without intravascular hypothermia therapy group~ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group"
32938176|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
32938177|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
32938178|NCT04611152|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
32938179|NCT04611152|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
32938180|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
32938181|NCT04590092|No Intervention|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
32938182|NCT04590092|Experimental|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
32938183|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
32956053|NCT05764837|Experimental|Intervention group|"Facilitation of the posterior chain was performed by foam rolling (BLACKROLL, standard hardness), where the left lower limb was rolled first, then the right lower limb and finally the spinal erectors. Rolling was performed with a sense of the highest intensity and at a high rolling speed, across the full length and width of the muscle with both cranial and caudal rolling directions. Facilitation was performed on each muscle group in the distoproximal direction, in the order of:~m. triceps surae, hamstrings, and m. gluteus maximus, with the proband attending to each muscle group for 30 s. Finally, bilateral facilitation of mm. erectores spinae in the lumbar and thoracic segments was performed, also for 30 s. The frequency of rolling was determined using a metronome at 1.5 Hz."
33286083|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
32780327|NCT04324619|Experimental|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
32780328|NCT04324619|Experimental|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
32780329|NCT04274465||Control|Negative high risk (HR)-HPV, cytology co-test
32780330|NCT04274465||CIN 1|Biopsy with low grade dysplasia
32938184|NCT04549532|Experimental|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
32938185|NCT04549532|Active Comparator|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
32938186|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
32938187|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
32938188|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
32938189|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
32938190|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
32938191|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
32938192|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
32938193|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
32938194|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
32938195|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
32938196|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
32938197|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
32938198|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
32938199|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
32938200|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
32938201|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
32938202|NCT03158714|No Intervention|Control|No programming is offered.
32938203|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
32938204|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
32938205|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
32938206|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
32938207|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
33402144|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
33402145|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
32938208|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
32780331|NCT04274465||CIN 2-3|Biopsy with high grade dysplasia
32938209|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
32938210|NCT03162458|Experimental|Anaferon for children|
32938211|NCT03162458|Placebo Comparator|Placebo|
32938212|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
32938213|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
32938214|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
32938215|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
32938216|NCT04468568||Atosiban|Intravenous Atosiban as main tocolytic agent
32938217|NCT04468568||Terbutaline|Intravenous Terbutaline as main tocolytic agent
32938218|NCT04393454|Experimental|Sirolimus|Participants will be instructed to take 2 mg every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
32938219|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
32938220|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
32938221|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
32938222|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
32938223|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
32938224|NCT03109015|Active Comparator|Schedule 4/2|
32938225|NCT03109015|Experimental|Schedule 2/1|
32938226|NCT04253756|No Intervention|18-gauge autogard catheter|Standard of care
32938227|NCT04253756|Experimental|20-gauge BD Nexiva Diffusics|Intervention
32938228|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
32938229|NCT05405881|Other|Children with upper motor neuron lesions|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. The comparator assessments on each level of the ICF-CY are conducted, and a feasibility questionnaire (detailed described under chapter outcome measures)
32938230|NCT05405881|Other|Children without UMN lesions (developing typically)|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. A feasibility questionnaire (detailed described under chapter outcome measures)
32938231|NCT04706780||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
32938232|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
32938233|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
32938234|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
32938235|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
32938236|NCT04201418||Patisiran Prospective Cohort|Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
32938237|NCT04201418||Patisiran Mixed Cohort|Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
32938238|NCT04201418||Patisiran Retrospective Cohort|Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
32956054|NCT05764837|No Intervention|Control group|The control group of probands rested in a resting sitting position for 4 minutes after pre-tests, corresponding to the intervention period.
32956055|NCT05764824|Active Comparator|Blueberry group|Blueberry arm
32956056|NCT05764824|Placebo Comparator|Control group|Control arm
32956057|NCT05764811|Active Comparator|Canagliflozin Treatment|Use Canagliflozin 100 mg daily, 1 month
32938239|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
32938240|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
32938241|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
32938242|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
33286084|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
33286085|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
33286086|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
33286087|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
32938243|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
33286088|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
33286089|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
33286090|NCT03520374|Other|Healthy adult volunteers|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 healthy adult volunteers using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
33286091|NCT03520374|Other|Pediatric patients|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 pediatric patients undergoing surgery in the preoperative area or the in-patient unit using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
33286092|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
33286093|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
33286094|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
33286095|NCT01028274|Placebo Comparator|Placebo|
32938244|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
32938245|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
32938246|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
32938247|NCT04736641||Patients group|Individuals with hip disease and chronic pain on hip
32938248|NCT00422630|Active Comparator|Average American Diet|
32938249|NCT00422630|Active Comparator|The DASH diet|
32956058|NCT05764811|No Intervention|non-Canagliflozin Treatment|Standard treatment
33084383|NCT04709328|Placebo Comparator|Placebo+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
32780332|NCT04231799|Experimental|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
32780333|NCT04231799|Experimental|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
32780334|NCT05508659|Experimental|Combined therapy (cohort A)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior PD-1/PD-L1 therapy
33084384|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
33286096|NCT01028274|Experimental|Investigational Product 1|
33286097|NCT01028274|Experimental|Investigational Product 2|
33286098|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
33286099|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
33286100|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
33286101|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
33286102|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
33286103|NCT01023048|Experimental|PGD testing|
33286104|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
33286105|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
33286106|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
33286107|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
33286108|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
32780335|NCT05508659|Experimental|Combined therapy (cohort C)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1.
32780336|NCT05508659|Active Comparator|SG001 injection monotherapy (cohort B)|SG001 monotherapy in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1
32780337|NCT05508581|Other|Varicose veins|Ablation of varicose veins by microwaves
32780338|NCT05500157|Active Comparator|Aspiration sclerotherapy|Aspiration sclerotherapy is a percutaneous procedure that evacuates fluid from the liver cyst and subsequently exposes cyst lining to a sclerosing agent (e.g. ethanol, minocycline) for a limited period of time.
32780339|NCT05500157|Active Comparator|Laparoscopic Fenestration|Laparoscopic fenestration exposes the liver through laparoscopic surgery. During this procedure the cyst is punctured and drained followed by resection of the extra-hepatic cyst wall
32780340|NCT05500079|Active Comparator|Wrist splint group|The group to be treated with a wrist splint
32780341|NCT05500079|Active Comparator|Transcutaneous pulsed RF group|The group to be treated with transcutaneous pulsed RF
32780342|NCT05499923|Active Comparator|Wing method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of wings and a squeezing force would be applied.
32780343|NCT05499923|Active Comparator|Base method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of the bracket base and a squeezing force would be applied.
32780344|NCT05508425|Active Comparator|water at room temperature|
32780345|NCT05508425|Experimental|hot water|
32780346|NCT05508425|Experimental|cold water|
32780347|NCT05508425|Experimental|hot water with tea bag|
32780348|NCT05508425|Experimental|room temperature water with tea bag|
32780349|NCT05508425|Experimental|cold water with tea bag|
32780350|NCT05508425|Experimental|bubble water at room temperature|
32780351|NCT05508425|Experimental|cold bubble water|
32780352|NCT05508347|Experimental|Experimental group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of 200mg nituzumab targeted therapy, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy.
32780353|NCT05508347|Placebo Comparator|control group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of placebo treatment, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy
32780354|NCT04280471|Experimental|Treatment (OpenBiome FMT capsule DE)|Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
32780355|NCT05499845||Group P (n=40) (Propofol),|
32780356|NCT05499845||Group PS (n=40) (Propofol-Sevoflurane),|
32780357|NCT05499845||Group S (n=40) (Sevoflurane).|
32780358|NCT04476953|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
32780359|NCT04476953|Placebo Comparator|Placebo Group|Subjects will receive placebo
32780360|NCT05508113|No Intervention|Control|No intervention was given to this group of patients
32780361|NCT05508113|Experimental|20-40ug/ml ozone|ozone autohemotherapy
32780362|NCT05499533|Experimental|Hybrid Funnel Technique|Hybrid funnel technique for implant site preparation
32780363|NCT05499533|Active Comparator|Conventional Technique|Conventional subtractive Drill technique for implant site preparation
32780364|NCT05508035|Experimental|sacubitril / valsartan|sacubitril / valsartan 200 mg twice a day PLUS placebo for ramipril 5 mg twice a day
32780365|NCT05508035|Active Comparator|ramipril|ramipril 5 mg twice a day PLUS placebo for sacubitril / valsartan 200 mg twice a day
33286109|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
33286110|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
33286111|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
33402146|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
32780366|NCT04411355|No Intervention|control group patients|non intervention. only rutin care
32780367|NCT04411355|Experimental|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
32780368|NCT04390139|Experimental|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
32938250|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
32780369|NCT04390139|Placebo Comparator|Treatment B|Placebo on D1 and D3
32780370|NCT04381637|Experimental|NIPE|
32780371|NCT05564663|Experimental|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include brief instruction and support for the use of the PTSD Coach App developed by the study team. The PTSD Coach App incorporates evidence-based assessment, psychoeducation, and self-management strategies for PTSD symptoms that are customizable to the user.
32780372|NCT05564663|Active Comparator|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation regarding PTSD and alcohol use disorder (AUD) and resources for PTSD-related mental health treatment.
32780373|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
32780374|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
32780375|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
32780376|NCT04785677|Experimental|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
32938251|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
32938252|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
32938253|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
32938254|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
32938255|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
32938256|NCT05405257|Placebo Comparator|Placebo|Placebo infusion: IV 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
32938257|NCT05405257|Active Comparator|Oxytocin|Treatment infusion: IV 1IU Oxytocin in 200ml of 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
32938258|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
32938259|NCT03177512|Experimental|LYNX Mobile App|
32938260|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
32938261|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
32938262|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
33286112|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33286113|NCT03510156|Experimental|Treatment|
33286114|NCT03510156|No Intervention|Observation|
33286115|NCT00443040|Placebo Comparator|Placebo|
33286116|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
32780377|NCT04785677|No Intervention|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
33286117|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
33286118|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
33286119|NCT03995160|Active Comparator|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
33286120|NCT03995160|Active Comparator|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
33286121|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
33286122|NCT01028508|Experimental|STABLE|ECT + VLF + Li
33286123|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
33286124|NCT00313300|Active Comparator|A1|
33286125|NCT00313300|Experimental|A2|
32938263|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
32938264|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
32938265|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
33286126|NCT00313300|Placebo Comparator|A3|
32938266|NCT04122170|Active Comparator|Bentracimab (PB2452)|PB2452 18 g Intravenous Infusion over a 16 hour duration.
32938267|NCT04122170|Placebo Comparator|Placebo|Placebo (0.9% Sodium chloride) intravenous Infusion over a 16 hour duration.
33286127|NCT00313300|Experimental|A4|
33286128|NCT01023282|Experimental|ACR325|
33286129|NCT01023282|Placebo Comparator|Placebo|
33286130|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
32938268|NCT04034030|Experimental|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI >85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
32938269|NCT05405101|Experimental|Radiofrequency ablation of adrenal aldosterone producing adenoma (s)|Ablation of adrenal aldosterone producing adenoma(s)
32938270|NCT05405101|Other|Unilateral adrenalectomy for aldosterone producing adenoma(s)|Unilateral adrenalectomy for laldosterone producing adenoma(s)
33286131|NCT01026714|Experimental|flurbiprofen 50mg po|
33286132|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
33286133|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
33286134|NCT03996252|Experimental|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
32938271|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
32938272|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
32938273|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
33286135|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
33286136|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
33286137|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33286138|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
33286139|NCT00458484|Experimental|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
33402147|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
33286140|NCT00458484|Experimental|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
33286141|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
32938274|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
32938275|NCT04736732||COVID-19 positive patients|"Patients who had previous asymptomatic or mild COVID-19 (mild=never required supplemental oxygen during the acute phase of the infection)~Patients who had previous moderate or severe COVID-19 (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation~Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis"
32938276|NCT04736732||COVID-19 negative patients|COVID-19 negative control group
32938277|NCT05401513|Experimental|Pilates Group|12-weeks exercise program, twice a week, with Pilates method exercises.
32938278|NCT05401513|No Intervention|Control Group|12-weeks maintaining their normal physical activity routine.
32938279|NCT05365022|No Intervention|Conventional Non-Robotic Assisted Knee Prosthetic Surgery|
32938280|NCT05365022|Active Comparator|ROSA® System Robotic Assisted Knee Prosthetic Surgery|
32938281|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
32938282|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
32938283|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
32938284|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
32938285|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
32938286|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
32938287|NCT05364866||Medical treatment group|Using class I or class III AAD to maintain sinus rhythm
32938288|NCT05364866||Cryoballoon ablation group|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
32938289|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
32938290|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
32938291|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
32938292|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
32938293|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
32938294|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
32938295|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
32938296|NCT03830840||Child family member with diabetes|Child, ≥7 years but <18 years, family member with diabetes
32938297|NCT03830840||Child family member without diabetes|Child, ≥7 years but <18 years, family member without diabetes
32938298|NCT05400421||Device Calibration & Algorithm Training|The data obtained from this group will be used to a) quantify the relationship between PWV measured at the groin versus the thigh for less intrusive future piezo sensor placement and b) train the proposed device for the next cohort.
32938299|NCT05400421||Device & Algorithm Testing|The gold-standard and new device values will be collected from this group to validate the previously trained system.
32938300|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
32938301|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
32938302|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
32938303|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
32938304|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
32938305|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
32938306|NCT03808922|Experimental|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
32938307|NCT03808922|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
32938308|NCT03808922|Experimental|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
32938309|NCT03808922|Experimental|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
32780378|NCT05564585|Experimental|Kinesio Tape|Kinesio Tape was applied over the Calf Muscle on Either leg.
32938310|NCT03808922|Experimental|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
32938311|NCT03808922|Placebo Comparator|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
32938312|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
32938313|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
32938314|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
32938315|NCT05347771|Experimental|Dupilumab|"Participants between 12-17 years of age, will receive an initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week (Q2W).~Participants between 6-11 years of age will not complete a loading dose and will receive injections based on their body weight:~Participants with a body weight of 15 kg to less than 30 kg, will receive 100mg Q2W.~Participants with a body weight of 30 kg or more, will receive 200 mg Q2W."
33402148|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
32744422|NCT04864977|Experimental|LY2963016|Participants with type 2 diabetes will be started on insulin glargine and dose will be titrated. Insulin glargine will be delivered via insulin pen each evening subcutaneously (SC). They will also check fasting blood glucose values on a study meter and prior to treating hypoglycemia. Participants will be asked to report the time and dose of their last administration.
32744423|NCT04869735||With information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
32744424|NCT04869735||Without information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
32744425|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
32744426|NCT04864821|Other|T cell injection targeting CD276 chimeric antigen receptor|
32744427|NCT04865055|Active Comparator|cyclic merocyanine|cyclic merocyanine long-UVA absorber
32938316|NCT05347771|Placebo Comparator|Placebo|"Participants between 12-17 years of age, will receive an initial dose of placebo (two injections) followed by a placebo injection given every other week (Q2W).~Participants between 6-11 years of age will not receive an initial loading dose of placebo and will receive injections Q2W based on their body weight."
32744428|NCT04865055|Placebo Comparator|placebo|
32744429|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
32744430|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
32744431|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
32744432|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
32938317|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
32938318|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
32938319|NCT05364632|Experimental|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
32938320|NCT05364632|Experimental|Aerobic Training|Participants will undergo an eight-week aerobic training protocol (twice a week) on a treadmill, each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down.
32938321|NCT05364398|Active Comparator|ACL reconstruction with stump preservation|
32938322|NCT05364398|Active Comparator|ACL reconstruction with stump resection|
32938323|NCT05364320||Men aged 50-64|
32938324|NCT05364320||Men aged 65 and over|
32938325|NCT05364320||Women aged 50-64|
32938326|NCT05364320||Women aged 65 and over|
32938327|NCT04736966|Experimental|Guselkumab 30mg|
32938328|NCT04736966|Experimental|Guselkumab 70 mg|
32938329|NCT04736966|Experimental|Guselkumab 100mg|
32938330|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
32938331|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
32938332|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
32938333|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
32938334|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
32938335|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
32938336|NCT03447782|No Intervention|Healthy Controls|These participants will be in the research study for the initial visit only. They will be evaluated by a physician or nurse practitioner
32938337|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
32938338|NCT03408704|No Intervention|Control-arm|No intervention at all.
33084385|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
33084386|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
33084387|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
33084388|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
33084389|NCT00265824|Active Comparator|bevacizumab alone|
32780379|NCT05564585|Sham Comparator|Sham Tape|Sham Tape was applied over the Calf Muscle on Either leg.
32780380|NCT05564507|Experimental|TEE simulation-based training group|"All participants of the TEE simulation group received:~1) a traditional didactic training using e-learning with a national free-access online course; and 2) two teaching sessions using a TEE simulator for 2 hours per session."
32780381|NCT05564507|No Intervention|TEE traditional group|All participants of the TEE traditional group received only a traditional didactic training using e-learning with a national free-access online course (same e-learning program allocated for the TEE simulation group).
32780382|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
32780383|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
32780384|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
32780385|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
32780386|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
32780387|NCT05564351|Experimental|Ear plug group|
32780388|NCT05564351|Experimental|Eye mask group|
32780389|NCT05564351|Experimental|Eye mask+Ear plug group|
32780390|NCT05564351|No Intervention|Control group|
33084390|NCT00265824|Experimental|Bevacizumab + erlotinib|
32780391|NCT04283201|Experimental|Diet|
32780392|NCT04283201|Experimental|Physical activity|
32780393|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
32780394|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
32780395|NCT04282109|Experimental|Arm 1|NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
32780396|NCT04282109|Active Comparator|Arm 2|ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
32780397|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
32780398|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
32780399|NCT04377971|Experimental|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
32780400|NCT04377971|Active Comparator|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
32780401|NCT03401489|Experimental|PACESETTER|
32780402|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
32780403|NCT05507801|Experimental|High Physically Active Group|Based on accelerometer data, women with 162 ≥ min/per day moderate and vigorous activity or men 133.25 ≥ min/per day moderate and vigorous activity.
32780404|NCT05507801|Experimental|Low Physically Active Group|Based on accelerometer data, women with 108.25 ≤ min/per day moderate and vigorous activity or men 100.1 ≤ min/per day moderate and vigorous activity.
32780405|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
32780406|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
32780407|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
32780408|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
32780409|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
32780410|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
32780411|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
32780412|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
32900361|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
33084391|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
33084392|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
33084393|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
33084394|NCT00258765|Experimental|Zoledronic Acid|
33084395|NCT00258765|Active Comparator|Docetaxel|
33084396|NCT00258843|Experimental|Group 1|Children at 18 months of age
33084397|NCT00258843|Experimental|Group 2|Infants at 2 months of age
33084398|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
33084399|NCT00201890|No Intervention|2|Standard of Care
33084400|NCT04709094|Experimental|Part 1: Danicopan and Warfarin|"Period 1: Participants received a single dose of warfarin.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.~Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2."
33084401|NCT04709094|Experimental|Part 2: Danicopan and Bupropion|"Period 1: Participants received a single dose of bupropion.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2."
33084402|NCT04709094|Experimental|Part 3: Danicopan and EE/NET|"Period 1: Participants received a single dose of EE/NET.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2."
33084403|NCT00171340|Experimental|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
32780413|NCT05563805|Experimental|Intervention|intervention participants will engage in a 30-minutes VR adventure games on a non-mobilized treadmill (5-min warm-up, 20-minutes treadmill, and 5-min cool-down) for a total of 24 sessions over 8 weeks. Participants in the V-RATE group will be instructed to self-pace walking/running on the treadmill while they are fully immersed in the VR games for two 10-minute bouts with a complete rest interval (heart rate reduces to normal range). Participants will complete measures at baseline, post-8-week training, and one-month follow-up.
32780414|NCT05563805|No Intervention|Control|Control participants will not receive the intervention. Participants will complete measures at baseline, 8 weeks, and one-month follow-up.
33286142|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
32780415|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
33084404|NCT00171340|Experimental|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
33084405|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
33084406|NCT00201968|Other|Control Group training|Aerobic and resistance training program
33084407|NCT00171301|Experimental|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
33286143|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
33402149|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
32780416|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
32780417|NCT05498207|No Intervention|No Intervention|Participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months. (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
32780418|NCT05498207|Experimental|Maya mobile app|
32780419|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
32780420|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
32780421|NCT05563571|Active Comparator|Intra-articular cortisone injection|Ultra-sound guided single injection of Methylprednisolon 40 mg (1 ml) + 1 ml 10 % Lidocaine to shoulder joint
32780422|NCT05563571|Active Comparator|pulsed radiofrequency of shoulder joint and suprascapular nerve|Ultra-sound guided single treatment of shoulder joint and suprascapular nerve with pulsed radiofrequency (PRF) STP (Sluijter Teixeira pulse) 45 V 4 minutes each with 1 ml 10% Lidocaine to both shoulder joint and suprascapular nerve.
32780423|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
32780424|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
32780425|NCT02489903|Experimental|Small Cell Lung Cancer (Arm 1)|RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
33402150|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
33402151|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
32780426|NCT02489903|Active Comparator|Small Cell Lung Cancer (Arm 2)|Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
32780427|NCT02489903|Experimental|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
32780428|NCT02489903|Experimental|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
32938339|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
32780429|NCT02489903|Experimental|Ovarian epithelial cancer (Arm 1)|RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
32780430|NCT02489903|Active Comparator|Ovarian epithelial cancer (Arm 2)|Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
32780431|NCT05563493|Experimental|Treatment group, Chair-Based Exercise Training|Treatment group will receive chair-based exercise training. Chair-based exercise training consisting of 20 different exercises will be applied in 2-3 sets with an average of 8-15 repetitions. Rest between sets will average 45-60 seconds.
32780432|NCT05563493|Other|Control group, Breathing exercise|Control group will receive breathing exercises.
32780433|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
32780434|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
32780435|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
32780436|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
32780437|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
32780438|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
32938340|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
32938341|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
32780439|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
32780440|NCT05563415|Other|Medicare AWV Toolkit|This is a stepped-wedged study. All practices will receive the intervention.
32780441|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
32780442|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
32780443|NCT05563337|Experimental|Denervation treatment|
32780444|NCT05563337|Sham Comparator|Control|
32938342|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
32938343|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
32938344|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
32938345|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
32938346|NCT05363540|Active Comparator|Pre-incisional parasternal block|ultrasound guided parasternal intercostal block will be administrated before surgical incision.
32938347|NCT05363540|Active Comparator|Post-incisional parasternal block|under direct vision parasternal intercostal block will be administrated after surgical incision and before closure of the sternum.
32938348|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
32938349|NCT05361200|Experimental|Adaptive dynamic cycling|For the patient-specific adaptive dynamic cycling group, the optimization process will be done after the 3rd, 6th, and 9th sessions. The optimization procedure is based on sample entropy of cadence calculation from the previous session's cycling performance. After optimization, participants will receive specific settings for the next session.
32938350|NCT05361200|Active Comparator|Non-adaptive dynamic cycling|For the non-adaptive group, individuals will cycle on the dynamic bike with pre-determined settings that will stay constant throughout the exercise protocol.
32938351|NCT05358236|Other|training + written and illustrated training brochure|"Postpartum first day was given wound care and genital hygiene training (one hour).~At the end of the training, the mothers were given a written and illustrated training brochure."
32780445|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780446|NCT05497973|Experimental|eHealth ecosystem of stepped psychosocial care|"Patients will be monitored allowing the delivery of timely and personalized care via a 4-level program:~Screening and psychosocial monitoring through a mobile application where patients have a messaging system to contact their psychologist and reference nurse.~Psychoeducation and health education campus, where patients can consult videos and online resources developed by health professionals, containing scientifically validated information.~Psychosocial support community where patients can share doubts, fears, and experiences with other patients with advanced lung cancer. This private social network is monitored by team specialists when necessary.~Online group psychotherapy of 8 weekly sessions of 90 minutes based on Meaning-Centered Group Psychotherapy (MCGP; Breitbart et al., 2010). Patients at this level will be on a waiting list, so the pool starts when there are 4-8 users available."
32780447|NCT05497973|Active Comparator|Usual psychosocial care|This group will receive standard psychosocial care for cancer survivors at ICO Hospitalet center led by a clinical psychologist. It consists of 7 individual sessions of 45-60 minutes, scheduled every 2-3 weeks during 9 months and focused on emotional support and psychoeducation. Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled in a website open to all patients and relatives.
32780448|NCT04475549|Experimental|IW-6463|Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.
32780449|NCT05497895|Experimental|Group I (SRP and TQ gel)|In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application
32780450|NCT05497895|Placebo Comparator|Group II (SRP and Placebo)|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
32780451|NCT05497895|Active Comparator|Group III (Only SRP and one stage prophylaxis)|The Group III patients will be subjected to one-stage oral prophylaxis.
32780452|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive GSK2556286 in any of the 11 cohorts. In each dosing cohort, 6 participants will receive a single dose of GSK2556286. Following initial dosing of cohorts in the fasted state, one cohort will investigate the effect of food administration (high fat meal) on safety, tolerability and PK data of GSK2556286. One cohort may also investigate the effects of a moderate fat meal.
32780453|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 11 cohorts. In each dosing cohort, 2 participants will receive a single dose of matching placebo.
32780454|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|"Participants will be randomized to receive GSK2556286 in any of the 4 cohorts. In each dosing cohort, 6 participants will receive repeat doses of GSK2556286 under either fasting or fed conditions, dependent on the results from Part A.~Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B."
32780455|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts. In each dosing cohort, 2 participants will receive repeat doses of matching placebo under either fasting or fed conditions, dependent on the results from Part A.
32780456|NCT04471337|Experimental|Arm A: Moderately impaired renal function|Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
32780457|NCT04471337|Experimental|Arm B: Normal renal function matched to Arm A|Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
32780458|NCT04471337|Experimental|Arm C: End stage renal disease on dialysis|Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
32780459|NCT04471337|Experimental|Arm D: Normal renal function matched to Arm C|Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
32780460|NCT05497739|Experimental|Intraperitoneal chemotherapy group|In this study, patients with positive peritoneal lavage fluid cancer cell DNA will be given intraperitoneal chemotherapy followed by adjuvant systemic chemotherapy.
32780461|NCT04356599|Experimental|Intervention Group|All participants will receive study intervention
33402152|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
33402153|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
32780462|NCT05562869|Experimental|Experimental: transient belatacept|IV, 5mg/Kg days 1, 15, 30, 45 and 60 then every months
32938352|NCT05358236|No Intervention|Standard of care|No intervention. Left to the usual care of the hospital
32938353|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
32938354|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
32938355|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
32938356|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
32780463|NCT04324463|Experimental|Colchicine|"Outpatients:~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).~Inpatients:~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.~(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
32780464|NCT04324463|Experimental|Interferon Beta [This arm is now closed to recruitment]|"Inpatients Only:~0.25 mg by subcutaneous injection on days 1, 3, 5 & 7"
32780465|NCT04324463|Experimental|Aspirin (ASA)|"Outpatients:~75 to 100 mg once daily for 28 days.~Inpatients:~75 to 100 mg once daily for 28 days"
32780466|NCT04324463|Experimental|Rivaroxaban|"Inpatients Only:~2.5 mg twice daily for 28 days."
32780467|NCT04324463|No Intervention|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
32780468|NCT04085237|Experimental|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
32780469|NCT04085237|Sham Comparator|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
32780470|NCT05497661|Experimental|Effects of Capacitive Resistive Monopolar Radiofrequency in patellar tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant patellar tendon.
32780471|NCT05497661|Placebo Comparator|Placebo Comparator: Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant patellar tendon
32780472|NCT04080869|Experimental|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
32780473|NCT04080869|Active Comparator|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
32780474|NCT05562791|Experimental|68Gallium PSMA-PET/CT|Patients will initially undergo a standard of care FDG PET with diagnostic CT scan followed by an investigational 68Ga PSMA PET/CT scan.
33084408|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
33084409|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
33084410|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
32780475|NCT05562635|Experimental|5 % polymers with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
32780476|NCT05562635|Experimental|10 % polymers with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
32780477|NCT05562635|Placebo Comparator|Placebo group|Application of polymers without CBD on the masseter muscles, bilaterally
32780478|NCT04078061|Active Comparator|MABA|
32780479|NCT04078061|Active Comparator|EIBI|
32780480|NCT05497505||Discharged patients with decision support (On-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. In addition, Pacmed Critical will be used as an additional source of information. Final discharge decision will be made by lead unit intensivist responsible for medical care.
33084411|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
32780481|NCT05497505||Discharged patients without decision support (Off-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. Final discharge decision will be made by lead unit intensivist responsible for medical care.
32780482|NCT05560451|Experimental|Peer health coach intervention|Participants will receive 20 virtual visits with a trained Veteran peer health coach over 12 months. Coaches will provide participants with brief health education, assist with goal setting and problem solving, enhance social support, and link participants to VA and community resources.
33318149|NCT05119036|Experimental|Adjuvant Radiation 54 Gray|If patients have 4 or fewer positive nodes with greater than 2 mm of cancer spread extending outside the lymph nodes or 5 or more positive nodes with 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 54 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
32780483|NCT05560451|No Intervention|Control group/no intervention|Participants will continue to receive their regular, usual primary care.
32780484|NCT05499299|Active Comparator|Government|Participants were shown with the government slogan for the COVID-19 vaccine campaign in 2021. This was the control arm.
32780485|NCT05499299|Experimental|Comparison|The ad emphasized that vaccine uptake in Hong Kong substantially lagged behind that in comparable populations such as Singapore and the UK.
32780486|NCT05499299|Experimental|Exemption|The ad emphasized that vaccinated people could be exempted from some disruptive control measures such as mandatory testing
32780487|NCT05499299|Experimental|Family|The ad prompted people to get vaccinated in order to protect their family.
33318150|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
33084412|NCT00171223|Experimental|All Participants With Chronic Myeloid Leukemia|Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).
33084413|NCT04571905|Other|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
33084414|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
33084415|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
33084416|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
33084417|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
33084418|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
33084419|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
32744433|NCT04869579|Experimental|Selenious Acid + Standard Of Care (SOC)|Participants who are moderately-ill, severely-ill, or critically ill will receive a Selenious Acid infusion of 2000µg on day 1 as a loading dose infusion, followed by a continuous infusion of Selenious Acid at a maintenance dose of 1000µg daily on days 2-14 together with continued Standard Of Care therapy.
32744434|NCT04869579|Active Comparator|Standard Of Care (SOC) + Placebo|Participants will receive a Saline-based placebo infusion of 2000µg on day 1 as a loading dose, followed by continuous infusion of a Saline-based placebo at a maintenance dose of 1000µg daily on days 2-14. Standard Of Care is to be determined according to patients' clinical picture and may include Dexamethasone, Azithromycin, Ceftriaxone, Remdesivir, Convalescent Plasma.
32744435|NCT04864587||Restorative colectomy with ileoanal pouch|Patients with restorative colectomy with ileoanal pouch who receive pouchoscopy for detection of pouchitis or neoplasm
32744436|NCT04864899|Experimental|Recovered COVID-19 patients|
32744437|NCT04864899|Experimental|Recovered non-COVID-19 viral respiratory infections patients|
32744438|NCT04864899|Experimental|Age and gender matched controls|
32744439|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
32744440|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
32744441|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
32744442|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
32744443|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
32744444|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
32744445|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
32744446|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
32744447|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
32744448|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
32744449|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
32744450|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
32744451|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
32744452|NCT03229577|No Intervention|Control|The control group will receive no intervention.
32744453|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
32744454|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
32744455|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
32744456|NCT03229265|Experimental|Patiromer|
32744457|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
32744458|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
32744459|NCT03229187||neoadjuvant chemotherapy|
32780488|NCT05499299|Experimental|Lottery|The ad prompted people to get vaccinated in order to be eligible for the numerous COVID-19 lotteries in Hong Kong
32780489|NCT05499299|Experimental|Mortality|The ad emphasized that COVID-19 has caused millions of deaths worldwide.
32780490|NCT05499299|Experimental|Reopen|The ad prompted people to get vaccinated to help Hong Kong reopen sooner.
32780491|NCT05499221|Active Comparator|Conventional anchorage|Buccal tubes will be bonded on the lower first molars, an alginate impression will be taken for the lower arch with the buccal tubes in place, and a cast will be poured. A hard vacuum sheet of 1.5- mm thickness will be used to fabricate the Essix appliance. The posterior end of the buccal surface will be trimmed in each lower first molar region, creating a window to allow for attachment of the elastics. Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally. During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily.
32780492|NCT05499221|Experimental|Skeletal anchorage|Closing coil springs will be attached from the maxillary canine to the infrazygomatic miniscrews bilaterally
32780493|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
32780494|NCT05492201|Experimental|LY3873862 (Part A)|LY3873862 administered orally as single dose.
32780495|NCT05492201|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
32780496|NCT05492201|Experimental|LY3873862 (Part B)|LY3873862 administered orally as multiple doses.
32780497|NCT05492201|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
32780498|NCT04049825|Experimental|Dose Escalation Stage|The dose of OPB-111077 in the first cohort will be 200 mg/day, increasing as appropriate to 400 mg/day in the second cohort and then to 600 mg/day in the third cohort.
32780499|NCT04049825|Experimental|Dose Expansion Stage|4 days on and 3days off of 21-day cycles of OPB-111077 Day 1 of 21-days cycles of rituximab Day 2 and 3 of 21-day cycles of bendamustine
32780500|NCT05497349|Experimental|Leukocyte Rich-PRP Injection|"Three infiltrations of Leukocyte Rich Platelet Rich Plasma~1 infiltration weekly, for 3 weeks"
32780501|NCT05497349|Active Comparator|Leukocyte Poor- PRP Injection|"Three infiltrations of Leukocyte Poor-Platelet Rich Plasma~1 infiltration weekly, for 3 weeks."
33084420|NCT00476554|Experimental|Arm A: High dose|High-dose (Arm A): 200 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
33084421|NCT00476554|Experimental|Arm B: High dose|Low-dose (Arm B): 100 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
33084422|NCT00476125|Experimental|3 day ketogenic diet|
33084423|NCT00476125|Experimental|12 day ketogenic diet|
32780502|NCT01358981|Experimental|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between periods (doses)."
32780503|NCT01358981|Placebo Comparator|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between periods (doses)."
32780504|NCT05499065|Experimental|75mg cetuximab + 15mg cetuximab-800CW|To investigate if study drugs can assist in tumor-positive margin detection
32780505|NCT05498987|Experimental|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon
32780506|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
32780507|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
32780508|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
32780509|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
32780510|NCT04227977|Experimental|Treatment|JuxtaFlow
32780511|NCT05498909||Treatment group|"Treatment group（Multidisciplinary assisted treatment model group）： Those who received any of the following treatments, as recommended by the standard medical procedure, were considered to have received the standard medical treatment; otherwise, they were not.~Surgical procedures: left atrial appendage ligation, left atrial appendage clip, valve repair or replacement, etc.~Medical procedures: atrial fibrillation radiofrequency ablation, valvular closure, left atrial appendage closure, etc.~Anticoagulant drug therapy: standardized anticoagulant drug therapy."
32780512|NCT05498909||Control group|"Control group（Routine diagnosis and treatment model group）:~Patients who did not agree to enter the multidisciplinary treatment mode were automatically admitted to the routine treatment mode group"
33084424|NCT00476125|Experimental|16 hour fast|
32780513|NCT04038437|Experimental|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
32780514|NCT05498753||Control|Healthy infants
32780515|NCT05498753||Experimental|Preterm Infants
32780516|NCT04277741|Experimental|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
32780517|NCT04277741|Active Comparator|Native wheat bar|The control group will consume one native wheat starch bar per day.
33084425|NCT04709289|Experimental|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
33084426|NCT00259038|Experimental|Experimental Drug|
33084427|NCT00259038|Placebo Comparator|Placebo|
33084428|NCT00230594|Active Comparator|1|desmopressin
33286144|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
32938357|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
32938358|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
32938359|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
32938360|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
32938361|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
32938362|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
32938363|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
32938364|NCT05357300|Active Comparator|Peripheral Nerve Stimulation|Implant of percutaneous leads and impulse generator for peripheral nerve stimulation
32938365|NCT05357300|No Intervention|Best Medical Treatment|Physical therapy and therapy with analgetic medication
32938366|NCT05247463||Women invited to Breast Cancer Screening in England|Women invited to Breast Cancer Screening in England up to 31st March 2018
32938367|NCT05247463||Women attending Breast Cancer Screening in England|Women attending mammography screening to examine the effect of screening test threshold on outcomes, up to 31st March 2018
32938368|NCT05347082|Experimental|Vitamin D|8000 IU of vitamin D orally, once a day, for four weeks.
32938369|NCT05235139|Experimental|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens.
32938370|NCT05235139|Active Comparator|IOL implantation active comparator|Comparator arm: EDOF intraocular lens.
32938371|NCT04736420||Warfarin|Reference group
32938372|NCT04736420||Rivaroxaban|Exposure group
32938373|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
32938374|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
32938375|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
32938376|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
32938377|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
32938378|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
32938379|NCT02807558|Experimental|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6mg/m2/day orally divided into twice a day dosing.
32938380|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with azacitidine|"SY-1425 days 8-28 of a 28-day cycle at 6mg/m2/day orally divided into twice a day dosing.~Azacitidine 75 mg/m2/day IV or SC days 1-7 of a 28-day cycle in combination with SY-1425."
32938381|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with daratumumab|"SY-1425 during a 7-day lead-in and days 1-28 of a 28 day cycle at 6mg/m2/day orally divided into twice a day dosing.~Daratumumab at 16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425."
32938382|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
32938383|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
32938384|NCT02907086||colorectal cancer|
32938385|NCT02907086||melanoma|
32938386|NCT05197231|Experimental|IV amino acids + standardized physiotherapy with lower limb resistance exercise.|Research subjects randomized to the intervention group will receive an infusion of IV amino acids during a session of protocolized physiotherapy that includes a knee extension resistance exercise targeting the thigh muscles. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
32938387|NCT05197231|Active Comparator|IV amino acids + standardized physiotherapy.|Research subjects randomized to the control group will receive an infusion of IV amino acids during a session of protocolized physiotherapy NOT including lower limb resistance exercise. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
33084429|NCT00230594|Placebo Comparator|2|placebo
33084430|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
33286145|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
33286146|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
33286147|NCT01028586|Placebo Comparator|Arm 3|Placebo
33084431|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
33084432|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
33084433|NCT00230711|Experimental|Exercise Counseling|
33084434|NCT00230711|Placebo Comparator|Contact Control|
33084435|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
33084436|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
33084437|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
33084438|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
33084439|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
33286148|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
33286149|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
33286150|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
33286151|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
33286152|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
33286153|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
33286154|NCT03440892||1|
33286155|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
32780518|NCT05498675||Sacubitril/valsartan group|Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
33286156|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
32780519|NCT05498675||ACEI/ARB group|"Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
33286157|NCT04898322|Experimental|2.5mg SY-005|
33286158|NCT04898322|Experimental|5mg SY-005|
33286159|NCT04898322|Experimental|10mg SY-005|
32780520|NCT05491421|Experimental|A (ZT002)|Drug: ZT002 Dose level: 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg Dose: Subcutaneous Injection
33286160|NCT04898322|Placebo Comparator|Placebo|
33286161|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
33286162|NCT01323036|Experimental|Krill Oil|
33286163|NCT01323036|Experimental|Fish Oil|
33286164|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
33286165|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
32780521|NCT05491421|Placebo Comparator|B (Placebo)|Dose level: 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg Dose: Subcutaneous Injection
32780522|NCT05498519|Experimental|Dose-escalation and Dose-expansion|SY-4798 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached. In dose-expansion phase, preliminary anti-tumor activity will be assessed in FGF19+ advanced tumor.
32780523|NCT04282733|Experimental|Mindfulness Rounds|Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
32780524|NCT04282733|No Intervention|Control|No intervention will take place on this Unit
32780525|NCT05491343|No Intervention|Conservative management|
32780526|NCT05491343|Experimental|Progesterone treatment|
33084440|NCT00479401|Placebo Comparator|Placebo|
33084441|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
33084442|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
33084443|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
33084444|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
33286166|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
32938388|NCT05339282|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
32938389|NCT05339282|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
32744460|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;~FOLFOX4 4 weeks after HR"
32938390|NCT05047705|Experimental|Distress Tolerance Skills Training|Distress tolerance skills training is a multicomponent intervention drawn from third-wave cognitive-behavioral therapy (CBT) protocols.
32938391|NCT05324384|Experimental|Low dose of sirolimus|The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 6 months. Then, The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 6 months.
32938392|NCT05324384|Active Comparator|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
32938393|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
32938394|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
32938395|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
32938396|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
32938397|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
32938398|NCT04736810|Experimental|AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride|
32938399|NCT04736810|Experimental|AK105 plus Cisplatin and Gemcitabine|
32938400|NCT04736810|Experimental|AK105 plus Gemcitabine and Anlotinib Hydrochloride|
32938401|NCT05267990|Active Comparator|coronary artery calcium-guide|"1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner If CAC score >0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged.~If CAC score > 100， Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score>100 at low bleeding risk indicated net benefit If CAC score > 400，statin therapy will be suggested to control lipidemia aggressively and target LDL level<70 mg/dL"
32938402|NCT05267990|No Intervention|usual care|The investigators will enroll 500 age, gender, risk factor matched T2DM patient from our hospital. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
32938403|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
32938404|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
32938405|NCT05267054|Experimental|Cohort 1 (participants with PD-L1 positive on the surface of tumor cells)|participants will receive ociperlimab in combination with tislelizumab
32938406|NCT05267054|Experimental|Cohort 2 (participants with PD-L1 negative on the surface of tumor cells|participants will receive ociperlimab in combination with rituximab
32938407|NCT05027503|Active Comparator|Control Group|Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks
32938408|NCT05027503|Experimental|Training Group|In addition to home-based respiratory physiotherapy, 30 min exercises with the hippotherapy simulator will be done.
32938409|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
32938410|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
32938411|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
32938412|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
32938413|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
33286167|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
33286168|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
33318151|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
33318152|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
32780527|NCT05498441|Experimental|Personalized HD-tDCS|"The experimental arm will receive the personalized HD-tDCS treatment with parameters as follows:~Neuroimaging biomarker-guided personalized selection for central electrode polarity: anode or cathodal;~Neuroimaging biomarker-guided personalized selection for stimulation site: dorsalmedial prefrontal cortex or occipital cortex;~Schedule: 2 sessions per day, five days per week for a total of 20 sessions over 2 weeks."
32780528|NCT05498441|Active Comparator|Routine HD-tDCS|Routine stimulation arm will receive the same scheme of HD-tDCS, but the stimulation target is L-DLPFC with anode as central electrode.
32938414|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
32780529|NCT05498285|Experimental|Intervention|Use of UPSCALER App
32780530|NCT05498285|No Intervention|Control|No app used. Conventional treatment.
32780531|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
32780532|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
32780533|NCT05491265|Experimental|Kangaroo mother care|To see the impact of intermittent kangaroo mother care on temperature ,oxygen saturation and heart rate.
32780534|NCT05491265|No Intervention|standard of care|To observe temperature ,oxygen saturation and heart rate in preterm neonates not given kangaroo care
32780535|NCT05486195|Experimental|SDI-118 Dose 1|
32780536|NCT05486195|Experimental|SDI-118 Dose 2|
32780537|NCT05486195|Experimental|SDI-118 Dose 3|
32780538|NCT05486195|Experimental|SDI-118 Dose 4|
32780539|NCT05486195|Experimental|SDI-118 Dose 5|
32780540|NCT05486195|Experimental|SDI-118 Dose 6|
33318153|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
32938415|NCT02596412|Experimental|augmented reality (Mini-Docs) on tablet|• Cerebral-palsied children using the module with augmented reality (Mini-Docs) on tablet during TB injections in addition to regular drug techniques (experimental group)
32938416|NCT02596412|No Intervention|Control|Cerebral-palsied children with the usual pain care during TB injections, which combines drug techniques to distractibility techniques (control group)
32938417|NCT04964089|Experimental|KSI-301 (Treatment Group A)|Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 44.
33402154|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
33402155|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
33402156|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
32780541|NCT05486195|Placebo Comparator|SDI-118 Placebo|
32780542|NCT05491187|Active Comparator|Group B (bupivacaine group)|Drug used: 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -11mg with volume of 2.2ml single administration, no repetition of intervention
32780543|NCT05491187|Experimental|Group BF(bupivacaine with fentanyl group)|Drug used:- 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -10mg, 2ml and fentanyl 10mg ,0.2ml with total volume of of 2.2ml single administration, no repetition of intervention
32780544|NCT05486039||Normal Posture|
32780545|NCT05486039||Lordotic Posture|
32780546|NCT05486039||Sway Back Posture|
32780547|NCT05486039||Hypolordotic Back Posture|
32780548|NCT05486039||Head Anterior Tilt Posture|
32780549|NCT05486039||Scoliotic Posture|
32780550|NCT05486039||Kyphotic Posture|
32780551|NCT04276727|Active Comparator|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
32780552|NCT04276727|Placebo Comparator|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
32780553|NCT05485883|Experimental|Advanced Renal Cell|Patients will receive treatment with Tislelizumab every 3 weeks,and take Lenvatinib 8mg every day
32780554|NCT05490953|Placebo Comparator|Group A with placebo|Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus placebo, during the first two cycles of chemotherapy.
32780555|NCT05490953|Experimental|Group B with pentoxifylline|"Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus pentoxifylline, during the first two cycles of chemotherapy.~Pentoxifylline dose of 20 mg/kg/day, maximum dose 1200 mg/day"
32780556|NCT05485727|Experimental|RG(Robotic group= study group)|14, Robotic-assisted gait training group (RG) will receive Lokomat gait training and conventional physiotherapy
32780557|NCT05485727|Active Comparator|& CG( Control group)|control group (CG) will only receive conventional physiotherapy
32780558|NCT05496959|Active Comparator|Arm 1 (SBRT)|Beginning on day 1, patients undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
32780559|NCT05496959|Experimental|Arm 2 (177Lu-PNT2002, SBRT)|Patients receive 177Lu-PNT2002 IV over 1-10 minutes on days -112 and -56 in the absence of disease progression or unacceptable toxicity. Beginning on day 1, patients then undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
33286169|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
33286170|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
32938418|NCT04964089|Active Comparator|Aflibercept (Treatment Group B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 44. Sham injections will be administered at each monthly visit where an active treatment is not administered.
32938419|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
33286171|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
33286172|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
33286173|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
33286174|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
32938420|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
32938421|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
32938422|NCT04736654||Patients group|Individuals with headache
32938423|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
32938424|NCT03134989|Other|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
32938425|NCT02002130|Placebo Comparator|Placebo GABA and Placebo GAD-alum|"Placebo formulation, Maltodextrin, for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste, but no active medication will be taken with meals.Number of pills based on body surface area.~Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month."
32938426|NCT02002130|Active Comparator|GABA and placebo GAD-alum|"Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.~Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month."
32938427|NCT02002130|Active Comparator|Active Oral GABA and Active GAD-alum Injection|"Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between 2 meals/day.~Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline."
32938428|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
32938429|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
32938430|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
32938431|NCT01306994||Control Group|Healthy individuals
32938432|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
32938433|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
32938434|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
32938435|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
32938436|NCT01930136|Active Comparator|Ad libitum health diet|
33084445|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
33084446|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
33084447|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
33286175|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
32780560|NCT04273607|Experimental|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
33402157|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
33402158|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
33084450|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
33084451|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
33084452|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
33286176|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
32780561|NCT04273607|No Intervention|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
32780562|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
32780563|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
32780564|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
32780565|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
33084453|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
33084454|NCT00230945|Experimental|1|Patient-oriented education and support intervention
33084455|NCT00230945|Experimental|2|Couple-oriented education and support intervention
33286177|NCT00441792|Experimental|Etomidate|
33084456|NCT00266253|Experimental|1|
33084457|NCT00266253|Experimental|2|
33084458|NCT00266253|Experimental|3|
33084459|NCT00266253|Experimental|4|
33084460|NCT00266253|Experimental|5|
33084461|NCT00266253|Active Comparator|6|
33084462|NCT04721678|Experimental|Interpersonal psychotherapy (IPT)|10 weeks of internet-administered interpersonal psychotherapy with therapist support.
33084463|NCT04721678|No Intervention|Wait-list control group|The participants in the control group will receive access to the treatment after the post-treatment assessment has been conducted.
33084464|NCT00415350|Active Comparator|Azithromycin treatment 1|
33084465|NCT00415350|Placebo Comparator|Placebo 2|
33084466|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
33084467|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
33286178|NCT00441792|Experimental|midazolam|
33286179|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
33286180|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
33286181|NCT00297778|Experimental|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
33286182|NCT00297778|Placebo Comparator|placebo|Placebo (matching) tablets
33286183|NCT03848832|Experimental|5 milligrams per kilogram per day (mg/kg/day) GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
33286184|NCT03848832|Experimental|15 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
33084468|NCT00415389|Active Comparator|1|interactive educational program
33084469|NCT00415389|Active Comparator|2|usual medical care
33084470|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
33084471|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
33084472|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
33286185|NCT03848832|Placebo Comparator|Placebo|Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
32780566|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
32780567|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
32780568|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
32780569|NCT05480605||Experimental Group|Children with autism ages 6-13
32780570|NCT05480605||Control Group|Typically developing children ages 6-13
32780571|NCT05480371|Active Comparator|Conventional endotracheal suctioning|Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations: closed suction system, suction catheter with maximal internal-to-external diameter ratio of 0.5, delivery of 100% oxygen 30 s immediately before and 1 min after the procedure, duration of 15 s, and vacuum pressure of ±150 mmHg
33084473|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
32780572|NCT05480371|Experimental|mechanical insufflation exsufflation|The mechanical insufflation-exsufflation will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause, and tracheal suctioning will be performed at the end of the procedure. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions. The secretion collected after each procedure will be stored in a disposable bronchial secretion collector for later weighing
32780573|NCT05476081||Patients (single cohort study)|Patients presenting with a mild-to-moderate ischemic stroke or high risk TIA
32780574|NCT05480215|Experimental|Experimental: TAPS delivered by Cala device with Trio band|Two 40-minute TAPS sessions daily for 14 days
32780575|NCT05480215|Experimental|Experimental: TAPS delivered by Cala device with Trio+ band|Two 40-minute TAPS sessions daily for 14 days
33084474|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
33084475|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
33084476|NCT00415428||1.|
33084477|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
33084478|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
33084479|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
33084480|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
33084481|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
33286186|NCT00450372|Experimental|ADI-PEG 20|
33286187|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
32780576|NCT04486573|Other|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.~CMRI will be performed:~Within 2 weeks before the first fraction of radiation therapy (RT)~Within 1 week of the final fraction of RT (before or after)~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.~Pre- and post-RT CMRI parameters will be compared.~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
32780577|NCT04480099|Active Comparator|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
32780578|NCT04480099|Experimental|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
32780579|NCT04479553||Qizhi Tongluo Capsules|Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
32780580|NCT05476003|Sham Comparator|Sham Technique|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of 10 ml normal saline bilaterally.
32900362|NCT05539716|No Intervention|No Intervention (Aim 1) Group|Participants in this group will not receive an intervention and will only undergo several testing procedures conducted within 3 to 4 weeks to assess OSA severity.
33084482|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
33084483|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
33402159|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
32780581|NCT05476003|Active Comparator|Ultrasound-guided Bilateral superficial cervical plexus block|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of total volume 10 ml containing Bupivacaine 0.25% (5 ml Bupivacaine 0.5 % and 5 ml normal saline).
32780582|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
32780583|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
32780584|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
32780585|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
32780586|NCT05460949|Experimental|HOLD RELAX STRETCHING OF ILIOPSOAS|"10-second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20-second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
32780587|NCT05460949|Experimental|• WILLIAM'S PROTOCOL|"Pelvic tilt~Single Knee to chest~Double knee to chest~Partial sit-up~Hamstring stretch~Hip Flexor stretch~Squat~Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols."
32780588|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
32780589|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
33286188|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
33286189|NCT03995316|Other|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
33402160|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
32780590|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
32780591|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
32780592|NCT05475847|Experimental|C-TIL052A treatment group|C-TIL052A autologous infiltrating lymphocytes injection followed by injection of Interleukin 2 (IL-2)
32938437|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
32780593|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
32938438|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
32938439|NCT00503438|Other|Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
32938440|NCT05171114|Experimental|moderate Scleroderma|Patients with Cochin hand score less than or equal to 16
32938441|NCT05171114|Experimental|severe Scleroderma|Patients with Cochin hand score greater than 16
32938442|NCT04954651||VAC|Vaccinated subject against Sars-Cov2
32938443|NCT04867525||Colorectal Cancer Metastatic|
32938444|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
32938445|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
32938446|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938447|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938448|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938449|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938450|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938451|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938452|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
32938453|NCT00913640||PD Group|
32938454|NCT00913640||Control Group|
32938455|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
32938456|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
32938457|NCT04791943|Experimental|Experimental Treatment - Melatonin|Premedication for three nights with 10mg melatonin
32938458|NCT04791943|Placebo Comparator|Control Treatment - Lactose|Premedication for three nights with lactose capsules
32780594|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
32780595|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
32780596|NCT03949465|Experimental|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
32780597|NCT05460247|Experimental|Pea protein diet|
32780598|NCT05460247|Experimental|Whey protein diet|
32780599|NCT05460247|Experimental|Soy protein|
32780600|NCT05460247|Experimental|Rice protein|
32780601|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
32780602|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
32780603|NCT05467423|Active Comparator|Standard-dose|The standard-dose arm takes one 100mg of iron per day together with a meal, no matter breakfast, lunch or dinner - one tablet a day.
33084484|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
33402161|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
32780604|NCT05467423|Experimental|Low-dose|The low-dose arm 12mg of iron a day. The first 6mg tablet in the morning on an empty stomach and the second 6mg tablet in the evening either one hour before or after eating - two tablets a day.
32780605|NCT05466643|Experimental|DWP16001|
32780606|NCT05466643|Placebo Comparator|Placebo|
32780607|NCT02320435|Experimental|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
33402162|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
32780608|NCT02543203|Active Comparator|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
32780609|NCT02543203|Sham Comparator|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
32780610|NCT05434039|Experimental|diclofenac phonophoresis|the patients will receive diclofenac phonophoresis and traditional therapy three times a week for four weeks
32780611|NCT05434039|Experimental|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy three times a week for four weeks
32780612|NCT05434039|Active Comparator|conventional therapy|the patients will receive traditional therapy three times a week for four weeks
32780613|NCT05433571|Experimental|Myopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780614|NCT05433571|Experimental|Myopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780615|NCT05433571|Experimental|Myopes - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780616|NCT05433571|Experimental|Myopes - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780617|NCT05433571|Experimental|Hyperopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32938459|NCT05113004|Placebo Comparator|Arm 1|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
32780618|NCT05433571|Experimental|Hyperopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at time bilaterally over 2 wear periods.
32780619|NCT05433571|Experimental|Hyperope - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780620|NCT05433571|Experimental|Hyperope - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
32780621|NCT05459233|Other|Doppler-echocardiography|Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements.
32780622|NCT05459233|Other|Invasive hemodynamic measurements|Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording).
33084485|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
33084486|NCT00415545|Experimental|1|Fluid Watchers LITE program
33084487|NCT00415545|Experimental|2|Fluid Watchers PLUS program
33084488|NCT00415545|No Intervention|3|Usual care control group
33084489|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
33084490|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
33084491|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
33286190|NCT03995316|Other|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
33286191|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
33084492|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
33084493|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
33084494|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
33084495|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
32780623|NCT05466175|Experimental|Treatment Group|combination of Olverembatinib with chemotherapy
32780624|NCT05459077|Other|Aim 3B|This aim will evaluate the feasibility and acceptability of the adapted health care delivery intervention to improve anti-hypertensive medication adherence and blood pressure control in persons living with HIV at 24 weeks.
32780625|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
33286192|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
32780626|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
32780627|NCT05458453|Experimental|Esketamine arm|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ e sketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
32780628|NCT05458453|No Intervention|Sufentanil arm|Continuous pumping with self-controlled intravenous analgesia pump. According to sufentanil 1.5ug/ml+16mg ondansetron. At the end of the operation, connect the analgesic pump, and pump it with sufentanil at 0.1ug/kg/h for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
32780629|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
32780630|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
32780631|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
32780632|NCT05432323||Adolescents|
32780633|NCT05432245|Experimental|Treatment group|
32780634|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
32780635|NCT05458063||Patients admitted in Surgical intensive care unit and trauma intensive care unit|all surgical patients who planned to admit in surgical and trauma intensive care unit in emergency room
33084496|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
33084497|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
33084498|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
33084499|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
33402163|NCT02376088||NC|age-matched healthy checkup subjects
33084500|NCT04561258|Experimental|Low Dose Cohort|A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
33084501|NCT04561258|Experimental|High Dose Cohort|A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
33084502|NCT04560985|Experimental|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
33084503|NCT04560985|Active Comparator|Hydrophobic sealant|Helioseal-F Sealant ®
33084504|NCT04721483|Active Comparator|T3-T4 sympathicotomy|In this group, patients underwent a classical T3 and T4 sympathicotomy to treat primary palmar hyperhidrosis
33084505|NCT04721483|Experimental|T3-T4 ramicotomy|In this group, patients underwent a selective T3 and T4 gray ramicotomy
33084506|NCT04560946|Experimental|PACT|Personalized Augmented Cognitive Training (PACT)
33402164|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
33286193|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
33286194|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
33286195|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)~Cohort A1~Cohort A2"
33286196|NCT05299385|Active Comparator|Comparator|"The investigator provide conventional-treatment to subjects when distributing respiratory rehabilitation education leaflets, Investigators explain the leaflets and self-practice until the subjects fully understand them. Compactor conducts respiratory rehabilitation treatment for 12 weeks according to the following procedures at home~☞ The investigator shall contact the subject every two weeks during the respiratory rehabilitation period and encourage them to perform respiratory rehabilitation treatment according to the assigned group. Subjects perform respiratory rehabilitation exercises at home.~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
33286197|NCT05299385|Experimental|Experimental treatment|"Subjects install software as a medical device for clinical trials on smart-phones, so that the subject can perform respiratory rehabilitation treatment at home.~Respiratory rehabilitation treatment for 12 weeks~☞ Respiratory rehabilitation treatment using a mobile-based software, consists of aerobic exercise and anaerobic exercise, and the subject performs themselves~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
32780636|NCT05465239|Experimental|SurePace Powered Walker User|"Before any formal experiments are conducted, participants will be given an opportunity to train with the new powered walker for a pre-defined period of time to eliminate the confounding effects of being unfamiliar with using the device. (See the description of UVA's facilities and Protection of Human Subjects document for additional discussion of safety measures/protocols and Institutional Review Board procedures.) Experiments will consist of one-hour sessions (with adequate rest periods between trials and time for evaluations) in which participants will be asked to walk at a self-selected (comfortable) walking speed through a pre-defined 8 m x 4 m oval course."
32780637|NCT05457517|Experimental|YL-13027+Sintilimab|"YL-13027 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the patient discontinues from the study treatment for other reasons.~Sindilizumab injection will be given 200mg every three weeks."
32780638|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
33286198|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
32780639|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
32900363|NCT05539716|Experimental|PAP Therapy and Lifestyle Intervention (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive the PAP therapy and Lifestyle Intervention for 12 weeks.
33286199|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
33286200|NCT04068311|No Intervention|Pre Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
33286201|NCT04068311|Active Comparator|Post Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
33286202|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
33286203|NCT00450216|Active Comparator|2|Ibuprofen 800mg
33286204|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
33286205|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
33286206|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
33286207|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
33286208|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
33286209|NCT05300165|Other|Normal population|20 participants representing a normal population will include a daily beer in their meals, changing the kind of beer every 2 weeks from alcohol-free lager beer, lager beer, or dark beer.
33286210|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
33286211|NCT00441480|Placebo Comparator|placebo|Corn oil
33286212|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
33402165|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
33402166|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
33402167|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
33402168|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
33402169|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
32780640|NCT04260529|Experimental|Arm A: CyPep-1 monotherapy|"Phase I of the trial, dose escalation, safety and tolerability will be documented and the MTD/RP2D will be determined. Cohorts of 3 subjects (in total 12 subjects) will receive IT injections with CyPep-1 by intratumoral injection at Day 1 of weeks 1, 3 and 5.~In Phase IIa of the trial, dose expansion, the safety and tolerability will be further evaluated in an expanded cohort of 9 subjects at the RP2D of CyPep-1, determined in Phase I. CyPep-1 administration is planned as Q2W injections"
32780641|NCT04260529|Experimental|Arm B: CyPep-1 in combination with pembrolizumab|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 15 subjects in total, using a staggered approach. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
32780642|NCT04260529|Experimental|Arm C: CyPep-1 monotherapy liver lesions|The safety and tolerability of at least two dose levels of CyPep-1, the RP2D and the dose immediately below that, are planned to be evaluated when CyPep-1 is administered intratumorally to a metastatic lesion in the liver. CyPep-1 administration is planned as Q2W injections.
32780643|NCT04260529|Experimental|Arm D: CyPep-1 monotherapy melanoma|The safety and tolerability of CyPep-1 at RP2D will be further evaluated with focus on assessing efficacy signals of CyPep-1 monotherapy in subjects with melanoma. CyPep-1 administration is planned as QW injections until the second iRECIST/itRECIST assessment at week 16, followed by a Q2W dosing scheme.
32780644|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
32780645|NCT05457205|Experimental|Neuromodulation with 50 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
32780646|NCT05457205|Experimental|Neuromodulation with 50 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
32780647|NCT05457205|Experimental|Neuromodulation with 100 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
33084507|NCT04560946|Active Comparator|ETAU|Enhanced Treatment As Usual (ETAU)
33402170|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
33402171|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
32780648|NCT05457205|Experimental|Neuromodulation with 100 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
32780649|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
32780650|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
32780651|NCT05456815|Other|Standardized diet|Standardized food products/meals will be tested
32780652|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
32780653|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
32780654|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
32780655|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
32780656|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
33402172|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
32780657|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
32780658|NCT05464771||Patients experiencing adverse event while in hospital|Patients that have experienced a patient safety incident according to the Patient Safety Indicators (PSIs) developed by the U.S. Agency for Healthcare Research and Quality (AHRQ)
32780659|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
32780660|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
32780661|NCT05485571|Active Comparator|GROUP 1|15 patient with alopecia areata treated by microneedling only one session weekly for 12 weeks
32780662|NCT05485571|Active Comparator|GROUP 2|15 patient with alopecia areata treated by combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks.
33084508|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
33084509|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
33084510|NCT04561336|Experimental|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
33402173|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
33084511|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
33084512|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
33084513|NCT04560907|Experimental|Aquablation|
33084514|NCT04560907|Active Comparator|HoLEP|
33084515|NCT02211898|Experimental|BNS003|
33084516|NCT04560322|Experimental|Venetoclax-Obinutuzumab +/- Acalabrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus acalabrutinib then stop therapy.~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.~Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6~Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22~Oral Drug: acalabrutinib daily for Days 1-28 (if applicable)"
33084517|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
33084518|NCT04560478|Active Comparator|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
33084519|NCT04560478|Active Comparator|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
33084520|NCT04560244|Experimental|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
33084521|NCT04559854|Experimental|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
32780663|NCT05485493|Experimental|experimental group|The counseling program is 6 sessions, and it is the sessions will last 60-90 minutes on average once a week and be conducted via online video-conference applications. The first session is informing group members about emotional eating and solution-oriented approach, determining members' goals and expectations. Second session; It aims to ensure that emotions are noticed, to clarify the goals with the miracle question technique, and to focus on the solution by getting away from the problems. In the third session; Exception questions focus on recognizing exceptional situations, strengths, and skills. In the fourth session; It is aimed to discuss the existing coping methods of the group members, to recognize the useful coping methods and strengths and to increase their use. In the fifth session; focuses on designing a positive future and steps towards achieving a positive future. In the sixth session, the sessions are summarized by the group leader and members.
32780664|NCT05485493|Experimental|control group|A one-session nutrition education will be given to the control group. Students will be informed about the emotional eating behavior and they will be informed about the physical exercise and nutrition regulation process. Measurements will be repeated at the end of the session and 2 weeks later.
32780665|NCT05485415|Active Comparator|Intervention|Personalised intervention
33084522|NCT04560205|Experimental|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
33084523|NCT04559971|Experimental|1.0mg/kg|Drug: SLN124
33084524|NCT04559971|Placebo Comparator|Placebo|
33084525|NCT04559971|Experimental|3.0mg/kg|Drug: SLN124
33084526|NCT04559971|Experimental|Optional Cohort|An additional dose level may be explored
32780666|NCT05485415|Placebo Comparator|Control|General sleep advice
32780667|NCT05485337||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
32780668|NCT05485337||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
32780669|NCT05496881|Experimental|Exercise Group 1|The intervention will focus on mobility and balance.
32780670|NCT05496881|Active Comparator|Exercise Group 2|This intervention will focus on physical fitness.
32780671|NCT05496881|Sham Comparator|Exercise Group 3|This intervention will focus on flexibility, range of motion, and muscle tone.
33084527|NCT04560049|Experimental|Phenolisation|Surgical pit excision and phenolisation of sinus tract
33084528|NCT04560049|Active Comparator|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
33084529|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
33084530|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
33084531|NCT04559503|Experimental|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
33084532|NCT04559503|No Intervention|Control group|The control group received standard treatment.
33084533|NCT04559776|Experimental|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
33084534|NCT04559776|Experimental|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
33084535|NCT04559308|Experimental|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
33084536|NCT04559308|Active Comparator|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
33084537|NCT04559191|No Intervention|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
33084538|NCT04559191|Active Comparator|CGM-guided group|Glycemic control is controlled by CGM-guided control.
33402174|NCT04630717|Active Comparator|control group|normal discussion before general anesthesia induction
33084539|NCT00231803|Experimental|Multifactorial intervention|Nurse led clinic involving a nephrologist administering protocol driven interventions aimed at preservation of kidney function, and cardiovascular risk reduction. Blood pressure targets were specified. No specific drugs were specified. Drug classes such as primarily statins for achieving LDL targets, use of an ACE inhibitor or ARB if possible, treatment of acidosis, anemia, hyperphosphatemia, advice on smoking cessation
32780672|NCT05496803|Other|study group|parents receiving routine education plus digital video disk before catheterization:pre-catheterization educational videos plus routine education
32780673|NCT05496803|Other|control group|parents receiving routine education: pre-catheterization routine education
33084540|NCT00231803|Active Comparator|Usual care|Usual care includes any intervention thought appropriate by the treating family doctor and or specialists involved in the case
33084541|NCT04559113|Experimental|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19~0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. *Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
33084542|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
32780674|NCT05496725|Experimental|Micafungin (Product name:Myfungin)|Single dose micafungin 50mg
32780675|NCT05496725|Active Comparator|Micafungin (Product name:Mycamine)|Single dose micafungin 50mg
32780676|NCT05490719|Experimental|QL1706 plus Chemotherapy and Radiotherapy|"Radiotherapy: Total 50.4Gy/28 fraction ,1.8Gy per time，5 fractions per week.~QL1706 will be administered at a dose of 5 mg/kg intravenously (IV), every 3 weeks, until progressive disease or intolerable or other reasons according to the criteria for termination of treatment). QL1706 will be administered up to 1 year.~Chemotherapy: Taxol 135 mg/m2, days 1, 22; Cisplatin 25 mg/m2, day 1-3, day 22-24."
32780677|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
32780678|NCT05496569|Experimental|TQB3616 capsules|TQB3616 capsule (180mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
32780679|NCT05496569|Placebo Comparator|TQB3616 placebo|TQB3616 placebo (0mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
32780680|NCT04179383|Other|Patient|"Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) :~Questionnaires about anxiety, depression ;~Constitution of a biobank (if specific consent) at inclusion and at 3 months"
32780681|NCT04179383|Other|Volunteers|"Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient :~Questionnaires about anxiety, depression ;~Constitution of a blood biobank (if specific consent)"
32780682|NCT05485259|Experimental|DL-alpha lipoic acid|600 mg (2x300 mg) of DL-alpha lipoic acid in capsules, per os daily for 3 months
32780683|NCT05485259|Placebo Comparator|Placebo|600 mg (2*300 mg) of placebo (rice starch) in capsules, per os, daily for 3 months
32780684|NCT05490485|Experimental|Camrelizumab|Camrelizumab (PD-1 MAB) combined with cisplatin for advanced cutaneous squamous cell carcinoma
32780685|NCT04027049|Experimental|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
32780686|NCT04027049|No Intervention|Control|Patients will receive usual care only.
32780687|NCT05485103|Experimental|Modified bowel preparation method group|One day before the colonoscopy, only asol (or other intestinal nutrient solution) was taken. On the examination day (4 hours before), 1 bag of polyethylene glycol solution + (2 hours before) glycerin enema 110ml was taken
32780688|NCT05485103|Active Comparator|Traditional bowel preparation method group|Low residue diet 2 days before the colonoscopy, take 2 bags of polyethylene glycol solution the night before the examination and 1 bag of which on the examination day (4 hours before)
32780689|NCT05496491|Experimental|Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy|"The experimental group will receive the standard 5-week neoadjuvant chemoradiotherapy (CRT). Thereafter, all patients will commence consolidation chemotherapy. At the 6th week after the end of CRT, patients will undergo MRI re-staging: In case of non-response (mrTRG 5) they will be submitted immediately to surgery, and, subsequently, excluded from the trial.~In case of response (mrTRG 2-4) they will receive consolidation chemotherapy for the whole waiting period between the end of CRT and surgery - 12 weeks."
33084543|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
33084544|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
33084545|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
33084546|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
32780690|NCT05496491|Active Comparator|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy|The control group will receive the standard 5-week neoadjuvant chemoradiotherapy regimen. Six weeks after completion the patient will be re-staged with rectal MRI and depending on the response will be operated (TME): immediately in case of non-response (mrTRG 5) or after an additional 6-week delay (overall 12 weeks after the end of chemoradiotherapy) in case of partial response (mrTRG 2-4). Adjuvant chemotherapy will be, also, administered.
32780691|NCT05490407|Other|HGSOC|high-grade serous ovarian cancer patients (FIGO stages III and IV) with ascites, for whom neoadjuvant chemotherapy is recommended.
32780692|NCT04137731|Experimental|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
32780693|NCT04137731|Placebo Comparator|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
32780694|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
32780695|NCT05490173|Experimental|Intranasal exosomes administration|ELWB newborns who will receive intranasal exosomes
32780696|NCT05490173|No Intervention|Control|ELWB newborns who will not receive intranasal exosomes
32780697|NCT05485025|Experimental|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
32780698|NCT05485025|Experimental|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
32780699|NCT05484947||HIV-positive|Those that were actually tested and had HIV-positive results
32780700|NCT05484947||HIV-Negative|Those tested and had HIV-negative results
32780701|NCT05484947||HIV-Unknown|those who had not volunteered for HIV testing
32780702|NCT05484869||Early Adolescent Pregnant Women (n:80)|Perinatal and neonatal results of adolescent pregnancies of 16 years and below
32780703|NCT05484869||Very Advanced Maternal Aged Pregnants (n:67)|Perinatal and neonatal results of pregnancies 45 years and older
32780704|NCT05484869||Reproductive period Control Group (n:150)|Reproductive period Pregnant Between 25-35 years
32780705|NCT05484791|Experimental|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization technique during two sessions per week
32780706|NCT05496413|Experimental|Active comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
32780707|NCT05496413|Sham Comparator|Sham comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
32780708|NCT05496257|Active Comparator|Group I (control): Calcium hydroxide cement|Pulp capping material
32780709|NCT05496257|Active Comparator|Group 2: Premixed bioceramic putty|Pulp capping material
33084547|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
33084548|NCT04559074|Experimental|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
32780710|NCT05490095|Experimental|Group I|"13 subjects will receive~First Dose: Afinitor 5mg, single dose~Wash out period : more than 10 days~Second Dose: SVG101 5mg, single dose"
32780711|NCT05490095|Experimental|Group II|"13 subjects will receive~First Dose: SVG101 5mg, single dose~Wash out period : more than 10 days~Second Dose: Afinitor 5mg, single dose"
33084549|NCT04559074|No Intervention|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
33084550|NCT04559152|Experimental|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
33084551|NCT04559152|Placebo Comparator|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
33402175|NCT04630717|Active Comparator|Hypnosis group|hypnosis session before general anesthesia induction
32780712|NCT05484635|Active Comparator|Diagnostic laparoscopy|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain.
33084552|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.~Determine the variables that are associated with more maternal and neonatal morbidity.~Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
32780713|NCT05484635|Experimental|Laparoscopic mesh removal|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain. If randomized to mesh removal, laparoscopic or robotic preperitoneal mesh removal.
33402176|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
32780714|NCT04424381|Active Comparator|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet [Xarelto] at a single oral dose of 20 mg
32780715|NCT04424381|Experimental|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
32780716|NCT05496179|Active Comparator|Prucalopride|Patients will receive prucalopride (2 mg) once daily for 7 days.
32780717|NCT05496179|Active Comparator|Metoclopramide|Patients will receive metoclopramide (10 mg) three times daily for 7 days.
32780718|NCT04157621|Active Comparator|Active taVNS|
32780719|NCT04157621|Sham Comparator|Sham Stimulation|
32780720|NCT05496101|Other|Breast Cancer undergoing BCS|Intraoperative CLI + FAR LightPath imaging compared with Standard-of-care histopathology (gold standard)
32780721|NCT05496023||Pre PCI state|The current study will analyze the angio-FFR and generate the virtual pullback. The pullback will be co-registered by overlaying the pullback onto coronary angiogram.
32780722|NCT05496023||Post-PCI state|The post-PCI FFR and angio-FFR will be meaured.
32780723|NCT05484401|Experimental|Test Product|Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
33084553|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
33084554|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
33084555|NCT02211976|Experimental|Bisacodyl|
33084556|NCT02211976|Experimental|Simeticone|
32780724|NCT05484401|Active Comparator|Reference Product|Ibuprofen 200mg Oral Tablet, Placebo of Ibuprofen 200mg Oral Liquid Capsule
32780725|NCT05484401|Placebo Comparator|Placebo|Placebo of Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
32780726|NCT05484323|Experimental|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
32780727|NCT05484323|Experimental|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
32780728|NCT05484323|Experimental|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
32780729|NCT05484323|Experimental|Cookie containing 2.5 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
32780730|NCT05495945|Experimental|Dorsolateral prefrontal cortex (DLPFC)|
32780731|NCT05495945|Experimental|Anterior insula cortex (AIC)|
32780732|NCT05495945|Experimental|Central thalamus (CT)|
32780733|NCT05495945|Active Comparator|Sham control|
32780734|NCT05495867|Experimental|NINA- MultiNeO NH|implant with bioactive surface
32780735|NCT05495867|Active Comparator|MultiNeO CS|implant with traditional surface
32780736|NCT05489861|Experimental|Experimental group A The Group to which the Mother Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the mother to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the mother with an affirmation note as a reminder."
32780737|NCT05489861|Experimental|Experimental group B The Group to which the Father Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the father to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the father with an affirmation note as a reminder."
32780738|NCT05489861|No Intervention|Control Group (C)|Parents will be asked to continue the implementation of routine sleeping techniques without being taught any practices.
33084557|NCT02211976|Experimental|Bisacodyl and simeticone|
33084558|NCT04558606|Experimental|Sonic toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
33084559|NCT04558606|Active Comparator|Manual toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
32780739|NCT05495789|Experimental|Virtual Reality Group|In addition to the routine procedure, virtual reality glasses will be applied to the high-risk pregnant in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After the NST device is connected and, the high-risk pregnant included in the experimental group will be made to watch a video lasting an average of 40 minutes with virtual reality glasses until the procedure is completed.
32780740|NCT05495789|Experimental|Music Group|In addition to the routine procedure, the high-risk pregnant women in the music group of the research will listen to the relaxing music used in the virtual reality application with headphones.
32780741|NCT05495789|No Intervention|Control Group|The high-risk pregnants in the control group of the study will not be subjected to any treatment other than the routine procedure.
32780742|NCT05489627|Experimental|Main arm of the study|"Medial knee instabilities will be addressed in this arm. Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with D concomitant ACL QTB reconstruction and MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well.~17 patients will be included in this arm - this number was calculated and rounded up as a mean of number patients from studies of Alm et al. 2021 (17 patients in ACLR+MCLR group), Lee et al. 2020 (10 patients in ACLR+MCLR group), Kitamura et al. 2013 (16 patients in ACLR+MCLR group), LaPrade et al. 2012 (8 patients in ACLR+MCLR group), Lind et al. 2009 (34 patients in ACLR+MCLR group) and Kim et al. 2008 (12 patients in ACLR+MCLR group). All above referenced studies apart from the study of LaPrade et al. were retrospective."
32780743|NCT04423991|Experimental|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
32780744|NCT05489393||Individuals with DRPLA|This registry is for people with a diagnosis of Dentatorubral-pallidoluysian atrophy (DRPLA)
32780745|NCT05495555||High IOP setting|Cataract removal with high IOP setting
32780746|NCT05495555||Low IOP setting|Cataract removal with low IOP setting
32780747|NCT05483699|Experimental|Squeezing a ball during intravenous cannulation reduces the child's pain and fear.|The soft ball has a diameter of about 8-10 cm and can return to its old form when it is squeezed.
32780748|NCT05483699|Experimental|Using a kaleidoscope during intravenous cannulation reduces the child's pain and fear.|Kaleidoscope includes shapes of flowers and mirrors in the shape of triangle placed with an angle of 600. While rotating one of the cylinders, various shapes and colourful eyes are formed when viewed with one eye. When the kaleidoscope is rotated, the patterns look different all the time because the colourful parts are moving, attracting the child's attention.
32780749|NCT05483699|Experimental|Blowing bubbles during intravenous cannulation reduces the child's pain and fear.|Children in this group were shown bubble blower before intravenous cannulation and they were shown how bubbles formed and how to blow. Children blew bubbles during intravenous cannulation
32780750|NCT04134767|Experimental|Health Linkage|Research staff will: 1) meet with participants in a community setting, by phone, or video call to ask them questions about drug use and related behaviors, access to needed health and social services, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct saliva drug testing, offer HIV and hepatitis C testing and counseling, naloxone, and harm reduction supplies, and connect participants with needed services; 2) follow up with participants once a month for three months to help participants overcome challenges; and 3) six months after enrollment to the study, contact participants to conduct saliva drug testing. Participants will complete surveys at baseline, 3 months, and 6 months. The baseline will be conducted in jail for incarcerated participants preparing for re-entry, or in a community setting for those recruited in the community. The 3 and 6-month surveys will be conducted in a community setting.
33084560|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
33084561|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
33084562|NCT04558684|Experimental|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
33084563|NCT00231959|Placebo Comparator|Sugar pill|Placebo
33084564|NCT00231959|Experimental|Pramipexole|
33084565|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
33084566|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
33084567|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
32780751|NCT04134767|Other|Overdose Education|"The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit.~As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort."
32780752|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
32780753|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
32780754|NCT05489315|Other|Traditional Positioning|Participants who are randomly assigned to NOT receive a peanut ball will undergo placement on a wedge pillow and/or traditional positioning during their labor progression at 6cm cervical dilation.
32780755|NCT05489315|Experimental|Peanut Ball Positioning|Participants who are randomly assigned to receive a peanut ball will be positioned with a peanut ball at 6cm cervical dilation.
32780756|NCT03999749|Experimental|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the DLT period.~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
32780757|NCT03997643|Active Comparator|Standard Radiotherapy|Radiotherapy to all dissected areas
32780758|NCT03997643|Experimental|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
32780759|NCT03977129|Experimental|QFR group|
32780760|NCT03977129|Active Comparator|CAG group|
32780761|NCT05495477|Active Comparator|Spontaneous breathing|Electrical impedance tomography (EIT).
32780762|NCT05495477|Active Comparator|CPAP mode|Electrical impedance tomography (EIT).
32780763|NCT05495477|Active Comparator|NIV- S/T mode|Electrical impedance tomography (EIT).
32780764|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
32780765|NCT05495399|Experimental|Spondylectomy with Conventional RT|Spondylectomy for involved spine level followed by conventional RT 20Gy in 5 fractions
32780766|NCT05495399|Active Comparator|Debulking surgery with Conventional RT|Debulking surgery for involved spine level followed by conventional RT 20Gy in 5 fractions
32780767|NCT05495399|Experimental|Debulking surgery with SBRT|Debulking surgery for involved spine level followed by SBRT 24Gy in 12 fractions
32780768|NCT05483621|Experimental|Hormonal therapy Group|Administration of hormonal therapy (as Beta HCG (5000 IU I.M) twice weekly for three months
32780769|NCT05483621|Other|L-carnitine Group (Control)|Administration of L-carnitine 1000 mg twice daily for three months
33084568|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
33084569|NCT04558411|No Intervention|Control Group (assessment only)|This group will receive assessments only.
33084570|NCT04558411|Experimental|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
33402177|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
33402178|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
32780770|NCT05483543|Experimental|Pamiparib monoagent|Drug: Pamiparib 40mg bid orally
32780771|NCT04139213|Active Comparator|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
32780772|NCT04139213|Experimental|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
32780773|NCT05489003||Patients with fatigue|Chronic pancreatitis patients with fatigue measured by professional assessment scales.
32780774|NCT05489003||Patients without fatigue|Chronic pancreatitis patients without fatigue measured by professional assessment scales.
32780775|NCT05495165|Other|Nutritional educative programme|5 days educative programme before treatment
32780776|NCT05495087|Experimental|IHT Treatment|Exposures to hypoxic air (10% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
32780777|NCT05495087|Placebo Comparator|Sham-IHT control|Exposures to normoxic air (21% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
32780778|NCT04112849||Heart failure subjects|Subjects who have heart failure, and meet inclusion/exclusion criteria, who will be enrolled in this study and will have their heart sounds measured with Nanowear vest (NCHFMS).
32780779|NCT05495009|No Intervention|Standard of care|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), FFL, VAS-P and VAS-A were filled and no intervention was applied. 20 min in active phase. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. The Perception of Birth Scale is filled after birth.
32780780|NCT05495009|Experimental|Standard of care+ virtual reality glasses|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), after filling FFL, VAS-P and VAS-A, video was watched with virtual reality glasses. 20 minutes in active phase after watching the video. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. After the birth, the Perception of Birth Scale and Virtual Reality Satisfaction Form were filled.
32780781|NCT05494931|No Intervention|control group|In this first group, the same classic method of Gunderson conjunctival flap surgery will be used.
32780782|NCT05494931|Active Comparator|intervention group|in the this group, Gunderson conjunctival flap surgery will be performed adjuncted by corneal neurotomy
32780783|NCT04071587|Experimental|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
32780784|NCT04071587|Active Comparator|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
32780785|NCT04069793|Active Comparator|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
32780786|NCT04069793|Experimental|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
32780787|NCT05494853||HCC|HCC positive
32780788|NCT05494853||Non HCC|HCC negative
33084571|NCT00231998|Experimental|1|
33084572|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
33084573|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
33084574|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
32780789|NCT05494775|Active Comparator|Diabetic macular edema|Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
32780790|NCT05494775|Active Comparator|Wet age related macular edema|Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
33084575|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
32780791|NCT05494775|Active Comparator|Retinal vein occlusion|Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
32780792|NCT05494775|Active Comparator|Myopic choroidal new vascularization|Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
32780793|NCT03937037|Experimental|Saline irrigation|CBD stone removal after routine ERCP procedure,100ml saline irrigation after a balloon occlusion cholangiogram confirming the absence of stones.
32780794|NCT03937037|No Intervention|None saline irrigation|CBD stone removal after routine ERCP procedure, a balloon occlusion cholangiogram confirms the absence of stones.
33084576|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
33084577|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
33084578|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
32780795|NCT05483153|Experimental|Infant-Directed Singing Coaching Group|At-risk mothers and infants will receive four, 30-minute sessions of an infant-directed singing coaching intervention.
32780796|NCT04272827|Active Comparator|Intervention group|In the intervention group, patients will receive liposuction treatment (number of surgeries at the discretion of the attending study physician: a maximum of 4 surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with concomitant complex decongestive therapy (CDT), if necessary, to maintain surgical outcomes as required by the patient.
32780797|NCT04272827|Other|Control group|"After randomisation, the control group will be treated for 12 months with complex decongestive therapy (CDT) alone.~After these 12 months, patients can opt for liposuction treatment if they continue to meet the inclusion and exclusion criteria."
32780798|NCT04272203|Experimental|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
32780799|NCT04272203|Experimental|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
33084579|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
33084580|NCT02212171|Experimental|TRIAP intervention|
33402179|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
32780800|NCT04272203|Experimental|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
32780801|NCT04272203|Experimental|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
32780802|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
32780803|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
32780804|NCT05482997|No Intervention|Control Group: Subjects with no protien intake|20 subjects will receive no intervention for 10 weeks but complete performance tests and assessments during weeks 0, 4, 6, and 10.
32780805|NCT05482997|Experimental|Whey Protein, Then Plant-based Protein|"Performance tests/assessments will be conducted as baseline testing without whey protein, followed by four weeks of whey protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the plant-based protein supplement."
33084581|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
33084582|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
33084583|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
33084584|NCT04558099|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
33084585|NCT04558099|No Intervention|Wait-list control|Usual practice
33084586|NCT04558060|Experimental|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
33084587|NCT04558060|Active Comparator|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
33084588|NCT00232115|Experimental|1|Pimecrolimus
33084589|NCT00232115|Placebo Comparator|2|Vehicle
33084590|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
33084591|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
33084592|NCT04558372|Experimental|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
32780806|NCT05482997|Experimental|Plant-based Protein, Then Whey Protein|"Performance tests/assessments will be conducted as baseline testing without plant-based protein, followed by four weeks of plant-based protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week, for four weeks. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the whey protein supplement."
32780807|NCT05482841||ENT cancer surgery patients|all patients undergoing ENT cancer surgery with tracheotomy or tracheostomy at the Centre Léon Bérard.
32780808|NCT05494463|No Intervention|Macintosh blade|laryngoscopy with Macintosh blade
32780809|NCT05494463|Active Comparator|Miller blade|laryngoscopy with Miller blade in the same patient
32780810|NCT05488925|Placebo Comparator|Vitamin E|
32780811|NCT05488925|Experimental|Diclofenac sodium|
32780812|NCT05488925|Experimental|Piroxicam|
33084593|NCT04558372|Experimental|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
33084594|NCT04558372|Experimental|Group 3- suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
33084595|NCT04558021|Experimental|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
33084596|NCT04558021|Placebo Comparator|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
33084597|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
33084598|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
33084599|NCT04557826|Experimental|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
33084600|NCT04557982||Children aged 3 < 4 years|Children aged 3 < 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
33084601|NCT04557982||Children aged 4 < 5 years|Children aged 4 < 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
33084602|NCT04557982||Children aged 5 < 6 years|Children aged 5 < 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
33084603|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
32780813|NCT05488925|Experimental|Tramadol|
32780814|NCT05494385|Placebo Comparator|Preoperative Gabapentin/Postoperative Placebo|
32780815|NCT05494385|Active Comparator|Preoperative Gabapentin/Postoperative Gabapentin|
32780816|NCT05482763||Patients with onychomycosis|All patients with clinical suspicion of onychomycosis at the Tor Vergata Polyclinic center will be enrolled according to the inclusion and exclusion criteria of the study. After signing the informed consent, the subjects will be subjected to scraping or clipping of the nail unit affected by the disease. The collected material will be stored in a sterile container to be sent to the Microbiology laboratory.
32780817|NCT05482685||Demographic variables|Include gender, age, BMI, education level, marital status, attended health promotion program or not, average monthly income, years of experience, average hours of work per week, chronic illness, smoking habit, drinking habit
32780818|NCT05482685||health literacy|The number of points scored by completing the scale
32780819|NCT05482685||self-perceived health|The number of points scored by completing the scale
32780820|NCT05482685||health-promoting behavior|The number of points scored by completing the scale
32780821|NCT05482607||SSc-ILD patients|
32780822|NCT05482529||colorectal cancer with metastasis|colorectal cancer patients with at least one distant metastasis(liver, lung)
32780823|NCT05482373|Placebo Comparator|Placebo|Patients will receive hard gelatin capsules containing placebo (only the excipients).
32780824|NCT05482373|Experimental|Oleuropein|Patients will receive the same hard gelatin capsules but containing 200 mg of an olive leaf extract.
32780825|NCT05482295|Experimental|Hepatitis B vaccine lot 1|3 doses Recombinant Hepatitis B new Bulk vaccine lot 1
32780826|NCT05482295|Experimental|Hepatitis B vaccine lot 2|3 doses Recombinant Hepatitis B new Bulk vaccine lot 2
32780827|NCT05482295|Experimental|Hepatitis B vaccine lot 3|3 doses Recombinant Hepatitis B new Bulk vaccine lot 3
32780828|NCT05482295|Active Comparator|Active Control: Hepatitis B vaccine (registered)|3 doses Recombinant Hepatitis B vaccine (registered)
32780829|NCT05482217|Experimental|Intervention group|This group was exposed to psychoeducational and problem-solving sessions for five weeks.
33084604|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
33084605|NCT02212327||PD subjects|
33084606|NCT02212327||Controls|
33084607|NCT04557943|Active Comparator|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
33084608|NCT04557943|Experimental|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
33084609|NCT04709133|Experimental|multi-ligament knee injures|A chart review will be performed to identify patients who underwent surgical treatment for multiligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
33084610|NCT00232232|No Intervention|Control|No fish oil
33084611|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
33084612|NCT04557904|Experimental|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
33084613|NCT04557904|Experimental|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
32780830|NCT05482217|No Intervention|The control group|No intervention was given: only the regular clinic advice for five weeks or treatment as usual.
32780831|NCT04245839|Experimental|Administration of JCAR017|"Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.~JCAR017 will be infused on Day 1 at a target dose of 100 × 10^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells."
32780832|NCT04069091|Experimental|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' (iloodottaa.fi) online self-help intervention employing elements of cognitive behavioral therapy (CBT)
32780833|NCT04069091|No Intervention|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
32780834|NCT05494307|Experimental|Terbutaline plus danazol|Terbutaline: A dose of 2.5 mg three times daily for 16 weeks Danazol: A dose of 200 mg twice daily for 16 weeks
32780835|NCT05494307|Active Comparator|Danazol monotherapy|Danazol: A dose of 200 mg twice daily for 16 weeks
32780836|NCT05488457|Other|Oxytocin PK/PD Arm|Eligible subjects will receive a single, 1 IU bolus of deuterated oxytocin (d5OT) intra-operatively, followed by an infusion of standard therapeutic d0 oxytocin immediately after umbilical cord clamping.
32780837|NCT05488379|No Intervention|Individual well child care|Individuals randomized to the control arm will receive routine individualized well child care after birth hospital discharge.
32780838|NCT05488379|Experimental|Group well child care|Individuals randomized to the intervention arm will participate in group well child care after birth hospital discharge.
33084614|NCT04557475|Experimental|ASA Group|Receives standard of care and intervention.
33402180|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
32780839|NCT05494151||SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
32780840|NCT05494151||SMuRF-less|Patients with acute myocardial infraction without history of any SMuRF
32780841|NCT05482061||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. The basic tool for pain intensity research was the VAS. The study of the neuropathic component of pain was carried out using the DN4. Study of the presence of an acute stress reaction - anamnesis + HADS. The diagnosis of ASR was established by a psychiatrist upon admission to the military mobile hospital. The presence of post-traumatic stress disorders (PTSD) was investigated using the Mississippi scale of post-traumatic stress disorders (military version). The presence of PTSD according to the MS PTSD (c). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
32900364|NCT05539716|Experimental|Lifestyle Intervention Only (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive only the Lifestyle Intervention for 12 weeks.
32900365|NCT05395260|Experimental|FL-101-IV|Open Label Infusion of FL-101 on Day 1 and Day 15
32900366|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
32900367|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
33084615|NCT04557475|No Intervention|SOC Group|Receives standard of care (SOC), only
33084616|NCT00232271|Active Comparator|clexane|patients received clexane
33084617|NCT00232271|No Intervention|non clexane|no clexane given
33084618|NCT04557397|Other|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
33084619|NCT04557397|Other|Part B|Subjects will receive fruquintinib, alone and with rifampin.
33084620|NCT04557241|Experimental|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
33084621|NCT04557241|Placebo Comparator|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
33084622|NCT04557319|Experimental|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
33084623|NCT04557319|Experimental|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
33084624|NCT04557319|Experimental|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
33084625|NCT04557514|Active Comparator|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes~Do not chill the blood at any time before or during platelet separation.~Centrifuge the blood using a 'soft' spin.~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
33084626|NCT04557514|Active Comparator|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
33084627|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
33084628|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
33084629|NCT04557202|Active Comparator|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
33084630|NCT04557202|Placebo Comparator|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
33084631|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
33084632|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
33084633|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
33286213|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
32780842|NCT05482061||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients who took part in the study with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception is the study period during treatment at the military medical clinical center: here it was 14 days.~In all patients with gunshot wounds, the outcome and effectiveness of pain management were assessed using the Visual Analogue Scale (VAS) and the Diagnostic Questionnaire for the Detection of the Neuropathic Pain Component Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36 (DN4)."
32780843|NCT04051619|Experimental|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
32780844|NCT04051619|Placebo Comparator|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
32780845|NCT05481983|Other|control group|Walk exercise
32780846|NCT05481983|Active Comparator|study group|One-on-one clinical exercise training
32780847|NCT05488223|Experimental|PUFA ω-3 (1.8g/day)|"ω-3 PUFAs (Triple Strength Fish Oil®) were purchased in advance, each capsule contained 540 mg of eicosapentaenoic acid (20:5 n-3) and 360 mg of docosahexaenoic acid (22:6 n-3), for a 0.9g total. Children and parents were told that they should take 2 capsules of ω-3 PUFAs daily, that is, they took 1.8g/day.~Parents and children were informed that the duration of the study would be 5 months, in the first three months, the children should take the capsules of the assigned treatment; in the fourth and fifth months they should continue their surveillance with the researchers. At the beginning, they were given 2 bottles of 30 capsules each, identified as formula A or B, according to the assigned group, and they were given a calendar sheet indicating that they should cross out a box if they had consumed the breakfast capsule and cross out another box if the consumed during the meal; Likewise, they were asked to write down any adverse effect, if any, on the same sheet."
33286214|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
33084634|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
33286215|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
33286216|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
33286217|NCT05352191|Active Comparator|Beclomethasone|800 ug inhaled once aday for 8 days
32938460|NCT05113004|Other|Arm 2|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
32938461|NCT05113004|Other|Arm 3|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
33286218|NCT05352191|Placebo Comparator|Placebo|one pill once aday for 8 days
33286219|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
33286220|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
33286221|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
33286222|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
33286223|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
33286224|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
33286225|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
32938462|NCT05113004|Placebo Comparator|Arm 4|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
32938463|NCT05113004|Other|Arm 5|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
33286226|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
33286227|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
33286228|NCT01023750||Fenofibrate|
32938464|NCT05113004|Other|Arm 6|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
32938465|NCT04707079|Experimental|Duvelisib|Eligible subjects will be given duvelisib (15mg, 25mg), orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
33286229|NCT05300009|Experimental|topical methotrexate hydrogel 1% coupled with microneedling|patients who will receive topical methotrexate hydrogel 1% coupled with microneedling
33286230|NCT05300009|Active Comparator|cryotherapy|patients who will receive cryotherapy
33286231|NCT05352113|Experimental|acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
33286232|NCT05352113|Experimental|acupuncture + placebo group|This group will include 40 patients with MDD who will be treated with acupuncture and a placebo. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
33286233|NCT05352113|Experimental|sham acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
33286234|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
33286235|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
32938466|NCT05092568||covid pregnancy|Pregnant patients with positive polymerase chain reaction assay COVID-19 test results, who were followed up and treated in the pandemic service of Başakşehir Çam and Sakura City Hospital.
32938467|NCT02983981|Experimental|open label|Topicort topical spray
32938468|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
32956059|NCT05764798|Experimental|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Shugan Jieyu Capsule was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
32780848|NCT05488223|Active Comparator|PUFAs ω-3 0.9 g/day + MUFAs (avocado oil) 0.9 g/day.|A commercial brand of avocado oil (MUFA) was purchased in advance by putting 0.9g in each capsule. The appearance of the ω-3 PUFA capsules and the avocado oil capsules were the same. Then we worked with the company that prepared the blinding of the treatments, packaging bottles of 30 capsules each, labeling them as bottles A and B. The design contemplated giving each child two bottles, one marked to take it for breakfast and another marked to take it with food. The child was instructed to take 1 capsule per day of PUFA ω-3 (0.9g/d) and 1 capsule of avocado oil (0.9g/d)
32780849|NCT05488223|Placebo Comparator|MUFAs (avocado oil) 1.8 g/day.|The child was instructed to take 2 capsules per day, 1.8g of avocado oil per day.
32780850|NCT05481905|Experimental|ENX-101 15mg daily|
33286236|NCT05352035||Prospective cohort|This cohort will enroll a total of 300 patients prospectively
33286237|NCT00297232|Experimental|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
33286238|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
33286239|NCT00954083|Active Comparator|routine care|2=routine care
33286240|NCT05351957|Experimental|dry needling|This study has only 1 arm and the control group is their baseline data
32780851|NCT05481905|Experimental|ENX-101 30mg daily|
32780852|NCT05481905|Placebo Comparator|Placebo daily|
32780853|NCT05494073|Experimental|Hybrid Remnant Repair|Patients in this arm will have an ACL reconstruction with preservation and incorporation of the the ACL remnant.
32780854|NCT05494073|Active Comparator|Control|Patients in this arm will have a ACL reconstruction where the ACL remnant is not incorporated into the graft.
32780855|NCT05493839||Plateau Criteria|mild ： 142mmHg < PaO2/ FiO2 ≤ 213 mmHg moderate ： 71mmHg < PaO2/ FiO2 ≤ 142mmHg severe： PaO2/ FiO2 ≤ 71 mmHg
32780856|NCT05493839||Berlin Definition|mild ： 200mmHg < PaO2/ FiO2 ≤ 300 mmHg moderate ： 100mmHg < PaO2/ FiO2 ≤ 200mmHg severe： PaO2/ FiO2 ≤ 100 mmHg
32938469|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
32938470|NCT05081726||Never had delirium|Older people recovering from hip fracture surgery who did not have postoperative delirium
32780857|NCT05493839||zhang|ARDS：PaO2/FiO2≤100mmHg ALI ：100mmHg<PaO2/FiO2≤150mmHg
32938471|NCT05081726||Recovered delirium|Older people recovering from hip fracture surgery who experienced delirium which has resolved
32938472|NCT04740229|Experimental|Moderate-intensity flow-based Yoga|The intervention will consist of participants engaging in a progressive series of moderate-intensity, flow-based yoga poses, along with breathing and relaxation, for eight weeks. The intervention will be titrated in terms of supervision, with first two weeks being completely supervised, followed by partial supervision for three weeks, and three weeks of unsupervised sessions. The sessions will be ~50 minutes long, 3 times/week. All supervised sessions will be conducted online through Google Meet (GM), which is a live video interaction platform. Videos will be provided to guide unsupervised sessions. Sessions will be led by a certified yoga instructor. An orientation will be provided in the first week, given that the participants will have no or minimal experience with yoga. The intervention will consist of basic sun salutations of hatha yoga sun salutation A, sun salutation B and flow sequences, and breathing exercises, and relaxation.
32938473|NCT04740229|No Intervention|Waitlist control|Participants in this group will not receive the 8-week intervention during the course of the study, and will be asked to engage in their regular activities. They will be asked to not start any new activities during the study period. After they complete the study, they will be provided with the same intervention (live instruction, feedback and supportive videos).
32938474|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
32938475|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
32938476|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
32938477|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
32938478|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
32938479|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
32938480|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
32938481|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
32938482|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
32938483|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
32938484|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
32938485|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
32938486|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
32938487|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
32938488|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
32938489|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
33084635|NCT04556929|Experimental|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
33084636|NCT04566367|Active Comparator|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
33084637|NCT04566367|Experimental|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
33084638|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
33084639|NCT04566055||Prospective observational cohort|
33084640|NCT04566211|Experimental|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
33084641|NCT04566211|Active Comparator|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
33084642|NCT04565626|Experimental|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
33084643|NCT04565626|No Intervention|Control|This arm will receive usual physiotherapy
33084644|NCT04565587|Other|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
33084645|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:~20 Hz, 3 Volts, 480 microseconds~20 Hz, 6 Volts, 480 microseconds~50 Hz, 3 Volts, 480 microseconds~50 Hz, 6 Volts, 480 microseconds~90 Hz, 3 Volts, 480 microseconds~90 Hz, 6 Volts, 480 microseconds"
32780858|NCT05481515||Critically ill adults|Adult patients admitted to an intensive care unit who require mechanical ventilation and supplemental oxygen
32780859|NCT03907475|Active Comparator|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33402181|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
32780860|NCT03907475|Experimental|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who discontinue gemcitabine hydrochloride continue receiving durvalumab alone as in Arm I.
32780861|NCT03907475|Experimental|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32780862|NCT03907475|Experimental|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, and durvalumab IV over 60 minutes on days 8 of cycle 1, day 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780863|NCT03907475|Experimental|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780864|NCT03907475|Experimental|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780865|NCT03907475|Experimental|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32780866|NCT03906227|Active Comparator|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
32780867|NCT03906227|Active Comparator|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
32780868|NCT03906227|Experimental|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
32780869|NCT05487677|Experimental|Pitch Patch Augmentation|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to the patch, patient will receive patch augmentation of the standard subscapularis repair.
32780870|NCT05487677|Active Comparator|Standard Repair with Sutures|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to standard repair, patient will receive the standard repair with sutures.
32780871|NCT05481437||Brentuximab Vedotin|Participants will receive Brentuximab Vedotin injection 50 mg once every 2 weeks and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine).
33084646|NCT00232466|No Intervention|2|conservative therapy (no intervention)
33084647|NCT00232466|Active Comparator|1|Vertebroplasty
33084648|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
33084649|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
33084650|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
33084651|NCT04565860|Active Comparator|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
33084652|NCT04565860|Active Comparator|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
33084653|NCT04565860|Active Comparator|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
33084654|NCT04565860|Active Comparator|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
32780872|NCT04239989|Experimental|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
33084655|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
32780873|NCT05487521|No Intervention|Patients without EEG changes or clinical seizures|
32780874|NCT05487521|Experimental|Patients with EEG changes or clinical seizures|
32780875|NCT05481281|Experimental|Group Dexmedetomidine|Group Dexmedetomidine receiving I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion till surgery completion
32780876|NCT05481281|Experimental|Group Ketamine|Group Ketamine receiving 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion till surgery completion
32780877|NCT05487443|Experimental|Chemotherapy combined with immunotherapy|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
32780878|NCT05481203|Experimental|The Kaleidescope Group|Kaleidoscope Group: it and asking about the colors and shapes seen within it. This distraction procedure started before the procedure and continued until it ended.
32780879|NCT05481203|Experimental|The Visual Illusion Cards Group|The Visual Illusion Cards Group: Just before the nasopharyngeal swab participants were allowed to check the cards and were asked what they saw in them.
32780880|NCT05481203|No Intervention|The Control Group|The control group received the routine nasopharyngeal swab procedure and did not receive any other nonpharmacological intervention
32780881|NCT04051229|Experimental|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
32780882|NCT05493527|Experimental|noninvasive high frequency oscillatory ventilation (NHFOV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NHFOV as post extubation noninvasive respiratory support
32780883|NCT05493527|Active Comparator|noninvasive positive pressure ventilation (NIPPV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NIPPV as post extubation noninvasive respiratory support
32780884|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
32780885|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
32780886|NCT05487365|Experimental|Patients with application|"Eligible patients are consecutive patients that are hospitalised for HF decompensation. The patients will be included in the programme during their hospitalisation or up to one month after hospitalisation. All eligible patients will be offered to participate. At the time of inclusion, patients must be in NYHA class II, III, or IV with a left ventricular ejection fraction (LVEF) of ≤50%. A total of 165 patients with app will be included over 6 month. Patients are not randomised and will all be participating in the smartphone digital support intervention.~Patients are not randomised and will all be participating in the smartphone digital support intervention.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
32780887|NCT05487365|Active Comparator|Patients without application|"Patients refusing participation will also be asked to complete a quality of life (QOL)-questionnaire at 6 months and 12 months which will be answered online. A total of 165 patients (who do not want to participate) will be asked to answer this questionnaire.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
32780888|NCT05487287||Ischemic stroke patients with functional deficit of the hand|
32780889|NCT05487287||Healthy subjects|
32780890|NCT04269785|Active Comparator|Radiofrequency ablation|These patients will receive ablation by radiofrequency catheter, guided by of 3-dimensional electro-anatomic mapping technology
32780891|NCT04269785|Active Comparator|Cryoballoon ablation|These patients will receive ablation by cryoballoon catheter, guided by X-ray fluoroscopy
32780892|NCT05487209||postmenopausal group|
33084656|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
32780893|NCT05487209||non-menopausal group|
32780894|NCT04275011|Active Comparator|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
33084657|NCT04565938|Experimental|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
33084658|NCT04565938|Experimental|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
33084659|NCT04565938|Experimental|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
33084660|NCT04565548|Experimental|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
33084661|NCT04565548|Active Comparator|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
33084662|NCT04565314|Experimental|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.
33084663|NCT04565002|Experimental|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
33084664|NCT04565002|No Intervention|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
33084665|NCT04565197|Experimental|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
33084666|NCT04564924||MRI & DXA patients|No intervention
33286241|NCT05351645|Active Comparator|Treatment|Participants in the Treatment arm were assigned to read one each day during the two-week trial period. These articles described a personal experience suicide from a first-person perspective, and included positive messages. Before and after reading these articles, participants in the Treatment arm answered brief questions assessing current suicidal thoughts and other constructs. Participants in the Treatment group were administered follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs.
33286242|NCT05351645|No Intervention|Control|Participants in the Control arm answered questionnaires one time per day assessing suicidal thoughts and among other constructs (the same items as the Treatment group) during the two-week trial. Control participants did not receive the positive suicide related stories during the two-week trial period. Participants in the control group completed follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs (the same items as the Treatment group). After the follow-up phase was complete, participants in the Control group received the same intervention as those in the Treatment group.
33286243|NCT01062802|Placebo Comparator|Placebo|
33286244|NCT01062802|Active Comparator|Statin group|
32780895|NCT04275011|Experimental|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
33084667|NCT04564924||MRI & DXA volunteers|No intervention
33286245|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
33084668|NCT04564729|Experimental|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
33286246|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
33286247|NCT03982108|Experimental|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
33286248|NCT03982108|Active Comparator|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
33286249|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
33286250|NCT00954317|Experimental|high epidural|high epidural
33286251|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
33286252|NCT03938909||Patients with dementia|100 patients and 100 control
33286253|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
33286254|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
32780896|NCT05481047|Experimental|prevention|investigator will prevent intraoperative arterial hypotension based on HPI index
32900372|NCT01792388|Placebo Comparator|Soya Bean oil|
33084669|NCT04564729|No Intervention|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
33084670|NCT04564651|Experimental|platelet transfusion treatment|
33084671|NCT04564651|No Intervention|standard medical treatment|
33084672|NCT04564690|Experimental|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
33084673|NCT04564690|Experimental|Control|Consumption of three regular hen eggs per day for three weeks
33084674|NCT04564456|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
33084675|NCT04564456|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
33084676|NCT04564144|Experimental|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
33084677|NCT04563949||PLA-|PLA- initially and repeat testing 1-2 years later
33084678|NCT04563949||PLA+|Not eligible for the study
33084679|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
33084680|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
32780897|NCT05481047|No Intervention|treatment|investigators will treat intraoperative arterial hypotension based on standard hemodynamic parameters
32780898|NCT05480969|Experimental|Intervention group 1|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through a combination of home visits and telephone calls performed at regular time intervals for a total period of 6 months.
32780899|NCT05480969|Experimental|Intervention group 2|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through telephone calls performed at regular time intervals for a total period of 6 months.
32780900|NCT05480969|No Intervention|Control group|Control patients and caregivers will receive usual care for heart failure.
32780901|NCT05480813|Other|Prof. Dr. K. Corten|The one participant of the study is an orthopaedic surgeon. He will execute 48 THA procedures during 4 study days. 24 THA procedures will be executed using the automated KINCISE™ impaction system and 24 THA procedures will be executed using a standard mallet. He will undergo physical and cognitive test before and after the OR day and during lunch breaks. Next to that, operational efficiency and ergonomic impaction will be analysed
32780902|NCT05480579|Experimental|Cohort 1: treated with different doses of single intravenous injection of IBI311|
32780903|NCT05480579|Placebo Comparator|Cohort 1: placebo group|
32780904|NCT05480501|Experimental|IM19 CAR-T cells|
32780905|NCT05493371|Experimental|Empagliflozin|
32780906|NCT05486819|Active Comparator|Group (L)|receive 3 ml (60 mg) of lignocaine 2% added to propofol during injection
32780907|NCT05486819|Active Comparator|Group (B)|receive 3 ml of sodium bicarbonate 8.5% added to propofol during injection
32780908|NCT05486819|Placebo Comparator|Group (S)|receive 3 ml of normal saline added to propofol during injection
32780909|NCT05480423|Experimental|Online mindfulness-based intervention|The online programme lasts for 28 days. Parents will receive the links of daily mini-lectures that introduced basic principles in mindfulness and mindful parenting, audio files of guided mindfulness practice, and exercises that facilitates parents to integrate mindfulness in their daily lives. The total time spent in each session will be around 15 to 20 minutes. Weekly meeting will be arranged with mindfulness instructor and participants.
32780910|NCT05480423|No Intervention|Waitlist controlled group|Participants will be offered same intervention three months later
32780911|NCT05480345|Experimental|Impedance cardiography|Impedance cardiography parameters recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany)
32780912|NCT02554877|Placebo Comparator|Placebo|
32780913|NCT02554877|Experimental|PF-06291874, 30 mg|
32780914|NCT02554877|Experimental|PF-06291874, 60 mg|
32780915|NCT02554877|Experimental|PF-06291874, 100 mg|
32780916|NCT05486741||Myopes|myopes (≤ -1.0 D)
32780917|NCT05486741||Hyperopes|hyperopia (≥ +1.0D).
32780918|NCT05486741||Emmetropes|"emmetropes (> -1.0 to <~1.0 D)"
32780923|NCT05486663|Experimental|Tactile/kinesthetic Group|After the stability of the general health status of the babies is ensured and the oral feeding decision is made, tactile / kinesthetic application will be made for 14 days, 2 times a day, for 15 minutes just before feeding.
32780924|NCT05486663|No Intervention|Control Group|Tactile / kinesthetic applications will not be applied to the control group and these babies will be followed for 14 days and at discharge after the stability of the general health status of the babies is ensured and the oral feeding decision is made.
32780925|NCT05480267|Experimental|UBE|The patient treated with unilateral biportal endoscopy (UBE)
32780926|NCT05480267|Active Comparator|MIS-TLIF|The patient treated with classical minimally invasive posterior spinal interbody fusion (MIS-TLIF)
32780927|NCT05486507|Experimental|Montmorency tart cherry juice|
32780928|NCT05486507|Placebo Comparator|Placebo|
33084681|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
33084682|NCT04721795|Experimental|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
33084683|NCT04721795|Active Comparator|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs only consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
33084684|NCT04675021|Experimental|AZD6094 (Savolitinib) D5084C00010|All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010
32780929|NCT05480189||patients in breast cancer with bone metastasis|patients in breast cancer with bone metastasis
32780930|NCT05493059||Patients|"Mucocutaneous Leishmaniasis proven by culture and/or polymerase chain reaction (PCR)~Seen in French Guiana between 01/01/2017 and 01/04/2022, in dispensaries (CDPS) or in the Dermatology Department of the CHC~Having received treatment with Miltefosine~Patient who consented to participate in the study~Age equal or superior to 18 years"
33084685|NCT04564066|Experimental|efgartigimod IV|intravenous infusions of efgartigimod
32780931|NCT05492981|Experimental|Intervention|The intervention was a 16-minute educational video created by the study investigators which provided information about Down syndrome, diagnostic tests and screening tests. The screening tests covered in the video included the triple test, the combined first trimester screen and non-invasive prenatal screening. Information about how and when each of the tests were performed, their detection rates and possible results and their interpretations were covered in the video. The video was viewed by several healthcare providers and experts in the field of prenatal screening before the commencement of this study to ensure that the content was appropriate and adequate. The intervention was viewed by subjects on a portable tablet in a quiet room in the antenatal clinic. Subjects were then invited to ask their doctor any questions that they may have had about the video during the clinic consult which followed.
32938490|NCT04554121|Experimental|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
32780932|NCT05492981|No Intervention|Control|Women in the control group were counselled by the referring doctor regarding the aneuploidy screening options of FTS or NIPS, and provided information about the procedures involved for each test, their detection rates, cost, and possible results of testing. The use of a written information leaflet was available to doctors as an adjunct to providing this information.
32780933|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
32780934|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
32780935|NCT05492903|Experimental|Intervention|Intervention during weeks 0-10 (10 weekly group sessions). Follow-up with no treatment during weeks 11-20.
32780936|NCT05492903|Other|Waitlist Control|Usual practice during weeks 0-10. Intervention during weeks 11-20 (10 weekly group sessions).
32780937|NCT05486351||Mantainance of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is mantained
32780938|NCT05486351||Interruption of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is interrupted.
32780939|NCT05475587||Prediabetes cases|
32780940|NCT05475587||Healthy controls|
32780941|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
32780942|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
32780943|NCT03860987|Experimental|1|Treatment
32780944|NCT05480111|Experimental|QL Block|
32780945|NCT05480111|Active Comparator|Local Anesthesia at incision site|
32780946|NCT05475431||The Charlson scores >= 2|Patients who are >= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores >= 2, they are divided into the Charlson scores >= 2 group.
32780947|NCT05475431||The Charlson scores < 2|Patients who are >= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores < 2, they are divided into the Charlson scores < 2 group.
32780948|NCT03853109|Experimental|Cohort 1|Cohort 1
32780949|NCT03853109|Experimental|Cohort 2|Cohort 2
32780950|NCT03853109|Experimental|Cohort 3|Cohort 3
32780951|NCT03853109|Experimental|Cohort 4|Cohort 4
33084686|NCT04564066|Experimental|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
32780952|NCT03853109|Experimental|Cohort 6|Cohort 6
32780953|NCT03853109|Experimental|Cohort 7|Cohort 7
32780954|NCT03853109|Experimental|Cohort 8|Cohort 8
32780955|NCT03853109|Experimental|Cohort 9|Cohort 9
32900373|NCT01792388|Active Comparator|Vitamin D|
32900374|NCT05395104|Experimental|Cefiderocol Plus Midazolam|A total of 2 doses of midazolam and 45 doses of cefiderocol will be administered to each participant per specified dosing schedule.
32900375|NCT05394558|Experimental|Radiotherapy + AsiDNA|"Patients will receive the IMP which is the AsiDNA (etidaligide). AsiDNA will be administered intravenously as a 1-hour infusion. All patients will receive a loading dose for three consecutive days, with Day 1 being the start day of radiotherapy, followed by once weekly administrations during 11 weeks.~The infusion of AsiDNA should be administered between 4 and 6 hours before the planned start of radiotherapy.~After the administration of AsiDNA, Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1."
32900376|NCT05394558|Active Comparator|Radiotherapy|Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1.
32900377|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
32900378|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
32780956|NCT05480033|Experimental|Intervention group|The imagery technique was applied to the students in this group on the day of the laboratory practice, before the lesson, once a week for 4 weeks. The laboratory practice consisted of 6 weeks. Pre-test was performed on the first week, followed by 4 weeks of imagery technique, and the pre-test was performed on the final week. In each application of the imagery technique, four scenarios that could be encountered in clinical practice that required skill practice were used for 30 minutes. The imagery technique was applied by the second author who had expertise and training in nursing and imagery technique. The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
32780957|NCT05480033|No Intervention|Control group|No intervention was performed on the students in this group.
32780958|NCT05479955|Experimental|5 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact was applied to the babies of the women in this group for 5 minutes immediately after birth. After the application, routine follow-up and care of the newborn was performed and kept under a radiant heater. When the woman became stable, her baby was given and breastfeeding was supported.
32780959|NCT05479955|Experimental|60 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact application was initiated to the babies of the women in this group immediately after birth and was applied continuously for 60 minutes as recommended by WHO. Follow-up and care of the newborn were done during the application. At the end of 60 minutes, the baby was dressed and given to its mother.
32780960|NCT05479877|Experimental|(Experimental group) collagen based Pulpotomy|(sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)
32938491|NCT04554121|Active Comparator|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
32938492|NCT05271240|Experimental|SIACI of Bevacizumab (Avastin) with Temozolomide and Radiation|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
32780961|NCT05479877|Active Comparator|(Control group) Biodentine pulpotomy|Biodentine (Septodont, Saint-Maur-des-Fossés, France)
32780962|NCT05479799||Anemia group|anemia was diagnosed with a hemoglobin level of less than 11.0 g/dl
32780963|NCT05479799||Non-anemia group|Normal hemoglobin was diagnosed with a hemoglobin level of more than 11.0 g/dl
32780964|NCT05492747|Experimental|Kangaroo Care Effects on Feeding|The researcher allocated the mothers blindly. Eligible mothers and their preterm babies were randomized to either the kangaroo care group or the standard care group (1:1) (Figure 1). The mothers' surnames were written and put in a bag. The surnames were drawn from the bag by lot. The lots were drawn by a neonatal nurse. Neonatal nurse is a research independent person. The first drawn surname was included in the kangaroo group, while the next one was included in the control group, respectively.
32780965|NCT05492669|Experimental|Lidocaine group|General anesthesia is induced in the lidocaine group with intravenous lidocaine 1.5mg/kg for ten minutes, followed by continuous injection of lidocaine 1.5mg/kg.h. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most).
32780966|NCT05492669|Placebo Comparator|Conventional analgesia group|The lidocaine is replaced by identical volumes and rates of 0.9% saline. At the end of the operation, the patient controlled intravenous analgesia without lidocaine is used.
32938493|NCT05271240|Active Comparator|Standard of care Temozolomide and Radiation|Standard of care Temozolomide and Radiation
32938494|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
32938495|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
32938496|NCT04759404|Active Comparator|Deep Oscillation Group|Individuals in the deep oscillation group will be treated by the researcher. During the application, individuals will be positioned face down on the stretcher. After the powder is applied to the lumbar region, deep oscillation treatment with a frequency of 80% -100% with a frequency of 145-150 Hz for the first 10 minutes and 55-60 Hz for 5 minutes will be applied with the Physiomed Deep Oscilation device. Each individual will be given a home exercise program (stretching and strengthening for waist, back and abdominal) consisting of stretching and strengthening. Individuals will be asked to come to the center where the research will take place, for a total of six sessions for two weeks, three times a week.
32938497|NCT04759404|Active Comparator|Myofascial Release Group|Individuals in the myofascial relaxation group will be treated by the researcher. During the application, individuals will lie face down on the stretcher. Myofascial release therapy will be applied in the lumbar region and each individual will be given home exercise (stretching and strengthening for waist, back and abdominal). Individuals will be asked to come to the center where the research will be conducted for a total of six sessions for two weeks, three times a week.
32938498|NCT04759404|No Intervention|Control Group|
32938499|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~medication treatment recommendation;~active link to access additional treatment analysis tools."
32938500|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
32938501|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
32938502|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
32938503|NCT04541329|Experimental|Tildrakizumab treatment|
32938504|NCT04706845||1|No evident disease
32938505|NCT04706845||2|Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
32938506|NCT04706845||3|Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
32780967|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
32780968|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
32780969|NCT05492591|Experimental|Group 1|5 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
32780970|NCT05492591|Experimental|Group 2|6 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
32780971|NCT05492591|Experimental|Group 3|7 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
32780972|NCT05492591|Experimental|Group 4|Both valacyclovir tablets and 6 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
32780973|NCT05492591|Experimental|Group 5|Both valacyclovir tablets and 7 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
32780974|NCT05492591|Active Comparator|Group 6|Only valacyclovir tablets in patients with herpes zoster, positive drug control group.
32780975|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
32780976|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
32780977|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
32780978|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
32780979|NCT03810911|Active Comparator|Early start|Participants given study drug immediately at randomization
32780980|NCT03810911|No Intervention|Delayed start|Participants given study drugs 12 weeks after randomization
32780981|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
32780982|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
32780983|NCT05492435|Experimental|m1 stimulation + dual task training|participants will receive real current over the primary motor area (M1)
32780984|NCT05492435|Experimental|stimulation in M1 and DLPF + dual task training|participants will receive real current over the M1 and over the dorsolateral prefrontal area (DLPFC)
32780985|NCT05492435|Sham Comparator|sham stimulation + dual task training|Participants will receive simulated stimulation
32780986|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
32780987|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
32780988|NCT05474339|Experimental|Cardiac rehabilitation group|
32780989|NCT05474339|No Intervention|Control group|
32780990|NCT05479721||LITMUS Imaging Study Group|Patients within the European NAFLD Registry who have also consented to participate in the LITMUS Imaging study
32938507|NCT04706845||4|Progressive Disease: Tumors bearing NOTCH Mutation
32938508|NCT04706845||5|Progressive Disease: Tumors bearing Notch Wild Type
32780991|NCT05474261||GROUP A-NO Valsalva maneuver|
32780992|NCT05474261||GROUP B- Valsalva maneuver|
32900379|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
32900380|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
32900381|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
32900382|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
32900384|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
32900385|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
32900386|NCT05394402|Experimental|SHR0410 Injection High dose|
32900387|NCT05394402|Experimental|SHR0410 Injection Low dose|
32900388|NCT05394402|Placebo Comparator|Placebo for SHR0410 Injection|
32900389|NCT04256850|Experimental|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
32900390|NCT04256850|Experimental|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
33286255|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
33286256|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
32938509|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
33286257|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
33286258|NCT05351567|Experimental|infertility educatıon group|women wıll educate with model about infertility
33286259|NCT05351567|No Intervention|control group (non-education)|Routıne care
33286260|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
32938510|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
33286261|NCT03855215|No Intervention|Control|Working as routine
33286262|NCT05351411||combined progressive functional exercise|The initial implementation for the 8-week (3 days per week) combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike. The second part of the combined exercise program, the progressive resistance training program, is designed to be consistent with the resistance training section of the Canadian Physical Activity Guidelines for adults with MS. Each prescribed session consisted of 1-3 sets and 10-15 repetitions of 10 exercises targeting major muscle groups of the upper and lower extremities. The specific exercises prescribed included lunges, chair raises/squats, calf raises, knee flexion, knee extensions, shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, and abdominal curls.
33286263|NCT05351411||Placebo|Participants in the control group maintained their routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
33286264|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
33286265|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
32938511|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
32938512|NCT04499833|Experimental|"liver transplant outside the Milan Criteria"|"patients with hepatocellular carcinoma, outside the Milan Criteria, that complied with the proposed HepatoPredictTool, submitted to liver transplant"
32938513|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
32938514|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
32938515|NCT02187744|Experimental|PF-05280014|
32938516|NCT02187744|Active Comparator|Herceptin®|
32938517|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
32938518|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
32780993|NCT05473949|Active Comparator|Propofol|"ASA Standard monitorization and nasal spectacle capnography (OC) were used. Supplementary supply of O2 is placed at 2-3 L/min also by OC.~The drugs were randomized of the study begins. The investigators didn't know whether ketamine is present in syringes prepared with propofol or not, acting in the same way for both drug combinations.~Sedation was performed with:~1. Propofol: induction with a bolus of 1% propofol (10mL syringe) administered at a dose of 0.75mg/kg; maintenance with 1% propofol infusion (20mL syringe), at an infusion rate of 6-7mg/kg/h.~In both arms:~4 mg of I.V. dexamethasone were administered.~At the beginning of the procedure and atropine and ephedrine were prepared.~At the end of the procedure, paracetamol I.V. 15mg/kg was administered.~If the patient reports VAS>3 pain in recovery, metamizole magnesium 15mg/kg is also administered.~In case of post-procedure nausea and/or vomiting, 4 mg of ondansetron would be administered as a rescue."
32780994|NCT05473949|Active Comparator|Ketofol|"2. Sedation with ketofol in a 1:4 dilution: induction of sedation with bolus of ketofol (dilution containing 9.5 mL of 1% propofol + 0.5 mL of 5% ketamine) (10mL syringe), administered at a dose of 0.75 mg/kg; maintenance with ketofol infusion (dilution containing 19 mL of 1% Propofol + 1 mL of 5% Ketamine), (20mL syringe), at an infusion rate of 6-7mg/kg/h.~The dose used for bolus induction of sedation in both arms of the study is titrated to the needs of each individual patient, although the target approximates the usual recommended dose. If a propofol or ketofol syringe is insufficient considering the patient's weight, another syringe will be prepared with exactly the same dilution as the first.~The study was always blind to the investigators."
32780995|NCT05479565||50 pregnant women with patological OGTT|50 pregnant women with patological OGTT ( glucose load test) and after delivery - 50 women with GDM in previous pregnancy.
32780996|NCT05479565||50 pregnant women with regular OGTT|50 pregnant women with regular OGTT ( glucose load test) and after delivery - 50 women without GDM in previous pregnancy
32780997|NCT04424069|Active Comparator|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
32780998|NCT04424069|Active Comparator|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
32780999|NCT04424069|Active Comparator|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
32781000|NCT04424069|Active Comparator|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
32781001|NCT04424069|No Intervention|Control group|Myopic control eyes with no surgical intervention
32781002|NCT05492279|Experimental|intervention|10 gr Sheep ghee
32781003|NCT05492279|Active Comparator|control group|10 gr sunflower oil
33402182|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
33402183|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
32781004|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
32781005|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
32781006|NCT05479487|Experimental|Fluzoparib+Apatinib combination|
32781007|NCT05479487|Active Comparator|Fluzoparib Monotherapy|
32781008|NCT03418961|Experimental|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
32781009|NCT03418961|Active Comparator|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
32781010|NCT03418961|Active Comparator|Arm III (observation)|Patients undergo observation for up to 108 weeks.
32781011|NCT05479409|Experimental|Neoadjuvant radiotherapy|Group 1:Patients undergo mastectomy or Breast conserving surgery after radiotherapy Group 2:Patients receive boost in the area of residual breast mass and regional lymph node. A total dose of 66Gy will be given.
32900391|NCT05535270||Mood Disorder patients|The participants completed a demographic questionnaire, the self-report Oxford Depression Questionnaire (ODQ-C), the Beck Depression Inventory-II(BDI-II), and the Montgomery-Asberg Depression Rating Scale (MADRS).
32900392|NCT05535270||Healthy Controls|The participants completed a demographic questionnaire, Patient Health Questionnaire - 9(PHQ-9), and the first two sections of Oxford Depression Questionnaire (ODQ-20).
32900393|NCT05374434|Active Comparator|Conventional irrigation|Root canal cleaning will be performed by manual irrigation with sodium hypochlorite NaOCl solution.
32900394|NCT05374434|Experimental|Inertial cavitation|Root canal cleaning will be performed by inertial cavitation-generating device.
32900395|NCT05374200|Experimental|Intervention group|Participants will receive the standard of care for PBC and access to the online intervention. During the intervention period, participants will also receive weekly brief (~10-minute) motivational interview style telephone check-ins.
32900396|NCT05374200|No Intervention|Wait list control group|During the 12-week wait list period, participants will receive the standard of care for PBC in addition to weekly emails with motivational messages.
32900397|NCT05590962|No Intervention|Control|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians will receive no further interventions beyond usual practice."
32900398|NCT05590962|Experimental|Intervention|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians in the intervention arm will receive an EHR nudge with option to opt-out for palliative care referral for any eligible high-risk patient."
32900399|NCT05393310|Experimental|post-isometric relaxation|effects of post-isometric relaxation on pain, disability and dynamic balance in athletes with chronic ankle sprain
32900400|NCT05393310|Experimental|mulligan mobilization with movement|effects of mulligan mobilization with movement on pain, disability and dynamic balance in athletes with chronic ankle sprain
32781012|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
32781013|NCT05479331||sarcopenia|CKD patients with sarcopenia, meeting the following two criteria (1) male LTI (lean tissue index)< 7.0 kg/m2, female LTI < 5.7 kg/m2; (2) Male HGS)(handgrip strength < 26 kg, female HGS < 18 kg.
32781014|NCT05479331||non-sarcopenia|CKD patients with non-sarcopenia
32781015|NCT05479253|Experimental|with Artificial intelligence assistant system|Endoscopists would complete the endoscopy report with the assistance of the artificial intelligence system.
32781016|NCT05479253|No Intervention|without Artificial intelligence assistant system|Endoscopists would complete the endoscopy report without special prompts.
32781017|NCT05492045|Experimental|Phase 1b Dose escalation of D-1553 combination therapies|Phase 1b will determine maximal tolerated dose and/or recommended phase 2 dose of D-1553 in combination with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
32781018|NCT05492045|Experimental|Phase 2 of D-1553 combination therapies|Phase 2 will evaluate the efficacy and safety of D-1553 combined with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
32781019|NCT03403283||Group 1|Diabetic
32781020|NCT03403283||Group 2|Healthy Controls
32781021|NCT05491967||Continuous Positive Airway Pressure (CPAP)|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Continuous Positive Airway Pressure (CPAP
32781022|NCT05491967||Mandibular Advancement Orthosis|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Mandibular Advancement Orthosis
32781023|NCT05479175|Active Comparator|Ibuprofen|Ibuprofen 600 mg will be given to the patient one hour before starting root canal treatment.
32781024|NCT05479175|Active Comparator|Diode laser|Low-level laser therapy will be applied with an 810 nm wavelength diode laser device for 30 seconds in the area of mesial root and 30 seconds in the area of distal root , total of 60 seconds.
32781025|NCT05479175|Active Comparator|Nonactive Diode laser|Placebo, will be explained to the patients that laser treatment will be applied as in group 2, but laser will not be activated.
32781026|NCT05479175|No Intervention|Control|Control, routine root canal treatment will be done. No medication or laser will be applied before the treatment procedure.
32781027|NCT05479019|Experimental|Positive stimuli|Images/trials that contain a target
32781028|NCT05479019|Experimental|Negative stimuli|Images/trials that do not contain a target
32781029|NCT05472857|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|anti-claudin18.2 chimeric antigen receptor T-cell therapy，infusion
32781030|NCT05478941|Active Comparator|Progressive Muscle Relaxation training via Zoom and Guided Imagery exposure|"A standardized protocol regarding the information on the training background is shared with participants. Then, they are invited to participate in four individual PMRT sessions (two sessions per week) deployed via Zoom.~The fifth session after a week (T1; day 7) is administered in-presence at the Virtual Reality laboratory (A10-A11)- University of Padova; here an in-imagination relaxing scenario is built up with the support of the Psychotherapist; then, participants are exposed to an in-vivo PMRT relaxing session conducted by the Psychotherapist, with the request to think about the in-imagination relaxing scenario, created before, during the progressive relaxation procedure. After two weeks (T2; day 14), at the follow-up phase, the therapist asks to recover the in-imagination relaxing scenario and relax, giving participants the time allowed for the last guided relaxing session."
32781031|NCT05478941|Experimental|Progressive Muscle Relaxation training via Zoom and personalized VR exposure|"PMRT sessions and expected time length are the same as for the first group. Differences regard the fifth session after a week (T1; day 7), where the relaxing scenario is built with the psychotherapist's support based on the VR's tools. Indeed, during the in-presence session, participants are exposed to a merged personalized relaxing VR scenario and PMRT session administered by the Oculus Quest 2 tool.~During the follow-up (T2; day 14), it is asked to recover the image and relax, making available the same time allowed for the last guided session."
32781032|NCT05478941|Experimental|Progressive Muscle Relaxation training based on audio-recording and personalized VR exposure|"A standardized protocol of information and the four PMRT sessions is administered individually based on an audio-track through the Moodle e-learning platform of the University of Padova.~During the fifth session after a week (T1; day 7), users are asked to participate in an in-presence session in which they are exposed to a merged personalized, relaxing VR scenario and a PMRT session administered based on the Oculus Quest 2 tool. The last follow-up session (T2; day 14) has the same features as the other groups."
32781033|NCT05491889||HCC patients with PPVT after TACE|determine frequency of short-term mortality (< 3month) among HCC patients with PPVT after TACE, and to explore its predictors.
32781034|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
32781035|NCT02534935|Active Comparator|Control|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
32781036|NCT05430295|Active Comparator|Eyhance intraocular lens|10 patients bilaterally implanted with Eyhance intraocular lens
32781037|NCT05430295|Active Comparator|Tecnis 1 piece intraocular lens|10 patients bilaterally implanted with Tecnis 1 piece intraocular lens
33402184|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
33402185|NCT01312987|No Intervention|Control|Receives food vouchers each month.
33402186|NCT03296527|Experimental|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
32781041|NCT05429359|Active Comparator|CSII users|Patients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps)
33402187|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
32781042|NCT05429359|Active Comparator|MDI users|Patients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)
32781043|NCT05428735|Active Comparator|Portal Vein Embolization (PVE) alone - (control arm)|Portal Vein Embolization (PVE) alone
32781044|NCT05428735|Experimental|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)
32781045|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
32781046|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
32781047|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
32781048|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
32781049|NCT02544451|Experimental|Treatment Period 1: LUM/IVA to LUM/IVA|
32781050|NCT02544451|Experimental|Treatment Period 1: Placebo (PBO) to LUM/IVA|
32781051|NCT02544451|No Intervention|Treatment Period 1: Observational Cohort|
32781052|NCT02544451|Experimental|Treatment Period 2: LUM/IVA|
32781053|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
32781054|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
32781055|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
33084687|NCT04564222|Experimental|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
33084688|NCT04564222|Placebo Comparator|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
33084689|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
33084690|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
33084691|NCT04674865|Active Comparator|Conventional treatment protocol group|Standardized treatment protocol including chest physical therapy as well as limb physical therapy and functional mobility was addressed.
33084692|NCT04674865|Experimental|ANB group|2 sessions per day was added to the standardized treatment protocol
33084693|NCT04674943|No Intervention|Control group|No physical therapy intervention was given. Only pharmacological treatment was provided.
33084694|NCT04674943|Experimental|Breathing exercise group|1. Pursed lip breathing 15 reps x 3 sets) 2: Diaphragmatic breathing (15 reps x 3 sets) 3:Lateral costal breathing 15 reps x 3 sets)
33084695|NCT04674904|Experimental|Group A|Dry Needling
33084696|NCT04674904|Active Comparator|Group B|Hot pack , TENS , Stretching
32781056|NCT04268615|Experimental|Patients|Patients suffering from chronic bilateral vestibular hypofunction
32781057|NCT04268615|Active Comparator|healthy subject group|
32900401|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
33084697|NCT04675060|Experimental|Cohort 1|TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
33084698|NCT04675060|Experimental|Cohort 2|TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
33084699|NCT04674982|Experimental|Vibration Group|In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
33084700|NCT04674982|No Intervention|Control Group|No interventions were made on the newborns in the control group during the heel lance procedure.
33084701|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
33084702|NCT04674709|Placebo Comparator|Safety of Oleander 4X HPUS|: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).
33084703|NCT04674709|Experimental|Pharmacokinetics evaluation of Oleander 4X HPUS|To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.
33084704|NCT00555841|Experimental|ALC|I g three times daily
33084705|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
33084706|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
32781058|NCT05472389|Other|Patients, adults and children, with Dravet Syndrome|An homogenous population of patients with DS. The patients will have a prospective baseline period of 3 to 6 months duration in order to collect seizure frequency. After this period, all patients will then undergo a 24-48 hours video-EEG recordings and a full-night polysomnography
32781059|NCT05491811|Experimental|Ensartinib and Bevacizumab|Ensartinib 225 mg oral once daily with Bevacizumab 7.5mg/kg intravenous every 3 weeks
32781060|NCT05472233|Active Comparator|2weeks|Suture removal at 2 weeks post intervention
32938519|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32781061|NCT05472233|Experimental|3+weeks|Suture removal at 3 weeks minimum post intervention
32781062|NCT04266041|Experimental|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
32781063|NCT04266041|Active Comparator|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
32781064|NCT04266041|Experimental|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
32781065|NCT04266041|Experimental|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
32781066|NCT04266041|Experimental|High-density EEG localization in stroke patients|High-density EEG will be used for brain localization in patients who have recently experienced a stroke
32938520|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32781067|NCT05491733|Active Comparator|APX001 Treatment A|Oral tablet with a 25% drug load (low-load) in fasted participants
32781068|NCT05491733|Experimental|APX001A Treatment B|Oral tablet with a high drug load in fasted participants
32781069|NCT05491733|Experimental|APX001A Treatment C|Oral tablet with a high drug load in participants that are not fasted.
32938521|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938522|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938523|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938524|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938525|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938526|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938527|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938528|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938529|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938530|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
32938531|NCT04393441|Active Comparator|Systane® Ultra Multidose|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of Systane® Ultra Multidose in each eye 3 times daily for up to 90 days.
32938532|NCT04393441|Experimental|011516X (New Artificial Tear Formulation)|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of 011516X in each eye 3 times daily for up to 90 days.
32938533|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
32938534|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
32938535|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
32938536|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
32938537|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
32938538|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
32938539|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
32781070|NCT05478785|Experimental|Cisplatin micelle injection (HA132)|"Dose-escalation: Five dose levels have been selected for evaluation in the Phase Ⅰ of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.~Dose-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD).~Cohort-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD)."
32781071|NCT05471297||Handball players|Professional handball players
32781072|NCT05478395||Questionnaires assessed adolescents and young adults|"Internet users aged 14-35;~Be able to read and communicate in Chinese."
32781073|NCT05478317|Active Comparator|Control group: Crown lengthening using a traditional open-flap approach (OF).|Esthetic Crown lengthening done using a traditional open-flap approach (OF).
32781074|NCT05478317|Experimental|Test group: Crown lengthening using a minimally invasive approach by piezoelectric (PZ).|Esthetic Crown lengthening done using a minimally invasive approach using piezoelectric (PZ).
32781075|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
32781076|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
32781077|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
32781078|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
32781079|NCT05461001|Experimental|Warm Up Exercises daily for Cardiorespiratory Fitness|Effect of warm up activities daily on cardiorespiratory fitness of Male Football Players
33084707|NCT00259974|Experimental|1|Rituximab
33084708|NCT00555919|Experimental|Arm 1|
33084709|NCT00555919|Experimental|Arm 2|
33084710|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
33084711|NCT04673968|Active Comparator|prehabilitation (P)|inhospital exercise training 5 times/week, 5~6 weeks during nCRT (neoadjuvant chemoraiotherapy); home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
33084712|NCT04673968|No Intervention|control group (C)|no prehabilitation
33084713|NCT04674046|Experimental|Nonoperative treatment if deltoid ligament is intact|AirCast Air-stirrup (DJO Global) functional orthosis for 6 weeks.
33084714|NCT04674046|Experimental|Operative treatment if deltoid ligament is ruptured|Open reduction, internal fixation of the fibular fracture using plate and screws.
32781080|NCT05461001|Experimental|Endurance based Exercises for Cardiorespiratory Fitness|Effect of sports-specific endurance based exercises on cardiorespiratory fitness of Male Football Players
32781081|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
32781082|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
32781083|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
32781084|NCT05471219|Experimental|Çalışma grubu|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces
32781085|NCT05471219|No Intervention|Kontrol grubu|Primiparous pregnant women who will undergo vaginal examination with standard care
32781086|NCT05478083|Active Comparator|Direct start|36 months of treatment with study medication
32781087|NCT05478083|Other|Delayed start|First 18 months standard care, hereafter 18 months treatment with study medication
32781088|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
32781089|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
32781090|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
32781091|NCT05427565|Experimental|Cortical hemodynamic variability of four weeks iTBS|"One healthy participant will be included in this study, which lasts for 4 weeks, 5 visits per week, involving 20 visits in total.~The participant will receive the following instructions the night before: to take 200 mg of caffeine one hour before the visit (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the visit; to attend the visit in the morning or afternoon. These assignments will be randomized in a counterbalanced manner."
32781092|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
32781093|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
32900402|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
33084715|NCT04673929||patients with HNC recurrence treated with TORS|Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS
33084716|NCT04673812|Active Comparator|Bupivacaine-Fentanyl Spinal Anaesthesia|
33084717|NCT04673812|Active Comparator|Bupivacaine-Fentanyl-Naloxone Spinal Anaesthesia|
33402188|NCT04431193|Experimental|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
33402189|NCT04431193|Experimental|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
33084718|NCT04673461|Experimental|STA363 containing 90 mg (60 mg/mL) lactic acid|"STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
33084719|NCT04673461|Experimental|STA363 containing 180 mg (120 mg/mL) lactic acid|"STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
33084720|NCT04673461|Placebo Comparator|Placebo|"Placebo will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
33084721|NCT04673500|Experimental|Propofol-lidocaine through large vein|Eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the antecubital fossa and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
32781094|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
33084722|NCT04673500|Placebo Comparator|Propofol-lidocaine through small vein|Another eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the dorsum of hand and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
33084723|NCT04673695|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
33084724|NCT04673695|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
33084725|NCT04673305|Experimental|Arm 1|patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
33084726|NCT04673344|No Intervention|Partial Rotator Cuff Repair|Routine partial rotator cuff repair
32781095|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
33286266|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
33286267|NCT05351177|Experimental|High-Intensity Interval Training Group|Participants in the High-Intensity Interval Training (HIIT) group will complete 8 weeks of twice-weekly HIIT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by 10 x 60 second repetitions on the cycle ergometer interspersed with 60 seconds rest. A five minute cooldown will follow on the cycle ergometer.
33286268|NCT05351177|Experimental|Concurrent Training Group|Participants in the Concurrent Training (CT) group will complete 8 weeks of twice-weekly CT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by two sets of four then eight repetitions of deadlift, squat, bench press and shoulder press resistance exercises. Thereafter, 5 x 60 second HIIT cycling intervals will be completed on a cycle ergometer, after which a five minute cooldown will ensue.
33286269|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
33286270|NCT03814889|Active Comparator|Vibration pattern 1|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286271|NCT03814889|Active Comparator|Vibration pattern 2|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286272|NCT03814889|Active Comparator|Vibration pattern 3|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286273|NCT03814889|Active Comparator|Vibration pattern 4|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286274|NCT03814889|Active Comparator|Vibration pattern 5|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286275|NCT03814889|Active Comparator|Vibration pattern 6|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
32781096|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
32781097|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
33084727|NCT04673344|Active Comparator|Partial Rotator Cuff Repair with Regeneten Scaffold|Routine partial rotator cuff repair with the addition of the Regeneten scaffolding patch
33084728|NCT04673110||Anastomotic leakage group|9 patients developed anastomotic leakage (8%) in a median of 8 days (range: 5-9) median CRP level postoperative day 4:164mg/dL
33084729|NCT04673110||no Anastomotic leakage group|117 patients (92%) median CRP level postoperative day 4: 64mg/dL
33084730|NCT04672954|Active Comparator|BI 474121|
33084731|NCT04672954|Placebo Comparator|Placebo|
33084732|NCT04672993|Experimental|Urine Collection Device for Men|Test of Urine Collection Device for Men for 7 (+/- 3/0 days).
33286276|NCT03814889|Active Comparator|Vibration pattern 7|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286277|NCT03814889|Active Comparator|Vibration pattern 8|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286278|NCT03814889|Active Comparator|Vibration pattern 9|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286279|NCT03814889|Active Comparator|Vibration pattern 10|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
33286280|NCT03814889|Placebo Comparator|No vibration|A light will blink instead of a vibration pattern being displayed.
33286281|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
33286282|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
33286283|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
33286284|NCT03741101|Experimental|single arm study|children treated with trametinib
33286285|NCT05350787|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
33286286|NCT05350787|Experimental|ThisCART19A 8×10^6 cells/kg as dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
33286287|NCT05350787|Experimental|ThisCART19A 12×10^6 cells/kg as dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
33286288|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
33286289|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
33286290|NCT00449670|Experimental|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
33286291|NCT00449670|Active Comparator|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
33286292|NCT04011449|Experimental|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
32900403|NCT04610372|Active Comparator|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
32900404|NCT04610372|Experimental|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
32900405|NCT04610372|Experimental|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
32900406|NCT04610372|Experimental|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
32900407|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
32900408|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
32900409|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
32900410|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
32900411|NCT00311246|Experimental|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
32900412|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
32900413|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
32900414|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
32900415|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
32900416|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
32900417|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
33286293|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
33286294|NCT04010903|Experimental|HEALTHY SUBJECTS|SUBJECTS WITH BMI<27 and HOMA<4
33286295|NCT04010903|Experimental|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA<4
33286296|NCT04010903|Experimental|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA>4
33402190|NCT04431193|Experimental|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
33402191|NCT04431193|Experimental|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
33084733|NCT04673227||Contact with active TB/ LTBI|After a close contact with bacteriologically confirmed TB suspicion for LTBI with an evidence of previous BCG vaccination status TB confirmed with TST (TST ≥ 5 mm or BCG unvaccinated or TST ≥ 15 mm for BCG vaccinated) 20 children and adolescents 20 adults
33084734|NCT04673227||Active TB group|Active TB group with positive microbial culture and pathological chest radiography or chest CT 20 children and adolescents 20 adults
33084735|NCT04673227||Contact with active TB/ negative|After a close contact with bacteriologically confirmed TB no evidence of TB in TST or IGRA test for 3 months 20 children and adolescents 20 adults
33084736|NCT00260091|Active Comparator|I.|Conventional infertility therapy
33402192|NCT04430335|Other|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
32781098|NCT04464187||Participants exposed to Elagolix-containing products|Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
32781099|NCT04464187||Participants not exposed to Elagolix-containing products|Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
32781100|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
32781101|NCT04423549||tested group|
32781102|NCT04423549||controlled group|
32781103|NCT05452915||Chronic Pain|Patients with chronic pain, aged 18 - 50 years for the neuropsychological assessment and 18-45 years for the fMRI examination
32781104|NCT05452915||Healthy Controls|Healthy controls matched on group level in terms of gender, age, and educational level
32781105|NCT05427019|Active Comparator|Distal adductor canal block|Participants receiving continuous distal adductor canal block
32781106|NCT05427019|Active Comparator|Distal adductor canal block and Periarticular block|Participants receiving continuous distal adductor canal block and periarticular block
32781107|NCT05426863|Experimental|Psychosocial Counselling|A multi-component intervention counseling package to prevent the reoccurrence of IPV and address psychological distress among women experiencing violence. The DeVI intervention is structured into five weekly sessions.
32781108|NCT05426863|No Intervention|Standard Usual Care|Provide standard usual care and information booklet similar to that of the intervention group that contains updated contact information for the referral services.
32781109|NCT05426707|Experimental|RIC group|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
32781110|NCT05426707|Sham Comparator|Sham RIC group|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
32781111|NCT02533453|Experimental|Bydureon|exenatide once weekly
32781112|NCT05426083||Physiological Assessment|Prospective physiological assessment of LV work and oxygen consumption in patients with SCAI D/E cardiogenic shock due to acute coronary syndrome treated with peripheral VA-ECMO support.
32781113|NCT05425615|Experimental|Active TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans (also known as an air-cooled coil) will be used for delivering active repetitive or rapid TMS to the target site.
32781114|NCT05425615|Active Comparator|Control TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering active repetitive or rapid TMS to the control site.
32781115|NCT05425615|Sham Comparator|Sham TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering sham repetitive or rapid TMS to the control or target site.
32781116|NCT05424835|Experimental|SHR-A1811|
32781117|NCT05424835|Experimental|Pyrotinib in combination with Capecitabine.|
32781118|NCT05424601|Experimental|Rethink game plus PsyPills|Rethink game followed by PsyPills
32781119|NCT05424601|Experimental|Rethink Game|Rethink game only
32781120|NCT05424601|No Intervention|Control|Control group
32781121|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
32781122|NCT04455841|Experimental|Treatment Group A (TGA)|INCB000928 will be administered once daily( QD).
32781123|NCT04455841|Experimental|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
32781124|NCT05410873|Experimental|MitoQ|Mitoquinol mesylate 40mg daily
32781125|NCT05410873|Placebo Comparator|Placebo|
33084737|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
33084738|NCT04673071|Active Comparator|Thread Embedding Acupuncture (TEA)|TEA once a month for 4 months + AEDs
33084739|NCT04673071|Sham Comparator|Sham-TEA (STEA)|STEA once a month for 4 months + AEDs
33084740|NCT04672642|Experimental|SpyGlass DS after endoscopic treatment|
33084741|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
33084742|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
33084743|NCT04672720|Experimental|Adding l-carnitine to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. In the experimental group, the women will receive 3 tablet of L-carnitine daily (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) from day 2 of the previous menstrual cycle until pregnancy test day.
32938540|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
32938541|NCT04376515|Experimental|HOPE Intervention|HOPE peer-led intervention
32938542|NCT04376515|No Intervention|Control|Control group- online community without peer leaders
32938543|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
33402193|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
32781126|NCT05410795||Healthy people|Healthy people refer to those who exclude pancreatic related diseases, such as acute and chronic pancreatitis, pancreatic trauma, pancreatic tumor, peripancreatic lesions, diabetes and other diseases that may affect the volume of the pancreas.
32781127|NCT05410795||Chronic pancreatitis|Patients with chronic pancreatitis are considered as study subjects.
32781128|NCT05410795||Acute pancreatitis|Patients with acute pancreatitis within 144 hours after the onset of typical symptoms are considered as study subjects.
32781129|NCT05410327|Experimental|Chokeberry consumption|Participants will be given 100ml of a water-infused chokeberry juice to consume twice per day for a period of 6 weeks.
32781130|NCT01553149|Experimental|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
32781131|NCT01553149|Experimental|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
32781132|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
32781133|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
32781134|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
32781135|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
32781136|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
32781137|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
32781138|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
32781139|NCT05470673|Experimental|Alveolar ridge preservation using demineralized dentin combined with I-PRF + metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft then inserted in the extraction socket and covered then suturing
32781140|NCT05470673|Active Comparator|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and inserted in the extraction socket and covered then suturing
32938544|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
32938545|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
32938546|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
32938547|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
32938548|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
32938549|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
32938550|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
32938551|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
33084744|NCT04672720|Placebo Comparator|Adding placebo to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. The patients in the control group will receive 3 placebo tablets in similar way for 8 weeks.
33084745|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
33084746|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
32781141|NCT05470361||People who suffer from PTSD|The sample will be composed of 30 patients from Stella's Chicago practice: 712 N Dearborn St, Chicago, Illinois 60654
32781143|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
32781144|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
32781145|NCT05459285|Experimental|14028 injection|Subjects receive 14028 injection in the study, 0.75mg, once
32781146|NCT05459285|Active Comparator|dulaglutide injection (TRULICITY®)|Subjects receive dulaglutide injection (TRULICITY®) in the study, 0.75mg, once
32781147|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
32781148|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
32781149|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
32781150|NCT03284957|Experimental|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
32781151|NCT03284957|Experimental|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
32781152|NCT03284957|Experimental|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
32781153|NCT03284957|Experimental|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
32781154|NCT03284957|Experimental|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
32781155|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
33084747|NCT00556036||1|lean healthy women, age 18-45
33084748|NCT00556036||2|overweight healthy women, age 18-45
33084749|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
33084750|NCT00556036||4|women with anorexia nervosa, age 18-45
33084751|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
33084752|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
33084753|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
33084754|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
33084755|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
33084756|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
33402194|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
32781156|NCT02542865|No Intervention|Control Group|No treatment was administered
32781157|NCT05469893|Active Comparator|Lenalidomide + Dexamethasone (LD)|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~Lenalidomine~Dexamethoasone"
32781158|NCT05469893|Experimental|Teclistamab|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~- Teclistamab-Per Protocol"
32781159|NCT05477927|Experimental|CAR-T cell therapy|Dual-targeting VEGFR1 and PD-L1 CAR-T cells
32781160|NCT05477771|Experimental|Anterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the anterior part were categorized in the anterior tear group.
32781161|NCT05477771|Experimental|Middle tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the middle part were categorized in the middle tear group.
32781162|NCT05477771|Experimental|Posterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the posterior part were categorized in the posterior tear group.
32781163|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
32781164|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual."
32781165|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
32781166|NCT03629171|Experimental|Treatment (CPX-351, venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and on days 1 and 3 of cycle 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
32781167|NCT03611153|Experimental|AZD4831 Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
32781168|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
32781169|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
32781170|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
32781171|NCT05459051||Patients with stable angina|"Symptomatic~Anatomically severe single-vessel coronary artery disease~Physiological evidence of myocardial ischaemia"
32781172|NCT05458973||Frontline cohort|
32781173|NCT05458973||recurrent cohort|
32781174|NCT03978689|Experimental|CUE-101 dose escalation and expansion|Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
32781175|NCT03978689|Other|Pembrolizumab and CUE-101|Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
32781176|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
32781177|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
32781178|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
32781179|NCT05457491|Experimental|Human platelet extract (HPE)|Subjects will follow a standardized twice daily skin care regimen of applying morning and night. Morning skin care routine includes Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine includes Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion
33402195|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
32781180|NCT05477615|Experimental|lazertinib/pemetrexed/carboplatin|"combination of lazertinib with pemetrexed/carboplatin chemotherapy~- Lazertinib 240mg once daily and chemotherapy (pemetrexed and carboplatin) is administered on the 1st day every 3 weeks."
32781181|NCT05477537|Experimental|Add-on group|Subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks)
32781182|NCT05477537|Active Comparator|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual).
33402196|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
32781183|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
32781184|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
32781185|NCT05469503|Experimental|TOTUM-854|Experimental active diet supplement TOTUM-854 3.71-g dose. Seven capsules per day to consume orally in two intakes
32781186|NCT05469503|Placebo Comparator|Placebo|Placebo comparator Seven capsules per day to consume orally in two intakes
32781187|NCT05477459|Experimental|Verum|Lysergic diethylamide tartrate (equivalent to 25 microgram LSD base), one dose every 3 days for 3 weeks (totalling 7 vials)
32781188|NCT05477459|Placebo Comparator|Placebo|Placebo vial looking like verum vial, one vial every 3 days for 3 weeks (totalling 7 vials)
32781189|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
32781190|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
32781191|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
32938552|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
33402197|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
32781192|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
32900418|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
32938553|NCT04290091||Patients with CAD|Patients who have hemodynamically significant CAD.
32938554|NCT04290091||Patients without CAD|Patients who don't have hemodynamically significant CAD.
32938555|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
32938556|NCT04227145|No Intervention|Usual Care|We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey and study staff will provide a referral for participants to seek more information on contraception and services. Study staff will record whether the participant accepted the referral. Follow-up will occur via phone call at 2-weeks, 1-month and 3-months post-enrollment to determine if they accessed contraceptive referral services if they initiated any contraceptive method, and if so: if they continued, changed, or discontinued this contraception method. We will recruit, complete baseline and usual care referral at recovery sites on a timely rotation that mirrors the intervention period (e.g., every fourth Friday morning at Site 1), in order to increase the chance of recruiting a comparable population.
33084757|NCT04672603|Experimental|Complete Preservation of Denonvilliers Fascia|Complete preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
33402198|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
33402199|NCT01732627|Experimental|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
33402200|NCT01732627|Active Comparator|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
33286297|NCT05350709|Active Comparator|mirror therapy|An exercise program has been prepared for patients for use in mirror therapy. In this exercise program, firstly, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages) is shown. The patient will repeat the movement for 3 minutes. The patient will hold the affected extremity behind the mirror with the healthy extremity, the patient will look towards the affected side from the mirror and try to do the movements with the affected extremity. . The treatment period will be 20 sessions, 5 days a week, for 4 weeks.The exercises will take 1 hour, including half an hour of mirror therapy and half an hour of conventional exercises.
33286298|NCT05350709|Active Comparator|action observational therapy|An exercise video has been prepared for the patients to watch for the action observation therapy. In this video, first of all, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist, etc.) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages, etc.). is shown. The patient will first watch the video of each movement, and then repeat the movement for 3 minutes. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks.The exercises will take 1 hour, including half an hour of action observational therapy and half an hour of conventional exercises.
33286299|NCT05350709|Active Comparator|conventional therapy|Conventional therapy includes range of motion exercises, walking and balance exercises. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks. The exercises will last for half an hour daily.
33286300|NCT04010513|Experimental|Hypnosis|
33286301|NCT04010513|Active Comparator|Standard of Care|
33286302|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
33286303|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
33286304|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
33286305|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
33286306|NCT05299931|Other|Subcutaneous (SC) ustekinumab every 8 weeks (Q8w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are Q8w responders at the end of REScUE~Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q8w will be able to cross-over to a OLE treatment regimen of ustekinumab 90 mg SC Q4w if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE"
33286307|NCT05299931|Other|Subcutaneous (SC) ustekinumab every 4 weeks (Q4w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w (Cross-over) if they are Q8w non-responders at the end of REScUE OR Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are Q4w responders at the end of REScUE"
33286308|NCT05350553||Healthy Control|Patients 45-75 years of age without Type 2 Diabetes and without chronic low back pain.
33286309|NCT05350553||Type 2 Diabetic with Painful Neuropathy|Patients 45-75 years of age with Type 2 Diabetes and experiencing painful neuropathy (painful numbness or tingling in hands and/or feet)
33286310|NCT05350553||Chronic Low Back Pain as a Result of Lumber Disc Aberrancy|Patients 45-75 years of age with chronic low back pain as a direct result of non-operative lumber disc aberrancy (lumbar disc herniation, protrusion, or extrusion).
33286311|NCT01023906||18-49 years|Younger
33286312|NCT01023906||50-85 years|Older
33286313|NCT00954629|Experimental|2PX|Pain medication
33286314|NCT00954629|Placebo Comparator|Placebo|
33286315|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
33286316|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with partial response, may receive up to 2 additional doses at monthly intervals.
33286317|NCT00296374|Experimental|1|Rosuvastatin 10 mg
33286318|NCT00296374|Experimental|2|Rosuvastatin 40 mg
33286319|NCT00296374|Active Comparator|3|Atorvastatin 80 mg
33286320|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
33286321|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
33286322|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
33286323|NCT05350475|Experimental|Proton therapy|"Radiation: Proton Therapy 78 Gray (Gy) in 39 fractions with 56 Gy to the Pelvic Lymph Nodes (LN), 5 days a week.~Androgen Deprivation Therapy (ADT) for three years, starting 3 months before Proton Therapy."
33286324|NCT05350475|Active Comparator|Photon Therapy|Radiation: Photon Therapy 78 Gy in 39 fractions with 56 Gy to the pelvic LN, 5 days a week. ADT for three years, starting 3 months before Photon Therapy.
33286325|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
33286326|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
33286327|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
33286328|NCT05350241|Experimental|Split-belt treadmill walking group|Participants in this group performed repeated split-belt treadmill training with an error-augmentation strategy.
33286329|NCT05350241|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
33286330|NCT05304923|Experimental|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
33286331|NCT05304923|Placebo Comparator|nasal cannula oxygen supply|Oxygen supplementation is delivered via a nasal cannula to the participants during sedation.
32781193|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
33286332|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v."
33286333|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
33286334|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
33286335|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
33286336|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
32781194|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
32781195|NCT02710097|Experimental|Active THC and Placebo Ethanol|
32781196|NCT02710097|Experimental|Active THC and Active Ethanol|
32781197|NCT02710097|Experimental|Placebo THC and Active Ethanol|
32781198|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
32781199|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
32781200|NCT05468957|Active Comparator|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
32781201|NCT05468957|Experimental|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
32781202|NCT05477147|Experimental|Treatment Group|Patients undergoing catheter ablation that qualify after initial screening.
32781203|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
32781204|NCT05408377|Experimental|MA group|Manual Acupuncture
32781205|NCT05408377|Placebo Comparator|SA group|Sham acupuncture
32781206|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
32781207|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
32781208|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
32781209|NCT04258111|Experimental|IBI310 + Sintilimab|
32781210|NCT05424367||NH Hispanic/Latino Adults|New Hampshire adults(at least 18 years of age) with cultural background in a Spanish-speaking Latin American country or territory surveyed between March 2021 - March 2022.
32781211|NCT05452213|Experimental|Ribociclib|
32781212|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
32781213|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
32781214|NCT05476991|Experimental|Colchicine + Ticagrelor|
32781215|NCT05476991|Experimental|Colchine + Aspirine|
32781216|NCT05476991|Experimental|SOC + Ticagrelor|
32781217|NCT05476991|Active Comparator|SOC + Aspirine|
32781218|NCT05476913|Experimental|geko™ T-3 interventional|The geko™ device will be applied bilaterally as soon as possible after randomisation and each geko™ device will be used to deliver one 24-hour dose. Devices will be worn continuously and changed every 24 hours. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
32781219|NCT05476913|No Intervention|Intermittent Pneumatic Compression (IPC)|Control treatment will be IPC using NHS approved devices as used for standard clinical care. They will be applied to both legs as soon as possible after randomisation. They will not be changed unless damaged or soiled. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
33286337|NCT04011059|Placebo Comparator|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
33084758|NCT04672603|No Intervention|Partial Preservation of Denonvilliers Fascia|Partial preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
33084759|NCT00233168|Experimental|1|Peer medication adherence counseling
33286338|NCT04011059|Active Comparator|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
33286339|NCT00954785|Placebo Comparator|Placebo drug|
33286340|NCT00954785|Experimental|Etoricoxib|
33286341|NCT00954785|Active Comparator|Diclofenac|
33286342|NCT00326950|Experimental|1|
32781220|NCT05468411|Active Comparator|Miracle fruit pill|A freeze-dried miracle fruit pill is orally administered prior to eating food samples.
33286343|NCT03981874|Experimental|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
33286344|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
32781221|NCT05468411|Placebo Comparator|Sugar candy|A chewable sugar candy is orally administered as a placebo prior to eating food samples.
33084760|NCT00233168|Active Comparator|2|Peer life skills counseling
33286345|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
33286346|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
33084761|NCT04672837|Experimental|Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
33286347|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
33286348|NCT00296140|Other|self management of PSD symptoms|
33286349|NCT00296140|Other|screening and treatment of PSD|
33286350|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
33286351|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
33286352|NCT03958331|Active Comparator|Control Group|Automated reminders and individualized adherence feedback reports
33286353|NCT03958331|Experimental|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
33286354|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
33286355|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
33286356|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
33286357|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
33286358|NCT03956615|Other|Clinically Suspected or Pathologically Confirmed Multiple Myeloma.|Patients with a clinically suspected or pathologically confirmed multiple myeloma.
33286359|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
33286360|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
33286361|NCT03325608|Experimental|Intervention|The POISED care management team consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) will conduct a biopsychosocial/environmental needs assessment by phone within 48 hours of emergency room discharge if not possible during the ED stay.
33286362|NCT03325608|Placebo Comparator|Usual Care|will receive referrals to services at the time of enrollment.
33286363|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
33286364|NCT03956225|Experimental|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
33286365|NCT03956225|Active Comparator|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
33286366|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
33286367|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
33286368|NCT05178329|Active Comparator|Intervention group|The patients undergoing intervention exercise.
33286369|NCT05178329|Placebo Comparator|Control Group|The patients undergoing the normal exercise program
33286370|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
33286371|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
33286372|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
33286373|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
33402201|NCT03307837|Active Comparator|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
33402202|NCT03307837|Active Comparator|CA-008 Cohort 2 1 mg|Intra-operative, local administration
32781222|NCT05476835|Experimental|experimental group (group A) - control group (groupB)|The experimental group (group A) performed respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
33084762|NCT04672837|Active Comparator|Stretching Group|"A protocol of Stretching at home. 3-5 sessions twice a day. Each stretch will be maintain10 to 30 seconds. Each session 15 will take no less than 15 minutes. 7 days a week.~Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
33402203|NCT03307837|Active Comparator|CA-008 Cohort 3 2 mg|Intra-operative, local administration
32781223|NCT05476835|No Intervention|control group (group B)|The control group (group B) did not receive any physical therapy program
32781224|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
32781225|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
33402204|NCT03307837|Active Comparator|CA-008 Cohort 4 3 mg|Intra-operative, local administration
32781226|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
32781227|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
32781228|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
32781229|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
32781230|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
32781231|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
32781232|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
32781233|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
32781234|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
32781235|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
32781236|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
32781237|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
32938557|NCT04227145|Experimental|SexHealth Mobile|We will train Swope providers in contraceptive counseling before intervention. We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey. Study staff will provide a referral for participants to seek more information on contraception and services. Women will have direct access to contraceptive counseling and services on-site via the mobile medical unit if they choose to use it. Counseling will focus on presenting the most effective contraceptive methods first (i.e., LARC). If women participate in contraceptive counseling, study staff will record the uptake of contraceptive medication and clinic referral at the time of enrollment and conduct follow-up surveys at 2-weeks, 1-month, and 3-months post-enrollment. If the participant refuses contraceptive counseling on MMU, a referral will be given.
32938558|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
32938559|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
33084763|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
32781238|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
32781239|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
32781240|NCT04883229|Experimental|tDCS +speech therapy followed by sham tDCS + speech therapy|
32781241|NCT04883229|Active Comparator|sham tDCS +speech therapy followed by tDCS + speech therapy|
32781242|NCT04882839|Experimental|Active participants|Participants undertaking to full therapeutic protocol including psychotherapy sessions and Psilocybin sessions
32781243|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
32781244|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
32781245|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
32781246|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
32781247|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
32781248|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
32781249|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
32781250|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
32781251|NCT04895085|Experimental|Caregiver of Children with medical complexity (CMC)|
32781252|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
32781253|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
33084764|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
33084765|NCT04672759||Cohort 1|Cohort 1 will include patients with unresectable stage III non-small cell lung cancer. Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
32781254|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
32781255|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
32781256|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
32781257|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
32781258|NCT02366637|Experimental|PF-03715455|
32781259|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
32781260|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
33084766|NCT04672759||Cohort 2|Cohort 2 will enroll patients with histologically or cytologically confirmed NSCLC or SCLC who will or have received chemotherapy/radiotherapy at the physician's discretion.
33084767|NCT04672408|Active Comparator|His bundle pacing|Pacing programmed from the His bundle lead
32781261|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
32781262|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
32781263|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
32781264|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
32781265|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
32781266|NCT05444517|Active Comparator|Interscalene Block|Patients randomized to receive an interscalene block.
32781267|NCT05444517|Experimental|Infraclavicular-Anterior Supraescapular Nerve Blocks|Patients randomized to receive a combined infraclavicular plus anterior suprascapular nerve blocks.
32781268|NCT02326155||Remsima™|Patients were not treated with infliximab before enrollment. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
33084768|NCT04672408|Placebo Comparator|Right ventricular pacing|Pacing programmed from the right ventricular lead
33084769|NCT04672096|Experimental|Neuronoff BASMATI Injectrode|Subjects will be provided with the placement of an Injectrode insert. The maximal placement duration will be 28 days.
33084770|NCT00260169|Experimental|1|Participants will receive collaborative care
33084771|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
33084772|NCT04672330|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 1 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
33084773|NCT04672018|Experimental|Treatment group|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
33286374|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
33286375|NCT00457626|Experimental|Valsartan Open Label|Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
32938560|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
33286376|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
33286377|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
33286378|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
33286379|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
33286380|NCT05177861|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
33286381|NCT05175209|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
33286382|NCT05131061||unilateral primary aldosteronism(UPA)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI ≥ 4; If LI between 2 and 4, should be combined with contralateral inhibition index < 1 or CT indicate typical adenomas on the dominant side.
33286383|NCT05131061||bilateral adrenal hyperplasia(BAH)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI < 2; or LI between 2 and 4 but does not meet the UPA conditions
33286384|NCT04010279|Active Comparator|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
33286385|NCT04010279|Active Comparator|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
33286386|NCT04010279|Active Comparator|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
33286387|NCT05105867|Experimental|anti-CD19 UCAR-T treatment|Anti-CD19 UCAR-T is an allogeneic CAR-T. A single infusion.
33286388|NCT05050487|Experimental|treatment|patient will recieve pericapsular nerve group block
33286389|NCT05050487|Experimental|treatement|patient will receive lumbar erector spinae plane block
33286390|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
33286391|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
33286392|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
33286393|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
33286394|NCT05014061|Experimental|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
33286395|NCT05014061|No Intervention|Controll|Standard of care
33286396|NCT05001503|Experimental|Intervention Group|The clinical team has access to the Stability UO software. All other care is given as standard.
33286397|NCT05001503|No Intervention|Control Group|Standard care given.
33402205|NCT03307837|Active Comparator|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
33402206|NCT03307837|Placebo Comparator|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
32938561|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
32938562|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
32938563|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
32938564|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
32938565|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
32938566|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
32956060|NCT05764798|Placebo Comparator|Control group: Placebo combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Placebo was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
32956061|NCT05764785|Experimental|MentorHub|Participants assigned to use MentorHub
32781269|NCT02326155||Switched to Remsima|Patients were treated with infliximab prior to enrollment of the study. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
33084774|NCT04672018|Active Comparator|Control group|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
33402207|NCT05065255||Patients|Adult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
33402208|NCT04296799|Experimental|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
32781270|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
32781271|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
32781272|NCT02540993|Experimental|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
32781273|NCT02540993|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
32781274|NCT03171545|Experimental|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
32781275|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
32781276|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
32781277|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
32781278|NCT05476757|Experimental|Flavivirus naïve|
32781279|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
32781280|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
32781281|NCT03138863|Experimental|FETO Group|Participants undergoing fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
32781282|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
32781283|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
32781284|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
32781285|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
32781286|NCT05476523||Healthy Data Collection|As a part of the study, a group of up to 2000 healthy subjects will undergo a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (approx. 15 minutes). The oculometric evaluation will occur for every patient 1 time, and all subjects will be recruited over a period of 36 months. All assessments will be performed during a clinic visit unless authorized to be conducted remotely
32781287|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
32781288|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
32781289|NCT03555851||Recipient|Cyclophosphamide
32781290|NCT03555851||Donor|Specimen collection
32781291|NCT05453981|Experimental|TranS-C group|The TranS-C group will receive weekly 2 hour TranS-C group intervention delivered by 2 clinical psychology trainees for 6 weeks, contents being core modules from Harvey et al. (2016)'s protocol.
32781292|NCT05453981|No Intervention|CAU group|The CAU group will receive care as usual.
32781293|NCT05453513|Other|PLWH|All participants will undergo neuroimaging and behavioral tests.
32781294|NCT03073031|Active Comparator|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
32781295|NCT03073031|No Intervention|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
32781296|NCT05467085|Experimental|LIFU in OCD group|"Each subject will receive 3 LIFU sessions epr week for two weeks (6 total image-guided treatments).~A total of 20 sonications will be administered to one side of the head, with a derated (based on FDA standard of 0.3 dB/cm-MHz) spatial-peak temporal-average intensity (i.e., Ispta) of approximately 720mW/cm2, each lasting 30 s, separated by 30 s pause intervals. Thus, total duration of sonication will be 10 minutes, the same as used in our study of VS LIFU in healthy subjects. Sonication will be administered within a 3T Siemens Prisma scanner. During sonication, we will use the 20-channel head coil as the 32-or 64-channel coil does not allow enough space to fit the transducer.~In summary, the entire sequence of 20 sonications, each lasting 30s, separated by 30s pause intervals, will be administered over 20 minutes for a total duration of sonication equal to 10 minutes."
32900419|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
33286398|NCT04977245|Experimental|MBSR Intervention|The intervention group will take part in a group-based mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. This MBSR program will have a shortened session length of 1.5 hours compared to the traditional 2 hours, to reduce caregiver burden. Caregivers will be trained in meditation practices, like awareness of one's breath, body scan, and loving kindness meditation. Participants will also learn about mindfulness and stress theory, and have group discussions covering topics such as self-compassion.
32781297|NCT05476445|Active Comparator|Control|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer.
33286399|NCT04977245|Active Comparator|Self-Guided Meditation eCourse|Participants in the active control group will participate in a self-guided, online program named GARDEN. The self guided material teaches skills about increasing the daily experience of positive emotion as a mechanism to assist with stress coping. The program consists of eight skills introduced and discussed over an eight week period.
33286400|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
33286401|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
33286402|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
33286403|NCT00407511|Experimental|Pregabalin|
32900420|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
33286404|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
32900421|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
32900422|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
33286405|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
33286406|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
32956062|NCT05764785|No Intervention|Control|Participants in mentoring program as usual
33286407|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
33286408|NCT00326716|Experimental|Treatment|
33286409|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
33286410|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
33286411|NCT03983356|Experimental|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
33286412|NCT03983356|No Intervention|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
33286413|NCT03978910|Experimental|Weigthlessness|during a flight
33286414|NCT03978988|Experimental|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
33286415|NCT03978988|No Intervention|Thrombectomy alone|"Endovascular procedure:~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
33286416|NCT01066078||CRT recipients|
33286417|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
33286418|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
33286419|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
33286420|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
33286421|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
33286422|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
32781298|NCT05476445|Experimental|Low level laser therapy|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer. Following the restoration in the LLLT group, the diode laser was activated in biostimulation mode for a total of 1 minute, 30 seconds in the buccal and lingual/palatal regions at the root apex.
32781299|NCT05476445|Experimental|Cryotherapy|"After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.~After the last wash, in the cryotherapy group, unlike the first two groups, each canal was washed with 5 ml of 2°C cold physiological saline for 5 minutes. After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer."
32781300|NCT05476367||patients with normal uric acid level|The uric acid level is below 420 μmol/L in men and 360 μmol/L in women
32781301|NCT05476367||patients with high uric acid level|The uric acid level is higher than 420 μmol/L in men and 360 μmol/L in women.
32781302|NCT05466461|Experimental|Beautifil Flow Plus X.|Giomers is a hybrid material category which contains Surface Pre-Reacted Glass-ionomer filler or S-PRG filler is produced from fluoroboro-alumino-silicate glass and polyacrylic acid through an acid-base reaction to form a stable glass ionomer phase on glass filler particle surfaces. S-PRG fillers can release and recharge fluoride. Also, the S-PRG filler-containing resinous materials are able to release various ions, such as aluminum (Al3+), boron (BO3 3-), fluoride (F- ), sodium (Na+), silicon (SiO3 2-), and strontium (Sr2+), in neutral and acidic conditions.
32781303|NCT05466461|Active Comparator|Activa bioactive restorative|Activa BioACTIVE Restorative (Activa), developed by Pulpdent (Watertown, MA, USA), is a new bioactive restorative material that combines the advantages of an RMGIC (resin modified glass ionomer cement) and RBC (resin based composite), representing a new category of restorative materials that are ion releasing. It contains methacrylate- based monomers, a modified polyacrylic acid, modified Diurethane Dimethacrylate (rubberized resin), and fillers
32781304|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
32781305|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
32781306|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
32781307|NCT02534909|Experimental|LFG316 then LNP023|LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4
32781308|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
32781309|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
32781310|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
32781311|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
33286423|NCT04919369|Experimental|Treatment (tretinoin, atezolizumab)|Patients receive tretinoin PO on days 1-3 of cycles 1-3. Patients also receive atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33286424|NCT00958607|Active Comparator|Self-Directed Program|
32781314|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
32781315|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
33084775|NCT04672057|Active Comparator|Right hemiparetics|right-sided affected hemiparetic individuals
33286425|NCT00958607|Active Comparator|Stroke Support Person|
33286426|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
33286427|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
33286428|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
33286429|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
33286430|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
33286431|NCT00958763|Other|Usual Care Group - UCG|
32781316|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
32781317|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
32781318|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
32781319|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
32781320|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
32781321|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
32781322|NCT02365467|Experimental|Treatment with Valiant Mona LSA device|
32781323|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
32781324|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
32781325|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
32781326|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
32781327|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
32781328|NCT05369871|Experimental|Closed-loop system followed by open-loop system|"An interventional cross-over study:~six weeks in closed-loop system with Accu-Chek Insight pump and continuous glucose monitoring (CGM) :consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~followed by six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks ,~Followed by an optional additional study: 4 weeks in closed-loop system."
32781329|NCT05369871|Experimental|Open-loop system followed by closed-loop system|"An interventional cross-over study:~six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~followed by six weeks in closed-loop system with Accu-Chek Insight pump and CGM (including two weeks of adaptation) : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~Followed by an optional additional study: 4 weeks in closed-loop system."
32781330|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
32900423|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
33084776|NCT04672057|Active Comparator|Left hemiparetics|left-sided affected hemiparetic individuals
33084777|NCT04672057|Active Comparator|Control|healthy individuals
33084778|NCT04671745||Expérimental|patient receiving care with interactive music
33084779|NCT04671745||Control|patient receiving care without interactive music
33286432|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
33286433|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
33286434|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
33286435|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
32781331|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
32781332|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
33286436|NCT05299775||HIV infected time|Group are divided by Infected time: 0-2W, 2W-12M, >1Y
32781333|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
32781334|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
32781335|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
33286437|NCT05299775||different constitutions|Group are divided by different constitutions:It includes 9 basic types of constitution, yang deficiency , yin deficiency , qi deficiency , phlegm dampness , damp-heat, blood stasis, special diathesis , qi depression , gentleness constitution .
33286438|NCT00295750|Experimental|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
33286439|NCT00295750|Experimental|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
33286440|NCT00295750|Active Comparator|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
33286441|NCT04850963|Active Comparator|Group 1 - anodal tDCS|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 1 (anodic tDCS) the anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
33286442|NCT04850963|Active Comparator|Group 2 - tDCS dualsite|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. In group 2 (dualsite tDCS) two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
33286443|NCT04850963|Placebo Comparator|Group 3 - tDCS sham|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 3 (simulated tDCS) the positioning of the electrodes will be the same as for group 1, however the device will be configured in sham mode in which the current will cease 30 seconds after the start of stimulation.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
33286444|NCT00959153|Experimental|Kidney stones|Kidney stones
33286445|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
33286446|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
33286447|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
33286448|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
33286449|NCT00959309|Experimental|Intervention|
33286450|NCT00959309|Active Comparator|Control|
33286451|NCT04720547|Experimental|Zolpidem, then No Treatment|Participants will be administered zolpidem for the first night study, and No Treatment during the second night study.
33286452|NCT04720547|Experimental|No Treatment, then Zolpidem|Participants will be administered zolpidem for the second night study, and No Treatment during the first night study.
33402209|NCT04296799|Experimental|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
32781336|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
32781337|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
32781338|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
32781339|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
32781340|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
32781341|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|
32781342|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
33084780|NCT04671940||Retrospective Cohort|"Patients who have previously had radiotherapy and then have had their local residual/recurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H&N cancer.~Potential participants will be asked to consent to provide blood/saliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood/saliva samples."
33286453|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
33286454|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
33286455|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
33286456|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
32781343|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
32781344|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|
32781345|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
32781346|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
32781347|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
32781348|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
32781349|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
32781350|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
32781351|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
32781352|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
32781353|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
32781354|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
32781355|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
32781356|NCT02294019|Experimental|Ibuprofen caplet arm|
32781357|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
33286457|NCT04718285|Experimental|Montelukast|3x10 mg oral montelukast first day (morning, noon time and evening) and rest of the 13 days 1 x 10 mg montelukast.
33286458|NCT04718285|Experimental|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast at the first day and rest of the 13 days1 x 10 mg, concurrently.
33286459|NCT04718285|Active Comparator|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
33286460|NCT05299619|Experimental|Tixel Group|Tixel treatments in Dry Eye Patients
33286461|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
33286462|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
33286463|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
33286464|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
33286465|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
33286466|NCT04585919|Experimental|Paired Screening Intervention|
33286467|NCT04585919|No Intervention|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
33286468|NCT05299541|Active Comparator|Control|Measurements and questioners
32781358|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
32781359|NCT05407909|Experimental|SYHX2001|SYHX2001 will be administered orally.
33286469|NCT05299541|Active Comparator|Group A|Receiving Food dish every night for 6 months Measurements and questioners
32781360|NCT05407363|Experimental|ABB and ATG with simultaneous implant placement|Using ABB with ATG to fill the gap around simultaneously placed dental implants
33286470|NCT05299541|Active Comparator|Group B|Receiving Food dish every night for 6 months, at this group extra attention have given to the dish plating and appearance by professional (BOCUSE), Measurements and questioners
33286471|NCT04557995|Experimental|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
33286472|NCT04557995|No Intervention|Routine treatment|Oxygen delivery and basic care
32781361|NCT05407363|Experimental|XBB and ATG with simultaneous implant placement|Using XBB with ATG to fill the gap around simultaneously placed dental implants
32781362|NCT05407363|Active Comparator|ABB and ABG with immediate implant|Using ABB with ABG to fill the gap around immediately placed dental implants
32781363|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
32781364|NCT05423509|Other|Standard treatment for AIS|These are the participants with AIS that recieved the standard treatment with observation or bracing depending on the size of their curve.
32781365|NCT05423509|Experimental|Treatment with Dynamic Myofascial Manipulation|These are the participants that still received the standard treatment with observation or bracing depending on the size of their curve, but also had weekly treatment with a chiropractor for 6 months for dynamic myofascial manipulation
32781366|NCT05450965|Experimental|Single Treatment Arm|Onvansertib
33286473|NCT00959777|Experimental|DA-3031|
33286474|NCT00959777|Active Comparator|filgrastim|
33286475|NCT04450745|Experimental|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
33286476|NCT04450745|Experimental|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
33286477|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
33286478|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
33286479|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
33286480|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
33286481|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
33286482|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
33286483|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
33286484|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
33286485|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
33286486|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
33286487|NCT00962117||Obese/Non-obese|
33286488|NCT00960089|Experimental|LIQUICURE|Medical Device
33286489|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
33286490|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
33286491|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
33286492|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
33286493|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
33286494|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
33286495|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
33286496|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
32781367|NCT05422417|Experimental|Prolonged intermittent theta-burst(iTBS)-DMPFC|This active group will receive prolonged intermittent theta-burst(iTBS) on the dorsomedial prefrontal cortex(DMPFC)
33286497|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
33286498|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
33286499|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
33286500|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
33286501|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
33286502|NCT00406653|Experimental|1|"4 arms for induction period~2 arms for maintenance period"
33286503|NCT00406653|Placebo Comparator|2|"4 arms for induction period~2 arms for maintenance period"
33286504|NCT00406653|Other|abatacept|1 arm for open-label extension phase
33286505|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
33286506|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
33286507|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
33286508|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
33286509|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
33286510|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
33286511|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
33286512|NCT00960635|Active Comparator|calcitriol|
33286513|NCT00960635|Placebo Comparator|pill without agent|
33286514|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
33286515|NCT04009889|Active Comparator|verum|probiotic bland with 5 different lactobacilli
33286516|NCT04009889|Placebo Comparator|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
33286517|NCT00962351|Other|Metal-on-Polyethylene|
32781368|NCT05422417|Experimental|20Hz rTMS-DMPFC|This active group will receive 20Hz rTMS on the DMPFC
33286518|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
33286519|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
33286520|NCT00960791|Experimental|1|14C-labelled AZD1656
33286521|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
33286522|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
33286523|NCT00384033|Placebo Comparator|Placebo|
33286524|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
33286525|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
33286526|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
33286527|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
33286528|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
33286529|NCT00961025|Placebo Comparator|Placebo|
33286530|NCT00961025|Experimental|DA-1229|DA-1229
33286531|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
33286532|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
33286533|NCT00962975|Experimental|Single Arm|
33286534|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
33286535|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
33286536|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
33286537|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
33286538|NCT04009655|Experimental|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
33286539|NCT04009655|No Intervention|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
33286540|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
33286541|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
33286542|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
32781369|NCT05422417|Sham Comparator|Sham prolonged iTBS-DMPFC or 20Hz rTMS-DMPFC|Patients in the sham group will receive the same prolonged iTBS or 20Hz rTMS performed by a sham coil.
32781370|NCT05450653|Experimental|FETO with GOLDBAL2|A detachable balloon will be inserted in the fetal airway during the FETO procedure.
33286543|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
33286544|NCT00963209|Experimental|Tamoxifen|
33286545|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
33286546|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
33286547|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
32781371|NCT05422105||Suspected Prostate Cancer|
33286548|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
33286549|NCT00963365|Experimental|AZD6765 oral solution|Active
33286550|NCT00963365|Experimental|AZD6765 IV infusion|Active
33286551|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
33286552|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
33286553|NCT00963443|Experimental|Arm 1|
33286554|NCT00963443|Active Comparator|Arm 2|
33286555|NCT00963443|Active Comparator|Arm 3|
33286556|NCT00963443|Placebo Comparator|Arm 4|
32781372|NCT05405725|Experimental|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
32781373|NCT05405725|Active Comparator|Prolia|Prolia Injection:- 60 mg Denosumab (Prolia) will be administered subcutaneously on day 1.
32781374|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
33286557|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
33286558|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
33286559|NCT00961493|Experimental|1|
32781375|NCT05404945|Experimental|Fit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab + intravenous AVD (q 2 weeks).
32781376|NCT05404945|Active Comparator|Non-Fit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab and concurrent (q 3 week) intravenous brentuximab vedotin (BV).
33286560|NCT00961493|Active Comparator|2|
33286561|NCT00961727||PEWS System of Care|
33286562|NCT00963833||Group 1|
33286563|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
33286564|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
33286565|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
33286566|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
33286567|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
33286568|NCT00967733|Active Comparator|High ALA-Low Linoleic|
33286569|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
33286570|NCT00967733|Active Comparator|High ALA-High Linoleic|
33286571|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
33286572|NCT00546377|Experimental|Mitoxantrone|
33286573|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
33286574|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
33286575|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
33286576|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
33286577|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
33286578|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
33286579|NCT00964379|Active Comparator|intraperitoneal colostomy|
33286580|NCT00964379|Active Comparator|extraperitoneal colostomy|
33286581|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
33286582|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
33286583|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
33286584|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
33286585|NCT00964535|Active Comparator|Symbicort Turbohaler|
33286586|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
33286587|NCT00968279||Atrial Fibrillation|
33286588|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
33402210|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
33286589|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
33286590|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
33286591|NCT00964847|Active Comparator|Blood pressure education/walking program|
33286592|NCT00964847|Active Comparator|Combined intervention|
33286593|NCT00964847|Experimental|Yoga Exercise Program|
33286594|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
33286595|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
33286596|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
33286597|NCT05253287|No Intervention|Standard Medical treatment|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
33286598|NCT05253287|Experimental|Growth hormone + Standard medical therapy|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
33286599|NCT03941483|Experimental|ASP1128|Participants received ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
33286600|NCT03941483|Placebo Comparator|Matching placebo|Participants received placebo matched to ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
33402211|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
32781377|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
32781378|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
32781379|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
32781380|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
32781381|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
32900424|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
32900425|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
32900426|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
32900427|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
32900428|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
32900429|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
32900430|NCT04462562|Experimental|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters~tissue attenuation imaging (TAI) parameter~tissue scatter-distribution imaging (TSI) parameter~Hepatorenal index (semi-auto, EzHRI)"
32900431|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
32900432|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
32900433|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
32900434|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
32900435|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
32900436|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
32900437|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
32900438|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
32900439|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
32900440|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
32900441|NCT04389242|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
32938567|NCT03822949|Placebo Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
33286601|NCT03941483|No Intervention|Observational cohort|Participant with postoperative negative NephroCheck® (NC) (AKIRisk score was ≤ 0.3 nanogram per milliliter (ng/mL)^2/1000 at all assessments between 2 to 22 hours after time point 0 (T0) were followed up for 90 days in observational cohort. Participants did not receive any intervention.
33286602|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
33286603|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
33286604|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
33286605|NCT00968591|Experimental|RAD001|
33286606|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
33286607|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
33286608|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
33286609|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
33286610|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
33286611|NCT00969137|Placebo Comparator|Saline|Saline infusion
33286612|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
32938568|NCT03822949|Experimental|Experimental: ICU Exposed to Day light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes intense light each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device. The patient will need to keep the box as close as possible to their eyes and not walk away during the treatment period. This will be facilities by a study nurse.
32956063|NCT05764759|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
33286613|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
33286614|NCT00969371|Experimental|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
33286615|NCT00969371|Active Comparator|Control IOL|commercially approved PCIOL implanted
33286616|NCT00969449|Experimental|Arm 1|
33286617|NCT00969449|Active Comparator|Arm 2|
33286618|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
33286619|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
33286620|NCT00965471|Experimental|managed group|
33286621|NCT00965471|Placebo Comparator|control group|
33286622|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
33286623|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
33286624|NCT00969527|Experimental|A|Oncoxin + Viusid
33286625|NCT00969527|Placebo Comparator|B|
33286626|NCT00969605|Active Comparator|Pressure support ventilation|
33286627|NCT00969605|Active Comparator|Adaptive support ventilation|
33286628|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
33286629|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
33286630|NCT00965705|Active Comparator|Guided Self Help|
33286631|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
33286632|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
33286633|NCT00965783|Experimental|1|Sleep time restriction
33286634|NCT00965783|Experimental|2|Sleep time extension
33286635|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
33286636|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
33286637|NCT04009187|Active Comparator|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
33286638|NCT04009187|Active Comparator|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
33286639|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
32781382|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
32781383|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
32781384|NCT02025985|Experimental|Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
32781385|NCT02025985|Experimental|Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
32781386|NCT02025985|Experimental|Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
32781387|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
32938569|NCT03822949|Placebo Comparator|Sham Comparator: ICU Exposed to Room light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes using a placebo/control device (dim/night light box) each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device.
32938570|NCT04068493|Experimental|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
33286640|NCT05194163|Experimental|10mg MW150 daily|10 mg MW150 daily (1 capsule of 10 mg daily)
33286641|NCT05194163|Placebo Comparator|placebo daily|placebo daily (1 capsule of matched placebo daily)
33286642|NCT00966017||DS|Those with Down syndrome
33286643|NCT00966017||Non-DS|Healthy controls
33286644|NCT00969995||migraine1|50 subjects with migraine without aura
33286645|NCT00969995||migraine 2|50 subjects with migraine with aura
33286646|NCT00969995||tension|50 subjects with tension headache
33286647|NCT00969995||cluster|50 subjects with cluster headache
33286648|NCT00969995||Healthy|50 healthy subjects
33286649|NCT00966095||men scheduled for prostate biopsy|
33286650|NCT00966251|Experimental|CT-011|
33286651|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
33286652|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
33286653|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
33402212|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
33286654|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
33286655|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
33286656|NCT00970463||GH|Patients with GHD
33286657|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
33286658|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
33286659|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
33286660|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
33286661|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
33286662|NCT00966563|Placebo Comparator|NaCl 0.9%|
33286663|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
33286664|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
33286665|NCT04009031|Experimental|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
33286666|NCT04083287|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
33286667|NCT04083287|Active Comparator|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
33286668|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
33286669|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
33286670|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
33286671|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
33286672|NCT00970775|Experimental|1. AZD2423|
33286673|NCT00970775|Placebo Comparator|2. Placebo|
33286674|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
33286675|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
33286676|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
33286677|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
33286678|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
33286679|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
33286680|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
33286681|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
33286682|NCT00970931|Placebo Comparator|placebo|
33286683|NCT00970931|Experimental|chlortalidone-amiloride|
33084781|NCT04671940||Prospective Cohort|Patients who have previously had radiotherapy and then are due to have their local residual/recurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood/saliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis
32781388|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
33084782|NCT04671589|Experimental|Meropenem|Meropenem 1 gram intravenous every 8 hours
33084783|NCT04671589|Placebo Comparator|Placebo|Placebo intravenous every 8 hours
33084784|NCT04671277|Experimental|Chewing of breads|"6 samples (2x3 full factorial design with 2 white sandwich bread types (a regular gluten-containing (GC) and a gluten-free version (GF)) and 3 spread conditions (no spread, butter and mayonnaise)) were evaluated in two sessions of 30 min each. The first session was designed for video recording and the second session for the evaluation of texture attributes and collection of food bolus.~Bread samples were served as two stacked cylinders resembling the consumption of a sandwich (diameter: 3.5 cm, approximate total height: 2.4 cm) (Figure 1). Due to differences in bread density, the average weight of two stacked cylinders was 5.1 ± 0.2 and 5.7 ± 0.4 for GC and GF breads, respectively. Butter and mayonnaise were added to breads at approximately 12% w/w."
33084785|NCT04671160||1|Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
33402213|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
33402214|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
32781389|NCT05450341|Experimental|Right frontal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right inferior frontal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right IFG (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
32781390|NCT05450341|Active Comparator|Right temporal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right posterior superior temporal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right posterior superior temporal gyrus (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
32781391|NCT04263181||Cohort 0|"-A technical run-in of 5 patients with any of the following:~Standard cytarabine/idarubicin induction, includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) & idarubicin 12 mg/m2 per day for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle.~Azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter.~Azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
32781392|NCT04263181||Cohort 1|"Patients treated with cytarabine/idarubicin induction therapy~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed (e.g. cytarabine/daunorubicin or Vyxeos)."
32781393|NCT04263181||Cohort 2|"Patients treated with decitabine~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle."
32781394|NCT04263181||Cohort 3|"Patients treated with azacitidine~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle"
32781395|NCT04263181||Cohort 4|"Patients treated with decitabine + venetoclax~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
32781396|NCT04263181||Cohort 5|"Patients treated with azacitidine + venetoclax~Patients will receive azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
32781397|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
32781398|NCT05450263|Active Comparator|Sub-acute low back pain active intervention|To assess the efficacy of IET on the chronification of LBP, participants who are found to have a higher risk of pain chronification due to the presence of a biomarker (positive mPFC-Nac connectivity) will be randomized to the intervention group (IET)
32781399|NCT05450263|Sham Comparator|Sub-acute low back pain passive intervention|Control group, treatment as usual.
32781400|NCT05450263|No Intervention|No intervention|
32781401|NCT05403775|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF.
32781402|NCT05403775|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
32781403|NCT05420701|No Intervention|Left Atrial Appendage Occlusion|
32781404|NCT05420701|Active Comparator|Left Atrial Appendage Closure,|
33286684|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
33286685|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
33286686|NCT00971009|No Intervention|Control group|The control group receives usual care
33286687|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
33286688|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
33286689|NCT00406419|Placebo Comparator|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
33286690|NCT00406419|Experimental|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
33286691|NCT00406419|Placebo Comparator|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
33286692|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
33286693|NCT00967265|Active Comparator|Usual care|Usual care
33286694|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
33286695|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
32900442|NCT04389242|Experimental|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
33286696|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
33286697|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
33286698|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
33286699|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
33286700|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
33286701|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
33286702|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
33286703|NCT00973505||CYP19|CYP19 genetic polymorphism
33286704|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
33286705|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
33286706|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
33286707|NCT00973583|Active Comparator|vitamin D|
33286708|NCT00973583|Placebo Comparator|placebo|
33286709|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
33286710|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
33286711|NCT00973661|Experimental|Electronic tools|
33286712|NCT00973661|No Intervention|Usual care|
33286713|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
33286714|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
33286715|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
33286716|NCT00974129||Patients with Infantile Hemangiomas|
33286717|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
33286718|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
33286719|NCT03833661|Experimental|M7824|
33286720|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33286721|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33286722|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
33286723|NCT03992859|Experimental|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
33286724|NCT03992859|No Intervention|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
33286725|NCT00383331|Experimental|A|
33286726|NCT00383331|Experimental|B|
33084786|NCT04671160||2|Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
32781405|NCT05420311|Experimental|A balanced hypocaloric diet in macronutrients (MedDiet).|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits (3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
33084787|NCT04671160||3|Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
32781406|NCT05420311|Experimental|A very low carbohydrate diet (KetoDiet).|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein
33286727|NCT03934541|Experimental|Group 1 (Treatment 1): MPER-656 Liposome Vaccine|Participants will receive 500 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
33286728|NCT03934541|Placebo Comparator|Group 1 (Control 1): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
33286729|NCT03934541|Experimental|Group 2 (Treatment 2): MPER-656 Liposome Vaccine|Participants will receive 2000 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
33286730|NCT03934541|Placebo Comparator|Group 2 (Control 2): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
33286731|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
33286732|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
33286733|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
33286734|NCT01063504|Placebo Comparator|Placebo|
33286735|NCT00366249|Active Comparator|A|
33286736|NCT00366249|Active Comparator|B|
33286737|NCT00325156|Experimental|Group A|
33286738|NCT01066234|Experimental|concurrent chemoradiotherapy|
33286739|NCT01066234|Active Comparator|chemotherapy only|
33286740|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
33286741|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
33286742|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
33286743|NCT00383019|Experimental|Xalatan|
33286744|NCT00383019|Experimental|Xalacom|
33286745|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
33286746|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
32781407|NCT05420311|Experimental|An intermittent fasting (IF) approach.|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
32781408|NCT05402761|Experimental|Nurse-guided BBTi group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
32781409|NCT05402761|Experimental|Mobile-delivered BBTi group|Participants will be shown how to download and use the app in their own mobile device after the baseline assessment.
32781410|NCT05402761|No Intervention|Sleep hygiene control group|Participants will receive sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
32781411|NCT05447065|Experimental|Participants using vitamin D supplements|Participants in the experimental group were given 150,000 IU (10 ml) of vitamin D3 supplementation, and it was used regularly for 2 months. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
32781412|NCT05447065|No Intervention|Participants not using vitamin D supplements|No supplement was given to the control group. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
32938571|NCT04068493|No Intervention|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
32938572|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
32938573|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
32938574|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
32938575|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
33286747|NCT00310804|Experimental|cTIV_lot 1|
33286748|NCT00310804|Experimental|cTIV_lot 2|
33286749|NCT00310804|Experimental|cTIV_lot 3|
33286750|NCT00310804|Active Comparator|TIV group|
33286751|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
33286752|NCT01066312||Testees|Healthy adults with no experience with MMT
32938576|NCT04058587|Experimental|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
33286753|NCT01046409||Main vessel, side branch vessel|
33286754|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
33286755|NCT00590187|Experimental|A sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
32938577|NCT03869437|Experimental|Cefiderocol|Participants will receive Cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for up to 14 days
33286756|NCT00590187|Experimental|B sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
33286757|NCT00590187|Experimental|C sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
33286758|NCT00590187|Experimental|D sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
33286759|NCT00590187|Experimental|E sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
33286760|NCT00590187|Experimental|F sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
33286761|NCT00590187|Experimental|G sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
33286762|NCT00590187|Experimental|H sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
33286763|NCT00590187|Experimental|I sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
33286764|NCT03978364|Experimental|azacitidine|"azacitidine~azacitidine 75mg/m2，iH，qd， d1-7"
32938578|NCT03869437|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines
33286765|NCT03978364|Active Comparator|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
33286766|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
33286767|NCT03978286|Experimental|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
33286768|NCT03978286|Experimental|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
32938579|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
33286769|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
32938580|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
32938581|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
32938582|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
32938583|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
33286770|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
33286771|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
32938584|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
32938585|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
33084788|NCT04671160||4|Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
33286772|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
33286773|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
33286774|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
33286775|NCT03933449|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to ~2 years). Participants who complete the first course of up to 35 administrations of pembrolizumab (~2 years) but progress after discontinuation, may be eligible for a second course of pembrolizumab at the investigator's discretion, at the same dose and schedule at 200 mg IV on Day 1 of each 3-week cycle for up to 17 cycles (up to ~1 year).
33286776|NCT03933449|Active Comparator|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to ~2 years).
32781413|NCT05402605|Active Comparator|ICSI with AOA|"The oocytes were transferred into the calcium ionophore activation solution for two times of post-ICSI AOA (Ionomycin concentration of 10 µM).~Then the oocytes will be washed several times using the medium drops in dish AOA and dish ICSI, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2."
32781414|NCT05402605|Active Comparator|ICSI without AOA|Post-ICSI oocytes will be cultured in drops containing the Sage - 1 - StepSM medium (maximum 3 oocytes per drop) at 37oC, 6% CO2 and 5% O2 in K-system G185 incubator.
32781415|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32781416|NCT05401903|Experimental|Chiropractic Maintenance Care|The intervention group will receive weekly chiropractic care, in the form of high-velocity, low amplitude (HVLA) chiropractic adjustments delivered to restricted vertebrae of the cervical, thoracic and lumbar spinal segments. The intervention duration is 8 weeks. Subjects in the intervention group who do not attend at least four (4) scheduled chiropractic visits will be withdrawn from the study.
32781417|NCT05401903|No Intervention|Control|The control group will not receive any chiropractic care during study protocol.
32781418|NCT05401357|Experimental|Bimatoprost 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
32781419|NCT05401357|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
32781420|NCT05401279|Experimental|Gemcitabine, Cisplatin and Tislelizumab|Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. 2-4 weeks after the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
32781421|NCT05400655|Experimental|Part 1: Children age 5-10: 5 mg/kg of L9LS|Enrolled individuals will receive 5 mg/kg of L9LS via SC injection.
32781422|NCT05400655|Placebo Comparator|Part 1: Children age 5-10: Placebo|1/4 of children age 5-10 will receive placebo of Normal Saline for comparison.
32781423|NCT05400655|Experimental|Part 1: Children age 5-59 months: 5 mg/kg of L9LS|
32781424|NCT05400655|Experimental|Part 1: Children age 5-10 years: 10 mg/kg of L9LS|
32781425|NCT05400655|Experimental|Part 1: Children age 5-10 years: 20 mg/kg of L9LS|
32781426|NCT05400655|Experimental|Part 1: Children age 5-59 months: 10 mg/kg of L9LS|
32781427|NCT05400655|Experimental|Part 1: Children age 5-59 months: 20 mg/kg of L9LS|
32781428|NCT05400655|Placebo Comparator|Part 1: Children age 5-59 months: Placebo|1/4 of subjects age 5-59 months will receive placebo of Normal Saline for comparison.
32781429|NCT05400655|Experimental|Part 2: Children age 5-17 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS via SC injection.
32781430|NCT05400655|Experimental|Part 2: Children age 5-17 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS and a second dose at 6 months via SC injection.
32781431|NCT05400655|Placebo Comparator|Part 2: Children age 5-17 months: Placebo|1/3 of subjects age 5-17 months will receive placebo of normal saline for comparison.
32781432|NCT05400655|Experimental|Part 2: Children age 18-59 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS via SC injection.
32781433|NCT05400655|Experimental|Part 2: Children age 18-59 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS, followed by a second dose at 6 months via SC injection.
32781434|NCT05400655|Placebo Comparator|Part 2: Children age 18-59 months: Placebo|1/3 of subjects age 18-59 months will receive placebo of normal saline for comparison.
32781435|NCT05400577|Experimental|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|
32781436|NCT05420077|Experimental|RVM-V001 10 µg|RVM-V001-10 µg administered as a single dose of by intramuscular injection on Day 1
32781437|NCT05420077|Experimental|RVM-V001 30 µg|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1
32781438|NCT05420077|Experimental|RVM-V001 60 µg|RVM-V001-60 µg administered as a single dose of by intramuscular injection on Day 1
32781439|NCT02532517|Experimental|Enterprise|
32781440|NCT05418595||Group-1|PCOS patients intraovarian stromal conventional and SMI doppler findings
32781441|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
32781442|NCT02545049|Placebo Comparator|Placebo|Matching placebo
32781443|NCT05451095|Experimental|Treatment sequence T1-T2-R|T1: Lower dose of BI 474121 and higher dose of placebo followed by intravenous ketamine infusion T2: Higher dose of BI 474121 and lower dose of placebo followed by intravenous ketamine infusion R: Lower dose of placebo and higher dose of placebo followed by intravenous ketamine infusion
32781444|NCT05451095|Experimental|Treatment sequence T2-T1-R|
32781445|NCT05451095|Experimental|Treatment sequence T1-R-T2|
32781446|NCT05451095|Experimental|Treatment sequence T2-R-T1|
32781447|NCT05451095|Experimental|Treatment sequence R-T1-T2|
32781448|NCT05451095|Experimental|Treatment sequence R-T2-T1|
32781449|NCT05476133|Experimental|study group|single group who had intervention and comparison of pre and post intervention assessment
32781450|NCT05476055||conventional NBS+ infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
32781451|NCT05476055||conventional NBS+ infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
32781452|NCT05476055||NICU infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
32781453|NCT05476055||NICU infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
32781454|NCT05476055||Premature infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
32781455|NCT05476055||Premature infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
32781456|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
33084789|NCT04671394|Experimental|Test (FMUD + DLIG)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by irrigation with indocyanine green solution and diode laser irradiation.
32781457|NCT05450705|Experimental|9 to 14 Years Old: Day 1 and Month 6|Chinese females 9 to 14 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 6
32781458|NCT05450705|Experimental|9 to 14 Years Old: Day 1 and Month 12|Chinese females 9 to 14 years old will receive a 0.5 mL iIM injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 12
32781459|NCT05450705|Experimental|20 to 26 Years Old: Day 1, Month 2 and Month 6|Chinese females 20 to 26 years old will receive a 0.5 mL IM injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
32781460|NCT02517125|Experimental|Patients with head and neck cancer|
32781461|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
32781462|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
32781463|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
32781464|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
32781465|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
32781466|NCT05399875|Experimental|Augmented reality virtual ruler|Patient's in this arm will have their physician use an augmented reality virtual ruler to measure catheter length during catheter placement.
32781467|NCT05446831|Experimental|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
32781468|NCT02431351|Experimental|Selinexor|60 mg once weekly
32781469|NCT01349959|Experimental|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
32781470|NCT01349881|Placebo Comparator|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
32781471|NCT01349881|Experimental|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
32781472|NCT01349881|Experimental|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
32781473|NCT01349881|Experimental|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
32781474|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
33084790|NCT04671394|Sham Comparator|Control (FMUD + ST)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by sham therapy.
33084791|NCT04671511|Experimental|Targeted Axillary Dissection|Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery
32781475|NCT05464277|Active Comparator|Intermediate normal oxygen|"For the intermediate normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 95-97% will be recommended in the light of the Improving Oxygen Therapy in Acute-illness (IOTA) meta-analysis. The acceptable lower limit of PaO2 will be set to 80 mmHg according to a recent consensus of experts endorsed by the European Society of Intensive Care Medicine. The lower-limit and higher-limit monitor alarm for SpO2 will be set at 94% and 98%, respectively.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the intermediate normal oxygen group should receive air mix."
32781476|NCT05464277|Active Comparator|High normal oxygen|"For the high normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 99-100% will be recommended. The lower-limit monitor alarm for SpO2 will be set at 98%. No upper alarm limit for SpO2 will be set.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the high normal oxygen group should receive FiO2 of 1.0."
32781477|NCT05418283|Active Comparator|Exercise|12-week aerobic exercise program will be applied (3/week)
32781478|NCT05418283|No Intervention|Control|No intervention will be applied.
32781479|NCT01728259|Experimental|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32781480|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
32781481|NCT05398705|Experimental|Low-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1~5: 20mg, Q8H X 5 days + standardized medical treatment
33084792|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
33084793|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
33084794|NCT04670926|Experimental|TruGraf - Group 1:|Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
33084795|NCT04670926|Active Comparator|CPMC Standard of Care - Group 2:|Patients randomized to Group 2 or CPMC Standard of Care Group patients will have current standard of care laboratory assessments.
33084796|NCT04670887|Active Comparator|Immediate surgery|Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
33286777|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
32781482|NCT05398705|Experimental|High-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1~5: 40mg, Q8H X 5 days + standardized medical treatment
32781483|NCT05398705|Placebo Comparator|placebo+standardized medical treatment|Drug: cepharanthine placebo (tablet) Day 1~5: placebo + standardized medical treatment
32781484|NCT05398627|Experimental|Amygdala Neurofeedback|Participants will undergo real-time fMRI neurofeedback training to increase their amygdala response while recalling positive autobiographical memories. 2 sessions will occur within a one week period.
32781485|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
33084797|NCT04670887|Active Comparator|Active surveillance|Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
33084798|NCT04671121|Active Comparator|Grup LP (n = 31)|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
32781486|NCT05397769|Experimental|Envafolimab group|Envafolimab is a PD-L1 antibody by hypodermic injection. Envafolimab will be administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
32781487|NCT04468061|Experimental|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
32781488|NCT04468061|Experimental|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
32781489|NCT04468061|Experimental|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions.~."
32781490|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
32781491|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
32781492|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
33084799|NCT04671121|Active Comparator|Grup SP (n = 31)|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
33084800|NCT04671316|Experimental|T1T2R|"Period I: T1, DA-5209 60mg without water Period II: T2, DA-5209 60mg with 150mL water Period III: R, Lixiana 60mg with 150mL water"
33084801|NCT04671316|Experimental|T1RT2|"Period I: T1, DA-5209 60mg without water Period II: R, Lixiana 60mg with 150mL water Period III: T2, DA-5209 60mg with 150mL water"
33084802|NCT04671316|Experimental|RT1T2|"Period I: R, Lixiana 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: T2, DA-5209 60mg with 150mL water"
33084803|NCT04671316|Experimental|RT2T1|"Period I: R, Lixiana 60mg with 150mL water Period II: T2, DA-5209 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
33084804|NCT04671316|Experimental|T2RT1|"Period I: T2, DA-5209 60mg with 150mL water Period II: R, Lixiana 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
33084805|NCT04671316|Experimental|T2T1R|"Period I: T2, DA-5209 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: R, Lixiana 60mg with 150mL water"
33084806|NCT04670614|Other|Nerve Block Procedure|Supra-orbital and Infra-orbital peripheral nerve blocks with 0.5% ropivicaine
33084807|NCT04670614|Sham Comparator|Placebo sham control|sham control 0.9% Normal Saline
32781493|NCT05475977||First Group|Thirty patients of COPD smokers patients.
32781494|NCT05475977||Second group|Thirty patients of COPD ex-smokers patients.
32781495|NCT05475977||Third group|Thirty patients of COPD non-smokers patients.
32781496|NCT05445037|Experimental|Continuos Monitoring|Continuos monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
32781497|NCT05445037|Experimental|Standard monitoring|Standard monitoring will be done with non-invasive
32900443|NCT04389242|Other|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
33286778|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33286779|NCT03932045|Experimental|SYB Filler (SF-01)|PCL filler
33286780|NCT03932045|Active Comparator|Ellansé M|PCL filler
33286781|NCT00972413|Experimental|Group I|
33286782|NCT00972413|Experimental|Group II|
33286783|NCT00972413|Experimental|Group III|
33286784|NCT00387075|Experimental|[123I]β-CIT and SPECT imaging|To Assess [123I]β-CIT and SPECT imaging
33286785|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
33286786|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
33286787|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
33286788|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
33286789|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33286790|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33286791|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
33286792|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
33286793|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
33286794|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
33286795|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
33286796|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
33286797|NCT01045395|Experimental|Golden brown algae, 90mg/d|
33286798|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
33286799|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
33286800|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
33286801|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
33286802|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
33286803|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
33286804|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
33286805|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
33286806|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
33286807|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
33286808|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
33286809|NCT04008719|Other|Patients|Assessments are made by a psychiatrist
33286810|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
33286811|NCT00974831|Placebo Comparator|Glucose drink|
33286812|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
33286813|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
33286814|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
33286815|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
33286816|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
33286817|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
33286818|NCT00974909|Active Comparator|Treatment group|Treatment group
33286819|NCT00974909|Sham Comparator|sham group|Sham group
33286820|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
33286821|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:~vildagliptin 50 mg bid plus metformin 1500mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
33286822|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:~metformin 1500mg plus metformin 500mg or 1000mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
33286823|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
33286824|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
33286825|NCT00975299|Experimental|Arm 1|
33286826|NCT00975299|Experimental|Arm 2|
33286827|NCT04008485|Experimental|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
33286828|NCT04008485|Experimental|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
33286829|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
33084808|NCT04670692|Experimental|5G-MCE examination|There will be 20 volunteers assigned to the 5G-MCE system group. These patients will accept the magnetically controlled capsule examination in Yinchuan. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the assistant in Yinchuan. Then, the assistant activated the capsule with the capsule locator. The patient is instructed to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. After the capsule entering into the stomach, the examination will be performed through the 5G-MCE system by the endoscopist (W.Z.), with experience of more than 1000 cases of MCE operation, in Shanghai.
33084809|NCT04670692|Active Comparator|MCE examination|There will be 20 volunteers assigned to the MCE system group as comparator group. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient is instructed to assume the left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist (W.Z.) face to face, subject continue the examination of stomach and duodenum.
33286830|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
33286831|NCT00973037||CYP2D6|CYP2D6 genotype
33286832|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
32900444|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
33286833|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
33286834|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
33286835|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
33286836|NCT04008563|Experimental|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
33286837|NCT04008563|No Intervention|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
33286838|NCT00975455||Subjects with hematuria|
33286839|NCT00973193|Experimental|panitumumab|
33286840|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
33286841|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
33286842|NCT00372567|Experimental|A|
33286843|NCT00372567|Active Comparator|B|
33286844|NCT04008251|Experimental|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
33286845|NCT00973271|Experimental|290 mg DCCR|
33286846|NCT00973271|Experimental|435 mg DCCR|
33286847|NCT00973271|Active Comparator|135 mg fenobric acid|
33286848|NCT00973271|Placebo Comparator|Placebo|
33286849|NCT00975767|Experimental|MGCD265+erlotinib|
33286850|NCT00975767|Experimental|MGCD265+docetaxel|
33286851|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
33286852|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
33286853|NCT00545441|Experimental|1|Surgisis® AFP
33286854|NCT00545441|Active Comparator|2|Flap
33286855|NCT03991767|Experimental|period 1|"Period 1: Retrospective period:~Collection of data from the 12 months preceding the start of the research of hospitalized patients:~number of hospitalizations,~number of HIV serologies performed,~number of patients with socio-demographic criteria justifying HIV screening.~Start of research: Implementation of the POP-UP electronic alert~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.~Six possibility to answer:~Patient accept to participate: patient is include and receive HIV serology during their hospitalization.~Not time to answer to the alert~Patient already has a serology less than 3 months old~Patient followed for a known HIV infection.~Patient who refused the test~Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
33286856|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
33286857|NCT00976001|Other|Follow-up with the general practitioner|
33286858|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
33286859|NCT00979589|Placebo Comparator|Asprin and placebo|
33286860|NCT00294658|Active Comparator|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
33286861|NCT00294658|Placebo Comparator|Prednisone alone|Drug: prednisone alone protocol
33286862|NCT00979667|Experimental|Oseltamivir|
33286863|NCT00979667|Experimental|Zanamivir|
33286864|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
33286865|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
33286866|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
33286867|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
33286868|NCT03978052|Experimental|1|"EGCG + multimodal intervention (n=50) Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~+ personalized intervention"
33084810|NCT04670809|Experimental|Clevidipine Butyrate Injection|
33084811|NCT04670809|Active Comparator|Ncardipine Hydrochloride Injection|
32781498|NCT05464043|Experimental|diabetic cohort|"Patients who receive liver or kidney transplants and immunosuppressive drugs with diabetogenic risk.~After 14 days of immunosuppressive therapy, all admitted patients will be evaluated for first-line glucose homeostasis. This patient cohort will be referred to as the diabetes risk cohort.~Subjects will then be stratified into two groups of patients: those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, the diabetic cohort, and those who have not developed glycemic dysregulation or diabetes, the control cohort. Only those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, i.e. the diabetic cohort, will be analysed in more detail with the evaluation of second-line glucose homeostasis at three different times."
33286869|NCT03978052|Active Comparator|2|"Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~non personalized intervention"
33286870|NCT03978052|Placebo Comparator|3|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~+ personalized intervention"
33286871|NCT03978052|Sham Comparator|4|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~non personalized intervention"
33084812|NCT04670575||Vivity|Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
33084813|NCT04670341|Experimental|chewing tapioca pearls in the bubble tea drinks|In the first week, the subjects drink as much as 100 ml of bubble tea over a span of 5 minutes once a day for 3 days
33084814|NCT04670341|Placebo Comparator|drink tea without chewing tapioca pearls|In the second week, the subjects drink tea without tapioca pearls as much as 100 ml for 5 minutes per day for 3 days.
33286872|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
33286873|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
33286874|NCT00372489|Experimental|Peginesatide|
33286875|NCT01066468|Experimental|Gleevec/Glivec|
33286876|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
33084815|NCT00267735|No Intervention|Module 1 Only|
33084816|NCT00267735|Experimental|Modules 1, 2, and 3|
33084817|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
33286877|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
33286878|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
33286879|NCT00976157||Ventilator-associated pneumonia|
33286880|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
33286881|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
33286882|NCT00976235|Experimental|IMT|
33084818|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
33286883|NCT03977740|Experimental|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
33286884|NCT03977740|Active Comparator|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
33286885|NCT00976313||1|male patients
33286886|NCT00976313||2|female patients
33286887|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
33286888|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
33286889|NCT03921047||Ancillary-correlative (next generation sequencing)|Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
33286890|NCT00980135|Experimental|Arm 1|
33286891|NCT00980135|Experimental|Arm 2|
33286892|NCT00980135|Other|Arm 3|
33286893|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
33286894|NCT04986527|Active Comparator|24 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 24 hours prior to water seal
33286895|NCT04986527|Experimental|48 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 48 hours prior to water seal
33286896|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
33286897|NCT00980369||Parallel incision, vertical insicion|
33286898|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
33286899|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
32781499|NCT05416411|No Intervention|Usual Care|Patients who are candidates for thoracic resection surgeries will be advised to stay active and quit smoking.
32781500|NCT05416411|Active Comparator|Intervention group|Patients who are candidates for thoracic resection surgeries will be handed a flow resistive device that helps inspiratory muscle training (2*30 repetitions a day for 7 days) and will be advised to walk 5000 steps a day.
32781501|NCT05475899|Active Comparator|Instrument assisted soft tissue mobilization|Patients in group A will be treated with the help of Instrument Assisted soft tissue mobilization GRASTON technique along with the conventional treatment. • Patient will be prone position with the foot over the edge of the table. Instrument will be applied from downward to upward direction with maximum of 10 - 15 strokes per session. These strokes will be applied in two sets of 10 strokes followed by stretches after each set. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week & at the end of 4th week.
32781502|NCT05475899|Experimental|kinesiology taping|Patients in group B will be treated with the help of kinesiology taping along with the conventional treatment. Patient will be in prone position with the dorsiflexion of the foot supported on the bed. Fan shaped taping will be applied with 60 - 100 % tension in the centre of the tape. The ends of the tape; the anchor will be applied without any stretch while centre of the tape will be stretched to approximately 60 - 100 %. Length of the tape may vary from person to person depending upon the size of the foot. Patient will be instructed to keep the tape till the next session. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week & at the end of 4th week.
32781503|NCT05416255|Active Comparator|Dextrose injection|Injection of 10 ml of 12.5% dextrose
32781504|NCT05416255|Active Comparator|Hematopoietic stem cells|Injection of 10 ml of of 7.5 ml hematopoietic stem cells, 2 ml of 25% dextrose (5% diluted), 0.5 ml of 1% lidocaine (0.05% diluted),and 0.25 ml dexamethasone (1.5 mg)
32781505|NCT05416255|Active Comparator|Platelet Rich Plasma injection|Injection of 10 ml of leukocyte rich platelet rich plasma
32781506|NCT05416255|Active Comparator|No injection|Aspiration of synovial fluid may be an active comparator.
32781507|NCT05396443|Experimental|Intervention|Adolescent participants receive 12 week telehealth lifestyle program consisting of a Wellness session, Cooking Experience, and Dance Classes. Caregiver participants are encouraged to participate in the program.
32781508|NCT05396443|Placebo Comparator|Control|Adolescent participants receive weekly newsletter to attend public events. The control group will receive a simplified version of the intervention post endpoint data collection. Caregiver participants are encouraged to attend events with the adolescent.
32781509|NCT05396443|Experimental|Intervention-Caregiver|Caregiver of adolescents randomized to the Intervention group are encouraged to participate in the program.
32781510|NCT05396443|Placebo Comparator|Control caregiver|Caregivers of adolescents in the control group receive weekly newsletter to attend public events. Caregiver participants are encouraged to attend events with the adolescent.
32781511|NCT05444725|Other|Stage of decision making|"Same questionnaire for all three arms except validated question Stage of decision making followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
32781512|NCT05444725|Other|Choice framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as a choice (between screening and alternative of no screening) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
32781513|NCT05444725|Other|Opportunity framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as an opportunity (no presentation of alternative) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
32781514|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
32781515|NCT05450549|Experimental|DNL919 (Healthy Participant)|
32781516|NCT05450549|Placebo Comparator|Placebo (Healthy Participant)|
32781517|NCT05444413|Experimental|ultrasound-guided platelet rich plasma nerve block combined with drugs|selected patients were treated by the ultrasound-guided platelet rich plasma nerve block once a week for the 4 consecutive weeks while they were given the regular medicine which are taking pregabalin and amitriptyline hydrochloride orally, and the dosage shall be increased or decreased according to the patient's condition.
32781518|NCT05463965|Experimental|Treatment Group|Single injection with QM1114-DP in glabellar lines
32781519|NCT05463965|Active Comparator|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
32781520|NCT05463965|Placebo Comparator|Placebo-Controlled Group|Single injection with placebo in glabellar lines
32781521|NCT05416021|Active Comparator|25 mg dapivirine ring|25 mg dapivirine vaginal ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A), followed by the 100 mg dapivirine ring (Ring-008) used continuously for 90 days (Treatment B)
32781522|NCT05416021|Active Comparator|100 mg dapivirine ring|100 mg dapivirine vaginal ring (Ring-008) used continuously for 90 days (Treatment B), followed by the 25 mg dapivirine ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A)
32781523|NCT05443555|Active Comparator|Intervention: Gabapentin|Participants randomized to the intervention group will receive active gabapentin for 3 months and brief (5-minute) evidence-based counseling for alcohol use.
33286900|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
33286901|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
32781524|NCT05443555|Placebo Comparator|Control: Placebo|Participants randomized to the control group will receive placebo capsules, identical in appearance to gabapentin, and the same brief (5-minute) one-time evidence-based counseling for alcohol use as the intervention group.
32781525|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
32781526|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
32781527|NCT05415865|Active Comparator|Alkalinized Lidocaine, then Placebo|"Participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have the matching placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
32781528|NCT05415865|Active Comparator|Placebo, then Alkalinized Lidocaine|"Participants will have placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
32781529|NCT05415787||adult patients with metastatic prostate cancer|
32781530|NCT05463887|No Intervention|Usual care|Control arm: Participants will not receive individualized preventive care recommendations (decision tool).
32781531|NCT05463887|Active Comparator|Individualized preventive care recommendations (decision tool)|Intervention arm: Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making.
33084819|NCT04670497|Active Comparator|ultrasound guided lumbar plexus block|patients were recieved lumbar plexus block ultrasound guided by shamrock technique using 0.5% bupavacaine in a dose 0.3ml/kg
33084820|NCT04670497|Active Comparator|ultrasound guided Fascia iliaca block|patients were received fascia iliaca block ultrasound guided using 0.5% bupoavacaine in a dose 0.3ml\kg
33084821|NCT04670302|Active Comparator|Control group (Tendon repair)|The control group will undergo tendon repair procedure only (without augmentation)
32781532|NCT05415709|Active Comparator|Arm I (carboplatin, paclitaxel, CRS)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM I: No chemotherapy immediately before, during or after surgery. Carboplatin/paclitaxel is given 3-4 weeks prior to surgery and again 2-4 weeks after surgery."
32781533|NCT05415709|Experimental|Arm II (carboplatin, paclitaxel, CRS, HIPEC, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM II: Patients undergo HIPEC and receive cisplatin IV over 90 minutes at the time of interval debulking surgery"
32938586|NCT03185546|Experimental|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
32938587|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
32938588|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
32938589|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
32938590|NCT03185546|Experimental|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
32938591|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
33084822|NCT04670302|Experimental|Experimental group (Tendon repair augmented with AAdMSC-HAM composite)|The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite
33084823|NCT04670107|Experimental|combination group|
33084824|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
33084825|NCT04670458||CA group|Patients with In-Hospital Cardiac Arrest
33084826|NCT04670458||CONTROL group|Patients without In-Hospital Cardiac Arrest
33084827|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
33084828|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
33084829|NCT04556812|Experimental|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
33084830|NCT04556812|Placebo Comparator|Control group|traditional soft tissue surgery
33084831|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
33084832|NCT00556192|Active Comparator|1|Rituximab
32781534|NCT05415709|Experimental|Arm III (carboplatin, paclitaxel, CRS, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM III: Patients receive cisplatin IV the day prior to interval debulking surgery"
32781535|NCT05463575|Experimental|PF-06835919|KHKi
32781536|NCT05463575|Placebo Comparator|Placebo|Placebo
32781537|NCT04262843|Experimental|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
32781538|NCT01631851|Experimental|Cognitive behavior therapy|
32781539|NCT05415553|Experimental|IOBT group|For IOBT, the whole belly of inferior oblique muscle is anchored to the sclera 5 mm behind the temporal insertion of the inferior rectus muscle.
32781540|NCT05415553|Active Comparator|IO-Rec group|For IO-Rec, the insertion of inferior oblique muscle is excised and anchored to the sclera 4 mm behind and 2 mm beside the temporal insertion of the inferior rectus muscle.
32938592|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
32938593|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
33286902|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
32781541|NCT05475743|Experimental|Self-management support group|
32781542|NCT05475743|Active Comparator|Control group|
32781543|NCT05394649|Experimental|Intravascular lithotripsy arm|Preparation of calcified lesions by intravascular lithotripsy before stenting
32781544|NCT05394649|Active Comparator|Rotational Atherectomy arm|Preparation of calcified lesions by rotational atherectomy before stenting
32781545|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
32781546|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
32781547|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
32781548|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
32938594|NCT05365009||EPIMAR group|EPIMAR (ARgentina's Autoimmune Mechanism Interstitial Pulmonary Disease) registry was created in 2016 by a group of multidisciplinary specialists with experience in the management of ILD.
32938595|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
32938596|NCT05364853|Other|In-Person Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) in-person.
32938597|NCT05364853|Other|Remote Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) remotely over video/telehealth.
32938598|NCT05364463|Experimental|Ultrasound and hyperemia|Use of ultrasound and hyperemia to puncture radial artery.
32938599|NCT05364463|Experimental|Ultrasound only|Use of ultrasound only to puncture radial artery.
32938600|NCT05364463|Experimental|Hyperemia only|Use of hyperemia and palpation to puncture radial artery.
32938601|NCT05364463|No Intervention|Palpation|Use of palpation to puncture radial artery (control group).
32938602|NCT05058482|Experimental|Non-adhesive Liquid Embolic System(NALES)|
32938603|NCT05058482|Active Comparator|Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter|
32938604|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
32938605|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
32938606|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
32938607|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
32938608|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
32938609|NCT02186652|Other|Pantoprazole|
32938610|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
32938611|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
32938612|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
32938613|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
32938614|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
33286903|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
33286904|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
32781549|NCT05394571||Newly diagnosed diabetes|Patients who have been diagnosed with type 2 diabetes within a month
32781550|NCT05394571||Had controlled diabetes before|Patients who had at least two HbA1c levels =<%7,5 before enrollment
32781551|NCT05394571||Had moderately uncontrolled diabetes|Patients who had at least two HbA1c levels between %7,5 and %9,49 before enrollment
32781552|NCT05394571||Had poorly controlled diabetes|Patients who had at least two HbA1c levels above %9,5 before enrollment
32781553|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
32781554|NCT05475665|Experimental|Irbesartan/Amlodipine|
32781555|NCT05475665|Active Comparator|Irbesartan|
32781556|NCT05443087|Experimental|Regorafenib - mCRC, GIST, HCC|"3 x 30 = 90 patients~Patients with mCRC, GIST or HCC treated with Regorafenib"
32781557|NCT05443087|Experimental|Everolimus - gepNET|"60 patients~Patients with gepNET treated with Everolimus"
32781558|NCT05443087|Experimental|Sunitinib - pNET, GIST|"2 x 30 = 60 patients~Patients with pNET and GIST, treated with Sunitinib"
32781559|NCT05443087|Experimental|Cabozantinib - HCC|"60 patients~Patients with HCC treated with Cabozantinib"
32781560|NCT05443087|Experimental|Encorafenib - Cetuximab - mCRC|"60 patients~Patients with mCRC treated with the association Encorafenib - Cetuximab"
32781561|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
32781562|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
32781563|NCT05442697|Experimental|Knee OA KL Grade2 PEMF Treatment|Patients with knee OA grade 2 will accept PEMF treatment
32781564|NCT05442697|Placebo Comparator|Knee OA KL Grade2 Placebo Treatment|Patients with knee OA grade 2 will accept placebo treatment
32781565|NCT05442697|Experimental|Knee OA KL Grade3 PEMF treatment|Patients with knee OA grade 3 will accept PEMF treatment
32781566|NCT05442697|Placebo Comparator|Knee OA KL Grade3 Placebo Treatment|Patients with knee OA grade 3 will accept placebo treatment
32781567|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
32781568|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
32781569|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
32781570|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
32781571|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
32781572|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)~Surgery: Tumor resection and arterial resection/reconstruction"
32781573|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
32781574|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
33286905|NCT00372411|Other|Arm 3|Usual Care
32781575|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
32781576|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
32781577|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
32781578|NCT05394103|Experimental|Dose escalation (Q901)|
32781579|NCT02914535|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
32781580|NCT02914535|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
32781581|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
32781582|NCT02914535|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
32781583|NCT02914535|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
32781584|NCT05432999|Experimental|Intervention|This group will receive a focused extracorporeal shockwave therapy treatment (three applications over three weeks), applied to the spastic medial gastrocnemius.
33286906|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
32781585|NCT05432999|Sham Comparator|Control|This group will go through the same procedures as the intervention group, but the shockwave device will not touch their skin and thus they will receive no therapeutic effect.
32781586|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
32781587|NCT05461313|Other|Constrained Liner|
32781588|NCT05461313|Other|Dual Mobility Cup|
32781589|NCT05411159|Experimental|Opioid-Free Anesthesia (OFA froup)|Opioid-free anesthesia group, avoid patients receive any kind of opioid during VATs.
32781590|NCT05411159|Active Comparator|Standard general anesthesia (OA)|Standard general anesthesia. Opioids allowed, including sufentanil, remifentanil, tramadol during VATs.
32781591|NCT05431907|Experimental|Cohorts 1-2|Escalating doses of Allocetra-OTS up to 10 x 10^9 cells.
32781592|NCT05431907|Experimental|Cohorts 3-4|Allocetra-OTS at the maximal tolerated dose.
32781593|NCT05431751|Experimental|Experimental Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where they will consume the active intervention. Following the second clinic day, the participant will consume active intervention for 7 days. The participant will then undergo a washout period of 7 days.
32781594|NCT05448911|Experimental|Experimental group|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
32781595|NCT05448911|Other|Control Group|This approach typically requires extensive surgical exposure and large-scale soft-tissue dissection, which quickly leads to some serious complications, including increased rates of infection, poor wound healing, increased damage to large vessels or nerves, and heterotopic ossification
32781596|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32781597|NCT02530385|Experimental|FMT|Active FMT capsules
32781598|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
32781599|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
32781600|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
32781601|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
32781602|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
32781603|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
32781604|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
32781605|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
32781606|NCT05431517||Non-migration group|Cases without migration after pancreatic stenting under ERCP.
32781607|NCT05431517||Migration group|Cases with migration after pancreatic stenting under ERCP.
32781608|NCT05410301|Experimental|Patients: sBE device applied during sleep, in combination with Lomustine and Bevacizumab|The sBE device is to be used 8 hours a day by the patients, during sleep, for 8 weeks, while also receiving standard chemotherapy Lomustine and Bevacizumab
32781609|NCT05410301|Experimental|Partners of Patients (who sleep in same bed): sBE|Up to 12 associated unaffected partners may agree to sleep within the investigational sBE device congruent with the period of exposure of their rGBM partner (8 weeks + possible extension)
32781610|NCT04260425|Experimental|High then low avenanthramides content oats|This arm will receive the high avenanthramides content oatmeal at the first session and the low avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
32781611|NCT04260425|Experimental|Low then high avenanthramides content oats|This arm will receive the low avenanthramides content oatmeal at the first session and the high avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
32781612|NCT05430815|Experimental|Enhanced Postpartum Care System|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, or hypertensive disorder of pregnancy (gestational hypertension or preeclampsia) who are randomized to receive enhanced postpartum care.
32781613|NCT05430815|No Intervention|Standard of Care|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, or hypertensive disorder of pregnancy (gestational hypertension or preeclampsia) who are randomized to receive standard postpartum care.
32938615|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
32938616|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
32938617|NCT05363917|Experimental|Natrunix with MTX placebo (+Folate)|Natrunix 400mg, subcutaneous injection with oral MTX placebo (+Folate). This arm will enroll 100 subjects.
32938618|NCT05363917|Active Comparator|Natrunix Placebo with MTX(+Folate)|Natrunix Placebo, subcutaneous injection with oral MTX(+Folate). This arm will enroll 50 subjects.
32938619|NCT03187730|Active Comparator|Intervention Arm|
32938620|NCT03187730|Placebo Comparator|Waitlist Control|
32938621|NCT05363761|Experimental|Ablation Treatment|Neurotronic Infusion Catheter Treatment
32938622|NCT05363683|Active Comparator|Control|Standard care.
32938623|NCT05363683|Experimental|Experimental|Squat biofeedback intervention.
32938624|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
32938625|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
32938626|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
32938627|NCT05359705|Experimental|Healthy subjects|Healthy subjects who meet the Inclusion/Exclusion.
32938628|NCT04947176|Active Comparator|Active|200mg of pentadecanoic acid (C15:0) supplementation in capsules form
32938629|NCT04947176|Placebo Comparator|Placebo|Matching placebo in capsules form
32938630|NCT00375661|No Intervention|interferon|
32781614|NCT05448209|Experimental|Experimental|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
32781615|NCT05448209|No Intervention|control group|control group will receive standard practice
32781616|NCT05447819|Experimental|DELTA Xtend Reverse Shoulder System Lateralized Glenosphere Line Extension|"By using a lateralized glensphere complications can be reduced and patients can achieve an improved outcome.~Currently, little is known about the results of the lateralized design. The initial results have been promising, but migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
32781617|NCT05447819|Active Comparator|Standard DELTA Xtend Reverse Shoulder System|A design with a standard glenosphere is currently regarded as the standard treatment
32781618|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
32781619|NCT05447585|Experimental|Coronary Atherectomy System|Subjects in experimental arm will be treated with the Coronary Atherectomy System manufactured by Shanghai Microport Rhythm Co. Ltd.
32781620|NCT05447585|Active Comparator|Rotablator Rotational Atherectomy System|Subjects in control arm will be treated with Rotablator Rotational Atherectomy System manufactured by Boston Scientific Corporation
32781621|NCT05429021|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
32781622|NCT05429021|Experimental|IV Cohort 2|Single intravenous (IV) dose 2 of IMM-BCP-01 or matching placebo
32781623|NCT05429021|Experimental|IV Cohort 3|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
32781624|NCT05429021|Experimental|IV Cohort 4 (optional)|Single intravenous (IV) dose 4 of IMM-BCP-01 or matching placebo
32781625|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
32781626|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
32781627|NCT05428709|Experimental|Acute exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
32781628|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
32781629|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
32781630|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
32781631|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
32781632|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
33084833|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
33084834|NCT00556192|Active Comparator|3|Cyclophosphamide
33084835|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
33084836|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
32781633|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
32781634|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
32781635|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
32781636|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
32781637|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
32781638|NCT04880187|Experimental|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
32781639|NCT04880187|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
32781640|NCT04880187|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
33084837|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
33084838|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
33084839|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
33286907|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
32781641|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
32781642|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
32781643|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
32781644|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
32781645|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
32781646|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
32781647|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
32781648|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
32781649|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
32781650|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
32781651|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
32781652|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
32781653|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
32781654|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
32781655|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
32781656|NCT01607905|Experimental|Arm A (Colorectal Cancer)|Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: >12mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781657|NCT01607905|Experimental|Arm B (Gynecological Cancer)|Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781658|NCT01607905|Experimental|Arm C (Squamous Cell Cancer)|Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781659|NCT01607905|Experimental|Arm D (Castrate-resistant Prostate Cancer)|Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781660|NCT01607905|Experimental|Arm E (Glioblastoma Multiforme)|Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32938631|NCT04736186|Experimental|Loperamide|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)
33286908|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
33286909|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
33286910|NCT00976625|Other|2|
33286911|NCT00980603|Active Comparator|docetaxel|
32781661|NCT01607905|Experimental|Arm F (Melanoma)|Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781662|NCT01607905|Experimental|Arm G (Other Solid Tumors)|Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
32781663|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
32781664|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
32781665|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
33084840|NCT00556231||3|
33084841|NCT00556231||4|
33084842|NCT00556231||5|
32781666|NCT05441605|Experimental|First group|1% chlorhexidine, n=24 patients.
32781667|NCT05441605|Experimental|Second group|2% chlorhexidine, n=24 patients.
32781668|NCT05441605|Experimental|Third group|4% chlorhexidine, n=24 patients.
32781669|NCT05441605|Other|Fourth group|control group, 70% iso-propyl alcohol, n=24 patients.
32781670|NCT00843037|Experimental|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
32781671|NCT05392543|Experimental|Group A|Brunnstrom movement therapy
32781672|NCT05392543|Experimental|Group B|Mirror therapy
32781673|NCT00602641|Active Comparator|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
32781674|NCT00602641|Experimental|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
32781675|NCT05414773|Experimental|Corneal Topography with IOLMaster and Sirius topography.|The experimental group will have the two exams: the topography with the IOLMAster and the topography with Sirius topography.
32781676|NCT02531113|Experimental|RPC1063 (Ozanimod)|
32781677|NCT05441527|Experimental|MI Paste, then, Biotene Dry Mouth Gel|Subjects in this arm will use 1 milliliter of MI Paste daily for 7 days. Then, the subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel daily for 7 days. There will be no wash-out period between the two products.
32781678|NCT05441527|Experimental|Biotene Dry Mouth Gel, then, MI Paste|Subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel for 7 days. Then, the subjects in this arm will use 1 milliliter of MI Paste for 7 days. There will be no wash-out period between the two products.
32781679|NCT05391919|Experimental|MT in early recovery period of IS|"Patients in early recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
32900515|NCT00367016|Experimental|Omalizumab|Subjects will receive subcutaneous Omalizumab for 6 months. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
33084843|NCT00556231||6|
33084844|NCT00556270||Matrix II|
33102367|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
33286912|NCT00980603|Experimental|doctaxel plus cisplatin|
32781680|NCT05391919|Experimental|MT in late recovery period of IS|"Patients in late recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
32781681|NCT05391919|Active Comparator|No MT Intervention: Conventional IS rehabilitation|Patients in early and late recovery period of IS recieve conventional complex rehabilitation: kinesiotherapy, physiotherapy, occupational therapy.
32781682|NCT05440435||Center A|Study center A that observe cohort populations (sample size=400).
32781683|NCT05440435||Center B|Study center B that observe cohort populations (sample size=400).
32781684|NCT05440435||Center C|Study center C that observe cohort populations (sample size=400).
32781685|NCT05440435||Center D|Study center D that observe cohort populations (sample size=400).
32781686|NCT05440435||Center E|Study center E that observe cohort populations (sample size=400).
32781687|NCT05413447|Experimental|Patients receiving digital consultations|Consultations for HFrEF will be prepared digitally using the Mychart patient portal, a digital elearning and questionnaires. The VC takes place via Teams (Microsoft, Redmond, United States of America). The cardiologist can choose to see a patient physically if deemed appropriate, but the consult will by default be planned as a VC.
32781688|NCT05413447|No Intervention|Standard care|The patients will receive standard care.
32781689|NCT05440045|Experimental|6MW3211|6MW3211 injection, 30mg/kg
32781690|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
32781691|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
32781692|NCT04258969|Experimental|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
32781693|NCT05389657|Experimental|Web-based training|Web-based training will provide online training primarily focused on family-based treatment and appropriate adaptations to the treatment model.
32781694|NCT05389657|Active Comparator|Live training|Live training will include two days of expert-led live training (via zoom). The content of the training will be similar to that provided in web-based training, primarily focused on family-based treatment and appropriate adaptations to the treatment model.
32781695|NCT05389111|Experimental|Internal discourses|Introduction to internal discourses with a brief definition and key elements for implementation.
32781696|NCT05389111|Sham Comparator|Non-internal discourses|Introduction to the risks associated with the practice of activity in the mountain environment and practical tips to prevent the risks
32781697|NCT04261777|Experimental|SPL-01-001|
32781698|NCT05387395||complete vaccination|Complete vaccination was defined as administering two doses of mRNA or AstraZeneca vaccine, administration of one dose of Jansen vaccine, or administration of one dose of any vaccine in patients with a history of COVID19 infection.
32781699|NCT05387395||incomplete vaccination|Other cases were defined as incomplete or absent vaccination.
32781700|NCT05386771|Experimental|Whey and collagen protein blend|A blend of 25g of whey protein and 5g of collagen protein
32781701|NCT05386771|Placebo Comparator|Placebo|Water, same volume as the experimental study beverage
32781702|NCT05004805|Experimental|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
32781703|NCT05004805|Placebo Comparator|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
32781704|NCT05412823||Hypoxic group|Participants with hypoxia during intubation (after induction and before endotracheal tube placement)
32781705|NCT05412823||Non-hypoxic group|Participants without hypoxia during intubation (after induction and before endotracheal tube placement)
32781706|NCT05412745|Experimental|group A|class I pullulan based medical device containing Allium cepa & HA
32938632|NCT04736186|Experimental|Loperamide and gold bifid|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + gold bifid2g T.I.D.
32781707|NCT05412745|Active Comparator|Group B|class I medical device silicone gel
32781708|NCT04261387|Experimental|LUT014 Gel|LUT014 Gel topical application to the dermatitis area qd for 28 days
32781709|NCT04261387|Placebo Comparator|Placebo for LUT014 Gel|
32781710|NCT05412199|Experimental|Percussion Massage Therapy Group|The group to which percussion massage therapy will be applied to the posterior leg muscles.
32938633|NCT04736186|Experimental|Loperamide and Montmorillonite SAN|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + Montmorillonite SAN 3 g, T.I.D.
32938634|NCT04736186|No Intervention|Non-intervention|Do not intervene and stop diarrhea as needed
32781711|NCT05412199|Experimental|Graston (IASTM) Group|The group in which instrument-assisted soft tissue mobilization will be applied to the posterior leg muscles.
32781712|NCT05412199|Experimental|Dynamic Stretching Group|The group to which dynamic stretching exercises will be applied to the posterior leg muscles.
32781713|NCT05411965|Experimental|Sequence Group A|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~*Sequence A [Period 1] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)~- Wash out for 7 days [Period 2] Administration of BR3003(T) (single dose)"
32781714|NCT05411965|Experimental|Sequence Group B|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~*Sequence B [Period 1] Administration of BR3003(T) (single dose)~- Wash out for 7 days [Period 2] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)"
32781715|NCT04261075|Experimental|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
32781716|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
32781717|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
32781718|NCT04452019|Active Comparator|Standing frame|Use of standard standing frame
33084845|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
33084846|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
33084847|NCT00267852||1.0|As per routinary clinical practice
33084848|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
32781719|NCT04452019|Experimental|"Innowalk Pro"|"Use of a new device; Innowalk Pro"
32781720|NCT04451473|Experimental|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
32781721|NCT04451473|Other|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
32781722|NCT05438485||Methylmalonic Acidemia (MMA)|Approximately 60 subjects with Methylmalonic Acidemia
32781723|NCT05438485||Propionic Acidemia (PA)|Approximately 60 subjects with Propionic Acidemia
32781724|NCT05438017|Experimental|Dreem + PSG|
32781725|NCT05378893|Experimental|Single-ascending dose (SAD), Part 1|Part 1 will have 6 cohorts and approximately 44 healthy subjects or mildly obese but otherwise healthy adult subjects; 4 subjects in Cohort A (all active), 8 subjects each (6 active: 2 placebo) in Cohorts B, C, D, E, and F; and an additional Cohort G of approximately 12 mildly obese or obese subjects with features of MetS (10 active: 2 placebo). The starting DR10624 dose in Part 1 will be 0.5 mg SubQ. The provisional doses in Cohorts B, C, D, E, and F are planned to be 1.5, 4.5, 12.5, 25, and 50 mg SubQ, respectively, with final doses for each cohort determined by the SRC following a full review of the data from the previous cohort. In Cohort G, the mildly obese or obese subjects with features of MetS will receive a single dose of DR10624 at the optimum therapeutic dose identified by the SRC in Part 1. The dose levels may be adjusted by the SRC.
32781726|NCT05378893|Experimental|Multiple-ascending dose (MAD), Part 2|"Part 2 will have 8 cohorts, 12 subjects each (10 active: 2 placebo) in Cohort H, I, J, K, L, M, N, and O, and a total of approximately 96 subjects; Cohorts H and I will enroll healthy subjects, or mildly obese but otherwise healthy adult subjects; Cohorts J, K, and L will enroll mildly obese or obese subjects with features of MetS; and Cohorts M, N, and O will enroll overweight or obese subjects with T2D. DR10624 will be administered as a SubQ injection in the abdomen.~The planned dose levels for the MAD cohorts are presented in Table S1. Additional interim dose levels may be added for the MetS and T2D subjects as evaluated and approved by the SRC."
32781727|NCT05436769|Experimental|Test Drug|Klaribact (Clarithromycin 500 mg) Film Coated Tablet (Merck Pvt. Ltd, Pakistan)
32781728|NCT05436769|Active Comparator|Reference Drug|Klaricid 500 mg (Clarithromycin 500 mg) Film Coated Tablet (Abbot Laboratories (Pakistan) Limited)
32781729|NCT05378737|Experimental|A/1.2mg/kg|Drug：BAT8006 for Injection, 1.2mg/kg
32781730|NCT05378737|Experimental|B/2.4mg/kg|Drug：BAT8006 for Injection, 2.4mg/kg
32781731|NCT05378737|Experimental|C/ 3.5mg/kg|Drug：BAT8006 for Injection, 3.5mg/kg
32781732|NCT05378737|Experimental|D/ 5.0mg/kg|Drug：BAT8006 for Injection, 5.0mg/kg
32781733|NCT05378737|Experimental|E/ 6.5mg/kg|Drug：BAT8006 for Injection, 6.5mg/kg
32781734|NCT05378737|Experimental|F/8.0mg/kg|Drug：BAT8006 for Injection, 8.0mg/kg
32781735|NCT00060541||Patients|Patients age 4 or older seeking care from, or being referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions
32781736|NCT05436379|Other|TBS|"In this open-label trial, all participants will undergo 2 continuous TBS (cTBS) sessions per visit over 10 days (weekdays, over 2 weeks; total = 20 TBS sessions in 10 visits). The total time of each pair of sessions (including pause between sessions) will be approximately 1 hour, with each session lasting approximately 100 seconds.~There is only 1 group and 1 arm of the study. All participants will receive the treatment."
32781737|NCT03937999|Experimental|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
32781738|NCT03937999|No Intervention|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
32781739|NCT05436067|Experimental|Older adults with dizziness|Clinical trial only has one arm or participant group. All participants undergo the same experiment. They will perform exercises with the Vestibular Rehabilitation App as well as without the App. The order is randomized.
32781740|NCT03929029|Experimental|Nivolumab+Ipilimumab+NeoVax plus Montanide|"Run in period will begin within 2 weeks of metastatic tissue biopsy, once the following criteria~Patients will receive Nivolumab at a flat dose I.V. infusion every 4 weeks (28 days)~Patients will receive Ipilimumab injection on weeks 12, 15, 18, and 21~Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21"
32781741|NCT05435989|Experimental|Normal-hearing listeners|
33084849|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
33084850|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
33084851|NCT04670419||HEV gt 3 clade abchijklm|patients infected with HEV gt 3 clade abchijklm
32781742|NCT05435209|Experimental|Quadrivalent HPV Vaccine|Gardasil® 0.5 mL administered intramuscularly in the deltoid or anterolateral area of the thigh
33402215|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
32781743|NCT05377567|Experimental|TAU + FIBRO-On|FIBRO-On is a virtual multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
32781744|NCT05377567|Active Comparator|TAU + FIBRO-Out|FIBRO-Out is a outdoor multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
32781745|NCT05377567|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
32781746|NCT05377177|Experimental|Bilateral aTBS|Patients will receive Bilateral accelerated theta-burst stimulation bilaterally for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions.
33084852|NCT04670419||HEV gt 3 clade efg|patients infected with HEV gt 3 clade efg
33084853|NCT04670185|Experimental|Internet-based parent training|Five weeks of therapist-guided online delivered parents training
33084854|NCT04670185|No Intervention|Waitlist|Five weeks of waitlist
32781747|NCT05377177|Active Comparator|Unilateral aiTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left side for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions. There will be a right DLPFC sham component to this treatment arm for all treatment sessions.
32781748|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
32781749|NCT05434741|Experimental|CBT Group|This 12-week intervention program leverages evidence-based traditional and contemporary CBT strategies, with the goal of improving the psychological and physical functioning of older people with HIV by providing education and support to learn strategies to: a.) better manage stressors associated with HIV and aging (e.g., treatment access and engagement, and multi-morbidity), and b.) increase health-promoting behaviors (e.g., physical activity).
32781750|NCT05434741|Experimental|Information-only Group|"Participants in the control group will receive a one-time trifold brochure titled HIV: 50 Years or Older."
32781751|NCT05376631|Active Comparator|Group Five|For emergence from general anesthesia, a fresh gas flow of 5 L/min is used.
32781752|NCT05376631|Experimental|Group Ten|For emergence from general anesthesia, a fresh gas flow of 10 L/min is used.
32781753|NCT05376553|Experimental|Cohort A|"3 cycles of Cemiplimab-TP induction chemotherapy will be delivered in cohort A.~Cemiplimab-TP chemotherapy will be given every 21 days starting on days 1, 22 and 43, etc. (+ 2 days) with TP given on days 1, 22, and 43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~Patients in cohort A will get 3 doses of Cemiplimab during induction therapy."
33084855|NCT04669873|Active Comparator|Active Comparator: Standard|Whole breast Radiotherapy, 40 Gray (40Gy) fractions
32781754|NCT05376553|Experimental|Cohort B|"In cohort B first dose of Cemiplimab will be given 7 days prior to TP followed by TP given on days 1,22,43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~Patient in cohort B will get 4 doses of Cemiplimab during induction therapy."
33084856|NCT04669873|Experimental|Experimental 1: Hypofractionated radiotherapy|Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions
33084857|NCT04669873|Experimental|Experimental 2: Accelerated Partial Breast Irradiation|Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.
33084858|NCT04669756|Experimental|A|ovariopexy for 2 days
33084859|NCT04669756|Experimental|B|ovariopexy for 4 days
33084860|NCT04669756|Experimental|C|ovariopexy for 6 days
33084861|NCT04669756|Placebo Comparator|D|Placebo Operation for 2 days
33084862|NCT04669795|Placebo Comparator|Group 1|Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
33084863|NCT04669795|Experimental|Group 2|Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)
32781755|NCT05385367|Other|Regional anesthetic|Patients only have nerve block with or without sedation
32781756|NCT05385367|Other|General anesthetic|Patients only have general anesthetic
33084864|NCT04670029|No Intervention|Standard|
33084865|NCT04670029|Experimental|APA|"During the first 3 cures, 3 APA sessions will be offered per week:~2 sessions of anaerobic type of 1 hour with muscle strengthening, stretching, flexibility and balance, supervised in the room,~1 aerobic type exercise session of 1.5 hours (Nordic walking: outdoors) or a 3rd indoor session if not possible,~+ home exercise book if the patient so wishes with record the time in minutes per session and the intensity felt and the modalities of the exercises carried out.~During the 5 remaining cycles, 3 APA sessions will be offered per week:~1 session of 1 hour in an anaerobic exercise room (muscle strengthening, stretching, flexibility, balance) supervised,~1 session of anaerobic exercise per week in autonomy at home (with exercise book),~1 or more session per week of one hour of walking or cycling independently at home (aerobic effort) with declaration in the logbook of the intensity of exertion felt and the time in minutes per session."
33084866|NCT04669951|Experimental|uPAR expression|Immunohistochemistry
33084867|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
33286913|NCT00980603|Experimental|docetaxel plus S-1|
33286914|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
33286915|NCT04008407|Active Comparator|ESD|Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
33286916|NCT04008407|Active Comparator|EMR|Lesion with no overt or a low risk for (<10%) for covert SMIC
33286917|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
33286918|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
33286919|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
33286920|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
33286921|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
33286922|NCT00976859|No Intervention|Waitlist control group|
33286923|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
33286924|NCT04011293|Experimental|A|Single dose of CNCT19
33286925|NCT03958019|Experimental|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
33286926|NCT03958019|No Intervention|Control|Usual care control group
33286927|NCT00372255|Experimental|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
33286928|NCT00372255|Active Comparator|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
33286929|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
33286930|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
33286931|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
33286932|NCT00274456|Experimental|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m^2 administered once every third week (q3w).
32781757|NCT05385367|Other|Combined general anesthetic and regional anesthetic|Patients have both general anesthetic and regional anesthetic together
32781758|NCT05610631||Pulmonary arterial hypertension|Pulmonary arterial hypertension
32781759|NCT05610631||PH due to left heart diseases|PH due to left heart diseases
32781760|NCT05610631||PH due to lung disease and/or hypoxia|PH due to lung disease and/or hypoxia
32781761|NCT05610631||Chronic thromboembolic PH|Chronic thromboembolic PH
32781762|NCT05610631||Miscellaneous PH|Miscellaneous PH
32781763|NCT05434351||Chinese women with moderate to severe symptoms of genitourinary syndrome of menopause|It is a single-group study.
32781764|NCT05541055|Experimental|Digital CBT-I|Digitally-delivered CBT for insomnia accessed via web and/or mobile app
33286933|NCT00274456|Experimental|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
33286934|NCT00274456|Experimental|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
33286935|NCT00274456|Active Comparator|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
33286936|NCT01045629||SchizoComp|Competence Ability of schizophrenia
33286937|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
33286938|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~Cohort 1 (MSS CRC)"
33286939|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab + cyclophosphamide|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~cyclophosphamide: 50 mg PO twice daily (Day 1-Day 7; Day 15-Day 21) with a 7-day drug free interval (Day 8-Day 14 and Day 22-Day 28)~Cohort 2 (PD-1 R/R melanoma) and Cohort 3 (PD-1 R/R NSCLC)"
33286940|NCT01049607|Active Comparator|Clamp-Crush technique|
33286941|NCT01049607|Experimental|Stapler hepatectomy|
33286942|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
33286943|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
33286944|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
32781765|NCT05541055|Active Comparator|Sleep hygiene education|This group will receive access to sleep hygiene education delivered via digital written materials
32781766|NCT05610553|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries.
32781767|NCT05610553|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
32781768|NCT05384353||Healthy controls|Synaptic density PET-MR and neuropsychological testing
32781769|NCT05384353||Patients with Alzheimer's disease|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
32781770|NCT05384353||Patients with Frontotemporal degeneration|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
32781771|NCT05384353||Patients with Dementia with Lewy Bodies|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
32781772|NCT05384353||Patients with late-life psychiatric disorders|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
32781773|NCT05591755|Experimental|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)|
32781774|NCT05591755|Experimental|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|
32781775|NCT05591755|Experimental|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|
32781776|NCT05591755|Experimental|Vehicle ophthalmic solution (n = 56)|
32781777|NCT05376163||Individuals with headache|Individuals with headaches caused by neck problems
33402216|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
32781780|NCT05374369||Subjects with positive SDC2 Gene Methylation Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive SDC2 Gene Methylation Test;~Subjects with colonoscopy results and/or pathological results."
32781781|NCT05374369||Subjects with positive Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive Q-FIT Test;~Subjects with colonoscopy results and/or pathological results."
32781782|NCT05374369||Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test;~Subjects with colonoscopy results and/or pathological results."
32781783|NCT04136587|Active Comparator|Healthy Controls|"Inclusion criteria:~Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss~Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia~Exclusion criteria:~Diagnosis of IBD or any other inflammatory condition of the small and large intestine~Diagnosis of irritable bowel syndrome (IBS)~Autoimmune disorders~Obesity (BMI> 30)~Regular intake of NSAIDs (> 2 tablets/ week), immunosuppressants~Intake of antibiotics within the last 3 months~Intestinal infection by enteric pathogens~Probiotic therapy"
32781784|NCT04136587|Active Comparator|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
32781785|NCT04136587|Active Comparator|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
32781786|NCT04136587|Active Comparator|Colorectal carcinoma|"Inclusion criteria:~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology~Exclusion criteria:~• None"
32781787|NCT04136587|Active Comparator|Colitis/Enteritis of other origin|"Inclusion criteria:~Diagnosis of intestinal inflammation at endoscopy or histology~E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause~Exclusion criteria:~• None"
32781788|NCT05345197|Experimental|Experimental-treatment|Treatment with emicizumab
32781789|NCT05610475|Active Comparator|Lung injury group|
32781790|NCT05610475|Sham Comparator|Non-lung injury group|
32781791|NCT05344339|Experimental|Billroth-II modified|An opening will be made at jejunum 25 cm from Treitz's ligament. Another at greater curvature of the stomach right above transected line. A straight stapling device will be used to make isoperistaltic anastomosis at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture and 3 -5 sutures to attach afferent loop to the remnant stomach
32781792|NCT05344339|Active Comparator|Roux-en-Y|Jejunum will be transected 25 to 30 cm from Treitz's ligament. Marginal vessels will be transected if needed to make sure the loop will reach the stomach without tension. Isoperistaltic gastrojejunostomy will be made at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture. Jejunojejunal mesenteric defect and Petersen's defect will be closed.
32781793|NCT05382637|Experimental|Growth hormone|The participant will receive escalating dose of growth hormone until an IGF-1 level is maintained between the mean and +2 standard deviations.
33286945|NCT00981071||A platoon with TB outbreak|
32781794|NCT05579431|Experimental|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-634.
32781795|NCT05579431|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-634.
32781796|NCT05579431|Experimental|Part B|Participants grouped in different cohorts will receive multiple doses of VX-634.The dose levels will be determined based on the data from Part A.
32781797|NCT05579431|Placebo Comparator|Placebo Part B|Participants will be randomized to receive placebo matched to VX-634.
32781798|NCT05576389|Experimental|Camrelizumab+Fluzoparib|
32781799|NCT05343793|Experimental|Path 1|Enhanced Monitoring and Feedback
33286946|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
32781800|NCT05343793|Experimental|Path 2|Enhanced Monitoring and Feedback + NIATx/MAT Academy
32781801|NCT05343793|Experimental|Path 3|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx External Facilitation
33286947|NCT01069822|Active Comparator|2|
32781802|NCT05343793|Experimental|Path 4|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation
32781803|NCT05343793|Experimental|Path 5|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation + NIATx External Facilitation
32781804|NCT04252807|Experimental|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
32781805|NCT04252807|Active Comparator|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
32781806|NCT05575687|Other|Water|Ingestion of 500 ml of mineral water
32781807|NCT05575687|Other|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
32781808|NCT05575687|Other|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
32781809|NCT05575687|Other|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
32781810|NCT05575687|Other|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
32781811|NCT05575687|Other|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
32781812|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase I|Alternate nostril breathing for normotensive women in 3rd trimester of pregnancy
32781813|NCT05341921|Active Comparator|Bhramari Breathing Phase I|Bhramari breathing for normotensive women in 3rd trimester of pregnancy
32781814|NCT05341921|Active Comparator|Sheetali Breathing Phase I|Sheetali breathing for normotensive women in 3rd trimester of pregnancy
32781815|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase II|Alternate nostril breathing for hypertensive women in 3rd trimester of pregnancy
32781816|NCT05341921|Active Comparator|Bhramari Breathing Phase II|Bhramari breathing for hypertensive women in 3rd trimester of pregnancy
32781817|NCT05341921|Active Comparator|Sheetali Breathing Phase II|Sheetali breathing for hypertensive women in 3rd trimester of pregnancy
32781818|NCT05372653|Experimental|OPA-15406|
32781819|NCT05568511|Experimental|Home-based, digitally delivered exercise training program|
32781820|NCT05568511|Active Comparator|Standard care control group|
32781821|NCT05372341||post-covid elective surgery patients|data of postcovid patients underwent elective surgery will be collected.
32781822|NCT01660243|Active Comparator|MT-9938 2.5μg|
32781823|NCT01660243|Active Comparator|MT-9938 5μg|
32781824|NCT01660243|Active Comparator|MT-9938 10μg|
32781825|NCT01660243|Placebo Comparator|Placebo|
32781826|NCT05610085|Experimental|Dose escalation with LEV|Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).
32781827|NCT05610085|Active Comparator|Standard of care Phenobarbital|Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg
32938635|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
32938636|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
32938637|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
32938638|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
32938639|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
32938640|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
32938641|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
32938642|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
32938643|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
32938644|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
32938645|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
32781828|NCT05567263|Active Comparator|Bulk- Fill|Restorative procedure of the teeth will be performed using Filtek-Bulk Fill Posterior Restorative, Bulk-fill resin composite, (3M, ESPE) following application of an etch-and-rinse single bottle adhesive (3M, ESPE).
32781829|NCT05567263|Experimental|Surefill One|Restorative procedure of the teeth will be performed using Surefil one™ Self-Adhesive Composite Hybrid (Dentsply, Sirona),
32781830|NCT05380921|Experimental|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
32781831|NCT05380921|Experimental|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
32781832|NCT05341609|Experimental|JT001(VV116)|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
33286948|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
33286949|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
33286950|NCT03977974|Experimental|LY3526318 - Part A|LY3526318 administered orally once.
32938646|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
32938647|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
32938648|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
33286951|NCT03977974|Placebo Comparator|Placebo - Part A|Placebo administered orally once.
33286952|NCT03977974|Experimental|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
33286953|NCT03977974|Placebo Comparator|Placebo - Part B|Placebo administered once orally on consecutive days.
33286954|NCT00955565|Experimental|Navigated|
33286955|NCT00955565|Active Comparator|Conventional|
33286956|NCT03976180|Active Comparator|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
33286957|NCT03976180|Experimental|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
33286958|NCT03976180|Experimental|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
33286959|NCT03976180|Experimental|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
33286960|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
33286961|NCT01066702|Active Comparator|Microfracture|surgical intervention
33286962|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
33286963|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
33286964|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
33286965|NCT00273052|Experimental|Carvedilol Phosphate modified release formulation|
33286966|NCT00273052|Active Comparator|metoprolol succinate|
33286967|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
33286968|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
33286969|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
33286970|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
32938649|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
32938650|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
33286971|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
33286972|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
33286973|NCT01046799|Experimental|Entecavir|
33286974|NCT00290290|Active Comparator|povidone-iodine|preoperative skin preparation with povidone-iodine
33286975|NCT00290290|Experimental|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
32938651|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
32938652|NCT04941170|Active Comparator|Group (T)|receive preoperative bilateral ultrasound-guided oblique subcostal transversus abdominis plane block.
32938653|NCT04941170|Active Comparator|Group (E)|receive preoperative bilateral ultrasound-guided erector spinae plane block.
32938654|NCT05357911|Experimental|digoxin cohort|
33286976|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
33286977|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
32938655|NCT04936958||patients having had an osteomyelitis since 2017|
33286978|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
33286979|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
33286980|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
33286981|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
32956064|NCT05764759|Active Comparator|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
33286982|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
33286983|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
33286984|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
33286985|NCT00272038|Experimental|Tarceva|Tarceva 150 mg QD
33286986|NCT01047033|Active Comparator|Microcredit only|
33286987|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
33286988|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
33286989|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
33286990|NCT00271024|Experimental|Male Naltrexone|50 mg Naltrexone tablet
33286991|NCT00271024|Experimental|Female Naltrexone|Females receiving either naltrexone (50 mg)
33286992|NCT00271024|Placebo Comparator|Male Placebo|Males receiving Placebo (sugar pill)
33286993|NCT00271024|Placebo Comparator|Female Placebo|Females receiving placebo (sugar pill)
33286994|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
33286995|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
33286996|NCT04011215|Experimental|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
33286997|NCT04011215|Active Comparator|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
33286998|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
33286999|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
33287000|NCT05059457||Controlled setting: single capillary and pooled capillary and venous blood|Single drop capillary blood, pooled capillary blood, and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a controlled setting.
33287001|NCT05059457||Field setting: single capillary and venous blood|Single drop capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
33287002|NCT05059457||Field setting: pooled capillary and venous blood|Pooled capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
33287003|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
33287004|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
33287005|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
33287006|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
33287007|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
33287008|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
33287009|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
33287010|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
33287011|NCT00977951|Experimental|Intradermal avotermin|
32781833|NCT05341609|Active Comparator|Paxlovid|Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
32781834|NCT05604391|Active Comparator|Free gingival grafts to be placed apical to the gingival recession.|It is the application of free gingival graft to the apical part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
32781835|NCT05604391|Active Comparator|Free gingival grafts to be placed coronal to the gingival recession.|It is the application of free gingival graft to the coronal part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
32781836|NCT05380375||Short-course|Group with short treatment of antibiotic of <= 5 days
32781837|NCT05380375||Very short-course|Group with short treatment of antibiotic of <= 3 days
32781838|NCT05565079|Experimental|Coronally positioned tunnel with AlloDerm RTM and Enamel Matrix Derivative|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons) and a porcine derived enamel matrix derivative (Emdogain, Straumann).
32781839|NCT05565079|Active Comparator|Coronally positioned tunnel with AlloDerm RTM|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons).
32781840|NCT05564611|Experimental|ADL-018|150 mg single dose Lyophilized vial
32781841|NCT05564611|Active Comparator|US-Licensed XOLAIR|150 mg single dose Lyophilized vial
32781842|NCT05341453|Active Comparator|Individual physiotherapy (SMA-SOC)|Individual physiotherapy will be performed according to the recommended SMA-SOC guidelines.
32781843|NCT05341453|Experimental|Hippotherapy by the children with cerebral palsy|Hippotherapy by the children with cerebral palsy is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators assume its effect for children with SMA.
32781844|NCT05341453|Other|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA.
32781845|NCT05538013||obese women|The study will consist of 70 obese women volunteers aged between 18-65 years.
32781846|NCT05534269|Experimental|Low dose|Already human tested low dose from phase I study
32781847|NCT05534269|Experimental|High dose|First in human dose used for efficacy reasons during phase II
32781848|NCT05371015|Experimental|quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine)|The subjects would have quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine) after vaginal delivery.
32781849|NCT05371015|Placebo Comparator|quadratus lumborum nerve block with normal saline|The subjects would have quadratus lumborum nerve block with normal saline after vaginal delivery.
32781850|NCT05370391|Experimental|Comprehensive Behavioral Intervention for Tics (CBIT)|"Experimental: Comprehensive Behavioral Intervention for Tics (CBIT) Group~Participants in this group will receive the CBIT intervention for up to 6 weeks."
32781851|NCT05598463|Experimental|Augmented reality and wearable sensor-based home rehabilitation exercise|Experimental group performs augmented reality and wearable sensor-based home rehabilitation exercise for 4 weeks. And then, their exercise compliance is monitored by medical staff.
32781852|NCT05598463|No Intervention|Control group|Control group is asked to maintain their own physical activity amount, not involve the regular exercise program additionally for 4 weeks after enrollment.
32781853|NCT05370079|Other|Control cohort|Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
32781854|NCT05340907|No Intervention|Patient undergoing Bronchoscopy without use of VR device|patients undergoing flexible bronchoscopy without the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
33084868|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
33084869|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
33084870|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
32781855|NCT05340907|Experimental|Patient Undergoing Bronchoscopy with the use of VR device|patients undergoing flexible bronchoscopy with the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
32781856|NCT05309161|Placebo Comparator|A group (placebo)|Placebo
32781857|NCT05309161|Active Comparator|B group (experimental)|Crassocephalum rabens extract
32781858|NCT05339659|Active Comparator|Control|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking.
32781859|NCT05339659|Experimental|Experimental|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking + additional experimental content targeted to smokers living with HIV who are ambivalent about quitting smoking.
32781860|NCT05308069|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
33084871|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
32781861|NCT05308069|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
32781862|NCT05509933|Experimental|Budesonide|
32781863|NCT05509933|No Intervention|nothing|
33084872|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
33084873|NCT04669405|Active Comparator|HILT group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving high intensity laser therapy.
33084874|NCT04669405|Other|Control group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving exercise.
33287012|NCT00977951|Placebo Comparator|Placebo (vehicle)|
32781864|NCT05369533|Active Comparator|Telerehabilitation + Sinemet|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Sinemet is taken one hour before starting TR, for the first 18 sessions.
33084875|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
33084876|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
33084877|NCT00556348|Experimental|1|
33287013|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
33287014|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
33287015|NCT00457392|Experimental|1|
33287016|NCT00457392|Active Comparator|2|
33287017|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
33084878|NCT04556539|Experimental|SC10914 group|
33287018|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
33287019|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
33287020|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
33287021|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
33287022|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
33287023|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
33287024|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
33287025|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
33287026|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
33287027|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
33287028|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
33287029|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
33287030|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
33287031|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor~Switch NRTI backbone to maraviroc 150 mg bid"
33287032|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
33287033|NCT04007549|Experimental|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
33287034|NCT04007549|Active Comparator|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
33287035|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
33287036|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
33287037|NCT05057585|Experimental|Exercise group|Each patient in the experimental group was given in-bed exercises for 15 minutes. An anxiety questionnaire was asked to both the experimental and control groups. It was expected that both the experimental and control group patients would be stable in the postoperative period. The same exercises were applied again for 15 minutes to the patients who were stable after the surgery. Then the patients were made to take steps around the bed. Pain levels were measured.
33287038|NCT05057585|No Intervention|No treatment group|Apart from clinical protocols, no application was made in patient follow-up. Anxiety scale was filled and pain level was evaluated. Pain and anxiety scales were refilled within the same period without any application.
33287039|NCT03935867|Experimental|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
33287040|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
33287041|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
33084879|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
32781865|NCT05369533|Placebo Comparator|Telerehabilitation + Placebo|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Placebo is taken one hour before starting TR, for the first 18 sessions.
33084880|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
32781866|NCT05369533|No Intervention|Usual care|Participants in the usual care group will receive no TR or study pill, but will continue with the recommendations made by their care team. All participants will be offered TR at the end of the study.
32781867|NCT05368519|Experimental|Right chest with Brijjit® FMTB|Patients will be assigned to have their right chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
32781868|NCT05368519|Experimental|Left chest with Brijjit® FMTB|Patients will be assigned to have their left chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
32781869|NCT05338333|Other|LID210464, then AOHG MF|Lehfilcon A multifocal contact lenses (LID210464) worn in Period 1, with lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
32781870|NCT05338333|Other|AOHG MF, then LID210464|Lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 1, with lehfilcon A multifocal contact lenses (LID210464) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
32781871|NCT04255693|Experimental|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
32781872|NCT04255693|Active Comparator|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
32781873|NCT05564221|Experimental|YH35324|"There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 2 (Q2W), 4 (Q2W), 4 (Q4W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4).~YH35324 and placebo will be administered in a double-blinded manner."
32781874|NCT05564221|Placebo Comparator|Placebo|"There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 2 (Q2W), 4 (Q2W), 4 (Q4W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4).~YH35324 and placebo will be administered in a double-blinded manner."
32781875|NCT05564221|Active Comparator|Omalizumab|For Cohort 4, omalizumab 300 mg will be administered in an open-label manner.
32781876|NCT04248595|Experimental|Azacitidine plus HAG|"Patients of de novo or relapsed AML(age≥60y or ineligibility to receive intensive chemotherapy) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), the AZA+HAG regimen was further given 4-6 cycles and followed by azacitidine maintenance or until the disease progresses.~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
32781877|NCT04248595|Experimental|Azacitidine plus HIA|"Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy. After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
32781878|NCT04248595|Experimental|Azacitidine plus HDA|"Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HDA -Homoharringtonie, Cytarabine, Daunorubicin"
32781879|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
32781880|NCT05337709|Experimental|treatment group|Patients from the pharmacies assigned as treatment group will receive intervention. Intervention are education (aid with leaflet and video) and medication review with counselling.
32781881|NCT05337709|No Intervention|control group|Patients from the pharmacies assigned as control group will receive as usual care they have been provided regularly.
32781882|NCT05306509|Experimental|Nurse-initiated conversations for early integration of palliative care (NiCE)|Participants will receive nurse-initiated conversations facilitating early integration of palliative care in pediatric oncology.
33084881|NCT04556422|Active Comparator|Sauna alone|Sauna exposure for 30 minutes
33084882|NCT04556422|Experimental|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
33084883|NCT04669483||Intervention group (post-interruption)|Patients receive evidence-based informed consent forms for total knee arthroplasty and related anaesthesia procedures
33084884|NCT04669483||Control group (pre-interruption)|Patients receive standard consent forms (of the study centre) for total knee arthroplasty and related anaesthesia procedures
33084885|NCT04552093|Experimental|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
33084886|NCT00260676|Other|conventional ventilation, protective ventilation|
33402217|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
33287042|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
33287043|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
33287044|NCT00981851|Placebo Comparator|placebo inhalation|
33287045|NCT00978575|Active Comparator|Intravenous iron|
33287046|NCT00978575|Active Comparator|Oral iron|
33287047|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
33287048|NCT04007315|Experimental|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
33287049|NCT04007315|Active Comparator|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
33287050|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
33287051|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
33287052|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
33287053|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
33287054|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
33287055|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
33287056|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
33287057|NCT02688777|Experimental|Immediate Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training immediately following baseline assessment.
33287058|NCT02688777|Active Comparator|Delayed Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training at 1-year post-strokeD
33287059|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
33287060|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
33287061|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
33287062|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
33287063|NCT00978809|No Intervention|control|healthy volunteers.
33287064|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
33287065|NCT00956033||Patients with multiple myeloma|
33287066|NCT00978887|Experimental|A|Retorna (facial cream)
33287067|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
33287068|NCT04891445|Active Comparator|As usual|"Patients will be directly referred to their family doctor with a report on the data obtained in the analysis (presence of HCV and positive viral load), so that they can follow the usual treatment (as usual) in these cases in the Andalusian Health Service.~The usual treatment implies, once the presence of Virus C has been confirmed, referral by the patient's family doctor to the specialized service, in this case the Gastroenterology Service of the referral Hospital, through the usual appointment procedure. Generally the delay in this process is usually approx. 2-3 months for the first appointment."
33287069|NCT04891445|Experimental|Nurse-Navigation Programme|"A Clinical Pathway (CP) of nursing monitoring will be activated, that is, patients will be accompanied throughout the evaluation and treatment process until their complete cure is guaranteed.~CP will include the activation of care in the Gastroenterology Service by the nurse. By requesting a first appointment in the Gastroenterology Service, via email, the nurse will activate the patients' access to this first appointment, which consist in a one-step intervention: liver evaluation analysis on the genotype, determine the most appropriate type of treatment and, dispensing treatment by the Hospital Pharmacy Unit. To guarantee attendance, in all cases the patient will be accompanied, either by a competent available family caregiver, or by the mental health nursing team.~All the intervention will be operationalized through the mentioned CP developed for this purpose, with the participation of those involved."
33287070|NCT04007237|Experimental|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
33287071|NCT04007237|Active Comparator|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
33287072|NCT00293722||Patients with Psoriatic Arthritis|
33287073|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
33287074|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
33084887|NCT04556110|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
33084888|NCT04556110|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
33084889|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
33084890|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
33084891|NCT04556227|Experimental|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
33084892|NCT04556227|No Intervention|Usual Care|After discharge from the hospital the group will complete baseline activies.
33287075|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
33287076|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
33287077|NCT00448812|Experimental|Alair Treatment|Subjects from PREDECESSOR STUDY (NCT00214526) treated with conventional therapy with ICS+LABA (inhaled corticosteroid + long-acting beta-agonist) plus Bronchial Thermoplasty with the Alair System.
33287078|NCT00448812|No Intervention|Control|Control group subjects from PREDECESSOR STUDY (NCT00214526).
33287079|NCT00364689|Experimental|lactulose given with a placebo (sugar pill)|
33287080|NCT00364689|Experimental|lactulose given with rifaximin|
33287081|NCT00364689|Active Comparator|rifaximin given alone|
33287082|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
33287083|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
33287084|NCT05279339|No Intervention|Control|Participants will not perform any exercise
33287085|NCT05279339|Experimental|Exercise|Participants will perform an exercise recommended for preventing neck and shoulder pain
33287086|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
33287087|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
33287088|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
33287089|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
33287090|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
33287091|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
33287092|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
33287093|NCT00978965||All patients|
33287094|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
33287095|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
33287096|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
33287097|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
33287098|NCT00982475|Active Comparator|PVI with robotic navigation|
33287099|NCT00982475|Placebo Comparator|PVI manually|
33287100|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
33287101|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
33287102|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
33287103|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
33287104|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
33287105|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
33287106|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
33287107|NCT00979511|Experimental|3Low-Calcium with exercise|
33287108|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
33287109|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
33287110|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
33287111|NCT00984581|Experimental|Intradermal avotermin|
33287112|NCT00984581|Placebo Comparator|Placebo|
33287113|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
33287114|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
32956065|NCT05764746|Experimental|Artemether-lumefantrine followed by artesunate amodiaquine|a standard 3-days dosage, twice a day course of Artemether-Lumefantrine (20/120mg) immediately followed by a standard 3-days, once a day course of Artesunate-Amodiaquine (40base)
33287115|NCT04007003|Experimental|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
33287116|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
32956066|NCT05764746|Experimental|Artemether-lumefantrine with Amodiaquine|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) given together with Amodiaquine hydrocloride(40 base) followed by placebo for another 3 days;
33084893|NCT04556032|Experimental|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
33287117|NCT04007081|Experimental|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
33287118|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
33287119|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
33287120|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
33287121|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
33287122|NCT00982787|Experimental|1|
33287123|NCT00982787|Placebo Comparator|2|
33287124|NCT00956345|Experimental|25U/kg|
33287125|NCT00956345|Experimental|50U/kg|
33287126|NCT00956345|Experimental|100U/kg|
33287127|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
33287128|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
33287129|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
33287130|NCT01047579|Other|Rivastigmine transdermal|
33287131|NCT04006847|Experimental|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
33287132|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
33287133|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
33287134|NCT00984893||Zoledronic acid|
32956067|NCT05764746|Active Comparator|Artemether-Lumefantrine alone|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) followed by placebo for another 3 days
32956068|NCT05764720|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
32956069|NCT05764707|Experimental|Intravenous Acetaminophen|Intravenous acetaminophen (1000mg) will be administered within 30 minutes of skin closure.
32956070|NCT05764707|Placebo Comparator|Intravenous Placebo|Intravenous normal saline will be administered within 30 minutes of skin closure.
33287135|NCT00984893||Oral Bisphosphonates|
33287136|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
33287137|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
33287138|NCT00983021|Experimental|A|
33287139|NCT00983021|Experimental|B|
33287140|NCT00983021|Active Comparator|C|
33287141|NCT00983021|Experimental|D|
33287142|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
33287143|NCT00984971|Experimental|Tenofovir|
33287144|NCT00984971|Placebo Comparator|HEC Placebo|
32781883|NCT05306509|Other|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
32781884|NCT05367037|Active Comparator|PhysioVP group|Physiological ventricular pacing
32781885|NCT05367037|Active Comparator|DDD-VPA group|Dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance
32781886|NCT05337397||Prior pTa low grade Non-Muscle invasive bladder cancer|Patient with recurrent Pta low grade Non-Muscle invasive bladder cancer, with negative urine cytology, and tumor size between 1 and 3 cm.
32781887|NCT05337241|Experimental|Single arm treatment|All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.
32781888|NCT05335993|Experimental|Combination of Oregovomab and Niraparib|"Niraparib (300/200 mg) will be administered orally once daily.~Oregovomab (2 mg) will be administered via IV infusion on Day 1 of Week 1, Week 4, Week 7, Week 12, and Week 20."
32781889|NCT05366335|Experimental|Live Combined Bifidobacterium and Lactobacillus|The experimental group receive basic treatment and a single infusion of Live Combined Bifidobacterium and Lactobacillus solution through colonoscopy.
32781890|NCT05366335|Placebo Comparator|Control|The control group receive basic treatment and a single injection of normal saline through colonoscopy.
32781891|NCT05507125||Control|Participants without inflammatory skin disease
32781892|NCT05507125||Patients with HS|Patients with HS
32781893|NCT05530915|Experimental|Active capsule 1: Lower dose guayusa ingredient|Oral administration of 175 mg guayusa extract providing 35 mg caffeine
32781894|NCT05530915|Experimental|Active capsule 2: Higher dose guayusa ingredient|Oral administration of 300 mg guayusa extract providing 60 mg caffeine
32781895|NCT05530915|Placebo Comparator|Placebo capsule|Oral administration of 0 mg guayusa extract, 0 mg caffeine. Capsule color-matched to actives 1 and 2 to disguise potential differences in color of contents.
32781896|NCT05305105|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including two doses of psilocybin with psychological support administered approximately 2 weeks apart.
32781897|NCT05304949||Lucentis|Patients prescribed with Lucentis
32781898|NCT05304871|Placebo Comparator|placebo|patients receive saline infusion prior to port placement
32781899|NCT05304871|Experimental|antibiotic|patients receive antibiotic (Cefazolin 2 g) infusion prior to port placement
32781900|NCT05365399|Other|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
32781901|NCT05365243|Experimental|Interventional|All patients will use AMMA
32781902|NCT05334277|Experimental|Group A: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
32781903|NCT05334277|Experimental|Group B1: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
32781904|NCT05334277|Experimental|Group B2: Furmonertinib plus chemotherapy|Furmonertinib 80 mg QD and platinum-based chemotherapy All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
32781905|NCT05334277|Experimental|Group B3: Furmonertinib plus chemotherapy and bevacizumab|Furmonertinib 80 mg QD plus platinum-based chemotherapy and bevacizumab All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
32781906|NCT05303935|Experimental|Quetiapine|Quetiapine 50mg in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
32781907|NCT05303935|Placebo Comparator|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
32781908|NCT05363527|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
32781909|NCT05363527|Placebo Comparator|Placebo|same volume of 0.9% saline
32781910|NCT05363371|Experimental|Mindfulness based relapse prevention and peer mentoring|Treatment will utilize a group format. The twelve-week mindfulness based relapsed prevention group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, followed by group sessions led by peer mentors for an additional four weeks.
32781911|NCT05363371|Active Comparator|12 Step Treatment Program|Participants in the attentional control group will attend 12 weeks of a enhanced 12 step treatment program.
32781912|NCT05363137|Experimental|Experimental|
32781913|NCT05363137|Active Comparator|Control|
32781914|NCT05332873|Experimental|Rivet Shunt Therapy|
33084894|NCT04556032|Experimental|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
32781915|NCT05332717|Experimental|Melatonin Group (Experimental)|Patients who will take one (1) 5mg Melatonin tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
32781916|NCT05332717|Sham Comparator|Placebo Group (Control)|Patients who will take one (1) placebo (Vitamin C) tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
32781917|NCT05332405|Experimental|Study Group|Participants will have planned surgical procedure to repair the median or ulnar nerve compression. During the procedure, the doctor will administer a small injection of indocyanine green (ICG) and laser angiography using the SPY Elite device will be used to evaluate blood flow and extent of nerve decompression at the surgical site. Participation will also involve filling out two questionnaires on pain and function level and an examination of hand strength and range of motion.
33084895|NCT04556032|Placebo Comparator|Placebo|Participants will receive placebo orally once daily for 16 weeks.
33084896|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
33084897|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
33084898|NCT04556071|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
32781918|NCT05360719|Experimental|Group Tele-exercise Class|Volunteers will be asked to participate in the group online exercise class 2 times per week for 8 weeks. Each activity session will last about 60 minutes and will focus on mind-body practices, tailored to physical and emotional needs of individuals with SCI. Class will be taught by a physical therapist who is an experienced community exercise instructor. Class will be co-led by a person who is living with SCI (one of our community partners). Classes will take place over a secure virtual platform (Zoom). Before beginning and after completion of the program, participants will be asked to participate in small group interviews to share expectations and experiences of the study
32781919|NCT05360719|Other|Waitlist Control|The waitlist control group will complete all quantitative measures as a baseline (baseline-control) and will be instructed to continue their activities as usual, with measures obtained again at 8-weeks (post-control/pre-program). Following the initial 8-week baseline, each waitlist group will participate in pre-intervention semi-structured interview or small focus group with the post-control measures as pre-intervention assessment. They will join the tele-exercise intervention with all measures at 8-weeks (post-intervention) and with leisure time physical activity and quality of life assessed at 16-weeks following initiation of the program.
32781920|NCT05506813|Experimental|experimental group|cognitive training and conventional training
32938656|NCT05355883|Experimental|Remote Ischemic Conditioning (RIC)|"RIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 250 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~Hand Arm Bimanual Intensive Therapy (HABIT)~Bimanual cup stacking training~Balance training"
32938657|NCT05355883|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~Hand Arm Bimanual Intensive Therapy (HABIT)~Bimanual cup stacking training~Balance training"
32938658|NCT04911920|Other|Patients with lateral epicondylitis|Patients with lateral epicondylitis who are treated with at least one ACP injection.
32938659|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
32938660|NCT04848272|Placebo Comparator|Saline control|Saline control
32938661|NCT04848272|Experimental|Lanadelumab 30 mg|Lanadelumab 30 mg
32781921|NCT05506813|Active Comparator|control group|motor dual task training and conventional training
32781922|NCT05300737||Symptomatic carotid stenosis with low risk features|50-99% symptomatic carotid stenosis with low clinical or radiologic risk features (see inclusion criteria) Patients will receive intensive medical therapy, including dual antiplatelet therapy, high potency statins, BP control, and lifestyle modification
32781923|NCT05300503|No Intervention|Control|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the standard video & education session on managing hypertension. They will watch the video at home on their own time. Participants will use a home blood pressure monitor to track their blood pressure (those without a blood pressure cuff will be provided one) for the 3-month intervention period. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160). They will be encouraged to track their blood pressure daily and any symptoms they may be feeling.
32781924|NCT05300503|Experimental|Intervention|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the educational session described above in the control group section. They will receive an Aetonix aTouchAway platform monitor, which is a disease specific home monitoring device to take home for 3 month intervention period. The device will prompt the participant to check their blood pressure on a daily basis and will send all readings to the UOHI Telehome monitoring program. The telehome monitoring nursing team will monitor the readings for each participant. For hypertensive patients who are not at target with their BP, the telehome monitoring nurse will titrate medications based on an advanced medical directive every 2 weeks. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160).
32781925|NCT05300269|Experimental|Perioperative treatment|Eligible subjects will receive standard chemoradiotherapy with SHR-1701 followed by XELOX combined with SHR-1701 and surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.
32781926|NCT05358301|Experimental|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l.
32781927|NCT05358301|Placebo Comparator|Placebo|Placebo food supplement.
32781928|NCT05329285|Experimental|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
32781929|NCT05329285|No Intervention|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
32781930|NCT05327959|Experimental|Treatment Group|The population target is all subjects suffering clavicle fracture suitable for open reduction and internal fixation by the A.L.P.S. Clavicle Plating System in accordance with the IFU.
32938662|NCT04848272|Experimental|Lanadelumab 100 mg|Lanadelumab 100 mg
32938663|NCT04848272|Experimental|Lanadelumab 300 mg|Lanadelumab 300 mg
32938664|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
32938665|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
32938666|NCT04823156|Experimental|Calcium Supplementation|1000 mg of calcium carbonate one hour before exercise
32938667|NCT04823156|No Intervention|No Calcium Supplementation|No calcium supplementation
32938668|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
32938669|NCT05355571|Active Comparator|Active|Participants will consume a probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day for 10 days alongside an oral antibiotic at standard dosage administered for fixed period
32938670|NCT05355571|Placebo Comparator|Placebo|Participants will consume a placebo alongside an oral antibiotic at standard dosage administered for fixed period
33287145|NCT00984971|Other|Open label tenofovir tablet|
33287146|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
33287147|NCT04661423|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last between 5 and 7 days during the post-ICU hospitalization, at rest and during rehabilitation exercises.
33287148|NCT04812899|Experimental|Parents who have a child/adolescent with an eating disorder on waitlist|"Each participant will receive a series of pre-recorded videos and book -(10 videos of about 10 minutes each, along with the book Help Your Teenager Beat an Eating Disorder). This will include content on empowering parents to renourish their child and interrupt binge/purge behaviors."
33287149|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
33287150|NCT00289978|Experimental|Fingolimod 1.25 mg|
33287151|NCT00289978|Experimental|Fingolimod 0.5 mg|
33287152|NCT00289978|Placebo Comparator|Placebo|
33287153|NCT00983177|Active Comparator|colchicine|
33287154|NCT00983177|Placebo Comparator|Lactose capsule|
33287155|NCT04862897||Patient-controlled admissions|Patients who have been granted access to patient-controlled admissions and agreed to its use with inpatient care and outpatient care
33287156|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
32781931|NCT05356273|Experimental|Massage Group|The incubator temperature was adjusted between 28-30 C, and it was administered while the baby was awake and one hour after feeding. Before the massage, the hands were washed and warmed. Just before each phototherapy application, 10-minute baby massage was performed by the researcher.Then phototherapy was applied.
32781932|NCT05356273|No Intervention|Control Group|Just received phototherapy twice a day
32781933|NCT05299177|Experimental|Automated Insulin Delivery|The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).
32781934|NCT05327569|Experimental|Experimental group|"xperimental group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. In addition to the conventional physiotherapy program, myofascial chain release techniques will be applied to this group.~Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.~Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
32781935|NCT05327569|No Intervention|Control group|"Control group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. Only conventional physiotherapy program will be applied to this group.~Conventional treatment will consist of muscle strengthening, stretching exercises and patellar mobilization. The muscle groups to be strengthened are: M. gluteus maximus, M. gluteus medius, M. Quadriceps, Core group of muscles. The muscle groups and tendons to be stretched are: M. Hamstrings, achilles tendon and iliotibial band. The exercises will be performed as 10 repetitions and 3 sets. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
32781936|NCT04254367|Experimental|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
32781937|NCT04254367|No Intervention|TAU - no intervention|Treatment as usual following local routines on each primary care center
32781938|NCT04253899|Active Comparator|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
32938671|NCT04520906|Experimental|single-arm|Subjects will be treated with microwave ablation.
33287157|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
33287158|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
33287159|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
33287160|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
33287161|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
33287162|NCT05279261|Experimental|Experimental group|Undergo the axillary approach
33287163|NCT00983333|Experimental|Web-based communication tool for health care professionals|
33287164|NCT00983333|Experimental|Web-based communication training tool for patients|
33287165|NCT00983333|No Intervention|Usual care for patient participants|
33287166|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
33287167|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
33287168|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
33287169|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
32938672|NCT04512560|Experimental|Structured Remote Surgical Coaching|Participants randomized to the intervention group will participate in a 3-month SRSC program in addition to CST. Participants will be asked to provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon prior to the coaching session. Each coach will review the video recording and will identify key themes for discussion. Coaching sessions will be structured using the modified PRACTICE model, will be conducted outside of the clinical environment, and will employ facilitative coaching methods to encourage participants to define specific intra-operative problems and conceptually troubleshoot various solutions.
32938673|NCT04512560|Active Comparator|Conventional Surgical Training|Participants randomized to the control group will continue of their usual general surgery residency training including attending scheduled teaching sessions, and continuing with assigned responsibilities on the ward and in the OR.
33287170|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
33402218|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
32781939|NCT04253899|Experimental|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
32781940|NCT04253899|Active Comparator|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
32781941|NCT04253899|Experimental|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
32781942|NCT05326945|No Intervention|Measurement without sheath|"Sample A: Investigator will take culture from the inside of the BPC, which will contact the patient's right upper arm, wearing sterile gloves, and will remove the gloves.~B:Investigator will wipe the right upper arm area of the patient with (70% alcohol+2% chlorhexidine) solution in accordance after wearing sterile gloves, wait for 30 seconds and after the alcohol dries investigator will take culture from the patient's right upper arm, wearing a new sterile glove.~C:investigator will measure ABP on the right upper arm of the patient with the same sterile glove, and after the measurement, the first investigator will take culture from the patient's right upper arm by wearing a new sterile glove, both researchers will remove the gloves.~D:investigator wore a new sterile glove after ABP measurement and wiped the inside and outside of the BPC with solution, the first investigator would wear a new sterile glove to take culture, both researchers will remove the gloves."
32781943|NCT05326945|Experimental|Sheathed Measurement|"Sample E: DCC sterile package will be opened the investigator will hold the sphygmomanometer, after investigator wears sterile gloves, DCC will put it cuff of the same cuff. Culture will be taken investigator from the inside of the DCC that will contact the patient's left upper arm, before the ABP measurement, the first investigator will remove the gloves.~F:Sterile gloves will be worn by the investigator and the left upper arm area of the patient will be wiped with solution before the ABP measurement wait 30 seconds, and after the solution dries, the first investigator will use a new sterile After wearing gloves, he will take a swab culture from the left upper arm region.~G:The investigator will measure ABP from the patient's left upper arm with the same glove, and after the measurement, the first investigator will take culture from the patient's left upper arm after wearing a new sterile glove.~Culture results taken from the patients will be compared statistically."
32781944|NCT05298319|Experimental|Group 1|10 L/min of oxygen flow
32781945|NCT05298319|Experimental|Group 2|20 L/min of oxygen flow
32781946|NCT05298319|Experimental|Group 3|30 L/min of oxygen flow
32781947|NCT05298319|Experimental|Group 4|40 L/min of oxygen flow
32781948|NCT05298319|Experimental|Group 5|50 L/min of oxygen flow
32781949|NCT05298319|Experimental|Group 6|60 L/min of oxygen flow
32781950|NCT05325853|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
32781951|NCT05325853|Active Comparator|Proparacaine|0.5% Proparacaine Hydrochloride
32781952|NCT05354167|Experimental|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session.
32781953|NCT05354167|Experimental|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow. This technique was repeated until there were no tender points on palpation. The duration varied from 30 seconds to 2 minutes.
32781954|NCT05353933|Experimental|TEA + PPI|Thread embedding acupuncture (TEA) every 2 weeks in 4 weeks (twice). Combined with oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
32781955|NCT05353933|Active Comparator|PPI|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
32781956|NCT05325463|Experimental|conventional|
32781957|NCT05325463|Active Comparator|ultrasound- guided|
32781958|NCT05353855||Early unmedicated PD patients converted from iRBD|"Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Having a diagnosis of PD confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank.~Onset of PD motor symptoms of < 3 years;~In view of the heterogeneity of PD, the investigator will only include those patients with RBD preceding the onset of motor symptoms of PD.~Drug naïve (dopaminergic medications have not been started)"
32781959|NCT05353855||Early medicated PD patients converted from iRBD|Inclusion criteria will be the same as that of early unmedicated PD except that they should be on dopaminergic medications.
32938674|NCT04736719||Warfarin|Reference group
33287171|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
33287172|NCT00983567|Experimental|Teen web|Main web - with all components
33287173|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
33287174|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
33287175|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
33287176|NCT00289900|Experimental|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
33287177|NCT00289900|Experimental|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
33287178|NCT00289900|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
33287179|NCT00289900|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
33287180|NCT00289900|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
33287181|NCT00289900|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
33287182|NCT01067014||iO-Flex|
33287183|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
33287184|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
33287185|NCT00985361|Experimental|Vitamin D 2000 international units daily|
33287186|NCT00985361|Active Comparator|Vitamin C 500mg daily|
32938675|NCT04736719||Apixaban|Exposure group
33084899|NCT04563871|Experimental|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
33287187|NCT04006613|Experimental|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
33287188|NCT04006613|Active Comparator|Usual Care|Unstructured intervention to improve mobility and balance
33287189|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
33287190|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
33287191|NCT00984113|Experimental|A-Patients with mild renal impairment|
33287192|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
33287193|NCT00984113|Experimental|C-Patients with moderate renal impairment|
33287194|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
33287195|NCT00984113|Experimental|E-Patients with severe renal impairment|
33287196|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
33287197|NCT00269152|Experimental|A: Pemetrexed + Cisplatin|
33287198|NCT00269152|Experimental|B: Pemetrexed + Carboplatin|
33287199|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
33287200|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
33287201|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
33287202|NCT01325740|Active Comparator|STX107 10 mg|
33287203|NCT01325740|Placebo Comparator|Placebo|
33287204|NCT01325740|Active Comparator|STX107 30 mg|
33287205|NCT03975166|Experimental|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
33287206|NCT03975166|Active Comparator|Reference Product|ADVAIR DISKUS® 100/50
33287207|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
33287208|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
33287209|NCT03976024|Experimental|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
33287210|NCT03976024|Active Comparator|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
33287211|NCT01067170|Experimental|Pneumatic compression stockings|
33287212|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin~Active Comparator Drug:rosuvastatin"
33287213|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
33287214|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
32938676|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
32938677|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
33287215|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
33287216|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
33287217|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
33287218|NCT00371787|Experimental|soft contact lens|
33287219|NCT00371787|No Intervention|non-lens wear|control group
32781960|NCT05353855||iRBD patients|"Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Having a diagnosis of RBD according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
32938678|NCT04736563|Experimental|patients with painful arthritis of the knee|Administration of joints and muscle gel Puressentiel containing of 14 essential oils
32938679|NCT04736797||Patient|Transgender people who seek hormone treatment
32938680|NCT04736797||Control participants|volunteers without gender dysphoria
32938681|NCT04429646|Experimental|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
32938682|NCT04429646|Active Comparator|Watchman (control)|Intervention device, Watchman® LAA Closure Device
32938683|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
32938684|NCT04736407||Repositioned|Allocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
32938685|NCT04736407||Non-repositioned|Allocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
32938686|NCT04809740|Other|Patient Group|7,500 Patients from UAB/MCI
32938687|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
32938688|NCT04736108|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before radical prostatectomy
32938689|NCT05344885|Active Comparator|DPT-standard|A standard digital parent training intervention
32938690|NCT05344885|Experimental|DPT-Enhanced|Enhanced digital parent training intervention
32781961|NCT05353855||Healthy controls|"Age-and sex-matched with the groups;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of self-report dream enactment behaviors and RSWA as measured by v-PSG."
33287220|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
33287221|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
33287222|NCT00268996|Experimental|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
33287223|NCT00268996|Placebo Comparator|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
33287224|NCT00268996|Experimental|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
33287225|NCT00268996|Placebo Comparator|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
33287226|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
33287227|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
33287228|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
33287229|NCT03975244|Experimental|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
33287230|NCT03975244|No Intervention|Control group|The control group only will perform the evaluations of the study.
33287231|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
33287232|NCT03977506|Experimental|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
33287233|NCT00289198|Experimental|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
33287234|NCT00289198|Placebo Comparator|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
33287235|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
33287236|NCT01067482||Glaucoma patients|
33287237|NCT01067482||Glaucoma suspect group|
33287238|NCT01067482||Normal population|
33287239|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
33287240|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
33287241|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
33287242|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
33287243|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
33287244|NCT03992391|No Intervention|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
33287245|NCT03992391|Experimental|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
33287246|NCT03992391|Experimental|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
33287247|NCT01047657|Experimental|weight loss|
33287248|NCT01047657|No Intervention|Control|
33287249|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
33287250|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
33287251|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
32781962|NCT05325307|Experimental|Acupressure Group (experimental)|The experimental group will be given acupressure.
32781963|NCT05325307|Placebo Comparator|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure
32781964|NCT05352685|Active Comparator|Healthy volunteers|
32781965|NCT05352685|Experimental|supratentorial glioma patients|
33287252|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
33287253|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
33287254|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
33287255|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
33287256|NCT02346747|Active Comparator|Group A|Group A will receive 1.0 x 10e7 cells of gene transfected, irradiated, autologous tumor cells via intradermal injection once a month.
32781966|NCT04249687|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
33287257|NCT02346747|Placebo Comparator|Group B|"Group B will receive freeze media (10% DMSO, 1% human serum albumin in Plasma-Lyte) via intradermal injection once a month."
33287258|NCT01047891|Experimental|Experimental|
33287259|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
33287260|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
33287261|NCT03831945|Active Comparator|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
33287262|NCT03831945|Placebo Comparator|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
33287263|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
33287264|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
33287265|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
33287266|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
33287267|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
33287268|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
33287269|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
33287270|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
33287271|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
33287272|NCT00362115|Placebo Comparator|Placebo QD|
33287273|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
33287274|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
33287275|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
33287276|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
33287277|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
33287278|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
33287279|NCT00293254|Experimental|1|raltegravir potassium
33287280|NCT00293254|Placebo Comparator|2|Placebo
33287281|NCT01018784|Experimental|MORAb-009|
33287282|NCT01018940||Plavix|
33287283|NCT01018940||Prasugrel|
33287284|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
33287285|NCT01019018|Experimental|Olive tip|Olive tip group
33287286|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
32781967|NCT04249687|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
32938691|NCT04736329|Active Comparator|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
33287287|NCT04498611|Experimental|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
33287288|NCT03975010|Experimental|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
33287289|NCT03975010|Experimental|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
33402219|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
33402220|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
32781968|NCT05561647||GATTEX: Participants|Participants who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in this Risk Evaluation and Mitigation Strategy (REMS) survey for up to 10 years via internet, telephone, and paper.
32781969|NCT05561647||GATTEX: Healthcare Providers (Prescribers)|HCPs (adult and pediatric) in the United States (US) who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training are eligible for participation in this REMS survey for up to 10 years via internet, telephone, and paper.
32781970|NCT05323045|Experimental|BYON3521|c-MET targeting Antibody-Drug Conjugate
32781971|NCT05351749|Experimental|New-prescription Alert / Existing-prescription notification to prescriber|
32781972|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber|
32781973|NCT05351749|Experimental|New-prescription Alert/ Existing-prescription notification to pharmacist|
32781974|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist|
32781975|NCT05351593|Experimental|Phase 1 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle.
32781976|NCT05351593|Experimental|Phase 2 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle at the recommended phase 2 dose.
32781977|NCT05351281|No Intervention|Standard of care|Patients in the standard of care arm will receive the usual treatment
32781978|NCT05351281|Experimental|CDSS-OPTIMED|In the experimental arm, attending physicians will receive weekly medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The CDSS-OPTIMED will send a medication advice on a weekly basis, based on a weekly analysis of patient's medication. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
32781979|NCT05351203|Active Comparator|caudal epidural group|"the patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock by betadine three times and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound linear transducer probe that is covered in sterile plastic bag . Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
32781980|NCT05351203|Experimental|Erector spinae group|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
32781981|NCT05499637|Experimental|acute cellular cardiac allograft rejection|[68Ga]Ga-PentixaFor PET/CT
32781982|NCT05499637|Experimental|cardiac sarcoidosis|[68Ga]Ga-PentixaFor PET/CT
32781983|NCT05499637|Experimental|immune checkpoint inhibitor induced myocarditis|[68Ga]Ga-PentixaFor PET/CT
32781984|NCT05296135||Main Cohort|
32781985|NCT05322655||infants living in low-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
32781986|NCT05322655||infants living in middle-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
32781987|NCT05322655||infants living in low-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
32781988|NCT05322655||infants living in middle-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
32781989|NCT05296057|Experimental|Participants Receiving VR-Exposure Therapy Treatment|All participants will be receiving the experimental VR-exposure therapy treatment.
32781990|NCT05295979|Experimental|Inflammatory skin disease formula (ISDF)|Subjects will receive ISDF granules (10.85g twice daily) for 12 weeks.
32781991|NCT05295979|Placebo Comparator|Placebo|Subjects will receive placebo granules (10.85g twice daily) for 12 weeks.
32781992|NCT05322343||Prospective cohort|The general population from the age of 55.
32781993|NCT05349565|Active Comparator|CONVENTIONAL PHYSICAL THERAPY|TENS , Open chain knee flexion and extension, Calf stretch , Quad set
32781994|NCT05349565|Experimental|MUSCLE ENERGY TECHNIQUE|MET ( isometric contraction with 6-10 sec )
32781995|NCT05321875|Experimental|Candesartan|Candesartan, 16 mg oral tablets. Target dose 32 mg or maximum tolerated dose after dose escalation from 16 mg
33084900|NCT04563754|Experimental|mHRME|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
33287290|NCT03975010|Experimental|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
33287291|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
33287292|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
33287293|NCT04534010|Experimental|NACgraft patients|uni- or bilateral engraftment surgery will be performed
33287294|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
33287295|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
33287296|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
33287297|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
33287298|NCT03975946|Active Comparator|the rheopheresis group|
33287299|NCT03975946|Placebo Comparator|the shamapheresis group|
33287300|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
33287301|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
33287302|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
33287303|NCT01017068|Experimental|A1 (glaucoma)|
33287304|NCT01017068|Experimental|A2 (glaucoma)|
33287305|NCT01017068|Experimental|A3 (glaucoma)|
33287306|NCT01017068|Experimental|A1 (normals)|
33287307|NCT01017068|Experimental|A2 (normals)|
33287308|NCT01017068|Experimental|A3 (normals)|
33287309|NCT04178564|Experimental|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
33287310|NCT04170608|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
33287311|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
33287312|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
33287313|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
33084901|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
33287314|NCT03324282|Experimental|Arm A: GC + avelumab group|
33084902|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
33084903|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
33084904|NCT02211157|Placebo Comparator|Placebo|
33084905|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
33084906|NCT04563364|Experimental|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
33084907|NCT04563364|Active Comparator|Control Intervention|Control group will receive a conventional treatment given by the institutions
33287315|NCT03324282|Active Comparator|Arm B: GC group|
33287316|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
33287317|NCT00448344|Other|Arm 2|Standard smoking cessation
33287318|NCT00484094||Rapamune|
33287319|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
33287320|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
33287321|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
33287322|NCT01024452|Experimental|DAWN AC|
33287323|NCT01024452|Active Comparator|Hamilton Nomogram|
33287324|NCT03995394|Experimental|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
33287325|NCT03995394|No Intervention|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
32781996|NCT05321875|Placebo Comparator|Placebo|Matching placebo. Target dose 2 tablets or maximum tolerated dose after dose escalation from 1 tablet
32781997|NCT05320237|Experimental|Virtual Reality Intervention|Eight weeks of two 30 minute sessions using virtual reality with the upper limb exercise games.
32781998|NCT05320237|No Intervention|Control Group|Participants will be asked to continue with their usual care independent of this study.
32781999|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
32782000|NCT05348005|No Intervention|No TENS unit use|All subjects will start with 3 months of no TENS use and diary tracking
32782001|NCT05348005|Active Comparator|TENS unit use|All subjects will then have 3 months of TENS use during episodes of endometriosis pain flare and diary tracking.
32782002|NCT05555875|Experimental|IntelliCare with Automated Motivational Messaging and Coach Support|IntelliCare Plus mobile application intervention with two engagement strategies, automated motivational messaging and coach support.
32782003|NCT05555875|Experimental|IntelliCare with Automated Motivational Messaging|IntelliCare Plus mobile application intervention with one engagement strategy, automated motivational messaging.
32782004|NCT05555875|Experimental|IntelliCare with Coach Support|IntelliCare Plus mobile application intervention with one engagement strategy, coach support.
32782005|NCT05555875|Active Comparator|IntelliCare Alone|IntelliCare Plus mobile application intervention with no additional engagement strategy applied.
32782006|NCT05347069|Active Comparator|Aspirin|Aspirin 100 mg/day
32782007|NCT05347069|Active Comparator|No Aspirin|No Aspirin
32782008|NCT05346367|Active Comparator|SRT (stereotactic radiotherapy)|stereotactic radiotherapy in 1 or 3 fractions of 8 Gy up to 15-24 Gy
32782009|NCT05346367|Experimental|fSRT (hypo fractionated stereotactic radiotherapy)|hypo fractionated stereotactic radiotherapy in 5 fractions of 7 Gy up to 35 Gy. Brain stem metastases 5 fractions of 6 Gy up to 30 Gy
32782010|NCT05496673|Experimental|Participants who are HIV negative|Patients who are assessed at Lira Regional Referral Hospital emergency room or are admitted to the pediatric, male or female medical wards at Lira Regional Referral Hospital with meningitis symptoms (defined as headache or irritability in combination with fever, confusion or Glasgow coma scale (GCS) <14, photophobia, neck pain/stiffness, seizure or bulging fontanel) will be approached to participate in the study.
32782011|NCT05496673|Experimental|Participants who are HIV positive, CrAg positive|All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test positive using the CrAg test will be included in this arm.
32782012|NCT05496673|Sham Comparator|Participants who are HIV positive, CrAg negative|All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test negative using the CrAg test will be included in this arm. All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test positive using the CrAg test will be included in this arm.
32782013|NCT05516953|No Intervention|Group 1(Control group)|include 50 patients scheduled for sleeve gastrectomy
32782014|NCT05516953|Experimental|Group 2|which include 50 patients scheduled for sleeve gastrectomy
32782015|NCT05294107|Experimental|Group Crohn's disease|4 additional biopsies for 30 patients with Crohn's disease
32782016|NCT05294107|Experimental|Group ulcerative colitis|4 additional biopsies for 30 patients with ulcerative colitis
32782017|NCT05294107|Active Comparator|Group No MICI|4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease
32782018|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
32782019|NCT02522767|Placebo Comparator|Placebo|Matching placebo
32782020|NCT05293717|Experimental|All Participants|You are being asked to apply topical medication called Ruxolitinib cream to your skin at home twice daily.
32782021|NCT05319847|Experimental|Intervention arm|Daily Skin Supplement - Fountain of Youth
32782022|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
32782023|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
32782024|NCT05345509|Active Comparator|Aricept Tablet|Aricept Tablet, QD, PO
32782025|NCT05345509|Experimental|IVL3003 (A mg)|SC, Single Dose
32782026|NCT05345509|Experimental|IVL3003 (B mg)|SC, Single Dose
32782027|NCT05345509|Experimental|IVL3003 (C mg)|SC, Single Dose
32782028|NCT05319613|Other|Telemedicine Clinical Care|Rural participants who enter PrEP clinical care with University of Colorado HIV Prevention Program will receive care via telemedicine with mailed lab kits and mailed HIV PrEP.
32782029|NCT05319067||Cases|Children aged 1 to 3 years with vesico ureteral reflux of grade 3 or higher, under antibiotic prophylaxis
32782030|NCT05319067||Controls|Children aged 1 to 3 years with uropathy, without antibiotic prophylaxis
32782031|NCT05319067||Healthy Controls|Healthy children aged 1 to 3 years.
32782032|NCT05318755||transgender men|People whose sex assigned at birth is female but whose self-identified gender is male.
32782033|NCT05318755||transgender women|People whose sex assigned at birth is male but whose self-identified gender is female.
32782034|NCT05318755||Healthy cisgender people|People whose sex assigned at birth corresponds with their self-identified gender.
32782035|NCT04249219|Experimental|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
32782036|NCT05553457|Experimental|MyHand-SCI Device Testing|Subjects will attend 1-20 sessions (of approximately 90 mins) to trial a variety of the MyHand-SCI device controls and/or components. Participants will practice various grasp and release activities with the device
32782037|NCT05292391|Experimental|Group A|Dose Escalation Study.0.5 mL of 100 micrograms of Sm-p80 administered intramuscularly on Days 1, 29, and 57. N=9
32782038|NCT05292391|Experimental|Group B|Dose Escalation Study.0.5 mL of 10 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9
33287326|NCT01029522|Experimental|Lipilou 20mg|
33287327|NCT01029522|Active Comparator|Lipitor 20mg|
32938692|NCT04736329|No Intervention|Enalapril|Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.
33287328|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
33287329|NCT00447876|Placebo Comparator|Placebo|
33287330|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
33287331|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
33287332|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
32938693|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
33287333|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
33287334|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
33287335|NCT03995550|Experimental|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
33287336|NCT03995550|Experimental|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
33287337|NCT03995550|Experimental|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
33287338|NCT03995550|Experimental|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
33287339|NCT03995550|Experimental|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
33287340|NCT03995550|Experimental|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
33287341|NCT03995550|Experimental|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
32938694|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
32938695|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
32938696|NCT02971033|Placebo Comparator|placebo|placebo
33287342|NCT03995550|Experimental|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
33287343|NCT03995550|Experimental|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
33287344|NCT03995550|Experimental|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
33287345|NCT03995550|Experimental|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
33287346|NCT03995550|Experimental|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
33287347|NCT03995550|Experimental|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
33287348|NCT03995550|Experimental|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
33287349|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
32938697|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
32938698|NCT02971033|Experimental|40mg/day ezetimibe|40mg/day ezetimibe
32938699|NCT05406674|Active Comparator|Arm A|Patients in Arm A are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cispaltin-based HIPEC with a dosage of 100 mg/m2
32938700|NCT05406674|Experimental|Arm B|Patients in Arm B are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cisplatin- based HIPEC with a dosage of 40 mg/L perfusate.
32938701|NCT05341375|Other|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE scale on one day before surgery, one day after surgery, and three months after surgery
32938702|NCT05341375|Experimental|Group TA|Group TA received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction
33084908|NCT04562857|Active Comparator|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
33287350|NCT00456300|Experimental|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
33287351|NCT00456300|Experimental|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
33287352|NCT00456300|Active Comparator|Insulin|Each subject received a baseline study with insulin alone
33287353|NCT00267748|Experimental|C|
33287354|NCT00267748|Experimental|A|
33287355|NCT00267202|Placebo Comparator|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
33287356|NCT00267202|Experimental|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
33287357|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
33287358|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
33287359|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
33287360|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
33287361|NCT03977116|Experimental|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
33287362|NCT03977116|Placebo Comparator|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
33287363|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
33287364|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
33287365|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
33287366|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
33287367|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
33287368|NCT00267046|Experimental|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
33287369|NCT00267046|Placebo Comparator|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);~AI = Doxorubicin (Adriamycin) + Ifosfamide:~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
33287370|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
33287371|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
33287372|NCT03305406||Focus Group Participants|Semi-structured focus groups
33287373|NCT03305406||Interview Participants|One-on-one interviews
33287374|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
33287375|NCT00441012|Active Comparator|2|COMVAX™
33287376|NCT01029678|Experimental|experimental|
33287377|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
33287378|NCT00286468|Experimental|Alogliptin 12.5 mg QD|
33287379|NCT00286468|Experimental|Alogliptin 25 mg QD|
33287380|NCT00286468|Active Comparator|Placebo|
33287381|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
33287382|NCT00507026|Active Comparator|B|IV Ketorolac
33287383|NCT00507026|Placebo Comparator|C|Placebo
33287384|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
33287385|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
33287386|NCT01029756|Active Comparator|Macintosh Laryngoscope|
33287387|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
33287388|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
33287389|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
33287390|NCT03847974|Experimental|LIB003|LIB003
33287391|NCT01011842|Experimental|radiation therapy arm|
33287392|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
33287393|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
33287394|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
33287395|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
32782039|NCT05292391|Experimental|Group C|If dose escalation halting criteria are not met in Group A and Group B, administer 0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 180. N=9.
33287396|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
33287397|NCT01017302|Experimental|1|
33287398|NCT01017302|Placebo Comparator|2|
33287399|NCT01017302|Experimental|3|
33287400|NCT01017302|Placebo Comparator|4|
33287401|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
33287402|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
33287403|NCT03976102|Experimental|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
33287404|NCT03976102|Active Comparator|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
32782040|NCT05292391|Experimental|Group D|If dose escalation halting criteria are not met in Groups A and B, administer 0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9.
33287405|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
33287406|NCT00286234|Placebo Comparator|1|Dual placebo
33287407|NCT00286234|Experimental|2|niaspan
33287408|NCT00286234|Experimental|3|lovaza
33287409|NCT00286234|Experimental|4|combined therapy
33287410|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
32782041|NCT05292391|Experimental|Group E|If dose escalation halting criteria are not met in Groups C and D, administer 0.5mL of 100 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29 and 57. N=9.
32782042|NCT05318599||IPF patients (group 1)|Consenting adult patients >18 years old with with already-diagnosed IPF
32782043|NCT05318599||NSIP patients (group 2)|Consenting adult patients >18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)
32782044|NCT05318599||COPD patients (group 3)|Consenting adult patients >18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)
32782045|NCT05318599||Control subjects (group 4)|"Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely:~patients with obstructive sleep apnea.~patients followed-up for occupational lung diseases (miners, chemical workers, etc.).~patients followed-up for pulmonary nodules (considered benign after 2 years)."
33287411|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
33287412|NCT01067950|Experimental|Isolated Pancreas Transplant|
33287413|NCT01067950|Active Comparator|Intensive Insulin Therapy|
33287414|NCT00445848|Experimental|Erlotinib and Bevacizumab|
33287415|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
33287416|NCT01068028|Experimental|ORM-12741|
33287417|NCT00286156|Experimental|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
33287418|NCT00286156|Experimental|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
33287419|NCT00286156|No Intervention|3|Standard Care
33287420|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
33287421|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
33287422|NCT03244098|Experimental|Transition Assistance Program (TAP)|
33287423|NCT03244098|No Intervention|Standard of Care|
33287424|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
33287425|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
33287426|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
33287427|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
33287428|NCT01029834|Active Comparator|Information control|Child intervention only
33287429|NCT00284050|Experimental|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
33084909|NCT04562857|Active Comparator|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
33084910|NCT04563052|Experimental|Education|Air pollution educational module exposure.
33084911|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
33084912|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
33084913|NCT04563169|Experimental|Video consultation|Patients in the video consultation group will receive video consultations.
33084914|NCT04563169|No Intervention|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
33084915|NCT04563091|Experimental|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
33084916|NCT04563013|Sham Comparator|Sham tVNS|The participants under conventional radiochemotherapy were applied with sham tVNS at the earlobe for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
33084917|NCT04563013|Active Comparator|tVNS|The participants under conventional radiochemotherapy were applied with transcutaneous vagus nerve stimulation at the tragus for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
32782046|NCT05318131|Experimental|Single Arm Prospective Study|
32782047|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
32782048|NCT05268757|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
32782049|NCT05268757|Placebo Comparator|Placebo|In this group participants will receiveplacebo twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
32782050|NCT05268367|Experimental|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
32782051|NCT05268367|Experimental|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
32782052|NCT05514223||Males of couples seeking fertility treatment|The study population will consist of males of couples that visit the Center reproductive Medicine of the UMCG where a semen analysis is planned for clinical purposes.
32782053|NCT05267743|Experimental|Tegoprazan 50mg QD|Tegoprazan 50mg tablet, once daily, oral administration
32782054|NCT05267743|Active Comparator|Lansoprazole 30mg QD|Lansoprazole 30mg capsule, once dauly, oral administration
32782055|NCT05291845|Experimental|Candida antigen group|25 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
32782056|NCT05291845|Experimental|Bivalent HPV vaccine|25 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
32782057|NCT05291845|Experimental|both agents group|25 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
32782058|NCT05291533|Other|Patients using VR Mindfulness Program|Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention.
32782059|NCT05266963|Active Comparator|CREON|CREON is a pancreatic enzyme replacement
32782060|NCT05266963|Placebo Comparator|Placebo|Placebo
32782061|NCT05317195|Experimental|NP-1|Nicotine Pouch 1.0 (variant NP-1)
32782062|NCT05317195|Experimental|NP-2|Nicotine Pouch 1.0 (variant NP-2)
32782063|NCT05317195|Experimental|NP-3|Nicotine Pouch 1.0 (variant NP-3)
32782064|NCT05317195|Experimental|NP-4|Nicotine Pouch 1.0 (variant NP-4)
32782065|NCT05317195|Active Comparator|Velo-NP|Velo® Ice Cool
32782066|NCT05317195|Active Comparator|Zyn-NP|Zyn® Cool Mint Mini Dry
32782067|NCT05266807|Experimental|SoC + oral Fecal Microbiota Transplantation|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days, followed 24h later by one oral FMT (15 capsules administered at D1 and 15 capsules at D2), and a second oral FMT depending on recurrent CDI severity.
33084918|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
33084919|NCT04562818||Idarrubicin|Patient treated with idarrubicin
33084920|NCT04562506|Active Comparator|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
33084921|NCT04562506|Sham Comparator|Sham rTMS stimulation|sham high frequency H-coil stimulation
33084922|NCT04562545|Active Comparator|Maximum Bite Advancement|
33084923|NCT04562545|Experimental|Incremental Bite Advancement|
33084924|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
33084925|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
32782068|NCT05266807|Active Comparator|SoC|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days.
33084926|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
33084927|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
33084928|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
32782069|NCT05317117|Other|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|All participants will be tested with two investigational IVDs at the point of care, the NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and the NxTek™ Malaria P.f/P.v RDT, in addition to comparator tests and the standard of care (microscopy). The investigational tests will not be used to determine any treatment or case management.
32782070|NCT05314621|Active Comparator|Pataday® Once Daily Relief Extra Strength and Saline Nasal Spray|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
32782071|NCT05314621|Active Comparator|Tears Naturale® II and Flonase® Allergy Relief|Tears Naturale® II will be administered bilaterally and Flonase® Allergy Relief (fluticasone propionate) will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
32782072|NCT05266729|Experimental|AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
32782073|NCT05266729|Experimental|AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
32782074|NCT05266729|Placebo Comparator|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
32782075|NCT05266339|Experimental|Cross-education group|Each subject in the cross-education group will receive a treatment protocol consisting of cross-education (training of the contralateral limb) and standard exercise program applied after arthroscopic rotator cuff repair.
32782076|NCT05266339|Active Comparator|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of standard exercise program applied after arthroscopic rotator cuff repair.
32782077|NCT05290597|Experimental|IBI363|Single arm
32782078|NCT05314543|Experimental|Track cyclists and rowers (males and females)|All female and male rowing and track cycling athletes at the national or international national or international level, registered in a selection process and likely to represent France at the likely to represent France at the 2024 Olympics will be asked to take part to take part in this study.
32782079|NCT05314465|Experimental|Median nerve mobilization|Experimental arm given Median nerve mobilization for 12mins 3sets for 3mins each with 1 minute interval in between for 5times a week for 4weeks
32782080|NCT05314075|Active Comparator|Upper Body|
32782081|NCT05314075|Active Comparator|Under body|
32782082|NCT05289505||Prospective phase|This prospective phase involves all patients with an initial HADS score > 7 and initiating treatment in the radiotherapy department. The treatment sessions will be performed with music, using the MUSIC-CARE device. In the event of technical problems, unavailability of equipment, or the patient's wishes, some radiotherapy sessions may be conducted without music. Nevertheless, a minimum of one weekly session with music is required for the analysis of the study.
32782083|NCT05289271|Experimental|Group 1: V, V, V|Participants who received a 2-dose regimen of Vaxelis™ as infants prior to enrollment will receive a Vaxelis™ booster at ~11 months of age.
32782084|NCT05289271|Experimental|Group 2: H, H, V|Participants who received a 2-dose regimen of Hexyon™ as infants prior to enrollment will receive a Vaxelis™ booster at ~11 months of age.
32782085|NCT05263609|Experimental|Arm A|"Arm A (CR/oPR on pembrolizumab monotherapy):~Patients will continue pembrolizumab monotherapy if CR/oPR on initial treatment with pembrolizumab monotherapy. If CR/oPR persists at 8 cycles (24 weeks) after assignment on arm A, pembrolizumab break will commence. Patients will be monitored for disease progression with imaging every 9 weeks (+/- 1 week). If patients develop progression, pembrolizumab will be resumed and continued until subsequent PD. At that point, axitinib may be added to pembrolizumab as part of the study or patients may discontinue study treatment per the treating investigator's discretion."
32782086|NCT05263609|Experimental|Arm B|"Arm B (sPR/SD/PD):~Patients with sPR, SD or PD after 6 cycles of pembrolizumab monotherapy will be started on axitinib in addition to continuing pembrolizumab. If patients develop subsequent PD, treatment will be discontinued. If the subsequent scans show SD/PR/CR, the combination treatment will be continued until PD or unacceptable toxicity."
32782087|NCT05263375|Experimental|MV replacement with Innovalve TMVR system|MV replacement with Innovalve TMVR system
32782088|NCT05312983|Experimental|people over the age of 40 who agree to participate in the research.|They are either people who have a hearing loss about 20 years older than their age and wear a hearing aid (or come in for a hearing aid), or people with normal hearing for their age.
32782089|NCT05260333|Experimental|Transperineal ultrasound cervical exam|Patients will undergo transperineal cervical exam via Butterfly iQ ultrasound.
32782090|NCT05260333|Active Comparator|Digital (manual) cervical exam|Patients will undergo traditional digital cervical exam via examiner's fingers.
32782091|NCT05310877|Experimental|Values-affirmation|
33084929|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
33084930|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
33084931|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
33084932|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
33084933|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
33287430|NCT00284050|Experimental|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
33287431|NCT00284050|Sham Comparator|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
33287432|NCT00293020|Experimental|1|BEMA Fentanyl
33287433|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
33287434|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
33287435|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
33287436|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
33287437|NCT01050309|Active Comparator|Cervix|
33287438|NCT01050309|Active Comparator|colon|
33287439|NCT01050309|Active Comparator|Intravenous|
33287440|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
33287441|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
33287442|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
33287443|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
33287444|NCT00292942|Experimental|2 mg/kg Intravenous Artesunate|2 mg/kg of Intravenous artesunate
33287445|NCT00292942|Experimental|4 mg/kg Intravenous Artesunate|4 mg/kg of Intravenous artesunate
33287446|NCT00292942|Experimental|8 mg/kg Intravenous Artesunate|8 mg/kg of Intravenous artesunate
33287447|NCT00292942|Placebo Comparator|Placebo|Mannitol (200 mg/vial) diluted in phosphate buffer and delivered in an equivalent volume by subject's weight as artesunate.
33287448|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
33287449|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
33287450|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
33287451|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
33287452|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
33287453|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
33287454|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
33287455|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
33287456|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
32938703|NCT05341375|Experimental|Group TE|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
32938704|NCT05341375|Other|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCD incidence to rule out learning effect
32938705|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
32782092|NCT05259241|Other|Single arm study|"Cohort A: patients undergoing TAVR to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status~Cohort B: patients undergoing PCI to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status"
32782093|NCT05511415|Active Comparator|Dexmedetomidine|The myometrial samples are bathed in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
32782094|NCT05511415|Active Comparator|Oxytocin|The myometrial samples are bathed in oxytocin 20nM.
32782095|NCT05511415|Active Comparator|Dexmedetomidine + Oxytocin|The myometrial samples are bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M).
32782096|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Dexmedetomidine|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
32782097|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM.
32782098|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Dexmedetomidine + Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M)
32782099|NCT05309551|Experimental|Powerbreathe Medic- Intervention group|Along with standard post-transplant physical therapy, the intervention group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with weekly incremental increases in respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
32782100|NCT05309551|Sham Comparator|Powerbreathe Medic - Placebo group|Along with standard post-transplant physical therapy, the placebo group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with no increase of respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
32782101|NCT05309551|No Intervention|Usual care group|Patients will only participate in standard post-transplant physical therapy.
32782102|NCT05219227|Experimental|body fat mass (BFM)|body fat mass will be measured before and after interventions
32782103|NCT05219227|Experimental|Body mass index (BMI)|BMI will be calculated before and after interventions
32782104|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
32782105|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
32938706|NCT02796001|Active Comparator|RV16 infected volunteers re-challenged with RV16|volunteers re-challenged with RV16
32938707|NCT02796001|Active Comparator|RV infected volunteers re-challenged with RV39|volunteers re-challenged with RV39
32938708|NCT02796001|Other|RV infected not rechallenged|Volunteers who were infected with RV16 and eligible for re-challenge but who were not re-challenged due to voluntary withdrawal (3) or removal for exclusion criteria
32938709|NCT04736264|Active Comparator|Rehabilitation group|"This is the phase 3 of the entire research protocol. Phase 3 will be initiated once the phase 2 (development of rehabilitation module) is completed. A user friendly and inexpensive device and program with minimal usage of low vision aid will be designed and piloted. There are 3 different rehabilitation modules.~A total of 300 primary glaucoma patients will be recruited and randomized using SNOSE: 150 intervention group and 150 non-intervention group. The intervention group will comprised of 150 primary glaucoma patients who will be assigned to different rehabilitation program:~navigation and mobility (50 patients)~physical activities including special exercise (50 patients)~reading (50 patients) There will be no patient who will be involved in more than one rehabilitation program at anytime."
32938710|NCT04736264|No Intervention|Non-rehabilititation group|Group of primary glaucoma patients who are not taught and practiced the new rehabilitation module for navigation, physical activity (exercise) and reading. They will be asked to continue their regular activities and provided with the similar reading material (book) to read daily.
32938711|NCT05268991||AGE Participants|Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
32938712|NCT05406518|Experimental|Intervention|Arm of intervention
32938713|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
32938714|NCT04373252|Experimental|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
32938715|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
32938716|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
32782106|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
32782107|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
32782108|NCT05256823|Experimental|Experimental Group|Patients will be given a combination of Celecoxib and one nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
32782109|NCT05256823|Other|Control group|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
32782110|NCT05218681|Other|"Control: Unit-based Person First Anti-stigma Awareness Rounds"|"The Person First Initiative was developed independent of this study by bedside nurses (including McFadden) in collaboration with HUP Nursing Executive Leadership. The objective of this initiative is to provide (1) unit-based huddles on person-first language as a mechanism to reduce the stigma around substance use; (2) socialize best practices and resources for patients with substance use disorder; and (3) provide overdose reversal training and kits, including Narcan nasal spray, to nurses. The planning and implementation of these activities fall under the purview of Nursing Shared Governance (NOT the research team), and oversight for these activities will be provided by HUP Nursing Executive Leadership."
32782111|NCT05218681|Other|"Unit-based Person First stigma rounds + Text-based Messaging"|Participating nurses will be randomized to receive weekly short text messages that employ evidence-based strategies to reduce stigma towards individuals with substance use disorder over the course of 6-months.
32782112|NCT05255887|Experimental|Informing patients group|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in the experimental group by face-to-face interview method.
32782113|NCT05255887|No Intervention|Control Group|patients who were no intervation
32782114|NCT05255653|Experimental|p53abn-RED trial: experimental|Adjuvant chemoradiation followed by olaparib (lynparza), 300 mg twice daily, for two years
32782115|NCT05255653|Active Comparator|p53abn-RED trial: control|Adjuvant chemoradiation
32782116|NCT05255653|Experimental|MMRd-GREEN trial: experimental|Adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)
32782117|NCT05255653|Active Comparator|MMRd-GREEN trial: control|Adjuvant pelvic external beam radiotherapy
32782118|NCT05255653|Experimental|NSMP-ORANGE trial: experimental|Adjuvant pelvic external beam radiotherapy followed by oral progestagens (medroxyprogesterone acetate or megestrol acetate) for two years
32782119|NCT05255653|Active Comparator|NSMP-ORANGE trial: control|Adjuvant chemoradiation
32782120|NCT05255653|Experimental|POLEmut-BLUE|no adjuvant therapy for stage I-II disease and no adjuvant therapy or pelvic external beam radiotherapy only for stage III disease
32782121|NCT05286307|Experimental|Participants receiving IPACK block|Patients in this study group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%). And receive the additional IPACK block performed using 20 mL of Bupivacaine (0.25%) injected into the interspace between the popliteal artery and capsule of the knee.
32782122|NCT05286307|No Intervention|Standard of care group|Patients in the control group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%).
32782123|NCT05286151|Experimental|Children who stutter|Children who stutter
32782124|NCT05286151|Experimental|Children who do not stutter|Children who do not stutter
32782125|NCT05285371|Placebo Comparator|CONT Group|CONT group will receive standard traditional intravenous fluid of D50.45% NaCl + 20 mEq/L KCl at 2/3 maintenance rate.
32782126|NCT05285371|Experimental|BOL Group|BOL group will receive intravenous boluses of Lactated Ringer's three times daily at 2/3 maintenance rate.
32782127|NCT05284591||DRd with daratumumab iv de novo|Patients either continue DRd with daratumumab iv, switch to daratumumab sc or switch multiple times iv/sc
32782128|NCT05284591||DRd with daratumumab sc de novo|Patients either continue DRd with daratumumab sc, switch to daratumumab iv or switch multiple times sc/iv
32782129|NCT05284357||Group 1: Subjects implanted with HUMELOCK I & II® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~97 patients were identified who could be included in this cohort in 11 investigational centers.~subjects implanted in 2011 to 2013"
32782130|NCT05284357||Group 2: Subjects implanted with HUMELOCK II® Reversible System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~Number of patient to be determined following patients files in 4 investigational centers.~subjects implanted in 2011 to 2013"
32782131|NCT05284357||Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~154 patients were identified who could be included in this cohort in 5 investigational centers.~subjects implanted in 2012 and 2013"
32782132|NCT05284357||Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~66 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
32782133|NCT05284357||Group 5: Subjects implanted with EASYTECH® Reversed System (Primary intention)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~7 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
33287457|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
32782134|NCT05284357||Group 6:Subjects implanted with EASYTECH® Reversible System (Revision of Easytech Anatomic)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~the number of subjects will depend of revised subjects primary implanted with Easytech Anatomic® along the dedicated period subjects implanted in 2013 to 2014"
33287458|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
33287459|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
33287460|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
33287461|NCT01019564|Active Comparator|Aquify MPS|
33287462|NCT03991845|Experimental|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
33287463|NCT03991845|Active Comparator|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
33287464|NCT03991845|No Intervention|Placebo|No Vit D supplementation will be given to patients in this group
33287465|NCT01017380|Experimental|placebo|identical placebo
33287466|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
33287467|NCT00266812|Experimental|Chemotherapy with temozolomide and radiotherapy|
33287468|NCT00266812|Active Comparator|Radiotherapy alone|
33287469|NCT04249544|Experimental|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
33287470|NCT04249544|Experimental|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
33287471|NCT04249544|Experimental|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
33287472|NCT04249544|Experimental|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
33287473|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
33287474|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
33287475|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
33287476|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
33287477|NCT00361569|Experimental|1|
33287478|NCT00361569|Experimental|2|
33287479|NCT00361569|Placebo Comparator|3|
33287480|NCT00361569|Placebo Comparator|4|
33287481|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
33287482|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
33287483|NCT01017458|Experimental|1|MK0773 + placebo injection
33287484|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
33287485|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
33287486|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
33287487|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
33287488|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
33287489|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
33287490|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
33287491|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
33287492|NCT01019642|Placebo Comparator|Placebo|placebo
33287493|NCT00266656|Experimental|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
33287494|NCT00266656|Experimental|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
33287495|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
33287496|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
33287497|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
33287498|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
33287499|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
33287500|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
33287501|NCT00445770|Experimental|1|
33287502|NCT00445770|Experimental|2|
33287503|NCT00445770|Active Comparator|3|
33287504|NCT00266032|Experimental|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
33084934|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
33084935|NCT04562584|Experimental|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
33084936|NCT04562350|Experimental|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
33084937|NCT04562350|No Intervention|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
33084938|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
33084939|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
33084940|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
33287505|NCT00266032|Experimental|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
33287506|NCT00266032|Active Comparator|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
33287507|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
33287508|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
33287509|NCT01019798|Experimental|open label|
33287510|NCT01012154|Experimental|All patients|
33287511|NCT00483002||Healthy smokers|
33287512|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
33287513|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
33287514|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
33084941|NCT04562311|Experimental|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
33287515|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
33287516|NCT00282568|Experimental|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
33287517|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
33287518|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
33287519|NCT00265564|Active Comparator|Seeking Safety|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
33287520|NCT00265564|Active Comparator|Usual Care|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
33287521|NCT01068184|Experimental|1|
33287522|NCT01068184|Placebo Comparator|2|
33287523|NCT00376623|Experimental|200 milligram (mg) of BI 2536|Day 1
33287524|NCT00376623|Experimental|50 milligram (mg) of BI 2536|Day 1, 2, and 3
33287525|NCT00376623|Experimental|60 milligram (mg) of BI 2536|Day 1, 2, and 3
33287526|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
33287527|NCT01029990|Experimental|Self-test arm|
33287528|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
33084942|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
33084943|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
33287529|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
33287530|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
33287531|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
33287532|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
33287533|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
33287534|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
33287535|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
32782135|NCT05284357||Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~11 patients were identified who could be included in this cohort in 3 investigational centers Subjects implanted in 2014 to 2015"
33287536|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
33287537|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
33287538|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
33287539|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
33287540|NCT00282412|Experimental|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
33287541|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
33287542|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
33287543|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
33287544|NCT00282334|Experimental|Home blood pressure telemonitoring|
33287545|NCT00282334|No Intervention|Conventional blood pressure monitoring|
33287546|NCT03974932|Experimental|Cohort 1|HTX-011 + MMA
33287547|NCT03974932|Experimental|Cohort 2|HTX-011 + MMA
33287548|NCT03974932|Experimental|Cohort 3|HTX-011 + MMA
33287549|NCT03974932|Experimental|Cohort 4|HTX-011 + MMA
33084944|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
33084945|NCT04562272|Active Comparator|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
33287550|NCT00282256|Experimental|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
33287551|NCT00265330|Experimental|Open|
33287552|NCT00292318|Active Comparator|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
33084946|NCT04562272|No Intervention|Standard care|Standard treatment of AMI after PCI according to guidelines.
33287553|NCT00292318|Experimental|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
33287554|NCT00281632|Experimental|Pazopanib|800 mg GW786034 administered orally on a daily basis.
33287555|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
33287556|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
33287557|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
33084947|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
33084948|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
33084949|NCT04561960|Active Comparator|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
33084950|NCT04561960|Experimental|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
33084951|NCT04561960|Experimental|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
33084952|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
33402221|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
33402222|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
33402223|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
33402224|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
32782136|NCT05284357||Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~72 patients were identified who could be included in this cohort in 2 investigational centers Subjects implanted in 2014 to 2015"
32782137|NCT05284201|Experimental|Functional task practice and ARC Therapy|FTP and ARC Therapy with the LIFT System at home for 1 month.
32782138|NCT05284045|No Intervention|Usual information|Subjects allocated to this arm will receive the usual information about OSA and CPAP treatment given in clinical practise
32782139|NCT05284045|Active Comparator|Detailed information|Subjects allocated to this arm will also receive the usual information about OSA and CPAP treatment and they will also receive information related to the possible adverse side effects of CPAP treatment. The healthcare professional will enumerate the possible side effects and indicate which are more and less common.
32782140|NCT05492149||Pulmonary rehabilitation group|Patients referred for a pulmonary rehabilitation program will be follow up.
32782141|NCT04243837|Experimental|LYT-100 in healthy volunteers with Food|LYT-100, multiple ascending
32782142|NCT04243837|Placebo Comparator|Placebo in healthy volunteers with Food|Placebo, multiple administrations
32782143|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fasted|LYT-100, Dose below MTD for 1 dose
32782144|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fasted|Placebo, for 1 administration
32782145|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fed|LYT-100, Dose below MTD for 1 dose
32782146|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fed|Placebo, for 1 administration
33084953|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
33084954|NCT04561921|Experimental|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
32782147|NCT04243837|Experimental|LYT-100 in patients with BCRL|LYT-100 BID for 6 months
32782148|NCT04243837|Placebo Comparator|Placebo in patients with BCRL|Placebo BID for 6 months
32782149|NCT04243759|Experimental|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
32782150|NCT04243759|Experimental|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
33084955|NCT04561921|Active Comparator|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
33084956|NCT04561882|Experimental|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
33084957|NCT04561999||Patients with Superficial Lymphadenopathy|
32782151|NCT04243759|Experimental|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
32782152|NCT05482867||Cohort 1|Cohort 1, healthy adults (n = 5), will receive an ICG infusion of 1 mg/min for 120 minutes.
32782153|NCT05482867||Cohort 2|If no dose limiting adverse effects are observed in Cohort 1, then Cohort 2, healthy adults (n = 10), will receive an ICG infusion of 2 mg/min for 120 minutes. If there are no dose limiting adverse events and there is evidence of ICG-labeling of PBMCs, the 2 mg/min infusion rate will be used for the remainder of the study.
32782154|NCT05482867||Cohort 3|Cohort 3, healthy elderly adults, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed in the satellite group, then a further 10 healthy elderly adults will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 3).
32782155|NCT05482867||Cohort 4|Cohort 4, AD patients, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed, then a further 10 AD patients will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 4). Recruitment of AD patients will begin if there are no dose limiting adverse effects observed in the satellite group of healthy elderly.
32782156|NCT05255263|Active Comparator|Programmed Intermittent Epidural Bolus|Intermittent epidural bolus as the first line labor epidural analgesia maintenance infusion
32782157|NCT05255263|Active Comparator|Continuous Epidural Infusion|Continuous epidural infusion as the first line labor epidural analgesia maintenance infusion
32782158|NCT05254717|Experimental|Interventional arm|Following baseline study, the interventional arm assigned to receive counselling intervention on complementary food flour soaking
32782159|NCT05254717|No Intervention|control arm|The control group will be monitored for presence of any other intervention that might have a potential to mask the effect of the current intervention.
32782160|NCT05254171|Experimental|Experimental Arm|SBP-101 + Nab-paclitaxel and Gemcitabine
32782161|NCT05254171|Placebo Comparator|Control Arm|Placebo + Nab-Paclitaxel and Gemcitabine
32782162|NCT05253937||Intracoronary Epinephrine administration during cardiac arrest|
32782163|NCT05253937||Peripheral intravenous Epinephrine administration during cardiac arrest|
32782164|NCT05253937||Central intravenous Epinephrine administration during cardiac arrest|
32782165|NCT05253703|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 5 minutes each.
32782166|NCT05218603||Maintenance with V-Dara after receiving VMP-Dara as induction regimen|Maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara)
32782167|NCT05217199||1/High risk of Infants|1/Term preterm infants with birth to 3 months of prenatal, postnatal and natal risk who stayed in the NICU for >2 weeks for any reason and were corrected after discharge
32782168|NCT05217199||2/Healty control infants|2/Healthy term infants
32782169|NCT05217121|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
32782170|NCT05217121|Active Comparator|Group M = mTLIP block group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
32782171|NCT05252377|Experimental|Breathing Exercise Group|Breathing exercise program; It was prepared by the researchers in accordance with the literature and based on the studies in which breathing exercise was applied to reduce invasive pain experienced during cannulation, blood collection and postoperative pain. Patients will be given an exercise based on rhythmic breathing. The exercise will be started before the cannulation application, the patient will be told to perform the breathing exercise twice, and he will be asked to continue doing the breathing exercise until the cannulation process is completed. The patient will wait by taking five normal breaths between each breathing exercise. The patient will be told that he can count by using his fingers in the steps he is asked to count up to three.
32782172|NCT05252377|No Intervention|Control Group|No intervention will be made by the researcher on the patients in this group, and a pain assessment will be made by the nurse in charge of dialysis immediately after the cannulation procedure by the dialysis nurse working in the unit.
32782173|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
32782174|NCT05280769|Experimental|Use of oral nicotine pouch - 2 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
32900516|NCT00367016|Experimental|Placebo|Subjects will receive subcutaneous placebo for 6 months. Prior to placebo administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
33287558|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
32782175|NCT05280769|Experimental|Use of oral nicotine pouch - 4 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
33084958|NCT04561687|Active Comparator|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
33084959|NCT04561687|Active Comparator|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
33287559|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
33287560|NCT01068574||Single Observational Cohort|
33287561|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
33287562|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
33287563|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
33287564|NCT04773821|Experimental|Experimental Arm|All men patients with low and intermediate risk prostate cancer (ISUP 1 and 2) who has already chosen to undergo focal treatment, in the referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. Follow-up visits are planned at 3, 6,12 and 13 month from the date of the focal treatment consistently with usual care. All patients will have a MpMRI and MpMRI targeted biopsy in the presence of a lesion suggestive of recurrence at 12 months. The subject will be his own control
33287565|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
33287566|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
33287567|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
33287568|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
33287569|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
33287570|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
33287571|NCT00984503|Experimental|Intradermal Juvista|
33287572|NCT00984503|Placebo Comparator|Placebo|
32900517|NCT05372250|Experimental|Order of body positions for ultrasound measurements : supine position, 45°, sitting, standing|
32900518|NCT05372250|Experimental|Order of body positions for ultrasound measurements : 45°, sitting, standing, supine position.|
33287573|NCT00984503|Experimental|Intradermal and topical Juvista|
33287574|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
33287575|NCT05596955|Experimental|Buprenorphine|Study participants receive three once-a-month injections of buprenorphine and complete weekly monitoring visits.
33287576|NCT05596955|Active Comparator|Naltrexone|Study participants receive three once-a-month injections of naltrexone and complete weekly monitoring visits.
33287577|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
33287578|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
33287579|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
33287580|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
33287581|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
33287582|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
33287583|NCT04487327|Experimental|Dry Needling within the Myofascial Trigger Point|Randomized to receive DN at the site of the MTrP
33287584|NCT04487327|Active Comparator|Dry Needling away from Myofascial Trigger Point Site|Randomized to receive DN 2 cm away from the site of the MTrP but within the same muscle
33287585|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
33287586|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
33287587|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
33287588|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
33287589|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
33287590|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
33287591|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
33287592|NCT00986141||Surgery|Glaucoma laser treatment
33287593|NCT05586113|Experimental|10-day treatment group|10-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
33287594|NCT05586113|Active Comparator|14-day treatment group|14-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
33287595|NCT05581901|Experimental|Methadone (Dose 1)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
33287596|NCT05581901|Experimental|Methadone (Dose 2)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
33287597|NCT05581901|Experimental|Methadone (Dose 3)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
33287598|NCT00986219||Asthma Language between patients and physicians|
33287599|NCT00986297|Other|arm one|IGRT
33287600|NCT00541385|Experimental|PA group|"Oral pyronaridine/artesunate (PA, 60:20mg granules) once a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
33287601|NCT00541385|Active Comparator|AL group|"Oral artemether/lumefantrine (AL, 20:120mg crushed tablets) twice a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
33287602|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
33287603|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
33287604|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
32782176|NCT05280769|Experimental|Use of oral nicotine pouch - 8 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
32900519|NCT05372250|Experimental|Order of body positions for ultrasound measurements : sitting, standing, supine, 45°.|
32900520|NCT05372250|Experimental|Order of body positions for ultrasound measurements : standing, supine, 45°, seated.|
33084960|NCT04561687|Placebo Comparator|Nasal Budesonide and Placebo|Placebo once daily
33287605|NCT04760951|Experimental|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
33287606|NCT04760951|Placebo Comparator|Placebo|Placebo comparator taken 2 times per day
33287607|NCT05543915|Experimental|Group with tDCS-MRI|Participants will have a cognitive assessment, an optional gait assessment, and a 1-hour MRI brain scan combined with 20 minutes of simultaneous tDCS. Participants may also complete the MRI on a separate visit.
33287608|NCT05543915|No Intervention|Group without tDCS- MRI|Participants will have include a cognitive assessment and an optional gait assessment
33287609|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
33287610|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
33287611|NCT00265096|Experimental|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
33287612|NCT00265096|Experimental|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
33287613|NCT00265096|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
33287614|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
33287615|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
33287616|NCT00986531|Experimental|1|80 mg AZD8529
33287617|NCT00986531|Placebo Comparator|2|Placebo
33287618|NCT05529329|Active Comparator|Group (Z)|patients received zirconia restorations group
33287619|NCT05529329|Experimental|Group (EC)|patients received IPS E.max Cad restorations group
33318154|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
33287620|NCT05523947|Experimental|YH32367|"Dose Escalation Part: 8 Cohorts (Dose level: 0.03, 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg). In Dose Escalation part, patients are assigned to receive YH32367 at a starting dose of 0.3 mg/kg and the dose being escalated/de-escalated in adjacent dose cohorts will be 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg.~Dose Expansion Part: 2 Cohorts (Cohort 1: Breast cancer, Cohort 2: Gastric cancer). Dose Expansion part will consist of multiple cohorts in patients who were treated with three or more prior lines of therapy including at least one trastuzumab-based regimen, HER2-positive, locally advanced or metastatic breast cancer(Cohort 1); in patients who were treated with two or more prior lines of therapy including at least one trastuzumab-based regimen, HER2-positive, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma(Cohort 2)."
32938717|NCT04356716|Active Comparator|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
33287621|NCT02201108|Placebo Comparator|Placebo|Matching placebo tablets
33287622|NCT02201108|Experimental|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
33287623|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
32938718|NCT04356716|Active Comparator|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
33287624|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
33287625|NCT00281320|Experimental|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
33287626|NCT00281320|Experimental|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
33287627|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
33287628|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
33287629|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
33287630|NCT05502965|Active Comparator|Exclusive Enteral Nutrition(EEN)|Subjects required exclusive enteral nutrition for one month
33287631|NCT05502965|Experimental|Specific Diet+ Partial Enteral Nutrition|Subjects received partial enteral nutrition with remaining energy and nutrients obtained through diet for one month
33287632|NCT05003258|Other|Patients with RVO|Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF
33287633|NCT03975556|Experimental|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
32938719|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
33287634|NCT03975556|Active Comparator|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
33287635|NCT05499689|Active Comparator|GON block group|30 patients who underwent greater occipital nerve block
33287636|NCT05499689|Active Comparator|Transcutaneous pulsed RF group|30 patients who underwent greater occipital nerve pulsed radiofrequency
33287637|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)~administered as intravenous bolus injections (A2)"
33287638|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
33287639|NCT03976804|Experimental|atherosclerotic cardiovascular event associated with tobacco|
33287640|NCT00986687||Vitrified oocytes|
33287641|NCT00986687||Control oocytes|
33287642|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
33287643|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
33287644|NCT03976570|Experimental|Occupational Therapy|Occupational Therapy
33287645|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
33287646|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
33287647|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
33287648|NCT00541229|Experimental|1|sitagliptin 100 mg
33287649|NCT00541229|Experimental|2|sitagliptin 200 mg
33287650|NCT00541229|Placebo Comparator|3|Placebo
33287651|NCT04128644|Other|Standard of care+Thoughts & health|12 sessions of Thoughts & Health. Baseline questionnaires and follow up assessments
33287652|NCT04128644|Other|Standard of care|Baseline questionnaires and follow up assessments, intervention as usual Student Health
33287653|NCT04006691|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
33287654|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
33287655|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
33287656|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
33287657|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
33287658|NCT02112188||Chinese patients with advanced cancer|IMCP intervention to be culturally & linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research & 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process & session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, & Applebaum), Drs. Leng, Gany, & Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process & content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline & Treatment Integrity Coding Manual. PHASE 3: Conduct feasibility study of IMCP-Ch for Chinese cancer patients
33287659|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
33287660|NCT01012310|Experimental|Cohort 1|
33287661|NCT01012310|Experimental|Cohort 2|
33287662|NCT01012310|Experimental|Cohort 3|
33287663|NCT01012310|Experimental|Cohort 4|
33287664|NCT04118270|Experimental|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
33287665|NCT04734821|Experimental|NIR Fluorescence guided lymphadenectomy and anastomosis|
33287666|NCT01019876|Experimental|Fludarabine|
33287667|NCT01019876|Experimental|Cyclohosphamide 200|
33287668|NCT01019876|Experimental|Cyclophosphamide 40|
33287669|NCT01019876|Experimental|Cyclophosphamide 30|
33287670|NCT05463419|Experimental|PIKA COVID-19 vaccine|One dose of the experimental vaccine should be administered on Study Day 0 in the deltoid muscle.
33287671|NCT05463419|Active Comparator|Inactivated Covid-19 vaccine|One dose of the control vaccine should be administered on Study Day 0 in the deltoid muscle.
33287672|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
33287673|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
33287674|NCT00493142|Active Comparator|Usual care|Usual care
33287675|NCT00493142|Experimental|Exercise|Exercise
33287676|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
33287677|NCT05712707|Experimental|BXCL501 (180 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
33287678|NCT05712707|Experimental|BXCL501 (240 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
33287679|NCT05712707|Active Comparator|Lofexidine (Positive Control)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
33287680|NCT05712707|Placebo Comparator|Placebo|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
33287681|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
33287682|NCT01017926|Experimental|Triazolam Trial Arm|
33287683|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
33287684|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
33287685|NCT05415449||No groups|"Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview parent on device--Every month complete 30-day satisfaction survey for a total of three data collection period-Discharge from study.~Nurse data collection scheme: Study participants hospitalized at time of enrollment in study or anytime during the study period. Nurse of patients using device will complete satisfaction survey."
33287686|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
33287687|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
33287688|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
33287689|NCT05407415|Experimental|Kardia Mobile Group|"The intervention arm will be given a KardiaMobile device synched to their smartphone at the time of enrollment. They will be instructed on proper device procedure and will use the device with the onset of potential AF-related symptoms or when requested to do so by their healthcare provider.~The device ECG recordings will be transmitted to participants physicians through MyChart who will incorporate this information into the patient's treatment as indicated.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
33287690|NCT05407415|No Intervention|Standard of Care Group|"The standard of care group will follow their routine care for their atrial fibrillation.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
33287691|NCT05401409|Experimental|Nitrate-rich beetroot juice|Beetroot juice containing naturally occurring nitrate (400mg total nitrate)
33287692|NCT05401409|Placebo Comparator|Nitrate-depleted beetroot juice|Beetroot juice with nitrate removed
33287693|NCT04006067|Experimental|Group A|
33287694|NCT04006067|No Intervention|Group B|
33287695|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
33287696|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
33287697|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
33287698|NCT04004975|Experimental|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
33287699|NCT04086992|No Intervention|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
33287700|NCT04086992|Experimental|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
33287701|NCT05318729|Experimental|Vibration tool|"Use of the vibration tool 3 times per day for 10 minutes for each session Morning, mid-day, and evening.~Volarly for 5 minutes and dorsally for 5 minutes, for a total of 10 minutes during each session:"
33287702|NCT05318729|No Intervention|Control|Standard of care, no vibration tool.
33287703|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
33287704|NCT05712473||Cohort 1|Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET
33287705|NCT05712473||Cohort 2:|Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
33287706|NCT01022372||control group|
33287707|NCT01022372||endometriosis group|
33287708|NCT01022372||endometrioma group|
33287709|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
33287710|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
33287711|NCT05712395|Experimental|NICE exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the NICE program will walk intermittently at a slow speed of approximately 1.4 mph for only 2-3 minute bouts that do not elicit claudication pain.
33287712|NCT05712395|Active Comparator|Standard exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the Standard program will walk intermittently at a speed of approximately two mph to near maximal claudication pain.
33287713|NCT05318105|Experimental|Aquadex ultrafiltration therapy|
33287714|NCT05318105|Active Comparator|IV loop diuretics|
33287715|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
33287716|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
33287717|NCT00987233|Placebo Comparator|Placebo|
33287718|NCT05318027|Experimental|Activity Monitoring and ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot
33287719|NCT05318027|No Intervention|Activity Monitoring without ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone
33287720|NCT04006301|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
33287721|NCT04006301|Experimental|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
33287722|NCT04715867|Experimental|Test Group for intramuscular route|110 adult participant will get Ravix-VC
33287723|NCT04715867|Active Comparator|Comparator group for intramuscular route|110 adult participant will get Rabipur
33287724|NCT04715867|Experimental|Test Group for Intradermal Route|110 adult participant will get Ravix-VC
33287725|NCT04715867|Active Comparator|Comparator Group for Intradermal Route|110 adult participant will get Rabipur
32938720|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
33287726|NCT04004897|Other|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
33287727|NCT04004897|Other|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
32938721|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
32938722|NCT05222659||Urologic surgery patients|
33287728|NCT04377503|Experimental|Tocilizumab|Patients will receive Tocilizumab, 8 mg / kg diluted in 100 ml of saline and administered IV for 60 minutes. The dose will be repeated only once 12 hours after the first dose.
33287729|NCT04377503|Active Comparator|Methylprednisolone|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days in two daily doses. Finally 0.5 mg / kg / day for another 7 days.
33287730|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
33287731|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
33287732|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
33287733|NCT00542789|Placebo Comparator|1|Placebo
33287734|NCT00542789|Experimental|2|Esomeprazole 20 mg
33287735|NCT00464672|Experimental|Influenza virus vaccine|
33287736|NCT00464672|Active Comparator|Comparator influenza vaccine|
33287737|NCT05712239|Other|Group A|
33287738|NCT05712239|Active Comparator|Group B|
33287739|NCT05712239|Experimental|Group C|
33287740|NCT03996434|Experimental|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
33287741|NCT03996434|Active Comparator|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.~GnRH agonist will be discontinued at the start of antagonist administration.~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
33287742|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
33287743|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
33287744|NCT01020266|Active Comparator|Electroacupuncture|
33287745|NCT01020266|Sham Comparator|Control|
33287746|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
33287747|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
33287748|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
33287749|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
33287750|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
33287751|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
33287752|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
33287753|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
33287754|NCT04895813|Experimental|Group 1:|The patient will be given training on the day the appointment is made for colonoscopy, educational material will be given as a reminder, information will be given on the phone and the training will be reminded on the day he should start diet for colonoscopy. No different application will be made on the day and after the colonoscopy.
33287755|NCT04895813|No Intervention|Group 2|Routine information in the service will be made
33287756|NCT04225286|Experimental|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (<33 weeks gestation at birth, stratified < and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
33287757|NCT05155319|Active Comparator|Cohort 1, 1A|Low dose (Day 1) plus placebo (Day 22)
33287758|NCT05155319|Active Comparator|Cohort 1, 1B|Low dose (Day 1) plus low dose (Day 22)
33287759|NCT05155319|Placebo Comparator|Cohort 1, 1C|Placebo (Day 1) plus Placebo (Day 22)
33287760|NCT05155319|Active Comparator|Cohort 2, 2A|High dose (Day 1) plus placebo (Day 22)
33287761|NCT05155319|Active Comparator|Cohort 2, 2B|High dose (Day 1) plus high dose (Day 22)
33287762|NCT05155319|Placebo Comparator|Cohort 2, 2C|Placebo (Day 1) plus Placebo (Day 22)
33287763|NCT05146427|Experimental|Active Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will play auditory tones to selectively enhance slow-wave activity.
33287764|NCT05146427|Sham Comparator|Sham Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will not be programmed to enhance slow-wave activity
33287765|NCT01018160||001|
33287766|NCT04218422|Experimental|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
32938723|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
32782177|NCT05280769|Active Comparator|Use of smokeless tobacco|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
32782178|NCT05216887|Active Comparator|Aducanumab IV|Participants will receive a single weight-based dose of aducanumab via IV infusion on Day 1.
32782179|NCT05216887|Experimental|Aducanumab SC|Participants will receive 2 fixed doses of aducanumab via SC injection on Days 1 and 15.
32782180|NCT05216653|Experimental|Preoperative Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 6 weeks) immunotherapy combined with two courses of CAPEOX chemotherapy was performed.~Two weeks after the end of the combined treatment plan in step 2), TME surgery is performed."
32782181|NCT04900831||Group 1|
32782182|NCT05251519|Experimental|Kinesio Taping Group (KTG)|Conventional rehabilitation application will be performed in addition to Kinesio Tex tape derotation taping.
32782183|NCT05251519|Active Comparator|Conventional Rehabilitation Group (CRG)|A conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
32782184|NCT05214001|Experimental|Almotriptan|12.5 mg almotriptan taken orally once
32782185|NCT05214001|Active Comparator|Ubrogepant|50 mg ubrogepant taken orally once
32782186|NCT05250505|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
32782187|NCT04242823|Other|Baseline screening cohort|This group undergoes HPV testing using self-collected swabs. Triage evaluation occurs in all women who test HPV positive which includes visual inspection with acetic acid, colposcopy and image capture for automated visual evaluation. The WLHIV in the cohort who test HPV positive at baseline but who have concurrent benign histopathology results will be invited back for re-screening at a 2-year interval, and undergo similar HPV testing and triage procedures. The WLHIV in the cohort who test HPV negative at baseline will be invited back for re-screening at a 3-year interval and undergo similar HPV testing and triage procedures.
32782188|NCT05249959|Experimental|Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy|R/R MCL after one, two or three lines of treatment including BTKi treatment (or BTKi intolerant), with complete response (CR) or partial response (PR) or with stable disease (SD) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C x 2 cycles) will undergo consolidation with loncastuximab tesirine. A patient with CR, PR or SD after one R-BAC course, which is unable to undergo a second course due to toxicity to chemotherapy, can be considered to proceed for consolidation.
32782189|NCT05249881|Other|semaglutide|semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and long-term weight management. Semaglutide acts like human glucagon-like peptide-1 in that it increases insulin secretion, thereby increasing sugar metabolism
32782190|NCT05280379||Participants with non-medullary thyroid carcinoma|30 patients with non-medullary thyroid carcinoma, who are going to get surgery
32782191|NCT05280379||Participants with colon carcinoma|30 participants with colon carcinoma, who are going to get surgery
32782192|NCT05280223|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmedetomidine + 10 cc saline injection nearby median nerve as hydrodissection
33287767|NCT04218422|Sham Comparator|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
33287768|NCT01018238|Placebo Comparator|Placebo arm|
32782193|NCT05280223|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
32782194|NCT05280067|Experimental|Investigational Device The ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. The ZetaFuse™ Bone Graft is only for implantation into the vertebral body.
32782195|NCT05279989|Experimental|Seated Tai Chi Qigong|Participants will receive daily text messages and emails to distribute videos and record which sessions were completed. Participants can participate in 10-, 20-, or 30- min TCQ practices. Total weekly practice time will be recommended between 50-150 minutes/week (~10-30 min/day on most days). A library of existing TCQ videos will be used. All videos will demonstrate seated practice with discussions on how to accommodate mobility limitations of various types.
32782196|NCT05279989|Placebo Comparator|Control|The control arm will receive text messages and emails with links to health information videos for the same time lengths as the intervention group. Existing video content will be reviewed and adapted to assure avoidance of topics that can impact outcome variables.
32782197|NCT05279677|Experimental|FMT|Fecal microbiota transplantation plus Sintilimab and Fruquintinib
32782198|NCT05486923||KPS less than 70|"The patients in this group have Karnofsky performance Status less than 70，and the proportion of them is not less than 15%.~Patients need regular follow-up surveys within 2 years after the date of surgery."
32782199|NCT05486923||KPS more than 70|The patients in this group have Karnofsky performance Status more than 70. Patients need regular follow-up surveys within 2 years after the date of surgery.
33287769|NCT01018238|Experimental|Cohort 1|
33287770|NCT01018238|Experimental|Cohort 2|
33287771|NCT01018238|Experimental|Cohort 3|
33287772|NCT01018238|Experimental|Cohort 4|
33287773|NCT03996512|Experimental|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
33287774|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
33287775|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
33287776|NCT03996668|No Intervention|Control|Subjects received standard operating room dress including sequential compression devices.
32782200|NCT05278117|Experimental|complete burst abdomen repair|complete burst abdomen repair
32782203|NCT05277337|Experimental|Group 1 (Alluzience)|Single treatment at the baseline visit with Alluzience. Glabellar lines will be treated with 10 U/0.05 mL per injection point. In total 50 s.U in 0.25 mL for 5 injection points.
32782204|NCT05277337|Active Comparator|Group 2 (powder BoNT-A: BOTOX/Vistabel)|Single treatment at the baseline visit with powder BoNT-A (BOTOX/Vistabel). Glabellar lines will be treated with 4 U/0.1 mL per injection point. In total 20 U in 0.5 mL for 5 injection points.
32782205|NCT05276947|Experimental|Peanut ball intervention|The experimental group. In the active phase of the labor (cervical dilatation = 5 cm), the peanut ball, which has a cover provided by the researcher and changed in each patient, will be placed between the knees of the participant for at least 30 minutes every hour, and a position change will be provided with the peanut ball in each time. The positions to be given with the peanut ball, semi sitting lunge, side lying, tucked, leaning forward, pushing and sitting position.
32782206|NCT05276947|No Intervention|Control group|Standard care will be given to the control group without positioning with a peanut ball.
32782207|NCT05248945|Experimental|Evobrutinib plus Carbamazepine|
32782208|NCT05248789|Experimental|OH2|OH2 dosage: 1x10e7 CCID50/mL Administration：intratumoral injection Frequency：once two weeks
32782209|NCT05248711|Experimental|Daily Move|Participants (n=107) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use the Daily Move component on the Calm app for ~10 minutes per day for 8 weeks.
32782210|NCT05248711|No Intervention|Usual Care|Participants (n=107) will be asked to continue with usual care/routine and complete survey measures at each time point. Participants will be provided with access to the intervention after their study participation.
32782211|NCT04242667|Experimental|Actionable gene result for cancer risk|
32782212|NCT04242667|Experimental|Actionable gene result for cardiovascular disease risk|
32782213|NCT05248399|Experimental|COVID-19 Group Problem Solving|
32782214|NCT05248399|Active Comparator|Control Group-standard of care|
32782215|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
32782216|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
32782217|NCT04239313|Experimental|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
32782218|NCT04239313|Active Comparator|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
32782219|NCT04239313|Placebo Comparator|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
32782220|NCT05212753|Active Comparator|Conventional Physical Therapy Group|The conventional physical therapy group will receive Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application.
32782221|NCT05212753|Active Comparator|Stabilization Group|The stabilization group will receive lumbar stabilization exercises and the conventional physical therapy program. That program includes lumbar stabilization exercises including activation of the transverses abdominals (TA) and multifidi muscles.
32782222|NCT05212753|Active Comparator|Breathing Exercise Group|The breathing exercise group will receive breathing exercises including sleep hygiene, and the stabilization group program. Breathing exercises include diaphragmatic breathing and pursed-lip.
32782223|NCT05276167|Experimental|The experimental group|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy.
32782224|NCT05276167|No Intervention|The control group|Participants in the control group will receive radical cystectomy alone.
33287777|NCT03996668|Experimental|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
33287778|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
33287779|NCT01020578||Control|Patients with normal blood glucose
33287780|NCT00463580|Experimental|Infliximab|Participants in this arm will receive an infusion of infliximab.
33287781|NCT00463580|Placebo Comparator|Placebo|Participants in this arm will receive an infusion of normal saline.
32782225|NCT05275855|Experimental|Part A: EDI048 or Placebo|Part A is a single ascending dose study
32782226|NCT05275855|Experimental|Part B: EDI048 or Placebo|Part B is a multiple ascending dose study
32782227|NCT05274919||Patients scheduled for brain MRI with contrast injection|Inclusion at Erasmus MC and LUMC: The first cohort consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. Usually, such testing would be done in healthy volunteers, but contrast agent is required for the vascular signature mapping sequence. To avoid unnecessary contrast agent administration, the sequence will be tested in this patient cohort instead. In this study part, the outcome is the optimized protocol itself, with which the investigators could obtain additional information about the vascular structure throughout the brain. Therefore this group of subjects is expected to be sufficiently homogeneous for the research aim of this part of the study.
33287782|NCT01020656||group 1|patients with no anticoagulants used as the control group
33287783|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
33287784|NCT01020656||group 3|patients treated with aspirin
33287785|NCT01020656||group 4|patients treated with clopidogrel therapy
33287786|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
33287787|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
33287788|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
33287789|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
33287790|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
33287791|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
33287792|NCT01021124||QFT (+) vs QFT (-)|
33287793|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
33287794|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
33287795|NCT04891289|Experimental|HAI FUDR plus GemOx (Arm 1)|Surgical HAI pump placement. 2. HAI FUDR [(0.12 mg/kg/day) x wt (kg) x (30ml) / pump flow rate ] and dexamethasone [1 mg/day * 30] / pump flow rate ] on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
33287796|NCT04891289|Active Comparator|GemOx alone (Arm 2)|Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.For patients in Arm 2, systemic therapy will be administered on Days 1 and Day 15 of each Cycle on a 28-day cycle basis, compromised of Gemcitabine and Oxaliplatin. If a patient randomized to Arm 2 has intrahepatic progression on any follow-up scan during study treatment, that patient will be eligible to crossover to Arm 1 and commence to pump placement surgery and HAI FUDR treatment. Patients with any extrahepatic progression will not be eligible to utilize the crossover arm. Arm 2 patients will have 28 days from date of the scan showing intrahepatic progression to proceed to the crossover arm.
33287797|NCT05712005||Group 1|Study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times. Next, study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test.
33287798|NCT05712005||Group 2|Study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
33287799|NCT05712005||Group 3|Study subjects will complete the Cognivue Plus test followed by completing up to eight additional neuropsychological assessments, intermittently separated. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
33287800|NCT04879745|Experimental|Decision Aid Users|Patients with a rheumatic disease who are given access to the MyVoice:Rheum decision aid
33287801|NCT04879745|Active Comparator|Pamphlet Users|Patients with a rheumatic disease who are given access to a widely-accessible pamphlet about family planning
33287802|NCT04879745|Experimental|Rheumatologists|Rheumatologists who interact with patients who have used the MyVoice: Rheum decision aid
33287803|NCT04872023|Experimental|Patients|All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
33287804|NCT05142527|Experimental|High Dose IM injection of active drug or Placebo (Phase 2)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 300 subjects will receive active drug and approximately 150 subjects will receive placebo in the Phase 2 segment."
33287805|NCT05142527|Experimental|High Dose IM injection of active drug or Placebo (Phase 3)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 3000 subjects will receive active drug and approximately 1000 subjects will receive placebo in the Phase 3 segment"
33287806|NCT05137769|Experimental|Body Scan|Participants will listen to a 20-minute, audio-guided mindfulness-based body scan exercise.
33287807|NCT04005131|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
33287808|NCT04005131|Active Comparator|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
33287809|NCT04852289||>=65 Female|Older Females
33287810|NCT04852289||>=65 Male|Older Males
33287811|NCT04852289||18-64 Female|Young Females
33287812|NCT04852289||18-64 Male|Young Males
33287813|NCT05135117|No Intervention|Control|Passive rest - no intervention provided
33287814|NCT05135117|Active Comparator|Ice towel cooling|About 6-12 cooling periods of ice towel lasting between 5-20 minutes will be done and equally distributed throughout the respective trials. Towels dipped in ice water will be placed on subjects necks during this time.
33287815|NCT05135117|Experimental|NeuroRescue Neck Cooling Collar|About 6-12 cooling periods of neck cooling with the NeuroRescue collar lasting between 5-20 minutes will be done and equally distributed throughout the respective trials.
33287816|NCT03911843|Experimental|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
33287817|NCT03911843|Active Comparator|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
33287818|NCT04833335|Experimental|Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus|Inclusion visit, 1 month later, 6 month later
33287819|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
33287820|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
33287821|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
33287822|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
33287823|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
33287824|NCT00264550|Placebo Comparator|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33287825|NCT00264550|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33287826|NCT00264550|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33287827|NCT00264550|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33287828|NCT04271033|Experimental|Carotid Artery Stenting|Consecutive male and female patients older than 18 year with symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
33287829|NCT04004507|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
33287830|NCT04004507|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
33287831|NCT01070290|Experimental|1|ARQ 197
33287832|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
33287833|NCT05067257|Experimental|Resiniferatoxin|15 mcg, 20 mcg, or 25 mcg in 2mL injected once into the epidural space
33287834|NCT05067257|Placebo Comparator|Placebo|2mL injected once into the epidural space
33287835|NCT05067257|No Intervention|Concurrent Control|No intervention
33287836|NCT01048203|Experimental|ABR-215050|
33287837|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
32782228|NCT05274919||Patients diagnosed with suspected glioma scheduled for brain MRI|Inclusion at Erasmus MC and LUMC: The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested specifically for glioma and for a direct comparison between 3T and 7T, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. This number of patients is sufficient to provide information on differences in the ability to measure tumor vascularity between 3T and 7T, while minimizing the extra patient burden.
32830364|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
33287838|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
33287839|NCT01070524|Experimental|CHF 5188 pMDI|
33287840|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
33287841|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
33287842|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
33287843|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
33287844|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
33287845|NCT05711927|Experimental|SNOO group|The SNOO Smart Sleeper will be used in accordance with the manufacturer's programming and instructions.
33287846|NCT05711927|Sham Comparator|Traditional bassinet group|The SNOO will remain powered off to mimic the conditions of sleeping in a traditional hospital bassinet.
33287847|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
33287848|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
33287849|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
33287850|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
33287851|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
33287852|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
33287853|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
33287854|NCT03976492||Normal group|normal population
33287855|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
33287856|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
33287857|NCT04004663|Experimental|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
33287858|NCT04004663|Experimental|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
33287859|NCT04004663|Experimental|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
33287860|NCT04004663|Experimental|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
33287861|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
33287862|NCT04759313|Experimental|Imagenarrative treatment group|INI Sessions: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
33287863|NCT04759313|Experimental|Wait List Control Group|In weeks 6 through 10, the same program will be delivered to the wait list control group.
33287864|NCT00368979|Active Comparator|Dutasteride|
33287865|NCT00368979|Placebo Comparator|Placebo|
33287866|NCT00264238|Experimental|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
33287867|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
33287868|NCT01070602|Experimental|anterior corneal incision|
33287869|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
33287870|NCT05005013|Experimental|Active tDCS + Mindfulness|
33287871|NCT05005013|Sham Comparator|Sham tDCS + Mindfulness|
33287872|NCT05003843|Other|Single Arm|Use of Indigo Aspiration System in patients with obstruction due to DVT
33287873|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
33287874|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
33287875|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
33084961|NCT04561414|Other|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
32782229|NCT05274919||Patients with (suspected) glioma|"Inclusion at Erasmus MC and LUMC: The third cohort consists of 100 adult patients referred for biopsy or surgery of suspected glioma. The diagnosis of glioma is based on a multitude of factors, such as initial presentation (headaches, vomiting, potential changes in character). Based on the initial presentation a patient may be suspected of having a glioma, which is often confirmed using imaging. Although a true conclusion requires analysis of tissue, in an overwhelming majority of the cases (99%), analysis of the imaging is sufficient to confirm the presence of glioma. Thus, the investigators can be relatively certain about the inclusion of glioma patients based on the initial presentation and imaging alone.~Since there is a close collaboration with the Neurology departments of both the LUMC and Haaglanden Medical Center (HMC) in The Hague, the investigators broaden their inclusion capacity also to this hospital."
32782230|NCT05211973||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
32782231|NCT05211973||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
32782232|NCT05211973||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
32782233|NCT05209867|Experimental|CBD Intervention|Participants will self-administer CBD daily for 2 months.
32782234|NCT05273983|Experimental|Behavioural Activation Treatment|Two intervention sessions with a psychologist and an use of a mobile scheduling app over the course of 6 weeks.
32782235|NCT05273827|Experimental|neoadjuvant immunotherapy group|Anti-PD-1 monoclonal antibody (Nivolumab，Pembrolizumab, Sintilimab, or Sugemalimab) 200 mg intravenously in combination with cis-platinum and paclitaxel/pemetrexed
32782236|NCT05273827|Placebo Comparator|control group|platinum-containing dual-agent chemotherapy(cis-platinum and paclitaxel/pemetrexed)
33287876|NCT04971941|Active Comparator|DV3 with first LB injection|Use of Dental Vibe with first long buccal block
33287877|NCT04971941|Active Comparator|DV3 with first LB and with IAN|Dental Vibe with first long buccal injection and inferior alveolar block
32782237|NCT05273515|Experimental|Pilot|3D scanning of participants. Images used to created 3D reconstruction of 15% and 25% total body weight loss. These are shown to participants using virtual reality. Qualitative outcomes measured using group discussion and questionnaires.
32782238|NCT05273437|Experimental|System Identification|All participants in the study will go through a system identification experiment everyday for 270 days.
32782239|NCT05245201|Active Comparator|Arm 1 - Standard of care|Standard of care
32782240|NCT05245201|Active Comparator|Arm 2 - Clinical decision support for PrEP|EHR-based decision support tools to support PrEP discussions and prescribing for patients who have increased predicted HIV risk
32900521|NCT04422678|Experimental|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
33084962|NCT04561414|Other|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
33084963|NCT04561726|Experimental|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
33287878|NCT04971941|Experimental|DV3 with 2nd LB|Use of DentalVibe with 2nd Long Buccal injection
33287879|NCT04971941|Experimental|DV3 with 2nd LB and IAN|Use of DentalVibe with 2nd long buccal and inferior alveolar nerve block
33287880|NCT04933643||well prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that the stomach is well prepared when GCS ≥ 18
33287881|NCT04933643||inadequate prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS < 18 is inadequate.
33287882|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
33287883|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
33287884|NCT05711849|Experimental|Bone marrow aspiration and intracoronary infusion of autologous cells|
33287885|NCT05711849|Sham Comparator|Sham bone marrow aspiration and insertion of vascular access sheath|
33287886|NCT03991065|Experimental|with endoscopy|high digestive endoscopy
33287887|NCT03991065|No Intervention|without endoscopy|no endoscopy
33287888|NCT03991143|Experimental|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
33287889|NCT03991143|Placebo Comparator|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
33287890|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
32782241|NCT05209789|Experimental|HUGS therapy|A structured group intervention that aims to observe mother's behavior and responses with her baby, promote mother-baby interaction through play, and provide tools for positive interaction. This therapy involves cognitive and behavioral work. Therapists observe the mother-baby duo and share their observations from a perspective of encouragement and support. A playful and non-judgmental interaction is cultivated within the group. The main objective is to change the negative trajectory of mother-child interactions through tools from cognitive-behavioral therapies as well as using knowledge about child development.
33084964|NCT04561726|Active Comparator|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
33084965|NCT04561531|Experimental|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
33084966|NCT04561531|Experimental|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
33084967|NCT00234806|Experimental|Telemedicine intervention group|
33084968|NCT00234806|Placebo Comparator|Control group|
33084969|NCT04561219|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
33084970|NCT04561219|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
33084971|NCT04561609|Active Comparator|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
33287891|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
33287892|NCT04699331|Experimental|Individualized stimulation group|Patients receive five sessions of individualized stimulation obtained from brain image-based transcranial direct stimulation simulation. The simulator generates the electrode's location on the scalp.
33287893|NCT04699331|Active Comparator|Conventional stimulation group|Patients receive five sessions of conventional stimulation with electrodes over C3 and C4 based on the 10-20 system.
33287894|NCT04699331|Sham Comparator|Sham stimulation group|Patients receive five sessions of sham stimulation with electrodes over C3 and C4 based on the 10-20 system.
33287895|NCT04674683|Experimental|Test Arm|HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
33287896|NCT04674683|Placebo Comparator|Control Arm|Placebo oral BIW + nivolumab IV at specific doses on specific days
33287897|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
33287898|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
33287899|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
33287900|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
33287901|NCT04645355|Experimental|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
33287902|NCT04645355|Experimental|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
33287903|NCT04617587|Experimental|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
33287904|NCT04573673|Experimental|PTNS verum|Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
33287905|NCT04573673|Sham Comparator|PTNS placebo|Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
33287906|NCT01845597||MAKOplasty® medial UKA|Patients who have received a MAKOplasty® robotically guided unilateral knee arthroplasty (UKA) and received a medial MCK onlay implant.
33287907|NCT04188041|No Intervention|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.~In Aim 1, 30 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
32782242|NCT05209789|Active Comparator|Playtime|The participants assigned to the control group will also be in the presence of two therapists, allowing to reproduce the framework of the HUGS therapy. The difference will be the lack of direct therapeutic intervention from the therapists, but only classic psychoeducational guidance. The mothers are offered a time to play with their baby as well as the opportunity to discuss and share their experiences with other mothers, which is generally seen as supportive by them.
32782243|NCT05209711|Other|FN blockade under ultrasound control with a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
32782244|NCT05209711|Other|FN blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
32782245|NCT05243563|Experimental|Fractionated CO2 laser plus topical steroids|3 laser treatments at 6 week intervals for 6 months by a single trained operator
32782246|NCT05243563|Active Comparator|topical steroids alone|self-applied topical steroid therapy using clobetasol propionate 0.05%
32782247|NCT05272969||LOPD group|50 Patients with genetically confirmed late-onset Pompe disease.
32782248|NCT05272969||Control group|15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group.
32782249|NCT05272033|Active Comparator|GROUP TEAS|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at PC-5, PC-6, and ST-36 with an electronic acupuncture device.
32782250|NCT05272033|Sham Comparator|Sham TEAS|In the sham TEAS group, the gel electrodes will be applied at the same anatomical points without stimulation.
32782251|NCT05209087||Children with Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy who are between Levels 1-4 (continuing ambulation) according to Brooke Lower Extremity Functional Classification will be included in the study. This classification method was designed on the basis of the classification method to determine the functional status of the lower and upper extremities in the clinical evaluation of Duchenne Muscular Dystrophy.
32782252|NCT05243017|Experimental|Cohort 1 (Low Dose of AMT-130)|Low dose AMT-130 (6 × 10^12 gc/subject)
32782253|NCT05243017|Experimental|Cohort 2 (High Dose of AMT-130)|High dose AMT-130 (6 × 10^13 gc/subject)
32782254|NCT04126681|Experimental|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
32782255|NCT04126681|Active Comparator|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
32782256|NCT05270395|Experimental|mPal intervention|Participants in this group will receive the mPal intervention. mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider. mPal's provider content (not randomized) will include education. System-level modifications will also be made to the electronic health record to facilitate palliative care discussions and referrals.
33084972|NCT04561609|Placebo Comparator|control|Patients receiving placebo treatment with air on lower limbs
33084973|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
32782257|NCT05270395|No Intervention|Standard of care|Participants in this group will receive standard of care (applies to patients only).
32782258|NCT05208619|Active Comparator|thoracic epidural analgesia|A thoracic epidural catheter is placed before induction of general anaesthesia. Sufentanil 10 µg and Ropivacaine are applied via the catheter.
32782259|NCT05208619|Active Comparator|paravertebral block|A single-shot paravertebral block (Ropivacaine 0,5%) is placed before induction of general anaesthesia.
32782260|NCT05207917|Active Comparator|Gastric bypass|Gastric bypass
32782261|NCT05207917|Active Comparator|Sleeve gastrectomy|Sleeve gastrectomy
32782262|NCT05207917|Experimental|Single anastomosis sleeve ileal (SASI) bypass|Exploratory small arm with a small number of particpants
32782263|NCT05269303|Experimental|Intervention group|Participants will receive a 3-month Live With Wearable Monitoring Device program.
32782264|NCT05269303|No Intervention|Control group|Usual care. As with the participants in the intervention group, those in the control group can utilize the features in the Wearable Monitoring Device.
32782265|NCT05269147|Placebo Comparator|SBGB with normal saline|patients will receive standardized general anesthesia + SBGB with normal saline.
32782266|NCT05269147|Active Comparator|SBGB with lidocaine 2%|patients will receive standardized general anesthesia + SBGB with lidocaine 2%
32782267|NCT05269147|Active Comparator|SBGB with bupivacaine 0.5%|patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
32782268|NCT05241691||Pediatric patients treated with GGPSP for the correction of femur and/or tibia deformities|
32782269|NCT05206747|Experimental|Blue-blocking glasses|Participants will wear orange/amber colored lenses that filter wavelengths of light in the blue spectrum while awake from 6 p.m. to 8 a.m.
32782270|NCT05206747|Sham Comparator|Lightly-tinted glasses|This control will involve glasses that selectively filter short wavelength (e.g., ultraviolet), but not visible blue light during the same time window. Participants will wear these glasses while awake from 6 p.m. to 8 a.m.
32782271|NCT05206435|Active Comparator|Electronic Cigarettes|Participants in this arm are randomized to receive electronic cigarettes for the 6-week study period.
32782272|NCT05206435|Active Comparator|Nicotine Lozenges|Participants in this arm are randomized to receive nicotine lozenge for the 6-week study period.
32782273|NCT05206123||Adolescents with perinatal acquired HIV infection|group of Adolescents with perinatal acquired HIV infection
32782274|NCT05205811|Experimental|Combination zonisamide and bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
33084974|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
33084975|NCT04561492|Experimental|[68Ga]Ga-PentixaFor|
32782275|NCT05205811|Experimental|Bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
32782276|NCT05205811|Placebo Comparator|Placebo with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
32782277|NCT05166967|Experimental|Individual dose of ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg), and the active ATG concentration ranges from 110 to 148.5UE/ml.
32782278|NCT05166967|Active Comparator|Fixed dose of ATG|A total amount of 10mg/kg ATG was divided into 4 days (from day -5 to day -2). The specific usage: 1.5mg/kg for day -5, 2.5mg/kg for day -4 and day -3, 3.5 mg/kg for day -2.
32782279|NCT05166343|No Intervention|Standard of Care|All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
32782280|NCT05166343|Other|Intramuscular Epinephrine Dose|"POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector. Dosing will be dependent on weight as follows:~3-<5kg=0.3mg IM epinephrine~5-<10kg=0.5mg IM epinephrine~10-<25kg=1.0mg IM epinephrine~25kg=1.5mg IM epinephrine"
32782281|NCT05238337|Experimental|[14C]-PBI-200 Treated|[14C]-labeled PBI-200 will be administered as a single dose
32782282|NCT04126525|Experimental|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days
32782283|NCT05205421|Experimental|Oncolytic Virus Injection(RT-01)|RT-01 will be administered by intravenously;
32782284|NCT05237947|Experimental|Arm I (Gardasil 9)|Patients receive one dose of Gardasil 9 IM.
32782285|NCT05237947|Experimental|Arm II (Cervarix)|Patients receive one dose of Cervarix IM.
32782286|NCT05237947|Active Comparator|Arm III (Adacel)|Patients receive one dose of Adacel IM.
32782287|NCT05166109|Experimental|Vamorolone 500mg/day [250mg if <50kg body weight]|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
32782288|NCT05166109|Placebo Comparator|Placebo|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
32782289|NCT05205265|Experimental|Rivet Shunt Therapy|
32782290|NCT05204407|Active Comparator|Luteolin|
32782291|NCT05204407|Placebo Comparator|Placebo|
32782292|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
32782293|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
33287908|NCT04188041|Other|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 20 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
32782294|NCT05237245||1|Adult T-cell leukemia / lymphoma (ATL) patients
32782295|NCT05237245||2|HTLV-1 chronically infected patients without ATL
32782296|NCT05236543|Experimental|Treatment Arm|Subjects will receive AZD4831 on Day 1; Itraconazole only on Days 8 through 10 , and AZD4831 and Itraconazole on Day 11 oral dosing of Itraconazole only on Days 12 through 17.
32782297|NCT05203237|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants
32782298|NCT05203237|Experimental|VK2735 (Part A)|Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
32782299|NCT05203237|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants
32782300|NCT05203237|Experimental|VK2735 (Part B)|Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
32782301|NCT05163769|Experimental|Multimodal Training|The participants in the Multimodal training arm (mBCI) will undergo 48 physical and cognitive training sessions over 24 weeks on the NeeuroCycle BCI Physical and Cognitive training system. Sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session.The mBCI training program will deliver cognitive training modules in tandem with a stationary cycling regime. The cognitive training program consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. The cycling regime is divided into seven non-consecutive sections. The participant will be tasked to complete a cognitive training activity that will last about 2-3 minutes between each cycling session.
32782302|NCT05163769|Experimental|Neurocognitive-Training only|The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 cognitive training sessions over 24 weeks on the NeeuroCycle BCI Cognitive training system. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. The nBCI training protocol will deliver cognitive training modules that consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. Participants will navigate the virtual space of the cognitive training program by using arrow keys on the tablet.
32938724|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
33084976|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
33084977|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
33084978|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
33084979|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
33084980|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)~stenting of the lesion with a Pulsar-18 stent (mandatory)~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
33287909|NCT04188041|Other|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
33287910|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
33287911|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
33287912|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
33287915|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
33287916|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
33287917|NCT04595747|Experimental|Treatment (rogaratinib)|Patients receive rogaratinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and CT, MRI, and PET-CT every 8 weeks.
33287918|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
33287919|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
33287920|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
33287921|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
33287922|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
33287923|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
33287924|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
33287925|NCT04552457|Experimental|No activity restrictions|
33287926|NCT04552457|Active Comparator|Activity restrictions|
33287927|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
33287928|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
33287929|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
33287930|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
33287931|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
33084981|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
33084982|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
33287932|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
33287933|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
33287934|NCT05711693|Experimental|Technique comparison|All patients will undergo successively LDV heart to carotid PWV and ascending aorta PWV by MRI, for comparison
33287935|NCT04005365|Experimental|Prop+neochemo|
33287936|NCT03994926|Experimental|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
33287937|NCT05711615|Experimental|Treatment (peposertib, liposomal doxorubicin)|Patients receive peposertib PO and pegylated liposomal doxorubicin hydrochloride IV on study. Patients also undergo CT or MRI throughout the trial.
33287938|NCT01027182|No Intervention|Raltegravir|
33287939|NCT03060629|Experimental|Group 1|Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
33084983|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
33287940|NCT03060629|Placebo Comparator|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
33287941|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
33287942|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
33287943|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
33287944|NCT04512209|Experimental|DCE-MRI|
33287945|NCT04571801|Active Comparator|1|Standard diagnostics
33287946|NCT04571801|Experimental|2|Standard diagnostics + NGS
33287947|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
33287948|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
33287949|NCT01048515|Experimental|Caffeine|
33287950|NCT01048515|Placebo Comparator|Placebo|
33287951|NCT04004195|Experimental|Healthy participants|
33287952|NCT04004195|Experimental|Participants with mild renal impairment|
33287953|NCT04004195|Experimental|Participants with moderate renal impairment|
33287954|NCT04004195|Experimental|Participants with severe renal impairment|
33287955|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
33287956|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
33287957|NCT01050777|Placebo Comparator|Placebo|
33084984|NCT04551937|Placebo Comparator|Control|4-5 week period where participant will consume control beverage
33084985|NCT04551937|Experimental|Prebiotic|4-5 week period where participant will consume the intervention beverage
33084986|NCT04552054|Active Comparator|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
33084987|NCT04552054|Experimental|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
33084988|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.~Intervention: Days 2-8"
33084989|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.~Intervention: Days 2-8"
33084990|NCT04551859|Other|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
33287958|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
33287959|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
33287960|NCT04099589|Experimental|MIBC Group|Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
33287961|NCT04099589|Experimental|UTUC Group|Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.
33287962|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
33287963|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
33287964|NCT01563809|No Intervention|High androgens FSH alone|
33287965|NCT01563809|No Intervention|Low androgens, FSH alone|
33287966|NCT00264004|Experimental|1|30 mg AZD2171
33287967|NCT00264004|Experimental|2|45 mg AZD2171
33287968|NCT03975478|Active Comparator|Gastric bypass|Bariatric surgery by gastric bypass (GB)
33287969|NCT03975478|Experimental|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
33287970|NCT01069198|Experimental|Intervention group|
33287971|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
33287972|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
33287973|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
33287974|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
32782303|NCT05163769|No Intervention|Active Control|The participants in the Active Control arm (AC) will undergo 48 sessions over 24 weeks. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. Participants in this arm will view informative documentaries on an electronic tablet and answer three general questions about documentary.
32782304|NCT05161819|Experimental|High-frequency rTMS at left DLPFC|Receive an rTMS course with high-frequency stimulation at left DLPFC
32782305|NCT05161819|Sham Comparator|High-frequency sham stimulation at left DLPFC|Receive an sham rTMS course with high-frequency stimulation at left DLPFC with the sham coil
32782306|NCT05161663|Experimental|PDI group|In this group, participants will receive education about HIV and pre-exposure prophylaxis (PrEP) and be referred to our study by peer educators. Referred participants will have free PrEP counseling and receive referrals if interested. We will follow up at three and six months and check participants' PrEP status.
32782307|NCT05161663|No Intervention|Control group|In the control group, participants do not receive any education from peers and will be directly recruited by research assistants from venues (e.g. gay bars, LGBTQ communities, LGBTQ events, and social media advertisements). Participants will receive PrEP counseling and referral if interested. We will follow up at three and six months and check participants' PrEP status.
32782308|NCT05202847|Experimental|pulsed radiofrequency ablation to modified points group|pulsed radiofrequency ablation aimed at the adjusted target point of Park et al. under C-arm guidance
32782309|NCT05202847|Active Comparator|pulsed radiofrequency ablation to conventional points group|pulsed radiofrequency ablation aimed at conventional target point under C-arm guidance
32782310|NCT05161117|Experimental|virtual reality education|The experimental group will receive both an online fall prevention education module and additional education using a virtual reality simulation app for mobile devices designed for specifically for hospital caregivers
32782311|NCT05161117|Active Comparator|online education only|The control group will receive an online fall prevention education module
32782312|NCT05202535|Experimental|Aerobic exercise training|hospital-based aerobic exercise training on treadmill/cycle ergometer with the intensity of 40-70% of HR max, for 15-30 mints for 8 weeks
33084991|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
33084992|NCT00424905|No Intervention|2|No treatment (reference group)
33084993|NCT04551703|Experimental|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
33084994|NCT04551703|No Intervention|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
33084995|NCT04551976|Experimental|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
33084996|NCT04551976|Experimental|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
33084997|NCT04551976|No Intervention|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
33084998|NCT04551976|No Intervention|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
33084999|NCT00235001|Experimental|1|
33085000|NCT04551781|Experimental|steroid|20 mg prednisolone for 14 days
33085001|NCT04551781|Placebo Comparator|control|controll
33085002|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
32782313|NCT05202535|Active Comparator|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
33085003|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
33085004|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
33287975|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
32782314|NCT05201911|Experimental|Injection of I-124 AT03.|Single arm only, no placebo or comparator
32782315|NCT05201755|Other|A|"Investigators will evaluate the diameter of the basilica vein and venous flow-velocity after 5 minutes of breathing at room air. Investigators will collect basic vital parameters (heart rate, blood pressure, pulsoximetry).~Afterwards, the investigators will administer CPAP through a helmet, with the straps placed under the armpits. After 5 minutes, the investigators will collect again ultrasound data (venous diameter of basilica vein, flow-velocity) and basic vital parameters (heart rate, blood pressure, pulsoximetry).~Then the CPAP helmet will be tied to the bed and the armpit straps removed. After 5 minutes the investigators will collect ultrasound data and basic vital parameters as in the steps before (venous diameter, flow-velocity, heart rate, blood pressure, pulsoximetry). After this three steps, the protocol ends."
33085005|NCT04551274|Experimental|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
33085006|NCT04551274|No Intervention|Control|Control group participants will not experience any intervention
33085007|NCT04551118|Experimental|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
33085008|NCT04551118|Experimental|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
33085009|NCT04551118|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
33085010|NCT04551079|Experimental|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
32938725|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
32938726|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
32938727|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
32938728|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
32938729|NCT05178043|Experimental|GT90001+Nivolumab|
33287976|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
33287977|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
33287978|NCT01030224|Experimental|AZD9742 IV Infusion|Active
33287979|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
33287980|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
32938730|NCT05406206|Experimental|HAIC combined with Fruquintinib|HAIC with fruquintinib until progression. Fruquintinib should be administrated within 1 week after HAIC.
32938731|NCT00716755|Experimental|Dose Reduction|See Intervention
32938732|NCT05406128|Active Comparator|preoperative group|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
32938733|NCT05406128|Active Comparator|intraoperative group|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
32938734|NCT05141383|Other|Patients with prostate cancer|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
32938735|NCT05141383|Other|Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
32938736|NCT05141383|Other|Healthy donors|Male from 50 to 70 years old with a PSA level <4 ng / mL
32938737|NCT05406050|Experimental|TR|Subjects first receive a single-dose of 0.75 μg test eldecalcitol soft capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the first treatment period and to receive the reference (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the second treatment period.
32938738|NCT05406050|Experimental|RT|Subjects first receive a single-dose of 0.75 μg reference eldecalcitol soft capsule (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the first treatment period and to receive test capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the second treatment period.
32938739|NCT04736095||3D ultrasound for diagnosis of submucous myomas|
32938740|NCT04736095||Hysteroscopy for diagnosis of submucous myoma|
32938741|NCT03199118|Experimental|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
32938742|NCT03199118|Active Comparator|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
32938743|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
32938744|NCT04200404|Experimental|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
32938745|NCT04200404|Experimental|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
32938746|NCT04171778|Experimental|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
32938747|NCT04171778|Other|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
32938748|NCT04135742|Experimental|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
32938749|NCT04135742|Sham Comparator|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
32938750|NCT04135742|Sham Comparator|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
32938751|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
32938752|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
32782316|NCT05201755|Other|B|Same interventions and measurements as A, in different order (breathing room air, then with a CPAP helmet tied to the bed, then with a CPAP helmet fastened with armpit straps).
32782317|NCT05201755|Other|C|Same interventions and measurements as A, in different order (breathing with a CPAP fastened with armpit straps, breathing with a CPAP helmet tied to the bed and breathing at room air).
32782318|NCT05201755|Other|D|Same interventions and measurements as A, in different order (breathing with a CPAP helmet tied to the bed, breathing with a CPAP helmet fastened with armpit straps and breathing at room air).
32782319|NCT05159557|Experimental|In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 1 Apple Watch to detect falls and activity outside the home] will be self-installed by caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
32782320|NCT05159557|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights], with the exception of the Apple Watch that those in the experimental condition receive will be self-installed by caregivers (N=60) in their homes. Only monitoring of the water leak and associated warnings will be activated remotely for those participants who have been randomly assigned to this limited (sham comparator) arm."
32782321|NCT05200117||Nulliparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
32782322|NCT05200117||Multiparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
33085011|NCT04551079|Experimental|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
33085012|NCT04551079|Experimental|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
33085013|NCT00235040|Other|1|Intervention
32782323|NCT05159245|Experimental|Alectinib|For patients with a molecular tumor profile that can potentially be targeted by alectinib.
32782324|NCT05159245|Experimental|Cobimetinib|For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.
32782325|NCT05159245|Experimental|Vismodegib|For patients with a molecular tumor profile that can potentially be targeted by vismodegib.
32782326|NCT05159245|Experimental|Trastuzumab+Pertuzumab|For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.
32782327|NCT05159245|Experimental|Entrectinib|For patients with a molecular tumor profile that can potentially be targeted by entrectinib.
32782328|NCT05159245|Experimental|Atezolizumab|For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.
32782329|NCT05159245|Experimental|Vemurafenib|For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.
33085014|NCT00235040|No Intervention|2|Control
33085015|NCT02214043||Group 2|
33287981|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
32782330|NCT05159245|Experimental|Regorafenib|For patients with a molecular tumor profile that can potentially be targeted by regorafenib.
32782331|NCT05159245|Experimental|Apalutamide|For patients with a molecular tumor profile that can potentially be targeted by apalutamide.
32782332|NCT05159245|Experimental|Abemaciclib|For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.
32782333|NCT05159245|Experimental|Selpercatinib|For patients with a molecular tumor profile that can potentially be targeted by selpercatinib.
32782334|NCT05159245|Experimental|Dabrafenib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.
32782335|NCT05159245|Experimental|Trametinib|For patients with a molecular tumor profile that can potentially be targeted by trametinib.
32782336|NCT05159245|Experimental|Dabrafenib+Trametinib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.
32782337|NCT05159245|Experimental|Pralsetinib|For patients with a molecular tumor profile that can potentially be targeted by pralsetinib.
32782338|NCT04232371|Active Comparator|New Ablation Technique|Will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
32782339|NCT04232371|Active Comparator|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
32782340|NCT05230381|Active Comparator|Continous infusion group|Infusion with 20mg/kg tranexamic acid and 5mg/kg/h tranexamic acid.
33085016|NCT02214043||group 1|
33085017|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
33085018|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
33085019|NCT04550806||GDM|
33085020|NCT04550806||non-GDM|
33085021|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
33085022|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
33085023|NCT04550767||local infections|local infections
32782341|NCT05230381|Active Comparator|Single infusion group|Infusion with 20mg/kg tranexamic acid and same volume 0.9% saline.
32782342|NCT05230381|Placebo Comparator|Placebo group|Infusion with same volume of 0.9% saline.
32782343|NCT05229601|Experimental|HFB301001|Participants will receive HFB301001 via intravenous infusions
33287982|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
32782345|NCT05227417|Experimental|Intervention|SMS-based intervention delivered with a web-based system, which will include weekly health check-ins, appointment reminders all delivered via SMS (text messages).
32782346|NCT05227417|No Intervention|Control|Standard of care: Those who test positive in both tests receive post-test counseling, including emotional support, and are linked to a facility for antiretroviral (ART) initiation, ideally within one week. During the 1st medical appointment after diagnosis, lab tests are requested including CD4 and viral load. In most cases, ART initiation occurs at the second medical appointment when safety lab results are available. Currently, it is not mandatory to have CD4/VL results available to start ART. It is recommended that patients have CD4 counts and viral load assessed twice during the first year. A one-month supply of ART is provided initially. If clients are adherent, ART is dispensed every 3 months by nurses who also assess adherence. Standard follow-up is performed by nurses when clients visit the center for their appointments.
32782347|NCT05157841|Experimental|Part A: EXPAREL 266 mg arm|subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
32782348|NCT05157841|Experimental|Part A: EXPAREL 133 mg arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
32782349|NCT05157841|Active Comparator|Part A: Bupivacaine HCl arm|Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
32782350|NCT05157841|Experimental|Part B: EXPAREL 133 mg arm OR EXPAREL 266 mg arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
32782351|NCT05157841|Active Comparator|Part B: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
32782352|NCT05157217||Group 1|COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization
32782353|NCT05157217||Group 2|COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU
32782354|NCT05198557|Experimental|MT-0551 group|Participants will receive intravenous (IV) inebilizumab on Day 1 and Day 15 of randomized controlled period (RCP). The participants who entered open label period (OLP) will receive IV inebilizumab on Day 1 and IV placebo on Day 15 of OLP and will be followed by IV inebilizumab every 26 weeks.
32782355|NCT05198557|Placebo Comparator|Placebo group|Participants will receive IV placebo on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab on both Day 1 and Day 15 in OLP and will be followed by IV inebilizumab every 26 weeks.
32782356|NCT05198089|Experimental|Arm I (MyInspiration)|Patients use MyInspiration for spiritual and/or religious guidance for 30 days.
32782357|NCT05155891|Experimental|Embosphere Microspheres group|Participants in this group who are undergoing standard of care (SOC) prostate artery embolization (PAE) for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive Embosphere Microspheres during scheduled SOC PAE surgery.
32782358|NCT05155891|Active Comparator|HoLEP Group|Participants in this group who are undergoing SOC PAE for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive SOC Holmium laser enucleation of prostate (HoLEP).
32782359|NCT05154487|Experimental|Apelisib and Fulvestrant|alpelisib 300mg orally daily of each 28-day cycle fulvestrant 500mg IM on Day 1 and Day 15 of Cycle 1, then 500mg IM on Day 1 of each 28-day cycle.
32782360|NCT04241965|Experimental|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
32782361|NCT04241965|Placebo Comparator|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
32782362|NCT04241419|Experimental|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
33402225|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
32782365|NCT04241029|Experimental|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
33287983|NCT01324713||Males|
33287984|NCT01324713||Females|
33287985|NCT03992547|Experimental|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
32782366|NCT05154253|Experimental|Device resisted gait training (treatment)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
33085024|NCT04550767||systemic infections|systemic infections
33085025|NCT04550689|Active Comparator|Xenograft|
33287986|NCT00280150|Experimental|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
33085026|NCT04550689|Active Comparator|Allograft|
33085027|NCT04550923|Experimental|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
33085028|NCT04550923|Active Comparator|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
33085029|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
33287987|NCT00280150|Experimental|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
33287988|NCT00280150|Experimental|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
33287989|NCT00280150|Experimental|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
33287990|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
33287991|NCT01582126|Experimental|Group balance training early start|
33085030|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
33085031|NCT04550416|Experimental|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
33085032|NCT04550416|No Intervention|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
33287992|NCT01582126|Experimental|Group balance training late start|
33287993|NCT03990675|Experimental|FNA, FNB|
33287994|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
33287995|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
33287996|NCT01582360||antiinfectiva: flukonazol|80 patients
33287997|NCT01582360||antiinfectiva: cefotaxim|80 patients
33287998|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
33287999|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
33288000|NCT01582360||antiinfectiva: cloxacillin|80 patients
33288001|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
33288002|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
33288003|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
33288004|NCT00279916|Active Comparator|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
33288005|NCT00279916|Sham Comparator|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
33288006|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
33288007|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
33288008|NCT01052649||Healthy volunteers|
33288009|NCT01325896|Other|All patients are receiving PEG-Intron|
33288010|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
33288011|NCT00358527|Experimental|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
33085033|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
33288012|NCT00358527|Placebo Comparator|Matching placebo nasal spray|
33288013|NCT00251758|Experimental|Dexlansoprazole MR 60 mg QD|
33288014|NCT00251758|Experimental|Dexlansoprazole MR 90 mg QD|
33288015|NCT00251758|Placebo Comparator|Placebo|
33288016|NCT03974776|Experimental|PF-06946860|Single subcutaneous administration of PF-06946860
33288017|NCT03974776|Placebo Comparator|Placebo|Single subcutaneous administration of placebo
33288018|NCT00262834|Experimental|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
33288019|NCT00539591|Experimental|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
33288020|NCT00539591|Experimental|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
33288021|NCT05711459|Experimental|Liver Injury Group|The patients have liver injuries caused by antitumor drugs.
33288022|NCT05709665||Out-of-hospital cardiac arrest|Patient characteristics; Rescue time intervals; Time to eCPR Decision during high quality CPR;
33288023|NCT05709665||In-hospital cardiac arrest|Patient characteristics; Emergency team time intervals; Time to eCPR Decision during high quality CPR;
33288024|NCT05707715||Slight Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
33288025|NCT05707715||Severe Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
33288026|NCT04417361|Experimental|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
33288027|NCT04417361|Placebo Comparator|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
33288028|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
33288029|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
33288030|NCT04386239|Experimental|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
33288031|NCT03396575|Experimental|Group A|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
33288032|NCT03396575|Experimental|Group B|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
33288033|NCT05699603|Experimental|Prevention (calcipotriene, fluorouracil)|Participants receive calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study.
33288034|NCT04365413|Experimental|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.~The temperature of their skin prior to and after MSOT imaging will also be measured."
33288035|NCT04004585|Experimental|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
33288036|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
33288037|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
33288038|NCT00541775|Placebo Comparator|Placebo|placebo
33288039|NCT05361473|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydregenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
33288040|NCT05361473|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
33288041|NCT04004117|Experimental|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
33288042|NCT04004117|Placebo Comparator|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
33288044|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
33288045|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
32782367|NCT05154253|Experimental|Standard gait training (control)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
32782368|NCT05154253|Experimental|Comparison to Standard PT (within subjects control)|We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy.
33288046|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
33288047|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
33288048|NCT05668013|Experimental|TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
33288049|NCT05668013|Experimental|TEV-48574 Dose Regimen A for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
33288050|NCT05668013|Experimental|TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
32782369|NCT05154253|Experimental|Device assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
32782370|NCT05154253|Experimental|Passive brace assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
32782371|NCT05154253|Experimental|No ankle aid ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
32782372|NCT05196529|Experimental|Inspiratory muscle training|The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
32782373|NCT05193643|Experimental|Sonovein Treatment|
33402226|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
32782374|NCT05152927|Experimental|Parathyroid Eye (PTeye)|For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
32782375|NCT05152927|No Intervention|Usual Standard of Care|The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
32782376|NCT05226091|Experimental|Intervention arm|GP practices randomised to the intervention will receive a mail and email about the result of the PLEASANT study and advising them to implement the study findings.
32782377|NCT05226091|No Intervention|Usual care arm|GP practices randomised to control will not receive either mail or email and they will continue with usual care.
32782378|NCT05225233|Experimental|Active tDCS with Cognitive Training|Participants will receive active tDCS stimulation with their cognitive training during a one-hour session each day which includes 20 minutes of stimulation at the beginning of a 46-minute task training session. Ten sessions will be completed over three weeks.
32782379|NCT05225233|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 seconds, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
32782380|NCT05225155||Control|Women without thrombophilia, submitted to in vitro fertilization techniques
32782381|NCT05225155||Untreated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin
32782382|NCT05225155||Treated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin
32782383|NCT05192239|Placebo Comparator|Placebo|Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout.
32938753|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
32938754|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
32938755|NCT04123886|Experimental|SCB-313|
32938756|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
32938757|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
32938758|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
32938759|NCT04088786|Experimental|Active|Cytoreductive surgery (CRS) followed by study treatment with nanoliposomal irinotecan administered intraperitoneally.
32938760|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
32938761|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
32938762|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
32938763|NCT03208166|Other|Usual Care|Standard medical care.
32938764|NCT05093335|Experimental|[68Ga]-Pentixafor|An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
32938765|NCT04051112|Experimental|SCB-313|
32938766|NCT04756609|Experimental|Systematic offer of nurse-driven SARS-CoV-2 screening + usual practice|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
32938767|NCT04756609|Active Comparator|Control group: Usual emergency department practice|Usual emergency department practice with physician-directed diagnostic testing
32938768|NCT04708171||Awake mapping under local anesthesia|
33288051|NCT05668013|Experimental|TEV-48574 Dose Regimen B for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
33288052|NCT04188119|Experimental|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
33288053|NCT04188119|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
33288054|NCT04506047||Acute Myocardial Infarction|Consecutive patients with acute myocardial infarction
33288055|NCT02997761|Experimental|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33288056|NCT04119791|Experimental|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
33288057|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
33288058|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
33288059|NCT04003727|Active Comparator|Neutral Position|Head and neck will be on neutral position.
33288060|NCT04003727|Active Comparator|Sniffing Position|Head and neck will be on sniffing position
33288061|NCT04003727|Active Comparator|Head Extension position|Head will be on simple extension position
33288062|NCT05625659|Other|DBT and CESM Diagnostic Imaging in Women with Dense Breasts|Interventional Diagnostic
33288063|NCT04094441|Experimental|additional pulmonary function tests|additional pulmonary function tests
33288064|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
33288065|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
33288066|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
33288067|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
33288068|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
33288069|NCT04221191||Standard of Care (SoC) Group|SoC neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice (non-coached participants).
33288070|NCT04221191||OroSEP PSP (OPSP) Group|OPSP neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice and the OroSEP PSP (coached participants).
33288071|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
33288072|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
33288073|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
33288074|NCT04204343|Active Comparator|Caudal Block|US-guided caudal block with 0.7 ml/kg 0.25% Bupivacaine
33288075|NCT04204343|Active Comparator|Erector Spinae Plane Block|US-guided erector spinae plane block with 0.5 ml/kg 0.25% Bupivacaine
33288076|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
33288077|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
33288078|NCT00445068|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
33288079|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
33288080|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
33288081|NCT05361083|Experimental|First-in-man investigastion of [18F]CETO|"15 patients were investigated with PET/CT after injection of 2,5 MBq/kg [18F]CETO. 5 healthy volunteers were investigated twice (Test-retest), with approximately 2 weeks in-between each PET/CT investigation, after injection of 1,3 MBq/kg [18F]CETO. Arterial blood samples were taken as well as urinary sampels.~3 out of 5 healthy volunteers were also investigated twice with PET/CT after injection of 13,2 MBq/kg [15O]water, performed before the [18F]CETO PET/CT."
33288082|NCT02403089||neonates|neonates 24-41 weeks gestational age
33288083|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
33288084|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
33288085|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
33288086|NCT05360147|Placebo Comparator|Placebo|treated with oral antidiabetic drugs alone or combined with insulin, except for glucagon-like peptide type 1 (GLP-1) analogue
33288087|NCT05360147|Active Comparator|Liraglutide|liraglutide started at an initial dose of 0.6 mg/day and a maximum dose of 1.8mg/day, adjusted once a week when hyperglycemia was uncontrolled
33288088|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
33288089|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
32782384|NCT05192239|Active Comparator|10 mg THC|Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout.
32782385|NCT05151835|Experimental|Robotic Surgery|Prospective single arm study to investigate effect of a novel robotic surgical system on safety, efficacy and outcomes for performance of minimally invasive surgery across urology, upper and lower GI surgery.
32782386|NCT05222815|Experimental|CGM (continuous glucose monitoring)|"Use CGM, with availability of Ambulatory Glucose Profile (AGP) data, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
32782387|NCT05222815|Active Comparator|SMBG (Self-monitoring of blood glucose)|"Use SMBG, as currently used in primary care, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
32782388|NCT04235491||Micra AV leadless pacemaker therapy|All Medicare patients implanted with a Micra AV leadless pacemaker system
32782389|NCT04235491||Dual Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) dual-chamber transvenous pacemakers
32782390|NCT05190679||Cardiomyopathy Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in cardiomyopathy (CM) gene which include inherited CM syndromes.
32782391|NCT05190679||Arrhythmia Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in arrhythmia genes.
32782392|NCT05190679||Controls|No rare variant in CM, arrhythmia, or other atrial fibrillation gene.
32782393|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel
32782394|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with tucatinib|Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen
32782395|NCT05189977|Active Comparator|Sertraline alone at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
32782396|NCT05189977|Active Comparator|Sertraline + brexpiprazole at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
32782397|NCT05149417|Placebo Comparator|Standard group|Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.
32782398|NCT05149417|Active Comparator|SMS group|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
32782399|NCT05149417|Active Comparator|telemonitoring group|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
32782400|NCT05188807|Experimental|The patient with cervical pathology|we will perform airway ultrasonography before the patients intubations and we will intubate the patients before cervical surgery
32782401|NCT05148949|Experimental|Investigational vaccine group 1|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac at a schedule of 0, 28, 56 days.
32782402|NCT05148949|Experimental|Investigational vaccine group 2|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days.
32782403|NCT05148949|Active Comparator|Standard regimen group|40 healthy subjects will receive two doses of standard dosage CoronaVac at a schedule of 0, 28 days.
32782404|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
32782405|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
32782406|NCT04422301|Experimental|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
32782407|NCT04422301|Experimental|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
32782408|NCT04422301|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
32782409|NCT04422301|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
33402227|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
32938769|NCT04708171||Asleep mapping under general anesthesia|
32782410|NCT05188729|Experimental|Part 1 LTX-315 Safety Run-in|In Part 1 of the trial, the starting total daily dose for the evaluation of LTX-315 will be 2 mg for the first subject. Subjects will receive ascending once daily doses (increasing in 1 mg increments for up to 3 days in a 7 day treatment week [≥4 days off between treatment weeks]) until the first lesion is necrosed or until the subject experiences a DLT, whichever occurs first.
33085034|NCT04550338|Experimental|Tranexamic Acid Treatment|
33288090|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
33288091|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
33288092|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
33288093|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
33288094|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
33288095|NCT00539981|Experimental|FluBlok (Lots A, B, C)|Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
33288096|NCT00539981|Placebo Comparator|Placebo|Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
33288097|NCT00990041||PBMC|
33288098|NCT00990041||periodontitis|
33288099|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
32782411|NCT05188729|Experimental|Part 2 LTX-315 Safety Run-in|Part 2 will be initiated upon completion of Part 1 to confirm the MTD. One subject will be enrolled to receive treatment at the preliminary MTD (ie, the dose below which any DLTs occurred on Part 1). The planned dosing regimen in Week 1 of Part 2 will be an LTX 315 loading dose on Week 1/Day 1 (W1D1) at half the target dose, followed by total daily doses at the full target dose for the remaining dosing days of the treatment week (up to 3) until the lesion is necrosed
33288100|NCT00990119|Active Comparator|NiPPV|
33288101|NCT05360069|Experimental|Linear stapler group|Linear stapler is adopted in esophagojejunostomy.
32782412|NCT05188729|Experimental|Part 3 LTX-315 Dose Expansion|Part 3 will be initiated with 2 dose cohorts of up to 20 subjects each that will be enrolled to receive LTX 315 at the confirmed MTD and the dose immediately below the MTD. Alternatively, the Safety Review Committee (SRC) may designate a lower dose for exploration of efficacy based on the results of Part 2. Subjects will receive LTX-315 until the target lesion is necrosed. Doses will be administered daily in accordance with the dosing regimen determined in Part 2.
32782413|NCT05188261|Experimental|Cohort 1: 100μg IW-3300|Dose 1: within the cohort, 6 participants receive active drug (IW-3300)
32782414|NCT05188261|Placebo Comparator|Cohort 1: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
32782415|NCT05188261|Experimental|Cohort 2: Dose 2|Dose 2: within the cohort, 6 participants receive active drug (IW-3300)
32782416|NCT05188261|Placebo Comparator|Cohort 2: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
32782417|NCT05188261|Experimental|Cohort 3: Dose 3|Dose 3: within the cohort, 6 participants receive active drug (IW-3300)
32782418|NCT05188261|Placebo Comparator|Cohort 3: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
32782419|NCT05188261|Experimental|Cohort 4: Dose 4|Dose 4: within the cohort, 6 participants receive active drug (IW-3300)
32782420|NCT05188261|Placebo Comparator|Cohort 4: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
32782421|NCT05466799|Active Comparator|FOLFIRINOX Chemotherapy|Subjects in Arm A will receive up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
32782422|NCT05466799|Experimental|OncoSil™ in addition to FOLFIRINOX Chemotherapy|Subjects in Arm B will be implanted with the OncoSil™ device in addition to up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
33288102|NCT05360069|Active Comparator|Circular stapler group|Circular stapler is adopted in esophagojejunostomy.
32782424|NCT05107999|Experimental|Zhizhu Kuanzhong（ZZKZ） group|Patients in ZZKZ group were given ZZKZ (2 capsules tid) plus omeprazole (20 mg bid). ZZKZ was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
32782425|NCT05107999|Active Comparator|Doxepin group|Patients in doxepin group were given doxepin (25 mg tid) plus omeprazole (20 mg bid). Doxepin was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
32782426|NCT05146921|Active Comparator|food supplement: multi-strain probiotic (Symprove)|70 ml daily for 12 weeks
32782427|NCT05146921|Placebo Comparator|Placebo|70 ml daily for 12 weeks
33085035|NCT04550338|Placebo Comparator|Placebo Treatment|
33085036|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
33085037|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
33085038|NCT04550611|Experimental|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
33288103|NCT03992157|Experimental|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
33288104|NCT03992157|No Intervention|Crontrole|No implementation of an ECG Holter
32782428|NCT05186545|Experimental|Experimental|surufatinib + fulvestrant + chidamide
32782429|NCT05107765|Experimental|Pioglitazone|
32782430|NCT05107765|Placebo Comparator|Placebo|
32782431|NCT05185999|Experimental|Intervention|Intraperitoneal infusion with 500 mL of sodium-free 30% Icodextrin/ 10% Dextrose solution
32782432|NCT05146141|Experimental|Intervention Group|The participants will have to perform a bent-arm throw program 5 minutes before each training session
32782433|NCT05146141|Sham Comparator|Control group|No intervention. They will perform their usual warm-up.
32782434|NCT05185843|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 49 weeks.
32782435|NCT05106985|Experimental|ApplTree Reminder app|Following a randomised baseline period, each participant will use the ApplTree reminder app for 22 days to support adherence to goal-related tasks
32782436|NCT04234867|Experimental|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
32782437|NCT04234867|Experimental|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
32782438|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
32782439|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
32782440|NCT04421833|Active Comparator|group starting with TOVERTAFEL activities|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
32782441|NCT04421833|Sham Comparator|group ending with TOVERTAFEL activities|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
32782442|NCT05106283|Active Comparator|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
32782443|NCT05106283|Active Comparator|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
32782444|NCT05106127|Experimental|EG-007 1000mg + Len + Pem|3 to 6 patients will receive EG-007 1000 mg once weekly starting on the day of injection of Pembrolizimab starting the next 21-day cycle of treatment.
32782445|NCT05106127|Experimental|EG-007 1000mg Loading + Len + Pem|6 to 10 patients will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab under this protocol.
32782446|NCT05106127|Experimental|EG-007 1000mg D-4 Loading + Len + Pem|6 to 12 patients initiating new regimens of Len+Pem will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab.
32900522|NCT04422678|Experimental|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
32938770|NCT04708171||Resection under general anesthesia without mapping|
32938771|NCT03209882|Experimental|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
32938772|NCT03209882|Experimental|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
32938773|NCT05073913|Active Comparator|Living kidney donors|complete vascular exploration before and one year after nephrectomy
32938774|NCT05073913|Sham Comparator|potential living kidney donors|complete vascular exploration before and one year after the first exploration (for patients with medical contraindication to donation or who have declined donation after the first exploration)
32938775|NCT05058391|Experimental|Elaprase 0.5 mg/kg|Participants will receive a single dose of Elaprase 0.5 milligrams per kilogram (mg/kg) body weight, intravenous infusion on Day 1, Week 1 followed by every week up to end of treatment (EOT) (Day 358, Week 52).
32938776|NCT03290378|Active Comparator|AVE-901 50 mg|
32938777|NCT03290378|Active Comparator|AVE-901 25 mg|
32938778|NCT03290378|Placebo Comparator|Placebo|
32938779|NCT04659967|Experimental|Pre/Post Training (Within subject)|Participants will complete a baseline questionnaire followed by immediate virtual training, and complete a post-training questionnaire. Participants will also be asked to complete a questionnaire 1-month, 3-months, and 6-months post-training.
32938780|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
32938781|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
32938782|NCT05030467|Experimental|Intervention Arm|Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
32938783|NCT05030467|No Intervention|Control Arm|Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.
32938784|NCT05016037|Other|Lexically Based Speech Intelligibility Recast|Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.
32782447|NCT05144893|Experimental|Virtual Mindfullness-Based Support Group|The virtual mindfulness-based intervention with social support groups will meet once a week for 4 weeks, each session will be 60 minutes. Each group will have 3-8 participants. The groups will be closed, meaning the same group of participants meet with the same instructor (unless a backup instructor is needed due to unavoidable reasons). Groups will be completed using the video conferencing application.
32782448|NCT05184205|Experimental|Active Intervention|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
32782449|NCT05184205|Sham Comparator|Sham Comparator: Control|Sham comparator
32782450|NCT05183737|Active Comparator|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis
32782451|NCT05183737|Placebo Comparator|Placebo Group|Participants will receive microcapsules containing arabic gum and cornstarch with the same weight and characteristics as the intersecting microcapsules
32782452|NCT05144347|Experimental|XL114 Dose-Escalation Cohorts|Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.
32782453|NCT05144347|Experimental|XL114 Expansion Cohorts|The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma [ABC-DLBCL] (Cohort B), mantle cell lymphoma [MCL] (Cohort C), chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).
32782454|NCT05183581|Other|Visually aroused erection (naked, clothing, blankets)|"Randomisation of the order of visually aroused erection will be conducted:~Naked - Naked & Blanket - Clothing & Blanket~Naked - Clothing & Blanket - Naked & Blanket~Naked & Blanket - Naked - Clothing & Blanket~Naked & Blanket - Clothing & Blanket - Naked~Clothing & Blanket - Naked - Naked & Blanket~Clothing & Blanket - Naked & Blanket - Naked"
32782455|NCT05144191|Other|Insignia uncemented Hip Stem|"The Insignia™ Hip Stem is a collared stem that features a plasma-sprayed Hydroxyapatite (HA) coating over plasma-sprayed titanium in the proximal region and a plasma-sprayed HA coating over grit blast in the distal region and collar underside.~Insignia™ Hip Stems are intended for 'cement less' use only and are intended for total arthroplasty procedures."
32782456|NCT05103475|Experimental|Rage Against the Pain (RAP)|The RAP program curriculum will mirror that of the Hatha Yoga classes, but will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the poses/movements (rather, poses will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the typical relaxation/meditation exercise used in yoga, referred to as savasana).
32782457|NCT05103475|Active Comparator|Treatment as Usual (i.e., yoga)|The 'treatment as usual' class will be conducted in the style of the yoga classes currently being offered to Veterans at the Hines VA Hospital, which is a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
33085039|NCT04550611|Experimental|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
32782458|NCT05183347|Experimental|SRD: Dose Group 1|SRD: single-rising dose
32782459|NCT05183347|Experimental|SRD: Dose Group 2|SRD: single-rising dose
32782460|NCT05183347|Experimental|SRD: Dose Group 3|SRD: single-rising dose
32782461|NCT05183347|Experimental|MD: Dose Group 4|MD: multiple doses
32782462|NCT05183347|Placebo Comparator|Placebo|
32782463|NCT05183113|Experimental|Acute Intermittent Hypoxia|Both healthy participants and those with spinal cord injury will receive the acute intermittent hypoxia (AIH) intervention. All participants are imaged pre- and post-AIH intervention, and thus serve as a self-comparison to observe the hypothesized improvement in bilateral hand strength.
32782464|NCT05143177|Placebo Comparator|Placebo|
32782465|NCT05143177|Active Comparator|DA-1229 5mg|
32782466|NCT05143177|Active Comparator|DA-1229 10 mg|
32782467|NCT05182411||Patients with spasticity|adult neurological patients with spasticities in their lower extremities
32782468|NCT05102851||Patient with acute coronary syndrome|All patients with the acute coronary syndrome were included in the study. Pre-diabetic patient. Non-diabetic patient(Controlled)
32782469|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
32782470|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
32782471|NCT05102617|Experimental|Group A: Split-Face Device Only Treatment|Subjects will receive a split face treatment with the PicoSure Pro and/or PicoSure devices using different device settings on each half of the face.
32782472|NCT05102617|Experimental|Group B: Split-Face Treatment with Cosmeceuticals|Subjects will receive a full face treatment with the PicoSure Pro or PicoSure device and will use topical cosmeceuticals on only half of their face.
32782473|NCT05102617|Experimental|Group C: Device Only Treatment|Subjects will receive treatments with the PicoSure Pro or PicoSure device on multiple areas of the body such as the face, décolletage, back, legs, arms, and hands.
32782474|NCT05180539|Experimental|SPLASH Intervention Condition|
32782475|NCT05180539|Other|Diet and Physical Activity Condition|
32782476|NCT05100589|Experimental|PeakATP|PeakATP formula dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
32900523|NCT04422678|Active Comparator|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
33085040|NCT04550182|Experimental|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
33085041|NCT04550182|No Intervention|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
33085042|NCT04550026|Experimental|Inhalation of HTP|Inhalation of HTP for 30 minutes
33288105|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
33288106|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
33288107|NCT03992079|No Intervention|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
33085043|NCT04550026|Active Comparator|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
33288108|NCT03992079|Experimental|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
33288109|NCT01051011|Experimental|1|
33288110|NCT01051011|Experimental|2|
33288111|NCT01051011|Active Comparator|3|
33288112|NCT05359913|Experimental|African American Women|
33288113|NCT05361005|Experimental|Cohort 2mg/kg|All participants (fasted) received either 2 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288114|NCT05361005|Experimental|Cohort 4mg/kg|All participants (fasted) received either 4 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288115|NCT05361005|Experimental|Cohort 8mg/kg|All participants (fasted) received either 8mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288116|NCT05361005|Experimental|Cohort 4mg/kg multiple doses|All participants (fasted) received either 4 mg/kg of BDB-001 as a multiple doses or doses-matched placebo.
33288117|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
33288118|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
33288119|NCT05360927|Experimental|Cohort 0.3mg/kg|All participants (fasted) received either 0.3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288120|NCT05360927|Experimental|Cohort 1mg/kg|All participants (fasted) received either 1 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288121|NCT05360927|Experimental|Cohort 3mg/kg|All participants (fasted) received either 3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288122|NCT05360927|Experimental|Cohort 8mg/kg|All participants (fasted) received either 8 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288123|NCT05360927|Experimental|Cohort 16mg/kg|All participants (fasted) received either 16 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288124|NCT05360927|Experimental|Cohort 20mg/kg|All participants (fasted) received either 20 mg/kg of BDB-001 as a single dose or dose-matched placebo.
33288125|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
33288126|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
33288127|NCT02181257|Other|Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)|"Participants with NEW BOS will be randomized to Early Photopheresis Intervention (EPI) or Control (Standard of Care). EPI patients will receive 24 treatments in a 6-month period and may continue maintenance treatments.~The Control group will receive local Standard of Care for the management of BOS. Therapy will involve changes in immunosuppressive agents."
33288128|NCT02181257|Other|Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)|Participants with REFRACTORY BOS will be electronically assigned to either ECP treatment or Observation based on the participant's pre-enrollment Forced Expiratory Volume in 1 second (FEV1). Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the ECP Treatment arm. If a patient does not meet these criteria, the participant will be assigned to the Observation arm.
33288129|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
33288130|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
33288131|NCT01048827|Experimental|experimental|dose-escalation Busulfan
33288132|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
33288133|NCT01302327|Experimental|Exenatide|
33288134|NCT01659749|Other|Metabolic Camp|Metabolic Camp is an educational and social support program for females age 11 through adult with phenylketonuria (PKU) and maple syrup urine disease (MSUD), two inherited metabolic disorders (IMD). Camp provides a supportive environment for adolescent girls and women to learn about the importance of nutrition and diet self-management, with the intention of arresting the disease process and minimizing the instances of miscarriages and severe birth defects, which are high in this population. After 20+ years, Metabolic Camp is established as a unique, national program allowing up to 35 campers to live and learn during a week of nutritional support and productive activities, while simultaneously providing researchers an opportunity to gather important data.
33288135|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
33288136|NCT01048983|Active Comparator|Curcumin Only|
33288137|NCT01048983|Active Comparator|Armodafinil Only|
33288138|NCT01048983|Active Comparator|Minocycline Only|
33085044|NCT04550299|Active Comparator|Group A|single bundle technique with the use of bioabsorbable implants
33085045|NCT04550299|Active Comparator|Group B|single bundle technique with the use of Bio-Intrafix
32782477|NCT05100589|Placebo Comparator|Placebo|Placebo formula (same as experimental with no PeakATP) dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
32782478|NCT05100355|Active Comparator|Opacification|Contrast agent injection
32782479|NCT05100355|Experimental|Physiological serum injection|Physiological serum injection
32782480|NCT05142397||Treated women|HPV positive，pathology result indicate cervical intraepithelial neoplasia
32782481|NCT05142397||Healthy controls|HPV negative, normal cytology
32782482|NCT05142007|Experimental|Hypnosis|"The first treatment arm (targeted suggestion) consist of suggestions about enhancing working memory functions through the instantiation of preinjury working memory ability in the present using age regression, visualizations of neuroplasticity in the present, and posthypnotic suggestions about continued improvement. The overarching theme of the suggestions is that thinking itself will become effortless and reliable, leading to reduced fatigue, better memory, and the absence of information overload."
32782483|NCT05142007|Active Comparator|Mindfulness-based stress reduction|"The second treatment arm (non-targeted suggestion or MBSR) contains no explicit mentioning of brain injury or working memory-related abilities and thus serves to isolate the 'targetedness' of suggestion as well as factoring out other influences from placebo, retest effects, etc."
32782484|NCT05142007|No Intervention|Control group|The (passive) control group receives no contact over and beyond testing.
32782485|NCT05141695|Experimental|therapeutic group|therapeutic repetitive peripheral magnetic stimulation
33085046|NCT04550299|Active Comparator|Group C|double bundle technique with the use of bioabsorbable implants
32782486|NCT05141695|Sham Comparator|sham group|sham repetitive peripheral magnetic stimulation
32782487|NCT05180383|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
32782488|NCT05141071|Experimental|Ivabradine|In the study group, Ivabradine(I) group; patients will receive an enteral Ivabradine (dissolved in distilled water) 5mg twice daily (every 12 hours) via a naso-gastric tube.
32782489|NCT05141071|Placebo Comparator|Placebo|the control group, Placebo (P) group; patients will receive 50 ml of saline twice daily also via a naso-gastric tube.
33085047|NCT04550299|Active Comparator|Group D|double bundle technique with the use of Bio-Intrafix
32782490|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
33085048|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
33085049|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
33288139|NCT01048983|Active Comparator|Bupropion Only|
32782491|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
32782492|NCT05097625||High Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
32782493|NCT05097625||Low Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
32782494|NCT05179993||Study Group|Proof of principle Study group: detection of microplastics in human granulosa cells and in the follicular fluid of women undergoing intracytoplasmic sperm injection (ICSI) treatment
32782495|NCT05178589|No Intervention|Control|During the control condition cycle (no TENS), participants will refrain from using or taking other analgesics, besides ibuprofen.
32782496|NCT05178589|Experimental|One Unit TENS|Participants will use one-unit TENS set-up where the TENS unit has 2 channels.
32782497|NCT05178589|Experimental|Two Unit TENS|Participants will use a two-unit TENS set-up where the TENS unit has 4 channels.
32782498|NCT05097001|Experimental|Computer|Programming based on computer-guided assessment
32782499|NCT05097001|Active Comparator|CLINICAL|Programming based on clinically-guided assessment
32782500|NCT05096845|Experimental|V-01 COVID-19 Vaccine|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
32782501|NCT05096845|Placebo Comparator|Placebo control|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
32782502|NCT05139745|Experimental|Histological evaluation of BTL-899 device´s effect on fat tissue|This group will be treated with 100% of the treatment parameter settings
32782503|NCT05139745|Sham Comparator|Sham treatment|This group will be treated with 5% of the treatment parameter settings
32782504|NCT05139433|Experimental|Intervention Group|Participants in this arm will receive 5 internet-delivered cognitive-behavioral intervention and will have access to 15 educational videos
32782505|NCT05139433|Active Comparator|Active Control Group|Participants in this arm will have access to 15 educational videos.
33085050|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
33085051|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
33085052|NCT04549714|Experimental|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
33085053|NCT04549714|Experimental|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
33288140|NCT01048983|Active Comparator|Curcumin + Armodafinil|
33288141|NCT01048983|Active Comparator|Curcumin + Minocycline|
32782506|NCT05177419|Experimental|High-dose LSD|High dose of lysergic acid diethylamide
32782507|NCT05177419|Active Comparator|Low-dose LSD|Low dose of lysergic acid diethylamide
32782508|NCT04229329|Experimental|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
32782509|NCT04229329|Sham Comparator|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
32782510|NCT04229017|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
32782511|NCT04229017|Experimental|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
32782512|NCT05094427||Lumbar spine surgery with preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery with a fluoroscopically-guided DR block placed by the operative neurosurgeon prior to surgery. These patients subsequently received standard of care general anesthesia and standard multimodality postoperative pain control.
32782513|NCT05094427||Lumbar spine surgery without preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery without placement of a fluoroscopically-guided DR block. These patients received standard of care general anesthesia and standard multimodality postoperative pain control.
32782514|NCT05176561|Experimental|Treatment: Auditory-Cognitive Training|Behavioral: AR Group will complete sessions in their home or office via internet. Sessions will include independent work using computer software two hours per week and one hour meeting with the clinician each week. One half of the training is devoted to auditory training and one half to auditory cognitive activities. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
32782515|NCT05176561|Sham Comparator|Control: Non-auditory Cognitive Training|Behavioral: The CT Group will complete two hours of training in their home or office via internet. Sessions will include independent work using computer software two hours per week. Training exercises will be chosen from: Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Differences. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
32782516|NCT05092711||in patients with coronary heart disease and COVID 19|
32782517|NCT05139043|Active Comparator|Arm I (standard dose dexamethasone)|Patients receive standard dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive standard dose dexamethasone IV before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
32782518|NCT05139043|Experimental|Arm II (lower dose dexamethasone)|Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
32782519|NCT05176405|Experimental|Elissa's EE Song|Participants will have to click on the watch button to start the YouTube video as it is without manipulation. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
32782520|NCT05176405|Active Comparator|Standard of Care|Participants will be assigned to read general infographic messages adopted from the Saudi Ministry of Health (MOH) in the breast cancer early screening context in Arabic/English. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
32782521|NCT05176405|No Intervention|Control Group|The third arm of this trial is the control group who will not be exposed to any preventative messages.
33085054|NCT04549714|Experimental|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
33085055|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
33085056|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
33085057|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
33085058|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
33085059|NCT04549675|Experimental|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
33085060|NCT04549675|Active Comparator|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
33085061|NCT04549948|Experimental|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
33288142|NCT01048983|Active Comparator|Curcumin + Bupropion|
33288143|NCT01048983|Active Comparator|Armodafinil + Minocycline|
33288144|NCT01048983|Active Comparator|Armodafinil + Bupropion|
33288145|NCT01048983|Active Comparator|Minocycline + Buproprion|
33288146|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
33288147|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
33288148|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
33288149|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
33288150|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
32938785|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
33288151|NCT03929783|Experimental|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
33288152|NCT01520597||Case|Patient with culture-proven listeriosis
33288153|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
33288154|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
33288155|NCT00990275|Experimental|Post-alcohol|
33288156|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:~Days 1 and 2:~Reduction of caloric intake to 5kcal/kg/day;~Replacement of serum phosforus, potassium and magnesium;~Administration of 100mg intravenous thiamine, vitamins and microelements.~From day 3:~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
33288157|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.~Electrolyte replacement will be provided at the clinician's discretion."
33288158|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
33288159|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
33288160|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
33288161|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
33402228|NCT04051918|Experimental|Socially Assistive Robot Intervention|Piano training intervention led by a semi-autonomous socially assistive robot
32938786|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
32938787|NCT04976647|Active Comparator|A arm: HLX10+chemo|Participants receive 300mg HLX10 IV every 3 weeks (Q3W) in combination with carboplaitin (AUC5 or 6) IV Q3W and nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle.
32938788|NCT04976647|Experimental|B arm: HLX10+HLX07+chemo|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W with chemo.
32938789|NCT04976647|Experimental|C arm: HLX10+HLX07|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W.
32938790|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
32938791|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
32938792|NCT04553731|Experimental|The mHealth-based program|The experimental group used the mHealth app and a wearable activity tracker (WAT) on managing and preventing excessive GWG among overweight and obese women during pregnancy
32938793|NCT04553731|No Intervention|The standard antenatal treatments with no mHealth-based elements|controls received standard antenatal treatments with no mHealth-based elements
32938794|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
32938795|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
32938796|NCT04874545|Experimental|Propofol group|Maintenance of anaesthesia will be done using Propofol total intravenous anesthesia (TIVA) 6-12 mg/ kg/h by syringe pump, 100 % O2.
33085062|NCT04549948|Experimental|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
33288162|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
33085063|NCT04549948|Experimental|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
33288163|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
33085064|NCT04549987|Experimental|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
33288164|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
33288165|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
33288166|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
33288167|NCT03990441|Experimental|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
33288168|NCT03990441|Placebo Comparator|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
33288169|NCT05359757|Experimental|Naturalistic therapeutic techniques and PECS therapy.|
33288170|NCT05359757|Active Comparator|PECS therapy Only.|
33288171|NCT03990597|Experimental|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
32782522|NCT05175781|Active Comparator|Dexmedetomidine|"patients will receive two NIV sessions during which intravenous continuous infusion of dexmedetomidine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. Dexmedetomidine will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions accounting for 1-h contextual half-life of dexmedetomidine. Patients received neither tested drug nor NIV during this 6-h interval."
32782523|NCT05175781|Active Comparator|Ketamine|"patients will receive two NIV sessions during which intravenous continuous infusion of ketamine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, infusion of ketamine will be at the dose of 0.20 mg/kg/h (or 3.3 mg/kg/min). to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of the infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
33288172|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
33288173|NCT01049061|Experimental|MORAb-003|
33288174|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
33288175|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
33288176|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
33288177|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
33288178|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
33288179|NCT00367341|Other|Escitalopram|
32782524|NCT05175781|Placebo Comparator|Placebo|"patients will receive two NIV sessions during which intravenous continuous infusion of placebo (0.9% sodium chloride solution) will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of any infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
32782525|NCT04421911|Experimental|ketoprofen|
33085065|NCT04549987|Experimental|With changing working archwire|The extraction space closed having the working archwire changed monthly.
33085066|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
33085067|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
33085068|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
33085069|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
33085070|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
33085071|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
33085072|NCT00268398|Active Comparator|FOLFOX4|
33085073|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
33085074|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
33288180|NCT00367341|Other|Cognitive Behavioral Therapy|
33288181|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
33288182|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
33288183|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
33288184|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
32782526|NCT04421911|Active Comparator|Diclofenac|
33288185|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
33288186|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
33288187|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
33288188|NCT03992313|Experimental|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
33288189|NCT03992313|Experimental|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
33288190|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
33288191|NCT01325441|Experimental|BBI608 and Paclitaxel 200mg BID|Patients will receive BBI608 orally continuously at 200mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
33288192|NCT01325441|Experimental|BBI608 and Paclitaxel 240mg BID|Patients will receive BBI608 orally continuously at 240mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
33288193|NCT01325441|Experimental|BBI608 and Paclitaxel 400mg BID|Patients will receive BBI608 orally continuously at 400mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
33288194|NCT01325441|Experimental|BBI608 and Paclitaxel 480mg BID|Patients will receive BBI608 orally continuously at 480mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
33288195|NCT01325441|Experimental|BBI608 and Paclitaxel 500mg BID|Patients will receive BBI608 orally continuously at 500mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
33402229|NCT04051918|Active Comparator|Content Only Intervention|Piano training intervention using the same curriculum displayed on a computer monitor, without the socially assistive robot tutor.
33402230|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
32782527|NCT05175313||normal people|people who don't complain of respiratory diseases will be examined by chest ultrasound and pulmonary function test.
33085075|NCT00235313|Other|2|normal following with a nicotine patch
33085076|NCT04549285|Experimental|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
33085077|NCT04549753|Experimental|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
33085078|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
32938797|NCT04874545|Active Comparator|sevoflurane group|Maintenance of anaesthesia will be done using sevoflorane1.5-2%, 100 % O2.
32938798|NCT04535713|Experimental|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
33288196|NCT05360849|Experimental|Practice Facilitation|Practice Facilitation is an established evidence-based intervention to improve primary health care processes and outcomes, including the delivery of preventive services, through the creation of an ongoing, trusting relationship between an external Practice Facilitator (PF) and a clinical practice. In Practice Facilitation, a trained PF uses organization development, project management, quality improvement, and practice improvement approaches to build the internal capacity of a clinic to support it in reaching its goals for healthcare delivery, A PF's work includes relationship-building, helping to identify a clinic change champion, and facilitating change through logistical support, technical assistance, and external partnership building.
33288197|NCT00537485|Experimental|1|
33288198|NCT00537485|Placebo Comparator|2|
33288199|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
33288200|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
33288201|NCT05360771|Experimental|treatment group|Percutaneously occlusion of PFO with SnowyTM PFO closure system
33288202|NCT05360771|Experimental|control group|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
33288203|NCT04003571|Experimental|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
33288204|NCT04003571|Active Comparator|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
33288205|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
33288206|NCT05358431|Experimental|participants|Patients fulfilling the El Escorial criteria for probable or definite ALS with a C9orf72 mutation or asymptomatics being a first-degree to a person carrying a C9orf72 mutation or Healthy controls
33288207|NCT05401643|Experimental|mHealth intervention|Installation of the mHealth application Xemio in the participant's smartphones. Voluntary use of the application for 12 months. Outcome measures collected every 3 months.
33288208|NCT05401643|No Intervention|Control|No application installed. Outcome measures collected every 3 months.
33288209|NCT05360537|Experimental|patients treated with liraglutide|Diabetes therapy with liraglutide and various combinations of metformin, repaglinide, sulfonylureas.
33288210|NCT05360537|Experimental|patients treated with liraglutide plus Basal Insulin|Diabetes therapy with liraglutide and various combinations of glargine insulin, metformin, repaglinide, sulfonylureas.
33288211|NCT05360537|Active Comparator|patients treated with Insulin regime Basal Bolus|Diabetes therapy with the combination of a single administration of glargine insulin and three administration of Aspart Insulin.
33288212|NCT05590949||Post- menopausal breast cancer patients|Participants are post- menopausal with a breast cancer diagnosis who received at least 2 doses of denosumab, and then discontinued therapy, and discontinued Aromatase Inhibitors/AI prior to or within 6 months of stopping denosumab
33288213|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
33288214|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
33288215|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
33288216|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
33288217|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
33288218|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
33288219|NCT05590637|Active Comparator|quetiapine|
33288220|NCT05590637|Active Comparator|pimavanserin|
33288221|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
33288222|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
33402231|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
33402232|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
32782528|NCT05175313||obstructive respiratory diseases|the patients who are diagnosed with either COPD or asthma.
33288223|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
33288224|NCT05590559|Active Comparator|paravertebral block|
33288225|NCT05590559|Experimental|Ultrasound-guided erector spinae plane block|
33288226|NCT05359601|Experimental|24-hour|Every 24-hour infusion set replacement
33288227|NCT05359601|Placebo Comparator|96-hour|Every 96-hour infusion set replacement
33288228|NCT05590325|Experimental|single arm, two-stage|"Participants will be enrolled in two stages:~Stage 1 will assess a single dose of the DTG dispersible tablet in two sequential cohorts: Cohort 1A (n=8) and Cohort 1B (n=8).~Stage 2 will assess multiple-doses of the DTG dispersible tablet in a single cohort: Cohort 2 (n=24)"
33288229|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
33288230|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
33288231|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
33288232|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
33288233|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
33288234|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
33288235|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
33288236|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
33288237|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
33288238|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
33288239|NCT05590247|Experimental|Intermittent Fasting Group|Patients in this group will do intermittent fasting dieting for 12 weeks, meaning they will only eat for 8 hours per day. They may choose whichever 8 hours they want. Only water can be consumed during the fasting period. For the last 12 weeks of the study, they will resume their normal diet.
33288240|NCT05590247|No Intervention|Standard Routine Diet Group|Patients will continue with their normal diets for the 24 week duration of the study.
33288241|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
33402233|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
32782529|NCT05175313||restrictive respiratory diseases|patient with either ILD
32782530|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
33085079|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
32782531|NCT05138341|Experimental|Mechanical Minimal Invasive Surgical (MIS) management|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
32782532|NCT05138341|No Intervention|Best Medical Management (MM)|Best medical management per standard of care
32782533|NCT05174611|Experimental|Treatment group|Subject in treatment group will receive one capsule of 2000IU Vitamin D3 supplement per day with the duration of 16 weeks.
32782534|NCT05174611|Placebo Comparator|Placebo group|Subject in placebo group will receive one capsule of placebo per day which looks exactly same as the Vitamin D3 capsule with the duration of 16 weeks.
32782535|NCT05090839|Experimental|Spanish-Only Writing Group|Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in Spanish only.
32782536|NCT05090839|Experimental|English-Only Writing Group|Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in English only.
32782537|NCT05090839|Experimental|Non-Trauma Daily Event Writing in Spanish Group|Participants in this group will be required to write once weekly for 4 consecutive weeks. Participants will be instructed to write objectively about what they did the day prior and to avoid writing about their emotions or opinions. The participant will be required to write in Spanish only.
33288242|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
33288243|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
33288244|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
33288245|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
33288246|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
33288247|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
33288248|NCT05359523|Active Comparator|Patients diagnosed with myofascial pain syndrome|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
33288249|NCT05359523|Active Comparator|Healthy volunteers|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
33288250|NCT05590091|Experimental|Experimental group|roup A were given precise dietary guidance and enteral and parenteral nutrition support treatment using only nutrition software. It is recommended that the precise recommended time covers the start of enrollment until 100 days after transplantation
32782538|NCT05136703|Experimental|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|Participants randomized to receive CBT-AD immediately will complete up to 12 individual sessions focused on depression and one session of ART Adherence counseling during the four months following randomization.
32782539|NCT05136703|Experimental|Wait-List Control (WLC)|Participants randomized to the WLC condition will receive one session of ART adherence counseling immediately following randomization. After six months, WLC participants will have the opportunity to receive 12 individually delivered CBT-AD sessions focused on depression.
32782540|NCT05173753|Active Comparator|Novel self-adhesive composite restoration (Surefil one)|
32782541|NCT05173753|Active Comparator|conventional composite resin restoration(VOCO Grandio)|
33288251|NCT05590091|No Intervention|The control group|Group B patients were given the routine nutritional support treatment plan commonly used in clinics. Patients in both groups were monitored and followed up at -5d before transplantation and at +6d, +30d, +60d, +100d, +180d, and +360d after transplantation.
33288252|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
32782542|NCT04226209|Experimental|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
32782543|NCT04226209|No Intervention|Control|Control group will be taken to the queue list.
33288253|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
33288254|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
33288255|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
33288256|NCT05589779||With cardiovascular disease|Asthma patients with cardiovascular disease
33288257|NCT05589779||Without cardiovascular disease|Asthma patients without cardiovascular disease
33288258|NCT05358275|Experimental|study group|Guided lid surgery is performed to reduce the loss of bone post operative
33288259|NCT05358275|Active Comparator|control group|The patient will receive active ordinary treatment for removal of odontogenic cysts
33085080|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
33288260|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
33288261|NCT00990743|Experimental|SYL040012|
33288262|NCT05358197|Experimental|Control group|
33288263|NCT00990977|No Intervention|controls|assessment only
33288264|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
33288265|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
33288266|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
33288267|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
33288268|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
33288269|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
33288270|NCT04754165|Experimental|Immersive Virtual Reality plus the enhanced recovery after surgery protocol|"Patients in the immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones in the post anesthesia care unit (PACU) after surgery. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~Patients in the VR group will also be treated according to the existing enhanced recovery after surgery protocol."
33288271|NCT04754165|No Intervention|Enhanced recovery after surgery protocol|Subjects in the control group will only undergo standard enhanced recovery after surgery care.
33288272|NCT04748549|Experimental|Immersive VR group|"Patients in the Immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~To reduce the influence of the anesthesia provider on the determination of sedative requirements, patients will administer their own sedation according to their needs for relaxation and comfort using a patient controlled system."
33288273|NCT04748549|Active Comparator|Music group|Patients randomized to the Music group will be equipped with VR headsets but won't view any content. They will also be equipped with noise cancelling headphones in the same fashion as the immersive VR group. A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient. Patients in the Sham VR group will also use patient controlled sedation.
33288274|NCT04748549|Sham Comparator|Sham VR + Usual Care Control Group|Subjects in the control group will wear VR headsets and headphones but will not view any content or listen to any audible content. They will undergo Monitored Anesthesia Care (MAC) according to a prespecified protocol targeting light or moderate sedation with a propofol infusion.
32782544|NCT05173207||Cardiothoracic surgical patients|Subjects will undergo one simultaneous instrumental examination of swallowing and concurrent monitoring of metrics of respiratory-swallow physiology. Research exam will be performed at bedside within Cardiac & Thoracic Intensive Care Units during their early postoperative recovery.
32782545|NCT04225507|Other|Lifestyle Intervention|Diet and exercise.
32782546|NCT04225507|Experimental|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
32782547|NCT05173129|Experimental|Haemophilic boys|Adolescent boys with haemophilia
32782548|NCT05173129|Active Comparator|Healthy boys|Healthy adolescent boys
32782549|NCT05172349|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring positioned by the investigator during patients' hospital visits.
32782550|NCT05133973|Experimental|Cohort A|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 3x between days 01-07, on Days 21 and 28. There will be safety visit at Day 14.~Finger pricking at home use will be intensified during days 00-07."
32782551|NCT05133973|Experimental|Cohort B|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 4x between days 07-14 and on Day 28. There will be safety visit at Day 21.~Finger pricking at home use will be intensified during days 07-14."
32782552|NCT05133817|Placebo Comparator|Control group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
32782553|NCT05133817|Experimental|0.025 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.
32782554|NCT05133817|Experimental|0.05 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.
32782555|NCT05133817|Experimental|0.075 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.
32782556|NCT05133817|Experimental|0.1μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.
32782557|NCT05172193|Experimental|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|One booster dose 0.5 mL IM injection of SARS-COV-2 Vaccine (Vero Cell) Inactivated
32782558|NCT05171335|Experimental|Lenvatinib in Combination with TACE Prior to Liver Transplantation|Regimen of six months neoadjuvant lenvatinib in combination with TACE prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria.
32782559|NCT05171335|Other|Matched Historical Control Patients|Historical controls will be liver transplant recipients matched on age, etiology of liver disease (viral vs. non-viral), listing tumor size, and number of TACE procedures to cases in the intervention group who receive a transplant.
33288275|NCT04730843|Experimental|Part A dose escalation|ES102 will be escalated in patients with advanced solid tumors.
33402234|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
32782560|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
32782561|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
32782562|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
32782563|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
32782564|NCT05088967|Experimental|IBI110+sintilimab|IBI110 and sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. IBI110 and sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
32782565|NCT05088967|Active Comparator|sintilimab|Sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. Sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
32782566|NCT05087329|Experimental|Virtual Mindfulness intervention|Four weekly group Zoom webinars with a 15-20 minute pre-recorded meditation
32782567|NCT05087329|No Intervention|Standard of Care|
32782568|NCT05086627|Experimental|Short-course radiotherapy sequential Tislelizumab combined with CapeOX (group A)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5) Sequential treatment period: After resting for 5 days following completion of SCRT, patients were treated with Tislelizumab (days 11, 33, 55, 77) and neoadjuvant chemotherapy with CapeOX (days 11 to 25, 33 to 47, 55 to 69, and 77 to 91).~Surgery: Total mesorectal excision will be performed between day 98 and 105, i.e., between 1 to 2 weeks after completion of Sequential treatment)~Postoperative adjuvant chemotherapy: Chemotherapy will be started 4-6 weeks after surgery, and the adjuvant regimen was CapeOX for 2 cycles."
32782569|NCT05086627|Active Comparator|Short-course radiotherapy sequential CapeOX (group B)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5) Sequential treatment period: After resting for 5 days following completion of SCRT, patients were treated with neoadjuvant chemotherapy with CapeOX (days 11 to 25, 33 to 47, 55 to 69, and 77 to 91).~Surgery: Total mesorectal excision will be performed between day 98 and 105, i.e., between 1 to 2 weeks after completion of Sequential treatment.~Postoperative adjuvant chemotherapy: Chemotherapy will be started 4-6 weeks after surgery, and the adjuvant regimen was CapeOX for 2 cycles."
32782570|NCT05170945|No Intervention|Retrospective Cohort|Colonoscopy was performed, either early bowel preparation, late bowel preparation or no bowel preparation patients.
32938799|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
33402235|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
32782571|NCT05170945|Experimental|Prospective Cohort|Early bowel preparation for colonoscopy patients
32782572|NCT05083741||Chitogel|Chitodex gel plus Kenalog inserted into the middle meatus
32782573|NCT05083741||Nexfoam|NexFoam plus Kenalog inserted into the middle meatus
32782574|NCT05131321||Group A: Fusion Group|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
32782575|NCT05131321||Group B: Internal Fixation|ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
32782576|NCT05130307|Experimental|Treatment Order 1|Treatment order 1: Low Tech (less interactive) Virtual Reality for 1st pain stimulus+ High Tech for 2nd pain stimulus
32782577|NCT05130307|Active Comparator|Treatment Order 2|Treatment order 2: High Tech VR (more interactive) for 1st pain stimulus + Low Tech for 2nd pain stimulus.
32782578|NCT05169151||Observational (physical activity tracking)|Patients utilize smartphone application to monitor physical activity and mobility up to 180 days during treatment or post-treatment.
32782579|NCT05168605|Experimental|Home Visit|Participants will receive home visit During the course of the first home visit, patients will receive routine care for diabetes and hypertension management (outcome variables are listed below) and data will be recorded in the EHR for primary outcomes. The resident physician will also assist the patient in completing enrollment in MyChart (if interested), utilizing either the resident's computer or smartphone and an internet hotspot. MyChart is a patient health platform that allows patients to contact their healthcare doctors, log health reminders, see test results, and a list of medications. The resident physician will also review a social determinants of health (SDH) screener (included in the EHR). The research faculty (licensed medical clinician) will collect blood pressure readings during this visit.
32782580|NCT05168605|No Intervention|Standard of care|Participants will receive a standard of care
32782581|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
32782582|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
32782583|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
32782584|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
33085081|NCT04555876|Experimental|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
32782585|NCT05082571|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
32782586|NCT05054257|Experimental|Autologous CAR19 T lymphocytes|Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19
33085082|NCT04555876|Experimental|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
33085083|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
33288276|NCT04730843|Experimental|Part B expansion|Subjects with advanced non-small cell lung cancer, advanced esophageal squamous cell carcinoma, other advanced solid tumors (such as nasopharyngeal carcinoma, cervical cancer, gastrointestinal tumors, other reproductive system tumors, etc.) will be treated with ES102 at the RP2D.
32782587|NCT05082181|Experimental|Arm 1: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is a telephone-based depression self-management program for people with epilepsy.
33288277|NCT05358119||Prospective cohort|Patients with long COVID and new-onset musculoskeletal pain
32782588|NCT05082181|Active Comparator|Arm 2: BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program for people with epilepsy.
32782589|NCT05082025|Experimental|Part 1: Dose confirmation|Up to 6 evaluable patients to confirm a single combination dose of copanlisib and fulvestrant
33288278|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
33288279|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by intravenous (IV) infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine maximum tolerated dose (MTD)
33288280|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
33288281|NCT05589311|Experimental|Intervention group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted following Transformative Learning principles
33288282|NCT05589311|Active Comparator|Control group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted using conventional didactic approach
33288283|NCT00991055|Experimental|Pioglitazone|
33288284|NCT00991055|Placebo Comparator|Placebo|
33288285|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
33288286|NCT05589155|No Intervention|Control|
33288287|NCT05589155|Experimental|Healthi|
33288288|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
33288289|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
33288290|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
33288291|NCT05588921||Aging group|Participants with baseline information, medical history of diseases, and lens photographs
33288292|NCT04672811|Experimental|App/Sensor Intervention|All subjects will be enrolled into the same experimental group for the duration of the study
33288293|NCT00357903|Other|1|
33288294|NCT03990519|Experimental|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
33288295|NCT03990519|Experimental|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
33288296|NCT03990519|Experimental|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
33288297|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
33288298|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
33288299|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
33288300|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
33288301|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
32782590|NCT05082025|Experimental|Part 2: Dose expansion:|The dose expansion part will enroll in 3 indication-specific cohorts with 13 to 26 patients
32938800|NCT04735939||morning dosing radiotherapy|
32938801|NCT04735939||evening dosing radiotherapy|
33288302|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
33288303|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
33288304|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
33288305|NCT01053117|No Intervention|Current Care Model|
33288306|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
33288307|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
33288308|NCT01051479|Experimental|C11-Choline|
33288309|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
33288310|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
33288311|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
33402236|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
32938802|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
33288312|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
33288313|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
33288314|NCT03896477|Experimental|Pneumosil|Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
33288315|NCT03896477|Active Comparator|Synflorix|Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
33288316|NCT03896477|Active Comparator|Prevenar 13|Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
33288317|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
33288318|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
33288319|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
33288320|NCT00444600|Active Comparator|Sham plus laser|
33288321|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
33288322|NCT00537095|Placebo Comparator|Placebo|Placebo
33288323|NCT05357027|Experimental|TC-E202 dose|"This study uses the 3+3 dose escalation method. The initial dose is Dose1, the maximum dose that patients can tolerate is determined as the phase II recommended dose (RPIID), and at least 6 patients are receiving RPIID treatment . If patients develop intolerance in Dose 1 (≥3 subjects with DLT), then the subsequent enrolled patients will receive Dose-1 infusion."
33288324|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
33288325|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
33288326|NCT00991367|Experimental|A|Cicatrix
33288327|NCT00991367|Placebo Comparator|B|Placebo
33288328|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
33288329|NCT00991445|Active Comparator|Conventional Exposure|
33288330|NCT00991523|Experimental|sweetened beverage|
33288331|NCT00991523|Placebo Comparator|placebo control|placebo
33288332|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
33288333|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
33288334|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
33288335|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
33402237|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
32938803|NCT04440865|Active Comparator|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
32938804|NCT04440865|Active Comparator|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
32938805|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
32938806|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
32938807|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
32938808|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
32938809|NCT04792411|Experimental|Prehabilitation group|This arm will be subject to at least 6 weeks of a tailored prehabilitation programme
32938810|NCT04430569|Experimental|Alteplase|
32938811|NCT04430569|Placebo Comparator|Placebo|
32938812|NCT03292952|Experimental|Double-blind KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
32938813|NCT03292952|Placebo Comparator|Double-blind Placebo|Placebo oral capsule
32938814|NCT03292952|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
32938815|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
32938816|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
32938817|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
32938818|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
32938819|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
32938820|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
32938821|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
32938822|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
32938823|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
32938824|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
33288336|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
33288337|NCT05358041||Electromagnetic Navigational Fixed Angle Bronchoscopy with CBCT Guidance|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
33288338|NCT05358041||Robotic Shape Sensing Bronchoscopy with CBCT Guidance|Patient is undergoing robotic navigation bronchoscopy using IOn robotic platform, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
33288339|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
33288340|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
33288341|NCT00348309|Placebo Comparator|Arm 3|Placebo
32782591|NCT05128903|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation following whole brain radiation therapy.
32782592|NCT04422145|Active Comparator|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
32782593|NCT04422145|Placebo Comparator|Standard|Participants returned to their standard diabetes care provider with no intervention.
32782594|NCT04422145|No Intervention|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
32782595|NCT05081869|Experimental|Online Yoga Based Exercise Program|A 50-minute online exercise program consisting of 5 categories will be created. The program will last 8 weeks, twice a week. In the first category, 20-30 seconds of stretching was applied to iliopsoas, hamstring, adductor, tensor fascia lata, piriformis, quadratus lumborum, quadriceps femoris and gastrocnemius muscles. In the second category, stabilization and pelvic mobilization exercises will be applied to the core muscles. Each exercise will be performed in 3 sets of 10 repetitions. In the third category, strengthening exercises will be done for the gluteal muscles, abdominal muscles, erector spine, quadriceps femoris and latissimus dorsi. Each exercise will be performed as 10 repetitions and 3 sets. In the fourth category, 3 sets and 10 repetitions of kegel exercises will be done. minute diaphragmatic breathing will be applied.
32782596|NCT05081869|Sham Comparator|Education Program|The informative training was given to both group members individually and online. In the training program; The female reproductive system organs, the structure of the pelvis, the location and functions of the pelvic floor muscles, the definition and physiology of menstruation, the types and risk factors of dysmenorrhea, the definition and symptoms of primary dysmenorrhea, treatment methods for coping with pain in primary dysmenorrhea were mentioned.
32782597|NCT05053711|Experimental|rTMS+rPMS_iTBS_M|In this group, they received iTBS on affected hemisphere after following iTBS at median nerve on affected hand.
32782598|NCT05053711|Experimental|rTMS+rPMS_cTBS_M|In this group, they received iTBS on affected hemisphere after following cTBS at median nerve on affected hand.
32782599|NCT05053711|Sham Comparator|rTMS+sham rPMS_M|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median nerve on affected hand.
32782600|NCT05053711|Experimental|rTMS+rPMS_iTBS_U|In this group, they received iTBS on affected hemisphere after following iTBS at ulnar nerve on affected hand.
32782601|NCT05053711|Experimental|rTMS+rPMS_cTBS_U|In this group, they received iTBS on affected hemisphere after following cTBS at ulnar nerve on affected hand.
32782602|NCT05053711|Sham Comparator|rTMS+sham rPMS_U|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at ulnar nerve on affected hand.
32782603|NCT05081479|Experimental|Participants with Lymphoma, Cohort 1|The first dose escalation cohort in the study will be treated at 25% of that target dose level
32782604|NCT05081479|Experimental|Participants with Lymphoma, Cohort 2|The second cohort in the study will be treated at 50% of that target dose level
32782605|NCT05081479|Experimental|Participants with Lymphoma, Cohort 3|The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.
32782606|NCT04421287|Experimental|Zhenyuan capsule|
32782607|NCT04421287|Placebo Comparator|Zhenyuan capsule placebo|
32782608|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
32782609|NCT05126329|Experimental|Participants with mild hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
32782610|NCT05126329|Experimental|Participants with moderate hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
32782611|NCT05126329|Experimental|Participants with normal hepatic function|Amcenestrant 200 mg single dose on Day 1 in fed condition
33288342|NCT05581433|Active Comparator|vapocoolan spray applied group before injection|Vapocoolant spray will be applied to patients in this group before intra-articular knee injection.
33288343|NCT05581433|Placebo Comparator|placebospray applied group before injection|Placebo spray will be applied to patients in this group before intra-articular knee injection.
33288344|NCT05581433|No Intervention|No administration group before injection|In this group, no pain reliever application will be made before the application.
33402238|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
33402239|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
33288345|NCT04451837|Active Comparator|semaglutide|Patients randomized to add semaglutide (Ozempic) will receive injection training at the study site and inject 0.25 mg subcutaneously once weekly during the first four weeks, followed by 0.5 mg weekly for the subsequent four weeks and finally 1.0 mg weekly throughout the study.
33288346|NCT04451837|Active Comparator|dapagliflozin|Those randomized to dapagliflozin will receive 10 mg orally once daily in addition to metformin.
33288347|NCT05356871||Healthy participants|Healthy men and women within the age of 18 and 75 yrs.
33288348|NCT04403165|Experimental|Cognitively Normal (CN) Older Adults|
33288349|NCT05580497|Experimental|Soft Wearable Robotic Knee System|30 minutes gait training wearing the Soft Wearable Robotic Knee System
33288350|NCT04003337|No Intervention|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
33288351|NCT04003337|Active Comparator|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
33288352|NCT05513261|Other|Control arm: High definition colonoscopy|Diagnostic test: Standard colonoscopy
33288353|NCT05513261|Experimental|PolyDeep assisted high definition colonoscopy|Diagnostic test: PolyDeep
33288354|NCT05512793|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist. The first colonoscopy will be performed without PolyDeep (standard technique) followed immediately by another colonoscopy with PolyDeep (combination technique).
33288355|NCT05512793|Active Comparator|Combination followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist. In this arm, the first colonoscopy with be performed with PolyDeep (combination technique) followed immediately by another colonoscopy without PolyDeep (standard technique)
33288356|NCT05493683|Experimental|Combination of Disitamab Vedotin and Tislelizumab|Disitamab Vedotin 2.0mg/kg q2w+Tislelizumab 400mg q6w. The treatment of Disitamab Vedotin + Tislelizumab will continue until the tumor progression confirmed by imaging, or up to 2 years, or intolerable toxic reactions, or other conditions determined by the researchers.
33288357|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
33288358|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
33288359|NCT05440487||Iron chelator|Patients prescribed with Iron Chelators
33288360|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
32782612|NCT05053165|Experimental|A (LB-P6)|Healthy volunteers will be administered once daily orally
33288361|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
33288362|NCT00440310|Experimental|Litx + Chemotherapy|
33288363|NCT00440310|Active Comparator|Chemotherapy alone|
33288364|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
33288365|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
33288366|NCT01055847|Placebo Comparator|Placebo|Placebo
33288367|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
33288368|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
33288369|NCT02533791|Placebo Comparator|placebo group|placebo
33288370|NCT05426681|Experimental|Glyburide treatment arm|
33288371|NCT05394935|Experimental|Polycystic Ovary Syndrome|Women with PCOS
33288372|NCT05394935|Active Comparator|Controls|Healthy, age and BMI matched controls
33288373|NCT01055925|Active Comparator|MPV|
33288374|NCT01055925|Active Comparator|Aquacel|
33288375|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
33288376|NCT00440232|Placebo Comparator|placebo|
33288377|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
33288378|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
33288379|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
33288380|NCT05379959|Experimental|Experimental: Placebo Then MDMA Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive 125 mg MDMA. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
33288381|NCT05379959|Experimental|Experimental: MDMA Then Placebo Then Methampetamine|Participants first receive 125 mg of MDMA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
33288382|NCT05379959|Experimental|Experimental: Methampetamine Then Placebo Then MDMA|Participants first receive 20 mg of MA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 125 mg of MDMA.
33288383|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
33288384|NCT03158064|Experimental|Duravalumab + Tremelimumab|"Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).~Participants enrolled now will receive tremelimumab *300mg with durvalumab 1500mg for 1 cycle followed by 12 cycles of durvalumab 1500mg every 4 weeks or until lack of clinical benefit or unacceptable toxicity."
33288385|NCT05366465||SMA adult patients|
33288386|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
33402240|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
33288387|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
32782613|NCT05053165|Experimental|B (LB-P8)|Healthy volunteers will be administered once daily orally
32782614|NCT05053165|Experimental|C (Placebo)|Healthy volunteers will be administered once daily orally
32782615|NCT05125471|Experimental|Investigational Drug|Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
32782616|NCT05052931|Experimental|treatment group|Nab-paclitaxel combined with oxaliplatin and S-1
32782617|NCT05079763|Experimental|Experimental arm|Application of bacterial cellulose-monolaurin hydrogel in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
32782618|NCT05079763|Placebo Comparator|Placebo Arm|Application of placebo cream in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
32782619|NCT04421521|Experimental|Acupuncture Group|
32782620|NCT04421521|No Intervention|Standard Therapy Group|
32782621|NCT05124925|Experimental|Treatment Arm|Ianalumab 300 mg subcutaneous monthly
32782622|NCT05050981||Hormone Therapy|Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.
32782623|NCT05050981||Selective Serotonin Reuptake Inhibitors|Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.
32782624|NCT05050981||Control Group|Women not using hormone replacement therapy or selective serotonin reuptake inhibitors
32782625|NCT05078983||HIGH RISK|HIGH RISK MEANS PATIENTS HAVE ASA SCORE OVER 2
33085084|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
33085085|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
33288388|NCT05329103|Experimental|PEEL-224 Dose Escalation|PEEL-224 is administered intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle. The study will begin at a low starting dose and will increase between cohorts according to mTPI-2 until a recommended phase 2 dose is determined. Approximately 10 dose levels are anticipated to be studied.
32782626|NCT05078983||LOW RISK|LOW RISK MEANS PATIENTS HAVE ASA SCORE BELOW 3
32782627|NCT05050903||Asthma|
32782628|NCT05050903||Healthy controls|
32782629|NCT05049889|Active Comparator|History of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
32782630|NCT05049889|Active Comparator|No history of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
32782631|NCT04421599|Experimental|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
32782632|NCT04421599|No Intervention|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
32782633|NCT04421599|Experimental|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
32782634|NCT05123131|Experimental|Isa-RVD|"Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.~Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32. Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 to <60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.~Dexamethasone (IV on the days of Isatuximab and PO on other days):~20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33.~If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32."
32782635|NCT05049655||Cohort 1|Babies who were fed commercial formula, study formula, or were fed with human milk in the SS-101-18 study that consented to the BH-10118-02 study
32782636|NCT05049655||Cohort 2|Babies fed with commercial formula (including ByHeart formula) or fed with human milk
33085086|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
33288389|NCT05329103|Experimental|PEEL-224 Dose Confirmation|An additional arm of patients will be enrolled after dose escalation is completed to confirm the recommended phase 2 dose.
32782637|NCT05074693|Experimental|EASE App|EASE is a intervention designed to address anxiety and depression symptoms in its users through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress.
32782638|NCT05074693|Other|INSIGHT (Control) APP|The Insight app provides users with educational videos on mindfulness and meditation techniques.
32782639|NCT05074459|Experimental|Eptinezumab Mammalian Cell Line|Participants will receive a single intravenous (IV) infusion of eptinezumab mammalian cell line on Day 1.
32782640|NCT05074459|Active Comparator|Eptinezumab Yeast Cell Line|Participants will receive a single IV infusion of eptinezumab yeast cell line on Day 1.
32782641|NCT05074303|Experimental|Beta-glucan|500 mg/day beta-glucan
32782642|NCT05074303|Placebo Comparator|Placebo|500 mg/day cellulose
32782643|NCT04221061|Other|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
33402241|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
33402242|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
32782644|NCT04221061|Other|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
32782645|NCT05073679|Experimental|Intervention|Oral naltrexone, to start as 25mg for three days then 50mg a day for 6 weeks. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
32782646|NCT05073679|Placebo Comparator|Control|Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for six weeks
32782647|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
32782648|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
32782649|NCT04222231|Experimental|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
32782650|NCT04222231|Experimental|Classical resistance training|Resistance training with high loads (60-80% RM).
32782651|NCT05120713||Young Adults|Young Adults aged 18-35
33085087|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
33085088|NCT04549012|Active Comparator|group A|will receive oxytocin
33085089|NCT04549012|Active Comparator|group B|will receive tranexamic acid plus oxytocin
33085090|NCT04555642||therapy group|lymphoma patients planned chemotherapy or immunotherapy scheme
33085091|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
33085092|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
33085093|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
32782652|NCT05120713||Older Adults|Older Adults aged 50-80
32782653|NCT05120557|Experimental|Main arm|Main study arm
32782654|NCT05120011|Experimental|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
32782655|NCT05120011|Placebo Comparator|leucine|4000 mg L-leucine per day for 24 weeks
32782656|NCT05047003||Patients under evaluation for Suspected Concussion|Device: EyeBOX Model EBX-4 (Portable version)
32782657|NCT05046301||Diagnostic (contrast-enhanced mammography)|Patients complete a questionnaire and undergo collection of a blood sample. Patients undergo CEM.
33085094|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
33085095|NCT04548856|Other|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
33402243|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
33402244|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
32782658|NCT05071807|Active Comparator|Pecan Group|Participants will consume their usual diet, but replace one snack with unsalted raw pecans incorporated as a snack
32782659|NCT05071807|Active Comparator|Usual Care Group|Participants will consume their usual diet devoid of nuts
32782660|NCT05046067|Experimental|Diagnostic (CT)|Patients undergo 4 CT scans during standard of care surgery.
32782661|NCT05043259|Active Comparator|Inactivated vaccine group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of inactivated SARS-CoV-2 vaccine
32782662|NCT05043259|Experimental|Low dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the low dose of aerosolized Ad5-nCoV.
32782663|NCT05043259|Experimental|High dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the high dose of aerosolized Ad5-nCoV.
32782664|NCT05071495|Experimental|Intervention group|
32782665|NCT05071495|No Intervention|Control group|
32782666|NCT05041153|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, Treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
33085096|NCT04548856|Other|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
33085097|NCT04548856|Other|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
33085098|NCT04548856|Other|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
32782667|NCT05069311|Experimental|Hysterectomy|Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
32782668|NCT05039281|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32782669|NCT05114161|No Intervention|Standard care|All participants/caregivers will be asked for consent for point-of-care (POC) blood C-reactive protein (CRP), nasopharyngeal swab for virology/Mycoplasma testing, and urine for pneumococcal antigen (UAg) testing, but, since this testing will not affect care, these are optional (ie. refusal will not preclude enrolment). The RA will phone the caregiver at Day 2-5, Day 14-21, and Day 30 post-enrollment, for outcome ascertainment. Caregivers will be asked to fill out a daily diary (either electronically or on paper) to record the participant's symptoms, clinical progress, and possible drug adverse effects. Caregivers will also be instructed on how to take patient temperature. All participants whose symptoms do not progressively improve will be encouraged to return to the ED to be reassessed, as per standard of care.
32782670|NCT05114161|Experimental|Novel Care Pathway|Once a child is diagnosed with non-severe CAP (community-acquired pneumonia) in the ED, specific radiographic findings and point-of-care CRP testing will identify those who require antibiotic treatment immediately. The next day, results of multiplex respiratory pathogen and urine pneumococcal antigen (UAg, optional) testing will be integrated into the care plan, along with additional clinical information about the child gathered remotely, to ensure that only children at appreciable risk for bacterial infection receive antibiotics. Our care pathway uses already-available testing (NPS) in new ways, integrates newer diagnostics (point-of-care CRP, UAg), and includes properly-timed clinical follow up to change how children with non-severe CAP are managed.The research team will follow-up with the participant and caregiver the next day, 2-5 days, 7-21 days and day 30 post-enrolment to ensure clinical stability.
33402245|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
33402246|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
32782671|NCT05036863||Patients with multiple myeloma|
32782672|NCT05113537|Experimental|Part A: Abemaciclib, 177Lu-PSMA-617|Patients receive abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32782673|NCT05113537|Experimental|Part B: Recommended Phase 2 dose of Abemaciclib, 177Lu-PSMA-617|Patients receive the recommended phase 2 dose of abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32782674|NCT05113381|Experimental|Intraventricular Hemorrhage Subjects|Intervention: Cerebrospinal Fluid (CSF) reduction Extra Ventricular Drainage (EVD) catheters will be used for cerebrospinal fluid drainage
32782675|NCT05065645|Active Comparator|APN01|Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml
32782676|NCT05065645|Placebo Comparator|NaCl|Sodium Chloride: 0.9% NaCl solution
32782677|NCT05034913|Experimental|Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference|Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.
32782678|NCT05064631|Experimental|Active intervention|Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 24 months
32782679|NCT05064631|Placebo Comparator|Placebo control|Matched placebo administered daily for 10 days per month for 24 months
33402247|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
32938825|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
33402248|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
32782680|NCT05063383||PCOS|"Oligomenorrhea/amenorrhea~Clinical androgen excess or biochemical androgen excess~Polycystic ovary showed by gynecological ultrasound"
32782681|NCT05063383||NOPCOS|not meet Rotterdam standards
32782682|NCT05112289|Other|Migraine cohort|Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
32782683|NCT05112289|Other|Small vessel ischemic (SVI) disease cohort|Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
32782684|NCT05112289|Other|Multiple sclerosis (MS) cohort|Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
32782685|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
32782686|NCT01364467|Active Comparator|Guaifenesin|
32782687|NCT04226365|Experimental|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
32782688|NCT04226365|Placebo Comparator|Control|10mg capsule once daily for 4 weeks of Thick-It filler
32782689|NCT05470387|Experimental|LB1148|
32782690|NCT05470387|Placebo Comparator|Placebo|
32938826|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
32938827|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
32938828|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
32956071|NCT05764668|Experimental|Zihua Wenfei Zhisou Granule|Patients in experimental treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.
33085099|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
33085100|NCT04548934|Active Comparator|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
33085101|NCT04548934|Experimental|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
33085102|NCT04548700|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
33085103|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
32782691|NCT05062837|Experimental|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
33288390|NCT04791228|Experimental|All Patients|LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle. MR-HIFU hyperthermia will follow infusion (+/- 30 minutes) for one hour to a target area with a target temperature of 40-45°C followed by ablation therapy (>55°C). The HIFU hyperthermia regimen will have a duration of at least 60 minutes and will then be followed by ablation therapy. Patients may receive up to a total of 6 cycles. Subsequent treatment cycles may treat alternative target lesions. Disease status will be evaluated using standard imaging techniques (CT/MR) post each cycle.
33288391|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
33288392|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
33288393|NCT05311553|Experimental|Zona pellucida thinning|thinning will be performed without reaching the inner membrane of the Zona pellucida thickness.
33288394|NCT05311553|Experimental|Zona pellucida drilling|an opening will be made from the outside to the inside of the Zona pellucida.
33288395|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
33085104|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
33288396|NCT01323348|No Intervention|Standard Care|Usual care
33288397|NCT05357807|Active Comparator|Standard RYGB|127 patients undergo a standard Roux-en-Y gastric bypass
33085105|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
33085106|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
33085107|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
33085108|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
33085109|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
33288398|NCT05357807|Experimental|Extended Pouch RYGB|127 patients undergo a Roux-en-Y gastric bypass with an extended pouch.
33288399|NCT05357807|Experimental|Banded Extended RYGB|127 patients undergo a Roux-en-Y gastric bypass with a minimizer around the extended pouch.
33288400|NCT02968836|Active Comparator|Active group|Blend of amino acids
33288401|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
33288402|NCT04003181|Active Comparator|Positive breath test|Patients with a positive breath test are treated with antibiotics.
32782692|NCT05468125|Active Comparator|care bundle|will be subjected to a bundle of care of four elements
33085110|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
33085111|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
33085112|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
33288403|NCT04003181|Active Comparator|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
33288404|NCT04003181|No Intervention|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
33288405|NCT05286047|Experimental|Bifidobacterium longum CCFM1029|
33288406|NCT05286047|Placebo Comparator|Placebo|
33288407|NCT04768608|Experimental|PD1-PSMA-CART|Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.
33288408|NCT05236049|Experimental|SclerFIX|Strip of umbilical cord lining membrane allograft wrapped around the bioceramic enucleation implant. The assembly is placed inside the void orbital cavity and the muscles are sutured to the SclerFIX strips.
33288409|NCT01031316|Experimental|Nondisclosure|
33288410|NCT01031316|Active Comparator|Disclosure|
33288411|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
33288412|NCT05186363|Active Comparator|Intervention|SMC eligible kids aged 3-59 months who will receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
33288413|NCT05186363|Active Comparator|Control|SMC eligible kids aged 3-59 months who will not receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
33288414|NCT04741308|Experimental|CBT group|Patients randomly assigned to CBT group will receive 8 times of CBT treatment during chemotherapy.
33288415|NCT04741308|No Intervention|non-CBT group|"Patients randomly assigned to non-CBT group will receive four sessions of health education in a month after surgery.~Each session will last 1 hour, including lectures and Q&A . The content of each session is different, including: diagnosis and treatment of colorectal cancer, adverse reactions and management of chemotherapy, nutritional support during chemotherapy and physical exercise during chemotherapy."
33288416|NCT05167565|Experimental|Infants aged around 3 month|80 infants aged around 3 months will be included in this study up to around 12.5 months
33288417|NCT03742323|Experimental|Idelalisib|
33288418|NCT04715022|Placebo Comparator|Placebo infusion|Saline will be administered over 2 hours
33288419|NCT04715022|Active Comparator|Ascorbic acid infusion|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
33288420|NCT05137691|Experimental|Experimental|Adapted NHS weight management 1:1 programme. Low carbohydrate dietary focus, enhanced behaviour change via telehealth, daily step target supported by pedometers
33288421|NCT05137691|Active Comparator|Active comparator NHS 1:1 weight management programme|12 week NHS 1:1 weight management programme
33288422|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
33288423|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
33288424|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
33288425|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
33288426|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
33288427|NCT05091671|Active Comparator|Free From Pain Exercise Programme Variation 1|"Participants will have the initial online consultation and will be provided with the exercise booklet and the 12 information/metaphor leaflets. The ongoing 12 Zoom online sessions are not included in this option. Instead, participants will be asked to independently engage in the exercises within the exercise booklet. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Rest day. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day."
33288428|NCT05091671|Experimental|Free From Pain Exercise Programme Variation 2|Participants will have the initial online consultation and will be provided with the exercise booklet and12 information/metaphor leaflets. This variation also includes the online zoom sessions. The online zoom session will involve a short presentation and a group discussion for 15 minutes followed by a 45-minute exercise class which will be delivered by a suitably trained individual. The exercise class will include the exercises from the Otago Exercise programme + the Motor Control Exercises for low back pain + Isometric and strengthening exercise for the neck. Participants assigned to this intervention will also be asked to independently engage in the exercises within the exercise booklet. They will be advised to use the same weekly structure described previously.
33288429|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
33288430|NCT05357339|Experimental|Interventional 20% Albumin|Septic patients requiring a fluid bolus randomised to receive 100ml 20% albumin as boluses until they are stable or no longer require fluid resuscitation.
33288431|NCT05357339|Active Comparator|Control Crystalloid|Septic patients requiring a fluid bolus randomised to receive 250ml boluses of crystalloid fluid until they no longer require fluid resuscitation.
33288432|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
33402249|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
33402250|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
32782693|NCT05468125|Active Comparator|best-evidenced practice|will be guided according to the best-evidenced performance consisting of three elements
32782694|NCT05033899|Experimental|group E: ERAS group|36 non-insulin dependent diabetic patients will undergo lumbar decompression surgery following ERAS protocol.
32782695|NCT05033899|No Intervention|group C: conventional group|conventional perioperative care.
32782696|NCT05110417|Experimental|Pyridostigmine (Mestinon)|Pyridostigmine (Mestinon) will be assigned to patients in this arm.
32782697|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
32782698|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
32782699|NCT05033665|Active Comparator|Euhydrated|Afternoon urine osmolality < 800 mmol/kg or urine specific gravity < 1.020.
32782700|NCT05033665|Experimental|Underhydrated|Afternoon urine osmolality ≥ 800 mmol/kg or urine specific gravity ≥ 1.020.
32782701|NCT05109871|Experimental|Kforce Link|
32782702|NCT05061199||ECA group|TCC with extracorporeal anastomosis (ECA)
32782703|NCT05061199||ICA group|TCC with intracorporeal anastomosis (ICA).
32782704|NCT05031481|Experimental|VENUS 20 + 0,064|Venus association vaginal cream, single dose.
32782705|NCT05031481|Experimental|VENUS 20 + 1|Venus association vaginal cream, single dose.
32782706|NCT05031481|Experimental|VENUS 20 + 4|Venus association vaginal cream, single dose.
32782707|NCT05031481|Active Comparator|Butoconazole nitrate 100 mg|Butoconazole nitrate vaginal cream, single-dose containing 100 mg.
32782708|NCT05061121|Experimental|sustained natural apophyseal glides|Investigate the short- and mid-term effects of Mulligan's SNAGs on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
32782709|NCT05061121|Experimental|Myofascial release|Investigate the short- and mid-term effects of Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
32782710|NCT05061121|Experimental|sustained natural apophyseal glides in addition to myofascial release|Investigate the short- and mid-term effects of Mulligan's SNAGs combined with Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
32782711|NCT05109559|Experimental|Ad26.COV2.S given at the interval ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A1, a total of 360 adult volunteers aged 18 years or older, will receive the full-dose (5x10^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
32782712|NCT05109559|Experimental|Ad26.COV2.S given at 45-75 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A2, a total of 110 adult volunteers aged 18 years or older, will receive the full-dose (5x10^10 vp) of the study product, at early (45-75 days) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
32782713|NCT05109559|Experimental|Half dose of Ad26.COV2.S given ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A3, a total of 110 adult volunteers aged 18 years or older, will receive the half-dose (2.5x10^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
32782714|NCT05109559|Experimental|Ad26.COV2.S given 28 days after receiving 1 dose of either Sinovac or Sinopharm|Study Part B is a prospective, multi-center, open-label Phase 1/2 heterologous prime-boost study to assess the Ad26.COV2.S (full dose 5x10^10 vp) as the 2nd vaccination in subjects who are documented to all have received the 1st dose of Sinovac or all received the 1st dose of Sinopharm COVID-19 vaccine, with an interval of 28 days +/- 3 days, followed from Visit 1 (V1) to Visit 7 (V7) at 336 days.
32782715|NCT04998331||Participants With CD30-positive Lymphoma|All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides [MF] and cutaneous anaplastic large cell lymphoma [pcALCL]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
32782716|NCT05031247|Experimental|Community Navigator Social Support|More intensive case management and weekly check-ins with older adults. The Community Navigator will be focused on increasing social contact and connection for older adult refugees and immigrants. Those who receive the intervention will be offered up to ten (30-minute-long) meetings with a Community Navigator and access to up to three group sessions over a 3-month period, alongside the standard services they receive for enrollment with the organization.
33085113|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
33402251|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
32782717|NCT05031247|No Intervention|Program Support as Usual|Standard program support will be provided to participants enrolled. These services are offered to all enrolled in the program and may include, but is not limited to the following: financial assistance services, case management, healthcare access services, employment and tax services, education services, citizenship and immigration services, community services and civic engagement, and refugee services.
32782718|NCT04998097|Experimental|experimental (iTBS group)|device: Magstim Rapid2 Stimulator
32782719|NCT04998097|Sham Comparator|sham group|device shame Magstim Rapid2 Stimulator
32782720|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
32782721|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
32782722|NCT05058859|Experimental|Study Drug|The study drug is Dapagliflozin
32782723|NCT05057767|Experimental|Pre-induction Group (I)|will receive intravenous midazolam premedication 2mg in a volume of 3 ml, 15 minutes before induction of anesthesia
32782724|NCT05057767|Experimental|Pre-extubation Group (II)|will receive intravenous midazolam 2mg in a volume of 3 ml 30 minutes before extubation at the end of surgery
32782725|NCT05057767|Placebo Comparator|Control Group (III)|will receive 3 ml normal saline 15 minutes before induction of anesthesia plus 3 ml normal saline 30 minutes before extubation at the end of surgery.
32782726|NCT04997317|Active Comparator|Phase 0: Group A|"Cycle 1: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group A patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
32782727|NCT04997317|Active Comparator|Phase 0: Group B|"Cycle 1: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group B patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
32782728|NCT04997317|Active Comparator|Phase I/II|3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
32782729|NCT04997239|Experimental|Experimental Group ：Vaccine-unprimed subjects with two doses|200 vaccine-unprimed children will receive two doses of quadrivalent influenza vaccine on the immunization schedule of day 0,28.
32782730|NCT04997239|Experimental|Experimental Group ：Vaccine-unprimed subjects with one dose|200 vaccine-unprimed children will receive one dose of quadrivalent influenza vaccine.
33085114|NCT04710407|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.
32782731|NCT04997239|Experimental|Experimental Group：Vaccine-primed subjects with one dose|200 vaccine-primed children will receive one dose of quadrivalent influenza vaccine.
32782732|NCT04216693|Experimental|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
32782733|NCT04216693|Placebo Comparator|Placebo|Digoxin-like oral placebo
32782734|NCT05057611|Active Comparator|Usual Care Group (UC)|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, HR (heart rate) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
32782735|NCT05057611|Experimental|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If <40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If <50 mmHg NE will be increased for MAP >65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
32782736|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
33085115|NCT04548622|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
33085116|NCT04710251|Active Comparator|Colonoscopy with the speedometer|
33085117|NCT04710251|No Intervention|Colonoscopy without the speedometer|
33085118|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
32782737|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
32782738|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
32782739|NCT05056831|Experimental|Group I (physical activity intervention)|Patients attend face-to-face mind-body sessions focused on stretching, breathing, and relaxation twice a week and receive targeted text messages daily on their smartphone for 8 weeks.
32782740|NCT05056831|Active Comparator|Group II (usual care)|Patients receive usual care.
32782741|NCT05055271||Delphi panel|The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
32782742|NCT04211155|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
32782743|NCT04211155|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
32782744|NCT04211155|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
32782745|NCT04211155|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
32782746|NCT05027737|Experimental|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
32782747|NCT05027737|No Intervention|Traditional closure (control)|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.
32782748|NCT04995835|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
32782749|NCT05026723|Experimental|Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)|The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
32782750|NCT05026723|Active Comparator|Standard MTM|The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.
32782751|NCT05054881|Other|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
32782752|NCT05054881|Other|Sciatic nerve block under ultrasound control without a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
32782753|NCT05054413||Observational (questionnaire)|Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.
32782754|NCT05025475|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), transseptal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present), and rate of a recurrent neurologic embolic event in patients with cryptogenic stroke and PFO.
32782755|NCT05025475|Active Comparator|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials
32782756|NCT04950283||Magnetic resonance examination and anthropometric, metabolic characterization|
32782757|NCT04949425|Experimental|Patients with advanced solid tumours|Patients with advanced solid tumours will receive Adavosertib once daily for 5 days followed by 2 days off for 2 weeks out of a 21-day cycle.
32782758|NCT04203901|Experimental|Combination Arm|CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
32782759|NCT04203901|Active Comparator|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
32782760|NCT05023525|Experimental|HSK31858, single dose|5 cohorts with single doses starting with 5 mg HSK31858 as tablet.
32782761|NCT05023525|Placebo Comparator|Placebe, single dose|5 cohorts with matching placebo to HSK31858 as tablet.
32782762|NCT05022589|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
32782763|NCT04991467|Experimental|Parents of children receiving mental health treatment at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app .
32782764|NCT04991467|Experimental|Parents of children being treated for autoimmune disorders at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
32782765|NCT04991467|Experimental|Healthcare workers at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
32782766|NCT05022511|Experimental|Intervention group|"All women aged 50-69 years attending breast cancer screening in the intervention unit on an intervention day. They will all be offered to receive information on their screening status in cerical cancer og colorectal cancer screening.~Women aged 50-64 years, who have not had a cervical cytology sample taken within 5 years and 6 months will be offered to receive a self-sample device for high risk human papilloma virus (hrHPV) screening by mail, or reminded to see her general practitioner (GP) to have a conventional cervical cytology sample taken.~Women aged 50-69 years, who have not had a Faecal Immunochemical Test (FIT) within 2 years and 4.5 months will be offered to receive a new self-sampling kit for FIT."
32782767|NCT05022511|No Intervention|Control group|Women in the control group will receive standard screening offers according to the national screening programme.
32782768|NCT04991311|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
32782769|NCT04411381|Active Comparator|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
32782770|NCT04411381|No Intervention|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
32782771|NCT05020951||Laboratory Data|Electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE
32782772|NCT04411303|Experimental|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
32782773|NCT04411303|Experimental|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
32782774|NCT04421209|Experimental|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
32782775|NCT04421209|Placebo Comparator|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
32782776|NCT05020249|Experimental|Bimekizumab arm|Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
32782777|NCT05020249|Placebo Comparator|Placebo arm|Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
32782778|NCT04947397|No Intervention|Group 1|Traditional deep extubation at 1.5 minimum alveolar concentration (MAC)
32782779|NCT04947397|Experimental|Group 2|Deep extubation guided by pupillometry -- at < 0.5 MAC of vapor + propofol and fentanyl
32782780|NCT05019937|Experimental|Multifaceted implementation strategy|Schools randomized to this arm will be exposed to a multifaceted implementation strategy, which contains five implementation components
32782781|NCT05019937|Active Comparator|Single implementation strategy|Schools randomized to this arm will be exposed to a single implementation strategy, which contains one implementation component
32782782|NCT05019703|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32782783|NCT04946305||Lutathera|Patients administered Lutathera by prescription
32782784|NCT05017753|Active Comparator|Control group|Standard-of-care medical treatment.
32782785|NCT05017753|Experimental|Intervention group|Thoracentesis in addition to standard-of-care medical treatment.
32900524|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
33085119|NCT04555993|Active Comparator|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
33085120|NCT04555993|Experimental|Erector spinae plane block|Patients will receive Erector spinae plane block.
33085121|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
32782786|NCT04945603||Poor Grade Subarachnoid Hemorrhage|"All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.~The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols."
32782787|NCT04986943||ABTHERA Advance without Wittmann patch|Patients with necrotizing pancreatitis that require an open abdomen after their initial operation will be treated with ABTHERA ADVANCE only, without the use of Wittmann patch.
32782788|NCT04986397|Experimental|Cold Therapy & Standard Post Operative Analgesia|Patients in the cryotherapy group will have the ice water in their cryotherapy device maintained continuously for 2 days from initial application as this is the reported time of average patient disability and children typically return to school by post-operative day 3. The device will not be placed directly on the skin to minimize tissue damage. An additional protective barrier pad included with the cold therapy device will provide a barrier between the skin and the cooling device. This allows for continuous cooling at a higher target skin temperature. Aside from the cryotherapy, all surgical treatment will be standard of care.
32782789|NCT04986397|Active Comparator|Standard Post Operative Analgesia|
32782790|NCT04944199|No Intervention|Control Group|
32782791|NCT04944199|Active Comparator|Intervention Group|
32782792|NCT05017363|Experimental|Intervention Group (ENGAGE)|Therapists will consist of pairs within sites providing similar interventions to similar children so that treatment and child characteristics other than the goal-setting intervention will be similar within each site. Therapists will use principles-based goal-setting approaches and strategies in the goal-setting toolbox. It is anticipated that treatment block lengths will vary from 3-8 sessions over 2-8 weeks, representing typical clinical variation.
32782793|NCT05017363|No Intervention|Usual Care Group (Control)|The control group will comprise usual care.
32782794|NCT01364233|Other|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
32782795|NCT04985539||PD de novo|Observational.
32782796|NCT05014945|Experimental|Atelocollagen group|After obtaining informed consent for the study, epidural nerve block was performed. The patient is asked to return to the outpatient clinic of the pain center after 2 weeks. At this time, when the NRS of back pain does not improve by more than 50% compared to before the epidural nerve block and the cross-sectional area of the multifidus muscle using ultrasound is 5 cm2 or less, final enrollment is decided. The evaluation of the cross-sectional area and thickness of the multifidus muscle using ultrasound is performed with the patient prone, and the cross-sectional area of the multifidus muscle is measured at the same position as the level of the lesion on MRI.
32782797|NCT04984993|Experimental|MED3000|MED3000 gel formulation topically applied to the glans penis
32782798|NCT04984993|Experimental|Tadalafil|Tadalafil (5 mg) tablets to be taken orally
32782799|NCT04984837|Experimental|Lacutamab|Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase
32782800|NCT04984837|Active Comparator|Standard of care|GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase
32782801|NCT04983355|Experimental|Peptidyss|"Dietary supplement : fish hydrolysate~The experimental product is a dietary supplement composed of a hydrolysate of fish containing low molecular weight peptides (4 capsules/day providing 1,4 g of fish hydrolysate)"
32782802|NCT04983355|Placebo Comparator|Placebo|The placebo product containing mainly silica is presented in the same form as the active product, so that people handling the product cannot distinguish both formula (4 capsules/day)
32782803|NCT04983121|Experimental|combine treatment group|This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
32782804|NCT04982731|Experimental|ED Positive Assurance Discharge Video Educational Intervention (EDUC).|The video intervention will be administered to participants that are randomly assigned to the EDUC group. In addition, current standard of care discharge instructions will also be provided to the participant. This EDUC intervention will consist of a brief, three to five-minute informative video message from the clinical neuropsychologist at the Inova Sports Medicine Concussion Program. In addition to the viewing of the video after ED discharge, all participants will be instructed to view the video at least once every 24 - 48 hours prior to their visit to the concussion clinic.
32782805|NCT04982731|No Intervention|Standard of Care ED Discharge Instructions (Treatment as Usual: TAU )|The Acute Concussion Evaluation (ACE) Care plan in place at the Inova PED is the standard-of-care discharge instruction for individuals with mTBI. This care plan provides patient and caregiver education about mTBI and emphasizes the monitoring of symptoms, signs of deterioration that may warrant urgent medical attention, and encourages the patient to follow up with their physician for follow up. Participants who are randomized into the TAU group will receive this standard of care treatment in video format as well, however these participants will not be given a QR code to watch the intervention video.
32782806|NCT04982653|Experimental|Arm I (hepatectomy using small bites fascial closure)|Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
32782807|NCT04982653|Active Comparator|Arm II (hepatectomy using conventional fascial method)|Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
32900525|NCT05387694|Experimental|Knee prosthesis group|
33085122|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
32782810|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
32782811|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
32782812|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
32782813|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
32782814|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
32782815|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
32782816|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
32782817|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
32782818|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
32938829|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
32938830|NCT05406271|Experimental|Hip Prosthesis with intraoperative fluoroscopy|
32938831|NCT05406271|No Intervention|Hip Prosthesis without intraoperative fluoroscopy|
32938832|NCT04415671|Experimental|Part A- AD-214 SAD in Healthy Volunteers|
32938833|NCT04415671|Placebo Comparator|Part A-Placebo SAD in Healthy Volunteers|
32938834|NCT04415671|Experimental|Part B-AD-214 MAD in Healthy Volunteers|
32938835|NCT04415671|Placebo Comparator|Part B-Placebo MAD in Healthy Volunteers|
32956072|NCT05764668|Placebo Comparator|Zihua Wenfei Zhisou Granule-matched placebo|"Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.~Placebo does not contain active pharmaceutical ingredients, and its main ingredients are lactose, beta-cyclodextrin, stevioside, and caramel."
33288433|NCT05013749|Active Comparator|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
33288434|NCT05013749|Active Comparator|Partial myometrial resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
33288435|NCT01056003||all patients admitting endoscopy for EGD|
33288436|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
33288437|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
33288438|NCT04975217|Experimental|Treatment (FMT, FMT capsules)|Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).
33288439|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
32782819|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
32782820|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
32782821|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
33288440|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
33288441|NCT03991689|Experimental|the six weeks solution-focused pain management groups|
33288442|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
33288443|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
33288444|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
33288445|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
33085123|NCT04555525|Experimental|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
33288446|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
33288447|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
33288448|NCT04950959||All subjects|Subjects undergoing CT-guided, minimally invasive percutaneous procedures in an interventional radiology setting
33288449|NCT03141060|Experimental|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
33288450|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
33288451|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
33288452|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
33288453|NCT04922021|Experimental|LEO 138558|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
32782822|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
32782823|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
33288454|NCT04922021|Placebo Comparator|Placebo|Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).
33288455|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
33288456|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
33288457|NCT05021549|Active Comparator|nasal prong.|the apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong.
33288458|NCT05021549|No Intervention|conventional|the conventional preoxygenation group (30 patients)
33288459|NCT04994561|Experimental|Subjects receiving study drugs and nutritional supplements|All eligible and consented subjects will receive study drugs and nutritional supplements as described in the intervention.
33288460|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
33288461|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
33288462|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
33288463|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
33288464|NCT04941443|Experimental|Oral methadone|Participants will be given a preemptive analgesic in addition to a standard dose of ibuprofen while undergoing early medication abortion with mifepristone and misoprostol (not provided as part of the study). All participants will also be provided with supplementary non- opioid analgesics to be used at their own discretion during the process.
33288465|NCT01030848||Patients with knee osteoarthritis|
33288466|NCT04876157|Experimental|Artificial intelligence-aimed ultrasound image interpretation|
33288467|NCT03994692|Experimental|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.~The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .~Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
32782824|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
32782825|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
33288468|NCT03994692|Active Comparator|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet & chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
33288469|NCT04868981|Experimental|GST-HG141|GST-HG141 tablets at varying dosages by mouth for 28 days
33288470|NCT04868981|Placebo Comparator|Matching Placebo for GST-HG141|Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days
33288471|NCT01030926|Experimental|A1, first period|
33288472|NCT01030926|Active Comparator|A2, second period|
33288473|NCT01030926|Active Comparator|B1, first period|
33288474|NCT01030926|Experimental|B2, second period|
33288475|NCT04822259|Experimental|JOURNEY II BCS TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
33288476|NCT04822259|Experimental|JOURNEY II CR TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
32782826|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
32782827|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
32782828|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
33402252|NCT04927780|Experimental|Arm 1: Perioperative mFOLFIRINOX|Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.
33288477|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
33288478|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
32782829|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
32782830|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
32782831|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
32782832|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
32782833|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
32782834|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
32782835|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
32782836|NCT02290821|Placebo Comparator|Placebo|Placebo
32782837|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
32782838|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
32782839|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
32782840|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
32782841|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
32782842|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
32782843|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
32782844|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
32782845|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
32782846|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
32782847|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
32782848|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
32782849|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
32782850|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) < 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
32782851|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
32830365|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
33085124|NCT04555525|Other|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
32782852|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
32782853|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
32782854|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
32782855|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
32782856|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
32782857|NCT04886739|Experimental|CGB-400 Topical Gel|Topical administration twice daily for 12 weeks
32782858|NCT04886739|Placebo Comparator|Vehicle Gel|Topical administration twice daily for 12 weeks
32782859|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
32782860|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
33288479|NCT04198805|Active Comparator|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
32782861|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
32782862|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
32782863|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
32782864|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
32782865|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
32782866|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
32782867|NCT04943887|Experimental|PwMS eSupport Groups|12-weeks active treatment of eSupport Health's Weekly Group Sessions, a formal semi-structured program of psychoeducational support delivered in a small group format by licensed therapists who specialize in MS. The active treatment period will follow a 12-week waitlist period that will be used to enable a within-subject control design. Note that the very first group enrolled (N~10) will not have a 12-week waitlist period but will instead enter directly into the 12-week treatment.
32782868|NCT05463055|Experimental|single-arm objective performance criteria, OPC|According to the NMPA Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response + Partial Response + Stable Disease (CR+PR+SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate whether reach the objective performance criteria (80%); the main safety evaluation index of CTCAE level 3 toxic reaction ratio whether is lower than the acceptable value (5%), CTCAE level 4 and 5 toxic reaction ratio whether is acceptable value (0%).
32782869|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
32830366|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
33288480|NCT04198805|Active Comparator|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
32782870|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
32830367|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
32830368|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
33288481|NCT04198805|Active Comparator|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
33288482|NCT04198805|Placebo Comparator|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
33288483|NCT00536939|Experimental|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
33288484|NCT00536939|Placebo Comparator|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
33288485|NCT04669925||Users of Lombardy Emergency System 2018-2020|Adults (affected or not affected by Covid-19) who asked for assistance to the Lombardy region's emergency system during the pandemic period and the previous two years
33288486|NCT05356793|Experimental|Treatment|Active treatment with SCH-1
33288487|NCT05356793|Placebo Comparator|Placebo|Vehicle minus active components
33288488|NCT04603781|Active Comparator|CBD-Isolate 300 mg.|Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days
33288489|NCT04603781|Active Comparator|Full-Spectrum CBD Oil 300 mg.|Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
33288490|NCT04603781|Active Comparator|Broad-Spectrum CBD oil 300 mg.|Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
33288491|NCT04603781|Placebo Comparator|Placebo Oil|Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days
33288492|NCT04104893|Experimental|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
33288493|NCT04597697|Experimental|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
33288494|NCT04597697|Experimental|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
33288495|NCT04597697|Experimental|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
33288496|NCT04597697|Experimental|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
33288497|NCT04463225|Other|Intervention condition|Participants assigned to the intervention condition will be invited to engage with an internet-based intervention three times during the course of the study.
33288498|NCT04463225|No Intervention|Control|The control group will not be offered the internet-based intervention.
33288499|NCT03883217|Experimental|Vibration first then no vibration|A session with PDVibe2 vibration turned on first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned off.
33288500|NCT03883217|Experimental|No vibration first then vibration|A session with PDVibe2 vibration turned off first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned on.
33288501|NCT05355623|Active Comparator|amniotic membrane graft|patients in which the surgical vaginal repair will be done with the application of a sterilized (gamma irradiated) amniotic membrane.
33288502|NCT05355623|Active Comparator|surgical vaginal repair|patients in which the surgical vaginal repair will be done without any graft.
33288503|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
33288504|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
33288505|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
33288506|NCT03987321|Experimental|Denali Group|Those who received Denali filter placement
33288507|NCT03987321|Experimental|Celect Group|Those who received Celect filter placement
33288508|NCT01051869|Active Comparator|simple decompression|
33288509|NCT01051869|Active Comparator|anterior subcutaneous transposition|
33288510|NCT03987087|Experimental|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
32830369|NCT04488744|Experimental|nicotine infusion 0.2mg|"nicotine infusion~0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) The day order will be randomized over 5 days."
33288511|NCT03987087|Active Comparator|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
33288512|NCT03987243|Other|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
33288513|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
33288514|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
33288515|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
33288516|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
33288517|NCT00356421|Active Comparator|Control|
33288518|NCT00356421|Experimental|Experimental|
33288519|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
33288520|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
33288521|NCT03990129|Other|Study population|All participants
33288522|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
33288523|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
33288524|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
33288525|NCT01052025|No Intervention|Placebo|
33288526|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
33288527|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
33288528|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
33288529|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
33288530|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
33288531|NCT00438672|Active Comparator|Lateral Epicondylitis|
33288532|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
33288533|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
33288534|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
33288535|NCT01027260|Active Comparator|Itopride 50 mg|
33288536|NCT01027260|Active Comparator|Itopride 100 mg|
33288537|NCT01027260|Placebo Comparator|Placebo|
33288538|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
33288539|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
33288540|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
33288541|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
33288542|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
33288543|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
33288544|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288545|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288546|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288547|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288548|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288549|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288550|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
33288551|NCT00437658|Experimental|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
33288552|NCT00437658|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
33288553|NCT00437658|Active Comparator|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
33288554|NCT04689516|Experimental|Control Group|will receive a hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively and will stop after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
33288555|NCT04689516|Experimental|The TFC Group|will receive hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively . The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
33288556|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
33288557|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
33288558|NCT04275791|Experimental|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
33288559|NCT04275791|No Intervention|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
33288560|NCT04002635|Active Comparator|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
33288561|NCT04002635|Experimental|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
33288562|NCT03828747|Experimental|Semorinemab|Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered intravenously in the optional open-label extension period.
33288563|NCT03828747|Placebo Comparator|Placebo|Placebo will be administered intravenously in the double-blind treatment period and semorinemab will be administered intravenously in the optional open-label extension.
33288564|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
33288565|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
33288566|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
33288567|NCT01056237|Active Comparator|Azathioprine|Aza
33288568|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
33288569|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
33288570|NCT03986775|Active Comparator|citrus drink with isomaltulose|
33288571|NCT03986775|Placebo Comparator|citrus drink with sucrose|
33288572|NCT00356265|Experimental|CKD|
33288573|NCT00356265|Active Comparator|Hypertension group|
33288574|NCT00356265|Active Comparator|Normotensive group|
33288575|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
33288576|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
33288577|NCT01056471|No Intervention|Placebo Control|
33288578|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
33288579|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
33288580|NCT01052337|Active Comparator|propofol|
33288581|NCT01052337|Active Comparator|sevofluorane|
33288582|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
32782871|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks:~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
32830370|NCT04488744|Experimental|nicotine infusion 2.0mg|0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries),
33288583|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
33288584|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
33288585|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
33288586|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
33288587|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
33288588|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
33288589|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
33288590|NCT03990831|Other|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
33288591|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
33288592|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
33288593|NCT03985995|Active Comparator|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
33288594|NCT03985995|Placebo Comparator|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
33288595|NCT04273061|Experimental|Breast Cohort|Cohort of participants whose primary tumour type is breast.
33288596|NCT04273061|Experimental|Lung Cohort|Cohort of participants whose primary tumour type is lung.
33085125|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
33288597|NCT04273061|Experimental|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
33288598|NCT04273061|Experimental|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
33288599|NCT04273061|Experimental|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
33288600|NCT04273061|Experimental|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
33288601|NCT04273061|Experimental|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
33288602|NCT04273061|Experimental|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
33288603|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
33288604|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
33288605|NCT03986697|Active Comparator|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
33288606|NCT03986697|No Intervention|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
33288607|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
33288608|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
33288609|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
33288610|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
33288611|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
33288612|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
33288613|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
33288614|NCT00437268|Experimental|enzastaurin + irinotecan + cetuximab|
33288615|NCT00437268|Active Comparator|irinotecan + cetuximab|
33288616|NCT04002089|Experimental|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
33288617|NCT04002089|Experimental|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
33288618|NCT04002089|Experimental|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
33288619|NCT04002089|Active Comparator|Cohort 4 - bupivacaine|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
33288620|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
33288621|NCT01056783|Placebo Comparator|Placebo|
32782872|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
32782873|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
32782874|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
32782875|NCT02512861|Placebo Comparator|Placebo|Normal Saline
32782876|NCT05014165||Ancillary-Correlative (Cord Blood collection)|Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)
32782877|NCT04980001|Experimental|FOCUS TIC-COM arm|"Health care providers will be trained in FOCUS TIC-COM through professional development and from this group the investigators plan to recruit participants for the surveys about the training, intervention feasibility and acceptability. Health care providers will be encouraged to implement FOCUS TIC-COM will all of their pediatric patients who are overweight/obese.~Parents / Caregivers of children who are overweight or obese will be recruited into the study after exposure to the intervention. Only those exposed to the intervention will be recruited to participate in the study which includes one survey and focus groups."
32782878|NCT04979611|Other|Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.
32782879|NCT04979299|Experimental|wheelchair group|"Patients included in the  wheelchair  group will be asked to sit in a wheelchair during the interview;"
32782880|NCT04979299|No Intervention|Control group|Patients included in the control group will sit in a regular chair during the interview.
32782881|NCT05012761|Experimental|SR419 capsules|Ascending single and multiple doses of SR419 orally
32782882|NCT05012761|Placebo Comparator|Placebo|Ascending single and multiple doses of SR419 placebo orally
32782883|NCT04979065|Experimental|Experimental Group|Probiotics and Vitamin D
32782884|NCT04979065|Placebo Comparator|Control Group|Placebo and placebo
32782885|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
33288622|NCT04002245|Experimental|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
32782886|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
32782887|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
32782888|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
32782889|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
32782890|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
32782891|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
32782892|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
32782893|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
32782894|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
32782895|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
32782896|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
32782897|NCT05012683|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
32782898|NCT05012683|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
32782899|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
32782900|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
32782901|NCT04978051|Active Comparator|Standard of Care (SoC)|
32782902|NCT04978051|Experimental|SoC + Icatibant|
33288623|NCT04002245|Experimental|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
33288624|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
33288625|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
33288626|NCT05355467|Experimental|Ricovir® group|
33288627|NCT05355467|Other|Historical Control Group|
33288628|NCT04139525|Experimental|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
32956073|NCT05764564|Experimental|Experimental: Patients with heart failure (Aim 1)|
33288629|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
33288630|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33288631|NCT04081259|Experimental|Arm B: Dose Escalation LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients with inhibitors for fungal prophylaxis/treatment
33288632|NCT04081259|Experimental|Arm A: Dose Expansion LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients without inhibitors for fungal prophylaxis/treatment
33288633|NCT01027338|Experimental|Tai Chi Exercise|
33288634|NCT01027338|No Intervention|Usual Care|
33288635|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
33288636|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
33288637|NCT00337467|Experimental|A1|
33288638|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
33288639|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
33288640|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
33288641|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
33288642|NCT03989739||robotic distal pancreatectomy|
33288643|NCT03989739||laparoscopic distal pancreatectomy|
33288644|NCT04079855|Experimental|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
33288645|NCT04079855|Experimental|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
33288646|NCT04079855|Experimental|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
33288647|NCT04079855|Experimental|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
33288648|NCT03985085|Experimental|Intervention arm|
33288649|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
33288650|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
33288651|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
33288652|NCT01058889|No Intervention|Treatment as usual|
33288653|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33288654|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
33288655|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
33288656|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
33288657|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
33288658|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
33288659|NCT01057407|Experimental|ASP group|
33288660|NCT01057407|Active Comparator|Sevelamer group|
33288661|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
33288662|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
33288663|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
33288664|NCT03986463||Cohort 1|"Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)~Appropriate to undergo concurrent chemotherapy and radiation~Planned radiation dose must be between 54 and 66 Gy~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
33288665|NCT03986463||Cohort 2|"Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.~Planning to start systemic cytotoxic chemotherapy, without concurrent radiation~Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently~Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
33402253|NCT04927780|Active Comparator|Arm 2: Adjuvant mFOLFIRINOX|Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.
33402254|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
32782903|NCT04214353|Experimental|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
33402255|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
32782904|NCT04977817||Control Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The control group will contain those that did not receive probiotics.
32782905|NCT04977817||Treatment Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The treatment group will contain those neonates that did receive the probiotic nutritional supplement.
32782906|NCT04977739||those with a condition|
32782907|NCT04977739||those without a condition|
32782908|NCT04977583|Experimental|Screening|Participants in this arm will be screened for unmet social needs and receive a post card that includes a list of generic VA crisis and homeless hotlines.
32782909|NCT04977583|Experimental|Awareness|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, and receive a Resource Sheet tailored to the unmet needs identified in the unmet need screen. The Resource Sheet will include the names of available resources within the VA and/or local community that can help to address the identified need(s) and contact information and hours of operation.
32782910|NCT04977583|Experimental|Assistance|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, receive a tailored Resource Sheet, and be offered assistance from a Social Worker. If accepted, the SW will contact the participant and work with them over a period of 8 weeks to help facilitate their connection to resources than can help to address the unmet need(s) identified in the unmet need screen.
32782911|NCT04976803||Group A|Deceased patients with archival tissue
32782912|NCT04976803||Group B|Living patients with archival tissue
32782913|NCT04976803||Group C|Living patients without archival tissue
32782914|NCT02508649|Placebo Comparator|Placebo|
32782915|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
32782916|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
32782917|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
32782918|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
32782919|NCT04213729|Active Comparator|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
32782920|NCT04213729|Experimental|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
32782921|NCT04213729|Experimental|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
32782922|NCT04213261|Experimental|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
32782923|NCT05011825|Experimental|Pregnant Moms' Empowerment Program|The PMEP is a 5-session program, delivered prenatally. The first three sessions address violence and mental health and the final two sessions address labor/delivery, infant health and early parenting.
32782924|NCT05011825|No Intervention|Control|Control group participants received information about community resources, but did not receive any study-related intervention.
32782925|NCT05010421|Active Comparator|Clobetasol Group|Treatment with clobetasol-0,05% over 3 months (month 1: daily, month 2: every other day, month 3: 3x per week)
32782926|NCT05010421|Experimental|Laser Group|3 applications every 14 days of a non-ablative CO2 laser treatment
33085126|NCT04555486|Experimental|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
33085127|NCT04555486|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
33085128|NCT04555213|Experimental|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
33085129|NCT04555213|Experimental|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
32782927|NCT05010031|Experimental|radiation|Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).
32782928|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
32782929|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32782930|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32782931|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32956074|NCT05764564|Active Comparator|Control: Healthy Volunteers (Aim 1)|
32956075|NCT05764564|Experimental|Experimental: Patients with heart failure (Aim 2)|
32782932|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32782933|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32782934|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
32782935|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
32782936|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
32782937|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
32782938|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
32782939|NCT04420065|Active Comparator|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
32782940|NCT04420065|Experimental|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving <50% preferential LV pacing evaluated over the total duration of the study (12 months).
32782941|NCT04973527|Experimental|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
32782942|NCT05009329|Experimental|Phase 1 Dose Exploration|Dose escalation of JAB-21822 to determine maximum tolerated dose
32782943|NCT05009329|Experimental|Phase 1 Dose Expansion|Conditionally required
32782944|NCT05009095|Experimental|The Listening Program® with bone conduction headphones|"The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized Waves ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes.~Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the fight or flight response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008)."
32782945|NCT04972279|Experimental|Aggressive adaptation strategy|Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
32782946|NCT04972279|Experimental|Moderate adaptation strategy|Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
32782947|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
32782948|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
32782949|NCT05007925|Experimental|Single-arm|
32782950|NCT04971889|Active Comparator|Diabetes MNT plus MI|--Group-based dietary/dietary motivation intervention
32782951|NCT04971889|Active Comparator|Diabetes MNT|-Group-based dietary intervention
32782952|NCT05007613|Experimental|cabozantinib plus atezolizumab|cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W
32782953|NCT04971499|Experimental|Dose Selection|Dapansutrile starting at 500 mg PO BID plus Pembrolizumab 200 mg IV every three weeks. Dose escalation is planned to a maximum of 1000 mg BID of dapansutrile + pembrolizumab.
32782954|NCT04971499|Experimental|Dose Expansion|Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks
32782955|NCT04971265|Experimental|Low SES/High Supports|"Participants assigned to the Low SES/High Supports arm will see the Low SES/High Supports intervention"
32782956|NCT04971265|Experimental|Low SES/Low Supports|"Participants assigned to the Low SES/Low Supports arm will see the Low SES/Low Supports intervention"
32782957|NCT04971265|Experimental|High SES/High Supports|"Participants assigned to the High SES/High Supports arm will see the High SES/High Supports intervention"
32830371|NCT04488744|Experimental|nicotine infusion 1.0mg|1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries)
32782958|NCT04971265|Experimental|High SES/Low Supports|"Participants assigned to the Low SES/High Supports arm will see the High SES/Low Supports intervention"
32782959|NCT04970407|Experimental|Dysport®|40 Units (U) Intramuscular (IM) injection at day 1.
32782960|NCT04970407|Active Comparator|Botox®|16U IM at day 1.
32782961|NCT04970407|Active Comparator|Xeomin®|16U IM at day 1.
32782962|NCT02502097|Experimental|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
32782963|NCT02502097|Experimental|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
32782964|NCT02502097|Experimental|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
32782965|NCT02502097|Experimental|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
32782966|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
32782967|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
32782968|NCT04969549|Other|Theta-burst stimulation (TBS)|Receive active iTBS, 1800 pulses, 100% MT over dlPFC.
32782969|NCT05007301||Standard of care|Patients who are receiving the geko device as part of standard of care for wound management
32782970|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
32782971|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
32782972|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
32782973|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
32782974|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
32782975|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
32782976|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
32782977|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
33085130|NCT04555213|Experimental|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
33085131|NCT04555213|Experimental|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
33085132|NCT04555213|Experimental|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
33085133|NCT04555213|Experimental|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
33085134|NCT04555369|Experimental|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
32782978|NCT05006521|Experimental|KN-002 for SAD (Part 1)|Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
33085135|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
33085136|NCT04555447|Experimental|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
32782979|NCT05006521|Placebo Comparator|Placebo for SAD (Part 1)|Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
32782980|NCT05006521|Experimental|KN-002 for MAD (Part 2)|Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
33085137|NCT04555447|Placebo Comparator|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
32782981|NCT05006521|Experimental|Placebo for MAD (Part 2)|Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
32782982|NCT05006521|Experimental|KN-002 for Part 3|Single cohort with up to 18 of 24 subjects randomised to active treatment
32782983|NCT05006521|Experimental|Placebo for Part 3|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
32782984|NCT05006521|Experimental|KN-002 for Part 4|Single cohort with up to 18 of 24 subjects randomised to active treatment
32782985|NCT05006521|Experimental|Placebo for Part 4|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
32782986|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
32782987|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
33085138|NCT04555447|Experimental|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
33085139|NCT04555447|Placebo Comparator|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
33085140|NCT04555408|Active Comparator|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
33085141|NCT04555408|Active Comparator|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
32782988|NCT05006443|Other|Moderate or severe tricuspid regurgitation|40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
32782989|NCT05004883|Experimental|Regulation of Cues Enhanced Treatment|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning, and it will be combined with aspects of BWL to capitalize on the strengths of both treatments.
32782990|NCT05004883|Active Comparator|Behavioral Weight Loss|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
32782991|NCT05004883|Active Comparator|Nutrition, Stress Management, and Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
32782992|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
32782993|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
32782994|NCT05003635|Active Comparator|AFT+ EVEBRA device (intervention arm)|"Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast.~Pre-operatively patients are required to wear the device for a total of 200 hours."
32782995|NCT05003635|No Intervention|AFT without EVEBRA device (control arm)|Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
32782996|NCT04967365||Case patients|500 patients who experience greater than or equal to 3 nights in a pediatric ICU with intensive care instrumentation.
32782997|NCT04967365||Control patients|250 patients who experience an overnight stay in a pediatric ICU without intensive care instrumentation.
32782998|NCT05003401|Experimental|HabitAware Keen 2|Participants will receive the wrist device device that alerts the participant when the participant is engaging in hair pulling behavior.
32782999|NCT04966819|Experimental|Survivorship Care|"Survivorship care will consist of:~Regular meetings with the rectal cancer oncology pivot nurse~Identification of a primary care physician~Development of an individualized survivorship plan~Educational resources for patients"
32783000|NCT04966819|No Intervention|Standard Care|The control arm will consist of patients treated at the same institution who are receiving standard of care. Standard of care consists of meeting with colorectal oncology pivot nurse as needed (i.e. by referral from specialist based on patient needs).
32783001|NCT04966585|Experimental|Posaconazole|Subjects administered posaconazole (Noxifil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
32783002|NCT04966585|Placebo Comparator|Placebo|Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
32783003|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
32783004|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
32783005|NCT05000359|Other|AYA Text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
32783006|NCT04205539|Experimental|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
32783007|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
32783008|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
32783009|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
32783010|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
32783011|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
32783012|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
32783013|NCT02287233|Experimental|Phase 1: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
32830372|NCT04488744|Experimental|nicotine infuison 1.0mg|1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
32830373|NCT04488744|Placebo Comparator|Saline|saline delivered over 2minutes ,2.5minutes,10 minutes
33085142|NCT04555408|Placebo Comparator|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
33288666|NCT03986463||Cohort 3|"Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions~Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.~Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days~No plans for concurrent chemotherapy to be given~Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
32783014|NCT02287233|Experimental|Phase 1: 800 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
32783015|NCT02287233|Experimental|Phase 2: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
32783016|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
32783017|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
33288667|NCT03986307|Experimental|Omega-3|Elderly supplemented with omega-3.
33288668|NCT03986307|Placebo Comparator|Placebo|Elderly supplemented with corn oil.
33288669|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
33288670|NCT01059045|Experimental|Cryocontact therapy|
33288671|NCT01059045|No Intervention|Control|
33288672|NCT02873975|Experimental|Homologous Repair (HR) Deficiency Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with homologous repair (HR) deficiency on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
32783018|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
32783019|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
32783020|NCT02281773|Experimental|dose 1|
32783021|NCT02281773|Experimental|dose 2|
32783022|NCT02281773|Experimental|dose 3|
32783023|NCT02281773|Experimental|dose 4|
32783024|NCT02281773|Placebo Comparator|placebo|
32783025|NCT02285361||GIOTRIF|
32783026|NCT04877613|Experimental|Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion|
32783027|NCT04877613|Experimental|Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion|
32783028|NCT04877613|Experimental|Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion|
32783029|NCT04877613|Experimental|Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion|
32783030|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
32783031|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
32783032|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
32783033|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
32783034|NCT02280291|Experimental|DR SSB|
32783035|NCT02280291|Experimental|DR OnQ|
33085143|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
32783036|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
32783037|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
32783038|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
32830374|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
33085144|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
33288673|NCT02873975|Experimental|Replicative Stress Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with advanced solid tumors exhibiting replicative stress on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
33288674|NCT02873975|Experimental|CCNE1 Amplification Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with CCNE1 amplification on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
33288675|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
33288676|NCT05356637|Other|Intervention Group Receiving Fastseal|
33288677|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
32783039|NCT04877535|Experimental|Intervention|ML will be used to create a report card for each patient that summarizes the preoperative assessment and intraoperative data. Report card data will be made available to providers through multiple methods: integration into electronic health records workflows, electronic health records notifications, mobile device notifications, and print outs in the paper chart
32783040|NCT04877535|No Intervention|Pre-intervention|The standard of care. The report card will be electronically generated (to determine eligibility) but it will not be visible to clinicians.
32783041|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
32783042|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
32783043|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
32783044|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
32783045|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
32783046|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
32783047|NCT02351349|Experimental|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
32783048|NCT02351349|No Intervention|Non adherence|Those who were offered the program but did not complete the prescription
32783049|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
32783050|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
32783051|NCT04966351|Experimental|Circadian misalignment (Condition A)|Participants will eat meals during the biological nighttime while remaining awake to mimic overnight work shifts.
32783052|NCT04966351|Experimental|Circadian misalignment with time-restricted feeding (Condition B)|Participants will fast during the biological nighttime while remaining awake to mimic overnight work shifts.
32783053|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
32783054|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol, iQuit Mindfully text messages, and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
32783055|NCT04965181|Experimental|iQuit Mindfully|"Participants will receive iQuit Mindfully text messages and nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
32830375|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
32830376|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
33085145|NCT04555057|Experimental|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
33288678|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
32783056|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT)|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
32783057|NCT04965181|Active Comparator|Usual Care|"Participants in the usual care condition are provided with nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
32783058|NCT04964557|Experimental|AZD8233|AZD8233 for subcutaneous use
32783059|NCT04964557|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection
32783060|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
32783061|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
32783062|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
32783063|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
32783064|NCT04963933|Experimental|Patients treated with the device|Patients treated with the Nautilus will be followed up
33288679|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
33288680|NCT02176967|Experimental|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression.
33288681|NCT02176967|Experimental|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
33288682|NCT02176967|Experimental|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
32783065|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
32783066|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
32783069|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
32783070|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
32783071|NCT04962919||Public institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
32783072|NCT04962919||Private institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
32830377|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
32783073|NCT04962529||Arm 1: Metastatic Breast Cancer Patients With Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI~If a tissue biopsy is performed, the matched tissue will be sent to the central pathology lab for reanalysis. If a tissue biopsy was performed, but the tissue block is exhausted or unavailable, patients are still eligible to participate in the study."
32783074|NCT04962529||Arm 2: Metastatic Breast Cancer Patients Without Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI.~A contemporaneous tissue biopsy is optional for this cohort."
32783075|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
32783076|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
32783077|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
32783078|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
32783079|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
32783080|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
32783081|NCT02495077|Experimental|Experimental|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
32783082|NCT02495077|Active Comparator|Control|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
32783083|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
32783084|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
32783085|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
32783086|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
32783087|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
32783088|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
32783089|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
32783090|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
32783091|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
33085146|NCT04555057|No Intervention|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
33085147|NCT04554901|Other|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
33085148|NCT04554628|Active Comparator|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
33085149|NCT04554628|Active Comparator|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
33085150|NCT04554823|Placebo Comparator|Control Group|Will attend lectures on health education.
33085151|NCT04554823|Experimental|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
32783092|NCT04876989|Active Comparator|US-SGB|5 ml of 1% mepivacaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
32783093|NCT04876989|Active Comparator|US-TPVB|10 ml of 1% mepivacaine is injected for thoracic paravertebral block using the Ultrasound(US)-guided sagittal approach at the second thoracic paravertebral space.
32783094|NCT02494921|Experimental|Treatment (Phase 1b)|The starting cohort dose level (1) for docetaxel will be 75 mg/m2, administered on day 1 of each cycle. Prednisone will be fixed at 5 mg twice a day. The starting dose level and schedule for ribociclib will begin at 200 mg orally once daily, starting on day 1 of the 21-day cycle. If dose level 1 is not tolerated, then alternative dosing schedules of docetaxel will be evaluated, starting with dose level 1A of 60mg/m2 docetaxel.
32783095|NCT02494921|Experimental|Treatment (Phase 2)|Participants in Phase 2 will receive the Recommended Phase 2 Dose for docetaxel and ribociclib
32783096|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
32783097|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
32783098|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
32783099|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
32783100|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
32783101|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
32783102|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
32783103|NCT04960735|Experimental|Patients with cancer (patients with breast cancer and patients with lung cancer)|"Health-related Quality of Life evidence was collected from patients with cancer (patients with breast cancer and patients with lung cancer) for six months. The evidence was collected by means of health related and patient reported questionnaires (ICHOM standard sets for breast cancer and lung cancer).~Patients were monitored for six months. Intervention outcomes were monitored at different times: for patients with breast cancer, at the start (on recruitment which coincided with diagnosis) and at six months; for patients with lung cancer, at the start (on recruitment which coincided with diagnosis), at three and at six months."
32783104|NCT04959331|Active Comparator|Short-course fosfomycin|3 g of fosfomycin once daily for two days (sachets)
32783105|NCT04959331|Active Comparator|Short-course nitrofurantoin|Five-day nitrofurantoin 100 mg t.i.d. (pills)
32783106|NCT04959331|Active Comparator|Short-course pivmecillinam|Three-day pivmecillinam 400 mg. t.i.d. (pills)
32783107|NCT04959331|Active Comparator|Single-dose fosfomycin|Single 3 g dose of fosfomycin (sachet)
32783108|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
32783109|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
32783110|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
32783111|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
32783112|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
32783113|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
32783114|NCT04957615|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32783115|NCT04957147||Group A: patients with dilated cardiomyopathy|Patients with recent-onset dilated cardiomyopathy
32783116|NCT04957147||Group B: healthy volunteers|Healthy volunteers with no known heart disease
32783117|NCT02516605|Experimental|LJN452|
32783118|NCT02516605|Placebo Comparator|Placebo|
32783119|NCT04955743|Experimental|Cohort 1: Melanoma|Participants who are melanoma (PD-1/PD-L1-experienced)
32783120|NCT04955743|Experimental|Cohort 2: Renal Cell Carcinoma|Participants who are Renal Cell Carcinoma (PD-1/PD-L1 experienced).
32783121|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
32783122|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
32830378|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
33288683|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
33288684|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
33288685|NCT05356559|Active Comparator|Fish protein|
33288686|NCT05356559|Placebo Comparator|Control|
33288687|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
33288688|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
33288689|NCT05354921|Experimental|Indwelling|Foley catheterization upon admission and removed the morning following surgery.
33288690|NCT05354921|Experimental|Intermittent|Intermittent catheterization when post-void residual volume is greater than 400 mL.
33288691|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
33288692|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
33288693|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
33288694|NCT05339243|Active Comparator|ES 1|Two capsules orally once daily after breakfast for 84 days
33288695|NCT05339243|Active Comparator|HT ES1|Two capsules orally once daily after breakfast for 84 days
33288696|NCT05339243|Placebo Comparator|Placebo|Two capsules orally once daily after breakfast for 84 days
33288697|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
33288698|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
33288699|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
33288700|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
33288701|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
33288702|NCT05262257|Experimental|Lifestyle intervention group|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
33288703|NCT05262257|Experimental|Metformin treatment group|on the basis of lifestyle intervention, patients were given metformin 2-3 times a day (starting with 2times), 0.5g each time.
33288704|NCT05262257|Experimental|Dapagliflozin treatment group|on the basis of lifestyle intervention, patients took Dapagliflozin orally, once a day, 10mg at a time.
33288705|NCT05262257|No Intervention|Healthy control group|no intervention.
33288706|NCT03989817|Active Comparator|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
33288707|NCT03989817|Placebo Comparator|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
33288708|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
33288709|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
33288710|NCT03986385|Experimental|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
33288711|NCT03986385|Active Comparator|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
33288712|NCT01054287|Experimental|Falls prevention|
33288713|NCT01054287|Placebo Comparator|Usual care|
33288714|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
33288715|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
33288716|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
33288717|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
33288718|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
33288719|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
33288720|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
33288721|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
33288722|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
33288723|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
33288724|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
33288725|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
33288726|NCT01059591|Experimental|Active|GSK424887 once daily
33288727|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
33288728|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
33288729|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
33288730|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
33288731|NCT03986151|Active Comparator|Conventional radial access|
33288732|NCT03986151|Experimental|Distal radial access|
33288733|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
33288734|NCT01059669||Control group|Healthy controls
33288735|NCT03606785|Active Comparator|tranexamic acid group|
33288736|NCT03606785|Placebo Comparator|placebo group|
33288737|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
33288738|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
33288739|NCT03441971|Experimental|Single Arm|Participants will receive the device on Day 1.
33288740|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33288741|NCT05356169|Experimental|Venetoclax combined with intensive chemotherapy|The experimental group receives two cycles of inducation chemotherapy consisting of venetoclax combined with standard DA 3+7 regimen. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age>55 years）or high（for age≤ 55 years） dose cytarabine combined with venetoclax.
33288742|NCT05356169|Active Comparator|Intensive chemotherapy only|The control group receives two cycles of inducation chemotherapy consisting of standard DA 3+7 regimen without venetoclax. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age>55 years）or high（for age≤ 55 years） dose cytarabine without venetoclax.
33288743|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
33288744|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
33288745|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
33288746|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
33288747|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
33288748|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
33288749|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
33288750|NCT01059747||treatment group|
33288751|NCT05072093|Experimental|All men in cohort: MSM|Prospective cohort of MSM who are followed either in-person at the PRISM Health Research Clinic and/or virtually with remote study visits. Participants will have the option to switch prevention options at any point during the study by indicating their interest during monthly surveys or contacting study staff directly.
33288752|NCT01057875|Experimental|coffee with caffeine|
33288753|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
33288754|NCT05293691|Experimental|Body, Breath & Mind|"The program Body, Breath & Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich & Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
33288755|NCT05293691|Active Comparator|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored.The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
33288756|NCT05293691|Other|Waitlist control group|Participants in the waitlist control group are given access to the Body, Breath & Mind program after eight weeks, provided they have participated in the previous surveys in the form of a diagnostic pre-, peri-, and post-module.
33288757|NCT04001387||Spinal anesthesia|
33288758|NCT00334737|Experimental|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
33288759|NCT00334737|Active Comparator|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
33288760|NCT00334737|Placebo Comparator|placebo/control|Sham injection
33288761|NCT01059981||1|Dialysis patients
33288762|NCT01059981||2|Trauma patients
33288763|NCT01059981||3|Patients with carbon monoxide poisoning
33288764|NCT01564433|Experimental|Gait trainer treatment|
33288765|NCT01564433|Active Comparator|Conventional group|
33288766|NCT03986073|Experimental|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
33288767|NCT03986073|Experimental|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
33288768|NCT03986073|Active Comparator|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
33288769|NCT03986073|Placebo Comparator|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
33288770|NCT05279729|No Intervention|Control|
33288771|NCT05279729|Experimental|Weight Watchers (WW)|
33288772|NCT05279729|Experimental|Healthi app|
33288773|NCT03989193|Experimental|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
33288774|NCT05347199|Placebo Comparator|Healthy Volunteers Placebo|placebo pill at two time points
33288775|NCT05347199|Active Comparator|Healthy Volunteers Amisulpride|amisulpride pill at two time points
33288776|NCT05347199|Active Comparator|MDD Patients Placebo|placebo pill at two time points
33288777|NCT05347199|Experimental|MDD Patients Amisulpride|amisulpride pill at two time points
33288778|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
33288779|NCT00991913||Delirium|Delirium was determined by CAM-ICU
33288780|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
33288781|NCT03989271|Active Comparator|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
33288782|NCT03989271|Placebo Comparator|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
33288783|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
33288784|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
33288785|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
33288786|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
33288787|NCT01057953|No Intervention|Patient|Blood sample for patient included
33288788|NCT05346029|No Intervention|Standard of care|Patients will be followed-up according to standard clinical practices
33288789|NCT05346029|Experimental|Lifestyle intervention|Patients will undergo a 12 week lifestyle intervention (physical therapy and nutritional assessment)
33288790|NCT01058031|Experimental|Arm 1|MBSR
32783123|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
32783124|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
32783125|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
32783126|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
32783127|NCT02489773||Group 2|HbA1c values <7.5%
32783128|NCT04940611||Participants With CPF-CD|Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
32783129|NCT04940611||Participants With CD-RVF|Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
32783130|NCT04940611||Participants With CCF|Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
32783131|NCT04939987|Active Comparator|Opioid Control Cohort|"One treatment selected:~Tramadol (50mg) Hydrocodone-Acetaminophen (2.5mg/325mg) Oxycodone-Acetaminophen (2.5mg/325mg)"
32783132|NCT04939987|Experimental|Experimental Cohort|"Multimodal Approach:~Gabapentin (100mg TID) Ketorolac (15mg q6) Acetaminophen (1mg IV q6) Ketamine (1.5mg/kg) Ketorolac tromethamine (15mg or 30mg Q4)"
32783133|NCT04953559|Experimental|Active cTBS first, then sham cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
32783134|NCT04953559|Experimental|Sham cTBS first, then active cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
32783135|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
32783136|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
32783137|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
32783138|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
32783139|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
32783140|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
32783141|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: MTD given on days 1 and 2"
32783142|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
32783143|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
32783144|NCT04951999|Other|Blood sampling|
32783145|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
32783146|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
33288791|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
33288792|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
32783147|NCT04925947|Experimental|KN046|KN046 will be given intravenously every 2 weeks.
32783148|NCT04942639|Experimental|Standard + JOE|Standard Maintenance Treatment plus JOE robot
32783149|NCT04942639|No Intervention|Standard|Standard maintenance Treatment
32783150|NCT02486653|Experimental|Tamsulosin|
32783151|NCT02486653|Placebo Comparator|Placebo|
32783152|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
32783153|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
32783154|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
32783155|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
33085152|NCT04554589|Active Comparator|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
32783156|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
32783157|NCT05460559|Active Comparator|Group A (p-PCNL) procedure|In lithotomy position, . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
32783158|NCT05460559|Experimental|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
32783159|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
32783160|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
32783161|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
32783162|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
32783163|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
32783164|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32783165|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32783166|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
32783167|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
33288793|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
32783168|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
32783169|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
32783170|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
32783171|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
32783172|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
32783173|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
32783174|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
32783175|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
32783176|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
32783177|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
32830379|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
33288794|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
33288795|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
33288796|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
33288797|NCT03079037||Stimulation|Traditional deep brain stimulation
33085153|NCT04554589|Placebo Comparator|placebo group|receive normal saline 2 ml IV every 8 hours daily .
33288798|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
33288799|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
33288800|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
33288801|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
33288802|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
33288803|NCT01060215|No Intervention|No infusion|
33288804|NCT05345093|Experimental|Ialuxid Gel|twenty-two patients affected by acne vulgaris; twenty-two patients affected by impetigo; twenty-two patients affected by folliculitis.
33288805|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
33288806|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
33288807|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
33288808|NCT03988959|Other|Control|Standard resection
33288809|NCT05343767|Active Comparator|Control Arm 1 Metformin ( 64 patients)|"Metformin 1000 mg tablets were used.~First Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~A total dose of 2000 mg was administered per day."
33288810|NCT05343767|Experimental|Experimental Arm 2: Low Dose NW Low-Glu ( 65 patients)|"The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
33288811|NCT05343767|Experimental|Experimental Arm 3: High Dose NW Low-Glu ( 69 patients)|"The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
33288812|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
33288813|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
33288814|NCT05253365|Experimental|Memory Support System participants|
33288815|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
33288816|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
33288817|NCT00992147|Experimental|autologous cultured adipocytes|
33288818|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
33288819|NCT01060449|Other|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
33288820|NCT04001699|Experimental|Intervention|Preoperative assessment conducted by an interprofessional team
33288821|NCT04001699|Active Comparator|Usual care|Usual care
33085154|NCT04554433|Active Comparator|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
33288822|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
33288823|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
33288824|NCT05338307|Experimental|BHB supplementation|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.
33288825|NCT03989037|Experimental|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
33085155|NCT04554433|No Intervention|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
33288826|NCT03989037|Active Comparator|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
33288827|NCT05243303|Experimental|Active taVNS|These patients will self-administer transcutaneous auricular vagus nerve stimulation (taVNS).
33288828|NCT05243303|Sham Comparator|Sham taVNS|These patients will self-administer a sham procedure mimicking the active taVNS procedure.
33288829|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
33288830|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
33288831|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
33288832|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
33288833|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
33288834|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
33288835|NCT04001465|Active Comparator|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
33288836|NCT04001465|Active Comparator|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
33288837|NCT00992381|Experimental|1|PN400
33288838|NCT00992381|Active Comparator|2|Naproxen
33288839|NCT05320913|Experimental|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|Participants receiving pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)
33288840|NCT05320913|Active Comparator|isolated periarticular multimodal drug injection (PMDI)|Arm Description: Participants receiving isolated periarticular multimodal drug injection (PMDI)
33288841|NCT00992537|Experimental|IDeg|
33288842|NCT00992537|Experimental|IDegAsp|
33288843|NCT00992537|Active Comparator|IAsp|
33288844|NCT00992615|Experimental|Arm 20 cores|
33288845|NCT00992615|Active Comparator|arm 12 cores|
33288846|NCT05317715|Other|without device information|this group of patients will complete a questionnaire before receiving information on contraceptive intrauterine devices (copper or hormonal)
33288847|NCT05317715|Other|with device information|This group of patients will receive information about contraceptive intrauterine devices (copper or hormonal) before completing a questionnaire
33288848|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
33288849|NCT05304065|Active Comparator|SAFETY-Acute within Usual ED Care|The SAFETY-Acute (A) approach to safety planning and stabilization will be integrated within usual ED Care. SAFETY-A was formerly called the Family Intervention for Suicide Prevention, FISP.
33085156|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
33085157|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
33085158|NCT04721054|Active Comparator|group receiving thoracic epidural anesthesia|
33085159|NCT04721054|Active Comparator|group receiving thoracic general anesthesia|
33288850|NCT05304065|Active Comparator|Combined|The combined treatment arm includes both 1) SAFETY-A integrated within usual ED Care, and 2) therapeutic follow-up contacts using the Coping Long Term with Active Suicidality Program (CLASP) model.
33288851|NCT00992771|Experimental|Varneicline|
33288852|NCT00992771|Placebo Comparator|Placebo|
33288853|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
33288854|NCT00993005|Experimental|A|Cicatrix
33288855|NCT00993005|Placebo Comparator|B|Placebo
33288856|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
33288857|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
33288858|NCT04001231|Experimental|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
33288859|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
33288860|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
33288861|NCT00993161|Experimental|Controls|healthy controls
33288862|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
33288863|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
33288864|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
33288865|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
33288866|NCT00993239|Experimental|Birinapant (TL32711)|
33288867|NCT05297591|Experimental|breast cancer patients|Women and men diagnosed with breast cancer waiting for surgery
33288868|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
33288869|NCT04001543|Experimental|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
33288870|NCT04001543|Active Comparator|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
33288871|NCT03892889|Experimental|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
33288872|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
33288873|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
33288874|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
33288875|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
33288876|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
33288877|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
33288878|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
33288879|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
33288880|NCT00993707|Placebo Comparator|Placebo|
33402256|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
33402257|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
33402258|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
33402259|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
33288881|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
33402260|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
33402261|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
32783178|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
32783179|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
32783180|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
32783181|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
32830380|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
33288882|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
33288883|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
33288884|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
32783182|NCT04912765|Experimental|Neoantigen Dendritic Cell Vaccine and Nivolumab|"NA DC vaccine every 2 weeks at a dose of 3-5 million cells.~Adjuvant nivolumab every 2 weeks at 240mg when given concurrently with the vaccine; every 4 weeks at 480mg after vaccine treatment is completed for a total duration of 1 year."
32783183|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
32783184|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
32783185|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
32783186|NCT02471755|Active Comparator|Electro-acupuncture Group|
32783187|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
32783188|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
32783189|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
32783190|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
32783191|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
32783192|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
32783193|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
32783194|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
32783195|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
32783196|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
32783197|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
32783198|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
32783199|NCT04938973|Experimental|NIF-Guided RAMIE using ICG Dye (Experimental Arm)|The patient will undergo NIF-guided RAMIE using ICG dye using the standard Ivor-Lewis approach. This will be a two-stage operation involving a first stage through a 5-port robotic approach through the abdomen to achieve a proximal gastrectomy and D2 nodal dissection. A feeding jejunostomy would not be inserted, as per the enhanced recovery pathway for esophagectomy. In addition, the vascularization of the conduit can be confirmed using the near-infrared camera of the robot with the ICG dye. The second stage of the operation will involve a 4-port robotic approach through the right chest to achieve thoracic nodal dissection, esophagectomy, and a hand-sewn anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein. During this second stage of the operation, NIF with ICG dye will be used to visualize the vascular supply of the gastric conduit, and assess the gastric conduit for any perfusions to potentially reduce anastomotic leaks.
32783200|NCT04938973|Active Comparator|Open Transthoracic Esophagectomy (OTE)|The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
32783201|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
32783202|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
32783203|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab (CON)|Participants will be prescribed 36 sessions of center-based CR. This includes supervised exercise sessions, cooking demonstrations, didactic lectures, video presentations, group support, and stress management education. During sessions, participants have direct access to the medical director, case manager, registered nurse, exercise physiologist, and stress management specialists.
33288885|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
33288886|NCT00416520|Experimental|1|
33288887|NCT00416520|Placebo Comparator|2|
33288888|NCT00416520|Active Comparator|3|
33288889|NCT00533429|Experimental|A|Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin
33288890|NCT00533429|Placebo Comparator|B|Pemetrexed + Carboplatin + Bevacizumab + Placebo
32783204|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab + mHealth (CON+)|"Participants will be prescribed 36 sessions of center-based CR as noted above. In addition, participants will be provided access to the mHealth platform which provides e-Learning modules with factsheets, videos, quizzes, and questionnaires (coinciding with activities being conducted during the CON program), a Social Network Module will allow patients to communicate via secure network with other patients who are part of their invited network. The Social Network Module also allows for secure two-way interaction with healthcare providers in the event that patients are experiencing signs or symptoms suggestive of worsening condition. This platform also contains a Personal Health Record Module allowing patients to upload, archive, and retrieve personal health data (e.g. fitness tracker data, heart rate monitor data, blood pressure recordings, etc.) and record vital signs, symptoms, treatments, and medical history."
32783205|NCT04938661|Active Comparator|Home-Based Cardiac Rehab + mHealth (HOM+)|Participants will be provided paper copies of educational content at the time of event/discharge. In addition, these participants will be provided access to the same mHealth platform as the CON+ group. Participants in this group will be encouraged to exercise three days per week while also completing the additional questionnaires and educational content provided by the mHealth platform in accordance with the CR program. Participation will be tracked using web/internet analytics.
32783206|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
32783207|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
32783208|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
32783209|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
32783210|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
32783211|NCT04911751|Experimental|Low dose group|39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
32783212|NCT04911751|Experimental|High dose group|39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
32783213|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
32783214|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
32783215|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
32783216|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
32783217|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
32783218|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
32783219|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
32783220|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
32783221|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
32783222|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
32783223|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
32783224|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
32783225|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
32783226|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
32783227|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
32783228|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
32783229|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
32783230|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
32783231|NCT02468557|Experimental|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
32783232|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
32783233|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
32830381|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
32783234|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
32783235|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
32783236|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
32783237|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
32783238|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
32783239|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
32783240|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
32783241|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
32783242|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
32783243|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
32783244|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
32783245|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
32783246|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
32783247|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
32783248|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
32783249|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
32783250|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
32783251|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
32783252|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
32783253|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
32783254|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
32783255|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
32783256|NCT05458219|Experimental|Single arm|"Phase 1a Dose Escalation: IBI343 will be administered intravenously (IV) at different dose levels following accelerated titration for the first 2 dose levels and traditional 3+3 dose escalation design for following levels.~Phase 1a Dose Expansion: IBI343 will be administered at dose levels which is equal or lower than MTD. Each dose level contains no more than 30 subjects (including subjects in dose escalation)~Phase 1b Dose Extension: IBI343 will be administered at RP2D."
32783257|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
32783258|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
32783259|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
32783260|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
32783261|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
32783262|NCT05650125||Patients with solid organ cancer|Prospective biosampling of blood/tissue
32783263|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
32783264|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
32783265|NCT05649969|Experimental|STRONG Program|the STRONG program includes consultations with a Moffitt dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
33288891|NCT01034124|Placebo Comparator|Water|
32783266|NCT05649891|Experimental|Patients managed with Emergency Manual access|Consecutive priority 1 patients managed by resuscitation teams with access to an Emergency Manual
33288892|NCT01034124|Active Comparator|Cranberry juice|
33288893|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
32783267|NCT05649813||CRSwNP|Participants with CRSwNP in the Gulf region
32783268|NCT05649735|Experimental|GROUP A- LOGUSGYN/CANDIDEP vaginal ovules,|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP vaginal ovules treatment for 10 consecutive days.
32783269|NCT05649735|Experimental|GROUP B- LOGUSGYN/CANDIDEP lavander|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP lavender treatment for 10 consecutive days.
32783270|NCT05649735|Placebo Comparator|GROUP C- vaginal irrigation with sterile saline AELAV PURLING|At the baseline visit, eligible and PAP test negative patients were randomly assigned to receive the vaginal irrigation with sterile saline AELAV PURLING treatment for 10 consecutive days.
32783271|NCT05649735|Experimental|GROUP D- Patients pap test positive|Patients eligible at baseline and PAP test positive will be assigned to GROUP D and treated for 10 days with sterile saline-based vaginal irrigation (Placebo/control group) AELAV PURLING- Subsequently after the initial 10-day treatment they will be randomised into two further groups, E and F, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP lavage, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP douche
32783272|NCT01642251|Experimental|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32783273|NCT01642251|Active Comparator|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32783274|NCT05649657|Experimental|CKD patients with exercise training intervention|The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases
32783275|NCT05649657|No Intervention|CKD stage 1 and 2|no inervention
32783276|NCT05649657|No Intervention|CKD stage 1 and 2 respectively, and 20 healthy subjects|no inervention
32783277|NCT04892823||Supportive care (EAR, questionnaires, biospecimen collection)|Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
32783278|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
32783279|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
32783280|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
32783281|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
32783282|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
32783283|NCT04875585|Experimental|Treatment Arm|neoadjuvant therapy with Pembrolizumab/Lenvatinib in combination with surgical resection of primary tumor followed by adjuvant Pembrolizumab therapy
32783284|NCT05649345|Experimental|TR64|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 25mg, with escalation to 400mg, and subsequent dose escalation using a modified Fibonacci algorithm.
32783285|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
32783286|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
32783287|NCT04860297|Experimental|mRNA-1273|"Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.~All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization.~SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1.~Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1."
32783288|NCT02273739|Experimental|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
32783289|NCT04859595|Experimental|telephone follow-up arm|"The experimental arm corresponds to the patient benefiting from a monthly telephone follow-up during the first 6 months of their discharge from the reeducation center : CRIL (from M1 to M6). They will be contacted each month by CRIL's speech therapist for a telephone interview (20 to 30 minutes)."
32783290|NCT04859595|No Intervention|control arm|The comparison group will follow the standard follow-up protocol. A technician will contact the patients in the control arm to obtain the TIMES score each month. No further telephone follow-up will be carried out.
32783291|NCT05649189||Participants testing positive for FA|these participants have tested positive for FA at a severe level using the YFAS-2 scale.
32783292|NCT05649189||Participants testing negative for FA|these participants have tested negative for FA using the YFAS-2 scale.
32783293|NCT05649111|Active Comparator|Group A|will receive Difluprednate 4 times per day for 1 week, then twice per day for 1 week and then once per day for 5 days starting 24 hours after the operation
33288894|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
33288895|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
33288896|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
33288897|NCT01034202|Experimental|NNC126-0083|
33288898|NCT01034202|Placebo Comparator|Placebo|
33288899|NCT00533273|Experimental|AA4500 0.58 mg|
33288900|NCT00533273|Placebo Comparator|Placebo|
33288901|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
33288902|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
33288903|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
33288904|NCT00995267|No Intervention|control arm|
33288905|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
33288906|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
33288907|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.~Intervention:~Home-based individualized exercise training program~Supervised group training sessions~Climb of the Mont Ventoux"
33288908|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
33288909|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.~Intervention:~Supervised group training sessions~Climb of the mont ventoux"
33288910|NCT03985917|Experimental|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
33288911|NCT03985917|Active Comparator|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
33288912|NCT01060527||IBS-D|
33288913|NCT01060527||IBS-C|
33288914|NCT01060527||Controll|
33288915|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
33288916|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
33288917|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
33288918|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
33288919|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
33288920|NCT01054833|Experimental|Needleless sling|Needleless® sling
33288921|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
33288922|NCT01325025|Other|Control|Epileptic population
33288923|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
33288924|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited.
33288925|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
33288926|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
33288927|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
33288928|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
33288929|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
33288930|NCT00993785|Experimental|OTW Catheter System|
33288931|NCT00993863|Placebo Comparator|Placebo|
33288932|NCT00993863|Experimental|ADL5859 30 mg|
33288933|NCT00993863|Experimental|ADL5859 100 mg|
33288934|NCT00993863|Experimental|ADL5859 200 mg|
33288935|NCT00993863|Active Comparator|ibuprofen 400 mg|
33288936|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
33288937|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
33288938|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
33288939|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
33288940|NCT00995579||Healthy college volunteers|
33288941|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
33288942|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
33288943|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
33288944|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
33085160|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
33085161|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
33288945|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
33288946|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
33288947|NCT04000919|Sham Comparator|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
33288948|NCT04000919|Placebo Comparator|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
33288949|NCT04000919|Active Comparator|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
33288950|NCT04000919|Active Comparator|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
33288951|NCT05223881|Experimental|Cystic Fibrosis|Patients who are diagnosed with Cystic Fibrosis.
33288952|NCT05223881|Active Comparator|Healthy Normal|Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
33288953|NCT05222789||TAP block|Patients receiving TAP block preoperatively, following routine clinical practice
33288954|NCT05222789||Non-TAP|Patients not receiving TAP block preoperatively, following routine clinical practice
33288955|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
33288956|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
33288957|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
33288958|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
33288959|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
33288960|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
33085162|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
33288961|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
33288962|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
33288963|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
33288964|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
33288965|NCT00994565|No Intervention|Usual care|
33288966|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
33288967|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
33288968|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
33288969|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
33288970|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
33085163|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
33288971|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
33288972|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
33288973|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
33288974|NCT01058499|Experimental|MBSR|
33288975|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
33085164|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
33085165|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
33288976|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
33288977|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (>10 minutes)
33085166|NCT00235820|Active Comparator|A|
33085167|NCT00235820|Active Comparator|B|
33085168|NCT00235820|Placebo Comparator|C|
33288978|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
33288979|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
33085169|NCT04554199|Experimental|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
33288980|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
33288981|NCT03988725|Experimental|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
33288982|NCT03984279||Sequentiel group (SEQ)|
33288983|NCT03984279||Siral group (SPI)|
33288984|NCT03984123|Other|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
33288985|NCT03984123|Other|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
33288986|NCT03984123|No Intervention|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
33288987|NCT00332241|Experimental|A1|Active Abilify
33288988|NCT00332241|Placebo Comparator|A2|
33288989|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
33288990|NCT01054989|Active Comparator|Fat orally|Oral fat load
33288991|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
33288992|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
33288993|NCT03985683|Active Comparator|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
33288994|NCT03985683|Experimental|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
33288995|NCT03983967|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
33288996|NCT03983889|Experimental|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
33288997|NCT03983889|Experimental|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
33288998|NCT03983889|Experimental|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
33288999|NCT03983889|Experimental|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
33289000|NCT00337935|Experimental|Epoetin Alfa|
33289001|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
33289002|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
33289003|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
33289004|NCT03983811|Experimental|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
33289005|NCT03983811|Placebo Comparator|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
33289006|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
33289007|NCT00533897|Experimental|Abatacept|
33289008|NCT00533897|Placebo Comparator|Placebo|
33289009|NCT05212727||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
33289010|NCT00426660|Experimental|1|
33289011|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
33289012|NCT00330681|Experimental|1|MCI-186
33289013|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
33289014|NCT01061073|Experimental|Omexel|
33289015|NCT01061073|Active Comparator|spasfon|
32783294|NCT05649111|Active Comparator|Group B|will receive Difluprednate 3 times per day for 4 days, then twice per day for 4 days and then once per day for 4 days starting 4 hours after the operation
33289016|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
33289017|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
33289018|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
33289019|NCT01061229|Experimental|Homeopathic drug, potency C12|
33289020|NCT01061229|Placebo Comparator|Placebo|
33289021|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
33289022|NCT01323504|Experimental|Music therapy group|Local care with music
33289023|NCT01323504|No Intervention|control group|Local care without music
33289024|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
33289025|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
33289026|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
33289027|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
33289028|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
33289029|NCT01324050|Active Comparator|Internet-delivered therapist support|
33289030|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
33289031|NCT01037556|Experimental|Arm 1: PR104|
33289032|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33289033|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33289034|NCT00324675|Active Comparator|Rosiglitazone|
33289035|NCT00324675|Placebo Comparator|placebo|
33289036|NCT03988413|Experimental|25mg|Tablets, Oral, 25mg, single dose
33289037|NCT03988413|Experimental|50mg|Tablets, Oral, 50mg, single dose
33289038|NCT03988413|Experimental|100mg|Tablets, Oral, 100mg, single dose
33289039|NCT03988413|Experimental|200mg|Tablets, Oral, 200mg, single dose
33289040|NCT03988413|Experimental|400mg|Tablets, Oral, 400mg, single dose
33289041|NCT03988413|Experimental|800mg|Tablets, Oral, 800mg, single dose
33289042|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
33289043|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
33289044|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
33289045|NCT01060683||Group 1: 15 patients|for elective hepatic resection
33289046|NCT01060683||Group 2: 15|for elective hepatic resection
33289047|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
33289048|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
33289049|NCT01055301|Experimental|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
33289050|NCT01589016||PUL (pregnancy of unknown location),|
33289051|NCT01589016||EP ( ectopic pregnancies P)|
33289052|NCT01589016||IUP-singleton intrauterine pregnancies|
33289053|NCT01055379|Experimental|Rasagiline|
33289054|NCT01055379|Placebo Comparator|Placebo|
33289055|NCT01031940|Active Comparator|macintosh|
33289056|NCT01031940|Active Comparator|C-MAC|
33289057|NCT01031940|Active Comparator|Airtraq|
32783295|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
32783296|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
33085170|NCT04554199|Experimental|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
33289058|NCT03988101|Experimental|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
33289059|NCT03988101|Placebo Comparator|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
33289060|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
33289061|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33289062|NCT01055535|Experimental|Microplasmin|
32783297|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
33289063|NCT03987867|Experimental|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
33289064|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
33289065|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
33289066|NCT00994721||pancreatic cancer|resected pancreatic cancer
33289067|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
33289068|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
33289069|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
33289070|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
33289071|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
33289072|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
33289073|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
33289074|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
33289075|NCT04000607|Experimental|Edwards Transcatheter Atrial Shunt System|
33289076|NCT00994877||Septic Patients|
33289077|NCT00994877||Healthy Control|
33289078|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
33289079|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
33289080|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
33289081|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
33289082|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
33289083|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
33289084|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
33289085|NCT00995033|Experimental|NicVAX conjugate vaccine|
33289086|NCT00995033|Placebo Comparator|Placebo|Biological
33289087|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
33289088|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
33289089|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
33289090|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
33289091|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
33289092|NCT00997061||HYCAMTIN|
33289093|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
33289094|NCT00351819|Placebo Comparator|Placebo|Placebo gel
33289095|NCT00998933|Experimental|1|
33289096|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
33289097|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
33289098|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
33289099|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
33289100|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
33289101|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
33289102|NCT00997295||HME and LFG|
33289103|NCT00351351|Experimental|A|Cyberwand
33289104|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
33289105|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
33289106|NCT00997451|Active Comparator|Symptom Monitoring|
33289107|NCT00997451|No Intervention|Standard Medical Care|
33289108|NCT03983187|No Intervention|Control|
33289109|NCT03983187|Experimental|Rotating Magnetic Therapy group|
33289110|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
33289111|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
33289112|NCT03983109|Experimental|Detection by EpiFaith syringe with air|
33289113|NCT03983109|Experimental|Detection by EpiFaith syringe with saline|
33289114|NCT00323115|Experimental|Vaccine|
33289115|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
33289116|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
33289117|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
33289118|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
33289119|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
33289120|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
32783298|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
33289121|NCT00436332|Experimental|Erlotinib and Bevacizumab|
33289122|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
33289123|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
33289124|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
33289125|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
33289126|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
33289127|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
33289128|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
33289129|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
33289130|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
33289131|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
33289132|NCT00997529|Experimental|1|
33289133|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
32783299|NCT04869345|Experimental|LARKSPUR intervention|Lessons in Affect Regulation to Keep Stress and Pain UndeR control
32783300|NCT04869345|No Intervention|Attention Control Condition|Daily emotion reporting/no intervention
33289134|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
33289135|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
33289136|NCT00322023|Experimental|D-serine 30 mg/kg|D-serine 30 mg/kg
33289137|NCT00322023|Experimental|D-serine 60 mg/kg|D-serine 60 mg/kg
33289138|NCT00322023|Experimental|D-serine 120 mg/kg|D-serine 120 mg/kg
33289139|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
33289140|NCT00414960|Experimental|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
33289141|NCT00414960|Placebo Comparator|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
33289142|NCT01061541|Experimental|Group A|
33289143|NCT01061541|Active Comparator|Group B|
33289144|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
33289145|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
32783301|NCT05561361||SAAE group|Subjects received super selective adrenal artery embolization treatment
33289146|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
33289147|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
33289148|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
32783302|NCT05561361||Spironolactone group|Subjects received spironolactone treatment
32783303|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
32783304|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
32783305|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
32783306|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
32783307|NCT05648955|Experimental|Test product|An enriched high protein and high energy oral nutrition supplement (ONS)
32783308|NCT05648955|Active Comparator|Control product|standard isocaloric high energy normal protein isocaloric ONS
32783309|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
32783310|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
32783311|NCT01650805|Experimental|ponatinib|
33289149|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
32783312|NCT01650805|Active Comparator|imatinib|
32783313|NCT04922827|Experimental|Infliximab + Standard of Care|
32783314|NCT04922827|Active Comparator|Standard of Care|
32783315|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
32783316|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
32783317|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
32783318|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
32783319|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
32783320|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
32783321|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
32783322|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
32783323|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
32783324|NCT02465203|Other|Follow up from feeder studies|Follow up arm
32783325|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
33085171|NCT04554355|Experimental|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
33289150|NCT00997919|Experimental|A|
33289151|NCT00997919|Experimental|B|
33289152|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
33289153|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
33289154|NCT00997997||Group 1|
33289155|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
33289156|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
33289157|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
33289158|NCT00998153|Experimental|1|RRFT
33289159|NCT00998153|Active Comparator|2|Usual care
33289160|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
32783326|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
32783327|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
33085172|NCT04554355|No Intervention|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
33289161|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
33289162|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
33289163|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
33289164|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
33289165|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
33289166|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
33289167|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
33289168|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
33289169|NCT00998621||Hepatitis C infection|
32783328|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
32783329|NCT04910503|Active Comparator|Usual strategy|
32783330|NCT04910503|Experimental|Innovative strategy|
32783331|NCT04910425|Experimental|Diagnostic (18F-DCFPyL PET/MRI, mpMRI)|Patients receive fluorine F 18 DCFPyL IV and undergo PET/MRI. Patients also receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo TRUS guided prostate biopsy per standard of care.
32783332|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
32783333|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
32783334|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
32783335|NCT04257929|Active Comparator|Low dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning."
32783336|NCT04257929|Active Comparator|High dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
32783337|NCT04257929|Placebo Comparator|Placebo|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
32783338|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
32783339|NCT05427149|Active Comparator|Group C|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 1 mL normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
32783340|NCT05427149|Active Comparator|Group M25|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 25mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
33289170|NCT00998621||Hepatitis C + HIV infections|
33289171|NCT00998699|Active Comparator|XOMA 052|
33289172|NCT00998699|Placebo Comparator|Placebo|
33289173|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
33289174|NCT01003847|Active Comparator|fenofibrate|
33289175|NCT01003847|Active Comparator|fatty acid|drug
33289176|NCT01003847|Active Comparator|Placebo|
33289177|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
33289178|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
33289179|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
33289180|NCT01004237|Active Comparator|pravastatin|
33289181|NCT01004237|Active Comparator|valsartan|
33289182|NCT01004237|Active Comparator|pravastatin combined with valsartan|
33289183|NCT01004315|Experimental|KUC-7483|
33289184|NCT01004315|Placebo Comparator|Placebo|
33289185|NCT01004315|Active Comparator|Tolterodine|
33289186|NCT05165459|Experimental|Cytori Celution System in Chronic Non-Healing venous Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
33289187|NCT05239637|Experimental|Previous|Heparin stopped before ECMO decannulation
33289188|NCT05239637|Experimental|Afterwards|Heparin reduced after ECMO decannulation
33289189|NCT01004549||Bilateral intraocular lens implantation.|
33289190|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
33289191|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
33289192|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
33289193|NCT01005017|No Intervention|Optimal medical treatment|
33289194|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
33289195|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
33289196|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
33289197|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
33289198|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
33289199|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
33289200|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
33289201|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
33289202|NCT05223335|Experimental|Genotype-Guided Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 LOF allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19*2 or*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.
33289203|NCT05223335|Active Comparator|Conventional Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 LOF allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers will continue with clopidogrel monotherapy.
33289204|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
33289205|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
33289206|NCT01005641|Experimental|A|phase II
33289207|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
33289208|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
33289209|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
33289210|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
33289211|NCT01005953||Families with autistic children (3-10)|
33289212|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
33289213|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
33289214|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
33289215|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
33289216|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
33289217|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
33289218|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
33289219|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
33289220|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
33289221|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
33289222|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
33289223|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
33289224|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
33289225|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
33402262|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
33289226|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
33289227|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
33289228|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
33289229|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
33289230|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
33289231|NCT01006811|Experimental|modified Atkins diet|
33289232|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
33289233|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
33289234|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
33289235|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
33289236|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
33289237|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
33289238|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
33289239|NCT01007279|Active Comparator|CLOPIDOGREL|
33289240|NCT01007279|Experimental|ROSUVASTATIN|
33289241|NCT00530621|Experimental|Pemetrexed + Enzastaurin|
33289242|NCT00530621|Placebo Comparator|Pemetrexed + Placebo|
33289243|NCT01007357|No Intervention|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
33289244|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
33289245|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
33289246|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
33289247|NCT04000451|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
33289248|NCT04000451|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
33289249|NCT03999905|Experimental|Intervention Arm|Online training on Oral anticoagulant counseling.
33289250|NCT03999905|No Intervention|Control Arm|No counseling training
33289251|NCT01007669|Active Comparator|Reference|Health check only
33289252|NCT01007669|Experimental|Intervention|Physical activity and Health check
33289253|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
33289254|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
33289255|NCT05121311||Newborns under bilirubin monitoring|Bilirubin monitoring according to standard of care of the participating center
33289256|NCT01007747|Experimental|Geranium oil|
33289257|NCT05114603|Experimental|Dose-escalation stage|Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.
33289258|NCT05114603|Experimental|Dose-expansion stage|Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.
33289259|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
33289260|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
33289261|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
33289262|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
33289263|NCT01007903|No Intervention|Usual Care|
33289264|NCT01007903|Experimental|Tai Chi|
33289265|NCT05260385|Experimental|QD regimen|KC1036 was administered orally in 60 mg once daily, 21 days as a cycle.
33289266|NCT05260385|Experimental|BID regimen|"Dose-Escalation part : KC1036 was administered orally in 20 mg BID, 30 mg BID, or 40 mg BID.~Dose-Expansion part : According to the results of Dose-Escalation, an appropriate BID regimen was selected for Dose-Expansion ."
33289267|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
33289268|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
32783341|NCT05427149|Active Comparator|Group M50|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 50 mg/mL MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 50mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
32783342|NCT05427149|Active Comparator|Group M100|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 100 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 100mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
32783343|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
32783344|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
32783345|NCT04257773|Experimental|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
32783346|NCT04257773|Experimental|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
32783347|NCT05406167||Stereotactic Body Radiotherapy [SBRT]|Patients treated with Reflexion X1 with SBRT as the standard of care
32783348|NCT05406167||Intensity -Modulated Radiation Therapy [IMRT]|Patients treated with Reflexion X1 with IMRT as the standard of care
32783349|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
32783350|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
33289269|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
33289270|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
33289271|NCT00999791|Active Comparator|Avastin|
33289272|NCT00999791|Active Comparator|Diclofenac|
32783351|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
33289273|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
33289274|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
33289275|NCT05103527|Experimental|Non-operated Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with no history of knee surgery
32783352|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
32783353|NCT05405309|Experimental|Phase Ib: Dose Escalation|To assess the MTD of RP-3500 in combination with olaparib
33289276|NCT05103527|Experimental|Surgically Repaired Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with history of surgical repair of the knee
33289277|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
33289278|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
33289279|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
33289280|NCT01008215|No Intervention|Care as usual|Control group
33289281|NCT01008293|Experimental|VSL#3|
33289282|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
33289283|NCT01000181||Patients undergoing carotid endarterectomy|
33289284|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
33289285|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
33289286|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
33289287|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
33289288|NCT03742661|Experimental|Treatment Group|SPEAC System
33289289|NCT03742661|No Intervention|Standard of Care|Standard of Care
33289290|NCT01008371||Obese|Healthy obese subjects
33289291|NCT01008371||Non-obese|Healthy non-obese subjects
33289292|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
33402263|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
33289293|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
33289294|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
33402264|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
33289295|NCT05177783|Experimental|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire.
32783354|NCT05405309|Experimental|Phase II: Dose Expansion Enrichment Cohort|All subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation
33289296|NCT05177783|Active Comparator|Control|Participants complete a standard physician intake health questionnaire.
33289297|NCT05097521||Veterans using practitioner delivered CIH therapies only|Veterans using practitioner-delivered (acupuncture, chiropractic care, massage) CIH therapies only
33289298|NCT05097521||Veterans using self-care CIH therapies only|Veterans using self-care (yoga, meditation, Tai Chi, Qi Gong) CIH therapies only
33289299|NCT05097521||Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)|Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)
33289300|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
33289301|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
33289302|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
33289303|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
33289304|NCT01008839||Old age group of healthy women|Old women over 70 years old
33289305|NCT01008839||young group of healthy women|aged 25-35 years
33289306|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
33289307|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
33289308|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
33289309|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
33289310|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
33289311|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
33289312|NCT00530075|Experimental|1|Gusperimus
33289313|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
33289314|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
33289315|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
33289316|NCT01009229|Other|1|
33289317|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
33289318|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
33289319|NCT03999671|Experimental|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
33289320|NCT03999671|Active Comparator|Checklist|Verify that the interventions of both groups were carried out
33289321|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
33289322|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
33289323|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
33289324|NCT05734313|Experimental|Unified Protocol for Cognitive Behavioral Therapy (UP-CBT) with Continuous Glucose Monitoring|Participants randomized to this arm will receive the Unified Protocol for Cognitive Behavioral Therapy (UP-CBT), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
33289325|NCT05734313|Active Comparator|Continuous Glucose Monitoring (CGM) Only|Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
33289326|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
33289327|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
33289328|NCT05734157|Experimental|Everolimus-coated balloon|Treatment of occlusion or stenosis in Superficial Femoral Artery and Proximal Popliteal Artery with drug-coated balloon
33289329|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
33289330|NCT01001819||2|No sinus disease
33289331|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
33289332|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
33289333|NCT05734079|Active Comparator|Standard of care|Standard of care includes a written paper sheet that summarizes information about the colonoscopy procedure and bowel preparation.
33289334|NCT05734079|Experimental|Standard of care + Video call|The video call will be performed at a designated time with a GE educated nurse. The purpose of the video call is (i) to clarify the patient in person about the colonoscopy procedure (ii) efficiently prepare the patient for bowel preparation by; asking the patient about her/his medical condition, the indication for colonoscopy, medical history, current medical status and medications currently taken. The patient will be inquired, whether she/he went through colonoscopy in the past, what preparation methods were undertaken and what the outcome of the examination was. Based on the information collected during the conversation, the designated nurse performing the interview will tailor the method of bowel preparation for the patient in terms of kind of relaxant, adjustment of medication intake and dietary adjustments before the examination.
33289335|NCT05734079|Experimental|Standard of care + Video call + Educational video film|The video film will explain the colonoscopy procedure and the bowel preparation procedure, in layman's terms and in the patient's preferred language (Hebrew or Arabic).
33289336|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
33289337|NCT05734001|Active Comparator|Conventional Haemostatic Tests|"Conventional Haemostatic Tests:~If INR: > 2.5 FFP will be transfused at 15 ml/kg~If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
33289338|NCT05734001|Experimental|ROTEM Based tests|"The second group will undergo ROTEM based correction. ROTEM correction will be based on the following protocol :~EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg~FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
33289339|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
33289340|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
33289341|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
33289342|NCT05064917||Children with suspected cow's milk allergy|
33289343|NCT05061797|Active Comparator|Active Study Product|An energy beverage formulated to improve the thermogenic (calorie burning) impact in humans via caffeine and ingredients for overall metabolic wellness.
33289344|NCT05061797|Placebo Comparator|Placebo|A carbonated soft-drink with the same appearance, aroma, and flavor as the active study product
33289345|NCT05733923|Active Comparator|Traditional excavation|Mechanical caries Removal with low-speed Carbide Burs on a micromotor handpiece with air and water cooling.
33289346|NCT05733923|Experimental|Carisolv CMCR|chemomechanical caries removal using Carisolv.
33289347|NCT05733923|Experimental|Sodium Hypochlorite CMCR|chemomechanical caries removal using Sodium Hypochlorite Gel 2.5%.
33289348|NCT05733923|Experimental|Papacarie duo CMCR|chemomechanical caries removal using Papacarie duo.
33289349|NCT05733923|Experimental|Selecti-solve CMCR|chemomechanical caries removal using Selecti-solve Gel.
33289350|NCT05733923|Experimental|Brix3000 CMCR|chemomechanical caries removal using Brix3000.
33289351|NCT05733845|Other|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
33289352|NCT01002365|Active Comparator|Post op care|
33289353|NCT01002365|Active Comparator|Oxygen administration- different %|
33289354|NCT01002443|Active Comparator|H. pylori eradication|
33289355|NCT01002443|Placebo Comparator|placebo|
33289356|NCT05733767|Active Comparator|Enhanced usual care (EUC)|The investigators will administer the enhanced usual care intervention to randomized patients.
33289357|NCT05733767|Experimental|Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)|The investigators will administer the personalized care NPT3 intervention to randomized patients.
33289358|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
33289359|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
33289360|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
33289361|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
33289362|NCT05733533|Experimental|HRS-2261 oral tablet|
33289363|NCT05733533|Placebo Comparator|Matching placebo to HRS-2261|
33289364|NCT05733455|Experimental|Alpelisib treatment|Participants will ingest a single dose of alpelisib 300 mg (two overencapsulated 150-mg tablets)
33289365|NCT05733455|Placebo Comparator|Placebo treatment|Participants will ingest a single dose of placebo (two capsules filled with microcrystalline cellulose)
33289366|NCT01002677|Experimental|Curriculum|
33289367|NCT01002677|Active Comparator|Self-directed|
33289368|NCT05733299|Active Comparator|Standard Care|
33289369|NCT05733299|Experimental|aflo™ digital respiratory management platform with standard care|The new aflo™ digital respiratory management platform will provide automated inhaler technique direction, with real time quantitative personalised feedback on inhaler technique and timing.
33289370|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
33289371|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
33289372|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
33289373|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
33289374|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
33289375|NCT05059535|Experimental|cryoneurolysis of the saphenous nerve|A cryoneurolysis of the saphenous nerve will be performed between 7 days and 5 days before the knee arthroplasty
33289376|NCT05059535|Experimental|cryoneurolysis of geniculate nerves|A cryoneurolysis of geniculate nerves will be performed between 7 days and 5 days before the knee arthroplasty
33289377|NCT05059535|Placebo Comparator|control|No cryoneurolysis will be performed before the knee arthroplasty
33289378|NCT05733221|Experimental|3D Model Generated|Patient will undergo an Open Reduction and Internal Fixation preformed by a surgeon who had pre-operative access to a 3D model printed to help pre-bend hardware.
33289379|NCT05733221|No Intervention|Normal Standards of Care without Aide of Model|Patient will undergo standard Open Reduction and Internal Fixation by a surgeon who did not have a pre-operative 3D model.
33289380|NCT05733143||Symptom high/T2-biomarker low (20 participants)|[ACQ≥ 1.5 FeNO<20 ppb AND blood eosinophil count<150 cells/µL]. During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
33289381|NCT05733143||Symptom low/T2-biomarker high (20 participants)|[ACQ<1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
33289382|NCT05733143||Symptom low/T2-biomarker low (12 participants)|[ACQ<1.5 AND FeNO<20 ppb AND blood eosinophil count<150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
33289383|NCT05733143||Symptom high/T2-biomarker high (12 participants)|[ACQ≥ 1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
33289384|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
33289385|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
33289386|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
33289387|NCT01003223|Experimental|PKM modeling with graphical report|
33289388|NCT05733065|Other|Monozygotic Twin|we will include natural conceived twin pairs born before 2002, with known birth weight, sex and gestational age, and where both twins were live born without congenital abnormality. Twins born after pregnancies complicated by conditions such as TTTS will be excluded. MZ twins pairs will be ranked according to intra-pair birth weight difference. Next, we intend to include the 120 most discordant monozygotic twin pairs, stratified by chorionicity (1:1 ratio) and in the case of DC by fusion of the placentas (1:1 ratio). Only pairs where both twins consent to inclusion in the study will be included.
33289389|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
33289390|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
33289391|NCT05051267|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
33289392|NCT05051267|Experimental|Mothers Embrace|A mothers embrace is one of the earliest and most common care events that mothers offer to their babies. Close physical contact between mother and baby during hugs can reduce stress by facilitating co-regulation of mother and baby. In a study conducted in Turkey, it was stated that holding the baby on the lap for pain relief in painful interventions is a practical and easy method.
33289393|NCT05051267|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb (Balci, 2006). It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvery Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies (Karp, 2015). In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position (Karakoç, & Türker, 2014).
33289394|NCT05051267|Experimental|Mother's Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, & Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, & Johnston, 2011).
33289395|NCT05051267|Experimental|Mothers Embrace and White Noise Applied Group|One minute after the procedure, the baby's pain score will be evaluated. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the white noise will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to pre-procedural basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
33289396|NCT05051267|Experimental|Mothers Embrace and Mother's Voice Group|After the procedure, the baby will continue to listen to the baby who is in the mother's arms. One minute after the procedure, the baby's pain score will be evaluated and the HR and O2 values will be noted. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the mother's voice will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
33289397|NCT04000295|Experimental|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
33289398|NCT04000295|Active Comparator|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
33289399|NCT05732909|Experimental|First Ketone, then placebo|Ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on first experimental day and ingestion of a fat placebo drink on the second experimental day.
33289400|NCT05732909|Experimental|First placebo, then ketone|Ingestion of a fat placebo drink on the first experimental day followed by ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on the second experimental day.
33289401|NCT01003457||detrusor overactivity|
33289402|NCT01003535||[123I]5-IA-85380 SPECT|
33289403|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
33289404|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
33289405|NCT05732597||Patients with ACS and no IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - no infarct-related artery (IRA) is found
33289406|NCT05732597||Patients with ACS and IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - an infarct-related artery (IRA) is found
33289407|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
33289408|NCT05732441|No Intervention|Conventional treatment group|Routine treatment protocol are used base on clinical guidelines
33289409|NCT05732441|Experimental|Conventional treatment group combined with Huange capsule|Based on the clinical guidelines, the routine treatment was used in addition to Huange Capsule.
32783355|NCT05405309|Experimental|Phase II: Dose Expansion Eligible Subjects Cohort|Cohort will include all other eligible subjects for Dose Expansion.
33289410|NCT05592977|Experimental|Intra-oral Distalizing Appliance|"Two infra zygomatic mini-implants will be placed Bands will be cemented to upper first molars. The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars.~Orthodontic force 300 mg per side Will be delivered by Niti closed coil spring which is attached from infra zygomatic mini screw to the hook soldered to the wire framework."
33289411|NCT05732363||1|"The population will consist of patients, who have participated in the MUSCLE study and have received bariatric surgery at the CON / MCL. A potential subject who meets any of the following criteria will be excluded from participation in this study:~Inability to communicate in either Dutch or English~Weight over 204 kilograms (due to limitations of the DXA)~Pregnancy~Pacemaker"
33289412|NCT00471146|Experimental|A|
33289413|NCT00471146|Active Comparator|B|
33289414|NCT04027556|Experimental|50 keV DLD images of the LBW-based low-dose group|Low CT contrast media dose calculated based on lean body weight and low monoenergetic images of dual-energy CT with deep learning-based denoising
33289415|NCT04027556|Active Comparator|ADMIRE images of the standard-contrast dose group|Standard CT contrast media dose calculated based on total body weight and conventional images with full model-based iterative reconstruction
33289416|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
33289417|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
33289418|NCT01021280||Controls|Age and sex- matched controls
33289419|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
33289420|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
33289421|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
33289422|NCT00529763|Experimental|1|
33289423|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
33289424|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
33289425|NCT05731271|Experimental|Phase 1a Part - TST003 Dose Escalation|"TST003 administered every 3 weeks at increasing doses~1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg"
33289426|NCT05731271|Experimental|Phase 1b Part - Dose Expansion at Recommended Phase 2 dose|Administer TST003 every 3 weeks to patients with positive GREM1 tumor expression at the recommended Phase 2 Dose,
33289427|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 1|
33289428|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 2|
33289429|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 3|
33289430|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 4|
33289431|NCT05728541|Experimental|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
33289432|NCT05725421|Experimental|cT1a Radical Nephrectomy + Donor Kidney Transplantation|Radical nephrectomy will be used to remove a cT1a renal mass in an altruistic kidney donor. The kidney obtained from the radical nephrectomy participant with the cT1a mass removed will be transplanted to the recipient using an allograft.
33289433|NCT04000139|Active Comparator|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
33289434|NCT04000139|Placebo Comparator|Placebo|3 doses of 2x 500mg in capsules daily
33289435|NCT05708729|Experimental|Patients with CPSP which is pharmacorefractory and have a good analgesic response to M1-rTMS|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in <50% VAS reduction and/or intolerable side-effects).~A good analgesic response to M1-rTMS is defined as: ≥50% mean 10-d VAS reduction immediately following vs. before active M1-rTMS minus mean 10-d VAS reduction immediately following vs. pre sham M1-rTMS. A good analgesic response gives a high positive predictive value for pain reduction by MCS."
33289436|NCT05708729|Experimental|Patients with CPSP which is pharmacorefractory with less analgesic M1-rTMS response|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in <50% VAS reduction and/or intolerable side-effects).~Patients with less analgesic M1-rTMS response (n≈20) will be 1:1 randomized to either MCS (≈10) or Vc-DBS (n≈10)."
33289437|NCT05538767|Experimental|Emodepside 30 mg|
33289438|NCT05538767|Active Comparator|Albendazole 400 mg|
33289439|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
33289440|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
33289441|NCT03999827|Experimental|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
33289442|NCT03999827|Active Comparator|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
33289443|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33289444|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33289445|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33289446|NCT05503823|Experimental|Participants|Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.
33289447|NCT05698121|Experimental|Intervention|The intervention group will use an eHealth application during the waiting period before cardiac rehabilitation starts.
33289448|NCT05698121|No Intervention|Control|The control group will go through the usual waiting period before the start of cardiac rehabilitation.
33289449|NCT05502107|Experimental|PRESS Intervention|Study sites will participate in the intervention phase for 6 to 18 months, depending on the order of cluster randomization. Sites will switch from the baseline phase in approximately 6 month blocks, with all sites delivering the intervention for the final 6 months of the study.
33289450|NCT05502107|No Intervention|Standard of Care|Study sites will participate in the standard of care phase to collect baseline data for 6 to 18 months, depending on the order of cluster randomization. All sites are in the baseline phase for the first 6 months then sites will switch one at a time, every 6 months, to the intervention phase of the study.
33289451|NCT05685953|Experimental|Active vaccine|Plasmid DNA vaccine, OC-007
33289452|NCT05685953|Placebo Comparator|Placebo|Sodium chloride solution (0.9 %)
33289453|NCT05655377|Experimental|At home exercise therapy with FitMi PD|Participants will be instructed to use FitMi PD exercise system for three hours per week over 3-week period.
33289454|NCT04973111|Experimental|CT-868|SC dose of CT-868 Intervention: Drug: CT-868
33289455|NCT04973111|Placebo Comparator|Placebo|SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
33289456|NCT04973111|Active Comparator|Active Comparator|SC dose of Active Comparator Intervention: Drug: Active Comparator
32830382|NCT00494182|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|Participants receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1, and sorafenib PO BID on days 2-19. Treatment repeats every 21 days for up to 6 courses. Starting with course 7, participants receive sorafenib PO daily in the absence of disease progression or unacceptable toxicity.
32830383|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
33289457|NCT05646251|Experimental|EC-LBBAP Participant|A heart ultrasound will be used during a pacemaker implant procedure
33289458|NCT05646251|No Intervention|Control participant|A pacemaker will be implanted using routine protocol. This is retrospectively collected; patients are not actively enrolled in this arm.
33289459|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
33289460|NCT00486434|Placebo Comparator|2|SMC021 Placebo, orally twice daily during 24 months
33289461|NCT04972019|Experimental|Telerehabilitation experimental group|Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals being measured and logged. Data will be uploaded on a secure cloud server to which clinicians will have access.
33289462|NCT04972019|Sham Comparator|Telerehabilitation control group|Participants will perform web-based game play while wearing sham equipment. Duration of sessions will be fixed and frequency of sessions will equal that of the experimental group training. Over the total training the control group will have an equal duration of training with the experimental group.
33289463|NCT00424632|Experimental|Single arm dose escalation|
33289464|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
33289465|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
33289466|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
33289467|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
33289468|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
33289469|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
33289470|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
33289471|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
33289472|NCT05641259|Experimental|Dose Escalation|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at escalating dose levels in participants with AML, MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
33289473|NCT05641259|Experimental|Safety Expansion|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: Participants with AML, MDS or CMML will be treated with LP-108 to enable selection of the recommended Phase 2 dose (RP2D).~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
33289474|NCT05641259|Experimental|Efficacy Expansion [AML]|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at RP2D level in participants with AML .~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~After the completion of Part 1, the Part 2 dose expansion phase will begin. Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
33289475|NCT05641259|Experimental|Efficacy Expansion [MDS&CMML]|"LP-108: Cycle 0: ramp-up, Cycle 1+: at RP2D level in participants with MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
33289476|NCT05408975|Experimental|Active to Sham Transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive active stimulation. After completion of active stimulation, subjects will be assigned to sham stimulation.
33289477|NCT05408975|Experimental|Sham to Active transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive sham stimulation. After completion of sham stimulation, subjects will be assigned to active stimulation.
33289478|NCT05405387|Experimental|Run-In Phase|Budesonide EC 3 mg three times a day, oral
33289479|NCT05405387|Experimental|Arm 1: Treatment|Budesonide EC 3 mg three times a day, oral
33289480|NCT05405387|Placebo Comparator|Arm 2: Placebo|Placebo 3 mg three times a day, oral
33402265|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
33402266|NCT02380222||ASM|
33402267|NCT02380222||SM-AHNMD|
33402268|NCT02380222||MCL|
33402269|NCT02380222||SSM|
33402270|NCT02380222||ISM|
33402271|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
33289481|NCT05401799|Active Comparator|Conventional Upper Extremity Neuroeducation|74 patients will receive the standard occupational therapy sessions that they would normally receive during their IRF stay. UE neuroeducation sessions are typically focused on improving strength and mobility of the upper arm. Clinicians will not be given instructions on how to run their sessions, however they will not be allowed to use BURT. Other devices that would normally be used during neuro-educational sessions (including X-cite, electrical stimulation and RT-300) will be allowed for use in this group. The therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur
33289482|NCT05401799|Experimental|BURT Upper Extremity|As part of routine therapy, 74 patients will receive up to 5 sessions per week of BURT UE therapy in place of conventional neuro re-education. Patients in this arm of the study will receive any conventional therapy during the remainder of their treatment sessions. When using BURT, therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur.
33289483|NCT03999437|Experimental|Treatment # 1|
33289484|NCT03999437|Experimental|Treatment # 2|
33289485|NCT03999437|Placebo Comparator|Placebo Control|
33289486|NCT05311631|Experimental|Intervention|Improved breastfeeding support provided by health visitors supporting families after discharge from maternity ward at hospital. The intervention is implemented into the existing national health visitor program that is offered free of charge to all. The program is accepted by more than 95% of families.
33289487|NCT05311631|No Intervention|Control|Health visitors in the control municipalities will give breastfeeding support according to standard care.
33289488|NCT05638217||Patients of 4 to 12 years old eligible to received dental cavity treatment|"Patients of 4 to 12 years old that are eligible to received dental cavity treatment. The goal of this observational study is to identify the efficacy of silver diamine fluoride 38% followed by sodium fluoride varnish 5%, using CaviGuard® as delivery method, in a population with untreated dental caries age range 4 to 12 years old."
33289489|NCT05281601|Experimental|AZD7442|All participants will receive a single dose of AZD7442 on Day 1, either IM (AZD8895 followed by AZD1061) or IV (AZD8895 + AZD1061 concurrently).
33289490|NCT05278871|Experimental|CSI ultrasound measurement|Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites.
33289491|NCT05637281|Placebo Comparator|convention|patients in convention arm receive conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
33289492|NCT05637281|Experimental|convention + indometacin|Besides the conventional treatment,patients in convention + indometacin arm receive 50-mg indomethacin suppositories at intervals of 12 hours for a total of 6 doses.
33289493|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
33289494|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
33289495|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
33289496|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
33289497|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
33289498|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
33289499|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
33289500|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
33289501|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
33289502|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
33289503|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
33289504|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
33289505|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
33289506|NCT01018472|Experimental|Bifidobacterium infantis|
33289507|NCT01018472|Placebo Comparator|Placebo|
33289508|NCT04193462|Experimental|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
33289509|NCT04193462|Active Comparator|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
33289510|NCT04193462|No Intervention|Control- Healthy mothers and their babies|No intervention for 8 weeks.
33289511|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
33289512|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
33289513|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
33289514|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33402272|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
33402273|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
33402274|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:~1st: Orange fruit; 2nd: Orange juice"
33402275|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:~1st: Orange juice; 2nd: Orange fruit"
33289515|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289516|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289517|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289518|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289519|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289520|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
33289521|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
33289522|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
33289523|NCT00327717|Experimental|Zonisamide 100 mg tablet|
33289524|NCT00327717|Placebo Comparator|Placebo|
33289525|NCT03917810|Active Comparator|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
33289526|NCT03917810|Experimental|LOWSUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
33289527|NCT03917810|Experimental|LOWCHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
33289528|NCT03995810|Experimental|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
33289529|NCT00463346|Experimental|Acamprosate|Acamprosate
33289530|NCT00463346|Placebo Comparator|placebo|placebo
33289531|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
33289532|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
33289533|NCT01022528|Experimental|Dexamethasone|
33289534|NCT01022528|Placebo Comparator|Saline|
33289535|NCT01025102|Experimental|Naropin 0.1%|
33402276|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
33402277|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
32783356|NCT04465799|Experimental|ENTREN Programme|This intervention consists in a total of 12 biweekly sessions: 9 sessions of 2-hr only for children, with a further three 3-hr sessions attended by both families and children together: nutrition, physical activity sessions, and a closing event session. Children content was developed based a cognitive-behavioural perspective, and included motivational interviewing tools. The aim of the children's programme is, to promote healthy eating habits, problem awareness, motivation to change unhealthy behaviours, health commitment, emotional regulation, social skills and self-esteem. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
32783357|NCT04465799|Experimental|ENTREN-F Programme|ENTREN-F has the same children's intervention than ENTREN. It has extra 6 2-hr sessions to work on family environment and communication, plus three 2-hr sessions attended by both families and children together. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
32783358|NCT04465799|Other|Control group|The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
32783359|NCT04462601||Patients with Sjögren Syndrome|
32783360|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
32783361|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
32783362|NCT02440789|Experimental|Sirolimus|
32783363|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
32783364|NCT02538341|Active Comparator|Zostavax (Zoster Vaccine Live)|Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
32783365|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
33289536|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
32783366|NCT05446181||Old with postoperative delirium|
33289537|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
32783367|NCT05446181||Old without postoperative delirium|
32783368|NCT05446181||Young|
32783369|NCT04257617|Experimental|Single arm, ZL-1201|Single arm, ZL-1201
32783370|NCT05404373|Placebo Comparator|Low flow oxygen group|patients were randomized into the Low flow oxygen group and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
32783371|NCT05404373|Experimental|NBO group (1h)|patients were randomized into the NBO group (1h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 1 hours.
32783372|NCT05404373|Experimental|NBO group (2h)|patients were randomized into the NBO group (2h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 2 hours.
32783373|NCT05404373|Experimental|NBO group (4h)|patients were randomized into the NBO group (4h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
32783374|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
32783375|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
32783376|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
32783377|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m2 IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
32783380|NCT05402579||Cases|Patients with type 2 diabetes mellitus who were hospitalized with SGLT2 inhibitor-associated DKA
33085173|NCT04554238|Experimental|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
33085174|NCT04554238|Active Comparator|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
33085175|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
33085176|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
33289538|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
33289539|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
33289540|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
33289541|NCT00424476|Placebo Comparator|Placebo|Placebo
33289542|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
33289543|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
33289544|NCT03994536|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
33289545|NCT03994536|Experimental|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
33289546|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
33289547|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
33289548|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
33289549|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
33289550|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
33289551|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
33289552|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
33289553|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
33289554|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
33289555|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
33289556|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
33289557|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
33289558|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
33289559|NCT01037712|Experimental|ZELITREX|ZELITREX
33289560|NCT01037712|Placebo Comparator|Placebo|placebo
33289561|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
33289562|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
33289563|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
33289564|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
33289565|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
33289566|NCT01021514||Type 2 DM, Heatlhy control|
33289567|NCT00461786|Experimental|Pemetrexed|
33289568|NCT01021592||001|
33289569|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
33289570|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
33289571|NCT01025258|Active Comparator|frequent clinic visits|
32783381|NCT05402579||Controls|There are two sources for controls. [1] Patients hospitalized at one of the participating hospitals who were on an SGLT2i and do not have DKA. [2] Population controls using publicly available data from the Canadian Longitudinal Study on Aging (CLSA) database.
32783382|NCT05445713||Cohort 1|Asymptomatic subjects found to be PCR/antigen/antibody-positive during routine screening for SARS-CoV-2 infection
32783383|NCT05445713||Cohort 2|Symptomatic outpatients who were confirmed to have COVID-19 through a positive PCR/antigen test
33289572|NCT00435162|Experimental|Low Dose|
33289573|NCT00435162|Experimental|Medium Dose|
33289574|NCT00435162|Experimental|High Dose|
33289575|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
33289576|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
33289577|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
33289578|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
33289579|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
33289580|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
33289581|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
33289582|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
32783384|NCT05445713||Cohort 3|Inpatients surviving hospitalisation for severe COVID-19 and who were PCR/antigen-positive
32783385|NCT05445713||Cohort 4|Participants vaccinated in clinical trials in 2020 prior to widespread community exposure, and hence protected from severe COVID-19 (and possibly Long-COVID) if subsequently infected.
32783386|NCT05402033||Survey / Interview Group|"All patients (or parent / caregiver, if relevant) who provide informed consent will be asked to complete baseline assessments utilizing validated questionnaires administered through the phone or video call. The clinical research coordinator will input responses into REDCap. Alternatively, patients may request assessments be sent through secure email.~Baseline assessment consisting of sociodemographic items and study eligibility questions (call #1)~In addition, each patient will complete the Comprehensive Score for financial Toxicity Patient Reported Outcome Measure (COST PROM) and Short Assessment of Health Literacy (SAHL) survey measures."
33289583|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
33289584|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
32783387|NCT05445401|Experimental|Pre-rehabilitation group|Triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period
32783388|NCT05445401|Placebo Comparator|Conventional group|Conventional group
32783389|NCT05401331|Other|Hemodynamic changes due to mask use|Hemodynamic changes due to mask use
32783390|NCT05401331|Other|Hemodynamic responses when we do not use masks|Hemodynamic responses when we do not use masks
32783391|NCT02272413|Experimental|BI 695502|
32783392|NCT02272413|Active Comparator|Avastin|
32783393|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
32783394|NCT02396381|Active Comparator|CC|Ad libitum use of CC
32783395|NCT05426291||Group I|At least two of the preoperative biomarkers (Mg<0.85 mmol/L, Hgb<8.5 mmol/L, proBNP>480 pg/mL, CRP>5 mg/L) that are thought to be closely related to acute kidney injury after cardiac surgery Group I,
32783396|NCT05426291||Group II|Patients who meet at least two of the preoperative biomarkers (Mg>0.85 mmol/L, Hgb>8.5 mmol/L, proBNP<480 pg/mL, CRP<5 mg/L) Group II .
32783397|NCT05425667|Experimental|Experimental|sensory integration training exercise for improving balance and walking ability of patients with lumbar stenosis and neurological claudication.
32783398|NCT05401175|Experimental|Autologous blood transfusion support therapy group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Peripheral blood stem cells were mobilized, frozen and stored before treatment. Resuscitate and reinfusion autologous peripheral blood 24 hours after completion of concurrent chemoradiotherapy.
32783399|NCT05401175|No Intervention|Conventional treatment group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Undergo standard radiotherapy for cervical cancer.
32783400|NCT05648877|Experimental|43 semirigid ureteropyeloscopy|43 Patients underwent semirigid ureteropyeloscopy
32783401|NCT05648877|Active Comparator|34 flexible ureteropyeloscopy|34 patients with flexible ureteropyeloscopy
32783402|NCT05424809|Experimental|Shared decision-making model|In the intervention group, the shared decision-making model will be carried out. This model was proposed and designed through a participatory and deliberative process.
32783403|NCT05424809|No Intervention|Usual care|Information without an estructured shared decision-making model
33085177|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
33085178|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
33085179|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
32783404|NCT05648799|Experimental|GP30341 capsules 200 mg|4 capsules containing 200 mg of molnupiravir p.o. twice a day during 5 days (daily dose 1600 mg) in combination with Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
32783405|NCT05648799|Active Comparator|Standart therapy|Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
33289585|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
33289586|NCT00434304|Experimental|Ropinirole PR/XR|
33289587|NCT00424008|Experimental|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
33289588|NCT00424008|Active Comparator|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
33289589|NCT03994068|Experimental|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
33289590|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
33289591|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
33289592|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
33289593|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
32783406|NCT05400863|Experimental|Avoid Sugary Drinks and Artificially Sweetened Drinks ( plus Metformin)|Counseling on Beverage Intake to avoid sugary sweetened and NNS (non-nutritive sweetened) drinks plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
32783407|NCT05400863|Active Comparator|Avoid sugary drinks only, allowed water and drinks with NNS (plus Metformin)|Counseling on Beverage Intake to avoid sugary drinks (allowed water and drinks sweetened with NNS) plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
32783408|NCT05369715|Experimental|Morning|60 minutes cycling on cycle ergometer in the morning (9:00). Steady-state test at an intensity of 10% less of participant's ventilatory threshold.
32830384|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
33289594|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
33289595|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
33289596|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
33289597|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
33289598|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
33289599|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
33289600|NCT01038024|Experimental|Antioxidant Supplements|
33289601|NCT03982875|Experimental|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
33289602|NCT03982719|Experimental|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
33289603|NCT03982719|Active Comparator|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
33289604|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
33085180|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
33085181|NCT04554394|Experimental|CellFX Treated Wart Lesion|CellFX device using pre-defined energy protocols
33085182|NCT00261300|Experimental|1|Pantoprazole 40 mg
33085183|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
32783409|NCT05369715|Experimental|Evening|60 minutes cycling on cycle ergometer in the evening (18:00). Steady-state test at an intensity of 10% less of participant's ventilatory threshold.
32783410|NCT05399615|Experimental|Hospitalized Patients|"Patients hospitalized in internal ward at Poriya Medical Center"
32783411|NCT05399615|Experimental|Controls|Healthy volunteers
32830385|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
33085184|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
33085185|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
33085186|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
33289605|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
33289606|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
33289607|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
32830386|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
33289608|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
33289609|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
33289610|NCT00461552|Active Comparator|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
33289611|NCT00461552|Placebo Comparator|Placebo|Placebo , sub-Q injection twice daily.
33289612|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
33289613|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
33289614|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
33289615|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
33289616|NCT03900806|Experimental|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
33289617|NCT03900806|Experimental|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
33289618|NCT03900806|No Intervention|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
33289619|NCT04002674|Placebo Comparator|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
33289620|NCT04002674|Active Comparator|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
33289621|NCT03894254|Experimental|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
33289622|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
33289623|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
33289624|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
33289625|NCT03995888|Experimental|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
33289626|NCT03995888|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
33289627|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
33289628|NCT01022684||Healthy patients|
33289629|NCT04877756|Experimental|Arm A 2.0 mg/cm OLX10010 biweekly|Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
33289630|NCT04877756|Experimental|Arm B 5.0 mg/cm OLX10010 biweekly|Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
33289631|NCT04877756|Experimental|Arm C 2.0 mg/cm OLX10010 weekly|Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo
32783412|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
33289632|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
33289633|NCT01022840|Experimental|Low dose|S-Ketamine
33289634|NCT01022840|Active Comparator|High dose|
33289635|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
33289636|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
33289637|NCT03983876|Experimental|AVT02 100mg/mL in PFS|Prefilled Syringe Arm
33289638|NCT03983876|Experimental|AVT02 100mg/mL in Autoinjector|Autoinjector Arm
33289639|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
33289640|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
33289641|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
33289642|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
33289643|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
33289644|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
33289645|NCT03983655|Experimental|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
33289646|NCT03983655|Sham Comparator|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
33289647|NCT03983499|Experimental|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
33289648|NCT03983499|No Intervention|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
33289649|NCT01063569|Active Comparator|Oral hydrocortisone|
33289650|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
33289651|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
33289652|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
33289653|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
33289654|NCT00468728|Active Comparator|1|Vancomycin
33289655|NCT00468728|Experimental|2|PAR-101/OPT-80
33289656|NCT01061931|Active Comparator|Arctic Front® catheter|
33289657|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
33289658|NCT03982082|Experimental|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
33289659|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
33289660|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
33289661|NCT00321555|Experimental|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
33289662|NCT03983265|Other|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
33402278|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
33402279|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
33289663|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
33289664|NCT00423150|Experimental|Temozolomide|
33289665|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
33289666|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
33289667|NCT01038180||pacemaker group|
33289668|NCT00433836|Experimental|Valsartan 80 mg|
33289669|NCT00433836|Experimental|Valsartan 160 mg|
33289670|NCT00433836|Experimental|Valsartan 320 mg|
33289671|NCT00433836|Active Comparator|Enalapril 10 mg|
33289672|NCT00433836|Active Comparator|Enalapril 20 mg|
33289673|NCT00433836|Active Comparator|Enalapril 40 mg|
33289674|NCT01038258|Other|No arms|No arms
33289675|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
33289676|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
33289677|NCT03996044|Experimental|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
33289678|NCT03996044|Experimental|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
33289679|NCT03996044|Experimental|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
33289680|NCT03996044|Experimental|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
33289681|NCT03952208|Experimental|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
33289682|NCT03952208|Experimental|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
33289683|NCT00433446|Experimental|CNTO 328|
33289684|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
33289685|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
33289686|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
33289687|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
33289688|NCT00433290|Experimental|A|
33289689|NCT00433290|Placebo Comparator|B|
33289690|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
33289691|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
33289692|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
33289693|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
33289694|NCT01022060|Experimental|A|Renalof
33289695|NCT01022060|Placebo Comparator|B|Placebo
33289696|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
33289697|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
33289698|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
33289699|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
33289700|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
33289701|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
33289702|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
33289703|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
33289704|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
33289705|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
33289706|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
33289707|NCT00452114|Active Comparator|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
33289708|NCT00452114|Active Comparator|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
33289709|NCT01323062|Other|Single-arm trial|Single-arm trial
33402280|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
32783413|NCT04457531|Experimental|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
32783414|NCT04457531|Other|Control Group|Patients will receive the standard medical treatment for 12 weeks.
32783415|NCT05398601|Active Comparator|MOBILIZATION WITH MOVEMENT|"MOBILIZATION with MOVEMENT~TENS, MWM techniques for Knee"
32783416|NCT05398601|Experimental|periosteal electrical dry needling|TENS, periosteal electrical dry needling 4 point technique for Knee
32783417|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32783418|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32783419|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32783420|NCT05443061|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (in 0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
32783421|NCT05443061|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
32783422|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
32783423|NCT05397119|Experimental|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
32783424|NCT05397119|Experimental|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
32783425|NCT05397119|Experimental|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
32783426|NCT05397119|Placebo Comparator|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
32783427|NCT05397119|Sham Comparator|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
32783428|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
32783429|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
32783430|NCT05422781|Experimental|Participants With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)|Eight participants with MCC (> 1.0 years since definitive treatment or participants who had recurrence >2 years since evidence of disease) and NEAD
32783431|NCT05422157||Control|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
32783432|NCT05422157||Hemophilia|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
32783433|NCT05422157||FV Leiden|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
32783434|NCT05422157||Cirrhosis|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
32783435|NCT05422157||Anticoagulation|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
32783436|NCT05648721|Experimental|Mobile health application|Use of GDM application for GDM management
32783437|NCT05648721|Other|Control|Regular follow-up without the GDM application
32783438|NCT05397041|Experimental|BMB-101|Participants receiving BMB-101 orally
32783439|NCT05397041|Placebo Comparator|Placebo|Participants receiving Matched Placebo orally
32783440|NCT04875351||Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing|Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.
32783441|NCT05396495|Experimental|Treatment arm|Treatment arm using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
32783442|NCT05420909||Cohort 1|Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database
32783443|NCT04859205|Experimental|Intervention|"All participants partaking the SUPPORT-Pro study will receive the full intervention for 3 months which implies: (1) Full access to the platform (2) a newsletter sent by email every 2 weeks to inform them on the new blogs posted on the platform.~During the following 9 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase)."
32783444|NCT05555199|Experimental|Intervention|One interventional arm that will undergo all interventional procedures (when applicable).
32783445|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
32783446|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
32783447|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
32783448|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 2 kg|press on the spinous processes with the algometer perpendicularly.
32783449|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 3 kg|press on the spinous processes with the algometer perpendicularly.
32783450|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
33289710|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
33289711|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
33289712|NCT03982563|Experimental|Growth Mindset|
33289713|NCT03982563|Experimental|Gratitude|
33289714|NCT03982563|Experimental|Behavioral Activation|
33289715|NCT03982563|Sham Comparator|Study Skills|
33289716|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
33289717|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
33289718|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
33289719|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
33289720|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
33289721|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
33289722|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
33289723|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
33289724|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
33289725|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
33289726|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
33289727|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
33289728|NCT03982797|Experimental|treated with IMUNO BCG Moreau RJ adjuvant.|
33289729|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
33289730|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
33289731|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
33289732|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
33289733|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
33289734|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
33289735|NCT00308997|Experimental|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
33289736|NCT00308997|Sham Comparator|2|sham rTMS to Wernicke's area and a right homologous area
33289737|NCT00308685|Experimental|Albuterol-HFA-BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
33289738|NCT00308685|Placebo Comparator|Placebo-HFA-BAI|Placebo
33289739|NCT01060839|Experimental|Single session counseling|
33289740|NCT01060839|No Intervention|Standard of care|
33289741|NCT03981159|Experimental|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
33289742|NCT03981159|No Intervention|Passive group (no physical training)|Subjects served as controls.
33289743|NCT03981237|Experimental|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
33289744|NCT03981237|Active Comparator|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
33289745|NCT03982251|Experimental|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
33289746|NCT03982251|Active Comparator|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
33289747|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
33289748|NCT01060995||Standard consent|Subjects receiving standard consent
33289749|NCT00317109|Experimental|AC primed Group|
33289750|NCT00317109|Active Comparator|AC unprimed Group|
33289751|NCT03982329|Active Comparator|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
33289752|NCT03982329|Sham Comparator|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
33289753|NCT03981081|Experimental|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is> 2%
33289754|NCT03981081|Active Comparator|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
33085187|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
32783451|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
33402281|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
33085188|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
32783452|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
32783453|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
32783454|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
32783455|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
32783456|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
32783457|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
32783458|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
32783459|NCT04875273|No Intervention|Pre: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
32783460|NCT04875273|Placebo Comparator|Post Pla: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
32783461|NCT04875273|Experimental|Post Exp: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
32783462|NCT04875273|No Intervention|Pre: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
32783463|NCT04875273|Placebo Comparator|Post Pla: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
32783464|NCT04875273|Experimental|Post Exp: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
32783465|NCT05395091|Experimental|AVT03|AVT03 is the proposed biosimilar for Prolia. Subjects in this arm will receive AVT03 60mg administered s.c. on Day 1 and Day 180/Month 6. At Month 12, subjects in the AVT03 arm will receive a third dose of AVT03 60 mg
32783466|NCT05395091|Active Comparator|Prolia|"Subjects will receive 60mg of commercially available Prolia, administered s.c. on Day 1 and Day 180/Month 6. At Month 12, subjects in the Prolia treatment group will be re-randomized in a 1:1 ratio to receive either:~Group 2a:Subjects will receive AVT03 60 mg administered s.c. on Day365.~Group 2b:Subjects will receive Prolia 60 mg administered s.c. on Day365."
32783467|NCT04859049|Experimental|Group 1|Infra- medial injection of local anesthesia mixture
32783468|NCT04859049|Experimental|Group 2|medial canthus injection of the local anesthesia mixture
32783469|NCT05420831|Active Comparator|Sacrospinous fixation of the vaginal apex with the synthetic mesh|
32783470|NCT05420831|Active Comparator|Laparoscopic sacrocolpopexy|
32783471|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
32783472|NCT04256213|Experimental|Nivolumab + Ipilimumab|
32783473|NCT05393765|Experimental|experimental|"Experimental: Intervention group Yönetebilirim Before the initiation of the program, patients who visit the outpatient clinic will be evaluated according to the inclusion-exclusion criteria, their consent will be obtained, and pre-tests will be administered. Then, randomization will be performed and participants will be assigned to the experimental and control groups. Participants in the experimental group will be registered on the web-based program. The individuals in the experimental group will use Yönetebilirim for 8 weeks as of the time the program is put into use. Yönetebilirim consists of modules and consultancy services. Participants will be able to watch informative videos as much as they want for 8 weeks and receive consultancy service if they wish."
32783474|NCT05393765|No Intervention|Control|The control group will receive standard care without any intervention. The group will not receive any other intervention.
32783475|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
32783476|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
32783477|NCT02536781|Placebo Comparator|Placebol|Placebo
32783478|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
32783479|NCT05440253|Experimental|dry needling group|
32783480|NCT05440253|Active Comparator|ischaemic compression group|
33085189|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
32783481|NCT01181375|Experimental|Assays on cervical cancer tissue|
32783482|NCT05544747|Experimental|Action Observation Therapy|The patients in the action observation therapy group will be required to observe the upper limb movements or functional actions in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability (i.e., the execution phase). Three common categories of movements and tasks will be elected in the action observation therapy protocol based on the related literature
33085190|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
33085191|NCT02213146|Active Comparator|Insulin lispro|Humalog®
33085192|NCT00268749|Experimental|1|
33402282|NCT02379910|Experimental|SAD 1|AM1030-CREAM
32783483|NCT05544747|Active Comparator|Mirror Therapy|During the mirror therapy, the patients will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm of the participants will be placed inside the mirror box and the unaffected arm in front of the mirror. The patient will be instructed to watch the mirror reflection of the movement performed by his/her unaffected hand carefully and to imagine that the movement was performed by the affected hand.
32783484|NCT05393297|Experimental|HNSCC receiving (chemo)radiotherapy|Radiation: Intra-treatment FDG-PET-CT and MRI will be used to identify tumours and patients for dose-escalation. Patients identified for dose-escalation (boost) will undergo adaptive radiotherapy replanning, with the primary tumour (GTVp) receiving 76.9Gy in 35 fractions.
32783485|NCT05544357|Experimental|Resistance training with short set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
32783486|NCT05544357|Experimental|Resistance training with short set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
32783487|NCT05544357|Experimental|Resistance training with long set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
32783488|NCT05544357|Experimental|Resistance training with long set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
32783489|NCT05439863||TAVR in aortic valve disease|
32783490|NCT04858503|Experimental|internet-based cardiac rehabilitation enhancement intervention|internet-based cardiac rehabilitation enhancement intervention
32783491|NCT04858503|No Intervention|conventional cares as arranged by hospital or community centers|Participants will receive conventional cares as arranged by hospital or community centers
32783492|NCT05392283|Experimental|Vacuum cupping|
32783493|NCT05647863|Experimental|F-CaST|The experimental group who will receive the Functional Cognitive and Sensory Treatment (F-CaST)- in which therapy is individually tailored for successful task performance and where the focus is on strategies for improving sensory and EF deficits.
32783494|NCT05647863|No Intervention|Standard Care|Standard care at the therapeutic community for SUD.
32783495|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
32783496|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
32783497|NCT05647785||cerena™|Subjects who took part in the cerena™ group during the original RESTORE study
32783498|NCT05647785||attune™|Subjects who took part in the attune™ group during the original RESTORE study
33402283|NCT02379910|Experimental|SAD 2|AM1030-CREAM
33402284|NCT02379910|Experimental|SAD 3|AM1030-CREAM
32783501|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
32783502|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
32783503|NCT05417789|Experimental|Group 1 in Part 1/Part 2: Emactuzumab|Group 1: Subjects receiving emactuzumab administered on Day(D)1 and repeated once every two weeks (Q2W) for a total of 5 times, followed by an observation period of 3 months leading to a total period of 24 weeks in Part 1 and continued with a follow-up phase in Part 2.
32783504|NCT05417789|Placebo Comparator|Group 2 in Part 1 and Part 2: Placebo|Group 2: Subjects receiving placebo administered as iv infusion on D1 and repeated once every two weeks (Q2W) for 5 times followed by an observation period of 3 months to a total period of 24 weeks in Part 1 will have the option to crossover under certain circumstances to open-label emactuzumab once every 2 weeks (Q2W) for a total of 5 times in Part 2.
32783505|NCT04422977|Other|CoVID exposure|
32783506|NCT05389787|Experimental|TMS|
32783507|NCT05389787|Sham Comparator|Sham|
32783508|NCT05389631||Trifecta VinV|VinV TAVI procedure in patients who have previously received a Trifecta valve
32783509|NCT05389631||Epic VinV|VinV TAVI procedure in patients who have previously received an Epic valve
32783510|NCT05389241|Experimental|Method A|Subjects in this arm will perform the task on the liver phantom with Method A (2D-CT). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method B (2D-CT + 3D augmented reality model). After that again a NASA Task load index questionnaire is performed
32783511|NCT05389241|Experimental|Method B|Subjects in this arm will perform the task on the liver phantom with method B (2D-CT + 3D augmented reality model). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method A (2D-CT). After that again a NASA Task load index questionnaire is performed
32783512|NCT05388929|Experimental|primary ventral hernia repair or inguinal hernia repair|"Primary ventral hernias, including umbilical, epigastric, and Spigelian hernias.~Primary or recurrent inguinal hernias."
33085193|NCT04553887|Experimental|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
32783513|NCT05388929|Experimental|open or robotic ventral hernia repair outpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
32783514|NCT05388929|Experimental|open or robotic hernia repair inpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
33085194|NCT04553887|Experimental|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
33402285|NCT02379910|Experimental|MAD 1|AM1030-CREAM
33402286|NCT02379910|Experimental|MAD 2|AM1030-CREAM
32900559|NCT05367492|Placebo Comparator|Double Blind Placebo|"Participants will...~Receive placebo tablets, identical in appearance to varenicline, up to 1 mg BID for 12 weeks.~Attend QuitVaping behavioral support sessions, completed in-person or via video-conferencing, once per week for 12 weeks.~Be encouraged to sign up for This Is Quitting (TIQ), a text message vaping cessation program for adolescents."
33085195|NCT00235898|Experimental|1|CoFactor, 5-FU
33289755|NCT03979287|Experimental|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
33402287|NCT04949269|Experimental|Part A|
33402288|NCT04949269|Experimental|Part B|
33402289|NCT04949269|Experimental|Part C|
33402290|NCT04949269|Experimental|Part D|
33402291|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
33289756|NCT03979287|Active Comparator|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
33289757|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
33289758|NCT03979209|Experimental|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
33289759|NCT03979209|Experimental|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
33289760|NCT03979209|Experimental|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
33289761|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
33289762|NCT00316719|Active Comparator|Lamivudine (LAM)|
33289763|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
33289764|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
33289765|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
33289766|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
33289767|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
33289768|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
33289769|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
33289770|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
33289771|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
33289772|NCT03978975|Active Comparator|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
33289773|NCT03978975|Experimental|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
33289774|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
33289775|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
33289776|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
33289777|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
33289778|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
33289779|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
33289780|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
33289781|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
33289782|NCT02724540|Experimental|Arm 1 - BE|Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.
33289783|NCT02724540|Experimental|Arm 2 - TACE|Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
33289784|NCT02724540|Experimental|Arm 3 - DEB - CLOSED|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
33289785|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
33289786|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
33289787|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
33289788|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
33289789|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
33289790|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
33289791|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
33289792|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing~shown a presentation on development of lung cancer~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
33289793|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
33289794|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
32783515|NCT05438615|Experimental|Corneal Refractive Therapy - spherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
32783516|NCT05438615|Experimental|Corneal Refractive Therapy - aspherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
32783517|NCT04422665|Experimental|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
32783518|NCT04422665|Experimental|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
33289795|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
33289796|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
33289797|NCT00420420|Experimental|MK0249|
33289798|NCT00420420|Placebo Comparator|placebo|
33289799|NCT01038570|Experimental|Oxytocin|
33289800|NCT01038570|Placebo Comparator|Physiological serum|
33289801|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
33289802|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
32783519|NCT05417321|Experimental|HB0036|HB0036 IV every 3 weeks (q3w)
32783520|NCT05388539|Active Comparator|Active Group - protocol of Theta Burst Stimulation|3 sessions of theta burst stimulation, 1200 pulses per session of 6 minutes duration, 30-minute interval between sessions. Stimulation directed to the left dorsolateral pre-frontal cortex. The protocol will be applied for 15 days, totalizing 45 sessions of stimulation.
33085196|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
33289803|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
33289804|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
33289805|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
33289806|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
33289807|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
33402292|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
33402293|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
33402294|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
33402295|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
33289808|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
33289809|NCT00432666|Placebo Comparator|Placebo|
33289810|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
33289811|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
33402296|NCT04938271|Experimental|Healables Wearable Microcurrent Electroceutical HEAL-122 with e-Textile Sports Sleeve|Subjects activate electroceutical at home for 60 minutes (+/- 20 minutes) daily, 5 times per week, for 4 weeks
33289812|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
33289813|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
33289814|NCT01025804||Infants|
33289815|NCT01023152|Experimental|Automated cuff-inflator|
33289816|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
33289817|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
33289818|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
33289819|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
33289820|NCT01026116|Active Comparator|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
33289821|NCT01026116|Experimental|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
33289822|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
33289823|NCT01026272||Patients with MS|
33289824|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
33289825|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
33289826|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
33289827|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
33289828|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
33289829|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
33289830|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
33289831|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
33289832|NCT03995186|Experimental|Behavioural activation group|
33289833|NCT03995186|Active Comparator|Activity monitoring group|
33289834|NCT03995186|No Intervention|Waiting list control group|
33289835|NCT01027520|Experimental|Intervention|Application of Coban dressing
33289836|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
32783521|NCT05388539|Placebo Comparator|Placebo Group - Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS.
32783522|NCT05416853|Active Comparator|Transradial artery|Carotid stent implantation via radial artery approach
32783523|NCT05416853|Active Comparator|Transfemoral artery|Carotid stent implantation via femoral artery approach
32783524|NCT05416775|Experimental|SHR-8068 in combination with adebrelimab|
32783525|NCT05416775|Experimental|SHR-8068 in combination with adebrelimab and platinum-based chemotherapy|
32783526|NCT05416775|Experimental|Adebrelimab in combination with platinum-based chemotherapy|
32783527|NCT05438225|Experimental|Automated Text Message Reminder|Participants will receive automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
32783528|NCT05438225|No Intervention|Control Group|
32783529|NCT05388227||Pole Walking|Attending pole walking sessions.
32783530|NCT05416229|Experimental|Psilocybin-assisted therapy|45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.
32783531|NCT05416229|Placebo Comparator|Placebo-assisted therapy|45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.
32783532|NCT01638533|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32783533|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
32783534|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
32783535|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
33289837|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
33289838|NCT01023230|Experimental|DV-601|
33289839|NCT03993990|Experimental|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
33289840|NCT03993990|No Intervention|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
33289841|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
33289842|NCT01027832|No Intervention|Control arm|no intervention
32783536|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
32783537|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
33289843|NCT01027832|Experimental|Experimental arm|antibiotics
33289844|NCT00413010|Placebo Comparator|Arm 2|
33289845|NCT00413010|Experimental|Arm 1|
33289846|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
33289847|NCT00443534|Experimental|1|
32783538|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
33085197|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
33289848|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
33289849|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
33289850|NCT00443456|Experimental|Single|
33289851|NCT00419562|Experimental|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
33289852|NCT00419562|Placebo Comparator|Placebo|Placebo capsule designed to match appearance of treatment capsule
33289853|NCT03557294|Experimental|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
33289854|NCT03557294|Experimental|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
33289855|NCT03557294|Placebo Comparator|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
33289856|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
33289857|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
33289858|NCT01026350|Experimental|study group|
33289859|NCT01026428|Experimental|Safinamide + Levodopa|
33289860|NCT01026428|Placebo Comparator|Placebo + Levodopa|
33289861|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
33289862|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
33289863|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
33289864|NCT00308139|Experimental|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
33289865|NCT00308139|Active Comparator|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
33289866|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
33289867|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
33289868|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
33289869|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
33289870|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
33289871|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
33289872|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
33289873|NCT01323374|Experimental|Droxidopa 200mg TID|
33289874|NCT01323374|Experimental|Droxidopa 400mg TID|
33289875|NCT01323374|Experimental|Droxidopa 600mg TID|
33289876|NCT01323374|Active Comparator|Carbidopa 25mg TID|
33289877|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
33289878|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
33289879|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
33289880|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
33289881|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
33289882|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
33289883|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
33289884|NCT01323374|Placebo Comparator|Placebo TID|
33289885|NCT01066221||Clostridium difficile patients|observational study
33289886|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
33289887|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
33289888|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
33289889|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
33289890|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
33289891|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
33289892|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
33289893|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
33289894|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
33289895|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
33289896|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
33289897|NCT00316017|Placebo Comparator|3|0.9% normal saline
33289898|NCT00451178|Experimental|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
33289899|NCT00451178|Active Comparator|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
33289900|NCT00450866|Experimental|Epothilone B|
33289901|NCT01322984|Active Comparator|Normal controls|Normal children and youths
33289902|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
33289903|NCT01026584|Other|drug|
33289904|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
33289905|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
33289906|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
33289907|NCT01023464|Other|Period 1|FID 114657 or SootheXP
33289908|NCT01023464|Other|Period 2|FID 114657 or SootheXP
33289909|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
33085198|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
33289910|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
33289911|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
33289912|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
32783539|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
32783540|NCT04934839|Experimental|Patients with osseointegrated prostheses|Patients with an osseointegrated prosthesis following a lower limb amputation
33289913|NCT03848312|Experimental|Computerized Cognitive Training|Participants will complete computerized cognitive training.
33289914|NCT03848312|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
33289915|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
33289916|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
32783541|NCT04934839|Experimental|Patients with socket prostheses|Patients with a socket-mounted prosthesis following a lower limb amputation
33085199|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
33289917|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
33289918|NCT03452150|Experimental|Daily oral dose of D-0316|
33085200|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
33085201|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
33085202|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
33289919|NCT03995342|Experimental|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
33289920|NCT03995342|Placebo Comparator|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
33289921|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
33289922|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
33289923|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
33289924|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
33289925|NCT01028612|Experimental|thermal ablation with external beam radiation|
33289926|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
33289927|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
33289928|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
33289929|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
33289930|NCT01023854|Placebo Comparator|Placebo|Placebo
33289931|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
33289932|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
33289933|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
33289934|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
33085203|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
33085204|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
33085205|NCT00268788|Active Comparator|2|Intravenous Ig
33085206|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
33289935|NCT00430716|Experimental|Sildenafil High dose|
33289936|NCT00430716|Experimental|Sildenafil Low dose|
33289937|NCT00430716|Experimental|Sildenafil medium dose|
33289938|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
33289939|NCT01023932||Auditory Neuropathy Patients|
33289940|NCT01028768|Experimental|Teduglutide|
33289941|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
33289942|NCT01024088||GBS PATIENT|
33289943|NCT01024088||CONTROL|
33289944|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
32783542|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
33085207|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
32783543|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
33289945|NCT01038726|Active Comparator|Exercise Training|
32783544|NCT05515887|Experimental|Shenqu Xiaoshi Oral liquid|Shenqu Xiaoshi Oral liquid will be taken orally.
32783545|NCT05511285|Experimental|Behavioural: Digital cognitive behavioural therapy for insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online.
32783546|NCT05511285|No Intervention|Treatment as usual|Participants will receive treatment as usual.
32783547|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
32783548|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
32783549|NCT04874259|Experimental|Colorectal cancer liver metastasis|Liver transplantation for the treatment of unresectable colorectal cancer liver metastasis
32783550|NCT05647707|No Intervention|Conventional Group|"This group will comprise 36 patients who will receive conventional supportive treatment for the management of acute CO poisoning that include the following:~Airway: maintaining clear patent airways.~Breathing:~High-flow normobaric oxygen (NBO)~Hyperbaric oxygen (HBO) (if indicated).~Mechanical ventilation ( if required).~Circulation: intravenous fluids, and treatment of arrhythmias according to ECG abnormalities."
32783551|NCT05647707|Experimental|L-Carnitine Group|The 36 patients will receive conventional supportive care as in the conventional group in addition to IV L-carnitine.
32783552|NCT02408887|Active Comparator|Arm 2/Total Thyroidectomy (TT) Plus Prophylactic Central Neck Dissection (pCND)|TT plus pCND
32783553|NCT02408887|Active Comparator|Arm 1/Total Thyroidectomy (TT) alone|TT alone
32783554|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
33289946|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
33289947|NCT01038726|Active Comparator|Cognitive Training|
33289948|NCT01038726|Active Comparator|Combined Low Intensity Training|
33289949|NCT03325946||Children and Adults with Cerebral Palsy|
33289950|NCT03325946||Children and Adults with Microcephaly|
33289951|NCT03325946||Children and Adults with other Neuromotor Impairments|
33289952|NCT03325946||Children who have had a stroke|
33289953|NCT01566552|Other|SINGLE DOSE AMBISOME|
33289954|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
33289955|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
33289956|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
33402297|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
32783555|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
32783556|NCT05647473|Experimental|add-on AM|
32783557|NCT05647473|Experimental|Routine treatment|
32783558|NCT05495841||Face Mask Alone|40 patients receiving the pre-oxygenation face mask alone method during clinical routine will be studied. As per clinical standard, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes. In case of suspected full stomach, it is recommended to perform a rapid sequence induction and the patient does not receive bag-mask ventilation during the apnea period (45-60s). In the other case, a standard pre-oxygenation will be performed (see figure 1: experimental design of the study).
33289957|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
33289958|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
32900560|NCT05367492|No Intervention|Single Blind Monitoring only|"Participants will...~Receive NO drug intervention.~Attend NO behavioral support sessions.~Will not be encouraged to sign up for text message vaping cessation support."
33289959|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
33289960|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
33289961|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
33289962|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
33289963|NCT01566110|Experimental|Diet Intervention Group|
33289964|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
33289965|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal experimental arm:~Letrozole + Ribociclib~PK Cohort: Open-label ribociclib + Letrozole treatment combination.~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
33402298|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
32783559|NCT05495841||Face Mask and Nasal Cannula|40 patients using the pre-oxygenation combined facemask + HFNO technique as part of routine clinical care will be studied. As to clinical standards, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes and HFNO at 100% with a flow at 40 L/minutes during the pre-oxygenation (the flow can be decreased to less than 40 L/minutes if no tolerance by the patient). Then, after a general anesthesia induction and/or a rapid sequence induction is performed, the patient receives HFNO at 100% FiO2 and the flow of HFNO is increased to up to 80 L/minutes (which corresponds to a close delivered FiO2 at 80%) during the apnea period (1 to 2 min) until correct position of the endotracheal tube is confirmed with capnography.
32783560|NCT04135443|Experimental|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app will include more than 30 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and communication forums. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk. The intervention/app is intended to be used regularly (e.g., two times per week) during the 90 day active participation period.
32783561|NCT04135443|Active Comparator|General Health App|Participants will download a general health mobile app (focused on promoting drinking water). The control mobile app is intended to be used regularly during the 90 day active participation period.
32783562|NCT05647395|Experimental|Slowly and evenly draw the gas in the cuff|
32783563|NCT05647395|No Intervention|One-time aspiration of tracheal catheter cuff gas|
32783564|NCT02438371|Active Comparator|Nifedipine|Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
33402299|NCT04914793|No Intervention|Reference phase|"At the start (month 0), a point prevalence surveys (PPS) on hospital antimicrobial use are performed (more details on conduct of PPS are given in following section) to collect baseline data before introducing paper-based guidelines.~All medical doctors of each participating hospital are asked to complete an AMS knowledge survey and pre-prescribing guidelines survey after PPS is conducted. Then, paper-based prescribing guidelines in both adult and paediatric versions (one adult guideline and one paediatric guideline) are distributed to all doctors at participating hospitals, followed by guideline introductory session of the guidelines. After introduction of the paper-based guidelines, all six hospitals are formally included in the reference period."
32783565|NCT02438371|Active Comparator|Nifedipine plus Indomethacin|Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.
32783566|NCT05647317|Other|Digital technology-based system for heart failure management|This is a single-arm study to assess the feasibility and preliminary effectiveness of a digital technology-based system for heart failure management
32783567|NCT04419987|Experimental|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
32783568|NCT05647239|Experimental|Intervention|Since the patients included in the study were discharged early (mean hospitalization duration was 3 days), the first, third and fifth SC heparin injection (0.6 ml) administrations were performed by the researcher for three days. The application was made to the arm area due to the fact that Shotblocker was difficult to place in the abdominal area, and the outer side of the arm was preferred for subcutaneous injection administrations in the clinic where the study was conducted. Shotblocker was placed on the injection site determined on the outer side of the upper arm of the patient and the injection was administered by gently pressing the tool with the fingertips during the injection. Shotblocker was removed after removal of the injector. Injections were completed in 20 seconds and the injection site was supported with cotton for 30 seconds.
32783569|NCT05647239|No Intervention|Control|"Verbal and written informed consents of the patients included in the control group were obtained after they were informed by the researcher. Before the application, questions in patient information form were asked to each patient and how to use the VAS pain and injection satisfaction scale was explained. During injection, SC Clexan (0.6 ml) was injected on the site without using Shotblocker. Injections were completed in 20 seconds and the site was supported for 30 seconds. In the first minute after each SC injection administration, the patients were asked about pain level felt during the injection and injection satisfaction status.~In this study, the researcher administered all SC injections by throughout the study by considering the reliability of the study results."
32783570|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
32783571|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
32783572|NCT04920565|Experimental|cardiac surgery patients with multiple organ dysfunction|hemoperfusion procedure with polymyxin B will be performed for 12 hours
32783573|NCT04920565|No Intervention|cardiac surgery patients|without hemoperfusion with polymyxin B
32783574|NCT04934683|Active Comparator|Routine Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
32783575|NCT04934683|Active Comparator|Routine Pressure Management with propofol induction|Propofol will be used as an induction agent.
32783576|NCT04934683|Active Comparator|Tight Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
32783577|NCT04934683|Active Comparator|Tight Pressure Management with propofol induction|Propofol will be used as an induction agent.
33289966|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal control arm:~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
33289967|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
33289968|NCT01038882|Placebo Comparator|Physiological serum|
32783578|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
33289969|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
33289970|NCT00430482|Active Comparator|2|Individual Counseling
33289971|NCT00449930|Experimental|1|Drug
33289972|NCT00449930|Active Comparator|2|Active comparator
33289973|NCT01034982|Experimental|1|tosylate salt tablet
33289974|NCT01034982|Experimental|2|free suspension
33289975|NCT01034982|Experimental|3|tosylate salt tablet
33289976|NCT01034982|Experimental|4|free suspension
33289977|NCT01038960|Experimental|Exercise training|training
33289978|NCT01038960|No Intervention|Not training|No organized training
33289979|NCT00449696|Experimental|Gel-200|
33289980|NCT00449696|Placebo Comparator|PBS|
33289981|NCT01024166||Patient|Patient computer system use questionnaire
33289982|NCT01024166||Caregiver|Caregiver computer system use questionnaire
33289983|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
33289984|NCT01566188|Experimental|omega-3 from vegetal origin|
33289985|NCT01566188|Placebo Comparator|Placebo|
33289986|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
33289987|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
32783579|NCT04933435|Active Comparator|Interventional Radiology Liver Directed Therapies (ILDT)|ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.
32783580|NCT04933435|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.
33289988|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
33289989|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
33289990|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
33289991|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
33289992|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
33289993|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
33289994|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
33289995|NCT01024322||Ciprofloxicine or Vigamox or other.|
33289996|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
33289997|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
33289998|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
33289999|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
33290000|NCT01566266|Experimental|Amoxicillin|
33290001|NCT01566266|Placebo Comparator|Placebo capsules|
33290002|NCT01024400|Experimental|vaccine|
33290003|NCT00430248|Experimental|Febuxostat 40 mg QD|
33290004|NCT00430248|Experimental|Febuxostat 80 mg QD|
33290005|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
33290006|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
33290007|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
33290008|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
33290009|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
33290010|NCT00429858|Experimental|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
33290011|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
33290012|NCT01323738|Experimental|Psychoeducation|Intervention group
33290013|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
33290014|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
33290015|NCT01035294|Experimental|mindfulness based intervention|
33290016|NCT01035294|Active Comparator|usual care (UC)|
33290017|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
33290018|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: 26 mg CET(1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
33290019|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: Placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
33290020|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:~Week 0: placebo (2 injections)~Week 2: placebo (1 injection)~Treatment course 2:~Week 26: placebo (2 injections)~Week 28: placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
33290021|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
33290022|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
33290023|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
33290024|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
33290025|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
33290026|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
33290027|NCT01039194|Active Comparator|BMS-708163|
33290028|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
33290029|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
33290030|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
33290031|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
33290032|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
33290033|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
33290034|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
33290035|NCT01033266||CPET CPAP|
33290036|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
33290037|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
33290038|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
33290039|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
33290040|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
33290041|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
33290042|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
33290043|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
33290044|NCT01039272||control group|healthy patients without any oral pathology
33290045|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
33290046|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
33290047|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
33290048|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
33290049|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
33290050|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
33290051|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
33290052|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
33290053|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
32783581|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
33290054|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
33290055|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
33290056|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
33290057|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
33290058|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
33290059|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
33290060|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
33290061|NCT01035450|Experimental|Everolimus-eluting stent|
33290062|NCT01035450|Active Comparator|Sirolimus-eluting stent|
33290063|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
33290064|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
33290065|NCT03994458|Experimental|Experimental|Participants get the full program for 6 weeks.
33290066|NCT03994458|Placebo Comparator|Placebo|Participants get the placebo program for 6 weeks.
33290067|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
33290068|NCT01039662|Placebo Comparator|Oolong tea|
33290069|NCT01033656|Experimental|Anakinra|experimental drug of study
33290070|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
33290071|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
33290072|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
33290073|NCT01589172||Pediatric Brain Trauma Patients|
33290074|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
33290075|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
33290076|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
33290077|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
33290078|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
33290079|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
33290080|NCT00448136|Experimental|1|
33290081|NCT00448136|Experimental|2|
33290082|NCT00307437|Placebo Comparator|Group I: Placebo|
33290083|NCT00307437|Experimental|Group II: Ustekinumab 45 mg|
33290084|NCT00307437|Experimental|Group III: Ustekinumab 90 mg|
33290085|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (>2 x 2cm) undergoing elective surgery
33290086|NCT00440726|Experimental|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
33290087|NCT00440726|Experimental|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
33290088|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
33290089|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
33290090|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
33290091|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
33290092|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
33290093|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
33290094|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
33290095|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
33290096|NCT03995420|Experimental|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
33290097|NCT03995420|Other|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
33290098|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
33290099|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
33290100|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.~There is no comparison group for this investigation."
33290101|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
33290102|NCT01024634|Other|African American Group|A group of young African American males and females
33290103|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
33290104|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
33290105|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
33290106|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
33290107|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
33290108|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
33290109|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
33290110|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
33290111|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
33290112|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
33290113|NCT01030328|Placebo Comparator|2|2 sugar pills
33290114|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
33290115|NCT00446966|Placebo Comparator|placebo|olive oil
33290116|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
33290117|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
33290118|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
32783582|NCT04909333|Experimental|Group A (EHH Patients)|Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.
33290119|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
33290120|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
33290121|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
33290122|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
33290123|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
33290124|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
33290125|NCT00456092|Experimental|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
32938836|NCT05406193|Experimental|Intervention (CIM2)|An extended overview consultation, lasting 45 minutes, with the general practitioner, the patient (and maybe a relative), and the care coordinator. An individual care plan is developed, covering planned activities in the three sectors (general practice, municipality, and hospital) that will take place within the 12-month intervention period. General practice coordinates the planned patient care between general practice, the municipality, and the hospital, and follow-up on the execution of planned healthcare activities. The individual care plan is shared electronically with the healthcare center in the municipality and with the outpatient clinics using the standard IT-communication tool provided by MedCom and a routinely used national standard in general practice, hospitals, and municipalities.
32938837|NCT05406193|No Intervention|Usual care|Patients with a general practitioner allocated to the control group will receive usual care.
32938838|NCT04398199|Experimental|Hypofractionated Radiation Therapy|Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
33290126|NCT00456092|Experimental|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
33290127|NCT00456092|Placebo Comparator|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
33290128|NCT01040442|Experimental|vibration stimuli|
33290129|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
33290130|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
33290131|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
33290132|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
33290133|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
33290134|NCT01030640|Placebo Comparator|placebo|formulation without active drug
33290135|NCT01030640|Active Comparator|tanezumab|
33290136|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
33290137|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
33290138|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
33290139|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
33290140|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
33290141|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
33290142|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
33290143|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
33290144|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
33290145|NCT03995732|Experimental|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
33290146|NCT03995732|Experimental|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
33290147|NCT03995732|Experimental|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
33290148|NCT03995732|Placebo Comparator|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
33290149|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
33290150|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
33290151|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
33290152|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
33290153|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
33290154|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
32783583|NCT04909333|Experimental|Group B (EHH Patients)|Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.
32783584|NCT04909333|Experimental|Group C (control subjects)|Control subjects without evidence for EHH defined by no glucose levels below 3.0 mmol/l during a 7-day CGFS (Freestyle libre) and matched to EHH patients for age, gender and BMI will receive only on one study day a single intravenous injection of 10μg Exenatide and compared to group A patients on Day 2. They will not receive a Placebo injection.
32783585|NCT04909021|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
32783586|NCT04909021|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
32783587|NCT04909021|Experimental|Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
32783588|NCT04909021|Experimental|Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
32783589|NCT04909021|Placebo Comparator|Placebo (Single-dose)|Participants in this arm will receive a single intranasal dose of placebo
32783590|NCT04909021|Placebo Comparator|Placebo (Two-dose)|Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
32783591|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
32783592|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
32783593|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
32783594|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
32783595|NCT04908943|Experimental|Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)|RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
32783596|NCT04908943|No Intervention|Waitlist|Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
32783597|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
32783598|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
32783599|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
32783600|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
32783601|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
32783602|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
32783603|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
32783604|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
32783605|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
32783606|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
32783607|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
33290155|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
33290156|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
33290157|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
33290158|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
33290159|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
33290160|NCT03847610|Experimental|Healthy volunteer|
33290161|NCT03995498|Active Comparator|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:~If sensor glucose level is under < 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is > 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
33290162|NCT03995498|Active Comparator|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
33290163|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
33290164|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
33290165|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
33290166|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
33290167|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
33290168|NCT01027130||healthy control|240 female subjects without preeclampsia
33290169|NCT01027130||preeclampsia|120 female subjects with preeclampsia
33290170|NCT03994718|Experimental|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
33290171|NCT03994718|Experimental|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
33290172|NCT03994718|Experimental|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
33290173|NCT00455858|Active Comparator|insulin detemir|
33290174|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
33290175|NCT00439556|Experimental|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
33290176|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
33290177|NCT00410202|Active Comparator|Adefovir + Lamivudine|
33290178|NCT00410202|Active Comparator|Entecavir + Adefovir|
33290179|NCT03011684|Experimental|ER Positive - Letrozole|
33290180|NCT03011684|Experimental|ER Positive - Tamoxifen|
33290181|NCT03011684|No Intervention|ER Negative|
33290182|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
33290183|NCT03893838||Post refractive surgery without HOA|Patients post refractive surgery that do not complain on the high order aberrations such as glare, halo and starburst.
33290184|NCT03893838||Post refractive surgery with HOA|Patients post refractive surgery that do complain on the high order aberrations such as glare, halo and starburst.
33290185|NCT03893838||Post refractive surgery with rainbow HOA|"Patients post refractive surgery that do complain on:~the high order aberrations such as glare, halo and starburst but with the chromatic aureola~difficulties working with LCD projectors, monitors, cell phones and tablets"
33290186|NCT00445328|Active Comparator|B|
33290187|NCT00445328|Experimental|A|
33290188|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
33290189|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
33290190|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
33290191|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
33290192|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
33290193|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
33290194|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
33290195|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
33290196|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
33290197|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
33290198|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
33290199|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
33290200|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
33290201|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
33290202|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
33290203|NCT03994640|Experimental|Cannabis cream|Cannabis cream topical skin application in experimental group
33290204|NCT03994640|Placebo Comparator|Placebo cream|Placebo cream topical skin application in control group
33290205|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
33290206|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
33290207|NCT01024790|Experimental|Exercise group|
33290208|NCT01024790|No Intervention|Usual care|
33290209|NCT01031264||Social drinkers|
33290210|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
33290211|NCT04748120|Active Comparator|Operative management|Treatment with surgery
33290212|NCT04748120|Active Comparator|Non-operative management|Treatment with antibiotics
33290213|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
33290214|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
33290215|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
33290216|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
33290217|NCT00404352|Placebo Comparator|Placebo three times weekly|
33290218|NCT03994380|Experimental|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
33290219|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
33290220|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
33290221|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
33290222|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
33290223|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
33290224|NCT04844762|Active Comparator|usual brand menthol cigarette (UBMC)|Study participant's usual brand menthol cigarette
33290225|NCT04844762|Active Comparator|menthol roll-your-own cigarette (mRYO)|Mentholated pipe tobacco in a roll-your-own cigarette tube
33290226|NCT04844762|Active Comparator|menthol filtered little cigar (mFLC)|The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)
33290227|NCT04844762|Active Comparator|non-menthol cigarette (nmC)|The non-menthol cigarette will be Newport non-menthol cigarettes.
33290228|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
33290229|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
33290230|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
33290231|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
33290232|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
33290233|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
33290234|NCT00437294|Experimental|Capecitabine + Enzastaurin|
33290235|NCT00437294|Placebo Comparator|Capecitabine + Placebo|
33290236|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
33290237|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
33290238|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
33290239|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
33290240|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
33290241|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
33290242|NCT01027208|Experimental|Ixabepilone|
33290243|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
33290244|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
33290245|NCT01031732|Experimental|Two-incision|MIS-2 THA
33290246|NCT01031732|Experimental|Watson-Jones|MIS-WJ
33290247|NCT01031732|Experimental|MIS-AL|
33290248|NCT01031732|Experimental|MIS-PL|
33290249|NCT02923544|Experimental|total laparoscopic or robotic-assisted hysterectomy|The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form.
33290250|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
33290251|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
33290252|NCT01033994|Experimental|AS902330|
33290253|NCT01033994|Placebo Comparator|Placebo|
33290254|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
33290255|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
33290256|NCT02911064||Assessment Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being.
33290257|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
33290258|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
33290259|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
33290260|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
33290261|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation [RNF] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
33290262|NCT00436826|Placebo Comparator|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
33290263|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
33290264|NCT00436826|Placebo Comparator|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
33290265|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
33290266|NCT00436826|Placebo Comparator|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
33290267|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
33290268|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
33290269|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
33290270|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
33290271|NCT03889860||Uveitis group|
33290272|NCT03889860||Control group|age and sex matched group to the uveitis group
33290273|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
33290274|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
33290275|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
33290276|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
33290277|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
33290278|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
33290279|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
33290280|NCT01037504|Experimental|A|Drug: AZD5423
33290281|NCT01037504|Placebo Comparator|B|Drug: Placebo
33290282|NCT00262600|Active Comparator|Dabigatran dose 2|twice a day
33290283|NCT00262600|Active Comparator|Warfarin|once a day
33290284|NCT00262600|Active Comparator|Dabigatran dose 1|twice a day
33290285|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
33290286|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
33290287|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
33290288|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
33290289|NCT03884088|Experimental|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
33290290|NCT03884088|Active Comparator|Control Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
33290291|NCT03881436|Experimental|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.~At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
33290292|NCT03881436|Experimental|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
33290293|NCT03880500|Sham Comparator|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
33290294|NCT03880500|No Intervention|Control|No intervention
33290295|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
33290296|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
33290297|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
33290298|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
33290299|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
33290300|NCT03827694||Patients with possible PIFI|
33290301|NCT01039896|Experimental|Group1|SLM0807
33290302|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
33290303|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
33290304|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
33290305|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
33290306|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
33290307|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
33290308|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
33290309|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33290310|NCT00262522|Experimental|LPV/r 800/200 mg QD Tablet|
33290311|NCT00262522|Experimental|LPV/r 800/200 mg QD SGC (Through Week 8)|
33290312|NCT00262522|Active Comparator|LPV/r 400/100 mg BID Tablet|
33290313|NCT00262522|Active Comparator|LPV/r 400/100 mg BID SGC (Through Week 8)|
33290314|NCT00436280|Experimental|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
33290315|NCT00250588|Experimental|Problem solving + care coordination|Problem solving skills training and asthma care coordination
33290316|NCT00250588|Experimental|Asthma care coordination|Asthma care coordination
33290317|NCT00250588|Active Comparator|Wait-list control|Usual care
33290318|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
32783608|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
33290319|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
33290320|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
33290321|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
33290322|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
33290323|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
33290324|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
33290325|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
33290326|NCT01032122|Experimental|rituximab|
33290327|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
33290328|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
33290329|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
33290330|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
33290331|NCT03819660|Experimental|amifampridine phosphate|Oral tablets, 15 to 80 mg per day in divided doses 3 to 4 times a day for up to 18 months.
33290332|NCT00394524|Experimental|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
33290333|NCT00394524|Active Comparator|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
33290334|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
33290335|NCT00409344|Placebo Comparator|1|Normal Saline
33290336|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
33290337|NCT01040754|Active Comparator|Acupuncture|
33290338|NCT01040754|No Intervention|Waitlist Control|
33290339|NCT00415610|Other|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
33290340|NCT00415610|Other|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
33290341|NCT00415610|Other|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
33290342|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
33290343|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
33290344|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left body side), Cromoglicate (on a lesion on right body side)
33290345|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right body side), Cromoglicate (on a lesion on left body side)
32783609|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
33290346|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
32783610|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
32783611|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
32783612|NCT04932109||Healthy Group|
32783613|NCT04932109||Hand Injuries Group|
32783614|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
32783615|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
32783616|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
32783617|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
32783618|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
32783619|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
33290347|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
32783620|NCT02459587|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
32783621|NCT02459587|Placebo Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care
32783622|NCT04931797|Experimental|Video|Video decision aid and advance care planning discussion
32783623|NCT04931797|Active Comparator|Control arm|A standardized written form that details advance care planning options.
32783624|NCT04908397|Experimental|Supplement|Form: 500 mg L-carnitine tablet Dosage: Subjects 50-90kg: 3g/day Subjects <50kg or >90kg: 50mg/kg/day Frequency: twice a day for 2 weeks
32783625|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
32783626|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
32783627|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
32783628|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
32783629|NCT05484219|Experimental|Surgery|Image-guided resection of brain tumors and vascular malformations
32783630|NCT02263365|No Intervention|Control|
33290348|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
32783631|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
32783632|NCT04858269|Experimental|Combination of Chemotherapy and Immunotherapy|The intervention will be administered on an outpatient basis. The treatment regimen will consist of combination chemotherapy and immunotherapy administered as: Pembrolizumab PLUS Carboplatin PLUS Paclitaxel.
32783633|NCT05647083|Experimental|Intervention group|A total of 24 massage sessions will be applied to the intervention group, 2 times a week during the 12-week working period. Sesame oil will be used as the main oil in the massage application. Massage times are recommended as 10-15 minutes for upper extremity massage and 15-20 minutes for lower extremity massage.
32783634|NCT05647083|No Intervention|Control group|Participants in the control group will continue their medical treatment protocols and massage will not be applied. Measurement tools and physiological measurements will be evaluated at the frequency specified in the intervention group, using the same measurement tools and the same measurement methods.
33290349|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
33290350|NCT00250432|Active Comparator|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
33290351|NCT00250432|Experimental|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
33290352|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
33290353|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
33290354|NCT00250276|Experimental|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
33290355|NCT00250276|Experimental|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
33290356|NCT00250276|Experimental|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
33290357|NCT00250276|Experimental|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
33290358|NCT02532088|Active Comparator|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
33290359|NCT02532088|Placebo Comparator|Placebo|Placebo
33290360|NCT00249808|Experimental|Efalizumab|
33290361|NCT00278512|Experimental|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
33290362|NCT00278512|Experimental|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
33290363|NCT03974698|Active Comparator|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
33290364|NCT03974698|Active Comparator|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
33290365|NCT01072240||Cohort|
33290366|NCT00427934|Placebo Comparator|2|
33290367|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
33290368|NCT00278200|Experimental|EBV Seronegative|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
33290369|NCT00278200|Experimental|EBV Seropositive|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
33290370|NCT03974542|Experimental|telephone outreach|
33290371|NCT03974542|No Intervention|control|
33290372|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
33290373|NCT00435188|No Intervention|Arm 2|Usual care
33290374|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
33290375|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
33290376|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
33290377|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
33290378|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
33290379|NCT00409188|Experimental|Tecemotide (L-BLP25)|
33290380|NCT00409188|Placebo Comparator|Placebo|
33290381|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
33290382|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
33290383|NCT00276484|Active Comparator|1|Atorvastatin 80 mg
33290384|NCT00276484|Experimental|2|Atorvastatin 40 mg + ezetimibe 10 mg
33290385|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
33290386|NCT00434876|Experimental|1|Quetiapine XR
33290387|NCT00434876|Placebo Comparator|2|Placebo
33290388|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
33290389|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
33290390|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
33290391|NCT01072552||Treated|Palivizumab treated
33290392|NCT01072552||Untreated|Palivizumab untreated
33290393|NCT00276094|Experimental|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
33290394|NCT00276094|Experimental|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
33290395|NCT00276094|Placebo Comparator|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
33290396|NCT03975088|Other|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
33290397|NCT00276016|Experimental|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules."
33290398|NCT00276016|Experimental|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
33290399|NCT00276016|Experimental|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
33290400|NCT00276016|Experimental|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
33290401|NCT00276016|Experimental|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules."
33290402|NCT00276016|Experimental|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
33290403|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
33290404|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
33290405|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
33290406|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
33290407|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
33290408|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
33290409|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
33290410|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
33290411|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
33290412|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
33290413|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
32783635|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
33290414|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
33290415|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
33290416|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
32783636|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
33290417|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
33290418|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
33290419|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
33290420|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
33290421|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
33290422|NCT01032668|Experimental|high dose clopidogrel|
33290423|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
33290424|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
33290425|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
33290426|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
33290427|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
33290428|NCT03994250|Active Comparator|Kinematic Arm|Kinematic Alignment for TKR surgery
33290429|NCT03994250|Placebo Comparator|Control Arm|Mechanical alignment for TKR surgery
33290430|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
33290431|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~The control group will not undergo a sham apheresis procedure. It is an open trial."
33290432|NCT00414908|Experimental|A|
33290433|NCT00414908|Placebo Comparator|B|
33290434|NCT01037582|Experimental|Trial part 1|
33290435|NCT01037582|Experimental|Trial part 2|
33290436|NCT00242710|Experimental|1|BZA 20mg/CE 0.625
33290437|NCT00242710|Experimental|Arm 2|BZA 20mg/CE 0.45
33290438|NCT00242710|Active Comparator|Arm 3|CE 0.45mg/MPA1.5mg
33290439|NCT00242710|Placebo Comparator|Arm 4|Placebo
33290440|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
33290441|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
32783637|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
32783638|NCT05646849|No Intervention|Classic care|Home exercise book, personalized advices and development of an individualized project post-cardiac rehabilitation.
32783639|NCT05646849|Experimental|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
32783640|NCT04855773|Experimental|PrEPmate|Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
32783641|NCT04855773|Experimental|Dot Diary mobile application|Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation.
33290442|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
33290443|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
32783642|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
32783643|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
32783644|NCT05473299|Experimental|aXess graft|
32783645|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
32783646|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
32900561|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
33290444|NCT00240994|Experimental|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
33290445|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
33290446|NCT00239590|Experimental|Testosterone|oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
33290447|NCT00239590|Placebo Comparator|Placebo|identical to active medication, taken in an identical way to the active arm
33290448|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
33290449|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
33085208|NCT04553614|Active Comparator|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
33085209|NCT04553614|Experimental|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
33290450|NCT00239356|Experimental|AI|
33290451|NCT03974386|Experimental|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
33290452|NCT03974386|No Intervention|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
33290453|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
33290454|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
33290455|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
33290456|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
33290457|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
33290458|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
33290459|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
33290460|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
33085210|NCT04553224|Other|All Subjects|Clinical and instrumental measurements
33085211|NCT04553653|No Intervention|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
33085212|NCT04553653|Experimental|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
33085213|NCT04553380|Experimental|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
33085214|NCT04553380|Active Comparator|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
33085215|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
33290461|NCT04648436|Other|Early surgery|
33290462|NCT04648436|Other|Initial conservative treatment|
33290463|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
33290464|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
33290465|NCT01323608|Placebo Comparator|Placebo|
33290466|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
33290467|NCT01323608|Experimental|Intermediate Vitamin D group|
33290468|NCT01323608|Experimental|High Vitamin D Group|
33290469|NCT00275002|Experimental|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
33290470|NCT00433004|No Intervention|1|No advance supply of emergency contraception
33290471|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
33085216|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
33290472|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
33290473|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
33290474|NCT00238264|Experimental|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
33290475|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
32783647|NCT05646537|Experimental|The group to which NLP techniques will be applied|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
33085217|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
33085218|NCT04553497|Active Comparator|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
33085219|NCT04553497|Sham Comparator|Rehabilitation and sham interferential current therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sahm interferential current therapy was applied to the patients in addition to the rehabilitation program.
33290476|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
33290477|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
33290478|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
33290479|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
33290480|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
33290481|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
33290482|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
33290483|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
33290484|NCT01041144|Experimental|Lifestyle counseling|
33290485|NCT01040286|Experimental|Flurbiprofen Chip|
33290486|NCT01040286|Active Comparator|Chlorhexidine chip|
33290487|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
33290488|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
33290489|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
33290490|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
33290491|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
33290492|NCT03761550||Stage 2|The Process Implementation Stage
33290493|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
33290494|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
33290495|NCT01043796|Experimental|Insecticide treated nets and wall liners|
33290496|NCT01043796|Active Comparator|Insecticide treated nets alone|
33290497|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
33290498|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
33290499|NCT00274924|Experimental|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
33290500|NCT00274924|Experimental|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33290501|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
33290502|NCT00274846|Experimental|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)
32783648|NCT05646537|No Intervention|Control group|Participants in the control group will be followed up for 6 months after the questionnaire and scale questions are asked. no attempt will be made. Scale questions will be asked again after 6 months
32783649|NCT05646459|Placebo Comparator|Control - Floss|Subjects will use only floss at study site
32783650|NCT05646459|Sham Comparator|Proxabrush - Control|Subjects will use only proxabrush at study site.
32783651|NCT05646459|Experimental|Proxabrush - CBD|Subject will use CBD + proxabrush on study site.
32783652|NCT05466201|Other|supportive care|patients in this group will receive supportive care, including blood products transfusion, anti-infective therapy rather than rhTPO or TPO-RAs.
32783653|NCT05466201|Experimental|Eltrombopag group|Eltrombopag treatment will be started at the dose of 50mg/d from the 1st day post hematopoietic stem cell transplantation, and the dose will be titrated by 25mg each every 7 days up to 100mg/d according to the tolerability. If not tolerable, reduce the dose to the previous tolerable level (if not tolerable at 50mg/d, reduce to 25mg/d) and maintain this dose for the following 7 days, with the attempt to restart dose escalation after this 7-day period.
32783654|NCT05646381|Experimental|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80 mg prefilled syringe injected monthly, administered subcutaneously
32783655|NCT05646381|Placebo Comparator|Matching placebo|Placebo to match pelacarsen (TQJ230) prefilled syringe injected monthly, administered subcutaneously
32783656|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
32783657|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
32783658|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
32783659|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
32783660|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
32783661|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
32783662|NCT02259231|Experimental|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
32783663|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
32783664|NCT05646225|Experimental|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning,self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
33085220|NCT00261378|Active Comparator|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
33085221|NCT00261378|Other|DC Bead|DC Bead with doxorubicin
33085222|NCT04553458||Favorable outcome|Cure or stable disease
32783665|NCT05646225|Active Comparator|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes.
32783666|NCT05449275|Experimental|Faradic current|This study will use the faradic current for treating foot drop. In Group A 15 number of patient with foot drop will get the 40 minutes of session with the frequency of 50-100hz alternative three days / week for 25 weeks
32783667|NCT05449275|Experimental|Ankle foot orthosis|Group B will get the treatment by Ankle foot orthosis.In group B 15 patients with foot drop will get the session alternative three days/week for 25 weeks. All participants have to use Ankle foot orthosis on a daily basis and patients have to walk for 10 minutes without walking aid.
32900562|NCT03935568|Experimental|Single Dose Placebo|Patients randomized to receive Placebo
32900563|NCT03935568|Experimental|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
32900564|NCT03935568|Experimental|Multiple Dose (Placebo)|Patients randomized to receive Placebo
32900565|NCT03935568|Experimental|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
33085223|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
33085224|NCT04553146|Experimental|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
33085225|NCT04552756|Experimental|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
33085226|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
33085227|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
33085228|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
33085229|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
33085230|NCT04552951|Active Comparator|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
33085231|NCT04552951|No Intervention|Control|No vitamin D
32783668|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
32783669|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
32783670|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
32783671|NCT05446857|Experimental|Active Drug|All enrolled participants will receive Glecaprevir/Pibrentasvir
32783672|NCT05438121||Patients with multivessel CAD undergoing DCB PCI|"I. Patients with significant multi-vessel coronary artery disease will be screened.~II. If the patient is found to have at least one lipid-rich plaque (LRP, LCBI>250) requiring revascularization (DS>70%) will undergo multi-vessel IVUS-NIRS imaging.~III. If multi-vessel NIRS screening revealed another LRP (LCBI>250) with DS<70%, the patient will be enrolled.~IV. The stenotic LRP lesion (DS>70%) will be subjected to DCB angioplasty while non-stenotic LRP lesion (DS<70%) will be left unintervened and treated medically.~V. Comparative lesions:~DCB-treated LRP (DS>70%, maxLCBI>250)~Unintervened, medically-treated LRP (DS<70%, maxLCBI>250)"
32783673|NCT05436249|Other|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
32783674|NCT05436249|Other|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where they will then perform respective motor and/or imagery tasks at home for 3 weeks.
32783675|NCT05646069|Experimental|Storz Flex-XC1 disposable flexible ureteroscope|A patient is randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
32783676|NCT05646069|No Intervention|Analogue scope|A patient is not randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
32783677|NCT05646069|Experimental|Digital ureteroscope|A patient is randomized to the experimental arm using a Digital ureteroscope.
33085232|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
33085233|NCT04552717|Experimental|Intervention|"Participants will complete a web based pre-assessment and then given access to the app My Grief for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app, and follow-up questionnaires."
33085234|NCT04552717|No Intervention|Waitlist controll|Participants will get access to the app after three months.
33085235|NCT04552483|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
33085236|NCT04552483|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
33085237|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
33085238|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
33085239|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
33085240|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
33085241|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
32783678|NCT05645991|Placebo Comparator|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
33085242|NCT02213653|Active Comparator|Epoietin zeta|
33290503|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
32783679|NCT05645991|Experimental|Coconut Sap Powder|Capsules containing coconut sap powder (CSP; 1.5 g/day) were taken orally once daily for 8 weeks.
33085243|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
33085244|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
33085245|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
33085246|NCT00268944|Experimental|1|
32783680|NCT05645913||Atrial fibrillation with oral anticoagulant|patients who were newly receiving an oral anticoagulant for atrial fibrillation during study period
32783681|NCT02256891|Experimental|Double Row|Double Row
32783682|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
32783683|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
33290504|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
33290505|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
33290506|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
33290507|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
33290508|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
33290509|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
33290510|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
33290511|NCT01071460|Other|SFA Stenting|
32783684|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
32783685|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
33290512|NCT03974308|Experimental|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
33290513|NCT03974308|Active Comparator|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
33290514|NCT03974308|Other|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
33290515|NCT03970798|Experimental|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
33290516|NCT00237796|Experimental|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
33290517|NCT00237796|Active Comparator|ARM 2|Goal Focused Supportive Contact (GFSC)
32783686|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
33290518|NCT03970876|Experimental|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
33290519|NCT03970876|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
33290520|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
33290521|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
33290522|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
33290523|NCT01073800|Placebo Comparator|placebo|
33290524|NCT03971032|Other|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
33290525|NCT01037660|Experimental|Metformin|Metformin
33290526|NCT01072864|Experimental|5 g of walnuts|
33290527|NCT01072864|Experimental|20 g of walnuts|
33290528|NCT01072864|Experimental|30 g of walnuts|
33290529|NCT01072864|Experimental|40 g of walnuts|
33290530|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
33290531|NCT01032824|Other|Group Arm|Attention-matched comparison arm
33290532|NCT01032824|Other|Book Arm|Information-matched control arm.
33290533|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
33290534|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
33290535|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
33290536|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
33290537|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
33290538|NCT00236080|Experimental|1|PROVIGIL 200 mg/day
33290539|NCT00236080|Experimental|2|Armodafinil 250 mg/day
33290540|NCT00236080|Experimental|3|Armodafinil 200 mg/day
33290541|NCT00236080|Experimental|4|Armodafinil 150 mg/day
33290542|NCT00236080|Placebo Comparator|5|Placebo
33290543|NCT01033058|Active Comparator|usual care|
33290544|NCT01033058|Experimental|intensive statin treatment|
33290545|NCT03973138|Experimental|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
33290546|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
33290547|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
33290548|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
33290549|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
33290550|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
33290551|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
33290552|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
33290553|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
33290554|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
33290555|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
32900566|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
33290556|NCT03970486|Active Comparator|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
33290557|NCT03970486|Active Comparator|In Situ|Participant will receive dry needling intervention without manipulation.
33290558|NCT03974074|Experimental|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
33290559|NCT03974074|No Intervention|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
33290560|NCT01072942|Experimental|Arm 1|
33290561|NCT01072942|Placebo Comparator|Arm 2|
33290562|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
33290563|NCT00234052|Experimental|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
33290564|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
33290565|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
33290566|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
33290567|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
33290568|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
33290569|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
32900567|NCT03932136|Active Comparator|SFN group|The intervention duration with SFN tablet is 52 consecutive weeks. The dosage is six active tablets (411 μmol GR) per day.
32900568|NCT03932136|Placebo Comparator|Placebo group|The intervention duration with placebo tablet is 52 consecutive weeks. The placebo group will be given six placebo tablets per day.
32900569|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
32900570|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
32900571|NCT05331378|Experimental|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
32900572|NCT05331378|Other|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
32830387|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
33290570|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
33290571|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
33290572|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
33290573|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
33290574|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:~Inclusion criteria~Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.~Age ranging from 30-50 years old.~The selected patient will be able to tolerate the entire standard neurodynamic technique.~Exclusion criteria~Symptoms referred to the neck.~Sever CTS~More than 10% limitation of neck flexion, rotation, and side bending ranges.~History of disease, trauma, or surgery to neck, thorax, or upper limbs.~Presence of peripheral neuropathy or cervical radiculopathy.~History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
33290575|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
33290576|NCT01034618|Placebo Comparator|Placebo|
33290577|NCT01034618|Experimental|Intact protein|
33290578|NCT01034618|Experimental|Protein hydrolysate|
33290579|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
33290580|NCT03973840|Experimental|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
33290581|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
33290582|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
33290583|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
33290584|NCT00413972|Placebo Comparator|Placebo|
33290585|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
33290586|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
33290587|NCT00259012|Active Comparator|Low dose|
33290588|NCT00259012|Active Comparator|High dose|
33290589|NCT01044108|Experimental|Trial, part 1 (males only)|
33290590|NCT01044108|Experimental|Trial, part 2 (males and females)|
33290591|NCT01044186|Experimental|ICL670|
33290592|NCT03970174|Experimental|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
33290593|NCT03970174|No Intervention|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
33290594|NCT01041456||complicated and/or failed BPD|
33290595|NCT03993600|Sham Comparator|Healthy volunteers|sweat test and skin biopsy
33290596|NCT03993600|Experimental|Patients with Cystic fibrosis|sweat test and skin biopsy
33290597|NCT03993600|Experimental|Heterozygotes subjects|sweat test and skin biopsy
33290598|NCT00209170|Experimental|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
33290599|NCT00209170|Active Comparator|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
33290600|NCT01071694||Group 1|
33290601|NCT00413894|Experimental|1|
33290602|NCT03973216|Experimental|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
33290603|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
33290604|NCT03972748|Experimental|Itraconazole|Oral Itraconazole capsules, 200 mg
33290605|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
33290606|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
33290607|NCT01581814|Active Comparator|Metformin plus Yasmin|
33290608|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
33290609|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
33290610|NCT00209092|Active Comparator|Sequential Therapy|Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
33290611|NCT00209092|Active Comparator|Concurrent Therapy|Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
33290612|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
33290613|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
32938839|NCT05406037||Patients with MM|"Age : from 3 to 75 years old ;~- Specific medical conditions : patient hospitalized in one of the departments of the University Hospital of Lille or Amiens, in whom the diagnosis of mucormycosis will have been made on the criteria below, with compatible clinical and radiological evolution :~conventional mycology data and/or~positive q-PCR and/or~pathology data confirmed by PCR;"
32938840|NCT05406037||High-risk patients without MM (control group 1)|"Age : from 18 to 75 ;~- Specific medical conditions : patients hospitalized at the University Hospital of Lille or Amiens for whom a diagnosis of candidiasis or invasive aspergillosis has been made according to specific classifications (EORTC/MSG criteria, AspICU criteria)"
33290614|NCT03972982|Experimental|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
32938841|NCT05406037||Patients with another IFI (control group 2)|"Age : from 18 to 75 ;~Specific medical conditions : patients undergoing assessment for haematopoietic stem cell transplantation, considered at risk of invasive fungal infection but for whom the pre-transplant assessment will have excluded an ongoing infection."
33290615|NCT03972982|Active Comparator|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
33290616|NCT00403494|Experimental|Sapropterin dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
33290617|NCT00403494|Placebo Comparator|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
33290618|NCT00403260|Experimental|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
32938842|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
33290619|NCT00403260|Active Comparator|Mefloquine plus artesunate|Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
33290620|NCT01324362|Active Comparator|Fluticasone propionate|
33290621|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
33290623|NCT00406848|Experimental|Duloxetine|
33290624|NCT00406848|Placebo Comparator|Placebo|
33290625|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
33290626|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
33290627|NCT03978663|Experimental|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
33290628|NCT03982017|Active Comparator|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
33290629|NCT03982017|Experimental|Application|Participants will be provided a special link to navigate to the online content and resources.
33290630|NCT03982173|Experimental|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
33290631|NCT01062633|Experimental|A, observation|dietary supplement
33290632|NCT01062633|Experimental|B|dietary supplement
33290633|NCT01062633|Experimental|C|dietary supplement
33290634|NCT00307125|Experimental|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
33290635|NCT00307125|Placebo Comparator|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
33290636|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
33290637|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
33290638|NCT03978429|Experimental|Intervention Arm|"Community-based Pre-eclampsia/Eclampsia Detection and Management~Strengthened Referral Network from Community to Referral hospital levels~Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors.~Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
33290639|NCT03978429|No Intervention|Enhanced Usual Care|"Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors."
33290640|NCT00307047|Experimental|XIENCE V®|
33290641|NCT00307047|Active Comparator|TAXUS™ EXPRESS2™|
33085247|NCT04721093|Experimental|PBM(Photobiomodulation)|Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
33290642|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
33085248|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
33085249|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
33290643|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
33290644|NCT00306891|Experimental|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
33290645|NCT00306891|Experimental|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
33290646|NCT00306891|Experimental|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
33290647|NCT00306891|Experimental|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
32783687|NCT05429463|Experimental|Arm A(3 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 3 cycles (cycle length: 3 weeks) of sintilimab [200 mg, intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel [260 mg/m^2, IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min, IV; given on cycle day 1 ] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year."
32783688|NCT05429463|Experimental|Arm B(4 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of sintilimab [200 mg, intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel [260 mg/m^2, IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min, IV; given on cycle day 1 ] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year."
32783689|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
32783690|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
32783691|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
32783692|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
32783693|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
32783694|NCT04863729|Experimental|Intervention|The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
32783695|NCT04863729|No Intervention|Control|Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be <$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group
32783696|NCT01642407|Experimental|Sildenafil|
32783697|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
32783698|NCT05424003|Experimental|Semaglutide|Semaglutide administered subcutaneously (under the skin) once weekly. There will be a 20 week lead in period of dose escalation before reaching the target dose of 2.4mg weekly. Semaglutide will then be administered at the maximum tolerated dose for 52 weeks.
32783699|NCT05424003|Placebo Comparator|Placebo|Placebo administered subcutaneously (under the skin) once weekly.
32830388|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
33085250|NCT04552600|Experimental|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
33085251|NCT04552600|Active Comparator|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
33085252|NCT04552561|Experimental|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
33085253|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
33085254|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
33085255|NCT04552678|Experimental|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
32783700|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
32783701|NCT05421663|Experimental|C-CAR039|Autologous C-CAR039 administered by intravenous (IV) infusion
32783702|NCT05651139|Experimental|Receiving vibration stimulation post-injection|Using a vibration device post-injection on the affected area.
33085256|NCT04552678|Experimental|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
33085257|NCT04552678|Experimental|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
33085258|NCT04552678|Experimental|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
33085259|NCT04552678|Experimental|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
33085260|NCT04552678|Experimental|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
32783703|NCT05651139|No Intervention|control group|No intervention will be conducted
32783704|NCT05642793|Experimental|group 1 (proactive use of conbercept after vitrectomy)|proactive use of conbercept after vitrectomy
32783705|NCT05642793|Experimental|group 2 (passive use of conbercept after vitrectomy)|passive use of conbercept after vitrectomy
32783706|NCT05642013|Experimental|Prospective group|50 patients prospectively included with early prosthesis reimplantation
32783707|NCT05642013|Other|Retrospective group|Last 50 patients with hip or knee prosthetic-joint infection managed with classical two-stage implant exchange
32783708|NCT05641857||Low back pain and disc degeneration among elite cross-country skiers|No intervention Interview, clinical examination and MRI
32783709|NCT05641857||Low back pain and disc degeneration among healthy volunteers|No intervention Interview, clinical examination and MRI
32783710|NCT05411133|Experimental|Phase 1a: Dose Escalation|
32783711|NCT05411133|Experimental|Phase 1b: Low dose ARB202|
32783712|NCT05411133|Experimental|Phase 1b: High dose ARB202|
32783713|NCT05411133|Experimental|Phase 1b: Low dose ARB202 + Immune Checkpoint Inhibitor|
32783714|NCT05411133|Experimental|Phase 1b: High dose ARB202 + Immune Checkpoint Inhibitor|
32783715|NCT05650983|Experimental|1.Aerobic exercise|play balloon volleyball for Aerobic exercise and aimed at maximizing the strain on the cardiovascular system (60-70% of heart rate recovery). Aerobic exercise intervention five times a week, one hour each time，for three months.
32783716|NCT05650983|Experimental|2.Resistance exercise|Resistance strength training for Resistance exercise and aimed at promoting the greatest hypertrophy response(65% of 1 repetition maximum and repeated up to 15 times). Resistance exercise intervention five times a week, one hour each time,for three months.
32783717|NCT05405985|Experimental|Nemolizumab With Auto-Injector (AI)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Auto-Injector (AI).
32783718|NCT05405985|Experimental|Nemolizumab With Dual Chamber Syringe (DCS)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Dual Chamber Syringe (DCS).
32783719|NCT05402007|No Intervention|Control|The control group will not receive intervention during the study.
32783720|NCT05402007|Active Comparator|Face-to-face intervention|The face-to-face intervention group will perform pulmonary rehabilitation at the professional-oriented Rehabilitation Center.
32783721|NCT05402007|Active Comparator|Home intervention|The home intervention group will carry out home intervention through a self-explanatory exercise booklet.
32783722|NCT05640375|No Intervention|Follow-up|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Just IV hydration and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
32783723|NCT05640375|Experimental|Single dose Steroid treatment|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Methylprednisolone 1 mg/ kg single dose was given and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
32783724|NCT05639673||NOPHO ALL2008|Children and adolescents treated according to the NOPHO ALL2008 protocol
33085261|NCT04552678|Experimental|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
33085262|NCT04552678|Experimental|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
33085263|NCT04552678|Experimental|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
32783725|NCT05639673||Australia|
32783726|NCT05639673||Poland|
32783727|NCT05639673||Dutch Childhood Oncology Group|
32783728|NCT05639673||St. Jude|
32783729|NCT05650671||"wheelchair user-seat group"|healthy subjects agreeing to participate in the study
32783730|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
32783731|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
32783732|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
32783733|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
32783734|NCT04861779|Experimental|Phase 1a Dose Escalation|Multiple dose levels of HSK29116 to be evaluated; determination of MTD/Phase 1b recommended dose
32783735|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R CLL or SLL|CLL/SLL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
32783736|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R MCL|MCL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
32783737|NCT04861779|Experimental|Phase 1b Dose Expansion in other R/R B-cell Malignancy|Patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
32783738|NCT05637879|Active Comparator|Active Drug|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
32783739|NCT05637879|Placebo Comparator|Placebo|Placebo, 3 oral tablets once daily for 8 weeks.
32783740|NCT05393583|Experimental|Outpatient|Discharge on the day of hysterectomy
32783741|NCT05393583|Active Comparator|Inpatient|Discharge after 1 night stay in the hospital
32783742|NCT05633121||Patient suffering from uremic calciphylaxis treated with rheopheresis|
32783743|NCT05633121||Patient suffering from uremic calciphylaxis not treated with rheopheresis|
32783744|NCT05650515||Experts|A panel of experts in the geriatric field consisting of older adults (65+ years) as well as experts (geriatric rehabilitation/medicine/research)
32783745|NCT05624307||Patient with chronic back pain|Patients admitted to the chronic pain service at the Calot Institute with chronic low back pain for at least three months, not responding to well-conducted conservative treatment
32783746|NCT05378997|Experimental|Dose group 1|0.15 mL of TCP-25 gel (0.86 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
32783747|NCT05378997|Experimental|Dose group 2|0.15 mL of TCP-25 gel (2.9 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
32783748|NCT05378997|Experimental|Dose group 3|0.15 mL of TCP-25 gel (8.6 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
32783749|NCT05623605|Experimental|Moringa mouthwash|5 ml Moringa mouthwash two times per day for 1 week
32783750|NCT05623605|Experimental|Star Anis mouthwash|5 ml Star Anis mouthwash two times per day for 1 week
32783751|NCT05623605|Experimental|Indian Costus mouthwash|5 ml Indian Costus mouthwash two times per day for 1 week
32783752|NCT05650437|Active Comparator|Ultraviolet therapy group|35 women will undergo three weekly sessions of UV therapy in addition to routine aerobic activity and vitamin D supplements (800 IU) daily for three months
32783753|NCT05650437|Active Comparator|Non Ultraviolet therapy group|35 women will undergo three weekly sessions of routine aerobic activity and vitamin D supplements (800 IU) daily for three months
32783754|NCT05620797|Experimental|Immediate loading implants|
33085264|NCT04552678|Experimental|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
32783755|NCT05620797|Active Comparator|Delayed loading implants|
32783756|NCT05617209||Severe and/or moderate haemophilia A and B|At the end of the consultation and follow-up of the disease, an additional blood sample of 35 ml (8 tubes) will be taken
32783757|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
32783758|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
32783759|NCT05650359|Experimental|Group 1|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
32783760|NCT05650359|Active Comparator|Group 2|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
33085265|NCT04552678|Experimental|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
32783761|NCT05614245|Experimental|Group G1, Subgroup G1-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1
33085266|NCT04552678|Experimental|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
33085267|NCT04552678|Experimental|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
33085268|NCT04552678|Experimental|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
32783762|NCT05614245|Experimental|Group G1, Subgroup G1-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1 and Day 28
32783763|NCT05614245|Experimental|Group G2, Subgroup G2-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1
32783764|NCT05614245|Experimental|Group G2, Subgroup G2-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1 and Day 28
32783765|NCT05614245|Experimental|Group G3, Subgroup G3-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1
32783766|NCT05614245|Experimental|Group G3, Subgroup G3-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1 and Day 28
32783767|NCT05650281||Patients|Patients with RRMS (2017 Mc Donald criteria) treated with highly active treatment in the first 5 years of symptoms onset, at least 1 year, with an EDSS below 4
32783768|NCT05107011|Experimental|Evaluation of LBL-015 Phase I/II study in patients with advanced malignancies|Drug: LBL-015 for Injection The test drugLBL-003will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, administered twice a week.
32783769|NCT05099991|Placebo Comparator|Dilapan-S|A number of Dilapan-S will be inserted for cervical preparation. The number will be determined by a standard protocol that is based on gestational age. The dilators will stay in until the next day prior to their procedure, or earlier if they fall out on their own.
32783770|NCT05099991|Experimental|Foley balloon|A Foley balloon will be inserted for cervical preparation and filled to 30mL of water or saline. The balloon will stay in until the next day prior to their procedure, or earlier if it falls out on its own.
32783771|NCT05091645||Hip fracture_GFI|Greek patients with hip fracture assessed for frailty syndrome with the adapted for the greek population GFI questionnaire
32783772|NCT05590065|Experimental|Arm 1 - Treatment|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device two times a week for five weeks for a total of 10 sessions.
32783773|NCT01639131|Experimental|Gemcitabine and Docetaxel|Patients were treated with gemcitabine 800 mg/m2 on days 1 and 8 and docetaxel 70 mg/m2 on day 8 of each 21-day cycle. Patients received filgrastim (granulocyte colony-stimulating factor [G-CSF]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle. Patients were treated until disease progression or unacceptable adverse events (AEs), or withdrawn of the consent.
33290648|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
33290649|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
33290650|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
32783780|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
32783781|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
32783782|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
32783783|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
32783784|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
32783785|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
32783786|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
32783787|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
32783788|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
32783789|NCT05345925|Experimental|Experimental group|Eligible subjects instrumented for CNT testing
32783790|NCT05342883|Other|Experimental: Resection, GammaTile and Stupp Protocol|Resection, Gamma Tile and Stupp Protocol
32783791|NCT05369481|Experimental|Sildenafil 2%|will receive topical sildenafil 2% twice daily for 6 months.
32783792|NCT05369481|Experimental|Minoxidil 5 %|will receive topical minoxidil 5 % twice daily for 6 months
32783793|NCT04853979|Experimental|PRONE|Any combination of prone or side position for 3 hours, 3 times a day for 3 days.
32783794|NCT04853979|Active Comparator|NO PRONE|Usual care
33290651|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
33290652|NCT03978507|Experimental|DeFOG group|feedback number of steps + cueing
33290653|NCT03978507|Active Comparator|Control group|feedback number of steps
33290654|NCT03980847|Active Comparator|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
33290655|NCT03980847|Active Comparator|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
33290656|NCT03978195|Experimental|Treatment|
33290657|NCT03978195|No Intervention|Control|
33290658|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
32783795|NCT04853589|Active Comparator|Hyaluronic acid|hyaluronic acid gel application
32783796|NCT04853589|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier
32783797|NCT04853589|No Intervention|Standard treatment|standard treatment (i.e., blood clot only)
33290659|NCT00391872|Experimental|Ticagrelor|Oral treatment
33290660|NCT01040364||Interna hernia after primary gastric bypass|
33290661|NCT00391170|Experimental|Dexamethasone oral rinse in stem cell transplant participants|Dexamethasone 0.01% (0.5mg/5 mL) oral rinse solution in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
33290662|NCT00391170|Placebo Comparator|Placebo oral rinse in stem cell transplant participants|Placebo oral rinse in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
33290663|NCT00402324|Experimental|1|olanzapine and divalproex
33290664|NCT00402324|Placebo Comparator|2|placebo and divalproex
33290665|NCT00294723|Experimental|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
33290666|NCT00294723|Experimental|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
33290667|NCT00294723|Active Comparator|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
33290668|NCT00294723|Active Comparator|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
33290669|NCT00402246|Experimental|Remote Arm|Remote Management
33290670|NCT00402246|Active Comparator|In-office Arm|In-Office Care
33290671|NCT00375492|Experimental|Group A|
33290672|NCT00375492|Placebo Comparator|Group B|
32900573|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
33290673|NCT00306189|Active Comparator|100 mg AMG 162|
33290674|NCT00306189|Active Comparator|60 mg AMG 162|
33290675|NCT00306189|Placebo Comparator|Placebo|
33290676|NCT00306189|Active Comparator|14 mg AMG 162|
33290677|NCT00312897|Placebo Comparator|corn oil|as stated
33290678|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
33290679|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
33290680|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
32900574|NCT05366868|Experimental|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
33290681|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
33290682|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
33290683|NCT00294645|Active Comparator|Control|Transtelephonic monitoring at 2 month intervals
33290684|NCT00294645|Active Comparator|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
33290685|NCT00305877|Experimental|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
33290686|NCT00305877|Experimental|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
33290687|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
33290688|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
33290689|NCT03978273|Experimental|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
33290690|NCT03978273|Active Comparator|Night-time brace only|Patients are conventionally treated with night-time brace only.
33290691|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
33290692|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
33290693|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
33290694|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
33290695|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
33290696|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
33290697|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
33290698|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
33290699|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
33290700|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
33290701|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
33290702|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
33290703|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
32783798|NCT04836195|Experimental|PCLX-001 intervention|"The Dose-Escalation phase will follow a standard 3+3 cohort design. Three patients will be treated at each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level. Escalation will terminate as soon as two or more patients experience any DLT attributable to study drugs, at a given dose level.~Oral PCLX-001 will be provided as continuous daily dosing on a 28-day cycle. The starting dose of PCLX-001 will be 20 mg daily Expansion Cohort Once the MTD has been defined, preliminary activity will be further evaluated in the expansion part of the study. The RP2D may be the MTD but not necessarily as not only safety data will be taken into account prior to its determination."
32783799|NCT04677153|Experimental|Test and Treat plus Peer Mentors Intervention Arm|Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.
32783800|NCT04677153|Active Comparator|Standard of Care Referral Arm|Participants referred to offsite (non-OTP) location for HCV treatment.
32783801|NCT01638429|Experimental|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
32783802|NCT04847973|Experimental|12 weeks of medically-tailored meals (MTMs)|12 weeks of home-delivered medically-tailored meals (MTMs), prepared and delivered by the non-profit Community Servings. The MTM has be developed specifically for patients with heart failure, with an approximate protein intake range of 1.1-1.5 g/kg body weight/day and a maximum of 2000 mg sodium/day.
32783803|NCT04847973|Experimental|12 weeks of protein supplementation shakes|Participants will receive 1 bottle of Ensure Max Protein shake every day (any flavor option without caffeine, daily for 12 weeks) to take in addition to their standard diet, without MTM delivery.
32783804|NCT04671771|Experimental|Experimental: InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
33085269|NCT04552639|Active Comparator|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
33085270|NCT04552639|Experimental|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
32783805|NCT04834401||Natalizumab|Natalizumab (minimum of 6 doses at standard interval)
32783806|NCT04834401||Fumarates|Fumarates (dimethyl fumarate or diroximel fumarate)
32783807|NCT04834401||Interferon Beta 1a|Interferon Beta 1a (or pegylated Interferon Beta-1a)
33085271|NCT04552405|Other|FAP patients|FAP patients who underwent prophylactic total colectomy
33085272|NCT04552249||Group 1|
33085273|NCT04552249||Group 2|
33085274|NCT04552249||Group 3|
33085275|NCT04552249||Group 4|
33085276|NCT04552249||Group 5|
33085277|NCT04552249||Group 6|
33085278|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
33085279|NCT00236210|No Intervention|Standard Care|
32783808|NCT04834401||Ocrelizumab|Ocrelizumab (minimum of 2 full cycles of 600mg)
32783809|NCT05058807|Experimental|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
32830389|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~size of surgical site~volume required to cover the area~individual patient factors that may impact the safety of an amide local anesthetic~maximum doe of 266 mg (20 mL)"
33085280|NCT04552366|Experimental|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
33085281|NCT04552366|Experimental|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
33085282|NCT04552366|Experimental|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
33085283|NCT04552366|Experimental|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
33085284|NCT04552366|Active Comparator|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
33085285|NCT04552366|Experimental|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
33085286|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
33085287|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
33085288|NCT04548544|Experimental|TARA training|
33085289|NCT04548544|No Intervention|Control|
33085290|NCT04548388|Experimental|Bobath approach|Bobath approach
33085291|NCT04548388|Experimental|whole body vibration|whole body vibration
33085292|NCT04548466|No Intervention|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
33085293|NCT04548466|Experimental|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
33290704|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
33290705|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
33290706|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
33290707|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
33290708|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
33290709|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
33290710|NCT03977805|Experimental|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
32783810|NCT05058807|Active Comparator|TAI CHI Group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions.~1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left;~.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week."
32783811|NCT04853511||OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment|Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging
33290711|NCT01062945|Placebo Comparator|Placebo|
33290712|NCT01062945|Active Comparator|Doxazosin|
33290713|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
33290714|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
33290715|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
33290716|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
33290717|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
33290718|NCT00305253|No Intervention|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
32783812|NCT04853355|Experimental|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
33085294|NCT04548427|Experimental|CKD-352|
33290719|NCT00305253|Experimental|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
33290720|NCT01066611|Active Comparator|1|CAL-263
33290721|NCT01066611|Placebo Comparator|2|Placebo
32783813|NCT05377281|Experimental|Implantation of peripheral nerve tissue|Bilateral deployment of peripheral nerve tissue to the substantia nigra.
32783814|NCT04419285|Experimental|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
33318155|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
32783815|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
32783816|NCT04844853|Experimental|Preterm 2|2-year-olds born prematurely
32783817|NCT04844853|Experimental|Term 2|2-year-olds born at term
32783818|NCT04844853|Experimental|Typical 6|6-year-olds with typical developement
32783819|NCT04844853|Experimental|NDD 6|6-year-olds with neurodevelopmental disorders
32783820|NCT05310981|Experimental|Experimental: CHAMPS and mEIS|"Brief mobile application-based psychological intervention based on the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT). This e-intervention will be completed by the participant using a smart phone. There will be up to a maximum of 24 individual sessions (which includes 3 booster sessions) each lasting approximately 10-15 minutes.~mEIS: iCC will be administered adjunctively to modified EIS (mEIS), which will include all interventions usually provided through EIS except for any specific psychological interventions (MI, CBT, contingency management) for CUD."
33085295|NCT04548427|Active Comparator|Diquafosol Sodium 3%|
33290722|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
33290723|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
33290724|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
33290725|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
33290726|NCT03980691|Experimental|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
33290727|NCT03980691|No Intervention|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
33290728|NCT00293709||Patients with Psoriatic Arthritis|
33290729|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
33290730|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
33290731|NCT03977649|Experimental|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
33290732|NCT03977649|Placebo Comparator|placebo|monthly subcutaneous masked placebo for 12 weeks.
33290733|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
33290734|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
33290735|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
33290736|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
33290737|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
33085296|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
33290738|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
33290739|NCT03980379|Experimental|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
33290740|NCT03980379|Active Comparator|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
33290741|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
33290742|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
33290743|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
33290744|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
33290745|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
33290746|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
33290747|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
33290748|NCT00293397|Experimental|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
33290749|NCT03981627|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
33290750|NCT03981627|Active Comparator|NovoRapid®|Subcutaneous injection of insulin aspart
33290751|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
33290752|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
33085297|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
33290753|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
33290754|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
33290755|NCT01064505|Experimental|QPI-1007|
33290756|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
33290757|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
33290760|NCT01067079||Arm 1|
33290761|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
33290762|NCT01069497|No Intervention|Usual care Nursing Homes|
33290763|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
33290764|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
33290765|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
33290766|NCT01067235|Experimental|BF2.649 + Modafinil|
33290767|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
32783821|NCT05310981|No Intervention|No Intervention: EIS alone|Early intervention services will be offered as per standard of care following EIS for psychosis and CUD guidelines, at participating clinical sites. Any visits and services offered in control arm will be considered 'usual care' and administered either through in-person clinic visits, community visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
32783822|NCT05369091|No Intervention|Placebo|Atraumatic Extraction Only (placement of gelatin sponge mixed with normal saline without SIMVASTATIN).
33290768|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33290769|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33290770|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
33290771|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
33290772|NCT00290745|Experimental|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
33290773|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33290774|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
32783823|NCT05369091|Experimental|Simvastatin|Atraumatic Extraction and administration of SIMVASTATIN (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket.
32783824|NCT05017623|Experimental|Intervention/treatment|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
32783825|NCT04652037|Experimental|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|
32783826|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
32783827|NCT05422365|Experimental|Main Group|"Patients included in the study will receive the intravenous immunoglobulin (IVIG, Bioven), 10% solution for infusion according to the protocol for the use of IVIG in ITP treatment - at a dose of 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.~The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG), and the Coombs test.~This procedure will also be carried out on days 7, 14, 21, and 28 after the first injection of the drug to monitor the patient's performance."
32783828|NCT04844151||Acute myocarditis|Patients hospitalized for an acute myocarditis.
32783829|NCT04641273|Experimental|Part A: BAY1817080 150 mg BID|In Part A, Participants will be randomized to this arm with BAY1817080 150 mg BID.
32783830|NCT04641273|Placebo Comparator|Part A: Placebo BID|In Part A, Participants will be randomized to this arm with placebo for BAY1817080.
32783831|NCT04641273|Experimental|Part B: BAY1817080 25 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 25 mg BID and placebo for pregabalin.
33290775|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33290776|NCT03980223|Experimental|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
33290777|NCT03980223|No Intervention|Control|The control arm will consist of standard of care STI testing and treatment
33290778|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
33290779|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
32938843|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
32938844|NCT04396249|Experimental|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
33290780|NCT00402168|Experimental|A: Belatacept|
33290781|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
33290782|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
33290783|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
33290784|NCT00290589|Experimental|Intramuscular methylprednisolone acetate|Methylprednisolone acetate 160mg intramuscular injection
33290785|NCT00290589|Placebo Comparator|Placebo|Placebo intramuscular injection
33290786|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
33290787|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
33290788|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
33290789|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
32938845|NCT04396249|Sham Comparator|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
32938846|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
32938847|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
32938848|NCT04361617|Active Comparator|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of their epigenetic age before the intervention.
32938849|NCT04361617|Active Comparator|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of their epigenetic age before the intervention.
33290790|NCT00290433|Experimental|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
33290791|NCT04323033|Experimental|PERS stent|20 Patients will receive PERS stent
33290792|NCT04323033|Active Comparator|NEPTUN C stent|20 Patients will receive NEPTUN C stent
33290793|NCT00304083|Experimental|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
33290794|NCT00304083|Experimental|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
33290795|NCT00293241|Other|MVP ON|Managed Ventricular Pacing programmed on
33290796|NCT00293241|Other|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
33290797|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
33290798|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
33290799|NCT01067625|Experimental|TOGA subjects|
32783832|NCT04641273|Experimental|Part B: BAY1817080 75 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 75 mg BID and placebo for pregabalin.
32783833|NCT04641273|Experimental|Part B: BAY1817080 150 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 150 mg BID and placebo for pregabalin.
32783834|NCT04641273|Placebo Comparator|Part B: Placebo BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and placebo for pregabalin.
33085298|NCT04548271|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
33085299|NCT04541719|Active Comparator|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
33290800|NCT03977103|Experimental|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
33290801|NCT01069887||adult with hematological malignancies|
33290802|NCT01069887||pediatrics with hematological malignancies|
33290803|NCT01069887||pediatrics receiving stem cell transplant|
33290804|NCT01069887||adult receiving stem cell transplant|
33290805|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
33290806|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
33290807|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
32783835|NCT04641273|Active Comparator|Part B: Pregabalin|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and pregabalin.
33290808|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
33290809|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
33290810|NCT01069965|Experimental|1. Placebo|Placebo BID
33290811|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
33290812|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test"
33290813|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test~Spirometry"
33290814|NCT01067703|Active Comparator|RIPC|
33290815|NCT01067703|Sham Comparator|CONTROL|
33290816|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
33290817|NCT00391092|Experimental|1|
33290818|NCT00391092|Active Comparator|2|
33290819|NCT00374868|Experimental|Pemetrexed + Cisplatin|
33290820|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
33290821|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
33290822|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
33290823|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
33290824|NCT00374556|Experimental|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
33290825|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
33290826|NCT00290355|Experimental|GSK 249553 Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of GSK 249553 vaccine, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
32783836|NCT04844073|Experimental|Dose Escalation Phase|MVC-101(TAK-186) initial 60 minutes infusion and 30 minutes subsequent infusions on Day 1 of every week in Dose Escalation Phase. Participants may receive additional treatment with MVC-101 (TAK-186). Dose escalation will be carried out in sequential cohorts of escalating doses.
32783837|NCT04844073|Experimental|Cohort Expansion Phase: HNSCC|Participants with head and neck squamous cell carcinoma (HNSCC) will receive MVC-101 (TAK-186) infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with MVC-101 (TAK-186).
33290827|NCT00290355|Placebo Comparator|Placebo Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of placebo, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
33290828|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
33290829|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
33290830|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
33290831|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
33290832|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
33290833|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
33290834|NCT00303459|Experimental|A|Bosentan
33290835|NCT00303459|Placebo Comparator|B|Placebo
33290836|NCT01070121||RA patients/participants|
33290837|NCT00289887|Experimental|1|Losartan
33290838|NCT00289887|Placebo Comparator|2|Placebo
33290839|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
33290840|NCT00303069|Experimental|V710 5 μg|V710 S. aureus vaccine
33290841|NCT00303069|Experimental|V710 30 μg|V710 S. aureus vaccine
33290842|NCT00303069|Experimental|V710 90 μg|V710 S. aureus vaccine
33290843|NCT00303069|Placebo Comparator|Placebo|Placebo
33290844|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
33290845|NCT01325727|Active Comparator|Resources only|
33290846|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
33085300|NCT04541719|Placebo Comparator|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
33290847|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
33290848|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
33290849|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
33290850|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
33290851|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
33290852|NCT01044420|Experimental|mFOLFIRI|
33290853|NCT00289731|Experimental|Twinrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.
33085301|NCT04548115|Experimental|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
33290854|NCT00289731|Active Comparator|Engerix-B+Havrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of Engerix™-B (20 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
33290855|NCT00289731|Active Comparator|HB VAX PRO+Vaqta Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of HB VAX PRO™ (10 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Vaqta™ (50 IU) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
33290856|NCT00289185|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
33290857|NCT00289185|Active Comparator|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
33290858|NCT03980067|Experimental|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
33290859|NCT03980067|No Intervention|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
33290860|NCT00292461|Active Comparator|zonisamide|tablet
33290861|NCT00292461|Active Comparator|lamotrigine|tablet
33290862|NCT03976869|Experimental|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
33290863|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
33290864|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
33290865|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
33290866|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
33290867|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
33290868|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
33290869|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
33290870|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
33290871|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
33290872|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
33290873|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
33290874|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
33290875|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
33290876|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
33085302|NCT04548115|Experimental|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
33318156|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
32783838|NCT04844073|Experimental|Cohort Expansion Phase: NSCLC|Participants with non-small cell lung cancer (NSCLC) will receive MVC-101 (TAK-186) infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with MVC-101 (TAK-186).
32783839|NCT04844073|Experimental|Cohort Expansion Phase: CRC|Participants with colorectal cancer (CRC) will receive MVC-101 (TAK-186) infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with MVC-101 (TAK-186).
32783840|NCT04833075|Other|Single arm|additional blood sampling (single arm)
32783841|NCT04832763|Experimental|Physical function testing, questionnaire|Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
33085303|NCT04548115|Experimental|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
33085304|NCT04548115|Experimental|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
33290877|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
32783842|NCT04852731|Experimental|Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,~And specifically for research purposes : injected cardiac MRI and a blood collection."
32783843|NCT04852731|Experimental|Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
32783844|NCT04852731|Experimental|Group B : patients with Mitral valve prolapse with trivial mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
32783845|NCT04852731|Experimental|Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
32783846|NCT04852731|Experimental|Group D : patients with asymptomatic Mitral valve prolapse with severe mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
32783847|NCT05287113|Experimental|Treatment Group 1: Retifanlimab Monotherapy|Retifanlimab will be administered intravenously every 4 weeks. Placebos for INCAGN02385 and INCAGN02390 will be administered intravenously every 2 weeks.
32783848|NCT05287113|Experimental|Treatment Group 2: Retifanlimab + INCAGN02385|Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and Placebo for INCAGN02390 will be administered intravenously every 2 weeks.
32783849|NCT05287113|Experimental|Treatment Group 3: Retifanlimab + INCAGN02385 + INCAGN02390|Retifanlimab plus INCAGN02385 and INCAGN02390 will be administered intravenously. Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and INCAGN02390 will be administered every 2 weeks.
32783850|NCT04635891||MOVE FSHD Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care and are anticipated to occur at least once a year.
32783851|NCT05006391|Experimental|Tele-Coaching (Online) Community-Based Exercise|This study involves two phases: a six month online Community-Based Exercise Intervention (Phase 1), followed by a six month Follow-Up Monitoring Phase (Phase 2).
32783852|NCT05000853||Patients with iron deficiency|
32783853|NCT05000853||Patients without iron deficiency|
33290878|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
33290879|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
33290880|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
33290881|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
33290882|NCT00302211|Experimental|DB inhaled iloprost 6x/day|inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
33290883|NCT00302211|Experimental|DB inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
33290884|NCT00302211|Placebo Comparator|DB inhaled placebo 6x/day|Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
33318157|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
33290885|NCT00302211|Experimental|OL inhaled iloprost 6x/day|Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
33290886|NCT00302211|Experimental|OL inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
33290887|NCT01045902|Experimental|Arm 1|
33290888|NCT01045902|Active Comparator|Arm 2|
33290889|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
33290890|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
33290891|NCT01041690|Experimental|Bevacizumab|
33290892|NCT01041768|Active Comparator|antidiabetic medical therapy|
33290893|NCT01041768|Experimental|Bariatric Surgery|
33290894|NCT01041846||Decitabine|
33290895|NCT00288015|Experimental|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
33290896|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
33290897|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
33290898|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
33290899|NCT01045980|Experimental|Bioimpedance and Vitamin D|
33290900|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
33290901|NCT01045980|Experimental|Bioimpedance and Placebo|
33290902|NCT01045980|Placebo Comparator|Usual Care and Placebo|
33085305|NCT04548115|Experimental|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
33290903|NCT00388674||A|
33290904|NCT00388674||B|
33290905|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
33290906|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
33290907|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
33290908|NCT01042002|Experimental|High intensity exercise|
33290909|NCT01042002|No Intervention|Control|
33290910|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
33290911|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
33290912|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
33290913|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
33085306|NCT04547764|Experimental|TAP group|
33290914|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
33290915|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
33290916|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
33290917|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
33290918|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
33290919|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
33290920|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
33290921|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
33290922|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
32783854|NCT04832529|Active Comparator|Perianal abscess cavity packing|
33085307|NCT04547764|Active Comparator|Vitapex group|
33085308|NCT04547608|Other|group PRi|received immediate injection of rocuronium after propofol administration,
33290923|NCT03993522|Experimental|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
33290924|NCT03992820|Experimental|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
33290925|NCT03992820|Other|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
33290926|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
33290927|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
32783855|NCT04832529|Experimental|Perianal abscess cavity no packing|
32783856|NCT04998591|Experimental|Fasting group|Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
33290928|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
33290929|NCT00413660|Experimental|CP 690,550 1 mg BID|
33290930|NCT00413660|Experimental|CP 690,550 10 mg BID|
33290931|NCT00413660|Experimental|CP 690,550 15 mg|
33290932|NCT00413660|Experimental|CP 690,550 3 mg BID|
33290933|NCT00413660|Experimental|CP 690,550 5 mg BID|
33290934|NCT00413660|Experimental|CP-690,550 20 mg QD|
33290935|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
33290936|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
33290937|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
33290938|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
33290939|NCT01323686|Experimental|Imaging guided LV lead placement|
32783857|NCT04998591|No Intervention|Waiting list|This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.
32783858|NCT04997577|Experimental|Auditory training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios.
32783859|NCT04997577|Experimental|Auditory-cognitive training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios. A short-term memory component is added to the training paradigm to make the task more engaging and challenging.
32783860|NCT04842747|Experimental|9mg of VERU-111 Oral daily|9mg of VERU-111
32783861|NCT04842747|No Intervention|Placebo Capsule once daily|Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.
33290940|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
33290941|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
33290942|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
33290943|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
33290944|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
32783862|NCT04419129|Active Comparator|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
32783863|NCT04419129|Active Comparator|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
32783864|NCT04586985|Experimental|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).
33290945|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
33290946|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
33290947|NCT00430352|Experimental|1|
33290948|NCT00287469|Experimental|20mcg Recombinant HEV|20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
33290949|NCT00287469|Placebo Comparator|Placebo|PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
33290950|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
33290951|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
33290952|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
33290953|NCT00287079|Experimental|Rebif®|
33290954|NCT00287079|Other|No Treatment|
33318158|NCT01202630|Placebo Comparator|Placebo|Placebo
33085309|NCT04547608|Other|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
33085310|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
33085311|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
33085312|NCT04547452|Experimental|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
33085313|NCT04547452|Active Comparator|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
33085314|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
33085315|NCT04547296|Experimental|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
33085316|NCT04547296|Experimental|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
33290955|NCT03976167|Active Comparator|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
32783865|NCT04586985|Experimental|Multiple Ascending Dose (MAD) cohorts in Healthy Subjects (Part B)|Subjects will be randomized 3:1 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).
32783866|NCT04586985|Experimental|Pilot Food Effect Cohort in Healthy Subjects (Part C)|Ten subjects will be randomized to receive a single 20 mg dose of FTX-6058 with and without a high-fat meal with a washout period of 4 days.
32783867|NCT04586985|Experimental|Potential for CYP3A Induction in Healthy Subjects (Part D)|Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
32783868|NCT04586985|Experimental|Multiple Dose Cohort in Sickle Cell Disease Subjects (Part E)|Subjects will be randomized 3:1 to receive FTX-6058 or placebo once daily by mouth for 14 days. Up to 8 subjects will be enrolled. The planned dose is 6mg.
32783869|NCT04582539|Experimental|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
32783870|NCT05273697|Active Comparator|Underwater cold snare polypectomy group|Cold snare polypectomy after complete immersion of the polyp in the water
32783871|NCT05273697|Active Comparator|Conventional cold snare polypectomy group|Cold snare polypectomy in colon lumen dilated with air
32783872|NCT05260749|Experimental|Neurofeedback training|Subjects in the neurofeedback training group are instructed to regulate their anterior insula activity based on the visual neurofeedback.
32783873|NCT05260749|Sham Comparator|Sham control1|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from a whole slice of top brain (a controlled sham region).
32783874|NCT05260749|Sham Comparator|Sham control2|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from the middle temporal gyrus (a controlled sham region).
32783875|NCT04969653||Cases|All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
32783876|NCT04969653||Controls|Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
32783877|NCT04969419||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
32783878|NCT04969419||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
32783879|NCT04572243|Experimental|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
32783880|NCT04572243|Placebo Comparator|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
32783881|NCT04561557|Experimental|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10^6 CAR-T cells/Kg instead of 0.5 × 10^6 CAR-T cells/Kg.~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
32783882|NCT04561557|Experimental|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 106 CAR-T cells/kg to assess DLT.
32783883|NCT04561557|Experimental|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
32783884|NCT04852419|Experimental|ZN-c5 50mg QD dose cohort|Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
32783885|NCT04852419|Experimental|Zn-c5 150mg QD dose cohort|Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
32783886|NCT05249673|Experimental|global postural reeducation|"global postural reeducation (GPR) interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
32783887|NCT05249673|Active Comparator|neck stabilization training|Each exercise session will be comprised of 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient.
32783888|NCT04952961|Experimental|Single Arm Intervention|Participants will be shown how to perform vulval self-examination in a face-to-face intervention and provided with an information leaflet. They will be sent reminders to self-examine each month.
33085317|NCT04547218||Elderly patients|"Above 65 year old patients undergoing elective surgery Inclusion criteria I. Geriatric patients ( age more than 65 y/o) II. All elective surgeries under GA~Exclusion criteria I. Refuse to participate in the study II. Patients with cognitive disorders such as dementia and Alzheimer's disease"
33290956|NCT03976167|Experimental|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
33290957|NCT03975933|Experimental|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
33290958|NCT03975933|Experimental|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
33290959|NCT03975933|Experimental|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
33290960|NCT03975933|No Intervention|Control Group|Control group. No intervention is implemented.
33290961|NCT03975933|Experimental|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
33290962|NCT03975933|Experimental|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
33290963|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
33290964|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
33290965|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
33290966|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
33290967|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
33290968|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
33290969|NCT00301821|Experimental|Epratuzumab + Rituximab + CHOP|One arm open label.
33290970|NCT03976713|Experimental|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
33290971|NCT03976713|Placebo Comparator|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
32783889|NCT05245539|Experimental|CVL-231 Dose Level 1|10 mg once daily
32783890|NCT05245539|Experimental|CVL-231 Dose Level 2|30 mg once daily
32783891|NCT05244057|Experimental|Hepalatide + TAF + PEG-IFN|Patients will receive 4.2mg Hepalatide +25mg Tenofovir alafenamide+ 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
32783892|NCT05244057|Placebo Comparator|Placebo+ TAF + PEG-IFN|Patients will receive Placebo +25mg Tenofovir alafenamide + 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
33085318|NCT02214511||MDD patients|emotional facial stimuli cyberball game
33290972|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
33290973|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
33290974|NCT00372996|Active Comparator|2|
33290975|NCT01046292|Experimental|Ginkgo biloba|
33290976|NCT01046292|Placebo Comparator|Placebo control|
33290977|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
33290978|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
33290979|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
33290980|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
33290981|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
33318159|NCT01205984|Active Comparator|oral methylprednisolone|
32783893|NCT05241405|Experimental|Qiseng|200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry
32783894|NCT05241405|Placebo Comparator|Placebo|neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract
33085319|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
33085320|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
32783895|NCT04840875|Experimental|chimeric antigen receptor T cell treatment|
32783896|NCT05342025|Experimental|PNF group|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases. The physiotherapist will apply patterns over the 2nd and 3rd ribs in a bilateral anterior manner including intercostal stretches.
33290982|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
33290983|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
33290984|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
32783897|NCT05342025|Active Comparator|Control Group|"Individuals in this group will be taught breathing exercises (diaphragmatic breathing, thoracic expansion, pursed-lip breathing, and respiratory control) after the assessments, and they will be informed about performing breathing exercises for 15 minutes a day, every day of the week. Patients will be asked to keep a treatment diary to control regular breathing exercises. Individuals will be re-evaluated after 2 months."
32783898|NCT05408403|Active Comparator|Transversalis Fascia Plane Block|Transversalis Fascia Plane Block (TFPB) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
32783899|NCT05408403|Active Comparator|Quadratus Lumborum Block|Anterior Quadratus Lumborum Block ( Anterior QLB) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
32783900|NCT04916223|Experimental|3 x 10-minute massage|Subject receives a 10-minute massage daily for three consecutive days
32783901|NCT04916223|Experimental|3 x 20-minute massage|Subject receives a 20-minute massage daily for three consecutive days
32783902|NCT04916223|Active Comparator|Single 20-minute massage|Subject receives one 20-minute massage
32783903|NCT04830735|Experimental|Arm I (dasatinib anhydrous)|Patients receive dasatinib anhydrous PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
32783904|NCT04830735|Placebo Comparator|Arm II (placebo administration)|Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
32783905|NCT04489095|Experimental|Electrophysiology Study pre and Post TAVR|In all patient's undergoing TAVR after informed consent will undergo an electrophysiology study pre and post device deployment in order to determine the need for permanent pacemaker implantation or further testing/monitoring.
32783906|NCT04840173|Experimental|Music at home|Caregivers will use Singing, music listening, or moving with music twice a week for 30 minutes with their care recipient.
32783907|NCT05335317|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
32783908|NCT05335317|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy, when the suppository will be used of 2 times a week for 1.5-2 months to prevent symptoms.
32783909|NCT05335317|Other|No treatment|Participants without vaginal atrophy (no complaints of vaginal health and a vaginal health index greater than 20) and not receiving any treatment.
33085321|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
33085322|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
33085323|NCT04546984|Experimental|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
33290985|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
33290986|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
33290987|NCT00300885|Experimental|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
33290988|NCT00300885|Active Comparator|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
33318160|NCT01205984|Placebo Comparator|placebo|
33290989|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
33290990|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
33290991|NCT01143116|Experimental|Catheter A|"Catheterization with Catheter A, which releases silver ions into the urethra and urinary bladder upon catheterization,.~After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
33290992|NCT01143116|Experimental|Catheter B|"Catheterization with Catheter B, which releases both silver ions and degradable silver particles.. After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
33290993|NCT01037972||Whole body vibration|
32783910|NCT04829721|Experimental|Educational Video Workshop|A single 20 minute video workshop on pelvic floor disorders.
32783911|NCT04829643|Experimental|PET/MRI|Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
32783912|NCT04840017|Experimental|Study group I|excessive body weight and flat feet
32783913|NCT04840017|Experimental|Study group II|normal body weight and flat feet
32783914|NCT04840017|No Intervention|Study group III|control, healthy children
32783915|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
32783916|NCT04876365||All Participants|All participants diagnosed with severe hemophilia A previous received prophylaxis regimen for Standard Half-life/Extended Half-life Factor VIII (SHL/EHL-FVIII) products will be compared to after the participants switched to regular prophylaxis with Adynovate with at least 6 months follow up.
32783917|NCT05329779|Experimental|brexanolone|Participants will receive a continuous 60-hr intravenous infusion of brexanolone
32783918|NCT05329779|Placebo Comparator|placebo|Participants will receive a continuous 60-hr infusion of placebo
32783919|NCT04464759|Experimental|Phase 1a: Nivolumab and Hydroxychloroquine (HCQ)|"Dose escalation:~Dose Level 1: HCQ 400 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Dose Level 2: HCQ 600 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
32783920|NCT04464759|Experimental|Phase 2: Nivolumab and Hydroxychloroquine (HCQ)|"HCQ 400-600 mg (maximum tolerated dose from Phase 1a) orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
33290994|NCT01037972||Conventional physiotherapy|
33290995|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
32783921|NCT04464759|Experimental|Phase 1b: Nivolumab + Ipilimumab +Hydroxychloroquine (HCQ)|"HCQ 400-600 mg orally every 12 hours and nivolumab 3 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks x4 cycles~Then 6 weeks after the last dose of ipilimumab/nivolumab begin maintenance nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
33290996|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
33290997|NCT00428714|Experimental|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
33290998|NCT00428714|Experimental|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
33290999|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
33291000|NCT00292227|Experimental|Rotigotine|Rotigotine Patch
33291001|NCT00292227|Placebo Comparator|Placebo|Placebo patch
33291002|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
33291003|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
33291004|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
33291005|NCT00300495|Experimental|1 - Amiodarone|Perioperative amiodarone
33291006|NCT00300495|Active Comparator|2 - Control|Control arm, standard care with no perioperative amiodarone
33291007|NCT01068639||A|
33291008|NCT03979989|Experimental|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
33291009|NCT03979989|Experimental|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
33291010|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
33085324|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
33085325|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
33085326|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
33085327|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
33291011|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
33291012|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment~Historical controls:~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
33291013|NCT01070199|Experimental|liquid to liquid,|
33291014|NCT01070199|Experimental|liquid to solid,|
33291015|NCT01070199|Experimental|solid to liquid|
33291016|NCT01070199|Experimental|solid to solid|
33291017|NCT01325571|Experimental|tacrolimus group|
33291018|NCT01325571|Placebo Comparator|placebo group|
33085328|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
33291019|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
33291020|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
33291021|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
33291022|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
33291023|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
33291024|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
33291025|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
33291026|NCT01068951|No Intervention|Control|
33291027|NCT00286455|Experimental|Alogliptin 12.5 mg QD|
33291028|NCT00286455|Experimental|Alogliptin 25 mg QD|
33291029|NCT00286455|Placebo Comparator|Placebo QD|
33291030|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
33291031|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
33291032|NCT01046370|Experimental|ARP intervention|
33291033|NCT01046370|No Intervention|No intervention|
33291034|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
33291035|NCT00286221|Experimental|Supratentorial PCA fentanyl|
33291036|NCT00286221|Active Comparator|Supratentorial PRN fentanyl|
33291037|NCT00286221|Experimental|Infratentorial PCA fentanyl|
33291038|NCT00286221|Active Comparator|Infratentorial PRN fentanyl|
33291039|NCT03976635|Active Comparator|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
33291040|NCT03976635|Experimental|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
33291041|NCT00285207|Placebo Comparator|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
33291042|NCT00285207|Experimental|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
33291043|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33291044|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
33291045|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
33291046|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
33291047|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
33291048|NCT03976791|Experimental|Enlarged internal incision|enlarged the internal incision about 0.4mm
33291049|NCT03976791|Placebo Comparator|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
33291050|NCT01042314|Experimental|Donepezil and BMS-708163|
32938850|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
33291051|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
33291052|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
33291053|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
33291054|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
33291055|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
33291056|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
33291057|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
33291058|NCT01065207|No Intervention|patient|
33291059|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
33291060|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
33291061|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
33291062|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
33291063|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
33291064|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
33291065|NCT00283959|Experimental|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
33291066|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
33291067|NCT00372528|Experimental|pregabalin|open label treatment
33291068|NCT00283803|Experimental|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
33291069|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
33291070|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
33291071|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
33291072|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
33291073|NCT03976089|Experimental|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
33291074|NCT03976089|Active Comparator|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
33291075|NCT03975777|Experimental|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
33291076|NCT03975777|Experimental|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
33291077|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
33318161|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
32783922|NCT04419753|Active Comparator|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
33085329|NCT04546789|Experimental|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
32783923|NCT04419753|Experimental|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
33291078|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
33085330|NCT04546789|Experimental|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
33085331|NCT04546789|Experimental|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
33085332|NCT00261690|Experimental|1|Virtual Reality distraction
33291079|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
33291080|NCT01033526|Placebo Comparator|Arm 2|
33291081|NCT01033526|Experimental|Arm 1|
33291082|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
33291083|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
33291084|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
33291085|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
33291086|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
33291087|NCT02900664|Experimental|PDR + ACZ 100mg Q8W|PDR + ACZ 100mg Q8W
33291088|NCT02900664|Experimental|PDR + ACZ 300mg Q8W|PDR + ACZ 300mg Q8W
33291089|NCT02900664|Experimental|PDR + ACZ RDE TNBC|PDR + ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
33291090|NCT02900664|Experimental|PDR + ACZ RDE NSCLC|PDR + ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
33291091|NCT02900664|Experimental|PDR + ACZ RDE CRC|PDR + ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
33291092|NCT02900664|Experimental|PDR + CJM 25mg Q4W|PDR + CJM 25mg Q4W
33291093|NCT02900664|Experimental|PDR + CJM 75mg Q4W|PDR + CJM 75mg Q4W
33291094|NCT02900664|Experimental|PDR + CJM 225mg Q4W|PDR + CJM 225mg Q4W
33291095|NCT02900664|Experimental|PDR + CJM 450mg Q4W|PDR + CJM 450mg Q4W
33291096|NCT02900664|Experimental|PDR + CJM 450mg Q2W|PDR + CJM 450mg Q2W
33291097|NCT02900664|Experimental|PDR + CJM 900mg Q4W|PDR + CJM 900mg Q4W
33291098|NCT02900664|Experimental|PDR + CJM 900mg Q2W|PDR + CJM 900mg Q2W
33291099|NCT02900664|Experimental|PDR + CJM 1200mg Q4W|PDR + CJM 1200mg Q4W
32783924|NCT04419753|Experimental|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
33291100|NCT02900664|Experimental|PDR + TMT 0.5mg QD|PDR + TMT 0.5mg QD
33291101|NCT02900664|Experimental|PDR + TMT 1mg QD|PDR + TMT 1mg QD
33291102|NCT02900664|Experimental|PDR + TMT 1mg QD, 3 Weeks on/1 Week off|PDR + TMT 1mg QD, 3 Weeks on/1 Week off
33291103|NCT02900664|Experimental|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off
33291104|NCT02900664|Experimental|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off
33291105|NCT02900664|Experimental|PDR + EGF816 25mg QD|PDR + EGF816 25mg QD
33291106|NCT02900664|Experimental|PDR + EGF816 50mg QD|PDR + EGF816 50mg QD
33291107|NCT02900664|Experimental|s.a. ACZ RDE TNBC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
33291108|NCT02900664|Experimental|s.a. ACZ RDE NSCLC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
33291109|NCT02900664|Experimental|s.a. ACZ RDE CRC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
33291110|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
33291111|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
33291112|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
33291113|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
33291114|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
33291115|NCT03976557|Experimental|BIP CVC|Polyurethane CVC with noble metal coating
33291116|NCT03976557|Active Comparator|Standard CVC|Standard CVC made of polyurethane
33291117|NCT01065363|Experimental|Lifestyle conseling|
33291118|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
33291119|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally~."
33291120|NCT00424190|Experimental|Ceftaroline for Injection|
33291121|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
33291122|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
33291123|NCT01045044||Normal control|Up to 15 normal, healthy women.
33291124|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
33291125|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
33291126|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
33291127|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
33085333|NCT04547179|Experimental|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
33291128|NCT00428246|Active Comparator|1|1 mcg paricalcitol
33291129|NCT00428246|Active Comparator|2|2 mcg paricalcitol
33291130|NCT00428246|Placebo Comparator|3|Placebo
33291131|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
32783925|NCT04850937|Experimental|Group S|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction During administration, blood pressure and heart rate were observed.
32783926|NCT04850937|Placebo Comparator|Group C|The control group will receive the same amount of normal saline after anesthesia induction
33291132|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
33291133|NCT00274287|Experimental|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
33291134|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
33291135|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
33291136|NCT01042626|Active Comparator|Healthy subjects|
33291137|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
33291138|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
33291139|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
33291140|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
33291141|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
33291142|NCT03932708|Experimental|Urgent Care Antibiotic Stewardship Intervention|All 38 urgent care clinics will implement CDC Core Elements of outpatient antibiotic stewardship as described above.
32783927|NCT04867317|Active Comparator|Growth Hormone Replacement Therapy|Recombinant Human Growth Hormone
32783928|NCT04867317|Placebo Comparator|Placebo|Placebo
32783929|NCT04850781|Active Comparator|Daily Meals|A lunch-time meal delivered to participants' homes multiple times per week with wellness check and socialization.
32783930|NCT04850781|Experimental|Frozen, Drop-shipped Meals|10 frozen meals that are mailed to participants every two weeks.
32783931|NCT04851717|Experimental|All Patients|All paediatric patients undergoing diagnostic and/or therapeutic procedures
32783932|NCT04464057|Experimental|experimental group|The patients in the experimental group would be given early oral feeding within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
32783933|NCT04464057|No Intervention|control group|The control group would be given early oral feeding within 4-5 days after intestinal anastomosis. Start taking it at 4-5 days after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
32783934|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
32783935|NCT01638819|Placebo Comparator|Placebo|Saline
32783936|NCT04445805|Active Comparator|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
32783937|NCT04445805|Experimental|Perinatal-enhanced behavioral therapy for insomnia|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
32783938|NCT04445805|Placebo Comparator|Attention Control Treatment Group|Minimal intervention control
32783939|NCT04827849|Experimental|Experiment group|The study group will be provided physical examination, pregnancy monitoring and training on transition to motherhood within the direction of nursing care based on Meleis's Transition Period Theory, in addition to the usual care provided by healthcare professionals.
32783940|NCT04827849|No Intervention|Control group|The control group continued to receive the routine care
32783941|NCT04849143|Experimental|Honey dressing group|A thin layer of honey will be applied to the wounds
32783942|NCT04849143|Active Comparator|Gel dressing group|A thin layer of gel will be applied to the wounds
32783943|NCT01363713|Experimental|1|
33291143|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
33291144|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
33291145|NCT00282243|Experimental|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
33291146|NCT00272961|Placebo Comparator|placebo|
33291147|NCT00272961|Experimental|ARM 1|
33291148|NCT00272961|Experimental|ARM 2|
33291149|NCT00272961|Experimental|ARM 3|
33291150|NCT00272961|Experimental|ARM 4|
33291151|NCT00282087|Other|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
33291152|NCT00404924|Placebo Comparator|1|Best Supportive Care
33291153|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
33291154|NCT00281697|Experimental|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
33291155|NCT00281697|Placebo Comparator|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
33291156|NCT01070901||Organ transplant recipients|
33291157|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
33291158|NCT00232180|Active Comparator|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
33291159|NCT00280683|Active Comparator|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
33291160|NCT00280683|Placebo Comparator|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
33291161|NCT00270855|Other|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
33291162|NCT00270855|Other|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
33291163|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
33291164|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
33291165|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
33291166|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
33291167|NCT00404768|Experimental|Treatment|GSK221149A
33291168|NCT00404768|Placebo Comparator|Placebo|Placebo
33291169|NCT00270231|Active Comparator|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
33291170|NCT00270231|Placebo Comparator|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
33291171|NCT02532309|Experimental|Rosuvastatin dose adjustment|
33291172|NCT02532309|Experimental|Rosuvastatin fixed dose|
33291173|NCT00258856|Experimental|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
33291174|NCT00258856|Experimental|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
33291175|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
33291176|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
33291177|NCT03909620|Experimental|LDCT arm|All eligible participants will undergo screening with LDCT
33291178|NCT00269919|Experimental|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
33291179|NCT03969628|Experimental|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
33291180|NCT03969628|Experimental|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
33291181|NCT01038284|Sham Comparator|Control|
33291182|NCT01038284|Active Comparator|Patient education|
32783944|NCT04414917|Experimental|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
32783945|NCT04414917|Sham Comparator|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
32783946|NCT04411329|Active Comparator|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
32783947|NCT04411329|Active Comparator|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
32783948|NCT04411329|Active Comparator|group c|we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery
32783949|NCT05171673|Experimental|Investigational|LicartTM topical system application once per day for a maximum of 14 days or until pain resolution, whichever occurs first.
32783950|NCT04811937|Experimental|Artificial intelligence for real-time Computer decision support of resection of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information about polypectomy procedures.
32783951|NCT05147415|Placebo Comparator|Placebo|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period
32783952|NCT05147415|Experimental|Tesomet Low Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
32783953|NCT05147415|Experimental|Tesomet Medium Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
32783954|NCT05147415|Experimental|Tesomet High Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
32783955|NCT04827069|Experimental|Arm 1|Clifutinib Besylate:10 mg
32783956|NCT04827069|Experimental|Arm 2|Clifutinib Besylate:20 mg
32783957|NCT04827069|Experimental|Arm 3|Clifutinib Besylate:40 mg
32783958|NCT04827069|Experimental|Arm 4|Clifutinib Besylate:55 mg
32783959|NCT04827069|Experimental|Arm 5|Clifutinib Besylate:70 mg
32783960|NCT04826991|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
33085334|NCT04547179|Experimental|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
33085335|NCT04547179|Placebo Comparator|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
33085336|NCT04547101|Experimental|AK104|
32783961|NCT04826991|Sham Comparator|Inactive UV Device|A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).
32783962|NCT04402125|Experimental|Intervention|Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
32783963|NCT04402125|Other|Waitlist|Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
32783964|NCT04800315|Experimental|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
32783965|NCT04800315|Experimental|Dose 2: CC-93538 and Placebo SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
32783966|NCT04800315|Experimental|Dose 3: CC-93538 and Placebo SC Q2W|"Starting at the baseline visit, active IP and matching placebo will be administered.~On the alternate weeks, placebo will be administered weekly to maintain the blind."
32783967|NCT04800315|Placebo Comparator|Placebo SC QW|Administration of placebo each week.
32783968|NCT04786743|Experimental|non-urgent endoscopy group|undergo endoscopy between 6 and 24 hours after gastroenterological consultation
32783969|NCT04786743|Other|urgent endoscopy group|undergo endoscopy within 6 hours after gastroenterological consultation
32783970|NCT04390581|Experimental|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
32783971|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33085337|NCT04546906|Experimental|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
33085338|NCT04546594||Orthopedic surgery|
33085339|NCT04546594||Thoracic surgery|
33085340|NCT04546594||Gynecological surgery|
33085341|NCT04546438|Experimental|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
33085342|NCT04546477|Other|Single Arm|"135 patients stratified in 2 groups:~90 FEM-POP patients: SFA-P1~45 Isolated POP Patients: P1, P2, P3 only"
33291183|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
33291184|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
32783972|NCT05122767|Experimental|Single Arm in 4 groups|There will be four groups. Group 1a and Group 1b will provide semi-intensive PK data and safety monitoring to allow for comparison of twice-daily dolutegravir exposures together with HP vs. when DTG is given alone. Group 2a and Group 2b will provide semi-intensive PK data and safety monitoring for either twice-daily or once-daily dolutegravir together with HIV vs when DTG is given alone. All groups will provide safety and tolerability data, HIV virologic outcome data, and information about dolutegravir and rifapentine PK.
32783973|NCT05114577|Experimental|Recovery Sleepers program.|
32783974|NCT05114577|Placebo Comparator|Email recommendations|
33291185|NCT00258154|Experimental|1|RotaTeq/Infanrix Hexa
33291186|NCT00258154|Placebo Comparator|2|Placebo/Infanrix Hexa
33291187|NCT00257920|Active Comparator|A|
33291188|NCT00257920|Active Comparator|B|
33291189|NCT00268983|Experimental|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
33291190|NCT00268983|Active Comparator|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
33291191|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
33291192|NCT01070511|Experimental|Tadalafil|
33291193|NCT01070511|Placebo Comparator|Placebo|
33291194|NCT01070589||Group 1: Obese|BMI>30
33291195|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
33291196|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
33291197|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
33291198|NCT00257608|Experimental|1|
33291199|NCT00257608|Placebo Comparator|2|
33291200|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
33291201|NCT00231478|Experimental|1|
33291202|NCT00231478|Experimental|2|
33291203|NCT00413192|Experimental|1|
33291204|NCT01038440|Placebo Comparator|Control|
33291205|NCT01038440|Active Comparator|EPA 0.5 g/d|
33291206|NCT01038440|Active Comparator|EPA 1.5 g/d|
33291207|NCT01038440|Active Comparator|EPA 3.0 g/d|
33291208|NCT01038440|Experimental|SDA 0.5 g/d|
33291209|NCT01038440|Experimental|SDA 1.5 g/d|
33291210|NCT01038440|Experimental|SDA 3.0 g/d|
33291211|NCT01038440|Experimental|SDA 6.0 g/d|
33291212|NCT00207142|Active Comparator|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
33291213|NCT00207142|Active Comparator|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
33291214|NCT00207142|Other|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
33291215|NCT00268905|Experimental|1|
33291216|NCT00268905|Experimental|2|
33291217|NCT00268905|Experimental|3|
33291218|NCT03974997|Other|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
33291219|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
33291220|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
33291221|NCT00206518|Experimental|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
33291222|NCT00206518|Experimental|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
33291223|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
33291224|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
33291225|NCT03972904|Experimental|Intervention group|The Light-Fat Rice® group
33291226|NCT03972904|Placebo Comparator|Control group|The comparable energy staple food group
33085343|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
32783975|NCT05114265|Experimental|Part 1: Single ascending dose|Single dose of oral KUR-101 or oral placebo
32783976|NCT05114265|Experimental|Part 2: Three-way crossover|Single dose of oral KUR-101, oral placebo and oral OxyNorm
33085344|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
33085345|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
32783977|NCT04772157||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
32783978|NCT04770831||Single Arm|QOL following MIBG
32783979|NCT05399121|Active Comparator|Group A: Piano Learning then Free Improvisation|This arm (n=29) will first begin the intervention with a Piano Learning exercise followed by a Free Improvisation exercise.
32783980|NCT05399121|Active Comparator|Group B: Free Improvisation then Piano Learning|This arm (n=29) will first begin the intervention with a Free Improvisation exercise followed by a Piano Learning exercise.
32783981|NCT04357353|Sham Comparator|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
32783982|NCT04357353|Experimental|PRP|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
32783983|NCT04826211|Experimental|Node positive BC patients undergoing PST|Patients with breast cancer of any size with positive axillary nodes and candidates to PST will undergo PET/MRI both prior to PST and after PST before surgery
32783984|NCT04312113|Experimental|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
32783985|NCT04759755||Study participants|18-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.
32783986|NCT05396859|Experimental|Treatment (ASTX727, entrectinib)|Patients receive entrectinib PO QD on days 1-28 and ASTX727 PO QD on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32783987|NCT04277715|Experimental|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a virtual group format. Groups will last 90-minutes and run for 6-8 weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
32783988|NCT04183335|Experimental|Dupilumab|Participants received dupilumab at a loading dose of 600 milligrams (mg), subcutaneously (SC) on Day 1 followed by dupilumab 300 mg once every 2 weeks (q2w) for 24 weeks added to background therapy of topical corticosteroids/topical calcineurin inhibitors (TCS/TCI) at stable dose.
32783989|NCT04183335|Placebo Comparator|Placebo|Participants received placebo matched to dupilumab 600 mg (loading dose), SC on Day 1 followed by placebo matched to dupilumab 300 mg q2w for 24 weeks added to background therapy of TCS/TCI at stable dose.
32783990|NCT04254549|Experimental|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
32783991|NCT04254549|Placebo Comparator|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
32783992|NCT04419363|Experimental|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
32783993|NCT04825431|Experimental|TAS-205, [14C]TAS-205|
32783994|NCT04241679|Experimental|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
32783995|NCT04225767|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for malignant cutaneous and subcutaneous tumours
32783996|NCT04212273|Experimental|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
32783997|NCT04824183|Experimental|Music intervention|Music intervention that begins with patient education on WhatsApp will be delivered to participants 3 times within 48 hours before surgery followed by face-to-face monitoring of intervention usage.
32783998|NCT04824183|No Intervention|Usual care|Participants in the control group will receive preoperative pain education via a one-on-one WhatsApp chat. The pain education will focus mainly on the type of pain to expect after surgery, how to report pain and how to request pain medication. MI will not be introduced to the participants in this group neither will there be any phone call for psychological support. Other preoperative care and postoperative care will be provided according to the hospital and ward practices.
32783999|NCT04199793|Active Comparator|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
32784000|NCT04199793|Active Comparator|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
32784001|NCT04823871|Other|High risk patients for breast and/or ovarian cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
32784002|NCT04823871|Other|Suspected Ovarian Epithelial Cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
33085346|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
32784003|NCT04821453|Placebo Comparator|Conventional Flow Triggered Mechanical Ventilation (CMV)|Subjects will be ventilated with conventional mechanical ventilation with data collected for the 5 day time frame to compare to the experimental arm
32784004|NCT04821453|Experimental|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be ventilated on neurally adjusted ventilatory assist (NAVA) mode with data collected for the 5 day time frame to compare with placebo arm
32784005|NCT04820985||Women undergoing IVF|
32784006|NCT04820829|Active Comparator|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
32784007|NCT04820829|Active Comparator|Moderate RM, moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
32784008|NCT04820829|Active Comparator|Low RM, high NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
32784009|NCT04820673||Sarecycline|Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.
32784010|NCT04145427|Experimental|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
32784011|NCT04145427|Active Comparator|Standard Dietary Advice Control Group|This arm will be randomized to control diet
32784012|NCT05302791|Experimental|Muscle Cooling|The intervention will be applying a cooling wrap during the bilateral resistance exercise.
32784013|NCT05302791|Placebo Comparator|Control|There will be no temperature alteration for this leg during bilateral resistance exercise.
32784014|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/90|Stimulation delivered at 30 seconds ON and 120 seconds OFF through patient's existing spinal cord stimulator.
32784015|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/360|Stimulation delivered at 30 seconds ON and 360 seconds OFF through patient's existing spinal cord stimulator.
32784016|NCT04114539|Experimental|Ecopipam|
32784017|NCT05298579|Experimental|Group A|"Yoga exercises applied by video-conference method accompanied by a physiotherapist.~Evaluations and yoga exercises will be applied to the participants in this group through the Zoom program. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes, at a time determined jointly by the physiotherapist and the participant (Table 1). Before starting the program, an informative broadcast will be made to the participants and groups of 6-8 people will be formed."
32784018|NCT05298579|Active Comparator|Group B|"Yoga exercises performed asynchronously accompanied by videos. Exercise videos will be broadcast to the participants in this group through the YouTube program. The shooting of the exercise videos will be completed in advance and uploaded to a channel opened on YouTube. All posts made in this channel will only be open to individuals participating in the research during the duration of the study. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes. Participants will be able to access the exercise videos at a time they want (Table 2). Participants will be encouraged to achieve weekly targeted training sessions and to keep an exercise diary."
32784019|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784020|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784021|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784022|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784023|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784024|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
33085347|NCT04546048|Experimental|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
33291227|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
33291228|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
33291229|NCT00206440|Experimental|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
33291230|NCT00206440|Placebo Comparator|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
33291231|NCT00268437|Experimental|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
33291232|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
33291233|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
33291234|NCT03969472|Experimental|probiotic group|apply probiotic after surgery
33291235|NCT03969472|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
33291236|NCT03969472|No Intervention|control|without electrophysiologic therapy and probiotic after surgery
33291237|NCT03972592|Experimental|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
32784025|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
33291238|NCT03972592|Placebo Comparator|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
33291239|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
33291240|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
33291241|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
33291242|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
33291243|NCT03993860|Experimental|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
33291244|NCT03993860|Placebo Comparator|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
32784026|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
32784027|NCT03301857|Experimental|Denosumab|"Cohort A (subjects who are still being treated with denosumab when 20062004 completes): 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).~For subjects undergoing retreatment with denosumab: 120 mg administered SC on Days 1, 8, 15 and 28 then every 4 weeks subsequently."
32784028|NCT03301857|No Intervention|Safety Follow up|"Subjects still receiving treatment will have follow-up study visits in the clinic every 6 months while receiving denosumab (Cohort A).~Subjects who completed denosumab treatment and were in safety follow-up at the conclusion of 20062004 will have follow-up visits performed every 6 months via telephone or in-person clinic visit (Cohort B)."
33291245|NCT03993548|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
33291246|NCT01038518||Health2010|Cross-sectional general population study
33291247|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
33291248|NCT01038596||healthy donors|age-matched healthy donors
33291249|NCT01038674|Experimental|Anti-IL-20|
32784029|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
32784030|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
33291250|NCT01038674|Placebo Comparator|Placebo|
33291251|NCT03844802|Experimental|Local dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 dry needling session a week during 3 consecutive weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
33291252|NCT03844802|Active Comparator|Distal dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in distant area from the location of active or latent myofascial trigger points of different neck-shoulder muscles. Therefore, dry needling will be applied in the same muscle but at a remote site from the locus of the myofascial trigger point, and, therefore, without evoking local twitch responses. Patients will receive 1 dry needling session a week during 3 weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
33318162|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
33318163|NCT05282576|Active Comparator|Experimental Group|We applied neurophysiological facilitation techniques in addition to conventional rehabilitation.
33318164|NCT05282576|Other|Control Group|Critical ill patients was applied their conventional physiotherapy
33085348|NCT04546048|No Intervention|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
33291253|NCT03844802|Active Comparator|Sham/placebo dry needling and exercise|"The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 placebo dry needling session a week during 3 weeks (3 sessions in total). Therefore, participants in this group will receive simulated dry needling (with sham placebo needles, that will not actually penetrate the skin) in those neck muscles with active or latent myofascial trigger points. As formerly stated, the placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.They will also undergo the neck exercise program at home during these three weeks, and for the next three months."
33085349|NCT04546165|Active Comparator|manipulation group|manipulation plus exercise
33085350|NCT04546165|Active Comparator|myofascial release group|suboccipital inhibition plus exercise
33085351|NCT04546165|Active Comparator|exercise group|only exercise
33085352|NCT04545970|Active Comparator|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
33085353|NCT04545970|Placebo Comparator|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
33291254|NCT03844802|Active Comparator|Neck Exercise|The intervention protocol will consist only a home-based neck and shoulder exercise program. Participants in this group will be also assessed for the presence of active or latent myofascial trigger points in the neck-shoulder muscles. As in the other groups, they will be advised to carry out the exercise protocol for three weeks and the following three months.
33291255|NCT00423332|Placebo Comparator|1|Cediranib placebo
33291256|NCT00423332|Experimental|2|Cediranib
33291257|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
33291258|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
33291259|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
33291260|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
33291261|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
33291262|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
33291263|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
33291264|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
33085354|NCT04545931|Experimental|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
33085355|NCT04545931|Experimental|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
33291265|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
33291266|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
33085356|NCT00261729|Experimental|1|paroxetine
33085357|NCT00261729|Placebo Comparator|2|placebo
33291267|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
33291268|NCT00423176|Experimental|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
33291269|NCT00423176|Placebo Comparator|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
33291270|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
33291271|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
33291272|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
33291273|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
33291274|NCT00412880|Experimental|BI 2536|Total Patients
33291275|NCT00384930|Placebo Comparator|1|placebo tablet
33291276|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
33291277|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
33291278|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
33291279|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
33291280|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
33291281|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
33291282|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
33291283|NCT00893516|Experimental|1|CHOP chemo therapy + CD4 therapy
33291284|NCT00893516|Active Comparator|2|CHOP chemotherapy
32784031|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
32784032|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
32784033|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
33085358|NCT00261729|Experimental|3|prazosin
33085359|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
32784034|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
32784035|NCT04699929|Experimental|Intervention/treatment|All subject will receive YH001 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
32784036|NCT04797273|Experimental|Internet-based cognitive behavior therapy|
32784037|NCT04797273|Active Comparator|Internet-based structured treatment-as-usual|
32784038|NCT05222451|Experimental|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
32784039|NCT05222451|Experimental|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
32784040|NCT05222451|Experimental|Ketogenic Diet|7 days of a ketogenic diet (KETO).
32784041|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
32784042|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
32784043|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
32784044|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
32784045|NCT04105257|Other|All patients|All patients seen at emergency with acute neurological deficit will be assessed if eligible to CTP/MRI
32784046|NCT04097769|Other|HX009|Study treatment: HX009 administered every 2 weeks (14 [±1] days) via intravenous infusion.
32784047|NCT04090125|Experimental|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
32784048|NCT04090125|Placebo Comparator|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
32784049|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
32784050|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
32784051|NCT04819893||Women giving birth prematurely|Delivery before 29 WA
32784052|NCT04819893||Women giving birth at term|Childbirth between 39WA and 31WA+6 days
32784053|NCT03253263|Experimental|OHB-607|Participants will receive continuous IV infusion of OHB-607 through from birth up to PMA 29 weeks +6 days.
32784054|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
32784055|NCT03252795|Experimental|Uterus transplantation|
32784056|NCT04797117|Other|blood sample|The blood samples for the study for each patient will be collected in the form of additional tubes.
33085360|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
33291285|NCT00750698|Experimental|1|"Erlotinib-responsive patients are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
33291286|NCT00750698|Experimental|2|"Erlotinib-nonresponsive patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
33291287|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
33291288|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
32784057|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
32784058|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
32784059|NCT05219799|Other|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
32784060|NCT05653011||Control group|Patients who are not diagnosed with inflammatory bowel disease and have colitis.
32784061|NCT05653011||TNF-alpha Inhibitor-naive IBD group|Patients who are diagnosed with inflammatory bowel disease but do not have a history of TNF-a inhibitor treatment.
32784062|NCT05653011||TNF-alpha Inhibitor-treated IBD group|Patients who are diagnosed with inflammatory bowel disease and have a history of TNF-a inhibitor treatment.
32784063|NCT03107247||Patients receiving Tc-99m MDP studies|All patients within the specified age ranges scheduled at Boston Children's Hospital for a nuclear medicine study utilizing Tc-99m MDP will be eligible to volunteer for inclusion in this study.
32784064|NCT05652777||Pregnant women|Pregnant women attending antenatal care clinic during routine community outreach activities in Lusaka, Zambia.
32784065|NCT05652699|Active Comparator|High Flow Nasal Oxygen|60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celcius.
32784066|NCT05652699|Active Comparator|Conventional Oxygen therapy|
32784067|NCT05652621|Experimental|Probiotic intervention group|"Adjuvant treatment of UC and IBS with Three-high Probiotics is given to patients three times a day, one pack of 2g, lasting for 1-4 months."
32784068|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
32784069|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
32784070|NCT05652387|Experimental|Father Inclusive Prenatal Care|Co parenting, parenting education, employment and educational readiness training and support.
32784071|NCT05652387|No Intervention|Standard Care|Participants will receive usual prenatal care services and information about community resources.
32784072|NCT05214027||Participants|This study follows a randomised crossover design. All participants will undergo a single 60-minute treadmill-based exercise intervention, and a resting period for equal duration in a randomised order.
32784073|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
32784074|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
32784075|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
32784076|NCT04808115|Experimental|KDS-1001|KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
32784077|NCT05652309||spinal anesthesia|spinal block will be performed to patients after monitoring
32784078|NCT05652309||spinal anesthesia and obturator nerve block|spinal block will be performed to patients after monitoring, and then the patients in the ONB block group will be given the appropriate position, with a USG-assisted distal approach, 5 cc %2 prilocain into the anterior and 5cc %2 prilocain into the posterior branch of the obturator nerve.
33291289|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
32784079|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
32784080|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
32784081|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
32784082|NCT04818801|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection
32784083|NCT04818801|Placebo Comparator|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection
33291290|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
33291291|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
33291292|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
33291293|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
33291294|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
33291295|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
33291296|NCT01046994|Experimental|surgery|biliopancreatic diversion
33291297|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
33291298|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
33291299|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
33291300|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
33291301|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
33291302|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
33291303|NCT01041092|Placebo Comparator|sugar pill|
33291304|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
33291305|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
33291306|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
33291307|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
33291308|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
33291309|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
33291310|NCT00422942|Experimental|1|
33291311|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
33291312|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
33291313|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
33291314|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
33291315|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
33291316|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
33291317|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
33291318|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
33291319|NCT00422084|Experimental|PA group|Pyronaridine artesunate (PA)
33291320|NCT00422084|Active Comparator|AL group|Arthemether lumefantrine (AL)
33291321|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
33291322|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
33291323|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
33291324|NCT00383292|Experimental|Tasisulam|
33085361|NCT04541758|Experimental|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
33291325|NCT01042860|Active Comparator|supplement|lutein supplement
33291326|NCT01042860|Placebo Comparator|placebo|Placebo
33291327|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
33291328|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
33291329|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
32784084|NCT05359185|Experimental|Treatment-only|Participants in the this group will receive core Relationship Education programming, which consists of six weekly 2.5-hour Family Wellness Workshops.
32784085|NCT05359185|Experimental|Treatment-Plus|Participants in this group will receive an enhanced model that includes the core RE programming, and adds economic-focused services which include two 2.5-hour workshops (one on financial planning and one on career coaching), as well as individual financial planning and career coaching services ongoing for up to one year.
32784086|NCT02980341|Experimental|Dose Escalation Part|Participants receive U3-1402 from 1.6 mg/kg to 9.6 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
33291330|NCT01045356||children less than 2 months old|
33291331|NCT01045356||children 2 months to 12 months old|
33291332|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
33291333|NCT00372060|Experimental|1|MK0431 + pioglitazone
33291334|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
33291335|NCT00421304|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) dose of placebo matched to motavizumab on Day 0 of the study.
33291336|NCT00421304|Experimental|Motavizumab 30 mg/kg|Participants will receive a single IV dose of motavizumab 30 mg/kg on Day 0 of the study.
33291337|NCT00421304|Experimental|Motavizumab 100 mg/kg|Participants will receive a single IV dose of motavizumab 100 mg/kg on Day 0 of the study.
33291338|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
33291339|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
33291340|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
33291341|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
33291342|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
32784087|NCT02980341|Experimental|Dose Finding Part|Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
32830390|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
33085362|NCT04541758|Experimental|Conservative treatment|analgesic treatment and chest strap fixation
33085363|NCT04541641|Experimental|osteotome group|
33085364|NCT04541641|Experimental|New Reverse Drilling technique|
33291343|NCT01043250||Risperidone|Receiving risperidone treatment
33291344|NCT01043250||Olanzapine|Receiving olanzapine treatment
33291345|NCT01043250||Aripiprazole|Receiving aripiprazole
33291346|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
33291347|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
33291348|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
33291349|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
33291350|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
33291351|NCT01039454|Active Comparator|Active|2 Way cross over
33291352|NCT01045512|Active Comparator|statins, standardised physical training|
33291353|NCT01045512|No Intervention|to continue with current lifestyle|
33291354|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
33291355|NCT01039532||Biphasic human insulin|Biphasic human insulin
33291356|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
33291357|NCT01045590|Placebo Comparator|glibenclamide + placebo|
33291358|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
33291359|NCT01047384|Active Comparator|Regular therapy|Regular therapy
33291360|NCT01043406|Experimental|Single Arm, Device Implant|
33291361|NCT01047462|Active Comparator|Laparoscopic lavage|
33291362|NCT01047462|Active Comparator|Primary resection|
33291363|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
33291364|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
33291365|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
33291366|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
33291367|NCT00396318|Experimental|Tenecteplase|
33291368|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
33291369|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
33291370|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
33291371|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
33291372|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
33291373|NCT00267969|Experimental|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
33291374|NCT00267969|Experimental|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
33291375|NCT00267969|Placebo Comparator|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
33291376|NCT00280293|Placebo Comparator|1|Placebo
33291377|NCT00280293|Active Comparator|2|LAmotrigine
33291378|NCT00421148|Experimental|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
33291379|NCT00421148|Experimental|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
33291380|NCT00421148|Experimental|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
33291381|NCT00421148|Experimental|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
33291382|NCT00421148|Placebo Comparator|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
33085365|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
33085366|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
32784088|NCT02980341|Experimental|Dose Expansion Part|Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
33085367|NCT00261768|Experimental|1|Noise reduction on
33085368|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
33085369|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
33085370|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
33085371|NCT04546243||osteosarcoma patients receiving resections|
33085372|NCT04546243||osteosarcoma patients receiving radiotherapy|
33085373|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
33085374|NCT02278627|No Intervention|Usual treatment|
33085375|NCT04545892|Experimental|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
33085376|NCT04541563|Experimental|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
33085377|NCT04541563|Sham Comparator|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
33085378|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
32784089|NCT05652153|Other|Longitudinal Assessments|Participants in both groups (Dep/SI and Dep/SB) will undergo identical assessments at baseline, 6 months, and 12 months. Assessments will include clinical interviews and rating scales, questionnaires (including a self-report scale of negative urgency), and single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) measurement of cortical inhibition.
33085379|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
33085380|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
33085381|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
33085382|NCT04541485|Experimental|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
33402300|NCT04914793|Experimental|Intervention phase|"Antimicrobial Prescribing guidelines mobile phone application (MicroGuide) Both paediatric and adult antimicrobial prescribing guidelines are transferred to MicroGuide; which is a medical guideline application. MicroGuide is an offline application, free-of-charge for the individual users. The app can monitor the number of users and which guidelines are being accessed. The app is installed to the personal smart phones of local physicians by the PI. Both mobile app and paper guidelines will be available in Lao languages.~Antimicrobial stewardship (AMS) training AMS training sessions are given to prescribers in participating hospitals when they firstly enter to the intervention phase. This session is given alongside an introduction of mobile phone app prescribing guideline. The training focus on good practices of antimicrobial prescription. Providing training after introducing treatment guidelines is not routine practice in many hospitals in Laos."
33402301|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
33402302|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
33402303|NCT04911673|Experimental|Music group|"Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song was composed by Juan Martin Saavedra.~In the first month, music group was filled the State Anxiety Inventory (SAI) between 10 and 20th of the menstruation that SAI consists of 20 statements that ask people to describe how they generally feel. In the second month, pain scores were measured on the first day of menstruation using a visual analogue scale (VAS) of 10 cm (0 no pain at all, and 10 the worst possible pain) and Trait Anxiety Inventory (TAI) was filled to assess the anxiety.In the third month, after the participants were listening the music in three days before menstruation and the first day of menstruation (during four days), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety."
33402304|NCT04911673|Experimental|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them. In the first month, chocolate group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation.In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety.In the third month, after the participants were eating 40 mg of dark chocolate per day in three days before menstruation and the first day of menstruation (during four days/total 160 mg), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
33402305|NCT04911673|No Intervention|Control group|Control group had no intervention. In the first month, control group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation. In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety. In the third month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
33402306|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
33402307|NCT01313377|Other|ARM B:|Observation until progression or death
33402308|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
33402309|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
33402310|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
33085383|NCT04541485|Experimental|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
33085384|NCT04541485|Experimental|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
33085385|NCT04541485|Experimental|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
32784090|NCT04793919|Active Comparator|Standard Risk (SR)|Patient with APL and WBC less than 10x10e9/L at presentation before start treatment
32784091|NCT04793919|Experimental|High Risk (HR)|Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation
32784092|NCT05356767||post-thromboticsyndrome|suffering from PTS (Villalta score) at 2 years after operation.
32784093|NCT05356767||n-post-thromboticsyndrome|none of PTS (Villalta score) at 2 years after operation.
32784094|NCT05651919||No-T2D +MS / No-HF (control group)|15 patients without T2D +MS and without Heart Failure will be included in group 1.
32784095|NCT05651919||No-T2D +MS / HFpEF or HFmrEF|15 patients without T2D+MS and presenting HFpEF or HFmrEF will be included in group 2
32784096|NCT05651919||T2D+MS / no-HF|15 patients presenting T2D +MS and without any type of HF will be included in group 3.
32784097|NCT05651919||T2D +MS / HFpEF or HFmrEF|15 patients presenting T2D +MS and HFpEF or HFmrEF will be included in group 4.
32784098|NCT05651763|Experimental|Stimulation and exercise group|30-minute exercise program (based on Pilates method) associated with active transcranial direct current stimulation.
32784099|NCT05651763|Sham Comparator|Exercise and sham stimulation group|30-minute exercise program (based on Pilates method) associated with sham transcranial direct current stimulation.
32784100|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
32784101|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
32784102|NCT02817633|Experimental|Part 1a: TSR-022 monotherapy|
32784103|NCT02817633|Experimental|Part 1b: TSR-022 in combination with nivolumab|
32784104|NCT02817633|Experimental|Part 1c: TSR-022 in combination with TSR-042|
32784105|NCT02817633|Experimental|Part 1d: TSR-022 in combination with TSR-042 and TSR-033|
32784106|NCT02817633|Experimental|Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)|
32784107|NCT02817633|Experimental|Part 1f: TSR-022 in combination with TSR-042 and Docetaxel|
32784108|NCT02817633|Experimental|Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin|
32784109|NCT02817633|Experimental|Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin|
32784110|NCT02817633|Experimental|Part 2: Cohort A Melanoma-TSR-022 as monotherapy|
32784111|NCT02817633|Experimental|Part 2: Cohort A Melanoma-TSR-022 with TSR-042|
32784112|NCT02817633|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy|
32784113|NCT02817633|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042|
32784114|NCT02817633|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy|
32784115|NCT02817633|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042|
32784116|NCT02817633|Experimental|Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042|
32784117|NCT02817633|Experimental|Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel|
32784118|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
32784119|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
32784120|NCT05651685||TDApp2|This cohort will use TDApp2: an eHealth tool that formulates participatory, individualized, explainatory and automated treatment recommendations for patients with Attention Deficit Hyperactivity Disorder
32784121|NCT05651607|Experimental|Cannabidiol (Epidyolex)|
32784122|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
32784123|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
32784124|NCT05651451|Active Comparator|Laser acupuncture group|All women in group (B) were received 24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point. Total duration of the training session was 30 minutes.Before starting the first treatment session, each woman was instructed briefly about the nature of the treatment to gain her confidence and cooperation. The surface of the treated skin was cleaned with alcohol wipe in order to remove any material that could absorb or disperse the radiationon the surface.The laser handheld device (laser beam spot size ≤ 36 mm2) was applied directly and perpendicularly to avoid scattering the beam, The Laser probe was applied to the surface of skin before switching on apparatus.
32784125|NCT05651451|Active Comparator|Diet regimen group|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
32784126|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
32784127|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
32784128|NCT05203419|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
32784129|NCT05203419|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
32784130|NCT05203419|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
32784131|NCT05203419|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
32784132|NCT05203419|Experimental|Part B: MHS552|Participants will receive MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
32784133|NCT05203419|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
32784134|NCT04791969|Experimental|Naltrexone with ecological momentary intervention|Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
32784135|NCT04791969|Placebo Comparator|Placebo with ecological momentary intervention|Placebo, intermittent with ecological momentary assessment (EMA)
32784136|NCT05651373||patients not using TNF inhibitors(TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response."
33402311|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
33402312|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
33402313|NCT03113344||Children with the usage of anti-infective drugs|
33402314|NCT02384434|Other|Single Arm|Low Level Laser Therapy
33402315|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
33402316|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
33402317|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
33402318|NCT02375230|Placebo Comparator|Control|"Control group~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
33402319|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
33402320|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
33402321|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
33402322|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
33402323|NCT02379598||Amino acid based formula|
33402324|NCT02379598||Whey protein formula|
33402325|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
33402326|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
33402327|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
33402328|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
33402329|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
33402330|NCT04723264|Experimental|Eating behavior activities|
33402331|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
33402332|NCT04715230|Experimental|IXT-m200|IXT-m200 is a high-affinity chimeric anti-METH monoclonal antibody that is well-tolerated in healthy volunteers and in non-intoxicated people with METH use disorder. The total dose will be given over 10 min for the 0.5-g dose and over 20 min for the 1-, 1.5-, and 2-g doses.
33085386|NCT04541485|Experimental|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
33402333|NCT04715230|Active Comparator|Treatment as Usual (TAU)|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.
33402334|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
33402335|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
33402336|NCT04655326|Experimental|Treatment Group|Each participant receives a customized probiotic based on the results of the test of their microbiota
33402337|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
33402338|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
33402339|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
33402340|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
33402341|NCT02375152|Experimental|Surgical Intervention|
33402342|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
33402343|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
33402344|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
33402345|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
33402346|NCT03105544|No Intervention|Control|No intervention.
33402347|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
33402348|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
33402349|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
33402350|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
33402351|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
33402352|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
32830391|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
33402353|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
33402354|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
33402355|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
33402356|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
33402357|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
33402358|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
33402359|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
33402360|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
33402361|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
33402362|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
33402363|NCT02378818|Other|Depressive patients|
33402364|NCT02378818|Other|Healthy volunteers (depression)|
33402365|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
33402366|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
33402367|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
32830392|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
33402368|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
33402369|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
33402370|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
32830393|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
32938851|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
32938852|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
32938853|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
32938854|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
33085387|NCT02214745||Mentally retarded Israeli Arab children|
33318165|NCT04478240|Experimental|Intervention (access to PeerLearning.net)|Teachers and students in intervention schools will be given access to PeerLearning.net software for the purposes of instruction for the 2021-2022 school year.
33318166|NCT04478240|No Intervention|Passive Control (no intervention)|Teachers and students in control schools will conduct instruction as usual without PeerLearning.net.
33318167|NCT01297868||exercise group|
33318168|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
33318169|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
33318170|NCT04475978|Experimental|IVUS group|
32737544|NCT05039697|Experimental|NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
32737545|NCT05039697|Placebo Comparator|Control group Inhale air placebo plus endovascular mechanical thrombectomy|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%
32737546|NCT05029245|Experimental|Sinovac 2 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
32737547|NCT05029245|Active Comparator|Sinovac 2 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
32737548|NCT05029245|Experimental|Aztrazeneca 1 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
32737549|NCT05029245|Active Comparator|Aztrazeneca 1 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
32737550|NCT05029245|Experimental|Naive vaccine followed by Comirnaty® 6 microgram Intradermal|Patients who had no history SAR-CoV vaccine before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
32737551|NCT05029245|Active Comparator|Naive vaccine followed by Comirnaty® 30 microgram Intramuscular|Patients who had no history SAR-CoV vaccine before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
32737552|NCT05029245|Experimental|Any history of vaccination with Anti-RBD< 650AU/ml followed by Comirnaty® 6 microgram Intradermal|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
32737553|NCT05029245|Active Comparator|Any history of vaccination with Anti-RBD <650AU/ml followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
32737554|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
32737555|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
32737556|NCT05050461|Active Comparator|Cases|Patients with a history of B-NHL
32737557|NCT05050461|Other|Controls|Spouses of cases
32737558|NCT05039853|Experimental|A brief cognitive task-based based intervention|Participants will engage in a brief cognitive task including: a memory reminder procedure, playing the computer game, Tetris, on a smart-device using mental rotation.
32737559|NCT05039853|Placebo Comparator|Placebo activity|Participants will engage with a placebo activity: listening to a pod-cast for approximately 15 minutes on a smart-device.
32737560|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
32737561|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
32737562|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
32737563|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
32737564|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
32737565|NCT05028543|Placebo Comparator|conventional TLH|women that will be subjected to conventional Total laparoscopic hysterectomy
32737566|NCT05028543|Experimental|TLH with prior uterine artery clipping at its origin|women that will be subjected to TLH with prior uterine artery clipping at its origin
33085388|NCT02214745||Israeli Arab children with cerebral palsy|
33085389|NCT02214745||Israeli Jewish children with cerebral palsy|
33085390|NCT02214745||Mentally retarded Israeli Jewish children|
33085391|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
33318171|NCT04475978|Placebo Comparator|Angio group|
33318172|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
33318173|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
33318174|NCT04451798|Experimental|Intervention|Impella implantation and hemodynamic measurement
33318175|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
33318176|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
33318177|NCT03211858|Experimental|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
33318178|NCT03211858|Active Comparator|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
33318179|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
33318180|NCT01202864||Cases|3000 Cases
33318181|NCT01202864||Controls|3000 Controls
33318182|NCT01206218|Active Comparator|Group A|FLOT Regimen
33318183|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
33318184|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
33318185|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
33318186|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
33318187|NCT01298180|Experimental|T|Patient Control
33318188|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
33318189|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
33318190|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
33318191|NCT01298258|Placebo Comparator|placebo|control group
33318192|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
33318193|NCT01298336|Experimental|Clarithromycin|
33318194|NCT01298336|Experimental|Moxifloxacin|
33318195|NCT01201148|Experimental|Oscillating or intermittent tDCS|
33318196|NCT04472494|Experimental|Abatacept + Standard of care|
33318197|NCT04472494|Placebo Comparator|Placebo infusion + Standard of care|
33318198|NCT04568200|Experimental|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
33318199|NCT04568200|Placebo Comparator|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
33318200|NCT04419506|Placebo Comparator|Placebo, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
33318201|NCT04419506|Experimental|BI 1015550, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
33318202|NCT04419506|Placebo Comparator|Placebo, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
33318203|NCT04419506|Experimental|BI 1015550, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
33318204|NCT05670158|Experimental|"Cochlear Implantation group"|50 patients with sensorineural hearing loss eligible for cochlear implantation surgery. The blood and perilymph sampling will be performed during surgery (visit V1). The blood sampling will be additionally done during the visits V2, V3 and V4. After the visit V4, this arm will be subdivided into 2 groups: group 1, 15 patients with the delayed residual hearing loss, and group 2,15 patients with preserved residual hearing. For these 30 patients, blood sampling will be also performed during the visit V5.
33318205|NCT05670158|Other|Control group|30 normally hearing patients who will undergo through an otological surgery other than cochlear implantation. A blood sampling will be performed during surgery (visit V1) as well as during the visits V2 and V3.
33318206|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
33318207|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
33402371|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
33402372|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
33402373|NCT04842448|Experimental|Hyperbaric oxygen treatment|HBO2 240 kPa, 90 min, maximum 10 treatments
33402374|NCT04842448|Placebo Comparator|Sham treatment|Air 134-120 kPa, 90 min, maximum 10 treatments
33402375|NCT01411267|Experimental|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
33402376|NCT01411267|Experimental|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
33402377|NCT01411267|Experimental|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
33402378|NCT01411267|Experimental|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
33402379|NCT01411267|Experimental|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
33402380|NCT01411267|Experimental|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
33402381|NCT01411267|Experimental|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
33402382|NCT01411267|Experimental|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
33402383|NCT01411267|Experimental|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
33402384|NCT01411267|Experimental|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
33402385|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
33402386|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
33402387|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
33402388|NCT04828486|Experimental|Treatment (futibatinib, pembrolizumab)|Patients receive futibatinib PO QD on days 1-21 for cycles 1-9, and days 1-42 for subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-9 and every 42 days for subsequent cycles for up to 2 years in the absence of disease progression or unacceptable toxicity.
33402389|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
33402390|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
33402391|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
33402392|NCT04805788|Experimental|Treatment (SBPT)|Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
33402393|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
33402394|NCT02383888|Experimental|BI 425809 Active dose group 1|
33402395|NCT02383888|Experimental|BI 425809 Active dose group 2|
33402396|NCT02383888|Experimental|Bi 425809 Active dose group 3|
33402397|NCT04664569||Cohort of bacterial meningitis in children|
33402398|NCT02378194|Placebo Comparator|Placebo group|
33402399|NCT02378194|Experimental|HD-003 (800mg/day)|
33402400|NCT02378194|Experimental|HD-003 (1600mg/day)|
33402401|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
33402402|NCT04628338|Experimental|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
33402403|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
33402404|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
33402405|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
33402406|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
32784137|NCT05651373||patients using TNF inhibitor (TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response.~Drug: TNFi ,such as Certolizumab Pegol (Cimzia)，200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response."
32784138|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
33402407|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
33402408|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
33402409|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
33402410|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
33402411|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
32784139|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
33402412|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
33402413|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
33402414|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
33402415|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
33085392|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
33085393|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
33402416|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
33402417|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
33402418|NCT02373748|Experimental|BioGaming YuGo System|
32784140|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
33402419|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
33402420|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
33402421|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
33402422|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
33402423|NCT03105232||Group B|Buprenorfin
33402424|NCT03105232||Group C|Fentanyl
33402425|NCT03105232||Group D|Opioid rotation
33402426|NCT03130959|Experimental|Module A|
33402427|NCT03130959|Experimental|Module B|
33402428|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
33402429|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
33402430|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
33402431|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
33402432|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
33402433|NCT04553692|Experimental|Ph1a: IGM-8444 Single Agent Alternate Dosing Escalation|IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.
33402434|NCT04553692|Experimental|Ph1a: IGM-8444 + FOLFIRI ± bevacizumab Escalation and Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI.
33402435|NCT04553692|Experimental|Ph1a: IGM-8444 + Birinapant Escalation and Expansion|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
33402436|NCT04553692|Experimental|Ph1a: IGM-8444 + Venetoclax Escalation and Expansion|IGM-8444 will be administered intravenously in combination with Venetoclax.
32784141|NCT05198583|Experimental|Intervention|The intervention group will have a play-based intervention, including online games, analogue card games as well as a weekly coaching session to enhance executive functions.
32784142|NCT05198583|No Intervention|Control|The control group does not receive any intervention.
32784143|NCT05605119|Experimental|AUR105 50mg to 750mg|Currently planned dose levels in Part 1 are 50mg, 100mg, 200mg, 300mg, 450mg, 600mg and 740mg once daily
32784144|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
32784145|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
32830394|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
33085394|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
33085395|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
33085396|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
33085397|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
33402437|NCT04553692|Experimental|Ph1a: IGM-8444 + Docetaxel + Gemcitabine Escalation and Expansion|IGM-8444 will be administered intravenously in combination with Docetaxel and Gemcitabine.
33402438|NCT04553692|Experimental|Ph1a: IGM-8444 + Venetoclax + Azacitidine Escalation and Expansion|IGM-8444 will be administered intravenously in combination with Venetoclax and Azacitidine.
33085398|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
32938855|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
33402439|NCT04553692|Experimental|Ph1b: IGM-8444 + FOLFIRI ± Bevacizumab|IGM-8444 will be administered intravenously in combination with FOLFIRI ± bevacizumab
33402440|NCT04553692|Experimental|Ph1b: FOLFIRI ± Bevacizumab|Standard of Care FOLFIRI ± bevacizumab will be administered intravenously
33402441|NCT04525222|Experimental|Arm I (Actify, text messages)|Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
33402442|NCT04525222|Active Comparator|Arm II (Current Standard Care, text messages)|Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
33402443|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
33402444|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
33402445|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
33402446|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
33402447|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
33402448|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
33402449|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
33402450|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
33402451|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
33402452|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
33402453|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
33402454|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
33402455|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
33402456|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
33402457|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
33402458|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
33402459|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
33402460|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
33402461|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
33402462|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
33402463|NCT01367925||Cruciate Substituting Tibial Insert|
33402464|NCT01367925||Posterior Stabilized Tibial Insert|
33402465|NCT01370187|No Intervention|Control|Control group
32938856|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
32938857|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
33085399|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
33085400|NCT04541134|Other|Group 1|
33085401|NCT04541134|Other|Group 2|
33085402|NCT04541368|Experimental|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
33085403|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
33085404|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
33085405|NCT04545463|Active Comparator|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
33402466|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
32737567|NCT05464745|Experimental|PERINDOPRES® DUO (Test)|A single oral dose of the test product PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets.
32737568|NCT05464745|Active Comparator|Noliterax® 10 mg/2.5 mg (Reference)|A single oral dose of the reference product Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets.
32737569|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
32737570|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
33085406|NCT04545463|Active Comparator|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
33085407|NCT04545463|Experimental|FIBRACEP|Cookies with FIBRACEP
33085408|NCT04545697|Experimental|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
33085409|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
33085410|NCT02214901|Placebo Comparator|Placebo|
33085411|NCT04541251|Experimental|Camrelizumab + Nab-paclitaxel + Carboplatin|
33085412|NCT04540783|Active Comparator|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
33085413|NCT04540783|Active Comparator|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
33085414|NCT04540783|Sham Comparator|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
32737571|NCT03330977|Other|Before and after use of compression garments|"At inclusion, patients will only have medication prescription as usual but without compression garments, and thus, for 4 months.~4 months after inclusion, patients will continue medication but will also be prescribed compression garments Then every 6 months, until 26 months, patients will come back to have new compression garments (as usual practice)"
32737572|NCT05028231||Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|
32737573|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
32737574|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
32737575|NCT05050071|Active Comparator|Calcium hydroxide (7 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
32737576|NCT05050071|Experimental|Allium sativum (7 days)|is a species of bulbous flowering plant in the onion genus Allium
32737577|NCT05050071|Experimental|Combination (7 days)|combination between Calcium hydroxide and Allium sativum
32737578|NCT05050071|Active Comparator|Calcium hydroxide (14 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
32737579|NCT05050071|Experimental|Allium sativum (14 days)|is a species of bulbous flowering plant in the onion genus Allium
32737580|NCT05050071|Experimental|Combination (14 days)|combination between Calcium hydroxide and Allium sativum
32737581|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
32737582|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
32737583|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
32737584|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
32737585|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
32737586|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
32737587|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
33402467|NCT04483960|No Intervention|Antiviral - Standard of care|Standard of care without nafamostat mesilate
33402468|NCT04483960|Experimental|Antiviral - nafamostat mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
33402469|NCT04483960|Active Comparator|(Arm Closed) Anticoagulation - standard dose thromboprophylaxis|Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site.
33402470|NCT04483960|Experimental|(Arm Closed) Anticoagulation - intermediate dose thromboprophylaxis|Patients will be administered an intermediate dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.
33318208|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
33318209|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
33402471|NCT04483960|Experimental|(Arm Closed) Anticoagulation - therapeutic anticoagulation|Therapeutic anticoagulation administered with LMWH daily until hospital discharge, admission to ICU or for a maximum of 28 days from randomisation. Choice of LMWH according to availability and local practice at the participating site
33402472|NCT04483960|No Intervention|(Arm Closed) Antibody - Standard of Care|No hyperimmune globulin
33402473|NCT04483960|Experimental|(Arm Closed) Antibody - hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation
33402474|NCT01370343|Experimental|PF-04991532 alone|
33402475|NCT01370343|Experimental|PF-04991532 + cyclosporine|
33402476|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
33402477|NCT01368003|Experimental|STA9090|STA9090
33402478|NCT01364571|Experimental|1|SA4Ag vaccine low dose
33402479|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
33402480|NCT01364571|Experimental|3|SA4Ag vaccine high dose
33402481|NCT01364571|Placebo Comparator|4|Placebo
33402482|NCT04469296|No Intervention|control arm|In the control arm, patients will continue their usual diet without further recommendation.
33402483|NCT04469296|Experimental|"specific diet arm Ketogenic arm"|In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
33402484|NCT04469296|Experimental|"specofoc diet arm protein restricted diet"|"In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.~Each diet will be respected by the patient during 9 days +/- 1 day."
33402485|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
33402486|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
33402487|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
33402488|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
32900575|NCT05366868|Active Comparator|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
33318210|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
33318211|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
33318212|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
33318213|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
33318214|NCT04933708|Experimental|Labor Podcast Group|"1) Labor Podcast Group - Women randomized to this arm will receive access to a link to download six HUP physician created labor podcasts in addition to usual care during labor, delivery, and postpartum~o Podcast topics: Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth~LAS-10 and Birth Satisfaction survey - Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS - Women will receive this survey on postpartum day 7 via method they desire"
33402489|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
33402490|NCT04223583|Experimental|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
33402491|NCT04222257|Experimental|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
33402492|NCT04222257|Active Comparator|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
33402493|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
33402494|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
33402495|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
33402496|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
33402497|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
33402498|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
33402499|NCT04981275||Women with PCOS|Women previously diagnosed with PCOS not using hormonal therapy and without other significant health or endocrine issues
33402500|NCT04981275||Healthy controls|Women self-identifying as generally healthy, not using hormonal therapy, and without any significant health or endocrine issues
33402501|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~hysteroscopic repair of cesarean section defect~IVF cycle"
33402502|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
33402503|NCT01370811|Placebo Comparator|OC oral solution treatment D|Placebo
33402504|NCT01370811|Experimental|OC oral solution treatment C|High dose oxybutynin and clonidine
33402505|NCT01370811|Experimental|OC oral solution treatment A|Low dose oxybutynin and clonidine
33402506|NCT01370811|Experimental|OC oral solution treatment B|Intermediate dose oxybutynin and clonidine
33402507|NCT03933904|Experimental|Sirolimus|Oral sirolimus: For adults, loading dose of 5 mg/m^2, rounded to the nearest mg, on day 1. For adults, starting on day 2, oral sirolimus daily at 2.5 mg/m^2/day (rounded to the nearest mg), target trough level 10-15 ng/mL by HPLC, for 12 months. For children, 2 mg/m^2/day, target trough level 5-15 ng/mL by HPLC.
33402508|NCT04961697|Experimental|PICU with diaries|"The main family member of a critically ill child will receive a diary upon PICU admission.~Except for the diaries intervention, this group of patients will be submitted to usual PICU routine care."
33402509|NCT04961697|No Intervention|PICU without diaries|This group of critically ill patients and family members will not receive diaries, but will also be submitted to usual PICU routine care.
33402510|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
33402511|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
33402512|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
33402513|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
33402514|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
33402515|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
33402516|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
33402517|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
33402518|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
33402519|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
32900576|NCT05366868|Active Comparator|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
32900577|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
33085415|NCT04545034|Experimental|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
33085416|NCT04545034|No Intervention|Control Group|No exercise intervention would be used.
33085417|NCT04540666|Experimental|VR group|VR program will be displayed throughout the surgery.
33085418|NCT04540666|Placebo Comparator|Non-VR group|VR program will be turned off throughout the surgery.
32784146|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
33085419|NCT04540549|Experimental|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
33085420|NCT04540549|No Intervention|control group|The control group was encouraged to maintain their lifestyle.
33085421|NCT04545073||Post-refractive trifocal IOL|
33085422|NCT04545307|Experimental|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
33085423|NCT04545190|Active Comparator|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
33291383|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
33291384|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
33291385|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
33318215|NCT04933708|No Intervention|Usual Care|"2. Usual care Women randomized to this arm will receive usual care during labor, delivery, and postpartum with the following exceptions:~LAS-10 and Birth Satisfaction survey Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS Women will receive this survey on postpartum day 7 via method they desire"
33318216|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
33318217|NCT01201382|Active Comparator|Group Counseling|Group Counseling
33402520|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
33402521|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
33402522|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
33402523|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
33402524|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
33402525|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
33402526|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
33402527|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
33402528|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
33402529|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
33402530|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
33402531|NCT01368237||Patients|Patients awaiting invasive coronary angiography
33402532|NCT04382404|Experimental|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
33402533|NCT01368315|Experimental|CT327|Cream
33402534|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
33402535|NCT01368315|Active Comparator|Active comparator|Cream
33402536|NCT01368315|No Intervention|No intervention|
33402537|NCT02371096|Experimental|RGB-03|
33402538|NCT02371096|Active Comparator|MabThera (rituximab)|
33402539|NCT04420455|Experimental|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
33402540|NCT04381936|No Intervention|Standard Care|Patient receives usual hospital care
33402541|NCT04381936|Active Comparator|Low dose corticosteroids|"First (main) randomisation part A~[This arm is now closed to recruitment]"
33402542|NCT04381936|Active Comparator|Hydroxychloroquine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
33402543|NCT04381936|Active Comparator|Lopinavir-Ritonavir|"First (main) randomisation part A~[This arm is now closed to recruitment]"
33402544|NCT04381936|Active Comparator|Azithromycin|"First (main) randomisation part A~[This arm is now closed to recruitment]"
33402545|NCT04381936|Active Comparator|Convalescent plasma|"First (main) randomisation part B~[This arm is now closed to recruitment]"
33402546|NCT04381936|Active Comparator|Tocilizumab|"Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
33402547|NCT04381936|Active Comparator|Intravenous Immunoglobulin|"First (main) randomisation part A (children only)~[This arm is now closed to recruitment]"
33402548|NCT04381936|Active Comparator|Synthetic neutralising antibodies|"First (main) randomisation part B.~[This arm is now closed to recruitment]"
33402549|NCT04381936|Active Comparator|Aspirin|"First (main) randomisation part C~[This arm is now closed to recruitment]"
33402550|NCT04381936|Active Comparator|Colchicine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
33402551|NCT04381936|Active Comparator|Baricitinib|"First (main) randomisation part D~[This arm is now closed to recruitment]"
33402552|NCT04381936|Active Comparator|Anakinra|"Randomisation for children only with PIMS-TS~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
33402553|NCT04381936|Active Comparator|Dimethyl fumarate|"First (main) randomisation part A (UK adults only; early phase assessment)~[This arm is now closed to recruitment]"
33402554|NCT04381936|Active Comparator|High Dose Corticosteroids|First (main) randomisation part E
33402555|NCT04381936|Active Comparator|Empagliflozin|First (main) randomisation part F
33402556|NCT04381936|Active Comparator|Sotrovimab|First (main) randomisation part J
33402557|NCT04381936|Active Comparator|Molnupiravir|First (main) randomisation part K
33402558|NCT04381936|Active Comparator|Paxlovid|First (main) randomisation part L
33402559|NCT01368393|Experimental|Electroacupuncture|
33402560|NCT01368393|Active Comparator|Sham acupuncture|
33402561|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
33402562|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
33402563|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
33402564|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
33402565|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
33402566|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
33402567|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
33402568|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
32784147|NCT05582187|Experimental|Cohort 1: Fosmanogepix participants with mild hepatic impairment|Participants with mild hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
32784148|NCT05582187|Experimental|Cohort 2: Fosmanogepix Participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
32784149|NCT05582187|Experimental|Cohort 3: Fosmanogepix Participants with severe hepatic impairment|Participants with severe hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
32784150|NCT04804059|Experimental|Cohort A|[14C]-APX001 Oral Solution
32784151|NCT04804059|Experimental|Cohort B|[14C]-APX001 Solution for Infusion
32784152|NCT05561829|Experimental|Sleep Hygiene|Administration of sleep hygiene education (single intervention)
32784153|NCT05561829|Experimental|Cognitive Therapy|Administration of cognitive therapy only (single intervention)
32784154|NCT05561829|Experimental|Relaxation Training|Administration of relaxation training only (single intervention)
32784155|NCT05561829|Experimental|Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of relaxation training, cognitive therapy, and sleep hygiene education (3 interventions)
32784156|NCT05561829|Experimental|Stimulus Control|Administration of stimulus control therapy only (single intervention)
32784157|NCT05561829|Experimental|Stimulus Control, Cognitive Therapy, Sleep Hygiene|Administration of stimulus control therapy, cognitive therapy, and sleep hygiene education (3 interventions)
32784158|NCT05561829|Experimental|Stimulus Control, Relaxation Training, Sleep Hygiene|Administration of stimulus control therapy, relaxation training, and sleep hygiene education (3 interventions)
32784159|NCT05561829|Experimental|Stimulus Control, Relaxation Training, Cognitive Therapy|Administration of stimulus control therapy, relaxation training, and cognitive therapy (3 interventions)
32784160|NCT05561829|Experimental|Sleep Optimization|Administration of sleep optimization only (single intervention)
32784161|NCT05561829|Experimental|Sleep Optimization, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, cognitive therapy, and sleep hygiene education (3 interventions)
32784162|NCT05561829|Experimental|Sleep Optimization, Relaxation Training, Sleep Hygiene|Administration of sleep optimization, relaxation training, and sleep hygiene education (3 interventions)
32784163|NCT05561829|Experimental|Sleep Optimization, Relaxation Training, Cognitive Therapy|Administration of sleep optimization, relaxation training, and cognitive therapy (3 interventions)
32784164|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, and sleep hygiene education (3 interventions)
32784165|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Cognitive Therapy|Administration of sleep optimization, stimulus control therapy, and cognitive therapy (3 interventions)
32784166|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Relaxation Training|Administration of sleep optimization, stimulus control therapy, and relaxation training (3 interventions)
33102368|NCT04805112|Experimental|Provision of multiple self-tests|Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s). The participant will be instructed to encourage their partner to test himself alone [partner testing] or with the participant [couple testing]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
33318218|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
33402569|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
33402570|NCT01370967||Study formula-fed only|
33402571|NCT01370967||Human milk-fed only|
33402572|NCT01370967||Mixed-fed using study formula only|
32784167|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, relaxation training, cognitive therapy, and sleep hygiene education (5 interventions)
32784168|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg BID in combination with ritonavir 100 mg BID and escalating to lonafarnib 75 mg BID and then 100 mg BID as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
32784169|NCT05475171|Experimental|MGD019|Participants will receive MGD019 by vein over about 30 minutes on Day 1 of each cycle
32784170|NCT04803201|Experimental|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32784171|NCT04803201|Experimental|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32784172|NCT04803201|Active Comparator|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32784175|NCT03853473|No Intervention|Standard of Care|Study participants will receive standard of care.
32784176|NCT03853473|Experimental|Remote Ischemic Preconditioning|Study participants will perform remote ischemic preconditioning daily, at home, from study enrollment to their date of surgery.
32784177|NCT03846765|Experimental|Phenylephrine continuous infusion|
32784178|NCT03846765|Experimental|Dobutamine continuous infusion|
32784179|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
32784180|NCT02482467|Other|controls|No prenatal diagnosis of cyst
32784181|NCT05474469|Experimental|Diaphragmatic breathing in combination with abdominal muscle strengthening exercises|Exprimental Group ( Group A) will receive diaphragmatic breathing in combination with abdominal muscle strengthening exercises .12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
32784182|NCT05474469|Active Comparator|Diaphragmatic breathing Exercises only without abdominal muscle strengthening exercises|Active comparator (Group B) will receive diaphragmatic breathing only. 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
32784183|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
32784184|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
32784185|NCT05444361|Active Comparator|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
32784186|NCT05444361|Sham Comparator|Sham Procedure|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
32784187|NCT02325531|Other|Low support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~EHR-based toolkit Basic webinar"
32784188|NCT02325531|Other|Medium support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low support arm, PLUS Staff training Adaptive webinars"
32784189|NCT02325531|Other|High support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low and medium support arms, PLUS Practice facilitation"
32784190|NCT02325531|Other|Comparison|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR."
32784191|NCT03822897|Other|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
32784192|NCT04789551||Multiple Sclerosis Stable Conditions|Multiple sclerosis patients presenting for a routine clinic visit.
32784193|NCT04789551||Multiple Sclerosis Acute Flare Up|Multiple sclerosis patients admitted to the hospital with acute symptoms.
32784194|NCT04789551||Control patients|Patients without any immunological diseases who present for elective surgery.
32784195|NCT04788069|Active Comparator|Wholemeal bread|Treatment with wholemeal bread
32784196|NCT04788069|Active Comparator|Sourdough bread|Treatment with sourdough bread
32784197|NCT04788069|Active Comparator|Bread with sourdough|Treatment with bread with sourdough
32784198|NCT05366985|Experimental|Socket shield with guided root sectioning|Tooth extraction and immediate implant placement using the socket shield technique with computer guided sectioning of the root.
32784199|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
32784200|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
32784201|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
32784202|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
32784203|NCT05393895|Experimental|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
32784204|NCT05393895|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
32784205|NCT04801953|Active Comparator|Nimodipine|During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII
33318219|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
32784206|NCT04801953|Placebo Comparator|Placebo|During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII
32784207|NCT05365737|Placebo Comparator|placebo oral rinse|Placebo comparator Volume Time Active molecule 15 mL 1 min No
32784208|NCT05365737|Active Comparator|CPC oral rinse|Volume Time Active molecule 15 mL 1 min CPC containing oral rinse
33318220|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
32784209|NCT05365737|Active Comparator|Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min Cymenol containing oral rinse
32784210|NCT05365737|Active Comparator|CPC + Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min CPC+cymenol containing oral rinse
32784211|NCT05355831|Active Comparator|Active Transcranial Direct Current Stimulation|Anodal TDCS 1mV for 2x 20 minutes.
33402573|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
33402574|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
33402575|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
33402576|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
33402577|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
33402578|NCT01364961|Placebo Comparator|Cellulose capsules|
33402579|NCT01364961|Experimental|Resveratrol capsules|
33402580|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
33402581|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
33402582|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
33402583|NCT01371045||Healthy Controls|
33402584|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
33402585|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
33402586|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
33402587|NCT04945083|Experimental|Experimental Nutritional Pudding|2 servings per day
33402588|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
33402589|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
33402590|NCT02929407|Experimental|FE 204205|
33402591|NCT02929407|Placebo Comparator|Placebo|
33402592|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
33402593|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
33402594|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
33402595|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
33402596|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
33402597|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
32784212|NCT05355831|Sham Comparator|Sham stimulation|2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).
32784213|NCT04787679||Osteoporotic patients|Osteoporotic patients, age > 18 years old
33085424|NCT04545190|Placebo Comparator|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
32784214|NCT04787679||Non osteoporotic patients|Non osteoporotic patients, age > 18 years old
32784215|NCT05190705|Experimental|Loncastuximab Tesirine + Dexamethasone|"Participants will be given~Loncastuximab Tesirine on Day 1 of every 28 day study cycle and continue for up to 6 cycles.~Participants will also receive pre-medications to reduce the chance of having a sensitivity reaction to the study treatment. Participants who tolerate the study treatment without a reaction may have pre-medications changed per determination of their doctor.~Dexamethasone will be given prior to study treatment on Day -1 or up to 2 hours prior to loncastuximab tesirine and the day after treatment"
32784216|NCT04787367|Experimental|Early-operative TAP block|The TAP block will be administered after the placement of the camera port.
32784217|NCT04787367|Experimental|Late-operative TAP block|The TAP block will be administered at the completion of the case just before removing the camera port.
32784218|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
32784219|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
32784220|NCT03797157|Experimental|H2MF|Human milk-based breast milk fortifier
32784221|NCT03797157|Active Comparator|Standard fortifier|Standard care: bovine milk-based breast milk fortifier
32784222|NCT03776643|Experimental|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
32784223|NCT03776643|Placebo Comparator|placebo|Subcutaneous injections of placebo
32784224|NCT02039739||Orsiro™ Drug Eluting Stent|
32784225|NCT05210049|Other|Patients undergoing routine screening via upper endoscopy (EGD)|All enrolled patients will complete upper endoscopy for screening for Barrett's esophagus and esophageal adenocarcinoma.
32784226|NCT05363163|Experimental|Gana X|Participants will receive Gana X in both buttocks
32784227|NCT05201469|Experimental|VIB4920|"Participants will receive VIB4920 1500 mg intravenously at Weeks 10, 12, 14, 18, 22, 26, 30, and 34.~Participants will receive induction therapy with Mycophenolate Mofetil (MMF) beginning at Week 0. The target dose is 2 to 3 g/d and must be reached by Week 4. MMF administration will continue at the target dose through Week 60.~Participants will also receive prednisone 25 mg per day beginning at day 0 or on the day after completion of methylprednisolone"
33085425|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
33085426|NCT04544878||Adult patients|All patients >18 years of age
33085427|NCT04545268|Sham Comparator|Control group|
33085428|NCT04545268|Experimental|NMES group|
33085429|NCT04544644|Experimental|treatment arm|AK104+anlotinib
32784228|NCT05201469|Placebo Comparator|VIB4920 Placebo|"Participants will receive VIB4920 placebo intravenously at Weeks 10, 12, 14, 18, 22, 26, 30, and 34.~Participants will receive induction therapy with MMF beginning at Week 0. The target dose is 2 to 3 g/d and must be reached by Week 4. MMF administration will continue at the target dose through Week 60. Participants will receive a total of 1000 mg of methylprednisolone at Day 0 or Day 1~Participants will also receive prednisone 25 mg per day beginning at day 0 or on the day after completion of methylprednisolone."
32784229|NCT05180097|Active Comparator|GDP|
32784230|NCT05180097|Active Comparator|Brentuximab vedotin + Pembrolizumab|
32784231|NCT03766113|Other|Healthy volunteer|"50 subjects~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
32784232|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects~Effectiveness of an electroencephalogram-neurofeedback"
32784233|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
33085430|NCT04540627|Placebo Comparator|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
33085431|NCT04540627|Active Comparator|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
33085432|NCT04540393|Experimental|Arm A|Single arm
33085433|NCT04544722|Experimental|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
33085434|NCT04544722|Active Comparator|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
33085435|NCT04544566|Experimental|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
32784234|NCT04785339|Experimental|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
32784235|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
32784236|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
32784237|NCT04418505|No Intervention|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
32784238|NCT04418505|Experimental|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
32784239|NCT05186259|Active Comparator|Patients with chronic tinnitus|Patients with chronic subjective tinnitus (> 3 months)
32784240|NCT05186259|Active Comparator|Patients with chronic idiopathic neck pain|Patients with chronic idiopathic neck pain (> 3 months)
32784241|NCT05186259|Active Comparator|Patients with chronic tinnitus and chronic musculoskeletal pain|Patients with chronic tinnitus and chronic musculoskeletal pain (> 3 months)
32784242|NCT05186259|Active Comparator|Healthy controls|Healthy controls without tinnitus or pain complaints
32784243|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
32784244|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
32784245|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
32784246|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
32784247|NCT01635153|Placebo Comparator|Micronutrient alone|
32784248|NCT05164341|Active Comparator|metreleptin|Metreleptin [Recombinant-methionyl human Leptin; r-metHuLeptin] for daily injection is a sterile, white, solid lyophilised cake
32784249|NCT05164341|Placebo Comparator|placebo|Placebo for daily injection is a sterile, white, solid lyophilised cake
32784250|NCT05269875|Other|Advance care planning in heart failure patients|The patient and their closest relative will be offered a palliative care intervention by the Department of Cardiology.
32784251|NCT05132127|Experimental|sutimlimab|Participants in Japan with CAD who have completed CARDINAL or CADENZA studies will receive sutimlimab (BIVV009). The dosing schedule consists of an initial dose (Day 0), followed by a dose one week later (Day 7), which is followed by a maintenance dose every other week beginning on Day 21.
32784252|NCT05172921||Exposed|High exposure to environmental pollutants
32784253|NCT05172921||Non-exposed|Low exposure to environmental pollutants
32784254|NCT04446039||1. Escitalopram Cohort|
32784255|NCT04446039||2. Paroxetine Cohort|
32784256|NCT04446039||3. Fluoxetine Cohort|
32784257|NCT04446039||4. Mirtazapine Cohort|
32784258|NCT04446039||5. Duloxetine Cohort|
32784259|NCT04446039||6. Sertraline Cohort|
32784260|NCT04446039||7. Venlafaxine Cohort|
32784261|NCT04446039||8. Tianeptine Cohort|
32784262|NCT04446039||9. Vortioxetine Cohort|
32784263|NCT04446039||10. Desvenlafaxine Cohort|
32784264|NCT04446039||11. Bupropion Cohort|
32784265|NCT05087979|Experimental|Intervention|An investigational device will be used to hold patient's head and airway in a stable position.
32784266|NCT05087979|No Intervention|Standard of care|Pillows and towels will be used to hold patient's head and airway in a stable position.
32784267|NCT03677427|Experimental|5 fractions|
32784268|NCT03677427|Experimental|15 fractions|
32784269|NCT05086419|Experimental|Exercise group|The exercise group will in addition to treatment as usual, receive sub-symptom threshold aerobic exercise for approx. 30 minutes 3-5x / week for 12 weeks. Sub-symptom threshold aerobic exercise is based on the individual patient's symptom threshold and will be between 80-90% of the maximum heart rate achieved during testing/BCTT. To ensure proper exercise dosage and progression, participants will be retested every 3 weeks. An experienced doctor and / or physiotherapist will carry out the testing and guide the participants in the content and dosage (duration, intensity, and frequency) of the sub-symptom threshold aerobic exercise/intervention.
32784270|NCT05086419|No Intervention|Treatment as usual group|"The treatment as usual group will receive assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive and mental health and functioning, followed by individually adapted rehabilitation. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, neuropsychologist, occupational therapist, physiotherapist, and social worker. The main focus is on stabilizing the level of function in everyday life and gradual return to work and education.~Participants receive general advice on physical activity based on recommendations from the Norwegian Directorate of Health, but not specific guidance in sub-symptom threshold aerobic exercise and help with exercise dosage (frequency, duration and intensity)."
32784271|NCT04192773|Experimental|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia <50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
32784272|NCT05036967||Heart Failure (HF) patients|Patients diagnosed with incident HF, in an outpatient setting in Colombia during the time period of 01 JUN 2019 to 31 MAY 2020
32784273|NCT05171205|Experimental|Spinal cord stimulation(SCS) implantation|"Phase I:~C2-4 is selected as the puncture location. Percutaneous puncture is performed under X-ray guidance. One or two electrodes are placed in the patient's epidural cavity, and the electrode position is adjusted intraoperatively by the patient's feedback of the current stimulation position until the current can cover the entire area.~An extension lead is connected, an external temporary stimulator is attached, and the patient decides whether to proceed to full implantation in phase II after 7-10 days of phase I testing experience.~Phase II:~The complete SCS system is implanted under local anesthesia or epidural anesthesia after successful testing. A subcutaneous capsular bag is usually created in the lower abdomen and the implanted electrodes are connected to the pulse generator through a connecting wire in the subcutaneous tunnel."
32784274|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
32784275|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
33402598|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
33402599|NCT01371123||On long-term PN|
33402600|NCT01371123||Never been on TPN|
33402601|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
33402602|NCT02365168|Experimental|Food Challenge with cod|
33402603|NCT02365168|Experimental|Food Challenge with salmon|
33402604|NCT02365168|Experimental|Food Challenge with mackerel|
33402605|NCT02365168|Placebo Comparator|Food Challenge with placebo|
33402606|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
32900578|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
32737588|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
32737589|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
32737590|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
32737591|NCT05038995||Cow milk elimination group|The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
32737592|NCT05038995||Healthy group|Healthy children will ve eligible for the study if they (1) did not have CMA and other allergic diseases (2) who had never been on a diet throughout their lives.
32737593|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
32737594|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
32737595|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
32737596|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
32737597|NCT02493101||Control|Healthy controls
32737598|NCT05049915|Experimental|Masquelet technique: bioactive glass|
32737599|NCT05049915|Active Comparator|Masquelet technique: RIA + TCP|
32737600|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
32737601|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
32737602|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
32737603|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
32737604|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
32737605|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
32737606|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
32737607|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
32737608|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
32737609|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
32737610|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
33402607|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
33402608|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
33402609|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
33402610|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
33402611|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
33402612|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
32784276|NCT04784247|Experimental|Leiomyosarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
33402613|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
33402614|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
33402615|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
33402616|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
33402617|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
33402618|NCT02364856||Children with cerebral palsy|
32938858|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
33402619|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
33402620|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
33402621|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
33402622|NCT03123939|Experimental|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
33402623|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
33402624|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~Placebo, intravenous."
33402625|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~Placebo, intranasal."
32938859|NCT04123093|Experimental|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
32938860|NCT04123093|Experimental|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
32938861|NCT02218008|Experimental|High Dose|
32938862|NCT02218008|Experimental|Low Dose|
32938863|NCT02218008|Placebo Comparator|Placebo|
32938864|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
32938865|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
32938866|NCT03216902|Experimental|Low dose 0.001% DE-126|
32938867|NCT03216902|Experimental|Medium dose 0.002% DE-126|
32938868|NCT03216902|Experimental|High dose 0.003% DE-126|
32938869|NCT03216902|Active Comparator|0.005% Latanoprost|
32938870|NCT03190213|Experimental|Pembrolizumab, all patients|
32938871|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
32938872|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
32938873|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
32938874|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
32938875|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
32938876|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
32938877|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
32938878|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
32938879|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
33402626|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
33402627|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
33402628|NCT01368705|Active Comparator|Control Group|
33402629|NCT01368705|Experimental|Intervention Group 1|
33402630|NCT01368705|Experimental|Intervention Group 2|
33402631|NCT04116645||Group 1|singleton pregnancies
33402632|NCT04116645||Group 2|Twin pregnancies
33402633|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
33402634|NCT01368783|Experimental|Atazanavir and Tenofovir|
33402635|NCT01368783|Experimental|Atazanavir and Ritonavir|
33402636|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
33402637|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
33402638|NCT01368861||control|water and normal physical comfort provided by mom
33402639|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
33402640|NCT01368861||physical intervention|physical intervention using the 5 S's and water
33402641|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
33402642|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
33402643|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
33402644|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
33402645|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
33402646|NCT01365117|Experimental|Cohort 1|
33402647|NCT01365117|Experimental|Cohort 2|
33402648|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
33402649|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
33402650|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
33402651|NCT02372500|No Intervention|Control|Normal post operative care
33402652|NCT03840447|Experimental|Chronic Disease Self-Management programme|
33402653|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
33402654|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
33402655|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
33402656|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
33402657|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
33402658|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
33402659|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
33402660|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
33402661|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
33402662|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
33402663|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
33402664|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
33402665|NCT01369251|Experimental|Hygiene with water and soap|
33402666|NCT01369251|Active Comparator|Usual alcohol care|
33402667|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
33402668|NCT02660944|Placebo Comparator|Placebo|Saline placebo
33402669|NCT01365351||Growth hormone|Children with growth hormone deficiency
33402670|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
33402671|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
33402672|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
33402673|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
33402674|NCT04562896|No Intervention|No Device|Participants will be evaluated without a CDO.
33402675|NCT04562896|Experimental|CDO-A|The first design variant will be designated CDO-A
33402676|NCT04562896|Experimental|CDO-B|The second design variant will be designated CDO-B
33402677|NCT04562896|Experimental|CDO-C|The third design variant will be designated CDO-C
33402678|NCT04894071|Experimental|QA102 group|
33402679|NCT04894071|Placebo Comparator|Placebo group|
33402680|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
33402681|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
33402682|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
33402683|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
33402684|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
33402685|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
33402686|NCT03293667|Other|Exploratory arm|
33402687|NCT01372449|Active Comparator|Memantine|
33402688|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
33402689|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
33402690|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
33402691|NCT04688541|Active Comparator|First standard Foley catheter than Optitip catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Standard Foley catheter Study period 2 = Optitip catheter"
33402692|NCT04688541|Active Comparator|First Optitip catheter than standard Foley catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Optitip catheter Study period 2 = Standard Foley catheter"
33402693|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
33402694|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
33402695|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
33402696|NCT04666389|Placebo Comparator|Control group|No statins being used for prevention
32784277|NCT04784247|Experimental|High grade undifferentiated pleomorphic sarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal . Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
32938880|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
33402697|NCT04666389|Active Comparator|Low-dose statin therapy|Atorvastatin 40 mg
33402698|NCT04666389|Active Comparator|High-dose statin therapy|Atorvastatin 80 mg
33402699|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
33402700|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
33402701|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
33402702|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
33402703|NCT03227211||COPD exacerbated patients admitted|No specific intervention
33402704|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
33402705|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
33402706|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
33402707|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
33402708|NCT04652505||Observational (questionnaires)|Patients complete 3 questionnaires online over 15 minutes regarding coping strategies that may have been used, mental health and physical well-being in the past month, and if they have been following certain behaviors which the WHO has recommended during the coronavirus pandemic, such as regular hand washing and social distancing.
33402709|NCT04374136|Experimental|AL001|AL001 every 4 weeks
33402710|NCT04374136|Placebo Comparator|Placebo|Placebo every 4 weeks
32938881|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
33402711|NCT04374136|Experimental|Open label - AL001|AL001 every 4 weeks
33402712|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
33402713|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
33402714|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
33402715|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
33402716|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
33402717|NCT02975336|Placebo Comparator|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
33402718|NCT02975336|Experimental|DBPC Period: M2951 25 mg QD|
33402719|NCT02975336|Experimental|DBPC Period: M2951 75 mg QD|
33402720|NCT02975336|Experimental|DBPC Period: M2951 50 mg BID|
33402721|NCT02975336|Experimental|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
33402722|NCT02975336|Experimental|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
33402723|NCT02975336|Experimental|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
33402724|NCT02975336|Experimental|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
33402725|NCT01371513||PSA level|more than 2.5ng/ml
33402726|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
33402727|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
33402728|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
33402729|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
33402730|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
33402731|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
33402732|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
33402733|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
33402734|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
33402735|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
33402736|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
33402737|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
33402738|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
33402739|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
33402740|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
33402741|NCT04479046|Active Comparator|Stainless steel crowns|3M ESPE
33402742|NCT04479046|Experimental|Zirconia crowns|Nu Smile
33402743|NCT04479046|Experimental|PMMA crowns|Dental Direkt
33402744|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
33402745|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
33402746|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
33402747|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
33402748|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
33402749|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
33402750|NCT04809831|Active Comparator|Trial Group - Biorepair Peribioma Toothpaste + Mousse|Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.
33402751|NCT04809831|Active Comparator|Control Group - Curasept Toothpaste (chlorhexidine 0,2%)|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.
33402752|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
33402753|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
33402754|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
33402755|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
32830395|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
32938882|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
33318221|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
33318222|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
33318223|NCT01298726|Other|PHARMACEUTICAL CARE|
33318224|NCT01298726|Other|HEALTH USUAL CARE|
33318225|NCT01298804|Experimental|Problem Solving Education|
33318226|NCT01298804|No Intervention|Control|
33318227|NCT05180578|Experimental|Tolerability of goat milk consumption in patients with EOE triggered by milk allergy|Elimination of cow milk from diet . Goat milk containing diet.
33318228|NCT01298882|Experimental|Diacerein|
33318229|NCT01298882|Placebo Comparator|Placebo|
33318230|NCT05180266|Experimental|Therapeutic Touch Group|In order to examine the effects of therapeutic touch on menopausal symptoms, sleep and quality of life, women will be given therapeutic touch for 15 minutes, once a week for four weeks.Therapeutic touchis a form of descriptive treatment that lasts approximately 15-20 minutes, in which hands are used on or near the body to correct abnormalities in the person's energy field and to achieve healing, and the energy in the universe is transferred from the practitioner's hands to the applied individual.
33318231|NCT05180266|Experimental|Music Listening Group|The women were asked to listen to the relaxation music included in the relaxation exercises CD prepared by the Turkish Psychological Association every day for four weeks in a comfortable environment at home for 30 minutes before bedtime.
33318232|NCT05180266|Other|Control Group|No action will be taken on the control group for four weeks.
33318233|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
33318234|NCT03828500|No Intervention|Control Arm|
33318235|NCT05281250|Experimental|Supervised physical exercise|Supervised exercise (aerobic + strength + flexibility) depending on the functional capacity of each patient, during hospitalization
33318236|NCT05281250|No Intervention|Control|Patients will receive recommendations about exercising during hospitalization.
33318237|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
33318238|NCT03210220|No Intervention|control group|There is no block.
33318239|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
33318240|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
33318241|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
33318242|NCT01201538|Experimental|Single arm|
33318243|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
33318244|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
33318245|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
33318246|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
33318247|NCT03725852|Experimental|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
33318248|NCT03725852|Placebo Comparator|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
33318249|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
33402756|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
33402757|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
33402758|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
33402759|NCT04716075|Experimental|Acalabrutinib 2x100mg oral capsule +alloSCT|Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT
33402760|NCT05653804|Experimental|tele-visit by HCP|Patients receive a annual CPAP remote visit by HCP technician, then home visit the following year
33402761|NCT05653804|No Intervention|home visit by HCP|Standard care : patients receive an annual CPAP home visit by HCP technician
33402762|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)~Nasal swab~Cough swab~Spontaneous expectorated sputum~Questionnaire"
33402763|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Questionnaire"
33402764|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Bronchoalveolar lavage (BAL)"
33402765|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
33402766|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
33402767|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
33402768|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
33402769|NCT03655184||MOH group|Patients with medication overuse headache
33402770|NCT03655184||Episodic migraine group|Patients with episodic migraine
33402771|NCT03655184||Healthy group|No headache or other special medical history
33402772|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
33402773|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
33402774|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
33402775|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
33402776|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
33402777|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
33402778|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
33402779|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
33402780|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
33402781|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
33402782|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
33402783|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
33402784|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
33402785|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
33402786|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
33402787|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
33402788|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
33402789|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
33402790|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
33402791|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
32737611|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
32737612|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
32737613|NCT02493023|Experimental|navigated bronchoscopy|
33402792|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
33402793|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
33402794|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
33402795|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
33402796|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
33402797|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
33402798|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
33402799|NCT04473807|Other|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
33402800|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
33402801|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
33402802|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
33402803|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~Identifies all patients eligible for any of the three cancer screening programs~Links patients with a specific clinician~Offers a visit-independent method for clinicians to review panels of their eligible patients~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~Screen their panel based upon risk~Defer patients, document exclusions, and update the EHR~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
33402804|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
33402805|NCT02358460|Active Comparator|Pressure-limited ventilation|
33402806|NCT02358460|Active Comparator|Volume-targeted ventilation|
33402807|NCT04422249|Experimental|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
33402808|NCT04422249|Active Comparator|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
33402809|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
33402810|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
33402811|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
33402812|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
33402813|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
33402814|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
32830396|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.~Intervention is the Nutrition Rating System - Traffic Light"
32830397|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.~Intervention is the Nutrition Rating System - Health Star Rating"
33085436|NCT04544566|Experimental|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
33402815|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
33402816|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
33402817|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
33402818|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
33402819|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
33402820|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
33402821|NCT01319955|Active Comparator|Inactivated polio vaccine|
33402822|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
33402823|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
33402824|NCT01316523|Experimental|Lenalidomide + Rituximab|Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
33402825|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
33402826|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
33402827|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis~No clinical suspicion of meniscus tear~Painless flexion-extension movements at knee joint."
33402828|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
33402829|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
33402830|NCT02362906|Experimental|Injection and medications|"Intravenous injection:~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
33402831|NCT02362906|Experimental|Injection and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
33402832|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
33402833|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
33402834|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
33402835|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
33402836|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
33402837|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
33402838|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
32830398|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.~Intervention is the Nutrition Rating System - Warning Labels"
32830399|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
33085437|NCT04544566|Active Comparator|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
32784278|NCT04784247|Experimental|Vascular sarcomas (including angiosarcoma and epithelioid hemangioendothelioma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
32784279|NCT04784247|Experimental|Other soft tissue sarcomas (including synovial sarcoma and malignant peripheral nerve sheath tumor|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
32784280|NCT04784247|Experimental|Bone sarcomas (including osteosarcoma and chondrosarcoma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
32784281|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
32784282|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
32784283|NCT05034861|Experimental|cCTG|cCTG group, that will undergo a following process: EFW and Doppler assessment biweekly, and instead of additional weekly Doppler-only assessment, the patients will be provided with an electronic cCTG device at no cost (Carebits). Women will be asked to apply Carebits device at least twice weekly for at least 30 minutes (e.g. Mondays-Thursdays) with minimum 72 hours interval in case of 2 sessions per week. The trace will be examined by an independent centre, available 24 hours daily. The person examining the trace is trained or already specialized in Obs&Gynae. In case of situation requiring medical intervention, the patient will be immediately contacted by phone and advised to self-refer to the nearest Antenatal Unit. In case of normal trace, a full report will follow within 30 minutes after last reading of the trace.
32784284|NCT05034861|Active Comparator|Doppler|Doppler group, that will undergo a standard process of antenatal care in case of FGR. The EFW and CTG STV will be assessed biweekly. In case of positive end-diastolic flow in UA, Doppler assessment (MCA PI, UA PI, DV PI, Ut PI) will be provided on a weekly basis. In case of deterioration to AEDF/REDF, further management will depend on clinical situation and the patient will be excluded from the study group (applies to both arms).
32784285|NCT05032677|Experimental|Conventional Epidural Technique|
32784286|NCT05032677|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
32784287|NCT05031897|Experimental|Radiation-Based Cohort (fludarabine, TBI, infusion)|Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
32784288|NCT05031897|Experimental|Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)|Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0.
32784289|NCT05002959||TESS Anatomic|Subjects who received the Anatomic T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
33085438|NCT04540510|Active Comparator|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
33085439|NCT04540510|Active Comparator|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
33085440|NCT04540471|Experimental|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
33085441|NCT04540471|Placebo Comparator|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
33085442|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
33085443|NCT04540237||Control|Healthy volunteers
33085444|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
33085445|NCT00236990|Experimental|001|pentosan polysulfate sodium
33085446|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
33085447|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
33085448|NCT04544371||obese patients|patients with body mass index >30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
33085449|NCT04539925||Industrial area|
33085450|NCT04539925||Non-industrial area|
32784290|NCT05002959||TESS Reverse|Subjects who received the Reverse T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
32784291|NCT04801329||Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)|
32784292|NCT01871727|Experimental|E7777|
32784293|NCT04949841|Experimental|As-needed treatment with delgocitinib|Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.
32784294|NCT05266989||Fibromyalgia|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
32784295|NCT05266989||Healthy Controls|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
32784296|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
32784297|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
32784298|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
32784299|NCT04193787|Experimental|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
32784300|NCT04801095|Experimental|WM-S1-030|Dose escalation (part 1) and Dose expansion (part 2)
32784301|NCT04800471|Active Comparator|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
32784302|NCT04800471|Placebo Comparator|Point of Care Glucose Group|Participants in this group will be monitored by point of care glucose values
32784303|NCT04875429|Experimental|Aortic abdominal aneurysm|
32784304|NCT04800237|Experimental|VQW-765|
32784305|NCT04800237|Placebo Comparator|Placebo|
32784306|NCT01582191|Experimental|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32784307|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~Laboratory studies prior to hospital admission and then at each follow-up visit~Hospital admission (3-5 day) to start the ketogenic diet~Standard of care chemotherapy with BCNU for up to 2 years~Ketogenic diet can continue for up to 2 years"
32784308|NCT04800159|Active Comparator|THC Cannabis|11.86% THC/ 1.12% CBD
32784309|NCT04800159|Active Comparator|CBD Cannabis|0.35% THC/ 11.27% CBD
32784310|NCT04800159|Placebo Comparator|Placebo|≤ 0.01% THC/ ≤ 0.01% CBD
32784311|NCT04832919|Experimental|Nurse-Community Health Worker-Family Partnership|The experimental arm will receive the Nurse-Community Health Worker-Family Partnership intervention
32784312|NCT04832919|No Intervention|Standard of Care|The control arm will receive standard access to NYC Department of Health COVID-19 testing sites and standard COVID-19 public health messaging
32784313|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
32784314|NCT05264961|Other|control group|dysphonic children without behavioral abnormalities
32784315|NCT05264961|Other|study group|dysphonic children with behavioral abnormalities
32784316|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
32784317|NCT04821297|Experimental|Supportive care (message)|Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.
33085451|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
33085452|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
33085453|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
33085454|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
33085455|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
33085456|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
33085457|NCT04544215|Experimental|MPCs-derived exosomes Dosage 1|low-dose group
33085458|NCT04544215|Experimental|MPCs-derived exosomes Dosage 2|high-dose group
33085459|NCT04544215|Placebo Comparator|No exosomes|No MPCs-derived exosomes
33085460|NCT04540081|Experimental|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
33085461|NCT04540081|No Intervention|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
33085462|NCT00237107|Experimental|curettage|
33085463|NCT02215681|Experimental|acupuncture|acupuncture treatment
33085464|NCT02215681|No Intervention|standard treament|watchful waiting
33085465|NCT00237146|Experimental|Zoledronic Acid|
33318250|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
33085466|NCT04544137|Experimental|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
33085467|NCT04544137|No Intervention|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
33085468|NCT04544059|Experimental|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
33085469|NCT04544176||Exposed Cohort|This group will include patients attending radiology outpatient appointments in 2020 in our period of interest from the peak of the first wave of the pandemic, who were subsequently tested for SARS-COV2 within 28-days of their attendance.
33085470|NCT04544176||Unexposed Cohort|This group will form the control group and comprises all individuals who attended radiological appointments during the same period for each hospital in 2019 but not 2020.
32784318|NCT03573297|Experimental|Cariprazine 3 mg/day|Cariprazine capsules, oral administration, once daily
32784319|NCT03573297|Experimental|Cariprazine 1.5 mg/day|Cariprazine capsules, oral administration, once daily
32784320|NCT03573297|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily
32784321|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
32784322|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
32784323|NCT04799535||Observational (ultrasound)|"AIM 1: Participants undergo a breast ultrasound over 15 minutes.~AIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy, 2 months after start of chemotherapy, and after the completion of chemotherapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and 1 month after start of chemotherapy.~AIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study."
32784324|NCT05257005||Patient cohort|Non interventional study
32784325|NCT04716387||Chlorfenapyr ITN|These study districts will receive Interceptor G2 ITNs during the mass distribution campaign.
32784326|NCT04716387||Piperonyl butoxide ITN|This study district will receive piperonyl butoxide ITN during the mass distribution campaign.
32784327|NCT04716387||Standard LLIN|These study districts will receive standard ITNs during the mass distribution campaign.
33318251|NCT03840512|Experimental|Oral CBD 75 BID|
33318252|NCT03840512|Experimental|Oral CBD 150 BID|
33318253|NCT03840512|Experimental|Oral CBD 300 BID|
33318254|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
33318255|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
33318256|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
33318257|NCT04286282|Active Comparator|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
33318258|NCT04286282|Experimental|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
33318259|NCT04286282|Active Comparator|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
33318260|NCT04284410|Experimental|CLASP-PE arm|
33318261|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
33318262|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
33318263|NCT05282420|Active Comparator|Ranibizumab group|Ranibizumab injection monthly for 3 successive months
33318264|NCT05282420|Active Comparator|Aflibercept group|Aflibercept injection monthly for 3 successive months
33318265|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
33318266|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
33318267|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
33085471|NCT04539769|Active Comparator|BI group|Conventional Billroth I reconstruction
33085472|NCT04539769|Experimental|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
33085473|NCT04539769|Experimental|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
32784328|NCT04716387||Pyriproxyfen ITN|This study district will receive Royal Guard ITNs during the mass distribution campaign.
33085474|NCT00237224|Experimental|FEM345|
33085475|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
33085476|NCT04539847|Experimental|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
33085477|NCT04539847|Experimental|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
33085478|NCT04539886|Experimental|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
33291386|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
33291387|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
33291388|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
33291389|NCT00280059|Experimental|1|
33291390|NCT00280059|Active Comparator|2|
33291391|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
33291392|NCT03993704|Experimental|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
33291393|NCT03993704|Placebo Comparator|Placebo|Placebo to match LHF-535 given once daily for 14 days
33291394|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
33291395|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
33291396|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
33291397|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
33291398|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
33291399|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
33291400|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
33291401|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
33291402|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
33291403|NCT00581672||questionnaires|Black men with prostate cancer
33291404|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
33291405|NCT00420290|Placebo Comparator|Placebo|
33291406|NCT00267189|Active Comparator|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
33291407|NCT00267189|Experimental|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
33291408|NCT03834350|Other|At-Home Breathes Program|Participants will participate in the at-home BREATHES program which will consist of a video education module and using a hand-held spirometry device, SpiroPD.
33291409|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
33291410|NCT01589120|Experimental|Video Arm|Video intervention group
33291411|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
33291412|NCT00402116|Experimental|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
33291413|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
33291414|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
32784329|NCT05250687|Experimental|MR guided high intensity focused ultrasound (MR-HIFU)|MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastases.
32784330|NCT05250687|Active Comparator|External beam radiation therapy (EBRT)|Patients will undergo radiotherapy for painful bone metastases.
32784331|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~Presence of Brain Arteriovenous Malformation"
33085479|NCT04539886|Active Comparator|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
33085480|NCT04543864|Experimental|electric welded metal framework|
33085481|NCT04543864|Experimental|conventional casted metal framework|
33085482|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
33085483|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
33291415|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
33291416|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
33291417|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
33291418|NCT03993366|Experimental|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
33291419|NCT03993366|Active Comparator|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
33291420|NCT01047618||Thromboembolism|
33291421|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
33291422|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
33291423|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
33291424|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
33291425|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
33291426|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
33291427|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
33291428|NCT01043718|Experimental|More-Intensive|
33291429|NCT01043718|Active Comparator|Less-Intensive|
33291430|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
33291431|NCT00395850|Experimental|2|disulfiram at 250 mg/day
33291432|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
33291433|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
33291434|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
33291435|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
33291436|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
33085484|NCT04543669|Experimental|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
33291437|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
33291438|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
33291439|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
33291440|NCT00380874|Experimental|1|flexible dosing
33291441|NCT00380874|Placebo Comparator|2|
33291442|NCT00420056|Experimental|PD-0332991|
33291443|NCT01589276||Emergency hernia repairs|
33291444|NCT01589276||Elective hernia repairs|
32784332|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
32784333|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
32784334|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
32784335|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
32784336|NCT00990483|Experimental|3D investigational imaging|patients returning with an area of interest will undergo 3D imaging in 2 modes of imaging to the breast of interest
33402839|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
33402840|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
33402841|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
33402842|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
33402843|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
33402844|NCT04059796|Experimental|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
33402845|NCT04059796|Active Comparator|Control Eye|approved monofocal or toric IOL after cataract extraction
33402846|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
33402847|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
33402848|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
33402849|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
33402850|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
33402851|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
33402852|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
33402853|NCT04497220|Placebo Comparator|Nocebo Group|Participants in this group will receive the control treatment
33402854|NCT04497220|Experimental|Positive Connotation Group|Participants in this group will receive the experimental treatment.
33402855|NCT04469530|Experimental|Maintenance Chemotherapy Regimen|"Participants with metastatic osteosarcoma, metastatic Ewing sarcoma, high-risk rhabdomyosarcoma, metastatic non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), desmoplastic small round cell tumor (DSRCT), and malignant rhabdoid tumor (MRT) in first complete remission (cohort 1) or participants with recurrent solid tumors (any histology) in second complete remission (cohort 2), receiving a maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy."
33402856|NCT04469530|No Intervention|Historical Control Cohort Receiving Standard Therapy|This study arm is a historical control cohort of patients matched with cohort 1 on diagnosis, age, metastatic site, and date of diagnosis. The matched historical controls will be obtained from the same treating institution as the corresponding case to account for institutional differences in treatment and supportive care. Patients in the historical control cohort received standard therapy.
33402857|NCT02358070||HCC group|
33402858|NCT02358070||control group|
33402859|NCT02368522||Patients treated with and without exposure|
33402860|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
32784337|NCT05362383|Experimental|Experimental group|transcutaneous electrical nerve stimulation (TENS) is applied
32784338|NCT05362383|No Intervention|Control group|no intervention
32784339|NCT00973011|Experimental|A|
32784340|NCT00580203||1|Patients with head and neck cancers
32938883|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
32938884|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
32938885|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
32938886|NCT04333004|Experimental|Pembrolizumab Combined With Chemotherapy|
32938887|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
33291445|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
32830400|NCT04378530|Experimental|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
32830401|NCT04378530|Active Comparator|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
32938888|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
32938889|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
32938890|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
32938891|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
32938892|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
32938893|NCT02184156|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
32938894|NCT02184156|Placebo Comparator|Placebo 4 mL dose|4 mL injection of placebo
32938895|NCT03291613|Experimental|Pinpoint App|Tablet application.
32938896|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
32938897|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
32938898|NCT04059913|Experimental|Part 1: ESA-Naïve Participants - Low Weight Based Dosing|ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
32938899|NCT04059913|Experimental|Part 1: ESA-Naïve Participants - Standard Weight Based Dosing|ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
33291446|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
33291447|NCT00400712|No Intervention|Control|natural progression post-stroke
33291448|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
33291449|NCT00380718|Experimental|Pemetrexed|
33291450|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
33291451|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
33291452|NCT01045668|Active Comparator|Clinical VT ablation|
33291453|NCT01045668|Active Comparator|clinical VT and substrate ablation|
33291454|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
33291455|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
33291456|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
33291457|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
33291458|NCT00395694|Experimental|lamictal|
33291459|NCT01041794||1|
33291460|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
33291461|NCT01047774|Experimental|Soy protein|
33291462|NCT01047774|Placebo Comparator|Milk protein|
33291463|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
33291464|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
33291465|NCT01047852|Experimental|NIV|
33291466|NCT01047852|No Intervention|Control|
33291467|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
33291468|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
33291469|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
33291470|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
33291471|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
33291472|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
32784341|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
32900579|NCT05366712|Experimental|Trident® II HA coated shells|Patients will receive a Trident® II acetabular component as part of primary total hip arthroplasty at the study centre. This component is CE marked and widely available for use by UK surgeons. The Trident® II shells are HA coated, cementless, press-fit acetabular shells composed of a Titanium (Ti-6Al-4V) substrate featuring a CpTi roughened surface with PureFix™ HA.
33291473|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
33291474|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
33291475|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
33291476|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
33291477|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
33291478|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
33291479|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
33291480|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
33291481|NCT00366444|Experimental|1|
33291482|NCT00366444|Placebo Comparator|2|
33291483|NCT00365976|Placebo Comparator|1|Placebo
33291484|NCT00365976|Active Comparator|2|Eszopiclone
33291485|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
33291486|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
33291487|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
33291488|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
33291489|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
33291490|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
33291491|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
33291492|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
33291493|NCT00378534|Experimental|T Cell Depletion Transplant Participants|Participants with hematological malignancies received a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90.
33291494|NCT00378534|Other|Stem Cell Donors|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. The stem cell collection aspect of this protocol is not investigational.
33291495|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
33291496|NCT00377676|Experimental|Drug Cycloset|
33291497|NCT00377520|Experimental|Pemetrexed|
33291498|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
33291499|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
33291500|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
33318268|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
33291501|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
32784342|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
32784343|NCT04812639|Experimental|buccal infiltartion technique|local anesthetic technique
32784344|NCT04812639|Active Comparator|Inferior alveolar nerve block technique|local anesthetic technique
32784345|NCT04812483|Other|Standard Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:~No planed further treatment. = standard therapy (without eltrombopag)"
32784346|NCT04812483|Experimental|Study Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:~The subjects in the experimental arm will be treated with eltrombopag:~Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows."
32784347|NCT05238597|Experimental|A197 Ophthalmic Solution, High Dose|
32784348|NCT05238597|Experimental|A197 Ophthalmic Solution, Low Dose|
32784349|NCT05238597|Placebo Comparator|A197 Vehicle Control|
32784350|NCT05238597|Active Comparator|Active Comparator|
32784351|NCT04418583|Experimental|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
32784352|NCT05157399|Experimental|OtoBand Efficacy on Vertigo and Dizziness|During the single site visit, participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand will be set to 92dB or 98dB bone conduction level (Re: 1 Dyne). The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
32784353|NCT05157399|Placebo Comparator|Placebo Device Efficacy on Vertigo and Dizziness|Participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand set to a bone conduction level 10dB lower than the level used in the experimental condition. Once fitted with the Otoband, participants will undergo the vestibular battery test. The investigator will record the outcome measurements.
32784354|NCT05157399|No Intervention|No Device|Participants will wear the OtoBand, but turned off, to collect baseline data. This will be randomized. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
32784355|NCT04418973|Experimental|A - load/apnea|Threshold inspiratory load then apnea
32784356|NCT04418973|Experimental|B- apnea/load|apnea than threshold inspiratory load
32784357|NCT00434343|Placebo Comparator|Global Therapeutic Massage (GTM)|Weekly massages consisting of full body Western massage for 1hour.
32784358|NCT00434343|Active Comparator|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
32784359|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
32784360|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
32784361|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
32784362|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
32784363|NCT04316559|Placebo Comparator|Placebo|Placebo capsule
32784364|NCT04316559|Experimental|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
32784365|NCT00098475|Active Comparator|Arm I (lenalidomide, dexamethasone)|Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.
32784366|NCT00098475|Experimental|Arm II (lenalidomide, low-dose dexamethasone)|Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
32784367|NCT00098475|Active Comparator|Arm III (thalidomide, dexamethasone)|Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20
32784368|NCT00098475|Experimental|Arm IV (thalidomide, low-dose dexamethasone)|Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
32784369|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
32784370|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
32784371|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
32784372|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
32784373|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
32784374|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
32784375|NCT04812093||Medical Tool|Spectroscopic otoscope
32784376|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
32784377|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
32784378|NCT04811469|Experimental|CBP-174|CBP-174 oral solution
33402861|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
33402862|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
33402863|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
33402864|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
33402865|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
33402866|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
33402867|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
33402868|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
33402869|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
33402870|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
33402871|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
33402872|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
33402873|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
33402874|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
32784379|NCT04811469|Experimental|Placebo|placebo oral solution
32784380|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
32784381|NCT02246439|Placebo Comparator|Placebo|Placebo
32784382|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
32784383|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
32784384|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
32784385|NCT04781361||Isotonic fluid|"Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~Dextrose 5% in 0.9% NaCl,~Intravenous fluid containing NaCl between 131 to 154 mmol/L"
32784386|NCT04781361||Hypotonic fluid|"Group, received hypotonic maintenance fluid containing NaCl < 130 mmol/L such as:~Dextrose 5 % in 0.02 % NaCl,~Dextrose 5% in 0.033 % NaCl~Dextrose 5% in 0.045 % NaCl~Intravenous fluid containing NaCl < 130 mmol/L"
32784387|NCT04191447|Experimental|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 200/12 capsule~1 Budesonide/formoterol Placebo capsule."
32784388|NCT04191447|Active Comparator|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 400/12 capsule~1 Flamboyant 200/12 Placebo capsule."
32830402|NCT04378530|Experimental|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
32830403|NCT02068846|Active Comparator|Ciprofloxacin|Active treatment twice daily for 28 days
32830404|NCT02068846|Placebo Comparator|Placebo|Placebo treatment twice daily for 28 days
32784389|NCT04274361|Experimental|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
32784390|NCT04274361|Placebo Comparator|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
32784391|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
32784392|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
32784393|NCT04251819|Placebo Comparator|Placebo|Participants randomized to this arm will receive Placebo.
32784394|NCT04251819|Experimental|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
32784395|NCT04251819|Experimental|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
32784396|NCT02243865|Experimental|Chordate S200 + control module (CT100), active|Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
32784397|NCT02243865|Placebo Comparator|Chordate S200 + control module (CT100), placebo|Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode. Non-inflated and non-vibrating treatment
32784398|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
32784399|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
32784400|NCT04780893|Active Comparator|Active VeNS|
32784401|NCT04780893|Sham Comparator|Sham VeNS|
32784402|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
32784403|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
32784404|NCT04183413|No Intervention|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform after the emergency decentralization motivated by the COVID-19 outbreak. Healthcare for diabetes and hypertension for complicated cases is provided through physician-led teams at hospitals and health centers. Healthcare for diabetes and hypertension for uncomplicated cases is provided at primary care clinics through nurses.
32784405|NCT04183413|Experimental|DSD|Clients are invited to participate in one of three Differentiated Service Delivery models tailored to their needs.
32784406|NCT04183413|Experimental|CDP|Health services for diabetes and hypertension are provided in the scope of outreach activities set up on a monthly basis in communities.
32784407|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
32784408|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
33085485|NCT04539691|Experimental|Magnet group|"Women wearing magnet~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
32784409|NCT03986229|Active Comparator|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
32784410|NCT03986229|Active Comparator|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
32784411|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
32784412|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
32784413|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
32784414|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
32784415|NCT05233449|Experimental|Children anesthetized|Inhalatory general anesthesia with sevoflurane 0.9 Minimal Alveolar Concentration and alfentanil 10 µg/kg
32784416|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
32784417|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
32784418|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
32784419|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
32784420|NCT03967977|Active Comparator|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
33085486|NCT04539691|Sham Comparator|Sham group|"Women wearing sham~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
33085487|NCT02214940|Experimental|BI 11634|multiple rising dose
33402875|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
33402876|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
33402877|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
33402878|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
33402879|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
33402880|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
33402881|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
33402882|NCT02467608|Other|Isoniazid|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
33402883|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
33402884|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
33402885|NCT01380054||patients with pulmonary hypertension|
33402886|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
33402887|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
33402888|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
33402889|NCT05421312|Other|cefazolin|The cefazolin antimicrobial prophylaxis (2000mg single dose intravenously 15-60 minutes before incision) is part of standard of care.
33402890|NCT05421312|Other|Clindamycin|The clindamycin (600mg three times daily orally) PJI therapy is part of standard care.
33402891|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
33402892|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
33402893|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
33402894|NCT01569282|Active Comparator|Double bypass|
33402895|NCT01569282|Active Comparator|Stent Strategy|
33085488|NCT02214940|Placebo Comparator|Placebo|
33085489|NCT04539652|Experimental|Experimental group|
33085490|NCT02214979|Experimental|Telmisartan/Ramipril|
33085491|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
33085492|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
33085493|NCT04539496|Experimental|dose confirmation and the phase II study|To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer
33402896|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
33402897|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
33402898|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
33402899|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
33402900|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
33402901|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
32830405|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
32784421|NCT03967977|Placebo Comparator|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
33291502|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
33291503|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
32938900|NCT04059913|Experimental|Part 1: ESA-Treated Participants - Low Weight Based Dosing|ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
32938901|NCT04059913|Experimental|Part 1: ESA-Treated Participants - Standard Weight Based Dosing|ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
33291504|NCT01049568|Experimental|Cell Phone Intervention|
33291505|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
33291506|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
33291507|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
33291508|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
33291509|NCT03992118|Experimental|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
33291510|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
32784422|NCT04780425|Experimental|DESMOND|receive usual care plus a structured diabetes self-management education program delivered once over 6hours
32784423|NCT04780425|Active Comparator|USUAL CARE|Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care
33291511|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
33291512|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
33291513|NCT00376506|Active Comparator|External Device|External vibrotactile device
33291514|NCT00410384|Placebo Comparator|Placebo|Placebo
33291515|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
33291516|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
33291517|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
33291518|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
33291519|NCT00409838|Experimental|Abatacept and Methotrexate|
33291520|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
33291521|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
33291522|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
33291523|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
33291524|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
33291525|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
33291526|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
33291527|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
33291528|NCT01041950|Experimental|Lumbar drainage|
33291529|NCT01041950|No Intervention|Control|
33291530|NCT01039766|Experimental|oxytocin|
33291531|NCT01039766|Placebo Comparator|Placebo|
32784424|NCT04780269|Experimental|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group.
32784425|NCT04780269|Experimental|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix.
32784426|NCT03856515|Experimental|Observational (e-cigarettes with or without nicotine, visits)|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
32784427|NCT02239263|Experimental|N6 Input Processing Features|
32784428|NCT02238483|Experimental|AZD7624|Active treatment
32784429|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
33291532|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
33318269|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
33402902|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
32938902|NCT04059913|Experimental|Part 2: Roxadustat QW|Participants will receive roxadustat once a week (QW). Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.
32938903|NCT04059913|Experimental|Part 2: Roxadustat BIW|Participants will receive roxadustat twice a week (BIW). Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.
32938904|NCT04059913|Experimental|Part 2: Roxadustat TIW|Participants will receive roxadustat TIW. Roxadustat dose will continue per dose adjustment guideline.
32938905|NCT02158884|Other|IDEO brace|IDEO brace
32938906|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
32938907|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
32938908|NCT04028557|Experimental|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
32938909|NCT04028557|Active Comparator|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
32938910|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
32938911|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
32938912|NCT04333069|Other|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
32938913|NCT03922087||Control Group|The pregnancy women without any diseases.
32938914|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
32938915|NCT03909139||BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~BMAC application at the time of arthroscopic labral repair."
32938916|NCT03909139||No BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~No BMAC application at the time of arthroscopic labral repair."
32938917|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
32938918|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
32938919|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
32938920|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
32938921|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
32938922|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
32938923|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
32938924|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
32938925|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
32938926|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
33085494|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
33402903|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
32784430|NCT01632891|Experimental|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
32784431|NCT01632891|Experimental|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
32784432|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
32784433|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
32784434|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
32784435|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
32784436|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
33291533|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
33291534|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
33291535|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
33291536|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
33291537|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
33291538|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
33291539|NCT03993782|Experimental|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33291540|NCT03993782|Experimental|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
33291541|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
33291542|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
33291543|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
33291544|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
33291545|NCT03993626|Experimental|CXD101 and Nivolumab combination|"CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.~Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.~CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
33291546|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
33291547|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
33291548|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
33291549|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
33291550|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
33291551|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
33291552|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
33085495|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
33085496|NCT04539535|Experimental|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
33085497|NCT04539535|Experimental|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
33085498|NCT00237380|Experimental|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
33085499|NCT04543708|Active Comparator|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
33085500|NCT04543708|Active Comparator|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
33085501|NCT04539145|Experimental|Chocolate PTA balloon|
33085502|NCT04539145|Other|POBA|Intervention with regular baloon
33085503|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
33085504|NCT04543318|Experimental|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
33085505|NCT04543318|Active Comparator|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
33085506|NCT04539340|Other|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
33085507|NCT04539340|Other|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
33085508|NCT04539340|Other|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
33402904|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
33402905|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
33402906|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
33402907|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
33402908|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
33402909|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
33402910|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
33402911|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
33402912|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
33402913|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
33085509|NCT04539340|Other|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
33085510|NCT04539340|Other|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
33085511|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
33085512|NCT04543474|Active Comparator|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
33085513|NCT04543474|Active Comparator|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
33085514|NCT00237497|Experimental|Ramelteon 8 mg QD|
33085515|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
33085516|NCT00237497|Placebo Comparator|Placebo QD|
33085517|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
33085518|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
33085519|NCT04538716|Experimental|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
33085520|NCT04538716|Experimental|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
33085521|NCT04543084|Other|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
33402914|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
33402915|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
33402916|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
33402917|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
33402918|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
32784437|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
33085522|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
33085523|NCT02215759|Experimental|BI 44370 TA|
33085524|NCT02215759|Placebo Comparator|Placebo|
33085525|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
33085526|NCT00416208|No Intervention|Observation|Observational arm
33402919|NCT04479280||Covid19 positive patients|
32784438|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
32784439|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
32784440|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
32784441|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
32784442|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
32784443|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
32784444|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
32784445|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
32784446|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
32784447|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
32784448|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
32784449|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
32784450|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
32784451|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
32784452|NCT03686397|Experimental|SVT-15652|1 vial twice daily
32784453|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
32784454|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
32830406|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
33085527|NCT02215798||Cymbalta|
33085528|NCT02215018|Experimental|BI 44370 TA solution|
33085529|NCT02215018|Experimental|BI 44370 TA tablet|
33085530|NCT02215018|Placebo Comparator|Placebo solution|
33085531|NCT02215018|Placebo Comparator|Placebo tablet|
33085532|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
33085533|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
33085534|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
33085535|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
32784455|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
33085536|NCT04710095|Active Comparator|Brief Alcohol Intervention|A brief intervention consisting of a 30-45 minute individual face-to-face session based on the principles of motivational interviewing.
33085537|NCT04710095|Sham Comparator|Attention-Matched Control Condition|Brief attention-matched control condition.
33085538|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
33085539|NCT04543123|Sham Comparator|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
32784456|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
32784457|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
33085540|NCT04543123|Experimental|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
33085541|NCT04539418|Active Comparator|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
32784458|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
32784459|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
33085542|NCT04539418|Placebo Comparator|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
33085543|NCT04538638|Active Comparator|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
33085544|NCT04538638|Active Comparator|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
33085545|NCT04542928|Placebo Comparator|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
33085546|NCT04542928|Experimental|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
33085547|NCT04543006|Other|Covid-19|only arm: Covid-19 proven by PCR
33085548|NCT04710017|Other|Tranexamic acid group|will tranexamic acid 500 mg 4 times daily in one group,
33085549|NCT04710017|Other|Medroxyprogesterone acetate|will receive 150mg of medroxyprogesterone acetate once intramuscular.
33085550|NCT04538521|Experimental|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
33085551|NCT04543630|Active Comparator|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
33085552|NCT04543630|Experimental|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
33085553|NCT04542967|No Intervention|Control group|They will receive the standard care for critically ill inpatients.
33085554|NCT04542967|Experimental|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
33085555|NCT04542811|Experimental|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
33085556|NCT04542811|No Intervention|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
33085557|NCT00269802|Experimental|001|OROS methylphenidate HCl
33085558|NCT00269802|Active Comparator|002|Ritalin
33085559|NCT00269802|Placebo Comparator|003|Placebo
33085560|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
33085561|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
33085562|NCT04542889|Experimental|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
33085563|NCT04538326|Other|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
33085564|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
33085565|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
32938927|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
33085566|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
33085567|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
33085568|NCT04538872|Experimental|MS group implicit|
33085569|NCT04538872|Experimental|MS group explicit|
33085570|NCT04538872|Active Comparator|HC group implicit (Healthy Controls)|
33085571|NCT04538872|Active Comparator|HC group explicit (Healthy controls)|
33085572|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
33085573|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
33085574|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
33085575|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
33085576|NCT04542616|Active Comparator|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
33085577|NCT04542616|Active Comparator|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
33085578|NCT04538365|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
33085579|NCT04538365|Experimental|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
33085580|NCT04542772|Experimental|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
33085581|NCT04542772|Active Comparator|Standard of Care|Participants in this group will receive only standard of care based on their needs.
33085582|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
33085583|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
32938928|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
32938929|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
32938930|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
32938931|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
32938932|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
32938933|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
32938934|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
32938935|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
32938936|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
32938937|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
32938938|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
32938939|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
32938940|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
32938941|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
32938942|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
32938943|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
32938944|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
32938945|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
32938946|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
32938947|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
32938948|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
32938949|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
32938950|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
32938951|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
33085584|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
33085585|NCT04542655|Other|Cycling first|Ergometer cycling then treadmill running then rest
33085586|NCT04542655|Other|Running first|Treadmill running then ergometer cycling then rest
33085587|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
33085588|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
32938952|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
32938953|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
32938954|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
32938955|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
32938956|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
32938957|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
32938958|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
33085589|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
33085590|NCT04539067|Experimental|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
33085591|NCT04539067|Experimental|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
33085592|NCT04538248||Continuous|Continuous
33085593|NCT04538248||Discontinuous|Discontinuous
33085594|NCT04538014|Experimental|Lu AF88434|
33085595|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
33085596|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
33085597|NCT00237731|Experimental|1|morphine 0.05
33085598|NCT00237731|Active Comparator|2|morphine 0.10
33085599|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
33085600|NCT04542265|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33085601|NCT04542265|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33085602|NCT04542265|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33085603|NCT04542265|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
33085604|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
33085605|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
33085606|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
33085607|NCT04537975|Active Comparator|C2Rx|Hemofiltration device
33085608|NCT04537975|Active Comparator|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
33085609|NCT04538131|Active Comparator|conventional SCS|
33085610|NCT04538131|Experimental|sensor-driven position-adaptive SCS|
33085611|NCT00262392|Experimental|Pamidronate|Pamidronate
33085612|NCT00262392|Active Comparator|radiation|radiation
33085613|NCT04537780|Placebo Comparator|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
32784460|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
32784461|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
32784462|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
32784463|NCT04778631|Experimental|Heat therapy|Local perineal heat therapy during active second stage of labor
32784464|NCT04778631|Experimental|Cryotherapy|Local perineal cryotherapy during the immediate postpartum period
32784465|NCT04778631|No Intervention|Active second stage usual car|Standard obstetrical care and perineal protection during active second stage of labor
32784466|NCT04778631|No Intervention|Postpartum usual care|Standard immediate (<2 hours) postpartum care
32784467|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
32784468|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
32784469|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
32784470|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
32784471|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
32784472|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
32784473|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
32784474|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
32784475|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
32784476|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
32784477|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
32784478|NCT04776837||Main Cohort|"Patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival)~Prior to starting anti-cancer therapy and at subsequent designated visits (every one month)~Collections include:~Blood sample~Questionnaires quality of life, mood, and symptoms~Tissue may be obtained for next-generation sequencing."
32784479|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
32784480|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
32784481|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
32784482|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
32784483|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
32784484|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
33085614|NCT04537780|Experimental|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.~The treatment duration will be 12 weeks."
33085615|NCT04537858|Experimental|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
32784485|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
32784486|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
32784487|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
33291553|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
33402920|NCT04479280||Covid19 negative patients|
33402921|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
33402922|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
33402923|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
32784488|NCT04776369|Active Comparator|Lidocaine group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
32784489|NCT04776369|Active Comparator|Magnesium group|30 patients will receive IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
32784490|NCT04776369|Active Comparator|Combination group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. after induction of anesthesia.
32784491|NCT04776369|Placebo Comparator|control group|30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia.
32784492|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
32784493|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
32784494|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
33402924|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
33402925|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
33402926|NCT01889238|Experimental|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
33402927|NCT04334356|Experimental|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
33402928|NCT02362516|Experimental|BI 425809|
33402929|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
33402930|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
32784495|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
32784496|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
32784497|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 4 years.
32784498|NCT04767945||Adults with liver cirrhosis admitted to hospital liver unit|Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
32784499|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
32784500|NCT03256773||Notmal|No lung Disease
32784501|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
32784502|NCT03256773||PCD|Primary Ciliary Dyskinesia
32784503|NCT03256773||COPD|Chronic Obstructive Lung Disease
32784504|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
33402931|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
33402932|NCT05421000|Experimental|WALANT|Wide awake local anesthesia without tourniquet was used for surgery
33402933|NCT05421000|Active Comparator|Locoregional anesthesia and tourniquet|Locoregional anesthesia (normally axillary block) and tourniquet was used for surgery
32784505|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
32784506|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
32784507|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
33402934|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
33402935|NCT05419362|Experimental|GEN-001 with avelumab|Up to 50 patients in total with metastatic GC/Gastroesophageal Junction Adenocarcinoma who have progressed after 2 prior systemic treatments and confirmed PD-L1 positive expression will be enrolled in this study.
32784508|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
32830407|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
32830408|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
32784509|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
32784510|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
32784511|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
33085616|NCT04537858|Experimental|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
33085617|NCT04537819|Experimental|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.~6. Paracetamol as antipyretic, if necessary."
32784512|NCT03155061|Experimental|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
33085618|NCT04537819|Other|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
33085619|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
33085620|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
33085621|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
33085622|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
33085623|NCT00237926|Experimental|1|aerobic exercise
33085624|NCT00237926|Experimental|2|Resistance Training
33085625|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
33085626|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
33085627|NCT04537546|Experimental|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
33085628|NCT04537702|Active Comparator|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
33291554|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
33291555|NCT04566380|Experimental|ONO-4538 Monotherapy cohort|480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
32784513|NCT03155061|Experimental|Part D (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
32784514|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
32784515|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
32784516|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
32784517|NCT02227875|Active Comparator|Lantus®|receive Lantus®
32784518|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
32784519|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
32784520|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
32784521|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
32784522|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
32784523|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
32784524|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
32784525|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
32784526|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
32784527|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
32784528|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
32784529|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
32784530|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
32784531|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
32784532|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
32784533|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
32784534|NCT04767789|Experimental|NZ-GHMH-01|Dietary supplement in shape of capsule to be taken once per day in the evening.
33291556|NCT04566380|Experimental|Combination therapy cohort|ONO-4538 at 360 mg IV Q3W, and Chemotherapies (S-1 + Oxaliplatin [SOX] therapy or Capecitabine + Oxaliplatin [CapeOX] therapy) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
32784535|NCT04767789|Placebo Comparator|Placebo|The placebo is in shape of capsule to be taken once per day in the evening and in which only the active ingredients are not present.
33291557|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
32784536|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
32784537|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
32784538|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
32784539|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
32784540|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
33291558|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
33291559|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
32784541|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
32784542|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
32784543|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
32784544|NCT01634139|Experimental|Tiotropium high dose QD|
33291560|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
33291561|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
32784545|NCT01634139|Experimental|Tiotropium low dose QD|
32784546|NCT01634139|Experimental|Placebo QD|
32784547|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
32784548|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
32784549|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
32784550|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
33291562|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
33291563|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
33291564|NCT03993470|Experimental|experimental|The short foot exercise daily for 4 weeks
33291565|NCT03993470|Placebo Comparator|Control|A placebo excercise daily for 4 weeks
33291566|NCT01040000|Experimental|NPC-1C/NEO-102|
33291567|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
32784551|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
33402936|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
33402937|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
32784552|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
32784553|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
32784554|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
32784555|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
32784556|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
32784557|NCT04775043||Control population|First part of the study for the HFRDIS Questionnaire French validation
32784558|NCT04775043||Patients on hormone therapy for breast cancer|Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
32784559|NCT02201277|Experimental|Denali|Denali IVC Filter
32784560|NCT02201277|Experimental|Option|Option Elite IVC Filter
32784561|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
32784562|NCT04762875|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
32784563|NCT04774731|Experimental|Whole Body Vibration|
32784564|NCT04774731|No Intervention|Control|
32784565|NCT04774107|Experimental|P1101 + Ribavirin|P1101 400 µg SC Ribavirin 800-1400 mg PO
32784566|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
32784567|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
32784568|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
32784569|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
32784570|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
32784571|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
32784572|NCT01650259||Oral antidiabetic drug (OAD)|
32784573|NCT01650259||Trazenta|
32784574|NCT04908085|Experimental|OPC|Occupational Performance Coaching delivered by telephone
33402938|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
32784575|NCT04908085|No Intervention|Waitlist control|Intervention provided after post intervention assessment
32784576|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
32784577|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
32784578|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
32784579|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
32784580|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].~Standary therapy"
32784581|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
32830409|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
33402939|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
33402940|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
33402941|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
33402942|NCT03630900|No Intervention|5% O2 culture|
33402943|NCT02367196|Experimental|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
32784582|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
32784583|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
32784584|NCT02222493|Experimental|PF-06438179|
33085629|NCT04537702|Experimental|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
33085630|NCT04719351|Experimental|Condition 1: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33085631|NCT04719351|Experimental|Condition 2: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33402944|NCT02367196|Experimental|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
33402945|NCT05418504|Active Comparator|Non- Tramadol|the control group represented by dental patients who are not a tramadol addict
33402946|NCT05418504|Active Comparator|Tramadol|The study group with patients seeking dental service but also are tramadol addict.
33402947|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
33402948|NCT05406414|Experimental|Transdiagnostic sleep and circadian treatment|The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks.
33402949|NCT05406414|Active Comparator|Active waitlist control group|The control group receives sleep hygiene education
33402950|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
33402951|NCT01377792|Active Comparator|5 ml|
33402952|NCT01377792|Active Comparator|10 ml|
32784585|NCT02222493|Active Comparator|Infliximab|
32784586|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
32784587|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
32784588|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
32784589|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
32784590|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
32784591|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
32784592|NCT04773249|Experimental|Lateral Epicondylitis Bandage|A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
32784593|NCT04773249|Experimental|Wrist Extension Splint|A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
32784594|NCT04773249|No Intervention|Wait-and-see Policy|These patients will be monitored with a wait-and-see policy. No splint or band will be given to the patient.
32784595|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
32784596|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
32784597|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
32784598|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
32784599|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
32830410|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
32830411|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~Patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
32900580|NCT05366556|Experimental|Experimental group|Patients in the experimental group will be informed about the using virtual reality glasses during the taking blood. During this process, their anxiety and pain will be assesed. Patients in the study group will be evaluated 2 times, before the intervention and after the intervention, through data collection tools.
32900581|NCT05366556|No Intervention|Control group|The control group will receive standard procedure without any intervention
32900582|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
32900583|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
32900584|NCT05366478|Experimental|Autologous tumor infiltrating lymphocytes (TILs)|In vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors
32900585|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
32900586|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
32900587|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
32900588|NCT05288036|Experimental|Proprioceptive Neuromuscular Rehabilitation group|PNF techniques; It is based on facilitating the responses of neuromuscular mechanisms by stimulating proprioceptors. It is a method used to improve active movement ability by increasing muscle strength, to increase muscle endurance, to improve stabilization at the point where the technique is applied within the movement pattern.
32900589|NCT05288036|Experimental|Progressive Resistance Exercise Group|Progressive resistance training (PRT) is a method for increasing muscle strength and endurance based on the determination of the amount of resistance appropriate for the individual. Free weights and resistance machines are used in the practice of this technique.To facilitate continued adaptation, training intensity (i.e. load) and training volume (i.e. number of sets) are progressively increased, and exercises are adjusted as indicated throughout the training regimen, to attenuate the onset of a plateau in physiological adaptation.
32900590|NCT05288036|Active Comparator|Control Group|This group was created to determine the amount of self-healing of the disease in the process. The approach was taken in a way that did not affect the outcome measures.
32900591|NCT05366400||Group I (CAT) ≥ 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score ≥10 is associated with a significantly impaired health status.
32900592|NCT05366400||Group II (CAT) < 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score < 10 is associated with a significantly preserved health status.
32900593|NCT05287958||Healthy|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
32900594|NCT05287958||ALS|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
32900595|NCT05330988|Experimental|Real|Randomly selected participants will receive 20 min. of anodal transcranial direct current stimulation to the the top of their heads. The current will slowly be ramped up over 30 secs.
32900596|NCT05330988|Sham Comparator|Sham|Randomly selected participants will receive 20 min. of sham transcranial direct current stimulation to the top of their heads. Sham stimulation is accomplished by turning on the device and slowly increasing and subsequently decreasing the amount of current to zero. This occurs over 30 secs.
32900597|NCT05287880||Non-N0 stage|Patients with malignant lymph nodes.
32900598|NCT05287880||N0 stage|Patients without malignant lymph nodes.
32900599|NCT05329662|Active Comparator|AD-MSCs infusions, then Placebo|Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 ± 7
32900600|NCT05329662|Placebo Comparator|Placebo, then AD-MSCs infusions|Patients in group B will receive two autologous AD-MSC administrations on day 180 ± 14 and day 270 ± 14
32900601|NCT05287802|Active Comparator|Biodex Training (BT) group|Biodex Balance System features a platform that can move simultaneously in the anteroposterior (AP) or medio-lateral (ML) direction in 12 different levels of stability within a 20-degree range of inclination, as well as a locked position for static environments. For this platform, 1 represents the least stable level and 12 represents the most stable level. Interactive, game-like training modes are provided with the on-screen grid and score-keeping functions. Patients in the BT group performed exercises with the Balance SystemTM SD once a day, three days a week for 10 weeks under the physicians' supervision. Furthermore this group received closed kinetic chain exercises (CKCE) in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
32900602|NCT05287802|Active Comparator|Classical balance training group (CT group)|Patients in the CT group completed the exercise program once a day and three days a week during the 10-week period under the physicians' supervision. The exercises consisted of standing on one leg, tandem walking (heel-to-toe), balance board exercises, Romberg exercise, backward walking, and side-to-side stepping exercises. The total duration of these exercises was 20-30 minutes. Furthermore this group also received CKCE in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
32784600|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
33402953|NCT00477100||Observational (biospecimen and medical data collection)|Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
33402954|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
33402955|NCT03408886|Experimental|Group A|Group A receives treatment in Part 1 and Part 2
33402956|NCT03408886|Other|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
33402957|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
33402958|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
33402959|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
33402960|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
33402961|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
33402962|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
33402963|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
33402964|NCT02361970||volunteer|Health persons
33402965|NCT03323476|Experimental|Discontinuation of maintenance treatment|
32784601|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
32784602|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
33402966|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
33402967|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
33402968|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
33402969|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
33402970|NCT04013334|Experimental|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
33402971|NCT03285412|Experimental|Ribociclib + Endocrine Rx|Ribociclib will be administered. Endocrine therapy will be administered.
33402972|NCT03285412|Active Comparator|Endocrine Rx|Endocrine therapy will be administered.
33402973|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
33402974|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
32784603|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
32784604|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
32784605|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
32784606|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
33402975|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
33402976|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
33402977|NCT01379742|Active Comparator|20 g needle|Thin Strand
33402978|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
32784607|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
32784608|NCT04929535|Experimental|30% hydrogen peroxide|30% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
32784609|NCT04929535|Placebo Comparator|3% hydrogen peroxide|3% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
32784610|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
32784611|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
32784612|NCT00752583|Experimental|1|Peritoneal dialysis
32784613|NCT00752583|Active Comparator|2|Haemodialysis
32784614|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
32784615|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
32784616|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
32784617|NCT04917133|Experimental|Adapted Physical workshops|The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests
32784618|NCT04917133|Other|Control|"Standard of care The control group will have the classic program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation)."
33402979|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
32784619|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
32784620|NCT04916431|Experimental|mRNA-6231 Dose Level 1|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 1 of mRNA-6231 once every 2 weeks."
32784621|NCT04916431|Experimental|mRNA-6231 Dose Level 2|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 2 of mRNA-6231 once every 2 weeks."
32784622|NCT04916431|Experimental|mRNA-6231 Dose Level 3|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 3 of mRNA-6231 once every 2 weeks."
32784623|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
32784624|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
32784625|NCT04929379|Experimental|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
32784626|NCT04929379|Placebo Comparator|Placebo|Inactive tablets identical to fenofibrate
33402980|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
32784629|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
32784630|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
32784631|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
32784632|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
32784633|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
32784634|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
33402981|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
33402982|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
33402983|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
33402984|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
33402985|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
33402986|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
33402987|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
33402988|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX or SOX regimens):~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
33402989|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
33402990|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
33402991|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
32938959|NCT03302780|Experimental|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
33402992|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
33402993|NCT02366962|Experimental|ASP7374 group|
33402994|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
33402995|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
33402996|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
33402997|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
33402998|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
33402999|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
33403000|NCT02355808|No Intervention|Non Superfast|
33403001|NCT02355808|Other|Non Superfast GP intervention|
33403002|NCT02355808|Other|Non Superfast Tailored Leaflet|
33403003|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
33403004|NCT02355808|No Intervention|Superfast|
33403005|NCT02355808|Other|Non Superfast GP|
33403006|NCT02355808|Other|Superfast Tailored Leaflet|
33403007|NCT02355808|Other|Superfast GP + Tailored Leaflet|
33403008|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
33403009|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
33403010|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
33403011|NCT02366650||Bern ED|appr 100 patients at Bern ED
33403012|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
33403013|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
33403014|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
33403015|NCT02356042||Nursing home residents practicing GIA activity|
33403016|NCT02356042||Nursing home residents no practicing GIA activity|
33403017|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
33403018|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
32938960|NCT03302780|Experimental|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
32938961|NCT04332848|Experimental|(B) Empirical therapy|choose antibiotics according to drug history
32938962|NCT04332848|Active Comparator|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
33403019|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
33403020|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
33403021|NCT02355652|Active Comparator|Cemented TKA|
33403022|NCT02355652|Active Comparator|Uncemented TKA|
33403023|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
33403024|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
33403025|NCT03160534|No Intervention|Control|Only measurements
33403026|NCT01379586|Experimental|E|ONO-4053
33403027|NCT01379586|Placebo Comparator|P|Placebo
33403028|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
33403029|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
33403030|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
33403031|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
33403032|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .~These 2 capsules are taken orally b.i.d. during 4 weeks"
33403033|NCT05347368|Other|Control group (conventional therapy)|
33403034|NCT05347368|Experimental|Primal Reflex release Technique|
33403035|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
33403036|NCT02363296|Experimental|EEG phase-triggered PAS|TMS triggered to a specific phase of the EEG mu rhythm
33403037|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
33403038|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
33403039|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
33403040|NCT01377558|No Intervention|Control group|control group
33403041|NCT05331612|Experimental|Blended intervention condition|"Blended intervention condition, consisting of 5 face-to-face group sessions lasting 2 hours every 2 weeks, alternated with the online treatment protocol carried out by the participants in a self-applied. The intervention has a period of duration of 13 weeks and it is composed by 8 modules (Motivation for change, Psychoeducation, Stimulus control, Cognitive restructuring, Urge surfing and emotion regulation, Planning of significant activities, Coping skills and exposure with response prevention, and Relapse prevention). These modules is based in the online platform and manualized protocol treatment Sin jugar, ganas (Díaz-Sanahuja et al., 2021)."
33403042|NCT05331612|No Intervention|Waiting list control condition|Waiting list control group receives the blended treatment when the intervention has finished in the experimental group (blended group intervention).
33403043|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
33403044|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
33403045|NCT02361112|Experimental|pyrotinib combined with capecitabine|
33403046|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
33403047|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
33403048|NCT05327712|Experimental|Control|The control group was assigned to receive no outreach beyond an initial eligibility determination notice
33403049|NCT05327712|Experimental|Email-only|An email-only group assigned to receive an initial eligibility determination plus email reminders about signing up for marketplace coverage
33403050|NCT05327712|Experimental|Phone-only|A phone-only group assigned to receive an initial eligibility determination plus a phone call offering enrollment assistance from a service center representative (SCR);
33403051|NCT05327712|Experimental|Phone and email|A phone + email group assigned to receive an initial eligibility determination, email reminders about signing up for marketplace coverage and a phone call offering enrollment assistance.
33403052|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
33403053|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
33403054|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
33403055|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).~The drug dose must be individualized."
33403056|NCT05461638|Active Comparator|Unrestricted Kinematic Alignment|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
33403057|NCT05461638|Active Comparator|Restricted Kinematic Alignment|Mechanical Alignment and restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
33403058|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
32784637|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
32784638|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
33403059|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
33403060|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
33403061|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
33403062|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
33403063|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
33403064|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
33403065|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
33403066|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
33403067|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
33403068|NCT05326854|Experimental|intervention group|"1., 2., 3. İnterview (in hospital) The patient will be educated. Measuring tools will be applied. (Personal Information Form- Coping and Adaptation Process Scale)( discharge: Perinatal Grief Scale, Depression Anxiety Stress Scale) The mobile application developed within the scope of post-termination support will be downloaded to the patient's phone. Informed consent form will be signed by the patient.~Sharing problems, presenting solutions. Follow-up of the patient and strengthening and supporting in this process.~4., 5., 6. Interview at home (following the patient with mobile application and phone calls)~7. and 8., Interview at home (following the patient with mobile application and phone calls) Measuring tools will be appliedPerinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
33403069|NCT05326854|No Intervention|Control Group|"In the control group, data collection forms will be applied at admission and discharge to the service. There will be no application other than the routine care of the hospital. The routine care of the hospital applied to the control group within the scope of the research includes the information that should be given before, during and after the procedure that should be done depending on the medical intervention. In addition, there is no support program planned in the hospital and at discharge, and there is no follow-up after discharge.~Interview at hospital Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale, Discharge time, labor pain.~and 3. Interview at home Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
33403070|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
33403071|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
32784639|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
32784640|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
32784641|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
32784642|NCT04927897||Observational|In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures if these are not part of standard workup yet.
32784643|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
33085632|NCT04719351|Experimental|Condition 3: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33085633|NCT04719351|Experimental|Condition 4: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33085634|NCT04719351|Experimental|Condition 5: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33403072|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
33403073|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
33403074|NCT03477630|Experimental|Platelet Rich Plasma|Four intra-articular infiltration of autologous PRP every 15 days.
33403075|NCT03477630|Active Comparator|Hyaluronic Acid|One intra-articular infiltration of SYNVISC-ONE
33403076|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
33403077|NCT01379040||Control|Healthy volunteers
33403078|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
33403079|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
33403080|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
33403081|NCT02794246|Experimental|Single Arm|
33403082|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
33403083|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
33403084|NCT02360722|Other|Control Group|Nutritional education only
33403085|NCT02639026|Experimental|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
33403086|NCT02639026|Experimental|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
33403087|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
33403088|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
33403089|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
33403090|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
33403091|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
33403092|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention: see below"
33403093|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
33403094|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
33403095|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
33403096|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
32784644|NCT02399449|Experimental|Brand sodium ferric gluconate then Generic sodium ferric gluconate|Crossover trial. Each arm will receive Brand sodium ferric gluconate (single dose of 125mg) then Generic sodium ferric gluconate (single dose of 125mg)
32784645|NCT02399449|Experimental|Generic sodium ferric gluconate then Brand sodium ferric gluconate|Crossover trial. Each arm will receive Generic sodium ferric gluconate (single dose of 125mg) then Brand sodium ferric gluconate (single dose of 125mg)
32784646|NCT02217345|Experimental|Growth hormone|Growth hormone (somatropin) administered by daily injection at starting dose of 0.3 mg daily for women and 0.2 mg daily for men, with dose titration for goal IGF-1 in the upper quartile of normal for age.
32784647|NCT02217345|Placebo Comparator|Placebo|Placebo will be administered by daily injection in this double blind study design. Sham dosing will be performed to maintain blinding.
32784648|NCT04906447|No Intervention|Control arm|Participants randomized to the control arm will receive usual care
32784649|NCT04906447|Experimental|Acupuncture|Acupuncture treatments twice a week for five weeks
32784650|NCT04906447|Experimental|Guided Relaxation|Daily use of a guided relaxation app for 6 weeks
32784651|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
32784652|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
32784653|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
32784654|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
33291568|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
33291569|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
32784657|NCT04189575|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
32784658|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
32784659|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~Dasatinib, oral, daily, predetermined dosage per cycle~Radiologic Response Assessment every 2 cycles"
32784660|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
32784661|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
32784662|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
32938963|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
33291570|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33291571|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
33291572|NCT03715166|Experimental|Bumetanide/S95008|
33291573|NCT03715166|Placebo Comparator|Placebo|
33291574|NCT01035164|Experimental|Arm 1|
33291575|NCT01035164|Experimental|Arm 2|
33291576|NCT01035164|Experimental|Arm 3|
33291577|NCT00397046|Experimental|Neratinib 80 mg|
33291578|NCT00397046|Experimental|Neratinib 160 mg|
33291579|NCT00397046|Experimental|Neratinib 240 mg|
33291580|NCT00397046|Experimental|Neratinib 320 mg|
33291581|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
33291582|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
33291583|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
33291584|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
33291585|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
33291586|NCT01042418|Experimental|Whole kernel breakfast|
33291587|NCT01042418|Placebo Comparator|Wheat reference breakfast|
33291588|NCT01042418|Active Comparator|Milled kernel breakfast|
33291589|NCT01042652|Active Comparator|Nevirapine|
33291590|NCT01042652|Experimental|Raltegravir|
33291591|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
33085635|NCT04719351|Experimental|Condition 6: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33085636|NCT04719351|Experimental|Condition 7: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
32784663|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
32784664|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
32784665|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
32784666|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
32784667|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
32784668|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
32784669|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
33291592|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
32784670|NCT04905589|Placebo Comparator|ARM A|"Subsequent order of intake :~Iso-voluminous water, breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
32784671|NCT04905589|Active Comparator|ARM B|"Subsequent order of intake :~MCT in liquid form (75 ml of BetaQuik™), breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
32784672|NCT04905589|Active Comparator|ARM C|"Subsequent order of intake:~MCT in liquid form (75 ml of BetaQuik™), breakfast, WPI in liquid from (12.5g of WheyBasics in 200ml water), lunch, WPI in liquid from (12.5g of WheyBasics in 200ml water)), dinner"
33291593|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
33291594|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
33291595|NCT01040156||LAmb|
33291596|NCT01040156||Cas|
33291597|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
33291598|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
33291599|NCT00396812|Experimental|Rituximab|
33291600|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
33291601|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
33291602|NCT01566578|Experimental|EGF Cream|
33291603|NCT01566578|Placebo Comparator|Placebo cream|
33291604|NCT01042808||1|HIV-1 Infected patients treated with Isentress
33291605|NCT01040234||Active pain treatment|Bilateral dual TAP block
33291606|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
33291607|NCT01042886|Experimental|Family plus community focused intervention|
33291608|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
33291609|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
33291610|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
33403097|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
32938964|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
32938965|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
32938966|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
32938967|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
32938968|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
32938969|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
32938970|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
32938971|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
32938972|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
32938973|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
32938974|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
32938975|NCT04706702|Experimental|Tele-EF|Tele-EnhanceFitness
32938976|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
32938977|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
32938978|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
32938979|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
32938980|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
32938981|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
32938982|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
32938983|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
32938984|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
33291611|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
33291612|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
33291613|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
33291614|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
33291615|NCT01043120|Experimental|Barusiban|
33291616|NCT01043120|Placebo Comparator|Placebo|
33291617|NCT00085982|Experimental|Leptin Treatment|300 mg of study drug administered via SC injections.
33291618|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
33291619|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
33291620|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
33291621|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
33291622|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
33291623|NCT01043276|Experimental|Treatment A|
33291624|NCT01043276|Experimental|Treatment B|
33291625|NCT01043276|Experimental|Treatment C|
33291626|NCT01043276|Experimental|Treatment D|
33291627|NCT01043276|Experimental|Treatment E|
33291628|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
33291629|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
33291630|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
33291631|NCT00418184|Experimental|1|
33291632|NCT00418184|Placebo Comparator|2|
33318270|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
33403098|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
33085637|NCT04719351|Experimental|Condition 8: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
33085638|NCT04719351|Experimental|Condition 9: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
33085639|NCT04719351|Experimental|Condition 10: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
33085640|NCT04719351|Experimental|Condition 11: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
33403099|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
33085641|NCT04719351|Experimental|Condition 12: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
33403100|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
33403101|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
33403102|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
33403103|NCT03428100|Experimental|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
33403104|NCT03428100|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
33403105|NCT03428100|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
33403106|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with topical corticosteroids.
33403107|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
33403108|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
33403109|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
33403110|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
33403111|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
33403112|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
33403113|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
33403114|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
33403115|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
32784673|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
33085642|NCT04719351|Experimental|Condition 13: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
32784674|NCT05370313|Experimental|Cigarette smokers - Tobacco Parity|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Tobacco Parity Tax Condition described in the intervention section.
32784675|NCT05370313|Experimental|Cigarette smokers - Nicotine-Content|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Nicotine-Content Tax Condition described in the intervention section.
32784676|NCT05370313|Experimental|Cigarette smokers - Harm-Reduction|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Harm-ReductionTax Condition described in the intervention section.
32784677|NCT05370313|Experimental|Cigarette smokers - Modified Risk Tobacco Products (MRTP)|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the MRTP Tax Condition described in the intervention section.
32784678|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
32784679|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
32784680|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
32784681|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
32784682|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
32784683|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
32784684|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
32784685|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
32784686|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
32784687|NCT04905277|Experimental|Atenolol|Study subjects will take Atenolol 50 mg daily over 2 years
32784688|NCT04905277|Placebo Comparator|Placebo|Study subjects will take a placebo daily over 2 years
32784689|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
32784690|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
32784691|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
32784692|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
32784693|NCT04916119|Experimental|IBI323|Phase Ia enrolls patients with advanced malignancies. Phase Ib cohort A enrolls patients with NSCLC(IO-refractory), cohort B NSCLC(IO-naive), cohort C NSCLC(PD-L1 TPS≥1%), cohort D ES-SCLC or neuroendocrine tumors, cohort E MPM, cohort F UC, cohort G nccRCC, cohort H HCC, cohort I NPC, cohort J CC or HNSCC, cohort K GC or GEJC with HER2 negative, cohort L TNBC
32784694|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
32784695|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
32784696|NCT05451199|Experimental|ICP-488|Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet;
33085643|NCT04719351|Experimental|Condition 14: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
33085644|NCT04719351|Experimental|Condition 15: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
32784697|NCT05451199|Placebo Comparator|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo
33085645|NCT04719351|Experimental|Condition 16: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
33403116|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
32784698|NCT02424253|Experimental|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
32784699|NCT02424253|Placebo Comparator|Placebo|1 capsule orally once daily for 8 weeks.
32784700|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
32784701|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
32784702|NCT05454319|Experimental|Biofeedback Treatment Group|Medical device
32784703|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
33318271|NCT04241510|Active Comparator|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
33318272|NCT04241510|Active Comparator|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
33318273|NCT04241510|No Intervention|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
33318274|NCT01298960|Experimental|rGH Group|
33318275|NCT01298960|No Intervention|Non rGH group|
33318276|NCT01206686|Experimental|1 Hour Planning Prompt|
33318277|NCT01206686|Experimental|2 Hour Planning Prompt|
33318278|NCT01206686|Experimental|1 Day Planning Prompt|
33318279|NCT01206686|Experimental|Default Planning Prompt|
33318280|NCT01206686|Active Comparator|Control|
33318281|NCT00304031|Active Comparator|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
33318282|NCT00304031|Experimental|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
33318283|NCT00304031|Other|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
33318284|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
33318285|NCT01206842|Experimental|social cognition training|
33318286|NCT01206842|No Intervention|treatment as usual|
33318287|NCT04214366|Experimental|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
33318288|NCT04214366|Active Comparator|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
33318289|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
33318290|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
33318291|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
33318292|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
33318293|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
33318294|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
33318295|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
33318296|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
33318297|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
33318298|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
33318299|NCT03556904|Active Comparator|Standard of Care|Standard of care therapy will be up to the treating medical oncologist and is not the study intervention. Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although other standard agents (e.g. docetaxel, cabazitaxel) are allowed. Patients should begin systemic treatment within 3 weeks of randomization. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
33318300|NCT03556904|Experimental|Standard of Care + Ablative Radiation|Standard of care systemic therapy plus radiation. Radiation will start within 8 weeks of randomization and complete by day 84. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
33318301|NCT01206998|Experimental|Vaginal progesterone gel|
33318302|NCT01206998|Placebo Comparator|Placebo vaginal gel|
33318303|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
33318304|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
33318305|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
33318306|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
33318307|NCT03826940|Experimental|NF1 - experimental|
33318308|NCT03826940|Placebo Comparator|NF1 - control|
33318309|NCT03826940|Experimental|ASD - experimental|
33318310|NCT03826940|Placebo Comparator|ASD - control|
33318311|NCT04177238|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
33318312|NCT04177238|Experimental|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
32938985|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
32938986|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
32938987|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
33318313|NCT04177238|Experimental|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
33318314|NCT00303953|Experimental|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
33318315|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
33318316|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
33318317|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
33318318|NCT01201928||Technosphere Insulin Inhalation Powder|
33318319|NCT01201928||Comparator|Based on parent trial
33318320|NCT01299428|Active Comparator|cerebral oxygenation|
33318321|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
33318322|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
33318323|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
33318324|NCT01203176|Experimental|Post-menopausal asymptomatic women|
33318325|NCT00303719|Experimental|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
33318326|NCT00303719|Experimental|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
33318327|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
33318328|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
33318329|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
33318330|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
33318331|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
33318332|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
33318333|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
33318334|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
33318335|NCT05622812|Experimental|Treatment group|Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment
33318336|NCT05622812|No Intervention|No-treatment control group|Optional treatment will be administered at 12 months
33318337|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
33318338|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
33318339|NCT01203254|Placebo Comparator|Placebo|
33318340|NCT01203254|Active Comparator|Cholestagel|
33318341|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
33318342|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
33318343|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
33318344|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
33318345|NCT05669690||Fresh breast milk|Fresh breast milk obtained from volunteer mothers will be divided into four parts. Fresh breast milk will be studied for microbiota composition immediately within 3 hours.
33318346|NCT05669690||Breast milk stored at +4'C for 3 days|One part of previously obtained fresh breast milk will be stored at +4'C at refrigerator for 3 days long, then microbiota composition will be studied.
33403117|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
32784704|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
33403118|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
33403119|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
33403120|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
33403121|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
33403122|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
33403123|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
33403124|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
33403125|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
33403126|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
33403127|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
33403128|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
33403129|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
33403130|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
33403131|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
33403132|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
33403133|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
33403134|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
33403135|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
33403136|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
33403137|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
33403138|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
33403139|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
33403140|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
33403141|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
33403142|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
33403143|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
33403144|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
33403145|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
33403146|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
33403147|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
32938988|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
32938989|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
32938990|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
32938991|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
32938992|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
33318347|NCT05669690||Breast milk stored at -20'C for 3 months|Last part of the same breast milk specimen will be freezed at -20'C for 3 months and microbiota composition of the 3 months frozen milk will be studied.
32938993|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
32938994|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
32938995|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
33318348|NCT05623826|Experimental|Experimental|Experimental (receiving EMA and Imager EMI)
33318349|NCT05623826|No Intervention|Control|Control (receiving EMA only)
33318350|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
33318351|NCT00303485|Experimental|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
33318352|NCT00303485|Placebo Comparator|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
33318353|NCT01299740|Other|Control Group|Treatment as usual
33318354|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
33318355|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
33318356|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
33318357|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
33318358|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
33318359|NCT03983915|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
33318360|NCT03983915|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
33318361|NCT01300754|Active Comparator|Dextrose|
33318362|NCT01300754|Active Comparator|Lidocaine|
33318363|NCT01300754|Active Comparator|Usual Care|
33318364|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
33318365|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
33318366|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
33318367|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
33318368|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
33318369|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
32784705|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
32784706|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
32784707|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
32784708|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
32784709|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).~Participants may continue to receive treatment until discontinuation criteria are met."
32784710|NCT04904341|Experimental|active|The first Cerebrolysin infusion (30 ml mixed with 250 mL of saline) is intended to be initiated as soon as possible after successful recanalization is achieved and within 8h of AIS stroke onset. Cerebrolysin treatment will be continued (30 ml/d) once daily until day 21 (first cycle). The patients will receive a second cycle of treatment (30 ml/d for 21 days given in the Outpatient Department or Neurorehabilitation Clinic) from day 69 to 90 (± 3 days).
32938996|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
33291633|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
33291634|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
33291635|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
33291636|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
33291637|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
33291638|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
33291639|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
33291640|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
33291641|NCT00406640|Active Comparator|A|
33291642|NCT00406640|Active Comparator|B|
33291643|NCT01043510|Experimental|A1, first period|
33291644|NCT01043510|Active Comparator|A2, second period|
33291645|NCT01043510|Active Comparator|B1, first period|
33291646|NCT01043510|Experimental|B2, second period|
33291647|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
33291648|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
33291649|NCT01043666|Experimental|YM178 group|oral
33291650|NCT01043666|Placebo Comparator|placebo group|oral
33291651|NCT01043666|Experimental|tolterodine ER group|oral
33291652|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
33291653|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
32784711|NCT04904341|No Intervention|historical control|Historical data will be obtained by retrospective clinical chart reviews of patients hospitalized in the study center between 2017 and Dec.2020 and fulfilling the same clinical and radiological inclusion criteria in whom 12-month follow-up (including mRS, NIHSS, BI, EQ-5D-5L) could be obtained.
32784712|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
32784713|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
32784714|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
32784715|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
32784716|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
32784717|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
32784718|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
32784719|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
32784720|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
32784721|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
32784722|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
32784723|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
32784724|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
32784725|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
32784726|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
32784727|NCT02384551|Active Comparator|HTHS|High total carbohydrate with high total simple carbohydrate diet
32784728|NCT02384551|Experimental|HTLS|High total carbohydrate with low total simple carbohydrate diet
32784729|NCT02384551|Experimental|LTHS|Low total carbohydrate with low total simple carbohydrate diet
32784730|NCT02384551|Experimental|LTLS|Low total carbohydrate with low total simple carbohydrate diet
32784731|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
32784732|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
32784733|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
32784734|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
32784735|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
32784736|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
32784737|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
32784738|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
32784739|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
32784740|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
32784741|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32784742|NCT01649557|Experimental|Open-label OPDC-34712|
33291654|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
32784743|NCT02390245|Experimental|Phase 1: Telemedicine Screening Participants|Participants across the Philadelphia, PA region were invited to participate in free eye screenings at primary care physician offices or health centers. Screenings included images of optic nerve and macula using non-contact, autofocus, hand-held fundus cameras (Volk Optical, Mentor, Ohio, USA) and measuring Intraocular Pressure (IOP) in millimeters of mercury (mm Hg) with non-contact rebound tonometers TA01I (ICare, Helsinki, Finland).
32907260|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
33291655|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
33291656|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
33291657|NCT00394706|Sham Comparator|2|Sham ITD
33291658|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
33291659|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
33291660|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
33291661|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
33291662|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
33291663|NCT00395486|Experimental|Rosuvastatin|
33291664|NCT00395486|Active Comparator|Atorvastatin|
33291665|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
33291666|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
33291667|NCT00395018|Experimental|entecavir|
33291668|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
33291669|NCT00375518|Active Comparator|1|Atorvastatin
33291670|NCT00375518|Placebo Comparator|2|placebo
33291671|NCT01045772|Experimental|IL-1 trap|
33291672|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
33291673|NCT03085316|Experimental|Investigational Device|Patient who meets eligibility to be implanted with the St. Jude Medical Infinity™ Implantable Pulse Generator System (P140049), St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) Directional Lead and Extension (P140009), Swift-Lock™ Anchor (K092371), Butterfly anchor (P140009), manufactured by St. Jude Medical, Inc.
33291674|NCT00256750|Active Comparator|Cyclosporine (CsA)|
33291675|NCT00256750|Experimental|Belatacept LI (less intensive)|
33291676|NCT00256750|Experimental|Belatacept MI (more intensive)|
33291677|NCT00279201|Active Comparator|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
33291678|NCT00279201|Experimental|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
33291679|NCT00279201|Experimental|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
33291680|NCT00279201|Experimental|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
32784744|NCT02390245|Experimental|Phases 2 and 3: Enhanced Intervention Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Enhanced Intervention Group and were referred to a general ophthalmologist for follow-up eye care. Patient navigation and a social worker and referred to a general ophthalmologist close to the current health center or primary care physician office where they received the non dilated eye exam. Prior to all follow-up visits, patients in the Enhanced Intervention Group were provided a scheduled appointment and received a personal phone call reminding them to attend. Patients received necessary interpretation services and educational materials.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
32784745|NCT02390245|Experimental|Phases 2 and 3: Usual Care Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Usual Care Group and were referred to a general ophthalmologist for follow-up eye care. These patients were scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team was able to track outcomes. This group represents a realistic choice currently available for patients. Practice patterns vary depending on the resources, staff time, and services available within each local ophthalmology practice.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
32784746|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
32784747|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
33403148|NCT01066052|Experimental|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
33403149|NCT01066052|No Intervention|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
33403150|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
33403151|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
33403152|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
33403153|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
33403154|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
33403155|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
33403156|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
33403157|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
33403158|NCT01569516|Experimental|low dose|1mg, tid
33403159|NCT01569516|Experimental|Moderate dose|2mg,tid
33403160|NCT01569516|Experimental|High dose|4mg,tid
33403161|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
33403162|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
33403163|NCT02359786||Topicals Subjects using topical compounds|
33403164|NCT02359786||Patients undergoing Spinal Surgery using IOM|
33403165|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
33403166|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
33403167|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
33403168|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
33403169|NCT02359942|No Intervention|Controlled group|No use of test meal
33403170|NCT05764278|Experimental|effectiveness of earlier rehabilitation intervention after IA thrombectomy(experimental)|The effectiveness of early rehabilitation interventions within 24 hours compared with the control group
32784748|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
32784749|NCT02347189|Other|Melody TPV PB1016|
32784750|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
32784751|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
32784752|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
32784753|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
32784754|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
32784755|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
32784756|NCT04900207||Observed Group|Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
32784757|NCT04902625|Active Comparator|Naltrexone-Bupropion combination|The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.
32784758|NCT04902625|No Intervention|Control|The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.
32784759|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
32784760|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
33291681|NCT00279201|Active Comparator|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
32784761|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
32784762|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
32784763|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
32784764|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
32784765|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
32784766|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
32784767|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
32784768|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
32784769|NCT02379637|Placebo Comparator|B Placebo|Placebo
32784770|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
32784771|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
32784772|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
32784773|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
32784774|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
32784775|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
32907261|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
32907262|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
32938997|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
32784776|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
32784777|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
33291682|NCT00279201|Active Comparator|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
33291683|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
33291684|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
33291685|NCT03969394|Experimental|Heart Failure Patients|Patients with Heart Failure
33291686|NCT03973060|Experimental|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
33291687|NCT03973060|Experimental|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
33291688|NCT03973060|Experimental|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
33291689|NCT03973060|Experimental|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
33291690|NCT03969784|Experimental|colorectal cancer patient with peritoneal carcinosis|
33291691|NCT03969784|Active Comparator|colorectal cancer patient without metastasis|
33291692|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
33291693|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
33291694|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
33291695|NCT00203476|Active Comparator|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
33291696|NCT00203476|Active Comparator|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
33291697|NCT00203476|Active Comparator|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
33291698|NCT00203242|Experimental|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
33291699|NCT00200356|Experimental|Edaravone|
33291700|NCT00200356|Active Comparator|Ozagrel|
33291701|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
33291702|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
33291703|NCT00227344|Experimental|1|Catheter ablation
33291704|NCT00227344|Active Comparator|2|Antiarrhythmic drugs
33291705|NCT01065909||Diabetes type 2|
33291706|NCT01065909||Chronic Pain|
33291707|NCT01065909||Atrial Fibrillation|
33291708|NCT00227266|Placebo Comparator|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
33291709|NCT00227266|Active Comparator|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
33291710|NCT00227266|Experimental|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
33291711|NCT00256282|Experimental|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
33291712|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
33291713|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
33291714|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
33403171|NCT05764278|Active Comparator|effectiveness of earlier rehabilitation intervention after IA thrombectomy(control)|The effectiveness of early rehabilitation interventions compared with the experimental group
33403172|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
32784778|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
32784779|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
32784780|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
32784781|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
32784782|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
32784783|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
32784784|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
32784785|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
32784786|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
32784787|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
32784788|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
32784789|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
32784790|NCT02250651|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32784791|NCT02250651|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32784792|NCT02250651|Active Comparator|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
32784793|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
32784794|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
32784795|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
32784796|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
32784797|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
32784798|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
32784799|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
32784800|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
32784801|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
33403173|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
33403174|NCT05461248|Experimental|Experimental group|The stoma drainage fluid was reinfused once a week for 2 months after radical rectal surgery. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
33403175|NCT05461248|Sham Comparator|Conventional group|The conventional group received no additional intervention.
33403176|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
33403177|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
33403178|NCT05171868|Experimental|EMDR receiving group|EMDR is a psychotherapeutic approach that emphasizes the role of the brain's information processing system in perfecting the psychological consequences of distressing events. EMDR is an eight-phase treatment protocol, including procedure that focuses on the memories underlying current problems and those that must be specifically addressed to bring the client to a robust state of psychological health. One of its distinguishing aspects is its use of bilateral physical stimulation, such as side-to-side eye movements, alternating hand taps, or alternating auditory tones while the person undergoing treatment is mentally focusing on aspects of various life experiences.
33403179|NCT05171868|No Intervention|Waiting list Control Group|The control group will receive their routine care as usual. Once the trial is completed they will be invited for EMDR sessions
33403180|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
33403181|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
33403182|NCT05457504|Experimental|Experimental|
33403183|NCT05457504|Placebo Comparator|Usual Care|
33403184|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
33403185|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
33403186|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
33403187|NCT05764200|Active Comparator|lean normoglycaemic individuals fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
33403188|NCT05764200|Placebo Comparator|lean normoglycaemic placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
33403189|NCT05764200|Active Comparator|overweight and/or obesity and prediabetes/insulin fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
32784802|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
32784803|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32784804|NCT02249091|Experimental|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a dose of 40 mg/m^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
32784805|NCT02249091|Experimental|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
32784806|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
32784807|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
32784808|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
32784809|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
33403190|NCT05764200|Placebo Comparator|overweight and/or obesity and prediabetes/insulin resistance placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
32784810|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
32784811|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
33403191|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
33403192|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
33403193|NCT05383482|Experimental|Afuresertib in combination with Sintilimab and Nab-paclitaxel|Afuresertib in combination with Sintilimab and Nab-paclitaxel in patients with Endometrial Cancer and Cervical Cancer
33403194|NCT05383482|Experimental|Afuresertib in combination with Sintilimab and Docetaxel|Afuresertib in combination with Sintilimab and Docetaxel in patients with Gastric and Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer and Esophageal Cancer
33403195|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
33403196|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
33403197|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
33403198|NCT05348382|Experimental|Intradermal acupuncture group|Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster.
33403199|NCT05348382|Sham Comparator|Sham intradermal acupuncture group|Sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling.
33403200|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
33403201|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
33403202|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
33403203|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
33403204|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
33403205|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
33403206|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
33403207|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
33403208|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
33403209|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
33403210|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
33403211|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
33403212|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
33403213|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
33403214|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
33403215|NCT01377246|Placebo Comparator|Saline solution.|
33403216|NCT01377246|Experimental|Octrotide-LAR|
33403217|NCT02353936|Experimental|afatinib group|
32784812|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
32784813|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
32784814|NCT04891315||Pregnant women|Women aged 16+ in early pregnancy (before 20 weeks of gestation).
32784815|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
32784816|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
33403218|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
33403219|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
32784817|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
32784818|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
33085646|NCT04719351|Experimental|Condition 17: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085647|NCT04719351|Experimental|Condition 18: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
33291715|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
33291716|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
33291717|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
32784819|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
32784820|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
32784821|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
32784822|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.~The last study drug administration was at the Week 22 visit."
32784823|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
32784824|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
32784825|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
32784826|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
32784827|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
32784828|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
32784829|NCT01915498|Experimental|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
32784830|NCT04886323|Experimental|cold atmospheric plasma treatment group|Patients are treated with a plasma device. Each treatment time was 3min/cm2 based on the skin lesion area.The frequency of treatment is once a day. The duration of the treatment period is 1-2weeks.
32784831|NCT04886323|Active Comparator|Itraconazole capsules treatment group|Patients are treated with Itraconazole capsules, 200mg a day.The duration of the treatment period is 1-2weeks.
32784832|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
32784833|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
32784834|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
32784835|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
32784836|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
32784837|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
32784838|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
32784839|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
32784840|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
32784841|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
33291718|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
33291719|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
33291720|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
33291721|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
33291722|NCT00266877|Experimental|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
33291723|NCT00266877|Experimental|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
33291724|NCT00266877|Experimental|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
33291725|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
33085648|NCT04719351|Experimental|Condition 19: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085649|NCT04719351|Experimental|Condition 20: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085650|NCT04719351|Experimental|Condition 21: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085651|NCT04719351|Experimental|Condition 22: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
32784842|NCT01617460|Experimental|Aripiprazole|administered orally once daily
33085652|NCT04719351|Experimental|Condition 23: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085653|NCT04719351|Experimental|Condition 24: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
33085654|NCT04719351|Experimental|Condition 25: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
33085655|NCT04719351|Experimental|Condition 26: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
33291726|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
33291727|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
33291728|NCT02532075|Other|Control Trial|No warm up
32784843|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
32784844|NCT01889602|Experimental|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
33291729|NCT00256204|Experimental|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
33291730|NCT00256204|Experimental|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
33291731|NCT00256204|Placebo Comparator|Placebo|Each arm is followed by 36 weeks of placebo
33291732|NCT00256126|Experimental|Turner Syndrome (TS)|
33291733|NCT00256126|Experimental|Growth Hormone Deficiency (GHD)|
33291734|NCT03972358|Experimental|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
33291735|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
33291736|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
33291737|NCT03969316|Active Comparator|Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
33291738|NCT03969316|Active Comparator|Transversus Abdominis Plane Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
33291739|NCT03972046|Experimental|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10^6 PFU/mL; Dose #2: 10^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10^8 PFU/mL every 14 (+/-3) days).~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.~May stop earlier than 3 months at physician discretion depending on side effects and response.~Ultrasound of tumor nodal basin(s) monthly.~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.~PET CT or brain MRI as needed at discretion of the investigator.~Manual tumor measurement in office prior to each injection."
33291740|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
33291741|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
32784845|NCT01889602|Experimental|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
32784846|NCT01889602|Experimental|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
33085656|NCT04719351|Experimental|Condition 27: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
33085657|NCT04719351|Experimental|Condition 28: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
32784847|NCT01935700|Experimental|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
32784848|NCT01618162|Experimental|Insulin degludec/liraglutide|
32784849|NCT01618162|Placebo Comparator|Placebo|
32784850|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
32784851|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
32784852|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
32784853|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
32784854|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
32784855|NCT04771767|Experimental|Ketamine + eCBT|Over 12 weeks, participants receive weekly sessions of asynchronous online cognitive-behavioural therapy as well as 6 sub-anesthetic infusions of Ketamine
32784856|NCT04771767|No Intervention|Control|Participants are in a control condition receiving treatment as usual, during which time they will not receive the experimental treatment and will have no change in their treatment regimen.
32784857|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
32784858|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
32784859|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
32784860|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
33085658|NCT04719351|Experimental|Condition 29: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
33085659|NCT04719351|Experimental|Condition 30: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
32784861|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
32784862|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
32784863|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
32784864|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
32784865|NCT02374957|No Intervention|Control|No Cilostazol
32784866|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
32784867|NCT02374255|No Intervention|Usual Care|
33291742|NCT01071772|Experimental|euglycemia|
33291743|NCT01071772|Experimental|hyperglycemia|
32938998|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
32938999|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
32939000|NCT04332536|Experimental|Chronic Heart Failure|
32939001|NCT04332536|Active Comparator|Age-matched healthy controls|
32939002|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
32939003|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
32939004|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
32939005|NCT04735952||AIM 1|No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
32939006|NCT04735952||AIM 2|No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
33291744|NCT03971890|Experimental|DanceTherapy Group|The experimental group will receive a dance treatment.
33291745|NCT03971890|Experimental|Control Group|The control group will be subjected to a educational treatment.
33291746|NCT00278889|Active Comparator|1|Bevacizumab + FOLFOX
33291747|NCT00278889|Experimental|2|AZD2171 + FOLFOX
33291748|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
33291749|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
33291750|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
33291751|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
33291752|NCT00278109|Experimental|PBI with Concurrent Chemotherapy|Phase I Single Arm study of PBI with concurrent chemotherapy. Primary endpoint is radiation toxicity. The intervention is partial breast radiation with doxorubicin and cyclophosphamide.
33291753|NCT00296517|Placebo Comparator|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
33291754|NCT00296517|Experimental|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
33291755|NCT00224770|No Intervention|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
32939007|NCT03320096|Experimental|Microfocused ultrasound with visualization|
32939008|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
32939009|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
32939010|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
32939011|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
32939012|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
32939013|NCT03446846|Experimental|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
32939014|NCT03446846|Experimental|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
32939015|NCT03446846|Placebo Comparator|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
32939016|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
32939017|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
32939018|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
32939019|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
32939020|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
32939021|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
32939022|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
32784868|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
32784869|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
32784870|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
32784871|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
32784872|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
33085660|NCT04719351|Experimental|Condition 31: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
33085661|NCT04719351|Experimental|Condition 32: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
33085662|NCT04537585|Experimental|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour
33085663|NCT04537585|Experimental|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour"
33085664|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
32784873|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
32784874|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
33085665|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
33085666|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
33085667|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
33085668|NCT04537468|Other|Skin sample collection|Skin sample collection for gene expression analyses.
33085669|NCT04537390|Other|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
33085670|NCT04536883|Experimental|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
33085671|NCT04536844|Experimental|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
33291756|NCT00224770|Active Comparator|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots."
33291757|NCT00224770|Active Comparator|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots."
33291758|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
33291759|NCT00266409|Experimental|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
33291760|NCT00266409|Experimental|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
33291761|NCT00266409|Experimental|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
33291762|NCT00266409|Experimental|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
33291763|NCT00277095|Experimental|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
33291764|NCT00265785|Experimental|Pemetrexed|pemetrexed
33291765|NCT00276159|Experimental|852A Treatment|Patients receiving at least one dose of 852A.
33291766|NCT02532153|Other|Open-Label Ketamine|
33291767|NCT01072227||Single Group|
33291768|NCT00265395|Active Comparator|Standard therapy|Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
33291769|NCT00265395|Experimental|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
33291770|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
33291771|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
32784875|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
32784876|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
32784877|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
32784878|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
32784879|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
32784880|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
32784881|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
32784882|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
32784883|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
32784884|NCT02210091|Experimental|<6 years old|
32784885|NCT02210091|Experimental|≥6 to <12 years|
32784886|NCT02338999|Experimental|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
33403220|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
33085672|NCT04536844|Placebo Comparator|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
33085673|NCT00415584|Experimental|Cinacalcet HCl|
32784887|NCT02338999|Experimental|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
33085674|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
33085675|NCT04536922|Experimental|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
33085676|NCT04536961|Experimental|Part A: Reference Treatment|
33085677|NCT04536961|Experimental|Part A Prototype|
32784888|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
32784889|NCT04750473|Experimental|Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.
32784890|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
32784891|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
32784892|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
32784893|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
32784894|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
32784895|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
33085678|NCT04536961|Experimental|Part C Reference Treatment|
33085679|NCT04536961|Experimental|Part C: Prototype|
33085680|NCT04536961|Experimental|Part B: Treatment 1|
33085681|NCT04536961|Experimental|Part B: Treatment 2|
33085682|NCT04536961|Experimental|Part B: Treatment 3|
33085683|NCT04536961|Experimental|Part B: Treatment 4|
33291772|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
33291773|NCT00195442||A|Patients with Hemophilia A
33085684|NCT04536961|Experimental|Part B: Treatment 5|
33085685|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
33291774|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
33291775|NCT01071135|Experimental|Quetiapine XR|
33291776|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
33291777|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
33291778|NCT00275301|Experimental|Open-label Olanzapine.|Open-label Olanzapine.
33403221|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
33403222|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
32784896|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
32784897|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
32784898|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
32784899|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
32784900|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
32784901|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
32784902|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
32784903|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
32784904|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
32784905|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
32784906|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
32784907|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
32784908|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
32784909|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
32784910|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
32784911|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
32784912|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
33403223|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
33403224|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
32784913|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
33403225|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
32784914|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
32784915|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
32784916|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
32784917|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
32784918|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
32784919|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
32784920|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
33403226|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
32784921|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
33403227|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
32784922|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
33403228|NCT02353546|No Intervention|Usual Care|
33403229|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
33403230|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
33403231|NCT02892149|Experimental|Vadadustat|
33403232|NCT02892149|Active Comparator|Darbepoetin alfa|
33403233|NCT02352532|Experimental|Low Back Pain - Dry Needling|
33403234|NCT02352532|Sham Comparator|Low Back Pain - Sham|
33403235|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
33403236|NCT05335356|Experimental|Bmab1200|Bmab 1200 45 mg Bmab 1200 90 mg
33403237|NCT05335356|Active Comparator|Stelara|Stelara 45 mg Stelara 90 mg
33403238|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
33403239|NCT05046912|Experimental|Clinical|Clinical participants with a primary diagnosis of psychosis or related disorder.
33403240|NCT05046912|Active Comparator|Non-clinical|Non-clinical participants with no mental health diagnoses.
33403241|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.~During follow up if disease gets worse, participant called by study staff every 3 months."
33403242|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
33403243|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
33403244|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
33403245|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
33403246|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
33403247|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
33403248|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
33403249|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
33403250|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
33403251|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
33403252|NCT05278338|Experimental|Group a|JMT103 45 mg
33403253|NCT05278338|Experimental|Group b|JMT103 60 mg
33403254|NCT05278338|Experimental|Group c|JMT103 90 mg
33403255|NCT05278338|Active Comparator|Group d|Denosumab 60 mg
33403256|NCT05278338|Placebo Comparator|Group e|Placebo
33403257|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
33403258|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
32784923|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
32939023|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
33403259|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
32784924|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
32784925|NCT01362790|Experimental|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m^2 on day 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
32784926|NCT01362790|Experimental|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
33403260|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
33403261|NCT05232942||Studied group|The study population will consist of patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (galcanezumab, fremanezumab or eptinezumab) or else its receptor (erenumab), with positive response, and discontinue the treatment.
33403262|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
33403263|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
33403264|NCT01310933||Kikuchi's disease|
33403265|NCT01310933||Malignant lymphoma|
33403266|NCT05157516|Active Comparator|group ESPB|Erector Spinae Plane Block
33403267|NCT05157516|Active Comparator|In group CEA|Caudal epidural block
33403268|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
33403269|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
33403270|NCT05665049|No Intervention|Control Group|Only educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided.
33403271|NCT05665049|Experimental|Intervention Group 1 - Non-Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice - which is meant to show our appreciation and support for their efforts in breastfeeding.
33403272|NCT05665049|Experimental|Intervention Group 2 - Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice if they are still exclusively breastfeeding.
33403273|NCT05130762||General Cohort|All patients who receive a VAD as standard of care in combination with needle-free connectors. A BD PureHub™ Disinfecting Cap will be placed on each eligible needle-free connector and all attachments/removals incl. reason for change will be documented up to 45 days post-enrollment date.
33403274|NCT04187092|Experimental|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
33403275|NCT04187092|Active Comparator|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
33403276|NCT05100966|No Intervention|Usual Care|Participants in the control arm will receive usual care which involves patient education that all participants who are scheduled for hip/knee replacement receive at the arthroplasty centre. This may include recommendations to attend fitness classes or discuss nutrition tips and smoking cessation initiatives with their family doctor or other healthcare provider before surgery.
33403277|NCT05100966|Active Comparator|FitJoints Multi-modal Intervention|
32939024|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
33403278|NCT05084976||Pediatric Technology Dependent Patients at Cohen Children's Medical Center|
32939025|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
32939026|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
32939027|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
32939028|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
32939029|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
33403279|NCT05084976||Pediatric Technology Dependent Patients at Ann & Robert H. Lurie Children's Hospital of Chicago|
33403280|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
33403281|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
33403282|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
33403283|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
33403284|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
33403285|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
33403286|NCT02896127|Experimental|Secukinumab|"Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
33403287|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
33403288|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
33403289|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
33403290|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
33403291|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
33403292|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
33403293|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
33403294|NCT03724097||Group 3|Patients receiving palliative care
33403295|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
33403296|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
33403297|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
33403298|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
33403299|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
33403300|NCT03546647|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
33403301|NCT03546647|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
33403302|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
33403303|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
32784927|NCT01362790|Experimental|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
32784928|NCT01362790|Experimental|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
32939030|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
33403304|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
32784929|NCT01362790|Experimental|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
33403305|NCT03727529|Experimental|Intervention group|
33403306|NCT03727529|Active Comparator|Control group|
33403307|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
33403308|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
33403309|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
33403310|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
33403311|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
33403312|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33403313|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33403314|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33403315|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33403316|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
33403317|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
33403318|NCT03077412|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
33403319|NCT03077412|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
33403320|NCT03077412|Experimental|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
33403321|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily (BID) for up to 12 weeks.
33403322|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, BID for up to 12 weeks.
33403323|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, BID for up to 12 weeks.
33403324|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, BID for up to 12 weeks.
32784930|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
32784931|NCT04759989|Active Comparator|30cc/kg ideal body weight (IBW)|"30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm~Using Devine's formula. (men: 50kg + 2.3kg * (height(in) - 60); women: 45.5kg + 2.3kg * (height(in) - 60)"
32784932|NCT04759989|Active Comparator|30cc/kg adjusted body weight (AdjBW)|"30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW)."
32784933|NCT04759989|Active Comparator|30cc/kg actual body weight (ABW)|"30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight"
32784934|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
32784935|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
32784936|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
32939031|NCT03210337|Experimental|Active|A-101 Topical Solution
32939032|NCT03210337|Placebo Comparator|Vehicle|Vehicle
32939033|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
32939034|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Autonomous minor consent
33403325|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
33403326|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
32939035|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
33403327|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
32939036|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Parental permission required
33403328|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
33403329|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
33403330|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
33403331|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
33403332|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
33403333|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~Activa PC Primary Cell Neurostimulator - (Model 37601)~Activa RC Rechargeable Neurostimulator - (Model 37612)~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~DBS Lead - (Model 3387)~DBS Extension - (Models 37085/6)~Patient Programmer - (Model 37642)~Test Stimulator - (Model 3625)~N'Vision Clinician Programmer - (Model 8840)~N'Vision Software Application Card - (Model 8870)"
33403334|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
33403335|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
33403336|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
33403337|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
33403338|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
33403339|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
33403340|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
33403341|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
33403342|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~Combination Product: microneedling and Platelet rich plasma.~radiation : NB-UVB phototherapy"
33403343|NCT00775476|Active Comparator|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
33403344|NCT00775476|Placebo Comparator|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
33403345|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
33403346|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
32939037|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
32939038|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
32939039|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
32939040|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
32939041|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
32939042|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
32939043|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
32784937|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
32784938|NCT02337907|Placebo Comparator|Placebo comparator|
32784939|NCT02337907|Experimental|BI 409306 dose 1|
32784940|NCT02337907|Experimental|BI 409306 dose 2|
32784941|NCT02337907|Experimental|BI 409306 dose 3|
32784942|NCT02337907|Active Comparator|Active Comparator Donepezil|
32784943|NCT02337907|Experimental|BI 409306 dose 4|
32784944|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
32784945|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
32784946|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
32784947|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
32784948|NCT04884685|Experimental|Experimental Group|Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
32784949|NCT04884685|Placebo Comparator|Control Group|Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.
32784950|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
32784951|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
33085686|NCT04536610|Experimental|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
33403347|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections~Weeks 3-25:~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:~Nivolumab (Opdivo), OR~Pembrolizumab (Keytruda), OR~Cemiplimab (Libtayo) OR~Atezolizumab (Tecentriq) OR~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
33403348|NCT04674228||Observational (medical record review)|Patients who participated in MAY2016-07-01 undergo review of medical records.
33403349|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
32784952|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
32784953|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
32784954|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams [mg] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram [mg/kg] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
32784955|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m^2 intravenously (IV) q3w, epirubicin 100mg/m^2 IV q3w, and cyclophosphamide 600mg/m^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m^2 in Cycle 5, then 100mg/m^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
32939044|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
32939045|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
32939046|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
32939047|NCT03460652|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
32939048|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
32939049|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
32939050|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
32939051|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
33403350|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
33403351|NCT03146728||able-bodied|age height and weight matched able bodied
33403352|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
33403353|NCT03968406|Experimental|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
33403354|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
33403355|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
32939052|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
33403356|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
33403357|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
33403358|NCT04917744||Ancillary-correlative (blood collection, chart review)|Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
33403359|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
33403360|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
32939053|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
32939054|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
32939055|NCT03247322|Experimental|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
32939056|NCT03247322|No Intervention|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
32939057|NCT04332679|Active Comparator|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
32939058|NCT04332679|Experimental|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
32939059|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
32939060|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
32939061|NCT03324607|Experimental|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
32939062|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
32939063|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
32939064|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
32939065|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
32939066|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
32939067|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
32939068|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
32939069|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
32939070|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
32939071|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
32939072|NCT03249272|Active Comparator|Control|
32939073|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
32939074|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
33085687|NCT04536610|Active Comparator|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
33403361|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
32939075|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
33403362|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
33403363|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
33403364|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
33403365|NCT04879914|Experimental|Butyrate|Patients taking butyrate
33403366|NCT04879914|Experimental|Placebo|Patients taking placebo
33403367|NCT03155074|Experimental|High-Intensity Training|
33403368|NCT03155074|No Intervention|Usual Care|
33403369|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
33403370|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
33403371|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
33403372|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
33403373|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
33403374|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
33403375|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
33403376|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
33403377|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
33403378|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
33403379|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
33403380|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
33403381|NCT04632654|Experimental|PAfitME|For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention.
33403382|NCT04632654|No Intervention|Attention Control|For 6 weeks, the attention control group will receive National Cancer Institute-based survivorship education and exergame equipment (Nintendo Switch).
33403383|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
33403384|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
33403385|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
33403386|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
33403387|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
33403388|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
33403389|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
33403390|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
32939076|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
32939077|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
32939078|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
32939079|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
32939080|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
32939081|NCT03470012|Experimental|Treatment Arm|Investigational tape
32939082|NCT04758624|Experimental|Deep Brain Stimulation(DBS)|
33403391|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
33403392|NCT04852224||Androgen Deprivation Therapy (ADT+)|Men diagnosed with prostate cancer and scheduled to receive greater than or equal to 6-months of treatment with androgen deprivation therapy
33403393|NCT04852224||Prostate Cancer Surveillance (ADT-)|Men diagnosed with prostate cancer under active surveillance (i.e., not receiving active treatment for prostate cancer)
33403394|NCT04852224||Non-cancer Control (PCa-)|Age-matched men without a history of cancer
33403395|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
33403396|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
33403397|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
33403398|NCT04808778||Participants with sickle cell anemia identified with neurological morbidity|"Successful completion of screening procedures inclusive of 1.) Cerebral blood flow velocity greater than or equal to 200 cm/sec measured twice or 2.) At least one measurement greater than or equal to 220 cm/sec in the middle cerebral artery or 3.) Two TCD measurements above 190 cm/sec within a three-month interval;~MRI showing cerebral infarcts with or without (based on Silent Cerebral Infarct Trial (SIT) criteria) neurological deficits on standard neurological examination;~Informed consent from a participant (> 18 years) or parent/legal guardian for participants (< 18 years) and assent of the participant completed;~Acceptance of hydroxyurea therapy for one year as standard care. After one year of therapy, the participant will have the option to continue therapy with follow-up visits to monitor adherence to therapy with his or her care provider."
33403399|NCT04808778||Participants with sickle cell anemia identified to be without neurological morbidity|"Successful completion of screening procedures inclusive of cerebral blood flow velocity less than or equal to 199 cm/sec in the middle cerebral artery;~Normal MRI and MRA;~No focal neurological deficit on standard neurological examination;~Informed consent from a participant (> 18 years), or parent/legal guardian for participants (< 18 years) and assent from the participant;~Agreement to be followed for at least one year in the study."
33403400|NCT05653570|Active Comparator|Ultrasound Guidance Only|
33403401|NCT05653570|Experimental|Electrical stimulation and Ultrasound Guidance|
33403402|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
33403403|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
33403404|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
33403405|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
33403406|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
33403407|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
33403408|NCT04438798|Placebo Comparator|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
33403409|NCT04438798|Active Comparator|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
33403410|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
33403411|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
33403412|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
33403413|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
33403414|NCT04530162||Emergency Medicine Herpes Zoster Patients|Emergency Medicine adult patients with herpes zoster pain onset within 30 days of characteristic dermatomal herpes zoster rash who receive nerve block using bupivacaine and dexamethasone. The patient will be then started on Acyclovir 800 mg five times daily for seven days. For mild to moderate breakthrough pain, the patient will be prescribed a 5-day course of Tylenol 650 mg and Ibuprofen 400 mg taken up to every 8 hours together. For severe breakthrough pain, the patients will be prescribed a two-day course of 7.5 mg morphine sulfate immediate release to be taken up to every 6 hours. The location of the nerve block and dosage of injected medications will depend on the distribution of the affected dermatome.
33403415|NCT04478422|Experimental|Muscle strengthening with vascular occlusion|Quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, with partial occlusion to blood flow. The occlusion equipment will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017).
33403416|NCT04478422|Active Comparator|Conventional muscle strengthening|Conventional quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, without occlusion to blood flow.
33403417|NCT04796922|Experimental|Treatment Group A|Participants will be administered with parsaclisib in combination with investigator choice of rituximab or obinutuzumab.
33403418|NCT04796922|Placebo Comparator|Treatment Group B|Participants will be administered with placebo in combination with investigator choice of rituximab or obinutuzumab
33403419|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
33403420|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
33403421|NCT05255692|Experimental|Complete evaluation UDO and fMRI|Evaluation including both urodynamic evaluation and functional MRI testing
33403422|NCT04305678|Experimental|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
32784956|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
32784957|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
32784958|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
32784959|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
32784960|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
32784961|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
32784962|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
33085688|NCT04536649|Experimental|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
33403423|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
33403424|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
33403425|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
33403426|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
33403427|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
33403428|NCT05255614|Active Comparator|First Group|the participants will start training on the pelvic trainer and assessment will be via assessment via a checklist. Then at a later time, they will be trained on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator.
33403429|NCT05255614|Active Comparator|Second Group|the participants will start training on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator. Then at a later time, they will be trained on the pelvic trainer and assessment will be via assessment via a checklist.
33403430|NCT04469868|Experimental|No opioids prescriptions at discharge|Patients will receive non-opioid analgesia, mostly over the counter, medications such as acetaminophen or ibuprofen. Opioids may be prescribed if the patients experience break through pain and call the office.
33403431|NCT05255458|Experimental|AK102 regimen 1|
33403432|NCT05255458|Placebo Comparator|Placebo|
33403433|NCT04441320|Experimental|CMUS group|Coated metal ureteral stent is indwelled.
33403434|NCT04441320|Other|DJS group|Double-J stent is indwelled
33403435|NCT04478656|Experimental|BBV121-2.5 µg|BBV121: Each 0.5ml vial contain purified10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
33403436|NCT04478656|Placebo Comparator|Placebo|Each 0.5ml vial contain purified 2.5 µg, 5 µg or 10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
33403437|NCT04478656|Experimental|BBV121-5 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
33403438|NCT04478656|Experimental|BBV121-10 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5ml
33403439|NCT03149926||Patients with Borderline Personality Disorder|
33403440|NCT03149926||Healthy controls|
33403441|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
33403442|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
33403443|NCT04478188||Cardiogenic Shock Patients Needing TMCS|Heart failure patients who undergo TMCS insertion for acute decompensated heart failure and cardiogenic shock.
33403444|NCT04747314|Experimental|Antidepressant (AD)|Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
32939083|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
33403445|NCT04747314|Experimental|Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
33403446|NCT04747314|Experimental|Antidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
33403447|NCT04747314|Experimental|AD -> EFAR|"Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable."
33403448|NCT04747314|Experimental|EFAR -> AD|"Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks."
33403449|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
33403450|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
33403451|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
33403452|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
33403453|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
33403454|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
33403455|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
33403456|NCT05763966||Early stage psychosis patients (EPP)|Diagnosis of psychotic disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) with onset of less than 2 years prior to inclusion.
33403457|NCT05763966||Individuals at clinical high risk for psychosis (CHR-P)|Fulfills criteria for clinical high risk for psychosis according to Structured Interview for Psychosis-risk Syndromes (SIPS).
33403458|NCT05763966||Healthy controls (HC)|Age- and sexmatched controls.
33403459|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
33403460|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
33403461|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
33403462|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
33403463|NCT03630276|Other|Neutrophil/lymphocyte ratio|
33403464|NCT03630276|Other|Platelet/lymphocyte ratio|
33403465|NCT03630276|Other|CRP|
33403466|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
33403467|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
33403468|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
33085689|NCT04536649|Experimental|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
33403469|NCT04173000|Experimental|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
33403470|NCT04478032|Sham Comparator|sham stimulation|20 patients will be randomly allocated into this group,they will receive sham stimulation.
33403471|NCT04478032|Active Comparator|real stimulation dTMS targeting the ACC|20 patients will be randomly allocated into this group,they will receive real stimulation.
33403472|NCT04158024|No Intervention|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
33403473|NCT04158024|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
33403474|NCT02039206|Experimental|Treatment|Deep TMS
33403475|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
33403476|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
33403477|NCT03630042|Experimental|Pembrolizumab and Rituximab|
33403478|NCT03149692|Experimental|Penile allograft|Penile human allografts transplanted
33403479|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
33403480|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
33403481|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
33403482|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:~GDM health care knowledge~self-awareness of health~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)~participation in discussions or browsing forums~healthy lifestyle guidance and counseling~reminder systems~a token system of earning points in exchange for prizes."
33403483|NCT03726983|No Intervention|Control group|only received usual care
33403484|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
33403485|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
33403486|NCT04428606|Experimental|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
33403487|NCT04428606|Experimental|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
33403488|NCT04428606|Placebo Comparator|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
33403489|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
33403490|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
33403491|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
33403492|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
33403493|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
33403494|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
33403495|NCT03073980|Experimental|Group 1: Intravenous (IV) acetaminophen/oral (PO) placebo|In the pre-operative suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
33403496|NCT03073980|Active Comparator|Group 2: Intravenous (IV) placebo/oral (PO) acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
33403497|NCT03073980|Placebo Comparator|Group 3: Oral and intravenous Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
33403498|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
33403499|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
33085690|NCT04536649|Experimental|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
33403500|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
33403501|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
33403502|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
32784963|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
32784964|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
33403503|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
32784965|NCT04749615|Placebo Comparator|No PAI + ACB & IPACK|Control: saline injection (same injection technique and volumes as described for the active intervention, of normal saline)
32784966|NCT04749615|Active Comparator|PAI + ACB & IPACK|Active intervention: Periarticular injection: one deep injection prior to cementation and then a second more superficial injection prior to closure. The deep injection will consist of bupivacaine 0.25% with 1:200,000 epinephrine, 30 cc; morphine, 8 mg/ml, 1cc; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 in 10 ml; normal saline, 22cc. The superficial injection will be 20 ml 0.25% bupivacaine
32784967|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
32784968|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
32784969|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
32784970|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
32784971|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
32784972|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
32784973|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
32784974|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
32784975|NCT01933672|Experimental|PF-04937319 once-daily|
32784976|NCT01933672|Experimental|PF-04937319 split-dose|
32784977|NCT01933672|Active Comparator|Sitagliptin once-daily|
32784978|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
32784979|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
32784980|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
32784981|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
32784982|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
32784983|NCT04759599|Active Comparator|Group 1|Group 1 will undergo Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks
32784984|NCT04759599|Active Comparator|Group 2|Group 2 will undergo Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
32784985|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
32784986|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
33403504|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
32784987|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
32784988|NCT02131311|Experimental|pessary|disposable, single-use pessary
32784989|NCT05269017|Experimental|Case group|The case group patients will receive vitamin D3 nasal drops
32784990|NCT05269017|Active Comparator|Control group|The control group will remove local corticosteroid spray
32784991|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
32784992|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
32784993|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
32784994|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
32784995|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
33403505|NCT04117932|Experimental|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
33403506|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
33403507|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
33403508|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
33403509|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
33403510|NCT03930186|Experimental|Apremilast|After a 5-day titration, participants received 30 mg apremilast tablets orally twice daily (BID) for up to 32 weeks in addition to their existing topical therapy. At week 16 participants were permitted to decrease their use of topical therapy at their own discretion under the direction of their physician.
33403511|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
33403512|NCT02351362|No Intervention|Control Group|Standard of care
33403513|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
32784996|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
32784997|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
32784998|NCT02131155|Placebo Comparator|Placebo|Once daily
33403514|NCT02351440|Placebo Comparator|Placebo|placebo
33403515|NCT03504917|Experimental|Balovaptan|
33403516|NCT03504917|Placebo Comparator|Placebo|
33403517|NCT02343172|Experimental|HDM201+LEE011|
33403518|NCT03899688|Experimental|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites. Bone to implant contact was measured at the turned and machined surface.
33403519|NCT03899688|Active Comparator|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites. Bone to implant contact was measured at the turned and machined surface.
33403520|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
33403521|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
33403522|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
33403523|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
33403524|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
33403525|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
33403526|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
33403527|NCT02342938|Experimental|Patient|
33403528|NCT02342938|Experimental|Volunteers|
33403529|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
33403530|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
33403531|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
33403532|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
33403533|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
32784999|NCT04749225||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
33403534|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
33403535|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
32785000|NCT04749225||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
33403536|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
33403537|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
33403538|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
33403539|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
33403540|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
33403541|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
33403542|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
33403543|NCT02346994|Experimental|Melt test blend 3.2|
33403544|NCT02346994|Active Comparator|Corn Oil|
33403545|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
33403546|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
33403547|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
33403548|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
33403549|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
33403550|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
33403551|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
33403552|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
33403553|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
32939084|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
32939085|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
33403554|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
33403555|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
32939086|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
32939087|NCT04761822|Experimental|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
32939088|NCT04761822|Experimental|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
32939089|NCT04761822|Experimental|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
33403556|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
33403557|NCT04459728|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
33403558|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
33403559|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
33403560|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
33403561|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
33403562|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
33403563|NCT04436952|Experimental|H7 coil only|patients undergoing DTMS treatment using the H7 coil
33403564|NCT04436952|Active Comparator|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
33403565|NCT04436952|Active Comparator|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
33403566|NCT04436952|Active Comparator|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
33403567|NCT04436952|Active Comparator|ERP only|20 patients undergoing ERP only
33403568|NCT03146494||STAAD|
33403569|NCT03146494||Normal|
33403570|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
33403571|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
33403572|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
33403573|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
33403574|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
33403575|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
33403576|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
33403577|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
33403578|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
33403579|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
33403580|NCT04300296|Experimental|Cutaneous lichen planus secukinumab 300mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1ml PFS in cutaneous lichen planus patients
33403581|NCT04300296|Placebo Comparator|Cutaneous lichen planus placebo|Placebo in 1ml PFS in cutaneous lichen patients
33403582|NCT04300296|Experimental|Mucosal lichen planus secukinumab 300 mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1 ml PFS in mucosal lichen planus patients
33403583|NCT04300296|Placebo Comparator|Mucosal lichen planus placebo|Placebo 1 ml PFS in mucosal lichen planus patients
33403584|NCT04300296|Experimental|Lichen planopilaris secukinumab 300 mg Q4W|Secukinumab 300 mg every 4weeks provided in 1ml PFS in lichen planopilaris patients
33403585|NCT04300296|Placebo Comparator|Lichen planopilaris placebo|Placebo in 1ml PFS in lichen planopilaris patients
33403586|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
33403587|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
33403588|NCT05764590|Experimental|AP-306|
33403589|NCT05764590|Active Comparator|Sevelamer Carbonate|
33403590|NCT04141774|Active Comparator|Passive FES|Subjects randomized to this control group will be asked to participate in a passive FES intervention or non-EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, and functional electric stimulation (FES) treatment.
33403591|NCT04141774|Experimental|Active FES|Subjects randomized to this experimental group will be asked to complete the active FES intervention which include EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, functional electric stimulation (FES) treatment, and EEG.
33403592|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
33403593|NCT03531827|Experimental|1/Lead-In Safety: CRLX101 with Enzalutamide|Combination treatment of increasing dose of CRLX101 (formerly IT-101) with enzalutamide
33403594|NCT03531827|Experimental|2/Efficacy: CRLX101 with Enzalutamide|Tolerable dose of CRLX101 (formerly IT-101) in combination with enzalutamide (8 participants, expandable to 21 total participants)
33403595|NCT05764512|Experimental|Intervention group|Is the group to which endorphin massage will be applied. Endorphin massage is a gentle touch and massage method that can improve the relaxation state in the body through the skin surface.
33403596|NCT05764512|No Intervention|Control gruop|No application will be made.
33403597|NCT04105816|Placebo Comparator|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
33403598|NCT04105816|Experimental|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
33085691|NCT04536454|Experimental|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.~After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
33085692|NCT00415701|Experimental|1|Etomidate as a single induction dose
33085693|NCT00415701|Active Comparator|2|Propofol as a single induction dose
33085694|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
33085695|NCT04536766|Experimental|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
33085696|NCT04536766|Active Comparator|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
33403599|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
33403600|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
33403601|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
33403602|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
33403603|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
33403604|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
33403605|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
33403606|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
33403607|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
33403608|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
33403609|NCT04075656|Experimental|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
33403610|NCT04075656|Active Comparator|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
33403611|NCT05763342|Experimental|Adult Cochlear Implant|Adult cochlear implant recipients receiving different focused multipolar maps that are programmed using either behavioural or objective methods
33403612|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
33403613|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
33403614|NCT03927612|Experimental|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
33403615|NCT03927612|Placebo Comparator|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
33085697|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
33085698|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
33085699|NCT04536727|Experimental|Intervention|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
33403616|NCT02342158|Experimental|Locally advanced /metastatic cancer|
33403617|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
33403618|NCT05764434||Patients with Amyotrophic Lateral Sclerosis|Patients with a possible, probable, or definite diagnosis of Amyotrophic Lateral Sclerosis according to the El Escorial Criteria.
33403619|NCT05764434||Healthy Control Persons|Healthy control persons matching the ALS patient group in sex and age
33403620|NCT05764434||Patients with other Motor Neuron Diseases|Patients with Motor Neuron Diseases other than ALS
33403621|NCT05462964|No Intervention|Control Group|Newborns in this group were started to camera recording 2 minutes before the procedure and routine OGT placement was performed. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.After OGT insertion, a light touch was provided if necessary to ensure routine comfort of the baby for ethical reasons.
32785001|NCT04749225||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
33085700|NCT04536727|Placebo Comparator|Wait list|Participants randomized to the wait list group, receive the 8-week Fit & Strong! intervention after the intervention group has completed it.
33403622|NCT05462964|Experimental|İntervention Group 1|Only a pacifier was given to the newborn.
33403623|NCT05462964|Experimental|İntervention Group 2|The newborn was given a pacifier sweetened with 25% dextrose.
33403624|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
33403625|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
33403626|NCT04478110|Experimental|Interactive education with linkage to care|Main intervention components included interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care
33403627|NCT04478110|Active Comparator|general health education|Receive a group education session focused on general health education and primary prevention issues.
33403628|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
33403629|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
33403630|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
33403631|NCT05230966|No Intervention|Group 1- angina pectoris|Patients with acute coronary syndrome; angina pectoris (chest pain with negative troponin T with or without changes in electrocardiographic findings);
33403632|NCT05230966|No Intervention|Group 2 - angina pectoris + STEMI+ PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
33403633|NCT05230966|Active Comparator|Group 3 - without angina pectoris + STEMi + RIC + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention during which it's carried out remote ischemic conditioning (RIC)
33403634|NCT05230966|No Intervention|Group 4 - without angina pectoris + STEMI + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
33403635|NCT05230966|Active Comparator|Group 5 - healthy + RIC|healthy volunteers of the same age and sex, whose samples will be taken after the RIC procedure
33403636|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
33403637|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
33403638|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
33403639|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
33403640|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
33403641|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
33403642|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
33403643|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
33403644|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
33403645|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
33403646|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
33403647|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
33403648|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
33403649|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
32785002|NCT01933594|Experimental|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785003|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
33403650|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
33403651|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
33403652|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
33403653|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
33403654|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
33403655|NCT05462808|Experimental|Atraumatic Restorative Treatment restorations with high-viscosity glass ionomer cement|Under cotton roll isolation, teeth were restored with EQUIA Forte cement. A layer of EQUIA Forte Coat was applied with a microbrush on surface and then light cured for 20 s
33403656|NCT05462808|Experimental|restorations with Hall technique|In the Hall technique group, the deposits on the occlusal surface of the teeth were gently removed, SSC (3M ESPE, St. Paul, USA) was placed and were cemented using GIC. The crown was pressed tightly.
33403657|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
33403658|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
33403659|NCT05763654||Linovera emulsion|No intervention. Routine clinical practice.
33403660|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
33403661|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
33403662|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
33403663|NCT04477954|Experimental|Experimental HBOT|Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
33403664|NCT04477954|No Intervention|Standard care|
33403665|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33403666|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
33403667|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
33403668|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.~Duration: 28 days."
33403669|NCT03895320|Experimental|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
33403670|NCT03895320|Other|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
33403671|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
33403672|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
33403673|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
33403674|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
32785004|NCT01933594|Experimental|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785005|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785006|NCT01933594|Experimental|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785007|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785008|NCT01933594|Experimental|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785009|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
32785010|NCT04623190|Experimental|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline. The providers will be delivering the PREVENT tool.
32785011|NCT04623190|Active Comparator|Patients - Wait-List Control|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
32785012|NCT04623190|Experimental|Patients - PREVENT Tool|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
32785013|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
32785014|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
32785015|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
32785016|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
32785017|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
32785018|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
32785019|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
32785020|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
32785021|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
32785022|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
32785023|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
32785024|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
33403675|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
33403676|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
33403677|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
32785025|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
32785026|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
32785027|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
32785028|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
32785029|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
32785030|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
32785031|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
32785032|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
32785033|NCT05415605|Experimental|healthy Volunteers|Healthy male or female volunteers between 18 and 50 years old
32785034|NCT05435885|Experimental|Tele-rehabilitation group|The Tele-rehabilitation group performs 12 training sessions during four weeks. (3 sessions/week)
32785035|NCT05435885|Other|Control group|The control group receives usual care with only one educational session.
32785036|NCT03936647|Active Comparator|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
32785037|NCT03936647|Experimental|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
32785038|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
32785039|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
32785040|NCT05435651|Experimental|Multitask game-based digital therapy|Multitask game-based digital therapy group will be asked to practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
33403678|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
33403679|NCT05763264|Active Comparator|Control Latex Condom C|Commercial Natural Rubber Latex Male Condom
33403680|NCT05763264|Experimental|Polyurethane Condom A|Polyurethane Condom A (002)
33403681|NCT05763264|Experimental|Polyurethane Condom B|Polyurethane Condom B (001)
33403682|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
33403683|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
33403684|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
33403685|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
32785041|NCT05435651|Active Comparator|Schulte Grid digital game|Schulte Grid digital game group will be asked to practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
32785042|NCT05435573|Active Comparator|Crystalloid group|The patients will receive 1000 mL of ringer's acetate solution (250 mL over 5 minutes starting immediately after intrathecal injection using a pressurizer then 500 mL over 55 minutes then 250 mL over 60 minutes).
32785043|NCT05435573|Active Comparator|Crystalloid-colloid group|Patients will receive 250 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride starting immediately after intrathecal injection then 500 mL of ringer's acetate solution then 250 mL of hydroxyethyl starch
32785044|NCT05415059|Other|Main Cohort|Cohort of healthy volunteers to have device affixed
32785045|NCT05610761|Experimental|Core Stabilization Exercises with Kegel Exercises|
32785046|NCT05610761|Active Comparator|Kegel Exercises|
32785047|NCT05414825||11 to 14 years old teenagers|Semi-structured discussion group with only young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the young teenagers suffering from severe dysmenorrhea.
32785048|NCT05414825||15 to 17 years old teenagers|Semi-structured discussion group with older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of these patients suffering from severe dysmenorrhea.
32785049|NCT05414825||11 to 14 years old teenagers' parents|Semi-structured discussion group with parents of young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
33085701|NCT04536415|Experimental|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
33085702|NCT04536415|Active Comparator|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
32785050|NCT05414825||15 to 17 years old teenagers' parents|Semi-structured discussion group with parents of older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
32785051|NCT05414825||caregivers|Semi-structured discussion group with medical staff in services potentially treating dysmenorrhea patients, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the caregivers on the care and feelings of the patients suffering from severe dysmenorrhea.
32785052|NCT04423133|Experimental|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
32785053|NCT05414357|Experimental|Patients with chemotherapy|
32785054|NCT05414357|Active Comparator|Patients without chemotherapy|
32785055|NCT05414357|Active Comparator|cancer-free volunteers|
32785056|NCT04423289|Experimental|Farmalarm|Farmalarm app for the follow-up
32785057|NCT04423289|No Intervention|Control|Regular primary care follow-up
32785058|NCT05413733|Experimental|Digital care pathway|Intervention group goes through a web-based neuropsychological intervention program. The program includes eight structured sessions regarding general neuropsychological symptoms after ABI - problems with fatigue, attention, executive functions and memory. A new session opens after the previous one is completed, and after a minimum of 3 days between the sessions. The intervention takes approximately 2 months depending on the progression pace of a patient. The eight sessions consist of psychoeducation, self-assessments, cognitive strategy training and feedback (automatic or given by a monitoring neuropsychologist). A neuropsychologist from HUS monitors patients' progression and provides personal feedback when needed. Participants can also be in contact with a monitoring neuropsychologist via message feature of the program.
32785059|NCT05413733|Active Comparator|Care as usual|Control group attends the standard care of patients with ABI in HUS including all necessary outpatient rehabilitation visits. When available, neuropsychological rehabilitation typically takes 1-2 months among the study target group.
32785060|NCT05413421|Experimental|Dose Escalation|ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles
32785061|NCT04423445|Experimental|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
32785062|NCT04423445|No Intervention|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
32785063|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
32785064|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
32785065|NCT05412875|Experimental|Arm I (JUUL)|Beginning 1 month before surgery, patients receive a JUUL e-cigarette and a 1 month supply e-liquid pods. After completion of surgery, patients receive another 1 month supply of e-liquid pods.
32785066|NCT05412875|Active Comparator|Arm II (usual care)|Patients receive usual care.
32785067|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
32785068|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
32785069|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
32785070|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
32785071|NCT03958487|Experimental|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
32785072|NCT05435261||Group I|with a score below 14
32785073|NCT05435261||Group II|with a score above 14
32785074|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 1)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
32785075|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 2)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
32785076|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 3)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
32785077|NCT05379179|Active Comparator|Fentanyl|"Drug administration: A single dose of fentanyl 1mcg/kg IV, maximum 100 mcg, over 15 minutes.~Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~Record vital signs (HR, B/P, resp rate, O2 sat)~Obtain and assess pain response scores~Pain Numerical Rating Score (NRS - 0-10)~Richmond Agitation Sedation Scale (RASS)~Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~Record any rescue meds, dose and time (Rescue medication - Fentanyl):~1 mcg/kg IV fentanyl (0.5 mcg/kg if age >55 yrs)~Defined as rescue if given <30 min post study intervention for pain score >5 or patient requesting additional medication.~Patient pain satisfaction score at discharge"
32785078|NCT05379179|Experimental|Ketamine|"Drug administration: A single dose of ketamine 0.3 mg/kg IV over 15 minutes. Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~Record vital signs (HR, B/P, resp rate, O2 sat)~Obtain and assess pain response scores~Pain Numerical Rating Score (NRS - 0-10)~Richmond Agitation Sedation Scale (RASS)~Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~Record any rescue meds, dose and time (Rescue medication - Fentanyl):~1 mcg/kg IV fentanyl (0.5 mcg/kg if age >55 yrs)~Defined as rescue if given <30 min post study intervention for pain score >5 or patient requesting additional medication.~Patient pain satisfaction score at discharge"
32785079|NCT05379023|Other|Face-to-face evaluation (FF), TeleNP evaluation|
33403686|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
33403687|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
32785080|NCT05379023|Other|TeleNP evaluation, Face-to-face evaluation (FF)|
32785081|NCT05378945|Experimental|OC-01|
32785082|NCT05378945|Placebo Comparator|Placebo|
32785083|NCT05610605|No Intervention|Control Group|Participants who do not receive attention from the Fragsalud program. The control group follows the usual care and preventive measures in Primary Care, according to different protocols implemented and the criteria of nurses and family doctors responsible for their care.
32785084|NCT05610605|Experimental|Intervention Group|The FRAGSALUD Programme is a multidomain intervention programme, which covers the prevention and treatment of frailty from different aspects, fundamentally from a physical and cognitive aspect and to maintain social integration, although other modifiable factors that are related to the presence of fragility such as hearing impairment, visual deficit or depression.
32785085|NCT05378477|Experimental|Test product|Hemisqualane & beeswax-based lotion (X92001752), killing lice and nits via suffocation.
32785086|NCT05378477|Active Comparator|RID Super Max Solution|Oligodecene oil-based lotion, killing lice and nits via suffocation.
32785087|NCT05378477|Active Comparator|Nix Crème|Conventional pesticide, containing 1% permethrin.
32785088|NCT05378477|Active Comparator|Pouxit Végétal|Fatty acid salt-based lotion, killing lice and nits via suffocation.
32785089|NCT05610527|Active Comparator|Etonogestrel contraceptive implant|Participants who randomize to the implant or choose it in the participant preference arm will have it inserted during their 2nd menses after their screening visit.
32785090|NCT05610527|Active Comparator|52mg levonorgestrel intrauterine device|Participants who randomize to the hormonal IUD or choose it in the participant preference arm will have it inserted during their 2nd menses after their screening visit.
32785091|NCT05596331|Other|Group of adult subjects without ASD (Autism Spectrum Disorders)|Age between 18 and 50 years
32785092|NCT05596331|Other|Group of children without ASD|Age between 2 and 12 years
32785093|NCT05596331|Other|Group of children with ASD|Age between 2 and 12 years Conformity with the diagnostic criteria of ASD according to DSM-V, ICD-10 or ICD-11
32785094|NCT05596331|Other|Group of children without NDD (NeuroDevelopmental Disorders)|Age between 0 and 12 years
33403688|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
33403689|NCT03790332|Experimental|Phase 1/2|"Part A: Subjects ≥1 to <12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.~Part B: Subjects ≥1 to <12 years of age( upper age limit is < 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
32785095|NCT05596331|Other|Group of children with NDD, or whose diagnosis is in progress|Conformity to the diagnostic criteria of NDD
32785096|NCT05383079|Experimental|Radium-223 and Lutetium-177 PSMA-I&T|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-I&T on Day 1 of every 6 week Cycle. Radium-223 will be administered concurrently every 6 weeks. The dose of Radium-223 will vary in dose-escalation. Up to 6 Cycles will be given.
32785097|NCT05377385||Study group|Children and adolescents with type 1 diabetes mellitus who started in 2021 in the Jessa Hospital with the Omnipod DASH insulin administration device.
32785098|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
32785099|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
32785100|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
32785101|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
32785102|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
32785103|NCT05549063|Experimental|Mobility and Stability Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
32785104|NCT05549063|Active Comparator|Stretching Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
32785105|NCT04255823|Experimental|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (>300DDD/patient/year).~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
32785106|NCT04255823|Experimental|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.~Their patients will not receive any patient education material."
32785107|NCT04255823|No Intervention|Control|Neither the patients nor their GP will receive information.
32785108|NCT05383001|Experimental|Arm A: tremelimumab /durvalumab (1 cycle), subsequently Durvalumab maintenance therapy|
32785109|NCT05383001|Other|Arm B: platinum-based chemotherapy (SoC)|
32785110|NCT05376293|Active Comparator|Behavioral internet program|Participants randomized to the Internet program will receive a 12-week behavioral Internet program designed to increase physical activity to recommended levels.
32785111|NCT05376293|Sham Comparator|Informational newsletter condition|Participants randomized to the newsletter condition will receive 6 newsletters, delivered every other week during the 3-month program.
32785112|NCT05381753||Ava-mGSIT-P18|Unresectable or metastatic PDGFRA exon 18 GIST
32785113|NCT05381753||Ava-Perioperative|Perioperative PDGFRA exon 18 GIST
32785114|NCT05381753||Ava-mGIST-other|Unresectable or metastatic GIST without KIT exon 13，14，or PDGFRA exon 18 mutation
32785115|NCT05381753||TKI|Unresectable or metastatic PDGFRA exon 18 GIST
32785116|NCT05381675|Experimental|Intervention|Participants will receive a supervised tele-rehabilitation program 2 days a week for 6 weeks.
32785117|NCT05381675|Other|Control|Participants will receive the same rehabilitation program as prescribed.
32785118|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
32785119|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
32785120|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
32785121|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
32785122|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
32785123|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
32785124|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
32785125|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
32785126|NCT05610371|Experimental|Lidocaine The study group|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml.
32785127|NCT05610371|Placebo Comparator|Saline The control group|The control group underwent hysteroscopy using a saline distension medium.
32785128|NCT05344001||Midlife former athletes with a prior knee injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season; history of at least 1 prior traumatic knee injury including but not limited to ACL or PCL rupture and/or reconstruction, medial and/or lateral meniscus tear or surgery, osteochondral defect, and/or intra-articular (i.e., tibiofemoral or patellofemoral) fracture.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
32785129|NCT05344001||Midlife former athletes without a prior major lower extremity injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., football, baseball, basketball, field hockey, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
32785130|NCT05344001||Midlife controls|"Inclusion Criteria: Age 40-64 years.~Exclusion Criteria: Prior participation in a collegiate varsity sport or professional sport; neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
32785131|NCT05344001||Young adult athletes|"Inclusion Criteria: Age 18-25 years. Participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the varsity collegiate level.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
32785132|NCT05344001||Young adult controls|"Inclusion Criteria: Age 18-25 years.~Exclusion Criteria: Prior or current participation in any collegiate varsity sport; prior major lower extremity injury or surgery (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation); current participation in competitive sport (e.g., collegiate club sport) more than 3x/week; joint replacement in the lower extremity (i.e., knee or hip replacement); current pregnancy; or neurologic condition (e.g., stroke, Parkinson's) and/or degenerative condition that impairs function."
32785133|NCT02163759|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
32785134|NCT02163759|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
32785135|NCT02163759|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
32785136|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
32785137|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
33403690|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
32785138|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
32785139|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
32785140|NCT04883827||RCC with clear cell component|
32785141|NCT04883827||Healthy Volunteer (no longer recruiting)|
32785142|NCT04883671|Active Comparator|Standard of Care (Cohort 1)|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
32785143|NCT04883671|Experimental|Stereotactic Body Radiotherapy (SBRT) 1-5 Metastatic Sites (Cohort 1)|"Participants will be randomly assigned and receive SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer.~After SBRT is completed participant may go on to receive systemic therapy (like chemotherapy, immunotherapy, or targeted therapies) per discretion of their treating physician."
32785144|NCT04883671|No Intervention|Local Ablative Therapy (Cohort 2)|Participants embarking on standard of care local ablative therapy (not limited to radiofrequency, microwave, or cryoablation, bland or chemoembolization, palliative radiotherapy, or surgical metastectomy) not eligible for cohort 1 will be enrolled and followed.
32785145|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
32785146|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
32785147|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
32785148|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
32785149|NCT04897711|Experimental|Perceptual training with a speaker with dysarthria|To examine the effect of perceptual training with speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases, in which speech samples from a single speaker with dysarthria are utilized for all three phases.
32785150|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
32785151|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
32785152|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
32785153|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
32785154|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
32785155|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
32785156|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
32785157|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
32785158|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
32785159|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
32785160|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
32785161|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
33403691|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
33403692|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
33403693|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
33403694|NCT05462496|Experimental|Participants who had Chemotherapy Following Pancreatic Adenocarcinoma|Participants to be given antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
33403695|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
33403696|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
33403697|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
33403698|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
33403699|NCT05462418|Active Comparator|diathermy group|Patients' incisions are completed using the unipolar diathermy from Whiteline until we reach the parietal peritoneum (cutting the Whiteline then coagulating until reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
33403700|NCT05462418|Active Comparator|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
33403701|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner~PET imaging will begin concomitant with radiotracer administration"
33403702|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
33403703|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
33403704|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
33403705|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
33403706|NCT05764356||Novel oral anticoagulants cohort|
33403707|NCT05764356||Ticagrelor cohort|
33403708|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
33403709|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
33403710|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
33403711|NCT03500159|Placebo Comparator|Placebo|Matching placebo
33403712|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
33403713|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
33403714|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
33403715|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
33403716|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
33403717|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
33403718|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
33403719|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
33403720|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
33403721|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
33403722|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
33403723|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
33403724|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
33403725|NCT05763576|Experimental|RO7565020|
33403726|NCT05763576|Placebo Comparator|Placebo|
33403727|NCT05462184|Active Comparator|Cognitive-Behavioral Therapy (CBT)|CBT followed Craske & Barlow´s (2007) manual, which contains a session-by-session description treatment of panic disorder with CBT. The treatment included the following components: (a) psychoeducation about the nature of anxiety and panic, (b) diaphragmatic breathing training, (c) identification and correction of maladaptive thoughts about anxiety and its consequences, (d) exposure to interoceptive sensations, and (e) exposure to feared situations.
33403728|NCT05462184|Experimental|Acceptance and Commitment Therapy (ACT)|"ACT was conducted following Eifert & Forsyth´s (2005) manual, which contains a session-by-session description of the application of ACT to anxiety disorders. In the current study, exercises were adapted to the panic disorder treatment. The treatment included the following components: (a) acceptance of internal experiences, (b) cognitive defusion, (c) work with the self as context, (d) contact with the present moment, (e) work with life values, and values, and (f) commitment to action."
33403729|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
33403730|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
33403731|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
33403732|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
33403733|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
33403734|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
33403735|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
33403736|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
33403737|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
33403738|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
33403739|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
33403740|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine + Cytarabine|
33403741|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
33403742|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
33403743|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
33403744|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
33403745|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
33403746|NCT02349880|Active Comparator|control|5 hour cognitive training
33403747|NCT02349880|Experimental|intervention|5 hour shared decision making training
33403748|NCT04029298|Experimental|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
33403749|NCT04029298|Other|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
33403750|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
33403751|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
33403752|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
33403753|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
33403754|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
33403755|NCT04007224|Active Comparator|Oxytocin|Intranasal Oxytocin
33403756|NCT04007224|Experimental|Autologous umbilical cord blood|Intravenous administration of autologous umbilical cord blood
33403757|NCT05664893|Experimental|Principal arm|registration phase : 3 cycles of 600mg per day of ribociclib Treatment phase : 3 cycles of dose de-escalation of ribociclib (600 or 400 or 200mg per day) Maintenance phase : 600mg per day of ribociclib until 24months of total treatment
33085703|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
33085704|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
32785162|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
32785163|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
32785164|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
32785165|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
32785166|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
32785167|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
32785168|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
32785169|NCT02130297|Active Comparator|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
32785170|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
32785171|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
32785172|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
32785173|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
33085705|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
33403758|NCT03971266|Experimental|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
33403759|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
33403760|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
33085706|NCT00262587|Active Comparator|Seretide|Seretide inhaler
33403761|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
33403762|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
33403763|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
33403764|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
33403765|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
33403766|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
33085707|NCT04536259|Experimental|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
33291779|NCT03973684|Active Comparator|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
33291780|NCT03973684|Experimental|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
33291781|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
33291782|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
33291783|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
33291784|NCT00251745|Experimental|Dexlansoprazole MR 60 mg QD|
33291785|NCT00251745|Experimental|Dexlansoprazole MR 90 mg QD|
33291786|NCT00251745|Placebo Comparator|Placebo|
33291787|NCT00255346|Experimental|Acute myeloid leukemia (AML)|Dasatinib 70 mg orally twice daily.
33291788|NCT00255346|Experimental|MDS/CMML|Dasatinib 70 mg orally twice daily.
33291789|NCT00255346|Experimental|HES/CEL|Dasatinib 70 mg orally twice daily.
33291790|NCT00255346|Experimental|Primary myelofibrosis (PMF)|Dasatinib 70 mg orally twice daily.
33291791|NCT00255346|Experimental|Systemic Mastocytosis (SM)|Dasatinib 70 mg orally twice daily.
33291792|NCT00255190|Experimental|Dexlansoprazole MR 60 mg QD|
33291793|NCT00255190|Experimental|Dexlansoprazole MR 90 mg QD|
33291794|NCT03973762|Experimental|DR Grading with CAD|DR Grading with CAD
33291795|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
33291796|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
33291797|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
33291798|NCT03991026|Experimental|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
33291799|NCT03991026|No Intervention|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
33291800|NCT02535234|Active Comparator|Arm 1|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Novel system followed by 7 nights with theTraditional system
33291801|NCT02535234|Active Comparator|Arm 2|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Traditional system followed by 7 nights with the Novel system
33291802|NCT01049646|Active Comparator|Angiotensin II|
33291803|NCT01049646|Placebo Comparator|Saline infusion|
33291804|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
33291805|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
33291806|NCT00255034|Active Comparator|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
33291807|NCT00255034|Experimental|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
33291808|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
33291809|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
33291810|NCT03991104|Experimental|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
33291811|NCT00254566|Experimental|1|
33291812|NCT00254566|Active Comparator|2|
32785174|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
32785175|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
32785176|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
33291813|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
33291814|NCT02531854|Active Comparator|Pemetrexed Only|
32785177|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
32785178|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
33085708|NCT04536259|Experimental|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
33291815|NCT02531542|Other|READ echography|
33291816|NCT00358956|Experimental|1|
33291817|NCT01048086|Experimental|Retinoic Acid|
33291818|NCT01048086|Placebo Comparator|Placebo|
33291819|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
33291820|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
33291821|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
33291822|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
33291823|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
33291824|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
33291825|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
33291826|NCT01049880|Experimental|Ascorbate|
33291827|NCT00253630|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33291828|NCT00358644|Experimental|1|
33291829|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
33291830|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
33291831|NCT03990480|Active Comparator|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
33291832|NCT03990480|Active Comparator|amlodipine|Group II amlodipine (10 mg/d, n = 100).
33291833|NCT03990480|No Intervention|Control|30 healthy subjects are enrolled as control group (Group III).
33291834|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
33291835|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
33291836|NCT00364182|Experimental|A|
33291837|NCT00364182|Experimental|B|
33291838|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
33291839|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
33291840|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
33291841|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
33291842|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
33291843|NCT03992664|Experimental|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
33291844|NCT03992664|No Intervention|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
33291845|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
33291846|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
33291847|NCT03990714|Experimental|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
33291848|NCT03990714|Experimental|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
33291849|NCT00223990|Experimental|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
33291850|NCT00223990|Active Comparator|RabAvert (rabies vaccine)|RabAvert vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
33291851|NCT01052922|Active Comparator|2 sample InSure|
33291852|NCT01052922|Active Comparator|1 sample OC-Micron|
33291853|NCT01052922|Active Comparator|3 sample g-SENSA|
33291854|NCT03990636|Experimental|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
33291855|NCT03990636|Placebo Comparator|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
33291856|NCT01048398|Experimental|Remifentanil|
32785179|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
32785180|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
32785181|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
33291857|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
33291858|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
33291859|NCT03990324|No Intervention|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
33291860|NCT03990324|Experimental|Stretching group|The stretching group received a standardized manual stretching protocol
33291861|NCT01073644||Sunitinb malate|
33291862|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
33291863|NCT03992586|Experimental|Pink lenses|Pink-colored lenses
33291864|NCT03992586|Placebo Comparator|Clear lenses|Clear lenses
33291865|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
33291866|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
33291867|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
33291868|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
33291869|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
33291870|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
33291871|NCT01581060|Experimental|WX-554|
33291872|NCT03990246|Experimental|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
33291873|NCT03990246|Experimental|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
33291874|NCT03990246|Experimental|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
33291875|NCT03990246|Experimental|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
33291876|NCT03992742|Experimental|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
33291877|NCT03992742|Experimental|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
32785182|NCT04622644|Experimental|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
32785183|NCT01912612|Experimental|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
32785184|NCT01912612|No Intervention|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
32785185|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
32785186|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
33291878|NCT00221104|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
33291879|NCT00221104|No Intervention|No intervention|Patient has no intervention.
33291880|NCT00189202|Experimental|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
33291881|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
33291882|NCT03969160|Experimental|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
33291883|NCT00187486|Experimental|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
33291884|NCT00220636|Experimental|Aripiprazole|Aripiprazole 5 to 30 mg/day
33291885|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
33291886|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
33291887|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
33291888|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
33291889|NCT00219544|Experimental|1|
33291890|NCT00219544|Experimental|2|
33291891|NCT00219544|Experimental|3|
33291892|NCT00219544|Placebo Comparator|4|
33291893|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
33291894|NCT00187096|Experimental|Stratum 1|"Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
33403767|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
32785187|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
32785188|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
33291895|NCT00187096|Experimental|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
33291896|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
33291897|NCT00186628|Experimental|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
33291898|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
33291899|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
33291900|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
33291901|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
33291902|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
33291903|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
33291904|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
33403768|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
33403769|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
32785189|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
32785190|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
32785191|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
32785192|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
32785193|NCT04890301|Experimental|Puncture Template and CT group|Puncture Template assisted CT guided lung biopsy was performed.
32785194|NCT04890301|Active Comparator|CT group|Simple CT guided lung biopsy was performed.
32785195|NCT04896151|Active Comparator|Standard MMPI|Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).
32785196|NCT04896151|Experimental|Simulation MMPI|Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.
32785197|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
32785198|NCT02527343|Experimental|Placebo/Volanesorsen|"Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen-matching placebo in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Weeks 105-156). Participants not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
32785199|NCT02527343|Experimental|Volanesorsen|"Randomized Period: 300 mg of volanesorsen as SC, QW for Weeks 1-52. Participants who received 300 mg of volanesorsen in RT period and did not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Week 105-156). Participants who were not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
32785200|NCT05539157|Experimental|Phase 1a:Dose escalation|"JCXH-211 will be delivered by intratumoral injection in 3 stages:~Single administration stage A single administration of JCXH-211 administered to cutaneous or subcutaneous lesions in escalating doses.~Multiple administration stage Up to 3 doses of JCXH-211 administered to a cutaneous or subcutaneous lesion in escalating doses. Assigned dose to be determined on the data from the single administration arm.~Visceral administration stage JCXH-211 administered to a visceral lesion in escalating doses. Assigned dose to be determined on the data from the single and multiple administration arms."
32785201|NCT05539157|Experimental|Phase 1b:Dose expansion|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase 1a.
33403770|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
32785202|NCT05342753|Experimental|Restylane Kysse|Hyaluronic Acid
32785203|NCT05342519|Experimental|Topical rapamycin 0.001%|Patients randomized to this arm of the study will apply 2 finger tip units (FTU) or 0.5 cc topical rapamycin 0.001% cream daily for 6 months
32785204|NCT05342519|Active Comparator|Topical rapamycin 0.1%|Patients randomized to this arm of the study will apply 2 FTU (0.5 cc) topical rapamycin 0.1% cream daily for 6 months
32785205|NCT05342519|Placebo Comparator|Placebo|All patients will apply 2 FTU (0.5 cc) topical placebo cream daily for 6 months to the corresponding anatomic location on the opposite side of the body where the experimental drug is not being applied
32785206|NCT05342363||cardiopulmonary resuscitation during treatment with extracorporeal membrane oxygenation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) during the retrospective observation period who required mechanical cardiovascular resuscitation (CPR) during their treatment.
32785207|NCT05342363||Treatment with extracorporeal membrane oxygenation without resuscitation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) without the need for cardiovascular resuscitation during the retrospective observation period.
33403771|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
32785208|NCT05374109|Active Comparator|SYV: Sauti ya Vijana (The Voice of Youth intervention)|"Sessions 1 to 3 - youth name their worries, discuss coping strategies, practice relaxation and breathing exercises, and learn components of cognitive behavioral therapy. Sessions 4 to 6 are dedicated to reflection and processing trauma. Caregivers (supportive adults) are invited at the discretion of enrolled youth to participate in Sessions 1 and 6. Session 7 - youth name their support network and any changes. Sessions 8 and 9 - youth consider stigma, disclosure, reproductive health, condom use, and gender-based violence. Sessions 9 and 10 expand the overall client-centered approach to emphasizing autonomy rather than imposing ideas about what the youth should do. In a final individual meeting, youth revisit their personal values, goals, and strategies for the next 6 months and review their support networks. A final gathering is used to review all session content, to celebrate all that has been shared and learned together, and to distribute certificates of completion."
32785209|NCT05374109|No Intervention|SOC - Standard of Care|"Participants in the SOC will not meet in study groups, thus are more at risk for attrition. They will be contacted by the study team on a monthly basis to check in and ensure their documented contact information remains accurate. SOC may vary by site depending on clinic structure, referral systems, and group activities. These differences could potentially dilute the SYV intervention effect and introduce content spillover whereby participants randomized to the intervention discuss intervention content with participants randomized to SOC. As part of the study survey, participants will be asked if they had friends who attended the SYV intervention and if they discussed content. Additionally, as part of the implementation science outcomes (Aim 3), the SOC group structure, adherence counseling, and any mental health referrals offered as part of SOC will be documented."
32939090|NCT04761822|Experimental|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
33291905|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
32785210|NCT05582057|Experimental|Experimental Group|Behavioral: Strengths to Grow Program In an online, self-directed format, the Strengths to Grow: Preteen program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
32785211|NCT05582057|No Intervention|Waitlist Control Group|
32785212|NCT05380115|Experimental|CBT|All subjects enrolled received CBT for 10 weeks.
32785213|NCT05379491|Active Comparator|3 L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day linaclotide.
32785214|NCT05379491|Placebo Comparator|3 L PEG + Placebo|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day placebo.
32785215|NCT05308901|Experimental|Pembrolizumab + Lenvatinib|Lenvatinib 20 mg daily plus pembrolizumab 200 mg IV every 3 weeks.
32785216|NCT05538065|No Intervention|No Alert (Usual Care)|Providers randomized to usual care will receive no intervention.
32785217|NCT05538065|Experimental|Open Encounter + Pre-commitment|There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
32785218|NCT05538065|Experimental|Open Encounter + Follow-up booster|There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.
32785219|NCT05535257|Experimental|Sequential Compression Device (SCD) on upper extremity|Subjects post stroke with upper extremity weakness have the SCD sleeve placed on the arm for up to 4 hours for one day only
32785220|NCT05308277|Other|Single Arm - Leo Device Monitoring|Child's respiratory impedance will be continuously recorded using the Leo device during hospital/ED stay after consent and enrollment, and then during 7 days at home after discharge. The Leo device provides no intervention, and will only monitoring chest impedance for the worn period. Oscillometry and spirometry testing and flow volume assessment using PNT will be performed during study visits with Leo device attached.
32785221|NCT05307887|Experimental|Virtual Reality Technology|Group receiving virtual reality technology in addition to standard therapy
32785222|NCT05307887|No Intervention|Standard Therapy Control Group|
32785223|NCT05373329|Experimental|self-guided app use|Participants receive the self-guided app intervention immediately (self-guided group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
32785224|NCT05373329|Experimental|app use supplemented by a Sanvello coach|Participants receive the app and a program coach (coaching group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
32939091|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
32939092|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
33291906|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
32785225|NCT05373329|No Intervention|waitlist control|Participants receive the self-guided intervention after an 8-week waiting period (waitlist control group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
32785226|NCT05576129|Active Comparator|TGP-tACS|Patients perform a motor skill acquisition task with the affected hand during TGP-stimulation over the sensorimotor cortex on the lesioned side.
32785227|NCT05576129|Sham Comparator|Sham-tACS|Patients perform a motor skill acquisition task with the affected hand during sham-stimulation over the sensorimotor cortex on the lesioned side.
32785228|NCT01931566|Placebo Comparator|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
32785229|NCT01931566|Placebo Comparator|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
32785230|NCT01931566|Experimental|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
32785231|NCT05511077|Other|Liquid oat product|
32785232|NCT05511077|Other|Solid oat product|
32785233|NCT05373095|Experimental|Enhanced Adherence Counseling and Conditional Cash Transfers|Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV clinical services according Tanzania's National Guidelines for the Management of HIV as the comparison arm, which includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required. In addition to enhanced adherence counseling, intervention participants will receive the offer of a cash transfer paired with attendance at each of the three enhanced adherence counseling sessions. The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions.
32785234|NCT05373095|No Intervention|Enhanced Adherence Counseling only for those who qualify|Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of a detectable viral load result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required.
32785235|NCT04248725|Experimental|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
32785236|NCT04248725|No Intervention|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
32785237|NCT05372939|Active Comparator|AMT-101 and Humira (adalimumab)|AMT-101 Tablet
32785238|NCT05372939|Placebo Comparator|Placebo and Humira (adalimumab)|Placebo Tablet
32785239|NCT05372705|Active Comparator|Positive|"~58-second selfie video (TikTok) of an adolescent presenting a can do / climate action / positive perspective on global warming"
32785240|NCT05372705|Active Comparator|Negative|"~58-second selfie video (TikTok) of an adolescent presenting an it's already too late / climate catastrophe / negative perspective on global warming"
32785241|NCT05372705|Active Comparator|Neutral|~58-second selfie video (TikTok) of an adolescent discussing a topic unrelated to climate change or global warming
32785242|NCT05341037||Postoperative complications +|Patients who have postoperative complications during hospital stay after cardiac surgery
32785243|NCT05341037||Postoperative complications -|Patients who have not postoperative complications during hospital stay after cardiac surgery
32785244|NCT04247477|Experimental|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
32785245|NCT04247477|Experimental|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
32785246|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
32785247|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
32785248|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
33291907|NCT00357006|Active Comparator|1|100 mcg Estradiol
33291908|NCT00357006|Active Comparator|2|200 mcg Estradiol
33085709|NCT04536259|Experimental|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
33085710|NCT04536493|Active Comparator|1 application|Patients receive single dose LET
32785249|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
32785250|NCT05307653|Experimental|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
32785251|NCT05307653|Experimental|Erector spinea plain block group|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
32785252|NCT05307653|Experimental|Caudal group|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
32785253|NCT05340491|Experimental|Chemoradiotherapy+anti-PD-1|Patients in this arm will receive three cycles of GP chemotherapy plus PD-1 antibody, then receive IMRT and PD-1 antibody maintenance for eight cycles.
32785254|NCT05340491|Active Comparator|Chemoradiotherapy|Patients in this arm will receive three cycles of GP chemotherapy, then receive IMRT.
32785255|NCT05372549|Other|Oncology preservation|
32785256|NCT05372549|Other|Social (elective) preservation|
32785257|NCT05306093|Experimental|Nutraceutical|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
33085711|NCT04536493|Active Comparator|3 applications|Patients receive 3 doses of LET
32785258|NCT05306093|Placebo Comparator|Maltodextrin|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
32785259|NCT04251065|Experimental|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.~The treatment consists of an induction phase and a maintenance phase."
32785260|NCT05338697||Ischemic & Hemorrhagic stroke patients|557 ischemic stroke patients and 100 hemorrhagic stroke patients
32785261|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
33085712|NCT04536181|Placebo Comparator|3 months group|Subjects will receive 12-weeks of placebo following randomization
33291909|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
32785262|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
32785263|NCT05509127|Experimental|Carious cervical lesions treated with modified universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of modified universal adhesive. The cavity is then restored with nano-filled resin composite.
32785264|NCT05509127|Active Comparator|Carious cervical lesions treated with conventional universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of conventional universal adhesive. The cavity is then restored with nano-filled resin composite.
33085713|NCT04536181|Experimental|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
33085714|NCT04535869|No Intervention|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
33085715|NCT04535869|Active Comparator|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
33085716|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
33085717|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
33085718|NCT02216188|Other|Control|Untreated control group
33291910|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
32785265|NCT05305859|Experimental|venetoclax combining chidamide and azacitidine (VCA)|"28 days per cycle × at least 2 cycles；~1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7"
32785266|NCT05338229|Experimental|video game in CP children (pilot study)|The cerebral palsy children will play the engineer-built system, video-game based Kinect sensor 3 times/week for 5 weeks. Each session will last for 40 minutes. The video-game Kinect sensor was developed by the researcher team.
32785267|NCT05338151|Other|Brief Negotiated Interview (with referral and telephone booster) alone|All participants will receive BNI with referral and a 15-20 minute telephone booster delivered by a trained Health Promotion Advocate (HPA) at 2 weeks. The purpose of the BNI is to assist patients in recognizing and changing levels of alcohol consumption that pose health risks. The main goals of the BNI are to: 1) lessen ambivalence about reducing alcohol use; and 2) negotiate strategies for change. During BNI, the HPA will: 1) Raise the subject of alcohol; 2) Provide feedback: review the patient's alcohol consumption, make a connection to the patient's medical condition and reason for hospitalization; review guidelines for lower risk alcohol use; 3) Enhance motivation: have the patient identify on a readiness change ruler and develop discrepancy; and 4) Negotiate and Advise: negotiate goal, give advice, have patient complete drinking agreement; summarize and arrange follow-up.
32785268|NCT05338151|Active Comparator|BNI+MAUD|For either BNI+facilitated provision of MAUD or BNI+facilitated provision of MAUD+CBT4CBT, the HPA will provide education and counseling regarding MAUD as part of the BNI to the participant and communicate to the primary medical team that MAUD is indicated. The specific MAUD chosen will be made at the discretion of the patient and the primary medical team with recommendations from the study physicians, with a goal of prioritizing FDA approved medications. Participants will be encouraged to initiate (or receive as in the case of injectable naltrexone) MAUD prior to discharge and will be provided a prescription for a 30-day supply. Medications will be obtained through regular means and not provided directly through the study. During the BNI telephone booster, the HPA will inquire about and address any barriers to MAUD and encourage continued adherence.
32785269|NCT05338151|Experimental|BNI+MAUD+CBT4CBT|Participants randomized to BNI+facilitated provision of MAUD+CBT4CBT will be given a username and password to access the web-based program and be encouraged to begin accessing the program during their hospitalization. The HPA will assist each participant with login during the first session and be available to answer any questions. Participants will be asked to complete no more than two modules per week, with an expectation of completing all seven modules by the end of the 34-day post-discharge. The program tracks, for each participant, time logged onto the program, modules accessed, progress through the program from session to session, completion of homework assignments, and learning of CBT principles through brief quizzes. Participants will be allowed to repeat modules as desired. During the BNI telephone booster, the HPA will inquire about engagement with CBT4CBT, address any questions and problems with the program, and encourage practice of coping activities (i.e., homework).
32785270|NCT05304689|Other|test system for the determination of interleukins|test system for the determination of interleukins
32785271|NCT05371691|Experimental|Myobrace group|Myobrace appliance will be used for children who have Cl.II div.a malocclusion
32785272|NCT05371691|Experimental|Twin-block group|Twin-block appliance will be used for children who have Cl.II div.a malocclusion
32785273|NCT05302583|Other|SOC only then SOC plus Aromatherapy Inhaler|"Participant will receive standard of care pharmacological intervention (SOC) as needed throughout the day.~Participants will complete the Standard of Care Pharmacological Intervention Use Log.~At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
32785274|NCT05302583|Other|SOC and Aromatherapy Inhaler then SOC only|"Participant will use the aromatherapy inhaler as needed for up to two (2) hours in the morning and complete the Aromatherapy Inhaler Use Log.~At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
32785275|NCT05336591||Medical doctor|
32785276|NCT05336591||Nurses (Pediatric department and youth healthcare)|
32785277|NCT05336591||Other professionals in treatment (e.g. dieticians, physiotherapists)|
32785278|NCT05336591||Other (such as policy makers)|
32785279|NCT05302505|Experimental|Simulation|"Theoretical training in e-learning for nurses on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication~And simulation-based training (procedural) on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
33291911|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
32785280|NCT05302505|No Intervention|Control|"Theoretical training for nurses in e-learning on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
32785281|NCT05301959|Experimental|Experimental group|A single weekly intervention of low intensity galvanic currents will be applied in an ultrasound-guided manner.
32785282|NCT05301959|Sham Comparator|Simulated group.|The application of a single weekly intervention of low intensity galvanic currents will be simulated in an echogenic way, with the equipment turned off.
32785283|NCT05335967|Experimental|Self-management group|The experimental group will receive the self-management program for 12 weeks.
32785284|NCT05335967|Other|Information group|The control group will receive an information package on a healthy diet.
32785285|NCT05335499|Experimental|TAS5315 Dose 1|
32785286|NCT05335499|Experimental|TAS5315 Dose 2|
32785287|NCT05335499|Experimental|TAS5315 Dose 3|
33291912|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
33291913|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
32785288|NCT05335499|Experimental|AS5315 Dose 4|
32785289|NCT05335499|Experimental|TAS5315 Dose 5|
32785290|NCT05335499|Placebo Comparator|Placebo|
32785291|NCT05531513|Experimental|Virtual Reality (VR) Meditation|The VR Meditation intervention will be administered in Arm 1.
33291914|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
33291915|NCT00165646|Experimental|1|
32785292|NCT05531513|Active Comparator|Psychoeducational Pamphlets|The Psychoeducation Pamphlet intervention will be administered in Arm 2.
32785293|NCT05301491|Experimental|Dance therapy group|This group included in the dance therapy program throughout the study.
32785294|NCT05301491|Experimental|Control group|This group included in the conventional low back pain exercise program throughout the study.
32785295|NCT05369273|Experimental|adipose graft + Platelet Rich Plasma|
32785296|NCT05369273|Other|adipose graft|
32785297|NCT05368415|Active Comparator|3 mcg grup|this group will receive Norepinephrine bolus of 3 mcg for management of hypotension.
32785298|NCT05368415|Active Comparator|4 mcg group|this group will receive Norepinephrine bolus of 4 mcg for management of hypotension
32785299|NCT05368415|Active Comparator|5 mcg group|this group will receive Norepinephrine bolus of 5 mcg for management of hypotension
32785300|NCT05529173|Experimental|treatment|Application of Povidone-Iodine 10% prior to surgery to Nares
32785301|NCT05529173|Placebo Comparator|placebo|Application of 0.9% Sodium Chloride (NaCl) solution prior to surgery to Nares
32785302|NCT05301101||Cancer patients receiving definitive radiation therapy with overlap of a previously treated field|This is a re-irradiation study in solid tumor patients receiving definitive high dose radiation therapy to treatment volumes that include overlap with previously irradiated organs at risk.
32785303|NCT05300867|Active Comparator|Robotic|
32785304|NCT05300867|Active Comparator|Controll|
32785305|NCT05335109|Experimental|Xenon|
32785306|NCT05335109|Placebo Comparator|Oxygen|
32785307|NCT05300399|Experimental|With mHealth app|
32785308|NCT05300399|No Intervention|Without mHealth app|
32785309|NCT05300087|Experimental|Test Group|Albuterol Sulfate Inhalation Aerosol
32785310|NCT05300087|Active Comparator|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
32785311|NCT05334329|Experimental|Treatment (fludarabine, cyclophosphamide, COH06, atezolizumab)|Patients receive fludarabine IV on days -5 to -3, cyclophosphamide IV on days -5 to -3, and COH06 IV on days 0, 7, 14, and 21 in the absence of disease progression or unacceptable toxicity. Patients assigned to dose level 4 also receive atezolizumab IV over 60 minutes on days 0, 14, 28, and 42 in the absence of disease progression or unacceptable toxicity.
32785312|NCT04137575|Experimental|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
32785313|NCT04137575|Placebo Comparator|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
32785314|NCT05299229||Heart and vascular function|All study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff to determine the best method of monitoring heart and vascular function in preeclampsia.
33291916|NCT00165646|Experimental|2|
32785315|NCT05333627|Experimental|Fast-Track Course|Clients who select the Fast-Track Course option will receive access to a single ICBT core lesson and Do-It-Yourself guide, followed by three additional Do-It-Yourself guides that they can access in any order. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive up to five weeks of optional therapist support.
32785316|NCT05333627|Experimental|5-Week Course|Clients who select the 5-week course will receive access to an ICBT course which consists of four lessons spread across the span of five weeks. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive five weeks of optional therapist support.
32785317|NCT05333627|Experimental|8-Week Course|Clients who select the 8-week course will receive access to an ICBT course which consists of five lessons spread across the span of eight weeks. The content in this course is not student-specific. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive eight weeks of optional therapist support.
32785318|NCT05333549|Experimental|Usual care plus istradefylline|Participants will receive usual care, and in addition, will be asked to take istradefylline daily for 26 weeks.
32785319|NCT05297825|Experimental|Vegan|Participants will be asked to consume a healthy vegan diet.
32785320|NCT05297825|Experimental|Omnivore|Participants will be asked to consume a healthy omnivore diet.
32785321|NCT05333237|Experimental|Sequence 123|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
32785322|NCT05333237|Experimental|Sequence 132|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
32785323|NCT05333237|Experimental|Sequence 213|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
32785324|NCT05333237|Experimental|Sequence 231|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
33291917|NCT00165646|Placebo Comparator|3|
33291918|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
33291919|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
32785325|NCT05333237|Experimental|Sequence 312|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
32785326|NCT05333237|Experimental|Sequence 321|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
32785327|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
32785328|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
32785329|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
32785330|NCT05367791|Other|POSTUR|Postural training only.
32785331|NCT05367791|Other|POSTUR + LV (localized vibration)|Postural training combined with localized vibration
32785332|NCT05367791|Other|POSTUR+SES (somatosensory electrical stimulation)|Postural training combined with somatosensory electrical stimulation
32785333|NCT05367791|Other|POSTUR+LV-SES|Postural training combined with somatosensory electrical stimulation and localized vibration
32785334|NCT05367401|Experimental|1L higher risk MDS|Participants with 1L MDS will receive sabatolimab and magrolimab in combination with azacitidine
32785335|NCT05367401|Experimental|1L unfit AML|Participants with 1L AML unfit for intensive chemotherapy will receive sabatolimab and magrolimab in combination with azacitidine
32785336|NCT05367401|Experimental|Relapsed/refractory AML previously treated with venetoclax and azacitidine|Participant with relapsed/refractory AML will receive sabatolimab and magrolimab (in absence of complete response (CR), Complete Remission with incomplete hematologic recovery (CRi) or Morphologic Leukemia-Free State (MLFS) after 2 cycles, participants will be allowed to also receive azacitidine)
32785337|NCT05296577|Experimental|anlotinib and vinorelbine|anlotinib combined with vinorelbine
32785338|NCT05296577|Placebo Comparator|vinorelbine|placebo and vinorelbine
32785339|NCT05366933|Experimental|Supplemented with B-Complex|Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
32785340|NCT05366855|Active Comparator|IV +SC Imsidolimab|IV loading dose followed by subcutaneous Imsidolimab
32785341|NCT05366855|Active Comparator|SC Imsidolimab|Subcutaneous Imsidolimab
32785342|NCT05366855|Placebo Comparator|SC Placebo|Subcutaneous Placebo
32785343|NCT05366855|No Intervention|Standard of Care|Any available therapy
32785344|NCT05332301|Experimental|High-fat test meal|All participants will consume a high-fat breakfast after an overnight fast. This meal will consist of a flour tortilla, eggs, bacon, cheddar cheese, mayonnaise, and hashbrowns. After the initial blood sample (0 min) is drawn during Visit 2, we will ask participants to consume this breakfast within 10 minutes. This meal has been designed to mimic the amount of energy (calories) and fat contained in a typical fast-food breakfast (e.g., from Tim Hortons or McDonalds). Each meal will provide 846 kcal, derived from 54 g fat (58% energy), 61 g carbohydrate (29% energy), and 29 g protein (13% energy).
32785345|NCT04250207|Experimental|K-321 QID|K-321 Ophthalmic Solution Dose A
32785346|NCT04250207|Experimental|K-321 BID|K-321 Ophthalmic Solution Dose B
32785347|NCT04250207|Placebo Comparator|Placebo|Vehicle Solution Dose
32785348|NCT05500703|Experimental|Dexmedetomidine group|1.5 µg kg-1 h-1 dexmedetomidine
32785349|NCT05500703|Active Comparator|Opioid group|0.9% sodium chloride injection
32785350|NCT04246151|Experimental|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
32785351|NCT04246151|Experimental|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
32785352|NCT04246151|Placebo Comparator|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
32785353|NCT05331833||study group|CTV-omitted IMRT under PET-CT guidance
32785354|NCT05331833||control group|CTV-delineated IMRT under PET-CT guidance
32785355|NCT05499767|Experimental|HEPPI|The HEPPI group attends weekly 90-minute intervention sessions at the participants' homes.
32785356|NCT05499767|No Intervention|Treatment as Usual (TAU)|The TAU group receives access to HEPPI at the end of the study.
32785357|NCT05331521|Active Comparator|RT PCV|"Radiotherapy (RT) for over approximately 5-6 weeks:~at 50.4/54 Gy in 1.8 Gy fractions for grade II and~at 59.4 Gy in 1.8 Gy fractions for grade III gliomas~PCV cycles are 6 weeks long and given as:~Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,~Days 8/29: Vincristine 1.4 mg/m2 i.v. (capped at 2 mg),~Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg)."
32785358|NCT05331521|Experimental|CETEG|"Six 42-day cycles of lomustine plus temozolomide according to the commonly used regimen:~Day 1: Lomustine (CCNU) at 100 mg/m2~Days 2-6: Temozolomide at 100 mg/m2 (cycles 1) and in 50 mg/m2 steps to 200 mg/m2 from cycle 2 on dependent on hematological toxicity"
33291920|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
32785359|NCT05366231|Experimental|Kesuting syrup group|Kesuting syrup, the tested drug of this study.
32785360|NCT05366231|Active Comparator|LianHuaQingWen Granules Control group|"LianHuaQingWen Granules, referring to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9), a NMPA approved drug for light and common patients with novel coronavirus during medical observation and clinical treatment,is adopted as active comparator in this study."
32785361|NCT05366153||Survivor Screening/Management Plan|"In cancer survivors;~A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~A clinical review to ensure optimal risk factor control and cardiac protection."
32785362|NCT05366153||Non-cancer Screening/Management Plan|"In matched non-cancer patients (from EDCAD trial);~A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~A clinical review to ensure optimal risk factor control and cardiac protection."
32785363|NCT05365451|Experimental|Arm 1A: metformin alone (baseline)|Arm 1A will consist of administration of a single dose of metformin (50 mg) by mouth as a liquid to 16 subjects (8 males, 8 females). Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1A and Arm 1B.
32785364|NCT05365451|Experimental|Arm 1B: metformin + cimetidine|Arm 1B will consist of administration of a single oral dose of cimetidine (400 mg) with water by mouth. One hour later, metformin (50 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1B and Arm 2A.
32785365|NCT05365451|Experimental|Arm 2A: furosemide alone (baseline)|Arm 2A will consist of administration of a single dose of furosemide (5 mg) by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. A washout of at least 7 days will occur between Arm 2A and Arm 2B.
32785366|NCT05365451|Experimental|Arm 2B: furosemide + probenecid|Arm 2B will consist of administration of a single oral dose of probenecid (1,000 mg) with water by mouth. One hour later, furosemide (5 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 1A and 1B. A washout of at least 7 days will occur between Arm 2B and Arm 1A.
32785367|NCT05295875|Experimental|ALT-801 Dose Level 1|
32785368|NCT05295875|Experimental|ALT-801 Dose Level 2|
32785369|NCT05295875|Experimental|ALT-801 Dose Level 3|
32785370|NCT05295875|Placebo Comparator|Placebo|
32785371|NCT05365295|Experimental|ADHD|- ADHD children aged between 8 to 10 years old
32785372|NCT05330585|Experimental|Participants with hearing loss.|Participants with hearing loss.
32785373|NCT05295407||Men 40-69 years old|Men with moderately-elevated PSA (2.5-10 ng/mL) undergoing prostate biopsy for detecting prostate cancer at NorthShore University HealthSystem, Northwestern University, or Johns Hopkins Hospital. The trial will not alter any clinical practice for diagnostic biopsy that includes state-of-the-art procedures (transperineal fusion biopsy, multiparametric MRI, and novel biomarkers).
32785374|NCT05329337|Experimental|10 patients with high insulin levels (13.3 ± 9.2 microU/mL) and markers of metabolic syndrome|These are individuals who were isolated from the previous MetACTIV study due to their specific immune profile (Profile 2) defined by 43 immune activation markers and characterized by a high percentage of differentiated T cells and activated T cells.
32785375|NCT05329337|Active Comparator|20 patients with other immune profiles|
32785376|NCT05294159||Clinic-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
32785377|NCT05294159||Community-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
33291921|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
33291922|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
33291923|NCT03968458|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
33291924|NCT03992508|Other|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
33291925|NCT03992508|Experimental|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
33291926|NCT03968770|Experimental|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
33291927|NCT03968770|Placebo Comparator|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
33291928|NCT03968614|Experimental|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
33291929|NCT03968614|Active Comparator|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
33291930|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
33291931|NCT00185614|Experimental|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (Auto-HCT)]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 & Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV & diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
33291932|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
33291933|NCT00361842|Experimental|Irinotecan|
33291934|NCT01324752|Experimental|PA21 and Losartan with food|
33291935|NCT01324752|Experimental|No PA21; Losartan with food|
33291936|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
33291937|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
33291938|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
33291939|NCT00361296|Experimental|K562/GM-CSF cell vaccine|Vaccinations of 1x10^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
33291940|NCT03990090|Experimental|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
33291941|NCT03990090|Placebo Comparator|Placebo|Placebo administered SC once in healthy participants.
33291942|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
33291943|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
33291944|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
33291945|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~Physical therapy~Specific exercises for the muscles~Injections into the knee joint~Brace~Medication~No therapy"
33291946|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
33291947|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
33291948|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
33291949|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
33291950|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
33291951|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
33291952|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
33291953|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
33291954|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
33291955|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
33291956|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
33291957|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
33291958|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
33291959|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
33291960|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
33291961|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
33291962|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
33291963|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
33291964|NCT03990168|Experimental|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
33291965|NCT03990168|Sham Comparator|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
33291966|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
33291967|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
33291968|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
33291969|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
33291970|NCT00367458|Experimental|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
33291971|NCT00367458|Experimental|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
33291972|NCT01053702|Experimental|Dose 1|R475
33291973|NCT01053702|Experimental|Dose 2|R475
33291974|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
33291975|NCT01050738|Active Comparator|Intracapsulare position|
33291976|NCT01050738|Active Comparator|Extracapsulare position|
33291977|NCT00162136|Experimental|A1|
33291978|NCT00252694|Experimental|candesartan|candesartan cilexetil 32 mg once daily
33291979|NCT00252694|No Intervention|placebo|control
33291980|NCT00185458|Experimental|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
33291981|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
33291982|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
33291983|NCT03968068|Experimental|Exercise|
33291984|NCT03968068|Experimental|Remote Ischaemic Conditioning|
33291985|NCT00185380|Experimental|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
33291986|NCT00185380|Experimental|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
33291987|NCT00185380|Active Comparator|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
33291988|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
33291989|NCT03967990|Experimental|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
33291990|NCT03967990|Experimental|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
33291991|NCT03967990|Experimental|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
33291992|NCT03967990|Experimental|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
33291993|NCT03967990|Experimental|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
33291994|NCT03967990|Experimental|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
33291995|NCT03968302|Experimental|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
33291996|NCT03968302|Experimental|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
33291997|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
33291998|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
33291999|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
32785378|NCT02525861|Experimental|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
32785379|NCT02525861|Experimental|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
32785380|NCT05293613|Experimental|Cases|
32785381|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
32785382|NCT05292365|Experimental|RE-PACT Intervention|Intervention participants receive respiratory illness action plans and weekly mobile health (mHealth) confidence surveillance. At times of low confidence or hospitalization, just-in-time action planning and coaching activities are conducted.
32785383|NCT05292365|No Intervention|Active Control (AC)|AC subjects will receive usual comprehensive medical care and coordination.
32785384|NCT05328401|Experimental|Intervention group (verum laser acupuncture group )|After blind random allocation, investigators applied verum laser acupuncture on patient with shoulder pain after stroke.
32785385|NCT05328401|Sham Comparator|Control group (sham laser acupuncture group)|After blind random allocation, investigators applied sham laser acupuncture on patient with shoulder pain after stroke.
32785386|NCT05526365|No Intervention|Control|Participants in the control group will receive an initial 12 question baseline test (same as intervention). They will after two weeks receive a second test that is linguistically the same as the national GPhC exam.
32785387|NCT05526365|Experimental|Intervention|Participants in the intervention group will receive an initial 12 question baseline test (same as control). They will after two weeks receive a second test that is reduced in idea density by around 10% overall.
32785388|NCT05363267|Experimental|Curcumin with high phenolic extra virgin olive oil (HP-EVOO)|Identical for all participants with the exception of the curcumin dose level, which is assigned at study enrollment.
32785389|NCT04422275|Active Comparator|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
32785390|NCT04422275|Active Comparator|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
32785391|NCT04422275|Active Comparator|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
32785392|NCT04422275|Placebo Comparator|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
32785393|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
32785394|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
32785395|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
32785398|NCT05361941|Experimental|Treatment Arm|The device will be placed in voids at Stage 1. This will be followed by IV therapy for a minimum of six weeks, followed by a pathology assessment of infection by needle aspiration, after week 8, with a stage 2 surgery scheduled after week 9. During the stage 2 surgery, the surgeon makes a qualitative assessment of new bone, and completes the procedure with affixing the revision implants. If the surgeon observes a depression in the surface layer resulting from subsidence due to partial resorption of the device, the surgeon may fill such gaps with additional granules of the device. An intraoperative set of radiographic images are taken during the stage 2 surgery.
32785399|NCT05361941|Active Comparator|Control Arm|In the standard of care arm, voids are left empty and a bone cement spacer placed during stage 1 surgery. This is followed by IV therapy for a minimum of six weeks, followed by a pathology assessment of infection by needle aspiration, after week 8, with a stage 2 surgery scheduled after week 9. During the stage 2 surgery, the spacer is removed and procedure completed by affixing the revision implants.
32785400|NCT05291507|Experimental|Muse MRgFUS System|Subjects will undergo partial ablation of half (~50%) of their tumor followed by surgical resection approximately 2-3 weeks after ablation.
32785401|NCT05290025|Experimental|Intervention|Patients will be offered brief weekly behavioural interventions for smoking cessation and prescription-free nicotine replacement products in addidition standard opioid replacement therapy.
32785402|NCT05290025|Other|Intitial screening only|Participants will receive standard opioid replacement therapy. At the start of the intervention number of cigarettes smoked during the past week will be recorded. Smokers will be adviced to make a cessation or reduction attempt. Advice that nicotine replacement products ( patches, lozenges or gum) may be bought over the counter in grocery-stores and pharmacies and information about goverment home-pages giving cessation advice.
32785403|NCT02129205|Experimental|PF-06650808|
32785404|NCT05289479|Active Comparator|"No pre-heating control group"|resin composite is used at room temperature without preheating
32785405|NCT05289479|Active Comparator|0ne cycle pre-heating|one cycle preheating of resin composite at 68 degree Celsius before application
32785406|NCT05289479|Active Comparator|ten cycles pre-heating|ten cycles preheating of resin composite at 68 degree Celsius before application
33292000|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
32785407|NCT05360693|Experimental|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface.
33292001|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
33292002|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
33292003|NCT00160654|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
33292004|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
33292005|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
32785408|NCT05360693|Active Comparator|immediate implant placement with bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface.
33292006|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
33292007|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
33292008|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
32785409|NCT05325047|Experimental|Speech rehabilitation|
32785410|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
32785411|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
32785412|NCT05523479|Active Comparator|Online education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
32785413|NCT05523479|Active Comparator|Interprofessional education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
32785414|NCT05523479|Active Comparator|Clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
32939093|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
32939094|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
32939095|NCT04735328|Other|Intervention|"When clinics join the intervention, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR and CT-PTSD)."
33292009|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
33292010|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
33292011|NCT01053858|Active Comparator|triamcinolone|
33292012|NCT01050894||osteoarthritis patients|
33292013|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
33292014|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
33292015|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
33292016|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
33292017|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
33292018|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
33292019|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
33292020|NCT00355368|Active Comparator|Succinylcholine|
33292021|NCT00355368|Active Comparator|Rocuronium|
33292022|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
33292023|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
33292024|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
33292025|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
32785415|NCT05523479|Active Comparator|Interprofessional education plus clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
32785416|NCT05523479|Active Comparator|Online education about post-extubation HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
32785417|NCT05523479|Active Comparator|Interprofessional education about post-extubation HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
32785418|NCT05523479|Active Comparator|Clinical protocol about post-extubation HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
32785419|NCT05523479|Active Comparator|Interprofessional education plus clinical protocol about post-extubation HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
32785420|NCT05523479|No Intervention|Usual care|During this period, ICU providers receive no structured education about preventive, post-extubation respiratory support therapies
32785421|NCT05324969|Experimental|MM-based MI group|Intervention group parents will receive 9 intervention sessions every other week by trained staff via 9 online sessions via Zoom or phone calls. Each intervention session will last 30-40 minutes. Intervention group parents will receive 3 text messages per week. No in-person contacts will be conducted without MSU department permission. All assessments will be delivered remotely with guided phone calls or zoom conference. The assessment of dyads' BMI, %BF, and WC will be obtained remotely from the parents using the scale and measuring tape delivered to their home.
32785422|NCT05324969|Other|Control group|Control group parents will receive a total of 9 emailed packets of educational materials (without information related to the mindfulness-based motivational interviewing [MM-based-MI]). The pre and post assessments will be collected the same way as the participants at intervention group.
32785423|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
32785424|NCT05324735|Experimental|Pentoxifylline|Pentoxifylline (tablet): 400 mg twice a day for 12 weeks
32785425|NCT05324735|Placebo Comparator|Control group|Placebo (tablet): twice a day for 12 weeks
32785426|NCT05360459||Control|Healthy postmenopausal patients (more than 12 months from the last 37 menstrual period).
32785427|NCT05360459||Gynecological Cancer|Women affected by cervical or endometrial cancer, in early stages, with a good prognosis for life, who have received radiotherapy with or without brachytherapy (radiotherapy) with or without concurrent chemotherapy.
32785428|NCT01626885|Experimental|MP-214 1.5-9 mg|
32785429|NCT05360225||Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS System (extraction kit, analytical kit, instrument and software) will be used to test FFPE biopsy (resected and core needle biopsy [CNB]/fine needle aspiration [FNA]) tumour tissue from NSCLC patients to establish KRAS G12C mutation status. This will be determined using the investigational device at Q2 Solutions Laboratories.
32785430|NCT05287763|Active Comparator|Gelatin Sponge|The palatal wound will be protected with an absorbable gelatin sponge, which will be stabilized by non-resorbable sling sutures.
32785431|NCT05287763|Experimental|Collagen Sponge|The palatal wound will be protected with a collagen sponge, which will be stabilized by non-resorbable sling sutures.
32785432|NCT05359055|Experimental|Cohort 1|SPH3127 tablet, Itraconazole
32785433|NCT05359055|Experimental|Cohort 2|SPH3127 tablet, Rifampin
32785434|NCT04249583|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
32785435|NCT04249583|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
32785436|NCT02524379|Experimental|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
32785437|NCT05286749|Active Comparator|Control|Participants take a workshop where they are provided education on standard-of-care for cervical cancer screening such as pap smear and HPV testing through clinician-collection methods using speculum and cervical swabs.
32785438|NCT05286749|Experimental|Intervention|Participants take a workshop where they are provided all the same education as control as well as additional education on self-collection for HPV-only testing using vaginal swab as an additional method.
32785439|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
32785440|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
32785441|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
32785442|NCT05357573|Experimental|KRN23|KRN23 administered subcutaneously (SC) every 4 weeks for 48 weeks. The dose varies according to serum phosphorus level which include 0.3,0.6,1.0,1.4 and 2.0 mg/kg.
32785443|NCT05357417|Experimental|cohort 1|HER2-negative advanced breast cancer with brain metastases who have received at least one prior anthracycline and one prior taxane
32785444|NCT05357417|Experimental|cohort 2|HER2-positive advanced breast cancer with brain metastases who have failed trastuzumab and pyrotinib
32785445|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
32785446|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
32785447|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
32785448|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
32785449|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
32785450|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
32785451|NCT05285423|Experimental|Prolene suture technique.|The Group of Patients who were offered Vocal Cord Lateralization with prolene suture technique.
32785452|NCT05323487|Active Comparator|Bumetanide 10 mg|Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
32785453|NCT05323487|Active Comparator|Bumetanide 5 mg|5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
32785454|NCT05323487|Active Comparator|Bumetanide 2.5 mg|2.5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
32785455|NCT05323487|Active Comparator|Bumetanide 1.25 mg|1.25 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
32785456|NCT05520593|Experimental|Complex Carbohydrate Drink Group|The patients will drink a 400ml drink that contains 50g of complex carbohydrates, 3 hours prior to the surgery. The drink will be given once at the preoperative holding area. Patients are not allowed to eat solid foods after 12am the morning of surgery and can only drink clear fluids up to 3 hours prior to the surgery.
32785457|NCT05520593|No Intervention|No-Complex Carbohydrate Drink Group|These patients will follow normal institutional preoperative fluid management guidelines, this consist of no solid foods after 12am the morning of surgery. Patients are allowed to drink clear liquids (water, clear fruit juices, coffee) from 12am the morning of surgery up to 3 hours prior to the surgery.
32785458|NCT05284409|Active Comparator|Pethidine|(control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
32785459|NCT05284409|Experimental|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
32785460|NCT05284409|Experimental|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
32785461|NCT05355857|Other|18F-FDG injection|Health volunteers with 18-F-FDG injection
32785462|NCT05355779||Interviewees|Paediatric cancer survivors, their parent/caregiver and health care professionals will be invited to express their views and perspectives in an interview with the researcher
32785463|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
32785464|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
32785465|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
32785466|NCT05322551||Obese only|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Non Diabetes: Fasting Plasma Glucose (FPG) < FPG 100 mg/dL (5.6 mmol/L)"
32785467|NCT05322551||Obese with prediabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Prediabetes: FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) OR A1C 5.7-6.4% (39-47 mmol/mol)"
32785468|NCT05322551||Obese with diabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Diabetes: (American Diabetes Association, 2020) FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.* OR A1C ≥6.5% (48 mmol/mol)."
32785469|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
32785470|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
32785471|NCT05492357|Experimental|Advanced platelet-rich fibrin plus + Liquid platelet-rich fibrin|A-PRF plus + Liquid-PRF are prepared from the patient's blood.
32785472|NCT05492357|Experimental|Advanced platelet-rich fibrin plus alone|A-PRF+ is prepared from the patient's blood.
32785473|NCT05490797|Experimental|app based training with conventional therapy|In experimental group app based training will be performed along with conventional hand fine motor skills and dexterity therapy.
32785474|NCT05490797|Active Comparator|conventional therapy|The control group will receive conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
32785475|NCT05283083|Experimental|Dexmedetomidine|"Patients will receive dexmedetomidine infusion according to the protocol plus the usual care.~We will evaluate patients for inclusion in the study after 6 hours on NE infusion, given stabilization of the MAP > 65 mmHg. In the DEX group, we will commence DEX infusion at the rate of 0.2 mcg.kg-1.h-1 without a loading dose, then titrate DEX infusion to maintain the HR from 60 to 90 bpm.~Titration of the DEX infusion rate will not be more than 0.1 mcg.kg-1.h-1 every 30 minutes at any time. The maximum DEX infusion rate will be 0.7 mcg.kg-1.h-1.~We aim to continue DEX infusion for 48 hours. After 48 hours of DEX infusion, we will taper the DEX infusion over one hour.~According to our protocol, DEX infusion would trigger either STOP events or hemodynamic assessment events:"
32785476|NCT05283083|No Intervention|Usual care without dexmedetomidine infusion|The patients in this group will receive the usual care.
32785477|NCT05321381|Active Comparator|RISE Early|RISE peer support program available early, launched study year 1
32785478|NCT05321381|Active Comparator|RISE Late|RISE peer support program available later, launched study year 2
32785479|NCT04254263|Experimental|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
32785480|NCT04254263|No Intervention|No Pyrotinib|Observation follow-up
32785481|NCT05321303|Experimental|Experimental: Serious game Experimental group|"The participants spend on one MetaHospital scenario in which Nursing Care (management of diabetic ketoacidosis)."
32785482|NCT05321303|Experimental|Experimental: Standardized Patients Control group|The participants spend one scenario 10 minutes; on a scenario designed to train Nursing Care (management of diabetic ketoacidosis).
32785483|NCT04422353|Experimental|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
32785484|NCT04422353|Active Comparator|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
32785485|NCT04422353|No Intervention|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
33085719|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):~ecolonize with intranasal Mupirocin ointment BID x 5 days~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)~efazolin plus Vancomycin (no Vanco for MSSA positive)~Patient has a known negative Staph aureus pre-op screening result:~HG bathing (night before & morning of surgery using wipes or liquid)~efazolin~Patient was not screened or results are unknown at time of surgery:~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)~efazolin plus Vancomycin"
33085720|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
32785486|NCT05320835|Experimental|Experimental|behavioral training with 6 sessions
32785487|NCT05320835|Active Comparator|comparison|Attention control
32785488|NCT05354999|Experimental|Creatine|Subjects ingest creatine monohydrate daily.
33085721|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
33085722|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
33085723|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
33292026|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
33292027|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
33292028|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
33292029|NCT03989622|Experimental|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
33292030|NCT03989622|No Intervention|usual care|control session followed by 10 re-education sessions
32785489|NCT05354999|Placebo Comparator|Placebo|Subjects ingest placebo daily.
32785490|NCT05354765|Experimental|"first type, called A Cohorts"|"The first type, called A Cohorts, corresponds to indications for which the treatment induces a high response rate (>30%). These patients will have a leukapheresis before and during treatment with immunotherapy. In addition, a blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression."
32785491|NCT05354765|Experimental|"second type, called B Cohorts"|"The second type, called B Cohorts, corresponds to indications for which a role of the immune system is suspected. Only the so-called informative patients (responders or surprising evolution) will have one leukapheresis during treatment. The leukapheresis will be performed between 8 weeks and 18 months after the start of treatment and depending on the clinical course determined by the clinicians in consultation with at least one immunologist (Olivier Lantz, Emanuela Romano, Cécile Alanio, Marion Alcantara)."
32785492|NCT05354531|Experimental|INFIX group|Those group of cases will be managed by INFIX for their pelvic ring disruption
32785493|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
32785494|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
32785495|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
32785496|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
32785497|NCT02335411|Experimental|Cohort 1: Pembrolizumab monotherapy, previously treated|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
33292031|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
33292032|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
33292033|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
33292034|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
33292035|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
32785498|NCT02335411|Experimental|Cohort 2: Pembrolizumab combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV each 3-week cycle (Q3W) + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
33292036|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
33292037|NCT00373958|Experimental|13vPnC vaccine|
33292038|NCT00373958|Active Comparator|7vPnC vaccine|
33292039|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
33292040|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
33292041|NCT00184600|Experimental|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
33292042|NCT00184600|Active Comparator|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
33292043|NCT00184600|Active Comparator|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
33292044|NCT03967756|Experimental|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
33292045|NCT03967756|No Intervention|Routine withdrawal group|Routine withdrawal without any assist.
33292046|NCT00265317|Experimental|A|
33292047|NCT00265317|Active Comparator|B|
33292048|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
33292049|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
33292050|NCT00251589|Experimental|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
33292051|NCT00251589|Experimental|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
33292052|NCT00251589|Experimental|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
33292053|NCT00251589|Experimental|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
33292054|NCT00265239|Active Comparator|1|Edaravone Group
33292055|NCT00265239|No Intervention|2|Placebo Group
33292056|NCT00350298|Experimental|GS-CDA1/MDX-1388|Biological: GS-CDA1/MDX-1388 One Intravenous dose
33292057|NCT00350298|Placebo Comparator|Placebo|Biological: normal saline (0.9% sodium chloride) One Intravenous dose
33292058|NCT00159874|Experimental|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
33292059|NCT00159874|Experimental|Sildenafil Low dose|
33292060|NCT00159874|Experimental|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
33292061|NCT03989778|Experimental|Vitamin D supplement|he intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
33292062|NCT03989778|No Intervention|Control|control group will receive Metformin treatment during the study period.
33292063|NCT03966430|Experimental|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
32785499|NCT02335411|Experimental|Cohort 3: Pembrolizumab monotherapy, treatment naive, PD-L1 positive|Programmed death-ligand 1 (PD-L1) positive participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W)
32785500|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
32785501|NCT02186301|Experimental|Rociletinib Mono-Therapy|
32785502|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
32785503|NCT02163057|Other|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
32785504|NCT02163057|Other|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
32785505|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
32785506|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
32785507|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
32785508|NCT02185053|Experimental|CPC-201|
32785509|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
32785510|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
32785511|NCT02124759|Placebo Comparator|Placebo|Placebo: maltodextrin, 6 g three times a day
32785512|NCT02124759|Active Comparator|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
32785513|NCT02124759|Active Comparator|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
32785514|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
32785515|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
32785516|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
32785517|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
32785518|NCT04895917|Experimental|Pomalidomide and daratumumab|
32785519|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
32785520|NCT04895293|Experimental|RBM-007 Injectable Solution - 2.0 mg|Single intravitreal injection in study eye
32785521|NCT04747353|Experimental|Catheter ablation procedure with heart 3D model|Experimental: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
32785522|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
32785523|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
32785524|NCT02161185|Other|USL261|
33085724|NCT04535830|Experimental|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
32785525|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
32785526|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
32785527|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
33085725|NCT04535830|No Intervention|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
33085726|NCT00262704|No Intervention|Group A|Control group
32785528|NCT04746573||Natrox Topical Oxygen Therapy managed by telehealth|Pilot study using topical oxygen managed by telehealth in the home setting.
32785529|NCT04746339|Active Comparator|Apixaban Group|
32785530|NCT04746339|Placebo Comparator|Placebo Group|
32785531|NCT02122887|No Intervention|control group|no intervention for 3 months
32785532|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
32785533|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
32785534|NCT04755075|Experimental|Cohort 1|Subjects with Normal Hepatic Function: All patients to receive study drug (Surufatinib 250mg) on Day 1
33085727|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
33085728|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
33085729|NCT04535752|Experimental|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
33292064|NCT03966430|Sham Comparator|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
33292065|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
32785535|NCT04755075|Experimental|Cohort 2|Subjects with Moderate Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
32785536|NCT04755075|Experimental|Cohort 3 (if enrolled)|Subjects with Mild Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
33292066|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
33292067|NCT00184054|Experimental|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
33292068|NCT03989856|Experimental|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
33292069|NCT03989856|Active Comparator|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
33292070|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
33292071|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
33292072|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
33292073|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
32785537|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
33292074|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
33292075|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
33292076|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
33292077|NCT00183430|Experimental|1|Participants will receive treatment with prazosin plus psychotherapy
33292078|NCT00183430|Placebo Comparator|2|Participants will receive treatment with placebo plus psychotherapy
33292079|NCT00183274|Active Comparator|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
33292080|NCT00183274|Active Comparator|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
33292081|NCT00183274|Placebo Comparator|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
33292082|NCT00183274|Active Comparator|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
33292083|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
33292084|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
33292085|NCT00183196|Active Comparator|1|Naltrexone plus placebo
33292086|NCT00183196|Active Comparator|2|naltrexone + gabapentin
33292087|NCT00183196|Sham Comparator|3|Placebo plus placebo
33292088|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
33292089|NCT00349752|Placebo Comparator|Placebo|Placebo
33292090|NCT01055652|Experimental|1|
33292091|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
33292092|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
33292093|NCT00174460|Active Comparator|Treatment Arm|
33292094|NCT00174460|No Intervention|Control Arm|
33292095|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
33292096|NCT03989310|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
33292097|NCT03989310|Experimental|anti-PD-1 antibody plus nPG chemotherapy|Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
33292098|NCT03966898|Experimental|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
33292099|NCT03966898|Placebo Comparator|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
33292100|NCT03989544|Experimental|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
33292101|NCT03989544|Experimental|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
33292102|NCT03989544|Experimental|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
33292103|NCT03966196|Other|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
33292104|NCT03966196|Experimental|COPD patients|oxymetry and finger pressure in COPD patients
33292105|NCT03987594|Placebo Comparator|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
33292106|NCT03987594|Experimental|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
33292107|NCT03989700|Experimental|Low dose|Low dose of thiamin supplementation
33292108|NCT03989700|Experimental|High dose|High dose of thiamin supplementation
33292109|NCT03989700|Placebo Comparator|Placebo|placebo supplementation
33292110|NCT03987750|Experimental|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
33292111|NCT03987750|Experimental|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
33292112|NCT03987750|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
33292113|NCT01055730||Pulmonary rehabilitation|
33292114|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
33292115|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
32785538|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
33292116|NCT01055808||Type 2 diabetes treated with insulin|
33292117|NCT00265083|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
33292118|NCT00265083|Placebo Comparator|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
33292119|NCT00265083|Experimental|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
33292120|NCT03971097|Active Comparator|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
33292121|NCT03971097|Experimental|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
33292122|NCT00264849|Experimental|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
33292123|NCT00264849|Active Comparator|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
33292124|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
33292125|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
33292126|NCT03974607|Experimental|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
33292127|NCT03974607|No Intervention|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
33292128|NCT00211809|Experimental|Body dysmorphic disorder|Participants with body dysmorphic disorder
33292129|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
33292130|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
32785539|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
32785540|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
32785541|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
33085730|NCT04535752|Placebo Comparator|Placebo, Single Ascending Doses|Single doses of matching placebo
32785542|NCT02301169|Active Comparator|T4P1001|
33085731|NCT04535752|Experimental|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
33085732|NCT04535752|Placebo Comparator|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
33085733|NCT00238316|Active Comparator|Letrozole|
32785543|NCT02301169|Sham Comparator|Placebo|
32785544|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
33085734|NCT00238316|Placebo Comparator|Placebo|
32785545|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
32785546|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
33085735|NCT04535518|Active Comparator|the standard group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
33085736|NCT04535518|Experimental|the standard + infliximab group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
33085737|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
33085738|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
33085739|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
32785547|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32785548|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32785549|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
32785550|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
32785551|NCT02158533|Experimental|High Dose|
32785552|NCT02158533|Experimental|Low Dose|
32785553|NCT02158533|Placebo Comparator|Placebo|
32785554|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
32785555|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
32785556|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
32785557|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32785558|NCT04758507|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
32785559|NCT04758507|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of saline solution)
32785560|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
32785561|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
32785562|NCT04754217||Group 1|VAVGJ
32785563|NCT04754217||Group 2|CAVGJ
33085740|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
33085741|NCT00262782|Experimental|Fludarabine|
33085742|NCT00262782|No Intervention|watch & wait|
33292131|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
33292132|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
32785564|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
32785565|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
32785566|NCT05262621|Experimental|Music intervention combined with progressive muscle relaxation|Music intervention combined with progressive muscle relaxation.
32785567|NCT05262621|No Intervention|Control group|no music therapy will be done.
32785568|NCT02179515|Experimental|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
33292133|NCT01073787|Active Comparator|Normal saline|
33292134|NCT01073787|Experimental|Normal saline and possible medication|
32900603|NCT05287802|Active Comparator|Control group|Isometric home exercises, which can be considered the most basic and feasible strengthening program, were selected to compare the effects they had when added to the intervention groups and administered alone. All patients in the study performed isometric exercises for the quadriceps and hamstrings at home once a day, three days a week for 10 weeks. The exercises were performed as 10 repetitive cycles of six-second contractions and two-second rest periods. All patients were given a daily exercise chart to mark the home program, and adherence to the exercises was monitored weekly by telephone call.
33292135|NCT00129766|Active Comparator|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
33292136|NCT00129766|Experimental|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
33292137|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
33292138|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
33292139|NCT00150592|Experimental|SPD503 (Guanfacine HCl)|
33292140|NCT00150592|Placebo Comparator|Placebo|
33292141|NCT00149890|Experimental|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
33292142|NCT00149890|Active Comparator|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
33292143|NCT00174382|Experimental|1|
33292144|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
33292145|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
33292146|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
33292147|NCT03987516|Experimental|Active intervention|Patients will be included in an active intervention.
33292148|NCT03987516|No Intervention|Control group|Patients in the control group will not receive any intervention
33292149|NCT00171730|Experimental|Pasireotide s.c. Overall|Participants received pasireotide as a daily subcutaneous (s.c) injection, every 12 hours at 9:00 AM and 9:00 PM at the dose at which the biochemical control was achieved (either 200, 400, or 600 microgram (μg)) for as long as the participant benefited from the treatment, and there were no safety or tolerability concerns (median duration of 22.7 months).
33292150|NCT00355056|Sham Comparator|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
33292151|NCT00355056|Experimental|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
33292152|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
33292153|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
33292154|NCT01324986|Active Comparator|Nissen fundoplication|
33292155|NCT01324986|Active Comparator|Toupet fundoplication|
33292156|NCT03989388|Experimental|Intervention Group|Occupational Self-Analysis Programme
33292157|NCT03989388|Active Comparator|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
33292158|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
33292159|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
33292160|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
33292161|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
33292162|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
32785569|NCT02120157|Experimental|Haploidentical BMT with PTCy for acute leukemias and MDS|"Patients with AML and MDS:~Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV~For patients with ALL and lymphoblastic lymphoma:~Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days~All patients Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30: Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180: Discontinue tacrolimus"
32785570|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
32785571|NCT04753827|Experimental|Experimental Group Stent only|Stents were implanted in MV and SB respectively, and DKcrush or Culotte technology was selected according to the lesion characteristics.
32785572|NCT04753827|Experimental|Experimental Group Stent+DCB|The MV was stented and the SB were treated with just drug-coated balloon(DCB)
32785573|NCT04753827|Experimental|Experimental Group L-Sandwich|Stents were implanted in the MV and the shaft of side branch SB respectively, then a DCB was applied to the ostium of the SB
32785574|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
32785575|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
32785576|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
32785577|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
32785578|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
32785579|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
32785580|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
32785581|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
32785582|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
32785583|NCT05279807|Active Comparator|Zofenopril 30mg|Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
32785584|NCT05279807|Active Comparator|Amlodipine 5mg|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
32785585|NCT05279495|Other|Loaded CANNAXR|"In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks.~In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks."
32939096|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
32939097|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
32939098|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
32939099|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
32939100|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
32939101|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
32939102|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
32785586|NCT05277935|Active Comparator|Use of the WeCancer app combined with the smartwatch|The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), feedback to the patient in the comments made, guidance on physical and eating exercises, reception and support from the Wecancer multidisciplinary team, consisting of a navigator nurse, psychologist, nutritionist and physiotherapist. During the survey period, participants should report their symptoms on the Wecancer app whenever possible, preferably daily.
32785587|NCT05277935|No Intervention|Using the WeCancer app|The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient feedback on the comments made, guidance on physical and dietary exercises, reception and support of the Multidisciplinary cancer team composed of a navigator nurse, a psychologist, nutritionist and physiotherapist. During the research period, participants must report your symptoms in the Wecancer app whenever possible, preferably daily.
32785588|NCT05319431|Experimental|AK104+Lenvatinib+TACE|Participants will receive AK104 IV every 3 weeks (Q3W) and Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD The first Transarterial chemoembolization will be performed at the beginning of study.
32785589|NCT05276531|Experimental|subcutaneous progesterone|PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland
32785590|NCT05276531|Active Comparator|vaginal progesterone|LUTINUS® 100 mg vaginal tablets, Ferring GmbH Wittland/Kiel/Germany
32785591|NCT05352581||BD Veritor|"Each subject will:~Self collect a nasal swab for testing on the BD Veritor At-home test (test device) Have a clinician collected nasal swab for testing on the BD Veritor Professional Test (test device) Have a clinical collected nasal swab for testing on an FDA cleared/approved RT-PCR assay (control device)"
32785592|NCT05318651|Experimental|mobile app users|
32785593|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
32785594|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
32785595|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
32785596|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
32785597|NCT05317481|Experimental|BE-SMART-DR|Participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions with a research therapist with the first, middle and last sessions in person, remaining sessions offered by secure video or audio telecommunication and 6-month in person follow-up.
32785598|NCT05317481|Active Comparator|control comparator condition|
32785599|NCT05561309|Experimental|dose 1|"Experimental: HR18034 190mg (10ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 50mg (10mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
32785600|NCT05561309|Experimental|dose 2|"Experimental: HR18034 285mg (15ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 75mg (15mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
32785601|NCT05561309|Experimental|dose 3|"Experimental:HR18034 380mg (20ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 100mg (20mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
32785602|NCT05352503|Experimental|watching video with virtual reality glasses|
32785603|NCT05352503|No Intervention|routine maintenance, no intervention|
32785604|NCT05270525|Experimental|Treatment Sequence 1|Treatment Period 1 (blinded Ensifentrine) followed by Treatment Period 2 (blinded Placebo)
32785605|NCT05270525|Experimental|Treatment Sequence 2|Treatment Period 1 (blinded Placebo) followed by Treatment Period 2 (blinded Ensifentrine)
32785606|NCT05317013|Experimental|Group A - 100 mg CBD|100 mg CBD per day
32785607|NCT05317013|Experimental|Group B - 300 mg CBD|300 mg CBD per day
32785608|NCT05317013|Placebo Comparator|Group C - Placebo|Placebo
33292163|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
32785611|NCT05316467|Experimental|overweight 24kg/m2≤BMI<28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
32785612|NCT05316467|Experimental|BMI≥28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
32785613|NCT05316077||Vectorio® kit|
32785614|NCT04949243||People who use the self administered SARs-CoV-2 antigen testing kits|
32785615|NCT04422509|Experimental|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
32785616|NCT04422509|Other|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
32785617|NCT05313893|Experimental|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalentinfluenza vaccine, 4 weeks apart. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
32785618|NCT05350085|Experimental|Remimazolam Group|Use remimazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
33292164|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
32785619|NCT05350085|Active Comparator|Midazolam Group|Use midazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
33085743|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
33085744|NCT04535284|Experimental|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
33292165|NCT03987438|Experimental|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
32785620|NCT05349773||endoscopic left radial artery harvesting|single group of 32 patients listed for coronary artery bypass surgery with endoscopic radial artery harvesting.
32785621|NCT05349617|Experimental|Group 1 - PXVX0317|
32785622|NCT05349617|Placebo Comparator|Group 2 - Placebo|
32785623|NCT05313035|Experimental|Vaccine Candidate Formula 1|2 doses of vaccine candidate formula 1 administered with 28 days interval (0.5 mL per dose)
33292166|NCT03987438|No Intervention|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
33292167|NCT02533752||Main Group|This an observational registry - there is only one group
33292168|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
32785624|NCT05313035|Experimental|Vaccine Candidate Formula 2|2 doses of vaccine candidate formula 2 administered with 28 days interval (0.5 mL per dose)
32785625|NCT05313035|Placebo Comparator|Control|2 doses of placebo administered with 28 days interval (0.5 mL per dose)
33085745|NCT04535284|No Intervention|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
33085746|NCT04535167|Experimental|PF-07304814|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
33085747|NCT04535167|Placebo Comparator|Placebo|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
33292169|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
33292170|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
33292171|NCT01051674|Experimental|High fiber diet|
33292172|NCT01051674|Experimental|Low-carbohydrate diet|
33292173|NCT01055964|Experimental|Tacrobell|
33085748|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
33085749|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
33085750|NCT02216461|Experimental|High dose of BIBW 2948 BS|
33085751|NCT02216461|Placebo Comparator|Placebo|
33292174|NCT01055964|Active Comparator|Prograf|
33292175|NCT03987204|Experimental|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
33292176|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
33292177|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
33292178|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
33292179|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
33292180|NCT01051830|No Intervention|Control group|Routine care
33292181|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
33292182|NCT00373256|Experimental|A|
33292183|NCT00373256|Active Comparator|B|
33292184|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
33292185|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
32939103|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
33292186|NCT00393848|Experimental|Experiment 2 - Experimental Group|
33292187|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
33292188|NCT00393848|Experimental|Experiment 1 - Experimental Group|
33292189|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
33292190|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33292191|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33292192|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
32939104|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
32939105|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
32939106|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
33292193|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
33292194|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
33292195|NCT01046006|Experimental|Bortezomib, Rituximab, Dexamethasone|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
33292196|NCT01036646||BSTE-0125-Original Protocol|
33292197|NCT01036646||BSTE-0125.a-Amended Protocol|
32939107|NCT03478904|Experimental|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
32939108|NCT03478904|Experimental|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
32939109|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
32939110|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
32939111|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
32939112|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
32939113|NCT04706390||Health care workers|500-1000 health care workers prioritized for early vaccination
33292198|NCT01913132|No Intervention|Standard wound dressing OPEN|Standard wound dressing
33292199|NCT01913132|Experimental|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith & Nephew)
33292200|NCT01913132|No Intervention|Standard dressing EVAR|Standard wound dressing
33292201|NCT01913132|Experimental|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith & Nephew)
33292202|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
33292203|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
33292204|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
33292205|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
33292206|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
32785626|NCT05268497|Experimental|Esketamine|Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.
32785627|NCT05312177||DS with CAVSD Repair|Children between the ages of 5 and 8 years with Down syndrome who had Complete atrioventricular septal defect (CAVSD) repair in the first year of life and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
32785628|NCT05312177||DS without major CHD|Children between the ages of 5 and 8 years with Down syndrome without major Congenital Heart Disease(CHD) and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
32785629|NCT05348993|Experimental|50 mg dose of G03-52-01|150 subjects randomized to 50 mg of G03-52-01
32785630|NCT05348993|Experimental|100 mg dose of G03-52-01|150 subjects randomized to 100 mg of G03-52-01
32785631|NCT05348993|Placebo Comparator|Placebo|75 subjects randomized to placebo
32785632|NCT05268341|Experimental|Treatment|computer assisted intervention targeting expressive grammar for preschoolers with DLD
32785633|NCT05268341|No Intervention|No treatment|business as usual classroom (educational) services
32785634|NCT05348837||Subthalamic nucleus (STN) DBS|Patients undergoing evaluation for subthalamic nucleus DBS implantation will be included in this group.
32785635|NCT05348837||Globus pallidus interna (GPi) DBS|Patients undergoing evaluation for globus pallidus interna DBS implantation will be included in this group.
32785636|NCT05311943|Experimental|olverembatinib|40mg, taken orally once every other day of a 28-day cycle
32785637|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
32785638|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
32785639|NCT05557175|Experimental|Active rTMS group|
32785640|NCT05557175|Sham Comparator|Sham rTMS group|
32785641|NCT05266859|Active Comparator|Group I- Calcium hydroxide (Control)|"Group I will receive Calcium hydroxide . Calcium hydroxide is a gold standard medicament for the pulpotomy in deciduous teeth. It has antibacterial effects and widely used to disinfect the root canals.~This group will act as a control"
32785642|NCT05266859|Experimental|Group II- MTA (Experimental)|Group II will receive MTA (Mineral Trioxide Aggregate). MTA is a calcium silicate based highly biocompatible material that is commonly used for pulpotomies in deciduous teeth along with the regenerative procedures in permanent and deciduous teeth
32785643|NCT05266859|Experimental|Group III- PRF (Experimental)|Group III will receive PRF. PRF is platelet-rich fibrin that is a biocompatible product derived from patient's own blood. It is formed by centrifugation of the blood of the patient. It provides the growth factors and promotes regeneration of the pulp
32785644|NCT05310851|Experimental|PIOMI group|Infants in the PIOMI group will receive a 5-minute PIOMI 30 minutes before feeding time. PIOMI will be applied once daily for 14 days.
32785645|NCT05310851|Experimental|Non-nutritive sucking group|Infants in the non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes. Non-nutritive sucking will be applied once daily for 14 days.
32785646|NCT05310851|No Intervention|control group|only feeding follow-up will be done in the infants in the control group.
32785647|NCT05266313|Experimental|Oncosexology program|Several workshops before and after the radical prostatectomy
32785648|NCT05266313|No Intervention|Usual care|Usual care of the urology department for patients with prostate cancer
32785649|NCT02154087|Experimental|HP802-247|
32785650|NCT05219201|Sham Comparator|Sham cryotherapy full time patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their full-time rehabilitation stay"
32785651|NCT05219201|Sham Comparator|sham cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their part-time rehabilitation stay"
32785652|NCT05219201|Active Comparator|cryotherapy full-time hospitalized patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their full-time rehabilitation stay"
32785653|NCT05219201|Active Comparator|cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their part-time rehabilitation stay"
32785654|NCT05346731|Active Comparator|Control group|"Weight category 30-40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg)~Weight category > 40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
32785655|NCT05346731|Experimental|Olanzapine|"Weight category 30-40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg), olanzapine (2.5 mg)~Weight category > 40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg), olanzapine (2.5 mg for <55 kg, 5 mg for >55 kg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
32785656|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
32785657|NCT01659125|Experimental|OCFighter|OCFighter
32785658|NCT05555771|Experimental|Counterpressure Maneuvers|"Participants will receive standard of care treatment (behavioural intervention and avoidance measures, as indicated in Usual Care), alongside training in counter pressure maneuvers. Training in counterpressure maneuvers will be delivered through a handout and video that will show three maneuvers (i.e. arm-tensing, squatting, and leg-crossing) that patients enrolled in the intervention arm can perform when they begin to experience common signs and symptoms of syncope. Patients will be instructed to start with one of the maneuvers and if their symptoms do not go away, move on to a second or third maneuver if needed."
32785659|NCT05555771|Active Comparator|Usual Care|Participants will receive standard of care treatment for their diagnosis of syncope. This primarily includes behavioural interventions and avoidance measures (e.g., stay hydrated, increase salt intake, avoid hot situations, avoid standing for long periods of time, engage in regular physical activity). Some patients may be prescribed medication (Midodrine, Fludrocortisone) at the discretion of their physician.
32785660|NCT05218889|Experimental|surufatinib + camrelizumab + nab-paclitaxel + S-1|
32785661|NCT05218889|Active Comparator|nab-paclitaxel + gemcitabine|
32785662|NCT05263739|Experimental|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.
32785663|NCT05263739|Experimental|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.
32785664|NCT05263739|Experimental|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.
32785665|NCT05263739|Experimental|ESG206 dose level 4|ESG206 will be administered intravenously at dose level 4 every two weeks in a 28-day cycle.
32785666|NCT05263739|Experimental|ESG206 dose level 5|ESG206 will be administered intravenously at dose level 5 every two weeks in a 28-day cycle.
32785667|NCT05345795||SSc-ILD patients|
32785668|NCT05263349||COPD patients|Arm with patients with respiratory disease in whom we study dreams
32785669|NCT05263349||healthy subject|Arm with healthy subjects whose dream analysis will be used as a basis to compare them to the dreams of COPD patients and see if the disease (COPD) has an influence on the patients' dreams
32785670|NCT05345561||Pregnant women|Women with higher risk of FNAIT
32785671|NCT05262569||ileus group|Patients developed postoperative ileus
32785672|NCT05262569||control group|Patients did not develop postoperative ileus
32785673|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
32785674|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
32785675|NCT05215457||development set|50 cases are the development set, which is used to develop the prediction model of diquat acute poisoning. These patients are all from the First Affiliated Hospital of Nanjing Medical University.
32785676|NCT05215457||validation set|50 patients are the validation set, from more than ten tertiary a-level hospitals in the surrounding area, to verify the prediction model.
32785677|NCT05261633||Healthy Volunteers|
32785678|NCT05261633||Known Liver Metastases|
32785679|NCT05554367|Experimental|Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)|Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
32785680|NCT05554367|Experimental|Monotherapy Cohort 1 (binimetinib)|Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
32785681|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
32785682|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
32785683|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
32785684|NCT05550311|Experimental|Robot group|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program will be applied for 45 minutes a day, two days a week.
32785685|NCT05550311|Active Comparator|Control Group|Participants in this group will be included in a conventional rehabilitation program
32785686|NCT05214443|Experimental|POEM + F arm|This arm will receive the POEM + F procedure
32785687|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
32785688|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
32785689|NCT05214287|Experimental|Intermittent with 5x5-minutes at 2000m (16.3% O2)|Delivered intermittently, with 16.3% O2 and room-air, each 5 minutes, for 5 cycles/session
32785690|NCT05214287|Experimental|Intermittent with 5x5-minutes at 4000m (12.7% O2)|Delivered intermittently, with 16.3% O2 and room-air, each 5 minutes, for 5 cycles/session
32785691|NCT05214287|Experimental|Continuous for 45 minutes, at 2000m (16.3% O2)|Delivered via the hypoxicator
32785692|NCT05214287|Experimental|Continuous for 45 minutes, at 4000m (12.7% O2)|Delivered via the hypoxicator
32785693|NCT05214287|Placebo Comparator|Continuous for 45 minutes, at sea level (20.9% O2)|Delivered via an open three-way valve in the circuitry from hypoxicator to the participant
32785694|NCT05213663||1/parents of the Cerebral Palsy children|parents of the children with cerebral palsy will be evaluated about the awereness of their children's disease, physical and social activities and physiotherapy and rehabilitation.
32785713|NCT05213351|Experimental|Graded Motor İmagery|Graded Motor İmagery (GMI) group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, traditional exercises and home exercises.
32785714|NCT05213351|Active Comparator|Exercise|Exercise group will receive training involves mobilizations, stretching, specific exercises for the frozen shoulder.
32785715|NCT05258981|Other|Brain MRI|Obtain Brain MRI in adults with congenital heart disease and age/sex matched controls
32785716|NCT05167253|Experimental|UB-612 100 μg, 0.5 mL|All subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine
33292207|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
33292208|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
32785719|NCT05257109|Experimental|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
32785720|NCT05257109|Experimental|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
32785721|NCT05257109|Experimental|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
32785722|NCT05257109|Experimental|"Experimental E-Liquid Order D"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
32785724|NCT05256017|Active Comparator|Acoziborole|Single dose administration of 3 tablets of 320 mg
32785725|NCT05256017|Placebo Comparator|Placebo|Single dose administration of 3 tablets of 320 mg
32785726|NCT05211791|Active Comparator|Group TEA|insertion of Thoracic epidural anesthesia plus GA with lung isolation using suitable size double lumen tube at level T6
32785727|NCT05211791|Active Comparator|Group ESB|U/S guided erector spinae block anesthesia using 15 ml local anesthesia plus GA with lung isolation using a suitable size double-lumen tube
32785728|NCT05211791|Active Comparator|Group PVB|U/S guided paravertebral block anesthesia using 15 ml local anesthesia as total volume plus GA with lung isolation using suitable size double lumen tube
32785729|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
32785730|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
32785731|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
32785732|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
32785733|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
32785734|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
33292209|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
33292210|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
33292211|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
33292212|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
33292213|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
33292214|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
33292215|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
33292216|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
33292217|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
33292218|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
33292219|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
33292220|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
33292221|NCT01046474|No Intervention|control -no intervention|
33292222|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
33292223|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
33292224|NCT01043978|Experimental|Novel nipple|
33292225|NCT01043978|Active Comparator|Coventional nipple|
33292226|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
33292227|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
33292228|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
33292229|NCT00249873|Experimental|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
33292230|NCT00249873|Placebo Comparator|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
33292231|NCT00392210|No Intervention|Spontaneous Fill|
33292232|NCT00392210|Active Comparator|Retrograde Fill|
33292233|NCT01037348|Experimental|ranibizumab 0.5mg|
33292234|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.~Trial enrollment will resume after at least 5 patients do not have a DLT during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
33292235|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
33292236|NCT01046630|Experimental|1|single infusion
33292237|NCT01046630|Active Comparator|2|single infusion
33292238|NCT01046630|Placebo Comparator|3|single infusion
33292239|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
33292240|NCT01046708|Experimental|micronized progesterone|
33292241|NCT01046708|No Intervention|no utrogestan|
33085752|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
33085753|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
33085754|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
33085755|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
33085756|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
33292242|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
33292243|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
32785735|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
33292244|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
33292245|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
33292246|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
33292247|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
33292248|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
33292249|NCT00762554|Active Comparator|1|Epidural Depodur after spinal bupivacaine
33292250|NCT00762554|Active Comparator|2|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
33292251|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
33292252|NCT00391898|Active Comparator|Levodopa/carbidopa|
33292253|NCT03993080|Experimental|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
33292254|NCT03993080|No Intervention|Treatment as usual|Seated in similar environment as experimental group for same time
32785736|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
33085757|NCT04534855|Experimental|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
33292255|NCT01046864|Experimental|Arm 1|
33292256|NCT01046864|Experimental|Arm 2|
33085758|NCT04534699|Experimental|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
33292257|NCT01046864|Experimental|Arm 3|Japanese Population
33085759|NCT04534699|Experimental|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
33292258|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
33292259|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
33292260|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
33292261|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
33292262|NCT01049282|Experimental|12 TST negative volunteers antigen only|
33292263|NCT01049282|Experimental|12 TST negative volunteers|
33292264|NCT01049282|Experimental|12 BCG vaccinated volunteers|
33292265|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
33292266|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
33292267|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
32785737|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
33085760|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
33292268|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
33292269|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
33292270|NCT01047176||1|Male or female > 18 year of age with indication to PCI
33292271|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
33292272|NCT01047254|Placebo Comparator|placebo capsule|Placebo
32785738|NCT05211401|Experimental|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
33292273|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
33292274|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
33292275|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
32939114|NCT04706390||prioritized patient populations|2000 individuals in patient populations prioritized for vaccinations
33318370|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
33318371|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
32785739|NCT05211401|Experimental|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera®) in 400 ml of NaCl 0.9%.
32785740|NCT05211401|Placebo Comparator|Placebo arm|1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
32785741|NCT04233671|Experimental|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
32785742|NCT04233671|No Intervention|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
32785743|NCT05163041|Experimental|BT7480 monotherapy dose escalation|Participants will receive increasing doses of BT7480. It is expected that approximately 40 patients will participate in this dose escalation arm.
32785744|NCT05163041|Experimental|BT7480 and nivolumab dose escalation|Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.
32939115|NCT03270332|Experimental|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
32785745|NCT05163041|Experimental|BT7480 monotherapy dose expansion|Participants will receive a selected dose of BT7480. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
32785746|NCT05163041|Experimental|BT7480 and nivolumab dose expansion|Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
32939116|NCT03270332|Experimental|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
32939117|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
32939118|NCT03483506|Experimental|All subjects|
32939119|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
32939120|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
32939121|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
32939122|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
32939123|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
32939124|NCT02156466|Experimental|MSB0010841 30 mg|
32939125|NCT02156466|Experimental|MSB0010841 60 mg|
32939126|NCT02156466|Experimental|MSB0010841 120 mg|
32939127|NCT02156466|Experimental|MSB0010841 240 mg|
32939128|NCT02156466|Placebo Comparator|Placebo|
33085761|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
33292276|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~Docetaxel 75 mg/m2, D1~Docetaxel 35 mg/m2, D1,8,15~Paclitaxel 200-225 mg/m2, D1~Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~Etoposide 100 mg/m2 D1-3~Etoposide 200 mg/m2 orally D1-3~Pemetrexed 500 mg/m2, D 1~Irinotecan 50 mg/m2 D1,8,15~Other regimens:~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
33292277|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
33292278|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
33292279|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
33292280|NCT00391274|Experimental|Pemetrexed|
33292281|NCT00391274|Active Comparator|Docetaxel|
33292282|NCT00391118|Experimental|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
33292283|NCT00391118|Placebo Comparator|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles~Placebo: oral tablet"
33292284|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
33292285|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
33292286|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
33292287|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
33292288|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
33292289|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
33292290|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
32785747|NCT05163041|Experimental|BT7480 monotherapy in patients with renal insufficiency|Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.
32785748|NCT05207657|Experimental|Lentiviral vector transduced CD34+ cells|The investigational product is patient-specific and corresponds to cryopreserved autologous CD34+ cells transduced ex vivo with the pCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
32785749|NCT05254925|Active Comparator|Phototoxicity evaluation of sunscreen oil with 6% BEMT (SU E 101413 85)|"Assessment of the phototoxicity potential of sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~The phototoxic response of the investigational product: SU E 101413 85 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
32785750|NCT05254925|Other|Phototoxicity evaluation of sunscreen oil vehicle (SU E 101413 91)|"Vehicle Control: Assessment of the phototoxicity potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (formulation: SU E 101413 91).~The phototoxic response of the investigational product: SU E 101413 91 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
32785751|NCT05254925|Active Comparator|Phototoxicity evaluation of dispersion of 6% BEMT in petrolatum (SU E 101413 82)|"Assessment of the phototoxicity potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum (formulation: SU E 101413 82).~The phototoxic response of the investigational product: SU E 101413 82 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
32785752|NCT05254925|Other|Phototoxicity evaluation of petrolatum vehicle (SU-E-101413-83)|"Vehicle Control: Assessment of the phototoxicity potential of petrolatum vehicle (SU-E-101413-83).~The phototoxic response of the investigational product: SU E 101413 83 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
32785753|NCT05254457|No Intervention|Observation Only Group|
32785754|NCT05254457|Experimental|Treated or Retreated Group|
32785755|NCT05206487|Experimental|Polydextrose|Patients will receive PDX 15 days prior and for a 6 month periods after TIPS.
32785756|NCT05253443|Experimental|Mentalizing Imagery Therapy and caregiver skills mobile application|
32785757|NCT05253443|Active Comparator|Caregiver skills mobile application|
32785758|NCT05205941|Other|MMV533 (single, oral doses).|Approximately 12 volunteers in 1 cohort, Up to six dose levels between 10 and 160mg
32785759|NCT05205473|Active Comparator|SN blockade under ultrasound control with a peripheral nerve stimulator 12.5 ml 1% lidocaine|Patients undergoing surgery on the knee, shin, ankle or foot
32785760|NCT05205473|Experimental|SN blockade under ultrasound control without a peripheral nerve stimulator|Patients undergoing surgery on the knee, shin, ankle or foot
32785761|NCT05161013|Experimental|The LINFU™ test|LINFU™ to increase sensitivity of pancreatic juice cytology LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
32785762|NCT05160935|Experimental|Coronary Angiography Training Manual|It is the form prepared by the researchers in line with the literature information and the opinion of the specialist physician was taken. It contains information about coronary artery disease, what to do before coronary angiography procedure and what kind of situations await individuals after the procedure.
32785763|NCT05253053|Experimental|Arm A: TT-00420 Tablet Monotherapy|TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
32785764|NCT05253053|Experimental|Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®)|TT-00420 tablets will be administered once daily in 21-day cycles. Atezolizumab(1200 mg/20 mL) will be administered intravenously on Day 1 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
32785765|NCT05253053|Experimental|Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)|TT-00420 tablets will be administered once daily in 21-day cycles. Nab-paclitaxel 125 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
32785766|NCT04945655|Experimental|Arm 1: component 1 + component 2 + component 3|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2) + Access to vaccination at school (component 3)
32785767|NCT04945655|Experimental|Arm 2: component 1 + component 2|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2)
32785768|NCT04945655|Experimental|Arm 3: component 1 + component 3|Adolescents and parents' education and motivation at school (component 1) + Access to vaccination at school (component 3)
33085762|NCT04534816|Experimental|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
33085763|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
33085764|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
32785769|NCT04945655|Experimental|Arm 4: component 1|Adolescents and parents' education and motivation at school (component 1)
32785770|NCT04945655|Experimental|Arm 5: component 2|General practitioners' training (component 2)
32785771|NCT04945655|No Intervention|Arm 6: Control|No intervention
32785772|NCT04422197|Active Comparator|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
32785773|NCT04422197|Active Comparator|Patients with no botox injection|Patients with major abdominal surgery without botox injection
32785774|NCT05252429|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression or up to 35 cycles.
32785775|NCT05204303||Patients with symptoms of LPR and objective evidence of GORD|
32785776|NCT05204303||Patients with symptoms of LPR and no objective evidence of GORD|
32785777|NCT05204303||Healthy volunteers|
32785778|NCT05203835|Experimental|Placebo and acebilustat|Participants will take acebilustat and placebo over a period of 9 months.
32785779|NCT05203367|Experimental|BAR 502|Each subject will receive an oral single-dose of BAR 502.
32785780|NCT05203367|Placebo Comparator|Placebo|Each subject will receive an oral single-dose of placebo.
32785781|NCT05252195||Participants|Participants with Multiple Sclerosis who meet eligibility criteria.
32785782|NCT05251571|Active Comparator|Conventional Exercise Group with Telerehabilitation|Exercises such as muscle strengthening exercises applied to antigravity muscles, agonist antagonist spastic muscles, stretching exercises for spastic muscles, weight transfer will be applied, and a telerehabilitation platform will be used in the home exercise program.
32900604|NCT05329428|Experimental|Vitamin D Supplementation 20 µg/day|Dietary supplements containing 20 µg of vitamin D per day will be provided to study subjects.
32900605|NCT05329428|Experimental|Vitamin D Supplementation 40 µg/day|Dietary supplements containing 40 µg of vitamin D per day will be provided to study subjects.
32900606|NCT05329428|Active Comparator|Usual Antenatal Care|Women randomized to usual antenatal care will receive advise about vitamin D supplementation according to usual antenatal care routines.
32900607|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
32900608|NCT05385666|Experimental|group experimental|
32900609|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
32900610|NCT05365776|Experimental|Arm 1: Graded Exposure Therapy|
32900611|NCT05365776|Active Comparator|Arm 2: Prescribed Aerobic Exercise|
32900612|NCT05365776|Active Comparator|Arm 3: Enhanced usual care|
32900613|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
32785783|NCT05251571|Experimental|Balance Coordination Group with Telerehabilitation|Sit and stand exercise from chair, standing posture, weight transfer to right and left extremities, stepping over obstacles, standing on one leg with support from the table, standing on two legs with support from the table, hip abduction with support from the table, extension, flexion, supported tandem walking exercises such as stepping on the stairs, standing functional stretches will be applied. Whatsapp application-based Telerehabilitation platform will be used to deliver the home exercise program.
33085765|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
32785784|NCT05251337|Experimental|Intervention - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - nausea/vomiting arm. This arm will receive peppermint inhaled aromatherapy patches (or mandarin as an alternative if they have a peppermint sensitivity).
32785785|NCT05251337|Experimental|Intervention - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - anxiety arm. This arm will receive lavender inhaled aromatherapy patches.
33085766|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
33085767|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
33085768|NCT04534504|Experimental|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
33085769|NCT04534504|Active Comparator|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
33085770|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
33085771|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
33085772|NCT04534426|Active Comparator|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
33085773|NCT04534426|Active Comparator|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
33085774|NCT04534426|Other|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
33085775|NCT04534465|Experimental|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
33318372|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
32785786|NCT05251337|Placebo Comparator|Control - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive control will be allocated to the control - nausea/vomiting arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
32785787|NCT05251337|Placebo Comparator|Control - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive control will be allocated to the control - anxiety arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
32785788|NCT05203289|Experimental|Solution for injection in prefilled syringe with higher concentration (Test)|
32785789|NCT05203289|Experimental|Solution for injection in prefilled syringe with lower concentration (Reference)|
32785790|NCT05157971|Experimental|Treatment (venetoclax, C10403 regimen)|See Detailed Description
32785791|NCT05370755|Experimental|Phase Ia: ICP-189 Dose Escalation|
32785792|NCT05250791|Active Comparator|lidocaine|
32785793|NCT05250791|Placebo Comparator|Placebo|
32785794|NCT05250713|Experimental|tDCS|Patients receiving tDCS during SEEG investigation
32785795|NCT05250713|Experimental|tACS|Patients receiving tACS during SEEG intervention
32785796|NCT05250089|Experimental|Emergency physicians|"Each participant will have to carry out two simulation sessions. The first simulation will correspond to the usual evaluation, that is to say it will take place on a day that will not be preceded by night duty during the three previous nights.~The second simulation will correspond to the assessment twenty-four hours after the end of a call, in the post-recovery period. The participant must therefore have performed a night shift the day before the day when the simulation takes place. This call must have a minimum duration of twelve hours on night shifts."
32785797|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785798|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785799|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785800|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785801|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785802|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785803|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785804|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32785805|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
32785806|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
32785807|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
32785808|NCT05249777|Experimental|TD0069|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment.
32785809|NCT05249777|Placebo Comparator|Placebo|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment
32785810|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
32785811|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
32785812|NCT05201027|Experimental|trifocal intraocular lens|Implantation of new trifocal intraocular lens
33292291|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
32785813|NCT05200403|Experimental|Crisabole 2%|Adult caregivers of children participants will be asked to apply a thin even-layer of Crisaborole (2%) twice daily for 2 weeks.
32785814|NCT05200403|Active Comparator|Vehicle Arm|Adult caregivers of children participants will be asked to apply a thin even-layer of vehicle treatment twice daily for 2 weeks.
32785815|NCT05156411|Experimental|Eccentric Training|This Group will train on the KREHA for 20 Trainings
32785816|NCT05248919|Active Comparator|12 weeks treatment with sofosbuvir/velpatasvir|134 first-line treatment failure patients randomly allocated to receive 12 weeks treatment with sofosbuvir/velpatasvir
32785817|NCT05248919|Active Comparator|24 weeks treatment with sofosbuvir/velpatasvir|134 first-line treatment failure patients randomly allocated to receive 24 weeks treatment with sofosbuvir/velpatasvir
33292292|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
33318373|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
32785818|NCT05248919|Active Comparator|Observational|50 patients with decompensated cirrhosis who will receive 24 weeks of sofosbuvir/velpatasvir.
32785819|NCT04231487||Essential tremor|"This is not an intervention study.~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
32785820|NCT04231487||Parkinson's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
32785821|NCT04231487||Huntington's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
32785822|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
33085776|NCT04534465|Experimental|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
33085777|NCT04534465|Experimental|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
33085778|NCT04534465|Experimental|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
33085779|NCT04534465|Experimental|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
32785823|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
32785824|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
33085780|NCT02216656|Placebo Comparator|Plascebo|
33085781|NCT02216656|Experimental|KHK7580 low dose|
33085782|NCT02216656|Experimental|KHK7580 middle dose|
33085783|NCT02216656|Experimental|KHK7580 high dose|
33085784|NCT02216656|Active Comparator|KRN1493|
33085785|NCT04534075|Experimental|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
33085786|NCT04534075|Placebo Comparator|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
33085787|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
33085788|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
32785825|NCT04231487||Healthy Controls|"This is not an intervention study.~People with Healthy Controls"
32785826|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
32785827|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
32785828|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
32785829|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
32785830|NCT05200325|No Intervention|Control Group|The control group does not receive educational materials about the TissueCypher diagnostic test and will treat their simulated patients with the current standard of care tools.
32785831|NCT05200325|Experimental|Intervention Group 1|Intervention group 1 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group is then forced to use the test results in treating their simulated patients.
33085789|NCT04534192|Experimental|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C & D lesions in patients with chronic limb threatening ischemia.
33085790|NCT04534036|Active Comparator|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
33085791|NCT04534036|Placebo Comparator|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
33085792|NCT04533724|Experimental|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
33085793|NCT04533724|No Intervention|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
33085794|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
33085795|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
33085796|NCT04533685|Active Comparator|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
33085797|NCT04533685|Active Comparator|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
33085798|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
33085799|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
33085800|NCT04533685|Active Comparator|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
32939129|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
33085801|NCT04533685|Active Comparator|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
33085802|NCT04533685|No Intervention|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
33085803|NCT04533490|Experimental|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
33085804|NCT04533334||Pediatric|FOB measurement of the distance between carinae and right upper lobe and carinae and labium oris in paediatric population
33085805|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
33085806|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
32939130|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
32939131|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
33085807|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
33085808|NCT04533217|Active Comparator|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
33085809|NCT04533217|No Intervention|Regular treatment|Patients treated with regular medical treatment.
33085810|NCT04533178|Active Comparator|Restriction of sports activities|No sports during the 6 week treatment period
32939132|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
32939133|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
32939134|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
32939135|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
32939136|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
32939137|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
32939138|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
32939139|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
32939140|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
32939141|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
32939142|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
32939143|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
32939144|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
32939145|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
32939146|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
32939147|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
32939148|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
32939149|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
32785832|NCT05200325|Experimental|Intervention Group 2|Intervention group 2 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group then gets to decide whether or not they want to use the TissueCypher test results for their simulated patients.
32939150|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
32939151|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
33292293|NCT00264537|Experimental|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33292294|NCT00264537|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
32939152|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
32939153|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
32939154|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
33292295|NCT00264537|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33292296|NCT00264537|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
33292297|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
33292298|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
33292299|NCT00371150|Experimental|Arm1|
33292300|NCT00264303|Experimental|Levocetirizine|Levocetirizine, once daily, 4 week duration
33292301|NCT00264303|Active Comparator|Desloratadine|Desloratadine, once daily, 4 week duration
33292302|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
32785833|NCT05248841|Experimental|HEC-Glargine Treatment A (Test)|Subjects will receive single doses of Test Formulation HEC-Glargine on Day 1 of Treatment periods 1 and 2 followed by at least 7-21 days washout.
32785834|NCT05248841|Active Comparator|US-Lantus Treatment B (Reference)|Subjects will receive single doses of Reference Formulation Lantus on Day 1 followed of Treatment periods 1 and 2 by at least 7-21 days washout.
32939155|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
32939156|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
32939157|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
32785835|NCT05248139|Experimental|Single-dose steroid medication delivered during surgery|Subconjunctival injection of Triamcinolone acetonide.
32785836|NCT05248139|Active Comparator|Standard of care post-operative steroid drops|Prednisolone acetate ophthalmic solution, 4-week taper.
32785837|NCT04230239|Experimental|CPX-351|
32785838|NCT05247905|Experimental|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32785839|NCT05247905|Experimental|Arm II (capecitabin, temozolomide)|Patients receive capecitabine PO BID days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
32785840|NCT05199389|Experimental|PBM1 group|The patients allocated to the first PBM-group will receive six PBM sessions of 6 J/cm² over three weeks (2x/week).
32939158|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
32939159|NCT04758546|Experimental|Aggressive screening criteria + high minimal ventilatory settings|
32785841|NCT05199389|Experimental|PBM2 group|The patients allocated to the first PBM-group will receive six PBM sessions of 8 J/cm² over three weeks (2x/week).
32939160|NCT04758546|Experimental|Aggressive screening criteria + low minimal ventilatory settings|
32939161|NCT04758546|Experimental|Conservative screening criteria + high minimal ventilatory settings|
32939162|NCT04758546|Active Comparator|Conservative screening criteria + low minimal ventilatory settings|
32939163|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
32939164|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
32939165|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
32785842|NCT05247125|Experimental|Blue light exposure + Melatonin treatment|The participants will receive the combination of blue light exposure according to the protocol described by Killgore et al. (2020) and 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) for 14 days
32785843|NCT05247125|Experimental|Melatonin treatment|The participants will receive 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) and the morning placebo-light exposure according to the protocol described by Killgore et al. (2020) for 14 days
32785844|NCT05247125|Experimental|Blue light exposure|The participants will receive the morning blue light exposure according to the protocol described by Killgore et al. (2020) for 14 days and placebo pill 1 hour before going to sleep (approximately at 20:00)
32785845|NCT05247125|Placebo Comparator|Placebo group|The participants will receive placebo light exposure in the morning (lamp turned off) and placebo pill treatment in the evening for 14 days
33085811|NCT04533178|Experimental|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
33085812|NCT04533295|Experimental|Acupuncture and IVF|Acupuncture and IVF
33085813|NCT04533295|Sham Comparator|Sham acupuncture and IVF|Sham acupuncture and IVF
33292303|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
33292304|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
33085814|NCT04532944|Other|patients with MS|20 relapsing-remitting and 20 progressive MS patients
33085815|NCT04532944|Other|healthy controls|15 age- and sex-matched healthy controls
33292305|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
33292306|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
33292307|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
33292308|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
33085816|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
33292309|NCT00264147|Experimental|Period I: 1|etoricoxib
33292310|NCT00264147|Experimental|Period I: 2|etoricoxib
33292311|NCT00264147|Experimental|Period I: 3|etoricoxib
33292312|NCT00264147|Experimental|Period I: 4|etoricoxib
33292313|NCT00264147|Placebo Comparator|Period I: 5|Placebo
33292314|NCT00264147|Experimental|Period II: 1|etoricoxib
33292315|NCT00264147|Active Comparator|Period II: 2|diclofenac
33292316|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
33292317|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
33292318|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
33292319|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
33292320|NCT00263757|Experimental|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
33292321|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
33292322|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
33292323|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
33292324|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
33292325|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
33292326|NCT01072461|Experimental|Train Both Hands Together in VE|
33292327|NCT03971019|Experimental|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
33292328|NCT03971019|Other|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
33292329|NCT03970707|Experimental|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
33292330|NCT03970707|Experimental|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
33292331|NCT03970707|No Intervention|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
33292332|NCT03974685|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
33292333|NCT03970551|No Intervention|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
33292334|NCT03970551|Experimental|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
33292335|NCT03970551|Experimental|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
33292336|NCT03970551|Experimental|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
33292337|NCT03970551|Experimental|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
33292338|NCT03970551|Experimental|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
33085817|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
33085818|NCT04532905|Sham Comparator|without previous strength training experience|control (untrained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
33085819|NCT04532905|Experimental|with previous strength training experience|experimental (trained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
33085820|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
33085821|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
33292339|NCT03970473|Active Comparator|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
33292340|NCT03970473|Active Comparator|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
33292341|NCT00263211|Experimental|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
33292342|NCT00263211|No Intervention|Observation only|Observation by treating physician
33292343|NCT03970317|Experimental|Broad Band Light|Broad Band Light (BBL) motion treatment
33292344|NCT00248625|Active Comparator|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
33292345|NCT00248625|Placebo Comparator|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
33292346|NCT00262821|Active Comparator|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
33292347|NCT00262821|Experimental|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
33292348|NCT00262743|Experimental|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
32785846|NCT05245955|Experimental|Robotic assessment of sensory hand function|This arm involves a group of persons with Parkinson's disease and an age-matched control group. Both groups undergo the assessments of kinaesthesia and haptic perception of the hand implemented on the ReHapticKnob.
32785847|NCT05154383|Experimental|High-Dose Quadrivalent Influenza Vaccine|One injection of the high-dose Efluelda vaccine will be given to the patient
32785848|NCT05154383|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|One injection of the standard-dose Influvactetra vaccine will be given to the patient
32785851|NCT05196815|Experimental|The Royal Wolverhampton NHS Trust- New Cross Hospital|
32785852|NCT05245877|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
32785853|NCT05245877|No Intervention|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
32785856|NCT05245331|Active Comparator|High-volume TAI|This group will be instructed on High-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to Low-TAI treatment for 2 months.
32785857|NCT05245331|Active Comparator|Low volume - TAI|This group will be instructed on Low-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to the Low-TAI treatment for 2 months.
32785858|NCT05194475|Experimental|Thermogenic Ready-to-drink Beverage|Arm in which a thermogenic ready-to-drink beverage is ingested.
32785859|NCT05194475|Placebo Comparator|Placebo Ready-to-drink Beverage|Arm in which a placebo ready-to-drink beverage is ingested.
32785860|NCT05245175|Experimental|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
32785861|NCT05245175|Experimental|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
33085822|NCT02216890|Experimental|SGN-CD70A|
33085823|NCT04532983|Active Comparator|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
33085824|NCT04532983|Active Comparator|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
33085825|NCT04532866|Experimental|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
33085826|NCT04532866|No Intervention|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
33085827|NCT04532476|Experimental|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
33085828|NCT04532476|Placebo Comparator|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
33085829|NCT04532671|Other|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering & medical applications due to its favorable mechanical and chemical properties.
33085830|NCT04532671|Other|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
33085831|NCT04532671|Active Comparator|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
33085832|NCT04532593|Experimental|Stem cell group|
33085833|NCT04532593|Placebo Comparator|Control|
33085834|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
33085835|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
33085836|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
33085837|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
33085838|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
33085839|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
33085840|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
32785862|NCT05245175|Placebo Comparator|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
33085841|NCT04532398|Other|Swallowing test|
33085842|NCT04532554|Experimental|Growth hormone|Recombinant GH will be used for those patients
33085843|NCT04532554|Placebo Comparator|Placebo|Saline will be used
33085844|NCT04532281|Experimental|Administration of Murine CD19 CAR T-cells|
33085845|NCT04532203|Experimental|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
33085846|NCT02217163|Experimental|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
33085847|NCT02217202|Experimental|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
33085848|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
33085849|NCT04531774|Experimental|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
33085850|NCT04531774|Active Comparator|Online self-study of stress management strategies|Self study during 2 weeks.
33085851|NCT04531930||Surgery Group|Colorectal surgery
33085852|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
33085853|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
33085854|NCT04532008|No Intervention|Control Group|No intervention
33085855|NCT04532008|Experimental|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
33085856|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
32785863|NCT05245175|Experimental|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
32785864|NCT05245175|Experimental|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
33292349|NCT03974529|Experimental|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
33292350|NCT03974529|Active Comparator|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
33292351|NCT01326117|Experimental|tadalafil|
33292352|NCT03970239|Experimental|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). [11C] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
33292353|NCT03970239|Experimental|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [18F]-altanserin.~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
33292354|NCT03970161|Experimental|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
33292355|NCT03970161|Experimental|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
33292356|NCT03974295|Experimental|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
33292357|NCT03974295|No Intervention|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
33292358|NCT00262119|Active Comparator|Control Group|PM programming according to actual clinical practice
32785865|NCT05152277|Experimental|Single dose escalation of HRS9531 injection in healthy subjects|
32785866|NCT05152277|Placebo Comparator|Single dose of placebo in healthy adults|
32785867|NCT05152277|Experimental|Multiple dose escalation of HRS9531 injection in healthy subjects|
32785868|NCT05152277|Placebo Comparator|Multiple dose of placebo in healthy adults|
32785869|NCT05243381|Other|Immune non-responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count < 350 cells/mm3 on the last two tests"
32785870|NCT05243381|Other|Immune responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count > 500 cells/mm3 on the last two tests"
32785871|NCT05150171|Experimental|e-self-management intervention|Patients will receive the HAPPY Hands e-self-management intervention delivered through a smartphone app.
33292359|NCT00262119|Active Comparator|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
33292360|NCT00262119|Active Comparator|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
33292361|NCT00170950|Experimental|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
33292362|NCT00170950|Active Comparator|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
33292363|NCT00239577|Experimental|DENGUE FORMULATION 17A GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Dengue vaccine Formulation 17a, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
32785872|NCT05149937|Experimental|Interventional group|Implementation of interprof Home measures to improve cooperation between nursing services, general practitioners and members of the therapeutic professions in the care of people living at home with care needs.
33292364|NCT00239577|Experimental|DENGUE FORMULATION 17B GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 17b, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6, and one booster dose approximately 5-12 months after the second dose.
33292365|NCT00239577|Experimental|DENGUE FORMULATION 19 GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 19, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6 and one booster dose approximately 5-12 months after the second dose.
33292366|NCT00239577|Placebo Comparator|PLACEBO GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Placebo, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
33292367|NCT00262041|Experimental|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
33292368|NCT00262041|Experimental|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
33292369|NCT00262041|Active Comparator|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
33292370|NCT03969849|Experimental|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
32785873|NCT05149859||BED+ : Participants with obesity and binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 positive score and a Binge Eating Scale score >16
33085857|NCT04531735||Group 1|COVID positive infants
33292371|NCT03969849|Experimental|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
33292372|NCT03969849|Experimental|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
33292373|NCT03969849|Experimental|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
33292374|NCT03969849|Experimental|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
33292375|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
33292376|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
33292377|NCT00208767|Active Comparator|Valsartan|Valsartan titrated up to 320 mg orally daily
33292378|NCT00208767|Placebo Comparator|Placebo|Patients received a placebo instead of Valsartan
33292379|NCT03969771|Experimental|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
33292380|NCT03969771|Active Comparator|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
32785874|NCT05149859||BED-: Participants with obesity but without binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 negative score and a Binge Eating Scale score < 12
32785875|NCT05149781||patients with EH|patients with endocrine hypertension
32785876|NCT05149781||patients with PH|patients with primary hypertension
32785877|NCT05192837|Experimental|Intervention group|The study intervention consists of a smoking cessation counselling meeting by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery. The goal of this first intervention meeting is to implement an individual treatment plan for preoperative smoking cessation.
32785878|NCT05192837|No Intervention|Control group|Patients randomised to the control arm will get advice only. Their preoperative course will be as if they were not participating in this study, meaning they will receive inconsistent perioperative smoking cessation advice from nurses, surgeons, or anaesthesiologists but no further study-specific smoking cessation intervention. Importantly, participants in the control group will not be discouraged from using perioperative smoking cessation aids and can still obtain help on one's own initiative.
32785879|NCT05192525|Experimental|mChemotherapy group|"The intervention group participants will adopt an app mChemotherapy to self-manage their symptoms under nurse-led supervision for six weeks."
32785880|NCT05192525|No Intervention|Control group|"Participants in control group will receive routine care, with no use of mChemotherapy during six weeks. Routine care is composed of a pre-chemotherapy visit and two follow-up visits. Through the Official WeChat platform, the patients in control group will be informed about the chemotherapy regimen, and chemotherapy-related symptoms and how to deal with them, during the pre-chemotherapy visit. The control group will have two scheduled visits by telephone with the follow-up nurse. Patients will be given a phone number for consulting the follow-up nurse should they have questions related to their symptoms, or concerns related to the chemotherapy. Patients in the control group cannot access the mChemotherapy until they have completed the pilot study."
32939166|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
33085858|NCT04531735||Group 2|RSV positive infants
33085859|NCT04531423|Experimental|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
33085860|NCT04531423|Active Comparator|SSRI +placebo|Participants will be administered with SSRI+placebo
33085861|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
33085862|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
33085863|NCT04531306|Active Comparator|Pre-tape|
33292381|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
33292382|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
33292383|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
33292384|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
33292385|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
33292386|NCT03969615|Active Comparator|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
33292387|NCT03969615|Experimental|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
33292388|NCT01072695|Experimental|Arm 1|
33292389|NCT01072695|Experimental|Arm 2|
33292390|NCT01072695|Experimental|Arm 3|
33292391|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
33292392|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
33292393|NCT01049516|Other|Minimal Contact Control|
33292394|NCT01049516|Experimental|PE-Massed|
33292395|NCT01049516|Active Comparator|PE-Spaced|
33292396|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
33292397|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
33292398|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
33292399|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
33292400|NCT00135200|Experimental|Bexxar therapeutic|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from the subject's body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated based on the scans performed following the dosimetric dose."
33292401|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
33292402|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
32939167|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
32939168|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
32939169|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
32939170|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
32939171|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
32939172|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
32939173|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
32939174|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
32939175|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
33292403|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
33292404|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
33292405|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
33292406|NCT00261495|Active Comparator|Oxycodone|
32939176|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
33292407|NCT00261495|Experimental|OROS hydromorphone HCl|
33292408|NCT00168844|Other|Tiotropium Respimat 5mcg (Tio R5)|
32939177|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
32939178|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
33292409|NCT00168844|Other|Tiotropium Respimat 10mcg (Tio R10)|
33292410|NCT00168844|Other|Placebo|
33292411|NCT00365456|Experimental|PTH (1-84)|
33292412|NCT00365456|Active Comparator|Risedronate|
32939179|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
32939180|NCT04761588|Experimental|Tyr sphere|All patients to receive Tyr sphere as part of their dietary management for tyrosinaemia or alkaptonuria (AKU).
32939181|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
32939182|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
32939183|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
32939184|NCT04753086||Gynecologic Cancer Pts|Gynecologic cancer patients being treated with radiation at UNC.
32939185|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
33292413|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
33292414|NCT01047956|Active Comparator|Methadone|Methadone alone
33292415|NCT03480698||Cerebrolysin and standard stroke care|
33292416|NCT03480698||Standard stroke care|
33292417|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
33292418|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
33292419|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
32785881|NCT05475197|Experimental|Kinesio taping Type 1|"For the first group; While the wrist is 30° extension, the forearm is supinated and the elbow is extended, the distance between the 1st metacarpal joint and the medial epicondyles of the patient up to 5 cm below the median epicondyle will be measured. Two strips with width of 2.5 cm will be prepared. For the median nerve, the first band will be adhered along the nerve trachea by stretching of moderate intensity (50%) from the 2nd and 3rd metacarpophalangeal joint to 5 cm below the medial epicondyle.~The second strip will be applied without stretching to a distance of 5 cm under the medial epicondyle from the 4th and 5th metacarpophalangeal joint. In addition, a strip half the length of the wrist circumference will be adhered to the volar face of the wrist by applying tension to the middle 1/3 of it, without applying tension to both ends."
32785882|NCT05475197|Experimental|Kinesio taping Type 2|"For the second group; While the elbow is in full extension and the wrist in the extension and supination position, the distal two free ends of the tape will be adhered to the thenar and hypothenar regions without stretching. The middle 1/3 of the X-shaped tape will be adhered to the forearm volar face by applying moderate stretching.The first half of the two proximal free ends will have adhered to the medial and lateral epicondyle with little or no stretching, and the last half without any stretching.~The I-shaped tape will be adhered to the radial region of the wrist with the elbow in full extension, the wrist in a neutral position, and the palm closed. The middle of the tape will be stretched lightly and moderately, and the last 1/3 of it will be adhered to the ulnar part of the wrist without stretching. Kinesio taping will be applied to both groups once."
33085864|NCT04531306|Experimental|With tape 1|
33085865|NCT04531306|Experimental|With tape 2|
33085866|NCT04531306|Experimental|Post-tape|
33085867|NCT04531267|Active Comparator|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
33085868|NCT04531267|No Intervention|Control group|Participants do not receive any supplements, they stay with the original medication plan.
33085869|NCT04531228|Experimental|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
33085870|NCT04531150|Experimental|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
33085871|NCT04531150|Experimental|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
33085872|NCT04531150|Experimental|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
33085873|NCT04531150|Experimental|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
33085874|NCT04531150|Experimental|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
33085875|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
33085876|NCT04531345||Control Group|Healthy volunteers
33085877|NCT04531072|Experimental|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
33085878|NCT04531072|Active Comparator|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
33085879|NCT04530955|No Intervention|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.~The criteria for dosing decrease will be clinical discretion."
33085880|NCT04530955|Active Comparator|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.~The criteria for dosing increase will be clinical discretion."
33085881|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
33085882|NCT04531033|Placebo Comparator|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
33085883|NCT04531033|Experimental|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
33085884|NCT04531033|Experimental|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
33085885|NCT04530448|Active Comparator|Standard of Care|Standard of Care treatment
33085886|NCT04530448|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
33085887|NCT04530721||stroke group|
33085888|NCT04530721||normal group|
33085889|NCT04530370|Experimental|Recovered covid 19 plasma|
33085890|NCT04530370|Placebo Comparator|controlled|
33085891|NCT00414401|Other|Arm 1|
33085892|NCT04530331|Experimental|Intervention group|Providing nutrition education.
33085893|NCT04530331|No Intervention|Control group|Without any intervention.
33085894|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
33085895|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
33085896|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
33085897|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
33085898|NCT02217397|Experimental|OA, CPAPm, combination therapy|
33085899|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
33085900|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
33085901|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
33085902|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
33085903|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
33085904|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
33085905|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
32785885|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
32785886|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
32785887|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
32785888|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
32785889|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
32785890|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
32785891|NCT05191277|Experimental|Open discontinuation (OD)|Participants will discontinue their antidepressant medication and will be fully informed about treatment (i.e., high expectation).
32785892|NCT05191277|Experimental|Hidden discontinuation (HD)|Participants will discontinue their antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
32785893|NCT05191277|Experimental|Open continuation (OC)|Participants will remain on their initial antidepressant medication and will be fully informed about treatment (i.e., high expectation).
32785894|NCT05191277|Experimental|Hidden continuation (HC)|Participants will remain on their initial antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
32785895|NCT04242173|Experimental|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
32785896|NCT05242289|Active Comparator|Treated|"Treatment using the medical cytokine adsorption device in conjunction with lung transplantation"
32785897|NCT05242289|No Intervention|Non-treated|No additional treatment in conjunction with lung transplantation
32785898|NCT05189015|Experimental|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
32785899|NCT05189015|Active Comparator|Amlodipine|- Comparator group: Amlodipine, 5 (10) mg once a day, oral administration
32785900|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
32785901|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
33085906|NCT04719312|Experimental|transconjunctival Y modification|
33085907|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
33085908|NCT02217631|Active Comparator|Prednisolone low dose|
33085909|NCT02217631|Active Comparator|Prednisolone high dose|
33085910|NCT02217631|Placebo Comparator|Placebo|
32785902|NCT05188703|Experimental|Intervention arm|Intervention consists of standard of care eye exam and enrollment in a patient navigation program.
32785903|NCT05188469|Experimental|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
32785904|NCT05188469|Experimental|EG-COVID-001|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
32785905|NCT05147129||Postmenopausal with vulvar lichen sclerosus|Includes postmenopausal patients with clinically-active vulvar lichen sclerosus, as determined by biopsy or examination by a vulvar specialist
32785906|NCT05147129||Postmenopausal without vulvar lichen sclerosus|Includes postmenopausal patients without vulvar lichen sclerosus
33292420|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
33085911|NCT04530292|Experimental|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
33085912|NCT04530292|No Intervention|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
33085913|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
33085914|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
33085915|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
33085916|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
33292421|NCT00206427|Experimental|Intervention|Intervention/Lapatinib (GW572016)
33085917|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
33292422|NCT00146848|Active Comparator|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
33292423|NCT00146848|Active Comparator|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
33292424|NCT00146848|Active Comparator|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
33292425|NCT00205881|Active Comparator|1|Bilaterally Implanted with HiRes 90K device.
33292426|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
33292427|NCT00365378|Placebo Comparator|2|Placebo
33292428|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
33292429|NCT00365300|Active Comparator|Pantoprazole|
33292430|NCT00365300|Placebo Comparator|Placebo|
33292431|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
33292432|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
33292433|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
33292434|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
33292435|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
33292436|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
33292437|NCT03992690|Experimental|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
33292438|NCT03992690|Active Comparator|Classical physiotherapy protocol|Training with classical physiotherapy protocol
33292439|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
33292440|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
33292441|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
33292442|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
33292443|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
33085918|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
33085919|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
33085920|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
33292444|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
33292445|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
33292446|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
33085921|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
33085922|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
33292447|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
32785907|NCT05239091|Experimental|Dextrose prolotherapy|:%15 dextrose prolotherapy injection will be applied to trigger point
33085923|NCT02217826|Experimental|DG3173|
33085924|NCT02217826|Placebo Comparator|Saline|
33085925|NCT02217826|Active Comparator|Octreotide|
33085926|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
33085927|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
33085928|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
33085929|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
33085930|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
33085931|NCT04530097|Experimental|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
33292448|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
33292449|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
33292450|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
33292451|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
33292452|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
33292453|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
33292454|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
33292455|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
33292456|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
33292457|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
33292458|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
33292459|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
33292460|NCT01048268|Experimental|Healthy volunteers|
33292461|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
33292462|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
33292463|NCT03993236|Experimental|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
33292464|NCT03993236|Active Comparator|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
33292465|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
33292466|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
33292467|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
33292468|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
33292469|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
33292470|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
33292471|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
33292472|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
33292473|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
33292474|NCT00386360|Placebo Comparator|Placebo|Placebo dose
33292475|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
33292476|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
33292477|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
33292478|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
32785908|NCT05239091|Active Comparator|Lidocaine|%2 lidocaine injection will be applied to trigger point
32785909|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
32785910|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
32785911|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
33292479|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
33292480|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
33292481|NCT00529373|Placebo Comparator|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
33292482|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
33292483|NCT03687125|Experimental|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
33292484|NCT03687125|Experimental|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m^2 IV injection on Day -1 followed by ASCT on Day 1.
33292485|NCT03999203||A - T2 High Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL and consistently high FeNO levels ≥30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
33292486|NCT03999203||B - T2 Low Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≤ 0.2x10^9/mL and consistently low FeNO levels <30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
33292487|NCT03999203||C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
33292488|NCT03999203||D - T2 Intermediate|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL OR consistently high FeNO levels ≥30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
33292489|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
33292490|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
33292491|NCT05000489||Minors 1|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
33292492|NCT05000489||Minor 2|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
33292493|NCT05000489||Spina Bifida|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Spina Bifida clinic
33292494|NCT05000489||Pulmonology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the pulmonology clinic
33292495|NCT05000489||Endocrinology 1|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type I Diabetes
33292496|NCT05000489||Endocrinology 2|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type II Diabetes
33292497|NCT05000489||Rheumatology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Rheumatology clinic
33292498|NCT05000489||Gastroenterology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Gastroenterology clinic
33292499|NCT05000489||Neurology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Neurology clinic
32939186|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
32939187|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
33292500|NCT05000489||Cardiology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Cardiology clinic
33292501|NCT05000489||Hematology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Hematology clinic
32939188|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
32939189|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
32939190|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
32939191|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
32939192|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
32939193|NCT03372434|Experimental|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
32939194|NCT03372434|Experimental|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
33292502|NCT05000489||Nephrology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Nephrology clinic
33292503|NCT05000489||Oncology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Oncology clinic
33292504|NCT05245409|Experimental|Stress|Individuals under various degrees of stress
33292505|NCT04854395|Active Comparator|Group A: Active FTB + Active PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml for IFCN + 10 ml Marcain 5 mg/ml is used for PPB
33292506|NCT04854395|Active Comparator|Group B: Active FTB + Sham PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml is used for IFCN
33292507|NCT04854395|Active Comparator|Group C: Sham FTB + Sham PPB + Active ACB|Single shot bolus of 25 ml Marcain 5 mg/ml is used for ACB
33292508|NCT05221931|Active Comparator|DES group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure"
33292509|NCT05221931|Experimental|DCB group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DCB group, SeQuent Please, SeQuent Please NEO (B-Braun, Germany) or Agent (Boston Scientific, USA) will be used during the index procedure."
33292510|NCT04927247|Experimental|inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
33292511|NCT04927247|Placebo Comparator|placebo|Placebo administered IV
33292512|NCT05173493||Amoxicillin-Furazolidone-containing quadruple group|Patients in amoxicillin-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33292513|NCT05173493||Amoxicillin-Levofloxacin-containing quadruple group|Patients in amoxicillin-Levofloxacin-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
33292514|NCT05173493||Tetracycline-Furazolidone-containing quadruple group|Patients in tetracycline-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), tetracycline 500 mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33292515|NCT04907513||Amotivational Syndrome|Patients required an external drainage of the cerebrospinal fluid.
33292516|NCT04886063|Experimental|Treatment|Daily subcutaneous (SC) injection of ATH-1017
33292517|NCT05163821||Participants|Somali migrants in UK, aged over 50.
33292518|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
33292519|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
33292520|NCT05117489|Experimental|Cohort 1 - 150 mg of miricorilant for 24 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.
33292521|NCT05117489|Experimental|Cohort 2 - 150 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.
33292522|NCT05117489|Experimental|Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.
33292523|NCT05117489|Experimental|Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.
32785912|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
33292524|NCT05117489|Experimental|Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.
32785913|NCT01656395|Experimental|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
32785914|NCT01656395|Experimental|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
32785915|NCT01656395|Experimental|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
32785916|NCT01656395|Experimental|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
32785917|NCT01656395|Active Comparator|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
32785918|NCT01656395|Placebo Comparator|Placebo|Participants will receive Placebo tablets QD for 12 weeks
33292525|NCT05117489|Experimental|Cohort 6 - 100 mg of miricorilant every MF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.
33292526|NCT05117489|Experimental|Cohort 7 - 50 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 50 mg once daily, for 12 weeks.
32785919|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
32785920|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
33292527|NCT05117489|Experimental|Cohort 8 - 100 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 12 weeks.
32785921|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
32785922|NCT05185739|Active Comparator|Pembrolizumab|
32785923|NCT05185739|Active Comparator|Lenvatinib.|
32785924|NCT05185739|Experimental|Pembrolizumab and Lenvatinib.|
32785925|NCT05184881|Active Comparator|Group medial branch block|cervical medial branch block will done at the affected dermatomal level using 1 mL of a mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml).
32785926|NCT05184881|Active Comparator|Group retrolaminar block|cervical retrolaminar block was done using 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) for each affected dermatomal level.
32785927|NCT05144711|Active Comparator|Selective excavation|Cries will be removed from the peripheries of the cavity, while only soft caries will be removed from the plural side leaving stained leathery dentine that can not be removed by hand instruments. Biodentine will be placed and the cavity will be restored.
32785928|NCT05144711|Active Comparator|Non selective excavation|Caries will be cleaned form all cavity peripheries and floor. Biodentine will be placed and the toothy will be restored.
32785929|NCT05238935|No Intervention|control group|this group will be treated as per the common practice postoperatively and will have the home program prescribed by the orthopedic surgeon
32785930|NCT05238935|Experimental|intervention (treatment) group|Patients in the intervention group will be treated with conventional physiotherapy 3 times a week for 6 weeks (18 times treatment).
32785931|NCT05184725|No Intervention|Control Group|Patients will follow the usual care procedures and after each procedure they answer questionnaires related to pain and stress levels (VAS), Anxiety and depression levels (HADS), health-related quality of life (HRQoL), mental wellbeing (SWEMWBS), self-efficacy (GSE) and Patient Activation status (PAM-13).
33292528|NCT05117489|Experimental|Cohort 9 - 30 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 30 mg once daily, for 12 weeks.
33292529|NCT05117489|Experimental|Cohort 10 - 200 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 200 mg once weekly, for 12 weeks.
32939195|NCT03372434|Active Comparator|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
33292530|NCT00146770|Active Comparator|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
33292531|NCT00146770|Active Comparator|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
33292532|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
33292533|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
33292534|NCT03967678|Placebo Comparator|Beef from standard supply|
33292535|NCT03967678|Experimental|n-3 enriched beef from dietary supplement finished cattle|
33292536|NCT03967678|Active Comparator|n-3 enriched beef from grass finished cattle|
33292537|NCT04815239|Active Comparator|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) for at-risk offspring includes 8 sessions over 6 months delivered via secure telemedicine platform. The basis of the intervention is the treatment manual iteratively developed and tested in close consultation with content experts during our open pilot study and R34.The intervention focuses on education about BP risk, stabilizing sleep and daily routines and interpersonal relationships.
33318374|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
33292538|NCT04815239|Active Comparator|Healthy Lifestyle Intervention (HL)|HL is based on the treatment manual developed in a prior trial for adults and adolescents with BP. HL includes psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health. In HL, patients are taught to develop and maintain an individualized lifestyle plan and provided support and encouragement for making progress toward their goals. HL clinicians will deliver 8 sessions over 6 months via secure telehealth platform.
33292539|NCT03966040|Experimental|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
33292540|NCT03966040|Experimental|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
33292541|NCT03966040|Experimental|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
33292542|NCT03966040|Experimental|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
33292543|NCT03999125|Active Comparator|Group 1|Aflibercept intravitreal injection for CSME
33292544|NCT03999125|Other|Group 2|Ranibizumab Intravitreal Injection for CSME
33292545|NCT03999125|Experimental|Group 3|Dexamethasone Implant for CSME
32900614|NCT05365230|Active Comparator|On-demand personalized follow-up care|On-demand personalized follow-up care (on-demand access to a Wellness Beyond Cancer Program (WBCP) nurse and an annual follow-up by telephone with WBCP nurse following the patient's annual mammogram). Both groups of participants will have yearly mammograms (current standard of care) organized by their healthcare provider.
33085932|NCT04530097|No Intervention|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
33292546|NCT05085119|Experimental|FiO2 stepwise modifications|Intubation ICU patients will be challenged with stepwise modifications of FiO2. The following steps will be done: 30, 40, 60, 80, 100, 80, 60, 40 and 30%.
33292547|NCT00168064|Active Comparator|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
33292548|NCT00168064|Active Comparator|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
33085933|NCT02218021|Experimental|Samidorphan Dose 1|
33292549|NCT04901507|Experimental|The Voutia System|The Voutia System oral irrigation device
33292551|NCT00166114|Active Comparator|Escitalopram|
33292552|NCT00166114|Active Comparator|Desipramine|
33292553|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
33292554|NCT03686969|Placebo Comparator|Placebo|Placebo
33292555|NCT04883411|Experimental|Treatment|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System.
33292556|NCT05036135|Experimental|Phase 2b low dose AV-101|
33292557|NCT05036135|Experimental|Phase 2b medium dose AV-101|
33292558|NCT05036135|Experimental|Phase 2b high dose AV-101|
33292559|NCT05036135|Placebo Comparator|Phase 2b Placebo|
33292560|NCT05036135|Experimental|Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)|
33292561|NCT05036135|Placebo Comparator|Phase 3 Placebo|
33292562|NCT05035901|Experimental|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
33292563|NCT00145600|Experimental|Unfavorable Risk, Group 2|Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
33292564|NCT00145600|Experimental|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
33292565|NCT00145600|Experimental|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
33292566|NCT00145600|Experimental|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
33292567|NCT05032781|Experimental|Intra-arterial neuroprotective substances|"Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in Study Description."
33292568|NCT05019521|Experimental|Danicopan: 100 mg|Participants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
33292569|NCT05019521|Experimental|Danicopan: 200 mg|Participants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
33292570|NCT05019521|Experimental|Danicopan: 400 mg|Participants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
33292571|NCT05019521|Placebo Comparator|Placebo|Participants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.
33292572|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
33318375|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
33318376|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
33318377|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
32900615|NCT05365230|Active Comparator|Guideline-based follow-up care|Guideline-based follow-up care (i.e. current standard of care). Both groups will have yearly mammograms (current standard of care) organized by their healthcare provider.
33292573|NCT04003415|Experimental|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
33292574|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
33292575|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
33292576|NCT04729751|Experimental|Maralixibat|Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.
33292577|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
33292578|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
33292579|NCT00129376|Experimental|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
33292580|NCT05359289|Experimental|Forest therapy training|Participants will expect to have an improvement of cognitive functions via a serial nature-based therapy/intervention.
33292581|NCT05359289|Active Comparator|Senior fitness training|Participants will expect to have an improvement of cognitive functions through a structural senior fitness program.
33292582|NCT05359289|Placebo Comparator|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
33292583|NCT04878107|Experimental|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
33292584|NCT04878107|Active Comparator|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
33292585|NCT03998969|Experimental|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
33292586|NCT03998969|Active Comparator|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
33292587|NCT04861415|Active Comparator|Conventional Fractionated Radiation|"Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes"
33292588|NCT04861415|Experimental|Stereotactic Body Radiotherapy|"Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes"
33292589|NCT01564043|Experimental|website and pedometer|
33292590|NCT04708847|Experimental|Pre-immobilization active drug group|Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.
33292591|NCT04708847|Experimental|Post-immobilization active drug group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.
33292592|NCT04708847|Placebo Comparator|Placebo group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.
33085934|NCT02218021|Experimental|Samidorphan Dose 2|
33292593|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
33085935|NCT02218021|Experimental|Samidorphan Dose 3|
33292594|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
33292595|NCT01564745|Other|Cough Determinants|
33292596|NCT04706663||Cohort 1|Subjects with histologically confirmed prostate cancer and genomic testing results
33292597|NCT04706663||Cohort 2|Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results
33292598|NCT04658381|Experimental|Genetic analysis|
33292599|NCT01564901||Cohort|
33292600|NCT04760405|Experimental|Tai Chi Easy Intervention|Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
33292601|NCT00129220|Experimental|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
33292602|NCT00129220|Active Comparator|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
33292603|NCT00129220|Placebo Comparator|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
33292604|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
33292605|NCT04638413|Experimental|Walking regimen (W)|
33085936|NCT02218021|Placebo Comparator|Placebo|
33085937|NCT02218021|Active Comparator|Oxycodone Dose 1|
33085938|NCT02218021|Active Comparator|Oxycodone Dose 2|
33292606|NCT04638413|Experimental|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
33292607|NCT01326286||Open Radical Prostatectomy|262
32785932|NCT05184725|Experimental|SaMD CARINAE|Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.
32785933|NCT05238623||Control cohort|lung-healthy volunteers get a EIT measurement
33292608|NCT01326286||Robotic Radical Prostatectomy|1303
33292609|NCT01326286||Intensity-Modulated Radiotherapy|638
32785934|NCT05238623||Case cohort|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement
32785935|NCT05237687|Active Comparator|Intervention|Patients randomized to the intervention will initially take 0.5 mg sirolimus. The dose will be adjusted weekly to obtain a sirolimus levels of 5-7 ng/ml whole blood in the first months. After the first month, the patient will have monthly blood work and will be followed in clinic every 3 months. Functional assessment and aging biomarkers will be obtained at baseline and 1 year follow up. Completion of the 1-year treatment period will be followed by a follow-up visit 4 weeks later.
32785936|NCT05237687|No Intervention|Control|Interventions: standard of care Patients are not going to receive any additional intervention.
33292610|NCT01326286||Interstitial Brachytherapy|171
33292611|NCT01326286||combined EBRT and Brachytherapy|143
32785937|NCT05184413|Experimental|Multimodal treatment|Therapeutic Exercise plus Pain Neuroscience Education
32785938|NCT05184413|Active Comparator|Unimodal treatment|Therapeutic Exercise
32785939|NCT05183789||Cases|Malnourished children with acute diarrhea
32785940|NCT05183789||Control|Non-malnourished children with acute diarrhea
32785941|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
33292612|NCT01326286||Active Surveillance|448
32785943|NCT05237453|Experimental|MR-guided adaptive radiotherapy|Patients receive Photon radiotheray as an MR-guided adaptive radiotherapy
32785944|NCT05182229|Active Comparator|Clinic-Based Lymphedema Therapy|
32785945|NCT05182229|Active Comparator|Home-Based (a hybrid model) Lymphedema Therapy|
33085939|NCT04719234|Other|lung ultrasound|lung ultrasonography protocol will be applied.
33085940|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
33085941|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
33085942|NCT04529746|Experimental|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
33085943|NCT04529746|No Intervention|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
32785946|NCT02329327|Experimental|Andexanet|Participants received andexanet as an intravenous bolus administered over ~15 to 30 minutes, followed immediately by a continuous infusion administered over ~120 minutes.
32785947|NCT05235269|Other|Single arm|I-124 AT-01
32785948|NCT05182151||Patient|istradefylline 40mg daily over 12 week period
32900616|NCT05364684|Other|Open-label Treatment|Open-label study of oral LUM-201 (ibutamoren mesylate) 25mg daily in otherwise healthy adults with BMI ≥25 kg/m2 and histologic or radiologic diagnosis of NAFLD.
33085944|NCT04529668|Experimental|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
33292613|NCT01326286||Various other treatments|300
33292614|NCT03686813|Placebo Comparator|Placebo|Each participant will be studied with active drug and placebo.
33292615|NCT03686813|Active Comparator|Sildenafil|Sildenafil 50 mg orally one hour (once) before immersed exercise
33292616|NCT04003259|Experimental|Overweight and obese subjects|1-year lifestyle programme
33292617|NCT04754945|Experimental|Treatment (isatuximab, chemotherapy)|"All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)~Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity."
33292618|NCT00128830|Experimental|Etravirine + 2 antiretrovirals|
33292619|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
33292620|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
33292621|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
33318378|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
32785949|NCT05181917|Experimental|Intervention|Patients assigned to the intervention group will receive the STUDIA application on their mobile device, which has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
32785950|NCT05181917|Active Comparator|Control|The patients assigned to the control group will also receive the STUDIA application on their mobile devices. The insulin dose calculation process is the same as that described for the intervention group. However, the simulation results will be kept hidden from the patient.
32785951|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
32785952|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
32785953|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
32785954|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
32785955|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
32785956|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
32785957|NCT05181605|No Intervention|No Intervention: No intervention - standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated per standard of care on site (surgical resection and adjuvant therapy)
32785958|NCT05181605|Experimental|Experimental: Neoadyuvant therapy plus standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated with neoadjuvant therapy before surgical resection and adjuvant therapy
32785959|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
32785960|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
32785961|NCT05180669|Experimental|OARSCM|OARSCM (n = 51) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
33318379|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
32785962|NCT05180669|Sham Comparator|TAU with MyMAT|TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
32785963|NCT04883281|Active Comparator|Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy|If a patient loses a significant amount of weight on treatment, or the tumor contour changes substantially, repeat CT simulation and re-planning is allowed in the CM arm. However, the gross tumor volume may not be reduced due to tumor shrinkage. The original extent of disease must be included in the replanned GTV.
32785964|NCT04883281|Experimental|Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy|Patients in the ML/DART Arm will have their radiation plan adapted with every fraction. The adaptation process will be performed automatically on the Varian Ethos adaptive therapy software under the supervision of the treating physician.
32785965|NCT05142293||Sites selected for the same-day organisation|Patients will be admitted to the hospital and leave it on the same-day of the procedure.
32785966|NCT05142293||Sites with standard overnight hospitalization|Standard organisation with a minimum of one night's stay
32785967|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
32785968|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
32785969|NCT05141903||Arm 1|Antibiotic conditioning
32785970|NCT05141903||Arm 2|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
32785971|NCT05141903||Arm 3|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
32785972|NCT05141903||Arm 4|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
32785973|NCT05141903||Arm 5|Antibiotic conditioning and probiotic treatment.
32785974|NCT05140499|Active Comparator|Single Shot Perineural Popliteal Nerve Block|Single shot perineural popliteal nerve block injection of 10cc 13.3% liposomal bupivacaine combined with 15cc 0.50% bupivacaine hydrochloride within one hour prior to surgery
33292622|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
33292623|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
33292624|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
33292625|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
33292626|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
33292627|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
33292628|NCT00128206|Active Comparator|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
33292629|NCT00128206|Active Comparator|A|rifampin (600 mg orally) given daily for 4 months
33292630|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
33292631|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
33292632|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
33292633|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
33292634|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
33292635|NCT03968146|Active Comparator|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
33292636|NCT03968146|Other|Group C|Control group will receive only intravenous fentanyl.
33292637|NCT03966118|Experimental|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
33292638|NCT03968224|Experimental|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
33292639|NCT03968224|Active Comparator|Metformin|Metformin 1,700 mg/day
33292640|NCT03823378|Experimental|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
33292641|NCT03823378|Experimental|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
33292642|NCT03823378|Experimental|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
33292643|NCT03823378|Experimental|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
33292644|NCT03823378|Experimental|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
33292645|NCT03823378|Experimental|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
33292646|NCT00142792|Active Comparator|A. Cyclic stim|"Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Uses NMES device with EMG-triggered and Cyclic capabilities"
33292647|NCT00142792|Active Comparator|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.~Uses NMES device with EMG-triggered and Cyclic capabilities"
33292648|NCT00142792|Active Comparator|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.~Uses NMES device with EMG-triggered and Cyclic capabilities"
33292649|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
32939196|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
32939197|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
33292650|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
33292651|NCT00141778|Placebo Comparator|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
33292652|NCT00141778|Experimental|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
33292653|NCT00141778|Experimental|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
33292654|NCT03967132|Active Comparator|Control Infant Formula|Milk-based infant formula
33292655|NCT03967132|Experimental|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
33292656|NCT03967132|Other|Reference Group|Human-milk fed
32939198|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
32939199|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
32939200|NCT03380624|Experimental|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.~."
33292657|NCT00127660|Experimental|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
33292658|NCT00127660|Experimental|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
33292659|NCT00127660|Experimental|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
32939201|NCT03380624|Experimental|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
32939202|NCT03380780|Experimental|Emicizumab|
32939203|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
32939204|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
32939205|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
32939206|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
32939207|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
32939208|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
32939209|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
32939210|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
32939211|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
32939212|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
32939213|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
33292660|NCT00127660|No Intervention|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
33292661|NCT01077934||Injured Extremity without compartment syndrome|
33292662|NCT01077934||Injured extremity with compartment syndrome|
33292663|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
33292664|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
33292665|NCT01326520|Experimental|Phospholipid enriched dairy product|
33292666|NCT01326520|Placebo Comparator|dairy product|
33292667|NCT03965884|Experimental|lumbal stabilization exercise group|
33292668|NCT03965884|Experimental|connective tissue massage group|
33292669|NCT03965884|No Intervention|control group|
33292670|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
33292671|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
33292672|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
33292673|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
32939214|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
33292674|NCT00115336|Active Comparator|1-Intravenous ketorolac and oral placebo|Intravenous ketorolac and oral placebo
33292675|NCT00115336|Active Comparator|2-Intravenous placebo and oral ibuprofen|Intravenous placebo and oral ibuprofen
33292676|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
33292677|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
32939215|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
32939216|NCT02177136|Experimental|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
32939217|NCT02177136|Experimental|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
32939218|NCT03393494|Experimental|Perrigo active|Test product
32939219|NCT03393494|Active Comparator|Reference active|RLD product
32939220|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
33085945|NCT04529668|Active Comparator|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
33292678|NCT00205803|Experimental|13vPnC|
33292679|NCT00205803|Active Comparator|7vPnC|
33292680|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
33292681|NCT03974373|Experimental|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
33292682|NCT00127192|Placebo Comparator|1|Placebo QD 12-week
33292683|NCT00127192|Experimental|2|25 mg QD 12-week
33292684|NCT00127192|Experimental|3|50 mg QD 12-week
33292685|NCT00127192|Experimental|4|100 mg QD 12-week
33292686|NCT00127192|Experimental|5|200 mg QD 12-week
33292687|NCT00205179|Experimental|Novasoy treated|100mg/day soy isoflavones
33292688|NCT00205179|Placebo Comparator|Placebo|100mg/day matching placebo
33292689|NCT03973125|Experimental|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
33292690|NCT00127036|Experimental|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
33292691|NCT00127036|Experimental|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
33292692|NCT00259857|Experimental|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
33292693|NCT00259857|Placebo Comparator|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
33292694|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
33292695|NCT01071681||Group 1|
33292696|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
33292697|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
33292698|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
33292699|NCT00203307|Other|Olanzapine then Placebo|Olazepam
33292700|NCT00203307|Other|Placebo then olanzapine|
33292701|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
33292702|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
33292703|NCT00126568|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33292704|NCT00114634|Experimental|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
32785975|NCT05140499|Active Comparator|Continuous perineural popliteal nerve block catheter|Placement of continuous perineural popliteal nerve block catheter with injection of 30cc 0.5% bupivacaine within one hour prior to surgery, followed by continuous infusion of 10cc 0.3% ropivacaine (current standard practice) for at least 72 hours following surgery. Saphenous single shot 20cc 0.2
32785976|NCT05233631||T-EUS Patients|Any patient who has undergone clinically indicated and/or standard of care T-EUS procedures from October 2014 - June 2022.
32785977|NCT05231915|Other|HOXB13 c.853delT mutation|Mutation is detected using Next Generation Sequencing (NGS) technique
32785978|NCT04229381|Experimental|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
32785979|NCT05178485|Experimental|The experimental group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL injectate (either the bupivacaine/triamcinolone mixture) and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
32785980|NCT05178485|Placebo Comparator|The control group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL saline and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
32785981|NCT05230433|Experimental|High-fat Metabolic Challenge|Participants will consume a high-fat agent one time, at the second study visit.
32785982|NCT05229185|Experimental|DeXtreme (Error-enhacement)|Training (error-enhancement): 5 consecutive days, 1 hour per day
32785983|NCT05175365|Experimental|Dance|Patients allocated to this group will attend dance classes for patients with Parkinson's disease given once a week over a 4-month period for a total of 16 dance sessions.
32785984|NCT05175365|No Intervention|Control|The control group will receive its rehabilitation care.
32785985|NCT04228289|Experimental|Oxytocin|40 IU intranasal oxytocin
32785986|NCT04228289|Placebo Comparator|Placebo|intranasal saline spray
32785987|NCT05228951|Experimental|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
32785988|NCT05227937||Single Dose Amikacin|Patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
33085946|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.~Positive patients' samples will be collected at baseline."
33085947|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
32785989|NCT05174039|Experimental|Oral miglustat|The proposed dosing regimen is daily oral miglustat (MTD, up to 200 mg TID)
32785990|NCT04422119|Experimental|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
32785991|NCT04422119|Active Comparator|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
32785992|NCT05138705|Experimental|Outcome|Quadrivalent influenza vaccine Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
33085948|NCT02218099|Experimental|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
33085949|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
33085950|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
33085951|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
33085952|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
33085953|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
33085954|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
32785993|NCT05138549|Placebo Comparator|Control: Placebo Group|Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
32785994|NCT05138549|Active Comparator|Experimental: Astaxanthin Supplementation Group|Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.
32785995|NCT02300233|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
32785996|NCT02300233|Experimental|Volanesorsen 300 mg weekly|Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
32785997|NCT02300233|Experimental|Volanesorsen 300 mg biweekly, post Week 13|Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.
32785998|NCT04241549|Experimental|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
33085955|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
33085956|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
33085957|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
33085958|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
33085959|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
32785999|NCT04241549|Experimental|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
32786000|NCT05137379||Elher-Danlos syndrome patients treated with orthopedic surgery|
32786001|NCT05171855|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
32786002|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
32786003|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
32786004|NCT05171153||IBD group|Subjects over 21 years old, with inflammatory bowel disease (both ulcerative colitis and Crohn's disease), diagnosed by clinical, biochemical, endoscopic and anatomo-pathological criteria.
33085960|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
33085961|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
33085962|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
33292705|NCT00114634|Placebo Comparator|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
32786005|NCT05171153||Control group|Subjects over 21 years old, without IBD or known metabolic bone disease, recruited voluntarily in the Endocrinology and Nutrition, Digestive System and Rheumatology departments of the Ruber Juan Bravo Hospital, during routine health control visits
32786006|NCT05170841|Active Comparator|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase film coated tablets (administered as one tablet)
32786007|NCT05170841|Active Comparator|Tramadol Hydrochloride 100 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase (administered as 2 capsules of Tramadol 50 mg)
32786008|NCT05170841|Placebo Comparator|Placebo and Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo film-coated tablets matching Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg MULTIPLE DOSE PHASE: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg film coated tablets (administered as one tablet)"
32786009|NCT05170841|Placebo Comparator|Placebo and Tramadol Hydrochloride 100 mg|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo capsules matching active comparator (administered as 2 capsules of Tramadol 50 mg) MULTIPLE DOSE PHASE: Tramadol Hydrochloride 100 mg (administered as 2 capsules of Tramadol 50 mg)"
32786010|NCT05169671|Experimental|ATH-1020|ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).
32786011|NCT05169671|Placebo Comparator|Placebo|Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.
32786012|NCT05107817|Experimental|Aquatic Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task in water.
32786013|NCT05107817|Active Comparator|Land Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task on dry land.
32786014|NCT05107583|Experimental|Low-Carbohydrate Pre-Exercise Meal|Participants will consume a low-carbohydrate (<10% carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
32786015|NCT05107583|Experimental|High-Carbohydrate Pre-Exercise Meal|Participants will consume a high-carbohydrate (~2.2 g/kg carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
32786016|NCT05107583|Experimental|Fasted Exercise|Participants will skip lunch, and continue fasting since breakfast (08:00) before commencing exercise at 16:00. Therefore, exercise will commence after an 8 hour period of fasting.
32786017|NCT05106491|Other|venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
32786018|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32786019|NCT05135273|Experimental|1a (Pilot Group)|(n=5) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
32786020|NCT05135273|Experimental|1b (Pilot Group)|(n=5) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
32786021|NCT05135273|Experimental|1c (Pilot Group)|(n=5) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
32786022|NCT05135273|Active Comparator|1d (Pilot Group)|(n=4) to receive rabies vaccine (standard dose) on D1, D29, D57
32786023|NCT05135273|Experimental|2a (Main Group)|(n=15) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
32786024|NCT05135273|Experimental|2b (Main Group)|(n=15) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
32786025|NCT05135273|Experimental|2c (Main Group)|(n=15) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
33085963|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
33085964|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
33085965|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
33085966|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
33085967|NCT02218567|Other|Patients|
33085968|NCT02218567|Other|Caregivers|
33292706|NCT00202839|Experimental|24-Week Treatment|Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
33292707|NCT00202839|Active Comparator|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
33292708|NCT00201201|Experimental|Education|PEP-NG targeted and tailored education intervention
32786026|NCT05135273|Active Comparator|2d (Main Group)|(n=16) to receive rabies vaccine (standard dose) on D1, D29, D57
32786027|NCT05133713||Catheter directed thrombectomy|
32786028|NCT05133713||Systemic anticoagulation|
32786029|NCT05129423|Experimental|Part 1: MTPS9579A Dose A|In Part 1, participants will receive MTPS9579A dose A every 4 weeks from randomization to Week 12.
32786030|NCT05129423|Placebo Comparator|Part 1: Placebo|In Part 1, participants will receive placebo matched with MTPS9579A, every 4 weeks from randomization through Week 12.
32786031|NCT05129423|Experimental|Part 2: MTPS9579A Dose A|In Part 2, participants will receive MTPS9579A dose A, every 4 weeks from randomization to Week 12.
33292709|NCT00201201|Other|Control|Control, intervention is care as usual.
33085969|NCT02218645|Experimental|WE 941 OD|
33085970|NCT02218645|Active Comparator|Brotizolam|
33085971|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
32786032|NCT05129423|Experimental|Part 2: MTPS9579A Dose B|In Part 2, participants will receive MTPS9579A dose B, every 4 weeks from randomization to Week 12.
32786033|NCT05129423|Experimental|Part 2: MTPS9579A Dose C|In Part 2, participants will receive MTPS9579A dose C, every 4 weeks from randomization to Week 12.
33085972|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
33292710|NCT00126490|Experimental|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
33292711|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
33292712|NCT00200967|Experimental|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
32786034|NCT05129423|Experimental|Part 2: MTPS9579A Dose D|In Part 2, participants will receive MTPS9579A dose D, every 4 weeks from randomization to Week 12.
32786035|NCT05129423|Placebo Comparator|Part 2: Placebo Dose A|In Part 2, participants will receive placebo matched with MTPS9579A dose A and B, every 4 weeks from randomization through Week 12.
32786036|NCT05129423|Placebo Comparator|Part 2: Placebo Dose B|In Part 2, participants will receive placebo matched with MTPS9579A dose C and D, every 4 weeks from randomization through Week 12.
32786037|NCT05129345||Aim 1|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit including being consented electronically and complete a demographic survey, a photography training visit and an interview visit.
32786038|NCT05129345||Aim 2|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit and be electronically consented to study and complete an electronic survey.
32786039|NCT05129345||Aim 3|Group composed of 10 willing participants recruited from the participating clinics and community based organizations and may include, HIV providers, nurses, pharmacists, people living with HIV who have cardiometabolic disorders, and representatives of the community advisory boards, and any other key stakeholders. There will be 3 one hour meetings over 3 months.
32786040|NCT05129189|Experimental|ASC22 group|ASC22 1mg/kg hypodermic injection Q4W+Chidamide 10mg PO BIW
33292713|NCT00200967|Experimental|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
33292714|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
33292715|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
33292716|NCT02533518|Experimental|patients with lung cancer|
33292717|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
33292718|NCT01052142|Experimental|Lipovaxin-MM|
33292719|NCT03991572|Active Comparator|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
33292720|NCT03991572|Sham Comparator|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
33318380|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
33292721|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
33292722|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
33292723|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
33292724|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
33292725|NCT01054794|Active Comparator|Stimulation ON|
32939221|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
33292726|NCT01054794|Sham Comparator|Stimulation OFF|
33292727|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
33292728|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
32939222|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
32939223|NCT03591068|Experimental|OPN-375 186 mcg BID|
32939224|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
33292729|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
32939225|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
33292730|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
32939226|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
32939227|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
32939228|NCT00376922|No Intervention|usual care|
32939229|NCT00376922|Experimental|Music therapy|
32939230|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
32939231|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
32939232|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
33292731|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
33292732|NCT00140140|Experimental|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
33292733|NCT00140140|Experimental|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
32939233|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
33085973|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
33292734|NCT00140140|Experimental|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m^2 ABI-007, followed by an infusion of 20 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
33292735|NCT03966976|Experimental|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
33292736|NCT03966976|Active Comparator|Conventional Arm|Conventional follow-up
33085974|NCT02218684|Placebo Comparator|Placebo|
32786041|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
33085975|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
33085976|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
33085977|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
33085978|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.~If there were any clinical adverse events the drug could be reduced to twice a week."
33085979|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
33085980|NCT02278900|No Intervention|Control group|No intervention.
33085981|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
33085982|NCT01642030|Other|Methadone Maintenance|
33085983|NCT01642030|Other|Buprenorphine Maintenance|
33292737|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
33292738|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
33292739|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
33292740|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
33292741|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
33292742|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
33292743|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
33292744|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
33292745|NCT03986892||COmPLETE-Health|No intervention
33292746|NCT03986892||COmPLETE-Heart|No intervention
33292747|NCT01052298|Experimental|Arm 1|
33292748|NCT01052298|Experimental|Arm 2|
33292749|NCT01052298|Experimental|Arm 3|
33085984|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
33292750|NCT01052298|Placebo Comparator|Arm 4|
33085985|NCT00263796|Experimental|Pitocin|
33085986|NCT00263796|Placebo Comparator|Placebo|
33085987|NCT01642108|Other|Sitagliptin|
33085988|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
33085989|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
33292751|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
33292752|NCT03986658|Experimental|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
33292753|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
32786042|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
32786043|NCT04421651|Experimental|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
32786044|NCT04421651|No Intervention|Control group|Participants in the control group continued treatment as usual in the health services.
32786045|NCT05102747|Experimental|Hypofractionated SRT (stereotactic radiotherapy)|
32786046|NCT05102747|Active Comparator|Historical single-dose SRS (stereotactic radiosurgery)|
32786047|NCT05224037|Experimental|Study group|This is a single-arm study. All the participants will undergo examinations with 2 devices
32786048|NCT05223959|Experimental|CaPE Intervention|CaPE is a manualized intervention consisting of 12 one-to-one psychoeducation sessions, one session per week. Each session will last for 60 minutes. All sessions will be delivered by a trained therapist who will receive two months training from senior therapists before starting intervention.
32786049|NCT05223959|No Intervention|Treatment as Usual|Treatment as usual (TAU) will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
32786050|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
32786051|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
32786052|NCT05221307|Experimental|1/Children with cerebral palsy|Modified Pilates Exercises (MPEs) will be applied 3 days a week, 45 minutes a day for 8 weeks.
32786053|NCT05221307|Active Comparator|2/children with cerebral palsy|Traditional Neurodevelopmental Therapy (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks.
32786054|NCT05102201|Experimental|Paro intervention group|Participants in the Paro intervention group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks.
32786055|NCT05102201|No Intervention|control group|The control group will receive care as usual activities, such as painting, drawing, and craft, which are provided by each facility.
32786056|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
32786057|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
32786058|NCT05101421|Experimental|Treatment arm|To receive rice ceramide supplementation for 3 months
32786059|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
32786060|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
33085990|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
33085991|NCT01642303|No Intervention|control|listen to the student book listening file
33085992|NCT01642381|Active Comparator|Psychotherapy|
33085993|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
33085994|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
33085995|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
33085996|NCT01642420||Healthy control persons|Age matched healthy persons
33085997|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
33085998|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
33085999|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
33086000|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
33086001|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
32786061|NCT05128877|No Intervention|Control group|No intervention was made in the control group.
32786062|NCT05128877|Experimental|intervention group|Progressive relaxation techniques were applied to the intervention group.
32786063|NCT04881799|Placebo Comparator|Placebo-Controlled Period|Participants in this phase of the study will be randomized 1:1 to receive either phentermine/topiramate or placebo.
33086002|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
33086003|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
33086004|NCT01642654|Active Comparator|Control|
33086005|NCT01642654|Experimental|Treatment|
33086006|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
33292754|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
32939234|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
33292755|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
32939235|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
33086007|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
33292756|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
33086008|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
33292757|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
33292758|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
33292759|NCT00114244|Experimental|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
33292760|NCT00114244|Experimental|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
33292761|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
33292762|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
33292763|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
33292764|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
33086009|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
33292765|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
33292766|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
33292767|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
33292768|NCT02533128|Placebo Comparator|Liberal blood pressure management|
33292769|NCT02533128|Active Comparator|Tight blood pressure management|
33292770|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
33292771|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
33292772|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
33292773|NCT01054950|Placebo Comparator|Control|Single phone call
33292774|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
33292775|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
33292776|NCT01056666|Experimental|Conveen optima urisheaths|
33292777|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
33292778|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
33292779|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
33292780|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
33292781|NCT00138424|Experimental|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
33292782|NCT00138424|Placebo Comparator|Placebo|16 subjects to receive placebo.
33292783|NCT00368966|Experimental|1|
33292784|NCT00368966|Active Comparator|2|
33292785|NCT00114166|Active Comparator|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
33292786|NCT00114166|Active Comparator|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
33292787|NCT00125242|Experimental|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
33292788|NCT00125242|No Intervention|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
33318381|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
33318382|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
33318383|NCT05622734|Experimental|VOCALE LBD+|
32786064|NCT04881799|Experimental|Open Label Extension|Participants in this phase of the study will receive open label phentermine/topiramate.
32786065|NCT04226729||Healthy group|
32786066|NCT04226729||Mild visual impairment group|
32786067|NCT04226729||Moderate and severe visual impairment group|
32786068|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
32786069|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
33318384|NCT01203410||Cohort 1|Term infants >2500g birthweight.
32786071|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
32786072|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
32786073|NCT05220605|Experimental|Bromac (100ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (100micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
32786074|NCT05220605|Experimental|Bromac (150ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (150micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
32786075|NCT05220605|Experimental|Bromac (200ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (200 micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
32786076|NCT05098457|Experimental|GP0112|Single injection and optional touch up injection with GP0112
32786077|NCT05098457|Active Comparator|Restylane Lyft Lidocaine|Single injection and optional touch up injection with Restylane Lyft Lidocaine
32786078|NCT05220371|Experimental|Collagen|15g of collagen peptides ingested daily
32786079|NCT05220371|Placebo Comparator|Placebo|15g of Placebo ingested daily
32786080|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
33086010|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
33086011|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
33086012|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
32786081|NCT05098379|Experimental|Tele-Rehabilitation Home Exercise Program|Subjects will participate in an 8-week customized home exercise program with weekly virtual exercise coaching sessions.
32786082|NCT05220293|Experimental|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
32786083|NCT05220137|Active Comparator|1|Core Session 1, Core Session 2, Module Choice, Final Session
33086013|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
33086014|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
33318385|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
33318386|NCT03823820||Cesarean section|Women attending for elective CS.
32786084|NCT05220137|Active Comparator|2|Core Session 1, Core Session 2, Modified A-B-C, Final Session
33318387|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
33318388|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:~Pre-eclampsia requiring hospital admission.~Hyperemesis gravidarum.~Major postpartum haemorrhage."
33318389|NCT03823820||control|Gestational age matched controls.
32939236|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
33292789|NCT03992534|Experimental|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
33292790|NCT00337428|Experimental|Group 1|Concomitant/CMF
33292791|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
33292792|NCT00337428|Experimental|Group 3|Concomitant/FMF
33292793|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
33292794|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
33292795|NCT01044524|Experimental|1|SLV 334
33292796|NCT00235989|Active Comparator|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
33292797|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
33292798|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
32939237|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
33292799|NCT00235989|Experimental|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
33292800|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
32939238|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
32939239|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
33292801|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
32939240|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
33292802|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
32939241|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
32939242|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
33292803|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
33292804|NCT00353262|Experimental|1|
33292805|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.~The investigators will proceed with whole exome sequencing"
33292806|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.~No further studies will be performed as part of the main study."
33292807|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
33292808|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
33292809|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
33292810|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
33292811|NCT00125164|No Intervention|Untreated|Observational Group
33292812|NCT00125164|Experimental|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
33292813|NCT00125164|Experimental|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
33292814|NCT00125164|Experimental|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
33292815|NCT03985410|Experimental|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
33292816|NCT03985410|Experimental|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
33292817|NCT03985410|Experimental|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
33292818|NCT03985410|Experimental|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
33292819|NCT03985410|Experimental|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
33292820|NCT03985410|Experimental|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
33292821|NCT03988530|Active Comparator|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
33292822|NCT03988530|Placebo Comparator|Placebo Nasal Gel|placebo nasal gel (0.12 g)
33292823|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
32939243|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
32939244|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
32939245|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
32939246|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
32939247|NCT04750512|Experimental|real ESP, placebo TAP|US-guided ESP block + sham US-guided TAP block
32939248|NCT04750512|Active Comparator|real TAP, placebo ESP|sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair
32939249|NCT01599234|Experimental|Sativex|Active treatment
32939250|NCT01599234|Placebo Comparator|Placebo|Control
32939251|NCT04750278|Experimental|FP-025 100 mg|Low dose for patient treatment.
32939252|NCT04750278|Experimental|FP-025 300 mg|High dose for patient treatment.
32939253|NCT04750278|Placebo Comparator|Placebo|Dose without any study drug, to make it a controlled study.
32939254|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
32939255|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
32939256|NCT05138406|Experimental|Graded Motor Imagery|Individuals will receive standard rehabilitation and graded motor imagery treatment.
32939257|NCT05138406|Active Comparator|Standard Rehabilitation Group|Standard rehabilitation will be applied.
32939258|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
32939259|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
32939260|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
32939261|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
32939262|NCT03600194|Active Comparator|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
32939263|NCT03600194|Placebo Comparator|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
32939264|NCT03600194|Active Comparator|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
32939265|NCT03600194|Placebo Comparator|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
32939266|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
32939267|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
33292824|NCT03988686|Experimental|Intervention Group|Radical prostatectomy plus standard care
32939268|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
33292825|NCT03988686|Active Comparator|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
33292826|NCT00136318|Active Comparator|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
33292827|NCT00136318|Placebo Comparator|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
33292828|NCT03988218|Experimental|Anorexia|Subjects with anorexia nervosa
33292829|NCT03988218|Active Comparator|Control|Subjects without eating disorders
33292830|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
33292831|NCT00136084|Experimental|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
33292832|NCT00136084|Experimental|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
32939269|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
32939270|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
32939271|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
32939272|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
32939273|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
32939274|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
32939275|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
32939276|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
32939277|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
32939278|NCT04734704|Experimental|vitiligo patients|Adult patients diagnosed with Vitiligo according to usual criteria
32939279|NCT04734704|Experimental|metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs|metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).
32939280|NCT04734704|Experimental|Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions|patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions
32939281|NCT04734704|Experimental|metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued|Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment
32939282|NCT03513848|Experimental|Bright Light|
32939283|NCT03513848|Placebo Comparator|Dim Light|
32939284|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
32939285|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
32939286|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
32939287|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
32939288|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
32939289|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
32939290|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
32939291|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
32939292|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
32939293|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
32939294|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
33292833|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292834|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33318390|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
33292835|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292836|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292837|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292838|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
32786085|NCT05220137|Active Comparator|3|Core Session 1, Core Session 2, Challenging Questions, Final Session
32786086|NCT05220137|Active Comparator|4|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Module Choice, Final Session
32786087|NCT05220137|Active Comparator|5|Core Session 1, Core Session 2, Problematic Patterns, Final Session
32786088|NCT05220137|Active Comparator|6|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Module Choice, Final Session
32786089|NCT05220137|Active Comparator|7|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Module Choice, Final Session
32786090|NCT05220137|Active Comparator|8|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Final Session
32786091|NCT05220137|Active Comparator|9|Core Session 1, Core Session 2, Challenging Beliefs, Final Session
32786092|NCT05220137|Active Comparator|10|Core Session 1, Core Session 2, Modified A-B-C , Challenging Beliefs, Module Choice, Final Session
32786093|NCT05220137|Active Comparator|11|Core Session 1, Core Session 2, Challenging Questions, Challenging Beliefs, Module Choice, Final Session
32786094|NCT05220137|Active Comparator|12|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Challenging Beliefs, Final Session
32786095|NCT05220137|Active Comparator|13|Core Session 1, Core Session 2, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
32786096|NCT05220137|Active Comparator|14|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Challenging Beliefs, Final Session
32786097|NCT05220137|Active Comparator|15|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Challenging Beliefs, Final Session
32786098|NCT05220137|Active Comparator|16|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
32786099|NCT04752189|Active Comparator|Standard MMH Curriculum Implementation|Teachers will receive the MMH curriculum manual, standard training and as-needed technical assistance, provided to them by the health coordinators
32786100|NCT04752189|Experimental|Michigan Model for Health: Learning to Enhance and Adapt for Prevention (MI-LEAP)|We will deploy Enhanced REP to include additional tailoring of the MMH curriculum to include trauma-informed approaches, tailored trauma-focused curriculum training, and implementation facilitation, ongoing specialized implementation support.
32939295|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
32939296|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
32939297|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
32939298|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
32939299|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
32939300|NCT04735484||Case|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
32939301|NCT04735484||Control|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
32939302|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
32939303|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
32939304|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
32786101|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
33292839|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292840|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292841|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
33292842|NCT01326598||T2DM patients with A1C<7.0%|
33292843|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
32786102|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
32786103|NCT04740879|Experimental|Intervention|"The Intervention condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful immediately after randomization to group."
32939305|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
32939306|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
33292844|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
33292845|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
33292846|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
32939307|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
32939308|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
32939309|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
33292847|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
33292848|NCT00235755|Placebo Comparator|Placebo|
33292849|NCT00235755|Experimental|Retigabine 600 mg|
33292850|NCT00235755|Experimental|Retigabine 900 mg|
33292851|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
33292852|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
33292853|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
33292854|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
33292855|NCT03973749|Experimental|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
33292856|NCT03973749|Experimental|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
33292857|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
33292858|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
33292859|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
33292860|NCT01056978||patients|Patients admitted in a palliative care unit
32786104|NCT04740879|Other|Waitlist Control|"The Waitlist Control condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful approximately 4 months after randomization to group."
32939310|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
32939311|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
32939312|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
32939313|NCT04735250||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
32939314|NCT04735250||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
33292861|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
33292862|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
32786105|NCT05053997|Experimental|NAVIGATE intervention arm|Nurse navigation
33292863|NCT03985254|Active Comparator|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
33292864|NCT03985254|Experimental|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
33292865|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
33292866|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
33292867|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
32786106|NCT05053997|No Intervention|Navigate control arm|Standard treatment and care
32786107|NCT04421885|Experimental|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
33292868|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
33292869|NCT01057056|No Intervention|control group|control group - receiving standard treatment
32786108|NCT04421885|Experimental|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
33292870|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
32786109|NCT04421885|Experimental|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
32786110|NCT04881643|Experimental|Blended treatment for PTSD|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
32786111|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
33292871|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
32786112|NCT05096663|Active Comparator|Arm A (standard of care)|Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32786113|NCT05096663|Experimental|Arm B (pembrolizumab, nogapendekin alfa)|Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa SC on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32786114|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
32786115|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
32786116|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
32786117|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
33292872|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
33292873|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
33292874|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
33292875|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
33292876|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
33292877|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
33292878|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
33292879|NCT00385736|Experimental|Adalimumab 80/40|
33292880|NCT00385736|Experimental|Adalimumab 160/80/40|
33292881|NCT00385736|Placebo Comparator|Placebo|
33292882|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
33292883|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
33318391|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
33318392|NCT04385758|Experimental|Diabetes-REM Program|
32786118|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
33086015|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
33292884|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
32786119|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
32786120|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
32786121|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
33292885|NCT03988452|Active Comparator|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
33292886|NCT03988452|Experimental|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
33292887|NCT03988452|Experimental|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
33292888|NCT03988452|Experimental|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
32786122|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
32786123|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
32786124|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
32786125|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
33292889|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
33292890|NCT03988140|Experimental|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
33292891|NCT03988140|Other|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
33292892|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
33292893|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
33292894|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
33292895|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
33292896|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
33292897|NCT00195819|Experimental|Adalimumab|
33292898|NCT00195819|Placebo Comparator|Placebo|
33292899|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
33292900|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
33292901|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
33292902|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
33292903|NCT03969147|Active Comparator|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
33292904|NCT03969147|Experimental|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
33292905|NCT03969147|Active Comparator|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
33292906|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
33292907|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
33292908|NCT00194025|Experimental|valproate|All participants received open-label, add-on valproate.
33292909|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
33292910|NCT01057368|Active Comparator|Health Enhancement Program|
33292911|NCT01057368|No Intervention|Wait List Controls|
33292912|NCT01057368|Active Comparator|Long Term Meditators|
33292913|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
33292914|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
33292915|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
32786126|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
32786127|NCT05096507||Study group|People age 65 years and older undergoing primary hip fracture surgery
32786128|NCT05096351||Patients with venous allograft|
32786129|NCT05095961|Experimental|Pre-operative oral steroids|Patients will be given a course of oral prednisone (30mg daily) for 5 days.
33292916|NCT02531685|Experimental|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
33292917|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
33292918|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
33292919|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
33292920|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI < 12 months following obstetric injury.
33292921|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI >12 months following obstetric injury.
33292922|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
32786130|NCT05095961|No Intervention|Control|No pre-operative medication will be prescribed
32786131|NCT05125367||multivessel coronary artery disease|From BEST trial study population_NCT00997828
32786132|NCT05124899|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32786133|NCT05124899|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
33086016|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
33086017|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
32786134|NCT05124899|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32786135|NCT05124899|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
32786136|NCT05124665|Experimental|Social Support|"CHWs will offer HIV testing to the individual nominated by the index patient as most likely to test. If this person is not present, CHWs will decide which contact should be offered testing first. CHWs will use a prosocial script for HIV testing: Knowing your status sets a good example for your household. CHWs will follow an opt-out strategy: This test kit is approved by the Ministry of Health and used in KCCA health facilities. I am going to offer you a free HIV test now, is that okay?. If the initial household contact who is offered HIV testing agrees to test, the CHW will ask if he/she is willing to share his/her decision to test with other members of the household: Would you like to share your decision to test with the others? Sharing is completely optional. However, learning that someone else in their household decided to test sometimes gives people the strength to test themselves. Sharing your decision might help another person find the strength to test."
32786137|NCT05124665|No Intervention|Standard of Care|As a control for the socio-behavioral intervention, the control arm will lack the socio-behavioral intervention components. The order of testing invitation will be decided by the CHW; and CHWs will be trained at baseline to provide standard, opt-in framing of test offers, without any mention of asking contacts to share their testing decision with other household contacts. Oral HIV kits will also be used in control households.
32786138|NCT05052905|Experimental|Study|Exercises
32786139|NCT05123807|Other|Cytoreductive surgery|
33086018|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
33086019|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
33086020|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
33086021|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
33292923|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
33292924|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
33292925|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
33292926|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
33292927|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
33292928|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
33292929|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
33292930|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
32939315|NCT04735250||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
32939316|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
33086022|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
33086023|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
33086024|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
33292931|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
33292932|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
33292933|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
33292934|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
33292935|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
33292936|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
33292937|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
33292938|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC))|"Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
33292939|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
32939317|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
32939318|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
33318393|NCT05623514|Experimental|Candidates for vaginal natural orifice trans-luminal surgery approach|Candidates for benign gynecological surgery in the vaginal natural orifice trans-luminal surgery approach
32939319|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
32939320|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
32939321|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
32939322|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
32939323|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
32939324|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
33086025|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
33086026|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
33086027|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
33086028|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
33086029|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
32786140|NCT05122013|Other|intervention group|The comprehensive 3-month remote intervention program by the multidisciplinary study team includes 6-weeks of online meetings with the study registered dietitian, sleep and physical activity consultants, followed by another 6-weeks of online meetings with the study's registered dietitian, overall 12 weeks containing a total of 12 remote consultations (6 dietitian, 3 physical activity consultant, 3 sleep consultant). In addition, the intervention group will receive weekly text messages to their mobile phone, meant to enhance happiness and subjective wellbeing.
32786141|NCT05122013|Other|control group|The control group will receive standard nutrition care: A one-time meeting with the study's registered dietitian at the clinic, focusing on nutrition and behavioral recommendations, followed by the standard recommendation to continue follow up, engage in physical activity and general lifestyle recommendations.
32786142|NCT05093855|Experimental|Treatment group|
32786143|NCT05093621|Active Comparator|Furosemide|"Furosemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
32786144|NCT05093621|Active Comparator|Torsemide|"Torsemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
32786145|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
32786146|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
32786147|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
32786148|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
32786149|NCT05136339|Experimental|Immediate Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions immediately after enrollment.
32786150|NCT05136339|Experimental|Delayed Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions approximately 12 months after enrollment.
32786151|NCT04186221|Experimental|Treatment arm|
32786152|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
32786153|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
32786154|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
32786155|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
32786156|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20 mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
32786157|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
32786158|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
32786159|NCT05051657|Experimental|PKU express pus|PKU express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.
32786160|NCT05090657|Other|Open label presurgical nasal decolonization|All patients presenting for surgery will be offered nasal decolonization with the combination product. After informed consent a nasal culture will be obtained followed by a 4-minute nasal decolonization treatment and a post-treatment culture. The intervention consists of swabbing the nose with a methylene blue/chlorhexidine gluconate solution followed by non-thermal nasal illumination with red light. There will only be a single treatment.
32786161|NCT05120843|Other|Intervention Arm|This intervention will combine care coordination and motivational interviewing strategies.
32786162|NCT05120765|Experimental|Intervention|"Intervention to be administered is The CONNECT Program. This is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT)."
32786163|NCT05120765|No Intervention|Waitlist|Waitlist intervention requires participants to wait 6 weeks. This waitlist group will receive the intervention after this 6 week waiting period, due to the exploratory nature of this Pilot Randomized Controlled Trial (RCT).
32786164|NCT05120375|Experimental|A/ Accelerated titration|1mg of BAT6021
32786165|NCT05120375|Experimental|B/ Accelerated titration|3mg of BAT6021
32786166|NCT05120375|Experimental|C/ Accelerated titration|10mg of BAT6021
32786167|NCT05120375|Experimental|"D/standard 3 + 3"|30mg of BAT6021
32786168|NCT05120375|Experimental|"E/standard 3 + 3"|100mg of BAT6021
32786169|NCT05120375|Experimental|"F/standard 3 + 3"|300mg of BAT6021
32786170|NCT05120375|Experimental|"G/standard 3 + 3"|600mg of BAT6021
32786171|NCT05120375|Experimental|"H/standard 3 + 3"|900mg of BAT6021
32786172|NCT05089409|Experimental|A (ATB1651, 2 mg/mL)|"The planned ATB1651 dose level of 2 mg/mL.~Six participants are expected to be enrolled in each arm."
32786173|NCT05089409|Experimental|B (ATB1651, 5 mg/mL)|"The planned ATB1651 dose level of 5 mg/mL.~Six participants are expected to be enrolled in each arm."
32786174|NCT05089409|Experimental|C (ATB1651, 10 mg/mL)|"The planned ATB1651 dose level of 10 mg/mL.~Six participants are expected to be enrolled in each arm."
32786175|NCT05089409|Experimental|D (ATB1651, 20 mg/mL)|"The planned ATB1651 dose level of 20 mg/mL.~Six participants are expected to be enrolled in each arm."
32786176|NCT05089409|Placebo Comparator|E (ATB1651, 30 mg/mL)|"The planned ATB1651 dose level of 30 mg/mL.~Six participants are expected to be enrolled in each arm."
32786177|NCT05089409|Placebo Comparator|F (placebo)|"The participants will apply placebo for 28 days.~Six participants are expected to be enrolled in each arm."
32786178|NCT05089019|Experimental|Selpercatinib (Test)|Selpercatinib given orally on days 1 and 15.
32786179|NCT05089019|Active Comparator|Selpercatinib (Reference)|Selpercatinib given orally on days 1 and 15.
33292940|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
33292941|NCT04090697|Experimental|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
32786180|NCT04226339|Experimental|total knee arthroplasty with a kinetic alignment|
33292942|NCT04090697|No Intervention|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
33292943|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
33292944|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
33292945|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
33292946|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
33292947|NCT01325220|Active Comparator|STX209 5 mg BID|
33292948|NCT01325220|Active Comparator|STX209 10 mg BID|
33292949|NCT01325220|Active Comparator|STX209 10 mg TID|
33292950|NCT01325220|Placebo Comparator|Placebo|
33292951|NCT01055418|Placebo Comparator|placebo|
33292952|NCT01055418|Experimental|Vitamin C|
33292953|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
33292954|NCT01324778|Experimental|A|
33292955|NCT01324778|Active Comparator|B|
32786181|NCT04226339|Active Comparator|total knee arthroplasty with a mechanical alignment|
33292956|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
33292957|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
33292958|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
33292959|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
33292960|NCT03992144|Experimental|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
33292961|NCT03992144|Experimental|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
33292962|NCT03992144|Active Comparator|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
32786182|NCT05050955||LungCare Surveillance (1000 Cases)|
33292963|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
33292964|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
32786183|NCT05050955||Control Group (500 Controls)|
33292965|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
33292966|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
33292967|NCT03992066|Experimental|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
33292968|NCT03992066|Experimental|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
33292969|NCT03992066|Experimental|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
33292970|NCT03992066|Other|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
33292971|NCT04812743|Experimental|Colorectal Health Research Champion trainees|Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
33292972|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
32786184|NCT05050643|Active Comparator|CACP-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
32786185|NCT05050643|Active Comparator|CACP-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
33292973|NCT03992222|Experimental|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
33292974|NCT03992222|No Intervention|control|
33292975|NCT03986268|Active Comparator|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
32786186|NCT05050643|Active Comparator|HCMA-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
32786187|NCT05050643|Active Comparator|HCMA-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
33086030|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
33292976|NCT03986268|Other|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
33292977|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
33292978|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
33292979|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
33292980|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
33292981|NCT01048892|Experimental|Treatment (NTX-010)|
33292982|NCT01259648|Experimental|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
33292983|NCT01259648|Experimental|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
33292984|NCT01259648|Placebo Comparator|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
33292985|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
32786188|NCT05088395|Other|"Cohort 1: SENOLOC"|"Detecting residual disease after surgery is absolutely crucial in oncology, as this detection could allow the personalisation of post-operative treatments based on the presence of residual disease.~The laboratory wishes to develop a new technique for the detection of circulating tumour DNA, based on the recognition of translocation fragments in circulating DNA by shallow whole genome sequencing. This is an original approach, which to our knowledge has not been tested so far with the envisaged bioinformatics approach and could potentially be more sensitive than the techniques currently used to detect residual disease after surgical removal of localised (non-metastatic) breast cancer.~The analysis will therefore focus on the search for tumour chromosomal translocations, which will need to be differentiated from possible germline chromosomal translocations. The collection of constitutional DNA is therefore planned in this cohort."
33292986|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
33292987|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
33292988|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
33292989|NCT01049126||Late stage endometrial cancer|
33292990|NCT01044836|Experimental|Etanercept|
33292991|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
33292992|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
33292993|NCT01045070||coronary heart disease|
33292994|NCT00520403|Experimental|1|
33292995|NCT04810403|Experimental|SOMEBODY Eating Disorder Prevention Program|All participants will be recruited to participate in the SOcial MEdia (SOME) adaptation of activities from the BODY Project (SOMEBODY).
33292996|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
33292997|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
33292998|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
33292999|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
33293000|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
33293001|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
33293002|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
33293003|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
33293004|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
32786189|NCT05088395|Other|"Cohort 2: Immuno-TNBC "|"The aim for this cohort is to study the role that variations in circulating tumour DNA might have as a marker associated with response during chemoimmunotherapy.~A fresh biopsy (subsequently stored frozen) is required for mutational profiling analysis (which will be used to track circulating tumour DNA in the blood). In addition, it will be used to analyse currently recognised biological tissue factors of response to chemoimmunotherapy (PD-L1 labelling, mutational load, ...) and to identify possible associations with circulating tumour DNA variations.~Constitutional DNA analysis is necessary for the determination of point mutations present in the tumour (to be differentiated from polymorphisms present at the constitutional level), as the determination of these mutations is essential to monitor circulating tumour DNA and will therefore be collected."
32939325|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
33293005|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m^2/d Monday through Friday) & weekly oxaliplatin 45 mg/m^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
33293006|NCT04746287|Experimental|Part A|Single dose administration
33293007|NCT04746287|Experimental|Part B|Multiple dose administration (food Effect)
33293008|NCT04746287|Experimental|Part C|Multiple dose administration
33293009|NCT04746287|Placebo Comparator|Placebo|Matching placebo
33293010|NCT04741919|Active Comparator|Superior LPI placement|Each participant will be randomized to receive an LPI placement superiorly in one eye.
33293011|NCT04741919|Active Comparator|Temporal LPI placement|Each participant will be randomized to receive an LPI placement temporally in one eye.
33293012|NCT04487561|Other|aspirative drainage|Drainage is the usual treatment after axillary lymphadenectoma for breast cancer
33293013|NCT04487561|Active Comparator|Hemopatch|The hemopatch group will be the group without drainage and with a product patch
33293014|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
33293015|NCT00524771||1|Users of NuvaRing
33293016|NCT00524771||2|Users of combined oral contraceptives
33293017|NCT00135694|Experimental|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
33293018|NCT00135694|Active Comparator|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
33293019|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
33293020|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
33293021|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
33293022|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
33293023|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
33293024|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
33293025|NCT03966508|Experimental|hyperalgesia measurement|
33293026|NCT00124618|Experimental|cetuximab/Radiation|Cetuximab (C225) and Radiation
33293027|NCT00124462|Other|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
33293028|NCT00124462|Other|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
33293029|NCT00124072|Active Comparator|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
33293030|NCT00124072|Active Comparator|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
33293031|NCT00124072|Active Comparator|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
33293032|NCT00124072|Active Comparator|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
33293033|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
33293034|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
33293035|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
33293036|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
33293037|NCT00362648|Experimental|1|RotaTeq™
33293038|NCT00362648|Placebo Comparator|2|Placebo
33086031|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
33086032|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
33086033|NCT04529317|No Intervention|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
33086034|NCT04529317|Experimental|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
33293039|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
33086035|NCT01643083|Active Comparator|Rifaximin|
33293040|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
33086036|NCT01643083|Placebo Comparator|Placebo|
33086037|NCT01643122||Group 1|
33086038|NCT01643122||Group 2|
33086039|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
33086040|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
33086041|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
33086042|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
33086043|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
33086044|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
33086045|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
33086046|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
33086047|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
33086048|NCT01643395|Experimental|vertebroplasty|
33086049|NCT01643395|Other|conservative therapy (brace)|
33086050|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
33086051|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
33086052|NCT01643590|Placebo Comparator|Placebo|
33086053|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
33086054|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
33086055|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
33086056|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
33086057|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
33086058|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
33086059|NCT04529200|Experimental|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
33086060|NCT04529200|Active Comparator|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
33086061|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
33086062|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
33086063|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
33086064|NCT04529161|Experimental|Group A|Diet followed by routine eating
33086065|NCT04529161|Experimental|Group B|Routine eating followed by diet
33086066|NCT04528966|Experimental|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
33086067|NCT04528966|Active Comparator|Control group|Group that have received conventional physiotherapy only
33086068|NCT01643863||Cohort|
33293041|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
33293042|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
33293043|NCT04461041|Active Comparator|Empagliflozin|Single 10 mg tablet, administered orally once daily for 6 months
32939326|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
32939327|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
32939328|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
32939329|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
33086069|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
33086070|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
33086071|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
33086072|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
33086073|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
33086074|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
33086075|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
33086076|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
33086077|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
33086078|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
33086079|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
33086080|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
33086081|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
33086082|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
33086083|NCT01644370|No Intervention|control|HIV negative children (n=10)
33086084|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
33086085|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
33086086|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
33086087|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
33086088|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
33086089|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
33086090|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
33086091|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
33086092|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
33086093|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
33086094|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
33086095|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
33293044|NCT04461041|Placebo Comparator|Placebo|Single 10 mg tablet, administered orally once daily for 6 months
33293045|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
33086096|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
33086097|NCT01644838|Experimental|Promethazine|25 mg of promethazine
32786190|NCT05088395|Other|"Cohort 3: Trans-TNBC"|"The objective of this cohort is the development of new plasma tests, for example based on the detection of chromosomal translocations of circulating tumor DNA.~The hypothesis is that these tests would allow the detection of relapse, the prediction of treatment efficacy and the monitoring of treatment efficacy at different stages of cancer in patients with triple-negative breast cancer, either in the non-metastatic phase with planned neo-adjuvant treatment, or in the metastatic phase. The number of inclusions between these 2 populations (neo-adjuvant and metastatic) will be monitored at the operational level to avoid an excessive imbalance towards one group."
32900617|NCT05328648|Experimental|Community Score Card|In the Community Score Card approach, community members come together to document challenges they encounter when seeking services and develop a corresponding set of indicators that can be used to produce a validated facility score. The score is shared with the community and a collaborative process between key community members and facility staff takes place to develop feasible solutions and a strategic action plan.
32900618|NCT05328648|Experimental|Citizen Report Card|In the Citizen Report Card approach, individual-level feedback is collected from actual clients of target facilities, via a structured questionnaire, to assess facility performance and generate a public record of service quality. In addition to sharing the final report card with communities, engaged policymakers are invited to use the citizen feedback to improve service delivery.
32900619|NCT05328648|No Intervention|Control|Communities in the control arm will not receive an intervention.
32900620|NCT05385432|Experimental|rabbit antithymocyte globulin (rATG)|The infusion of rATG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. The recommended initial tacrolimus dose is Prograf® 0.1mg/kg/day twice day.
33086098|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
33086099|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
33086100|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
33086101|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
33086102|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
33086103|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
33086104|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
33086105|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
33086106|NCT01645150|No Intervention|Control group|No intervention
33086107|NCT01645189|Experimental|Test drug|Idursulfase-beta
33086108|NCT04528888|Active Comparator|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
33318394|NCT04375462|Experimental|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
33318395|NCT04375462|Active Comparator|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
33318396|NCT03723590|Experimental|Esterified hyaluronic acid matrix|
33318397|NCT04343872|Active Comparator|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
33318398|NCT04343872|Experimental|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
33318399|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
33318400|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
33318401|NCT01299818||spinal surgery|patients who undergo spinal surgery
32900621|NCT05385432|Active Comparator|Basiliximab|The infusion of Basiliximab (Simulect® (20mg)) starts before the surgery on peripheral vein for 15 minutes and the second infusion at day 4.
33293046|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
33293047|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
33293048|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
32900622|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33293049|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
33293050|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
33293051|NCT00518687|Experimental|V710 60 µg|
33293052|NCT00518687|Placebo Comparator|Placebo|
33293053|NCT00134056|Active Comparator|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
32900623|NCT05384808|Experimental|No dog present|Conventional psychotherapy with no dog being present.
32900624|NCT05384808|Experimental|Dog present and active part of therapeutic narrative.|The dog is actively integrated into the therapeutic narrative.
33293054|NCT00134056|Experimental|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
33293055|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
33293056|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
32900625|NCT05384808|Experimental|Dog present but not active part of therapeutic narrative.|The dog is present but not actively integrated into the therapeutic narrative.
32900626|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
32900627|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
33293057|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
33293058|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
32900628|NCT00392678|Placebo Comparator|Placebo|Placebo, appearance matched to active drug
32900629|NCT00392678|Active Comparator|3 gram|Salsalate 3.0 grams daily, divided
33293059|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
33293060|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
33293061|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
33293062|NCT00350844|Experimental|Hydroxyurea|
33293063|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
33293064|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
33293065|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
33293066|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
33293067|NCT03986346|Experimental|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
33293068|NCT03986346|Active Comparator|Control group|Participants in this group receive standardized care.
33293069|NCT01059396|Experimental|Propranolol|
33293070|NCT01059396|Experimental|carvedilol|
33293071|NCT01059396|Placebo Comparator|Placebo|
33293072|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
32786191|NCT05088395|Other|"Cohort 4: Treg"|"The purpose of this cohort, based on the previous results, is to:~quantify the expression level of target genes on tumor Regulatory T (Tregs) at the protein level,~perform multiparametric FACS analysis on blood and tumor samples from patients treated at the Institut Curie, with breast or ovary cancer and to understand the potential of these targets as biomarkers of disease.~In the context of this ALCINA-4 cohort n°4, for breast and ovary patients, 40 ml of blood will be collected and tumor fragments obtained from surgery (50 breast patients) or therapeutically required biopsy (30 ovary patients). No additional biopsy than the ones belonging to the therapeutic process will be performed in this protocol. Biopsies performed as part of standard of care will be used if sufficient material is available."
32786192|NCT05048849|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
32786193|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
32786194|NCT05085275|Experimental|Ferric citrate|Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
33293073|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
32786195|NCT05085275|Placebo Comparator|Placebo|Tablets, matching in color and size to ferric citrate.
32786196|NCT05117333|Active Comparator|Basic letter|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed.
32786197|NCT05117333|Active Comparator|Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland.
32786198|NCT05117333|Active Comparator|GP-Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland, AND informs recipients that the new law did not abolish co-payments related to general practitioner visits.
32786199|NCT05117333|No Intervention|Control treatment|There is no intervention in the control treatment. The entire population aged 55 and above in the treatment regions will serve as a control group.
32786200|NCT05117177|Experimental|Part 1a|Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors.
32786201|NCT05117177|Experimental|Part 1b|The effect of food on the exposure to inupadenant will be investigated.
33293074|NCT00523367|No Intervention|esomeprazole|
32786202|NCT05116865|Experimental|Single Ascending Dose Cohort A1|Subjects will receive a single dose of either dose level 1 of HH-120 or placebo
32786203|NCT05116865|Experimental|Single Ascending Dose Cohort A2|Subjects will receive a single dose of either dose level 2 of HH-120 or placebo
32786204|NCT05116865|Experimental|Single Ascending Dose Cohort A3|Subjects will receive a single dose of either dose level 3 of HH-120 or placebo
32786205|NCT05116865|Experimental|Multiple Ascending Doses Cohort B1|Subjects will receive multiple doses of either Dose level 1of HH-120 or placebo
32786206|NCT05116865|Experimental|Multiple Ascending Doses Cohort B2|Subjects will receive multiple doses of either Dose level 2 of HH-120 or placebo
32786207|NCT05116865|Experimental|Multiple Ascending Doses Cohort B3|Subjects will receive multiple doses of either Dose level 3 of HH-120 or placebo
32786208|NCT05048537|Other|18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.|
32786209|NCT05116085|Experimental|Tislelizumab|Tislelizumab administered intravenously before surgery during the neo-adjuvant phase
32900630|NCT00392678|Active Comparator|3.5 gram|Salsalate 3.5 g daily, divided
33293075|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
33293076|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
33293077|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
33293078|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
33293079|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
33293080|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
33293081|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
32786210|NCT05115695|Active Comparator|PNF/Interventional|Upper extremity and scapular patern of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
32786211|NCT05115695|Experimental|NDT/Experimental|Upper extremity strengthening exercises consisting of Neurodevelopmental Therapy (NGT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
32786212|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
32786213|NCT05082077||LIVERguard patient|Patients whose donor liver was transported with the LiverGuard device.
32786214|NCT05082077||Standard Transport Patients|Patients whose donor liver was transported with a method other than the LiverGuard
33293082|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
33293083|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
33293084|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
33293085|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
33293086|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
32786215|NCT05081141||SOT Donors|Solid organ transplantation donors
32786216|NCT05081141||LuTx candidates and recipients|Lung transplant candidates and recipients
32786217|NCT05081141||LTx candidates and recipients|Liver transplant candidates and recipients
32786218|NCT05081141||KTx candidates and recipients|Kidney transplant candidates and recipients
32786219|NCT05081063|Experimental|Low Titer O+ Whole Blood|Low Titer O+ Whole blood provided to Level A trauma patients
32786220|NCT05081063|Active Comparator|Component Therapy|Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas
32786221|NCT05114993|Experimental|Effects of donning a disposable surgical mask|"Participants will be observed and monitored without wearing a mask for a 5-minute control period. Measurements will include End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute without a mask x 5 minutes.~After 5 minutes, all study subjects will don the same model of disposable surgical mask. The same measurements will be taken, including End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute with a mask x 15 minutes."
32786222|NCT05047913|Experimental|18F-FTX|The radioactive tracer (FAZA)
32939330|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
32786223|NCT05047679|Experimental|Perioperative Pain Neuroscience Education|Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
32939331|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
32939332|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
32939333|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
32939334|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
32939335|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
32939336|NCT02133924|Experimental|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 2 or 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
32939337|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
32939338|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
32939339|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
32939340|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
32939341|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
32939342|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
32939343|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
32939344|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
33293087|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
33293088|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
33293089|NCT04780841|Experimental|RDX013 Cohort 1|RDX013 low dose oral dosage, twice daily
33293090|NCT04780841|Experimental|RDX013 Cohort 2|RDX013 low, mid dose oral dosage, twice daily
33293091|NCT04780841|Experimental|RDX013 Cohort 3|RDX013 high, mid dose oral dosage, twice daily
33293092|NCT04780841|Experimental|RDX013 Cohort 4|RDX013 high dose oral dosage, twice daily
33293093|NCT04780841|Experimental|RDX013 Part B|RDX013 dose from Part A oral dosage, twice daily
33293094|NCT04780841|Placebo Comparator|Placebo Part B|oral dosage, twice daily
33293095|NCT01061190|Active Comparator|Propranolol|
33293096|NCT01061190|Placebo Comparator|Placebo|
33293097|NCT04441619|Active Comparator|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
33293098|NCT04441619|Active Comparator|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
33293099|NCT04441619|No Intervention|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
33293100|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
33293101|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
33293102|NCT00324168|Active Comparator|1|
33293103|NCT00324168|Placebo Comparator|2|
33293104|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
33293105|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
33293106|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
33293107|NCT00343512|Experimental|Therapeutic Intervention|
33293108|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
33293109|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
33293110|NCT00112294|Active Comparator|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
33293111|NCT00112294|Active Comparator|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
33293112|NCT00235443|Experimental|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
33293113|NCT03973437|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
33293114|NCT03973437|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
33293115|NCT00234039|Experimental|Intravesical Gemcitabine|
33293116|NCT03973359|No Intervention|Epidemiology|HCMV-seropositive pregnant women receiving standard care
33293117|NCT03973359|Experimental|Prevention|HCMV-seropositive pregnant women receiving hygienic information
33293118|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
33293119|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
33293120|NCT03973203|Experimental|Niacin in controls|The arm includes healthy controls supplemented with niacin.
33293121|NCT03973203|Experimental|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
33293122|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
32900631|NCT00392678|Active Comparator|4 gram|Salsalate 4.0 g daily, divided
33293123|NCT01073007|Placebo Comparator|Placebo|
33293124|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
33293125|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
33293126|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
33293127|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
33293128|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
33293129|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
33293130|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
32939345|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
32939346|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
32939347|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
32939348|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
32939349|NCT04332380|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
33293131|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
33293132|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
33293133|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
33293134|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
33293135|NCT00189423|Experimental|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
33293136|NCT00189423|Active Comparator|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
33293137|NCT00323310|Experimental|Gadobenate Dimeglumine|
33293138|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
33293139|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
32939350|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
32939351|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
32939352|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
32939353|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
33293140|NCT01071759||pregnancy|
33293141|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
33293142|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
33293143|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
33293144|NCT00186537|Active Comparator|fenofibrate|160 mg daily for 12 weeks
33293145|NCT00186537|Active Comparator|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
33293146|NCT00186537|Active Comparator|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
32786224|NCT05047679|Active Comparator|Perioperative Biomedical Education|Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
32786225|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus On (SCAN)|
32786226|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus Off (SCAN)|
32786227|NCT05080283|Active Comparator|Nucleus 7 Sound Processor (model: CP1000) system|
33293147|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
32786228|NCT05046431|Active Comparator|EU Simponi|
32786229|NCT05046431|Experimental|BAT2506|
32786230|NCT05078957||Frail PLWH|
32786231|NCT05078957||Pre frail PLWH|
32786232|NCT05078957||No frail PLWH|
32786233|NCT05078879|Experimental|Treatment Arm|Patients with GCPC3 will receive daily Empagliflozin for 12 months.
32786234|NCT05078723|Experimental|CYP2C19*2 and CYP2C19*3 Variants|The group of participants has been genotyped to have the CYP2C19*2 and/or CYP2C19*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.
33293148|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
33293149|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
33293150|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
33293151|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
33293152|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
32786235|NCT05078723|Experimental|Wildtype CYP2C19|The group of participants has been genotyped to have wild-type CYP2C19. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the CYP2C19*2 and/or CYP2C19*3 study subjects.
32786236|NCT05077787|Experimental|Experimental Group|Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.
32786237|NCT05077787|No Intervention|Control Group|Neonates recruited in control group will receive phototherapy alone along with regular care
32786238|NCT05046275||MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
32786239|NCT05046275||Non MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
32786240|NCT04422041|Active Comparator|Early discharge|Discharge between 24 and 48 hours
32786241|NCT04422041|Experimental|Very early discharge|Discharge in less than 24 hours
33293153|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
33293154|NCT04726085|Active Comparator|Ibuprofen|Ibuprofen 600 mg q6 hours for 24 hours- total dose of 2400mg- after emergent cerclage placement
33293155|NCT04726085|Active Comparator|Indomethacin|Indomethacin 50 mg q8 hours for 24 hours- total dose of 150mg- after emergent cerclage placement
33293156|NCT00255723|Experimental|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
33293157|NCT00255723|Experimental|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
32786242|NCT05045027|Experimental|Basic science (MRI, metabolic imaging, tissue collection)|"AIM 1: Previous scan data from healthy subjects is collected and analyzed.~AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."
32786243|NCT05043857|Experimental|Adjuvant Stereotactic Pancreatic Radiotherapy|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after pancreatic tumor resection.~Stereotactic Body Radiotherapy (SBRT) is a novel radiotherapy technique consisting of highly focused irradiation with a steep dose gradient, thus allowing the delivery of ablative radiation doses and significant sparing of proximity critical structures. Higher doses per fraction allows for more intensive treatments and shorter duration of the radiation course."
33403772|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
33293158|NCT01060176|Experimental|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
33293159|NCT01060176|Experimental|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
33293160|NCT01060176|Experimental|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
32786246|NCT05075993|Experimental|Regimen A: LVGN3616 + LVGN6051 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
32786247|NCT05075993|Experimental|Regimen B: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
32786248|NCT05075993|Experimental|Regimen C: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
32786249|NCT05075993|Experimental|Regimen D: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
33293161|NCT01060176|Placebo Comparator|Control|Saline solution
33293162|NCT04719845|Experimental|Endoscopic laser resection|Using CO2, diode or similar wavelenght laser the stenotic tracheal segment will be vaporized allowing a less than 20% residual stenosis. Dilatation will not be performed after laser resection for residual stenosis.
33293163|NCT04719845|Experimental|Dilatation|Using a ballon or rigid bronchoscope the stenotic tracheal segment will be dilated with or without previous radial incision with electrocautery or laser.
33293164|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
33293165|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
33293166|NCT01057836|Experimental|Neck strength training|
33293167|NCT01057836|Experimental|Neck endurance training|
33293168|NCT01057836|Active Comparator|Stretching|
33293169|NCT04305977|Other|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
33293170|NCT00132808|Experimental|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
33293171|NCT00132808|Experimental|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
33293172|NCT00132808|Placebo Comparator|Placebo|Placebo given at randomization and Month 12
33293173|NCT03983148|Experimental|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
33293174|NCT03983148|Placebo Comparator|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
33293175|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
33293176|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
33293177|NCT04714463||Immediate breast reconstruction|Women undergoing immediate breast reconstruction due to breast cancer or a high risk for breast cancer
33293178|NCT04714463||Delayed breast reconstruction|Women undergoing delayed breast reconstruction due to breast cancer or a high risk for breast cancer
33293179|NCT03982992|Experimental|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
33086109|NCT04528888|Experimental|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
33086110|NCT04528888|Experimental|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
33086111|NCT00250224|Experimental|Stent|
33086112|NCT04528615|Experimental|CCK In-Person Sessions|This group received the in-person CCK intervention.
33293180|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 cycles or until complete response in the absence of disease progression or unacceptable toxicity.
33293181|NCT01061268|Experimental|BLINK™ tears|
33293182|NCT01061268|No Intervention|No topical artificial tear|
33293183|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
33293184|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
33293185|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
33293186|NCT01057914|Experimental|Supplemention|
33293187|NCT01057914|Experimental|Dietary advice|
33293188|NCT01057914|Experimental|Combination treatment|
33293189|NCT01057914|No Intervention|Usual care|
32786250|NCT04421807|Experimental|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
32786251|NCT04421807|Active Comparator|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
33293190|NCT00517361|Experimental|Carboplatin + Avastin|
33293191|NCT03984864|Experimental|Exercise therapy Chosen|
33293192|NCT03984864|Active Comparator|Exercise therapy no Chosen|
32786252|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
32786253|NCT04421261||I-Gel|
33086113|NCT04528615|Active Comparator|CCK Printed Materials|This group received select printed CCK materials.
32786254|NCT05075603|Experimental|Single Arm|Drug: NT-I7 (efineptakin alfa)
33086114|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
33293193|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
33293194|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
33293195|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
33293196|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
33293197|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
33293198|NCT01565213|Other|CAU|Care as usual given by the GPs
33293199|NCT04279067|Experimental|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
33293200|NCT04279067|Experimental|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.~In the dose-matched control group (Group 2), it will be 2 hours/session."
33293201|NCT04270955|Active Comparator|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
33293202|NCT04270955|Experimental|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
33086115|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
33086116|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
33086117|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
33086118|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
33086119|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
33086120|NCT01645774|Experimental|10s injections duration|10s injections duration
33086121|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
33086122|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
33086123|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
33086124|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
33086125|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
33086126|NCT01645969||Cohort|
33293203|NCT04270955|Active Comparator|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
33293204|NCT04270955|Experimental|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
33293205|NCT04772027||Muscular dystrophies group|40 patients with limb girdle muscular dystrophie
33293206|NCT04772027||Comparator group|40 healthy volunteers without neuromuscular or squeletic disorder
33293207|NCT04171661|Experimental|SASS|SASS applied on chronic skin wounds as skin graft
33293208|NCT03677141|Experimental|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
33086127|NCT01646008||respiratory|
33086128|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
33293209|NCT03677141|Experimental|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
33086129|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
33086130|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
33293210|NCT03677141|Experimental|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
33293211|NCT03677141|Experimental|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
33293212|NCT03677141|Active Comparator|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
33293213|NCT03677141|Experimental|Phase II: M-CHOP 1L DLBCL|Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
33293214|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33293215|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
33293216|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
33293217|NCT04171115|Experimental|10mg of G03-52-01|8 subjects randomized to 10 mg of G03-52-01 and 2 subjects randomized to placebo
33293218|NCT04171115|Experimental|25mg of G03-52-01|8 subjects randomized to 25 mg of G03-52-01 and 2 subjects randomized to placebo
33293219|NCT04171115|Experimental|50 mg of G03-52-01|8 subjects randomized to 50 mg of G03-52-01 and 2 subjects randomized to placebo
33293220|NCT04171115|Experimental|100 mg of G03-52-01|8 subjects randomized to 100 mg of G03-52-01 and 2 subjects randomized to placebo
33293221|NCT00522431|Experimental|1|2% testosterone gel
33293222|NCT00185211|Experimental|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
33293223|NCT00185211|Experimental|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
33293224|NCT00516737|Experimental|1|Active Drug
33293225|NCT00516737|Placebo Comparator|2|Matching Pbo Comparator
33293226|NCT03540485|Experimental|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
33293227|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
33086131|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
33086132|NCT00264030|Other|1|PTCA
33086133|NCT00264030|Other|2|PTCA with angioguard
32786255|NCT02111577|Experimental|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
32786256|NCT02111577|Placebo Comparator|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
32786257|NCT05074433|Experimental|casirivimab+imdevimab Initial + Q4W|Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)
32786258|NCT05074433|Experimental|casirivimab+imdevimab Q4W|SC dose Q4W
32786259|NCT05074433|Experimental|casirivimab+imdevimab Q12W|SC dose every 12 weeks (Q12W)
32786260|NCT05074433|Placebo Comparator|Placebo|SC dose Q4W
32786261|NCT05216445|Experimental|Mindfulness Training|The participants in this group will receive the training for 8 weeks, with 60 minute online weekly sessions. The first session will be for 90 minutes.
32786262|NCT05216445|No Intervention|Wait-list Control|The wait-list control group will not receive any intervention. Once the study has been completed they will be offered the Mindfulness Training course.
33086134|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
33086135|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
33086136|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
33086137|NCT04709510|Other|AllPatients|There is only one cohort in this study. They all received the same follow up and ultrasound protocol.
33086138|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
33086139|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
33086140|NCT01646242|Experimental|Cold snare polypectomy|
32786263|NCT04751877|Experimental|Isatuximab/Lenalidomide/Dexamethasone/Bortezomib|
32786264|NCT04751877|Active Comparator|Isatuximab/Lenalidomide/Dexamethasone|
32786265|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
32786266|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
32786267|NCT04751799|No Intervention|Control Group (no VR)|Patients undergoing colposcopy and colposcopically-guided biopsy without further intervention
32786268|NCT04751799|Experimental|VR before and during colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy as well as during colposcopy.
32786269|NCT04751799|Experimental|VR before colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy but not during colposcopy.
32786270|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
32786271|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
32786272|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
32786273|NCT02146599||Pseudophakic|
32786274|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
32786275|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
32786276|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
32786277|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
32786278|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
32786279|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
33086141|NCT01646242|Experimental|Double biopsy polypectomy|
33086142|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
33086143|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
33086144|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
33086145|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
33086146|NCT01646359|Experimental|corrected flow time|
33086147|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
33086148|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
33086149|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
33293228|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
32786280|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
32786281|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
32786282|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
32786283|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
32786284|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
32786285|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
32786286|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
32786287|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
32786288|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
32786289|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
32786290|NCT05133765|Experimental|SMART B1 - Usual care insulin pump|Usual care pump therapy arm with carbohydrate consumption before exercise
32786291|NCT05133765|Experimental|SMART B2 - Advanced hybrid closed loop insulin pump with carbohydrates before exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption before exercise
32786292|NCT05133765|Experimental|SMART B3 - Advanced hybrid closed loop insulin pump with carbohydrates during exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption during exercise
32786293|NCT04740333||Group A- Normal ICU admission blood glucose level|Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
32786294|NCT04740333||Group B- High ICU admission blood glucose level|Patients with admission blood glucose level higher than 180 mg / dL.
32786295|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
32786296|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
32786297|NCT04739709|Experimental|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
32786298|NCT04739709|Placebo Comparator|Matching Vehicle Placebo|1 drop matching vehicle place twice daily for 14 days to study (operated) eye
32786299|NCT04417881||patients with acurate heart failure|
32786300|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
32786301|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
33293229|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
33293230|NCT00132730|Experimental|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
32786304|NCT05110625|Experimental|Intervention A|Participants will receive Messaging Intervention
32786305|NCT05110625|Experimental|Intervention B|Participants will receive messaging intervention plus online education to their primary healthcare workers
32786306|NCT05110625|No Intervention|Control|Participants will receive usual care only, and their healthcare workers will not receive online education
32786307|NCT04224233|Experimental|Home-based physical activity group|The experimental group will receive the iLiFE.
32786308|NCT04224233|Active Comparator|Control group|The control group will receive a leaflet with exercises and PA recommendations.
33293231|NCT00132730|Experimental|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
33293232|NCT00132730|Experimental|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
32786309|NCT04222829||Megadose Shinbaro Pharmacopuncture Group|"The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
32786310|NCT04222829||Control Group|"The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
32786311|NCT05037539|Experimental|Injectable Fentanyl in Sublingual Route|Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route
32786312|NCT05037539|Active Comparator|Oral Morphine Syrup|Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred
32786313|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
32786314|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
33293233|NCT00132730|Placebo Comparator|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
33293234|NCT00132730|Experimental|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
33293235|NCT00132730|Active Comparator|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
32786315|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
33293236|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
33293237|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment High-dose chemotherapy~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~*if not available at study site, Busulfan can be administered instead:~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
33293238|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33293239|NCT00232557|Experimental|TLC-Asthma|Telephone-based home education and asthma monitoring
33293240|NCT00232557|Active Comparator|TLC-health education|Telephone-based home education
33293241|NCT03973983|Experimental|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
33293242|NCT03973983|Experimental|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
33293243|NCT03973047|Placebo Comparator|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
33293244|NCT03973047|Active Comparator|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
33293245|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
33293246|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
33293247|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
33293248|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
33293249|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
33293250|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
33293251|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
33293252|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
33293253|NCT04603859|Experimental|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
33293254|NCT04603859|No Intervention|Expectant management|Awaiting spontaneous labor.
33293255|NCT03519971|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
33293256|NCT03519971|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
33293257|NCT00122980|Active Comparator|1|Hydroxyurea and phlebotomy
32786316|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
33293258|NCT00122980|Active Comparator|2|Transfusion and chelation
33293259|NCT04671251|Experimental|AEVI-007|
33293260|NCT01080508||10 Asa I & II patients|
33293261|NCT03868631|Active Comparator|Soy protein group|
33293262|NCT03868631|Active Comparator|Whey protein group|
33293263|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
33293264|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
33293265|NCT00340704|Experimental|1. Low dose group|
33293266|NCT00340704|Experimental|2. Medium dose group|
33293267|NCT00340704|Experimental|3. High dose group|
33293268|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
33293269|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
33293270|NCT03965416|Experimental|Doctor with white coat|Doctor during consultation is wearing a white coat
33293271|NCT03965416|Experimental|Doctor without white coat|Doctor during consultation is not wearing a white coat
33293272|NCT03984630|No Intervention|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
33293273|NCT03984630|Experimental|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
33293274|NCT00231777|Experimental|1|40 mg MK0517 IV
33293275|NCT00231777|Active Comparator|2|4 mg ondansetron IV
33293276|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
33293277|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
33293278|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
33293279|NCT01060332||diabetics|
33293280|NCT01060410||Cyclophosphamide,low dose,continuous|
33293281|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
33293282|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
33293283|NCT00231465|Experimental|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
33293284|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
33293285|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
33293286|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
33293287|NCT00254397|Experimental|gp100 + Leuprolide|Group IA: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
33293288|NCT00254397|Experimental|gp100 - No Leuprolide|Group IB: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
33293289|NCT00254397|Experimental|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
33293290|NCT00254397|Experimental|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
33293291|NCT03972735|Experimental|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
33293292|NCT03972735|Placebo Comparator|TAU|"Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder~Support in day-care hospital~No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
33293293|NCT00254163|Active Comparator|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
32786317|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
32786318|NCT04998539|Experimental|Upright wheelchair forward and occupant upright|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
32786319|NCT04998539|Experimental|Upright wheelchair backward and occupant upright|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
32786320|NCT04998539|Experimental|Wheelie wheelchair forward and occupant upright|Participant will push a wheelchair using the wheelie technique forward over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
32786321|NCT04998539|Experimental|Wheelie wheelchair backward and occupant upright|Participant will pull a wheelchair using the wheelie technique backwards over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
32786322|NCT05036603|No Intervention|1/routin medical care and neonatal intensive care unit's daily care|Group 1 (n=20) routine medical treatment for newborns on mechanical ventilator respiratory support and CPAP; Appropriate antibiotics given according to the needs of the baby, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care will be provided.
32786323|NCT05036603|Experimental|2/active chest physiotherapy in modified drainage positions|Group 2 (n=20) newborns on mechanical ventilator respiratory support and CPAP; A single session of active chest physiotherapy (CP) will be applied using modified drainage positions (avoiding the trendelenburg position, excessive position change and avoiding hand contact in babies younger than 30 weeks or who are sensitive to position change). Active CP in various modified drainage positions; It will consist of percussion and vibration methods with proprioceptive replacement stimulations. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
33293294|NCT00254163|Experimental|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
32786324|NCT05036603|Experimental|3/active chest physiotherapy in prone positions|Group 3 (n=20) newborns on mechanical ventilator respiratory support and CPAP; a single session of active chest physiotherapy treatment to be applied only in the prone position; Starting with proprioceptive stimulation, percussion and vibration methods will be applied. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
33293295|NCT03869333|Experimental|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
32786325|NCT05071235|Placebo Comparator|CG (control group) + dressing|The group will receive placebo LLLT (low-level laser therapy) application associated with Helianthus annuus oil dressing.
32786326|NCT05071235|Active Comparator|LG1 (LLLT group 1) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
32786327|NCT05071235|Active Comparator|LG2 (LLLT group 2) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
33293296|NCT03869333|Experimental|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
33293297|NCT03869333|Experimental|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
33293298|NCT03869333|Placebo Comparator|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
33293299|NCT00110890|No Intervention|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
33293300|NCT00110890|Other|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
33293301|NCT00182637|Experimental|bortezomib|
33293302|NCT01076920|Experimental|Intervention arm|
33293303|NCT00182325|Experimental|personalized web prenatal information|Personalized health information for pregnancy through personal health record
33293304|NCT00182325|Active Comparator|general web prenatal information|General pregnancy health related websites
33293305|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
33293306|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
33293307|NCT04587167|Experimental|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
33293308|NCT04587167|Experimental|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
33293309|NCT04587167|No Intervention|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
33293310|NCT00122278|Experimental|Dexamethasone|Dexamethasone 10 mg
33293311|NCT00122278|Placebo Comparator|Placebo|Placebo Dexamethasone, 10 mg
33293312|NCT00182091|Active Comparator|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
32786328|NCT05071235|Active Comparator|LG3 (LLLT group 3) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
32786329|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
32786330|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
33293313|NCT00182091|Placebo Comparator|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
33293314|NCT00182091|No Intervention|AcroGHS|
33293315|NCT00182091|No Intervention|Active Acromegaly|
33293316|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
32786331|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
32786332|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
32786333|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
32786334|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
32786335|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
32786336|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
32786337|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
32786338|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
32786339|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
32786340|NCT01364597|Experimental|Brivaracetam|
32786341|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
32786342|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
32786343|NCT04998149|No Intervention|standard care|The control group subjects will receive standard of care during labor using pillows and wedges as positional devices.
32786344|NCT04998149|Experimental|Peanut ball intervention|The experimental group will receive peanut ball as positioning device during labor
32786345|NCT04738149|Experimental|Area 1: Excimer laser, bimatoprost, and microneedling|
32786346|NCT04738149|Active Comparator|Area 2: Excimer laser|
32786347|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
32786348|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
32786349|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
33293317|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
33293318|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
33293319|NCT03398135|Experimental|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
33293320|NCT03398135|Experimental|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
33293321|NCT03398135|Experimental|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
33293322|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
33293323|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
33293324|NCT00181155|Experimental|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
32786350|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
32786351|NCT05070455|Experimental|Asceniv|Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.
33293325|NCT00181155|Placebo Comparator|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
33293326|NCT00322452|Experimental|1|gefitinib
33293327|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
33293328|NCT03968523|Active Comparator|TAP block|TAP block technique.
32786352|NCT05034575|Experimental|Novice and experienced medical personnel|Participants will be asked to complete two tasks each taking approximately 10 minutes while wearing eye-tracking technology to understand focus of gaze during laryngeal endoscopy and stroboscopy interpretation.
32786353|NCT05070143|Experimental|Brief education|"Participants will be randomly allocated to the Brief Education condition or one of the five treatment conditions (see below).~In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time."
32786354|NCT05070143|Experimental|Treatment condition|All participants will receive the Brief Education intervention described above. Then, participants will be randomly allocated to one of the following conditions for habit formation.
32786355|NCT05069987|Experimental|VR-immersion|
32786356|NCT05069987|No Intervention|Non-VR control|
32786357|NCT05034419|Experimental|Active stimulation|Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
32786358|NCT05034419|Sham Comparator|Sham stimulation|Patients undergoing cardiac surgery will be randomized to sham stimulation for 30 min. The Parasym device will be placed on the patient's tragus, but no current will be delivered.
32786359|NCT05069207||Monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
32786360|NCT05069207||Non-monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
32786361|NCT05069207||Daytime Urinary Incontinence|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
32786362|NCT05069207||Control Group Healthy Individuals|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
32786363|NCT05068817|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
32786364|NCT05068817|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
32786365|NCT05068817|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
32786366|NCT04421183||1|preeclampsia
32786367|NCT04421183||4|normal pregnancy without complication
32786368|NCT04421183||2|hellp
32786369|NCT04421183||3|eclampsia
32786370|NCT05030675|Experimental|Treatment (fostamatinib)|Patients receive fostamatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles (week 24) in the absence of disease progression or unacceptable toxicity.
32786371|NCT05066321|Experimental|Mindfulness Oriented Recovery Enhancement (MORE) Arm|During hospitalization, participants will receive brief mindfulness training individually in person and complete a series of quantitative baseline questionnaires. Participants will complete 1 MORE session weekly for 8 sessions delivered in small groups of up to 10 people. These sessions will be delivered by a social worker in-person at baseline, and via telehealth after discharge. Follow-up surveys will be conducted at 3-, 6-. 9-, and 12- weeks, and an audio-recorded qualitative exit interview (45-60 minutes) will be completed upon completion of the intervention and the 12-week follow-up survey.
32786372|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
32786373|NCT04212143||healthy control|Healthy children age 3 to 21 years
32786374|NCT04219319|Experimental|Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
32786375|NCT04996121|Experimental|XZP-5955 tablets|XZP-5955 tablets
32786376|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
32786377|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
32786378|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
32786379|NCT04995887||C-Section Delivery with EBL ≥ 1500 mL|Patients with ≥ 1500 mL estimated blood loss (EBL) at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
32786380|NCT04995887||C-Section Delivery with EBL < 1500 mL|Patients with < 1500 mL EBL at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
32786381|NCT04995887||Vaginal Delivery with EBL ≥ 1000 mL|Patients with ≥ 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
33293329|NCT03968523|Experimental|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
33293330|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
33293331|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
33293332|NCT00110812|No Intervention|No IL-2|Participants will receive no aldesleukin or HAART
33293333|NCT00110812|Experimental|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
32786382|NCT04995887||Vaginal Delivery with EBL < 1000 mL|Patients with < 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
32786383|NCT04218539|Experimental|Placebo/Placebo|Subjects will receive a dose of placebo, followed by a dose of placebo approximately 7 days later.
33293334|NCT00110812|Experimental|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
33293335|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
33293336|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
33293337|NCT04642859|Experimental|Dyslexia|Students with dyslexia before and after the intervention
33293338|NCT04639037|Active Comparator|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
33293339|NCT04639037|Experimental|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
32786384|NCT04218539|Experimental|Placebo/Psilocybin|Subjects will receive a dose of placebo, followed by a dose of psilocybin approximately 7 days later.
33293340|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
33293341|NCT03973515|Experimental|PB-201 50/50mg by mouth,every morning and noon for 7 days|
33293342|NCT03973515|Experimental|PB-201 100/50mg by mouth,every morning and noon for 7 days|
33293343|NCT03973515|Experimental|PB-201 100/100mg by mouth,every morning and noon for 7 days|
33293344|NCT03973515|Placebo Comparator|placebo|
33293345|NCT00228813|Other|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
33293346|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
33293347|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
33293348|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
33293349|NCT00174447|Experimental|A1|
33293350|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
33293351|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
33293352|NCT00321984|Placebo Comparator|Placebo|
33293353|NCT03982758|Experimental|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
33293354|NCT03982758|Experimental|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
33293355|NCT03984708|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
33293356|NCT03984708|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
33293357|NCT01060488|Active Comparator|Group 1:|
33293358|NCT01060488|Active Comparator|Group 2:|
33293359|NCT01060566|Experimental|VX-770|
33293360|NCT01060566|Experimental|Midazolam|
33293361|NCT01060566|Experimental|Rosiglitazone|
33293362|NCT01060566|Experimental|Fluconazole|
33293363|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
33293364|NCT02533284|Experimental|B group|TAP bupevecaine
33293365|NCT02533284|Placebo Comparator|C group|control TAP saline
33293366|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
33293367|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
33293368|NCT03998423|Experimental|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
33293369|NCT03998423|Experimental|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
33293370|NCT03998423|Experimental|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
33293371|NCT00110266|Experimental|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
33293372|NCT00174291|Experimental|Somatropin|
33293373|NCT00366548|Experimental|1|
33293374|NCT00366548|Active Comparator|2|
33086150|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
33086151|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
33086152|NCT00250263|Active Comparator|2|Drug Staloral (active group)
33086153|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
32786385|NCT04218539|Experimental|Psilocybin/Placebo|Subjects will receive a dose of psilocybin, followed by a dose of placebo approximately 7 days later.
32786386|NCT04218539|Experimental|Psilocybin/Psilocybin|Subjects will receive a dose of psilocybin, followed by a dose of psilocybin approximately 7 days later.
32786387|NCT04995731||Women with pre or peri-menopausal abnormal uterine bleeding or post menopausal bleeding|Eligible women presenting to Women's Health hospital with pre or peri-menopausal AUB or PMB will be prospectively enrolled after obtaining their informed consent. AUB will be deﬁned by symptoms of heavy menstrual bleeding, inter-menstrual bleeding, meno-metrorrhagia, irregular menses, or other AUB among women aged ≥40 years who are not in menopause. Peri-menopausal bleeding will be defined as vaginal bleeding after 6 months of menopause after the age of 40 years. Postmenopausal status will be defined as the absence of menstruation for at least 12 months after the age of 40 years, where any pathological condition of amenorrhea is excluded.
32786388|NCT04217525||Spinal Disorders|This group includes patients with any spinal deformity or disorder coming in for treatment.
32786389|NCT04217525||Spinal Tumors|This group includes patients with spinal tumors or metastasis of the spine, coming in for treatment.
32786390|NCT04995497|Experimental|Erector Spinae Plane Block-Administration of Lidocaine|Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
32786391|NCT04995497|Active Comparator|Intravenous-Administration of Lidocaine|Sham block procedure (catheter will be taped to subjects skin). Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours after sham catheter placement.
32786392|NCT05063279|Experimental|Resistance training group|Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
33293375|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
33293376|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
33293377|NCT00252057|Experimental|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
33293378|NCT00252057|No Intervention|Standard hospital discharge|Participants received the routine, standard hospital discharge.
33293379|NCT00132028|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
33293380|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
33293381|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
33293382|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
33293383|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
33293384|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
33293385|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
33293386|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
33293387|NCT03992378|Experimental|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
33293388|NCT03992378|Sham Comparator|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
33293389|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
33293390|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
33293391|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
33293392|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
33293393|NCT03992300|Experimental|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
32786393|NCT05063279|No Intervention|Negative control group|A negative control group is included in the study which will not receive any resistance training.
32786394|NCT05063201|Experimental|Cariprazine|
32786395|NCT05063201|Placebo Comparator|Placebo|
32786396|NCT04217057|Experimental|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
32786397|NCT05026853|Experimental|PRO Integration into Clinical Practice|PRO scores will be shared with patients and healthcare providers (HCPs) via an emailed report card
32786398|NCT05026853|No Intervention|Usual Care|Patients and HCPs will not receive an emailed PROMIS score report. PROMIS scores, however, will be available in the EMR as usual.
32786399|NCT04994873|Experimental|STEP: Positivity skill enhancement|This intervention includes the Enhanced TAU described below plus it entails 4 in-person sessions delivered during an inpatient psychiatric admission, followed by mood monitoring and skills messages delivered post-discharge via app, to promote the practice of increasing attention to positive affect and experiences as a means of reducing risk for suicidal behavior.
32786400|NCT04994873|Active Comparator|Enhanced TAU|his comparison intervention involves regular programming of the inpatient psychiatric unit, followed by safety plan and resources loaded onto an app that the participant has access to post-discharge.
32786401|NCT04993859||Male Cancer Survivors with DVSS Score ≥ 9|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
32786402|NCT04993859||Female Cancer Survivors with DVSS Score ≥ 6|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
32786403|NCT04993859||Male Cancer Survivors with DVSS Score < 9|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
32786404|NCT04993859||Female Cancer Survivors with DVSS Score < 6|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
32786405|NCT05060627|Experimental|Belantamab-Mafodotin + Carfilzomib+ dexametasona|"In the phase 1 of the study, aiming to establish the recommended phase 2 dose (RP2D), patients will be included following the classic 3 + 3 design.~Once the DLT assessment period is completed and the MTD is defined, the recruitment will continue in the expansion phase 2.~Combination treatment will be administered at the recommended Phase 2 dose (RP2D) based on the results of the phase 1 dose escalation part of the study:~Belantamab mafodotin on day 1 at the RP2D, every 8 weeks, intravenously (IV).~Carfilzomib will be given at the RP2D weekly IV on days: 1, 8, and 15 of every 4-week cycle (Q4W).~Dexamethasone will be given at the dose of 40 mg (or 20 mg if patient > 75 years old) on days: 1, 8, 15 and 22 Q4W.~From month 13 onwards carfilzomib treatment will be given on day 1 and 15 of every 4-weeks cycles. Belantamab will be given at the RP2D every 8 weeks and Dexamethasone 40mg on days 1, 8, and 15 of every 4-week cycle."
32786406|NCT05025605|Experimental|80 Micrograms|Sublingual film containing 80 micrograms Dexmedetomidine
32786407|NCT05025605|Experimental|120 Micrograms|Sublingual film containing 120 micrograms Dexmedetomidine
32786408|NCT05025605|Placebo Comparator|Placebo|Sublingual Placebo film
32786409|NCT05025605|Experimental|60 Micrograms|Sublingual film containing 60 micrograms Dexmedetomidine Europe Only
32786410|NCT04421105|Experimental|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
32786411|NCT04421105|Experimental|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
32786412|NCT04421105|Experimental|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
32786413|NCT04421105|Placebo Comparator|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
32786414|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
33086154|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
33086155|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
33086156|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
32786415|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
33086157|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
32786416|NCT05025059|Experimental|Supportive care (coaching, exercise, questionnaire)|Patients participate in one-on-one coaching sessions with a health coach QW to discuss the content offered in the program, and challenges they are currently facing in achieving their exercise goals. Patients receive a copy of the WWE workbook, wear a fitness tracker and are encouraged to achieve 150 minutes of walking per week during chemotherapy and up to 1 month after chemotherapy. Patients also participate in the Growing Stronger Strength Training Program and receive instruction manuals. They perform the initial 2 exercises 2 days per week for 4 weeks, and subsequent 2 exercises 2 days per week for the remainder of the chemotherapy course. Patients maintain exercise logs and complete questionnaires over 30-45 minutes at baseline, end of chemotherapy and at 1 month after chemotherapy.
32786417|NCT05024747|Experimental|Test Product|Participants will receive a single NicoDerm CQ patch (GSK Dungarvan) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
33086158|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
33086159|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
33086160|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
33086161|NCT00264069||001|
33086162|NCT00264069||002|
32786418|NCT05024747|Active Comparator|Reference Product|Participants will receive a single NicoDerm CQ patch (Alza) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
32786419|NCT05058833||Patients with cardiac diastolic dysfunction|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
32786420|NCT05058833||Patients with coronary microcirculatory dysfunction|Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
32786421|NCT05023967|Experimental|Arm I (fasting, glucose monitoring, counseling, metformin)|Patients fast for >= 16 hours every night and use the continuous glucose monitoring system for 4-6 weeks. Patients also receive nutritional counseling sessions on days 0 and 10. Beginning week 2, patients also receive metformin hydrochloride extended release PO QD until the day of surgery. Treatment continues for 4-6 weeks (until surgery) in the absence of disease progression or unacceptable toxicity. Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
32786422|NCT05023967|Active Comparator|Arm II (glucose monitoring)|Patients continue their usual dietary pattern and use the continuous glucose monitoring system for 4-6 weeks (until surgery). Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
32786423|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine, Arm 1|
32786424|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 2|
32786425|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3|
32786426|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 4|
32786427|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
32786428|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
32786429|NCT05056883|Experimental|Treatment A|K-237 0.3-0.4mg/kg (once daily)
32786430|NCT05056883|Placebo Comparator|Control A|Placebo (once daily)
32786431|NCT05055323|Experimental|Treatment (pyrvinium pamoate)|Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
32786432|NCT04991753|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 10 along with standard-of-care background therapy.
32786433|NCT04991753|Experimental|Group 2: Nipocalimab|Participants will receive nipocalimab IV q2w through Week 10 along with standard-of-care background therapy.
32786434|NCT04991597|Experimental|Left Forearm Injection Sites Cooled, Right Forearm Injection Sites at Room Temperature|Palmar aspect of participants left forearm will have a cold compress pack placed on it. The palmar aspect of the right forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
32786435|NCT04991597|Experimental|Right Forearm Injection Sites Cooled, Left Forearm Injection Sites at Room Temperature|Palmar aspect of participants right forearm will have a cold compress pack placed on it. The palmar aspect of the left forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
32786436|NCT04216667|Active Comparator|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
32786437|NCT04216667|Experimental|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
32786438|NCT04216667|Experimental|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
32786439|NCT04216667|Experimental|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
32786440|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
32786441|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
32786442|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
32786443|NCT04950101|Active Comparator|HAS-N|In this arm the patient without HIV using PrEP will be included
32786444|NCT04950101|Active Comparator|HAS-P|In this arm the patient with HIV will be included
32786445|NCT04949867|Active Comparator|Dual-hormone Closed-loop|FiAsp® and GlucaGen®.
32786446|NCT04949867|Placebo Comparator|Single-Hormone Closed-loop|FiAsp® and isotonic saline.
32786447|NCT05018897|Experimental|To Share or Not to Share|"Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
33086163|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
33086164|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
33086165|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
33086166|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
32786448|NCT05018897|Active Comparator|Peer Support|"Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
32786449|NCT04989491|Experimental|Experimental group|Prophylactic treatment with Rituximab: one single dose of 375mg/m2 intravenous 7 days before transplantation in case of living donor or at time of transplantation (D0 or D1) in case of transplantation with a deceased donor.
32786450|NCT04989491|Active Comparator|control group|Immunosuppression treatment will be given according to the practice of the centers; use of Thymoglobuline is strongly discouraged because of EBV seronegativity and risk of lymphoma. Basiliximab is recommended for induction therapy. Recommended maintenance immunosuppression consists in a calcineurin inhibitor (tacrolimus or ciclosporine), MMF and Steroids
32786451|NCT05018117|Experimental|Young (18-28 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
32786452|NCT05018117|Experimental|Old (60-85 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
32786453|NCT05018117|Placebo Comparator|Young (18-28 years) participants - placebo gum|placebo gum, one time before fMRI measurements
32786454|NCT05018117|Placebo Comparator|Old (60-85 years) participants - placebo gum|placebo gum, one time before fMRI measurements
32786455|NCT04949165|Experimental|Iron Supplementation|
32786456|NCT04949165|No Intervention|Control|
32786457|NCT05017181||BioVal|BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
32786458|NCT05017181||ProVal|ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
32786459|NCT05017181||TecVal|TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.
32786460|NCT04203329||Paroxysmal A-Fib|
32786461|NCT04203329||Persistent A-Fib|
32786462|NCT04203329||A-Fib|
32786463|NCT05016869|Experimental|Experimental|fruquintinib plus capecitabine
32786464|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
32786465|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
33086167|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
33086168|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
33086169|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
33086170|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
33086171|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:~Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~Day 1: Nikkomycin Z 500 mg under fasted conditions"
33086172|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:~Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
33086173|NCT04528927|Experimental|HCQ+Azithromycin|"Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Usual standard treatment"
33086174|NCT04528927|Experimental|HCQ+Azithromycin+Zinc|"HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Zinc: 220 mg per day for 10 days~Usual standard treatment"
33086175|NCT04528927|Experimental|Azithromycin+Doxycycline|"Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Doxycycline: 200 mg per day for 10 days.~Usual standard treatment"
32786466|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
32786467|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
32786468|NCT04411433|Experimental|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
32786469|NCT04411433|Experimental|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
32786470|NCT04411433|Experimental|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
32786471|NCT04411433|Experimental|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
33086176|NCT04720287|Active Comparator|Group 1(QL group)|
33086177|NCT04720287|Active Comparator|Group 2 (CB group)|
33293394|NCT03992300|Active Comparator|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
33293395|NCT00131248|Other|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
33293396|NCT00131248|Other|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
33293397|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
32786472|NCT04411433|Active Comparator|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
32786473|NCT04411433|Active Comparator|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
32786474|NCT04987463|Experimental|Vigabatrin arm|Vigabatrin in capsules co-administered with placebo in liquid.
32786475|NCT04987463|Experimental|Rapamycin arm|Rapamycin in liquid co-administered with placebo in capsules.
32786476|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
32786477|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
32786478|NCT04948853|No Intervention|Treatment as usual|Treatment as usual, with respect to employment, for individuals on probation typically entails the probation officer informing the probationer that probationer is responsible for obtaining employment or could entail a referral from a probation officer to an employment or job assistance service, such as vocational rehabilitation. The probationer is responsible for follow up with that service.
32786479|NCT04948853|Experimental|Intervention - Individual Placement Support-Supported Employment|Subjects in this condition will receive services from a 1.5 FTE IPS-SE team that will work to provide one-on-one person-centered services to help obtain employment, including but not limited to career profiling, resume assistance, job placement, training and other activities.
32786480|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
32786481|NCT05012735|Experimental|Treatment Group: Prototype Ultrathin Hydrocolloid Bandage and Study Cleanser|Participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the evening prior to bandage application and in the morning after removing the bandage(s) on Days 0 through 7. On Days 7 through 14, no bandages will be worn and participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the morning and evening. Participants will cover their closed and popped pimples in the evening with 1 or 2 bandages on Days 0 through 6.
32786482|NCT05012735|Active Comparator|Control Group: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face twice daily using the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
32786483|NCT04946903|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008,~Period 2: Fasted state + HCP1902"
32786484|NCT04946903|Experimental|Sequence 2|"Period 1: Fasted state + HCP1902,~Period 2: Fasted state + RLD2007 + RLD2008"
32786485|NCT04985825|Experimental|Imgatuzumab monotherapy|
32786486|NCT05012657|Experimental|Prosthesis|Patient is temporarily fit with Point Partial partial finger prosthetic system
32786487|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A received placebo for MVC and placebo for DTG.
32786488|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B received DTG and placebo for MVC.
33293398|NCT01080820|Placebo Comparator|Placebo + Viread|
33293399|NCT01080820|Active Comparator|Viread|
32786489|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C received MVC and DTG
32786490|NCT04985513|No Intervention|Group N|Stopping ventilation during cardiopulmonary bypass
32786491|NCT04985513|Active Comparator|Group V|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
32900632|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
33293400|NCT01080820|Experimental|CMX157 + Viread|
33293401|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
33293402|NCT01048346|Experimental|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
33293403|NCT03964558|Other|100 mg [14C]-acebilustat|a single oral dose of 100 mg [14C]-acebilustat
33293404|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
32786492|NCT04213859|Experimental|Virtual Reality Exposure Therapy (VRET)|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).~rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.~th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
32786493|NCT04213859|No Intervention|control|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)~rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.~th stage: Participants will complete measures of fear of flying and emotional variables."
32786494|NCT05008913|Experimental|[14C]Adavosertib|Patients will receive a single administration of [14C]adavosertib as an oral solution on Day 1.
32786495|NCT04982705|Experimental|[Part 1.1] IDG-16177|6 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
32786496|NCT04982705|Placebo Comparator|[Part 1.1] Placebo of IDG-16177|2 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
32786497|NCT04982705|Experimental|[Part 1.2] IDG-16177|8 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo.
32786498|NCT04982705|Placebo Comparator|[Part 1.2] Placebo|2 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo (QD).
32786499|NCT04982705|Experimental|[Part 2] IDG-16177|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
32786500|NCT04982705|Placebo Comparator|[Part 2] Placebo|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
32786501|NCT04982705|Active Comparator|[Part 2] Sitagliptin|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator (1:1:1 ratio).
32786502|NCT04202783|Experimental|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
32786503|NCT04944095||SARS-CoV-2 Antibody Levels|This is a single arm study by Southlake Diagnostics Inc. whereby changes in plasma antibody levels (IgG and total) are determined over 12 months on individuals residing in over 300 associated nursing homes, extended care facilities and over-55 residences following vaccination with one of the authorized SARS-CoV-2 vaccines (Pfizer, Moderna or J &J). No interventions are involved. The investigators are not responsible for administering the vaccines or determining subject eligibility or willingness to receive the vaccine. Blood samples will be drawn and plasma IgG and total antibodies will be determined at baseline, 3, 6, 9 and 12 months post-vaccination.
32786504|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
32786505|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
32786506|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
32786507|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
32786508|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
32786509|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
32786510|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
32786511|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
32786512|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
32786513|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
32786514|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
32786515|NCT04736667||Subjects fail screening for TMVI|Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.
32786516|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
32786517|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
32786518|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
33293405|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
32786519|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
32786520|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
32786521|NCT02138253|Placebo Comparator|Placebo|Placebo BID
32786522|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
32786523|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
32786524|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
32786525|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
32786526|NCT05006885|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
32786527|NCT05006885|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
32786528|NCT05006885|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
33293406|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
33293407|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
32786529|NCT05006885|Placebo Comparator|Placebo|Administered once a week for 12 weeks
32786530|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
32786531|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
32786532|NCT02104557||prevention of pregnancy|Non intervention
32786533|NCT02104557||management of endometriosis-associated pain|Non intervention
32786534|NCT04209023|Experimental|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
32786535|NCT04982081|Experimental|hiPSC-CM therapy low dosage|
32786536|NCT04982081|Experimental|hiPSC-CM therapy high dosage|
32786537|NCT04725513|Active Comparator|Physical Therapy Only|
32786538|NCT04725513|Experimental|Shockwave Therapy and Physical Therapy|
32786539|NCT04725513|Experimental|Photobiomodulation, Shockwave Therapy and Physical Therapy|
33293408|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
33293409|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
32786541|NCT04725201|Experimental|Intravenous unfractionated heparin|Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.
33293410|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
33293411|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
33293412|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
33293413|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
33293414|NCT00359294|Experimental|Zalypsis (PM00104)|
33293415|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
33293416|NCT00384332|Experimental|Arm 2|regular olanzapine
33293417|NCT00096226|Experimental|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
33293418|NCT01078714|Experimental|Bumetanide|
33293419|NCT01078714|Placebo Comparator|Control|
33293420|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
33293421|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
33293422|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
33293423|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
33293424|NCT03964324|Experimental|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
33293425|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
33293426|NCT03963076|Experimental|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
33293427|NCT00105508|Experimental|Sarizotan|
33293428|NCT00105508|Placebo Comparator|Placebo|
33293429|NCT01082848|Experimental|aripiprazole|
33293430|NCT01082848|Placebo Comparator|placebo|
33293431|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
33293432|NCT01083004|Active Comparator|Indocyanine green arm|
33293433|NCT01083004|Active Comparator|Brilliant blue|
33293434|NCT03962920|Active Comparator|Surgical treatment + antibiotics|Use antibiotic
33293435|NCT03962920|Placebo Comparator|surgical treatment + placebo|Use placebo
33293436|NCT01078870|Experimental|A|
33293437|NCT01078870|Experimental|B|
33293438|NCT01078870|Experimental|C|
33293439|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
33293440|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
33293441|NCT03965338|Other|fMRI brain activity|screening
33293442|NCT00105196|Experimental|A1|
33293443|NCT00105196|Placebo Comparator|A2|
33293444|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
33293445|NCT03820024|No Intervention|No Messages|No feedback messages
33293446|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
33293447|NCT00104572|Experimental|(Androgel) testosterone gel|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
33293448|NCT00104572|Experimental|anastrozole (Aromatase inhibitor)|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
33293449|NCT00104572|Placebo Comparator|placebo|13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
33293450|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
33293451|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
33293452|NCT02531074|Experimental|Mobile Application plus Usual Care|
33293453|NCT02531074|Active Comparator|Food Journal plus Usual Care|
33293454|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
33293455|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
33293456|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
33293457|NCT01079104|Active Comparator|Control|Standard Medical Therapy
33293458|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
33293459|NCT01081444|Active Comparator|1|Active rTMS
33293460|NCT01081444|Placebo Comparator|2|sham rTMS
33293461|NCT03963934|Experimental|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
33293462|NCT00514943|Experimental|BIBW 2992|once daily taken orally
33293463|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
33293464|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
33293465|NCT01083550|No Intervention|Control|Usual care
33293466|NCT01079260|Active Comparator|Standard ONS|
33293467|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
32786542|NCT04725201|Sham Comparator|Control|"No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.~The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion."
32786543|NCT05006105|Experimental|PPG-based mHealth on smartphone|Participants used PPG-based mHealth on a smartphone for 6 months. Participants were asked to perform two spot-check measurements and additional measurements in case of symptoms. The use of PPG-based mHealth on a smartphone was initiated on the day of insertable loop recorder insertion.
33293468|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
33293469|NCT00103402|Experimental|Alfuzosin|10 mg of alfuzosin once daily for 12 weeks
33293470|NCT00103402|Placebo Comparator|Placebo|10 mg of an identical-looking placebo once daily for 12 weeks
33293471|NCT03864341|Experimental|Homelessness Prevention Services|
32786544|NCT05006105|Experimental|PPG-based mHealth on smartwatch|Participants used PPG-based mHealth on a smartwatch for 6 months. Participants were asked to wear the smartwatch continuously (except during battery charging). The use of PPG-based mHealth on a smartwatch was initiated on the day of insertable loop recorder insertion.
32786545|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
32786546|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
32786547|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
32786548|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
33293472|NCT01739309|Experimental|Abemaciclib|200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle
33293473|NCT00095836|Experimental|Gefitinib 250mg|
33293474|NCT00168831|Other|Tiotropium Respimat 5mcg (Tio R5)|
32786549|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
32786550|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
32786551|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
32786552|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
33293475|NCT00168831|Other|Tiotropium Respimat 10mcg (Tio R10)|
33293476|NCT00168831|Other|Placebo|
33293477|NCT03330821|Experimental|Treatment (idarubicin, cytarabine, pevonedistat)|"INDUCTION: Patients receive idarubicin IV over 10-15 minutes on days 1-3, cytarabine IV over 1-3 hours on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Patients with gross residual disease on day 14 bone marrow may receive a second course of induction chemotherapy.~CONSOLIDATION: Patients who achieve CR and will not undergo bone marrow transplant receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28-35 days for 4 courses in the absence of disease progression or unaccepted toxicity."
33293478|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
32786553|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
33293479|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
33293480|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
33293481|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
33293482|NCT00103012|Experimental|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
33293483|NCT00103012|Experimental|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
33293484|NCT00103012|Experimental|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
33293485|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
33293486|NCT04629521|Experimental|CyPass Micro-Stent|CyPass Micro-Stent placed in the angle of the eye at the conclusion of cataract surgery (COMPASS trial)
33293487|NCT03235505|Experimental|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
33293488|NCT03235505|Active Comparator|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
33293489|NCT03235505|Placebo Comparator|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + MI
33293490|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
33293491|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
33293492|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
33293493|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
33293494|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
33293495|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
33293496|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
33293497|NCT04580147|Experimental|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
33293498|NCT04580147|Sham Comparator|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
33293499|NCT03862625|Experimental|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
33293500|NCT03862625|Active Comparator|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
33293501|NCT00163215|Experimental|Somatropin|
33293502|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
33293503|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
33293504|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~Avelumab will be administered intravebously once every 2 weeks"
33293505|NCT00228423|Active Comparator|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
33293506|NCT00228423|Placebo Comparator|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
33293507|NCT00511667|Experimental|MK0941|
33293508|NCT00511667|Placebo Comparator|Placebo|
33293509|NCT00227877|No Intervention|Control - New England, USA|"Control participants will receive care as usual from their provider"
33293510|NCT00227877|Experimental|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
33293511|NCT00227877|No Intervention|Control - Prague, CZR|"Control participants will receive care as usual from their provider"
33293512|NCT00227877|Experimental|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
33293513|NCT04610099|Active Comparator|Standard SG|100 patients undergo a standard sleeve gastrectomy
33293514|NCT04610099|Experimental|Banded SG|100 patients undergo a banded sleeve gastrectomy
33293515|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
33293516|NCT00162981|Experimental|Clobazam Low Dose|
33293517|NCT00162981|Experimental|Clobazam High Dose|
33293518|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
33293519|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
33293520|NCT00099268|Experimental|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
33293521|NCT00099268|Active Comparator|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
33293522|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
33293523|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
33293524|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
33293525|NCT01083784|No Intervention|Control group|control group
33293526|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
33293527|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
33293528|NCT03998345|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
33293529|NCT04576637|Experimental|Neurophysiological monitoring during induction|
32786554|NCT05005247|Experimental|GBS-NN/NN2|Single dose 0.5 millilitre (mL) intramuscular injection of GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
33293530|NCT00095212|Active Comparator|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
33293531|NCT00095212|Placebo Comparator|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
32786555|NCT02137785|Experimental|ALA|
32786556|NCT02137785|Placebo Comparator|Vehicle|
33293532|NCT04606979|Experimental|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
32786557|NCT05003453|Experimental|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
32786558|NCT05003453|Placebo Comparator|Placebo comparator|A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
32786559|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
32786560|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
33293533|NCT04606979|Sham Comparator|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
33293534|NCT04606979|Experimental|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
33293535|NCT04606979|Sham Comparator|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
33293536|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
33293537|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:~Pembrolizumab 200mg intravenously (IV);~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);~Carboplatin IV area under the curve (AUC) of 6."
33293538|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
33293539|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
33293540|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
33293541|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
33293542|NCT00120874|Experimental|Group 1|Individualized Management including caregiver training and Memantine
33293543|NCT00120874|Active Comparator|Group 2|Only Memantine
33293544|NCT00120406|Experimental|1|Zilver® PTX™ Drug Eluting Vascular Stent
33293545|NCT00120406|Active Comparator|2|Angioplasty
33293546|NCT00120250|Experimental|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
33293547|NCT00120250|Placebo Comparator|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
33293548|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
33293549|NCT01079338|Experimental|caffeine|
33293550|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
33293551|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
33293552|NCT03964012|Experimental|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~A single dose of 0.5 mL will be administered intramuscularly."
33293553|NCT03964012|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~A single dose of 0.5 mL will be administered intramuscularly."
33293554|NCT01083940|Experimental|Reminders to providers|
33293555|NCT01083940|No Intervention|usual care|
33293556|NCT01009385|Active Comparator|prone position|
33293557|NCT01009385|Active Comparator|sitting position|
33293558|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
33293559|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
33293560|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
33293561|NCT00384176|Experimental|2|Cediranib + FOLFOX
32786561|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
32786562|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
33293562|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
33293563|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
33293564|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33293565|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
33293566|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
33293567|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
33293568|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
33293569|NCT01012505||20 preterm infants|20 preterm infants without active disease
33293570|NCT03997877|Active Comparator|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
32786563|NCT02068599|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
32786564|NCT02068599|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
33293571|NCT03997877|Experimental|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
33293572|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
33293573|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
32786565|NCT02068599|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
33293574|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
33293575|NCT00358826|Placebo Comparator|Placebo|Placebo
33293576|NCT04564313|Experimental|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
33293577|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
33293578|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
33293579|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
33293580|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
33293581|NCT04562207|Experimental|Patients|Addition of a nasopharyngeal swab before surgery
32939354|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
33293582|NCT01052558|Active Comparator|Cataract Surgery Only|
33293583|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
33293584|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
32939355|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
33293585|NCT04555967||Transcatheter aortic valve implantation|
33293586|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
33293587|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
33293588|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
33293589|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
33293590|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
33293591|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
33293592|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
33293593|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
33293594|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
33293595|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
33293596|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
33293597|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
33293598|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
33293599|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
33293600|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
33293601|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
33293602|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
33293603|NCT05408507|Experimental|Older patients with advanced bladder cancer|Older patients with bladder cancer
33293604|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
33293605|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
32939356|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
32939357|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
32939358|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
32939359|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
32939360|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
32939361|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
32939362|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
32939363|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
32939364|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
32939365|NCT04501640|Experimental|Mirabegron 25 mg fed/Mirabegron 25 mg fasted|Participants received single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 25 milligram (mg) mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
33293606|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
33293607|NCT05408273||Postmenopausal women|Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated.
33293608|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
33293609|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
33293610|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
33293611|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
33293612|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine & Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 & -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
33293613|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
33293614|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
33293615|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
32737614|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
32737615|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
32737616|NCT05038605|Active Comparator|Topical metronidazole|Topical application of metronidazole cream on the anal verge after surgery
32737617|NCT05038605|Active Comparator|Oral metronidazole|oral metronidazole 500 mg tablets after surgery
33293616|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
33293617|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
33293618|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
33293619|NCT00383786|Placebo Comparator|placebo|sugar pill
33293620|NCT05358977|Experimental|Tisseel|Patients are undergoing bilateral blepharoplasty. In this arm (Tisseel), the patient with undergo blepharoplasty with topical Tisseel placed in the incision prior to standard closure. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
33293621|NCT05358977|No Intervention|Control|Patients are undergoing bilateral blepharoplasty. In this arm (Control), the patient with undergo blepharoplasty with standard closure along. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
33293622|NCT01010165||septic arthritis|
33293623|NCT01010165||crystal arthritis|
32737618|NCT05038605|No Intervention|Control|No metronidazole was received
32737619|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
32737620|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
32737621|NCT04467411||Breast Cancer Group|Breast Cancer Group
32737622|NCT04467411||Healthy Volunteer|Healthy Volunteer Group
32737623|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
32737624|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
32737625|NCT03329729||Hyperlipidemic patients|
32737626|NCT05038683|Experimental|HOT|Holbæk Obesity Treament
32737627|NCT05038683|Active Comparator|COT|Conventional Obesity Treatment
32737628|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
32737629|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
32737630|NCT05049759|Experimental|Feasibility testing|The feasibility trial, aims to assess the feasibility of the intervention, including assessment of acceptability and outcome measures. Twenty youths with anxiety and/or depressive symptoms will be recruited to the intervention. Physical activity will be measured using the Actigraph GT3X+ monitor at baseline and post-intervention. Outcome measures concerning symptom change will be assessed (anxiety and depression). Semi-structured qualitative interview with participants, caregivers and referring specialists will help identify possible contextual and practical factors associated with delivery of the intervention and explore acceptability of assessment procedures, the intervention, and perceived benefits and barriers to participation.
32737631|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
32737632|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
32737633|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
33403773|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
32786566|NCT04708509|Experimental|Intervention Arm|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
32786567|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
32786568|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
32786569|NCT01654523|Other|Treatment arm|Open trial with no randomization
32786570|NCT04979429|Experimental|PePS|4 sessions of telephone CBT-based pain self-management in addition to standard perioperative care.
32786571|NCT04979429|No Intervention|Standard Care|Standard perioperative care.
32786572|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
32786573|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
32786574|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
32786575|NCT05001113|Experimental|the subxiphoid approach thoracoscopic thymectomy|The subxiphoid approach thoracoscopic thymectomy is performed in enrolled patients.
32786576|NCT05001113|Active Comparator|the lateral intercostal approach thoracoscopic thymectomy|The lateral intercostal approach thoracoscopic thymectomy is performed in enrolled patients.
32786577|NCT04978649|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
32786578|NCT04978649|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
32786579|NCT04978415|Experimental|subtenon's block|we use the subtenon cannula to inject the local anesthetic mixture
32786580|NCT04978415|Experimental|peribulbar block|we use the usual 25G sharp needle to inject the local anesthetic mixture
32786581|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
32786582|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
32786583|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
32786584|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
32786585|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
32786586|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
32786587|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
32786588|NCT05000177|Other|Experimental group: Non-specific chronic neck pain group|Subjects with non-specific chronic neck pain will be included to perform 30-minute computer typing task and assess neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation.
32786589|NCT05000177|Other|Control group: Healthy subjects group|Healthy subjects will be included to compare the differences in neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with non-specific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
32786590|NCT05000177|Other|Pilot study: Healthy subjects group|Healthy subjects will be included to test reliability of single-pulse and paired-pulse TMS, including its associated neurophysiological measurements, and also to test reliability of Liberty electromagnetic tracing system and surface electromyography. Subjects in this group will received the same assessment as the NCNP group.
32786591|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
32786592|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
32786593|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
33293624|NCT01010165||rheumatismal disease|
32786594|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
32786595|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
32786596|NCT04999709|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
32786597|NCT04999709|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
32786598|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
32786599|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
32786600|NCT02047227|Experimental|Pergoveris®|
32786601|NCT02047227|Active Comparator|GONAL-f®|
32786602|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
32786603|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
32786604|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring~. record their BP readings into the smart phone with downloaded application."
32786605|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement~. Record BP readings in their diary"
32786606|NCT05461157|Experimental|Preoperative silicone ointment|Participants will apply silicone ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
32786607|NCT05461157|Placebo Comparator|Preoperative placebo ointment|Participants will apply placebo ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
32786608|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
32786609|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
32786610|NCT04974593|Experimental|H2BT-positive|
32786611|NCT04974593|Experimental|H2BT-negative|
32786612|NCT04706793|Experimental|Etrasimod 2 mg|
32786613|NCT04706793|Placebo Comparator|Placebo|
33403774|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
32786614|NCT04974281|Other|PD-1+TACE+Len|PD-1 Antibody and Lenvatinib Plus TACE
32786615|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
32786616|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
32786617|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
32786618|NCT04736121|Experimental|Open-label Single Arm|Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.
32786619|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
32786620|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
32786621|NCT02503865|No Intervention|Healthy people|64 healthy people
32786622|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
32786623|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
32786624|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
32786625|NCT04943471||All patients will be given a questionnaire|All patients will be given the Big Five Questionnaire
32786626|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
32786627|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
33403775|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
33403776|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
32786628|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
33293625|NCT05358665||Group 1|There are individuals who use masks for less than 4 hours daily.
32786629|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
32786630|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
33293626|NCT05358665||Group 2|There are individuals who use masks for 4-8 hours daily.
33293627|NCT05358665||Group 3|There are individuals who use masks for more than 8 hours daily.
33293628|NCT00383708|Experimental|1|
32786631|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
33293629|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
33293630|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
33293631|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
33293632|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
33293633|NCT01010321||all study Population|all
33293634|NCT05407883|Experimental|Intervention-School traffic warden programme|"The intervention will address multiple risk factors related to behaviour through placing traffic wardens at school crossing points. The assumption is that school traffic wardens situated at safe crossing points will increase yield rates of drivers to pedestrians and reduce the risk of pedestrian motor-vehicle collision. They will be placed at safe locations. Visibility and safety at pedestrian crossings will be enhanced by one trained school traffic warden placed a designated safe crossing point. The school traffic warden will assist pupils in crossing at all times during peak hours i.e. 6:00am-8:00am; 01:00pm-02:00pm; 03:00-07:00pm. In total, 11 school traffic wardens will under-go a 3 day road safety training prior to the start of the study. A similar follow up training will be conducted after 3 months and these will be motivated with non-monetary incentives e.g. high visibility jackets and a lollipop stop sign."
33293635|NCT05407883|No Intervention|Control-road safety manuals|The control schools will receive road safety manuals and leaflets developed by the Uganda Red Cross Society and the Uganda National Curriculum Development Centre.
33293636|NCT00383240|Experimental|MF/F MDI 200/10 mcg BID|
33293637|NCT00383240|Experimental|MF MDI 200 mcg BID|
33293638|NCT00383240|Experimental|F MDI 10 mcg BID|
33293639|NCT00383240|Placebo Comparator|Placebo BID|
33293640|NCT05130788|Experimental|Intervention Group|
33293641|NCT05130788|Active Comparator|Control Group|
33293642|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
33293643|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
33293644|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
33293645|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
33293646|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
33293647|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
33293648|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
33293649|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
33293650|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
33293651|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
33293652|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
33293653|NCT01050140|Experimental|fructose|25% dietary energy from fructose
33293654|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
33293655|NCT03990584|Experimental|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
33293656|NCT03990584|Active Comparator|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
33293657|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
33293658|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
33293659|NCT03990350||Hispanic children with obesity|
33293660|NCT03990350||Hispanic children without obesity|
32786632|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
32786633|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
32786634|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
33293661|NCT03990350||Caucasian non-Hispanic children with obesity|
32786635|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
32786636|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
32786637|NCT04207619|Experimental|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
32786638|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
32786639|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
32786640|NCT02046603|Experimental|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
32786641|NCT02046603|Experimental|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
32786642|NCT01885078|Experimental|4 milligram (mg) Baricitinib|"4 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
32786643|NCT01885078|Experimental|2 mg Baricitinib|"2 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
32786644|NCT01885078|Experimental|2 mg Baricitinib Step-down|"2 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
32786645|NCT01885078|Experimental|4 mg Baricitinib Step-down|"4 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
32786646|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
32786647|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
32786648|NCT04705935||Term pregnant women without labor contractions or rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.
32786649|NCT04705935||Term pregnant women with labor contractions|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.
32786650|NCT04705935||Term pregnant women with spontaneous rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
32786651|NCT04705935||Preterm labor contractions (PLC)|One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.
33293662|NCT03990350||Caucasian non-Hispanic children without obesity|
33293663|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
33293664|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
33293665|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
33293666|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
33293667|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
32786652|NCT04705935||Preterm Prelabor Rupture of the Fetal Membranes (PPROM)|One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.
33293668|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
33293669|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
32786653|NCT04705935||Control group|Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
33293670|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
33293671|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
32939366|NCT04501640|Experimental|Mirabegron 25 mg fasted/Mirabegron 25 mg fed|Participants received single dose of 25 mg mirabegron tablet under fasted condition orally, on day 1 of period 1 followed by single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
33293672|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
32939367|NCT04501640|Experimental|Mirabegron 50 mg fed/Mirabegron 50 mg fasted|Participants received single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
33293673|NCT01045616||Prematurity|
33293674|NCT03992924|Active Comparator|angiography-guided PCI|
33293675|NCT03992924|Experimental|FFR-guided PCI|
33293676|NCT03992924|Experimental|OCT-guided PCI|
33293677|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
33293678|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
33293679|NCT03990272|Experimental|artemisia annua allergen extract drops|
33293680|NCT03990272|Placebo Comparator|Placebo drops|
33293681|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
33293682|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
33293683|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
33293684|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
33293685|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
33293686|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
33293687|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
33293688|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
33293689|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
33293690|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
33293691|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
33293692|NCT00357110|Active Comparator|1|Anastrozole monotherapy
33293693|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
33293694|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
33293695|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
33293696|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
33293697|NCT04467866|Experimental|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
33293698|NCT04467866|Experimental|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
32786654|NCT04705935||Longitudinal cohort during pregnancy|Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.
32786655|NCT04705935||Longitudinal cohort post partum|Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.
32786656|NCT04725123|Experimental|Clostridioides difficile infection|Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome
32786657|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
32786658|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
32786659|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
33086178|NCT04528654|Experimental|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
33086179|NCT04528654|No Intervention|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
33086180|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
33086181|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
33086182|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
33086183|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
33086184|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
33086185|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
33086186|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
33086187|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
33086188|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
33086189|NCT00240032|Experimental|Copaxone® with placebo|
33086190|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
33086191|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
33086192|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
33086193|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
33086194|NCT04528849|Active Comparator|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
33086195|NCT04528849|Active Comparator|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
33086196|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
33086197|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
33086198|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
33293699|NCT04467866|Active Comparator|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
33293700|NCT04467866|Active Comparator|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
33293701|NCT00098722|Experimental|1|
33293702|NCT00098722|Placebo Comparator|2|
33293703|NCT00098722|Experimental|3|
33293704|NCT01079416||Capsule endoscopy|Study device
33293705|NCT01079416||Esophagogastroduodenoscopy|Gold standard
33293706|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
33293707|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
33293708|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
33293709|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
32939368|NCT04501640|Experimental|Mirabegron 50 mg fasted/Mirabegron 50 mg fed|Participants received single dose of 50 mg mirabegron under fasted condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
32939369|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
32939370|NCT04758390|Experimental|IMARA intervention arm|Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).
32939371|NCT04758390|Experimental|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
32939372|NCT04757610|Experimental|0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
32939373|NCT04757610|Experimental|0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
32939374|NCT04757610|Sham Comparator|0.5 mg ranibizumab with sham|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
32939375|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
32939376|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
32737634|NCT03095547|Experimental|F901318|F901318 alone
32737635|NCT03329651|Experimental|Metformin treatment|
32737636|NCT03329651|Placebo Comparator|Placebo treatment|
32737637|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
32737638|NCT05049447|Active Comparator|Verum arm|Intervention: Drug: Verum (Pascoflair)
32737639|NCT05049447|Placebo Comparator|Placebo arm|Intervention: Drug: Placebo
32737640|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
32737641|NCT04969107|Active Comparator|transanal TME (taTME)|patients with rectal cancer receiving transanal TME
32939377|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
32939378|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
32737642|NCT04969107|Active Comparator|abdominal TME (abTME)|patients with rectal cancer receiving open, laparoscopic or robotic TME
32737643|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
32737644|NCT05465447||Toric IOL|This study included the patients who underwent cataract surgery with the toric IOL(SN6ATX) implantation. Preoperative and postoperative corneal astigmatism, short-term and long-term postoperative total astigmatism were the main outcome indicators. Preoperative corneal astigmatism (Pentacam and IOLMaster) would be obtained from outpatient and inpatient medical records, and the IOL axis should be calculated before surgery. Short-term postoperative (1-3 months) subjective optometry results; Long-term postoperative (3-5 years) corneal astigmatism (Pentacam and IOLMaster), subjective optometry results, and axial lens would be observed using SSOCT after pupil dilation.
32737645|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
32737646|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
32737647|NCT04968951|Active Comparator|FMT with Antibiotics|Participants will receive antibiotics before receiving Fecal Microbiota Transplantation
32737648|NCT04968951|Placebo Comparator|FMT with placebo|Participants will receive placebo before receiving Fecal Microbiota Transplantation
32737649|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
32737650|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
32737651|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
32737652|NCT05049681|Experimental|SHR-1210（Camrelizumab）+Apatinib|Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
32786660|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
32786661|NCT01885000|Placebo Comparator|Vehicle|Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.
32786662|NCT04735341||Subjects with planned Ion Endoluminal Procedure with pulmonary nodule|
32786663|NCT04171960||Acute Blood Biomarker Branch|"Blood draw within 12 hours of injury for i-STAT Testing then processing for storage for future use~Blood draw between 12 to 24 hours of injury then processing for storage for future use~In-Person Outcome Assessment"
32786664|NCT04171960||Acute Blood Biomarker Plus Follow-up Branch|"Blood draw at 2 weeks and 6 months following injury then processing for storage for future use~In-Person Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury~Phone Outcome Assessment at 3 months following injury~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury"
32786665|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
32786666|NCT01883362|Experimental|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
32786667|NCT01883362|Active Comparator|Standard of Care|Patients received standard of care alone in the post SCT setting
32786668|NCT04613440|Other|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
32786669|NCT04613440|Other|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
32786670|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
32786671|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
32786672|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
32786673|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
32786674|NCT04613128||Pediatric|Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.
32786675|NCT04724967|Experimental|CeraVe Group|Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.
32786676|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
32786677|NCT04630912|Experimental|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
32786678|NCT05124886|Active Comparator|Healthy Controls|
32786679|NCT05124886|Experimental|Enteric Hyperoxaluria|
32786680|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
32786681|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
32786682|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
32786683|NCT01929226|Experimental|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
32786684|NCT01929226|Placebo Comparator|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
32786685|NCT04703751|Experimental|CIRCULATE Catheter|CIRCULATE Catheter will be used to deliver nitroglycerin and CardioCell to evaluate safety and efficacy of the device
32786686|NCT05122702|Experimental|Active Arm|"18.75g of Modified Shenling Baizhu San granules will be taken twice daily for 12 weeks."
32786687|NCT05122702|Placebo Comparator|Placebo Arm|18.75g of placebo granules will be taken twice daily for 12 weeks.
32786688|NCT04734405|Experimental|ProF-001 Group|"ProF-001 Group:~• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and~• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks"
32786689|NCT04734405|Active Comparator|Fluconazole Group|"Fluconazole Group:~During induction period:~1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and~During maintenance period:~capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)"
32786690|NCT02045433|Experimental|SABR Boost Therapy|
32786691|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
32786692|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
32786693|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
32786694|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
32786695|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
32786696|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
32786697|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
32786698|NCT01614886|Experimental|1 step|
32786699|NCT01614886|Active Comparator|3 step|
32786700|NCT04622254|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection.
32786701|NCT04622254|Experimental|MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL|Intramuscular injection.
32786702|NCT04622254|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection.
32786703|NCT04622254|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection.
33086199|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
33086200|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
33086201|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
33403777|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
32786704|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
32786705|NCT04171726|Experimental|Edoxaban|treatment with edoxaban
32786706|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
32786707|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
32786708|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
32786709|NCT04702737|Experimental|Part 1: Dose Exploration|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
32786710|NCT04702737|Experimental|Part 2: Dose Expansion|Participants will received the recommended phase 2 dose (RP2D) identified in Part 1 (dose exploration) of the study.
32786711|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
32786712|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
32786713|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
32786714|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
32786715|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
32786716|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
32786717|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
32786718|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
32786719|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
32786720|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
32786721|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
32786722|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
32786723|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
32786724|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
32786725|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
32786726|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
32786727|NCT04611568|Experimental|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
33086202|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
33086203|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
33086204|NCT00240188|Other|1|
33086205|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
33086206|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
33086207|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
33086208|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
33086209|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
33293710|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
32786728|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
33293711|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
33293712|NCT01084408|Active Comparator|Sequent®Please|
33293713|NCT01084408|Active Comparator|Taxus™Liberté™|
33293714|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
33293715|NCT01079494|No Intervention|control|physician only team
33293716|NCT00098254|Experimental|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
33293717|NCT00095056|Experimental|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
33293718|NCT00095056|Placebo Comparator|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
32786729|NCT01926886|Experimental|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
33293719|NCT03962764||Incarcerated|Incarcerated fathers include fathers recruited in re-entry centers, detention facilitation and in county jails.
33293720|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals.
33293721|NCT00098020|Experimental|Isotretinoin|Subjects will be treated with Isotretinoin.
33293722|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
33293723|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
33293724|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
33293725|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
32939379|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
33293726|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
33293727|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
33293728|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
33293729|NCT04546568|Experimental|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
33293730|NCT04546568|Active Comparator|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
33293731|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
33293732|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
33293733|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
33293734|NCT01050374|Active Comparator|2|mebendazole + praziquantel
33293735|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
33293736|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
33293737|NCT03990116|Experimental|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
33293738|NCT03990116|Active Comparator|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
33293739|NCT01053416|No Intervention|observation|
33293740|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
33293741|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
33403778|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
33403779|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
33086210|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
33293742|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.~(Screening period July 1, 2015-June 30, 2016)~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
33293743|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
33293744|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
33293745|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
33293746|NCT00380978|Active Comparator|late analgesia (systemic)|
33293747|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
33293748|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
33293749|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
33293750|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
32786730|NCT01926886|No Intervention|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
32786731|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
33293751|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
33293752|NCT00162123|Experimental|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
33293753|NCT00162123|Experimental|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
33293754|NCT00162123|Experimental|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
33293755|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
33403780|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
32786732|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
33403781|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
33403782|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
33403783|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
32786733|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
32786734|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
32786735|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
32786736|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
32786737|NCT01925950|Placebo Comparator|Placebo|Control
32786738|NCT01925950|Experimental|orBec|Investigational drug
32786739|NCT04415320|Experimental|X-396(Ensartinib) Capsule|
32786740|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
32786741|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
32786742|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
32786743|NCT01908634|Active Comparator|Milk-based Strawberry Beverage no meal|Milk-based Strawberry beverage without meal
32786744|NCT01908634|Experimental|Water-based Strawberry Beverage no meal|Water-based Strawberry beverage without meal
32786745|NCT01908634|Active Comparator|Milk-based strawberry Beverage with meal|Milk-based Strawberry beverage with meal
32786746|NCT01908634|Experimental|Water-based strawberry Beverage with meal|Water-based Strawberry beverage with meal
32786747|NCT01878214|Experimental|Intervention group|Targeted messaging
32786748|NCT01878214|Active Comparator|Control group|Standard messaging
32786749|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
32786750|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
32786751|NCT02480153|Experimental|PF-06410293|
32786752|NCT02480153|Active Comparator|Adalimumab|
32939380|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
32939381|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
32939382|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
32939383|NCT04777214|Active Comparator|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
32939384|NCT04777214|Sham Comparator|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
32939385|NCT04749810||Elizaria®|Eculizumab
32939386|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
32939387|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
32939388|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
32939389|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
32939390|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
32737653|NCT05049681|Active Comparator|SHR-1210（Camrelizumab）|SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.
32737654|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
32737655|NCT05038215|Experimental|multifactor intervention|The experimental group will receive adherence promotion techniques in addition to routine care.
32737656|NCT05038215|Active Comparator|Control|The control group will receive routine care
32737657|NCT05038449|Experimental|Colchicine group|"The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.~+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)."
32737658|NCT05038449|Placebo Comparator|Standard therapy group|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).
32737659|NCT05038059|Active Comparator|1. Ethylene diammine tetra acetic acid group|samples will be rinsed with ethylene diamine tetra acetic acid group, which is the gold standard for final rinse and compares with the experimental group.
32737660|NCT05038059|No Intervention|2. Control group|no final irrigant will be used and evaluate the outcomes
32737661|NCT05038059|Experimental|3. Experimental group|final irrigation of root canal will be done with ethanolic extract of sapindus mukorossi
32737662|NCT05232695||metabolically healthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have only high waist circumference without any other metabolic syndrome criteria.
32737663|NCT05232695||metabolically unhealthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have more than one metabolic syndrome criteria (as defined below) including high waist circumference.
32746121|NCT04800549|Experimental|METHOD|The power of the test in the study was calculated by using G*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.
32939391|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
32939392|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
32939393|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
32939394|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
32939395|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
32939396|NCT04448210|No Intervention|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
32939397|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
33086211|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
33086212|NCT01647919|Experimental|cogniVida™ 100 mg/day|
33086213|NCT01647919|Placebo Comparator|Placebo|
33086214|NCT01648036|Experimental|Unfractionated Heparin|
33086215|NCT01648036|Active Comparator|Dalteparin|Standard of care
33086216|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
33086217|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
33403784|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
32786753|NCT04972253|Experimental|Infigratinib|"Infigratinib daily dosage per protocol 3-week on/1-week off schedule. 4 weeks will constitute 1 cycle of therapy.~Participants will receive 2 cycles (i.e. 8 weeks) and the treatment will be administered as an outpatient.~After completion of therapy, patients will undergo a CT of the chest, abdomen and pelvis (within 2 weeks of the last dose of therapy) and then proceed to Radical cystectomy 2-4 weeks after the last dose of therapy."
32786754|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
32786755|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
32786756|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
32786757|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786758|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786759|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786760|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786761|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786762|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
32786763|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
32786764|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
32786765|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
32786766|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
32786767|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
32786768|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
32786769|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
32786770|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
32786771|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
32786772|NCT04629352|Experimental|Verum Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
32786773|NCT04629352|Placebo Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Sham-tDCS, no current will be delivered beyond initial ramp-up time.
32786774|NCT04629196|Experimental|IV Weight-Based Induction Dose|
33086218|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
33086219|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
33086220|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
33086221|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
33086222|NCT01648192|Experimental|20 mg|Losmapimod for single dose
33086223|NCT01648192|Placebo Comparator|Placebo|Placebo
33086224|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
33086225|NCT01648192|Placebo Comparator|Placebo BID|Placebo
33086226|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
33086227|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
32786775|NCT04629196|Active Comparator|Standard Subcutaenous Dose|
32786776|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
32786777|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
32786778|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
32786779|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
32786780|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
32786781|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
32786782|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
32786783|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
32786784|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
32786785|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
32786786|NCT04608682|Experimental|Sugammadex group|
32786787|NCT04608682|Sham Comparator|control group|
32786788|NCT04627870|Experimental|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
32786789|NCT04627870|Active Comparator|PTA group|use PTA balloon to treat intracranial in-stent restenosis
32786790|NCT04619602|Experimental|GSNO therapy|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
32786791|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
32786792|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
32786793|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
32786794|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
33086228|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
33086229|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
33086230|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
33086231|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
33086232|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
33086233|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
32786795|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
32786796|NCT01875250|Experimental|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
32786797|NCT01875250|Experimental|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
32786798|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
32786799|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
32786800|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
32786801|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
32786802|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
32786803|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
32786804|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
33086234|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
33086235|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
33293756|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
33293757|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
32939398|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
33293758|NCT00162123|No Intervention|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
33293759|NCT00227721|Experimental|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
33293760|NCT01074723|Experimental|b-cryptoxanthin|
33293761|NCT01074723|Experimental|phytosterols|
33293762|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
33293763|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
33293764|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
32939399|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
32939400|NCT04456634|Experimental|AL&RUX|"Oral administration of:~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
33293765|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
33293766|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
33293767|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
33293768|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
33293769|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
32786805|NCT02325739|Experimental|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
32786806|NCT02325739|Experimental|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
32786807|NCT02325739|Experimental|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
32786808|NCT02325739|Experimental|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
32786809|NCT02325739|Experimental|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
32786810|NCT02325739|Experimental|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
32786811|NCT02325739|Experimental|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
32786812|NCT02325739|Experimental|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
32786813|NCT02325739|Experimental|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
32786814|NCT02325739|Experimental|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
32786815|NCT02325739|Experimental|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
32786816|NCT04619056|Experimental|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
32786817|NCT04619056|Experimental|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
32939401|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
32939402|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
32939403|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
32939404|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
32939405|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
32939406|NCT03558074|Experimental|Active|ALK4290 800 mg daily
32939407|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
32939408|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
32939409|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
32939410|NCT03562988|Other|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
33293770|NCT00226941|Experimental|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)~Oxaliplatin 100 mg/m², Days 2 and 23"
32786818|NCT04619056|Experimental|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
32786819|NCT05121922|Experimental|Intervention|All patients recieve active treatment
32786820|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
32786821|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
32786822|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
32786823|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
32786824|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
32786825|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
32786826|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
32786827|NCT04415398|Experimental|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:~Operational feasibility (Legislation, Weather conditions, conflict in airspace)~Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)~Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
32786828|NCT05103280|Experimental|Progressive improvement in walking performance|A total of ten patients with peripheral artery disease will be enrolled for this arm and wear the assistive tennis shoes for three-months as an intervention.
32786829|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
32786830|NCT04415476|Other|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
32786831|NCT04415476|Experimental|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects.~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect"
32786832|NCT05112952|Experimental|Part A: Group 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.
33086236|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
33086237|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
33293771|NCT00226941|Experimental|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"Cetuximab 250 mg/m² / week~Capecitabine 700 mg/m²~Radiotherapy (XRT)~Oxaliplatin 85 mg/m², Days 2 and 23"
32786833|NCT05112952|Active Comparator|Part A: Group 2: Normal Hepatic Function|Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.
32786834|NCT05112952|Experimental|Part B: Group 3 (Optional): Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of lazertinib.
32786835|NCT05112952|Experimental|Part B: Group 4 (Optional): Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of lazertinib.
32786836|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
32786837|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
32786838|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.~Celecoxib was not administered in Part B.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
32786839|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
33086238|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
33086239|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
33086240|NCT01648972|Experimental|Gastrografin|
33086241|NCT01648972|Placebo Comparator|Placebo|
33086242|NCT01649011||Scores of the ODI and RMQ for low back pain|
33086243|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
33086244|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
33086245|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL1981, Expiry Date Mar 2015."
33086246|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number G30349, Expiry Date Mar 2015."
32786840|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
32786841|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
32786842|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
33086247|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL0781, Expiry Date Mar 2015."
33086248|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
33293772|NCT00226941|Experimental|Group A - Cetuximab + Capecitabine-800 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)"
32786843|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
32786844|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
32786845|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
32786846|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
32786847|NCT01901848|Active Comparator|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
32786848|NCT04415632|Experimental|LGI Diet|low glycemic index diet
32786849|NCT04415632|Other|HGI Diet|High glycemic index diet
32786850|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
32786851|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
32786852|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
32786853|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
32786854|NCT04606420|Experimental|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks.
32786855|NCT04606420|No Intervention|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. After 20 weeks in the randomized control group, patients who no longer meet these eligibility criteria (e.g, a MoCA score <18) will not cross over and will not receive the lifestyle intervention; their data during the first 20 weeks in the control group (when they met the entry criteria) will be used."
32786856|NCT04415242|Active Comparator|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
32786857|NCT04415242|Experimental|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
32786858|NCT01919398|Experimental|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
32786859|NCT04626154|Active Comparator|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
32786860|NCT04626154|Sham Comparator|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
32786861|NCT02500043|Experimental|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
32786862|NCT02500043|Experimental|Placebo+BSC|Participants received 35 mg/m^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
32786863|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
33086249|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
33086250|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
33086251|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
33086252|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
33086253|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
33086254|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
33086255|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
33086256|NCT01649167||normal weight|Pregnant women with normal weight
33086257|NCT00264264|Active Comparator|Direct Compression|
32786864|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
32786865|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
32786866|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
32786867|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
33086258|NCT00264264|Active Comparator|Closure Device|
33086259|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
32786868|NCT04940663|Other|Ecological Momentary Assessment|EMA collected daily (4x/day) for two weeks
32786869|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
32786870|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
32786871|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
32786872|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
32786873|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
32786874|NCT04970225|Experimental|Stable state|"45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With severe cftr mutations~With or without PA chronic infection~Treated or not with Ivacaftor-Lumacaftor"
32786875|NCT04970225|Experimental|Starting Ivacaftor-Tezacaftor-Elexacaftor|"40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With at least one severe cftr mutation~With or without PA chronic infection~Initiating Ivacaftor-Tezacaftor-Elexacaftor"
32786876|NCT04970225|Experimental|Exacerbation|15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation
32786877|NCT04939883|Experimental|Intervention Group|Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.
32786878|NCT04939883|Placebo Comparator|Control Group|Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
32786879|NCT04969367||Observational (activity monitor)|Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
32786880|NCT04968353|Active Comparator|Incisally-beveled|Use of incisally-beveled attachment to extrude lateral incisor
32786881|NCT04968353|Active Comparator|Gingivally-beveled|Use of gingivally-beveled attachment to extrude lateral incisor
32786882|NCT04968353|Active Comparator|Optimized|Use of optimized attachment to extrude lateral incisor
32786883|NCT04968353|Active Comparator|Horizontal|Use of horizontal (unbeveled) attachment to extrude lateral incisor
32786884|NCT04968119|Experimental|Arm A (telehealth intervention)|Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
32786885|NCT04968119|Active Comparator|Arm B (delayed exercise intervention)|Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
32786886|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
32786887|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
32786888|NCT04701489|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.
32786889|NCT04701489|No Intervention|Control Group|Standard clinical care with no ultrasound stimulation.
32786890|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
33086260|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
33086261|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
32786891|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
33086262|NCT04721210|Experimental|Frequency of 1 Hz|continuous stimulation with a frequency of 1 Hz, 2000 pulses, 10 days-daily;
33086263|NCT04721210|Experimental|Frequency of 10 Hz|continuous stimulation with a frequency of 10 Hz-10 seconds with a pause of 50 seconds, 2000 pulses, 10 days-daily;
33086264|NCT04721210|Placebo Comparator|Continuous stimulation placebo|continuous stimulation placebo
33086265|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
33293773|NCT00226941|Experimental|Group B - Cetuximab + Capecitabine-1000 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 1000 mg/m²~Radiotherapy (XRT)"
33293774|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
33293775|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
33293776|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
33293777|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
32786892|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
32786893|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
32786894|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
32786895|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
32786896|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
32786897|NCT04939727|Experimental|OUD-CDS + Suicide Risk Model associated CDS (Intervention arm)|Providers that practice in the clinics in this intervention arm will receive access to the OUD-CDS + Suicide Risk Model associated CDS, for all eligible encounters.
32786898|NCT04939727|No Intervention|Control|"Providers that practice in the clinics in this control arm will not receive any access to the OUD-CDS + Suicide Risk Model associated CDS, however these clinical decision-support tools will run silently in the background, collecting data on eligible encounters."
32786899|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
32786900|NCT02065557|Experimental|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
32786901|NCT02065557|Experimental|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
32786902|NCT02065557|Experimental|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
32786903|NCT02065557|Placebo Comparator|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
32786904|NCT02065557|Experimental|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg [maximum dose of 40 mg] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
33086266|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
33086267|NCT01649440||Normal control|Healthy volunteers
33086268|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
33086269|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
33293778|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
33293779|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
33293780|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
33086270|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~sepsis with arterial hypotension, despite adequate fluid resuscitation."
32786905|NCT02065557|Experimental|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg [maximum dose of 40 mg] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
32786906|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
33293781|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
33293782|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
33293783|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
33086271|NCT01649440||death|sepsis patients within 48 hours before death.
33086272|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
33086273|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
33086274|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
33086275|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
33086276|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
33293784|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
33293785|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
33293786|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
32786907|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
33086277|NCT00240617|Placebo Comparator|arm 2|placebo to match
33293787|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
33293788|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
33293789|NCT05407649|Experimental|Radiotherapy Combined with GM-CSF|
33293790|NCT05407493||Buccal flap|The buccal flap is slid over the fistula and sutured to the undermined palatal mucosa using horizontal mattress sutures.
33293791|NCT05407493||Double-layer|A combination between a buccal trapezoidal flap and a palatal connective pedicle flap.
33293792|NCT05407493||Buccal flap with L-PRF|A L-PRF plug is interposed between the fistula and the buccal sliding flap.
33293793|NCT05407337|Experimental|Experimental group|Beneficiaries of NET therapy + standard Sindiane program management.
33293794|NCT05407337|No Intervention|Control group|Beneficiaries of the standard care of the Sindiane program.
33293795|NCT05162105|Experimental|Evening shift followed by day shift (Quick Return)|Participants work a simulated evening shift, from 03:00PM to 11:00PM, followed by a simulated day shift, 07:00AM to 03:00PM, the following day.
33293796|NCT05162105|Active Comparator|Day shift followed by day shift|Participants work a simulated day shift, from 07:00AM to 03:00PM, followed by another simulated day shift, from 07:00AM to 03:00PM, the following day.
33293797|NCT03968367|Experimental|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
33293798|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
33293799|NCT01013051||Post Gastric Bypass|
33293800|NCT01013051||Obese Controls|age, BMI, gender matched
33293801|NCT03997955|Experimental|Experimental group|Myofascial induction
32786908|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
32786909|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
32786910|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
32786911|NCT02065245|Experimental|Randomized Phase - Group A|Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
32786912|NCT02065245|Experimental|Randomized phase - Group B|Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
32786913|NCT02065245|Experimental|Randomized Phase - Group C|Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.
32786914|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
32786915|NCT04701021|Experimental|TENDU|Three different doses of the TENDU vaccine are to be investigated: 40, 400 and 960μg.
32786916|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
32786917|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
32786918|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
32786919|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
32786920|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
32786921|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
33293802|NCT03997955|Sham Comparator|Control group|Sham myofascial induction
33293803|NCT00509093|Experimental|Imatinib Mesylate|
33293804|NCT05407103|Experimental|Cold Acupressure Group|"Personal information form (PIF ) , Labor Monitoring Form (LMF), Visual Analog Scale (VAS), and Childbirth Comfort Questionnaire (CCQ) as pre-test during the latent phase before going about the cold acupressure. Next, she applied the cold acupressure pouches on the respective cold group on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Cold group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after cold group to monitor how they were feeling."
32786922|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
33293805|NCT05407103|Experimental|Warm Acupressure Group|"PIF, LMF, VAS, and CCQ as pre-test during the latent phase before going about the warm acupressure. Next, she applied the warm acupressure pouches on the respective warm groups on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Warm group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling."
33293806|NCT05407103|No Intervention|Control Group|The researcher ran PIF, LMF, VAS, and CCQ as pre-test during the latent phase. No intervention was applied to the control group. Last, posttest took place. Control group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling.
32786923|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
32786924|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
32786925|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
32786926|NCT04182555|Experimental|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
32786927|NCT04733079|Experimental|E-mail follow-up group|Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
32786928|NCT04733079|Active Comparator|Usual follow-up group|Adaptation and follow-up of ULT according to referring physician's habits
33293807|NCT05358509|Experimental|IV iron intervention arm 1|Intervention arm 1 involves a single dose of an IV iron formulation - ferric carboxymaltose - given during pregnancy.
32786929|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
33086278|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
33086279|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
33086280|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
32786930|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
32786931|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
33086281|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
33086282|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
33086283|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
33086284|NCT04708743||CKD group|patients with CKD stage 3-5 including dialysis, followed tongue images by Automatic Tongue Diagnosis System
32786932|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
33086285|NCT04708743||Health group|patients who had no past history or systemic disease, CKD followed tongue images by Automatic Tongue Diagnosis System
32786933|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
32786934|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
32786935|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
32786936|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
32786937|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
32786938|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
32786939|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
33086286|NCT01649908||sectional cross clamping|
33086287|NCT01649908||simultaniously cross clamping|
33086288|NCT01649908||EVAR|
33086289|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
33086290|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
33086291|NCT01645696|Experimental|BD Continuous Glucose Monitor (CGM) with outer layer|A subcutaneous glucose binding protein sensing device to continuously monitor glucose in diabetics.
33086292|NCT01645696|Experimental|BD CGM without outer layer|A continuous glucose binding protein sensing device used to monitor glucose in Diabetics
33293808|NCT05358509|Experimental|IV iron intervention arm 2|Intervention arm 2 involves a single dose of an IV iron formulation - iron isomaltoside - given during pregnancy.
33293809|NCT05358509|Active Comparator|Active comparator|Participants randomly assigned to the active comparator arm will receive oral iron tablets to take daily, which is the current standard of care.
32786940|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
32786941|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
32786942|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
33086293|NCT01645696|Active Comparator|Medtronic iPro 2 Professional CGM|Commercial glucose oxidase continuous glucose monitor
33086294|NCT01647451|Experimental|Active|
33086295|NCT01647451|Placebo Comparator|Placebo|
33086296|NCT00250575|Experimental|1|
33086297|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
33086298|NCT04528381|Other|Laparoscopy|Diagnostic and therapeutic laparoscopy
33086299|NCT04528186||1|Low eating index scores(50-70)
33086300|NCT04528186||2|High eating index scores(Above 70)
33086301|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
33086302|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
33086303|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
33086304|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
33086305|NCT04720248||Metamizol postoperatively|Patients submitted to scheduled craniotomy receiving metamizol as analgesic medication postoperatively
32939411|NCT03562988|Other|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
33293810|NCT05406869|Experimental|pulsed sonic balloon dilatation catheter and pulsed sonic generater|All subjects will receive treatment from the pulsed sonic balloon dilatation catheter
33293811|NCT00160641|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
33293812|NCT04544501|Experimental|Culturally-Targeted Video|
33293813|NCT04544501|Active Comparator|FORCE Fact Sheet|
33293814|NCT03997331|Experimental|Intervention|"Subjects in the Intervention arm will receive the following:~Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).~Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.~Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).~Push notifications that alert the subject that they have missed a scheduled regimen event.~In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
33293815|NCT03997331|Active Comparator|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
33293816|NCT00493025|Experimental|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
33293817|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
33293818|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
32939412|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
32939413|NCT04713956|Experimental|G-CSF+DAC+BF|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
33293819|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
33293820|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
32939414|NCT04713956|Active Comparator|G-CSF+DAC+BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 to -2.
32939415|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
32939416|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
32939417|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
32939418|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
32939419|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
32939420|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
32939421|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
32939422|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
32939423|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
32939424|NCT04734782||Protective Mothers (high IGG titers)|Protected group Newborns with congenital heart disease + high titers of anti-RSV IGG in the mother's serum before birth
32939425|NCT04734782||Non-protective mothers (low IGG titers)|Unprotected group Newborn with congenital heart disease + negative anti-RSV IGG titers in the mother's serum before birth.
32939426|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
32939427|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
32939428|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
33318402|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
32939429|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and blood flow was measured. The other forearm was used as the control.
32939430|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
33086306|NCT04720248||Paracetamol or other analgesics postoperatively|Patients submitted to scheduled craniotomy receiving paracetamol or other drugs as analgesic medication postoperatively
33293821|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
33293822|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
33293823|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
33293824|NCT03972267|Sham Comparator|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
33293825|NCT03972267|Experimental|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
33293826|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
33293827|NCT01073319|Active Comparator|Rivastigmine 3 mg|
32939431|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse. The other forearm was used as the control.
33293828|NCT01073319|Active Comparator|Rivastigmine 6 mg|
33293829|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
33293830|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
32939432|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
32939433|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
33293831|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
33293832|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
33293833|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
32939434|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
32939435|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
32939436|NCT03572972||Patients prescribed apixaban|
32939437|NCT03572972||Patients prescribed dabigatran|
32939438|NCT03572972||Patients prescribed rivaroxaban|
32939439|NCT03572972||Patients prescribed warfarin|
32939440|NCT03572972||Patients prescribed antiplatelet|
32939441|NCT05314790||control group (CG)|Without intervening Educational Program
33293834|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
33293835|NCT00380744|Experimental|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
33318403|NCT04303390|Active Comparator|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
32786943|NCT04700163|Experimental|S1 - low dose|100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
33318404|NCT04303390|Active Comparator|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
32746122|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
32746123|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
32746124|NCT04794855||preganant women|observation from 6-8 weeks.
32746125|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
32746126|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
32746127|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
32746128|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
32746129|NCT04794309|Experimental|Experimental Group|The participants will receive circuit training exercise and dietary intervention.
32746130|NCT04794309|Active Comparator|Control group|The participants will be only involved in dietary intervention.
32746131|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
32746132|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
32746133|NCT04794231|Active Comparator|Standard dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
32746134|NCT04794231|Active Comparator|Chlorhexidine gluconate -impregnated dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
32746135|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
32746136|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
32746137|NCT04800081|Experimental|Sacubitril/Valsartan|receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan
32746138|NCT04800081|Active Comparator|Valsartan|receive once-daily treatment with 80-320 mg of Valsartan
32746139|NCT03202979|Experimental|Group 1|Trazodone 20 mg
32746140|NCT03202979|Experimental|Group 2|Trazodone 10 mg
32746141|NCT03202979|Placebo Comparator|Group 3|Placebo
32746142|NCT04799925||Intervention group|Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).
32746143|NCT04799925||Placebo group|Hyperuricemic group will take placebo pills.
32746144|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
32746145|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
32746146|NCT04786431||Controls, CVD, IS, SLE|"Control (n = 85) were taken from the population of the Coimbra and Lisbon, Portugal, regions. They satisfied the criterion that they had never had any CVD- or SLE-related health complaints.~The CVD patients (n = 238) were divided into 6 groups. CVD1 (n = 61) contains individuals who went to the hospital with chest pain but had no indicators for stable angina pectoris, unstable angina pectoris or myocardial infarction.~Acute ischemic stroke (IS) (n = 21) were patients admitted at the emergency room of the Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, who suffered from acute ischemic stroke.~The SLE cohort (n = 104) were patients from Hospital Dr. Fernando Fonseca, Amadora, Portugal."
32746147|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
32746148|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
32746149|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
32746150|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
32746151|NCT04793997|Active Comparator|Verum Microbiome spray group|Daily use of microbiome spray for two weeks
32746152|NCT04793997|Placebo Comparator|Placebo spray group|Daily use of placebo spray for two weeks
32746153|NCT04793997|No Intervention|Household member group|No use of spray
32746154|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
32746155|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
32746156|NCT04786509||ECG sensor|All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests.
32746157|NCT03107273||Diagnostic patient|
32746158|NCT03107273||Control|
32786944|NCT04700163|Experimental|S2 - mid dose|200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
32786945|NCT04700163|Experimental|V1 - low dose|1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
32786946|NCT04700163|Experimental|V2 - mid dose|5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
32786947|NCT04700163|Experimental|V3 - high dose|15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
32786948|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
32786949|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
32786950|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
32746218|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
33293836|NCT00380744|Experimental|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
32746219|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
32746220|NCT04786041||underwent Appendectomy during march-april of 2019|all patients who underwent Appendectomy during the period of march-april of 2019
32746221|NCT04786041||underwent Appendectomy during march-april of 2020 (during covid pandemic)|all patients who underwent Appendectomy during the period of march-april of 2020 (during the COVID19 pandemic lockdown)
32746222|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
32746223|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
32746224|NCT04346979|Experimental|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
33293837|NCT00380744|Experimental|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
33318405|NCT04303390|Active Comparator|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
32746225|NCT04346979|Experimental|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
32746226|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
32746227|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
32746228|NCT05615337|Experimental|Mindfulness-based stress reduction - MBSR|Traditional MBSR curriculum
32746229|NCT05615337|Active Comparator|Health Promotion Program - HPP|the HPP has the same structure of MBSR, but training different components, not including mindfulness practice.
32746230|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
32746231|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
32786951|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
32786952|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
32786953|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
32786954|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
32786955|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
32786956|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
32786957|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
32786958|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
32786959|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
32786960|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
32786961|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
32786962|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.
32786964|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
32786965|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
32786966|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
32786967|NCT01645111|Active Comparator|Clevidipine|
32786968|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
32786969|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
32786970|NCT01919164|Placebo Comparator|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
32786971|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
32786972|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
32786973|NCT01919164|Experimental|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
32786974|NCT01919164|Placebo Comparator|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
32786975|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
32786976|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
32786977|NCT05109676|Experimental|Patients having embryo transfert|Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
32786978|NCT01901146|Experimental|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
32786979|NCT01901146|Active Comparator|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
32786980|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
32786981|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
32786982|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
32900633|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
32900634|NCT05327400||pancreatic cancer patients|pathologically confirmed pancreatic cancer patients
33086307|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
33086308|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
33086309|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
33086310|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
33086311|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
33086312|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
33086313|NCT01688401|Experimental|IA melphalan|IA melphalan is administered via the basilar artery.
33086314|NCT04708821|Experimental|DEXTENZA|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
33086315|NCT04708821|Active Comparator|Antihistamine|PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
33086316|NCT04708821|Active Comparator|Topical Steroid|ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.
33086317|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
33086318|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
33086319|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
33086320|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
33086321|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
33086322|NCT05140681|Experimental|apical group|FibReORS with apically flap positioning 2 mm below the bone crest (apical group)
33086323|NCT05140681|Active Comparator|Crestal group|FibReORS with apically flap positioning at the level of bone crest (crestal group).
33086324|NCT00240851|Experimental|001|acetaminophen extended release
33086325|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
33293838|NCT00380744|Experimental|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
33293839|NCT00380744|Placebo Comparator|Placebo|IV, once weekly x 4 wks
33293840|NCT01050452|Placebo Comparator|1|albendazole treatment
33293841|NCT01050452|Active Comparator|2|mebendazole treatment
33293842|NCT01050452|Active Comparator|3|ivermectin treatment
33293843|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
33293844|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
33293845|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
33293846|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
32737664|NCT01236547|Experimental|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
32900635|NCT05327400||healthy people|people without no neoplastic lesions and other organic diseases
33086326|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
33086327|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
33293847|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
33293848|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
33293849|NCT03990038|Active Comparator|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
33293850|NCT03990038|Active Comparator|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
33293851|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
33293852|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
33086328|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
33086329|NCT05140603||Cases|Patients who received a doravirine-based regimen.
33086330|NCT04708977|Active Comparator|Group 1: Indirect Decompression|Lateral lumbar interbody fusion (LLIF), with indirect decompression
33086331|NCT04708977|Active Comparator|Group 2: Direct Decompression|Lateral lumbar interbody fusion (LLIF), with direct decompression
33086332|NCT05140486|Experimental|Shortwave diathermy and perceptual training|The subjects in this group will receive shortwave diathermy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks after endoscopic optic nerve decompression surgery.
32786983|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
32786984|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
32786985|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
33086333|NCT05140486|No Intervention|Nonrehabilitation|The subjects in the nonrehabilitation group will not only receive any rehabilitation therapy after endoscopic optic nerve decompression surgery.
33086334|NCT05140447|Active Comparator|Admira 50º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 50º C
33086335|NCT05140447|Active Comparator|Admira 70º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 70º C
32786986|NCT04420351|Experimental|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
32786987|NCT04420351|Other|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
32786988|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33086336|NCT05140447|Active Comparator|Viscalor 50º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 50º C
33086337|NCT05140447|Active Comparator|Viscalor 70º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 70º C
33086338|NCT01688713|Experimental|Icotinib,Brain metastases|
32786989|NCT04604314|Experimental|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
32786990|NCT04604314|Experimental|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
32786991|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
32786992|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
32786993|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
32786994|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
32786995|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
32786996|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
32786997|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
32786998|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
32786999|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
32787000|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
33086339|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
33086340|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
32787001|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
32787002|NCT04967495|Experimental|TACE-MKI-I|TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy
32787003|NCT04967495|Active Comparator|TACE-MKI|TACE combined with sorafenib/lenvatinib
32787004|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
32787005|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
32787006|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
32787007|NCT01653743|Experimental|MSJ-0011|
32787008|NCT01653743|Active Comparator|urinary hCG|
32787009|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
32787010|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
32787011|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
32787012|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
32787013|NCT04206215|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
32787014|NCT04206215|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
32787015|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
32787016|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
32787017|NCT04888273|Experimental|All adolescents and parents who meet the eligibility criteria|The adolescents and parents will be invited to participate in a 5-component intervention that will hopefully empower and prepare the pair for the transition to adult care.
32787018|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
32787019|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
33086341|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
32787020|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
32787021|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
33086342|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
33086343|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
33086344|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
32787022|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
32787023|NCT01646827|Experimental|Deltoid|Deltoid injection site
32787024|NCT01646827|Experimental|Gluteal|Gluteal injection site
32787025|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
32787026|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
32787027|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
32900636|NCT05327244|Experimental|Intervention|All CAI participants will complete the same intervention and will walk 6, 1-mile paths in the real wold (ie: around campus) with vibration feedback within 2 weeks of baseline assessment. A study team member will accompany each participant during each training.
33293853|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
33293854|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
33293855|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
33293856|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
33293857|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
33293858|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
33086345|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
33293859|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
33293860|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
33293861|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
33293862|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
33293863|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
33293864|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
33293865|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
33293866|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
33293867|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
33293868|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
33293869|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
33293870|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
33293871|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
33293872|NCT00355472|Experimental|1|KW-0761
33293873|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
33293874|NCT03282266|Experimental|PADN + 5-phosphodiesterase|A total of 64 patients are assigned to PADN + 5-phosphodiesterase group after randomization schedule.
33293875|NCT03282266|Sham Comparator|Sham operation + 5-phosphodiesterase|A total of 64 patients are assigned to sham operation + 5-phosphodiesterase group after randomization schedule.
33293876|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
33293877|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
33293878|NCT03991754|Experimental|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
33293879|NCT03991754|Placebo Comparator|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
33293880|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
33293881|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
33293882|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
33293883|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
33293884|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
33293885|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
33293886|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
33293887|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
33293888|NCT01010789|Placebo Comparator|Mathing Placebo|
33293889|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
33293890|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
33293891|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
33293892|NCT00508157|Experimental|A|
33293893|NCT00508157|Active Comparator|B|
33293894|NCT04331717|Experimental|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose >5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
33293895|NCT05108441|Other|Echo|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
33293896|NCT01015313|Experimental|intensive sodium management|
33293897|NCT01015313|No Intervention|standard care|
32746232|NCT04798599|Experimental|Intervention|In the intervention group there will be the application of the intervention - use of telemonitoring and teleorientation applied to children in primary care in Dentistry.
33293898|NCT00378560|Placebo Comparator|1|Placebo
33293899|NCT00378560|Experimental|2|Vaccine
33293900|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
33293901|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
33293902|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
33293903|NCT01015391|Experimental|T2|
32746233|NCT04798599|Active Comparator|Waiting list|In the control group, children waiting to be booked to the intervention (in implementation in the unit because of the pandemic) will be evaluated for the outcomes. Only after the evaluation, the control group's children will be invited to perform the teleconsultation (proposed intervention).
32746234|NCT03202199|Experimental|PET/MRI|PET/MRI examination
32746235|NCT04793451|Experimental|Group A|Endurance training
33293904|NCT01015391|Active Comparator|AZA|
33293905|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:~Patient with mild clinical symptoms & clinically table.~CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
33293906|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:~Patient with non-specific and specific respiratory infection (pneumonia).~CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
33293907|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:~Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air).~Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.~CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
33293908|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
33293909|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
33293910|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
33293911|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
33293912|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
33293913|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
33293914|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
33293915|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
33293916|NCT04539899|Experimental|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
33293917|NCT04539899|No Intervention|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
33293918|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
33293919|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
33293920|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
33293921|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
33293922|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
33293923|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
33293924|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
33293925|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
33293926|NCT04302623|Experimental|Online yoga program|An 8-week online live facilitator-led yoga program.
33293927|NCT04302623|Experimental|Control|Advice only group.
33293928|NCT03998267|Active Comparator|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:~Educate/train patients on app usage~Patients will be subscribed to the app and their profile on the app will be created~Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app~Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs~Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes~Throughout the study; patient interaction and app usage will be tracked~Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
32746236|NCT04793451|Experimental|Group B|Endurance-strength training
33293929|NCT03998267|Placebo Comparator|Standard of care arm|"For the subjects not using the app (the standard of care group):~At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care~The educators contact number and diabetes hotline number will be provided to the patients~o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.~Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
33293930|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
33293931|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
33293932|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
33293933|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
33293934|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
33293935|NCT04287569|Experimental|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
33293936|NCT03997565||Patients TKR|
33293937|NCT03997565||Healthy subjects|
33293938|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~Unstable angina~Acute myocardial infarction~Congestive heart failure"
33293939|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
33293940|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
33293941|NCT04275713|Experimental|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
33293942|NCT04275713|Active Comparator|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:~45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week~55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)~4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix~Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
33293943|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
33293944|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
33293945|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
33293946|NCT01013441|Experimental|Treatment Arm|
33293947|NCT01011881||patients with pleuritis|
33293948|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
33293949|NCT04269551|Experimental|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
33293950|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
33293951|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
33293952|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
33293953|NCT04506437|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
33293954|NCT04506437|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
33293955|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
33293956|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
33293957|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
32787028|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
32787029|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
32787030|NCT04894825|Experimental|Dose Escalation Cohort|"Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days)."
32787031|NCT04894825|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, 1~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.
32787032|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
32787033|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
32787034|NCT04880473|Experimental|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
32787035|NCT04880317|Experimental|Single arm|
32787036|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
32787037|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
32787038|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
32787039|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
32787040|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
32787041|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
32787042|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
32787043|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
32787044|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
32787045|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
32787046|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
32787047|NCT04880083|Experimental|Formula-Fed (FF) Group|Subjects will be fed commercial bovine milk-based, whey-predominant, α-lactalbumin-enriched term formula with high sn-2 palmitate fat blend, supplemented with oligofructose for 6 weeks.
32787048|NCT04880083|No Intervention|Breast-Fed (BF) Group|Subjects will continue exclusive/ predominant breastfeeding for 6 weeks. Breastmilk may be consumed directly from the breast or breast milk may be expressed and fed through infant feeding bottle.
32787049|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
32787050|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
32787051|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
32787052|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
32787053|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
32787054|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
32787055|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
32787056|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
33086346|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
32787057|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
32787058|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
32787059|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
32787060|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
32787061|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
32787062|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
32787063|NCT04887337|Active Comparator|Arthroscopic stabilization|Patients will have an initial evaluation with a diagnostic shoulder arthroscopy and examination under anesthesia will be performed to confirm the degree of anterior instability and assess range of motion of the affected shoulder. Diagnostic arthroscopy will commence with the use of 3 standard shoulder portals (posterior viewing and two anterior working portals for suture passing), and a detailed arthroscopic examination will be performed. Once the soft tissue tear (including the labrum, and capsule labrum ligaments) is identified, it will be mobilized using a rasp or elevator and a burr will then be used to create a surface for a bleeding bone bed. Capsulolabral repair will then commence with the labrum fixed to the glenoid using suture anchors (the Bankart repair). Following surgery, subjects in this group will follow the same rehabilitation protocol as the comparison group.
32787064|NCT04887337|Active Comparator|Rehabilitation including a period of immobilization followed by physical therapy|Subjects in this group will use an internal-rotation shoulder immobilizer, using a standard sling for 6 weeks from the day of enrollment. Subjects will be advised to maintain range of motion (ROM) in the elbow and wrist during this period of time. The immobilizer can be removed for passive pendulum exercises and elbow ROM during the period of immobilization up to 4 times per day. Formal physiotherapy commences at 4 weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
32787065|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
33086347|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
33086348|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
33086349|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
33086350|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
33086351|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
33086352|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
33086353|NCT01688947|Placebo Comparator|Placebo|Placebo
33086354|NCT00250731|Experimental|1|Telephone support and behavior change for couples
33086355|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
33086356|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
32787066|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
32787067|NCT04599868|Active Comparator|Low dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h
32787068|NCT04599868|Active Comparator|High dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h
32787069|NCT04414774|Experimental|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
33086357|NCT01689025|Experimental|NNC0114-0006|
33086358|NCT01689025|Placebo Comparator|Placebo|
33086359|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
33086360|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
33086361|NCT01689181||chronic schizophrenic patients|
33086362|NCT01689181||healthy volunteers|
33086363|NCT01689220|Experimental|SP-02L|
33086364|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
33086365|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
33086366|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
33086367|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
33086368|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
33086369|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
33086370|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
33293958|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
33293959|NCT01011959|Active Comparator|1|dose 1 vs. placebo
33293960|NCT01011959|Active Comparator|2|dose 2 vs. placebo
33293961|NCT01011959|Active Comparator|3|dose 3 vs. placebo
33293962|NCT01011959|Active Comparator|4|dose 4 vs. placebo
33293963|NCT01011959|Active Comparator|5|dose 5 vs. placebo
33293964|NCT01011959|Active Comparator|6|dose 6 vs. placebo
33293965|NCT00503867|Experimental|SIR-Spheres microspheres|SIR-Spheres microspheres
32787070|NCT04414774|Active Comparator|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
33293966|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
33293967|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
32787071|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
32787072|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
32787073|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
33293968|NCT04266353|Experimental|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
33293969|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
33293970|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
32787074|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
33293971|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
33293972|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
33293973|NCT00506519|Experimental|AT-150|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 125-175%
33293974|NCT00506519|Experimental|AT-250|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 225-275%
33293975|NCT00506519|Active Comparator|Control|The best standard treatment for the underlying condition only
33293976|NCT00503009|Active Comparator|Arm 1|
33293977|NCT00503009|Active Comparator|Arm 2|
32787075|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
32787076|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
32787077|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
32787078|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
33293978|NCT00503009|Placebo Comparator|Arm 3|
33293979|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
33293980|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
33293981|NCT00160251|Active Comparator|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
33293982|NCT00160251|Active Comparator|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293983|NCT00160251|Experimental|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293984|NCT00160251|Experimental|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
32787079|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
32787080|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
32787081|NCT01615822|Placebo Comparator|Placebo|Placebo
32787082|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
32787083|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
32787084|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
32787085|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
32787086|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787087|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787088|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787089|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787090|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787091|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
32787092|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
32787093|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
32787094|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
33086371|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
33086372|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
33086373|NCT02272075|Active Comparator|active colposcope|Mobile OCT M3 scope
33086374|NCT02272075|No Intervention|Standard of Care|Standard of Care
32787095|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
32787096|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
32787097|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
32787098|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
33086375|NCT02277106|Experimental|Stage 1 (Double-blind): SAGE 547, Then Placebo|Participants received a 12-hour intravenous (IV) infusion of SAGE 547, at ascending doses of 29, 58, and 86 micrograms per kilogram of body weight per hour (μg/kg/h), 4 hours each, on Day 1 of Stage 1 [Treatment Period 1 (TP 1)]. After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE-547 matching-placebo, on Day 10 of Stage 1 [Treatment Period 2 (TP 2)].
33086376|NCT02277106|Experimental|Stage 1 (Double-blind): Placebo, Then SAGE-547|Participants received a 12-hour IV infusion of SAGE-547 matching-placebo on Day 1 of Stage 1 (TP 1). After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE 547 at ascending doses of 29, 58, and 86 μg/kg/h, 4 hours each, on Day 10 of Stage 1 (TP 2).
33086377|NCT02277106|Experimental|Stage 2 (Open Label): SAGE-547|Participants who completed Stage 1 were invited to receive a 10-hour IV infusion of SAGE 547, at ascending doses of 90 μg/kg/h for 1 hour, 120 μg/kg/h for 1 hour, and 150 μg/kg/h for 8 hours on Day 1 of Stage 2.
33086378|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
33086379|NCT00414804|Active Comparator|Nerve Blocks and PT|
33086380|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
33086381|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
33086382|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
33086383|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
33086384|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
33318406|NCT04303390|Active Comparator|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
32787099|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
32787100|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
32787101|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
32787102|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
32787103|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
32787104|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
32787105|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
32787106|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
32787107|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
33293985|NCT00160251|Experimental|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293986|NCT00160251|Experimental|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293987|NCT00160251|Experimental|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293988|NCT00160251|Experimental|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
33293989|NCT00160251|Experimental|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
33293990|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33293991|NCT00506441|Experimental|1|
33293992|NCT00506441|Placebo Comparator|2|
33293993|NCT04190693|Placebo Comparator|Follow-up|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
33293994|NCT04190693|Experimental|IMCY_0098|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
33293995|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
33293996|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
33293997|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
33293998|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
33293999|NCT04184687|Experimental|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
33294000|NCT04184687|Active Comparator|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
33294001|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
33294002|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
33294003|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
33294004|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
33294005|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
33294006|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
33294007|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
33294008|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
33294009|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
33294010|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
33294011|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
33294012|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
33294013|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
33294014|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
33294015|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
32787108|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
33294016|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
32787109|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
33294017|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
32787110|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
32787111|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
32787112|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
32787113|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
32787114|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
32787115|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
32787116|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
32787117|NCT02289469|No Intervention|Usual care|Usual medication history process
32787118|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
32787119|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
32787120|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
32787121|NCT02317705|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
32787122|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
32787123|NCT02474069|Active Comparator|Secukinumab 4-weekly|
32787124|NCT02317627|Experimental|Cohort 1|KD025 400 mg QD PO for 12 weeks
33294018|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
33294019|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
33294020|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
32787125|NCT02317627|Experimental|Cohort 2|KD025 200 mg BID PO for 12 weeks
32787126|NCT02317627|Experimental|Cohort 3|KD025 400 mg BID PO for 12 weeks
32787127|NCT02517905|Experimental|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
32787128|NCT02517905|Placebo Comparator|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
32787129|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
33294021|NCT03997253|Experimental|blood and urine samples|blood and urine samples at D0, D7, D14, M1, M3, M6 and M12
33318407|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
33318408|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
33318409|NCT05620550|Experimental|ozonated oil|treatment of scar area with ozonated oil
33318410|NCT05620550|Sham Comparator|non ozonated oil|treatment of scar area with non ozonated oil
33318411|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
33318412|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
33086385|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
33086386|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
33086387|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
33086388|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
33086389|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
33086390|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
33294022|NCT03989726|Experimental|High density voltage and fractionation map guided group|"Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.~The mapping should be performed in AF.~First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes < 0.5mV.~A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.~Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.~If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (<0.5mV) should be targeted."
33294023|NCT03989726|Active Comparator|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
32787130|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
33086391|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
33294024|NCT03989804|Experimental|Targeted follow-up|
33086392|NCT01689727|Other|Technetium Tc 99m EC20|
33086393|NCT01689766|Other|Technetium Tc 99m EC20|
33086394|NCT01689805||Patients with atopic dermatitis|
33086395|NCT01689805||Non-atopic controls|
33086396|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
33294025|NCT03989804|No Intervention|Usual practice|Usual practice at the fitness center is self-directed use
33294026|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
33294027|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
33086397|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
33294028|NCT03989648|Active Comparator|Esmarch bandages|
33294029|NCT03989648|Active Comparator|simple leg elevation|
33294030|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
33294031|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
33086398|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
32746237|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
32746238|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
32746239|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
32746240|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
32746241|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
32746242|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
32746243|NCT03201887|No Intervention|Chronic pain|optimal effort
32746244|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
32746245|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
32746246|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
32746247|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
32746248|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
32746249|NCT04798443|Active Comparator|Subureteral endoscopic injection|The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
32746250|NCT04798443|Active Comparator|open ureteral reimplantation (lich-gregoir)|extravesical ureteral reimplantation (lich-gregoir) by open surgery
33294032|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
33294033|NCT00485069|Experimental|Ropinirole Hydrochloride|
33294034|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
33294035|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
33318413|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
33086399|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
33086400|NCT01689922||Control group|1) Standard postoperative rehabilitation program
33086401|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
32746251|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
32746252|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
32746253|NCT05234333||Patients presenting a malaise after the vaccination by any vaccine|
32746254|NCT05234333||Patients presenting any other adverse event after the vaccination by any vaccine|
32746255|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
32746256|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
32746257|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
32746258|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
32746259|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
32746260|NCT02593539|Experimental|Participants recieving nemiralisib|
32746261|NCT00919763|Experimental|CD2027 Ointment 3 mcg/g, twice daily|Participants applied 3 mcg/g CD2027 Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
32746262|NCT00919763|Placebo Comparator|Vehicle Ointment, twice daily|Participants applied Vehicle Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
32746263|NCT05615571||Patients with NBIA who remain without molecular diagnosis|A group of 40 patients with NBIA, who remain without molecular diagnosis
32746264|NCT05615571||Patients with NBIA with identified mutations in genes|A group of patients with 2 frequent forms of NBIA, carrying mutations in genes (already studied in the CHU molecular diagnostic laboratory)
32746265|NCT00306917|Active Comparator|1|DuoFix HA
32746266|NCT00306917|Active Comparator|2|Porocoat porous coated
32746267|NCT05615493|Active Comparator|Group I|Will receive rESWT once weekly for one month
32746268|NCT05615493|Sham Comparator|Group II|Will receive Sham rESWT once weekly for one month
32746269|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
32746270|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
32746271|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
32746272|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
32746273|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
32746274|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
32746275|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
32746276|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
32746277|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
32746278|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
32746279|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
32746280|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
32746281|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
32746282|NCT04389411|Experimental|Montelukast|10mg Oral Montelukast once daily for 60 days
32746283|NCT04389411|Placebo Comparator|Placebo|Placebo.
32746284|NCT04785417|No Intervention|CONTROL GROUP|received conventional occupational therapy program
32746285|NCT04785417|Experimental|STUDY GROUP|received conventional occupational therapy program in addition to using tablet
32746286|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
32746287|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
32746288|NCT04384965|Experimental|Accelerated iTBS|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
33294036|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
33294037|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
33294038|NCT03989336|Experimental|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese primed Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
33294039|NCT03989336|Active Comparator|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
33294040|NCT01054430|Other|Normal|Subjects with normal hepatic function
33294041|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
33294042|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
33294043|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
33294044|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
33294045|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
33294046|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
33294047|NCT03989492|Experimental|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
33294048|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
33294049|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
33294050|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
33294051|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
33294052|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
33294053|NCT00377234|Experimental|1|
33294054|NCT00377234|Active Comparator|2|
33294055|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
33294056|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
33294057|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33294058|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
33294059|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
33294060|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
33294061|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
33294062|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
32746289|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
32746290|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
32746291|NCT04792593|Experimental|Senl-h19 CAR-T|Patients will be treated with Senl-h19 CAR-T cells
32746292|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
32746293|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
32746294|NCT04792671||Perinatal group|females who are pregnancy
32746295|NCT04792671||postpartum group|female who get delivery(from day 1 up to 1 year)
32746296|NCT04785495||Cancer Patients Exposed to Highly Emetogenic Chemotherapy|Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
32746297|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
32746298|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
32746299|NCT04792827||analgosedation group|analgosedation concept
32746300|NCT04792827||historical group|standard historical concept
32787131|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
32787132|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
32787133|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
32787134|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
32787135|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
33086402|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
33086403|NCT01686061||Blepharospasm Survey Group|
33086404|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
32787136|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
32787137|NCT04966169|Experimental|Sonendo GentleWave|Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.
32787138|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
32787139|NCT04965701||Untreated EGFR-mutant advanced non-small-cell lung cancer patients|
32787140|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
32787141|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
33294063|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
33294064|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
33086405|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
33086406|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
33086407|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
33086408|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
33294065|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
33294066|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
33294067|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
33294068|NCT01016327|Experimental|1|
33294069|NCT03996629|Experimental|Pharmacist-managed anticoagulation service|
33294070|NCT03996629|No Intervention|Usual medical care|
32787142|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
32787143|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
32787144|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
32787145|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
33086409|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
33086410|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
33086411|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
33086412|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
33294071|NCT01013909|Experimental|Arm 1|
33294072|NCT01013909|Experimental|Arm 2|
33294073|NCT01013909|Placebo Comparator|Arm 3|
33294074|NCT01013909|Placebo Comparator|Arm 4|
33294075|NCT01013909|Active Comparator|Arm 5|
33294076|NCT03996551|Experimental|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
33294077|NCT03996551|No Intervention|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
33294078|NCT04150445|Experimental|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
32787146|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
32787147|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
32787148|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
32787149|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787150|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787151|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787152|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787153|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787154|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787155|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
32787156|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
32787157|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
32787158|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
32787159|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
33086413|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33294079|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
32787160|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
32787161|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
32787162|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
32787163|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
32787164|NCT02060487|Experimental|Low dose|
32787165|NCT02060487|Experimental|Medium dose|
32787166|NCT02060487|Experimental|High dose|
32787167|NCT04696029|Experimental|Difluoromethylornithine (DFMO)|study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.
32787168|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
32787169|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
32787170|NCT04973085|Experimental|Cold circulated water|Research staff will help position the participant on the bed of the MRI scanner. An adhesive wrap will be applied to the front of the participant's neck. Participants will be in constant communication with study personnel throughout the intervention by means of a 2-way intercom. When ready, the water circulation machine will be turned on. Water will circulate from the machine, through a long set of tubes, to the neck wrap, then back to the machine in a closed-loop system. At the beginning of the intervention, body temperature water will be circulated through the neck wrap. Over 5-10 minutes, the study coordinator and the participant will work together to slowly lower the temperature of the circulated water to identify the lowest tolerable temperature. The participant will be maintained at the lowest tolerable temperature for the remainder of the 2 hour intervention, and can adjust the temperature of the circulated water as often as desired throughout the study.
32787171|NCT04973085|Active Comparator|Body temperature circulated water|The procedure for the body temperature study arm is identical to the cold study arm, except the water temperature will be kept at body temperature for the duration of the 2 hour intervention.
32787172|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
33294080|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
33294081|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
33294082|NCT01019291|Experimental|NO2|NO2 400 µg/m3
32787173|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
32787174|NCT04722783|Experimental|ESDM and PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months PCIT-A for 8 months (see Study Protocol, Figure 2).
32787175|NCT04722783|Experimental|ESDM and active control for PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months 1h-ESDM as active control instead of 1h-PCIT-A for 8 months
32787176|NCT04722783|Experimental|PCIT-A and active control for ESDM|Participants receive after 4 month PCIT-A for 8 months and early special needs education as an active control for ESDM.
32787177|NCT04722783|Active Comparator|Active control for ESDM and PCIT-A|Participants receive early special needs education as an active control for ESDM and PCIT-A.
32787178|NCT04721925|No Intervention|Control group|Link to an educational website about alcohol; link to resources.
32787179|NCT04721925|Experimental|Social media messaging|Health coaching via social media for 8 weeks
33294083|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
32787180|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
32787181|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
33403785|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
32787184|NCT04417647|Experimental|Group 1|Proximal wound SoC treatment - Distal wound VZ application
32787185|NCT04417647|Experimental|Group 2|Distal wound SoC treatment - Proximal wound VZ application
32787186|NCT01897714|Experimental|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
32787187|NCT01897714|Experimental|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
32787188|NCT01897714|Experimental|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
33294084|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
33294085|NCT01019291|Placebo Comparator|Placebo|
33294086|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
33294087|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
33294088|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
33294089|NCT00490529|Experimental|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
33294090|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
33294091|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
33294092|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
32787189|NCT01897714|Experimental|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
32787190|NCT01897714|Experimental|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
32787191|NCT01897714|Experimental|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
32787192|NCT05131737|Experimental|Constant work-rate at altitude 2500 m above sea level (high altitude)|Cycling at high altitude
32787193|NCT05131737|Active Comparator|Constant work-rate at altitude 470 m above sea level (low altitude)|Cycling at low altitude
32787194|NCT04732065|Experimental|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
33294093|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
32787195|NCT04732065|Experimental|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
32787196|NCT04732065|Experimental|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
32787197|NCT04732065|Experimental|Arm D: ONC206 Therapy, Primary malignant CNS tumors with progression|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
32787198|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
32787199|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
32787200|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
32787201|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
32787202|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
32787203|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
32787204|NCT04618744|Placebo Comparator|Placebo|Fish oil
32787205|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
32787206|NCT01896934|Experimental|Sertraline|50-200mg daily
32787207|NCT02039505|Placebo Comparator|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
32787208|NCT02039505|Experimental|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
32787209|NCT02039505|Experimental|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
32787210|NCT02039505|Experimental|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
32787211|NCT02039505|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
32787212|NCT02039505|Placebo Comparator|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
32787213|NCT02039505|Experimental|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
32787214|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
32787215|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
32787216|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
32787217|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
32787218|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
33294094|NCT00490451|Experimental|LY573636|
33294095|NCT01019603|Experimental|1|Tazarotene foam 0.1%
33294096|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
33294097|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
33294098|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
33294099|NCT00339144|Experimental|Dasatinib (100 mg)|
32787219|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
32787220|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
32787221|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
32787222|NCT01896856|Experimental|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
33294100|NCT00339144|Experimental|Dasatinib (150 mg)|
33294101|NCT00339144|Experimental|Dasatinib (200 mg)|
32787223|NCT01896856|Experimental|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
32900637|NCT05327244|No Intervention|Healthy Control|Posttest data from CAI participants will be compared to de-identified healthy control data collected as part of a previous study. Healthy control participants completed a single research session to collect walking biomechanics using the same methods as this project. They received no further follow up or intervention and the inclusion/ exclusion criteria for this group match those of the chronic ankle instability cohort.
33294102|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
33294103|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
33294104|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
33294105|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
33294106|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
33294107|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
33294108|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
33294109|NCT00332202|Experimental|A|
33294110|NCT00332202|Placebo Comparator|B|
33294111|NCT01061658|Experimental|Vaccine - High dosage|
33294112|NCT01061658|Experimental|Vaccine - Lower dosage|
33294113|NCT01061658|Placebo Comparator|Placebo|
33294114|NCT03982836|Experimental|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
33294115|NCT03982836|Experimental|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
33294116|NCT03982836|Placebo Comparator|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
33294117|NCT01058382||Progesterone Vaginal Suppositories|
33294118|NCT01058382||Intramuscular Progesterone-in-Oil|
33294119|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
33294120|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
33294121|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
33294122|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
33294123|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
33294124|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
33294125|NCT03983928|Experimental|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
33294126|NCT01058538|Experimental|L19IL2|
33294127|NCT00321672|Experimental|NGX-4010, 60 minutes|
33294128|NCT00321672|Experimental|NGX-4010, 30 minutes|
33294129|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
33294130|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
33294131|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
33294132|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
33294133|NCT03985566|Experimental|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
33294134|NCT03985566|Placebo Comparator|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
33294135|NCT00321048|Experimental|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
33294136|NCT00321048|No Intervention|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
33294137|NCT00330174|Experimental|1|Acamprosate tablets
33294138|NCT00330174|Placebo Comparator|2|Matching placebo tablets
33294139|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
33086414|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33294140|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
33294141|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
33294142|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
33294143|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
33294144|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
33294145|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
33294146|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
33294147|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
33294148|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
33294149|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
33294150|NCT03981666|Experimental|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
33294151|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
33294152|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
33294153|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
33294154|NCT00375674|Experimental|A|
32787224|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
32787225|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
33294155|NCT00375674|Placebo Comparator|B|
33294156|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
33294157|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
33294158|NCT03991910|Placebo Comparator|control|control patients will be given a placebo
33294159|NCT03991910|Experimental|treatment|Ramipril 5 mg treatment group
33294160|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
33294161|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
33294162|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
33294163|NCT01050920||Blood Collection|
33294164|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
33294165|NCT02534402|No Intervention|Control Group|no treatment
33294166|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
33086415|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33086416|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33086417|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33086418|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33294167|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
33294168|NCT03982524|Experimental|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
33294169|NCT03982524|Active Comparator|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
33294170|NCT01063608|Experimental|Anti-H1N1v Vaccine|
33294171|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
33294172|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
33294173|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
33294174|NCT01060722|Experimental|MOD-4023, dose level 1|
33294175|NCT01060722|Experimental|MOD-4023, dose level 2|
33294176|NCT01060722|Experimental|MOD-4023, dose level 3|
33294177|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
33294178|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
33294179|NCT03987698|Experimental|Arm 1: CIK+PD-1i|"SHR-1210 & CIK cells~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
33294180|NCT03987698|Active Comparator|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
33294181|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
33294182|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
33294183|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
33294184|NCT03989258|Active Comparator|Cohort 1|High monogenic breast cancer risk
33294185|NCT03989258|Active Comparator|Cohort 2|High polygenic breast cancer risk
33294186|NCT03989258|No Intervention|Cohort StMG|Standard mammography screening in age 50-69
33294187|NCT03989960|Experimental|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
33294188|NCT03989960|Active Comparator|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
33294189|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
33294190|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
33294191|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
33294192|NCT01054508|Other|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
33294193|NCT01054508|Other|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
33294194|NCT01054664||impaired liver enzymes|
33294195|NCT01054664||normal liver enzymes|
33294196|NCT01054664||hepatitis C antibodies positive|
33294197|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
33294198|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
33294199|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
33294200|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
33294201|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294202|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294203|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294204|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294205|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294206|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294207|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
33294208|NCT03988946|Experimental|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
33294209|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
33294210|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
33294211|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
33294212|NCT03989024|Experimental|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
33294213|NCT03989024|Experimental|Clomiphene|Use Clomiphene for 3 months to treat PCOS
33294214|NCT03988790|Experimental|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
33294215|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
33294216|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
33294217|NCT03987308|Experimental|Beinaglutide|Five-week Beinaglutide pump treatment group
33294218|NCT03987308|Experimental|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
33294219|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
33294220|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
33294221|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
33294222|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
33294223|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
33294224|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
33294225|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
33294226|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
33294227|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
33294228|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
33294229|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
33294230|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
33294231|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
33403786|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
33403787|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
33086419|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33086420|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33294232|NCT03988478|Experimental|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) & psychotherapy
33294233|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
33294234|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
33294235|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
33294236|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
33294237|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
33294238|NCT03991442|Experimental|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
33294239|NCT03991442|Active Comparator|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
33294240|NCT03988556|Experimental|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.~."
33403788|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
33403789|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
33294241|NCT03988556|Experimental|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
33403790|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
33403791|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
33403792|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
33403793|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
32787226|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
32787227|NCT04599556|Experimental|T-ALL|
32787228|NCT04599556|Experimental|T-NHL|
32787229|NCT04599556|Experimental|AML|
32787230|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.~Other name: Ritalin"
33294242|NCT03988556|Experimental|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
33294243|NCT03988556|Experimental|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated."
33294244|NCT03988244|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
33294245|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
33403794|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
32787231|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
32787232|NCT02352493|Active Comparator|ALN-CC5|
32787233|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
32787234|NCT04879927|Experimental|RESOURCE Matching|Participants randomized into the intervention arm will receive customized resource matching
32787235|NCT04879927|Active Comparator|Usual Care|Participants randomized into the control group will receive a pre-existing pamphlet detailing DFCI resources
32787236|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
32787237|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
32787238|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
32787239|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W|Single-agent LAG525 1 mg/kg Q2W
32787240|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q2W|Single-agent LAG525 3 mg/kg Q2W
32787241|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q2W|Single-agent LAG525 5 mg/kg Q2W
32787242|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q2W|Single-agent LAG525 10 mg/kg Q2W
32787243|NCT02460224|Experimental|Phase 1: LAG525 15 mg/kg Q2W|Single-agent LAG525 15 mg/kg Q2W
32787244|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W|Single-agent LAG525 240 mg Q2W
32787245|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q2W|Single-agent LAG525 400 mg Q2W
32787246|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q4W|Single-agent LAG525 3 mg/kg Q4W
32787247|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q4W|Single-agent LAG525 5 mg/kg Q4W
32787248|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q4W|Single-agent LAG525 10 mg/kg Q4W
32787249|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W|Single-agent LAG525 400 mg Q4W
32787250|NCT02460224|Experimental|Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
32787251|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
32787252|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W|Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
32787253|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
32787254|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
32787255|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
32787256|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
32787257|NCT02460224|Experimental|Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
32787258|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W|Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
32787259|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
33294246|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
33294247|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
32787260|NCT02460224|Experimental|Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
32787261|NCT02460224|Experimental|Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
32787262|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
32787263|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
33294248|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
33294249|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
32787264|NCT02460224|Experimental|Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
33294250|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
33294251|NCT00348140|Placebo Comparator|Arm 3|Placebo
33294252|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
33294253|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
33294254|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
32787265|NCT02460224|Experimental|Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
33294255|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
33294256|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
33294257|NCT04370756|Active Comparator|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
33294258|NCT04370756|Experimental|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
33294259|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
33294260|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
33294261|NCT03988322|Experimental|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
32787266|NCT02460224|Experimental|Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
32787267|NCT02460224|Experimental|Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
32787268|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
32787269|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
32787270|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
32787271|NCT04181307|No Intervention|standard EPIC instantiation|As per standard procedure at NewYorkUniversity Langone Health
32787272|NCT04181307|Experimental|standard EPIC instantiation plus the BE-EHR module.|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
32787273|NCT01858636||Angio-Seal VIP Vascular Closure|
32787274|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
32787275|NCT02058849|Placebo Comparator|Placebo|Placebo
32787276|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
32787277|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
32787278|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
32787279|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32787280|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32787281|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32787282|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
32787283|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
32787284|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
32787285|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
32787286|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
32787287|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
32787288|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
32787289|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
32787290|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
32787291|NCT04618354||T1DM group|The patient was diagnosed with type 1 diabetes (T1DM).
32787292|NCT01895452|Experimental|ALKS 9072, Low Dose|
33086421|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33086422|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
33403795|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
32787293|NCT01895452|Experimental|ALKS 9072, High Dose|
32787294|NCT02094417|Experimental|AMG531 (Dose 1)|
32787295|NCT02094417|Experimental|AMG531 (Dose 2)|
32787296|NCT02094417|Experimental|AMG531 (Dose 3)|
32787297|NCT02094417|Experimental|AMG531 (Dose 4)|
32787298|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
33294262|NCT03988322|Active Comparator|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
33294263|NCT04140695|Experimental|Tradipitant|Oral Capsule
33086423|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
33086424|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
33086425|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
33086426|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
33086427|NCT02218879||Patients with relapsing MS|
33086428|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
33086429|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
33294264|NCT04140695|Placebo Comparator|Placebo|Oral Capsule
33294265|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
33294266|NCT04265105|Active Comparator|standard of care|Short acting beta agonist or inhaled corticosteroids
33294267|NCT04265105|Experimental|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
33294268|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
33294269|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
33294270|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
33294271|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
33294272|NCT03996707|Other|Immediate protected weight-bearing|Immediate protected weight-bearing
33294273|NCT03996707|Other|Traditional non weight bearing|Strict non-weight-bearing
33294274|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
33294275|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
33294276|NCT01016639|Experimental|Chemoradiotherapy|
33294277|NCT00501293|Experimental|1|Methylphenidate Transdermal System
33294278|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
33294279|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
33294280|NCT00482729|Experimental|1|Arm 1: drug
33294281|NCT00482729|Active Comparator|2|Arm 2: active comparator
33294282|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
33294283|NCT00359762|Experimental|Exenatide|
33294284|NCT00359762|Active Comparator|Glimepiride|
33294285|NCT03988010|Experimental|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
33294286|NCT03988010|Placebo Comparator|Placebo group|iv 500 cc %0.9 sodium chloride
33294287|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
33294288|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
33294289|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
33294290|NCT03987152|Other|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
33294291|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
33294292|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
33294293|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
33294294|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
33294295|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
33294296|NCT03987230|Active Comparator|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
33294297|NCT03987230|Active Comparator|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
33086430|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
33086431|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
33086432|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
33086433|NCT02219035||stroke-ischaemic|no interventions
33294298|NCT03987230|Active Comparator|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
33294299|NCT03987230|Active Comparator|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
33403796|NCT05763420|Experimental|SBO with AH Plus Bioceramic Sealer|The teeth will be obturated using a single cone technique with AH Plus Bioceramic Sealer.
33086434|NCT02219035||stroke -haemorrhagic|no intervention
33294300|NCT03987230|Active Comparator|Blephademodex|Participant cleans eyelids with Blephademodex
33294301|NCT03987230|Placebo Comparator|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
33294302|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
33294303|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
33294304|NCT00328926|Active Comparator|Luveris® 75 IU|
33086435|NCT02219035||stroke: not confirmed|no intervention
33086436|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
33086437|NCT02219074|Sham Comparator|Vehicle and laser treatment|
33294305|NCT00328926|Active Comparator|Luveris® 25 IU|
33294306|NCT00328926|Placebo Comparator|Placebo|
33294307|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
33294308|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
33294309|NCT01063686|No Intervention|Insemination cervical cap|
33294310|NCT00319254|Experimental|Advanced breast cancer|
33294311|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
33294312|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
33294313|NCT00347360|Experimental|lisinopril|lisinopril
33294314|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
33294315|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
33294316|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
33294317|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
33294318|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
33294319|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
33294320|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
33294321|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
33294322|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
33294323|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
33294324|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
33294325|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
33294326|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
33294327|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
33294328|NCT03982680|Experimental|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
33294329|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
33294330|NCT01325376|No Intervention|Self directed|
33294331|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
32787299|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
33086438|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
33294332|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
33294333|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
33294334|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
33294335|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
33294336|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
33294337|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
33294338|NCT03982290|Active Comparator|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
33294339|NCT03982290|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
33294340|NCT03982290|No Intervention|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
32787300|NCT04694313|Experimental|OPM|Two types of measurement will be compared (SQUID and OPM) with the reference that constitutes the in-depth recordings (Stereotactic-EEG or SEEG) used to precisely define the region of the brain to be resected in order to cure epileptic patients of their seizures.
32787301|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
33294341|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
33294342|NCT00317772|Experimental|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m^2 by vein Days 1, 8 and 15 of 28 day cycle.~Gefitinib: 250 mg by mouth daily.~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.~Gefitinib: 250 by mouth daily for 28 Days."
33294343|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
33294344|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
33294345|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
33294346|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
33294347|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
33294348|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
32787302|NCT01894516|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
33294349|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
33294350|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
33294351|NCT03985670|Experimental|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
33294352|NCT03985670|Active Comparator|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
33294353|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
33294354|NCT00346268|Active Comparator|Morphine plus Parecoxib|
33403797|NCT05763420|Active Comparator|WVC with resin-based AH Plus Sealer|The teeth will be obturated using warm vertical compaction with resin-based AH Plus Sealer.
33294355|NCT00346268|Active Comparator|Morphine and Placebo|
33294356|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
33294357|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
33294358|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
33403798|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
33403799|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
33403800|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
32787303|NCT01894516|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
32787304|NCT01894516|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
32787305|NCT01894516|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
32787306|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
32787307|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
32787308|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
32787309|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
32787310|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
32787311|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
32787312|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
32787313|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
32787314|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
32787315|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
32787316|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
33086439|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
33086440|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
33086441|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
33086442|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
33086443|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
32787317|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
32787318|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
32787319|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
32787320|NCT02491073||Eslicarbazepine acetate treated|
32787321|NCT02491073||Non-Eslicarbazepine acetate treated|
32787322|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
32787323|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
32787324|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
33403801|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
33403802|NCT04894266|Other|Standard of Care|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
32787325|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
32787326|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
32787327|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
32787328|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
32787329|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
32787330|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
32787331|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
32787332|NCT02489981||Spiriva|Patients with severe persistent asthma
32787333|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.~Lactose breath test; Gut permeability test; Milk test."
32787334|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.~Intervention to be performed:~Lactose breath test; Gut permeability test; Milk test."
32787335|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
32787336|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
32787337|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
32787338|NCT04964063|Other|Sensodyne Fresh Mint Toothpaste|"Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing."
32787339|NCT04204967|Experimental|transdermal fentanyl|transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
32787340|NCT04204967|Active Comparator|IV Remifentanil alone|remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit
32787341|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
33086444|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
33086445|NCT04529512|Experimental|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
32787342|NCT04417335|Experimental|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
32787343|NCT04417335|Placebo Comparator|Placebo|0.9% NaCl
32787344|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
32787345|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
32787346|NCT04417491|Experimental|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
32787347|NCT04417491|Sham Comparator|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
32787348|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
32787349|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
32787350|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
32787351|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
32787352|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
33086446|NCT04529512|Experimental|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
33086447|NCT04529512|Experimental|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
32787353|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
32787354|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
33086448|NCT04529512|No Intervention|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
33086449|NCT04720131|Experimental|Camrelizumab combined with Apatinib and Capecitabine|Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
33086450|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
33086451|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
33086452|NCT02219425|Other|endometrial biopsy|
33086453|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
33294359|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
33294360|NCT03982134|Experimental|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
33294361|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
33294362|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
33294363|NCT01062282||Group 1|
33294364|NCT01324856|Experimental|Pancreaticogastro anastomosis|
33294365|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
33294366|NCT03981042|No Intervention|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
33294367|NCT03981042|Experimental|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
33294368|NCT03985280|Experimental|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
33294369|NCT03985280|Active Comparator|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
33294370|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
33294371|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
33294372|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
33294373|NCT03986840|Experimental|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
33294374|NCT03986840|Active Comparator|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
32787355|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
33294375|NCT03986762|Experimental|Open Label Clav|
33294376|NCT01051700|Experimental|5 mg|GW786034
33294377|NCT01051700|Experimental|10 mg|GW786034
33294378|NCT01051700|Experimental|20 mg|GW786034
33294379|NCT01051700|Placebo Comparator|Placebo|Placebo
33294380|NCT01056458|Active Comparator|Acupressure acupressure|
33294381|NCT01056458|Sham Comparator|sham acupressure|
33294382|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
33294383|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
33294384|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
33294385|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
33294386|NCT01059032|No Intervention|Unenhanced images|
32787356|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
32787357|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
33294387|NCT01059032|Other|Enhanced images|Enhanced images
32787358|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
33294388|NCT03991676|Experimental|Values-Based Behavioral Treatment|
33294389|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
33294390|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
33294391|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
33294392|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
32787359|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
32787360|NCT04967703|Experimental|Ultrasound therapy protocol|Patients in group A received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes).
32787361|NCT04967703|Experimental|Radial shock wave therapy protocol|Patients in group B received radial shock wave therapy protocol with the following parameters: (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz.
32787362|NCT04967703|Experimental|Combined therapy protocol|Patients in group C received a combination of both ultrasound therapy and radial shock wave therapy protocol.
32787363|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
32787364|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
32787365|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
32787366|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
32787367|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
32787368|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
32787369|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
32787370|NCT04731831||Patient with arthritis starting infliximab or adalimumab|Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
32787371|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
32787372|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
32787373|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
32787374|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
33086454|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
33086455|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
33086456|NCT02219620|Active Comparator|Social Control|social control/interaction group
33294393|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
33294394|NCT00316602|Experimental|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
33294395|NCT00316602|Experimental|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD [SCORAD] <= 30), receiving two doses of MVA-BN (IMVAMUNE)"
32787375|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
33086457|NCT00241670|Experimental|5-aminolevulinic acid|
33086458|NCT00241670|No Intervention|Conventional resection|
33294396|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
33294397|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
33294398|NCT03983304|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
32787376|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
32787377|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
32787378|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
32787379|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
32787380|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
33403803|NCT04894266|Experimental|Standard of Care plus apabetalone|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
32787381|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
32787382|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
32787383|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
32787384|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
32787385|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
32787386|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
32787387|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
32787388|NCT04963439|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as final market image (FMI) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of macitentan as the clinical service formulation (CSF) in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
33086459|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33086460|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
33086461|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
33086462|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
33403804|NCT04872426|Experimental|Low intensity exercise|70% of maximal leg work load capacity
32787389|NCT04963439|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
32787390|NCT04939103||1|Those patients with rectal cancer after neoadjuvant treatment and completed the examination of TRUS-FNA, TRUS, CT, MR, enteroscopy and superficial biopsy
32787391|NCT04937777||Group pre-2010|Patients who initiated first-line treatment between 2004 and 2010 (pre-2010).
32787392|NCT04937777||Group post-2010|Patients who initiated first-line treatment between 2011 and 2018 (post-2010).
32787393|NCT04962581||Group 1 : Covidien|This cohort will be monitored with the Covidien capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
32787394|NCT04962581||Group 2: General Électrique|This cohort will be monitored with the General Electrique capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
32787395|NCT04961957|Active Comparator|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
32787396|NCT04961957|Active Comparator|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
32787397|NCT01855126|Experimental|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
33086463|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
33086464|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33086465|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33086466|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33086467|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33086468|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33294399|NCT03983460|Experimental|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
33086469|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
33086470|NCT04720170|Other|Single Arm|This is a 26 week, single arm, single-site, Investigator-initiated, exploratory trial evaluating the efficacy of the standard of care revascularization of the lower extremity with the addition of revascularization of the lateral plantar artery and anterior pedal loop of the foot as treatment for participants with PAD, diabetic neuropathy and have a clinical diagnosis of type 1 or type 2 diabetes whose main symptoms are numbness and/or tingling of the feet with or without pain.
33086471|NCT00241748||1|Rhabdomyolysis Case Subjects
33086472|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
33294400|NCT03983460|Active Comparator|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
33294401|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
33294402|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
33294403|NCT00346034|Experimental|1|
33294404|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
33294405|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
33294406|NCT01052090|Experimental|Lifestyle counseling|
33294407|NCT01056692|Active Comparator|Active compound|OC000459 orally
33294408|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
33294409|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
33294410|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
33294411|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
33294412|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
33294413|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
33294414|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
33294415|NCT03991364|Experimental|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
33294416|NCT03991364|Other|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
33294417|NCT03985436|Experimental|Trek for Surgical Success|Cognitive behavioral therapy for pain
33294418|NCT03985124|Experimental|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
33294419|NCT03985124|No Intervention|wait list control|24 kindergartens will be in the 12-month wait list condition
33294420|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
33086473|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
33086474|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
33086475|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
33086476|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
32787398|NCT01855126|Placebo Comparator|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
32787399|NCT04937699|Active Comparator|Standard-DAPT of Ticagrelor plus aspirin (DAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and continue to receive standard-DAPT till 1 year in this arm after as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1month; Ticagrelor 90mg bid+Aspirin 100mg qd for another 11 months;"
32787400|NCT04937699|Experimental|Sequential monotherapy of Ticagrelor and Clopidogrel (SAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and switch to ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 90mg bid, for 5 months; clopidogrel 75mg qd, for 6 months."
32787401|NCT04717479|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
32787402|NCT04717479|Other|Wait-list Control|Participants will wait 8 weeks and then they will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
32787403|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
32787404|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
32787405|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
32787406|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
32787407|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
32787408|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
32787409|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
33086477|NCT02210650|Other|Symptomatic stone removal|Group 1 will receive the standard treatment of having only the symptomatic stone removed
33086478|NCT02210650|Other|Asymptomatic kidney stones and symptomatic stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the symptomatic stone
33086479|NCT04720014|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training.
33086480|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
33086481|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
33086482|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
33086483|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
33294421|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
33294422|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
32787410|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
32787411|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
32787412|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
32787413|NCT04960865|Experimental|Experimental Group|Participants will be applied Kinesio tape with 50% tension.
33086484|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
33086485|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
33086486|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
33086487|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
33294423|NCT02533076|Other|Healthy volunteers|Healthy volunteers
33294424|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
33294425|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
33294426|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
33294427|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
32787414|NCT04960865|Sham Comparator|Sham Group|Participants will be applied Kinesio tape without any tension.
32787415|NCT04960865|Placebo Comparator|Placebo Group|Participants will be applied rigid tape without any tension
32787416|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
32787417|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
32787418|NCT02469623|Experimental|Dipole Density Mapping|
32787419|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
32787420|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
32787421|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
32787422|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
33294428|NCT03991598|Experimental|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
32787423|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
32787424|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
33294429|NCT03991598|No Intervention|control|During the first 6 months and throughout CTRL time
33294430|NCT03991520|Experimental|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
33294431|NCT03991520|Placebo Comparator|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
33294432|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
33294433|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
33294434|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
33294435|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
33294436|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
33294437|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
33294438|NCT01059500|Experimental|Webtool Output|The webtool output group will receive the numeric PTP estimate from webtool output.
33294439|NCT01059500|No Intervention|Standard of Care/No Webtool Output|The control group will not receive the numeric PTP estimate.
33294440|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
32787425|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
32787426|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
33294441|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
33294442|NCT01059578|Experimental|Active|GSK206136 once daily
33294443|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
33294444|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
33294445|NCT00334958|Placebo Comparator|Placebo|For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
32787427|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
32787428|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
33086488|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
33086489|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
33086490|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
33086491|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
33086492|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
33086493|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
33086494|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
33086495|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
33086496|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
33086497|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
33086498|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
33086499|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
33086500|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
33294446|NCT00334958|Active Comparator|Rufinamide|For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
33294447|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
33294448|NCT03986528|Experimental|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
33294449|NCT03986528|Active Comparator|Chemotherapy|first-line chemotherapy.
33294450|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
33294451|NCT01057082|Placebo Comparator|Placebo|
33294452|NCT00326898|Experimental|Arm A (sunitinib malate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
32787429|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
32787430|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
32787431|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
33294453|NCT00326898|Experimental|Arm B (sorafenib tosylate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
32787432|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
33294454|NCT00326898|Placebo Comparator|Arm C (placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
33294455|NCT01062360|Experimental|Arm 1|
33294456|NCT01062360|Active Comparator|Arm 2|
33294457|NCT01062360|Active Comparator|Arm 3|
33294458|NCT01062360|Placebo Comparator|Arm 4|
33294459|NCT03982056||Main study group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
33294460|NCT03982056||Validation group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
33403805|NCT04872426|Experimental|High intensity exercise|70% and 95% of maximal work load capacity (alternately every 5 min)
32787433|NCT04936217||Patients operated for Continent Cutaneous Urinary Diversion, April 2004 - October 2017|The study focuses of a population of 70 patients operated between April 2004 and October 2017 au Nîmes University Hospital for Cutaneous Urinary Diversion.
32787434|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
32787435|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
32787436|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
32787437|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
32787438|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
33294461|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
33294462|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
32787439|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
32787440|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
33294463|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
33294464|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
33294465|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
33294466|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
33294467|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
33294468|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
33294469|NCT03981120|No Intervention|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
33294470|NCT03981120|Experimental|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:~Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.~Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)~Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
33294471|NCT01062594|Active Comparator|Supervised exercise group|
33294472|NCT01062594|No Intervention|Control group - no exercise|
33294473|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
33294474|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
33294475|NCT00334802|Experimental|A|
33294476|NCT03985358|No Intervention|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
33294477|NCT03985358|Experimental|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
33294478|NCT00307164|Active Comparator|NucleomaxX|Participants received NucleomaxX for 48 weeks
33294479|NCT00307164|Placebo Comparator|Placebo|Participants received NucleomaxX placebo for 48 weeks
33294480|NCT01059890|Experimental|Cefotaxime|
33294481|NCT01059890|Experimental|Metrodinazole|
33294482|NCT01059890|Experimental|Ciprofloxacine|
33294483|NCT01059890|Experimental|Fosfocine|
33294484|NCT01057160|Experimental|intake of rizatriptan 10 mg|
33294485|NCT01057160|Active Comparator|previous used analgesic|
33294486|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
33294487|NCT01057238|No Intervention|Control|usual care
32787441|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
33086501|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
33086502|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
33086503|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
33086504|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
33294488|NCT03990974|Experimental|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
33294489|NCT03990974|Sham Comparator|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
33086505|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
33086506|NCT02214550|No Intervention|Pain Discovery Aim|"This arm will receive no treatments and will be used as reference to compare to the other groups.~255 Reproductive age women (18-45) will be identified and divided into 5 groups~Healthy Controls~Chronic Pain (Positive Controls)~Dysmenorrhea (D)~Dysmenorrhea with Cross Organ Sensitization (D+COS)~Painful bladder syndrome (PBS)/interstitial cystitis (IC)~After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
33086507|NCT02214550|No Intervention|D+COS-no OC|For Aim #2, ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
33294490|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
33294491|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
33294492|NCT00307086|Other|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
33086508|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
33086509|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
33086510|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|For Aim #2, 26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
33086511|NCT02212015|Experimental|Pazopanib + Paclitaxel|Paclitaxel administered every 28 days at day 1, day 8 and day 15 as a 2h intravenous infusion in a dose of 70mg/m2 in combination with pazopanib in a daily oral dose of 800mg (2x400mg)
33086512|NCT04720859|Experimental|Patients with PHH following Roux-en-Y-gastric bypass (cases)|Patients diagnosed with PHH following Roux-en-Y-gastric bypass.
33294493|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
33294494|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
33086513|NCT04720859|No Intervention|Healthy individuals (controls)|Healthy normoweight individuals, matched by age and gender with the cases.
33294495|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
33294496|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
33294497|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
33294498|NCT01060202||Bortezomib|
33294499|NCT01057316|Experimental|Study Group A|
33294500|NCT01057316|Experimental|Study Group B|
33294501|NCT01057316|Experimental|Study Group C|
33294502|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
33294503|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
33294504|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
33294505|NCT03991208|Experimental|Rest|Pharmacokinetics of Single Dose Malarone at Rest
33294506|NCT03991208|Experimental|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
33294507|NCT01057472||Term born babies|Term born babies
33294508|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
33294509|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
33294510|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
33294511|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
33294512|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
33294513|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
33294514|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
33294515|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
33294516|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
33086514|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
33294517|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
33294518|NCT00314808|Experimental|Dronabinol|
33294519|NCT03984734|Active Comparator|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
33294520|NCT03984734|Experimental|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
33294521|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
32787442|NCT02485691|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).
32787443|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).
33294522|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
33294523|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
33294524|NCT01060514|Experimental|Pazopanib + Vinorelbine|
33294525|NCT03986606|Experimental|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
33294526|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
33294527|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
33294528|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
33294529|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
33294530|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
33294531|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
33294532|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
33294533|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
33294534|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
33294535|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
33294536|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
33294537|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
33086515|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
33294538|NCT00306852|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C
33294539|NCT00306852|Active Comparator|Implant|Baerveldt Implant
33294540|NCT00314262|Experimental|Erlotinib & Celecoxib|
33294541|NCT00333866|Experimental|1|
33294542|NCT00333866|Experimental|2|
33294543|NCT00333866|Experimental|3|
33294544|NCT00333866|Placebo Comparator|4|
33294545|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33294546|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
33294547|NCT00324116|Experimental|Active|
33294548|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
33294549|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
32787444|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
32787445|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
33294550|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
33294551|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
33294552|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
33294553|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
32787446|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
32787447|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
33086516|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
33294554|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
33294555|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
33294556|NCT00313170|Experimental|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
33294557|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
33294558|NCT00313170|Experimental|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
33294559|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
33294560|NCT03986450|Active Comparator|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
33294561|NCT03986450|No Intervention|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
33294562|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
33294563|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
33294564|NCT03984110|Experimental|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
33294565|NCT03984110|Active Comparator|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
33294566|NCT01057628|Experimental|ASP1941 group|oral
33294567|NCT01057628|Placebo Comparator|placebo group|oral
33294568|NCT03967821||Intervention|
33294569|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
33294570|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
33294571|NCT00225147|Experimental|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
33294572|NCT00225147|Experimental|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
33294573|NCT00225147|Placebo Comparator|Saline|
33294574|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
33294575|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
33294576|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
33294577|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
33294578|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
33294579|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
33294580|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
33294581|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
33294582|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
33294583|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
33294584|NCT00157209|Experimental|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
33294585|NCT00157209|Active Comparator|Best Supportive Care (BSC) Alone|
33294586|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
33294587|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
33294588|NCT00130533|Experimental|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
33294589|NCT00130533|No Intervention|Observation|Observation. No intervention.
33294590|NCT03972189|Experimental|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
33294591|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
32787448|NCT04957979||Nursing/Medical Model of Care Coordination|Someone with medical/nursing training coordinates involvement of various medical resources and provides patients with education, self-management support, and referrals to community resources.
33403806|NCT04872426|Experimental|Low intensity exercise + intermittent ischemia-reperfusion|70% of maximal leg work load capacity with intermittent ischemia (25 seconds every 2 min)
32787449|NCT04957979||Medical/Social Model of Care Coordination|In addition to the services provided in the Medical/Nursing Model, a social worker by education has dedicated FTE as a member of the care team at the clinic, providing some direct services for care coordination patients and either spending some time on-site or in regular communication with its clinicians in addition to providing social work services.
33294592|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
33294593|NCT01060878|Experimental|Dose I|
33294594|NCT01060878|Experimental|Dose II|
33294595|NCT01060878|Experimental|Dose III|
33294596|NCT01060878|Placebo Comparator|Placebo|
33294597|NCT00156819|Active Comparator|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
33294598|NCT00156819|Experimental|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
33294599|NCT00156819|Experimental|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
33294600|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
33294601|NCT02532894|No Intervention|Control|
33294602|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
33086517|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
33294603|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
33294604|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
33294605|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
33294606|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
33086518|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
33086519|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
33294607|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
33294608|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
33294609|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
33294610|NCT00129987|Experimental|Nurse group|An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
33294611|NCT00129987|Experimental|Lay educator group|An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
33294612|NCT00224133|Experimental|Silodosin|Silodosin 8 mg per day with food
33294613|NCT00224055|Experimental|IV iron|Sodium ferric gluconate
33294614|NCT00224055|Active Comparator|oral iron|ferrous sulfate
33294615|NCT00150969|Experimental|phyloquinone|5 mg Vitamin K1
33294616|NCT00150969|Placebo Comparator|placebo|
33294617|NCT03966573|Other|Evaluating function, Radiographic imaging, Forms|"Tests for lower extremity function~Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation radiographically~Evaluating quality of life, function and pain by forms"
33294618|NCT00150345|Experimental|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (< 38.0 °C) for 7 days with neutrophil counts < 500/µL, or if the patient is afebrile (< 38.0 °C) for 2 days with neutrophil counts > 500/µL.
33294619|NCT00150345|Other|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
33294620|NCT01582737||Group 1|Patients treated with Xarelto for the purpose of prevention of ischemic stroke and systemic embolism
33294621|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
33294622|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
33294623|NCT00223977|Experimental|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
33294624|NCT00223977|Experimental|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
33294625|NCT00223977|Active Comparator|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
33294626|NCT00148941|Experimental|SB213503 lot 1 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 1 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
33294627|NCT00148941|Experimental|SB213503 lot 2 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 2 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
33294628|NCT00148941|Experimental|SB213503 lot 3 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 3 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
32787450|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
32787451|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
32787452|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
32787453|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
32787454|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
32787455|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
32787456|NCT04306367|Experimental|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)~Olaparib bid, Oral tablet continuously"
32787457|NCT04925687|Experimental|Intravitreal autologous CD34+ cells|Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
32787458|NCT04925609|Other|Phase 1|"Phase 1:~To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~Note that:~If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.~Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen."
32787459|NCT04925609|Other|Phase 2|"Phase 2:~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."
32787460|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 milliliter (mL) unit dose in a 5mL glass syringe
32787461|NCT01891396|Experimental|Hyaluronic Acid and TH (Cingal®)|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
32787462|NCT01891396|Active Comparator|Hyaluronic Acid (Monovisc®)|Single injection of sodium hyaluronate supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
32787463|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
32787464|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
32787465|NCT04925453|Experimental|Active tDCS|"Based on previous studies targeting working memory, focality of current delivery, and comfort and tolerance levels, (Paulo S. Boggio et al., 2006; Hill et al., 2016; Hoy et al., 2013; Teo, Hoy, Daskalakis, & Fitzgerald, 2011), we will use a 2 mA current administered via two circular carbon rubber core electrodes in saline-soaked surface sponges (25 cm2), placed in a neoprene headcap with marked locations based on the 10-10 EEG system. The anodal stimulating electrode will be at location F3, over left dorsolateral prefrontal cortex (DLPFC) and the cathodal electrode at location F4, over right DLPFC. Two reference electrodes, CMS and DRL, will be attached to the EarClip and applied to the earlobe with conductive gel.~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
32939442|NCT05314790||training group (TG)|Group who has received an Educational Program (EP). The implementation of an EP based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1.
32939443|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
32939444|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
32939445|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
32939446|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
32939447|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
32939448|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
32939449|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
32939450|NCT04338074|Experimental|Tranexamic Acid Treatment|
32939451|NCT04338074|Placebo Comparator|Placebo Treatment|
32939452|NCT03964220||Patients with Asthma|
32939453|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
32939454|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
32787466|NCT04925453|Sham Comparator|Sham tDCS|"For sham stimulation, the electrodes will be placed at the same positions as for active stimulation (F3 and F4). After an initial ramp-up period of 30 seconds, stimulation fades out over a period of 30 seconds. Additionally, at the end of the sham stimulation period, stimulation will fade in over a period of 30 seconds and then end with a final 30 second ramp-down period. Participants will feel the initial itching sensation associated with tDCS and experience the ramp-down period at the end of the sham stimulation period but will receive no active current during the rest of the sham stimulation period. This method of sham stimulation has been shown to be reliable (Gandiga et al., 2006).~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
32787467|NCT04616014|Other|ORMD-0801 QD|8 mg QD, daily, in the morning
32787468|NCT04616014|Other|ORMD-0801 BD|8 mg BD, daily in the morning and in the evening
32787469|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
32787470|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
32787471|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
32787472|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
32787473|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
32787474|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
32787475|NCT04956731|Experimental|Pharmacist provision of medication abortion|This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
32787476|NCT04956263|Experimental|Treatment A|YG1699 10 mg
32787477|NCT04956263|Experimental|Treatment B|YG1699 25 mg
32787478|NCT04956263|Active Comparator|Treatment C|Dapagliflozin 10 mg
32787479|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
32787480|NCT05458193|Experimental|Daridorexant|50 mg once daily from Day 1 to Day 5
32787481|NCT05458193|Placebo Comparator|Placebo|Matching placebo once daily from Day 1 to Day 5
32787482|NCT04898348|Placebo Comparator|Placebo|3 capsules twice a day dosing of Placebo
32787483|NCT04898348|Experimental|KBL697|3 capsules twice a day dosing of KBL697
32787484|NCT01853878|Experimental|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
33086520|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
33086521|NCT04720898|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG once a week for 12 weeks.
32787485|NCT01853878|Placebo Comparator|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
32787486|NCT04891484|Experimental|Ondansetron group|Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
32787487|NCT04891484|Placebo Comparator|Control group|Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
32787488|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
32787489|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
32787490|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
32787491|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
32787492|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
32787493|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
33086522|NCT04720898|No Intervention|Control|The control group will receive its rehabilitation care.
33294629|NCT00148941|Active Comparator|Infanrix + IPOL + M-M-R Group|Subjects aged 4 to 6 years received a dose of Infanrix and a dose of IPOL vaccines separately and a dose of M-M-R II vaccine. Infanrix was administered by deep intramuscular injection in the upper left deltoid. IPOL was administered subcutaneously in the lower right deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid.
33294630|NCT01073553|Experimental|Arm 1|
33294631|NCT01073553|Active Comparator|Arm 2|
33294632|NCT00148317|Experimental|Treatment Arm|
33294633|NCT01077765|Experimental|treatment|treatment
33294634|NCT00323882|Experimental|MDX-010|
33294635|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33294636|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
33294637|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
33294638|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
33294639|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
32787494|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
33294640|NCT00331136|Experimental|Group A (Tablets)|Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
33294641|NCT00331136|Experimental|Group B (Tablets)|Pyronaridine artesunate 9:3 mg/kg. The tablet strength is 72:24 mg oral PA, with the number of tablets depending on body weight.
33294642|NCT00331136|Experimental|Group C (Tablets)|Pyronaridine artesunate 12:4 mg/kg. The tablet strength is 96:32 mg oral PA, with the number of tablets depending on body weight.
33294643|NCT00331136|Experimental|Group D (Granules)|Pyronaridine artesunate 9:3 mg/kg. The sachet of granules strength is 60:20 mg PA, with the number of sachets depending on body weight, and is administered as a suspension with water.
33294644|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
33294645|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
33294646|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
33294647|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
33294648|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
33294649|NCT03984032|Experimental|LMA Protector Cuff Pilot|
33294650|NCT03984032|Active Comparator|LMA Supreme|
33294651|NCT01325324|Other|Study group|Study group
33294652|NCT03983642|Experimental|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
33294653|NCT03983642|No Intervention|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
33318414|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
32787495|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
32787496|NCT02373098|Experimental|FTY720|
32787497|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
32787498|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
32787499|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
32787500|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
32787501|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
32787502|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
32787503|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
32787504|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
32787505|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
32787506|NCT01852942|Experimental|Losartan|
32787507|NCT01852942|Placebo Comparator|Sugar Pill|
32787508|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
32787509|NCT01852162|Placebo Comparator|Placebo|Placebo
32787510|NCT04590040|Placebo Comparator|Toothpaste 1|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
33318415|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :~light drinkers (score between 1 to 3)~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
32787511|NCT04590040|Active Comparator|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
32787512|NCT04590040|Active Comparator|Toothpaste 3|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
32787513|NCT04596124|Experimental|fitostimoline plus cream|
32787514|NCT04596124|Experimental|fitostimoline plus gauze|
32787515|NCT04596124|Active Comparator|connettivina bio plus cream|
32787516|NCT04596124|Active Comparator|connettivina bio plus gauze|
32787517|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
32787518|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
32787519|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
32787520|NCT02372006|Experimental|afatinib|dose escalation
32787521|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
32787522|NCT02450903|Experimental|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
32787523|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
32787524|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
32787525|NCT02370914||Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a Sport Concussion Assessment Tool (SCAT) test.
32787526|NCT02370914||Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a Sport Concussion Assessment Tool (SCAT) test.
32787527|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
33102369|NCT04805112|No Intervention|Referral vouchers for clinic testing|Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites. The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone [partner testing] or together with the participant [couple testing]. The coupon will also have information on testing and a list of facilities where he can go for HTS. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
33102370|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
32787528|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
32787529|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
32787530|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
32787531|NCT04897256|Experimental|TURN-IT group|Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.
32787532|NCT04897256|No Intervention|No Intervention Control Group|Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.
32787533|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
32787534|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
32787535|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32787536|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33318416|NCT05281796||healthy patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
33318417|NCT05281796||gingivitis patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
33294654|NCT00330668|Experimental|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms [μg]/ kilogram [kg] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
32939455|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
33294655|NCT00306384|Experimental|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
33294656|NCT00306384|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
33294657|NCT01062750|Other|adipose tissue derived stromal cells|
33294658|NCT03980964|Experimental|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
33294659|NCT03980964|Sham Comparator|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
33294660|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
33294661|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
33294662|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
33294663|NCT00305604|Active Comparator|1|sitagliptin
32939456|NCT04334876|Other|High Risk Healthcare Workers|At home, finger prick, antibody test.
32939457|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
33294664|NCT00305604|Placebo Comparator|2|Placebo
33294665|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
33294666|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
33294667|NCT03979014|Experimental|Vaccinated Arm|Add vaccine
32939458|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
32939459|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
33294668|NCT03979014|No Intervention|Control|No intervention
33294669|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
33294670|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
33294671|NCT03979092|Experimental|IP-ACLS|
33294672|NCT03979092|Other|Waitlist|
33294673|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
32939460|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
32939461|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
32939462|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
32939463|NCT04332757|Experimental|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
32939464|NCT04332757|No Intervention|Usual care control|Usual care acting as a control group.
32939465|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
32939466|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
32939467|NCT04326842||Control|Patients without carotid artery stenosis
32939468|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
32939469|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
32939470|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
33102371|NCT04799652||Doctors within Belgian Hospitals|
33294674|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
33294675|NCT00344318|Experimental|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
33294676|NCT00344318|Experimental|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
33294677|NCT00344318|Active Comparator|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
33294678|NCT00344318|Active Comparator|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
32787537|NCT02337764|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
33294679|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
33294680|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
33294681|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
33294682|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
33294683|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
33294684|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
33294685|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
33294686|NCT04260737|No Intervention|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
33294687|NCT04260737|Experimental|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:~An overview about prostate cancer;~An overview of different treatment options (e.g. surgery and active surveillance)~The pros and cons of different treatment options (e.g., physical, emotional, social).~A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
33294688|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
33294689|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
33294690|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
33294691|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
33294692|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
33294693|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
33294694|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
33294695|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
33294696|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
33294697|NCT03983174|Experimental|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
33294698|NCT03983174|Experimental|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
33294699|NCT00329108|Experimental|A|
33294700|NCT00329108|Active Comparator|B|
33294701|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
33294702|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
33294703|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
33294704|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
33294705|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
33294706|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
33294707|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
33294708|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
33294709|NCT00328172|Active Comparator|Metformin|Metformin
33294710|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
33294711|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
33294712|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
33294713|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
33294714|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
33294715|NCT01061372|Placebo Comparator|Placebo|
33294716|NCT01061372|Experimental|Pregabalin 150 mg/day|
33294717|NCT01061372|Experimental|Pregabalin 300 mg/day|
32787538|NCT04420442|Active Comparator|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
32787539|NCT04420442|No Intervention|Control Group|No Intervention.
32787540|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
32787541|NCT04594642|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
32787542|NCT04594642|Experimental|Dose Expansion in Subjects with DLBCL or HGBL|An expansion cohort in subjects with DLBCL or HGBL will be enrolled after RP2D is established.
32787543|NCT04594642|Experimental|Dose Expansion in Subjects with FL|An expansion cohort in subjects with FL will be enrolled after RP2D is established.
32787544|NCT01833832|Experimental|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
32787545|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
32787546|NCT01850602|Experimental|PA21|
32787547|NCT01850602|Active Comparator|Sevelamer hydrochloride|
32787548|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
32787549|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
32787550|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
32787551|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
32787552|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
32787553|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
32787554|NCT01650194|Experimental|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
32787555|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
32787556|NCT05369936|Experimental|Lavender group|On the day of the lavender group, after filling the first phase questionnaire, 20 drops of the lavender oil will be added to the electrical aromatherapy vaporizer near the patient's chair at a distance of 20 cm in the waiting room. After 20 minutes, the second phase questionnaire will be given to the patient, and then the patient will be transformed to dental clinics in which the lavender vaporizer will be placed near the dental unit at a distance of 20 cm. The vaporizer will be also prepared by adding 20 drops of the lavender which will be added added every 20 minutes until the dental sitting will be finalized, and the third questionnaire will be answered. At home, the patients will be asked to pour 3 drops of the lavender on a pad and inhale it for 5 minutes from 10 cm distance every one hour until they attend on the next day to answer the fourth questionnaire.
32787557|NCT05369936|Placebo Comparator|Placebo group|The plain distal water vapors will be used as placebo, the good ventilation of the waiting room and clinics will be performed to ensure that the lavender scent is completely removed from the environment. The patients will inhale the vapors of the plain distal water
32787558|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
32939471|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
32787559|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
32787560|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
32787561|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
33318418|NCT05281796||patients with Stage III periodontitis|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
33318419|NCT04170946|Experimental|Talazoparib in Combination with Low Dose RT|Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of RT (until day 20-23). Patient will start low dose RT on day 6-9, and will continue for 10 fractions throughout 2 weeks. Talazoparib dose levels will start at 0.5mg daily and increase to 1mg if dose limiting toxicites are not observed. Toxicities include renal impairment and other treatment related toxicities Grade ≥3. Patients will be monitored weekly during study treatment, and followed up at 3 weeks, and every 3 months after for 1 year.
33318420|NCT01300130|Experimental|low docosahexaenoic acid formula|
33318421|NCT01300130|Experimental|medium docosahexaenoic acid formula|
33318422|NCT01300130|Experimental|high docosahexaenoic acid formula|
33318423|NCT01300130|Active Comparator|human milk|
32787562|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
32787563|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
32787564|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
32787565|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
32787566|NCT02335658|Experimental|DSP-5423P|Percutaneous
32787567|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
33294718|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
33294719|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
33294720|NCT00500903|Experimental|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
32787568|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
32787569|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
32787570|NCT05370560||Type 2 diabetes mellitus|In this case-control study, T2DM was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. T2DM was confirmed when fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h post-glucose load (OGTT2h) ≥ 11.1 mmol/L.
33294721|NCT00500903|Experimental|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
33294722|NCT00500903|Experimental|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
33294723|NCT00295932|Experimental|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33294724|NCT00295932|Experimental|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33294725|NCT01063140||RabAvert|
33294726|NCT01063140||Imovax|
33294727|NCT00305448|Experimental|1|Fulvestrant 250 mg intramuscular injection
33294728|NCT00305448|Experimental|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
33294729|NCT00305448|Experimental|3|Fulvestrant 500 mg
32787571|NCT05370560||Impaired glucose regulation|In this case-control study, IGR was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. IGR was defined as impaired fasting glucose ([FPG] ≥ 6.1 mmol/L and < 7.0 mmol/L, and [OGTT2h] < 7.8 mmol/L) and/or impaired glucose tolerance (FPG < 7.0 mmol/L, and OGTT2h ≥ 7.8 mmol/L and < 11.1 mmol/L).
33294730|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
33102372|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
33294731|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
33294732|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
33294733|NCT03981198|Other|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
33294734|NCT03980652|Other|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
32787572|NCT05370560||Control|Those with FPG < 6.1 mmol/L and OGTT2h < 7.8 mmol/L were considered controls.
33294735|NCT03980652|No Intervention|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
33294736|NCT00305058|Experimental|Hydromorphone|0.0075 mg/kg IV hydromorphone
33294737|NCT00305058|Active Comparator|Morphine|0.05 mg/kg IV morphine
33294738|NCT01064388|Experimental|1|
33294739|NCT01064388|Placebo Comparator|2|
33294740|NCT00295854|Experimental|MN-001|
32787573|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
32787574|NCT02403674|Experimental|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
32787575|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
32787576|NCT04908020||Follow up|"The group is made up by children and adolescents, aged from 9 to 17, who received a cancer diagnosis, who completed oncological treatment and who are included in a clinical follow-up program since less than 3 years.~Furthermore, the study involves one parent for each patient to collect demographics and clinical data."
32787577|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
32787578|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
32787579|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
32787580|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
33294741|NCT00295854|Placebo Comparator|MN-001 once daily|placebo tablets
33294742|NCT00327470|Experimental|Open Label|
32787581|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
32787582|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
32787583|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
32787584|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
32787585|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
32787586|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
32787587|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
32830412|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~All patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
32830413|NCT03289806||Cases|Glaucoma surgery
33294743|NCT03983408|Active Comparator|KRG group|"Enrollment: 60 patients~Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
33294744|NCT03983408|Placebo Comparator|Placebo group|"Enrollment: 60 patients~Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
33294745|NCT01061450|Placebo Comparator|Placebo|Placebo
33294746|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
33294747|NCT03983330|Experimental|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
33294748|NCT03983330|Other|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
32787588|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
32787589|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
32787590|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
32787591|NCT04877587|Experimental|Ascorbate in combination with Gemcitabine|"The study will begin with a safety run-in.~A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. Gemcitabine is administered following standard fixed dose infusion practice adopted at The University of Iowa Hospitals & Clinics. Ascorbate is infused prior to gemcitabine. Cycles are 28 days. Patients will be treated for a total of 6 cycles and assessed every 2 cycles for disease response."
32787592|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
32787593|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
32787594|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
32787595|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
32787596|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
32787597|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
32787598|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
32787599|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
32830414|NCT03289806||Controls|Strabismus surgery
33294749|NCT03986294|Experimental|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
33294750|NCT03986294|Experimental|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
33294751|NCT00322556|Experimental|IgPro10|See Intervention Description
33294752|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
33294753|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
33294754|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
33294755|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
33294756|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
33294757|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
33294758|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
33294759|NCT03983720|Experimental|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
33294760|NCT03983720|Experimental|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
33294761|NCT03983720|Active Comparator|Healthy subjects|"Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
33294762|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
33294763|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
33294764|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
33294765|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
33294766|NCT00325130|Experimental|Group 1|Concomitant Administration
32787600|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
32787601|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
32787602|NCT02400476|Experimental|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
32787603|NCT02400476|Experimental|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
32787604|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
32787605|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
32787606|NCT04894526|Experimental|Alternating energy intake schedule|To alternate between caloric overconsumption and caloric underconsumption from day-to-day
32787607|NCT04894526|Active Comparator|Regular energy intake schedule|To consume the usual energy intake on a daily basis
32787608|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
32787609|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
32787610|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
32787611|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
32787612|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
32787613|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
33102373|NCT05465577|Experimental|Financial Navigation- Patients Only|Patients only participated in financial navigation program.
33294767|NCT00325130|Experimental|Group 2|Non-concomitant administration
33294768|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
33294769|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
33294770|NCT03983252|Experimental|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.~Subjects will undergo [F-18]PBR06 PET scans at baseline, 6 months and 18 months."
33318424|NCT05669300||Yilmaz Technique|the patients underwent ceserean section and uterus closed with Yilmaz Technique
32787614|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
32830415|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.~- Low or intermediate risk patients will receive optimal medical treatment."
32830416|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
33294771|NCT03982862|Active Comparator|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
33294772|NCT03982862|Experimental|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
33294773|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
33294774|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
33294775|NCT01058174|Experimental|micafungin|intravenous infusion
33294776|NCT01058174|Active Comparator|standard care|intravenous infusion
33294777|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
33294778|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
33294779|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
33294780|NCT01058252||Letrozole, recFSH, INVOCell, Monitoring|Infertile couple following MSP with INVO IVF
33294781|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
33294782|NCT01058330|No Intervention|Control Group|This group will have no intervention
33294783|NCT01058408|Experimental|Rad001 with cisplatin|
33294784|NCT01060982|Experimental|HIFU treatment|
33294785|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
33294786|NCT01061060|Placebo Comparator|Placebo group|
33294787|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
33294788|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
33294789|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
33294790|NCT03981692|Active Comparator|Consecutive Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
33294791|NCT03981692|Active Comparator|Integrated Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
33294792|NCT01063556|Experimental|1|
33294793|NCT01063556|Experimental|2|
33294794|NCT03981458|Active Comparator|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
33294795|NCT03981458|Active Comparator|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
33294796|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
33294797|NCT04110041|Experimental|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
33294798|NCT04110041|Experimental|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
33294799|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
33294800|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
33294801|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
33294802|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
33294803|NCT01063790|Experimental|Individualized Education|
32830417|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
33102374|NCT05465577|Experimental|Financial Navigation- Patient and Caregiver|Patients and their caregivers participated as a dyad in financial navigation program.
33294804|NCT03985982|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
33294805|NCT03985982|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
32830418|NCT05235048|Placebo Comparator|Standard of care control|Tooth extraction and spontaneous healing
33102375|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
33102376|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
33294806|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
33294807|NCT03982472|Experimental|TENS right side|TENS stimulation at the right side
33294808|NCT03982472|Experimental|TENS left side|TENS stimulation at the left side
33294809|NCT03982472|No Intervention|sham stimulation|Sham stimulation
33294810|NCT01058486|Experimental|Activity-Self Management|
33294811|NCT01058486|No Intervention|Usual Care|
33294812|NCT04252703|Active Comparator|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
33294813|NCT04252703|Experimental|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
32830419|NCT05235048|Experimental|Socket seal with CT graft|Tooth extraction and socket sealing with autologous connective tissue graft
32830420|NCT05235048|Experimental|Socket seal with CT graft and bone replacement graft|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket
32830421|NCT05235048|Experimental|Tooth extraction and socket sealing and BRG with membrane|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket and positioning of collagen membrane
32830422|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the PIPAC procedure (injection and nebulisation in intraperitoneal).
33102377|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
32830423|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
32830424|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
32830425|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
32830426|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
32830427|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
32830428|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
32830429|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
32830430|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
32830431|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
32830432|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
33086523|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
33086524|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
33294814|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
33086525|NCT00265044|Other|Arm 1|
33086526|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
33294815|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
33294816|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
33294817|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
33294818|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
33294819|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
33294820|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
33294821|NCT00308750|Experimental|Enzastaurin/Pemetrexed/Carboplatin|
33294822|NCT00308750|Experimental|Pemetrexed/Carboplatin|
33294823|NCT00308750|Active Comparator|Docetaxel/Carboplatin|
33294824|NCT01061918|Active Comparator|Tecnis MF|
33294825|NCT01061918|Active Comparator|ReSTOR|
33294826|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
33294827|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
33294828|NCT03985748|Experimental|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
33294829|NCT03985748|Active Comparator|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
33294830|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
33294831|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
33294832|NCT00481247|Experimental|Dasatinib|
33294833|NCT00481247|Active Comparator|Imatinib|
33294834|NCT04101461|Active Comparator|Group I: 27 mg elemental iron|will receive PharaFerro27; Devart Lab Company, Egypt; once daily starting at 12 -14 weeks until 37-38 weeks
33294835|NCT04101461|Active Comparator|Group II: 54 mg elemental iron|will receive two tablets of PharaFerro27; Devart Lab Company, Egypt; daily starting at 12 -14 weeks until 37-38 weeks
33294836|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
33294837|NCT01016951|Experimental|A|AZD9164
33294838|NCT01016951|Placebo Comparator|B|Placebo
33294839|NCT01017107|Experimental|Activated protein C|
33294840|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
33294841|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
33294842|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
33294843|NCT03996863|Experimental|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
33318425|NCT05669300||single layer continue locked suturation|the patients underwent ceserean section and uterus closed with single layer continue locked suturation
33086527|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
33294844|NCT03996863|Placebo Comparator|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
33294845|NCT03997019|Active Comparator|group A|opioid analgesia
33294846|NCT03997019|Active Comparator|group B|ESP block
33294847|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
33294848|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
33294849|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
33294850|NCT00480857|Experimental|Docetaxel|
32939472|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
32939473|NCT04322396|Placebo Comparator|Control|"This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2"
32939474|NCT04322396|Active Comparator|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2"
32939475|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
32939476|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
32939477|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
32939478|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
32939479|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
32939480|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
32939481|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
32939482|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
32939483|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
32939484|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
32939485|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
32939486|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
32939487|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
32939488|NCT03222505|Experimental|Treadmill|
32939489|NCT03222505|Experimental|Overground Walking|
32939490|NCT03224299|Experimental|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
32939491|NCT03224299|Experimental|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
32939492|NCT03224299|Active Comparator|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
32939493|NCT03224299|Placebo Comparator|Negative Control|sterile 0.9% saline applied with single use applicator
32939494|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
32939495|NCT03334825|Experimental|Enhanced housing placement assistance|
32939496|NCT03334825|Active Comparator|Standard housing placement assistance|
32939497|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
32939498|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
32939499|NCT03444961|Experimental|CAREN system training|CAREN training
33086528|NCT04720586|Experimental|triple procedure|lower eyelid retractors plication , transcutaneous blepharoplasty and wedge resection
33086529|NCT04720586|Active Comparator|combined procedure|lower eyelid retractors plication and transcutaneous blepharoplasty
33086530|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
33294851|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
33294852|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
33294853|NCT04061993|Experimental|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
33086531|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
33086532|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
33294854|NCT04061993|Active Comparator|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
33086533|NCT04718883|Experimental|JWCAR029 treatment|JWCAR029 be administrated at dose level: 1 x 10^8 CAR+T cells
33086534|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
33086535|NCT00242606|Active Comparator|2|Lamotrigine
33294855|NCT04061993|Experimental|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
33294856|NCT04061993|Active Comparator|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
33294857|NCT01020383|Experimental|ALX-0081|
33294858|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
33294859|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
33294860|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
33294861|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
33294862|NCT01017341|No Intervention|No hip protector|no hip protector
33294863|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
33294864|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
33294865|NCT01017419||Audiology counseling|
33294866|NCT04242329|Experimental|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
33294867|NCT04242329|Active Comparator|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
33294868|NCT05045261|No Intervention|A - Standard of care NUC|Patients will continue their standard of care NUC treatment
33294869|NCT05045261|Experimental|B - NUC discontinuation|Patients will stop their NUC treatment 28 weeks after enrolment
33294870|NCT05045261|Experimental|C - NUC discontinuation after SLGN treatment|"Patients will take from enrolment~their standard of care NUC treatment for 28 weeks then stop~3mg SLGN weekly for 24 weeks then stop"
33294871|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
33086536|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
33086537|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
33086538|NCT00282711||1|Standard Exercise treadmill test
33086539|NCT00282711||2|Exercise treadmill testing with nuclear imaging
33086540|NCT00282906|Experimental|PET-CT|
33086541|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
32787615|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
32787616|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
32787617|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
32787618|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
32787619|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
32787620|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
32787621|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
32787622|NCT04907162||Neuromuscular disease (NMD) Patients|"The patient has one of the following neuromuscular diagnoses:~histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or~genetically confirmed late-onset Pompe disease (LOPD), or~genetically confirmed spinal muscular atrophy type 3 (SMA3), or~genetically confirmed myotonic dystrophy type 1, or~genetically confirmed myotonic dystrophy type 2, or~genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD)."
32787623|NCT04907162||Healthy control|no known neuromuscular disorder
32787624|NCT04906616|No Intervention|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
32787625|NCT04906616|Experimental|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
32787626|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
32787627|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
32787628|NCT04906382|Experimental|Treatment (tislelizumab)|"Chemo naïve patients receive tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients who are chemotherapy naive with progressive disease, stable disease, or partial response, also receive carboplatin IV and paclitaxel IV every 21 days per standard of care for 6-9 cycles at the discretion of the treating physician.~Patients who have received prior chemotherapy will receive single agent tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
32787629|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)|Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
32787630|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)|Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
32787631|NCT04892875|Active Comparator|Concurrent Cisplatin/Radiation Therapy|Concurrent weekly cisplatin with radiation therapy control arm
32787632|NCT04892719|Other|Participants who underwent a lung transplant at Duke|Participants will undergo fluoroscopic chest imaging with 4Dx technology software analysis
32787633|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
32787634|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
32787635|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
32939500|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
33086542|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
33086543|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
33086544|NCT00283101|Experimental|1|SGN-40
33086545|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
33086546|NCT00273741|Placebo Comparator|2|placebo capsules
33086547|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
33086548|NCT00243893|Active Comparator|Aneurysms|
33294872|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
33294873|NCT04442009|Active Comparator|Group S = SCPB group|"US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used.~Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine)."
33294874|NCT04442009|No Intervention|Group C = Control group|Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
33294875|NCT00295620|Experimental|Arm A: Anastrozol|1 mg per day for 2 years
32787636|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
33294876|NCT00295620|Experimental|Arm B: Anastrozol|1 mg per day for 5 years
33294877|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
33294878|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
33294879|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
33294880|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
33294881|NCT03980496|Active Comparator|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
33294882|NCT03980496|Active Comparator|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
33294883|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
32787637|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
32787638|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
32939501|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
32939502|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
32939503|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
32939504|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
32939505|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
32939506|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
32939507|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
32939508|NCT03954626|Experimental|RTH258|Intravitreal injection
32939509|NCT04332835|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
32939510|NCT04332835|Active Comparator|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
32939511|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
32939512|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
32939513|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
32939514|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
32939515|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
32939516|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
32939517|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
32939518|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
32939519|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
32939520|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
32787639|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
33086549|NCT00244049|Experimental|Brief clinician advice|
33294884|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
33294885|NCT01066260|Experimental|Probiotic|
33294886|NCT01066260|Placebo Comparator|Placebo|
33294887|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
33294888|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
33294889|NCT03981510|Experimental|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:~Healthy children (1)~Children with chronic constipation (2)~Children with neurofibromatosis type 1 (2)~Children with cancer receiving treatment with Vincristine (1)"
33294890|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
33294891|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
33294892|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
33294893|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
33294894|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
33294895|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
33403807|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
32787640|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
32787641|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
32787642|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
32787643|NCT01649804|Experimental|RoActemra/Actemra single arm|
32787644|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
32787645|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
32787646|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
32787647|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
32787648|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
32939521|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
32939522|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
32939523|NCT05313932|Experimental|Sleep deprivation|Two hours of sleep deprivation (Six hours of sleep)
32939524|NCT05313932|No Intervention|No intervention|No sleep deprivation (Eight hours of sleep)
32939525|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
32939526|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
32939527|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
32939528|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
32939529|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
32939530|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
32939531|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
32939532|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
32939533|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
32939534|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
32787649|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
32787650|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
32907086|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
33086550|NCT00273780|Active Comparator|Adherence counseling|
33294896|NCT03978390|Experimental|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
33294897|NCT03978390|Experimental|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
33294898|NCT03978390|Experimental|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
33294899|NCT03978390|Active Comparator|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
33086551|NCT00273780|Active Comparator|Alarm device|
33294900|NCT00304356|Other|active drug|500 mg nitazoxanide bid given to patient
33294901|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
33294902|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
33294903|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
33294904|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
33294905|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
33294906|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
33294907|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
33294908|NCT00321620|Active Comparator|zoledronic acid|
33294909|NCT00321620|Experimental|denosumab|
33294910|NCT00304278|Experimental|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:~Drug: Erlotinib (Tarceva)~150 mg daily X 7 weeks~Other Names:~Tarceva~Drug: Intra-arterial Cisplatin (PLAT)~1 dose (150 mg/sq) per week X 4 weeks~Other Names:~Cisplatin~Radiation: Radiation Therapy (RAD)~5 days per week X 7 weeks"
33294911|NCT03981068|Experimental|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
33086552|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
33086553|NCT00273780|No Intervention|Control|
33086554|NCT04718844|Experimental|1.0mg/kg - Thalassaemia|
33086555|NCT04718844|Experimental|3.0mg/kg - Thalassaemia|
33294912|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
33294913|NCT02532686|Placebo Comparator|placebo|
33294914|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
33294915|NCT00291018|Experimental|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
33294916|NCT00291018|Active Comparator|Control|ACDF
33294917|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
33294918|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
33294919|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
33294920|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
33294921|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
33086556|NCT04718844|Experimental|6.0mg/kg - Thalassaemia|
33086557|NCT04718844|Placebo Comparator|Placebo - Thalassaemia|
32787651|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
32787652|NCT04905446|Other|Healthy male subjects|
32787653|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
32787654|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
32901933|NCT05124132|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) as delivered in the parent study (Protocol ID #201410093) consisted of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content included instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life. For the current study, participants will continue monthly approximately 2.5 hour booster sessions covering similar content for the duration of the study. Participants will be encouraged to maintain daily formal meditative activities at home.
33086558|NCT04718844|Experimental|Xmg/kg - Thalassaemia|
33294922|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
33294923|NCT00307736|Experimental|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
33294924|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
33294925|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
33086559|NCT04718844|Experimental|1.0mg/kg - Myelodysplastic Syndrome|
33294926|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
33294927|NCT03979586|Experimental|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
33294928|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
33294929|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
33294930|NCT00294762|Experimental|Erlotinib|150 mg erlotinib daily
33294931|NCT00294762|Experimental|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
33294932|NCT00294684|Experimental|Corticosteroids|
33294933|NCT00294684|Placebo Comparator|Placebo|
33294934|NCT00307034|Experimental|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
33086560|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome|
33086561|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome|
33086562|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome|
33086563|NCT04718844|Experimental|3.0mg/kg - Thalassaemia multi dose|
33086564|NCT04718844|Experimental|10.0mg/kg - Thalassaemia multi dose|
33086565|NCT04718844|Experimental|Xmg/kg - Thalassaemia multi dose|
32787655|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
33086566|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome multi dose|
33294935|NCT00307034|Experimental|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
33294936|NCT01061996|Experimental|1|
33294937|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
33294938|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
33294939|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
33294940|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
33294941|NCT01069536|Active Comparator|2 minutes bolus infusion|
33294942|NCT01069536|Active Comparator|15 minutes slow infusion|
33294943|NCT01069614|Experimental|Skin stretching device|Skin stretching device
33294944|NCT03980106|Experimental|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
33294945|NCT03980106|Experimental|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
33294946|NCT03976674|Experimental|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
33294947|NCT03976674|No Intervention|Control group|Standard practice
33294948|NCT01064778|Active Comparator|Low GI|
33294949|NCT01064778|Experimental|High GI|
33294950|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
33294951|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
33294952|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
33294953|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
33086567|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome multi dose|
33086568|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome multi dose|
33086569|NCT04718844|Placebo Comparator|Placebo - Thalassaemia multi dose|
33086570|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome|
33294954|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
33294955|NCT00290706|Experimental|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
33294956|NCT03978156|Experimental|Dronabinol, Then Placebo|Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase.
33086571|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome multi dose|
33086572|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
33086573|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
33294957|NCT03978156|Experimental|Placebo, Then Dronabinol|Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase.
33294958|NCT03978234|Experimental|Single group|Single group
33294959|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
33294960|NCT01064934|Active Comparator|Standard care|Standard care
33294961|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
33086574|NCT00244439|Experimental|1|MALG
33086575|NCT00244439|Active Comparator|2|Ovide
33086576|NCT00244439|Active Comparator|3|Permethrin 1%
33294962|NCT03977766|Experimental|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
33294963|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
33294964|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
33294965|NCT00303108|Experimental|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
33294966|NCT00302952|Experimental|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes.
33294967|NCT00302952|Placebo Comparator|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
33294968|NCT00302718|Experimental|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
33294969|NCT00302718|Experimental|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
33294970|NCT00302718|Experimental|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
33294971|NCT00302718|No Intervention|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
33294972|NCT03976206|Experimental|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
33294973|NCT03976206|Experimental|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
33294974|NCT03976206|Experimental|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
33294975|NCT03976206|No Intervention|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
33294976|NCT01069848|Experimental|Vedera KXS|
33294977|NCT01066572|Experimental|Lisinopril|Experimental
33294978|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
33294979|NCT01066650|Active Comparator|Endeavor Resolute|
33294980|NCT01066650|Active Comparator|Xience V|
32939535|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
32939536|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
33294981|NCT00302328|No Intervention|macular hole operation no peeling|
33294982|NCT00302328|Active Comparator|Macular hole operation ICG peeling|
33294983|NCT00302328|Experimental|Macular hole operation TB peeling|
32939537|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
32939538|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
32939539|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
32939540|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
32939541|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
32939542|NCT03672032|Active Comparator|Fork-tip Needle|
32939543|NCT03672032|Active Comparator|Franseen Needle|
32939544|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
32939545|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
32939546|NCT00375895|Experimental|Ciclosporin|
32939547|NCT05314322|Experimental|High frequency group|Deep brain stimulation's parameter: Frequency adjusted to 130Hz, with other parameters fixed
32939548|NCT05314322|Experimental|Low frequency group|Deep brain stimulation's parameter: Frequency adjusted to 60Hz, with other parameters fixed
32939549|NCT03338803||Patients with a written prescription for linagliptin|
32939550|NCT05314244|Experimental|pylorus resecting group|The patients who underwent pylorus resecting pancreaticoduodenectomy for periampullary tumors
32939551|NCT05314244|No Intervention|pylorus preserving group|The patients who underwent pylorus preserving pancreaticoduodenectomy for periampullary tumors
32939552|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
32939553|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
32939554|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
32787656|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
32787657|NCT02279719|Experimental|BBI608 and Sorafenib|
33294984|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
33294985|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
33294986|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
33294987|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
33294988|NCT03977844|Active Comparator|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
33294989|NCT03977844|Experimental|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
32787658|NCT02279719|Experimental|BBI503 and Sorafenib|
32787659|NCT02279719|Active Comparator|Sorafenib|
33294990|NCT03977844|Active Comparator|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
33294991|NCT03977844|Experimental|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
33294992|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
33294993|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
32787660|NCT02279407|Placebo Comparator|placebo|
32787661|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
32787662|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
33294994|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
32787663|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
32787664|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
32787665|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
32787666|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
32787667|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
32787668|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
32787669|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
32787670|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
32787671|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
32787672|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
33294995|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
33294996|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
33294997|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
33294998|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
33294999|NCT01066806|Experimental|high calcium diet|
33295000|NCT01066806|Active Comparator|normal calcium diet|
33295001|NCT03977610|Experimental|Ga68-PSMA ligand|Glass vial with 4~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
33295002|NCT01066884|Experimental|1|
33295003|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
33295004|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
33295005|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
33295006|NCT00290238|Experimental|PNT|
33295007|NCT00290238|Sham Comparator|TENS|
33295008|NCT01070082||Adult ICU patients undergoing procedure|
33318426|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity~radiotherapy, 12Gy in 3 fractions"
32787673|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
32787674|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
33295009|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
33295010|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
33295011|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
33295012|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
32787675|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
33295013|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
33295014|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
33295015|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
33295016|NCT03976284|Experimental|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
32787676|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
32787677|NCT04860505|Experimental|Doxycycline and Biktarvy|Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.
32787678|NCT05650099||Implants in the posterior region|126 patients with one or two missing tooth/teeth in the posterior region were treated 10 years ago with dental implant treatment and implant-supported restorations
32907087|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
33295017|NCT00289848|Experimental|1|sitagliptin 100 mg
33295018|NCT00289848|Placebo Comparator|2|placebo
33295019|NCT00289770|Experimental|Group A|Was vaccinated with Lot A in the primary study.
32907088|NCT05672381||Lower leg Trauma|High-energy lower leg trauma at risk for Acute Compartment Syndrome
32907089|NCT05672381||Forearm Trauma|High-energy forearm trauma at risk for Acute Compartment Syndrome
33295020|NCT00289770|Experimental|Group B|Was vaccinated with Lot B in the primary study.
33295021|NCT00289770|Experimental|Group C|Was vaccinated with Lot C in the primary study.
33295022|NCT00289536|Experimental|Low Dose|
33295023|NCT00289536|Experimental|Medium Dose|
33295024|NCT00289536|Experimental|High Dose|
33295025|NCT00289458|Experimental|Aquatic Education|Exercise combined with education
33295026|NCT00289458|Experimental|Aquatic|
33295027|NCT00289458|Placebo Comparator|Control|
33295028|NCT00288912|Active Comparator|Health Education Intervention|Health Education Intervention
33295029|NCT00288912|No Intervention|Usual Medical Care|Usual Medical Care
33295030|NCT00288912|Experimental|Osteoarthritis Self-Management|Osteoarthritis Self-Management
33295031|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
33295032|NCT01066962|Experimental|darunavir/r + raltegravir|
33295033|NCT03977532|Experimental|patients with sickle cell disease|
33295034|NCT01067118|Active Comparator|Humalog U-100 Insulin|
33295035|NCT01067118|Experimental|LINjeta U-100|
33295036|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
33295037|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
33295038|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
33295039|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
33295040|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
33295041|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
33295042|NCT01065246|Experimental|catumaxomab|
33295043|NCT01325844|No Intervention|G group|G group = General anesthesia group
33295044|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
33295045|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
32907090|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
33295046|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
33295047|NCT04307628|Active Comparator|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
33295048|NCT04307628|Placebo Comparator|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
33295049|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
33295050|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
32907091|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
33295051|NCT00305864|Experimental|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33295052|NCT00305864|Experimental|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33295053|NCT00305864|Experimental|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33295054|NCT00305864|Active Comparator|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33295055|NCT00295880|Experimental|Transplant Patients|Patients receiving umbilical cord blood transplantation.
33295056|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
33295057|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
33295058|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
33295059|NCT03979196|Active Comparator|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
33295060|NCT03979196|Active Comparator|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
33295061|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
33295062|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
33295063|NCT03982784|Experimental|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
33295064|NCT03982784|Active Comparator|Control|postoperative IPCA is given alone
33295065|NCT03978884|Experimental|Mild Hypertensive|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg
33295066|NCT03978884|Experimental|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg and diabetes.
33295067|NCT03978884|Experimental|Severe Hypertension|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg
33295068|NCT03978884|Experimental|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg with diabetes
33295069|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
33295070|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
33295071|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
33295072|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
32939555|NCT05314634|Experimental|concurrent exercise group, CE|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
33295073|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295074|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295075|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295076|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295077|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295078|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
33295079|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
32939556|NCT05314634|Experimental|aerobic exercise group, AE|Participants conduct 5-min warm up, 25-min aerobic exercise, and 5-min cool down.
32939557|NCT05314634|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
33295080|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
32939558|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
32907092|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
32907093|NCT03830372|Experimental|VR Tier One|"Patients will receive:~10 sessions of 20 minutes of VR Tire One therapeutic game,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
32907094|NCT03830372|Active Comparator|Control|"Patients will receive:~10 sessions of 20 minutes of Schultz Autogenic Training,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
32939559|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
32907095|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
32907096|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
32907097|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
32907098|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
32907099|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
32907100|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
32907101|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
32907102|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
32907103|NCT05672303|No Intervention|Control|Routine procedure will be applied
32907104|NCT05672303|Experimental|Experimental|Palmar grasp reflex will be stimulated with routine procedure.
32907105|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
32907106|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
32907107|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
32907108|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
32907109|NCT03403322|Other|First test|All measures were evaluated
32907110|NCT03403322|Other|Second test|All measures were evaluated
32907111|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
32907112|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
32907113|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
33086577|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
33086578|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
33086579|NCT04709588|Placebo Comparator|placebo group|subjects drank 50 ml every night for 14, 28 days
33086580|NCT04709588|Experimental|collagen drinks|subjects drank 50 ml every night for 14, 28 days
33086581|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
33295081|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
33086582|NCT00244517|Active Comparator|II|Sevoflurane
33086583|NCT00244517|Active Comparator|III|Desflurane
33086584|NCT00283413|Experimental|1|Symbiot Covered Stent System
33086585|NCT00283413|Active Comparator|2|Commercially available bare metal stent
33295082|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
33086586|NCT00244790|Experimental|low protein|
33086587|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
33295083|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295084|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
33295085|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
33295086|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
33295087|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
33295088|NCT00295490|Experimental|960mg Devil Claw|Active dose
33295089|NCT00295490|Experimental|1920 mg Devil claw|Active dose
33295090|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
33295091|NCT03980990|Experimental|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
33295092|NCT03980990|No Intervention|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
33295093|NCT03980756|Experimental|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
33295094|NCT03980756|Experimental|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
33295095|NCT03980756|Experimental|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
32907114|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
32907115|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
32907116|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
33086588|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
33086589|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
33086590|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
33086591|NCT00283491|Active Comparator|A|
33086592|NCT00283491|Placebo Comparator|B|
32907117|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
32907118|NCT04840199|Experimental|Arm A: Letermovir|"Letermovir 480 mg will be administered by one of the following strategies:~Letermovir 240 mg tablets administered orally as two tablets once daily with or without food.~Letermovir 480 mg tablets administered orally as one tablet once daily with or without food.~Participants will be able to switch administration strategy during treatment duration based on availability of study supply."
32907119|NCT04840199|Other|Arm B: No anti-CMV treatment|
32907120|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
33086593|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
33295096|NCT03980756|Experimental|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
33295097|NCT00305006|Experimental|CIMT Intervention|Participants randomized to this arm were provided with 90 minutes of Constraint-Induced Movement Therapy (CIMT), which requires hand restraint and progression of unimanual tasks.
33295098|NCT00305006|Experimental|HABIT Intervention|Participants randomized to this arm were provided with 90 minutes of Hand-Arm Bimanual Intensive Therapy (HABIT), which requires that tasks are progressed bimanually.
33295099|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
33295100|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
33086594|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
33295101|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
33295102|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
33295103|NCT03980444|Experimental|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
33295104|NCT03980444|Sham Comparator|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
33295105|NCT03980600|Experimental|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
33295106|NCT03978572|Active Comparator|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
33295107|NCT03978572|Active Comparator|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
33295108|NCT03978572|Experimental|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
33295109|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
33295110|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
33295111|NCT03978494|Experimental|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
33295112|NCT03978494|Experimental|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
33295113|NCT03978416|No Intervention|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.~A total of 30 participants will be recruited for the focus groups."
33102378|NCT05465304||Control group|control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy.
33295114|NCT03978416|Experimental|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
33295115|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
33295116|NCT03980288|Experimental|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
33295117|NCT03980678|Active Comparator|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
33295118|NCT03980678|Placebo Comparator|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
33295119|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
33295120|NCT01581164||HSCT patients|Patients who have been treated with HSCT
33295121|NCT00319046|Experimental|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
33295122|NCT03980366|Experimental|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
33295123|NCT03980210|Experimental|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)~Five successive steps:~FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
33295124|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
33295125|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
33295126|NCT01325402|Experimental|Part 2|Healthy Volunteers
33295127|NCT03978338|Experimental|Intervention group|The experimental group will take the brain polypeptide solution .
33295128|NCT03978338|Placebo Comparator|Control group|The control group was treated with the same package of placebo .
33295129|NCT00303602|Experimental|A|Sublingual orally disintegrating olanzapine (SODO)
33295130|NCT00303602|Active Comparator|B|Oral olanzapine
33295131|NCT03979976|Active Comparator|ramipril group|Use of ramipril 10mg/day per 12 weeks
33295132|NCT03979976|No Intervention|Control Group|Without ramipril
33295133|NCT00299130|Active Comparator|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
33295134|NCT00299130|Experimental|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
33295135|NCT00299130|Experimental|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
33295136|NCT00288054|Experimental|Cetuximab + Radiotherapy (no Docetaxel)|
33295137|NCT00288054|Experimental|Cetuximab + Radiotherapy + Docetaxel|
33295138|NCT00287586|Active Comparator|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
33295139|NCT00287586|Placebo Comparator|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
33295140|NCT03979716|Experimental|Anosmic patients|
33295141|NCT03979716|Experimental|Hyposmic patients|
33295142|NCT03979716|Experimental|Normosmic patients|
33295143|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
33295144|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
33295145|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
33295146|NCT00287118|Experimental|Efalizumab|
33295147|NCT03977298|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
33295148|NCT03977298|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
33086595|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
33086596|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration~minus Day 7 Carmustine 300 mg/m2 x 1 dose~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 2 Melphalan 140 mg/m2 x 1 dose~minus Day 1 Day of Rest~Day 0 Transplant"
33086597|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
33295149|NCT03977220|Experimental|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
33086598|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
33086599|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
33086600|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
33086601|NCT00283725||Galantamine|
33086602|NCT00283725||No Alzheimer's disease (AD) treatment|
33086603|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
33086604|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
33086605|NCT00245336|Experimental|1|rThrombin
33086606|NCT00245336|Active Comparator|2|bThrombin
33086607|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
33086608|NCT00245414|Experimental|1|Interferon (IFN)-Treated
33086609|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
33086610|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
33086611|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
33086612|NCT00245453|Active Comparator|1 Azithromycin|
33086613|NCT00245453|Active Comparator|2 Clarythromycin|
33086614|NCT00245453|Active Comparator|3 Telithromycin|
33086615|NCT00245492|Experimental|1|Chromocolonoscopy
33086616|NCT00245531||+IDU/+HIV or -HIV|
33086617|NCT00245531||-IDU and -HIV (controls)|
33086618|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
33086619|NCT00245726|Active Comparator|2|
33086620|NCT00245726|Experimental|3|
33086621|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
33086622|NCT00245804||Adult dyslexia|Adult dyslexia
33086623|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
33086624|NCT00245804||Adult-Control|Adult-Control
33086625|NCT00245804||Minor-Control|Minor-Control
33086626|NCT00274677|Placebo Comparator|Placebo|
33086627|NCT00274677|Experimental|lamotrigine|
33086628|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
33086629|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
33086630|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
33086631|NCT00274794|Other|Etoposide + G-CSF|
33086632|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
33086633|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
33086634|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
33086635|NCT04709666||Endsocopic Retrograde ColangioPancreatography (ERCP)|Endsocopic Retrograde ColangioPancreatography (ERCP)
33086636|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
33086637|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
33086638|NCT00246350|Active Comparator|1|8 light massage treatments
33086639|NCT00246350|Active Comparator|2|16 light massage treatments
33086640|NCT00246350|Experimental|3|8 spinal manipulation treatments
33086641|NCT00246350|Experimental|4|16 spinal manipulation treatments
33086642|NCT00246428|Experimental|1|MI
33086643|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
33086644|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
33086645|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
33086646|NCT00284427|Experimental|1|Vitamin C
33086647|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
33086648|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
33086649|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
33086650|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
32939560|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
32939561|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
33295150|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
33295151|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
32939562|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
33295152|NCT00293202|Active Comparator|Etanercept 25 mg|Etanercept 25 mg injection twice a week
33295153|NCT00293202|Placebo Comparator|Saline|Saline injection twice a week
33295154|NCT00298896|Experimental|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
33295155|NCT03977376|Experimental|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
33295156|NCT03977376|No Intervention|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
33295157|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
33295158|NCT00286494|Active Comparator|Placebo|
32939563|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
32939564|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
32939565|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
33295159|NCT00286494|Experimental|Alogliptin 12.5 mg QD|
33295160|NCT00286494|Experimental|Alogliptin 25 mg QD|
33295161|NCT03976050|Experimental|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in <33.3% of subjects at the 18 mg dose.
33295162|NCT00298740|Experimental|Aventis U-400 Insulin|
33295163|NCT03979326|Experimental|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
33295164|NCT03975972|Experimental|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
33295165|NCT03975972|No Intervention|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
33295166|NCT01067742||Subjects with Mucolipidosis Type IV|
32939566|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
33295167|NCT01067820|Experimental|RVX000222, 200 mg daily|
33295168|NCT01067820|Placebo Comparator|Placebo|
33295169|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
32939567|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
32939568|NCT03691844|Experimental|AMZ001|on the target knee
32939569|NCT03691844|Placebo Comparator|Placebo|on the target knee
32939570|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
32939571|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
32939572|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
32939573|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
32939574|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
32939575|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
33295170|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
33295171|NCT01067898|Placebo Comparator|placebo every three months|
33086651|NCT00277368||001|
33086652|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
33295172|NCT01065636|Experimental|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
33086653|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
33086654|NCT00247052|Active Comparator|diclofenac|diclofenac
33086655|NCT00247052|Placebo Comparator|2|
33086656|NCT04720703|Experimental|Intervention Group|The Intervention Group will receive the Family-based Telehealth Intervention for the first three months of the study period. Once they have completed the intervention, there will be a two-week washout period. After the washout period, they will receive monthly newsletters, with similar information learned in the intervention, for three months until the end of the study period.
33086657|NCT04720703|Active Comparator|Wait-list Control Group|The Waitlist Control Group will receive monthly newsletters, with similar information learned in the intervention, for the first three months of the study period while the Intervention Group receives the intervention. Then, there will be a two-week washout period. After the washout period, they will receive the Family-based Telehealth Intervention for 3 months until the end of the study period.
33086658|NCT00277641|Experimental|1|lamotrigine
33295173|NCT01065636|Experimental|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
33295174|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
33295175|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|No diet No exercise training
33295176|NCT03979248|Experimental|BMS-986165 + Rabeprazole|
32737665|NCT01236547|Active Comparator|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
32737666|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
32737667|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
33086659|NCT00277641|Placebo Comparator|2|
33086660|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
33086661|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
33295177|NCT00285012|Placebo Comparator|placebo|
33295178|NCT00285012|Experimental|varenicline|
33295179|NCT00284934|Active Comparator|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
33295180|NCT00284934|Experimental|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
33295181|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
33295182|NCT00284856|Experimental|1|Arm 1: Montelukast
33295183|NCT00284856|Active Comparator|2|Arm 2: Fluticasone
33295184|NCT00284856|Placebo Comparator|3|Arm 3: Placebo
33318427|NCT03224182|Experimental|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
33318428|NCT03224182|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
33318429|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
33318430|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
32737668|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
32737669|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
32737670|NCT05037591|Placebo Comparator|placebo A|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737671|NCT05037591|Placebo Comparator|placebo B|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
33086662|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
33086663|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
33086664|NCT00247208|Active Comparator|1|Express 2 bare metal stent
33086665|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
33086666|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
33086667|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
33086668|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
33086669|NCT00247286|Active Comparator|b|Biofeedback
33086670|NCT00284817|Experimental|1|MEDI-522
33086671|NCT00284817|Experimental|2|MEDI-522
33086672|NCT00284817|Experimental|3|MEDI-522
33086673|NCT00284817|Experimental|4|MEDI-522
33295185|NCT00298272|Experimental|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
33086674|NCT00284817|Experimental|5|MEDI-522
32939576|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
32939577|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
33295186|NCT00298272|Other|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
33295187|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
33295188|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
33295189|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
33295190|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
33295191|NCT00283842|Placebo Comparator|Placebo|
33295192|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
33295193|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
32939578|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
32939579|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
32737672|NCT05037591|Placebo Comparator|placebo C|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737673|NCT05037591|Placebo Comparator|placebo D|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737674|NCT05037591|Placebo Comparator|placebo E|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737675|NCT05037591|Placebo Comparator|placebo F|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737676|NCT05037591|Placebo Comparator|placebo G|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32939580|NCT03892460|No Intervention|Control|No treatment control
32939581|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
32939582|NCT00377936|Active Comparator|1|Gemcitabine
32939583|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
32939584|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
32939585|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
32939586|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
32939587|NCT03696758|Experimental|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
32939588|NCT03696758|Experimental|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
32787679|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
33295194|NCT00298038|Experimental|Rifaximin|Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
33295195|NCT00298038|Placebo Comparator|Placebo|Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
33295196|NCT00283686|Active Comparator|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
33295197|NCT00283686|Active Comparator|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
33295198|NCT00283686|Placebo Comparator|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
32787680|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
32787681|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
33295199|NCT00283686|Placebo Comparator|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
33295200|NCT00297882|Active Comparator|1 Artemether-Lumefantrine (AL)|Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.
33295201|NCT00297882|Active Comparator|2 Amodiaquine-Artesunate (AQ-AS)|Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.
33086675|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
33295202|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
33295203|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
33295204|NCT03975894|Experimental|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of <30%.
33295205|NCT03975894|No Intervention|Control|Symptom directed blood transfusion during pregnancy.
33295206|NCT00297648|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
33295207|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
33295208|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
33295209|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
33295210|NCT00283296|Experimental|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
33295211|NCT00297492|Experimental|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
33295212|NCT00297492|Active Comparator|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
33295213|NCT00297492|Active Comparator|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
33295214|NCT00496769|Experimental|Apixaban|
33295215|NCT00496769|Active Comparator|Acetylasalicylic acid|
33295216|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
33295217|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
33295218|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
33295219|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
33295220|NCT04401605|Experimental|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
33295221|NCT04401605|Placebo Comparator|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
33295222|NCT04400357|Experimental|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
33295223|NCT04400357|Active Comparator|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
33318431|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
33086676|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
33086677|NCT00247403|Experimental|2DG|
33086678|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
33295224|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
33295225|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
33086679|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
33086680|NCT04719039|Experimental|Yoga Group|Restorative Yoga intervention
33295226|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
33086681|NCT04719039|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
33295227|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
33295228|NCT00283062|Active Comparator|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
33086682|NCT00285051|Experimental|Group 1|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 300 mcg of delta-8-THC per dose
33086683|NCT00285051|Experimental|Group 2|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 600 mcg of delta-8-THC per dose
33086684|NCT00285051|Experimental|Group 3|Chemo cycle 1 - 300 mcg of delta-8-THC per dose, Chemo cycle 2 - IV Ondansetron
33086685|NCT00285051|Experimental|Group 4|Chemo cycle 1 - 600 mcg of delta-8-THC per dose Chemo cycle 2 - IV Ondansetron
33086686|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
33086687|NCT00247715|Other|Step-up|"Stepwise treatment:~step1: antacid (+placebo proton pump inhibitor)~step2: H2-receptor antagonist~step3: proton pump inhibitor (+ placebo antacid)"
33086688|NCT00247715|Other|step-down|"Stepwise treatment:~step1: proton pump inhibitor (+placebo antacid)~step2: H2-receptor antagonist~step3: antacid (+proton pump inhibitor)"
33086689|NCT00285090|Experimental|Early Treatment|
32737677|NCT05037591|Placebo Comparator|placebo H|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737678|NCT05037591|Placebo Comparator|placebo I|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737679|NCT05037591|Placebo Comparator|placebo J|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737680|NCT05037591|Placebo Comparator|placebo K|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737681|NCT05037591|Placebo Comparator|placebo L|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737682|NCT05037591|Placebo Comparator|placebo M|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737683|NCT05037591|Placebo Comparator|placebo N|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737684|NCT05037591|Placebo Comparator|placebo O|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737685|NCT05037591|Placebo Comparator|placebo P|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737686|NCT05037591|Placebo Comparator|placebo Q|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
33086690|NCT00285090|Experimental|LateTreatment|
33086691|NCT00285090|Experimental|Total Treatment|
33086692|NCT00285090|Placebo Comparator|No Treatment|
33086693|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
33086694|NCT00417222|No Intervention|Standard therapy|Standard therapy
33086695|NCT00247832|No Intervention|1|
33086696|NCT00247832|Experimental|2|Self-directed motivation
33086697|NCT00247832|Experimental|3|Personal motivational interviewing
33086698|NCT00278070|Active Comparator|1|
33086699|NCT00278070|Active Comparator|2|
33086700|NCT00278070|Active Comparator|3|
33086701|NCT00417261|Experimental|1|ATF936
33086702|NCT00417261|Experimental|2|AXT914
33086703|NCT00417261|Placebo Comparator|3|Placebo
33086704|NCT00424983|Experimental|Zometa q 4 weeks|
33086705|NCT00424983|Active Comparator|Zometa q 12 weeks|
33086706|NCT04718610|Active Comparator|Control|Patients will receive only caner treatment. No osteopathic treatment.
33086707|NCT04718610|Experimental|Osteopathic intervention|Patients will receive cancer treatment associated with osteopathic intervention
33086708|NCT00248105|Experimental|PAM|
33295229|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
33295230|NCT00283062|Active Comparator|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
33295231|NCT00282984|Placebo Comparator|placebo|
33295232|NCT00282984|Experimental|varenicline|
33295233|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
33295234|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
33295235|NCT00282438|Experimental|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
33086709|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
33086710|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
33086711|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
33295236|NCT00282438|Experimental|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
33086712|NCT00285168||1 - Control|Usual Bone Density Report
33295237|NCT01065948|Experimental|Patients|
33295238|NCT04282356|Experimental|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
33295239|NCT01068288|Experimental|Expectant Management|Expectant Management
33295240|NCT01068288|Experimental|Operative management|Operative management
33295241|NCT00296244|Other|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
33295242|NCT00296244|Other|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
33295243|NCT00274716|Experimental|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
33295244|NCT00274716|Experimental|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
33295245|NCT00274716|Experimental|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
33295246|NCT00274716|Placebo Comparator|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
33295247|NCT00274716|Experimental|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
33295248|NCT00274716|Placebo Comparator|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
32787682|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
32787683|NCT05565235|Active Comparator|Group B|bupivacaine
32787684|NCT05565235|Active Comparator|Group BMG|bupivacaine/ magnesium.
32787685|NCT05565235|Active Comparator|Group BN|bupivacaine /nalbuphine.
32787686|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
32787687|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
33086713|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
33086714|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
33086715|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
33086716|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
33086717|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
33086718|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
33295249|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
33295250|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
33295251|NCT00282048|Experimental|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
33295252|NCT03975348|Other|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
33295253|NCT03975348|Experimental|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
33295254|NCT03975348|Experimental|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
33295255|NCT03975348|Experimental|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
33295256|NCT03975348|Experimental|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
33295257|NCT03975348|Experimental|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
33295258|NCT03975348|Experimental|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
33295259|NCT03975348|Experimental|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
33295260|NCT03975348|Other|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
33295261|NCT03975348|Active Comparator|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
33295262|NCT03975192|Experimental|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
33295263|NCT03975192|No Intervention|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
33295264|NCT00474539|Experimental|1|
33295265|NCT00474539|Active Comparator|2|
33295266|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
33295267|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
33295268|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
32737687|NCT05037591|Placebo Comparator|placebo R|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32787688|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
32787689|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
33295269|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
33295270|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
33295271|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
33295272|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
33295273|NCT00281580|Placebo Comparator|Placebo|Placebo once daily for eight weeks
33295274|NCT00281580|Experimental|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
33295275|NCT00281580|Experimental|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
33295276|NCT00281580|Experimental|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
33295277|NCT00281580|Experimental|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
33295278|NCT00281580|Experimental|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
33295279|NCT00281580|Active Comparator|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
33295280|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
33295281|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
33295282|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
33295283|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
33295284|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
32737688|NCT05037591|Placebo Comparator|placebo S|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737689|NCT05037591|Placebo Comparator|placebo T|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
32737690|NCT05037591|Experimental|sea grape extract A|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737691|NCT05037591|Experimental|sea grape extract B|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
33086719|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
33086720|NCT00248768|Other|Arm 1|
33086721|NCT00278499||1|Female sex workers
33086722|NCT00278499||2|Female sex workers' clients (miners)
33086723|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
33086724|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
33086725|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
33086726|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
33086727|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
33086728|NCT00285402|Experimental|A|
33086729|NCT00285402|Experimental|B|
33086730|NCT00285402|Placebo Comparator|C|
33086731|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
33295285|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
33295286|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
33295287|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
33295288|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
33295289|NCT03997175|Experimental|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
33295290|NCT03997175|Placebo Comparator|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
33295291|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
33295292|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
33295293|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
33295294|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
33086732|NCT04720508||Group A (patient group)|"included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University.~blood samples will be obtained after getting informed consent."
33295295|NCT01020695||PTSD veterans|18 PTSD veterans
33086733|NCT04720508||Group B (control group)|included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
33295296|NCT01020695||controls|20 controls
33295297|NCT00495755|Experimental|Campath (alemtuzumab)|
33295298|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
33295299|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
33295300|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
33295301|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
33295302|NCT01070862|Experimental|Thalidomide, Dexamethasone|
33295303|NCT01070862|No Intervention|watch and wait|
33295304|NCT00495677|Active Comparator|PF-00232798 40 mg|
33086734|NCT00249041|Experimental|Etanercept liquid|
33086735|NCT00278772|Experimental|1|Divalproex
33086736|NCT00278772|Placebo Comparator|2|
33086737|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
33086738|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
33086739|NCT00414713|Active Comparator|1|Regular transfusion
33086740|NCT00414713|Active Comparator|2|Restricted transfusion
33295305|NCT00495677|Active Comparator|PF-00232798 300 mg|
33295306|NCT00495677|Active Comparator|PF-00232798 400 mg|
33295307|NCT00495677|Active Comparator|PF-00232798 5 mg|
33295308|NCT00495677|Active Comparator|PF-00232798 20 mg|
33295309|NCT00495677|Active Comparator|PF-00232798 150 mg|
33295310|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
33295311|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
33295312|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
33295313|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
33086741|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
33295314|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
33295315|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
33295316|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
33295317|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
33295318|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
33295319|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
33295320|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
33295321|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
33295322|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
33295323|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
33295324|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
33295325|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
33295326|NCT01018121|Active Comparator|Pediatrician Counseling|
33295327|NCT00292188|Experimental|Active|
33295328|NCT00292188|Placebo Comparator|Placebo|
33295329|NCT00272844|Experimental|Cholesterol supplementation|
33295330|NCT00271596|Experimental|Citalopram|20mg daily citalopram
33295331|NCT00271596|Placebo Comparator|Placebo|Matching daily placebo
33295332|NCT01068756|Other|Dapagliflozin/Rifampin|
33295333|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
32787690|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
32787691|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
33295334|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
33295335|NCT00291642|Placebo Comparator|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
32787692|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
32787693|NCT05649787|No Intervention|Usual care|Patients allocated to this arm will receive the usual care
32787694|NCT05649787|Active Comparator|Supervised aerobic training|Patients allocated to this arm will receive the usual care plus supervised aerobic training
33295336|NCT00291642|Experimental|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
32787695|NCT05649787|Active Comparator|Supervised aerobic plus low to moderate-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and low to moderate-intensity strength training
32939589|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
32939590|NCT03461965|Active Comparator|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
32939591|NCT03702608|Other|EluNIR 38mm|
32939592|NCT03708770|Other|endoAVF|
32939593|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
32939594|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
33295337|NCT00291642|Experimental|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
33295338|NCT00291642|Experimental|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
33295339|NCT00291642|Experimental|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
33295340|NCT00280566|Experimental|Ziprasidone|Active treatment, double-blind, randomized arm
33295341|NCT00280566|Placebo Comparator|Placebo|Placebo treatment, double-blind, randomized arm
33295342|NCT00270894|Experimental|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.
33295343|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
33295344|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
33295345|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
33295346|NCT01070940|Placebo Comparator|Isotonic saline infusion|
33295347|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
32787696|NCT05649787|Active Comparator|Supervised aerobic plus moderate to high-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training.
32787697|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
33295348|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
33295349|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
33295350|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
33295351|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
33295352|NCT01064726|Experimental|Ibuprofen|
33295353|NCT01064726|Experimental|Fluticasone propionate|
33295354|NCT01064726|Placebo Comparator|Placebo|
32787698|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
33295355|NCT01064804||relative bioavailability|
33295356|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
33295357|NCT00295022|Placebo Comparator|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
33295358|NCT00295022|Experimental|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
33295359|NCT00295022|Experimental|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
33295360|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
33295361|NCT00303446|Active Comparator|Dutasteride|Dutasteride 0.5 mg/day
33295362|NCT00303446|Placebo Comparator|Placebo|Matched placebo
33295363|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
33295364|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
33295365|NCT03980132|Experimental|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
33295366|NCT03980132|No Intervention|No preparation|Patients will not receive preparation before thyroidectomy
33295367|NCT01065038|Experimental|Anagrelide|
33295368|NCT01065038|Active Comparator|Hydroxyurea|
33295369|NCT03980054|Experimental|Arm Pyrotinib|Intervention: Drug: Pyrotinib
33295370|NCT03980054|Placebo Comparator|Arm Placebo|Intervention: Drug: Placebo
33295371|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
33295372|NCT00291486|Experimental|Cohort 1|"20 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
33295373|NCT00291486|Experimental|Cohort 2|"30 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
33318432|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
32787699|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
32787700|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
32787701|NCT05555407|Experimental|Wireless patch system (WPS)|Subjects scheduled for a gastric emptying scan will have a wireless patch system (WPS) placed.
32939595|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
32939596|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
33295374|NCT00291486|Experimental|Cohort 3|"30 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
33295375|NCT00291486|Experimental|Cohort 4|"40 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
33295376|NCT00291486|Experimental|Cohort 5|"40 millicurie (mCi) 131I-huA33, 1250 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
32939597|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
32939598|NCT05440747||Newly diagnosed CML-CP patients|Treat with TKI (Imatinib or Flumatinib or Nilotinb or Dasatinib).
33295377|NCT00301964|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
33295378|NCT03976986|Experimental|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
33295379|NCT03976986|Experimental|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
33295380|NCT00301808|Experimental|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
33295381|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
33295382|NCT03978026|Experimental|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
33295383|NCT03978026|Experimental|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
33295384|NCT03978026|Experimental|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
33295385|NCT03978026|Sham Comparator|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
33295386|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
33318433|NCT05623436|Experimental|Experimental|"Ventrogluteal injection training given by virtual reality technology is effective in increasing the knowledge and skill levels of students. It also has an impact on students' motivation and anxiety levels.~Intervention: Behavioral: Education"
32939599|NCT05440747||Patients with suboptimal response|"Treat with original TKI~Treat with original TKI combined with interferon/thymosin;~Replace other TKI ;~Replace other TKI and combined with interferon/thymosin."
32939600|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
32939601|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
32939602|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
32939603|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
32939604|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
32939605|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
32939606|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
32939607|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
32939608|NCT04147442|Experimental|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
32939609|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
33086742|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
33295387|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
33295388|NCT00268242|Experimental|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m^2/day I.V. on days 1, 2, and 3.
32939610|NCT04146272|Active Comparator|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
32939611|NCT04146272|Active Comparator|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
32939612|NCT04146272|Active Comparator|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
33295389|NCT00294554|Active Comparator|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
33295390|NCT00294554|Placebo Comparator|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
33295391|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
32939613|NCT04146272|Active Comparator|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
32939614|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
32939615|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
32939616|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
32939617|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
32939618|NCT03863210|Experimental|Participants who received informations about lifestyle change|
32939619|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
32939620|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
32939621|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
32939622|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
32939623|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
32939624|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
32939625|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
32939626|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
32939627|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
32939628|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
32939629|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
32939630|NCT04735705|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
32939631|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
32939632|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.~2 Liters of lactated ringers administered by anesthesia intraoperatively.~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).~Normal diet postoperatively."
33086743|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
33086744|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
33086745|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
32939633|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)~NPO Food/Milk: none beginning 8 hours prior to procedure time.~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
33295392|NCT00294398|Experimental|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
33295393|NCT00279708|Active Comparator|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
33295394|NCT00279708|Placebo Comparator|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
33295395|NCT03978182|Active Comparator|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
32939634|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
33295396|NCT03978182|Sham Comparator|sham|Built-in sham in the H1 Helmet (same device as active treatment)
33295397|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
33295398|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
33295399|NCT01581372|Experimental|Pharmacist care|
33295400|NCT01581372|No Intervention|Usual care|
33295401|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
32939635|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
33295402|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
33295403|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
33295404|NCT03976518|Experimental|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
33295405|NCT03974958|Experimental|AAA patients|Patients with abdominal aortic aneurysm (AAA)
33295406|NCT03974958|Experimental|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
33295407|NCT00299702|Active Comparator|002|
33295408|NCT00299702|Experimental|001|
33295409|NCT03979898|Experimental|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
33295410|NCT00291330|Experimental|dabigatran etexilate 150 mg|twice daily
33295411|NCT00291330|Active Comparator|warfarin (INR 2-3)|prn to maintain INR (2-3)
33295412|NCT03975036|Experimental|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
32939636|NCT04706611|Experimental|Irritable Bowel Syndrome|Fecal Microbiota Transplantation will be performed.
32939637|NCT04706611|Experimental|Constipation|Fecal Microbiota Transplantation will be performed.
32939638|NCT04706611|Experimental|Clostridium Difficile Infection|Fecal Microbiota Transplantation will be performed.
32737692|NCT05037591|Experimental|sea grape extract C|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737693|NCT05037591|Experimental|sea grape extract D|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32939639|NCT04706611|Experimental|Functional Dyspepsia|Fecal Microbiota Transplantation will be performed.
32939640|NCT04706611|Experimental|Parkinson's Disease|Fecal Microbiota Transplantation will be performed.
32939641|NCT04706611|Experimental|Metabolic Syndrome|Fecal Microbiota Transplantation will be performed.
32939642|NCT04706611|Experimental|Non-Alcoholic Fatty Liver Disease|Fecal Microbiota Transplantation will be performed.
32939643|NCT04706611|Experimental|Autism Spectrum Disorder|Fecal Microbiota Transplantation will be performed.
33295413|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
33295414|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
33295415|NCT00267150|Experimental|1|
33295416|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
33295417|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
33295418|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
33295419|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
33295420|NCT00278148|Experimental|Dose Level A|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level A: 50 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
33295421|NCT00278148|Experimental|Dose Level B|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level B: 100 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
33295422|NCT00278148|Experimental|Dose Level C|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level C: 150 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
33295423|NCT00299546|Placebo Comparator|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
32787702|NCT05649709|Experimental|vonoprazan and low-dose amoxicillin dual therapy|1000 mg amoxicillin capsules twice daily and 20 mg vonoprazan Fumarate Tablets twice daily for 14 days
32787703|NCT05649709|Active Comparator|vonoprazan and high-dose amoxicillin dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
32787704|NCT05649631|Experimental|Normal sodium diet(100mmol/d)|
32787705|NCT05649631|Experimental|Low sodium diet(50mmol/d)|
32787706|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
32787707|NCT02395172|Experimental|Avelumab|
32787708|NCT02395172|Active Comparator|Docetaxel|
32787709|NCT04876651|Experimental|Group A|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
32787710|NCT04876651|Active Comparator|Group B|Participants will receive the Standard of Care
32787711|NCT04876027|Experimental|GLP-1 RAs and calorie restrict diet group|Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)
32787712|NCT04876027|Active Comparator|calorie restrict diet group|Intervention with calorie restrict diet until reaching the target weight loss(7%)
32787713|NCT04859101|Experimental|Gum|Group 1 will receive gum immediately prior to transport to the operating room. They will be asked to chew the gum for 2 minutes and then spit the gum in the garbage.
33295424|NCT00299546|Experimental|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
33295425|NCT00299546|Experimental|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
33295426|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
33295427|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
33295428|NCT03975270|Experimental|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
32787714|NCT04859101|Other|Control|Group 2 will not receive any gum. They will be asked to swallow twice and have no other intervention.
32787715|NCT05543551|Experimental|Diaphragmatic breathing with Resistance Training|"Diaphragmatic breathing with Resistance Training:~Wall press-up: Attempt 3 sets of 5 to 10 repetitions. Dumbbell biceps curls: Attempt 3 sets of 5 to 10 repetitions. Back squats: 1 set of 10 repetitions Leg press:1 set of 10 repetitions"
32939644|NCT04706611|Experimental|Radiation Enteritis|Fecal Microbiota Transplantation will be performed.
32939645|NCT04706611|Experimental|Atopic Dermatitis|Fecal Microbiota Transplantation will be performed.
32939646|NCT04706611|Experimental|Food Allergic|Fecal Microbiota Transplantation will be performed.
32939647|NCT04706611|Experimental|Graft-versus-Host Disease|Fecal Microbiota Transplantation will be performed.
33295429|NCT01065116|Experimental|AL Blister-pack|
33295430|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
33295431|NCT03977792|Experimental|Experimental treatment|"Subjects treated with BOR15001L7.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
33295432|NCT03977792|Active Comparator|Comparator treatment|"Subjects treated with Docosanol 10%.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
33295433|NCT01062542||Breast Cancer Survivors|
33295434|NCT01062542||Pediatric Cancer Survivors|
33295435|NCT01062542||Control group|
33086746|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
33295436|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
33295437|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
33295438|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
33295439|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
33295440|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
33295441|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
33295442|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
33295443|NCT00299156|Experimental|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
33295444|NCT00277212|Experimental|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
33295445|NCT00277212|Placebo Comparator|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
33295446|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
33295447|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
33295448|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
33295449|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
33295450|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
33295451|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
33295452|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
33295453|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
33295454|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
33295455|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
32939648|NCT04706611|Experimental|Obesity|Fecal Microbiota Transplantation will be performed.
32939649|NCT04706611|Experimental|Diabetes mellitus|Fecal Microbiota Transplantation will be performed.
32939650|NCT04706611|Experimental|Multi-Drug Resistant Infection|Fecal Microbiota Transplantation will be performed.
32939651|NCT04706611|Experimental|Hepatic Encephalopathy|Fecal Microbiota Transplantation will be performed.
32939652|NCT04706611|Experimental|Enteric Dysbacteriosis|Fecal Microbiota Transplantation will be performed.
32939653|NCT04706611|Experimental|Multiple Sclerosis|Fecal Microbiota Transplantation will be performed.
32939654|NCT04706611|Experimental|Pseudomembranous Enteritis|Fecal Microbiota Transplantation will be performed.
32939655|NCT04706611|Experimental|Acute Pancreatitis|Fecal Microbiota Transplantation will be performed.
32939656|NCT04706611|Experimental|Chronic Fatigue Syndrome|Fecal Microbiota Transplantation will be performed.
32939657|NCT04706611|Experimental|Acute-on-chronic Liver Failure with HBV Infection|Fecal Microbiota Transplantation will be performed.
32939658|NCT04706611|Experimental|Alcoholic Liver Disease|Fecal Microbiota Transplantation will be performed.
33295456|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
33295457|NCT00276744|Experimental|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
33295458|NCT00251316|Experimental|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
33295459|NCT00251316|Placebo Comparator|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
32939659|NCT04706611|Experimental|Anorexia|Fecal Microbiota Transplantation will be performed.
32939660|NCT04706611|Experimental|Decompensated Cirrhosis|Fecal Microbiota Transplantation will be performed.
32939661|NCT04706611|Experimental|Henoch-Schonlein Purpura|Fecal Microbiota Transplantation will be performed.
32939662|NCT04706611|Experimental|Autoimmune Liver Disease|Fecal Microbiota Transplantation will be performed.
32939663|NCT04706611|Experimental|Systemic Lupus Erythematosus|Fecal Microbiota Transplantation will be performed.
32939664|NCT04706611|Experimental|IgG4-Related Disease|Fecal Microbiota Transplantation will be performed.
32939665|NCT04706611|Experimental|Celiac Disease|Fecal Microbiota Transplantation will be performed.
33295460|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
33295461|NCT00293462|Active Comparator|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
33295462|NCT00293462|Active Comparator|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
32939666|NCT04706611|Experimental|Protein-losing Enteropathy|Fecal Microbiota Transplantation will be performed.
33295463|NCT00293462|Active Comparator|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
33295464|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
33295465|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
33295466|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
33295467|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
32939667|NCT04706611|Experimental|Asperger Syndrome|Fecal Microbiota Transplantation will be performed.
32939668|NCT04706611|Experimental|Rheumatoid arthritis|Fecal Microbiota Transplantation will be performed.
32939669|NCT04706611|Experimental|Ulcerative colitis|Fecal Microbiota Transplantation will be performed.
33295468|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
33295469|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
33295470|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
33295471|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
33295472|NCT00298766|Experimental|1|VELCADE
33295473|NCT03979664|Active Comparator|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
33295474|NCT03979664|Sham Comparator|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
33295475|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
33295476|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
33295477|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
33295478|NCT01062620|Experimental|AXL1717|
33295479|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
33295480|NCT01065740|No Intervention|Usual care|
33295481|NCT01066910|Experimental|Parent-only|
33295482|NCT01066910|Active Comparator|Parent and child|
33295483|NCT01581242|Experimental|A|
33295484|NCT01581242|Experimental|B|
33295485|NCT01581242|Experimental|C|
33295486|NCT03982238|Active Comparator|Control group|continuous subcutaneous insulin infusion therapy
33295487|NCT03982238|Experimental|Metformin|metformin therapy
32939670|NCT04706611|Experimental|Crohn's disease|Fecal Microbiota Transplantation will be performed.
32939671|NCT04706611|Experimental|Psoriasis|Fecal Microbiota Transplantation will be performed.
32939672|NCT04706611|Experimental|Ankylosing spondylitis|Fecal Microbiota Transplantation will be performed.
33295488|NCT03982238|Experimental|Dapagliflozin|Dapagliflozin
33295489|NCT00293384|Experimental|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.~Days 2 & 3: Aprepitant 80 mg once daily in the morning."
33295490|NCT00297830|Experimental|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
33295491|NCT00297830|Experimental|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
33295492|NCT01065896||Group 1|
33295493|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
33295494|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
33295495|NCT00296816|Experimental|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
33295496|NCT03977870||patients with Venous thromboembolism (VTE)|
33295497|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
33295498|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
32787716|NCT05543551|Active Comparator|Diaphragmatic breathing exercises without Resistance Training|"Diaphragmatic Breathing:~Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~Place one hand on your upper chest and the other on your belly, just below your rib cage.~Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
33295499|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
33295500|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
33295501|NCT03977558|Experimental|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily ~50g canola oil
33295502|NCT03977558|Active Comparator|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
33295503|NCT00097786|Experimental|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum [ac] before meals) and valsartan 80 mg (once daily [od] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
33295504|NCT00097786|Experimental|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily [od] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals).
33295505|NCT00097786|Experimental|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum [ac] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily [od] in the morning).
33295506|NCT00097786|Placebo Comparator|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals) and 1 valsartan placebo capsule (once daily [od] in the morning).
33295507|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
33295508|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
33295509|NCT03965182|Active Comparator|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
33295510|NCT03965182|Active Comparator|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
33295511|NCT03965182|Active Comparator|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
33295512|NCT01081990|Placebo Comparator|Placebo Pill|
33295513|NCT01081990|Experimental|Flexeril|
33295514|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
33295515|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
33295516|NCT01079650||children suffering from abdominal or testicle pain|
33295517|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
33295518|NCT01084564||1|moderate to severe uncontrolled asthma
33295519|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
33295520|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
33295521|NCT00117988|Experimental|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
33295522|NCT03963466|Experimental|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
33295523|NCT03963466|Experimental|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
33295524|NCT03963466|Experimental|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
33295525|NCT03963466|Experimental|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
33295526|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
33295527|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
33295528|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
33295529|NCT00117676|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
33295530|NCT00117676|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
32787717|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
32787718|NCT02275819|No Intervention|control|Will not receive intervention with exercise
32787719|NCT02275819|Active Comparator|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
32787720|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
32787721|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
32787722|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
32787723|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
32787724|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
32787725|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
32787726|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
32787727|NCT05649475||Patients receiving neoadjuvant therapy|
32787728|NCT04869553|Experimental|ABC's arm|The 3 pain managements are in the ABC's order.
32787729|NCT04869553|Experimental|BCA's arm|The 3 pain managements are in the BCA's order.
32787730|NCT04869553|Experimental|CAB's arm|The 3 pain managements are in the CAB's order.
32787731|NCT05649319|Experimental|ERAS group|Perioperative care for laparoscopic distal gastrectomy is managed according to ERAS protocol.
32787732|NCT05649319|No Intervention|Conventional group|Perioperative care for laparoscopic distal gastrectomy is managed according to our current perioperative practice.
32787733|NCT05649241|Experimental|QuitAid, 8 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
32787734|NCT05649241|Experimental|QuitAid, 4 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
32787735|NCT05649241|Experimental|QuitAid, 8 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
32787736|NCT05649241|Experimental|QuitAid, 4 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
32787737|NCT05649241|Experimental|No QuitAid, 8 weeks, Patch + Gum|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
33403808|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
32787738|NCT05649241|Experimental|No QuitAid, 4 weeks, Patch + Gum|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
32787739|NCT05649241|Experimental|No QuitAid, 8 weeks, Patch|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
32787740|NCT05649241|Experimental|No QuitAid, 4 weeks, Patch|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
32787741|NCT05507827|Experimental|Dose escalation|Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells
32787742|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
32787743|NCT05500651|Experimental|Experimental group|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
32787744|NCT05500651|No Intervention|Control group|
32787745|NCT05488873|Experimental|Placebo|Participants will apply 4 mL QD Placebo topical solution
32787746|NCT05488873|Experimental|WST-057 Active|Participants will apply 4 mL QD WST-057 Active topical solution.
32787747|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
32787748|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
32787749|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
32939673|NCT04706611|Experimental|Immune checkpoint inhibition-related colitis|Fecal Microbiota Transplantation will be performed.
32939674|NCT04706611|Experimental|Autoimmune enteropathy|Fecal Microbiota Transplantation will be performed.
32939675|NCT04706611|Experimental|Drug-induced diarrhea|Fecal Microbiota Transplantation will be performed.
32939676|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
32939677|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
33086747|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
33086748|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
33086749|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
33086750|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
33086751|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
33086752|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
33295531|NCT00251004|Experimental|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
33295532|NCT00251004|Experimental|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
33295533|NCT00251004|Active Comparator|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
33295534|NCT03973632|Experimental|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
33295535|NCT03973632|Experimental|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
32787750|NCT01850524|Active Comparator|IXAZOMIB|"IXAZOMIB 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
33295536|NCT01325922|Other|50/50% Tilt|
32787751|NCT01850524|Placebo Comparator|Placebo|"IXAZOMIB matching-placebo capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib placebo-matching capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
32787752|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
32787753|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
32787754|NCT05648929|Active Comparator|the conventional expander Mentor CPX4 (MENTOR)|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with conventionally textured expander with surface roughness 60µM Ra"
32787755|NCT05648929|Active Comparator|the expander SmoothSilk(Motiva) with reduced surface roughness|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with reduced textured expander with surface roughness 4µM Ra"
33086753|NCT04720352|Sham Comparator|Sham Comparator|Sham delivers non therapeutic levels of radiofrequency and cryogen
33086754|NCT04720352|Experimental|Active Arm|Active arm delivers radiofrequency and cryogen
33086755|NCT00249704|Experimental|C|
33086756|NCT00249704|Experimental|B|
33086757|NCT00249704|Experimental|A|
33086758|NCT00249704|Placebo Comparator|D|
33086759|NCT00249860|Experimental|Interferon-beta-1a|
33295537|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
33295538|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
33086760|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
33086761|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
33086762|NCT00249899|Active Comparator|Stable statin therapy|
32787756|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32787757|NCT04858243|Active Comparator|Facility-Based ART|Men escorted to nearest health facility for ART initiation and continuation.
33295539|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
33295540|NCT00275262|Experimental|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
33295541|NCT00275262|Placebo Comparator|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
32787758|NCT04858243|Experimental|Home-Based ART|Home-based ART initiation and continuation provided for 3-months.
32939678|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
33295542|NCT00275028|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33295543|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
33295544|NCT01072422|Experimental|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
33295545|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
33295546|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
33295547|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
33295548|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
33295549|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
33295550|NCT04357457|Experimental|Almitrine|
33295551|NCT04357457|Placebo Comparator|Placebo|
33295552|NCT01015079||Entire Taiwan women|
33295553|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
33295554|NCT00471107|Sham Comparator|Sham TDCS|
33295555|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
33295556|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
33295557|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
33295558|NCT00488033|No Intervention|1|Standard of Care
33295559|NCT00488033|Other|2|CT Angiography
33295560|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
33295561|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
33295562|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
33295563|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
33295564|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
33295565|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
33295566|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
33295567|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
32737694|NCT05037591|Experimental|sea grape extract E|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737695|NCT05037591|Experimental|sea grape extract F|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737696|NCT05037591|Experimental|sea grape extract G|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737697|NCT05037591|Experimental|sea grape extract H|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737698|NCT05037591|Experimental|sea grape extract I|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737699|NCT05037591|Experimental|sea grape extract J|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
33295568|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
33295569|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
32939679|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
32939680|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
33295570|NCT00117598|Experimental|A|
33295571|NCT00117598|Experimental|B|
33295572|NCT00117598|Active Comparator|C|
33295573|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
33295574|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
33295575|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
33295576|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
33295577|NCT03964948|Other|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
32737700|NCT05037591|Experimental|sea grape extract K|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32939681|NCT03374683|Experimental|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
33295578|NCT03964948|Other|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
33295579|NCT03964948|Other|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
33295580|NCT03964948|Other|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
33295581|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
32939682|NCT03374683|Active Comparator|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
32939683|NCT03374683|Sham Comparator|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
32939684|NCT03480685|Other|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
32939685|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
32939686|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
33086763|NCT00279435|Placebo Comparator|placebo|
33086764|NCT00279435|Experimental|visilizumab|
33102379|NCT05465304||Azithromycin group|the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month
33295582|NCT01021475|Active Comparator|Usual drug FD therapy|
33295583|NCT04265170|Experimental|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
33295584|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
32787759|NCT05648617|Active Comparator|Protein Supplement group|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein supplement. The participants will be asked to add it to their soft food or their beverages to reach the goal of consuming 30g daily for 12 weeks (3months).
32787760|NCT05648617|No Intervention|control group|Receive no intervention- usual care, will receive the standard care of the clinic without supplemented with PS.
33086765|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
33295585|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
33295586|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
33295587|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
33295588|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
33295589|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
33295590|NCT01018433|Other|Treatment as Usual|
33295591|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
33295592|NCT03998111|Experimental|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
33295593|NCT00093808|Experimental|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
33295594|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
33295595|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
33295596|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
33295597|NCT01326754|Other|Artemether-lumefantrine|
33295598|NCT01326754|Other|Artesunate-amodiaquine|
33295599|NCT01326754|Other|Dihydroartemisinin-piperaquine|
33295600|NCT00093496|Experimental|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
33295601|NCT00117286|Experimental|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
33295602|NCT00117286|Experimental|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
33295603|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
33295604|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
33295605|NCT00265122|Experimental|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
33295606|NCT00265122|Experimental|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
33295607|NCT00265122|Experimental|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
33295608|NCT00265122|Experimental|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
33295609|NCT00265122|Experimental|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
33102380|NCT05465304||Azithromycin plus Clindamycin group|the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.
33295610|NCT00265122|Experimental|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
33102381|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
33102382|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
33295611|NCT00116584|Other|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
33295612|NCT00116584|Other|oxygen|oxygen-driven nebulizations for children with moderate to severe bronchiolitis
33295613|NCT00096538|Experimental|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
33295614|NCT00239928|Experimental|EYE001|
33295615|NCT00116428|Experimental|NAVISTAR® THERMOCOOL® Catheter|
33295616|NCT00116428|Active Comparator|Antiarrhythmic drug|
33295617|NCT03971448|Active Comparator|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
33295618|NCT03971448|Experimental|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
33295619|NCT03971214|Experimental|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
33295620|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
33295621|NCT01073748|Other|Healthy children|Children with no asthma as control group.
33295622|NCT00468845|Experimental|1|
33295623|NCT00468845|Experimental|2|
33295624|NCT00468845|Placebo Comparator|3|
33295625|NCT03996317|No Intervention|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
33295626|NCT03996317|Experimental|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
33295627|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
33295628|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
33295629|NCT01021865||With type 2 Diabetes|
33295630|NCT01021865||Without type 2 diabetes|
32787763|NCT05648539|Experimental|The clinical response of the music therapy|To assessthe efficacy of music therapy of MT group compared to Waiting group in mental subhealth.
32787764|NCT05648539|Experimental|The alterations of acoustic features in the music therapy|To understand the possible biological mechanism underlying the efficacy of music therapy by analyzing alterations of acoustic features.
32787765|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
32787766|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
32787767|NCT01850446|Experimental|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
32787768|NCT01850446|Active Comparator|Oseltamivir (Tamiflu)|"The treatment period is 5 days.~1 capsule (75 mg) twice a day during the meal or regardless of meal."
32787769|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
33102383|NCT05463315|Experimental|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
33102384|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
33102385|NCT05460819|Experimental|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
33295631|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
33295632|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
32787770|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
32787771|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
33295633|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
33295634|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
33295635|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
33295636|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
33295637|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
32737701|NCT05037591|Experimental|sea grape extract L|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32787772|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
32787773|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
32787774|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
32787775|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
32787776|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
32787777|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
32787778|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
32787779|NCT04856917|Experimental|High Dose Arm: Imsidolimab Biological humanized antibody|
32787780|NCT04856917|Experimental|Low Dose Arm: Imsidolimab Biological humanized antibody|
33295638|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
33295639|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
33295640|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
33295641|NCT01022021|Active Comparator|rituximab|
33295642|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
33295643|NCT00467597||Group 1|
32737702|NCT05037591|Experimental|sea grape extract M|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737703|NCT05037591|Experimental|sea grape extract N|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737704|NCT05037591|Experimental|sea grape extract O|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737705|NCT05037591|Experimental|sea grape extract P|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737706|NCT05037591|Experimental|sea grape extract Q|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737707|NCT05037591|Experimental|sea grape extract R|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32787781|NCT04856917|Placebo Comparator|Placebo|
32787782|NCT05648461|Experimental|Five fraction of post operative Radiotherapy|The present study is a non -randomised phase II study that will enroll 50 patients and test feasibility of 30 Gy in 5 fractions of the primary disease and ipsilateral level I-III disease.
32787783|NCT04856761||Cape Group|In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
32787784|NCT04856761||S-1 Group|In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
32787785|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
32787786|NCT05648383|Experimental|Pre-diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
32787787|NCT05648383|Experimental|Diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
32787788|NCT05648383|Active Comparator|Prediabetes group, control|Participants will receive standard care, including lifestyle recommendations
32787789|NCT05648383|Active Comparator|Diabetes group, control|Participants will receive standard care, including lifestyle recommendations
32787790|NCT04856059|Other|Cardiac MRI, ECG and Blood Biomarkers|Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
32787791|NCT05369689||spinal tumors, CT, MRI, PET-CT stereotactic radiosurgery|Patients who had spinal tumors and completed the CT, MRI or PET-CT examination before and after stereotactic radiosurgery.
32787792|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
32787793|NCT05648305||General Dental Practitioners|Cohort 1 consisted UK Armed Forces Personnel that received root canal treatment within the study period by General Dental Practitioners.
32787794|NCT05648305||Dentists with Specialist Interest (DWSI)|Cohort 2 consisted UK Armed Forces Personnel that received root canal treatment within the study period by DWSI, clinicians that had undertaken a 1-year post-graduate programme in Endodontics.
32787795|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
32787796|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
32787797|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
32787798|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
32787799|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
32787800|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
33403809|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
33086766|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
33086767|NCT02961608|Experimental|study group|
33086768|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
33086769|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
33086770|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
33086771|NCT00279630|Experimental|type of exericse|type of exercise
32787801|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
33295644|NCT00115804|Experimental|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
33295645|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
33295646|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
33295647|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
33295648|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
33295649|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
33295650|NCT00467519|Experimental|Group 2|Pentacel primed participants
33403810|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
33403811|NCT04806594|Experimental|Papix acne scar|Papix acne scar gel for 8 consecutive weeks, 2 times per day
33295651|NCT00264810|Active Comparator|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
33403812|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
33403813|NCT02344888|Active Comparator|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
33086772|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
33086773|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
33086774|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
33295652|NCT00264810|Sham Comparator|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
33295653|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
32787802|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
33086775|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
33086776|NCT04720235|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
33295654|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
33295655|NCT03970980|Experimental|FIO2 >90% group|This group receives FIO2 >90% during the surgery.
33295656|NCT03970980|Active Comparator|FIO2 <70% group|This group receives FIO2 <70% during the surgery.
33295657|NCT00091390|Experimental|External Beam Radiotherapy and High Dose brachytherapy boost|
33086777|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
33086778|NCT00250523||2|Healthy volunteers
33295658|NCT00239226|Experimental|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos >50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
33295659|NCT00239226|Experimental|2. IAS pacing-control group|"(Delta CTos<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos <50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
33318434|NCT05623436|No Intervention|Control|Ventrogluteal injection training given by virtual reality technology doesn't effective in increasing the knowledge and skill levels of students. It also hasn't an impact on students' motivation and anxiety levels.
33318435|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
32737708|NCT05037591|Experimental|sea grape extract S|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737709|NCT05037591|Experimental|sea grape extract T|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
32737710|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
32737711|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
32737712|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
32737713|NCT05048901|Experimental|Cabozantinib and Lanreotide|Oral cabozantinib 40-60 mg/day and lanreotide 120mg deep subcutaneous injection (SC) in day 1 every 4 weeks.
32737714|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
32737715|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
32737716|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
32737717|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
32737718|NCT05037435|Experimental|The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
32737719|NCT05037435|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
32737720|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
32737721|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
32737722|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
32737723|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
32737724|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
32737725|NCT05027373|Experimental|SSGJ-613|
32737726|NCT05027373|Placebo Comparator|Placebo|
32737727|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
32737728|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
32737729|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
32737730|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
32737731|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
33086779|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
33295660|NCT00239226|Active Comparator|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos >50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
33295661|NCT00239226|Active Comparator|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos <50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
33295662|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
33086780|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
33295663|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
33295664|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
33295665|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
33086781|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
33295666|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
33318436|NCT03362294|Experimental|GA Depot 25mg once monthly|Monthly IM injection
33318437|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
33318438|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
33318439|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
33318440|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
33318441|NCT01203488|Experimental|Experimental|Vitamin A group.
33318442|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
33318443|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
33318444|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
33318445|NCT03819998||PCOS group|women who have PCOS
33318446|NCT03819998||control group|women who donnot have PCOS
33318447|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
33318448|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
33318449|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
33318450|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
33318451|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
33318452|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
33318453|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
33318454|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
33318455|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
33318456|NCT05281640|Experimental|Affect Dysregulation intervention|"The AD module focuses on skills training in relation to identifying and labelling feelings, emotion management, distress tolerance, and acceptance of feelings and experiencing positive emotions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
33318457|NCT05281640|No Intervention|Treatment as usual (1)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
33318458|NCT05281640|Experimental|Negative Self Concept intervention|"The NSC module focus on the impact of trauma on one's self concept, how to stay in the present moment and combat dissociation, introduce self - compassion and mindfulness skills, challenge thinking patterns including tackling negative thoughts rules and assumptions that relate to ones-self, how to be more nurturing towards one's self, explore personal qualities and develop a balanced view of self.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
33318459|NCT05281640|No Intervention|Treatment as usual (2)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
33318460|NCT05281640|Experimental|Disturbed Relationships intervention|"The DR module will focus on exploration and revision of maladaptive schemas, effective assertiveness, awareness of social context, and flexibility in interpersonal expectations and behaviours that are displayed in social interactions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
33318461|NCT05281640|No Intervention|Treatment as usual (3)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
33295667|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
33295668|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
33295669|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
33295670|NCT01022099|Active Comparator|navigated TKA|
33295671|NCT01022099|Other|conventional TKA|
33295672|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
33295673|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
33295674|NCT01022255|Experimental|Arm 1|
33295675|NCT00264576|Experimental|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
33295676|NCT00264576|Active Comparator|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
33295677|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
33295678|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
33295679|NCT00466505|Experimental|Therapeutic Intervention|
33295680|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
33295681|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
33295682|NCT00264498|Active Comparator|1|Gemcitabine + Carboplatin
33295683|NCT00264498|Experimental|2|Gefitinib
33295684|NCT00466193|Experimental|Zolpidem 3.5mg|
33295685|NCT00466193|Placebo Comparator|Placebo|
33295686|NCT01072578|Experimental|1|
33295687|NCT01072578|Experimental|2|
33295688|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
33295689|NCT01024985||multiple sclerosis|
33295690|NCT01024985||neuromyelitis optica|
33295691|NCT01024985||controls|
33295692|NCT03971058|Active Comparator|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
33295693|NCT03971058|Active Comparator|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
33295694|NCT01025063||Lucentis (PRN group)|
33295695|NCT01025063||Lucentis (3 Injections over three months)|
33295696|NCT01025063||PDT (Reduced Fluence) and Lucentis|
33295697|NCT01025141|Experimental|MINISCREW|device
33295698|NCT01025141|Active Comparator|Reference|dental anchorage
33295699|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
33295700|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
33295701|NCT01022411|Experimental|A|Brown rice
33295702|NCT01022411|Placebo Comparator|B|White rice
33295703|NCT00263562|Experimental|Steroid arm|Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
33295704|NCT00263562|Placebo Comparator|Comparison Group|Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.
33295705|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
33295706|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
33295707|NCT03970434|Experimental|Metformin|
33295708|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
33295709|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
33295710|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
33295711|NCT00237744|Experimental|Wrist/Hand FES + Whole Arm Motor Learning|Subjects > 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
33295712|NCT00237744|Experimental|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
33295713|NCT00237744|Experimental|Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
33295714|NCT01072812|Experimental|Posiphen® tartrate capsules|
33295715|NCT00237042|Active Comparator|Self Management|Dental hygienist-delivered pain self-management treatment
33295716|NCT00237042|Experimental|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
33295717|NCT00237042|Experimental|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
33295718|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
33295719|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
33295720|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
33295721|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
33295722|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
33295723|NCT00465569|Placebo Comparator|Placebo|
33318462|NCT03818126|Experimental|del Nido cardioplegia|
33318463|NCT03818126|Active Comparator|cold blood cardioplegia|
33295724|NCT00090766|Experimental|Valganciclovir Age Group <= 2 Years|Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
33295725|NCT00090766|Experimental|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
33295726|NCT00090766|Experimental|Valganciclovir Age Group >= 12 Years|Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
33295727|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
33295728|NCT03961828|Experimental|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
33295729|NCT01087060||cysts surgically removed|
33295730|NCT01087060||cysts under surveillance|
33295731|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
33295732|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
33295733|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
33295734|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
33295735|NCT00465101|Other|GreenLight HPS|
33295736|NCT00084136|Experimental|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
33295737|NCT00084136|Experimental|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
33295738|NCT00084136|Experimental|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
33295739|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
33295740|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
33295741|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
33295742|NCT01583140|Active Comparator|Control|Bilingual health education booklets
33295743|NCT01085422|Experimental|Arm A|
33295744|NCT01090570|Experimental|PLX3397 25 mg|
33295745|NCT01090570|Experimental|PLX3397 50 mg|
33295746|NCT01090570|Experimental|PLX3397 100 mg|
33295747|NCT01090570|Experimental|PLX3397 200 mg|
33295748|NCT01090570|Experimental|PLX3397 300 mg|
33295749|NCT01090570|Placebo Comparator|Placebo|
33295750|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
33295751|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
33295752|NCT03961906|Active Comparator|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
33295753|NCT03961906|No Intervention|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
33295754|NCT01087138|Experimental|Exercise|exercise class 3x's/week
33295755|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
33295756|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
33295757|NCT00464945|Experimental|1|
33295758|NCT00464945|Active Comparator|2|
33295759|NCT01025297|Experimental|CYT107|
33295760|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
33295761|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
33295762|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
33295763|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
33295764|NCT00069784|Experimental|Insulin glargine + omega-3 polyunsaturated fatty acids|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of omega-3 polyunsaturated fatty acids once daily"
33295765|NCT00069784|Experimental|Insulin glargine + placebo|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of placebo once daily"
33295766|NCT00069784|Experimental|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
33295767|NCT00069784|Placebo Comparator|Standard care + placebo|• One capsule of placebo once daily
33295768|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
33295769|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
33318464|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
33086782|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
33086783|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
33086784|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
33086785|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
33295770|NCT03811834|Experimental|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by [14C]-mobocertinib 50 mcg (approximately 2 microcurie [mcCi]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
33295771|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
33295772|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
33295773|NCT03958084|Experimental|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
33295774|NCT03958084|Experimental|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
33295775|NCT03958084|Experimental|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
33295776|NCT03958084|Experimental|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
33295777|NCT03958084|Experimental|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
33295778|NCT03958084|No Intervention|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
33295779|NCT00090610|Experimental|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
33295780|NCT00090610|Experimental|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
33295781|NCT03957772|Active Comparator|Extrafascial injection|"Extrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
33086786|NCT00250640||Group 1|
33086787|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
33295782|NCT03957772|Experimental|Intrafascial injection|"Intrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
33295783|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
33295784|NCT03962296|Experimental|Entelon|Three daily oral doses of 50mg tablets were administered to patients
33295785|NCT03962296|Active Comparator|Doxium|Three daily oral doses of 250mg tablets were administered to patients
33086788|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
33295786|NCT03962296|Placebo Comparator|Placebo|Three masking tablets were administered to patients
33295787|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
33295788|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
33295789|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
33295790|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
33086789|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
32787806|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
32787807|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
33086790|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
33295791|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
33295792|NCT04224064|Experimental|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
33295793|NCT04224064|Experimental|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
33295794|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).~After 6 cycles,apatinib single drug maintained until progress."
33295795|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
33295796|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
33295797|NCT03962218|Experimental|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
33295798|NCT03962218|Other|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
33295799|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
33295800|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
32787808|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
32787809|NCT05469139||Portable MRI group|Patients on ECMO who undergo portable MRI to assess brain injury within 24-48 hours of ECMO initiation
32787810|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
33295801|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
33295802|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
33295803|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
33295804|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
32787811|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
32787812|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
33086791|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
33295805|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
33295806|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
33295807|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
33295808|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
33295809|NCT03839693|Placebo Comparator|Vehicle|Vehicle
33295810|NCT03839693|Experimental|ET-01 345U|botulinum toxin, Type A, Dose 1, 345 U
33295811|NCT03839693|Experimental|ET-01 1100U|botulinum toxin, Type A, Dose 2, 1100 U
33295812|NCT00068692|Experimental|Group I, Arm I|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
33295813|NCT00068692|Experimental|Group I, Arm II|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
33295814|NCT00068692|Experimental|Group I, Arm III|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
33295815|NCT00068692|Experimental|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
33295816|NCT00068692|Experimental|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
33295817|NCT00068692|Experimental|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
33295818|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
33295819|NCT01086202||Lateral offset arthroplasty|
33295820|NCT00463151|Placebo Comparator|1|0mg rebamipide
33295821|NCT00463151|Experimental|2|60mg rebamipide
33295822|NCT00463151|Experimental|3|150mg rebamipide
33295823|NCT00463151|Experimental|4|300mg rebamipide
33295824|NCT01025687|Experimental|glucose beverage|
33295825|NCT01025687|Experimental|noncaloric beverage with TV|
33295826|NCT01025687|Experimental|glucose beverage with TV|
33295827|NCT01025687|Experimental|noncaloric beverage|
33295828|NCT00068380|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33295829|NCT01086280||Patients exposed to Saxagliptin|
33295830|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
33295831|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
33295832|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
33295833|NCT00067990|Experimental|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
33295834|NCT00067990|Placebo Comparator|Placebo|No intervention with continuing follow-up for five years.
33295835|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
33295836|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
32787813|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
32787814|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
32787815|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
32787816|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
32787817|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
32787818|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
32787819|NCT04415164|Experimental|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
32787820|NCT04415164|Placebo Comparator|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
32787821|NCT04875481||ASD group|450 ASD from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
32787822|NCT04875481||TD group|100 healthy typical developing control (TDC) from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
32787823|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
32787824|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
32787825|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
32787826|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
33086792|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
33086793|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
33086794|NCT04719962|Experimental|Disseminated Lyme infection|Only patients presenting with disseminated Lyme borreliosis will be part of the study.
32787827|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
32787828|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
32787829|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
32787830|NCT05648149|Experimental|hierarchical multi-dimensional cognitive training scheme based on computer|Cognitive training was carried out by three trained and certified nurses in accordance with the cognitive training program. Twice a day, 30min each time, for 4 weeks, the difficulty of the training content is divided into 2 levels, the correct rate of more than 80% can enter the next level. During hospitalization, the patients and their families were taught how to use cognitive training programs. After discharge, special personnel were assigned to supervise and urge the patients to carry out cognitive training through the background.
32787831|NCT05648149|No Intervention|routine rehabilitation|Routine treatment, rehabilitation and care
32787832|NCT05648071|Experimental|Sintilimab Plus Bevacizumab and Platinum-Based Doublet Chemotherapy|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus bevacizumab until disease progression or intolerable toxicity.
32787833|NCT04924361||Early onset dementia|Dementia patients with onset age lower than 65y/o
32787834|NCT04924361||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
32787835|NCT04924361||Oldest old dementia|Dementia patients with onset age older than 85y/o
32939687|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face~Fraxel Restore: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
33086795|NCT02214160|Experimental|UX007|Participants previously treated with UX007 or treatment-naive participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
33086796|NCT01640002|Active Comparator|Propantheline|
33086797|NCT01640002|Placebo Comparator|Placebo|
33086798|NCT01640041|Experimental|Implanted|All participants.
33086799|NCT00279903|Active Comparator|Cortisone|
33295837|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
33295838|NCT00090220|Experimental|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
33295839|NCT00090220|Placebo Comparator|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
33295840|NCT00263328|Active Comparator|Treatment group 1|Standard of care
33295841|NCT00263328|Experimental|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
33295842|NCT00263328|Experimental|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
33295843|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
33295844|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
33295845|NCT00262860|Experimental|Bortezomib, Gemcitabine Hdrochloride|
33295846|NCT00236184|Placebo Comparator|Placebo|Oral placebo tablet
33295847|NCT00236184|Experimental|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
33295848|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
33295849|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
32737732|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
33086800|NCT00279903|Experimental|Low Dose Btx-A|
33295850|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
33295851|NCT03781817|Active Comparator|Intravenous ketamine|Participants randomized to IV ketamine will be receive IV ketamine and Intranasal normal saline.
33295852|NCT03781817|Experimental|Intranasal ketamine|Participants randomized to Intranasal Ketamine group will receive Intranasal ketamine and IV normal saline.
33295853|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
33295854|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
33295855|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring~Stimulus control~Changing eating behaviors~Goal setting~Problem solving~Social support~Cognitive restructuring~Relapse prevention"
33295856|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
33295857|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~Food structure~Energy density~Reduce variety of foods high in energy density and increase variety of foods low in energy density~Protein intake~Controlling the personal food environment~Individualized weight loss maintenance prescriptions"
33295858|NCT00235872|Experimental|Adalimumab 40 mg every other week (eow)|
33295859|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
33295860|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
33295861|NCT03970122|Experimental|GFB-887 SAD active|GFB-887 single dose active
33295862|NCT03970122|Placebo Comparator|GFB-887 SAD placebo|GFB-887 single dose placebo
33295863|NCT00296036|Experimental|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
32787836|NCT04924361||Cognitive normal control|cognitive normal control
33086801|NCT00279903|Experimental|High Dose Btx-A|
33086802|NCT02961452||Peanut allergic children|
33086803|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
33086804|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
33086805|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
33086806|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
32787837|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
32787838|NCT04868617|Experimental|Test Product|The non-CE marked test product is a stoma product based on the flat SenSura® Mio 1-piece (1-pc) and the flat 2-piece with mechanical coupling (2-pc MC) product that includes a novel skin protective layer in the baseplate.
32787839|NCT04868617|Active Comparator|Sensura Mio Comparator - Standard of Care|"The following comparator products will be used in this investigation:~SenSura® Mio 1-piece (1-pc) flat, Midi bag with normal outlet and~SenSura® Mio 2-piece with mechanical coupling (2-pc MC) flat, Maxi or Midi bag with normal outlet"
32787840|NCT04954391|Active Comparator|PRF one nerve|Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone
32787841|NCT04954391|Active Comparator|PRF three nerves|Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve
32787842|NCT05464069||Postpartum with migraine who used Nerivio during their pregnancy|Postpartum patients with migraine who used Nerivio at least 3 times during their pregnancy. Participants will be recruited from Nerivio's user database
32787843|NCT05464069||Postpartum with migraine who used other migraine therapy during their pregnancy|Postpartum patients with migraine who used did not used Nerivio prior to their pregnancy, during their pregnancy and at least 3 months postpartum. Participants will be referred to the study by site co-investigators, who are US-licensed healthcare providers seeing women with headache disorders and/or women during their pre-pregnancy and/or pregnancy period
33295864|NCT00296036|Experimental|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
33295865|NCT00296036|Experimental|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
32787844|NCT04954001|Experimental|Single Arm|
33295866|NCT00296036|Placebo Comparator|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
33295867|NCT00296036|Experimental|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
33295868|NCT00296036|Placebo Comparator|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
33295869|NCT01072890|Experimental|Temsirolimus and Pazopanib|
33295870|NCT00089674|Experimental|AMG 162|
33295871|NCT00089674|Placebo Comparator|Placebo|
33295872|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
33295873|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
33295874|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
33295875|NCT04187482|Experimental|Exercise training group|All participants will be receiving same exercise training intervention
33295876|NCT01090960|Experimental|A|
33295877|NCT03976388|Experimental|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
33295878|NCT03976388|Active Comparator|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
33295879|NCT03898973|Other|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
33295880|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
33295881|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
33295882|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
33295883|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
33295884|NCT01069328|Experimental|Arm 1|
33295885|NCT01069328|Experimental|Arm 2|
33295886|NCT01069328|Experimental|Arm 3|
33295887|NCT01069328|Experimental|Arm 4|
33295888|NCT01069328|Experimental|Arm 5|
33295889|NCT01069328|Experimental|Arm 6|
33295890|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
33295891|NCT01067222|Experimental|BF2.649|
33295892|NCT01067222|Active Comparator|Modafinil|
33295893|NCT01067222|Placebo Comparator|Placebo|
32787845|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
32787846|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
33295894|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
33295895|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
33295896|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
33295897|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
32787847|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
32787848|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
33295898|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
32787849|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
33295899|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
32787850|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
32787851|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
33295900|NCT00290888|Active Comparator|ACR|Arthroscopic rotator cuff repair without acromioplasty
33295901|NCT00290888|Experimental|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
33295902|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33295903|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33295904|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
33295905|NCT00290732|Experimental|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
33295906|NCT00290732|Active Comparator|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
33295907|NCT00312494|Placebo Comparator|Placebo|
33295908|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
33295909|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
33295910|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
33295911|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
33295912|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
33295913|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
33295914|NCT00290498|Experimental|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
32787852|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
32787853|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
32787854|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
32787855|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
32787856|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
32787857|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
32787858|NCT04953923|Experimental|Treatment A|Cedazuridine at a therapeutic dose
33295915|NCT00290498|Active Comparator|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))~No longer recruiting for this study arm."
32787859|NCT04953923|Experimental|Treatment B|Cedazuridine at a supratherapeutic dose
32787860|NCT04953923|Placebo Comparator|Treatment C|Placebo control
32787861|NCT04953923|Active Comparator|Treatment D|Moxifloxacin positive control
32787862|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
32787863|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
32787864|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
32787865|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
32787866|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
32939688|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face~Fractora: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
32939689|NCT04121078|Experimental|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
32939690|NCT04121078|Experimental|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
32939691|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
33295916|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15~paclitaxel 80mg/m2 in IV, D1 to D8 and D15~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
33295917|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
33295918|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
32939692|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
32939693|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
33295919|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
33295920|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
33295921|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
33295922|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
33295923|NCT01062698|Active Comparator|IV thrombolysis|
33295924|NCT03976232|Experimental|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
33295925|NCT03976232|Experimental|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
33295926|NCT03976232|Active Comparator|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
33295927|NCT03977324|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
33295928|NCT03977324|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
33295929|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
33295930|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
33295931|NCT01022645||Levonorgestrel IUD|
33295932|NCT01022645||Copper IUD or Tubal Ligation|
33295933|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
33295934|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
33295935|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
33295936|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
33295937|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
33295938|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
33295939|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
33295940|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
33295941|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
33295942|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
33295943|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
33295944|NCT01022723||Breast Cancer patients|Breast cancer patients
33295945|NCT01022723||Prostate Cancer patients|Prostate cancer patients
33295946|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
33295947|NCT01022723||Gastric Cancer patients|Gastric cancer patients
33295948|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
33295949|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
33295950|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
33295951|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
32737733|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
32737734|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
32787867|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
33295952|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
33295953|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
33295954|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
33295955|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
33295956|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
33295957|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
33295958|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
33295959|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
33295960|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
33295961|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
33295962|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
33295963|NCT00290342|Experimental|Infanrix-IPV Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh.
33295964|NCT00290342|Active Comparator|Infanrix + IMOVAX Polio Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs.
33295965|NCT00460811|Active Comparator|72 ug linaclotide acetate|
33295966|NCT00460811|Active Comparator|145 ug linaclotide acetate|
33295967|NCT00460811|Active Comparator|290 ug linaclotide acetate|
33295968|NCT00460811|Active Comparator|579 ug linaclotide acetate|
33295969|NCT00460811|Placebo Comparator|Matching Placebo|
33295970|NCT00290186|Experimental|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
33295971|NCT00290186|Active Comparator|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
33295972|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
33295973|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
33295974|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
33295975|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
33295976|NCT03977246|Experimental|Open-placebo|The open-placebo intervention session
33295977|NCT03977246|Placebo Comparator|Control|The control session
32737735|NCT05027529|Experimental|VA-ECMO and CytoSorb|standard ICU care WITH CytoSorb
32737736|NCT05027529|Placebo Comparator|VA-ECMO only|standard ICU care WITHOUT CytoSorb
32737737|NCT03329105|Experimental|Sea Salt Mouth Rinse|
32737738|NCT03329105|Active Comparator|Standardized Oral Health Practices|
32737739|NCT05048823|Experimental|Intervention Protocol|Visceral techniques for the gastrointestinal system
32737740|NCT05048823|Sham Comparator|Placebo Protocol|simulated visceral techniques in the region of the gastrointestinal system, without therapeutic intent
32737741|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
32737742|NCT05048511||Normal|Women with sufficient vitamin D level, when 25(OH)D >20 ng/ml
32737743|NCT05048511||Deficient|women deficiency vitamin D level, when 25(OH)D <20 ng/ml
32737744|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
32737745|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
32737746|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
33295978|NCT03977480|Active Comparator|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
33295979|NCT03977480|Active Comparator|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
33295980|NCT03977480|Active Comparator|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
33295981|NCT03977480|Placebo Comparator|placebo group|Patients will orally take placebo tablets for 12 weeks.
33295982|NCT03977090|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
33295983|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.~-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
33295984|NCT01067924|Experimental|Motivational interviewing|
33086807|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
33295985|NCT01067924|Active Comparator|Standard of care|
33295986|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
33295987|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
33295988|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
33295989|NCT00460655|Active Comparator|BTX|
33295990|NCT00460655|Placebo Comparator|Placebo|
33295991|NCT03982004|Experimental|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)~Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)~Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.~Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
32787868|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
33086808|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
33086809|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
33295992|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
33295993|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
33295994|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
33295995|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
33295996|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
33295997|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
33086810|NCT04719923||Subjects with autism spectrum disorders|Children affected by autism spectrum disorders
33086811|NCT04719923||Healthy controls|Healthy children
33295998|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
33295999|NCT01026233|Experimental|1|brentuximab vedotin
33296000|NCT01062932|Placebo Comparator|Placebo|
33296001|NCT01062932|Active Comparator|Cycloserine|
33296002|NCT01026311|Placebo Comparator|placebo|
33296003|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
33296004|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
33296005|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
33296006|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
33296007|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
33296008|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
33296009|NCT01581320|Experimental|DP-R206|
33296010|NCT01581320|Active Comparator|Bonviva|
33296011|NCT04909463|No Intervention|Unilateral rib fractures only, no device intervention|Unilateral rib fractures only, no device intervention
33296012|NCT04909463|Experimental|Unilateral rib fractures, device intervention|Unilateral rib fractures, will receive device intervention
33296013|NCT04909463|No Intervention|Bilateral rib fractures, no device intervention|Bilateral rib fractures, no device intervention
33296014|NCT04909463|Experimental|Bilateral rib fractures, device intervention|Bilateral rib fractures, will receive device intervention
33296015|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
33296016|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
33296017|NCT00289016|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
33296018|NCT00288860|Experimental|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
33296019|NCT00288860|Active Comparator|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
33296020|NCT00288704|Placebo Comparator|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
33318465|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
32787869|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for up to 1 year."
32787870|NCT05647915|Experimental|berberine group|Berberine hydrochloride plus lifestyle intervention
32787871|NCT05647915|Placebo Comparator|placebo group|Placebo plus lifestyle intervention
32787872|NCT04135963||Participants with MM|Participants diagnosed with MM from 8 investigative sites will be observed retrospectively for previous 5 years before enrollment until Day 1.
33296021|NCT00288704|Active Comparator|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
33296022|NCT00288704|Other|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
33296023|NCT00288626|Experimental|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
33296024|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
33296025|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
33296026|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
33296027|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
33296028|NCT00288080|Active Comparator|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
33296029|NCT00288080|Experimental|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
33296030|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
33296031|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
33296032|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
33296033|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
33296034|NCT01091194|Other|Exercise|Interval-based aerobic exercise
33296035|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
33296036|NCT01086592|Active Comparator|Control|
33296037|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
33296038|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
33296039|NCT01086592|Experimental|Electrotherapy+weights|
32787873|NCT01829230|Experimental|Test lens C|Test lens C from previous study
32787874|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
32939694|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
32939695|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
33296040|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
33296041|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
33296042|NCT03957538|No Intervention|Standard care|Standard consent and explanation
33296043|NCT03957538|Experimental|Virtual reality|Addition of VR headset
33296044|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
33403814|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
33086812|NCT04529356|Sham Comparator|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
32787875|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
32787876|NCT04588714|Experimental|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
33296045|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
33296046|NCT01086826|Experimental|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
33086813|NCT04529356|Active Comparator|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
33086814|NCT04529356|Experimental|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
33086815|NCT04529083|Experimental|Intervention|Mixed Reality System for virtual mirror therapy
33086816|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
33086817|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
33086818|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
33296047|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
33296048|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
33296049|NCT03741764|Other|Vivosorb|Only arm in study
33296050|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
33296051|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
32787877|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
32787878|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
32787879|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
33086819|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
33086820|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
33086821|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
33296052|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
33296053|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
33296054|NCT00287690|Experimental|Genistein|Supro drink once daily for 3 days
33296055|NCT00287690|Placebo Comparator|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
33086822|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
33086823|NCT00251147|Active Comparator|Open Repair|
33086824|NCT00251147|Active Comparator|Mini-open Repair|
33296056|NCT01063400||Activity monitoring|
33296057|NCT00286754|Experimental|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
33296058|NCT00286754|Active Comparator|Health Education Intervention (HEI)|Health Education Intervention (HEI)
32787880|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
32787881|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
32787882|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
33086825|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
33086826|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
32939696|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
33296059|NCT00286754|No Intervention|Usual Care (UC)|Usual Care (UC)
33296060|NCT03976154|Experimental|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
33296061|NCT03976154|Active Comparator|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
33296062|NCT03976154|Active Comparator|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
33296063|NCT01070186|Experimental|Treatment|See intervention descriptions
33296064|NCT01068470||patients with melanoma or kidney cancer|
33296065|NCT00066742|Experimental|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.~Treatment continues in the absence of disease progression or unacceptable toxicity."
33296066|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
32939697|NCT03817580|Experimental|Project X 26ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.
33296067|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
33296068|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
33296069|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
33296070|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
33296071|NCT03956914|Experimental|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
33296072|NCT03956914|Placebo Comparator|Placebo group|Placebo, 440 ml/day for 8 weeks
33296073|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
33296074|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
33296075|NCT03956290|Experimental|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
32939698|NCT03817580|Experimental|Project X 5.1ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.
32939699|NCT03817580|Active Comparator|Prevantics Maxi Swabstick|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.
33296076|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
33086827|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
32787883|NCT05647837|Experimental|patients wit IIH|"patient that complains of symptoms of chronic increase intracranial pressure especially visual with absent of organic cause through visual assessment, routine laboratory investigation and brain imaging.~these patients will undergo lumper puncture to assess CSF opening pressure and Neurofilament Light Chain (NFL) and HYpoxia Induced Factor (HIF) both in CSF and blood."
32787884|NCT05434117|Experimental|High-intensity interval Nordic walking|Participants will receive high-intensity interval Nordic walking training.
33086828|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
33086829|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
32787885|NCT05434117|Active Comparator|Control|Participants will undergo standard cardiovascular rehabilitation.
32787886|NCT05432635|Experimental|Treatment (CMV-specific CD19-CAR T cells, triplex vaccine)|"CONDITIONING REGIMEN: Patients receive standard conditioning regimen (typically carmustine, etoposide, cytarabine, melphalan) beginning approximately on day -9 in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION: Patients undergo autoHSCT on day -2.~CAR T-CELLS AND VACCINATION: Patients receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of disease progression or unacceptable toxicity."
32787887|NCT01827670|Experimental|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
32787888|NCT01827670|Active Comparator|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
32787889|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
32787890|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
32787891|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
33086830|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
33086831|NCT00286845||II|
33086832|NCT00286845||1|
33086833|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
33086834|NCT01641211|Other|Control|This group will watch a nutrition video.
33086835|NCT01641250|Experimental|Part A: RO5429083|
33086836|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
33086837|NCT00251264|Active Comparator|Open|
33086838|NCT00251264|Active Comparator|Arthroscopic|
33086839|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
33086840|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
33086841|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
33086842|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
33086843|NCT00280020|Experimental|CBT|
33086844|NCT00280020|Experimental|TCC|
33086845|NCT00280020|Active Comparator|SS|
33086846|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
33086847|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
33086848|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
33086849|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
33086850|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
33086851|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
33086852|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
33086853|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
33086854|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
33086855|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
33086856|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
33086857|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
33086858|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
33086859|NCT04823845|Experimental|Plantar Wart Treatment Using Adapalene Gel 0.1%|patients treated for plantar warts with Adapalene 0.1% gel
33086860|NCT00280098|Experimental|single group|
33086861|NCT01681147|No Intervention|Group One|Standard postpartum care after a pregnancy with gestational diabetes
33086862|NCT01681147|Experimental|Group Two|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
32787892|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
32787893|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
32787894|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
32787895|NCT05426473|Experimental|Patients with a completed form|
32787896|NCT04874467|Experimental|Keratinized Mucosa ≥ 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
32787897|NCT04874467|Experimental|Keratinized Mucosa < 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
32787898|NCT04594096|Experimental|Immediate Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual."
32787899|NCT04594096|Experimental|Delayed Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits)."
32787900|NCT01827592|Experimental|EBX 10|Elobixibat 10 mg/day
32787901|NCT01827592|Experimental|EBX 5|Elobixibat 5 mg/day
32787902|NCT01827592|Placebo Comparator|PLCBO|Placebo
33296077|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
33296078|NCT03742583|Active Comparator|Square Knot|
33296079|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
33296080|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
33296081|NCT01091506|Placebo Comparator|Placebo|Placebo
33296082|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
33296083|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
33296084|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
33296085|NCT01094080|Other|breast milk|infants are breast fed
33296086|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
33296087|NCT01094158|Experimental|low dose|100 mg daily (low dose)
33296088|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
33296089|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
33296090|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
33296091|NCT01094236|Experimental|Students|3rd grade students at participating study schools
33296092|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
33296093|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
32787903|NCT02323334|Placebo Comparator|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
32787904|NCT02323334|Experimental|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
33296094|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
33296095|NCT01094314|Active Comparator|sequential medium|
33296096|NCT01094314|Active Comparator|single medium|
33296097|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
33296098|NCT01091584|No Intervention|control group|usual care
33296099|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33296100|NCT03956212|Experimental|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
33296101|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
33296102|NCT01091740|Active Comparator|EES (Xience)|
33296103|NCT01094392||treatment every 6th week during 6 months|
33296104|NCT01094392||treatment every 2nd week during 6 months|
33296105|NCT01091818|Active Comparator|midazolam|
33086863|NCT01681147|Experimental|Group Three|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
33086864|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
33296106|NCT01091818|Experimental|dexmedetomidin|
33296107|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
33296108|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
33296109|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
32787905|NCT02323334|Experimental|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
33296110|NCT00065260|Experimental|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
33296111|NCT00065260|Experimental|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
33296112|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
33296113|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
32787906|NCT02323334|Experimental|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
32787907|NCT02323334|Experimental|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
32787908|NCT02323334|Experimental|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
33296114|NCT01327066|Placebo Comparator|Placebo|Placebo
33086865|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
33086866|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
33296115|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
33296116|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
33296117|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
33296118|NCT03956134|Experimental|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
33296119|NCT03956134|Experimental|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
33296120|NCT03956134|Experimental|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
33296121|NCT03956134|Experimental|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
33296122|NCT03956134|Active Comparator|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
33296123|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
33296124|NCT00451217|Experimental|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
33296125|NCT00451217|Active Comparator|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
33296126|NCT00451217|Experimental|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
33296127|NCT00451217|Active Comparator|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
33296128|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
33296129|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
33296130|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
33296131|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
33086867|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~1 800 mg (3 tablets) once a day for 4 days,~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
33086868|NCT05126719|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
33086869|NCT05108584|Experimental|Group 1 - Level 3 PPE and video laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
33296132|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
33296133|NCT00311402|Other|Aggrenox Capsule|
33296134|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
33296135|NCT01026545|Experimental|Cohort 1|
33296136|NCT01026545|Experimental|Cohort 2|
33296137|NCT01026545|Experimental|Cohort 3|
33296138|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
33296139|NCT01026545|Experimental|Cohort 5 (Japanese)|
33296140|NCT01026545|Experimental|Cohort 6 (Japanese)|
33296141|NCT03996083|Experimental|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
33296142|NCT03996083|Experimental|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
33296143|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
33296144|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
33296145|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
33296146|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
33296147|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
33296148|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
33296149|NCT00292370|Other|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
33296150|NCT00292370|Placebo Comparator|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
33296151|NCT00292370|Experimental|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
33296152|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
33296153|NCT01092052|Experimental|1|
33296154|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
33296155|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
33296156|NCT01094938||Repair|
33296157|NCT00064792|Placebo Comparator|OraPlus|
33296158|NCT00064792|Active Comparator|Simvastatin Susp|
33296159|NCT01095016|Experimental|Meptin swinghaler|
33296160|NCT01095016|Active Comparator|Berotec|
33296161|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
33296162|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
33296163|NCT03956992|Experimental|Mouth gel|A mouth gel with hydroxyapatite
33296164|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
33296165|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
33296166|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
33296167|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
33296168|NCT00286442|Experimental|Alogliptin 12.5 mg QD|
33296169|NCT00286442|Experimental|Alogliptin 25 mg QD|
33296170|NCT00286442|Placebo Comparator|Metformin|
33296171|NCT00063934|Experimental|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.~Patients with resectable tumors after 6 courses undergo surgical resection."
33296172|NCT03955744|Experimental|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
33296173|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
33296174|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
33296175|NCT00063154|Experimental|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
33296176|NCT01092520|Experimental|Gabapentin|
33296177|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
33296178|NCT03996161|Active Comparator|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
33296179|NCT03996161|Experimental|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
33296180|NCT03955666|Experimental|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
33296181|NCT03955666|Experimental|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
33296182|NCT00311168|Experimental|VIP On, Then VIP Off|Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
33296183|NCT00311168|Experimental|VIP Off, Then VIP On|Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.
33296184|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
33296185|NCT00062374|Experimental|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
33296186|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
33296187|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
33296188|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
33296189|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
33296190|NCT00285818|Active Comparator|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
33296191|NCT00285818|Placebo Comparator|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
33296192|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
33296193|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
33296194|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
33296195|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
33296196|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
33296197|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
32787909|NCT02323334|Experimental|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
32787910|NCT02323334|Experimental|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
32787911|NCT02323334|Experimental|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
32787912|NCT02323334|Experimental|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
32787913|NCT02323334|Experimental|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
32787914|NCT02323334|Placebo Comparator|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
32787915|NCT02323334|Experimental|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
32787916|NCT02323334|Experimental|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
32787917|NCT02323334|Experimental|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
32787918|NCT02323334|Placebo Comparator|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
32787919|NCT02323334|Experimental|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
32787920|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
32787921|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
32787922|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
32787923|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
32787924|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
32787925|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
32787926|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
32787927|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
32787928|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
32787929|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
32787930|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
33403815|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
32787931|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
32787932|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
32787933|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
32787934|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
32787935|NCT04198376|Experimental|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
32906912|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
32906913|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
32906914|NCT04378712|Experimental|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
33296198|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
33296199|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
33296200|NCT00285584|Active Comparator|Bupropion|Participants in this arm received bupropion.
33296201|NCT00285584|Placebo Comparator|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
32830433|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
33296202|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
33296203|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
33296204|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
33296205|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
33296206|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
33296207|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
33296208|NCT03671447|Active Comparator|ICU usual care|control condition
33296209|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
33296210|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
33296211|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
33296212|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
33296213|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
33296214|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
33403816|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
32830434|NCT03294096|Experimental|experimental group|
33296215|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
33296216|NCT01583842|Active Comparator|Imaging Only|Participants with high-risk neuroblastoma will receive imaging only without 124I-MIBG
33296217|NCT01092754|Other|A: Other|
33296218|NCT01092754|Other|B: Other|
33296219|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
33296220|NCT00291668|Experimental|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
33296221|NCT00291668|Experimental|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
33296222|NCT00291668|Placebo Comparator|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
33296223|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
33296224|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
33296225|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
33296226|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
33296227|NCT03955354|Experimental|experimental arm|SHR1210 plus apatinib
33296228|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
32830435|NCT03294096|Active Comparator|control group|
33296229|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
33296230|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
33296231|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
33296232|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
33296233|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
33296234|NCT01323101|Sham Comparator|Control|No doxycycline
33296235|NCT01323101|Experimental|Doxycycline|
33296236|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
33296237|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
33296238|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
33296239|NCT01023893||End-stage renal disease|
33296240|NCT03995615|No Intervention|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth< 3mm and ≤ 10% sites with bleeding on probing.
32787936|NCT04198376|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
32787937|NCT05405491|Experimental|PCR group|
32787938|NCT05405491|Sham Comparator|Control group|
32787939|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
32787940|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
33102386|NCT05460819|Sham Comparator|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
33296241|NCT03995615|No Intervention|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented >25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
33296242|NCT03995615|No Intervention|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1with out scaling and root planing
33296243|NCT03995615|Active Comparator|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
33296244|NCT03670355|Experimental|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
32787941|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
32787942|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
32787943|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
32787944|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
32787945|NCT01827046|Experimental|MIS plus rt-PA management|Subjects randomized to the Minimally Invasive Surgery (MIS) plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
32787946|NCT01827046|No Intervention|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
32787947|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
32787948|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
32787949|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
32787950|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
33296245|NCT03670355|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
32787952|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
32787953|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
32787954|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
32787955|NCT04904276||Initiating treatment with fostamatinib as second-line therapy|
32787956|NCT04904276||Treated with fostamatinib for at least 12 weeks as second-line therapy|
32787957|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:~placebo ultrasound during 5min ;~scapular squeezing in the sitting position (3x10repetitions);~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
32787958|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~external rotators strengthening in sidelying positions with load (3x10repetitions);~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
32787959|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
33102387|NCT05460819|No Intervention|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
33102388|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
33102389|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
33296246|NCT01068782|Experimental|Arm 1|
33296247|NCT01068782|Experimental|Arm 2|
33296248|NCT01068782|Experimental|Arm 3|
33296249|NCT01068782|Experimental|Arm 4|
32787960|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
32787961|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
32787962|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
32787963|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
32787964|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
32787965|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
32787966|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
32787967|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
33296250|NCT01023971||Group A|Patients investigated with mfERG and MP-1
33296251|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
33296252|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
33296253|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
33296254|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
33296255|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
33296256|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
33296257|NCT01024049||chronic heart failure patients|patient with chronic heart failure
33403817|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
33403818|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)~a brief moderate pressure massage session (massage: 15 min)"
32787968|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
32787969|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
33296258|NCT01024049||acute heart failure patients|acute heart failure patients
33296259|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
33296260|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
33296261|NCT01566305|Experimental|Buttermilk with added egg yolk|
33296262|NCT01566305|Experimental|Buttermilk without added egg-yolk|
33296263|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
33296264|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
33296265|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
33296266|NCT00283712|Experimental|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
33296267|NCT00283712|Placebo Comparator|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
33296268|NCT03981536|Experimental|AP-101: Dose Level 1|Single dose of AP-101
33296269|NCT03981536|Experimental|AP-101: Dose Level 2|Single dose of AP-101
33296270|NCT03981536|Experimental|AP-101: Dose Level 3|Single dose of AP-101
33296271|NCT00048724|Experimental|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
33296272|NCT00048724|No Intervention|Untreated Control|
33296273|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
33403819|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
32787970|NCT02321462|Experimental|Eziclen|
32787971|NCT02321462|Active Comparator|Fortrans®|
32787972|NCT04904120|Active Comparator|[203Pb]VMT01 first|Participants randomized to this arm will receive imaging agent [203Pb]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive [68Ga]VMT02 and undergo PET/CT imaging.
32906915|NCT04378712|Other|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
33403820|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
33403821|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
32787973|NCT04904120|Active Comparator|[68Ga]VMT02 first|Participants randomized to this arm will receive imaging agent [68Ga]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive [203Pb]VMT01 and undergo SPECT/CT imaging.
32787974|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
32787975|NCT02391584|Other|Control|Continued medical management
32787976|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
32787977|NCT04873843|Experimental|Functional digital game training group|These functional digital game programs have been developed to improve the intelligence and vitality in the community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
32787978|NCT04873843|Experimental|Individual cognitive training|Individual cognitive training has been used to improve the intelligence and cognitive function in community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
32787979|NCT04865965|Experimental|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
32787980|NCT04865965|No Intervention|No Exercise|No Exercise Session
33296274|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
33296275|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
33296276|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
33296277|NCT01024361|No Intervention|Routine|Routine protocol of the service
33296278|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
32787981|NCT05647135||Group A|Group A - enteral formula with 6.3 g/100 ml protein
32787982|NCT05647135||Group B|enteral formula with 10 g/100 ml protein
32787983|NCT05402917||Thoracic Epidural Analgesia (TEA)|For patients undergoing TEA is done under general anesthesia after surgery procedure.Once the catheter is secured, a bolus dose of 15 ml of 0.25% bupivacaine will be administered as an epidural injection through the catheter, followed by a continuous infusion of 0.125% bupivacaine at a rate of 0.1 mL/kg/h for the postoperative 24-hour period.
32787984|NCT05402917||Erector Spina Plan Block (ESPB)|For patients undergoing ESPB is done under general anesthesia after surgery procedure.A bolus dose of 15 mL of 0.25% bupivacaine will be administered from the inserted catheter. Subsequently, 0.125% bupivacaine will be given continuously at a rate of 0.1 mL/kg/h for up to 24 hours post-operatively.
32787985|NCT05647057|Active Comparator|A: gelofusine + ringers|Prime fluid strategy containing gelofusine and ringers
32787986|NCT05647057|Active Comparator|B: albumin + ringers|Prime fluid strategy containing albumin and ringers
32787987|NCT05647057|Active Comparator|C: ringers + retrograde autologous priming|Prime fluid strategy containing ringers combined with retrograde autologous priming
32787988|NCT05395039|No Intervention|Usual Care: Control Group|No interventions administered. Participant will receive usual care in the hospital.
32787989|NCT05395039|Experimental|VCHIPS: Intervention Group|Individuals in this group will work with a study nurse to schedule the intervention.
32787990|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
32787991|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
32787992|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
32787993|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
32787994|NCT05386147|Experimental|Study group|"Women with recurrent BV use the Flourish HEC Vaginal Care System, consisting of three components: 1) Balance external wash; 2) BioNourish vaginal moisturizing gel (an FDA 510k cleared class II medical device); and 3) BiopHresh homeopathic vaginal suppository with probiotics. All system components are currently available to the public at national retailers. Women will use the system for six months. They will have vaginal microbiome composition (next-generation sequencing and Nugent score) and vaginal pH tested at baseline, 3 months, and 6 months. At each timepoint they will also complete the vulvovaginal symptoms questionnaire (VSQ)."
32787995|NCT05385055|Active Comparator|Cigarette|Current cigarette smokers
32787996|NCT05385055|Active Comparator|THS|THS users with a minimum of 2 years of THS use
32787997|NCT05385055|Active Comparator|SA|Former cigarette smokers with minimum of 2 years of smoking abstinence
33296279|NCT00457691|Experimental|1|
33296280|NCT00457691|Placebo Comparator|2|
33296281|NCT00457301||Control|
33296282|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
33296283|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
33296284|NCT03820271|Other|SuperMELD|
32787998|NCT04854889|Experimental|Decitabine|Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.
32787999|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
32788000|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
32788001|NCT05646823|Placebo Comparator|Placebo|vehicle only - Maltodextrin gluten free
32788002|NCT05646823|Experimental|Treatment|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
33296285|NCT00447005|Experimental|Open|
33296286|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
33296287|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
33296288|NCT01024517|Experimental|Single oral dose, solution|
32788003|NCT04864405|Active Comparator|Morning administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient wake up time
33296289|NCT01024517|Experimental|Single oral dose, solid, fasted|
33296290|NCT01024517|Experimental|Single oral dose, solid, fed.|
33296291|NCT01024595||Without treatment|
33296292|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
33296293|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
33296294|NCT00446849|Experimental|MMX Mesalamine|
33296295|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
32788004|NCT04864405|Active Comparator|Evening administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient bed time
32788005|NCT04864249|Experimental|SNOO Responsive Bassinet|Will receive and be instructed on the use of the SNOO responsive bassinet for their newborn + the current standard of care of safe sleep education in the postpartum period
32788006|NCT04864249|Active Comparator|Usual Care|Will receive the current standard of care of safe sleep education in the postpartum period
32788007|NCT05356741|Experimental|Part 1 (dose escalation)|Participants will receive single-agent AMX-818
32788008|NCT05356741|Experimental|Part 2 (dose escalation)|Participants will receive AMX-818 plus pembrolizumab
32788009|NCT05356741|Experimental|Part 3 (dose expansion)|Participants will receive single-agent AMX-818
33296296|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
33296297|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
33296298|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
33296299|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
32788010|NCT05356741|Experimental|Part 4 (dose expansion|Participants will receive AMX-818 plus pembrolizumab
32788011|NCT05646667|Experimental|Interscalene with erector spinae plane block group|Patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and ultrasound guided erector spinae plane block at thoracic (T2) using 10 ml of bupivacaine 0.5%.
32788012|NCT05646667|Experimental|Interscalene group|Patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
32788013|NCT05646589|Experimental|Person-centred care transition support|
32788014|NCT05646589|Active Comparator|Regular care transition|
32788015|NCT05646511|Active Comparator|Control arm SCRT+CAPOX|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).
32906916|NCT04378556|Other|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
33296300|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
33296301|NCT00456365|Experimental|Pravastatin|Pravastatin
33296302|NCT00456365|Placebo Comparator|Placebo|Placebo
33296303|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
33296304|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
33296305|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
33296306|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
33296307|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
33296308|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
33296309|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
33296310|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
33296311|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
33296312|NCT00445679|Experimental|A|DVS SR 50mg/day
33086870|NCT05108584|Experimental|Group 2 - Level 3 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and direct laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
33086871|NCT05108584|Experimental|Group 3 - Level 2 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 2 PPE (surgical gown/apron, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
33086872|NCT01686841|Experimental|Fat Reduction|
33086873|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
33086874|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
33086875|NCT05140096|Experimental|Treatment AB|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A) and later will receive single oral loading dose of 400 mg fluconazole tablets on Day 1, one hour prior to a single oral dose of 100 mg acalabrutinib in Period 2 (Treatment B).
33296313|NCT00445679|Experimental|B|DVS SR 100mg/day
33296314|NCT00445679|Experimental|C|DVS SR 200mg/day
33296315|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
33296316|NCT00455429|Placebo Comparator|Placebo|
33296317|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
33296318|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
33296319|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
33296320|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
33296321|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
33296322|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
33296323|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
33296324|NCT00444587|Active Comparator|Only Chemotherapy|
33296325|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
33296326|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
33296327|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
33296328|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
33296329|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
33296330|NCT00235716|Experimental|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
33296331|NCT00235716|Experimental|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
33296332|NCT00235716|Experimental|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
33296333|NCT00235716|Placebo Comparator|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
33296334|NCT00274742|Experimental|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
33296335|NCT03973398|Active Comparator|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
33296336|NCT03973398|Active Comparator|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
33296337|NCT03973398|Placebo Comparator|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
33296338|NCT03973398|Placebo Comparator|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
33296339|NCT03970044|Experimental|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
33296340|NCT03970044|Active Comparator|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
33296341|NCT03970044|Active Comparator|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
33296342|NCT00283400|Active Comparator|dosage tier 1|0.625 g/kg 25% human albumin
33296343|NCT00283400|Active Comparator|dosage tier 2|1.25 g/kg 25% human albumin
33296344|NCT00283400|Active Comparator|dosage tier 3|1.875 g/kg 25% human albumin
33296345|NCT00283400|Active Comparator|dosage tier 4|2.5 g/kg 25% human albumin
33296346|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
33296347|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
33296348|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
33296349|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
33296350|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
33296351|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
33296352|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
33296353|NCT00283244|Active Comparator|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
33296354|NCT00283244|Experimental|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
33296355|NCT00283244|Experimental|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
33296356|NCT03975686|Experimental|intervention|
33296357|NCT03975686|No Intervention|control|
33296358|NCT00282464|Active Comparator|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
33296359|NCT00282464|Placebo Comparator|Placebo|
33296360|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
33296361|NCT03976856|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
33296362|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
32788016|NCT05646511|Experimental|Experimental arm SCRT+CAPOXIRI|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).
32788017|NCT02260921|Experimental|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
32788018|NCT02260921|Sham Comparator|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
32788019|NCT05348083||ESPB|A prospective cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided ESPB at T9 level at the end of surgery.
32788020|NCT05348083||p-QLB|A historical cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided p-QLB at the end of surgery.
32788021|NCT01643473|Active Comparator|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
32788022|NCT01643473|Experimental|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
32788023|NCT05646277||Test|first remote-assisted orthodontic teleconsultation
32788024|NCT05646277||Control|classic first consultation (face-to-face consultation)
32788025|NCT05344651|Active Comparator|Baerveldt glaucoma drainage device|
32788026|NCT05344651|Experimental|Paul glaucoma drainage device|
32788027|NCT05341843|Experimental|sertraline|they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
32788028|NCT05341843|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks
33296363|NCT03976700|Experimental|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
33296364|NCT03976700|Placebo Comparator|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
33296365|NCT00209274|Experimental|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
33296366|NCT00209274|Active Comparator|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
33296367|NCT03976778|Other|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
33296368|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
33296369|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
33296370|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
33296371|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
33296372|NCT00262080|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
33296373|NCT00262080|Placebo Comparator|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
33296374|NCT01073904|Experimental|Arm 1|
33296375|NCT01073904|Active Comparator|Arm 2|
33086876|NCT05140096|Experimental|Treatment AC|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A), and later will receive oral dose of 200 mg iscavuconazole capsules three times daily (approximately every 8 hours apart) on Day 1, followed by 200 mg iscavuconazole capsule once daily from Day 2 to Day 5 with a single oral dose of 100 mg acalabrutinib capsule coadministered on Day 5 in Period 2 (Treatment C).
32788029|NCT05646199|Active Comparator|Metformin|Participants in this group will be given metformin
32788030|NCT05646199|Active Comparator|Semaglutide|Participants in this group with receive Semaglutide
33296376|NCT03969810|Experimental|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
33296377|NCT03969810|No Intervention|Usual Care|Usual ICU care
33296378|NCT03973554|Experimental|pearl powder|natural product, support bone and joint health
33296379|NCT03973554|Active Comparator|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
33296380|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
33296381|NCT00282308|Experimental|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
33296382|NCT00282308|Active Comparator|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
33296383|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
33296384|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
33296385|NCT03969732|Experimental|amyloid PET、T807 PET|PET/CT
33296386|NCT03975608|Experimental|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
33296387|NCT00282152|Active Comparator|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
33296388|NCT00282152|Experimental|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
33296389|NCT00281840|Experimental|bevacizumab with docetaxel and radiation therapy|
32788031|NCT05646121||wounds at risk of infection|Ideally 71 patients with wounds at risk of infection (W.A.R. Score ≥ 3) to be included.
33296390|NCT00281684|Experimental|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
33296391|NCT00281684|Experimental|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
33296392|NCT00281684|Experimental|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
33296393|NCT00281684|Experimental|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
33296394|NCT03975452|Experimental|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
33296395|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
33296396|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
33296397|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
33296398|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
32788032|NCT05646121||infected wounds|Ideally 28 patients with infected wounds (TILI Score ≥ 5) to be included.
32788033|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
32906917|NCT03404492|Other|Patients with pulmonary hypertension|
32906918|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
33296399|NCT00272792|Experimental|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
32906919|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
32788034|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
32788035|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
32788036|NCT05333263|Experimental|Balance assessment on specialized treadmill|Subjects will undergo a balance assessment on a microprocessor-controlled treadmill
32788037|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
32788038|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
32788039|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
32788040|NCT02092467|Experimental|Treatment Arm 1|
32788041|NCT02092467|Experimental|Treatment Arm 2|
32788042|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
32788043|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
32788044|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
32788045|NCT04951583|Experimental|Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).|"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab.~Metastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab."
32788046|NCT04951115|Experimental|Radiation + Chemo-Immunotherapy|
32788047|NCT04420871|Active Comparator|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
32788048|NCT04420871|Experimental|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
32788049|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
32788050|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
32788051|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
32788052|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
32788053|NCT04935047|Experimental|Experimental (Multilingual Support)|The treatment group will receive seven hours multilingual support weekly.
32788054|NCT04935047|No Intervention|Control group|The control group will receive the same amount of support as the experimental group, but from a person without multilingual qualifications.
32788055|NCT04934891|Experimental|ION547|Ascending single multiple doses of ION547 will be administered by SC injection.
32788056|NCT04934891|Placebo Comparator|Placebo|Ascending single multiple doses of ION547-matching placebo will be administered by SC injection.
32788057|NCT04892888||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
32788058|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
32788059|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
32788060|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
32788061|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
32788062|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
32788063|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
32788064|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
32788065|NCT04693221|Sham Comparator|Control|VNS therapy with randomly-set combination of parameters (similar to current practice)
32788066|NCT04693221|Experimental|Experimental|VNS therapy with set combination of parameters chosen based on the lowest phase lag index
32788067|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
32788068|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
32788069|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
32906920|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
32788070|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
32788071|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
32788072|NCT04716933|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
32788073|NCT04716933|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
32788074|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
32788075|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
32788076|NCT02462603|Experimental|PTC589|Participants with Parkinson's disease (idiopathic and mitochondrial genetic subtype participants) will receive PTC589 at a dose of 500 milligrams (mg) (2 tablets of 250 mg each) orally twice daily (BID) for up to 3 months unless discontinued for safety or tolerability issues.
32788077|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
32788078|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
32788079|NCT05370248|Experimental|The six|The group who received tidal volume of 6 ml/kg from mechanical ventilation
32788080|NCT05370248|Active Comparator|The ten|The group who received tidal volume of 10 ml/kg from mechanical ventilation
32788081|NCT04923347|Experimental|Participants receiving FF/UMEC/VI via ELLIPTA inhaler|
32788082|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
32788083|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
32788084|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
32788085|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
32788086|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
32788087|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
32788088|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
32788089|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
33086877|NCT04823065|No Intervention|Control group|4FMFES injection is performed as usual, no supplemental medication is used.
32788090|NCT02461745|Active Comparator|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
32788091|NCT02461745|Active Comparator|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
32788092|NCT02034435|Active Comparator|Aim1-Low Sodium then High Sodium|"Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made."
32906921|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
33086878|NCT04823065|Experimental|Loperamide|Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
33102390|NCT05458830|Experimental|Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
32788093|NCT02034435|Active Comparator|Aim 1-high salt diet then low salt diet|"Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made."
32788094|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone then amlodipine|Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.
32788095|NCT02034435|Active Comparator|aim2- low salt diet and amlodipine then epleronone|Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.
32788096|NCT04691427|Experimental|Active Virtual Reality-Based Vision Therapy|Virtual reality vision therapy where participants will be playing a custom-designed video game to act as a therapeutic intervention on a consumer-available virtual reality headset.
32788097|NCT04714281|Other|Hemodiafiltration HDF|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
32788098|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
32788099|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
32788100|NCT02033889|Placebo Comparator|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
32788101|NCT02447003|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
32788102|NCT02447003|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
32788103|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
32788104|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
32788105|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
32788106|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
32788107|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
32788108|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
32788109|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
32788110|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
32788111|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
33102391|NCT05458830|Other|Care as usual|Plain advisory text
32788112|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
32906922|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
32788113|NCT04594018|Experimental|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride placebo, oral, once a day.~1 mL Finlândia hair lotion, topical, twice a day."
32788114|NCT04594018|Active Comparator|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride, oral, once a day.~1 mL minoxidil hair lotion, topical, twice a day."
33296400|NCT00272792|Placebo Comparator|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
32788115|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
32788116|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
32788117|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
32788118|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
32788119|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
32788120|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
33296401|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
33296402|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
33296403|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
32788121|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
32788122|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
32788123|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
32788124|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
33296404|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
33296405|NCT01069094|Placebo Comparator|placebo|Placebo capsule
33296406|NCT00048568|Experimental|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
33296407|NCT00048568|Active Comparator|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
32788125|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
32830436|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
33296408|NCT00048568|Experimental|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
33296409|NCT00262002|Experimental|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
33296410|NCT00262002|Experimental|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
33296411|NCT00262002|Experimental|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
33296412|NCT00262002|Experimental|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
33296413|NCT00262002|Experimental|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
32788126|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
32788127|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Doses TBD|Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
32788128|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300|LYT-300, Dose TBD with and without food, separated by 7-day washout
32788129|NCT05129865|Experimental|LYT-300, Dose TBD QAM every 24 h for 7 days|
32788130|NCT05129865|Placebo Comparator|Placebo QAM every 24 h for 7 days|
32788131|NCT05129865|Placebo Comparator|Placebo QHS every 24 h for 7 days|
33296414|NCT00262002|Experimental|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
32788132|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD QHS every 24 h for 7 days|
32788133|NCT04690335|Experimental|MV-012-968|Dose: 1 x10^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).
33296415|NCT00262002|Experimental|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
33296416|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
33296417|NCT03955120|Experimental|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
33296418|NCT03955120|Active Comparator|Sleep Apnea- Treatment as Usual|"The treatment as usual [TAU] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
33296419|NCT03955120|Experimental|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
33296420|NCT03955120|Active Comparator|Insomnia - Treatment as Usual|"The treatment as usual [TAU] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments [e.g. relaxation therapies], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
33296421|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
33296422|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
33296423|NCT01584076|Experimental|Donepezil|
33296424|NCT03954964|No Intervention|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
32788134|NCT04690335|Placebo Comparator|Placebo|Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.
32788135|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
32788136|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
32788137|NCT04713033|Experimental|Experiment 1|Experiment 1 (Aim 1) will utilize a 16-channel sEMG array to characterize cervical-cranial muscle activity networks in typical speakers at baseline and after a vocal loading task. Flexible laryngoscopy will be performed to exclude any existing pathology and confirm eligibility in the healthy control group. Aim 2 will quantify how cervical muscle networks are perturbed in patients with two different types of dysphonia and examine if standard-of-care treatment restores cervical-cranial muscle networks to more typical states.
32788138|NCT04713033|Experimental|Experiment 2|In Experiment 2 (Aim 2), the study will measure muscle networks in patients with muscle tension dysphonia before and after a course of voice therapy. Patients with muscle tension dysphonia represent an intact but potentially maladaptive network.
32906923|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
33296425|NCT03954964|Experimental|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
33296426|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
33296427|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
33296428|NCT00281528|Experimental|130 mg/m^2 ABI-007 weekly|130 mg/m^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
32788139|NCT04713033|Experimental|Experiment 3|In Experiment 3 (Aim 2), the study will measure patients with unilateral vocal old paralysis, representing a neurologically impaired network, before and after a vocal fold medialization procedure.
32788140|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
32788141|NCT04689867|Experimental|CBSPp|Cognitive Behavioral Suicide Prevention for psychosis is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions.
32788142|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
32788143|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
32788144|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
32788145|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
33296429|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
32788146|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
33296430|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
33296431|NCT01095640|Placebo Comparator|Vehicle Control|
33296432|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
33296433|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
32788147|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
33296434|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
33296435|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
33296436|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
33296437|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
33296438|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
33296439|NCT00280748|Other|Single Arm Study|Single Arm Study
33296440|NCT00271856|Experimental|0|Mindfulness Based Stress Reduction (MBSR)
32788148|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
32788149|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
32788150|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
32788151|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
32788152|NCT01826422|Experimental|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
32788153|NCT01826422|Placebo Comparator|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
32788154|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
32788155|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
32788156|NCT02032173|Experimental|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
33296441|NCT00271856|Active Comparator|1|HIV education/self-management workshop
33296442|NCT03975374|Experimental|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
33296443|NCT03975374|Active Comparator|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
33296444|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
33296445|NCT01070420|Active Comparator|FFR via central venous line|
33296446|NCT01070420|Experimental|FFR via peripheral vein|
33296447|NCT00061048|Experimental|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
33296448|NCT01070498|Experimental|Trichuris suis ova (TSO)|
33296449|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
32788157|NCT04712409|Active Comparator|SADI-S as a primary surgery|
32788158|NCT04712409|Active Comparator|BPD-DS as a primary surgery|
32788159|NCT04712409|Active Comparator|SADI-S as a revisional procedure|
32788160|NCT04712409|Active Comparator|BPD-DS as a revisional procedure|
32788161|NCT04689477||COVID-19|Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
32788162|NCT04689477||Control|Healthy subjects
32788163|NCT04689477||Non-COVID critically ill patients|Non-COVID critically ill patients admitted to the ICU.
33296450|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
33296451|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
33296452|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
33296453|NCT03957148|Experimental|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
33296454|NCT03957148|Sham Comparator|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
33296455|NCT03954808|Experimental|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
33296456|NCT03954808|Active Comparator|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
33296457|NCT03954808|No Intervention|Typically developing control group|Age matched healthy individuals, with no treatment.
33296458|NCT03976544|No Intervention|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
32788164|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
33296459|NCT03976544|Experimental|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
33296460|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
33296461|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
33296462|NCT01093378||Fertile group|fertile group
33296463|NCT01093378||Infertility group|Fertility troubles
32788165|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
32788166|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
32788167|NCT02461589|Placebo Comparator|Placebo 50 µL|
32788168|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
32788169|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
32788170|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
32788171|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
32788172|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
32788173|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
32788174|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
32788175|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
32788176|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
32788177|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
32788178|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
32788179|NCT04934189|Other|Empowerment Self-Defense Training- Pre-Post Single Arm Design Pilot Trial|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.
33296464|NCT00270998|Experimental|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
33296465|NCT00270998|Experimental|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
32788180|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
32788181|NCT04688853|Experimental|Single Arm, Open label|"This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.~For the Dose escalation segment, 3-9 patients per dose cohort will receive:~Dose level 1: Low~Dose level 2: Medium~Dose level 3: High~For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose"
32788182|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
32788183|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
32788184|NCT04923191|Other|Angiography-derived Physiology Guidance (Quantitative Flow Ratio, QFR)|
32788185|NCT04923191|Other|Local routine diagnostic procedure (LRDP) and usual care|
32788186|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
32788187|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
32788188|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
32788189|NCT04687761|Experimental|AZA-Based|"Azacitidine 75 mg/m2/daily SC on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle plus Venetoclax (ramp-up) 400 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the AZA-based schedule.~AZA and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of AZA + Venetoclax + Quizartinib regimen (30 patients)."
32906924|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
33296466|NCT00270998|Experimental|Pessary combined with behavioral therapy|Combination of the explanations above.
33296467|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
33296468|NCT01070576||atrophic|patients in which an atrophic non-union occured
33296469|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
33296470|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
33296471|NCT01581632|Other|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
33296472|NCT03973502|Experimental|18F-DOPA PET|PET/CT
33296473|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
33296474|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
33296475|NCT01325948||Patients with COPD|
33296476|NCT01582256||ASD+CNVs|
33296477|NCT01582256||ASD-CNVs|
33296478|NCT01582256||Unaffected siblings of ASD+CNVs|
33296479|NCT01582256||Unaffected siblings of ASD-CNVs|
33296480|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
33296481|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
33296482|NCT00279812|Placebo Comparator|Placebo|Placebo
33296483|NCT00279812|Experimental|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
33296484|NCT00279812|Experimental|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
33296485|NCT00279812|Experimental|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
33296486|NCT00279812|Experimental|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
33296487|NCT00279812|Experimental|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
33296488|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
33296489|NCT00207714|Experimental|Golimumab (CNTO 148) with Methotrexate (MTX)|
33296490|NCT00207714|Experimental|Infliximab with MTX|
33296491|NCT00207714|Placebo Comparator|Placebo with MTX|
33296492|NCT00207090|Experimental|Ixabepilone + rifampin|
33296493|NCT03969576|Experimental|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
33296494|NCT03969576|Active Comparator|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
33296495|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
33296496|NCT01071408|No Intervention|Usual care|
33296497|NCT00059332|Experimental|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
33086879|NCT04823065|Experimental|Hyoscine-N-butylbromide|In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
33086880|NCT04820257|Experimental|Home based exercise|Home based exercise with health coaching
33086881|NCT04820257|No Intervention|Usual care|Usual care, waiting list
32939700|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
32939701|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
32939702|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
32939703|NCT00376831|Active Comparator|0|fentanyl
32939704|NCT00376831|Active Comparator|1|ketamine
32939705|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
32939706|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
32939707|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
32939708|NCT03491917||FFDM alone|Breast images using FFDM alone only
33086882|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
33086883|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
33086884|NCT04829539|Experimental|Group I (BBT-CI)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
33086885|NCT04829539|Active Comparator|Group II (HEAL)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
33086886|NCT04829305|Experimental|Low dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 1).
33086887|NCT04829305|Experimental|Medium dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 2).
33086888|NCT04829305|Experimental|High dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 3).
33086889|NCT04825873||Cohort 1|Participants with non-small cell lung cancer (NSCLC)
33086890|NCT04825873||Cohort 2|Participants with squamous cell carcinoma of head and neck (SCCHN)
33086891|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
33086892|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
33086893|NCT04828135|Experimental|subjects with diagnosis of COVID-19 (Long-hauler)|23 subjects with a confirmed diagnosis of COVID-19 infection, and after 60 days or longer
33086894|NCT04826185|Experimental|IMB-1018972 200mg|
33086895|NCT04826185|Placebo Comparator|Placebo|
33086896|NCT04820530|Experimental|LNP023|Participants will receive LNP023 at a dose of 200 mg orally b.i.d
33086897|NCT04826029|Other|Standard arm|
33086898|NCT04826029|Experimental|Interventional arm|
33086899|NCT00417456|Active Comparator|1|Office Visits
33086900|NCT00417456|Experimental|2|Evisit
33086901|NCT04826224|Experimental|Subjects with Osteoarthritis of the shoulders|Subjects diagnosed with Osteoarthritis of the shoulders will be injected with concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
33086902|NCT04828447|Experimental|High Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet high in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
33086903|NCT04828447|Experimental|Low Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet low in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
33086904|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
33086905|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
33086906|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
33086907|NCT04720040|Experimental|YMS-201B|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 6 weeks (total of 30~42 applications)
33086908|NCT04825834||Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis|
32788190|NCT04687761|Experimental|LDAC-Based|"Low-dose subcutaneous cytarabine 20 mg/m2/daily SC, days 1 to 10 plus Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the LDAC-based schedule.~LDAC and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily-Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of LDAC + Venetoclax + Quizartinib regimen (30 patients)."
32788191|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
32788192|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
32788193|NCT04730583|Active Comparator|Kybella Injection|
32788194|NCT04730583|Active Comparator|980nm laser|
32788195|NCT04730583|Active Comparator|755nm laser|
32788196|NCT04730583|Active Comparator|Radiofrequency|
32788197|NCT04730193|Placebo Comparator|Control|Participants randomized to placebo group will receive placebo capsule
32788198|NCT04730193|Experimental|Caffeine|Participants randomized to caffeine group will receive 100mg caffeine capsule
32788199|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
32788200|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
32788201|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
32788202|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
32788203|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
32788204|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
32788205|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
32788206|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
32788207|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
32906925|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
33296498|NCT00059332|Placebo Comparator|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
33296499|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
33296500|NCT01096030|Experimental|Regorafenib|
33296501|NCT00233454|Experimental|Midostaurin|100 mg midostaurin twice daily as oral capsules
32788208|NCT04687215||Diabetic patients receiving a spinal cord stimulator|Patients that have been seen in the diabetic foot clinic will be evaluated for participation in the study once they have been referred to one of our pain clinics.
32788209|NCT02418845|Experimental|SYM-1219|Administered orally
32788210|NCT02418845|Placebo Comparator|Placebo|Administered orally
33086909|NCT04825834||Individuals eligible for Lung Cancer screening with no cancer diagnosis|
33086910|NCT04825834||Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis|
32788211|NCT02030847|Experimental|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
32788212|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
32788213|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
32788214|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
32788215|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
32788216|NCT04710537|Active Comparator|AlloDerm|AlloDerm will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. AlloDERM will be placed in the breast opposite to the breast in which DermACELL is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
32788217|NCT04710537|Active Comparator|DermACELL|DermACELL will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. DermACELL will be placed in the breast opposite to the breast in which AlloDERM is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
32788218|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
32788219|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
32788220|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
32788221|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
32788222|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
32788223|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
32788224|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
32788225|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
32788226|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
32788227|NCT04730037|Active Comparator|Edoxaban group|
32788228|NCT04730037|Active Comparator|Warfarin group|
32788229|NCT04710303|Experimental|Cohort 1 (n = 10): hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose|hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose on Days 1 and 22
33086911|NCT04826653|Experimental|Timing suture removal_1 week|
33086912|NCT04826653|Experimental|Timing suture removal_2 weeks|
33086913|NCT04826653|Experimental|Timing suture removal_3 weeks|
33086914|NCT05140057|Experimental|Protocol 1|1L of Moviprep® solution the night before the procedure
33086915|NCT05140057|Experimental|Protocol 2|1L of Moviprep® solution up to 2h before the procedure
33086916|NCT05140057|Experimental|Protocol 3|0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum
33086917|NCT05140057|Experimental|Protocol 4|1L of Moviprep® solution after the capsule had reached the duodenum
33086918|NCT04821739|Experimental|Treatment with AGN1 LOEP SV Kit|VCF is treated with the AGN1 LOEP SV Kit
33086919|NCT04829812||Prospective cohort|Prospective cohort with inclusion of consecutive or pseudo-consecutive patients by vascular specialist at their place of practice. Patient follow-up to assess wound progression and compression tolerance
33086920|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
33086921|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
33086922|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
32788230|NCT04710303|Experimental|Cohort 2 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose on Days 1 and 22
32788231|NCT04710303|Experimental|Cohort 3 (n = 15): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose (or 5 × 10e10 VP per dose if safety concerns identified at higher dose) on Days 1 and 22
33086923|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
33086924|NCT00280332||A|colonic adenoma
33086925|NCT00280332||B|colonic without adenoma
33296502|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
33296503|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
32788232|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
32788233|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
32788234|NCT04685811|Experimental|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
33086926|NCT05140018||Kidney Transplant Recipients with an immunological high risk for ABMR|"Kidney transplant recipients ≥18 years old~About to receive a post mortal or living donor renal transplant~Immunological high risk for rejection~Luminex positive DSAs ; or~Retransplantation with repeated mismatch ; or~Husband to wife donation (after fathering children); or~Offspring to mother donation"
33086927|NCT05140018||Living Kidney Donors|Participants who are about to donate their kidney to a Recipient with a high immunological risk (as described above)
33086928|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
33086929|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
33086930|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
32788235|NCT04709211|Active Comparator|Group I: Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca Block using bupivacaine 0.25%
32788236|NCT04709211|Active Comparator|Group Q: Anterior Quadratus lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using bupivacaine 0.25%
32788237|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
32788238|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
32788239|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
33086931|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
33086932|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
33086933|NCT04824430||SLH 3M|Second look hysteroscopy (SLH) performed 3 months post-ablation
33086934|NCT04824430||SLH 6M|Second look hysteroscopy (SLH) performed 6 months post-ablation
32788240|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
32788241|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
32788242|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
33403822|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
33403823|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
33403824|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
32788243|NCT03669809||male, non-obese|male with BMI<28
32788244|NCT03669809||male, obese|male with BMI≥28
32788245|NCT03669809||female, non-obese|female with BMI<28
32788246|NCT03669809||female, obese|female with BMI≥28
32788247|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
32788248|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
33086935|NCT04824430||SLH 12M|Second look hysteroscopy (SLH) performed 12 months post-ablation
33086936|NCT04826419|Active Comparator|Non-invazive ozone therapy in a group|ozone therapy
33403825|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
33086937|NCT04826419|No Intervention|Control group|control groups do not take ozone therapy
33086938|NCT04822480||DPP Patients|UMMC Patients with prediabetes or risk for diabetes based on risk parameters referred to and enrolled in the DPP.
32788249|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
32788250|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
32788251|NCT03667781||Providers Interviewed|Providers in cardiology clinic
32788252|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
32788253|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
33086939|NCT04822480||Non-DPP Patients|Control matched UMMC patients with prediabetes or risk for diabetes based on risk parameters not enrolled in the DPP.
33086940|NCT04826926|Experimental|Non-surgical periodontal treatment NSPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
33086941|NCT04825132|Experimental|Bacteremia and/or acute respiratory infection|Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for with bacteraemia and/or acute respiratory infection
33086942|NCT04825132|Active Comparator|Without suspicion of infection|The control patient will undergo the exact same procedures as the case patient described before except for the blood and respiratory sample part. • The typical control patient will be of the same age (+/- 3 years, but aged above 65 years), same sex, without suspicion of infection and hospitalized during the past or upcoming month in the same centre. There will be 2 controls for one case.
33086943|NCT04824820|Experimental|Vibrator|Participants will be using commercially available genital vibrator for at least 5 minutes and/or reaching an orgasm three times a week for 3-4 months.
33086944|NCT04826536||Cohort 1|Participants with psoriasis
33086945|NCT04900246|Experimental|Visual Inspection + BWX Radiographic Assessment + Assessment of the iTero Element 5D scan|In this group, the evaluations will follow this order. First the visual inspection, then the bitewing X-ray assessment and, lastly, the iTero assessment.
33086946|NCT04900246|Experimental|Visual Inspection + Assessment of the iTero Element 5D scan + BWX Radiographic Evaluation|In this group, the evaluations will follow this order. First the visual inspection, then the iTero assessment and, lastly, the bitewing X-ray assessment.
33086947|NCT04455139|Active Comparator|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
33086948|NCT04455139|Experimental|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
33086949|NCT04455139|Active Comparator|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
33086950|NCT04455139|Experimental|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
33086951|NCT04455139|No Intervention|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
32788254|NCT04931927|Active Comparator|Control|Participants are randomized to treatment as usual (TAU)
32788255|NCT04931927|Experimental|MCI-T|Participants are randomized to the Making Connections Intervention-Telehealth (MCI-T) plus treatment as usual (TAU)
33086952|NCT04455139|No Intervention|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
33086953|NCT04455139|No Intervention|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
33086954|NCT04822168|Active Comparator|Standard Care|Standard Care through detox-based opioid treatment with B/N and weekly urine toxicology screening
33086955|NCT04822168|Experimental|MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure medication storage device, and a standardized protocol for supervising self-administration of medication via videoconferencing.
32788256|NCT04922957|Placebo Comparator|Placebo|Ringer's lactate solution
32788257|NCT04922957|Experimental|ALLOCETRA-OTS|Single IV dose of Allocetra-OTS containing 10x10^9 cells
32788258|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
32788259|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
33086956|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
33086957|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
33086958|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
33086959|NCT04088539|Experimental|Group A|"CSD participants will receive a combined intervention:~Brief intervention using AWARD advice at baseline,~Video-based health education"
33086960|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
33086961|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
33086962|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
33086963|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
33086964|NCT04011826|Experimental|Experimental: Experimental trial nasal mask|Experimental trial nasal mask: Participants will be placed on this arm for a total of 14±3 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm. Participants on the extension will use this trial mask for a further six months after Visit 3.
33086965|NCT04006756|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
33086966|NCT04006756|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
33086967|NCT00251771|Experimental|I|
33086968|NCT00251771|No Intervention|II|
33086969|NCT03946462|Experimental|NO Group|
32788260|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
32788261|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
32788262|NCT04685577|Experimental|Nefopam|NEFOPAM 3% cream will be applied topically to healing deep dermal scratches in the lateral hip of burn patients daily (twice) for 3 weeks during the proliferative phase of wound healing.
32788263|NCT04685577|Placebo Comparator|Placebo|This will work as a placebo for the experimental drug.
32788264|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
32788265|NCT04685343|Experimental|fMRI and laboratory pain induction|
33296504|NCT00047320|Experimental|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
33296505|NCT00233064|Active Comparator|1|Liquid Palivizumab
33296506|NCT00233064|Active Comparator|2|Lyophilized Palivizumab
33296507|NCT03973242|Active Comparator|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
33296508|NCT03973242|Placebo Comparator|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
32788266|NCT04684251|Experimental|Treatment arm|The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
32788267|NCT02443103|Experimental|Guanabenz|
32788268|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
33296509|NCT03954730|Experimental|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
33296510|NCT03954730|Active Comparator|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
33296511|NCT03973086|Experimental|Citrus flavonone-O-glycosides (Low dose)|
33296512|NCT03973086|Experimental|Citrus flavonone-O-glycosides (High dose)|
32788269|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
32788270|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
32788271|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
32788272|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
33086970|NCT03946462|Placebo Comparator|Placebo Group|
33296513|NCT03973086|Placebo Comparator|Microcrystaline Cellulose- 400mg|
33296514|NCT00268892|Experimental|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
33296515|NCT00268892|Experimental|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
33296516|NCT00268892|Experimental|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
33296517|NCT00206076|Experimental|1|mycophenolate mofetil monotherapy
33296518|NCT00206076|Active Comparator|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
33296519|NCT03974490|Experimental|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
33296520|NCT03974490|No Intervention|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
33296521|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
33086971|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
33086972|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
33086973|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
33086974|NCT03658486|Other|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
32788273|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
32788274|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
32788275|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
33296522|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
33296523|NCT00278954|Other|Gammaplex|Gammaplex
32788276|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
32788277|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
32788278|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
32788279|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
32788280|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
32788281|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
32788282|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
32788283|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
32788284|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
33296524|NCT03973008|Experimental|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
32788285|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
32788286|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
33086975|NCT00251810||general anaesthesia|
32788287|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
32788288|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
33086976|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
33086977|NCT03486301|Experimental|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
33296525|NCT03973008|Active Comparator|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
33296526|NCT00278564|Experimental|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
32788289|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
32788290|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
32788291|NCT04682535||Cohort 1|Spousal/partner family caregivers to persons living with dementia. Participants will complete 14-days of surveys about their relationships, social interactions, as well as health and health behaviors. A subsample of n=15 may volunteer to provide diurnal saliva samples.
32906926|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
33296527|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32788292|NCT04684173||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight >2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
32788293|NCT04684173||Preterm infants|The inclusion criteria for preterm infants are: gestational age <37 weeks, birth weight <2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
32788294|NCT04681833|Experimental|Cohort 1: BARS13 low repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.
32788295|NCT04681833|Placebo Comparator|Cohort 1: BARS13 placebo low repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
32788296|NCT04681833|Experimental|Cohort 2: BARS13 high repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.
32788297|NCT04681833|Placebo Comparator|Cohort 2: BARS13 placebo high repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
32788298|NCT04681833|Experimental|Cohort 3: BARS13 high repeat multiple dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.
32788299|NCT04681833|Placebo Comparator|Cohort 3: BARS13 placebo high repeat multiple dose|Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
32788300|NCT02085135|Experimental|Titration Schedule 1|
32788301|NCT02085135|Experimental|Titration Schedule 2|
33296528|NCT03975296|Experimental|TMQLB group|
32788302|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
32788303|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
33296529|NCT03975296|Active Comparator|TPVB group|
33296530|NCT03974256|No Intervention|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
33296531|NCT03974256|Experimental|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
32788304|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
32788305|NCT02027025|Active Comparator|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
32788306|NCT02027025|Active Comparator|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
32788307|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
32788308|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
32788309|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
32788310|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
32906927|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
32906928|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
33296532|NCT03973580|Active Comparator|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
33296533|NCT03973580|Placebo Comparator|Control group|Participants in this arm will participate in a six-session control task, one session per week.
33296534|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
33296535|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
33296536|NCT00268346|Experimental|ZD1839|
32830437|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
33296537|NCT00203892|Experimental|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
33296538|NCT00203892|Experimental|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
33296539|NCT00203892|Experimental|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
33296540|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
33296541|NCT00276614|Experimental|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
33296542|NCT00276458|Active Comparator|1|Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
33296543|NCT00276458|Experimental|2|Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
33296544|NCT00276380|Experimental|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
33296545|NCT00276380|Placebo Comparator|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
33296546|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
33296547|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
33296548|NCT02531984|Other|ongoing Azithromycin treatment|
33296549|NCT00267956|Experimental|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
33296550|NCT00267956|Placebo Comparator|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
33296551|NCT01072292|Experimental|CBT-I|CBT-I
33296552|NCT01072292|Active Comparator|Wellness Education|Wellness Education
33296553|NCT01073696|Active Comparator|granisetron IV|
33296554|NCT01073696|Experimental|granisetron patch|
33296555|NCT00046930|Experimental|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
33296556|NCT00046930|Active Comparator|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
33296557|NCT03954496|Experimental|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
33296558|NCT03954496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
33296559|NCT03954418|Experimental|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
33296560|NCT03954418|No Intervention|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
33296561|NCT03954340|Active Comparator|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
33296562|NCT03954340|Sham Comparator|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
33296563|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
33296564|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
33296565|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
33296566|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
33296567|NCT03954028|Active Comparator|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
33296568|NCT03954028|Active Comparator|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
33086978|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
33296569|NCT00044512|Experimental|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
33296570|NCT03956524|Experimental|Test group|Single dose of EuTCV will be administered intramuscularly
33086979|NCT00287001|Other|1|1= cool air cooling
32788311|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
33086980|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
33086981|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
33086982|NCT04719650|Experimental|zoledronic acid 1mg|Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
33296571|NCT03956524|Active Comparator|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
33296572|NCT03956524|Active Comparator|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
33296573|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
32788312|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
33296574|NCT01584154|Experimental|cryoablation|
33296575|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
33296576|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
33296577|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
33296578|NCT01096420|Experimental|acupuncture|
33296579|NCT01096420|Active Comparator|topiramate|
33296580|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
32788313|NCT04921631|Experimental|Intervention|The intervention arm will receive early specialty palliative care integrated with standard critical care.
32788314|NCT04921631|No Intervention|No intervention|Usual ICU care; each study ICU has a policy for family meetings within 72 hours of admission and at least weekly thereafter.
33296581|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
33296582|NCT03953716|Experimental|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
33296583|NCT03953716|Placebo Comparator|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
32788315|NCT04681287|Experimental|inetetamab and PD-1 inhibitor combined with chemotherapy.|
32788316|NCT04683627|Experimental|HP-5000 Treatment|HP-5000 Topical Patch will be evaluated against placebo topical patches.
32788317|NCT04683627|Placebo Comparator|Placebo Treatment|Placebo patches without diclofenac sodium will be used.
32788318|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
32788319|NCT04920695|Placebo Comparator|Placebo Control|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquid Healthcare, Montreal, Quebec, Canada).
32788320|NCT04920695|Active Comparator|Inhaled Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX™ gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; Control # 198879, DIN 02451328).
32788321|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
32788322|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
32788323|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
32788324|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
32788325|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
32788326|NCT04931771|Experimental|vFFR guided revascularization|
33086983|NCT04719650|Experimental|zoledronic acid 2.5mg|Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
32788327|NCT04931771|Active Comparator|FFR guided revascularization|
32788328|NCT01843348|Active Comparator|TAC+MPA|
32788329|NCT01843348|Experimental|TAC+Certican|
33086984|NCT04719650|Experimental|zoledronic acid 5mg|Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.
33086985|NCT04719650|Placebo Comparator|placebo|Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
33086986|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
33086987|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
33086988|NCT03218605|Experimental|healthy active participants|
33086989|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
33086990|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
33086991|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
33086992|NCT02960802|No Intervention|healthy control|no intervention
33086993|NCT04822597|Active Comparator|Ice Pack|Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
33086994|NCT04822597|Experimental|Lidocaine Patch|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
33296584|NCT03953716|Experimental|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
33296585|NCT03953716|Active Comparator|Marvelon|1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
33296586|NCT01096498|Experimental|Arm 1|
33296587|NCT01096498|Active Comparator|Arm 2|
33296588|NCT01096576|Experimental|A|
33296589|NCT01096576|Placebo Comparator|B|
33296590|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
33296591|NCT00147537|Experimental|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
33296592|NCT00147537|Experimental|Phase 1b|"Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
33296593|NCT00222729|Experimental|Pemetrexed & Bevacizumab|
33296594|NCT00147225|Experimental|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
33296595|NCT00147225|Experimental|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
33296596|NCT00147225|Experimental|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
33296597|NCT00147225|Experimental|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
33403826|NCT04752150|Active Comparator|Group ESPB = Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
32788330|NCT01843348|Experimental|CycA+Certican|
32788331|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
32788332|NCT01825876|Active Comparator|Warfarin|15 milligrams (mg) warfarin administered as a single oral dose
32788333|NCT01825876|Experimental|Evacetrapib + Warfarin|130 mg evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 10
32788334|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
32788335|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
32788336|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
32788337|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
32788338|NCT01825798|Placebo Comparator|Placebo Hydrochloride Oral Solution|
32788339|NCT01825798|Experimental|Metformin|
32788340|NCT05370599|Active Comparator|Amlodipine 2.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of amlodipine and use of a home BP monitoring device for BP monitoring
32788341|NCT05370599|Experimental|Chlorthalidone 12.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of chlorthalidone and use of a home BP monitoring device for BP monitoring
32788342|NCT05370599|Experimental|Losartan 12.5 mg daily + home BP monitoring with cuffed device|Use of at least the minimum dose of losartan and use of a home BP monitoring cuffed device only for BP monitoring
32788343|NCT05370599|Experimental|amlodipine 2.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
32788344|NCT05370599|Experimental|Chlorthalidone 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
32788345|NCT05370599|Experimental|Losartan 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
33403827|NCT04752150|Active Comparator|Group RIB = RIB group|In group RIB, RIB block will be performed with patients in the lateral decubitus position while the surgical site up. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 30 ml 0,25% bupivacaine will be injectted into the fascial plane.
33403828|NCT05254444|No Intervention|Group 1: Control|No activities will take place in group 1.
33403829|NCT05254444|Experimental|Group 2: Social Marketing|Households in this arm will receive a multi-tiered social marketing campaign focusing on sustainable fish nutrition, dietary diversity and food safety.
33403830|NCT05254444|Experimental|Group 3: Social Marketing + Gear Modification|Households in this arm will receive a bundled intervention of the social marketing campaign as well as modified fishing gear (basket traps with fish escape gaps) and training on proper utilization and management.
33403831|NCT04682340||Hashimoto's Group|Thyroid antibody positive and hypothyroidism
33403832|NCT04682340||Graves' Group|Thyroid antibody positive and hyperthyroidism
33403833|NCT04682340||Control Group|Thyroid antibody negative and euthyroidism
33403834|NCT05254366||Cohort 1|Painless gastroscopic sedation cohort
33403835|NCT05254366||Cohort 2|Painless colonoscopy sedation cohort
33403836|NCT05254132||aRECIST|Treatment naive patients with metastatic NSCLC (stage four) with life expectancy of more than three months.
33403837|NCT05254132||rATLAS|Treatment naive patients diagnosed with NSCLC.
33403838|NCT05254054|Experimental|Vibration group|Participants in Vibration group will receive an 8-week whole body vibration training in addition to conventional exercise training.
33403839|NCT05254054|Active Comparator|Control group|Participants in Vibration group will only receive conventional exercise training.
33403840|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
33403841|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
33403842|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
33403843|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
33403844|NCT04871087|Other|Allay lamp (narrow band green light)|Comparing effects of NBGL vs. white light on anxiety level before and after psychotherapy treatment sessions.
33403845|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
33403846|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
32788346|NCT05370599|Experimental|amlodipine 2.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
32788347|NCT05370599|Experimental|chlorthalidone 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
32788348|NCT05370599|Experimental|losartan 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
32788349|NCT04911491|Experimental|IMST|This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.
32788350|NCT04911491|Sham Comparator|Control|This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.
32788351|NCT01824472|Active Comparator|CPAP+CC|Continuous Positive Airway Pressure (CPAP) therapy for sleep apnea and contact control (CC) (placebo/sham for cognitive-behavioral therapy for insomnia)
32788352|NCT01824472|Sham Comparator|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
32788353|NCT01824472|Active Comparator|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy (CBT) for insomnia
32788354|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788355|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788356|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788357|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788358|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788359|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
32788360|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
32788361|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
32788362|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
32788363|NCT04593628|Experimental|All Participants|
32788364|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
32788365|NCT04918121|Experimental|Yutiq|A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
32788366|NCT04918121|No Intervention|Control|Non-study eye will not receive the Yutiq insert
32788367|NCT04931381|Experimental|Organoid-Guided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
32788368|NCT04931381|No Intervention|Physician-decided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
32788369|NCT04931303||Study Group|Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
32788370|NCT02457065|Experimental|Receive Plaque|"Treatment~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
32788371|NCT02457065|No Intervention|Do Not Receive Plaque|"Control~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
32788372|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
32788373|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
32788374|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
32788375|NCT02436239|Experimental|Vilazodone|
32788376|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
32788377|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
32788378|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
32788379|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
32788380|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
32788381|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
32788382|NCT04930289||LungGuard patients|Patients whose donor lung(s) was transported with the LungGuard device.
32788383|NCT04930289||Standard Transport Patients|Patients whose donor lung(s) was transported with a method other than the LungGuard
32788384|NCT04930055||Group 1|Patients with solid tumors receiving courses of cytotoxic therapy.
32788385|NCT04930055||Group 2|Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
32788386|NCT04930055||Group 3|Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
32788387|NCT04930055||Group 4|Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
32788388|NCT04930055||Group 5|Patients receiving immune checkpoint inhibitors.
32788389|NCT04930055||Group 6|Patients who underwent allogeneic stem cell transplant within 12 months.
33296598|NCT00147225|Experimental|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
33296599|NCT00147225|Experimental|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
32788390|NCT04930055||Group 7|Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
32788391|NCT04930055||Group 8|Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
32788392|NCT04930055||Group 9|Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
32788393|NCT04930055||Group 10|Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
32788394|NCT04930055||Group 11|Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
32788395|NCT04930055||Group 12|Patients who have a cancer diagnosis but do not fall into group 1-11
32788396|NCT04199273|Experimental|Magnetic stimulation and electric stimulation|The patient receive first the magnetic stimulation with MagStim 200 tool. Then 15 min after he will receive the electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
32788397|NCT04199273|Experimental|Electric stimulation and magnetic stimulation|The patient receive first electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager). Then 15 min after he will receive the magnetic stimulation with MagStim 200 tool
32788398|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
32788399|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
32788400|NCT04729023|Experimental|Combined surgery group|In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.
32788401|NCT04729023|Active Comparator|Subsequent surgery group|In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.
32788402|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
33296600|NCT00222105|Experimental|1|Doxil, Thalidomide, Dexamethasone
33296601|NCT00146757|Experimental|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
33296602|NCT00146757|Experimental|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were >200µg/mg creatinine at Week 22.
32788403|NCT02024529|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
32788404|NCT02024529|Placebo Comparator|Placebo 4 mL dose|4 mL injection of placebo
32788405|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
32788406|NCT01824394|Experimental|nMARQ Catheter|nMARQ Catheter System
32788407|NCT01824394|Active Comparator|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
33086995|NCT04822597|Experimental|Buzzy(R)|A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
32788408|NCT01823536|Experimental|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
33296603|NCT00267098|Experimental|Biventricular pacing|
33296604|NCT00267098|Active Comparator|Right ventricular pacing|
32788409|NCT01823536|Experimental|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
32788410|NCT01823536|Experimental|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
32788411|NCT01823536|Experimental|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
32788412|NCT01823536|Experimental|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
32788413|NCT01841554|Experimental|Single|
32788414|NCT01823224|Experimental|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
32788415|NCT01823224|Experimental|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
32788416|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
32788417|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
32788418|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
32788419|NCT01823146|Experimental|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
32788420|NCT01823146|Placebo Comparator|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
32788421|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
32788422|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
32788423|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
32788424|NCT04180059|Experimental|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg.
32788425|NCT04179669|Experimental|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
32788426|NCT04179669|Experimental|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
32788427|NCT02019927|Experimental|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
32788428|NCT02019927|Experimental|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
33296605|NCT00247676|Experimental|A|
33296606|NCT01073774|Experimental|Side by Side|
33296607|NCT01073774|Active Comparator|couples control condition|
32788429|NCT02019927|Experimental|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
33296608|NCT00267020|Experimental|Enzastaurin+Gemcitabine|
33296609|NCT00267020|Active Comparator|Gemcitabine|
33296610|NCT03975062|Experimental|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
33296611|NCT03975062|Active Comparator|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
33296612|NCT03970772|Experimental|Glucagon injection|Dilute Glucagon (1 mg/ml)
33296613|NCT03970772|Active Comparator|Glucose tablets|Dextrose glucose tablets
33296614|NCT03970928|Active Comparator|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
33296615|NCT03970928|No Intervention|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
33296616|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
32788430|NCT02019927|Sham Comparator|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
32788431|NCT02019927|Sham Comparator|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
32788432|NCT02019927|Sham Comparator|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
32788433|NCT04185441|Experimental|TANZÂNIA|"The study is double-dummy. The patient must take 2 pills, as follow:~1 capsule Tanzânia association, oral, once a day, and~1 tablet tamsulosin placebo, oral, once a day."
32788434|NCT04185441|Active Comparator|Omnic Ocas|"The study is double-dummy. The patient must take 2 pills, as follow:~1 tablet Omnic Ocas, oral, once a day, and~1 capsule Tanzânia association placebo, oral, once a day."
32788435|NCT04416945|Experimental|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
32788436|NCT04416945|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
32788437|NCT04185363|Experimental|Maralixibat|All subjects will receive Maralixibat oral solution
32788438|NCT04682925|Experimental|skin care arm of where evidence-based practices in the implementation guide|Participants in this arm will be given evidence-based skin care interventions, which are included in the guidelines to prevent medical device-related pressure injuries, and are implemented by the researcher nurse. After the nasogastric tube is inserted by the patient's physician.
32788439|NCT04682925|Experimental|hydrocolloid (Convatec Granuflex-extra thin) dressing|Patients in this arm will be applied a translucent hydrocolloid cover, which is compatible with the sensitive skin structure, can be applied to all body surfaces and nasal mucosa, and allows the underlying mucosa and skin to be observed after the nasogastric tube is inserted by the patient's physician. This cover will be applied to the nasal mucosa and nasal wing under the nasogastric tube.
32788440|NCT04682925|Other|control|Participants in the control group will be given no intervention , these patients will receive the routine clinical care(dressing change and nasal skin cleaning once a day) applied in the intensive care unit.
32788441|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
33296617|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
32788442|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
33296618|NCT03970850|Active Comparator|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
33296619|NCT00242216|Active Comparator|Atazanavir oral once daily|HIV treatment
33296620|NCT00242216|Active Comparator|Fosamprenavir oral once daily|HIV treatment
32788443|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
32788444|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
32788445|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
33296621|NCT00240110|Placebo Comparator|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
32788446|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
32830438|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
33296622|NCT00240110|Experimental|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
33296623|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
33296624|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
33296625|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
33296626|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
33296627|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
33296628|NCT00266864|Experimental|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
33296629|NCT00266864|No Intervention|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
33403847|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
32788447|NCT01822756|Experimental|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
32788448|NCT01822756|Experimental|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
32788449|NCT01822678|Experimental|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
32788450|NCT01822678|Experimental|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
32788451|NCT01822678|Placebo Comparator|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
32788452|NCT01822366|No Intervention|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
32788453|NCT01822366|Experimental|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
32788454|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
32788455|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
32788456|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar during the same type of interventional radiology procedures as Comparator arm above
32788457|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar during the same type of interventional radiology procedures as Comparator arm above.
32788458|NCT01611298|Experimental|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
32788459|NCT01822132|Experimental|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
32788460|NCT01822132|Placebo Comparator|Placebo|One dose of intramuscular injection of placebo.
32788461|NCT04593004|Experimental|Teledermatology|
32788462|NCT04593004|Active Comparator|Face-to-face consultation|
32788463|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
33296630|NCT00266708|Experimental|Risedronate|subjects received Risedronate for one year
33296631|NCT00266708|Placebo Comparator|subjects received placebo|subjects received placebo for 1 year
33296632|NCT00266630|Experimental|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.~Patients received olanzapine 5-20 mg for 18 weeks."
33296633|NCT00266630|Experimental|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
33296634|NCT00129129|Experimental|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
33296635|NCT00129129|Active Comparator|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
33296636|NCT00129129|Active Comparator|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
33403848|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
32788464|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
32788465|NCT04592614|Experimental|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
32788466|NCT04592614|Experimental|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
32830439|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
32830440|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
32788467|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
32788468|NCT04929899|Other|Bright Ideas- CIN Training|"The PSST will be delivered by a trainer in a minimum of three 30-minute to 1-hour sessions with a parent and patient (if developmentally appropriate).~During the first session, the study team member will build rapport by understanding relevant personal background and medical information; introduce PSST and the Bright IDEAS paradigm; review the patients experience with nausea as reported in Phase 1 and at other times during treatment; promote problem-solving strategies and skills; and develop an anti-nausea action plan. During the second session, the trainer will discuss how well the prior action plan worked and reinforce successful outcomes or, if unsuccessful, return to the problem-solving steps to generate a new action plan. The third session will review progress on CINV control, assist in problem-solving as needed, and discuss how to continue to use the Bright IDEAS framework to resolve future issues with CINV or symptom management more broadly."
33296637|NCT00129129|Experimental|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
32788469|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
32788470|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
32788471|NCT01821118|Experimental|1|
32788472|NCT01821118|Placebo Comparator|2|
32788473|NCT01650779|Experimental|Agalsidase beta|
32788474|NCT02411201|Experimental|DOTAREM|
32788475|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
32788476|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
32788477|NCT02410811||Age Stratum A|"Age 6 to 13.99 years~Cardiac magnetic resonance imaging (CMR)"
32788478|NCT02410811||Age Stratum B|"Age 14 to 20.99 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
32788479|NCT02410811||Age Stratum C|"Age ≥21 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
32788480|NCT02410811||Age Stratum D|"Age ≥6 years.~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.~Cardiac magnetic resonance imaging (CMR)"
32788481|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
32788482|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
32788483|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
33403849|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
32788484|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
32788485|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
32788486|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
32830441|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
33086996|NCT04822597|Experimental|Lidocaine Patch and Buzzy(R)|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
33296638|NCT00129129|Experimental|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
33403850|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
33296639|NCT00221403|Active Comparator|Valproate (VPA)|VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
33296640|NCT00221403|Active Comparator|Risperidone|Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
32788487|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
32788488|NCT04917809|Experimental|Participants with FGFR3-mutant or -fusion noninvasive bladder tumors|25 participants with FGFR3-mutant or -fusion noninvasive bladder tumors will be accrued.
32788489|NCT04917731|Experimental|Botox|The patients in this arm will receive Botox injection to the digital arteries of all affected digits.
32788490|NCT04917731|Placebo Comparator|Placebo|The patients in this arm will receive placebo injection of saline to the digital arteries of all affected digits.
32788491|NCT04927559||Observational (survey)|Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.
32788492|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
32788493|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
32788494|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
32788495|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
32788496|NCT01820572|Experimental|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
33296641|NCT00221403|Placebo Comparator|Placebo|The placebo was administered in liquid form, matched for taste and color with the active comparator.
33296642|NCT00145977|Experimental|Experimental|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
32788497|NCT01820572|Active Comparator|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
33296643|NCT00145977|Active Comparator|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
33296644|NCT00238238|Active Comparator|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
33296645|NCT00238238|Experimental|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32788498|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.005%|Open-label, dose escalation, 3 days treatment
32788499|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 3 days treatment|Randomized, 3 days treatment
32788500|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 2 days treatment|Randomized 2 days treatment
32788501|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 3 days treatment|Randomized 3 days treatment
32788502|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 2 days treatment|Randomized 2 days treatment
33296646|NCT00238238|Experimental|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
33296647|NCT03970460|Active Comparator|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
33296648|NCT03970460|Active Comparator|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
33296649|NCT03970460|Experimental|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
33296650|NCT03970460|Experimental|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
33296651|NCT03970148|Experimental|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
33296652|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
33296653|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
33296654|NCT01071122|Experimental|Arm 1|
33296655|NCT01071122|Active Comparator|Arm 2|
33296656|NCT01071122|Active Comparator|Arm 3|
33296657|NCT03973190|Placebo Comparator|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
33086997|NCT04823221||Rezūm system|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
33086998|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
33086999|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
32788503|NCT01820260|Placebo Comparator|Part 2: Placebo for 3 days treatment|Randomized 3 days treatment
32788504|NCT01820260|Placebo Comparator|Part 2: Placebo for 2 days treatment|Randomized 2 days treatment
32788505|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.008%|Open-label, dose escalation, 3 days treatment
33296658|NCT03973190|Active Comparator|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
33296659|NCT03973190|Active Comparator|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
33296660|NCT01072604|Experimental|Arm 1|
33296661|NCT01072604|Experimental|Arm 2|
33296662|NCT01072604|Active Comparator|Arm 3|
33296663|NCT01072604|Active Comparator|Arm 4|
33087000|NCT03147508||Neck pain patients|
33087001|NCT02699086|Experimental|Low dose + Low dose|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 + 28 days
33087002|NCT02699086|Experimental|Low dose + High dose|1 PDC-1421 Capsule for 28 days + 2 PDC-1421 Capsules for 28 days, trice daily, p.o. after meals
33087003|NCT01805284|Experimental|Linezolid|
33087004|NCT01471834|Experimental|Device and Medical Management|Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
33296664|NCT00128661|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
33296665|NCT00128661|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
33296666|NCT03975140|Experimental|Hypersensitive acupoint group|
33296667|NCT03975140|Active Comparator|Hyposensitive acupoint group|
33296668|NCT01072760|Experimental|K wire|
33296669|NCT00145509|Active Comparator|Asenapine|Asenapine
33296670|NCT00145509|Placebo Comparator|Placebo|Placebo
33296671|NCT03965871|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33296672|NCT03965871|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33296673|NCT03965871|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33296674|NCT03965871|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33296675|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
33296676|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
33296677|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
33296678|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
33296679|NCT00220779|Experimental|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
33296680|NCT00220779|Experimental|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
33296681|NCT00220779|Placebo Comparator|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
33296682|NCT00207740|Experimental|CNTO 148 (golimumab)|
33296683|NCT00207740|Placebo Comparator|Placebo|
33296684|NCT00265382|Other|Open|
33318466|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
32788506|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.012%|Open-label, dose escalation, 3 days treatment
32788507|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.027%|Open-label, dose escalation, 3 days treatment
32788508|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 3 days treatment
32788509|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.06%|Open-label, dose escalation, 2 days treatment
32788510|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.018%|Open-label, dose escalation, 3 days treatment
32788511|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 2 days treatment
32788512|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
32788513|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
32788514|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
32788515|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
32788516|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
32788517|NCT01818700|Other|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
33087005|NCT01337128|Experimental|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
33087006|NCT01337128|Experimental|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
33296685|NCT03969602|Experimental|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
33296686|NCT03969602|Active Comparator|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
33296687|NCT03969602|No Intervention|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
33296688|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
33087007|NCT01337128|No Intervention|matched control group|Matched control group.
33296689|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
33296690|NCT00206726|Experimental|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
33296691|NCT00237692|No Intervention|Arm 1|Control group - a group of hypertensive patient who receive usual care
33296692|NCT00237692|Experimental|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
33296693|NCT00237692|Experimental|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
33296694|NCT00237692|Experimental|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral & medication management interventions
33296695|NCT00237458|Experimental|Lacosamide|Open-label active treatment
33296696|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
33296697|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
33296698|NCT03973346|Experimental|Intervention group|Encounters at primary care clinics with the risk screening tool
33296699|NCT03973346|No Intervention|Comparison group|Propensity score matched comparison encounters
33296700|NCT00265148|Experimental|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
33296701|NCT00265148|Other|Placebo|Placebo dummy to match
33087008|NCT04719884|No Intervention|Control group|Standard perioperative anesthesia management
33296702|NCT01072838|Other|Dose Escalation|
33296703|NCT03973424|Experimental|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
33296704|NCT03973424|Experimental|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
32788518|NCT04727554|Experimental|Part 1a: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
32788519|NCT04727554|Experimental|Part 1b: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
32788520|NCT04727554|Experimental|Part 1c: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
32788521|NCT04727554|Experimental|Part 2: Dose Expansion|Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
32788522|NCT01817764|Experimental|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
32788523|NCT01817764|Active Comparator|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
32788524|NCT01803880|Active Comparator|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
32788525|NCT01803880|Active Comparator|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
33296705|NCT00043186|Placebo Comparator|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
33296706|NCT00043186|Experimental|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
33296707|NCT00043186|Experimental|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
33296708|NCT00043186|Experimental|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
33296709|NCT00043186|Experimental|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
33296710|NCT00043186|Experimental|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
33296711|NCT00043186|Experimental|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
33296712|NCT00043186|Experimental|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
33296713|NCT00043186|Active Comparator|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
33296714|NCT00041470|Experimental|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.~Paclitaxel weekly. Dose levels:~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
33296715|NCT03953950|Experimental|Combination of spironolactone and losartan|
33296716|NCT03953950|Active Comparator|Losartan Alone|
33296717|NCT00206102|Experimental|1|Quetiapine fumarate
33296718|NCT00206102|Active Comparator|2|Risperidone
33296719|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
33296720|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
33296721|NCT00041080|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
33296722|NCT00041080|Experimental|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
32788526|NCT01803646|Experimental|AM-101 injection|AM-101
32788527|NCT01803646|Placebo Comparator|Placebo injection|Placebo
32788528|NCT01817530|Placebo Comparator|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
32788529|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
32788530|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
32788531|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
32788532|NCT01817530|Placebo Comparator|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
32788533|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
32788534|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
32788535|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
32788536|NCT01816984|Experimental|Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)|"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.~All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32788537|NCT01816906|Active Comparator|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
33296723|NCT00205712|Placebo Comparator|Ketamine plue saline|Ketamine without dexmedetomidine
33296724|NCT00205712|Experimental|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
33296725|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
33296726|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
32788538|NCT01816906|Active Comparator|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
32788539|NCT01816594|Experimental|BKM120 + Trastuzumab + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
32788540|NCT01816594|Placebo Comparator|BKM120 PBO + Trastuzumab + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
32788541|NCT01802320|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32788542|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
32788543|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
32788544|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
32788545|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
32788546|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
32788547|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
32788548|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
32788549|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
32788550|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
32788551|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
32788552|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
32788553|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
32788554|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
32788555|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
32788556|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
33296727|NCT03953404||septic shock|
33296728|NCT03953404||severe sepsis|
33296729|NCT03953404||sepsis|
33296730|NCT03953404||sirs positive, not septic|
33296731|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...~a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician~experienced a flare within the past 24 months as determined by a clinician~had quiescent disease for at least 3 months as determined by a clinician"
33296732|NCT03969758|Active Comparator|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
32788557|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
32788558|NCT04917107|Experimental|Qigong First|Participants in this group will complete the 12-week Qigong intervention first and then the 12-week observation period.
32788559|NCT04917107|Experimental|Observation First|Participants in this group will complete the 12-week observation period first and then the 12-week Qigong intervention.
32788560|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
32788561|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
32788562|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
32788563|NCT02453555|Placebo Comparator|Linagliptin placebo|
32788564|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
32788565|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
32788566|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
32788567|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
32788568|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
32788569|NCT04927091|No Intervention|Specialty Addiction Clinic|
32788570|NCT04927091|Experimental|ECHO-IC/QI-enhanced primary care clinic|
32788571|NCT04927091|Active Comparator|ECHO-IC/QI-enhanced primary care clinic with Pay for Performance|
32788572|NCT01610284|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
32788573|NCT01610284|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
32788574|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32788575|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32830442|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
32788576|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
33296733|NCT03969758|Active Comparator|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
33296734|NCT03974672||T drain|Patients treated with a T drain approach
32788577|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
32788578|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
32788579|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
32788580|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
33296735|NCT03974672||Stoma|Patients treated with a stoma
33296736|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
32788581|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
32788582|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
32788583|NCT04916327|Experimental|Antioxidant then Placebo|Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit
32788584|NCT04916327|Experimental|Placebo then Antioxidant|Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.
32788585|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
32788586|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
32788587|NCT01801930|Experimental|Dose level 1|
33296737|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
33296738|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
32788588|NCT01801930|Experimental|Dose level 2|
32788589|NCT01801930|Experimental|Dose level 3|
33296739|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
33296740|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
33296741|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
33296742|NCT01072916||IBS|Subjects with IBS-D
33296743|NCT01072916||Healthy|Healthy Subjects
33296744|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
33296745|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
33296746|NCT00264290|Experimental|Valganciclovir|900mg PO qd
33296747|NCT00264290|Placebo Comparator|Placebo|900mg PO qd
33296748|NCT00234494|Experimental|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
33296749|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
32788590|NCT01801930|Experimental|Dose level 4|
33296750|NCT00263666|Experimental|Rotarix Group|Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
33296751|NCT00263666|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
32788591|NCT01610206|Active Comparator|gemcitabine|
32788592|NCT01610206|Experimental|Gemcitabine + pazopanib|
32788593|NCT04586296|Experimental|Telemedicine Group|Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
32788594|NCT04586296|No Intervention|Standard Treatment|Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.
32788595|NCT04582864|Experimental|Flotetuzumab|"Will start on cycle 1 day 1 on the dose escalation ramp schedule of flotetuzumab as a continuous intravenous (IV) infusion. Patients will be initiated at 30 ng/kg/day and have their dose increased daily to a target goal of 500 ng/kg/day by day 7~Patients will continue on flotetuzumab at 500 ng/kg/day for the remaining 21 days of the 28 day cycle.~On cycle 1 day 28, patients will undergo bone marrow biopsy for assessment of disease status. Patients who have achieved a CR/CRi will proceed to a second cycle per protocol, while patients with a PR or SD or better may proceed to cycle 2 with permission of the investigator. Patients with available donor lymphocytes may receive DLI concurrently with flotetuzumab during Cycle 1 and/or Cycle 2."
33296752|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
32788596|NCT04414462|Experimental|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
32788597|NCT04414462|Active Comparator|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
32788598|NCT01816048|Experimental|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
32788599|NCT01612858|Experimental|Metformin|
32788600|NCT01612858|Experimental|Pioglitazone|
32788601|NCT04585984|Placebo Comparator|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
32788602|NCT04585984|Experimental|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
32788603|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
32788604|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
32788605|NCT01612702|No Intervention|Control|No dexamethasone
32788606|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
32788607|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
32788608|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
32788609|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
32788610|NCT04910399|Experimental|Blue fish hydrolysate|The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.
32788611|NCT04910399|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
32788612|NCT04926545|Experimental|Irinotecan naive cohort|"This cohort will enroll 6 postmenopausal female patients who have never received irinotecan treatment before. Patients in irinotecan naive cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 4 rounds of pharmacokinetic studies will be conducted.~Round 0 (before chemotherapy): pharmacokinetic testing (raloxifene 60mg as probe) before XCHT administration, then XCHT for 4 days with pharmacokinetic testing (raloxifene 60mg as probe) on the 4th day of XCHT administration.~Round 1(1st cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (without raloxifene) on day 4.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
32830443|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
32830444|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
32830445|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
32830446|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
32788613|NCT04926545|Experimental|Irinotecan used cohort|"This cohort will recruit 18 patients who were treated with irinotecan previously and have at least one diarrhea episode with a severity of more than grade 2. Patients in irinotecan used cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 3 rounds of pharmacokinetic studies will be conducted.~Round 1(1st cycle of chemotherapy): FOLFIRI, with pharmacokinetic testing (raloxifene 60mg as probe) on the first day of chemotherapy.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 4.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
32788614|NCT04909541||Patient with ureteral stent|Patients with ureteral stent that meet the inclusion, exclusion criteria complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
32788615|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
32788616|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
32788617|NCT04909385||Bronchoalveolar lavage (BAL) samples for pulmonary TB|
32788618|NCT04909385||(EBUS-TBNA) samples for mediastinal TB|
32788619|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
32788620|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
33296753|NCT00039130|Experimental|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m^2/day (d) IV (d 1-5), Prednisone 60 mg/m^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 & 6 (21 day): Ifosfamide 800 mg/m^2/d (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 25 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m^2/d over 2 h (d 4-5), Etoposide 80 mg/m^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m^2 d 8 cycle 2 only, 375 mg/m^2/d (d 10, 12 cycle 2, d 8 cycle 4 & 6) Cycle 3, 5 & 7 (21 day): Cyclophosphamide 200 mg/m^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 50 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m^2/d (d 8)
33296754|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
33296755|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
33296756|NCT00035932|Active Comparator|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
33296757|NCT00035932|Active Comparator|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
32788621|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
32788622|NCT02388191|Placebo Comparator|Placebo|Placebo
33296758|NCT00035932|Active Comparator|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
33296759|NCT03953248|No Intervention|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
33296760|NCT03953248|Active Comparator|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
32788623|NCT01815736|Experimental|E/C/F/TAF|"Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
32830447|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
32788624|NCT01815736|Active Comparator|Stay on Baseline Treatment Regimen (SBR)|"Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
32788625|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
32788626|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
32788627|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
32788628|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
33087009|NCT04719884|Active Comparator|Study group|Perioperative extended haemodynamic monitoring of fluid loading, cardiac output and changes of peripheral vascular resistance by analysing the arterial curve was provided by non-invasive haemodynamic monitoring (LIDCO Rapid, Lidco Ltd., United Kingdom).In SG fluid optimisation was performed before pneumoperitoneum and after abdominal desuflation with actions to achieved CI, MAP and SI within 80% of baseline values.
33403851|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
32788629|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
32788630|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
32788631|NCT01800916|Experimental|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (B)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
32788632|NCT01800916|Experimental|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test~Coloplast Adhesive baseplate B (B)~Coloplast Adhesive baseplate C (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
32788633|NCT01800916|Experimental|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
32788634|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):~prior to any treatment;~following AD and prior to RT; and~following the end of RT (1-3 months afterwards).~six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination~The quantification of CTC in blood samples will be done with the CellSearch® system."
33087010|NCT01191073|Experimental|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
33087011|NCT01191073|Active Comparator|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
33087012|NCT01134601|Experimental|Selumetinib (AZD6244): 50 mg & Capecitabine: 825 mg/m^2|LEVEL 1 - Cycle = 49 days: AZD6244: 50 mg by mouth (PO) everyday (QD) Capecitabine: 825 mg/m^2 by mouth (PO)
33087013|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
33087014|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
33403852|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
32788635|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
32788636|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
32830448|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
32830449|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
32830450|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
33087015|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
33087016|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
33087017|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
33087018|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
33087019|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
33087020|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
33087021|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
33087022|NCT00252317|Placebo Comparator|2|
32788637|NCT04585906|Experimental|Sessions with a community mental health specialist|"Those randomized into the intervention group will receive 4-8 hour-long sessions with a community mental health specialist, taking place over approximately 12 weeks. The common elements treatment approach intervention (called My Pathway to Healing) includes psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping. The exact number of sessions delivered will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues)."
32788638|NCT04585906|Active Comparator|Case management|This study employs a randomized control design in which participants in the control group will receive case management and offered the intervention upon completion of their enrollment period.
32788639|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
32788640|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
32788641|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
32788642|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
32788643|NCT01799590|Experimental|Topiramate|
32788644|NCT04902131|Experimental|MENOPUR pen|
32788645|NCT04902131|Active Comparator|MENOPUR powder|
32788646|NCT04585750|Experimental|Phase 1 Dose Escalation|Multiple dose levels of PC14586 will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D).
32788647|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort A|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort A participants will have advanced solid tumors harboring a p53 Y220C mutation who meet all eligibility criteria and have measureable disease per RECIST 1.1.
32788648|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort B|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort B participants will have advanced solid tumors harboring a p53 Y220C mutation who do not meet all eligibility criteria (e.g. have a primary central nervous system (CNS) tumor) and do not have measurable disease per RECIST 1.1.
32788649|NCT01815424|Placebo Comparator|Placebo BID|
33296761|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.~The UriCap is held in position by means of a single-use medically approved adhesive tape."
33296762|NCT03953326|Experimental|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
33296763|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
33296764|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
33296765|NCT01096732|Experimental|GDC-0449|Study drug.
32788650|NCT01815424|Experimental|5mg BID CP-690,550|
32788651|NCT01815424|Experimental|10mg BID CP-690,550|
32830451|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
33296766|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
33296767|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
33296768|NCT01100788|Placebo Comparator|Placebo|No treatment
33296769|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
33296770|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
33296771|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
33296772|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
33296773|NCT00022516|No Intervention|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
33296774|NCT00022516|Experimental|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
33296775|NCT03953092|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
33296776|NCT03953092|Experimental|SAD Cohort 2|10 mg YG1699 or placebo
33296777|NCT03953092|Experimental|SAD Cohort 3|25 mg YG1699 or placebo
33296778|NCT03953092|Experimental|SAD Cohort 4|50 mg YG1699 or placebo
33296779|NCT03953092|Experimental|SAD Cohort 5|100 mg YG1699 or placebo
33296780|NCT03953092|Experimental|MAD Cohort 1|5 mg YG1699 or placebo
33296781|NCT03953092|Experimental|MAD Cohort 2|20 mg YG1699 or placebo
33296782|NCT03953092|Experimental|MAD Cohort 3|50 mg YG1699 or placebo
33296783|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
33296784|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
33296785|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
33296786|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
32788652|NCT02431247|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
32788653|NCT02431247|Active Comparator|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
32788654|NCT01814878|Experimental|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
32788655|NCT01814878|Active Comparator|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
32788656|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
32788657|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
32788658|NCT01814800|Experimental|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
32788659|NCT01814332|Experimental|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
32788660|NCT01814332|Placebo Comparator|Placebo|Placebo compound treatment for comparison with IP
32788661|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
32788662|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
32788663|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
32788664|NCT01797562|Experimental|Positive Response Rates: 7 new and 4 reformulated allergens|Subjects will be patched with TRUE Test Panels 1.3, 2,2 and 3.2. Panel 1 allergens nickel sulfate (0.60 mg/cm2), potassium dichromate (0.054 mg/cm2), fragrance mix (0.050 mg/cm2) and ethylenediamine dihydrochloride (0.050 mg/cm2), Panel 2 allergen Methyldibromoglutaronitrile (0.0053 mg/cm2) and Panel 3 allergens Gold sodium thiosulfate (0.075 mg/cm2), Hydrocortisone-17-butyrate (0.020 mg/cm2), Bacitracin (0.60 mg/cm2), Parthenolide (0.0030 mg/cm2), Disperse blue 106 (0.050 mg/cm2 in PVP), 2-Bromo-2-nitropropane-1,3-diol (Bronopol) (0.25 mg/cm2) will be evaluated
32788665|NCT04602754|Experimental|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
32788666|NCT04602754|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association placebo, oral;~1 tablet empagliflozin, oral;~1 tablet rosuvastatin calcium, oral."
32788667|NCT01813474|Experimental|olaparib tablet monotherapy|olaparib tablet
32788668|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
32830452|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
32830453|NCT00378742||Participants|Participants with inherited eye diseases or relative of affected participant
32830454|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
32830455|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
33296787|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
32788669|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
32788670|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
32788671|NCT01797094|Experimental|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
32788672|NCT01797094|Experimental|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
32788673|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
32788674|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
32788675|NCT01810432|Experimental|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
32788676|NCT01810432|Experimental|Evacetrapib (Fed)|130 mg oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
32788677|NCT01796860|Other|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
32788678|NCT04908449|Experimental|Serratus anterior plane block with PIFB (experimental arm)|PIFB with local anesthetic with SAPB with local anesthetic (bupivacaine)
32788679|NCT04908449|Placebo Comparator|Serratus anterior plane block with PIFB (placebo arm)|PIFB with local anesthetic with SAPB placebo (saline)
32788680|NCT01796548|Experimental|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
32788681|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
33296788|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
33403853|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
32788682|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
32788683|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
32788684|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
32788685|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
32788686|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
32788687|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
32788688|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
32788689|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
33296789|NCT00033514|Experimental|treatment|please see intervention description
33296790|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
33296791|NCT03952936|Other|Mobility|Self comparison of data from pre-post intervention.
33296792|NCT03952858|Experimental|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
32788690|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
32788691|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32788692|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
32788693|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
32788694|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
32788695|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
32788696|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
32788697|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
32788698|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
32788699|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
32788700|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
32788701|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
32788702|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
32788703|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
32788704|NCT04916171||Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome|"The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.~The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation."
32788705|NCT04916171||Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis|For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.
32788706|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
32788707|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
32788708|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
32830456|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
32830457|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
32830458|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
32788709|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
32788710|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
32788711|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
32788712|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
32788713|NCT04907903|Experimental|RinasciMENTE|Participants will receive the internet-based intervention.
32788714|NCT04907903|No Intervention|Waiting-list|Participants will no receive the internet-based intervention.
32788715|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
32788716|NCT05370365|Experimental|4 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 4 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
32788717|NCT05370365|Experimental|6 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 6 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
32788718|NCT01796470|Experimental|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
32788719|NCT01796392|Experimental|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
32788720|NCT01796392|Other|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
32788721|NCT05102890|Experimental|Intervention group|Patients 65 years old and older will receive a pre-consultation screening questionnaire by phone prior to their virtual or in-person visit. A summary report based on the results of the questionnaire will be placed in the patient electronic chart for use by the clinician at the time of visit.
32788722|NCT05102890|No Intervention|Control Group|Usual care in the primary care clinic
32788723|NCT05102656||Group A (video call)|Patients receive standard of care via video call with treating physician.
32788724|NCT05102656||Group B (in-person)|Patients receive standard of care in-person physician visits.
32788725|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
32788726|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
32788727|NCT04414852|Experimental|mild renal impairment|
32788728|NCT04414852|Experimental|moderate remal impairment|
32788729|NCT04414852|Active Comparator|normal renal impairment|
32788730|NCT04415008|Experimental|treatment arm|prospective, open-label, multicenter,single arm
32788731|NCT04171024|Sham Comparator|Sham Group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (2 hertz); wave length (300 µs);"
32788732|NCT04171024|Experimental|Transcutaneous diaphragm electrical stimulation group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (35 hertz); wave length (300 µs); Intensity to achieve a visual contraction"
33403854|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
32788733|NCT04601506|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
32788734|NCT04601506|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
32788735|NCT04601506|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
33403855|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
33403856|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
33403857|NCT03145870|Other|Patient with multiple symptomatic myeloma|
33403858|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
32788736|NCT04601506|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
32788737|NCT01810042|Experimental|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
32788738|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
32788739|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
32788740|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
32788741|NCT01809262|Experimental|olodaterol 2 mcg|solution for inhalation
32788742|NCT01809262|Experimental|olodaterol 5 mcg|solution for inhalation
32788743|NCT01809262|Experimental|olodaterol 10 mcg|solution for inhalation
32788744|NCT01809262|Experimental|olodaterol 20 mcg|solution for inhalation
32788745|NCT01809262|Experimental|olodaterol 40 mcg|solution for inhalation
32788746|NCT01809262|Placebo Comparator|placebo|solution for inhalation
32788747|NCT04915703|Experimental|Intervention|flushing of internal external PTBD catheter 3 times a day
32788748|NCT04915703|No Intervention|Standard of Care|no flushing of PTBD catheter
32788749|NCT01808248|Experimental|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
32788750|NCT04914845|Active Comparator|De-escalation Cohort; 20mg|For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
32788751|NCT04914845|Active Comparator|Cohort 1; 30 mg|The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg.
32788752|NCT04914845|Active Comparator|Cohort 2; 40mg|Dose escalation to 40 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
32788753|NCT04914845|Active Comparator|Cohort 3; 60mg|Dose escalation to 60 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
32788754|NCT04914845|Active Comparator|Cohort 4; 80mg|Dose escalation to 80 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
32788755|NCT04914845|Active Comparator|Cohort 5; 100mg|Dose escalation to 100 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
32788756|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
32788757|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
32788758|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
32788759|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
32788760|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
32788761|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
32788762|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
32788763|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
32788764|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
32788765|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
32788766|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
32788767|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
32830459|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
32788768|NCT01866826|Experimental|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
32788769|NCT01866826|Placebo Comparator|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
32788770|NCT04600336|Experimental|low-dose oxybutynin|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
32788771|NCT04600336|Experimental|high-dose oxybutynin chloride|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
32788772|NCT04600336|Placebo Comparator|low-dose placebo|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - low-dose oxybutynin per physician discretion.
32788773|NCT04600336|Placebo Comparator|high-dose placebo|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - high-dose oxybutynin chloride per physician discretion.
32788774|NCT04579276|Experimental|"surgical method"|
32788775|NCT04579276|Active Comparator|"anesthetic method"|
32788776|NCT04584970|Experimental|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
32788777|NCT04584970|Active Comparator|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
32788778|NCT01791244|Active Comparator|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
32788779|NCT01791244|Experimental|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
32788780|NCT01865812|Experimental|OCA: 10 mg|Obeticholic acid, oral administration, 10 milligrams (mg), 8 weeks
32788781|NCT04600258|Experimental|Chocolate Group|Administration of 40g dark chocolate per day, for 2 months
32788782|NCT04600258|No Intervention|Control Group|No intervention and analysis will be performed before and after 2 months
32788783|NCT01808092|Experimental|CAZ-AVI|Intra-Venous treatment
32788784|NCT01808092|Active Comparator|Meropenem|Intra-Venous treatment
32788785|NCT04584814|Experimental|Babies born Preterm|Preterm babies, healthy at the time of the study, free of neonatal diseases and/or sequelae or malformations or genetic diseases. They were random assigned to two-hours blocks of basal, and dorsal stimulation protocol at 20 or 40 times per minute, each.
32788786|NCT01774084|Active Comparator|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
33296793|NCT03952858|Active Comparator|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
33296794|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
33296795|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
33296796|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
33296797|NCT02529982|Placebo Comparator|control|placebo
33296798|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~plus carboplatin/paclitaxel in three different schedules~plus paclitaxel~plus docetaxel/carboplatin~plus docetaxel~plus capecitabine~plus gemcitabine/cisplatin~plus pemetrexed/cisplatin"
32788787|NCT01774084|Placebo Comparator|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
32788788|NCT01807234|Experimental|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
32788789|NCT01807234|Experimental|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
32788790|NCT01807234|Placebo Comparator|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
32788791|NCT04571242|Active Comparator|DTM-SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and participants tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
33296799|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
33296800|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
33296801|NCT01323179||Opioid native|Patients not taking opioids preoperatively
32788792|NCT04571242|Active Comparator|Conventional SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and subjects tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
32788793|NCT01790932|Experimental|BKM120|"BKM120: 100 mg capsule once daily each day of a 28 day cycle .~Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."
33296802|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33296803|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
32788794|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
32788795|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
33296804|NCT03598439|Experimental|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
33296805|NCT03598439|Experimental|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
32788796|NCT01807156|Experimental|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
32788797|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
32788798|NCT02421887|Placebo Comparator|Placebo|
32788799|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
32788800|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
32788801|NCT01789606|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
32788802|NCT01788358|Experimental|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram [mg] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
32788803|NCT01773226|Experimental|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
32788804|NCT01773070|Other|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
32788805|NCT01772368|Experimental|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
32788806|NCT01772368|Experimental|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
32788807|NCT01772368|Experimental|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
32788808|NCT01772368|Experimental|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
32788809|NCT01772368|Active Comparator|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
32788810|NCT01772368|Active Comparator|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
32788811|NCT01788046|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
32788812|NCT01788046|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
32788813|NCT01806298|Experimental|Saizen®|
32788814|NCT01772134|Experimental|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
32788815|NCT01772134|Active Comparator|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
32788816|NCT01772134|Placebo Comparator|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
32788817|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
32788818|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
32788819|NCT01994889|Placebo Comparator|Placebo|Placebo control
32788820|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
32906929|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
32788821|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
32788822|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
32788823|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
32788824|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
32788825|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
32788826|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
32788827|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
32788828|NCT01993329|Experimental|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32788829|NCT01993329|Experimental|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32788830|NCT01993329|Experimental|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32788831|NCT01993329|Experimental|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32906930|NCT04378010|Experimental|EDP-305 1.5 mg|Once a day orally for 72 weeks
32906931|NCT04378010|Experimental|EDP-305 2 mg|Once a day orally for 72 weeks
33296806|NCT03598439|Active Comparator|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
33296807|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
33296808|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
33296809|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
33296810|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
33296811|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
33296812|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
33296813|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
33296814|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
33296815|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
33296816|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
33296817|NCT00443729|Experimental|1|Raltegravir & Placebo
33296818|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
33296819|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
33296820|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
33296821|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
33296822|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
33296823|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
33318467|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
33318468|NCT05623202|Experimental|Capacity-oriented behavior-change intervention|
32788832|NCT01993329|Experimental|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32788833|NCT01993329|Experimental|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
32788834|NCT04417101|Experimental|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
32788835|NCT04417101|No Intervention|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
32788836|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
32788837|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
32788838|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
32788839|NCT04899245|Experimental|School Staff|"50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time.~Additionally, staff who are vaccinated will be asked to participate in testing."
32906932|NCT04378010|Placebo Comparator|Placebo|Once a day orally for 72 weeks
33296824|NCT03607799|Experimental|Dietary Intervention|"A personalized nutrition plan will be developed for each woman and will respect faith-based food choices and regional preferences. The plan will be delivered by a culturally congruent health coach, and consider baseline dietary intake, energy balance for recommended gestational weight gain, personal values and preferences, through setting 2-4 SMART goals. Participants assigned to the intervention group will receive text messages. Participants assigned to the intervention group will be given a Fitbit to track their steps and will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community."
33296825|NCT03607799|Active Comparator|Control|Participants in the control group will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community.
33296826|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
33296827|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
33296828|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
33296829|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
33296830|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
33296831|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
33296832|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
33296833|NCT01027403||Healthy volunteers|
33296834|NCT01027403||Acute decompensated heart failure|
33296835|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
33296836|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
33296837|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
33296838|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
33296839|NCT03567473|Placebo Comparator|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
33296840|NCT01030991||HFpEF|HFpEF cohort (observational study)
33296841|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
33296842|NCT00439517|Experimental|1|UFOX + Cetuximab
33296843|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
33296844|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
33296845|NCT01031225|Experimental|1|
33296846|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
33296847|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
33296848|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
33296849|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
33296850|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
32788840|NCT04899245|Experimental|Parent/Child with Children with medical complexity (CMC)|"65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing.~Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study."
32788841|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
32788842|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
32788843|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
32788844|NCT02420717|Experimental|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32788845|NCT02420717|Experimental|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32788846|NCT02420717|Experimental|Phase 1|Patients Receive ruxolitinib Phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32788847|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
32788848|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
32788849|NCT02400905|Experimental|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
32788850|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
32788851|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
32788852|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
32788853|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
32788854|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
32788855|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
32788856|NCT04898465|Experimental|Social Paediatric Intervention|Multiprofessional social paediatric meeting with the family.
32788857|NCT04898465|No Intervention|Control group|Normal post-DGA dental programme.
32788858|NCT04420559|Experimental|Virtual Reality|
32788859|NCT04420559|Experimental|Distraction Card|
32788860|NCT04420559|No Intervention|Control|
32788861|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
32788862|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
32788863|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
33296851|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
33296852|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
32788864|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
32788865|NCT02347631|Experimental|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
32788866|NCT02347631|Active Comparator|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
32788867|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
32788868|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
32788869|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
33296853|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
33296854|NCT01028261|Experimental|ZGN-433|
33296855|NCT01028261|Placebo Comparator|Normal Saline|
33296856|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
33296857|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
33296858|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
33296859|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
33296860|NCT04771403|Experimental|FMPD AP system|Participants will use the FMPD AP system for automated insulin delivery for a 76 hour study visit.
32788870|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
32788871|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
32788872|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
32788873|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
32788874|NCT04906499|Experimental|Physical Activity Promotion Group|Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
32788875|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
32788876|NCT02374307|No Intervention|Control|The control group performs activities as usual.
32788877|NCT04898075|Experimental|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
32788878|NCT04898075|Placebo Comparator|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
32788879|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
32788880|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
32788881|NCT04891757|Experimental|FHD-286 dose escalation|Approximately 25-50 patients will be enrolled in the dose escalation arm.
33296861|NCT04771403|Experimental|MPC AP System|Participants will use the MPC AP system for automated insulin delivery for a 76 hour study visit.
33296862|NCT01031303|Experimental|Study Group|
33296863|NCT04726709|Experimental|Poised for Parkinson's|Alexander-technique-based online course to increase embodied agency in people with Parkinson's disease and their care partners.
32788882|NCT05443685|Experimental|ADX-629 treatment|Open label treatment with ADX-629
32788883|NCT02344745|Placebo Comparator|Control|Distilled water
32788884|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
32788885|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
32788886|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
32788887|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
32788888|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
32788889|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
32788890|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
32788891|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
32788892|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
32788893|NCT04420715|Experimental|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
33296864|NCT01028339|Active Comparator|Mannitol|
33296865|NCT01028339|Experimental|Hypertonic saline|
33296866|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
33296867|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
33296868|NCT04700501|Other|EYB Implementation study|All participants will have the opportunity to access an online CBT life skills learning programme.
33296869|NCT04695119||Adult patients with septic shock|"All adult (>=18 yo) patients admitted to participating ICUs with septic shock defined according to the Sepsis III criteria.~Purely observation study with no intervention. Patients are exposed to septic shock and treatment according to standard departmental protocols at each centre."
32788894|NCT04420715|Experimental|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
33296870|NCT01031459||Group 1|
33296871|NCT03495791|Experimental|EI development phase.|
33296872|NCT03495791|No Intervention|Pilot-testing phase.|
33296873|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
33296874|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
33318469|NCT01300364|Placebo Comparator|sugar pill|
32788895|NCT04897451||Women with cervical ripening in the context of artificial labor induction|
32788896|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
32788897|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
32788898|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
32788899|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
32788900|NCT02396849|Experimental|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
32788901|NCT02396849|Sham Comparator|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
32788902|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
32788903|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
32788904|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
32788905|NCT04891367|Experimental|Group CBT|Group cognitive behavioral therapy for obsessive compulsive disorder in youth
32788906|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
32788907|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
32788908|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
32788909|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
32788910|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
32788911|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
32788912|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
32788913|NCT01992549|Experimental|Human-cl rhFVIII|
32788914|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
32788915|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
32788916|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
33403859|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
32788917|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
33403860|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
32788918|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
32788919|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
32788920|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
32788921|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
32788922|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
32788923|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
32788924|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
32788925|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
32788926|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
32788927|NCT04726449||psychiatric diagnosis|psychiatric diagnosis : patients who were given a psychiatric diagnosis at the end of the follow up
33318470|NCT01300364|Active Comparator|reboxetine (NRI)|
33403861|NCT05663567|Experimental|experimental group 1|Implementing a solution-focused approach to support breastfeeding ONE TO ONE STUDY
33403862|NCT05663567|Experimental|experimental group 2|Implementing a solution-focused approach to support breastfeeding GROUP STUDY
32788928|NCT04726449||somatic diagnosis|somatic diagnosis: patients who were given a somatic diagnosis at the end of the follow up
32788929|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
32788930|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
32788931|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
32788932|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
32788933|NCT04178031|Experimental|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
32788934|NCT04677387|Placebo Comparator|Prescribe to Prevent Naloxone Training Module|This a 55-minute online module that covers basic information about naloxone that is relevant to community pharmacists.
32788935|NCT04677387|Experimental|Nalox-Comm|This is a newly developed 30-60 minute online module focused on teaching pharmacists how to overcome naloxone communication barriers.
32788936|NCT02014467|Experimental|Denosumab 60mg|injection
32788937|NCT02014467|Placebo Comparator|Placebo|injection
32788938|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
32788939|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
32788940|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
32788941|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
32788942|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
32788943|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
32788944|NCT01988337|Experimental|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
32788945|NCT01988337|Sham Comparator|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will receive a placebo treatment to mimic resin infiltration."
32788946|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
32788947|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
32788948|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
32788949|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
32788950|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
33403863|NCT05663567|No Intervention|No Intervention|ROUTINE MAINTENANCE WILL BE DONE SOLUTION-FOCUSED APPROACH WILL NOT BE APPLIED.
32788951|NCT04676217|Active Comparator|FDP|Face down positioning
32788952|NCT04676217|Experimental|NSP|"No positioning named non-supine positioning. Participants are to avoid recumbent positioning."
32788953|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
32788954|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
32788955|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
32788956|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
32788957|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
32788958|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
33403864|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
33403865|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
33403866|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
33403867|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
32788959|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
32788960|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
32788961|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
32788962|NCT01620489|Experimental|Lira 1.8 mg|
32788963|NCT01620489|Placebo Comparator|Placebo|
32788964|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
32788965|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
32788966|NCT01620255|Placebo Comparator|Placebo|
32788967|NCT01620255|Experimental|Drug Dose Level 1|
32788968|NCT01620255|Experimental|Drug Dose Level 2|
32788969|NCT01620255|Experimental|Drug Dose Level 3|
32788970|NCT01620255|Experimental|Drug Dose Level 4|
32788971|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
32788972|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
32788973|NCT01806064|Experimental|TRC105 and Axitinib|Patients randomized to receive TRC105 at 3 mg/kg on day 1, 7 mg/kg on day 4, and 10 mg/kg on day 8 and weekly thereafter in combination with axitinib 5 mg twice daily
32788974|NCT01806064|Active Comparator|Axitinib|Patients randomized to receive axitinib 5 mg twice daily
32788975|NCT01804582|Experimental|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
32788976|NCT01804582|No Intervention|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
32788977|NCT01787188|Experimental|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
32788978|NCT01787188|Experimental|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
32788979|NCT01787188|Placebo Comparator|Placebo Capsule QD|Placebo Capsule QD
32788980|NCT01787032|Experimental|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
32788981|NCT01787032|Experimental|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
32788982|NCT01787032|Experimental|Period 1: BI 113608|tablets with 240 ml water
32788983|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
32788984|NCT01737268|Experimental|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
32788985|NCT01769404|Experimental|LY2605541|Stable dose of LY2605541 (0.2 to 0.6 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
32788986|NCT01769404|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 to 0.6 U/kg) administered SQ once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
32788987|NCT04562662|Experimental|Intervention group|Single arm (all participants receive interventions)
32788988|NCT01769326|Experimental|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
32788989|NCT01769326|Active Comparator|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
32788990|NCT01769326|Experimental|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
33403868|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
33403869|NCT05665283|Active Comparator|Reference Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
32788991|NCT01769326|Active Comparator|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
32788992|NCT01786330|Experimental|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
32788993|NCT01786330|Active Comparator|Control|Group receives standard of care
32788994|NCT01786174|Experimental|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
32788995|NCT01786174|Placebo Comparator|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
32788996|NCT01736566|Experimental|Family History + Whole Genome Sequencing|Doctors and their patients receive a Genome Report and an Annotated Family History Report.
32788997|NCT01736566|Active Comparator|Family History Only|Doctors and their patients receive an Annotated Family History Report only.
32788998|NCT01768858||Participants receiving adalimumab|Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.
32788999|NCT01736254|Experimental|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
32789000|NCT01736254|Experimental|Evacetrapib|Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
32789001|NCT01736254|Experimental|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
32789002|NCT01767376|Experimental|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
32789003|NCT01767376|Experimental|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
32789004|NCT01767376|Experimental|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
32789005|NCT01767142|Experimental|Outer Thigh CoolSculpting Treatment|Treatment with the CoolSculpting System and a modified belt applicator will be performed on one outer thigh; the remaining thigh is considered the untreated control. Subjects will receive one cooling cycle applied to the thigh area intended for treatment with a protocol-defined cooling rate and duration of 120 minutes.
32789006|NCT01785628|Experimental|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
32789007|NCT01785628|Placebo Comparator|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
32789008|NCT01785472|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
32789009|NCT01785472|Experimental|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
32789010|NCT01785472|Active Comparator|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
32789011|NCT01785160|Active Comparator|Raltegravir|coated tablets, oral administration with 240 ml water
32789012|NCT01785160|Experimental|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
32789013|NCT01736176|Experimental|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
32789014|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
32789015|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
32789016|NCT04575922|Experimental|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
32789017|NCT04569682|Active Comparator|transrenal artery perfusion group|
32789018|NCT04569682|Experimental|transrenal vein perfusion group|
32789019|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
32789020|NCT01766206|Experimental|MenACWY-CRM Group|Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.
32789021|NCT01734850|Experimental|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
32789022|NCT01734850|Experimental|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
32789023|NCT01734850|Experimental|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
32789024|NCT01766050|Experimental|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
32789025|NCT02341625|Experimental|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
32789026|NCT02341625|Experimental|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
32789027|NCT02341625|Experimental|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
32789028|NCT02341625|Experimental|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
33296875|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
32789029|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
33087023|NCT01118026|Experimental|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).~All patients will be followed for a maximum of ten years."
32789030|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
33296876|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
32789031|NCT05370053|Experimental|ELF-test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
32789032|NCT05370053|No Intervention|Control|No intervention.
32789033|NCT04894877||Active Comparator: Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
32789034|NCT04894877||Active Comparator: Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
32789035|NCT01784068|Experimental|Nilotinib followed by treatment-free|Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
32789036|NCT01783678|Experimental|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
32789037|NCT01783678|Experimental|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
32789038|NCT01783678|Experimental|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
32789039|NCT01734772|Experimental|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
32789040|NCT01734772|Experimental|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
32789041|NCT01734772|Experimental|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
32789042|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
32789043|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
32789044|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
32789045|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
32789046|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
32789047|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
33087024|NCT00280800|Active Comparator|1|constant CPAP
33296877|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
33296878|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
33296879|NCT03995147|Experimental|Treatment Arm|
33296880|NCT03477383||Adult patients|Adult patients (18 years or older) undergoing heart transplantation
32789048|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
33403870|NCT05665283|Active Comparator|Test Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
32789049|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
32789050|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
32789051|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
32789052|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
32789053|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~Subjects ≥12 years will receive a dose of 600 mg.~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~Subjects < 6 months will receive a dose of 8 mg/kg."
32789054|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
32789055|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
32789056|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
32789057|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
32789058|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
32789059|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
32789060|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
32789061|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
32789062|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
32789063|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
32789064|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
32789065|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
32789066|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
32789067|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
32789068|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
32789069|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
32789070|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
33087025|NCT00280800|Experimental|2|automatic CPAP
32789071|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
32789072|NCT01783444|Experimental|Capecitabine 1250 mg/m2|Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
32789073|NCT01783444|Experimental|Everolimus 10 mg|Everolimus (10 mg daily) (investigational arm).
32789074|NCT01783444|Active Comparator|Everolimus 10 mg + Exemestane 25 mg|Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).
32789075|NCT02367131||Jardiance|
32789076|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
32789077|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
32789078|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
32789079|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
32789080|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
32789081|NCT02364947|Placebo Comparator|Placebo|
32789082|NCT02392481||Healthy subjects|
32789083|NCT02392481||Mild asthma|
32789084|NCT02392481||Moderate asthma|
32789085|NCT02392481||Severe asthma|
32789086|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
32789087|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
32789088|NCT05370287|Experimental|Glaucoma with oxygen|Primary open angle glaucoma subjects as well as pre-perimetric glaucoma suspects will be classified by clinical exam by an experienced glaucoma specialist according to the American Academy of Ophthalmology Practice Patterns. Glaucoma subjects and suspects will undergo adaptive optics (AO) imaging of several macular locations. A subset of subjects will undergo oxygen challenge intervention, which involves breathing 100% oxygen through a mask during AO imaging at pre-determined retinal vessel locations.
32789089|NCT05370287|Experimental|Healthy control with oxygen|Age-matched healthy control cohort will undergo the same AO imaging procedures as glaucoma cohort. A subset of subjects will undergo the same oxygen challenge intervention as the glaucoma cohort.
32789090|NCT05370287|Experimental|Healthy control with stimulation|Healthy control subjects will undergo AO imaging at several macular locations while flashes of visible light stimulus are delivered.
32789091|NCT05370287|Experimental|Glaucoma|Glaucoma subjects and suspects will undergo AO imaging at several macular locations without intervention.
32789092|NCT05370287|Experimental|Healthy control|Healthy control subjects will undergo AO imaging at several macular locations without intervention
32789093|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
32789094|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
32789095|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
32789096|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
32789097|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
32789098|NCT01765582|Experimental|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
32830460|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
32830461|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
33403871|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
33403872|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
32789099|NCT01765582|Experimental|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
32789100|NCT01765582|Experimental|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
32789101|NCT04413838|Experimental|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND aspartate aminotransferase (AST) > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
32789102|NCT04413838|Other|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND AST > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
32789103|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
32789104|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
32789105|NCT01649375|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
32789106|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
33296881|NCT03477383||Pediatric patients|Pediatric patients (0-17 years) undergoing heart transplantation
33296882|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
33296883|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
33296884|NCT03465371|Active Comparator|Virtual InPerson Intervention|Participants receiving the Virtual InPerson Intervention (the InPerson training via Zoom)
33296885|NCT00437489|Active Comparator|Control|
33296886|NCT00437489|Experimental|Experimental|
33296887|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
33296888|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
33296889|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
33296890|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
33296891|NCT03994913|Experimental|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
33296892|NCT04683575|Experimental|experimental group|Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.
33296893|NCT04683575|Placebo Comparator|Placebo control group|Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）
33296894|NCT04683575|No Intervention|No intervention group|Patients with differentiated thyroid cancer with low blood selenium are not treated.
33296895|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
33296896|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
33296897|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
33296898|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
33296899|NCT04681625|Active Comparator|Standard silodosin treatment|Peroral treatment with silodosin at a dose of 8 mg daily
33296900|NCT04681625|Experimental|Standard silodosin treatment with PFMT|Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique
33296901|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
33318471|NCT01300364|Active Comparator|citalopram (SSRI)|
32789107|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
32789108|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
32789109|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
32789110|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
32789111|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
32789112|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
33296902|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
33296903|NCT01031693|Active Comparator|Group A|Active TMS
33296904|NCT01031693|Sham Comparator|Group B|Sham TMS
33296905|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
33296906|NCT01323413||stroke|acute ischemic stroke patients
33296907|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
33296908|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
33296909|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
33296910|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
33296911|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
33296912|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
33296913|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
32789113|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
33296914|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
33296915|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
33296916|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
33296917|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
33296918|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
33296919|NCT03995381|Experimental|DAs group|Shared decision making using decision aids
33296920|NCT03995381|No Intervention|Control group|Standard oral explanation guided with booklets
33296921|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
33296922|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
33296923|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
33318472|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
33318473|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
33318474|NCT05617352||2F Group|Patients with Two-field Lymphadenectomy
33318475|NCT05617352||3F Group|Patients with Three-field Lymphadenectomy
33318476|NCT05623124||Dementia|Participants have cognitive impairment and difficulty in daily activity.
33318477|NCT05623124||Mild cognitive impairment|Participants have cognitive impairment, but no difficulty in daily activity.
32789114|NCT01648205|Experimental|Placebo followed by Ranolazine Administration|Placebo for 1 month and Ranolazine for 5 months.
32789115|NCT04894253||Single group of 30 patients with systemic lupus|
32789116|NCT04903691|Experimental|Exercise training|130 patients who underwent open heart surgery and are cleared for exercise.These will include patients who enter supervised cardiac rehabilitation as well as patients who enter a supervised exercise program focusing strength training, endurance of functional training.
32789117|NCT04903691|No Intervention|Additional controls|5 patients who choose not to enter any organized exercise program.
32789118|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
32789119|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
32789120|NCT02362451|Experimental|1/Lead-in T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|All patients to receive autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine before randomization
32789121|NCT02362451|Experimental|2/Active T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|Autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine after randomization
32789122|NCT02362451|Placebo Comparator|3/Placebo|Autologous elutriated monocyte vaccine placebo after randomization
32789123|NCT01734382|Experimental|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants < 30 kg; 8 mg/kg for participants >/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
32789124|NCT01734382|Experimental|Part 2: TCZ IV 12 mg/kg Q3W/Q4W|Participants with weight < 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
33318478|NCT05623124||cognitively normal|Participants do not have cognitive impairment.
32789125|NCT01734382|Experimental|Part 2: TCZ IV 8 mg/kg Q3W/Q4W|Participants with weight >/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
32789126|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
32789127|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
32789128|NCT01765426|Experimental|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
32789129|NCT01765426|Experimental|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
32789130|NCT01765426|Experimental|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
32789131|NCT01765426|Experimental|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
33087026|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
33403873|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
33403874|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
33318479|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
33318480|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
33318481|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
32789132|NCT01765270|Active Comparator|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
32789133|NCT01765270|Placebo Comparator|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
32789134|NCT04605484|Experimental|Posoleucel|Arm 1: Regimen A
32789135|NCT04605484|Experimental|Posoleucel and Placebo|Arm 2: Regimen B
32789136|NCT04605484|Placebo Comparator|Placebo|Arm 3: Regimen A
32789137|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
32789138|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
32789139|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
32789140|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
32789141|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
32789142|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
32789143|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
32789144|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
32789145|NCT01765192|Experimental|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
32789146|NCT01765192|Experimental|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
32789147|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
32789148|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
32789149|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
32789150|NCT04892498|Experimental|RT+PD-1+GM-CSF+IL-2|
32789151|NCT04887506|Experimental|TAVT-45|TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.
32789152|NCT04887506|Active Comparator|Reference abiraterone acetate (Zytiga®) - R-AA|Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.
32789153|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
32789154|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
32789155|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
32789156|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
32789157|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
32789158|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
32789159|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
32789160|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
32789161|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
32789162|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
32789163|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
32789164|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
32789165|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
32789166|NCT04196738|Experimental|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
32789167|NCT04196738|Experimental|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
32830462|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
32789168|NCT04902482|Experimental|iCycle training|Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
32789169|NCT02317562|Experimental|I10E Arm|
33296924|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
33296925|NCT00441467|Experimental|Glufosfamide|Glufosfamide
32789170|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
32789171|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
32789172|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
32789173|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
32789174|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
32789175|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
32789176|NCT02281760|Experimental|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
32789177|NCT02390531|Experimental|Bevacizumab 0.250 mg|Dosage of injected Bevacizumab to be studied
32789178|NCT02390531|Experimental|Bevacizumab 0.125 mg|Dosage of injected Bevacizumab to be studied
32789179|NCT02390531|Experimental|Bevacizumab 0.063 mg|Dosage of injected Bevacizumab to be studied
32789180|NCT02390531|Experimental|Bevacizumab 0.031 mg|Dosage of injected Bevacizumab to be studied
32789181|NCT02390531|Experimental|Bevacizumab 0.016 mg|Dosage of injected Bevacizumab to be studied
32789182|NCT02390531|Experimental|Bevacizumab 0.008 mg|Dosage of injected Bevacizumab to be studied
32789183|NCT02390531|Experimental|Bevacizumab 0.004 mg|Dosage of injected Bevacizumab to be studied
33296926|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
33296927|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
33296928|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
33296929|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
33296930|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
33296931|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
33296932|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
33296933|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
32789184|NCT02390531|Experimental|Bevacizumab 0.002 mg|Dosage of injected Bevacizumab to be studied
32789185|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
32789186|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
32789187|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
33296934|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
33296935|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
32789188|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
32789189|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
32789190|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
32789191|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
32789192|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
32789193|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
32789194|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
32789195|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
33296936|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
33296937|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
33296938|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
33296939|NCT01032083|Placebo Comparator|Placebo|
33296940|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
33296941|NCT01028963|Placebo Comparator|Placebo|
33296942|NCT01028963|Active Comparator|Active control|
33296943|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
32789196|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
32789197|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
32789198|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
33296944|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
33296945|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
33296946|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
33296947|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
33296948|NCT00006604|Experimental|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
33296949|NCT00006604|Experimental|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
32789199|NCT04902599|Active Comparator|Vaser ulstrasound-assisted dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with the Vaser ultrasound-assisted dissection technique.
32789200|NCT04902599|Active Comparator|Blunt dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with blunt dissection technique.
32789201|NCT04889729||GENOMED4ALL - MDS patients|Information on targeted mutation screening (NGS including 60 genes related to MDS) from 13284 MDS patients
32789202|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
32789203|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
32789204|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
32789205|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
32789206|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
33087027|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
33296950|NCT00006604|Experimental|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2"
33296951|NCT00006604|Experimental|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2"
33296952|NCT00006604|Experimental|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
33087028|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
33087029|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
33087030|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
33087031|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
33087032|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
33087033|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
33087034|NCT02759731|Experimental|Arm 1|Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a CR and there has not been a DLT, the dose will be remain at 2mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks, the dose will be decreased to 1mg daily, and will continue at this dose as tolerated. If there has been DLT at this dose (1 mg), patients will be taken off treatment.
33296953|NCT00006604|Experimental|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
33296954|NCT00006604|Experimental|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
33403875|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
33296955|NCT00006604|Experimental|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
33296956|NCT00006604|Experimental|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
33296957|NCT03951376|Experimental|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
33296958|NCT03951376|No Intervention|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
33296959|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
33296960|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
33296961|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
33296962|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
33403876|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
33403877|NCT05761392|Experimental|Precise management|"Participants will be asked to take daily pain state and monthly health condition assessments.~A warning for the physicians will be given when participants reach daily assessment threshold. Remote interventional meeting will be scheduled and stimulation parameters will be adjusted accordingly.~Participants will also be asked to take conventional follow-up at 1-, 3-, and 6-month post-operative."
33087035|NCT02759731|Experimental|Arm 2|If the response is a PR or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily. For patients who experience cGVHD progression at any time within the first 12 weeks on 2mg daily, the dose can be increased to 4mg daily until 24 weeks.
33087036|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
33087037|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
33087038|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
33087039|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
33296963|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
33296964|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), RN4 (Guan Yuan), ST36 (Zusanli) (front treatment) or Du20, GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 6 required points, acupuncturist will be allowed to choose 4 more points. The 4 supplemental points may be chosen from the following: LR2 (Xin Jian), HT7 (Shenmen), PC6 (Neiguan), GB34 (Yang Ling Quan), GB39 (Xuan Zhong), SI3 (Hou Xi), RN6 (Qi Hai), RN24 (Cheng Jiang),KI 3 (Taixi), KI 6 (Zhao Hai), ST40 (Feng Long), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL19 (Dan Shu), BL20 (Pi Shu), BL60 (Kun Lun). Auricular acupuncture will be employed.
33296965|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. In the sham procedure, a needle guiding tube will be tapped on the surface of the skin near, but not on, each of the 10 acupuncture points that would have been selected for true acupuncture. The needle guiding tube will be used to create sensations that mimic needle manipulation.
32789207|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
33296966|NCT02868671|No Intervention|No Intervention|All participants in this study will receive usual care. For those assigned to true acupuncture and sham acupuncture, the usual care will be in addition to their acupuncture.
33296967|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
33296968|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
33296969|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
33296970|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
33296971|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
33087040|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
33087041|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
33087042|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
33296972|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
33296973|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
33296974|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
33296975|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
33296976|NCT00006436|Experimental|Arm 1-Combination Chemo and Biological Therapy|Combination chemo and biological therapy
33296977|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
33296978|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
33296979|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
33296980|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
33296981|NCT01098058|Experimental|CBT plus treatment as usual|
33296982|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
33296983|NCT03994445|Experimental|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
33296984|NCT03994445|No Intervention|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
33296985|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
33296986|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
33087043|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
33087044|NCT00280839|Active Comparator|topiramate|
33087045|NCT00280839|Placebo Comparator|placebo|
33087046|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
33087047|NCT04719728||pre lingual|aided response, speech perception threshold impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
33087048|NCT04719728||post lingual|aided response, speech perception threshold speech in noise impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
33087049|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
33087050|NCT00414869|Placebo Comparator|Placebo|Placebo powder
33087051|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
33087052|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
32789208|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
32789209|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
32789210|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
32789211|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
32789212|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
32789213|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
32789214|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
33087053|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
33296987|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
33296988|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
33296989|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
33296990|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
33296991|NCT04829903|Active Comparator|Group DUL|Group taking Dulaglutide injections
33296992|NCT04829903|Placebo Comparator|Group LIR|Group taking Liraglutide injections
32789215|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
32789216|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
32789217|NCT02355665|Experimental|Nicotine|Nicotine Spray
32789218|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
33087054|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
33087055|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
33087056|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
33087057|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
33087058|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
33087059|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
33087060|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
33296993|NCT01323569|Placebo Comparator|Placebo|
33296994|NCT01323569|Experimental|Sativex 4 sprays|
33296995|NCT01323569|Experimental|Sativex 8 sprays|
33296996|NCT01323569|Experimental|Sativex 16 sprays|
33296997|NCT01323569|Active Comparator|Marinol low dose|
33296998|NCT01323569|Active Comparator|Marinol high dose|
33296999|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
33297000|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
33087061|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
33087062|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
33087063|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
33297001|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
33297002|NCT00440999|Experimental|pyronaridine artesunate|The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
33297003|NCT00440999|Active Comparator|chloroquine|"The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2."
33297004|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
33297005|NCT01029743||Group 1|
33297006|NCT01029743||Group 2|
33297007|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
33297008|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
32789219|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
32789220|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
32789221|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
32789222|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
32789223|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
32789224|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
32789225|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
32789226|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
32789227|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
32789228|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
33087064|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
33087065|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
33087066|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
33087067|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the~Subject's weight as follows:~30-37 kg: 2 tablets;~38-54 kg: 3 tablets;~55-70 kg: 4 tablets;~71 kg and over: 5 tablets."
33087068|NCT04827901|Active Comparator|XEN1101|Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
33087069|NCT04827901|Placebo Comparator|Placebo|Subjects will take a matching placebo daily for eight weeks.
33087070|NCT04824508|Active Comparator|Conventional position (head position)|Leaderposition at the patient's head
33087071|NCT04824508|Active Comparator|Remote position|Leaderposition remote from patient and hands-off
33087072|NCT00252551|Experimental|1|osteosynthesis
33087073|NCT00252551|Active Comparator|2|Simple surgery
33087074|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
33087075|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
33087076|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
33087077|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
33297009|NCT00006184|Experimental|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
33297010|NCT00006184|Other|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
32789229|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
32789230|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
32789231|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
32789232|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
32789233|NCT04666701|Experimental|Escócia association|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Escócia association, oral~1 dragee Placebo Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual"
32789234|NCT04666701|Active Comparator|Ketorolac|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Ketorolac, sublingual~1 tablet Placebo Escócia association, oral~1 dragee Placebo Scopolamine, oral"
32789235|NCT04666701|Active Comparator|Scopolamine|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 dragee Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual~1 tablet Placebo Escócia association, oral"
32789236|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
32789237|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
32789238|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
32789239|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
32789240|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
32789241|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
33087078|NCT04822675|Experimental|Percutaneous mitral repair|Percutaneous mitral repair +/- coronary artery bypass grafting within 14 days of mitral repair.
32789242|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
32789243|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
32789244|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
32789245|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
32789246|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
32789247|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
32789248|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
32789249|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
32789250|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
32789251|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
32789252|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subjects untreated fresh whole blood."
32789253|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
32789254|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
32789255|NCT01986855|Placebo Comparator|Placebo|Matching placebo
32789256|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
32789257|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
33087079|NCT04822675|Active Comparator|Mitral valve surgery|Surgical mitral valve surgery +/- coronary artery bypass grafting
33087080|NCT04821349|Other|Single arm study|Standard reading Group vs AI-assisted reading Group
33087081|NCT05139667|Experimental|tacrolimus/corticosteroid|topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch
33087082|NCT05139667|Active Comparator|corticosteroids|topical corticosteroid
33087083|NCT05139667|Active Comparator|tacrolimus|topical tacrolimus patch and tacrolimus paste
33297011|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
33297012|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
33297013|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
33087084|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
33087085|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
33087086|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
33087087|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
33087088|NCT04823962|Experimental|GM-CSF|rhGM-CSF (molgramostim) + hydrogel
33087089|NCT04823962|Placebo Comparator|Placebo|Hydrogel
33087090|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
33087091|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
33087092|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
33087093|NCT04821076|Active Comparator|Energy balance|
33297014|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
32789258|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
32789259|NCT04673175|Experimental|Ceftolozane-Tazobactam|Participants receive ceftolozane-tazobactam by injection directly into the vein (intravenously, IV) every 8 hours for 10-14 days.
32789260|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
33297015|NCT00433199|Placebo Comparator|Placebo|Placebo
32789261|NCT04666311||Adult presumptive TB cases|Adult presumptive TB cases (age ≥18years) with one or more TB symptoms (WHO recommended four-symptom screening; cough, weight loss, night sweats, fever) of any duration.
32789262|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
32789263|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
33087094|NCT04821076|Experimental|Energy restriction|
33087095|NCT04821076|Active Comparator|Energy balance + exercise|
33297016|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
33297017|NCT03950986|No Intervention|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
33297018|NCT03950986|Experimental|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
33297019|NCT01101256||Fondaparinux Prophylaxis group|
32789264|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
32789265|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
32789266|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
32789267|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
33297020|NCT01101256||Fondaparinux Therapy group|
33087096|NCT04821076|Experimental|Energy restriction + exercise|
33087097|NCT00281034||OASIS Study Group|
33087098|NCT05139082|Other|CDK4/6 inhibitor (TQB3616) + PD-L1 monoclonal antibody (TQB2450)|TQB3616 capsules (120/150/180mg p.o. qd, d1-d21) combined with TQB2450 injection (1200mg ivgtt, d1)
33087099|NCT04719767|Experimental|visual|In the visual group, a visual laryngeal mask was placed and endotracheal intubation was guided under visual conditions. The endotracheal tube was removed 10 minutes before the end of the operation, and the laryngeal mask was retained.
33087100|NCT04719767|No Intervention|Non-visual|In the non-visual group, laryngeal mask airway was inserted. After clinical judgment of good counterpoint, endotracheal intubation was inserted blindly through LMA. Endotracheal intubation was removed 10 minutes before the end of the operation, and the laryngeal mask airway was retained.
33297021|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
33297022|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
33297023|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
33297024|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
33297025|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
33087101|NCT05138926|Experimental|Cervical manipulation group|high speed, low amplitude cervical manipulation
33297026|NCT01030055|Experimental|TKI258 - bioavailability|
33297027|NCT01030055|Experimental|TKI258 - food|
33297028|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
32789268|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
32789269|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
32789270|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
32789271|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
32789272|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
32789273|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
32789274|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
33297029|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
32789275|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
32789276|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
32789277|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
33297030|NCT00006046|Experimental|Hu3S193 10 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
33297031|NCT00006046|Experimental|Hu3S193 25 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
33297032|NCT00006046|Experimental|Hu3S193 50 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
33297033|NCT00006046|Experimental|Hu3S193 100 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
33297034|NCT00006046|Experimental|Hu3S193 200 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
32789278|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
32789279|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
33087102|NCT05138926|Sham Comparator|Control group|placebo mobilization without manipulation
33087103|NCT04826770||BNT/BNT/BNT|Subjects receiving two doses of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as homologous basic immunization and one dose of BNT162b2 as booster vaccination
33297035|NCT03994991|Experimental|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
33297036|NCT03994991|Sham Comparator|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
33297037|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
33297038|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
33297039|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
33297040|NCT03994757|Experimental|MRBI group|
33297041|NCT03994757|Sham Comparator|Control group|
33297042|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
32939709|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019~blood for laboratory tests~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
32939710|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~blood for laboratory tests~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
32939711|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
32939712|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
32939713|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
33297043|NCT01098448|Experimental|Periodontal surgery|
33297044|NCT01098448|Experimental|systemic antibiotics|
33297045|NCT01098448|Experimental|Local delivery of tetracycline|
33297046|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
33297047|NCT01098448|Experimental|local antibiotics and surgery|
33297048|NCT01098448|Experimental|systemic antibiotics and surgery|
33297049|NCT01098448|Experimental|local and systemic antibiotics and surgery|
33297050|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
33297051|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
33297052|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
33297053|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
33297054|NCT01030367|Experimental|1|PETN
33297055|NCT01030367|Experimental|2|ISDN
33297056|NCT01030367|No Intervention|3|
33297057|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
33297058|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
32939714|NCT04084028|Active Comparator|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
33297059|NCT00005908|Experimental|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
33297060|NCT00005908|Experimental|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m^2 intravenous day 1, capecitabine 937.5 mg/m^2 orally twice daily day 2-15 for 4 cycles
33297061|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
33297062|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
33297063|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
33297064|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
33297065|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
33297066|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
33297067|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
33297068|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
33297069|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
33297070|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
33087104|NCT04826770||AZD/BNT/BNT|Subjects receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
33087105|NCT04826770||AZD/AZD/BNT|Subjects receiving two doses of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) as homologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
33297071|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
33297072|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
33087106|NCT04826770||AZD/MOD/BNT|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
33297073|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
33297074|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
33087107|NCT04826770||AZD/BNT/MOD|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as booster vaccination
33403878|NCT05761392|No Intervention|Conventional management|Participants will be only asked to take conventional follow-ups at 1-, 3-, and 6-month post-operative. During these follow-ups, they will be asked to score VAS based on general pain state, and take questionnaires including EQ-5D-5L, PSQI, PGIC, CGI-I.
33087108|NCT04826770||Control/validation group|"Control samples for the validation of the used methods from the pre-SARS-CoV-2 era were transferred from the study Blood Donations from Healthy Blood Donors to Investigate Circannual Variations in Tryptophan Metabolism and Adaptive Immune Response to Bacterial Infectious Agents (in short TRP study). Subjects had not received any SARS-CoV-2 vaccination at that time. Remaining plasma samples were transferred to the AICOVI study."
33087109|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
33087110|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
33087111|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
33087112|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
33087113|NCT00281073|Active Comparator|ICE or TEE|
33297075|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
33297076|NCT00004978|Experimental|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
33297077|NCT00004978|No Intervention|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
33297078|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
33297079|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
33297080|NCT01030679|Experimental|CKD-501 0.5mg|
33297081|NCT01030679|Experimental|CKD-501 1mg|
33297082|NCT01030679|Experimental|CKD-501 2mg|
33297083|NCT01030679|Placebo Comparator|Placebo|
33297084|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
33403879|NCT04478968||Active AVF|Patients after kidney transplantation with functioning AVF
33403880|NCT04478968||No AVF|Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)
33403881|NCT04595292||older adults, assessment|
33403882|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
33403883|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
33087114|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
33297085|NCT00430937|Active Comparator|Pooled Comparator|
33297086|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
33297087|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
33297088|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
33297089|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
33297090|NCT00004888|Experimental|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
33087115|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
33087116|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
33087117|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
33087118|NCT00252746|Experimental|ZD6474 100mg|Daily dose
33087119|NCT00252746|Experimental|ZD6474 200mg|daily dose
33297091|NCT00004888|Experimental|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
33297092|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
33297093|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
33297094|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
33403884|NCT04438876|Experimental|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
33297095|NCT00004732|Active Comparator|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
33297096|NCT00004732|Active Comparator|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
33297097|NCT01098760|Experimental|Arm 1|
33297098|NCT03950830|Experimental|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
32789280|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
32789281|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
32789282|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
33297099|NCT03952390||control|healthy volunteers
33297100|NCT03952390||sepsis|patients with sepsis
33297101|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
33297102|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
33297103|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
33297104|NCT01033097|Experimental|DNK333 5 mg|
33297105|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
33297106|NCT01033097|Experimental|DNK333 25 mg|
33297107|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
33297108|NCT01033097|Experimental|DNK333 100 mg|
33297109|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
33297110|NCT01033097|Active Comparator|Betamethasone 4 mg|
33297111|NCT01033097|Experimental|DNK333 1 mg|
33297112|NCT01033097|Placebo Comparator|placebo 1mg|
32789283|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
32789284|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
32789285|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
32789286|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
32789287|NCT02257567|Experimental|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
32789288|NCT05646043|Active Comparator|Patients with cancer of the digestive system|Patients with cancer of the digestive system (oesophageal and stomach cancer) will be enrolled in this study arm.
33087120|NCT00252746|Experimental|ZD6474 300mg|daily dose
33087121|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
33087122|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
33087123|NCT01680484|No Intervention|Control|Sit and rest
33087124|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
33087125|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
33297113|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
33297114|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
33297115|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
33297116|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
33297117|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
32939715|NCT04084028|No Intervention|Control|Participants will receive no interventions.
32939716|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
32939717|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
32939718|NCT03852524|Experimental|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
32939719|NCT03852524|Placebo Comparator|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
32939720|NCT03388645|Experimental|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
33297118|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
33297119|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
33297120|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
33297121|NCT01033799|Sham Comparator|Control Product|
32939721|NCT03388645|Experimental|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
32939722|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
32939723|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
33297122|NCT01033799|Active Comparator|Tested Product|
32939724|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
32939725|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
32939726|NCT04713878|Active Comparator|Group 1|Intubated without comorbidity
32939727|NCT04713878|Active Comparator|Group 2|Intubated with comorbidity
32939728|NCT04713878|Active Comparator|Group 3|No intubated
32939729|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
32939730|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
32939731|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
32939732|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
32939733|NCT04735783|Experimental|Very low-energy, viscous placebo breakfast|Participants will consumed a viscous breakfast meal from a standard bowl with a standard spoon. The volume of the meal will be 5 mL/kg body mass, consisting of 15% (0.75 mL/kg body mass) low-energy flavoured squash, with the remainder made up of tap water. To thicken the solution and increase the perception of energy intake, 0.1 g/kg xanthan gum (a soluble fibre often used as a low-energy thickening agent) will be added and the mixture will be blended thoroughly. An additional 3 mL/kg tap water will be consumed as a drink alongside the meal in this trial.
32939734|NCT04735783|Active Comparator|Typical, whole-food breakfast|Participants will consume a standardised meal consisting of puffed rice cereal, semi-skimmed milk, white bread, seedless strawberry jam, and apple juice. This meal will provide 20% of estimated energy requirements, determined by multiplying estimated resting metabolic rate by a physical activity level of 1.6. A measured volume of tap water will be consumed alongside this meal, in order to match total water content of the typical whole-food breakfast to the very low-energy, viscous placebo breakfast.
32939735|NCT04735783|Active Comparator|Water-only control|Participants will consume 8 mL/kg body mass of plain tap water to match the total water content of the typical whole-food breakfast and the very low-energy, viscous placebo breakfast.
32939736|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
32939737|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
32939738|NCT04332302|Experimental|Power training group|Participants will be enrolled in a resistance training program.
32939739|NCT04332302|No Intervention|Control group|Participants will be doing their normal life.
32789289|NCT05646043|Active Comparator|Patients with cancer of the rectum|Patients with cancer of the rectum will be enrolled in this study arm.
32789290|NCT04419961|No Intervention|Control|Routine care.
32789291|NCT04419961|Experimental|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
32789292|NCT05330299|Experimental|COMPASS (single arm)|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of IBD.
32789293|NCT05327257|Experimental|iTBS rTMS Left Dorsolateral Prefrontal Cortex (DLPFC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
32789294|NCT05327257|Experimental|iTBS rTMS Lateral Parietal Cortex (LPC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
32789295|NCT05327257|Experimental|iTBS rTMS Vertex then Left Dorsolateral Prefrontal Cortex (DLPFC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC.
33087126|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
33087127|NCT04528147|Experimental|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
33087128|NCT04528147|Experimental|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
33087129|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
33087130|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
33403885|NCT04438876|Active Comparator|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
33403886|NCT04477798|Experimental|PCT-DIA/MS|PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
32789296|NCT05327257|Experimental|iTBS rTMS Vertex then Lateral Parietal Cortex (LPC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC.
32789297|NCT05327257|Sham Comparator|iTBS rTMS Vertex only|Cognitively normal and healthy controls will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days. The vertex serves as a control as there are no functional improvements in cognition with stimulation of the vertex region.
32789298|NCT05645965||Patients who underwent implantable cardioverter-defibrillator (ICD) insertion during study period|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
32789299|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
32789300|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
32789301|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
32789302|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
32789303|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
32789304|NCT04853329|Experimental|PartA- Arm A|"Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg).~Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments)."
32789305|NCT04853329|Experimental|PartA- Arm B|Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.
32789306|NCT04853329|Experimental|Part B|Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.
32789307|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
32789308|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
32789309|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
32789310|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
32789311|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
32789312|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
32789313|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
33087131|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
33087132|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
33297123|NCT01033877|Experimental|TdaP vaccine|
33297124|NCT01033877|Active Comparator|Td vaccine|
33297125|NCT00428597|Experimental|A|
33297126|NCT00428597|Placebo Comparator|B|
33297127|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
33297128|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
33297129|NCT02520713||Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
33297130|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
33297131|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
33297132|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
33297133|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
33297134|NCT03994211|Experimental|Arm A (core phase)|
33297135|NCT03994211|Experimental|Arm B (core phase)|
33297136|NCT03994211|Experimental|Extension phase|
33297137|NCT02488967|Active Comparator|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
33297138|NCT02488967|Experimental|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
33297139|NCT03967665|Experimental|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
33297140|NCT03967665|No Intervention|Control arm|No-NAC concurrent control according to a 2:1 schedule.
33297141|NCT00144027|No Intervention|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
33297142|NCT00144027|Experimental|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
33297143|NCT00127803|Placebo Comparator|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
33297144|NCT00127803|Experimental|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
33297145|NCT00127803|Experimental|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
33297146|NCT00127803|Experimental|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
33297147|NCT03967431|Experimental|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
33297148|NCT03967431|No Intervention|Control group|The patients in the control group received routine care.
33297149|NCT03967509|Experimental|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
33297150|NCT03967509|No Intervention|Waiting list control group|Preschool teachers worked with children as usual.
33297151|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
33297152|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
33297153|NCT00127413|Experimental|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
33297154|NCT00127413|Experimental|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
33297155|NCT00127413|Experimental|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
33297156|NCT00127413|Other|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
33403887|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
32789314|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
33087133|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
33087134|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
33087135|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
32789315|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
32789316|NCT04893395|Experimental|Pharmacogenomic Screening|Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.
33297157|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
32789317|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
32789318|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
32789319|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
32789320|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
32789321|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
32789322|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
32789323|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
32789324|NCT05645887|Experimental|Human Albumim (20%, 300mL, 60gr) in 180 min IV|Further doses of albumin (60g/l) will be administered daily from day 0 to day 7 in patients with serum albumin concentrations <35 g/L.
32789325|NCT05645887|Placebo Comparator|Saline solution 0,9% (500mL) in 180 min IV|Saline solution will be given from day 0 to day 7.
32789326|NCT05309863||Residential treatment|Patients administered for residential treatment of severe obesity will be included. Patients are treated according to standard of care in a multimodal program, focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support. Residential treatment is possible for a duration of maximum 1 year.
32789327|NCT05309863||Ambulatory treatment|Patients in specific pediatric obesity care pathways will be included. Patients are treated according to standard of care in a multimodal ambulatory program focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
32789328|NCT05645809|Experimental|MONOFIX® PGCL|An absorbable suture
32789329|NCT05645809|Active Comparator|Quill Monoderm™|An absorbable suture
33297158|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
33297159|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
32789330|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
33403888|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
32789331|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
32789332|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
32789333|NCT05645419|Experimental|personalized chronoprevention|the main group (n=30), where patients with T2D, in addition to their traditional prescriptions, will receive the intervention method of personalized chronoprevention
32789334|NCT05645419|No Intervention|traditional prescriptions|the control group (n=30), where patients with T2D will only be under observation in addition to their traditional prescriptions
32789335|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
32789336|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
32789337|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
32939740|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
32939741|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
32939742|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
33297160|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
33297161|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
32789338|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
32789339|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
32789340|NCT05309083|Experimental|Mindfulness Based Walking Therapy (MBWT)|Participants will participate in MBWT.
32789341|NCT05305807|Experimental|Study group|Postural exercises will be done to this group
32789342|NCT05305807|No Intervention|Control group|Postural exercises will not be done to this group
32789343|NCT05644873|Active Comparator|Magnesium sulfate|Before induction, a bolus of 20 mg/kg magnesium sulfate in 100 mL saline was administered for 15 minutes, followed by a continuous infusion of 20 mg/kg/hour until the skin was closed.
32789344|NCT05644873|Active Comparator|Placebo|The control group received only 100 ml of saline 15 minutes before induction.
32789345|NCT05302297||Treatment Group (Cemiplimab)|Patients treated with cemiplimab in monotherapy through the Cohort Temporary Authorization for Use (cATU) or patients included in the Nominative Temporary Authorization for Use( nATU) that evolved into the cATU and meeting the inclusion/exclusion criteria of the study.
32789346|NCT05302297||Control Group|Patients treated with other systemic treatments meeting the inclusion/exclusion criteria of the study who initiated at least one systemic treatment for advanced CSCC before start date of the cemiplimab nATU
32789347|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
32789348|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
33297162|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
33297163|NCT01037465|Placebo Comparator|Placebo|Placebo
33297164|NCT03971331|No Intervention|control group|Patients in control group received usual care that was decided by attending.
33403889|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
33297165|NCT03971331|Experimental|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
33297166|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
33297167|NCT00143403|Experimental|1|
33297168|NCT00143403|Active Comparator|2|
33297169|NCT00220701|Experimental|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
33297170|NCT00220701|Placebo Comparator|Placebo|inactive comparator
32789349|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
32789350|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
32789351|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
32789352|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
32789353|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
33297171|NCT00127101|Experimental|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
33297172|NCT00127101|Experimental|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
32789354|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
32939743|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
32939744|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
33297173|NCT00127101|Experimental|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
33297174|NCT00127101|Experimental|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
33297175|NCT00127101|Experimental|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
33297176|NCT00127101|Experimental|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
33297177|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
33087136|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
33297178|NCT00126555|Experimental|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
33297179|NCT00126555|Experimental|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
33297180|NCT00004228|Experimental|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
33297181|NCT00004228|Experimental|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
33297182|NCT00004228|Experimental|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
33087137|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
33297183|NCT00004228|Experimental|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
33297184|NCT00004228|Experimental|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
33403890|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
33403891|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
33403892|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
33087138|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
32789355|NCT04892693|Experimental|Talazoparib|; Talazoparib should be taken orally once daily (ie, continuous daily dosing) at approximately the same time each day (preferably in the morning). Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the discretion of the treating physician.
33297185|NCT00004228|Experimental|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
33297186|NCT00004228|Experimental|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
33297187|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
33297188|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
33297189|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
33297190|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
33297191|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
33297192|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
33297193|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
33297194|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
33297195|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
33297196|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
33297197|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
33297198|NCT01099072|Experimental|methylphenidate+carnitine|
33297199|NCT00003526|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33297200|NCT00195260|Experimental|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
33297201|NCT00195260|Experimental|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
33297202|NCT00195260|Experimental|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
33297203|NCT00195260|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
33297204|NCT00031486|Experimental|Valacyclovir|
33403893|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
32939745|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
32939746|NCT04045964|Experimental|Motivational advice and free NRT|
32939747|NCT04045964|Active Comparator|Quitline referral|
32939748|NCT03941912|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
32939749|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
32939750|NCT05314400|Active Comparator|Full Protocol|Routine Primovist MRI
32939751|NCT05314400|Experimental|Abbreviated Protocol|Shortened Primovist MRI
32939752|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
32939753|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
32939754|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
33297205|NCT00031486|Placebo Comparator|Placebo|
33297206|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
33297207|NCT00003508|Experimental|Arm: Experimental: Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33297208|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
32939755|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
33297209|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
33297210|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
33297211|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
33297212|NCT03952000|Experimental|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
33297213|NCT03952000|No Intervention|No Intervention: Control|Participants will rest on day 1.
33297214|NCT03951922|Experimental|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
33297215|NCT03961594|Other|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
33297216|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
33297217|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
32939756|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
32939757|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
33297218|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
32939758|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
32939759|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
32939760|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
32939761|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
32939762|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
32939763|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
32939764|NCT04033640|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as finger-stick capillary blood samples.~At the clinic site, study staff performed the SD Biosensor STANDARD G6PD test and the POC HemoCue hemoglobin test on finger stick blood samples.~At the reference laboratories, G6PD activity was measured from whole blood samples using the SD Biosensor STANDARD G6PD test and the Pointe Scientific G6PD reference assay and hemoglobin was measured using the HemoCue hemoglobin test and by a complete blood count (CBC) using an automated hematology analyzer (Manaus site only)."
32789356|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
32789357|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
33297219|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
33297220|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
32789358|NCT02309723|No Intervention|No beta amyloid information|
32789359|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
32789360|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
32789361|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
32789362|NCT04198649|Experimental|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
32789363|NCT04198649|Placebo Comparator|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
32789364|NCT04867551|Experimental|KDT-3594|
32789365|NCT04862871|No Intervention|Healthy Controls|A cohort (n=10) of participants will be recruited who do not have any neurological conditions and are age and sex-matched to participants in Arms 2 and 3.
32789366|NCT04862871|No Intervention|Chronic Widespread Pain|A cohort (n=10) of participants who have not yet begun the exercise program and are currently on the waitlist for the exercise program at the PPRC
32789367|NCT04862871|Active Comparator|Chronic Widespread Pain - Exercise|A cohort (n=10) of participants who have completed the exercise program at the PPRC. These individuals will be evaluated the day of their last treatment visit
32789368|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
32789369|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
32789370|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
32789371|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
32789372|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
32789373|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
32789374|NCT04411095|Experimental|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
32789375|NCT04411095|Placebo Comparator|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
32789376|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
32789377|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
32789378|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
32789379|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
32789380|NCT01983111|Experimental|buprenorphine|Patch
32789381|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
32789382|NCT04672941||COPD patients|COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol
32789383|NCT02348489|Experimental|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
32789384|NCT02348489|Active Comparator|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
32789385|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
32789386|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
33297221|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
33403894|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
33087139|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
33087140|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
33087141|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
33087142|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
33087143|NCT01680952|Active Comparator|A) TEST|
33087144|NCT01680952|Experimental|B) CONTROL|
33087145|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
32789387|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
33087146|NCT01681303|Experimental|AST-120 group|Administration of AST-120
33087147|NCT01681303|No Intervention|2|
32789388|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
33087148|NCT04528420|Experimental|Optimised arm|Patients will be taken care of early and optimally way.
33087149|NCT04528420|No Intervention|Standard arm|Patients will be monitored as in standard practice
33087150|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
33297222|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
33297223|NCT01101724|Experimental|Intervention|Mandated Rest.
33297224|NCT01584700|Other|Renal Artery Denervation|Ontervention
32789389|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
32789390|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
32789391|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.~Olaratumab + Doxorubicin:~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
32789392|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
32789393|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
33297225|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
33297226|NCT01101802|Placebo Comparator|Sugar pill|
33297227|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
33297228|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
33297229|NCT00003472|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33297230|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
32789394|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
33087151|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
33087152|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
33087153|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
33087154|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
33297231|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
33297232|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
33297233|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
33087155|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
33087156|NCT00281190||COPD patients|COPD patients
33087157|NCT01681498||Pregnancy|
33087158|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
33087159|NCT00287625|Active Comparator|1|PRP
33087160|NCT00287625|No Intervention|2|control
33087161|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
33087162|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
33087163|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
33087164|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
32789395|NCT02005887|Experimental|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
32789396|NCT02005887|Experimental|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
32789397|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
32789398|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
32789399|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
32789400|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
33087165|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
33087166|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
33297234|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
33297235|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
32789401|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
32789402|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
32789403|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
32789404|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
32789405|NCT04672161|Experimental|Vaccine Education|Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
32789406|NCT04672161|No Intervention|No Vaccine Education|Patients randomized to the No Intervention arm will not receive the Vaccine Education. They will only complete the survey on their vaccination history.
32789407|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
32789408|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
32789409|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
32789410|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
32789411|NCT02004873|Experimental|Micra Pacemaker Implant|
32789412|NCT04672005|Experimental|Treatment Regimen: mFOLFIRINOX + mGnabP|"All study participants will receive the following treatment:~mFOLFIRINOX (28-day cycle)~Day 1 and Day 15:~Oxaliplatin 85 mg/m2 2-hour intravenous infusion followed by leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion. 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours will follow irinotecan.~Day 3 and Day 17:~Pegylated-Granulocyte Colony Stimulating Facotr (peg-GCSF) 6 mg subcutaneous injection following disconnection of 5-FU infusion, first cycle and then per investigator discretion.~Biweekly mGnabP (28-day cycle)~Day 1 and Day 15:~Nab-paclitaxel 125 mg/m2 infused over 30 minutes, immediately followed by Gemcitabine 1200 mg/m2 intravenously infused at the rate of 10mg/m2/min (over 120 minutes).~Patients will receive one month of each regimen, alternately monthly until progression of disease."
32789413|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
32789414|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
32789415|NCT04416399|Experimental|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
32789416|NCT04416399|No Intervention|Standard of care|Standard of care
32789417|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
32789418|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
33087167|NCT01681732|Active Comparator|Control|This arm will be standard care
32789419|NCT01732822|Experimental|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
32789420|NCT01732822|Active Comparator|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
32789421|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
32789422|NCT02004093|Active Comparator|Chemotherapy|
32789423|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
33087168|NCT01681888|Experimental|Surface EMG Biofeedback|
33087169|NCT04528264|Experimental|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
33087170|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
33087171|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
33087172|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
33087173|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
33087174|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
33087175|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
33087176|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
33087177|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
33087178|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
33087179|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
33087180|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
33087181|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
33087182|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
33087183|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
33087184|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
33087185|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
33087186|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
33087187|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
33087188|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
33087189|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
33087190|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
33087191|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
33087192|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
33087193|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
33087194|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
33087195|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
32789424|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, & DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, & DRV/RTV"
32789425|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
32789426|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
32789427|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
32789428|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
32789429|NCT02325713|Experimental|Sequence A-B-C1-D1|
32789430|NCT02325713|Experimental|Sequence A-B-C1-D2|
32789431|NCT02325713|Experimental|Sequence A-B-C2-D1|
32789432|NCT02325713|Experimental|Sequence A-B-C2-D2|
32789433|NCT02325713|Experimental|Sequence A-B-D1-C1|
32789434|NCT02325713|Experimental|Sequence A-B-D2-C1|
33087196|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
33087197|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
32789435|NCT02325713|Experimental|Sequence A-B-D1-C2|
32789436|NCT02325713|Experimental|Sequence A-B-D2-C2|
32789437|NCT02325713|Experimental|Sequence B-A-C1-D1|
33087198|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
33087199|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
33087200|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
33087201|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
33087202|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
32789438|NCT02325713|Experimental|Sequence B-A-C1-D2|
32789439|NCT02325713|Experimental|Sequence B-A-C2-D1|
32789440|NCT02325713|Experimental|Sequence B-A-C2-D2|
32789441|NCT02325713|Experimental|Sequence B-A-D1-C1|
32789442|NCT02325713|Experimental|Sequence B-A-D2-C1|
32789443|NCT02325713|Experimental|Sequence B-A-D1-C2|
32789444|NCT02325713|Experimental|Sequence B-A-D2-C2|
32789445|NCT04877639|Active Comparator|Esmketamine group|Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine
32789446|NCT04877639|Active Comparator|Dexmedetomidine group|Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes
32789447|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
32789448|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
32789449|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
32789450|NCT01764256|Experimental|10 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 10 μg of active ingredient.
32789451|NCT01764256|Experimental|30 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 30 μg of active ingredient.
32789452|NCT01764256|Experimental|60 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 60 μg of active ingredient.
32789453|NCT01764256|Placebo Comparator|Placebo|3 doses of placebo delivered intramuscularly.
32789454|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
32789455|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32789456|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
32789457|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
32789458|NCT01764022|Experimental|BCD-022|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
32789459|NCT01764022|Active Comparator|Herceptin®|In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
32789460|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
32789461|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
32789462|NCT04852627|Active Comparator|Exercise group|Will brisk walk 30 minutes 3 times weekly
32789463|NCT04852627|No Intervention|Control group|No intervention
32789464|NCT04658901|Experimental|test group|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) made by Acotec Scientific Co.,Ltd.
32789465|NCT04658901|Active Comparator|control group|use the ClosureRFG™ and ClosureFast™ made by Medtronic Inc.
32789466|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
32789467|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
32789468|NCT05276557|Experimental|Indication for H. pylori testing|Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
32789469|NCT04872595|Experimental|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)~Hyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6~Thiotepa (5mg/kg/day x 2 day) Day -5 to -4~Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2~GCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
32789470|NCT04872595|Experimental|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)~Busulfan -Day -9 to -7~Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5~Fludarabine (25mg/m2/day x 5 days) Day -6 to -2~GCSF Day +7"
32789471|NCT05651191|Experimental|Human CD19 Targeted DASH CAR-T Cells Injection|Single administration：0.5×10^6 CAR+T, 1.0×10^7 CAR+T, 2.0×10^7 CAR+T
32789472|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
32789473|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
32789474|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
32789475|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
32789476|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
32789477|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
32789478|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
32789479|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
32789480|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
32789481|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
33087203|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
33297236|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
33297237|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
33297238|NCT01099462||Children with fever|
32789482|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
32789483|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
32789484|NCT05651113||Positive NBS for SCID|Parents whose baby was referred to an immunologist due their SCID screening result (minimum n= 10-25)
32789485|NCT05651113||Normal NBS result|Parents who received a normal screening result (minimum n=10-25)
32789486|NCT05651113||False positive NBS result|Parents who have received a false positive result elsewhere in screening (minimum n=2-10)
32789487|NCT05651113||CFSPID Designation|Parents who received a CFSPID result (minimum n=~10)
32789488|NCT05651113||SCID via family history or clinical presentation|Parents whose baby was identified with SCID due to family history or clinical presentation (minimum n=10)
33297239|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
33297240|NCT01099540|Experimental|Pazopanib|
33297241|NCT00003298|Experimental|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
33297242|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
33297243|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
32789489|NCT05651113||Parents whose babies have died|Parents who have received an abnormal screening result (T cell receptor excision circles (TRECs) or who were identified with SCID due to family history or clinical presentation and whose baby has subsequently died (n=~10)
33297244|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
33297245|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
33297246|NCT03961360|Experimental|162 mg/day Aspirin|
33297247|NCT03961360|Active Comparator|81 mg/day Aspirin|
32789490|NCT05642143||T2D F-/N-|Subjects with T2D and no previous history of any fractures or diabetic neuropathy (n=160)
33297248|NCT03961282|Experimental|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
33297249|NCT03961282|Experimental|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
33297250|NCT03950908|Other|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
33297251|NCT03950908|Other|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
32789491|NCT05642143||T2D F+|Subjects with T2D with a previous history of a fracture(s) (any fracture, major osteoporotic fracture (MOF) and peripheral) (n=100)
32789492|NCT05642143||T2D N+|Subjects with T2D matched by age and sex with severe peripheral (vibration perception threshold (VPT) > 50) or a history of autonomic neuropathy (n=40)
33297252|NCT03951844|Experimental|Experimental group|Each participant is evaluated while wearing or not wearing the device.
32789493|NCT05262439|Experimental|New generation CPAP mask|The intended purpose of mask systems is to provide airflow from a CPAP device, through tubing, and to the patient. The air acts as a pneumatic splint to keep the airway open and prevent collapse during sleep. The masks to be used in this study are released masks approved and released.
32830463|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
33087204|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
33087205|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
33297253|NCT03960970|Active Comparator|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
33297254|NCT03960970|Experimental|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
33297255|NCT00002842|Experimental|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
33297256|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
33297257|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
33087206|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
32789494|NCT05640661|Experimental|Terminal visual feedback therapy plus Immersive Virtual reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study. Subjects will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
32830464|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
33087207|NCT01682902|Experimental|Formulation 1|
33087208|NCT01682902|Experimental|Formulation 2|
33087209|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
33087210|NCT01683097|No Intervention|Control|Questionnaire
33297258|NCT03950596|Active Comparator|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
33297259|NCT03950596|Active Comparator|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
33297260|NCT03950596|Active Comparator|Control Group|One hundred volunteers will participate in study as a control group
33297261|NCT01100008|Experimental|Magnetic resonance imaging|
33297262|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
33297263|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
33297264|NCT03951688|Experimental|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
33297265|NCT03951688|No Intervention|Control Group|No intervention
33297266|NCT00143247|Experimental|Exubera® (inhaled insulin)|Open label, no comparator
33297267|NCT00125853|Experimental|atenolol 25mg daily|atenolol 25mg daily
33297268|NCT00125853|Active Comparator|nebivolol 2.5mg daily|nebivolol 2.5mg daily
33297269|NCT00219141|Experimental|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
33297270|NCT00219141|Active Comparator|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
33297271|NCT00219141|Experimental|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
33297272|NCT03971487|Active Comparator|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
33297273|NCT03971487|Placebo Comparator|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
33403895|NCT02340442||High risk group|"40 pregnant women:~20 Pregnant women with preeclampsia~20 Obese pregnant women"
33403896|NCT02340442||Healthy control subjects|40 subjects
33403897|NCT04477642|Experimental|AbataceptTreatment Arm|Enrolled patients who will receive treatment with abatacept
33087211|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
33087212|NCT01683136|Experimental|Deep TMS treatment|
33087213|NCT01683136|Sham Comparator|inactive stimulation|
33087214|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
33403898|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
32789495|NCT05640661|Active Comparator|Immersive Virtual Reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
32789496|NCT04871971|Placebo Comparator|Glucose|Glucose 50 g available carbohydrate
32789497|NCT04871971|Experimental|10 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 10 g NUTRALYS®S85 Plus pea protein
32789498|NCT04871971|Experimental|20 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 20 g NUTRALYS®S85 Plus pea protein
32789499|NCT04871971|Experimental|10 g Whey protein concentrate|50 g available carbohydrate Glucose + 10 g Whey protein concentrate
32789500|NCT04871971|Experimental|20 g Whey protein concentrate|50 g available carbohydrate Glucose + 20 g Whey protein concentrate
32830465|NCT04137042|Active Comparator|Saline|intraoperative fluid therapy by using 0.9% saline
33297274|NCT00142935|Experimental|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
33297275|NCT00142935|Experimental|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
33297276|NCT00142935|Active Comparator|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
33297277|NCT03967041||Sarcopenic patients|
33297278|NCT03967041||Non-sarcopenic patients|
33297279|NCT00233948|Experimental|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33297280|NCT00233480|Experimental|active treatment|atorvastatin 10mg QD x 3 months
33297281|NCT00233480|Placebo Comparator|placebo|matched placebo QD x 3 months
33297282|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
33297283|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
33297284|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
33297285|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
33297286|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
33297287|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
33297288|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
33297289|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
33297290|NCT03950518|Experimental|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
33297291|NCT03950518|Experimental|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
33297292|NCT03950518|Experimental|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
33297293|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
33297294|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
33297295|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
33297296|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
33297297|NCT03950284|Experimental|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
33087215|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
33297298|NCT01102114|Placebo Comparator|Placebo Vaccine|
33297299|NCT01102114|Experimental|NicVAX Vaccine|
33297300|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
33297301|NCT01327222|No Intervention|control|monthly follow-up
33297302|NCT03950362|Experimental|Radiotherapy associated to immunotherapy|"Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder~Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
33297303|NCT00263588|Experimental|single arm|750 mg lapatinib administered orally twice daily
33297304|NCT00213135|Experimental|Cladribine 5.25 mg/kg|
33297305|NCT00213135|Experimental|Cladribine 3.5 mg/kg|
33297306|NCT00213135|Placebo Comparator|Placebo|
33297307|NCT00077974|Experimental|1|
32789501|NCT05651035|Experimental|Breastfeeding group|Preterm infants in this group are breastfed by their mothers during their first oral feeding. Before, during and after feeding, the preterm infant's oxygen saturation level and peak heart rate are measured for 30 minutes. In addition, the test test weighing is determined by weighing the baby before and after feeding.
32789502|NCT05651035|No Intervention|Bottle-feeding group|Preterm infants in this group are fed with their mother's milk in the bottle during their first oral feeding.
32789503|NCT05260177|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
32789504|NCT05260177|Sham Comparator|Sham|Exposure to LTS device set to continuous color matched white light for 1 hour a day for consecutive days
32789505|NCT05431153|Experimental|PF-07104091 Sequence 1|Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
32789506|NCT05431153|Experimental|PF-07104091 Sequence 2|Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
32789507|NCT05431153|Experimental|PF-07104091 Sequence 3|Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
32789508|NCT05431153|Experimental|PF-07104091 Sequence 4|Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
32789509|NCT05431153|Experimental|PF-07104091 Sequence 5|Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
32789510|NCT05431153|Experimental|PF-07104091 Sequence 6|Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
32789511|NCT05650801|Experimental|Intervention Group 1|Participants who will be given music therapy 3 times a week for 4 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
32789512|NCT05650801|Experimental|Intervention Group 2|Participants with burnout syndrome who will be given music therapy 5 times a week for 2 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
32789513|NCT05650801|No Intervention|Neutral Group|Participants in this group will not get any music intervention. The maslach burnout inventory and heart rate variability score will be evaluated before and after four weeks without any intervention
32789514|NCT05650723|Experimental|Double Therapy (Zanubrutinib plus Venetoclax)|All participants will receive an initial 3 cycles of zanubrutinib monotherapy. This lead-in period will then be followed by 12 cycles of zanubrutinib and venetoclax combination therapy. All participants will complete 12 cycles of zanubrutinib and venetoclax combination therapy or 15 cycles of total treatment. Peripheral blood and bone marrow MRD assessments will occur at C16D1. Participants will continue on double combination treatment for an additional 1 month while results of MRD testing are obtained. In total, all participants will be on treatment for at least 16 full cycles. Participants that meet definition of MRD negativity will stop therapy at C17D1 and enter an observation phase with study visits every 3 months. Participants that remain MRD positive at C16D1 will enter the triple therapy (zanubrutinib, venetoclax, and obinutuzumab) arm.
32789515|NCT05650723|Experimental|Triple Therapy (Zanubrutinib, Venetoclax, and Obinutuzumab)|Participants that meet definition of MRD positivity at C16D1 will enter the triple therapy arm (zanubrutinib, venetoclax, and obinutuzumab). These participants will continue combination therapy with zanubrutinib and venetoclax, but will also receive 6 cycles of obinutuzumab starting at C17D1. In this subgroup, peripheral blood and bone marrow MRD assessments will occur after an additional 6 cycles of the triplet combination therapy (C23D1) at which point all participants will stop study treatment regardless of MRD status.
32789516|NCT05636215|Experimental|IBI354|Single arm
32789517|NCT05249647|Experimental|Instrument based fascial abrasion technique|IASTM using tools over Myofascial trigger points of the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping.
32789518|NCT05249647|Active Comparator|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
32789519|NCT05650645|Experimental|Incobotulinium toxin A group|Individuals with symptoms of tetanus will receive three serial injections of incobotulinum toxin A into the auricular muscles.
32789520|NCT05650645|Placebo Comparator|Placebo|Individuals with symptoms of tetanus will receive placebo saline injections.
32789521|NCT05247697|Experimental|Treatment|Mirtazapine 7.5 mg
32789522|NCT05247697|Placebo Comparator|Control|Matching placebo
32789523|NCT05243797|Experimental|Arm A: Teclistamab-Lenalidomide (Tec-Len)|Teclistamab will be administered via a subcutaneous injection (SC)
32789524|NCT05243797|Active Comparator|Arm B Lenalidomide Alone (Len)|Lenalidomide orally.
32789525|NCT05243797|Experimental|Arm C Teclistamab-Alone (Tec)|Teclistamab will be administered via a subcutaneous injection (SC)
32789526|NCT05238961|Experimental|Cohort 1 - Critical Asymptomatic Carotid Stenosis Group|Critical Stenosis Group: Diagnosis of Asymptomatic Carotid Artery Disease (aCAD) with >70% stenosis or peak systolic velocity on duplex ultrasound (DUS) ≥ 230 cm/s plus computed tomography angiography (CTA) or magnetic resonance angiography (MRA) confirmation.
32789527|NCT05238961|Experimental|Cohort 2 - Controls-Non-Critical Asymptomatic Carotid Stenosis Group|<40% carotid stenosis No planned revascularization
32789528|NCT05232175|Experimental|Part I (Allergy assessment) - ALT-BB4|
32789529|NCT05232175|Placebo Comparator|Part I (Allergy assessment) - 0.9%NaCl|
32789530|NCT05232175|Experimental|Part II-A (PK assessment)|
32789531|NCT05232175|Experimental|Part II-B (Safety assessment) - ALT-BB4|
32789532|NCT05232175|Placebo Comparator|Part II-B (Safety assessment) - 0.9% NaCl|
32789533|NCT05215171||World Trade Center - Airway Hyperreactivity (WTC-AHR)|WTC-AHR cases are defined as having either a positive MCT (PC20<16) and/or positive BDR (by ATS/ERS guidelines with improvement of FEV1 by 12% and at least 200mL) post-9/11.
32789534|NCT05215171||Control Group|Cohort Controls will be randomly selected 10% of the baseline cohort
32789535|NCT05193331|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks (28 days).
32789536|NCT05100199|Placebo Comparator|Placebo|Placebo will be injected into the Glabellar Complex on Day 1.
32789537|NCT05100199|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X Dose A will be injected into the Glabellar Complex on Day 1.
32789538|NCT05100199|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X Dose B will be injected into the Glabellar Complex on Day 1.
32789539|NCT05100199|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X Dose C will be injected into the Glabellar Complex on Day 1.
32789540|NCT05608915|Experimental|Augmented-Reality Visual Cues|In this single-arm study, all participants will receive all interventions on the same day. They will be wearing an augmented-reality headset that will display a digital obstacle course. Walking performance will be captured with no visual cues, with conventional visual cues, and with augmented-reality visual cues.
32789541|NCT02001987|Experimental|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
32789542|NCT05596747|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
32789543|NCT05596747|Active Comparator|Insulin glargine|Insulin glargine administered SC.
32789544|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
32789545|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
32789546|NCT02001051|Other|Operative Arm|operative arm
32789547|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
32789548|NCT05586217|Experimental|Incentive Spirometry|12 weeks, 1 session per week; each session took about 1 hour.
32789549|NCT05586217|Active Comparator|Active Cycle of Breathing|Breathing Control Deep Breathing Exercises or Thoracic Expansion Exercises Huffing or Forced Expiratory Technique (FET)
32789550|NCT05577013|Experimental|(Kinesiotaping and motor relearning program group|"The experimental group will receive kinesiotaping; Instructions before applying kinesiotape~Patients' skin must be clean, free of dirt, oil or sweat.~Long hair must be removed for proper adhesion to the skin.~Leave the tape upstretched 2-3 cm at start and end point of tape over the skin"
32789551|NCT05577013|Active Comparator|motor relearning program group|"The control group will receive motor relearning programme exercises for 40 minutes.~Hitting a target on table from flexed elbow to extension of elbow~Hitting a target on front of table with shoulder flexion (reaching fwd)~Hitting a target on table with wrist extension~Pronation to supination while holding a bottle of water.~Rolling ball on table in forward, backward and sideways~Holding polystyrene cup and placing it on other side~Picking up blocks and placing them to other side~Holding polystyrene cup and placing them above and below level of sitting to front and sideways~Holding polystyrene cup and placing them above and below level of standing to front and sideways~pick small objects from one container to another"
32789552|NCT05429593|Experimental|Part 1 sequence A|Semaglutide followed by Semaglutide/dapagliflozin
32789553|NCT05429593|Experimental|Part 1 sequence B|Semaglutide/dapagliflozin followed by Semaglutide
32789554|NCT05429593|Experimental|Part 2 sequence A|Dapagliflozin followed by Semaglutide/dapagliflozin
32789555|NCT05429593|Experimental|Part 2 sequence B|Semaglutide/dapagliflozin followed by dapagliflozin
32789556|NCT05429437|Active Comparator|Group I|will include 9 patients
32789557|NCT05429437|Active Comparator|Group II|will include 9 patients.
32789558|NCT04850677||Total|All subjects in the study belong to the same group/cohort. As this is an observational study there is no intervention planned.
32789559|NCT01763164|Experimental|MEK162|
32789560|NCT01763164|Active Comparator|Dacarbazine|
32789561|NCT01782742|Active Comparator|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
32789562|NCT01782742|Placebo Comparator|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
32789563|NCT01782664|Experimental|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
32789564|NCT01782664|Experimental|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
32789565|NCT01782664|Experimental|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
32789566|NCT01782664|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
32789567|NCT01782664|Experimental|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
32789568|NCT04414072|Active Comparator|laparoscopic sleeve gastrectomy|
32789569|NCT04414072|Active Comparator|mini gastric bypass|
32789570|NCT04414072|Active Comparator|sleeve gastrectomy with loop bipartition|
32789571|NCT04561180|Placebo Comparator|Arm 1: SOC + DEX + EG-009A placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A placebo for 3 additional weeks.
32830466|NCT04137042|Experimental|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
33087216|NCT00281346|Experimental|transthoracic Doppler echocardiography|
33087217|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
32789572|NCT04561180|Experimental|Arm 2: SOC + DEX + Low Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A Low dose for 3 additional weeks.
32789573|NCT04561180|Experimental|Arm 3: SOC + DEX + High Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A High dose for 3 additional weeks.
32789574|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
32789575|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
33087218|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
33297308|NCT00124917|Experimental|Radiation Therapy|Radiation to tumor area as per protocol
33297309|NCT03967353|No Intervention|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
33297310|NCT03967353|Experimental|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
33297311|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
33297312|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
33297313|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
33297314|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
32789576|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
32789577|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
32789578|NCT04560790|Experimental|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
32789579|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
33087219|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
33297315|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
33297316|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
33297317|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
33297318|NCT00141921|Experimental|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
33297319|NCT00029146|Experimental|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
33297320|NCT00029146|Active Comparator|Non-surgical group|Receives best current practice medical therapy
33297321|NCT01079793|Experimental|ixabepilone|Adjuvant therapy
33297322|NCT03950206|Other|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
33297323|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
33297324|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
33087220|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
33087221|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
33297325|NCT00026494|Experimental|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
33297326|NCT03950128|Experimental|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
33297327|NCT03950128|Active Comparator|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
33297328|NCT03950050|Experimental|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
33297329|NCT05627596|Active Comparator|Electric Toothbrush|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and an electric toothbrush.
33297330|NCT05627596|Experimental|Nicotine Replacement Therapy|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and a two week supply of 14mg nicotine patches and 4mg lozenges.
33297331|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
32789580|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
32789581|NCT04849507|Active Comparator|active taVNS|We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) < perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
33297332|NCT01102504|Placebo Comparator|Placebo|Placebo
33297333|NCT01088776|Experimental|Supplement|
32789582|NCT04849507|Sham Comparator|sham taVNS|The ear electrode positioned on left tragus as for active taVNS. We will test the PT with active stimulation, and then program a sham setting on the BabyStrong unit to deliver no current after the PT is determined.
32789583|NCT05572333|Experimental|EP395|EP395 in repeated doses. Oral, once-daily administration of 3 EP395 capsules for 12 weeks.
32789584|NCT05572333|Placebo Comparator|Placebo|Matched placebo capsule. Oral, once-daily administration of 3 placebo capsules for 12 weeks.
32789585|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
32789586|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
32789587|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
32789588|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
32789589|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
32789590|NCT01641133|Active Comparator|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
32789591|NCT01641133|Experimental|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
32789592|NCT01641133|Experimental|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
32789593|NCT04849429|Placebo Comparator|Placebo|Placebo (trigger point injection under C-arm)
32789594|NCT04849429|Experimental|Platelet rich plasma (PRP) with exosomes|PRP with exosomes at the center of the nucleus pulposus (2ml)
32789595|NCT05112757|Experimental|Intervention|Smartphone app use
32789596|NCT04836637|Placebo Comparator|Product with placebo (no calcium supplementation).|Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.
32789597|NCT04836637|Active Comparator|Product with calcium-carbonate|800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.
33297334|NCT01088776|Placebo Comparator|Control|
32789598|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac"|800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.
32789599|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac and Inulin"|800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.
33297335|NCT00023764|Experimental|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
33297336|NCT01088854|Experimental|positive airway pressure|
33297337|NCT03961126|Experimental|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
33297338|NCT03961126|Active Comparator|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
33297339|NCT03949816|Experimental|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
33297340|NCT03949816|Experimental|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
33297341|NCT03949816|Active Comparator|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
33297342|NCT01584778||Behçet patients|
33297343|NCT01584778||Healthy controls|
33297344|NCT01584778||Allergic rhinitis (diseased) controls|
33297345|NCT00189488|Experimental|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
32789600|NCT04835467|Experimental|Intracoronary imaging|Intracoronary imaging during PCI
32789601|NCT04419259|Experimental|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
32789602|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
32789603|NCT05382013|Experimental|Trial Group|30 patients receive treatment of avatrombopag, DPMAS, LPE, and comprehensive internal medical treatment.
32789604|NCT05382013|Active Comparator|Control Group|30 patients receive treatment of DPMAS, LPE, and comprehensive internal medical treatment.
32789605|NCT04678921|Experimental|Dose Level 1|1mg/kg Q1W
32789606|NCT04678921|Experimental|Dose Level 2|3 mg/kg Q1W
33297346|NCT00189488|Placebo Comparator|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
33297347|NCT03974906|Experimental|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
32789607|NCT04678921|Experimental|Dose Level 3|10mg/kg Q1W
32789608|NCT04678921|Experimental|Dose Level 4|15 mg/kg Q1W
32789609|NCT04673851|Experimental|FEP Clients|Approximately 90 first episode psychosis (FEP) clients recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in the online platform Horyzons for 3 months (cohort 1) or 6 months (cohort 2) as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
32789610|NCT04673851|Other|FEP Clinicians|Approximately 40 providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
32789611|NCT05425303||Healthy athletes|Healthy professorial team sports athletes will be monitored for the occurrence of an acute lower extremity injury during a competitive season. After the end of the season, the cohort will be divided into a healthy athlete group, athletes injured in the hamstring muscles, and athletes with other types of lower extremity injuries.
32789612|NCT05044273||Coronary Artery Disease|
32789613|NCT04847635|Experimental|Subthreshold laser group|To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.
32789614|NCT04847635|Sham Comparator|Sham group|The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.
32789615|NCT04846231|Active Comparator|Rosuvastatin|5 mg once per day
32789616|NCT04846231|Placebo Comparator|Placebo|comparable to rosuvastatin 5 mg once per day
32789617|NCT04846231|Active Comparator|Fish Oil|Nature Made 2 soft gels per day
33297348|NCT03974906|No Intervention|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP >65 mm Hg, heart rate 50-100 bpm, and urine output >0.5 ml/kg/h.
33297349|NCT03969290|Experimental|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
33297350|NCT03969290|Active Comparator|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
33297351|NCT00233402|Active Comparator|Standard White Light Cystoscopy|
33297352|NCT00233402|Experimental|Standard White Light and Hexvix Fluorescence Cystoscopy|
33297353|NCT00233324|Experimental|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
33297354|NCT00233324|Experimental|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
33297355|NCT00233324|Experimental|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
32789618|NCT04846231|Active Comparator|Cinnamon|1200mg, 2 capsules per day
32789619|NCT04846231|Active Comparator|Garlique|Manufactured by Focus Consumer Health Marketgate,1 tablet per day
32789620|NCT04846231|Active Comparator|Turmeric|Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
32789621|NCT04846231|Active Comparator|Plant Sterol|Nature Made CholestOff Plus, 2 soft gels twice a day
32789622|NCT04846231|Active Comparator|Red Yeast Rice|Arazo Nutrition 1200 mg, 2 capsules per day
32789623|NCT05032573|Experimental|Olive Oil|Incorporating 60 mL of olive oil into usual diet and Dietary Guidelines recommendations
32789624|NCT05032573|Active Comparator|Control|Dietary Guidelines recommendations
32789625|NCT04823377|Other|Period A: Usual management|Period of end-of-life care as usual
32789626|NCT04823377|Other|Period B: Process of optimization of the medical decision|Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
32789627|NCT04845217|Experimental|Peppermint Oil|Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
32830467|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
32789628|NCT04845217|Placebo Comparator|Coconut Oil|Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).
32789629|NCT05379829|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab at weeks 0, 4 and 8.
33297356|NCT00233324|Experimental|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
32789630|NCT05379829|Placebo Comparator|Placebo|Participants will receive placebo at weeks 0, 4 and 8.
32789631|NCT04662073|Experimental|Camostat|Participants are randomized to receive camostat for 10 days.
32789632|NCT04662073|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match camostat for 10 days.
32789633|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
32789634|NCT05359393|Experimental|resectable group|In this group, we propose a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis.
32789635|NCT04188301|Active Comparator|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
32789636|NCT04188301|Experimental|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
32789637|NCT04188301|Experimental|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
32789638|NCT04833439|Experimental|Fasting Mimicking Diet|2 cycles of 3-day fasting mimicking spaced by a 2 week interval
32789639|NCT04178707|Other|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
32789640|NCT04195477|Experimental|vDPP|Participants will take part in a 4 week study to develop the program.
32789641|NCT04650919|Experimental|Experimental arm|
33297357|NCT00023452|Active Comparator|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
33297358|NCT00023452|Experimental|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
33297359|NCT03974516|Experimental|Careseng 1370|"Four dose cohorts are employed for Careseng 1370 oral administration in healthy volunteers:~Level A (1 sachet): 1 sachet before breakfast;~Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch;~Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch;~Level D (4 sachets): 2 sachets before breakfast, 2 sachets before lunch"
33297360|NCT03972878|Active Comparator|control snack|control snack
33297361|NCT03972878|Experimental|control cream|control spreadable cream
33297362|NCT03972878|Experimental|cream version 1|control spreadable cream, version 1
33297363|NCT03972878|Experimental|cream version 2|control spreadable cream, version 2
33297364|NCT03972878|Experimental|cream version 3|control spreadable cream, version 3
32789642|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
32789643|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
32789644|NCT05354947|Experimental|30 minute, dual site stimulation|Ultrasound Deliveryfor 30 minutes total: 15 minutes on the liver target site and 15 minutes on the intestinal target site.
32789645|NCT05354947|Experimental|60 minute, dual site stimulation|Ultrasound Delivery for 60 minutes total: 30 minutes on the liver target site and 30 minutes on the intestinal target site.
32789646|NCT04626349|Experimental|FOCUS+|Dyads in the FOCUS+ arm will receive the face-to-face nurse-led FOCUS+ program.
33087222|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
33297365|NCT03972878|Experimental|control chocolate bar|control chocolate bar
33297366|NCT03972878|Experimental|chocolate bar version 1|control chocolate bar version 1
33297367|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
33297368|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
33297369|NCT01088932|Experimental|SRX246|SRX246
33297370|NCT01088932|Placebo Comparator|Placebo|placebo
32789647|NCT04626349|Experimental|iFOCUS|Dyads in the iFOCUS arm will receive the web-based iFOCUS program.
32789648|NCT04626349|No Intervention|Standard care|Dyads in the control group will receive standard care as usual, as determined by the healthcare system in the participating countries. The dose and frequency of usual care will be as deemed appropriate by the medical practitioner in charge of their treatment.
32789649|NCT05011513|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
32789650|NCT05011513|Placebo Comparator|Placebo|Orally administered Placebo
32789651|NCT05369455|Experimental|group 1|group of ultrasound guided Erector spine plane block:
32789652|NCT05369455|Active Comparator|group 2|group of ultrasound guided Caudal block:
32789653|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
32789654|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
32789655|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
32789656|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
32789657|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
32789658|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
32789659|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
32789660|NCT05297305|Active Comparator|Onlay Component-Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
32789661|NCT05297305|Active Comparator|Inlay Component-Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
32789662|NCT04842799|Experimental|Digital delivery of genetic pre-test information|Half of participants will be provided with genetic pre-test information via the BRCA-DIRECT digital platform.
32789663|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss genetic pre-test information|Half of participants will be provided with genetic pre-test information via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
32789664|NCT04842799|Experimental|Digital delivery of BRCA-gene testing results|97.5% of participant's with a negative (normal) result will receive their BRCA-gene testing result via the BRCA-DIRECT digital platform.
32789665|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss BRCA-gene testing results|2.5% of participants with a negative (normal) result and those with positive results will receive their BRCA-gene testing result via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
33297371|NCT03969056|Experimental|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
33297372|NCT03969056|Active Comparator|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
33297373|NCT01100554|Experimental|all patients|
33297374|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories~Pembrolizumab monotherapy first-line~Pembrolizumab or nivolumab monotherapy in second or later line"
33297375|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
33297376|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories~Nivolumab/ipilimumab combination treatment 1L~Pembrolizumab or nivolumab monotherapy treatment 1L~Ipilimumab monotherapy 2L"
33297377|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
33297378|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
33297379|NCT03961048|Experimental|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
33297380|NCT03961048|Experimental|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
33297381|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
33297382|NCT01100632|Placebo Comparator|Placebo|Placebo.
33297383|NCT01100710||healthy volunteers|
33297384|NCT03949426|Experimental|KPG-818|Dose escalation
33297385|NCT03949426|No Intervention|Placebo|Matching placebo
33297386|NCT03949348|Active Comparator|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
33297387|NCT03949348|Active Comparator|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
33297388|NCT03949582|Experimental|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
33297389|NCT03949582|Experimental|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
33297390|NCT00022672|Experimental|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
33297391|NCT00022672|Active Comparator|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
33297392|NCT05626036|Active Comparator|Arthrex Tightrope|Syndesmosis fixation performed with Arthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
33297393|NCT05626036|Experimental|Synthes Fibulink|Syndesmosis fixation performed with Synthes Fibulink device. This is a high-tension suture fixation with a screw based anchor system.
33297394|NCT00076804|Experimental|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
33297395|NCT00076804|No Intervention|2|Self administration of ARVs
33297396|NCT00141453|Experimental|1|Olmesartan medoxomil tablets 10mg to 40 mg
33297397|NCT00141453|Placebo Comparator|2|Matching placebo tablets
32789666|NCT05369377|Experimental|Zanubrutinib and eltrombopag|Zanubrutinib 80mg po qd 6 weeks and eltrombopag 50 mg qd for up to 6 weeks.
32789667|NCT05369377|Active Comparator|Eltrombopag monotherapy|Eltrombopag is given as 50 mg qd for up to 6 weeks.
32789668|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
32789669|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
32789670|NCT04832269||MP exposed group|children and adolescents (aged 8 to 18 years) of mothers with prenatal exposition to MP in the context of an MS relapse therapy
32789671|NCT04832269||MP non-exposed group/control group|children and adolescents of mothers suffering from MS aged 8 to 18 years
32789672|NCT04623931|Experimental|Treatment (temozolomide, radiation therapy)|Patients receive temozolomide PO daily and radiation therapy over 5 days a week (weekdays only) for 6 weeks. Beginning 28 days after the last dose of radiation therapy, patients receive temozolomide PO for 12 months in the absence of disease progression or unacceptable toxicity.
32789673|NCT05353153|Experimental|hypnosis group|
32789674|NCT05353153|Active Comparator|Control group|
32789675|NCT04608331|Experimental|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
32789676|NCT04608331|Placebo Comparator|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
32789677|NCT04589689|Experimental|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
32789678|NCT04589689|Experimental|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
32789679|NCT04065295|Experimental|Single Rising Dose Part|
32789680|NCT04065295|Experimental|Bioavailability Part|
33297398|NCT00076570|Experimental|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
33297399|NCT00076570|Active Comparator|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
33297400|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
33297401|NCT01078311||HCC patients on Sorafenib|
33297402|NCT03966963|Experimental|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
32789681|NCT05348941|No Intervention|Control|Hypocaloric balanced diet
32789682|NCT05348941|Experimental|TECADRIOL|Hypocaloric balanced diet plus a food supplement with D-chiro-inositol and alpha-lactalbumin
32789683|NCT04842097|Experimental|Mindfulness-based stress reduction intervention|Online 8-week group program, once per week
32789684|NCT04842097|No Intervention|Waiting list|Controls will not receive any intervention during this time. They are on chronic pain clinics waiting list
32789685|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
32789686|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
32789687|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
32789688|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
32789689|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
32789690|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
32789691|NCT04419493|Experimental|Part B: Test treatment (T)|
32789692|NCT04419493|Active Comparator|Part B: Reference treatment (R)|
32789693|NCT04419493|Experimental|Part A: Test|Open-label
32789694|NCT05412979|Experimental|ST-1891|
32789695|NCT05412979|Active Comparator|Levothyroxine|
32789696|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.~Status: ACTIVE, NOT ENROLLING."
32789697|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).~Status: ACTIVE, NOT ENROLLING."
33297403|NCT00124449|Active Comparator|1|
33297404|NCT00124449|Placebo Comparator|2|
33297405|NCT00076336|Experimental|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
33297406|NCT00076336|Active Comparator|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
33297407|NCT00185588|Experimental|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
32789698|NCT02000115|Experimental|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve~Status: ACTIVE, ENROLLING."
33297408|NCT00185588|Experimental|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
33297409|NCT00185588|Experimental|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
33297410|NCT00185588|Experimental|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
33297411|NCT01074476|Experimental|1|Glucosamine sulphate tablets
33297412|NCT01074476|Placebo Comparator|2|Placebo tablets
33297413|NCT00232544|Experimental|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
33297414|NCT00232544|Placebo Comparator|TLC-Control|A TLC system for providing general health education
33297415|NCT03974126|Experimental|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
33297416|NCT03974126|Experimental|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
33297417|NCT00231842|Experimental|Ifosfamide with or without cisplatin|Participants with surgically staged carcinosarcoma (CS) with no gross residual disease were initially administered ifosfamide (1.2 g/m2/day for 5 days) with cisplatin (20 mg/m2/day for 5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin with cisplatin (20 mg/m2/day for 5 days) evrey 3 weeks. cisplatin added toxicity without additional efficacy, so mid-study, cisplatin was eliminated.
33297418|NCT00076102|Experimental|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
33297419|NCT03968588|Experimental|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5~2.0g per day.
33297420|NCT03968588|Active Comparator|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5~1g per day and MMF started within 72 hours after transplantation.
32789699|NCT02000115|Experimental|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system~Status: ACTIVE, NOT ENROLLING"
32830468|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
32830469|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
32830470|NCT03293862|Active Comparator|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
32830471|NCT03293862|Experimental|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
32830472|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
32830473|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
32830474|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
32830475|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
32830476|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
32830477|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
32830478|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
32830479|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
32830480|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
32830481|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
32830482|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
32830483|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
32830484|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
32830485|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
32830486|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
32830487|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
32830488|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
32830489|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
32830490|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
32830491|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
32830492|NCT04092816|Experimental|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
32830493|NCT03288636|Experimental|Experimental|"PKGroup:~Ravidasvir + Danoprevir/ Ritonavir"
33297422|NCT05625880|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns using Picterus JP.
33297423|NCT03974282|Other|Low psychopathy distribution|Participants who score at the low end of the psychopathy distribution
33297424|NCT03974282|Other|High psychopathy distribution|Participants who score at the high end of the psychopathy distribution
32830494|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:~Placebo"
32830495|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
32830496|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
32830497|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
32830498|NCT01959178|Experimental|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
32830499|NCT01959178|Active Comparator|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
32830500|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
32830501|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
32830502|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
32830503|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
32830504|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
32830505|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
32830506|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
32830507|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
32830508|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
32830509|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
32830510|NCT02071810|Experimental|Placebo|Placebo, PLC
32830511|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
32830512|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
32830513|NCT01959490|Experimental|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
32830514|NCT01959490|Experimental|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
32830515|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
32830516|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
32830517|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
32830518|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
32830519|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
32830520|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
32830521|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
33087223|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
32789700|NCT05347537|Experimental|Mulligan mobilization|Group A will be treated with only mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
32789701|NCT05347537|Active Comparator|Mulligan mobilization with clamshell exercise|Group B will be treated with mulligan's mobilization with movement and clamshell exercises.
32789702|NCT04819711|Active Comparator|Intervention|Thinking Healthy group intervention integrated into antenatal pregnancy school classes
33087224|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
33087225|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
33087226|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
33087227|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
33087228|NCT01683721||Winx|
33087229|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
33087230|NCT01683799|No Intervention|Control|
33087231|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
33087232|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
32789703|NCT04819711|No Intervention|Control|Participants randomized to the control arm will not be offered the THP intervention but will attend the 5 sessions of the routine group antenatal pregnancy school classes. The class provides education about pregnancy, birth and new-born care and offers support to women. The women will also be able to access all usual care and support offered by the participating hospitals
32789704|NCT04556851|Experimental|HSK7653 10 mg|
32789705|NCT04556851|Experimental|HSK7653 25 mg|
32789706|NCT04556851|Placebo Comparator|Placebo|
32789707|NCT04969081|Active Comparator|treatment as usual|usual substance use treatment
32789708|NCT04969081|Experimental|treatment as usual plus referral to work focused program|usual substance use treatment plus referral to a competitive or non-competitive work-focused program
32789709|NCT04039399|Experimental|Ischemic Conditioning|Study participants will receive one session of ischemic conditioning on their affected leg with cuff inflation to 225 mmHg.
32789710|NCT04039399|Sham Comparator|Sham Ischemic Conditioning|Study participants will receive one session of sham ischemic conditioning on their affected leg with cuff inflation to 10 mmHg.
32789711|NCT04554745|Other|Non-scared uterus of pregnant women|
32789712|NCT04554745|Other|Scared uterus of pregnant women|
32789713|NCT04549363|Experimental|Participants undergoing IC|IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
32789714|NCT04549363|Experimental|Participants undergoing SK|SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
32789715|NCT04038697|Experimental|Ischemic Conditioning + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning and treadmill training.
32789716|NCT04038697|Placebo Comparator|Ischemic Conditioning Sham + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning sham and treadmill training.
32789717|NCT04038697|Active Comparator|Ischemic Conditioning Only|Study participants with prior history of stroke will receive only ischemic conditioning.
32789718|NCT04038697|Active Comparator|Healthy Control - Ischemic Conditioning + Treadmill Training|Healthy control participants will receive both ischemic conditioning and treadmill training.
32789719|NCT04819477|Other|Cate Plots|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.
32789720|NCT04819477|Other|Fact box only|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior
32789721|NCT04818775|Experimental|HemaClear|
33087233|NCT04527640|Experimental|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
33087234|NCT04527640|Placebo Comparator|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
33087235|NCT04527562|Active Comparator|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
33297425|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
33297426|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
33297427|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
33297428|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
33297429|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
33297430|NCT03974360|Experimental|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
33297431|NCT00184028|Experimental|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
33297432|NCT00183872|Experimental|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
33297433|NCT03815175|Experimental|XIENCE|XIENCE + 1 month DAPT
33297434|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
33297435|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
33297436|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
33297437|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
33297438|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
33297439|NCT00262028|Experimental|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
33297440|NCT00262028|Experimental|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
33297441|NCT00262028|Active Comparator|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
33297442|NCT00262028|Experimental|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
33297443|NCT00262028|Experimental|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
33297444|NCT00183248|Experimental|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
33297445|NCT00183248|Active Comparator|Control Group|Kidney transplantation, followed by immunotherapy
32789722|NCT04818775|Active Comparator|Pneumatic Tourniquet|
32789723|NCT05411575|Placebo Comparator|Placebo|continuous intravenous infusion for 7 days of Placebo
32789724|NCT05411575|Experimental|Plerixafor|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
32789725|NCT04030507|Experimental|Inflammatory Breast Cancer Managed with Curative Intent|"Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain~If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
32789726|NCT04030507|Experimental|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
32789727|NCT04030507|No Intervention|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
32789728|NCT04030507|Experimental|Triple Negative Breast Cancer|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
32789729|NCT04966273|Experimental|Biosensors Microcatheter (BM)|Use of Biosensors Microcatheter
32789730|NCT05411029||Healthy Somali Americans|Somali Americans with no known history of hypertension, diabetes, or sleep disorders will have a 24 hour blood pressure monitoring and polysomnography.
32789731|NCT05344105|Active Comparator|Transversalis fascia plan block (Group T)|After local cleaning of the skin area, the transducer will be placed on the iliac crest in the transverse plane with a low-frequency convex probe, and the skin, subcutaneous tissue, external oblique muscle will be placed with a 20 G, 100 mm needle. After visualization of the internal oblique muscle and transversus abdominis muscles and finally the deep fascia of the transversus abdominis, local anesthetic will be given unilaterally between the last part of the transversus abdominis muscle and the transversalis fascia with the out-off plan technique.
32830522|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
32830523|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
32830524|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
32830525|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
32830526|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
32830527|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
32830528|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
33087236|NCT04527562|Placebo Comparator|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.~Standard care of enrolled study patients will consist:~Isolation facility~Symptomatic treatment with Paracetamol, Fexofenadine~Steam inhalation/Gurgle of Lukewarm water.~Ensuring of hand wash (20 seconds each time) and ideally wearing mask.~Monitoring by the attending nurses."
33087237|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
32789732|NCT05344105|Active Comparator|Erector spina plan block (Group E)|After local cleaning of the skin area, a convex probe is determined to be placed longitudinally 3 cm lateral to the spinous process of the T11 vertebra, after determining the erector spina muscle, with a 20 G, 100 mm needle inplane method in the craniocaudal direction will be advanced and a local anesthetic will be administered between the erector spinae muscle and the transverse process.
32789733|NCT04533373|Experimental|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
32789734|NCT04533373|No Intervention|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
32789735|NCT04018807|Other|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
32789736|NCT04018807|Experimental|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
33297446|NCT00183170|Experimental|Alcohol then Placebo|Participants report for their first dosing night where they receive several alcohol drinks. After a wash out period of 1 week they then return and receive several placebo drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
33297447|NCT00183170|Experimental|Placebo then Alcohol|Participants report for their first night where they receive several placebo drinks. After a wash out period of 1 week they then return and receive several alcohol drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
32789739|NCT04830787||hypertrophic cardiomyopathy|patients with hypertrophic cardiomyopathy
32789740|NCT04830787||control without hypertrophic cardiomyopathy|controls without hypertrophic cardiomyopathy
32789741|NCT04018729|Experimental|Endobronchial valve + marrow-derived mesenchymal stromal cell|
32789742|NCT04018729|Active Comparator|Endobronchial valve|
32789743|NCT04817371|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
32789744|NCT04817371|Other|Symptomatic patients with positive PCR for other respiratory virus|Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses
32789745|NCT04817371|Other|Asymptomatic patients or healthy volunteers|Patients or healthy volunteers with negative RT-PCR and negative serology
32789746|NCT04817371|Other|Volunteers or patients vaccinated against COVID-19|Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)
32789747|NCT05408533|Active Comparator|Silver-Coated Catheter|
32789748|NCT05408533|Placebo Comparator|Standard Catheter|
32789749|NCT04001647|Experimental|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
32789750|NCT04001647|Placebo Comparator|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
32789751|NCT03989947|Experimental|Active BMN 111|Once daily subcutaneous injections of recommended dose of BMN 111 based on weight-band dosing.
33087238|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
33403899|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
32789752|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
32789753|NCT04419571||Negative or non-suspected COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
32789754|NCT04511455|Experimental|Experimental|"Cabozantinib peroral 60 mg/day~A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.~The study treatment will be limited to a maximum of 12 months (including interruptions)."
32789755|NCT03958903|Experimental|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
32789756|NCT04816981|Experimental|EBUS-Elastography|
32789757|NCT04490161|Experimental|Interventional|Subjects will receive reinstallation of CSF intravenously.
33087239|NCT00281424|No Intervention|control|no pedometer
33087240|NCT00281424|Experimental|pedometer|given pedometer
32789758|NCT04490161|No Intervention|Observational|Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
32789759|NCT04923997|Experimental|Health Coaching|All participants will be in the health coaching group. Participants on study will receive a health coach for 6 months.
32789760|NCT03939637|Experimental|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
32789761|NCT03939637|Active Comparator|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.~Standard therapy will be administered as commercially available drug.~Investigator may choose amongst the following:~IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)~Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days~Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
32789762|NCT04907851|Experimental|Module 1 - RNF43 Mutated Advanced (unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)|Patients (Karnofsky performance status ≥70) will be recruited and dosed with RXC004 (2 mg once daily [QD], orally) within 6 weeks of progression following 1st line SoC treatment.
32789763|NCT04907851|Experimental|Module 2 -Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)|Patients (Eastern Cooperative Oncology Group [ECOG] performance status 0-1) will be recruited and dosed with RXC004 within 6 weeks of progression, following 1st line SoC treatment.
32789764|NCT04907851|Experimental|Module 3-Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage Ill/IV) Combination Therapy|Patients (ECOG performance status 0-1) will be recruited and dosed with RXC004 (1.5 mg QD, orally) in combination with pembrolizumab 400 mg IV infusion every 6 weeks (q6w) within 6 weeks of progression, following 1st line Soc treatment.
32789765|NCT05333029|Experimental|MSCs + ECP|"The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.~Participants will be followed for up to 1 year for assessment of endpoints."
32789766|NCT04829461|Experimental|Ambu® aScope™ 4 Cysto|Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).
32789767|NCT04829461|Active Comparator|Standard of Care (SOC)|Ureteral stent removal procedure performed with standard of care (reusable cystoscope).
32789768|NCT04479241|Experimental|Lerapolturev|
32789769|NCT03930199|Experimental|Not Meeting Mobility Goals|After the first three months of sensor monitoring, participants not meeting goals will receive an intervention (others will be removed from the study). The intervention assigned is not pre-determined, but will be assigned by an expert panel based on the individual needs determined from the assessment results and monitoring data. The intervention may include prosthetic care, physical therapy, motivational interviewing or other related psychological interventions, or a combination thereof. After three months of intervention, assessments are performed again and if improvement in prosthesis use is determined, participants are monitored for another three months to assess maintenance of prosthesis use (participants showing no improvement are removed from the study before these final three months of monitoring).
32789770|NCT05407285|Experimental|0 mg CBD, ingested placebo|Ingested placebo containing 0 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
32789771|NCT05407285|Experimental|20 mg CBD, ingested CBD|Ingested cannabis containing 20 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
33087241|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33403900|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
33403901|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
32789772|NCT05407285|Experimental|50 mg CBD, ingested CBD|Ingested cannabis containing 50 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
32789773|NCT05407285|Experimental|100 mg CBD, ingested CBD|Ingested cannabis containing 100 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
32789774|NCT05407285|Experimental|200 mg CBD, ingested CBD|Ingested cannabis containing 200 mg CBD Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
32789775|NCT03916237|No Intervention|CONTROL|Control group
32789776|NCT03916237|Experimental|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
32789777|NCT03916237|Experimental|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
32789778|NCT03916237|Experimental|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
32789779|NCT03916237|Experimental|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
33297448|NCT00230282|Experimental|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
33297449|NCT00261950|Experimental|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
32789780|NCT03916237|Experimental|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
32789781|NCT03916237|Experimental|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
32789782|NCT03898453|Experimental|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
32789783|NCT03898453|Other|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
32789784|NCT04829071|Experimental|Evaluating motor learning and brain structures post-stroke|We will use a single arm design to determine the impact of post-stroke cognitive impairment on two forms of motor learning (implicit and explicit) and evaluate the structural integrity of relevant brain structures in 65 individuals post stroke
32789785|NCT03876457|Experimental|Endovascular Thrombectomy plus Medical Management|
32789786|NCT03876457|Active Comparator|Medical Management|
32789787|NCT04193917|Other|conjunctival swab|A conjunctival swab of both eyes will be taken
32789788|NCT04828681||Patients with Angio-IMR>40 Unit|Patients with angio-IMR>40U in the culprit vessel after successful primary PCI.
32789789|NCT04828681||Patients with Angio-IMR≤40 Unit|Patients with angio-IMR≤40U in the culprit vessel after successful primary PCI.
32789790|NCT04828369||EUS group|Patients who received EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
32789791|NCT04828369||BRTO group|Patients who received balloon-occluded retrograde transvenous obliteration (BRTO)
32789792|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
32789793|NCT04428385|Experimental|Arm 2 (consumer-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
32789794|NCT04408729|Experimental|PrEP My Way intervention|PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
32789795|NCT04408729|No Intervention|Control|These participants will continue to receive PrEP at the clinic.
32789796|NCT05323591||Filgotinib|Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
33297450|NCT00230048|No Intervention|Assessment only|
33297451|NCT00230048|Experimental|Brief intervention|
33297452|NCT00229658||Type 1|Patients with type 1 diabetes
33297453|NCT00229658||Type 2|Patients with type 2 diabetes
32789797|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
32830529|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
33297454|NCT00182078|Placebo Comparator|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
33297455|NCT00182078|Experimental|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
33297456|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
33297457|NCT00181844|Experimental|Lamotrigine|
33297458|NCT00181766|Experimental|Strattera (atomoxetine)|
33297459|NCT00180674|Experimental|Warfarin anticoagulation|Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).
33297460|NCT00076024|Other|Docetaxel + Placebo|Docetaxel + Placebo
33297461|NCT00076024|Experimental|Docetaxel + AG-013736|Docetaxel + AG-013736
33297462|NCT05626426|Experimental|Active SASm|Patients will receive active treatment with the device every other day over 8 weeks.
33297463|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
33297464|NCT01103050|Experimental|QAV680 + Cetirizine|
33297465|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
33297466|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
33297467|NCT01102816|Experimental|Individualized acupuncture|
33297468|NCT01102816|No Intervention|Routine care|
33403902|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
32789798|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
33297469|NCT00075478|Experimental|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
33297470|NCT00075478|Active Comparator|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
32789799|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
32789800|NCT04402489|Placebo Comparator|Placebo Comparator|Oral tablet of placebo once a day.
32789801|NCT04402489|Experimental|MT-7117 Low Dose|Oral tablet of MT-7117 Low Dose once a day.
32789802|NCT04402489|Experimental|MT-7117 High Dose|Oral tablet of MT-7117 High Dose once a day.
32789803|NCT04827199|Experimental|ARTUS®|The subjects will be implanted with the experimental medical device ARTUS® Artificial Urinary Sphincter (AUS) during the surgical procedure and will be trained to the use of the Remote Control to control themselves the micturition.
32789804|NCT04399369|Experimental|SDF|38% silver diamine fluoride solution
32789805|NCT04399369|Active Comparator|NaF|5% sodium fluoride varnish
32789806|NCT04840147|Experimental|Intervention|JointRep® plus microfracture
32789807|NCT04840147|Other|Control|Microfracture alone
32789808|NCT04419415|Experimental|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
32789809|NCT04419415|Experimental|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
32789810|NCT04419415|Experimental|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
32789811|NCT04419415|Experimental|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
32789812|NCT04880707|Active Comparator|Twin Block with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
32789813|NCT04880707|Placebo Comparator|Twin Block with sterile normal saline|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block using sterile normal saline, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
32789814|NCT05369221|Experimental|ReSpace™|The subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will be enrolled in this study. Subjects will undergo placement of ReSpace™ hydrogel.
32789815|NCT04826809|Experimental|Health care workers|Health care workers will complete a fit test while wearing the Nordell Single E-100 layer + (cotton layer) mask, Nordell Double E-100 layer mask and an N95 mask
32789816|NCT04383223|No Intervention|YLH Historical Control Group|"Participants in this group will have the following phases:~Screening~Single visit assessment"
33087242|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33297471|NCT00175916|Experimental|Brivaracetam|Flexible dosing, can up and down titrate as needed.
33297472|NCT03968432|Sham Comparator|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
33297473|NCT03968432|Active Comparator|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS&Q. MIAS&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
33297474|NCT00075400|Experimental|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33297475|NCT03972722|Experimental|GLS-010|Full-human anti-pd-1 monoclonal antibodies
33297476|NCT03972644|Active Comparator|Early intervention|Patients will undergo aortic valve replacement immediately
33297477|NCT03972644|No Intervention|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
32789817|NCT04383223|Experimental|YLH iTransition Intervention Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3 and 9 month"
32789818|NCT04383223|Experimental|Provider Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
32789819|NCT04383223|Experimental|Transition Champion Group|"Participants in this group will have the following phases:~Screening~Baseline Visit and Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
32789820|NCT04815109||critical ill COVID-19|Critically ill COVID-19 patients with need for ventilation and appropriate sedation
32789821|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
32789822|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
32789823|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
32789824|NCT01999335|Experimental|Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
32789825|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
32789826|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
32789827|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
32789828|NCT01999179|Other|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
32789829|NCT04670445|Experimental|Refine Intervention and Study Procedure|"Small open pilot (n=10) to refine the intervention and study procedures.~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team."
32939765|NCT04033640|No Intervention|Health Workers|Participants were trained on use of the SD Biosensor STANDARD G6PD test by members of the study team with extensive experience with G6PD diagnostics and the STANDARD G6PD test. Health worker participants were surveyed to assess label and packing comprehension as well as results interpretation.
33297478|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
33297479|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
33297480|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
33297481|NCT01105468||Mamma Carcinoma, no treatment|
33297482|NCT01105468||Mamma Carcinoma, treatment|
33297483|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
33297484|NCT03949114|Experimental|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;~(2) Do the early rehabilitation intervention process:"
33297485|NCT03949114|Active Comparator|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
33297486|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
33297487|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
33297488|NCT00074152|Active Comparator|Arm I|Patients receive radiotherapy* within 6 months after surgery.
33297489|NCT00074152|Experimental|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
33297490|NCT00261846|Experimental|SKI-606|
33297491|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
32789830|NCT04670445|Experimental|Educational Video and QPL List|"Randomized into Intervention Arm~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team.~Audio Recorded Conversation with oncologist"
32789831|NCT04670445|Active Comparator|Usual Care|"Randomized into Usual Care Arm~The control group will have three surveys (one before first infusion, one after, and one six weeks later)~Audio Recorded Conversation with oncologist"
32789832|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
32789833|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
32789834|NCT01998477|Experimental|TIVc|flu vaccine
32789835|NCT01998477|Active Comparator|TIV|flu vaccine
33297492|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
32789836|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
32789837|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
32789838|NCT01781572|Experimental|Phase Ib|"The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.~Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).~Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).~Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle)."
32789839|NCT01781572|Experimental|Phase II|"The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.~Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination."
32789840|NCT01977651|Experimental|Enzalutamide 160 mg|Participants received 160 mg of enzalutamide orally once a day, for 4 months. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment continued in the extension period. The total study drug treatment duration for the extended period depended on individual clinical benefit. If a participant experienced a Grade 3 or higher toxicity that was attributed to enzalutamide and could not be ameliorated by the use of adequate medical intervention, treatment with enzalutamide was allowed to be interrupted for 1 week or until the toxicity grade improved to Grade 2 or lower severity. Subsequently, enzalutamide was restarted at the original dose 160 mg per day or a reduced dose 120 or 80 mg per day in consultation with the medical monitor.
32789841|NCT01998243|Experimental|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
32789842|NCT01998243|Placebo Comparator|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
32789843|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
32789844|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
32789845|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
32789846|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
33297493|NCT00169442|Experimental|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
33403903|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
32789847|NCT01761292|Experimental|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
32789848|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
32789849|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
33297494|NCT00169442|Experimental|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
33297495|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
33297496|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
33297497|NCT05625724|Experimental|Aspirin|Low-dose Aspirin: 150mg, daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
33297498|NCT05625724|Placebo Comparator|Control|Matching placebo administrated daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
33297499|NCT02530762|Placebo Comparator|Negative control|No added fiber
33297500|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
33297501|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
33297502|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
33297503|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
33297504|NCT00261716|Experimental|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
33297505|NCT00261716|Active Comparator|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
33297506|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
33297507|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
32789850|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
33297508|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
33297509|NCT00203502|Experimental|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
33297510|NCT03799198|Experimental|WMP + Rx|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately one year. After discussing with the study doctor, participants will receive one of the following listed 5 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) lorcaserin or lorcaserin extended-release, 3) phentermine/topiramate extended-release, 4) naltrexone/bupropion extended-release and 5) liraglutide 3.0 mg.
33297511|NCT03799198|Active Comparator|WMP alone|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately one year.
33297512|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
33297513|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
33297514|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
32789851|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
32789852|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
32789853|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
33297515|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
33297516|NCT03947086|Active Comparator|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
33297517|NCT03947086|Sham Comparator|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
33297518|NCT04928482|Experimental|27 session group|Participants in this arm will receive 27 sessions of backward walking training.
33297519|NCT04928482|Active Comparator|18 session group|Participants in this arm will receive 18 sessions of backward walking training.
33297520|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
33297521|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
33297522|NCT03948724|Experimental|Therapeutic patient education|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
33297523|NCT03948724|Active Comparator|Standard Care|Patient receive usual informations
33297524|NCT04924504||Type A|Healthy pregnant women without pregestational or gestational diabetes
33297525|NCT04924504||Type B|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose <= 75 units/day
33297526|NCT04924504||Type C|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose >= 100 units/day
32789854|NCT01779856|Other|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
32789855|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
32789856|NCT01729156|Placebo Comparator|Placebo|Placebo
32789857|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
32789858|NCT01779700|Active Comparator|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
32789859|NCT01779700|Placebo Comparator|placebo|placebo, oral administration, daily, for 8 weeks.
32789860|NCT04572256|Experimental|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
32789861|NCT04572256|Placebo Comparator|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
32789862|NCT01778530|Experimental|TRC105 for Recurrent Glioblastoma|
33297527|NCT03947008|Experimental|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
33297528|NCT03947008|Experimental|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
33297529|NCT03946852|Experimental|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
33297530|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
33297531|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
33297532|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
33297533|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
33297534|NCT01103674|Other|Numeris-AF Guided Coagulation System|
33297535|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
33297536|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
33297537|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
33297538|NCT05625568|Placebo Comparator|Placebo|
33297539|NCT05625568|Experimental|5 mg VYNT-0126|
33297540|NCT05625568|Experimental|10 mg VYNT-0126|
33297541|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
33297542|NCT05625490|Experimental|Rest/ Stress imaging day 1|Participants will receive two [68Ga]Galmydar intravenous administrations, 4 mCi during rest and 8 mCi during stress for the PET MPI performed on Imaging Day-1.
33297543|NCT05625490|Experimental|rest/ stress imaging day 2|On Imaging Day-2, participants will receive two single administrations each of 10 mCi of 13N-Ammonia during the rest and stress PET MPI.
33297544|NCT01089400||Influenza A/H1N1 patients|
33297545|NCT01089400||Non influenza A/H1N1 patients|
33297546|NCT05614882|Active Comparator|Written Stroke Education|Participants in this arm will be given the current written standard of care for stroke education. Assessments will be completed during the participants inpatient stay.
33297547|NCT05614882|Experimental|Verbal Stroke Education|Participants in this arm will be given the experimental verbal stroke education. Assessments will be completed during the participants inpatient stay.
32789863|NCT01778062|Experimental|Indacaterol|Indacaterol 150 µg once daily
32789864|NCT01778062|Placebo Comparator|Placebo|Placebo once daily
32789865|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
32789866|NCT01757704|Experimental|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
32830530|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
32830531|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
33297548|NCT03960736|Active Comparator|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
33297549|NCT03960736|Active Comparator|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
33297550|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
33297551|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
32939766|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
32939767|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
32939768|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
32939769|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
32939770|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
32939771|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
32939772|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
32939773|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
32939774|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
32939775|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
32939776|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
32939777|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
32939778|NCT04036292|Active Comparator|OC-01 Low Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.6 mg/ML
32939779|NCT04036292|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/ML
32939780|NCT04036292|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
32939781|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
32939782|NCT00377390||Cockroach sensitive|
32939783|NCT00377390||Control (cockroach insensitive)|
32939784|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
32939785|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
32939786|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
32939787|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
32939788|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
32939789|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
32939790|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
32939791|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
32939792|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
32939793|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
33087243|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
33087244|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
33297552|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
33297553|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
32789867|NCT01757704|Experimental|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
32789868|NCT01757392|Experimental|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
32789869|NCT01756846|Other|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
32789870|NCT01756846|Other|use of HEART risk score|see intervention
32789871|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
32789872|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
32789873|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
32789874|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
32789875|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
32789876|NCT04662645|Experimental|Supportive care (embedded palliative care)|Participants and caregivers undergo embedded palliative care comprising symptom management (physical and psychological), advanced directives and goals of care discussion, caregiver support, and referral for adjunctive supportive services as needed at each clinic visit.
32789877|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
32789878|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
32789879|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
32789880|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
32789881|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
32789882|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
32789883|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
32789884|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
32789885|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
32789886|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
32789887|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
32789888|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
32789889|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
32789890|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
33297554|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
33297555|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
33087245|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
33087246|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
33087247|NCT01684267|Experimental|Healthy|Healthy individuals
32789891|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
32789892|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
33297556|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
33297557|NCT00232596|Placebo Comparator|Placebo|
33297558|NCT00232596|Experimental|Retigabine|
33297559|NCT04771936|No Intervention|Control Group|The control group who shall be awaiting surgery and not receiving a regular physiotherapy exercise intervention
33297560|NCT04771936|Active Comparator|Conventional Exercise Group|The conventional exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000).
33297561|NCT04771936|Experimental|Conventional Exercise Group with added core exercises|This exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000) and core exercises aimed at the activation of the core muscles as adapted from Imai et al (2010).
33297562|NCT00073918|Experimental|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
33297563|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
33297564|NCT01071642|Active Comparator|group b|
33297565|NCT01071642|Active Comparator|group c|
33297566|NCT00231894|Active Comparator|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
33297567|NCT00231894|Placebo Comparator|Placebo and life style group|Placebo capsules daily plus life-style diet group
33297568|NCT00203424|Experimental|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
33297569|NCT00203268|Experimental|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
33297570|NCT00168818|Experimental|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
33297571|NCT00168818|Experimental|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
32789893|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
32789894|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
33297572|NCT00168818|Active Comparator|enoxaparin|40 mg once daily
33087248|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
33087249|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
33297573|NCT00260832|Experimental|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
33297574|NCT00260832|Active Comparator|B|
33297575|NCT00168038|Experimental|IgPro10|
33297576|NCT00167414|Experimental|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
33297577|NCT00166712|Active Comparator|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
33297578|NCT00166712|Active Comparator|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
33297579|NCT03972566||CREST with Calcinosis cutis|
33297580|NCT03972566||CREST without Calcinosis cutis|
33297581|NCT03973034||Normal people|
33297582|NCT03973034||Benign breast disease patients|
33297583|NCT03973034||Breast cancer patients in early stage|
33087250|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
33087251|NCT01684345|Placebo Comparator|Placebo|
33087252|NCT01684345|Experimental|Dose 1 gevokizumab|
33087253|NCT01684345|Experimental|Dose 2 gevokizumab|
33087254|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
33087255|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
33087256|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
33087257|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
32789895|NCT04847011|Experimental|RA - longitudinal arm|
32789896|NCT04847011|Experimental|PD - longitudinal arm|
33087258|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
33087259|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
32789897|NCT04847011|No Intervention|RA - crosssectional arm|
32789898|NCT04847011|No Intervention|PD - crossectional arm|
32789899|NCT04847011|No Intervention|Healthy controls - crosssectional arm|
32789900|NCT04844827||malignant pleural effusion|Patients with malignant pleural effusion who underwent pleural biopsies and blood tests under general anesthesia
32789901|NCT04841317|Experimental|Single-arm: Blood pressure intervention|Participants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
32789902|NCT01995825|Experimental|Brand lamotrigine then Generic lamotrigine|Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.
32789903|NCT01995825|Experimental|Generic lamotrigine then Brand lamotrigine|Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.
33087260|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
33087261|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
33087262|NCT02961413||cohort 3|Bicyclol
33087263|NCT02961413||cohort 4|Silibinin capsules
33087264|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
33087265|NCT02961413||cohort 6|N- acetylcysteine
33087266|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
33087267|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
33087268|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
33087269|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
33087270|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
33087271|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
33087272|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
33087273|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
33087274|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
33087275|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
33087276|NCT00287820|Active Comparator|1|olanzapine
33087277|NCT00287820|Active Comparator|2|risperidone
33087278|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
33087279|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
33087280|NCT02278744|Experimental|single-fraction radiosurgery|
33087281|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
33087282|NCT02279095|Experimental|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
33087283|NCT02279095|Experimental|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
33087284|NCT02279095|Experimental|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
33297584|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
33297585|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
33297586|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
33297587|NCT03974438|Experimental|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
32789904|NCT04829929|Experimental|One arm|Patients with Non-Valvular Atrial Fibrillation and High Bleeding Risk
32789905|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
32789906|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
32789907|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
32789908|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
33087285|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
33087286|NCT01684891|Experimental|RG1662|
33087287|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
33087288|NCT01684969|Placebo Comparator|Placebo|
33297588|NCT03974438|Sham Comparator|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
33297589|NCT03972410|Experimental|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
33297590|NCT03972410|Active Comparator|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
33297591|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
33297592|NCT01074710|Placebo Comparator|Placebo|2 same subjects
33297593|NCT01074788|Experimental|mind body intervention group|
33297594|NCT00073528|Placebo Comparator|Placebo + Letrozole 2.5 mg|Letrozole (2.5 mg once daily orally) with Placebo (which matched with Lapatinib tablet)
33297595|NCT00073528|Experimental|Lapatinib 1500 mg + Letrozole 2.5 mg|Lapatinib (1500 mg once daily orally) with Letrozole (2.5 mg once daily orally)
33297596|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
33297597|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
33297598|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
33297599|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
33297600|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
33297601|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
32789909|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
33087289|NCT01685086||Patients with severe chronic kidney disease|
33087290|NCT01685086||Patient with peritoneal dialysis|
33087291|NCT01685086||Patients with hemodialysis|
33087292|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33087293|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33403904|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
32789910|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
32789911|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
32789912|NCT05309629|Experimental|QL1706+chemotherapy|Participants received intravenous infusions of QL1706 5mg/kg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle for 4-6 cycles. On Days 2 and 3 of every 21-day cycle, etoposide 100 mg/m^2 was administered alone for 4-6 cycles. Thereafter, participants received maintenance QL1706 5mg/kg on Day 1 of every 21-day cycle until progressive disease, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
32789913|NCT05270239|Experimental|Working Memory Training in MS patients|This group of patients will perform a computerized n-back training, which includes a sequence of 2-back and 3-back blocks.
32789914|NCT05270239|Experimental|Virtual Reality Training in MS patients|"This group of patients will perform a Virtual Reality Ball Task training. This task contains 6 trials of increasing difficulty."
32789915|NCT04312399|Other|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789916|NCT04312399|Other|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789917|NCT04312399|Other|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789918|NCT04312399|Other|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789919|NCT04312399|Other|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789920|NCT04312399|Other|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789921|NCT04312399|Other|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789922|NCT04312399|Other|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789923|NCT04312399|Other|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
33297602|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
33297603|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
33297604|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
33297605|NCT04692532|Experimental|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
33297606|NCT04692532|Experimental|Calorie restriction|25% energy restriction every day
33297607|NCT04692532|No Intervention|Control|Usual diet, Ad libitum intake, eating within >10 hours per day
33297608|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
33297609|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
33297610|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
33297611|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
33297612|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
33297613|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
33297614|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
33297615|NCT05562466|Experimental|QMF149|QMF149 75/40μg
33297616|NCT05562466|Active Comparator|Budesonide|Budesonide 200μg o.d
33297617|NCT01106482|Active Comparator|Arm 1|
33297618|NCT01106482|Active Comparator|Arm 2|
33297619|NCT01106482|Active Comparator|Arm 3|
33297620|NCT01106482|Active Comparator|Arm 4|
33297621|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
33297622|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
33297623|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
33297624|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
33297625|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
33297626|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
33297627|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
33297628|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
33297629|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
33297630|NCT04633408|Experimental|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
33297631|NCT04633408|No Intervention|Control|12 to 15 participants, will not have access to the app.
33297632|NCT04631770|Experimental|Mediastinal lymph node dissection group|A
33297633|NCT04631770|Active Comparator|Mediastinal lymph node non-dissection group|B
33297634|NCT00072280|Experimental|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)"
33297635|NCT00072280|Experimental|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
33297636|NCT05527834|Experimental|Cohort 1|Cohort 1 will assess the impact of a high fat meal.
32789924|NCT04312399|Other|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
32789925|NCT04307563|Other|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
32789926|NCT04817761|Experimental|Calaspargase pegol (S95015)|
32789927|NCT03706963|Experimental|Phone Call|"Patients will be provided with a Fitbit wristband & assistance to set up on smart phone~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery~The group will receive a phone call 7 days into their preoperative period to identify barriers, provide available resources, & encourage continuation of prehabilitation activities~The physician extender will talk with the patient to identify barriers to prehabilitation activities that the patient may have experienced during the first 7 days of activity tracking & provide recommendations & resources to overcome those barriers when possible. The physician extender will encourage the patient to continue prehabilitation activities until the day of operation to meet goals. Following surgery, we will analyze Fitbit data to determine if the intervention had an impact on the patient's prehabilitation activity with the non-intervened patient group used as a control"
32789928|NCT03706963|No Intervention|No Phone Call|"Eligible patients will be provided with a Fitbit wristband & assistance to set up on smart phone~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery"
32789929|NCT04267081|Experimental|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
32789930|NCT04267081|Experimental|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
32789931|NCT04258267|Experimental|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
32789932|NCT04258267|Experimental|Delayed mobilization|The immobilization period is longer.
32789933|NCT05309005||ABI group|The patient group consists of 100 patients with acquired brain injury (e.g. cerebrovascular incidents, anoxia, encephalitis and non-progressive brain tumors)
32789934|NCT05309005||Healthy control group|100 healthy adults will be matched to the patients with respect to age, gender and education.
32789935|NCT04814173|Experimental|One jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a one-jaw mechanic (mini-implants in the maxillary arch).
32789936|NCT04814173|Experimental|Two-jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a two-jaw mechanic (mini-implants in the mandibular arch with class II elastics).
32789937|NCT04814173|Experimental|Traditional treatment|traditional en-mass retraction with first premolars extraction with mini-implants in the maxillary arch.
32789938|NCT04797559|Experimental|SZMN Treatment Group|Patients randomized into the SZMN-treatment group will receive a bilateral single injection SZMN block under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthestic per side.
33297637|NCT05527834|Experimental|Cohort 2|Cohort 2 will be conducted to assess the impact of an alternative lower fat meal if administration with high fat meal has a food effect on drug exposure.
33297638|NCT05527834|Experimental|Cohort 3|Cohort 3 will evaluate realistic fasting intervals and/or additional meal types if administration with food has a food effect on drug exposure.
33297639|NCT03948412|Experimental|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
33297640|NCT03948412|Active Comparator|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
33297641|NCT05514964|Experimental|Intervention Arm|The experimental arm will benefit from the Acceptance and Commitment Therapy Manual of John Forsyth & Georg Eifert (2016). The Mindfulness & Acceptance Workbook for Anxiety: A Guide to Breaking Free from Anxiety, Phobias & Worry Using Acceptance & Commitment Therapy, New Harbinger Publications and also taking into consideration the APA Guidelines for Psychological Practice With Lesbian, Gay and Bisexual Clients.
33297642|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
33297643|NCT01103986|No Intervention|Control Group|
33297644|NCT01103986|Experimental|motivational/ health literacy education|
33297645|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
33297646|NCT01104064|Experimental|Real rTMS combined with CIT|
33297647|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
33297648|NCT04593394||Severe asthma|Gina-guidlines treatment-step 5
33297649|NCT04593394||Mild-moderate asthma|Gina-guidlines treatment-step 1-4
32789939|NCT04797559|No Intervention|Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
32789940|NCT03698071|Experimental|ANCA associated vasculitis|
32789941|NCT05406583|Experimental|Cohort 1|"Cohort 1 will be opened first to accrual, with Strata 1A and 1B being opened concurrently, to evaluate the PK and safety of two single DTG liquid suspension doses for the relevant stratum. Stratum 1C will only be opened to accrual if PK and safety data from Strata 1A and 1B infants support administration of DTG 5 mg DT across all neonates, or only in neonates with a minimum birth weight.~Stratum 1A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~Stratum 1B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)~Stratum 1C (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)."
32789942|NCT05406583|Experimental|Cohort 2|"Cohort 2, Strata 2A and 2B, will be opened to accrual when the DTG dose and formulation to be administered for each stratum are established based on the PK and safety data from all Cohort 1 strata (Strata 1A and 1B, and 1C if applicable) and available data from other studies.~Stratum 2A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~Stratum 2B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)"
32789943|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
32789944|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
32789945|NCT04794829||Vaccinated|Received influenza and/or SARS-CoV-2 vaccine
32789946|NCT04792567|Experimental|Siponimod - continuous|Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
32789947|NCT04792567|Experimental|Siponimod- interrupted|Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
32789948|NCT04792567|Active Comparator|Comparator|Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination
33297650|NCT04593394||Subjects without asthma|Matches control-group without asthma
33297651|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
33297652|NCT01106716|Experimental|A2: KAI-1678|Experimental
32789949|NCT04792489|Experimental|Single, open label|
32789950|NCT04825171|Experimental|Bryophyllum pinnatum 50% chewing tablets|Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of chewing tablets, 350mg per tablet, 0-2-2-2/d: 2 tablets at midday, 2 tablets in the evening, 2 tablets before bedtime.
33297653|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
33297654|NCT00071812|Placebo Comparator|Placebo plus SOC|
32789951|NCT03604783|Experimental|Single Arm TP-1287|TP-1287 by oral administration
33297655|NCT00071812|Experimental|Belimumab 1 mg/kg plus SOC|
33297656|NCT00071812|Experimental|Belimumab 4 mg/kg plus SOC|
33297657|NCT00071812|Experimental|Belimumab 10 mg/kg plus SOC|
33297658|NCT00071110|Experimental|1|Electroacupuncture (EA).
33297659|NCT00071110|Placebo Comparator|2|Sham
32789952|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
32789953|NCT05307523|Experimental|Enriched Environment Play With Harness Support|Enriched environment play, movement, and exploration for children with Down Syndrome while using a portable partial body weight support harness to facilitate movement and exploration.
32789954|NCT05307523|Active Comparator|Enriched Environment Play Without Harness Support|Enriched environment play, movement, and exploration without additional partial body weight support provided.
33297660|NCT03960346|Other|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
32789955|NCT04419025|Active Comparator|NAC|Patients receiving N-acetylcysteine (NAC)
32789956|NCT04419025|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
32789957|NCT04837417||Pathologic group|At least 10 male participants who underwent anterior cruciate ligament arthroscopic reconstruction using semitendinosus and gracilis tendons graft, between 6 and 18 months before the tests
32789958|NCT04781647|Active Comparator|ABI-H0731 + ETV|Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks
33297661|NCT01104142||MDI|Subject on multiple Daily Injections
33297662|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
33297663|NCT01327924||Norditropin NordiFlex® users|
33297664|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
33297665|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
33297666|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
33297667|NCT04013152|Other|clinical database|
33297668|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
33297669|NCT00071032|Experimental|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
33297670|NCT00071032|Active Comparator|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
33087294|NCT04527679|Experimental|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
33087295|NCT01685164||LNG-IUS|Nulliparous women
33087296|NCT01685164||Cu-IUD|Nulliparous women
32789959|NCT04781647|Experimental|ABI-H0731 + ETV + Peg-IFNα|Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
32789960|NCT04781647|Active Comparator|ETV + Peg-IFNα|Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
32789961|NCT04837339|Other|Patients with lung disease requiring transplantation or who have undergone lung transplantation|There is no intervention to be administered.
33297671|NCT03960268|Experimental|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
33403905|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
32789962|NCT04813003||Obesity group (group 1)|"Pilot phase:~5 adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery will undergo functional imaging and neurobehavioural tasks before bariatric surgery.~Refined protocol phase:~20 overweight adults (BMI≥30kg/m2 or BMI≥28kg/m2 with adiposity-related comorbidities (prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia)), referred for obesity treatment (surgical or non-surgical)."
32789963|NCT04813003||Control group (group 2)|"Pilot phase:~5 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age-, sex- and education will serve as a control group and undergo the same experiment.~Refined protocol:~20 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age and sex will serve as a control group and undergo the same experiment."
32789964|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
32789965|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
32789966|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
32789967|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
32789968|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
32789969|NCT04210999|Experimental|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
32789970|NCT04210999|Active Comparator|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
32789971|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
32789972|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
32789973|NCT03588481||Coronary stenosis|
32789974|NCT05259787|Experimental|Etomidate combined with propofol（EP）|0.2ml/kg IV
32789975|NCT05259787|Active Comparator|Propofol（P）|0.2ml/kg IV
32789976|NCT04196413|Experimental|GD2-CAR T|"Rolling-6 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG.~GD2CART will be administered intravenously or intracerebroventricularly in escalating doses on Day 0 in hospitalized subjects with either DIPG or spinal DMG.~intravenously (IV), starting with Dose~Dose Level -1: 3x10^5 transduced T cells/kg(± 20%)~Dose Level 1: 1x10^6 transduced T cells/kg (± 20%)~Dose Level 2: 3x10^6 transduced T cells/kg (± 20%)~intracerebroventricularly (ICV), starting with Dose~Dose Level -1: 10x10^6 transduced T cells (±20%)~Dose Level 1: 30x10^6 transduced T cells (±20%)~Dose Level 2: 50x10^6 transduced T cells (±20%)~Dose Level 3: 100x10^6 transduced T cells (±20%)~Dose expansion in subjects with DIPG and spinal DMG: Once the MTD or RP2D is determined, up to 20 evaluable subjects with H3K27M-mutant DIPG and 10 evaluable subjects with H3K27M-mutant spinal DMG will be treated at the RP2D (including subjects treated during dose escalation)."
32789977|NCT04809571|Experimental|Photoacoustic imaging and Confocal Raman spectroscopy measurement|
32789978|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
32789979|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
33087297|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
33087298|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
33087299|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
33087300|NCT04527952|Experimental|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
33087301|NCT04527952|Active Comparator|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
33087302|NCT04527952|Active Comparator|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
33403906|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
32789980|NCT01756456|Experimental|1_rhNGF10_Phase 1_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
32789981|NCT01756456|Experimental|2_rhNGF20_Phase 1_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
32789982|NCT01756456|Placebo Comparator|3_vehicle group_Phase 1_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
32789983|NCT01756456|Experimental|4_rhNGF10_Phase 2_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
32789984|NCT01756456|Experimental|5_rhNGF20_Phase 2_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
32789985|NCT01756456|Placebo Comparator|6_vehicle group_Phase 2_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
32789986|NCT03329677|Experimental|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
33297672|NCT05485480|Experimental|Opioid-sparing: Lidocaine, Ketamine, Magnesium, Clonidine, Fentanyl, Remifentanil, Propofol|"Ketamine: started at 5mg/h; continued until 30min before end of surgery, then reduced to 1mg/h until discharge from recovery.~Fentanyl: bolus of 50mcg before skin incision (in case of insufficient analgesia further boluses of 25mcg, upper limit is 100mcg).~Lidocaine: bolus of 1.5mg/kg of ideal body weight (IBW),(maximum 100mg) at induction of anaesthesia, then continuous infusion of 1.5mg/kg IBW/h (maximum 100mg/h) until discharge from recovery.~Magnesium: infusion of 2g/h for a maximum of 2h after induction of anaesthesia (maximum dose 4g). In case of bradycardia or hypotension, rate is reduced to 1g/h.~Clonidine: bolus of 15mcg if needed. Maximum amount 150mcg. Remifentanil: started at time of induction of anaesthesia until end of surgery."
33297673|NCT05485480|Active Comparator|Conventional group: Fentanyl, Remifentanil, Propofol|"Control Intervention:~Remifentanil: Remifentanil is given as a target controlled infusion using the Minto-model. It is started at the timepoint of induction of anaesthesia and given until the end of surgery.~Fentanyl: 2mcg/kg i.v. is given at the time of induction of anaesthesia and another 1-2mcg/kg is given prior to incision. Further fentanyl boluses (1-2mcg/kg boluses) are given in case there seems to be insufficient analgesia."
33297674|NCT03960502|Experimental|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of [14C]AG-881 followed 2 hours later by a single intravenous (IV) infusion of [13C315N3]AG-881.
33297675|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
33297676|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
33297677|NCT05470270|Experimental|New formulation of hydroxycarbamide|Single arm study with a single administration of hydroxycarbamide
32789987|NCT05226325|Active Comparator|G0.2|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.2 mcg/kg/hour
33297678|NCT05372926|Experimental|Venturi mask|Patients will be placed under oxygen therapy with Venturi mask at a constant flow of 15L/min and a set FiO2 of 50%. The real FiO2 will be mesured in the mask at rest.
33297679|NCT05372926|Experimental|High flow nasal canulae|Patients will be placed under high flow nasal canulae oxygen therapy with a constant flow of 50L/min and the real FiO2 provided by Venturi mask.
33297680|NCT04468906|Experimental|"Biceps self-locking T tenotomy"|
32789988|NCT05226325|Active Comparator|G0.4|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.4 mcg/kg/hour
33297681|NCT04468906|Active Comparator|Biceps tenodesis (control)|
33297682|NCT03945994|No Intervention|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
33297683|NCT03945994|Experimental|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
33297684|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
33297685|NCT01107106||Adults|250 adult women
33297686|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
33297687|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
33297688|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
33297689|NCT01107184|Sham Comparator|Control|
33297690|NCT00259610|Active Comparator|1|methotrexate (MTX) + etanercept
33297691|NCT00259610|Active Comparator|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
33297692|NCT00259610|Active Comparator|3|methotrexate (MTX) or MTX + Etanercept
33297693|NCT00259610|Active Comparator|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
33297694|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
33297695|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
32789989|NCT05226325|Active Comparator|G0.6|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.6 mcg/kg/hour
32789990|NCT04418635|Experimental|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
32789991|NCT04418635|Placebo Comparator|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
32789992|NCT04809259|Experimental|Continuous infusion of meropenem|The meropenem solution will be administered continuously using elastomeric pumps which will be changed every 24 hours and which will be inserted in an isothermal pouch to ensure that the antibiotic solution is maintained at a temperature between 10° and 15°
33403907|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
32789993|NCT05237713|Other|Canakinumab treatment|200 mg canakinumab subcutaneously every three weeks
32789994|NCT04193371|Experimental|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
32789995|NCT04193371|Sham Comparator|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
32789996|NCT04745299|Experimental|Single cycle administration group|Study drug injections twice in a 26-day interval followed by three times comparator injections every three months.
33403908|NCT05253742||Pregnant women presenting for MRI|Alternative motion-robust MR imaging sequences and procedures for automatic positioning while be tested during fetal brain imaging
33403909|NCT05253664|Experimental|Woman-Centered Care Group|Woman-centered care was given to the experimental group. At the time of the study, 6 women were discharged early, 4 women did not want to continue the study, and the babies of 1 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 109 women in the experimental group.
32789997|NCT04745299|Experimental|Multiple administation group|Study drug injections twice in a 26-day interval followed by repeated three times study drug injections every three months.
32789998|NCT04745299|Placebo Comparator|Control group|Comparator injections twice in a 26-day interval followed by three times comparator injections every three months.
33087303|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
33403910|NCT05253664|No Intervention|Control Group|Standard care was given to the control group. At the time of the study, 2 women were discharged early, 7 women did not want to continue the study, and the babies of 2 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 218 mothers, with 109 women in the control group.
33403911|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
32789999|NCT05394883|Experimental|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week.
32790000|NCT05394883|Experimental|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking and exercise program.
32790001|NCT05394883|No Intervention|Usual Care|The Usual Care group will receive an exercise log to record any weekly activity in addition to a weekly phone call/text/email to remind the individual to complete the weekly exercise log.
32790002|NCT01756300|Experimental|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
32790003|NCT05393401|Experimental|VOP1k|Medical Device
32790004|NCT04168528|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
32790005|NCT04168528|Experimental|Part II: tumor targeting potential and correlation to ICH|Phase II
32790006|NCT04811131|Active Comparator|Active IP and Active Phototherapy|ARQ-252 cream 0.3% BID with phototherapy.
32790007|NCT04811131|Active Comparator|Active IP and Sham Phototherapy|ARQ-252 cream 0.3% BID with sham phototherapy
32790008|NCT04811131|Placebo Comparator|Vehicle and Active Phototherapy|ARQ-252 Vehicle cream BID with active phototherapy
32790009|NCT04811131|Placebo Comparator|Vehicle and Sham Phototherapy|ARQ-252 Vehicle cream BID with sham phototherapy
32790010|NCT05388565|Experimental|The DOVE in China Intervention Group|Our intervention consists of four major components: a) information about IPV and effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
32790011|NCT05388565|Placebo Comparator|The Control Group|The control group will be provided with a standard of care including usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV, and mental health resources).
32790012|NCT04724161||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Changara, Guro, and Chemba districts.
32790013|NCT05221021|Active Comparator|Vaginal Estradiol with placebo oral pill|Patient will receive 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
32790014|NCT05221021|Active Comparator|Oral Mirabegron with placebo vaginal cream|Patient will receive 50 milligrams oral Mirabegron once daily and placebo vaginal cream (Medisca's VersaPro Cream Base) once nightly for two weeks then three times per week
32790015|NCT03190057||Consecutive percutaneous coronary intervention|
32790016|NCT03169075|Experimental|ARM A: A|Supervised physical exercise programs (SPEP)
33087304|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
33087305|NCT01685476|Other|Intracranial pressure|
32790017|NCT03169075|Active Comparator|ARM B: B|Adapted physical activity (APA)
32790018|NCT03167437|Experimental|1|participants will receive Vorinostat 100mg PO BID for 12 weeks
32790019|NCT03167437|Experimental|2|participants will receive Vorinostat 100mg PO BID for 6months
32790020|NCT03167437|Active Comparator|3|participants will receive ustekinumab (weight base induction dose followed by 90mg SC every 8 weeks for 24 months)
32790021|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~plus orally placebo-azathioprine for 24 months"
32790022|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
32790023|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
32790024|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
32790025|NCT05218915|Experimental|GLP1-ra plus basal insulin (BGLP)|Dulaglutide and insulin degludec in combination with CGM
32790026|NCT05218915|Active Comparator|Basal bolus insulin (BB)|Insulin aspart/lispro and insulin degludec in combination with CGM
32790027|NCT05237089|Active Comparator|EA group：Electroacupuncture+health education|Acupuncture is the most popular adjuvant and alternative therapy in China, and it has been used to treat various diseases for thousands of years. Electroacupuncture is an innovation of traditional Chinese acupuncture, which improves the clinical effect by transmitting electrical pulses to the needles and then enhances the stimulation at the acupoints to receive better effects. Studies show that EA has been used as an alternative therapy for obesity in clinical practice.
32790028|NCT05237089|Sham Comparator|Sham acupuncture group：shallow acupuncture+health education|Sham acupuncture method in this study is set as the superficial acupuncture manipulated at the same main acupoints with the thinner and shorter needles. The aim of the sham acupuncture is to eliminate the possible placebo effect of EA treatment.
32790029|NCT03462511|Active Comparator|Control Group|"Dyads randomized to the control group will receive:~Standard care Education handouts."
32790030|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
32790031|NCT03424603|Experimental|STRO-001|intravenous
32790032|NCT04706689||Unresponsive wakefulness syndrome patients (UWS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
32790033|NCT04706689||Minimally conscious patients MINUS (MCS-)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
32790034|NCT04706689||Minimally conscious patients PLUS|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
32790035|NCT04706689||Patients emerging from the minimally conscious state (EMCS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
32790036|NCT03398161|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
32790037|NCT05384197|Active Comparator|Enhanced regimen|"They will receive two days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days according to the assigned randomization group with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
32790038|NCT05384197|Active Comparator|Extended regimen|"They will receive seven days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule ( 7 days with the last day of AP course being one day prior to intervention)"
32790039|NCT01995201|Experimental|Part 1: All patients|
32790040|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
32790041|NCT01995201|Experimental|Part 2 B: Low disease activity|
32790042|NCT05383651||Adults|
32790043|NCT05383651||Pediatric/ Neonates|
32790044|NCT04690699|Experimental|Cohort E: Lerapolturev|Subjects will be treated with lerapolturev by intravesical instillation
32790045|NCT04690699|Experimental|Cohort F: Lerapolturev + 5% DDM|Subjects will be treated with lerapolturev by intravesical instillation after a sequence of 5% DDM and saline washes
32790046|NCT04193215|Experimental|V114|Participants will receive an intramuscular (IM) injection.
32790047|NCT04193215|Other|Control|
32790048|NCT04783363|Experimental|Arm A|"Visit 1: with Snoezelen session before invasive care~Visit 2: standard care (=without Snoezelen session) before invasive care"
32790049|NCT04783363|Experimental|Arm B|"Visit 1: standard care (=without Snoezelen session) before invasive care~Visit 2: with Snoezelen session before invasive care"
32790050|NCT04638387|Experimental|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
32790051|NCT04638387|Placebo Comparator|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
32830532|NCT04349410|Experimental|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
32790052|NCT01728454|Placebo Comparator|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
32790053|NCT01728454|Experimental|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
32790054|NCT01728454|Experimental|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
32790055|NCT04568590|Experimental|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
32790056|NCT04568434|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
32790057|NCT04568434|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
32790058|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
33087306|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
33087307|NCT01685515|Placebo Comparator|Placebo|Placebo
33087308|NCT04527250|Experimental|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
33087309|NCT04527250|Experimental|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
33087310|NCT04527250|Experimental|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
33087311|NCT04527250|Experimental|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
33087312|NCT04527250|Experimental|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
32790059|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
32790060|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.~A blood sample will be taken on 1 day and at 1 time point."
32830533|NCT04349410|Experimental|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
33087313|NCT04527250|Placebo Comparator|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
33087314|NCT04527250|Placebo Comparator|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
33087315|NCT04527250|Placebo Comparator|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
33297696|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
33297697|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
33297698|NCT05371132|Experimental|Basic science (zirconium Zr 89-Df-crefmirlimab, PET, SBRT)|Patients receive zirconium Zr 89-Df-crefmirlimab IV over 5-10 minutes and then under PET imaging 24 hours after infusion before and after SBRT. Patients undergo SBRT every 2-5 days for a total of 5 fractions. For lymphoma patients only, IMRT on consecutive days may be used.
33087316|NCT04527250|Placebo Comparator|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
33297699|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
33297700|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
33297701|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
33297702|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
33297703|NCT04460482|Active Comparator|NIRS-guided PCI|Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
33087317|NCT04527250|Placebo Comparator|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
33087318|NCT04527484|Active Comparator|Group A|SHR-1314 Vial
33297704|NCT04460482|Active Comparator|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
33297705|NCT04459468||HCC for Lipiodol TACE|These patients will standard of care Lipiodol TACE treatment. No research intervention is planned
33297706|NCT04459468||Healthy controls|Healthy controls from public database
33297707|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
33297708|NCT04404400|Experimental|Active|For CIRCI patients: hydrocortisone + fludrocortisone therapy.
33297709|NCT04404400|Placebo Comparator|Placebo|For CIRCI patients: hydrocortisone placebo + fludrocortisone placebo
33297710|NCT03968198|Experimental|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
33297711|NCT04389112|Experimental|Patients with actinic keratoses|
33297712|NCT04389112|Experimental|patients with squamous cell carcinoma in situ|
33297713|NCT04389112|Experimental|patients with squamous cell carcinomas|
33087319|NCT04527484|Active Comparator|Group B|SHR-1314 PFS
33087320|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
33087321|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
33087322|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
33087323|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
33087324|NCT01685593|Experimental|abdominal binder|binder
33087325|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
33087326|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
33087327|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
33087328|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
33087329|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
33087330|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
33087331|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
33087332|NCT01685788||study participants|
33087333|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
33087334|NCT04527211|Experimental|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
33087335|NCT04527211|Placebo Comparator|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
33297714|NCT04389112|Experimental|patient with invasive metastates|
33297715|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
33297716|NCT05337748|Experimental|Experimental : Lexie Self Test and Fit Group (Lexie STF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
33297717|NCT05337748|Active Comparator|Control: Lexie Professional Test and Fit Group (Lexie PTF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
33297718|NCT00165698|Active Comparator|1|
33297719|NCT00165698|Active Comparator|2|
33297720|NCT05331196||Patients with colorectal cancer|Patients with colorectal cancer who underwent elective surgery.
33297721|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
33297722|NCT01075022|Experimental|Vitamin D|
33297723|NCT01075022|Placebo Comparator|Placebo|
33297724|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
33297725|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
33297726|NCT03944824|Experimental|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
33297727|NCT03944824|Placebo Comparator|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
33297728|NCT00225758|Experimental|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
33087336|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
33087337|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
33087338|NCT01685944|Placebo Comparator|Placebo|
33087339|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
33087340|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
33087341|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
33087342|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
33087343|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
33087344|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
33087345|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
33087346|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
33087347|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
32790061|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.~For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months).~However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months)."
32790062|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
32790063|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
32790064|NCT04568044||Group G: SARS-CoV-2 vaccinated pregnant/postnatal women|"Current pregnant or postnatal (within 6 weeks of birth) and due to receive the SARS-CoV-2 vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
32790065|NCT04568044||Group H: SARS-CoV-2 vaccinated non-pregnant women|"Non-pregnant and due to receive the SARS-CoV-2 vaccine (age 18-50 years old).~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
32790066|NCT01636687|Placebo Comparator|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
32790067|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
32790068|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
32790069|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|"Experimental: Cyclophosphamide and Bendamustine Control: Cyclophosphamide~Interventions:~Drug: Bendamustine~Drug: Cyclophosphamide"
32790070|NCT05213377|No Intervention|Group C|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will not receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
32790071|NCT05213377|Experimental|Group W|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
32790072|NCT04797169|Experimental|Noom Health|
32790073|NCT04797169|Active Comparator|Noom Digital Health|
33087348|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
33087349|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
33087350|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
33087351|NCT04719572|Other|Basic treatment group|elemental calcium 600mg/ day + vitamin D 1000IU/day
33087352|NCT04719572|Active Comparator|Basic treatment+ anti-osteoporosis drug group|alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
33087353|NCT04719572|Other|Basic treatment + non-drug treatment group|diet, exercise, rehabilitation therapy
33087354|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
33297729|NCT03945214|Experimental|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
33087355|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
33087356|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
33087357|NCT04528030|Other|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
33087358|NCT04528030|Other|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
33087359|NCT01686412|Active Comparator|Healthy patients|
33087360|NCT01686412|Active Comparator|Oncology patients|
32790074|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
32790075|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
32790076|NCT05652985|Experimental|interventional group|Inter-professional Collaboration Training
32790077|NCT05652985|No Intervention|control group|Regarding the control group, the participants will receive no training
32790078|NCT04418713|Experimental|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
32790079|NCT04418713|No Intervention|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
33087361|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
32790080|NCT05165641|Other|segmental spinal anesthesia|thoracic spinal anesthesia at T 10 level
32790081|NCT04796467|Experimental|68Ga-PSMA617 and 68Ga-P16-093 PET/CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/CT scan after intravenous administration of 68Ga-PSMA617 and 68Ga-P16-093, respectively.
32790082|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
33087362|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
33297730|NCT03945214|Experimental|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
33297731|NCT03945214|Experimental|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
33297732|NCT03945214|No Intervention|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
33297733|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
33297734|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
33297735|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
33297736|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
32790083|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
32790084|NCT04601467|Experimental|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
32790085|NCT04601467|Placebo Comparator|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
32790086|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
32790087|NCT04544293|Experimental|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
32790088|NCT04544293|Placebo Comparator|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
32790089|NCT05212207||PBH|
32790090|NCT05209633|Experimental|Active treatment (Granules Dendrobii)|6g each, 3 times per day, total 18 weeks
33087363|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
33087364|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
33087365|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
33087366|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
33087367|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
33087368|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
33087369|NCT05140720|Experimental|6 weeks - 6 months of age|Group 1: Age group from 6 weeks - 6 months
33087370|NCT05140720|Experimental|7 - 11 months of age|Group 2: Age group from 7 - 11 months
33087371|NCT05140720|Experimental|12 - 24 months of age|Group 3: Age group from 12 - 24 months
33087372|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
33087373|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
32790091|NCT05209633|Placebo Comparator|Placebo|6g each, 3 times per day, total 18 weeks
33087374|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
32790092|NCT05652829||Children aged 9-12|We are recruiting 30 children aged 9-12 with one parent.
32790093|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
32790094|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
32790095|NCT04499677|Experimental|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
32790096|NCT04499677|Placebo Comparator|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
32790097|NCT05652751|Placebo Comparator|sham EA + placebo group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the sham EA intervention.
32790098|NCT05652751|Active Comparator|EA + placebo group|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the EA intervention."
32790099|NCT05652751|Active Comparator|sham EA + NGF group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The 20ug nerve growth factor will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the sham EA intervention. Dose modification is not allowed for mNGF.
32790100|NCT05652751|Active Comparator|EA + NGF group|Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness . Then, the needles are stimulated by using an acupuncture point nerve stimulator , 28 days as a course of treatment, once a day;The 20ug nerve growth factor will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the EA intervention. Dose modification is not allowed for mNGF.
32790101|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
32790102|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
32790103|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
32790104|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
32790105|NCT02893267|Experimental|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
32790106|NCT02893267|Active Comparator|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
32790107|NCT02893267|Active Comparator|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
32790108|NCT04471909|Experimental|Chronic Dissection|
33087375|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
33087376|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
32790109|NCT04471909|Experimental|Aneurysm|
32790110|NCT04471909|Experimental|Penetrating Aortic Ulcer and/or Intramural Hematoma|
32790111|NCT04417699|Experimental|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
32790112|NCT02805517|Experimental|PEAL laparoscopic nephrectomy|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.
32790113|NCT02797561||Tandem lesion evaluated by FFR|
32790114|NCT05652595|Experimental|TR Sequence|first Intervention period - subjects are administered test medecine (GP40141) and in seconde Intervention period subjects are administered reference medecine (Nplate)
32790115|NCT05652595|Experimental|RT Sequence|first Intervention period subjects are administered reference medecine (Nplate) and in seconde Intervention period subjects are administered test medecine (GP40141)
32790116|NCT04418323|Active Comparator|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
32790117|NCT04418323|Active Comparator|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
32790118|NCT04418323|Active Comparator|Conventional seton|Conventional seton in the Management of anal fistula
32790119|NCT05652517|Active Comparator|Fluoroscopy-guided VOMEI|Vein of Marshall ethanol infusion guided by fluoroscopy alone
32790120|NCT05652517|Experimental|UNIVU-guided VOMEI|Vein of Marshall ethanol infusion guided by CARTO UNIVU and fluoroscopy
32790121|NCT05163847|Experimental|M2SR only dose|Intranasal M2SR vaccine and intramuscular placebo dose
32790122|NCT05163847|Experimental|M2SR with IIV dose|Intranasal M2SR vaccine and intramuscular IIV dose
32790123|NCT05163847|Active Comparator|IIV only dose|Intranasal placebo dose and intramuscular IIV dose
32790124|NCT05163847|Placebo Comparator|Placebo only dose|Intranasal placebo dose and intramuscular placebo dose
32790125|NCT04807153||Patients|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
32790126|NCT04807153||Healthy Controls|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
32790127|NCT04196569||trifocal intraocular lens|
32790128|NCT04806373|Placebo Comparator|Talc Slurry Pleurodesis (TSP) plus placebo|Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.
32790129|NCT04806373|Experimental|Talc Slurry Pleurodesis (TSP) plus Cathflo Activase|Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter
32790130|NCT02720419||Synergy stent|
32790131|NCT02619253|Experimental|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
32790132|NCT02619253|Experimental|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer.
32790133|NCT04804579|Experimental|Fall Prevention Intervention|"The Intervention involves 3 primary components: virtual group sessions, at-home exercises, and weekly phone check-ins.~Virtual Group Session will be held via phone/video call for approximately 30 minutes per week for 10 weeks.~At-Home Exercises will be assigned by a registered occupational therapist member of the study team, and participants will be instructed to complete them independently at home 3 times per week. Participants will record the exercises that they complete.~Weekly Phone Check-Ins will occur once per week. These check-ins will be used to provide support and problem solving as needed, and individualized reminder systems will be set up to prompt the participant to engage in their weekly exercises (e.g., set up alarm on phone, notifications through calendar app)."
32790134|NCT04804579|No Intervention|Control Group|Participants will be provided with an educational pamphlet that includes resources related to falls and alcohol use.
32790135|NCT04795141|Active Comparator|Group A|ABY-035 SC injection Cohort 1
32790136|NCT04795141|Active Comparator|Group B|ABY-035 SC injection Cohort 1
32790137|NCT04795141|Active Comparator|Group C|ABY-035 SC injection Cohort 1
32790138|NCT04795141|Placebo Comparator|Group D|Placebo injection Cohort 1
32790139|NCT04795141|Active Comparator|Group E|ABY-035 SC injection Cohort 2
32790140|NCT04795141|Active Comparator|Group F|ABY-035 SC injection Cohort 2
32790141|NCT04795141|Placebo Comparator|Group G|Placebo injection Cohort 2
32790142|NCT05652361|Experimental|Additional visualisation of surgical assistance during surgery|
32790143|NCT05652283|Experimental|experience group|Pamiparib 40 mg, BID, oral, 3 weeks as a cycle Surufatinib 250 mg, QD, oral, 3 weeks as a cycle
32790144|NCT05652049||short-term peritoneal dialysis|the time of treatment of peritoneal dialysis less 12 months
32790145|NCT05652049||long-term peritoneal dialysis|the time of treatment of peritoneal dialysis more than 10 years
32790146|NCT04137211|Experimental|Prolonged sitting with social break|
32790147|NCT04137211|Experimental|Prolonged sitting with walk break|
32790148|NCT04137211|Experimental|Prolonged sitting with simple resistance activities|
32790149|NCT05651815|Experimental|Graphene adjuvant therapy combined with conventional therapy group (treatment group)|Graphene adjuvant therapy combined with conventional therapy group (treatment group)：Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.
32790150|NCT05651815|No Intervention|Conventional therapy group (control group)|Conventional therapy group (control group)：Patients will only receive the conventional treatment for COVID-19.
32790151|NCT04136275|Experimental|CAR-37 T cells|"CAR-37 will be administered intravenously on day 0~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0"
32790152|NCT04136275|Experimental|CAR-37 T cells Dose Escalation|"CAR-37 will be administered intravenously on day 0~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~CAR-37 will undergo dose escalation"
32790153|NCT04132219|Experimental|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
33297737|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
32790154|NCT04132219|Other|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
32790155|NCT03998293|Other|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
32790156|NCT05651503|Experimental|Experimental group 1: patients, age 12-18, conventional brackets, Oral probiotics lozenges|30 patients, age 12-18,with conventional brackets,will get Oral probiotics lozenges
32790157|NCT05651503|Experimental|Experimental group 2: patients, age ≥18, Invisalign™ appliances, Oral probiotics lozenges|30 patients, age ≥18, Invisalign™ appliances,wil get Oral probiotics lozenges
32790158|NCT05651503|Placebo Comparator|Control group 1: patients, age 12-18, conventional brackets, placebo lozenges|30 patients, age 12-18, conventional brackets,will get placebo lozenges
32790159|NCT05651503|Placebo Comparator|Control group 2: patients, age ≥18, Invisalign™ appliances, placebo lozenges|30 patients, age ≥18, Invisalign™ appliances,will get placebo lozenges
32790160|NCT05651425||surgeon-independent group|the coiling diameter is predicted by experienced surgeon alone.
32790161|NCT05651425||surgeon-software-assistant group|the coiling diameter is predicted by experienced surgeon with software assistant.
32790162|NCT04793737|Experimental|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
32790163|NCT01755598|Experimental|M72AS01 Group|Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
32790164|NCT01755598|Placebo Comparator|Control group|Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
32790165|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
32790166|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
32790167|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
32790168|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
32790169|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
32790170|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
32790171|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
32790172|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
32790173|NCT04567108|Active Comparator|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs
32790174|NCT04567108|Experimental|Substitute Aspartame ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame
32790175|NCT04567108|Experimental|Substitute Sucralose ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose
32790176|NCT04567108|Experimental|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water
33297738|NCT05330260||Endo-CABG|Group that underwent retrograde arterial cardiopulmonary bypass flow.
33297739|NCT05330260||PCI|Surgical control group
33297740|NCT05330260||Healthy controls|Non-surgical control group
32790177|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype1|
32790178|NCT01753570|Experimental|RBV+IFN beta, Genotype1|
33297741|NCT03968354||Steatosis group - Experimental1|Steatosis group
33297742|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
33297743|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
32790179|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype2|
32790180|NCT01753336|Experimental|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
32790181|NCT01777282|Active Comparator|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
32790182|NCT01777282|Active Comparator|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
32790183|NCT01777282|Active Comparator|Albiglutide + Glinide|Albiglutide in combination with background glinide
32790184|NCT01777282|Active Comparator|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
32790185|NCT01777282|Active Comparator|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
32790186|NCT04169776|Experimental|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
32790187|NCT04169776|Experimental|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
32790188|NCT04571632|Active Comparator|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
32790189|NCT04571632|Active Comparator|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
32790190|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
32790191|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
32790192|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
32790193|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
32790194|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
32790195|NCT01945593|Experimental|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
32790196|NCT01945593|Experimental|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
32790197|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
32790198|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
32790199|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
32790200|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
32790201|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
32790202|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
32790203|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
32790204|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
33297744|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
33297745|NCT03968354||Control group - Active Comparator|Control group
33297746|NCT03947944|Active Comparator|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
33297747|NCT03947944|Active Comparator|vector planning group|The subjects underwent SMILE using vector planning.
33087377|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
33087378|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
33087379|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
32737747|NCT05048277|Experimental|Single Arm Study|"The intervention will consist of one 60-minute long session conducted through NYU ZOOM. Each session will be between one parent and one study consultant. The session is goal-oriented and solution-focused. During the SSC, consultants will identify the participant's hope for the session and a specific modifiable goal. From this, the consultant will discuss the smallest-possible step participants can take toward overcoming their identified problem and work together in creating an Action Plan, which will present three specific actions the participant can take to accomplishing the session's established goals. Following completion of the two-week follow-up assessment, additional resources personalized to participants will also be provided (i.e., referrals for further services and online resources for parents/children). Ultimately, this intervention is a way to potentially jumpstart progress and facilitate hope and agency."
33087380|NCT00253721|Experimental|All subjects|
33087381|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
33297748|NCT05326750|Experimental|Real tACS|Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
33297749|NCT05326750|Placebo Comparator|Sham tACS|Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)
32737748|NCT05025969||Glioma|(20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
32737749|NCT05025969||Brain metastasis|"The brain metastasis cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available"
32737750|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
32737751|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
32737752|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
32737753|NCT05048355|Experimental|Power Knee Mainstream Dynamic|
32737754|NCT05048355|Active Comparator|Passive MPK|
32737755|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
32737756|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
32737757|NCT05464589|Experimental|Transcutaneous Tibial Nerve Stimulation + Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises along with the transcutaneous tibial nerve stimulation.~Pelvic Floor Muscle-strengthening exercises - Kegels' exercises 15 repetitions, 3 times a day For 6 weeks, daily.~Transcutaneous Tibial Nerve Stimulation for 30 minutes on the right lower limb 6 sessions, one per week."
32737758|NCT05464589|Active Comparator|Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises.~Pelvic floor muscle exercises - Kegels; exercises 15 repetitions, 3 times a day For 6 weeks, daily."
32737759|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
32737760|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
32737761|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
32737762|NCT03093831|Experimental|Ibrutinib|
32737763|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
32737764|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
32737765|NCT05025891|No Intervention|Arm 1: control|Patients continue consultations as usual in HDJA or at UMIT.
32737766|NCT05025891|Experimental|Arm 2: teleconsultation alone|Patients are directed to the tele-monitoring platform without specific accompaniment.
32737767|NCT05025891|Experimental|Arm 3: teleconsultation and mediation|Patients are referred to the tele-monitoring platform with specific support with mediation.
32737768|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
33087382|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
32790205|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
32790206|NCT04661397|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
32790207|NCT04661397|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COBI] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
32790208|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
32790209|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
32790210|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
32790211|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
32790212|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
32790213|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
32790214|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
32790215|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
32790216|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
32790217|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
32790218|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
32790219|NCT04416165|Experimental|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
33087383|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
33087384|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
33297750|NCT01104532|Experimental|Dosing Regimen 1|
32790220|NCT01774786|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
32790221|NCT01774786|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
32790222|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
32790223|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
32790224|NCT04654845|Experimental|Pulpotomy|Only the tissue in the pulp chamber will be removed.
32790225|NCT04654845|Active Comparator|Pulpectomy|Both the chamber´s and root´s pulp tissue will be removed up to a 25 gauge.
32790226|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
32790227|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
32790228|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
32790229|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
33087385|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
33087386|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
33087387|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
33297751|NCT01104532|Experimental|Dosing Regimen 2|
33297752|NCT01104532|Experimental|Dosing Regimen 3|
32790230|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
32790231|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
32790232|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
32790233|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
32790234|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
32790235|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
32790236|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
32790237|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
32790238|NCT04661241|Experimental|Investigational Scan|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging if subjects agree to participate.
32790239|NCT04661241|Active Comparator|Current Clinical Practice|All patients will undergo a routine clinical preoperative MRI of the brain under general anesthesia to reduce movement artifacts.
32790240|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
32790241|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
32790242|NCT04653831|Other|Standard of Care - Control|Standard of care (Soc) according to current guidelines and the discretion of treating physician.
32790243|NCT04653831|Experimental|Pirfenidone Treatment|"In addition to SoC, Pirfenidone 2,403 mg administered orally or per nasogastric tube as 801mg TID, for 4 weeks.~Pirfenidone dose will be 2,403mg daily, from day one of admission to the ICU, titrated over 3 days:~Day 1 - 801mg x 1/d (801mg) Day 2 - 801mg x 2/d (1,602 mg) Day 3 - 801mg x 3/d (2,403 mg) Feeding and medication delivery will be upon the discretion of the treating physician according to tolerability. Powdered 801mg tablets will be administered through the nasogastric tube: Each tablet will be crushed and dissolved in 20cc of water. The nasogastric tube will be flushed afterwards to avoid obstruction..~If the patient is able to swallow and the nasogastric tube is removed, pirfenidone will continue to be delivered orally."
32790244|NCT04653753|Experimental|Orthosis Group|Use of kneeSOFT500 device
32790245|NCT04653753|No Intervention|Control Group|No use of the device
32790246|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
32790247|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
32790248|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
32790249|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
33087388|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
33297753|NCT01104532|Experimental|Dosing Regimen 4|
33297754|NCT03945916|Experimental|Dark chocolate|180g/d dark chocolate
33297755|NCT03945916|Placebo Comparator|Placebo|180g/d of artificial dark chocolate
33297756|NCT03945682|Experimental|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
32790250|NCT01708954|Experimental|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32790251|NCT01708954|Experimental|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32790252|NCT01708954|Experimental|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32790253|NCT01708954|Experimental|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32830534|NCT04349410|Experimental|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
33297757|NCT03945682|No Intervention|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
32790254|NCT01939899|Experimental|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
32790255|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
32790256|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
32790257|NCT01970241|Experimental|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
32790258|NCT01970241|Active Comparator|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
32790259|NCT01939353|Experimental|Centanafadine SR 100-500 mg|Following a 1-week SB placebo run-in treatment, participants with <30% improvement and ≥28 total score on Adult ADHD-RS-IV scale score received centanafadine (CTN) 100 mg, sustained release (SR) tablet, once daily (1 tablet in the morning) on Days 1 and 2, followed by 200 mg, SR tablets, twice daily (1 tablet in the morning and 1 tablet 5 hours later) on Days 3 and 4, followed by 300 mg, SR tablets, twice daily (2 tablets in the morning and 1 tablet 5 hours later) on Days 5, 6, and 7. After 1 week of treatment, CTN doses were maintained or titrated in 100-mg increments up to the maximum of 500 mg daily or reduced based on the safety and tolerability, as judged by the investigator at Weeks 2, 3 and 4.
32790260|NCT01970007|Experimental|Zilver Vena Venous Self-Expanding Stent|
32790261|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
32790262|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
32790263|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
32790264|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
32790265|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
32790266|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
32790267|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
32790268|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
32790269|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified~**Not participating: Japan, Korea, and Taiwan"
33087389|NCT02276443|Experimental|Arm A (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, after 4 cycles of treatment, and after completion of treatment (before surgery). Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
32790270|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
32790271|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~**Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~**Not participating in cohort expansion: France, Germany, Korea and Taiwan"
32790272|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
33102392|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
32790273|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
32790274|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
32790275|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
32790276|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
32790277|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
32790278|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
32790279|NCT02416609|Experimental|Gem-based doublets with LDR & sequential SBRT|Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.
32790280|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
33087390|NCT02276443|Experimental|Arm B (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
32790281|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
32790282|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
32790283|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
32790284|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
32790285|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
32790286|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
32790287|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
32790288|NCT04791553|Experimental|Normal Hepatic Function|Group 1 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to Matching healthy subjects with normal hepatic function
32790289|NCT04791553|Experimental|Hepatic Impairment|Group 2 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to subjects with severe hepatic impairment
32790290|NCT04192747|Experimental|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
32790291|NCT04192747|Active Comparator|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
32790292|NCT05651347|Placebo Comparator|Placebo|Visually identical placebo tablets containing no active ingredient to the active treatment, administered three times a day.
32790293|NCT05651347|Active Comparator|Melatonin|10mg Melatonin tablets, administered three times a day (a total daily dose of 30mg per day)
32790294|NCT05651269|Experimental|Milciclib plus gemcitabine|"Name: milciclib Dose: 150 mg/day Mode of administration: oral~Combination product:~Name: gemcitabine Dose: 1000 mg/m2 Mode of administration: intravenous"
32790295|NCT05650255|Experimental|A Digital Twin for Exoskeleton Pilot|This project is expected to use different machine learning models to make accurate predictions of human intent when healthy people drive different actions or action transitions of common human actions. Drivers will wear sensors such as inertial measurement unit (IMU) and electromyography (EMG) in the lower limbs to measure body signals of participants during actions in a non-invasive way, and let the system calculate the joint angle, angular velocity and angular acceleration of each joint of the driving lower limb related human signals.
32790296|NCT03887455|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|
32790297|NCT03887455|Placebo Comparator|Core Study: Placebo|
32790298|NCT03887455|Experimental|Extension Phase: Lecanemab 10 mg/kg biweekly|
32790299|NCT03887455|Experimental|Extension Phase: Lecanemab 720 mg Subcutaneous Injection Weekly|This will include approximately 40 de novo participants (those that did not participate in the core study) with early Alzheimer disease (AD).
32790300|NCT05647525||status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis|To study the relationship between autoimmune-related antibody titres and prognosis during the six-month follow-up
32790301|NCT04791163|Experimental|Sub-ischial socket|Start using the sub-ischial socket for four weeks and be tested with this socket.
32790302|NCT04791163|Active Comparator|Ischial containment socket|Start using the ischial containment socket for four weeks and be tested with this socket.
32790303|NCT05638009|No Intervention|Control|regular salt (99% sodium chloride)
32790304|NCT05638009|Experimental|Salt substitute 1|Salt substitute 1 is a potassium-enriched salt substitute composed of 66% potassium chloride and 33% sodium chloride
32790305|NCT05638009|Experimental|Salt substitute 2|Salt substitute 2 is a potassium-enriched salt substitute composed of 33% potassium chloride and 66% sodium chloride
32790306|NCT05636683|Experimental|Periodontitis treated with Root surface debridement|Immediately after inclusion in the study, the patient's examination with saliva sampling will be conducted as follows: At a base line visit (Zero time visit), subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
32790307|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
32790308|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
32790309|NCT03759379|Experimental|Vutrisiran + Vutrisiran (HELIOS-A)|Participants will receive vutrisiran 25 mg subcutaneous (SC) injection once every 3 months (q3M) for 18 months during the Treatment Period followed by vutrisiran SC injection once every 6 months (q6M) or q3M during the Randomized Treatment Extension (RTE) Period.
32790310|NCT03759379|Active Comparator|Patisiran + Vutrisiran (HELIOS-A)|Participants will receive patisiran 0.3 mg/kg intravenous (IV) infusion once every 3 weeks (q3w) for 18 months during the Treatment Period followed by vutrisiran SC injection q6M or q3M during the RTE Period.
32790311|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
32790312|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
32790313|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
32790314|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
32790315|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790316|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790317|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790318|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790319|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790320|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
32790321|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
32790322|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
32790323|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
32790324|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:~Capecitabine~Eribulin~Gemcitabine~Paclitaxel~Nab-paclitaxel"
32790325|NCT04778761|No Intervention|Usual Care|Usual care entails receiving usual medical care by the home-based care team.
32790326|NCT04778761|Experimental|Video intervention|In addition to usual care, the intervention will entail having a visit by a trained study clinician to provide access to the ACP video. The study clinician will discuss the content of the video and answer any questions.
32790327|NCT05182645|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
32790328|NCT05182645|Active Comparator|waiting control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
33087391|NCT02276443|Experimental|Arm C (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy with immunotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype
32790329|NCT01969851|Experimental|Lacosamide|
32790330|NCT04801771|Experimental|Subjects implanted with Inspire UAS System|Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
32790331|NCT05179837|Experimental|Optical coherence tomography (OCT) probe|After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.
32790332|NCT04661085||Patients with a suspected infection|Acutely admitted patients from the emergency department across 3 sites who have a suspected infection.
32790333|NCT04659759||COVID-19 Positive|Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
32790334|NCT04659759||COVID-19 vaccine|Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
32790335|NCT04659759||Controls|Reproductive age women exposed to COVID-19 vaccine
32790336|NCT04659759||Pregnant Control|Pregnant women who delivered at TJUH, COVID negative
32790337|NCT05560243|Experimental|Intervention|Patients will receive a tobacco cessation intervention
32790338|NCT05553847|No Intervention|Usual oxygen dose|A Glittre-ADL tests will be performed and the patients will use their usual fixed dose of oxygen. Pulse rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
32790339|NCT05553847|Experimental|Automated oxygen dose|A Glittre-ADL tests will be performed and the patients will use automated oxygen titration set at an SpO2-target of 90 to 94 % and an oxygen flow of 0 - 8 liters/min. Pulse rate, oxygen flow rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
32790340|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
32790341|NCT05546515|Active Comparator|Suvorexant|20mg Suvorexant
32790342|NCT05546515|Placebo Comparator|Placebo|Placebo oral capsules
32790343|NCT05496907|Experimental|Intervention|"After the participants consent, they will be asked to complete 7 validated questionnaires. An interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. A physical assessment will be conducted including Blood pressure, BMI and Blood Tests for HbA1c, Glucose test, Total Cholesterol, Renal Function.~Participants in the intervention arm will see the diabetes nurse up to 10 times, during these sessions motivational interviewing will be used to discuss areas to improve, goal setting and action planning. Participants and the nurse will collaboratively discuss practical strategies to improve their HbA1c, blood pressure, cholesterol, BMI and mental health.~The same measures that were completed at the beginning will be re-assessed again at 6 months."
32790344|NCT05496907|No Intervention|Control|Participants will be asked to complete the same 7 validated questionnaires, the brief psychiatric rating scale and a physical health assessment at the start. The will continue to receive standard care from their usual care professionals. The same measures that were completed at the beginning will be re-assessed again at 6 months.
32790345|NCT05362981|Experimental|CAT|induction of cognitive dissonance
32790346|NCT05362981|Experimental|MBCT|TCA-specific mindfulness approach
32790347|NCT05362981|No Intervention|TAU|usual support
32790348|NCT04777513||Standard of care: FFR, ICA, CCTA|Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with Cardiolens FFR-CT Pro technology.
32790353|NCT03542695|Experimental|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
32790354|NCT05169931|Experimental|Study group|Treatment group to receive study drops (RegenerEyes) twice daily for 12 weeks
32790355|NCT04789837|Experimental|Cilostazol|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
32790356|NCT04789837|Placebo Comparator|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
32790357|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
32790358|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
32790359|NCT04789681|Experimental|Prevention (canakinumab)|Patients receive canakinumab SC on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
32790360|NCT05167669|Other|Prospective, interventional, single-center, feasibility pilot study.|10 patients with radiologically confirmed bone metastases and eligible for a course of palliative EBRT. Eligible patients will be mainly discussed and recruited in a dedicated tumor-board for bone metastases performed in a weekly basis at HUG.
32790361|NCT05167201|Experimental|Nasal High Flow|"The Nasal High Flow device is an integrated flow generator that delivers warmed and humidified air to spontaneously breathing patients through a variety of patient interfaces.~Flow rates up to 60 litres/minute are available to the user, depending on the patient interface and mode of operation."
32790362|NCT02000089|Active Comparator|Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and~have a first-degree relationship with at least one of the relatives with pancreatic cancer.~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
33087392|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
33087393|NCT02274571|Placebo Comparator|Placebo|Non active comparator
32737769|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
32737770|NCT03235297||Healthy subjects|Healthy subjects
32737771|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
32737772|NCT03093987|No Intervention|control group|usual care
32737773|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
32737774|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
32737775|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
32737776|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
32737777|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
32737778|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
32737779|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
32737780|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
32737781|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
32737782|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
32737783|NCT05048121|Experimental|CLS02021 - Investigational Product arm|Cosmetic cream with proprietary cosmetic ingredient CLS02021.
32737784|NCT05048121|Placebo Comparator|PLC01021 - Placebo Control arm|Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.
32737785|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
32737786|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
32737787|NCT05026515||4 years and under|Children coming at dental appointment, aged 4 years and under
32737788|NCT05026515||5 to 6 years|Children coming at dental appointment, aged 5 to 6 years
32737789|NCT05026515||7 years and over|Children coming at dental appointment, aged 7 years and over
32737790|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
32737791|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
32737792|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
32737793|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
32737794|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
32737795|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
32737796|NCT05025579|Experimental|Exercise group|Considering the protocol suggested in the literature and by examining exercise samples for geriatric individuals, an exercise protocol was created. The first week started with aerobic exercises with a total of 120 minutes, and the next week increased to 160 minutes . A 6-week exercise program was planned and applied 4 days a week in which the intensity was increased gradually. People 's heart rate, blood pressure and respiratory frequency exercise program implementation before and after was recorded in the evaluation form.
32737797|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
32737798|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
32737799|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
32737800|NCT05025189|Active Comparator|Table Grape|Subjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
32790363|NCT02000089|Active Comparator|Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):~a. > 50 years old or 10 years younger than the age of the youngest relative affected, if pancreatic cancer is in family, and b. The Patient is a carrier of a confirmed BRCA2, ATM or PALB2 mutation, regardless of family history of pancreatic cancer. b.> Individual is a carrier of a confirmed FAMMM (p16/CDKN2A) mutation, age 40 years or older, regardless of family history of pancreas cancer."
32790364|NCT02000089|Active Comparator|Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and~The patient is a carrier of a confirmed BRCA1 or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
33297758|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
32790365|NCT02000089|Active Comparator|Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
32790366|NCT02000089|Active Comparator|Peutz-Jeghers Syndrome|"At least 30 years old, and~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,~known STK11 gene mutation carrier"
32790367|NCT02000089|Active Comparator|Negative control|"are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
32790368|NCT02000089|Active Comparator|Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,~have no clinical or radiologic suspicion of pancreatic cancer"
32790369|NCT02000089|Active Comparator|Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
32790370|NCT02000089|Active Comparator|Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
32790371|NCT01981993||patients at ICU with sepsis|
32790372|NCT05166187|Experimental|Intervention|Patients randomized to the intervention arm will have a Best Practice Advisory (BPA) displayed as part of the discharge order workflow. This BPA requires clinicians to choose an option before completing the discharge documentation. Options include ordering one of the appropriate statins or documenting that the medication is contraindicated, the patient declined, or the patient does not meet criteria for a high-intensity statin.
32790373|NCT05166187|No Intervention|Usual Care|Patients randomized to the usual care arm will have the identical set of windows displayed in the discharge workflow minus the BPA window.
32790374|NCT04788901|Experimental|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
32790375|NCT03329521|Experimental|Multi-component quality improvement intervention|A multi-component quality improvement intervention will be provided at chronic kidney disease (CKD) programs.
32790376|NCT03329521|No Intervention|Usual Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
32790377|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
32790378|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
32790379|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
33087394|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
33087395|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
33297759|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
33297760|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
33297761|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
33297762|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
33297763|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
33297764|NCT03971500|Experimental|IVUS-guidance|In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is >5.0 mm^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is <55%; and 3) absence of >=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.
33297765|NCT03971500|Active Comparator|Angiography-guidance|In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of >Type B dissection.
33087396|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
32790380|NCT01942135|Experimental|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
33087397|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
33087398|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
33087399|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
33087400|NCT01687348|Experimental|lidocaine|lidocaine traitment
33087401|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
33087402|NCT01687426|Placebo Comparator|Vehicle|
33087403|NCT04719689|Experimental|Dry needling|Dry needling, hot pack, stretching exercises.
33087404|NCT04719689|Experimental|Dry Cupping|Dry cupping, hot pack, stretching exercises.
33087405|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
33087406|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
33087407|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
33087408|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
33087409|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
33087410|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
33297766|NCT03971500|Experimental|SAPT group|Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.
33297767|NCT03971500|Active Comparator|DAPT group|Ticagrelor + aspirin for 12 month.
33297768|NCT00259298|Experimental|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
32790381|NCT01942135|Active Comparator|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
32790382|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
32790383|NCT04775875|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the caudate. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
33087411|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
33087412|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
32790384|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|Daily vitamin D placebo and daily fish oil placebo
32790385|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|Daily vitamin D placebo and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
33297769|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
33297770|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
32790386|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|Daily vitamin D (2,000 IU/d) and daily fish oil placebo
32790387|NCT01747447|Active Comparator|Vitamin D + fish oil|Daily vitamin D (2,000 IU/d) and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
32790388|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
33087413|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
33087414|NCT01687699|Experimental|spironolactone|
33297771|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
33297772|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
33297773|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
32790389|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
33297774|NCT01075334|Active Comparator|Folate and Zinc|
32790390|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
33087415|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
33087416|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
33087417|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
33087418|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
33087419|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
33087420|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
33087421|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
32790391|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
32790392|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
32790393|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
32790394|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
32790395|NCT04775407||Screening|Serological SARS-CoV-2 test
32790396|NCT05380063|Active Comparator|Dual Antiplatelet Therapy (DAPT)|DAPT with ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year after CABG.
32790397|NCT05380063|Experimental|De-escalated Dual Antiplatelet Therapy (De-DAPT)|De-DAPT referred to ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switch to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
33403912|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
33403913|NCT04029844|Experimental|Colibri Device|Treatment
32790398|NCT02740699|Other|Moderate to High Statin Treatment in Participants with Coronary Artery Plaque|Participants with coronary artery plaque will receive moderate to high statin treatment at either 20-40 mg once daily Rosuvastatin or 40-80 mg once daily of Atorvastatin.
32790399|NCT05349955|Experimental|Intensive guideline algorithm implementation|SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk. The targets of intervention will be achieved at HbA1C <7%, blood pressure <130/80mmHg， LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD.
32790400|NCT05349955|Active Comparator|Conventional guideline algorithm implementation|Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians.
32790401|NCT01287091|Experimental|Part 1|
32790402|NCT01287091|Experimental|Part 2|
32790403|NCT01287091|Experimental|Part 3: Group A|
32790404|NCT01287091|Experimental|Part 3: Group B|
32790405|NCT01269463|Experimental|Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Placebo: Capsule without active drug for 1 week Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Dosed once daily in the morning"
32790406|NCT01269463|Experimental|Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Placebo: Capsule without active drug for 1 week Dosed once daily in the morning"
32790407|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
32790408|NCT05362825||Un-resectable synchronous liver limited metastasis colorectal cancer|Un-resectable synchronous liver limited metastasis colorectal cancer patients undergoing neo-adjuvant chemotherapy FOLFOXIRI regimen, up to 12 cycles.
32790409|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
33087422|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
32790410|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
32790411|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
33087423|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
33087424|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
33087425|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
33087426|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
32790412|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
32790413|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
32790414|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
33087427|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
33087428|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
33087429|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
32790415|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
33297775|NCT03892642|Experimental|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
33297776|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
33297777|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
33297778|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
33297779|NCT03947554|Experimental|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
32790416|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
32790417|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
33297780|NCT03947554|Active Comparator|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
33297781|NCT03947554|Placebo Comparator|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
33297782|NCT04370626||Registry Group|Patients who sustain and present with a PLI injury will have two options for participating in the study. This first arm will evaluate clinical presentations, patient demographic, treatment methods and baseline patient-rated and radiographic outcomes. However, no research-related follow up visits will be conducted. Ongoing data from these participants will be collected from chart reviews of clinical follow-ups alone.
33297783|NCT04370626||Prospective Group|Participants who choose to enroll in the prospective arm will experience the same baseline data collection as those in the registry, with the addition of research-related follow up appointments that will allow research staff to measure and assess patient-rated and clinical outcomes, such as questionnaires and range of motion data.
33297784|NCT04370626||Retrospective Group|In this group, a chart review will be conducted to identify previously treated patients with perilunate injuries. Once identified, the patient will be contacted and ask if they are willing to come in for a long-term follow up visit where clinical, patient-rated, and radiographic data will be collected. If patients are unwilling to attend a long-term visit, our analysis will still include data collected from their chart reviews and electronic questionnaires.
33297785|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
33297786|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
32790418|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
32790419|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
33297787|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
33297788|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
33297789|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
33297790|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
33297791|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
33297792|NCT03849820|Active Comparator|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
33297793|NCT03849820|Active Comparator|Open partial nephrectomy|Open partial nephrectomy surgery
33297794|NCT03844672|Experimental|Low Concentration / Low Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a low power for three weeks.
32790420|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
32790421|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
32790422|NCT04497454|Active Comparator|ARDSNet|ARDSNet protocol (low PEEP-FiO2 table). Ventilatory mode: volume-controlled ventilation Tidal volume (VT) will be adjusted to 4-6 mL/Kg of PBW and Plateau pressure < 30 cmH2O for the at least the first 12 hours after inclusion in the protocol pH should be maintained between 7.35-7.45 Oxygenation (SpO2) target ranges 90-95% Maximum respiratory rate = 35 breaths/min PEEP and FIO2 adjusted according to the low PEEP-FiO2 Table.
32790423|NCT04497454|Experimental|EIT-Group|The goal is to maintain driving pressure (DP) < 16 cmH2O. Ventilatory mode: pressure-controlled ventilation After a recruitment a maneuver, PEEP will be chosen according to a PEEP titration maneuver monitored with electrical impedance tomography Plateau pressure may exceed 30 cmH2O and VT may exceed 6 mL/Kg if DP < 16 cmH2O pH should be maintained between 7.15-7.40 Oxygenation (SpO2) target ranges 90 -95% Maximum respiratory rate = 50 bpm
33087430|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
33297795|NCT03844672|Experimental|Low Concentration / High Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a high power for three weeks.
33297796|NCT03844672|Experimental|High Concentration / Low Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a low power for three weeks.
32790424|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
32790425|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
32790426|NCT01937559|Experimental|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
32790427|NCT01937559|Placebo Comparator|Saline|Normal saline
32790428|NCT01937559|Active Comparator|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
32790429|NCT04634331|Active Comparator|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
33297797|NCT03844672|Experimental|High Concentration / High Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a high power for three weeks.
32790430|NCT04634331|Experimental|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
33297798|NCT03945526|Active Comparator|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
33297799|NCT03945526|Placebo Comparator|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
33297800|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
32790431|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
32790432|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
32790433|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
32790434|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
33297801|NCT03761212||Healthy controls|Age and sex matched healthy controls
32790435|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
33297802|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
33087431|NCT00253877|Other|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
33087432|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
33087433|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
33297803|NCT01105156||Gastric Band Patients|
33297804|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
33297805|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
33297806|NCT03945058|Experimental|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
33297807|NCT03945058|Sham Comparator|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
33087434|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
33087435|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
33087436|NCT01688245|No Intervention|Control|No SMS dialog
33087437|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
33087438|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
33087439|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
33087440|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
33087441|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
33087442|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
33087443|NCT00288132|Active Comparator|Usual Care|
33087444|NCT00288132|Experimental|Intervention|
33087445|NCT00253916|No Intervention|Control Arm|No exercise measured
33297808|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
32737801|NCT05025189|Placebo Comparator|Beige Diet|Subjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
32737802|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
33297809|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
33297810|NCT01108120|Experimental|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
33297811|NCT05268250|Experimental|R2D2 mHealth treatment for diabetes distress|This is a mHealth supported, cognitive behavioral treatment for parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program
33297812|NCT05268250|No Intervention|Standard Care Control|Parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program will receive local resources (print or electronic).
32737803|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
33297813|NCT01105234|Experimental|Calcipotriol ointment|
33297814|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
33297815|NCT01108198|Placebo Comparator|moisturizer|
33297816|NCT05237674|Experimental|Intervention schools|School children exposed to 1-2 weekly sessions, a total of at least five hours pr week, of education outside the classroom.
32737804|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
33087446|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
33297817|NCT05237674|No Intervention|Waiting control schools|The waiting control schools will receive the two-day training course on EOtC one year later immediately after post measurements are conducted.
32737805|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
32737806|NCT05047809|Experimental|"Jingchuang Ointment(JCO) group"|"Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration. Besides, JCO was applied once a day on the wounds, last 3 months.~Jingchuang Ointment (JCO) is made by Chuang Song Zong Pharmaceutical Co., Ltd. (Taiwan)"
32737807|NCT05047809|Other|Regular treatment group|Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration.
32737808|NCT03240913|Experimental|Treatment Group|
32737809|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
32737810|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
32737811|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
32737812|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
32737813|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
32737814|NCT01191697|Experimental|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
32737815|NCT05026359|Experimental|Bilateral ankle coordination training group|Exercise training of bilateral ankle coordination training group consisted of 30 minutes of bilateral ankle coordination training 3 days per week for 4 weeks (total 12 sessions)
32790436|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
33087447|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
32790437|NCT04633551|Experimental|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
32790438|NCT04633551|No Intervention|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
32790439|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
32790440|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
32790441|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
32790442|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
32790443|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
32790444|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
32790445|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
32790446|NCT04648839||Benralizumab|Patients that received at least one dose of benralizumab according to routine clinical practice
32790447|NCT04625127|Experimental|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
32790448|NCT04625127|Experimental|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
33297818|NCT03947710|Experimental|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
32790449|NCT01959243|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
32790450|NCT01959243|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
33297819|NCT03947710|Experimental|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
33297820|NCT03947710|Experimental|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
33297821|NCT03945370|Active Comparator|Intervention sequence 1|Ketone drink first - Placebo drink secondly
33297822|NCT03945370|Placebo Comparator|Intervention sequence 2|Placebo drink first - Ketone drink secondly
33297823|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
33297824|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
33297825|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
33297826|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
33297827|NCT04250662|Experimental|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
32790451|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
32790452|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
32790453|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
32790454|NCT01959165|Placebo Comparator|Placebo|Double blinded
32790455|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
33087448|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
33297828|NCT04250662|Experimental|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
33297829|NCT04250662|Sham Comparator|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
32790456|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
32790457|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
32790458|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
32790459|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
32790460|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
32790461|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
32790462|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
32790463|NCT01752634|Experimental|Secukinumab (AIN457) 75 mg s.c.|Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
32790464|NCT01752634|Experimental|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
32790465|NCT01752634|Experimental|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
32790466|NCT01752634|Placebo Comparator|Placebo s.c.|Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.
32790467|NCT01933113|Experimental|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
32790468|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
32790469|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
32790470|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
32790471|NCT04787341|Active Comparator|Panitumumab followed by Regorafenib|
33297830|NCT04250662|Sham Comparator|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
32790472|NCT04787341|Experimental|Regorafenib followed by Panitumumab|
32790473|NCT05278039|Experimental|Respiratory-Swallow Phase Training|Participants will be trained to initiate swallowing during expiration.
32790474|NCT05278039|Sham Comparator|Swallow Practice|Participants will practice swallowing, but will not learn the key therapeutic element (i.e., initiating swallowing during expiration).
32790475|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
32790476|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
32790477|NCT02102269|No Intervention|controle group|no orthosis
33297831|NCT05164120|Experimental|Interventional|900mg dose TID Administration Total: 2700mg
33297832|NCT05164120|Placebo Comparator|Placebo|900mg dose TID Administration Total: 2700mg
33297833|NCT04162366|Experimental|Aprocitentan 25 mg|
33297834|NCT04162366|Experimental|Placebo|
33297835|NCT04162366|Experimental|Aprocitentan 25 mg or Placebo|
33297836|NCT03947242|Experimental|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
33297837|NCT03604432|No Intervention|Control group|Electric cardiac surgery only
33297838|NCT03604432|Experimental|Treatment group|Elective cardiac surgery plus prophylactic maze procedure
33087449|NCT00288171|Placebo Comparator|Placebo|
33297839|NCT03944980|Experimental|Arm 1: CIK|"Docetaxel & PD1-T cells~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
33297840|NCT03944980|Active Comparator|Arm 2: Control|"Docetaxel~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
33297841|NCT05094700|Experimental|Non-marketed Cosmetic Facial Cleanser|Participants will receive non-marketed cosmetic facial cleanser to apply on cleanse facial skin, twice daily for 4 weeks.
33297842|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
33297843|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
32790478|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
32790479|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
32790480|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
32790481|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
32790482|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
32790483|NCT00559819|Active Comparator|Alcohol|Alcohol
32790484|NCT00559819|Placebo Comparator|Placebo|Orange juice
32790485|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
32790486|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
32790487|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
32790488|NCT04646889|Experimental|Renal Impairment|Subjects with various degrees of renal impairment
32790489|NCT04646889|Experimental|Normal Renal Function|Subjects with normal renal function
32790490|NCT04646499|Experimental|Gamma Stimulation Group|This group will receive gamma stimulation
32790491|NCT04173663|Experimental|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
33297844|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
33297845|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
32790492|NCT04173663|Other|Written materials only control group|This group will receive the ASSIST curriculum and written materials developed for the program but will not attend the in-person sessions.
32790493|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
32790494|NCT01617447|Experimental|Aripiprazole|administered orally once daily
32790495|NCT00432679|Experimental|arm 1|study drug
32790496|NCT04798027|Experimental|Group 1|1 injection of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1
32790497|NCT04798027|Experimental|Group 2|1 injection of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1
32790498|NCT04798027|Experimental|Group 3|1 injection of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1
32790499|NCT04798027|Placebo Comparator|Group 4|1 injection of placebo at Day 1
32790500|NCT04798027|Experimental|Group 5|2 injections of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1 and Day 22
32790501|NCT04798027|Experimental|Group 6|2 injections of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1 and Day 22
32790502|NCT04798027|Experimental|Group 7|2 injections of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1 and Day 22
32790503|NCT04798027|Placebo Comparator|Group 8|2 injections of placebo at Day 1 and Day 22
32790504|NCT05238025|Experimental|Group 1: Single dose MVA-BN-RSV|Single dose (Week 0): MVA-BN-RSV virus with a titer of at least 3x10E8 Inf.U/0.5mL (intramuscular vaccination)
32790505|NCT05238025|Experimental|Group 2: Single dose Placebo|Single dose of TBS (intramuscular injection; 0.5mL)
32790506|NCT05232487|Experimental|Swiss low back acupuncture group|Participants in this group will be treated with the Swiss low back acupuncture method.
32790507|NCT05232487|Active Comparator|Standard acupuncture group|Participants in this group will be treated with the standard acupuncture method.
32790508|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
32790509|NCT01077895|Experimental|CVVH with fluid removal|
32790510|NCT01077895|Active Comparator|CVVH without fluid removal|
32790511|NCT04785079|Experimental|Graston effect medial arch, plantar fascia, and trapezius|Pre and post Graston change in blood flow at the medial arch foot, plantar fascia, and the trapezius region
32790512|NCT04797481|Experimental|Novel Intervention|Novel Intervention Exercise group.
32790513|NCT04797481|Active Comparator|Control|Self-managed Exercise group.
32790514|NCT04797325|Active Comparator|vedolizumab|
33297846|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
33297847|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
33297848|NCT01108978|Placebo Comparator|Placebo|
33297849|NCT01108978|Active Comparator|Dehypotin|
33297850|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
33087450|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
33087451|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
33087452|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age > 18 years, age < 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
33087453|NCT04518592||Severe Major Depressive Disorder|
32790515|NCT04797325|Active Comparator|Standard treatment|
32790516|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
33087454|NCT04518592||control , healthy|
33403914|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
33403915|NCT05664815|Experimental|Application of human amniotic membrane (hAM)|After conventional/standard treatment, hAM will be applied in a single layer against the bone defect before closure.
33087455|NCT00253955|Experimental|1|
33087456|NCT00253955|Active Comparator|2|
33087457|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
33297851|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
33297852|NCT04111588||Glioma|"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC.~30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery."
33403916|NCT05664815|Active Comparator|Conventional/standard treatment|Conventional/standard surgery.
33403917|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
33403918|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
33403919|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
32790517|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
32790518|NCT00752245|Experimental|1|Dialysis during 4 hours
32790519|NCT00752245|Active Comparator|2|Dialysis during 6 hours
32790520|NCT00752245|Active Comparator|3|Dialysis during 8 hours
32790521|NCT04771351|Experimental|COVI-AMG 100 mg|A single injection of 100 mg of COVI-AMG will be administered.
32790522|NCT04771351|Experimental|COVI-AMG 200 mg|A single injection of 200 mg of COVI-AMG will be administered.
32790523|NCT04771351|Placebo Comparator|Placebo|A single injection of placebo will be administered.
32790524|NCT04770727|Experimental|Workshop Intervention|A psychoeducation workshop will be provided alongside a workbook containing the content to review and refresh skills learnt. The psychoeducational intervention will be delivered by trainee clinical psychologists with interests in food allergy and delivered in line with a protocol.
32790525|NCT04770727|No Intervention|Treatment as usual|Adolescents randomised to the control arm will continue treatment as usual and receive the workshop materials after the active treatment group have completed their final follow-up at 3 months.
32830535|NCT04349410|Experimental|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
33297853|NCT04111588||Brain Metastases|Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.
33297854|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
33297855|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
33297856|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
33297857|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
33297858|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
33297859|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
33297860|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
33297861|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
33297862|NCT01208818|Active Comparator|BD|
33297863|NCT01208818|Experimental|C-BD|
33297864|NCT01208818|Experimental|HCO|
33297865|NCT01208818|Active Comparator|Control HD|
33297866|NCT05078866|Experimental|Prevention (Nous-209 vaccine)|Patients receive GAd20-209-FSPs IM on day 1 and MVA-209-FSPs IM at week 8.
33297867|NCT05067712|Active Comparator|Open Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposed with the Open Technique followed by the Orthodontic Treatment phase
33297868|NCT05067712|Active Comparator|Closed Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposure with the Closed technique followed by the Orthodontic Treatment phase.
33297869|NCT05047120|Experimental|Intervention group|HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT to identify adaptive cognitions and make adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). Participants will undergo 4 sessions during inpatient rehabilitation admission, each lasting 30-60 minutes. Sessions will include brief assessments of pain intensity, adverse events, and between session practice. Participants in this group will also complete baseline, follow-up, and post-discharge assessments.
33297870|NCT05047120|No Intervention|Measures only|People who consent to the measures only and usual care group will be encouraged to continue using the health care services available to them to address their pain. This includes a Rehabilitation Psychologist who can offer nonpharmacological pain management strategies. Participants in this group will baseline, follow-up, and post-discharge assessments.
33297871|NCT03947320|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
33297872|NCT01111630|Experimental|once weekly|
33297873|NCT01111630|Active Comparator|three times weekly|
33297874|NCT01208896|Experimental|Rituximab|
33297875|NCT03944278|Experimental|Thulium Device|1927 Laser Treatment
33297876|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
33297877|NCT03942796|Active Comparator|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
33297878|NCT03942796|Active Comparator|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
33297879|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
33297880|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
33297881|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
33297882|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
33297883|NCT03944122|Experimental|continuous ultrasound|continuous ultrasound were applied to the patients
33297884|NCT03944122|Experimental|pulsed ultrasound|pulsed ultrasound were applied to the patients
33297885|NCT03944122|Experimental|placebo|placebo (sham) ultrasound were applied to the patients
33297886|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
33297887|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
33297888|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
33297889|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
33297890|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
33297891|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
33297892|NCT01211782|Experimental|AC-1204|
33297893|NCT01211782|Placebo Comparator|Placebo|
33297894|NCT01111942|Active Comparator|radiation and weekly carboplatin|
33297895|NCT01111942|Other|conservation surgery|
33297896|NCT01112020|Experimental|CHG Catheter Dressing Patch|
33297897|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
33297898|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
33297899|NCT03944200|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
33403920|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
33087458|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
33087459|NCT04472533||Control|Healthy control subjects
33087460|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
33087461|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
32790526|NCT05107687||Assisted Smoking Cessation|"Subject participates in a structured smoking cessation program hosted at Virtua Health which may be either smoking cessation group sessions or individual sessions and/or both. All participants will be provided with a list of smoking cessation resources.~Description of Group Smoking Education and Support: These sessions are led by a Tobacco Treatment Specialist and include 2-3 sessions in-person or virtually and cover the following topics: Biological changes caused by nicotine, addiction, tips to quit smoking, health benefits to quitting smoking, types of nicotine replacement therapy, e-cigarettes and devices, aromatherapy, meditation and various resources. In addition, access to nicotine replacement therapies is optional."
33087462|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
32790527|NCT05107687||Unassisted Smoking Cessation|The subject receives no professional support but is provided with a list of smoking cessation resources, in this cohort the subject engages in smoking cessation with no assistance from a provider.
33297900|NCT03944200|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
33297901|NCT01109290||HED children|
33087463|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
33087464|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
33087465|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
33087466|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
33087467|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
33087468|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
33297902|NCT01109290||HED adults|
33297903|NCT01109290||Control children|
33297904|NCT01109290||Control adults|
33297905|NCT03940534|Active Comparator|Start with Mobile Device|
32790528|NCT04773067|Experimental|UB-612|A proprietary high-precision designer S1-RBD protein based vaccine incorporating Th/CTL peptides to activate T cells.
32790529|NCT04773067|Placebo Comparator|Placebo|Normal saline 0.9%.
32790530|NCT04784845|Experimental|N. lactamica Y92-1009|Nasal inoculation with 10^5 CFU N. lactamica in 1ml phosphate-buffered saline via pipette to both nostrils; single inoculation at 36+0 to 37+6 weeks gestation
32790531|NCT04784455|Experimental|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within 100 days of HSCT
33087469|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
33087470|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
33087471|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
33087472|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
33087473|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
33087474|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
33087475|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
33297906|NCT03940534|Active Comparator|Start without Mobile Device|
33297907|NCT03942640|Other|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years~Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :~Suprascapular nerve.."
33297908|NCT03942640|Other|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
33297909|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
33297910|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
33297911|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
33297912|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
33403921|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
33087476|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
33087477|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
33087478|NCT01600768|Active Comparator|intermittent infusion|
33297913|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
33297914|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
32790532|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
32790533|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
32790534|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
32790535|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
33297915|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
33403922|NCT05233306||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
33297916|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
33297917|NCT03940768|Experimental|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
33297918|NCT03940768|Placebo Comparator|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
33297919|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
33297920|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
33297921|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
33403923|NCT05233306||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
32790536|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks.~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
33403924|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
33403925|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
33403926|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
32790537|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:~Placebo administered by mouth once a day (QD) for 13 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
32790538|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
32790539|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
32790540|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
32790541|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
32790542|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
32790543|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
33087479|NCT01600768|Experimental|extended infusion|
33087480|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
33087481|NCT00288327|Other|2|Minimum Intervention
33087482|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
33087483|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
33087484|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
33087485|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
32790544|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
32790545|NCT04631055|Experimental|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
32790546|NCT04631055|Active Comparator|Stent group|use the Intracranial Stent System made by MicroPort.
32790547|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
32790548|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
32790549|NCT04630821|Experimental|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
32790550|NCT04645953|Experimental|1mg AZ010|Single orally-inhaled dose
32790551|NCT04645953|Experimental|3mg AZ010|Single orally-inhaled dose
32790552|NCT04645953|Experimental|Placebo|Single orally-inhaled dose
32790553|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
32790554|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
32790555|NCT04645017|Experimental|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
32790556|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
32790557|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
32790558|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
32790559|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
32790560|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
32790561|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
32790562|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
32790563|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
32790564|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
32790565|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
32790566|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
32790567|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
33087486|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
33087487|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
33087488|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
33087489|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
33087490|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
32790568|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
32790569|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
32790570|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
32790571|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
32790572|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
32790573|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
32790574|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
32790575|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
32790576|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
32790577|NCT04630197|Experimental|e-CBT|16 weekly sessions will be conducted through OPTT and consist of approximately 30 slides and interactive therapist videos. The content and format will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, thought records, and ERP will be incorporated. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went.
33087491|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
33087492|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
33087493|NCT04451512||CSP|
33087494|NCT04451512||HSP|
32790578|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
33087495|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
33087496|NCT04448626||Healthy subject|Healthy subject
33087497|NCT04448626||Stable COPD patients|Stable COPD patients
33087498|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
33087499|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
33087500|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
33087501|NCT01600963|Experimental|Arm A|
33087502|NCT01600963|Placebo Comparator|Arm B|
33087503|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
33087504|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
33087505|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
33087506|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension. The priming (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total priming for one day is 30 minutes. Total task specific training for one day is 90 minutes"
33087507|NCT02277028|Active Comparator|Health Education|The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as above. The health education (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total time on health education website for one day is 30 minutes. Total task specific training for one day is 90 minutes
33087508|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
33087509|NCT00254306||1|"ex-ecstasy users"
33087510|NCT00254306||2|control subjects
33087511|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
33087512|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
33087513|NCT01607125|Experimental|Vortioxetine|
33087514|NCT01607125|Placebo Comparator|Placebo|
33087515|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
33087516|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
33087517|NCT01601041||control group|less than three urinary tract infections / year
33297922|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
33297923|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
32790579|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
32790580|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
33297924|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
33297925|NCT01209130|Experimental|A|
33297926|NCT01209130|Experimental|B|
33297927|NCT01209208|Experimental|A|Budesonide
33297928|NCT01209208|Experimental|B|Mesalazine
32790581|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
33297929|NCT01209208|Placebo Comparator|C|
32790582|NCT04420481|Active Comparator|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
32790583|NCT04420481|Placebo Comparator|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
32790584|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
32790585|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
32790586|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
32790587|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
32790588|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
32790589|NCT02278367|Experimental|Flortaucipir PET Scans|
32790590|NCT04886141|No Intervention|Standard of Care treatment with Scales|Patients will receive the standard of care restorative procedure with the addition of the FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale to create a baseline data of pain to compare with the experimental group.
32790591|NCT04886141|Experimental|Virtual Reality Headset|Instead of receiving the Nitrous that would be used to help calm patients during the standard of care restorative procedure. Patients will be given a the Oculus Quest 2 Virtual realty headset and a video will be played. The FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale data will be collected to compare the patients pain level between the two groups.
32790592|NCT04885985|Experimental|DEB catheter|Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm
32790593|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
32790594|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
32790595|NCT04885907|Active Comparator|Experimental group|Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
32790596|NCT04885907|Placebo Comparator|Comparator Group|Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle
33087518|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
33087519|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
33087520|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
33087521|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
33087522|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
33087523|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
33087524|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
33087525|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
33087526|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
33297930|NCT03940612|Experimental|STP4 (product with probiotics)|Dietary Supplement: STP4
33297931|NCT03940612|Experimental|Placebo (product without probiotics)|Dietary Supplement: Placebo
33297932|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
33297933|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
33297934|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
33297935|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
33297936|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
32790597|NCT04884737|No Intervention|Pre-Intervention|Pre-Intervention Group participants will have 6 visits. During the pre-intervention baseline (3 months) participants will undergo visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, conducted by the research staff: 1.) consent and preoperative, 2.) immediately following surgery in the Post Anesthesia Recovery (PAR) Unit, 3.) on transfer to the floor unit, 4.) post-operative day 1, 5.) post-operative day 3 and 6.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 40 minutes.
32790598|NCT04884737|Experimental|Intervention|Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
32790599|NCT04622241|Experimental|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
33087527|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
32790600|NCT04622241|Experimental|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
32790601|NCT04622241|Experimental|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
32790602|NCT04622241|Experimental|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
32790603|NCT04622241|Experimental|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
32790604|NCT04622241|Experimental|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
32790605|NCT04622241|Experimental|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
32790606|NCT04622241|Experimental|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
32790607|NCT04622241|No Intervention|Control - Traditional House|Control group with no intervention in traditional homes
32790608|NCT04622241|No Intervention|Control - Modern House|Control group with no intervention in modern homes.
32790609|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
32790610|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
32790611|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
32790612|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
32790613|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
32790614|NCT01957137|Other|Continuous|The device parameter will be continuous.
32790615|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
33087528|NCT00254657|Placebo Comparator|Placebo|
33403927|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
32790616|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
32790617|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
32790618|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
32790619|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
32790620|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
32790621|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
32790622|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
32790623|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
32830536|NCT04349410|Experimental|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
33087529|NCT00254657|Experimental|Levetiracetam|
33087530|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
33087531|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
33087532|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
33087533|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33087534|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32790624|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
32790625|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
33087535|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33087536|NCT00288795|No Intervention|1|Standard Care
32790626|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
33297937|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
33297938|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
32790627|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790628|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790629|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
32790630|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790631|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790632|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
32830537|NCT04349410|Experimental|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
32830538|NCT04349410|Experimental|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
33087537|NCT00288795|Other|2|Massage Treatment
33297939|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
33297940|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
33297941|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
33297942|NCT03942406|Experimental|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
33297943|NCT03942406|Experimental|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
33297944|NCT03942406|Experimental|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
33297945|NCT03942406|Active Comparator|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
33297946|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
33297947|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
33087538|NCT00288795|Other|3|Polarity Treatment
33297948|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
33087539|NCT01607632|Experimental|loving-kindness meditation|
33087540|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
33297949|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
33297950|NCT03942250|Experimental|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
33297951|NCT01109446|Experimental|Platelet Rich Plasma|
33297952|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
33087541|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
33087542|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
33087543|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
33087544|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
33297953|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
33297954|NCT03940378|Experimental|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
33087545|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
33087546|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
33297955|NCT03940378|Experimental|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
33297956|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
33297957|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
33297958|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
33297959|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
33297960|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
33297961|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
33297962|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
33297963|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
33297964|NCT01112488|No Intervention|Control|usual care
33297965|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
33297966|NCT03940222|Experimental|I-BiT group|Amblyopic patients will play I-BiT games without patching.
33297967|NCT03940222|Placebo Comparator|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
33297968|NCT01783288|Other|All participants|"All participants will be administered all procedures as described previously.~Interventions:~Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test"
33297969|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
33297970|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
33297971|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
33297972|NCT01115140|Active Comparator|Group A1|metformin plus placebo
33297973|NCT01115140|Experimental|Group A2|metformin plus folic acid
33297974|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
33297975|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
33297976|NCT01115140|No Intervention|Group B|observation
33297977|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
33297978|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
33297979|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
33297980|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
33297981|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
33297982|NCT03941938|Experimental|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
33297983|NCT03941938|Active Comparator|No reinforcement|No reinforcement will be applied on the anastomosis line
33297984|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
33297985|NCT00962728|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
33297986|NCT00962728|Sham Comparator|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
33297987|NCT01115218||Glaucoma patients|
33297988|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
33087547|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
33087548|NCT01607944||Normal Glucose Tolerance|
33087549|NCT01607944||Type 2 Diabetes|
33087550|NCT01608022|Experimental|PF804|
33087551|NCT04719494|Experimental|Training Group|During the 12-training day sessions, subjects will walk on the treadmill for a total of 30 minutes. Participants will walk at a comfortable pace while we perform controlled movements to the treadmill system. Subjects will be fitted with a fall-arrest harness and assisted onto the treadmill system. In the dynamic balance training group, we will move the motion base as participants walk in order to challenge their balance.
33297989|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
33297990|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
33297991|NCT01115296|Placebo Comparator|Placebo|Placebo
33297992|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
33297993|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
33297994|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
32790633|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790634|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790635|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
32790636|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
33297995|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
33297996|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
33297997|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
33297998|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
33297999|NCT03943420||Negative Control Group|Therapy B : Basic treatment
33298000|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
33298001|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
33298002|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
33298003|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
33298004|NCT01209988|Placebo Comparator|Control|No medication
33298005|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
33298006|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
33298007|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
33298008|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
33298009|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
33298010|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
33403928|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
32790637|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
32790638|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
32790639|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
32790640|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
32790641|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
33298011|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
33298012|NCT01115530|Experimental|2|Resistance exercise (2x/week)
33298013|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
33298014|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
33298015|NCT03942172|Experimental|SpotOn Balance|SpotOn Balance Glasses
33298016|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
33298017|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
33298018|NCT03939988|Active Comparator|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
33298019|NCT03939988|Placebo Comparator|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
33298020|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
33298021|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
33298022|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
33298023|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
33403929|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
33087552|NCT04719494|No Intervention|Control Group|Subjects who are in the control group will also walk on the treadmill, but the motion base will remain stationary. They will complete 12-training day sessions.
33298024|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
33087553|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
33087554|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
33087555|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
33087556|NCT01608334|Experimental|group A|Fentanyl
33087557|NCT01608334|Active Comparator|Group B|Sufentanil
33298025|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
33298026|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
33298027|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
33298028|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
33298029|NCT01212406|Placebo Comparator|Placebo|Olive oil
33298030|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
33298031|NCT03939910|Active Comparator|Control arm|bupivacaine 0.25% for pudendal block
33298032|NCT03939910|Experimental|Intervention arm|ropivacaine 0.2 % for the pudendal block
33298033|NCT01109758|Experimental|1|
33298034|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
33298035|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
33298036|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
33087558|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
33298037|NCT03939754||Adult living in Vercelli|Adult aged 40-75
33298038|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
33298039|NCT03939832|Active Comparator|FiO2 0.5|
33298040|NCT03939832|Active Comparator|FiO2 1.0|
33298041|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
33298042|NCT01113034|Placebo Comparator|Lactose Placebo|
33298043|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
33298044|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
33298045|NCT01115842|No Intervention|control|
33298046|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
33298047|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
33298048|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
33298049|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
33298050|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
33298051|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
33298052|NCT01116076|No Intervention|Control|Usual Care
33298053|NCT01210378|Experimental|Nitroglycerin|
33298054|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
33298055|NCT01109836|No Intervention|Control|Standard stroke care
33298056|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33298057|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
33087559|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
33087560|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
32790642|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
33087561|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
33298058|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
33087562|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
33087563|NCT01608529|Experimental|Cyclist group|
33087564|NCT04718454||Equator attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,Equator Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
33087565|NCT04718454||ball attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,ball Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
33298059|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
33298060|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
33298061|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
33298062|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
33298063|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
33298064|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
33298065|NCT01210612|Active Comparator|Without Unilateral CAI|
33298066|NCT01210612|Active Comparator|With Unilateral CAI|
33298067|NCT01207804|Experimental|Device|
33298068|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
33403930|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
32790643|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
32790644|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
32790645|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
32790646|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
33298069|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
33298070|NCT01210846|Experimental|tivozanib|
33298071|NCT01116388|Other|test product|product free of gluten and casein
33298072|NCT01116388|Other|control product|product containing gluten and milk protein
33298073|NCT01210924||Pediatric ART patients|
33298074|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
33298075|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
33298076|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
33298077|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
33298078|NCT01110070|Experimental|ChonDux plus microfracture|
33298079|NCT01110070|Active Comparator|Microfracture|
33298080|NCT03941626|Experimental|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
33298081|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
33298082|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
33298083|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
33298084|NCT01113346|Experimental|Filtrum-STI|
33298085|NCT01113346|Placebo Comparator|Placebo|
33298086|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
33298087|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
33298088|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
33298089|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
33298090|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
33087566|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
33087567|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
33298091|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
32790647|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
32790648|NCT02322047|Experimental|Praz/Nal|"Prazosin and Naltrexone.~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
32790649|NCT02322047|Active Comparator|Praz/Pl|"Prazosin and Placebo (Naltrexone)~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
32790650|NCT02322047|Active Comparator|Nal/Pl|"Naltrexone and Placebo (Prazosin)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
32790651|NCT02322047|Placebo Comparator|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
32790652|NCT02254291|Experimental|Semaglutide 0.5 mg|
32790653|NCT02254291|Experimental|Semaglutide 1.0 mg|
32790654|NCT02254291|Active Comparator|Sitagliptin 100 mg|
32790655|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
32790656|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
32790657|NCT04191811||Social Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for social anxiety.
32790658|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
32790659|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
32790660|NCT04784143|Active Comparator|Two MDMA-assisted Psychotherapy Sessions|Two Experimental Sessions of MDMA-assisted Psychotherapy
32790661|NCT04784143|Active Comparator|Three MDMA-assisted Psychotherapy Sessions|Three Experimental Sessions of MDMA-assisted Psychotherapy
32790662|NCT04770181|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
32790663|NCT04770181|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
32790664|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
32790665|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
32790666|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
32790667|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
32790668|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
32790669|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
32790670|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
32790671|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
32790672|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
32790673|NCT04197479|Experimental|Open label: resmetirom|100 mg daily
32790674|NCT04197479|Placebo Comparator|Double blinded: matching placebo|Placebo daily
32790675|NCT04197479|Experimental|Double blinded: resmetirom 80 mg|80 mg daily
32790676|NCT04197479|Experimental|Double blinded: resmetirom 100 mg|100 mg daily
32790677|NCT04884659|Experimental|Timed restricted feeding|"Time restricted feeding then usual feeding pattern Day 1, testing~Day 2-7 all meals will be consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm. Day 8 testing. Day 9-14 crossover to usual feeding pattern arm (meals consumed ad lib with 50% of calories consumed after 4 PM) for 6 days."
32830539|NCT04349410|Experimental|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days [with each infusion given over 30-minutes]; then Solumedrol dose pack to taper off steroids.
33087568|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
33087569|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
33298092|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
33298093|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
33298094|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
33298095|NCT01116778|Experimental|eN-Lac® Capsules|
33298096|NCT01116778|Other|Placebo Capsules|
33298097|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
33298098|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
33298099|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
33298100|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
33298101|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
33298102|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
33298103|NCT01110226|Experimental|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
33298104|NCT01110226|Experimental|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
33298105|NCT01110226|Experimental|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
33298106|NCT01211236|Experimental|Maggot Debridement Therapy|
33298107|NCT01211236|Active Comparator|control|
33298108|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
33298109|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
33298110|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
33298111|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
33298112|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
33298113|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
33298114|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
33298115|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
33298116|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
33298117|NCT03942874|Experimental|Treatment|Participants will complete baseline sessions and then complete treatment right away.
33298118|NCT03942874|Experimental|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
33298119|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
33298120|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
33298121|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
33298122|NCT03941002|Placebo Comparator|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
33298123|NCT03941002|Active Comparator|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
33298124|NCT03941002|Active Comparator|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
33298125|NCT03939130|Experimental|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
33298126|NCT03939130|Active Comparator|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
33298127|NCT03939130|Experimental|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
32737816|NCT05026359|No Intervention|General rehabilitation intervention group|Exercise training of walking and balance training consisted of 30 minutes of general rehabilitation intervention group 3 days per week for 4 weeks (total 12 sessions)
32737817|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
32737818|NCT05047497||less than 10 years working|workers who work in cement factories in a period of time less than 10 years
32737819|NCT05047497||from 10-15 years working|workers who work in cement factories in a period of time from 10-15 years
32737820|NCT05047497||more than 15 years working|workers who work in cement factories in a period of time more than 15 years
32737821|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
32790678|NCT04884659|Experimental|Usual feeding pattern|"Usual feeding pattern, then time restricted feeding Day 1 testing~Day 2-7 all meals will be consumed as follows:~Meals consumed ad lib with 50% of calories consumed after 4 PM. Day 8 testing. Day 9-14 crossover to time restricted feeding arm with all meals consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm for 6 days."
32790679|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
32790680|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
32790681|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
32790682|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
32790683|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
32790684|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
32790685|NCT04197089|Experimental|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
32790686|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
32790687|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
32790688|NCT02252965|Active Comparator|Metformin IR|
32790689|NCT02252965|Experimental|Metformin XR|
32790690|NCT04772911||Strata A: One-time OCT Measurements|The indication for Strata A is that some participants will elect not to undergo laser treatment, particularly if they have been extensively treated with laser previously, or have a light pink vascular stain that has been stable.
32790691|NCT04772911||Strata B: Serial OCT Measurements|Participants will have serial OCT measurements of their vascular stain performed prior to the start of standard of care laser treatment. OCT will be performed prior to each standard of care laser treatment if the participant has elected to have standard of care laser treatment as treatment of their vascular stain at the time of enrollment.
32790692|NCT04772911||Strata C: Laser SOC without OCT|Participants will have serial evaluation with standard of care laser treatment without use of OCT.
32790693|NCT02242435|Experimental|Ampion 4ml dose|4 mL intra-articular injection of Ampion
32790694|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
32790695|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
32790696|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
32790697|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
33087570|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
33087571|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
32790698|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
32790699|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
32790700|NCT02242045|Experimental|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
32790701|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
32790702|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
33087572|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
32790703|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
33087573|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
33087574|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
33087575|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
33087576|NCT00288990||1|subjects who are NAb positive
33298128|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
33298129|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
33298130|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
33298131|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
33298132|NCT01208194|Experimental|MGN1703|Study medication
33298133|NCT01208194|Placebo Comparator|Placebo|
33298134|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
33298135|NCT01114126|Experimental|Neu-P11 2mg|
33298136|NCT01114126|Experimental|Neu-P11 5 mg|
33298137|NCT01114126|Experimental|Neu-p11 20 mg|
32790704|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
32790705|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
33298138|NCT01114126|Experimental|Neu-P11 50 mg|
33298139|NCT01114126|Placebo Comparator|Placebo|
33298140|NCT03939052|Experimental|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
33298141|NCT01208350|Experimental|1|
33298142|NCT01208350|Experimental|2|
32790706|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
32790707|NCT04191577|Placebo Comparator|Placebo|Placebo to be administered once daily.
32790708|NCT04191577|Active Comparator|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
32790709|NCT04191577|Active Comparator|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
32790710|NCT04966741|Experimental|Setmelanotide|Investigational product: Setmelanotide,10 mg/mL in a sterile solution for Subcutaneous (SC) injection
32790711|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
32790712|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
32790713|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
32790714|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
32790715|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
32790716|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
32790717|NCT04783675|Experimental|Intervention/treatment|
32790718|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
32830540|NCT04349410|Experimental|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
32830541|NCT04349410|Experimental|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
33087577|NCT00288990||2|Subjects who are antibody negative
33087578|NCT00288990||3|subjects who are BAb positive
33087579|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
33298143|NCT01208350|Active Comparator|3|
33298144|NCT03939208|Experimental|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
33298145|NCT03939208|Active Comparator|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
33298146|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
33298147|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
33298148|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
33298149|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
33298150|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
33298151|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
33298152|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
33298153|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
32939794|NCT04029584|Experimental|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.~Before starting hepatic induced period, subjects will have a washout for greater than one week.~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
32939795|NCT04029584|Experimental|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.~Before starting induction periods, subjects will have a washout greater than one week.~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
32939796|NCT04028960|Placebo Comparator|Placebo|No active drug
33298154|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
33298155|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
33298156|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
33298157|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
33298158|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
32939797|NCT04028960|Experimental|Humulin-R|Insulin
32939798|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
32939799|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
33298159|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
32737822|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
32737823|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
33298160|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
33298161|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
32737824|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
32737825|NCT03327935|No Intervention|Control|Standard Hospital Procedure
32737826|NCT05025501|Experimental|Intervention group|"Subjects in this group will receive the Famliy based Executive Function Training  program in aiming to reduce ADHD symptoms and improve the executive function."
32737827|NCT05025501|No Intervention|Waiting group|"Subjects in this group will not receive the Famliy based Executive Function Training  program during the study period."
33298162|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
33298163|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
32737828|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
32939800|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
32939801|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
32939802|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
32939803|NCT04018664|Placebo Comparator|Placebo|"Placebo~150 mL flavored beverage"
33298164|NCT03939286|Other|movement group|intensified training (equipment, coordination, balance)
33298165|NCT03939286|Other|control group|continuation of physical activity as usual
33298166|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
33298167|NCT01208506|Experimental|Dose level 1|
33298168|NCT01208506|Experimental|Dose level 2|
33298169|NCT01208506|Experimental|Dose level 3|
33298170|NCT01208506|Experimental|Dose level 4|
32790719|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
32790720|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
32790721|NCT02207725|Placebo Comparator|Placebo|Placebo
32790722|NCT04892953|Experimental|Cohort A (oligoprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32790723|NCT04892953|Experimental|Cohort B (polyprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.
32790724|NCT04783441|Active Comparator|Continuous glucose monitoring (CGM)|Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
32790725|NCT04783441|Placebo Comparator|Self monitoring of blood glucose (fingersticks)|The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
32790726|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
32790727|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
32790728|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
32790729|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
32790730|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
32790731|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
32790733|NCT04769167|Placebo Comparator|Healthy Non Pregnant Women (HNPW)|HNPW are healthy women and not pregnant
32790734|NCT04769167|Active Comparator|Diabetic Non Pregnant Women (DNPW)|DNPW are diabetic and not pregnant
32790735|NCT04769167|Placebo Comparator|Healthy Pregnant Women (HPW)|HNPW are healthy women and currently pregnant
32790736|NCT04769167|Active Comparator|Diabetic Pregnant Women (DPW)|DNPW are diabetic and currently pregnant
32790737|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
32790738|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
33298171|NCT01208506|Experimental|Dose level 5|
33298172|NCT01208506|Experimental|Dose level 6|
33298173|NCT01208506|Experimental|Dose level 7|
33298174|NCT01208506|Experimental|Dose level 8|
33403931|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
33298175|NCT03938896|Other|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
33298176|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
33298177|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
33298178|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
33298179|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
32939804|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
32939805|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
33298180|NCT01208584||Volunteers|Volunteers without any neurological deficits
32939806|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
33298181|NCT01213108|Experimental|Örebro prevention program|
33298182|NCT01213108|Active Comparator|Control|Business as usual
33298183|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
33298184|NCT03938818|Experimental|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:~PrEP sensitization for men (community level).~Buddy Days (partner level).~Adherence support clubs (individual and peer levels)."
33298185|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
33298186|NCT01117636|Experimental|Arm 1|
33298187|NCT01117636|Active Comparator|Arm 2|
33298188|NCT01117636|Placebo Comparator|Arm 3|
33298189|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
33298190|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
33298191|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
33298192|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
33298193|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
33298194|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
32939807|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
32939808|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
32939809|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
32939810|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
32939811|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
32939812|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
32939813|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
32790739|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
32790740|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
32790741|NCT04797715|Experimental|AXS-05|Up to 26 weeks in double-blind period
33403932|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
33403933|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
32790742|NCT04797715|Placebo Comparator|Placebo|Up to 26 weeks in double-blind period
32790743|NCT02315066|Experimental|PF-04518600|OX40 agonist
32790744|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
32790745|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
32790746|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
32790747|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
32790748|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
32790749|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
32790750|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
32790751|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
32790752|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
32790753|NCT02276027|Experimental|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
32790754|NCT02276027|Experimental|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
32790755|NCT02276027|Experimental|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
32790756|NCT02276027|Experimental|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
32790757|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
32790758|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
32790759|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
32790760|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
33087580|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
33087581|NCT01608841|No Intervention|Gemcitabine|
33087582|NCT01608841|Experimental|Gemcitabine plus erlotinib|
33087583|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
33087584|NCT01609036||Cohort|
33087585|NCT00254969|Experimental|1|
33087586|NCT01609075||Cohort|
33403934|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
33403935|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
32790761|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
32790762|NCT04761133|Experimental|Pleural irrigation with antiseptic|Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
32790763|NCT04761133|No Intervention|No pleural irrigation|Standard care
32790764|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
32790765|NCT04779697|Experimental|GLP-1a|GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
32790766|NCT04779697|Placebo Comparator|Placebo|Placebo pen administered weekly over 12 weeks
32790767|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
32790768|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
32790769|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
32790770|NCT04773457||Spine Surgery|Pediatric patients presenting for elective spine fusion surgery at Boston Children's Hospital
32790771|NCT04773457||Abdominal Surgery|Pediatric patients presenting for elective abdominal surgery at Boston Children's Hospital
32790772|NCT04748653|Experimental|Multi-component reintegration intervention|There is one arm for the feasibility and acceptability study - all intervention participants will receive the intervention: health education, psychosocial counseling, physiotherapy, and economic investment.
32790773|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
32790774|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
32790775|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
32790776|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
32790777|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
32790778|NCT04745689|Experimental|AZD2811 + Durvalumab|"Induction:~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin & Etoposide)~Maintenance:~AZD2811 + Durvalumab"
32790779|NCT04768543||Exposure|Patients with moderate to severe OSA treated with UAS (Inspire Medical Systems, Inc)
32790780|NCT04768153||Patients|
32790781|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
32790782|NCT04767997|Experimental|Experimental group|Participants in this group will be randomized to receive probiotic formulation for the following 12 weeks.
32790783|NCT04767997|Placebo Comparator|Control group|Participants in this group will be randomized to receive placebo for the following 12 weeks.
32790784|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
33087587|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
33087588|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
33087589|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
33087590|NCT02273440|Experimental|BIIL 284 BS with theophylline|
33087591|NCT02273440|Placebo Comparator|Placebo with theophylline|
33087592|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
33087593|NCT04719455|Experimental|Intervention treatment experienced patients|AIMS
33087594|NCT04719455|Experimental|Intervention starting patients|AIMS
33087595|NCT04719455|Other|Control group treatment experienced patients|Regular care
33087596|NCT04719455|Other|Control group starting patients|Regular care
33087597|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
33087598|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
32737829|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
32737830|NCT05024799|Experimental|F-P group|the combination of fentanyl and propofol
32737831|NCT05024799|Experimental|F-D group|the combination of fentanyl and dexmedetomidine
32737832|NCT05024799|Experimental|B-P group|the combination of butorphanol and propofol
32737833|NCT05024799|Experimental|B-D group|the combination of butorphanol and dexmedetomidine
32737834|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
32737835|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
32737836|NCT05018637|Experimental|WJ-MSC group|intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
32737837|NCT05018637|Active Comparator|Teriparatide group|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
32737838|NCT03333395|Active Comparator|HS Group (study group)|
32737839|NCT03333395|Active Comparator|S Group (control group)|
32737840|NCT05018949||Patients who have undergone LL angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
32737841|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
32737842|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
32737843|NCT05018559|Experimental|Intervention group nursing care|Participants receive a co-created physical activity intervention called BuG lesson (German: 'Bewegt und Gesund'-Stunde; English: PA and health lesson).
32737844|NCT05018559|No Intervention|Control group nursing care|Participants do not receive any treatment in addition to their vocational education and training curriculum.
32737845|NCT05018559|Experimental|Intervention group automotive mechatronics|Participants receive a co-created physical activity intervention called tutoring system.
32737846|NCT05018559|No Intervention|Control group automotive mechatronics|Participants do not receive any treatment in addition to their vocational education and training curriculum.
32737847|NCT03333239|Experimental|psychodynamic psychotherapy|
32737848|NCT03333239|Experimental|cognitive behavioral psychotherapy|
32737849|NCT03333239|Active Comparator|psychodynamic family intervention|
32737850|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
32737851|NCT05425199|Experimental|habituation exercises|head and eye movements first slowly then rapidly, head and body movements e.g., picking object from the ground standing and rotation in standing
32737852|NCT05425199|Experimental|proprioceptive training|Single leg stance (right side) + Single leg stance (left side) Lifting of right knee as high as comfortable and then alternative knee Tandem walking ,Toe walking ,Heel walking
32737853|NCT05425199|Active Comparator|Conventional vestibular therapy|Epley's Manuever
32737854|NCT05047029||Patients with cirrhosis|Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.
32737855|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
32737856|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
32737857|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
32737858|NCT03231319|Placebo Comparator|IV PCA only|
32737859|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
32737860|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
32737861|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
32737862|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
32737863|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
32737864|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
32737865|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
32737866|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
32737867|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
32737868|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
32790785|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
32790786|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
32790787|NCT02232061|Experimental|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
32790788|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
32790789|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
32790790|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
32790791|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
32790792|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
32790793|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
32790794|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
32790795|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
32790796|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
32790797|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
32790798|NCT02230891|Other|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
32790799|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
32790800|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
32790801|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
32790802|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
32790803|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
32790804|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
32790805|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
32790806|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
32790807|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
32790808|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
32790809|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
32790810|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
32790811|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
32790812|NCT04870580|Other|Intervention arm|PET/CT with fluorodopa tracer
32830542|NCT04349410|Experimental|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
32830543|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
32790813|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
32790814|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
32790815|NCT05650034|Experimental|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
33403936|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
33403937|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
33403938|NCT03145246||tooth loss|regeneration treated teeth loss
33403939|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
33403940|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
33403941|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).~No intervention is going to be administered but exposure to alcohol will be analysed"
33403942|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
33403943|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
33403944|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
32790816|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
32790817|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
32790818|NCT05649956|Experimental|Letrozole|Letrozole 2.5 mg orally
32790819|NCT05649956|No Intervention|Observation|Observation
32790820|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
32790821|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
32790822|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
32790823|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
33403945|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
33403946|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
33403947|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
33403948|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
33403949|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
33403950|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
33403951|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
33403952|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
33403953|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
33403954|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
33403955|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
33403956|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
33403957|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
33403958|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
33403959|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
32939814|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
32939815|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
32790824|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
32790825|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
32790826|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
32790827|NCT04884152|Active Comparator|Home Exercise Group|"The home Exercise program includes an educational training program about parafunctional activities of patients having bruxism with myofascial temporomandibular disorders. The program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
32790828|NCT04884152|Experimental|Telerehabilitation Group|"The program includes the same stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises using telerehabilitation once a week by video call, and reminder messages will be sent to the patients 3 times a week.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
32790829|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
32790830|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
32790831|NCT04877054|Experimental|Intervention Arm|Intervention sessions will occur ~once per week, with all 4 sessions being completed within 4-8 weeks. Each session will include an education and motivational interviewing (MI) component.
32790832|NCT04877054|Active Comparator|Education only Arm|Participants in the education-only control arm will receive one education session. The education session will occur via telephone or telehealth. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
33298195|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
33298196|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
33298197|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
33298198|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
33298199|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
33298200|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
33298201|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
33298202|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
33298203|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
33298204|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
33298205|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
33298206|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
33298207|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
33298208|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
33298209|NCT03938662|Experimental|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
33298210|NCT03938662|Placebo Comparator|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
33298211|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
33298212|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
33298213|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
33298214|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
33298215|NCT01213420|Active Comparator|Eucerin Calming cream|
33298216|NCT01213420|Active Comparator|Nivea Cream|
33298217|NCT01118104|Other|Pulmonary vocational rehabilitation|
33298218|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
33298219|NCT01110928||Norditropin®|
33298220|NCT01213498|Active Comparator|Atorvastatin|
33298221|NCT01213498|Placebo Comparator|Unikalk|
33298222|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
33298223|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
33298224|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
33298225|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
33298226|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
33298227|NCT01121692|Experimental|VCT/Women's CoOp|
33298228|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
33298229|NCT01121692|Experimental|Couples CoOp|
33298230|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
33298231|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
33298232|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
33298233|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
33298234|NCT03937492|Experimental|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
33298235|NCT03937492|Active Comparator|B group|In this group patients follow standard treatment after radius fracture
33298236|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
33298237|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
33298238|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
33298239|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
33298240|NCT01121770|Experimental|Arixtra|
33298241|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
33298242|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
33298243|NCT01585480|Experimental|weight gain prevention intervention|
33298244|NCT01585480|No Intervention|No treatment comparison group|
33298245|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
33298246|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~This chemotherapy regimen will be administered each two weeks."
33298247|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~This chemotherapy regimen will be administered each two weeks."
33298248|NCT01122004|Active Comparator|Gabapentin|
33298249|NCT01122004|Active Comparator|Pregabalin|
33298250|NCT03933982|Experimental|Pyrotinib plus Vinorelbine|
33298251|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
33298252|NCT01118572|Experimental|YM177 group|
33298253|NCT01118572|Active Comparator|etodolac group|
33298254|NCT01118572|Placebo Comparator|placebo group|
33298255|NCT03937648|Experimental|COL-144 50mg|
33298256|NCT03937648|Experimental|COL-144 100mg|
33298257|NCT03937648|Experimental|COL-144 200mg|
33298258|NCT03937648|Experimental|COL-144 400mg|
33298259|NCT03937648|Placebo Comparator|Placebo|
33298260|NCT01219036|Other|Non-adherent|
33298261|NCT01219036|Other|Adherent|
33298262|NCT01216150||aspirin|group treated with aspirin alone
32737869|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
32737870|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
32737871|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
32737872|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
32737873|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
32737874|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
32737875|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
32737876|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
32737877|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
33298263|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
33298264|NCT03936010||DPP4i|Reference group
33298265|NCT03936010||Canagliflozin|Exposure group
33298266|NCT01118806||medical residents, vit d|vitamin
33298267|NCT01118806||levels of vitamin d|resident
33298268|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
33298269|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
33298270|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
33298271|NCT03937414|Experimental|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
33298272|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
33298273|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
33298274|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
33298275|NCT01219114||1|
33298276|NCT03933592|Active Comparator|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
33298277|NCT03933592|Experimental|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
33298278|NCT01219192|Experimental|M2ES 15mg|
33298279|NCT01219192|Experimental|M2ES 30mg|
33298280|NCT01219192|Experimental|M2ES 45mg|
33298281|NCT01219192|Experimental|M2ES 60mg|
33298282|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
33298283|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
33298284|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
33298285|NCT01119274|Experimental|Genotype-guided dosing algorithm|
33298286|NCT01119352|Experimental|1|
32737878|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
33298287|NCT01119352|Placebo Comparator|2|
33298288|NCT03935776|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend a 12-week intensive lifestyle programme.~The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.~Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
32737879|NCT03327545|Placebo Comparator|Control group|Control group
32737880|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
32737881|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
32737882|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
32737883|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
32737884|NCT03231163|Placebo Comparator|No Music|
32737885|NCT03231163|Experimental|Relaxing Classical Music|
32737886|NCT03231163|Experimental|Self-Selected Relaxing Music|
33298289|NCT03935776|Active Comparator|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
32737887|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
33298290|NCT01213888|Experimental|Arm II|
33298291|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
33298292|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
33298293|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
33298294|NCT01124578||Control|Existing used daily change-out device
33298295|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
33298296|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
33298297|NCT03781336|No Intervention|Life as usual control|Life as usual control (5 weeks)
32939816|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
33298298|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
32939817|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
32939818|NCT03270943|Active Comparator|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
33298299|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
33298300|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
33298301|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
33298302|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
33298303|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
33298304|NCT03937336|No Intervention|Control Group|
33298305|NCT03937336|Experimental|Bike Intervention Group|A 1-month bike-based program (1 session/week)
32939819|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
32939820|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
32939821|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
32939822|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
32939823|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
32939824|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
33298306|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
33298307|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
33298308|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
33298309|NCT01216618|No Intervention|Control|Subject starts with clamps without device
32737888|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
32939825|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
32939826|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
32939827|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
32939828|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
32939829|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
32939830|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
32939831|NCT03999944|Other|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.~Second intervention within 1 - 10 days of first intervention."
32939832|NCT03999944|Other|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.~Second intervention within 1 - 10 days of first intervention."
33298310|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
33298311|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
33298312|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
33298313|NCT01119742|Placebo Comparator|Vehicle A|4
33298314|NCT01119742|Placebo Comparator|Vehicle B|5
33087599|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
33087600|NCT04719104|Experimental|Participating group of neonates|Participating group: Neonates that have had both a serum bilirubin measurement and transcutaneous measurement post phototherapy. This is a single arm study as we are only targeting one group of individuals with the intervention (transcutaneous bilirubin measurement). However, we will compare the serum bilirubin measurement to the transcutaneous measurement from the same neonate to determine if there is a clinically significant difference between the two measurements.
33087601|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
33087602|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
32830544|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
33087603|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
33087604|NCT04718532||patients|patients with retinal diseases
33087605|NCT00107380|Experimental|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
33087606|NCT00270153|Placebo Comparator|enalapril|
33087607|NCT00270153|Placebo Comparator|Placebo|
32830545|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
33298315|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
33298316|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
33298317|NCT01219270||GFR <60|Under MDRD eGFR 60
33298318|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
33298319|NCT01216696|Experimental|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
33298320|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
33298321|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
33298322|NCT01216774|Experimental|Low load + fatigue|
33298323|NCT01216774|Active Comparator|High load|
33298324|NCT01216774|Placebo Comparator|Low load|
33298325|NCT03935386|Active Comparator|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
33298326|NCT03935386|Active Comparator|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
33298327|NCT03937258|Other|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
33298328|NCT03937258|Other|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
33298329|NCT03937258|Other|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
33298330|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
33298331|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
33298332|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
33298333|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
33298334|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
33298335|NCT03935152|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
33298336|NCT03935152|Placebo Comparator|Placebo|placebo by mouth every 8 hours until delivery
33298337|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
33298338|NCT03936946|Experimental|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
33298339|NCT03936946|Other|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
33298340|NCT03936946|Sham Comparator|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
33298341|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
33298342|NCT01328860|Experimental|Biologic; Stem Cells|
33298343|NCT01216930||All colorectal cancer patients|
33298344|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
33087608|NCT04050085|Experimental|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
33087609|NCT00289224|Experimental|1|Cholera Vaccine
33087610|NCT00289224|Placebo Comparator|2|Placebo
33087611|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
33087612|NCT04054843||Control|First trimester healthy pregnancies
33298345|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
32790833|NCT04876430|Experimental|Meropenem plus Best Available Therapy plus|"Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
33087613|NCT04055038|Experimental|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);~Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;~Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;~Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;~Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
33087614|NCT04055038|Active Comparator|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);~Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;~Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;~Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;~Etoposide 100 mg once daily orally d 1-10 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
33087615|NCT04054609|Other|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
33298346|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
33298347|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
33298348|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
32790834|NCT04876430|No Intervention|Best Available Therapy|"The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
33298349|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
33298350|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
33298351|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
33298352|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
33298353|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
33298354|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
33298355|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
33298356|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
33298357|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
33298358|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
32790835|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
32790836|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
33298359|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
33298360|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
33298361|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
33298362|NCT01217086|Active Comparator|CT-P13|
33298363|NCT01217086|Active Comparator|Remicade|
33298364|NCT01217164|No Intervention|higher protein|
33298365|NCT03933436|Experimental|Iodine|Iodine swabs.
33298366|NCT03933436|Active Comparator|Normal Saline|Saline flush.
33298367|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
33298368|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
33298369|NCT03934996|No Intervention|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
33298370|NCT03934996|Experimental|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
33298371|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
33087616|NCT04054531|Experimental|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
32790837|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
32790838|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
32790839|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
32790840|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
32790841|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
32790842|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
32790843|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
32790844|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
32790845|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
32790846|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
32790847|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
32790848|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
32790849|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
32790850|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
33087617|NCT04054531|Experimental|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
33087618|NCT04054336|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
33087619|NCT04054336|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
32790851|NCT04634617||Observational (questionnaires)|Patients complete questionnaires over 45-60 minutes consisting of demographic, treatment, lifestyle, disease, and comorbidity questions, as well as multiple study instruments assessing quality of life as it pertains to common toxicities of uterine cancer treatment.
32790852|NCT05650073|Experimental|Immersive Soundscapes Environment|Subjects having endovenous laser therapy with Vascular Surgery at Mayo Clinic will have relaxing music and relaxing sounds played during the procedure.
32790853|NCT05650073|No Intervention|Control Environment|Subjects having endovenous laser therapy with Vascular Surgery at Mayo Clinic will have no music played during the procedure.
32790854|NCT04870229|Active Comparator|Carnosine|Each participant will be given a daily oral dose 1g of methycellulose powder for 6 months
32790855|NCT04870229|Placebo Comparator|Placebo|Each participant will be given a daily oral dose 1g of placebo for 6 months
33087620|NCT04054336|Sham Comparator|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
33087621|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
33087622|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
32790856|NCT05649644|Active Comparator|Selective Trunk Block (SeTB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SeTB.It will be performed through two skin punctures and as three separate injections to the three trunks of the brachial plexus.
32790857|NCT05649644|Active Comparator|Supraclavicular Brachial Plexus Block (SC BPB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SC BPB. It will be performed using a single ultrasound window demonstrating the trunks and divisions of the brachial plexus in a superolateral position relative to the subclavian artery at the supraclavicular fossa.
32790858|NCT05649761|Experimental|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
32790859|NCT05649566|Experimental|Virtual Reality Game Group|"A total of 24 interventions will be carried out for each participant, separated by 2 each week for 3 months. Each intervention will consist of a VR session lasting 30 minutes. Each participant must play for 30 minutes in the game Beat know. The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
32790860|NCT05649566|No Intervention|Control Group|No intervention during 12 weeks.
32790861|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32790862|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32790863|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32790864|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32790865|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
32790866|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
32790867|NCT04875884|Experimental|MRI group|Subjects enrolled in this study will undergo both standard and new MRI techniques. The standard MRI is needed for your routine care and as ordered by the referring doctor. The new MRI is performed for research purposes. Participants will be imaged with both methods and the results will be compared.
32790868|NCT05649488|Experimental|Experimental group|184 patients were enrolled in the experimental group
32790869|NCT05649488|Other|Optical Coherence Tomography Subgroup|70 patients in the test group were enrolled in the OCT subgroup.
32790870|NCT04869956|Other|Standard diet|Dietary pattern: Standard diet
32790871|NCT04869956|Experimental|High - Fiber diet rich in PUFA|High - Fiber diet rich in PUFA
32790872|NCT05649332|Experimental|Subjects affected by pressure ulcers|Percentage of subjects whose wounds condition is improved during the four-week treatment with the medical device evaluated by Investigator, according to the pressure ulcers evaluation of PUSH ver. 3.0 score (according to evaluation of the following parameters: length times width, exudate amount and tissue type), performed by the Investigator at 4 weeks after the initiation of treatment, compared to day 0 (baseline).
32790873|NCT05649332|Experimental|Subjects affected by burns|Percentage of subjects whose wounds condition is improved during the four-week treatment with the medical device evaluated by Investigator, according to the evaluation of burn wound VSS score (according to evaluation of the following parameters: vascularity, height/thickness, pliability and pigmentation), performed by the Investigator at 4 weeks after the initiation of treatment, compared to day 0 (baseline).
32790874|NCT02230189|Experimental|Allergen challenge subjects|"Intervention: Segmental airway allergen challenge~Three types of subjects are studied in this arm:~1) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)"
32790875|NCT04196348|Active Comparator|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
32790876|NCT04196348|Active Comparator|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
32790877|NCT04196348|Active Comparator|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
32790878|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
33087623|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
32790879|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
32830546|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
33087624|NCT00255515|Experimental|1|quetiapine fumarate
33087625|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
33087626|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
33087627|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
33087628|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
33087629|NCT00289419|Active Comparator|A|
33087630|NCT00289419|Experimental|B|
32790880|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
32790881|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~Surgical intervention"
32790882|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
33298372|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
33298373|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
33298374|NCT03936712|Experimental|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
33298375|NCT03936712|Placebo Comparator|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
33298376|NCT01214590|Experimental|VascuActive Treatment|
33298377|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
33298378|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
33298379|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
33298380|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
33298381|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
33298382|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
33298383|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
33298384|NCT01214746|Placebo Comparator|Placebo|
33298385|NCT01214746|Active Comparator|Atorvastatin|
32790883|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
32790884|NCT05649254||study group|in which TENS application will be applied
33298386|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
33298387|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
33298388|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
33298389|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
33298390|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
33298391|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
33298392|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
33298393|NCT01120678||Neonates assessed for sepsis.|
33298394|NCT03933280|Active Comparator|Group P|nalbuphine/propofol group
33298395|NCT03933280|Active Comparator|Droup D|Nalbuphine/dexmedetomidine group
33298396|NCT01217788|Experimental|PH94B intranasal spray|
33298397|NCT01217788|Placebo Comparator|Placebo intranasal spray|
33298398|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
32790885|NCT05649254||Control group|placebo treatment
32790886|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
32790887|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
33298399|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
33298400|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
33298401|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
33298402|NCT03936556|Experimental|Marketed Stannous Fluoride Paste|Brush twice daily
33298403|NCT03936556|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
33298404|NCT01120912|Experimental|Oral insulin and placebo|
33298405|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
33298406|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
33298407|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
33087631|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
33087632|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
33087633|NCT01600144||data collection|
32790888|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
32790889|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
32790890|NCT05649020|Other|Prilocaine dose|to determine the ED50 and ED90 of intrathecal HP for patients undergoing undergoing ambulatory MRI/ultrasound fusión prostate biopsy.
33087634|NCT04504162||outpatient|Patients visiting a psychiatric hospital
32790891|NCT04869488|Experimental|Fluzoparib|
32790892|NCT04869488|Active Comparator|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|
32790893|NCT04869488|Experimental|Fluzoparib Combined With Apatinib|
32790894|NCT04883606||All Participants|Retrospective data will be collected from participants who followed up at least 6 months before teduglutide initiation or intestinal failure associated with SBS-IF diagnosis and at least 6 months of follow-up after teduglutide treatment initiation.
32790895|NCT05434286||Cirrhosis/ACLF of any etiology|Cirrhosis with hepatorenal syndrome-acute kidney injury (HRS-AKI) as per International Ascites Club criteria.
32790896|NCT04883528|Experimental|Sacubitril/valsartan|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.~Other Name: LCZ696"
33087635|NCT04503577||Bladder cancer patients|
33087636|NCT00270387|Experimental|001|Natrecor (nesiritide)
32790897|NCT04883528|Placebo Comparator|Placebo|"Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally."
32830547|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
32830548|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
32830549|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
33087637|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
33087638|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
33087639|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
33087640|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
33087641|NCT04490122||Inhalational|will receive inhalational anesthesia
33087642|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
33087643|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
33087644|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
33087645|NCT00255788|Active Comparator|Arm A|Everolimus - 28 days q 4 wk
33087646|NCT00255788|Active Comparator|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
33087647|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
33087648|NCT01600261||eye exam|
33087649|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
33087650|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
33087651|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
33087652|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
33087653|NCT04482205||covid|those operated from March 16, to May 31, 2020
33087654|NCT00255983|Experimental|1|faropenem medoxomil
33087655|NCT00255983|Placebo Comparator|2|
33087656|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
33087657|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
33087658|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
33087659|NCT00415259|Other|Flat control insoles|
32790898|NCT05648942|Experimental|Experimental - anemia testing|"All patients in the experimental group will undergo a point of care test. Patients who meet the higher point-of-care-testing thresholds as possibly having anemia (female: 130g/L; male: 140g/L) will have a formal complete blood count (CBC) test. Formal CBC will not be ordered for all patients in the experimental group to limit the burden on hospital resources. The study co-ordinator will review CBC levels and contact patients to inform them of their results. Patients identified as having anemia in the formal CBC test will be invited to be reviewed in the PBOC.~Patients in the experimental group who do not meet the threshold for possible anemia on the point-of-care test will continue the current pathway and be reassessed in the preoperative assessment clinic at the time of scheduled surgery. Patients in the experimental group who are determined not to have anemia after formal CBC tests will follow the same pathway."
33087660|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
33298408|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
32939833|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
33298409|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
33298410|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
33298411|NCT01219582||Group 1|
33298412|NCT03934918|Experimental|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
33298413|NCT03934918|No Intervention|Control|Patients for IOL admitted to Labor and Delivery
33298414|NCT03933358||Euthyroid|
33298415|NCT03933358||Low T3|low triiodothyronine syndrome
33298416|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and <45 years
33298417|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed < 45 years of age.~Age between 1 and <45 years"
33298418|NCT01121068||Health care workers|
33298419|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
33298420|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
33298421|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
33298422|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
33298423|NCT03934762|Active Comparator|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
32939834|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
32939835|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
32939836|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
32939837|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
32939838|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
32939839|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
32939840|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
32939841|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
32939842|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
32939843|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
33087661|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
32939844|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
33087662|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
33087663|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
33298424|NCT03934762|Experimental|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
33298425|NCT03934762|Experimental|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
33087664|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
33087665|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
33298426|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
32939845|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
33298427|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
33087666|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
33298428|NCT01121302|Experimental|1|dose escalating
33298429|NCT01121302|Placebo Comparator|2|placebo
33298430|NCT01121380|Experimental|Cohort A - 10 mg|
33298431|NCT01121380|Experimental|Cohort B - 20 mg|
33298432|NCT01121380|Experimental|Cohort C - 40 mg|
32939846|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
33298433|NCT01121380|Experimental|Cohort D - 80 mg|
33298434|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
33298435|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
33298436|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
33298437|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
33298438|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
33298439|NCT01215058||1|
33298440|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
33298441|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
33298442|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
33298443|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
33298444|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
33298445|NCT03936322|Experimental|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
33298446|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
33298447|NCT03936166|Experimental|Single Ascending Dose (Part 1)|
33298448|NCT03936166|Experimental|Multiple Ascending Dose (Part 2)|
33298449|NCT03936166|Placebo Comparator|Elderly Cohort (Part 3)|
33298450|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
33298451|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
33298452|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
33298453|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
33298454|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
33298455|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
33298456|NCT03936400|Experimental|Randomized controlled trial|Experimental group receiving a couple-based intervention
33298457|NCT03936400|Active Comparator|Active comparator: control group|A control group that receives same but delayed couple-based intervention
33298458|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
33298459|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
33298460|NCT01125670|Experimental|fast-fed sequence group|
33298461|NCT01125670|Experimental|fed-fast sequence group|
33298462|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
33298463|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
33298464|NCT03934528|Experimental|Pilot Study|
33298465|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
33298466|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
33087667|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
33087668|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
33087669|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
33087670|NCT01600417||clinical suspicion of lumbar instability|
33087671|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
33087672|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
33087673|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
33087674|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
33087675|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
33087676|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
33087677|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
33087678|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
33087679|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
33087680|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
33087681|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
33087682|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
33087683|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
33087684|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
33087685|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
33087686|NCT01609192|Experimental|hydroxyurea|
33087687|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
33087688|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
33087689|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
33087690|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
33087691|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
33087692|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
33087693|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
33087694|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
33087695|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
33087696|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
33087697|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
33087698|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
33087699|NCT01609465||Stable angina|
33087700|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
33087701|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
33087702|NCT00256178|Active Comparator|Simvastatin|
33087703|NCT00270738|Experimental|1|TrA training group
33087704|NCT00270738|Active Comparator|2|PFMT group
33087705|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
33087706|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
33087707|NCT01609504|Active Comparator|Total Mesorectal Excision|
33087708|NCT01609621||Retrograde access|
32790899|NCT05648942|No Intervention|Control|Patients in the control group will not be tested at point of care and will continue on the current pathway and be assessed in the preoperative assessment clinic at the time of scheduled surgery.
32790900|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
32790901|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
32790902|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
32790903|NCT04882046|Other|patients diagnosed by a clinician who suspects leptospirosis|
32790904|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
33298467|NCT03934450|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
33298468|NCT03934450|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
33298469|NCT03934450|Active Comparator|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
33298470|NCT03934450|Placebo Comparator|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
33298471|NCT01215682|Active Comparator|vit D|
32790905|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
32790906|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
32790907|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
32790908|NCT01646021|Experimental|Ibrutinib|
32790909|NCT01646021|Experimental|Temsirolimus|
32790910|NCT01750918|Experimental|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams [mg] twice daily) and panitumumab (6 milligrams per kilogram [mg/kg] every-2-week [Q2W]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
32790911|NCT01750918|Experimental|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
32790912|NCT01750918|Experimental|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
32790913|NCT01750918|Experimental|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
32790914|NCT01750918|Experimental|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
32790915|NCT01750918|Experimental|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
32790916|NCT01750918|Experimental|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
32830550|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
33298472|NCT01215682|Placebo Comparator|placebo|
33298473|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
33298474|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
33298475|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
33298476|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
33298477|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~if alive at 100 days post-transplant~and who gave informed consent"
33298478|NCT01220050|Experimental|Paricalcitol|
33298479|NCT01220050|Active Comparator|Standard therapy|
33403960|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.~Temsirolimus starting dose:~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
33403961|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
33087709|NCT02488408|Experimental|Part A|To identify the maximum tolerated dose (MTD) of bemcentinib (BGB324) in participants with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in participants with high risk MDS (Norway only).- This Arm of the study has completed recruitment
33087710|NCT02488408|Experimental|Part B|"To identify the safety and tolerability of bemcentinib:~as a single agent in participants with AML who are unsuitable for intensive chemotherapy~in a combination with cytarabine in participants with AML who are unsuitable for intensive chemotherapy~in a combination with decitabine in participants with AML who are unsuitable for intensive chemotherapy~as a single agent in participants with previously treated MDS"
32790917|NCT01750918|Experimental|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
32790918|NCT01750918|Experimental|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
32790919|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
32790920|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
32790921|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
33087711|NCT01580176|Experimental|GlucoseMonitor|
32790922|NCT01606228|Experimental|Paliperidone ER|
32790923|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
32790924|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
32790925|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
32790926|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
32790927|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
32790928|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
32790929|NCT04882319|Experimental|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously.
32790930|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
32790931|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
32790932|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
32790933|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
32790934|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
32790935|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
32790936|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
32790937|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
32790938|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
32790939|NCT01605136|Experimental|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
32790940|NCT01605136|Placebo Comparator|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
32790941|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
32790942|NCT04168450|Other|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
32790943|NCT04168450|Other|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
32790944|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
32790945|NCT01750684|Placebo Comparator|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
32790946|NCT01750684|Active Comparator|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
32790947|NCT01749982|Placebo Comparator|Placebo|Placebo tablets
32790948|NCT01749982|Experimental|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
32790949|NCT01749982|Experimental|Betaine|Betaine 1000 mg by mouth daily
33087712|NCT01609660|No Intervention|Control group|No intervention at all
33087713|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
33087714|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
33403962|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
33403963|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
33298480|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
33298481|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
33298482|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
33298483|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
33298484|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
33298485|NCT00141297|Experimental|PD-0332991|
33298486|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
33298487|NCT01123564|Experimental|Lucentis (ranibizumab)|
33298488|NCT01123564|Active Comparator|Laser|
33298489|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
33298490|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
32939847|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
32939848|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
33298491|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
33298492|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
33298493|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
33298494|NCT01218334||1|Cardiac Inpatient
33298495|NCT01218334||2|Cardiac Outpatient
32939849|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
32939850|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
32939851|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
32939852|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
32939853|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
32939854|NCT04005404|Experimental|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
32939855|NCT04005404|Experimental|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
33298496|NCT01218334||3|Cardiac Clinic Patient
33298497|NCT03932266|Experimental|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
33298498|NCT03932266|Other|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
33298499|NCT03933046|Experimental|children referred to PSG due to suspected SDB|
33298500|NCT03932110|Other|psoriasis vulgaris,|patients who have only psoriasis vulgaris
33298501|NCT03932110|Other|psoriatic arthritis|patients who have psoriatic arthritis
33298502|NCT03932110|Other|healthy control|healthy people
33298503|NCT00141219|Experimental|1|
33298504|NCT00141219|Placebo Comparator|2|
33298505|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
33298506|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
33298507|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
33298508|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
33298509|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
32939856|NCT04005404|Experimental|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
33298510|NCT03931798|Experimental|Treatment|Healthy participants were administered the Visual Scanning Test
33298511|NCT01222546|Experimental|CH5132799|
33298512|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
33298513|NCT01222624|Experimental|PankoMab-GEX™, 2-weekly|application q2w
33298514|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
32939857|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
32939858|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
33298515|NCT03931720|Experimental|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
33298516|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
33298517|NCT03934060|Experimental|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
33298518|NCT03934060|No Intervention|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
33298519|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
33298520|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
33298521|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
33298522|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
33298523|NCT01127464|Placebo Comparator|Placebo|sterile saline
33298524|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
33298525|NCT01222780|Experimental|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
33298526|NCT03931876|Placebo Comparator|Placebo|placebo
33298527|NCT03931876|Active Comparator|Active|AV-006
33298528|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
33298529|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
33298530|NCT01223014||1|Single cohort of 6 subjects
33298531|NCT01125904|Experimental|crizotinib|
33298532|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
33298533|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
33298534|NCT01220362|Other|Group 1|Bupivacaine 0.125%
33298535|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
33298536|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
33298537|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
33298538|NCT01123954|Other|Arm 1|
33298539|NCT01124032|Experimental|ADHD adults|
33298540|NCT01124032|Experimental|healthy adults|
33298541|NCT03934294|Experimental|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
33298542|NCT03934294|Placebo Comparator|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
33298543|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
33298544|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
33298545|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
33298546|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
33298547|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
33298548|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
33298549|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
33298550|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
33298551|NCT01218568|Experimental|Rifaximin plus lactulose|
33298552|NCT01218568|Active Comparator|lactulose|30-60ml/day
33298553|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
33298554|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
33298555|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
33298556|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
33298557|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
33298558|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
33298559|NCT01220518|Active Comparator|CT-P13|infliximab
33298560|NCT01220518|Active Comparator|Remicade|infliximab
33298561|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
33298562|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
33298563|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
33298564|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
33298565|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
33298566|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
33298567|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
33298568|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
33298569|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
33298570|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
32790950|NCT01749982|Experimental|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
32830551|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
33298571|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
33298572|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
33298573|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
33298574|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
33298575|NCT01223326|Placebo Comparator|Placebo|Placebo
33298576|NCT03934138|Active Comparator|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
33298577|NCT03934138|Placebo Comparator|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
33298578|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
33298579|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
33298580|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
33298581|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
33298582|NCT01124266|Experimental|endoscopist only|
33298583|NCT01124266|Experimental|nurse participation|
33298584|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
33298585|NCT01223638||Controls|Patients without any endocrine or hearing problems
33298586|NCT01127776|Experimental|Apos System|
33298587|NCT01127776|Placebo Comparator|CONTROL|
32790951|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
32790952|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
32790953|NCT01749826|Experimental|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
32790954|NCT01749826|Experimental|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
32790955|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
32790956|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
32790957|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
32939859|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
33403964|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
33403965|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
32939860|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
33403966|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
32790958|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
32790959|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
32790960|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
32790961|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
32790962|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
32790963|NCT05649527||Main sample|Sample of 880 children spontaneously recruited and representative of the French population according to the criteria defined for the study. Includes breastfed children.
32790964|NCT05649527||Additional sample|Children in the appropriate age group selected because of their specific consumption in order to increase the number of children in the concerned age group to allow a statist test.
32790965|NCT05649449|Experimental|Experimental|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
32790966|NCT05649449|Active Comparator|Control|Subjects receive routine mental health care from community agencies consisting of outpatient services coordinated at community behavioral health programs.
32790967|NCT05649371|Experimental|Prehabilitation|
32790970|NCT05649215||Patients group|Patients with low back pain
32790971|NCT01724866|Experimental|Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 milligram/ square metre (mg/m^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
32790972|NCT01724866|Experimental|Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
32790973|NCT01724866|Experimental|Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
32790974|NCT01724866|Experimental|Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|"Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
32790975|NCT04874441|No Intervention|blood culture-based diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
32790976|NCT04874441|Experimental|C. glabrata / krusei PCR diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
32790977|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
32790978|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
32790979|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
32790980|NCT05648981|Experimental|Test group|
32790981|NCT05648981|Active Comparator|Control group|
32790982|NCT04869215|Experimental|EverVita Pro consumed at breakfast followed by an ad lib meal|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include EverVita Pro bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
32790983|NCT04869215|Placebo Comparator|Control consumed at breakfast followed by an ad lib meal.|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include the control bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
32790984|NCT01747876|Experimental|LEE011|
33298588|NCT03932890|Active Comparator|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
32790985|NCT02273726|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
32790986|NCT02273726|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC.
32830552|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
32830553|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
32830554|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
32830555|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
32790987|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
32790988|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
32790989|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
32790990|NCT05648630|Experimental|Exercise Rehabilitation+PB125|Participants will be assigned to the Exercise+Placebo or Exercise+PB125 rehabilitation interventions using block randomization.
32790991|NCT05648630|Placebo Comparator|Exercise Rehabilitation with Placebo|Participants will be assigned to the Exercise+Placebo rehabilitation interventions using block randomization.
32790992|NCT01747486|Experimental|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
32790993|NCT01747486|Experimental|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
33102393|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
33298589|NCT03932890|Experimental|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
33298590|NCT03933124|Experimental|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.~20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.~20 participants will receive a Relaxmaker with 2D nature videos~20 participants will receive CareVRx with 3D nature videos and meditation videos."
33298591|NCT03933124|No Intervention|Control group|The control group receives standard postoperative care.
33298592|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
32790994|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
32790995|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
32790996|NCT01746862|Experimental|Saizen Test Group|
32790997|NCT01746862|Active Comparator|Saizen Control Group|
32790998|NCT01745848|Experimental|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
32790999|NCT01745380|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
32791000|NCT01745380|Placebo Comparator|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
32791001|NCT01745146|Experimental|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
32791002|NCT01745146|Active Comparator|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
32791003|NCT02272634|Experimental|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
32791004|NCT02272634|Experimental|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
32791005|NCT02272634|Placebo Comparator|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
32791006|NCT04550104|Active Comparator|Radiotherapy only|
32791007|NCT04550104|Experimental|Olaparib + radiotherapy|
32791008|NCT04550104|Experimental|AZD1390 + radiotherapy|
32791009|NCT04550104|Experimental|TBD1 + radiotherapy|DDRi to be decided
32791010|NCT04550104|Experimental|TBD2 + radiotherapy|DDRi to be decided
32791011|NCT04550104|Experimental|TBD3 + radiotherapy|DDRi to be decided
32791012|NCT05648474||Adult undergoing 1- or 2-level lateral lumbar interbody fusion surgery, inclusive of the L4-5 level|
32791013|NCT05648396||Revascularization|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are referred for coronary revascularization (PCI/CABG).
32791014|NCT05648396||Deferral|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are assigned to conservative management (optimal guidelines directed medical treatment).
32791015|NCT05648318|Experimental|Lactulose oral solution (LOS)|
32791016|NCT05648318|Active Comparator|polyethylene glycol (PEG)|
32791017|NCT02203513|Experimental|Arm 1-Prexasertib|Prexasertib (LY2606368) monotherapy treatment
32791018|NCT04881890|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
32791019|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
32791020|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
33298593|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
33298594|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
32791021|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
32791022|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
32791023|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
32791024|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
33102394|NCT04748016|Experimental|3D-printed models plus CT imaging|Fracture repair surgery using sterilized 3DP models, CT-MPR and CT-3DR for planning and intraoperative visualization
33298595|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
33298596|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
33298597|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
33298598|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
33298599|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
33298600|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
33298601|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
33298602|NCT01218880|Experimental|M2ES-A|
33298603|NCT01218880|Experimental|M2ES-B|
33298604|NCT01218880|Experimental|M2ES-C|
33298605|NCT01218880|Experimental|M2ES-D|
33298606|NCT00162266|Experimental|Abatacept (10 mg/Kg) - Open Label|
33298607|NCT00162266|Experimental|Abatacept (2 mg/kg) - Double blind|
33298608|NCT00162266|Experimental|Abatacept (10 mg/kg) - Double blind|
33298609|NCT00162266|Experimental|Placebo - Double blind|
33298610|NCT01223716|Experimental|Perceptual learning|
33298611|NCT01223716|Experimental|Video Game|
33298612|NCT01223716|Experimental|Occlusion Therapy|
33298613|NCT03931018|Experimental|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
33298614|NCT03931018|Experimental|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
33298615|NCT01223794||Experimental Group|Fall in higher risk
33298616|NCT01223794||Control Group|Fall in lower risk
33298617|NCT03928444|Experimental|stem cells|one side of the face to be treated with intradermal stem cells
33298618|NCT03928444|Placebo Comparator|control|one side of face treated with intradermal saline
33298619|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33298620|NCT03930940|Experimental|RIC group|RIC treatment and regular treatment.
33298621|NCT03930940|Other|Control group|Regular treatment alone.
33298622|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
33298623|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
33298624|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
33298625|NCT01223872||Routine Patient Care|
32791025|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
32791026|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
33298626|NCT01223872||Previously-enrolled REACH Clinic Patients|
33298627|NCT01223872||New REACH Clinic Patients|
33298628|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
33298629|NCT01073384|Experimental|BDP 3 mg|1 mg TID
33298630|NCT01073384|Experimental|BDP 6 mg|2 mg TID
33298631|NCT01073384|Experimental|BDP 9 mg|3 mg TID
33298632|NCT01073384|Experimental|BDP 12 mg|4 mg TID
33298633|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
33298634|NCT01126528|Placebo Comparator|Control|Placebo control group
33298635|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
33298636|NCT01329172|Placebo Comparator|placebo|sun flower oil
33298637|NCT00225212|Experimental|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
33403967|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
32791027|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
32791028|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
32791029|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
32791030|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
32791031|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
32791032|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
32791033|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
32791034|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
32791035|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
32791036|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
32791037|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
32791038|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
32791039|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
32791040|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
32791041|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
32791042|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
32791043|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
32791044|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
32791045|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
32791046|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
32791047|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
32791048|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
32791049|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
32791050|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
32791051|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
32791052|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
32791053|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
32791054|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
32791055|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
32791056|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
32791057|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
33102395|NCT04748016|Active Comparator|CT imaging alone|Fracture repair surgery using CT-MPR and CT-3DR for planning and intraoperative visualization
32791058|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
32791059|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
32791060|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
32791061|NCT05648162|Experimental|Electrical acupuncture+ tDCS + NDT-Bobath Rehabilitation|Electrical acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
32791062|NCT05648162|Active Comparator|Acupuncture + tDCS + NDT-Bobath Rehabilitation|Acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
32791063|NCT05648162|Active Comparator|Acupuncture + sham tDCS + NDT-Bobath Rehabilitation|Acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
32791064|NCT05648162|Active Comparator|Electrical acupuncture + sham tDCS + NDT-Bobath Rehabilitation|Electrical acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
32791065|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
32791066|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
32791067|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
32791068|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
32791069|NCT05296993|Experimental|Extracts|The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance
32791070|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32791071|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32791072|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
32791073|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
32791074|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
32791075|NCT04868396||Glioblastoma patients|Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).
32791076|NCT05647928||retinal redetachment after silicone oil removal|
32791077|NCT05647928||NO retinal redetachment after silicone oil removal|
32791078|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
32791079|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
32791080|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
32791081|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
32791086|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
32791087|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
32791088|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
32791089|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
32791090|NCT05647850||Baseline characteristics of all patients|
32791091|NCT05647850||General characteristics of the patients.|
32791092|NCT04766749|Experimental|Experimental|40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
32791093|NCT04766749|No Intervention|Control|A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
32791094|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
32791095|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32791096|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
32791097|NCT02225665|Experimental|Cohort 1|
32791098|NCT02225665|Experimental|Cohort 2|
32791099|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
32791100|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
32791101|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
32791102|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
32791103|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
32791104|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
32791105|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
32791106|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
32791107|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
32791108|NCT02296190|Placebo Comparator|Placebo|1 dose of placebo via 4 intranasal applications at time 0
32791109|NCT04875026|Experimental|5-fluorouracil 4% (Tolak) + Dexeryl|This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.
32791110|NCT04875026|Other|5-fluorouracil 4% (Tolak)|This group will only apply 5-FU once daily for 4 weeks.
32791111|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32791112|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
32791113|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
32791114|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
32791115|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
32791116|NCT05647772|Experimental|Group 1: Standalone App|Standalone parenting app called UseIt!
32791117|NCT05647772|Experimental|Group 2: App plus Coach|Standalone parenting app called UseIt! plus a coach.
32791118|NCT05647772|Active Comparator|Group 3: Control App|Control condition: mindfulness app called SmilingMind.
32791119|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
32791120|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
32791121|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
32791122|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
32791123|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
32791124|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
32791125|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
32791126|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
32791127|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
32791128|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
32791129|NCT02200939|Experimental|Partial-Thickness Tear|Intermediate or High partial-thickness tear (PTT) or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
32791130|NCT02200939|Experimental|Full Thickness Tear|Medium or large full thickness tear (FTT) of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
32791131|NCT05152381|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
32791132|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
32791133|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
32791134|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 100mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
33087715|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
33087716|NCT00289965|Active Comparator|1|in-person brief motivational intervention
33087717|NCT00289965|Active Comparator|2|Alcohol 101plus
33087718|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
33087719|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
32791135|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
32791136|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
32791137|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
32791138|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
32791139|NCT04880876|Experimental|Open Label 12-17 years of age: Eluxadoline 100 mg|Eluxadoline one 100mg tablet, oral administration, twice daily with food. May use 25mg tablets to administer 100mg dose. Take at approximately the same time each day.
32791140|NCT04880876|Experimental|Open Label 6-11 years of age: Eluxadoline 50mg|Eluxadoline two 25mg tablets, oral administration, twice daily with food. Take at approximately the same time each day.
32791141|NCT05647694|Experimental|V-NAV users|Users who try the V-NAV for navigation tasks.
32830556|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
33087720|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
33087721|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
33087722|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
33087723|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
33087724|NCT01609855|Placebo Comparator|Placebo arm|
33087725|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
33087726|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
32791142|NCT02269124|No Intervention|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
32791143|NCT02269124|Experimental|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
32791144|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
32791145|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
32791146|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
32791147|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
32791148|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
32791149|NCT05647616|Experimental|Strengthening exercises|The participants in this group will be given instructions to follow a resistance exercises to strengthen the peroneus longs muscle.
32791150|NCT05647616|No Intervention|Control|Participants in this group will be given no treatment.
32791151|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
32791152|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
32791153|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
32791154|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
32791155|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
32791156|NCT01956123|Experimental|A|Follitropin Delta (FE 999049) (COS cycle 2)
32791157|NCT01956123|Active Comparator|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
32791158|NCT01956123|Experimental|C|Follitropin Delta (FE 999049) (COS cycle 3)
33087727|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
32791159|NCT01956123|Active Comparator|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
33298638|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
32791161|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
32791162|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
32791163|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
32791164|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
33087728|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
33087729|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
33087730|NCT00256412|Placebo Comparator|1|
33087731|NCT00256412|Active Comparator|2|Low Dose
33087732|NCT00256412|Active Comparator|3|High Dose
33087733|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
33087734|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
33087735|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
33087736|NCT01602367|Experimental|Arm4: Placebo|
32791165|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
32791166|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
32791167|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
32791168|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
33087737|NCT01606891|Experimental|parent-targeted intervention|experimental
33087738|NCT01606891|No Intervention|Primary Care|Standard primary care
33298639|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
33298640|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
33298641|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
33298642|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
33298643|NCT01226056|Experimental|RAD001 in combination with sorafenib|
33298644|NCT01127932|Experimental|CBT for suicide|
33298645|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
33298646|NCT00162032|Other|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
33298647|NCT00162032|Other|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
33298648|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
33298649|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
33298650|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
33298651|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
33298652|NCT03968120|No Intervention|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
33298653|NCT03968120|Active Comparator|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
33298654|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
33298655|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
33298656|NCT00258674|Active Comparator|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
33298657|NCT00258674|Experimental|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
33298658|NCT00258674|Experimental|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
33298659|NCT01126684|Active Comparator|Atorvastatin|
33298660|NCT01126684|Placebo Comparator|Placebo|
33298661|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
33298662|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
33298663|NCT01224028|Experimental|Tacrolimus group|
33298664|NCT01224028|Placebo Comparator|Placebo|
33298665|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
33298666|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
33298667|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
33298668|NCT01226212|Placebo Comparator|Placebo|maltodextrose
33298669|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
33298670|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
33298671|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
33298672|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
33298673|NCT01128088||PCA and Volulyte|
33298674|NCT01128088||PCA and Hartmann's|
33298675|NCT01128088||Spinal and Volulyte|
33298676|NCT01128088||Spinal and Hartmann's|
33087739|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
33087740|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
33087741|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
33087742|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
33087743|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
33087744|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
32791169|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
33087745|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
33087746|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
33087747|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
33087748|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
33087749|NCT02270047|Placebo Comparator|B|Orange nectar
33087750|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
33087751|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
33087752|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
33087753|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
33087754|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
33298677|NCT03930706|Experimental|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
33087755|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
33298678|NCT03930706|Active Comparator|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
33298679|NCT03930862|Active Comparator|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
33298680|NCT03930862|Experimental|Locator attachment|attachment retaining implant overdentures
33298681|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
33298682|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
33298683|NCT03932578|Active Comparator|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
33298684|NCT03932578|Active Comparator|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
33298685|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
33298686|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
33087756|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
33087757|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
33087758|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
33087759|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
33087760|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
33087761|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
33087762|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
33087763|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
33087764|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
33298687|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
33298688|NCT00258440|Active Comparator|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
33298689|NCT00258440|Experimental|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
33298690|NCT00258440|Experimental|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
33298691|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
33298692|NCT01220986||Right hepatectomy|Intervals from inflow division.
33298693|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
33298694|NCT00224120|Experimental|Silodosin|Silodosin 8 mg/Day with food
33298695|NCT00224120|Placebo Comparator|Placebo|Matching placebo capsule once daily with food
33298696|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
33298697|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
33298698|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
33298699|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
33298700|NCT01224418|Experimental|Tacrolimus group|
33298701|NCT00257660|Experimental|1|Drug: abobotulinumtoxinA (Dysport®)
33298702|NCT00257660|Placebo Comparator|2|Placebo
33298703|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
33298704|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
33298705|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
33298706|NCT03972020|Experimental|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
33298707|NCT03972020|Active Comparator|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
33298708|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
33298709|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
33298710|NCT00224042|Experimental|IV iron|
33298711|NCT00224042|Active Comparator|oral iron|
33298712|NCT01129258|Experimental|PF-04991532|
33298713|NCT01129258|Placebo Comparator|Placebo|
33298714|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
33298715|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
33298716|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~Yin deficiency of spleen and kidney~Yang deficiency of spleen and kidney~Deficiency of both Yin and Yang~Stagnation of dampness and poison in the blood~Excessive heat and poison"
33298717|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
33298718|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
33298719|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
33298720|NCT01221376|Experimental|Imatinib Mesylate|
33298721|NCT03928132|Experimental|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
33298722|NCT03928132|Sham Comparator|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
33298723|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
33298724|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
33298725|NCT00160706|Experimental|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
32939861|NCT03510481|Experimental|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
32939862|NCT03510481|Experimental|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
33298726|NCT03928210|Experimental|Digoxin|
32939863|NCT03510481|Placebo Comparator|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
32939864|NCT03510481|Placebo Comparator|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
32939865|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
32939866|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
32939867|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
32939868|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
32939869|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
32939870|NCT03404401|Experimental|BLI4700 Bowel Preparation|
32939871|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
32939872|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
32939873|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
32939874|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
32939875|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
32939876|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
32939877|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
32939878|NCT04331990|Active Comparator|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
32939879|NCT04331990|Experimental|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
32939880|NCT04331990|Experimental|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
33102396|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
33298727|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
33298728|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
33298729|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
33298730|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
32791170|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
32791171|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
32791172|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
32791173|NCT02298023|Experimental|Mesenchymal stem cell group|Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.
32791174|NCT02298023|Active Comparator|Active control (fibrin glue) group|Received fibrin glue and normal saline.
32791175|NCT02298023|Placebo Comparator|Control (normal saline )group|Received only normal saline.
32791176|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
32791177|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
32791178|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
32791179|NCT01909479|Experimental|MOD-4023|
32791180|NCT01909479|Placebo Comparator|Placebo|
32791181|NCT04764721|Experimental|Patients enrolled in Neurocog-Covid study in Nancy hospital|Young patients (< 65 year old) who contracted VIDOC 19 and were hospitalized for less than 7 days during the first wave, and who present cognitive disorders may be definitively included in the Neurocog-Covid study if their neuropsychological assessment is abnormal. They will then have a prescription for a cerebral MRI and will be enrolled in the TEP-Covid study. If they accept, they will receive a 18F-FDG PET-CT .
32791182|NCT04764175|Experimental|Telephone All Nations Breath of Life|This is a culturally targeted smoking cessation program developed for American Indian communities. It includes individual telephone counseling, text messaging, and educational materials.
32791183|NCT04764175|Active Comparator|Comparison Program|This is a non-culturally targeted smoking cessation program. It includes individual counseling, text messaging, and educational materials.
32791184|NCT04760977||Trauma patients in shock|The study focuses on hypotensive trauma patients assisted by HEMS teams
32791185|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
32791186|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
32791187|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
32791188|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
32791189|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
32791190|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
33087765|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
33087766|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
33087767|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
33087768|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
33087769|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
33087770|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
33087771|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
33087772|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
33087773|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
33087774|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
33087775|NCT00290121|Active Comparator|Olanzapine|
33087776|NCT02270905|Experimental|dCELL® Meniscus|
33087777|NCT04709744||SLE patients|SLE patients were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Vit D was measured in serum by ELISA. Vit D was added to anti COVID-19.
32791191|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
33298731|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
33298732|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
32791192|NCT02223715||CDI|
32791193|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
33298733|NCT01224808|Experimental|Experimental|
33298734|NCT03927976|Experimental|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
33298735|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
33298736|NCT01221532|No Intervention|Usual Care|
33102397|NCT04736901||Group 1|Enoxaparin therapeutic dose
33298737|NCT01226680|Experimental|Tasocitinib 0.005% QD|
33298738|NCT01226680|Experimental|Tasocitinib 0.003% QD|
33298739|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
33298740|NCT00257192|Placebo Comparator|2.0|
33298741|NCT00257192|Active Comparator|1.0|
33298742|NCT01226758|Experimental|FLU-v with adjuvant|
33298743|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
33298744|NCT03927898|Experimental|SBRT+Toripalimab|Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
33298745|NCT01224964|Active Comparator|Montelukast|
33298746|NCT01224964|Active Comparator|long-acting beta2-mimetic|
33298747|NCT03932734||survey|
33298748|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
33102398|NCT04736901||Group 2|Enoxaparin prophylactic dose
33298749|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
33298750|NCT00256724|Sham Comparator|Sham ITD|sham Impedance Threshold Device
33298751|NCT00256724|Active Comparator|active ITD|active impedance threshold device
33298752|NCT03928054|Experimental|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
33298753|NCT03928054|Experimental|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
33298754|NCT03930550|Experimental|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is without the infrared light"
33298755|NCT03930550|Active Comparator|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is with the infrared light as guide"
33298756|NCT03967964|Experimental|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
33298757|NCT03967964|Experimental|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
33298758|NCT03967964|Experimental|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
33298759|NCT03967964|Active Comparator|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
33298760|NCT03967964|Active Comparator|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
33298761|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
33298762|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
33298763|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
33298764|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
33298765|NCT03967730|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
33298766|NCT03930238|Experimental|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
33403968|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
33087778|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
33087779|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
33403969|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
32791194|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
33087780|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
33087781|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
33087782|NCT02271178|Other|Conventional treatment|Usual therapy
33087783|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
33087784|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
33087785|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
33403970|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
33403971|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
33403972|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol~RER Interim Maintenance #1~RER Delayed Intensification~RER Interim Maintenance #2~RER Maintenance (12 weeks=84 days)"
33403973|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL~1. SER Consolidation~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance~Intrathecal triple chemotherapy at d0"
33403974|NCT05166304|Placebo Comparator|placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
33403975|NCT05166304|Experimental|rebamipide|100 mg rebamipide taken orally daily plus Methotrexate 7.5 mg weekly
33403976|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
33403977|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
33403978|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
33403979|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
33403980|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
33403981|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
33403982|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
33403983|NCT03148288|Placebo Comparator|placebo|
33403984|NCT02339272||NOA|Infertile males with non obstructive azoospermia
33403985|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
33403986|NCT02348944||15 healthy volunteers|Other: serum and urine sample
33403987|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
33403988|NCT04948138|Experimental|MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome|Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)
33403989|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
33403990|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
33087786|NCT02271373|No Intervention|control group|The control school did not have any interventions.
33087787|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
33087788|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
33087789|NCT00271050|Experimental|1|
33403991|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
33403992|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
33403993|NCT04895956|Active Comparator|Intra-sheath injection|In patients randomized to the intra-sheath, corticosteroids will be injected directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
33403994|NCT04895956|Experimental|Extra-sheath injection|In patients randomized to the extra-sheath arm, corticosteroids will be injected surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
33403995|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Insertion of finished dentures."
33403996|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.~Mandibular second impression with border molding using compound and impression rubber in custom tray.~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Finished dentures insertion."
33403997|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
33403998|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
33403999|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
33404000|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
33404001|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
33404002|NCT03964402||Control|Control arm, i.e., as per standard procedures
33404003|NCT03964402||Experimental|Experimental arm, i.e. investigational product
33404004|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
33404005|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
33404006|NCT04824274|Experimental|Transversus abdominis plane block and intrathecal fentanyl|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.
33404007|NCT04824274|Active Comparator|Intrathecal morphine|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.
33404008|NCT03112018|Active Comparator|Standard care|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation"
33404009|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation~Health provider training (PRONTO)~Quality Improvement (QI) Cycles"
33404010|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
33087790|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
33087791|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
33087792|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
33404011|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
33404012|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
33087793|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
33102399|NCT04736901||Group 3|Rivaroxaban therapeutic dose
32791195|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
32791196|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
33298767|NCT03930238|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
33298768|NCT03967886|Experimental|YYD601 20mg|Esomeprazole magnesium Dihydrate.
33298769|NCT03967886|Active Comparator|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
33298770|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
33298771|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
33298772|NCT03968042|Placebo Comparator|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
33298773|NCT03968042|Experimental|RT with NGF|Nerve growth factor adding to regular treatment
33298774|NCT03968042|Experimental|RT with EDV|Edaravone adding to regular treatment
33298775|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
33298776|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
33298777|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
33298778|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
33298779|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
33298780|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
33298781|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
33298782|NCT01128322|Active Comparator|S-Amlodipine 5mg|
33298783|NCT01128322|Active Comparator|Telmisartan 40mg|
33298784|NCT01128322|Active Comparator|Telmisartan 80mg|
33298785|NCT01128322|Placebo Comparator|Placebo|
33298786|NCT00157820|Active Comparator|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
33298787|NCT00157820|Experimental|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
33298788|NCT00157820|Experimental|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
33298789|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
33298790|NCT01129570|Experimental|Siliphos - dose escalation|
33298791|NCT00223808|Experimental|Robot-Low|low-dose mechanically-assisted upper limb therapy
33298792|NCT00223808|Experimental|Robot-High|high-dose mechanically-assisted upper limb therapy
33298793|NCT00223808|Active Comparator|Control|additional traditional therapy
33298794|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
33298795|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
33298796|NCT03971942|Experimental|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
33298797|NCT03971942|Experimental|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
33298798|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
33298799|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
33298800|NCT01073540|Experimental|Arm 1|
33298801|NCT01073540|Active Comparator|Arm 2|
33298802|NCT03930472|Experimental|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F&V only
33298803|NCT03930472|Experimental|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
33298804|NCT03930472|No Intervention|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
33298805|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
33298806|NCT03741608|Active Comparator|Education only|High blood pressure management education
33298807|NCT03930160||Mortality outcome|
33298808|NCT01075724|Active Comparator|Forced air|Forced Air Warming
33298809|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
33298810|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
33298811|NCT01225120|Experimental|Gait Training|
33298812|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
33298813|NCT03740386|Experimental|articaine|articaine 4% 1:200000
33298814|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
33298815|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
33298816|NCT03927352|Experimental|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
33298817|NCT03927352|Active Comparator|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
33087794|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
32791197|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
33298818|NCT03929770|Active Comparator|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
33298819|NCT03929770|Experimental|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
33298820|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
33298821|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
33298822|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
33298823|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
33298824|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
33298825|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
32791198|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
32791199|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
33298826|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
33298827|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
33298828|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
33298829|NCT03927586|Experimental|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
33298830|NCT03927586|Experimental|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
33298831|NCT03927586|Experimental|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
33087795|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
33298832|NCT03927586|Experimental|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
33102400|NCT04736901||Group 4|Rivaroxaban prophylactic dose
33102401|NCT04736901||Group 5|Apixaban therapeutic dose
33102402|NCT04736901||Group 6|Apixaban prophylactic dose
33298833|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
33298834|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
33298835|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
33298836|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
33298837|NCT01227070||Asthmatic|
33298838|NCT01227070||Healthy Control|
33298839|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
33298840|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
33298841|NCT01225432|Experimental|Gait Training|
33298843|NCT03929692|Other|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
33298844|NCT03929692|Other|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
33298845|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
33298846|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
33298847|NCT03928990|Experimental|Experimental arm|
33298848|NCT03929380|Experimental|10x10 squat protocol|
33298849|NCT03929380|Experimental|As Fast As Possible 100 squat protocol|
33298850|NCT01128634|Other|GSK573719|GSK573719
33298851|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
33298852|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
33298853|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
33298854|NCT01227148|Experimental|Tightly glucose conntrol|
33298855|NCT01227148|Active Comparator|Conventional glucose control|
33298856|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
33298857|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
33298858|NCT01227226|Active Comparator|Visine|Visine artificial tear
33298859|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
33087796|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
33087797|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
33298860|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
33298861|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
33298862|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
33298863|NCT01225510|Experimental|Primary Cohort|
33298864|NCT01225510|Experimental|Exploratory Cohort|
33298865|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
33298866|NCT03929146|Experimental|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
33298867|NCT03929146|Other|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
33087798|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
33298868|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
33087799|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
33102403|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
33298869|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
33298870|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
33298871|NCT03927196|Experimental|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
33298872|NCT03927196|No Intervention|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
33298873|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
33298874|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
33298875|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
33298876|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
33298877|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
33298878|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
33298879|NCT01130038||Children with DCD and Typical Development|
33298880|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
33298881|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
33298882|NCT03928834|Experimental|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
33298883|NCT03928834|No Intervention|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
33087800|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
32791200|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
32791201|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
32791202|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
33298884|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
33298885|NCT01222000|Experimental|right controlled against moisturizing cream|
33298886|NCT01222000|Experimental|left controlled against moisturizing cream|
33298887|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
33298888|NCT03925090|Experimental|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
33298889|NCT03925090|Placebo Comparator|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
33298890|NCT03927040|Experimental|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
33298891|NCT03925012|Experimental|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
33298892|NCT03928756|Experimental|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
33298893|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
32791203|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
32791204|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
33298894|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298895|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298896|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298897|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298898|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
32791205|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
32791206|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
32791207|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
32791208|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
32791209|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
32791210|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
33087801|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
33087802|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
33298899|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298900|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
33298901|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
33298902|NCT03926806|Active Comparator|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
33298903|NCT03926806|Experimental|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
33298904|NCT03926962|Experimental|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
33298905|NCT03926962|Placebo Comparator|Placebo|Visually matching placebo
33298906|NCT03926884|Experimental|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
33298907|NCT03926884|Placebo Comparator|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
33298908|NCT01228240|Experimental|Metformin, Apo-metformin|
32791211|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
32791212|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
32791213|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
32791214|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
32791215|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
32791216|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
32791217|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
32791218|NCT04881461|Placebo Comparator|Placebo|Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily
33298909|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
33298910|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
33298911|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
33298912|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
33298913|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
33298914|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
33298915|NCT02528578|Experimental|healthy volunteers|
33298916|NCT03919786|Experimental|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
33298917|NCT03919786|Placebo Comparator|normal saline group|Same volume of normal saline will be administrated
33298918|NCT03926572|Other|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
33298919|NCT03920020|Other|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
33298920|NCT03920020|Other|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
33298921|NCT03920020|Other|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
33298922|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
33298923|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
33298924|NCT03924544|Experimental|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
33298925|NCT03924544|Active Comparator|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
33298926|NCT03832192|Experimental|care.coach Avatar|
33298927|NCT03832192|No Intervention|Control|
33298928|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
33298929|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
33298930|NCT00154310|Experimental|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
33298931|NCT00154310|Active Comparator|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
33404013|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
32791219|NCT04881461|Experimental|5-grass mix SLIT-drops|Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
33087803|NCT02271841||Before introduction of PVI|Physicians' practices
32791220|NCT05648903|Experimental|One-to-one|All participants are offered a choice of three dietary approaches.
32791221|NCT05648903|Experimental|Group|All participants are offered a choice of three dietary approaches.
33087804|NCT02271841||After introduction of PVI|Physicians' practices
32791222|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
32791223|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
32791224|NCT05648825|Experimental|Experimental: Apical Hypertrophic Cardiomyopathy|Transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy
32791225|NCT05648747||Complicated Pelvic Inflammatory Disease|The development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
32791226|NCT05648747||Non-Complicated Pelvic Inflammatory Disease|No development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
32791227|NCT05648669|Experimental|Elagolix|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
33404014|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
33404015|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
33404016|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
32791228|NCT05648669|Placebo Comparator|Elagolix placebo|Placebo BID for the 6-month Treatment Period
32791229|NCT05648591|Experimental|Iloperidone|Open-label iloperidone
32791230|NCT04172805|Experimental|anlotinib combined with Toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks.
32791231|NCT02263547|Other|teriflunomide elimination with colestipol|
33298932|NCT03771664|Placebo Comparator|Placebo|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217 matching placebo capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217 matching placebo capsules, orally, once daily, 30 minutes prior to lights out [polysomnography (PSG)] on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
32791232|NCT04620759|Experimental|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
32791233|NCT04620759|Placebo Comparator|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
32791234|NCT05648513|Experimental|Motivational Interview|"Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the pregnant women consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.~Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines."
32791235|NCT05648513|No Intervention|Control Group|Control Group Experimental Group ( n=26 ) Routine antenatal monitoring will be kept with the control group. Routine antenatal monitoring Completion of motivational interviewing session Inspection of the vaccine card 1st and 2nd postnatal months and implementation of Parent Attitudes About Childhood Vaccines Survey (PACV) Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines.
32791236|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
32791237|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
32791238|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
32791239|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
32791240|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
33087805|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
32791241|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
32791242|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
32791243|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
33087806|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
33298933|NCT03771664|Experimental|SAGE-217|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217, 30 milligrams (mg) capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217, 30 mg capsules, orally, once daily, 30 minutes prior to lights out (PSG) on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
33298934|NCT03771352|Other|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
33404017|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
33298935|NCT03770728|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) subcutaneous (SC) injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
33298936|NCT03770728|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
32791244|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
32791245|NCT04869059|Experimental|Transcranial direct current stimulation|20 minutes of 1 milliamp transcranial direct current stimulation to presupplementary motor area for 15 sessions
32791246|NCT04869059|Sham Comparator|Sham transcranial direct current stimulation|20 minutes of sham transcranial direct current stimulation to presupplementary motor area for 15 sessions
33087807|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
33298937|NCT03770728|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and was maintained at the 4 mg dose through-out the treatment duration, up to Week 30.
33298938|NCT03770728|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 3 and later up-titrated to 6 mg and was maintained at the 6 mg dose through-out the treatment duration, up to Week 30.
33298939|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
33298940|NCT01227850||Parenteral nutrition patients.|
33298941|NCT02529358|Experimental|EG stand|Standardized text messages
33298942|NCT02529358|Experimental|EG ind|Personalized text messages
33298943|NCT02529358|Other|Control|Standardized text messages after 10 weeks
33298944|NCT01228474|Experimental|SET|Single embryo transfer
33298945|NCT01228474|Active Comparator|DET|Double embryo transfer
33298946|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
33298947|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
33298948|NCT03926182|Experimental|Fasted AST2818 tablets following a period of fasting|
33298949|NCT03926182|Experimental|High-fat meal AST2818 tablets following a high-fat meal|
33298950|NCT01132300|Experimental|Treatment|
33298951|NCT03926416|Experimental|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10^3 PFU in 200 uL) and an intramuscular injection of placebo
33298952|NCT03926416|Active Comparator|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
33298953|NCT03926416|Experimental|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10^5 PFU in 500 uL)
33298954|NCT03926416|Placebo Comparator|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
33298955|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
33298956|NCT01130584||Cancer patient|
33298957|NCT01130662|Experimental|Decitabine Midostaurin combination|
33298958|NCT01228006|Experimental|Treatment|NatusGerin
33298959|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
33298960|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
33298961|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
32791247|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
32791248|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
32791249|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
33404018|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
32791250|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
32791251|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
32791252|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
32791253|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
32791254|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
32791255|NCT05647967||the consolidation perfusion/the consolidation size|Patients with respiratory failure and lung consolidation proved by chest imaging underwent lung ultrasound to evaluate the regional perfusion and the size of consolidation.
32791256|NCT04873193|Other|Oscillometry + Pneumotach Procedure with Leo Device measurements|"All patients will undergo oscillometry procedure, followed by pneumotach procedure to measure tidal volume in different sitting positions. The Leo device will be worn throughout both procedures to measure the chest electrical impedance and compare against pneumotach measurements.~Oscillometry and pneumotach are part of standard of care."
32791257|NCT04873037|Active Comparator|Emsella Chair Active Treatment|Active subjects will be asked to sit on the center of the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the reminder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
32791258|NCT04873037|Placebo Comparator|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (less than 10% power).
32791259|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
32791260|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
32791261|NCT04868357|Experimental|Hypnosis|Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group hypnosis. It includes 1 hypnotic induction, multiple suggestions of relaxation and a feeling of air entering the lungs, and a closing exercise. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness. This arm is structured following the classic format of didactic hypnosis interventions, were patients discover the exercise by doing it, and receive keys to be able to recreate the hypnotic state on their own.
32791262|NCT04868357|Active Comparator|Relaxation|"Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group dynamic relaxation. It includes 1 exercise to liberate tension, 3 exercises to increase proprioception and calmness, and 3 exercises for calming and regulating the breath. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness.~Provides additional care that motivates the patients to participate in the control group.~Allows the controlling of number of group interventions accross arms (2).~Allows to control for motivation, as both arms are introduced identically: the benefits and interest of using self-relaxation techniques for complementary care in anxiety and anxiety-related dyspnea are underscored.~It allows the disentanglement of hypnosis and relaxation effects . This was crucial, inasmuch as hypnosis too includes physical relaxation and breathing exercises."
32791263|NCT05647499|Experimental|The Back 2 School program (B2S) for problematic school absenteeism|The B2S program is a modular trans-diagnostic cognitive behavioral program aimed at helping children and youth with problematic levels of school absenteeism.
32791264|NCT05647421|Active Comparator|The AcrySof™ IQ Vivity™ intraocular lens group|The AcrySof™ IQ Vivity™ will be implanted in 20 eyes of 10 patients (group 1)
32791265|NCT05647421|Active Comparator|TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) group|The TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) will be implanted in 20 eyes of 10 patients
32791266|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
32791267|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
32791268|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
32791269|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
32791270|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
33298962|NCT03924388|Experimental|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and ~ 70° upright (adjusted by tilt-up table)."
33298963|NCT03924388|Experimental|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and ~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
33298964|NCT03924388|Experimental|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
33298965|NCT03925948|Experimental|Intervention|This is a one arm study with all participants enrolled into this arm.
33298966|NCT03919630|Experimental|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
33298967|NCT03919630|Active Comparator|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
33298968|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
33298969|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
33298970|NCT03925792|Experimental|Treatment Group|Lifestyle Medicine Group 1
33298971|NCT03925792|Experimental|Waitlist Control Group|Lifestyle Medicine Group 2
33298972|NCT03919552|Experimental|Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for three cycles during radiotherapy.
33298973|NCT03919552|Active Comparator|Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during radiotherapy.
33298974|NCT03925714|Other|life style|life style control only
33298975|NCT03925714|Active Comparator|Metformin|Metformin 500 mg twice daily
33298976|NCT03925714|Experimental|Nigetella salivata|NS 450 mg twice daily
32791271|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
32906933|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
33298977|NCT03919240|Experimental|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells
33298978|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
33298979|NCT01228552|Placebo Comparator|Placebo gel|
33298980|NCT03924076|Experimental|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
33298981|NCT03924076|Placebo Comparator|Placebo Group|Received UHT milk (125 mL) for 90 days
33298982|NCT03925558|Active Comparator|Probiotic formula|Lactobacillus strains
33298983|NCT03925558|Placebo Comparator|Placebo formula|Placebo
33298984|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
33298985|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
33298986|NCT03919084|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
33298987|NCT03919084|Experimental|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
33298988|NCT03919318|Experimental|AH-Plus|
33298989|NCT03919318|Experimental|EndoSeal MTA|
33298990|NCT03919318|Experimental|Endosequence BC Sealer|
33298991|NCT01329484|Experimental|Cognitive training|
32791272|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
32791273|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
32791274|NCT04643925|Experimental|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
32791275|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
32791276|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
32791277|NCT04628949|Experimental|aScope™ Duodeno endoscope and aBox™ Duodeno|Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.
32791278|NCT04620603|Experimental|LDR + SOC Immunotherapy|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with SOC immunotherapy at the standard FDA approved dose. SOC immunotherapy will be given on the first day of every 28-day cycle. Participants can receive up to 12 doses of SOC immunotherapy.
32791279|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
33087808|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
33298992|NCT01329484|Experimental|Reminiscence therapy|
33298993|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
33298994|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
33298995|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
33298996|NCT03923842|Experimental|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
33298997|NCT03923842|Active Comparator|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
33298998|NCT01130818|Experimental|1|single ascending doses
33298999|NCT01130818|Placebo Comparator|2|single dose placebo
33299000|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
33299001|NCT01130818|Experimental|4|single dose, capsules (fasting)
33299002|NCT01130818|Experimental|5|single dose, capsules (fed)
33299003|NCT03924154|Experimental|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 [Anticipated])
33404019|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
33299004|NCT03924154|Placebo Comparator|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 [Anticipated])
33299005|NCT03923998|Experimental|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
33299006|NCT03923764|Experimental|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
33299007|NCT03923764|Active Comparator|Kontrol group|habitual diet
33299008|NCT03919006|Active Comparator|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
33299009|NCT03919006|Active Comparator|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
33299010|NCT03919006|Placebo Comparator|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
33299011|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
33299012|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
33299013|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
33299014|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
33299015|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
33299016|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
33299017|NCT03925168|Experimental|Experimental|Music therapy
33299018|NCT03925168|No Intervention|Control|No music therapy
33299019|NCT03918694|Active Comparator|Experimental|Participants will receive Vit C tablets
33299020|NCT03918694|Placebo Comparator|Placebo|Participants will receive placebo tablets
33299021|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
33299022|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
33299023|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
33299024|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
33299025|NCT05402644||Non-CSPH|BCLC stage A patients who underwent hepatectomy in the group without clinically significant portal hypertension (Non-CSPH)
33102404|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
33299026|NCT05402644||CSPH|BCLC stage A patients who underwent hepatectomy in the group with clinically significant portal hypertension (CSPH)
33299027|NCT03918538|Experimental|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
33299028|NCT03918538|No Intervention|The control group|Participants in the control group received regular medication education.
33299029|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
33299030|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
33299031|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
33299032|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
33299033|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
33299034|NCT05402488|Experimental|Verum stimulation|Verum condition: Auditory stimulation during sleep
33299035|NCT05402488|Sham Comparator|Sham stimulation|Sham condition: Playing no tones during sleep but still recording brain activity (muted tones)
33299036|NCT03923062|Experimental|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
33299037|NCT03923062|Experimental|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
33299038|NCT03923062|Experimental|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
33299039|NCT03923062|Experimental|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
33299040|NCT01228786||Group A|~ 20 sporadic PHPT patients
33299041|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
33299042|NCT03918226|Other|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
33299043|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
33299044|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
33102405|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
33299045|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
33299046|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
33299047|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
33299048|NCT01231828|Experimental|Carnitine|Versus placebo.
33299049|NCT01231828|Experimental|Lactulose|Versus placebo
33299050|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
33299051|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
33299052|NCT03923218||periodontally healthy patients|periodontally healthy patients
33299053|NCT03923140|Experimental|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
33299054|NCT05402410||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
33299055|NCT05402410||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
32791280|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
33299056|NCT03922984|Experimental|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
33299057|NCT01133080|Experimental|Minocycline|
33299058|NCT01133080|Placebo Comparator|Placebo|
33299059|NCT05402098|Active Comparator|Endodontic treatment using traditional access|Straight line access will be achieved following complete removal of pulp chamber roof
33299060|NCT05402098|Experimental|Endodontic treatment using conservative access|Part of pulp chamber roof will be preserved and no efforts will be directed to achieve straight line access
33299061|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
33299062|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
33299063|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
33299064|NCT05401942|No Intervention|Routine monitoring|patients with breast cancer who will receive adjuvant treatment and will be followed up during treatment with routine visits.
33299065|NCT05401942|Active Comparator|Tele-monitoring through mobile application|Patients with breast cancer who will receive adjuvant therapy and will be followed up during treatment through tele-monitoring with mobile application and CTCAE checklist for PRO.
33299066|NCT01585792|Experimental|TAK-875 25 mg|
33299067|NCT01585792|Experimental|TAK-875 50 mg|
33299068|NCT01585792|Active Comparator|Glimepiride|
33299069|NCT01585792|Placebo Comparator|Placebo|
32791281|NCT05647265|Experimental|Treatment (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
33299070|NCT03922672|Experimental|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
33299071|NCT01134484|Experimental|VTD|
33299072|NCT01134484|Active Comparator|TD|
33299073|NCT03922906|Experimental|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
33299074|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
33299075|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
33299076|NCT03917680|Experimental|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
33299077|NCT03917680|Experimental|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
33299078|NCT03917680|Experimental|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
33299079|NCT03917680|Experimental|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
33299080|NCT03917680|Experimental|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
33299081|NCT03917680|Other|Control|Healthy individuals, no angioedema.
33299082|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
33299083|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
33299084|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
33299085|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
33299086|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
33299087|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
33299088|NCT03922360|Active Comparator|Best Practices|
33299089|NCT03922360|Experimental|Best Practices + Financial Incentives|
33299090|NCT05401708||DM Naïve|a new patient without a history of DM medication
33299091|NCT01228864|Experimental|Brody Belt|
33299092|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
33299093|NCT01131442||The patient group|
33087809|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
33087810|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
33087811|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
33087812|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
33087813|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
32791282|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
33087814|NCT02272192|Experimental|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
33087815|NCT02272192|Experimental|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
33299094|NCT01131442||healthy control group|
32791283|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
33299095|NCT03917758|Experimental|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
33299096|NCT05206474|Experimental|IRADYN|"One group, all patients will receive IRADYN® (intra-articular administration).~One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
33299097|NCT01134874|Experimental|Standard weight loss intervention|
33299098|NCT01134874|Experimental|Standard weight loss intervention plus technology|
33299099|NCT01134874|Experimental|Technology only|
33299100|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
33299101|NCT05401552|Active Comparator|Convenience breakfast meal|One cheese tea biscuit and Eggo waffle
33299102|NCT05401552|Active Comparator|Healthy breakfast meal|One cup of All-Bran breakfast cereal with milk and a piece of fruit
33299103|NCT01133548|Experimental|1|Testosterone Gel 1.62%
33299104|NCT03917368|Experimental|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
33299105|NCT03922438|Experimental|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
33299106|NCT03922516|Other|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
32791284|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
32791285|NCT01645280|Placebo Comparator|Group 1|
32791286|NCT01645280|Experimental|Group 2|
32791287|NCT01645280|Experimental|Group 3|
33299107|NCT03922516|Other|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
32791288|NCT01645280|Experimental|Group 4|
32791289|NCT01645280|Experimental|Group 5|
33299108|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
33299109|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
33299110|NCT01135030|Active Comparator|Posterior referencing|
33299111|NCT01135030|Active Comparator|Anterior referencing|
33299112|NCT05401474|Active Comparator|30 L/min|HFNC at 30L/min. FiO2 adjusted to reach SpO2 95%
33299113|NCT05401474|Experimental|45 L/min|HFNC at 45L/min. FiO2 adjusted to reach SpO2 95%
33299114|NCT05401474|Experimental|60 L/min|HFNC at 60L/min. FiO2 adjusted to reach SpO2 95%
32791290|NCT02256917|Experimental|Human-cl rhFVIII|
32791291|NCT05647187|Active Comparator|NB-UVB group|fourty patients will be treated with NB-UVB. The initial radiation dose was determined according to the patient's skin type; initial dose will be increased by 20% per session. Sessions will be given three times weekly with 48 hours apart for three months.
32791292|NCT05647187|No Intervention|Control group|fourty healthy controls without psoriasis , any family history of psoriasis or any dermatological diseases.
32791293|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
32791294|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
33087816|NCT02272192|Experimental|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
33087817|NCT02272192|Experimental|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
32791295|NCT04880681|Experimental|Novel needle|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
32791296|NCT04880681|Active Comparator|Standard Tru Cut needle|Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).
32791297|NCT04188223|Experimental|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
32791298|NCT04188223|Active Comparator|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
32791299|NCT02256839||non TB infection|Group tested with CST_001
32791300|NCT02256839||low exposure risk|Group tested with CST_001
32791301|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
32791302|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months~."
32791303|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
32791304|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
32791305|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
32791306|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
32791307|NCT04865783|Active Comparator|Cryospray|Cryospray will be sprayed from a distance of 20-30 cm to the back of one hand.
32791308|NCT04865783|Placebo Comparator|Placebo|A saline solution will be sprayed from a distance of 20-30 cm to the back of the hand.
32791309|NCT05647109||Set of training|A total of 148 patients with endometrial cancer and atypical endometrial hyperplasia were included in the training set of the prediction model. They were divided into progesterone sensitive group and progesterone insensitive group.
32791310|NCT05647109||Set of verification|A verification set of the prediction model was established, consisting of 96 patients with endometrial cancer and atypical endometrial hyperplasia.
32791311|NCT05369741|Experimental|TIME™ at Home|TIME™ at Home is a licensed, pre-recorded video-based, group, community exercise program. One program will have a maximum of 10 participants registered. March of Dimes Canada will run two programs. A 1.5-hour session will be hosted by two facilitators using Zoom twice a week for 8 weeks, starting with the Level 1 video (beginner level). All participants will switch to the Level 2 video (advanced level) mid-program.
32791312|NCT04420247|Experimental|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.~+~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
32791313|NCT04420247|Active Comparator|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
32791314|NCT01644890|Experimental|NK105|
32791315|NCT01644890|Active Comparator|Paclitaxel|
32791316|NCT04865315||Low grade glioma patients|Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
32791317|NCT04865315||High grade glioma patients|Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
32791318|NCT04868006|Experimental|End-range mobilization + proprioception training|End-range Maitland mobilization performed in end-range internal rotation of the shoulder accompanied with 8--week long proprioception training
32791319|NCT04868006|Active Comparator|Non end-range mobilization+ proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
32791320|NCT04868006|Sham Comparator|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
32791321|NCT04865237|Experimental|Healthy Volunteers|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
32791322|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
32791323|NCT05647460|Active Comparator|computer guided plates|computer guided screw holes locating guide and custom-made plates in management of parasymphseal mandibular fracture
32791324|NCT05647460|Active Comparator|conventional plates|conventional plate osteosynthesis in management of parasymphseal mandibular fracture
32791325|NCT05647382|Active Comparator|Lung injury group|Lung injury is defined as lung damage when the patient has an oxygen and index below 300 24 hours after cardiopulmonary bypass
32791326|NCT05647382|Sham Comparator|Non-lung injury group|Patients with oxygen and an index above 300 24 hours after cardiopulmonary bypass are defined as non-lung injury
32791327|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
32791328|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
32791329|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
32791330|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
32791331|NCT04865159|Other|Single Group Assignment|Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.
33299115|NCT03917602|Experimental|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
33299116|NCT03922282|Experimental|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
33299117|NCT03922282|Active Comparator|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
33299118|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
33299119|NCT01135108|Experimental|A2: KAI-1678|Experimental
33299120|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
33299121|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
33299122|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
33299123|NCT03917212||Controls|Healthy humans
33299124|NCT05201092|Experimental|[14C]-Lu AG06466|Participants will receive a single oral dose of [14C]-Lu AG06466 on Day 1 in the fed state.
33299125|NCT03917290|Experimental|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
33299126|NCT03917290|No Intervention|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
33299127|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
33299128|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
33299129|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
33299130|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
33299131|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
33299132|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
32791332|NCT05647031||20 participants were interviewed on a voluntary basis|A total of 20 participants were interviewed on a voluntary basis (7 competitive athletes with 17 physical disabilities, 4 physiotherapists, 5 coaches and 4 psychologists)
33299133|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
33299134|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
33299135|NCT05401396|Experimental|Swimming immediately after eating|Two arms but all participants are performing both the intervention and the comparison.
33299136|NCT05401396|No Intervention|Swimming 30 minutes after eating|Two arms but all participants are performing both the intervention and the comparison.
33299137|NCT03917134|Experimental|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
33299138|NCT03917134|Placebo Comparator|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
33299139|NCT03916900|Experimental|Pulpotomy|"Group A (Experimental group) Pulpotomy:~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
33299140|NCT03916900|Active Comparator|Root canal treatment|"Group B (control group) Root canal treatment:~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
33299141|NCT03917056|Experimental|Long needle group|Participants were treated with CAES using long needle.
33299142|NCT03917056|Experimental|Short needle group|Participants were treated with CAES using short needle.
33299143|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
33299144|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
33299145|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
33299146|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
33299147|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
32791333|NCT05647304|Other|5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
32791334|NCT05647304|Other|10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
32791335|NCT05647226|Experimental|Intervention arm|Intervention participants will be given an initial 12-week low energy-diet (LED) and will have continual use of an intensive behaviour education programme delivered through an app.
32791336|NCT05647226|Other|Standard of care arm|All participants in the control arm will receive standard care provided by the National Health Service.
32791337|NCT04874714|Experimental|MM09-MG01(30.000-30.000)|30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
32791338|NCT04874714|Experimental|MG01(30.000)|30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
32791339|NCT04874714|Experimental|MM09(30.000)|30,000 AU/mL of MM09 of subcutaneous immunotherapy once a month for 11 months
32791340|NCT04874714|Placebo Comparator|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
32791341|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
32791342|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
33299148|NCT03921892|Other|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
33299149|NCT03921892|Active Comparator|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
32791343|NCT04867070|Active Comparator|LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
32791344|NCT04867070|No Intervention|LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
32791345|NCT04866524||ICSI technique|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
32791346|NCT04866524||Conventional IVF|In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
33299150|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
33299151|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
33299152|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
33299153|NCT05401162|Experimental|Experimental group|transfusion of autologous blood containing haematopoietic stem cells after conventional chemotherapy
33299154|NCT05401162|No Intervention|Control group|enrolled ovarian cancer patients receive conventional chemotherapy
32791347|NCT05647148|Experimental|intervention group|progressive relaxiation exercises Will do sixty minutes of progressive relaxation exercise for three consecutive days
32791348|NCT05647148|No Intervention|Control group:|no intervention
32791349|NCT05369858|Experimental|[14C] SKLB1028|Eligible healthy male subjects received a single oral 150 mg (radioactivity of 120µCi) dose of [14C] SKLB1028
32791350|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
32791351|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
32791352|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
32791353|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
32791354|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
32791355|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
32791356|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
32791357|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
33102406|NCT04734678||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
33299155|NCT01133938||Closed reduction < 12 months of age|
33299156|NCT01133938||Open reduction < 12 months of age|
33299157|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
33299158|NCT01135654|Experimental|Non-Physician Provider|
33299159|NCT01135654|No Intervention|Control|
33299160|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
33299161|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
33299162|NCT01231126|Placebo Comparator|elective caesarians|
33299163|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
33299164|NCT01231126|Experimental|caesarians section with induction attempt|
32791358|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
32791359|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
32791360|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
32791361|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
32791362|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
33299165|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
33299166|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
33299167|NCT01135732||study group-previous sphincterotomy|
33299168|NCT01135732||control group-not previous sphincterotomy|
33299169|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 high dose
33299170|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 low dose
33299171|NCT03769090|Active Comparator|AS MDI (PT007) 180 µg|Albuterol sulfate MDI, PT007
33299172|NCT01135888||HED children|
33299173|NCT01135888||HED adolescents|
33299174|NCT01135888||Control children|
32791363|NCT02293460|Experimental|I10E Arm|
32791364|NCT04880642|Experimental|C21|50 mg capsules, oral administration twice daily,for 14 days
33299175|NCT01135888||Control adolescents|
32791365|NCT04880642|Placebo Comparator|Placebo|placebo capsules, oral administration twice daily,for 14 days
32791366|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
32791367|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
32791368|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
33299176|NCT03921736|No Intervention|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
33299177|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
33299178|NCT03921736|Experimental|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
33299179|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
33299180|NCT03921736|Experimental|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
33299181|NCT03921736|Experimental|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
33299182|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
33299183|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
33299184|NCT05401006|Active Comparator|Acitretin|Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .
33299185|NCT05401006|Active Comparator|Narrowband ultraviolet B|Patients will receive Narrowband UVB( 3session /week ) for 3months.
33299186|NCT05401006|Active Comparator|Combination of Narrowband ultraviolet B and Acitretin|Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.
33299187|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
33299188|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
33299189|NCT01135966|Active Comparator|Conventional training|
33299190|NCT01135966|Experimental|Whole body vibration training|
33299191|NCT05400928|Experimental|Three-dimensional Directed Pulsed Field Ablation|Paroxysmal atrial fibrillation will be ablated with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
32791369|NCT05647070|Experimental|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, ~1 cm× ~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
32791370|NCT04865276|Active Comparator|Intervention|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
32791371|NCT04865276|Active Comparator|Control|Home visit by a Community Health Worker during which the participant is scheduled to attend the tobacco cessation program at the public health system
32791372|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
32791373|NCT04864652|Experimental|Single Arm|CHILLS Procedure
32791374|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
32791375|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
32791376|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
32791377|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
32791378|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
32791379|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
32791380|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
32791381|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
32791382|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
32791383|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
32791384|NCT05651243|Experimental|Ketone Ester|Oral ketone ester supplement
32791385|NCT05651243|Placebo Comparator|Placebo|Taste and viscosity matched placebo
32791386|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
33299192|NCT01231282|Experimental|diffusion-weighted MRI|MRI
33299193|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
32791387|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
32791388|NCT05436665|Active Comparator|UT-DSAEK|Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty refers to the use of a corneal endothelial/Descemet graft with a thin layer of stroma (<110um) attached.
32791389|NCT05436665|Active Comparator|DMEK|Descemet membrane endothelial keratoplasty refers to the use of a corneal endothelial/Descemet graft with no layer of associated stroma (15-20um thick)
32791390|NCT05646875|Experimental|post-ROSC|patients directly post-ROSC receiving HBOT
32791391|NCT05646875|Active Comparator|cardiac arrest survivors discharged home receiving HBOT|cardiac arrest survivors discharged home
32791392|NCT05646875|Active Comparator|healthy volunteers receiving HBOT|healthy volunteers receiving HBOT
32791393|NCT05651165|Active Comparator|Group A|Patients receiving pharmacoactive balloon angioplasty. Lutonix®
32791394|NCT05651165|Experimental|Group B|Patients receiving mimetic stent. Supera®
32791395|NCT02264990|Experimental|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
32791396|NCT02264990|Active Comparator|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:~Carboplatin AUC 6 mg/mL*min + paclitaxel 200 mg/m²~Cisplatin 75 mg/m² + pemetrexed 500 mg/m²~Carboplatin AUC 6 or AUC 5 mg/mL*min + pemetrexed 500 mg/m²~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
32791397|NCT05646914|Experimental|Complex training group|Plyometric exercises along with resistance exercises were performed.
32791398|NCT05646914|Active Comparator|Plyometric training group|Plyometric exercises were performed.
32791399|NCT05646914|No Intervention|Control group|Routine training was performed.
32791400|NCT05646758|Experimental|TQB2934 injection|"intravenous injection. 0.09mg, 0.36 mg, 1mg, 2mg, 3mg, 5mg, 6mg, 10mg, 12mg, 16mg, 20mg each time.~once a week in Cycle 1-3. once every 2 weeks in Cycle 4-6. if reach PR and above remission after 6 cycles of administration, once every 4 weeks,28 days as a treatment cycle."
32791401|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
32791402|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
33299194|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
33299195|NCT01229098|Experimental|LEO 80185|
33299196|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
33299197|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
33299198|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
33299199|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
33299200|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
33299201|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
33299202|NCT05609890|Experimental|Active intervention|A formulation made of natural components. Each sachet contains saffron, tea extract, lemon balm and valerian.
33299203|NCT05609890|Placebo Comparator|Placebo|Placebo sachet will contain inert excipient.
33299204|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
33299205|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
33299206|NCT05608330|Experimental|PETRUSHKA tool|The intervention is the PETRUSHKA web-based App (also called PETRUSHKA tool), a clinical decision-support system that incorporates a personalised evidence-based prediction model with individual patient preferences, to prescribe the best antidepressant to adults with depression
33299207|NCT05608330|Placebo Comparator|Usual Care|Routine care delivered in the NHS (i.e. selection of the antidepressant based primarily on the clinicians' judgement) termed 'usual care' in this study.
33299208|NCT05604196||STUDY GROUP|Study group included 79 people (48 women and 31 men), with BMI = 30.0-39.9 kg / m2) and excessive total body fat percent (TBF%) content (>30% TBF women and >25% TBF men).
33299209|NCT05604196||CONTROL GROUP|Control group included 41 people (31 women and 10 men), with BMI = 18.5-24.9 kg / m2) and normal total body fat percent (TBF%) content (20-30% TBF women and 15-20% TBF men).
33299210|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
33299211|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
33299212|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
33299213|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
33299214|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
33299215|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
33299216|NCT01231672||Septic shock patients|
33299217|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
33299218|NCT05402722|Experimental|Eribulin in combination with anti-PD-1 antibody|Participants receive eribulin1.4mg/m2 and anti-PD-1 antibody intravenously (IV) every 3 weeks (Q3W) .
33299219|NCT03921268|Experimental|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
33299220|NCT03921268|Experimental|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
33299221|NCT03921268|Experimental|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
33299222|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
33299223|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
33299224|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
32791403|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
32791404|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
33299225|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
32791405|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
32791406|NCT05651087|Experimental|Experimental|Breast cancer patient who treated with LACUD
32791407|NCT05651087|No Intervention|Observation|Breast cancer patient who does not treated with LACUD
33299226|NCT01232608|Experimental|Exercise|12 months of exercise training
32791408|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
32791409|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
33299227|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
33299228|NCT05597332|Other|Intervention|Insertion of care bundle in the electronic medical record of patients who develop AKI.
33299229|NCT03921346|Experimental|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
33299230|NCT03921346|Active Comparator|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
33299231|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
33299232|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
33299233|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
33299234|NCT05480488|Other|• A (midazolam & warfarin), B (daridorexant, midazolam, & warfarin), & C (daridorexant & midazolam)|"Treatment A - midazolam and warfarin: In the morning of Day 1, subjects will receive a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~Treatment B - daridorexant, midazolam, and warfarin: Subjects will receive an o.d. oral dose of 50 mg daridorexant in the morning from Day 1 to Day 7 under fasted conditions. In addition, in the morning of Day 1, the oral administration of 50 mg daridorexant will be followed 1 h later by a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~Treatment C - daridorexant and midazolam: In the morning of Day 1, subjects will receive a single oral dose of 50 mg daridorexant followed 1 h later by a single oral dose of 2 mg midazolam under fasted conditions."
33299235|NCT03921112|Active Comparator|lung ultrasound|
33299236|NCT03921112|Active Comparator|x-ray, ABG, RSBI, Vetilator parameters|
33299237|NCT01229332|Placebo Comparator|Carbidopa|
33299238|NCT01229332|Placebo Comparator|Placebo|
33299239|NCT03921034|Active Comparator|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
32791410|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
32791411|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
32791412|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
32791413|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
32791414|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
32791415|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
32791416|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
32791417|NCT05651009|Experimental|Control group|Cementless Triathlon Tritanium 3D printed TKA
32791418|NCT05651009|Experimental|Study group|GMK Sphere cementless 3D printed TKA
32791419|NCT05646407|Experimental|Exercise training with Fan-to-face|Participants randomized to the fan-to-face group will perform supervised exercise training with a basic, portable fan (Honeywell HT-900 Turbo Force Air Circulator). The fan will be placed to the front of the treadmill with airflow directed toward the area of the face innervated by the second and third branches of the trigeminal nerve. The previous study to explore use of a fan during constant-load cycle exercise used a fan with airflow of 4.3 m/sec. An anemometer will measure the airflow from the fan, and the investigators will use this previous study as a guide when determining the appropriate airflow for the current study.
32791420|NCT05646407|No Intervention|Exercise training with no fan|Participants randomized to the no fan group will perform supervised exercise training with no fan. The exercise duration and intensity titration will follow the same format as the experimental group.
32791421|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
33299240|NCT03921034|Sham Comparator|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
33299241|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
32791422|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
32791423|NCT05646329|Experimental|Experimental|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session. The session will last a maximum of 40 minutes. The session will be once a week. Motivational interview will be conducted individually and online with the experimental group. For individual interviews, the appropriate day and time will be determined with the researcher before the first session and the sessions will continue on the same day and time every week.
32791424|NCT05646329|No Intervention|Waiting list group|"If the students in the control group make a request at the end of the study, an online individual motivational interview will be held. The intervention applied to the experimental group will also be applied to the control group at the end of the study.~Intervention: Behavioural Intervention Based on Problematic Internet Use"
32791425|NCT01702558|Experimental|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 [on Day 2 for Cycle 1] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared [mg/m^2]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
32791426|NCT01702558|Experimental|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
32791427|NCT01702558|Active Comparator|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
32791428|NCT01702558|Experimental|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
32791429|NCT05650931|Experimental|Patients who underwent the upper limb amputation and have phantom limb pain|
32791430|NCT05646173|Active Comparator|grup 1|"Grup 1: Participants will be treated with ultrasound (5 min), TENS with a hot pack for (20 minutes). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~1.5w/cm² continuous ultrasound wiil applied with Chattanooga Intelect Mobile Ultrasound device.TENS: It will be applied to the lumbar region with a COMPEX brand stim device, together with a hot pack.The current intensity was opened by questioning according to the sensory threshold of the people.~Home based exercise program:In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week"
32791431|NCT05646173|Experimental|grup 2|"Grup 2: Participants will be given auricular vagus stimulation (25 min). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~Vagus stimulation: A specially manufactured earphone that can be selected according to the size of the ear placed in the outer ear will be applied from the vagustim device (frequency 10 Hz, pulse duration less than 500 microseconds, in modulated TENS mode and biphasic asymmetric waveform) connected to it.~Home based exercise program: In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week."
32791432|NCT05650775|Active Comparator|Methylphenidate Trial|3-week methylphenidate trial with weekly dose adjustments.
32791433|NCT05650775|Active Comparator|Mixed Amphetamine Salts Trial|3-week trial of mixed amphetamine salts with weekly dose adjustments.
32791434|NCT05650619||Enrolled participants prior to transplant|Participants will be consented.
32791435|NCT05650619||Enrolled participant after transplant|Participants will be consented.
32791436|NCT05650619||Retrospective participant data|Waiver of consent for secondary use of existing data.
32791437|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
32791438|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
32791439|NCT01743040||CADence plus Standard Angiogram|All patients who were indicated for angiogram due to results of SPECT nuclear stress test
32791440|NCT01743040||CADence plus CT Angiogram|All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram
32791441|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
32791442|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
32791443|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
32791444|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
32791445|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
32791446|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
32791447|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
32791448|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
32791449|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
32791450|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
32791451|NCT04564846|Placebo Comparator|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
32791452|NCT04564846|Active Comparator|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
32791453|NCT05645939||Patients diagnosed with HCMP during study period|Patients newly diagnosed with HCMP between January 2015 and December 2020
32791455|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
32791456|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
32791457|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
32791458|NCT05645861|Active Comparator|Augmented - Systolic Blood Pressure (SBP) at 170mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
32791459|NCT05645861|Active Comparator|Standard - Systolic Blood Pressure (SBP) at 140mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
32791460|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
32791461|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
32791462|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
32791463|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
32791464|NCT05650385|Experimental|Cohort 1|B1962 0.035mg Open Lable
32791465|NCT05650385|Experimental|Cohort 2|B1962 0.12mg Open Lable
32791466|NCT05650385|Experimental|Cohort 3|B1962 0.4mg Open Lable
32791467|NCT05650385|Experimental|Cohort 4|B1962 1.2mg Open Lable
32791468|NCT05650385|Experimental|Cohort 5|B1962 4mg Open Lable
32791469|NCT05650385|Experimental|Cohort 6|B1962 8mg Open Lable
32791470|NCT05650385|Experimental|Cohort 7|B1962 11mg Open Lable
32791471|NCT05650385|Experimental|Cohort 8|B1962 15mg Open Lable
32791472|NCT05650385|Experimental|Cohort 9|B1962 20mg Open Lable
32791473|NCT05650385|Experimental|Cohort 10|B1962 25mg Open Lable
32791474|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
32791475|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
32791476|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
32791477|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
32791478|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
32791479|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
32791480|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
32791481|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
32791482|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
32791483|NCT04878575||ASD group|120 ASD patients (aged 5-18 years)
32791484|NCT04878575||ADHD group|120 ADHD patients (aged 5-18 years)
32791485|NCT04878575||TDC group|120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders
33102407|NCT04734678||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.
32791486|NCT04878185|Experimental|Exercise|"A high-intensity, home-based, exercise program consisting of inspiratory muscle training (IMT), endurance- and functional strength exercise. The sessions will supervised by a physiotherapist during six occasions and start 2-3 weeks before surgery. IMT will be conducted with an intensity starting from 50 % of maximal capacity, with a self-reported effort of 5-7 on the Borgs CR-10 scale. Endurance and functional strength exercises will be performed at a self-reported effort of 7-8. Interval training, chair stand- and step-up exercises will be key components of the exercise program. Furthermore, the program will include task-specific exercises based on the participants self-expressed needs.~On non-supervised days, participants will perform IMT twice a day as well as endurance and strength training, 2-3 days per week with 1-2 days per week of active recovery in the form of moderate intensity walks. This will be monitored with an activity journal and an accelerometer."
32791487|NCT04878185|No Intervention|Control group|Participants in the control group receive pre- and postoperative care as usual. In addition, they will be encouraged to follow the WHO guidelines of moderate intensity aerobic physical activity for at least 150 min per week. Their activity level will be monitored with an accelerometer.
32791488|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
32791489|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
32791490|NCT02263508|Experimental|Phase 1b: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ plaque-forming units (PFU)/mL by intralesional injection. Subsequent doses of talimogene laherparepvec at up to 4 mL of 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until disappearance of injectable lesions, complete response (CR), confirmed disease progression (PD) per modified Immune-related Response Criteria (irRC), intolerance of study treatment, 24 months from the date of the first dose of pembrolizumab, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 2 weeks starting at the time of the third dose of talimogene laherparepvec (week 6) until confirmed PD per modified irRC, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
33087818|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID~Followed by 28 day break followed by~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
32791491|NCT02263508|Placebo Comparator|Phase 3 : Placebo + Pembrolizumab|Participants received up to 4 mL placebo to talimogene laherparepvec by intralesional injection on day 1 of week 0. Subsequent doses of placebo (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, complete response per modified Immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST) (iCR), confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of placebo, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
32791492|NCT02263508|Experimental|Phase 3: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ PFU/mL by intralesional injection on day 1. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection of talimogene laherparepvec (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, iCR, confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
32791493|NCT02291432|Experimental|AMDC-USR|Cell treatment
32791494|NCT05369780|Experimental|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
32791495|NCT05369780|Placebo Comparator|Placebo|This arm will be allocated randomly and receive placebo daily throughout the study.
32791496|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
32791497|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
32791498|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
32791499|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
32791500|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
32830557|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
33087819|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
33087820|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
33299242|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
33299243|NCT03920956|Experimental|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
33299244|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
33299245|NCT05469958|Experimental|Intervention group|a bundle of hypothermia prevention measures will be applied
32939881|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
32939882|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
33299246|NCT05469958|Active Comparator|Control group|Conventional care with textile blankets under patient demand.
33299247|NCT01137760|Placebo Comparator|Sugar pill|
32939883|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
33299248|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
32939884|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
32939885|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
32939886|NCT05313386|Experimental|Cohort 1- 120 Micrograms|"120 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
33299249|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
33087821|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
33299250|NCT01233388||Text message surveillance|enroll for text message surveillance
33299251|NCT01137838||Patients with RA and new to abatacept|
33299252|NCT01137838||Patients with RA and new to infliximab|
33299253|NCT01137838||Patients with RA and new to etanercept|
33299254|NCT01137838||Patients with RA and new to adalimumab|
33299255|NCT03920878|Experimental|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
33299256|NCT03920878|Active Comparator|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
33299257|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
33299258|NCT03920644|Experimental|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
33299259|NCT03920644|Placebo Comparator|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
33299260|NCT03920644|Active Comparator|TDS Patch|Receives one patch per treatment.
33299261|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
33299262|NCT01137916|Experimental|drug|Imatinib 800 mg
33299263|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
33299264|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
33299265|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
33299266|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
33299267|NCT05434390|Experimental|Latino MSM PrEP intervention|The Latino MSM PrEP intervention consists of 4 small group sessions with concurrent peer navigation and counseling.
33299268|NCT05434390|Active Comparator|Control condition|The control condition consists of usual care at the study site (i.e., referrals to PrEP services).
33299269|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
33299270|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
33299271|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
33299272|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
33299273|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
33299274|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
33299275|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
33299276|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
33299277|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
32791501|NCT01741792|Experimental|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
32791502|NCT02289950|Experimental|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
32791503|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
32791504|NCT01741012|Experimental|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
32791505|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
33087822|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
32791506|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
32791507|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
32791508|NCT01740388|Experimental|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
32791509|NCT01740388|Placebo Comparator|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
32791510|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
32791511|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
32791512|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
32791513|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
32791514|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
32791515|NCT05646602|Experimental|Collagenase Clostridium Histolyticum with LiSWT for PD Group|Subjects be treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection with focused low-intensity shockwave therapy (LiSWT).
32791516|NCT05646602|Active Comparator|Collagenase Clostridium Histolyticum for PD Group|Subjects be treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection
32791517|NCT05646602|Active Comparator|Radial Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have radial shockwave therapy.
32791518|NCT05646602|Experimental|Linear Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have linear shockwave therapy
32791519|NCT05646446|Experimental|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to experiences of harm among bisexual women.
33087823|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
33102408|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
33102409|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
32791520|NCT05646446|No Intervention|Wait List Control Group|The Wait List Control Group will have the opportunity to complete the REACH program after completing study assessments at the 4-month follow-up.
32791521|NCT05646212|No Intervention|Standard of Care|Standard of care (with SSRI medications provided for free).
32791522|NCT05646212|Experimental|SOC+ECHO|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians
32791523|NCT05646212|Experimental|SOC+ECHO+P4P|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians, plus Payment for Performance intervention
32791524|NCT05646134|Experimental|Low Frequency Experimental Group|Participants in this Arm will receive 10 sessions of Low Frequency (1 Hz) rTMS Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
32791525|NCT05646134|Experimental|High Frequency Experimental Group|Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
32791526|NCT05646134|Sham Comparator|Sham Stimulation Control Group|Participants in this Arm will receive 10 sessions of Sham rTMS
32791527|NCT05646056||Healthy subjects|
32791528|NCT05646056||Asymptomatic left ventricular hypertrophy|
32791529|NCT05646056||Asymptomatic subjects with a history of HF|
32791530|NCT05646056||Subjects with a history of hypertrophic cardiomyopathy NYHA Class I, II|
32791531|NCT05645978||Patients who underwent pacemaker insertion during study period|Patients who underwent pacemaker insertion between January 2015 and December 2020
32791532|NCT04873466|Experimental|Enzyme-rich malt extract|Enzyme-rich malt extract (15 ml b.i.d with food)
32791533|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
32791534|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
32791535|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
32791536|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
32791537|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
32791538|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
32791539|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
33299278|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
33299279|NCT05410288|Experimental|Acu-TENS+SHP|Participants in the Acu-TENS group will receive Acu-TENS coupled with a sleep hygiene program (SHP). 4 weeks and comprise thrice-weekly 30-min sessions.
33299280|NCT05410288|Experimental|acupressure+SHP|The acupressure group will receive acupressure and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
33299281|NCT05410288|Placebo Comparator|placebo stimulation+SHP|The placebo group will receive a placebo stimulation and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
33299282|NCT01229566|Active Comparator|Active Comparator|Active comparator
33299283|NCT01229566|Placebo Comparator|Placebo|Placebo control
33299284|NCT01229566|Experimental|AKR-963|Investigational drug
33299285|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
33299286|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
33299287|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
33299288|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33299289|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
33299290|NCT01136980|Placebo Comparator|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
33299291|NCT01136980|Active Comparator|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
33299292|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
33299293|NCT05533372|Experimental|IA-14069 MAD|Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.
32791540|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
32791541|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
32830558|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
32830559|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
32830560|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
32906934|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
32906935|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
32791542|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
32791543|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
32939887|NCT05313386|Experimental|Cohort 2- 180 Micrograms|"180 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
33087824|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
33087825|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
33299294|NCT05533372|Experimental|IA-14069 DDI|"Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.~On day 11, subjects will be adminiatrated oral dose of IA-14069 or matching placebo with methotrexate.~On day 21, subjects will be administrated methotrexate alone."
33299295|NCT05533372|Experimental|IA-14069 MAD RA patients|"Patients will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 28 days.~Patients will be on a stable dose of methotrexate throughout the study period."
33299296|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
33299297|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
33299298|NCT01137058|No Intervention|control|conventional treatment
33299299|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
33299300|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
33299301|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
33299302|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
33299303|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
33299304|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
33299305|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
33299306|NCT05513014||Secukinumab: Overall Cohort|Patients with Psoriasis who initiated Secukinumab
33299307|NCT05513014||Biologic Experienced|Patients who had the history of use of ≥1 biologic medication for the treatment of PsO at the time of SEC initiation
33299308|NCT05513014||Biologic Naive|Patients who had no history of use of biologic medication for the treatment of PsO at the time of SEC initiation
33299309|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
33299310|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
33299311|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
33299312|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
33299313|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
33299314|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
33299315|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
33299316|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
33299317|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
33299318|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
33299319|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
32791544|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
32791545|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
32791546|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
32791547|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
32791548|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
32791549|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
32791550|NCT04879862|Experimental|Locomotion|Participants will receive 160 locomotor training sessions with epidural stimulation. These sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
32791551|NCT04879862|Experimental|Bladder+Locomotion|Participants will receive 80 sessions of bladder training alone followed by 80 sessions of locomotor training sessions with epidural stimulation. They will be asked to continue with your bladder training once you start locomotor training. Locomotor Training sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
32791552|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
32791553|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
32791554|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
32791555|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
32791556|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
32791557|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
32791558|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
32791559|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
32791560|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
33087826|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
33087827|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
33087828|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
33087829|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
33087830|NCT02272543|Placebo Comparator|Placebo|Placebo
33404020|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
32791561|NCT02285114|Experimental|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
32791562|NCT04420052|Experimental|OMT group|
32791563|NCT04420052|Placebo Comparator|Placebo group|
32791564|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
32791565|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
32791566|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
32791567|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
32791568|NCT04878458|Experimental|PEI+GSL+GT|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
32791569|NCT04878458|Experimental|PEI+Trab|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.
32791570|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
32791571|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
32791572|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
32791573|NCT01643408|Experimental|Open-Label Erwinaze|
32791574|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
32791575|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
32791576|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
32791577|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
33299320|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
33299321|NCT05497258|Experimental|Experimental: with Artificial intelligence assistant system|"The physicians were additionally provided with the feature extracted by the system, a list of suspicious diagnoses predicted by IDEAS-AAP, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction.~IDEAS-AAP extracted feature from electronic health record, provided a list of suspicious diagnoses, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction."
33299322|NCT05497258|No Intervention|No Intervention: without Artificial intelligence assistant system|
33299323|NCT01232998||Patient Satisfaction with nursing care|
33299324|NCT01232998||satisfaction of waiting time for first time visit|
32791578|NCT01739764|Experimental|Vemurafenib 480mg BID|Participants received oral vemurafenib at 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
32791579|NCT01739764|Experimental|Vemurafenib 720mg BID|Participants received oral vemurafenib at 720 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
32791580|NCT01739764|Experimental|Vemurafenib 960mg BID|Participants received oral vemurafenib at 960 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
32791581|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
33299325|NCT01232998||patient satisfaction|
33299327|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
33299328|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
32791582|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
33299329|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
33299330|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
33299331|NCT04797364|Experimental|Pharmacogenetic Testing|Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
33299332|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
33299333|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
33299334|NCT01138930|Experimental|Berberine|
33299335|NCT01138930|Placebo Comparator|Placebo|
33299336|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
33299337|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
33299338|NCT01139086||Control|Age and body built matched with chronic heart failure group
33299339|NCT05487196|Experimental|Clonidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Clonidine 60 mcg"
33299340|NCT05487196|Experimental|Dexmedetomidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Dexmedetomidine 30 mcg"
32791583|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
32791584|NCT01700140|Experimental|SyB D-0701: high dose group|
32791585|NCT01700140|Experimental|SyB D-0701: low dose group|
32791586|NCT01700140|Placebo Comparator|placebo group|
33299341|NCT05487196|Active Comparator|Ropivacaine + Fentanyl|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Fentanyl 100mcg"
33299342|NCT01233154|Experimental|L. paracasei|L. paracasei
32791587|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
32791588|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
32791589|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
32791590|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
32791591|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
32791592|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
32791593|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
32791594|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
32791595|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
32791596|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
32791597|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
32791598|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
33299343|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
33299344|NCT01142752||Control|Control group of women with uneventful pregnancy
33299345|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
33299346|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
33299347|NCT01233778|Experimental|Canola Oil|
33299348|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
33299349|NCT01233778|Experimental|High Oleic Canola Oil|
32791599|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
33299350|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
33299351|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
33299352|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
33299353|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
33299354|NCT04764994|Active Comparator|Control Group|"Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities.~The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
33299355|NCT04764994|Experimental|Study Group|"Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares.~The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
32791600|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
32791601|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
33299356|NCT01585870|Experimental|Sorafenib + Eribulin|
33404021|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
33404022|NCT05763108||Recurrent patellar dislocation group|50 patients with recurrent patellar dislocation and without any genetic disorders.
32791602|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
32791603|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
32791604|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
32791605|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
32791606|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
32791607|NCT01738984|Experimental|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
32791608|NCT01738984|Experimental|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
32791609|NCT01738594|Experimental|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
32791610|NCT01738594|Experimental|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
32791611|NCT01738438|Experimental|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
32791612|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
32791613|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
32791614|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
32791615|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
32791616|NCT04548310||Healthy group|Healthy individuals without chronic disease
32791617|NCT04548232||LSG in obese|Patients with obesity underwent LSG. Divided into simple obese patients (without complications) and obese patients with complications
32791618|NCT04548232||Control group|healthy individuals with normal BMI
32791619|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
32791620|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
32791621|NCT04555564|Experimental|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
32791622|NCT04555330|Experimental|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
32791623|NCT04555330|Other|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
32791624|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
32791625|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
32791626|NCT01697800|Placebo Comparator|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
32791627|NCT01697800|Active Comparator|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
33299357|NCT03754660|Experimental|Untreated patients (Part A and Part B)|"Part A: Untreated PAH and CTEPH patients will be enrolled to test 5 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 4000 µg.~Part B: The highest safe, well tolerated and effective dose of Part A will be tested in further untreated patients."
33404023|NCT05763108||Patients without joint hipermobility|200 patients without recurrent patellar dislocation and genetic disorders.
32791628|NCT04553770|Active Comparator|Arm A (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
32791629|NCT04553770|Experimental|Arm B (trastuzumab deruxtecan, anastrozole)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole PO QD on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
32791630|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
32791631|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
32791632|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
32791633|NCT04877834|Experimental|DelanzoTMDR group|Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
32791634|NCT04877834|Active Comparator|Dexilant® Group|Subjects will take Dexilant® 60 mg Capsule, manufactured by Takeda Pharmaceutical Company Limited after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
32791635|NCT05645822||People with symptoms attributable to gHAT|The study will include any person that attends any of the participating healthcare facilities with symptoms that could be attributed to gHAT (long-term fever (unless other obvious causes), headache for a long period (more than 14 days), presence of enlarged lymph nodes in the neck, severe weight loss, weakness, pruritus, amenorrhea, abortions or sterility, psychiatric problems (aggressiveness, apathy, mental confusion, anxiety), sleep disturbances, motor weakness, logorrhea, speech impairment, ataxia, abnormal gait, abnormal movements or seizures) and accepts to participate.
33299358|NCT03754660|Experimental|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in pre-treated patients with any kind of monotherapy for PAH/CTEPH.
33404024|NCT04811482|Experimental|Intervention Group|This study consists of one arm, an intervention group.
33404025|NCT04435158|Experimental|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
33404026|NCT04435158|Experimental|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
33404027|NCT04435158|Experimental|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
32791636|NCT04872608|Experimental|Letrozole, Palbociclib, and Onapristone ER|This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
33299359|NCT03754660|Experimental|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in pre-treated patients with any kind of double combination treatment for PAH/CTEPH.
32791637|NCT05645120|Experimental|Health Professionals|Education intervention for health professionals
32791638|NCT05645120|Experimental|Non-health Professionals|Education intervention for non-health professionals
32791639|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
32791640|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
33299360|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
32791641|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
32791642|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
32791643|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
32791644|NCT01716052|Placebo Comparator|Placebo|Lactulose
32791645|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
32791646|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
32791647|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
32791648|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
32791649|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
32791650|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
32791651|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
32791652|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
32791653|NCT04859816|Experimental|Roux-en-Y gastric bypass operated participants|Roux-en-Y gastric bypass operated participants in weight stable phase > 1 year from surgery
32791654|NCT04859816|Experimental|Control participants|Age, sex, and BMI-matched un-operated participants.
32791655|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
32791656|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
32791657|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
32791658|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
32791659|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
32791660|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
32791661|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
32791662|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
32791663|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
32791664|NCT05560646|Experimental|OG-6219 Dose 1|OG-6219 Dose 1 BID
33299361|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
33299362|NCT04746820|Experimental|Experimental (unconscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
33299363|NCT04746820|Sham Comparator|Control group (healthy, conscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
33299364|NCT04738474|Experimental|PRISM Intervention|Subjects in this group will receive the PRISM intervention
33299365|NCT04738474|Placebo Comparator|Usual Care|Subjects in this arm will receive usual care
33404028|NCT04435158|Experimental|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 4 every 2 months × 6 months
32791665|NCT05560646|Experimental|OG-6219 Dose 2|OG-6219 Dose 2 BID
32791666|NCT05560646|Experimental|OG-6219 Dose 3|OG-6219 Dose 3 BID
32791667|NCT05560646|Placebo Comparator|Placebo|
32791668|NCT05558384|Experimental|Aerobic exercise|15-week standardized aerobic exercise intervention
32791669|NCT05644886|Experimental|Intervention Arm|"Male Family Physicians allocated to intervention arm will receive following:~Training and technical support and integrates them with the nearest pharmacies or drug shops for vertical referrals.~Technical support will include:~Supportive supervision~Peer-to-peer support~Strengthening referrals for long-acting reversible contraceptives (LARC) and permanent methods~Provision of information, education, and communication (IEC) material and LCD for display of visual material.~Branding of clinics with name boards~Provision of family planning prescription booklets"
32791670|NCT05644886|No Intervention|Control Arm|the providers in the control group will continue to provide their services as usual with no exposure to intervention activities. After the end of the intervention period, providers that fall into control areas will be provided the same training.
32791671|NCT04863794|Experimental|RO7248824|In Part 1 of the study RO7248824 and [89Zr]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
32791672|NCT04863716|Active Comparator|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered to this group.
32791673|NCT04863716|Active Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
32791674|NCT05644418|Experimental|Postcardiac surgery ICU-patients|After postcardiac surgery patients are brought to the ICU and are ventilated on PCV (Pressure Controlled Ventilation). Measurements of the lung volume (by Electrical Impedance Tomography; EIT), the minute volume and Mechanical Power/Dissipated energy are started and continued for the duration of the study. After a few minutes the patient is switched to FCV (Flow Controlled Ventilation) for 90 minutes and afterwards PCV is resumed with the measurements lasting for another 30 minutes (total study time 120 minutes).
33299366|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
33299367|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
33299368|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
33299369|NCT05222464|Other|Standard of Care Intervention|Standard of care intervention - The intervention will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
33299370|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
33299371|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
33299372|NCT05210140||Standard dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram treatment resulted in optimal escitalopram exposure (25-50 ng/ml) as measured at VK. These patients will continue their treatment with 10 mg/day during the V1-V2 period.
33299373|NCT05210140||Adjusted dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram dose resulted in to high (>50 ng/ml) or to low (<25 ng/ml) escitalopram exposure, as measured at VK. These patients will be treated with the adjusted escitalopram dose, different from 10 mg/day, during the V1-V2 period.
33299374|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
33299375|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
33299376|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
33299377|NCT01329718|Experimental|CRC Group|
33299378|NCT03711214|Active Comparator|pSS patients|We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.
33299379|NCT03711214|Active Comparator|Healthy individuals|We will evaluate 40 healthy controls before and after periodontal disease treatment.
33299380|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
33299381|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
33299382|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
33299383|NCT05195944|Experimental|Semaglutide|In the Semaglutide Arm, participants will receive daily: 1 tablet of Semaglutide and 1 tablet of Sitagliptin placebo for 26 weeks. The dosages of Semaglutide are 3 mg, 7 mg, and 14 mg.
33299384|NCT05195944|Active Comparator|Sitagliptin|In the Sitagliptin arm, participants will receive daily: 1 tablet of 100 mg Sitagliptin and 1 tablet of Semaglutide placebo for 26 weeks.
33299385|NCT05185882||1|"Single leg squat without a clue or focusing method~Single leg squat with an external focus~Sinlge leg squat with an internal focus"
33299386|NCT04713124|Experimental|R2C-M intervention|"R2C-M telephone intervention - Six approximately weekly sessions of R2C-M telephone-delivered intervention (50 minutes in duration), delivered by the same R2C-M Counsellor each session (a qualified clinical psychologist trained in the R2C protocol by the developer, Dr Kate Hall). Call duration will be recorded. Sessions will be digitally recorded, and an independent researcher will randomly select and rate fidelity of intervention sessions for 20% of participants.~R2C-M workbooks - Two workbooks to facilitate counsellor-delivered exercises within sessions, and between-session practice, will be mailed/emailed to participants.~Self-help booklet - (as in control group) R2C-M participants will also receive a booklet of information and self-help strategies for methamphetamine use problems."
33299387|NCT04713124|Active Comparator|Control|"Self-help booklet - Control participants will receive (by mail/email) a booklet of information and self-help strategies for methamphetamine use problems.~Telephone check-ins + information on further support - (to control for frequency of contact across treatment arms) Participants in this group will receive 6 telephone calls from the research team (lasting maximum 5 minutes, call duration will be recorded). During these calls, participants will be asked about their use of the booklet. Whenever required, the researcher will provide participants with information on further support (e.g. DirectLine or other state/territory AOD helpline for advice or referral)."
33299388|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
32791675|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
33299389|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
33299390|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
33299391|NCT04709692|Other|Arm 1 A (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
33299392|NCT04709692|Other|Arm 1 B (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
33299393|NCT04709692|Other|Arm 2 A (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
33299394|NCT04709692|Other|Arm 2 B (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
33299395|NCT04709692|Other|Arm 3 A (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
32791676|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
33299396|NCT04709692|Other|Arm 3 B (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
33299397|NCT03559270|Experimental|Placebo/Baricitinib 2-milligram (mg)|Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).
33299398|NCT03559270|Experimental|Baricitinib 1-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).
33299399|NCT03559270|Experimental|Baricitinib 2-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).
33299400|NCT03559270|Experimental|Baricitinib 2-mg Open-Label Addendum|Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.
33299401|NCT05136586|Experimental|Biofeedback|Relaxing breathing exercise coupled with biofeedback before the circuit, no intervention after
33299402|NCT05136586|Experimental|Meditation|Meditative stimulation audio tape before the circuit, no intervention after
33299403|NCT05136586|Experimental|Control and biofeedback post OSCE|Standardised video before the circuit, Relaxing breathing exercise coupled with biofeedback after the OSCE
33299404|NCT05136586|Sham Comparator|Control and control post OSCE|Standardised video before the circuit, no intervention after
33299405|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
33299406|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
33299407|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
32791677|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
32791678|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
32791679|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
32791680|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
32791681|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
32791682|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
32906936|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
32906937|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
33299408|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
33299409|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
32939888|NCT05313386|Experimental|Cohort 3- 240 Micrograms|"Two 120 Micrograms films or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
32939889|NCT05313386|Experimental|Cohort 4- 300 Micrograms|"One 120 Micrograms film and one 180 Micrograms film or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
33299410|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
33299411|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
33299412|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
33299413|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
33299414|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
33299415|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
33299416|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
32939890|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
32939891|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
33299417|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|"Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.~This is an exploratory arm, per FDA. The results of this arm are not included in the primary analysis."
33299418|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
33299419|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
33299420|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
33299421|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
33299422|NCT03467932|Placebo Comparator|Cohort B - Matched Placebo Oral Capsule|Cohort B - Matched Placebo Oral Capsule: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
33404029|NCT04435158|Experimental|Cohort 5：SHR-1222|Subcutaneous injection of SHR-1222 dosage 5 every 2 months × 6 months
33404030|NCT04435158|Experimental|Cohort 6：placebo|Subcutaneous injection of placebo × 6 months
32939892|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
32939893|NCT03031340|Placebo Comparator|Placebo|
32939894|NCT03031340|Experimental|Pregabalin|
32939895|NCT03760796|Experimental|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
32939896|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
32939897|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
32939898|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
32939899|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
33087831|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
33087832|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
33087833|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
33087834|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
33087835|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
33087836|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
33087837|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
33087838|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
33087839|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
33299423|NCT05110300|Active Comparator|Body weight support system control group|The Body weight support system (BWSS) active comparator control group will conduct 2 to 6, 30 minute sessions, over two-weeks. To be as pragmatic and clinically relevant as possible, treatment sessions will be incorporated directly to the participants' normal care. Furthermore, participants are allowed to complete 2 to 6 sessions as dictated by short or unexpected changes to the discharge planning timeline. During each session, participants will conduct balance exercises, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. Participants will also conduct various standard gait exercises, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
33299424|NCT05110300|Experimental|Body weight support system with balance perturbations|The BWSS with balance perturbations (BWSS-P) experimental intervention group will also conduct 2 to 6, 30 minute sessions, over two-weeks. Participants in the BWSS-P group will conduct the same balance and gait exercises as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions. However, each sessions will include eight, resistive or assistive, balance perturbations, two in each cardinal direction (lateral, anterior, and posterior).
32791683|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
32791684|NCT04862312|Experimental|VideoDine|Use of video chat to eat a meal with a dining partner.
32791685|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
32791686|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
32791687|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
32791688|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
32791689|NCT04858802|Experimental|PROPEL Contour Sinus Implant|Following successful in-office bilateral balloon dilation, placement of PROPEL Contour Sinus Implant in the randomized side.
32791690|NCT04858802|Active Comparator|Balloon Sinus Dilation Alone|Following successful in-office bilateral balloon dilation, placement of no implant on the contralateral side.
32791691|NCT05642780|Experimental|cohort A|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
32791692|NCT05642780|Experimental|cohort B|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
32791693|NCT05642780|Experimental|cohort C|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
32791694|NCT05642780|Experimental|cohort D|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
32791695|NCT01714726|Experimental|1|MEDI2070 iv infusion
32791696|NCT01714726|Placebo Comparator|2|placebo iv infusion
32791697|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
32791698|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
32791699|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
32791700|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
32791701|NCT05642702|Experimental|Test Product Code A|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide -
32791702|NCT05642702|Experimental|Test Product Code B|Peptide complexed HA Age Defying Gel with Natural Extracts
32791703|NCT05642702|Experimental|Test Product Code C|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts
32791704|NCT05642702|Active Comparator|Positive Control|Sodium Lauryl Sulphate (SLS) analytical grade 1 % w/v
32791705|NCT05642702|Active Comparator|Negative Control|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v
32791706|NCT05544734|Active Comparator|Hydrocodone 5mg/acetaminophen 325mg|Participants receive oral hydrocodone 5 mg/acetaminophen 325 mg every 4 hours for 2 days, followed by oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 4 days
32791707|NCT05544734|Active Comparator|Acetaminophen 1000mg + Ibuprofen 400mg|Participants receive oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 6 days
33299425|NCT05109052|Experimental|Experimental|"Open label safety and tolerability assessment of PXS-5505:~(PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks"
33299426|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
32791708|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
32791709|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
33299427|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
33299428|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
33299429|NCT05098444|Experimental|Cognitive behavioral psychotherapy|"Internet-based CBT for patients with endometriosis:~The experimental group has access to an online training consisting of 8 modules, one per week.~Modules comprise of 1) psychoeducation (e.g., information about endometriosis and its treatment); 2) & 3) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions); 4&5) pain and stress management (e.g. activity plans, relaxation techniques); 6) emotion regulation strategies (e.g. recognition and acceptance of emotions); 7) communication training (e.g. detection and communication of needs); 8) prophylaxis (e.g. summary of intervention, plans for the future).~Participants are in weekly written contact with their assigned therapist via the news function of the training platform, receiving feedback on the content or getting answers to open questions."
33299430|NCT05098444|Other|Waiting list|During the waiting period, patients receive no treatment. After a waiting time of 5 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
33299431|NCT03414502|Active Comparator|Methotrexate Therapy|Subjects will receive methotrexate therapy for RA treatment.
33299432|NCT03414502|Active Comparator|Abatacept Therapy|Subjects will receive abatacept therapy for RA treatment.
32791710|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
32791711|NCT05540054|Experimental|Standard pulmonary rehabilitation group (PR)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
33299433|NCT03414502|Active Comparator|Adalimumab Therapy|Subjects will receive adalimumab therapy for RA treatment.
33299434|NCT03414502|Active Comparator|Azathioprine Therapy|Subjects will receive azathioprine therapy for RA treatment.
33299435|NCT03414502|Active Comparator|Barcitinib Therapy|Subjects will receive barcitinib therapy for RA treatment.
33299436|NCT03414502|Active Comparator|Certolizumab Therapy|Subjects will receive certolizumab therapy for RA treatment.
32791712|NCT05540054|Experimental|Inspiratory muscle training group (PR+IMT)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
32791713|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
33299437|NCT03414502|Active Comparator|Etanercept Therapy|Subjects will receive etanercept therapy for RA treatment.
33299438|NCT03414502|Active Comparator|Golimumab Therapy|Subjects will receive golimumab therapy for RA treatment.
33299439|NCT03414502|Active Comparator|Hydroxycholoroquine Therapy|Subjects will receive hydroxychloroquine therapy for RA treatment.
33299440|NCT03414502|Active Comparator|Infliximab Therapy|Subjects will receive infliximab therapy for RA treatment.
33299441|NCT03414502|Active Comparator|Leflunomide Therapy|Subjects will receive leflunomide therapy for RA treatment.
33299442|NCT03414502|Active Comparator|Minocycline Therapy|Subjects will receive minocycline therapy for RA treatment.
33299443|NCT03414502|Active Comparator|Rituximab Therapy|Subjects will receive rituximab therapy for RA treatment.
33299444|NCT03414502|Active Comparator|Sarilumab Therapy|Subjects will receive sarilumab therapy for RA treatment.
33299445|NCT03414502|Active Comparator|Sulfasalazine Therapy|Subjects will receive sulfasalazine therapy for RA treatment.
32791714|NCT05640986|Experimental|Patients|Risky behaviors assessed through BART-EEG among Parkinsonian patients newly treated with dopaminergic agonists
32791715|NCT05640986|Active Comparator|Control|Risky behaviors assessed through BART-EEG among healthy volunteers
33299446|NCT03414502|Active Comparator|Tofacitinib Therapy|Subjects will receive tofacitinib therapy for RA treatment.
33299447|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
33299448|NCT01236664|Experimental|Memory Training|
32791716|NCT05651204||Dravet|
32791717|NCT05651204||Age-Matched Control|
32791718|NCT05640596||exposed group (121 patients)|"Extrated from the population of full-term newborns (> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who received at least one course of betamethasone before 34 weeks of amenorrhea for a threat of preterm delivery.~Exposure to an antenatal corticosteroid therapy was defined as the administration of at least one course of betamethasone (i.e. two doses of 12 mg, 24 hours apart). in intramuscular, before 34 weeks of amenorrhea, for a threat of premature delivery."
32791719|NCT05640596||nonexposed group (242 patients)|came from the population of full-term newborns (> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who who had not been exposed to antenatal steroid therapy. Two controls were selected for a case, appaired on the month and year of birth and on the sex of the case patient.
32791720|NCT05651126|Experimental|Placebo, Psilocybin_2, Psilocybin_5|Dose order: Placebo, Psilocybin 2mg, Psilocybin 5mg
32791721|NCT05651126|Experimental|Psilocybin_2, Placebo, Psilocybin_5|Dose order: Psilocybin 2mg, Placebo, Psilocybin 5mg
32791722|NCT05651126|Experimental|Psilocybin_2, Psilocybin_5, Placebo|Dose order: Psilocybin 2mg, Psilocybin 5mg, Placebo
32791723|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
32791724|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
32791725|NCT05638334|Experimental|89Zr-S095012 tracer with S095012|
32791726|NCT05494814|Experimental|Child Care Centers Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that purchases meals prepared by a central kitchen.
32791727|NCT05494814|No Intervention|Child Care Centers Not Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that does not purchase meals prepared by a central kitchen.
33299449|NCT01236664|Active Comparator|Control workshop|
33299450|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
33299451|NCT01234090||Persons with Aphasia|
33299452|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
33299453|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
33299454|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
33299455|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
32791728|NCT05651048|Experimental|BEMER Group|BEMER application with routine treatment protocol
32791729|NCT05651048|Experimental|Kinesiotape Group|Kinesiotape application with routine treatment protocol
32791730|NCT05651048|Experimental|Control Group|routine treatment protocol
33299456|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
32791731|NCT05493566|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients will be treated with pembrolizumab 200 mg IV once every 3 weeks in combination with IL-2 given at 5 million IU subcutaneously twice daily for 3 weeks (5 days on, 2 days off each week, first dose in clinic and subsequent doses at home). IL-2 will be given only for the three weeks, after which pembrolizumab will be continued as monotherapy at either 200 mg every 3 weeks or 400 mg every 6 weeks.
32791732|NCT05493020||Questionnaires assessed children with cancer|Children with cancer who received at least one radiotherapy and chemotherapy during hospitalization
32791733|NCT05637710|Experimental|Group 1|Investigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.
32791734|NCT05637710|Active Comparator|Group 2|Comparator group: Levocetirizine 5mg (Zina® - comparator drug)
32791735|NCT05635448|Experimental|Intervention|Will be offered the BT coaching intervention over 4-months (February 1st 2023- May 31st 2023).
32791736|NCT05635448|Placebo Comparator|Waitlist control|Will be offered the coaching intervention following 4-month waitlist control (September 1st 2023 - December 31st 2023).
32791737|NCT04871594|Experimental|Nivolumab monotherapy|Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
32791738|NCT05485922|Experimental|Investigational device - intermittent catheter with a micro-hole zone|A ready-to-use, sterile, hydrophilic-coated male catheter for intermittent catheterisation with a flexible tip and a micro-hole zone for urinary drainage in sizes CH12 and CH14. The catheterization was performed by a trained nurse.
32791739|NCT05485922|Active Comparator|Comparator device - VaPro intermittent catheter|Hollister VaPro, a single-use hydrophilic sleeved soft/flexible catheters in the sizes CH12 or CH14. The catheterization was performed by a trained nurse.
33299457|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
33299458|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
33299459|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
33299460|NCT01143376|Experimental|Short springs|short springs training
33299461|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
33299462|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
33299463|NCT04618822|Experimental|Teaching involving whole-body movements|
33404031|NCT04754230|Experimental|1,000mg IV Tranexamic acid|Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
32939900|NCT05313308||Midazolam|Participants will receive a single age-specific dose midazolam oromucosal solution through buccal mucosa upon onset of seizures. Dose will be dependent by age of participants as follows: >= 52 weeks and < 1 year; 2.5 mg/dose of midazolam, for >= 1 year and < 5 years; 5 mg/dose of midazolam, for >= 5 years and < 10 years; 7.5 mg/dose of midazolam, for >= 10 years and < 18 years; 10 mg/dose of midazolam. Participants received interventions as part of routine medical care.
32939901|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
32939902|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
33299464|NCT04618822|Experimental|Teaching involving hand movements|i.e. arms and hands
33299465|NCT04618822|Active Comparator|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
33299466|NCT04595968|Experimental|Vestal DM active device|100 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
33299467|NCT04595968|Sham Comparator|Vestal DM sham device|100 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
32939903|NCT03407053|Active Comparator|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
32939904|NCT03407053|Active Comparator|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
32939905|NCT03756506|Active Comparator|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
32939906|NCT03756506|No Intervention|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
32939907|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
32939908|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
32939909|NCT04735237|Experimental|Autogenous fat injection|Fat will first be harvested from the abdomen, then injected into the lip
32939910|NCT04735237|Active Comparator|Surgical revision with orbicularis oris muscle reconstruction|
32939911|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
32939912|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
32939913|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
33299468|NCT01139788|Experimental|LY2624587|
33299469|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
33299470|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
33299471|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
33299472|NCT05632666|Experimental|Active treatment group|
33299473|NCT05632666|Sham Comparator|Sham-controlled group|
33404032|NCT04754230|No Intervention|Normal saline|Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
33404033|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
32791740|NCT04871516|Experimental|Treatment (radiation therapy boost, WBI)|Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
32791741|NCT05626244|Experimental|Intervention Group|The intervention group will be receiving the parenting intervention (name of the intervention: Being a Parent).
32791742|NCT05626244|No Intervention|Waitlist Control Group|The control group will be in a waitilist condition, in which they will not receive any intervention during the trial, but posteriorly will have the opportunity to receive the parenting intervention.
32791743|NCT04871204|No Intervention|Control|Standard treatment
33102410|NCT05421507||Patients with head and neck tumors with local recurrence or metastasis|"The patients in the group were treated with routine clinical treatment: 3D-PCT combined with CT-guided I-125 seeds implantation in the treatment of head and neck malignant tumors.~The prescription dose is given 110-150Gy according to tumor pathological type, tumor volume, history of previous radiotherapy and different surrounding normal tissues according to experience and routine diagnosis and treatment."
32791744|NCT04871204|Experimental|Octreotide|3 monthly intramuscular injections of 10 mg Octreotide
32791745|NCT05625776|Experimental|Pain Stimulus|Capsaicin combined with heat applied to intact skin
32791746|NCT05625776|Active Comparator|Distractor Somatosensory Stimulus|Sensory transcutaneous electrical nerve stimulation (TENS) applied to intact skin
32791747|NCT05625776|No Intervention|No Stimulus|Nothing applied to skin
32791748|NCT05650970|Active Comparator|routinely treated control group|Unlike the study group, radial nerve mobilization will not be included in the treatment program of this group. only massage, ice and activity modification training will be included.
32791749|NCT05650970|Experimental|radial nerve mobilization study group|The treatment program of this group will include massage, radial nerve mobilization, ice and activity modification training.
32791750|NCT05650580|Experimental|Dose Escalation and Expansion|Participants with relapsed/Refractory Non-Hodgkin's Lymphoma or Advanced solid tumor will receive TR115 at escalating and expansion dose levels.
32791751|NCT05619770|Experimental|101-PGC-005 (Intervention arm)|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
32791752|NCT05615948|Other|Intervention Group|All individuals 18 years old or older who have Major Depressive Disorder and have failed to achieve response or remission to at least one proven antidepressant trial with minimum affective dose for a duration of at least 6 weeks.
32791753|NCT05612828|Experimental|Conventional training|Combat Life Savers trained by conventional combat medicine approach.
32791754|NCT05612828|Experimental|Simulation manikin training|Training based on principles of simulation medicine.
32791755|NCT04857710|Active Comparator|Control (CONT)|A control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations
32791756|NCT04857710|Experimental|Conventional neuromuscular electrostimulation (CONV)|The CONV (conventional) modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES (neuromuscular electrostimulation) training.
32791757|NCT04857710|Experimental|Wide-pulse neuromuscular electrostimulation (WP)|The use of wide-pulse (WP) stimulations allows, in addition to the direct activation of the muscle fibers, the use of sensory pathways. This more global solicitation of the neuromuscular system (i.e. information going back to the spinal cord and even to the brain) prejudges more nervous adaptations and therefore a greater functional benefit.
32791758|NCT05478746|Other|Routine Care|Participants enrolled in the control arm will undergo routine care for localized provoked vulvodynia according to the doctor's usual recommendations. These may include lidocaine cream, physical therapy, a compounded cream containing a blend of lidocaine, baclofen, amitryptyline, estradiol, testosterone, and bupivacaine, radiofrequency treatment, Naropin or botulinum toxin injections.
32791759|NCT05478746|Experimental|Flourish HEC|"Participants in the Flourish HEC arm will undergo routine care as described for the control arm. Instead of lidocaine cream, they will be given a 4% lidocaine gel (called Relief, to be used up to 4x/day as needed) in an iso-osmotic, pH-balanced gel base. In addition, they will be given 3 products to use as described here, comprising the Flourish HEC kit (HEC = hydroxyethylcellulose, the principal gelling compound in the vaginal gel, to distinguish from the original Flourish kit using aloe).~Balance - external vulvar wash to be used daily in the shower.~BioNourish - vaginal moisturizing gel to be used every day before bed. Iso-osmotic and pH-adjusted with lactic acid to match healthy vaginal fluid.~BiopHresh - vaginal homeopathic suppository with 7 vaginal probiotic strains, including Lactobacillus crispatus, to be used every 3rd day before bed."
32791760|NCT04870658||Complication|Any patients with biological or mechanical complication in dental implant treatment.
32791761|NCT05465798|Experimental|Beta-Glucans|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans daily for up to three consecutive days.
32791762|NCT05465798|Placebo Comparator|Placebo|Participants allocated to this arm will receive a placebo that will be identical in form to the MC 3x3 pills used the interventional arm. These doses will be scheduled daily and administered orally for up to three consecutive days.
32791763|NCT04860596|Experimental|collaborative health management model program|nursing education and self care program
32791764|NCT04860596|No Intervention|Routine care|Tranditional education program
32791765|NCT05591066|No Intervention|Usual care|Unstructured communication during rounds and unstandardized interpretation at provider discretion.
32791766|NCT05591066|Experimental|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
32791767|NCT05591066|Experimental|PFC I-PASS+ Intervention|PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters on and after rounds and training doctors about communication and cultural humility.
32791768|NCT05650424|Active Comparator|Wait-listed Control|wait-listed control group will be put on wait list and receive abdominal massage class training on week 4 (posttest)
33087840|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
32791769|NCT05650424|Experimental|Intervention (Receive abdominal massage training)|Intervention group will receive abdominal massage training class and they will perform abdominal massage on their baby for 4 week. Parental stress level will be assessed on week 0 and week 4
32791770|NCT05650268|Experimental|Vitamin D3|The experimental group will receive 576000 IU in single oral dose of liquid vitamin D3~7 days prior to the surgery.
32791771|NCT05650268|Placebo Comparator|Control group|The control group will receive 95% MCT D3~7 days prior to the surgery.
32791772|NCT05650190|Experimental|Test Arm|Single vision, impact resistant spectacle lenses; Test Arm
32791773|NCT05650190|Placebo Comparator|Control Arm|Single vision, impact resistant spectacle lenses; Control Arm
32791774|NCT05438264|Experimental|Experimental|Donepezil 5 mg, QD
32791775|NCT05438264|Placebo Comparator|Control|Placebo, QD
32791776|NCT05434598|Experimental|Patients: ChromSeq|ChromoSeq will be performed on bone marrow or peripheral blood DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
32791777|NCT05434598|No Intervention|Stakeholders (Treating Physicians)|Stakeholders (treating physicians) will complete surveys/questionnaires
32791778|NCT05577494||Clinicians|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 100 clinicians are recruited in total. Then, they will receive an online questionnaire and complete the Clinician Questionnaire. Finally, the survey results need to be qualitatively analyzed.
32791779|NCT05577494||Clinician interviewers|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 30 clinicians are recruited in total (10 in each clinical institution). Each clinical institution shall select 2-3 interviewers, who shall participate in interview consistency training. Semi-structured interviews are conducted with the enrolled clinicians using the Clinician Interview Guide. The interview process needs to be recorded, and the interview results need to be qualitatively analyzed.
32791780|NCT05577494||Outpatients with MDD:|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 600 patients with MDD are recruited in outpatient clinics (200 in each institution). The patient questionnaire will be completed online. The enrolled patients need to conduct an online questionnaire survey and complete the Patient Questionnaire. Finally, the survey results need to be qualitatively analyzed.
32791781|NCT05577494||Patients with MDD receiving focus group discussion|Each center will hold 1-2 focus group symposiums for 8-10 patients according to the Patient Focus Group Symposium Manual. The content of the symposium needs to be recorded and written. Finally, the interview results need to be qualitatively analyzed.
32791782|NCT05573048|Experimental|Trans-Perineal Grid for prostate interventions|Subjects will have the trans-perineal guide grid placed the prostate biopsy or ablation procedure.
32791783|NCT05092178|Experimental|Calorie restricted diet and exercise intervention|"The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.~The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months."
32791784|NCT05092178|Active Comparator|exercise group|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
32791785|NCT01640366|Experimental|PICO negative pressure|Single-use Negative Pressure Wound Therapy
32791786|NCT01640366|No Intervention|Standard of care dressing arm|Sterile gauze adhesive strips
33087841|NCT00271245|Experimental|1|200 µg selenium as selenate
33087842|NCT00271245|Experimental|2|400 µg selenium as selenate
33087843|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
32791787|NCT05431088|Active Comparator|Part A|"Initially, participants will be randomized 1:1 to 100 mg and 150 mg daily. Upon review of the 150 mg safety data from at least 6 participants, there will be 1:1:1 randomization: 100 mg, 150 mg, and up to 200 mg.~Participants will then receive maintenance once daily doses through Week 12."
32791788|NCT05431088|Placebo Comparator|Part B|Following the selection of the optimal safe and effective dose from Part A of the study, Part B of the study will assess the efficacy and safety of 48 weeks of the optimal dose, compared to placebo
32791789|NCT05431088|Experimental|Part C|100 mg dose in cohort C1, dose level for cohorts C2 to C4 to be determined based on emerging data
32791790|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
33087844|NCT00271245|Placebo Comparator|4|placebo
33087845|NCT02272855|Experimental|HF10 plus ipilimumab|
32791791|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
32791792|NCT04688996||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
32906938|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
32906939|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
33087846|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
33087847|NCT02272894||Group B|D2 Radical Gastrectomy
33087848|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
32791793|NCT04688996||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
32791794|NCT04835870|Experimental|R-CHOP + Zanubrutinib|Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
32791795|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
32791796|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
32791797|NCT04687904|Active Comparator|Therapeutic education group|"The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview (control group)."
32791798|NCT04687904|Experimental|Mindfulness meditation group|"The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) (active group)"
32791799|NCT04685486|Experimental|Virtual Reality|Virtual reality-enhanced distraction using a portable head mounted display during panful events (such as wound dressing changes or physical therapy sessions) in addition to standard of care.
33087849|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
32791800|NCT04685486|No Intervention|Treatment as Usual|Standard of care during painful event (such as wound dressing changes or physical therapy sessions).
32791801|NCT05380076|Experimental|Mindfulness|Mindfulness meditation video before the circuit
32791802|NCT05380076|Experimental|Mobilization of inner resources|Standardised video before the circuit
32791803|NCT05380076|Experimental|Biofeedback|Cardiac biofeedback before the circuit
32791804|NCT05380076|Sham Comparator|Control|Standardised video before the circuit
32791805|NCT05421338|Experimental|BI 456906 (C-14)|
32791806|NCT05420090|Experimental|eating banana for 6 weeks before bedtime|Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
32791807|NCT05420090|Experimental|drinking milk for 6 weeks before bedtime|Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
33404034|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
33404035|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
32791808|NCT05420090|Experimental|Control|Not making any changes in diet
32791809|NCT05065970|Placebo Comparator|Placebo|
32791810|NCT05065970|Experimental|Felzartamab Arm #1|
32791811|NCT05065970|Experimental|Felzartamab Arm #2|
32791812|NCT05065970|Experimental|Felzartamab Arm #3|
32791813|NCT05400746|Experimental|Group 1 - low dose|8-10 volunteers receiving three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
32791814|NCT05400746|Experimental|Group 2 - standard dose|8-10 volunteers receiving three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
32791815|NCT05400746|Experimental|Group 3 - fractional dose|8-10 volunteers receiving two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56 via intramuscular injection (IM) in the deltoid region of the arm
32791816|NCT04834388|Experimental|Anakinra High dose|500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
32791817|NCT04834388|Experimental|Anakinra Low dose|100mg s.c. loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.
32791818|NCT04834388|No Intervention|Standard care|Standard care group
32791819|NCT04834310|Experimental|Intraoperative and Postoperative Antibiotics|The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.
32791820|NCT04834310|Placebo Comparator|Intraoperative Antibiotics and Placebo|The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively
32791821|NCT05397782|Experimental|Pilot Group: Flourish HEC|All women in the study will use the Flourish HEC Vaginal Care System for 6 months. Flourish HEC consists of 3 products: 1) Balance, an external feminine wash; 2) BioNourish, a vaginal moisturizing gel; and 3) BiopHresh, a homeopathic vaginal suppository with probiotics. Products are pH-balanced to match healthy vaginal pH (3.5-4.5). BioNourish is formulated to be iso-osmotic with vaginal fluid. Balance and BioNourish contain lactic acid. BiopHresh contains 7 strains of lactobacilli, including Lactobacillus crispatus and other species found in healthy vaginas or shown to be effective probiotics strains.
32791822|NCT05060042|Experimental|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week.
33087850|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
32791823|NCT05060042|Active Comparator|Bilateral proprioceptive training Group|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
32791824|NCT04848116|Experimental|Cohort 1|Nivolumab + HuMax (BMS-986253) will be administered as an IV infusion.
33087851|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
32791825|NCT04848116|Experimental|Cohort 2|Nivolumab + Cabiralizumab will be administered as an IV infusion.
32791826|NCT04848116|Experimental|Cohort 3|Nivolumab + another agent (which will be determined depending on results from Cohort 1 and Cohort 2) will be administered as an IV infusion.
33087852|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
32791827|NCT05392868|Experimental|SDF|38% silver diamine fluoride solution
32791828|NCT05392868|Active Comparator|KNO3|5% potassium nitrate solution
32791829|NCT05390606|No Intervention|Control arm|Women follow routine care only, including prescribed medications and recommended techniques and supplements for attempting to become pregnant at home for up to three months.
32791830|NCT05390606|Experimental|Flourish HEC + BioGenesis arm|In addition to routine care followed by women in control arm, women in this arm also use the Flourish HEC (Hydroxyethylcellulose) vaginal care system and BioGenesis fertility lubricant for up to three months.
33087853|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age~Who understand and voluntarily sign an informed consent form~FEV1 > 15% predicted and < 45% predicted~RV >180% predicted~Diagnosis of emphysema with CT evidence of hyperinflation~Absence of collateral ventilation according to Chartis Assessment System~Treated with Zephyr Endobronchial Valve (EBV)"
33087854|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
33087855|NCT00290550|Other|1|MK-0457
33087856|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
33087857|NCT02273401|Experimental|BI 11054 CL|
33087858|NCT02273401|Placebo Comparator|Placebo|
33087859|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
32791831|NCT05372198|Experimental|Cohort 1: Surufatinib Monotherapy|Patients who met the eligibility criteria took Surufatinib 300mg qd, every 3 weeks as a cycle
32791832|NCT05372198|Experimental|Cohort 2: Surufatinib with immunotherapy|"Patients who met the eligibility criteria took Surufatinib with immunotherapy:~Surufatinib:250mg qd, every 3 weeks as a cycle Immunotherapy: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle"
32791833|NCT04854980||Experimental:|Blood Sample Taken
32791834|NCT05048732|Experimental|Cohort 1 = Healthy Volunteers|"Healthy volunteers (N=6, three male, three female) will be recruited to undergo a single 18F-FAT PET/CT imaging session for radiation dosimetry estimates.~18F-FAT administration followed by body imaging at 3 time points~0-60 min = multiple quick body scans~120 min post injection = body scan~240 min post injection = body scan"
32791835|NCT05048732|Experimental|Cohort 2a: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N= 6 : 18F-FAT imaging session at baseline and Day 2-4 following Cycle 1 standard of care therapy.
32791836|NCT05048732|Experimental|Cohort 2b: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N=9: 18F-FAT imaging session at baseline and best time point determined from Cohort 2a (2 days post Cycle 1 standard of care therapy)
32791837|NCT05359406|Experimental|unresectable group|Patients will receive tislelizumab in combination with radiotherapy and targeted therapy. 2 weeks after large fractionated radiotherapy for primary rectum lesion and metastasis, patients will be treated with systemic treatment including chemotherapy combined with targeted therapy and immunotherapy. Patients will be evaluated by MDT every 2 months since the beginning of the treatment. Those who are regarded as NED will be treated surgically/locally. Those in stable or partial remission will continue with combination therapy. Those with progressive disease will be withdrawn from study. Patients who are not surgically treatable will continue with combination therapy until disease progression or receiving surgical treatment.
32791838|NCT05038904|Experimental|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
32791839|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
32791840|NCT04654208||HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)|Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
32791841|NCT04654208||HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant|Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
33404036|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
32906940|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
33087860|NCT01601353|No Intervention|Control|No intervention through 9 months
33087861|NCT01601392|Experimental|Anodal tDCS|
33087862|NCT01601392|Active Comparator|Cathodal tDCS|
33087863|NCT01601392|Sham Comparator|Sham|
33087864|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
33087865|NCT01601509|Placebo Comparator|Placebo|
33087866|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
33087867|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
33087868|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
33087869|NCT00257465|Placebo Comparator|D|0 cells
33404037|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
33299474|NCT03199612|Active Comparator|Sildenafil|Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
33299475|NCT03199612|Placebo Comparator|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
33299476|NCT05043454|Experimental|Vascular Density Improvement in Hypertensive Participants|Participants will undergo baseline visits and follow-up visits to include neurocognitive testing, VO2 max testing (graded exercise test), blood draws, and retinal scans. Potential subjects must pass an exercise stress test with 12-lead ECG, and training sessions (exercise protocol). Standardized neurocognitive tests assessing functions such as memory and attention will be administered and retinal scans will be conducted. The at-home exercise intervention will be supervised via the Polar beat/flow applications by study personnel. Subjects will engage in cardiovascular exercise with heart rate monitoring on 4 days per week for a total of 10 weeks.
33299477|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
33299478|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
33299479|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
33299480|NCT01140100|Active Comparator|propofol-propofol|
33299481|NCT01140100|Experimental|thiopental-propofol|
33299482|NCT01141036|Active Comparator|propofol|propofol
33299483|NCT01141036|Active Comparator|Midazolam|Midazolam
33299484|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
33299485|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
33299486|NCT01141114|Experimental|Use of a Patient Navigator|
33299487|NCT01141114|Other|Usual Care|No Intervention - usual care
33299488|NCT04983940|Experimental|Jatenzo Arm|Participants in this group will receive Jatenzo for 26 consecutive weeks.
33299489|NCT04978090|Experimental|Enteroatmospheric fistula (EAF) management solution|Participants will receive a custom fitted device designed to isolate EAF effluent independent of negative pressure wound therapy (NPWT) utilizing 3D printing technology to design a participant-matched device that more easily and effectively separates the participant's fistula and any emanated intestinal contents surrounding the wound.
33299490|NCT04977856|Experimental|Guided ICBT|Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
33299491|NCT04977856|Experimental|Self-guided ICBT|The self-guided arm is identical to the guided arm, however without the therapist support. To ensure patient safety, there will be clear instructions to the patients and primary caregivers on how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
33299492|NCT04977856|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical, or a combination of both. The content of TAU and the treatment techniques used will be monitored.
33299493|NCT04971850|Experimental|Sleep-disordered breathing (SDB)|Patients aged 1 to 20 years old with a suspicion of SDB or a high-risk of SDB due to their pathology and hospitalized at Necker Hospital for a sleep study for their clinical care.
33299494|NCT01236820||Normal|Healthy population
33299495|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
33299496|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
33299497|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy~At least 1 year from completion of chemotherapy and/or radiation therapy~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
33404038|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
32906941|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
32906942|NCT04377854||MCS recipients|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
32906943|NCT04377854||Recipient of cardiac transplant|All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.
32906944|NCT04377854||Watchful waiting at Rigshospitalet|Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.
33404039|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
33404040|NCT05114902||PCV13 Non-vaccinated Settting|Pneumococcal vaccine-naïve children at the PCMC
32791845|NCT04652960|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32791846|NCT05360420|Experimental|Immediate CEUS group|CEUS (SonoVue) was performed immediately after routine US screening of suspicious lesions. The lesions were classified according to CEUS examination by the diagnosing physician, including consideration of HCC, suspected HCC, and benign lesions. Further hepatobiliary-specific MRI (Modis/Primexian) was performed for lesions considered HCC or suspicious for HCC, and benign lesions were followed up. The diagnostic findings of hepatobiliary-specific MRI were classified by the diagnosing physician and included consideration of HCC, suspected HCC, and benign lesions. For hepatobiliary-specific MRI lesions considered HCC or suspicious for HCC, pathological examination was performed, and benign lesions were followed up.
32791847|NCT05360420|No Intervention|Current clinical procedure group|After the suspicious lesions were screened by routine US, CECT, CEMRI and hepatobiliary-specific MRI (the first enhanced imaging examination) were independently selected by clinicians. According to the first examination results of the contrast-enhanced image, the diagnosis was classified by the diagnosing physician, including considering HCC, suspicious HCC, and benign lesions. Another contrast-enhanced imaging examination (CECT or CEMRI or hepatobiliary-specific MRI or CEUS) was performed again for lesions considered or suspected of HCC (second contrast-enhanced imaging study), and negative lesions were followed up. According to the examination results of the second enhanced imaging, the classification includes considering HCC, suspicious HCC, and benign. Pathological examination was performed for lesions considered HCC or suspicious for HCC on the second enhanced image, and benign lesions were followed up.
32791848|NCT05357846|Experimental|NCRT+IO group|"• NCRT+IO group consists of the PD-1 inhibitor combined with concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks.PD-1 inhibitor is given by intravenous infusion on days 1 and 22. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (40 or 45 Gy/20 fractions)~Drug: Sintilimab~Drug: Paclitaxel~Drug: Cisplatin"
32791849|NCT05357846|Active Comparator|NCRT group|"• NCRT group consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (40 or 45 Gy/20 fractions)~Drug: Paclitaxel~Drug: Cisplatin"
33087870|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
33087871|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
33087872|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
32791850|NCT05358470|Experimental|Exercise therapy and adapted physical activity-based intervention|The intervention in the experimental group (EG) consists of a exercise therapy and adapted physical activity program based on racket sports. The immediate EG will receive sixteen, twice a week, one-hour sessions of group-based, racket sports specific fundamental movement skills training. All sessions will be guided and supervised by a physiotherapist and delivered in groups of 5 participants to promote exchange and conviviality and to optimize the rates of participation and compliance.
32791851|NCT05358470|No Intervention|Usual care|Participants in the CG receive conventional management with general physical activity recommendation.
32791852|NCT05031494|Experimental|YH003 with Toripalimab in subjects with unresectable /metastatic melanoma|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment;
33404041|NCT05114902||PCV13 Vaccinated Setting|Pneumococcal vaccine-exposed children at the SPMC
32791853|NCT05031494|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment;
32791854|NCT05031494|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment;
33404042|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
33404043|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
33404044|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
33404045|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
33404046|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
33404047|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
33404048|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
33404049|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
33404050|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
33299498|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
33299499|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
33299500|NCT04948060|Experimental|Control 1-1|Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS).
33299501|NCT04948060|Experimental|Intervention 1-1|In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator.
33299502|NCT04948060|Experimental|Control 1-2|Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced.
33299503|NCT04948060|Experimental|Intervention 1-2|In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing.
33299504|NCT04948060|Experimental|Intervention 1-3|In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation.
33299505|NCT04948060|Experimental|Intervention 1-4|In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative.
32791855|NCT04845542|Experimental|ReStoreD|8-week intervention that is remotely delivered, consisting of psychoeducation and positive psychology activities. Participants complete two activities individually and two together each week.
33299506|NCT04948060|Experimental|Intervention 1-5|In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support.
33299507|NCT04936594|Experimental|Intermittent Theta Burst Stimulation (iTBS)|Subjects randomized to the experimental arm will receive 1800 pulses of intermittent TBS using MagVenture B65 A/P coil
33299508|NCT04936594|Sham Comparator|Sham TMS|Sham TMS will be delivered using MagVenture B65 A/P coil
33299509|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
33299510|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
33299511|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
33299512|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
33299513|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
33299514|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
32791856|NCT04845542|No Intervention|Waitlist-control|Participants will be waitlisted for 8 weeks.
32791857|NCT04844216|Experimental|Nasolabial fold treated with experimental device|"STYLAGE® L Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
32791858|NCT04844216|Active Comparator|Nasolabial fold treated with comparator|"The active comparator is a hyalorunic acid injectable gel whose intended purpose is the filling of mid and/or deep depressions of the skin via mid and/or deep dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
33299515|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
33299516|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
32791859|NCT05349422|Experimental|Intervention Group|
32791860|NCT05349422|No Intervention|Usual Care Group|Usual Care Clinical Decision Support (CDS) Tools
32791861|NCT05345288|Experimental|Intervention|Subjects randomized to the intervention group will complete prescribed cognitive training activities 3 times a week for 20-30 minutes each time for 6 weeks. Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
32791862|NCT05345288|Active Comparator|Control|Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
32791863|NCT05357222|Experimental|Straw Phonation|Participants will undergo one session of voice habilitation via a straw phonation exercise protocol. This protocol has been extensively studied and validated in the largest randomized clinical trial in voice therapy by our team.
32791864|NCT05013554|Experimental|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.
32791865|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.
32906945|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
32906946|NCT03000335||Remission|B-ALL patients who are in remission
33087873|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
33087874|NCT00416364||1|
33087875|NCT00416364||2|
33087876|NCT00416364||3|
33087877|NCT00416364||4|
33087878|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
33087879|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
33087880|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
33087881|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
33087882|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
33299517|NCT04917406|Experimental|Use of iontophoresis|Lidocaine (local anesthetic) associated with dexamethasone (corticosteroid) will be administered by iontophoresis technique. Dose per session and iontophoresis: 10 minutes with an intensity of 4 mA.
33299518|NCT04917406|Active Comparator|Use of ultrasound|The treatment for the control group will be applied with a frequency of 3 times a week as usually performed in the ACP of the University of Seville. The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and 1MZ head.
33299519|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
33299520|NCT01235104||Total nephrectomy|
33299521|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
33299522|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
33299523|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
32791866|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
32791867|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
32791868|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.
32791869|NCT04832594|Experimental|Supplemental MRI|Women randomized to MRI will be examined using a shortened MRI protocol on a Signa Premier 3T MRI scanner. The MRI examination will be reviewed by two radiologists and assigned BI-RADS score. Appropriate clinical work-up will follow according to the BI-RADS score. BI-RADS 3 or higher at initial MRI will be recalled for a second look ultrasound.
32791870|NCT04832594|No Intervention|No MRI (standard-of-care)|"Standard-of-care. Both arms will have had a regular screening mammography examination prior to randomization. The No MRI arm will have no further intervention."
32791871|NCT05353556|Experimental|Study Group|Patients who perform inspiratory muscle training (IMT) with %50 loading
32791872|NCT05353556|Sham Comparator|Sham Group|Patients who perform Sham IMT
32791873|NCT05335070|Experimental|Temporo-masseteric Nerve Block (TMNB) Injection with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the side/s of lower wisdom molar extraction/s
33299524|NCT01234246||Partners|Partners of patients with colorectal cancer are included
33404051|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
32791876|NCT05327738|Experimental|Treatment (atezolizumab, Y-90, cabozantinib)|"CYCLE 1: Patients receive atezolizumab IV over 60 minutes on day 1. Within 14 days, patients receive Y-90 intra-arterially.~CYCLES 2+: Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Treatment repeats every 21 days for a total of 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit may continue receiving atezolizumab and cabozantinib beyond cycle 12 at the discretion of the PI."
32791877|NCT05325788|Other|Single daily message followed by location-based messaging|Participants in this condition receive a single daily message through the intervention app for two weeks (14 days) followed by location-based messaging for two weeks (14 days).
32791878|NCT05325788|Other|Location-based messaging followed by single daily message|Participants in this condition receive location-based messaging through the intervention app for two weeks (14 days) followed by a single daily message for two weeks (14 days) .
32791879|NCT05008874||Males with AMN|Adult males with confirmed diagnosis of ALD and symptoms of AMN.
32791880|NCT04419662|Experimental|All patients included|
32791881|NCT04621526|Active Comparator|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
33087883|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
33087884|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
33087885|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
33087886|NCT01602055|Experimental|Azivol|
33087887|NCT01602055|Active Comparator|Zithromax|
33404052|NCT02338024|No Intervention|Standard of care|"Oral referrals to a network of government AIDS Centers or their departments (Trust offices) located in each study region."
32791882|NCT04621526|Active Comparator|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
32791883|NCT04614740|Experimental|VC004|1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.
32791884|NCT05353088|Experimental|Scapular stabilization exercises|Group A performed scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II).
32791885|NCT05353088|Active Comparator|Thoracic extension exercises|Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
32791886|NCT05351918||migrain days|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
32791887|NCT05351918||consumption of analgesics|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
32791888|NCT05419076|Experimental|Participants with small cell lung cancer with brain metastases|Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.
32791889|NCT04589546|Experimental|Vitamin B3|
32791890|NCT04589546|Placebo Comparator|Placebo|
32791891|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
32791892|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
32791893|NCT04411238||Patients|
32791894|NCT04411238||Caregivers|
33404053|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
32791895|NCT04411238||Home help|
32791896|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
32791897|NCT05317832|Active Comparator|Web-based physical activity intervention (WI) program|Participants in the WI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24).
32791898|NCT05317832|Experimental|Web-based physical activity intervention (WI) program + just-in-time adaptive intervention (JITAI)|Participants in the WI + JITAI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24). In addition, participants will have access to the JITAI that will provide just-in-time feedback and physical activity recommendations (weeks 3 to 24). The type of the feedback and recommendation messages in the WI + JITAI arm will be delivered using micro-randomization, which involves random selection of intervention components at each possible time of delivery.
32791899|NCT05311670|Other|Single-arm|Participants will be assigned to the single-arm involving monitoring of their symptoms.
32791900|NCT05416736|Experimental|Experimental Group|"Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~Genital area will be cleaned.~Newborn will be held under the armpit by a nurse, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Newborn with spontaneous voiding during the period from the beginning of the research procedure until the newborn is positioned will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~After the maneuvers are started, the newborn's heart rate and saturation comfort scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
32791901|NCT05416736|Active Comparator|Control Group|"Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~Genital area will be cleaned.~Newborns will be fitted with a sterile urine bag suitable for their gender.~Babies who urinate spontaneously during the period until the sterile urine bag is fitted, the next feeding hour will be waited.~Newborn will be observed for 3 minutes. Newborn's heart rate and saturation comfort pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
32791902|NCT05369468|Placebo Comparator|group 1|Group 1: will receive bilateral ESP block with injection of 20 ml of 0.25% Bupivacaine in each site of injection .
33404054|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
33404055|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
32791903|NCT05369468|Experimental|group 2|Group 2: will receive bilateral ESP block with injection of 18ml of 0.25% Bupivacaine plus 2ml dexmedetomidine 0.5 ug /kg in each site of injection .
32791904|NCT05291468|Active Comparator|C Acnes present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
32791905|NCT05291468|Placebo Comparator|C Acnes present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
32791906|NCT05291468|Active Comparator|C Acnes NOT present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
32791907|NCT05291468|Placebo Comparator|C. Acnes NOT present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
32791908|NCT04981496||Study A: ILR implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation and have an ILR implanted during their procedure.
32791909|NCT04981496||Study B: ICD implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation who will not have an ILR implanted.
32791910|NCT04981496||Study C: VT Ablation|These are participants having a clinically indicated VT ablation who we will record ventricular arrhythmias during the procedure.
32791911|NCT04981496||Study D: Exercise Treadmill Test|These are participants who already have a cardioverter defibrillator implanted who can safely exercise and bring up their heart rate.
32791912|NCT04981496||Study E: Spontaneous Arrhythmias|These are participants who already have a cardioverter defibrillator implanted and come into hospital with an atrial or ventricular arrhythmia.
32791913|NCT05278130|Active Comparator|Intervention Arm|The intervention-arm will have a pelvic exam performed with vaginal swab collection at their initial obstetric visit (standard of care). The women undergoing the intervention will then subsequently undergo additional vaginal swab collections in 2 week intervals starting at 16 weeks gestational age until 34 weeks gestational age. Subjects will be informed of the results of the vaginal swab. If positive for an infection, subjects will be provided with the appropriate treatment in pregnancy.
32791914|NCT05278130|No Intervention|Control Arm|The control arm will undergo the standard of care with vaginal swab collection at their initial obstetric visit. The control arm will not undergo additional vaginal swab collections unless otherwise indicated under standard of care (further testing for bacterial vaginosis is completed in women who describe symptoms with the diagnosis or present for preterm contractions and/or pelvic cramping). There will be no placebo for the control group.
32791915|NCT05274854|Experimental|Preconsultation Intervention|Pre-consultation intervention includes 4 arms ((a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing)
32939914|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
32939915|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
33404056|NCT02039440|Other|Single arm|1 blood draw
32791916|NCT05274854|Experimental|Consultation Intervention|Consultation intervention includes 2 arms (a) consultant-led outpatient clinic or b) a integrated care clinic depending on their response to the initial preconsultation intervention.
32939916|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
33087888|NCT00257543|Experimental|single arm study|this is a single arm study
32791917|NCT05348564|Experimental|Direct contact|Study team contact of family members
32791918|NCT05348564|No Intervention|Indirect contact|Proband initiated contact of family members
32791919|NCT05347550|No Intervention|Control - No graduated compression stockings|In those centres randomised to the control arm, participants will not receive Graduated Compression Stockings (GCS).
33087889|NCT01602133|Experimental|one intervention arm|
33404057|NCT02332330|Experimental|VEST|
32791920|NCT05347550|Experimental|Intervention - The provision of graduated compression stockings|Centres randomised to the intervention arm, which is the current standard of care, will consist of participants receiving Graduated Compression Stockings (GCS). Clinical staff (e.g. theatre support workers) will issue stockings to all patients who are scheduled to undergo short-stay surgery. Participants will be instructed to wear their stockings just before undergoing the surgical procedure and to remove the stockings as soon as they are ambulant (i.e. after the procedure).
32791921|NCT05415098|Experimental|Cohort 1 in Dose expansion|
32791922|NCT05415098|Experimental|Cohort 2 in Dose expansion|
32791923|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
32791924|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
32791925|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
32791926|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
32791927|NCT04969094|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
32791928|NCT04969094|Active Comparator|MMBI|Participation in a multi-modality balance intervention
32791929|NCT05369078|Experimental|THR-1442 20mg Single dose group|THR-1442 20mg Single dose group: subject will be administrated 1 dose of 20mg THR-1442 on day1, the follow up till day 7.
33087890|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
33087891|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
33087892|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
33087893|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
33087894|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
33087895|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
33087896|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
32791930|NCT05369078|Experimental|THR-1442 20mg Multiple dose group|THR-1442 20mg Multiple dose group: subject will be administrated THR-1442 20mg QD on Day1-Day7, the follow up till day 14.
32791931|NCT04540016|Other|Arm Ⅰ|25 mg of 80 µCi [14C]HSK7653.
33087897|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
33087898|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
33087899|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
33087900|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
33299525|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
33299526|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
33299527|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
33299528|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
32791932|NCT04852562|Experimental|Modified radical endoscopic sinus surgery(MRESS)|The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus. Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
32791933|NCT04852562|Experimental|Functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
32906947|NCT04377698|Active Comparator|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
33299529|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
33299530|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
33299531|NCT04906720|No Intervention|Standard of care|Usual standard of care post atrial fibrillation ablation.
33299532|NCT04906720|Experimental|Colchicine|0.6mg colchicine oral twice daily for 7 days.
32906948|NCT04377698|Active Comparator|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
33299533|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
33299534|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
33299535|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
32906949|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
32906950|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
32791934|NCT05412290|Experimental|Consolidation Mosunetuzumab|Mosunetuzumab is a CD3xCD20 bispecific antibody administered intravenously in the consolidation setting after autologous stem cell transplant (autoSCT). Mosunetuzumab will be given in a step-up dosing schedule beginning on Day 49 after autoSCT on C1D1, C1D8, C1D15, and then Day 1 of all cycles thereafter. Patients will undergo PET-CT restaging around Day 100 post-autoSCT (approximately Cycle 3) and patients in complete response will continue mosunetuzumab for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients not in complete response will discontinue treatment and enter follow-up. All cycles are planned to be 21 days.
32791935|NCT05256134|Experimental|Gantenerumab|Gantenerumab will be administered as subcutaneous (SC) injection with gradual uptitration.
32791936|NCT05256134|Placebo Comparator|Placebo|Placebo will be administered as SC injection with gradual uptitration.
32791937|NCT05255744|Experimental|Whitsundays nasal mask|Participants will be asked to take home the investigational mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
32791938|NCT05255744|Active Comparator|AirFit N30i Quiet mask|Participants will be asked to take home the comparator mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
32791939|NCT05252390|Experimental|Phase 1 Monotherapy Dose Escalation|NUV-868 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
32791940|NCT05252390|Experimental|Phase 1b Dose Escalation: NUV-868 + Olaparib|"NUV-868 will be administered at escalating dose levels in combination with olaparib until the recommended Phase 2 combination dose (RP2cD) is determined.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
32791941|NCT05252390|Experimental|Phase 1b Dose Escalation: NUV-868 + Enzalutamide|"NUV-868 will be administered daily at escalating dose levels in combination with enzalutamide until the RP2cD is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
32791942|NCT05252390|Experimental|Phase 2 Monotherapy Expansion|NUV-868 will be administered at the RP2D.
32791943|NCT05252390|Experimental|Phase 2b Combination Expansion: NUV-868 + Olaparib|"NUV-868 will be administered at the RP2cD.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
32791944|NCT05252390|Experimental|Phase 2b Combination Expansion: NUV-868 + Enzalutamide|"NUV-868 will be administered at the RP2cD.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
32791945|NCT04532372|Experimental|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
32791946|NCT04532372|Experimental|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
32791947|NCT04532372|Placebo Comparator|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
32791948|NCT04953338||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
32791949|NCT04953338||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
32791950|NCT04831736|Experimental|Treatment|
32791951|NCT04831736|Placebo Comparator|Control|
32791952|NCT04524104|Experimental|Lumen treatment|Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 16 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
32791953|NCT04524104|No Intervention|Waitlist Control|"Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at Baseline and 16 weeks.~Participant will receive an encrypted study iPad at baseline. Participants will complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series.~Participants in the waitlist control arm will only complete assessments but will have the option to receive Lumen at the end of the study. The PST module on the study iPad will be disabled until their 16-week assessment is completed, at which time they will have the option to complete 8 PST sessions on their assigned iPads."
32791954|NCT05341154|Active Comparator|Ketamine group|"An anesthesiologist who is not involved in the study will prepare the intervention, ketamine1 mg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
32791955|NCT05341154|Active Comparator|Dexmedetomidine group|"An anesthesiologist who is not involved in the study will prepare the intervention, Dexmedetomidine 1 μg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
32906951|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
33299536|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
32791956|NCT05341154|Placebo Comparator|Placebo group|"An anesthesiologist who is not involved in the study will prepare the intervention, normal saline 0.9% in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
32791957|NCT05232188|Experimental|22French (Fr)|After renal access, dilatation is provided up to 22Fr with a dilatator set, and fragmentation is started with a 19Fr nephroscope.
32791958|NCT05232188|Experimental|28F|After renal access, dilatation is provided up to 28Fr with a dilatator set, and fragmentation is started with a 25Fr nephroscope.
32791959|NCT04950920|Experimental|Y-2 sublingual test group|Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.
33299537|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
32791960|NCT04950920|Sham Comparator|placebo group|60 μg d-borneol
33299538|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
33299539|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
33299540|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
33299541|NCT01140412|Experimental|Cohort 1|Twice daily regimen
32791961|NCT05337020|Experimental|Intervention group|240 patients will receive the questionnaire to assess patients vision on telemedicine.
33299542|NCT01140412|Experimental|Cohort 2|Once daily regimen
33299543|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
33299544|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
33299545|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
32791962|NCT05410418|Experimental|Mosunetuzumab and Polatuzumab Vedotin|Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.
33299546|NCT01234324|Active Comparator|Arm 2: EXC alone|
33299547|NCT01236976|Experimental|Intervention Group|Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT) using the Therastride Treadmill System, functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower limb exercise. These interventions will be provided at the spinal unit.
33299548|NCT01236976|Other|Control Group|Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
33299549|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
33299550|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
32791963|NCT05230706|No Intervention|Control (CBL)|The control group was kept under normal room light conditions (CBL) 24 hours a day (level of illumination was 275.82±14 lux during the day and 145.28±14 lux at night).
32906952|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
32906953|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
32906954|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
33299551|NCT04884334||VAC-Stent® treatment|spontaneous, iatrogenic or postoperative leakage of the oesophagus or colon
33299552|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
33299553|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
33299554|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
33299555|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
33299556|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
33299557|NCT02528812|No Intervention|control group|received no intervention
33299558|NCT01141270|Experimental|AFOLIA|225 IU sc
33299559|NCT01141270|Active Comparator|Gonal-f|225 IU sc
33299560|NCT01141348|Experimental|Special Intervention|
33299561|NCT01141348|Experimental|Delayed Intervention|
32791964|NCT05230706|Experimental|Experimental (LDC)|The experimental group were allocated to alternating light/darkness conditions as follows: from 07:00 to 19:00 hours the subjects were kept under normal room light conditions; from 19:00 to 07:00 of the following day the conditions were modified by placing the patient under an acrylic cephalic helmet (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm). The helmet was covered with surgical cloth (green or blue) folded to 50x60cm rectangles, leaving the frontal part open in order to maintain an adequate air flow. This intervention exposed infants in the experimental group to light at 25 lux for 12 hours every day, while during daytime the cloth was removed in order for study subjects to be exposed to regular room lighting.
32791965|NCT05220488||Asthma Group|Asthma Group
33299562|NCT04860934|Active Comparator|Physical therapy|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks
33299563|NCT04860934|Experimental|Physical therapy + Dual Task Training Program|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the selected physical therapy program as control group three times weekly for 8 successive weeks.
33299564|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
33299565|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
32791966|NCT05220488||Healthy Group|Healthy Group
32791967|NCT04513184|Active Comparator|Standard therapy (ST) only|Control. Standard care and treatment only
32791968|NCT04513184|Experimental|DXM|Nasal dexamethasone plus Standard care and treatment
32791969|NCT04756531|Experimental|PF-07321332 Dose 1|Dose level 1 of PF-07321332
32791970|NCT04756531|Experimental|PF-07321332 Dose 2|Dose level 2 of PF-07321332
32791971|NCT04756531|Experimental|PF-07321332 Dose 3|Dose level 3 of PF-07321332
32791972|NCT04756531|Experimental|PF-07321332 Dose 4|Dose level 4 of PF-07321332
32791973|NCT04756531|Experimental|PF-07321332 Dose 5|Dose level 5 of PF-07321332
32939917|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
32939918|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
32939919|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
32939920|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
32939921|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
32939922|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
32939923|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
32939924|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
32939925|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
32939926|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
32939927|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
33087901|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
33299566|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
33299567|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
33299568|NCT05632432|Active Comparator|CABG arm (control)|In total, 25 patients are recruited to form the CABG group. During CABG surgery, RAA tissue is removed as detailed for the AAMs-patch group. However, the tissue is collected as a sample for later analyses rather than processed to AAMs (Method 4). CABG is performed without epicardial transplantation of AAMs-patch.
33087902|NCT01602328|Active Comparator|AC607|Treatment with AC607
33087903|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
32791974|NCT04756531|Experimental|PF-07321332 Dose 4 (Fed)|Dose level 4 of PF-07321332 with high fat meal
32791975|NCT05409872|Experimental|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
32791976|NCT05409872|Placebo Comparator|Placebo|The subject takes the placebo twice a day for three months
32791977|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
32791978|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
32791979|NCT05205512|Experimental|Group I (telehealth exercise)|Patients participate in telehealth exercise intervention for 30 minutes per day, 3 days a week for 8 weeks.
32791980|NCT05205512|Active Comparator|Group II (delayed control)|Patients maintain current levels of physical activity for 8 weeks. Patients may then participate in telehealth exercise intervention for 8 weeks.
32791981|NCT04419740|Experimental|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
32791982|NCT04419740|No Intervention|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
33299569|NCT05632432|Experimental|CABG + AAMs arm (intervention)|In total, 25 patients are recruited to the AAMs-patch group. Here, the AAMs are prepared from the RAA tissue sample by mechanical processing in the operating room during the CABG surgery. The RAA tissue piece is removed during right atrial cannulation, a part of the routine setup of cardiopulmonary bypass. To form an AAMs-patch, the AAMs, embedded in fibrin matrix gel, are placed onto an ECM sheet. This AAMs-patch is kept cold, covered, and sterile until the last stages of CABG surgery. After all the coronary anastomoses are done, the AAMs-patch is epicardially transplanted onto the area identified by preoperative LGE-CMRI to have most suffered from ischemia.
33299570|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
32791983|NCT05202626||Sun Yat-Sen University Cancer Center|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Sun Yat-Sen University Cancer Center. The clinicians in Sun Yat-Sen University Cancer Center consider it necessary to perform an endoscopic image-guided biopsy.
32791984|NCT05202626||Guangdong Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Guangdong Provincial People's Hospital. The clinicians in Guangdong Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
32791985|NCT05202626||Nanfang Hospital, Southern Medical University|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Nanfang Hospital. The clinicians in Nanfang Hospital consider it necessary to perform an endoscopic image-guided biopsy.
33087904|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
33087905|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
33299571|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
33299572|NCT05396950|Experimental|CPAP Planned|Radiotherapy planning with CPAP in addition to standard plans
33299573|NCT01144858||patients with persistent atrial fibrillation ablation|
33299574|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
33299575|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
33299576|NCT01144312|Experimental|pharmacokinetics of fentanyl|
33087906|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
33087907|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
33299577|NCT05395780|Experimental|High-dose MAX-40279 group|High-dose MAX-40279 capsule group (10-15 subjects, 70 mg, BID, PO)
33299578|NCT05395780|Experimental|Low-dose MAX-40279 group|Low-dose MAX-40279 capsule group (10-15 subjects, 50 mg, BID, PO)
33299579|NCT01237288|Experimental|Z-521|
33299580|NCT05394064|Experimental|Active Treatment|Patients treated with SBT101
33299581|NCT05394064|Sham Comparator|Imitation Procedure|Procedure that mimics treatment with SBT101, but does not infuse anything into the spinal cord
33299582|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
33087908|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
33299583|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
33299584|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
33299585|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
33299586|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
32791986|NCT05202626||Fujian Provincial Cancer Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Fujian Provincial Cancer Hospital. The clinicians in Fujian Provincial Cancer Hospital consider it necessary to perform an endoscopic image-guided biopsy.
32791987|NCT05202626||Hainan Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Hainan Provincial People's Hospital. The clinicians in Hainan Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
32791988|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
32791989|NCT01713946|Experimental|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
32791990|NCT01713946|Experimental|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
33299587|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
33299588|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
32791991|NCT01713946|Placebo Comparator|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
33299589|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
33299590|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
32791992|NCT05407844|No Intervention|Standard care|Standard cancer care
32791993|NCT05407844|Experimental|Standard care + DeCIDE PC intervention|Community health worker support and standard cancer care
32791994|NCT05332262||High ABCD-GENE score (≥10)|"All patients in this cohort will have an ABCD-GENE score ≥10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
32791995|NCT05332262||Low ABCD-GENE score (<10)|"All patients in this cohort will have an ABCD-GENE score <10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
33299591|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
33299592|NCT05350540|Experimental|ICG|This study will use intraoperative ICG imaging to assess recipient pharyngeal tissue perfusion. The ICG is the vascular contrast agent and the SPY Elite is the imaging device. 3mL of ICG will be injected using a peripheral IV access, followed by a 10mL saline flush. The pharyngeal mucosa will be imaged to quantify the tissue perfusion. Poorly perfused areas (less than 25%) will be debrided
32791996|NCT04918784|Experimental|Treatment with Synthetic Hybrid-Scale Fiber Matrix|Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
32791997|NCT04918784|Active Comparator|Treatment with Standard of Care|Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
32791998|NCT04916444|Active Comparator|Active rTMS|Active rTMS will use a figure of eight TMS coil that will deliver real neurostimulation pulses to the patients.
32791999|NCT04916444|Sham Comparator|Sham rTMS|Sham rTMS will use a sham figure of eight TMS coil that sounds and looks like a real rTMS coil, except no neurostimulation is being delivered to the patient.
32792000|NCT04903106||Meniscal Tear|Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
32792001|NCT04903106||Meniscal Insufficiency|Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
32792002|NCT04465136|Experimental|Received CES intervention|CES with the frequency of 0.5 Hertz; current of 100~600micro-ampere, for 60 minutes, everyday for 6 weeks, total 42 sessions intervention
32792003|NCT05329688|Experimental|Arm A|"Novel nutrition program :~Give nutrition health education every week and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease."
32792004|NCT05329688|Active Comparator|Arm B|Routine nutrition education Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
32906955|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
32906956|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
32906957|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
33087909|NCT01602640|Experimental|Morphine|
33299593|NCT05350540|No Intervention|Control|Patients assigned to the observation (control) group will undergo standard of care reconstruction of mucosa
33299594|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
33299595|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
33299596|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
33299597|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
33299598|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
33299599|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
33299600|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
33299601|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
32792005|NCT04464512|No Intervention|Standard (control) treatment|"The control group receives 1mcg/kg fentanyl followed by fentanyl 0.5-1mcg/kg q10 minute PRN, ketorolac 0.5mg/kg up to 30mg max IV, and acetaminophen 1000mg IV for pain control intraoperatively. The patient is then treated with hydromorphone 0.005mg/kg q10minutes the post-anesthesia recovery. The patient would then receive hydromorphone 0.005 mg/kg q1hr PRN, 1 gram acetaminophen IV scheduled q6hr, and methocarbamol 750mg QID following discharge from the PACU and transfer to the hospital floor. The patient is converted to oxycodone 10mg (Roxicodone) q4hr PRN and 975 mg PO APAP scheduled for pain control on postoperative day number 1 or when appropriate for PO intake. The patients receives their home dose of suboxone onpostoperative day number 1 or when appropriate for PO intake.~On postoperative day number 2 number 3, patients are transitioned to an increased dose of their Suboxone for pain control in preparation for discharge."
32792006|NCT04464512|Active Comparator|Treatment Group|Buprenorphine-sufentanil group receives sufentanil 0.03mcg/kg followed by sufentanil 0.01-0.03 mcg/kg q10 min PRN, IV ketorolac 0.5mg/kg up to 30mg max and IV acetaminophen 15mg/kg up to 1000mg for pain control intraoperatively. In the PACU, IV buprenorphine 0.3mg IV q30 minutes would be given as the first line choice for pain control for 3 doses. IV PCA sufentanil is used as a second line therapy if patient comfort is not achieved by IV buprenorphine alone. The patient receives 0.3 mg buprenorphine IV Q6hr PRN, scheduled IV acetaminophen 1 gram for 24 hrs and methocarbamol 750mg QID after discharge from the PACU and transfer to the floor. The patient is converted to buprenorphine2mg q6hr PRN and 975 gram PO APAP scheduled for pain control on postoperative day 1. The patient receives their home dose of Suboxone starting on postoperative day 1 if tolerating PO intake. On postoperative day 2, patients would be transitioned to an increased dose of their Suboxone.
32792007|NCT04899908|Experimental|Stereotactic Radiation plus AGuIX gadolinium-based nanoparticles|"Randomly assigned participants will receive:~AGuIX gadolinium-based nanoparticles 3-5 days before radiation is initiated~AGuIX gadolinium-based up to 2x during radiation, depending on standard of care radiation treatment.~If standard of care radiation treatment involves only one day of radiation, participant will receive AGuIX gadolinium-based nanoparticles on the day of radiation.~If standard of care radiation treatment involves 5 or 6 days of radiation, participant will receive AGuIX gadolinium-based nanoparticles two-times (2x) in total, on the first and third day of radiation."
32792008|NCT04899908|Experimental|Stereotactic Radiation plus placebo|"Randomly assigned participants will receive:~Placebo 3-5 days before radiation is initiated~Placebo up to 2x during radiation, depending on standard of care radiation treatment.~If standard of care radiation treatment involves only one day of radiation participant will receive Placebo on the day of radiation.~If standard of care radiation treatment involves 5 or 6 days of radiation participant will receive Placebo two-times (2x) in total, on the first and third day of radiation."
32792009|NCT04897412|Experimental|CBL-514 Injection|Participant will receive CBL-514 2 mg/cm² administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
32792010|NCT04897412|Placebo Comparator|Placebo: 0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
32792011|NCT04849130|Active Comparator|Static reconstruction technique according to Schöttle|Static reconstruction technique according to Schöttle
32792012|NCT04849130|Active Comparator|Dynamic reconstruction technique according to Becher|Dynamic reconstruction technique according to Becher
32792013|NCT05369234|Experimental|Cohort 1--Arm 1|Aloe Vera Juice + Standard of Care Treatments Swish and spit ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
32792014|NCT05369234|Active Comparator|Cohort 1--Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
32792015|NCT05369234|Experimental|Cohort 2--Arm 1|Aloe Vera Juice + Standard of Care Treatments Drink ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
33087910|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
33087911|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
33087912|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
33087913|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
33087914|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
33299602|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
33299603|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
33299604|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
33299605|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
33299606|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
33299607|NCT05335018|Experimental|Treatment|"total 2years. Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
33299608|NCT00114777|Active Comparator|Cyclosporin A|
33299609|NCT00114777|Experimental|Belatacept Less Intensive Regimen (LI)|
33299610|NCT00114777|Experimental|Belatacept More Intensive Regimen (MI)|
33299611|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
32939928|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
32939929|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
32939930|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
32939931|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
32939932|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
32939933|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
32939934|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
32939935|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
32939936|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
32939937|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
32939938|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
32939939|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
32939940|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
32939941|NCT00378404|Experimental|1|
32939942|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
32939943|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
32939944|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
32939945|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
32939946|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
32939947|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
32939948|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
32939949|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
32939950|NCT05313230||CITRASAFE|Patient underwent CITRASATE dialysis session
32939951|NCT03738020|Experimental|HA IDF|
32939952|NCT03738020|Active Comparator|Restylane|
32939953|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
33087915|NCT02961101|Experimental|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
33087916|NCT02961101|Experimental|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
32792016|NCT05369234|Active Comparator|Cohort 2-- Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
32792017|NCT05179148|Experimental|intervention|The arm will receive motivational interviewing
32792018|NCT04839692|Other|Young females (21-30 years old)|young healthy females (21-30 years old) from all phototypes who have thin or moderately thick lips
32792019|NCT04839692|Other|post menopausal females|post menopausal females from all phototypes who have thin or moderately thick lips
32792020|NCT05173766|Experimental|Ergonomic Principals|Ergonomic Principal for computer users will be used.
32792021|NCT04828070||Registry participant|Prospective collection of clinical information, completion of anxiety/depression, microaggressions, and quality of life questionnaires
32792022|NCT04421378|Experimental|Phase 1: Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
32792023|NCT04421378|Active Comparator|Arm A Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
32792024|NCT04421378|Experimental|Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
32792025|NCT04421378|Active Comparator|Arm B Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
32792026|NCT04421378|Experimental|Arm C: Selinexor+Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of lomustine or 150-200 mg/m^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
32792027|NCT04421378|Active Comparator|Arm C Control: Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of lomustine or 200 mg/m^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
32792028|NCT04421378|Experimental|Arm D: Selinexor+Bevacizumab|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
33299612|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
33299613|NCT03965793|Active Comparator|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
32792029|NCT04421378|Active Comparator|Arm D Control: Bevacizumab|Participants with rGBM will receive 10 mg/kg of Bevacizumab IV infusion Q2W in each cycle in a 28 Day cycle for all cycles.
32792030|NCT04421378|Experimental|Arm E: Selinexor+TTField|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
32792031|NCT04421378|Active Comparator|Arm E Control: TTField|Participants with rGBM will receive scalp application of 200 kHz of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
32792032|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
32792033|NCT04827446|Experimental|Intervention Arm|Light intervention delivered through SYNC app + blue-light blocking glasses.
32792034|NCT04827446|Active Comparator|Control Arm|Placebo light intervention delivered through SYNC app + clear glasses.
32792035|NCT04827368||Crohns Disease|
32792036|NCT04827368||Ulcerative Colitis|
32792037|NCT04827368||Non-IBD|
32792038|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
32792039|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
32792040|NCT05145452|Experimental|Intervention Group|Subjects randomized to n-3 PUFA will receive a total of 4.2 g/d of fish oil.
32792041|NCT05145452|Placebo Comparator|Placebo Group|Subjects randomized to placebo will receive 4.2 g/d sunflower oil.
32792042|NCT05145452|No Intervention|Control group|Subjects assigned to the control group will be tested once
32792043|NCT04419116|Experimental|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
32792044|NCT04419116|Experimental|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
32906958|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
33299614|NCT03965793|Experimental|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
33299615|NCT00122187|Experimental|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
33299616|NCT00122187|No Intervention|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
32792045|NCT04839614|Experimental|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY|"Upon enrollment in the study at first appointment with gynecologic oncologist, referral to the BWH Center for Metabolic and Bariatric Surgery (CMBS).~Schedule a series of appointments with a bariatric surgeon, nutritionist and psychologist, which is part of the approval process for weight loss surgery.~Hysterectomy and weight loss surgery will then be scheduled on the same day within 8 weeks from first visit with the gynecologic oncologist for endometrial cancer or 12 weeks if you have endometrial pre-cancer.~Series of post-operative visits with the bariatric surgeon and gynecologic oncologic surgeon as well as the nutritionist and psychologist."
32792046|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
32792047|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
32792048|NCT05139680||Patients with mixed phenotype ATTRv-CM|Hereditary ATTR-CM patients presenting with mixed phenotype
32792049|NCT05138510||Stage 0|Ductal carcinoma in situ. Timing: start of endocrine therapy
33299617|NCT00139659|Experimental|Inhaled Insulin|
33299618|NCT00139659|Active Comparator|Subcutaneous Insulin|
32792050|NCT05138510||Stages I-III Surgery first|Invasive cancer. Surgery first Timing: start of endocrine therapy
32792051|NCT05138510||Stages I-III, neoadjuvant chemotherapy first|Invasive cancer. Neoadjuvant chemotherapy first Timing: during neoadjuvant chemotherapy
32792052|NCT05138510||Stage IV|Metastatic cancer, chemotherapy only, no invasive surgery Timing: 2 months into treatment
33299619|NCT00137631|Experimental|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
33299620|NCT00137631|No Intervention|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
33299621|NCT01582815|Experimental|JNJ-40411813|
33299622|NCT01582815|Placebo Comparator|Placebo|
33299623|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
33299624|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
32792053|NCT05138510||Survivors|Timing: any time
32792054|NCT04756141|Experimental|CGM Use|Determine CGM accuracy when compared with POC (point of care) glucometers.
32792055|NCT05125250|Experimental|Motor Control Group|This group will receive treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day
32792056|NCT05125250|Active Comparator|Vestibular Group|This Group will receive vestibular exercises which comprises of postural awareness training; Standing on a balance board, Foveal vision exercises.
33299625|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
33299626|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
33299627|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
33299628|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
33299629|NCT01582893|Active Comparator|P210H|High flux Filter P210H
32792057|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
32792058|NCT05324462||IDegLira|Adult patients with T2D who have initiated treatment with IDegLira a minimum of 26 weeks
32792059|NCT04873856|Experimental|Intervention group|"Intervention contains:~individual nutritional plan~regular contact~friendly reminder/informal caregiver and~weight dairy."
32792060|NCT04873856|No Intervention|Control Group|Standard of care
32792061|NCT04838756|Experimental|Intervention arm|AI-integrated mammography screening
32792062|NCT04838756|Experimental|Control arm|Conventional mammography screening (standard of care)
32792063|NCT01363700|Experimental|1|
32792064|NCT01363700|Placebo Comparator|2|
32792065|NCT01363700|Active Comparator|3|
32792066|NCT05305040|Active Comparator|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
32792067|NCT05305040|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
33299630|NCT03965715|No Intervention|Gait analysis with barefoot|Participants walk without assistance under gait detection.
33299631|NCT03965715|Experimental|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
33299632|NCT03965715|Experimental|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
33299633|NCT03965637|Experimental|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
33299634|NCT03965637|No Intervention|Control|Control patients will not be received any intervention
33299635|NCT01078779|Experimental|Chloroquine|
33299636|NCT01078779|Placebo Comparator|Placebo|
33404058|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
33299637|NCT00114231|Experimental|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
33299638|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
32792068|NCT04824794|Experimental|GEN3014 - Dose-escalation part|"Patients with:~Relapsed or refractory myeloid myeloma (RRMM)~R/R acute myeloid leukemia (AML)~Patients will be treated with increased doses of GEN3014 till the RP2D is defined and/or MTD is reached."
32792069|NCT04824794|Experimental|GEN3014 - Expansion Part A|"Patients with:~RRMM (anti-CD38 mAb naïve)~RRMM (anti-CD38 mAb-refractory)~R/R diffuse large B-cell lymphoma (DLBCL)~R/R AML~Patients will be treated at the RP2D defined in the dose-escalation phase."
32792070|NCT04824794|Experimental|GEN3014 - Expansion Part B|"Patient with:~• RRMM (anti-CD38 mAb-naïve)"
32792071|NCT04824794|Active Comparator|Daratumumab - Expansion Part B|"Patient with:~• RRMM (anti-CD38 mAb-naïve)"
32792072|NCT04822688||Basic Science (Biospecimen collection)|Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
32792074|NCT04838678|Experimental|Healthy Control|Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
32792075|NCT04838678|Experimental|Hypertensive|Hypertensive adults who are not obese
33299639|NCT00113841|Experimental|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
33299640|NCT00113841|Experimental|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
32792076|NCT04838678|Experimental|Obese|Obese adults who are not hypertensive
32792077|NCT04838678|Experimental|Obese-hypertensive|Obese adults who are being treated for hypertension
33299641|NCT00113607|Experimental|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
32792078|NCT04838522||All Study Participants|Participants with chronic idiopathic constipation who are treated with prucalopride 2 milligrams (mg) oral tablets which was initiated prior to enrollment, and are breastfeeding their infant at the time of enrollment and sample collection will be observed prospectively.
32792079|NCT04372706|Experimental|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors
32792080|NCT04372706|Experimental|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers
32792081|NCT04372706|Experimental|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
32792082|NCT04372706|Experimental|Part 4: RTX-240 Plus Pembrolizumab Dose Escalation|Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors
33299642|NCT00113607|Active Comparator|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
32792083|NCT04178642|Experimental|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
32792084|NCT04178642|Active Comparator|(standard group)|The absence of adjuvant treatment (standard group).
32792085|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
32792086|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
32792087|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
32792088|NCT04838288|Experimental|Change from Prograf to Envarsus|All participants will be switched from Prograf to Envarsus
32792089|NCT04821752|Experimental|Toxicant avoidance and glucose dysregulation|To investigate whether or not the excretion of urinary toxicant metabolites is reduced by dietary modification and lifestyle intervention in people with glucose dysregulation; whether the participant's ranked glucose dysregulation correlates with the amount and/or type of toxic metabolites excreted at baseline; and whether the body's immediate response to glucose is improved by the reduction of toxicant burden.
32792090|NCT04815278|Experimental|Control Group|Participants will receive usual DSS employment services that include, but are not limited to, consultation with an employments specialist, resume writing guidance, educational classes and attendance at job fairs. Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
32792091|NCT04815278|Experimental|Employer Intervention Only|Participants will receive usual DSS employment services and an employer level workplace equity, job & health supports intervention. The employer intervention will include an implicit bias workshop and supervisor support training in addition to regular supervisor check-ins every other week.
33299643|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
33299644|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
33299645|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
33087917|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
33087918|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
33299646|NCT00113529|Experimental|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
32792092|NCT04815278|Experimental|CDPP Only|Participants will receive the individual level CDPP intervention and no employer intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions. Content for the program will include healthy lifestyle habits, managing stress and staying motivated.
33299647|NCT01079013|Experimental|treosulfan|
33299648|NCT00134901|Experimental|Memantine|Memantine
32792093|NCT04815278|Experimental|CDPP and Employer Intervention|Participants will receive the individual level CDPP intervention and employer level workplace equity, job & health supports intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions and check-ins. Content for the program will include healthy lifestyle habits, managing stress and staying motivated. The employer intervention will include an implicit bias workshop and supervisor support training, in addition to regular supervisor check-ins every other week..
32792094|NCT04821674|Experimental|Cohort A1: DS-5670a 10 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
32792095|NCT04821674|Experimental|Cohort A2: DS-5670a 30 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
32792096|NCT04821674|Experimental|Cohort A3: DS-5670a 60 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
33299649|NCT00134901|Placebo Comparator|Placebo|Placebo
33299650|NCT01076595||Group 1|
33299651|NCT00122109|Experimental|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
33299652|NCT00122109|Active Comparator|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
33299653|NCT01326663|Active Comparator|divalproex sodium|
33299654|NCT01326663|Placebo Comparator|sugar pill|
33299655|NCT00113373|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33299656|NCT01079091|Experimental|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
33299657|NCT01326351|Experimental|Regenerative Injection Therapy|
33299658|NCT01326351|Sham Comparator|Dry needle|
33299659|NCT01326351|Active Comparator|Exercise|
33299660|NCT01079169|Experimental|Cranberry capsule|
32792097|NCT04821674|Experimental|Cohort A4: DS-5670a 100 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
32792098|NCT04821674|Placebo Comparator|Cohort A: Placebo|Healthy adults participants will be randomized to receive a intramuscular injection of placebo.
33087919|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2~Phase 2 : 400mg Bid"
33087920|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
33087921|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
33087922|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
33087923|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
33087924|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
33087925|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
33299661|NCT01079169|Placebo Comparator|Placebo capsule|
33299662|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
33299663|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
33299664|NCT00113295|Active Comparator|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
33299665|NCT00113295|Experimental|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
33299666|NCT00112905|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
33299667|NCT03964857|Other|Refined olive oil (ROO)|Control
33299668|NCT03964857|Experimental|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
33299669|NCT03964857|Experimental|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
33299670|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
32792099|NCT04821674|Experimental|Cohort B1: DS-5670a 10 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
33299671|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
33299672|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
32792100|NCT04821674|Experimental|Cohort B2: DS-5670a 30 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
32792101|NCT04821674|Experimental|Cohort B3: DS-5670a 60 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
32792102|NCT04821674|Experimental|Cohort B4: DS-5670a 100 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
32792103|NCT04821674|Placebo Comparator|Cohort B: Placebo|Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.
33299673|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
33299674|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
33299675|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
33299676|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
33299677|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
33299678|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
33299679|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
33299680|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
33299681|NCT02459327|No Intervention|Control|
33299682|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
33299683|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
32792104|NCT04367480|Experimental|Group I (TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
32792105|NCT04367480|Placebo Comparator|Group II (placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
32792106|NCT04340180|Experimental|Subjects with enhancing breast lesions|
32792107|NCT04327934|Active Comparator|Healthy Control|Healthy control participants.
32792108|NCT04327934|Experimental|AE-PCOS|Participants with AE-PCOS.
32792109|NCT04791566|Active Comparator|Intestinal obstruction, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
32792110|NCT04791566|Placebo Comparator|Intestinal obstruction, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
32792111|NCT04791566|Active Comparator|Perforated viscus, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
32792112|NCT04791566|Placebo Comparator|Perforated viscus, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
32792113|NCT04318964|Experimental|TAEST16001 cells treat tumor antigen NY-ESO-1|"The dose escalation was carried out according to the principle of 3 + 3 increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient."
32792116|NCT04307576|No Intervention|R1 - SR standard arm|Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
32792117|NCT04307576|Experimental|R1 - SR experimental arm|Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
32792118|NCT04307576|No Intervention|R2 - IR-low standard arm|Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
32792119|NCT04307576|Experimental|R2 - IR-low experimental arm A|Standard treatment with omission of Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase.
32792120|NCT04307576|No Intervention|R3 - IR-high standard arm|Intermediate risk high arm receiving Standard Maintenance Therapy.
32792121|NCT04307576|Experimental|R3-InO - IR-high experimental arm|Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
32792122|NCT04307576|Experimental|ABL-class fusions intervention|Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to Standard IR-high chemotherapy.
32792123|NCT04307576|Experimental|R3-TEAM - IR-high experimental arm|6-tioguanine p.o, 2,5-12,5 mg/m2, given daily in addition to Standard Maintenance Therapy.
32792124|NCT04307576|Experimental|ALLTogether1 DS Blinatumomab intervention|Blinatumomab IV, 5 mcg/m2/day up to 28 mcg/day (detailed dosing in protocol) continous infusion. Two 28 day courses with a two week treatment free interval in between. Blinatumomab courses replace Consolidation 1 and Consolidation 2 in the standard protocol adapted for Down syndrome patients.
32792125|NCT04307576|Experimental|R2 - IR-low experimental arm B|Standard treatment with omission of monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
32792126|NCT04129736|Other|Teriflunomide 14 mg tablets|Single arm
32792127|NCT04129502|Experimental|TAK-788 Group (Arm A)|TAK-788 160 milligram (mg) with or without food, capsules, orally, once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
32792128|NCT04129502|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 milligram per meter square (mg/m^2) plus cisplatin 75 mg/m^2, infusion, IV, once on Day 1 of 21-day cycle pemetrexed 500 mg/m^2 plus carboplatin, infusion, IV, once at a dose calculated to produce area under curve (AUC) of 5 milligram*minute per milliliter (mg*min/mL) on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/cisplatin or pemetrexed/carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m^2, on Day 1 of a 21-day cycle thereafter.
32792129|NCT04115540|Experimental|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
32792130|NCT05301218|Active Comparator|angiography-guided group|the treatment (including lesion preparation, stent sizing and post implantation optimization) will be performed by angiography. Once the result is considered optimal by the operator, a control OCT run will be acquired.
32792131|NCT05301218|Experimental|OCT-guided group|a preliminary OCT run will be recorded. An initial predilation with 1.5 to 2.0 mm balloon could be accepted in order to facilitate OCT catheter delivery through the target lesion. The PCI strategy will be guided by a pre-defined algorithm based on initial OCT findings. Post PCI result will be assessed by control OCT and potential optimization steps could be applied according to the results. The MLD-MAX optimization approach will be applied. Final OCT run will be performed at the end of the procedure.
32792132|NCT04257578|Experimental|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
32792133|NCT04769960||Participants with breast tissue expanders|Participants with breast tissue expanders that require an MRI for clinical purposes are eligible for this study.
32792134|NCT01637402|Experimental|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
32792135|NCT01637402|Experimental|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
33087926|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
33087927|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
33299684|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
32792136|NCT04419350|Experimental|treatment|microneedling.
32792137|NCT04419350|No Intervention|No treatment|No treatment will be done to these hypopigmented lesions
33087928|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
32792138|NCT04419038|Active Comparator|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
32792139|NCT04419038|Active Comparator|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
32792140|NCT04739852|Active Comparator|Healthy Participants|
32792141|NCT04739852|Active Comparator|Metabolic Syndrome|
32792142|NCT04739852|Active Comparator|Rheumatoid Arthritis|
32792143|NCT04825730|Experimental|Long Term Follow-up after Jointstem Transplantation|
32792144|NCT04824638|Experimental|Group 1: SARS-CoV-2 naive participants|participants without antecedent of SARS-CoV-2 infection
32792145|NCT04824638|Experimental|Group 2: Previously SARS CoV-2 infected participants|participants with antecedent of SARS-CoV-2 infection (more than 5 months)
32792146|NCT04219670||Patient Group|Individuals diagnosed with stroke admitted to the Shirley Ryan AbilityLab (inpatient), or individuals in the community who had a stroke (chronic)
32792147|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
32792148|NCT05306834|Active Comparator|Minimal cSVD patient group|little or no white matter hyperintensities
32792149|NCT05306834|Active Comparator|Extensive cSVD patient group|moderate to severe white matter hyperintensities
32792150|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
33087929|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
33087930|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
33087931|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
33087932|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
33087933|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
33087934|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
33087935|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
33087936|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
33087937|NCT00271284|Experimental|I|
33087938|NCT00271284|Active Comparator|II|
33087939|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
33087940|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
33087941|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
33087942|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
33299685|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
33299686|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
33299687|NCT00121641|Experimental|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
33087943|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
33087944|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
33299688|NCT00121641|Experimental|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
33299689|NCT00121641|Experimental|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
33299690|NCT00121641|Placebo Comparator|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
33087945|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
33087946|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
33299691|NCT00121641|Experimental|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)"
33299692|NCT00425555|Experimental|Previously treated with oral bexarotene|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
33299693|NCT00425555|Experimental|No prior oral bexarotene treatment|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
33299694|NCT01686191||Cardiac transplant recipients|
33299695|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
33299696|NCT01323881|Experimental|intermittent theta burst stimulation|
33299697|NCT01323881|Placebo Comparator|sham stimulation|
33299698|NCT00121485|Experimental|HeartMate II|Implantation of HeartMate II LVAS
33299699|NCT00121485|Active Comparator|HeartMate XVE|Implantation of HeartMate XVE LVAS
32939954|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
32939955|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
32939956|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
32939957|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
32939958|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
32939959|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
32939960|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
33299700|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
33299701|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
33299702|NCT01763866|Placebo Comparator|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
33299703|NCT01763866|Placebo Comparator|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
33299704|NCT01763866|Active Comparator|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
32939961|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
32939962|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
32939963|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
32939964|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
32939965|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
32939966|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
32939967|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
32939968|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
32939969|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
32939970|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
32939971|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
32939972|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
32939973|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
32939974|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
32939975|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
33087947|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
33087948|NCT01603342|Experimental|clopidogrel|
33087949|NCT01603342|Placebo Comparator|Placebo|
33087950|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
33087951|NCT01603381|No Intervention|Monitor Only (M.O.)|
33299705|NCT01763866|Active Comparator|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
33087952|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
33087953|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
32792151|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
32792152|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
32792153|NCT04213820|Active Comparator|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
32792154|NCT04213820|Experimental|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
33087954|NCT01603498|Experimental|Dexamethasone 8mg|
32792155|NCT04213820|Sham Comparator|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
33087955|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
33299706|NCT01763866|Experimental|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
33299707|NCT01763866|Experimental|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks
32792158|NCT04076462|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
32792159|NCT04076462|Placebo Comparator|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
32792160|NCT05296148|Experimental|Treatment|Treatment with the CroíValve DUO Coaptation Valve System
32792161|NCT04054154|Experimental|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
32792162|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
32792163|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
32792164|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
33087956|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
33087957|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
33087958|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
33087959|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
33087960|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
32792165|NCT05293886|Active Comparator|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
33087961|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
32906959|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
32906960|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
32906961|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
32906962|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
33087962|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
32906963|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
33087963|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
33087964|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
33087965|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
33087966|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
33102411|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
33102412|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
33299708|NCT01763866|Placebo Comparator|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
33299709|NCT01763866|Placebo Comparator|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
33299710|NCT01763866|Active Comparator|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
33299711|NCT01763866|Active Comparator|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
32939976|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
32939977|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
32939978|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
32939979|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
32939980|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
32939981|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
32939982|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
32939983|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
32939984|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
32939985|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
32939986|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
32939987|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
32939988|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
32939989|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
32939990|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
32939991|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
32939992|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
32939993|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
32939994|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
32939995|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
32939996|NCT01184456|Placebo Comparator|Placebo|
33102413|NCT04731753||Group treated with study product|Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean
32939997|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
32939998|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
32939999|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
32940000|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
32940001|NCT01155518|Experimental|clomiphene|oral drug thrice a week
32940002|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
32940003|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
32940004|NCT01155518|No Intervention|eugonadal obese|obese men with normal testosterone level
32940005|NCT01155518|No Intervention|lean|healthy lean men (control)
32940006|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
32940007|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
32940008|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32940009|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
32940010|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
32940011|NCT02417870|Experimental|aldesleukin|
32940012|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
32940013|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
32940014|NCT01139294|No Intervention|standard IV therapy|control arm of the study
32940015|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
32940016|NCT05600582|Experimental|10e7 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
32940017|NCT05600582|Experimental|10e7 PFU dose 5 injections|10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
32940018|NCT05600582|Experimental|10e8 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
32940019|NCT05600582|Experimental|10e8 PFU dose 5 injections|10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
32940020|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
32940021|NCT05600504||Elderly patients over the age of 65|no intervention
32940022|NCT05600504||Elderly patients over the age of 65 undergoing elective non-cardiac surgery|no intervention
32940023|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
32940024|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
32940025|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
32940026|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
32940027|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
32940028|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
32940029|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
32940030|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
32940031|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
32940032|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
32940033|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
32940034|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
32940035|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
32940036|NCT05600348|Experimental|0 oz Pork|Participants receive 0 oz pork and 6 oz 50:50 blend of chicken and beef per day
32940037|NCT05600348|Experimental|3 oz Pork|Participants receive 3 oz pork and 3 oz 50:50 blend of chicken and beef per day
32940038|NCT05600348|Experimental|6 oz Pork|Participants receive 6 oz pork and 0 oz 50:50 blend of chicken and beef per day
32940039|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
32940040|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
32940041|NCT03577171|Experimental|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
32792166|NCT05293886|Experimental|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
32792167|NCT04418245||Patients positive for SARS-CoV-2|
32792168|NCT04818944|Experimental|Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))|Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
32792169|NCT04818944|Placebo Comparator|Placebo Arm|Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
33299712|NCT01763866|Experimental|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
32792170|NCT04818866||Patients hospitalized for Covid-19|
32792171|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
32792172|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
32792173|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
32792174|NCT04194476|Experimental|120 neonates less than 28 days old|Each neonate will be tested for blood glucose level twice on the same heel stick site using two glucose meters. additional 200-300 ul blood will be collected and centrifuged. Plasma will be tested blood glucose in the lab analyzer in the clinical laboratory.
32792175|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
32792176|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
32792177|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
33299713|NCT01763866|Experimental|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
32792178|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
32792179|NCT04818398|Experimental|DS-6016a dose level 1|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792180|NCT04818398|Experimental|DS-6016a dose level 2|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792181|NCT04818398|Experimental|DS-6016a dose level 3|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792182|NCT04818398|Experimental|DS-6016a dose level 4|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792183|NCT04818398|Experimental|DS-6016a dose level 5|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792184|NCT04818398|Experimental|DS-6016a dose level 6|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
32792185|NCT04818398|Placebo Comparator|Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
32792186|NCT04207190|Experimental|Treatment (talazoparib, gemtuzumab ozogamicin)|Patients receive talazoparib PO daily on days 1-21 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32792187|NCT04824482|Experimental|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
32792188|NCT04824482|Active Comparator|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
32792189|NCT04824248|Experimental|Experimental intervention|10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care
32906964|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
33299714|NCT01763866|Placebo Comparator|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
33102414|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
32792190|NCT04824248|Active Comparator|Control intervention|Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
32792191|NCT04836962|Placebo Comparator|control|normal saline is administrated to patients.
32792192|NCT04836962|Experimental|dexamethasone|0.5mg/kg dexamethasone is administered to patients.
32792193|NCT04199702|Other|Same day discharge|
32792194|NCT05289440|Experimental|Low-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
32792195|NCT05289440|Experimental|High-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
32792196|NCT05289440|Experimental|Saline infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
32792197|NCT04718870|Experimental|Dupilumab|Double dose on day 1 and followed by single dose every 14 or 28 ± 2 or 3 days through week 12 or 14
32792198|NCT04718870|No Intervention|Healthy Volunteer|serve as reference for normal skin
32792199|NCT04709900|Active Comparator|Intervention group|CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
32792200|NCT04709900|No Intervention|Standard care group|Evaluation and treatment strategy according to contemporary clinical practice
32792201|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) with postoperative ARDS|
32792202|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) without postoperative ARDS|
32792203|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
32940042|NCT03577171|Experimental|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
32940043|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
32792204|NCT04016090|Placebo Comparator|Placebo treatment|Participant will be asked to ingest a placebo capsule.
32792205|NCT04016090|Experimental|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
32792206|NCT04809974|Placebo Comparator|Placebo|Placebo: 40 participants will take placebo in the form of a capsule.
32792207|NCT04809974|Experimental|Niagen|Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
32792208|NCT05226884||Clareon IOL Group|Patients with bilateral implantation of Clareon IOLs.
32940044|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
32940045|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
32940046|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
32940047|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
32792209|NCT05226884||Eyhance IOL Group|Patients with bilateral implantation of EyhanceIOLs.
32792210|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
32792211|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
32792212|NCT05384834|Experimental|AYA participants|AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.
32940048|NCT03534427|No Intervention|Control group|No exercise intervention
32940049|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
32792213|NCT05384834|Experimental|HCP participants|HCP participants will complete a survey consisting primarily of demographic information and the #HerHeart tool. HCP participants will then rate the usability of the tool using the WAMMI, the usefulness of the #HerHeart to their practice and the likelihood they would incorporate it into usual clinical care.
32792214|NCT03317990|Experimental|NeuroSAFE procedure|These patients will undergo robotic radical prostatectomy with bilateral nerve spare.The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade.The tissue sample will be snap frozen and embedded in OCT.Using a cryostat, 10 micron thick slices will be placed on slides.The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side.The slides will be stained with H&E and will be examined by a consultant pathologist.As soon as examination is complete the pathologist will telephone the operating surgeon to give the result.Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected
32792215|NCT03317990|Active Comparator|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
32792216|NCT04691960|Experimental|Ketogenic Diet|
32792217|NCT04796792|Experimental|Treatment group|This study is currently in Phase 1 where all subjects undergo the investigational study.
32792218|NCT05225012|Experimental|PrEliMS Intervention|"We will ask participants to complete the anxiety/depression questionnaires and visual analogue scales once a week throughout the participants involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue.~The procedure will then repeated with newly recruited participants, and the newly refined workbook will be used. Participants within this phase will also be invited to feedback interviews a week after completion of the intervention."
32792219|NCT05279612||neoadjuvant chemoradiotherapy group|preoperative 1 circle chemotherapy(CapeOX) combined with short-course radiotherapy ，Surgical treatment(CME+D3) after four weeks of 2 circle chemotherapy(CapeOX).
32792220|NCT05279612||neadjuvant chemotherapy group|preoperative 3 circle chemotherapy(CapeOX) combined with surgical treatment(CME+D3)
32792221|NCT03948854|Experimental|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
32792222|NCT03948854|Experimental|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
32792223|NCT03948854|Experimental|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
32792224|NCT03948854|Experimental|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
32792225|NCT04816916|Experimental|AXA1665 53.8 g per day|AXA1665 administered orally TID
32792226|NCT04816916|Placebo Comparator|Matching placebo|Placebo administered orally TID
32792227|NCT04809038|Experimental|dry needling|dry needling will be received twice a week for four weeks
32792228|NCT04809038|Experimental|magnesium sulphate iontophoresis|magnesium sulphate iontophoresis will be received twice a week for four weeks
33102415|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
32792229|NCT04809038|Active Comparator|stretching exercise|stretching will be received twice a week for four weeks
32792230|NCT05652998|Active Comparator|Candida antigen|patients will be injected with intralesional C.albicans antigen
32792231|NCT05652998|Active Comparator|Autologous platelets rich plasma|patients will receive intralesional autologous PRP injection
32792232|NCT05652998|Placebo Comparator|Saline|patients will receive intralesional saline
32792233|NCT05362136|Active Comparator|Control|standard sinus floor elevation
32792234|NCT05362136|Experimental|Test|standard sinus floor elevation with additional perforation of the sinus floor
32792235|NCT05221190|Experimental|Single buccal infiltration of articaine anesthesia|The local anesthetic solution will be administered using single buccal infiltration with articaine anesthesia.
32792236|NCT05221190|Active Comparator|Inferior alveolar nerve block of lidocaine anesthesia|The anesthetic solution will be administered using inferior alveolar nerve block with lidocaine anesthesia.
32792237|NCT04816682|Active Comparator|LAGOSA ARM|Consecutively admitted patients will be allocated silymarin tablets (150 mg each) T.I.D. 3-2-2
32792238|NCT04816682|No Intervention|Control arm|Consecutive patients with the same inclusion/exclusion criteria as in active arm, hospitalised at the same department before the initiation of the study (historical controls)
32792239|NCT05165498||Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures|Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.
32792240|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
32792241|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
32792242|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
32792243|NCT05652842||Day workers|Includes people working from 9 a.m. to 5 p.m./8 a.m. to 4 p.m. We will be recruiting 15 day workers.
32792244|NCT05652842||Shift workers|Includes those involved in any arrangement of daily working hours other than the standard daylight hours, 8 a.m. - 5 p.m. It also includes on-call or casual workers. We will be recruiting 15 shift workers.
32792245|NCT05652842||Rotational workers|Includes those who work on a set schedule and whose working hours are rotating on a set schedule. We do not include offshore workers here. We will be recruiting 15 rotational workers.
32792246|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
32792247|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
32792248|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
32792249|NCT05652686|Experimental|Dose Escalation|A standard 3+3 dose escalation design will be employed. The starting dose to be evaluated in the dose escalation study is 0.2 mg/kg weekly (QW). Additional provisional dose levels include: 0.6 mg/kg QW, 2 mg/kg QW, 6 mg/kg QW, 12 mg/kg QW.
32792250|NCT05652686|Experimental|Dose Expansion|Two doses from dose escalation phase will be evaluated in dose expansion, likely the Maximum Tolerated Dose (MTD) and a lower dose, or 2 lower doses.
32792251|NCT05652530|Experimental|BCMA CAR-NK|
32792252|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
32792253|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
33102416|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
33102417|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
33404059|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
33404060|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
33404061|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
32792254|NCT05274776|No Intervention|NVK Guidelines|The NVK guidelines use 8 maternal and 15 neonatal risk factors, each categorized as either red flag or non-red flag. These criteria guide clinicians on the management in case of suspected EOS. Briefly, antibiotic treatment is recommended if at least one red flag and, or, two or more non-red flags are present. An observation period of at least 12 hours is recommended if one non-red flag is present. Antibiotics are recommended when an infection is suspected during this observation. Newborns without EOS risk factors, with a good clinical condition, and a gestational age of more than 36 weeks will be discharged. If the guidelines recommend an observation period, the newborn with a good clinical condition is discharged after repeating physical examination. In case antibiotic treatment is started, discharge depends on the duration of treatment and the clinical course. At discharge, parents are instructed to call the hospital in case of signs of infection within the first 14 days of life.
32792255|NCT05274776|Experimental|EOS Calculator|Using the EOS calculator application between 0-24 hours after birth, maternal EOS risk factors combined with the physical examination of the newborn are used to assign a risk category and accompanying clinical recommendation based on estimated EOS incidence for each newborn at-risk for an infection. The EOS calculator results are used to guide clinical management on performing either a diagnostic work-up and start of antibiotics for (suspected) EOS, or a conservative approach with routine controls of vital parameters every 3 hours. In case of routine controls, re-evaluation of physical appearance by a pediatric resident or pediatrician will take place within 24 hours postpartum. Newborns will be observed for at least 24 hours. In case antibiotics are started, the need for further treatment is depending on blood culture results, infection parameters, and clinical condition of the newborn. Discontinuation of antibiotics and discharge is at the discretion of the treating physician.
32792256|NCT04808882|Experimental|Low dose prophylactic anticoagulation|LD-PA
32792257|NCT04808882|Experimental|High dose prophylactic anticoagulation|HD-PA
32792258|NCT04808882|Experimental|Therapeutic anticoagulation|TA
32792259|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
32792260|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
32792261|NCT05652452|Experimental|Neurodynamics|
32792262|NCT05652452|Active Comparator|Static stretch|
32792263|NCT05164796|Experimental|IVUS-guided|
32792264|NCT03081806|Experimental|Group A|High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
32792265|NCT03081806|Placebo Comparator|Group B|Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
32792266|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
32792267|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
32792268|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
32940050|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
33299715|NCT01763866|Placebo Comparator|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
32940051|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
32940052|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
33299716|NCT01763866|Experimental|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
33299717|NCT01763866|Experimental|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
33299718|NCT01763866|Placebo Comparator|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
33404062|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
32940053|NCT00376909|No Intervention|Usual Care|Usual care
32940054|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
32940055|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
32940056|NCT00422851||1|Normal tympanic membrane
32940057|NCT00422851||2|tympanosclerosis
32940058|NCT00422851||3|dimeric (atrophic)
32940059|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
32940060|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
32940061|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
32940062|NCT05312840|Other|Routine dose group|Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
32940063|NCT05312840|Other|Low dose group|Low dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
32940064|NCT00376129|Experimental|I|
32940065|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
32940066|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
32940067|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
32940068|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
32940069|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
32940070|NCT05599568|Other|Exercise challenge|At baseline, subjects will perform the selected exercise challenge followed by blood samples collected at rest and 0, 2, 4, 24 hours and 4 days after end of exercise. Muscle soreness will be measured by asking the participant how sore their muscles in their thighs are on a visual-analog scale (1-10) at the same timepoints. After 4 weeks (+/- 3 days) of normal daily activity, the same test will be performed including blood samples.
32940071|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
32940072|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
33102418|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
33299719|NCT01763866|Placebo Comparator|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
32792269|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
32792270|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
32792271|NCT05164484|Other|Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS|Standard of care procedure for patient with severe ARDS
32792272|NCT05652374|Experimental|Intervention group|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
32792273|NCT05652374|Active Comparator|Control group|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 1 year. In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily will be given.
32792274|NCT04815668|Experimental|Acupuncture group|
32792275|NCT04815668|Placebo Comparator|Placebo acupuncture group|
32792276|NCT04815668|Other|Rescue medication|
32792277|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
32792278|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
32792279|NCT04794842|Active Comparator|Tetracaine|Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.
32792280|NCT04794842|Active Comparator|Phenol|Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).
32792281|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
32792282|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
32792283|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
32792284|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
32792285|NCT04793984|Experimental|Inhaleen|Iota-Carrageenan inhalation
32792286|NCT04793984|Placebo Comparator|Placebo|NaCl inhalation
32792287|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
32792288|NCT03023150|Experimental|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
32792289|NCT03023150|Sham Comparator|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
32792290|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
32792291|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
32792292|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
32792293|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
32792294|NCT03780920|Active Comparator|Osteopathic treatment|
32792295|NCT03780920|No Intervention|Control group|
32792296|NCT05652062|Experimental|Treatment|
32792297|NCT05271032||Septic Patients|
32792298|NCT05651984|Active Comparator|Communication board|The communication board consists of a printed paper interface with a size of 42 x 30 cm.
32792299|NCT05651984|Experimental|Eye tracking|The eye tracking device combines a laptop computer with a screen size of 29 x 16 cm, an eye tracker (PCEye Mini, Tobii dynavox, Danderyd, Sweden), an interface generated by a communication software (Communicator 5, Tobii dynavox) and a telescopic support.
32792300|NCT05651906||Donors|
32792301|NCT05651906||Recipients|
32792302|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
32792303|NCT04807868||Biopsy Group|Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
32792304|NCT04807868||Non-Biopsy Group|Adults without any history of NAFLD
32792305|NCT05651750|Experimental|Montelukast tab|
32792306|NCT05651750|Experimental|Fluticasone nasal spray|
32792307|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
32792308|NCT03754790|Experimental|Fitusiran|Participants will be administered fitusiran as a subcutaneous injection once monthly or every other month for up to 48 months post initiation of modified IMP dose/frequency or until fitusiran becomes commercially available, whichever comes first.
32792309|NCT05651672|Experimental|experimental group|Pemigatinib
32792310|NCT03740204|Experimental|17-β estradiol with cyclic progesterone|
32792311|NCT03740204|Placebo Comparator|Placebo|
32792312|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
32792313|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
32792314|NCT02160145|Placebo Comparator|Placebo|Placebo
32792315|NCT04807478||Pediatric patients|Pediatric patients with new-onset PNAC
32792316|NCT01696396|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32792317|NCT01696396|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32792318|NCT01696396|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32792319|NCT01696396|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
33102419|NCT04727775||Complications|Evaluathion
33102420|NCT04727775||Oxygen status|Evaluathion
33102421|NCT04727775||Oxugen support|Evaluathion
33299720|NCT01763866|Experimental|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
33299721|NCT01763866|Experimental|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
33299722|NCT01763866|Placebo Comparator|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
33299723|NCT01763866|Placebo Comparator|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
33299724|NCT01763866|Experimental|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
33299725|NCT01763866|Experimental|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
33299726|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
33299727|NCT01034423|Experimental|omega-3 high quality|
33299728|NCT01034423|Experimental|omega-3 low quality|
33299729|NCT01034423|Placebo Comparator|placebo|
33299730|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
33299731|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
33299732|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
33299733|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
33299734|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
33299735|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
33299736|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
33299737|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
33299738|NCT00120627|Experimental|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
33299739|NCT00120627|Active Comparator|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
33299740|NCT01588925|Experimental|Control group|Cochlear Implantation
33299741|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
33299742|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
33299743|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
33299744|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
33299745|NCT05332756||Moyamoya disease patients|
33299746|NCT05332756||First-degree relatives of patients with Moyamoya Disease|
33299747|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
33299748|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
33299749|NCT05292196|Experimental|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation, four weeks as a treatment cycle.
33299750|NCT05292196|Placebo Comparator|TQC3721 suspension placebo for inhalation|TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
33299751|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
33299752|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
33087967|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
32792320|NCT04793906|Experimental|Beef|
33087968|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
33087969|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
33087970|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
33087971|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
33087972|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
32792321|NCT04793906|Experimental|Plant-based alternative|
33087973|NCT01603888||infants, BNP, NT-proBNP|infants
33087974|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
32792322|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
33299753|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
33087975|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
33087976|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
33299754|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
33299755|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
33299756|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
32792323|NCT05269784|Experimental|Completely Tubeless Group|minimally invasive lung surgery under ERAS with completely tubeless protocol: no intubation, no urinary catheter, move the chest drainage as fast as possible according the ERAS guideline on the premise of safety.
32792324|NCT05269784|Active Comparator|Partially Tubeless Group|minimally invasive lung surgery under ERAS with partially tubeless protocol.
32792325|NCT04793750|Experimental|POC HIV VL Testing|Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.
32792326|NCT04793750|Active Comparator|SOC HIV Testing|Participants will receive routine standard of care HIV testing.
32792327|NCT03654638|Experimental|Arm I Soy Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
33087977|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
33087978|NCT01604005|Experimental|PIT Arm|
33087979|NCT01604005|No Intervention|No PIT Arm|
33087980|NCT01604044|Active Comparator|HP-hMG|
33087981|NCT01604044|Active Comparator|rFSH plus rLH|
33087982|NCT01604161||Somatropin|
33087983|NCT01604200||Dentists|Dentists in practice
33087984|NCT01604239|Experimental|Shinbaro|
33087985|NCT01604356|Experimental|Electro-acupuncture|
33087986|NCT04708314|Other|30 mg/kg|Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study.
33102422|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
33102423|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
33102424|NCT05420376|Active Comparator|Whole Mesh|For the patients in the first group, the whole patch will be laid on the area without being fixed.
33299757|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
33299758|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
33299759|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
33299760|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
33299761|NCT01145248|Experimental|Malignant biliary disease|
33299762|NCT01145248|Experimental|Benign biliary disease|
33299763|NCT03762616|Experimental|Micro-Ultrasound Biopsy|
33299764|NCT03762616|Experimental|MRI Targeted Biopsy|
33299765|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
33299766|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
32792328|NCT03654638|Active Comparator|Arm II Wheat Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of wheat bread for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
32792329|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
32792330|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
32792331|NCT04418570|Experimental|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
32792332|NCT04418570|Other|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
33299767|NCT04316806|Experimental|Probiotic|Treatment with probiotic formula
32792333|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
32792334|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
32792335|NCT04418726|Experimental|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
32792336|NCT04418726|No Intervention|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
32792337|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula Probio-Tec® BG-VCap-6.5 will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
33299768|NCT04316806|Other|Antibiotic|Treatment with antibiotic rifaximin
33299769|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
33299770|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
33404063|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
33404064|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
32792338|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
32792339|NCT04552912|Experimental|Build Stamina Group|The Build StaMINA (Biobehavioral Self-Management INtervention using physical Activity) is a tailored evidence-based physical activity (PA) program designed to improve endurance, strength, and balance which are all areas of physical function, that adults with acute leukemia (AL) post-induction are known to have diminished capacity. The Build StaMINA program will be tailored to their current Physical Function, per assessment. The detailed PA prescription includes each exercise in the program as well as the frequency, number of repetitions each day and rate of perceived exertion (RPE) for each exercise. The repetitions and RPE are based on the participants' current Physical Function Assessment and will be assigned based on our evidence-based algorithm.
32792340|NCT04552912|No Intervention|Attention-Control Group|Participants assigned to the attention control group will have a Physical Function Assessment at baseline after informed consent has been provided and prior to randomization. Participants will also be asked to complete questionnaires regarding at baseline, 6-weeks and 3 months. Those in the attention-control group will also receive a newsletter detailing the benefits of participating in regular PA as well as regular phone calls by study team to discuss general health and wellbeing at the same schedule as intervention group.
32792341|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
33087987|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
32792342|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
32792343|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
32792344|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
32792345|NCT04793282|Placebo Comparator|Control|Post-test satisfaction
32792346|NCT04793282|Experimental|Experimental|Treatment and satisfaction
32792347|NCT04759183|Experimental|Arm I (Angry Birds, TRIPP)|Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery.
32792348|NCT04759183|Experimental|Arm II (TRIPP, Angry Birds)|Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.
32792349|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
32792350|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
33087988|NCT01604395||growth hormone|
32792351|NCT04813796|Experimental|mRNA-1283 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.
32792352|NCT04813796|Experimental|mRNA-1283 Dose Level 2|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.
32792353|NCT04813796|Experimental|mRNA-1283 Dose Level 3|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.
32792354|NCT04813796|Experimental|mRNA-1273|Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.
32792355|NCT04813796|Experimental|Placebo / mRNA-1283|Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29. Participants may be offered an opportunity to receive an additional injection of mRNA-1273 at the pre-specified dose on Open-Label Day 1.
32792356|NCT04192136|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
33087989|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
33087990|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
33087991|NCT01604590||glioblastoma patients on bevacizumab|
33087992|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
33087993|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
33299771|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
32792357|NCT04192136|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
32792358|NCT04192136|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
32792359|NCT04192136|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo."
32792360|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
32792361|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
32792362|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
32792363|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
33087994|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
33087995|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
33087996|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
33087997|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
33087998|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
33087999|NCT01604707|No Intervention|Control group|Standard care
33088000|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
33088001|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
33088002|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
33088003|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
33299772|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
33299773|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
33299774|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
33299775|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
33299776|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
33299777|NCT01238302|Placebo Comparator|Conventional group|
33299778|NCT01238302|Experimental|PRP group|
33299779|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
33299780|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
33299781|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
33299782|NCT04246996|Active Comparator|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
33299783|NCT04246996|Sham Comparator|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
33299784|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
33299785|NCT00424463|Experimental|1|
33299786|NCT00424463|Placebo Comparator|2|
33299787|NCT01034735|Experimental|Arm A|
33299788|NCT01034735|Experimental|Arm B|
33299789|NCT01034735|Experimental|Arm C|
33299790|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
33299791|NCT01034813||control range of motion|control subjects without scaring
33299792|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
33299793|NCT03994055|Experimental|Anti-inflammatory Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).~This group will include the consumption of foods that contain immune modulating nutrients:~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
33299794|NCT03994055|Active Comparator|Low residue Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
33299795|NCT01037699|Active Comparator|FSH YOUNGER|
33299796|NCT01037699|Active Comparator|FSH OLDER|
33299797|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
33299798|NCT01037699|Experimental|FSH LH OLDER|
33299799|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
33088004|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
33088005|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
33299800|NCT00845026|Experimental|LY2140023|LY2140023 (80 mg/day), given orally twice daily as two 40-mg tablets for 24 weeks
33299801|NCT00845026|Active Comparator|aripiprazole|aripiprazole (20 mg/day), given orally once daily for 24 weeks
33299802|NCT00845026|Active Comparator|olanzapine|olanzapine (15 mg/day), given orally once daily for 24 weeks
33299803|NCT00845026|Active Comparator|risperidone|risperidone (4 mg/day), given orally, once or BID for 24 weeks
32792364|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
32792365|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
33088006|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
33088007|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
33088008|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
33088009|NCT00258479|Experimental|Modafinil|
33088010|NCT00258479|Placebo Comparator|Placebo|
33088011|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
33299804|NCT01145716|Other|Surgical exploration|Descriptive
33299805|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
33088012|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
33088013|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
33088014|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
33088015|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
33088016|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
33088017|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
33088018|NCT00258518||1|ALI/ARDS patients
33088019|NCT00291057|Experimental|1|MALG
33088020|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
33088021|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
33299806|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
33299807|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
33299808|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
32792366|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
32792367|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
32792368|NCT03597464|Experimental|Voclosporin|Voclosporin
32792369|NCT03597464|Placebo Comparator|Placebo Oral Capsule|Placebo
32792370|NCT01695772|Experimental|Bevacizumab|
33088022|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
33088023|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
33088024|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
33299809|NCT00423605|Experimental|1|
33299810|NCT01237600|Experimental|Cultivated limbal transplantation|
33299811|NCT01237756|Experimental|pediatric|
33299812|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
33299813|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
33299814|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
33299815|NCT03994289|No Intervention|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
33299816|NCT03994289|Experimental|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
33299817|NCT03994289|Experimental|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
33299818|NCT05158972||Dymista®|Dymista® (Azelastine hydrochloride and Fluticasone propionate) nasal spray as prescribed within routine clinical practice
33299819|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
33299820|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
33088025|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
33088026|NCT00271635|Experimental|1|Ascorbic acid
33299821|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
33299822|NCT00003838|Other|Donor|The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
32792371|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
33404065|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
33404066|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
32792372|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
32792373|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
32792374|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
32792375|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
32792376|NCT04552522|Experimental|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
32792377|NCT04552522|No Intervention|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
32792378|NCT01693120|Experimental|Ablation|Phased RF ablation
32792379|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
32792380|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
32792381|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
32792382|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
32792383|NCT01712074|Experimental|30 mg QD of PF-05212377|
32792384|NCT01712074|Placebo Comparator|Placebo|
32792385|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
32792386|NCT04124692|No Intervention|No-treatment control group|
32792387|NCT04124692|Experimental|Treatment group|
32792388|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
32792389|NCT04767724|Experimental|Extracorporeal shock wave|Participants received three ESWT sessions once per week for three consecutive weeks. The probe of the ESWT machine (FT-174; Swiss Dolor Class; Switzerland) was placed perpendicularly on the patient's palm over the median nerve on the carpal tunnel after application of the ultrasound gel as a coupling agent. Afterward, the ESWT was administered with 1000 shots, 1.5 bar of pressure, and a frequency of 6 Hz
32792390|NCT04767724|Active Comparator|Local corticosteroid injection|A single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
32792391|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
32792392|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
32792393|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
32792394|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
33088027|NCT00271635|Placebo Comparator|2|Placebo
33088028|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
33088029|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
33102425|NCT05420376|Active Comparator|Split Mesh|The patients in the second group will be given a patch of the same size, but partially divided horizontally and wrapped around the spermatic cord.
33299823|NCT00003838|Experimental|Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality|Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.
33299824|NCT00003838|Experimental|Group B: Stem Cell Transplant in Debilitating Hematologic Diseases|Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.
32792395|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
32792396|NCT04547686|Experimental|Smoke-Free Homes Intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention coupled with a connection to the quitline. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
32792397|NCT04547686|Active Comparator|Control|The usual care/control arm will receive mailed information on the quitline and a connection to the quitline at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
32792398|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
32792399|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
32792400|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
32792401|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
32792402|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
32792403|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
32792404|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
32792405|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
32792406|NCT05635838|Experimental|Ruxolitinib Cream|Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
32792407|NCT05635838|Experimental|Vehicle Cream|Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
32792408|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
32792409|NCT02661464|Experimental|Exposed to Ad26.ZEBOV and/or MVA-BN Filo|Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
32792410|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
32792411|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
32792412|NCT04804124|Experimental|Short Sleepers|Reported nightly sleep time of ≤6 hours
32792413|NCT04804124|Experimental|Long Sleepers|Reported nightly sleep time of ≥9 hours
32792414|NCT04804124|Experimental|Average Duration Sleepers|Reported nightly sleep time of 7-8 hours
32792415|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
32792416|NCT02593994||Onyx Drug Eluting Stent|
32792417|NCT04754581|Other|All Participants|
32792418|NCT05261282|Experimental|Mindful Hand Hygiene Intervention|"Participants in the Mindful Hand Hygiene Intervention will complete the same surveys as participants in the Control Arm at baseline, post-intervention, and 6-months post-intervention. Data will also be collected on baseline hand-hygiene rates during the habituation period, intervention period, and 3-12 months post-intervention. In addition, intervention participants will be asked to complete 3 mindfulness online educational modules and attend group-facilitated discussions on mindfulness. They will be offered the option of using a mobile application program Mindfulness Coach to enhance their mindfulness practices. A key message of the intervention is using hand hygiene as a prompt to practice mindfulness."
33299825|NCT05258188|Experimental|Instrument-assisted Soft Tissue Mobilization|"Warm-up will be performed for 10 to 15 minutes by light jogging, elliptical machine, stationary cycle or an upper body ergometer~Instrument-assisted Soft Tissue Mobilization , will be applied at 30 to 60 degrees angle for 40 to 120 seconds~Stretching, for 30 seconds (3 rep)~Strengthening exercises, high repetitions with low intensity exercise~Cryotherapy for 10 to 20 min"
33299826|NCT05258188|Experimental|Compressive Myofascial Release Technique|Compressive myofascial release technique will be applied 5 minutes, after a warmup of 10 to 15 minutes.
33299827|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
33299828|NCT01145872|Active Comparator|Health Enhancement Program|
32792419|NCT05261282|No Intervention|Control Arm|Participants that are assigned to the control arm will be observed for hand hygiene adherence and duration during the habituation period, intervention period, and 3-12 months post-intervention. They will also be asked to complete study surveys at baseline, post-intervention and 6-months post intervention. They will not receive any of the intervention components.
33299829|NCT05400772||Healthy subjects|
33299830|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
33299831|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
33299832|NCT01237834||Non smokers|
33299833|NCT05398354|Experimental|Active Retirement - intervention|The duration of the program is 24-weeks, 2-times a week, for up to 50 minutes per session. The sessions will be divided into three phases: the initial phase (10 minutes) will consist of a 5-minute walk followed by a joint warm-up; fundamental phase (25 minutes) will work in an exercise circuit, this circuit will consist of 4 cycles, with 8 exercises each, with a duration of 50 seconds and a rest of 15 seconds, for the exchange of exercise; and return to calm (10 minutes), where we will perform muscle stretching.
33299834|NCT05398354|No Intervention|Active Retirement - control|The control group will only carry out the assessments and will be offered the same intervention as the intervention group at the end of the intervention.
32907121|NCT05672147|Experimental|Treatment (anti-CD33 CAR T-cells)|Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells IV on day 0. Patients with persistent CD33+ AML who are > 28 days past the initial CAR T infusion, have additional product available and did not experience a dose-limiting toxicity, may optionally receive anti-CD33 CAR T-cells IV.
32907122|NCT04797221||Veteran study group|The investigators will recruit approximately 20 Veterans who were identified as having elevated suicide risk while being treated in a VA Emergency Department.
32907123|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
32907124|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
32907125|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
32907126|NCT04763759|Experimental|Dose Level 1- 6mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
32907127|NCT04763759|Experimental|Dose Level 2- 15mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
32907128|NCT04763759|Experimental|Dose Level 3- 30 mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
32907129|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
32907130|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
32907131|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
32907132|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
32907133|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
32907134|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
32907135|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
32907136|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
32907137|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
32907138|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
32907139|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
33088030|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
33088031|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
32792420|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
32792421|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
32792422|NCT05239364|Experimental|Standard approach|Patients will receive a standard approach for ablation of atrial tachycardia.
32792423|NCT05239364|Experimental|Minimalized approach|Patients will receive a minimalized approach for ablation of atrial tachycardia.
32792424|NCT04812392|Experimental|Acute Physical Inactivity|Subjects will undergo 3 days of reduced physical activity.
33088032|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
33088033|NCT04709315|Active Comparator|saline pretreatment/succinyl group (SS group).|patients receive pretreatment with 10 ml 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg is the intubating muscle relaxant.
32792425|NCT04812314|Experimental|Exercise|"This exercise prescription represents a common or conventional form of physical activity (e.g., moderate/brisk walking). If assigned to this group, participants will perform 45 minutes of moderate intensity continuous steady-state exercise at 70% maximal heart rate (HRmax) to expend 250 calories 4 days per week."
32792426|NCT04812314|Experimental|No exercise|Subjects assigned to this group are to remain sedentary (no planned physical exercise) throughout the duration of the study.
32792427|NCT04803734|Experimental|Test Group|Albuterol Sulfate inhalation aerosol
32792428|NCT04803734|Active Comparator|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
32792429|NCT04802408|Active Comparator|Baby Shampoo Nasal Wash|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
33088034|NCT04709315|Experimental|Dex pretreatment/ rocuronium group (DR group),|patients receive pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg is the intubating muscle relaxant.
32792430|NCT04802408|Active Comparator|Listerine Gargle|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
32792431|NCT04802408|Experimental|Combination of Baby Shampoo Nasal Wash and Listerine Gargle|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
32792432|NCT04802408|Placebo Comparator|Saline Wash and Gargles|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
33404067|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
33404068|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
32792433|NCT02494700|Experimental|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
32792434|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
33404069|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
32792435|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
32792436|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
32792437|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
32792438|NCT05628428|Experimental|Exercise|Exercising through educational videos for eight weeks. In addition, they will receive educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
33088035|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
33088036|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
33088037|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
33088038|NCT00258713|Active Comparator|1|
32792439|NCT05628428|Active Comparator|Control|Educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
32792440|NCT05609162||local treatment group vs non-local treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
32792441|NCT05609162||systemic treatment group vs non-systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
32792442|NCT05609162||local treatment group vs systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
32792443|NCT05609162||local treatment group vs local treatment+systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
32792444|NCT05609162||systemic treatment group vs local treatment+systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
33088039|NCT00258713|Active Comparator|2|
33088040|NCT00258713|Active Comparator|3|
33088041|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
33088042|NCT01334554|Placebo Comparator|Placebo|placebo
33088043|NCT00291213|Experimental|Levetiracetram Administration|
33299835|NCT05214586|Experimental|Spiculotomy and application of a Gel Nail|A nail spicule removal technique will be performed of the edge or nail edges affected by ingrown toenail. After, a gel nail will be applied to remodeling the nail apparatus and avoid damage of the nail in the lateral fold.
32792445|NCT05609162||local treatment+systemic treatment group vs non-local treatment+systemic treatment group|Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group
33299836|NCT05214586|Active Comparator|Spiculotomy and Nail Re-education with Gauze Bandage|A nail spicule removal technique will be performed and a cord of gauze bandage between the nail channel and the sheet will be applied. This technique consists in the removal of the portion of the nail sheet that causes ingrown toenail in order to release the soft parts.
33299837|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
32792446|NCT05578430|Experimental|TACE+Cadonilimab+Surgery|After appropriate screening and randomization, patients enrolled will receive TACE plus 2-cycle of Cadonilimab treatment before surgery. Four weeks later after surgery, Cadonilimab treatment will be followed up to 16 cycles.
32792447|NCT03492164|Other|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
32792448|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
32792449|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
32792450|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
32792451|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
32792452|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
32792453|NCT03432260|Experimental|Part B (Severe AH) DUR-928 30 mg|Lowest dose of dose escalation arms: 30mg, 90 mg and 150 mg
32792454|NCT03432260|Experimental|Part B (Severe AH) DUR-928 90 mg|Middle dose of dose escalation arms: 30mg, 90 mg and 150 mg
32792455|NCT03432260|Experimental|Part B (Severe AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
33088044|NCT00291213|Placebo Comparator|Placebo|
33088045|NCT01332799|Active Comparator|Allopurinol|
33088046|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
33088047|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
33299838|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
33299839|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
33088048|NCT00258752|Experimental|2|Enhanced IPT-AST
33088049|NCT00258752|Active Comparator|3|Typical school counseling
33088050|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
33088051|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
33088052|NCT00258869||1|Emergency department patients with sepsis
33088053|NCT00271791|Experimental|1|Prednisone
33088054|NCT00271791|Placebo Comparator|2|Placebo
32792456|NCT04790162|Active Comparator|Meditation Intervention|Heartfulness meditation
32792457|NCT04790162|No Intervention|Control|Wait listed control group
32792458|NCT03397628|No Intervention|Control|
32792459|NCT03397628|Experimental|Intervention|
32792460|NCT03370718|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
33299840|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
32792462|NCT03351764|Other|arm 1|these are within subject repeated measures studies across a number of conditions
32792463|NCT03351764|Placebo Comparator|arm 2|
32792464|NCT05475392|Experimental|Stretching Exercise with PIR on neck pain and muscle spasm in breastfeeding women|Experimental Group (Group A) will receive stretching with Post Isometric Relaxation and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
32792465|NCT05475392|Active Comparator|Stretching Exercise without PIR on neck pain and muscle spasm in breastfeeding women|Active Compatitor (Group B) will receive only stretching and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
33088055|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
33299841|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
32792466|NCT05474456|Experimental|SNAGs Group|Group A sustained natural apophyseal glides will be provided to wrestlers in the sitting position. SNAG technique applied on the dorsal side of the neck. The treatment will be given for 6 weeks, 2 sessions per week.
32792467|NCT05474456|Active Comparator|Manipulation Group|group bWrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
32792468|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
32792469|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
32792470|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
32792471|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
32792472|NCT05228444|Experimental|Circadiancare|limits the circadian impact of hospitalisation by enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
32792473|NCT05228444|No Intervention|Control|
33299842|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
33299843|NCT01145950|Experimental|Group 1|
33299844|NCT01145950|Experimental|Group 2|
33299845|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
32792474|NCT05227430|Experimental|Surgical trainees|Surgical trainees that would be given educational video tutorials before entering gynecological laparoscopic surgeries
32792475|NCT05227430|No Intervention|Control|Surgical trainees that would not be given educational video tutorials before entering gynecological laparoscopic surgeries
32792476|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
32792477|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
32792478|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
32792479|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
32792480|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
32792481|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
32792482|NCT02407028|Experimental|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
32792483|NCT02407028|Active Comparator|Usual care|Usual care for severe TBI
33299846|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
33299847|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
33299848|NCT05138380|Experimental|Foot orthoses|
33299849|NCT05138380|Sham Comparator|Flat shoe insert|
33299850|NCT01238926|Experimental|PD vitamin supplementation|
33299851|NCT01238926|Experimental|PD exercise intervention|
33299852|NCT01238926|Experimental|PD vitamin + exercise|
33299853|NCT01238926|No Intervention|PD control|
33088056|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
33088057|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
33088058|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
32792484|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
33088059|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
32792485|NCT04810598|Experimental|Group 1: Participants With Normal Renal Function|Participants with normal renal function will receive single dose of venetoclax on Day 1.
33088060|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
32792486|NCT04810598|Experimental|Group 2: Participants With End Stage Renal Disease|Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).
32792487|NCT05462990|Experimental|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to complete the 300 mg
32792488|NCT05462990|Placebo Comparator|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to ensure blinding
32792489|NCT04627064|Experimental|Abemaciclib-Arm 1|"Arm 1~Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
32792490|NCT04627064|Experimental|Abemaciclib and MK-6482-Arm 2|"Arm 2~Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,~Dose escalation will occur following a 3+3 design.~Abemaciclib will be taken 2X daily uring 28 day study cycle~MK-6482 will be taken 1x daily during 28 day study cycle~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
32792491|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
32792492|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
32792493|NCT05195918|Active Comparator|EGCG 300 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Nintedanib for 12 weeks.
32792494|NCT05195918|Active Comparator|EGCG 300 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
32792495|NCT05195918|Placebo Comparator|Placebo for EGCG 300 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 300 mg EGCG.
32792496|NCT05195918|Active Comparator|EGCG 600 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided Nintedanib for 12 weeks.
32792497|NCT05195918|Active Comparator|EGCG 600 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
32792498|NCT05195918|Placebo Comparator|Placebo for EGCG 600 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 600 mg EGCG.
32792499|NCT04570280|Placebo Comparator|Range of Motion Exercises|The patients in the control group will be given the practice of range of motion exercises for 12 weeks, 3 days a week for 50 minutes (1 day accompanied by a physiotherapist).
32792500|NCT04570280|Active Comparator|Range of Motion and Resistive Exercises Group|Patients in this group will be given joint range of motion and resistive exercises with sandbag to the lower extremity for 12 weeks, 3 days a week for 50 minutes (1 day in the presence of a physiotherapist). For the exercises with resistance, the repetition maximum will be calculated and the intensity of the exercises will be adjusted in accordance with the DeLorme protocol.
32792501|NCT04570280|Active Comparator|Range of Motion and Aerobic Exercises Group|Joint range of motion exercises and aerobic exercises on the treadmill will be given to the aerobic exercise arm, 3 days a week for 12 weeks (1 day in the presence of a physiotherapist). For aerobic exercises, the maximum heart rate of the patients will be calculated during exercise and the exercise intensity will be determined by increasing the target heart rate level during the exercise.
32792502|NCT05444504|Other|Group 1|24 hours of use each of leaking freely, leaking freely, cup, and then cup+
32792503|NCT05444504|Other|Group 2|24 hours of use each of leaking freely, cup, cup+, and then cup
32792504|NCT04788758|Experimental|Health Services Research (G8 screening tool, referral)|"PHASE I: Registered Nurses receive training on how to administer the G8 screening tool utilizing an Epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician.~PHASE II: Patients complete the G8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their EHR flowsheet. Patients who score =< 14 on the G8 are referred for a CGA at SAOC, and these patients and their medical oncologists are made aware. Within 2 weeks of the initial screening, the results are communicated with the patient and medical oncologist at a 2-hour SAOC visit. Patients with a score of > 15 on the G8 are made aware of their results without any referral generated."
32792505|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
33404070|NCT03493451|Experimental|Cohort 1: ENKTL|Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
32792506|NCT04782986|Experimental|Pan-intestinal capsule endoscopy|PillCam Crohn's capsule protocol
32792507|NCT04782986|Active Comparator|Conventional colonoscopy|Same-day colonoscopy under propofol sedation
32792508|NCT02158052|Experimental|Bone Marrow and Kidney RECIPIENTS|combined bone marrow and kidney transplantation
32792509|NCT02158052|Other|Bone Marrow and Kidney DONORS|Donors who donate bone marrow and kidney
32792510|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
32792511|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
32792512|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
32792513|NCT05193500|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
32792514|NCT05193500|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
32792515|NCT05406362|Experimental|30 mg|30 mg VAD044
32792516|NCT05406362|Experimental|40 mg|40 mg VAD044
32792517|NCT05406362|Placebo Comparator|Placebo|Placebo
32792518|NCT05351684|Experimental|Intensified|Group of patients whose treatment will be intensified with an additional 50mg of dolutegravir on top of regular treatment (Triumeq: ABC/3TC/DTG).
32792519|NCT05351684|No Intervention|Control|Group of patients without modification of baseline treatment (Triumeq: ABC/3TC/DTG).
32792520|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
32792521|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
32792522|NCT05185856|Sham Comparator|Start with: Concentric (normal) cycling|Patients that are allocated to this arm will start with normal cycling
32792523|NCT05185856|Experimental|Start with: Eccentric cycling|Patients that are allocated to this arm will start with eccentric cycling
32792524|NCT04421222|Experimental|Cohort 1|200 mg EPI-7386
32792525|NCT04421222|Experimental|Cohort 2|400 mg EPI-7386
32792526|NCT04421222|Experimental|Cohort 3|600 mg EPI-7386
32792527|NCT04421222|Experimental|Cohort 4|800 mg EPI-7386
32792528|NCT04421222|Experimental|Cohort 5|1000 mg EPI-7386
32792529|NCT04421222|Experimental|Cohort 6|800 mg EPI-7386
32792530|NCT04421222|Experimental|Cohort 7|1200 mg EPI-7386
32792531|NCT04787744|Active Comparator|Standard Systemic Therapy (SST)|All Veterans will receive SST
32792532|NCT04787744|Experimental|SST + PET-directed local therapy|"In addition to SST, all Veterans will receive PET-directed local therapy to all metastases using surgery or radiation. The selection of surgery or radiation to each metastasis will be determined using shared decision-making between the physician and Veteran.~For Veterans with a local recurrence, this will be treated with salvage local therapy."
32792536|NCT04307186|Experimental|BAY1747846 + Gadobutrol|Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of BAY1747846.
32792537|NCT04297826|Experimental|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
32792538|NCT05180942|Experimental|Statin treatment|Atorvastatin 40mg, daily, orally for 18 months
32792539|NCT05180942|No Intervention|No statin treatment|
32792540|NCT05180552|Experimental|Experimental|Participants will wear HEALiX Device while intubated and sedated in the critical care setting
32792541|NCT05180552|Active Comparator|Control|Participants will wear wrist restraints while intubated and sedated in the critical care setting
32792542|NCT05269394|Experimental|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
32907140|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
32792543|NCT05269394|Placebo Comparator|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
32792544|NCT04274894|Experimental|AndroGel 1.62%|AndroGel 1.62% was applied topically once daily in the morning beginning at the Day 1 Visit after confirmed valid ambulatory blood pressure monitoring (ABPM) assessment and was applied at approximately the same time each day after that during the study, for approximately 16 weeks. The starting dose of AndroGel 1.62% was 40.5 mg of T (2 pump actuations, applied to the upper arms and shoulders) and was titrated up or down by 20.25 mg or remained the same as assessed by morning serum T levels at Weeks 2 and 4.
32792545|NCT05243966||Myriad™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
32792546|NCT04786964|Experimental|Cosibelimab|Participants receive cosibelimab 1200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by cosibelimab 1200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
32792547|NCT04786964|Active Comparator|Control|Participants receive pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pemetrexed 500 mg/m^2 IV Q3W until progression.
33404071|NCT03493451|Experimental|Cohort 2: PTCL-NOS, AITL, and ALCL|Participants with other R/R mature T-cell neoplasms [limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
33088061|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
33088062|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
33088063|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
33088064|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
33088065|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
33088066|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
33088067|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
32792548|NCT05177120||FMF patients|Patients with diagnosed FMF
32792549|NCT04269200|Active Comparator|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
32792550|NCT04269200|Experimental|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
32792551|NCT04269200|Experimental|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
32792552|NCT02213263|Experimental|PF-05280586|
32792553|NCT02213263|Active Comparator|MabThera®|
32792554|NCT04781036|No Intervention|Normal feet|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography"
32792555|NCT04781036|Experimental|Foot odor without pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 1 month~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
33088068|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
33088069|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
33088070|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
33088071|NCT00259220|Experimental|drug|erythromycine
33088072|NCT00259220|Other|2|gastric lavage alone
32792556|NCT04781036|Experimental|Foot odor with pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 1 month~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
32792557|NCT05190068|Experimental|Relapsed/refractory B-NHL|"The starting dose of HMPL-760 is initially set as 50 mg, and then the doses of 100 mg, 200 mg, 300 mg, and 400 mg are escalated successively (this dose gradient is assumed).~HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles."
32792558|NCT04216784|Active Comparator|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
33088073|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
32792559|NCT04216784|Active Comparator|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
32792560|NCT05173298||analytic group|advanced HCC Patients
32792561|NCT05168930|Experimental|Cohort A: BTKi and BCL2i naive|Participants who have never received a BTK inhibitor or a BCL-2 inhibitor
32940073|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
32940074|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
32792562|NCT05168930|Experimental|Cohort B: BTKi or BCL2i exposed without disease progression|Participants who have received prior treatment with a BTK or BCL-2 inhibitor and discontinued treatment for any reason other than disease progression
32792563|NCT05168930|Experimental|Cohort C: BTKi exposed and with disease progression|Participants who experienced disease progression on a prior BTK inhibitor. Participants with BTK C481X mutation at enrollment will be excluded.
32792564|NCT04785092|Experimental|Treatment - All Autologous Cartilage Regeneration|
32792565|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
32792566|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
32940075|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
32940076|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
32792567|NCT04149860|Experimental|Part A: Lu AF87908 or Placebo|Participants in Cohorts A1 to A6 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
32792568|NCT04149860|Experimental|Part B: Lu AF87908 or Placebo|Participants in Cohorts B1 to B3 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
32792569|NCT04149860|Experimental|Part C: Lu AF87908 or Placebo|Participants in Cohorts C1 and C4 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
32792570|NCT04801472|Other|Patients with oral cavity or oropharyngeal squamous cell carcinoma|
32792571|NCT05156996||Treatment Group|
32792572|NCT05156996||Control Group|
32792573|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
32792574|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
32792575|NCT05135702|Experimental|Sodium Propionate First|Subjects in this arm will consume 500mg sodium propionate powder twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of placebo twice daily.
32792576|NCT05135702|Placebo Comparator|Placebo First|Subjects in this arm will consume a placebo twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of 500mg sodium propionate powder, twice daily.
32792577|NCT05166980|Experimental|FePP-Q5S|Salt fortified with iron in the form of ferric pyrophosphate (at 1.3 mg of iron per gram of salt) plus ethylenediaminetetraacetic acid (EDTA) as an enhancer of absorption, zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the FePP-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
32940077|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
32940078|NCT04331834|Experimental|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
32940079|NCT04331834|Placebo Comparator|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
32940080|NCT04735159|Active Comparator|Study group-SCS Impanted|30 patients with chronic pain (at least 6 months) with pre- and post-surgery evaluation (imaging and clinical evaluation) implanted with Precision SpectraTM for the validation study and for the construction of the predictive model.
32940081|NCT04735159|No Intervention|Comparator-chronic pain|20 patients with chronic pain (at least 6 months) with degenerative spine pain. Non-specific low-back pain, nociceptive pain / mixed neuropathic. This will be the comparator group
32940082|NCT04735159|No Intervention|Control-healthy volunteers|10 volunteers without pain or related disease, age less than 25 years, to establish a control group whose pattern is used as a comparator with chronic pain groups. This is the control group
32940083|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
32940084|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
32940085|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
32940086|NCT01023620|Sham Comparator|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
32940087|NCT03595579|Experimental|AXS-05|
32940088|NCT03595579|Active Comparator|Bupropion|
32940089|NCT05599178||Term gestation|
32940090|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
32940091|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
32792578|NCT05166980|Experimental|eFF-Q5S|Salt fortified with iron in the form of encapsulated ferrous fumarate (at 1.3 mg of iron per gram of salt), zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the eFF-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
32792579|NCT05166980|Active Comparator|Iodized Salt|Iodized salt containing 30 mg of iodine per gram of salt. Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the iodized salt will deliver an average of 138 mg of iodine to each participating woman per day.
32792580|NCT05134454|Experimental|Extended ECG investigation|Participants will undergo 0-48 hours of continuous ECG recording and at least two long-term continuous ambulatory ECG recordings with a duration of 14 days each.
32792581|NCT05134454|No Intervention|Standard of care|Participants will undergo 24-48 hours of continuous ECG recording.
32792582|NCT05051696|Experimental|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.
32792583|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
32792584|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
33088074|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
33088075|NCT00272025|Placebo Comparator|2|to be filled in
33088076|NCT04709081|Experimental|Part 1: ACH-0145228, Midazolam, and Digoxin|"Period 1: Participants received single doses of midazolam and digoxin.~Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.~Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2."
32792585|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
32792586|NCT04062266|Experimental|Treatment (azacytidine, venetoclax)|Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32792587|NCT04025138|Experimental|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
32792588|NCT04025138|Experimental|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
32792589|NCT04025138|Experimental|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
32792590|NCT04025138|Experimental|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
32792591|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
32792592|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
33088077|NCT04709081|Experimental|Part 2: ACH-0145228 and Itraconazole|"Period 1: Participants received a single dose of ACH-0145228.~Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.~Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2."
33088078|NCT00272064|Other|1|Telecare system
33088079|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
33088080|NCT00259337|Experimental|1|
33088081|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
33088082|NCT00259376|Experimental|Placebo|matching placebo tablets
33088083|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
33088084|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
33088085|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
33088086|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
33088087|NCT04718688|Experimental|CO-OP intervention|CO-OP intervention
32940092|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
33088088|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
33102426|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
33299854|NCT05137990|Experimental|HIIT Exercise Intervention|At home (N=12): Participants will complete an exercise session 3 times a week for 14 weeks. Each participant will receive a pre-assembled stationary bicycle to use to complete each session, an iPad to receive the intervention virtually from exercise trainers through Zoom, and a Fitbit to assess real-time heart rate.
33299855|NCT05137990|Placebo Comparator|Stretching Intervention|At home (N=12): Participants will complete a stretching protocol 3 times a week for 14 weeks. Participants will be asked to complete weekly records of flexibility compliance.
33299856|NCT01239004|Placebo Comparator|Placebo|
32940093|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
32940094|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
33299857|NCT01239004|Experimental|Colesevelam|
33299858|NCT05161156|Experimental|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|2 inhalations of test product, followed by 2 inhalations of reference placebo product
33299859|NCT05161156|Active Comparator|Treatment B: 18 mcg of Reference Product (Spiriva)|2 inhalations of reference product, followed by 2 inhalations of test placebo product
33299860|NCT05161156|Placebo Comparator|Treatment C: Zero-dose (Placebo)|2 inhalations of reference placebo powder, followed by 2 inhalations of test placebo product
33299861|NCT04006288|Active Comparator|Aspirin and clopidogrel|aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
33299862|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and clopidogrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
32940095|NCT05598710||Group 1|Group who have pigtail 5-26
32940096|NCT05598710||Group 2|Group who have pigtail 6-26
32940097|NCT05598710||Group 3|Group who have pigtail 5-28
32940098|NCT05598710||Group 4|Group who have pigtail 6-28
32940099|NCT04343287|Active Comparator|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
32940100|NCT04343287|Placebo Comparator|Placebo|A vehicle ophthalmic drops
32940101|NCT05597774|Experimental|Exercise training + Inspiratory and expiratory muscle training group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
32940102|NCT05597774|Sham Comparator|Exercise training + Inspiratory and expiratory muscle training sham group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a sham threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
32940103|NCT04369885|Experimental|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
32940104|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
32940105|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
32940106|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
32940107|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
32940108|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
32940109|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
32940110|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
32940111|NCT04418947|No Intervention|No intervention|
32940112|NCT04418947|Active Comparator|MPM control letter|
32940113|NCT04418947|Experimental|MPM intervention letter|
32940114|NCT04418947|Active Comparator|Mailed control letter|
32940115|NCT04418947|Experimental|Mailed intervention letter|
32940116|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
33299863|NCT04006288|Active Comparator|Aspirin and prasugrel|aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
33299864|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and prasugrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
33299865|NCT04006288|Active Comparator|Aspirin and ticagrelor|aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
33299866|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and ticagrelor|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
33299867|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
33088089|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
32792593|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
32792594|NCT04780178|Experimental|TACTICs|Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.
32792595|NCT04780178|No Intervention|Minimally Enhanced Usual Care|All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials.
32792596|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a~Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
32792597|NCT04418492|Experimental|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
32792598|NCT03965468|Experimental|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);~Tremelimumab 75mg administered intravenously every 3 weeks for the first 4-6 cycles (only cohort 2)~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
33088090|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
33088091|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
33088092|NCT00259688|No Intervention|1|Women with gestational hypertension
32792599|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
33088093|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
33404072|NCT03493451|Experimental|Cohort 3: MF and SS|Participants with R/R cutaneous T-cell lymphoma [limited to mycosis fungoides (MF) and Sèzary syndrome (SS)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
32792600|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
32792601|NCT01469156|Experimental|Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)|"Intraocular injection of 1.0 or 2.0 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
32792602|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|"Intraocular injection of 0.5 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
32792603|NCT04799834||CASES|Subjects who have had a severe form of COVID-19 and developed respiratory failure requiring oxygen supplementation or CPAP mechanical ventilation or intubation
32792604|NCT04799834||CONTROLS 1|Subjects, comparable in age, sex and risk factors (such as concomitant diseases) with the CASES, who contracted the virus but either did not fall ill or had mild symptoms
33088094|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
33088095|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
33088096|NCT00272220|No Intervention|2|
33088097|NCT00259727||1|
33088098|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
33088099|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
33088100|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
33088101|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
33299868|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
33299869|NCT01142440|Experimental|behavioral intervention|
32940117|NCT05596058|Experimental|Dual task (active exercise and cognitive task)|"The dual task protocol is going to be in 15 one-hour sessions once a week in the headache free days.~This protocol will be set up in the clinic of physiotherapy degree (University of Trieste in the Department of Medical, Surgical, and Health Sciences).~The physical training tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises.~-"
33404073|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
32940118|NCT05596058|Active Comparator|active exercise only|The active exercise only intervention is going to consist of aerobic and flexibility training with a targeted duration of 1 hour, twice per week for 3 months.
32940119|NCT05596058|Active Comparator|Cognitive task trainig only|The Cognitive task training only engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).
32940120|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
32940121|NCT02074904|Placebo Comparator|Placebo|placebo
32940122|NCT03542305|Experimental|Mild|Mild renal impairment
32940123|NCT03542305|Experimental|Moderate|Moderate renal impairment
32940124|NCT03542305|Experimental|Severe|Severe renal impairment
32940125|NCT03542305|Other|Normal|Normal renal function
32940126|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
32940127|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
32940128|NCT05592548|Experimental|Study|Single arm study: split face treatment
32940129|NCT05589116|Experimental|Intervention group|Participants given immediate access to two-week, online compassionate imagery course.
32940130|NCT05589116|No Intervention|Wait-list control group|Participants will not access intervention during 10-week study period (access will be given to online compassionate imagery course after all outcome measures have been completed).
32940131|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
32940132|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
32940133|NCT05572892||Adult patients hospitalised in the Neurology Department of Caen University Hospital|Measurement of walking dependency according to the FAC scale (in the first week after stroke by physiotherapists, at 6 weeks, 12 weeks and 6 months by telephone).
32940134|NCT05560490|Experimental|FibroFix Cartilage P Implant + Drill set|Participants that have been implanted with FibroFix Cartilage P Implant using the FibroFix Drill Set
32940135|NCT05554796|Experimental|Endoscopic classic stapedotomy|This groups contains 30 patients and will undergo classic stapedotomy
32940136|NCT05554796|Experimental|Endoscopic reversal stapedotomy|This groups contains 30 patients and will undergo reversal stapedotomy
32940137|NCT03604705|Experimental|APX001 Treatment|
32940138|NCT00929474|Experimental|QuickOpt|
32940139|NCT00929474|Active Comparator|Control|
32940140|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
32940141|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
32940142|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
32940143|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
32940144|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
32940145|NCT05293340|Experimental|Hispanic/Latino adults with or at risk of T2D- Active Group|Eligible participants receive vouchers for free avocados.
32940146|NCT05293340|No Intervention|Hispanic/Latino adults with or at risk of T2D- Control Group|Eligible participants will not receive vouchers for free avocados.
32940147|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
32940148|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
33299870|NCT01142440|No Intervention|convention dental treatment|
33299871|NCT03942328|Experimental|Treatment (EBRT, autologous dendritic cells, Prevnar)|Patients undergo standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8, and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
33299872|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
33299873|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
33299874|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
33299875|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
33299876|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
32940149|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
32940150|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
33299877|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
33299878|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
32940151|NCT04734769||Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group)|Collect retrospectively clinical data on reproductive outcomes
33299879|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
33299880|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
33299881|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
33299882|NCT00423137|Placebo Comparator|Placebo - low dose|Twice daily (b.i.d.)
32940152|NCT04734769||Rebiopsy group:|Collect retrospectively clinical data on reproductive outcomes
32940153|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
32940154|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
33299883|NCT00423137|Placebo Comparator|Placebo - high dose|Twice daily (b.i.d.)
33299884|NCT00423137|Experimental|BIBW2948 - low dose|Twice daily (b.i.d.)
33299885|NCT00423137|Experimental|BIBW2948 - high dose|Twice daily (b.i.d.)
33299886|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
32940155|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
32940156|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
32940157|NCT05514158|Experimental|RC48 combind with RC98|
32940158|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
32940159|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
32940160|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
33299887|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
32940161|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
33299888|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
33404074|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
33299889|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
33299890|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
33299891|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
33299892|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
33299893|NCT00202878|Experimental|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
33299894|NCT00202878|Active Comparator|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
32940166|NCT05503160|Active Comparator|Intervention|With validated questionnaires, patient reported outcome monitoring data on quality of life, distress and therapy-adherence are collected. In case of pathologic values, the attending breast center gets advised to intervene according to individual requirements.
32940167|NCT05503160|No Intervention|Control|Standard of care
32940168|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
33102427|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
33102428|NCT04724070||NGS and PDO/PDX establishment|
32792605|NCT04799834||CONTROLS 2|Subjects, comparable in age, sex and risk factors (such as concomitant pathologies) with the CASES, who did not contract the virus
33088102|NCT04709159|Active Comparator|Intervention|"Participants on this arm will use Interactive Voice Response (IVR) daily pill reminders, thrice-weekly health messages, clinic appointment reminders, remote symptom reporting service and a 24 hour toll-free number to access services. These participants will also have the option to co-register a caregiver who will also receive daily pill reminders, clinic appointment reminder, weekly health tips and remote symptom reporting service.~In addition, these participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines."
33088103|NCT04709159|No Intervention|Standard|These participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines.
33088104|NCT00292110|Active Comparator|Arm Four|
33088105|NCT00292110|Experimental|Arm One|
33088106|NCT00292110|Active Comparator|Arm Three|
32792606|NCT05008172|Experimental|Splenic Artery Embolization (SAE)|If a patient is randomized to the SAE arm, the Interventional Radiology (IR) team will be notified of the patient's enrollment. The timing of embolization is left to the IR team but will occur within 6-12 hours of enrollment.
32792607|NCT05008172|No Intervention|Observation|Patients assigned to the observation arm will be transferred from the trauma bay to floor or the ICU for monitoring and continuous care under the Trauma team.
32792608|NCT04799054|Experimental|Part 1 Monotherapy Dose Escalation and Optimization: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
32792609|NCT04799054|Experimental|Part 2 Combination Dose Escalation and Optimization: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
33088107|NCT00292110|Active Comparator|ArmTwo|
32792610|NCT04799054|Experimental|Part 3 Phase 2 Combination Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination in indication-specific dose expansion cohorts.
32792611|NCT04191434|Experimental|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 125/12 capsule~1 Budesonide/formoterol 200/6 Placebo capsule."
33088108|NCT00259805|Experimental|IV Infusion|
33088109|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
33088110|NCT04718376|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
33088111|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
33088112|NCT00272415|Experimental|1|
33299895|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
33404075|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
32792612|NCT04191434|Active Comparator|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 200/6 capsule~1 Flamboyant 125/12 Placebo capsule."
32792613|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
32792614|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
32792615|NCT03762590|Experimental|Doxy.me plus Color Genomics Arm (Arm 1)|"Participants in this arm will receive genetic education through an online platform called Doxy.me~The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor~After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing~Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
32792616|NCT03762590|Experimental|Color Genomics Only Arm (Arm 2)|"Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video~After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing~Intervention is genetic education via Color Genomics website"
32792617|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine and plasma.~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
32792618|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
32792619|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a liver preparation of O.formigenes
33088113|NCT00259922|Placebo Comparator|Placebo|
33088114|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
33088115|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
33088116|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
33088117|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
33088118|NCT00292266|Experimental|Rebif®|
33088119|NCT00292266|Active Comparator|Avonex®|
32792620|NCT04963400||Patients with low disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of low severity (e.g. patients with retinal detachment)
32792621|NCT04963400||Patients with medium disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of medium severity (e.g. patients with an uncomplicated acute pancreatitis oder an acute exacerbation of a chronic inflammatory bowel disease)
32792622|NCT04963400||Patients with high disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of high severity (e.g. patients with a proximal femoral fracture)
32792623|NCT04192760|Active Comparator|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
32792624|NCT04192760|Active Comparator|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
32792625|NCT04938440||Prescribers of Instanyl®|Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the implementation of the updated EMs via web-based survey questionnaire.
32792626|NCT00909740|Experimental|1|
33088120|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
33088121|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
33088122|NCT00260039|Active Comparator|1|Gardasil
33088123|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
33088124|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
33088125|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
33088126|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
33299896|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
32792627|NCT04783532|Experimental|Telehealth Mindfulness Program|Telehealth mindfulness sessions
32792628|NCT04779008|Experimental|Experimental Group 1|Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
32792629|NCT04779008|Experimental|Experimental Group 2|Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
32792630|NCT04779008|No Intervention|Control group|routine treatment, no RIPC
33299897|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
33299898|NCT00231816|Experimental|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
33299899|NCT00231816|Experimental|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
32792631|NCT04886258|Active Comparator|DFV890|DFV890
32792632|NCT04886258|Placebo Comparator|Placebo|Placebo
33404076|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
33404077|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
32792633|NCT02188303|Placebo Comparator|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
32792634|NCT02188303|Experimental|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
32792635|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
32792636|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
32792637|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
32792638|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
32792639|NCT03651128|Experimental|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
33404078|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
33404079|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
32792640|NCT03651128|Experimental|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:~Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR~DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR~Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR~Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR~Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)"
32792641|NCT03597620|Experimental|Nonsystemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were not on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
32792642|NCT03597620|Experimental|Systemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
33404080|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
32792643|NCT00664898|Experimental|1|
32792644|NCT04867382|Experimental|Intervention|This arm received a case-based training on how to use the Opioid Wizard tool, including patient narratives and videos and person-first language.
32792645|NCT04867382|Placebo Comparator|Comparison training|This arm received a case-based training on how to use the Opioid Wizard tool.
32792646|NCT04418336|Active Comparator|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
32792647|NCT04418336|Active Comparator|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
32792648|NCT04418336|Active Comparator|lay open technique|lay open technique
32792649|NCT04850300|Experimental|Total knee prosthesis 1|prosthesis with medial condylar stabilization
32792650|NCT04850300|Active Comparator|Total knee prosthesis 2|traditional prosthesis with central pivot stabilization
32792651|NCT04827992|Experimental|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
32792652|NCT04827992|Active Comparator|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
32792653|NCT04776980|Experimental|Ferumoxytol Infused MRI|Ferumoxytol is an iron replacement product that is FDA approved to treat iron deficiency anemia in patients with chronic kidney disease (CKD). In this study, ferumoxytol is used to quantify tumor-associated macrophages. The infused dose would be 5mg/kg.
32792654|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
32792655|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
32792656|NCT02187055|Active Comparator|Adalimumab with methotrexate|
32792657|NCT00119366|Experimental|Dose Level 1: 12 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
32792658|NCT00119366|Experimental|Dose Level 7: 22 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
32792659|NCT00119366|Experimental|Dose Level 8: 24 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
32792660|NCT00119366|Experimental|Dose Level 9: 26 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
32907141|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
33088127|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
32792661|NCT00119366|Experimental|Dose Level 10: 28 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
32792662|NCT05348486|Experimental|Dose escalation|Dose escalated radiotherapy protocol: 75,9 - 79,2 Gy in 33 fractions GTV hypoxic or any hypoxic LN > 2cm - PTV (0mm): dose 75,9 - 79,2 Gy/33 (Contours must be subtracted and reduce by 3mm in case of close relation to the skin, bones or large blood vessels) GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
32792663|NCT05348486|No Intervention|Standard fractionation|Standard fractionation regimen: 70 Gy/54 Gy in 33 fractions GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 GTV LN bulky (> 3cm) - PTV (5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
32792664|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
32792665|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
32792666|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
32792667|NCT04750447||Open Angle Glaucoma|Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery
32792668|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
32792669|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
32792670|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32792671|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
32792672|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
32792673|NCT04741802|Experimental|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors
32792674|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
32792675|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
32792676|NCT02135107|Experimental|Arm A|
32792677|NCT02135107|Experimental|Arm B|
32792678|NCT02135107|Experimental|Arm C|
32792679|NCT02135107|Experimental|Arm D|
32792680|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
32792681|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
32792682|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
32792683|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
32792684|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
32792685|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
32792686|NCT01633112|Experimental|fingolimod 0.5 mg|orally once daily
32792687|NCT01633112|Experimental|fingolimod 0.25mg|orally once daily
33088128|NCT00260234|Experimental|PEG Islet Cells|
33088129|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
33088130|NCT00260273|No Intervention|2|supportive therapy
33088131|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
33088132|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
33088133|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
33088134|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
32792688|NCT01633112|Active Comparator|glatiramer acetate 20 mg|subcutaneous once daily
32792689|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
33088135|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
33088136|NCT00260663|Other|Arm 1|
32792690|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
32792691|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
32792692|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
32792693|NCT04776356||QuickFix Small Staple|The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.
32792694|NCT04715750|Experimental|Tau deposition in the brains of Alzheimer Disease and Progressive Supranuclear Palsy patients|All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose)
32792695|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
32792696|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
32792697|NCT04776044|Experimental|ATR-002|Participants will receive 900mg ATR-002 on day 1 (6 tablets with 150mg ATR-002; once daily), and 600mg ATR-002 on days 2 - 6 (4 tablets; once daily)
32792698|NCT04776044|Placebo Comparator|Placebo|Participants will receive matching tablets placebo on day 1 (6 tablets, once daily), and matching tablets placebo on days 2 - 6 (4 tablets per day, once daily)
32792699|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
32792700|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
33404081|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
33404082|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
32792701|NCT01710046|Experimental|Cohort 1|
32792702|NCT01710046|Experimental|Cohort 2|
32792703|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
32792704|NCT03267758|Placebo Comparator|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
32792705|NCT04633616|Experimental|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
32792706|NCT04633616|Placebo Comparator|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
32792707|NCT03148418|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
32792708|NCT02154529|Experimental|Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 150 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
32792709|NCT02154529|Experimental|Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 250 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
32792710|NCT02154529|Experimental|Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 300 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
32792711|NCT02154529|Experimental|Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 350 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
32792712|NCT01954017|Experimental|STP206|Biological
32792713|NCT01954017|Placebo Comparator|Control|Sterile water
32792714|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
33088137|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
33088138|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
33088139|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
33088140|NCT00298311|Sham Comparator|peer social support|social support
33088141|NCT00298428|Other|SPACE group|
33088142|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
33088143|NCT02960451|Active Comparator|Usual care|Usual care in the community
33088144|NCT00424853|Experimental|A|
33088145|NCT00424853|Experimental|B|
33088146|NCT00298506|Active Comparator|FK506+MMF|
32792715|NCT02245568|Experimental|LMTM|
32792716|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
32792717|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
32792718|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with MDM2 amplification|"The aim of each extension cohort is to provide preliminary evidence of anti-tumor activity while refining toxicity data, and to gain insight progressive disease activity and exploratory biological analyses. A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with MDM2 amplification . Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
32792719|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with no MDM2 amplification|"A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with no MDM2 amplification. Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
32792720|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
32792721|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
33088147|NCT01331239|Experimental|Part l: Core cohort|Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
33088148|NCT01331239|Experimental|Part II Core: Expansion cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
32792722|NCT01953783|Experimental|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
33088149|NCT01331239|Experimental|Part II Core: Follow-up cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study
33088150|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
33088151|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
32792723|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
33088152|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
33088153|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
33299900|NCT00260208|Active Comparator|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
32792724|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
32792725|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
32792726|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
32792727|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
32792728|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
32792729|NCT04619979||preoperative anxiety group|
32792730|NCT04619979||Non-preoperative anxiety group|
32792731|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
32792732|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
32792733|NCT01630135|Placebo Comparator|Placebo|Placebo
32792734|NCT04749901|Other|Patients with epilepsy|
32792735|NCT04749901|Other|Patients with PTSD|
33088154|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
33088155|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
33088156|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
33088157|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
33088158|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
33088159|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
32792736|NCT04749901|Other|Patients with type 1 diabetes|
32792737|NCT04749901|Other|Patients with a heart rhythm disorder|
32792738|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
33404083|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
33404084|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
32792739|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
32792740|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
32792741|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
32792742|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
32792743|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
33404085|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
32792744|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
32792745|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
32792746|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
32792747|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
32792748|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
32792749|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
32792750|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
32792751|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
32792752|NCT04749667|Experimental|Arm A - Crossover with MSCs at baseline and placebo at 6 months|Receives mesenchymal stem cells at baseline and placebo at 6 months
32792753|NCT04749667|Experimental|Arm B - Crossover with placebo at baseline and MSCs at 6 months|Receives placebo at baseline and mesenchymal stem cells at 6 months
32792754|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
32792755|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
32792756|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
32792757|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
32792758|NCT04752631|Experimental|TNK-tPA|TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
32792759|NCT04752631|No Intervention|Routine Therapy|Patients will be treated with standard of care in compliance with guidelines for acute stroke
32792760|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
32792761|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
32792762|NCT01691014||adalimumab|
32792763|NCT01691014||Etanercept|
33404086|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
33088160|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
32792764|NCT01691014||infliximab|
32792765|NCT01691014||Certolizumab|
32792766|NCT04546672|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
32792767|NCT04546672|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
32792768|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
32792769|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
32792770|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
32792771|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
32792772|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) is administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab is basically administered every 12 weeks. The interval between treatments is adjusted as appropriate according to the symptoms. The interval between two doses should not be shorter than 8 weeks
33088161|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
32792773|NCT01689532|Experimental|Sirukumab 100 mg|
32792774|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
32792775|NCT01924689|Experimental|Clostridium novyi-NT spores|
32792776|NCT01591330|Experimental|LY2140023 Reference Form|LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
32792777|NCT01591330|Experimental|LY2140023 Test-Low|LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
32792778|NCT01591330|Experimental|LY2140023 Test-Medium|LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
32792779|NCT01591330|Experimental|LY2140023 Test-High|LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
32792780|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
32792781|NCT04867174|Placebo Comparator|Control Arm|No messaging about COVID-19 vaccination
32792782|NCT04867174|Experimental|Emotional message|Participants view an emotional video from the state of California about getting back to normal.
32792783|NCT04867174|Experimental|Safety and effectiveness message|Participants view a video with information about the safety and effectiveness of the COVID-19 vaccines
32792784|NCT04867174|Experimental|Consequences message|Participants view a video with information about the consequences of not getting vaccinated against COVID-19.
32792785|NCT01953003|Experimental|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
33404087|NCT03725969|Experimental|Healthy individuals (camel milk)|
33404088|NCT03725969|Experimental|Healthy individuals (cow milk)|
33404089|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
32792786|NCT01953003|Active Comparator|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
32792787|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
32792788|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
32792789|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
32792790|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
32792791|NCT01599806|Active Comparator|Doripenem|IV treatment
32792792|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
32907142|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
33404090|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
33404091|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
33404092|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
32792793|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
32792794|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
32792795|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
32792796|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
32792797|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
32792798|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
32792799|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
32792800|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
32792801|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
32792802|NCT04770350|Experimental|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
32792803|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
32792804|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
33404093|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
32792805|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
32792806|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
32792807|NCT02929004|Experimental|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.~Training programme: vibration training 3/week from Day 1 to Day 60"
32792808|NCT02929004|No Intervention|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
32792809|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
32792810|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
32792811|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
32792812|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
33404094|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
33404095|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
33404096|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and concurrent etoposide and cisplatin
32792813|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
32792814|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
32792815|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
32792816|NCT02130427|Other|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
32792817|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
32792818|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
32792819|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
32792820|NCT05156606|Experimental|treatment|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
32792821|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
32792822|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
32792823|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
32792824|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
33404097|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and concurrent etoposide and cisplatin
32792825|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
32792826|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
32792827|NCT04769570|Active Comparator|Group IPSB|In the first group of patients (Group IPSB), ultrasound-guided interscalene brachial plexus block will be applied 30 minutes before surgery.
32792828|NCT04769570|Active Comparator|Group SSNB|In the second group of patients, ultrasound-guided interscalene brachial plexus block and suprascapular nerve block will be applied 30 minutes before surgery.
32792829|NCT04769570|Active Comparator|Group Control|Patients in the third group (Group C), will be considered the control group and no block will be performed.
32792830|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
32792831|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
32792832|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
32792833|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
32792834|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
32792835|NCT01590628|Experimental|NiCord|NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
33088162|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
32792836|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
32792837|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
32792838|NCT01590082|Experimental|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
32792843|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
32792844|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
32792845|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
32792846|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
32792847|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
32792848|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
32792849|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
32792850|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
32792851|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
32792852|NCT04774328|Active Comparator|CA-008 (vocacapsaicin)|Single administration
32792853|NCT04774328|Placebo Comparator|Placebo|Single administration
32792854|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
32792855|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
32792856|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
32792857|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
32792858|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
32792859|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
32792860|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
32792861|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
32792862|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
32792863|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
32792864|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
32792865|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
32792866|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
32792867|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
32907143|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
32792868|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
32792869|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
32792870|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
32792871|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
32792872|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
32792873|NCT02150863|Active Comparator|Ultrapulse laser alone|
32792874|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
32792875|NCT02150863|No Intervention|Control|
32792876|NCT01445366|Experimental|Patients with end-stage renal disease|
32792877|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
32792878|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
32792879|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
32792880|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
32792881|NCT01627249|Active Comparator|Ranibizumab|
32792882|NCT01627249|Experimental|Aflibercept|
32792883|NCT01627249|Experimental|Bevacizumab|
32792884|NCT04758403|Experimental|Navigation Bronchoscopy ALONE|"This research study involves a screening period, a procedure and follow up visits~Procedure Visit Navigation Bronchoscopy Alone~Follow-Up Visits at Week 1, 4 and 12"
32792885|NCT04758403|Experimental|CBCT-GUIDED Navigation Bronchoscopy|"This research study involves a screening period, a procedure and follow up visits Procedure Visit- Cone Beam Computed Tomography - Guided Navigation Bronchoscopy for Peripheral Pulmonary Nodules~-Follow-Up Visits at Week 1, 4 and 12"
32792886|NCT01688830|Experimental|BI 655075|
32792887|NCT01688830|Placebo Comparator|Placebo|
32792888|NCT01688830|Experimental|BI 655075 with dabigatran|
32792889|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
32792890|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
32792891|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
32792892|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
32792893|NCT01629823|Experimental|CPAP 10cm H₂O|
32792894|NCT01629823|Experimental|CPAP 5cm H₂O|
32792895|NCT01688050|Experimental|Endovascular Repair|
32792896|NCT01604278|Active Comparator|NVA237 + indacaterol|
32792897|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
32792898|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
32792899|NCT01589770|Other|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
32792900|NCT01589770|Other|controls|people who do not have RA or other inflammatory disease underwent cMRI
32792901|NCT01588990|Experimental|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
32792902|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
32792903|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
32792904|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
32792905|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
32792906|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
32792907|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
32792908|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
32792909|NCT04747795|Placebo Comparator|standard care + placebo|The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
32792910|NCT04747795|Active Comparator|standard care + Vitamin C|The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
32792911|NCT02125279|Experimental|Calcitriol ointment|
32792912|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
32792913|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
32792914|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
32792915|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
32792916|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
32792917|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
32792918|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
32792919|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
32792920|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
32792921|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
32792922|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
32792923|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
32792924|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib Monotherapy (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Monotherapy : Participants will receive Abemaciclib orally 2x daily"
32792925|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
32792926|NCT04751929|Experimental|CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle"
32792927|NCT04751929|Experimental|CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
32792928|NCT02176291|Experimental|Buprenorphine|Buprenorphine
33299901|NCT00260208|Active Comparator|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by center was to be given to all patients enrolled in trial from this center."
33299902|NCT00202644|Experimental|A|
33299903|NCT00202644|Active Comparator|B|
33299904|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
33299905|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
33299906|NCT00259740|Experimental|Denosumab|
33299907|NCT00201006|Experimental|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
32940169|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
33299908|NCT00201006|Experimental|Telephone Counseling|26 biweekly telephone counseling sessions
33299909|NCT00201006|Active Comparator|Mail contact|26 biweekly newsletters with weight management advice
33299910|NCT00200850|Active Comparator|Low dose SLIT|Low dose SLIT
33299911|NCT00200850|Active Comparator|High dose SLIT|High dose SLIT
33299912|NCT00200850|Placebo Comparator|Placebo|Placebo
33299913|NCT01073202|Active Comparator|ursodeoxycholic acid|
33299914|NCT01073202|Placebo Comparator|identical-appearing placebo|
33299915|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
33299916|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
33299917|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
33299918|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
33299919|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
33299920|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
33299921|NCT03812224|Experimental|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
33299922|NCT03812224|Placebo Comparator|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
33299923|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
32940170|NCT05486468|Experimental|Treatment Arm|This group will receive two YUTIQ implants at day 1.
32940171|NCT05486468|Sham Comparator|Control Arm|This group will receive two sham injections at day 1.
32940172|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
32940173|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
32940174|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
32940175|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
32940176|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
32940177|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
32940178|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
32940179|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
32940180|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
32940181|NCT03545893|Active Comparator|Ibuprofen|
33299924|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
33299925|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
33299926|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
32940182|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
32940183|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
32940184|NCT04734691|Experimental|Experimental Arm|
32940185|NCT04734691|Active Comparator|Control Arm|
32940186|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
32940187|NCT04658797|Active Comparator|Single Vision Spectacle for Vision correction|Single Vision Spectacle
32940188|NCT04658797|Experimental|somofilcon A Daily disposable contact lenses|Daily disposable contact lenses
32940189|NCT05290844|Other|Pediatric cricoid force|one arm 135 pediatric patients
32792929|NCT02176291|Placebo Comparator|Placebo|Placebo
33299927|NCT00231114|Experimental|Alair|Treatment of airways with the Alair System
33299928|NCT00231114|Sham Comparator|Sham|Sham treatment of airways
33299929|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
32792930|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
32792931|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
32792932|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
33299930|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
32792933|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
32792934|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
32792935|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
32792936|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
32792937|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
32792938|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
32792939|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
32792940|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
32792941|NCT02175121|Placebo Comparator|Treatment A- Placebo|
32792942|NCT02175121|Experimental|Treatment B- PF-06291874|
32792943|NCT02175121|Experimental|Treatment C- PF-06291874|
32792944|NCT02175121|Experimental|Treatment D- PF-06291874|
32792945|NCT02175121|Experimental|Treatment E- PF-06291874|
32792946|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
32792947|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
32792948|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
32792949|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
32792950|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
32792951|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
32792952|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
32792953|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
32792954|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
32792955|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
32792956|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
32907144|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
33299931|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
32792957|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
32792958|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
32792959|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
32792960|NCT01587898|Experimental|2mg GSK1278863|Once daily
32792961|NCT01587898|Experimental|5mg GSK1278863|Once daily
32792962|NCT01587898|Experimental|Placebo|Once daily
32792963|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
32792964|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
32792965|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
32792966|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
32792967|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
32792968|NCT01567306|Placebo Comparator|Placebo - Group 6|
32792969|NCT04115878|Active Comparator|High dose ato-oxy|
32792970|NCT04115878|Active Comparator|Low dose ato-oxy|
32792971|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
32792972|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
32792973|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
32792974|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
32792975|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
32792976|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
32792977|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years.
32792978|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
32792979|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
32792980|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
32792981|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
32792982|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
32792983|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
32792984|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
32792985|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
32792986|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
32792987|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
32792988|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
32792989|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
32792990|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
32792991|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
32792992|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
32792993|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
32792994|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
32792995|NCT04416087|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
32792996|NCT01923363|Experimental|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
32792997|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
32792998|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
32792999|NCT04627857|Active Comparator|Arm 1: Manual toothbrush|
32793000|NCT04627857|Experimental|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
32793001|NCT04627857|Experimental|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
32793002|NCT04627857|Experimental|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
32737889|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
32737890|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
32793003|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
32793004|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
32793005|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
32793006|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
32793007|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
32793008|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
32793009|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
32793010|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
32793011|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
32793012|NCT05122533||Study group|"18-30 year-old, healthy volunteers~Age: 18-30 years~BMI: <30~No previous surgery on lower limb or spine~No known developmental disorder~Without any orthopaedic complaint"
32793013|NCT01922895|Placebo Comparator|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
32793014|NCT01922895|Active Comparator|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
32793015|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
32793016|NCT02236988|Experimental|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
32793017|NCT02236988|Experimental|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
32793018|NCT02236988|Experimental|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
32907145|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
32793019|NCT02236988|Experimental|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
32793020|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
32793021|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
32793022|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
32793023|NCT01922349|Experimental|Dose 1, Single dose|Low dose
33404098|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
33404099|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
32793024|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
32793025|NCT01922349|Experimental|Dose 3, Single dose|High dose
32793026|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
32793027|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
32793028|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
32793029|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
32793030|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
32793031|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
32793032|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
32793033|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
32793034|NCT04769414|Experimental|Chemotherapy|"Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation~Doses as follows:~Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15"
32793035|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
32793036|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
32793037|NCT02236130|Active Comparator|General|General Anesthesia only
32793038|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
32793039|NCT05153564|Experimental|One-sequence cross-over arm|
32793040|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
32793041|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
32793042|NCT04768634|No Intervention|Observation|Patients will be observed for arrhythmias and treated if they occur.
32793043|NCT04768634|Experimental|Testing|Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.
32793044|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
32793045|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
32793046|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
32793047|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
32793048|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
32793049|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
32793050|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
32793051|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
32793052|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
32907146|NCT05441345||SBS patients|
33404100|NCT02337556|Active Comparator|Control Group|Replete
32793053|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
32793054|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
32793055|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
32793056|NCT00752804|Experimental|1|Dialysis during 4 hours
32793057|NCT00752804|Active Comparator|2|Dialysis during 6 hours
32793058|NCT00752804|Active Comparator|3|Dialysis during 8 hours
32793059|NCT04773158|Experimental|Intervention Arm|The intervention clinic sites will be provided access to both the Functional gastrointestinal disorders (FGIDs) Screening Module and the Treatment Module
32793060|NCT04773158|No Intervention|Control Arm|The control clinics will have the Functional gastrointestinal disorders (FGIDs) Screening Module. However, control clinics will not have access to the FGIDs Treatment Module. These clinic sites will be given access to the pre-screener form section of the module, so that providers are made aware of a positive screen for a FGID.
32793061|NCT05645081||Healthy Control|A group of participants with no previous symptoms or diagnosis of TIA or stroke.
32793062|NCT05645081||Non-TIA Control|A group of participants who were referred to TIA clinic with symptoms of a TIA, however, were subsequently confirmed as not suffering with a TIA.
32793063|NCT05645081||TIA, non-stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants did not suffer a stroke within 12 months of TIA diagnosis.
32793064|NCT05645081||TIA, stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants went on to suffer a stroke within 12 months of TIA diagnosis.
32793065|NCT04863521|Experimental|MHP Users|A subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
32793066|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
32793067|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
32793068|NCT04863287|Experimental|0.5 mg/kg of 2217LS|Single dose subcutaneous injection
32793069|NCT04863287|Experimental|1.5 mg/kg of 2217LS|Single dose subcutaneous injection
32793070|NCT04863287|Experimental|5 mg/kg of 2217LS|Single dose subcutaneous injection
32793071|NCT04863287|Experimental|10 mg/kg of 2217LS|Single dose subcutaneous injection
32793072|NCT04863287|Placebo Comparator|0.9% Sodium Chloride (NaCl)|Single dose subcutaneous injection
32793073|NCT05643365||Hypothyroidism|decreased hormone levels (FT3 < 3.5 pmol/L, FT4 < 11.5 pmol/L, TSH > 4.78 μU/mL) and symptoms of hypothyroidism within 6 months' follow-up.
32793074|NCT05643365||Euthyroidism|normal hormone levels (FT3 3.5 to 6.5 pmol/L, FT4 11.5 to 22.7 pmol/L, TSH 0.55 to 4.78 μU/mL), and no symptoms of hyperthyroidism after 6 months' follow-up
32793075|NCT05643365||Hyperthyroidism|increased hormone levels (FT3 > 6.5 pmol/L, FT4 > 22.7 pmol/L, TSH < 0.55 μU/mL) and symptoms of hyperthyroidism after 6 months' follow-up
32793076|NCT05642897|Experimental|Experimental Group|The Mind programme is an ACT, mindfulness and compassion intervention for women with breast cancer. It will include 8 weekly group sessions, with the duration of 120 minutes each, and will be delivered at the Radiotherapy Service of the CHUC. All participants will continue on receiving the recommended medical treatment for their clinical diagnosis.
32793077|NCT05642897|Active Comparator|Control Group|"A 8-week support group intervention will be delivered to the active control group.~All participants will continue on receiving the recommended medical treatment for their clinical diagnosis."
32793078|NCT04420091|Experimental|Cartidyss|
32793079|NCT04862195|Active Comparator|Attune™|Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
32793080|NCT04862195|Active Comparator|Cerena™|Cerena™ is a completely digital, 10-session, health education and wellness intervention.
32793081|NCT04861961|Active Comparator|Laparoscopic duodenal switch (DS)|Standard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
32793082|NCT04861961|Active Comparator|Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)|"Simplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction (Billroth II-like)."
32793083|NCT04861961|Active Comparator|Laparoscopic one anastomosis gastric bypass (OAGBP)|Gastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
32793084|NCT05642741||Hypoparathyroidism after total thyroidectomy|Adult patients definitive post-thyroidectomy HoPT defined by a parathyroid hormone (PTH) concentration ≤ 25 pg/mL more than 6 months after the operation and who require treatment with vitamin D and/or calcium supplementation. Each patient will complete a questionnaire twice (3 weeks apart +/- 7 days). The questionnaire, which evaluates the severity of clinical symptoms related to HoPT and their impact on quality of life, is adapted to this pathology.
32793085|NCT05650307||Healthy controls|
32793086|NCT05650307||Bariatric Surgery patients|
32793087|NCT05650307||Cardiac rehabilitation patients|
32793088|NCT04861805|Other|Vienna Aortic Valve|transcatheter aortic valve implantation (TAVI)
32793089|NCT05650151|Experimental|Vitamin D group|
32793090|NCT05650151|Placebo Comparator|Control group|
32793091|NCT02174731|Experimental|Roxadustat|
32793092|NCT02174731|Active Comparator|Epoetin alfa|
32793093|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
32793094|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
32793095|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
32793096|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
32793097|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
32793098|NCT05566067||Anesthesiology residents|We plan to distribute a survey to the Stanford anesthesiology residents to investigate the factors that influence residents' decision to pursue a career as a critical care physician.
32793099|NCT04188535|Experimental|Esophageal Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
32793100|NCT04188535|Experimental|Glioblastoma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
32793101|NCT04188535|Experimental|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
32793102|NCT04188535|Experimental|Prostate Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
32793103|NCT04188535|Experimental|Prostate Cancer Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
32793104|NCT04188535|Experimental|Vulvar Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
32793105|NCT04188535|Experimental|Pediatric Glioma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
32793106|NCT04878029|Experimental|Treatment (cabozantinib, enfortumab vedotin)|Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32793107|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
32793108|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
32793109|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
32793110|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
32793111|NCT05640557|Experimental|Experimental group|The participants of the study will take part in exercises (proprietary exercise program), 2 times per week, 45 minutes, for 6 weeks. They will be measured before and after the 6-week exercise program.
32793112|NCT05640557|No Intervention|Control group|The study participants will not be subjected to any intervention, they will be measured twice, 6 weeks apart. They will be asked to lead their habitual lifestyle.
32793113|NCT04746469|No Intervention|Control|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
32793114|NCT04746469|Experimental|Intervention|This group will receive standard FIT mailer protocol (as above) PLUS delayed automated phone reminder
32793115|NCT05638529|Experimental|Treatment Arm- Group A|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU).
33088163|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
32793116|NCT05638529|Placebo Comparator|Control Arm- Group B|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL) (sham-placebo).
32793117|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
32793118|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
32793119|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
32793120|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
32793121|NCT04859933||AVNA group|Group of historical controls beeing treated with AV-node ablation
32793122|NCT04859933||AVNI group|Inculudes all patients beeing treated with AV-node isolation
32793123|NCT04859465|Experimental|Abraxane combined with liposomal doxorubicin|Abraxane combined with liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma
32793124|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
33088164|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
33088165|NCT01330459|Placebo Comparator|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
32793125|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
33299932|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
32793128|NCT05637593|Experimental|the RAS group|The RAS group will receive upper-limb movement training with the aid of RAS;
32793129|NCT05637593|Active Comparator|the no-RAS group|The no-RAS group will receive upper-limb movement training without the aid of RAS.
32793130|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
32793131|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
32793132|NCT01587040|Experimental|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
32793133|NCT01587040|Experimental|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
32793134|NCT01587040|Experimental|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
32793135|NCT01587040|Experimental|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
32793136|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
32793137|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
32793138|NCT05556161|Experimental|Intervention Group|The 12-month general practitioners and diabetes specialists co-management will be received by intervention group participants.
32793139|NCT05556161|No Intervention|Control group|Routine primary health care will be received by control group participants during the course of the Study.
32793140|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
32793141|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
32793142|NCT05071859||GOBACK|The patient must have been diagnosed with cancer at ≤25 years of age and have been diagnosed with one or more congenital anomalies reported through the APEC14B1 registry intake data. For all patients in APEC14B1 with self-reported congenital anomalies the investigators will: 1) recruit cases; 2) administer the GOBACK Study questionnaire; 3) collect biological samples for sequencing; and 4) obtain medical records to verify anomalies. Medical records will be used to validate self-reported congenital anomalies and is a crucial step prior to sequencing. Additionally, the investigators will be able to identify those with well-established cancer predisposition syndromes that involve congenital anomalies, such as WAGR syndrome.
32793143|NCT01586806|Placebo Comparator|Control|
32793144|NCT01586806|Active Comparator|Dexamethasone 1 mg|
32793145|NCT01586806|Active Comparator|Dexamethasone 4 mg|
32793146|NCT05631041|No Intervention|Control group|Group I (Control group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab).
32793147|NCT05631041|Active Comparator|Silymarin group|Group II: (Silymarin group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab). plus silymarin 140 mg once daily.
32793148|NCT04545502||Gelsoft Plus - Straights and Bifurcated|Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
32793149|NCT04545502||Gelsoft Plus - Extra-Anatomical|Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
32793150|NCT04545502||Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall|Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
32907147|NCT05671913|Active Comparator|Treatment|Intranasal Ketamine
32793151|NCT04545502||Gelweave - Abdominal, Thoracic, Thoracoabdominal|"Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:~Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.~Thoracic aorta or arteries arising from the thoracic aorta.~Abdominal and thoracic aorta requiring a thoracoabdominal repair"
32793152|NCT04545502||Gelweave - Valsalva|Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
32793153|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
32793154|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
32793155|NCT04860869||symptomatic Post-COVID|32 patients with Post-COVID syndrome
33299933|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
33299934|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for 10 weeks weeks.
32793156|NCT04860869||non-symptomatic post-COVID|32 patients with that recovered without lingering symptoms after being infected with COVID
32793157|NCT05545553|Experimental|Piezosurgery group|In the experimental group, a piezosurgery device was used to remove the bone surrounding the impacted third molar.
32793158|NCT05545553|Active Comparator|Conventional group|In the control group, conventional burs were used to remove the bone surrounding the impacted third molar.
32793159|NCT05544071|Active Comparator|rTMS Active|Blinded Active TMS coil. Active repetitive Transcranial Magnetic Stimulation (rTMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
32793160|NCT05544071|Sham Comparator|rTMS Sham|Blinded Sham TMS coil. Sham Transcranial Magnetic Stimulation (TMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
32793161|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
32793162|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
32793163|NCT05619653|Active Comparator|Verum|Prednisolone and Losartan
32793164|NCT05619653|Placebo Comparator|Placebo|Placebo 1 and Placebo 2
32793165|NCT04544956|Experimental|Participants receiving 300 mg GSK3228836|Eligible participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
32793166|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
32793167|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
32793168|NCT04410016|Experimental|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
32793169|NCT05425433|Experimental|Serial casted joint|Tailored serial casting intervention following 1 week of usual care
32793170|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
32793171|NCT04858295|Active Comparator|Texting Arm|"Participants will receive automated text message reminders to check their blood pressure (BP) at least three days per week (participants will choose which days and times to receive reminders). Participants will transmit BP readings with text message to the Way to Health server. If a BP reading is not received within 3 hours, another reminder will be sent. Automated text message feedback will be sent with a tailored message. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
32900638|NCT05326542|Experimental|ESWL and ERCP|The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
32793172|NCT04858295|Active Comparator|mHealth app Arm|"Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
32793173|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic|SMART will be administered per each individual disease site standards
32793174|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal|SMART will be administered per each individual disease site standards
32793175|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung|SMART will be administered per each individual disease site standards
32793176|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-ADRENAL METASTASES|SMART will be administered per each individual disease site standards
32793177|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-LIVER METASTASES|SMART will be administered per each individual disease site standards
32793178|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- METACHRONOUS OLIGOMETASTATIC NODES|SMART will be administered per each individual disease site standards
32793179|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- OLIGOPROGRESSIVE OLIGOMETASTATIC NODES/SOFT TISSUE|SMART will be administered per each individual disease site standards
32793180|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SYNCHRONOUS OLIGOMETASTATIC NODES/SOFT TISSUE METASTASES|SMART will be administered per each individual disease site standards
32793181|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE CANCER|SMART will be administered per each individual disease site standards
32793182|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BORDERLINE RESECTABLE PANCREAS|SMART will be administered per each individual disease site standards
32793183|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BRAIN METASTASIS|SMART will be administered per each individual disease site standards
32793184|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- MESOTHELIOMA|SMART will be administered per each individual disease site standards
32793185|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE BOOST|SMART will be administered per each individual disease site standards
32793186|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PELVIC RE-IRRADIATION|SMART will be administered per each individual disease site standards
32793187|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SPINE|SMART will be administered per each individual disease site standards
32793188|NCT04115254|Experimental|PHASE1:SBRT MR IMAGE GUIDANCE/ADAPTATION-Single-Fraction Precision Adaptive Radiation Kidney Tumors|SMART will be administered per each individual disease site standards
32793189|NCT04115254|Experimental|PHASE1:SBRT MR IMAGE GUIDANCE/ADAPTATION- 1/3 Fraction for Oligometastatases in the Abdomen & Pelvis|SMART will be administered per each individual disease site standards
32793190|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- Post-Operative Radiation Therapy Lung Cancer|SMART will be administered per each individual disease site standards
32793191|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
32793192|NCT05598905|Experimental|Oxycodone + Pregabalin|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg pregabaline capsule.
32793193|NCT05598905|Experimental|Oxycodone + Lacosamide|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg Lacosamide capsule.
32793194|NCT05590871|Experimental|Renal Denervation|Percutaneous renal denervation using the FlashPoint radio-frequency ablation system under the Columbus 3D mapping system guidance
32793195|NCT05590871|No Intervention|Control|Maintenance of anti-hypertensive medications
32793196|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
32793197|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
32793198|NCT05535959|Experimental|Sequence 1|Participants will receive a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
32793199|NCT05535959|Experimental|Sequence 2|Participants will receive a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
32793200|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
32793201|NCT05528159||Robotic and Laparoscopic Urologic Surgery Group|Patients scheduled for robotic/laparoscopic urologic surgeries that will be performed under supine and trendelenburg position
32793202|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
32793203|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
32793204|NCT04816708|Active Comparator|Arm 1: Intervention group (access to LIFT mindfulness app)|Participants randomized to the intervention arm will be provided access to LIFT app's daily mobile mindfulness therapy for 30 days.
32907148|NCT05671913|Placebo Comparator|Control|Normal Saline
32940190|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
32793205|NCT04816708|No Intervention|Arm 2: Control waitlist group (delayed access to LIFT mindfulness app)|Control participants will not receive access to the LIFT app daily mobile mindfulness therapy during study period. They may have access to LIFT app daily mobile mindfulness therapy after completion of the study period.
33404101|NCT04564534||Study cohort|"Adult (>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.~The MoCA will be administered by trained professionals with MoCA certification.~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
33404102|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
33404103|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
32793206|NCT05520047||COVID19-severe Patient|modified Medical Research Council dyspnea scale (mMRC), European Quality of Life 5 Dimensions and 5 Lines (EQ-5D-5L), the impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS), the Montreal Cognitive Assessment (MoCA)- BLIND, Lawton instrumental activities of daily living (IADL) and Return to work scales
32793207|NCT05520047||family of COVID19-severe Patient|impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS) scales
32793208|NCT04472104|Active Comparator|MBCT-S|Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) which incorporates several empirically supported therapeutic approaches, integrating elements of education, mindfulness meditation skills, and sex therapy.
32793209|NCT04472104|Active Comparator|SexEd|Sexuality education on sexual desire, sexual distress, and sexual pain.
33404104|NCT04490902|Active Comparator|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
32793210|NCT05500469|Active Comparator|GDD-tube in anterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the anterior chamber.
32793211|NCT05500469|Experimental|GDD-tube in posterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the posterior chamber.
32793212|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
32793213|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
32793214|NCT05581745|Experimental|A2 donor transplant to O recipient|
33404105|NCT04490902|Experimental|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
32793216|NCT05036525|Experimental|use HANBIO BarriGel|
32793217|NCT05036525|No Intervention|No anti-adhesive product|
32793218|NCT05033561|Experimental|2 doses, 1 week apart|Administration of 2 doses of nOPV2, 1 week apart
32793219|NCT05033561|Experimental|2 doses, 2 week apart|Administration of 2 doses of nOPV2, 2 weeks apart
32793220|NCT05033561|Active Comparator|2 doses, 4 week apart|Administration of 2 doses of nOPV2, 4 weeks apart
32793221|NCT04845347|Experimental|Bright Light Therapy|
32793222|NCT04845347|Sham Comparator|Dim Light Therapy|
32793223|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
32793224|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
32793225|NCT05497583|Experimental|Acetone based HEMA free Universal Adhesive|Patients with non-carious cervical lesions will be treated with Acetone Based HEMA-free Universal Adhesive (BeautiBond universal adhesive ) applied in a self-etch approach with (SE) selective enamel etching.
32793226|NCT05497583|Active Comparator|Isopropanol based HEMA-free universal Adhesive|Patients with non-carious cervical lesions will be treated with isopropanol-based HEMA-free universal Adhesive (Prime&Bond universal™ Adhesive system) applied in a self-etch approach with (SE) selective enamel etching.
32793227|NCT05492513|Experimental|Grade 1 CI Therapy + Sensory Components|All participants will receive the Grade 1 CI Therapy + Sensory Components administered over a two-week period of time.
32793228|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
33404106|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
32793229|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
32793230|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
32793231|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
33088166|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
33088167|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
33404107|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
32793232|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
32793233|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
32793234|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
32793235|NCT05153018|Other|A representative random sample of the population|1,200 non-febrile individuals aged older than 6 years old
32793236|NCT01585558|Experimental|Treatment Group 1|
32793237|NCT01585558|Experimental|Treatment Group 2|
32793238|NCT01585558|Placebo Comparator|Treatment Group 3|
32793239|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
32793240|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
32793241|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
32793242|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
32793243|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
33088168|NCT00298623|Placebo Comparator|Placebo|
32793244|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
32793245|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
33088169|NCT00298623|Experimental|XP13512 (GSK1838262)|
33088170|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
33404108|NCT02337400|No Intervention|Waiting Control Group|
32793246|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
32793247|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
32793248|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
32793249|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
32793250|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
32793251|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
32793252|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
32793253|NCT02142283|Active Comparator|Medical Management|Medical Management
32793254|NCT02231918|Experimental|MIRAPEX® - low|
32793255|NCT02231918|Experimental|MIRAPEX® - medium|
32793256|NCT02231918|Experimental|MIRAPEX® - high|
32793257|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
32793258|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
32793259|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
32793260|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
32793261|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
32793262|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
32793263|NCT04772534|Experimental|3-dose in 9 to 15 year old boys|9 to 15 year old boys will receive a 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine (Day 1, Month 2 and Month 6).
32793264|NCT04772534|Experimental|2-dose in 9 to 14 year old boys|9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
33088171|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
32793265|NCT04772534|Experimental|2-dose in 9 to 14 year old girls|9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
33088172|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
33088173|NCT01330381|Experimental|prucalopride|drug
32793266|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
32793267|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
32793268|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
32793269|NCT02230670|Placebo Comparator|Placebo|Placebo BID
32793270|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
32793271|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
32793272|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
32793273|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
32793274|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
33088174|NCT01330381|Placebo Comparator|Placebo|
33088175|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
33088176|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
33088177|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
33088178|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
33404109|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
32793275|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
32793276|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
32793277|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
32793278|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
32793279|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
32793280|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
32793281|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
32793282|NCT05490875||Carotid Ultrasound Group|Head and neck cancer survivors treated with radiotherapy, at least 2 years since end of radiotherapy with no evidence of disease will receive a carotid ultrasound to measure carotid velocities and intima-media thickness of the carotid arteries.
32793283|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
32793284|NCT01640873|Experimental|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
32793285|NCT01640873|Placebo Comparator|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
32793286|NCT04419623|Experimental|Dose Finding - 200mg BID|200mg TL-895 orally BID taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
32793287|NCT04844801|Active Comparator|Risk control strategy|Magnesium sulfate + control of the modifiable NOSVA risk factors
32793288|NCT04844801|Active Comparator|Rate control strategy|"Risk-control + low-dose amiodarone"
32793289|NCT04844801|Active Comparator|Rhythm control strategy|"Risk-control + high-dose amiodarone +/- electrical cardioversion"
32793290|NCT01683994|Experimental|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
32793291|NCT01683994|Active Comparator|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
32793292|NCT01683994|Active Comparator|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
32793293|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~For genotypes 1, 4, 5 and 6:~800 mg/day, if bodyweight <65 kg,~1000 mg/day, if bodyweight between 66-80 kg,~1200 mg/day, if bodyweight between 81-105 kg,~1400 mg/day, if bodyweight >105 kg.~Duration: 48 weeks"
33088179|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
33088180|NCT00261170|Placebo Comparator|2|placebo medication
33088181|NCT04718493|Experimental|Stent|
33088182|NCT04718493|Active Comparator|Dilatation|
33088183|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
33088184|NCT04718298|Experimental|Inguinal hernia repair laparoscopic|recurrent inguinal hernia after open repair or bilateral hernia patients
33088185|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
33088186|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
33088187|NCT00261365|Active Comparator|A1|
33088188|NCT00261365|Active Comparator|A2|
33088189|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
33088190|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
33404110|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
32793294|NCT05487989||optic neuritis patients|Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up.
32793295|NCT04760054|Experimental|HUBOD martial arts practice|Participants will be trained in the Hubod exercise over 5 separate training sessions. Sessions will last approximately 30 minutes, involving a warm up, review of material from the previous session and the learning of the next movement in the HUBOD sequence. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
32793296|NCT04760054|Active Comparator|Active Comparator - Stationary Bicycle|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of mild to moderate intensity cardiovascular training on a stationary bicycle. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate exercise as in the Experimental group.
32793297|NCT04760054|Placebo Comparator|Attentional Control Group|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of watching videos on martial arts training methods and techniques. These sessions will be completely sedentary.
32793298|NCT05421377||lymph node dissection for treatment of urogenital, gynaelogical or skin cancer|Patients with any type of skin melanoma (at the level of the lower limb), urogenital or gynaecological cancer scheduled for lymph node dissection
32793299|NCT05011721|Experimental|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
32793300|NCT04844099|Experimental|Intervention arm|The intervention will be oral dihydroartemisinin (20mg) and piperaquine (160 mg) and administered once weekly at approximate doses of dihydroartemisinin 2.5mg/kg/day and piperaquine 20mg/kg/day based on participants' weight categories
32793301|NCT04844099|Active Comparator|Comparator|The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
33088191|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
32793302|NCT04419077|Other|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
33088192|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
32793303|NCT04857203||Group 1|Low levels of Vitamin D
33088193|NCT00298974|Placebo Comparator|Placebo|
33088194|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
32793304|NCT04857203||Group 2|High levels of Vitamin D
32793305|NCT05381597|Experimental|Combination cream of 5-fluorouracil and calcipotriene|Participants randomized to this group will receive treatment with the combination cream consisting of 5-fluorouracil and calcipotriene twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
32793306|NCT05381597|Active Comparator|5-fluorouracil cream|Participants randomized to this group will receive treatment with 5-fluorouracil cream twice a day for 28 days.
33088195|NCT00261794|Active Comparator|2|computer-based cognitive activity
33404111|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
32793307|NCT05479643|Experimental|Patients with Aphonia or Dysphonia|Participants with Aphonia or Dysphonia will be asked to recite phrases with sEMG attached to articulatory muscles.
32793308|NCT05479643|Placebo Comparator|Healthy Volunteers|Healthy Volunteer will be asked to recite phrases with sEMG attached to articulatory muscles.
33404112|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
33404113|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
32793311|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
32793312|NCT01683838|Placebo Comparator|Placebo|
32793313|NCT05474573|Experimental|Fluorescence and Ultrasound|Extent of tumor resection will be intraoperatively assessed using both fluorescence with 5-aminolevulinic acid and sonography
32793314|NCT05474573|Active Comparator|Fluorescence|Extent of tumor resection will be intraoperatively assessed using fluorescence with 5-aminolevulinic acid
32793315|NCT05006261|Experimental|Tele-Tai Chi|Tele-Tai Chi intervention
32793316|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
32793317|NCT05417243|Experimental|Advanced Trauma Life Support (ATLS)|Training in ATLS for residents providing trauma care.
32793318|NCT05417243|Experimental|Primary Trauma Care (PTC)|Training in PTC for residents providing trauma care.
33088196|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33088197|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
33088198|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
33088199|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
33088200|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
33088201|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
33088202|NCT00299052|Active Comparator|B|Bone reamings
33088203|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
33088204|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
33088205|NCT00299169|Experimental|1|N of 1 trials of statin therapy
33088206|NCT00299169|Other|2|usual care
33088207|NCT00293592|Active Comparator|Dexamethasone|
33088208|NCT00293592|Placebo Comparator|Placebo|
33088209|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
32793319|NCT05417243|No Intervention|Standard Care|Trauma care according to the current standard with no intervention.
32793320|NCT05417165|Experimental|Arm A (yearly booster)|Patients receive PCV13 IM at week 1 and PSV23 IM at week 8. Patients then receive PSV23 IM booster at years 1, 2, 3, 4 and 5.
32793321|NCT05417165|Active Comparator|Arm B (5 year booster)|Patients receive PCV13 IM at week 1 and PSV23 IM at week 8. Patients then receive PSV23 IM booster at year 5.
32793322|NCT04843709|Experimental|MRG004A|All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
33088210|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
33404114|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
32793323|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
33404115|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
33404116|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
32793324|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
32793325|NCT04660643|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
32793326|NCT04660643|Placebo Comparator|Placebo|Placebo administered SC
32793327|NCT04659317|Active Comparator|Opioid Group|"Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
33404117|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
32793328|NCT04659317|Experimental|Placebo Group|"Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
32793329|NCT05369585|Experimental|TOTUM-63|Experimental active are supplemented with TOTUM-63, taken 3 times per day.
32793330|NCT04855643|Experimental|Treatment|
32793331|NCT04855643|Sham Comparator|Control Group|
32793332|NCT05358821|Experimental|SAGE-718|Participants will receive SAGE-718 1.2 mg softgel lipid capsule orally once daily in the morning for up to 28 days.
32793333|NCT05358821|Placebo Comparator|Placebo|Participants will receive SAGE-718-matching placebo capsule orally once daily in the morning for up to 28 days.
32793334|NCT05358353|Experimental|Bare Temporary Spur Stent System|Treatment with the Temporary Bare Spur Stent System (Spur Stent System).
32793335|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
32793336|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
32793337|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
32793338|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
32793339|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
32793340|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
32793341|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
32793342|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
32793343|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
32793344|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
32793345|NCT01640249|Placebo Comparator|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
32793346|NCT01640249|Experimental|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
32793347|NCT04638881|Experimental|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
32793348|NCT04638881|Placebo Comparator|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
32793349|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
32793350|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
32793351|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
33088211|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
33088212|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
33088213|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
33088214|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
33088215|NCT00262457|Other|Arm 1|
32793352|NCT05422703|Experimental|Study group|patients who will receive manual therapy and Kinesio taping, in additional to basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ) 3 times per week for two weeks.
32793353|NCT05422703|Placebo Comparator|Control group|patients who will receive basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ).
32793354|NCT04841525||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
32793355|NCT04841525||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
32793356|NCT02227862|Experimental|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
32793357|NCT02227862|Active Comparator|Lantus®|Receive Lantus® plus insulin lispro
32793358|NCT05422391|Other|Pre- post-dietary intervention|Single arm pre-post dietary intervention (caloric restriction)
32793359|NCT02120833|Active Comparator|EPI|
32793360|NCT02120833|Experimental|NEE|
32793361|NCT04615949|Experimental|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx
32793362|NCT04615949|Placebo Comparator|Placebo|Placebo
32793365|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
32793366|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
32793367|NCT04597307||IN.PACT™ Admiral™ DCB Cohort|De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).
32793368|NCT04591379|Experimental|Intervention arm|
33088216|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
33088217|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
33404118|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
32793369|NCT05413265|Experimental|Incentives intervention condition|Subjects will receive generic, existing resources and referral information on evidence-based tobacco/nicotine cessation treatment services including the Alaska quitline, regional Tribal cessation programs, and smokefree.gov services and Alaska Native Tribal Health Consortium (ANTHC) family wellness resources on general health topics (e.g., injury prevention, household air quality) that include regional links to programs for domestic violence. Subjects will additionally receive individual cash card rewards for achieving biochemically verified smoking abstinence at each time point.
32793370|NCT05413265|Active Comparator|No incentives control condition|Subjects will receive generic, existing resources and referral information on evidence-based tobacco/nicotine cessation treatment services including the Alaska quitline, regional Tribal cessation programs, and smokefree.gov services and ANTHC family wellness resources on general health topics (e.g., injury prevention, household air quality) that include regional links to programs for domestic violence.
32793371|NCT05411627|Experimental|Treatment Group|Pilot group of all 8 anticipated participants
32793372|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
32793373|NCT05399927|Experimental|Intervention|The intervention group underwent exposure to relaxing music with sounds from nature
32793374|NCT05399927|No Intervention|Control|The control group under the usual transfer conditions.
32793375|NCT04968275|Experimental|CHAMPS and EIS|The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
32793376|NCT04968275|No Intervention|EIS alone|Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
32793377|NCT04746079|Experimental|Positive Imagery Therapy|"Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy below:~Relax and close your eyes. Take deep breaths in through your nose and out through your mouth as you listen to the sound of my voice. (Three second pause.) I want you to picture yourself lying on a towel on a soft sandy beach. (Three second pause.) You can see a palm trees swaying in the wind beneath a bright blue sky with a few white puffy clouds. (Three second pause.) You can feel the sand between your toes, the warm sunlight on your skin and a cool breeze. (Three second pause) You can smell coconut lotion in the breeze. (Three second pause.) You can hear the sound of waves gently crashing on the beach and seagulls crying in the distance. **End of vignette**"
32793378|NCT04746079|No Intervention|Control|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds with no positive imagery therapy.
33088218|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
33088219|NCT00415649|Placebo Comparator|B|Placebo vaccine
33088220|NCT00293826|Experimental|1|196 subjects
32793379|NCT04855097|Experimental|Standard care group|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.
32793380|NCT04855097|Experimental|BVA-guided treatment arm|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.
32793381|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
32793382|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
33088221|NCT00293826|Experimental|3|196 subjects
33088222|NCT00293826|Experimental|2|196 subjects
33088223|NCT00293826|Placebo Comparator|4|196 subjects
33088224|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
33088225|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
33088226|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
33088227|NCT00299442|No Intervention|2|Wait-list control
33404119|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
33404120|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
32793383|NCT05382299|Experimental|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.
32793384|NCT05382299|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens:~Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle~Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle~Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle"
32793385|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
32793386|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
32793387|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
32793388|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
32793389|NCT04419701|Experimental|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
32793390|NCT04419701|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
32793391|NCT04841213|Active Comparator|Group after vitamin D3 level stabilization|Patients with loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who will undergo dental implant placement after stabilization of vitamin D3 levels
32793392|NCT04841213|Active Comparator|Group before vitamin D3 level stabilization|Patients with the loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who undergo the dental implantation during treatment by an endocrinologist
32793393|NCT01565668|Experimental|AC220 Dose Level 1|
32793394|NCT01565668|Experimental|AC220 Dose Level 2|
32793395|NCT04581551|Experimental|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
32793396|NCT04581551|Active Comparator|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
32793397|NCT04577807|Experimental|Arm 1: Lerapolturev Only|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
33088228|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
33088229|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
33088230|NCT00299559|Other|1|cross over application of both specimen
33088231|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
33088232|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
33088233|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~Letrozole 2.5 mg PO once daily~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~Letrozole 2.5 mg PO once daily"
33088234|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
33088235|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
33088236|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
33088237|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
33088238|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
33088239|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
33088240|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
33088241|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
33088242|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
33088243|NCT00263276|Experimental|Arm 1|
33088244|NCT00263276|Experimental|Arm 2|
33088245|NCT00263276|Experimental|Arm 3|
33088246|NCT00263276|Experimental|Arm 4|
33088247|NCT00263276|Experimental|Arm 5|
32793398|NCT04577807|Experimental|Arm 2: Lerapolturev and anti-PD-1|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
32793399|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
33088248|NCT00263276|Placebo Comparator|Arm 6|
33088249|NCT00263276|Active Comparator|Arm 7|
33088250|NCT00417807|Experimental|Gleevec/Glivec|
33088251|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
33088252|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
33088253|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
32793400|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
32793401|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
32793402|NCT04574921|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
33404121|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
32793403|NCT04574921|Sham Comparator|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
32793404|NCT05374421|Active Comparator|Erchonia® THL™|The Erchonia® EVRL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device.
32793405|NCT05374421|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light.
32793406|NCT01626859|Experimental|MP-214 3mg|
32793407|NCT01626859|Experimental|MP-214 6mg|
32793408|NCT01626859|Experimental|MP-214 9mg|
32793409|NCT04568369|Experimental|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. A standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-50, 30, 36). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and an inter-train interval of 45s.
33088254|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
33088255|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
33088256|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
33088257|NCT00263744|Experimental|1|MEDI517
33088258|NCT00263744|Active Comparator|2|Aluminum hydroxide
33088259|NCT00263783|Experimental|1|MEDI-522
33088260|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
33088261|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
33088262|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
33088263|NCT00300261|No Intervention|1|receives home care
33088264|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
33088265|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
33088266|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
33088267|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
33088268|NCT00300300|Experimental|4|hamstring graft CAOS
33088269|NCT00264095||001|
33088270|NCT00294567|Active Comparator|1|Amlodipine
33088271|NCT00294567|Active Comparator|2|Azelnidipine
33088272|NCT04708925||group A- conservative therpay|hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
33088273|NCT04708925||group B- plasmapharesis therapy|hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
33088274|NCT04708769|Experimental|Smartphone App Participants (APP)|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist
33088275|NCT04708769|Experimental|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist
32793410|NCT04568369|Sham Comparator|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
32793411|NCT04413682|Experimental|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
33404122|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
32793412|NCT04413682|Experimental|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
32793413|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
33404123|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
32793414|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
32793415|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
32793416|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
32793417|NCT04740697|Other|Patient with localized breast cancer.|
32793418|NCT05373407|Experimental|moderate intensity aerobic training|The exercises were conducted at a heart rate of 50-70% of maximum heart rate for 30 minutes. Exercises were included strengthening muscles groups (shoulder flexors, extensors, abductor's muscles, hip flexors, extensor muscles, knee flexors, extensor muscles, abdominal muscles, and back muscles).
32793419|NCT05373407|Experimental|low intensity aerobic training|"Exercises were performed at 40-50% of the maximum heart rate Starting by 15 minutes of Warm-up time included static stretching of upper and lower body muscles.~After that, participants performed 30 minutes of low-intensity aerobic training exercises, which included 20 minutes on the treadmill, followed by 10 minutes of cooling down.~A set of 5-10 exercises was performed by each muscle group, three sets per exercise were performed, and 10-15 repetitions per series were performed 4 days per week"
32793420|NCT04840979|Experimental|Cognitive Impairment|Subjects diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo a 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
32793421|NCT04840979|Active Comparator|No Cognitive Impairment|Healthy volunteers who are cognitively normal will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo an 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
32793422|NCT05358587|Experimental|PENG (20 mL)|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %)
32793423|NCT05358587|Experimental|PENG (30 mL)|In this group, US guided PENG block will be performed with 30 ml of Bupivacaine solution (0.25 %)
32793424|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
32793425|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
32940191|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
32940192|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
32940193|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
32940194|NCT03615001|Experimental|Urodynamics Arm|
32940195|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
32940196|NCT01877564|No Intervention|Group 2 - No treatment|
32940197|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
32793426|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
32793427|NCT05344625|Experimental|Ketamine Assisted Psychotherapy|3 KAP sessions lasting approximately 3 hours using less than or equal to 60mg or 1mg/kg of intramuscular Ketalar as the facilitating chemical. KAP sessions will be supplemented with integration sessions occurring the following day and 1 month after the final KAP session.
32793428|NCT02169830|Active Comparator|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
32793429|NCT02169830|Active Comparator|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
32793430|NCT02169830|Other|diet modification|Participants will begin with diet modification for four (4) weeks.
32793431|NCT04854551|Experimental|Healthy adults: placebo first|This arm will receive placebo first, then active medication second
32793432|NCT04854551|Experimental|Healthy adults: active medication first|This arm will receive active medication first, then placebo second
32793433|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
32793434|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
32793435|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
32793436|NCT04536467|Other|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
32793437|NCT04536467|Other|control Arm|Standard chemotherapy
32793438|NCT04532489|Other|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of [18F]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
32793439|NCT04946981|Other|Randomized Crossover_Sequence 1|Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
32793440|NCT04946981|Other|Randomized Crossover_Sequence 2|Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
32793441|NCT04942457|Experimental|Fasting|Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision.
32793442|NCT04942457|No Intervention|Control group|waiting list, usual diet should be maintained
32793443|NCT05341349|Experimental|Arm I (SRS, pembrolizumab, TTFields)|Patients receive standard of care pembrolizumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
32793444|NCT05341349|Experimental|Arm II (nivolumab, ipilimumab, SRS, TTFields)|Patients receive standard of care nivolumab and ipilimumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
32793445|NCT04530149|Active Comparator|serratus anterior plane block group|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.
32793446|NCT04530149|Placebo Comparator|Placeoo injection group|The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.
32793447|NCT04853225||Main cohort|COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
32793448|NCT04853225||Sub-cohort|COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.
32793449|NCT04525547||Patients treated with Nintedanib|
32793450|NCT04524689|Experimental|Tusamitamab ravtasine + Pembrolizumab|Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
32793451|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
32793452|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + cisplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
32907149|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
32793453|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
32793454|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
32793455|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
33088276|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
32793456|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
32793457|NCT04907357|Active Comparator|rTMS|Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
32793458|NCT04907357|Sham Comparator|Sham (Placebo)|Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
32793459|NCT02119819|Experimental|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
32793460|NCT02119819|Experimental|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
32793461|NCT02119819|Experimental|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
32793462|NCT02119819|Experimental|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
32793463|NCT02119819|Experimental|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
32793464|NCT02119819|Placebo Comparator|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
32793465|NCT04766450|Active Comparator|Group 1, NAC group|Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months
32793466|NCT04766450|No Intervention|Group 2, Control group|Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.
32793467|NCT04852991|Active Comparator|Modified Purandare cervicopexy|Apical prolapse will be corrected by Modified Purandare cervicopexy
32793468|NCT04852991|Active Comparator|Abdominal sacrohysterpexy|Apical prolapse will be corrected by Abdominal sacrohysterpexy
32793469|NCT04765982|Active Comparator|patients with less than 80% time in range|Better control group
32793470|NCT04765982|Placebo Comparator|patients with more than 80% time in range|poor control group
32793471|NCT05322239|Experimental|Intermittent Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 iTBS sessions will be administered at 30 min intervals.
32793472|NCT05322239|Experimental|Continuous Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 cTBS sessions will be administered at 30 min intervals.
32793473|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
32793474|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
32793475|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
32793476|NCT05315921|Experimental|OsrhAAT 1 mg/kg IV|
32793477|NCT05315921|Experimental|OsrhAAT 3 mg/kg IV|
32793478|NCT05315921|Experimental|OsrhAAT 10 mg/kg IV|
32793479|NCT05315921|Experimental|OsrhAAT 20 mg/kg IV|
32793480|NCT05315921|Experimental|OsrhAAT 40 mg/kg IV|
32793481|NCT05315921|Experimental|OsrhAAT 60 mg/kg IV|
32793482|NCT04895033|Experimental|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
32793483|NCT04505813|Experimental|Safety Evaluation Phase|Treatment with NEXI-002 T cells, derived from PBMCs of the patient
32793484|NCT04505813|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI- 002 T cell product at the dose established from the Safety Evaluation Phase.
32793485|NCT05307107|Experimental|Intervention group (IG)|Participants are educators working in health and social care education receiving 8 work week-SHINE.
32793486|NCT05307107|No Intervention|Control group (CG)|Participants are educators working in health and social care education without the program continuing their normal daily routines receiving SHINE for their voluntary use after this study (waitlist).
32793487|NCT04840667|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.
32793488|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
33404124|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
32793489|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
32793490|NCT05306249|Experimental|CBD LGP 50 group|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
32793491|NCT05306249|Placebo Comparator|Control group|Patients will receive the MCT oil placebo without CBD until the end of week 12.
32793492|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
32793493|NCT04840121|Active Comparator|Study Group - AdhesioRT|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.
32793494|NCT04840121|Active Comparator|Control Group - Standard of Care|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.
32793495|NCT04877483|Experimental|Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
32793496|NCT04877483|Experimental|Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
32793497|NCT04877483|Other|Healthy control|Healthy control group will not received any treatment. And we could use the oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.
32793498|NCT04877483|Other|Waiting list|Group Waiting list will not received any treatment. at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
32793499|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
32793500|NCT02119663|Active Comparator|Placebo plus capecitabine|
32793501|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
32793502|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
32793503|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
32793504|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
32793505|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
32793506|NCT05327231|Experimental|IN10018 Monotherapy|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
32793507|NCT05327231|Experimental|IN10018 Combination with Docetaxel|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours. Docetaxel 75mg/m2 every 21 days a cycle.
32793508|NCT04453085|Experimental|JR-171|Until the dose determination, subjects will intravenously receive either the low dose or high dose of JR-171 (the same dose as at Week 12 of the JR-171-101 study). Thereafter, all subjects will receive the optimal dose of JR-171 determined based on the results of JR-171-101 study.
32793509|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
32793510|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
32793511|NCT04855721|Experimental|AUR101 400 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
32793512|NCT04855721|Experimental|AUR101 200 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
32793513|NCT04855721|Experimental|AUR101 400 mg PO QD|Patients will receive AUR101 / placebo in double blind, double dummy manner
32793514|NCT04855721|Placebo Comparator|Placebo|Patients will receive AUR101 / placebo in double blind, double dummy manner
32793515|NCT02193074|Experimental|nusinersen|
32793516|NCT02193074|Sham Comparator|Sham procedure|
32793517|NCT04852601|Experimental|ToolboxDetect Strategy|"All practices randomized to the intervention arm will implement the ToolboxDetect battery as the standard of care routine cognitive assessment to fulfill the Medicare Annual Wellness Visit (AWV) requirement. The 7-8 minute ToolboxDetect battery contains self-administered versions of the NIH ToolBox Picture Sequence Memory Test (PSM) and the NIH ToolBox Dimensional Change Card Sorting (DCCS). PSM measures episodic memory and DCCS tests executive functioning.~The validated ToolboxDetect application will be imparted either as an application on an iPad or on a PC desktop/laptop computer commonly found in a clinical exam room for EHR access."
32793518|NCT04852601|No Intervention|Enhanced Usual Care|"At Northwestern Medicine, cognitive assessments included in Annual Wellness Visits or other routine or sick/problem-based visits vary by practice and also by clinician. However, the choice of test was limited to either a Mini-Cog©, Montreal Cognitive Assessment (MoCA), or Mini Mental Status Exam (MMSE).~While we will not make any explicit recommendations to these practices with regard to their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to an Epic SmartData element, which will allow the clinician to record the results of the test as discrete data (which can then be queried), and that 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will also be provided to each clinic's medical leadership."
32793519|NCT05269589|Sham Comparator|Thermoneutral|Participants will immerse their feet in a foot bath with water maintained at 36°C
32793520|NCT05269589|Experimental|Heat|Participants will immerse their feet in a foot bath with water maintained at 42°C
32793521|NCT04839575|Active Comparator|Latiglutenase|IMGX003
32793522|NCT04839575|Placebo Comparator|Placebo|Placebo
32793523|NCT04418102|Experimental|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
33299935|NCT03479008|Other|Healthy volunteers (iterative device development)|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Volunteers will be randomized to receive alternating 5 minute episodes of various vibration frequencies.
32793524|NCT04418102|Active Comparator|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
32793525|NCT04848779||Cohort 1|
32793526|NCT04765592|Experimental|WeFlow-Arch Modeler Embedded Branch Stent Graft System|Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
32793527|NCT04764968|No Intervention|Usual care|During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
32793528|NCT04764968|Experimental|Dasiglucagon|During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.
32793529|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
32793530|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
32793531|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
32793532|NCT04764734|Experimental|PSG and NightOwl|During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
32793533|NCT04740151|Experimental|BEST PEEP|During OLV an individualized PEEP will be applied i.e. the one corresponding to the lower driving pressure, + 2 cmH2O
32793534|NCT04740151|Active Comparator|STANDARD PEEP|During OLV a PEEP of 5 cmH2O will be applied
32793535|NCT04745377||Control Group|Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
32793536|NCT04745377||Cancer patients|Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
32793537|NCT04739683|Active Comparator|Foley bulb|16F latex or silicone Foley catheter inflated with 30-40 cc of sterile water. The catheter will be taped to the inner thigh with gentle traction.
32793538|NCT04739683|Active Comparator|DILAPAN-S®|Synthetic hydrogel cervical dilator consists of the dilating part, the polypropylene handle, and the marker string. The dilating part is manufactured from an anisotropic xerogel of AQUACRYL.
32793539|NCT01583530|Active Comparator|Belimumab IV 240 mg|
32793540|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
32793541|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
32793542|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
32793543|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
32793544|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
32793545|NCT01639001|Experimental|Crizotinib|Crizotinib
32793546|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
32793547|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
32793548|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
32793549|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
32793550|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
32793551|NCT04443959|Experimental|PUMAS Treatment|Prenatal insomnia program that places behavioral sleep strategies within a mindfulness-based intervention framework that is geared toward pregnant women.
32793552|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
32793553|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
32793554|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
32793555|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
32793556|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
32793557|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
32793558|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
32793559|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
33404125|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
32793560|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
32793561|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
32793562|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32793563|NCT04416581|Experimental|P-CAB 50mg group|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily. Target enrollment: 1300
32793564|NCT04416581|Active Comparator|PPI group|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily. Target enrollment: 1300
32793565|NCT04827251|Other|Caffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days.
32793566|NCT04827251|Other|Decaffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume decaffeinated coffee during 28 days, followed by caffeinated coffee during more 28 days.
32793567|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
32793568|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
32793569|NCT05323955|Experimental|Experimental Group|"Trastuzumab/pertuzumab + tucatinib or T-DM1 + tucatinib~300mg of tucatinib taken orally twice a day. Taken on Days 1-21 of a 21 Day cycle (3 Weeks).~Trastuzumab/Biosimilar administered per current package insert based on site standard of care guidelines~Pertuzumab or Biosimilar administered per current package insert based on site standard of care guidelines~Trastuzumab Emtansine (T-DM1) administered per current package insert based on site standard of care guidelines"
32793570|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
32793571|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
32793572|NCT04839185|Other|Diagnostic: Ferumoxytol MRI|The subject will receive an infusion of an iron supplement, ferumoxytol, followed by a same day MRI scan and then a second MRI scan 3-5 days later.
32793573|NCT04824131|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or join an open-label extension CAB study in their area, if available.
32793574|NCT04851899|Experimental|Low dose Phaeosol group|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 440mg/day look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant
32793575|NCT04851899|Experimental|High dose Phaeosol group|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant
32793576|NCT04851899|Placebo Comparator|Placebo group|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day containing Microcellulose (look like capsule of natural stimulant)
32793577|NCT04838171||Specimen collection to support development of engineering Treg|
32793578|NCT05320367|Experimental|CBD (Group 1)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
32793579|NCT05320367|Experimental|CBD (Group 2)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
32793580|NCT05320367|Experimental|CBD (Group 3)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
32793581|NCT05320367|Experimental|CBD (Group 4)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
32793582|NCT05320367|Experimental|CBD (Group 5)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
32793583|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
32793584|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
32793585|NCT04803305|Experimental|Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment|subcutaneous injection
32793586|NCT04803305|Placebo Comparator|Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment|subcutaneous injection
32793587|NCT05237609|Experimental|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Participants will receive weekly physical therapy sessions for 20 weeks, during their usual follow-up at the day hospital. In addition to the standard treatment, muscle strengthening exercises using elastic bands of varying resistance will be performed. These sessions can be completed by a muscle strengthening session at home during the week, given by a private physiotherapist according to the indication given by a doctor taking care of the patient, during and outside the periods of follow-up at the day hospital. In addition to muscle strengthening, participants will receive a systematic protein intake via Oral Nutritional Supplements (ONS) to improve muscle strength. Compliance with these oral nutritional supplements will be monitored by means of a booklet filled in by the patient or his entourage.
32793588|NCT05237609|Active Comparator|standard rehabilitation +/- Oral Nutritional Supplements|"The participants in the control group will receive the usual care at the day hospital, i.e. a rehabilitation program focused on the prevention of falls. The prescription of ONS will be made on a case-by-case basis by the day hospital's physician. If participants require follow-up by a physiotherapist at home, sessions will be prescribed.~After the treatment, participants in the experimental group will be advised to continue the muscle strengthening sessions independently at least once a week. All participants, regardless of their group, who require follow-up by a physiotherapist will benefit from it."
32793589|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
32793590|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
32793591|NCT05236517|Experimental|Semaglutide|
32793592|NCT05236517|Placebo Comparator|Placebo|
32793593|NCT04851587|Experimental|In-Person (or Remote) Intervention Visits|Participants will initially complete a baseline assessment assessing study eligibility. The intervention includes 8 core in-person group sessions and 8 optional in-person group sessions (1.5 hours each) targeting standard weight loss and pain treatment content and eight individual phone calls (30 minutes each) focusing primarily on increasing environmental reward and positive affect. Due to COVID-19, intervention sessions may be delivered online through PHI Zoom. Group sessions will be delivered every-other week and phone calls will occur every-other week (during weeks with no group). Sessions will be administered by a study interventionist with bachelors- or masters-level training and certification in health education or a related field (e.g., Certified Health Education Specialist), and materials will be developed to be appropriate for delivery by this level of training, given the potential for greater availability of these types of health professionals.
32793594|NCT04764110|Experimental|Cyplexinol|900 mg daily (2 capsules) for 15 days
32793595|NCT04764110|Placebo Comparator|Placebo|2 capsules daily for 15 days
33299936|NCT04982146|Experimental|Bromelain + N-Acetylcysteine|Patients with pseudomyxoma peritonei that are not candidates to surgical resection
33299937|NCT04958746|Experimental|Ciprofol|Ciprofol group：0.4/0.2mg/kg
33299938|NCT04958746|Placebo Comparator|Propofol|Propofol group：2.0/1.0mg/kg
33299939|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
33299940|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
33299941|NCT05631340|Experimental|case group|Recieving additional discharge education by the researcher and supported by a booklet and mobile app
33299942|NCT05631340|Active Comparator|control group|Recieving standart hoapital discharge education
33299943|NCT03431584|Active Comparator|Infiltration of corticosteroids|
33299944|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
33299945|NCT04916392||liposomal bupivacaine|Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.
33299946|NCT00259272|Experimental|A|
33299947|NCT01239706|Experimental|NTx 265|
33299948|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
33299949|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
33299950|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
33299951|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
33299952|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
33299953|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
33299954|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
33404126|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
32793596|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in 1 nostril|Nalmefene Hydrochloride nasal spray, 3mg, 1 spray in 1 nostril
32793597|NCT05219669|Experimental|Intranasal Nalmefene 2 sprays in 1 nostril|Nalmefene Hydrochloride nasal spray, 6mg, 2 sprays in 1 nostril
32793598|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in each nostril|Nalmefene Hydrochloride nasal spray, 6mg, 1 spray in each nostril
32793599|NCT04763798|Experimental|Dominant|All subjects will receive the three stretching techniques on dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will be one week. Stretching exercises will be perform in a random order. A random-number generator will be used for randomization
32793600|NCT04763798|Active Comparator|Non dominant|All subjects will receive the three stretching techniques on non dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will bé one week. Stretching exercises will be perform in a random order. A random-number generator will bé used for randomization
32793601|NCT04837859|Experimental|Arm A age 18-60|Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score >3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.
32793602|NCT04837859|Experimental|Arm B Age 60+|Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
32793603|NCT04763252||Canadian|
32793604|NCT04392167|Experimental|a/LCI-OCT Imaging of the Esophagus|
32793605|NCT05369039|Experimental|Case Group|The case group will receive a 10 days course of Roflumilust in a dose of 500 mg once daily.
32793606|NCT05369039|Active Comparator|Control group|The Control group will receive a 10 days course of systemic steroids in the form of oral prednisolone in a dose of 40 mg per day.
32793607|NCT04851509|Active Comparator|Dynamic rotational locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance less than 25mm. The compression nut will be used to compress the fracture. The helical screw will be rotationally locked by using the 5mm hex flexible screwdriver by advancing the set screw until it stops completely. The screw will then be turned counterclockwise by a ½ turn.
32793608|NCT04851509|Experimental|Static locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The helical screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
32793609|NCT04373369|Experimental|Vorolanib + Atezolizumab|Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily. Participants can continue to receive treatment up to two years.
32793610|NCT05181761|Experimental|Left Hand with gel polish|The participants will receive gel nail polish on their left hand. The right hand will remain natural (no gel polish)
32793611|NCT05181761|Experimental|Right Hand with gel polish|The participants will receive gel nail polish on their right hand. The left hand will remain natural (no gel polish).
32793612|NCT04285853|Experimental|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
32793613|NCT04285853|Placebo Comparator|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
32793614|NCT04791059|Experimental|Combined analgesia group|Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
33088277|NCT04708964|Active Comparator|Flurbiprofen|5 ml of flurbiprofen solution 0.25% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
32793615|NCT04791059|Placebo Comparator|Control group|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
32793616|NCT05405855|Experimental|Experimental Group|"The eLIFEwithIBD intervention is an ACT, mindfulness and compassion eHealth intervention for people with inflammatory bowel disease (IBD). The eLIFEwithIBD intervention is delivered through 9 sessions available on an online platform throughout a 9-week period. Each session is composed of real-image videos, texts with illustrative images, exercises in editable text format, and audio files with the experiential exercises and practices targeting topics such as acceptance, mindfulness, compassion, and gratitude.~Participants in this group also continue to receive a standard, personalised treatment for IBD."
32793617|NCT05405855|No Intervention|Control Group|Treatment as Usual (TAU) - Standard, personalised treatment for inflammatory bowel disease.
32793618|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
32793619|NCT05402657|Experimental|Frontoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with a frontoparietal placement of ECT electrodes.
32793620|NCT05402657|Active Comparator|Temporoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with the conventional temporoparietal placement of ECT electrodes.
32793621|NCT05402111|Experimental|SEP-363856|
32793622|NCT05402111|Active Comparator|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
32793623|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
32793624|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
32793625|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
32793626|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
32793627|NCT05369117|Experimental|indocyanine green labeled fluorescent laparoscopy|The experimental group was marked with indocyanine green, while the control group was not marked with indocyanine green
32793628|NCT05369117|Experimental|The pathological staging|They were grouped by different pathological stages
32793629|NCT04766099|No Intervention|Standard Treatment|Standard bedside coaching by labor and delivery staff
32793630|NCT04766099|Experimental|Educational Video|Patients will watch the provided coaching video in addition to standard bedside coaching by labor and delivery staff
32793631|NCT05399069|Experimental|VGR-R01|Subretinal injection of VGR-R01
32793632|NCT05398913|Placebo Comparator|Placebo|Two pills of placebo will be administered for 5 consecutive days, once per day.
32793633|NCT05398913|Active Comparator|Rimonabant 2.5 mg|One pill of placebo and one pill of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
32793634|NCT05398913|Active Comparator|Rimonabant 5 mg|Two pills of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
32793635|NCT05154305|Experimental|Children 6 months post acute treatment|children and adolescents between 6 months and 8 years post acute cancer treatment
32793636|NCT04260347||Patients >80 years after approval|
32793637|NCT04260347||Patients >80 years before approval|
32793638|NCT04256837|Experimental|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
32793639|NCT04256837|Sham Comparator|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
32793640|NCT04256837|Experimental|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
32793641|NCT04256837|Sham Comparator|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
32793642|NCT05396729|Experimental|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes
32793643|NCT05396729|No Intervention|Control|Electrodes are placed at acupoints but no electrical stimulation is given
32793644|NCT05393219|Experimental|Cardiac Biofeedback|Relaxing breathing exercise coupled with cardiac biofeedback
32793645|NCT05393219|Experimental|Mindfulness|Mindfulness guided through a video tape
32793646|NCT05393219|Experimental|Inner resource mobilization|Resources and inner strength mobilization guided through a video tape
32793647|NCT05393219|Sham Comparator|Control|Standardized video tape
32793648|NCT05118503|Active Comparator|Customized education app|A customized URL-based platform will present brief education videos addressing a patients stroke etiology, risk factors, stroke prevention medications, and post-stroke lifestyle issues. This URL will be made available to the patient and caregiver.
32793649|NCT05118503|Placebo Comparator|Standard of care discharge education|Standard discharge education is performed by the bedside nurse at the time of hospital discharge.
32793650|NCT04738799|Experimental|Carbohydrate-Last Meal Sequence, Then Carbohydrate-First Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals last during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals first during mealtimes for the following 6 days.
32793651|NCT04738799|Experimental|Carbohydrate-First Meal Sequence, Then Carbohydrate-Last Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals first during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals last during mealtimes for the following 6 days.
32793652|NCT04737239||Patient with CTS/Mild EMG|
32793653|NCT04737239||Patient with CTS/Negative EMG|
32793654|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
32793655|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
32793656|NCT01583374|Placebo Comparator|Placebo|Identically matched placebo tablets were taken orally twice a day
32793657|NCT05390567||Standard of Care in-clinic Pap-Test|Participant cervical cancer screening method of choice: Standard of Care Pap-Test
32793658|NCT05390567||HPV Self-Test|Participant cervical cancer screening method of choice: HPV Self-Test
32793659|NCT04251377|Experimental|Single-stage surgery + DAC® + topical antibiotics|Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
32793660|NCT04251377|No Intervention|control group : two-stage surgery|Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
32793661|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
32793662|NCT04245215|Placebo Comparator|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
32793663|NCT04245215|Active Comparator|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
32737891|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
32793664|NCT05387759|Experimental|Treatment Sequence 1|Healthy participants will receive single oral dose of Aticaprant (Dose 1) (Treatment A) in Treatment Period 1, followed by Moxifloxacin (Dose 2) (Treatment D) in Treatment Period 2, followed by Aticaprant (Dose 3) (Treatment B) in Treatment Period 3 and then placebo (Treatment C) in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
32793665|NCT05387759|Experimental|Treatment Sequence 2|Healthy participants will receive single oral dose of Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 and then Treatment D in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
32793666|NCT05387759|Experimental|Treatment Sequence 3|Healthy participants will receive single oral dose of Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3 and then Treatment A in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
32793667|NCT05387759|Experimental|Treatment Sequence 4|Healthy participants will receive single oral dose of Treatment D in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 and then Treatment B in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7 to 15 days between each treatment period.
32793668|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
32793669|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
32793670|NCT04724915|Experimental|Robot-assisted TKA|Patients undergoing TKA with the assistance of robot technology.
32793671|NCT04724915|Active Comparator|Conventional TKA|Patients undergoing TKA with manual instrumentarium
32793672|NCT04721015|Experimental|Part 1: ABBV-637 Monotherapy|Participants will receive escalating doses of ABBV-637 in 28-day cycles.
32793673|NCT04721015|Experimental|Part 2a: ABBV-637 + Docetaxel|Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.
32793674|NCT04721015|Experimental|Part 2b: ABBV-637 + Docetaxel|Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.
32793675|NCT04721015|Experimental|Part 3a: ABBV-637 + Osimertinib|Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.
32793676|NCT04721015|Experimental|Part 3b: ABBV-637 + Osimertinib|Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.
32793677|NCT05386745|Experimental|Intervention|An online, asynchronous, self-paced, 10-week long, physical activity intervention.
32793678|NCT05386745|No Intervention|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 10 weeks following all measurements.
32793679|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
32793680|NCT04823585|Placebo Comparator|subcutaneous injections of placebo|Subcutaneous injections of placebo (physiological sodium chloride solution) once per month for 16 weeks. A total of 4 injections.
32793681|NCT04823585|Experimental|subcutaneous injections of Mepolizumab 100 mg|Subcutaneous injections of Mepolizumab 100 mg once per month for 16 weeks. A total of 4 injections.
32793682|NCT04165577|Experimental|OCD, Active TMS|Participants with OCD who receive active rTMS
32793683|NCT04165577|Sham Comparator|OCD, Sham TMS|Participants with OCD who receive sham rTMS
32793684|NCT04165577|Other|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
32793685|NCT04165577|Other|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
32793686|NCT04165577|Other|Healthy Control, Active TMS (1 session)|Healthy control participants who receive 1 session of active, open-label rTMS
32793687|NCT04165577|Other|Healthy Control, Active TMS (3 sessions)|Healthy control participants who receive 3 sessions of active, open-label rTMS
32793688|NCT04165577|Other|OCD, Active TMS (3 session)|Participants with OCD who receive 3 sessions of active, open-label rTMS
32793689|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
32793690|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
32793691|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
32793692|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
32793693|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
32940198|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
32793694|NCT04836767||people with a history of COVID-19|"COVID-19 Group Inclusion Criteria~Having been diagnosed with COVID-19 at least 12 weeks ago,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research,~To be clinically stable, to be under control if any accompanying comorbid conditions (such as hypertension, diabetes),~Not having any orthopedic and neurological problems that might interfere with evaluating peripheral muscle strength, balance and exercise capacity.~COVID-19 Group Exclusion Criteria~Those with an ICU hospitalization history due to the diagnosis of COVID-19,~Recent myocardial infarction and pulmonary embolism.~Having accompanying chronic diseases,~Those who have any orthopedic or neurological disorders that will prevent walking,~Another COVID-19 PCR Test positivity in the last 12 weeks,~Not being able to cooperate and adapt to exercise test due to neurological influences such as cerebrovascular disease or psychiatric disorders,"
32793695|NCT04836767||healthy people|"Healthy Group Inclusion Criteria~Not having COVID-19,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research. The Criteria for Not Including the Healthy Group in the Study~Those who have any orthopedic or neuromuscular disorders that will prevent walking,~Having any chronic illness or psychiatric conditions or mental afflictions that may interfere with cooperation or compliance with exercise tests."
32793696|NCT04836689|Other|30 breaths per minutes|Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2
32793697|NCT04836689|Other|10 breaths per minute|Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2
32793698|NCT04809467|Experimental|tafasitamab + parsaclisib|"Participants will be assigned to disease specific cohorts based on the histology of their underlying disease.~Cohort 1: R/R DLBCL Cohort 2: R/R MCL Cohort 3: R/R FL Cohort 4: R/R MZL Cohort 5: R/R CLL/SLL"
32793699|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
32793700|NCT04216589|Experimental|Semaglutide|All participants will receive a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
32793701|NCT04821401|Experimental|Males study product|25 men will be randomized to Rejuvant
32793702|NCT04821401|Placebo Comparator|Males placebo|25 man will be randomized to placebo
32793703|NCT04821401|Experimental|Females study product|25 women will be randomized to Rejuvant
32793704|NCT04821401|Placebo Comparator|Females placebo|25 women will be randomized to placebo
32793705|NCT05226143|Experimental|Gel Cream|Participants will be provided with the Gel Cream to apply on clean, dry face (facial skin) once per day and on the target lesion on the face or body at least 2 times per day or more as needed, in the morning and at night for 14 days.
32793706|NCT04809311||Lifestyle intervention ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician.
32793707|NCT04809311||Other oral antidiabetic drugs (OADs) ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
32793708|NCT04809311||Basal insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
32793709|NCT04809311||Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
32793710|NCT04809311||Basal + Bolus or premixed insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
32793711|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
32793712|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
32793713|NCT04145219|Experimental|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
32793714|NCT04145219|Placebo Comparator|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
32793715|NCT03259763|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
32793716|NCT03259763|Active Comparator|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
32793717|NCT04808921|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
32793718|NCT05164991|Experimental|MR imaging|The experiment is aimed to induce a virtual rubber hand illusion, in which the individuals can potentially experience an embodiment illusion
32793719|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
32793720|NCT05652881|No Intervention|Standard of care|Standard of care treatment for axially unstable tibial pilon fracture will include temporary external fixation followed by delayed definitive fixation. Arthrocentesis of the injured and uninjured ankles will be performed at the time of initial temporary external fixation and again at the time of definitive fixation.
32793721|NCT05652881|Experimental|Intervention|Additional intra-articular joint lavage with 1L normal saline will be performed at the time of initial temporary external fixation in addition to standard of care treatment.
32793722|NCT04107935|Experimental|Intervention|
32793723|NCT04107935|Other|Usual Care|
33088278|NCT04708964|Placebo Comparator|Placebo|5 ml of saline solution 0.9% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
33088279|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
32793724|NCT05652803|Experimental|bibliotherapy-based psychoeducation program|In the bibliotherapy-based psychoeducation program sessions, techniques such as information and discussion based on the bibliotherapy method were included. Brief information will be given for 5-10 minutes in each session. At the end of the sessions, exercises will be given to reinforce the knowledge and skills acquired by the group members in the sessions and to transfer them to daily life, and the sessions will be concluded.
32793725|NCT05652803|Experimental|Psychoeducation Program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
32793726|NCT03184571|Experimental|Bemcentinib + pembrolizumab|"Cohort A enrols participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort B enrolls participants who received a maximum of one prior line of an anti-PD-(L)1 therapy (monotherapy) to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort C enrolls participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.~Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks."
32793727|NCT04107857||Smoking Cessation|"Patients enter the program through clinic appointments or community outreach programs.~Patients will be given brief advice to quit smoking and referral options to receive evidence-based treatment through Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov dependent on the patient's preference for counseling~Patient can also be prescribed smoking cessation pharmacotherapy"
32793728|NCT04102865|Other|single use NPWT dressing|single use NPWT dressing
32793729|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
33299955|NCT04899856|Other|Control / Crossover to TransAeris Therapy|"The Control group will be treated per standard hospital policy following electrode implant. If the participant is not liberated from mechanical ventilation after 120 hours (5 days), the participant will begin using TransAeris therapy. The participant will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
33299956|NCT04899856|Experimental|Treatment with TransAeris Therapy|"The Treatment group will start TranAeris therapy shortly after arrival in the Intensive Care Unit (ICU). Participants will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
32793730|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
32793731|NCT03132155|Experimental|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
32793732|NCT05216861|Experimental|Experimental|The rehabilitation coordinators are trained in the intervention (0,5 day).
32793733|NCT05216861|Active Comparator|Active comparator|the rehabilitation coordinators participate in a 1 hour lectur including a brief overview about work ability. Thereafter, they provide care-as-usual (collaboration) to patients and employer.
32793734|NCT03107195||Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
32793735|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
32793736|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33299957|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
33299958|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
33299959|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
33299960|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
33299961|NCT05135806||Group 1|Remote evaluation first: participants will undergo a comprehensive neuropsychological assessment administered remotely via telephone calls or videoconferencing. Each participant will take part to the second evaluation (face-to-face) 8 weeks later.
33299962|NCT05135806||Group 2|Face-to-face evaluation first: participants will undergo a comprehensive neuropsychological assessment administered face-to-face. Each participant will take part to the second evaluation (remotely via telephone calls or videoconferencing) 8 weeks later.
33299963|NCT01250782|Placebo Comparator|Physiological Serum|
33299964|NCT01250782|Active Comparator|Glutamine|
33299965|NCT03913624|Experimental|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
32793737|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).~Cetuximab:~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window~RT:~6930 cGy IMRT starting D15-D18"
32793738|NCT04073225|Experimental|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
32793739|NCT04073225|Active Comparator|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
32793740|NCT03104543|Experimental|Education|Educational materials
32793741|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
32793742|NCT04060277|Experimental|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
32793743|NCT04060277|Active Comparator|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
32793744|NCT04794569|Experimental|Tinzaparin|initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months
32793745|NCT04794569|Active Comparator|Rivaroxaban|Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months
32793746|NCT04049981|Experimental|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
32793747|NCT04049981|Experimental|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
32793748|NCT05652179|Experimental|Stellate ganglion block|
32793749|NCT05652179|No Intervention|Control|
32793750|NCT05652101||Patients suffering from hereditary hyperekplexia, above 2 years of age|"40 patients suffering from hereditary hyperekplexia will be included. The investigators study patients suffering from hereditary hyperekplexia. The diagnostic is clinical, based on the following symptoms, appearing shortly after birth: stiffness, exaggerating response startles to unexpected stimuli, generalized stiffness after the startles.~Children above 2 years old and adults are included, so the neurodevelopment can be evaluated."
32793751|NCT05290259||Ballroom Basics for Balance Program|The Ballroom Basics for Balance program is a 12-week physical activity program which uses dance to focus on balance for community dwelling adults.
32793752|NCT04818125|Other|Patients with breast cancer|
32793753|NCT05651789|Experimental|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
32793754|NCT05651789|Active Comparator|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
32793755|NCT05651633|Experimental|Lidocaine ear drops with usual care|usual care: oral analgesic with/without antibiotics
32793756|NCT05651633|No Intervention|usual care|usual care: oral analgesic with/without antibiotics
32793757|NCT05651477||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
32793758|NCT05651477||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
32793759|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 15 weeks"
32793760|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 14 weeks"
32793761|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
32793762|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
32793763|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
32793764|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
32793765|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
32793766|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
32793767|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
32793768|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
32793769|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
32793770|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
32793771|NCT04807517|Experimental|Buspirone|Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
32793772|NCT05287529|Experimental|8-Week Yoga Class|Randomized to immediately begin an 8-week Yoga Class via Telehealth
32793773|NCT05287529|Active Comparator|Waitlisted for 8-Week Yoga Class|Randomized to start an 8-week Yoga Class via Telehealth 8-weeks from the start of the study.
32793774|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
32793775|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
32793776|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
32793777|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
32793778|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
33299966|NCT03913624|Experimental|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
33299967|NCT03913624|No Intervention|Control group|Conventional treatment
33299968|NCT05153122|Experimental|Investigational SenseGuard Device|Patients undergo SG monitoring at least twice daily before and after receiving treatment.
33299969|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
33299970|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
33299971|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
33299972|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
33299973|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
33299974|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
33299975|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
33299976|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
33299977|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
33299978|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
33299979|NCT04877314|Experimental|Intermittent fasting|
33299980|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
33299981|NCT01247896|Experimental|Active|
33299982|NCT01247896|Placebo Comparator|Placebo|
33299983|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
32793779|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
32793780|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
32793781|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
32940199|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
33299984|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
32793782|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
33299985|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
33299986|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
32793783|NCT04793633|Experimental|LINFU™ to increase sensitivity of pancreatic juice cytology|LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
32793784|NCT04793555|Experimental|Experimental_Arm|Assessment of behavior during day and night by unobtrusive sensors
32793785|NCT04792697|Experimental|Advance/Extend Manipulation|"For ~2 weeks, Advance/Extend participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days will be instructed to:~Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)~Increase morning bright light exposure via bright light goggles (30 min after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
32793786|NCT04792697|Active Comparator|Control|Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 13 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments, thereby controlling for effort.
32793787|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
33299987|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
33299988|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
32793788|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
32793789|NCT04792151||PHP Youth|Youth ages 6-17 receiving standard of care treatment (i.e., transdiagnostic intervention for emotional disorders) in a partial hospitalization program
33299989|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
33299990|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
33299991|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
33299992|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
33299993|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
33299994|NCT03913312|Experimental|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC>1.5*107/kg), d0.
33299995|NCT03913546|Sham Comparator|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
33299996|NCT03913546|Experimental|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
33299997|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
32793790|NCT02221934|Experimental|Signal more likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
33088280|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
33299998|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
33299999|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
33300000|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
33300001|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
33300002|NCT01248286|Experimental|Whole grain rice|
33300003|NCT01248286|Active Comparator|Refined grain rice|
33300004|NCT04744480|Experimental|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
33300005|NCT04744480|No Intervention|The routine induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group，all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.
33300006|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
32793791|NCT02221934|Active Comparator|Signal less likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
32793792|NCT04013555|Experimental|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
32793793|NCT04013555|Placebo Comparator|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
32793794|NCT04190030|Experimental|Mindfulness|
32793795|NCT04190030|Active Comparator|Cognitive reappraisal|
32793796|NCT04791839|Experimental|Cohort A: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort A participants are those that have PD-L1 1-49%"
32793797|NCT04791839|Experimental|Cohort B: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort B participants are those that have PD-L1 ≥ 50%."
32793798|NCT03991949|Experimental|Experimental Infant Formula|Ready-to-feed, milk-based formula
33300007|NCT03913780|Active Comparator|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
33300008|NCT03913780|Experimental|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
33404127|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
33404128|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
33300009|NCT03913780|Experimental|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
33404129|NCT02335996|Active Comparator|patients with active hypercortisolism|
32793802|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
32793803|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
33404130|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
32793804|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
32793805|NCT02792075||OCT|Patients with Optical coherence tomography
32793806|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
32793807|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
32793808|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
32793809|NCT02220920|Placebo Comparator|Placebo＋insulin|
32793810|NCT03966053|Experimental|Cohort A|"Cohort A: Three subjects will receive Trifluoperazine (TFP) 1 mg PO daily.~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort B will start.~If 1/3 subjects in Cohort A demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort A.~If 2 or more of the 6 subjects in Cohort A demonstrate toxicity Grade 3, the trial will be stopped; no MTD will be declared.~If less than 2 of the 6 subjects in Cohort A demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort B will start."
33088281|NCT00300612|Experimental|vaccine group|
33088282|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
33088283|NCT00294918|Experimental|Serostim® (1 mg)|
33088284|NCT00294918|Experimental|Serostim® (2 mg)|
33088285|NCT00294918|Experimental|Serostim® (4 mg)|
33404131|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
33404132|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
33404133|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
33404134|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
33404135|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
32793811|NCT03966053|Experimental|Cohort B|"Cohort B: Three subjects will receive TFP 2 mg PO daily.~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort C will start.~If 1/3 subjects in Cohort B demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort B:~If 2 or more of the 6 subjects in Cohort B demonstrate toxicity Grade 3, the study will be stopped, and 1 mg/day will be declared the MTD.~If < 2 of the 6 subjects in Cohort B demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort C will start."
32793812|NCT03966053|Experimental|Cohort C|"Cohort C: Three subjects will receive TFP 5 mg PO daily.~If there is no non-neurologic toxicity ≥ Grade 3 at the end of the 21 days, Cohort D will start.~If 1/3 subjects in Cohort C demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort C:~If 2 or more of the 6 subjects in Cohort C demonstrate toxicity Grade 3, the study will be stopped, and 2 mg/day will be declared the MTD.~If < 2 of the 6 subjects in Cohort C demonstrate toxicity Grade 3 within 21 days of starting therapy, cohort D will start."
32793813|NCT03966053|Experimental|Cohort D|"Cohort D: Three subjects will receive TFP 10 mg PO daily.~If 0/3 subjects in Cohort D demonstrates toxicity Grade 3, the study will be stopped, and 10 mg/day will be declared the MTD.~If 1/3 subjects in Cohort D demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort D.~If 2 or more of the 6 subjects in Cohort D demonstrate toxicity Grade 3, the study will be stopped, and 5 mg/day will be declared the MTD.~If <2 of the 6 subjects in Cohort D demonstrate toxicity > Grade 3 within 21 days of starting therapy, 10mg/day will be declared the MTD."
32793814|NCT05204693|Sham Comparator|Start with: Concentric (normal) cycling|
32793815|NCT05204693|Experimental|Start with: Eccentric cycling|
33088286|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
32793816|NCT05647889|Experimental|Jet lidocaine group|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
32793817|NCT05647889|Experimental|Ice group|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
32793818|NCT05647889|Active Comparator|Control group|Standard PVC procedure will be applied
32793819|NCT03946631||Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
32793820|NCT05203133|Experimental|Baseline Assessment (Days -5 to -1)|Participants will complete a a 5-day baseline assessment in which habitual energy intake (remote food photography method) and exercise energy expenditure will be monitored.
32793821|NCT05203133|Experimental|Energy Balance (Days 1 to 5)|Participants will be provided with all food intake for five days, to provide an energy intake of 54 kcal/kg FFM/day. On days 1, 3 and 5, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy balance (energy availability = 45 kcal/kg of FFM/day, required for weight maintenance.
32793822|NCT05203133|Experimental|Energy Deficit (Days 6-11)|Participants will be provided with all food intake for five days, to provide an energy intake of 19 kcal/kg FFM/day. On days 6, 8 and 10, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy deficit (energy availability = 10 kcal/kg of FFM/day) resulting in ~2.5 kg of weight-loss.
32793823|NCT04791293||Group 1|Patients with postoperative complications
32793824|NCT04791293||Group 2|Patients without postoperative complications
32793825|NCT03943901|Experimental|Split Dose R-CHOP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for 6 cycles~Day 1 (A part of cycle)~Rituximab 375 mg/m2 IV (or biosimilars Ruxience or Truxima)~Cyclophosphamide 375 mg/m2 IV~Doxorubicin 25 mg/m2 IV~Vincristine 1 mg IV~Prednisone 50 mg (Days 1-5) PO~Pegfilgrastim (supportive care) 6 mg on Day 2 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor.~Day 15 (B part of cycle)~Cyclophosphamide 375 mg/m2 IV~Doxorubicin 25 mg/m2 IV~Vincristine 1 mg IV~Prednisone 50 mg (Days 15-19) PO~Pegfilgrastim (supportive care) 6 mg on Day 16 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor."
33300010|NCT01147432|Experimental|PF-04427429|
32793827|NCT05199467|Experimental|Health Coaching|Receipt of up to 12 sessions of health coaching, plus printed materials providing information on VA benefits
33088287|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
32793828|NCT05199467|Active Comparator|VA Benefits Information|Receipt of printed materials providing information on VA benefits
33088288|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
32793829|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
32793830|NCT02710721|Active Comparator|Control|mediterranean diet
32793831|NCT03903107|Placebo Comparator|Conventional Conduction System Pacing(CSP) using fluoroscopy|Subjects in this arm will receive Conduction System Pacing(CSP) using conventional fluoroscopy technique.
32793832|NCT03903107|Experimental|Fluoroless Conduction System Pacing(CSP) utilizing EAM with the CARTO 3 mapping system|Subjects in this arm will receive Conduction System Pacing(CSP) utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure.
32793833|NCT02710253|Experimental|Treatment (SBRT or EBRT)|Patients undergo either 4, 5, or 10 fractions of SBRT, or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
33088289|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
33300011|NCT01147432|Placebo Comparator|Placebo|
32793834|NCT02696993|Experimental|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
32793835|NCT02696993|Experimental|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
32793836|NCT02696993|Experimental|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
32793837|NCT02696993|Experimental|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
32793838|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
32793839|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
32793840|NCT04805333|Experimental|Dose 1 - 450mg Artemisia annua|Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).
32793841|NCT04805333|Experimental|Dose 2 - 900mg Artemisia annua|Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).
32793842|NCT04805333|Experimental|Dose 3 - 1350mg Artemisia annua|Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).
32793843|NCT04805333|Experimental|Dose 5 - 1800mg Artemisia annua|Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).
32793844|NCT04805333|Experimental|Dose Expansion - Recommended Phase II Dose|This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).
32793845|NCT05627219|Experimental|Supportive care (training, education, discussion)|"AIM 1: Peer genetic coaches undergo training and education on study.~AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study."
32793846|NCT05593445|Experimental|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
32793847|NCT05593445|Placebo Comparator|Vehicle Cream|Vehicle cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
32793848|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 1|sapanisertib 3 mg once daily (QD)
32793849|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 2|sapanisertib 2 mg twice daily (BID)
32793850|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 1|sapanisertib 3 mg QD
32793851|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 2|sapanisertib 2 mg BID
32793852|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
32793853|NCT04790279|Experimental|Amlodipine|
32793854|NCT04790279|Active Comparator|Nifedipine ER|
32793855|NCT05577845|Experimental|Ramosetron|
32793856|NCT05577845|Active Comparator|Loperamide|
32793857|NCT04418843|Experimental|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
32793858|NCT04418843|Experimental|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
32793859|NCT02610023||Observational (Willett FFQ, Fred Hutchinson FFQ, CCAT)|After consenting to participate in this study, participants will visit the Clinical Research Center (CRC) on 3 occasions. One of the three FFQ's will be completed at each visit and there will be 4 to 6 weeks between visits. Participants will also complete a blood draw and assessment of skin carotenoids at this CRC visit. Prior to each visit, participants will complete a 3-day diet record, a daily sun exposure diary, and a 3-day activity record.
32793860|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
32793861|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
32793862|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
32793863|NCT04194047||RBC group|Patients who received RBC transfusion
33300012|NCT01147432|Active Comparator|EMLA|
32793864|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
32793865|NCT04194047||control group|Patients not receiving RBC nor crystalloids
32793866|NCT02530463|Experimental|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
32793867|NCT02530463|Experimental|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
32793868|NCT02530463|Experimental|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
32940200|NCT00835328|Experimental|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
33088290|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
33300013|NCT03916510|Experimental|Dosing schedules 1 to 6|"Dosing Group 1:~- Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp)~Dosing Group 2:~Loading dose pre CRT - 1x10^12 vp~Maintenance dose post CRT - 1x10^12vp~Dosing Group 3:~Loading dose pre CRT - 1x10^12vp~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 1x10^12vp~Maintenance dose post CRT - 1x10^12vp~Dosing Group 4:~- Loading dose pre CRT - 3x10^12vp~Dosing Group 5:~Loading doses pre CRT - 3x10^12vp~Maintenance dose post CRT - 3x10^12vp~Dosing Group 6:~Loading dose pre CRT - 3x10^12vp~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10^12vp~Maintenance post CRT - 3x10^12vp"
33300014|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
33300015|NCT01147510|Experimental|Combination of low ICS and montelukast|
33300016|NCT03916432|Experimental|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
33300017|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
33300018|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
33300019|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
33300020|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
33300021|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
33300022|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
33300023|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
33300024|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
33300025|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
33300026|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
33300027|NCT03915808|Experimental|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
33300028|NCT03915808|Placebo Comparator|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
33300029|NCT03915730|Experimental|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
33300030|NCT03915730|Experimental|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
33300031|NCT03915730|No Intervention|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
33300032|NCT03915730|No Intervention|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
33300033|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
33300034|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
33300035|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
33300036|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
33300037|NCT03908710|Other|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
33300038|NCT03915886|Experimental|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
33300039|NCT03915886|Experimental|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
33300040|NCT03915886|Experimental|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
33300041|NCT01253434|Experimental|1|
33300042|NCT01253434|Experimental|2|
33300043|NCT01253434|Experimental|3|
33300044|NCT01253434|Experimental|4|
33300045|NCT01253434|Experimental|5|
33300046|NCT03916120||Postoperative Analgesic Failure|
33300047|NCT03916120||Postoperative Analgesic Success|
33404136|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
33088291|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
33088292|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
33088293|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
33088294|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
33088295|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
33088296|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
33088297|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
33088298|NCT00300846|Active Comparator|A1|
33300048|NCT03908164|Experimental|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
33088299|NCT00300846|Placebo Comparator|A2|
33088300|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
33088301|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
33300049|NCT03908164|Experimental|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
33300050|NCT03908164|Experimental|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
33088302|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
33300051|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
33300052|NCT01147120|Active Comparator|Clinical Massage Therapy|
33300053|NCT03908242|Experimental|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
33300054|NCT03908242|Placebo Comparator|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
33300055|NCT00230178|Experimental|Arm A|Rasburicase alone given as a single agent for 5 days
33300056|NCT00230178|Experimental|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
33300057|NCT00230178|Active Comparator|Arm C|Oral allopurinol alone given as a single agent for 5 days
33300058|NCT03908008|Active Comparator|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
33300059|NCT03908008|Experimental|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
33300060|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
33300061|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
33300062|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
33300063|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
33300064|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33300065|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
33088303|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
33088304|NCT00295191|Active Comparator|1|high-flux dialyser
33300066|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
33300067|NCT03912922|Experimental|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
33088305|NCT00295191|Active Comparator|2|low-flux dialyser
33088306|NCT00295191|Active Comparator|3|conventional dialysate
33088307|NCT00295191|Active Comparator|4|ultrapure dialysate
33088308|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
33088309|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
33088310|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
33088311|NCT00295308|Experimental|Arm 1|
33088312|NCT00295308|Placebo Comparator|Arm 2|
33088313|NCT00265967|Experimental|1|Irbesartan
33088314|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
33088315|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
33088316|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
33088317|NCT00415805|Experimental|1|
33088318|NCT00415805|Active Comparator|2|
33088319|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
33088320|NCT00266240|Experimental|1|
33088321|NCT00266240|Experimental|2|
33088322|NCT00266240|Experimental|3|
32793869|NCT02530463|Experimental|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32793870|NCT02530463|Experimental|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32793871|NCT02530463|Experimental|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32793872|NCT05554679|Active Comparator|group A|obese pregnant women who take metformin
32793873|NCT05554679|No Intervention|group B|obese pregnant women who take no metformin
32793874|NCT05494619|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.
32793875|NCT05494619|Placebo Comparator|Placebo|Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.
33088323|NCT00266240|Experimental|4|
32793876|NCT03826043|Experimental|Experimental arm|Hospitalized patient
32793877|NCT05474495|Experimental|Pelvic floor muscle training|Experimental Group (Group A) will receive pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
32793878|NCT05474495|Active Comparator|Transverse abdominas strength training|Active Comparator (Group B) will receive transverse abdominas strength training. Treatment will be given 5 days a week and continued for 6 weeks.
32793879|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
32793880|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
32793881|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
32793882|NCT04789733|Experimental|Tight pressure management|"Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
32793883|NCT04789733|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
32793884|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
32793885|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
32793886|NCT05355155|Experimental|Bevacizumab combine with FOLFOX4|"Bevacizumab biosimilar：7.5mg/kg，IV，D1，Q2W FOLFOX4：~Oxaliplatin: 85 mg/m2 , IV, D1，Q2W~Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W~Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W Treatment will continue until disease progression, an unacceptable toxicity, or the patient voluntarily discontinues the study, whichever comes first."
32793887|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
32793888|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
32793889|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
32793890|NCT04815317|Active Comparator|Basal|"The impact of these stimulations will be compared to that of a control stimulus.~The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.~The sensitive control condition will be achieved by administering fresh air on the calf.~An pressure support (+5) increment will be performed to ensure comparability of subsequent experimental sequences and their effect on dyspnea."
33088324|NCT00266240|Placebo Comparator|5|
33088325|NCT00295542|Active Comparator|1|Treatment on awakening
33088326|NCT00295542|Active Comparator|2|Treatment at bedtime
33088327|NCT04719026||Cases|Patients for the case study group will be recruited from those hospitalized for acute myocardial infarction on the Cardiology Ward and Coronary Care Unit at Aberdeen Royal Infirmary. All patients will be diagnosed using current clinical criteria for type-1 myocardial infarction according to the ESC guidelines10 and recruited within 3 days of admission. Recruitment of this arm is now complete.
33088328|NCT04719026||Controls|A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
33088329|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
32793891|NCT04815317|Experimental|Intervention|"Patients will be subjected to sensory stimuli that may be auditory or sensitive.~The sensory stimulations will be administered by a research nurse. The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.~Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes."
32793892|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32793893|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32793894|NCT02321501|Experimental|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32793895|NCT04815083|Placebo Comparator|Standard of Care Arm|Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.
32793896|NCT04815083|Experimental|PD G 506 A + Fluorescence-Guided Resection Arm|Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
32793897|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
33404137|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
32793898|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
33088330|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
33088331|NCT04719299|Experimental|smart phone application|Behavior modification of patients will be done by showing them smartphone application game. The game demonstrates the use of common dental equipment like mirrors, ultrasonic scalers, handpieces and suction tips, etc. in the form of animated pictures with visual and sound effects. The dentist will play the game to show the child the dental procedure that will be performed on him later.
32793899|NCT04104646|Experimental|CHF6563|Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
33088332|NCT04719299|Active Comparator|traditional behavior management technique|Using traditional behavior management techniques (Tell-Show-Do) which will be applied prior to local anesthesia administration
32793900|NCT04104646|Active Comparator|Morphine|Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.
33088333|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
32793901|NCT05271929|Active Comparator|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~Casirivimab~Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~Imdevimab~Sotrovimab (Xevudy)~Tixagevimab / Cilgavimab (Evusheld)~Molnupiravir (MK-4482)~Nirmatrevlir / Ritonavir (Paxlovid)~Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
33088334|NCT00266786|Placebo Comparator|Intranasal Placebo|
33088335|NCT00295815|Experimental|A|
33088336|NCT00295815|Active Comparator|B|
33088337|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
33088338|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
33088339|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
33088340|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
33088341|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
33088342|NCT00296049|Active Comparator|vancomycin|
33088343|NCT00296049|Experimental|daptomycin|
33088344|NCT04718649|Experimental|Celebrex + Joins|"The experimental group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and Joins (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only Joins (taken 3 times a day) at week 12. They will only take Joins for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
33088345|NCT04718649|Placebo Comparator|Celebrex + Placebo|"The control group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and placebo (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only placebo (taken 3 times a day) at week 12. They will only take Joins placebo for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
33088346|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
33088347|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
33088348|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
33404138|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
32793902|NCT05271929|Experimental|Current standard of care and convalescent plasma|Current standard of care and the infusion of two plasma units collected from two different COVID-19 convalescent patients.
32793903|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
33300068|NCT03912922|Experimental|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
33300069|NCT03912922|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
32793904|NCT05428397||Contrast enhanced X-ray based examination with Ultravist|Patients who received a contrast enhanced X-ray based examination with Ultravist for various clinical reasons and having experienced a hypersensitivity reaction.
32793905|NCT05428397||Control group|Patient who received contrast enhanced X-ray based examination with Ultravist for various indications who had not adverse event.
32793906|NCT04853056|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the peripheral IV line insertion
32793907|NCT04853056|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be inserted peripheral IV line
32793908|NCT04853056|No Intervention|Control group|Standart care
32793909|NCT05418647|Experimental|high dialysate Na|They will receive high dialysate sodium (Na = 141 mmol/L) for 8 weeks.
32793910|NCT05418647|Experimental|low dialysate Na|They will receive low dialysate sodium (Na = 136 mmol/L) for 8 weeks.
32793911|NCT04814615|Experimental|CD38-positive multiple myeloma|Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
32793912|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32793913|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32793914|NCT03799991|Experimental|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
32793915|NCT03799991|Active Comparator|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
32793916|NCT04814537|Experimental|Dural Puncture Epidural Technique|Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
32793917|NCT04814537|Active Comparator|Epidural Technique|Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
32793918|NCT01582282|Placebo Comparator|placebo|matched placebo BID
32793919|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
33300070|NCT01250080|Experimental|Glutamine|
32793920|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
32793921|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
32793922|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
32793923|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
32793924|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
32793925|NCT04114084||A. patients with MGUS and sleep apnea|
32793926|NCT04114084||B. patients with MGUS and no sleep apnea|
32793927|NCT04114084||C. patients with MM and sleep apnea|
32793928|NCT04114084||D. patients with MM and no sleep apnea|
32793929|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
32793930|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
33088349|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
33300071|NCT01250080|Sham Comparator|Control|
33300072|NCT03908320|Experimental|Menstrual Cycle Timing|
33300073|NCT03908320|Active Comparator|Menstrual Cycle Monitoring|
33300074|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
33300075|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
33088350|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
33088351|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
33404139|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
32793931|NCT04756700|Experimental|Healthy Participants|Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
33404140|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
33404141|NCT03756688|No Intervention|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
33404142|NCT03756688|Experimental|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
32793932|NCT04756700|Experimental|PwMS: Participants with MS|Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
32793933|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
32793934|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
32793935|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
32793936|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
32793937|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
32793938|NCT03774875|Experimental|Apremilast 30 mg|Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.
32793939|NCT03774875|Placebo Comparator|Placebo / Apremilast 30 mg|Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.
32793940|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
32793941|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
32793942|NCT05264324|Experimental|High altitude 2500 m above sea level (high altitude)|Maximum Exercise Capacity in high altitude
32793943|NCT05264324|Active Comparator|Low altitude 470 m above sea level (low altitude)|Maximum Exercise Capacity in low altitude
32793944|NCT04755920|Experimental|Patients with colorectal brain metastases|10 mg SGM-101, administration 3 to 5 days prior to surgery.
32793945|NCT04758806|Experimental|Fecal microbial transplantation from unrelated donor|Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
32793946|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
32793947|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
32793948|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
32793949|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
32793950|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
32793951|NCT04755764||Beta blockade|Beta blocker (labetalol or atenolol) will be given for a cardiac output >8 l/min.
32793952|NCT04755764||Nifedipine|Nifedipine will be given for a mean arterial pressure >100.
32793953|NCT05365607|Experimental|NightWare|In individuals randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awaking.
32793954|NCT05365607|Sham Comparator|Sham NightWare|In individuals randomized to the sham condition, the NightWare intervention will not be enabled.
33088352|NCT04717869||ICU Patients|Adult Surgical, Cardiothoracic, and Neuro- ICU patients will be enrolled within 48 hrs of admission
33088353|NCT04717947||Short interval group|≤ 8weeks between the end of neoadjuvant therapy and surgery
33088354|NCT04717947||Intermediate interval group|> 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery
33088355|NCT04717947||Long interval group|> 12 weeks between the end of neoadjuvant therapy and surgery
33088356|NCT00296361|Active Comparator|1|
33088357|NCT00296361|Experimental|2|
33088358|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
33088359|NCT00416039|Experimental|1|Midazolam and morphine
33088360|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
33088361|NCT00296478|Experimental|1|Endometrin 100mg BID
33088362|NCT00296478|Experimental|2|Endometrin 100mg TID
33088363|NCT00296478|Active Comparator|3|Crinone
33088364|NCT00302172|Experimental|ARQ 197|
33088365|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
33404143|NCT03756688|Experimental|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
33300076|NCT01148290|Active Comparator|Tension free vaginal tape|
33300077|NCT01148290|Experimental|Bulking agent injection|
33300078|NCT00197028|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
32793958|NCT04113616|Experimental|Part A - Arm 1|"KRT-232+LDAC:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle."
33300079|NCT00197028|Active Comparator|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
33300080|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
32793959|NCT04113616|Experimental|Part A - Arm 2|"KRT-232(7-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
32793960|NCT04113616|Experimental|Part A - Arm 3|"KRT-232(14-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
32793961|NCT04113616|Experimental|Part B - Arm 1|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle
32793962|NCT04113616|Experimental|Part B - Arm 2|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle in Cycle 1, followed by 240 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day cycle, in the subsequent cycles.
32793963|NCT04113616|Experimental|Part B - Arm 3|KRT-232 administered at 180 mg orally, once daily (QD) on Days 1-7 with 14 days off on a 21-day treatment cycle.
32793964|NCT05330195|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group
32793965|NCT05330195|Active Comparator|Control Group|Home Based Exercise Group Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 3-5 days a week.
33300081|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
32793966|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
32793967|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
33088366|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
33088367|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
33300082|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
33300083|NCT01073982|Experimental|tart cherry juice|
33300084|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
33300085|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
33300086|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
33300087|NCT03907930|Active Comparator|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
33300088|NCT03907930|Active Comparator|tubeless|the arm will have only ureteric catheter rafter completing the operation
33404144|NCT03756688|Experimental|Group 4: Treatment|PTT for 30 min 2x day x 6 months
33300089|NCT03915340|Other|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33300090|NCT03915340|Other|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33300091|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
33300092|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
33300093|NCT00258960|Other|Caelyx,Cyclophosphamide,Trastuzumab|Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)
33300094|NCT01250314|Other|With fracture|Patients with fracture
33300095|NCT01250314|Other|Without fracture|Patients without fracture
33300096|NCT03907696|Other|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
33300097|NCT03907696|No Intervention|control|regular curriculum with no addition educational contents
32793968|NCT02161718|Placebo Comparator|Placebo + olanzapine|
32793969|NCT05309915|Other|Cohort 1|Dose 3mg of STP707 (8 subjects) + placebo (2 subjects) randomized
32793970|NCT05309915|Other|Cohort 2|Dose 6mg of STP707 (8 subjects) + placebo (2 subjects) randomized
32793971|NCT05309915|Other|Cohort 3|Dose 12mg of STP707 (8 subjects) + placebo (2 subjects) randomized
32793972|NCT05309915|Other|Cohort 4|Dose 24mg of STP707 (8 subjects) + placebo (2 subjects) randomized
32793973|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
32793974|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
32793975|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
32793976|NCT05292989|Experimental|Group 1- Personalised tailored approach|If patients are assigned to this group they will be asked to complete a frailty assessment which includes the Fraility Index short form, an assessment of grip strength, time to complete 5 sit-to-stands, balance test, and gait speed along with some questionnaires on comorbid medical condition. The treating Gastroenterologist will then go through the results of the frailty assessment with the patient and based on this information will discuss the benefits and risks associated with having a surveillance colonoscopy. The patient will then decide if they would like to go ahead with a surveillance colonoscopy and the treating Gastroenterologist will provide further advice as required. The frailty assessment is intended to be done at the time of the appointment with the specialist. However, operational requirements may dictate that e.g. a telehealth delivered occasion of service is done at a separate date.
32793977|NCT05292989|Placebo Comparator|Group 2- Standard Care|Patients assigned to this group will discuss the benefits and risks associated with having a surveillance colonoscopy with the treating Gastroenterologist and will decide whether to proceed with the colonoscopy.
33088368|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
33088369|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
33404145|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
33088370|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
33088371|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
33088372|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
33088373|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
33088374|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
33088375|NCT00268580|No Intervention|Control|Standard of care provided
33088376|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
32793978|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
32793979|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
32793980|NCT05186987|Sham Comparator|Start with: Concentric (normal) cycling|
32793981|NCT05186987|Experimental|Start with: Eccentric cycling|
32793982|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
32793983|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
32793984|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
32793985|NCT02219048|Experimental|PF-03715455|PF-03715455
32793986|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
32793987|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
32793988|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
33088377|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
33088378|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
33088379|NCT00268697|Active Comparator|Ezetimibe|
33088380|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
33088381|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
33088382|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
33300098|NCT03973710|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
33300099|NCT03973710|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
33088383|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
33300100|NCT03915028|Experimental|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
33300101|NCT03915028|No Intervention|Control group|Control group will receive a thermal cure after the end of the study
33300102|NCT03972618|Experimental|School and village|Simultaneous installation of filters in schools and the village
33300103|NCT03972618|Experimental|School only|Initial installation in school only
33300104|NCT03972618|Experimental|Village only|Initial installation in village only
33300105|NCT03972618|No Intervention|Control|Control group. No filter installation initially.
33300106|NCT03907306|Experimental|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
33300107|NCT03907306|Active Comparator|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
33300108|NCT01582542|Experimental|Desmopressin|
33300109|NCT03907384|Experimental|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
33300110|NCT03907384|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
33300111|NCT03913000|Experimental|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
33300112|NCT03913156|Other|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
33300113|NCT03913156|Other|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
33300114|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
33300115|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
33300116|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
33300117|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
33300118|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
33300119|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
33300120|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
33300121|NCT00420641|Other|Placebo|Placebo to Match
33300122|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
33300123|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
33300124|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
33300125|NCT00257556|Experimental|Menotrophin|
33300126|NCT00257556|Active Comparator|Follitropin alfa|
33300127|NCT03907228|Experimental|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
33300128|NCT03907228|Placebo Comparator|Placebo|Dextrose Anhydrous
33300129|NCT03906916|Experimental|Patients with suspicion of invasive candidiasis|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
33300130|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
33300131|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
33300132|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
33300133|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
33300134|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
33300135|NCT03907150||Pneumothorax|Pneumothorax
32793989|NCT05185661|Experimental|Intervention Group|"Two surveys: Demographic, lifestyle, hygiene-related (1) & knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
32793990|NCT05185661|No Intervention|Control Group|"Two surveys: Demographic, lifestyle, hygiene-related (1) & knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
32793991|NCT04192799|Experimental|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
32793992|NCT04192799|Active Comparator|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
33300136|NCT03907150||Normal|Normal lung
32793993|NCT04786145|Active Comparator|Cryoneurolysis|40 patients are randomized to receive one treatment of cryoneurolysis on the facet joints of three lumbar level corresponding to their facet joint pain generator
33300137|NCT03972540|Experimental|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
33300138|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
33300139|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
33300140|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
33300141|NCT03912688|Experimental|single acupoint stimulation|
33300142|NCT03912688|Experimental|dual acupoints stimulation|
33300143|NCT03912688|No Intervention|no stimulation|
33300144|NCT01250548|Active Comparator|2|
33300145|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
32793994|NCT04786145|Active Comparator|Radiofrequency ablation|40 patients are randomized to receive one treatment of radiofrequency ablation on the facet joints of three lumbar level corresponding to their facet joint pain generator
33300146|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
33300147|NCT03906838|Experimental|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
33300148|NCT03906838|No Intervention|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
33300149|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
33300150|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
33300151|NCT03914638|Experimental|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
33300152|NCT03914638|Placebo Comparator|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
33300153|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
33300154|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
33300155|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
33300156|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
33300157|NCT00228384|Active Comparator|Gore VIABAHN Endoprosthesis|
33300158|NCT00228384|Active Comparator|Bare Nitinol Stent (BNS)|
33300159|NCT03914404|Experimental|Test group|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
33300160|NCT03914404|Experimental|Control Group|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
33300161|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
33300162|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
33300163|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
33300164|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
33300165|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
33300166|NCT01251562|Experimental|Cohort 1|"5.62 mg/kg~Sterile Compound C31510 for Injection"
33300167|NCT01251562|Experimental|Cohort 2|"11.25 mg/kg~Sterile Compound C31510 for Injection"
33300168|NCT01251562|Experimental|Cohort 3|"22.5 mg/kg~Sterile Compound C31510 for Injection"
33300169|NCT01251562|Experimental|Cohort 4|33.0 mg/kg
32793995|NCT04786145|Sham Comparator|Placebo|40 patients are randomized to receive sham treatment. Subjected to similar procedures as cryoneurolysis and radiofrequency ablation, but without active treatment.
32793996|NCT04813991|Experimental|Arm 1 - Ibuprofen Breakthrough|600 mg Ibuprofen for breakthrough pain.
32793997|NCT04813991|Active Comparator|Arm 2 - Oxycodone Breakthrough|5 mg of Oxycodone for breakthrough pain.
32793998|NCT03624101|Experimental|Trikafta|If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days
32793999|NCT03624101|Experimental|Symdeko/Trikafta|If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days
33300170|NCT01251562|Experimental|Cohort 5|"44.0 mg/kg~Sterile Compound C31510 for Injection"
33300171|NCT01251562|Experimental|Cohort 6|"58.7 mg/kg~Sterile Compound C31510 for Injection"
32794000|NCT03624101|Experimental|Ivacaftor/Trikafta|If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days
32794001|NCT04801901|Experimental|Distal transradial access (dTRA)|Subjects randomized to the experimental arm will undergo left heart catheterization using distal transradial access (dTRA) to facilitate coronary angiography and/or percutaneous coronary intervention.
32794002|NCT04801901|Active Comparator|Forearm radial access (fTRA)|Cardiac catheterization to facilitate coronary angiography and/or percutaneous coronary intervention using the standard forearm radial artery which is the current standard of care in interventional cardiology.
32794003|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
33300172|NCT01251562|Experimental|Cohort 7|"78.2 mg/kg~Sterile Compound C31510 for Injection"
32794004|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
32794005|NCT03623243|Experimental|Siponimod 2 mg|Siponimod 2mg tablets taken once daily after a 5 day titration
32794006|NCT04813055||Therapeutic EUS|Procedures involving Linear Echoendoscopes to create a communication between the gastrointestinal tract and a target organ (biliary tree, pancreatic duct, fluid collection, gallbladder, downstream gastrointestinal tract) through plastic or metal stents.
33300173|NCT01251562|Experimental|Cohort 8|"104.3 mg/kg~Sterile Compound C31510 for Injection"
32794007|NCT04813055||Controls|Patients eligible for T-EUS procedures, but undergoing alternative surgical interventions, percutaneous interventions (e.g. Percutaneous Biliary Drainage) or non-EUS based endoscopic procedures (e.g. enteral stenting)
32794008|NCT04418687|Active Comparator|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
32794009|NCT04418687|Experimental|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
32794010|NCT05268965||Patients meeting DSM-5 criteria for PTSD.|
32794011|NCT05268965||Group 2: Healthy controls who experienced a traumatic event but did not meet DSM-5 criteria for PTSD|
32794012|NCT05268965||Group 3: Healthy controls who did not experience a traumatic event|
32794013|NCT05266781||Open surgical repair|Aneurysmectomy and aortic reconstruction with a surgical graft
32794014|NCT05266781||Endovascular repair|Off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR
32794015|NCT04801589|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 4 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr."
32794016|NCT04801589|Active Comparator|Midazolam|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 0.5 mg/mL midazolam. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr."
32794017|NCT05179187|Experimental|Parkinson disease patients|Participants diagnosed with Parkinson's disease
32794018|NCT05179187|Active Comparator|Healthy adults|Healthy adult age-matched controls
32794019|NCT05084261|Experimental|BT051 200 mg|Participants will receive oral BT051 200 mg once daily for 28 days.
32794020|NCT05084261|Experimental|BT051 800 mg|Participants will receive oral BT051 800 mg once daily for 28 days.
32794021|NCT05084261|Experimental|BT051 3200 mg|Participants will receive oral BT051 3200 mg once daily for 28 days.
32794022|NCT05084261|Placebo Comparator|Placebo|Participants will receive oral Placebo to match BT051 once daily for 28 days.
33300174|NCT01251562|Experimental|Cohort 9|"139.0 mg/kg~Sterile Compound C31510 for Injection"
33300175|NCT01251640|Experimental|Arm 1|
33300176|NCT00257166|Experimental|Ziprasidone oral capsules|
33300177|NCT00257166|Placebo Comparator|Placebo|
33300178|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .~The planned interventions are:~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
33300179|NCT03914092|Experimental|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
33300180|NCT03914092|Active Comparator|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
33300181|NCT03905824|Experimental|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
33300182|NCT03905824|Active Comparator|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
33300183|NCT01254058||Glaucoma Group|
33300184|NCT01254058||Age-Matched Controls|
33300185|NCT01251718||Donepezil Hydrochloride|
33300186|NCT03913936|Experimental|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
33300187|NCT03913936|Experimental|SURVIVOR|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
33404146|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
33404147|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
32794025|NCT05037149|Experimental|Part 1: Arm A|Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
32794026|NCT05037149|Experimental|Part 1: Arm B|Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
33300188|NCT03913936|Experimental|LIVING WITH ADVANCED DISEASE|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
33300189|NCT03913858|Other|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
33300190|NCT03913858|Other|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
33300191|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
33300192|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
33300193|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
33300194|NCT01254682|Other|Standard arthroscopic procedure|
33300195|NCT05577754|Placebo Comparator|Group A|
33300196|NCT05577754|Experimental|Group B|
33300197|NCT05570188|Experimental|Treatment group|Patients will get infused with anti-CD19 CAR-NK cells within 1 week after hematopoietic stem cell infusion.
33300198|NCT03905278|Experimental|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.~Assessments are conducted at two periods : before and after the intervention."
33300199|NCT03905278|No Intervention|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.~Assessments are conducted at 9 weeks of interval."
33300200|NCT03905590|Experimental|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
33300201|NCT03905590|Active Comparator|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
33300202|NCT03905512|Experimental|SEL-212|IV infusion of SEL-212 every 28 days for a total of up to 6 infusions of SEL-212.
33300203|NCT03905512|Active Comparator|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for a total of up to 12 infusions of KRYSTEXXA®.
33300204|NCT00227370|Active Comparator|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
32794027|NCT05037149|Experimental|Part 1: Arm C|Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
32794028|NCT05037149|Experimental|Part 1: Arm D|Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
32794029|NCT05037149|Experimental|Part 1: Arm E|Cohort 5: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
33300205|NCT00227370|Placebo Comparator|2|placebo for 9 months post lung transplant
33404148|NCT04423614|Experimental|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
33404149|NCT04423614|Experimental|Relaxation Breathing (RLX)|Relaxation breathing exercises
32794030|NCT03580421|Active Comparator|standard pathway group|this group will benefit from standard care including: one surgical consultation, one anesthesia consultation, surgery followed by 2-4 days of hospitalization and most of the time 3 post-operative consultations (M1, M6, M12) during the first operative year
32794031|NCT03580421|Experimental|ambulatory pathway group|Preoperative and postoperative protocols will be applied for optimizing same-day discharge. Gynaecologists, anaesthetists, and nursing staff will work as a team. A specific anesthesia consultation will focus on ambulatory surgery management. A geriatric evaluation will be offered to women over 70 years old with a score ≤14 according to G8 screening tool. A dietetic evaluation will be offered to women with BMI ≥ 35. A nursing consultation will be offered, as patient and their family preparation prior to ambulatory surgery is important.
32794032|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
32794033|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
32794034|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
32794035|NCT01540474|Other|Control group-Challenged Only|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
32794036|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
32794037|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
32794038|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
32794039|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
32794040|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
32794041|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
33088384|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
33300206|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
33300207|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
33404150|NCT05230654|Experimental|fosaprepitant|Patients received intravenous Ganisetron plus dexamethasone followed by fosaprepitant infusion
32794042|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
32794043|NCT01562782|Experimental|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
32794044|NCT01562782|Active Comparator|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
32794045|NCT01579006||Cohort|
32794046|NCT01578850|Experimental|Group A|
32794047|NCT01578850|Placebo Comparator|Group B|
32794048|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
32794049|NCT01539538|Active Comparator|morphine IV PCA|
32794050|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
32794051|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
32794052|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
32794053|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
32794054|NCT03027934|Active Comparator|Group 1|
32794055|NCT03027934|Active Comparator|Group 2|
32794056|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
32794057|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
33088385|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
33088386|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
32794058|NCT04112368|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
32794059|NCT04112368|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
32794060|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
32794061|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
32794062|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
32794063|NCT04769674|Experimental|STAR intervention|Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
32794064|NCT01537432|Placebo Comparator|placebo|placebo
32794065|NCT01537432|Experimental|secukinumab|secukinumab
32794066|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
32794067|NCT04409938|Experimental|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
32794068|NCT04409938|Experimental|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
32794069|NCT04409938|No Intervention|Standard Practice|The standard practice of the lab was made.
32794070|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
32794071|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
33300208|NCT03969030|Experimental|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
33300209|NCT03969030|No Intervention|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
32794072|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
32794073|NCT04111666|Experimental|AL101 IV|"Up to four single ascending doses (SAD IV cohorts)~Multiple doses of AL101 administered IV (MD IV cohort)"
33300210|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
32794074|NCT04111666|Placebo Comparator|Saline Solution|"Saline solution will be administered with the following:~Single IV infusion for four single ascending doses (SAD IV cohorts) in a ratio of 8 active and 3 placebo subjects~Multiple IV infusions for the MD IV cohort in a ratio of 8 active and 2 placebo subjects"
32794075|NCT04111666|Experimental|AL101 SC|"Single fixed dose levels of AL101 administered SC~Multiple fixed dose of AL101 administered SC"
33088387|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
33300211|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
33300212|NCT03911986|Other|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
33300213|NCT03911986|Other|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
33300214|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
33300215|NCT03911674|Experimental|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
33300216|NCT03911674|No Intervention|Control|No intervention
33300217|NCT03903250|Placebo Comparator|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
33300218|NCT03903250|Experimental|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
32794076|NCT03897712|Experimental|Custom Samfilcon B Contact Lenses|Participants will wear Bausch + Lomb investigational custom samfilcon B contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store their worn study lenses in a lens case filled with Biotrue multi-purpose solution (MPS).
33300219|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
33300220|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
32794077|NCT03897712|Placebo Comparator|Alden Optical HP Sphere contact lenses|Participants will wear Alden Optical HP Sphere contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store worn study lenses in a lens case filled with Biotrue MPS.
32794078|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
32794079|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
32794080|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
32794081|NCT04410094|Experimental|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
32794082|NCT04410094|Experimental|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
33300221|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
32794083|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
32794084|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
32794085|NCT04123054|Active Comparator|Sensor-Augmented MDI + Mobile App (control)|Participants will continue their usual multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data.
32794086|NCT04123054|Experimental|Sensor-Augmented MDI + Mobile App + Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
32794087|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
32794088|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
32794089|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
32794090|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
32794091|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
32794092|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
32794093|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
32794094|NCT03897556|Active Comparator|High-dose|This arm consists of cancer survivors who receive two guarana energy bars to take per day for six weeks; one in the morning and one around lunch time.
32794095|NCT03897556|Active Comparator|Low-Dose|This arm consists of cancer survivors who receive one guarana energy bar to take per day for six weeks; one in the morning only.
33300222|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
32794096|NCT03897556|Other|Usual Care|This arm receives usual-care only as cancer survivors.
32794097|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
32794098|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
32794099|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
32794100|NCT03889132||Premenopausal women with obesity|
32794101|NCT03889132||Postmenopausal women with obesity|
32794102|NCT03889132||Men with obesity|
32794103|NCT03889132||Premenopausal women without obesity|
32794104|NCT03889132||Postmenopausal women without obesity|
32794105|NCT03889132||Men without obesity|
32794106|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
33300223|NCT01252108|Experimental|Treatment|All subjects receive SQ109
33300224|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
33300225|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
33300226|NCT05560048|Experimental|treatment to placebo|Participants should eat rice protein RP-80NY once a day for 28 days, then exchange the treatment sample to placebo after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
33300227|NCT05560048|Experimental|placebo to treatment|Participants should eat placebo once a day for 28 days, then exchange the treatment sample to rice protein RP-80NY after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
32794107|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
32794108|NCT04102618|Experimental|Cohort 1 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole
32794109|NCT04102618|Experimental|Cohort 2 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
33088388|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
33088389|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
33300228|NCT03904810|No Intervention|Control|Subjects in this group do not received any intervention
32794110|NCT04102618|Experimental|Cohort 3 (closed to enrollment)|TNBC patients who will receive pelareorep plus atezolizumab
32794111|NCT04102618|Experimental|Cohort 4 (closed to enrollment)|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
33300229|NCT03904810|Active Comparator|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
32794112|NCT04102618|Experimental|Cohort 5 (closed to enrollment)|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
32794113|NCT04102618|Experimental|Cohort 6|HER2+ (irrespective of HR status) (6 patients) who will receive pelareorep + trastuzumab
33300230|NCT03904810|Active Comparator|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
32794114|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
33300231|NCT03904810|Active Comparator|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
33300232|NCT03904810|Active Comparator|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
32794115|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
33300233|NCT03904966|Experimental|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
33300234|NCT03904966|Sham Comparator|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
32794116|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|
33300235|NCT03904966|Other|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
33300236|NCT03905044||CC|eyes with congenital cataracts
33300237|NCT03911440|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
33300238|NCT03911440|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
33300239|NCT00191100|Experimental|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
33300240|NCT00191100|Active Comparator|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week"
33300241|NCT01254916||Patients with chronic rhinosinusitis|
33300242|NCT03911518|Active Comparator|Control|Incision and drainage.
32794117|NCT05254535|Other|Intervention|Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.
32794118|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
32794119|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
32794120|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
32794121|NCT04783727|Experimental|Experimental arm|The individualised treatment durations defined by the RNA transcriptomic signature-based model
32794122|NCT04783727|No Intervention|Control arm|The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients
32794123|NCT04963283|Experimental|Cabozantinib 40 mg orally daily in combination with nivolumab 480 mg IV every 28 days.|"Cabozantinib is supplied as 20-mg tablets and will be administered orally at a dose of 40 mg/day.~Nivolumab is supplied in 100 mg/Vial (10 mg/mL) vials and will be administered IV at a dose of 480 mg every 28 days."
32900639|NCT05326542|Active Comparator|LL and ERCP|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
33088390|NCT00268853|Experimental|1|
33088391|NCT00268853|Active Comparator|2|
33088392|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
33300243|NCT03911518|Experimental|Intervention|Loop drainage.
33300244|NCT03911362|Active Comparator|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
33088393|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
33088394|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
33088395|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
33088396|NCT00269048|Experimental|Arm 1|SB-480848
32794124|NCT04858451|Experimental|All participants|"In Part 1a, up to 48 patients will be administered single ascending doses of RESP301 (1-6ml; 8 patients per dose cohort). Provided that individual stopping criteria are not met in ≥3 participants, and there are no serious adverse events that are at least possibly related to RESP301, the next dose cohort can be enrolled. Patients can be enrolled into more than one dose cohort provided they did not meet individual stopping criteria.~In Part 1b, 8 participants will receive RESP301 at MTD determined in Part 1a, with short-acting bronchodilator administered 10min prior to RESP301.~In Part 2, a minimum of 150 patients will be enrolled. This may include patients who took part in Part 1. At least the first 50 patients will receive a test dose of RESP301 before enrolment into the dormant phase. Patients who experience flare-up symptoms while in the dormant phase, may proceed to the treatment phase where they will self-administer RESP301 at home for 7 days."
33088397|NCT00269048|Placebo Comparator|Arm 2|placebo
33088398|NCT00302523|Active Comparator|FK506|
33088399|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
33300245|NCT03911362|Active Comparator|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
33300246|NCT01148758|Experimental|Single Arm|
33300247|NCT03902782|Experimental|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
32794125|NCT05168657|Active Comparator|EN-IP-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794126|NCT05168657|Experimental|EN-TH-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794127|NCT05168657|Experimental|EN-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
33300248|NCT03902782|Sham Comparator|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
33300249|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
33300250|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
33300251|NCT03902548|Experimental|Brain uptake and kinetics in Alzheimer's patients|
33300252|NCT03902548|Experimental|Dosimetry in healthy volunteers|
33300253|NCT03904576|Experimental|Treatment (T)|
33300254|NCT03904576|Placebo Comparator|Reference Treatment (R)|
32794128|NCT05168657|Experimental|EN-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794129|NCT05168657|Active Comparator|PC-IP-UC|Random-order cross-over participants on USUAL CARE intervention managed by PRIMARY CARE with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794130|NCT05168657|Experimental|PC-TH-UC|Random-order cross-over participants on USUAL CARE managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794131|NCT05168657|Experimental|PC-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
32794132|NCT05168657|Experimental|PC-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
33088400|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
33088401|NCT00297024|Experimental|MRI for brain mets|
33088402|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
33088403|NCT04718064|Experimental|fingolimod with standard therapy|Patients will be treated with intravascular therapy and fingomod.
32794133|NCT05168267|Experimental|Cognitive Processing Therapy (CPT) group|Arm = Cognitive Processing Therapy (CPT) Group = 4 groups of 12 (48 total; 24F/24M) receive CPT to treat PTSD
32794134|NCT04443569|Experimental|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
32794135|NCT04443569|No Intervention|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery.
32794136|NCT04443335|Sham Comparator|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
33404151|NCT05230654|Placebo Comparator|Placebo|Patients received intravenous Ganisetron plus dexamethasone followed by normal saline
32794137|NCT04443335|Experimental|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
32794138|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
32794139|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
32794140|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
32794141|NCT04801355|Other|laparoscopic resection|patients with colonic adenomas who will undergo to laparoscopic segmental resection
32794142|NCT04801355|Experimental|full-thickness laparo-endoscopic colon adenomas excision|patients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
32794143|NCT01906385|Experimental|186Rhenium Liposome Treatment|"Arm~Phase I:~Experimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:~COHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi)~Phase 2:~Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume)."
32794144|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
32794145|NCT01792583||Retrospective Cohort|Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal test.
33404152|NCT05761314|Experimental|Case group|To report the prevalence of solid tumors in a monocentric cohort of individuals with RASopathies
33404153|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
32794146|NCT03511157|Experimental|Ischemic Preconditioning|A standard blood pressure cuff will be placed on the right or left thigh, depending on the affected side, to occlude blood flow. The cuff will be inflated to 225 mmHg to prevent blood flow. Each session will consist of 4 cycles of 5 minute IPC applications, followed by 5 minutes of reperfusion for a total of 35 minutes.
32794147|NCT03511157|Sham Comparator|Control|The sham intervention protocol will be identical to the IPC protocol except blood flow to the affected leg is unchanged as cuff pressure will be raised to between the venous and diastolic pressures
32794148|NCT04800965|No Intervention|Holdout Arm|In the Holdout arm, patients will not receive text messages about COVID-vaccine.
32794149|NCT04800965|Experimental|Simple Text Sub-arm|In the Simple Text sub-arm, participants will not receive any additional information.
32794150|NCT04800965|Experimental|Simple Text + Video Sub-arm|In the Simple Text+Video sub-arm, together with the appointment link, participants will also receive a link to a 2-minute video in the text message. The video contains information about the prevalence of COVID-19 and the effectiveness and safety of the COVID-19 vaccine.
32794151|NCT04800965|Experimental|Enhanced Text sub-Arm|In the Enhanced Text sub-arm, in addition to the appointment link, the text message will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
32794152|NCT04800965|Experimental|Enhanced Text + Video Sub-arm|In the Enhanced Text+Video sub-arm, in addition to the appointment link, the text message will encourage patients to watch a 2-minute video (the same as in the Simple Text+Video sub-arm) and use enhanced language aimed at reducing patients' psychological barriers of following through on scheduling an appointment.
32794153|NCT01340261||Pediatric Pain Rehab Patients|
32794154|NCT04712591||Traumatic Brain Injury Patients|Traumatic brain injury (TBI) patients will be recruited and studied using electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
32794155|NCT04712591||Healthy Volunteers|Healthy volunteers will serve as the control group and will undergo electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
32794156|NCT04691375|Experimental|Part A: PY314 Single agent dose level 1|PY314 single agent dose level will depend on any safety signal observed in this cohorts only. Following the determination of the safety and tolerability of at least two PY314 dose levels by the safety review committee.
32794157|NCT04691375|Experimental|Part A: PY314 Single agent dose level 2|PY314 single agent dose level 2 dose escalation of PY314 as a single agent will continue in the absence of unacceptable dose limiting toxicity to the maximum administered dose as defined in the predefined dose escalation schema.
32794158|NCT04691375|Experimental|Part A: PY314 Single agent dose level 3|PY314 single agent dose level 3 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314
32794159|NCT04691375|Experimental|Part A: PY314 Single agent dose level 4|PY314 single agent dose level 4 to characterize the pharmacokinetic profile of PY314 as a single agent.
32794160|NCT04691375|Experimental|Part A: Combination dose level 1|Combination dose level 1 to characterize the safety and tolerability of PY314 as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including refractory to check point inhibitor.
32794161|NCT04691375|Experimental|Part A: Combination dose level 2|PY314 combination dose level 2 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314 administered alone and in combination with pembrolizumab.
32794162|NCT04691375|Experimental|Part A: Combination dose level 3|PY314 combination dose level 3 to characterize the pharmacokinetic profile of PY314 as a single agent and in combination with pembrolizumab.
32794163|NCT04691375|Experimental|Part A: Combination dose level 4|PY314 combination dose level 4 to describe, in subjects selected by pre-specified tumor histology, anti-tumor activity of PY314 administered alone and in combination with pembrolizumab.
32794164|NCT04691375|Experimental|Part B: Single agent dose expansion dose level 1|PY314 single agent dose expansion dose level 1 to define further the safety and tolerability of PY314 alone.
32794165|NCT04691375|Experimental|Part B: Combination dose expansion cohort 1|PY314 in combination with pembrolizumab dose expansion cohort 1 to define the safety and tolerability of PY314 alone and in combination with pembrolizumab over multiple treatment cycles in subjects with pre-defined tumor histologies and confirmed TREM2 expression.
32794166|NCT04691375|Experimental|Part B: Combination dose expansion cohort 2|PY314 in combination with pembrolizumab dose expansion cohort 2 to further characterize the PK profile of PY314 as a single agent and in combination with pembrolizumab.
33300255|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
33300256|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
33300257|NCT03902626||Physiotherapy students|Degree course
33300258|NCT03902626||Medical students|Degree course
33300259|NCT01149226|Placebo Comparator|placebo control|
32794167|NCT04691375|Experimental|Part B: Combination dose expansion cohort 3|PY314 in combination with pembrolizumab dose expansion cohort 3 to characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
33300260|NCT01149226|Experimental|oral medication chloral hydrate|
33300261|NCT01252342|Experimental|Intramyometrial oxytocin|
33300262|NCT01252342|Placebo Comparator|Intramyometrial Saline|
33300263|NCT03902470|Experimental|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
32794168|NCT04691375|Experimental|Part B: Combination dose expansion cohort 4|PY314 in combination with pembrolizumab dose expansion cohort 4 to evaluate the incidence of ADA formation and TREM2 expression.
32794169|NCT04691375|Experimental|Part B: Combination dose expansion cohort 5|PY314 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
32794170|NCT04676633|Experimental|Cohort 1: STP705 20 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
32794171|NCT04676633|Experimental|Cohort 2: STP705 40 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
33300264|NCT03902470|Active Comparator|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
33404154|NCT02039518|Other|observation group|observation
33404155|NCT02228304|Experimental|NT-503-3 ECT implantation|
33300265|NCT03911050|Experimental|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
33300266|NCT03911050|Placebo Comparator|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
33300267|NCT00189540|Active Comparator|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
33300268|NCT00189540|Placebo Comparator|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
33300269|NCT03904654|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
33300270|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
33300271|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
33300272|NCT01148914||Baseline level of biomarkers|
33300273|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
32794172|NCT04676633|Experimental|Cohort 3: STP705 80 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
32794173|NCT04676633|Experimental|Cohort 4: STP705 160 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
33088404|NCT04718064|Placebo Comparator|Placebo with standard therapy|Patients will be treated with intravascular therapy and placebo.
33088405|NCT00302601|Other|None relevant|Not relevant
32794174|NCT04676633|Experimental|Cohort 5: STP705 320 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
32794175|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
32794176|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
33088406|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
33088407|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
33088408|NCT00297219|Active Comparator|2|high dialysate calcium
33088409|NCT00297219|Active Comparator|1|low dialysate calcium
33088410|NCT00269321|Experimental|1|
32794177|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
32794178|NCT03507491|Experimental|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
32794179|NCT01313351||Device testing|Tears were collected from subjects to apply to the RPS InflammaDry detector and were clinically evaluated.
32794180|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
32794181|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
32794182|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
32794183|NCT04626791|Experimental|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
32794184|NCT04811261|Experimental|3+3 dose escalation|The first 3 subjects' patients will be administered 50 x 10^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
32794185|NCT04582409|Experimental|HSY244|HSY244 concentrate solution for injection via intravenous infusion
32794186|NCT04582409|Placebo Comparator|Placebo|Placebo concentrate solution for injection via intravenous infusion
32794187|NCT03418259|Experimental|Active KCS Medical Device|
32794188|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
32794189|NCT04566653||dialysis-dependent|chronic kidney disease patients with hyperkalaemia and dialysis-dependent
32794190|NCT04566653||non-dialysis-dependent|chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent
32794191|NCT04521569|Experimental|EVLP with Regadenoson|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
32794192|NCT04521569|Placebo Comparator|EVLP with Steen solution|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
32794193|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
32794194|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
32794195|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
32794196|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
32794197|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
32794198|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
32794199|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
33088411|NCT00269321|Experimental|2|
33088412|NCT00269321|Active Comparator|3|
33088413|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
33088414|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
33088415|NCT00269360|Experimental|1|
33088416|NCT00269360|Experimental|2|
33088417|NCT00269360|Active Comparator|3|
33088418|NCT00269516|Experimental|1|
33088419|NCT00269516|Experimental|2|
33088420|NCT00269516|Experimental|3|
33088421|NCT00269516|Placebo Comparator|4|
33088422|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
33088423|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
33088424|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
33088425|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
32794200|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
33088426|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
33088427|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
33300274|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
33300275|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
33300276|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
33300277|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
33404156|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
32794201|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
33300278|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
33300279|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
32794202|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
33300280|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
33300281|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
33300282|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
33300283|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
32794203|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
32794204|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
32794205|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
32794206|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
32794207|NCT04761094||Insulin pump|All patient treated with insulin pump.
32794208|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
32794209|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
32794210|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
32794211|NCT04721314|Experimental|Lower rate set to a higher, personalized backup heart rate (myPACE)|Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.
32794212|NCT04721314|Active Comparator|Lower rate left at 60 beats-per-minute|Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.
32794213|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
32794214|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
32794215|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
32794216|NCT03919942|Experimental|OxyFlower gel|pericoronitis treatment with oxyflower gel.
33088428|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
32794217|NCT03919942|Experimental|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
32794218|NCT03919942|Placebo Comparator|Placebo gel|pericoronitis treatment with placebo gel.
32794219|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
32794220|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
32794221|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
32794222|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
32794223|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
32794224|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
33088429|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
33088430|NCT00269789|Experimental|001|OROS Methylphenidate HCl
33300284|NCT03911206|Experimental|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
33300285|NCT03911206|Experimental|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
33300286|NCT03911206|Experimental|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
33300287|NCT03911206|No Intervention|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
33300288|NCT03902158|Experimental|Glasses|
33300289|NCT03902158|No Intervention|Distraction techniques|No glasses will be used
33300290|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
33300291|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
33088431|NCT00269789|Active Comparator|002|Ritalin
33088432|NCT00269789|Placebo Comparator|003|Placebo
33088433|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
33088434|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
32794225|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
32794226|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
32794227|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
32794228|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
32794229|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
32794230|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
32794231|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
32794232|NCT01557400|Experimental|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
32794233|NCT03918850|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
32794234|NCT03918850|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
32794235|NCT04122118|Experimental|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
32794236|NCT04121806|Experimental|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
32794237|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
32794238|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
32794239|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
32794240|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
32794241|NCT01533922|Placebo Comparator|Placebo QD|
32794242|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
32794243|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
32794244|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
32900640|NCT05364372|Active Comparator|Attention control|Dyads will receive mailed print education materials regarding healthy lifestyle (nutrition and physical activity) disseminated by ACS and NCI. They will also receive 12 weekly phone calls to assess post-treatment related symptoms.
33088435|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
33088436|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
33088437|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
33088438|NCT00303030|Active Comparator|1. Anal injection|
33088439|NCT00303030|Active Comparator|2. Biofeedback|
33088440|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
33088441|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
33300292|NCT03902002|Experimental|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
33300293|NCT03902002|Experimental|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
33300294|NCT03902002|Experimental|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
32794245|NCT01532986|Other|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
32794246|NCT01532986|Experimental|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
32794247|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
32794248|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
32794249|NCT02160782|Experimental|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
33300295|NCT03902002|Experimental|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
33300296|NCT01254526|Experimental|A|
33088442|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
33300297|NCT01254526|Experimental|B|
33300298|NCT01148992|Active Comparator|Lofexidine|
33300299|NCT01148992|Placebo Comparator|Placebo|
33300300|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
33300301|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
33300302|NCT03910582|Experimental|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
33300303|NCT03910582|Active Comparator|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
33300304|NCT03901846|Other|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
33300305|NCT01148134||Bcr-Abl positive ALL|
33300306|NCT01148134||Bcr-Abl negative ALL|
33300307|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
33300308|NCT03904186|Experimental|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
33300309|NCT03904186|Active Comparator|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
33300310|NCT03904186|No Intervention|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
33300311|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
33300312|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
33088443|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
33088444|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
33088445|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
33088446|NCT00297336||001|
33088447|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
32794250|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
32794251|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
32794252|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
32794253|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
32794254|NCT02160314|Placebo Comparator|pad|absorbent pad control
33088448|NCT02960984|No Intervention|Baseline|No intervention is planned
32794255|NCT02160314|Experimental|pessary|disposable, single-use pessary
32794256|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
32794257|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
33300313|NCT03901612|Placebo Comparator|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
32794258|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
33300314|NCT03901612|Experimental|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
33300315|NCT03904342|Active Comparator|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
33300316|NCT03904342|Active Comparator|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
33300317|NCT03903952|Other|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
32900641|NCT05364372|Experimental|Symptom management and lifestyle intervention|Dyads will receive 12 weekly telephone-based coaching sessions, a participant educational handbook, and a pedometer for self-monitoring physical activity.
32900642|NCT05363904||Atopic Dermatitis (Europe)|
33300318|NCT03903952|Other|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
33300319|NCT01149382||islet cell transplant recipients|
32900643|NCT05363904||Healthy Controls (Europe)|
32900644|NCT05363904||Atopic Dermatitis (Africa)|
32900645|NCT05363904||Healthy Controls (Africa)|
33088449|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
33088450|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
33088451|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
33088452|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
33088453|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
33088454|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
33300320|NCT03910348|Experimental|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
33300321|NCT03910348|Experimental|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
33300322|NCT03910348|No Intervention|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
33300323|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
33300324|NCT00257010|Experimental|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
33088455|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
33088456|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
33088457|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
33088458|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
33088459|NCT00270374|Experimental|001|nesiritide
33088460|NCT00297804|Experimental|Arm 1|
33088461|NCT00297804|Active Comparator|Arm 2|
32794259|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
32794260|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
32794261|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
32794262|NCT04189640|Active Comparator|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
32794263|NCT04189640|Active Comparator|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
32794264|NCT04189640|Active Comparator|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
32794265|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
32794266|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
32794267|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
33088462|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
33088463|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
33088464|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
33088465|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
33088466|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
33088467|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
33088468|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
33088469|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
33088470|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
33088471|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
33088472|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
33088473|NCT02960256||Patients admitted to an internal medicine department due to an|
33088474|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
33088475|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
33088476|NCT00418587|Experimental|1|800 IU oral daily dose level
33088477|NCT00418587|Experimental|2|2000 IU oral daily dose level
33088478|NCT00418587|Experimental|3|4000 IU oral daily dose level
33088479|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
33088480|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
33088481|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
33088482|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
33088483|NCT00306501|Other|Button Press|Training with button press
33088484|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
33088485|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
33088486|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
33088487|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
33088488|NCT00306540|Experimental|2|Seroquel + existing therapy
33088489|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
33088490|NCT00306735|Experimental|Palonosetron|
33088491|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
33088492|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
33300325|NCT03901768|Experimental|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
33300326|NCT03901768|Experimental|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
33300327|NCT03901768|Experimental|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
33300328|NCT03901768|Placebo Comparator|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
33088493|NCT00271700|No Intervention|Usual Care|admission to medical team floor to usual care
33088494|NCT00271700|Experimental|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
33088495|NCT04717986|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 12 months
33300329|NCT03903718|Experimental|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
33300330|NCT03903718|Sham Comparator|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
33300331|NCT03903718|Active Comparator|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
33300332|NCT03903718|Experimental|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
33300333|NCT03903718|Experimental|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
33300334|NCT03903718|Experimental|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
33300335|NCT03910504|Active Comparator|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
33300336|NCT03910504|Experimental|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
33300337|NCT03901690|Experimental|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
33300338|NCT03901690|Active Comparator|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
33300339|NCT03901378|Experimental|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
33300340|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
33300341|NCT03909958|Other|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
33300342|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
33300343|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
33088496|NCT04717986|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 12 months
33300344|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
33300345|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
33088497|NCT04718142|Experimental|vNEP with various shapes and sizes and overnight PSG|Administer vNEP therapy to study participants on the throat's anterior surface with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O. Assess participants for a reduction in Apnea-Hypopnea Index (AHI) for at least 120 minutes using polysomnography (PSG) and treatment tolerance compared to CPAP.
33088498|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
33088499|NCT00307008|Experimental|Group A|
33088500|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
33088501|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
33300346|NCT05619016|Experimental|Patients with HER2 positive GEAC or HER2 low cancer (pilot)|"The participants of the study will undergo two sessions of HER2 PET and one 18F-FDG PET/CT for study purposes. The first HER2 PET is performed within 21 days before initiation of the systemic oncological treatment including HER2-targeted drugs, and is followed by tumor biopsies. A second HER2 PET and a second 18F-FDG PET will be performed adjacent to response evaluation after 3 courses of oncological therapy. Data from the PET investigations will be compared to HER2 expression analyses of the biopsy specimen and correlated to disease and survival data at follow up one year after inclusion.~Within the pilot study, participants with HER2 low mBC will undergo one HER2 PET followed by biopsies."
32794268|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
32794269|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
33088502|NCT00307320|No Intervention|1|
33088503|NCT00307320|Experimental|2|Relaxation techniques
33300347|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
33300348|NCT03901222|Active Comparator|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
33300349|NCT03901222|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
33300350|NCT03900676|Experimental|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
32794270|NCT04758650|Experimental|Cancer, lymphoma, carotid plaque, patients suspected for hemophagocytic lymphohistiocytosis|"Cohort 1: Patients diagnosed with pathology-proven squamous cell carcinomas of the head and neck in need of a non-surgical therapy.~Cohort 2: Patients diagnosed with any malignancy with a solid component in need of immune checkpoint inhibitor-type immunotherapy.~Cohort 3: Patients diagnosed with carotid plaque, planned for standard-of-care carotid endarterectomy.~Cohort 4: Patients with a biopsy-proven Hodgkin (HL) or non-Hodgkin lymphoma (NHL) eligible for systemic treatment, radiotherapy or a combination of both.~Cohort 5: Patients suspected for hemophagocytic lymphohistiocytosis (HLH), planned for (SOC) bone marrow biopsy in case it is not done before.~Cohort 6 : Patients with endomyocardial biopsy proven cardiac sarcoidosis or suspected CS according to HRS consensus recommendation (2014)"
32794271|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
32794272|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
32794273|NCT04755452|Experimental|Low Intra-abdominal pressure|Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
32794274|NCT04755452|Active Comparator|High (standard) intra-abdominal pressure|Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
32794275|NCT04755218|Experimental|Vaginal Misoprostol|Patients will receive vaginal misoprostol 25 micrograms given every 3 hours for a maximum of 5 doses
33088504|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
33088505|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
33088506|NCT00272285|Experimental|1|Intravenous (IV)
33088507|NCT00272285|Active Comparator|2|Intravenous (IV)
33088508|NCT00307593|Active Comparator|1|Rituximab
33300351|NCT03900676|Experimental|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
33300352|NCT03900676|Placebo Comparator|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
33300353|NCT03900676|Placebo Comparator|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
33300354|NCT00256854|Experimental|Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4.
33300355|NCT00256854|Experimental|Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
33300356|NCT00256854|Experimental|Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4.
33300357|NCT00256854|Experimental|Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
33300358|NCT00256854|Experimental|Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4.
33300359|NCT00256854|Experimental|Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
33300360|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
33300361|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
33300362|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
32940201|NCT00835328|Experimental|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
32940202|NCT00835328|Experimental|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
32940203|NCT00835328|Experimental|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
33300363|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
33300364|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
33300365|NCT03898492|Other|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
33300366|NCT03898492|No Intervention|Control|The participants in the control group were instructed to maintain their daily routines.
33300367|NCT00189462|Active Comparator|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
33300368|NCT00189462|Placebo Comparator|Placebo|Treatment with placebo for 4 months
33300369|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
33300370|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
32940204|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
32940205|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
33300371|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
33300372|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
33300373|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
33300374|NCT03910114||Dotarem Enhancement Group|
33300375|NCT03910114||Gadovist Enhancement Group|
33300376|NCT03910114||Magnevist Enhancement Group|
32940206|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
32940207|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
33300377|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
32940208|NCT05454956|Experimental|BID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically twice a day and TP-03 vehicle administered once a day to maintain masking for approximately 85 days
33300378|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
32940209|NCT05454956|Experimental|TID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically three times a day for approximately 85 days
32940210|NCT05441384|Experimental|CBT/Existential Group Therapy for Fear of Cancer Recurrence|Participants will receive 7 weekly group therapy sessions consisting of psychoeducation on fear of cancer recurrence, relaxation training, CBT, and evidenced-based tips to decrease avoidance and anxiety surrounding fear of cancer recurrence.
32940211|NCT05441384|No Intervention|Wait-list Control Group|Participants assigned to this arm wait about 3-months to receive the intervention.
32940212|NCT05437562|Other|Ewing Amputation|Single Arm Pilot Study : To implement lead-in surgeon training and test the feasibility of recruiting and retention of veterans undergoing Ewing Amputation in a single arm study at Atlanta VAMC.
32940213|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
32940214|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
32940215|NCT04512703||Front Position Devices|All devices placed in the front position
32940216|NCT04512703||Side Position Devices|All devices placed in the side position
32940217|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
33300379|NCT03900364|Other|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
33300380|NCT03900364|Other|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
33088509|NCT00307593|Active Comparator|2|Infliximab
33088510|NCT00272402|Other|1|Simulated case-based learning
33088511|NCT00272402|Other|2|EMR clinical decision support tool.
32794276|NCT04755218|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
32794277|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
32794278|NCT04754594|Experimental|BNT162b2|2 doses
32794279|NCT04754594|Placebo Comparator|Placebo|2 doses
32794280|NCT04761770|Experimental|Geriatric participants with various blood disorders|"Geriatric assessment (GA) pre-transplant~Risk-adapted allocation of conditioning intensity based on GA~GA-directed, longitudinal supportive care management"
33088512|NCT00272402|No Intervention|3|Control group
32794281|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
32794282|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
32794283|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
32794284|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
32794285|NCT04761692|Experimental|Arm 1|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan
32794286|NCT04761692|Experimental|Arm 2|This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
32794287|NCT04761692|Experimental|Arm 3|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
32794288|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
32794289|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
32794290|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
32794291|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
32794292|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
32794293|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
32794294|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
32794295|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
32794296|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
32794297|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
32794298|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
32794299|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
32794300|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
32794301|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
32794302|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
32794303|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
32794304|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
32794305|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
32794306|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
33088513|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
33088514|NCT00272480|Placebo Comparator|Placebo|Placebo in HAM/TSP 24
33088515|NCT00272480|Active Comparator|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
33088516|NCT00307671|Other|A|conventional treatment
33088517|NCT00307671|Experimental|B|reduction dose
33088518|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
33088519|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
33088520|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
33088521|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
33088522|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
33088523|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
33088524|NCT00307749|Placebo Comparator|1|
33088525|NCT00307749|Experimental|2|
33088526|NCT00307749|Experimental|3|
33088527|NCT00307749|Experimental|4|
33088528|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
33088529|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
33088530|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
33088531|NCT00282009|Active Comparator|Basic Internet|Basic Internet
33088532|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
32794307|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
32794308|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
33088533|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
33088534|NCT00307866|Experimental|Arm 1|
33088535|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
33300381|NCT03910192|Experimental|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
33088536|NCT00272831|Placebo Comparator|Placebo|
33088537|NCT00417105||1|hemodialysis twice weekly 4 hours
33088538|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
33088539|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
33088540|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
33300382|NCT03910192|Active Comparator|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
33088541|NCT00307905|Active Comparator|A|TRAUMEEL S
33088542|NCT00307905|Placebo Comparator|B|placebo remedy
33088543|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
33300383|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
33300384|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
33300385|NCT03910036|Experimental|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
33300386|NCT03910036|No Intervention|control group|The other fifteen patients were not injected and constituted control group.
33300387|NCT05667298|Experimental|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|The primary/preferred adjuvant therapy will be immunoradiotherapy (ARM1); however, if this combination is felt to be too high-risk for specific patients, the next preferred therapy will be immunotherapy without radiation (ARM1B).
33088544|NCT02960828|No Intervention|Control|Contralateral eye
33088545|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
33088546|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
33088547|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
33088548|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
33088549|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
33088550|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
33088551|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
33088552|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
33088553|NCT00272948|Experimental|Prophylaxis Arm|
33088554|NCT00272948|Active Comparator|Control Arm|
33088555|NCT00308100|Experimental|1|
33088556|NCT00308100|Active Comparator|2|
33088557|NCT00282204|No Intervention|Control|Usual care control
33088558|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
33088559|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
33088560|NCT00418626|Experimental|Nilotinib|
33088561|NCT00313950|Experimental|Group 1|
33088562|NCT00313950|Experimental|Group 2|
33088563|NCT00313950|Experimental|Group 3|
33300388|NCT05667298|Experimental|Adjuvant chemoradiotherapy|Some patients have medical conditions, i.e., severe auto-immune disease that prohibits them from receiving immunotherapy. In such patients, adjuvant therapy will be provided in the form of concurrent chemoradiotherapy (ARM2).
33088564|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
33088565|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
33088566|NCT04708691|Experimental|Aerobic exercise|aerobic exercise for 30 mins
33088567|NCT04708691|No Intervention|Control|sitting for 30 mins
33088568|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
33088569|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
32794309|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
32794310|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
32794311|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
32794312|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
33088570|NCT00314028|Active Comparator|1|Standard of care treatment
33088571|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
33088572|NCT00418782|Active Comparator|1|
33088573|NCT00418782|Experimental|2|
33088574|NCT00418782|Placebo Comparator|3|
32794313|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
32794314|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
32794315|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
32794316|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
32794317|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
32794318|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
32794319|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
32794320|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
32794321|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
32794322|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
32794323|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
32794324|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
32794325|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
32794326|NCT04753970|Experimental|Cilostazol|Cilostazol 100mg BID
32794327|NCT04753970|No Intervention|No intervention|
32794328|NCT04753892|Experimental|Arm 1|The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.
33088575|NCT00314067|Experimental|1|
33088576|NCT00314067|Experimental|2|
32794329|NCT04187690|Experimental|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
32794330|NCT04187690|Placebo Comparator|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
32794331|NCT01920477|Experimental|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
33088577|NCT00314067|Active Comparator|3|
33088578|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
33088579|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
33088580|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
33088581|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
33088582|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
33088583|NCT00273611|No Intervention|Usual care|Usual care
33088584|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
32794332|NCT01920477|Placebo Comparator|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
32794333|NCT04626687|Experimental|test DCB group|use the DCB made by Acotec Scientific
32794334|NCT04626687|Active Comparator|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
32794335|NCT04641741||Control|Healthy adults
32794336|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (>300 cells/μL)
32794337|NCT04641663|Experimental|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
32794338|NCT04641663|Experimental|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
32794339|NCT04641663|Experimental|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
32794340|NCT04641195|Placebo Comparator|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
32794341|NCT04641195|Experimental|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
32794342|NCT04641195|Experimental|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
32794343|NCT04641195|Experimental|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
32794344|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
32794345|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
32794346|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
32794347|NCT04418180|Active Comparator|GROUP1|group receiving single dose fenofibrate
32794348|NCT04418180|Active Comparator|GROUP2|group receiving double dose fenofibrate
32794349|NCT04418180|Placebo Comparator|GROUP3|photo therapy only
32794350|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
32794351|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
32794352|NCT02178956|Experimental|BBI608 plus Paclitaxel|
33088585|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
32794353|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
32794354|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
32794355|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
32794356|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
32794357|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
32794358|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
33088586|NCT00308334|Experimental|Domperidone|Domperidone
33088587|NCT00308334|Placebo Comparator|placeob- Sugar pill|
33088588|NCT00273767|Experimental|1|epoetin beta
33088589|NCT00273767|Placebo Comparator|2|placebo of NaCl
33088590|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
33088591|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
33088592|NCT00273845|Experimental|1|One session of motivational interviewing
33088593|NCT00273845|Experimental|2|Five sessions of strengths-based case management
32794359|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
32794360|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
32794361|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
32794362|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
33088594|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
33088595|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
33088596|NCT00419055||1 Control|Patients are discharged the day after PCI
32794363|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
32794364|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
32794365|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
32794366|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
32794367|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
32794368|NCT02155712|Active Comparator|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
32794369|NCT02155712|Active Comparator|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
32794370|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
32794371|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
32794372|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
32794373|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
32794374|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
32794375|NCT01531894|Experimental|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
32794376|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
32794377|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
32794378|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
32794379|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
32794380|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
32794381|NCT01557166|Experimental|Liraglutide 3.0 mg|
32794382|NCT01557166|Placebo Comparator|Placebo|
32794383|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
33088597|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
33088598|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
33088599|NCT00308724|Experimental|1|Cognitive Behavior Therapy
33088600|NCT00308724|Active Comparator|2|Usual Care
33088601|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
33088602|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
33088603|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
33088604|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
33088605|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
33088606|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
33088607|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
33088608|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
33088609|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
33088610|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
33088611|NCT00314925|Experimental|1|
32794384|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
32794385|NCT02985736|Experimental|open label|
32794386|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
33088612|NCT00277433||Atopic Dermatitis|
33088613|NCT00277433||Non-atopic control|
33088614|NCT00277472|Experimental|valsartan HCTZ|
33300389|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
33300390|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
33300391|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
33300392|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
33300393|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
33300394|NCT00256698|Active Comparator|1|Anastrozole
33300395|NCT00256698|Experimental|2|Anastrozole + Fulvestrant
33300396|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
33300397|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
33300398|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
33300399|NCT03909880|No Intervention|Control|Without kinesio tape on the forearm of subjects
33300400|NCT03909880|Placebo Comparator|kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm of subjects
33300401|NCT03909880|Experimental|kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm of subjects
33300402|NCT03909568|Experimental|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
33300403|NCT03969342|Experimental|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
33300404|NCT03900052|No Intervention|Naïve|Conventional cane with no instruction given
33300405|NCT03900052|Active Comparator|Scale training|Conventional cane, scale training, and instruction on proper cane use
33300406|NCT03900052|Active Comparator|Scale recall|Conventional cane with no further instruction or practice given
33300407|NCT03900052|Experimental|Haptics training|Haptic biofeedback cane with explanation and training.
33300408|NCT03900052|Experimental|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
33088615|NCT00277472|Active Comparator|HCTZ|
33088616|NCT00277589|Experimental|1|
33088617|NCT00277589|Active Comparator|2|
33088618|NCT00277589|Active Comparator|3|
33088619|NCT00277589|Placebo Comparator|4|
33088620|NCT00277706|Experimental|FORTEO|
33088621|NCT00277706|Placebo Comparator|Placebo|
33088622|NCT00309075|Experimental|Arm 1|
33088623|NCT00419133|Experimental|1|Cholera Vaccine
33088624|NCT00419133|Placebo Comparator|2|Placebo
33088625|NCT00277784||1|Individuals with age related macular degeneration
33300409|NCT03909802|Experimental|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
33300410|NCT03909802|Placebo Comparator|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
33300411|NCT00189306|Experimental|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
33300412|NCT03898102|Experimental|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
32794387|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
32794388|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
32794389|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
33300413|NCT03898102|Active Comparator|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
33300414|NCT03898336|Experimental|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
33300415|NCT03898336|Placebo Comparator|placebo|capsules containing placebo
33300416|NCT03972462|Experimental|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
32794390|NCT01555762||Cohort|
32794391|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
32794392|NCT04753346||Mild Disease|Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.
33300417|NCT03972462|Active Comparator|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
33300418|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
33300419|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
33300420|NCT01149694|Other|Cohort 1|
33300421|NCT01149694|Other|Cohort 2|
33300422|NCT01149694|Other|Cohort 3|
32794393|NCT04753346||Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air
32794394|NCT04753346||Severe Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air.
33300423|NCT01149694|Other|Cohort 4|
33300424|NCT01256710||Trifecta Valve Group|
33300425|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
33300426|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
33300427|NCT03900130|Experimental|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
33300428|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
33300429|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
33300430|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
33300431|NCT03909724|Active Comparator|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
33300432|NCT03909724|Experimental|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
33300433|NCT03899974|Experimental|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
33300434|NCT03899974|Experimental|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
33300435|NCT03899974|Active Comparator|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
32794395|NCT04753346||Critical Disease|Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.
32794396|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
32794397|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
33300436|NCT01253122|Experimental|TRx0037|
33300437|NCT01253122|Active Comparator|TRx0014|
33300438|NCT01149928||C/S delivered, wet lung|
33300439|NCT01149928||C/S delivered, healthy infants|
33300440|NCT03909646|Active Comparator|Surgical excision|Standard surgical excision with 5 mm safety margin
33300441|NCT03909646|Active Comparator|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
33300442|NCT03909646|Active Comparator|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
33300443|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
33300444|NCT01256866|Active Comparator|Midazolam, sedation,|
33300445|NCT03897946|Experimental|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
33300446|NCT03897946|No Intervention|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
32794398|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
33300447|NCT03897946|Experimental|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
33300448|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
33300449|NCT01257022|No Intervention|Treatment as Usual|Control
33300450|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
32794399|NCT04752566|Experimental|Eculizumab|Participants will receive eculizumab.
33300451|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
32794400|NCT04752566|Placebo Comparator|Placebo|Participants will receive placebo.
32794401|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
33300452|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
33300453|NCT01257100||Cases with NPC|Cases with NPC
33300454|NCT01257100||Hospital based controls|Hospital based controls
33300455|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.~Biomarker blood draw"
33300456|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
33300457|NCT03897400||study group|women in reproductive age with crohn's disease
33300458|NCT03897400||control group|women in reproductive age without crohn's disease,
32794402|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
33300459|NCT03909256|Experimental|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:~a five day residential stay with patient education~a two day follow-up residential stay after 3 months~two telephone consultations with clinical dietitian between the two residential stays."
33300460|NCT03909256|No Intervention|Control group|"The control group receives no intervention other than usual care in the study period.~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
33300461|NCT01253278|Experimental|20 mg LY2393910|
33300462|NCT01253278|Experimental|60 mg LY2393910|
33300463|NCT01253278|Experimental|150 mg LY2393910|
33300464|NCT01253278|Experimental|450 mg LY2393910|
32794403|NCT01571362|Experimental|ALO-02|
33088626|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
33300465|NCT01253278|Placebo Comparator|Placebo|
33300466|NCT03899818|Other|new generation DEB|drug-eluting balloon (DEB)
33300467|NCT03899818|Other|second generation DES|standard therapy with second generation drug-eluting stent (DES)
33300468|NCT03899662|Experimental|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
33300469|NCT01150006||Healthy male participants|
33300470|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
32794404|NCT01571362|Placebo Comparator|Placebo|
33088627|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
33088628|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b~Ribavirin for 24 weeks (patients with RVR)"
33300471|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
33300472|NCT03908944|Active Comparator|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
33300473|NCT03908944|Experimental|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
33300474|NCT03897010|Active Comparator|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
32794405|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
32794406|NCT04825756|Experimental|Treatment Group|A total of up to 80 child/caregiver dyads will be enrolled in the study, anticipating that 40 dyads will complete the 10 week intervention. An equine assisted therapy called Reining in Anxiety for children with anxiety and their caregivers.
32794407|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
32794408|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
33300475|NCT03897010|Placebo Comparator|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
33300476|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
33300477|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
33300478|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
33300479|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
32794409|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
32794410|NCT04410250|Active Comparator|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
32794411|NCT04410250|Experimental|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
32794412|NCT04418024|Experimental|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
32794413|NCT04418024|Placebo Comparator|Placebo|Placebo administered orally twice daily (BID)
32794414|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
32794415|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
32794416|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
32794417|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
32794418|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
32794419|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
32794420|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~IV meropenem (2 g infused over 3 hrs q 8 hr);~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
32794421|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
32794422|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
32794423|NCT02136914|Placebo Comparator|Placebo|Placebo
32794424|NCT01530256|Experimental|ALD518|
32794425|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
33088629|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b~Ribavirin for 36 weeks (patients with complete EVR)"
33300480|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
33300481|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
33300482|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
33300483|NCT03897166|Experimental|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
33300484|NCT03896932|Experimental|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
32940218|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
32940219|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
33300485|NCT03908866|Experimental|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
33300486|NCT03908866|Active Comparator|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
33300487|NCT03908554|Experimental|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
33300488|NCT03908554|No Intervention|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
33300489|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
33300490|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
33300491|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
33300492|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
33300493|NCT01150084|Experimental|lunchtime walking|
33300494|NCT01150084|Other|waiting-list control|
33300495|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
33300496|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
33300497|NCT01257412|Experimental|1|
33300498|NCT01257412|Experimental|2|
33300499|NCT01257412|Placebo Comparator|3|
33300500|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
33300501|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
33300502|NCT03896542|Experimental|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
33300503|NCT03896542|Experimental|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
33300504|NCT03896542|No Intervention|The control group|The control group received 30 minutes of conventional therapy
33300505|NCT03896698|Experimental|TUS treatment|AD patients with TUS treatment
33300506|NCT03896698|No Intervention|Non-TUS treatment|AD patients with Non-TUS treatment
32940220|NCT05372042|Experimental|Loss Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward preventing future losses from trauma exposure, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
32940221|NCT05372042|Experimental|Loss Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward prevent future losses from trauma exposure, and day 3 will have a simple reminder to use the skill.
32940222|NCT05372042|Experimental|Gain Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
32940223|NCT05372042|Experimental|Gain Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a simple reminder to use the skill.
32940224|NCT05372042|Experimental|No Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
33088630|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (patients with partial EVR)"
33300507|NCT03894280|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
33300508|NCT03894280|Active Comparator|Reference Product|SERETIDE DISKUS 250/50
33300509|NCT03893968|Experimental|Informed by a doctor|Information by a doctor
33300510|NCT03893968|Experimental|Informed by an assistant nurse|Information by an assistant nurse
33300511|NCT01255462|Experimental|LFG316 0.15mg|
33300512|NCT01255462|Experimental|LFG316 0.5mg|
33300513|NCT01255462|Experimental|LFG316 1.5mg|
33300514|NCT01255462|Experimental|LFG316 5mg|
33300515|NCT03899584|Active Comparator|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
33300516|NCT03899584|Placebo Comparator|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
32794426|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
32794427|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
33300517|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
33300518|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
32794428|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
33300519|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
33300520|NCT01150162|Experimental|Mucosta and Omeprazole|
33300521|NCT01150162|Active Comparator|Omeperazole|
33300522|NCT03893734|Active Comparator|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
33300523|NCT03893734|Placebo Comparator|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
33300524|NCT03899194|Active Comparator|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
33300525|NCT03899194|Experimental|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
33300526|NCT01151800|Experimental|IVR group|
33300527|NCT01151800|No Intervention|Usual care|
33300528|NCT03893578|Experimental|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
33300529|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
33300530|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
32794429|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
32794430|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
32794431|NCT01553188|Experimental|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
32794432|NCT01553188|Active Comparator|Abiraterone and Prednisone only|Abiraterone and prednisone only
33300531|NCT03896074|Experimental|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
32794433|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
32794434|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
32794435|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
32794436|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
32794437|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
32794438|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
32794439|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
32794440|NCT01529008|Experimental|Core decompression/PREOB® implantation|
32794441|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
32794442|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
32794443|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
32794444|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
32794445|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
32794446|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
32794447|NCT05255432||Group A|Selection of tasks
32794448|NCT05255432||Group B|Selection of tasks
33088631|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (control)"
33300532|NCT03896074|Experimental|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
33088632|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
33088633|NCT04719260|Experimental|Nutrition Thinking®|Nutrition Thinking® approach to promote weight loss and healthy diet pattern.
33088634|NCT04719260|Active Comparator|Standard Nutritional Approach|The traditional nutritional prescriptive approach.
32794449|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
33088635|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
33088636|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
33088637|NCT00315237|Experimental|1|
33088638|NCT00315237|No Intervention|2|best supportive care for 18 week duration
33300533|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
32794450|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
32794451|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.~Between the ages of 21-35 years old."
32794452|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
32794453|NCT05218694|Experimental|CT-guided algorithm (CTGA)|In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.
32794454|NCT05218694|No Intervention|Standard treatment (ST)|"ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions.~Additional projections may be included if deemed necessary for optimal angiographic evaluation"
32794455|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
32794456|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
32794457|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
32794458|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
32794459|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
32794460|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
33088639|NCT00278135|Active Comparator|1|
33088640|NCT00278135|Placebo Comparator|2|
33088641|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
33088642|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
33088643|NCT00416702|Experimental|1|QAB149
33088644|NCT00315354|Experimental|1|Low glycemic index diet
33088645|NCT00315354|Active Comparator|2|Low fat diet
33088646|NCT00315354|Active Comparator|3|Very low carbohydrate diet
33088647|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
33088648|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
33088649|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
33088650|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
33088651|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33300534|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
33300535|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
33300536|NCT03899038|Experimental|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
33300537|NCT03899038|Active Comparator|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
33088652|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
33088653|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33300538|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
33300539|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
33300540|NCT03893422|Experimental|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
33300541|NCT03893422|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
33300542|NCT03893422|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
33404157|NCT04352608|Experimental|Emergency schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
32794461|NCT04099888|Experimental|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
32794462|NCT04099888|Active Comparator|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
32794463|NCT04098718|Other|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
32794464|NCT04098718|Experimental|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
33300543|NCT03898882||BMI 20 - 29.9 kg/m2|
33300544|NCT03898882||BMI > 30 kg/m2|
32794465|NCT04098718|Experimental|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
32794466|NCT04098718|Active Comparator|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
32794467|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
32794468|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
32794469|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
32794470|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
32794471|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
32794472|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
32794473|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
32794474|NCT01527682|Other|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
32794475|NCT01527370|Experimental|Zoster Vaccine Live|
32794476|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
33300545|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
33300546|NCT03893344||Control|Healthy peaple
33300547|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
33300548|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
33300549|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
33300550|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
33300551|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
33300552|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
33300553|NCT01255618||study group, control group|
33300554|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
32794477|NCT01527292|Experimental|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
32794478|NCT04748692|Experimental|Local exercise therapy|The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
32794479|NCT04748692|Experimental|Spinal manual therapy|The spinal manual therapy group was treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots were used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment included manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation was conducted if a restriction of range of motion was found in any of the regions. Patients were also asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
32794480|NCT01516216|Active Comparator|Chemotherapy + Standard Dose Vitamin D|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 400 IU vitamin D3 orally once daily~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
32794481|NCT01516216|Active Comparator|Chemotherapy + Higher Dose|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 8000 IU daily x 2 weeks as loading dose, followed by 4000 IU daily as maintenance dose.~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
32794482|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
33300555|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
33300556|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
32794483|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
32794484|NCT04097860|Experimental|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
32794485|NCT04097860|No Intervention|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
33300557|NCT03895918|Experimental|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
33300558|NCT03895918|Experimental|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
33300559|NCT03895918|Experimental|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
33300560|NCT01258426||Normal, IGT, T2DM|
33300561|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
33300562|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
33300563|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
33300564|NCT01153360|Experimental|T3|triiodothyronine
33300565|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
33300566|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
33300567|NCT03895138|Active Comparator|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
33300568|NCT03895138|Experimental|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
33300569|NCT01257958|Experimental|19 nor vitamin d|
33300570|NCT05521672|Experimental|Single Dose|"This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.~All patients will receive one single dose of 120 million cells"
33300571|NCT03893032|Experimental|Modafinil 200mg|single, 200 mg dose of modafinil
33300572|NCT03893032|Experimental|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
33300573|NCT03893032|Placebo Comparator|placebo|placebo
32794486|NCT04742608||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and at the first routine blood test following surgery. Patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. Patients also undergo collection of tissue samples following surgical resection of thyroid nodule or thyroid cancer. Patients' medical records are also reviewed.
32794487|NCT04767490|Active Comparator|BPD-DS|Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
32794488|NCT04767490|Experimental|SADI|Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
33300575|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
33300576|NCT03893110|Experimental|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
33300577|NCT03893110|Active Comparator|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
33300578|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
33300579|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
32794489|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
32794490|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
32794491|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
32794492|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
32794493|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
32794494|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
32794495|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
32794496|NCT04415775|Experimental|Dual-task walking Intervention|
32794497|NCT04415775|Active Comparator|Conventional Gait Rehabilitation|
32794498|NCT04415775|No Intervention|Healthy Controls|
32794499|NCT05110911||Healthcare Workers|"Eligible participants will be recruited from 1 of 6 participating hospitals in Australia and will meet the following criteria: personnel (including staff, honorary staff, students and volunteers) located at a participating hospital or healthcare service at the time of recruitment who would be eligible for the hospital's free vaccination programme; be aged ≥18 years old and ≤60 years old; have a mobile phone that can receive and send SMS messages; willing and able to provide blood samples; available for follow-up over the next 7 months; able and willing to complete the informed consent process.~There are no restrictions on the type of healthcare worker (HCW) that can be recruited into the study in terms of their job role. HCW will be any hospital staff, including clinical, research, administrative and support staff."
32794500|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
32794501|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
32794502|NCT01523392|Experimental|Ticagrelor|
32794503|NCT01523392|Active Comparator|Clopidogrel|
32794504|NCT01512160|Experimental|PF-04531083 2000 mg|
32794505|NCT01512160|Experimental|PF-04531083 1000 mg|
32794506|NCT01512160|Active Comparator|Ibuprofen 400 mg|
32794507|NCT01512160|Placebo Comparator|Placebo|
32794508|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
32794509|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
32794510|NCT01901289|Experimental|Drug-Eluting Stent|
33300580|NCT01259986|Experimental|Laser treatment|
33300581|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
33300582|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
33300583|NCT03889366|Experimental|NXP001 Oral Capsule|
33300584|NCT03889366|Experimental|NXP001 Oral Suspension|
33300585|NCT03889366|Active Comparator|Emend®|
33300586|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
32794511|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
32794512|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
32794513|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
32794514|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
32794515|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
32794516|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
32794517|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
32794518|NCT04626375|Placebo Comparator|Placebo|Placebo (2 vials per os without active substance every 12 hours)
32794519|NCT04626375|Active Comparator|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
32794520|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
32794521|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
32794522|NCT04615377|Experimental|Kaia hip and knee pain app|Kaia software application: Kaia Knee and Hip pain app (version 2.37.0) The Kaia Knee and Hip pain app is an investigational device, which is intended as a digital aid for the self-management of osteoarthritis for use by adults (between 22 to 75 years old) without supervision by healthcare professionals in a home setting.
32794523|NCT04615377|Active Comparator|Treatment as usual|Participants will be encouraged to continue the treatment that they have been on without restriction
32794524|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
32794525|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
32794526|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
32794527|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
32794528|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
32794529|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
32794530|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
32794531|NCT04615221|Other|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
32794532|NCT04615221|Other|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
32794533|NCT04615221|Other|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
32794534|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
32794535|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
32794536|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
32794537|NCT04409626||Cases|
32794538|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
32794539|NCT01545934|No Intervention|Standard Care|
32794540|NCT01545934|Experimental|Lifestyle intervention|
32794541|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.~Intervention：tomotherapy"
32794542|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
32794543|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
32794544|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
32794545|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
32794546|NCT01545076|Experimental|IgPro20 low dose|
32794547|NCT01545076|Experimental|IgPro20 high dose|
32794548|NCT01545076|Placebo Comparator|Placebo|
32794549|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
32794550|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
32794551|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
32794552|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
32794553|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
33300587|NCT03895294|Experimental|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
33300588|NCT03895294|Active Comparator|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
33300589|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
33404158|NCT04352608|Experimental|Emergency schedule & Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
33404159|NCT04352608|Placebo Comparator|Emergency schedule &Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
33300590|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
33300591|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
33300592|NCT05086432|Experimental|Sputum-guided management|During Weeks 0 to 16, participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation (Table 1 in protocol) identified during screening (Figure 2 in protocol). Airway eosinophilia will be treated with regular inhaled corticosteroids based on the severity of eosinophilic inflammation. In participants with airway neutrophilia, as per the standard of care, sputum culture and sensitivity will be sent, and pathogenic organisms treated. Those participants with airway neutrophilia with negative cultures will be treated with thrice weekly Azithromycin (250mg). Combined eosinophilia and neutrophilia will receive treatment with both ICS and Azithromycin as per Table 2 in protocol.
33300593|NCT05086432|Active Comparator|Standard of Care|Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.
33300594|NCT03895060|Experimental|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
33300595|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.~These symptoms are ongoing and get better with asthma medicines."
33300596|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
33300597|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
33300598|NCT03889054|No Intervention|Control|Current clinical management
33300599|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
33300600|NCT01153438||Gastric bypass, Gastric banding|
33300601|NCT03894826|Experimental|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat [100 mg tablets] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
33300602|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
33300603|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
33300604|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
33300605|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
33300606|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
33300607|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
33300608|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
32794554|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
32794555|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
32794556|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
32794557|NCT04409704|Experimental|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
32794558|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
32794559|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
32794560|NCT04096222||Active pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
32794561|NCT04096222||Inactive pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
32940225|NCT05372042|Active Comparator|No Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a simple reminder to use the skill.
33088654|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
33088655|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
33300609|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
33300610|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
33300611|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
33300612|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
33300613|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
33300614|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
33300615|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
33300616|NCT03894748|Experimental|MT10109L(Botulinum toxin type A)|
33300617|NCT03894748|Active Comparator|BOTOX® 50U(Botulinum toxin type A)|
33300618|NCT03894670|Active Comparator|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
33300619|NCT03894670|Experimental|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
33300620|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
33300621|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
33300622|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
33300623|NCT03894592|Active Comparator|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
33300624|NCT03894592|No Intervention|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
33300625|NCT00187278|Active Comparator|RV Pacing|Standard Pacemaker implant
32794562|NCT04096222||Healthy subjects|Healthy subjects will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) Demographic data will be documented, 2) biometric data, 3) A 34 ml blood sample will be taken
32794563|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
32794564|NCT01520506|Experimental|Rapid Renal Denervation|
32794565|NCT01519960|Experimental|A Pegasys|
32794566|NCT01519960|No Intervention|B Untreated Control|
32794567|NCT01519960|Experimental|C Fibrosis non-randomized|
32794568|NCT01519960|Experimental|Switch|
32794569|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
32794570|NCT01488994|Experimental|BAX326 < 6 years of age|
32794571|NCT01488994|Experimental|BAX326 6 to <12 years of age|
33088656|NCT00278447|Active Comparator|2) Standard care|Standard care
33088657|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
32794572|NCT01508650|Active Comparator|No intervention|Usual care control group
32794573|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
33088658|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
33300626|NCT00187278|Experimental|Biventricular Pacing|Biventricular Pacemaker implant
33300627|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
32794574|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
32794575|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
32794576|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
32794577|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
32794578|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
32794579|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
32794580|NCT01518946|Active Comparator|Midodrine HCl|
32794581|NCT01518946|Placebo Comparator|Placebo|
32794582|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
32794583|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
32794584|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
32794585|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
32794586|NCT03026998|Other|MRI|
32794587|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
32794588|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
32794589|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
32794590|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
32794591|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
32794592|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
32794593|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
33088659|NCT00278486|Experimental|stem cell transplantation|
33088660|NCT00278642|Experimental|stem cell transplantation|
33088661|NCT00278681|Experimental|I|Zinc and ORS
33088662|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
33088663|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
33300628|NCT03894124|Other|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
33300629|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
33088664|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
32794594|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
32794595|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
32794596|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
33088665|NCT00315900|Experimental|Depakote ER|Depakote ER
32794597|NCT01487200|Experimental|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
32794598|NCT01487200|Experimental|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
32794599|NCT01487200|Experimental|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
32794600|NCT01487200|Active Comparator|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
32794601|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
32794602|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
33088666|NCT00315900|Active Comparator|Seroquel|Seroquel
33088667|NCT00279110|Experimental|A|
32794603|NCT04080856||Participants with endometriosis|Premenopausal participants with endometriosis receiving elagolix in real-world setting
32794604|NCT04080544|Experimental|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
32794605|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
32794606|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
32794607|NCT01486966|Experimental|Insulin detemir / IAsp|
33088668|NCT00279110|No Intervention|B|
33088669|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
32794608|NCT01486966|Active Comparator|insulin NPH|
32794609|NCT04080076|Active Comparator|ACTHar gel combined with Tacrolimus|ACTHar Gel units 2 times per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
32794610|NCT04080076|Active Comparator|ACTHar gel|ACTHar Gel units 2 times per week for 52 weeks
32794611|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
32794612|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
33088670|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
33088671|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
33088672|NCT00279149|Experimental|surgery|surgery
33088673|NCT00418860|Experimental|A|
33088674|NCT00316134||Pts scheduled to remove pleural fluid|
33088675|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
33088676|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
33088677|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
33088678|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
33088679|NCT00316290|Experimental|1|Participants will receive integrated parent training.
33088680|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
33088681|NCT00279422|Placebo Comparator|placebo|
33088682|NCT00279422|Experimental|visilizumab|
33088683|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
33088684|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
33088685|NCT00279617|Active Comparator|Levetricetam|open label treatment
33088686|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
33088687|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
33088688|NCT00279695||1|Subjects with glaucoma and age-matched normals
33088689|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
33088690|NCT00279695||3|subjects with tumors of the iris and ciliary body
33088691|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
33088692|NCT00279734|Experimental|Group 1|
33088693|NCT00279734|Active Comparator|Group 2|
33088694|NCT00279734|Active Comparator|Group 3|
33088695|NCT00279734|Active Comparator|Group 4|
33088696|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
32794613|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
32794614|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
32794615|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
32794616|NCT01899729|Experimental|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
32794617|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
32794618|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
32794619|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
33300630|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
32794620|NCT01899729|Experimental|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
32794621|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
32794622|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
32794623|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
32794624|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
33404160|NCT04352608|Experimental|Routine schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
32794625|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
32794626|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
32794627|NCT01888497|Experimental|Arm A|
32794628|NCT01888497|Experimental|Arm B|
32794629|NCT01888497|Active Comparator|Arm C|
32794630|NCT01888497|Placebo Comparator|Arm D|
32794631|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
32794632|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
32794633|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
32794634|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
32794635|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
32794636|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
32794637|NCT04613674|Experimental|Arm A|
32794638|NCT04613674|Experimental|Arm B|
32794639|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
32794640|NCT01887717|Experimental|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
32794641|NCT01887717|Active Comparator|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
32794642|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
33088697|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
33088698|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
33088699|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
33088700|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
32794643|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
32794644|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
32794645|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
32794646|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
32794647|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
32794648|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
32794649|NCT01463098|Experimental|Part A: E2006 1.0 mg|
32794650|NCT01463098|Experimental|Part A: E2006 2.5 mg|
32794651|NCT01463098|Experimental|Part A: E2006 5.0 mg|
32794652|NCT01463098|Experimental|Part A: E2006 10.0 mg|
32794653|NCT01463098|Experimental|Part A: E2006 25.0 mg|
32794654|NCT01463098|Experimental|Part A: E2006 50.0 mg|
32794655|NCT01463098|Experimental|Part A: E2006 100 mg|
32794656|NCT01463098|Experimental|Part A: E2006 200 mg|
32794657|NCT01463098|Experimental|Part B: Zolpidem 10 mg|
32794658|NCT01463098|Experimental|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
32794659|NCT01463098|Experimental|Part A: E2006 Matched Placebo|
32794660|NCT01463098|Experimental|Part B: E2006 2.5 mg|
32794661|NCT01463098|Experimental|Part B: E2006 10 mg|
32794662|NCT01463098|Experimental|Part B: E2006 25 mg|
32794663|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
32794664|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
32794665|NCT01626079|Experimental|COAPT CAS Group|Percutaneous mitral valve repair using MitraClip System
32794666|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
32794667|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
32794668|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
32794669|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
32794670|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
32794671|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32794672|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
32794673|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
32794674|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
32794675|NCT04745065|Experimental|Connect2BWell Condition|The Connect2BWell program delivers feedback on SUD risk, 3 brief online intervention sessions over 3 months, and text messages for 6 months. Sessions and text messages are tailored to the patient's most problematic drug based on the ASSIST; stage of change for quitting or reducing use of that drug; and stage of change for seeking treatment, if indicated. Online sessions are followed by a dashboard-guided telehealth session with a nurse care manager. The dashboard summarizes the patient's ASSIST risk scores and stage of change data; presents patients' responses to key questions in the online session; and provides tools for collaborating with the patient to select action steps matched to risk level and stage and stage of change for seeking treatment, if indicated. The program provides a patient portal with activities, resources, and tools for tracking progress on action steps.
33088701|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
33088702|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
33088703|NCT00316563|Active Comparator|1|
33088704|NCT00316563|Placebo Comparator|2|
33088705|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
33088706|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
33088707|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
33088708|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
33088709|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
33088710|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
33088711|NCT00280007|Placebo Comparator|2|placebo infusion
33088712|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
33300631|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
33300632|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
33300633|NCT00256308|Experimental|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
33300634|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
33300635|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
33088713|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
33300636|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
33300637|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
33300638|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
33300639|NCT03968952|Active Comparator|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:~Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).~An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
33300640|NCT03968952|No Intervention|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:~An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.~Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
33300641|NCT01151722|No Intervention|no injection|no bevacizumab
33300642|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
33300643|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
33300644|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
33300645|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
33300646|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
33300647|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
33300648|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
33300649|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
33300650|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
33300651|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
33300652|NCT01260298||MC1 Ultrasonic Device|
33300653|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
33300654|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
33300655|NCT03894358|Active Comparator|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
33300656|NCT03894358|Active Comparator|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
33300657|NCT03894358|Active Comparator|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
33300658|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
33300659|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
33300660|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
33300661|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
33300662|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
33300663|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
33300664|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
33300665|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
33300666|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
32940226|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
33300667|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
33300668|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
32940227|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
32940228|NCT05286554|Experimental|Group 1|Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.
32940229|NCT05286554|Experimental|Group 2|Will receive routine LPS and additional multiple mid-luteal GnRH-a, triptorelin 0.1 mg subcutaneous injection on the 5th, 7th and 9th days after oocyte retrieval.
33300669|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
33300670|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
33300671|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
33300672|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
33300673|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
33300674|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
33300675|NCT01259050|Experimental|Zinc and Copper|
33300676|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
33300677|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
32940230|NCT05286554|Active Comparator|Group 3 (Control)|Will receive the routine LPS without GnRH-a
32940231|NCT03558061|Experimental|Active|ALK4290 800 mg daily
32940232|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
32940233|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
32940234|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
33088714|NCT00316758|Experimental|1|
33088715|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
32794676|NCT04745065|No Intervention|Comparison Condition|Patients assigned to the Comparison Condition will receive a brief SBIRT session delivered via telehealth by a member of their clinic care team. The session will include the clinic's standard scripted feedback matched to level of risk for alcohol use and for other drug use; encouragement to quit; and referral to specialty treatment, if indicated.
32794677|NCT04744987||Hypovolemic hyponatremia|Patients with any cause of hypovolemic hyponatremia were included.
32794678|NCT04744987||Euvolemic hyponatremia|Only patients with euvolemic hyponatremia secondary to Syndrome of inappropriate antidiuresis were included.
32794679|NCT04744207|Experimental|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
32794680|NCT04744207|Placebo Comparator|Placebo|placebo, capsule, once daily for 4 weeks
32794681|NCT02118961|Experimental|BK1301|
33088716|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
33088717|NCT00280319|No Intervention|control|those who are wait-list controls
33404161|NCT04352608|Experimental|Routine schedule &Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
32794682|NCT02118961|Active Comparator|DT toxoid|
32794683|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
32794684|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
32794685|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
32794686|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
32794687|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
32794688|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
32794689|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
32794690|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
32794691|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
32794692|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
32794693|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
32794694|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
32794695|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
32794696|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
32794697|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
32794698|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
32794699|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
32794700|NCT04418011|Active Comparator|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
32794701|NCT04418011|Active Comparator|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
32794702|NCT04418011|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
32794703|NCT04411225|Experimental|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
32794704|NCT04411225|Placebo Comparator|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
32794705|NCT04743349|Experimental|Experimental arm|Steam inhalations
32794706|NCT04743349|No Intervention|Control arm|No intervention
32794707|NCT04742491|Experimental|Immediate Intervention Arm Descovy in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
32794708|NCT04742491|Experimental|Deferred Intervention Arm Descovy in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
32794709|NCT04742491|Experimental|Immediate Intervention Arm Truvada in Brazil|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
32794710|NCT04742491|Experimental|Deferred Intervention Arm Truvada in Brazil|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
32794711|NCT04742491|Experimental|Immediate Intervention Arm Truvada in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
33088718|NCT00316797|Experimental|123-I INER|To assess 123-I INER
33088719|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
32794712|NCT04742491|Experimental|Deferred Intervention Arm Truvada in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
32794713|NCT04742413||A|Patients who are prescribed to switch to lurasidone (lurasidone cohort)
32794714|NCT04742413||B|Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)
32794715|NCT04737265|Experimental|Biomarker Guided Arm|"NTproBNP will be monitored serially prior to start of anthracycline based chemotherapy, at each cycle of anthracycline based chemotherapy, and at 3 month intervals for a total of 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy."
32794716|NCT04737265|No Intervention|Usual Care|NTproBNP will not be monitored while patients are on study unless clinically indicated. Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy. Biomarker data will also be collected at each cycle of Anthracycline chemotherapy.
32794717|NCT05132491|Experimental|Online Training Program|An online intervention for people with disabilities intended to increase social skills and interest in coding careers.
32794718|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
32794719|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
32794720|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
32794721|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
32794722|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
32794723|NCT04408378||mild pneumonia|The patients who has followed in the ward
32794724|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
32794725|NCT04408378||control group|patients who has not covid 19 pneumonia
32794726|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
32794727|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
32794728|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
33088720|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
33088721|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
33088722|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
33088723|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
33088724|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
33088725|NCT00310557|Experimental|Arm 1|
33088726|NCT00280592|Placebo Comparator|Placebo|
33088727|NCT00280592|Experimental|Cranberry|Cranberry
33088728|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
33088729|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
32794729|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
32794730|NCT04079686|Experimental|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
32794731|NCT04079686|Placebo Comparator|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
32794732|NCT04094584|Experimental|Multimodal Intervention|"The intervention is multimodal and consists of:~Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 3 months.~Case Management services"
32794733|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
32794734|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
32794735|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
32794736|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
32794737|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
33088730|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
33088731|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
33088732|NCT00280670|Experimental|Cognitive Behavioral Therapy|
32794738|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
32794739|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
33088733|NCT00280670|No Intervention|Waitlist|
33088734|NCT00280709|Active Comparator|1|Covered metal stent
33088735|NCT00280709|Active Comparator|2|Uncovered metal stent
33088736|NCT00310596|Experimental|Arm 1|
33404162|NCT04352608|Placebo Comparator|Routine schedule & Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
32794740|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
32794741|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
32794742|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
32794743|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
32794744|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
32794745|NCT02134028|Experimental|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1* Dose every 2 weeks added to current controller medications.~For participants coming from other studies: dupilumab 1 * Dose SC every 2 weeks added to current controller medications."
33088737|NCT00310596|Experimental|Arm 2|
33088738|NCT00310596|Experimental|Arm 3|
33088739|NCT00310596|Experimental|Arm 4|
33088740|NCT00310596|Active Comparator|Arm 5|
33088741|NCT00310596|Placebo Comparator|Arm 6|
33088742|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
33088743|NCT00317031|Active Comparator|1|Acamprosate
33088744|NCT00317031|Active Comparator|2|Naltrexone
33088745|NCT00317031|Placebo Comparator|3|Placebo
33088746|NCT00317070|Active Comparator|DMSO|Intravesical installation
33088747|NCT00317070|Experimental|Cocktail|
33088748|NCT00317148|Experimental|Placebo|
33088749|NCT00317148|Experimental|DHEA|
33088750|NCT00310713|Experimental|Group 1|
33088751|NCT00310713|Experimental|Group 2|
33088752|NCT00310713|Experimental|Group 3|
33088753|NCT00310713|Experimental|Group 4|
33088754|NCT00310713|Experimental|Group 5|
33088755|NCT00281255|Experimental|allopurinol|
33088756|NCT00281255|Placebo Comparator|placebo|
32794746|NCT04752488|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
32794747|NCT04752488|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
32794748|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
32794749|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
32794750|NCT04757636|Experimental|2.0 mg aflibercept with Standard Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
32794751|NCT04757636|Experimental|2.0 mg aflibercept with Extended Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
32794752|NCT04757636|Sham Comparator|2.0 mg aflibercept with sham|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
32794753|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
32794754|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
32794755|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
32794756|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
32794757|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
32794758|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
32794759|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
32794760|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
32794761|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
32794762|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
32794763|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
32794764|NCT04749680|Experimental|Peritoneal dialysis PD|Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
32794765|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
32794766|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
32794767|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
32794768|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
32794769|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
32794770|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
32794771|NCT04757012|Experimental|Calinage exposition|exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D2, D4 and D6
32794772|NCT04757012|No Intervention|no exposition|No exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D1, D3 and D5
32794773|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
32794774|NCT04188392|Experimental|open-label treatment|pimavanserin 34mg at bedtime for 6 weeks
32794775|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
32794776|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
32794777|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
32794778|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
32794779|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
32794780|NCT04749524||Newborns|Otoacoustic Emissions to be measured with and without suppression noise
32940235|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
32794781|NCT04749524||Newborns failing initial hearing screening test|Otoacoustic Emissions to be measured with and without suppression noise
32794782|NCT04749524||Adults with normal hearing|Otoacoustic Emissions to be measured with and without suppression noise
32794783|NCT04749524||Adults with hearing loss|Otoacoustic Emissions to be measured with and without suppression noise
32794784|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
32794785|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
32794786|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
32794787|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
32794788|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
33404163|NCT04352608|Experimental|Emergency schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
32794789|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
32794790|NCT04740164|Experimental|Arm I (ERCP with LMA Gastro)|Patients undergo ERCP with LMA Gastro.
32794791|NCT04740164|Active Comparator|Arm II (ERCP with standard nasal cannula)|Patients undergo ERCP with standard nasal cannula.
32794792|NCT04739306|Experimental|CT-P42|
32794793|NCT04739306|Active Comparator|Eylea|
32794794|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
32794795|NCT04748822|Other|Quality of life of patients with AUD.|Patients' demographic data, socioeconomic status, physical diseases, medication use, clinical features of AUD, psychiatric variables, impulsivity, autonomy, sexual functioning, sleep quality, and cognitive functioning will be measured at baseline. The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
32794796|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
32794797|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
32794798|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
32794799|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
32940236|NCT00379106|Active Comparator|Group1|
32794800|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
32794801|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
32794802|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
32794803|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
32794804|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
32794805|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
32794806|NCT04752020|Experimental|Netarsudil use|Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
32794807|NCT05209178|Experimental|Self-collection of specimen|Participants allocated to this arm will perform specimen collection for the antigen tests independently using written instructions and access to a video. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
33300678|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
32794808|NCT05209178|Active Comparator|Healthcare-collection of specimen|Participants allocated to this arm will initially have specimen collection for the antigen tests done by a healthcare personnel. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
32794809|NCT04737356|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
32794810|NCT04737356|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
32794811|NCT04751708|Active Comparator|best medical management|Unless contra-indicated patients are treated with a standard full dose of open-label IV rt-PA (0.9mg/kg; 90mg maximum). IVT has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. For the patients in whom the rtPA is contraindicated, the standard medical treatment follows the current guidelines for the early management of patients with acute ischemic stroke from the American Heart Association/American Stroke Association.
32794812|NCT04751708|Experimental|endovascular treatment+ best medical management|Device: endovascular treatment For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
32794813|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
32794814|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
32794815|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
32794816|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
32794817|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
32794818|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
32794819|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
32794820|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
33300679|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
33300680|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
32794823|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
32794824|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
32794825|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
32940237|NCT00379106|Experimental|Group 2|
32940238|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
33300681|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
33300682|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
33300683|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
33300684|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
33300685|NCT00255840|Active Comparator|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
33300686|NCT00255840|Active Comparator|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
33300687|NCT01154062|Experimental|low dose|Pazopanib tablet
33300688|NCT01155544|Active Comparator|Aripiprazole|
33300689|NCT01155544|Placebo Comparator|Placebo|
32794826|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
32794827|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
32794828|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
33404164|NCT04352608|Experimental|Emergency schedule & Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
33404165|NCT04352608|Placebo Comparator|Emergency schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
32794829|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
33404166|NCT04352608|Experimental|Routine schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
33404167|NCT04352608|Experimental|Routine schedule &Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
33404168|NCT04352608|Placebo Comparator|Routine schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule
32794830|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
33404169|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
32794831|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32794832|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
32794833|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
32794834|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
32794835|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
32794836|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
32794837|NCT04748042|Experimental|Abiraterone, ADT, Radiation and Olaparib|Abiraterone, ADT, radiation to all metastases and Olaparib.
32794838|NCT01626872|Experimental|MP-214 3mg|
32794839|NCT01626872|Experimental|MP-214 6mg|
32794840|NCT01626872|Experimental|MP-214 9mg|
32794841|NCT01626872|Active Comparator|Risperidone 4mg|
32794842|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
32794843|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
32794844|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
32794845|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
32794846|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
32794847|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
32794848|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
32794849|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
32794850|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
32794851|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
32940239|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
32940240|NCT04706312|Experimental|hAMSCs injection|hAMSCs were injected via venous in the dorsum of hand.
32940241|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
32940242|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
32940243|NCT00379184||C|Healthy volunteers
32940244|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
32940245|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
32940246|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
32940247|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
32794852|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
32794853|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
32794854|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
32794855|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
32794856|NCT04751552|Active Comparator|Levobupivacaine group|Patients receive an ESPB with the local anaesthetic levobupivacaine
32794857|NCT04751552|Placebo Comparator|Placebo group|Patients receive an ESPB with 0,9% saline
32794858|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
33404170|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
32794859|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
32794860|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
32794861|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
32794862|NCT02141516|Experimental|Group A|Complement deficiency
33404171|NCT05203146|Experimental|Arm A (PIMPmyHospital)|Participants that will use the mHeath PIMPmyHospital tool during the semi-simulation-based scenario.
33404172|NCT05203146|Active Comparator|Arm B (Conventional methods)|Participants that will use conventional methods (i.e., without mobile app support) during the semi-simulation-based scenario.
32794863|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
32794864|NCT02141516|Active Comparator|Group C|age-matched healthy controls
32794865|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
33404173|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
32794866|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
32794867|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
32794868|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
32794869|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
32794870|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
32794871|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
32794872|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
32794873|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
32794874|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
32794875|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
32794876|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
32794877|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
32794878|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
32940248|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
33300690|NCT03972228|Experimental|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
33300691|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
32794879|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
32794880|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
33300692|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
33300693|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
33300694|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
33300695|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
33300696|NCT03885700|Experimental|intervention group|
33300697|NCT03885700|No Intervention|control group|
33300698|NCT01260532||Graves' disease|no intervention
32794881|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
33300699|NCT01260532||Hashimoto's thyroiditis|no intervention
33300700|NCT01260532||Healthy subjects|no intervention
33300701|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
33300702|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
33300703|NCT00224874|Experimental|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
33300704|NCT00224874|Experimental|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
33300705|NCT00224874|Experimental|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
33300706|NCT00224874|Experimental|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
33300707|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
33300708|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
33300709|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
32794882|NCT01160861|Experimental|A|
32794883|NCT01160861|Experimental|B|
33300710|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
32794884|NCT01160861|Experimental|C|
32794885|NCT03368729|Experimental|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
32794886|NCT03368729|Experimental|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
32794887|NCT03368729|Experimental|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
32794888|NCT04432883|Active Comparator|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
32794889|NCT04432883|Sham Comparator|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
32794890|NCT04782869|Experimental|tDCS (transcranial direct current stimulation)|Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.
32794891|NCT04355975||Medical Therapy / Anticoagulation|
32794892|NCT04355975||Systemic Lysis|
32794893|NCT04355975||Interventional Therapy for PE|
32794894|NCT04355975||Surgical Embolectomy|
32794895|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
33300711|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
33300712|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
33300713|NCT00186186|Experimental|Depakote ER|Depakote ER up to 1500 mg/day
33300714|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
33300715|NCT03892408|No Intervention|Standard|standard anesthesia
33300716|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
33300717|NCT03969108|Experimental|Indocyanine Green|
33300718|NCT03973944|Other|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
32794896|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
33300719|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
33300720|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
33300721|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
33300722|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
33300723|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
32794897|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
32794898|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
32794899|NCT04338581|Experimental|AMG 714|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
32794900|NCT04338581|Placebo Comparator|Placebo|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
32794901|NCT00864227|Experimental|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
32794902|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Treatment Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
32794903|NCT05230511|Other|Intravesical Bladder Wash (Treatment Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
32794904|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Prophylaxis Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. They will then instill the LGG® mixture every 2 days for the remainder of the 6 months. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
32794905|NCT05230511|Other|Intravesical Bladder Wash (Prophylaxis Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
32794906|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
32794907|NCT04810715||Patient Group|Anklyosing Spondilitis
32794908|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
32940249|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
32940250|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
32940251|NCT03620383|Experimental|Heat|Distal topical heat application
32940252|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
32940253|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
32940254|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
33300724|NCT00185640|Experimental|Non-myeloablative transplantation|Pre-transplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) infusion with Day 0 allogeneic hematopoietic cell transplant (HCT), followed by post-transplant immunosuppression by cyclosporine and mycophenolate mofetil.
33300725|NCT01262248||patients with colorectal polyps|
33300726|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
33300727|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
33300728|NCT03973788|Experimental|Intervention|repetitive transcranial magnetic stimulation
33300729|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
33300730|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
33300731|NCT03968640|Active Comparator|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
33300732|NCT03968640|Placebo Comparator|Placebo|Allocation-concealed placebo will be used as an appropriate control.
33300733|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
33300734|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
33300735|NCT01260610|Active Comparator|Tenofovir|
33300736|NCT01260610|Active Comparator|Telbivudine|
33300737|NCT01260610|Experimental|Tenofovir plus Telbivudine|
33300738|NCT01152424||Acute eosinophilic pneumonia|
33300739|NCT01152424||Community acquired pneumonia|
33300740|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
33300741|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
33300742|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
33300743|NCT05477836|Experimental|Experimental group|Microwave-based colonoscopy
33300744|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
33300745|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
33300746|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
33300747|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
33300748|NCT02527486||No predefined subgroups|
33300749|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
33300750|NCT03892252||before surgery|no intervention(s)
33300751|NCT03892252||after surgery|no intervention(s)
33300752|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
33300753|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
33300754|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
33300755|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
33300756|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
33300757|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
33300758|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
33300759|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
33300760|NCT03892174|No Intervention|Treatment protocol without adsorption|
33300761|NCT03892174|Active Comparator|Treatment protocol with adsorption|
33300762|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
33300763|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
33300764|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
33300765|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
33300766|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
33300767|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
33300768|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
33300769|NCT05077852||Cystoscopy Bladder Cancer|Patients diagnosed with primary bladder cancer at the base, trigone or neck of the bladder by cystoscopy.
33300770|NCT05077852||Cystoscopy IPP|Patients diagnosed with intravesical prostate protrusion (IPP) at the base, trigone or neck of the bladder by cystoscopy.
33300771|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
33300772|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
32794909|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
32794910|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
32794911|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
32794912|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
32794913|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
32794914|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
32794915|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
32794916|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
33300773|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
33300774|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
33300775|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
32794917|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32794918|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32794919|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32794920|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
32794921|NCT04733768|Experimental|18F-PSMA-1007 PET/CT scan|Single Arm study - all enrolled patients will undergo an experimental 18F-PSMA-1007 PET/CT scan
32794922|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
33300776|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
33300777|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia~Aged from 20-80 years old"
33300778|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
33300779|NCT03891472|Experimental|Arm 1|
33300780|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
33300781|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
33300782|NCT01154608|Experimental|pancreatic enzymes|
33300783|NCT01154608|Placebo Comparator|control|
33300784|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
33300785|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
33300786|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
33300787|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
33300788|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
33300789|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
33300790|NCT03884218|Other|Thermal Comfort|Infra red thermal image
33300791|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
33300792|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
32794923|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
32794924|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
32794925|NCT04798469|Experimental|Testosterone|Intramuscular injections of testosterone undecanoate 750 mg.
32794926|NCT04798469|Placebo Comparator|Placebo|Intramuscular injections of placebo.
32794927|NCT04782323|Experimental|Group A aQII-1 Investigational|
32794928|NCT04782323|Experimental|Group B aQII-3 Investigational|
32794929|NCT04782323|Experimental|Group C aQII-6 Investigational|
32794930|NCT04782323|Experimental|Group D aQII-7 Investigational|
32794931|NCT04782323|Experimental|Group E aQII-9 Investigational|
32794932|NCT04782323|Experimental|Group F aQII-10 Investigational|
32794933|NCT04782323|Experimental|Group G aQII-11 Investigational|
32794934|NCT04782323|Active Comparator|Group H QII Active Comparator|
32794937|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
32794938|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
32794939|NCT04219007|Experimental|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
32794940|NCT04168073|Experimental|High sodium diet|
32794941|NCT04168073|Experimental|Low sodium diet|
32794942|NCT04167527|Experimental|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
32794943|NCT04167527|Active Comparator|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
32794944|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
32794945|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
32794946|NCT04150913|Experimental|Anakinra and Axicabtagene Ciloleucel|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.~Screening~Enrollment/Leukapheresis period~Bridging therapy (if applicable)~Lymphodepleting chemotherapy period~Investigational Product (IP) treatment period~Anakinra~Axicabtagene Ciloleucel~Post treatment assessment period~Long term follow-up period"
32794947|NCT04798235|Experimental|TSHA-101|Subjects who will receive one-time intrathecal TSHA-101, brain volume based sliding scale for dosage
33088757|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
32794948|NCT04733378|Experimental|Peri-operative neurological monitoring|
32794949|NCT04798001|Experimental|Cohort A / Dosage Group 1 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
32794950|NCT04798001|Experimental|Cohort A / Dosage Group 2 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
32794951|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
32794952|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Two Doses|Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
32794953|NCT04798001|Experimental|Cohort A / Dosage Group 3b (intranasal spray) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
32794954|NCT04798001|Experimental|Cohort B / Dosage Group 4 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
32794955|NCT04798001|Experimental|Cohort B / Dosage Group 5 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
32794956|NCT04798001|Experimental|Cohort B / Dosage Group 6 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
32794957|NCT04797845|Experimental|telemonitoring of non invasive ventilation at home|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
32794958|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
32794959|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
32794960|NCT04191161|Experimental|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
32794961|NCT04191161|Placebo Comparator|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
32794962|NCT04081493|Experimental|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
32794963|NCT04081493|No Intervention|Group 2 (CON)|No training before TKR
32794964|NCT04073303|Active Comparator|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
32794965|NCT04073303|Placebo Comparator|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
32794966|NCT04070573|Active Comparator|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
32794967|NCT04070573|Active Comparator|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
32794968|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
32794969|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
32794970|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
32794971|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
33088758|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
33300793|NCT03891628|Experimental|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
32794972|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
32794973|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
33300794|NCT03891628|Active Comparator|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
32794974|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
33300795|NCT01259206||diabetic patients|
32794975|NCT04020341|Experimental|Gepotidacin|Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
32794976|NCT04020341|Active Comparator|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
32940255|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
32940256|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
32940257|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
32940258|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
32940259|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
32940260|NCT00790478|Placebo Comparator|Placebo|Placebo -- lactose pill.
32940261|NCT00790478|Active Comparator|Melatonin|Melatonin
32794977|NCT02072174|Experimental|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
32794978|NCT02072174|Placebo Comparator|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
32794979|NCT02209181|Experimental|JNJ-10450232 250 mg|
32794980|NCT02209181|Experimental|JNJ-10450232 1000 mg|
32794981|NCT02209181|Placebo Comparator|Placebo|
32794982|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
32794983|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
32794984|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
32794985|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
32794986|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
32794987|NCT03978611|Experimental|Part 1: Dose Escalation Phase|
32794988|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
32794989|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
32794990|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
32794991|NCT04769687|Experimental|Symbiotic Treatment : probiotic Vivomixx® + prebiotic Orafti®Synergy1|"The prebiotic, Orafti®Synergy1, is made from a volume-to-volume mixture of oligofructoses and Raftiline HP. Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets that can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~The probiotic, Vivomixx®, consists of 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. Bulgaricus) from 3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis) and a strain of streptococcus (S. salivarius subsp thermophilus). Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria which can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~For the study, the symbiotics will be packaged by the probiotic manufacturer in the same sachet (at the same doses as mentioned above) whether for the symbiotics or for the placebo."
32794992|NCT04769687|Placebo Comparator|Placebo|
32794993|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
33088759|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
33088760|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
33088761|NCT00310869|Experimental|E|
33088762|NCT00317304|Experimental|MBSR|
33088763|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
32794994|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
33088764|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
33088765|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
33088766|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
33088767|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
33088768|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
33088769|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
33088770|NCT00317460|Active Comparator|1|Physician Management
33088771|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
33088772|NCT00317499|Experimental|Etanercept|
33088773|NCT00317499|Placebo Comparator|Placebo|
33088774|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
33088775|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
33088776|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
33102429|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
32794995|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
32794996|NCT02240693|Experimental|BI 409306 dose 1|
32794997|NCT02240693|Experimental|BI 409306 dose 2|
32794998|NCT02240693|Experimental|BI 409306 dose 3|
32794999|NCT02240693|Experimental|BI 409306 dose 4|
32795000|NCT02240693|Placebo Comparator|Placebo|
32795001|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
32795002|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
32795003|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
32795004|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
32795005|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
32795006|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
32795007|NCT05107700|Experimental|Start with: Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
32795008|NCT05107700|Placebo Comparator|Start with: Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m as comparator.
32795009|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
32795010|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
32795011|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
32795012|NCT03843359|Experimental|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
32795013|NCT03843359|Experimental|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
32795014|NCT02123108|Experimental|Basiliximab|Tacrolimus with Basiliximab induction
32795015|NCT02123108|Active Comparator|Tacrolimus Group|Tacrolimus (without basiliximab induction); standard of care group
32795016|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
32795017|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
32795018|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
32795019|NCT03797183||Healthy Controls|Age and height matched healthy controls
32795020|NCT03797183||V/Q Scan validation|Adults or children who are having or have recently had a V/Q scan
32795021|NCT03797183||Premature Infants (Longitudinal Cohort)|Premature infants ages 2 weeks to 1 year with diagnosed or suspected bronchopulmonary dysplasia
32795022|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32795023|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
32795024|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
32795025|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
32795026|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
32795027|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
32795028|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
32795029|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
32795030|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
32795031|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
32795032|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
32795033|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
32795034|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
32795035|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
32795036|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
32795037|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
33300796|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
32795038|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
33088777|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
33102430|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
32795039|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
32795040|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
32795041|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
32795042|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
32795043|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
32795044|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
32795045|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
32795046|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
32795047|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
33300797|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
33300798|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure~."
32795048|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
32795049|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
32795050|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
32795051|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
32795052|NCT04732208||Diabetic patients|
32795053|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
32795054|NCT02068352|Experimental|0.3% OPA-15406|OPA-15406 0.3% ointment was applied topically twice daily (BID) to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
32795055|NCT02068352|Experimental|1% OPA-15406|OPA-15406 1% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
32795056|NCT02068352|Placebo Comparator|Vehicle Ointment|OPA-15406 1%-matching placebo (vehicle ointment) was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
32795057|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
32795058|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
32795059|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
33300799|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
32795060|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
32795061|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
32795062|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
33300800|NCT01261156|Experimental|Study Arm 1|
33300801|NCT01261156|Experimental|Study Arm 2|
33300802|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
32795063|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
32795064|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
32795065|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
32795066|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
32795067|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
32795068|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
32795069|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
32795070|NCT02119676|Active Comparator|Placebo plus regorafenib|
32795071|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
32795072|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
32795073|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
32795074|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
32795075|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
32795076|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
32900733|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
33300803|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
33300804|NCT05477680|Experimental|Surgery|Removing different brain lesions using neuronavigation
33300805|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
33300806|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
33300807|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
33300808|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
33088778|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.~Interventions:~Undertake and record a formalized clinical assessment of hydration status~Take a measurement of body weight on calibrated scales~RF wristband hydration status measurement~Measure capillary refill time with manual stopwatch~CRT device hydration status measurement"
33300809|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
33300810|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
32795077|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
32795078|NCT02068118|No Intervention|Standard care|Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
32795079|NCT02068118|Experimental|Tele-cardiology group|Telecardiology Program
32795080|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
32795081|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
32795082|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
32795083|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
32795084|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
32795085|NCT04731896|No Intervention|Late Amniotomy|Initiating induction of labor with oxytocin infusion followed by amniotomy 4-6 hours later
32795086|NCT04731896|Active Comparator|Early Amniotomy|Early amniotomy initiating induction of labor followed by oxytocin infusion 30 minutes later
32795087|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
32795088|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
32795089|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
32795090|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
32795091|NCT03631043|Experimental|Stage I (personalized vaccine)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32795092|NCT03631043|Experimental|Stage II (personalized vaccine, lenalidomide)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32795093|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
32795094|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
32795095|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
32795096|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
32795097|NCT04778579|Experimental|ARI-0001|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
32795098|NCT04777955|Experimental|Group 1, core stabilization exercises group|core stabilization exercises will be performed using swissball. Program: Sitting on the ball will include (weight shifts, forward, backward and lateral sides), (pelvic bridge), (curl-up), (curlsup with diagonal reaching), (bird-dog exercise), (push-up) exercises. The application will be carried out for 6 weeks, 3 days a week for 30-45 minutes daily.
32900734|NCT04271384|Experimental|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
32900735|NCT05353998|Experimental|Sleep Navigation group|Caregiver-child dyads in this study arm (intervention condition) will participate in the Sleep Navigation program.
33088779|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
33088780|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
33088781|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
33088782|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
32795099|NCT04777955|Experimental|Group 2, electrical stimulation|"An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec on (muscle contraction), 1 sec beat reduction time and 20 sec off (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
33404174|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
33404175|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
32795100|NCT04777955|Experimental|group 3, kinesiotape|"For anterior diaphragm banding, the patient will stand with arms raised. Next, the central part of the tape will be applied to the xiphoid protrusion with a tension of 50% to 70% after the maximum inhalation. While the patient is breathing, the ends of the tape will be pulled with 10 to 15% tension towards the lower ribs. To tape the rear diaphragm, the patient's body will bend forward, and the arms will be joined crosswise over the chest. After the maximum inhalation, the central part of the tape will be applied over the T10 with a tension of 50% to 70%. As the patient exhales and stretches the trunk, the ends of the tape will be attached to the lower ribs with a tension of 10 to 15%.~The supine position will be used in the Kinesiological taping of the right and left external oblique and internal oblique muscles. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
32795101|NCT02204579|Experimental|NPSP795|intravenous
32795102|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
32795103|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
32795104|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
32795105|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
32795106|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
32795107|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
32795108|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
32795109|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
32795110|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
32795111|NCT02232893|Placebo Comparator|Placebo|Placebo TID
32795112|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
32795113|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
32795114|NCT01618695|Experimental|Perampanel|
32795115|NCT01618695|Placebo Comparator|Placebo|
32795116|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
32795117|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
32795118|NCT01618305|Experimental|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
32795119|NCT01618305|Experimental|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
32795120|NCT01618305|No Intervention|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
32795121|NCT01618305|No Intervention|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
32795122|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
32795123|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
32795124|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
32795125|NCT04618263|Experimental|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
32795126|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
32795127|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
32795128|NCT04618263|Experimental|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
32795129|NCT04618263|Experimental|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
32795130|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
32795131|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
32795132|NCT04618263|Experimental|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
32795133|NCT04618263|Experimental|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
32795134|NCT04618263|Experimental|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
32795135|NCT04618263|Placebo Comparator|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
32795136|NCT04618263|Placebo Comparator|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
32795137|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
32795138|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
32795139|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
32795140|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
32795141|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
32795142|NCT01895361|Experimental|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
32795143|NCT01895361|Experimental|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
32795144|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
32795145|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
32795146|NCT04617951|Experimental|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
32795147|NCT04617951|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
32795148|NCT01864005|Experimental|Ticagrelor|
32795149|NCT01864005|Active Comparator|clopidogrel|
33404176|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
32795150|NCT01863849|Experimental|Age group 1: adults (18-59 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
32795151|NCT01863849|Experimental|Age group 2: elderly (> 60 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
32795152|NCT01863771|Experimental|Golimumab|
32795153|NCT01863771|Placebo Comparator|Placebo|
32795154|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
32795155|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
32795156|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
32795157|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
32795158|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
32795159|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
32795160|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
32795161|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
32795162|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
32795163|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
32795164|NCT04776629|Active Comparator|Active Treatment|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
32795165|NCT04776629|Placebo Comparator|Placebo|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
32795166|NCT04191395||Inflammatory bowel disease|
32795167|NCT04191395||Chronic inflammatory rheumatic disease|
32795168|NCT04191395||Chronic inflammatory skin diseases|
32795169|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
32795170|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
33088783|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
33088784|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
33088785|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
33404177|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
33404178|NCT05203068|Experimental|Recombinant tuberculosis allergen (CFP10-ESAT6)|RTA (CFP10-ESAT6) 0.2 µg/0.1 mL RTA given intradermally on the middle of the forearm
33404179|NCT03558503|Experimental|UGN-102|Patients were treated with 6 once-weekly intravesical instillations of UGN-102.
32746301|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
32746302|NCT04785183|Experimental|Melatonin Group|
33404180|NCT04351984||Severe Mitral Regurgitation|
32746303|NCT04785183|Placebo Comparator|Control Group|
32746304|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
32746305|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
32746306|NCT04297917|Experimental|Healthy Volunteers with low dose vaccination|5 Healthy Volunteers receiving low dose vaccination
32746307|NCT04297917|Experimental|Healthy Volunteers with high dose vaccination|5 Healthy Volunteers receiving high dose vaccination
32746308|NCT04297917|Experimental|Chronic Hepatitis B participants with low dose vaccination|6 participants with Chronic Hepatitis B infection receiving low dose vaccination
32746309|NCT04297917|Experimental|Chronic Hepatitis B participants with high dose vaccination|6 participants with Chronic Hepatitis B infection receiving high dose vaccination
32746310|NCT04297917|Experimental|Healthy Volunteers who have had COVID-19 AZD1222 vaccine|15 participants who have had 2 doses of COVID-19 AZD1222 vaccine
32746311|NCT04297917|Experimental|Healthy Volunteers who have had Pfizer/Moderna mRNA COVID 19 vaccine|15 participants who have had Pfizer/Moderna mRNA COVID 19 vaccine
32746312|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
32746313|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
32746314|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
32746315|NCT04792749|Experimental|Metformin treatment|Patients who receive metformin in addition to progestin therapy
32746316|NCT04792749|No Intervention|Conventional treatment|Patients who receive progestin therapy only
32746317|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
32746318|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
32746319|NCT04338399|Experimental|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
32746320|NCT04338399|Active Comparator|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
32746321|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
32746322|NCT03912753|Experimental|Comunică|Comunică is delivered over eight 60-min live chat sessions, delivered by trained psychologists, on our mHealth study platform compatible with any mobile device (laptops, smartphones).
32746323|NCT03912753|Active Comparator|Education Attention Control (EAC)|"The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) HIV 101, 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen."
32746324|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
32746325|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
32746326|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
32746327|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
32746328|NCT04792983||Older (≥ 65 years of age)|Older surgical patients presenting for elective spine surgery.
32746329|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
32746330|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
32746331|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
32746332|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
32940262|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.~Acute phase:~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~Chronic phase:~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
32940263|NCT00791336|Experimental|Nelfinavir|
32940264|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
32940265|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
32940266|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
32940267|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
32940268|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
32940269|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
32940270|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
32940271|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
32940272|NCT04332146|Experimental|Mindfulness-based intervention|
32940273|NCT04332146|Active Comparator|Booklet-based psychoeducation group|
32940274|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
32940275|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
32940276|NCT00769652|Active Comparator|Standard care|Standard care
32940277|NCT05277818||Patient with medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated with DIVA® implant
32940278|NCT05277818||Patient without medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated without DIVA® implant
32940279|NCT05246384|Experimental|Part I (dose escalation) RP7214 + Azacitidine|Participants will receive RP7214 orally in combination with Azacitidine in a 28-day cycle. The dose levels will be escalated until MTD/a recommended Phase 2 dose (RP2D) has been identified.
32940280|NCT05246384|Experimental|Part II (dose expansion) RP7214 + Azacitidine|Participants will receive RP7214 orally at the MTD/RP2D in combination with Azacitidine in a 28-day cycle.
32940281|NCT05238740|Active Comparator|Intervention group -5.4 cc ViviGen®|Biological: 5.4 cc ViviGen®The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 5.4 cc ViviGen®
32940282|NCT05238740|Active Comparator|Control group -4mg rhBMP-2|Biological: 4mg rhBMP-2The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 4mg rhBMP-2
32940283|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
32940284|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
32940285|NCT05149742|Experimental|Cases: Patients with severe to profound hearing loss|Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL
32940286|NCT05149742|Active Comparator|Controls: 90 matched subjects with normal hearing|Healthy controls aged between 45 to 64 years with normal hearing on pure-tone audiometry (as function of ISO 7029 reference)
32940287|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
32940288|NCT04459585|Experimental|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
32940289|NCT05080556|Active Comparator|Arm 1 (control) - standard dosing carboplatin|Arm 1 (Standard Dosing): Carboplatin AUC5 based on nuclear medicine renal clearance.
32940290|NCT05080556|Experimental|Arm 2 (experimental) - adaptive therapy carboplatin according to CA125|Arm 2 (Adaptive Therapy): Carboplatin dose will be calculated according to the CA125 value.
32940291|NCT05044676||patients with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
33088786|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
33088787|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
32795171|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
32795172|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
32795173|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
32795174|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
32795175|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
32795176|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
32795177|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
32795178|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
32795179|NCT02230085||CPAP therapy|
32795180|NCT01882803|Experimental|Duvelisib|
32795181|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
32795182|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
32795183|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
32795184|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
32795185|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
32795186|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
32795187|NCT04612413|Placebo Comparator|Cohort 1|Single IV dose of placebo solution
32795188|NCT04612413|Experimental|Cohort 2|Single IV dose of 5x10^9 Allocetra-OTS cells in suspension
32795189|NCT04612413|Experimental|Cohort 3|Single IV dose of 10x10^9 Allocetra-OTS cells in suspension
32795190|NCT04612413|Experimental|Cohort 4|Single or two doses of 10x10^9 Allocetra-OTS cells in suspension
32795191|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
32795192|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
32795193|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
32795194|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
32795195|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
32795196|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
32795197|NCT02202317|Experimental|Y90 Based PET/CT Scan|
32795198|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
32795199|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
32795200|NCT02118337|Experimental|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
33088788|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
33088789|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
33088790|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
33088791|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
33088792|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
33088793|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
32795201|NCT02118337|Experimental|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
32795202|NCT02118337|Experimental|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
32795203|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
32795204|NCT02118337|Experimental|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
32795205|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
32795206|NCT02118337|Active Comparator|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
32795207|NCT05131555|Placebo Comparator|1: Placebo|lactose
32795208|NCT05131555|Experimental|H1 blockade|540 mg Fexofenadine
32795209|NCT05131555|Experimental|H2 blockade|40 mg Famotidine
32795210|NCT02117713|Experimental|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
32795211|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
32795212|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
32795213|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
32795214|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
32795215|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
32795216|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
32795217|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
32795218|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
32795219|NCT04761107||GU participants with active or past infection of SARS-Co-V-2|GU patients from medical records with active or past infection of SARS-Co-V-2
32795220|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
32795221|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
32795222|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
32900736|NCT05353998|Other|CDS-only group|Caregiver-child dyads in this study arm (control group) will not participate in the Sleep Navigation program, but will be directed to follow up with their primary care clinician as needed.
32900737|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
32900738|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
32900739|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
33088794|NCT00282581|Placebo Comparator|placebo|
33088795|NCT00317967|Experimental|1|Atorvastatin
33088796|NCT00317967|Placebo Comparator|2|Placebo
33088797|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
32795225|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
32795226|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
32795227|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
32795228|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
32795229|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
32795230|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
32795231|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
32795232|NCT04775381|Experimental|Vitamin D|During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.
32795233|NCT04775381|No Intervention|Fruit juice|During preoperative visit (Month -2) patients will receive only fruit juice.
32795234|NCT04078672|Experimental|AMD|NOTAL-OCT V3.0 scan
32795235|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
32795236|NCT04775069|Active Comparator|mRNA Group|The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
32795237|NCT04775069|Active Comparator|Inactivated Virus Group|The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
32795238|NCT04775069|Active Comparator|Adenovirus-vector Group|The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
32795239|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
32795240|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
32795241|NCT01500694|Experimental|Extended-release Guanfacine HCl|
32795242|NCT04188977|Other|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
32795243|NCT04188977|Experimental|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
32795244|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
32900740|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
33404181|NCT05761236|Active Comparator|Training group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates.It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session. After a 2-week joint training week, the training group switched to hybrid type telerehabilitation and continued their exercise sessions with a physiotherapist 3 days a week via synchronous video conferences (Zoom Application) and by themselves at home on the rest of the week.
32795245|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
32795246|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
32795247|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
32795248|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
32795249|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
32795250|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
32795251|NCT01483690|Experimental|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
32795252|NCT01483690|Experimental|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
32795253|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
32795254|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
32795255|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
32795256|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
32795257|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
32795258|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
32795259|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
32795260|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
32795261|NCT01483144|Active Comparator|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
32795262|NCT01483144|Active Comparator|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
32795263|NCT01881789|Experimental|Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
32795264|NCT01881789|Experimental|Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
32795265|NCT01881789|Experimental|Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
32795266|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
32900741|NCT05319444|Experimental|Healthy Scalp and one treatment|Participants with healthy scalps who will receive one treatment with the device and complete one in-person follow-up.
32940292|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
33300811|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
33300812|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
33300813|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
33300814|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
33300815|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
32746333|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
32746334|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
32746335|NCT04792125|Experimental|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed external electrical stimulation (EES) added to pelvic floor muscle training (PFMT).
32795267|NCT01881789|Experimental|Oprozomib 240 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
32900742|NCT05319444|Experimental|Healthy Scalp and three treatments|Participants with healthy scalps who will receive three treatments with the device and complete one in-person follow-up.
32900743|NCT05319444|Experimental|Dandruff and one treatment|Participants with dandruff who will receive one treatment with the device and complete one in-person follow-up.
32900744|NCT05319444|Experimental|Dandruff and three treatments|Participants with dandruff who will receive three treatments with the device and complete one in-person follow-up.
32900745|NCT05319444|Experimental|Hair loss disease and one treatment|Participants with hair loss disease who will receive one treatment with the device and complete one in-person follow-up.
32900746|NCT05319444|Experimental|Seborrheic Dermatitis with one treatment|Participants with seborrheic dermatitis disease who will receive one treatment with the device and complete one in-person follow-up.
32900747|NCT05319444|Experimental|Seborrheic Dermatitis and three treatments|Participants with seborrheic dermatitis who will receive three treatments with the device and complete one in-person follow-up.
32900748|NCT05319444|Experimental|Hair loss disease and three treatments|Participants with hair loss disease who will receive three treatments with the device and complete one in-person follow-up.
32940293|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
32746336|NCT04792125|Other|External electrical stimulation (EES) group|This arm is going to include the patients who are performed external electrical stimulation (EES).
32900749|NCT05381142|Experimental|Elinzanetant (BAY3427080)|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized to treatment with elinzanetant.
32900750|NCT05381142|Placebo Comparator|Placebo|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized and assigned to treatment with placebo.
32900751|NCT05353530|Experimental|8R-70CAR T cells|Cohort 1 will receive 1 x 10^6 cells/kg. Cohort 2 will receive 1 x 10^7 cells/kg. Cohort 3 will receive 1 x 10^8 cells/kg. Cohort 4 will receive Cy/Flu + CAR T cells at established maximum tolerated dose.
32900752|NCT05610384|Active Comparator|Ketorolac group|ketorolac 30 mg
32900753|NCT05610384|Active Comparator|Ibuprofen group|ibuprofen 800 mg
32900754|NCT05353296|Experimental|Culturally adapted digital cognitive behavioral therapy for insomnia (CBT-I) (Somryst)|Somryst is an FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) program that has been translated and culturally adapted for Spanish speakers. Group will have access to this culturally-adapted Somryst, along with the usual care provided by their primary care provider, and will be provided a sleep hygiene brochure during group assignment.
32900755|NCT05353296|Active Comparator|Minimally Enhanced Usual Care (mEUC)|Usual care by their primary care provider and a sleep hygiene brochure. Group will continue their typical standard care with their primary care provider, which may include pharmacotherapy. In addition, we will provide a sleep hygiene brochure during group assignment.
32900756|NCT03570632|No Intervention|Usual care|
32900757|NCT03570632|Experimental|Metformin|
32900758|NCT05286944|Experimental|Mobile daily alarm|A mobile smartphone with functioning alarm system and solely owned by the patient. The alarm will be set by the second investigator to alert the participant between 6am - 10am (based on participant's preference) in the morning daily. A recorded dual-language (English and Malay version) tone for alarm mobile phone will be used. Apart from that participants are also counseled and educated about allergic rhinitis and are also asked to fill up self monitored adherence card to document their nasal steroid intake.
32900759|NCT05286944|No Intervention|Control|This group of participant will receive counseling and education regarding allergic rhinitis and the importance of compliance. Patients are also given a self monitored adherence card to document their nasal steroid intake.
32900760|NCT05352828|Experimental|Nivolumab and CD30.CAR-T|Study treatment will include 4 cycles of nivolumab and a single CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy of Fludarabine and Bendamustine).
33300816|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
33300817|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
33300818|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
32795268|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Cyclophosphamide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with oral cyclophosphamide 300 mg/m² on days 1, 8, and 15 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 8 cycles, whichever occurred first. After completing 8 cycles of treatment, participants with stable disease or better were to continue on oprozomib with dexamethasone premedication for a total of 24 cycles or until progression of disease or unacceptable toxicity. After completing 24 cycles of treatment, participants without evidence of disease progression could have continued on oprozomib with or without dexamethasone pretreatment.
33300819|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
32795269|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
33300820|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
32795270|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
32795271|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
32795272|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
32795273|NCT01892163|Experimental|Ozurdex fixed dosing|
32795274|NCT01881009|Experimental|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
32795275|NCT01881009|Experimental|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
32795276|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
33300821|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
32795277|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
32795278|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
32795279|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
32795280|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
32795281|NCT02075047|Placebo Comparator|1|
32795282|NCT02075047|Experimental|ziprasidone|
32795283|NCT01859949|Experimental|Genotropin (somatropin)|
32795284|NCT05108181|Active Comparator|Slow muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
32795285|NCT05108181|Active Comparator|Fast muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
32795286|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
32795287|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
32795288|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
32795289|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
32795290|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
32795291|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
32795292|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
32940294|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
32940295|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
33300822|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
33300823|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
33300824|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
33300825|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
33300826|NCT01586494|Experimental|Group 1|
33300827|NCT01586494|Experimental|Group 2|
33300828|NCT03886948|Experimental|Prefilled Syringe (PFS) with LY3074828|PFSs containing LY3074828
33300829|NCT03886948|Experimental|AutoInjector (AI) with LY3074828|AI containing LY3074828
32795293|NCT04617327|Experimental|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
32795294|NCT04599465|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
32795295|NCT04616235|Placebo Comparator|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
32795296|NCT04616235|Active Comparator|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
32795297|NCT04615923|Experimental|Pridopidine|Pridopidine is administered orally twice daily for 24 weeks.
32795298|NCT04615923|Placebo Comparator|Matching Placebo|Matching placebo is administered orally twice daily for 24 weeks.
32795299|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
32795300|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
32795301|NCT04590495|Active Comparator|300 mg Cannabidiol (CBD) oil|
32795302|NCT04590495|Placebo Comparator|Placebo|
32795303|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
32795304|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
32795305|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
32795306|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
32795307|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
32795308|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
32795309|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
32795310|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
32940296|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
33300830|NCT05666986||Adolescents who had CDH surgery in the first month of life,|without any other pathology, now aged 12-18 and followed up at the CDH Lille Reference Center
33300831|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
33300832|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
33300833|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
33300834|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
33300835|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
33300836|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
33300837|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
33300838|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
33300839|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
33300840|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
33300841|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
33300842|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
32795311|NCT02117479|Active Comparator|Placebo plus capecitabine|
32795312|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
32795313|NCT02229851|Active Comparator|Daily hGH|
32795314|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
32795315|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
32795316|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
32795317|NCT04077190|Experimental|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
32795318|NCT04077190|Active Comparator|cortisone injection|Ultrasound guided injection of cortisone
32795319|NCT04595422|Experimental|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
32795320|NCT04595422|Experimental|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
33300843|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
33300844|NCT01152736|Experimental|NSC018|Nicotine
33300845|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
33300846|NCT01154764|Experimental|CG100649|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
32795321|NCT01626391|Experimental|TRx0237|
32795322|NCT01626391|Placebo Comparator|Placebo|
32795323|NCT04742257|Experimental|Active Stimulation|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
32795324|NCT04742257|Sham Comparator|Sham Stimulation|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
32795325|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
32795326|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
32795327|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
32795328|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
32795329|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
32795330|NCT01835223|Experimental|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32795331|NCT01835223|Experimental|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32795332|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
32795333|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
32795334|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
32795335|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
32795336|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
32795337|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
32795338|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
32795339|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
32795340|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
32795341|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32940297|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
32940298|NCT00737594|Placebo Comparator|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
32795342|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32795343|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
32795344|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
33088798|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
32795345|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
32795346|NCT01499290|Active Comparator|Meropenem|IV treatment
32795347|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
32795348|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
32795349|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
32795350|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
32795351|NCT04591366|Active Comparator|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
32795352|NCT04591366|Experimental|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
32795353|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
32795354|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
32795355|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
32795356|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 0.3x10^6 IU/m^2/day.~Cohort 2: 1.0x10^6 IU/m^2/day.~Cohort 3: 1.5x10^6 IU/m^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum effective dose has been identified, a further 10 subjects will receive IL-2 at the maximum effective dose."
32795357|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
32795358|NCT01460368|Experimental|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
32795359|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
32795360|NCT01460368|Active Comparator|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
32795361|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
32795362|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
32795363|NCT01911533|Experimental|extracorporeal CO2|
32795364|NCT04408456|Active Comparator|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
32795365|NCT04408456|Other|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
32795366|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
32795367|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
32795368|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
33088799|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
33088800|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
33088801|NCT00282854||Group I: Cases|Children with rolandic epilepsy
33088802|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
33300847|NCT01154764|Experimental|CG100649 and ketoconazole|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
33300848|NCT05092750|Experimental|FerroTraceTM (magnetic tracer)|a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
32795369|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
33300849|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
33300850|NCT01262794|Experimental|CDP6038 1 mg/kg|
32795370|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
32795371|NCT01459666|Placebo Comparator|Placebo|
33300851|NCT01262794|Experimental|CDP6038 3 mg/kg|
32795372|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
32795373|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
32795374|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
32795375|NCT04767113|Experimental|Heparin group|Continuous infusion of heparin was used to maintain the patency of CVC.
32795376|NCT04767113|Placebo Comparator|Control group|Continuous infusion of heparin was used at the corresponding speed.
32795377|NCT04774991|Active Comparator|Azithro 1-59 fixed point|Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
32795378|NCT04774991|Active Comparator|Azithro 1-59 door-to-door|Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
32795379|NCT01458574|Placebo Comparator|Placebo Comparator|
32795380|NCT01458574|Experimental|CP-690,550 5 mg Arm|
32795381|NCT01458574|Experimental|CP-690,550 10 mg Arm|
32795382|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
32795383|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
32795384|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
32795385|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
32795386|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
32795387|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
32795388|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
32795389|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
32795390|NCT02074384|Other|Clinicians|Clinicians completing study visits.
32795391|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
32795392|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
33300852|NCT01262794|Experimental|CDP6038 6 mg/kg|
33300853|NCT01262794|Placebo Comparator|Placebo|
33318482|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
33318483|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
32795393|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
32795394|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
32795395|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
32795396|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
32795397|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
32795398|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
32795399|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
32795400|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
32795401|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
32795402|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
32795403|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
33300854|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
33300855|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
33300856|NCT01261468|Active Comparator|Active SCS|
32795404|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
33300857|NCT01261468|Sham Comparator|Inactive SCS|
33300858|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
32795405|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
32795406|NCT04773587|Experimental|ARQ-151 Cream 0.15%|Active comparator
32795407|NCT04773587|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
32795408|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
32795409|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
32795410|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
32795411|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
33300859|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
33300860|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
32795412|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
33300861|NCT01259518|Experimental|Once monthly administration of TRIN2755|
33300862|NCT01259518|Experimental|Once weekly administration of TRIN2755|
33300863|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
33300864|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
33300865|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
32795413|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
32795414|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
32795415|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
32795416|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
32795417|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
32795418|NCT01195493|Experimental|test mouthrinse|
32795419|NCT01195493|Active Comparator|control group|
32795420|NCT04094038|Experimental|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
32795421|NCT04094038|Placebo Comparator|Placebo|5% glucose three times weekly during 16 weeks
32795422|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
32795423|NCT04764305||Patients|Patients with Fontan circulation. No intervention planned (observational study)
32795424|NCT04764305||Controls|Healthy, biventricular controls. No intervention planned (observational study)
32795425|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
32795426|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
32940299|NCT00737594|Experimental|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
32795427|NCT00752453|Experimental|1|Dialysis during 4 hours
32795428|NCT00752453|Experimental|2|Dialysis during 6 hours
32795429|NCT00752453|Experimental|3|Dialysis during 8 hours
32795430|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
32795431|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
32795432|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
32795433|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
32795434|NCT04763291|No Intervention|Control group|Continue habitual diet and lifestyle.
32795435|NCT04763291|Experimental|Fruit, Vegetable and Berry (FVB) group|Participants have to ingest an encapsulated juice powder concentrate, otherwise continue their habitual diet and lifestyle.
32795436|NCT04763291|Experimental|Omega group|Participants have to ingest a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
32795437|NCT04763291|Experimental|Fruit, Vegetable, Berry and Omega (FVBO) group|Participants have to ingest an encapsulated juice powder concentrate along with a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
32795438|NCT04773119|Active Comparator|Pulmonary vein isolation (PVI) only|
32795439|NCT04773119|Active Comparator|PVI with substrate|
32795440|NCT01481116|Experimental|TAK-875 25 mg QD|
32795441|NCT01481116|Experimental|TAK-875 50 mg QD|
32795442|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
32795443|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
32795444|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795445|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795446|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795447|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795448|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795449|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
32795450|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
32795451|NCT04092946|Experimental|Patients with musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
32795452|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
32795453|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
32795454|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
32795455|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
32795456|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
32795457|NCT04773041||Patients with DLB|Patients diagnosed with DLB enrolled from the HealthPartners Neuroscience Center.
32795458|NCT04773041||Patients with Alzheimer's disease (AD)|Patients diagnosed with AD age and sex-matched, selected from the ADNI database.
32795459|NCT04773041||Patients with normal cognition (CN)|Patients diagnosed with normal cognition age and sex-matched, selected from the ADNI database.
32795460|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
32795461|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
32795462|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
32795463|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
32795464|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
32795465|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
32795466|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
32795467|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
32795468|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
32795469|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
32795470|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
32795471|NCT04189757|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
32795472|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
32795473|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
32795474|NCT01623752||Patients with Rheumatoid Arthritis|
32795475|NCT01623752||Patients with Psoriasis Arthritis|
32795476|NCT01623596|Experimental|Fingolimod|
32795477|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
33300866|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
33300867|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
32795478|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
32795479|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
33300868|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
33300869|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
33300870|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
33300871|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
33300872|NCT01263184||sportive wheelchair users|
32795480|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
32795481|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
32795482|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
32795483|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
32795484|NCT02250443|Experimental|BYM338|BYM338 Group
32795485|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
32795486|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
32795487|NCT02194985|Experimental|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
32795488|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
32795489|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
32795490|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
32795491|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
32795492|NCT02219009|Experimental|MIND1 System|
32795493|NCT02248649|Experimental|Physical Activity|Structured walking program
32795494|NCT02248649|Active Comparator|Control|Health education attention control
32795495|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
33300873|NCT01263184||sportive non disabled|
33300874|NCT01263184||non sportive wheelchair users|
33300875|NCT03890770|Experimental|Normal renal function|Single dose
33300876|NCT03890770|Experimental|Mild renal disease|Single dose
33300877|NCT03890770|Experimental|Moderate renal failure|Single dose
33300878|NCT03890770|Experimental|Severe renal failure|Single dose
33300879|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
33300880|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
33300881|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
33300882|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
33300883|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
33300884|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
33300885|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
33300886|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
33300887|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
33300888|NCT01263340||People with COPD|
32795496|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
32795497|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
32795498|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
32795499|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
32795500|NCT01456936|Active Comparator|varenicline|
33300889|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
33300890|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
32795501|NCT01456936|Active Comparator|bupropion|
33300891|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
32940300|NCT00737594|Experimental|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
33300892|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
33300893|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
33300894|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
33300895|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
33300896|NCT03890458|Experimental|Experimental|
33300897|NCT03890458|No Intervention|Control|
33300898|NCT01154998||Cases|
33300899|NCT01154998||Controls|
33300900|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
33300901|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
32795502|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
32795503|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
32795504|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
32795505|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
32795506|NCT01480258|Experimental|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
32795507|NCT01480258|Active Comparator|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
32795508|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
32795509|NCT01478620|Experimental|Canephron® N|
32795510|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
32795511|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
32795512|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
32795513|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
32795514|NCT04542850|Other|Moderate group and Severe Group|Moderate group and Severe group - . Both groups will be administered 5-aminolevulinic acid (5-ALA) is a natural delta amino acid widely present in nature that can be found in common food. 5-ALA combined with sodium ferrous citrate (SFC) produces the nutritional dietary supplement 5-ALA-Phosphate + SFC (5-ALA + SFC).
32795515|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
32795516|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
32795517|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
32795518|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
33088803|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
33088804|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
33088805|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
33300902|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
32795519|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
32795520|NCT04541290|Experimental|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
32795521|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
32795522|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
32795523|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
33300903|NCT01155076|Placebo Comparator|Placebo|Placebo
33300904|NCT01263418|Experimental|Ofatumumab|
33300905|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
33300906|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
33300907|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
33300908|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
33300909|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
33300910|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
32795524|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
32795525|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
33088806|NCT00283010|Active Comparator|Active Control|Educational DVDs
33088807|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
33088808|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
33088809|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
33088810|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
33088811|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
33088812|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
33088813|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
33300911|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
33300912|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
33300913|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
33300914|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
33300915|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
33300916|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
33300917|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
32795526|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
32795527|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
32795528|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
32795529|NCT01630889|Experimental|Roxadustat|Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
32795530|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
32795531|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
32795532|NCT04762277|Experimental|Spesolimab|
32795533|NCT04762277|Placebo Comparator|Placebo|
32795534|NCT01494922|Experimental|Open Label|
32795535|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
32795536|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
32795537|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
32795538|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
32795539|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
32795540|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32795541|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32795542|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
32795543|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
33300918|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
33300919|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
33300920|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications~Intervention: the use of an IQOS"
32900761|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
32900762|NCT05610228||LLC|
33300921|NCT01153048|Experimental|Specific education intervention with peer educators|
33300922|NCT01153048|No Intervention|General education session in the health structure|
33300923|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
33300924|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
33300925|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
32900763|NCT05352516|Experimental|Treatment group|60 mg, once every 6 months
33300926|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
33300927|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
33300928|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
33300929|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
33300930|NCT03882502|Experimental|stimulation group|
33300931|NCT03882502|Sham Comparator|sham stimulation|
33300932|NCT01156636|Active Comparator|Sildenafil|
33300933|NCT01156636|Placebo Comparator|Placebo|
33300934|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
33300935|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
33300936|NCT03881722|Active Comparator|thickened formula|
32795544|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
32795545|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
32795546|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
32795547|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
32795548|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
33300937|NCT03881722|Experimental|Mg alginate|
33300938|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
33300939|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
33300940|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
33300941|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
33300942|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
33300943|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
33300944|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
32795549|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
32795550|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
32795551|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
32795552|NCT03027076||Women with UCPPS|Collect midstream urine samples
32795553|NCT03027076||Asymptomatic Women|Collect midstream urine samples
32795554|NCT04091464|Experimental|TRAIN-BW|1x/week for 8 weeks + home exercise program
32795555|NCT04091464|Active Comparator|TRAIN-FW|1x/week for 8 weeks + home exercise program
32795556|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
32795557|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
32795558|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
32795559|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
32795560|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
32795561|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
32795562|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
32795563|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
32795564|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
32795565|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
32900764|NCT05352516|Active Comparator|Control group|60 mg, once every 6 months
33300945|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
33300946|NCT03760666|Experimental|Brequinar/Brequinar + Ribavirin|Brequinar and ribavirin were dosed orally; brequinar starting doses ranged from 200 mg/m2 to 500 mg/m2. Brequinar doses were adjusted by cohort for starting dose and regimen (either twice-weekly or once-weekly). In addition, the dose for each participant was also adjusted (either escalated or decreased) based on safety, brequinar PK and levels of dihydroorotate (DHO). Ribavirin 1000 mg twice a day (bid) was added in combination with brequinar for the final 3 study participants.
32795566|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
32795567|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
32795568|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
32795569|NCT04076410|Experimental|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
32795570|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
32795571|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
32795572|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
32795573|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
32795574|NCT01475734|Placebo Comparator|placebo|single dose of placebo
32795575|NCT04076176|Active Comparator|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
32795576|NCT04076176|Experimental|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
32795577|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
32795578|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
32795579|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
32795580|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
32795581|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
32795582|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
32795583|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
32795584|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
32795585|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
32795586|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
32795587|NCT01491178||Patients with NVAF|
32795588|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
32795589|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
32795590|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
32795591|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
32795592|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
32900765|NCT05286710|Experimental|modified access group|modified access: PMT was performed via distal calf venous access or contralateral femoral access
32900766|NCT05286710|Active Comparator|traditional access group|traditional access: PMT was performed via ipsilateral popliteal venous access
32795593|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
32795594|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
32795595|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
32795596|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
32795597|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
32795598|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
32795599|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
32795600|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
32795601|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
32795602|NCT04418219|Experimental|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32795603|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
32795604|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
32795605|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
32795606|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
32795607|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
32795608|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
32795609|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
32795610|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
32795611|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
32900767|NCT05610150|Active Comparator|Myobrace functional Appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Myobrace functional appliance for six months.
33300947|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
33300948|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
33300949|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
33300950|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
33300951|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
33300952|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
33300953|NCT03882190|No Intervention|group 1|
33300954|NCT03882190|Experimental|group 2|
32795612|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
32795613|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
32795614|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
32795615|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
32795616|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
32795617|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
32795618|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
32795619|NCT04726111|Other|Control patients|Control patients (negative serology and PCR)
32795620|NCT04726111|Other|asymptomatic patients|asymptomatic patients (PCR positive)
32795621|NCT04726111|Other|symptomatic patients|symptomatic patients (PCR positive)
32795622|NCT04726111|Other|Cured patients|cured patients who contracted the disease during pregnancy (positive serology in the 15 days preceding childbirth or history of positive PCR during pregnancy and negative PCR within 72 hours)
32795623|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
32795624|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
32795625|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
32795626|NCT04075552|Experimental|Participants|Participants are students from a specialized school for children with autism.
32795627|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
32795628|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
32795629|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
32795630|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
32795631|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
32795632|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
32795633|NCT02100631|Experimental|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
32795634|NCT02100631|Placebo Comparator|Placebo in Older Adults|Placebo physiological saline
32795635|NCT02100631|Other|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
32795636|NCT01451164|Experimental|High dose|
32795637|NCT01451164|Experimental|Mid dose|
32795638|NCT01451164|Experimental|Low dose|
32795639|NCT01451164|Placebo Comparator|Placebo|
32795640|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
32940301|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
32795641|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
32795642|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
32795643|NCT02071225|Experimental|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
32795644|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
32795645|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
32795646|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
32795647|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
32795648|NCT02114515|Other|Usual Care|"Hospital usual care~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
32795649|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
32795650|NCT01490086|Experimental|15mg RP5063 daily|
32795651|NCT01490086|Experimental|30mg RP5063 daily|
32795652|NCT01490086|Experimental|50mg RP5063 daily|
32795653|NCT01490086|Placebo Comparator|Placebo|
32795654|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
32795655|NCT02114203|Experimental|cohort 1 PF-04447943|
32795656|NCT02114203|Experimental|cohort 2 PF-04447943|
32795657|NCT02114203|Placebo Comparator|placebo comparator|
32795658|NCT02114203|Experimental|optional cohort of PF-04447943|
32795659|NCT04091308|Active Comparator|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
32795660|NCT04091308|Experimental|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
32795661|NCT04091308|Experimental|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
32795662|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
32795663|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
32795664|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
32795665|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
32795666|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
32795667|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
32795668|NCT04741087|Active Comparator|AMT-101 (Dose A)|Dose A: AMT-101 Tablet
32795669|NCT04741087|Active Comparator|AMT-101 (Dose B)|Dose B: AMT-101 Tablet
32795670|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
32795671|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
32795672|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
32795673|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
32795674|NCT01450540|Active Comparator|Group 1|REMStar auto A-Flex
32795675|NCT01450540|Experimental|Group 2|modified REMstar Auto A-Flex with AGPAP
32795676|NCT04075240|Active Comparator|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
32795677|NCT04075240|Experimental|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
32795678|NCT04075240|Active Comparator|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
32795679|NCT04075240|Experimental|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
32795680|NCT02070757|Experimental|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
32795681|NCT02070757|Active Comparator|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
32940302|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
33300955|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
33300956|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
33300957|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
33300958|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
33300959|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
33300960|NCT01156948|Experimental|oral misoprostol|oral misoprostol
33300961|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
33300962|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
33300963|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
33300964|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
33300965|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
33300966|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
33300967|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
33300968|NCT01157026|Active Comparator|Placebo plus tamoxifen|
33300969|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
32940303|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
32940304|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
32940305|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
32940306|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
33300970|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
33300971|NCT01259752|Experimental|compression stockings|
33300972|NCT01259752|Placebo Comparator|standard non compressive stockings|
33300973|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigran infusion (0.4 mg/min) for 10 mins"
33300974|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
33300975|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
33300976|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
33300977|NCT01265368|Experimental|Study medication|
33300978|NCT01259830|Experimental|Arcoxia® 120 mg|
33300979|NCT01259830|Placebo Comparator|Sugar pill|
33300980|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
33300981|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
33300982|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
33300983|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) :~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
33300984|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
33300985|NCT00224484|Experimental|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
33300986|NCT00224484|Active Comparator|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
33300987|NCT00224484|Placebo Comparator|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
33300988|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
33300989|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
33300990|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
32795682|NCT04417933|Experimental|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
32795683|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
32795684|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
32795685|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
32795686|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
32795687|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
32795688|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
32795689|NCT04408846|Other|Minimally invasive lumbar fusion|
32795690|NCT04408846|Other|Open posterior lumbar fusion|
32795691|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
32795692|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
33300991|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
33300992|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
32795693|NCT01832727|Experimental|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795694|NCT01832727|Experimental|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
33300993|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
33318484|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
33318485|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
33318486|NCT01300520|Other|Control|Without target tape in the procedure
33318487|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
33318488|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
33318489|NCT05369000|Experimental|LAVA-1207|"In part 1 (dose escalation) LAVA-1207 will be administered via intravenous infusion with dose escalation~In part 2 (dose expansion) patients will receive LAVA-1207 at the dose established in part 1 of the study"
32795695|NCT01832727|Experimental|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795696|NCT01832727|Experimental|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
32795697|NCT01832727|Experimental|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795698|NCT01832727|Experimental|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795699|NCT01832727|Experimental|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795700|NCT01832727|Experimental|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795701|NCT01832727|Experimental|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
32795702|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
32795703|NCT04647058|Active Comparator|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
32795704|NCT04647058|Experimental|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
32795705|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
32795706|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
32795707|NCT04598529|Active Comparator|A2 milk|A2 milk, organic, 200ml, twice daily
32795708|NCT04598529|Placebo Comparator|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
32795709|NCT04408144|Experimental|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
32795710|NCT04408144|No Intervention|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
32795711|NCT04597359|Experimental|Arm A (green tea catechins)|Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
32795712|NCT04597359|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO BID for up to 6 months.
32795713|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
32795714|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
32795715|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
32795716|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
32795717|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
32795718|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
32795719|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
32795720|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
32795721|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
32795722|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
32795723|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.~Post-Quit Period:~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
32795724|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
32795725|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
32795726|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
32795727|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
32795728|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
32795729|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
32795730|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
32795731|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
32795732|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
32795733|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
32795734|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
32795735|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
32795736|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
32795737|NCT02165735|Experimental|Usual Care|Usual care for HIV
32795738|NCT02069899|Other|Enrolled-04 Cohort|"Participants enrolled in Study NI-0501-04 (NCT01818492) will be invited to participate for long-term follow-up for 1 year either after haematopoietic stem cell transplantation (HSCT) or after the last administration of emapalumab.~In Study NI-0501-04, participants received emapalumab for 4 to 8 weeks. After the treatment period, participants could have undergone HSCT.~Participants for whom an appropriate donor was not identified by Week 8, or in a case where HSCT will be delayed for reasons unrelated to the administration of emapalumab, can continue receiving treatment with emapalumab beyond the foreseen 8 weeks in the current study (NI-0501-05, NCT02069899) at the request of the investigator, providing a favorable benefit/risk assessment of treatment is established.~The dose and timing was either carried forward from the last administered emapalumab dose as part of the parent protocol or an adjusted dose was administered, if necessary."
32795739|NCT02069899|No Intervention|Enrolled-06 Cohort|"All participants who received at least 1 dose of emapalumab and were monitored for at least 4 weeks after the last drug administration in Study NI-0501-06 (NCT03311854) will be invited to participate for long-term follow-up for 1 year after the last administration of emapalumab.~Participants will not receive emapalumab in the current study (NI-0501-05, NCT02069899)."
32795740|NCT02069899|Other|Enrolled-CU Cohort|"In exceptional cases, at the spontaneous request of a treating physician, CU treatment will be granted to the participants who had exhausted all possible treatment options and who could not be enrolled in a clinical study. All participants who receive at least 1 dose of emapalumab under CU will be invited to participate for long-term follow-up for 1 year either after HSCT or after the last administration of emapalumab.~Participants can continue treatment in the context of the current Study (NI-0501-05, NCT02069899) while stem cell donor search is ongoing, or if the investigator assesses that continuation of treatment is beneficial."
32795741|NCT01831089|Experimental|Treatment|PM01183 + paclitaxel +/- bevacizumab
32795742|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
32795743|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
32795744|NCT02098369|Other|Usual care|Written education material (basic)
32795745|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
32795746|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
32795747|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
32795748|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
32795749|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
32795750|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
32795751|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
32795752|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
32795753|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
32795754|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
32900768|NCT05610150|Active Comparator|Twin Block Functional appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Twinblock functional appliance for six months.
32900769|NCT00398918|Experimental|Zonisamide|
32900770|NCT00398918|Placebo Comparator|Placebo|
32900771|NCT05352048|Experimental|Intraoperative MMG vs EMG for cortical breach detection|Participants in this arm will be assessed with both MMG and EMG during their lower spine fusion surgery.
33318490|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
32795755|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
32795756|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
32795757|NCT01830855|Experimental|rLP2086 lot 1|
32795758|NCT01830855|Experimental|rLP2086 lot 2|
32795759|NCT01830855|Experimental|rLP2086 lot 3|
32795760|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
32795761|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
32795762|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
32795763|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
32795764|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
32795765|NCT01856907|Active Comparator|Metformin|1000 mg BID
32795766|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
32795767|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
32795768|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
32795769|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
32795770|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
32795771|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
32795772|NCT02097745|Experimental|MabThera/Rituxan|
32795773|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
32795774|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
32795775|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
32795776|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
32795777|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
32795778|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
32795779|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
32795780|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
32795781|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
32795782|NCT02212379|Experimental|raltegravir and etravirine|
32795783|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
32795784|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
33088814|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
33088815|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
33088816|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
33088817|NCT00283166|Experimental|A|Tailored Coaching and Education
33088818|NCT00283166|Other|B|Active Control
33088819|NCT00318240|Experimental|1|High Intensity Focused
33088820|NCT04708652||preterm children|Our previous intervention study enrolled 178 VLBW (birth body weight less than 1,500 gm) preterm children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
33088821|NCT04708652||term children|Our previous intervention study enrolled 62 term children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
33300994|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
33300995|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
33300996|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
33300997|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
33300998|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
33300999|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
33301000|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
33301001|NCT01263808|Placebo Comparator|Placebo|Placebo
33301002|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
33301003|NCT01159678|Experimental|online psychoeducation|
33301004|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
33301005|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
33301006|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
33301007|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
32795785|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
32795786|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
32795787|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
32795788|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
32795789|NCT04750811||Small Bowel obstruction|Patients admitted with a diagnosis of small bowel obstruction at 1 of the 6 participating centres
32795790|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
32795791|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
32795792|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
32795793|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
32795794|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
32795795|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
32795796|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
32795797|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
32900772|NCT05514444|Experimental|MK-4464|Participants will receive MK-4464 administered in escalating doses as an intravenous (IV) infusion every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of previous dose.
33088822|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
33088823|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
33088824|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
33088825|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
33088826|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
33088827|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
33088828|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
33088829|NCT00311805|Active Comparator|1|
33088830|NCT00311805|Active Comparator|2|
33088831|NCT00311805|Placebo Comparator|3|
32795798|NCT04756505|Experimental|Treatment (bintrafusp alfa, NHS-IL12, radiation therapy)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 14 and immunocytokine NHS-IL12 SC on day 14. Beginning on day 14 of cycle 1, patients undergo radiation therapy QD for up to 4 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32795799|NCT04750655|Placebo Comparator|Intraoperative antibiotics (Abx) only; no postoperative topical antibiotics|intraoperative/ intracameral antibiotic (moxifloxacin) only; no postoperative topical antibiotic drops
32795800|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics four times a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops four times a day for 1 week
32795801|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics once a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops once a day for 1 week
32795802|NCT04750265|Experimental|Robotic assisted early mobilization|Early mobilization therapy assisted with robotics
32795803|NCT04750265|No Intervention|Standard Care|Mobilization according to standard care by staff
32795804|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
32795805|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
32795806|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
32795807|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
32795808|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
32795809|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
32795810|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
32795811|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
32795812|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
32795813|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
32795814|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
32795815|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
32795816|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
32795817|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
32795818|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
32795819|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
32795820|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
32795821|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
32795822|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
32900773|NCT05514444|Experimental|MK-4464 + Pembrolizumab|Participants will receive MK-4464 administered in escalating doses as an IV infusion and Pembrolizumab 200 mg IV infusion every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of MK-4464 monotherapy arm.
32900774|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
33088832|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
33088833|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
33088834|NCT00283517||001|
32900775|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
32737892|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
32737893|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
32737894|NCT03333083|Experimental|Raltegravir + Lamivudine|
32737895|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
32737896|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
32737897|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
32737898|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
32737899|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
32737900|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
32737901|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
32737902|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
32737903|NCT05465135|Experimental|Dihydroartemisinin Group|The subjects take Dihydroartemisinin, 40mg tid for 12 weeks
32737904|NCT05018247|Active Comparator|Urgent revascularization with Optimal Medical Therapy|Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
32737905|NCT05018247|Other|Optimal Medical Treatment with delayed revascularization|OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
32737906|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
32737907|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
32737908|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
32737909|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
32737910|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
32737911|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
32737912|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
32737913|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
32737914|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
32737915|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
32737916|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
32737917|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
32737918|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
32737919|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
32737920|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
33088835|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
33088836|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
33301008|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
33301009|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
32746337|NCT04792125|Active Comparator|Pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed pelvic floor muscle training (PFMT).
32746338|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
32746339|NCT03195257|Experimental|Hypoglycemia-GIP|
32746340|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
32746341|NCT03195257|Experimental|Hyperglycemia-GIP|
32746342|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
32746343|NCT04792281||Patients with suspected native valve endocarditis|
32746344|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
32746345|NCT02447393|Other|levocetirizine|Study Drug
32746346|NCT02447393|Other|cetirizine|Study Drug
32746347|NCT02447393|Other|placebo|Study Drug
32746348|NCT04785105||patient with isolated SMA stenosis|patient with isolated SMA stenosis on initial scanner
32746349|NCT04785105||patient with both SMA stenosis and CA or/and IMA stenosis|patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner
32746350|NCT04785027|Other|PSORI-CM01 group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
32746351|NCT04785027|Experimental|Gu Ben Hua Yu group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
32746352|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
32746353|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
32746354|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
32746355|NCT04792359|Experimental|Equinometer|Measurement with Equinometer
32746356|NCT04792437||glioma patients|glioma patients with routine surgery
32746357|NCT02447471||study group|all participants
32746358|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
32746359|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
32746360|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
32746361|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
32746362|NCT04792515|Experimental|treatment group|Patients were treated with camrelizumab combined with SOX/ or apatinib
32746363|NCT04792047||Lesions with perivasular FAI greater than ≥-70.1|
32746364|NCT04792047||Lesions with perivasular FAI greater than <-70.1|
32746365|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
32746366|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
32746367|NCT04791657||Patients without complications|Patients with uneventful recovery
32746368|NCT04791657||Patients with complications|Patients experiencing complications within 30 days postoperatively
32746369|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
32746370|NCT04784793|No Intervention|Phase1: Design and development|"We conducted focus group meetings to discuss the content, features and design of the app.~The focus group consisted of physiotherapists and young adults. The focus group members discussed the variety of topics in subgroups (login parameters, self-monitoring, exercises content, video or animation types, exercise diary, reminders, encouragement, method, etc)."
32746371|NCT04784793|No Intervention|Phase 2: Testing the app|We tested the prototype version app interface in the 2nd phase. All participants downloaded the prototype app and used the app for one week.
32746372|NCT04784793|No Intervention|Phase 3: Usability evaluation|"We conduct a think-aloud interview and evaluate the quantitative usability in the third phase.~The quantitative usability was assessed by the System Usability Scale (SUS), and the adapted Usability, Satisfaction and Ease to Use (USE) Questionnaire."
32746373|NCT04784793|Active Comparator|Phase 4: Pilot randomized controlled trial/ The app-based group|"The app-based group:~Participants in the intervention group received their smartphone-based- home exercise program."
32746374|NCT04784793|Experimental|Phase 4: Pilot randomized controlled trial/ The control group|"The control group:~Participants in the control group received their home exercise programs as a paper handout."
32795823|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
32795824|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
33088837|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
32795825|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
33088838|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
32795826|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
32795827|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
32795828|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
32795829|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
32795830|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
32795831|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
32795832|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
32795833|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
32795834|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
32795835|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
32795836|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
32795837|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
32795838|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
32795839|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
32795840|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
32795841|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
32795842|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
32795843|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
32795844|NCT04724629|Experimental|IL-17 inhibitor (Ixekizumab)|Patients will receive study medication Ixekizumab 80 mg per week, (SC) once a week for 4 weeks or until discharge.
32795845|NCT04724629|Experimental|IL-2 (Aldesleukin)|1.5 million IU per day (SC) for 7 days or until discharge. Patients will receive study medication Aldesleukin 1.5 million IU per day (SC), for 7 days or until discharge.
32795846|NCT04724629|Experimental|Indirect IL-6 inhibitor (Colchicine)|Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
32795847|NCT04724629|Active Comparator|Standard of care|Standard treatment, supplementation of O2 ventilation + standard treatment of the institution, which may include Dexamethasone according to the institutional protocol.
32795848|NCT04723537|Experimental|Part A: Upamostat 200 mg|Each day participants will receive a single 200 mg dose of upamostat along with a single matching placebo, for a total of 14 days.
32795849|NCT04723537|Experimental|Part A: Upamostat 400 mg|Each day participants will receive two 200 mg doses of upamostat, for a total of 14 days.
32795850|NCT04723537|Placebo Comparator|Part A: Placebo|Each day participants will receive two matching placebos, for a total of 14 days.
33088839|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
32795851|NCT04723537|Experimental|Part B: Upamostat|Based on dose selected from Part A, each day participants will receive EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
32795852|NCT04723537|Placebo Comparator|Part B: Placebo|Based on dose selected from Part A, each day participants will receive EITHER a single matching placebo OR two matching placebos, for a total of 14 days.
33301010|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
32795853|NCT04183465|Active Comparator|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
32795854|NCT04183465|Experimental|Multi-domain lifestyle intervention|All patients randomized to experimental arm will receive diet counselling, aggressive control of CV risk factors, smoke cessation program and exercise training. The physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
32795855|NCT02093923|Experimental|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
32795856|NCT02093923|Experimental|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
32795857|NCT02093923|Experimental|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
32795858|NCT02093923|Experimental|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
32795859|NCT02093923|Placebo Comparator|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
32795860|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
32795861|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
32795862|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
32795863|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
32795864|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
33088840|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
33301011|NCT01157572|Active Comparator|Metoprolol|
33301012|NCT01157572|Placebo Comparator|Placebo|
32795865|NCT02186015|No Intervention|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
33301013|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
33301014|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
33301015|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
32795866|NCT02066389|Placebo Comparator|Placebo|Participants received placebo capsules twice daily for 12 weeks.
32795867|NCT02066389|Experimental|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
33301016|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
32795868|NCT02066389|Experimental|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
32795869|NCT02066389|Experimental|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
32795870|NCT02066389|Experimental|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
32795871|NCT02066389|Experimental|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
32795872|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
33301017|NCT01161784|Placebo Comparator|Nutrient drink|
33301018|NCT01161784|Experimental|Probiotics|
33301019|NCT01159834||Gardasil, HPV infection|
33301020|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
33301021|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
33301022|NCT01265836||1|
33301023|NCT01265914|Placebo Comparator|placebo|
33301024|NCT01265914|Experimental|FP-01.1|
33301025|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
33301026|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
33301027|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
32795873|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
32795874|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
32795875|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
32795876|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
32795877|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
32795878|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
32795879|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
33301028|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
33301029|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:~Pelvic Diaphragm Release.~Respiratory Diaphragm Release.~Thoracic Inlet Release.~Hyoid release.~Sacral technique for stabilize L5/sacrum.~CV-4 Still Point Induction."
32795880|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
32795881|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
33301030|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
32795882|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
32795883|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
32795884|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
32795885|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
32795886|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
32795887|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
32795888|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
32795889|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
32795890|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
32795891|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
32795892|NCT01625611|Experimental|Naltrexone|
32795893|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
32795894|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
32795895|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
32795896|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
32795897|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
32795898|NCT04755491||Chloride transfer by continuous veno-venous hemofiltration|Chloride transfer over 24h of continuous veno-venous hemofiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
32795899|NCT04755491||Chloride transfer by continuous veno-venous hemodialysis|Chloride transfer over 24h of continuous veno-venous hemodialysis in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
33301031|NCT00254982|Experimental|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
33301032|NCT00254982|Experimental|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
33301033|NCT01264042|Experimental|FeSo4|
33301034|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
32795900|NCT04755491||Chloride transfer by continuous veno-venous hemodiafiltration|Chloride transfer over 24h of continuous veno-venous hemodiafiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
32795901|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
32795902|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
32795903|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
33088841|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
33088842|NCT00283829|Other|I|Docetaxel followed by IL-2
33088843|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
32795904|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
32795905|NCT04749563|Active Comparator|Active|IGC AD1
32795906|NCT04749563|Placebo Comparator|Placebo|IGC AD1 Placebo
32795907|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
32795908|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
32795909|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
32795910|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
32795911|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
32795912|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
32795913|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
32795914|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
32795915|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
32795916|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
32795917|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
32795918|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
32795919|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
32795920|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
32900776|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
33088844|NCT00419211|No Intervention|No Intervention|Usual care group
33088845|NCT00283946|Experimental|1|
33088846|NCT00283946|Active Comparator|2|
33088847|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
33088848|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
33088849|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
33088850|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
33088851|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
32795921|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
32795922|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
32795923|NCT02158949|No Intervention|Usual Care|Usual care in ED
32795924|NCT04707157|Experimental|LY3556050|LY3556050 given orally
32795925|NCT04707157|Placebo Comparator|Placebo|Placebo given orally
32795926|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
32795927|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
32795928|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
32795929|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
32795930|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
32795931|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
32795932|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
32795933|NCT02131259||Afatinib|
32795934|NCT01856595|Experimental|PF-06291874|
32795935|NCT01856595|Placebo Comparator|Placebo|
32795936|NCT02158247||Conventional group, Touch and Read group|
32795937|NCT04589559|Experimental|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a chest-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
32795938|NCT01829295|Experimental|Methotrexate|oral methotrexate
32795939|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
32795940|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
32795941|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
32795942|NCT04589403|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
32795943|NCT04589403|Experimental|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
32795944|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
33088852|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
32795945|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
32795946|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
32795947|NCT04754399|Experimental|Cannabidiol (CBD)|Oral solution given 2x daily.
32795948|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
32795949|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
32795950|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
32795951|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
32795952|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
32795953|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
32795954|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
32795955|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
32795956|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
32795957|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
32795958|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
32795959|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
33088853|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
33088854|NCT00312039|Experimental|A|
32795960|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
32795961|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
32795962|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
32795963|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
33088855|NCT00312039|Active Comparator|B|
32795964|NCT04731103|Active Comparator|Abacavir (ABC)|Participants receive Abacavir (ABC) for 6 weeks and 4 weeks of washout.
32795965|NCT04731103|Active Comparator|Lamivudine (3TC)|Participants receive Lamivudine (3TC) for 6 weeks and 4 weeks of washout.
32795966|NCT04731103|Active Comparator|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Participants receive Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) for 6 weeks and 4 weeks of washout.
32795967|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
32795968|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
32795969|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
32795970|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
32795971|NCT01827267|Experimental|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
32795972|NCT01827267|Experimental|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
32795973|NCT01855425|Other|Investigational CBCT|Radiation
32795974|NCT01854879|Experimental|Nucleus 6|
32795975|NCT01827111|Experimental|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
32795976|NCT02045095|Experimental|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
32795977|NCT02045095|Experimental|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
32795978|NCT02045095|Experimental|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
32795979|NCT02045095|Experimental|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
32795980|NCT02045095|Experimental|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
32795981|NCT02045095|Experimental|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
32795982|NCT02045095|Experimental|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
32795983|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
32795984|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
32795985|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
32795986|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
32795987|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
32795988|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
32795989|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
32795990|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
33088856|NCT00284102|Experimental|1|ALI/ARDS patients
33088857|NCT04718831|Other|Baseline|Did not take nutritious food
33088858|NCT04718831|Experimental|General dose|Taking 6g spirulina
32795991|NCT01826487|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren orally 3 times a day (TID) at morning, midday, and evening for 48 weeks.
33088859|NCT04718831|Experimental|Double dose|Taking 12g spirulina
33404182|NCT05761236|Active Comparator|Control group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates. It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session.The patients in the control group continued the exercise program every day of the week for 12 weeks. Exercise lists were sent to the patients in the form of electronic booklets via an electronic communication application every week, and their continuity with the exercise program was checked with the diaries they were asked to fill in.
33404183|NCT02331706|Experimental|Subject Recipients|
33404184|NCT02331706|Experimental|Subject Donors|
33404185|NCT04400838|Experimental|Group 1 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
33088860|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
33404186|NCT04400838|Experimental|Group 1 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
32795992|NCT01826487|Experimental|Ataluren|Participants will receive ataluren suspension orally TID, 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
32795993|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
32795994|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
32795995|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
32795996|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
32795997|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
32795998|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
32795999|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
32796000|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
32796001|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
32796002|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
32796003|NCT04418089|Experimental|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
32796004|NCT04418089|Experimental|Placebo|The group received standard treatment with the oral administration of Placebo
32796005|NCT01825941|Active Comparator|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
32796006|NCT01825941|Placebo Comparator|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
32796007|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
32796008|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
32796009|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
32796010|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
32796011|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
32796012|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
32796013|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
32796014|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
32796015|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
32796016|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
32796017|NCT04753931|Experimental|Sensory Training in addition to Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
32796018|NCT04753931|Experimental|Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
32796019|NCT04748705|Experimental|IMC-1 Oral Tablet|2X IMC-1 Tablet taken orally, each morning and evening.
32796020|NCT04748705|Placebo Comparator|Placebo|2X Placebo Tablet taken orally, each morning and evening.
32796021|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
32796022|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
32796023|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
32796024|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
32796025|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
32796026|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
32796027|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
33088861|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
33088862|NCT00284258|Experimental|1|CPT-11 and TS-1
32796028|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
32796029|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
32796030|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
33301035|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
33301036|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
33301037|NCT03968796|Active Comparator|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
33301038|NCT03968796|Active Comparator|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
32796031|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
32796032|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
33301039|NCT03968796|Active Comparator|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
33301040|NCT03968796|Placebo Comparator|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
32796033|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
32796034|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
32796035|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
33088863|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
33088864|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
33301041|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
33301042|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
32796036|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
32796037|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
32796038|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
32796039|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
32900777|NCT05599776|No Intervention|Control group|The control group of this trial will receive standard postoperative care which includes physiotherapy appointments 4 weeks and 3 months after the surgery. The 4-week physiotherapy appointment will be at local health center, occupational health clinic or in private physiotherapy clinic and patients are instructed to book the appointments independently according to the standard of care in Coxa Hospital. The 3-month physiotherapy appointment in Coxa Hospital will be carried out by physiotherapists who are dedicated to research projects at Coxa outpatient clinic.
32900778|NCT05599776|Experimental|Intervention group|The patients in the intervention group will receive standard physiotherapy care but patients also use smart rings (Oura ring) 3 months postoperatively. Patients will be remotely monitored to follow their recovery from TKR surgery: the study group physiotherapists will follow the patients' activity and sleep and if necessary, make a contact with patient if there seems to low activity indicating difficulties with recovering from the surgery. If there is a constantly decreasing trends in these parameters or patient improvement plateaus, patient is contacted and their status is evaluated by telephone. Based on the information from this contact, the patients may be asked to visit the physiotherapist at the outpatient clinic to assess the situation, and also anesthetist may be consulted on the pain medication. Data collected with the Oura ring will also be used in physiotherapy appointments as a part of therapeutic treatment and guidance.
32900779|NCT05286476|Experimental|group A|received Whole-body Vibration, pelvic floor exercise and static abdominal exercises interventions In addition to diet instructions
32900780|NCT05286476|Other|group B|received pelvic floor exercises and static abdominal exercises in addition to diet instructions only
32900781|NCT05351580||Advanced Parkinson's disease patients who receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who receive advance therapy during the study.
32900782|NCT05351580||Advanced Parkinson's disease patients who do not receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who do not receive advance therapy during the study.
32900783|NCT05599074|Experimental|AOB adults|adult patients over 18 years having an anterior open bite of more than 2 mm, requiring incisors extrusion
33301043|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
33301044|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
33301045|NCT03968718|Experimental|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
33301046|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
33301047|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
33318491|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
32900784|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
32900785|NCT05351112||Patients who received the Anatomical Shoulder 2.0 Fracture|Anatomical Shoulder 2.0 Fracture
32796040|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
32796041|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
32796042|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
32796043|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
32796044|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
32796045|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
32796046|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
32796047|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
32796048|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
32796049|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
32796050|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
32796051|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
32796052|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
32796053|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
32796054|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
32796055|NCT04748237|Experimental|Coronary computed tomopraphic angiography|"Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and referred to a CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days. Local scanning protocols can be used on ≥64-slice multi-detector CT scanners able to perform ECG-gated coronary angiography.~The coronary angiography will be classified as normal (or near normal) or as having atherosclerosis (CAD). The report will also classify each vessel (left main, prox LAD, mid or distal LAD, LCX and RCA regarding degree of stenosis (no stenosis, 0-49%, ≥50%, or not possible to estimate because of calcification or technical reason).~The result will be presented to the responsible physician as soon as possible and who will plan further care of the patients."
32796056|NCT04748237|No Intervention|No Coronary computed tomopraphic angiography|"Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always.~Regardless of diagnostic strategy, the responsible physician is encouraged to initiate secondary prevention measures if the investigations indicate signs of CAD, including medication with aspirin and statins."
32796057|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
32796058|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
32796059|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
32796060|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
32796061|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
32796062|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
32796063|NCT01628549|Experimental|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
32900786|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
32796064|NCT01628549|Experimental|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
33404187|NCT04400838|Experimental|Group 1 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost (4-6 weeks apart)
32796065|NCT01628549|Experimental|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
32796066|NCT01628549|Placebo Comparator|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
32796067|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
32796068|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
33404188|NCT04400838|Experimental|Group 2 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
32796069|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
32796070|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
32796071|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
32796072|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
32796073|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
32796074|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
32796075|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
32796076|NCT04417751|Experimental|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
32796077|NCT04417751|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
32796078|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
32796079|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
32796080|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
32796081|NCT04702165|Experimental|VATS resection with J-bar|Each patient with a lung nodule meeting criteria will undergo a lung resection which could be one of three approaches: iVATS with Dyna-CT, VATS, or open. Each approach will use a the experimental device the Lung Resection Marker Locator Kit
32796082|NCT04701151|Experimental|Intervention|"Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.~If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm."
32796083|NCT04701151|Active Comparator|Control|The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.
32796084|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
32796085|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
32796086|NCT04730557|Experimental|Weight-Loss|Participants in the weight-loss intervention arm of the study will be enrolled in an individualized 6-month intervention designed to achieve a 10% reduction of body weight relative to baseline. Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Intervention activities include individual diet counseling, group support, goal setting, self-monitoring, stress management, and problem solving. Weekly group support and education sessions, along with daily food journaling and weekly weigh-ins, are recognized approaches for successful weight loss [30-32]. Once the weight loss goal is achieved, diets will be liberalized for weight maintenance.
32796087|NCT04730557|No Intervention|Wellness Education|Control participants will be counseled to maintain their baseline body weight and level of physical activity. They will report weights weekly and if their weight deviates from baseline they will be asked to keep daily food logs and counseled to return calorie intakes to weight maintenance level. To document diet intakes/adherence, 3-day food records will be collected at months 0, 3, and 6 and analyzed for calorie and nutrient composition. Participants will be encouraged not to change their physical activity levels from baseline and their activity will be monitored by Actigraph activity monitors worn in 7-day periods at months 0, 3, and 6. In addition, each participant will be invited to enter the weight loss intervention after completion of the health education control course.
32796088|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
32796089|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
32796090|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
32796091|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
32796092|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
33301048|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
33301049|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
33301050|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
33301051|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
33301052|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
33301053|NCT03971916|Experimental|HBM9161 340mg|
33301054|NCT03971916|Experimental|HBM9161 510mg|
33301055|NCT03971916|Experimental|HBM9161 680mg|
33301056|NCT03971916|Placebo Comparator|Placebo|
33301057|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
33301058|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
33301059|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
33301060|NCT00224016|Experimental|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
32796093|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
32796094|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
32796095|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
32796096|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
32796097|NCT04700839|Experimental|SGLT2 inhibitors group|Intervention with SGLT2 inhibitors (100mg/d) for 3 months
32796098|NCT04700839|Active Comparator|Metformin group|Intervention with metformin (1500-2000mg/d) for 3 months
32796099|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
32796100|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
32796101|NCT01825785|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months.
32796102|NCT01825785|Experimental|Romosozumab|Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, or 3 mg/kg Q4W for 3 months.
32796103|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
32796104|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
32796105|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
32796106|NCT01598753|Active Comparator|Tramadol|
32796107|NCT01598753|Placebo Comparator|Placebo|
32796108|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
32796109|NCT01598753|Sham Comparator|Health Education|
32796110|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
33301061|NCT00224016|Active Comparator|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
33088865|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
33088866|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
33088867|NCT04718753|Experimental|Mindful Breathing Group|Mindful breathing intervention which has been used in mindfulness-based interventions
33088868|NCT04718753|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
33088869|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
33088870|NCT00284492|Active Comparator|Lifestyle advice|
33301062|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
33088871|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
33088872|NCT00284609|Experimental|1|
33088873|NCT00284609|Active Comparator|2|
33088874|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
33301063|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
33301064|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
33301065|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
33301066|NCT03881410|Experimental|Shear-wave elastography-guided|
33301067|NCT03881410|Active Comparator|Convention ultrasound-guided|
33301068|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
33301069|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
33301070|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
33301071|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
33301072|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
33301073|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
33301074|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
33301075|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
33301076|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
33301077|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
33301078|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
33301079|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
33301080|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
33301081|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
33301082|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
33301083|NCT01162018|Experimental|Acupuncture Arm|
33301084|NCT01162018|Sham Comparator|Sham Acupuncture|Sham Acupuncture
33301085|NCT01162174|Experimental|100 mg of Oligonol|
33301086|NCT01162174|Experimental|200 mg of Oligonol|
33088875|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
33088876|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
33088877|NCT00312390|Other|Healthy Control Subjects|
33088878|NCT00312390|Other|Subjects with amblyopia|
33088879|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
33088880|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
33088881|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
33088882|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
33088883|NCT00312585|Experimental|Acupuncture|
33088884|NCT00312585|Sham Comparator|Sham Acupuncture|
33088885|NCT00312585|No Intervention|Usual care only|
33301087|NCT01162174|Placebo Comparator|0 mg of Oligonol|
33301088|NCT01157728||Relapsing Multiple Sclerosis patients|
33301089|NCT01157728||healthy volunteer|
33301090|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
32796111|NCT01824693|Experimental|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
32796112|NCT01824693|Experimental|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
32796113|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
32796114|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
32796115|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
32796116|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
32796117|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
32796118|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
32796119|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
32796120|NCT01622569|Active Comparator|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
32796121|NCT01622569|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
32796122|NCT01622569|Active Comparator|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
32796123|NCT01622569|Active Comparator|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
32796124|NCT01824303|Experimental|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
32796125|NCT01824303|Placebo Comparator|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
32796126|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
32796127|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
32796128|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
32796129|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
32796130|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
32796131|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
32796132|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
32796133|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
32796134|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
32796135|NCT01823991|Experimental|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza and VitaBlue. Participants will be asked to take 1 tablet of Lovaza two times a day and 1 tablet of VitaBlue three times a day.
32796136|NCT01823991|Placebo Comparator|Placebo Administration|Participants will be provided with two bottles containing placebo. Participants will be asked to take 1 tablet of one placebo two times a day and 1 tablet of other placebo three times a day.
32796137|NCT04729855||colorectal cancer patients|"Colorectal cancer patients( n = 74 ) from stage I-III with the following criteria:-~a. Inclusion criteria:~No sex predilection.~Age (25-65 yr).~Colorectal carcinoma confirmed by histopathological examination"
32796138|NCT04729855||Healthy controls ( n = 74)|matched as regarding age and sex as much as possible with cases.
32796139|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
32796140|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
32796141|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
32796142|NCT04747301|Other|Double-balloon catheter group|Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA).
32900787|NCT05350722|Experimental|Pre-operative single dose partial breast irradiation|
32900788|NCT04750694|Experimental|RT + BFRE|High intensity Resistance training combined with Blood Flow
32900789|NCT04750694|Active Comparator|RT|Resistance training alone
33301091|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
33301092|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
32796143|NCT04747301|Other|Vaginal insertion Prostaglandin E2 group|Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).
32796144|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
33301093|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
32796145|NCT02152163|Placebo Comparator|IV Saline|IV Saline
32796146|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
32796147|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
32900821|NCT05307666|No Intervention|Usual Care|Patients will continue to receive care as appropriate but no dedicated visit to review and minimize medications will be organized as a result of the study. Medications are free to be minimized during the normal course of care should the need arise.
33301094|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
33301095|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
33301096|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
33301097|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
33301098|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
33301099|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
33301100|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
33301101|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
33301102|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
33301103|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
33301104|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
33301105|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
33301106|NCT01162252|Active Comparator|Living Well|
33301107|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
33301108|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~Logging foods for accountability and counting calories~Close attention to portion control and appropriate serving sizes of foods consumed~Consumption of appropriate calorie and sugar free beverages~Good meal distribution and avoidance of meal skipping~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
33301109|NCT01157806|Experimental|radiochemotherapy instead of surgery|
33301110|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
33301111|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
33301112|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
33301113|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
33301114|NCT05001958|Experimental|Action observation|
33301115|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
33301116|NCT01157884||Kidney Transplantation|
33301117|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
33301118|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
33301119|NCT01264354|Experimental|1|Clevudine 30mg
33301120|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
33301121|NCT01264354|Experimental|3|Clevudine 20mg
33301122|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
33301123|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
33301124|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
33301125|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
33301126|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
33301127|NCT03876730||Study group|3-18 aged children with cerebral palsy
33301128|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
33301129|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
33301130|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
33088886|NCT04718402|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
33088887|NCT00285233|Experimental|1|
33088888|NCT00285389|Experimental|VAD Clorambucil Rituximab|
33088889|NCT00312780|Experimental|Arm 1: XL784|
33088890|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
32796148|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
32796149|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
32796150|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32796151|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
33088891|NCT00285428|Experimental|Dose level 1|120 mg/m2
33088892|NCT00285428|Experimental|Dose level 2|200 mg/m2
33088893|NCT00285428|Experimental|Dose Level 3|375 mg/m2
33088894|NCT00285428|Experimental|Dose level 1B|80 mg/m2
33088895|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
33088896|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
33088897|NCT00312936|No Intervention|Wait List|
33088898|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
33088899|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
33088900|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
32796152|NCT04747145|Experimental|Pulsed reduced dose-rate radiotherapy|Chemoradiation, adjuvant chemotherapy.
32796153|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
32796154|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
32796155|NCT04725110|Experimental|T3 Intervention|Participants in this arm will receive the experimental intervention.
32796156|NCT04725110|Placebo Comparator|Placebo Therapy|Participants in this arm will receive placebo therapy.
32796157|NCT04723862|Experimental|Spironolactone|Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
32796158|NCT04723862|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
32796159|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
32796160|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
32796161|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
32796162|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
32796163|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
32796164|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
32796165|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
32796166|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
32796167|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
32796168|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
32796169|NCT02060383|Experimental|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
32796170|NCT02060383|Experimental|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
32796171|NCT02060383|Other|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
32796172|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
32796173|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
32796174|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
32796175|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
32796176|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
32796177|NCT02065622|Experimental|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
32796178|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
32796179|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
32796180|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
32796181|NCT02124161|Other|13vPnC+SIIV/Placebo|
33404189|NCT04400838|Experimental|Group 2 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks apart
32796182|NCT02124161|Other|Placebo+SIIV/13vPnC|
33404190|NCT04400838|Experimental|Group 2 b1|.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
32796183|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
32796184|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
32796185|NCT02117570|Experimental|High dose of C. difficile vaccine|
32796186|NCT02117570|Experimental|Low dose of C. difficile vaccine|
32796187|NCT02117570|Placebo Comparator|Placebo|
32796188|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
32796189|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
32796190|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
32796191|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
32796192|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
32796193|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
32796194|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
32796195|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
32796196|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
32796197|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
32796198|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
32796199|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
32796200|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
32796201|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
32796202|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
32796203|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
32796204|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
32796205|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
32796206|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
33088901|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
33088902|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
32796207|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
33301131|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
33301132|NCT01266928|No Intervention|no drug|no drug
33301133|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
33301134|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
33301135|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
33301136|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
33301137|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
33301138|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
33301139|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
33301140|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
33301141|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
33301142|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
33301143|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
33301144|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
33301145|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
33301146|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
33301147|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
33301148|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
33301149|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
33301150|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
33301151|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
33301152|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
32796208|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
33301153|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
33301154|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
33301155|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
33301156|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
33301157|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
33301158|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
33301159|NCT01268254||red wine|red wine usual consumer versus abstemious
33301160|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
33301161|NCT03878290|No Intervention|Control|Treatment as usual
33301162|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
33301163|NCT01264588|No Intervention|standard-of-care|
33301164|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
33301165|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
33088903|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
33301166|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
33301167|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
33301168|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
33301169|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
33301170|NCT01162798|Active Comparator|Control|commercially available formula
33301171|NCT01162798|Experimental|Test|test formula
33301172|NCT01158196|Experimental|infra-red diode laser|one session, one dose
33301173|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
33301174|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
32796209|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
32796210|NCT04746131|Experimental|IMM0306|IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.
32796211|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
33301175|NCT05666908|Experimental|HFNO group|Direct guidance and positioning of DLT intubation with FOB visualization, using HFNO during intubation asphyxia.
33301176|NCT05666908|No Intervention|Control group|The DLT cannula was directly guided and positioned under FOB visualization, and no oxygen therapy equipment was used during intubation.
33301177|NCT05075200|Experimental|Group I|Participants with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (and dialysis)
33301178|NCT05075200|Experimental|Group II|Participants with GFR ≥ 60 mL/min/1.73m2
33301179|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
33301180|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
33301181|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33301182|NCT05666830||1|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
33301183|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
33301184|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
33301185|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
33301186|NCT01267162||TDF Treatment|
33301187|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
33301188|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
33301189|NCT01162954|Experimental|DA-6034|
32796212|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
32796213|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
32796214|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
32796215|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
32796216|NCT05136053|Experimental|Part A: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
32796217|NCT05136053|Placebo Comparator|Part A: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
32796218|NCT05136053|Experimental|Part B: Lu AG22515 and Immune System Activator|Participants will receive a single IV infusion of Lu AG22515 and a subcutaneous (SC) injection of immune system activator 14 days prior to and 14 days following the start of Lu AG22515 IV infusion.
33301190|NCT01162954|Placebo Comparator|Placebo|
33301191|NCT01268410||acute respiratory failure|
33301192|NCT01264666|Experimental|Chinese tea flavor liquor|
32796219|NCT05136053|Placebo Comparator|Part B: Placebo and Immune System Activator|Participants will receive a single IV infusion of placebo matching to Lu AG22515 and an SC injection of immune system activator 14 days prior to and 14 days following the start of placebo IV infusion.
32796220|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
32796221|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
32796222|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
32796223|NCT02063984|Experimental|Intensive Outpatient Treatment (IOP) + Contingency Management (CM) + Working Memory Training (WMT)|IOP + CM + WMT
32796224|NCT02063984|Active Comparator|IOP + CM|IOP + CM
33301193|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
33301194|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
33301195|NCT01160692|Experimental|Arm 1|
33301196|NCT01160692|Placebo Comparator|Arm 2|
33301197|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
32796225|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
33301198|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
33301199|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
32796226|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
32796227|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
33301200|NCT05025280||hearing loss|According to the audiological test results, individuals with a pure tone average of more than 25 dB in the better ear and with less than 10 dB difference between the air-bone conduction thresholds
33301201|NCT05025280||normal hearing|According to the audiological test results, individuals with a pure tone average of 25 dB or less in both ears and with less than 10 dB difference between the air-bone conduction thresholds
32796228|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
32796229|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
32796230|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
32796231|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
33301202|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
33301203|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
33301204|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
32796232|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
32796233|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
32796234|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
33301205|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
33301206|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
32796235|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
33404191|NCT04400838|Experimental|Group 4 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp (Abs 260)
33404192|NCT04400838|Experimental|Group 4 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
32796236|NCT02063828|Experimental|Group B|Group B - Device guided breathing high dose
32796237|NCT02063828|Sham Comparator|Group C|Group C - Usual Breathing Control Group
32796238|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
32796239|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
32796240|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
32796241|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
32796242|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
32796243|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
32796244|NCT02090114|Experimental|Cohort A:Post-enzalutamide|Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
32796245|NCT02090114|Experimental|Cohort B: Post-abiraterone|Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
32796246|NCT02090114|Experimental|Cohort C: Castration Only|Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
32796247|NCT02090114|Experimental|Cohort D: Mutation|Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
32796248|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
32796249|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
32796250|NCT04742036|Experimental|capivasertib|single-dose and multiple-dose capivasertib as monotherapy (Part A) and then in combination with paclitaxel (Part B)
33088904|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
33088905|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
33088906|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
33088907|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
33404193|NCT04400838|Experimental|Group 4 c1|Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs260) prime and 2.2x10^10vp (qPCR) boost*, at least 4 weeks apart
33404194|NCT04400838|Experimental|Group 5 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (Abs 260)
32796251|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
32796252|NCT04729634|Other|Mobilization and breathing training|Usual clinical care
32796253|NCT04741646|Experimental|Treatment Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
32796254|NCT04741646|Placebo Comparator|Control Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
32796255|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
32796256|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
32796257|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
32796258|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
32796259|NCT04722224|Experimental|Intervention: Home-based pulmonary rehabilitation|Patients will be treated for 12 weeks. The intervention consists in a strategic mixture of home visits and phone calls. The program includes exercise training and the self-management educational program Living Well with COPD.
33088908|NCT00313053|Experimental|Human mAb 216|
33088909|NCT00285896|Active Comparator|Active|GLP-1
33088910|NCT00285896|Placebo Comparator|Placebo|Placebo
33088911|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
33088912|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
33088913|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
33301207|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
33301208|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
32796260|NCT02087774|No Intervention|Control School|Control School received no intervention.
32796261|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
32796262|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
32796263|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
32796264|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
32796265|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
32796266|NCT04728620|Experimental|Intervention|Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.
33301209|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
33301210|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
33301211|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
33301212|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
33301213|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
33301214|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
33301215|NCT01268722|Active Comparator|Balloon|
33301216|NCT01268722|Experimental|Stent|
33301217|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
33301218|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
33301219|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
33301220|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
33301221|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
33301222|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
33301223|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
33301224|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
33301225|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
32796267|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
32796268|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
33088914|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
32796269|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
32796270|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
33102431|NCT05407935|Experimental|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
33301226|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
33301227|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
33301228|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
33301229|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
33301230|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
33301231|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
33301232|NCT05018884||Patients without SSI|Patients who underwent surgery and who developed a surgical site infection (SSI) during 30 days after surgery
33301233|NCT05018884||Patients with SSI|Patients who underwent surgery and who didn't develop a surgical site infection (SSI) during 30 days after surgery
32796271|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
32796272|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
33088915|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
33088916|NCT00319917|Experimental|1|
33088917|NCT00319917|Placebo Comparator|2|
32796273|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
32796274|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
32796275|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
33088918|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
33088919|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
33404195|NCT04400838|Experimental|Group 5 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
32796276|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
32796277|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
32796278|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
32796279|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
32796280|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
32796281|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
32796282|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
32796283|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
32796284|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
32796285|NCT04721600|Experimental|treatment|
32796286|NCT04720820|Experimental|Early Supported Discharge (ESD) Group|Patients in the ESD group will be discharged to home as soon as the acute medical treatment is finished. The patients will follow a pre-planned ESD program which consists of home-based rehabilitation (at least 30 minutes of physical therapy and 30 minutes of occupational therapy per week) offered by therapists. The ESD team will also provide social/medical services as needed. The ESD program will be provided till 1 months after discharge point.
32796287|NCT04720820|Active Comparator|Conventional Rehabilitation (CR) Group|The patients in CR group will be provided with inpatient rehabilitation after the acute medical treatment is finished. The length of inpatient rehabilitation may depend on the hospital's current program. Patients will be provided with outpatient based rehabilitation program if needed after discharge.
32796288|NCT04720742|Experimental|Experimental group|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.
32796289|NCT02058992||Ramelteon 8 mg administered orally once daily|
32796290|NCT04719416|Active Comparator|Active Treatment with Relaxation|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
32796291|NCT04719416|Active Comparator|Remission with Relaxation|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
32796292|NCT04719416|No Intervention|Active Treatment without|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
32796293|NCT04719416|No Intervention|Remission without|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
32796294|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
32796295|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
32796296|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
33088920|NCT00286481|Active Comparator|Simvastatin|
33301234|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
33301235|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
32796297|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
32796298|NCT02174627|Experimental|Roxadustat|
32796299|NCT02174627|Placebo Comparator|Placebo|
32796300|NCT02173769||Adults with COPD|
32796301|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
33301236|NCT01158898|Active Comparator|TPI ASM8 low dose|
33301237|NCT01158898|Active Comparator|TPI ASM8 high dose|
32796302|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
32796303|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
33301238|NCT01158898|Placebo Comparator|Placebo|
33301239|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
33301240|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
33301241|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
33301242|NCT01267474|Experimental|Nutritional education|
33301243|NCT01267474|No Intervention|Control|
33301244|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
33301245|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
33301246|NCT01265134||Experimental Group|the healthy elders
32796304|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
32796305|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
32796306|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
32796307|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
32796308|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
32796309|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
33301247|NCT01265134||Control Group|the elders who have fallen once
33301248|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
33301249|NCT01159132|Active Comparator|1|RAL 400 mg OD
33301250|NCT01159132|Active Comparator|2|RAL 800 mg OD
33301251|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
33301252|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
33301253|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
33301254|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
33301255|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
33301256|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
33301257|NCT01267708||Study Group|All those tested
33301258|NCT03879460|Experimental|Open Label|Open label
33301259|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
33301260|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
33301261|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
33301262|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
33301263|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
33301264|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
33301265|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
33301266|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
33301267|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
33301268|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
33301269|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
33301270|NCT01265290|Experimental|24 hours standard Holter monitoring|
33301271|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
33301272|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
33301273|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
33301274|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
33301275|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
32796310|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
33088921|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
33301276|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
33301277|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
33301278|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
33301279|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
32796311|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
32796312|NCT05135585|Other|Adults vaccinated with a complete COVID-19 vaccine regimen|Adults of Melanesian, Polynesian, European, and other communities vaccinated with a complete COVID-19 vaccine regimen, residing in New Caledonia.
32796313|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
32796314|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
32796315|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
32796316|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
32796317|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
33088922|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
33088923|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
33088924|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
33301280|NCT03872050||Migraine|Patients who have been diagnosed with migraine
33301281|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
33301282|NCT01167088|Placebo Comparator|Matching placebo tablet|
33301283|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
33301284|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
33301285|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
33301286|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
33301287|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
33301288|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
33301289|NCT05406310||Ablation-Index guided ablation group|This is the prospective study group that will undergo persistent atrial fibrillation ablation guided by Ablation Index.
33301290|NCT05406310||High-power, short-duration ablation Group|This is another prospective group of patients who will undergo persistent atrial fibrillation ablation by high-power, short-duration using QDOT Micro catheter.
33301291|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
33301292|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
33088925|NCT00286598|No Intervention|Control|Usual care
33088926|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
33301293|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
33301294|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
33301295|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
33301296|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
33301297|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
32940307|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
33301298|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
33301299|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
33301300|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
33301301|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
33301302|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
33301303|NCT01280734|Placebo Comparator|Placebo|
33301304|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
33301305|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
33301306|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
33301307|NCT01269892|Other|conventional milk|it is kind of nutritional regime
33301308|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
33301309|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
33301310|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
32940308|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
32940309|NCT00691652|Experimental|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg~Phase II:~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
32940310|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
32940311|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
32940312|NCT03630679||Preterm|born at <37 weeks of gestation
32940313|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
33301311|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
33301312|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
32940314|NCT03631927||Patient|Patients admitted to participating ICUs on the specified dates
33301313|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
33301314|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
33301315|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
32940315|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
32940316|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
32940317|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
33088927|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
33088928|NCT00286832||Single group study|
33088929|NCT00417326|Placebo Comparator|P|
33301316|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
33301317|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
33301318|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
33301319|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
33301320|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
33088930|NCT00417326|Experimental|E|
33088931|NCT00417404|Active Comparator|vitamin A|
33301321|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
33301322|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
33301323|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
33301324|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).~Group 1 participants are categorised into 4 groups as follows:~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
33301325|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
33301326|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
33301327|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
33301328|NCT01165606|Experimental|Physiotherpy|
33301329|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
33301330|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
33301331|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
33301332|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
33301333|NCT01281280||VNS Therapy|
33301334|NCT01281280||Best Medical Practice|
33301335|NCT01167478|Experimental|Caffeine|
32940318|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
32940319|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
32940320|NCT05035394|Active Comparator|Cataract surgery as stand alone|Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.
32940321|NCT05035394|Active Comparator|Cataract surgery in combination with Kahook Dual Blade glide goniotomy|Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.
32940322|NCT05035394|Active Comparator|Cataract surgery in combination with iStent Inject W implantation|Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
33301336|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
33301337|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
33301338|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
33301339|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
33301340|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
33301341|NCT01281514|Experimental|Treatment|See Detailed Description
33301342|NCT00223080|Active Comparator|Vaccine|ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
33301343|NCT00223080|Placebo Comparator|Placebo|ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
33301344|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
33301345|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
33301346|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
33301347|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
33301348|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
33301349|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
32940323|NCT05010980||retrospective|For the retrospective part of the study, the existing echocardiographic database will be used to retrieve data. The database query includes the last 2 years.
32940324|NCT05010980||prospective|For the prospective part of the study, patients will be included who have the clinical indication for cmr and scintigraphy due to suspected cardiac amyloidosis and fulfill the inclusion criteria.
32940325|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
32940326|NCT04933916|Experimental|EMB-001 Active|720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
33301350|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
33301351|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
33301352|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
33301353|NCT03971682|Experimental|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
33301354|NCT03971682|Active Comparator|Treatment As Usual - TAU|"Treatment As Usual:~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
33301355|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
33301356|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
32940327|NCT04929002||McArdle Disease|
33301357|NCT03971604|Experimental|group 1|treated with VA
33301358|NCT03971604|Experimental|group 2|treated with VE
33301359|NCT03971604|Experimental|group 3|treated with VA+VE
33301360|NCT03971604|No Intervention|group 4|No intervention
33301361|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
33301362|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
32940328|NCT04929002||Pompe disease|
32940329|NCT04929002||Controls|
32940330|NCT03574441|Active Comparator|TegadermTM only|
32940331|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
32940332|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
32940333|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
32940334|NCT01756586|Active Comparator|Control|Plain bupivacaine
32940335|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
32940336|NCT03636061|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
32940337|NCT03636061|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
32940338|NCT03636061|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
32940339|NCT03636061|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
32940340|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
32940341|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
32940342|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
32940343|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
33088932|NCT00417404|Sham Comparator|sham injection|
33301363|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
33301364|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
33301365|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
33301366|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
33301367|NCT03871114||Control group|
33088933|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
33088934|NCT00417521|Experimental|Family therapy|
33088935|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
33088936|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
32796318|NCT04185428|Experimental|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
32796319|NCT04185428|No Intervention|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
32796320|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
32796321|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
33088937|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
33088938|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
32796322|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
33088939|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
33088940|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|"ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
33088941|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|"ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
33301368|NCT01073592||CNV patiens|
33301369|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
33301370|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
33301371|NCT01281670|No Intervention|No vibration|
33301372|NCT01281670|Active Comparator|vibration|
33301373|NCT01281748|Experimental|methylprednisolone|
33301374|NCT01281748|Placebo Comparator|normal saline solution|
33301375|NCT03873610|Experimental|Stress and Symptom Management Program 1|
33301376|NCT03873610|Experimental|Stress and Symptom Management 2|
33301377|NCT00220740|Experimental|Group 1|IGIV-C
33301378|NCT00220740|Placebo Comparator|Group 2|
33301379|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
33301380|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
33301381|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
33301382|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
33301383|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
33301384|NCT01165918||Donated embryos|
33301385|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
33301386|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
33301387|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
33301388|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
33301389|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
33301390|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
32796323|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
32796324|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
32796325|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
32796326|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
32796327|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
32796328|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
32796329|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
32796330|NCT04718480|Placebo Comparator|Placebo|2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
32796331|NCT04718480|Experimental|Fluvoxamine|2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
32796332|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
32796333|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
32796334|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
32796335|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
33301391|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
33301392|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
33301393|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
33301394|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
33301395|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
33301396|NCT00184002|Experimental|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
33301397|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
32796336|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
32796337|NCT02057666|Experimental|Tasquinimod|One capsule (0.25, 0.50 or 1 mg), taken orally once a day with water and food (preferably the main evening meal).
32796338|NCT02057666|Placebo Comparator|Placebo|One capsule, taken orally once a day with water and food (preferably the main evening meal).
32796339|NCT04417400|Experimental|Intervention|Patients who received MUR at visit 1
32796340|NCT04417400|No Intervention|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
32796341|NCT01625000|Experimental|MP-214 3mg|
32796342|NCT01625000|Experimental|MP-214 6mg|
32796343|NCT01625000|Experimental|MP-214 9mg|
32796344|NCT01625000|Active Comparator|Risperidone 4mg|
32796345|NCT01625000|Placebo Comparator|Placebo|
33301398|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
32796346|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
32796347|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
32796348|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
32796349|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
32796350|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
32796351|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
32796352|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
32796353|NCT02057198|Active Comparator|Fidaxomicin|200 mg. 2 times a day for 10 days
32796354|NCT02057198|Active Comparator|Metronidazole|500 mg.orally 3 times daily for 10 days
32796355|NCT02057198|Active Comparator|Vancomycin|125 mg. orally 4 times a day for 10 days
32796356|NCT04417478|Active Comparator|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
32796357|NCT04417478|Experimental|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
32796358|NCT04417478|Experimental|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
32796359|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
32796360|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
32796361|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
32796362|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
32796363|NCT04705220|Experimental|Nutritional Supplementation with Test Product|Subjects will receive 1 tablet of MERIVA® in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months. This treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
33088942|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
33088943|NCT04717830|Experimental|Gamezumab 1/10 therapeutic dose|1/10 therapeutic dose (5 volunteers)
33088944|NCT04717830|Experimental|Gamezumab 1/2 therapeutic dose|1/2 therapeutic dose (5 volunteers)
33088945|NCT04717830|Experimental|Gamezumab full therapeutic dose|therapeutic dose (10 volunteers)
33088946|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
33088947|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
33088948|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
33088949|NCT00287183|Placebo Comparator|Placebo|
33088950|NCT00419406|Experimental|A: UVA1|
33088951|NCT00419406|Experimental|B: NB UVB|
33088952|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
33088953|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
33088954|NCT00287378|Experimental|1|
33088955|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
33088956|NCT00320619|Experimental|1|Participants will receive either EACA.
33088957|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
33088958|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
33088959|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
33088960|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
33088961|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
33088962|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
33088963|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
33088964|NCT00287534|Experimental|1|Anastrozole
33088965|NCT00287534|Active Comparator|2|Tamoxifen
33088966|NCT00313872|Experimental|FOLFIRI|
33088967|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
33088968|NCT00287573|Experimental|Arm 1|
32796364|NCT04705220|Placebo Comparator|Control Group without Nutritional Supplementation|Subjects will receive 1 tablet of placebo in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months.
32796365|NCT04726592|Placebo Comparator|Control arm|"placebo and standard care :~Placebo IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
32796366|NCT04726592|Experimental|Experimental arm|"clorazepate and standard care :~Clorazepate 20 mg IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
33088969|NCT00287573|Active Comparator|Arm 2|
33088970|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
33088971|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
33102432|NCT05407935|Active Comparator|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
33301399|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
33088972|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
33088973|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
33088974|NCT00287612|Experimental|2|
33088975|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
33088976|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
33404196|NCT04400838|Experimental|Group 5 b1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)
33404197|NCT04400838|Experimental|Group 5 c1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (qPCR)
33404198|NCT04400838|Experimental|Group 5 d1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
33404199|NCT04400838|Experimental|Group 5 e1|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10^11 vp/mL), 4-6 weeks apart
33404200|NCT04400838|Experimental|Group 5 f1|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
33404201|NCT04400838|Experimental|Group 6 a1|Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)
32796367|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
33404202|NCT04400838|Experimental|Group 6 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)* boost* at least 4 weeks apart
33404203|NCT04400838|Experimental|Group 7 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
32796368|NCT04704362|Active Comparator|Training and Supervision as Usual|Non-specialists are trained in a psychological intervention under standard conditions. No feedback from competency-based evaluations is provided to modify the training or supervision curriculum.
33088977|NCT00287768|Experimental|1|Docetaxel + S-1
33088978|NCT00287768|Active Comparator|2|S-1
33088979|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
33088980|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
33088981|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
33088982|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
33088983|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
33088984|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
33088985|NCT04717713|Experimental|steroid group|patients receiving steroid injection for preventing postoperative dysphagia
33088986|NCT04717713|Placebo Comparator|placebo group|patients receiving saline injection for comparator
33088987|NCT00322530|Active Comparator|SLED|
33088988|NCT00322530|Active Comparator|CVVHD|
33088989|NCT00287963|Experimental|Vinorelbine + topotecan|
33088990|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
33088991|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
33088992|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
33088993|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
33088994|NCT00322608|Experimental|Dose escalation|
33088995|NCT00288158|Experimental|Allopurinol|
33088996|NCT00288158|Experimental|Probenecid|
33088997|NCT00288158|Active Comparator|Placebo|
33088998|NCT04717752|Experimental|Double trigger unit|HCG: 6000IU (Ovidrel: 250ug) + GnRH-a (Troprilin) 0.2mg
33088999|NCT04717752|Sham Comparator|HCG trigger unit|HCG: 6000IU (Ovidrel: 250ug)
33089000|NCT00322686|Experimental|Oglemilast followed by placebo|
33089001|NCT00322686|Experimental|Placebo followed by Oglemilast|
33089002|NCT00321087|Experimental|1|T2000 dose escalation
33089003|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
33089004|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
33089005|NCT00288314||PTSD|
33089006|NCT00288314||CONTROLS|
33089007|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
33089008|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
33301400|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
32796369|NCT04704362|Experimental|Competency-based Training and Supervision|Non-specialists are trained and supervised in a competency-based approach in which trainers and/or supervisors are provided with the competency scores of trainees in order to modify the training and supervision content and approach as needed.
32796370|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
32796371|NCT02080832|Placebo Comparator|Placebo|
32796372|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
32796373|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
33301401|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
32796374|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
32796375|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
32796376|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
32796377|NCT02045732|Experimental|Cohort 1|
32796378|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
32796379|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
33404204|NCT04400838|Experimental|Group 7 b1|Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)* 4-6 weeks apart
32796380|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
33404205|NCT04400838|Experimental|Group 8 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
32796381|NCT02044874|Experimental|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
32796382|NCT02044874|Experimental|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
32796383|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
32796384|NCT04716920|Experimental|Supportive Care (Tai Chi, Fitbit, Tai4Chijoint group)|Patients attend Tai Chi exercise classes over 1 hour BIW and wear a Fitbit device for up to 12 weeks. Patients are encouraged to complete self-practice over 30 minutes and record practice times daily in a diary log form. Patients also join a Facebook private TaiChi4joint group where they receive instructional videos matching the progress of weekly classes for at-home practices and peer support in Tai Chi engagement.
32796385|NCT04716608|Active Comparator|Group 1 INT (= intervention)|"physiotherapy program with~Myofascial Release Massage (quadriceps)~Foam Rolling lower extremity~Knee Isometrics in knee extension (sitting position)~Dynamic and static stretching (quadriceps) in half knee position~Core Stability (planks)~Strengthening (calf raises, good morning,squats, squat jump)~Balance (single leg stance)"
32796386|NCT04716608|Placebo Comparator|Group 2 USC (= usual care)|"usual care treatment with~Core Stability (prone plank)~Strengthening: (Hip extension, abduction; Calf raises)~Stretching (M. rectus femoris (static) in standing position; Hamstring in sitting position)~Balance (single leg stand)"
32796387|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
32796388|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
32796389|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
32796390|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
32796391|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
32796392|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
32796393|NCT04702646||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
32796394|NCT04702178|Experimental|Group A-2|COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
32796395|NCT04702178|Placebo Comparator|Group B-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
32796396|NCT04702178|Experimental|Group C-2|COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
32796397|NCT04702178|Placebo Comparator|Group D-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
32796398|NCT04702178|Experimental|Group E-2|COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
32796399|NCT04702178|Placebo Comparator|Group F-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
32796400|NCT04702178|Experimental|Group G-2|COVAC-2 25 µg: 8 or 9 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
33301402|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
33301403|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
32796401|NCT04702178|Placebo Comparator|Group H-2|Placebo Control: 4 or 5 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
33301404|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
33301405|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
33301406|NCT01166074||SCIG|
33301407|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
33301408|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
33301409|NCT01275508|Experimental|FITC-Adalimumab|
33301410|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
33301411|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
33301412|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
33301413|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
33301414|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
33301415|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
33301416|NCT03971370|Experimental|Experimental 1|
33301417|NCT03971370|Experimental|Experimental 2|
32796402|NCT04702178|Experimental|Group I-2|COVAC-2 50 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
32796403|NCT04702178|Placebo Comparator|Group J-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
33301418|NCT03971370|Active Comparator|Positive Control|
33301419|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
33301420|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
33301421|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
33301422|NCT01168336|Placebo Comparator|placebo|
33301423|NCT00165672|Experimental|1|
33301424|NCT00165672|Experimental|2|
33301425|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
33301426|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
33301427|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
33301428|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
33301429|NCT00180414|Experimental|Ventricular Rate Regulation feature ON|
33301430|NCT00180414|Active Comparator|Ventricular Rate Regulation feature OFF|
33301431|NCT01277224|Experimental|Movi2 Program|
33301432|NCT01277224|No Intervention|Control|
33301433|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
33301434|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
33301435|NCT03968484|Experimental|<50.000/µl|Transfusion of platelets starting with a platelet count <50.000/µl
33301436|NCT03968484|Experimental|<20.000/µl|Transfusion of platelets starting with a platelet count <20.000/µl
33301437|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
33301438|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
33301439|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
33301440|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
33404206|NCT04400838|Experimental|Group 8 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
33404207|NCT04400838|Experimental|Group 9 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
33089009|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
33089010|NCT04718363|Experimental|PNF stretching group|
33089011|NCT04718363|Experimental|Non-vibration foam rolling prior to PNF stretching group|
32796404|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
33089012|NCT04718363|Experimental|Vibration foam rolling prior to PNF stretching group|
33404208|NCT04400838|Experimental|Group 10 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
33404209|NCT04400838|Experimental|Group 11|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
33404210|NCT04400838|Experimental|Group 12|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
32796405|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
33089013|NCT04718363|No Intervention|Control Group|
33089014|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
32796406|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
32796407|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
32796408|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Coloplast Test; Secondly to either~Own product (baseline)~Competitor soft convex"
32796409|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Competitor soft convex; Secondly to either~Own product (baseline)~Coloplast Test"
33089015|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
33089016|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
33089017|NCT00417638|Experimental|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
33089018|NCT00417638|Active Comparator|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
33089019|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089020|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089021|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089022|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089023|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089024|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089025|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089026|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089027|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089028|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
33089029|NCT00321516|Experimental|1|
33089030|NCT02960633|Active Comparator|THA with Collar|THA with Collar
33089031|NCT02960633|Active Comparator|THA without Collar|THA without Collar
33089032|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
33089033|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
33089034|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
33089035|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
33089036|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
33089037|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
33089038|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
33089039|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
33089040|NCT00321867|Active Comparator|1|Native tissue repair
33404211|NCT04400838|Active Comparator|Single dose MenACWY|Groups 1 a2, 2 a2, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 & 8 a2 will receive a standard single dose of MenACWY vaccine
32796410|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Own product; Secondly to either~Coloplast Test~Competitor soft convex"
32940344|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
33089041|NCT00321867|Experimental|2|Posterior repair with graft
33089042|NCT00288977|Experimental|islet cell transplant|
33301441|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
33301442|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
32940345|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
32940346|NCT05278598|Active Comparator|ESPB group|Erector Spinae Plane Block
33301443|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
33301444|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
33301445|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
33301446|NCT00174252|Experimental|Genotonorm (Somatropin)|
33301447|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
32940347|NCT05278598|Active Comparator|TPVPB group|Thoracic Paravertebral Plane Block
32940348|NCT05278598|Active Comparator|QLPB group|Quadratus Lumborum Plane Block
33301448|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
32940349|NCT00639626|Experimental|Levemir|
33301449|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
33301450|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
33301451|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
33301452|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
33301453|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
33301454|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
33301455|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
33301456|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
33301457|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
33301458|NCT00169104|Active Comparator|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
33301459|NCT00169104|Placebo Comparator|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
33301460|NCT01582074||Cases|women with breast cancer
33301461|NCT01582074||Controls|Matched women without breast cancer
33301462|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
33301463|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
33301464|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
33301465|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
33301466|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
33301467|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
32940350|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~CC 50 mg oral for 5 days (Days 3-7)~If no ovulation, CC 100 mg for 5 days (Days 12-16)~If no ovulation, CC 150 mg for 5 days (Day 21-25)~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
32796411|NCT04701008||Patients with significative post-operative pain despite|Patients with significant pain despite receiving narcotics in PACU will receive a bolus dose of IV ketamine to assess its efficacy for pain score reduction. Bolus doses are given by 10mg IV increments, to reach approximate dose of 0,25mg/kg.
33089043|NCT00323076|Experimental|1|18F-FAZA PET Imaging
33089044|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
33089045|NCT00289055|Active Comparator|2|balloon angioplasty
33301468|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
33301469|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
33301470|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
33301471|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
33301472|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
33301473|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
33301474|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
33301475|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
33301476|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
33301477|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
33301478|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
33301479|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.~Treatment Period:~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
33301480|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
33301481|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
33301482|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
33301483|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
33301484|NCT00163020|Active Comparator|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
33301485|NCT00163020|Placebo Comparator|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
33301486|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
33301487|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
33301488|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
33301489|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
33301490|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
33301491|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
33301492|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
33301493|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
33089046|NCT00323466|Experimental|IMRT|
33301494|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
33301495|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
33301496|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
33301497|NCT05377294|Experimental|MOL therapy|Participants with Psychosis and/or Suicidality receiving MOL therapy
33301498|NCT01166698|Experimental|AZD9819|Inhaled suspension
33301499|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
33301500|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
33301501|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
33301502|NCT03872362||Training dataset|No interventions
32796412|NCT04700696|Experimental|EPIC Participants|EPIC participants are 1) matched with trained peer recovery supporters with lived experience related to child welfare and substance EPIC participants are also incentivized to participate in 2) family treatment drug court (FTDC), with medications for opioid use disorders (MOUD); and 3) home-based parenting supports based on the Nurturing Parenting Program.
33301503|NCT03872362||External validation1|No interventions
33301504|NCT03872362||External validation2|No interventions
33301505|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
33301506|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
33301507|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
33301508|NCT01282450|Experimental|Single arm|Eligible patients
33301509|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
33301510|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
32796413|NCT04700696|Active Comparator|Ohio Sobriety Treatment And Reducing Trauma (START) participants|Adapted from the evidence-based national START model (Sobriety Treatment and Recovery Teams) this intervention matches child welfare parents in need of addiction services to caseworker and family peer mentor (FPM) dyads for intensive case management services.
32796414|NCT04700696|No Intervention|Treatment as usual (TAU)|Treatment as usual includes home visits by the assigned caseworker, referrals to SUD assessment/treatment, family group decision making, and (non-incentivized) referral to FTDC.
33301511|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
33301512|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
33301513|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
33301514|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
32796415|NCT04700540|Experimental|Intervention Group|The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.
32796416|NCT04700540|No Intervention|Attention Control Group|Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.
32796417|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
32796418|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
32796419|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
32796420|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
32796421|NCT04712318|Other|ReLex Smile surgery|"The aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation.~At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment."
32796422|NCT04712318|Other|ReLex Smile surgery-fresh corneal lenticule implantation|At hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
32796423|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
32796424|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
32796425|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
32796426|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
33089047|NCT00289523||Escitalopram|
33089048|NCT00289523||Bupropion XL|
33301515|NCT01169506|Experimental|COPD patients and healthy individuals|
33301516|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
33301517|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
33301518|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
33301519|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
33301520|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
33301521|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
33089049|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
33089050|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
33301522|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
33301523|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
32796427|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
32796428|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
32796429|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33301524|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
32796430|NCT01621880|Active Comparator|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
32796431|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
32796432|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
32796433|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
32796434|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
32796435|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
33301525|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
33301526|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
33301527|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
32796436|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
32796437|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
33301528|NCT01169662|Placebo Comparator|Placebo juice|
33301529|NCT01283074||Cohort|
33301530|NCT01282840|Other|Bladder wall blood perfusion pattern|
33301531|NCT05328622|Experimental|Adherence Incentives Program|The intervention administered to participants is an incentive program designed to motivate participants to attend to/adhere to their prescribed prenatal course of care via the Aqueduct platform.
33301532|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
33089051|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
33089052|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
33089053|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
33089054|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
33301533|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
33301534|NCT01172548|Experimental|imatinib mesylate|
33301535|NCT03869476|Experimental|BioscoreSMP cohort|
33301536|NCT05323474|Experimental|Standard rehabilitation|Classical rehabilitation carried out by a physiotherapist with an evaluation at 6 months post-surgery to authorize the return to sport.
33301537|NCT05323474|Active Comparator|Optimized rehabilitation|Classical rehabilitation carried out by a physiotherapist + expert physiotherapist performing monthly clinical and functional assessments with recommendations for exercises and running program sent to the physiotherapist.
33301538|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
33301539|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
33301540|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
33301541|NCT01169974||healthy volunteers|
33301542|NCT02526082||Total, observational|Various cardiovascular risk groups described below
33301543|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
33301544|NCT02526082||High-risk control|Healthy but at high risk in 1974
33301545|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
33301546|NCT02526082||Sick control|Medications or clinical disease in 1974
33301547|NCT02526082||Refused|Refused or no response in 1974
32796438|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.~150mg, participants were uptitrated to open-label canakinumab 300 mg."
32796439|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
32796440|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
33301548|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
32796441|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
32796442|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
32796443|NCT01621568|Experimental|Group 1 (Thymoma and thymic carcinoma)|Group 1 (Thymoma and thymic carcinoma) treated with sunitinib 50 mg/day, 4 weeks on, 2-weeks off (6 week cycle).
33301549|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
33301550|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
32796444|NCT01621568|Experimental|Group 2 (Thymic carcinoma only)|Group 2 (Thymic carcinoma only) treated with sunitinib 50 mg/day, 2 weeks on, 1 week off (3 week cycle).
32796445|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
32796446|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
32796447|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
32796448|NCT04699994|Experimental|FLOT therapy|
33301551|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
33301552|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
33301553|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
33301554|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
33301555|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
33301556|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
32796449|NCT04711226|Experimental|AT-1501 Single Arm|
33301557|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
33301558|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
32796450|NCT04699292||Cohort A|MLS patients managed by surgery only
32796451|NCT04699292||Cohort B|MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery
32796452|NCT04699292||Cohort C|MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery
33089055|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
33301559|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
33301560|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
32796453|NCT04699292||Cohort D|MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)
32796454|NCT04699292||Cohort E|MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)
32796455|NCT02041429|Experimental|Phase I Dose Level 0: Paclitaxel + Ruxolitiniib 10 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 10 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 10 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
32796456|NCT02041429|Experimental|Phase I Dose Level 1: Paclitaxel + Ruxolitiniib 15 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 15 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 15 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
32796457|NCT02041429|Experimental|Phase I Dose Level 2: Paclitaxel + Ruxolitiniib 20 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 20 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
32796458|NCT02041429|Experimental|Phase I Dose Level 3: Paclitaxel + Ruxolitiniib 25 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 25 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
32796459|NCT04699981|Experimental|Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
32796460|NCT04699981|Experimental|Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
32796461|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
32796462|NCT02083783|Placebo Comparator|Placebo|Placebo
32796463|NCT04698109||recurrent cervicovaginitis|patients with recurrent cervicovaginitis
32796464|NCT04698109||endometriosis|patients with endometriosis
32796465|NCT04698109||repeated implantation failures|patients with repeated implantation failures
32796466|NCT04698109||healthy volunteers|healthy volunteers
32796467|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
32796468|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
32796469|NCT02040805|Experimental|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
32796470|NCT02040805|Experimental|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
32796471|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
32796472|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
32796473|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
32796474|NCT04728841|Experimental|Treatment group|Arm of GS001
32796475|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
32796476|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
32796477|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
33404212|NCT04400838|Active Comparator|Two dose MenACWY 4 - 6 weeks|Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 & 10 a2 will receive two doses of MenACWY 4-6 weeks apart
32796478|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
32796479|NCT04720105|Experimental|Participants with plaque type psoriasis|Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.
32796480|NCT04720027||Closurefast|Patients who were randomised to and underwent radiofrequency ablation using the Closurefast device in the original 3RF Study
32796481|NCT04720027||Radiofrequency Induced Thermal Therapy (RFITT)|Patients who were randomised to and underwent radiofrequency ablation using the RFITT device in the original 3RF Study
32796482|NCT04720027||EndoVenous Radiofrequency (EVRF)|Patients who were randomised to and underwent radiofrequency ablation using the EVRF device in the original 3RF Study
32796483|NCT04695769|Experimental|Group A: SOF/VEL/VOX with RBV|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: < or > 60 kg).~Another name: Vosevi, RBV"
32796484|NCT04695769|Active Comparator|Group B: SOF/VEL/VOX|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi"
32796485|NCT04417309|Experimental|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
32796486|NCT04417309|Active Comparator|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
33089056|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
33089057|NCT00289835|Other|Standard medical treatment|
33089058|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
33089059|NCT04718259|Experimental|Group A|Will include patients who will receive bupivacaine intrathecal injection without adjuvant.
33089060|NCT04718259|Experimental|Group B|Will include patients who will receive bupivacaine and midazolam.
33089061|NCT00323973|Experimental|1|
33301561|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
33301562|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
33301563|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
33301564|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
33301565|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
33301566|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
33301567|NCT01283620|Other|Usual Care|
33301568|NCT01283620|Experimental|modified CIMT (mCIMT)|
33301569|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
33301570|NCT00252720|Experimental|candesartan|candesartan cilexetil 32 mg once daily
33301571|NCT00252720|No Intervention|placebo|control
33301572|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
33301573|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
33301574|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
33301575|NCT01283698|Placebo Comparator|placebo|once daily
33301576|NCT01283698|Active Comparator|Reference|once daily
33301577|NCT03869164|Experimental|ValmpClamp Arm|
33301578|NCT00167778|Experimental|Arm 1|Novel prosthetic pylon
33301579|NCT00167778|Active Comparator|Arm 2|rigid pylon
33301580|NCT01284556|Placebo Comparator|Placebo|placebo tablets
33301581|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
33301582|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
33301583|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
33301584|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
33301585|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
33301586|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
33301587|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
33301588|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
33301589|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
33301590|NCT00167310|Experimental|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
33089062|NCT00323973|Placebo Comparator|2|Placebo
33089063|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
33089064|NCT00303303|Experimental|1|Active initial and maintenance therapy
33089065|NCT00303303|Experimental|2|Active initial therapy; placebo maintenance therapy.
33089066|NCT00303303|Placebo Comparator|3|Placebo initial and maintenance therapy.
33301591|NCT00167310|Placebo Comparator|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
33301592|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
33301593|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
33089067|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
33089068|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
33089069|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
33089070|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
33089071|NCT00303381|Placebo Comparator|Placebo|
33301594|NCT03973476|Experimental|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
33301595|NCT03973476|No Intervention|Control group|Mothers received standard postpartum care
33404213|NCT04400838|Active Comparator|Two dose MenACWY minimum 4 weeks|Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart
33404214|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
33301596|NCT03754582|Experimental|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
32796487|NCT04694911||Health Services Research (focus group, interview, OOCAT)|"FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.~COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.~FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference."
32796488|NCT04694521|Experimental|antegrade colorectal single stapler anastomosis|open Side to end antegrade colorectal anastomosis colo rectal cancers.
32796489|NCT04694521|Experimental|open end to end colorectal stapler anastomosis|open end to end colorectal single anastomosis in non-emergent colo rectal cancers.
33089072|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
33301597|NCT03866824|Experimental|PRP group|
33301598|NCT03866824|Active Comparator|reference treatment|
33089073|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
33089074|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
33301599|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
33301600|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
33301601|NCT00161616|Active Comparator|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
33301602|NCT00161616|Other|B|Standard of Care: Surgical fixation only
33301603|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
33301604|NCT01283776|Experimental|treatment arm|Cyclophosphamide
33301605|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
33301606|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
33301607|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
33301608|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
33301609|NCT01163500|Placebo Comparator|Pill|
33301610|NCT01163500|Experimental|Coenzyme Q10|
33301611|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
33301612|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
33301613|NCT01284790|Experimental|Cochlear implants|
33301614|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
33301615|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
33301616|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
33301617|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
33301618|NCT01163734|Experimental|Ranolazine|
33301619|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
33301620|NCT01284868|Experimental|Mirabegron|
33301621|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
33301622|NCT01170442|Experimental|vitamin D3 2000 IU|
33301623|NCT01170442|Experimental|vitamin D3 5000 IU|
33301624|NCT01170442|Placebo Comparator|Placebo|
33301625|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
33301626|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
33301627|NCT01173328|Experimental|Pursed-lip Breathing|
33301628|NCT01170520|Experimental|rTMS|
33301629|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
33301630|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
32940351|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~CC 50 mg oral for 5 days (Day 3-7)~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
32940352|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
33301631|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
33301632|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
33301633|NCT03876184|Experimental|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
33301634|NCT03876184|Experimental|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
33301635|NCT03876184|Experimental|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
33301636|NCT03876184|Active Comparator|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
33301637|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
33301638|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
33301639|NCT01163890|Experimental|WHI|
33301640|NCT01163890|Active Comparator|Usual Care|
33301641|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
33301642|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
33301643|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
32940353|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
33301644|NCT00252564|Experimental|Bev-FOLFOX|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.~Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU~Dosing on Days 1 and 15 of each 28-day cycle"
33301645|NCT00252564|Experimental|FOLF-CB|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.~Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
33301646|NCT03868462|Other|Optical Coherence Tomography (OCT)|
33301647|NCT01284946|Experimental|Exjade|Safety and efficacy
32940354|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
32940355|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
32940356|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
32940357|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
32940358|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33301648|NCT01173562|Experimental|Mebendazole|
33301649|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
33301650|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
33301651|NCT00166296|Experimental|Escitalopram|Escitalopram, 15 mg/day
33301652|NCT00166296|Placebo Comparator|Placebo pill|Placebo
32940359|NCT00626444|Experimental|1|Intravenous vitamin C
33089075|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
33089076|NCT00324129|Experimental|1|
33089077|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
33089078|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
33089079|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
32796490|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
32796491|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
32796492|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
32796493|NCT04727593|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|Group intervention on Mindfulness-Based Cognitive Therapy classic program plus 4 monthly consolidation sessions of 90 minutes each.
32796494|NCT04727593|Other|Treatment as Usual (TAU)|TAU will be the control condition.
33301653|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
33301654|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
33301655|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
33301656|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
33301657|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
32796495|NCT04693663|Other|ReLex Smile surgery|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).
33089080|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
33301658|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
33301659|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
33301660|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
33089081|NCT00291200||1|Participants with basic symptoms of psychosis
33089082|NCT00291200||2|Control participants
33301661|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
33301662|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
33301663|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
33301664|NCT01077180|Experimental|Rheos Device|
33301665|NCT01077180|Active Comparator|Medical Management|
33301666|NCT01171066|Experimental|Tasman CPAP|
33301667|NCT01164046|Active Comparator|vitamin K antagonists|
33301668|NCT01164046|Active Comparator|Low molecular weight heparin|
33301669|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
33301670|NCT01075464|Experimental|A|
33301671|NCT01075464|Experimental|B|
33301672|NCT01285180||DINO|
33301673|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
33301674|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
33301675|NCT01077336||Hospitalized patients with candidemia|
33301676|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
33301677|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
33301678|NCT03968250|Experimental|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
33301679|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
33301680|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
33301681|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
33301682|NCT01074918|Experimental|Potassium Magnesium Citrate|
33301683|NCT01074918|Active Comparator|Potassium Chloride|
33301684|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
33301685|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
33301686|NCT00160680|Experimental|Continuous Treatment|5 mg of Levocetirizine (LCTZ) was taken orally once a day.
33301687|NCT00160680|Experimental|On Demand Treatment|5 mg of Levocetirizine (LCTZ) was taken whenever needed.
33301688|NCT00160524|Experimental|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
33301689|NCT01077570||Repaglinide|
33301690|NCT01075698|Active Comparator|Non-ARB group|
32796496|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
32796497|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
32796498|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
32796499|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
32796500|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
33301691|NCT01075698|Active Comparator|ARB group|
33301692|NCT03966300|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
33301693|NCT03966300|No Intervention|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
33301694|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
33301695|NCT00159822|Experimental|1|
32796501|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
32796502|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
33301696|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
32796503|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
32796504|NCT02037295|Experimental|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
32796505|NCT02037295|Placebo Comparator|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
32796506|NCT02037295|Experimental|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
33301697|NCT01164124|Placebo Comparator|Routine feedings|
32796507|NCT02037295|Placebo Comparator|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
32796508|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
32796509|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
32796510|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
32796511|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
32796512|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
32796513|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
32796514|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
32796515|NCT04417075|Experimental|Impacto|This is the mobile app to be developed and evaluated in this project.
32796516|NCT04417075|Active Comparator|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
32796517|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
32796518|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
32796519|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
32796520|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
33301698|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
32796521|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
33089083|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
33089084|NCT00324402||1|Healthy pregnant women, 18-40
33089085|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
32796522|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
32796523|NCT02034877|Experimental|1|
32796524|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
32796525|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
32796526|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
32796527|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
32796528|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
32796529|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
32796530|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
32796531|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
32796532|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
32796533|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
32796534|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
32796535|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
32796536|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
32796537|NCT02034409|Sham Comparator|Sham|Treatment to index knee with sham device for 48 weeks
32796538|NCT02034409|Experimental|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
32796539|NCT04691323|Other|HU-Go app intervention arm|Participants will use the HU-Go app intervention arm for 12 months.
32796540|NCT04691011|Other|Muscle|
32796541|NCT04691011|Other|Spinal cord|
32796542|NCT04691011|Other|Brain|
32796543|NCT04417543|Active Comparator|Memantine hydrochloride group|included 50 patients who received memantine
32796544|NCT04417543|Placebo Comparator|Placebo group|included 50 patients who received placebo
32796545|NCT02021318|Experimental|Roxadustat|Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg (milligram) given thrice weekly (TIW) to participants weighing up to 70 kg (kilogram) and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL (gram per deciliter) and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat up to a maximum of 104 weeks.
32796546|NCT02021318|Active Comparator|Darbepoetin alfa|Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
32796547|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
32796548|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
32796549|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
32796550|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
32796551|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
33089086|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
33089087|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
33089088|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
33301699|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
32796552|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
32796553|NCT04710446||NSTEMI Patients presenting with normal ECG|NSTEMI Patients presenting with normal ECG
32796554|NCT04710446||NSTEMI Patients presenting with isolated T wave inversion|NSTEMI Patients presenting with isolated T wave inversion
32796555|NCT04710446||NSTEMI Patients presenting with transient ST-segment elevation|NSTEMI Patients presenting with transient ST-segment elevation
32796556|NCT04710446||NSTEMI Patients presenting with resting U wave inversion|NSTEMI Patients presenting with resting U wave inversion
33301700|NCT00158262|Experimental|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
33301701|NCT00158262|Placebo Comparator|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
33301702|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
33301703|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T~Period 2: XELJANZ 5Mg Tablet 1T"
33301704|NCT02526394|Active Comparator|1|Repevax + Meningitec
33301705|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
33301706|NCT02526394|Active Comparator|3|Repevax + Menitorix
33301707|NCT02526394|Active Comparator|4|Boostrix + Meningitec
33301708|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
33301709|NCT02526394|Active Comparator|6|Boostrix + Menitorix
32796557|NCT04710446||NSTEMI Patients presenting with low QRS voltage|NSTEMI Patients presenting with low QRS voltage
33089089|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33089090|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
32796558|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg QW|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks
32796559|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg QW|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks
32796560|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg QOW|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks
32796561|NCT02047604|Experimental|Cohort D - SAN-300 4.0 mg/kg QOW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
32796562|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg QW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
32796563|NCT02047604|Placebo Comparator|Placebo|Placebo dosing
32796564|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
33301710|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
32796565|NCT04697498|Active Comparator|The Control Group|The control group will include patients who will undergo surgery under general anesthesia.
32796566|NCT04697498|Experimental|The Study Group|The study group will include patients who will undergo surgery under general anesthesia using a bilateral bi-level Erector spine plane block.
33301711|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
33301712|NCT00157950|Experimental|Gardasil™|Gardasil™ 3 dose regimen
33301713|NCT00157950|Placebo Comparator|Placebo|Gardasil™ matching placebo 3 dose regimen
32796567|NCT04680182|Experimental|Study group|Wound drain is kept until until a scheduled visit three weeks after the surgery unless the drain produced less than 30 ml/day for two consecutive days, in which case it could be removed earlier.
33301714|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
33301715|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
33301716|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
33301717|NCT01171222||veteran soccer players from Saarland County, Germany|
33301718|NCT05666752|Experimental|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
33301719|NCT05666752|Placebo Comparator|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
33301720|NCT03966144|Experimental|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
33301721|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
33301722|NCT01075386||Benign|Patients without endometrial cancer
33301723|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
33301724|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
33301725|NCT03964896|Experimental|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
33301726|NCT01171378|Other|Ofatumumab|Single arm study
33301727|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
32796568|NCT04680182|Active Comparator|Control group|When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
32796569|NCT04708730|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
32796570|NCT04708730|No Intervention|control group|
32796571|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
32796572|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
32796573|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
32796574|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
32796575|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
32796576|NCT04696718|Experimental|Traitement 1|Lactobacillus salivarius
32796577|NCT04696718|Experimental|Traitement 2|Lactobacillus Rhamnosus GG
32796578|NCT04696718|Experimental|Traitement 3|Bifidobacterium lactis
33404215|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
32796579|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
32796580|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
32796581|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
32796582|NCT02055157|Experimental|Cohort 1|Cohort 1: 2.5 ug/kg
32796583|NCT02055157|Experimental|Cohort 2|Cohort 2: 7.5 ug/kg,
32796584|NCT02055157|Experimental|Cohort 3|Cohort 3: 15 ug/Kg
32796585|NCT02055157|Experimental|Cohort 4|Cohort 4: 30 ug/kg
32796586|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
32796587|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
32796588|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
32796589|NCT04682509|Experimental|Study group|All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.
32796590|NCT04716595|Experimental|morning administration|K-877 ER 0.2 mg/day morning administration (once daily)
32796591|NCT04716595|Experimental|evening administration|K-877 ER 0.2 mg/day evening administration (once daily)
32796592|NCT04715659||COPD patients|
32796593|NCT04715035|Active Comparator|Conventional treatment|Physical therapy: education, mobilizations, stretch, active exercises, home excercises.
32796594|NCT04715035|Experimental|Conventional treatment + eccentric exercises|Physical therapy: education, mobilizations, stretch, active exercises, home exercises, eccentric exercises.
32796595|NCT04689919|Active Comparator|Reference Group [Xarelto 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
32796596|NCT04689919|Experimental|Test Group [Xaroban 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
32796597|NCT04681963||Suspected pneumonia diagnosis|Acutely admitted patients suspected having pneumonia.
32796598|NCT04681729|Experimental|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
32796599|NCT04681729|Placebo Comparator|Matched Placebo|Placebo,on top of regular/as needed non-sedating H1-antihistamine
32796600|NCT04680949|Placebo Comparator|Placebo|Patients receiving standard-of-care (SOC) and placebo. Placebo is injected subcutaneously once daily for 10 days
32796601|NCT04680949|Experimental|Anakinra|Patients receiving SOC and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
32796602|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
33089091|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
33089092|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
33089093|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
33301728|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
33089094|NCT00324558|Experimental|1|Bemiparin 3,500 IU
33301729|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
33301730|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
33301731|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
33301732|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
33301733|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
33301734|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
33301735|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
33301736|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
33301737|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
33301738|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
33301739|NCT01171456|Placebo Comparator|Metformin Placebo|
33301740|NCT01171456|Active Comparator|Metformin|
33301741|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
33301742|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
33301743|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
33301744|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
33301745|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
33301746|NCT01268956||Control|healthy people
33301747|NCT03866122|Experimental|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
33301748|NCT03875404|Experimental|Deep Brain Stimulation subjects|
33301749|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
33301750|NCT01285336|Experimental|The genetic and the functional study|
33301751|NCT01171768||patients with hemoptysis within 2 weeks|
33301752|NCT01171768||patients without hemoptysis within 2 years|
33301753|NCT03359434|Experimental|Two measuring methods of blood pressure|
33301754|NCT01171846|Active Comparator|Physiotherapy|
33301755|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
33301756|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
33301757|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
33301758|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
33089095|NCT00324558|No Intervention|Control|
33089096|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
33089097|NCT00291941|Experimental|1|Henogen HB vaccine
33089098|NCT00291941|Active Comparator|2|Fendrix vaccine
33089099|NCT00291980|Experimental|1|HB-AS02V vaccine
33089100|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
33089101|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
33089102|NCT00304317|Experimental|I|Celecoxib
33089103|NCT00304317|Placebo Comparator|II|Placebo
33089104|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
33301759|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
33301760|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
33301761|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
33301762|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
33301763|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
33301764|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
33301765|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
33301766|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
33301767|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
33301768|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
33301769|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
32940360|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
32940361|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
32940362|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
32940363|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
32940364|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
32940365|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
32940366|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
32940367|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
32940368|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
32940369|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
32940370|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
32940371|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
32940372|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
32940373|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
33089105|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
33301770|NCT03875014||group 1|Bipolar hemiarthroplasty grop
33301771|NCT03875014||group 2|Total hip replacement dual mobility group
33301772|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
33301773|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
33301774|NCT01172002|Experimental|leflunomide group|
33301775|NCT01172002|Active Comparator|Azathioprine group|
33301776|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
33089106|NCT04717908|Experimental|PZA sensitivity guided all oral regimen|"This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.~The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).~PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .~PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) ."
33089107|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
33089108|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
33089109|NCT00304434|Other|1|
33301777|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
33301778|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
33301779|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
33301780|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
33301781|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
33301782|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
33301783|NCT01172158||Forgotten ureteral stents|
33301784|NCT01164670||Men|Men over 70 years old.
33301785|NCT01164670||Women|Women over 70 years old.
33301786|NCT01285570|Experimental|Experimental 2|
33301787|NCT01285570|Experimental|experimental 1|
33301788|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
33301789|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
33301790|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
33301791|NCT01172236|Experimental|Lactoferrin|
33301792|NCT02525926|Experimental|denervation|
33301793|NCT02525926|Sham Comparator|control group|
33301794|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
33301795|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
33301796|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
33301797|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
33301798|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
33301799|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
33301800|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
33301801|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
33301802|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
33301803|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
33301804|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
33301805|NCT01172314|Experimental|EAA+LEU vs total AA|
33089110|NCT00304551|Experimental|1|
33089111|NCT00304551|Experimental|2|
33301806|NCT01172314|Experimental|Total AA vs EAA+LEU|
33089112|NCT00304551|No Intervention|3|
32796603|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
32796604|NCT04689139|Experimental|Thoracic aorta surgery patients|Blood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
33301807|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
33301808|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
33301809|NCT01174420|Experimental|ologen Collagen Matrix|
33301810|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
33301811|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
33301812|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
33301813|NCT03867370|Experimental|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
33301814|NCT03867370|Experimental|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
33301815|NCT03867370|Active Comparator|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
33301816|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group~Tranexamic acid, Study group tranexamic acid 1g,~intravenous injection, pre-operationally"
33301817|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group~Not receiving tranexamic acid, Control group Normal~saline 100mL, intravenous injection, pre-operationally"
33301818|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
33301819|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
33301820|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
33301821|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
33301822|NCT01284322|Experimental|Fresolimumab|
32796605|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
33089113|NCT00292526|Experimental|enalapril arm|treatment with enalapril
33301823|NCT01284400|Experimental|Disease management|
33089114|NCT00292721|No Intervention|Control|
33089115|NCT00292721|Active Comparator|Celecoxib|
33301824|NCT01284400|No Intervention|Usual treatment and care|
33301825|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
33301826|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
33301827|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
33301828|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
33301829|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
33301830|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
33301831|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
33301832|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
33301833|NCT03865186|Experimental|control group|no intervention was applied to the control group
32796606|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
32796607|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
32796608|NCT04713007|Experimental|Group 1|Supportive Care Materials and Resources
32796609|NCT04713007|Experimental|Group A|Ted Talks/Educational videos
32796610|NCT04687501|Experimental|VR-group|"The participants randomised into this group can choose for an immersive guided relaxation VR experience or an interactive VR experience. The VR intervention is additional to the standard postoperative care management, the standard pain protocol is explained below.~The VR-intervention will be given using the Oculus Go Virtual Reality glasses with touchpad."
32906965|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
33089116|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
33089117|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
33301834|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
33301835|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
33301836|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
33301837|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
33301838|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
33301839|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
32906966|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
33089118|NCT04718324|Experimental|e-PROMS|Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
33301840|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
33301841|NCT03864016|Other|Standard group|
33089119|NCT04718324|Active Comparator|p-PROMS|Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
33089120|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
33301842|NCT03864016|Experimental|Pupillometry group|
33301843|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
33301844|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
33301845|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
33301846|NCT01177696|No Intervention|Control|
33089121|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
33089122|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
33089123|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
33089124|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
33089125|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
33089126|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
33301847|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
33301848|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
33301849|NCT01177930||Feeding with milk with DHA and ARA|
33301850|NCT01177930||Feeding with milk without DHA and ARA|
33301851|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
33301852|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
33089127|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
33301853|NCT01285804|Active Comparator|Cuffed ETT|
33301854|NCT01285804|Active Comparator|Uncuffed ETT|
33301855|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
33301856|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
33301857|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
33301858|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
33301859|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
33301860|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
33301861|NCT01175200|Active Comparator|Prasugrel|
33301862|NCT01175200|Active Comparator|Clopidogrel|
33301863|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
33301864|NCT01175200|Placebo Comparator|Placebo|
33301865|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
33089128|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
33301866|NCT01288300|Other|Control|Diabetes self-management lecture
33301867|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
33301868|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
33301869|NCT01178164|Experimental|Diagnosis of Fabry disease|
33301870|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
33301871|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
33301872|NCT01174654|No Intervention|Referral to community resources|
33301873|NCT01174654|Experimental|Contingency Management|
33301874|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
33301875|NCT01175278|Experimental|Balloon Kypholasty|
33301876|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
33301877|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
33301878|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
33301879|NCT01285882||Representations|
33301880|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
33301881|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
33301882|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
33301883|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
33301884|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
33301885|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
33301886|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
33301887|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
33301888|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
33301889|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
33301890|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
33301891|NCT01286506||Mechanically ventilated patients|
33301892|NCT01286506||Non-mechanically ventilated patients|
33301893|NCT03864718||complex anal fistula|
33301894|NCT01175512|Active Comparator|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
33301895|NCT01175512|Placebo Comparator|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
33301896|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
33301897|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
33301898|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
33301899|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
33301900|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
33301901|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
33301902|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
33301903|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
33301904|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
33301905|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
33301906|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
33301907|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
33301908|NCT03859726||Non compliance group|6hLC<10%
33089129|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
33089130|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
33301909|NCT03745768|Experimental|Active iTBS Treatment|Participants received Intermittent theta burst stimulation to the dorsolateral prefrontal cortex for 6 weeks
33301910|NCT03745768|Sham Comparator|Sham Stimulation|Participants received Sham stimulation to the dorsolateral prefrontal cortex for 6 weeks.
33301911|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
33301912|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
33301913|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
33089131|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
33301914|NCT01286584|Active Comparator|varenicline group|
33301915|NCT01286584|Placebo Comparator|placebo group|
33301916|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
33301917|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
33301918|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
33301919|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
33301920|NCT03864250|Experimental|Tacrolimus monotherapy|
33089132|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
33089133|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
33089134|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
33301921|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
33301922|NCT01175746|Experimental|nicardipine|
33301923|NCT01175746|Active Comparator|remifentanil|
33301924|NCT01174810|No Intervention|Control|
33301925|NCT01174810|Experimental|Exenatide|
33301926|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
33301927|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
33301928|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
33301929|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
33301930|NCT03859492||Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
33089135|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
33301931|NCT01178710|Experimental|treatment|
33301932|NCT01178710|No Intervention|untreated|control
33301933|NCT03864328|Experimental|RVT-1601 Low Dose|
33301934|NCT03864328|Experimental|RVT-1601 Mid Dose|
33301935|NCT03864328|Experimental|RVT-1601 High Dose|
33301936|NCT03864328|Placebo Comparator|Placebo|
33301937|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33301938|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
33301939|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
33301940|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
33301941|NCT01178788|Active Comparator|Control|Routine clinical controls
33301942|NCT00153816|Experimental|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
33301943|NCT00153816|Experimental|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
33301944|NCT00153816|Experimental|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
33301945|NCT00153816|Experimental|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
33301946|NCT00153816|Experimental|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
33301947|NCT00153816|Experimental|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
33301948|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
33404216|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
33089136|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
33089137|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
33089138|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
33089139|NCT00293735|Active Comparator|1. Labetolol|
33089140|NCT00293735|Active Comparator|2. Magnesium Sulfate|
33089141|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
33301949|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
33089142|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
33301950|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
33301951|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement
33301952|NCT03966222|Active Comparator|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
33301953|NCT03966222|Experimental|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
33089143|NCT00293852|No Intervention|Usual Care|
33301954|NCT03862846|Experimental|Group|REN001 Low Dose
33301955|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
33301956|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
33301957|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
33301958|NCT01174966||Survivor Nonsurvivor|
33301959|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
33301960|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
33301961|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
33301962|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
33089144|NCT00293852|Experimental|Collaborative Care|
33301963|NCT01077726|Experimental|1|
33089145|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
33301964|NCT01286116|Experimental|Treatment|Parachute implant
33301965|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
33301966|NCT01179100|Active Comparator|Lidocaine|
33301967|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
33301968|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
33301969|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
33301970|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
33301971|NCT01179178||COPD-patients|
33301972|NCT01179178||Older adults (65-81 y)|
33301973|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
33301974|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
33301975|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
33301976|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
33301977|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
33301978|NCT01286194||Experimental 1|
33301979|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
33301980|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
33301981|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
33301982|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
33089146|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
33301983|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
33301984|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
33301985|NCT01179412|Experimental|2% povidone-iodine|
33301986|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
33301987|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
33301988|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
33301989|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
33301990|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
33301991|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
33301992|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
33301993|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
33404217|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~6 subjects per each cohort~twice administration with 4-week intervals"
32940374|NCT00613886|Experimental|Comparison for patients of lumbar drain and shunt surgery|"Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery.~Device: Programmable Shunt Insertion (Codman Medtronic)~Behavioral: Assessments in physical therapy, occupational therapy, and speech therapy~Follow-up testing to be administered by trained physician assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, mini-mental status exam, 9-hole grooved pegboard, motor visual perception test (MVPT), modified rankin score (MRS)"
32940375|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
32940376|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
32940377|NCT00610532|Experimental|A|intravenous phenytoin alone
32940378|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
32940379|NCT04713722||MDD/childhood adversity group|subjects with current MDD who experienced childhood adversity
32940380|NCT04713722||rMDD/ childhood adversity|subjects with a history of MDD who experienced childhood adversity
32940381|NCT04713722||MDD|subjects in a current episode of MDD, with no history of childhood adversity
32940382|NCT04713722||Healthy Control|healthy control subjects, with no history of childhood adversity
32940383|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
32940384|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
32940385|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
32940386|NCT04708808|Experimental|MVA case undergone music therapy|case undergone manual vacuum aspiration are randomised to receive music therapy during the procedure.
32940387|NCT04708808|No Intervention|Control|Routine Care
32940388|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
32940389|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
32940390|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
32940391|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
32940392|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
32940393|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
32940394|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
32940395|NCT01633814|Placebo Comparator|Placebo|placebo patch.
32940396|NCT04332133|Active Comparator|group 1|group 1 of DME which treated by SML
32940397|NCT04332133|Active Comparator|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
32940398|NCT04332133|No Intervention|group 3|control group of diabetic patients received no treatment
32940399|NCT04713943|Experimental|>Your< Iron Syrup|
32940400|NCT04713943|Other|Placebo|
32940401|NCT04585490|Experimental|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy [carboplatin/pemetrexed] and durvalumab (1500 mg IV every 21 days, for 1 year), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks.Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
32796611|NCT04687501|No Intervention|Standard care-group|"The participants randomized into the standard care- group will receive the usual standard pre-and postoperative management.~Standard pain protocol:~Preoperative (arrival day-care unit) start with 1000mg paracetamol orally administered.~Postoperative Meloxicam 15mg orally administered, or when oral medication is not possible (due to nausea e.g.) than diclofenac supp 100mg or diclofenac i.v. 75mg.~On recovery ward, when necessary depending on pain score (NRS>4): dipidolor 2.5-5mg i.v. and 10-15mg i.m. after consulting the anesthesiologist.~Postoperative at home 4dd1000mg paracetamol will be continued, in combination with meloxicam 1dd15mg during 3 days. Also tramadol 50mg with a maximum of 4dd will be prescribed."
32796612|NCT02019667|Experimental|Placebo|Participants with SSADH Deficiency when on placebo for six months
33089147|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
33089148|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
33089149|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
33089150|NCT00305097|Active Comparator|No coffee|
33089151|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
33089152|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
32796613|NCT02019667|Experimental|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
33089153|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
33089154|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
33089155|NCT00294164|Experimental|Serostim® 4 mg daily|
33089156|NCT00294164|Experimental|Serostim® 4 mg alternate days|
33089157|NCT00294164|Placebo Comparator|Placebo|
33089158|NCT00325728|Experimental|Ramelteon 8 mg QD|
33089159|NCT00325728|Placebo Comparator|Placebo|
33089160|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
33089161|NCT00417794|Placebo Comparator|2|
33089162|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
33089163|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
32796614|NCT02030821|Active Comparator|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
32796615|NCT02030821|Active Comparator|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
32796616|NCT02052739|Experimental|SAGE-547 Standard Dose|Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.
32796617|NCT02052739|Experimental|SAGE-547 High Dose|Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.
32796618|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
33089164|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
32796619|NCT04712773|Other|Cardiac surgery patients|Patients scheduled for elective cardiac surgery (CABG or valve surgery).
32796620|NCT04712539|Experimental|Arm I (oseltamivir, baloxavir marboxil)|Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
32796621|NCT04712539|Active Comparator|Arm II (oseltamivir)|Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.
32796622|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
33089165|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
33089166|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
33089167|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
33089168|NCT00294437|No Intervention|no intervention|no reference therapy
33089169|NCT00294866|Active Comparator|A|Receive Paricalcitol
33089170|NCT00294866|No Intervention|B|Paricalcitol on hold
33089171|NCT00326040|Experimental|A|
32796623|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
32796624|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
33404218|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)~2 subjects per each cohort~twice administration with 4-week intervals"
32796625|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
32796626|NCT04686331||Suspected CAP|All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician
32796627|NCT01823835|Experimental|Phase Ia - Cohort 1|100 mg GDC-0810 once daily (QD) in fasting state.
32796628|NCT01823835|Experimental|Phase Ia - Cohort 2|200 mg GDC-0810 QD in fasting state.
33089172|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
33089173|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
33089174|NCT00326079|Active Comparator|1|
32796629|NCT01823835|Experimental|Phase Ia - Cohort 3|400 mg GDC-0810 QD in fasting state.
32796630|NCT01823835|Experimental|Phase Ia - Cohort 4|600 mg GDC-0810 QD in fasting state.
32796631|NCT01823835|Experimental|Phase Ia - Cohort 5|600 mg GDC-0810 QD in non-fasting state.
33089175|NCT00326079|Active Comparator|2|
33089176|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
32796632|NCT01823835|Experimental|Phase Ia - Cohort 6|300 mg GDC-0810 twice daily (BID) in fasting state.
32796633|NCT01823835|Experimental|Phase Ia - Cohort 7|800 mg GDC-0810 QD in fasting state.
32796634|NCT01823835|Experimental|Phase Ia - Cohort 8|800 mg GDC-0810 QD in non-fasting state.
32796635|NCT01823835|Experimental|Phase Ia - Cohort 9|400 mg GDC-0810 BID in fasting state.
32796636|NCT01823835|Experimental|Phase IIa - Cohort A1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).
32796637|NCT01823835|Experimental|Phase IIa - Cohort A2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.
32796638|NCT01823835|Experimental|Phase IIa - Cohort B1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤1 prior therapy with an aromatase inhibitor (AI).
32796639|NCT01823835|Experimental|Phase IIa - Cohort B2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤1 prior therapy with an AI.
32796640|NCT01823835|Experimental|Phase Ib - Cohort C1|400 mg GDC-0810 + 125 mg Palbociclib QD.
32796641|NCT01823835|Experimental|Phase Ib - Cohort D1|≤600 mg GDC-0810 QD + LHRH agonist once monthly.
32796642|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
32796643|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
32796644|NCT01823679|Experimental|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
32796645|NCT04414293|Experimental|Treatment|All the patients will be treated with low dose lung radiation
32796646|NCT01823289|Experimental|Itraconazole Sequential Therapy|
32796647|NCT01822899|Experimental|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
32796648|NCT01822899|Active Comparator|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
32796649|NCT01822821|Experimental|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
33089177|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
33301994|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
33089178|NCT00295295|Active Comparator|Standing|Standing 10 min/day
33089179|NCT00305916|Active Comparator|1|conventional coronary angiography
33089180|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
33301995|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
33089181|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
33301996|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
32796650|NCT01822821|Placebo Comparator|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
32796651|NCT01822665|Active Comparator|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
32796652|NCT01822665|Active Comparator|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
32796653|NCT01822665|Placebo Comparator|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
32796654|NCT01822665|Active Comparator|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
32796655|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
32796656|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
32796657|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
32796658|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
32796659|NCT01822587|Placebo Comparator|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
32796660|NCT01822587|Active Comparator|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
32796661|NCT01822587|Active Comparator|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
32796662|NCT04588233|Experimental|Administration of Melatonin|
32796663|NCT04588233|Placebo Comparator|Administration of Placebo|
32796664|NCT04588077|Experimental|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
32796665|NCT04588077|Active Comparator|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
32796666|NCT04588077|Experimental|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
32796667|NCT04588077|Active Comparator|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
32796668|NCT04595331|No Intervention|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
32796669|NCT04595331|Experimental|Control Group in the pivotal study|receiving treatment in the extension study
32796670|NCT04587999|Experimental|bladder stimulation|
32796671|NCT04587999|Active Comparator|Quick wee|
32796672|NCT01822353|Experimental|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
32796673|NCT01822353|Experimental|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
32796674|NCT01822353|Experimental|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
32796675|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
32796676|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
32796677|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
32796678|NCT01821729|Experimental|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
32796679|NCT01820637|Experimental|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
32796680|NCT02172911|Experimental|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
33301997|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
32796681|NCT02172911|Experimental|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
32796682|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
32796683|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
33301998|NCT02524678|Placebo Comparator|Placebo|Placebo
32796684|NCT01850823|Placebo Comparator|placebo|Placebo
33301999|NCT02524678|Active Comparator|URC102|URC102
33302000|NCT01181206|Active Comparator|Arm 1|
33302001|NCT01181206|Active Comparator|Arm 2|
33302002|NCT05274880|Experimental|Sequence 1|Period 1: CKD-393 administration after a high-fat meal/ Period 2: CKD-393 administration at fasting state
32796685|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
32796686|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
33302003|NCT05274880|Experimental|Sequence 2|Period 1: CKD-393 administration at fasting state/ Period 2: CKD-393 administration after a high-fat meal
33302004|NCT00149994|Experimental|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; > 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
33302005|NCT00149994|Active Comparator|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; > 6 months: range of 5-10 ng/ml is recommended.
33302006|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
33302007|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
33302008|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
33302009|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
33302010|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
33302011|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
33302012|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
33302013|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
33302014|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
32796687|NCT01820559|Active Comparator|ESL 1200 mg|eslicarbazepine acetate 1200 mg
33302015|NCT03965988|Experimental|Docosahexaenoic Acid|Docosahexaenoic acid
33302016|NCT03965988|Placebo Comparator|Placebo drug|Placebo
33302017|NCT01286974|Experimental|ADME|[14C]linifanib
33302018|NCT01286974|Experimental|Extension|linifanib
33302019|NCT03857854|Experimental|treatment group|pirfenidone group
33302020|NCT03857854|Placebo Comparator|placebo group|control group
33302021|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
33302022|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
33302023|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
33302024|NCT01287052|Experimental|Nitrous Oxide|
33302025|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
33302026|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
33302027|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
33302028|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB~preoperative CT lymphography~SLNB with stained non-SLN resection~SLNB with ARM dissection"
33302029|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
33302030|NCT01181362|Other|Endoscopy|
33302031|NCT01179724|Experimental|high dose proton pump inhibitor|
33302032|NCT01179724|Active Comparator|H2 receptor antagonist|
33302033|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
33302034|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
33302035|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
33302036|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
33302037|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
33302038|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
33302039|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
33302040|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
33302041|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
33302042|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
33302043|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
32796688|NCT01820559|Active Comparator|ESL 800 mg|eslicarbazepine acetate 800 mg
33302044|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
33302045|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
33302046|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
33302047|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
33302048|NCT00149214|Experimental|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
33302049|NCT00149214|Active Comparator|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
33302050|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
33302051|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
33302052|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
33302053|NCT03965910|Other|group 1|Group 1:Early rehabilitation
33302054|NCT03965910|Other|group 2|Group 2:Late rehabilitation
33302055|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
33302056|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
33302057|NCT03967782|Experimental|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
33302058|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
33302059|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.~-No treatment"
33302060|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
33302061|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
33302062|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
33089182|NCT00295529|No Intervention|No education|Educational materials at end of study
33089183|NCT00419601|Active Comparator|2|Fentanyl
33089184|NCT00419601|Experimental|1|Remifentanyl
33089185|NCT00295607|Active Comparator|1|
33089186|NCT00295607|Experimental|2|
33089187|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
33089188|NCT00306150|Experimental|Arm 1|
33089189|NCT00306150|Placebo Comparator|Arm 2|
33089190|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
33089191|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
33089192|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
33089193|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
33089194|NCT00295763|Other|1|
33089195|NCT00417911|Active Comparator|No treatment|
33089196|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
33089197|NCT00326469|Experimental|1|
33089198|NCT04718597||Open hernia repair|Patients who underwent inguinal hernia repair via an open Liechtenstein procedure
33089199|NCT04718597||Robotic assisted hernia repair|Patients who underwent inguinal hernia repair via robotic assisted laparoscopy
33089200|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
33302063|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
33302064|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
33302065|NCT01179880|Experimental|1|
33302066|NCT01179880|Placebo Comparator|2|
33302067|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
33089201|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
33089202|NCT00326586|Experimental|1|
33089203|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
33089204|NCT04957173|Other|Intensive lifestyle intervention|Participants will undergo an intensive lifestyle intervention, implemented virtually by a medical team with expertise in the management of T2DM. This team will be made up of an endocrinologist, a nutritionist and a nurse.
33089205|NCT04930809|Experimental|VER-01 single dose (2.5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).
33089206|NCT04930809|Experimental|VER-01 single dose (5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).
33089207|NCT04930809|Experimental|VER-01 single dose (10 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).
33089208|NCT04930809|Experimental|VER-01 single dose (20 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).
33089209|NCT04930809|Experimental|VER-01 multiple dose (5 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).
33089210|NCT04930809|Experimental|VER-01 multiple dose (10 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).
33089211|NCT04930809|Experimental|VER-01 multiple dose (12.5 / 20 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).
33089212|NCT04893057||Pregnant women|Women admitted to hospital for a live birth.
33089213|NCT04893057||Blood donors|Subjects qualified for whole blood donation
33089214|NCT04887480|Active Comparator|Negative Wound Pressure Therapy|Negative Pressure Would Therapy
33089215|NCT04887480|Active Comparator|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation
33089216|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
33089217|NCT00296153|Placebo Comparator|2|
33089218|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
33302068|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
33302069|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
33302070|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
33302071|NCT01181440|Experimental|Dermagraft(R) and conventional care|
33302072|NCT01181440|Other|Conventional care only|
33302073|NCT01176214|Experimental|early tracheostomy|see study description
33302074|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
33302075|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
33302076|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
33302077|NCT00114972|Experimental|PCI with DES|
33302078|NCT00114972|Active Comparator|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
33302079|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
33302080|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
32796689|NCT01820559|Placebo Comparator|Placebo|Placebo tablets
33302081|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
33302082|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
32796690|NCT01818765|Experimental|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation~Trans-ventricular-septal placement of LV pacing lead~Acute response assessment"
32796691|NCT01850589|Other|Conservative Therapy|"Conservative therapy:~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.~Counseling consists of:~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
33302083|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
33302084|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
33302085|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
33302086|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
33302087|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
33302088|NCT01289158||non-classical CMAMMA, classical CMAMMA|
33302089|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
33302090|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
33302091|NCT00129402|Experimental|Pooled subjects who received ezetimibe with simvastatin|Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
33302092|NCT00129402|Active Comparator|Pooled subjects who received simvastatin monotherapy|Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
33302093|NCT01180192|Experimental|oxygen|
33302094|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
33302095|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
33302096|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
33302097|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
33302098|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
33302099|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
33302100|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
33302101|NCT01587586|Active Comparator|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
33302102|NCT01587586|Experimental|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
33302103|NCT01587586|Experimental|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
33302104|NCT01587586|Experimental|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
33302105|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
33302106|NCT01180270||healthy volunteers|control group
33302107|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
33302108|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
33302109|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
33302110|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
33302111|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
33302112|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
33302113|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
33302114|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
33302115|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
33302116|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
33302117|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
33302118|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
33302119|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
33302120|NCT00114738|Experimental|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
33302121|NCT00114738|Experimental|"Bortezomib window"|Bortezomib alone
33302122|NCT00114738|Active Comparator|Bortezomib maintenance|Bortezomib maintenance
32796692|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:~One hour group counseling sessions, focusing on patient education and behavior modification.~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.~Counseling including information on nutrition, exercise, and chemical dependency.~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
32796693|NCT01818531|Experimental|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
32796694|NCT01818531|Active Comparator|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
33302123|NCT00114738|Other|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
33302124|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
33302125|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
32796695|NCT02171429|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
32796696|NCT02171429|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
33302126|NCT01180426|Experimental|Tosedostat|
33302127|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
33302128|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
32796697|NCT02171429|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
32796698|NCT01818297|Active Comparator|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
32796699|NCT01818297|Other|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
32796700|NCT01818141|Active Comparator|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
32796701|NCT01818141|Active Comparator|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
32796702|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
32796703|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
32796704|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
32796705|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
32796706|NCT04170465|Experimental|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
32796707|NCT04170465|Active Comparator|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
32796708|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
32796709|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
32796710|NCT01816893|Sham Comparator|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
32796711|NCT01816893|Active Comparator|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
33302129|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
33302130|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
33302131|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
33302132|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
33302133|NCT01182064||Non infarct|
33302134|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
33302135|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
33302136|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
33302137|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
33302138|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
33302139|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
33089219|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
32796712|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
32796713|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
32796714|NCT05133479|Experimental|Intervention|Participants receive the Let's Know! intervention in small groups as provided by research staff
32796715|NCT05133479|No Intervention|Business-As-Usual|Participants continue to receive only their typical classroom instruction (i.e., no small groups)
32796716|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
32796717|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
32796718|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
32796719|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6 mg daily
32796720|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
32796721|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
32796722|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
32796723|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
32796724|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
32796725|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
32796726|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
32796727|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
32796728|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
32796729|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
32796730|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
32796731|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
32796732|NCT04740593|Experimental|Group 1 - High refractive error: Intervention|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the intervention group
32796733|NCT04740593|Other|Group 2 - High refractive error: Control|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the control group
32796734|NCT04740593|Other|Group 3 - Mild or no refractive error|Children with mild or no refractive error (i.e. not exceeding the AAPOS 2003 criteria) at age one
32796735|NCT04742153|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
32796736|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
32796737|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
32796738|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
32796739|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
32796740|NCT04737707|Experimental|Dialectical Behavior Therapy (DBT)|Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.
32796741|NCT04737707|Other|Therapy|waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.
32796742|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
32796743|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
32796744|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
33089220|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
33302140|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
32940402|NCT04585490|Experimental|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab(10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
33302141|NCT00148122|Experimental|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
33302142|NCT03857308|Experimental|Mindfulness Training|
32940403|NCT04713865||PFA slightly jailed by proximal SFA stent(100 pts)|
33302143|NCT03857308|Active Comparator|Reappraisal Training|
32940404|NCT04713865||PFA moderately jailed by proximal SFA stent(100 pts)|
33302144|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
33302145|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
33302146|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
33302147|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
33302148|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
33302149|NCT01180738|Active Comparator|Body weight supported treadmill training|
33302150|NCT01180738|Active Comparator|Overground walking training|
33302151|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
33302152|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
33302153|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
32940405|NCT04713865||PFA totally jailed by proximal SFA stent (100pts)|
33302154|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
33302155|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
33302156|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
33302157|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
33302158|NCT01180816|Experimental|Temozolomide (Temodar)|
33302159|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
33302160|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
33302161|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
32940406|NCT04571216|Experimental|NFL-101 Dose 1|50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
32940407|NCT04571216|Experimental|NFL-101 Dose 2|100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
33302162|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
33302163|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
33302164|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
32940408|NCT04571216|Placebo Comparator|Placebo|The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on
32940409|NCT04714099|Experimental|Topical CsA|Group A received topical CsA 0.05% for 3 months
32940410|NCT04714099|Placebo Comparator|Control|Placebo group
33302165|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
33302166|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
33302167|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
33302168|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
33302169|NCT01182532|Active Comparator|Western therapy|
33302170|NCT01182532|Experimental|TCM treatment|
33302171|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
33302172|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~Dexamethasone 12 mg will be added on day 1 only of each cycle."
33302173|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
33302174|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
33302175|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
33302176|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
33302177|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
33302178|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
33089221|NCT04869969|Experimental|supine percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the supine position
33089222|NCT04869969|Active Comparator|prone percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the prone position
33089223|NCT00296309|Active Comparator|1|
33089224|NCT00296309|Experimental|2|
33302179|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
33302180|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
33089225|NCT00296348|Active Comparator|1|
33302181|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
33302182|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
33302183|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
33302184|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
33302185|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
33302186|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
33302187|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
33302188|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
33302189|NCT01290328|No Intervention|Standard of care|
33302190|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
33302191|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
33302192|NCT01184716|No Intervention|Non-fortified bread and milk|
33302193|NCT01184794|Placebo Comparator|Saline|Placebo solution
33302194|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
33302195|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
33302196|NCT01587508|Active Comparator|meloxicam - Movatec®|
33302197|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
33302198|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
33302199|NCT00147498|Experimental|5 mg BID|CP 690,550 5 mg BID
33302200|NCT00147498|Experimental|15 mg BID|CP 690,550 15 mg BID
33302201|NCT00147498|Experimental|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
33302202|NCT00147498|Placebo Comparator|Placebo|Placebo
33302203|NCT05267704|Experimental|VR Arm|Pediatric patients age 5-17 using the VR headset during renal biopsy.
33302204|NCT02974036||Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
33302205|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
33302206|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
33089226|NCT00296348|Experimental|2|
33302207|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
33302208|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
33302209|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
33302210|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
33302211|NCT01080066||Non-Interventional Study|
33302212|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
33302213|NCT01077882|Placebo Comparator|current therapy|
33302214|NCT01077882|Experimental|current therapy with educational program|
33302215|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
33302216|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
33302217|NCT04988464|Experimental|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
32796745|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
32796746|NCT02141399|Experimental|ALKS 5461|
32796747|NCT04586673|Experimental|ChAdOx1.tHIVconsv1 low dose|3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^9 vp
32796748|NCT04586673|Experimental|ChADOx1.tHIVconsv1 higher dose|10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10^8 pfu and MVA.tHIVconsv4 at 0.9 x 10^8 pfu.
32796749|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
32796750|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
32796751|NCT01628393|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
32796752|NCT01628393|Experimental|Ozanimod 1 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
32796753|NCT01628393|Placebo Comparator|Placebo|Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
32796754|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
32796755|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
32796756|NCT01815099|Experimental|rTMS Treatment|Clinical participants will receive rTMS
32796757|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
32796758|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
32796759|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
32796760|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
32796761|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
32796762|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
32796763|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
32796764|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
32796765|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
32796766|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
32796767|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
32796768|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
32796769|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
32796770|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
32796771|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
32796772|NCT04594239|Experimental|Treatment, needle|
32796773|NCT04594239|Experimental|Treatment, cannula|
32796774|NCT04594239|Other|Untreated-control / delayed-treatment, needle|
32796775|NCT04594239|Other|Untreated-control / delayed-treatment, cannula|
32796776|NCT04585737|Experimental|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
32796777|NCT04585737|Active Comparator|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
32796778|NCT01814553|Experimental|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
32796779|NCT01814553|Experimental|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
33404219|NCT05763030|Experimental|Intervention|Parent questionnaires and sleep characteristics of children (actigraphy and parent report) will be collected at three-time points- Time 1, 2, and 3. Time 1 is the first Baseline Data Collection for the Control Group and Intervention Group, and these data will be collected before the intervention group starts the 3-week intervention. Between Time 1 and Time 2, the Intervention Group will receive the 3-week intervention at the childcare center.
32796780|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
32796781|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
32796782|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
32796783|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
32796784|NCT01844583|Experimental|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
32796785|NCT01844583|Experimental|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
32796786|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
32796787|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
32796788|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
32796789|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
32796790|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
32796791|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
33404220|NCT05763030|No Intervention|Control|The control arm will not receive the intervention. They will be assessed at time 1 and again at 2, following the completion of intervention in the intervention arm
33404221|NCT05665205|Active Comparator|Aerobic exercise plus strength|The purpose is to verify if the aerobic exercise plus a strength program improves more than aerobic exercise alone in COVID patients.
32796792|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
32796793|NCT04742075|Active Comparator|(A) Olaparib|Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
33404222|NCT05665205|Sham Comparator|Aerobic exercise alone|The purpose is to verify if COVID patients can improve the status of their health only with an aerobic exercise program alone.
32796794|NCT04742075|Experimental|(B) Olaparib + durvalumab|"Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity."
32796795|NCT04742075|Experimental|(C) Olaparib + durvalumab + UV1|"Olaparib 300 mg tablets twice daily until disease progression or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity.~Eight UV1 vaccinations during the first 5 month: Four UV1 vaccinations 300 μg (+ 75 μg of sargramostim) during the first 10 days with a minimum of 2 days apart. From cycle 2-5 subjects will receive one UV1 (+ sargramostim) vaccination every 4th week."
32796796|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
32796797|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
32796798|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
32796799|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
32796800|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
32796801|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
32796802|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
33404223|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
32796803|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
32796804|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
32796805|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
33404224|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
33404225|NCT04344444|No Intervention|Arm A|Supportive Care only
33404226|NCT04344444|Experimental|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
32796806|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
32796807|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
32796808|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
32796809|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
32796810|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
32796811|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
32796812|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
32796813|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
32796814|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
32796815|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
32796816|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
32796817|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
32796818|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
32796819|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
32796820|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
32796821|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
32796822|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
32796823|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
32796824|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
32796825|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
32796826|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
32796827|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
32796828|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
33404227|NCT04344444|Experimental|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
32796829|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32796830|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
32796831|NCT01994720|Experimental|ticagrelor|
33089227|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 1|The standard percussor palm cups are made out of a soft vinyl material molded into shape. The outer diameter of the infant palm cup is 1-3/4 inches and there is a 1-inch diameter pocket inside this product similar to a suction cup.
33302218|NCT04988464|Placebo Comparator|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
32796832|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
32796833|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
32796834|NCT01814007|Experimental|CoolSculpting Treatment Group|CoolSculpting treatments will be performed on all subjects with 1 cooling cycle on the lower abdomen, plus simultaneous treatment of both flanks, one cooling cycle each. Two control units will be utilized at protocol-defined temperatures and durations.
32796835|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
32796836|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
33302219|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
32796837|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
33302220|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
33302221|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
33302222|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
33302223|NCT00113568|Experimental|XP12B (tranexamic acid tablets)|
32796838|NCT04667390|Active Comparator|total knee arthroplasty using the active robotic system|total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
32796839|NCT04667390|Active Comparator|total knee arthroplasty using computer navigation|Primary total knee arthroplasty using computer navigation and intraoperation control system
33302224|NCT05266768|Experimental|IBI346|Single arm
33302225|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
33302226|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
32796840|NCT04667390|Active Comparator|total knee arthroplasty using the standard manual tekhnik|Primary total knee arthroplasty using the standard recommended set of instruments
33302227|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
32796841|NCT01813305|Active Comparator|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
32796842|NCT01813305|Placebo Comparator|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
32796843|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
32796844|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
33302228|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
33302229|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
32796845|NCT01843803|Experimental|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
33302230|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
32796846|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
32796847|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
33302231|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
33302232|NCT00113490|Experimental|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
33302233|NCT00113490|Active Comparator|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
33302234|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
33302235|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
33302236|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
33302237|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
33302238|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
33302239|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~Hospitalization for cardiac decongestion and stabilization.~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~Awaiting cardiac transplantation"
32796848|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
32796849|NCT04686097|Experimental|experimental group (electrocoagulation)|Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.
32796850|NCT04686097|Active Comparator|control group (sclerotherapy)|Participants in the control group will receive an ultrasound-guided sclerosing agent injected.
32796851|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
32796852|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
32796853|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
32796854|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
32796855|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
32796856|NCT04694846|Experimental|Arm I (ETIP)|Patients receive nicotine replacement therapy via trans-dermal patch, gum, nasal spray, inhaler or lozenges for 12 weeks in the absence of unacceptable toxicity. Patients also receive bupropion PO QD BID or varenicline PO QD and BID for 24 weeks in the absence of unacceptable toxicity. Patients undergo 3 cessation counseling sessions in person, via telehealth or phone within 7 days of enrollment into study, 1 week after established quit date and 3 weeks after establishing quit date.
32796857|NCT04694846|Active Comparator|Arm II SOC|Participants randomly assigned to the standard treatment (ST) group will receive an in-office smoking cessation recommendation by the physician and referral to a quit line.
32796858|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
32796859|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
32796860|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
32796861|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
32796862|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
32796863|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
32796864|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
32940411|NCT04566770|Experimental|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
33302240|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~Coronary revascularization within 3 calendar months prior to enrollment.~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
33302241|NCT01326624||Awaiting ICD re-implantation|
32796865|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
33302242|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
33302243|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
33302244|NCT00146640|Experimental|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
33302245|NCT00146640|Active Comparator|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
33302246|NCT01183000|Active Comparator|peritoneal closure|
33302247|NCT01183000|No Intervention|Non closure of the peritoneum|
33302248|NCT01185418||risperidone|
33302249|NCT01185418||aripiprazole|
33302250|NCT01185418||haloperidol|
33302251|NCT01185418||amisulpride|
33302252|NCT01185418||lactose|
33302253|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
32796866|NCT02028871|Active Comparator|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
32796867|NCT02028871|Placebo Comparator|Placebo First|Placebo First, Intranasal Insulin Second
32796868|NCT04679467|Experimental|Experimental - single arm|All patients to recieve PKU sphere as part of their dietary management for phenylketonuria (PKU)
32796869|NCT02028715|Placebo Comparator|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
32906967|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
33302254|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
33302255|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
33302256|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
33302257|NCT01183156|Active Comparator|Re-invitation letter|
33302258|NCT01183156|Active Comparator|Educational Meeting|
33302259|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
33302260|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
33302261|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
33302262|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
33302263|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
33302264|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
33302265|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
33302266|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
33302267|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
33302268|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
33302269|NCT05250466|Experimental|Radiofrequency group|AI Temperature-controlled Radiofrequency Technology
33302270|NCT05250466|Active Comparator|Electrical stimulation group|Electrical Stimulation
33302271|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
33302272|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
33302273|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
33302274|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
33302275|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
33302276|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
33302277|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
32796870|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
32796871|NCT04684615||AmBiGen|Individuals who are enrolled in AmBiGen over the last 3 years
32796872|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
32796873|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
32796874|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
32796875|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
32796876|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
32796877|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
32796878|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
32796879|NCT04684459|Experimental|CAR-T cell therapy|Dual-targeting HER2 and PD-L1 CAR-T cell therapy
32796880|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
32796881|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
32796882|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
32796883|NCT04693598|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the lower dose (N=3 participants)
32796884|NCT04693598|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the higher dose (N=3 participants)
32796885|NCT04693286|Active Comparator|Vaccine candidate arm|In this arm, participants will get nOPV2 vaccine candidate 1
32796886|NCT04693286|Placebo Comparator|Placebo arm|In this arm, participants will get inactive substance like sucrose in BME media and buffer.
32796887|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
32796888|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
32796889|NCT04684381|Experimental|L-glutamine|Pharmacokinetic characteristics of L-glutamine
32940412|NCT04566770|Placebo Comparator|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
32940413|NCT04566770|Experimental|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
32940414|NCT04566770|Placebo Comparator|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
32940415|NCT04566770|Experimental|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
32940416|NCT04566770|Experimental|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
32940417|NCT04566770|Placebo Comparator|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
32940418|NCT04566770|Experimental|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
32940419|NCT04566770|Placebo Comparator|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
32940420|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
32940421|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
32940422|NCT04536584|Experimental|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
32940423|NCT04536584|Active Comparator|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
32940424|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
32940425|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
32940426|NCT04526990|Experimental|Experimental group|20000 participants, Ad5-nCoV , single dose, Intramuscular administration
32940427|NCT04526990|Placebo Comparator|Placebo group|20000 participants, placebo, single dose, Intramuscular administration
32940428|NCT04516538|Experimental|Young people|Men or Women under 35 years old
32940429|NCT04516538|Experimental|Old people|Men or Women between 60 and 80 years old
32796890|NCT02027545|Experimental|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
33302278|NCT01183624|Experimental|Experimental Patch|Herbal Patch
33302279|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
33302280|NCT01291186|Experimental|BPV6NO|
32940430|NCT04516538|Experimental|Very old people|Men or Women over 80 years old
33302281|NCT01291186|Experimental|BPV7NO|
33302282|NCT01291186|Experimental|BPV8NO|
33302283|NCT01291186|Experimental|BPV9NO|
33302284|NCT01291186|Experimental|BPV10NO|
33302285|NCT01291186|Experimental|BPV11NO|
33302286|NCT01291186|Active Comparator|BPV6O|
33302287|NCT01291186|Active Comparator|BPV7O|
33302288|NCT01291186|Active Comparator|BPV8O|
33302289|NCT01291186|Active Comparator|BPV9O|
33302290|NCT01291186|Active Comparator|BPV10O|
33302291|NCT01291186|Active Comparator|BPV11O|
33302292|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine)~Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine)~Ultrasound guided Continuous Infraclavicular Brachial Plexus Block~Ultrasound guided Continuous Femoral Nerve Block~Pecs I & II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)"
33302293|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points:~Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
33404228|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
32796891|NCT02027545|Other|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
32796892|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
32796893|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
32796894|NCT04678843|Experimental|Virtual Family-Based Treatment|Family-based treatment is the gold standard treatment for youth and adolescents with anorexia nervosa. A therapist works with the family to help parents take charge of the process of re-feeding their child, and with progress this control is gradually given back to the youth/adolescent. Other developmental issues are discussed in order to help the youth/adolescent get back to normal development.
32796895|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
32796896|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
32796897|NCT02047903||Afatinib|
32796898|NCT02015065|Experimental|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
32796899|NCT02015065|Experimental|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
32796900|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
32796901|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
32796902|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
32796903|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
32796904|NCT02026063|Experimental|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
32796905|NCT02026063|Experimental|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
32796906|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
32796907|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
32796908|NCT01813071|Experimental|Part A (Adults): Cohort A1|One oral dose of ~3x10^4 cfu WRSS1(10 participants) or placebo (3 participants)
32796909|NCT01813071|Experimental|Part A (Adults): Cohort A2|Three oral doses of ~3x10^5 cfu WRSS1(10 participants) or placebo (3 participants)
32796910|NCT01813071|Experimental|Part A (Adults): Cohort A3|Three oral doses of ~3x10^6 cfu WRSS1(10 participants) or placebo (3 participants)
33089228|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 2|This product was developed by MMRI personnel using a small custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
33089229|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 3|This product was developed by MMRI personnel using a large custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
33302294|NCT04979338|Active Comparator|Surgery-specific general anesthetic + local anesthetic at incision site|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
33302295|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
33302296|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
33302297|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
33302298|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
33302299|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
33302300|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
33302301|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
33302302|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
33302303|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
33302304|NCT01290406|Experimental|BEZ235|
33302305|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
33302306|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
33302307|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
33302308|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
33302309|NCT01186042||Aging in HIV|20-40 years of age or older than 50
33302310|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
33302311|NCT01177462||Control stroke patients|Stroke patients without hemineglect
33302312|NCT01177462||Normal control|Normal subjects
33302313|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
33302314|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
33302315|NCT03860896|Experimental|GB004|GB004 for oral administration daily
33302316|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
33302317|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
33302318|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
33302319|NCT01184092|Experimental|Sequence 1|
33302320|NCT01184092|Experimental|Sequence 2|
33302321|NCT01184092|Experimental|Sequence 3|
33302322|NCT01184092|Experimental|Sequence 4|
33302323|NCT01184092|Experimental|Sequence 5|
33302324|NCT01184092|Experimental|Sequence 6|
33302325|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
33302326|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
33302327|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
33302328|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
33302329|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|
33302330|NCT01287910|Other|All Patients|All patients undergo the same study procedures
33302331|NCT05666674|Experimental|TSA-ON|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
33302332|NCT05666674|Active Comparator|TSF-OFF control|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
33302333|NCT03860506|Experimental|PSI-697|
33302334|NCT03860506|Placebo Comparator|Placebo|
33302335|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
33302336|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
33089230|NCT00296426|No Intervention|Usual Care|control patients admitted to hospital floors received usual care
33302337|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
33302338|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
33302339|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
33302340|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
33302341|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
33302342|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
33302343|NCT01186510|Experimental|Lung perfusion|
32796911|NCT01813071|Experimental|Part B (Children): Cohort B1|One oral dose of ~3x10^3 cfu WRSS1(12 participants) or placebo (4 participants)
32796912|NCT01813071|Experimental|Part B (Children): Cohort B2|Three oral doses of ~3x10^4 cfu WRSS1(12 participants) or placebo (4 participants)
33302344|NCT01186510|Active Comparator|no lung perfusion|
33302345|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
33302346|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
33302347|NCT03860818|No Intervention|Control Arm|Usual Care
32796913|NCT01813071|Experimental|Part B (Children): Cohort B3|Three oral doses of ~3x10^5 cfu WRSS1(12 participants) or placebo (4 participants)
32796914|NCT01813071|Experimental|Part B (Children): Cohort B4|Three oral doses of ~3x10^6 cfu WRSS1(12 participants) or placebo (4 participants)
32796915|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
32796916|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
33302348|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
32796917|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
32796918|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
33302349|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
33302350|NCT01184404|No Intervention|Control|
33302351|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.~DC Bead is produced from polyvinyl alcohol."
32796919|NCT01812837|Experimental|20 minutes incubation - with pretreatment|
32796920|NCT01812837|Experimental|40 minutes incubation - with pretreatment|
32796921|NCT01812837|Experimental|60 minutes incubation - with pretreatment|
32796922|NCT01812837|Sham Comparator|60 minutes incubation - no pretreatment|
32796923|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
32796924|NCT02014597|Experimental|Normal - No glaucoma|HOCD
32796925|NCT02014597|Experimental|Glaucoma|HOCD
32796926|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
32796927|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
33302352|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
33302353|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
33302354|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
33302355|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
33302356|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
32796928|NCT01812759|Experimental|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
33302357|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
33302358|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
33302359|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
33302360|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
33302361|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
33302362|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
33302363|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
33302364|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
33302365|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
33302366|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
33302367|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
32796929|NCT01812759|Experimental|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
32796930|NCT01812057|Experimental|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
32796931|NCT01812057|Placebo Comparator|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
32796932|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
32796933|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
32796934|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
32796935|NCT01810263|Experimental|high protein supplement|high protein supplement given
32796936|NCT01810263|No Intervention|Control|no intervention
33302368|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
32940431|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
32940432|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
32940433|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
33302369|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
33302370|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
33302371|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
32940434|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
33302372|NCT01191112|Experimental|Peptide Based enteral formula|
33302373|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
33302374|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
33302375|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
33302376|NCT01186900|Active Comparator|open incision and drainage|
33302377|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
33302378|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
33302379|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
33302380|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
33302381|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
33302382|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
33302383|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
33302384|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
33302385|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
33302386|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
33302387|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
33302388|NCT01188148|Experimental|VPA & memantine|
33302389|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
33302390|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
33302391|NCT01187134|Active Comparator|Intervention group|
33302392|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
33302393|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
33302394|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
33302395|NCT01588600|Active Comparator|Control|Breakfast without fiber
33302396|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
33302397|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
33302398|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
33089231|NCT00296426|Experimental|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
33089232|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
33089233|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
33089234|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
33302399|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
33302400|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
33302401|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
33302402|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
33302403|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
33302404|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
33302405|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
33302406|NCT05671432|Experimental|Group A|Group A: CM326, subcutaneous (SC)
33302407|NCT05671432|Experimental|Group B|Group A: CM326, subcutaneous (SC)
33302408|NCT05671432|Placebo Comparator|Group C|Group C: placebo, subcutaneous (SC)
33302409|NCT04912492|Active Comparator|RealConsent 1.0 with Alcohol|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target breath alcohol concentration (BrAC=.08).
33302410|NCT04912492|Active Comparator|RealConsent 1.0 with Placebo|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
33302411|NCT04912492|Experimental|RealConsent2.0 with Alcohol|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target BrAC=.08).
33302412|NCT04912492|Experimental|RealConsent2.0 with Placebo|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
33302413|NCT04912492|Active Comparator|Stress Management with Alcohol|Men assigned to complete a web-based stress management program. Men assigned to alcohol intoxication arm (target BrAC=.08).
33302414|NCT04912492|Active Comparator|Stress Management with Placebo|Men assigned to complete a web-based stress management program. Men assigned to a no-alcohol placebo control arm.
33302415|NCT01291810|Experimental|TNF Kinoid|
33302416|NCT01291810|Placebo Comparator|Placebo|
33302417|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
33302418|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
33302419|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
33302420|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
33302421|NCT05177770|Experimental|SRF617 in combination with etrumadenant and zimberelimab|All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).
33302422|NCT01188304|Experimental|1|
33302423|NCT01188304|Placebo Comparator|2|
33302424|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
33302425|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
33302426|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
33302427|NCT04909216|Experimental|Mindful Attention Workshop|50 participants will be randomized to the Mindful Attention Training (MAT) workshop. The 90-minute workshop will be conducted in group, online format.
33302428|NCT04909216|No Intervention|Waitlist Control|"50 participants will be randomized to the waitlist control condition (as usual condition)."
33302429|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
33302430|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
33302431|NCT01291966|Experimental|Motivational interview|
33302432|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
33302433|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
33302434|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
33089235|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
33302435|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
33302436|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
33302437|NCT03853408||First Admission|Cholecystectomy during first admission
33302438|NCT03853408||Second Admission|Cholecystectomy during second admission
33302439|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
33302440|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
33302441|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
33302442|NCT01291576|Active Comparator|Rectal nodule excision|
33302443|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
33302444|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
33302445|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
32796937|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
33404229|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
33404230|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
32796938|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
32796939|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
32796940|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
32796941|NCT01809327|Experimental|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
32796942|NCT01809327|Experimental|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
32796943|NCT01809327|Experimental|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
32796944|NCT01809327|Experimental|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
32796945|NCT01809327|Experimental|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
32906968|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
33302446|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
33302447|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
33302448|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
33302449|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
33302450|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
33302451|NCT01294072|Experimental|Arm 3: no treatment|
33302452|NCT01191346||3T MRI|Patients receiving 3T MRI
33302453|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
33302454|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
32796946|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
32796947|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
32796948|NCT01808313|Experimental|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
32796949|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
32796950|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
32796951|NCT04593381|Experimental|SBRT treatment|Intervention: Radiation: SBRT
32796952|NCT04585269|Experimental|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
32796953|NCT04585269|No Intervention|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
32796954|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
32796955|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
32796956|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
32796957|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"4 week Mindfulness foundation course face to face (MF-NE) or~8 week Mindfulness Based stress reduction face to face (MBSR-NE)~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
32906969|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
33089236|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
33089237|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
33089238|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
33089239|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
33089240|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
33302455|NCT04956718|Other|CPT first|"Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa."
33089241|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
33089242|NCT00326976|Placebo Comparator|2|Matching placebo
33089243|NCT00296621|Experimental|1|
33089244|NCT00296621|Placebo Comparator|2|
33089245|NCT00296660||1|Proven acute HIV-1 infection
32796958|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"4 week Mindfulness foundation course face to face (MF-Orange) or~8 week Mindfulness Based stress reduction face to face (MBSR-Orange)~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
32796959|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"4 week Mindfulness foundation course online (MF-Covid) or~8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
33089246|NCT00296660||1A|Sexual partners of members of Group 1
33089247|NCT00296660||2|Established HIV-infection
33089248|NCT00296660||3|HIV-1 uninfected
33404231|NCT05762952|Experimental|Dapagliflozin|Dapagliflozin 10mg oral tablet.
33404232|NCT05762952|Placebo Comparator|Placebo|Placebo matching tablet.
33404233|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
33404234|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
33404235|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
33404236|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
33089249|NCT04762407|Experimental|Sequence 1|Period 1 : Fasted state + HGP1910 + HGP1909, Period 2 : Fasted state + HCP1903
33089250|NCT04762407|Experimental|Sequence 2|Period 1 :Fasted state + HCP1903, Period 2 : Fasted state + HGP1910 + HGP1909
33089251|NCT04726956||case cohort|Pancreatic ductal adenocarcinoma patients (140)
33089252|NCT04726956||control cohort|healthy donors (140)
33089253|NCT04726956||Benign cohort|patients with Intraductal papillary mucinous tumor of the pancreas (IPMN), mucinous cystadenoma, or pancreatic cyst (30)
33089254|NCT04717089||postoperative patients admitted to TMH extended post anaesthetic care in PACU|"Exclusion criteria:~Patients awaiting ICU admission in the ordinary recovery room~Patients requiring level 3 intensive care on arrival at the recovery room"
32907034|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
32907035|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
33089255|NCT04717089||Postoperative patient admitted to ICU with case matched|"Inclusion criteria:~o Based on case matched with the extended post anaesthetic care in PACU"
33089256|NCT04708275|Experimental|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
33089257|NCT04708275|Active Comparator|Waitlist|PaCT after a waiting period (3 months)
33089258|NCT04581486|Experimental|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
33089259|NCT04581486|Other|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
33089260|NCT04523220|Experimental|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
33089261|NCT04523220|Placebo Comparator|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
33089262|NCT04523220|Experimental|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
33089263|NCT04523220|Experimental|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
33089264|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
33089265|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
33089266|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
33089267|NCT00327054|Experimental|Nigella sativa seed|
33089268|NCT00327054|No Intervention|Control|
33089269|NCT00296855|Experimental|Arm 1|
32796960|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
33302456|NCT04956718|Other|CPT+placebo first|"Participant will be told and read about the 'pain medication' (= Placebo NaCl Nasal spray). Thereafter participant will self-administer a nasal spray, which is in fact a placebo nasal spray containing NaCl solution and Cold Pressor Test (CPT) is performed.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa"
33302457|NCT01187680|Experimental|Spraygel|
33302458|NCT01187680|Active Comparator|Control|
33302459|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
33302460|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
33302461|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
33302462|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
33302463|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
33302464|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
33302465|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
33089270|NCT00296894|Experimental|1|Drug - adalimimab sc
33302466|NCT05671276|Active Comparator|Standard Antiplatelet Therapy|DAPT (aspirin 100 mg and clopidogrel 75 mg) from 45 days to 6 month-follow-up, then aspirin alone
33302467|NCT05671276|Experimental|Half-Dose NOAC|Long-term half-dose NOAC (rivaroxaban 10 mg after 45 days)
33302468|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
33302469|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
32796961|NCT02013817|Experimental|MabThera/Rituxan|
32796962|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
32796963|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
32796964|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
32796965|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
32796966|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
32796967|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
32796968|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
32796969|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
32796970|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
32796971|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
32796972|NCT04416607|Experimental|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
33089271|NCT00296894|Placebo Comparator|2|Placebo
32796973|NCT04416607|Active Comparator|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
32796974|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
33089272|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
32796975|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
33318492|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
33089273|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
32796976|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
32796977|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
32796978|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
32796979|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
32796980|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
32796981|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
32796982|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
32796983|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
32796984|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
32796985|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
32796986|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
32796987|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
32796988|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
32796989|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
32796990|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
32796991|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
32796992|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
32796993|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
32796994|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
32796995|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
32796996|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
32796997|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
32796998|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization."
32907036|NCT05128487|Experimental|NDI-101150 (Monotherapy)|Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
32907037|NCT05128487|Experimental|NDI-101150-Pembrolizumab (Combination therapy)|Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
33089274|NCT04494672|Experimental|Intramedullary nailing with ADAPT system (arm-A)|A commercial product, namely ADAPT will be used as investigation product in arm-A
33089275|NCT04494672|Active Comparator|Intramedullary nailing without ADAPT system (arm-B)|No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B
33089276|NCT00327093|Experimental|1|Bevacizumab
33089277|NCT00327093|Experimental|2|Cetuximab
33089278|NCT04708587|Active Comparator|dual anti-platelet therapy at least 6 months|
33089279|NCT04708587|Experimental|dual anti-platelet therapy 3months or less|
33089280|NCT00297128|Active Comparator|1|
33089281|NCT00327132|Experimental|Experimental Arm|
33089282|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
33089283|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
33302470|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
33302471|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
33302472|NCT01193998|Active Comparator|Clinician exposed to Model result|
33302473|NCT01193998|Experimental|Clinician blinded to Model result|
33302474|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
33302475|NCT01294540|Experimental|Experimental: 1|
33302476|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
33302477|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
33302478|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
33302479|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
33302480|NCT01194076|Experimental|5day intensive treatment|
33302481|NCT02524210|Experimental|Arm A|"Period  Dabigatran~Washout period (at least 6 days)~Period  Rabeprazole + Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
33302482|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran ~Washout period (at least 6 days)~Period  Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
33302483|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran~Period  Omeprazole + Dabigatran~Period  Dabigatran"
33302484|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
33302485|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
33302486|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
33302487|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
33302488|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
33302489|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
33302490|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
33302491|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
33089284|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
33302492|NCT01292278||control group|no neurological disease but spinal anesthesia
33302493|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
33302494|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
33302495|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
33302496|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
33302497|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
33302498|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
33089285|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
33089286|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
33102433|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
33302499|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
33302500|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
32940435|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
32940436|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
33302501|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
32940437|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
32940438|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
32940439|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
32940440|NCT00568802|Experimental|Hydroxyurea|
32940441|NCT00568802|Placebo Comparator|Placebo|
32940442|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
32940443|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
32940444|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
32940445|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
32940446|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
32940447|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
32940448|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
32940449|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
32940450|NCT04474730|Active Comparator|Watch Only|
32940451|NCT04474730|Experimental|Watch+App|
32940452|NCT05313919||1. Coronary microcirculatory disease|
32940453|NCT05313919||2. Epicardial vasospastic angina|
32940454|NCT05313919||3. Microvessel vasospastic angina|
32940455|NCT05313919||4. Non-cardiac disorder|
32940456|NCT04429880|Experimental|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
32940457|NCT04706546|Experimental|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
32940458|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
32940459|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
32940460|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.~The content of each EFT session was as follows:~Preparation~Tapping Series~The Nine Gamut Sequence and Eye Movements"
32940461|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
32940462|NCT05600738|Experimental|Treatment|
32940463|NCT04706234||Multiple System Atrophy|Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
33302502|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
33302503|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
33302504|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
33302505|NCT01294774|Experimental|KRP203 - 1.2 mg|
33302506|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
33302507|NCT01292356|Experimental|cetuximab|
33302508|NCT01194388||MicroFx™ PGLA Treated Subjects|
33302509|NCT01194544||population undergoing EGD in health examination.|
33302510|NCT01294852|Experimental|immediate bolus surfactant|
33302511|NCT01294852|Experimental|post-resuscitation surfactant|
33302512|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
33302513|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
32796999|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization."
32797000|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
32797001|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
32797002|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
32797003|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
32797004|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
32797005|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
32797006|NCT04416139|Active Comparator|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
32797007|NCT04416139|No Intervention|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
32797008|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32797009|NCT04678310||Intervention Group|A patient will be assessed as 'eligible' for participation in the iLIVE Volunteer Study if they have an advanced, incurable illness that is unlikely to be cured, and they have been assessed by their clinical team as being in the last month of life. If patients meet this criteria, they will be offered support from the hospital palliative and end of life care volunteer service (developed for this study). Patients who agree to support will be recruited to the 'Intervention Group'.
32797010|NCT04678310||Case Control Comparison Group|If a patient is 'eligible' to receive support from the hospital palliative and end of life care volunteer service (see 'Intervention Group'), but declines involvement, they will be approached for inclusion in the study, as part of the 'Case Control Comparison' group for comparative analysis to assess the 'impact' of the volunteer service.
32797011|NCT04416698||Youth smokers|Participants of Youth Quitline
33302514|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
32797012|NCT04678154|Active Comparator|Control|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
32797013|NCT04678154|Experimental|Treatment|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
33302515|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
32797014|NCT04178798|Experimental|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
32797015|NCT04178798|No Intervention|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch & wait) until disease progression or early withdrawal."
32797016|NCT01989572|Experimental|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
32797017|NCT01989572|Experimental|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
32797018|NCT01989572|Experimental|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
32797019|NCT01989572|Placebo Comparator|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
32797020|NCT01989572|Experimental|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
33302516|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
33302517|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
33318493|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
32797021|NCT01989572|Placebo Comparator|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
32797022|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
32797023|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
33089287|NCT04485195|Active Comparator|Vernakalant|Patients randomized to this arm will receive an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump.82 For patients ≤ 100 kg the infusion is prepared by adding 25 mL of BRINAVESS 20 mg/mL to 100 mL of diluent creating a total volume of 125 mL at a concentration of 4 mg/mL. For patients > 100 kg the infusion is prepared by adding 30 mL of BRINAVESS 20 mg/mL to 120 mL of diluent creating a total volume of 150 mL at a concentration of 4 mg/mL. For patients weighing ≥ 113 kg, the maximum initial dose is 339 mg (84.7 mL of 4 mg/mL solution).
33089288|NCT04485195|Active Comparator|Procainamide|Patients randomized to this arm will receive a continuous infusion of IV procainamide with a dose of 15 mg/kg in 500 mL of normal saline given over 60 minutes (maximum dose 1,500 mg), by a pre-programmed pump. While the CAEP Best Practices Checklist suggests an infusion time of 30-60 minutes, we believe that a 60-minute period will avoid some adverse events.
32797024|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
32797025|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
32797026|NCT04178018|Experimental|Transvaginal photoacoustic imaging/ultrasound|"Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled~Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound~For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery~For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
32797027|NCT02014376|Experimental|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
32797028|NCT02014376|Experimental|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
32797029|NCT02014376|Placebo Comparator|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
32797030|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
32797031|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
33404237|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
32797032|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
32797033|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
32797034|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
32797035|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
32797036|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
32797037|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
32797038|NCT02011945|Experimental|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
32797039|NCT02011945|Experimental|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
32797040|NCT02011945|Experimental|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
32797041|NCT04666909||Hypertension Group|Participants will receive a free blood pressure screening and receive educational counseling about the importance of maintaining a healthy blood pressure. In addition, educational counseling will be administered in months 3 and 6.
32797042|NCT02013830|Experimental|Avastin + Xeloda|
32797043|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
32797044|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
32797045|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
32797046|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
32797047|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
32797048|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
32797049|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
32940464|NCT04706234||progressive supranuclear palsy|Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
33302518|NCT01292512|Experimental|Intervention group|"A) Professional level. B) Patient level.~Intervention~Professional level:~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
33302519|NCT01292512|Other|Control group|Treatment as usual (in the Danish health care system).
33302520|NCT05282914|Experimental|UI058|
32940465|NCT04706234||Parkinson Disease|Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
32940466|NCT04327700|Experimental|Regorafenib and TheraBionic|"TheraBionic is a device that consists of battery-driven radiofrequency electromagnetic field generator. The metal mouth spoon antenna is placed on the anterior part of the tongue during treatment.~Regorafenib is a 40 mg tablet administered orally."
33302521|NCT05282914|Active Comparator|UIC202004|
33302522|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
33302523|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
33302524|NCT01292590|Experimental|High fat meal|
33302525|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
32940467|NCT04311632|Experimental|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
32940468|NCT04311632|Experimental|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
32940469|NCT04311632|Experimental|Arm 3|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
33302526|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
33302527|NCT05282836|Experimental|Intervention|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
33302528|NCT05282836|No Intervention|No intervention|Usual care refers to the standard-of-care (including oxygen therapy) recommended by guidelines.
33302529|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
33302530|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
33302531|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
32940470|NCT04311632|Experimental|Arm 4|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
32940471|NCT04311632|Active Comparator|Arm 5|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
32940472|NCT04706078||thick-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thick-gingiva (outline if the probe cannot be seen through the gingival)
33302532|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
33302533|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
33302534|NCT01189084||Observational immunotherapy follow-up|
33302535|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
32940473|NCT04706078||thin-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thin-gingiva (outline of the probe can be seen through the gingival)
33302536|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
33302537|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
33302538|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
33302539|NCT01296802|Placebo Comparator|Placebo|
33302540|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
33302541|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
33302542|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
33302543|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
33302544|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
33302545|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
33089289|NCT04478019|Other|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
33089290|NCT04478019|Other|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
32797050|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
33089291|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
32797051|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
32797052|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
32797053|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
32797054|NCT04691804|Experimental|Treatment group A|Fuzuloparib plus AA-P
33302546|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
32797055|NCT04691804|Placebo Comparator|Treatment group B|Fuzuloparib Placebo plus AA-P
32797056|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
32797057|NCT04176757|Experimental|ZN-c5|
32797058|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
32797059|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
32797060|NCT04690634|Experimental|PCOS group|obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
32797061|NCT04690634|Active Comparator|control group|obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
33302547|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
32797062|NCT04416854|Experimental|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
33302548|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
33302549|NCT01295008||Patients with the classic form|
33302550|NCT01295008||Fabry disease and healthy controls|
32797063|NCT04416854|Active Comparator|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
32797064|NCT01807923|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
32797065|NCT01807923|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
32797066|NCT01807923|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
32797067|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
32797068|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
33302551|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
32797069|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
32797070|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
32797071|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
32797072|NCT01807299|Experimental|Physical Training|The training group will make physical exercise for three months (three times a week).
33089292|NCT00327210|No Intervention|Control|No intervention
33089293|NCT04392531|Active Comparator|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
33089294|NCT04392531|Experimental|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
32940474|NCT04285346|Other|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
33302552|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
33302553|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
33302554|NCT01295086|Experimental|Her-TEX|
33302555|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
33302556|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
32940475|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
33302557|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
33302558|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
33302559|NCT01194700|Experimental|Evohaler|
33302560|NCT01194700|Experimental|Volumatic spacer|
33302561|NCT01194700|Experimental|Aerochamber Plus|
33302562|NCT01194700|Experimental|Synchro-Breathe|
32940476|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
33302563|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
33302564|NCT01189318|No Intervention|healthy control|
33302565|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
33302566|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
32940477|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
32940478|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
33302567|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
33302568|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
33302569|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
33302570|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
33302571|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
33302572|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
33302573|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
33302574|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
32940479|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
32940480|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
32940481|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
32940482|NCT03648853|Experimental|intervention|all participants receive the same intervention
32940483|NCT00652574|Experimental|Dasatinib|Dasatinib = BMS-354825, Sprycel
32940484|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
32940485|NCT01550510|Experimental|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
32940486|NCT01550510|Active Comparator|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
32940487|NCT04333225|Experimental|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
33089295|NCT00297323||001|
33302575|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
33302576|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
33089296|NCT00327288|Experimental|A|Docetaxel plus imexon
32797073|NCT01807299|Other|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
33302577|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
33302578|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
32797074|NCT01807299|Placebo Comparator|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
32797075|NCT01807299|Experimental|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
33302579|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
33302580|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
33302581|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
32797076|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
32797077|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
32797078|NCT04659577|Experimental|internet based CBT|all patients will be offered active treatment via internet based CBT
32797079|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:~Chemotherapy: Up to 6 cycles, 21 days each:~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;~Antiviral-Based Therapy~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
32797080|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
32797081|NCT04416295|Active Comparator|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
32797082|NCT04416295|Other|Control group Standard COPD Care|
32797083|NCT01992757||Cardiac surgery with cardiopulmary bypass|
32797084|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
32797085|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
32797086|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
32797087|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
32940488|NCT04333225|No Intervention|Control|Subjects who declined taking HCQ were considered as controls
32940489|NCT00566462|Experimental|perampanel|
32940490|NCT00566462|Placebo Comparator|1|
32940491|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
32940492|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
33302582|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
33302583|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
33302584|NCT01292902|Active Comparator|healthy volunteers|
33302585|NCT01292902|Other|chronic heart failure|
33302586|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
33302587|NCT01195012|Experimental|Intervention arm|see intervention description
33302588|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
33302589|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
33302590|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
33302591|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
33302592|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
33302593|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
33302594|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
33302595|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
32797088|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
32907038|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
33302596|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
33302597|NCT03737110|Experimental|Rilonacept|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
33302598|NCT03737110|Placebo Comparator|Placebo|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
33302599|NCT03848884|Experimental|Adherence monitoring and education|
33302600|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
33302601|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
33302602|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
33302603|NCT01195168||Control cohort|Women without PCOS
33302604|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
33302605|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
33302606|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
33302607|NCT01189864||Ciprofloxicin or Vigamox or other.|
33302608|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
33302609|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
33302610|NCT05598814|Experimental|Intervention group - FESS|Biologic treatment with Mepolizumab and functional endoscopic sinus surgery (FESS).
33302611|NCT05598814|Active Comparator|Control group - No-FESS|Biologic treatment with Mepolizumab
33302612|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
33302613|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
33302614|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
33302615|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
33302616|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
33302617|NCT05671120|Other|Transcutaneous levator recession|
33302618|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
33302619|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
33302620|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
33302621|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
33302622|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
33302623|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
33302624|NCT05596474|Experimental|Beet-root juice plus red-light therapy|
33302625|NCT05596474|Sham Comparator|Beet-root juice plus sham light therapy|
33302626|NCT05596474|Placebo Comparator|Placebo plus red-light therapy|
33302627|NCT05596474|Active Comparator|Placebo plus sham light therapy|
33302628|NCT05594680|Active Comparator|Cilostazol and Methotrexate|Participants in this arm will receive Cilostazol 50 mg twice daily with Methotrexate for rheumatoid arthritis for 12 weeks.
33302629|NCT05594680|Placebo Comparator|Placebo and Methotrexate|Participants in this arm will receive Placebo with Methotrexate for rheumatoid arthritis for 12 weeks.
33302630|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
33302631|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
33302632|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
33302633|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
33302634|NCT05671042||Patients with Upper excretory tract tumors|Adult patient with Upper excretory tract tumors Neoadjuvant chemotherapy treatment received between 2010 and 2020.
33089297|NCT04344600|Experimental|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
33089298|NCT04344600|Placebo Comparator|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
33089299|NCT04333134|Experimental|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
33089300|NCT04303104|Active Comparator|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
33089301|NCT04303104|Placebo Comparator|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
33089302|NCT00297362||Galantamine hydrobromide|
33089303|NCT05459220|Experimental|Treatment group A|SHR0410 Injection（Low Dose）
33302635|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
33302636|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
33302637|NCT05561530|Experimental|ALG-125755|Subcutaneous injections of ALG-125755 in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
33302638|NCT05561530|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
33302639|NCT05555056|Active Comparator|Active Stimulation|MxN-9 HD-tES Stimulator (Soterix Inc.) will be used to deliver direct current (High-Definition Transcranial Direct Current Stimulation) to the target brain areas via electrodes and conducive gels. A constant current will be applied for 20 minutes with peak current of 2 mA. The 9 electrodes (8 channels + 1 ground) positions and current intensity have been determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left VLPFC (x=-50, y=+26, z=+8) and the PCC (x=1, y=-61, z=38) with inward field orientation.
33302640|NCT05555056|Sham Comparator|Inactive Stimulation|The current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down, and thus no active stimulation will be administered except for the initial and last 1 minutes of 20 minute stimulation duration.
33302641|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
33302642|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
33302643|NCT01192360|Experimental|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
33302644|NCT01192360|Experimental|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
33302645|NCT05671588|Experimental|Controlled combined program (aerobic-resistant)|Patients randomized into the Experimental arm will undergo controlled exercise on a cycling ergometer in combination with strength training on a multifunctional fitness device for 1-hour duration, twice a week for one month, and once a week for the next month (12 therapies in total).
33302646|NCT05671588|Active Comparator|Conventional rehabilitation|Patients randomized into this study arm will undergo conventional rehabilitation.
33302647|NCT05671588|No Intervention|No intervention|Patients randomized into this study arm will undergo no intervention and will serve as the control group.
33302648|NCT01190332|Placebo Comparator|conventional technique of ERCP|
33302649|NCT01190332|Active Comparator|Rendezvous technique|
33302650|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
33089304|NCT05459220|Experimental|Treatment group B|SHR0410 Injection（High Dose）
33089305|NCT05459220|Placebo Comparator|Treatment group C|Placebo for SHR0410 Injection.
33089306|NCT04231773|Experimental|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
33302651|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
33302652|NCT05668390|Experimental|STALORAL® Birch 300 IR|"Escalation Phase:~The escalation phase starts with 10 IR/mL solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL solution the next 5 days (daily increase from 1 to 5 actuations).~Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL solution from Day 11 onwards"
33302653|NCT05668390|Placebo Comparator|Placebo|"Escalation Phase:~The escalation phase starts with 10 IR/mL Placebo solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL Placebo solution the next 5 days (daily increase from 1 to 5 actuations).~Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL Placebo solution from Day 11 onwards"
33302654|NCT01192438|Experimental|Procedure/surgery|
33089307|NCT04231773|Placebo Comparator|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
33089308|NCT04231773|Experimental|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
32797089|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
32797090|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
32797091|NCT01990573|Experimental|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
32797092|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
32797093|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
32797094|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
32797095|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
33302655|NCT03846466|Experimental|Part1 Dose 1A|Single administration
33302656|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
33302657|NCT03846466|Experimental|Part1 Dose 2A|Single administration
33302658|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
33089309|NCT04231773|Placebo Comparator|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
33089310|NCT04229316|Experimental|zLock Facet Locking Implant System|
33302659|NCT03846466|Experimental|Part1 Dose 3A|Single administration
32797096|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
32797097|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
33404238|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
32797100|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
32797101|NCT04658095|Active Comparator|Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System|
32797102|NCT04658095|Active Comparator|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System|
32797103|NCT04658095|Active Comparator|Ab-interno implantation of iStent inject (2 microstents)|
32797104|NCT01963117|Experimental|Combined hypertermia and RT|Combined hypertermia and radiothearpy
32797105|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
32797106|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
32797107|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
32797108|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
32797109|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
32797110|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
32797111|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
33089311|NCT04224012|No Intervention|Conventional therapy group (control group)|patients of the control Group receive usual care
33302660|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
33302661|NCT03846466|Experimental|Part1 Dose 4A|Single administration
33302662|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
33302663|NCT03846466|Experimental|Part1 Dose 5A|Single administration
33302664|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
33302665|NCT03846466|Experimental|Part1 Dose 6A|Single administration
33302666|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
33302667|NCT03846466|Experimental|Part1 Dose 7A|Single administration
33302668|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
32797112|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
32797113|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
33302669|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
33302670|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
33302671|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
32797114|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
33302672|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
32797115|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
33302673|NCT01293136||intravenous opioids|
33302674|NCT01293136||femoral nerve block|
33302675|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
33302676|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
33302677|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
33302678|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
33302679|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
33302680|NCT03846388|Other|Patients with unexplained infertility|
33302681|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
33302682|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
33302683|NCT01195714|Experimental|Ofatumumab|
33302684|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
33302685|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
32797116|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
32797117|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
32797118|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
32797119|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
32797120|NCT04657159||2010-2016|Patients treated 2010-2016
32797121|NCT04657159||2017-2019|Patients treated 2017-2019
32907039|NCT05672849|Experimental|Modified Devices in fetoscopic NTD repair|Single arm study. All patients will undergo fetoscopic NTD repair with the use of the modified devices.
33302686|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
33302687|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
33302688|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
33302689|NCT05668468|Placebo Comparator|Control Group|Daily cellulose capsule
33302690|NCT05668468|Experimental|Experimental Group|Daily Bifidobacterium adolescentis IVS-1,capsule
33302691|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
33302692|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
33302693|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
33302694|NCT01582750||Local advanced rectal cancer EUS|
33302695|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
33302696|NCT01190722|Experimental|etoricoxib|active study drug, coxib
33302697|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
33302698|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
33302699|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
32797122|NCT04174651|Experimental|Participants with AD with MRI|Participants that are diagnosed with AD will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
32797123|NCT04174651|Experimental|Healthy Participants with MRI|Healthy participants will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
32797124|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
33089312|NCT04224012|Experimental|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
33089313|NCT04207593|Active Comparator|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
33089314|NCT04207593|Sham Comparator|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
33089315|NCT00297752|Active Comparator|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
32797125|NCT04676204||Cladribine|Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.
32797126|NCT04676204||Dimethyl Fumarate|Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.
32797127|NCT04676204||Fingolimod|Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.
32797128|NCT04676204||Teriflunomide|Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.
33089316|NCT00297752|Active Comparator|flammazine|facial burns treatment with silver sulfadiazine
33089317|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
33302700|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
32797129|NCT04676204||Ozanimod|Participants with MS commencing Ozanimod disease modifying treatment as clinically prescribed.
32797130|NCT04676204||Diroximel Fumarate|Participants with MS commencing diroximel fumarate disease modifying treatment as clinically prescribed.
32797131|NCT01986920|Active Comparator|A-101 25%|Low dose group
32797132|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
33302701|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
33302702|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
33302703|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
33302704|NCT05103436|No Intervention|Control Group|Participants will not receive intervention for the first 2 months. This period will be used for comparison with the intervention group. At the end of the 2-month delay, they will receive TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit).
33302705|NCT05103436|Experimental|Intervention Group|Participants will receive 2 months of TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit) immediately upon entry to the study.
33302706|NCT03850210|Experimental|Short Splint|
33302707|NCT03850210|Active Comparator|Traditional, Long Splint|
33302708|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
33302709|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
32797133|NCT01986920|Active Comparator|A-101 40%|High Dose Group
32797134|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
32797135|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
32797136|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
32797137|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
32797138|NCT01986140|Other|Control No treatment|Control
32797139|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
33089318|NCT00297869|No Intervention|1|
33089319|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
33302710|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
33302711|NCT01192984|Experimental|KW-0761|
32797140|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
32907040|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
33089320|NCT05459103|Experimental|Intervention group|Participants in the intervention group received a 12-week bidirectional remote interaction intervention.
33089321|NCT05459103|Experimental|Control group|Participants in the control group received a 12-week unidirectional remote interaction intervention.
33302712|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
33302713|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
33302714|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
33302715|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
33302716|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
33302717|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
33302718|NCT01196494|Experimental|intraoperative colon lavage|
32797141|NCT01985360|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
32797142|NCT01985360|Active Comparator|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
33302719|NCT01196494|Active Comparator|stent and deferred surgery|
33302720|NCT05412082|Experimental|SMART TNT Plan I|"Participants will initiate therapy with neoadjuvant chemotherapy of either six (6) 14-day cycles of 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) or four (4) 21-day cycles of capecitabine+oxaliplatin (CAPOX). Participants will then receive chemo-radiation therapy according to Plan I as follows:~Plan I (5 weeks):~MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.~Concurrent chemotherapy beginning on Day 1 of RT either:~5-FU delivered 5 or 7 days per week.~Capecitabine (Xeloda) delivered 5 days per week.~After completing Plan I, participants achieving complete Clinical Response (cCR) after completing Plan I chemo-radiation will forgo the Plan II boost and continue to follow-up. Participants not achieving cCR will begin Plan II, one week after completing Plan I."
33302721|NCT05412082|Experimental|SMART TNT Plan II|"Plan II boost RT (1 week): For participants not achieving cCR after chemo-radiation. Participants will receive MRI-guided accelerated radiation therapy (ART) boost to the primary tumor.~Participants achieving a cCR will continue to follow-up. Participants still showing residual tumor will undergo standard of care treatment including surgery and adjuvant chemotherapy per institutional guidelines during follow-up."
33302722|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
33302723|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
33302724|NCT01196650|Active Comparator|1|IN 10 003 formulation A
33302725|NCT01196650|Active Comparator|2|IN 10 003 formulation B
33302726|NCT01196650|Placebo Comparator|3|Placebo capsules
32797143|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
32797144|NCT04690010|Active Comparator|Ambulatory tubeless PCNL|Patients will be discharged home on the same day as surgery. No nephrostomy tube will be placed (tubeless).
33302727|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance is provided~If needed legal assistance is provided"
33302728|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
33302729|NCT01193296|Experimental|Vildagliptin|
33302730|NCT01193296|Active Comparator|Sitagliptin|
32797145|NCT04690010|Active Comparator|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days with a nephrostomy tube placed at the time of surgery that will then be removed prior to discharge.
32797146|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
33302731|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.~The intervention is to use the three-finger method."
33302732|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.~The intervention is to use the weight-related method."
33302733|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
33302734|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
33302735|NCT04888156||GAT IOP below 15 mmHg|Glaucoma patients with an IOP measured with GAT below 15 mmHg prior performance of self-tonometry with iCare Home
32797147|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
33302736|NCT04888156||GAT IOP equal or above 15 mmHg|Glaucoma patients with an IOP measured with GAT equal or above 15 mmHg prior performance of self-tonometry with iCare Home
33302737|NCT01196884||Asymptomatic ITP patients|
33302738|NCT01196884||ITP patients treated with Rituximab|
33302739|NCT01196884||ITP patients treated with steroids|
33302740|NCT01196962|Experimental|Internal jugular vein|
33302741|NCT01197040|Experimental|B-Experimental|Experimental
33302742|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
32797148|NCT04689074||ADPKD|Patients with ADPKD
32797149|NCT04689074||advanced CKD|Patients with advanced CKD
32797150|NCT04689074||DKD|Patients with DKD
32797151|NCT04689074||IgAN|Patients with IgAN
32797152|NCT04689074||Healthy volunteers|Healthy volunteers
32797153|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33302743|NCT05387824|Active Comparator|Group 1: Bladder Training - Control group|BT, consisting of four stages, won't contain any PFMT programs in all groups. In these stages, including urgency supression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women will be encouraged to pause/ stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
33302744|NCT05387824|Experimental|Group 2: Bladder Training + TTNS|Two self-adhesive surface electrodes will be positioned according to the protocol which previously explained, with the negative electrode 2 cm behind the medial malleolus and positive electrode 10 cm proximal. Correct positioning wil be determined by noting a hallux reaction (plantar flexion of great toe or fanning of all toes). The stimulation protocol will be delivered at fixed 20 Hz and pulse width 200 ms in continous mode in accordance with the PTNS stimulation protocol. The intensity of the stimulation current (range 0-50 mA) will be determined once correct positioning are established, according to the comfort level of the person. TTNS sessions will be performed twice a week for 6 weeks. Every session will be lasted 30 min. Treatment will consist of 12 sessions of stimulation.
33302745|NCT05387824|Experimental|Group 3: Bladder Training + MStim|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is in serted by this magnetic field, an eddy current flow is generated. This eddy current stimulates nerve or muscle of the pelvic floor. To apply MS, the device will be set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients will be interviewed so that they receive the stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
33302746|NCT05440864|Experimental|Tremelimumab in combination with Durvalumab preoperatively, followed by adjuvant Durvalumab|Patients will receive 1 dose Tremelimumab (300 mg) with Durvalumab (1500mg) at cycle 1 (4W) and 1 further cycle of Durvalumab (1500mg) pre surgical resection. Post-surgical resection patients will begin adjuvant Durvalumab (1500mg Q4W) to complete 13 cycles of treatment (or 11 post operatively) in total.
33302747|NCT05436340|Experimental|EHepIcu|
33302748|NCT05436340|No Intervention|Control Grubs|
33302749|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
33302750|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
33302751|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
33302752|NCT05670886|Experimental|uterine artery ligation + carbetocin|Group (A) , study group (N=55) : patients with multiple pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received carbetocin.
33302753|NCT05670886|Active Comparator|carbetocin only|Group (B ) , control group (N=55) : patients with twin pregnancy undergoing cesarean section received carbetocin only.
33302754|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
33302755|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
33302756|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
33302757|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
33302758|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
33302759|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
33302760|NCT01197196|Experimental|Behavioral weight loss|
33302761|NCT01197196|Active Comparator|Migraine Education|
33302762|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
33302763|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
33302764|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
33302765|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
33302766|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
33302767|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
33302768|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
33302769|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
33302770|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
33302771|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
33302772|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
33302773|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
33302775|NCT05416450|Active Comparator|Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
33302776|NCT05416450|Active Comparator|Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
33302777|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
33302778|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
33302779|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
33302780|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
33302781|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
32797154|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33089322|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
32797155|NCT04688450|Experimental|Intervention group|The investigational system will be evaluated for safety and user acceptance in 20 patient-subjects and associated nurse-subjects
32797156|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
32797157|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
32797158|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
32797159|NCT04440566|Experimental|Systemic lupus erythematosus (SLE)|
32797160|NCT04416620|Active Comparator|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
32797161|NCT04416620|No Intervention|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
32797162|NCT04416620|Active Comparator|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
32797163|NCT04416620|No Intervention|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
32797164|NCT01807221|Experimental|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
32797165|NCT01807221|Experimental|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
32797166|NCT01807221|Experimental|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
32797167|NCT01807221|Experimental|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
32797168|NCT01807221|Experimental|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
32797169|NCT01807221|Active Comparator|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
32797170|NCT01838499|Experimental|MEDI8968|
32797171|NCT01838499|Placebo Comparator|Saline|
32797172|NCT01807065|Experimental|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
32797173|NCT01807065|Experimental|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
32797174|NCT04583709|Experimental|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
32797175|NCT02031458|Experimental|Atezolizumab|
32797176|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
32907041|NCT05048459|Active Comparator|Standard surveillance|This surveillance approach involves the participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
32940493|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
32940494|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
32940495|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
32940496|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
32940497|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
32940498|NCT01553240|Experimental|TMS and fMRI|"functional MRI~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
32940499|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
33302782|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
33302783|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
33302784|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
33302785|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
32940500|NCT01545518|Experimental|all subjects|IVIG
32940501|NCT04320823|Experimental|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
33302786|NCT01197274||Mite-sensitized person|
33302787|NCT00146328|Experimental|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
33302788|NCT00146328|Experimental|Group 2|Highly Tipranavir Treatment Experienced Patients
33302789|NCT00146328|Experimental|Group 3|Tipranavir Treatment Naive Patients
33302790|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
33302791|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
33302792|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
32940502|NCT04320823|Active Comparator|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
33302793|NCT04918030|Active Comparator|In-hospital staged PCI|Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.
33302794|NCT04918030|Experimental|Out-hospital staged PCI|Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.
33302795|NCT04916938|Experimental|Interactive Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
33302796|NCT04916938|Active Comparator|Treatment as usual|Mother child psychotherapeutic sessions without video feed back.
33302797|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
33302798|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
33302799|NCT01295866||nasal nitric oxide, atypy status|
33302800|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
32940503|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
33302801|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
33302802|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
33302803|NCT03345784|Experimental|Treatment (radiation therapy, adavosertib, cisplatin)|Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
33302804|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
33302805|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
33302806|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
33302807|NCT05670808|Experimental|Epinephrine 1:200,000|In this group participants will receive the epinephrine concentration of 1:200,000 in normal saline
33302808|NCT05670808|Experimental|Epinephrine 1:400,000|In this group participants will receive the epinephrine concentration of 1:400,000 in normal saline
32940504|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
32940505|NCT00380042|Active Comparator|Active Stimulation|
32940506|NCT00380042|Sham Comparator|Sham|
32940507|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
33302809|NCT05670808|Placebo Comparator|Placebo|In this group participants will receive only 10 ml of normal saline (control group)
33302810|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
33302811|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
33302812|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
33302813|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
32797177|NCT01806597|Experimental|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
32797178|NCT01806597|Experimental|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
33302814|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
32907042|NCT05048459|Experimental|Telemedicine surveillance (tele-surveillance)|Tele-surveillance involves the participant staying at home while their healthcare providers follow their condition and give them the care they need. They can communicate with their healthcare team through face-to-face video conferencing on their desktop computer, laptop, smart phone, or tablet. They can also communicate with their healthcare team by phone.
33302815|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
33302816|NCT05670730|Experimental|AOC 1044-CS1 Part A - Single Dose Levels 1-5|AOC 1044 will be administered once.
33302817|NCT05670730|Placebo Comparator|AOC 1044-CS1 Part A - Single Dose: Placebo|Placebo will be administered once.
33302818|NCT05670730|Experimental|AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3|AOC 1044 will be administered three times.
33302819|NCT05670730|Placebo Comparator|AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo|Placebo will be administered three times.
33302820|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
33302821|NCT03733444|Experimental|GLPG1690, 600 milligrams (mg)|Participants received GLPG1690 (ziritaxestat) 600 mg as film-coated tablet orally, once daily (mean treatment duration was 332.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
33302822|NCT03733444|Experimental|GLPG1690, 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet orally, once daily (mean treatment duration was 336.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
33302823|NCT03733444|Experimental|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets orally, once daily (mean treatment duration was 346.2 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
33302824|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
33302825|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
33302826|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
33302827|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
33302828|NCT04881526|Active Comparator|Ketone ester drink|
33302829|NCT04881526|Placebo Comparator|Placebo drink|
33302830|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
32907043|NCT00914186|Placebo Comparator|Vehicle|
32907044|NCT00914186|Experimental|TS-022 0.005% lotion|
32907045|NCT00914186|Experimental|TS-022 0.010% lotion|
32907046|NCT00914186|Experimental|TS-022 0.020% lotion|
32907047|NCT05046353|Experimental|D-serine|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
32907048|NCT05046353|Placebo Comparator|placebo|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
32907049|NCT05672771|Experimental|Different Mixed Condition (DM)|Training in both Lexical Decision Span and Category Span in Phase 1 (which are both different from the target task Reading Span in Phase 2).
32907050|NCT05672771|Experimental|Different Single Condition (DS)|Training in the Lexical Decision Span in Phase 1 (which is different from the target task Reading Span in Phase 2).
32907051|NCT05672771|Active Comparator|Same Task (ST) Practice Control|Training in Reading Span task in Phase 1 (which is the same as target task in Phase 2).
32907052|NCT05672771|Placebo Comparator|Non-WM Placebo Control (PC)|Training in a speeded Lexical Decision task only (which has no memory component) in Phase 1 prior to Phase 2 training in WM.
32907053|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
32907054|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
32907055|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
33089323|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
33302831|NCT04871854|Experimental|Svere infected Covid-19 control|Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
33302832|NCT04871854|Active Comparator|sever infected Covid -19 pateints study|Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab
33302833|NCT04839406|Experimental|Intervention|"Structured follow up at the ICU~1-3 days after admittance: Map caregivers' prioritized symptoms, needs and preferences with a digital assessment tool, followed by a meeting with a nurse to address these issues.~Every 1-2 weeks: Repeat assessment of symptoms and needs with the assessment tool followed by a meeting with a nurse.~At discharge: Structured conversation focusing on information and preparation for the transition to a regular ward or to another hospital including a card with information and support.~Bereavement: Individualized support based on caregiver expressed needs, preferences and previous mapping, including a card with information and support.~Follow up: Caregivers or bereaved will be contacted after 4-6 weeks, and will be offered a follow up conversation either on phone or at the unit."
33302834|NCT04839406|No Intervention|Follow up as usual (Control)|Follow up as usual at the ICU
33302835|NCT05282758|Experimental|Interdisciplinary team treatment + add on Intervention - Free Movement Dance|Interdisciplinary team treatment + add on Intervention - Free Movement Dance as a physiotherapy intervention
33302836|NCT05282758|Active Comparator|Interdisciplinary team treatment + add on Modified person-centered progressive resistance exercise|Interdisciplinary team treatment + add on Control group - modified person-centered progressive resistance exercise as a physiotherapy intervention
33302837|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
33302838|NCT04834336|Experimental|Physical training plus inspiratory muscle training|"Inspiratory Muscle Training (IMT) will be implemented by using the Power Breathe® device. IMT training will begin with mild to moderate intensity of maximal inspiratory pressure. It will be performed 6 to 10 breaths, 4 sets, and twice daily during the hospitalization when as soon as hemodynamic stability is provided.~Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided."
33302839|NCT04834336|Active Comparator|Physical training|Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
32737921|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
32737922|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
33302840|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
32737923|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
32737924|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
33302841|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
33302842|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
33302843|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
32737925|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
32737926|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
32737927|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
32737928|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
32737929|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
32737930|NCT05018169|Experimental|BA-A|Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
32737931|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
32737932|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
32737933|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
33089324|NCT05459025|Experimental|Aromatherapy yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
33089325|NCT05459025|Active Comparator|Yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
33089326|NCT04718714|Active Comparator|midazolam|postoperative ventilation and sedation with continuous intravenous infusion of midazolam only for 24 hours
33089327|NCT04718714|Active Comparator|propofol|postoperative ventilation and sedation with continuous intravenous infusion of propofol only for 24 hours
33089328|NCT04718714|Experimental|dexmedetomidine|postoperative ventilation and sedation with continuous intravenous infusion of dexmedetomidine only for 24 hours
33089329|NCT04718519||Migrant Workers|
33089330|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.~They will have an urinary sample."
33089331|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
33089332|NCT04009239|Experimental|Early Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
33089333|NCT04009239|Experimental|Mid-day Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
33089334|NCT00297986||1|healthy subjects
33089335|NCT05458635|No Intervention|HP without Pulmonary hypertion|HRCT chest , pulmonary functions and echocardiography
33302844|NCT04809688|Experimental|Single arm|Single arm
33302845|NCT04793620|Experimental|TQL1055|TQL1055 + acellular pertussis vaccine
33302846|NCT04793620|Active Comparator|Acellular pertussis vaccine|Acellular pertussis vaccine
33302847|NCT04789486|Experimental|AGUIX + SMART Phase 1|"Dose escalation of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).~Central lung tumor cohort will receive:~five fractions of stereotactic body radiation therapy (SBRT)~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation and for patients receiving radiation over a two (2) week period with the 4th fraction of radiation .~Locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC cohort, will receive:~five fractions of stereotactic body radiation therapy (SBRT)~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation."
33302848|NCT04789486|Experimental|AGUIX + SMART Phase 2|Randomized participants will receive recommended phase 1 dose established for their disease group (central lung tumor or locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC) of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
33302849|NCT04789486|Experimental|SMART Phase 2|Randomized participants will receive standard of care SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
33302850|NCT01296256|Experimental|Bendamustine-EAM|
33302851|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
33302852|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
33302853|NCT04781062|Experimental|Breast Cancer Stage T1 Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed T1 breast cancer, patients will undergo a second peripheral blood and urine collection after primary breast cancer surgery."
33302854|NCT04781062|Active Comparator|Benign Breast Lesion Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed benign lesion, no other samples will be collected."
33302855|NCT05670340|Experimental|Swithed-platform|In this group the implants will be rehabilitated with a narrower emergence profile for the prosthetic rehabilitation.
33302856|NCT05670340|Active Comparator|Matched-platform|This the conventional approach in wich the prosthetic rehabilitation is matched with the implant-platform dimensions
32907056|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
33089336|NCT05458635|Active Comparator|HP with Pulmonary hypertion|HRCT chest , pulmonary functions ,echocardiography and RT heart catheter in high echocardiographic probability of PH
33089337|NCT00298025|Experimental|Cetrotide®|
33089338|NCT00298025|Active Comparator|Antagon ™|
33089339|NCT03974412|Experimental|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
33089340|NCT03923439|Experimental|MRI protocol|For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
33302857|NCT05344378|No Intervention|1 Month Baseline Period|Initial baseline period for rollout at 6 different clinics throughout the year-long intervention period using a step-wedge design.
33302858|NCT05344378|Experimental|Stage 1 Enrollment|Enrollment of 2 clinics over 4 months including 5 PCPs per clinic (2 total clinics).
33089341|NCT03917745|Experimental|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
33302859|NCT05344378|Experimental|Stage 2 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
33302860|NCT05344378|Experimental|Stage 3 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
33302861|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
32797179|NCT01806597|Placebo Comparator|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
32797180|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
32797181|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
33302862|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
33302863|NCT05668312|Experimental|TELE-pre group|Subjects in the TELE-prehabilitation group receive remote prehabilitation using advanced technologies.
32797182|NCT01610037|Experimental|QVA149|
33302864|NCT05668312|Active Comparator|Control group|"The control group is composed by the Con-O (Control Older) group and the Con-Y (Control Young) group. In the Con-O group (n=24) subjects receive home-based prehabilitation using a printed booklet; in the Con-Y group (n=10) subjects do not receive any prehabilitation program.~Subjects in the Con-Y group will be recruited from patients waiting for anterior cruciate ligament reconstruction, thus they will be only assessed with muscular biopsy and blood sampling."
33302865|NCT05339308|Experimental|Experimental|Magnesium oil application
33302866|NCT05339308|Placebo Comparator|Control|Natural mineral-free oil application
32797183|NCT01610037|Active Comparator|Tiotropium|
32797184|NCT01610037|Placebo Comparator|placebo|
32797185|NCT04687514|Experimental|Phase a (V1a-Ev2a): Dulaglutide first- Phase b (V1b-Ev2b) Placebo second|Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
33302867|NCT03730012|Experimental|Gilteritinib 120 mg + Atezolizumab 420 mg|Participants received 120 milligrams (mg) giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 420 mg adminstered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab).
33302868|NCT03730012|Experimental|Gilteritinib 120 mg + Atezolizumab 840 mg|Participants received 120 mg giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 840 mg administered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 126 days for gilteritinib and 70 days for atezolizumab).
33302869|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
33302870|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
33302871|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
33302872|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
33302873|NCT05288842||Group 1: Controls|
33302874|NCT05288842||Group 2: Alzheimer's Disease|
33302875|NCT05288842||Group 3: Frontotemporal Dementia|
33302876|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
33302877|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
33302878|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
33302879|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
33302880|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
33302881|NCT01199770|Other|No Load|Only water
33302882|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
33302883|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
33302884|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
33302885|NCT05273008||Active hockey players|Observational study on 180 Hockey players
33302886|NCT05266300||Retrospective|Historic group. Patients treated in the historic control group did not receive DPYD-genotype before treatment with fluorouracil, capecitabine, tegafur. They received standard start doses of 5-FU, capecitabine, tegafur.
32940508|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
32940509|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
32940510|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
33302887|NCT05266300||Prospective|"Participants enrolled in the prospective group will give a blood sample for immediate DPYD genotyping. Once the results from these tests are in, the treating oncologist have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription. The recommended starting doses for 5-FU, capecitabine, tegafur are.~No DPYD-gene variant = normal starting dose (100%)~1 DPYD-gene variant (heterozygous) = Reduced starting dose (50%) Homozygous for 1 DPYD variant or compound heterozygous (>1 variants) = Treatment with 5-FU, capecitabine, tegafur is not recommended ."
33302888|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
33302889|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
33302890|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
32940511|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
32940512|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
33302891|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
33302892|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
33302893|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
33302894|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
33302895|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
33302896|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
33302897|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
33302898|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
33302899|NCT04704544|Experimental|Tele-rheumatology first visit and Usual Care second visit|Participants randomized to this visit will receive a tele-rheumatology visit first.
33302900|NCT04704544|Experimental|Usual Care first visit and Tele-rheumatology second visit|Participants randomized to this visit will receive a usual care visit first.
33302901|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
33302902|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
33302903|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
33302904|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
33302905|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
33302906|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
33302907|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
33302908|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
33302909|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
33302910|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
33302911|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
32940513|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
32940514|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
32940515|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
32940516|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
32940517|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
32940518|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
32940519|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
32940520|NCT04713644||Burst Suppression|Patients who present burst suppression after standardized propofol administration during anesthetic induction
32940521|NCT04713644||No Burst Suppression|Patients who did not present burst suppression after standardized propofol administration during anesthetic induction
32940522|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
32940523|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
32940524|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
32940525|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
32940526|NCT03923582|No Intervention|Ecological needs assessment|To conduct a needs assessment of sexual health care delivery in Tanzania. To determine whether midwifery, nursing, medical and allied health science students would benefit from one curriculum or separate curricula tailored by discipline. We will conduct focus groups and key informant interviews of all three groups.
32940527|NCT03923582|No Intervention|Develop a sexual health training curriculum|We will further adapt a sexual health training curriculum tailored to Tanzanian/East African/Sub-Saharan context and pilot test it and train local faculty to implement it.
32940528|NCT03923582|Placebo Comparator|To evaluate the effectiveness of the sexual health curriculum|We will conduct a randomized, controlled, single blinded trial of the curriculum against a waitlist control assessing effects on sexual health knowledge, attitudes and sexual history and counseling skills.
33302912|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
32940529|NCT03896438|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
33302913|NCT05282680||Type 2 diabetes|Subjects with a diagnosis of type 2 diabetes
32940530|NCT03896438|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
33089342|NCT03917745|No Intervention|Control group|Care as usual
33302914|NCT05282680||Type 1 diabetes|Subjects with a diagnosis of type 1 diabetes
33302915|NCT05282680||Diabetic kidney disease|Subjects with diabetic kidney disease (presence of albuminuria +/- eGFR<=60m/kg/m2) or history or presence of end stage renal disease
33302916|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
33302917|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
33302918|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
33302919|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
33302920|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
33302921|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
33302922|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
33302923|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
33302924|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
33302925|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
33302926|NCT05668234||Parents|Parent having carried out and completed parent-child psychotherapy with a child in CHU Minjoz (child under 5 years old).
33302927|NCT04088578|Experimental|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
33302928|NCT04088578|Sham Comparator|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
33302929|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~the patients' clinical conditions;~the patient's adherence to the pharmacological treatments prescribed~the patient's compliance in filling out the clinical diary and the ADL diary"
32940531|NCT03896438|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
32940532|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
32940533|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
33302930|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
33302931|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
33302932|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
33302933|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
33302934|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
33302935|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
33302936|NCT01200472|Placebo Comparator|Placebo|
33302937|NCT01200550||1|
33302938|NCT05669950|Experimental|Lu AG13909|Participants in Part A will receive multiple intravenous (IV) doses of Lu AG13909 per a prespecified dosing schedule. After data from Part A has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part B will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule.
32940534|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
33302939|NCT04082884|Experimental|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
33302940|NCT04080778|Experimental|MST|
33302941|NCT04080778|Active Comparator|ECT|
33302942|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
33302943|NCT04638790|Experimental|Early favorable HL|HL without adverse prognostic factors
32940535|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
32940536|NCT03663283|Active Comparator|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
33302944|NCT04638790|Experimental|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
33302945|NCT04638790|Experimental|Advanced stages HL|(age less than 50 years)
33302946|NCT05225428|Experimental|QUALITATIVE ASSESSMENT|"This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review.~It is expected that about 20 people will take part in this part of the research study.~In the larger part of the study that will happen after this part of the study, it is expected 1000 people will participate."
33302947|NCT05225428|Experimental|RCT-VERDI|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
33302948|NCT05225428|Experimental|RCT-Genetic Counseling|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
33302949|NCT05212402|Experimental|Test Product|28 participants will be given the test product (TP)
33302950|NCT05212402|Placebo Comparator|Placebo|28 participants will be given the placebo product.
33302951|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
32940537|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
32940538|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
32940539|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
32940540|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
32940541|NCT00484718|Active Comparator|A|
32940542|NCT00484718|Active Comparator|B|
32940543|NCT00484718|Placebo Comparator|C|
32940544|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
32940545|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
33302952|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
33302953|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
33302954|NCT04075864|Experimental|behavioral intervention to improve physical activity|"The proposed study is prospective single-arm feasibility clinical trial that will enroll 12 hospitalized patients with CF in accordance with consensus criteria.~Standard care for an acute CF exacerbation includes i.v. antibiotics and airway clearance therapies for 10-14 days. Routine care following hospitalization is an outpatient CF clinic visit 2-4 weeks after discharge, and then regular follow up every 2-3 months.~In addition, to standard care in the hospital, study participants will receive a 1) tailored exercise prescription, 2) daily, individual, supervised, aerobic and strength/power training, as well as 3) daily behavioral counseling focused on topics related to long-term adherence to exercise (details below)."
32940546|NCT00477230|Active Comparator|2|Medication
32940547|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
33302955|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
32940548|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
33302956|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
33302957|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
33302958|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
33302959|NCT04581928||COVID-19|Highly educated people Low educated people
33302960|NCT05282602|Experimental|Wii Fit Based Exercises|Group A will receive Wii fit Based Exercises
33302961|NCT05282602|Experimental|Proprioceptive Training|Group B will receive proprioceptive training
33302962|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
33302963|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
33302964|NCT01200706|Active Comparator|Amoxicillin given twice a day|
33302965|NCT01200706|Active Comparator|Amoxicillin given three times a day|
33302966|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
33302967|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
33302968|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
33302969|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
33302970|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
33302971|NCT01200862|Experimental|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
32940549|NCT04713488|Experimental|Sputnik Light Vaccine|solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10*11 particles per dose.
32940550|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.~Followed by prostatectomy"
32940551|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: a bronchoscopy surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
32940552|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: bronchoscopy surveillance at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
32940553|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
33302972|NCT01200862|Placebo Comparator|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
33302973|NCT01200862|Experimental|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
32797186|NCT04687514|Experimental|Phase a (V1a-Ev2a): Placebo first- Phase b (V1b-Ev2b) Dulaglutide second|The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
33302974|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
33302975|NCT01200940|Experimental|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302976|NCT01200940|Experimental|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302977|NCT01200940|Placebo Comparator|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302978|NCT01200940|Experimental|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
33302979|NCT01200940|Placebo Comparator|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302980|NCT01200940|Experimental|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302981|NCT01200940|Experimental|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302982|NCT01200940|Experimental|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
33302983|NCT01201018|Experimental|Oshadi DR|
33302984|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
33302985|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
33302986|NCT05282368|Experimental|Intervention (PHM)|This pathway is intended to be a tool to enhance support for a mother/birthing person and her caregiving partner, facilitate communication with healthcare providers, and promote development of caregiving to optimize maternal-fetal, infant, and family health.
33302987|NCT05282368|No Intervention|Usual Care Group (UC)|The control group participants will receive care as usual.
33302988|NCT05667844|Experimental|mind-body intervention|
33302989|NCT05132920|Experimental|Experimental arm|3 x 8 mg (2 ml) dexamethasone daily for days 1-7 and 1 x 8 mg (2 ml) dexamethasone daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
33302990|NCT05132920|Placebo Comparator|Control arm|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
33302991|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
33302992|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
33302993|NCT05123482|Experimental|Sub-Study 1 AZD8205 Monotherapy|"Sub-Study 1 has two parts:~Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose(RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205.~Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors."
33302994|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
33302995|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
33302996|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
33302997|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
33302998|NCT04507594||Patients undergoing Thoracic Surgery|
33302999|NCT04498078|Experimental|Creatine|Twenty grams per day b.i.d.
33303000|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
33303001|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
33303002|NCT04484974|Experimental|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted roasted pecan nuts will be administered.
33303003|NCT04484974|Active Comparator|Tortilla chip snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted pretzels will be administered.
33303004|NCT01198444||Group 1|
33303005|NCT05670184|Experimental|LSD condition|60 participants will receive LSD.
33303006|NCT05670184|Placebo Comparator|Ethanol condition|60 participants will receive placebo.
33303007|NCT05084248|Active Comparator|Low-dose|400 IU Per Orem
33303008|NCT05084248|Experimental|High-dose|4000 IU Per Orem
33303009|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
33303010|NCT04469452||Healthy Adults (19-99yrs)|Healthy adults already enrolled in separate studies using indirect calorimetry to measure RMR within our lab will be recruited for this study. Fifty participants (25 male, 25 female) will be heterogeneous in age, body composition, and physical activity based on the inclusion and exclusion of their respective studies. To test reliability, 25 of the 50 participants will repeat RMR measurements within 1 week of initial measurements.
33303011|NCT04467814|Experimental|Intervention|
33303012|NCT04467814|Active Comparator|Usual Care|
33089343|NCT05458518|Active Comparator|Dressing removal at 24 hours|The wound dressing will be removed 24 hours after emergency cesarean delivery
33089344|NCT05458518|Placebo Comparator|Dressing removal at 48 hours|The wound dressing will be removed 48 hours after emergency cesarean delivery
33089345|NCT00298220|Active Comparator|training|tailored multi-component implementation program
33089346|NCT00298220|No Intervention|control|
33303013|NCT04429516|Experimental|Morphine Sulfate|
33303014|NCT04429516|Placebo Comparator|Placebo|
33303015|NCT01201096||peptide radioreceptor therapy and liver transplantation|
33303016|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
33303017|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
33303018|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
33303019|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
33303020|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
33303021|NCT04415788|Experimental|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
33303022|NCT04415788|Experimental|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
33303023|NCT04415788|Sham Comparator|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
33303024|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
33303025|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
33303026|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
33303027|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
33303028|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
33303029|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
33303030|NCT05033782||MS patients|"This group includes patients living in Ile de France, followed in the neurology department of the Pitié Salpêtrière Hospital in Paris for relapsing-remitting MS.~Clinical examination will be performed to evaluate the disability (EDSS scale), as part of the care (systematic for all MS consultations)~- A paper questionnaire is given to the patient during the consultation. The patient will be contacted by telephone within 15 days after the consultation by a health care staff to collect the answers to the questionnaire."
33303031|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
33303032|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
33303033|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
33303034|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
33303035|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
33303036|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
33303037|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
33303038|NCT03842644|No Intervention|Control|No tension reduction
33303039|NCT01201408||Dental Caries assessment|
33303040|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
33303041|NCT01201564|Active Comparator|sublay mesh repair|
33089347|NCT05458089||tuberculous pericarditis with 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting 18F-FDG uptake
33089348|NCT05458089||tuberculous pericarditis without 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting no 18F-FDG uptake
33089349|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
33089350|NCT00298259|No Intervention|conservative management|current standard conservative management
33089351|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
33089352|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
33089353|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
33089354|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
33089355|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
33089356|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
33404239|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
33089357|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
33089358|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
33089359|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
33089360|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
33089361|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
33089362|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
33089363|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
33089364|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
33089365|NCT00298415|Active Comparator|A|Chemotherapy (mono)
33089366|NCT00298415|Experimental|B|Chemotherapy (doublet)
33089367|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
33089368|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
33089369|NCT04708392|Experimental|Tonic spinal cord stimulation|Patients are programmed with tonic (continuous) spinal cord stimulation for a period of four weeks.
33089370|NCT04708392|Experimental|Burst spinal cord stimulation|Patients are programmed with burst (intermittent) spinal cord stimulation for a period of four weeks.
33089371|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
33089372|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
33089373|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
33089374|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
33089375|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
33089376|NCT05457894|Experimental|Flu-M, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with the Flu-M vaccine.
33089377|NCT05457894|Active Comparator|Ultrix®, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with Ultrix®.
33089378|NCT05457894|Experimental|Flu-M, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), will be immunized once with the Flu-M vaccine.
33089379|NCT05457894|Active Comparator|Ultrix®, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), immunized once with Ultrix®.
33089380|NCT03448653|Experimental|Colonoscopy with NBI|
33089381|NCT03439839|Experimental|Arm 1|10 patients receiving LNP023 high dose daily over up to approximately 3 years
33089382|NCT03439839|Experimental|Arm 2|5 patients receiving LNP023 low dose daily over up to approximately 3 years
33089383|NCT05457777|Experimental|Motivational interview group|Motivational interviews will be held to the participants with digital game addiction in this group.
32797187|NCT04687358||Active RP|Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).
32797188|NCT04687358||Inactive RP|Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.
32797189|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
32797190|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
32797191|NCT04592289|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
32797192|NCT04592289|Active Comparator|Mechanical bowel preparation only|"Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
32797193|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
32797194|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
32797195|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
32797196|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
32797197|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
32797198|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
33404240|NCT04210180|Experimental|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
33404241|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
32797199|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
32797200|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
32797201|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
32797202|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
32797203|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
32797204|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
32797205|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
33089384|NCT05457777|No Intervention|Control group|This group will be control group and any motivational interviews will not be held to the participants with digital game addiction in this group.
33089385|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
33089386|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
33089387|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
33089388|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
33089389|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
33089390|NCT05457738|Experimental|patients randomized to using the smartphone app|
33089391|NCT05457738|Active Comparator|patients randomized to not using the smartphone app|
33089392|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
32940554|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
33303042|NCT05018104||Lower Limb Orthopedic Surgery Patients who Received Popliteal Sciatic Nerve Blocks|All patients undergoing lower limb surgery who received popliteal sciatic nerve blocks (with or without other peripheral nerve blocks) at St. Paul's Hospital from January 4, 2016 to November 1, 2019
33303043|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
32940555|NCT03690206|Experimental|Glepaglutide SC injections twice weekly|Intervention: Glepaglutide
33303044|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
33303045|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
32940556|NCT03690206|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|Intervention: Glepaglutide
32940557|NCT03690206|Placebo Comparator|Placebo SC injections twice weekly|Intervention: Placebo
32940558|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
32940559|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
32940560|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
32940561|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
32940562|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
32940563|NCT00383630|Other|Group 3|LVAD alone
32940564|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
32940565|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
32940566|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
32940567|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
32940568|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
32940569|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
32940570|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
32940571|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
32940572|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
32940573|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
32940574|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
32940575|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
32940576|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
32940577|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
32940578|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
32940579|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
32940580|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
32940581|NCT03198416|Experimental|Investigational Device|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) with the Solar GI High Resolution pharyngeal Manometry system.
33303046|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
33303047|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
33303048|NCT01198912|Placebo Comparator|placebo|
33303049|NCT01198912|Experimental|doxycycline 100 mg|
33303050|NCT04316572|Experimental|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
33089393|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
33303051|NCT04316572|No Intervention|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
33303052|NCT04300894|No Intervention|Usual care group|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
33303053|NCT04300894|Experimental|Mamma Mia group|"Usual prenatal/postpartum care plus use of the Mamma Mia program"
33303054|NCT04300894|Experimental|Mamma Mia Plus group|"Usual prenatal/postpartum care plus use of the Mamma Mia program plus occasional contacts from study staff"
33303055|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
33303056|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
32797206|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
32797207|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
32797208|NCT04675580|Experimental|Tele Toy Talk|Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.
32797209|NCT04675580|No Intervention|Multiple Baseline|Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).
32797210|NCT04675190||Case|Cases will be patients in the department of surgery above 18 years with ultrasound findings of gall stone disease.
32797211|NCT04675190||Control|Controls will be patients in the department of surgery above 18 years with ultrasound findings showing evidence of no gallstones
32797212|NCT04674800|Experimental|Single, test arm|MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval
32797213|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
32797214|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
32797215|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
32797216|NCT01805037|Experimental|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
32797217|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
32797218|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
32797219|NCT02030834|Experimental|Cohort A|murine CART19
32797220|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
32797221|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
32797222|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
32797223|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
32797224|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
32797225|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
32797226|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
32797227|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
32797228|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
32797229|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
32797230|NCT01802775|Experimental|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
32797231|NCT01802775|Active Comparator|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
32797232|NCT04591041|Experimental|Training by Mixed Reality Simulation|
32797233|NCT04591041|Active Comparator|Training by Mannequin Based Simulation|
32797234|NCT01802385|No Intervention|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) + placebo
32797235|NCT01802385|Experimental|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
32797236|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
32907057|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
32907058|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
33089394|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
33089395|NCT00299039|Active Comparator|1|
33089396|NCT00299039|Active Comparator|2|
33089397|NCT05457621|Experimental|Effaclar serum|Participants are asked to apply Effaclar serum once daily in the evening on the whole face avoiding contact with eyes for 2 months.
33089398|NCT00299234|Placebo Comparator|2|placebo
33089399|NCT00299234|Experimental|1|atomoxetine
33089400|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
33089401|NCT05457543||Adult|A venous blood and capillary blood collection is taken from each participant and tested with investigative diagnostic tests.
33089402|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
33089403|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
33089404|NCT00299390|Experimental|Sagopilone|
33089405|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
33089406|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
33089407|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
33089408|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
33089409|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
33089410|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
33089411|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
33089412|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
33089413|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
33089414|NCT05457348|Experimental|Group A:experimental group|those who receive planned incisions
33089415|NCT05457348|Active Comparator|Group B:Controlled group|the patients who were operated by conventional phacoemulsification
33089416|NCT00299819|Active Comparator|1|MEDI-545
33089417|NCT00299819|Active Comparator|2|MEDI-545
33089418|NCT00299819|Active Comparator|3|MEDI-545
33089419|NCT00299819|Active Comparator|4|MEDI-545
33089420|NCT00299819|Active Comparator|5|MEDI-545
33089421|NCT04716660||Women receiving epidural analgesia for labor|
33089422|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
33089423|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
33089424|NCT05455944|Active Comparator|Pregabalin Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
33089425|NCT05455944|Placebo Comparator|Control Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
33089426|NCT02348112||Altis Sling|Subjects will have an Altis sling placed to treat stress urinary incontinence.
33089427|NCT02348112||Transobturator or Retropubic Sling|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
33089428|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
33089429|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
33089430|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
33089431|NCT05455632||Group1:PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy, surgery, and postoperative radiotherapy.
33089432|NCT05455632||Group2:non-PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy and surgery, without postoperative radiotherapy
33089433|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
33089434|NCT01820910|Experimental|Doxycycline|
33089435|NCT01785459|Active Comparator|standard care|intravenous Prochlorperazine
33089436|NCT01785459|Experimental|treatment|0.5% bupivacaine
33089437|NCT04716894|Experimental|BI 474121 alone|
33089438|NCT04716894|Experimental|BI 474121 + itraconazole|
33089439|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
33089440|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
33089441|NCT05451732|Experimental|Nanofat grafting|Nanofat grafting with tissue transfer by injection in the urethral stricture
33089442|NCT05451654|Placebo Comparator|Placebo + SoC (N=30)|"This arm is composed by 30 patients.~Placebo: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Standard of care"
33303057|NCT04256824|Experimental|Coated Polyglactin 910 with Triclosan|Coated vicryl plus
33303058|NCT04256824|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated vicryl
33303059|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
33303060|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
33303061|NCT03864562||White European|Healthy individuals of white European descent
33303062|NCT01202500|Other|12 months|
33303063|NCT01202500|Experimental|3 months|
33089443|NCT05451654|Experimental|NanoManganese® + SoC (N=90)|"This arm is composed by 90 patients.~NanoManganese® + standard of care group:~NanoManganese®: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Standard of care"
32940582|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
32940583|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
32940584|NCT00244010|Other|1|
33089444|NCT01539447|Active Comparator|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
33089445|NCT01539447|Placebo Comparator|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
33303064|NCT04223050|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94%
33404242|NCT04031820|Active Comparator|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
33303065|NCT04223050|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
32940585|NCT03684265|Experimental|Test to Reference|
32940586|NCT03684265|Experimental|Reference to Test|
32940587|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
32940588|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
32940589|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
32940590|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
32940591|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
33089446|NCT05400564|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU app and telehealth coaching/ support provided by a trained mental health provider. The FCU app includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
33089447|NCT05400564|No Intervention|Control|Parents in this arm will receive school support as usual.
33089448|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
33089449|NCT04718051|Experimental|Shen Pu Yang Gan Wan|Traditional Chinese Medicine
33089450|NCT04718051|Placebo Comparator|Placebo Comparator|Placebo Comparator
33089451|NCT04717167|Experimental|DN group|All identified MTrPs were inserted with a sterile filiform needle (0,30mm x 40mm or 0,30mm x 75mm, depending on the muscle) that moved up- and downwards until a local twitch response was elicited. When the repeated local twitch response fade away or the subject reported too much pain, the needle was removed. After the treatment, a 15 minutes break(51) was set up and the subjects were not permitted to use a hot pack or to stretch the muscle.
33089452|NCT04717167|Sham Comparator|Sham needling (SN) group|The SN technique was similar to DN, except for penetrating the muscle. In this technique, the needle only penetrated the skin and was therefore impossible to provoke a local twitch response.
33089453|NCT05373303|Experimental|Test Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
33089454|NCT05373303|Active Comparator|Reference Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
33089455|NCT00327600|Experimental|imexon + DTIC|
33089456|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
33089457|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
33089458|NCT00300950|Active Comparator|1|Gencitabine
33089459|NCT00300950|Experimental|2|Gemcitabine with GI-4000
33303066|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
33303067|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
33303068|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
33303069|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
33303070|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
33303071|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
33303072|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
33303073|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
32940592|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
33303074|NCT05004064|Experimental|Acalabrutinib and rituximab|Patients with untreated mantle cell lymphoma will receive acalabrutinib and rituximab for up to six cycles. Each cycle will comprise of acalabrutinib 100mg twice daily orally for 28 days and rituximab 375mg/m2 IV on day 1 (+/1 3 days) of every cycle.
33303075|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
33303076|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
33303077|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
33303078|NCT04982692|Experimental|Intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
33303079|NCT04982692|Placebo Comparator|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
33303080|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
33303081|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
33303082|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
33303083|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
32940593|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
32940594|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
33303084|NCT04971148|Active Comparator|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level that matches patient peak tidal inspiratory flow
33303085|NCT04971148|Experimental|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
33303086|NCT04971148|Experimental|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
33303087|NCT04971148|Experimental|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
33303088|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs first for up to 3 years.
33303089|NCT03037684||chronic pain|individuals suffering from chronic pain
32940595|NCT05314699|Experimental|resistance-aerobic exercise group, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
33303090|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
33303091|NCT01202812|Experimental|LOVAZA|
33303092|NCT01202812|Placebo Comparator|Placebo capsule|
32940596|NCT05314699|Experimental|aerobic-resistance exercise group, AR|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
32940597|NCT05314699|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
32940598|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
32940599|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
32940600|NCT00233090|Placebo Comparator|Placebo|
32940601|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
33303093|NCT04948918|Experimental|Distal renal denervation|The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.
33303094|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
33303095|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
33303096|NCT01203748|Experimental|PVI + Lines Ablation|
33303097|NCT01203748|Active Comparator|PVI Ablation|
33303098|NCT01203748|Experimental|PVI + CFE|
33303099|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
33404243|NCT04031820|Active Comparator|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
33404244|NCT04017390|Experimental|Arm 1: Theraworx Foam alone|Theraworx foam only
33303100|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
33303101|NCT01203904||Pulmicort|
33303102|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
32940602|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
32940603|NCT05182502|Experimental|Tixel treatment arm|subjects will receive 3 monthly treatments with the Tixel device
33303103|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
33303104|NCT04938154|Experimental|DBS On|
33303105|NCT04938154|Sham Comparator|DBS Off|
33303106|NCT01204060|Active Comparator|Nasal allergen challenge|
32940604|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
32940605|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
33303107|NCT01204060|Placebo Comparator|Nasal placebo challenge|
33303108|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
33303109|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
33303110|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
33303111|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
33303112|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
33303113|NCT01199224|Experimental|Arm A|
33303114|NCT01199224|Experimental|Arm B|
33303115|NCT01199224|Experimental|Arm C|
32940606|NCT04247581|Other|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
32940607|NCT04247581|Other|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
33303116|NCT01199224|Experimental|Arm D|
33303117|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
33303118|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
33303119|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
33303120|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
33303121|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
33303122|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:~st: 10 Days after patients received radical resection.~nd: When patients finished the chemotherapy or target drug delivery two cycles.~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
33303123|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
33303124|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
33303125|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Repeat until the end of the surgical procedure"
33303126|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
33303127|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
33303128|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
33303129|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
33303130|NCT05668078|Experimental|School-type 1, intervention school-1|We will test all symptomatic students, teachers, and support staff ; and track students symptoms and absenteeism
33303131|NCT05668078|Experimental|School-type 2, intervention school-2|We will test all students, teachers, and support staff every 3 days, irrespective of symptoms (also test whenever develops symptoms) and track students symptoms and absenteeism
33303132|NCT05668078|Experimental|In School-type 3, control school|We will not do any test, only track the students for symptom notification and absenteeism
33303133|NCT01206088|Experimental|nilotinib|
33303134|NCT05281900|Experimental|Physically active volunteers|All volunteers who meet the inclusion criteria will be included in the study.
33303135|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
33303136|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
33303137|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
33303138|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
33303139|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
33303140|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-23 years
33303141|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-23 years
33303142|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-23 years
33303143|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
33303144|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
33303145|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
33303146|NCT02671240||- Patients with behavioral addiction|
33303147|NCT02671240||- Patients with no behavioral addiction|
33303148|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
33303151|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
33303152|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
33303153|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
33303154|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
33303155|NCT02605486|Experimental|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
33303156|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
33303157|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
33303158|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
33303159|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
33303160|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
33303161|NCT01204528|Placebo Comparator|Placebo|
33303162|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
33303163|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
33303164|NCT02178046||Gingivitis|optical measurements
33303165|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
33303166|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
33303167|NCT01566994|Experimental|TTM Tailored|
33303168|NCT01566994|Experimental|Motivational Enhancement Therapy|
33089460|NCT05372601|Experimental|Relax+|Relax+ consists of a powder containing a blend of two prebiotics.
33303169|NCT01566994|Experimental|Integrated Treatment|
33303170|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
33303171|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
33303172|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
33303173|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
33303174|NCT01203124|Experimental|5|Active treatment once daily on 7 days
33303175|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
33303176|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
33303177|NCT05281822|Experimental|Experimental group|The BMI (kg/m2) was calculated by measuring the height and weight of the women in the experimental groups. Then, the women in the experimental group were provided with stress management training to help cope with stress conditions, how to use positive coping in conditions in case of stress and tension. In terms of the reliability of the training, each woman was interviewed face-to-face, which lasted for 30-40 minutes.
33303178|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
33303179|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
33303180|NCT01203202|Placebo Comparator|PED 0|placebo
33303181|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
33303182|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
33303183|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
33303184|NCT03829384|Placebo Comparator|Placebo|Saline
33303185|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
33303186|NCT02047474|Experimental|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33303187|NCT01204606|Experimental|MMA group|
33303188|NCT01204606|Placebo Comparator|Control group|
32940608|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
33303189|NCT01206244||Normal|Normal subjects
33303190|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
33303191|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
33303192|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
33303193|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
32940609|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
32940610|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
32940611|NCT04243369|Other|Experimental - Collaboration Live software|
32940612|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
32940613|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
32940614|NCT02741180|Other|Patients with Arrhythmias|
32940615|NCT02741180|Other|Healthy Control|
32940616|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
32940617|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
32940618|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
32940619|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
32940620|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
32940621|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
32940622|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
32940623|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
32940624|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
32940625|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
32940626|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
32940627|NCT05177900|Active Comparator|Biphasic pulse without interphase gap|
32940628|NCT05177900|Experimental|Biphasic pulse with interphase gap|
32940629|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
32940630|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
32940631|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
32940632|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
32940633|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
32940634|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
32940635|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
32940636|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
33303194|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
32940637|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
32940638|NCT03879044|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
32940639|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
32940640|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
33303195|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
32940641|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
32940642|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
32940643|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
32940644|NCT04298918|Experimental|Dose Escalation Phase|Participants received venetoclax in combination with a fixed dose of trastuzumab emtansine.
32940645|NCT04298918|Experimental|Dose Expansion Phase|Participants were to receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
33303196|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~<EVL\GVS Combined Propranolol>"
33303197|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
32940646|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants were to receive trastuzumab emtansine + placebo.
32940647|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants were to receive trastuzumab emtansine + venetoclax.
32940648|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
32940649|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
32940650|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
32940651|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
32940652|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
33303198|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
33303199|NCT05281432||Pes planus individuals|The aim of this study was to evaluate the static and dynamic balance status of male individuals diagnosed with pes planus.
33303200|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
32940653|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
32940654|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
32940655|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
33303201|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
33303202|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
33303203|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
32940656|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
33303204|NCT05669560|No Intervention|Control group|Will receive SRP alone.
33303205|NCT05669560|Experimental|Test group|Will receive SRP + PerioProtect ™.
33303206|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
33303207|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
33303208|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
33303209|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
33303210|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
33303211|NCT03840070|Experimental|Potenfill|
33303212|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
33303213|NCT03312010|Experimental|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
33303214|NCT03312010|Sham Comparator|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
33303215|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
33303216|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
33303217|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
33303218|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
33303219|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
33303220|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
33303221|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
33303222|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
33303223|NCT01169194||Affected|Patients with IBD
33303224|NCT01169194||Unaffected|Individuals who do not have IBD
33303225|NCT00842764|Experimental|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
33303226|NCT05668000|Experimental|AIDA/KT-app with devices|AIDA/KT-app with devices : with device link and with feedback
33303227|NCT05668000|Placebo Comparator|AIDA/KT-app only|AIDA/KT-app only : no device link or no feedback
33303228|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
33303229|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
33303230|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
33303231|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
33404245|NCT04017390|Active Comparator|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
32940657|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
33303232|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
32940658|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~Newly diagnosed primary PD patients, diagnosed within 3-6 months;~informed consent to the study;~age > 18 older."
33303233|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
33303234|NCT01205074|Experimental|Repeatability|
33303235|NCT01205074|Experimental|COPD|
33303236|NCT01205074|Experimental|Smokers|
33303237|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
33303238|NCT01205074|Experimental|Cirrhosis Beta Blockers|
33303239|NCT01205074|Experimental|Alcohol|
33089461|NCT05372601|Placebo Comparator|Placebo|The placebo contains maltodextrin.
33303240|NCT05667376|Other|Study group|Study group treated with curcumin gel
33303241|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
33303242|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
33303243|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
33303244|NCT05667220|Active Comparator|Sitagliptin monotherapy group (Group A)|
33303245|NCT05667220|Experimental|Sitagliptin combined with Beidougen capsule treatment group (Group B)|
33303246|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
33303247|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
33303248|NCT01298830|Experimental|GLP-1 CellBeads|
33303249|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
33303250|NCT05281276|Experimental|chidamide (20 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (20 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
33303251|NCT05281276|Experimental|chidamide(30 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (30 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
33303252|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
33303253|NCT05669326|Experimental|NODDI TRACT|"Diffusion MRI (tractography) Tractography is performed on the basis of a diffusion MRI sequence which, after computer processing, will result in a map of the apparent diffusion coefficient and a diffusion tensor beam reconstruction (DTI tractography) performed with the Sisyphus software.~Multi-shell diffusion MRI (NODDI-tract)"
33303254|NCT01297582|Experimental|E|
33303255|NCT01297582|Placebo Comparator|P|
33303256|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
33303257|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
33303258|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
33303259|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
33303260|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
33303261|NCT01205386||CROSSER|
33303262|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
33303263|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
33303264|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
33303265|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
33303266|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
33303267|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
33303268|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
33303269|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
33303270|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
33303271|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
33303272|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
33404246|NCT04017390|Placebo Comparator|Arm 3: Placebo foam alone|Placebo foam alone
33404247|NCT04017390|Other|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
32940659|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
32940660|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
32940661|NCT00000884|Experimental|2|Participants will undergo treatment orally
32940662|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
32940663|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
32940664|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
32940665|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
32940666|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
32940667|NCT04331600|Experimental|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
32940668|NCT04331600|Other|CONTROL GROUP|Standard of care + telemedical approach.
32940669|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
32940670|NCT03844321|Experimental|Brief Mindfulness|3 sessions of online mindfulness therapy
32940671|NCT04331678|No Intervention|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
32940672|NCT04331678|Active Comparator|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
32940673|NCT04207333|Experimental|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
32940674|NCT04207333|Experimental|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
32940675|NCT05440682|Experimental|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI
32940676|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
32940677|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
32940678|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
32940679|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
32940680|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
32940681|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
32940682|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
32940683|NCT00000254|Sham Comparator|0% isoflurane|
32940684|NCT00000254|Active Comparator|0.2% isoflurane|
32940685|NCT00000254|Active Comparator|0.4% isoflurane|
32940686|NCT00000254|Active Comparator|0.6% isoflurane|
32940687|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
32940688|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
32940689|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
33303273|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
33303274|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
33303275|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
33303276|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
33303277|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
33303278|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
32940690|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
32940691|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
33303279|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
33303280|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
33303281|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
33303282|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
33303283|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
33303284|NCT05099536|Experimental|3D011-08|
33303285|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
33303286|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
33303287|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
33303288|NCT03830554|No Intervention|control group|participants of this group received no intervention.
33303289|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
32940692|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
32940693|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
32940694|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
32940695|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
32940696|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
33303290|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
33303291|NCT01205932|Experimental|Arm 1|
33303292|NCT01205932|Experimental|Arm 2|
32940697|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
32940698|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
32940699|NCT03748771|Experimental|ApneaLink Air|Half of the participants will undergo HST no greater than one week prior to their in-laboratory PSG, while the other half will undergo HST no greater than one week following their in laboratory PSG. All participants will also undergo their HST concurrent to their in-laboratory PSG. The rational for splitting participants in these two groups is to equally distribute the effects of the first night evenly, in which the sleep architecture including reduced total rapid eye movement (REM) sleep time can vary during the first ever sleep study. As the HST will be compared to the in-lab PSG, we would like to evenly distribute this effect by having two groups of ten participants.
32940700|NCT05228912||BNT162b2 mRNA|Group of patients of any age, any sex, that will receive a complete scheme of approved BNT162b2 mRNA vaccination , assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940701|NCT05228912||mRNA-1273|Group of patients of any age, any sex, that will receive a complete scheme of approved mRNA-1273 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940702|NCT05228912||ChAdOx1-S|Group of patients of any age, any sex, that will receive a complete scheme of approved ChAdOx1-S vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940703|NCT05228912||Ad26.COV2|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad26.COV2 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940704|NCT05228912||Ad5-nCoV|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad5-nCoV vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940705|NCT05228912||Gam-COVID-Vac|Group of patients of any age, any sex, that will receive a complete scheme of approved Gam-COVID-Vac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940706|NCT05228912||Coronavac|Group of patients of any age, any sex, that will receive a complete scheme of approved Coronavac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
32940707|NCT03836989|Experimental|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
32940708|NCT03836989|Placebo Comparator|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
32940709|NCT04942106|Other|Side-lying position followed by Supine position|In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position.
32940710|NCT04942106|Other|Supine position followed by Side-lying position|In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position.
32940711|NCT04888988|Experimental|Arm 1 (EXCAP exercise)|Patients undergo the EXCAP exercise intervention consisting of a home-based, self-directed, individually tailored progressive walking and resistance program for up to 6 weeks. In addition, patients meet with a certified exercise instructor over 45 minutes at baseline and 2 additional booster meetings over 15-30 minutes during weeks 2 and 3 or weeks 4 and 5.
32940712|NCT04888988|No Intervention|Arm 2 (usual care)|Patients receive usual care for 6 weeks. At the end of the study, patients may receive the exercise kit and complete the EXCAP program as in Arm 1.
32940713|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
32940714|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
32940715|NCT04816526|Experimental|Descartes 08|
32940716|NCT05220956|Other|Intermittent fasting|This arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks.
32940717|NCT05220956|Other|DGE diet|This control arm is not a subject to any time restrictions concerning eating, solely patients will be trained according to the 10 rules of healthy nutrition of the DGE.
32940718|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
33303293|NCT01205932|Experimental|Arm 3|
33303294|NCT01205932|Active Comparator|Arm 4|
33303295|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
33303296|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
33303297|NCT01297816|Placebo Comparator|placebo|100mg-
32940719|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
32940720|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
32940721|NCT05218148|Experimental|Group A|Group A: SOX regimen (oxaliplatin + Seggio) ) + sintilimab + trastuzumab; 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
33303298|NCT01297816|Placebo Comparator|minocyclin|
33303299|NCT01206634|Experimental|Regenerative injection therapy|
32940722|NCT05218148|Active Comparator|Group B|Group B: SOX regimen, 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
32940723|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
33303300|NCT01206634|Active Comparator|Exercise|
33303301|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
33303302|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
33303303|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
33303304|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
33303305|NCT01298908|Other|Operative treatment|vein stripping
33303306|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
33303307|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
33303308|NCT05666362|Active Comparator|Group 1 : ( benoxinate hydrochloride 0.4% group )|They will receive benoxinate hydrochloride 0.4% immediately before fundus examination .
33303309|NCT05666362|Placebo Comparator|Group 2 : ( control group )|They will receive saline drops instead of benoxinate hydrochloride 0.4%. Randomization: simple randomization sampling using sealed envelope technique.
33303310|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
33303311|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
33303312|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
33303313|NCT05621824||Solid mass|Patients with solid mass of pancreas during pancreas MR examination.
33303314|NCT05621824||Cystic lesions|Patients with cystic lesions or expansion of MPD during pancreas MR examination.
33303315|NCT05621824||No clear focus|Patients with no clear focus during pancreas MR examination.
32940724|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
32940725|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
32940726|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
32940727|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
32940728|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
32940729|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
32940730|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
32940731|NCT00001964|Experimental|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
33303316|NCT05665582||Affected family members of patients with Substance use disorders|The family sample was recruited from at a Norwegian addiction treatment unit where close relatives of patients in treatment for SUD participated in a family program.
33303317|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
33303318|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
33303319|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
33303320|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
33303321|NCT05665114|Experimental|QN-030a|QN-030a in Adult subjects with r/r AML
33303322|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
33303323|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
33303324|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
33303325|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
33303326|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
32940732|NCT00001964|Experimental|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
32940733|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
32940734|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
32940735|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
32940736|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
32940737|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
32940738|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
32940739|NCT00000308|Experimental|3|placebo
32940740|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
32940741|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
32940742|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
32940743|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
32940744|NCT03978403|Experimental|ABDC|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
32940745|NCT03978403|Experimental|BCAD|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
32940746|NCT03978403|Experimental|CDBA|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
32940747|NCT03978403|Experimental|DACB|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
32940748|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
32940749|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
32940750|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
32940751|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
32940752|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
32940753|NCT00380276|Other|Open Label Arm|Treatment is open-label
32940754|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
32940755|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
32940756|NCT03799783|Experimental|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
32940757|NCT04713566|Experimental|Group A|will be using Salvadora Persica oral rinse
32940758|NCT04713566|Experimental|Group B|will be using Commercial Phenolic mouthwash.
33089462|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
33404248|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
33404249|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
32940759|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
32940760|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
32940761|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
32940762|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
32940763|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
32940764|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
32940765|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
33089463|NCT05366946||COPD - prevalence|Diagnosed with COPD (based on GOLD criteria and history of > 10 pack years of smoking) and no history of recent musculoskeletal injuries (within last 4 weeks) - prevalence study
33089464|NCT05366946||Healthy controls - prevalence|Not diagnosed with COPD or other respiratory conditions or recent musculoskeletal injuries (within last 4 weeks) - prevalence study
33089465|NCT05320302|Experimental|[11C]-Lu AF88370|Participants will receive [11C]-Lu AF88370 via an intravenous cannula on Day 1.
33089466|NCT04717206|Experimental|Plyomtric training to male badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to male badminton players.
33089467|NCT04717206|Experimental|Plyomtric training to female badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to female badminton players.
33089468|NCT05318625|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
33089469|NCT00301535|Experimental|1|
33089470|NCT00301535|No Intervention|2|
33089471|NCT00301613|Active Comparator|Mycophenolate mofetil|
33089472|NCT00327873|Experimental|A|Oxygen
33089473|NCT00327873|Active Comparator|B|Medical Air
33089474|NCT00301652|Experimental|mycophenolate mofetil|
33089475|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
33089476|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
33089477|NCT05252871|Experimental|Experimental: The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
33089478|NCT05252871|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
33089479|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
33089480|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33089481|NCT00301886|Experimental|zoledronate|zoledronate
33089482|NCT00301886|Experimental|ibandronate|ibandronate
33089483|NCT05238831|Experimental|Treatment (SMMART-ACT)|"PRE-SCREENING: Patients undergo a screening biopsy and blood collection to assess their tumor. Clinical assays may be used to provide an individualized treatment which may or may not include a SMMART-ACT treatment regimen.~SMMART-ACT TREATMENT: Prior to enrollment, patients must receive a recommendation of one or more SMMART-ACT treatment regimens based on the SMMART-CAP clinical assays. Treatment may be administered alone or as part of a combination. For specific treatment recommendations, a monotherapy lead-in may be considered for up to 4 weeks which proceeds to a combination therapy. After about 2 weeks of single agent, participants undergo an on-study tumor biopsy. All other patients have the option to undergo a repeat biopsy during treatment. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are based on the study agent(s). At disease progression, patients have the option to undergo an additional biopsy."
33089484|NCT00301925|Active Comparator|Epi-CMF|
33089485|NCT00301925|Experimental|Accelerated Epi-CMF|
33089486|NCT00301925|Experimental|Epi-Capecitabine|
33089487|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
33089488|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
33089489|NCT05234775|Experimental|LIB003 (lerodalcibep) Process 1|300 mg LIB003 Process 1 drug product administered SC
33089490|NCT05234775|Active Comparator|LIB003 (lerodalcibep) Process 2|300 mg LIB003 Process 2 drug product administered SC
33089491|NCT05231889|Placebo Comparator|Below the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located below the shoulder
33089492|NCT05231889|Active Comparator|Above the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located above the shoulder
33089493|NCT05194917|Experimental|OSMI|
33089494|NCT05194917|Active Comparator|Control Motivational Message|
33089495|NCT05194917|No Intervention|Control Treatment as Usual|
33404250|NCT03980730|Experimental|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
32797237|NCT01802073|Experimental|Oral Vancomycin|1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
32797238|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
32797239|NCT01773291|Experimental|acupuncture|acupuncture on GV26 and 12 Well points
32797240|NCT01773291|Experimental|laser acupuncture|laser acupuncture on GV26 and 12 Well points
32797241|NCT01773291|Sham Comparator|control group|laser acupuncture without laser output in control group.
32797242|NCT01801917|Placebo Comparator|Placebo|5 placebo tablets daily during non-titration phase
32797243|NCT01801917|Experimental|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
32797244|NCT01801917|Experimental|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
32797245|NCT04170075|No Intervention|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
32797246|NCT04170075|Experimental|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
33303327|NCT01206790|No Intervention|Waitinglist Control Group|
33303328|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
33404251|NCT03980730|Placebo Comparator|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
32797247|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
32797248|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
32797249|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
32797250|NCT01772823|Experimental|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
32797251|NCT01772823|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
32797252|NCT04177082|Experimental|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
32797253|NCT04177082|Experimental|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
32797254|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
32797255|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
32797256|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
32797257|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
32797258|NCT04177004|Experimental|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
32797259|NCT04177004|Active Comparator|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
32907059|NCT01045460|Experimental|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
33303329|NCT05619874|Experimental|HIFCT-S|For sessions 7 to 14, a concentrated circuit divided into four blocks of three exercises will be carried out, with a duration of 40 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest. For sessions 15 to 30, four blocks of two exercises will be performed, with a duration of 60 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. Two sets will be performed, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE).
33303330|NCT05619874|Active Comparator|HIFCT-P|"For sessions 7 to 14, a concentrated circuit divided into two blocks of six exercises will be carried out, with a duration of 60 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest.~For sessions 15 to 30, five blocks of two exercises will be performed, with a duration of 120 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. The total time per block is four minutes, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE)."
33303331|NCT05619796|Experimental|group 1: Kedo-S Square rotary files|Primary root canals(n=20) were instrumented using rotary P1 Kedo-S Square files (Reeganz Dental Care Pvt. Ltd. India) at 300 rpm and 2.2N cm torque. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
33303332|NCT05619796|Experimental|group II: Fanta AFTM-Baby rotary system|Primary root canals(n=20) were instrumented using Fanta AFTM-Baby rotary system (Shanghai Fanta Dental Materials, SUNGO Certification Company Limited, London, England) at 350 rpm and 2 N cm torque. Four files were used sequentially in the following order; open file #17/0.08, #20/0.04 yellow, #25/0.04 red and #30/0.04 blue. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
33303333|NCT05619796|Active Comparator|group III: manual K-files|Primary root canals(n=20) were instrumented using No.15 till 35 size manual K-files (Mani, Inc, Japan) using the quarter-turn-pull technique.
33303334|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
33303335|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
33303336|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
33303337|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
33303338|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
33303339|NCT01299064||Buddhist Clergy and Laypersons|
33303340|NCT05345002|Experimental|Arm A (failed prior TMZ + one other alkylating chemotherapy)|Subjects in Arm A are alkylator-refractory and at high risk for progression of disease, have failed temozolmide and another alkylating agent. Subjects in Arm A will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
33303341|NCT05345002|Experimental|Arm B (failed only one prior alkylating chemotherapy)|Subject in Arm B are patients who have failed only one prior alkylating chemotherapy regimen and have gone at least 12 months since the last treatment. Subjects in Arm B will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
33303342|NCT05345002|Experimental|Arm C (surgical arm, ATRA alone pre-operatively)|Subject in Arm C will receive ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery, then undergo surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
33303343|NCT05345002|Experimental|Arm D (surgical arm, ATRA + retifanlimab pre-operatively)|Subject in Arm D will receive the combination of ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery plus a 500mg IV dose of retifanlimab 14 days prior to the date of surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
33303344|NCT05618704|Experimental|Hydrolyzed protein infant formula|All subjects will take the hydrolyzed protein infant formula
33303345|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
33303346|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
33303347|NCT05618314|Experimental|Group A-Mild Renal Impairment|single dose AT-527
33303348|NCT05618314|Experimental|Group B-Moderate Renal Impairment|single dose AT-527
33303349|NCT05618314|Experimental|Group C-Severe Renal Impairment (optional)|single dose AT-527
33303350|NCT05618314|Experimental|Group D-End-Stage Renal Disease (optional)|single dose of AT-527 pre- and post-dialysis
33303351|NCT05618314|Experimental|Group E-Matched Healthy Subjects|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
33303352|NCT05281120|Active Comparator|mechanical intervention group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
33303353|NCT05281120|Placebo Comparator|mechanical placebo group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
33303354|NCT00146172|Experimental|Neratinib 40 mg|
33303355|NCT00146172|Experimental|Neratinib 80 mg|
33303356|NCT00146172|Experimental|Neratinib 120 mg|
33303357|NCT00146172|Experimental|Neratinib 180 mg|
33303358|NCT00146172|Experimental|Neratinib 240 mg|
33303359|NCT00146172|Experimental|Neratinib 320 mg|
33303360|NCT00146172|Experimental|Neratinib 400 mg|
33303361|NCT00146172|Experimental|Neratinib 320 mg MTD|
33089496|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
33089497|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
33303362|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
33303363|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
33303364|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
33303365|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
33303366|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
33303367|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
33303368|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
33303369|NCT05332054||Patients who received a Caribou-sponsored allogeneic CAR-T therapy|in a Caribou-sponsored clinical study or special access program
33303370|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
33303371|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
33303372|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
33303373|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
33089498|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
33089499|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
33303374|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
33303375|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
33303376|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
33303377|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
33303378|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
33303379|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
33303380|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
33303381|NCT01300936||patients with abdominal wall hernias|
33303382|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
33303383|NCT05316532||Mechanically ventilated ECCO2R group|Adult, mechanically ventilated critically ill patients with respiratory failure and incapacity to sustain lung protective ventilation
33303384|NCT05316532||Awake spontaneously breathing ECCO2R group|Awake, spontaneously breathing critically ill patients suffering from respiratory exhaustion
33303385|NCT05283928|Experimental|OsseoDensification (OD) protocol|
33303386|NCT05283928|Active Comparator|standard drilling (SD) protocol|
33303387|NCT05659030|Experimental|Experimental|It is planned to provide training on perinatal mental health to the experimental group in order to eliminate the lack of knowledge of women and to raise awareness. The pre-test will be applied during the pregnancy period before the training. These trainings, which will be held during pregnancy, consist of 3 modules. A training booklet in their preferred language (Turkish or Arabic) will be distributed to women at the end of each module. In addition, the effectiveness of the training will be evaluated at the end of each module and the knowledge deficiencies of women will be eliminated. The trainings will be carried out in the form of group training of 10-12 people, taking into account the physical conditions of the environment. A module training will be given every week and the training will be completed within three weeks. The effectiveness of the training will be evaluated in the postpartum period with the post-test.
33303388|NCT05659030|No Intervention|Control|Routine clinical care will be given to women in the control group. The pre-test will be applied during the pregnancy period and the post-test will be applied in the postpartum period. At the end of the post-test, three module training booklets will be distributed to the women in their preferred language (Turkish or Arabic). In line with their needs, the information deficiencies they request will be corrected.
33303389|NCT00145626|Experimental|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
33303390|NCT01206946|Experimental|Antenatal steroids|
33303391|NCT01206946|Placebo Comparator|Normal saline|
33303392|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
33303393|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
33303394|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
33303395|NCT03967938|Experimental|Olaparib|tablets of 300mg twice daily until disease progression
33303396|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
33303397|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.~Their CO increases >15% after passive leg raising."
32940766|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
32940767|NCT03782701|Active Comparator|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
32940768|NCT03782701|Active Comparator|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
32940769|NCT05314387||SMR TT Hybrid Glenoid without Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid without Cementless Finned Short Stem
33303398|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
33303399|NCT05617066|Active Comparator|therapy vs psychological support and usual care|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
33303400|NCT05617066|No Intervention|therapy and psychological support versus control group|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
33303401|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
33303402|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
33303403|NCT00153062|Placebo Comparator|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
33303404|NCT00153062|Placebo Comparator|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
33303405|NCT00153062|Placebo Comparator|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
33303406|NCT00153062|Placebo Comparator|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
33303407|NCT05616208|Experimental|Implantation|This is a non-randomized, single group treatment study with a single arm and is not subject or investigator masked or blinded. BioSphincters will be implanted in every study subject.
33303408|NCT05264974|Experimental|mRNA-nanoparticle (mRNA-NP) vaccine|
32940770|NCT05314387||SMR TT Hybrid Glenoid with Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid with Cementless Finned Short Stem
32940771|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
32940772|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
32940773|NCT03789175|Other|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
32940774|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
32940775|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
32940776|NCT00001214||Group 1|Patients with pancytopenia
32940777|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
32940778|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
32940779|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
32940780|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
32940781|NCT00380666|Other|PET/CT defined target|Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.
32940782|NCT04714021|Experimental|Single steep arm- CO2 insufflation|PEG will be performed by single step technique and CO2 will be insufflated during the endoscopy
32940783|NCT04714021|Active Comparator|Single steep arm- air insufflation|PEG will be performed by single step technique and air will be insufflated during the endoscopy
32940784|NCT04714021|Experimental|Pull technique arm- CO2 insufflation|PEG will be performed by pull technique and CO2 will be insufflated during the endoscopy
32940785|NCT04714021|Active Comparator|Pull technique arm- air insufflation|PEG will be performed by pull technique and air will be insufflated during the endoscopy
33303409|NCT05255380|Experimental|Mindful Activity group|Participants complete mindfulness and compassion-based practices via the study app.
33303410|NCT05255380|Sham Comparator|Mindful Awareness group|Participants monitor and report their thoughts and feelings via the study app.
33303411|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
32797260|NCT01771809|Experimental|SHP647 75 mg|Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
33089500|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
32797261|NCT01771809|Experimental|SHP647 225 mg|Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
33089501|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
33089502|NCT00328146||Observation of Sternal Re-entry|All subjects.
32797262|NCT01771731|Experimental|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
32797263|NCT01771731|Placebo Comparator|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
32797264|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
32797265|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
32797266|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
32797267|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
32797268|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)~Participants assigned to this group receive automatic text-messages.~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
33089503|NCT00302471|Experimental|1600 mg twice a day|MK0429
33089504|NCT00302471|Experimental|200 mg twice a day|MK0429
33089505|NCT00302471|Experimental|800 mg twice a day|MK0429
32797269|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
32797270|NCT04581915|Experimental|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
32797271|NCT04581915|Placebo Comparator|Control|Participants to receive placebo po 8 hourly for 5 days
32797272|NCT01769391|Experimental|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
32797273|NCT01769391|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
32797274|NCT01800903|Active Comparator|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
32797275|NCT01800903|Experimental|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
32797276|NCT01800903|Experimental|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
32797277|NCT01800903|Experimental|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
32797278|NCT01800903|Experimental|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
32797279|NCT01800903|Experimental|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
32797280|NCT04413747|Experimental|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
32797281|NCT01767987|Active Comparator|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
32797282|NCT01767987|Placebo Comparator|Placebo|Oral treatment Intervention: Drug: Placebo
33089506|NCT00302471|Experimental|400 mg twice a day|MK0429
33089507|NCT00302510|Placebo Comparator|immunoadsorption|
33089508|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
33089509|NCT00419913|Placebo Comparator|B|
33089510|NCT00302549|Active Comparator|FK506|
33303412|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
33303413|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
32940786|NCT00000512|Experimental|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
32940787|NCT00000512|Experimental|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
33303414|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
33303415|NCT00145470|Experimental|Asenapine|Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
33303416|NCT00145470|Placebo Comparator|Placebo|Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.
33303417|NCT03813706|Active Comparator|LN-prRLN dissection|
32940788|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
33303418|NCT03813706|Experimental|no LN-prRLN dissection|
33303419|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
33303420|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
32940791|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
33303421|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
33303422|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
33303423|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
33303424|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
33303425|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
33303426|NCT03813004|Experimental|Young healthy adults|
33303427|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
33303428|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
33303429|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
33303430|NCT05624086|Experimental|Exercised group|In this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
33303431|NCT05624086|No Intervention|control group|in this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will act as a control (waitlist) group that will receive no trainning
33303432|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
33303433|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
33303434|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
33303435|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
33303436|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
33303437|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
33303438|NCT03817684|Placebo Comparator|Placebo|
33303439|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
33303440|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
33303441|NCT01301326|Experimental|subthreshold laser treatment|
33303442|NCT01301326|Active Comparator|threshold laser treatment|
33303443|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
33303444|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
33303445|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
33303446|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
33303447|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
33303448|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
33303449|NCT00152516|Experimental|Levetiracetam|
33303450|NCT00145158|Experimental|Cohort 1: 8 HLA-A2-restricted peptides and CpG 7909|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, NA17.A2 and Tyrosinase.A2), mixed with CpG 7909. Patients received six sequential injections at 2-week intervals.
33303451|NCT00145158|Experimental|Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, and NA17.A2), mixed with Montanide ISA 51. Tyrosinase.A2 was administered without Montanide ISA51. Patients received six sequential injections at 2-week intervals.
33303452|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
33303453|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
33303454|NCT05161390|Experimental|LM-302 Dose Escalation at different dose levels|LM-302 Dose Escalation. 6 dose levels were pre-defined, and the initial accelerated titration followed by the i3+3 design was adopted during phase I.
33303455|NCT05161390|Experimental|LM-302(RP2D) Dose Expansion|LM-302 Dose Expansion, RP2D will be selected for dose expansion, with the aim to further evaluate the preliminary anti-tumor activity, safety and tolerability, etc.
33303456|NCT01302184|Experimental|Experimental Group|Lokomat®
33303457|NCT01302184|Active Comparator|Control Group|Treadmill training
33303458|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
33303459|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
33303460|NCT05624008|Experimental|Bioceramic glass ionomer restoration|Calcium aluminate modified glass ionomer
33303461|NCT05624008|Active Comparator|Resin modified glass ionomer restoration|type II resin modified glass ionomer cement
33303462|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
33303463|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
33303464|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
33303465|NCT05623930|Active Comparator|laser on acupuncture points|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
33303466|NCT05623930|Active Comparator|cupping (with scarification)|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
33303467|NCT05623852|Experimental|Arm A: Fucoidan arm|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
33303468|NCT05623852|No Intervention|Arm B, Observational arm|observation
33303469|NCT05154058|Active Comparator|Control: electrocautery|Primary patients with Osteoarthritis (OA) undergoing Total Knee arthroplasty (TKA) will be randomly assigned into either the control or investigational group. The control arm of the study will undergo medial sub periosteal release with electrocautery.
33303470|NCT05154058|Active Comparator|Investigational: sharp dissection.|Primary patients with OA undergoing TKA will be randomly assigned into either the control or investigational group. The investigational arm will undergo medial sub periosteal release using sharp dissection.
33303471|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
33303472|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
33303473|NCT03812536|No Intervention|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
33303474|NCT03812536|Experimental|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
33303475|NCT03817294|Active Comparator|Eccentric cycling|
33303476|NCT03817294|Active Comparator|Concentric cycling|
33303477|NCT03817294|Active Comparator|Single leg cycling|
33303478|NCT03817294|Active Comparator|Lower limb resistance training|
33303479|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
33303480|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
33303481|NCT05623696|Experimental|Stimulation of Left DLPFC|Intervention applied to Left DLPFC located by the BeamF3 technique
32940792|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
32940793|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
33303482|NCT05623696|Active Comparator|Stimulation of Right DLPFC|Intervention applied to Right DLPFC located by the BeamF3 technique
32940794|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
32940795|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
32940796|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
32940797|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
32940798|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
33303483|NCT05623696|Sham Comparator|Sham Stimulation|Sham intervention applied to either the left or right DLPFC
33303484|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
33303485|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
33303486|NCT00150800|Experimental|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
33303487|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
33303488|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
33303489|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
33303490|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
33303491|NCT00144300|Active Comparator|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
33303492|NCT00144300|Active Comparator|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
33303493|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
33303494|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
33303495|NCT01582724|Experimental|Self-care acupressure|1
33303496|NCT01582724|No Intervention|Usual care|2
33303497|NCT00149630|Experimental|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
33303498|NCT00149630|Active Comparator|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
33303499|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
33303500|NCT00127842|Other|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
33303501|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
33303502|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
33303503|NCT03968016|Placebo Comparator|Healthy|Control group
33303504|NCT03968016|Active Comparator|Stable heart disease|Stable heart disease and non-hospitalized
33303505|NCT03964740|Experimental|Intervention|Mobile App intervention group
33303506|NCT03964740|No Intervention|Control Group|No intervention group
33303507|NCT00112866|Experimental|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
33303508|NCT00112866|Experimental|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
33303509|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
33303510|NCT00127608|Experimental|Varicella Group|Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.
33303511|NCT00149396|Experimental|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
33303512|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
33303513|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
33303514|NCT03741348|Placebo Comparator|control|the control group will not receive block
33303515|NCT05080504||Study Population|Subjects with implanted CardioMEMS who are compliant with their measurements.
33303516|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
33404252|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
33404253|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
33404254|NCT02512510|Active Comparator|TD-4208-1|88 mcg
32940799|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
32940800|NCT05065424|Experimental|IV Atropine and Fentanyl Premedication Arm|Participants will receive premedication regimen of 20 micrograms/kilogram intravenous atropine and 0.5 micrograms/kilogram intravenous fentanyl prior to performance of LISA.
32940801|NCT05065424|Placebo Comparator|IV Normal Saline Placebo Arm|Participants will receive two intravenous Normal Saline infusions in quantities equivalent to the calculated volumes of atropine and fentanyl for participant's weight prior to performance of LISA.
32940802|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
32940803|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
32940804|NCT03776539|Experimental|ELX-02|Drug: ELX-02
32940805|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
32940806|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
32940807|NCT03769207|Other|Ambulatory ECG|
32940808|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
32940809|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
32940810|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
32940811|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
32940812|NCT03766165|Other|Control|Job announcements only
32940813|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
32940814|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
32940815|NCT04948892||Father/partner present, Kolding hospital|All father/partners, mothers and hospital staff involved in hyperacute cesarean section category 1 in general anesthesia (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) in Kolding Hospital, where the father is present in the OR during the cesarean section category 1
33404255|NCT02512510|Active Comparator|TD-4208-2|175 mcg
33404256|NCT02512510|Placebo Comparator|Placebo|Placebo
32940816|NCT04948892||Father/partner not present, Aabenraa hospital|"All father/partners and mothers involved in hyperacute cesarean section category 1 in general anesthesia in Aabenraa hospital, where the father is not present in the OR during the cesarean sectio category 1.~All relevant hospital staff, who sometimes participates in cesarean sectio category 1 (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) will be asked to fill in a questionnaire on their thoughts and opinions on having the father/partner present during hyperacute cesarean sectio category 1."
32940817|NCT04713254|Experimental|Lu AG06466|
32797283|NCT01800201|No Intervention|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
32797284|NCT01800201|Experimental|Intervention|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
32940818|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
32940819|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
32940820|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
32940821|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
32797285|NCT01767909|Experimental|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
32797286|NCT01767909|Placebo Comparator|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
32797287|NCT02029274|Experimental|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
32797288|NCT02029274|Experimental|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
32797289|NCT02029274|Experimental|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
32797290|NCT02029274|Placebo Comparator|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
32797291|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
32797292|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
32797293|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
32797294|NCT04896866|Experimental|Antimicrobial stewardship|Antimicrobial stewardship prospective audit and feedback on physicians attending to patients admitted with community-acquired COVID-19 pneumonia to beds randomized to antimicrobial stewardship intervention.
32797295|NCT04896866|No Intervention|No antimicrobial stewardship|No antimicrobial stewardship prospective audit and feedback.
32797296|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
32797297|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
32797298|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
32797299|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
32797300|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
32797301|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
32797302|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
32797303|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
33404257|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
33404258|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
33303517|NCT03967314|Active Comparator|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
33303518|NCT03967314|Active Comparator|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
33303519|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
33303520|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
33303521|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
33303522|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
33303523|NCT00223496|Experimental|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
33303524|NCT05623618|Experimental|Intervention (PACE labelling)|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
33303525|NCT05623618|No Intervention|Control (usual practice)|PACE labelling not implemented. Secondary schools continue with their usual practice.
33303526|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
33303527|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
33303528|NCT00255944|Experimental|Youthnet messages on Facebook|Participants will receive internet-based messages from the Youthnet program
33303529|NCT00255944|Active Comparator|Messages on Facebook about current events|Participants will receive internet-based messages from the control program
32797304|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
32797305|NCT01962103|Experimental|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
32940822|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
32940823|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
32940824|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
32940825|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
32940826|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
32940827|NCT03061279|Experimental|Fixation by Acutrak headless screw|
32940828|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
32940829|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
32940830|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
32940831|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
32940832|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
32940833|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
32940834|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
32940835|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
33303530|NCT03811990|No Intervention|Control|
33303531|NCT03811990|Active Comparator|Intervention|
33303532|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
33303533|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
33303534|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
33303535|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
33303536|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
33303537|NCT00143598|Active Comparator|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
32940836|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
32940837|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
32940838|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
33303538|NCT00143598|Placebo Comparator|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with < 5 mm Hg compression at the ankle.
33303539|NCT03971240|Experimental|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
33303540|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
33303541|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
33303542|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
33303543|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
33303544|NCT01299844|No Intervention|Standard Care|
33303545|NCT01299844|Experimental|Diabetes Peer Counseling|
33303546|NCT01301404|No Intervention|control|patient receive nothing
33303547|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
32940839|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
32940840|NCT04072237|Experimental|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
32940841|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
32940842|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
32940843|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
32940844|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
32940845|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
32940846|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
32940847|NCT04714177|Experimental|Edaravone Dexborneol|Edaravone Dexborneol injection
32940848|NCT04714177|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
33303548|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
33303549|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
33303550|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
33303551|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
33303552|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
33303553|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
33303554|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
33303555|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
33303556|NCT05054530|Experimental|GMA106|9 different dosages will be subcutaneously injected into the abdomen.
33303557|NCT05054530|Placebo Comparator|Matching placebo|9 different dosages will be subcutaneously injected into the abdomen.
33303558|NCT00126672|Experimental|Ramaycin|Rapamycin treatment was initiated with a loading dose of 6 mg by mouth on day 1 followed by 2 mg by mouth daily. The dose was then adjusted to maintain a target blood level of 3-9 ng/ml for the first 16 weeks. After week 16, the dose of Rapamycin was increased to a target level of 9-15 ng/ml unless there was evidence for a partial response or complete response by kidney MRI. Trough Rapamycin levels were checked every 8-12 weeks (at 24 weeks, 32 weeks, 40 weeks, and 52 weeks) in all patients until the 12-month (week 52) study visit. If the Rapamycin dose was below target, the dose was increased by 1-2 mg until the target trough level was achieved. Rapamycin levels were checked every 2-3 weeks while the dose was adjusted. Amendment 20 (Jan 2009) permitted additional Rapamycin treatment during months 12-24 if the treating site investigator judged that this was in the best interest of the study participant.
33303559|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
33303560|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
33303561|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
33303562|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
33303563|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
33089511|NCT04716855||Evaluation tests|RCS cases between the ages of 19-64 (n:40) who agreed to participate were included in the study. Pain severity (Visual Analogue Scale - VAS), range of motion (Universal Goniometer), muscle test (Manual muscle test), upper extremity functional status and disability (Quick-DASH questionnaire), physical activity level (International Physical Activity Questionnaire - UFAA) ) and quality of life (Short Form-36 - SF-36) were evaluated
33089512|NCT00419991|No Intervention|1 Tigecycline|
33089513|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
33303564|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
33303565|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
33303566|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
33303567|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
33303568|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
33303569|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
33303570|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
33303571|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
33303572|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
33303573|NCT00145574|Experimental|high dose colesevelam|colesevelam HCl 3.750 g
33303574|NCT00145574|Experimental|Low dose colesevelam|Low dose colesevelam 1.875 g
33303575|NCT00145574|Placebo Comparator|placebo|placebo comparator
33303576|NCT05660668|Experimental|Transbond LR|in finished orthodontic cases a light cured resin composite (Transbond LR) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
33404259|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
33404260|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
33404261|NCT04477408|Other|plantar exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
33404262|NCT05762016||incision and drainage group|patients with breast abscess who undergo incision and drainage
33404263|NCT05762016||percutaneous drainage group|patients with breast abscess who undergo percutaneous drainage
33404264|NCT05762016||MISE group|patients with breast abscess who undergo MISE
33404265|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
33089514|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
33089515|NCT04718090|Active Comparator|interscalene block|
33089516|NCT04718090|Active Comparator|PENG block|
33089517|NCT04716816|No Intervention|traditional treatment|received conventional analgesics.
33089518|NCT04716816|Experimental|Stripping massage|received SM twice daily in the active trigger points of the rhomboid for two weeks.
33089519|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
33089520|NCT05129943|Active Comparator|active distraction group|local anesthesia with video game using VR device
33089521|NCT05129943|Active Comparator|passive distraction group|local anesthesia with cartoon video using VR device
33303577|NCT05660668|Active Comparator|Transbond XT|in finished orthodontic cases a light cured resin composite (Transbond XT) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
33303578|NCT04978870||1 - Validation|Group 1 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. A subgroup of patients will receive an additional delirium screening using the CAM-PACU. This screening will be performed by another operator blinded for the results from the initial delirium screening.
33303579|NCT04978870||2 - Cognition|"Group 2 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison.~This group will undergo additional assessment of preoperative and postoperative cognitive function as well as a POD screening using the 3D-CAM starting at postoperative day 1 until discharge from hospital but no longer than postoperative day 5."
33303580|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
33303581|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
33089522|NCT00302666|Sham Comparator|Arm 1|
33089523|NCT00302666|Sham Comparator|Arm 2|
33089524|NCT05070741|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.
33089525|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
33089526|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
33089527|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
33089528|NCT05024721|Experimental|HIP2101|Taking HIP2101+HPP2102 once daily for 2 weeks.
33089529|NCT05024721|Active Comparator|RLD2101|Taking RLD21012101+HPP2101 once daily for 2 weeks.
33089530|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
33089531|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
33303582|NCT05599750|Active Comparator|Hernia repair with mesh (Control arm)|Participants will undergo incisional hernia repair with prolene mesh in the retrorectus position with at least 4cm of overlap.
33303583|NCT05599750|Active Comparator|Primary closure (Intervention arm)|Participants will undergo incisional hernia repair with suture alone using modern surgical techniques.
33303584|NCT05034562|Experimental|Diagnostic (gallium Ga 68-labeled PSMA-11, PET/CT, PET/MRI)|Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
33303585|NCT00145496|Experimental|asenapine|
33303586|NCT00145496|Active Comparator|olanzapine|
33303587|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
33303588|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
33303589|NCT03967574|Experimental|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
33303590|NCT03967574|Sham Comparator|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
33303591|NCT03967574|No Intervention|Control|Participants received no further intervention two weeks following their CSI
33089532|NCT00328419|Experimental|1|photoprotected parenteral nutrition
33089533|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
33089534|NCT05015712|Experimental|moderate intensity continuous training|
33089535|NCT05015712|No Intervention|guideline control|Patients assigned to the guideline control just received 1-time advice on training according to guidelines.
33089536|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
33089537|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
33089538|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
33089539|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
33089540|NCT04716582|Experimental|SIT group|participants will sitting 4 hours continuously.
33303592|NCT05030818|Experimental|Polypill|Patients will be receiving the polypill at the adequate doses during 3 months
33303593|NCT05030818|Active Comparator|Drugs taken separately|Patients will be receiving during 3 months the same components and at the same doses than with the polypill
33303594|NCT01582022|Experimental|local anesthetic|local anesthetic agent
33303595|NCT01582022|Placebo Comparator|normal saline|comparator
33303596|NCT03967418|Other|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction, excessive use of video games and eating disorders with bulimia episodes) will be recruited
33303597|NCT03967418|Other|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
33303598|NCT01301482|Experimental|battlefield auricular acupuncture|
33303599|NCT01301482|No Intervention|placebo|
33303600|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
33303601|NCT01300000|Active Comparator|Human Milk|ad lib
33303602|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
33303603|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
33303604|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
33303605|NCT04979806|Experimental|Cefepime-zidebactam (FEP-ZID)|
33303606|NCT04979806|Active Comparator|Meropenem|
33303607|NCT00255164|Experimental|Dexlansoprazole MR 60 mg QD|
33303608|NCT00255164|Experimental|Dexlansoprazole MR 90 mg QD|
33303609|NCT00255164|Placebo Comparator|Placebo|
33303610|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
33303611|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
33303612|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
33303613|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
33089541|NCT04716582|Experimental|INTERRUPT group|participants will sitting 25 minutes with 5 minutes walking per half hour,40minutes walking in total
33089542|NCT04716582|Experimental|COGN group|participants will perform GED test as cognitive loading task during 4-hour sitting
33089543|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
33089544|NCT00302900|Experimental|2|Pre-donation water
33089545|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
33089546|NCT00302900|No Intervention|4|Standard donation
33089547|NCT04716621|Experimental|Early intervention|Three sites received the Pain Management Support System for Primary Care (PMSS-PC) integrated into the Electronic Health Record.
33089548|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. Three additional sites received the intervention 6 months after the first arm.
33089549|NCT05008224|Experimental|Pembrolizumab Monotherapy + Chemotherapy + Pembrolizumab Consolidation|"Participants receive pembrolizumab monotherapy followed by chemotherapy with doxorubicin in combination with vinblastine & dacarbazine (AVD) or chemotherapy with escalated bleomycin in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone (escBEACOPP) followed by pembrolizumab consolidation.~All participants receive pembrolizumab monotherapy intravenous (IV) for 3 cycles (cycle length = 3 weeks (wks); up to 9 wks). All participants receive AVD IV for 2 cycles (cycle length = 4 wks; up to 8 wks) after Positron Emission Tomography (PET) 2. Participants who are PET 3 -ve, or +ve & age ≥ 60 years, receive up to 4 additional cycles of AVD IV (cycle length = 4 wks, up to 16 wks), or up to 4 cycles of escBEACOPP IV if PET 3 +ve, age <60 years; cycle length = 3 wks; up to 12 wks. All participants receive pembrolizumab consolidation IV for 4 cycles (cycle length = 6 wks; up to 24 wks). Total treatment duration is up to 57 wks."
33089550|NCT00303017|Experimental|flavocoxid|medical food
33089551|NCT00303017|Active Comparator|naproxen|NSAID
33089552|NCT05001126|Experimental|HIFT 1x/week|HIFT exercise performed one time per week.
33089553|NCT05001126|Experimental|HIFT 2x/week|HIFT exercise performed two times per week.
33089554|NCT05001126|Experimental|HIFT 3x/week|HIFT exercise performed three times per week.
33089555|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
33089556|NCT00303134|Experimental|Islet Cell Transplantation|
33089557|NCT04999917|Experimental|intraoperative high-resolution PET-CT imaging of resected breast tumor.|
33089558|NCT04998669|Experimental|Loncastuximab tesirine + Rituximab|"During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.~Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.~Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:~Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving SD or PD will be taken off treatment."
33089559|NCT00303212|No Intervention|UC|Usual HF guideline-base care
33089560|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
33089561|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
33303614|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
33303615|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
33303616|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
33303617|NCT03967652||Normal|Healthy volunteers
33303618|NCT04977154||Trainers|
33303619|NCT01300078|Experimental|MF101 10 grams/day|
33303620|NCT01300078|Experimental|MF101 15 grams/day|
33303621|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
33303622|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
33303623|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
33303624|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
33303625|NCT05578690|Experimental|Lifestyle group|A tailored multifactorial lifestyle intervention consisting of diet, exercise and mentorship in women with overweight or obesity to obtain a healthy lifestyle before and during pregnancy.
33303626|NCT05578690|No Intervention|Standard of care group|The standard of care group will receive no active intervention but are encouraged to seek any possible guidance from the general practitioner for management of pre-pregnancy obesity according to current guidelines.
33303627|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
33303628|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
33303629|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
33303630|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
33303631|NCT00126594|Experimental|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
33303632|NCT00126594|Experimental|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
33303633|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
33303634|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
33303635|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
33089562|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
33089563|NCT00328692|Experimental|2|
33089564|NCT00328692|Placebo Comparator|1|
32797306|NCT01962103|Experimental|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
32797307|NCT01962103|Experimental|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
32797308|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
32797309|NCT04656145|Experimental|Chlorhexidine Gluconate Gel Dressing|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
32797310|NCT04656145|No Intervention|Standard of Care|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
32797311|NCT04186403|Experimental|Prior Brexpiprazole 2-3 Milligrams Per Day|Participants who received blinded brexpiprazole 2 to 3 milligrams per day (mg/day) in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
33089565|NCT04718246|Other|Dental Implants in hyperlipidemia patients|Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
32797312|NCT04186403|Experimental|Prior Placebo|Participants who received blinded brexpiprazole matching placebo in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
32797313|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
32797314|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
32797315|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
32797316|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
32797317|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
32797318|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
32797319|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
32797320|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
32797321|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
32797322|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
32797323|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
32797324|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
32797325|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
32797326|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
32797327|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
32797328|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
32797329|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
32797330|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
32797331|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
32797332|NCT04416919|Other|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
33089566|NCT04982796|Experimental|Psilocybin-enhanced psychotherapy|Psilocybin will be administered twice (25mg & 30mg two weeks apart) in addition to a 6-week psychotherapy protocol while admitted to a residential rehabilitation treatment program.
33303636|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
32797333|NCT04672369|Experimental|IBI939 in combination with Sintilimab|
33303637|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
33303638|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
33303639|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
33303640|NCT00126438|Experimental|123I-mIBG (meta-iodobenzylguanidine)|Single dose
33303641|NCT03821818||Control|Food Allergen Elimination only
33303642|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
32797334|NCT04672369|Active Comparator|sintilimab|
32797335|NCT04652479|Experimental|Treatment Group 1|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
33303643|NCT04903756||Patients|Adult patients where major lower limb amputation is being considered.
33303644|NCT04903756||Healthcare professionals|Surgeons, anaesthetists, and allied health professionals involved in decision making with patients where a major lower limb amputation is being considered.
32797336|NCT04652479|Experimental|Treatment Group 2|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days (in the opposite sequence from Treatment Group 1)
32797337|NCT04652167||Patients suspected of community-acquired pneumonia|All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician
32797338|NCT01959919||Arm 1: Device|
33303645|NCT03967392|Active Comparator|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
33303646|NCT03967392|Active Comparator|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
33303647|NCT04898764|No Intervention|Healthy Volunteers|This study arm will only participate in part A of the study (Characterisation study) and thus will not receive the study drug. A maximum of 35 healthy volunteers will be included in this study arm.
33303648|NCT04898764|Experimental|Patients with long-term use of nasal decongestants|"A maximum of 100 patients with long-term use of nasal decongestants will be included in this study arm, for part A of the study (Characterisation study).~The investigators will consecutively recruit patients from part A (Characterisation study) into part B of the study (Intervention study) until a total of 35 patients completed all study-related visits of part B. During the intervention study, patients with long-term use of nasal decongestants will administer Mometasone furoate intranasally, two doses (50µg/actuation) in each nostril, twice daily (total daily dose of 400µg) during a 12 week period."
32797339|NCT04176601|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
32797340|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
33303649|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
33303650|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
33303651|NCT04896736|Experimental|Multisite tissue oxygenation monitoring-guided care|"Details are as follows. • Monitoring: SctO2 monitored using two probes placed on left and right forehead. SstO2 monitored using one probe placed over the forearm brachioradialis muscle on the arm not used for non-invasive blood pressure monitoring.~• Baseline: The first baseline is measured 12-48 hours before surgery, with the patient supine, awake, calm, eyes closed, and breathing room air or oxygen that is equivalent to the home oxygen rate for patients using home oxygen.~Goals: Maintain both SctO2 and SstO2 within 90-110% of the baseline level.~Trigger of intervention: SctO2/SstO2 outside of the 90-110% baseline range.~Diagnosis:~Care team: The caregivers providing SctO2/SstO2-guided care will be trained and given the opportunity to use the intervention protocol in at least 20 patients before the formal study.~Treatments: Refer to the algorithm to restore SctO2/SstO2 within 90-110% baseline range."
33303652|NCT04896736|Active Comparator|Usual care|Patients in the control group will be managed by clinical staff according to usual care. Patients in this group will be monitored using the same tissue oximeter used in the intervention group; however, the screen will be covered by an opaque cloth to prohibit the care givers seeing the monitoring data. The same baseline measurements will be performed in patients allocated to the usual care group.
33303653|NCT00142584|Experimental|1-NEB|Nebivolol
33303654|NCT00142584|Active Comparator|2-MET|Metoprolol
33303655|NCT04848064|Experimental|Treatment (mogamulizumab, chemotherapy, NK cells)|Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
33303656|NCT00126126|Experimental|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
33303657|NCT00126126|No Intervention|Wait List Control|Wait List Control Group
33303658|NCT04817644|Experimental|Oral semaglutide|All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
33303659|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
33303660|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
33303661|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
33303662|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
33303663|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
33303664|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
33303665|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
33303666|NCT03964662|Experimental|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
33303667|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
33303668|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
33303669|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
33303670|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
33303671|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
33303672|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
33303673|NCT05623384|Experimental|Stellate ganglion block combined with facial and glossopharyngeal nerve block group|
33303674|NCT05623384|Experimental|Stellate ganglion block group|
33303675|NCT05623384|Other|Control group|
33303676|NCT00125190|Experimental|rhIGF-1 QD|Subjects received subcutaneous injection (SC) injections of rhIGF-1 once a day.
33303677|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
33303678|NCT04786600|Experimental|ctDNA assay-guided intervention|Subjects on this arm will be tested with the Signatera ctDNA assay while receiving treatment on a pre-specified sequence of FDA-approved drugs and drug combinations. Subjects will move through this sequence based on the results of the ctDNA assay. Subjects will move to a new drug or drug combination in the sequence when the ctDNA assay indicates a significant increase in ctDNA level. Subjects will also have imaging scans every 12 weeks while on each drug or drug combination and subjects will move to a new drug or drug combination if these scans indicate disease progression.
33303679|NCT04786600|Active Comparator|Scan-guided Intervention|Subjects on this arm will be treated with the same pre-specified sequence of FDA-approved drugs and drug combinations as those on the ctDNA assay- guided intervention arm. Subjects will move through the sequence based on the results of imaging scans, moving to a new drug or drug combination if imaging shows progressive disease.
33303680|NCT03810664|Experimental|Somatrogon pre-filled PEN|
33303681|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
33303682|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
33303683|NCT00141726|Experimental|etanercept treatment|Etanercept for lung injury
33303684|NCT03967548|Experimental|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
33303685|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
33303686|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
33303687|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
33303688|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
33303689|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
33089567|NCT04982796|Other|Treatment-as-Usual|Treatment-as-usual while admitted to a residential rehabilitation treatment program.
33089568|NCT00303524|Experimental|1|Zoladex 3-month depot
33303690|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
33303691|NCT01301716|Experimental|A|
33303692|NCT01301716|Experimental|B|
33089569|NCT00303524|Experimental|2|Zoladex 1-month depot
33303693|NCT01301716|Experimental|C|
33303694|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
33089570|NCT00303563|Experimental|1|
33089571|NCT00303563|Experimental|2|
33089572|NCT00303563|Experimental|3|
33089573|NCT00303563|Placebo Comparator|4|
33303695|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
33303696|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
33303697|NCT01303042|Experimental|Insulin lispro mix 50/50|
33303698|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
33303699|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
33303700|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
33303701|NCT01300312|Experimental|1|
33303702|NCT01300312|Active Comparator|2|
33303703|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
33303704|NCT00111228|Experimental|Continuous use of the Guardian RT|Continuous use of the Guardian RT group
33303705|NCT00111228|Experimental|Bi-weekly use of the Guardian RT (once every 2 weeks)|Bi-weekly use of the Guardian RT (once every 2 weeks) group
33303706|NCT00111228|Active Comparator|Control group. SMBG monitoring|Control group. SMBG monitoring group
33303707|NCT04742842|Experimental|Part A: Arm1 (COVIGEN (C19) 0.8 mg ID or Placebo ID)|Participants will be randomized to receive either COVIGEN C19 (0.8 mg) given by ID (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
33303708|NCT04742842|Experimental|Part A: Arm2 (COVIGEN (C19) 2.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (2 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
33303709|NCT04742842|Experimental|Part A; Arm 3 (COVIGEN (C19) 4.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (4 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart
33303710|NCT04742842|Experimental|Part B: Arm 1 (COVIGEN (C20) 1.0 mg ID) in BNT162b2 primed participants|Participants in Part B who have received a 2 dose primary course of Pfizer BNT162b2 vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
33303711|NCT04742842|Experimental|Part B: Arm 2 (COVIGEN (C20) 1.0 mg ID) in ChAdOx1-S primed participants|Participants in Part B who have received a 2 dose primary course of Astra Zeneca ChAdOx1-S vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
33303712|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
33303713|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
33303714|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
33303715|NCT01080612|Other|300 mg pregabalin immediate release|
33303716|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
33404266|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
33303717|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
33303718|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
33303719|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
33303720|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
33303721|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
33303722|NCT05529862|Experimental|Locally advanced or metastatic Breast Cancer Women|"Study Procedures:~Additional tumour sampling during the pre-treatment biopsy scheduled as per routine care,~A post-treatment tumour biopsy,~One pre-treatment and one post-treatment blood sampling."
33303723|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
33303724|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
33303725|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
33303726|NCT01560364||Hemofilter|
33303727|NCT01560442||buprenorphine|
33303728|NCT01560442||Methadone Hydrochloride|
33303729|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
33303730|NCT03819712|Experimental|Recurrent UTI|
33303731|NCT05623150||Descriptive study|"The patients included in this observational study are patients with hepatic steatosis either related to NAFLD or to alcohol-related liver disease.~Patients included in the study may have hepatocellular carcinoma.~Thus, 4 groups of patients can be recruited:~patients with NAFLD without hepatocellular carcinoma,~patients with NAFLD with hepatocellular carcinoma,~patients with alcohol-related liver disease without hepatocellular carcinoma, -patients with alcohol-related liver disease with hepatocellular carcinoma."
33303732|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
33303733|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
33303734|NCT01300468|Experimental|Dose-escalation|
33303735|NCT01303120|Active Comparator|Femoral Nerve Block|
33303736|NCT01303120|Active Comparator|Combined Nerve Blocks|
33303737|NCT01303120|Active Comparator|Patient-controlled analgesia|
33089574|NCT00328809|Experimental|Spirnolactone|
33303738|NCT04484818|Active Comparator|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
33303739|NCT04484818|Experimental|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
33303740|NCT00110994|Experimental|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
33404267|NCT05179434|Experimental|Retrograde graft reperfusion|Kidney transplantation with retrograde venous reperfusion of renal graft followed by arterial reperfusion
32940849|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
32940850|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
32940851|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
32940852|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
32940853|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
32940854|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
32940855|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
32940856|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
32940857|NCT05313295|Experimental|Home-based Physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques) + 3 hours extra of home-based physiotherapy (stretching, active mobilizations)
32940858|NCT05313295|Active Comparator|Usual physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
32940859|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
32940860|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
32940861|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
32940862|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
32940863|NCT05752526|Experimental|DARE-PDM1 1% Diclofenac Vaginal Gel|1% Diclofenac in 2.5 mL Hydrogel
32940864|NCT05752526|Experimental|DARE-PDM1 3% Diclofenac Vaginal Gel|3% Diclofenac in 2.5 mL Hydrogel
33404268|NCT05179434|Active Comparator|conventional antegrade perfusion|Kidney transplantation with conventional arterial reperfusion of renal graft (without retrograde venous reperfusion)
33404269|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
32940865|NCT05752526|Placebo Comparator|Placebo|2.5 mL Hydrogel
32940866|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
32940867|NCT05752448|Experimental|Intervention group|Group received care Using POSTCare process
32940868|NCT05752448|No Intervention|Usual Care|Group received usual care
32940869|NCT03733483|Experimental|Sleep Deprivation|
32940870|NCT05752370|Experimental|High flow oxygen|High flow nasal oxygen
32940871|NCT05752370|Active Comparator|Usual care|room air or normal flow oxygen
32940872|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
32940873|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
32940874|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
32940875|NCT02658877|Experimental|Omalizumab|
32940876|NCT02658877|Placebo Comparator|Placebo|
32940877|NCT05752292|Experimental|Condition 1|Standard health message + VA + TRI + MI+ AP
32940878|NCT05752292|Experimental|Condition 2|Standard health message + VA + TRI + MI
32940879|NCT05752292|Experimental|Condition 3|Standard health message + VA + TRI + AP
32940880|NCT05752292|Experimental|Condition 4|Standard health message + VA + TRI
33303741|NCT00110994|Active Comparator|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
32940881|NCT05752292|Experimental|Condition 5|Standard health message + VA + MI+ AP
32940882|NCT05752292|Experimental|Condition 6|Standard health message + VA + MI
32940883|NCT05752292|Experimental|Condition 7|Standard health message + VA + AP
32940884|NCT05752292|Experimental|Condition 8|Standard health message + VA
32940885|NCT05752292|Experimental|Condition 9|Standard health message + TRI + MI+ AP
32940886|NCT05752292|Experimental|Condition 10|Standard health message + TRI + MI
32940887|NCT05752292|Experimental|Condition 11|Standard health message + TRI + AP
32940888|NCT05752292|Experimental|Condition 12|Standard health message + TRI
32940889|NCT05752292|Experimental|Condition 13|Standard health message + MI+ AP
32940890|NCT05752292|Experimental|Condition 14|Standard health message + MI
32940891|NCT05752292|Experimental|Condition 15|Standard health message + AP
32940892|NCT05752292|Experimental|Condition 16|Standard health message
32940893|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
32940894|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
32940895|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
32940896|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
32940897|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
32940898|NCT05722418|Experimental|CB-011|"Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design.~Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A"
32940899|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
32940900|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
32940901|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
32940902|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
32940903|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
32940904|NCT05722262|Experimental|Sequence A|Three period alternative intervention and fed/fasted sequence
32940905|NCT05722262|Experimental|Sequence B|Three period alternative intervention and fed/fasted sequence
32940906|NCT05722262|Experimental|Sequence C|Three period alternative intervention and fed/fasted sequence
32940907|NCT05722262|Experimental|Sequence D|Three period alternative intervention and fed/fasted sequence
32940908|NCT05722262|Experimental|Sequence E|Three period alternative intervention and fed/fasted sequence
32940909|NCT05722262|Experimental|Sequence F|Three period alternative intervention and fed/fasted sequence
32940910|NCT05719844|Experimental|Neuropsychological tests|The neuropsychological tests are computerized (TAP battery) or paper-and-pencil tests. They assess processing speed, short-term memory and auditory-verbal working memory capacity, episodic memory and selective attention.
32940911|NCT05717348|Experimental|Part 1 dose escalation|ES014 doses will be escalated in patients with advanced solid tumors.
32940912|NCT05717348|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 4 expansion cohorts at the recommended optimal biological dose determined in Part 1 dose escalation.
32940913|NCT05709626|Active Comparator|No aspirin (Prasugrel monotherapy)|To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).
32940914|NCT05709626|Active Comparator|12-month DAPT|To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).
32940915|NCT05707364||Practices Engaged for Pre-Visit Lab Clinic Workflow|Providers and patients/ at the designated practice sites
33089575|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
33089576|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
33303742|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
33303743|NCT04435990|Experimental|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
32797341|NCT01986907|Experimental|Ranibizumab|Administered as an Intravitreal injection
32797342|NCT01959841|Experimental|ASP2151(200 mg)|once daily
32797343|NCT01959841|Experimental|ASP2151(400mg)|once daily
33089577|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
33089578|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
33089579|NCT00332280|Experimental|AMT2003|
33089580|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33102434|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
32797344|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
32797345|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
32797346|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
32797347|NCT04650451|Experimental|HER2-targeted dual-switch CAR-T cells|Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
32797348|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
32797349|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
32797350|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
32797351|NCT02074553|Experimental|Part 1 (Fasted): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation (four 150 mg capsules) orally in Part 1 of the study according to following treatment sequences. Treatment A (Reference Treatment: formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (Test Treatment: formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (Test Treatment: formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (Test Treatment: formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797352|NCT02074553|Experimental|Part 1 (Fasted): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797353|NCT02074553|Experimental|Part 1 (Fasted): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797354|NCT02074553|Experimental|Part 1 (Fasted): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32830561|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
32797355|NCT02074553|Experimental|Part 2 (Fed): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment A (formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797356|NCT02074553|Experimental|Part 2 (Fed): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797357|NCT02074553|Experimental|Part 2 (Fed): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797358|NCT02074553|Experimental|Part 2 (Fed): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
32797359|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
32797360|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. daily for 26 weeks
32797361|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
32797362|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
32797363|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
33089581|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
33089582|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33089583|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
33089584|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
33089585|NCT00420186|Experimental|1|
33089586|NCT00303992|Experimental|Trastuzumab and Irinotecan|
33089587|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
33303744|NCT04435990|Experimental|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
33303745|NCT04435990|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
33089588|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
32797364|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
33089589|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
33404270|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
32797365|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
32797366|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
33089590|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
33089591|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
32797367|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
32797368|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
33089592|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
33089593|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
33089594|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
33089595|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
32797369|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
32797370|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
32797371|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
32797372|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
32797373|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
32797374|NCT04186325|No Intervention|Group C|Group C: the regular mechanical ventilation protocol will be followed.
32797375|NCT04186325|Experimental|Group T|Group T: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
32797376|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
32797377|NCT04186169|Placebo Comparator|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
32797378|NCT04186169|Placebo Comparator|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
32797379|NCT04186169|Experimental|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
32797380|NCT04736537|Experimental|Healthy Controls|
32797381|NCT04725851|Experimental|High concentration Oxygen Therapy|12-15 Litre/min O2 delivery via Non-Rebreather Mask (NRM) consecutively for 24 hours.
32797382|NCT04725851|Placebo Comparator|Room air or low concentration oxygen|Room air or low concentration oxygen (0-2 Litre/min O2 ) consecutively for 24 hours.
33089596|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
33089597|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
33089598|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
33089599|NCT00329004|Experimental|1|
33089600|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
33089601|NCT00304772|Active Comparator|1|
33089602|NCT00304772|Active Comparator|2|
33089603|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
33089604|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
33089605|NCT00304850|Experimental|R+ / K+|
33089606|NCT00304850|Experimental|R+ / K-|
33089607|NCT00304850|Experimental|R- / K+|
33089608|NCT00304850|Placebo Comparator|R- /K-|
33089609|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
33102435|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
33102436|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
33102437|NCT04707651|Experimental|Lifestyle intervention|Nutrition advices and formula diet
33089610|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
33303746|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
32797383|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
32797384|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
32797385|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
32797386|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
32797387|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
32797388|NCT04736303|No Intervention|POD without BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery, with CAM and Nu-DESC tools.
32797389|NCT04736303|Active Comparator|POD with BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery with the implementation of BIS monitoring, with CAM and Nu-DESC tools.
32797390|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
32797391|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
32797392|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
32797393|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
32797394|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
32797395|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
32797396|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
32797397|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
32797398|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
32797399|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
32797400|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
32797401|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
32797402|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
32797403|NCT04734977|Experimental|HILT+exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
33102438|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
33303747|NCT01560052|Placebo Comparator|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
33303748|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
33303749|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
33303750|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
33303751|NCT05515588|Experimental|Part A: BI 690517 (C-14)|
33303752|NCT05515588|Experimental|Part B: BI 690517 fasted (test treatment, T) / BI 690517 (C-14) (reference treatment, R)|
33303753|NCT05098132|Experimental|Part A: STK-012 weekly (QW) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy subcutaneously (SC) QW until unacceptable toxicity, disease progression, or withdrawal of consent.
33303754|NCT05098132|Experimental|Part B: STK-012 every three weeks (Q3W) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy SC Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
33303755|NCT05098132|Experimental|Part C: STK-012 Q3W + pembrolizumab dose escalation|STK-012 will be administered in sequential ascending doses SC Q3W in combination with a fixed dose of pembrolizumab intravenously (IV) Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
32797404|NCT04734977|Sham Comparator|Sham HILT+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
33303756|NCT05098132|Experimental|Part D: Dose expansions|STK-012 will be administered at the RP2D SC as monotherapy and in combination with a fixed dose of pembrolizumab IV Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
33303757|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
32797405|NCT04734977|Active Comparator|Exercise only|Exercise program was applied in five sessions a week for four weeks, with a total of 20 sessions a day.
33303758|NCT05494762|Experimental|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
33303759|NCT05494762|Experimental|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
33303760|NCT04356352|Active Comparator|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
33303761|NCT04356352|Active Comparator|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
33303762|NCT04356352|Placebo Comparator|Placebo|Saline water
33303763|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
33303764|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
32797406|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
32797407|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
32797408|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
33303765|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
33303766|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
33303767|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
33303768|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
33303769|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
33303770|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
33303771|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
33303772|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
33303773|NCT05622994|Active Comparator|Rimonabant|Rimonabant 5mg
33303774|NCT05622994|Placebo Comparator|Placebo|Placebo
33303775|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
33303776|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
33303777|NCT05622916|Experimental|Intervention|Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.
33303778|NCT05622916|Active Comparator|Comparison|Weekly application (1x/week) by the physician for 8 weeks
33303779|NCT05467150|Experimental|Probiotic Supplement|Participants (mothers) randomized to this arm will take one Culturelle® Digestive Daily Probiotic Capsule per day from study enrollment through the first postpartum month. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG
33303780|NCT05467150|No Intervention|No intervention|Participants (mothers) randomized to this arm will agree to continue not taking any over the counter probiotic supplements from study enrollment through the first postpartum month.
33303781|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
32797409|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
33089611|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
33089612|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
33089613|NCT00305279|Active Comparator|1|
33303782|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
33303783|NCT04285606|Experimental|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
32797410|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
32797411|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
32797412|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
32797413|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
32797414|NCT04664426||Kidney transplant recipients|Kidney transplant recipients will undergo examination according to the E-PSS, amTCNS, QST (thermal threshold testing), and NCS (amplitude, velocity and distal latency of measurements at the sural sensory nerve, ulnar sensory nerve, peroneal motor nerve, tibial motor nerve and ulnar motor nerve, soleus H reflex will be measured).
32797415|NCT04175678|Active Comparator|Normal/Active|No intervention
32797416|NCT04175678|Placebo Comparator|Obese/Inactive|Observational clinic visits
32797417|NCT04175678|Experimental|Diet|low fat/low caloric diet
32797418|NCT04175678|Experimental|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
32797419|NCT04175678|Experimental|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
32797420|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
32797421|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
32797422|NCT02107703|Experimental|Abemaciclib + Fulvestrant (Endocrine Naïve Cohort)|150 milligrams mg Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
32797423|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
32797424|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
32797425|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
32797426|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
32797427|NCT04740827|Active Comparator|Atogepant 60 mg|Taken once daily
32797428|NCT04740827|Placebo Comparator|Placebo|Taken once daily
32797429|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
32797430|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
32797431|NCT05089487|Experimental|High altitude 2500 m above sea level|
32797432|NCT05089487|Active Comparator|Low altitude 470 m above sea level|
32797433|NCT01625897|Experimental|MP-214 1.5-9mg|
32797434|NCT01625897|Active Comparator|Risperidone 2-12mg|
32797435|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
32797436|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
33089614|NCT00305279|Active Comparator|2|
33089615|NCT00305279|Active Comparator|3|
33089616|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
33089617|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
33303784|NCT04285606|No Intervention|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
32797437|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
33089618|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
33303785|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
33303786|NCT03819556|No Intervention|Control|Diet free from milk protein
33303787|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
33303788|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
33303789|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
33089619|NCT00305435|Experimental|romiplostim (AMG-531)|
33303790|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
33303791|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
33303792|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
33303793|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
33303794|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
33303795|NCT01303588|No Intervention|Waiting Group|
33303796|NCT01303588|Active Comparator|Qigong|
33303797|NCT01303588|Active Comparator|Yoga|
33303798|NCT04965142|Experimental|Home Exercise Group|The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
33303799|NCT04965142|No Intervention|Control Group|Participants will receive one counselling session on healthy eating and physical activity at the start of the study.
33303800|NCT02855554|Experimental|Additional 5 minute research MR scan of heart.|The purpose of this is to evaluate new, faster MR scans
33303801|NCT05417932|Experimental|SCG101|"This is a single arm study.~Patients will receive infusion and will be observed for dose limiting toxicity (DLT) over a 28-day period, and thereafter enter the progression free survival observation period and continuous long term survival follow up at time of disease progression."
33303802|NCT01303666|Active Comparator|TI of the knee|
33303803|NCT01303666|Active Comparator|Intra-articular CSI|
33303804|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
33303805|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
33303806|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
33303807|NCT03801460|No Intervention|SOC|Standard of Care
33303808|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
33303809|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
33303810|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
33303811|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
33303812|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
33303813|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
33404271|NCT05761158||patient|patients answer the same questionnaire whether they have frontal alopecia or lichen planus pilaris
33303814|NCT04246762|Experimental|Olokizumab 128 mg +Cocktail drugs|"All subjects will receive the following treatment:~Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered with 240 mL of water on Day 1, single subcutaneous injection of OKZ 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered on Day 22"
33303815|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
33303816|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
33303817|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
33303818|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
33303819|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
33303820|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
33303821|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
33303822|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
33303823|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
33303824|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
33303825|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
33303826|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
33303827|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
33303828|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
33303829|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
33303830|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
33303831|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
33303832|NCT00144170|Other|Tipranavir(TPV)/low dose ritonavir(r)|
33303833|NCT00144170|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
33303834|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
33303835|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
33303836|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
33303837|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
33303838|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
33303839|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
33303840|NCT03798730|Experimental|Solid Model|"Cake~-Control Vanilla Cake and Protein Fortified Vanilla Cake~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
33303841|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages~Native sample (protein unheated)~Denatured whey protein (protein heated to denature)"
33303842|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
33303843|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
33303844|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
33303845|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
33303846|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
33303847|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
33303848|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
33303849|NCT04186468|Experimental|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
33303850|NCT04186468|No Intervention|Usual care|Participants will solely receive usual care.
33089620|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
33089621|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
33303851|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
33089622|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
33089623|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
33089624|NCT00329511|Active Comparator|A|methyldopa
33089625|NCT00329511|Active Comparator|B|clonidine patch
33089626|NCT00305552|Experimental|1|THALIDOMIDE
33089627|NCT00329589|Experimental|CNS|Velcade (bortezomib)
33089628|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
33089629|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
33089630|NCT00329628|Experimental|Arm 1|
33089631|NCT00329628|Active Comparator|Arm 2|
33089632|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
33089633|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
33089634|NCT04716543||ILI Investigation|The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (> 37.5˚C axillary temperature or > 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
33089635|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
33089636|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33089637|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
33089638|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
33089639|NCT00306137|Experimental|Arm 1|
33089640|NCT00306137|Placebo Comparator|Arm 2|
33089641|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
33089642|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
33089643|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
33089644|NCT00329979||1|Radial access
33089645|NCT00329979||2|Femoral access
33089646|NCT00330018|Experimental|1|PO Valganciclovir
33089647|NCT00330018|Active Comparator|2|PO Acyclovir
33089648|NCT00306215|Experimental|1|Blinded study arm
33089649|NCT00306215|Experimental|2|Blinded study arm
33089650|NCT00306215|Experimental|3|Blinded study arm
33089651|NCT00306215|Experimental|4|Blinded study arm
33089652|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
33089653|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
33089654|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
33089655|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
33089656|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
33089657|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
33089658|NCT00330096|Experimental|Hesperidin-rich food|
33089659|NCT00330096|Placebo Comparator|No intervention: Placebo|
33089660|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
33089661|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
33089662|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
33089663|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
33089664|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
33089665|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
33089666|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
33089667|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
33089668|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
33089669|NCT02956694|Experimental|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
33089670|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
33303852|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
33303853|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
33303854|NCT00255086|Experimental|Memantine|10mg Memantine
33303855|NCT00255086|Placebo Comparator|Control|10 mg Placebo pill
33303856|NCT00110214|Experimental|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
33303857|NCT00110214|Experimental|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
33303858|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
33303859|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
33303860|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
33303861|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
33303862|NCT05625334|Experimental|Arm 1: I-ASA 100mg, then C-ASA 162mg tablet|"Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.~Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)."
33303863|NCT05625334|Experimental|Arm 2: C-ASA 162mg tablet, then I-ASA 100mg|"Treatment A: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA).~Treatment B: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI."
32797438|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
33102439|NCT04702113|No Intervention|Conventional Therapy (Controls)|Treatment with clopidogrel and no pre-emptive genotyping
32797439|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
32797440|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
32797441|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
33303864|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
33303865|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
32797442|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
32797443|NCT02028182|Experimental|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
33303866|NCT05625178|Experimental|tVNS group|This will be a single-arm study where all study participants will receive transcutaneous vagus nerve stimulation (tVNS) at the cymba concha of the left ear for 60 minutes. The tVNS parameters will be a below-discomfort-threshold intensity with 25 Hz and a pulse width of 250 uS.
33303867|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
33303868|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
33303869|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
33303870|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
33303871|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
33303872|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
32797444|NCT04684472|Experimental|Modified anti-CD19 CAR T cell therapy|CAR T cell therapy
33303873|NCT05669170|Active Comparator|Treatment|Methylphenidate 20 mg
33303874|NCT05669170|Placebo Comparator|Placebo|Placebo
33303875|NCT03792568|Experimental|ALK mutation|
32797445|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
33303876|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
33303877|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
33303878|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
33303879|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
33303880|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
33303881|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
33303882|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
32907060|NCT01045460|Experimental|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
33303883|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
33303884|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
33303885|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
33303886|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
33303887|NCT05589688|Experimental|acyclovir|Subjects take a single dose of 5 mg/kg infused over 1 hour.
33303888|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
33303889|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
33303890|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
33303891|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
33303892|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
33303893|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
33303894|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
33303895|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
33303896|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
33303897|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
33303898|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
33303899|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
33303900|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
33303901|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
33303902|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
33303903|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
33303904|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
33303905|NCT05625022|Experimental|Lianhua Qingke plus conventional therapy|
33303906|NCT05625022|No Intervention|Conventional therapy|
33303907|NCT05624866|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
33303908|NCT05624866|Active Comparator|Triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
33303909|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
33303910|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
33303911|NCT01303978|Experimental|APD421 starting dose|
33303912|NCT03994900|Experimental|Blood sampling for HbNO assessment|
33303913|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
33303914|NCT01304056||Interventional volunteer group|Healthy volunteers
33303915|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
33303916|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
33303917|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
33303918|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
33303919|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
33303920|NCT00124020|Experimental|Telavancin|
33303921|NCT00124020|Active Comparator|Vancomycin|
33303922|NCT05630794|Experimental|Prevention (ONC201, biopsy, sigmoidoscopy, colonoscopy)|Patients receive ONC201 PO QW or Q3W for 12 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study.
33303923|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
33303924|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
33303925|NCT05626270|Other|LunulaLaser OTC|
33303926|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
33303927|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
33303928|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
33303929|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
33303930|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
33303931|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
33303932|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
33303933|NCT05624710|Experimental|Group 1: Severe Hepatic Impairment|Participants with severe hepatic impairment (Class C Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
33303934|NCT05624710|Experimental|Group 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Class B Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
33303935|NCT05624710|Experimental|Group 3: Mild Hepatic Impairment|Participants with mild hepatic impairment (Class A Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
33303936|NCT05624710|Experimental|Group D: Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of INCB054707 on Day 1.
33303937|NCT03966066|Experimental|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
33303938|NCT03966066|No Intervention|Non-erythromycin treatment group|systemic treatment
33303939|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
33303940|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
33303941|NCT00215540|Experimental|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
33303942|NCT00215540|Experimental|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
33303943|NCT00215540|Placebo Comparator|Placebo|Sham air using 3.0 mL/kg volume of air
33303944|NCT03966846|Experimental|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
33303945|NCT03966846|Placebo Comparator|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
33303946|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
33303947|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
33303948|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
33303949|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
33303950|NCT03797950|No Intervention|Control|No active intervention
33303951|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
33303952|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
33404272|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
33303953|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
32907061|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging (during and outside of a migraine attack)"
33089671|NCT04698473|Active Comparator|NCPAP|"Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
33303954|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
33089672|NCT04698473|Active Comparator|NIPPV|"Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
33303955|NCT01304212|Active Comparator|femoral block|
33303956|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
33303957|NCT01304212|Active Comparator|several drugs local infiltration|
33303958|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
33303959|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
33303960|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
33303961|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
33303962|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
33089673|NCT04698707||lower limb lymphedema patients|This retrospective cohort study enrolled 131 lower limb lymphedema patients including 10 patients who have received VLNT as their primary lymphedema surgery showing minimal post-VLNT improvement (Group I) and 121 patients without previous lymphatic surgery (Group II).
33089674|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
33303963|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
33303964|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
33303965|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
33089675|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
33089676|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
33089677|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
33089678|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
33089679|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
33089680|NCT00451295|Placebo Comparator|1|
33303966|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
33089681|NCT00451295|Experimental|2|
33303967|NCT01560520||Accelerometer|
33303968|NCT05624632||Cognitively unimpaired|Cognitively unimpaired participants from BBRC-sponsored studies
33303969|NCT00143390|Experimental|1|
33303970|NCT00143390|Experimental|2|
33303971|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
33303972|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
33303973|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo; Lunch: Neobianacid® placebo; Midafternoon: Neobianacid® placebo; Dinner: Neobianacid® placebo; Before going to bed: Neobianacid® placebo.~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo on demand Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
33404273|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
32940916|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
32940917|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
32940918|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
32940919|NCT05752214||Group A|
32940920|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
32940921|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
32940922|NCT04331210|Active Comparator|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
32940923|NCT04331210|Active Comparator|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
32940924|NCT05752136|Experimental|Neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Name: KN053~Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
32940925|NCT05752136|No Intervention|Neoadjuvant chemoradiotherapy and total mesorectal excision|"Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
32940926|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
32940927|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
32940928|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
32940929|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
32940930|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
32940931|NCT05701436|Experimental|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.
32940932|NCT05701436|Active Comparator|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.
33404274|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
33404275|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
32940935|NCT05691686|Experimental|Finely milled whole wheat-legume bread|Treatment with finely milled whole wheat-legume bread.
32940936|NCT05691686|Experimental|Less processed whole wheat-legume bread|Treatment with less processed whole wheat-legume bread.
32940937|NCT05691686|Experimental|Less processed whole wheat bread|Treatment with of less processed whole wheat bread.
32940938|NCT05691686|Active Comparator|Reference Food (white wheat bread)|Treatment with reference food.
32797446|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
33089682|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
33303974|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
33303975|NCT05624476||experimental group|Patients with urinary tract infection received treatments guided by both culture and mNGS
33303976|NCT05624476||control group|Patients with urinary tract infection received treatments guided by culture first
33303977|NCT03792022||Group 1|Adherence to timely vaccine uptake
33303978|NCT03800134|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy|"Durvalumab (MEDI4736) in concurrence with platinum-based chemotherapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:~carboplatin/paclitaxel~cisplatin/gemcitabine~pemetrexed/cisplatin~pemetrexed/carboplatin"
32797447|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
32797448|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
33303979|NCT03800134|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy|"Placebo in concurrence with platinum-based chemotherapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:~carboplatin/paclitaxel~cisplatin/gemcitabine~pemetrexed/cisplatin~pemetrexed/carboplatin"
33303980|NCT01304290|No Intervention|Control|
33303981|NCT01304290|Experimental|Glucose/Insulin Clamp|
33303982|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
33089683|NCT00330447||Control group|Children from the general population
33303983|NCT03797248||Cohort 2|adjuvant chemotherapy only
33303984|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
33303985|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
33303986|NCT00141102|Experimental|A|
33303987|NCT00141102|Active Comparator|B|
32797449|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
33303988|NCT03663712|Experimental|Dose|"Drug: Talimogene Laherparepvec~There will be two parts to this phase I study: 1) Dose Escalation Cohort; 2.) Dose Expansion Cohort~In the Dose Escalation Cohort, three subjects will be enrolled at the starting dose of 4x106 PFU, and the dosing will continue in the standard '3+3' dose escalation scheme. If the starting dose is tolerated, enrollment will continue at 4x107 and 4x108 PFU. Once the MTD is determined, six subjects will be enrolled to the Dose Expansion Cohort at the MTD. All subjects will be dosed with talimogene laherparepvec intraperitoneal (IP) once every 2 weeks for up to 4 doses (in addition to the initial seroconversion dose, which all patients will receive)."
33303989|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
33303990|NCT03797092|No Intervention|Control group|No treatment
33303991|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
33303992|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
33303993|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
33303994|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
33089684|NCT00451412|Experimental|Certoparin|
33089685|NCT00451412|Active Comparator|Unfractionated Heparin|
33089686|NCT04717245|Active Comparator|Fractional CO2 LASER|Vaginal fractional CO2 LASER 3 sessions applications
32797450|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
32797451|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
33404276|NCT05173350|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
32797452|NCT04724603||patients having had avderse event after phagotherapy for bone or joint infection|
32797453|NCT04724369|Experimental|Study Cohort: Subjects with known or presumed neuroblastoma|"Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.~Other Names:~meta-fluorobenzylguanidine~IRP101"
32797454|NCT02067533|Experimental|flexion position|
32797455|NCT02067533|Experimental|extension position|
32797456|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
32797457|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
32797458|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
32797459|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
33303995|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
32797460|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
32797461|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
32797462|NCT04085068||control group (group B):|shame group
32797463|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
32797464|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
32797465|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
32797466|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
32797467|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
32797468|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
32797469|NCT04723511|Experimental|GPR|participants in this group receive global postural reeducation technique+ Kendall exercises
32797470|NCT04723511|Active Comparator|Kendall|Kendall exercises
32797471|NCT04723355|Experimental|Holter device|In this single arm of the study, the participant will use 2 Holter systems simultaneously for 24 hours, an innovative 3-lead wireless water resistant device and a conventional device.
32797472|NCT04417985|Experimental|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.~The blood sample was collected on the same day of PET/CT scan."
32797473|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
32797474|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
32797475|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
32797476|NCT04185545|Placebo Comparator|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
32797477|NCT04185545|Experimental|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
32797478|NCT04185545|Placebo Comparator|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
33089687|NCT04717245|Active Comparator|Microablative fractional radiofrequency|Vaginal Microablative fractional radiofrequency 3 sessions application
33303996|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
33303997|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
33089688|NCT04717245|Active Comparator|Promestriene Vaginal|Promestriene vaginal use during 3 months
33089689|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
33089690|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
33089691|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
33089692|NCT04716738||Irritable Bowel Syndrome with Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
33303998|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
33303999|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
33304000|NCT03573856|Active Comparator|Active Living|Three component behavioral intervention consisting of group-based classes, individual motivational interviewing-based sessions, and resource toolbox
33304001|NCT03573856|Placebo Comparator|Health and Safety|One component health and safety program consisting of group classes
33304002|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
33304003|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
33304004|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
33089693|NCT04716738||Irritable Bowel Syndrome without Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
33089694|NCT00451568|Active Comparator|1|metformin
33304005|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
33304006|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
33304007|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
33304008|NCT03789136||Primary colon cancer|
33304009|NCT03789136||Liver metastases|
33304010|NCT03789136||Inguinal hernia (control)|
33304011|NCT03789136||Abdominal hysterectomy (control)|
33304012|NCT03789058|Active Comparator|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
33304013|NCT03789058|Experimental|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
33304014|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
33304015|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
33304016|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
33089695|NCT00451568|Active Comparator|2|desorelle
33089696|NCT00451568|Active Comparator|3|desorelle + metformin
33102440|NCT04702113|Experimental|Genotype-guided therapy (experimental)|"Treatment with clopidogrel 75 mg daily for non-carriers~Treatment with ticagrelor 90 mg twice daily for carriers"
33304017|NCT05408260|Experimental|Screening (automated breast ultrasound, handheld ultrasound)|Participants undergo HHUS and ABUS in no required order over 1 hour.
33304018|NCT05068414||Patients with atrial fibrillation|
33304019|NCT05669092|Experimental|ARM A: dMMR/MSI-H patients|patients will receive 12 cycles of PD-1 antibody
33304020|NCT05669092|Experimental|ARM B: dMMR/MSI-H patients|patients will receive 5*5Gy short-course radiotherapy, followed by 12 cycles of PD-1 antibody
33304021|NCT05669092|Experimental|ARM C: pMMR/MSS patients|patients will receive CRT followed by 6 cycles of XELIRI
33304022|NCT05669092|Experimental|ARM D: pMMR/MSS patients|patients will receive CRT followed by 12 cycles of FOLFRINOX
33304023|NCT00255008|Active Comparator|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
33304024|NCT00255008|Active Comparator|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
33304025|NCT00255008|Experimental|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
33304026|NCT00255008|Active Comparator|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
33304027|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
33304028|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
33304029|NCT03714022|Experimental|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
33304030|NCT03714022|Active Comparator|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
33304031|NCT05624164|Experimental|Lateralized microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair with microfracture at the lateral side of the footprint immediately.
33304032|NCT05624164|No Intervention|No microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair without microfracture.
33304033|NCT00143312|Experimental|1|
33304034|NCT05619640||Group 1|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Uninfected; No viral RNA detected
33404277|NCT05173350|Active Comparator|Active Comparator|The active comparator group does not receive the full set of RETAIN intervention activities.
32797479|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
32797480|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
33089697|NCT04716465||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 (symptomatic and asymptomatic) will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
33089698|NCT00451646|Experimental|1|SMOFlipid
33089699|NCT00451646|Active Comparator|2|Intralipid
32797481|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
32797482|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
32797483|NCT04416308|Other|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
32797484|NCT04416308|Other|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
32797485|NCT04416308|Other|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
33089700|NCT04716348|Experimental|group A|suboccipital muscle energy technique
33089701|NCT04716348|Sham Comparator|group B|sham muscle energy technique
33304035|NCT05619640||Group 2|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Ambulatory mild disease Viral RNA detected but asymptomatic course, Symptomatic but not given any medication and Symptomatic given medication
33304036|NCT05619640||Group 3|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Hospitalized moderate disease Hospitalized but no oxygen therapy and Hospitalized and given oxygen by mask or nasal cannula
33304037|NCT03967028||Study group|primigravida scheduled for cesarean section
33304038|NCT03791866|Experimental|30% target total enteral nutrition|
33304039|NCT03791866|Experimental|60% target total enteral nutrition|
32797486|NCT04416308|Other|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
32797487|NCT02027558|Experimental|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
32797488|NCT02027558|Active Comparator|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
32797489|NCT04684238|Active Comparator|Drug: Midazolam|Midazolam for sedation in the ICU
32797490|NCT04684238|Experimental|Drug: Isoflurane|Volatile for sedation in the ICU
32797491|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
32797492|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
32797493|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
32797494|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
32797495|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
32797496|NCT01448824|Experimental|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
32797497|NCT01448824|Experimental|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
32797498|NCT01448824|Experimental|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
33304040|NCT03791866|Active Comparator|100% target total enteral nutrition|
33304041|NCT03967262|Experimental|Intervention|
33304042|NCT03967262|No Intervention|Control|
33304043|NCT04833946|Active Comparator|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
32797499|NCT01448824|Experimental|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
32797500|NCT01448824|Experimental|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
32797501|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
33089702|NCT00451841||1|Chronic cough caused by GERD
33089703|NCT00451841||2|Chronic cough without GERD
33089704|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
33089705|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
33089706|NCT00451880|Experimental|Arm 1|XL281 administered once a day
33089707|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
33089708|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
33089709|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
33089710|NCT00452036||Minor head injury|patients with minor head injury
33089711|NCT00452036||minor head injury|patients with minor head injury
33089712|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
33089713|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
32797502|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
32797503|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
33089714|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
32797504|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
32797505|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
32797506|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
33089715|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
32797507|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
32797508|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
33089716|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
33089717|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
32797509|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
32797510|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
32797511|NCT04084834|Experimental|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
32797512|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
32797513|NCT04083898|Experimental|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
32797514|NCT04083898|Experimental|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
32797515|NCT04083898|Experimental|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
32797516|NCT04083898|Experimental|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
32797517|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
33089718|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
33089719|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
33089720|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
33089721|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
33089722|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
33089723|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
33304044|NCT04833946|Placebo Comparator|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
33304045|NCT01077206|Active Comparator|Simvastatin 80mg|
33304046|NCT01077206|Active Comparator|Simvastatin 40mg|
33304047|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
33304048|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
33304049|NCT05623540||bisphosphonates users|Patients who underwent primary total joint arthroplasty with bisphosphonates use
33304050|NCT05623540||bisphosphonates nonusers|Patients who underwent primary total joint arthroplasty without bisphosphonates use
33304051|NCT05622838||Pregnant Pre-eclamptic women with IUGR at 32-36 weeks|
33304052|NCT05622838||Pregnant Pre-eclamptic women with healthy fetus at 32-36 weeks|
33304053|NCT05622838||Normal pregnant women with healthy fetus|
33304054|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
33304055|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
33304056|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
33304057|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
33304058|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
33304059|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
33304060|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
33304061|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
33304062|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
33304063|NCT05620732|Experimental|Treatment group|Patients treated with Claudin 18.2 CAR-T cells.
33304064|NCT04796350|Experimental|Treated group|Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
33304065|NCT04796350|No Intervention|Control group|Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip
33304066|NCT01306318|Experimental|1|
33304067|NCT01306318|Active Comparator|2|
33089724|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
33304068|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
33304069|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
33304070|NCT05385328||Healthy people|Undiagnosed persons will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, to establish outcome measures in healthy population.
33304071|NCT05385328||people with physical or psychological diagnoses|People with various clinical diagnoses will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, in order to establish outcome measures in comparison with healthy population and with other diagnoses.
33304072|NCT00254540|Experimental|SU-011248 capsule|
33304073|NCT05380726|Experimental|Experimental group|"A pilot study will be conducted for 2 months with a sample of 10 participants, in order to gather initial data to test the algorithm from the eHealth tool. During the QUAN phase the algorithm will provide individualized feedback and responses to the patients based on their different variables analyzed in real-time by the wrist receiver device: cardiovascular parameters, sleep quality and structure of sleep, physical activity, oxygen saturation.~The eHealth tool will contain all the educational materials developed by the researchers of the study. Depending on the information received from the electronic wrist device the eHealth tool will make recommendations of educational topics as hygienic-dietary measures, sleep related habits, or physical activity. The information provided in this regard will be dependent upon the subjects' knowledge gaps/beliefs identified in the QUAL phase and the parameters measures by the electronic wrist device in each subject."
33304074|NCT05380726|Active Comparator|Control group|In the control group, the participants will be provided with the same electronic wrist device and access to the eHeatlh tool as the experimental group. However, the electronic wrist device will not provide feedback based on the parameters of each individual. The information provided by the eHealth tool will be general information from the sleep unit of the Arnau de Vilanova - Santa María Hospital instead of the materials developed from the QUAL phase.
33304075|NCT05380492|Experimental|Low Dose|VOY-101 Low Dose (single dose, IVT)
33304076|NCT05380492|Experimental|Mid Dose|VOY-101 Mid Dose (single dose, IVT)
33304077|NCT05380492|Experimental|High Dose|VOY-101 High Dose (single dose, IVT)
33304078|NCT05380492|Active Comparator|Randomized Cohort--MTD|VOY-101 MTD (single dose, IVT)
33304079|NCT05380492|Active Comparator|Randomized Cohort--MTD-1|VOY-101 Lower Dose than MTD (single dose, IVT)
32797518|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
32797519|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
33304080|NCT05380492|Sham Comparator|Randomized Cohort--Sham|Control arm (sham procedure)
32797520|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
32797521|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
32797522|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
32797523|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
32797524|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
32797525|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
32797526|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
32797527|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
32797528|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
32797529|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
32797530|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
32797531|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
32797532|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
32797533|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
32797534|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
32797535|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
32797536|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
33304081|NCT05368402|Experimental|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg b.i.d. for 7 cycles of 14 days with an interval of 14 days off, for a total duration of 26 weeks.
33304082|NCT05368402|Placebo Comparator|Placebo|Matching placebo will be administered with the same treatment schedule of the IMP.
33304083|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
32797537|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
32797538|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
33304084|NCT01077440||Men - age 18+|
33304085|NCT05359822|No Intervention|Clinical Standard Report Only|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report only.
33304086|NCT05359822|Experimental|Clinical Standard Report plus Image-Based Report|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report plus additional image-based report.
32797539|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
32797540|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
32797541|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
32797542|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
32797543|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
32797544|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
32797545|NCT02024750|No Intervention|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
32797546|NCT01597973|Active Comparator|colistin and meropenem|
32797547|NCT01597973|Active Comparator|colistin and placebo|
32797548|NCT04671680||Pregnant women with suspected placenta accreta|Pregnant women undergoing cesarean delivery with suspected placenta accreta spectrum.
32797549|NCT02023268|Experimental|T2762|
32797550|NCT02023268|Active Comparator|Vismed®|
32797551|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
32797552|NCT05127161|Experimental|Early Intervention|The early intervention arm will begin receiving the intervention in study period 1.
32797553|NCT05127161|Other|Delayed Intervention (Control)|The delayed intervention (control) arm will begin receiving the intervention in study period 2. They will receive no intervention during period 1.
32797554|NCT04707131|Experimental|LEM-S401|
32797555|NCT04707131|Placebo Comparator|Placebo|
32797556|NCT04706975|Active Comparator|Difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg tablet administered twice daily
32797557|NCT04706975|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
32797558|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
32797559|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
32797560|NCT04705571|Experimental|MorpheusV Applicator (active)|
32797561|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
32797562|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
32797563|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
32797564|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
32797565|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
32797566|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
32797567|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
32797568|NCT02062151|Experimental|NAS babies|Acupuncture for NAS
32797569|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
33304087|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
32797570|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
32797571|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
32797572|NCT02095535||Study group|All study participants
32797573|NCT04704323||Experimental: Phase Ia - Dose escalation|Cohorts of 3 subjects will receive intravenous [IV] administrations of escalating doses of CAP-100.
32797574|NCT04704323||Experimental: Phase Ib - Dose expansion|Six subjects will receive intravenous [IV] administrations of CAP-100 at the Recommended Phase 2 Dose determined in Phase Ia - Dose Escalation of this trial.
32797575|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
32797576|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
32797577|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
32797578|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
32797579|NCT04722029|No Intervention|Donor|"Donors will be evaluated to determine suitability to undergo apheresis collection and their infectious disease status. Donor evaluation will include history and physical examination, laboratory tests, FDA- approved donor testing of communicable diseases (HIV, HVB, HCV, HTLV-I, II, WNV, T. pallidum, T. cruzi, and Zika virus), ABO and Rh typing, pregnancy tests, and donor serology for ADV.~Qualified donors will undergo leukapheresis. Collection will proceed for 2 hours or 2 blood volumes, whichever occurs first."
32797580|NCT04722029|Experimental|Recipient|"Recipient will undergo a screening period that will include history and physical examination, laboratory tests, performance status, HLA typing and pregnancy test (if needed).~Qualified patients will receive ADV-VSTS infusion from haploidentical donors up to a maximum of 5.0 x 104 interferon gamma-negative cells/kg. All patients will be followed for laboratory and clinical response, safety, efficacy and tolerance."
32797581|NCT04702373|Experimental|Passive range-of-motion|daily assisted exercise sessions lasting 15-20 minutes, conducted by trained physical therapists, for up to 21 days prior to hospital discharge, plus standard of care
32797582|NCT04702373|No Intervention|Standard of care|standard of care at study site
32797583|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
32797584|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
32797585|NCT02043899|Experimental|Single Arm Trial|This was a single arm trial, all patients were to undergo the same assessments and interventions.
32797586|NCT04719611|Experimental|Healthy Women|Healthy women between the ages of 18-40 years will be given a probiotic supplement to evaluate the detection and persistence of the strains in biological samples.
32797587|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
32797588|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
32797589|NCT04719377|Experimental|Powerme midline catheter|Powerme midline catheter
32797590|NCT04719377|Sham Comparator|peripheral intravenous catheter|BD Pegusas peripheral intravenous catheter
32797591|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
32797592|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
32797593|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
32797594|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
32797595|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
32797596|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
32797597|NCT02042183|Experimental|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
32797598|NCT02042183|Placebo Comparator|Placebo|Participants receive placebo BID up to 12 weeks
33304088|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
33304089|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
33304090|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
33089725|NCT04698512||Arteriovenous Fistuloplasty with MagicTouch™ Balloon|Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
33089726|NCT04698668||1|Patients with pancreatic fluid collection treated with traditional EUS-drainage
33089727|NCT04698668||2|Patients with pancreatic fluid collection treated with fusion imaging
33304091|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
33304092|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
33304093|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
33304094|NCT05316220|Experimental|Mesalamine Dose A|Participants will receive mesalamine Dose A twice daily for 26 weeks.
33304095|NCT05316220|Experimental|Mesalamine Dose B|Participants will receive mesalamine Dose B twice daily for 26 weeks.
33304096|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
33304097|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
33304098|NCT05060146|No Intervention|Standard care|
33404278|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
32797599|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
33304099|NCT05060146|Experimental|Structured medico-pharmaceutical collaboration|
33304100|NCT05297188||experimental group|Patients will be divided into experimental and control groups by block randomization. No application will be applied to the experimental group for first night sleep. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. The second night, an ergonomic sleep mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. The patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, the noise level will be minimized, and patients will not wake up during the night outside their treatment.
33089728|NCT04698551||16 pregnant women and their spouses|16 pregnant women and their spouses
33089729|NCT04698356|Experimental|Validation of auditory-cognitive training paradigm|In order to provide maximal speech-in-noise training benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate the translated and adjusted sentences (based on the Nottingham UK PLUS training paradigm), the adaptive procedure, and the short-term memory component, in young, normal-hearing adults (18-30 years). Based on the results of this pilot study, the investigators can further optimize the sentences and procedures to be used during the training paradigm for older adults.
33089730|NCT00334347|Active Comparator|Depakote ER|
33304101|NCT05297188||control group|Patients will be divided into experiment and control groups by block randomization. No application will be made to the control group for sleep on the first night. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. On the second night, ear plugs and eye mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. Patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, noise level will be minimized and patients will not wake up during the night outside their treatment. It will be collected using the form.
33304102|NCT05292118||Coronary Artery Disease (CAD)|
33304103|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
33304104|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
33089731|NCT00334347|Active Comparator|Depakote DR|
33089732|NCT03275207|Placebo Comparator|control group|an equal volume of saline
33089733|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
33089734|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
33089735|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
33089736|NCT04698395|Experimental|HABIT-ILE|Baby HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks
33089737|NCT04698395|Active Comparator|Regular care|Usual customary care intervention during two weeks
33089738|NCT00334581|Experimental|1|Irbesartan 150mg
33304105|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
33304106|NCT03791242|Active Comparator|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
33304107|NCT03791242|Active Comparator|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
32797600|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
33304108|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
33304109|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
32797601|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
32797602|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
32797603|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
32797604|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
32797605|NCT02058095|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
32797606|NCT02058095|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
32797607|NCT04718207||Patient with Alzheimer disease|Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
32797608|NCT04663022||Child with cochlear implant|15 childs with coclear implant but without autism spectrum disorder
32797609|NCT04663022||Child with cochlear implant and autism spectrum disorder|15 childs with coclear implant and with autism spectrum disorder
32797612|NCT04670900|Active Comparator|Operative|Patients will be operated according to Orthopedic Trauma Association (OTA) principles with either tension band wiring or plate fixation with an anatomical precontoured plate.
32797613|NCT04670900|Experimental|Non-operative|Patients will be offered a plaster cast for 1-2 weeks
32797614|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
32797615|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
32797616|NCT04670666|Experimental|MADALENA|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association, oral;~1 tablet empagliflozin + linagliptin association placebo, oral;~1 tablet metformin placebo, oral."
32797617|NCT04670666|Active Comparator|Metformin + empagliflozin + linagliptin|"The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association placebo, oral;~1 tablet empagliflozin + linagliptin association, oral;~1 tablet metformin, oral."
32797618|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
32797619|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
32797620|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
32797621|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
32797622|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
32797623|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
32797624|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
32797625|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
33304110|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
33304111|NCT01305850|Active Comparator|Aliskiren|
33304112|NCT01305850|Active Comparator|Aliskiren plus Losartan|
33304113|NCT01305850|Active Comparator|Enalapril plus Losartan|
32797626|NCT04717973||patients undergo sleeve gasterectomy|
32797627|NCT04717973||patients undergo gasteric bypass|
33304114|NCT01305850|Placebo Comparator|placebo|
33304115|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
33304116|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
33304117|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
33304118|NCT01306630|Other|tivozanib + capecitabine|
33304119|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
33304120|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
32797628|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
32907062|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging"
33304121|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
33304122|NCT05566288|Experimental|Sequence 1|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Placebo (negative control) (8 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
33304123|NCT05566288|Experimental|Sequence 2|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
33304124|NCT05566288|Experimental|Sequence 3|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
33304125|NCT05566288|Experimental|Sequence 4|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
33304126|NCT05566288|Experimental|Sequence 5|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
33304127|NCT05566288|Experimental|Sequence 6|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Placebo (negative control) (8 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
33304128|NCT05566288|Experimental|Sequence 7|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
33304129|NCT05566288|Experimental|Sequence 8|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
33304130|NCT05557864|Experimental|Parkinson's disease with DBS|Participants will have a diagnosis of idiopathic PD and have undergone/will undergo neurosurgery to implant deep brain stimulators in the globus pallidus (GP DBS) or subthalamic nucleus (STN)
33304131|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
33089739|NCT00334581|Experimental|2|Irbesartan 300mg
33089740|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
33089741|NCT00452465|No Intervention|Control|Usual Care
33089742|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
33089743|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
33089744|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
33304132|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
33304133|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
33304134|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
33304135|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
33304136|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
33304137|NCT05604976|Experimental|SC-PCI|Primary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.
33304138|NCT05604976|Active Comparator|Conventional|Primary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.
33304139|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
33304140|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
33304141|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
33304142|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
33304143|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
33304144|NCT01304758|Experimental|ExAblate Treatment|
33089745|NCT03274973||Zomacton|
33089746|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
33089747|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
33089748|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
33089749|NCT00334971|Other|2|Healthy African-American women 18-35 years old
33089750|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
33089751|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
33089752|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
33089753|NCT00452816|Active Comparator|2|Delayed Intervention
33089754|NCT00335166|Experimental|1|
33089755|NCT00335166|Active Comparator|2|
33304145|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.
33304146|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.
33304147|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.
33304148|NCT05571748|Experimental|G6PD deficiency (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 G6PD deficient individuals.
33304149|NCT05571748|Placebo Comparator|G6PD deficiency (only) - Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 120 G6PD deficient individuals.
33304150|NCT05571748|Experimental|G6PD deficiency and CHO metabolism disorder - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
33304151|NCT05571748|Placebo Comparator|G6PD deficiency and CHO metabolism disorder - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
33089756|NCT00335166|Placebo Comparator|3|
33089757|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
33089758|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
33089759|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
33089760|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
33089761|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
33404279|NCT05761080||Experimental branch|"Patients will be included in the study during the anesthetic surgery evaluation.~Randomization of patients on the third postoperative day.~If belonging to the FT group:~Application of discharge criteria in the experimental branch at 72 hours post-surgery, administration of oral antibiotic therapy with a similar spectrum to that of the control group for a total of 5 days and sending the patient home with oral analgesia.~Amoxicillin - clavulanic acid Dose: 100mg/Kg/day every 8 hours Oral route, oral Augmentin, for 5 days.~Regardless of the group to which the patient belongs, there will be a follow-up at 5, 7 and 30 days after telephone discharge. In addition, there will be a face-to-face visit 2 weeks after the intervention.~The approximate duration of the patient under study will be 35 days."
33089762|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
33089763|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
33089764|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
33089765|NCT00453167|Experimental|study arm|
33089766|NCT00420654|Active Comparator|A1|
33089767|NCT00420654|Placebo Comparator|A2|
33089768|NCT00420654|Other|A3|
33089769|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
33089770|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
33089771|NCT00453323|Experimental|study arm|
33089772|NCT04698083||Group1:normal SpO2(NS,n = 80) and low SpO2(LS, n = 80).|Patients with normal oxygen saturation (SpO2; ≥ 90%) who did not receive oxygen therapy and patients with low SpO2(<90%) who received nasal oxygen therapy were included in this study
33089773|NCT04698083||Group2:Rightward axis shift(Rws) and Leftward axis shift (Lws)|Both groups were divided into two main subgroups:patients with Rws and patients with leftward shift(Lws) of the QRS axis.The patient numbers were as follows: NS Rws (n=37),NS Lws(n=43),LS Rws (n=40),andLS Lws (n=40)
33089774|NCT00335595|Active Comparator|1|XELOXA
33089775|NCT00335595|Experimental|2|XELOXA-A
33089776|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
33089777|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
33089778|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
33089779|NCT04698278||Surgical Treatment Group|This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.
33089780|NCT04698200|Experimental|Blood pressure|Measurement of brachial, central and beat-to-beat blood pressure.
33089781|NCT00335985|Experimental|1|
33089782|NCT00335985|Placebo Comparator|2|
33089783|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
33089784|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
33089785|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
33089786|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
33404280|NCT05761080||Control branch|"Patients will be included in the study during the anesthetic surgery evaluation. The patient will be randomized at the time of informed consent to know the postoperative guideline to be used. Randomization of patients on postoperative day 3. If it belongs to the control group:~Application of discharge criteria in control branch 5 days postoperative, according to current clinic guidelines.~Amoxicillin - clavulanic acid. Dose: 100mg/Kg/day every 8 hours, intravenous, Augmentin Iv.~Duration of treatment: 5 days~Regardless of the group to which you belong, you will be followed up 5, 7 and 30 days after telephone discharge. In addition, an in-person visit will be made 2 weeks after the intervention. The approximate duration of the patient under study will be 35 days."
32940939|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
32940940|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
32940941|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
32940942|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
32940943|NCT05684510|Experimental|Experimental : clear aligners with class II elastics technique|clear aligners technique A group of patients in which participants will be undergo to clear aligners treatment with class II elastics ( clear aligners will be applied to the upper and lower arch, then a class II elastics 1\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
32940944|NCT05684510|Experimental|: traditional treatment Fixed appliances with class II elastics.|A group of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
32940945|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
32940946|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
32940947|NCT05751746||Control|Control group with participants who do not get magnesium sulfate administration.
32940948|NCT05751746||Magnesium group|Intervention group with participants who get magnesium sulfate administration.
32940949|NCT05681546||Observational Group|The investigators are going to observe the risk factors about inferior alveolar nerve block anesthesia.
32940950|NCT05674370|Experimental|Novel, graphene-based, point-of-care device|Subjects will receive one additional nasal swab at the same time as clinical collection.
33089787|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
33089788|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
33089789|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
33089790|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
33089791|NCT00336141|Experimental|Vorinostat|
33089792|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
33089793|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment~Small vessels (≤2.75 mm) approx. 150 subjects~Chronic total occlusion (CTO) approx. 50 subjects~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects~Multivessels approx. 250 subjects~In stent restenosis approx. 100 subjects~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
33089794|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
33089795|NCT04698239|Experimental|Laser application ( BEFORE/AFTER)|"All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself.~The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study."
33089796|NCT00336336|Experimental|1|N-3PUFA
33089797|NCT00336336|Placebo Comparator|2|
33089798|NCT00336336|Experimental|3|Rosuvastatin
33089799|NCT00336336|Placebo Comparator|4|
33089800|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
33089801|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
33089802|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
33089803|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
33089804|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
32797629|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
32797630|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
32797631|NCT04698161||NSCLC|Patients with non-small-cell lung cancer (NSCLC)
32797632|NCT04698161||metastatic melanoma|patients with metastatic melanoma
32797633|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
32797634|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
33404281|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
32797635|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
33089805|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
33089806|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
33404282|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
32797636|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
32907063|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
32907064|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
33089807|NCT00454025||Glaucoma|Patients with Glaucoma
33089808|NCT00454025||Healthy Patients|Patients without glaucoma
33089809|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
33089810|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
33089811|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
33089812|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
33089813|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
33089814|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
33089815|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
33089816|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
33089817|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
33089818|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
33089819|NCT00322179||Obese|
33089820|NCT00322179||Non-Obese|
33089821|NCT00230438|Experimental|External Beam Radiation Therapy|
33089822|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
33089823|NCT00230477|Active Comparator|Mono therapy|Hepsera
33089824|NCT00230477|Active Comparator|Combo therapy|
33089825|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
33089826|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
33089827|NCT00336921|Active Comparator|1|Alfuzosin 10mg
33089828|NCT00336921|Placebo Comparator|2|Placebo
33089829|NCT00336960|Experimental|treatment intervention|
33304152|NCT05571748|Experimental|CHO metabolism disorder (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
33304153|NCT05571748|Placebo Comparator|CHO metabolism disorder (only) - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
32797637|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
33089830|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
33304154|NCT05571748|Experimental|Controls - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
33304155|NCT05571748|Placebo Comparator|Controls - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
33304156|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
33304157|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
33304158|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
33304159|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
33304160|NCT05695144|Experimental|tDCS active stimulation combined with rTMS sham stimulation group|1
33304161|NCT05695144|Experimental|rTMS active stimulation combined with tDCS sham stimulation group|2
33304162|NCT05695144|Experimental|tDCS active stimulation combined with rTMS active stimulation group|3
33304163|NCT05695144|Experimental|tDCS sham stimulation combined with rTMS sham stimulation group|4
33304164|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
33304165|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
33304166|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
33089831|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
33304167|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
33304168|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
33304169|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
33102441|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
33304170|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
33304171|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
33304172|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
33304173|NCT01304914||Healthy, term-delivered babies|
33304174|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
33304175|NCT01307254||Non alcoholic fatty liver disease|
33304176|NCT01307254||control|
33304177|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
33304178|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
33304179|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
33304180|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
33304181|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
33304182|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
33304183|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
33304184|NCT01305928|Active Comparator|Fax|
33304185|NCT01305928|Experimental|Warm Hand-off|
33304186|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
33304187|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
32797638|NCT01967888|Experimental|Reparixin|Solution for intravenous (IV) infusion with active compound
32797639|NCT01967888|Placebo Comparator|Placebo|Physiologic solution
33089832|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
33089833|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
33089834|NCT00418613|Experimental|1|MK0633
32797640|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
32797641|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
32797642|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
32797643|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
33089835|NCT00418613|Placebo Comparator|2|Placebo
32797644|NCT01967576|Experimental|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
32797645|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
32797646|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
32797647|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
33089836|NCT04715841||group A|Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations .
33089837|NCT04715841||group B|Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university .
33089838|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
33089839|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
32797648|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
32797649|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
32797650|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
32797651|NCT05127473|Experimental|Dose level 1|All participants will receive a single dose of Mim8
32797652|NCT05127473|Experimental|Dose level 2|All participants will receive a single dose of Mim8
32797653|NCT05127473|Experimental|Dose level 3|All participants will receive a single dose of Mim8
32797654|NCT05127473|Experimental|Dose level 4|All participants will receive a single dose of Mim8
32797655|NCT05127473|Experimental|Dose level 5|All participants will receive a single dose of Mim8
32797656|NCT05127473|Experimental|Dose level 6|All participants will receive a single dose of Mim8
32797657|NCT05127473|Experimental|Dose level 7|All participants will receive a single dose of Mim8
32797658|NCT05127473|Experimental|Dose level 8|All participants will receive a single dose of Mim8
32797659|NCT05127473|Experimental|Dose level 9|All participants will receive a single dose of Mim8
32797660|NCT05127473|Experimental|Dose level 10|All participants will receive a single dose of Mim8
32797661|NCT05127473|Experimental|Dose level 11|All participants will receive a single dose of Mim8
32797662|NCT05127473|Experimental|Dose level 12|All participants will receive a single dose of Mim8
33089840|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
33089841|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
33089842|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
33089843|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
33089844|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
33089845|NCT00306644|Experimental|Arm 1|study drug
33089846|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
33089847|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
33089848|NCT00306839|Other|1|Tissel group
33089849|NCT00306839|Other|2|Suture group
33089850|NCT04715724|Experimental|Baby doll with remote controlled jaw|In this arm, participants will complete a simulation using the Newborn Oral Assessment and Latch Simulator (NORALSim), which is designed to look, feel, and weigh like a healthy human newborn. The NORALSim's jaw can be remotely operated by the user to demonstrate attachment at the breast.
33089851|NCT04715724|Active Comparator|Baby doll with hand controlled jaw|In this arm, participants will complete a simulation using a cloth baby with a puppet-style jaw which can be opened and closed by the user to demonstrate attachment at the breast.
32797663|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
33089852|NCT04715724|Active Comparator|Static baby doll|In this arm, participants will complete a simulation using a rigid, plastic baby with a static, open mouth.
33089853|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
33089854|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
33089855|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
32797664|NCT02054897|Experimental|Semaglutide 1.0 mg|
32797665|NCT02054897|Experimental|Semaglutide 0.5 mg|
32797666|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
32797667|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
33089856|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
33089857|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
33089858|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
33089859|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
32797668|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
32797669|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
32797670|NCT02039219|Placebo Comparator|Placebo|Placebo
32797671|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
32797672|NCT04693793|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.
32797673|NCT04693793|Experimental|Educational Materials and Janssen Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
32797674|NCT04693793|Experimental|Educational Materials and Janssen Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
32797675|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
33089860|NCT00307190||Controls|Weight, age, and gender-matched control subjects
33089861|NCT04717856|Other|drug users|
33089862|NCT04715607|Active Comparator|Nasopharyngeal swab, oropharyngeal swab, and salvia collection|"The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
33089863|NCT04715607|Active Comparator|Oropharyngeal swab, salvia collection, and nasopharyngeal swab|"The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
33089864|NCT04715607|Active Comparator|Salvia collection, nasopharyngeal swab, and oropharyngeal swab|"The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
33089865|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
33089866|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
33089867|NCT00337701|Experimental|1|
33089868|NCT00337701|Experimental|2|
33089869|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
33089870|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
33089871|NCT00421005|Experimental|1|Fluvastatin 80mg
33089872|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
33089873|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
33089874|NCT00307502|Experimental|NVP|Nevirapine
33089875|NCT00307502|Experimental|EFV|Efavirenz
33089876|NCT00307502|Experimental|INV|Indinavir/ritonavir
33089877|NCT00307502|Experimental|NFV|Nelfinavir
33089878|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
33089879|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
33089880|NCT00307502|Experimental|ATV|Atazanavir
33089881|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
33089882|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
33089883|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
33089884|NCT00307502|Experimental|DRV|Darunavir/ritonavir
33089885|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
33089886|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
33304188|NCT05694910|Experimental|Reiki Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After the protests will be completed, the primary investigator with Reiki second degree will apply Reiki to the patients for 30 minutes. On the second day and the third day, 30 minutes distance Reiki will be applied to the patients. Post-tests will be applied to all patients after one week and vital signs and laboratory findings will be recorded.
33304189|NCT05694910|No Intervention|Control Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After a week, the posttest will be applied to the patients and vital signs and laboratory findings will be recorded.
33304190|NCT04915924|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
33304191|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
33304192|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
33304193|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
33304194|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
33304195|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
33304196|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
33304197|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
33304198|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
33304199|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
33304200|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
33304201|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
33304202|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
33304203|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
33304204|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
33304205|NCT05694754|Experimental|1 session|Participants will receive 1 session from monday to friday,during 4 weeks, with 600 total pulses per session
33304206|NCT05694754|Experimental|3 sessions|Participants will receive 3 sessions from monday to friday,during 4 weeks, with 1800 total pulses per session with a 10 minutes rest interval
33304207|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
33304208|NCT03794128||2 - shared neoantigen cancer vaccine screening|
33304209|NCT03794440|Experimental|Sintilimab +IBI305|
33089887|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
33089888|NCT00337974|Active Comparator|Active Control|Educational DVDs
33089889|NCT00337974|No Intervention|No Contact Control|
32797676|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
32797677|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
33304210|NCT03794440|Active Comparator|Sorafenib|
33089890|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
33304211|NCT05534542|Active Comparator|core stabılızatıon|use of ıntradıalıtıc core stabılızatıon ın hemodıalysıs patıents
33304212|NCT05534542|Active Comparator|aerobıc exercıse|use of ıntradıalıtıc aerobıc exercıse ın hemodıalysıs patıents
33304213|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
33304214|NCT05527522|Placebo Comparator|Control|Control arm: Who received the usual practice.
33304215|NCT05527522|Experimental|Intervention|Intervention arm: Who received an individualized diet, educational intervention with/without nutritional supplements depending on the degree of malnutrition plus usual practice
32797678|NCT04661540|Experimental|Auxora|"Auxora will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
32797679|NCT04661540|Placebo Comparator|Placebo|"Placebo will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
32797680|NCT04175210|Experimental|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
33089891|NCT04715919||Patients in ICU|ICU patients with COVID-19
33089892|NCT04715919||Patients in Hospital Ward|Patients with COVID-19 in hospital wards
33089893|NCT00307853|Active Comparator|1|TraumeelS
33089894|NCT00307853|Placebo Comparator|Placebo|
33089895|NCT00307892|Active Comparator|A|TRAUMEEL S
33089896|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
33089897|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
33089898|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
33089899|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
33089900|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
33089901|NCT00338130|Active Comparator|1|Temozolomide
33089902|NCT00338130|Experimental|2|AZD6244
33089903|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
33089904|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
33089905|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
33089906|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
33089907|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
33089908|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
33089909|NCT04715568|Experimental|Placebo then Losartan|Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
33089910|NCT04715568|Experimental|Losartan then Placebo|Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.
33089911|NCT00418730|Experimental|1|
33089912|NCT00418730|Active Comparator|2|
33089913|NCT00418730|Placebo Comparator|3|
33089914|NCT00418769|Experimental|Nilotinib Tablet Formulations|
33089915|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
33089916|NCT00308204|Experimental|Raptiva|raptiva injection
33089917|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
33089918|NCT00425334|Active Comparator|Control|Ringer's lactate
33089919|NCT04715802||PAAG removal + Immediate implant reconstruction|Patients who had a one-stage operation comprising gel removal and immediate breast reconstruction.
33089920|NCT04715802||PAAG removal + Delayed implant reconstruction|Patients who had a two-stage operation comprising gel removal and delayed breast reconstruction at least 3 months later. The first included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
33089921|NCT04715802||PAAG removal + No breast reconstruction|Patients who only underwent surgical PAAG removal without breast reconstruction.
33102442|NCT04691817|Experimental|Atezolizumab and Tocilizumab|Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
33089922|NCT04715802||PAAG removal + Delayed autologous fat grafting reconstruction|Patients who underwent a two-stage operation comprising surgical PAAG removal and autologous fat injection at least 3months later. Usually, the amount of transplanted fat was 150-200mL/side. A multilayer and multi-tunnel injection method was commonly used.
32797681|NCT04175210|Experimental|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
33089923|NCT04715802||PAAG removal + breast reconstruction with implants|Patients who underwent surgical PAAG removal with immediate or delayed implant breast reconstruction.
32797682|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
32797683|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
33089924|NCT04715802||Primary breast augmentation with implants|Patients who had undergone conventional breast augmentation(BA) with implants during the study period who matched the study cohort by age(±5 years).
33089925|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
33089926|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
33089927|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
33089928|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
33089929|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
33089930|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
33089931|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
33089932|NCT00308789|Experimental|1|Biphasic NCPAP
33089933|NCT00308789|Active Comparator|2|Continuous CPAP
32797684|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
32797685|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
32797686|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
32797687|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
32797688|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
32797689|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
32797690|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
32797691|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
32797692|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
33089934|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
33089935|NCT00341406||Patients overweight|Those who are generally healthy but overweight
33089936|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
33089937|NCT00308906||1|Hospitalized, untreated infants and children
33089938|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
33089939|NCT00308906||3|Aminoglycoside treated infants with renal injury
33089940|NCT00308945|Experimental|2|cross-over comparison of two substances
33089941|NCT00308945|Experimental|1|
33089942|NCT00338481|Active Comparator|1|
33089943|NCT00338481|Active Comparator|2|
33089944|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
33102443|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
33102444|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
32797693|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
33304216|NCT05694598|Experimental|VGR-R01|Single-dose Subretinal Administration of VGR-R01
33304217|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
33304218|NCT00139776|Active Comparator|Celecoxib - Continuous use|
33089945|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
33089946|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
33089947|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
33089948|NCT00309101|Experimental|1. tacrolimus|
33304219|NCT00139776|Active Comparator|Celecoxib - Intermittent use|
33089949|NCT00309218|Active Comparator|A|Steroid withdrawal
33089950|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
33089951|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
33089952|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
33089953|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
33089954|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
33304220|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
33089955|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
33089956|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
33089957|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
33304221|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
32797694|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
32797695|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
32797696|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
32797697|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
32797698|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
33089958|NCT04715880|Active Comparator|Paravertebral Block (PVB) group|"Under complete aseptic precaution, Patient will be in lateral decubitus position a paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity.~The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour"
33089959|NCT04715880|Active Comparator|Paravertebral block/Intercostal Block (PVB/ICB) group|Under complete aseptic precaution, patient will be in lateral decubitus position a paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
33089960|NCT00309491|Experimental|Group I|Tamoxifen alone
33089961|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
33304222|NCT03787420|Active Comparator|traditional communication system|
33304223|NCT03787420|Experimental|intelligent communication system|
33304224|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
33304225|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
33304226|NCT01037777||presymptomatic carriers|
33304227|NCT01037777||non carrier relatives|
33304228|NCT01037855||Group 1: 6-23 months|
33304229|NCT01037855||Group 2: 2-8 years|
33304230|NCT01037855||Group 3: 9-17 years|
33304231|NCT01037855||Group 4: 18-44 years|
33304232|NCT01037855||Group 5: 45-60 years|
33304233|NCT01037855||Group: >60 years|
33304234|NCT03713320|Experimental|Cobomarsen|Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
33304235|NCT03713320|Active Comparator|Vorinostat|Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.
33304236|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
33304237|NCT00420407|Experimental|I|Vasopressin
33304238|NCT00420407|Placebo Comparator|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
33304239|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
33304240|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
33304241|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
33304242|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
33304243|NCT05694520|No Intervention|Stand care control group (CG)|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for the included participants, who all have the pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating nuts intake of less than 2.5 oz per week.
33304244|NCT05694520|Experimental|Intervention group (IG)|The participants in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
33304245|NCT05694442|Experimental|Lipmatte K|Participants will used Lipmatte K everyday for 4 weeks
33304246|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
33304247|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
33304248|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
33304249|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
33304250|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
33304251|NCT00420095|Active Comparator|1|Human insulin mix 30/70
33304252|NCT00420095|Experimental|2|Insulin lispro low mix
33304253|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
33304254|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
33304255|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
33304256|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
33304257|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
33304258|NCT04904692||COVID-19 positive|"Peripheral blood draw:~Day 1 of admission: blood draw.~Day 7-10 of hospitalization: blood draw.~Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.~Day 7-14 of hospitalization: NP swab or clinically available alternative will be executed on day 7 repeated weekly."
33304259|NCT04904692||COVID-19 negative|"Peripheral blood draw:~Day 1 of admission: blood draw.~Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~o Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative."
33304260|NCT01038089|Experimental|resveratrol|Resveratrol
33304261|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
33304262|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
33304263|NCT05495464|Experimental|Acalabrutinib and Rituximab (Part 1)|Participants may receive acalabrutinib and rituximab for up to 12 cycles. Each cycle is 28 days.
33304264|NCT05495464|Experimental|Brexucabtagene Autoleucel (Part 2)|Participants will have a procedure called leukapheresis to collect enough T cells.
33304265|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
33304266|NCT04738708||Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients attending genetic counselling for Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome in Clinical Genetic Services (CGS) at National Cancer Centre Singapore (NCCS)
33304267|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
33304268|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
33304269|NCT04690738||Post Pancreas Transplant Patients|Pancreas transplant recipients
33304270|NCT02257229||Surgical|Corrective Surgery only
33304271|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
33304272|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
33089962|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
33102445|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
33102446|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
33102447|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
33304273|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
33304274|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
32797699|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
32797700|NCT02038829|Placebo Comparator|Placebo|Placebo bid
32797701|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
32797702|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
32797703|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
32797704|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
32797705|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
32797706|NCT04693247|Active Comparator|Refraction with a Hand-held Refraction Device|This is the device that will be compared to a standard device.
32797707|NCT04693247|Other|Autorefractor|Standard Device
32797708|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
32797709|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
32797710|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
32797711|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
32797712|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
32797713|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
32797714|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
32797715|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
32797716|NCT02051933|Active Comparator|Botox|"Botox: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
32797717|NCT02051933|Placebo Comparator|Placebo|"Placebo: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
32797718|NCT02050373|Experimental|Low-Level laser|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
32797719|NCT02050373|No Intervention|Control|In the control group, patients receive only the preventive protocol bone marrow transplant industry, consisting of mouthwashes and sodium fluoride. For ethical reasons, individuals who present oral mucositis grade 2 (WHO) will receive LLLT.
32797720|NCT02049437|Active Comparator|Arm A: TCZ, then placebo|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
32797721|NCT02049437|Placebo Comparator|Arm B: Placebo, then TCZ|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
33304275|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
33304276|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
32797722|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
33304277|NCT03993977|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
33304278|NCT03993977|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
33304279|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
33304280|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
33304281|NCT02174549|Experimental|Tirapazamine|Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.
33304282|NCT03786562|Placebo Comparator|Placebo group|
33304283|NCT03786562|Active Comparator|Nalbuphine group|
33304284|NCT05694364|Experimental|Phase 1 Dose Escalation (Group A)|"Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m^2) and cyclophosphamide (500 mg/m^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10^6 cells/kg Dose Level 2: 3x10^6 cells/kg Dose Level 3: 1x10^7 cells/kg"
33304285|NCT05694364|Experimental|Phase 1 Dose Escalation (Group B)|"Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10^6 cells/kg Dose Level 2: 3x10^6 cells/kg Dose Level 3: 1x10^7 cells/kg"
33304286|NCT05694364|Experimental|Phase 1b Dose Expansion (Group A)|Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m^2) and cyclophosphamide (500 mg/m^2) prior to study day 0. Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
33304287|NCT05694364|Experimental|Phase 1b Dose Expansion (Group B)|Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m^2) prior to study day 0.Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
33304288|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
33304289|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
33304290|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
33304291|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
33304292|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
33304293|NCT01038401|Other|HIV-1-infected patients on effective HAART|
33304294|NCT01038401|Other|Non Infected HIV Volunteers|
33304295|NCT05694286|Experimental|Infraorbital Filler|Receives 1-2mL injection of approved filler in infraorbital region
33304296|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
33304297|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
33304298|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
33304299|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
33304300|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
33304301|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
33304302|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
33304303|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
33304304|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
33304305|NCT05694208|Experimental|Experimental group|The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
33304306|NCT05694208|No Intervention|Control Group|It is the group in which no intervention will be made other than data collection.
33304307|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
33304308|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
33304309|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day~Placebo will be delivered in similar, packaging, appearance and taste."
33304310|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
33304311|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
33304312|NCT05693818||PersonaIQ|Patients indicated for a PersonaIQ total knee arthroplasty
33304313|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
33304314|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
33304315|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
33304316|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
33304317|NCT05694130|Placebo Comparator|Prednisolone monotherapy|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
33304318|NCT05694130|Experimental|Prednisolone plus Tacrolimus|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
33304319|NCT01308112|Experimental|Supplemental iron|
33304320|NCT01308112|Placebo Comparator|Placebo|
33304321|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
33304322|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
33304323|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:~Incision of the anterior palatal arch~Locating of the cranial pole of the tonsil~Dissection of the tonsil capsule~Localized coagulation of bleeding vessels~Detaching of the inferior pole from the pharynx tissue"
33304324|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
33304325|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
33304326|NCT05567302|Experimental|Manual therapy|Manual therapy, manipulative therapy, is a completely manual treatment method that includes special techniques and is known as a treatment that aims to correct bony deformities and is highly effective when combined with exercise.
33304327|NCT05567302|Active Comparator|myofascial release|Foam rollers are a popular tool for helping athletes release muscle knots or trigger points.Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use.
33304328|NCT05693974||stage I-II ovarian cancer|30 patients with stage I-II ovarian cancer
33304329|NCT05693974||stage III-IV ovarian cancer|30 patients with stage III-IV ovarian cancer
33304330|NCT05693974||benign ovarian cancer|40 patients with benign ovarian cancer
33304331|NCT05693974||healthy people|30 healthy people
33304332|NCT03786094|Active Comparator|Eribulin|
33304333|NCT03786094|Experimental|Balixafortide + eribulin|
33304334|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
33304335|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
33304336|NCT05693896|Experimental|Centering Appetite Intervention, Then Attention- Control Group|Participants randomized to the attention-control group will participate remotely via a smartphone app and online lessons. The intervention will build participants' self-efficacy to reduce binge eating and to assist them in preventing weight gain.
32797723|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
32797724|NCT04711733||Patients 6-14 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
33089963|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
33089964|NCT00309569|Experimental|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
33089965|NCT00309569|Experimental|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
33089966|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
32797725|NCT04711733||Parents of 6-14 years old patients|Individual interview + Self-report questionnaire
32797726|NCT04711733||Patients 15-25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
32797727|NCT04711733||Parents of 15-25 years old patients|Individual interview + Self-report questionnaire
32797728|NCT04711733||Patients > 25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
32797729|NCT04711733||Parents of > 25 years old patients|Individual interview + Self-report questionnaire
33089967|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
33089968|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
33304337|NCT05693896|No Intervention|Attention- Control Group, Then Centering Appetite Intervention|Participants randomized to the centering appetite intervention group will receive weekly psychoeducation emails about general wellness topics, discussion of binge eating, diet, and physical activity.
33304338|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
32797730|NCT01445080|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32797731|NCT04417205|Active Comparator|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
32797732|NCT04417205|Experimental|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
32797733|NCT04417205|No Intervention|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
32797734|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
32797735|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
32797736|NCT04692779||Intubated ARDS patients undergoing prone positioning|All intubated ARDS patients undergoing prone positioning will be assessed with LUS before and after prone positioning and before and after placing back in the supine position.
32797737|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
32797738|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
32797739|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
32797740|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
32797741|NCT04709549|Active Comparator|Diabetes Prevention Program|The DPP is a behavioral obesity and diabetes prevention program run by the YMCA, over a 12-month period.
32797742|NCT04709549|Experimental|Diabetes Prevention Program + Job and Legal Services|Participants meet with service connectors to receive an individual assessment of your needs and create an individual service plan for job services and be referred to legal support services if also needed.
32797743|NCT04748536|Experimental|Group 1: Dose A IRL201104 or placebo|IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days
33089969|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
33304339|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
32797744|NCT04748536|Experimental|Group 2: Dose B IRL201104 or placebo|IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days
32797745|NCT04692701|Experimental|Pulvinar stimulation|Medial pulvinar deep brain stimulation
33089970|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
33089971|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
33089972|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
33089973|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
32797746|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
32797747|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
32797748|NCT04709471|Experimental|Switch to low nicotine e-cigarettes|Switch to e-cigarettes containing 60% of baseline e-cigarette nicotine content.
32797749|NCT04709471|Experimental|Reduce number of e-cigarette pods|Reduce e-cigarette use to 60% of baseline number of pods per week.
32797750|NCT04709471|No Intervention|Use e-cigarettes as usual|Continue using usual nicotine e-cigarettes as usual.
32797751|NCT04690985|Sham Comparator|Control group|The control group will be asked to continue their own daily routes. One research assistant, who will not be involved in other procedures of the study, will contact with the participants to talk about different issues except the SO related topic. The frequency of face-to-face meetings and telephone calls will be similar to the experimental group. The issues talked in the control group could be as follows but not limited: a) normal social communication topics such as greetings, recent living conditions, news in the past week; b) health consultations asked by the participants; c) avoid to mention dietary or exercise related information. An appointment of post-test will be made in the last time telephone call.
32797752|NCT04690985|Experimental|Experimental group|The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
32797753|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
32797754|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
32797755|NCT04690205|Experimental|End of Life (EOL) Care at at Home|End of Life (EOL) Care at at Home intervention entails the following: patient-reported symptoms and home monitored vital signs and body weight with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
32797756|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
32797757|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
32797758|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
32797759|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
32797760|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
32797761|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
32797762|NCT04681469|Experimental|Single Arm Treatment|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
33089974|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
33318494|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
32797763|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
32797764|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
32907065|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
32797765|NCT04690127|Experimental|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). Except for one session that will be applied every two weeks, all other trainings will be given on the basis of telerehabilitation via distance education tools.
33304340|NCT05693662|Experimental|Patient Education Booklet|"Before applying to the parents of the children with ASD included in the experimental group, After the pre-test data are collected, 8 sessions of Awareness-Based Self-Compassion training will be given to the parents in the experimental group. The first two sessions will be held face-to-face, and the remaining sessions will continue online. Each session will be planned for 3 days to 7 days for its activity and continuity. One week after the Awareness-Based Self-Compassion training (after 8 sessions were completed), parents were given the Parental Stress Scale (PASS), Adult Resilience Scale, Warwick-Edinburgh Mental Well-Being Scale, Self-Compassion Scale. Short Form (SSS-F), Conscious Awareness Scale (CIFS) post-test will be filled face to face."
33304341|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
33304342|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
33304343|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
33304344|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
33304345|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
33304346|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
33304347|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
33304348|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
33304349|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
33304350|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
33304351|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
33304352|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
33304353|NCT05693584|Experimental|Virtual reality glasses|Experimental group:Group applying virtual reality glasses
33304354|NCT05693584|No Intervention|Routine practices|No procedure was performed on the patients other than the routine practices of the clinic.
33304355|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
33304356|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
33304357|NCT01310920||sick sinus syndrome|
33304358|NCT01310920||control|
33304359|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
33304360|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
33304361|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
33304362|NCT01988584|Experimental|umbilical cord blood (UCB) cells|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
33304363|NCT01988584|Experimental|bone marrow-derived mononuclear cells (BMMNCs)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
33304364|NCT01988584|Experimental|saline infusion (placebo), then umbilical cord blood (UCB) cells|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
32797766|NCT04690127|No Intervention|Control Group|Volunteers in this group will not participate in any training.
33304365|NCT01988584|Experimental|saline infusion (placebo), then bone marrow-derived mononuclear cells (BMMNCs)|
33304366|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
33304367|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
33304368|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
33304369|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
33304370|NCT01308502|Experimental|Probe|Children with airway obstruction
33304371|NCT01310998|Experimental|schizophrenic disorder|
33304372|NCT01310998|Experimental|other psychotic disorder|
33304373|NCT01310998|Experimental|no mental disorder|
33304374|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
33304375|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
33304376|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
33304377|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
32797767|NCT04689659|Experimental|chimeric antigen receptor T cell treatment|
33304378|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
32797768|NCT02020967||Acromegaly patients|
32797769|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
33304379|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
33304380|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
33304381|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
32797770|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
33089975|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
33304382|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
33304383|NCT01035125|No Intervention|Waiting list|
33304384|NCT01035125|Experimental|Self-management program|One week self-management program
33304385|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).~drugs described in the clinic."
33089976|NCT00418847|Experimental|1|
33304386|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
33304387|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
33304388|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
33304389|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
33304390|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
33304391|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
32797771|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
32797772|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
32797773|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
32797774|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
33304392|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
33304393|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
33304394|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
33304395|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
33304396|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
33304397|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
33304398|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
33304399|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
33304400|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
33304401|NCT01035203|Active Comparator|Cognitive behavioural therapy|
33304402|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
32940951|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
32940952|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
32940953|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
32940954|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
32940955|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
33089977|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
32940956|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
32940957|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
32940958|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
32940959|NCT05751668|Experimental|Arm I (paclitaxel, GM1)|Patients receive GM1 IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
32940960|NCT05751668|Placebo Comparator|Arm II (paclitaxel, placebo)|Patients receive placebo IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
32940961|NCT05670470|Experimental|CTP0303|
32940962|NCT05670470|Active Comparator|Orafang Tab|
32940963|NCT05751590|Active Comparator|Glidescope + Fiberoptic broncscopy|
32940964|NCT05751590|Active Comparator|Fiberoptic broncscopy|
32940965|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
32940966|NCT05751512|Experimental|MRG003|MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
32940967|NCT05751512|Active Comparator|cetuximab/ methotrexate|cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW)
32940968|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
32940969|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
32940970|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
32940971|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
32940972|NCT05667974|Experimental|PIKA Rabies|Receive 1 of the 3 lots of PIKA rabies vaccine via IM administration that 2-2-1 schedule with a double-dose injection on Day 0 and 3 and a single-dose injection on Day 7
32940973|NCT05667974|Active Comparator|Control|Receive Rabipur via IM administration that the classic Essen 5-dose regimen 1-1-1-1-1 schedule on Days 0, 3, 7, 14 and 28PPT中
32940974|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
33304403|NCT05693428|Other|Propofol|Anesthesia
33304404|NCT05693428|Other|Isofluran|Anesthesia
32797775|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
32940975|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
32940976|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
32940977|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
32940978|NCT05665790|Experimental|radiotherapy|
33304405|NCT05693428|Other|Sevofluran|Anesthesia
32797776|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
32940979|NCT05665790|Experimental|palliative surgery|
32940980|NCT05665790|No Intervention|no primary leison treatment|
32940981|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
32940982|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
33089978|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
33089979|NCT00341991||1|Cases from hospitals
33089980|NCT00341991||2|Controls from the general populations
33089981|NCT00341991||3|Biological Samples
33304406|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
33304407|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
33304408|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
33304409|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
33304410|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
33304411|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
33089982|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
33089983|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
33089984|NCT00338871|Experimental|study|home exercise
32797777|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
32797778|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
32797779|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
32797780|NCT04635670|Placebo Comparator|Placebo|Soluble powder for oral use twice daily
33089985|NCT00338871|No Intervention|control|regular therapy
33089986|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
33089987|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
33089988|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
33089989|NCT04715217|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
33089990|NCT04715217|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10^6 CAR+Tcells/kg.
33089991|NCT04715217|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10^6 CAR+Tcells/kg.
33089992|NCT04715217|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
33089993|NCT00339027||Preschool children|Children aged 3-5 years who are enrolled in federally-subsidized early care and education centers in underserved communities in Miami-Dade County
33089994|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
32797781|NCT04635670|Active Comparator|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
32797782|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
33089995|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
32797783|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
32797784|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
32797785|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
32797786|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
32797787|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
32797788|NCT01444300|Experimental|Dalfampridine|
32797789|NCT01444300|Placebo Comparator|Placebo|
32797790|NCT04681001|Experimental|Coldamaris pro|One puff per nostril three puffs into mouth
32797791|NCT04681001|Placebo Comparator|Coldamaris sine|One puff per nostril three puffs into mouth
32797792|NCT01443364|Experimental|Certolizumab pegol|
32797793|NCT04680533|Experimental|TENS device|The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
32797794|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
32797795|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
32797796|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
32797797|NCT04179305|Experimental|Oncolo_GIST Arm|Physicians assigned to this arm will receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.
32797798|NCT04179305|Placebo Comparator|Usual Care Arm|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.
32797799|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
32797800|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
32797801|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
33089996|NCT00342147||1|This is a high risk population of families for NPC
33089997|NCT00310544|Experimental|Arm 2|
33089998|NCT00310544|Experimental|Arm 1|
33089999|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
33090000|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
33090001|NCT00421044|Experimental|Arm A (Normal liver function)|
32797802|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
32797803|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
32797804|NCT02030405|Experimental|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32797805|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
32797806|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
33090002|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
32797807|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
32797808|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
33090003|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
33090004|NCT04715256|Experimental|KCNQ1 mutated subjects|"This arm includes :~KCNQ1-mutated subjects with long QT Romano-Ward syndrome~KCNQ1-mutated subjects without phenotypic expression of the Romano-Ward syndrome~family relatives of a KCNQ1-mutated enrolled subject, carrying the KCNQ1 family mutation"
33090005|NCT04715256|Sham Comparator|Healthy subjects|Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, > 28-38 years, > 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; > 30 kg/m2).
33090006|NCT00310778|Experimental|1|treatment
33090007|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
33090008|NCT00421122|Active Comparator|1|Bricasol®
33090009|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
32797809|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
33090010|NCT00421122|Experimental|3|Bricasol® + Symbicort®
33304412|NCT03793036|No Intervention|FAST group|preoperative fasting
33318495|NCT05622890|Experimental|treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
32797810|NCT04066192|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
32797811|NCT04066192|Active Comparator|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
32797812|NCT04066192|Active Comparator|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
32797813|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32797814|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32797815|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
32797816|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
32797817|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
32797818|NCT03026686||Controls|women with similar risk factors but did not require readmission
33090011|NCT00425295|Active Comparator|1|
33090012|NCT00425295|Experimental|2|
33090013|NCT00339222||1|Melanoma-prone families from dermatology clinics.
33090014|NCT00311129|Experimental|Arm 1|
33090015|NCT00311129|Active Comparator|Arm 2|
33090016|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
33090017|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
33090018|NCT04715412|Other|Study group|"The standard training sessions were conducted for individual patient by the transplant physician to explain rejections, infections and tumor risks, post-transplant medication. After discharge, all patients had scheduled follow-up visits at the outpatient clinic of the transplant center, where immune suppressant blood levels were measured and their dosing adjusted accordingly. Patients also had the opportunity to discuss any concern of their condition or drug therapy with the transplant physician in charge.~in addition to this standard transplant training, patients received intensified care by a dedicated clinical pharmacist combining educational and technical interventions aiming at achieving and maintaining adherence to his/her prescribed medication and improving health outcomes."
33318496|NCT00303329|Experimental|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
32797819|NCT04065256|Experimental|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
32797820|NCT04065256|Experimental|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
33090019|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
32797821|NCT04065256|No Intervention|Control group|The control group involves neither music intervention nor using earplug at night.
33304413|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
33304414|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
33304415|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
32797822|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
33304416|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
33304417|NCT01035437|Experimental|HPPH|HPPH
33304418|NCT04835428|Experimental|Treatment with AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
33304419|NCT04835428|Active Comparator|Treatment with PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
33304420|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
33304421|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
33304422|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
33304423|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
33304424|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
33304425|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
33304426|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
33304427|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
33304428|NCT05397340|Experimental|L-GPi/R-STN|Participants randomized in this arm will receive L-GPi/R-STN stimulation for 1 year.
33304429|NCT05397340|Active Comparator|Bi-STN|Participants randomized in this arm will receive bilateral STN stimulation for 1 year.
32797823|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
32797824|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
32797825|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
32797826|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
32797827|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
32797828|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
32797829|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
32797830|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
32797831|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
32797832|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
32797833|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
32797834|NCT04670653|Experimental|MAGNÓLIA|Two applications in each nostril, once a day.
32797835|NCT04670653|Active Comparator|MOMETASONE FUROATE|Two applications in each nostril, once a day.
33304430|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
33304431|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
33304432|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
33304433|NCT05357170||Sepsis Survivors|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
33304434|NCT05357170||Healthy Control Population|One time collection of feces and blood upon enrollment used for comparison to identify microbial genes associated with persistent systemic inflammation in sepsis survivors.
33304435|NCT05357170||Trauma Survivor|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
32797836|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
32797837|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
32797838|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
32797839|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
32797840|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
32797841|NCT04069936|Experimental|MILs™ - NSCLC plus nivolumab with or without tadalafil|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
32797842|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
32797843|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
32797844|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
32797845|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
32797846|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
32797847|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
32797848|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
32797849|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
32797850|NCT01965860|Experimental|E-LEARNING|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire, no simulation.
32797851|NCT04415827|Experimental|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
32797852|NCT04415827|Experimental|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
32797853|NCT04415827|Experimental|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
33304436|NCT05357170||Traumatic Brain Injury (TBI)|"Feces collected at admission (day 1(+5)) and between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first and second feces collection."
33304437|NCT05692726||Patients|Patients with non-hypervolemic hypotonic hyponatremia
33304438|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
33304439|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
33304440|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
33304441|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
33304442|NCT05154214||Adenotonsillectomy|Excision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques.
33318497|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
33304443|NCT05154214||Drug-induced sleep endoscopy directed surgery (DISE)|DISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE.
33304444|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
33304445|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
33090020|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
33090021|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
33304446|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
33304447|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
33304448|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~Participants in this group will also receive oral vitamin C as a placebo."
33304449|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
33304450|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
33304451|NCT01313260||control group|Healthy volunteers
33304452|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
33304453|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
33304454|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
33304455|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
33090022|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
33090023|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
33304456|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
33090024|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
33090025|NCT00311675|Experimental|1|
33090026|NCT00311753|Experimental|1|Certoparin
33090027|NCT00311753|Active Comparator|2|Heparin
33304457|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
33304458|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
33304459|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
33304460|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
33304461|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
33304462|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
33318498|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
33318499|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
33318500|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
32797854|NCT04415827|Experimental|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
33090028|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
33090029|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
33090030|NCT00311792|Experimental|1|Simulator training
33090031|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
33090032|NCT00311831|Active Comparator|1|
33090033|NCT00311831|Experimental|2|
33090034|NCT00342771||NCI Maryland pop-based controls|population-based controls
33090035|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
33090036|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
33090037|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
33090038|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
33090039|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
33090040|NCT00342849|Experimental|1|Scuccimer Treatment Group
33318501|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
33318502|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
33318503|NCT03818048|Experimental|Group Propofol|propofol infusion
33304463|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
33304464|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
32737934|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
32737935|NCT03240289|Other|Texting|Texting group
33304465|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
33304466|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33090041|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
33090042|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
33090043|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
33090044|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
33090045|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
33090046|NCT00312260|Experimental|1|
33090047|NCT00312260|Active Comparator|2|
33304467|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33304468|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
33304469|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
33304470|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
32737936|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
32737937|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
32737938|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
32737939|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
33090048|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
33090049|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
33090050|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
33090051|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
32737940|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
33090052|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
33090053|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
33090054|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
33304471|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
33304472|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
33304473|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
33318504|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
33318505|NCT01325519|No Intervention|no intervention control group|control subjects
32940983|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
32940984|NCT05751356|Experimental|TR128|
32940985|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
32940986|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
32940987|NCT05751200||CARS group|continuous aortic root suture group: Schematic diagram of root repair of acute type A aortic dissection using continuously sutured with the vascular grafts with 3-0 polypropylene, then 3-0 polypropylene pledgeted interrupted suture to reinforce the anastomosis for one circle.
32940988|NCT05751200||XJ-procedure group|"intermittent mattress type built-in skirt forming method group: 1.5 - 2cm wide bovine pericardial patch and graft ring were placed inside and outside the aortic root respectively and attached to the aortic wall, suited above the aortic valve commissures by continuous mattress suture using 5-0 polypropylene. The vascular graft with an eversion margin of about 15mm was implanted into the vascular cavity of the aortic root. The eversion margin of graft was sutured with the inner and outer membranes of the aorta by intermittent mattress suture using 2-0 padded polyester suture. Aortic root repair was completed by continuous anastomosis of the eversion margin of the artificial vessel to the reinforced upper end of the aorta using 3-0Prolene thread."
32940989|NCT05751200||Bentall group|aortic root replacement group
32940990|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
32940991|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
32940992|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
32940993|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
33318506|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
32940994|NCT05751122|Experimental|Dynamic flex cast with neurodevelopmental Group|Dynamic flex cast with neurodevelopmental treatment
32940995|NCT05751122|Active Comparator|Rigid Ankle foot Orthosis with neurodevelopmental Group|Rigid Ankle foot Orthosis with neurodevelopmental treatment
32940996|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
32940997|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
32940998|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
32940999|NCT05655884|Experimental|Music Listening Application|"Children in this group; 15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher (who has received music therapy training) via the creatone music pillow for 15 minutes."
32941000|NCT05655884|Experimental|Foot Reflexology Practice|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher (who has received reflexology training), only to the left foot, for 10 minutes.
32941001|NCT05655884|No Intervention|Control Group|Children in this group will not be subjected to any non-pharmacological application to reduce nausea, pain and anxiety before and after surgery. They will receive routine perioperative care administered in the clinic.
32941002|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
32941003|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
32941004|NCT05751044|Experimental|Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide + cytarabine|"Sub-study B~Each cycle lasts 28 days.~Cycle 1: All patients in cycle 1 will receive 28 days of of dasatinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles: Dasatinib and ventoclax one a day (day 1-28); one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, receive a lower dose of venetoclax. Patients in dose level 2 receive a higher dose of venetoclax.~All patients receive age adapted intrathecal chemotherapy."
32941005|NCT05649176|Active Comparator|Diet without soy|Participants receive a diet to moderate the blood glucose response that does not include soy
32941006|NCT05649176|Experimental|Diet with soy|Participants receive a diet to moderate the blood glucose response that includes soy
33090055|NCT00312455|Experimental|1|Drug Treatment
33090056|NCT00312455|Placebo Comparator|2|Placebo treatment
33090057|NCT00339885||AADM|Family and Population based individuals
33090058|NCT00339885||Action-LADA|Population based individuals
33090059|NCT00339885||D2D 2004|Population based individuals
33304474|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
33304475|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
33304476|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
33304477|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
33304478|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
33304479|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
33304480|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
33304481|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
33304482|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
33304483|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
33304484|NCT03780166|Experimental|Parsaclisib|
33304485|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
33304486|NCT01561222|Placebo Comparator|placebo|
33304487|NCT01561222|Experimental|Calcitriol|
33304488|NCT05289154|Experimental|self- applied acupressure plus Qigong plus advice literature|"daily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders.~The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise."
33304489|NCT05289154|Active Comparator|advice literature|advice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19.
33304490|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
33304491|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
33304492|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
33304493|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
33304494|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
33304495|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
33304496|NCT01308892|Active Comparator|High flavaonol chocolate|
33304497|NCT01308892|Placebo Comparator|Low flavanol chocolate|
33304498|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
33304499|NCT01308970|Experimental|Stress Management Group 1|
33304500|NCT01308970|Experimental|Stress Management Group 2|
33304501|NCT01308970|Experimental|Stress Management Group 3|
33304502|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
33304503|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
33304504|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
33304505|NCT05106478||Moderate lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in moderate lateral position.
33304506|NCT05106478||Extreme lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in extreme lateral position.
32941007|NCT05648864|Experimental|Viamigo intervention|All eligible and consenting dyads will be asked to participate in the Viamigo intervention (mobile application), consisting of three main components: (1) a face-to-face technology training session of 60 minutes, (2) a 3-month period of using the Viamigo intervention with support phone calls of approximately 5 minutes by the coordinating investigator once every two weeks, and (3) an evaluation phone call of 5-10 minutes.
33304507|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
33304508|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
33304509|NCT04532242|Experimental|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
33304510|NCT05510440|Experimental|Effect of citrulline supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of citrulline.
33304511|NCT05510440|Placebo Comparator|Effect of placebo supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of placebo.
33304512|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
33304513|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
33304514|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer~anatomical MRI (T1 and tensor imaging) scan)"
33304515|NCT03784534|Experimental|Patients|"Patients will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth~anatomical MRI (T1 and tensor imaging) scan)"
32941008|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
32941009|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
32941010|NCT05750966|Experimental|Very short-course antibiotics|The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis (e.g. dosage form, dosage, frequency)and/or the national SWAB guideline in the Netherlands. In the experimental group, duration of ABT after adequate drainage will be 1 day. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis.
32941011|NCT05750966|Active Comparator|Standard course antibiotics|"The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis, which are based on the previously mentioned national SWAB guideline. This means that the type of ABT, dosage and frequency will be comparable to the experimental group.~In the comparator group treatment duration with ABT after ERCP will be according to the international well known and widely used TG18. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis."
32941012|NCT05314153|Experimental|Open Label - Active Drug|Brexanolone (zulresso) infusion arm. All patients enrolled will receive active treatment with brexanolone.
32941013|NCT05750888|Experimental|Experimental group 1|A novel-designed intrinsic foot muscle-strengthening exerciser using 3D printing techniques will be used in the experimental group.
32941014|NCT05750888|Sham Comparator|Experimental group 2|A regular exercise program will be provided in this group.
32941015|NCT05750888|No Intervention|Control group|There is no exercise or other intervention in this group.
32941016|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
32941017|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
32941018|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
32941019|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
32941020|NCT00002570|No Intervention|Observation|
32941021|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
33090060|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
33090061|NCT00339885||FINRISK 1987|Population based individuals
33090062|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
33090063|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
33090064|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
33090065|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
33090066|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
33304516|NCT03776734|Experimental|cryotherapy application|effect of cold application
33304517|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
33304518|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
33304519|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
33304520|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
33304521|NCT04589650|Experimental|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
33304522|NCT04589650|Placebo Comparator|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
33304523|NCT04589650|Experimental|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
33304524|NCT04589650|Placebo Comparator|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
33304525|NCT04589650|Experimental|Pediatric cohort (group 3: 2 to 5 years old)- Alpelisib granules|Pediatric participants (2 to 5 years old) will receive alpelisib with the alpelisib granules formulation at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 and 5 as available. An extrapolation approach will be used for dose selection for this group.
33304526|NCT04589650|Experimental|Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCT|Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
33304527|NCT04589650|Experimental|Pediatric cohort (group 5: 6-17 years old)-Alpelisib FCT|Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.
33304528|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
33304529|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
32797855|NCT04415827|Experimental|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
32797856|NCT04415827|Experimental|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
32797857|NCT04415827|Experimental|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
32797858|NCT04415827|Experimental|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
32797859|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
32797860|NCT04666129|Experimental|Part 1: Relugolix plus Abiraterone plus a Corticosteroid|Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
32797861|NCT04666129|Experimental|Part 2: Relugolix plus Apalutamide|Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
32797862|NCT04666129|Experimental|Part 3: Relugolix plus Docetaxel with or without Prednisone|Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
32797863|NCT04666051|Experimental|Fibrin glue|A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
32797864|NCT04666051|No Intervention|Control|Lymphadenctomy wound was closed after insertion of a drain,
32797865|NCT01965704|Experimental|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
32797866|NCT01965704|Placebo Comparator|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
32797867|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
32797868|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
32797869|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
32797870|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
32797871|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
32797872|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
32797873|NCT04665583||Prehabilitation|All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.
32797874|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
32797875|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
32797876|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
32797877|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
33304530|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
33304531|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
33304532|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
33304533|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
33304534|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
33304535|NCT05489380|Other|Accumeasure last|Optical polyp size assessment, followed by biopsy forceps and then AccuMeasure measurement
33304536|NCT05489380|Other|AccuMeasure first|optical assessment, followed by AccuMeasure measurement and then biopsy forceps assisted assessment (2)
33304537|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
33304538|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
33304539|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
33304540|NCT01314820|Sham Comparator|sham injection|knee injection without saline
33304541|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.~Intervention: App-technology for healthy eating habits."
33304542|NCT03784612|No Intervention|Control group|The control group will receive standard care.
33304543|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
33304544|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
33304545|NCT05091502|Other|Healthy volunteers|
33304546|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
33304547|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
33304548|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
32797878|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
32797879|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
32797880|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
33304549|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
33304550|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
33304551|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
33304552|NCT01314898|Experimental|Treatment|
33304553|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
33304554|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
33304555|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
33304556|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
33304557|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
33304558|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
33304559|NCT05224258|Experimental|MiniMed 780G System Utilizing Insulin Fiasp|Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Fiasp® for a period of three months.
33304560|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
33304561|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
33304562|NCT05519644|Active Comparator|Placebo First|Patients will be randomize to take the placebo for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a ketone ester.
33304563|NCT05519644|Experimental|Ketone Ester First|Patients will be randomize to take the ketone ester for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a placebo
33318507|NCT05614388|Experimental|Study participants|The study procedure is universal to all the participants from both the institutes. There are no control arms defined separately. The groups within the participants include - include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College.
33318508|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
32941024|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
33304564|NCT05022550|Experimental|DEEP VR Experiment Group|Participants identified from the Dane County Juvenile Court Program will be asked to experience up to 6 VR-B sessions. Participants will wear a lightweight, ultra-high-resolution, wireless, head-mounted display (Oculus Quest 2 Enterprise VR Headset). Each session will proceed through a series of four stages. First, participants will begin with a 5 minute acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 minute resting period where participants will be asked to sit quietly in a serene virtual environment. Third, participants will progress through the DEEP VR experience for 15 minutes. Finally, participants will complete a short series of online questionnaires.
33304565|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
32941025|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
32941026|NCT05750732||Study group|Age range 20-50, BMI range of 25-40 kg/m2
32941027|NCT05750732||Control group|Age range 20-50, BMI range18.5-24.9 kg/m2
33304566|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
33304567|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
33304568|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
33304569|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
33304570|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
33304571|NCT01315756|No Intervention|Control group|Treatment as usual.
33304572|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
33304573|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
33304574|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
33304575|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
33304576|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
33304577|NCT03778684|Experimental|Normal Body mass index without central obesity|
33304578|NCT03778684|Experimental|High Body mass index with central obesity|
32941028|NCT03985657|Active Comparator|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
32941029|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
32941030|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
33090067|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
33090068|NCT00339885||Health-2000|Population based individuals
33090069|NCT00339885||HUNT 2|Population based individuals
33090070|NCT00339885||METSIM|Population based individuals
33090071|NCT00339885||Savitaipale|Population based individuals
33090072|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
33304579|NCT05505214|Experimental|Bacterial decolonization|Validated decolonization regimen
33304580|NCT05505214|Experimental|Topical corticosteroid|Mometasone furoate 0.1% cream
33304581|NCT05505214|Experimental|Combination|Validated decolonization regimen and mometasone furoate 0.1% cream
33304582|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
33304583|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
33304584|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
33318509|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
33090073|NCT00343200|Placebo Comparator|Placebo|
33090074|NCT00343200|Experimental|Sildenafil|
32797881|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
32797882|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
33090075|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
33090076|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
33090077|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
33090078|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
33090079|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
33090080|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
33090081|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
33090082|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
33090083|NCT00343395|Placebo Comparator|Placebo|
33090084|NCT00347763|No Intervention|control|no active fly spray intervention
33090085|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
33090086|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
33090087|NCT04715334|Experimental|Single arm study|The intervention is the Mollii suit which is fitted and programmed by the Mollii suit distributor, Inerventions and will be administered by trained physiotherapists from KKH. Participants will be involved in the Intervention phase of the study for 4 weeks with treatment duration of 60 min/ session every day.
33090088|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
33090089|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
33090090|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
33090091|NCT00348075|Experimental|Neurovision|
33090092|NCT00313430||Dialysis patients|
33090093|NCT00313430||with or wthout glucose added to dialysis fluid|
33090094|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
32797883|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
32797884|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
32797885|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
33090095|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
33090096|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
33090097|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
33090098|NCT00343980|Experimental|A|
33090099|NCT00343980|Active Comparator|B|
33090100|NCT00313976|Experimental|Arm 1|
33090101|NCT00313976|Experimental|Arm 2|
33090102|NCT00314054|Experimental|1|HCV-796 1000mg single dose
33090103|NCT00348387|Experimental|Group 1|
33090104|NCT00348387|Active Comparator|Group 2|
33090105|NCT00314171|Experimental|Brinzolamide + Timolol|
33090106|NCT00314171|Active Comparator|Dorzolamide + Timolol|
33090107|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
33090108|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
33090109|NCT00344253|Experimental|1|Interferon beta 3x weekly
33090110|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
33090111|NCT04715295|Experimental|Doxycyclin and Rivaroxaban|Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban
32797886|NCT04665115|Experimental|Cohort I (ibrutinib)|Patients may continue to receive ibrutinib PO daily or stop ibrutinib per provider's discretion.
32797887|NCT04665115|Experimental|Cohort II Arm 2A (ibrutinib)|Patients continue to receive ibrutinib PO daily in the absence of disease progression or unacceptable toxicity.
33090112|NCT04715295|Active Comparator|National Standard|Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5
32797888|NCT04665115|Experimental|Cohort II Arm 2B (temporary interruption)|Patients undergo temporary interruption of ibrutinib for up to 28 days unless they are discharged home and are thought to be medically fit by the primary caregiver to resume therapy according to their primary treating oncologist.
33090113|NCT04717817|Experimental|Group 1: experimental|Daily inspiratory muscle training (IMT) using an IMT Threshold device (Philips) prior to surgery
33090114|NCT04717817|Active Comparator|Group 2: comparator|Standard physiotherapy prior to surgery
33090115|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
33090116|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
33090117|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
33090118|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
33090119|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33090120|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
33090121|NCT00348738|No Intervention|2|control group receiving no treatment
32797889|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
32797890|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
32797891|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
32797892|NCT02001181|Experimental|Treatment group A|
32797893|NCT02001181|Placebo Comparator|Treatment B|
32797894|NCT04644679|Active Comparator|48-hr|48-hr electrocardiographic monitoring
32797895|NCT04644679|Experimental|7-day|7-day electrocardiographic monitoring
32797896|NCT04176055|Experimental|HALO|
32797897|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
32797898|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
32797899|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
32797900|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
32797901|NCT01974206|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
32797902|NCT01974206|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
32797903|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
32797904|NCT04659278|Placebo Comparator|Group 1 Placebo|Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
32797905|NCT04659278|Active Comparator|Group 2 Isolate Comparator|Isolate Placebo Isolate (CBD no terpenes Hemp seed oil [slightly lower concentration of CBD ratio])
32797906|NCT04659278|Placebo Comparator|Group 3 Placebo Comparator|Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
32797907|NCT04659278|Experimental|Group 4 Experimental Placebo|OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
32907066|NCT05014919|Experimental|Vortioxetine -open label treatment period|"Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events."
33090122|NCT00315029|Experimental|1|Receives combined patient centred intervention
33090123|NCT00315029|No Intervention|2|Standard treatment
33090124|NCT00348777|Active Comparator|1|group with 18 days thermal cure
33090125|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
33090126|NCT04715490|Experimental|The Multimedia Symptom Management Program Intervention|The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support.
33090127|NCT04715490|Active Comparator|Control group|Participants in the control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
33090128|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
33090129|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
33090130|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
33090131|NCT00348855|No Intervention|2|
33318510|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
32797908|NCT04659044|Experimental|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive venetoclax PO daily and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
32797909|NCT01999868|Experimental|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
32797910|NCT01999868|Active Comparator|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if <=100 kg or 90 mg if >100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
32797911|NCT01957579|Experimental|MEDI-551|
32797912|NCT03511963|Experimental|HLX04|
32797913|NCT03511963|Active Comparator|Bevacizumab|
32797914|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
32797915|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
32797916|NCT05126966|Experimental|Ranibizumab|Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
32797917|NCT05126966|Active Comparator|Aflibercept|Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.
32797918|NCT05125952|Experimental|Acute Respiratory Failure|Patients with acute respiratory failure managed with pressure-support ventilation.
32797919|NCT01996982|Experimental|Device|CCS Device application
32797920|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
32797921|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
32797922|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32797923|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
32797924|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
32797925|NCT01442038|Experimental|Ranolazine|
32797926|NCT01442038|Placebo Comparator|Placebo|
32797927|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
32797928|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
32797929|NCT01957111||Individuals with insomnia|
32797930|NCT01957111||Good sleepers|
32797931|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
32797932|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
32797933|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
32797934|NCT04416230|Experimental|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
32797935|NCT04416230|Active Comparator|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
32797936|NCT04416074|Experimental|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
32797937|NCT04416074|Other|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
32797938|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
32797939|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
32797940|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
32797941|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
32797942|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
32797943|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
33090132|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
33090133|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
33090134|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
33090135|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
33090136|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
33090137|NCT00348894|Other|Standard Care|Standard Care
33090138|NCT00315575||1|Individuals with high risk for Alzheimer's disease
33304585|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
33090139|NCT00315575||2|Individuals with low risk for Alzheimer's disease
33090140|NCT00315692||Premenopausal women|
33090141|NCT00315692||Postmenopausal women|
33090142|NCT00349050|Active Comparator|1|laboratory pain assessment
33304586|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
33304587|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
33304588|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
33304589|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
33304590|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
32746375|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
33090143|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
33090144|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
33090145|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
33090146|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
33090147|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
33090148|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
33090149|NCT00315926|Experimental|Melatonin|
33090150|NCT00315926|Placebo Comparator|Placebo|
33090151|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
33090152|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
33090153|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
33090154|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
33090155|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
33304591|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
33304592|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
33304593|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
33304594|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
33304595|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
33304596|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
33304597|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
33304598|NCT05000164|Experimental|Market Product|Eligible subjects will be dispensed the study lenses in a bilateral fashion and will be in the treatment for approximately 5 weeks.
33304599|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
33304600|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
33304601|NCT04996264|Experimental|Varespladib-methyl|"Varespladib-methyl is an immediate-release (IR), oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.~Scaled pediatric doses of varespladib-methyl are supplied as 50 mg IR capsules for oral administration.~Adult subjects will receive an initial loading dose of 500 mg (2 × 250 mg oral tablet) varespladib-methyl upon randomization, followed by dosing with 250 mg varespladib-methyl (1 × 250 mg oral tablet) approximately 12 hours later, and subsequent twice daily (BID) dosing with 1 × 250 mg varespladib-methyl oral tablets for the remainder of the 7-day treatment period. Tablets may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation.~Pediatric subjects (5 to < 18 years) will be administered doses of varespladib-methyl determined by allometric scaling, provided as 50 mg capsules. Age-appropriate capsules may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation."
33304602|NCT04996264|Placebo Comparator|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an immediate-release capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~The dosing of placebo will match that of varespladib-methyl."
33304603|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
33304604|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
33304605|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
33304606|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
33304607|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
33304608|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
33304609|NCT05616130||Trauma|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
33304610|NCT05616130||Elective Hip Repair|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
33304611|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
32746376|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
32746377|NCT04784949|Experimental|Portland cement|pulpotomy with PRF and white Portland cement
32941031|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
32941032|NCT05750654|Experimental|Small Tube Group|
32941033|NCT05750654|Active Comparator|Standard Tube Group|
32941034|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
32941035|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
32941036|NCT05750576|Experimental|Chlorhexidine-impregnated dressings|
32941037|NCT05750576|Placebo Comparator|Non impregnated dressings|
33090156|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
33090157|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
33090158|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
33304612|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
33304613|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
32941038|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
33304614|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
33304615|NCT03777670||Cases|Infants with suspected sepsis
33304616|NCT03777670||Controls|Infants with no suspicion of sepsis
33304617|NCT04933552||Siponimod-Exposed|Pregnant women with MS exposed to siponimod during pregnancy
33304618|NCT04933552||Disease-Matched Comparison|Pregnant women with MS not exposed to siponimod during pregnancy
33304619|NCT04933552||Healthy Comparison|Pregnant women who are neither diagnosed with MS nor with any other autoimmune disease, and not exposed to siponimod or any known teratogenic agent during pregnancy
33304620|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
33304621|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
32941039|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
32941040|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
33304622|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
32941041|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
32941042|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
33304623|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
33304624|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
33304625|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
33304626|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
33304627|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
33304628|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
33090159|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
33090160|NCT00349440|Active Comparator|1|
33304629|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
33304630|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
33304631|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
33304632|NCT05588440|Experimental|Phase 1: Dose Escalation|Patients will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by ONCT-808 IV infusion escalated sequentially with a target dose consistent with the dose required by cohort being enrolled to determine Phase 2 dose (RP2d) regimen(s). Participants may receive bridging therapy that is appropriate to the subject's disease and treatment history if clinically indicated to maintain disease stability.
33304633|NCT05588440|Experimental|Phase 2: Dose Expansion|Patients with LBCL or MCL will receive ONCT-808 for each RP2D regimen determined in Phase 1.
33304634|NCT01320514||Fibrin Sealant (Artiss)|
33318511|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
32797944|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
32797945|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
32797946|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
32797947|NCT04069702|Experimental|VR Blue|VR Blue is a protocol for patients with advanced stage colorectal cancer who experience persistent pain. Participants will complete a single 30-minute laboratory-based virtual reality underwater/sea environment (VR Blue) session. VR Blue is an immersive computer-generated environment featuring calming scenic graphics and relaxing nature music.
33304635|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
33304636|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
33304637|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
33304638|NCT01320592|Experimental|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
33304639|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
33304640|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
32797948|NCT04508062|Active Comparator|pectopexy group|this group will only have pectopexy operation
32797949|NCT04508062|Active Comparator|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
32797950|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
32797951|NCT04408534|Active Comparator|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
32797952|NCT04408534|Experimental|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
33304641|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
33318512|NCT05656430|Experimental|Treatment group|Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
32797953|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
32797954|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
32797955|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
32797956|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
32797957|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
32797958|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
32797959|NCT04069624|Active Comparator|Services as Usual (SAU)|Substance abuse program (SAP) managed by the Kentucky Department of Corrections, with the option to initiate MOUD prior to jail release.
32797960|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth|Telehealth connection to a community MOUD provider.
32797961|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth and Peer Navigator|Telehealth connection to a community MOUD provider, in addition to a peer navigator
32797962|NCT01972568|Experimental|Atacicept 75 mg|
32797963|NCT01972568|Experimental|Atacicept 150 mg|
32797964|NCT01972568|Placebo Comparator|Placebo|
32797965|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
32797966|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
32797967|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
32797968|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
32797969|NCT01441414|Active Comparator|ARM B|AG-013736 alone
32797970|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
32797971|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
32797972|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
32797973|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
32797974|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
32797975|NCT04664335||endometriosis cases|endometriosis laparoscopically removed / child wish
32797976|NCT04664335||controls|endometriosis laparoscopically excluded / child wish
33090161|NCT00349440|Placebo Comparator|2|
33090162|NCT00349479|Active Comparator|Intervention|
33090163|NCT00349479|No Intervention|Control|
32746378|NCT04784949|Experimental|Mineral trioxide aggregate|pulpotomy with PRF and Mineral trioxide aggregate
32746379|NCT04784949|Experimental|Biodentine|pulpotomy with PRF and Biodentine
32941043|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
32941044|NCT05750498||Children and adolescents with Autoimmune Liver Disease|Pediatric patients with a diagnosis of autoimmune hepatitis, or primary sclerosing cholangitis.
32941045|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
32941046|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
32941047|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
32941048|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
32941049|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
32941050|NCT05750342|Experimental|Caqui|Subjects will consume two capsules daily. Each capsule will be taken before the two main meals.
33304642|NCT04905316|Experimental|Canakinumab with Chemoradiation and Durvalumab|Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first. Patients that come off treatment for progression, or have progression after completion of all protocol-related therapy, can be followed for survival outcomes by chart review based on standard of care evaluations.
32941051|NCT05750342|Placebo Comparator|Placebo|The product will have the same characteristics as the experimental product. They will consume two capsules per day, one before the two main meals.
32941052|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
32941053|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
32941054|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
32941055|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
33304643|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
33304644|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
33304645|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
33304646|NCT01320748|Experimental|Dual Processing|
33304647|NCT01320748|Active Comparator|Relapse Prevention|
33304648|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
33304649|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
33304650|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
33304651|NCT04422886|Experimental|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
33304652|NCT04422886|Sham Comparator|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
33304653|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
33304654|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
33304655|NCT05582200||Healthy subjects|Healthy subjects
33304656|NCT05582200||Patients with Alzheimer's disease|Patients with Alzheimer's disease
33304657|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
33304658|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
33090164|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
33090165|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
33090166|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
33090167|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
33090168|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
32797977|NCT01998841|Experimental|Mutation Carriers: Crenezumab|"Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
32797978|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
32797979|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued."
32797980|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
32797981|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
32797982|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
32797983|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
32797984|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
32797985|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
33090169|NCT00317018|Other|Arm 1|Implementation Group
33090170|NCT00317018|No Intervention|Arm 2|Control Group
33090171|NCT00349869|Experimental|1|8-week yoga program
33090172|NCT00349869|No Intervention|2|Usual care control
33090173|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
33090174|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
33090175|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
32797986|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
32797987|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
32797988|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
32797989|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
32797990|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
32797991|NCT04663087|Experimental|Treatment with XSTAT|Participants randomized to the treatment arm will be treated using the study device - XSTAT.
32797992|NCT04663087|Other|Standard Care|Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
33090176|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
33090177|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
33090178|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
33090179|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
33304659|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
33304660|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
32797993|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
33304661|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
33304662|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
33304663|NCT01320982|Active Comparator|minocycline|minocycline
33304664|NCT01320982|Active Comparator|pramipexole|pramipexole
33304665|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
33304666|NCT01320982|Placebo Comparator|Placebo|Placebo
33304667|NCT04431232|Experimental|Band Ligation|Band ligation of gastric body for weight loss
33304668|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
33304669|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
33304670|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
33304671|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
33304672|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
33304673|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
33304674|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
33304675|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
33304676|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
33304677|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
33304678|NCT04893382|Experimental|PlasmaLyte|Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
33304679|NCT04893382|Experimental|Ringer's Lactate|Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
33304680|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
33304681|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
33304682|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
33304683|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
32797994|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
33090180|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
33090181|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
33090182|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
33090183|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
33090184|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
33090185|NCT04714788|Experimental|Intervention group RECAP_MyLife mobile app|Participants in the intervention group will be instructed to use the mobile app daily for four weeks.
33090186|NCT04714788|Active Comparator|Control group|Comparator will be the usual data collection method applied by the cohorts.
33090187|NCT00317291|Experimental|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
33304684|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
33090188|NCT00317291|Sham Comparator|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
33090189|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
33304685|NCT05540782||Survivors of Prostate Cancer|
33304686|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
33304687|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
33304688|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
33304689|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
33304690|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
33304691|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
33304692|NCT04664998|Active Comparator|Male participants|200 male participants whose partners are enrolled in the parent study (Kampala Women's Bone study). All male participants will undergo the same study procedures at each visit, such as HIV and STI testing, and urine tenofovir testing if on PrEP.
33304693|NCT04664998|Active Comparator|Female participants|300 female participants from the parent study (Kampala Women's Bone study) will be enrolled to recruit their male sexual partner(s). All female participants will receive HIV testing, STI testing, and urine tenofovir testing (if on PrEP) at quarterly visits.
33304694|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
33304695|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
33304696|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
33304697|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
33304698|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
33304699|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
33304700|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
33304701|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
33304702|NCT03772366||Warfarine|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Warfarine
33304703|NCT03772366||Fluindione|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
33304704|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
33304705|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
33304706|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
33304707|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
33304708|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
33304709|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
33304710|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
32797995|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
32797996|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
32797997|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
33304711|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
33304712|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
33304713|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
33304714|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
33304715|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
33304716|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
33304717|NCT01309984|Active Comparator|arm 1|
33304718|NCT01309984|Active Comparator|arm 2|
32797998|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
32797999|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
32798000|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
32798001|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
32798002|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
32798003|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
32798004|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
32798005|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
32798006|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
32798007|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
32798008|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
32798009|NCT01962896|Experimental|Erlotinib + sirolimus|
32798010|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
32798011|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
32798012|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
32798013|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
32798014|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
32798015|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
32798016|NCT01968980|Placebo Comparator|Placebo|
33304719|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
32798017|NCT01961882|Experimental|OCV-501 arm|
32798018|NCT01961882|Placebo Comparator|Placebo arm|
33304720|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
33304721|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
32798019|NCT04174118|Experimental|belcesiran|Healthy volunteers will be administered a single dose of belcesiran.
32798020|NCT04174118|Placebo Comparator|Placebo|Healthy volunteers will be administered a single dose of matching placebo.
33304722|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
32798021|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
32798022|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
32798023|NCT04659902|Placebo Comparator|CON|Participants will ingest a drink containing a control protein only
32798024|NCT04659902|Active Comparator|CON-C|Participants will ingest a drink containing a control protein plus Capolac® (9547 mg to provide 2500mg of calcium)
32798025|NCT04659902|Active Comparator|PRO|Participants will ingest a drink containing an aggregate protein only
32798026|NCT04659902|Active Comparator|PRO-C|Participants will ingest a drink containing an aggregate protein plus Capolac® (9547 mg to provide 2500mg of calcium)
33304723|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
33304724|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
32798027|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
32798028|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
32798029|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
33304725|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
33304726|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
32798030|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
32798031|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
32798032|NCT01946282|Active Comparator|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
33090190|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
33304727|NCT03774940|Experimental|fever|patients that have fever after PNL
32798033|NCT01946282|Active Comparator|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
32798034|NCT01945580|Active Comparator|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
32798035|NCT01945580|Active Comparator|Control|Prolapse Repair with Native Tissue Only
32798036|NCT01945034|Experimental|Topical IBU twice daily|
32798037|NCT01945034|Placebo Comparator|Placebo twice daily|
32798038|NCT01945034|Experimental|Topical IBU three times daily|
32798039|NCT01945034|Placebo Comparator|Placebo three times daily|
33090191|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
33090192|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
32798040|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
32798041|NCT04655768|Active Comparator|Operative Arm|Radius fractures C1/C2 treated by palmar plate fixation
32798042|NCT04655768|No Intervention|Conservative Arm|Radius Fractures C1/C2 treated by cast fixation
32798043|NCT04638062|Experimental|Post Isometric Relaxation|"This study ARM will receive following therapies~Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)~Isometric neck strengthening exercises~Cryotherapy"
33090193|NCT00350181|Experimental|Regimen Treatment 1|For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
33090194|NCT00350181|Experimental|Regimen Treatment 2|For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
32798044|NCT04638062|Experimental|Myofascial Release Therapy|"This study ARM will receive following therapies~Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles~Isometric neck strengthening exercises~Cryotherapy"
33090195|NCT00350181|Experimental|Regimen Treatment 3|For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis
33090196|NCT00345501|Experimental|1|Iloprost
33090197|NCT00345501|Placebo Comparator|2|Placebo
33090198|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
32798045|NCT04636970|No Intervention|Control group|Patients randomised to control group will get usual recommendations regarding physical activity after a discharge from inpatient cardiac rehabilitation.
32798046|NCT04636970|Experimental|Intervention group|Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.
33090199|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
33090200|NCT04714827|Experimental|Low Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10^6 CAR+T cells/kg.
33090201|NCT04714827|Experimental|Middle Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10^6 CAR+T cells/kg.
33090202|NCT04714827|Experimental|High Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10^6 CAR+T cells/kg.
33090203|NCT04714827|Experimental|Amplification Dose Group|CD19-BCMA CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10^6 CAR+Tcells/kg.
32798047|NCT01618214|Experimental|Subject-driven titration|
32798048|NCT01618214|Active Comparator|Investigator-driven titration|
32798049|NCT01917968|Active Comparator|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
32798050|NCT01917968|Active Comparator|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
33090204|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
33090205|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
32798051|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
32798052|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
32798053|NCT02018861|Experimental|Parsaclisib 5 mg QD|Parsaclisib 5 milligrams (mg) as an oral tablet once a day (QD) in 21-day treatment cycles
32798054|NCT02018861|Experimental|Parsaclisib 10 mg QD|Parsaclisib 10 mg as oral tablets QD in 21-day treatment cycles
32798055|NCT02018861|Experimental|Parsaclisib 15 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
32798056|NCT02018861|Experimental|Parsaclisib 20 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
32798057|NCT02018861|Experimental|Parsaclisib 30 mg QD|Parsaclisib 30 mg as oral tablets QD in 21-day treatment cycles
32798058|NCT02018861|Experimental|Parsaclisib 45 mg QD|Parsaclisib 45 mg as oral tablets QD in 21-day treatment cycles
32798059|NCT02018861|Experimental|Parsaclisib 20 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 20 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
32798060|NCT02018861|Experimental|Parsaclisib 30 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 30 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
32798061|NCT02018861|Placebo Comparator|Parsaclisib 15 mg QD + R-ICE|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 milligrams per meters squared (mg/m^2) intravenously (IV) on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m^2 IV on Day 3 of each cycle, carboplatin area under the curve (AUC) = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration
33090206|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
32798062|NCT02018861|Placebo Comparator|Parsaclisib 20 mg QD + R-ICE|20 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 mg/m^2 IV on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m^2 IV on Day 3 of each cycle, carboplatin AUC = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration.
32798063|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
32798064|NCT04415918|Experimental|Intervention group|Recruited patient according inclusion/exclusion criteria
32798065|NCT04415918|No Intervention|Historical control|Cohort of historical patients matched to study population to serve as control
32798066|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
32798067|NCT02017535|Active Comparator|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
32798068|NCT02017535|Active Comparator|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
32798069|NCT02017535|Experimental|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
32798070|NCT02017535|Experimental|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
32798071|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
33090207|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
33090208|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
33090209|NCT04708236|Experimental|ORTD-1 Low dose|Arm 1: ORTD-1
32798072|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
32798073|NCT02017223|Experimental|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
32798074|NCT01944020|Experimental|Intervention - CPAP use|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
32798075|NCT01944020|No Intervention|Control - No CPAP use|Control will be no use of CPAP for 2 months
33090210|NCT04708236|Experimental|ORTD-1 Mid Dose|Arm 2: ORTD-1
32798078|NCT04624178|Experimental|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
32798079|NCT01943552|Experimental|ipratropium|500 mcg four times a day
32798080|NCT01943552|Placebo Comparator|placebo|
33090211|NCT04708236|Experimental|ORTD-1 High Dose|Arm 3 : ORTD-1
33090212|NCT04708236|Placebo Comparator|Vehicle Control|Arm 4: Vehicle control
33090213|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
33090214|NCT00318188|No Intervention|Control group|Habitual care
33090215|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
33090216|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
33090217|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
33090218|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
33090219|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
33090220|NCT00318266||patients with suerficial transitional cell carcinoma|
32798081|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
32798082|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
32798083|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
32798084|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
32798085|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
32798086|NCT05119166||Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study|The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
32798087|NCT05119166||The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study|(NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 & 5 months postnatal.
32798088|NCT05119166||VITAL Pakistan|Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 2-3 months.
32798089|NCT05119166||Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712)|MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 3-4 months.
32798090|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
32798091|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
32798092|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
32798093|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
32798094|NCT01617434|Experimental|Liraglutide|
32798095|NCT01617434|Placebo Comparator|Placebo|
32798096|NCT04623398|Experimental|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
33090221|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
33090222|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
33090223|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
33090224|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
33090225|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
33090226|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
33090227|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
33090228|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
33090229|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
33090230|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
33090231|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
33090232|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
33090233|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
33090234|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
33090235|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
33090236|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
33090237|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
33090238|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
33090239|NCT00350688|Other|Helical tomotherapy IMRT|Helical tomotherapy IMRT
33090240|NCT00419198|Experimental|1|Post-conditioning during angioplasty
32746380|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
32746381|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
32746382|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
32746383|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
32746384|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
32746385|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
32746386|NCT04791501||Hypoxemic Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more and FiO2 of 0.3 or more.
32746387|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
32746388|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
32746392|NCT03194711||Patients with stable CAD|
32746393|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
32746394|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
32746395|NCT04336293|Experimental|active|active sTMS
32746396|NCT04336293|Sham Comparator|sham|sham sTMS
32746397|NCT04791345|Experimental|Methylprednisone single-dose|Subjects receive a single dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
32746398|NCT04791345|Experimental|Methylprednisone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 7 days after administration in 20 fractions.
32746399|NCT04791345|Experimental|Deflazacort single-dose|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
32746400|NCT04791345|Experimental|Dexamethasone single-dose|"Subjects receive a single-dose treatment. Urine samples will be collected until 13 days after administration in 11 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration.~Blood samples will be collected until 9 days after administration in 6 fractions: pre-administration and 24h, 48h, 72h, 120h and 192h post-administration."
32746401|NCT04791345|Experimental|Dexamethasone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 10 days after administration in 34 fractions. Blood samples will be collected until 13 days after the first administration.
32746402|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
32746403|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
32746404|NCT04483895|Active Comparator|The OHL method|the ETT insertion depth was estimated according to the OHL method.
32746405|NCT04483895|Active Comparator|The 7-8-9 method|the ETT insertion depth was estimated according to the 7-8-9 method.
32746406|NCT03711435||Training set|The training set is composed of 30 IPF patients and 15 controls. The group is designed to identify differential metabolites between IPF and control groups.
32746407|NCT03711435||Validation set|The validation set is composed of 15 IPF patients and 15 controls. The group is designed to validate differential metabolites identified in the previous groups.
32798097|NCT04623398|Placebo Comparator|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
33090241|NCT00419198|Active Comparator|2|standard angioplasty
33090242|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
33090243|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
32798098|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
33090244|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
33090245|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
33090246|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
33090247|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
33090248|NCT00346047|Placebo Comparator|0|
33090249|NCT00346047|Experimental|1|
32798099|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
32798100|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
32798101|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
32798102|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
32798103|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
32798104|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
32798105|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
33090250|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
32907067|NCT05014919|Experimental|Vortioxetine -double-blind relapse prevention period|"Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period"
33090251|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
33090252|NCT00350805||Healthy volunteers|
33090253|NCT00350805||Patients|
33090254|NCT00318851|Experimental|Carotid Artery Stenting|
33090255|NCT00350883|Other|Treatment as Usual|
33090256|NCT00350883|Experimental|Cognitive Therapy|
33090257|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
33090258|NCT00319124||Case|Patients with hip Osteoarthritis
33090259|NCT00319124||Control|Healthy controls without hip osteoarthritis
33090260|NCT00319202|Experimental|1|
33090261|NCT00319202|Placebo Comparator|2|
33090262|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
33090263|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
33090264|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
33090265|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
33090266|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
33090267|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
33090268|NCT00319358|Placebo Comparator|Placebo|
33090269|NCT00346437|Experimental|1|Ad5FGF-4
33090270|NCT00346437|Experimental|2|Ad5FGF-4
33090271|NCT00346437|Placebo Comparator|3|Placebo
32746408|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
32798106|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
32798107|NCT02015819|Experimental|Treatment (neural stem cells, flucytosine, leucovorin)|"Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, they may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation used the following dose levels:~Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)~Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)~Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)~Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis"
32798108|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
32746409|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
32746410|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
32746411|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
32798109|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
32798110|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
32798111|NCT04636268|Experimental|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
32798112|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
32798113|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
32798114|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
32798115|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
32798116|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
32798117|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
32798118|NCT01937390||LAMA/LABA Patients|
32798119|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
32798120|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
32798121|NCT04651712|No Intervention|Standard care|A treating physician must perform a clinical assessment within half an hour of patient arrival. This assessment includes the decision whether the patient is suspected of having pneumonia and if this is the case, a sputum specimen and chest x-ray will be ordered. Patients with suspected pneumonia who can deliver a sputum specimen will be randomly allocated with a 1:1 computer-generated randomization schedule with permuting blocks in relation to optimal therapeutical intervention strategy. All standard care sputum samples will be cultured and analysed according to the sites' standard procedures. Under standard care, the treating physician alone decides on the optimal therapeutical intervention.
32798122|NCT04651712|Active Comparator|POC-PCR analysis supplied with a recommended action list developed by a microbiologist|Along with standard analyses, the specimens will be analysed with POC-PCR and the treating physician will receive an action-list with the results from POC-PCR.
32798123|NCT04685681|Experimental|Hiking Challenge|This group receives access to the local hiking challenge after completion of baseline measure
32798124|NCT04685681|Active Comparator|Activity list|This group receives access to a resource sheet with activity ideas after completion of baseline measure and does not receive the main resource of interest (hiking challenge) until after the post-test (delayed intervention)
32798125|NCT04685291|Active Comparator|Group 1: Control|Systemic conventional pain management. Adult patients with acute fractures of the clavicle, who are scheduled to have internal fixation of the fracture within the next 24 hours receive oral and intravenous pain management.
32798126|NCT04685291|Active Comparator|Group 2: Nerve Block|Adult patients with acute fractures of the clavicle, who are scheduled for an internal fixation of the fracture within the next 24 hours will receive an ultrasound-guided block of the supraclavicular nerves using a maximum of 3 ml of a long-acting local anesthetic. The injection is carried out directly in the emergency department following a sonographic or radiological diagnosis.
32798127|NCT04685057|Placebo Comparator|Placebo|This arm will receive placebo for 6 months then probiotic for 6 more months.
32907068|NCT05014919|Placebo Comparator|Placebo -double-blind relapse prevention period|Placebo - encapsulated tablets, orally once daily.
33090272|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
33090273|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
33090274|NCT00319826||1|Subjects with Staphylococcus Bacteremia
33090275|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
33090276|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
32746412|NCT03231137|No Intervention|Control|Spontaneously healed socket
32746413|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
33090277|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
33090278|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
32746414|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
32746415|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
32746416|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
33090279|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
33090280|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
32746417|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
32746418|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
32746419|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
32746420|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
32746421|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
32746422|NCT04784481|Experimental|Experimental Group|"The EG received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.~All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol"
32746423|NCT04784481|No Intervention|Control Group|Conventional treatment. All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol
32746424|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
32746425|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
32746426|NCT04790877|Active Comparator|First sub-study: Glucose beverage|This intervention entails the intake of a beverage including 25 g of glucose.
32746427|NCT04790877|Experimental|First sub-study: Regular alcohol-free beer|This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
32746428|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
32746429|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
32746430|NCT04790877|Active Comparator|Second sub-study: White bread + Water|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
32746431|NCT04790877|Experimental|Second sub-study: White bread + Regular alcohol-free beer|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
32746432|NCT04790877|Experimental|Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
32746433|NCT04790877|Experimental|Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrin|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
32746434|NCT04790877|Active Comparator|Second sub-study: Extra-White bread + Water|This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
32746435|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
32746436|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
32746437|NCT04790799|Experimental|Intervention group|Treatment in a hospital setting at Gentofte Hospital skin department with patient education, glove counselling, personal product screening by a chemistry engineer, extended allergy testing and the standard treatment of hand eczema.
32746438|NCT04790799|No Intervention|Control group|Treatment as usual (at a dermatologist office).
32746439|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
32746440|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
32798128|NCT04685057|Experimental|Probiotic|This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.
32798129|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
32798130|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
32798131|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
32798132|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
32798133|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
32798134|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
32798135|NCT04678895|Experimental|Group A, Low-Dose Naltrexone, Then Placebo|Group A will receive active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the first 8 weeks. Capsules of different dosages will be indistinguishable. Then followed by 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily).
32798136|NCT04678895|Experimental|Group B, Placebo, Then Low-Dose Naltrexone|Group B will receive 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily). Then followed by active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the last 8 weeks. Capsules of different dosages will be indistinguishable.
32798137|NCT04651244||Patients with suspected acute pyelonephritis|Patients admitted in the ED with suspected infection, where the initial medical assessment raises suspicion of APN.
32798138|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
32798139|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
32798140|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
32798141|NCT04683965|Experimental|Pemetrexed + TAS-102 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ TAS-102, capsule, 35mg/m2, bid,po, d1~5, d8~12 + Bevacizumab 5 mg/kg d1, d14; Repeated every 4 weeks
32798142|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798143|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798144|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798145|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798146|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798147|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798148|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
32798149|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
32798150|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
32798151|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
32798152|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
32798153|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months~Device: Vibration 10 min/day for 12 months"
32798154|NCT04677179|Experimental|LY3471851 (High Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
32798155|NCT04677179|Experimental|LY3471851 (Low Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
32798156|NCT04677179|Placebo Comparator|Placebo|"Stage 1 Placebo given SC~Stage 2 Placebo given SC"
32798157|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
32798158|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
32798159|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
32798160|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
32798161|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
32798162|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
32798163|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
32798164|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
32907069|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
32746441|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
33090281|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
33090282|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
33090283|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
33090284|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
32746442|NCT05473221|Experimental|CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
32746443|NCT05234489|Active Comparator|Low Dosage Group|This group will receive the lower dose (75mg) of the investigational product.
33090285|NCT00320138|Active Comparator|Acupuncture|
33090286|NCT00320138|No Intervention|Wait List|Usual Care
33090287|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
33090288|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
33090289|NCT00346749|Experimental|Arm 1|
33090290|NCT00346788|Experimental|MIS|minimally invasive incision
32746444|NCT05234489|Active Comparator|High Dosage Group|This group will receive the higher dose (150mg) of the investigational product.
32746445|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
33090291|NCT00346788|Active Comparator|Standard|Standard incision length
33090292|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
32746446|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
32746447|NCT03526185|Experimental|Cohort 1|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
33090293|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
33090294|NCT00351429|Experimental|1|
33090295|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
33090296|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
32746448|NCT03526185|Experimental|Cohort 2|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).~Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
32746449|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
33090297|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
33090298|NCT00346944|Experimental|Treatment group|
32746450|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
32746451|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
32746452|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
32746453|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
32746454|NCT03476343|Experimental|MRI for Neonates|MRI
32746455|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
32746456|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
32746457|NCT03194399|Experimental|Breast cancer patients|
32746458|NCT04791189||Patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Major male or female patient [18 to 45 years of age] with juvenile idiopathic arthritis reported before the age of 16.~- Able to understand and complete the questionnaire online (speaking and reading French, with an internet connection for completion via RedCap°). ¬~- Able to give informed consent to participate~- Involving one's parents in the survey is not a prerequisite for inclusion."
33090299|NCT00346944|No Intervention|Reference group|
33090300|NCT00346983|Experimental|A|
33090301|NCT00346983|Placebo Comparator|B|
32798165|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
32798166|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
32798167|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
32798168|NCT01953601|Experimental|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
32798169|NCT01953601|Experimental|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
32798170|NCT01953601|Placebo Comparator|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
32798171|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
33090302|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
33090303|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
33090304|NCT00347139|Experimental|GW642444|
33090305|NCT00347139|Active Comparator|Salmeterol|
33090306|NCT00321074|Active Comparator|1|
32737941|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
32798172|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
32798173|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
32798174|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
32798175|NCT04416529|Experimental|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
32798176|NCT04416529|No Intervention|Control Group|Participants in the control group continued their usual caregiving activities.
32798177|NCT04668235|Experimental|Arm AZVUDINE|"Experimental:~AZVUDINE 1mg tablet,~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days"
32798178|NCT04668235|Placebo Comparator|Arm Placebo|"Control:~AZVUDINE placebo,~Interventions:~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days"
32798179|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
32798180|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
33090307|NCT00321074|Experimental|2|
32907070|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
33090308|NCT04717544|Active Comparator|Intervention Arm|"Healthcare providers from clinics participating in the intervention refer existing clients to study coordinators for smoking cessation services, wherein the coordinators link clients to the smoking cessation services, which include: 1) a weekly cognitive-behavioral therapy smoking cessation (CBT) counseling group; and 2) smoking cessation medication, which include varenicline (Chantix), bupropion (Zyban) and nicotine patches, gum, and lozenges. Clients interested in these medications will meet with the prescribing clinician to help choose the best prescription option.~In addition to linking clients to the smoking cessation services, coordinators will invite clients to participate in the outcome study.~Existing clients can sign-up for these services and/or the outcome study directly with the study coordinators and do not require a healthcare provider referral."
33090309|NCT04717544|No Intervention|Treatment As Usual Arm|Existing clients can be referred to the outcome study by their healthcare providers from clinics designated as TAU or they can sign-up directly with the study coordinators.
33090310|NCT00321113|Active Comparator|1|oral
33090311|NCT00321113|Experimental|2|oral
33090312|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
33304728|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
32798181|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
32798182|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
32798183|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
33090313|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
33090314|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
32798184|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
32798185|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
32798186|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
32798187|NCT02023151|Other|Omalizumab|Active
32798188|NCT04667767|Experimental|Intervention|"In addition to the national standard outpatient treatment for uncomplicated severe acute malnutrition, caregivers of participants will receive a WASH kit containing a plastic container, a supply of Aquatabs® (effervescent chlorine tablets), and training in their use and associated hygiene practices."
32798189|NCT04667767|Active Comparator|Control|National standard outpatient treatment for uncomplicated severe acute malnutrition
32798190|NCT04667585|Experimental|Interim PET-CT with dose de-escalation|Participants will receive an interim PET-CT approximately 2 weeks into radiation therapy.
32798191|NCT04667585|Active Comparator|Interim PET-CT with standard radiation|
32798192|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
32798193|NCT04642885||dyad|parent with dementia and an adult child who is a caregiver
32798194|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
32798195|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
32798196|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
32798197|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
32798198|NCT01946191|Experimental|Coaching Group|"24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts~Online self-monitoring~Real-time updates to primary care physicians"
32798199|NCT01946191|Active Comparator|Tracking Group|-Online self-monitoring
32798200|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32798201|NCT04650698|Experimental|Tranexamic acid (TXA)|IV TXA
32798202|NCT04650698|No Intervention|Control|No TXA
32798203|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
32798204|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
32798205|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
32798206|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
32798207|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
32798208|NCT04648904|Experimental|Post-Mastectomy Radiotherapy|Treatment will consist of PMRT delivered using external beam RT techniques to a dose of 26 Gy in 5 fractions of 5.2 Gy delivered on consecutive weekdays with an optional chest wall boost of 5.2 Gy for 1-2 fractions or an alternate boost schedule of 2.5 Gy for 1-4 fractions at the discretion of the treating physician.
33090315|NCT00321191|Experimental|N2O|
32798209|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
32907071|NCT05010473|Experimental|Neurotypical Human Participants|Native speakers of Chinese and native speakers of English
32907072|NCT05620862|Experimental|mitoxantrone hydrochloride liposome|Children with relapsed and refractory lymphoma and solid tumors will receive mitoxantrone hydrochloride liposome alone at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 for up to 6 cycles (21 days per cycle).
33090316|NCT00321191|Placebo Comparator|No N2O|
33090317|NCT00351624|Active Comparator|DHA|
33090318|NCT00351624|Placebo Comparator|placebo|
32798210|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
32798211|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
33090319|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
33090320|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
33090321|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
33090322|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
33090323|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
33090324|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
33090325|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
33090326|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
33090327|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
33090328|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
33090329|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
33090330|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
33090331|NCT00322127|Experimental|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
33090332|NCT00322127|Experimental|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
33090333|NCT00322127|Experimental|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
32798212|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
32798213|NCT04622150|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
32798214|NCT04622150|Active Comparator|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
32798215|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
32798216|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
32798217|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
32798218|NCT01959230|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
32798219|NCT01959230|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
32798220|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
32798221|NCT04648202|Experimental|FS120|Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts
32907073|NCT05672537|Experimental|Durvalumab Combined with GemCis Neoadjuvant Therapy Group|
32907074|NCT05672537|Experimental|Surgical treatment group|
33090334|NCT00322127|Experimental|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
33090335|NCT00352170|Experimental|1|calcium supplementation
33090336|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
33090337|NCT00352170|Experimental|3|placebo
33090338|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
33090339|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
33090340|NCT00322166|No Intervention|Group C|Control group
33090341|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
33090342|NCT02959580|Active Comparator|surgical|lesion extended excision
32798222|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
33090343|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
33090344|NCT00322283|Experimental|Oglemilast|
33090345|NCT00322283|Placebo Comparator|Placebo|
33090346|NCT00322322|Experimental|1|L-Carnitine
32798223|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
32798224|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
32798225|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
33090347|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
32798226|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
32798227|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
32798228|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
32798229|NCT01958918|Experimental|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
32798230|NCT01958918|Active Comparator|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
32798231|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
32798232|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
32798233|NCT04173559|No Intervention|Usual care|Women randomized to this group will receive no guidance regarding exercise / activity / sleep during pregnancy.
32798234|NCT04173559|Experimental|Activity Intervention|Women randomized to this group will receive detailed information and reminders about physical activity and sleep in pregnancy. .
32798235|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)~Lapatinib PO once daily (dose to be determined)~Treatment cycles will be repeated every 3 weeks."
32798236|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
32798237|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
32798238|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
32798239|NCT01934504||Tolerant AAV|Tolerant participants with AAV
32798240|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
32798241|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
32798242|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
32798243|NCT01950013|No Intervention|Passive Control|Hearing aid alone
32798244|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
32798245|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
32798246|NCT04632524|Active Comparator|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
32798247|NCT04632524|Placebo Comparator|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
33090348|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
33090349|NCT00322361|Active Comparator|2|Recombivax HB™
32798248|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
32798249|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
32798250|NCT01909466|Other|Gluteal Injection|
32798251|NCT01909466|Other|Deltoid Injection|
32798252|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
32798253|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
32798254|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
32798255|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
32798256|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
32798257|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
32798258|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798259|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798260|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798261|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798262|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798263|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798264|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798265|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798266|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798267|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798268|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798269|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32798270|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
32798271|NCT02010593|Experimental|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
32798272|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
32798273|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
32798274|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
32798275|NCT04675931|Experimental|IV KAE609 Dose regimen 1|Intravenous KAE609 (cipargamin) 20 mg
33090350|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
33304729|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
32798276|NCT04675931|Experimental|IV KAE609 Dose regimen 2|Intravenous KAE609 (cipargamin) 40 mg
32798277|NCT04675931|Experimental|IV KAE609 Dose regimen 3|Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
32798278|NCT04675931|Active Comparator|IV Artesunate|IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
32798279|NCT04675931|Other|Coartem|Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
32798280|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
32798281|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
32798282|NCT04667195||Suspected acute pyelonephritis|Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician
32798283|NCT04667039|Experimental|GNR-067|Ranibizumab
32798284|NCT04667039|Active Comparator|Lucentis®|Ranibizumab
32798285|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
32798286|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
32798287|NCT04673123|Experimental|Core Stabilization Group|Core stabilization + Multifactorial Education Program (patient-specific upper and lower extremity stretching and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
32798288|NCT04673123|Active Comparator|Multifactorial Education Program Group|Multifactorial Education Program (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
32798289|NCT01993667|Active Comparator|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
32798290|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
32798291|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
32798292|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
32798293|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
32798294|NCT04673045|Active Comparator|Active neuromuscular electrical stimulation|This group will receive active NMES delivered the electrical current through electrodes inserted in saline-soaked sponges.
32798295|NCT04673045|Sham Comparator|Sham neuromuscular electrical stimulation|This group will receive sham NMES
32798296|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
32798297|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
32798298|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
32798299|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
32798300|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
32798301|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
32798302|NCT04647578||Child with IBD|
32798303|NCT04647578||Healthy child witnesses|
32798304|NCT04647032|Experimental|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
32798305|NCT04647032|Active Comparator|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
32798306|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
32798307|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
32798308|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
33090351|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
32798309|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
32798310|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
32798311|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
32798312|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
32798313|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
32798314|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
32907075|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
32798315|NCT02008565|Placebo Comparator|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
32798316|NCT02008565|Experimental|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
33090352|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
33090353|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
33090354|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
33090355|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
33090356|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
33090357|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
33090358|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
33090359|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
33090360|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
33090361|NCT00352599|Active Comparator|Lovastatin|Lovastatin
33090362|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
33090363|NCT04714632||Children with idiopathic scoliosis|Adolescent between 10-18y with diagnosing idiopathic scoliosis
33090364|NCT04714632||Healthy children|Healthy children between 10-18y without any orthopedics problems
33090365|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
33090366|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
33090367|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
33090368|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
33090369|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
33090370|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
33090371|NCT00353028|Experimental|F|
33090372|NCT00353028|Placebo Comparator|P|
33090373|NCT00353106||Patients|Patients with chronic GVHD
33090374|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
33090375|NCT00353106||Caregivers|Caregivers of patients with cGVHD
33090376|NCT00323375|Experimental|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
33090377|NCT00323375|Active Comparator|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
33090378|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
33090379|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
33090380|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
33090381|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
33090382|NCT00323648|Experimental|postoperatively antibiotics|
33090383|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
33090384|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
33090385|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
33090386|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
33090387|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
33090388|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
33090389|NCT00331890|Experimental|Active|Receives active drug
33090390|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
33090391|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
32798317|NCT02008565|Placebo Comparator|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
33304730|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
33304731|NCT01320358|Experimental|ECMPS-IEM|
33304732|NCT05531890|Experimental|Group 1 GTX-102 medium dose fast or slow in Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered fast or slow over two periods
33304733|NCT05531890|Experimental|Group 2a GTX-102 high dose fast in Period 1 and Period 2|"GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods~Note: Note under US IND"
33304734|NCT05531890|Active Comparator|Group 2b Oral comparator in Period 1 and Period 2|"0.1 mg/kg betamethasone solution oral drops solution over two periods~Note: Not under US IND"
33304735|NCT05531890|Experimental|Group 3 GTX-102 high dose fast or low dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) or GTX-102 Betamethasone oral spray low dose (0.025 mg/kg) administered fast over two periods
33304736|NCT05531890|Experimental|Group 4a GTX-102 high dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods
33304737|NCT05531890|Active Comparator|Group 4b betamethasone intramuscular in Period 1 and Period 2|0.1 mg/kg betamethasone solution as intramuscular injection administered over two periods
33304738|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
32798318|NCT02008565|Experimental|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
33304739|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
33304740|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
33304741|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
33304742|NCT00123474|Experimental|1|
33304743|NCT00123474|Experimental|2|
33304744|NCT00123474|Experimental|3|
32798319|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
33304745|NCT00123474|Experimental|4|
33304746|NCT00142298|Experimental|telbivudine|telbivudine 600 mg p.o. daily for 104 weeks.
33304747|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
33304748|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
33304749|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
33304750|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
33304751|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
33304752|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
33304753|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
33304754|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
33304755|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
33304756|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
33304757|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
33304758|NCT03964350|Experimental|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
33304759|NCT03964350|Placebo Comparator|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
33304760|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
33304761|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
33304762|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
33304763|NCT04562116|Experimental|CYP 450 Substrates plus Nemolizumab|Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.
33304764|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
33304765|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
33304766|NCT01035671|Placebo Comparator|Placebo|Placebo
32798320|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
32798321|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
32798322|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
32798323|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
32798324|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
32798325|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
32798326|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
32798327|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
32798328|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
32798329|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
32798330|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
32798331|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
32798332|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
32798333|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
32798334|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
32798335|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
32798336|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
32798337|NCT04618874|Experimental|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
32798338|NCT04618874|No Intervention|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
32798339|NCT04645004|Other|Aspirin|81mg aspirin daily
32798340|NCT04644224|Experimental|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
32798341|NCT04644224|Experimental|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
32798342|NCT04644224|Active Comparator|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
32798343|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
32798344|NCT04630808|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
32798345|NCT04630808|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
32798346|NCT04629950|Experimental|Rimegepant|Participants receive a rimegepant 75 mg tablet orally every other day for 16 weeks.
32798347|NCT04629950|Placebo Comparator|Placebo|Participants receive a placebo tablet matching rimegepant orally every other day for 16 weeks.
32798348|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
33304767|NCT05510284|Active Comparator|Doula Coordinated-Care Arm|Postpartum care will be doula-coordinated. The doula will meet with the mother at least once a week during their infant's NICU stay, with a minimum of 3 meetings. Participants will be given the option of seeing the study nurse midwife or their own provider. If the participant opts to see the nurse midwife, they can meet in a private office located in the NICU. The doula, as typical of the doula role, will coordinate any needed community services in the transition to home.
32798349|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
32798350|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
32798351|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
32798352|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
32798353|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
33090392|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
33090393|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
33090394|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
32798354|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
33090395|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
32798355|NCT01616654|Experimental|CD5789 25 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
32798356|NCT01616654|Experimental|CD5789 50 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
32798357|NCT01616654|Active Comparator|CD5789 100 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
32798358|NCT01616654|Placebo Comparator|Tazarotene 0.1% Gel|Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
32798359|NCT01616654|Experimental|Vehicle Cream|Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
32798360|NCT01902290|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.
32798361|NCT01902290|Experimental|Brodalumab 210 mg|Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.
32798362|NCT01927562|Experimental|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
32798363|NCT01467466|Active Comparator|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
32798364|NCT01467466|Active Comparator|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
32798365|NCT01467466|Active Comparator|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
32798366|NCT01467466|Active Comparator|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
32798367|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
32798368|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
32798369|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
32798370|NCT01441102|Experimental|Dextromethorphan hydrobromide|
32798371|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
32798372|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
32798373|NCT04068922|Experimental|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
32798374|NCT04061980|Experimental|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32798375|NCT04061980|Experimental|Arm II (encorafenib, binimetinib, nivolumab) - CLOSED|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32798376|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
32798377|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
32798378|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
32798379|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
32798380|NCT04504864|Experimental|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
33090396|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
33090397|NCT00324311|Experimental|DGD|
33090398|NCT00324311|Active Comparator|SOC|
33090399|NCT00353613|Other|1|LBJ Hospital
33090400|NCT00353613|Other|2|Ben Taub Hospital
33090401|NCT00332007|Experimental|1|Tonabersat 40 mg daily
33090402|NCT00332007|Placebo Comparator|2|
33090403|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
33090404|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
33304768|NCT05510284|No Intervention|Standard Postpartum Care Arm|In this arm participants will receive usual postpartum care. They will be discharged from the hospital while their baby is still in the NICU and a plan will be made to for follow-up with their provider as an outpatient at some point in the next 6 weeks. The study coordinator will provide the participant with a community postpartum resources list.
33304769|NCT03966534|No Intervention|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
33304770|NCT03966534|Experimental|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
33304771|NCT05502328|Placebo Comparator|Control 1|Energy Product Form 1 - control
33304772|NCT05502328|Placebo Comparator|Control 2|Energy Product Form 2 - control
33304773|NCT05502328|Experimental|Energy Product 1.1|Energy Product Form 1 - active product 1
32798381|NCT04504864|Active Comparator|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
33304774|NCT05502328|Experimental|Energy Product 1.2|Energy Product Form 1 - active product 2
33304775|NCT05502328|Experimental|Energy Product 2.1|Energy Product Form 2 - active 1
33304776|NCT05502328|Experimental|Energy Product 2.2|Energy Product Form 2 - active 2
32798382|NCT04501276|Experimental|Part A : Dose escalation of ADG116 monotherapy|
32798383|NCT04501276|Experimental|Part B : Dose escalation of ADG116 combined with anti PD1 drug|
33304777|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
33304778|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
33304779|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
33304780|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
33304781|NCT04869982|Experimental|RZV Group|Participants randomized to the RZV Group receive 1 dose of RZV at Day 1 and 1 dose at Month 2 and are followed up until the study end.
33304782|NCT04869982|Placebo Comparator|Placebo Group|Participants randomized to the Placebo Group receive 1 dose of placebo at Day 1 and 1 dose at Month 2 and are followed up until the study end.
33304783|NCT04560868|Active Comparator|Control|
32798384|NCT04501276|Experimental|Part C : Dose escalation of ADG116 combined with ADG106|
33304784|NCT04560868|Experimental|Experimental|
33304785|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
33304786|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
33304787|NCT03769558||JIA patients prescribed abatacept|
33304788|NCT03769480||Study Group|Study Group=Athletes with Disability
33304789|NCT03769480||Control Group|Control Group=Healthy Athletes
33304790|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
33304791|NCT03769402|Placebo Comparator|Control|Control test
33304792|NCT04466410|Experimental|0.015 milligram (mg) XT-150|0.015 mg of XT-150. Cohort 1 of the study
33304793|NCT04466410|Experimental|0.15 mg XT-150|0.15 mg of XT-150. Cohort 2 of the study
33304794|NCT04466410|Experimental|0.45 mg XT-150|0.45 mg of XT-150. Cohort 3 of the study
33304795|NCT04466410|Placebo Comparator|Placebo|PBS for injection.
33304796|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
33304797|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
33304798|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
33304799|NCT01321294|Active Comparator|Nissen fundoplication|
33304800|NCT01321294|Active Comparator|Toupet fundoplication|
33304801|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
33304802|NCT04419688|Experimental|STT-5058|
33304803|NCT04419688|Placebo Comparator|Placebo|
33304804|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
33304805|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
33304806|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
33304807|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
33304808|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
33090405|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
32798385|NCT04060342|Experimental|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
32798386|NCT04060342|Experimental|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
32798387|NCT04060342|Experimental|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
33304809|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
32798388|NCT04060342|Experimental|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
32798389|NCT04060342|Experimental|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
32798390|NCT04060342|Experimental|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
32798391|NCT04060030|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
32798392|NCT04060030|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
32798393|NCT01435018|Experimental|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
32798394|NCT01435018|Experimental|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
32798395|NCT01435018|Active Comparator|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
32798396|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
32798397|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
32798398|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
32798399|NCT01417234||SNaP® Wound Care System|
32798400|NCT01417156|Experimental|All patients|
32798401|NCT01417078|Experimental|Diazepam Nasal Spray|
32798402|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
32798403|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
32798404|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
32798405|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
32798406|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
32798407|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
32798408|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
32798409|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
32798410|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
32798411|NCT05110586|Experimental|1st group: TENS|Tens will be applied.
32798412|NCT05110586|Experimental|2nd group: Interferential current|Interferential current will be applied.
32907076|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
33304810|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
33304811|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
33304812|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
33304813|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
32798413|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
33090406|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
33090407|NCT00324506|Active Comparator|Cellcept and Avonex|
33090408|NCT00332124|Placebo Comparator|1|Participants will take placebo
32798414|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
32798415|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
33090409|NCT00332124|Active Comparator|2|Participants will take choline
33090410|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
33090411|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
33090412|NCT04714554|Experimental|Part 1: Relugolix/E2/NETA Plus Erythromycin|"Treatment Period 1: Healthy premenopausal women will receive a relugolix/E2/NETA (40 mg/1 mg/0.5 mg) alone on Day 1.~Treatment Period 2: Healthy premenopausal women will receive erythromycin on Day 1 through 12 (500 mg, QID), with co-administration of a single dose of relugolix/E2/NETA (40 mg/1 mg/0.5 mg) with the morning dose of erythromycin on Day 8."
33090413|NCT04714554|Experimental|Part 2: Relugolix Plus Erythromycin|"Treatment Period 1: Male participants will receive a single 120-mg dose of relugolix alone on Day 1.~Treatment Period 2: Male participants will receive erythromycin on Days 1 through 12 (500 mg, QID), with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8."
33090414|NCT00419471|Experimental|Escitalopram|
33090415|NCT00419471|Placebo Comparator|Placebo pill|
33090416|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
33090417|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
33090418|NCT00353808|Experimental|s, s reboxetine|
33090419|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
33090420|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
33090421|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
33090422|NCT00426426|Other|Waiting List|Waiting List
33090423|NCT00324974|Experimental|Lansoprazole QD|
33090424|NCT00324974|Placebo Comparator|Placebo QD|
33090425|NCT00325013|Experimental|II|
33090426|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
33090427|NCT04705467|Other|Patients|Device: Gynecological brachytherapy requiring an Interstitial or ring and tandem insert involves insertion of the needle and applicators with no standard real-time image guidance. Occasionally 2-dimensional ultrasound is used, but it greatly limited by its flat nature, preventing a volumetric view of the needle pathways. Interstitial brachytherapy is done under general anesthesia. The trans-abdominal and trans-rectal standard 2D ultrasound that are used in some cases, will be expanded to 3D dimensional imaging through the use of an investigational device. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning.
33090428|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
33090429|NCT04705428|Experimental|Group I: intervention group 1|Professional hygiene will be carried out with the application of fluoride varnish (Duraphat) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
33090430|NCT04705428|Experimental|Group II: intervention group 2|Professional hygiene will be carried out with the application of fluorine varnish (Tiefenfluoride) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
33090431|NCT04705428|Experimental|Group III: intervention group 3|Professional hygiene will be carried out with the application of fluorine varnish (Fluor Protector S) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
33090432|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
33090433|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
33090434|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
33090435|NCT00354081|Placebo Comparator|4|placebo
33090436|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
33090437|NCT00325520||Healthy controls|
33090438|NCT04705311|Experimental|pain neuroscience education plus rotator cuff repair rehabilitation|
33304814|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
33304815|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
33304816|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
33304817|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
33304818|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
33304819|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
33304820|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
33304821|NCT01561846|Experimental|CLA enriched cheese|
33304822|NCT01321450||Group A|Preparation with Harmonic WAVE
33304823|NCT01321450||Group B|Preparation with conventional modalities
33304824|NCT03769870|Other|Teneligliptin|
33304825|NCT03769870|Other|Atorvastatin|
33304826|NCT03769870|Other|Teneligliptin + Atorvastatin|
33304827|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
33304828|NCT01321918|Other|Case subjects|
33304829|NCT01321918|Other|Control subjects|
33304830|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
33304831|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
33304832|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
33304833|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
33304834|NCT03769012|Experimental|Treatment|Beta-Glucan
33304835|NCT03769012|Placebo Comparator|Placebo|Placebo
33304836|NCT03835481|Experimental|25 mg BI 730357|25 mg BI 730357 + placebo under fasted conditions.
33304837|NCT03835481|Experimental|50 mg BI 730357|50 mg BI 730357 + placebo under fasted conditions.
33304838|NCT03835481|Experimental|100 mg BI 730357|100 mg BI 730357 + placebo under fasted conditions.
33304839|NCT03835481|Experimental|200 mg BI 730357|200 mg BI 730357 + placebo under fasted conditions
33304840|NCT03835481|Experimental|400 mg BI 730357|400 mg BI 730357 + placebo under fasted conditions.
33304841|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
33304842|NCT03768934|Experimental|1X Incentive|1X airtime incentive
33304843|NCT03768934|Experimental|2X incentive|2X airtime incentive
33304844|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
33304845|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
33090439|NCT04705311|Active Comparator|rotator cuff repair rehabilitation|
33090440|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
33304846|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
33304847|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
33304848|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
33304849|NCT03768778|Other|Debridement|
33304850|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
33304851|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
33304852|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
33304853|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
33304854|NCT00708695||Treatment 2: Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
33304855|NCT00708695||Treatment 4: Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
33090441|NCT04714593|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
33090442|NCT04714593|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2×10^6 CAR+T cells/kg.
32798416|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
32798417|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
32798418|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
33090443|NCT04714593|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5×10^6 CAR+T cells/kg.
33090444|NCT04714593|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
33090445|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
32798419|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
32798420|NCT01415986|Experimental|Subjects receiving Temoporfin|
32798421|NCT01415908|Active Comparator|Control Group|
32798422|NCT01415908|Experimental|Investigational Group|
33090446|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
33090447|NCT04717583|Experimental|IPL-treated side|For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits, the IPL-treated side of the face will be treated with IPL, once every 4 weeks for 3 consecutive times.
33090448|NCT04717583|No Intervention|Control side|"For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits (before Week 12), the control side of face will not be treated by IPL.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
33090449|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
33090450|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
33090451|NCT00325715|Experimental|1|
33090452|NCT00325715|Active Comparator|2|
32798423|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
32798424|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
32798425|NCT04059406|Experimental|sapablursen|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks
32798426|NCT04058392|Experimental|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
32798427|NCT04057846|Active Comparator|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
32798428|NCT04057846|Experimental|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
32798429|NCT04767412|Active Comparator|aerobic exercise|
32798430|NCT04767412|Active Comparator|aerobic exercise and inspiratory muscle training|
32907077|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
33090453|NCT00354237|Other|B|No intensive treatment
33090454|NCT00354237|Experimental|A|Intensive insulin treatment
33090455|NCT04717661||76 healthy early pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
33090456|NCT04717661||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
33090457|NCT00426621|Experimental|1|
33090458|NCT00426621|Placebo Comparator|2|
33090459|NCT04717778|Experimental|pH milk|Group of children who were given the different types of milk and only the pH was measured
33090460|NCT04714242||Patients underwent anti-VEGF therapy|intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
33304856|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
33304857|NCT01039259||subjects with lip piercing|
32798431|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
32798432|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
32798433|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
32798434|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
32798435|NCT04767568|Experimental|Blood test|"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
32798436|NCT04767178||Ibuprofen group|Infants that received oral ibuprofen were categorized into the ibuprofen group
32798437|NCT04767178||Paracetamol group|Infants that received oral paracetamol were categorized into the paracetamol group
33304858|NCT01039259||subjects with tongue piercing|
32798438|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
32798439|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
32798440|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
32798441|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
32798442|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
32798443|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
32798444|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
32798445|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
32798446|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
32798447|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
32798448|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
32798449|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
32798450|NCT04048252||Focus group|
32798451|NCT04048252||Workshop|
32798452|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
32798453|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
32798454|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
32798455|NCT01431976|Experimental|Lamotrigine|No comparison
32798456|NCT01392742||Cohort|
32798457|NCT01413958|Experimental|Phenylephrine|
33304859|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
33304860|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
33304861|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
33090461|NCT04714242||Control Group|Healthy eyes without actual and previous ocular diseases
33090462|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
33090463|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
33304862|NCT04047472|Experimental|Brolucizumab 6 mg|
33304863|NCT04047472|Active Comparator|Aflibercept 2 mg|
33304864|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
33304865|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
33304866|NCT01036841|Active Comparator|desmopressin tablet|
33304867|NCT01036841|Experimental|desmopressin MELT-formulation|
33304868|NCT01039493||Patients|
33304869|NCT01039493||Providers|
33304870|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
33304871|NCT00122460|Experimental|Cetuximab Plus Chemotherapy|
33304872|NCT00122460|Active Comparator|Chemotherapy alone|
33304873|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
33304874|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
32737942|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
32737943|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
33304875|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
33304876|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
33304877|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
33304878|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
33304879|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
33304880|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
33304881|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
33304882|NCT04794088|Active Comparator|Intravenous imatinib mesylate (Impentri®)|Patients receiving the active investigational medicinal product will be receiving imatinib 200mg b.i.d. (administered as an 8 mg/mL solution for i.v. infusion) for 7 days.
33304883|NCT04794088|Placebo Comparator|Placebo solution|Patients receiving the placebo comparator will be receiving the same amount of intravenous solution, however containing 0.01M acetate buffer with 1.9% glycerol.
33304884|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
33304885|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
33304886|NCT03763006|Experimental|Ocudox lid wiped|
33304887|NCT03763006|Active Comparator|Povidone Iodine|
33304888|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
33304889|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
33304890|NCT03762928|Experimental|midazolam/efavirenz|
33304891|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
33304892|NCT01561456|Experimental|AXL1717|AXL1717
33304893|NCT01561456|Active Comparator|Docetaxel|Docetaxel
32737944|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
32737945|NCT05024877|Experimental|Hetrombopag treatment group|stanozolol 2mg tid + Hetrombopag (started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
33304894|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
33304895|NCT00137436|Experimental|A|SU011248 in combination with docetaxel and prednisone
33304896|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
33304897|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
33304898|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
33090464|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
33304899|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment
33304900|NCT03721822|Experimental|Non-Smokers|Reported non-smoking history or < 100 lifetime cigarettes, < 100 e-cigarette use episodes and < 100 lifetime cannabis use episodes
33304901|NCT03721822|Experimental|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
33304902|NCT03721822|Experimental|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
33304903|NCT03721822|Experimental|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
33304904|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
33304905|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
33304906|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
33304907|NCT04005352|Experimental|Brolucizumab|Intra-vitreal injection
33304908|NCT04005352|Active Comparator|Aflibercept|Intra-vitreal injection
33304909|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
33090465|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
33090466|NCT00325949|Placebo Comparator|Arm label (3) placebo|
33090467|NCT04714476|Experimental|Fit test of made-to-measure garments|Healthy subjects will test made-to-measure compression garments
33304910|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
33304911|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
33304912|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
33304913|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
33304914|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
33304915|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
33304916|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
33304917|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
33304918|NCT03767764||Control|Normal human serum from donors without liver disease
33304919|NCT03993743|Experimental|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
33304920|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
33304921|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
33304922|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
33304923|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
33304924|NCT01039727|No Intervention|care as usual|care as usual
33304925|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
33304926|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
33304927|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
33304928|NCT03993899|Active Comparator|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
32798458|NCT01413958|Placebo Comparator|Placebo|
33090468|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
33090469|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
32798459|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
33090470|NCT01059318|Experimental|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
33090471|NCT00326066|Active Comparator|1|
33090472|NCT00326066|Placebo Comparator|2|
33090473|NCT04714515||Hydroxychloroquine and Montelukast|Group 1 was given Standard of care (SOC) + HCQ + Montelukast
33090474|NCT04714515||Montelukast|Group 2 was given Standard of care (SOC) + Montelukast
32798460|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
32798461|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
32798462|NCT01799889|Experimental|CLL, Entospletinib MM/SDD|Participants with CLL, receive original formulation (mono-mesylate [MM]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion [SDD]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798463|NCT01799889|Experimental|FL, Entospletinib MM/SDD|Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798464|NCT01799889|Experimental|DLBCL, Entospletinib MM/SDD|Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798465|NCT01799889|Experimental|MCL, Entospletinib MM/SDD|Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798466|NCT01799889|Experimental|non-FL iNHL, Entospletinib MM/SDD|Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798467|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg|Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798468|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798469|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798470|NCT01799889|Experimental|CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798471|NCT01799889|Experimental|CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798472|NCT01799889|Experimental|CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32798473|NCT01799889|Experimental|CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
32907078|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
33090475|NCT04714515||Hydroxychloroquine|Group 3 was given Standard of care (SOC) + HCQ
33090476|NCT04714515||Hydroxychloroquine, Montelukast and Invermectin|Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
33090477|NCT00354354|Experimental|1|Combivent
33090478|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
33090479|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
33090480|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
32798474|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
33304929|NCT03993899|Active Comparator|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
33304930|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
33304931|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
33304932|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
33304933|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
33304934|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
33304935|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
33304936|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
33304937|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
33304938|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
33304939|NCT01589159|Experimental|Experimental|
33304940|NCT03974711||All study subjects|"Note: No interventions are administered under this evaluation.~This is a real-world population. The determination to undergo a lateral lumbar interbody fusion procedure is made outside of this evaluation and is a standard of care, on-label procedure."
33304941|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
33304942|NCT03937895|Experimental|Experimental: single arm|"Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to *cycle 3, Phase 2a: up to cycle 9)~Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle.~Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period."
33304943|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
33304944|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
33304945|NCT03625648|Experimental|PTX|Active drug
33304946|NCT03625648|Placebo Comparator|Placebo|Placebo
33304947|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
33304948|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
33304949|NCT04731142|Experimental|T2DEx remote care service|
33304950|NCT04731142|Other|Matched control group|This study will create a matched control group using propensity score matching (PSM), a quasi-experimental method used to mimic the characteristics of a randomised control trial that has been shown to reduce biases. PSM uses statistical techniques to construct an artificial control group by matching each study participant with a non-treated participant of similar characteristics. PSM computes the probability that a person would enrol in a program based on pre-defined characteristics, giving a 'propensity score'.
33304951|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
33304952|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
33304953|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
33304954|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
33304955|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
33304956|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
33304957|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
33304958|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
33304959|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
33304960|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.~The Serum selenium concentrations are 18-40μg/L."
33304961|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.~The Serum selenium concentrations are more than 40μg/L."
33304962|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.~The Serum selenium concentrations are less than 18μg/L."
33304963|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
33304964|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
33304965|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
33304966|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
33304967|NCT05466916|Experimental|Exercise and diet education and instruction|The intervention will be 12 weeks in duration. The five intervention components (e.g., educational sessions and instructional sessions) will be supervised. Research staff will conduct the intervention. Participants will be instructed to gradually aim for 30 minutes of physical activity for five days per week by Week 12 Participants will also aim for improved healthy dietary practices including > 200 grams/day (g/d) of fruits and vegetables, > 15 g/d of fiber (whole grains and beans), < 250 g/d of sugar-sweetened drinks and lower percent of total kcal from fast foods18 by Week 12. Sessions will be about 35- to 50-minutes in duration and be structured as follows: (a) review of previous session and an opportunity to ask questions (~5 minutes); (b) presentation of content (20- to 30-minutes); (c) opportunity for questions (~5 minutes); and (d) preview of next sessions and research activity reminders (2- to 3-minutes).
33304968|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
33304969|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
33304970|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
33304971|NCT02366572|Experimental|Cereal with pea protein|Pea protein
33304972|NCT02366572|Experimental|Cereal with pea starch|Pea starch
33304973|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
33304974|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
32941056|NCT05750186|Experimental|Abdominal Massage Group|"At the first encounter with the patient; Patient Information Form, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied.~From the morning of the first day, abdominal massage will be applied to the patients 2 times a day, in the morning and in the evening, for 3 days (15 minutes).~Then, applying abdominal massage to the patients in the experimental group. After each massage application, the patient's bowel sounds/movements will be listened to.~Medicines such as laxatives, suppositories and enemas will not be given to the experimental group and Bristol Stool Scale will be filled in for patients who defecate within this period.~In order to evaluate the abdominal massage and its effect on the comfort level of the patients, the Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again at the end of the 3rd day after the application of abdominal massage."
32941057|NCT05750186|No Intervention|Control Group|"Patients who did not defecate within the first 3 days after surgery will constitute the control group.~At the first encounter with the patient; A Patient Information Form, Gastrointestinal Symptom Rating Scale (GSS), General Comfort Scale (GAS) and Functional Independence Scale (FIM) will be administered.~From the first encounter, patients will be given medications that are in line with their clinical routine, such as laxatives, suppositories and enemas, according to the doctor's request.~Intestinal sounds/movements of the patients will be listened to 6 times, 2 times a day for 3 days.~Bristol Stool Scale will be filled in for patients who defecate within this period.~At the end of the 3-day follow-up of the patients, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again and the first stool of the patients who defecate will be evaluated with the Bristol Stool Scale."
33304975|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
33304976|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
33304977|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
33304978|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
33304979|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
32941058|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
33304980|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
33304981|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
33304982|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
33304983|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
33304984|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
33304985|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
33304986|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
33304987|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
33304988|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
33304989|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
33304990|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
33304991|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
33304992|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
33304993|NCT03766828||inside-out-access technique with inside-out access device|
33304994|NCT03766828||access technique including Sharp recanalization|
33090481|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
33304995|NCT03928600|Experimental|Combined method induction group|"25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)~After 4 hours of last misoprostol initiate oxytocin.~Cervical Foley will be removed after 12h of placement or when fails out."
32798475|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
32798476|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
32798477|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
33318513|NCT05656430|No Intervention|Control group|The control group is a wait-list control condition. Participants are instructed to wait. After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
32798478|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
33090482|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
33090483|NCT00326222|Experimental|1|Lifestyle counseling
33090484|NCT00326222|No Intervention|2|Usual care
33090485|NCT04714164|Experimental|Teletherapy Group CBT participants|Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy
33090486|NCT00426777|Active Comparator|risedronate|
33090487|NCT00426777|Placebo Comparator|placebo|
32798479|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
32798480|NCT04055272|Experimental|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
32798481|NCT04055272|No Intervention|Control|Participants in the control arm receive no intervention
32798482|NCT04054414|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
32798483|NCT04054414|Experimental|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
32798484|NCT04053712|Placebo Comparator|Single-hormone|FiAsp (R) - Saline
32798485|NCT04053712|Active Comparator|Dual-hormone|FiAsp(R) - GlucaGen(R)
32798486|NCT01798485|Experimental|Ganetespib and Docetaxel|Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
32798487|NCT01798485|Active Comparator|Docetaxel|Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
32798488|NCT01767597|Active Comparator|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
32798489|NCT01767597|Experimental|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
32798490|NCT01767519|Experimental|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
32798491|NCT01767519|Active Comparator|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
32798492|NCT01767519|Placebo Comparator|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
32798493|NCT01797783|Experimental|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
32798494|NCT01797783|Active Comparator|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
32798495|NCT01766817|Experimental|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
33090488|NCT00326339|Experimental|1|R788 50 mg PO bid
33090489|NCT00326339|Experimental|2|R788 100 mg PO bid
33090490|NCT00326339|Experimental|3|R788 150 mg PO bid
33090491|NCT00326339|Placebo Comparator|4|Placebo PO bid
33090492|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
33090493|NCT01058421|Active Comparator|control group|
33090494|NCT00419549|Active Comparator|1|Valdecoxib
33090495|NCT00419549|Active Comparator|2|
33090496|NCT00419549|No Intervention|3|
33090497|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications for more than one time~Small for gestational age at birth~More than one respiratory illness~More than one episode of wheezing"
33090498|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~Congenital cardio-respiratory disease~Severe developmental delay"
33090499|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
33090500|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
33090501|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
33090502|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
33090503|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
33090504|NCT04717232|Experimental|The blended learning approach to mentoring education for dental health care professionals|The blended learning approach to mentoring education for dental health care professionals will last five weeks, including four face-to-face seminars, interprofessional group work and self-reflection assignments lasting for two days. The educational content will include mentoring as a process, mentoring as a relationship, challenges of mentoring, and personal mentoring.
32798496|NCT01766817|Experimental|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
32798497|NCT01766817|Placebo Comparator|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
33304996|NCT03928600|Placebo Comparator|Current department guidelines group|"Following current department guidelines, as usual, with the method considered more suitable.~If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.~If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
33304997|NCT03924856|Experimental|Pembrolizumab + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.
33304998|NCT03924856|Placebo Comparator|Placebo + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.
32798498|NCT01797705|Experimental|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
32798499|NCT04581603|Active Comparator|TOP + CBT-I|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Cognitive Behavioral Therapy for Insomnia (CBT-I) and TOP for the next 8 weeks.
32798500|NCT04581603|Placebo Comparator|TOP + SHE|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Sleep Hygiene Education (SHE) and TOP for the next 8 weeks.
32798501|NCT01797081|Experimental|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
33304999|NCT05419960||Patients|Patients between the ages of 12-20 years with a diagnosis of Osteogenesis Imperfecta of any type and followed by a physician at the Centre de Référence des Maladies Rares des maladies osseuses constitutionnelles (CRMR OI) of Hôpital Necker-Enfants malades.
33305000|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
33305001|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
33305002|NCT01322152|Experimental|wXELIRI regimen|
32798502|NCT01797081|Experimental|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
32798503|NCT01797081|Other|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
32798504|NCT01797081|Other|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
32798505|NCT01794117|Experimental|Arm A/Anakinra 100 mg/day|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg at week 8.
32798506|NCT01766037|Experimental|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
32798507|NCT01766037|Active Comparator|Lifestyle Therapy|Lifestyle Therapy only
32798508|NCT04413903|Active Comparator|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
32907079|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
32907080|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
32798509|NCT04413903|Active Comparator|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
33090505|NCT04717232|Experimental|The interprofessional online mentoring education|The intervention group will attend mentoring competence education. The Interprofessional online mentoring educations includes videos of specialist lectures, e-learning materials, along with assignments concerning reflection skills and participant-based evaluation. The education content included the processes and interactions of mentoring, goal-oriented mentoring, along with student-based feedback and student-centered evaluation. The mentoring education can be completed in an online learning environment and participants can complete the education at their own pace within six weeks.
33090506|NCT04717232|Active Comparator|The Control group|The control group are dentists´ and dental hygienists´ who are working at health care centers on the Finnish Dental Association site, participate in student mentoring and have not received any education before.
32798510|NCT01765569|Experimental|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
32798511|NCT04414605|Experimental|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
32798512|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
32798513|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
32798514|NCT04569357|Experimental|Prospecta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
32798515|NCT04569357|Placebo Comparator|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
32798516|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
32798517|NCT01765179|Experimental|Oral testosterone undecanoate|
32798518|NCT04580667||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity. Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
32798519|NCT04580043|Experimental|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
32798520|NCT04580043|Active Comparator|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
33090507|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
32798521|NCT04580043|Active Comparator|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
32798522|NCT04580043|Sham Comparator|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
32798523|NCT01764945|Experimental|1 BI 201335|low dose
32798524|NCT01764945|Experimental|2 BI 201335|high dose
32798525|NCT04578249|Placebo Comparator|Clear goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given clear goggles to wear at nighttime.
32798526|NCT04578249|Experimental|Blue-light blocking goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given blue-light blocking goggles to wear at nighttime.
32798527|NCT01793883|Active Comparator|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
32798528|NCT01793883|Active Comparator|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
32798529|NCT01793883|Placebo Comparator|Placebo|Matching Placebo
32798530|NCT01792635|No Intervention|Part A (Pilot Study)|
32798531|NCT01792635|Experimental|Monotherapy (Part B)|
32798532|NCT01953692|Experimental|Cohort 1: Myelodysplastic Syndrome (MDS)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
32798533|NCT01953692|Experimental|Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
32798534|NCT01953692|Experimental|Cohort 3: Relapsed/Refractory (R/R) Hodgkin lymphoma (HL)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
32798535|NCT01953692|Experimental|Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
32907081|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
32798536|NCT01953692|Experimental|Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
32798537|NCT01953692|Experimental|Cohort 4C: R/R Follicular Lymphoma (FL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
32798538|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
32798539|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 20 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles.
32798540|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 25 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.
32798541|NCT01791153|Experimental|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
32907082|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
33090508|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
33090509|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
33090510|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
33090511|NCT04717037|Experimental|Study|The olive oil massage will be applied initially at 72 hrs of life then twice daily with a dose of 4ml/kg till 28 days .
33090512|NCT04717037|No Intervention|Control|Patients who are assigned to the control group will receive standard care as per unit policies.
33090513|NCT04716842||sepsis|In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.
33090514|NCT04716842||septic shock|Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate> 2 mmol/l will be included in the septic shock group.
33090515|NCT04716842||control|It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.
33090516|NCT04716998|Experimental|MesenCure treatment|"Clinical interventions:~Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.~Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels."
33090517|NCT01057251|Experimental|1|
33090518|NCT01057251|Placebo Comparator|2|
33090519|NCT04708457|Active Comparator|Early ECMO|Early ECMO therapy for patients who have SARI and have been mechanically ventilated for 5-7 days.
33090520|NCT04708457|No Intervention|Standard Care|Patients with SARI who are already mechanically ventilated will continue to receive the standard intensive care therapies, including ECMO if required.
33090521|NCT04708353|Placebo Comparator|control group|the patient will receive one placebo capsule (vitamin c) once one hour before the operation.
33090522|NCT04708353|Active Comparator|Group Pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
33090523|NCT04708353|Active Comparator|Group Pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
33090524|NCT04708574|Experimental|Intervention|The intervention group attended a supervised exercise program for women only that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym. The intervention lasted 12 weeks. There was also a nutrition education component that occurred once per week for the duration of the intervention. The lifestyle intervention group was instructed to walk 10,000 steps per day for the 12 weeks of the program. They were given instructions to take a 30-min walk on days when no formal exercise sessions were offered.
33090525|NCT04708574|Placebo Comparator|Control|The control group participants followed their typical work and leisure routines during the weeks of investigation. The women in the control group were offered the same intervention at the end of the 12 weeks.
33090526|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
33090527|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
33090528|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
33090529|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
33090530|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
33090531|NCT00425763|Experimental|AQAS|
33090532|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
33090533|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
33090534|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
33305003|NCT05414344|Experimental|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
33090535|NCT00327509||4-Juvenile|juvenile glaucoma
33090536|NCT00327509||5-Control1|healthy subjects (age group 1)
33090537|NCT00327509||6-Control2|healthy subjects (age group 2)
33090538|NCT00425880||Pregnant Asthmatics|
33090539|NCT00425880||Pregnant Smokers|
33090540|NCT00425880||Healthy Pregnant Controls|
33305004|NCT05414344|Experimental|Trauma-Informed and Peer-Supported Brief Intervention (TIPS-BI)|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
33305005|NCT05414344|Experimental|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
33305006|NCT01446016|Experimental|Chloroquine with Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy|Chloroquine (250 mg) was given daily orally with either Paclitaxel or Docetaxel or Abraxane or Ixabepilone chemotherapy every 3 weeks (1 cycle) fro a maximum of 6 cycles.
33305007|NCT00137046|Active Comparator|Subcutaneous Insulin|
33305008|NCT00137046|Experimental|Inhaled Insulin|
33305009|NCT03456076|Experimental|Alectinib|
33305010|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
33305011|NCT03383458|Experimental|Arm A|
33305012|NCT03383458|Placebo Comparator|Arm B|
33305013|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
33305014|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
33305015|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
33090541|NCT05459168|Other|Calm Meditation Smartphone App Feedback (Aim 1)|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
33090542|NCT05459168|Other|Cancer-Specific Meditation App Prototype Design (Aim 2)|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
33090543|NCT05459168|Other|Cancer-Specific Meditation App Prototype (Aim 3)|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
33090544|NCT05458934||Lung-/Airway diseases|Patients with lung-/airway diseases
33090545|NCT05458934||Controls|Participants without lung-/airway disease
33090546|NCT05458895|Experimental|High concentration free-base nicotine (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090547|NCT05458895|Experimental|High concentration nicotine salt (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090548|NCT05458895|Experimental|High concentration free-base nicotine (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33305016|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
33090549|NCT05458895|Experimental|High concentration nicotine salt (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090550|NCT05458895|Experimental|Low concentration free-base nicotine (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090551|NCT05458895|Experimental|Low concentration nicotine salt (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090552|NCT05458895|Experimental|Low concentration free-base nicotine (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090553|NCT05458895|Experimental|Low concentration nicotine salt (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
33090554|NCT00427089|Experimental|1|2L gut cleansing solution
33090555|NCT00427089|Active Comparator|2|
33090556|NCT05458661|Other|recruited patient population|
33305017|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
33305018|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
33305019|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
33305020|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
33305021|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
32941059|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
32941060|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
32941061|NCT05611424|Experimental|FT003 Dose 1|Low dose of FT-003
32941062|NCT05611424|Experimental|FT003 Dose 2|Mid dose of FT-003
32941063|NCT05611424|Experimental|FT003 Dose 3|High dose of FT-003
32941064|NCT01434511|Experimental|OBI-1|
32941065|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
32941066|NCT05750108|Active Comparator|Active Transcutaneous Vagal Nerve Stimulation|
32941067|NCT05750108|Sham Comparator|Sham Transcutaneous Vagal Nerve Stimulation|
32941068|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
32941069|NCT05750030|Experimental|FMT combined with Atezolizumab plus Bevacizumab|
32941070|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
33305022|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (<16weeks) mothers who have opioid use disorder and are taking buprenorphine
33305023|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (>16weeks) mothers who do not have any history of opioid use disorder.
33305024|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
33305025|NCT03758794|Active Comparator|online educational module|online educational using a special link
33305026|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
33305027|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
33305028|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
33305029|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
33305030|NCT00122382|Active Comparator|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
32941071|NCT04331054|Active Comparator|1: Usual practice|arm will be follow during 30 days
32941072|NCT04331054|Experimental|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
32941073|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
32941074|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
32941075|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
32941076|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
33305031|NCT00122382|Active Comparator|Placebo (PLA) + MTX|placebo IV + methotrexate
33305032|NCT01028716|Experimental|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
32941079|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
32941080|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
32941081|NCT05602610||VL patients|VL infected individuals residing in/ with travel history to VL-endemic areas in Northern Ethiopia
32941082|NCT01434745|Placebo Comparator|Placebo|placebo
32941083|NCT01434745|Experimental|Simvastatin|0.5 mg/kg body weight/day
33305033|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
33305034|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
33305035|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
33305036|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
33102448|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
33305037|NCT03760198|Experimental|botulinum toxin type A|
33305038|NCT03760198|Placebo Comparator|Placebo|
33305039|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
33305040|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
33305041|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
33305042|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
33305043|NCT00106704|Experimental|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
33305044|NCT00106704|Placebo Comparator|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
33305045|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
33305046|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
33305047|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
33305048|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
33305049|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
33305050|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
33305051|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
32798542|NCT01791153|Experimental|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
33102449|NCT05405673||Colorectal neoplasia screening/surveillance cohort|Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy
33305052|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
33305053|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
33305054|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
33305055|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
33305056|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
33305057|NCT00105066|Placebo Comparator|Placebo|placebo
33305058|NCT00105066|Experimental|Metformin|Metformin 850 mg twice daily
33305059|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
33305060|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
33305061|NCT05232838|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
33305062|NCT01081236||Compensated liver cirrhosis|
33305063|NCT01081236||Decompensated liver cirrhosis|
33305064|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
33305065|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
33305066|NCT05208268||Pariet|Participants with gastric and duodenal ulcer being administered with Pariet 5 mg, tablet within the scope of the approved label for Korea under the medical judgment of the investigator will be observed up to maximum of 24 weeks.
33305067|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
33305068|NCT03766048|Sham Comparator|Double-Mesh, DM|
33305069|NCT05195710|Experimental|Yttrium-90|Help to control the tumor(s) on the right side of the liver while the remaining left side of the liver, which is clear of cancer, grows.
33305070|NCT00104520|Placebo Comparator|Placebo (pooled two times a day [BID]/three times a day [TID])|
33305071|NCT00104520|Experimental|AZLI (pooled two times a day [BID]/three times a day [TID])|
33305072|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
33305073|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
33305074|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
32798543|NCT01791153|Placebo Comparator|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
33305075|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
33305076|NCT03963882|Experimental|Group A|Patients in group A don't receive neoadjuvant chemotherapy
33305077|NCT03963882|Experimental|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
32798544|NCT01791153|Placebo Comparator|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
32798545|NCT01791153|Experimental|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
33305078|NCT03963882|Experimental|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
33305079|NCT03963882|Experimental|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
33305080|NCT05180188|No Intervention|Placebo periode|In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health.
33305081|NCT05180188|Experimental|Exercise periode|In the second period, participants will perform regular moderate-intensity exercise 3 times/week.
33305082|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
33305083|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
33305084|NCT03165292|Experimental|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
33305085|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
32798546|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
32798547|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
32941084|NCT05595902||Young older adults|≥65-<75 years of age
32941085|NCT05595902||Older adults|≥75-<90 years of age
32941086|NCT05595902||≥90 years old|
32941087|NCT05591924||ESTABLISH|Adults over 18 years of age admitted to the ICU within 48 hours and whose presentation to the Emergency Department was within 72h of ICU admission.
33305086|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
33305087|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
33305088|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
33305089|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
33305090|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
33305091|NCT03109288|Experimental|Combination Therapy|Any two-drug combination of study interventions
33305092|NCT03109288|Experimental|Monotherapy|Any of the study Interventions
33305093|NCT05161078||All Patients Enrolled|Patients will be treated with CARPEDIEM per standard of care.
33305094|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
33305095|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
33305096|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
33305097|NCT05145322|Experimental|Group 1|Group 1: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins
33305098|NCT05145322|Experimental|Group 2|Lesion-specific cavity design with wide bevel throughout the cavity margins
33305099|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
33305100|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
33305101|NCT00135330|Experimental|Exenatide Arm|
33305102|NCT00135330|Experimental|Exenatide plus Rosiglitazone Arm|
33305103|NCT00135330|Experimental|Rosiglitazone Arm|
33404283|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
33404284|NCT03478787|Experimental|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
33404285|NCT03478787|Active Comparator|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
33404286|NCT05761938||cohort A|pathologically confirmed membranous nephropathy
33090557|NCT05458466|Experimental|Pilates training Group|The Pilates Training program consisted of warm-up, work-out and cool-down sections. For the warm-up section, breathing, standing roll down, and spine twist exercises were selected; for the work-out section, the hundred, shoulder bridge, scissors, swimming, and quadruped exercises, and for cool-down section, torso twist, cat-camel, and standing stretches. The Pilates Training progression was achieved by increasing the number of repetitions of the selected exercises and adding some equipment (balls, foam rollers) to challenge postural stability. In the first five sessions, after each exercise was performed for six to eight repetitions, the number of repetitions was increased to 10-12. Moreover, the environment where the training took place was carefully arranged according to the needs of children with autism.
33090558|NCT05458466|Experimental|Aerobic Training Group|Each training session consisted of a 20-minutes treadmill workout (using the motorized Ultıma Ac 3500 treadmill) followed by 20-minutes bicycle workout (Voit Yellow Collection 112u exercie bike). The intensity of training, which began at 50% to 60% of maximum heart rate (HR), was increased each week so that by week five, the children were at 75% to 80% maximum HR. The maximum HR, as recommended for children, was calculated using the formula 208 - 0.7 x (age) (Mahon et al., 2010). To ensure that the exercise intensity remained in the target HR zone during training, the child's HR was continuously monitored from the used treadmill and exercise bike monitors.
33090559|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
33090560|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
33404287|NCT05761938||cohort B|pathologically confirmed minimal change disease (MCD) or primary focal segmental glomerulosclerosis (FSGS)
33090561|NCT05458388|Active Comparator|Kimura-Takemoto classification|
33404288|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
33090562|NCT05458388|Active Comparator|EGGIM|
33090563|NCT05458349|Experimental|dermis group|Group will receive standard of care treatment and interventions plus the use of the acellular dermal graft during surgery
33090564|NCT05458349|No Intervention|control group|Group will receive standard of care treatment and interventions but the acellular dermal graft will not be used during surgery
33090565|NCT05458154|Experimental|Experimental group|"Seven of the 22 pain measures demonstrated satisfactory psychometric properties and clinical utility and are thereby recommended for clinical and research use in adults with a diagnosis of cancer.~Participants received Physical therapy program is critical to preserve flexibility, strength, range of motion, and normal neuromuscular recruitment. Patients' efforts to cut back their pain through avoidance behaviors can severely undermine function if mobility, activity of daily living, performance, or vocational capacity are affected. Physical therapy may involve trials of analgesic modalities like desensitization techniques, transcutaneous electrical nerve stimulation (TENS), and topical cold. Modality trials are rapid, relatively harmless, and inexpensive with the additional benefit that patients can self-administer effective treatments The pain management protocol of physiotherapy of PMPS depends mainly on education regarding the subsequent points that are paramount."
33090566|NCT05458115||liver resection group|
33090567|NCT05458076|Experimental|QLS1128 A-Dose 1~5|single dose
33404289|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
33404290|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
33090568|NCT05458076|Experimental|QLS1128 C-Dose 1~3|Twice daily for 7 days
33090569|NCT05458076|Experimental|QLS1128 D-Dose 1|fasting，high fat meal
33090570|NCT05458037|Experimental|Fast tenaculum application|
33090571|NCT05458037|Experimental|Slow tenaculum application|
33090572|NCT05457920|Experimental|Group A (continuous treatment group)|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180μg once a week, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
33090573|NCT05457920|Experimental|Group B (pulse therapy group)|The treatment period is 12 weeks as a treatment unit. From the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180 μg, every injection for 8 weeks, stop for 4 weeks, periodically, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
33090574|NCT05457881|Experimental|Protein-calorie restriction|Four day dietary intervention immediately before surgery of Scandi-Shake [any of 4 flavors - vanilla, strawberry, banana cream, and caramel] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk) calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on gender, age, height, weight, and activity level.
33090575|NCT05457881|No Intervention|Control|Ad libitum diet for four days immediately before surgery
33090576|NCT01056822|Active Comparator|1|Mycophenolate mofetil
33090577|NCT01056822|Experimental|2|Miycophenolate sodium
33090578|NCT05457764|Experimental|Virtual Reality|Participants use Virtual reality headsets as medium of erotica to produce their sperm sample
33090579|NCT05457764|No Intervention|No Virtual Reality|Participants did not use Virtual reality headsets as medium of erotica to produce their sperm sample. They used a computer screen to display erotica.
33090580|NCT05457530|Active Comparator|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Participants to receive DOR/3TC/TDF tablet once daily for 48 weeks
33090581|NCT05457530|Active Comparator|Doravirine + Emtricitibine/Tenofovir alafenamide Fumerate|Participants to receive DOR + FTC/TAF tablets once daily for 48 weeks
33090582|NCT05457530|Active Comparator|Bictegravir/Emtricitibine/Tenofovir alafenamide|Participants to receive BIC/FTC/TAF tablet once daily for 48 weeks
33090583|NCT04705194||One stage resection|Patients that are selected for a single hepatectomy of 2 segments or more.
33404291|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
33404294|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
33404295|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
33404296|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
33404297|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
33404298|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
33404299|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
32907083|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
33090584|NCT04705194||Two stage resection|Patients that are selected for a two-stage resection, where the first stage consists of either PVE or ALPPS and the second stage is a hepatectomy of 2 or more segments.
33090585|NCT05457452|Experimental|Knee Brace|Use of a Knee Brace after ACL Reconstruction, the patient is put on a knee brace by an orthopedic doctor or orthopedic resident after ACL reconstruction
33090586|NCT05457452|No Intervention|No Knee Brace|
33090587|NCT04705857||test group|"bone reconstructive surgery with the use of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery"
33090588|NCT04705857||control group|bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest
33090589|NCT04705506|Experimental|Gemigliptin group|The participants will receive gemigliptin 50 mg daily
33090590|NCT04705506|Placebo Comparator|Control|The control received standard care of diabetes
33090591|NCT05457374|Experimental|Partial hepatectomy+LVD|
33090592|NCT05457374|Experimental|Partial hepatectomy+PVE|
33090593|NCT04704960||Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)|patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
33090594|NCT05457335||PGT-A group|For patients undergoing PGT-A, trophectoderm biopsy was performed on good quality blastocysts and about five cells were aspirated gently and separated from the blastocyst by applying multiple pulses of a noncontact 1.48- μm diode laser (Saturn 5 ActiveTM, Cooper Surgical, Inc., CT, USA) through a zona pellucida opening created by the laser. The biopsied cells were washed three times in 1 × phosphate buffered saline (PBS) (Life Technologies, NY, USA), transferred to a PCR tube containing 2.5 μl 1× PBS and cryopreserved at -80◦C until analysis. Genetic laboratories analyzed and interpreted biopsies. The genetic screening was performed using the next-generation sequencing (NGS)-based assay VeriSeq PGS following standard protocols and manufacturer recommendations (Illumina Inc., San Diego, USA）. The PGT-A report can be euploid, aneuploidy, mosaic and non-conclusive. Euploid embryos were transferred while aneuploid and mosaic embryos were not replaced.
33090595|NCT05457335||Expectant management group|In the this group, one attempt at conception was defined as one calendar months trying to conceive spontaneously. Either in natural cycles for ovulatory women and in clomiphene/letrozol induced cycles for anovulatory women with or without ultrasound monitoring.
33090596|NCT05455385|Active Comparator|Control group|
33090597|NCT05455385|Experimental|Hydrotherapy group|
33090598|NCT05455385|Experimental|Ground exercise group|
33090599|NCT04705077|Experimental|Single Dose Treatment|"Each subject will be assigned to the fixed period sequence.~Period 1: SR419 suspension in the fasted state;~Period 2: SR419 capsule in the fasted state;~Period 3: SR419 capsule in the fed state (high-fat meal)."
33090600|NCT04705077|Experimental|Repeated Dose Treatment|Each subject will receive 30 mg of SR419 capsule, once every 8 hours (Q8h), for 5 days.
33090601|NCT05454722|Experimental|Adex Gel|Dry Skin Emollient with Nicotinamide
33090602|NCT05453045|Experimental|Albendazole|400 mg po single dose
33090603|NCT05451251|Experimental|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
33090604|NCT00432432|Placebo Comparator|2|placebo with infliximab
33090605|NCT05430113|Experimental|Spinal Cord Stimulation|All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
33090606|NCT05421494|Experimental|WET-R|
33090607|NCT05421494|Placebo Comparator|MCC|
33102450|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells~FURESTEM-CD Inj. 1.0x10^7 cells~FURESTEM-CD Inj. 2.0x10^8 cells"
33102451|NCT05400096|Experimental|CFT based online group intervention|The group will consist of 12 weekly 1.15h long online sessions.
33305104|NCT05128318|Experimental|Patients with BMI < 30 kg/m2|Collection of subcutaneous and visceral adipose tissue pieces of 1-2 cm3 during abdominal surgery procedures
33305105|NCT03765580|Placebo Comparator|Control group|No fish
33305106|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
33305107|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
33305108|NCT05119192||Veterans with Dysvascular Lower Limb Amputation|Self-report assessments, performance-based assessments, and optional individual interview with Veterans with dysvascular lower limb amputation.
33305109|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
33305110|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
33305111|NCT02914600|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 390 weeks
33305112|NCT02914600|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 390 weeks
33305113|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg for up to 390 weeks
33305114|NCT02914600|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 390 weeks
33305115|NCT02914600|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 390 weeks
33305116|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
33305117|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
33305118|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
33305119|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
33305120|NCT00134784|Experimental|Assess [123I]B-CIT SPECT imaging|To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
33305121|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
33305122|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
33305123|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
33305124|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
33305125|NCT00134082|Experimental|Immunotherapy|All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.
33305126|NCT01326312|Experimental|GTX 758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
33305127|NCT01326312|Experimental|GTx-758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
33305128|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
33305129|NCT05108818|Experimental|Influenza vaccination|Adults will receive a seasonal, inactivated, quadrivalent influenza vaccine administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
33305130|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
33305131|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
33305132|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
33305133|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
33305134|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
33305135|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
33305136|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
33305137|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
33305138|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
33305139|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
33305140|NCT01078818|Active Comparator|Oral ferrous fumarate|
33305141|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
33305142|NCT03964038|Active Comparator|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
33305143|NCT03964038|Experimental|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
33305144|NCT03964038|Experimental|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
33305145|NCT03964116|Other|AYA|Questionnaires set all 3 months and psychological interviews if needed
32798548|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
32798549|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
32798550|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
32798551|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
32798552|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
32798553|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
32798554|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
32798555|NCT04643912|Experimental|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:~Will receive vibration analysis blinded to x-ray findings."
32798556|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
32798557|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
32798558|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
32798559|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
32798560|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
32798561|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
32798562|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
32798563|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
32798564|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
32798565|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
32798566|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
32798567|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
32798568|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
32798569|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
32907084|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
32941088|NCT05591924||Healthy Controls|Adults over 18 years of age with no infectious symptoms, interaction with the health care system, or antimicrobial use in the past 14 days and no history of immunosuppression.
33102452|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
32941089|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
33305146|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
33305147|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
33305148|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
33305149|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
33305150|NCT03703336|Experimental|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
33305151|NCT03703336|Active Comparator|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
33305152|NCT01076634|Experimental|IDeg 100 U/mL|
33305153|NCT01076634|Experimental|IDeg 200 U/mL|
33305154|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
33305155|NCT00132678|Experimental|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
33305156|NCT00132678|Placebo Comparator|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
33305157|NCT01081548|Experimental|Generic|
33305158|NCT01081548|Active Comparator|Lipitor|
33305159|NCT00101868|Experimental|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
33305160|NCT00101868|Active Comparator|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
33305161|NCT00101400|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
33305162|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
33305163|NCT00121992|Active Comparator|Arm A: FAC|FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
33305164|NCT00121992|Experimental|Arm B: TAC|TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
33305165|NCT03963726|Experimental|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
33305166|NCT03963726|Experimental|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
33305167|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
33305168|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
33305169|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
33305170|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
33305171|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
33305172|NCT01076712|Other|Education|Education
33305173|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
33305174|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
33305175|NCT03965520|Active Comparator|usual training|exercise intensity arranged by cardiopulmonary exercise test results
33305176|NCT03965520|Experimental|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
33305177|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
33305178|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
33305179|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
33305180|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
33305181|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
33305182|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
32798570|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
33090608|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
33090609|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
32798571|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
32798572|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
32798573|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
32798574|NCT01411228|Experimental|60 Units/kg|
32798575|NCT01411228|Experimental|30 Units/kg|
32798576|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
32798577|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
32798578|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
32798579|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
32798580|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
32798581|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
32798582|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
32798583|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
32798584|NCT04037176|Active Comparator|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
32798585|NCT04037176|Placebo Comparator|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.~Placebo is administered subcutaneously"
32798586|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
32798587|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
32798588|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
32798589|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
32798590|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
33305183|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
33102453|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
33305184|NCT01079208|Experimental|test starter formula|test infant formula
33305185|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
33305186|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
33305187|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
33305188|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
33305189|NCT00141518|Experimental|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
33305190|NCT00141518|Experimental|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for < 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
33305191|NCT00141518|Experimental|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
33305192|NCT03973736||PDAC patients diagnosed in 2008-2011|
33305193|NCT03973736||PDAC patients diagnosed in 2013-2016|
33305194|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
33305195|NCT03967106|Experimental|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
33305196|NCT03967106|Sham Comparator|Sham|Remote sham intervention daily for six weeks.
33305197|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
33305198|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
33305199|NCT00098748|Experimental|1|
33305200|NCT00098748|Experimental|2|
33305201|NCT00098748|Experimental|3|
33305202|NCT00130520|Experimental|open label|
33305203|NCT01076946||TLVBS|patients with transient left ventricular ballooning
33305204|NCT00132132|Experimental|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
33305205|NCT00132132|No Intervention|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
32941090|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
32941091|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
33305206|NCT00130442|Experimental|Arm 1- PI-88 plus dacarbazine|PI-88 (muparfostat) 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
33305207|NCT00130442|Active Comparator|Arm 2- dacarbazine alone|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
32941092|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
32941093|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
32941094|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
32941095|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
32941096|NCT01397695|Experimental|bevacizumab|
32941097|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
32941098|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
32941099|NCT05586776|Active Comparator|Decolonization|Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).
32941100|NCT05586776|Placebo Comparator|Routine Care|Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.
32941101|NCT05600647|Experimental|Electromagnetic Field therapy with an exercise program|The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. Every patient is lying on the mattress in a supine position. In addition to exercise training program included postural correction strengthening exercises, stretching, proprioception and balance training
32798591|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
32798592|NCT01990313|Experimental|Activa PC+S|
32798593|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
32798594|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
32798595|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
32798596|NCT01947283|Experimental|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
32798597|NCT01947283|Experimental|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
32798598|NCT01947283|No Intervention|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
32798599|NCT01947283|No Intervention|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care."
32798600|NCT01947283|No Intervention|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
32798601|NCT01947283|No Intervention|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
32798602|NCT01947283|Experimental|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
32798603|NCT02006693|Other|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
32798604|NCT02006693|Other|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
32798605|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
32798606|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
32798607|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
32798608|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
32798609|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
32798610|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
32798611|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
32798612|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
32798613|NCT04638595||Normative|50 neurotypical pediatric subjects
32798614|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
32798615|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
32798616|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
32798617|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
32798618|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
32941102|NCT05600647|Active Comparator|exercise program|Every patients will practice the exercise training program alone. the program included postural correction, strengthening exercises, stretching, proprioception and balance training
32941103|NCT05749640|Active Comparator|"Palodent® plus sectional matrix system Control group"|
33090610|NCT05420402|Active Comparator|Bolus group A|42 participants will receive 1 mg/kg intravenous bolus of propofol 3 min before the end of surgery.
33305208|NCT00130208|Experimental|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
33305209|NCT00130208|Placebo Comparator|Placebo|All patients will be on standard of care ACE or ARBs.
32941104|NCT05749640|Experimental|"PerForm™ Experimental"|
32941105|NCT05749640|Experimental|"Trimax™ Experimental"|
33305210|NCT00253370|Experimental|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33305211|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
33305212|NCT01071980|No Intervention|Control|Control group
33305213|NCT03966482|Experimental|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
32941106|NCT05749640|Experimental|"Contact Pro™ Experimental"|
33305214|NCT03966170|Experimental|Citicoline|Citicoline as neuroprotector
33305215|NCT03966170|Placebo Comparator|Placebo drug|Placebo
33305216|NCT01076426|Experimental|Probiotics|probiotics treatment
33305217|NCT01076426|Placebo Comparator|Placebo|
33305218|NCT00140426|Placebo Comparator|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
33305219|NCT00140426|Active Comparator|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
33305220|NCT03966560|Experimental|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.~Medical treatment was initiated for the diagnosed participants."
33305221|NCT03966560|No Intervention|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
33305222|NCT01072058|Other|TNF blockers|
32941107|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
32941108|NCT01356667|Experimental|DARTNA|12-week DARTNA program
32941109|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
32941110|NCT05600491|Experimental|Early TMZ chemotherapy|Patients were treated with standard concomitant radiochemotherapy regimen (Stupp) plus early postsurgical temozolomide.
33305223|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
33305224|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
33305225|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
33305226|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
33305227|NCT00121134|Experimental|Group A|Bevacizumab Alone
33305228|NCT00121134|Experimental|Group B|Bevacizumab with cyclophosphamide and methotrexate
33305229|NCT00121134|Experimental|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
33305230|NCT00121134|Experimental|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
32941111|NCT05749484||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
32941112|NCT05600413|Experimental|L-Citrulline|L-Citrulline: 6 grams/day
32941113|NCT05600413|Placebo Comparator|Placebo|Crystalline Cellulose
32941114|NCT05579600|Experimental|Caring Contact letters|Caring Contact letters will be mailed to a randomly selected group of managed care subscribers over a 6-month period following jail release.
32941115|NCT05579600|Experimental|Reports, re-engagement, and training|Behavioral health providers (n=120) will be trained in evidence-based suicide prevention screening and intervention practices, in addition to receiving weekly reports with information on clients who have been released from jail to encourage outreach efforts for re-engagement with the healthcare system.
32941116|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
32941117|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
32941118|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
33305231|NCT03966690|Experimental|leg curl device starters|Group A randomly assigned to start with legcurl device
33305232|NCT03966690|Experimental|legpress device starters|Group A randomly assigned to start with legpress device
33305233|NCT03966378|Experimental|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
33305234|NCT03966378|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
33305235|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
32941119|NCT05440526|Active Comparator|Herbst Group|• Group I: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
33090611|NCT05420402|Active Comparator|Continuous infusion group|42 participants will receive 1 mg/kg continuous intravenous pumping of propofol 3 minutes before the end of the operation, and the pumping time was 3 minutes.
33090612|NCT05420402|Active Comparator|Bolus group B|42 participants will receive 1 mg/kg intravenous bolus of propofol at the end of surgery.
33090613|NCT05420402|No Intervention|Blank Comparator group|42 participants will not receive propofol
33090614|NCT02957448|Experimental|BMS 986141 and Rifampin|
33090615|NCT05389319|Experimental|Cohort 1|Prime-2-CoV_Beta, dose: 30 000 PFUs
33090616|NCT05389319|Experimental|Cohort 2|Prime-2-CoV_Beta, dose: 300 000 PFUs
33090617|NCT05389319|Experimental|Cohort 3|Prime-2-CoV_Beta, dose: 3 000 000 PFUs
32941120|NCT05440526|Active Comparator|TFBC Group|• Group II: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
32941121|NCT05578118||ICSI + AOA|Children born after ICSI + AOA
32941122|NCT05578118||Control|Children born after ICSI
32941123|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
32941124|NCT05572736|Experimental|Conduction system pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
32941125|NCT05572736|Active Comparator|Biventricular pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
32941126|NCT00379561|Experimental|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
32941127|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
32941128|NCT01890577||Study population|Single cohort of dialysis patients
32941129|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
32941130|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
32941131|NCT01315873|Experimental|Bortezomib and Bendamustine|
32941132|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
32941133|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
32941134|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
32941135|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
32941136|NCT05313061|Active Comparator|MTX continue|Group will continue MTX after vaccination
32941137|NCT05313061|Experimental|MTX 1 week hold|Group will continue MTX for 1 week after vaccination
32941138|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
32941139|NCT05749328|Experimental|Carbohydrate group|Fasting at 20:00 on the eve of surgery, give 800ml of carbohydrate drink, the patient drinks freely, no more than 200ml per hour, to 3h before surgery, give carbohydrate drink again, according to 5ml/kg calculated dose, maximum 400ml, drink within 30 minutes.
32941140|NCT05749328|No Intervention|Contral group|Fasting at 20:00 on the eve of surgery, fasting at 24:00, until the induction of anesthesia on the day of surgery
32941141|NCT05600023|Experimental|Nitrofurantoin|
32941142|NCT05600023|Experimental|Double antibiotic paste|
32941143|NCT05600023|No Intervention|Control|
33090618|NCT05389319|Experimental|Cohort 4|Prime-2-CoV_Beta, dose: 150 000 000 PFUs
33090619|NCT05389319|Experimental|Cohort 5|Prime-2-CoV_Beta, dose: 30 000 000 PFUs
33090620|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
33090621|NCT04704765|Experimental|The effectiveness of receiving abdominal breathing training|The patients receiving the intervention of abdominal breathing training were in the experimental group. The experimental group received the abdominal breathing training for a total of 8 weeks. During this period, they received the abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time). The control group without training.
33090622|NCT04704765|No Intervention|The effectiveness of not receiving abdominal breathing training|The control group who did not receive abdominal breathing training. The effectiveness assessment used the Beck anxiety inventory and physiological index (heart beats, breath and blood pressure), required to be completed by the control group.
33102454|NCT05394987|Experimental|Optical correction|Prescription of spectacles for full-time wear to correct refractive error
32941144|NCT05566262|Experimental|Bodewell Treatment|All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.
32941145|NCT05271643|Experimental|CF-CBT-A intervention|Participants will meet with a therapist, a mental health provider on their cystic fibrosis care team who has received training in CF-CBT-A, for a baseline interview and introduction plus 9 weekly sessions of CF-CBT-A.
33090623|NCT05371964|Experimental|Imetelstat + Ruxolitinib|"Part 1: Participants who have received ruxolitinib orally (PO) as part of standard of care (SOC) for at least 12 weeks (maximum 24 weeks) prior to Screening will be enrolled. After enrollment, participants will initiate imetelstat therapy. Dose levels of imetelstat may include 4.7, 6, 7.5, 9.4mg, until a RP2D is established.~Part 2: JAK inhibitor naïve participants will receive initial treatment with ruxolitinib for at least 12 weeks (maximum 24 weeks), including 4 weeks at a stable dose, followed by imetelstat treatment at the RP2D in combination with ruxolitinib."
33305236|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
32941146|NCT05566184|Experimental|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure and the data will be collected.
32941147|NCT05566184|No Intervention|Without modified pacifier|Data will be collected without giving the child in the control group a modified pacifier during the procedure.
33305237|NCT02652052|Other|Group 1: Observational|Standard of Care - Observation Only
33305238|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
33305239|NCT00119262|Experimental|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
33305240|NCT00119262|Active Comparator|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
32941148|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
33305241|NCT01077102|Experimental|Eccentric exercise training|
33305242|NCT01077102|Active Comparator|Concentric exercise training|
32941151|NCT05599789|Experimental|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab in Combination with Plinabulin and Docetaxel
32941152|NCT05749250|Experimental|Cavitation therapy|Subjects treated with cavitation energy
32941153|NCT05749250|No Intervention|Control|Control subjects not treated with cavitation energy
32941154|NCT05599555||Unvaccinated blood donors|Blood donors who were unvaccinated with any COVID-19 vaccine by study recruitment
32941155|NCT05599555||Blood donors vaccinated with BNT162b2|Blood donors who were vaccinated with one or more doses of the mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China) by study recruitment.
32941156|NCT05599555||Blood donors vaccinated with CoronaVac|Blood donors who were vaccinated with one or more doses of the inactivated CoronaVac (Sinovac life Sciences, Beijing, China) vaccine by study recruitment.
32941157|NCT04706455|Active Comparator|sodium hyaluronate 0.1%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then, corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.1% will be installed and biometry and corneal topography will be repeated after 5 minutes.
32941158|NCT04706455|Active Comparator|sodium hyaluronate 0.3%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then,corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.3% will be installed and biometry and corneal topography will be repeated after 5 minutes.
32941159|NCT00002744|Experimental|Arm I|Therapy defined in description.
32941160|NCT00002744|Experimental|Arm 2|Therapy defined in description.
32941161|NCT00002744|Experimental|Arm 3|Therapy defined in description.
32941162|NCT00002744|Experimental|Arm 4|Therapy defined in description.
33102455|NCT03825575|Experimental|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
33305243|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
33102456|NCT04678167|Experimental|Boarding ring glasses|"Realization of the following examinations WITH Boarding ring glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
33102457|NCT04678167|Placebo Comparator|Placebo glasses|"Realization of the following examinations WITH Placebo glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
33305244|NCT03703882|Placebo Comparator|Placebo|Matching placebo
33305245|NCT00131664|Active Comparator|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
32941163|NCT01788475|Active Comparator|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
33305246|NCT00131664|Active Comparator|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
33305247|NCT00131664|Active Comparator|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
33305248|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
33305249|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
33305250|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
33305251|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
33305252|NCT00131508|Experimental|2|Glutamine
33305253|NCT00131508|Placebo Comparator|1|
33305254|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
33305255|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
33305256|NCT05088772||Hyperbaric Oxygen Therapy - Experimental Group|Patients receiving hyperbaric oxygen therapy at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada)
33305257|NCT05050318|Experimental|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
33305258|NCT05050318|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to <9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
33305259|NCT05050318|Experimental|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged >= 65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
33305260|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
33305261|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
33305262|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
33305263|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
33305264|NCT01321762||1|Pregnant Women with singleton pregnancy
33305265|NCT03764722|Experimental|Levosimendan|
33305266|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
33305267|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
33305268|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
33305269|NCT05024734|Experimental|Epirubicin|"Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.~If no significant drug selection can be performed in-vitro, Epirubicin will be the default for instillation."
33305270|NCT05024734|Experimental|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
33305271|NCT05024734|Experimental|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
32737946|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
32737947|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
32737948|NCT03327077|No Intervention|Control Group|
32737949|NCT03327077|Experimental|Intervention Group|Music group
32737950|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
32737951|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
32737952|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
32737953|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
32737954|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
32737955|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
32737956|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
32737957|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
33305272|NCT05024734|Experimental|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
33305273|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
33305274|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
33305275|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
33305276|NCT05461066|Experimental|Intervention|Smoking cessation intervention in community pharmacies
33305277|NCT05461066|Active Comparator|Control|Usual care of smoking cessation in community pharmacies
33305278|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
33305279|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
33305280|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
32798619|NCT04672655|Experimental|ONBOARD Intervention Group|Those randomized to the ONBOARD group will receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study. They will also receive the intervention which consists of four 60-minute sessions with study interventionist, held 2 weeks apart.
32798620|NCT04672655|No Intervention|CGM Only Group|Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study.
32798621|NCT01942837|Experimental|Enzalutamide|"Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.~Dosing: 160 mg orally taken once daily as four 40 mg capsules."
33305281|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
33305282|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
32798622|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
32798623|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
32798624|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
32798625|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
32798626|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
32798627|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
32798628|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
32798629|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
32798630|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
32798631|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
32798632|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
32798633|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
32798634|NCT01429792|Experimental|Single Arm|
32798635|NCT04034446|Experimental|A|Single dose of CD19-CD22 CAR-T cells
32798636|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
32798637|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
32798638|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
32798639|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
33102458|NCT04678167|Other|No glasses|"Realization of the following examinations WITHOUT glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
33102459|NCT00532545|Experimental|A|Teriparatide
33102460|NCT03819062|Experimental|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
33305283|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
33305284|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
33305285|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
33305286|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
33305287|NCT05460988|Experimental|Non surgical re-instrumentation|The sites showing remaining pockets (PD>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
33305288|NCT05460988|Active Comparator|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
33305289|NCT05002972|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
33305290|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
33305291|NCT03756298|Active Comparator|Control|Capecitabine alone arm
33305292|NCT05460910|Experimental|core stability exercise, treadmill|core stability exercises and treadmill training
33305293|NCT05460910|Experimental|core stability exercises|core stability exercises without treadmill training
33305294|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
33305295|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
33305296|NCT04651114|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
33305297|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
33305298|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
33305299|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
33305300|NCT04980040||Nesina® Tablet|Participants with a diagnosis of Type 2 Diabetes who took Nesina® tablet (alogliptin), as prescribed by the physician, are observed in this study.
33305301|NCT04647916|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33305302|NCT00131352|Experimental|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
33305303|NCT00131352|Placebo Comparator|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
33305304|NCT04646200|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
33318514|NCT05655806|Active Comparator|group A|will receive aminophylline loading dose 5mg/kg on a 50 cm syringe using syringe pump over 5 minutes and maintenance dose 1.5 mg/kg/hr as a continuous infusion half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given over 5 minutes
32737958|NCT05464433|Experimental|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with tislelizumab for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 16 mg/m2.
32737959|NCT05024409|Experimental|Orthotic + Occupational Therapy|
32737960|NCT05024409|Active Comparator|Occupational Therapy alone|
32737961|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
32737962|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
32737963|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
33305305|NCT04646200|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
33090625|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
33305306|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
33305307|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
33305308|NCT04633642|Experimental|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
33305309|NCT04633642|Active Comparator|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
33305310|NCT00136916|Experimental|Inhaled Insulin|Inhalable short-acting insulin
33305311|NCT00136916|Active Comparator|Subcutaneous insulin|
33305312|NCT04633564|Experimental|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
33305313|NCT04633564|Active Comparator|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
33305314|NCT04960228|Experimental|Altruism Video Intervention|Participants will watch a 3-minute video about COVID-19 vaccination that elicits altruistic motives. The role of this arm is to test whether altruistic themes are an effective way to promote COVID-19 vaccination amongst young people and whether a video format is preferable for this group.
33305315|NCT04960228|Active Comparator|Informational Text Intervention|Participants will read a brief informational text including information drawn from the Public Health Agency of Canada website (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html#self). The purpose of this arm is to provide an active comparator with information about COVID-19 preventative health behaviors that has been strongly recommended to the public since the beginning of the pandemic. By doing this, we will assess if the video intervention changes vaccination intentions more than a presentation of general, well-known COVID-19 related information.
33305316|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
33305317|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
33305318|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
33305319|NCT04628416|Experimental|Experimental arm|
33305320|NCT04628416|Other|Control|
33305321|NCT04619992|Other|Current users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are current users of Hollister standard with tip hydrophilic intermittent catheters.
33305322|NCT04619992|Other|New users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are new users of Hollister standard with tip hydrophilic intermittent catheters.
33305323|NCT04607980|Experimental|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [<=] 100 kg) or 90 mg (baseline BW greater than [>] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
33305324|NCT04607980|Experimental|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW <= 100 kg) or 90 mg (baseline BW > 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
33305325|NCT00136604|Experimental|ACAC GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccines at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
33305326|NCT00136604|Experimental|ACHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33404300|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
33404301|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
33404302|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
33404303|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
33404304|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
33404305|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
33404306|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
32737964|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
33090626|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
33090627|NCT05354258|Placebo Comparator|Vitamin A + Zinc supplements on Day 0, followed by SMC course on Day 1,2 & 3|
33090628|NCT05354258|Experimental|Praziquantel + Vitamin A on Day 0, followed SMC course on Days 1,2 & 3|
33090629|NCT05354258|Experimental|Albendazole + Praziquantel on Day 0, followed by SMC course on Days 1, 2 & 3|
33090630|NCT05338580|Experimental|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
33090631|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
33090632|NCT05306366|Experimental|[11C]-Lu AF90103|Participants will receive [11C]-Lu AF90103 via an intravenous bolus injection on Day 1.
33090633|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
33090634|NCT05296070|Experimental|Loncastuximab tesirine Cycles 1-6|Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
33090635|NCT02273466|Active Comparator|Desipramine alone|
33090636|NCT02273466|Experimental|Desipramine with Crobenetine|
33090637|NCT05245643|Other|Patients with severe and resistant Anorexia Nervosa|12 consecutive patients fulfilling the inclusion criteria and consenting to participate in the research, recruted in the three inclusion centers.
33090638|NCT05228171||Standard Recall|Standard interviewer-administered 24-hour dietary recall.
33090639|NCT05228171||Augmented Recall|Interviewer use of the mCC app for 24-hour dietary recall.
33090640|NCT02273505|Experimental|Asasantin (ER)|
33090641|NCT02273505|Active Comparator|Combination of Persantin and ASA|
33090642|NCT05210621|Other|Patients with MS who have completed the CONSONANCE study|
33090643|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
33090644|NCT05198960|Experimental|Experimental group|Patients randomized to receive Direct Oral Anticoagulants, at the choice of the investigator Apixaban 2.5 mg both in day or Rivaroxaban 10 mg one per day, at the choice of the investigator
33090645|NCT05198960|Active Comparator|Control group|Patients randomized to receive Low-Dose Aspirin Aspirin 100 mg one per day
33090646|NCT05174156|Experimental|biomarker study and treatment study|"All enrolled patients undergo biomarker study and treatment study.~Biomarker study: the baseline tumor tissue will be collected and analyzed via NGS and mIHC~Treatment study: SHR-1210 plus albumin-bound paclitaxel and platinum-based chemotherapy"
33090647|NCT05091632||Observational (EEG, questionnaires)|Patients undergo EEG over 30 minutes daily until death or discharge and complete questionnaires over 30 minutes daily until death or discharge to check level of consciousness, thought, and ability to communicate.
33090648|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
33090649|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
33090653|NCT00428025|Placebo Comparator|placebo suppository|
33090654|NCT00428025|Active Comparator|diclofenac suppository|
33090655|NCT05011253|Experimental|Intervention|The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.
33090656|NCT05011253|No Intervention|Control|The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)
33090657|NCT00432627|Experimental|Mild hepatic impaired|
33090658|NCT00432627|Experimental|Moderate hepatic impaired|
33090659|NCT00432627|Experimental|Severe hepatic impaired|
33090660|NCT00432627|Experimental|Healthy volunteers|Controlled group
33090661|NCT00419705|Experimental|Transcranial Laser Therapy|
33090662|NCT00419705|Sham Comparator|Sham control procedure|
33090663|NCT00419783|Experimental|1|Bilastine 20 mg
33090664|NCT00419783|Experimental|2|Bilastine 100 mg
33090665|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
33090666|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
33305327|NCT00136604|Experimental|HibACPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33305328|NCT00136604|Experimental|HibHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
33305329|NCT00136604|Experimental|CC GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix + Meningitec vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
33305330|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
33305331|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
33305332|NCT04953910|Experimental|Group B: Moderate hepatic impairment|Cancer participants with moderate hepatic impairment [total bilirubin > 1.5x - 3x upper limit of normal (ULN); any aspartate aminotransferase (AST) level]
33305333|NCT04953910|Experimental|Group C: Severe hepatic impairment|Cancer participants with severe hepatic impairment (> 3x ULN; any AST level)
33090667|NCT00419783|Placebo Comparator|5|Placebo
33090668|NCT04704492|Experimental|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0 , 2.
33305334|NCT04953910|Active Comparator|Group A: Normal hepatic function|Cancer participants with normal hepatic function (total bilirubin ≤ ULN; AST ≤ ULN)
33305335|NCT03764020|Experimental|Melatonin|"Intervention group1:~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
33305336|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
33305337|NCT04325386|Experimental|Education sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
33305338|NCT04325386|Placebo Comparator|No education sessions|
33305339|NCT00130728|Experimental|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
33305340|NCT00130728|Placebo Comparator|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
33305341|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation|
33305342|NCT04947436|Active Comparator|Mechanical insufflation/ exsufflation|
33305343|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
33305344|NCT03966326|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
33305345|NCT03966326|Active Comparator|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
33305346|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
33305347|NCT01321840|Experimental|Treatment|This group will be treated with SART.
33305348|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
33305349|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
33305350|NCT00119106|Experimental|tenofovir disoproxil fumarate|Participants in the Tenofovir arm will receive daily oral tenofovir
33305351|NCT00119106|Placebo Comparator|Placebo|Participants in the Placebo are will receive daily oral placebo
33305352|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
33305353|NCT04944706|Experimental|Low dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
33305354|NCT04944706|Experimental|High dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
33305355|NCT04944706|Experimental|Placebo group|The standard basic treatment is given according to the guidelines related to the underlying disease
33305356|NCT05460598|Active Comparator|interventional group: beddings with cooling effects|"Cooling beddings: linen made of the Outlast Technology https://www.outlast.com/en/. This product is made of 100 % lyocell and utilizes phase change materials based on natural wax. When this phase change material melts, heat is extracted from the environment and stored in microcapsules called thermocules. When the body cools down, these thermocules harden again release the heat from the linen. This might help to balances the body temperature and prevent warmth-aggravated itch.~- The mattress is made of polyurethane foam and designed as a cool gel topper to be placed onto the standard hospital mattress. Heat is also absorbed and stored into this topper. This topper is covered with an Obatex cover. It protects the cool gel topper from moisture and organic liquids and is made of polyamide fabric."
33305357|NCT05460598|Placebo Comparator|control group: commonly used bedding|
33305358|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
33305359|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
33305360|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
33305361|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
33305362|NCT04925908||Control Group|Infants of mothers with suspected but negative for COVID-19
33305363|NCT04925908||Case Group|Infants Born to COVID-19 positive mothers
33305364|NCT00135356|Active Comparator|Switch arm|
33305365|NCT00135356|Active Comparator|Control Arm|
33305366|NCT00118716|Experimental|FSC 100/50 mcg BID|Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
33305367|NCT00118716|Experimental|FP 100 mcg BID|Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.
33305368|NCT04584346|Experimental|Arm A|Ketogenic Diet
33305369|NCT04584346|Active Comparator|Arm B|Standard American Diet
33305370|NCT04907032|Experimental|Posterior Tibial Nerve Stimulation with Mirabegron|One arm of the study will receive PTNS combined with mirabegron. In the PTNS with mirabegron arm, the patient will take a 50 mg dose daily for 12 weeks of the trial. This arm of the study will have 27 patients randomized to this arm of the study. The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
33305371|NCT04907032|Placebo Comparator|Posterior Tibial Nerve Stimulation Plus Placebo|The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
33305372|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
33305373|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
33305374|NCT01081860||Trigger finger|Patients with trigger fingers
33305375|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
33305376|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
33305377|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
33305378|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
33305379|NCT05124782||Patients with rheumatoid arthritis|Patients seen in virtual consultation
33305380|NCT00118482|Experimental|fludrocortisone acetate|
33305381|NCT00118482|Placebo Comparator|Placebo|
33305382|NCT03966950|Experimental|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
33305383|NCT03966950|Placebo Comparator|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
33305384|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
33305385|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
33305386|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
33305387|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
33305388|NCT01076582|Experimental|Arm 1|
33305389|NCT01076582|Active Comparator|Arm 2|
33305390|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
33305391|NCT01081938|Active Comparator|2|Insulin Glulisine
33305392|NCT03763864|Other|Inherited disorders|
33305393|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
33305394|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
33305395|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
33305396|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
33305397|NCT03965936|Placebo Comparator|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
33305398|NCT03965936|Active Comparator|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
33305399|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
33305400|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
33305401|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
33305402|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
33305403|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
33305404|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
33305405|NCT03763630|Placebo Comparator|Control arm|Normal saline
33305406|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
33090669|NCT00419822|Active Comparator|Acupuncture|
33090670|NCT00419822|Sham Comparator|Sham Acupuncture|
33305407|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
33305408|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
33305409|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
33305410|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
33090671|NCT00419822|Placebo Comparator|Standard of Care|
33090672|NCT04703517|Other|Self Controlled|Patients will active as their own comparator
33090673|NCT04959305|Experimental|Experimental 1|HCP1803-3
33090674|NCT04959305|Active Comparator|Active Comparator 1|RLD2003
33090675|NCT04959305|Active Comparator|Active Comparator 2|RLD2004
33090676|NCT04959305|Active Comparator|Active Comparator 3|RLD2005
33090677|NCT04704687|Experimental|tDCS|
33305411|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
33305412|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
33305413|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
33305414|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
33305415|NCT00129272|Active Comparator|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
33305416|NCT00129272|Placebo Comparator|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
33090678|NCT04704687|Active Comparator|Sham|
33090679|NCT04942340|Active Comparator|Phase 1: Atipamezole & caffeine's in a 1:1 ratio|Is this arm, subjects will be randomized to IV administration of Atipamezole & caffeine's in a 1:1 ratio
33305417|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
33305418|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
33305419|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
33090680|NCT04942340|Placebo Comparator|Phase 1: Precedex & Saline in a 1:1 ratio|Is this arm, subjects will be randomized to receive IV administration of Precedex & Saline in a 1:1 ratio
33090681|NCT04906109|Experimental|Reference-Test|
33090682|NCT04906109|Experimental|Test-Reference|
33090683|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
33305420|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
33305421|NCT03963648|Experimental|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
33305422|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
33090684|NCT04871438|Experimental|FGM|Flash glucose monitoring at weeks 0-2, weeks 6-8 post-discharge
33090685|NCT04871438|No Intervention|SMBG|Self-monitoring of blood glucose at least 4 times a day, 3 days a week
33090686|NCT04823897|Experimental|Dose Escalation and Expansion|"Dose escalation phase: CCI-001 will be administered at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, or recommended dose for the dose expansion cohort.~Dose expansion phase: patients with the following tumour types will be permitted to enroll: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined during the dose escalation phase."
33090687|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
33090688|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
33090689|NCT04803422|Active Comparator|Arm 1- Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim."
33102461|NCT04674111|Experimental|Vortex Feasibility Study (Vortex FIH)|Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)
33090690|NCT04803422|Active Comparator|Arm 2 - Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin."
33090691|NCT04703478|Experimental|Single group|Implementation of a mobile application for the rehabilitation of patients with respiratory sequelae of COVID-19
33090695|NCT04781153|Experimental|Immediate intervention (A)|Subjects will receive the full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) immediately after baseline.
33090696|NCT04781153|Experimental|Delayed intervention (B)|"Subjects will receive a full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) 3-4 weeks after baseline. The delayed intervention will enable the study team to explore the effect of the participants change in behavior due to participation in a research project, and furthermore how change in oral hygiene habits might affect the lung function."
33090697|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
33090698|NCT00432861|Placebo Comparator|2|
33090699|NCT04768946||Adolescents with Acquired Brain Injury|Adolescents with traumatic brain injury, stroke, and other acquired brain injury ages 12 - 17 will participate in interviews about home safety. They also will have the opportunity to look at and, if desired, try the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
33090700|NCT04768946||Caregivers of Adolescents with Acquired Brain Injury|Caregivers of adolescents with traumatic brain injury, stroke, and other acquired brain injury will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
33305423|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
33305424|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
33305425|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
33305426|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
33305427|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
33305428|NCT04899232|Experimental|AT3 less than 100% with SOC plus AT3 supplement|Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
33305429|NCT04899232|No Intervention|AT3 less than 100% with SOC only|Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
33305430|NCT04899232|No Intervention|AT3 more than 100% with SOC only|Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
33305431|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
33305432|NCT04574908|Active Comparator|Blinded Ward|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert <70, no Mean Arterial Pressure alert, heart rate >150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
33318515|NCT05655806|Active Comparator|group B|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5cm syringe of aminophylline bolus 5mg\kg will be given over 5 minutes
33318516|NCT05655806|Placebo Comparator|group C|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given
33318517|NCT03979781|Experimental|Treatment Group|Intervention group
33090701|NCT04768946||Healthcare Workers|This cohort includes health professionals involved in discharge planning and community re-integration of adolescents with ABI. Healthcare workers will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
33090702|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
33090703|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
33318518|NCT03979781|Active Comparator|Control Group|Standard of Care group
32798640|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
32798641|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
32798642|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
32798643|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
32798644|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
32798645|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
32798646|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
32798647|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
32798648|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
32798649|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
32798650|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
32798651|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
32798652|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
32798653|NCT04045600|Experimental|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
32798654|NCT04045600|Experimental|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
32798655|NCT04033978|Experimental|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
32798656|NCT04033978|Active Comparator|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
33318519|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
33318520|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
33318521|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
33305433|NCT04574908|Experimental|Unblinded Ward|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered. Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) <65 mmHg, heart rate >110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
33305434|NCT05460364|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
33305435|NCT05460364|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
33305436|NCT05460364|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
32941164|NCT01788475|Active Comparator|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
33090704|NCT04627805|No Intervention|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
33305437|NCT05460364|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
33305438|NCT05460364|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
33305439|NCT05460364|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
33090705|NCT04627805|Experimental|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
33090706|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
33305440|NCT00096174|Experimental|Cisplatin, C225, Radiation|"Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.~Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.~Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
33305441|NCT04559698|Experimental|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
33090707|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
33090708|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
33090709|NCT04602377|Experimental|Pembrolizumab|Single arm study
33090710|NCT04575233|Experimental|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
33090711|NCT04575233|Active Comparator|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
33090712|NCT04565951|Experimental|treatment arm|Participants in this arm will receive the intervention, PsychArmor S.A.V.E.
33090713|NCT04565951|Sham Comparator|sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
33090714|NCT04558073|Experimental|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
33404307|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
33404308|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
33090715|NCT04558073|Experimental|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
33090716|NCT04558073|No Intervention|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
33090717|NCT04507412|Experimental|arm A|• 9 mg of i.v. dexamethasone
33090718|NCT04507412|No Intervention|arm B|• no steroid supplementation
33090719|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
32900822|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
33090720|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
33090721|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
33090722|NCT04489940|Experimental|Bintrafusp alfa|
33090723|NCT04476602||COVID-19 (SARS-CoV-2) patients|adults 18 or older, ambulatory , with COVID-19 (SARS-CoV-2)
33090724|NCT00433056|Experimental|1|STI
33090725|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
33090726|NCT04460612|Placebo Comparator|Placebo Sock|Placebo Socks will be placed on participants feet either first or second for 60 minutes
33090727|NCT04460612|Active Comparator|Active IR Sock|Active IR socks will be placed on participants feet either first or second
33090728|NCT04401332|Experimental|Intervention|
33090729|NCT04401332|No Intervention|Usual Care|
33090730|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
33090731|NCT04378049|Active Comparator|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
33090732|NCT04378049|Experimental|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
33090733|NCT01056510|Experimental|A|
33090734|NCT01056510|Experimental|B|
33090735|NCT04329767||IRIS Arm|Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
33090736|NCT04329767||CT Arm|Utilize only the standard 2D CT scan preoperatively and intraoperatively
33090737|NCT01051323||1|
33090738|NCT04326257|Experimental|Nivolumab+Relatlimab|"Nivolumab will be dosed 480mg IV q 4 weeks and Relatlimab 160mg IV q 4 weeks~One cycle is defined as 4 weeks of treatment and both drugs are given on the same day.~Patients will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
33090739|NCT04326257|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be dosed at 3mg/kg IV q 2 weeks and Ipilimumab 1mg/kg IV q 6 weeks.~Patients will receive four doses of Ipilimumab and the last dosage of Nivolumab 3mg/kg IV q 2 weeks will be given at the time of the 4th dose of Ipilimumab, followed 2 weeks later by Nivolumab 480 mg IV q 4 weeks. A cycle of therapy will be defined as 4 weeks of treatment. The patient will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
33090740|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:~who are feeling sick but have not tested positive for COVID-19~who are feeling sick and have tested positive for COVID-19~People who are not feeling sick but want to participate"
33090741|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
33305442|NCT04559698|Experimental|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
33305443|NCT03963258|Active Comparator|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
33305444|NCT03963258|Experimental|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
33305445|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
33305446|NCT03763474|No Intervention|Control|
33305447|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
33305448|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
33305449|NCT01082172|Experimental|Thoracic Stent Graft|Thoracic Stent Graft implanted device
33305450|NCT03757858|Experimental|HT+ACT|
33305451|NCT03757858|Experimental|HT+ACT+PD-1|
33305452|NCT03757858|Experimental|HT+ACT+CT|
33305453|NCT03757858|Active Comparator|HT+CT|
33305454|NCT01079676|Experimental|Filgrastim|
33305455|NCT01079676|Active Comparator|Granulokine|
33305456|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm~the development of demineralization~its adverse effects after application"
32941165|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
32941166|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
33305457|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
33305458|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
33305459|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
33305460|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
33305461|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
33305462|NCT05460286|Experimental|CSMT group|Chiropractic Spinal Manipulative Treatment group
33305463|NCT05460286|Experimental|SD group|Spinal Decompression group
33305464|NCT01082406|Experimental|Trial part 1|
33305465|NCT01082406|Experimental|Trial part 2|
33305466|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
32941167|NCT00381914|Experimental|1|400 IU / day vitamin D
32941168|NCT00381914|Experimental|2|800 IU / day vitamin D
32941169|NCT00381914|Experimental|3|1200 IU / day vitamin D
32941170|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
32941171|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
33305467|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
33305468|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~For the pregnant women included in the experimental group:~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
33318522|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
33305469|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.~Birth action follow-up form and postpartum interview forms were applied"
33305470|NCT00133952|Experimental|Ruboxistaurin|32 mg taken orally daily for up to 48 months
33305471|NCT00133952|Placebo Comparator|Placebo|Taken orally daily for up to 48 months
33305472|NCT03755050||Sleigh Accident|Accident while using a sleigh
33305473|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
33305474|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
33305475|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
33305476|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
33305477|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
33305478|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
33305479|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
33305480|NCT00118092|Experimental|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
33305481|NCT01083030|Placebo Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
33305482|NCT01083030|Active Comparator|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
33305483|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
33305484|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
33305485|NCT03965208|Active Comparator|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
33305486|NCT03965208|Experimental|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
33305487|NCT04555096|Experimental|Active GC4419|Arm A
33305488|NCT04555096|Placebo Comparator|Placebo|Arm B
33305489|NCT00097500|Experimental|Exenatide Arm|Exenatide and Metformin
33305490|NCT00097500|Active Comparator|Insulin Glargine Arm|Insulin Glargine and Metformin
33305491|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
33305492|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
33305493|NCT01082484|Placebo Comparator|NaCl 0.9%|
33305494|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
33305495|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
33305496|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
33305497|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
33305498|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
33305499|NCT04849780|Experimental|ARM 1|Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.
33305500|NCT04849780|Experimental|ARM 2|Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
33305501|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
33305502|NCT03757702||Healthy group|healthy women and being volunteereed
33305503|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
33305504|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
33305505|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
33305506|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
33305507|NCT04823494|Experimental|Pro-Fit followed by Self Fit|Hearing aids fit by a professional hearing care provider using best practices followed by patient ...
33305508|NCT04823494|Experimental|Self-Fit followed by ProFit|Hearing aids fit by patient followed by ...
33305509|NCT05384392|Experimental|Intervention|All patients included in the study will be required to complete the examinations specified in the protocol.
33305510|NCT05459974|Active Comparator|Colchicine arm|
33305511|NCT05459974|Placebo Comparator|Placebo arm|
33305512|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
33318523|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
33318524|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
33090742|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
33318525|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
33090743|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
33090744|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
33090745|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
33090746|NCT04301804|Experimental|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
33090747|NCT04301804|Experimental|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
33090748|NCT04301804|Experimental|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
33090749|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
33090750|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
33090751|NCT04258319|Experimental|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
33090752|NCT04258319|Active Comparator|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
33090753|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
33090754|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
33090755|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
33090756|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
33090757|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
33090758|NCT04100291|Active Comparator|FMT|Faecal microbiota transplantation
33090759|NCT04100291|Placebo Comparator|Placebo|Placebo mixture
33090760|NCT04703283|Experimental|Lifestyle Medicine Group|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
33090761|NCT04703283|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
33090762|NCT04046120|No Intervention|Heel included|The bandage is made by including the heel as recommended in routine.
33090763|NCT04046120|Experimental|Heel not included|he bandage is made by leaving the heel uncovered.
33090764|NCT04716647|Experimental|Ayurveda Intervention|Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.
33090765|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
33090766|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
33090767|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
33090768|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
33090769|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
33090770|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
33090771|NCT00428649|Placebo Comparator|7|placebo
33090772|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
33090773|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
33090774|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
33090775|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
33090776|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
33090777|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
33090778|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
33090779|NCT04702854|Experimental|Experimental|Measure of cutaneous melanomas by ultrasound biomicroscopy
33090780|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
33090781|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
33090782|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
33090783|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
33090784|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
33090785|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
33318526|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
33090786|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
33090787|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
33090788|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
33090789|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
33090790|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
33090791|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
33090792|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
33090793|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
33090794|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
33090795|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
33090796|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
33090797|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
33090798|NCT00428727|Experimental|1|Nitric oxide patches
33090799|NCT00428727|Placebo Comparator|2|Placebo patches
33090800|NCT03474029|Experimental|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
33090801|NCT03474029|Active Comparator|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
33305513|NCT04542694|Experimental|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
33318527|NCT05050058||Neonates born to diabetic mothers|
33404309|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.~Intervention-B: Drink extra water at anytime over 24 hours"
32900823|NCT05556876|Active Comparator|Intervention|the intervention group will be provided with oral nutritional supplements for 12 weeks after discharge
33090802|NCT03440957|Other|Osteopathy treatment|
33318528|NCT05050058||Neonates born to non-diabetic mothers (control)|
33318529|NCT03983759|Experimental|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.~the dose of sintilimab is fixed dose of 200mg every three weeks"
33318530|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
33318531|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
33318532|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
33318533|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
33090803|NCT04716569|Experimental|intranasal Ivermectin group|Ivermectin group Patients who will receive intranasal ivermectin
33090804|NCT04716569|Other|Control group|patients who will receive regular protocol drugs
33090805|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
33090806|NCT00428805|No Intervention|control 2|measurement only control arm
33090807|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
33090808|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
33090809|NCT04703127|Active Comparator|Patients with lifelong premature ejaculation and non-responding to dapoxetine alone|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
33318534|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
33305514|NCT04542694|Active Comparator|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
33305515|NCT00117312|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
33305516|NCT00117312|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
33090810|NCT04703127|Active Comparator|Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
33090811|NCT03082391|Active Comparator|Heavy weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavy weight mesh.
33090812|NCT03082391|Active Comparator|Medium weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a medium weight mesh.
33305517|NCT00117312|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
33305518|NCT00117312|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
33305519|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
33305520|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
33305521|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
33305522|NCT01083264|Experimental|Arm 1|
33305523|NCT01083264|Experimental|Arm 2|
33305524|NCT01083264|Experimental|Arm 3|
33305525|NCT00129116|Experimental|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
33305526|NCT00129116|Experimental|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
33305527|NCT00129116|Experimental|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
33305528|NCT00129116|Experimental|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
33305529|NCT00129116|Active Comparator|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
33305530|NCT04276584|Active Comparator|Positive airway pressure|Deep inspiration followed by expiration to a resistance of 10-15 cm of water pressure. Done three times, each time with 10 inspiration/expiration cycles
33305531|NCT04276584|Experimental|Speaking loudly|Speaking loudly during 3 minutes.
33305532|NCT04276584|Experimental|Singing|Singing a Swedish song. The study will end with this song.
33305533|NCT00117156|Experimental|Fludarabine and Rituximab|"Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts > 10x10^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
33305534|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
33305535|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
32900824|NCT05556876|No Intervention|Control|the control group will receive usual care after discharge
33090813|NCT04702971|Experimental|patients with migraine|patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
33090814|NCT04702971|Other|healthy control|healthy control
32798657|NCT04626037|Experimental|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with Nurture Science program staff virtually. The entire procedure will be done on Zoom or in person depending on school opening. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Mommy Baby Book (5) Bottle of Emotions (6) Plans for continuing the work in the family. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been.
32798658|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
32798659|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
32798660|NCT01976299|No Intervention|Standard of Care|
32798661|NCT04661683|Experimental|Peripheral Endothelial Function|Brachial artery flow-mediated dilation will be used to measure endothelial function
32798662|NCT04661683|Experimental|Central Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness.
32798663|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
32798664|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
32798665|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
33090815|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
33090816|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
33090817|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
32798666|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
32798667|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
32798668|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
32798669|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
32798670|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
32798671|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
32798672|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
32798673|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
32941172|NCT04713787|Experimental|Group A|400 mg (4 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
32941173|NCT04713787|Experimental|Group B|800 mg (8 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
32941174|NCT04713787|Active Comparator|Group C|400 mg (1 tablet of 400 mg) of Albendazole administered orally as a single dose on Day 1. N=83.
32941175|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
32941176|NCT05599477|Experimental|Endoscopic sutured gastroplasty|
32941177|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
32941178|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
32941179|NCT05558150|Experimental|ilaprazole & aceclofenac 1|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
32941180|NCT05558150|Experimental|ilaprazole & aceclofenac 2|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
32941181|NCT05558150|Experimental|ilaprazole & aceclofenac 3|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
32941182|NCT05558150|Experimental|ilaprazole & aceclofenac 4|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
32941183|NCT05558150|Experimental|ilaprazole & aceclofenac 5|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
32941184|NCT05558150|Experimental|ilaprazole & aceclofenac 6|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
33305536|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
33305537|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
33305538|NCT00096954|Experimental|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
33305539|NCT00096954|Placebo Comparator|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
33305540|NCT00096486|Experimental|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.~Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
33305541|NCT00116844|Experimental|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
33305542|NCT00116844|Experimental|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
33305543|NCT03963336|Active Comparator|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
33305544|NCT03963336|Active Comparator|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
33305545|NCT03963336|No Intervention|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
33305546|NCT03966794|Experimental|Epidural Electrical Stimulation|
33090818|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
33305547|NCT03966794|Experimental|Functional scaffold & Epidural Electrical Stimulation|
33305548|NCT01076738||single group study|
33305549|NCT00132314|Experimental|Arm 1|long-acting injectable risperidone
33305550|NCT00132314|Active Comparator|Arm 2|oral antipsychotic medication
33305551|NCT04539262|Experimental|Remdesivir (RDV), Part A|Participants will receive inhaled RDV 31 mg administered daily for 5 days.
33305552|NCT04539262|Experimental|RDV + Placebo, Part A|Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.
33305553|NCT04539262|Placebo Comparator|Placebo, Part A|Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.
33305554|NCT04539262|Experimental|RDV, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.
33305555|NCT04539262|Experimental|RDV + Placebo, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.
33305556|NCT04539262|Placebo Comparator|Placebo, Part B|Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.
33305557|NCT04539262|Experimental|RDV, Part C|Participants will receive inhaled RDV 39 mg administered daily for 5 days.
33305558|NCT04539262|Placebo Comparator|Placebo, Part C|Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.
33305559|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
33305560|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
33305561|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
33090819|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
33305562|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
33305563|NCT04538170||ORC|Group orchidectomy following cancer
33305564|NCT04538170||GAC|Group sex reassignment surgery
33305565|NCT05280964|Experimental|Intervention|Enrolled into a 6 month coaching program from January 1 2021 to June 30 2021
33305566|NCT05280964|No Intervention|Control/Wait-list|No intervention from January 1 2021 to July 1 2021 (they were offered the coaching program from July 1 2021-Dec 31 2021)
33305567|NCT04537234|Experimental|Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD)|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
33305568|NCT04537234|Active Comparator|Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD)|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
33318535|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
33318536|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
33318537|NCT00329303|Experimental|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
33305569|NCT04537078|Active Comparator|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphaston at 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
33305570|NCT04537078|Active Comparator|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle >18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle >18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
33305571|NCT04532164|Experimental|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
32941185|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
32941186|NCT05749016|Experimental|Study group|Eligible patients received inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen every three weeks for a maximum of 6 cycles, followed by surgery.
32941187|NCT01756573|Active Comparator|Bupivacaine|Control
32941188|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
33305572|NCT01561924|Experimental|Ex vivo|
33305573|NCT00116688|Experimental|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
33305574|NCT04531540|Experimental|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
33305575|NCT04799782|Active Comparator|Mirtazapine|The drug will be taken for a one week peroid.
32941189|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
33305576|NCT04799782|Placebo Comparator|Placebo|The drug will be taken for a one week peroid.
32941190|NCT01126801|Experimental|Estradiol|
32941191|NCT01126801|Placebo Comparator|Placebo control|
32941192|NCT05445830|Experimental|Post-covid patients|
32941193|NCT05445830|Experimental|Control|
32941194|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
32941195|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
32941196|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
32941197|NCT05748938|Experimental|RD14-01 treated group|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--ROR1 CAR-T Cells after lymphodepleting therapy.
32941198|NCT01702909|Experimental|Interleukin-2|Interleukin-2
32941199|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
32941200|NCT05599243|Experimental|experimental drug|0.15% w/w dutasteride topical O/W emulsion.
32941201|NCT05599243|Placebo Comparator|Placebo|vehicle (excipients)
32941202|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
32941203|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
32798674|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
32798675|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
32798676|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
32798677|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
32798678|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
32798679|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
32798680|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
32798681|NCT01898078|Experimental|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
32798682|NCT01898078|Experimental|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
32798683|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided as peanut protein in pull-apart capsules
32798684|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
33090820|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
33305577|NCT04790812|Placebo Comparator|Celecoxib plus Placebo|Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure
33305578|NCT04790812|Active Comparator|Celecoxib plus Acetaminophen|Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.
32798685|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
32798686|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
32798687|NCT01924754||Standard intramuscular injection (NS-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)
33090821|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
33102462|NCT03792737|Experimental|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
33305579|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
33305580|NCT03754504|Placebo Comparator|Placebo|Placebo
33305581|NCT03697252|Experimental|KarXT|
33305582|NCT03697252|Placebo Comparator|Placebo|
33305583|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
33305584|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
33305585|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
33305586|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
33305587|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
33305588|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
33305589|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
32798688|NCT01924754||PharmaJet needle-free Stratis device (JI-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)
32798689|NCT01924754||PharmaJet needle-free Tropis device (JI-ID)|HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)
33305590|NCT01322620||A|
33305591|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
33305592|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
33305593|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
33305594|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg~period 2: receive CJ-30060 5/160/10mg"
32798690|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
32798691|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
33305595|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
32798692|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
32798693|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
32798694|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
32798695|NCT04671797|Experimental|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
32798696|NCT04671797|Experimental|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
32798697|NCT04671797|Experimental|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
32798698|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
32798699|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
32798700|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
32798701|NCT04416815|No Intervention|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
32798702|NCT04416815|Experimental|eHealth|The intervention will be delivered for 6 months on top of usual care.
32798703|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
32798704|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
32798705|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
32798706|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
32798707|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
32798708|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
32798709|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
32798710|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
32798711|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
32798712|NCT04415749|Experimental|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
32798713|NCT04415749|Placebo Comparator|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
32798714|NCT04415749|Experimental|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
32798715|NCT04415749|Placebo Comparator|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
32798716|NCT04415749|Experimental|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
33305596|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
32798717|NCT04415749|Placebo Comparator|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
32798718|NCT04624399|Experimental|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
32798719|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
32798720|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
32798721|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
32798722|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
33090822|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any other reason~Pomalidomide and Dexamethasone"
33090823|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any oher reason~Pomalidomide and Dexamethasone"
33090824|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
33090825|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
33090826|NCT01370486|Active Comparator|melatonin|
33090827|NCT01370486|Placebo Comparator|placebo|
33090828|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
33090829|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
33090830|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
33090831|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
33090832|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
33090833|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
32798723|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
32798724|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
32798725|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
33090834|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
33090835|NCT00429156|Active Comparator|1|Home non-invasive ventilation
33090836|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
32798726|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
33090837|NCT00327665|Experimental|Group A|
33090838|NCT00327665|Experimental|Group B|
33090839|NCT00327665|Experimental|Group C|
33090840|NCT00327665|Active Comparator|Group D|
33090841|NCT00327665|Active Comparator|Group E|
33090842|NCT00433641|Placebo Comparator|1|placebo tablet
33090843|NCT00433641|Experimental|2|sibutramine
33090844|NCT00433641|Experimental|3|sibutramine
32798727|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
32798728|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
32798729|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
32798730|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
32798731|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
32798732|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
32798733|NCT04670627||Seasonal Allergic Rhinitics|"Non-smoking males and females aged 18-70 years, inclusive with history of Seasonal Allergic Rhinitis defined by:~Sensitization to at least one seasonal aeroallergen via skin prick testing (wheal =3 mm than negative control), AND History of physician-diagnosed seasonal allergic rhinitis, OR Symptoms consistent with seasonal allergic rhinitis, such as runny nose, nasal congestion, sneezing, or nasal pruritis."
33305597|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
33305598|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
33305599|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
33305600|NCT05459428||Confocal laser endomicroscopy scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by confocal laser endomicroscopy in order to calculate the CGGIM score.
32941204|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
32941205|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
33305601|NCT05459428||Artificial intelligence scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by Artificial intelligence in order to calculate the CGGIM score.
33305602|NCT05458804|Experimental|Active experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions
33305603|NCT05458804|No Intervention|Passive Control group|Participants in the control group did not participate in the training, and were instructed not to perform specific physical activities aimed at improving the examined abilities
33305604|NCT05457244|Experimental|Participant arm|
33305605|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
33305606|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
33305607|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
32941206|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
32941207|NCT05748860||Adult patients commencing on VA-ECMO|The study population is adult patients on VA-ECMO for cardiogenic shock or cardiac arrest that are or will be enrolled in the national ECMO registry (EXCEL).
32941208|NCT05539040|Experimental|Intervention|Right atrial GP ablation in addition to pulmonary vein isolation
33305608|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
32941209|NCT05539040|Active Comparator|Control|PVI alone with no GP mapping or ablation
32941210|NCT01127503|Experimental|Metyrosine|
33305609|NCT05420662|Experimental|Vaginal Manipulator Group|In this group of patients, abdominal hysterectomy surgery will be performed with the vaginal manipulator. After cutting and suturing uterine arteries, cardinal and sacrouterine ligaments are preserved by using a vaginal manipulator. The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point of the vagina.
33305610|NCT05420662|Active Comparator|Classical Abdominal Hysterectomy Group|In this group of patients, abdominal hysterectomy surgery will be performed in a conventional way, by cutting the cardinal and sacrouterine ligaments.
32941211|NCT01127503|Placebo Comparator|Placebo|
32941212|NCT05748782||BASKA GROUP|the BASKA mask will be inserted, and its size will be chosen according to the manufacturer's weight-based recommendations.
33305611|NCT05401240|Experimental|CEPT informed|the patient is informed and asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, as well as to take an important examination (cardiopulmonary exercise testing) for his/her cardiorespiratory fitness.
33305612|NCT05401240|No Intervention|CPET not informed|the patient is asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, but not informed about the cardiopulmonary exercise testing.
33305613|NCT04728802|Active Comparator|Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
33305614|NCT04728802|Placebo Comparator|Placebo + Usual Care|Placebo + usual care as determined by care provider
33318538|NCT00329303|Experimental|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
33318539|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
32941213|NCT05748782||ETT GROUP|Patients in this group will be anesthetized using an endotracheal tube of appropriate size.
32941214|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
33305615|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
33305616|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
33305617|NCT00114530|Experimental|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
33305618|NCT00114530|Experimental|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m^2, followed by 11 doses of 750 mg/m^2)."
32941215|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
32941216|NCT05535218|Other|Single Arm|Single Arm treatment
32941217|NCT05531708|Experimental|Anti-mesothelin CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, anti-mesothelin CAR-T cells.
32941218|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
32941219|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
32941220|NCT05599087|Experimental|Acellular system|Regenerative Endodontic Procedure (REP) the acellular system derived from umbilical cord-derived mesenchymal stem cells encapsulated in a platelet-poor plasma-derived biomaterial.
32941221|NCT05748704|Experimental|Short-term modified fasting|The STMF regimen consists of a low-calorie diet lasting five days and aimed at providing between 800 and 1,000 kcal/day (tentatively 10% carbohydrates, 15% proteins, 75% lipids).
32941222|NCT05598385|Active Comparator|Percutaneous cannulation|Percutaneous peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
32941223|NCT05598385|Active Comparator|Open cannulation|Open peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
32941224|NCT05526248|Experimental|Lead-in phase: Darolutamide treatment|Darolutamide treatment arm is single cohort in lead-in phase.
32941225|NCT05526248|Experimental|Randomized phase: Darolutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
32941226|NCT05526248|Active Comparator|Randomized phase: Enzalutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
32941227|NCT05598307|Active Comparator|magnesium bolus|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, normal saline will be administered at a rate of 20 mL/h
32941228|NCT05598307|Active Comparator|magnesium bolus and magnesium infusion|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
32941229|NCT05598307|Placebo Comparator|placebo|100 mL of normal saline will be administered within 10 minutes preoperatively. Followingly, normal saline will be administered at a rate of 20 mL/h
32941230|NCT05747612|Other|Patients with Bipolar Disorder|
32941231|NCT05521880|Other|Historical outcomes with standard of care treatment|Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
32941232|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
32941233|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
32941234|NCT05521178||Ibrutinib|Patients receiving ibrutinib for the treatment of CLL.
33318540|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
33404310|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
32941235|NCT05521178||Acalabrutinib|Patients receiving acalabrutinib for the treatment of CLL.
32941236|NCT05597293|Active Comparator|FreeStyle Libe 2|Participants in this group will wear the FreeStyle Libre 2 device
32941237|NCT05597293|Active Comparator|FreeStyle Libre pro iQ|Participants in this arm will wear the FreeStyle Libre pro iQ device
32941238|NCT05597059||Shortness of breath|
32941239|NCT05597059||Extremity pathologies|
32941240|NCT05597059||Abdominal pain|
32941241|NCT05597059||Urological pathologies|
32941242|NCT05597059||Chest pain|
32941243|NCT05597059||Back pain|
32941244|NCT05517980|Experimental|IgAN Cohort Stage 1 Dose 1|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
32941245|NCT05517980|Experimental|IgAN Cohort Stage 1 Dose 2|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
32941246|NCT05517980|Experimental|IgAN Cohort Stage 2|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
32941247|NCT05517980|Experimental|C3G Cohort|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
33090845|NCT00327704|Active Comparator|Albumin|
33090846|NCT00327704|Placebo Comparator|Saline|
33090847|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
32798734|NCT04670627||Control|Non-smoking males and females aged 18-70 years, inclusive with no history of physician-diagnosed allergic rhinitis and no history of seasonal runny nose, nasal congestion, sneezing or nasal pruritis. Negative results to a panel of aeroallergens via skin prick testing.
32798735|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
32798736|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
32798737|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
32798738|NCT01790295|Experimental|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
32798739|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
32798740|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
32798741|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
32798742|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
32798743|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
32798744|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
32798745|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
32798746|NCT01789281|Experimental|Everolimus|Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.
32798747|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
32798748|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
32798749|NCT01789203|Active Comparator|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
32798750|NCT01789203|Placebo Comparator|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
32798751|NCT01789047|Active Comparator|Topiramate|Topiramate as adjunct to amantadine.
32798752|NCT01789047|Placebo Comparator|Placebo (sugar pill)|Placebo
32798753|NCT01788423|Experimental|Audiologist-Based|Audiologist selects hearing aid for patient
32798754|NCT01788423|Experimental|Consumer Decides|Consumer selects hearing aid
32798755|NCT01788423|Placebo Comparator|Placebo|Patient fitted with hearing aid that is acoustically transparent.
32798756|NCT01617187|Experimental|Asenapine 2.5 mg BID|
32798757|NCT01617187|Experimental|Asenapine 5 mg BID|
32798758|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
32798759|NCT01617187|Placebo Comparator|Placebo BID|
32798760|NCT01759407|Active Comparator|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
32798761|NCT01759407|No Intervention|Standard Anesthetic Management|
32798762|NCT01787331|Experimental|Treatment (itraconazole)|Patients receive twice/day 300mg itraconazole (oral)
32798763|NCT01757847|Active Comparator|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
32830562|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
33090848|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
33090849|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
32798764|NCT01757847|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
33090850|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
33090851|NCT04704297|Active Comparator|Standard Therapy (ST)|ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV. Upon discharge ST will consist of prescriptions for acetaminophen 650mg every 4 hours by mouth, Ibuprofen 400mg every 4 hours by mouth, and 10 mg of cyclobenzaprine nightly by mouth. Additionally, participants will be provided a handout going over these medications and the use of heat for low back pain and instructions on the performance of McKenzie stretching exercises for low back pain.4
33090852|NCT04704297|Active Comparator|ST plus Trigger Point Injections (TPI) with 8 mL of 0.5 percent Bupivacaine|ST plus TPI with 8 mL of 0.5 percent Bupivacaine
33090853|NCT04704297|Active Comparator|ST plus TPI with 8 mL of Normal Saline (NS)|ST plus TPI with 8 mL of Normal Saline
33090854|NCT04704414|Experimental|Validation of smartphone face scanner|Validation of smartphone face scanner in comparison to Hertel Exophthalmometer and high-definition face scanner.
32798765|NCT01787097|Active Comparator|COPD|Participants with COPD
32798766|NCT01787097|Active Comparator|Symbicort® total dose 400ug/12ug|Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)
32798767|NCT01787097|Active Comparator|Symbicort® total dose 800ug/24ug|Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose
32798768|NCT01787097|Active Comparator|BUD total dose 800ug|BUD total dose 800ug: is an intermediate dose of ICS
32798769|NCT04414371|Experimental|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
32798770|NCT04414371|Other|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
32798771|NCT01757691|Experimental|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
32798772|NCT01757691|Placebo Comparator|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
32798773|NCT01786707|Experimental|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
32798774|NCT01786707|Active Comparator|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
32798775|NCT01786629|Experimental|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
32798776|NCT01786629|Active Comparator|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
32798777|NCT01786551|Experimental|Eplerenone|Eplerenone 50 mg daily for 14 days
32798778|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
32798779|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
32798780|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
32798781|NCT01973491|Experimental|ATX-MS-1467|
32798782|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
32798783|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
32798784|NCT01951586|Placebo Comparator|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
32798785|NCT01951586|Experimental|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
32798786|NCT04643678|Active Comparator|Anakinra Group|Anakinra + Standard of Care
32798787|NCT04643678|Other|Standard of Care Group|Standard of Care Alone
32798788|NCT04641728|Experimental|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
33090855|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
32798789|NCT01785849|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
32798790|NCT01785849|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
32798791|NCT01756833|Active Comparator|Doxycycline|100 mg capsules, twice a day, for a period of two years.
32798792|NCT01756833|Placebo Comparator|Placebo|100 mg capsules, twice a day, for a period of two years.
32798793|NCT01617967|Experimental|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks [Q4W]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks [Q3W]), and an alternative premedication regimen.
32798794|NCT01785615|Experimental|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
32798795|NCT01785615|Placebo Comparator|sugar pill|44 women randomized to placebo for 6 weeks
32798796|NCT04172779|Experimental|Erlotinib treatment|
32798797|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
32798798|NCT01756053|Active Comparator|ABT-089|"During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
32900825|NCT05347446|Active Comparator|Hybrid ESD|Hybrid ESD is a modified ESD technique that uses snare-assisted resection as part of the procedure. With hybrid ESD, a circumferential mucosal incision followed by limited submucosal dissection is performed. Following this, a snare is placed around the lesion, slowly closed to allow resection by traversing the submucosal space
33090856|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
33305619|NCT04426318|Experimental|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
33305620|NCT04426318|No Intervention|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
33305621|NCT05322148|Active Comparator|cyclosporine 0.1% / loteprednol 0.2% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
33305622|NCT05322148|Active Comparator|cyclosporine 0.05% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
33305623|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.~Atorvastatin (80 mg), oral administration daily."
33305624|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
33305625|NCT01076894|Active Comparator|epidural anesthesia|
33305626|NCT01076894|Active Comparator|intercostal anesthesia|
33305627|NCT04715932|Active Comparator|Hesperidin 1000mg|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
33305628|NCT04715932|Placebo Comparator|Placebo 1000mg|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
33305629|NCT00130832|Experimental|1|RotaTeq and OPV concomitantly
33305630|NCT00130832|Experimental|2|RotaTeq and OPV on staggered schedule
33305631|NCT04964362||Individuals with Spinal Cord Injury|Individuals with recent spinal cord injuries, both veterans and civilians, will be followed for 1 year for inquiry into injustice appraisals.
33305632|NCT00096018|Experimental|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
33305633|NCT04713748|Other|Tasso- SST blood collection|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
33305634|NCT04713748|Other|Regular Venipuncture|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
33305635|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
33305636|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
33305637|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
33305638|NCT04706416|Experimental|N-Acetyl Glucosamine|All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
33305639|NCT04706416|Placebo Comparator|Control|All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.
33305640|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
33404311|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
33404312|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
33090857|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
33090858|NCT04704180|Experimental|Experimental Group: Facilitation Tuchking Group|The experimental group neonates received facilitated tucking under the radiant heater after birth of the NICU as well as the routine interventions.
33305641|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
33305642|NCT04702984|Experimental|LID021201|LID021201 contact lenses worn in both eyes for 7 days. Lenses will be removed nightly for cleaning and disinfection with OPTI-FREE multipurpose solution.
33305643|NCT04701658|Experimental|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
33305644|NCT04701658|No Intervention|Controls|"Matched controls who received standard of care.~[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]"
33305645|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
33305646|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
33305647|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
33305648|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
33305649|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
33305650|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
33305651|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
33305652|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
33305653|NCT05320198|Experimental|Phase 1b: Dose Escalation|In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
33305654|NCT05320198|Experimental|Phase 2a: Expansion|In the Phase 2a (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
33305655|NCT04937998|Experimental|Autologous PRP injection|This group of patients will be treated with single intra-articular injection of Autologous PRP.
33305656|NCT04937998|Active Comparator|HA injection|This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
33305657|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
33305658|NCT03933202||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
33305659|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
33305660|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
33305661|NCT04877470||Newly referred patients visiting the spine-centre|Newly referred patients visiting the spine-centre at Zuyderland Medical Centre Heerlen in 2019, from 01.01.2019 until 31.12.2019.
33305662|NCT00128102|Experimental|Vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
33305663|NCT00128102|Placebo Comparator|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
33305664|NCT04867954||Healthy volunteers|7 healthy participants will be recruited.
33305665|NCT04867954||Patients with small, low-risk GEV|7 patients with small, low-risk Gastroesophageal varices (GEV) will be recruited.
33305666|NCT04867954||Patients with large, high-risk GEV|7 patients with large, high-risk Gastroesophageal varices (GEV) will be recruited.
33305667|NCT04867954||Patients scheduled for screening or surveillance esophagogastroduodenoscopy (EGD)|"100 patients diagnosed with cirrhosis and scheduled for screening or surveillance esophagogastroduodenoscopy (EGD) procedure will be recruited. Participants will complete a single research visit, lasting approximately 2 hours, that will include the following procedures:~Participants will fast for 12 hours prior to arriving.~An IV will be placed and a blood sample collected (~11 mL, if necessary).~All participants will undergo research MRI lasting approximately 1.5 hours"
33305668|NCT04867954||Obese patients|20 obese patients will be recruited
33305669|NCT03966092|No Intervention|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
33404313|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
33305670|NCT03966092|Experimental|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.~In addition, patients receiving a bilateral QLB at the end of the surgery"
33305671|NCT03965858|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33305672|NCT03965858|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33305673|NCT03965858|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33305674|NCT03965858|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
33305675|NCT03965780|Experimental|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
33305676|NCT03965780|No Intervention|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
33305677|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 200 mg (Treatment A)|Participants received JOTROL (resveratrol) 200 (2*100) milligram (mg) (Treatment A), gelatin capsule (gelcap), orally, once on Day 1 in fasted conditions in Study Period 1.
33305678|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 500 mg (Treatment B)|Participants who completed Study Period 1 received JOTROL (resveratrol) 500 (5*100) mg (Treatment B), gelcap, orally, once on Day 1 in fasted conditions in Study Period 2. A 14 days washout period was maintained in study period 1 and 2.
33305679|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 700 mg (Treatment C)|Participants who completed Study Period 2 received JOTROL (resveratrol) 700 (7*100) mg (Treatment C), gelcap, orally, once on Day 1 in fasted conditions in Study Period 3. A 14 days washout period was maintained in study period 2 and 3.
33305680|NCT04668274|Experimental|Part 2: JOTROL (Resveratrol) 500 mg (Treatment D)|Participants who completed Study Period 3 (Part 1) received JOTROL (resveratrol) 500 (5*100) mg (Treatment D), gelcap, orally, once on Day 1 in fed conditions in Study Period 4. A 14 days washout period was maintained in study period 3 and 4.
33305681|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
33305682|NCT01077908|Active Comparator|Best available antiviral drug therapy|
33305683|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
33305684|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
33305685|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
33305686|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
33305687|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
33305688|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
33305689|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
33305690|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
33305691|NCT04405570|Experimental|Molnupiravir 200 mg|Molnupiravir 200 mg, twice daily (BID) for 5 days
33305692|NCT04405570|Experimental|Molnupiravir 400 mg|Molnupiravir 400 mg, twice daily (BID) for 5 days
33305693|NCT04405570|Experimental|Molnupiravir 800 mg|Molnupiravir 800 mg, twice daily (BID) for 5 days
33305694|NCT04405570|Placebo Comparator|Placebo (PBO) twice daily (BID) for 5 days|
33305695|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
33305696|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
33305697|NCT00127712|Experimental|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
33305698|NCT00127712|No Intervention|No treatment|Patients in this group receive no intervention
33305699|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
33305700|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
33305701|NCT05461144||Type1diabetes patients|Males and females diagnosed with T1D, aged over 18 years old who are currently under the care of the Warwickshire Institute for the Study of Diabetes, Endocrinolgy and Metabolism (WISDEM) at the University Hospitals Coventry and Warwickshire.
33305702|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
33305703|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
33305704|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
33305705|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
32746459|NCT04791189||Parents of patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Parents of adult patients with JIA~- Parents able to understand and complete the questionnaire online (speaking and reading French, having an internet connection for completion via Red Cap°).~- Able to give informed consent to participate~- The parents must have been in charge of the patient as a teenager."
32746460|NCT03194555|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
33090859|NCT04704180|No Intervention|Control Group|The control group underwent the routine interventions of the observation unit of the NICU. The group did not receive any other intervention
33090860|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
33090861|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
33090862|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
33090863|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
33090864|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
33090865|NCT00433797|Experimental|1|Tomato
33090866|NCT00433797|Experimental|2|Multi-diet
33090867|NCT00433797|Active Comparator|3|Control
33090868|NCT00328367|Experimental|A|clozapine plus aripiprazole
33090869|NCT00328367|Placebo Comparator|B|clozapine plus placebo
33090870|NCT04703088|Experimental|INTERVENTION GROUP - ONDANSETRON|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
33090871|NCT04703088|Placebo Comparator|CONTROL GROUP - NORMAL SALINE|2 mL of 0.9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
33090872|NCT00328445|No Intervention|Control|Business as usual
33090873|NCT00328445|Experimental|Treatment|Positive Action
33090874|NCT00328484|Experimental|1|Eleven month lifestyle activity program
33090875|NCT00328484|Active Comparator|2|Three month exercise program
33090876|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
33090877|NCT04702932||Patient with Monoclonal gammopathies of inflammatory significance|This group of patient will present a monoclonal gammopathy associated with inflammatory symptoms without known origin.
33090878|NCT04702932||Control group|The Control group will be healthy subject and patients with monoclonal gammopathies without inflammatory symptoms.
33090879|NCT00328679|Experimental|A|
33090880|NCT01054443|Placebo Comparator|Placebo|Participants received placebo tablets orally once a day for 42 days.
33090881|NCT01054443|Experimental|Lusutrombopag 0.5 mg|Participants received 0.5 mg lusutrombopag orally once a day for 42 days.
33090882|NCT01054443|Experimental|Lusutrombopag 0.75 mg|Participants received 0.75 mg lusutrombopag orally once a day for 42 days.
33090883|NCT01054443|Experimental|Lusutrombopag 1.0 mg|Participants received 1.0 mg lusutrombopag orally once a day for 42 days.
33090884|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
33090885|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
33090886|NCT00420173||Patients with CLE|
33090887|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence A-B-C|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
33090888|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence A-C-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
33090889|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-A-C|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
33090890|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-C-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
33090891|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence C-A-B|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
33090892|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence C-B-A|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
33090893|NCT04702698|Experimental|Part 2: Peposertib Treatment Sequence A-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period.
33090894|NCT04702698|Experimental|Part 2: Peposertib: Treatment Sequence B-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period.
33090895|NCT04702542|Experimental|Enteral oxygen therapy for the improvement of children with chronic gastroduodenal pathology.|Enteral oxygen therapy is prescribed for children with chronic gastroduodenal pathology during the recovery period, after inpatient treatment, for 14 days, every day, in the form of an oxygen cocktail. An oxygen cocktail is prepared on the basis of a pharmaceutical product using herbal ingredients. The patient takes a 200 ml oxygen cocktail. using a small spoon, during the daytime.
33090896|NCT00328874|Placebo Comparator|Placebo|
33090897|NCT00328874|Active Comparator|Coenzyme Q10|
33090898|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
33090899|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
33090900|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
33090901|NCT02957643|Experimental|pregnant women with anemia|iron dosage 1 per day for 6 months
33090902|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
33090903|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
33090904|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
33305706|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
32746461|NCT03194555|Placebo Comparator|Placebo|
32746462|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
33090905|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
32746463|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
32746464|NCT05473065|Experimental|Multiaxial Prosthetic Foot Emulator (PFE)|The multiaxial Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how prosthesis users will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
32746465|NCT05473065|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
32746466|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
32746467|NCT04344717|Experimental|Anticoagulation and teduglutide naive short bowel syndrome|Anticoagulation and teduglutide naive patients with short bowel syndrome requiring long term parenteral support
32746468|NCT04344717|Experimental|Healthy volunteers|Anticoagulation naive healty volunteers
32746469|NCT04344717|Other|Short bowel syndrome on apixaban|Patients with short bowel syndrome requiring long term parenteral support and taking apixaban 2.5 mg twice daily or 5 mg twice daily
32746470|NCT04344717|Other|Patients with a normal gastrointestinal tract on apixaban|Patients with a normal gastrointestinal tract taking apixaban 2.5 mg twice daily or 5 mg twice daily
32746471|NCT04344717|Experimental|Anticoagulation naive short bowel syndrome on teduglutide|Anticoagulation naive patients with short bowel syndrome requiring long term parenteral support and initiated on teduglutide
33404314|NCT02326480||Familial obesity|Identification of genetic causes of obesity
32746472|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
32746473|NCT04790643||Stage 1 - Development of the new cardiac risk stratification protocol|This will be a prospective cohort study, in which individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables that will be used to guide the elaboration of the cardiac risk stratification protocol. After this initial evaluation, the volunteers will be followed for 2 months during their habitual cardiac rehabilitation routine for the evaluation and registry of the occurrence of minor adverse events, defined as signs and symptoms (arrhythmias, blood pressure alterations, tachypnea, pallor, chest pain, cramps, muscle pain, fatigue, and nausea). The cardiac rehabilitation program in which the volunteers will be recruited is based on moderate-intensity aerobic exercise.
32746474|NCT04790643||Stage 2 - Reproducibility and efficiency of the new protocol|"This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: low risk, moderate risk, and high risk accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated."
32746475|NCT04790643||Stage 3 - Protocols´ agreement between evaluators|This will be a cross-sectional observational study in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.
32746476|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
32746477|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
33305707|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
33305708|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
33305709|NCT04401202|Experimental|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
33305710|NCT04401202|No Intervention|Control|Standard of care
33090906|NCT04702503|Experimental|10% WP1220 ointment|10% WP1220 ointment topically applied 2x day for 84 days
33305711|NCT00096356|Active Comparator|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
33305712|NCT00096356|Placebo Comparator|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
33305713|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
33305714|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
33305715|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
33305716|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
33305717|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
33305718|NCT04567732|Experimental|Filtered Autologous Adipose Tissue|based on randomization one of the two knees will be treated with a single injection of Filtered Autologous Adipose Tissue
33305719|NCT04567732|Placebo Comparator|Placebo|based on randomization one of the two knees will be treated with a single injection of Placebo
33305720|NCT03777982|Experimental|LHRH Agonist or Antagonist|-LHRH agonist or antagonist should be prescribed per standard of care
33305721|NCT03777982|Experimental|Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist|"LHRH agonist or antagonist should be prescribed per standard of care~Abiraterone acetate will be taken once daily~Prednisone will be taken twice daily~Apalutamide will be taken once daily"
33305722|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
33305723|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
33305724|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
33305725|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
33305726|NCT04384822|Experimental|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
33305727|NCT04384822|Active Comparator|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
33305728|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
33305729|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
33305730|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
33305731|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
33305732|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
33305733|NCT01562158|Placebo Comparator|Placebo|
33305734|NCT01562158|Experimental|Low dose|
33305735|NCT01562158|Experimental|Medium dose|
33305736|NCT01562158|Experimental|High dose|
33404315|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
33404316|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
33404317|NCT02331160|No Intervention|Control|Standard
33404318|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
33090907|NCT01050543|Experimental|Sugammadex|
33305737|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
33305738|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
33305739|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
33305740|NCT05297110|Active Comparator|atherolive group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
33305741|NCT05297110|Placebo Comparator|placebo group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
33305742|NCT04315246|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.
33305743|NCT04297384|Active Comparator|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
33305744|NCT04297384|Experimental|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
33305745|NCT04358068|Experimental|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
33305746|NCT04358068|Placebo Comparator|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
33305747|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
33305748|NCT04339972|Experimental|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
33305749|NCT04339972|Sham Comparator|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
33305750|NCT04172038|Experimental|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
33305751|NCT04172038|Experimental|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
33305752|NCT04172038|Experimental|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
33305753|NCT04172038|Experimental|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
33305754|NCT00096278|Active Comparator|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
33305755|NCT00096278|Experimental|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
33305756|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
33305757|NCT00095940|Experimental|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
33305758|NCT00114218|Experimental|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
33305759|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
33305760|NCT04380688|No Intervention|Arm 2|Best Supportive Care
33305761|NCT00095628|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33305762|NCT01082562|Experimental|Arm 1 - BMS-844421|
33305763|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
33305764|NCT01082562|Experimental|Arm 3 - BMS-844421|
33305765|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
33305766|NCT01082562|Experimental|Arm 5 - BMS-844421|
33305767|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
33305768|NCT01082562|Experimental|Arm 7 - BMS-844421|
33305769|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
33305770|NCT01082562|Experimental|Arm 9 - BMS-844421|
33305771|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
33305772|NCT01082562|Experimental|Arm 11 - BMS-844421|
33305773|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
33305774|NCT01082562|Experimental|Arm 13 - BMS-844421|
33305775|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
33305776|NCT01082562|Experimental|Arm 15 - BMS-844421|
33305777|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
33305778|NCT04157062|Experimental|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
33305779|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks using the ReJoyce Workstation.~The training will be supervised by a therapist and provided to the target hand. The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~reaching~grasping~manipulating~pulling~rotating~releasing"
33305780|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
33090908|NCT01050543|Active Comparator|Neostigmine|
33305781|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
33305782|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
33305783|NCT03963180|No Intervention|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
33305784|NCT03963180|Experimental|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
33305785|NCT03963024|Experimental|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
33305786|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
33305787|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
33305788|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
33305789|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
33305790|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
33305791|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
33305792|NCT04380142|Experimental|ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)|After an open-label LD/CD Stabilization Period, participants will receive double-blind ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
33305793|NCT04380142|Active Comparator|Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951|After an open-label LD/CD Stabilization Period, participants will receive double-blind oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks
33305794|NCT04375696|Experimental|Product|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
33305795|NCT04375696|Placebo Comparator|Placebo|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
33305796|NCT04045132|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
33305797|NCT04045132|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
33305798|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
33305799|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
33305800|NCT04336228|Placebo Comparator|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
33305801|NCT04336228|Placebo Comparator|Obsessive-Compulsive Disorder / High Compulsivity Control Group|The OCD/high compulsivity placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
33305802|NCT04336228|Experimental|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
33305803|NCT04336228|Experimental|Obsessive-Compulsive Disorder / High Compulsivity Intervention Group|The OCD/high compulsivity intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
33305804|NCT03937180|Other|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
33305805|NCT03937180|Experimental|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
33305806|NCT03917446||Euvolaemic|Patients with stroke volume variation less than 8%
33305807|NCT03917446||Hypovolaemic|Patients with stroke volume variation greater than 13%
33305808|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
33305809|NCT04335136|Placebo Comparator|Group B (placebo control)|
33305810|NCT04332874|Experimental|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
33305811|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
33305812|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
33305813|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
33305814|NCT04328740|Experimental|Monotherapy|TP-1454
33305815|NCT04328740|Experimental|Combination Therapy|TP-1454, ipilimumab and nivolumab
33305816|NCT04167670|Experimental|Vonoprazan dual therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
33305817|NCT04167670|Experimental|Vonoprazan triple therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
33305818|NCT04167670|Active Comparator|Lansoprazole triple therapy|Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
33305819|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
33305820|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
33305821|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
33305822|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
33305823|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
32798799|NCT01756053|Placebo Comparator|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.~During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
32798800|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
32798801|NCT01785069|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
32798802|NCT01785069|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
32798803|NCT01785069|Experimental|Revision-Augmentation|Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.
33305824|NCT00113516|Experimental|1|
32798804|NCT01785069|Experimental|Revision-Reconstruction|Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.
32798805|NCT01784523|No Intervention|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
32798806|NCT01784523|Experimental|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg.
32798807|NCT01784211|Experimental|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SC) once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
32798808|NCT01784211|Active Comparator|Glargine (Part A)|0.5 U/kg insulin glargine SC once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
32798809|NCT01784211|Experimental|First LY2605541 + Exercise,Then LY2605541 Alone (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20).Participants remained on their regular physician-prescribed mealtime insulin.
33305825|NCT04142242|Experimental|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MEQ00066).
33305826|NCT04142242|Experimental|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0 in the present study (MEQ00066).
33305827|NCT04142242|Experimental|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
33305828|NCT04142242|Experimental|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
33305829|NCT04142242|Other|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
33305830|NCT04142242|Other|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
33305831|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
33305832|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
33305833|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
33305834|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
33305835|NCT04140292|Experimental|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
33305836|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
33305837|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
33404319|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
33404320|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
33305838|NCT00127166|Experimental|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
33305839|NCT00127166|Experimental|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
33305840|NCT00125138|Experimental|Melperone HCl - 20 mg|
33305841|NCT00125138|Experimental|Melperone HCl - 40 mg|
33305842|NCT00125138|Experimental|Melperone HCl - 60 mg|
33305843|NCT00125138|Placebo Comparator|Placebo|
33305844|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
32798810|NCT01784211|Experimental|First LY2605541 Alone, Then LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17). Participants remained on their regular physician-prescribed mealtime insulin.
32798811|NCT01784211|Active Comparator|First Glargine + Exercise, Then Glargine Alone (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20). Participants remained on their regular physician-prescribed mealtime insulin.
32798812|NCT01784211|Active Comparator|First Glargine Alone, Then Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17).
32798813|NCT01783821|Experimental|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
32798814|NCT01783821|Placebo Comparator|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
33305845|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
33305846|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
32798815|NCT01783743|Experimental|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
32798816|NCT01783743|No Intervention|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
33305847|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
33305848|NCT04132336|Active Comparator|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
33305849|NCT04132336|Active Comparator|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
32798817|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
32798818|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
32798819|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
32798820|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
32798821|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
32798822|NCT01912963|Experimental|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)~Cycle duration=21 days~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
32798823|NCT01912963|Experimental|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
32900826|NCT05347446|Active Comparator|Non-Hybrid ESD|A partial or complete circumferential mucosal incision will be performed to expose the submucosa around and underneath the polyp. Endoscopic resection will then proceed via conventional ESD, submucosal tunneling or pocket technique.
32900827|NCT04750382|Experimental|HX008+Cisplatin+Gemcitabine|
32900828|NCT04271150|Experimental|Self-etch|Self-etch mode of the universal adhesive will be used
32900829|NCT04271150|Active Comparator|Total-etch|Total etch mode of the universal adhesive will be used
33305850|NCT04132336|Placebo Comparator|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
33305851|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305852|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305853|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305854|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305855|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305856|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
33305857|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
33305858|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
32941250|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
32941251|NCT05513612|Experimental|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
32941252|NCT05596045|Experimental|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
32941253|NCT05596045|Placebo Comparator|Placebo|Participants will be randomized to receive placebo
32941254|NCT05512208|Experimental|VS-6766 + Defactinib|"VS-6766: will be administered at 3.2 mg orally twice a week~Defactinib: will be administered at 200 mg orally twice a day (BID)."
32941255|NCT05594407|Active Comparator|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine, ketamine and lidocaine in one syringe
32941256|NCT05594407|Active Comparator|remifentanil group|syringe of remifentanil
32941257|NCT05747456|Experimental|IPN-21-SENSE Treatment Group|Subjects randomized (5:1 ratio) to receive an initial treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
32941258|NCT05747456|Other|No-Treatment Control Group, then Delayed Treatment with IPN-21-SENSE|No-Treatment for the first 6-month, then subjects will receive a delayed treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
32941259|NCT05746754|Experimental|Craniospinal proton radiotherapy|30 Gy in 10 fractions to CNS
32941260|NCT04706377|Active Comparator|Active treatment group|Patients were given oral dispersible tablet with 1000μg of vitamin B12 daily for 12 months.
32941261|NCT04706377|Placebo Comparator|Placebo group|Patients were given placebo tablet similar to the tablet given to the active group once a day for 12 months.
32941262|NCT05509166|Experimental|LGBTQ-affirmative Cognitive Behavioral Therapy|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual minority women's depression, anxiety, and alcohol abuse.
32941263|NCT05509166|Active Comparator|LGBTQ-affirmative Treatment-as-Usual|Individuals assigned to LGBTQ-affirmative Treatment-as-Usual will receive 10 weekly sessions from a therapist at the Institute for Human Identity who will provide their LGBTQ-affirmative therapy services via telehealth.
33090909|NCT04704141||Infertile men with leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
32798824|NCT01912963|Experimental|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
32798825|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
32798826|NCT01912807|Experimental|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
32798827|NCT01912807|Active Comparator|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
32798828|NCT01782885|Active Comparator|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
32798829|NCT01782885|Experimental|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
33090910|NCT04704141||Infertile men without leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
33090911|NCT04704141||Infertile men with hypogonadism|Standard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
33090912|NCT00329342|Experimental|1|
33090913|NCT00329342|No Intervention|2|
33090914|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
33090915|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
33305859|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
33305860|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
32798830|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
33305861|NCT04315636|Experimental|Surfactant nebulisation|The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
32798831|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
32798832|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
32798833|NCT01754493|Experimental|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
32798834|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
32798835|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
32798836|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
32798837|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
33090916|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
33090917|NCT00429780|No Intervention|Placebo|BCG diluent
33090918|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
33090919|NCT00329459|Placebo Comparator|arm 2|placebo to match
33090920|NCT00329537|Experimental|Arm 1|
33090921|NCT00329537|Placebo Comparator|Arm 2|
33090922|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
33090923|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
32798838|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
33090924|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
33090925|NCT00430014|Experimental|Atiprimod|
33090926|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
33090927|NCT04716686|Experimental|Niraparib as maintenance therapy for Endometrial Serous Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
33090928|NCT04716686|Experimental|Niraparib as recurrent therapy for Endometrial Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
33090929|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
33090930|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
33090931|NCT04716491|Experimental|Intervention group|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
33090932|NCT04716491|No Intervention|Control group|Participants will not use the devices at any time of admission to the intensive care unit
33090933|NCT01055106|Active Comparator|1D|
33090934|NCT01055106|Active Comparator|3D|
33090935|NCT01055106|Active Comparator|5D|
33090936|NCT01055106|Active Comparator|Metronidazole|
33090937|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
33090938|NCT00329693|Experimental|2|Daily Tablets Dose
33090939|NCT00329693|Experimental|3|Daily Tablets Dosing
33090940|NCT00329693|Experimental|4|Daily Tablets Dosing
33090941|NCT00329810|Experimental|Switch|
33090942|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
33090943|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
33090944|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
33090945|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
33090946|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
33305862|NCT04315636|No Intervention|Standard care|The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).
33305863|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
33305864|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
32798839|NCT01912339|Other|Control|Control: Rigid Cystoscopy
33090947|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
33090948|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
33090949|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
33090950|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
33090951|NCT04716530||born before 2000|No patient treatment is associated with the study.
33090952|NCT04716530||born between 2000-2010|No patient treatment is associated with the study.
33090953|NCT04716530||born after 2010|No patient treatment is associated with the study.
33090954|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
33090955|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
33090956|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
33090957|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
33090958|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
33090959|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
33090960|NCT00330317|Experimental|Letrozole|
33090961|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
33090962|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
33090963|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
33090964|NCT00430560|Active Comparator|1|work therapy
33090965|NCT00430560|Experimental|2|work therapy plus cognitive remediation
33090966|NCT01054170|Experimental|AZD9668|
33090967|NCT01054170|Placebo Comparator|Placebo|
33090968|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
33305865|NCT03691948|Experimental|ROPEs|
33305866|NCT03691948|Active Comparator|Control|
33305867|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
33305868|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
33305869|NCT04124926|Experimental|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
33305870|NCT04124926|Active Comparator|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
32798840|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
33305871|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
33305872|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
33305873|NCT04124926|Active Comparator|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
33305874|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
32941264|NCT04706299|Active Comparator|No Mask|Will not wear a mask
33305875|NCT05321056|Experimental|Intervention group: Mask on model face|"The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
33305876|NCT05321056|No Intervention|Control group: No mask on model face|"No mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
33305877|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
33305878|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
33305879|NCT03747094|Active Comparator|Fentanyl group|
33305880|NCT03747094|Experimental|Ketamine group|
33305881|NCT04274686|Experimental|Bag-Mask Ventilation with Tegaderm|Patients will receive bag-mask ventilation with Tegaderm placement
33305882|NCT04274686|Active Comparator|Bag-Mask Ventilation without Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement
33305883|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
33305884|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
33305885|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
33305886|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
33305887|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
33305888|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
33305889|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
33305890|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
33305891|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
33305892|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
33305893|NCT04105972|Active Comparator|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
33305894|NCT04105972|Experimental|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
33305895|NCT04102540|Experimental|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
33305896|NCT00124982|Experimental|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
33305897|NCT00124982|Experimental|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
33305898|NCT00124982|Experimental|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
33404321|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
32941265|NCT04706299|Experimental|Surgical mask|Will wear a surgical nose and face covering
32798841|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
32798842|NCT04632511|Other|Obese group|Metabolome measurements on feces and urine.
33090969|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
32798843|NCT04632511|Other|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
32798844|NCT04632511|Other|Normal-weight control group|Metabolome measurements on feces and urine.
32798845|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
33090970|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
32798846|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
32798847|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
32798848|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
32798849|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
32798850|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
32798851|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
32798852|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
32798853|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32798854|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
32798855|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
33090971|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
33090972|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
33090973|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
33090974|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
33090975|NCT04702230||post-TAE|
33090976|NCT04702230||post-TARE|
33090977|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
33090978|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
33090979|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
33090980|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
33090981|NCT00434616|Placebo Comparator|1|saline injections
33090982|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
33090983|NCT04703868|Experimental|YPI-011 10/500mg|Part A: 1 tablet administered before the breakfast during 7 days
33090984|NCT04703868|Experimental|YPI-011 20/500mg|Part B: 1 tablet administered before the breakfast during 7 days
33090985|NCT04716296|Experimental|Ketamine arm|Treatment arm consisting of patients randomized to receive a low dose of ketamine for the second stage of DBS surgery.
33090986|NCT04716296|Active Comparator|Control arm|Control arm consisting of patients randomized to receive sham control of saline during the second stage of DBS surgery.
33090987|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
33090988|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
33090989|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
33090990|NCT00434655|Active Comparator|1 LAP BAND|
33090991|NCT00434655|Experimental|2 Sleeve gastrectomy|
33090992|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
33090993|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
33090994|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
33090995|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
33090996|NCT00331097|Experimental|B|Weekly docetaxel
33090997|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
33090998|NCT00331214|Experimental|Testosterone|Testosterone patch
33090999|NCT04702074|Experimental|Traditional Chinese medicine granules|The experimental group will be given Bu Fei Jian Pi Hua Tan granule or Yi Qi Yang Yin Qing Fei granule based on TCM syndrome differentiation.
33305899|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33305900|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33305901|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33305902|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
32798856|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
33305903|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
33305904|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
33305905|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
33305906|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
33305907|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
32798857|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
32798858|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
32798859|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
32798860|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
32798861|NCT01427608|Active Comparator|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
32798862|NCT01427608|Placebo Comparator|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
32798863|NCT01408030|Placebo Comparator|Placebo spray|sterile saline
32798864|NCT01408030|Active Comparator|Bevacizumab spray|bevacizumab 1%
32798865|NCT01408030|Active Comparator|Estriol spray|Estriol 0.1%
32798866|NCT01408030|Active Comparator|Tranexamic acid spray|tranexamic acid 10%
32798867|NCT04407832|Active Comparator|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
32798868|NCT04407832|Active Comparator|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
32798869|NCT01897532|Experimental|Linagliptin|
32798870|NCT01897532|Placebo Comparator|Placebo|
32798871|NCT04641026|Active Comparator|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
32941266|NCT04450004|Experimental|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
32941267|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
33091000|NCT04702074|Placebo Comparator|Traditional Chinese medicine granules placebo|The control group will be given Bu Fei Jian Pi Hua Tan granule placebo or Yi Qi Yang Yin Qing Fei granule placebo based on TCM syndrome differentiation.
33091001|NCT04703907|Experimental|Intervention group|This group is constituted from patients who will receive the intervention first within 15 weeks
33091002|NCT04703907|No Intervention|Waiting list|This group is constituted from patients who will receive the intervention after 15 weeks
33091003|NCT00434889||1|Memory problems
33091004|NCT00434889||2|No memory problems
33091005|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
33091006|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
33091007|NCT00431106|Active Comparator|2|Capecitabine (Cap)
33091008|NCT00331487|Experimental|Pioglitazone QD|
33091009|NCT00331487|Active Comparator|Rosiglitazone QD|
33091010|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
33091011|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
33091012|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
33091013|NCT00331565|Experimental|Surgery|Bariatric surgery
33091014|NCT00331604|Experimental|A|
33091015|NCT00331604|Active Comparator|B|
33091016|NCT00331604|Active Comparator|C|
33091017|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
33091018|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
33091019|NCT04716764||Case Group|The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
33091020|NCT04716764||Healthy (Control) participants|The control group consists of healthy adult women who applied to the Internal Diseases (Internal Medicine) outpatient clinic of Necmettin Erbakan University Meram Medical Faculty Hospital, who are at the same age as the case group, and who have not been diagnosed with any disease by the doctor, and who are willing to participate in the study. Healthy individuals will be interviewed once. The obtained data will be compared with the preoperative data of breast cancer patients.
33091021|NCT00431301||Case|PSP Cases
33091022|NCT00431301||Control|Healthy Controls
33091023|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
33091024|NCT00331721|Active Comparator|1|Enecadin
33091025|NCT00331721|Placebo Comparator|2|Placebo
33091026|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091027|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091028|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091029|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091030|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091031|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
33091032|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
33091033|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
33091034|NCT00431418|Active Comparator|1|Sildenafil oral solution.
33091035|NCT00431418|Placebo Comparator|2|Placebo oral solution.
33091036|NCT04702191|Experimental|Triple P (Positive Parenting Program)|Triple P - level 4 group: All 600 participants will undergo screening and a baseline assessment before randomization. Once randomized, the Triple P group (n=200) will be provided with 8-week group/individual sessions.
33091037|NCT04702191|Experimental|Circle of Security Parenting|Circle of Security - Parenting (COS-P): Once randomized to the COSP group (n=200), caregivers will be provided with an 8-week group session.
33091038|NCT04702191|No Intervention|Treatment As Usual|Treatment as usual: Caregivers randomized to this arm (n=200) will receive either a different program, or brief services depending on the organization.
33102463|NCT03792737|Experimental|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
33305908|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
33305909|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
33305910|NCT04093414|Active Comparator|Selective or Non selective His Bundle Pacing|Pacemaker wires placed in Bundle of His
32798872|NCT04641026|Active Comparator|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
33305911|NCT04093414|Active Comparator|Left Bundle Area Pacing|Pacemaker wires placed in Left Bundle Branch area
33305912|NCT04093258|Experimental|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
33305913|NCT04093258|Experimental|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
33305914|NCT04090528|Experimental|Arm 1: One DNA vaccine|"100 µg pTVG-HP administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
33305915|NCT04090528|Experimental|Arm 2: Two DNA vaccines|"100 µg pTVG-AR administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
33305916|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
33305917|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
33305918|NCT03433456|Experimental|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
32798873|NCT04641026|Placebo Comparator|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
32798874|NCT04641026|Placebo Comparator|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
32798875|NCT01923428|Experimental|5 mg BID|AZD1722
33305919|NCT03433456|Active Comparator|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
33305920|NCT04087720|Experimental|Pegloticase|Participants receive 8 mg pegloticase every 2 weeks from Day 1 through Week 22
33305921|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
33305922|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
33305923|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
33305924|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
33305925|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
33305926|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
32798876|NCT01923428|Experimental|20 mg BID|AZD1722
32798877|NCT01923428|Experimental|50 mg BID|AZD1722
32798878|NCT01923428|Placebo Comparator|Placebo|
32798879|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~receiving immunosuppressant therapy~not on immunosuppressant therapy"
32798880|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
32798881|NCT04627376|No Intervention|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
32900830|NCT05347212|Experimental|Nivolumab+Relatlimab|nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years
32900831|NCT05313438|Experimental|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
33091039|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
33091040|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy~*q4 weeks durvalumab for 13 cycles or until progression"
33091041|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
33305927|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
32798882|NCT04627376|Experimental|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
32798883|NCT04618718|Experimental|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
32798884|NCT04173416|Experimental|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
32798885|NCT04173416|No Intervention|Treatment As Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, contingency management, and home delivery of medication. This often includes a referral and warm hand off to intensive outpatient SUD services and/or mental health care.
32798886|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
32798887|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
32798888|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
32798889|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
32798890|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
32798891|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32798892|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32798893|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32798894|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32798895|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
32798896|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
32798897|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
33091042|NCT00331994|Experimental|1|
33305928|NCT04086472|Experimental|Clesrovimab 100 mg|Participants receive a single IV infusion of clesrovimab 100 mg on Day 1.
32798898|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
32900832|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
32900833|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
33091043|NCT00331994|Active Comparator|2|
33091044|NCT00435279|Experimental|Eszopiclone|
33091045|NCT00435279|Experimental|Placebo|
33091046|NCT00431613|Experimental|1|DG -> RT
33091047|NCT00431613|Experimental|2|DG -> RT -> DCarbo
33091048|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
33091049|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
32798899|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
33091050|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
33091051|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
33091052|NCT00431691|Active Comparator|1|
33091053|NCT00431691|Placebo Comparator|2|
32798900|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
32798901|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
32798902|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
32798903|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
32798904|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
32798905|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
32798906|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
32798907|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
32798908|NCT01426438|Experimental|Arm B: Fenofibrate|
32798909|NCT04032106|Active Comparator|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
32798910|NCT04032106|Experimental|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
32798911|NCT04032106|Experimental|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
32798912|NCT04407910|Experimental|Air-powder polishing device|
32798913|NCT04407910|Experimental|Rubber-cup+paste|
32798914|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
32798915|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
32798916|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
33091054|NCT00435357|Experimental|mobile-bearing TKA|
33091055|NCT00435357|Active Comparator|fixed- bearing TKA|
33091056|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
33091057|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
33091058|NCT00435396|Experimental|Group A|
33091059|NCT00420485|Experimental|Daily times five schedule|
33091060|NCT00420485|Experimental|Continuous schedule, twice daily|
33091061|NCT00435474|Active Comparator|1|Silver product
33091062|NCT00435474|Experimental|2|Honey product
33091063|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
33091064|NCT00435513||Controls|Healthy blood donors
33091065|NCT04704102|Experimental|Muscle energy technique group|Use one of the muscle energy technique methods -- postisometric relaxation technique(PIR) as the intervention method.
33091066|NCT04704102|Experimental|Strain-counterstrain group|Use the Strain-counterstrain technique as the intervention method.
33091067|NCT04704102|Sham Comparator|Control group|Use the modified Strain-counterstrain technique as the intervention method.
33091068|NCT00332774|Experimental|Nevanac|
33091069|NCT00332774|Active Comparator|Acular|
33091070|NCT00332774|Placebo Comparator|Vehicle|
33091071|NCT00431769|Experimental|Bortezomib|
33091072|NCT04703439|Experimental|Experimental group|This group consisted of 116 participants who received a medication-taking reminder every morning at a random time between 7-8 am on WeChat app. Also, participants received a piece of educational material every five days at a random time between 8 am and 9 am regarding improving medication adherence and preventing coronary heart disease.
33091073|NCT04703439|Placebo Comparator|Control group|This group consisted of 114 participants who only received a piece of educational material every five days at a random time between 8 am and 9 am. The educational materials sent to this group were general medical information, which were not specifically about improving medication adherence or preventing coronary heart disease.
33091074|NCT00435630|Other|1|Completing simulator training sessions
33091075|NCT00332852|Experimental|Letrozole|
33091076|NCT00435708|No Intervention|1|
33091077|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
33091078|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
33091079|NCT00332969|Experimental|Sandostatin|
33091080|NCT00333125|Experimental|Travoprost/Timolol|
33091081|NCT00333125|Active Comparator|Dorzolamide/Timolol|
33091082|NCT00333203|Experimental|NGOIS|
33091083|NCT00333203|Active Comparator|BSS Plus|
33091084|NCT01052493|Experimental|2mg PP 1420|PP 1420 single dose, subcutaneous
33091085|NCT01052493|Experimental|4mg PP 420|PP 1420 single dose, subcutaneous
33091086|NCT01052493|Experimental|8mg PP 1420|PP 1420 single dose, subcutaneous
33091087|NCT01052493|Placebo Comparator|Placebo|0.9% saline
33091088|NCT04703634|Experimental|erector spinae group|All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.
33305929|NCT04086472|Experimental|Clesrovimab 200 mg|Participants receive a single IV infusion of clesrovimab 200 mg on Day 1.
33305930|NCT04086472|Experimental|Clesrovimab 300 mg|Participants receive a single IV infusion of clesrovimab 300 mg on Day 1.
33305931|NCT04086472|Experimental|Clesrovimab 900 mg|Participants receive a single IV infusion of clesrovimab 900 mg on Day 1.
33305932|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
33305933|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
33305934|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
33305935|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
33305936|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
33305937|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
33305938|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
33305939|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
33305940|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
33305941|NCT04245202|Active Comparator|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation >92%.
33305942|NCT04245202|Active Comparator|Active Comparator: St-FMOT|To obtain oxygen saturation >92%
33305943|NCT03979924|Other|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
32941268|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
32941269|NCT04450004|Experimental|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
32941270|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
33305944|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
33305945|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
33305946|NCT03752242|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
33305947|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
33305948|NCT04079842|Experimental|INVSENSOR00029|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
33305949|NCT04078126|Experimental|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
33305950|NCT04078126|Active Comparator|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
32941271|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
33305951|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
33305952|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
33305953|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
33305954|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
33305955|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
33305956|NCT00124748|Experimental|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
33305957|NCT00124748|Experimental|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
33305958|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
33305959|NCT04070326|Experimental|Lanadelumab 150 mg: Age 2 to <6 Years|Participants aged 2 to <6 years received lanadelumab subcutaneous (SC) injection at a dose of 150 milligrams (mg) for every 4 weeks (q4wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B).
33305960|NCT04070326|Experimental|Lanadelumab 150 mg: Age 6 to <12 Years|Participants aged 6 to <12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.Participants aged 6 to <12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.
33305961|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
32941272|NCT04450004|Experimental|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
32941273|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
32941274|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
32798917|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
32798918|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
32798919|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
32798920|NCT01782495|Experimental|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
32798921|NCT01782495|Experimental|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
32798922|NCT01782495|Experimental|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
32798923|NCT01782495|Experimental|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
32798924|NCT01782495|Experimental|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
32798925|NCT01782495|Experimental|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
32798926|NCT01782495|Experimental|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
32798927|NCT01782495|Experimental|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
32798928|NCT01782495|Experimental|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
32798929|NCT01782495|Experimental|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
32798930|NCT01782495|Experimental|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
32798931|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
32798932|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
32798933|NCT01922102|Active Comparator|Group III|verteporfin PDT
32798934|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
32798935|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
32798936|NCT01754259|Experimental|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
32798937|NCT01754259|Placebo Comparator|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
32798938|NCT04574505|Experimental|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
32798939|NCT04574505|Placebo Comparator|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
32798940|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
32798941|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
32798942|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
32798943|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
32798944|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
33091089|NCT04703634|Placebo Comparator|placebo group|No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.
33091090|NCT00435864|Other|allogeneic donor from a file|
33305962|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
33305963|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
33305964|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
33305965|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
33091091|NCT00435864|Other|Registry geno-identical donor family|
33091092|NCT00435864|Other|transplantation of HSCs derived from placental blood|
33091093|NCT00333320|Placebo Comparator|- Control|
33305966|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
33091094|NCT00333320|Experimental|-postconditioning group|
33091095|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
33305967|NCT00096200|Experimental|Arm I (closed to accrual 10/10/2008)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II
33305968|NCT00096200|Experimental|Arm II|Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33305969|NCT04059094|Placebo Comparator|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
33305970|NCT04059094|Experimental|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
33305971|NCT04059094|Experimental|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
33305972|NCT04059094|Experimental|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
33305973|NCT04059094|Experimental|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
33305974|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
33305975|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
33305976|NCT00096044|Experimental|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
33305977|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
33305978|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
33305979|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
33305980|NCT03963128|Active Comparator|Supplemented Vitamin D3|
33305981|NCT03963128|Placebo Comparator|Placebo|
33305982|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
33091096|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
33091097|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
33091098|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
33091099|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
33091100|NCT04716452|Experimental|Open Label Administration of Ceramide NanoLiposome|Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
33091101|NCT01052103|Experimental|LY2140023|40 mg/day, given orally twice daily (BID) as a 20-mg tablet. LY2140023 dosage was adjustable from 10 mg to 40 mg BID.
33091102|NCT01052103|Placebo Comparator|Placebo|Placebo tablets to match LY2140023 tablets
33305983|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
33305984|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
33305985|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
33305986|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
33305987|NCT03963050|Experimental|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
33305988|NCT03963050|Experimental|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
33305989|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :~laser stimulations on lower limbs~laser stimulations cervical~20 laser stimulations for each site on the upper limbs~laser stimulations on face and neck"
33305990|NCT01083056||Epimacular Gliosis Without Macular Hole|
33305991|NCT01083056||Epimacular Gliosis With Macular Hole|
33305992|NCT01083134||percentage of stenosis|
33305993|NCT03962660|Experimental|HaRTS-TRENDS|See description below.
32941275|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
32941276|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
32941277|NCT05745428||First group with aortic dissection|19 patients admitted to our Department of Cardiovascular Sciences with a radiological diagnosis of AD within 14 days of the onset of symptoms
32941278|NCT05745428||Control Group|19 healthy outpatient or inpatient controls at our Department with another diagnosis and no evidence of AD, matched for demographic and clinical characteristics.
32941279|NCT04403516|Experimental|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
32941280|NCT04403516|Experimental|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
32941281|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
32941282|NCT05243654|Experimental|Metformin 1000mg extended release (XR) once daily + standard-of-care MDT|Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
33305994|NCT03962660|Active Comparator|Standard Care (SC)|See description below.
33305995|NCT03962582|Experimental|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
33305996|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
33305997|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
33305998|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
33305999|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
33306000|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
33306001|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
32941283|NCT05243654|Placebo Comparator|Placebo + MDT|Matching metformin placebo tablets once daily by mouth for 2 weeks, escalating to two tablets for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
32941284|NCT01035073|Experimental|Duloxetine|
32941285|NCT05236868|Experimental|Seltorexant|Participants will receive a single oral dose of seltorexant. At 2 hours after oral dosing, participants will receive 14C-seltorexant as an intravenous (IV) infusion over 15 minutes.
32941286|NCT01561495|Experimental|All Participants|Proton Radiotherapy
32941287|NCT04330976|Experimental|Nutrition and physical activity intervention|
32941288|NCT04330976|Other|Control|
32941289|NCT04331743|Experimental|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
32941290|NCT05296759|Active Comparator|botulinum toxin A injection|botulinum toxin A injection
32941291|NCT05296759|Active Comparator|gabapentin|gabapentin
32941292|NCT05296759|Active Comparator|duloxetine|duloxetine
33306002|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
33306003|NCT03689374|Experimental|Semaglutide|"Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
33306004|NCT03689374|Active Comparator|Insulin aspart|"Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
33306005|NCT00113360|Experimental|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
33306006|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
33306007|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
33306008|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
33306009|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
33306010|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
33306011|NCT00112736|Experimental|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.~pharmacological study: Correlative studies"
33306012|NCT00112736|Experimental|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.~therapeutic conventional surgery: Undergo surgical resection~laboratory biomarker analysis: Correlative studies"
33306013|NCT00123422|Experimental|Breathing retraining|Exercise training with computerized training program
33306014|NCT00123422|Experimental|Heliox|Exercise training with helium oxygen combination
32941293|NCT05546047|Active Comparator|Treatment with Acthar gel|Group 1 - (17 patients) Acthar gel 80 units 2 times a week alone for 12 months of therapy.
33306015|NCT00123422|Active Comparator|Exercise|Exercise training
33306016|NCT04052620|Experimental|Diclofenac diethylamine (DDEA) 2.32%/ Placebo gel|Participants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
33306017|NCT04052620|Active Comparator|DDEA 1.16% gel|Participants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2) in morning, noon, late afternoon, and late evening for 7 days.
33306018|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
33306019|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
33306020|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
33306021|NCT05018260|Experimental|GCMRT|Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces
33306022|NCT05018260|Experimental|attention control|Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes
33306023|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
33306024|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
33306025|NCT04244032|Experimental|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
33306026|NCT04244032|Experimental|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
33306027|NCT04244032|Active Comparator|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
32941294|NCT05546047|Active Comparator|Treatment with combination Acthar gel and Tacrolimus therapy|Group 2 - (17 patients) Acthar get 80 units 2 times a week plus oral Tacrolimus 1.0 mg two times a day titrated to trough Tacrolimus levels between 4-6 ng/ml
33306028|NCT04244032|No Intervention|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
33306029|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
33306030|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
33306031|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
33306032|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
33306033|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
33306034|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
33306035|NCT00095576|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
33306036|NCT00095576|Placebo Comparator|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
33306037|NCT04049578|Experimental|Balovaptan|
33306038|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
33306039|NCT04043962|Experimental|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
32798945|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
33091103|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
33306040|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
33306041|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
33306042|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
33306043|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
33306044|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
33306045|NCT00095498|Experimental|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
33306046|NCT00095498|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
33306047|NCT00095498|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
33091104|NCT00333515|Placebo Comparator|2|Administration of placebo
33091105|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
33091106|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
32798946|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
33091107|NCT00436020|Active Comparator|1|Active
32798947|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
32798948|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
32798949|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
32798950|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
32798951|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
32798952|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
32798953|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
32798954|NCT01389232|Experimental|SeriScaffold® Surgical Scaffold|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
33091108|NCT00436020|Placebo Comparator|2|Sham TMS
32941295|NCT05743556|Experimental|HILT group|Therapy of muscle hypertonus by Hight intensive laser applied on cervical muscles.
32798955|NCT01404208|Active Comparator|D-Cycloserine|
32798956|NCT01404208|Placebo Comparator|Sugar Pill|
33404322|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
33404323|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
32798957|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
32798958|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
32798959|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
32798960|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
32798961|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
32798962|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
32798963|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
32798964|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
32798965|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
32798966|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
32798967|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
32941296|NCT05743556|Active Comparator|TRT group|Muscle hypertonus of the cervical area treated by Target radio frequency current.
32941297|NCT05743556|No Intervention|Control group|Group of patients with muscle cervical hyper tone without any therapy.
32941298|NCT05492006|Active Comparator|Group A: intentional contact with nature|Group A volunteers will take a light walk along the park with green space in a single 1-hour session with an emphasis on sense-directed appreciation guided by research team.
32941299|NCT05492006|Active Comparator|Group B: indirect contact with nature|The members of Group B will watch a video with the images of nature during 4 consecutive 15-minute sessions accompanied by the researcher, totaling 1 hour.
32941300|NCT05490446|Experimental|Core Period: Phase 2a - AG-946 5 mg|Participants will receive AG-946, 5 milligrams (mg) orally, once daily for up to 16 weeks. Participants who complete Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
32941301|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 2 mg|Participants will receive AG-946, 2 mg orally, once daily for up to 24 weeks.
32941302|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 3 mg|Participants will receive AG-946, 3 mg orally, once daily for up to 24 weeks.
32941303|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 5 mg|Participants will receive AG-946, 5 mg orally, once daily for up to 24 weeks.
32941304|NCT05490446|Placebo Comparator|Double-blind Period: Phase 2b - Matching-placebo|Participants will receive AG-946-matching placebo orally, once daily for up to 24 weeks.
32941305|NCT05490446|Experimental|Extension Period: AG-946 2 mg|Participants who received placebo in the Double-blind Period will receive AG-946, 2 mg orally, once daily for up to 156 weeks.
32941306|NCT05490446|Experimental|Extension Period: AG-946 3 mg|Participants who received placebo in the Double-blind Period will receive AG-946, 3 mg orally, once daily for up to 156 weeks.
32941307|NCT05490446|Experimental|Extension Period: AG-946 5 mg|Participants who received placebo in the Double-blind Period will receive AG-946, 5 mg orally, once daily for up to 156 weeks.
33091109|NCT00420524|Experimental|Arm A (Normal liver function)|
33404324|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
32941308|NCT05234762|Experimental|ES-481|Week 1 - 25 mg qd (2 x 25 mg capsule in the mornings Days 1 to 7 in Treatment Period 1 and Days 44 to 50 in Treatment Period 2) Week 2 - 50 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 8 to 14 in Treatment Period 1 and Days 51 to 57 in Treatment Period 2) Week 3 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 15 to 21 in Treatment Period 1 and Days 58 to 64 in Treatment Period 2) Week 4 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 22 to 28 in Treatment Period 1 and Days 65 to 71 in Treatment Period 2)
33306048|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
33306049|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
33306050|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
32941309|NCT05234762|Placebo Comparator|Placebo|Placebo will be dosed at the same quantity and frequency as ES-481 just as Placebo HPMC capsules
33306051|NCT04233580|Active Comparator|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
33306052|NCT04233580|Active Comparator|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
33306053|NCT00122954|Experimental|Fish oil concentrate|Fish oil concentrate
33306054|NCT00122954|Placebo Comparator|Placebo oil|Placebo oil
33306055|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
33306056|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
33306057|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
32941310|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
33306058|NCT04041700|Experimental|Osia 2 system|
33306059|NCT03414034|Experimental|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
33306060|NCT03414034|Experimental|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
32941311|NCT05225324||Equfina 50 mg|Participants who will be prescribed with Equfina 50 mg tablets, orally within the scope of the approved label for Korea under the medical judgment of the investigator will be observed prospectively for 24 weeks.
32941312|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
33404325|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
32941313|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
32941314|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
32941315|NCT05742074|Experimental|FMT (faecal microbiota transplantation)|25-30 capsules of faecal material.
32941316|NCT05742074|Placebo Comparator|Placebo|25-30 placebo capsules.
32941317|NCT05295511|Experimental|Team Handball 1|Team handball group participants were instructed to perform one weekly 60-min recreational team handball training sessions for 16 weeks.
32941318|NCT05295511|Experimental|Team Handball 2|Team handball group participants were instructed to perform two weekly 60-min recreational team handball training sessions for 16 weeks.
32941319|NCT05295511|Experimental|Team Handball 3|Team handball group participants were instructed to perform three weekly 60-min recreational team handball training sessions for 16 weeks.
32941320|NCT05295511|No Intervention|Control Group|The control group participants were instructed to keep their regular daily physical activity for 16 weeks.
32941321|NCT05488496|Experimental|Intervention arm|"The intervention arm will undergo the following steps:~Groups of 5-15 persons living in the same area. Two trained facilitators support the group dynamics fostering empowerment.~Each participant undergoes a one-to one personalized interview with the facilitator(s) to build the relationship and know participants' expectations and characteristics.~9 sessions of group-based activities to promote peer support and accessibility and engagement with nature-based activities available in their area according to participant's preferences. A collaborative mapping of nature-based community assets will guide the group to the activities they want to approach and test."
32941322|NCT05488496|Active Comparator|Control arm|The control arm will receive individually usual care (e.g. the existing social prescription as available) and a list of community resources based in nature in the area. Usual care is the appropriate comparison rather than a placebo for complex interventions.
32941323|NCT00986947|Experimental|IvIg with Rituximab|
32941324|NCT05736224|Experimental|Sunscreen|Portion of skin covered by sunscreen.
32941325|NCT05736224|Other|No treatment control|Portion of skin not covered by sunscreen.
33091110|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
33404326|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
33091111|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
33091112|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
33091113|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
33091114|NCT00436098|Experimental|1|physical training
33091115|NCT00436098|No Intervention|2|
33091116|NCT00432198|Experimental|1|Oral
33091117|NCT00432198|Experimental|2|Oral
33091118|NCT00432198|Placebo Comparator|3|Oral
33306061|NCT03414034|Experimental|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
33306062|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
33306063|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
33306064|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
33306065|NCT04036630|Experimental|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306066|NCT04036630|Sham Comparator|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306067|NCT04036630|Experimental|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306068|NCT04036630|Sham Comparator|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306069|NCT04036630|Experimental|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306070|NCT04036630|Sham Comparator|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306071|NCT04036630|Experimental|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306072|NCT04036630|Active Comparator|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33306073|NCT04036630|Sham Comparator|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
33404327|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
32798968|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
32798969|NCT01424722|Experimental|ST Monitoring Feature|ST segment continous monitoring feature enabled and programmed ON
32900834|NCT05313204||Pregnant with Multiple Sclerosis|Pregnant individuals (> 13 weeks) with a Multiple Sclerosis diagnosis.
32900835|NCT05313204||Pregnant without Multiple Sclerosis|Pregnant individuals (> 13 weeks) without Multiple Sclerosis.
33091119|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
33091120|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
33091121|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
33091122|NCT00420563|Active Comparator|MEGESTROL|
33091123|NCT00432315|Experimental|1|Resectable NSCLC
33091124|NCT00432315|Experimental|2|Unresectable NSCSC
33091125|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
33091126|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
33091127|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
33091128|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
33091129|NCT00333827|Experimental|cell therapy|stem cell
33091130|NCT03278184|Sham Comparator|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
33091131|NCT03278184|Active Comparator|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
33091132|NCT03278184|Active Comparator|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
33091133|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
33091134|NCT04716374||Patients with epithelial ovarian cancer|Patients with epithelial ovarian adenocarcinoma with archival tumor tissue available for analysis were identified through the Hellenic Cooperative Oncology Group (HeCOG)'s tumor repository. Patients had received treatment at HeCOG-affiliated institutions following standard international guidelines.
33091135|NCT00438009|Experimental|CAVATAK|
33091136|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
32798970|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
32798971|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
32798972|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
32798973|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
32900836|NCT05313204||Postpartum with Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) with a Multiple Sclerosis diagnosis.
33091137|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
33091138|NCT04701528|Experimental|Voclosporin (VCS)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the experimental arm tacrolimus is switched to voclosporin 6 capsules (of 7.9 mg each) BID for a treatment period of minimal 56 days with a possible extension up to 1 year.~Safety drug monitoring will take place during the study to ensure that VCS trough levels are maintained between 30-60 ng/mL. If trough levels are not within these levels, dose adjustments will take place."
33091139|NCT04701528|Active Comparator|Tacrolimus (TAC)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the Active comparator arm tacrolimus dosage is maintained.~Safety drug monitoring will take place during the study to ensure that TAC trough levels are maintained between 3-7 ng/ml. If trough levels are not within these levels, dose adjustments will take place."
33091140|NCT00334100|Other|Arm 1|
33091141|NCT04701294|Experimental|Giomer Beautifil flow plusF03 Shofu-Japan|Giomer beautifil flow plusF03 shofu-Japan an application of flowable resin with sprg as a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the experiment.
33091142|NCT04701294|Active Comparator|Tetric N flow ivoclar vivadent-Germany|Tetric N flow ivoclar vivadent-Germany an application of flowable resin a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the comparator.
33091143|NCT00334139|Experimental|zoledronic acid|
33091144|NCT04702035|Experimental|iNPH patients|20 patients with completed diagnostics concerning NPH, in which the indication for implantation of a VP shunt for NPH treatment was found by the responsible surgeon independently from the study.
33091145|NCT04702035|Active Comparator|Healthy volunteers|20 volunteers, matched with group 1 concerning sex and age.
33091146|NCT04702035|Active Comparator|Young healthy volunteers|20 volunteers, matched with group 1 concerning sex only and between 18 and 40 years old.
33091147|NCT03279978|Experimental|BI 730357|
33091148|NCT03279978|Placebo Comparator|Placebo|
33091149|NCT00334217|Experimental|1|PSS CogRehab exercises
33091150|NCT00334217|No Intervention|2|On-line computer games
33091151|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
33091152|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
33091153|NCT00438087|Experimental|1|placebo versus methylprednisolone
33091154|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
33091155|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
33091156|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
33091157|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
33091158|NCT00438165|No Intervention|1|Control group
33091159|NCT00438165|Experimental|2|Nurse home visits
33091160|NCT04701879|Active Comparator|Spine decompression with core stability exercises|Interventions in experimental group includes Hot pack, Spinal decompression therapy and core stability exercises
33091161|NCT04701879|Experimental|Spine decompression|Intervention includesHot pack and spinal decompression therapy ..
33091162|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
33091163|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
33091164|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
33091165|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
33091166|NCT04716218|Placebo Comparator|neutral position|The initial percentage of glottic opening (POGO) by laryngoscopy was recorded in the ramped position. Thereafter, a second POGO (laryngeal view) was scored in the neutral position and then intubation was performed.
33091167|NCT04716218|Experimental|back up head elevated position|The initial POGO was recorded in the neutral position. The second POGO was scored in the ramped position and then the trachea was intubated.
33091168|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
33091169|NCT00334568|Experimental|Rosi XR|Rosi XR
33091170|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
33306074|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
33306075|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
33306076|NCT04227340|Experimental|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
33306077|NCT04489732|Experimental|Treatment with MSCs|A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia
33306078|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
33306079|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
33306080|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
33306081|NCT04033432|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay >= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
33306082|NCT04223830|Experimental|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
33306083|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
33306084|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
33306085|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
33306086|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
33306087|NCT05256628|Other|Early Weightbearing|Patients randomized to early weightbearing will be permitted to begin immediate postoperative weightbearing as tolerated with crutches for additional stability.
33306088|NCT05256628|Other|Protected Weightbearing|Patients in the protected weightbearing group will be instructed to be touch weightbearing for a period of 6-weeks postoperatively before commencing to be weightbearing as tolerated.
33306089|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
33306090|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
33306091|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
33306092|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
33306093|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
33306094|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
33306095|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
33306096|NCT03751696|Active Comparator|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
32900837|NCT05313204||Postpartum without Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) without Multiple Sclerosis.
33091171|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
33091172|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
33091173|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
33091174|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
33091175|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
33091176|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
33091177|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
33091178|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
32798974|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
33091179|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
32798975|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
33091180|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
33091181|NCT04701606|Experimental|Artecom® (pyronaridine-artesunate)|Artecom® is treated orally once a day for 3 consecutive days.
33091182|NCT04701606|Placebo Comparator|Placebo|Placebo is treated orally once a day for 3 consecutive days.
33091183|NCT00334685|Experimental|[S,S]-Reboxetine + Pregabalin|
33091184|NCT00334685|Active Comparator|Pregabalin|
33091185|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
33091186|NCT00334724|Active Comparator|1|Home blood pressure group
33091187|NCT00334724|Active Comparator|2|Office blood pressure group
33091188|NCT04716062||subjects who underwent open-air surgery|Fifty-one (37%) out of 138 subjects underwent open-air surgery.
33091189|NCT04716062||subjects underwent laparoscopic-assisted surgery|A total of 87 (63%) out of 138 subjects underwent laparoscopic-assisted surgery.
33306097|NCT05358106|Active Comparator|AntiBKV neutralising antibody|AntiBKV infused i.v. over 30 minutes. Infusion parameters may be adjusted to bodyweight so that infusion rate does not exceed 60mg/kg per hour. AntiBKV will be administered as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2 (100, 500, 1000 or 2000 mg).
33306098|NCT05358106|Placebo Comparator|Placebo|Solution containing no active excipients, infused i.v. over 30 minutes as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2.
33306099|NCT04476784|Other|LID018869, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
33306100|NCT04476784|Other|Biofinity, then LID018869|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
33306101|NCT04026568|Experimental|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
33306102|NCT04026568|Placebo Comparator|Placebo|Opaque capsule identical looking to the 4AP placebo pill
33306103|NCT04025632|Experimental|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
33306104|NCT04025632|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection
33306105|NCT04024228|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
33306106|NCT04024228|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
33306107|NCT04023994|Placebo Comparator|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
33091190|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
33091191|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
33091192|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
33091193|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
33091194|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
33306108|NCT04023994|Experimental|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
33306109|NCT04023994|Experimental|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
33306110|NCT04023994|Experimental|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
33306111|NCT04023994|Experimental|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
33306112|NCT04023994|Experimental|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
33306113|NCT04023682|Other|Anesthesia Provider hands|"Each provider will serve as their own control.~Control phase is at baseline using standard hygiene practices.~Intervention phase will include the addition of Provodine hand sanitizer"
33306114|NCT04018612|Active Comparator|High Dose Acetaminophen|High Dose Acetaminophen Post Op
33306115|NCT04018612|Active Comparator|Low Dose Acetaminophen|Low Dose Acetaminophen Post Op
33306116|NCT04018612|Placebo Comparator|Placebo|Placebo Post Op
33306117|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
33306118|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
33306119|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
33306120|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
33306121|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
33306122|NCT03395080|Experimental|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
33306123|NCT03395080|Experimental|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
33091195|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
33091196|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
33306124|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
33306125|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
32798976|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
32798977|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~100 mg BID~150 mg BID~100 mg BID~100 mg and 150 mg BID~150 mg capsules BID~Safety Follow-up Phase:~Initial dose: ~84 doses Maintenance dose-Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
33306126|NCT04209400|Experimental|Sci-B-Vac®|The 3-antigen HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
33306127|NCT04209400|Active Comparator|Engerix-B®|The single-antigen HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
33306128|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
32798978|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~2.5 g of 1% transdermal T-gel applied QD~5 g of 1% transdermal T-gel applied QD~7.5 g of 1% transdermal T-gel applied QD~10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: ~42 doses Maintenance dose-Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
33306129|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
33306130|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
33306131|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
33306132|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
33306133|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
33306134|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
33306135|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
33306136|NCT05226520|Experimental|Probiotic NCC3001|Sachets of NCC3001 and excipient (maltodextrin) to be administered orally every day for 6 weeks
33306137|NCT05226520|Placebo Comparator|Matched Placebo Comparator|Sachets of matching placebo containing maltodextrin, yeast extract, cystein HCl and pea flour to be administered orally every day for 6 weeks
33306138|NCT04195828|Experimental|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
33306139|NCT04195828|Active Comparator|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
33306140|NCT05163496|Experimental|Psilocybin arm|psychedelic assisted psychotherapy + 25mg psilocybin
33306141|NCT05163496|Active Comparator|Placebo|Psychedelic assisted psychotherapy + 250mg niacin
33306142|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
33306143|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
32798979|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
32798980|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
32798981|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
32798982|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
32900838|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
32900839|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
33306144|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
33306145|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
33091197|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
33091198|NCT00436995|Other|Single|
33091199|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
33091200|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
33306146|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
33306147|NCT04191148|Experimental|LBP-EC01|crPhage cocktail
32900840|NCT00371540|No Intervention|I|Routine care in the clinic
32900841|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
33306148|NCT04191148|Placebo Comparator|Placebo|Lactated Ringer's solution, injection, USP
33306149|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
33306150|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
33306151|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
33306152|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
33306153|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
33306154|NCT05069896|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
33306155|NCT05069896|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by SC via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
33306156|NCT01562626|Experimental|Dose escalation|
33091201|NCT04716179|Experimental|Patients with COVID-19|Patients with confirmed COVID-19 infection
33306157|NCT04470622|Experimental|Treatment Group 1|Aprepitant injectable emulsion.
33306158|NCT04470622|Placebo Comparator|Treatment Group 2|Saline placebo.
33306159|NCT04466566|Placebo Comparator|Saline|Saline will be infused during the study
33306160|NCT04466566|Active Comparator|Exendin-9,39|Exendin-9,39 will be infused during the study
33306161|NCT04465630|Other|Pseudophakic eyes with Open Angle Glaucoma|Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
33306162|NCT04182880|Placebo Comparator|Placebo|Placebo
33306163|NCT04182880|Experimental|CPL-01|CPL-01
33306164|NCT04465396|Experimental|Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)|Teduglutide, 3 mg, subcutaneous (SC) injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A1), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B1). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants with >=40.0 kg to <=75.0 kg of weight were included in Cohort 1.
32900842|NCT04248738|Experimental|SocNSuppR|Inpatient teams systematically provided with information about patients' social needs and supportive resources.
32900843|NCT05345886|Experimental|Hippotherapy|The experimental group will receive 30 minutes of hippotherapy once a week for 12 weeks.
32900844|NCT05345886|No Intervention|Control|The control group will receive its rehabilitation care
33091202|NCT04716179|Other|Healthy participants|The controlled group with healthy participants without COVID-19 infection.
33091203|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
33306165|NCT04465396|Experimental|Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)|Teduglutide, 3 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B1), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A1). A Washout Period of 7 days was maintained between the Treatment Periods 1 and 2. Participants with >=40.0 kg to <=75.0 kg of weight were included in Cohort 1.
33306166|NCT04465396|Experimental|Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)|Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants >75.0 kg to <=120.0 kg of weight were included in Cohort 2.
33306167|NCT04465396|Experimental|Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)|Teduglutide, 4 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B2), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants >75.0 kg to <=120.0 kg of weight were included in Cohort 2.
33306168|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
33306169|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.~Diagnostic Test: Contrast-enhanced Ultrasound"
33306170|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
33091204|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
33091205|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
33091206|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
33091207|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
33091208|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
33306171|NCT03999892|Experimental|Pilot weight management module|Consumers with serious mental illness who attend a psychiatric rehabilitation program will participate in a pilot of modules of a group-based diet and physical activity program. Staff/ peer leaders a psychiatric rehabilitation program will observe sessions.
33306172|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306173|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306174|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306175|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306176|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306177|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
33306178|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
33091209|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
33306179|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
33306180|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
33306181|NCT03994120|Active Comparator|Motor Cortex rTMS|Motor Cortex rTMS
33306182|NCT03994120|Active Comparator|PPC rTMS|PPC rTMS
33306183|NCT03994120|Placebo Comparator|vertex rTMS|vertex rTMS
33306184|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
33306185|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
33306186|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
33306187|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
33306188|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
33306189|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
33306190|NCT03746392|Experimental|Jumpstart Intervention|
33306191|NCT03746392|No Intervention|Usual Care|
33306192|NCT03743896|No Intervention|Control group|No intervention
33306193|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
33306194|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
33306195|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
33306196|NCT04175392|Active Comparator|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
33306197|NCT04175392|Placebo Comparator|Control Group: Placebo|Placebo Capsule Once Daily
33306198|NCT01562938|Placebo Comparator|Placebo|Placebo
33306199|NCT01562938|Active Comparator|MEDI-557 low-dose|
33306200|NCT01562938|Active Comparator|MEDI-557 high-dose|
33306201|NCT03737422|Active Comparator|hesperidin and flaxseed|
33306202|NCT03737422|Placebo Comparator|control|
33306203|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
33306204|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
33306205|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
33306206|NCT03986866|No Intervention|No Video|Patients are not shown the informational video on the safe usage of opioids.
33306207|NCT03986866|Experimental|Video|Patients are shown an informational video on the safe usage of opioids.
33091210|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
33091211|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
33091212|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
33091213|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
33091214|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
33091215|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
32941326|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
33091216|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
32941327|NCT05488340|Experimental|Part 1- Arm 4 (previously 1)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10^11 PFU) and oral TMP/SMX on D1 through D3.
32941328|NCT05488340|Experimental|Part 1- Arm 5 (previously 2)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10^10 PFU) and oral TMP/SMX on D1 through D3.
32941329|NCT05488340|Experimental|Part 1- Arm 6 (previously 3)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 infusion (1x10^12 PFU) and oral TMP/SMX on D1 through D3.
32941330|NCT05488340|Experimental|Part 2: LBP-EC01|LBP-EC01 given by dose regimen selected from Part 1 and oral TMP/SMX.
32941331|NCT05488340|Placebo Comparator|Part 2: Placebo|Placebo given by dose regimen selected from Part 1 and oral TMP/SMX.
32941332|NCT05482802|Active Comparator|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short-lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
32941333|NCT05482802|Placebo Comparator|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
33091217|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
33091218|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
33091219|NCT00437424|Experimental|1|
33091220|NCT00335348|Experimental|Bortezomib and Dexamethasone|
33091221|NCT00437463|Experimental|1|Ramipril
33091222|NCT00437463|No Intervention|2|
33091223|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
33091224|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
33091225|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
33091226|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
33091227|NCT00420680|Placebo Comparator|Arm 3|Placebo
33091228|NCT04701567||Liver disease|
33091229|NCT04701567||Pancreatic disease|
33091230|NCT00420758|No Intervention|Control|
33091231|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
33091232|NCT00420758|Experimental|CSB|Corn-soy blend supplement
33091233|NCT00437619|Experimental|1|
33091234|NCT00437736|Experimental|Single arm dose escalation|
33091235|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
33091236|NCT00437892|Active Comparator|lipid lowering diet|
33091237|NCT00437931||A|patients with subclinical hypothyroidism
33091238|NCT00437931||B|patients with subclinical hyperthyroidism
33091239|NCT00437931||C|patient with normal thyroid function.
33091240|NCT00437970|Active Comparator|A|Arm A- Metformin
33091241|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
33091242|NCT03279003|Experimental|Light-emitting diode therapy|Exposure to LED light
33091243|NCT04716140|No Intervention|MTP1 joint with no cartillage laesion or grade I|Patients in whom no treatment of the cartilage lesions is performed: these patients have no cartilage lesion or a grade I cartilage lesion at the MTP I joint that has been found peroperatively. The degree of the cartilage lesions will be determined on the basis of the ICRS scale and an MS Hololens.
33091244|NCT04716140|No Intervention|MTP1 joint with cartillage laesion > grade I - non treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the no treatment group
33091245|NCT04716140|Experimental|MTP1 joint with cartillage laesion > grade I - treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the treatment group. They will be treated through debridement of the lesion and microfracture.
33091246|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
33091247|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
33091248|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
33091249|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
32941334|NCT05213000|Experimental|Exercise post-immunization|After the mRNA-based COVID-19 vaccine is received (either initial immunization or booster dose- 3rd dose), a supervised 90 minute light to moderate exercise session will take place.
33306208|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
33306209|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
33306210|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
33306211|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
33306212|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
33306213|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
33306214|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
33306215|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
33306216|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
33306217|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
33306218|NCT05006248|Active Comparator|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions.
33306219|NCT05006248|Experimental|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
33306220|NCT05006248|Experimental|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
33306221|NCT05006092|Experimental|surveillance endoscopy with CADe support|Endoscopy perfomed with CADe support.
33306222|NCT05006092|No Intervention|conventional surveillance endoscopy|Endoscopy perfomed without CADe support.
33306223|NCT05668546|Experimental|surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
33306224|NCT05668546|Experimental|non surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
33306225|NCT03980938|Experimental|neflamapimod first|"neflamapimod in Treatment Period 1, placebo in Treatment Period 2~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food."
33306226|NCT03980938|Placebo Comparator|placebo first|"placebo in Treatment Period 1, neflamapimod in Treatment Period 2~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food."
33306227|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
33306228|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
33306229|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection
33306230|NCT03108352|Sham Comparator|Sham Comparator|sham / Conbercept ophthalmic injection
33306231|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
33306232|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
33306233|NCT03751150|No Intervention|Control|Normal training, no intervention
33306234|NCT03751150|Experimental|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
33306235|NCT03656692|Other|Acthar Gel|Participants received Acthar 1 mL (80 units [U]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
33306236|NCT04439266|Experimental|Treatment (crizotinib)|Patients receive crizotinib 250mg PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
33306237|NCT03751072||Relapse/Refractory|
33306238|NCT03751072||MRD positive|
33306239|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
33306240|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
33306241|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
33306242|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
32941335|NCT05213000|No Intervention|Daily routine as usual (control)|After the mRNA-based COVID-19 vaccine is received (either initial immunization or booster dose), participants will be asked to go about their daily routine as usual, but avoid exercise for that day.
32941336|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
33306243|NCT03736642||restrictive anorexia nervosa with hunger|
33306244|NCT03736642||restrictive anorexia nervosa without hunger|
33306245|NCT03736642||constitutional thinness|
33306246|NCT03736642||control subjects without eating disorders|
33306247|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
33306248|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
33306249|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
33306250|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
33306251|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
33306252|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
33306253|NCT01562080|Placebo Comparator|microcrystalline cellulose|
33306254|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator~Route of Administration:~Intratumoral injection of cutaneous, subcutaneous or nodal lesions~Mechanism of Action:~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.~Physiological Effect:~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
33306255|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
33306256|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
33306257|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
33306258|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
33306259|NCT00095238|Active Comparator|1|
33306260|NCT00095238|Placebo Comparator|2|
33306261|NCT01083888|Experimental|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
33306262|NCT03962478|Experimental|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
33306263|NCT03962478|Active Comparator|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
33306264|NCT01087008|Experimental|Zoledronate acid|
32941337|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
33091250|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
33306265|NCT01087008|Other|No treatment control|
33306266|NCT01087086|Experimental|Crononutrition|"Dietary pattern:~Personalized diet~Caloric restriction (-30% Total energy intake)~High adherence to the Mediterranean Diet~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~Low glycemic index/load~Increased antioxidant capacity of the diet"
33306267|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:~Personalized diet~Caloric diet (-30% Total energy intake)~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
33306268|NCT01084044|Experimental|ulinastatin|
33306269|NCT01084044|Active Comparator|saline solution|
33306270|NCT01084044|Placebo Comparator|Sugar pill|
33306271|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
33306272|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
33306273|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
33306274|NCT01090362||Cohort 4|Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
33306275|NCT01090362||Cohort 5|Final cohort completed with 12,186 patients enrolled.
33306276|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
33306277|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
33306278|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
33306279|NCT00082368|Experimental|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
33306280|NCT03960216|Sham Comparator|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
33306281|NCT03960216|Experimental|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
33306282|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
32941338|NCT05203172|Experimental|Binimetinib only treatment|For those participants receiving binimetinib treatment in parent studies
33306283|NCT01090596|Active Comparator|Naproxen-Treated|
33306284|NCT01090596|Placebo Comparator|placebo|
33306285|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
33306286|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
33306287|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
33306288|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
33306289|NCT01084356||thyroid|patients admitted for Tc thyroid scan
33306290|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
32941339|NCT05203172|Experimental|Encorafenib only Treatment|For those participants receiving encorafenib only treatment in parent studies
32941340|NCT05203172|Experimental|Encorafenib & Binimetinib Treatment|For those participants receiving encorafenib & binimetinib treatment in parent studies.
33306291|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
33306292|NCT03957798|No Intervention|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
33306293|NCT03957798|Experimental|Intervention (Treatment as usual + game)|
33306294|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
33091251|NCT00336245|Active Comparator|Hormonal Contraception|
33306295|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
33306296|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
33306297|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
33306298|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
33306299|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
33306300|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
33306301|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
33306302|NCT00094770|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
33306303|NCT00094770|Active Comparator|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
33306304|NCT00069576|Active Comparator|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
33306305|NCT00069576|No Intervention|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
33306306|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
33306307|NCT01087398|Experimental|Intervention|
33306308|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
33306309|NCT00069264|Experimental|E7389|
33306310|NCT00069108|Experimental|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m^2 intravenous (IV) infusion over 2 hours (every 3 weeks [Day 1]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
33306311|NCT00069108|Active Comparator|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin [LV] and 5-fluorouracil [5-FU] combination). Oxaliplatin was administered as an 85 mg/m^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m^2 over 2 hours followed by 5-FU, given as 400mg/m^2 bolus injection over 2-4 minutes, and then as a 600 mg/m^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
33306312|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
33306313|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
33306314|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
33306315|NCT00094536|Experimental|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
33306316|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
33306317|NCT01040429|Active Comparator|Clonidine capsula|
33306318|NCT01040429|Placebo Comparator|Lactose capsula|
33306319|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
33306320|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
32798983|NCT01753401|Experimental|Period 2: Placebo/Acthar|Participants receive Placebo in Part 1, but after completion of Week 8 in the double-blind phase, patients who received Placebo may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen during Part 2 may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
32900845|NCT05555394|Experimental|Basic Body Awareness Therapy|the Basic Body Awareness Therapy is usual therapy of physiotherapy in mental health in nord europe. BBAT is based in twelve movements and massage that improve the movements quality of patient, also improves other movement qualities like biomechanical, physiologic, socio-cultural and existential
33306321|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
33306322|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
33306323|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
33091252|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
33091253|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
33091254|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
33091255|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
33091256|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
33091257|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
33102464|NCT03792737|Active Comparator|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
33102465|NCT04686942||Before sonazoid|US detection liver metastases before sonazoid
33306324|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
33102466|NCT04686942||After sonazoid|US detection liver metastases after sonazoid
33306325|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
33306326|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
33306327|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
33306328|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
33306329|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
33306330|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
33306331|NCT03908021||children with type 1 diabetes mellitus|Saliva from 50 children ages 5 to 15 years old who had been diagnosed with type 1 diabetes mellitus and are followed at the Pediatric Endocrinology Clinic, Hadassah University Hospital Mt. Scopus and Ein Kerem, Jerusalem, Isreal,
33306332|NCT03908021||Control|50 healthy children, preferably their siblings, matched in age and gender.
33306333|NCT00404495|Experimental|Temozolomide + Irinotecan|
33306334|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
33306335|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
33306336|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
33306337|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
33306338|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
32798984|NCT01753401|Experimental|Period 2: Acthar/Acthar|After completion of Week 8 in the double-blind phase, patients who received Acthar may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
32798985|NCT01753401|Placebo Comparator|Period 1: Placebo|Participants receive matching placebo (in 0.5 mL daily or in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
32798986|NCT01753401|Experimental|Period 1: Acthar|Participants receive Acthar (40 units in 0.5 mL daily or 80 units in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
32798987|NCT01618916|Experimental|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
32798988|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
32798989|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
32798990|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
32798991|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
32798992|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
32798993|NCT01753323|Experimental|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
32798994|NCT01753323|Experimental|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
32798995|NCT01753323|Experimental|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
32798996|NCT01894568|Experimental|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
32798997|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
32798998|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
32798999|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
32799000|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
32799001|NCT01752933|Experimental|SGI-110|SGI-110 administered subcutaneously (SC) daily on Days 1 - 5 every 28 days
32799002|NCT01752855|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
32799003|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
32799004|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
32799005|NCT01402492|Active Comparator|PLB+XR-NTX|naltrexone for 8 weeks of treatment
32799006|NCT01402102|Experimental|Aged garlic powder|
32799007|NCT01402102|Placebo Comparator|Placebo|
32799008|NCT04029220|Experimental|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
32799009|NCT04029220|Active Comparator|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
32799010|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
32799011|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
32799012|NCT04042168|Experimental|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
32799013|NCT04026334|Experimental|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
32799014|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
32799015|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
32799016|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
32799017|NCT01780935|Experimental|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
33091258|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
33091259|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
33306339|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
33306340|NCT00409175|Experimental|1.|Fx-1006A
33306341|NCT00409175|Placebo Comparator|2.|Placebo
33306342|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
33306343|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
33306344|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
33306345|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
33306346|NCT01040507||primary laparoscopic gastric bypass|
33306347|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
33306348|NCT01040039||HCV+HIV+|
33306349|NCT01040039||HCV+HIV-|
33306350|NCT01040117|Experimental|Sensory-motor Integration Training|
33306351|NCT01040117|Active Comparator|Conventional neurorehabilitation|
33306352|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
33306353|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
33306354|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
33306355|NCT01040741||Group 1: 6-23 months|
33306356|NCT01040741||Group 2: 2-8 years|
33306357|NCT01040741||Group 3: 9-17 years|
33306358|NCT01040741||Group 4: 18-44 years|
33306359|NCT01040741||Group 5: 45-60 years|
33306360|NCT01040741||Group: >60 years|
33306361|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
33306362|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
33306363|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
33306364|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
33306365|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
33306366|NCT01040975|No Intervention|Control|MD receives Summary Report only
33306367|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
32799018|NCT01780935|Experimental|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
32799019|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
32799020|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
32799021|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
32799022|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
32799023|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
32799024|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
32799025|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
32799026|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
32799027|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
32799028|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
32799029|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
33091260|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
32799030|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
32799031|NCT01422538|Active Comparator|Group B|Sculptra® only
33091261|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
33091262|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
33091263|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
33091264|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
33091265|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
33102467|NCT03782519|Experimental|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
33102468|NCT03782519|Active Comparator|Conventional hemodialysis|Patients who will begin HD three times a week
33306368|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
32799032|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
32799033|NCT04026256|Active Comparator|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
32799034|NCT04026256|Active Comparator|Denosumab only|one dose of subcutaneous injection denosumab
32799035|NCT04026256|Active Comparator|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
32799036|NCT04025866|Active Comparator|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
32799037|NCT04025866|Active Comparator|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
32799038|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
32799039|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
32799040|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
32799041|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
32799042|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
32799043|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
32799044|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
32799045|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
32799046|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
32799047|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
32799048|NCT01400698|Other|Observation only|
32799049|NCT04041622|Other|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
32799050|NCT01890746|Experimental|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
32799051|NCT01890746|Placebo Comparator|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
32799052|NCT04614350|Experimental|A-Active|Markman Biologics microsurfaced ADM
32799053|NCT04614350|Active Comparator|B-Control|AlloDerm ADM
32799054|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
32799055|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
32799056|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
32799057|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
32799058|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
32799059|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
32799060|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
32799061|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
32799062|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
32799063|NCT01421134|Placebo Comparator|Placebo|Placebo
32799064|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
33306369|NCT00408629|Experimental|adalimumab group|
33306370|NCT00408629|Experimental|placebo group|
32799065|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
32799066|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
33306371|NCT00408317|Experimental|Ultrase® MT20|
32799067|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
32799068|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
33306372|NCT00408317|Placebo Comparator|Placebo|
32799069|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
32799070|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
32799071|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
32799072|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
32799073|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
32941341|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Ribociclib|For those participants receiving treatment of encorafenib & binimetinib & ribociclib in parent studies
32941342|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Cetuximab|For those participants receiving treatment of encorafenib & binimetinib & cetuximab in parent studies
32941343|NCT04829318|Experimental|Esketamine|Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. The duration of the study participation is 2 years or when esketamine is commercially available.
33306373|NCT01041131||Failed and/or Complicated VBG|
33306374|NCT00112502|Active Comparator|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.
33306375|NCT00112502|Experimental|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
33306376|NCT00112502|Experimental|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.
33306377|NCT00112502|Experimental|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
33306378|NCT00112502|Experimental|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
33306379|NCT00112502|Experimental|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
33306380|NCT00112502|Experimental|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
33306381|NCT00112502|Experimental|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
33306382|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
33306383|NCT01080170||Control group - 2|Healthy controls.
33306384|NCT03965546|Experimental|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
33306385|NCT03965546|Experimental|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
33306386|NCT03965546|Experimental|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
33306387|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
33306388|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
33306389|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
33306390|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
33306391|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
33306392|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
33306393|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
33306394|NCT01083992|Other|Galvus|vitagliptin as monotherapy
33306395|NCT01084070|Experimental|Early oral feeding|
33306396|NCT01084070|Active Comparator|Traditional Care|
33306397|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
33306398|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
33306399|NCT01084304||Active|Use of ovulation tests to aid conception
33306400|NCT01084304||Control|No ovulation tests to aid conception
33306401|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
33306402|NCT01078532|Other|Passive PHR|Usual PHR Care
33306403|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
33306404|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
33306405|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
33306406|NCT01078610||Psoriatic arthritis patients|
33306407|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
33306408|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
33306409|NCT03964766|Experimental|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
33091266|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
33091267|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
33091268|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
33091269|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
33091270|NCT00421239||A|
33091271|NCT00421239||B|
33091272|NCT00421278|Experimental|1|Arm 1: Drug
33091273|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
33091274|NCT04699734|Active Comparator|Xylocaine|Nerve block
33091275|NCT04699734|Placebo Comparator|Isotonic saline|Nerve block
33091276|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
33091277|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
33091278|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
33091279|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
33091280|NCT00421356||Non amputee control group|Healthy, non-amputee control group
33091281|NCT04699851|Experimental|Intervention|The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey.
33091282|NCT04699851|Active Comparator|Control|The control group will receive general recommendations about health prevention in a pandemic.
33091283|NCT00337376|Experimental|1|
33091284|NCT04699968|Experimental|Treatment group A|
33091285|NCT04699968|Experimental|Treatment group B|
33091286|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
33091287|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
33091288|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
33091289|NCT00337493|Experimental|1|
33091290|NCT00337493|Experimental|2|
33091291|NCT00337493|Experimental|3|
33091292|NCT04715789|Experimental|physical therapy intervention|"core stability exercises:~Multifidus exercises~Frontal & Side Plank exercise~Pelvic floor exercises~abdominal exercises~Strengthening exercises~Bridging~straight leg raise~gluteus medius strength~gluteus maximus strengthening for about 20 min to 30 min to strength back and proximal hip control muscles"
33091293|NCT04715789|Experimental|graded exposure and graded activity in addition to phycal therapy intervention|"Graded exposure:This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities for about 10 min before physical therapy program (strengthening)"
33091294|NCT00337649|Experimental|1|
33091295|NCT00444834|Experimental|1|Egalet carvedilol
33091296|NCT00444834|Active Comparator|2|Coreg
33091297|NCT04698486|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified no steatosis"
33091298|NCT04698486|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified steatosis"
33091299|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
33091300|NCT00337766|Placebo Comparator|Placebo|
33091301|NCT00444873|Experimental|28 day dose interval|
33091302|NCT00444873|Experimental|42 day dose interval|
33091303|NCT00444873|Experimental|56 day dose interval|
33091304|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
33091305|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
33091306|NCT01580397|Experimental|INNO-206|
33091307|NCT04715594||CONNECT DES Registrty|
33091308|NCT04699617|Experimental|Active arm|The active arm will include 3 days a week of training with the Dolphin 2.0 for 12 consecutive weeks. Each session will have the duration of 60 minutes.
33091309|NCT04699617|Active Comparator|Delayed-start control arm|The delayed-start control arm will have six-weeks of physiotherapy specialized for PD (3 times/week, 60 minutes/session) and six-weeks of 3 days a week of training with the Dolphin 2.0, with sessions of 60 minutes.
33102469|NCT05381883|Other|Epidemiology|"Participants will answer sociodemographic questions, questions about the experience of potentially traumatic lifelong events, the presence of a known psychological or medical disorder and the taking of drug treatment.~These questionnaires will make it possible to detect the main psychological disorders (post-traumatic stress disorder, depression, panic disorder, generalized anxiety disorder), to evaluate coping strategies, the presence of professional exhaustion (burnout), the consumption of psychoactive substances and quality of life."
33306410|NCT03964766|Active Comparator|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
32799074|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
33306411|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
33306412|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
32799075|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
32799076|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
33306413|NCT03965624|Experimental|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
33306414|NCT00111800|Placebo Comparator|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
33306415|NCT00111800|Experimental|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
33306416|NCT00111800|Experimental|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
33306417|NCT00111800|Experimental|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
33306418|NCT00111800|Experimental|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
33306419|NCT00111800|Experimental|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
33306420|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
33306421|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
33306422|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
33306423|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
33306424|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
33306425|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
33306426|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
33306427|NCT00094328|Other|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
33306428|NCT00094172|Experimental|Atorvastatin|80 mg/day
33306429|NCT00094172|Placebo Comparator|Placebo|Once daily.
33306430|NCT01084616||Vaginal Dryness|
33306431|NCT01084616||Non-vaginal dryness|
33306432|NCT00094094|Experimental|Axitinib|AG-013736 is a vascular endothelial growth factor [VEGF] inhibitor
33306433|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
33306434|NCT03962816|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
33306435|NCT03962816|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
33306436|NCT03962816|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
33091310|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
33091311|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
33091312|NCT00338195|No Intervention|Delayed intervention control|
33091313|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
33091314|NCT00451308|Active Comparator|2|Foley balloon with 30cc
33091315|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
33091316|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
33306437|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
32799077|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
33091317|NCT00338273|Active Comparator|A1|
33306438|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
33306439|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
33306440|NCT01084850||Control|Patients with no diabetes
32746478|NCT05472831|Experimental|BAILAMOS dance program plus MIND diet|BAILAMOS dance program plus MIND diet: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute MIND diet session per week.
32746479|NCT05472831|Experimental|BAILAMOS dance program plus Health Education|BAILAMOS dance program plus Health Education: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute health education session per week.
32746480|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
33306441|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
33306442|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
33306443|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
33306444|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
32746481|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
33091318|NCT00338273|Placebo Comparator|A2|
33091319|NCT04715672||copper|
33091320|NCT04715672||no-copper|
33091321|NCT04715672||normal|
33091322|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
33091323|NCT03277833|Placebo Comparator|Placebo|Placebo
33091324|NCT00338312|Placebo Comparator|1|Placebo patch
33306445|NCT03965312|Experimental|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
33306446|NCT00110396|Experimental|Rebif New Formulation Cohort|
33306447|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
33306448|NCT00093470|Experimental|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33306449|NCT00093470|Other|Arm B (clinical observation)|Patients undergo observation only.
33306450|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
33306451|NCT00094458|Experimental|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
33306452|NCT00094458|Experimental|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
33306453|NCT00094458|Experimental|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
32746482|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
32746483|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
32746484|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
33091325|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
33091326|NCT00451425|No Intervention|control|standard maternity care
33091327|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
33306454|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
33306455|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
33306456|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
33306457|NCT01084512||Healthy group|control subjects
33306458|NCT01084512||Paraplegic group|Paraplegic subjects
33306459|NCT01084512||Tetraplegic group|tetraplegic subjects
33306460|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
33306461|NCT03961464|Experimental|d-cycloserine|oral, capsule, 250 mg
33306462|NCT03961464|Experimental|Placebo|oral, capsule, lactose
33306463|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
33091328|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
33091329|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
33306464|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
33306465|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
33306466|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
33306467|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
33306468|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
33306469|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
33306470|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
33091330|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
33091331|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
33102470|NCT03771989|Active Comparator|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
33102471|NCT03771989|Placebo Comparator|Control|Patients are treated with an intra articular injection with saline (placebo).
33306471|NCT00068406|Experimental|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
33306472|NCT00403559|Experimental|Elidel Cream (pimecrolimus)|Elidel Cream to be applied twice daily for 4 weeks
33306473|NCT00403559|Active Comparator|Ketoconazole Cream (Nizoral)|Ketoconazole Cream to be applied twice daily for 4 weeks
33306474|NCT01087710|Experimental|novel nutritional formula|
33306475|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
33306476|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
33306477|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
33306478|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
33306479|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
33306480|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
33091332|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
33306481|NCT00092534|Experimental|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
33306482|NCT00092534|Placebo Comparator|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
33306483|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
33306484|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
33306485|NCT00068250|Experimental|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
33306486|NCT00068250|Experimental|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
33306487|NCT00068250|Experimental|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
33306488|NCT00068250|Experimental|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
33306489|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
33306490|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
33306491|NCT00393887|Experimental|1|Biodesign IHM Graft placement
33306492|NCT00393887|Active Comparator|2|Polypropylene mesh placement
33306493|NCT03957720|Experimental|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
33306494|NCT03957720|Experimental|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
33306495|NCT03957720|Experimental|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
33306496|NCT03957720|Experimental|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
33306497|NCT03957720|Experimental|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
33102472|NCT03763136|Experimental|hPSC-CM Therapy|Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
33102473|NCT03763136|Sham Comparator|Control|Procedure: Coronary artery bypass grafting surgery only.
33306498|NCT03957720|Experimental|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
33306499|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
33306500|NCT00393029|Experimental|Patients with other metastatic cancers|
33306501|NCT00402233|Other|Placebo|
33306502|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
33306503|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
33306504|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
33306505|NCT03993431|Experimental|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
33091333|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
33091334|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
32799078|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
32799079|NCT05365984|Experimental|innavative modeled strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and end tidal carbon monoxide corrected for ambient carbon monoxide. Assessment result includes high risk, median risk, low risk and delayed discharge. Internet Plus technology is applied in follow-up management.
32799080|NCT05365984|No Intervention|traditional strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and the follow-up table advised by the Chinese guideline for neonatal hyperbilirubinemia. Assessment result includes high risk, median risk and low risk. Traditional outpatient is applied in follow-up management.
32799081|NCT01780545|Experimental|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
32799082|NCT01780545|Active Comparator|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
32799083|NCT01780389|Experimental|Milnacipran|Open-label flexibly dosed milnacipran
32799084|NCT01778985|Experimental|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
32799085|NCT01778985|Placebo Comparator|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
32799086|NCT01778751|No Intervention|Control|Veterans will receive diabetes educational materials and management per their primary provider
32799087|NCT01778751|Experimental|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 < 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
32799088|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
32799089|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
32799090|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
32799091|NCT01778127|Experimental|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
32799092|NCT01778127|Experimental|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
32799093|NCT01778127|Experimental|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
32799094|NCT01892540|Experimental|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
32799095|NCT01892540|Experimental|Cohort 2: New positioning device|
32799096|NCT01892540|Experimental|Cohort 3: Current positioning device until new is available|
32799097|NCT01399372|Active Comparator|Chemotherapy|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.
32799098|NCT01399372|Experimental|Chemotherapy + Low-Dose WBRT|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.
32799099|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
32799100|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
32799101|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
32799102|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
32799103|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
32799104|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
32799105|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
32799106|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
33091335|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
33091336|NCT00451503|Experimental|1|surgery
33091337|NCT00451620|Experimental|2.|GlucoNorm
33091338|NCT00451620|Experimental|1.|Glyburide
33091339|NCT00338858|Active Comparator|1|TD
33091340|NCT00338858|Experimental|2|TBI
33091341|NCT00338858|Experimental|a|Cerebral palsy
33091342|NCT04716023||Chronic Airflow obstruction / COVID-19|Patients with either chronic airflow obstruction of COVID-19
33091343|NCT00451776|Experimental|1|patients who received etomidate
32799107|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
32799108|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
33091344|NCT00451776|Active Comparator|2|patients who received propofol
33091345|NCT00445575|Experimental|1|treatment duration: 1 year
32799109|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
32799110|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
32799111|NCT01778049|Experimental|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
32799112|NCT01778049|Experimental|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
32799113|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
32799114|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
32799115|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
32799116|NCT01778049|Experimental|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
32799117|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
32799118|NCT01778049|Experimental|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
32799119|NCT01777581|Experimental|milnacipran|Milnacipran, flexibly dosed
32799120|NCT01777581|Placebo Comparator|Sugar pill (placebo)|Placebo
32799121|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.~Avonex once-weekly intramuscular (IM) injection up to Week 84."
32799122|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
32799123|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
32799124|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
32799125|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
32799126|NCT01751139|Other|Total Group|Subjects six months of age and older at the time of enrolment, recruited from randomly selected households originating from preselected mapped communities. Preferably the recruitment period occurred outside of the peak dengue transmission season, and continued until each site had reached its foreseen target. The expected period for recruiting the target sample size was approximately three months. Recruitment of replacement subjects was done during the low dengue transmission and the recruitment period depended on the number of subjects that need to be replaced. Enrolled subjects were subjects who either lived in households in study areas with support from the Family Health Physician Program (FHP) or the Larval Index Rapid Assay (LIRA) or with field research experience in the community (preferred) or where a similar system of mapped communities with potential for surveillance existed.
32799127|NCT04415138||Robotic-assisted Group|
32799128|NCT04415138||Video-assisted Group|
32799129|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
32799130|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
32799131|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
32799132|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
32799133|NCT01397890|Other|1|Add-on treatment
32799134|NCT01397890|Other|2|Add-on treatment
32799135|NCT01777269|Experimental|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
32799136|NCT01777269|Placebo Comparator|Sugar Pill|A capsule once daily during 12 months
33091346|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
33091347|NCT00445575|Experimental|3|duration treatment: 3 years
33091348|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
33091349|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
33091350|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
33091351|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
33091352|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
33091353|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
33091354|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
33091355|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
33091356|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
33091357|NCT00339014|Placebo Comparator|Group 7|
33091358|NCT04715828||"control arm fresh"|Fresh semen treated without irradiation before cryopreservation
33306506|NCT03993431|Active Comparator|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
32799137|NCT04616456|Experimental|Multiple System Atrophy (MSA)|Twenty to twenty-five subjects with probable MSA diagnosis will be recruited for this study. Each subject will undergo an [F-18]PBR06 PET and MRI scan at baseline, and will receive the experimental drug, verdiperstat (BHV-3241) under supervision of clinic staff. A follow-up [F-18]PBR06 PET and MRI scan will be performed after 6 months (26 weeks) of taking verdiperstat.
33306507|NCT01044017|Experimental|A|
32799138|NCT05365360|Sham Comparator|Sham LaserCap|Sham device
33306508|NCT01044017|Experimental|B|
33306509|NCT01044017|Placebo Comparator|C|
33306510|NCT00092456|Experimental|RotaTeq™ Lot 1|~8.81 X 10^7 IU/Dose of RotaTeq™
33306511|NCT00092456|Experimental|RotaTeq™ Lot 2|~8.01 X 10^7 IU/Dose of RotaTeq™
33306512|NCT00092456|Experimental|RotaTeq™ Lot 3|~6.91 X 10^7 IU/Dose of RotaTeq™
32799139|NCT05365360|Experimental|Lasercap SD|Low fluence LLLT
32799140|NCT05365360|Experimental|Lasercap HD+|High fluence LLLT
32799141|NCT05365282||Group A|Access pathway a. radialis (right or left) and neurophysiological measurements of the same hand (ipsilateral intervention group).
32799142|NCT05365282||Group B|Access pathway a.radialis (right or left) and neurophysiological measurements of opposite hand (contralateral intervention group).
32799143|NCT04016272|Experimental|Active tDCS|
32799144|NCT04016272|Placebo Comparator|Sham tDCS|
32799145|NCT04371250||Youth|Assessed group
32799146|NCT01751061|Experimental|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
32799147|NCT01751061|Active Comparator|Usual care|usual care in an intensive care unit setting
32799148|NCT04024696|Experimental|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
32799149|NCT01777191|Experimental|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
32799150|NCT01777191|Experimental|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
32799151|NCT01775787|Other|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
32799152|NCT01775787|Other|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
32799153|NCT01775553|Experimental|Carfilzomib|All patients will receive Carfilzomib
32799154|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32799155|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32799156|NCT01774929|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
32799157|NCT01888874|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
32799158|NCT01888874|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
32799159|NCT01888874|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
32799160|NCT01888874|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
32799161|NCT01888874|Experimental|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
32799162|NCT01888874|Experimental|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
32799163|NCT01888874|Experimental|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
32900846|NCT05555394|Active Comparator|Stretching group|"Stretching exercise will be developed in control group in order to blind the intervention of interest. It will consist in analytic stretching of trunk, upper and lower limb.~It will last around 45 min twice a week during 12 weeks."
33306513|NCT00092456|Placebo Comparator|Placebo|
33306514|NCT00067470|Placebo Comparator|Placebo|
33306515|NCT00067470|Active Comparator|rhASB|
33306516|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
33091359|NCT04715828||"control arm cryopreserved"|cryopreserved semen without irradiation (n=60)
33091360|NCT04715828||acute irradiation at low dose|Pelvis scanning : acute irradiation (1 or 2 second) using low dose (n=30),
33091361|NCT04715828||long irradiation at low dose|Bone scintigraphy : long irradiation (3h) using low dose (n=30),
33091362|NCT04715828||long irradiation at medium dose|Radioactive Iodine 131 therapy (RAT) applied for thyroid cancer : long irradiation (3h) using medium dose (n=60),
33091363|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
33306517|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
33306518|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
33306519|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
33306520|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
33306521|NCT00401375|Experimental|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
33306522|NCT00401375|Experimental|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
33306523|NCT00401375|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
33306524|NCT00400985|Other|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
33306525|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
33306526|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
33306527|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
33306528|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
32799164|NCT01749735|Experimental|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
32799165|NCT01749735|Sham Comparator|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
32799166|NCT01749033|Active Comparator|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA (Laryngeal Mask Airway)recommended in the LMA manual.
33091364|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
33091365|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
33091366|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
33091367|NCT00339092|Active Comparator|Control|Participants who receive standard care
33091368|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
32941344|NCT00539617|Experimental|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
33091369|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
33091370|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
33091371|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
33091372|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
33306529|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
33306530|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
33306531|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
33306532|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
33306533|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
33306534|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
33306535|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
33306536|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
33306537|NCT00091832|Experimental|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
33306538|NCT00091832|Experimental|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
33306539|NCT00091832|Experimental|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
33306540|NCT00091832|Active Comparator|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
33306541|NCT00091832|Experimental|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
33306542|NCT00091832|Experimental|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
33306543|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
33306544|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
32746485|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
32941345|NCT05182580|Experimental|Intervention Group|Autonomous AI results are used to evaluate if the participant needs to see the retina specialist (positive result) or not (negative result).
32941346|NCT05182580|No Intervention|Control Group|All participants see the retina specialist irrespective of the results of their autonomous AI evaluation.
32941347|NCT05467514|Experimental|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
32941348|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
32941349|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
32941350|NCT05456828|Experimental|ASKG712|Single or multiple ascending dose of ASKG712 by intravitreal injection
32941351|NCT04579640|No Intervention|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
32941352|NCT04579640|Experimental|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
32941353|NCT04579640|Experimental|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
32941354|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
32941355|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
32941356|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
32941357|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
32941358|NCT04579172|Experimental|Group A|Circular isthmic-cervical sutures
32941359|NCT04579172|Experimental|Group B|Resection of the infiltrated part of anterior uterine wall
32799167|NCT01749033|Active Comparator|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer
33091373|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
33091374|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
33091375|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
33091376|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
33306545|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
32799168|NCT01749033|Active Comparator|Group 3 ELL-PIC technique|Group 3 (ELL-PIC): Using the ELL-PIC technique.
32799169|NCT01774305|Experimental|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
32799170|NCT01774305|Placebo Comparator|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
32799171|NCT01737021|Experimental|Psycho-educational intervention|Psycho-education
32799172|NCT01737021|No Intervention|Treatment as usual|
33306546|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
32799173|NCT04562649|Experimental|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
32799174|NCT04562649|No Intervention|Control|Standard of care
32799175|NCT01397422|Placebo Comparator|Treatment A|
32799176|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
32799177|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
32799178|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
32799179|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
33306547|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
32799180|NCT01736553||Healthy controls|Healthy control infants
32799181|NCT01888640|Active Comparator|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
32799182|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
32799183|NCT01888640|No Intervention|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
32799184|NCT01736475|Experimental|Prophylaxis|
32799185|NCT01736475|Experimental|On-demand|
32799186|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
32799187|NCT01863680|Experimental|COL-1620|
32799188|NCT01747629|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
32799189|NCT01747629|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
33306548|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
33306549|NCT01044329|Active Comparator|Intravitreal bevacizumab|
33306550|NCT01044329|Active Comparator|Intravitreal triamcinolone|
33306551|NCT01018589|Experimental|A|Cicatrix cream
32799190|NCT04170920|Experimental|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
32799191|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
32799192|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
32799193|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
32799194|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
32799195|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
32799196|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Participants everyday use of prosthesis
32799197|NCT04616378|Experimental|Phase 2 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
32799198|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Participants everyday use of prosthesis
32799199|NCT04616378|Experimental|Phase 3 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
32799200|NCT04616378|Experimental|Phase 3 No Prosthesis|Participant performs tasks with no prosthetic device attached
32900847|NCT05345496||WORKERS GROUP|44 physiotherapists with a history of at least 1 painful episode of work-related thumb pain in the last 3 months will be enrolled.
32900848|NCT05345496||STUDENT GROUP|44 physiotherapy students in their first academic year will be enrolled.
32900849|NCT00373334|Experimental|1|
32900850|NCT00373334|Experimental|2|
32900851|NCT00373334|Sham Comparator|3|
33306552|NCT00091442|Experimental|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
33306553|NCT00091442|Active Comparator|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
33306554|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
33306555|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
33306556|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
33306557|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
33404328|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
33306558|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
33306559|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
33306560|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
33306561|NCT03965156|Active Comparator|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
33306562|NCT03965156|Active Comparator|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
33306563|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
33306564|NCT01080950||sepsis zinc vit. d|patients with sepsis
33306565|NCT00121238|Experimental|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA < 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
33306566|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
33306567|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
33306568|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33306569|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33306570|NCT03812510|Experimental|A-101|Topical Solution
33306571|NCT01583114|Experimental|perindopril|
33306572|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
33306573|NCT04258046|Experimental|Oral Trametinib|Patients will receive oral trametinib once daily
33306574|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
33091377|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
33306575|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
33306576|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
33306577|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
33306578|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
33306579|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
33306580|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
33306581|NCT00119678|Active Comparator|Abatacept + Prednisone|Double Blind Period
33306582|NCT00119678|Placebo Comparator|Placebo + Prednisone|Double Blind Period
33306583|NCT00119678|Experimental|Abatacept|Open Label
33306584|NCT00110084|Experimental|Nab-paclitaxel/Gemcitabine|
33306585|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
33306586|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
33306587|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
33306588|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
33306589|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
33306590|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
33306591|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
33306592|NCT00389519|Placebo Comparator|Placebo|once per day
33306593|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
33306594|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
33306595|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
33306596|NCT00389441|Experimental|A|
33306597|NCT01018667||CRT group|
33306598|NCT01018667||OPT group|
32941360|NCT05163938|Experimental|REThink therapeutic game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
33091378|NCT00339326||Controls without KS|Controls from Southern Italy.
33091379|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
33306599|NCT00118898|Experimental|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
33306600|NCT00118898|Experimental|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
33306601|NCT00118898|Experimental|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
33306602|NCT00118898|Experimental|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
33306603|NCT00118430|Experimental|Stepped Care|Stepped care group
33306604|NCT00118430|Active Comparator|Usual Care|Treatment as usual group
33306605|NCT00118430|No Intervention|No Treatment|Participants without depression group
33306606|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
33306607|NCT03962426|Active Comparator|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
33306608|NCT03962426|No Intervention|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
33306609|NCT01085708|Experimental|1|
33306610|NCT01085708|Experimental|2|
33306611|NCT01085708|Experimental|3|
33306612|NCT01085708|Active Comparator|4|
33306613|NCT01081106|Other|Low-Level Laser Therapy|
33306614|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
33306615|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
33306616|NCT00090584|Experimental|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
33306617|NCT00090584|Active Comparator|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
33306618|NCT01326884|Other|1|Endovascular Repair
33306619|NCT03965000||Patients|Patients carrying one or both mutations.
33306620|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
33306621|NCT01079468||Total Hip Arthroplasty|
33306622|NCT01079468||Total Hip Resurfacing Arthroplasty|
33306623|NCT01081184||primary Sjögren syndrome|
33306624|NCT01081184||Healthy volunteers|
33306625|NCT03964922|Experimental|immune escape mecanims|Cohort study with a representative sample of patients
33306626|NCT01079546||Sq.CC of head and neck TASMC|
33306627|NCT01079546||hadassa Jerusalem|
33306628|NCT01079546||sheba hospital|
33306629|NCT01079546||rambam Haifa|
33306630|NCT01079546||belinson Petah Tikva|
33306631|NCT01079546||Nazeret|
33306632|NCT01079546||soroka beer sheva|
33306633|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
33306634|NCT01079624|Placebo Comparator|Saline infusion|Control
33306635|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
33306636|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
33306637|NCT03670810|Experimental|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
33306638|NCT03670810|Experimental|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
32799201|NCT04616144|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity (far, intermediate, near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values. Fresh corneal lenticule implantation as allogenic implant that we took from myopic patients (-5.0D) to implant in hyperopic patients (+4.0 D +3.0cyl) according to high K2 values. The stromal pocket diameter was 8 mm, 4mm super incision and 130-µm cap thickness.
32799202|NCT04590404|Experimental|MIST (Metabolism-Informed Smoking Treatment)|At hospital discharge, participants randomized to the MIST precision care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescriptions will be informed by nicotine metabolism (i.e., NMR result) such that faster metabolizers are prescribed varenicline and slower metabolizers are prescribed NRT.
33091380|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
33091381|NCT00339365|Experimental|1|Promoting first relationships group
32799203|NCT04590404|Active Comparator|Usual Care|At hospital discharge, participants randomized to the Usual Care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescription will not be informed by nicotine metabolism.
32799204|NCT01886300||Cohort|
32799205|NCT01885208|Experimental|Semaglutide 1.0 mg|
32799206|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
32799207|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
32799208|NCT04599686|Active Comparator|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
32799209|NCT04599686|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
32799210|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
32799211|NCT01747551|Active Comparator|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
32799212|NCT01747551|Active Comparator|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
32799213|NCT01736397|Experimental|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
32799214|NCT01736397|Placebo Comparator|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
32799215|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
32799216|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
32799217|NCT01746225|Experimental|A: nab-Paclitaxel 150 mg/m2 days 1,15|"Arm A: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
32799218|NCT01746225|Experimental|B: nab-Paclitaxel 100 mg/m2 days 1,8,15|"Arm B: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
32941361|NCT05163938|Active Comparator|Treatment as usual|In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
32941362|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
32941363|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
32941364|NCT05453396|Experimental|Treatment (loncastuximab tesirine)|Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32941365|NCT00954187|Experimental|Gabapentin|Neurontin
32941366|NCT00954187|Experimental|Pregabalin|Lyrica
32941367|NCT04802018|Experimental|Monitored group|Monitoring of vital signs and following with the conventional telephone protocol
32941368|NCT04802018|No Intervention|Control group|Conventional telephone follow-up by health staff
32941369|NCT04796012|Experimental|Feasibility Cohort: Patients with relapsed or refractory solid tumors|Six (6) participants with relapsed or refractory solid tumor will be enrolled. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
33306639|NCT03670810|Placebo Comparator|Control 1 Sequence|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
33306640|NCT03670810|Placebo Comparator|Control 2 Sequence|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
33306641|NCT03670810|Experimental|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
33306642|NCT03670810|Experimental|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
33306643|NCT03670810|Placebo Comparator|Control 1 Sequence MEE|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
33306644|NCT03670810|Placebo Comparator|Control 2 Sequence MEE|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
33306645|NCT03670810|Experimental|Open Label Extension|Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
33404329|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
33306646|NCT01086098||All paced patients|
33306647|NCT03962192|Experimental|Survey tools|Survey instruments are shared with reviewers.
33306648|NCT01086176||Patient-control|
33306649|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
33306650|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
33306651|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
33091382|NCT00339365|Active Comparator|2|Early education support group
33091383|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
33306652|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
33306653|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
33306654|NCT03962270|Experimental|Treatment group|
33306655|NCT03962270|Sham Comparator|Control group|
33306656|NCT01811368|Experimental|Treatment (ibritumomab tiuxetan, allogeneic PBSCT)|"CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28."
33306657|NCT00089648|Experimental|1|
33306658|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
33306659|NCT00118040|Experimental|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
33306660|NCT00118040|Experimental|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
33306661|NCT00118040|Placebo Comparator|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
33306662|NCT03961958|No Intervention|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
33306663|NCT03961958|Experimental|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
33091384|NCT00452088|Active Comparator|2|Hepatitis B comprator group
32799219|NCT01746225|Experimental|C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22|"Arm C: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
32799220|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
32799221|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
32799222|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
32799223|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
33091385|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
33091386|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
33091387|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
33091388|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
33091389|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
33091390|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
33091391|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
33091392|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
33091393|NCT00339560||Controls without cancer|Hospital controls with cancer
32799224|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
33091394|NCT00446082|Experimental|SOM230 LAR|
33091395|NCT00339677||Volunteers|Volunteers
33404330|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
32799225|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
32799226|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
32799227|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
33091396|NCT03275376|Experimental|Statin treated group|
33091397|NCT03275376|Placebo Comparator|Control group|
33404331|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
33404332|NCT02459080|Active Comparator|TD-4208-1|88 mcg
32799228|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
32799229|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
32799230|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
32799231|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
32799232|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
32799233|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
32799234|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
33091398|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
33091399|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
33091400|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
33091401|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
33091402|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
33091403|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
33091404|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
33091405|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
33091406|NCT04698447|Experimental|Dietary Supplement blinded|20 subjects with the metabolic syndrome receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
33091407|NCT04698447|Placebo Comparator|Placebo blinded|20 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
33091408|NCT04698447|Active Comparator|Dietary Supplement open-label|20 healthy volunteers receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
33091409|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
33404333|NCT02459080|Active Comparator|TD-4208-2|175 mcg
33404334|NCT02459080|Placebo Comparator|Placebo|Placebo
32799235|NCT01734993|Experimental|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of >1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
33091410|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
33091411|NCT00340262||FIT Participants|
33091412|NCT04698408|Experimental|high-protein, carbohydrate-reduced diet|
33091413|NCT04698408|Active Comparator|Dutch Nutritional Guidelines|
33091414|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
33306664|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
33306665|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
33306666|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
33091415|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
33306667|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
33306668|NCT01018745|Experimental|BMS-907351 (XL184)|
33306669|NCT00085202|Experimental|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
33306670|NCT00085202|Experimental|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
33306671|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
33306672|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
33306673|NCT00117572|Active Comparator|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
33306674|NCT00117572|Active Comparator|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
33306675|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
33306676|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
33306677|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
33306678|NCT00117338|Placebo Comparator|1|Placebo
33306679|NCT00117338|Active Comparator|2|montelukast sodium
33306680|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33306681|NCT00387881|Placebo Comparator|Placebo|
33306682|NCT00387881|Experimental|Treximet|
33306683|NCT00084656|Experimental|Arm 1|
33306684|NCT00387725|Experimental|Group A|20ug Experimental
33306685|NCT00387725|Experimental|Group 2|60ug Experimental
33306686|NCT00387725|Experimental|Group 3|200ug Experimental
33306687|NCT00387725|Active Comparator|Group 4|Active comparator
33306688|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
33306689|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
33091416|NCT00340340||Cases|Newly diagnosed lung cancer cases
33091417|NCT00340340||Controls|Population-based controls
32799236|NCT01745367|Active Comparator|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
33091418|NCT00446394|Experimental|1|
33091419|NCT00446394|Active Comparator|2|
32799237|NCT01745367|Experimental|Tivo in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
32799238|NCT01733121|Experimental|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
33306690|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
32799239|NCT01733121|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
32799240|NCT01744977|Experimental|Adherence Packaging Intervention Group|[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
32799241|NCT01744977|No Intervention|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
32799242|NCT01383928|Experimental|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
32799243|NCT01383928|Experimental|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
32799244|NCT04023604|Active Comparator|Controlled diet with beef raised without antibiotics|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in RWA (raised without antibiotics) systems for three weeks.
32799245|NCT04023604|Experimental|Controlled diet with beef produced in conventional systems|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in conventional systems for three weeks.
32799246|NCT05365048|Experimental|Local Tailoring|The intervention arm will include 20 clinics randomly assigned to the intervention arm. All physicians, nurses, department administrator and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
32799247|NCT05365048|Experimental|Prescribed Strategy|The intervention arm will include 20 clinics randomly assigned to the intervention arm.. All physicians, nurses, department administrator,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
32799248|NCT05365048|No Intervention|Usual Care|The intervention arm will include 20 clinics randomly assigned to the usual care arm. All physicians, nurses, department administrators,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
32799249|NCT05368012|Other|Active MIDCAB|USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous nerve (5ml), Deep peroneal Nerve (5ml), Superficial peroneal nerve (5 ml), and Sural Nerve (5ml).
32799250|NCT05367388|Experimental|Treatment Sequence A/P|Subject will receive a single oral dose (200mg) of Treatment A on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment P.
32799251|NCT05367388|Experimental|Treatment Sequence P/A|Subject will receive a single oral dose (200mg) of Treatment P on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment A.
32799252|NCT05363176|Experimental|CBT for Treatment Seeking|CBT delivered over the course of 1, ~45 minute session delivered via telehealth.
32799253|NCT05363176|Active Comparator|Pain Treatment Education|Pain treatment education is delivered over the course of 1, ~45 minute session delivered via telehealth
32799254|NCT01606137|Experimental|GW-1000-02|Active treatment
32799255|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
33091420|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
33091421|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
33102474|NCT04687098|Other|Risk-adapted postremission treatment.|Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.
32799256|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
32799257|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
33091422|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
33091423|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
32799258|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
32799259|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
32799260|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
33091424|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
32799261|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
33091425|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
33091426|NCT03275025|Experimental|YRA-1909 low dose|
33091427|NCT03275025|Experimental|YRA-1909 medium does|
33091428|NCT03275025|Experimental|YRA-1909 high dose|
33091429|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
32799262|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
32799263|NCT01744665|Experimental|Treatment Free Remission|Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
32799264|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
32799265|NCT03025126|Active Comparator|Usual care program|usual care program
32799266|NCT05367232|Experimental|ICP-033 Dose Escalation|Drug: ICP-033 tablet Administered orally，once a day，every 28 days is a cycle.
32799267|NCT01744197|Experimental|Arm 1|First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
32799268|NCT01744197|Experimental|Arm 2|First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
32799269|NCT05369416|Active Comparator|Low sodium diet|-Subjects will be randomized to start a low sodium diet (1200 mg/day) for two weeks (this will be followed by a high sodium diet - crossover design)
32799270|NCT05369416|Active Comparator|high sodium diet|-Subjects will be randomized to start a high sodium diet (4200 mg/day) for two weeks (this will be followed by a low sodium diet - crossover design)
32799271|NCT04565301|Placebo Comparator|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
32799272|NCT04565301|Active Comparator|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
32799273|NCT04565301|Active Comparator|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
32799274|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
32799275|NCT01743027|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
32799276|NCT01743027|Active Comparator|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
32799277|NCT01743027|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
32799278|NCT01743027|Placebo Comparator|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
32799279|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
32799280|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
32799281|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32799282|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32799283|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
32799284|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
33091430|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
33091431|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
33091432|NCT00446472|Experimental|1|Randomized to Regranex gel
33091433|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
33091434|NCT04715711|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
33306691|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
33306692|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
33306693|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
33306694|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
33306695|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
33306696|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
33306697|NCT01086800|Other|HLSE plus PAP|
33306698|NCT01086800|Other|HLSE plus Oxygen|
32941370|NCT04796012|Experimental|Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcoma|Seventeen (17) participants with RMS, including the six participants from the Feasibility Cohort, will be enrolled. At least 8 of the RMS participants must have a tumor that expresses the protein PD-L1. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
32941371|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
32941372|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
32941373|NCT05139992||Observational Cohort|Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.
32941374|NCT00504985||Fatigue in Emergency Center Patients|
33091435|NCT04715711|Placebo Comparator|No Intervention|"Participants will participant in passive cooling where they sit in a chair during rest."
33306699|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
33306700|NCT00386009|Placebo Comparator|1|Placebo
33306701|NCT00386009|Active Comparator|2|tadalafil
33306702|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
33306703|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
33306704|NCT00373685|Active Comparator|NSAIDs|
33306705|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
33306706|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306707|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306708|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306709|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306710|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306711|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
33306712|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
33306713|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
33306714|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
33306715|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
32941375|NCT05136326|Experimental|Catartic: chemoradiotherapy plus temozolomide|"External-beam radiation: 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks) in association with:~Capecitabine 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks plus Temozolomide 75 mg/sqm p.o. 5 days/week for 5 weeks."
32941376|NCT05387941|Experimental|Dexamethasone treated infants|15 infants that receive dexamethasone eye drops for treatment of retinopathy of prematurity will be included, and both serum and saliva samples will be collected in order to find out the pharmacokinetic properties of dexamethasone in eye drops according to a pre-specified sampling scheme specifically designed for this purpose by experts in pediatric pharmacokinetics.
32941377|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
33091436|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
33091437|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
33091438|NCT00340808||endometrial cancer cases|endometrial cancer cases
33091439|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
33091440|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
33091441|NCT00452478|Experimental|1|
33091442|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
33306716|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
32799285|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32799286|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32799287|NCT05364034|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
32799288|NCT04010968|Active Comparator|FCR|"FCR :~rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.~fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.~cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
32799289|NCT04010968|Experimental|venetoclax and ibrutinib (I+VEN)|"ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27~venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
32799290|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
32799291|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
32799292|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
32799293|NCT01380184|Experimental|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
32799294|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
32799295|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
32799296|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
32799297|NCT05362552|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
32799298|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
32941378|NCT05133440|Experimental|Experimental Arm|Participants will receive two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease.
32941379|NCT05133440|Active Comparator|Control Arm:|Participants will receive SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice.
32941380|NCT05447000|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
32941381|NCT05447000|Experimental|Deep Relaxation Exercises|Deep Relaxation Exercises therapy
32941382|NCT05447000|Other|Control|Control
33306717|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
33306718|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
33091443|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
33091444|NCT00446667|Experimental|1|
33091445|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
33306719|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
33306720|NCT01044719|Active Comparator|10 days|
32799299|NCT04331938|Experimental|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
32799300|NCT05362084|Active Comparator|Oblique group|medial branch block with oblique group
32799301|NCT05362084|Placebo Comparator|Anteroposterior group|medial branch block with anteroposterior group
32799302|NCT05365594|Active Comparator|Self Selected Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
32799303|NCT05365594|Active Comparator|Speed Walking Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
32799304|NCT01742091|Experimental|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
32799305|NCT01742091|Experimental|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
32799306|NCT01742091|Experimental|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
32799307|NCT01742091|Experimental|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
32799308|NCT01742091|Experimental|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
32799309|NCT01742091|Placebo Comparator|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
32799310|NCT01731951|Experimental|Arm A: Imetelstat 9.4 mg/kg (Myelofibrosis [MF])|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 milligram per kilogram (mg/kg), intravenously (IV) as 2-hour infusion on Day 1 of each 21-day cycle in Core Phase up to 9 cycles. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
32799311|NCT01731951|Experimental|Arm B: Imetelstat 9.4 mg/kg as Induction + Maintenance (MF)|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 mg/kg, IV as 2-hour infusion on Days 1, 8, and 15 of 21-day cycle in Cycle 1 followed by 9.4 mg/kg on Day 1 of each 21-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
32799312|NCT01731951|Experimental|Arm D: Imetelstat 9.4 mg/kg (Blast-phase MF/Acute Myeloid Leukemia)|Participants with blast-phase myelofibrosis/acute myeloid leukemia (MF/AML) received imetelstat 9.4 mg/kg, IV as 2-hour infusion weekly on Days 1, 8, 15, 22 of a 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
32799313|NCT01731951|Experimental|Arm E: Imetelstat 7.5 - 9.4 mg/kg (MF [with Spliceosome Mutation or Ring Sideroblasts])|Participants with MF and spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
33091446|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
33091447|NCT03277677|Active Comparator|normal saline|
33091448|NCT03277677|Active Comparator|balanced solution|
33091449|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
32941383|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
32941384|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
32941385|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
32941386|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
32941387|NCT04771442|Experimental|Stromal vascular fraction injection|"Intervention:~Single injection with autologous adipose tissue-derived stromal vascular fraction cells in and around the plaque."
32941388|NCT05381857||Individual from the initial Milieu Intérieur study|Individual who provided samples for the initial Milieu Intérieur study
32941389|NCT05438030|Experimental|Paired cardiac MRI and echocardiographic measurements|
32941390|NCT05361343|Other|Arm 1|"Nutrition: intermittent fasting;~Physical activity: medium-intensity or high-intensity physical activity;~Hypoxic training (at least three per visit to the center);~correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~Individual motivational counseling."
32941391|NCT05437250||CLL patients treated with acalabrutinib at their physician's discretion|In each center, all patients meeting the inclusion criteria and no exclusion criteria will be offered to participate in this study.
32941392|NCT05352061|Experimental|Cognitive Behavioral Therapy (CBT) for Syndemic and Adherence Factors Group|Participants in this group will receive the CBT for Syndemics and Adherence Factors intervention for a total of 14 sessions over 4 months.
32941393|NCT00911053|No Intervention|Baseline|
32941394|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
32941395|NCT00911053|Experimental|Light|
32941396|NCT00911053|Experimental|Regular Sleep Schedule|
32941397|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
33306721|NCT01044719|Active Comparator|14 days|
33306722|NCT01044719|Active Comparator|21 days|
32941398|NCT04765046|Other|BIS™ System|Enrolled subjects who are undergoing a standard of care elective surgery under general anesthesia, will be equipped with the BIS system to non-invasively measure and interpret brain waive activity directly related to the effects of anesthetic agents during the surgery duration.
32941399|NCT04755530|Active Comparator|Regular whole milk|Substitution of a part of the habitual diet with 400 g/day of regular whole milk
33306723|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
32941400|NCT04755530|Experimental|Yogurt with live bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria
32941401|NCT04755530|Experimental|Yogurt with inactivated bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria
32941402|NCT04755530|Experimental|Acidified whole milk|Substitution of a part of the habitual diet with 400 g/day of acidified whole milk
32941403|NCT05100368||Patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
32941404|NCT04713176|Experimental|DWJ1248 with Remdesivir|Camostat mesylate 200 mg, Remdesivir
32941405|NCT04713176|Placebo Comparator|Placebo with Remdesivir|Placebo, Remdesivir
32941406|NCT04754984|Experimental|Intervention|One-time in-person workshop with pelvic floor physiotherapist
32941407|NCT04754984|No Intervention|Control|Standard care
32941408|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
32941409|NCT04330508||Chronic hepatitis C with Cirrhosis|
32941410|NCT04330508||Healthy Volunteers|
32941411|NCT05424926||Patients|Patients
32941412|NCT05424146|Placebo Comparator|Placebo Non-Prebiotic Bar Group|This group of participants will be consuming non-prebiotic bars for the duration of the trial.
32941413|NCT05424146|Active Comparator|Prebiotic Bar Group|Participants will be asked to consume prebiotic bars for the duration of the trial.
32941414|NCT05423912|Experimental|Mild Cognitive Impairment (MCI) Participant|All participants will be asked to complete the quantitative endpoint measures at baseline and 4 and 8 weeks after the end of the course. These measures will be administered verbally by a study staff member by phone (20-30 minutes) or Zoom call to ensure survey questions are clear and participants' questions are answered. These quantitative measures will assess the effect of the program on participants' sense of mastery or control over caregiving tasks as well as their emotional well-being and communication. In addition, qualitative semi-structured interviews will be conducted following program participation. These interviews will focus on participants' perceptions of the effect of the program on them but will also seek information that might help to further strengthen the program
32941415|NCT05423912|Experimental|Person living with MCI participant|All participants will be asked to complete the quantitative endpoint measures at baseline and 4 and 8 weeks after the end of the course. These measures will be administered verbally by a study staff member by phone (20-30 minutes) or Zoom call to ensure survey questions are clear and participants' questions are answered. These quantitative measures will assess the effect of the program on participants' sense of mastery or control over caregiving tasks as well as their emotional well-being and communication. In addition, qualitative semi-structured interviews will be conducted following program participation. These interviews will focus on participants' perceptions of the effect of the program on them but will also seek information that might help to further strengthen the program.
32941416|NCT05097170||1|patients under the age of 65
32941417|NCT05097170||2|patients above the age of 65
32941418|NCT05095532|Experimental|BM-MSCs at 20x10^6|One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14
32941419|NCT05095532|Experimental|BM-MSCs at 50x10^6|One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14
32941420|NCT05095532|Placebo Comparator|Placebo|One time infusion of islets only.
32941421|NCT04725656|Active Comparator|Active arm, low concentration (18 mg/mL) nicotine salt e-liquids|
32941422|NCT04725656|Active Comparator|Active arm, high concentration (59 mg/mL) nicotine salt e-liquids|
32941423|NCT04725656|Other|Control group|Receive only smoking cessation counseling
33306724|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
33306725|NCT01046201||Obese Children|
32941424|NCT04330352|Experimental|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
32941425|NCT04330352|No Intervention|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
32941426|NCT04713410|Experimental|Group A|Steroids will be given for short duration of time i-e 12 weeks
32941427|NCT04713410|Active Comparator|Group B|Steroid will be given for longer duration i-e 20 weeks
32941428|NCT04713332|Active Comparator|vitamin E|Oral intake of Vitamin E treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. Patients in the group receiving 500 IU of d-alpha-tocopherol capsules orally (3 times daily).
32941429|NCT04713332|Active Comparator|Hydrogen rich water|Oral intake of HRW (2 ppm) treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The group of patients receiving Hydrogen water took an amount of 250 ml orally 3 times a day.
32941430|NCT04713332|Placebo Comparator|placebo|Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
32941431|NCT05089682|Experimental|Deep Brain Stimulation (DBS) system|Subjects with existing DBS systems implanted for neurological disease (e.g., Parkinson's, pain, epilepsy) will have targeted stimulation patterns during specific stages of sleep using their existing DBS device.
32941432|NCT05087186|Experimental|Intervention|Group sessions with psychological therapists
32941433|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
32941434|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
32941435|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
32941436|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
32941437|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
32941438|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
32941439|NCT05084300|Experimental|Pain Neuroscience Education|Pain neuroscience education in addition medical treatment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
32941440|NCT05084300|Other|Usual care|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
32941441|NCT05411588|Experimental|Active|PF-07275315
32941442|NCT05411588|Placebo Comparator|Placebo|Placebo
32941443|NCT00901303|Other|Early Stage Disease|Group A
32941444|NCT00901303|Other|Advance Stage Disease|Group B
32941445|NCT05083676|Experimental|Acceset Intervention|The qualified participants (seekers) will be randomly allocated into two arms. Arm 1 (n = 50) seekers will engage with the Acceset platform for a period of 3 weeks, together with befrienders (n = 30) and moderators (n = 30). Both seekers and befrienders will be monitored using a questionnaire battery listed (including help seeking behaviors beyond the Acceset platform) at 4 time points: baseline (before the intervention), 3 weeks (the end of the intervention), 6 weeks and 9 weeks (to measure carry over effects).
32941446|NCT05083676|Active Comparator|waitlist for Acceset intervention|Arm 2 (n = 50) a control group will be placed on a waitlist for Acceset intervention. These individuals will be age and gender matched with the intervention group (i.e., arm 1). Their mental well-being, as well as their help seeking behavior, at the same time points and via the same questionnaire battery will be compared with those in arm 1.
32941447|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
32941448|NCT04696796|Experimental|BasIQ-4 Surgical Knife|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with BasIQ-4 Surgical Knife according to computer generated randomization.
33306726|NCT01044953||Soccer Players|German professional soccer players
33306727|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
33306728|NCT04556981|Experimental|M72/AS01E vaccine|
33306729|NCT04556981|Placebo Comparator|Placebo|
33091450|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
33091451|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
33091452|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
33306730|NCT01045343|Active Comparator|Control Arm|
33306731|NCT01045343|Experimental|Integrated Diagnostics Arm|
33306732|NCT00094302|Placebo Comparator|Placebo|Placebo of spironolactone
33306733|NCT00094302|Experimental|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
32830563|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
33306734|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
33306735|NCT00384839|Experimental|1|azacitidine for injectable suspension
33306736|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
33306737|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
33306738|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
33306739|NCT00384293|Experimental|1|MK0524A
33306740|NCT00384293|Placebo Comparator|2|placebo
33306741|NCT01087866|Experimental|Metformin|
33306742|NCT01087866|Active Comparator|Insulin|
33306743|NCT01046357|Experimental|Active|AZD7687 oral suspension
33306744|NCT01046357|Experimental|Placebo|placebo oral suspension
33306745|NCT01084746|Active Comparator|PC-based tailored intervention|
33306746|NCT01084746|Active Comparator|Printed educational materials|
33306747|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
33306748|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
33306749|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
33306750|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
33306751|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
33306752|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
33306753|NCT00067002|Experimental|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
33306754|NCT00067002|Experimental|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
33306755|NCT03961698|Experimental|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
33404335|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
33404336|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
33404337|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
33091453|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
33306756|NCT03961698|Experimental|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
33306757|NCT01090908||Ages 6-11 years|
33306758|NCT01090908||Ages 12-17 years|
33306759|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
33306760|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
33306761|NCT03962556||Non-Trigger Point|
33306762|NCT03962556||Trigger Point|
33306763|NCT01084902|Experimental|latnoprost|once daily
33306764|NCT01084902|Active Comparator|Brinzolamide|two times daily
33306765|NCT01084980|Experimental|Tacrolimus|
33306766|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
33306767|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
33306768|NCT01085058|Experimental|A: lenograstim|total group
33306769|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
33306770|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
33306771|NCT03961542|Experimental|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
33306772|NCT03961542|No Intervention|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
33306773|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
33306774|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
33306775|NCT01088178|Experimental|Interval|After 6 weeks postpartum
33306776|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
33306777|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
33306778|NCT01091142|Experimental|NP001|
33306779|NCT01091142|Placebo Comparator|Placebo|
33306780|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
33306781|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
33306782|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
33306783|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
33306784|NCT03957486|Experimental|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
33306785|NCT03957486|Placebo Comparator|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
33306786|NCT03957408|Experimental|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
33306787|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
33306788|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
33306789|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
33306790|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
33306791|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
32799314|NCT01731951|Experimental|Arm F: Imetelstat 7.5 - 9.4 mg/kg (MF [without spliceosome mutation and ring sideroblasts])|Participants with MF without spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 9.4 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or imetelstat 7.5 mg/kg twice weekly on Days 1, 3 for 2 cycles of 28-day cycle (Cycles 3-4) followed by imetelstat 7.5 mg/kg 3-times-weekly on Days 1, 3, 5 of Cycles 5 and beyond of 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
32799315|NCT01731951|Experimental|Arm G: Imetelstat 7.5 - 9.4 mg/kg (MDS/MPN or MDS with Spliceosome Mutations or Ring Sideroblasts)|Participants with either myelodysplastic syndromes/ myeloproliferative neoplasm (MDS/MPN) or MDS and spliceosome mutations or ring sideroblasts present received 2 cycles of 28-day cycle (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
32799316|NCT04560777|Experimental|experimental arm|CO-OP intervention
32799317|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
32799318|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
32799319|NCT01741701|Experimental|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
33404338|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
32799320|NCT01741701|Placebo Comparator|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
32799321|NCT01741545|Experimental|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
32799322|NCT01741545|Experimental|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
32799323|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
32799324|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
32799325|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
32799326|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
32799327|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
32799328|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
32799329|NCT01597778|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
32799330|NCT01597778|Experimental|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
32799331|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
32799332|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
32799333|NCT04559607|Experimental|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
32799334|NCT04559607|Active Comparator|Control group: TACE|TACE
32799335|NCT04559373|Experimental|Virtual Reality and Field Practice Training (VRFT)|Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.
32799336|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
33306792|NCT00091572|Experimental|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
33306793|NCT00091572|Active Comparator|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
33306794|NCT01091220|Placebo Comparator|Placebo|0.9% saline
32941449|NCT04696796|Active Comparator|Episiotomy Scissors|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with episiotomy scissors according to computer generated randomization.
33306795|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
33306796|NCT03961386|Experimental|FallsTalk-C|FallsTalk CG intervention
32941450|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
32941451|NCT05061680|Active Comparator|short sphincterotomy +Short duration papillary large balloon dilation|Patients with short sphincterotomy
32941452|NCT05061680|Active Comparator|full sphincterotomy + short duration papillary balloon dilation|Patients with full lenght sphincterotomy
32941453|NCT05061680|Active Comparator|previous sphincterotomy + short duration papillary balloon dilation|Patients with previous sphincterotomy
32941454|NCT05348863|Experimental|SPARK app|Access to the SPARK app which will provide support for a healthier diet and increased physical activity as well as daily monitoring of blood glucose levels.
32941455|NCT05348863|No Intervention|Control arm|Standard care i.e., the routine treatment program for GDM delivered by the care provider.
32941456|NCT05390918|Experimental|TAILOR|Half of the participants will be randomized into the experimental arm of this study. A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary. The TAILOR intervention will then be administered. TAILOR includes the assessment of existing sleep problems and sleep practices and education on Cognitive Behavioral Therapy (CBT) strategies for insomnia, with Motivational Interviewing (MI) as the communication style.
32941457|NCT05390918|Other|Enhanced Usual Care (EUC)|Half of the participants will be randomized into Enhanced Usual Care (EUC). A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
32941458|NCT05347303|Experimental|Experimental group|The experimental group (EG) after taking initial measurements and signing their informed consent will be subjected to an 8-week intervention plan with 2 sessions per week where they will receive 1 MTOH and 1 Foam roller on discontinuous days. MTOH consists of first evaluating the structures that have restrictions, whether soft tissues or joints, to later be treated with a specific manual technique. For this, evaluation methods based on Kaltenborn are used when it comes to joints and Pilat when focusing on soft tissues. Interventions will not exceed 20 minutes per subject. For the foam roller, subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
32941459|NCT05347303|Active Comparator|Control group|After taking measurements, they will perform 2 foam roller sessions per week following the same indications expressed in the experimental group.
32941460|NCT05343403||Family Integrated Care|During the intervention period, Family Integrated Care (FICare) will be implemented on the neonatal wards of the participating hospitals. Families that are included during this intervention period will participate in Family Centred Rounds (FCR), while being supported by the principles of FICare. FICare incorporates psychological, educational, communication, and environmental strategies to support parents and to prepare them emotionally, cognitively, and physically to care autonomously for their infant at the time of discharge. In FCR, parents actively participate in the medical rounds and decisions are made based on shared-decision making. Not only are parents informed about the clinical condition of their child, they can ask questions and share their own valuable information on their child. Such information can include the overall wellbeing but also specific medical information.
32941461|NCT05343403||Standard Neonatal Care|In the control period, standard neonatal care (SNC) will be provided. Medical rounds will be held between healthcare professionals, and parents are not (structurally) participating during these rounds. Parents are updated daily by the nurses, and (usually) weekly by their attending physician. Care for the infants is provided mostly by the nurses. Parents usually have (unlimited) access to the ward, but are not supported by the concept of FICare. As such, they do not receive education and are not structurally supported by veteran parents. Healthcare professionals stimulate parents to participate in daily care (such as feedings or skin-to-skin care), but do not receive structural education on how to incorporate parents as equal partners into the care team.
32941462|NCT04691024|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
32941463|NCT04691024|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
32941464|NCT00904423|Experimental|Vitamin D|
32941465|NCT04689698|Experimental|experimental group|
32941466|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
32941467|NCT04683848|Experimental|MT-3921|Intravenous (IV)
32941468|NCT04683848|Placebo Comparator|Placebo|Intravenous (IV)
33306797|NCT03961386|Active Comparator|FallsTalk|FallsTalk intervention
33306798|NCT03961386|No Intervention|PostCardOnly|Postcard only- Control group
33306799|NCT00084266|Experimental|1|Subjects receiving linezolid for the treatment phase of the study
33306800|NCT00084266|Active Comparator|2|Subjects receiving vancomycin for the treatment phase of the study
33306801|NCT01091298|Experimental|Group 1|
33306802|NCT01091298|Placebo Comparator|Group 2|
33306803|NCT03957564|Experimental|Patients receiving neoadjuvant chemotherapy.|"Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.~Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.~Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.~To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
33306804|NCT01086878|Experimental|Cotrimoxazole|
33306805|NCT00091026|Experimental|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
33306806|NCT00091026|Experimental|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
33306807|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
33306808|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
33306809|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
33306810|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
33306811|NCT01583634||Healthy volunteers|9 subjects (male and female)
33306812|NCT01088490||critically ill|Critically ill patients admitted to ICU
32941469|NCT05328895|Experimental|taVNS group|taVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the cymba conchae and concha around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
32941470|NCT05328895|Placebo Comparator|Control Group|tnVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the antihelix around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
32941471|NCT05380466|Experimental|Quantum Touch|Those who are planned to be hospitalized from the emergency department and applied quantum touch
32941472|NCT05380466|No Intervention|Control|Those who are planned to be hospitalized from the emergency department and who have not intervention
32941473|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 followed by T8 during the trial implant period
33306813|NCT01583790||no group|laparoscopic sleeve gastrectomy
32941474|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 followed by T7 during the trial implant period
33306814|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
32941475|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
32941476|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
32941477|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
32941478|NCT04669808|Experimental|Cohort A: STP705 30 μg dose|Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
32941479|NCT04669808|Experimental|Cohort B: STP705 60 μg dose|Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
32941480|NCT04669808|Experimental|Cohort C: STP705 90 μg dose|Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
32941481|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
32941482|NCT05040698|Experimental|Open Label Fostamatinib|Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
33306815|NCT00116558|Experimental|Early NIPPV Intervention|Participants with >80% predicted forced vital capacity (FVC).
32941484|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
32941485|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
32941486|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
32941487|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
32941488|NCT05371652|Experimental|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)
32941489|NCT04529174|Active Comparator|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
33306816|NCT00116558|Active Comparator|Standard of Care NIPPV|Participants with 50-74% predicted forced vital capacity (FVC).
33306817|NCT00116558|Active Comparator|Standard of Care NIPPV and Nutritional Monitoring|Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.
33306818|NCT01085292|Experimental|Group A|
33306819|NCT01085292|Experimental|Group B - D|
33306820|NCT01085370|No Intervention|Control Group|standard medical care only
33306821|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
33306822|NCT00116168|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
33306823|NCT00116168|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
33306824|NCT00116168|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
32941490|NCT04529174|Placebo Comparator|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
32941491|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
32941492|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
33306825|NCT00116168|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
33306826|NCT00115934|Active Comparator|MBTS|Blalock-Taussig pulmonary artery shunt
33306827|NCT00115934|Active Comparator|RVPAS|Right ventricular to pulmonary artery shunt
33306828|NCT00115778|Experimental|First IVIG, then Placebo|Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.
32941493|NCT04661072||Patients with Congenital Uterine Anomalies (CUA)|The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
33306829|NCT00115778|Experimental|First Placebo, then IVIG|Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.
33306830|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
32941494|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
32941495|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
32941496|NCT04652180|Experimental|Robot-assisted thoracic approach in Ivor Lewis esophagectomy|Robot-assisted thoracic approach in Ivor Lewis esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
32941497|NCT04652180|Active Comparator|Open transthoracic approach in Ivor Lewis esophagectomy|Traditional open transthoracic esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
32941498|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
32941499|NCT05034614|Other|Pap smears using the Papette|Papette brush used to collect a Pap smear sample as standard of care.
32941500|NCT05034614|Other|Pap smears using the traditional spatula/cytology brush|Spatula/cytology brush used to collect a Pap smear sample as standard of care.
32941501|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
32941502|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
32941503|NCT05033522|Experimental|AlloStim®|AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration
32941504|NCT05033522|Active Comparator|Physician's Choice|Physician's Choice is sorafenib or levantinib or FOLFOX4 monotherapy
32941505|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
32941506|NCT00314353|Experimental|1|
32941507|NCT00314353|Experimental|2|
32941508|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
32941509|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
32941510|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
32941511|NCT04630028|Experimental|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
32941512|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
33306831|NCT00100178|Experimental|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
33306832|NCT00100178|Experimental|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
33306833|NCT00100178|Placebo Comparator|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
33306834|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
33306835|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
33306836|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
33306837|NCT00099632|Experimental|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
33306838|NCT00099632|Experimental|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
33306839|NCT00099632|Experimental|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
33306840|NCT00099632|Experimental|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
33306841|NCT00099632|Experimental|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
32941513|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
32941514|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
32941515|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
32941516|NCT05278975|Experimental|Phase 1 - Dose Escalation|RSO-021 administered in increasing doses as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle.
32941517|NCT05278975|Experimental|Phase 2 - Dose Expansion - MPE from non-mesothelioma solid tumors|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors.
32941518|NCT05278975|Experimental|Phase 2 - Dose Expansion - MPE from mesothelioma|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from mesothelioma.
32941519|NCT05011058|Experimental|Nanatinostat with Valganciclovir|"Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.~Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week."
32941520|NCT05235919|Experimental|repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 rTMS sessions for 3 weeks.
32941521|NCT05235919|Sham Comparator|Sham|Participants will receive 15 sessions of sham stimulation for 3 weeks.
32941522|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
32941523|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
32941524|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
32941525|NCT05007392|Experimental|Drug: Dotinurad + Febuxostat Matched Placebo|Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
32941526|NCT05007392|Active Comparator|Drug: Febuxostat + Dotinurad Matched Placebo|Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
32941527|NCT04998812|Experimental|Women with CIS or MS|Women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
32941528|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
32941529|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
32941530|NCT04998422|Experimental|Part A: HG381 Monotherapy Dose Escalation Cohort|Subjects will receive HG381 IV at every one week intervals (Q1W). Escalating doses of HG381 will be evaluated by the traditional 3+3 design.
32941531|NCT04998422|Experimental|Part B: HG381 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of HG381 IV Q1W established in Part A of the study.
32941532|NCT05357690|Experimental|Stellate ganglion block with local anesthetic|Subjects will receive a single injection of bupivacaine in a stellate ganglion block
32941533|NCT05357690|Sham Comparator|Stellate ganglion block with saline placebo|Subjects will receive a single injection of saline in a stellate ganglion block
33306842|NCT00099632|Experimental|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
33306843|NCT03961802|Experimental|systematic early rehabilitation|systematic early rehabilitation
33404339|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
32941534|NCT04621916|Active Comparator|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
32941535|NCT04621916|Active Comparator|Emicizumab only|Participants will only receive emicizumab prophylaxis.
32941536|NCT00801931|Experimental|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
32941537|NCT00801931|Experimental|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
32941538|NCT00801931|Experimental|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
32941539|NCT00801931|Experimental|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
32941540|NCT00801931|Experimental|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
32941541|NCT00801931|Experimental|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
32941542|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
32941543|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
32941544|NCT05348642|Experimental|Experimental group receiving pasteurized Akkermansia muciniphila|pasteurized Akkermansia muciniphila - daily oral dose
32941545|NCT05348642|Placebo Comparator|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
32941546|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
32941547|NCT05345990|Experimental|Hepatitis B immunoglobulins|"20 patients treated in two cohorts for 12 weeks with hepatitis B Immunoglobulins (HBIG, Hepatect®CP/ Zutectra®).~Cohort A:~10 HBsAg positive, HBeAg-negative patients being treated with anti-HBV nucleotide or nucleoside analogous (NAs) for at least 12 months before screening. HBV-DNA should be below the lower limit of detection at screening. HBsAg should be positive and below 100 IU/ml.~Cohort B:~10 HBsAg positive, HBeAg-negative patients untreated with NAs for at least 12 months before screening. Patients with HBV-DNA levels below 2000 IU/ml and ALT < 1.5 times upper the limit of normal. HBsAg should be positive and below 100 IU/ml.~Trial duration: A recruiting period of approximately 6 months is planned. The total time per patient to complete all study visits is approximately 40 weeks including:~an 28 day screening period~an 12 week treatment period~an 24 week follow-up period"
32941548|NCT04278326|Experimental|Experimental|"Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer~Patients with cervical or vaginal cancer~All patients"
32941549|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
32941550|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
32941551|NCT04619420|Experimental|JNJ-63733657|Participants will receive single dose of JNJ-63733657 low dose or high dose administered by intravenous (IV) infusion every 4 weeks.
32941552|NCT04619420|Placebo Comparator|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks.
33306844|NCT03961802|No Intervention|without systematic rehabilitation|without systematic rehabilitation
33306845|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~INH 300 mg po qd for 9 months"
33306846|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)~no treatment"
33306847|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)~no treatment"
33306848|NCT04116398|Experimental|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
33306849|NCT00098774|Experimental|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)"
33306850|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
33306851|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
33306852|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
33404340|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
33306853|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
33306854|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
33306855|NCT03961412|Experimental|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
33306856|NCT03961412|Active Comparator|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
33306857|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
33306858|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
33306859|NCT03958058||Anti-borrelial antibiotic therapy|
33306860|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
33306861|NCT01090622|Placebo Comparator|Matching Placebo|
33306862|NCT01090622|Experimental|XPF-001|
33306863|NCT01081730||001|ustekinumab as prescribed
33306864|NCT01081730||002|anti-TNF biologics as prescribed
33306865|NCT01081730||003|non-anti-TNF biologics as prescribed
33306866|NCT01081730||004|systemic non-biological treatments as prescribed
33306867|NCT01081730||005|general population non-treated cohort
33306868|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
33306869|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
33306870|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
33306871|NCT03957980|Other|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
33306872|NCT03957980|Other|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
33306873|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
33306874|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
33306875|NCT03957902|Experimental|Arm 1 (100 mg/24h)|
33306876|NCT03957902|Experimental|Arm 2 (300 mg/24h)|
33306877|NCT03957902|Experimental|Arm 3 (100 mg/12h)|
33306878|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
33306879|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
33306880|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
33306881|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
33306882|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
33306883|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
33306884|NCT00382967|Experimental|Datscan Product|
33306885|NCT00382967|No Intervention|Control|
33306886|NCT01046591||Cleft|Those with a repaired cleft palate
33306887|NCT01046591||Comparison|Those without a cleft palate repair
33306888|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
32941553|NCT02970799|Experimental|Intranasal then Extranasal Application|Intranasal Neurostimulator applied intranasally (active) followed by extranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence for Days 15 and 29.
32941554|NCT02970799|Experimental|Extranasal then Intranasal Application|Intranasal Neurostimulator applied extranasally (control) followed by intranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence at Days 15 and 29.
33306889|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
33306890|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
33306891|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
32941555|NCT05048719|Experimental|LY3502970 Dose 1|Participants will receive escalated doses of LY3502970 administered orally
32941556|NCT05048719|Experimental|LY3502970 Dose 2|Participants will receive escalated doses of LY3502970 administered orally
32941557|NCT05048719|Experimental|LY3502970 Dose 3|Participants will receive escalated doses of LY3502970 administered orally
32941558|NCT05048719|Experimental|LY3502970 Dose 4|Participants will receive escalated doses of LY3502970 administered orally
32941559|NCT05048719|Experimental|LY3502970 Dose 5|Participants will receive escalated doses of LY3502970 administered orally
32941560|NCT05048719|Active Comparator|Dulaglutide|Participants will receive Dulaglutide subcutaneously (SC)
32941561|NCT05048719|Placebo Comparator|Placebo Matching LY3502970|Participants will receive placebo matching LY3502970 orally
32941562|NCT05048719|Placebo Comparator|Placebo Matching Dulaglutide|Participants will receive placebo matching Dulaglutide subcutaneously
33404341|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
33404342|NCT03487445|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
32941565|NCT00759577|Other|Home titration|Patients were given drug to self titrate
32941566|NCT05338112||Patients with active pemphigus lesions|
32941567|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
32941568|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
32941569|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
32941570|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
32941571|NCT05329922|Experimental|ALICE (experienced hearing aid/cochlear implant users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device for 8 weeks.
32941572|NCT05329922|No Intervention|Control (experienced hearing aid/cochlear implant users)|This arm will receive the standard of care given to the client. Persons with a moderate to profound hearing loss are provided with a hearing aid. Persons with a profound to severe HI are provided with a cochlear implant and concomitant rehabilitation. Most persons with a cochlear implant receive intensive rehabilitation during the first 6 months after their implantation. Afterwards, they mainly return for mapping of the device but not for listening training therapy.
32941573|NCT05329922|Experimental|ALICE (new hearing aid users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device during the hearing aid trial period (4-6 weeks on average).
32941574|NCT05329922|No Intervention|Control (new hearing aid users)|This arm will receive the standard of care given to the client during the hearing aid trial period.
32941575|NCT05002777|Experimental|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
32941576|NCT04599764|Active Comparator|Cognitive training|Participants will receive Cognitive training daily for two weeks
32941577|NCT04599764|Active Comparator|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
32941578|NCT04524962|Experimental|Descartes 30|
32941579|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
32941580|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
32941581|NCT04977674|Experimental|A: Visit 1) Naltrexone + Ketamine, Visit 2) Placebo + Ketamine|"Participants randomly assigned to arm A:~VISIT 1) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~VISIT 2) Placebo before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
32941582|NCT04977674|Experimental|B: Visit 1) Placebo + Ketamine, Visit 2) Naltrexone + Ketamine|"Participants randomly assigned to arm B:~VISIT 1) Placebo before the administration of ketamine 0.5mg/kg.~VISIT 2) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
32941583|NCT04972136|Active Comparator|Active bilateral theta burst stimulation|An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). BL-TBS will be delivered at 90% RMT, corrected for scalp to cortex distance, to targeted left and right DLPFC sites, differing only in stimulation pattern and total number of pulses (triplet 50 Hz bursts, repeated at 200 msec (i.e., 5 Hz); right DLPFC (continuous TBS, cTBS): 120 seconds uninterrupted bursts (total of 600 pulses); left DLPFC (intermittent TBS, iTBS: 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds/hemisphere).
33306892|NCT03992885|Experimental|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
33404343|NCT03487445|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
33306893|NCT05668702|Experimental|capillary blood glucose measurement|the researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
33306894|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
33306895|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
33306896|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
33306897|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
33306898|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
33306899|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
33306900|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
33306901|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
33404344|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
33404345|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
33404346|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
32799337|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
32799338|NCT01739595|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
32799339|NCT01739595|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
32799340|NCT01739595|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
32799341|NCT01833494|Experimental|PA21|
32799342|NCT01738971|No Intervention|control (standard care)|standard verbal and written advice on contraception from pharmacy
32799343|NCT01738971|Experimental|rapid access|rapid access to family planning service
32799344|NCT01738971|Experimental|progestogen only pill|one month progestogen only pill
32799345|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
32799346|NCT01738581|Experimental|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
32799347|NCT01738581|Experimental|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
32799348|NCT01738503|Experimental|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
32799349|NCT01738503|Experimental|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
33306902|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
33306903|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
33306904|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
33306905|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
33306906|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
33306907|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
33306908|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
33306909|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
33306910|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
33306911|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
33306912|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
33306913|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
33306914|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
33306915|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.~A radiation dose reduction from 120 to 90 kV.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
33306916|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
33306917|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
33306918|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
33306919|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
33306920|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
32941584|NCT04972136|Sham Comparator|Sham bilateral theta burst stimulation|"An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used with the active coil facing away from the scalp, for sham stimulation. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). To reproduce the nociceptive qualities of the stimulation, the B65-type stimulation coil - sham side - includes a built in electrical stimulator in the coil connector which fires a synchronous electrical pulse along with the TMS stimulus through electrodes mounted on the forehead or near the area of stimulation, to generate auditory and somatosensory (vibration) stimuli."
32941585|NCT04965038|Active Comparator|Thrombolysis (interventional study)|Alteplase (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
32941586|NCT04965038|Placebo Comparator|Placebo (interventional study)|Placebo (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
32941587|NCT04965038|No Intervention|Observational study|The prospective REVISION observational study will enroll patients within 12 hours of symptom onset
33306921|NCT05668624|Experimental|Full Subsidy Arm|This arm receives free LPG and stove for cooking following the baseline measures, for the duration of the 3-year follow-up period. For those households in Government of Rwanda designated areas for solar microgrids, this arm will also be connected to and provided free access to solar electricity for lighting.
33306922|NCT05668624|No Intervention|Control Arm|This arm will remain using traditional forms of energy for cooking and lighting.
33404347|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
32941588|NCT04963790|Experimental|Tailored COVID-19 vaccine messaging|Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
32941589|NCT04963790|Active Comparator|Other health-related messaging|Patients assigned to the control group will receive health messages unrelated to COVID-19.
32941590|NCT04960124|Experimental|Part 1: Cohort 1 (JNJ-42847922)|Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.
32941591|NCT04960124|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.
32941592|NCT04960124|Experimental|Part 1: Cohort 3 (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.
32941593|NCT04960124|Experimental|Part 2: Cohort 4 (Optional) (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.
32941594|NCT04960124|Experimental|Part 2: Cohort 5 (Optional) (JNJ-42847922)|Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.
33091454|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
33404348|NCT02334592|Experimental|Low Pressure 100W sunbed|
32941595|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
32941596|NCT04573478|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 132 weeks
33306923|NCT05668624|Experimental|Discount Subsidy Arm|This arm will be randomized to a discounted price (at baseline and every 6-months during the 3-year study) for solar electricity (in areas marker for solar grids by the Government of Rwanda) and LPG gas in a pay-as-you-go (PAYG) service model (i.e., pre-pay an affordable amount through mobile money, a common form of currency transactions in Rwanda). For example, this arm will be asked to cook as normal and decide whether or not to cook with the discounted LPG or their traditional stove (i.e., they will not be required to pay for LPG).
33306924|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
33306925|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
33306926|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
33306927|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
33306928|NCT00112437|Placebo Comparator|Placebo|
33306929|NCT00112437|Experimental|Odanacatib 3 mg|
33306930|NCT00112437|Experimental|Odanacatib 10 mg|
33306931|NCT00112437|Experimental|Odanacatib 25 mg|
33306932|NCT00112437|Experimental|Odanacatib 50 mg|
33306933|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
33306934|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
33306935|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
33306936|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
33306937|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
33306938|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
33306939|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
33306940|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
33306941|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
33306942|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
33306943|NCT00112359|Placebo Comparator|Placebo three times a day (TID)|
33306944|NCT00112359|Experimental|AZLI 75 mg three times a day (TID)|
33306945|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
33306946|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
33306947|NCT00119379|Experimental|uridine supplementation|NucleomaxX 36 grams TID every other day
33306948|NCT00119379|Active Comparator|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
33306949|NCT00118911|Experimental|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
33306950|NCT00118911|Active Comparator|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
33306951|NCT01076751||CRPC patients|
33306952|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
33306953|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
33306954|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
33306955|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
33306956|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
33306957|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
33306958|NCT01079481|Experimental|taxol plus everolimus|
33306959|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
33306960|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
33306961|NCT03965169|Experimental|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
33306962|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
32941597|NCT04573478|Placebo Comparator|Placebo|Once daily oral administration of placebo for 132 weeks
32941598|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
33404349|NCT02334592|Experimental|Low Pressure 160W sunbed|
33306963|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
33306964|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
33306965|NCT00131937|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33306966|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
33318541|NCT02960230|Experimental|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
33404350|NCT02334592|Experimental|High Pressure sunbed|
32799350|NCT01738503|Experimental|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
32799351|NCT01738503|Experimental|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
32799352|NCT01738503|Experimental|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
32799353|NCT01738503|Experimental|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
32799354|NCT01738191|Active Comparator|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
32799355|NCT01738191|Placebo Comparator|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
32799356|NCT01737879|Experimental|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
32799357|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
32799358|NCT04415307|Experimental|Acupuncture|Acupuncture over acupoints.
32799359|NCT04415307|Experimental|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
32799360|NCT04415307|Experimental|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
32799361|NCT04415307|Placebo Comparator|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
32799362|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
32799363|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
32799364|NCT04558905|Active Comparator|Usual Medical Care Model|All the patients will receive face-to-face medical visits
32799365|NCT04558905|Experimental|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
32799366|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
32799367|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
33091455|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
33091456|NCT00452634|Experimental|study arm|
33091457|NCT04715555||Atrial Fibrillation|Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
33091458|NCT04715555||Non-Atrial Fibrillation|Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
33091459|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
33091460|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
33091461|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
33091462|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
33404351|NCT02334592|No Intervention|Control group|
33091463|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
33091464|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
33091465|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
33091466|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
33404352|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
32799368|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
32799369|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
32799370|NCT04564053|Experimental|LNA043|LNA043
32799371|NCT04564053|Placebo Comparator|placebo|
32799372|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
32799373|NCT01726803|Experimental|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
32799374|NCT04563741|Experimental|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
32799375|NCT04563741|Active Comparator|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
32799376|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
32799377|NCT04563273|Experimental|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
32799378|NCT04563273|Experimental|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
32799379|NCT04563273|Experimental|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
32799380|NCT04563273|Experimental|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
32799381|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
32799382|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
33091467|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
33091468|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~Obtain wax bite registration.~Record face-bow transfer.~Duplication of articulating model for surgical simulation.~Measure all casts and bases in standard model surgery fashion.~Fabricate intermediate splint & Final splint.~Condylar repositional splint."
33091469|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
32941599|NCT05311826|Active Comparator|STANDARD PHYSIOTHERAPY TREATMENT - CTL GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
32941600|NCT05311826|Experimental|EXPERIMENTAL diaphragmatic breathing exercise - EXP GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
33091470|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
33091471|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
33306967|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
33306968|NCT01079637|Experimental|Midfoot Fusion Bolt|
33306969|NCT01079637|Experimental|Cast treatment|
33306970|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
33306971|NCT00131469|Active Comparator|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
33306972|NCT00131469|Placebo Comparator|Placebo|Daily SQ placebo for 18 months
33306973|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
33306974|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
33306975|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
33306976|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
33306977|NCT03992807|Experimental|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
33091472|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
33091473|NCT00452985||1|"Injection of Docetaxel~3-hour gap~Injection of carboplatin"
33306978|NCT03992807|Active Comparator|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
33306979|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
33306980|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
33091474|NCT00341900||Case|Male pilots with high cosmic radiation exposure
32941601|NCT04940312||Usual Care Group|Individuals with heart failure receiving standard medical care
32941602|NCT04940312||Intervention Group 1 (pedometer-monitoring only)|Individuals with heart failure receiving a pedometer for measurement of daily step count
32941603|NCT04940312||Intervention Group 2 (app-based coaching)|Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count
33091475|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
33091476|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
33091477|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
33091478|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
33091479|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
33091480|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
33091481|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
33091482|NCT03277287|No Intervention|Group C|No intervention
32799383|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
33091483|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
33091484|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
33091485|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
33091486|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
33091487|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
33091488|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
33091489|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
33091490|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
33091491|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
33091492|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
33091493|NCT00421070|No Intervention|Treatment as usual|Observational component
33091494|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
33091495|NCT03274908||Group|
33091496|NCT00421109|Experimental|1|Bilastine 20 mg
33091497|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
32799384|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
32799385|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
33091498|NCT00421109|Placebo Comparator|3|Placebo
33091499|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
33091500|NCT02273583|No Intervention|Control|31 weeks of MAP.
33091501|NCT00453258||Study Subject|Subjects receiving eye examination
33091502|NCT00342368|Active Comparator|1|CPAP through an helmet
33091503|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
33091504|NCT00446901|Placebo Comparator|Placebo|Placebo
33091505|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
33091506|NCT00342407||Cohort|Female flight attendants
33091507|NCT00453375|Experimental|1|BHT-3021
33091508|NCT00453375|Placebo Comparator|2|BHT-Placebo
33091509|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
33091510|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
33091511|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
33091512|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
33091513|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
33091514|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
33091515|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
33091516|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
33091517|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
33091518|NCT05649033||"group recently graduated midwives practicing in the delivery room"|Midwives graduated for less than three years and practicing in the delivery room
33091519|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
33091520|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
33091521|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
33091522|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
33091523|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
33091524|NCT00447174|Experimental|treatment|treatment manual
33091525|NCT00447174|No Intervention|control group|
33091526|NCT00343265|Active Comparator|1|Progesterone gel
33091527|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
33091528|NCT00447213|Experimental|1|
33091529|NCT00447213|Experimental|2|
33091530|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
33091531|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
32799386|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
32799387|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
32799388|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
33091532|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
33091533|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
33091534|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
33091535|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
33091536|NCT00453687|Experimental|Arm 1|Drug
33091537|NCT04715360|Other|Control|Only received standard medication (avigan) for severe COVID-19 management
33091538|NCT04715360|Experimental|PRP Group|received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion
32799389|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
32799390|NCT01877421|Placebo Comparator|Placebo|Placebo
32799391|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
32799392|NCT01726023|Active Comparator|Meropenem|
32799393|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
32799394|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
32799395|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
32799396|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
32799397|NCT04609761|Experimental|IVIG treatment|Single-arm open-label
32799398|NCT01858532|Active Comparator|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
32799399|NCT01858532|Placebo Comparator|Placebo|Placebo once daily by mouth for up to 52 months
32799400|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
32799401|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
32799402|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
32799403|NCT01832480|Experimental|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
32799404|NCT04613960|Active Comparator|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
32799405|NCT04613960|Placebo Comparator|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
32799406|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
32799407|NCT04599140|Experimental|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
32799408|NCT04598984||Low levels of serum adipokines|
32799409|NCT04598984||High levels of serum adipokines|
33091539|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
33091540|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
33091541|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
33091542|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
33091543|NCT00453765|Experimental|A|montelukast
33091544|NCT00453765|Placebo Comparator|B|placebo
33091545|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
33091546|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
33091547|NCT00343928|Experimental|1|
33091548|NCT00453843|Experimental|proximal to distal training|
33091549|NCT00453843|Experimental|distal to proximal|
33091550|NCT00453843|Experimental|proximal and distal on alternate days|
33091551|NCT00453843|Experimental|proximal and distal same day|
33404353|NCT05076916|Experimental|Intervention group|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. During the follow-up period, the patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the intervention group who came to the hospital for follow-up or treatment.
33091552|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
33091553|NCT00447525|Experimental|1|
33091554|NCT00447525|Active Comparator|2|
33091555|NCT00344006|Experimental|Arm 1|
33091556|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
33091557|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
32799410|NCT04598828|Experimental|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
32799411|NCT04598828|Experimental|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
33091558|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
33091559|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
33091560|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
33091561|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
33091562|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
33091563|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
33091564|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
33091565|NCT04715282|Other|Epley maneuver|The Epley maneuver was performed for all patients (both EpleyM and EpleyM&Exe groups) included in this study until nystagmus had disappeared in each position. If nystagmus/vertigo was not seen, the Epley maneuver was not performed for patients at the 1st, 3rd, and 6th week assessments.
33091566|NCT04715282|Other|Cawthorne-Cooksey exercises combined with the Epley maneuver|Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
33091567|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
33091568|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
33091569|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
33091570|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
33091571|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
33091572|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
33091573|NCT00447759|Experimental|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
33091574|NCT00447759|Active Comparator|Diclofenac|continue usual nsNSAID
33091575|NCT00454155|Experimental|Opebacan|
33091576|NCT00344552|Experimental|1|
33091577|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
33091578|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
33091579|NCT00447837|Experimental|1|
33091580|NCT00447837|Experimental|2|
33091581|NCT00447837|Placebo Comparator|3|
33091582|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
33091583|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
33091584|NCT00447915|Experimental|1|
33091585|NCT00447915|Experimental|2|
33091586|NCT00447915|Active Comparator|3|
33091587|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
32941604|NCT04939844|Experimental|NDMM ineligible for transplant|"All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.~Isatuximab will be administered IV at a dose of 10 mg/kg~on D1, D8, D15 and D22 during Cycle 1~on D1 and D15 during Cycles 2-18~Bortezomib will be administered SC at a dose of 1,3mg/m2~-on D1, D8 and D15 during Cycles 1-8~Lenalidomide will be administered PO at a dose of 25mg/day (15 mg/day in participants with GFR <30mL/minute/1.73m2)~-on D1 to D21 during all Cycles.~Dexamethasone will be administered PO at a dose of 20 mg -on D1, D8, D15 and D22 during Cycles 1 and 2"
33102475|NCT03756155|Experimental|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
32941605|NCT04936568|No Intervention|control|standard oncology care
32941606|NCT04936568|Experimental|intervention|standardized referral to outpatient palliative care by oncologists
32941607|NCT05301062||Radium-223 dichloride treatment|Castration-resistant prostate cancer (CRPC) patients with bone metastases for whom a decision has been made independently by the treating physician and the patient to treat with Radium-223.
32941608|NCT05295212|No Intervention|Cohort A|MRD revealed negative
32941609|NCT05295212|Experimental|Cohort B|MRD revealed positive
32941610|NCT05294120|Experimental|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation TherapY|"If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT.~Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years."
32941611|NCT05287178|Experimental|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
32941612|NCT04920578|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts (Double-blind)|Healthy male participants will receive JNJ-69095897 or matching placebo orally in Cohorts 1-8.
32941613|NCT04920578|Experimental|Part 2: Single Dose Cohort (Open-label)|Healthy male participants will receive JNJ-69095897 orally in Cohort 9.
32941614|NCT04920578|Experimental|Part 3: Single or Divided Dose Cohort (Double-blind)|Healthy male participants and women of non-childbearing potential (WONCBP) will receive JNJ-69095897 or matching placebo orally in Cohort 10.
32941615|NCT04539470|Experimental|Cohort A: Efmarodocokin Alfa Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
32941616|NCT04539470|Experimental|Cohort B: Efmarodocokin Alfa Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
32941617|NCT04539470|Experimental|Cohort C: Efmarodocokin Alfa Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
32941618|NCT04328948|Experimental|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
32941619|NCT04328948|Active Comparator|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
32941620|NCT04538144||Younger participants|Individuals aged 18-39 years
32941621|NCT04538144||Older participants|Individuals aged 65 years or older
32941622|NCT04313972|Experimental|Low-dose naltrexone|2mg low-dose naltrexone capsules
32941623|NCT04313972|Placebo Comparator|Placebo|Placebo capsules
32941624|NCT04309682|Experimental|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
32941625|NCT04309682|Active Comparator|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
32941626|NCT05286320|Experimental|Target-/Immuno-therapy for advanced HCC w PVTT Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
32799412|NCT04598282|Placebo Comparator|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
33091588|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
33091589|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
32799413|NCT04598282|Active Comparator|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
32799414|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
32799415|NCT01831856|Experimental|F373280|
32799416|NCT01831856|Placebo Comparator|Placebo|
32799417|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
32799418|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
32799419|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
33091590|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
33091591|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
33091592|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
33091593|NCT00344786|Experimental|CNF2024|
33091594|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
33091595|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
33091596|NCT04715165|Active Comparator|Group I|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.
33091597|NCT04715165|Placebo Comparator|Group II|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
33091598|NCT00454233|Experimental|1|Dose 1
33091599|NCT00454233|Experimental|2|Dose 2
32799420|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
32799421|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
32799422|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
32799423|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
32799428|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
32799429|NCT04557423|Active Comparator|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
32799430|NCT04557423|Experimental|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
33091600|NCT00454233|Experimental|3|Dose 3
33091601|NCT00454233|Experimental|4|Dose 4
33091602|NCT00454233|Active Comparator|5|
33091603|NCT00454233|Placebo Comparator|6|
33091604|NCT04715477||Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
33091605|NCT04714931|Other|Sentinel Lymph Node|Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
33091606|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
33091607|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
33091608|NCT00344825||Group 1|
32799431|NCT04557033|Experimental|Mindful Meditation|"The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.~The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media~Participants will be asked to complete brief surveys before and after the intervention activity."
32799432|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
32799433|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
32799434|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
32799435|NCT01722669|Active Comparator|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
33091609|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
32799436|NCT01707147||Patients with Type 2 Diabetes Mellitus|
32799437|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
32799438|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
32799439|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
32799440|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
32799441|NCT01874535|Active Comparator|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
32799442|NCT01874535|Active Comparator|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
32799443|NCT01722045|Experimental|Open label IAI|
32799444|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
32799445|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
32799446|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
32799447|NCT04415385|Experimental|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
32900852|NCT05507346|Experimental|Dayspring, Non-Pneumatic Active Compression Device (NPCD)|The Dayspring, an Non-Pneumatic Active Compression Device (NPCD) Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
33091610|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
33091611|NCT00448110|Active Comparator|C|intravenous ketorolac
33091612|NCT00448110|Placebo Comparator|D|placebo
33091613|NCT00454311|Active Comparator|One cell biopsy|
33091614|NCT00454311|Other|Two cell biopsy|
33091615|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
33091616|NCT00344942|Experimental|1|
33091617|NCT00344942|Placebo Comparator|2|
33091618|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
33091619|NCT00454389|Active Comparator|B|Lucentis only
33091620|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
33091621|NCT00448266|Active Comparator|1|3 courses ddAC
33091622|NCT04715048|Experimental|Onabotulinumtoxin A|8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.
33091623|NCT04715048|Experimental|Prabotulinumtoxin A|8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.
33091624|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
33091625|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
33091626|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
33091627|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
33091628|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
33091629|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
33091630|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
33091631|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
33404354|NCT05076916|No Intervention|Control group|The control group received routine patient education and routine hospital follow-ups given by Oncology Education Nurses during the three-month follow-up period. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the control group who came to the hospital for follow-up or treatment.
32799448|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
32799449|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
32799450|NCT01831466|Experimental|Treatment Group A|
32799451|NCT01831466|Experimental|Treatment Group B|
32799452|NCT01831466|Placebo Comparator|Treatment Group C|
32799453|NCT01831466|Experimental|Treatment Group D|
32799454|NCT01831466|Experimental|Treatment Group E|
32799455|NCT01831466|Placebo Comparator|Treatment Group F|
32799456|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
32799457|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
32799458|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
32799459|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
32799460|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
32799461|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
32799462|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
32799463|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
32799464|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
32799465|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
32799466|NCT01829360|Experimental|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
32799467|NCT01829360|Experimental|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
32799468|NCT01829360|Experimental|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
32799469|NCT01829360|Experimental|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
32900853|NCT05507346|Active Comparator|Advanced Pneumatic Compression Device (APCD)|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
32900854|NCT04749914|Experimental|Lasmiditan + Dabigatran (Part 1)|Participants will receive single doses of dabigatran followed by combination of lasmiditan along with dabigatran etexilate administered orally.
33091632|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
33091633|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
33091634|NCT00448305|Experimental|2|EndoTAG-1
33091635|NCT00448305|Active Comparator|3|Paclitaxel
33091636|NCT00448383|Experimental|1|Open-label adalimumab
33091637|NCT00448461|Active Comparator|1|heparin
33091638|NCT00448461|Active Comparator|2|bivalirudin
33091639|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
33091640|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
33091641|NCT00345644|Experimental|1|
33091642|NCT00345644|Placebo Comparator|2|
33091643|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
32941627|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
32941628|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
32941629|NCT04306016|Experimental|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
32941630|NCT04306016|No Intervention|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
33404355|NCT02331082|Active Comparator|Control|Existing healthcare system
32941631|NCT04531982|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg taken as two tablets + background antipsychotic, once daily by mouth
32941632|NCT04531982|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
32941633|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
32941634|NCT04890860|Experimental|Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass.|
32941635|NCT04928053|Experimental|phenotypic data and a blood prelevment|
32941636|NCT05278676|Experimental|Cohort A Single Dose: Dotinurad|Participants will receive dotinurad 1 milligram (mg) (1*1 mg tablet) as a single oral dose after 10-hour fasting on Day 1 in the morning.
32941637|NCT05278676|Experimental|Cohort B Multiple Dose: Dotinurad|Participants will receive dotinurad 4 mg (2*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning. A washout period of 3 days will be maintained after single dose on Day 1 and then participants will receive dotinurad 4 mg (2*2 mg tablets) after 10-hour fasting from Day 4 to Day 10 once daily in the morning.
32941638|NCT05278676|Experimental|Cohort C Single Dose: Dotinurad|Participants will receive dotinurad 10 mg (5*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning.
32941639|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
32941640|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
32941641|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
33404356|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
32941644|NCT04330586|Experimental|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
32941645|NCT04330586|No Intervention|Control|Standard care without ciclesonide
32941646|NCT04516772|Other|Visian TICL|STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
32941647|NCT00673309|Experimental|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
32941648|NCT00673309|Experimental|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
32941649|NCT00673309|Experimental|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
32941650|NCT00673309|Experimental|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
32941651|NCT00673309|Experimental|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
32941652|NCT00673309|Experimental|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
32941653|NCT00673309|Experimental|Itraconazole|Itraconazole will be administered until 95% wound healing.
32941654|NCT00673309|Experimental|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
32941655|NCT00673309|Experimental|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
32941656|NCT00673309|Placebo Comparator|Control/Placebo|Placebo or Control will be administered until 95% wound healing
32941657|NCT04508036||Study Group|Premature newborns born before 32nd gestational week and weighing less than 1500 grams.
32941658|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
32941659|NCT04495556||Atypical|Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS.
32941660|NCT04795765||Patients treated with SpineJack system|SpineJack system procedure
33091644|NCT00345761|Experimental|Step 1|
33091645|NCT00345761|Experimental|Step 2|
32941661|NCT04795765||Patients treated with vertebral augmentation|Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).
33091646|NCT00345761|Experimental|Step 3|
33306981|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
33306982|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
33404357|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
33404358|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
32830564|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
32941662|NCT04857866|Experimental|Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F|
32941663|NCT04857866|Placebo Comparator|Single Ascending Dose - Placebo Subcutaneous injection of placebo|
32830565|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
32830566|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
32830567|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
32830568|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
32830569|NCT04351776|Other|VR-Biofeedback|
32830570|NCT04351776|Other|VR-Distraction|
32830571|NCT04351776|Other|360 Video|
32830572|NCT03292536|Experimental|Merestinib, all patients|
32830573|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
32830574|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
32830575|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
32830576|NCT03292302|Placebo Comparator|Placebo Comparator Arm|
32830577|NCT03292302|Active Comparator|Active treatment|ELX-02
32830578|NCT03287076|Experimental|Active|Patients will receive exenatide injections
32830579|NCT03287076|No Intervention|Standard Care|Standard care for stroke as per hospital protocol
32830580|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
32830581|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
32830582|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
32941664|NCT05253326|Experimental|Exercises Group|Patients will be taught Progressive Muscle Relaxation Exercises before the surgery and will be applied twice a week for 2 months after the surgery.
32941665|NCT05253326|No Intervention|Control Group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital.
33404359|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
32830583|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
32830584|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
32830585|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
32830586|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
32830587|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
32830588|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
32830589|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
32830590|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
33091647|NCT00345800|Experimental|Sodium Oxybate|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
33091648|NCT00454740|Experimental|1|
33091649|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
33091650|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
33091651|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
33091652|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
33091653|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
33091654|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
33091655|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
33091656|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
33091657|NCT00454896|Experimental|1|
33091658|NCT00454896|Placebo Comparator|2|
33091659|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
33091660|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
33091661|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
33091662|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
33091663|NCT04699305||ActiGraft|Whole blood clot (WBC) gel
33091664|NCT04699344||Pre-tissue biopsy patients|Pre-tissue biopsy patients with suspected prostate carcinoma will be the experimental group to determine the sensitivity and specificity of PROUD analysis, the result will be compared with histological results and PCA3 test.
33091665|NCT04699344||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of PROUD analysis.
33091666|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.~Intervention: Rivaroxaban"
33091667|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
33091668|NCT02273778|Other|Routine radiotherapy treatment|
33091669|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
32799470|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
32799471|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
32799472|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
32900855|NCT04749914|Experimental|Lasmiditan + Rosuvastatin (Part 2)|Participants will receive single doses of rosuvastatin followed by combination of lasmiditan along with rosuvastatin administered orally.
33091670|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
33102476|NCT03756155|Experimental|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
33102477|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
32799473|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
32799477|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
32799478|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
32799479|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
32799480|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
32799481|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
32799482|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
32799483|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
32799484|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
32799485|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
32799486|NCT01829048|Experimental|PF-02545920|
32799487|NCT01829048|Placebo Comparator|Placebo|
32799488|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799489|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799490|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799491|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799492|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799493|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
32799494|NCT04588922|Experimental|GFH009|
32799495|NCT01828034|Experimental|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 & 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
32799496|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
32799497|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
32799498|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
32799499|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
32799500|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
32799501|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
32799502|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
32799503|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
32799504|NCT04551807|Active Comparator|Modified natural cycle|corpus luteum present
32799505|NCT04551807|Active Comparator|Programmed cycle|corpus luteum absent
32799506|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
33091671|NCT04698213|Experimental|intermittent axitinib plus Avelumab|"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."
33091672|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.~Strength: 50 μg per actuation.~Batch/Lot number (Expiry date): JM6697 (May 2012)~Manufacturer: Apotex, Inc."
33091673|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide~Strength: 50 μg per actuation~Batch/Lot number (Expiry date): 131657 (03/2012)~Manufacturer: Sepracor, Inc."
33091674|NCT02273817|Placebo Comparator|Placebo|"Placebo~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.~Batch/Lot number (Expiry date): JR3808 (Nov 2012)~Manufacturer: Apotex, Inc."
33091675|NCT00346853|Experimental|1|
33091676|NCT00346853|Placebo Comparator|2|saline
33091677|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
33091678|NCT00448734|Active Comparator|2|Docetaxel
33091679|NCT00346970|Experimental|1|Extended-release Niacin
33091680|NCT00346970|Placebo Comparator|2|Placebo
33091681|NCT00347048|Experimental|1|
33091682|NCT00347048|Placebo Comparator|2|
33091683|NCT00455169||1|Premature infants
33091684|NCT00455169||2|Full term infants
33091685|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
33091686|NCT00448851|Experimental|1|inhaled allergen challenge
33091687|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
33091688|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
33091689|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
33404360|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
32799507|NCT01853618|Experimental|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
32799508|NCT01853618|Experimental|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
32799509|NCT01853618|Experimental|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
32799510|NCT01853618|Experimental|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
32799511|NCT01853618|Experimental|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
32799512|NCT01853618|Experimental|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
32799513|NCT01853462|Experimental|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
32799514|NCT01853462|Experimental|Balance|Supervised balance training
32799515|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
32799516|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
32799517|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
32799518|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
32799519|NCT04415619|Experimental|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
32799520|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
32799521|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
33091690|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
33091691|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
33091692|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
32799522|NCT01878890|Experimental|Efavirenz: 600 mg|Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
32799523|NCT01878890|Experimental|Efavirenz: 1200 mg|Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
32799524|NCT01878890|Experimental|Efavirenz: 1800 mg|Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
33091693|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
33091694|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
33091695|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
33091696|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
33091697|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
32799525|NCT01878890|Experimental|Efavirenz: 2200 mg|Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
32799526|NCT04415606|Experimental|QuikClot Control+|QuikClot Control+
33091698|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
32799527|NCT04415606|Placebo Comparator|Standard gauze|Standard gauze per standard of care
32799528|NCT04596644|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
32799529|NCT01827332|Active Comparator|Oxytocin|intranasal administration
32799530|NCT01827332|Placebo Comparator|Saline|intranasal administration
32799531|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
32799532|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
32799533|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
32799534|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
32799535|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
32799536|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
32799537|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
32799538|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
32799539|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
32799540|NCT01853228|Experimental|Decitabine and cytarabine|
32799541|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
32799542|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
32799543|NCT01718535||CYP2C19 Genotyping|
32799544|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
32799545|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
32799546|NCT04551183|Experimental|OnlyGroup|Patients are their own witnesses
32799547|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
32799548|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
32799549|NCT04555785|Experimental|Platelet transfusion with Wilate ®|
32799550|NCT04555785|Placebo Comparator|Platelet transfusion with Placebo|
32799551|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
32799552|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
32799553|NCT01870869|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
32799554|NCT01870869|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
32799555|NCT01870869|Experimental|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
32799556|NCT01870869|Experimental|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
32799557|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
32799558|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
32799559|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
32799560|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
32799561|NCT04605393|Experimental|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
33091699|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
33091700|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
33091701|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
33091702|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
33091703|NCT00455637|Experimental|Dysport 5 units|
33091704|NCT00455637|Experimental|Dysport 10 units|
33091705|NCT00455637|Experimental|Dysport 15 units|
33091706|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
33306983|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
32799562|NCT04605393|Experimental|CBD/THC|Oral CBD 1000mg followed by inhalation of cannabis containing THC.
32799563|NCT01827254||Non-Interventional Study|
32799564|NCT01824602|Experimental|Group 1|Eslicarbazepine acetate 1800 mg
32799565|NCT01824602|Experimental|Group 2|Eslicarbazepine acetate 1200 mg
32799566|NCT01824602|Experimental|Group 3|Eslicarbazepine acetate 600 mg
32799567|NCT01824602|Placebo Comparator|Group 4|Placebo pills
32799568|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
32799569|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
32799570|NCT04610294||Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
32799571|NCT04610294||Conventional air handling|Only routine room air filtration will be used in an operation room.
32799572|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
32799573|NCT04609592|Experimental|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
32799574|NCT01876082|Experimental|PAZOPANIB|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
32799575|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
32799576|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
32799577|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
32799578|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
32799579|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
32799580|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
32799581|NCT04604301|Experimental|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
32799582|NCT04604301|Experimental|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
32799583|NCT04604301|Experimental|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
32799584|NCT04604301|Experimental|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
32799585|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32900856|NCT05553288||active group|Every study participant will actively receive daily text messages asking about their change in health and concomitant medication.
32900857|NCT05286086|Sham Comparator|PREHAB-PREOP|PREHABILITATION BEFORE SURGERY
33091707|NCT03276312|No Intervention|Control|Routine clinical practice
33091708|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
33091709|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
33091710|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
33091711|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
33306984|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
32941666|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
32941667|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
32941668|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
32941669|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
32941670|NCT04849364|Experimental|Arm 1|"Arm 1a: Patients who are ctDNA-positive and harbor a genomic target. DNA repair pathway = talazoparib + capecitabine (CLOSED)~Arm 1b: Patients who are ctDNA-positive and harbor a genomic target. Immunotherapy pathway = atezolizumab + capecitabine~Arm 1c: Patients who are ctDNA-positive and harbor a genomic target. PI3K Pathway = inavolisib + capecitabine ---> atezolizumab~Arm 1d: Patients who are ctDNA-positive and harbor a genomic target. DNA Repair + Immunotherapy = talazoparib + atezolizumab + capecitabine"
32941671|NCT04849364|Active Comparator|Arm 2|Arm 2 subjects have plasma ctDNA positive but do not have a genomically driven treatment option. Treatment of physician's choice will be given with consideration for capecitabine and/or pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
32941672|NCT04849364|Active Comparator|Arm 3|Arm 3 subjects have plasma ctDNA negative. Treatment of patient and physician's choice will be given with consideration for capecitabine and/or pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
32941673|NCT04485104|Experimental|GWP42003-P|"The 52-week treatment period includes a fixed 2-week titration schedule followed by flexible dose optimization.~Day 1: 5 mg/kg/day (2.5 mg/kg twice daily (b.i.d.))~Day 8: 10 mg/kg/day (5 mg/kg b.i.d.)~Day 15 to Week 52: Flexible dosing based on the participant's observed efficacy, safety, and tolerability per the investigator's clinical judgement. Up to a maximum of 20 mg/kg/day (10 mg/kg b.i.d.) for LGS and DS or 25 mg/kg/day (12.5 mg/kg b.i.d.) for TSC, in maximum weekly increments of 5 mg/kg/day (≤ 2.5 mg/kg b.i.d.)."
32941674|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
33091712|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
33091713|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
32941675|NCT04847804||Positive case|The sample will be tested by microfluidic device and shows positive
32941676|NCT04847804||Negative control|The sample will be tested by microfluidic device and shows negative
32941677|NCT04844840|Experimental|Cohort 1: STP705 10 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
32941678|NCT04844840|Experimental|Cohort 2: STP705 20 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
32941679|NCT04844840|Experimental|Cohort 3: STP705 30 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
32941680|NCT04844840|Experimental|Cohort 4: STP705 40 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
32941681|NCT04844840|Placebo Comparator|Cohort 5: Placebo control|Placebo (saline) will be injected intradermal into the excised keloid site
32941682|NCT04844840|No Intervention|Cohort 6: SOC alone|SOC (no injection)
32941683|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
32941684|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
32941685|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
32941686|NCT04365374|Experimental|Surgical Resection and GammaTile Therapy|Surgical Resection and GammaTile Therapy
32941687|NCT04365374|Active Comparator|Surgical Resection and Stereotactic Radiation Therapy|Surgical Resection and Stereotactic Radiation Therapy
32941688|NCT04765657|Experimental|inclisiran sodium 300 mg|Subcutaneous injection
32941689|NCT04765657|Placebo Comparator|Placebo|Subcutaneous injection
32941690|NCT04358432|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32941691|NCT04358432|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32941692|NCT04358432|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
32941693|NCT04358432|Experimental|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
32941694|NCT04358432|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32941695|NCT04358432|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
32941696|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
32941697|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
32941698|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
32941699|NCT04353830|Experimental|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
32941700|NCT04476446|Experimental|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
32941701|NCT04744285|Active Comparator|Condition 1 (normal cigarettes)|Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
33091714|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
33091715|NCT00455793||1|HIV
33091716|NCT00455793||2|Non-HIV infected controls
33091717|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
33091718|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
32799586|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32799587|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
33091719|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
33091720|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
33091721|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
33091722|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
33091723|NCT00348335|Active Comparator|1: Restasis|
33091724|NCT00348335|Active Comparator|2: Refresh Endura|
33091725|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
33091726|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
32799588|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
32799589|NCT01715805|Other|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
32799590|NCT01715805|Placebo Comparator|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
32799591|NCT01715805|Experimental|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
32799592|NCT01715805|Other|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
32799593|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
32799594|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
32799595|NCT04594772|Experimental|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
32799596|NCT01393990|Experimental|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
33091727|NCT00348569|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
33091728|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
33091729|NCT00348608|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
33091730|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
33091731|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
33091732|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
33091733|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
33091734|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
33091735|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
33091736|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
33091737|NCT04715009||participants use smartphone less than 4 hours per day|participants use smartphone less than 4 hours per day
33091738|NCT04715009||participants use smartphone more than 4 hours per day|participants use smartphone more than 4 hours per day
33404361|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
33091739|NCT00456144||Group 1|GnRH agonist for 24 months
33091740|NCT00456144||Group 2|GnRH agonist for 6 months
33091741|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
33091742|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
33091743|NCT00456222||Luteal|
33091744|NCT00456222||Follicular|
33091745|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
33091746|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
33091747|NCT00449553||Pioglitazone 15 mg QD + Metformin|
33091748|NCT00449553||Pioglitazone 30 mg QD + Metformin|
33091749|NCT00449592|Experimental|1|Oral zinc therapy, intervention
33091750|NCT00449592|Placebo Comparator|2|oral placebo
33091751|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
33091752|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
32900858|NCT05286086|Experimental|PREHAB-NEOADJ|PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
33091753|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
33091754|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
33091755|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
33091756|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
33091757|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
33091758|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
33091759|NCT00349271|Active Comparator|Standart therapy|Standart therapy
33091760|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
33091761|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
33091762|NCT00349427|Experimental|Rosiglitazone|4mg
33091763|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
33091764|NCT00456690|Experimental|1|Thalassemia Mayor Patients
33091765|NCT00349856|Active Comparator|1|
33091766|NCT00349934|Experimental|A|IMP321
33091767|NCT00450099|Experimental|1|Epidural, bupivacaine
33091768|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
33091769|NCT00350012||2|Healthy age- and education-matched volunteers
33091770|NCT00450138|Experimental|1|Radiation + vandetanib
33091771|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
32900859|NCT05268666|Experimental|JBI-802|10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle
32900860|NCT05305404|Active Comparator|Guanfacine|single dose of dexamethasone (1.5mg) administered orally
32900861|NCT05305404|Placebo Comparator|Placebo|single dose of placebo administered orally
32900862|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
32900863|NCT05268120|Active Comparator|A|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
32900864|NCT05268120|Active Comparator|B|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
32900865|NCT05218902||Retrospectively enrolled cohort|Participants who initiate Azacitidine (AZA) before enrollment
32900866|NCT05218902||Prospectively enrolled cohort|Participants who initiate AZA initiation at enrollment
32900867|NCT05303610||Experimental group|This group will consist of 28 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years.
32900868|NCT05303610||Control group|Healthy individuals between the ages of 25-50 and without any orthopedic (Anterior cruciate ligament rupture, Meniscal tears etc.), neurological (Multipl sclerosis, Stroke etc) and rheumatological disorders (Rheumatoid arthritis, Ankylosing spondylitis etc.).
32900869|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
32900870|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
33091772|NCT00350051|Experimental|Arm 1|
33091773|NCT04699110|Experimental|Treatment group|Patients receiving intracoronary adrenaline
33091774|NCT04699110|Active Comparator|Control group|Patients receiving intracoronary adenosine
33091775|NCT00350129||1|healthy vasospastic subjects
33091776|NCT00350129||2|healthy non-vasospastic subjects
33091777|NCT04698759||Stunted subject|Children with stunted status condition based on Z score criteria
33091778|NCT04698759||Normal subject|Children with normal status condition based on Z score criteria
33091779|NCT03274089|Experimental|Kiosk intervention group|
33091780|NCT03274089|No Intervention|Nurse clinician control group|
32900871|NCT01657266|Experimental|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
33091781|NCT00350285|Experimental|1|Motivational enhancement therapy
33091782|NCT00350285|Active Comparator|2|Marijuana education
33091783|NCT00350285|No Intervention|3|Delayed treatment control condition
33091784|NCT04698954|Experimental|AIMS intervention group|A nurse-delivered behavioural intervention focussing on medication adherence, physical activity, and symptom management integrated in routine clinical care. AIMS-CHF incorporates nurse-counselling and feedback from electronic monitoring of medication use (using MEMS-buttons) and physical activity (using pedometers).
33091785|NCT04698954|Active Comparator|Treatment-as-usual group|Participants in the control group will receive treatment as usual. They will visit the out patient clinic each 3 or 6 months for 30 minutes.
33102478|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
32900872|NCT01657266|Active Comparator|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
32900873|NCT00375830|Experimental|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
32900874|NCT00375830|Experimental|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
32900875|NCT00375830|Experimental|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
32900876|NCT05479734|Experimental|mHealth Intervention + EMA|When families are in the mHealth intervention condition, the mHealth app will deliver parenting tips and strategies daily for 14 days. Furthermore, we plan to administer brief surveys via the mHealth app twice once a day at a pre-determined time. These surveys will ask parents to provide information about where they are and with whom, their emotional state, any recent parent-child interactions, and any current stressors or challenges. Parents will receive these daily surveys and the parenting tips for every day for two weeks. Then they will switch to EMA Only + Services As Usual.
32900877|NCT05479734|No Intervention|EMA Only+ Services As Usual|In the EMA only condition, families will continue to receive services utilizing the home visiting model for the program they are enrolled in, including modules on healthy parent-child interaction and promoting parenting skills in high-risk families, but they will not receive parenting tips via the mHealth app during this period (2 weeks). Then, they will switch to mHealth Intervention + EMA.
32900878|NCT05302440||single-group|All care staff who manage the system will complete a very brief survey (1-minute) after each work shift for 14 days. Detection of abnormal vital signs will be recorded by the system. Hospital admission and further medical assistance due to the use of the system will be documented by the care team. The staff will be interviewed about their perceived benefits and acceptability of the system.
32900879|NCT05286008|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
32900880|NCT05286008|Experimental|Ropivacaine at high concentration|Before the induction of anesthesia, 0.375% Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
32900881|NCT05286008|Experimental|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
32900882|NCT05265624|Experimental|Early Genetic Results Disclosure|Early disclosure group receives results of genetic testing at Month 1
32900883|NCT05265624|Active Comparator|Late Genetic Results Disclosure|Late disclosure group receives results of genetic testing at Month 12
32900884|NCT05265546|Experimental|Experimental|Psilocybin 0-14 mg, before fMRI measurement
32900885|NCT05265546|Other|Comparator|Psilocybin 0-14 mg, before fMRI measurement
32900886|NCT05215314|Experimental|Healthy Minds Program (HMP)|Fully remote, 4-week meditation intervention
32900887|NCT05215314|No Intervention|Waitlist Control|Control participants will not complete the Healthy Minds Program during the study, but can use it after they have completed the study
32900888|NCT05302284|Experimental|RC48-ADC + JS001|Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
32900889|NCT05302284|Active Comparator|Gemcitabine + cisplatin/carboplatin|Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
32900890|NCT05265078||Participants Diagnosed With VWD|Participants who have been diagnosed with VWD and prescribed VEYVONDI for the approved indications for the index infusion (first eligible VEYVONDI infusion) will be assessed using secondary data obtained from medical records to evaluate the safety of VEYVONDI in real-world clinical practice. All study data will be retrospectively abstracted from medical records by dedicated clinical research staff in partnership with the treating physician. The data window for this study will begin on 01 January 2019 and end one day before site activation at each site.
32941702|NCT04744285|Experimental|Condition II (cigarettes with neutral message)|"Participants receive cigarettes with neutral message Nothing about this product's color or name means that it will protect a smoker from the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection."
32941703|NCT04744285|Experimental|Condition III (cigarettes with compensation message)|"Participants receive cigarettes with compensation message This product has a ventilated filter. Filter vents increase how deeply a smoker inhales without them knowing, which can increase the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
32941704|NCT04744285|Experimental|Condition IV cigarettes with blocking message|"Participants receive cigarettes with blocking message This product has a ventilated filter. Be sure not to block the vent holes with your fingers or lips, which can increase the health risks of smoking for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
32941705|NCT04458272|Experimental|DS-1001b|
32941706|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
32941707|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
32941708|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
32941709|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
32941710|NCT03662126|Experimental|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
32746486|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
32941711|NCT03662126|Active Comparator|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
32941712|NCT00630487|Placebo Comparator|Placebo|
32941713|NCT00630487|Active Comparator|Verum|
32941714|NCT03659240|Experimental|Cranberry beverage|
32941715|NCT03659240|Placebo Comparator|Placebo beverage|
32941716|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
32941717|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
32941718|NCT04456946|Experimental|Group of Low Level Laser Therapy|
32941719|NCT04456946|Experimental|Group of Occlusal Splint Treatment|
32941720|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
32941721|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
32941722|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
32941723|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
32941724|NCT04712552||Stereotactic robot-guided deep brain stimulation procedure|Patients requiring a stereotactic robot-guided deep brain stimulation procedure (Parkinson's disease, disabling tremor, dystonia)
32941725|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
32941726|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
32941727|NCT00000259|Active Comparator|0.3% sevoflurane|
32941728|NCT00000259|Active Comparator|0.6% sevoflurane|
32941729|NCT00000259|Active Comparator|15% Nitrous oxide|
32941730|NCT00000259|Active Comparator|30% Nitrous oxide|
32941731|NCT04330664|Experimental|Phase 1 Dose Exploration|Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849
32941732|NCT04330664|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens
32941733|NCT04330664|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination
32941734|NCT00000265||Low anxiety|
32941735|NCT00000265||Moderate anxiety|
32941736|NCT00000265||High anxiety|
32941737|NCT04331665|Experimental|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
32941738|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
32941739|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
32941740|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
32941741|NCT00379483|Experimental|Arm 1|
32941742|NCT04509427|Active Comparator|Handouts Only (HO) group|The HO only group will receive program instructions via handouts and videoconferencing with a physical therapist who will provide intervention instruction, assist with program progression, and monitor participant quality of movement and safety.
32941743|NCT04509427|Active Comparator|Handouts plus web-based video (HO+) group|The HO+ group will receive the same intervention as the HO group but they will also have access to web-based videos that will lead them through all exercise/posture routines like a commercial exercise video.
32941744|NCT00607477|Active Comparator|1|Minoxidil
32941745|NCT00607477|Active Comparator|2|Hydralazine
33404362|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
32941746|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
32941747|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
32941748|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
33091786|NCT04715087|Other|Atopic dermatitis patients|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be re-applied (via patchtest) to AD patient. After reading the patch test results, skin biopsies will be performed
33306985|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
33306986|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
33306987|NCT05665972|Experimental|Mandala coloring group|Mandala painting will be applied to women suffering from premenstrual syndrome.
33306988|NCT05665972|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce premenstrual syndrome symptoms.
33306989|NCT05667532||Contrast Enhanced Mammography|
33306990|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
33306991|NCT03738358|Experimental|Trehalose|
33306992|NCT03738358|Placebo Comparator|Placebo|
33306993|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
32941749|NCT04423861|Experimental|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
32746487|NCT05613699|Other|supervised, group-based, online-social media exercise program|
32941750|NCT04423861|Placebo Comparator|Placebo|Patients will receive matching placebo BID for 7 days.
32941751|NCT04418869|Experimental|Exercise|All subject will perform three different exercise bouts and one control session.
32941752|NCT04330196|Experimental|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
32941753|NCT04330196|Placebo Comparator|Control condition|In the control condition patients ingest 200ml of water sweetened with 700mg of aspartame
32941754|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
32941755|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
32941756|NCT04444622|Experimental|AlloStim|"AlloStim is administered in three cycles:~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
32941757|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
32941758|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
32941759|NCT04302350|Experimental|Group75|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group75 set to N2O:O2=6:2). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
33102479|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
33091787|NCT04715087|Other|Healthy controls|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. After reading the patch test results, skin biopsies will be performed.
32799597|NCT00210184|Experimental|Irinotecan associated to fluorouracil and leucovorin|"On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months"
32799598|NCT00210106|Experimental|Intraoperative radiofrequency ablation (IRFA)|IRFA treatment, either with or without resection, was performed at laparotomy within 28 days of inclusion in the study. The type of IRFA current generator and probes, and whether or not resection was performed, was at the discretion of the surgeon.
32799599|NCT05361694||Participants with MGUS or SMM|Participants with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) will be followed for disease progression to active multiple myeloma (MM) for up to 5 years.
33091788|NCT00105534|Experimental|AzaSite|
33091789|NCT00105534|Sham Comparator|Vehicle|
33091790|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
33091791|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
33091792|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
33091793|NCT00350753|Experimental|Erlotinib and bevacizumab|
33091794|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
33091795|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
33091796|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
33091797|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
33091798|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
33091799|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
33306994|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
33306995|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
32799600|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
32799601|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
32799602|NCT05368168|Experimental|Group 1: Posterior tibial nerve stimulation (PTNS)|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization, WILL BE treated with posterior tibial nerve stimulation.
32799603|NCT05368168|No Intervention|Group 2: Standard of care|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization,WILL NOT BE treated with posterior tibial nerve stimulation.
32799604|NCT05364190|Experimental|Group A(Intervention group)|patients will receive 100 mg canagliflozin initiated within 24 hours from patients hospital admission due to signs of hypervolemic state. All patients also will be prescribed the conventional diuretic therapy and other medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI) and mineralocorticoid receptor antagonists (MRAs). Canagliflozin will be continued for 90 days after hospital discharge
32900891|NCT05301036|Experimental|Active stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of deep brain target (subgenual cingulate or alternative targets)
32900892|NCT05301036|Sham Comparator|Sham stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of lateral ventricle
32900893|NCT05263674|No Intervention|"Non-sedative medical treatment"|"The patient is treated with an additional high-dose intravenous antiepileptic drug, which is selected by the treating neurologist. If NCSE continues to be detected at cEEG or clinically> 3 hours after starting treatment, the patient should receive standard treatment (i.e. sedation in the intensive care unit or addition of additional intravenous antiepileptic drugs) in accordance with local guidelines and the assessment of the treating neurologist. The following preparations are permitted as additional treatment:~Levetiracetam (60 mg / kg as saturation dose followed by maintenance dose of 2-4 g / day), valproate (60 mg / kg as saturation dose followed by maintenance dose of 20 mg / kg / day), phosphenytoin (20 PE as saturation dose followed by maintenance dose 5 mg PE / kg / day), lacosamide (400 mg as a saturation dose followed by a maintenance dose of 200-400 mg / day), topiramate (200-400 mg per probe as a saturation dose followed by a maintenance dose of 200-400 mg / day)."
32941760|NCT04302350|Experimental|Group50|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group50 set to N2O:O2=4:4). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
33306996|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
33306997|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
33306998|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
33306999|NCT03665038|Experimental|Brexanolone|Participants will receive a 60-hour single continuous IV infusion of brexanolone, at 30 mcg/kg/hour (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
33307000|NCT03664024|Experimental|Pembrolizumab Standard of Care|Participants will receive standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin.
33307001|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
33091800|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
33307002|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
33307003|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose Cohorts
33307004|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts
33307005|NCT03639688|Active Comparator|Left sided|
33307006|NCT03639688|Active Comparator|Right sided|
33307007|NCT00381641|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
33307008|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
33307009|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
33307010|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
33307011|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
33307012|NCT04516733|Other|single arm|patient with glioblastoma
33307013|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
33307014|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
33307015|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
33307016|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
33307017|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
33307018|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
33307019|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
33307020|NCT00381095|Experimental|1|flexible dosing
33307021|NCT00381095|Placebo Comparator|2|
33307022|NCT03619174|Active Comparator|Active Treatment|Treatment dose
33307023|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
33307024|NCT05665894||Breast hematoma group|Patients of age between 18 and 75 years old after breast conservative surgery (BCS), VAB or vacuum-assisted excision (VAE) procedure in our facility, who developed clinically significant and large hematoma (>25 mm). In our institution, we routinely offer a trial of Vacuum-Assisted Evacuation (VAEv) for >25 mm hematoma that does not fulfill the criteria for immediate surgery and causes discomfort, pressure symptoms, infection, or pain classified on VAS > 3.
33307025|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
33307026|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
33307027|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
33307028|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
33307029|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
33307030|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
33307031|NCT00112047|Active Comparator|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir ([CBV]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla ([ATR]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
33318542|NCT02960230|Experimental|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
32746488|NCT05613699|Other|unsupervised individual home-based training with an online-training app|
32746489|NCT05613699|Other|supervised, in-person exercise program close to place of residence|
32941761|NCT04302350|Active Comparator|Group0|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group0 set to O2=8). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
32941762|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
32941763|NCT04297358|Experimental|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
32941764|NCT04295486|Experimental|Treatment Once Daily|Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.
32941765|NCT04295486|Active Comparator|Treatment Twice Daily|Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.
32941766|NCT04294628|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline and every 3 cycles for up to 1 year and then every 4 cycles thereafter while on treatment. Patients also undergo biopsies at baseline, on day 1 of cycles 1 and 3, and at the time of disease progression.
32941767|NCT04384939|Experimental|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
32941768|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
32941769|NCT04348591|Experimental|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
32941770|NCT04348591|Active Comparator|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
32941771|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
32941772|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
32941773|NCT04246723|Experimental|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
32941774|NCT04246723|Experimental|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
32941775|NCT04423718|Active Comparator|Aflibercept 2q8|In the double-masked study part (Years 1 and 2), Aflibercept 2 mg administered every 8 weeks after a loading phase. (Active Comparator) In Year 3, high dose aflibercept administered according to individual patient response. (Experimental)
32941776|NCT04423718|Experimental|Aflibercept HDq12|Aflibercept high dose (HD) administered every 12 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
32941777|NCT04423718|Experimental|Aflibercept HDq16|Aflibercept high dose administered every 16 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
33307032|NCT00112047|Experimental|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada ([TVD] the fixed-dose combination pill containing FTC/TDF [200/300 mg] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
33307033|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
33307034|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
33307035|NCT03658876|Active Comparator|EPO group|
33307036|NCT03658876|Active Comparator|Iron group|
33307037|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
33307038|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
33307039|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
33307040|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
33307041|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
33307042|NCT03617770|Active Comparator|Healthy Living|Health education
33307043|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
33307044|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
33307045|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
33307046|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
33307047|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
33307048|NCT03616600|No Intervention|Control|Not wearing any contact lenses
33307049|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
33307050|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
33307051|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
33307052|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
33307053|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
33307054|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
33307055|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
33307056|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
33307057|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
33307058|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
33307059|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
33307060|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
33307061|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
33307062|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
33307063|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
33307064|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
33307065|NCT03729934|No Intervention|Control|This arm receives no treatment control.
33307066|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
33091801|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
33307067|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
33307068|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
33307069|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
33307070|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
33307071|NCT00098306|Experimental|1|
33307072|NCT00098306|Experimental|2|
33307073|NCT00098306|Experimental|3|
33307074|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
33307075|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
33307076|NCT02531204|Experimental|ASP1585 granules preceding group|
33307077|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
33307078|NCT00068822|Experimental|Vertebroplasty|Participants will receive percutaneous vertebroplasty
33307079|NCT00068822|Placebo Comparator|Control Group|Participants will receive sham vertebroplasty without PMMA
33307080|NCT03964064|Experimental|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
33307081|NCT03964064|Experimental|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
33404363|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
32799605|NCT05364190|Active Comparator|Group B|patients will receive 10 mg Empagliflozin initiated within 24 hours from patients hospital admission due to signs of a hypervolemic state.All patients also will be prescribed conventional diuretic therapy and other medications including ACEIs, ARBs, beta-blockers, ARNI, and MRAs.Empagliflozin will be continued for 90 days after hospital discharge
33307082|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
33307083|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
33307084|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
33307085|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
33307086|NCT00068588|Experimental|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33307087|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
33307088|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
33307089|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
33307090|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
33307091|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
33307092|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
32799606|NCT05368480|Experimental|Senior Companion|Receives a companion to socialize with them, help with daily tasks, etc.
32799607|NCT05368480|No Intervention|Control|Referred to other services available in the community
33307093|NCT03963752|Experimental|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
33307094|NCT03963752|Active Comparator|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
33307095|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
33307096|NCT03650452|Placebo Comparator|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
33307097|NCT03650452|Experimental|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
33307098|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
33307099|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
33404364|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
32799608|NCT05362786|Experimental|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in two intravenous infusions of 100x10^6 cells at time zero and three months
32799609|NCT05362786|Experimental|Dose Arm 2|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) single intravenous infusion of 200x10^6 cells
33091802|NCT00457158|Experimental|1|ALN optional filter
33091803|NCT00457158|No Intervention|2|No ALN optional filter
32799610|NCT05369572||Bile Reflux Group|"Gastroscopic reports of enrolled patients will be extracted and patients will be identified as having bile reflux according to Kellosalo J classification.~Grade I: small amount of yellowish reflux emerging from the pyloric orifice and/or yellowish staining of the mucus lake, which is pale yellow in colour.~Grade II: intermittent gush of reflux from the pyloric opening and/or yellowish staining of the mucus lake, which is dark yellow.~Grade III: frequent gush of yellow-green reflux from the pyloric orifice and/or yellow-green mucus covering the stomach."
32799611|NCT05369572||Non-biliary reflux group|Gastroscopic reports will be extracted from patients enrolled in the group that do not meet the Kellosalo J classification as the non-biliary reflux group.
33091804|NCT00350987|Experimental|PCT|PCT guidance
33091805|NCT00350987|Active Comparator|Guidelines|enforced guidelines
33091806|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
33307100|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
33091807|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
33307101|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
33307102|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
33307103|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
33307104|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
33307105|NCT03731962|Other|Without CIN|Coronary Angiography
33307106|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
33307107|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
33307108|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
33307109|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
33307110|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
33307111|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
33307112|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
33307113|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
33307114|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
33307115|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
33307116|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
33307117|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
33307118|NCT05665816||Intervention|Subjects with PAD treated with the PULSAR® -18 T3 Stent will be assessed for eligibility for the registry and consecutively included in the registry. Once informed consent is obtained, the required data will be collected.
33307119|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
33307120|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
33091808|NCT03276039||25 patients with non-alcoholic fatty liver disease|
33091809|NCT03276039||25 patients with NAFLD and chronic HCV|
33091810|NCT03276039||20 healthy controls|
33404365|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
32737965|NCT05232773||Experimental group|"Enrolled patients will undergo supervised rehabilitation treatment for rotator cuff repair according to a standardized protocol (5 days/week) and will undergo clinical, kinematic and shoulder muscle strength assessments to collect data useful to define objective criteria for progression between rehabilitation phases. Assessment will be performed at four different times.~The clinical evaluation of the shoulder is carried out through the Constant-Murley Score (CMS).~Pain will be assessed through the visual analogical scale (VAS). Kinematic assessment (shoulder ROM, scapula-humeral rhythm, movement smoothness, movement speed) will be assessed through magneto-inertial measurements units (M-IMU).~The maximal voluntary isometric contraction (MVIC) of shoulder flexor, abductor and rotator cuff muscles of the affected limb will be measured by the Chronojump Boscosystem® Force Sensor Kit"
32737966|NCT05232773||Healthy subjects|Healthy subjects will undergo evaluations with the same timing as patients in the Experimental group.
32941778|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
32941779|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
32941780|NCT04181203|Active Comparator|SRT + 6 months of LHRHa|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
32941781|NCT04181203|Experimental|SRT + 6 months of LHRHa + 6 months of Apalutamide|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
32941782|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain score will be obtained at baseline, 15, 30, 45, 60, 90, 120, and 180 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
32941783|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS pain score will be checked at 5 minutes and every 15 minutes thereafter for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
32941784|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
32941785|NCT05440591|Active Comparator|Metformin|Metformin XR 500 mg tablets - up-to twice daily orally.
32746490|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
32941786|NCT05440591|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablets - once daily
32941787|NCT05440591|Experimental|MetforminXR 500/Dapagliflozin 5mg|MetforminXR 500/Dapagliflozin 5mg , tablets- once daily
32941788|NCT04099303|Experimental|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
32941789|NCT04099303|Active Comparator|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
32941790|NCT04099303|Experimental|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
32941791|NCT04099303|Active Comparator|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
32941792|NCT04099303|Experimental|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
32941793|NCT04099303|Active Comparator|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
32941794|NCT04099303|Active Comparator|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
32941795|NCT04099303|Experimental|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
32941796|NCT04099303|Active Comparator|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
32941797|NCT04099303|Experimental|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
32941798|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
32941799|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
32941800|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
32941801|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
32941802|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
32941803|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
32941804|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
33307121|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
33307122|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
33307123|NCT01310140||Major Depressive Disorder|
33307124|NCT01310140||Major Depressive Disorder with Psychotic Features|
32941805|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
32941806|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
32941807|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
32941808|NCT04712708|Active Comparator|Control Group|Eighteen children with spastic CP will receive especially designed physical therapy program based on Neuro-Developmental treatment (NDT) approach with emphasis on exercise encourage independent standing, stretches exercises, strengthening exercises, approximation, enhancement and facilitation of gait patterning and ankle ROM exercises for one hour for 24 sessions
32941809|NCT04712708|Experimental|Study Group|ighteen children with spastic CP will receive the same program that the control group received in addition to especially designed exercises using rebound therapy (Mini Trampoline) that include push up exercise, standing, squatting, single limb squatting, kneeling position, catching and throwing a ball over head in kneeling position, catching and throwing a ball over head in standing position, kicking the ball, broad jumping with assistance, jumping in place, for 1 hour three times per week for three successive months.
32941810|NCT04276064|Experimental|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
32941811|NCT04276064|Experimental|Healthy controls|Healthy controls
33307125|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
33307126|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
33307127|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
33307128|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
33307129|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
33307130|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
33307131|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
33307132|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
32941812|NCT04270682|Experimental|Adult Cohort|Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
32941813|NCT04270682|Experimental|Pediatric Cohort|Pediatric cohort patients (≥1 month and <16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
32941814|NCT04022785|Experimental|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
32941815|NCT04246970|No Intervention|Control group|Conventional medical care
32941816|NCT04246970|Experimental|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
32941817|NCT04246970|Experimental|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
32941818|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
32941819|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
32941820|NCT04240886|Experimental|Cohort A: fosmanogepix (APX001)|
32941821|NCT04240886|Experimental|Cohort B: fosmanogepix (APX001)|
32941822|NCT04235660|Active Comparator|Yttrium-90 Radiation Segmentectomy|
32941823|NCT04235660|Active Comparator|Stereotactic Body Radiation Therapy|
32941824|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
32941825|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
32941826|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
32941827|NCT00000385|Placebo Comparator|2|Matching placebo
33307133|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
33091811|NCT04714697|Experimental|Cohort 1(post nivolumab and ipilimumab combination)|the subject who failed one prior line by nivolumab and ipilimumab
33091812|NCT04714697|Experimental|Cohort 2 (post pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or avelumab and axitinib)|the subject who failed one prior line by PD-1/PD-L1 inhibitors in combination with VEGF TKI
33091813|NCT04714697|No Intervention|Cohort 3 (post sequential immunotherapy after VEGFR TKI)|the subject who failed the second line by immunotherapy (PD-1 antibody or PD-L1 antibody) following the first line VEGFR TKI
33091814|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
33091815|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
33307134|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
33307135|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
33307136|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
33307137|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
33307138|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
33307139|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
33307140|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
32799612|NCT00210964|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
33091816|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
33307141|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
33307142|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
33307143|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
33307144|NCT05666440|Active Comparator|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.
33307145|NCT05666440|Active Comparator|Rigid probe Viscotrabeculotomy|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.
33307146|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
33307147|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
33091817|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
33091818|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
33307148|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
33307149|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation~local anesthesia~use of dental clamp and rubber dam~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
33307150|NCT03733522|Experimental|Relative isolation|"Relative isolation~no local anesthesia~use of cotton roll and saliva ejector~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
33307151|NCT03731650|Experimental|active comparator|
33307152|NCT03731650|Experimental|placebo|
33091819|NCT04714658|Experimental|Immediate PTE|
33091820|NCT04714658|Other|6-month deferred PTE|
33091821|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
33091822|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
33307153|NCT03605836|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
33091823|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
33091824|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
33091825|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
33091826|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
33091827|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
33091828|NCT02956902|No Intervention|Waiting list control|
33091829|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
33091830|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
33091831|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
33091832|NCT04698642|Experimental|CBL-514 180 mg, 1.2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
33091833|NCT04698642|Experimental|CBL-514 240 mg, 1.6 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
33091834|NCT04698642|Experimental|CBL-514 300 mg, 2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
33091835|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
33091836|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
33091837|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
33091838|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
33091839|NCT00457509|Active Comparator|Group 5|Control
33307154|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
33307155|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
33091840|NCT04714307||Symptomatic|Molecularly diagnosed SCA3/MJD Symptomatic subjects.
33091841|NCT04714307||Non-related Controls|Controls matched with symptomatic by age and educational level.
33091842|NCT04714307||At 50% risk for SCA3/MJD group|The offspring of affected individuals with SARA<3. This group will be comprised of two subpopulations: pre-symptomatic individuals and related controls. The determination will be made upon molecular diagnosis to be done in a double-blind manner.
33091843|NCT00450684|Experimental|Group A|Implantation and testing of CRT
33091844|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
33091845|NCT04714268||Procedures with EndoNaut|Endovascular interventions using the EndoNaut workstation. 3D image fusion is used for overlaying arterial information on top of fluoroscopic images
33091846|NCT04714268||Procedures without EndoNaut|Control group, endovascular interventions without 3D image fusion
33091847|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
33091848|NCT00351806|Experimental|Chinese herbal medicine|
33091849|NCT00351806|Placebo Comparator|placebo|
33091850|NCT00457938|Other|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
33091851|NCT00458016|Experimental|1|
33091852|NCT00458016|Experimental|2|
33091853|NCT00458016|Experimental|3|
33091854|NCT00458016|Experimental|4|
33091855|NCT00458016|Placebo Comparator|5|
33091856|NCT00351884|Experimental|vildagliptin am|
33091857|NCT00351884|Experimental|vildagliptin pm|
33091858|NCT00351884|Placebo Comparator|placebo|
33091859|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
33091860|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
33091861|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
33091862|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
33091863|NCT04698798|Experimental|Skeletal muscle wasting|investigating acute skeletal muscle wasting in patients infected with SARS-CoV-2 and admitted to the ICU
33091864|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
33091865|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
33091866|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
33091867|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
33307156|NCT03605836|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
33307157|NCT03605680|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
32746491|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
33307158|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
33307159|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
33404366|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
32746492|NCT05613621||training cohort|Consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort.
32941828|NCT04365920|No Intervention|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
32941829|NCT04365920|Experimental|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
32941830|NCT04365920|Experimental|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
32941831|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
32941832|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
32941833|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
32941834|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
32941837|NCT03896425|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
32941838|NCT03896425|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
32941839|NCT03896425|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
32941840|NCT03889093|Other|Yttrium-90|This single arm study is to evaluate immunologic changes following the treatment of primary or secondary malignancies of the liver utilizing beta-emitting, Yttrium-90.
32941841|NCT04233164|Experimental|1 mg/kg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
32941842|NCT04233164|Experimental|250 mg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
32941843|NCT04226456|No Intervention|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
32941844|NCT04226456|Experimental|N-acetylcysteine|"Experimental arm (Arm B):~0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.~Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
32941845|NCT04195568|Experimental|Surpass Evolve Flow Diverter System|This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).
32941846|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
32941847|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
32799613|NCT00210964|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
33307160|NCT03605680|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
32799614|NCT00210652|Experimental|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
32799615|NCT05365516|No Intervention|Medical Safety Huddles - Pre-implementation|
32799616|NCT05365516|Experimental|Medical Safety Huddles - Post-implementation|
32799617|NCT03997786|Active Comparator|Part A|Part A is a DOSE FINDING COMPONENT: OPEN LABEL PK lead-in and safety component
32799618|NCT03997786|Experimental|Part B Part 1: Placebo and active comparator controlled study|
32799619|NCT03997786|Experimental|Part B-1 and B-2: Randomized withdrawal and retreatment after relapse|
32799620|NCT03997786|No Intervention|Part B 3: Efficacy and Safety Follow-up|
32799621|NCT03997786|Experimental|Part C: LTE|
33307161|NCT03728764|Other|single arm|
33307162|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
32799622|NCT05369104|Experimental|Bacteriophages arm|1 mL (PP1493 or PP1815) or 2 mL (PP1493 and PP1815) of suspension of bacteriophages diluted in solution of NaCl 0,9% at the end of DAIR procedure.
32799623|NCT05369104|Placebo Comparator|Control Arm|One local administration of NaCl 0,9% solution is administered at the end of the DAIR procedure.
32799624|NCT05365126|Experimental|Complete Vocal Technique Voice Therapy|Up to six 45 minute sessions delivered by a CVT Practitioner using a video link within an eight week therapy period
32799625|NCT05630638|Experimental|Delstrigo|doravirine/lamivudine/tenofovir disoproxil 100 mg/ 300 mg/ 245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
32799626|NCT05630638|Active Comparator|Standard of care|dolutegravir/lamivudine/tenofovir disoproxil 50 mg/300 mg/245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
32799627|NCT05362162|Active Comparator|Group S|Superficial cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent into the subcutaneous area in the anterolateral neck region, from the anatomical region that fits the carotid artery bifurcation point, under the guidance of USG.
32799628|NCT05362162|Active Comparator|Group I|Intermediate cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent under the investing fascia from the anatomical region that fits the carotid artery bifurcation point under the guidance of USG.
32799629|NCT03997708|Active Comparator|Group A|MED-LFD Diet (diet A) for 2 - 6 weeks. After this period there will be a reintroduction phase protocol that will last 6 - 8 weeks.
32799630|NCT03997708|Active Comparator|Group B|Diet according to guidelines from the National Institute for Health and Care Excellent (NICE) Managing IBS (diet B) for 4 weeks.
32799631|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
32799632|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
32799633|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to ON"
32799634|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
32799635|NCT05366842|Experimental|Stravix|Direct placement of LPT over the spared neurovascular bundles during bilateral nerve sparing radical prostatectomy for prostate cancer.
32799636|NCT05366842|Sham Comparator|Standard of Care|Standard care (no placement of tissue) bilateral nerve sparing radical prostatectomy for prostate cancer.
32799637|NCT05630560||Psychologists in Danish private practice|All psychologists with a Danish university degree in psychology who have registered themselves as seeing clients in private practice (app. 1,750) have been invited to participate in the study. Thus, the sample of psychologists consists of psychologists employed in the Danish practice sector, where clients obtain a refund of 60% of the psychologist's salary, as well as psychologists working privately without any reimbursement of their salaries. Each psychologist enrolled in the study has agreed to aim to recruit no less than 10 clients each for the study. We aim to include 100 psychologists, which will yield a sample of 1,000 clients beginning therapy.
32799638|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
32799641|NCT05630482|Experimental|Healthy Family Foundations Intervention|Participants randomized to the HFF intervention condition will participate in 10 weekly 2 hour classes (5 prenatal and 5 postnatal) in groups of 5-10 couples. Due to COVID, all classes will take place via Zoom. The classes will be led by male/female facilitator teams. The facilitators will be hired, trained and supervised by Penn State. Postnatal classes will occur 2-8 months after birth and will also be weekly and last 2 hours each.
32799642|NCT05630482|Active Comparator|Control Condition|Participants randomized to the control condition will receive standard of care and opportunities for education at their site, including information about infant growth and development, infant care (including brief, standard information regarding breastfeeding/introduction to solid food), and quality childcare selection.
33404367|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
33404368|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
32941848|NCT03746431|Experimental|[225Ac]-FPI-1434 Single-Dose Escalation|
32941849|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose Escalation|[225Ac]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
32941850|NCT03746431|Experimental|FPI-1175 Cold Antibody|
32941851|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose|Phase 2 Tumour Cohort - Head & Neck Squamous Cell Carcinoma (HNSCC), Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative, Adrenocortical Carcinoma (ACC), Uveal Melanoma, [225Ac]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
32941852|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
32941853|NCT03731845|Experimental|patient|
32941854|NCT04183790|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
32941855|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
32941856|NCT00000451|Experimental|1|Naltrexone plus Sertraline
32941857|NCT00000451|Experimental|2|Naltrexone alone
32941858|NCT04175600|Experimental|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
32941859|NCT04175600|Placebo Comparator|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
32941860|NCT04169672|Experimental|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
32941861|NCT04169672|Experimental|Surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
32941862|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
32941863|NCT04151498|Experimental|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
32941864|NCT04151498|Other|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
32941865|NCT04151498|No Intervention|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
32941866|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
32941867|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
32941868|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
32941869|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
32941870|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
32941871|NCT03541291|Experimental|SMART-SYNC LM03|All participants
32941872|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
32941873|NCT03344731|Other|Control Group|Healthy volounteers
32941874|NCT03121586|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
33404369|NCT02974868|Experimental|Cohort 1|PF-06651600
33404370|NCT02974868|Experimental|Cohort 2|PF-06700841
33404371|NCT02974868|Placebo Comparator|Cohort placebo|placebo
33307163|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
33307164|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
32941875|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
32941876|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
32941877|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
32941878|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
32941879|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
32941880|NCT03321799|Experimental|NPWT|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
33307165|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
32941882|NCT03278119||Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, having mild to severe obstructive sleep apnea~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
32941883|NCT03278119||No Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, without OSA~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
32941884|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32941885|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
32941886|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
32941887|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941888|NCT02924402|Experimental|CLL/SLL (Group CLL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941889|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941890|NCT02924402|Experimental|CLL/SLL (Group CLL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941891|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941892|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion|XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
32941893|NCT05440669|Experimental|White Noise|white noise will reduce pain and stress
32941894|NCT05440669|No Intervention|control|white noise will not reduce pain and stress
32941895|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
32941896|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
32941897|NCT04329416|Other|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula [0.249 x (BH) 0.916] before induction of anesthesia using an application on the smartphone
32941898|NCT02859727|Experimental|CDZ173|140mg/day
32941899|NCT04329338|No Intervention|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
32941900|NCT04329338|Experimental|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
32941901|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
32941902|NCT00002942|Experimental|Autologous Bone Marrow Collection|
32941903|NCT00000955|Other|A|All eligible study participants
32941904|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
32941905|NCT04048304|Experimental|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
32941906|NCT04048304|Active Comparator|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
32941907|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
32941908|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
32941909|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
32941910|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
32941911|NCT02769962|Experimental|1/Phase I|EP0057 + olaparib
32941912|NCT02769962|Experimental|2/Phase II|EP0057 + olaparib at MTD/RP2D
32941913|NCT02757794|Active Comparator|Cognitive remediation parents|
32941914|NCT02757794|Placebo Comparator|Remediation standard|
33307166|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
33091868|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33091869|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
33091870|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
33091871|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
33091872|NCT03275844||Group 1|Children with congenital heart disease
33091873|NCT03275844||Group 2|Control healthy subjects
33091874|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
33091875|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
33091876|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
33091877|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
33091878|NCT00352742|Experimental|1|ATN-224 + bortezomib
33091879|NCT00352820||Interview + Questionnaire|
33091880|NCT00352859|Experimental|Arm 1|
33091881|NCT00352859|Experimental|Arm 2|
33091882|NCT00105183|Active Comparator|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
33091883|NCT00105183|Placebo Comparator|Placebo|USP 0.9% sodium chloride solution
33091884|NCT00105183|Active Comparator|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
33307167|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
33307168|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
33307169|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
33307170|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
33307171|NCT03728374|Experimental|Anlotinib|
33307172|NCT03728296|Experimental|islet body treatment group|
33091885|NCT00466089|Experimental|1|RT + Tarceva
33091886|NCT00466089|No Intervention|2|RT
33091887|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
33091888|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
33091889|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
33091890|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
33091891|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
33091892|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
33091893|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
33091894|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
33091895|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
33091896|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
33091897|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
33091898|NCT03272256|Experimental|IM156, Dose escalation|
33091899|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
33091900|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
33307173|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
33307174|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
33307175|NCT03728218|Experimental|Orthokeratology Contact lenses|
33307176|NCT03728218|Experimental|Soft Multifocal Contact lenses|
33307177|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
33307178|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
33307179|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
32941915|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
32941916|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
32941917|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
32941918|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
32941919|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
32941920|NCT02677064||patients with acute leukemia (AML or ALL)|
33404372|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
32799643|NCT05630404|Active Comparator|Group IE= Surgical Injection ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
32941921|NCT02341807|Experimental|Dose Group 1|Single, unilateral administration of a single low dose range of AAV2-hCHM.
32941922|NCT02341807|Experimental|Dose Group 2|Single, unilateral administration of a single high dose range of AAV2-hCHM.
32799644|NCT05630404|Active Comparator|Group UE= US guided ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
32941923|NCT02508038|Experimental|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.
32941924|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - total body irradiation (TBI) first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment~11 Anti-thymocyte globulin (ATG)~10 ATG~9 ATG~8 TBI~7 TBI~6 TBI~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
32941925|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment~9 ATG~8 ATG~7 Thiotepa + ATG~6 Thiotepa~5 Cyclophosphamide~4 Cyclophosphamide~3 TBI~2 TBI~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
32941926|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment~9 Busulfan + ATG~8 Busulfan + ATG~7 Busulfan +ATG~6 Busulfan~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 0 Transplant with alpha beta T cell depleted stem cells"
32941927|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
32941928|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
33091901|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
33091902|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
33091903|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
33091904|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
33091905|NCT00466518|Experimental|1|
33091906|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
33091907|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
33091908|NCT04714580|Experimental|Animal Fun Group|Baseline assessment with MABC-2; Animal Fun activity with a certified trainer (physiotherapist) for one month, three times a week, for 30 minutes; one-month follow-up assessment with MABC-2.
33091909|NCT04714580|No Intervention|Control Group|Baseline assessment with MABC-2; normal curricular activity at school with the teachers; one-month follow-up assessment with MABC-2.
33091910|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
33091911|NCT00353561|Other|2, Fluconazole|
33091912|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
33091913|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
33091914|NCT02959736||Spectrum|Music Therapy (MATADOC)
33091915|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
32799645|NCT05630404|No Intervention|Group C = Control group|"Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.~Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit."
32799646|NCT05630326||ESBL UTI|all infants with UTIs caused by ESBL producing organisms
32799647|NCT05630326||Non-ESBL UTI|all infants with UTIs caused by non-ESBL producing organisms
32799648|NCT05630326||ESBL UTI with COVID-19|all infants with UTIs caused by ESBL producing organisms with COVID-19 infection
32799649|NCT05630326||ESBL UTI without COVID-19|all infants with UTIs caused by ESBL producing organisms without COVID-19 infection
32799650|NCT04019314|Experimental|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
32799651|NCT05366608||RA patients|188 patients with RA he RA activity parameters were evaluated in RA patients. BMD was measured. Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
32799652|NCT05366608||Control|192 matched controls were enrolled. T
32799653|NCT03995992|Active Comparator|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
32799654|NCT03995992|Experimental|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
32799655|NCT03995056|No Intervention|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
33091916|NCT00466674|Experimental|Allogenic Transplant|
33091917|NCT00353717|Experimental|1|
33091918|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
33091919|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
33091920|NCT00458289|No Intervention|1|P-containing meal alone
33091921|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
33091922|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
33091923|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
33091924|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
33091925|NCT00458445|Experimental|SPD465 then Placebo|
33091926|NCT00458445|Experimental|Placebo then SPD465|
33091927|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
33091928|NCT00354263|Experimental|B|
33091929|NCT04714229|Experimental|EuMCV4|Healthy adults received 0.5mL single intramuscular dose on Day 0.
33091930|NCT04714229|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
33091931|NCT04714502||Infants enrolled in AAMBI1|
33091932|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
33091933|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
33091934|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
32799656|NCT03995056|Experimental|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
32799657|NCT03792958|Experimental|CM082|CM082 tablet
32799658|NCT03789604|Experimental|CS1001 monoclonal antibody|
32799659|NCT03789604|Placebo Comparator|CS1001 placebo|
32799660|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
32799661|NCT04407208|Experimental|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
32799662|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
32799663|NCT04766554|Active Comparator|Cerebral Oxymetry Monitoring|"The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds:~The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected;~In case of arterial hypotension, the causal factors should be assessed and treated;~In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 > 150 mmHg;~In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation;~In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion;~In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility;~Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors."
32799664|NCT04766554|No Intervention|Control Group|Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels <3 mmol/L and urine output> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb <6 to 7g/dL during CPB or Hb <8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
32799665|NCT05632510|Other|EPDS Group|
32799666|NCT05632510|No Intervention|Courent practice Group|
32799667|NCT03595228|Experimental|BN-Brachyury plus radiation|MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
32799668|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
32799669|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
32799670|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
32799671|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
32799672|NCT05632354|Experimental|Treatment|open-label GBT021601
32799673|NCT04017130|Experimental|Part 1: Dose Escalation|"Weekly Dosing Intravenous (IV) infusion of MT-0169 every 7 days: Days 1, 8, 15, and 22 in a 28-day treatment cycle.~Every 2 Weeks IV infusion of MT-0169 every 14 days: Days 1 and 15 in a 28-day treatment cycle with escalating doses starting at the MTD/RP2D determined by the weekly dose escalation cohort.~Patients will continue to receive treatment until progressive disease, unacceptable toxicity or withdraw from the study for other reasons. Decision to escalate/deescalate/stay on the same dose/discontinue MT-0169 will be based on number of DLTs per number of patients enrolled at each dose level as predetermined by the mTPI-2 statistical model. Subsequent doses will be determined by the frequency and severity of adverse events in previous cohorts. The investigator and sponsor review of available safety, PK, pharmacodynamics, and efficacy data in the previous cohorts will also be factored in the decision."
32799674|NCT04017130|Experimental|Part 2: Dose Expansion in patients with RRNHL: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
32799675|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are also Daratumumab RR: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
32799676|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are Anti-CD38 Therapy naïve: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
32799677|NCT04017130|Experimental|Part 2: Dose Expansion in patients with RRNHL: Every 2 Weeks|This cohort will receive intravenous infusion of MT-0169 every 14 days on Days 1 and 15 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Biweekly Dose Escalation of Part 1.
32799678|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are also Daratumumab RR: Every 2 Weeks|Each cohort will receive intravenous infusion of MT-0169 every 14 days on Days 1 and 15 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Biweekly Dose Escalation of Part 1.
32799679|NCT05366296|Active Comparator|: A Lyophilized COVID-19 mRNA Vaccine(RH109)|Participants received A Lyophilized COVID-19 mRNA Vaccine 0.5ml reconstituted by sterile water, 1 shots at Day0, intramuscular injection
32799680|NCT05366296|Placebo Comparator|Placebo control|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 1 shots at Day0, intramuscular injection
33307180|NCT00111813|Experimental|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
33307181|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
33091935|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
33307182|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
32799681|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
32799682|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
33307183|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
32799683|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
32799684|NCT03990532|Experimental|treatment group|
32799685|NCT03990454|Experimental|Dose escalation|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met."
32799686|NCT03990064|Experimental|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
32799687|NCT03990064|No Intervention|waiting list|waiting list
32799688|NCT05632042|Experimental|lifestyle-modification group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (group = 30 patients) will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
32799689|NCT05632042|No Intervention|control group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (number of the patients will be 30) that will receive no lifestyle changes/modifications.
32799690|NCT03595306|Experimental|Prebiotic A|
32799691|NCT03595306|Experimental|Prebiotic B|
32799692|NCT03595306|Experimental|Prebiotic C|
32799693|NCT05631652|Experimental|PillSense System|All subjects were asked to swallow a PillSense Capsule, followed by the ingestion of autologous blood mixed with water, to verify the ability of the PillSense System to correctly identify blood.
32799694|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
32799695|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
32799696|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
32799697|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
32799698|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
32799699|NCT03989440|Experimental|AXER-204|Part 1 - Single ascending doses; Part 2 - Repeated dose
32799700|NCT03989440|Placebo Comparator|Placebo|Part 2 only - Repeated dose
32799701|NCT03989362|Experimental|LM1|Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
32799702|NCT03989362|Experimental|LT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
32799703|NCT03989362|Experimental|UM1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
32799704|NCT03989362|Experimental|UT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
32799705|NCT03989362|Experimental|LM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
32799706|NCT03989362|Experimental|LT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
32799707|NCT03989362|Experimental|UM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
32799708|NCT03989362|Experimental|UT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
32799709|NCT03989206|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
32799710|NCT04009096|Experimental|Group 1|3 volunteers receiving 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later.
32799711|NCT04009096|Experimental|Group 2|Up to 10 volunteers receiving one dose of 5 x 10^10 vp ChAd63 PvDBP, 12-18 months later receiving a second dose of 5 x 10^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10^8 pfu MVA PvDBP, followed by blood-stage CHMI 2-4 weeks later.
32799712|NCT04009096|Experimental|Group 3|"If fewer than 6 volunteers complete the study in Group 2, then new volunteers will be recruited into Group 3, to make up a total of 6 volunteers between Groups 2 and 3 who complete all vaccinations and CHMI.~Volunteers in Group 3 will receive 5 x 10^10 vp ChAd63 PvDBP and 2 x10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later."
32799713|NCT04007848|Experimental|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
32799714|NCT04007848|Placebo Comparator|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
33091936|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
32737967|NCT05024565|Experimental|prolonged intravenous infusion of β-lactams Antibiotics|Administer according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
32737968|NCT05024565|No Intervention|short-term intravenous infusion of β-lactams Antibiotics|The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
32737969|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
32737970|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
33091937|NCT00354419|Experimental|Arm I|See Detailed Description
33091938|NCT02273856||Treatment naïve patients with CLL|
33091939|NCT02273856||Treatment naïve patients with iNHL|
33091940|NCT02273856||Relapsed/refractory patients with CLL|
33091941|NCT02273856||Relapsed/refractory patients with iNHL|
33091942|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
33307184|NCT00118287|Experimental|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
33307185|NCT03965247|Experimental|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
33307186|NCT03965247|Placebo Comparator|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
33307187|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
33307188|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
33307189|NCT00130689|Other|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
33307190|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
33307191|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
32737971|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
32941967|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
32941968|NCT00380185||2|Subjects with coronary artery disease only
32941969|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
32941970|NCT00380497|Experimental|Pico-Salax|
32941971|NCT00380497|Active Comparator|PEGlyte|
33307192|NCT03964935|Experimental|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
33307193|NCT03964935|Active Comparator|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
33307194|NCT03964935|Placebo Comparator|Distilled water|Used to irrigate periodontal pockets after SRP
33307195|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
33307196|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
33307197|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
33307198|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
33307199|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
32941980|NCT02352896|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
32941981|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
33091943|NCT00354458|Placebo Comparator|1|
33307200|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
33091944|NCT00354458|Experimental|2|
33091945|NCT00354536|Active Comparator|albiglutide|albiglutide injection
33091946|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
33091947|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
33091948|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
33091949|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
33091950|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
33091951|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
33091952|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
33091953|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
33091954|NCT00425906|Experimental|Nicotine inhaler|
33091955|NCT00425906|Placebo Comparator|Placebo inhaler|
33091956|NCT00467376|Experimental|1|Administration of Insulin Glulisine
33091957|NCT00467376|Active Comparator|2|Administration of Lispro
33091958|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
33091959|NCT00426023|Active Comparator|2|
33091960|NCT00467454|Active Comparator|1|Naltrexone
33091961|NCT00467454|Placebo Comparator|2|Placebo
33091962|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~Cyclosporin A is administered from day 1 and~Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
33091963|NCT00426140|Experimental|EPO906|
33091964|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
32737972|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
32737973|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
32737974|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
33091965|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
33091966|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
33091967|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
33091968|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
33091969|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
32737975|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
32737976|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
32737977|NCT05024331||Pediatric physicians|"Assigned Interventions~Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018~Sees the result of the prediction algorithm.~Change or maintain their prediction values.~Participate in the usability questionnaires."
32737978|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
32737979|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
32737980|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
32737981|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
32737982|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
32737983|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
33091970|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
33091971|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
33091972|NCT00426218|Experimental|1|ACZ885
33091973|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
33102480|NCT03694262|Experimental|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
33307201|NCT00117507|Experimental|Deferasirox|Participants received deferasirox 20mg/kg/day OD for 12 months. Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
33307202|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~• The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
32941982|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
32941983|NCT04331431|Other|spinal cord tumors|
32941984|NCT04925713|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
32941985|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
32941986|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
32941987|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
32941988|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
32941989|NCT00001981||Patients with acromegaly|Patients with acromegaly
32941990|NCT04716907||Case : COVID-19 positive patients|patients hospitalized for COVID-19 infection
32941991|NCT04716907||Control : COVID-19 negative patients|patients hospitalized for other reasons
32941992|NCT02335424|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.
32941993|NCT04329650|Experimental|Siltuximab 11mg/Kg|
32941994|NCT04329650|Active Comparator|Methylprednisolone 250mg/24h|
32941995|NCT03912662|Other|Hernia prevention cohort|single arm safety study, no control arm
32941996|NCT02312960|Other|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
32941997|NCT00001621||1|Pulmonary Patients
32941998|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
32941999|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
32942000|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
32942001|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
32942002|NCT04329884|Active Comparator|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
32942003|NCT04329884|Active Comparator|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD* COOLIEF* SINERGY* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF* SINERGY* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
32942004|NCT00001627||Group 1|Normal Volunteers and patients.
32942005|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
32942006|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
32942007|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
33102481|NCT05356104|Active Comparator|Exenatide extended release|Prescribe study drug: Exenatide extended release. The dosage and frequency is 2mg once weekly via subcutaneous injection for 78 weeks
33091974|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
33307203|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
33307204|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
33307205|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
33307206|NCT03965013|Experimental|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
33307207|NCT03965013|Placebo Comparator|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
32942008|NCT02114372||Cognitive Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
32942009|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
32942010|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
32942011|NCT05752591||Enrolled patients with DM|
32942012|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
32942013|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
32942014|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
32942015|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
32942016|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
32942017|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
32942018|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
32942019|NCT04713397||LLD group|Patients who have functional scoliosis due to structural LLD
32942020|NCT04713397||LLD concurrent with AIS|Patients who have structural LLD concurrent with AIS
32942021|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
32942022|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
32942023|NCT05752513|Placebo Comparator|Group 1|18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta
32942024|NCT05752513|Experimental|Group 2|18 pregnant women scheduled for bladder last cesarean hysterectomy
32942025|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20- or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 3 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
33102482|NCT05356104|No Intervention|Standard of care|Standard medical therapy
33102483|NCT03686150|Experimental|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
32942026|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20 or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 6 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
32942027|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
33091975|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
33091976|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
33091977|NCT03271944|Other|Single group 30 post menopause females.|
33091978|NCT03273933|Active Comparator|10 children with DragONE only|
33091979|NCT03273933|Experimental|10 children with DragONE and SmartOne|
33091980|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
32942028|NCT05752435|Active Comparator|BLEOMYCIN|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
32942029|NCT05752435|Active Comparator|CRYOTHERAPY|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
32942030|NCT05752357||single arm, observational arm|Patients who received surgery will routinely followed up by pre-op CTC, post-op CTC until 6 months after surgery.
32942031|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
32942032|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
32942033|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
32942034|NCT05752279|Active Comparator|Plasma-Lyte® 148|Plasma-Lyte® 148 fluid 1L given intravenously for fluid replacement
32942035|NCT05752279|Active Comparator|0.9% sodium chloride|Normal saline fluid 1L given intravenously for fluid replacement
32942036|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
32942037|NCT01719458||Obese|Subjects diagnosed with obesity
32942038|NCT01719458||Healthy|Subjects deemed to be medically healthy
32942042|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
32942043|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
32942044|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
32942045|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
32942046|NCT05752045|Other|Diabetic patient group assessed for multiple eye diseases|Each patient eye disease status will be assessed by expert readers so to provide ground truth against which algorithms performances will be assessed
32942047|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
32942048|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
32942049|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
32942050|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
32942051|NCT03726320|Experimental|Intervention Group|a decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW)
32942052|NCT03726320|Active Comparator|Control Group|a decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control.
32942053|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
33091981|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
33091982|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
33091983|NCT04705337|Experimental|Levosimendan|administration of levosimendan
33091984|NCT04705337|Placebo Comparator|Placebo|administration of placebo
33404373|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
33307208|NCT03965013|Experimental|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
32942054|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
33091985|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
32942055|NCT04712630|Experimental|NIPSA without grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
32942056|NCT04712630|Active Comparator|NIPSA with grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied and the bone defect will be filled with a composite of xenograft and enamel matrix derivates. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
32942057|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
32942058|NCT05751889|Experimental|Serious Game Intervention|Provided with a single session serious game intervention regarding HCV and safe sexual practice.
32942059|NCT05751889|Active Comparator|Traditional Health Education|Provided with a single session of traditional online healthcare education regarding HCV and safe sexual practice.
32942060|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
32942061|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
32942062|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
32942063|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
32942067|NCT00002527|Experimental|Aspirin|325 mg/day PO
32942068|NCT00002527|Placebo Comparator|Placebo|
32942069|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
33091986|NCT00426257|Active Comparator|2|Secondary debulking surgery
33091987|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
33307209|NCT03965013|Active Comparator|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
33307210|NCT03603496|Experimental|Transitional Tobacco Care Management (TTCM)|TTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call. At each contact the patient is offered a return call from the hospital-based tobacco coach for counseling, medication advice, and coordination of care with the patient's outpatient health care team.
33307211|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Quitline staff will contact patient to offer up to 5 proactive telephone calls from a tobacco coach. Patient may also be eligible for NRT sample. Feedback from the quitline will be sent back to the patient's medical chart.
33307212|NCT03964389|Experimental|Intervetion group|"A sessions of Therapeutic Neuroscience Education (TNE) joint a physical exercises programs"
33307213|NCT03964389|No Intervention|Control group|Only a therapeutic physical exercises programs
33307214|NCT03603028|Experimental|Exergaming|
33307215|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
33307216|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
33091988|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
33091989|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
33102484|NCT03686150|Experimental|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
33102485|NCT03686150|Experimental|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
33102486|NCT03686150|Active Comparator|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
33102487|NCT03686150|Experimental|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
33102488|NCT03686150|Active Comparator|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
33307217|NCT00096135|Experimental|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
33307218|NCT00096135|Experimental|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
32942070|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
32942071|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
32942072|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
32942073|NCT00381589|Experimental|A|Random assignment to investigational spray
32942074|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
32942075|NCT04331197|Active Comparator|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
32942076|NCT04331197|Active Comparator|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
32942077|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
32942078|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
32942079|NCT05751733|Experimental|Experimental group|Subjects received Apatinib mesylate
32942080|NCT05751733|Active Comparator|Control group|Subjects received TKI second-line therapy such as Sunitinib, Imatinib plus, Dasatinib, and Reveratinib.
32942081|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
32942082|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
33102489|NCT00533559|Experimental|buphenyl|
33102490|NCT00533559|Placebo Comparator|Placebo|
33102491|NCT03685253|Placebo Comparator|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
33102492|NCT03685253|Experimental|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
33102493|NCT04673604|Placebo Comparator|Triple preservative-free therapy with placebo in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use placebo (artificial tears) in the evening (21:00) for 6 months. At the end of this period patients will be crossed over to the other therapy (cyclosporine 0.1% in the evening)
33102494|NCT04673604|Active Comparator|Triple preservative-free therapy with cyclosporine 0.1% in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use cyclosporine 0.1% drops in the evening (21:00) for 6 months. At the end of this period all patients will be crossed over to the other therapy (placebo in the evening)
33102495|NCT05349513|Experimental|interventionnal arm|Administration of the experimental questionnaire ESSME in patient's environment.
33102496|NCT03640754|Active Comparator|Experimental: G-CSF|Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
33307219|NCT00116805|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
33307220|NCT00116805|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
33307221|NCT00116649|Experimental|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
33307222|NCT01082835||the group of Jiangzhuo Qinggan prescription|
33307223|NCT01082835||the group of irbesartan|
33307224|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
33307225|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
33307226|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
33307227|NCT01082913|No Intervention|control|
33307228|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
33307229|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
33307230|NCT01082991|Other|prevention|
33307231|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
33307232|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
33307233|NCT03961893|Experimental|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
33307234|NCT03961893|Experimental|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
33307235|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
33307236|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
33307237|NCT01083069||COOL|Patients after therapy with mild hypothermia
33307238|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
33307239|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
33307240|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
33307241|NCT03962907|Experimental|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
33307242|NCT03962907|No Intervention|Carrier group - control|
33307243|NCT03962907|Experimental|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
33307244|NCT03962907|No Intervention|Non - carrier group - control|
33307245|NCT00083889|Active Comparator|2|
33307246|NCT00083889|Experimental|1|
33307247|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
33307248|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
33307249|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
33307250|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
33307251|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
33307252|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
33307253|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
33307254|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
33307255|NCT03572062|Experimental|M0M2 Arm 1|High dose formulation B
33307256|NCT03572062|Placebo Comparator|M0M2 Arm 2|Placebo
33307257|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
33307258|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
33307259|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
33307260|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
33307261|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
33307262|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
33307263|NCT03727828||healthy control|
33307264|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
33307265|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
33307266|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
33307267|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
33307268|NCT03961659|Active Comparator|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
33091990|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
33091991|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
33307269|NCT03961659|Active Comparator|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
33307270|NCT03961659|Active Comparator|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
33307271|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
33307272|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
33307273|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
33307274|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
33307275|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
33307276|NCT03598036|Experimental|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
33307277|NCT00082407|Experimental|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
33091992|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
33091993|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
33091994|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
33091995|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
33091996|NCT00426413||2|obese nondiabetic subjects, age 19-65.
33091997|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
33091998|NCT00459264|Active Comparator|1|Folic Acid
33091999|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
33092000|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
33092001|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
33092002|NCT00426491|Placebo Comparator|B|
33092003|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
33092004|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
33092005|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
33092006|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
33092007|NCT00459420|Placebo Comparator|Placebo|
33092008|NCT00459420|Experimental|Caffeine|
33102497|NCT03640754|Placebo Comparator|Comparator: Placebo/Saline|Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
33102498|NCT04602819|Experimental|Experimental|
33102499|NCT05348109||well fininshed cases|
33307278|NCT00082407|Active Comparator|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
33307279|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
33307280|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
33307281|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
33307282|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
33307283|NCT01083225|Experimental|Client feedback|
33307284|NCT01083225|Active Comparator|Treatment as usual|
33307285|NCT01080963|Active Comparator|Daptomycin|
33307286|NCT01080963|Active Comparator|Cefuroxime|
33307287|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
33307288|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
33307289|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
33307290|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
32737984|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
32942083|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
32942084|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
32942085|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
32942086|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
32942087|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
32942088|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
32942089|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
32942090|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
32942091|NCT05751577|Experimental|EXPERIMENTAL ARM: TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI within 7-10 days in their hospital without on-site surgery
32942092|NCT05751577|Active Comparator|CONTROL ARM: TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
32942093|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
32942094|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
32942095|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
32942096|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
32942097|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
32942098|NCT05751499||CASE GROUP|"Both male & Female patients~Age group 18-60 Years~Diagnosed with nonspecific low back pain in acute/flared stage"
32942099|NCT05751499||CONTROL GROUP|MALE AND FEMALE AGE GROUP 18 TO 60 YEARS NOT SUFFERING FROM LOW BACK PAIN
32942100|NCT05751421|Experimental|primary total knee replacement + Zynrelef|Patients undergoing primary total knee replacement with Extended Relief Bupivacaine and Meloxicam (Zynrelef)
32942101|NCT05751421|Active Comparator|primary total knee replacement + adductor canal block (ACB)|Patients undergoing primary total knee replacement with routine adductor canal block
32942102|NCT05751265|Experimental|Tislelizumab combined with chemotherapy|
32942103|NCT05751187|Experimental|Pembrolizumab + Bevacizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4-6 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
32942104|NCT00003416|Experimental|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
33102500|NCT03429218|Experimental|Single Arm TP-0184|Weekly dose of TP-0184 by oral administration
33404374|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
33092009|NCT04705415|Experimental|ANA001|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned treatment as a single oral dose (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal. Each capsule is 250 mg.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned treatment twice daily (BID) or thrice daily (TID) (total daily dose is to be determined following the completion of the SAD portion of the study and will not exceed 2000 mg ANA001) with a standardized light meal for 7 consecutive days. Each capsule is 250 mg."
33092010|NCT04705415|Placebo Comparator|Matching Placebo|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) as a single dose (4, 8, or 12 capsules) with a standardized light meal.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) dose twice daily (BID) or thrice daily (TID) with a standardized light meal."
33092011|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
33092012|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
33092013|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
33092014|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
33092015|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
33092016|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
33092017|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
33092018|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
33092019|NCT00468078|Experimental|A|Parkinson's disease
33092020|NCT00468078|Active Comparator|B|ET+Normal
33092021|NCT00468156|Active Comparator|1|written materials only
33092022|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
33092023|NCT00468156|Experimental|3|same as arm 2 plus telephone support
33092024|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
33092025|NCT00426725|No Intervention|Control|
33092026|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
33092027|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
33092028|NCT01059071|Experimental|DFMO and Etoposide|
33092029|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
33092030|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
33092031|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
33092032|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
33092033|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
33092034|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
33092035|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
33092036|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
33092037|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
33092038|NCT00459771|Placebo Comparator|Placebo|Placebo
33092039|NCT00459771|Active Comparator|Candesartan|Candasartan
33092040|NCT01058369|Experimental|Deferasirox|
33092041|NCT04705103||initial|
33092042|NCT04705103||relapse|
33092043|NCT04705103||inactive|
33092044|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
33092045|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
33092046|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
33092047|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
33092048|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
33092049|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
32942105|NCT05751109||ipack+adductor canal block|The 40 patients received ACB + IPACK (Group 1, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
32942106|NCT05751109||epidural analgesia|The 40 patients received combine spinal epidural (Group 2, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
33092050|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
33092051|NCT03271437|Experimental|PC-trained therapists|
33092052|NCT03271437|Experimental|EMDR-trained therapists|
33404375|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
33404376|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
33404377|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
32942107|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
32942108|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
32942109|NCT05720767|Experimental|Part A - Itraconazole|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 400 mg (combination of 2 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 10) in Part A. Itraconazole will be supplied as 100 mg capsules and will be administered as doses of 200 mg (2 × 100 mg) PO BID on Day 6 and 200 mg PO QD on Days 7 to 14 in Part A.
32942110|NCT05720767|Experimental|Part B - Rifampin|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 700 mg (combination of 4 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 13) in Part B. Rifampin will be supplied as 300 mg capsules and will be administered as doses of 600 mg (2 × 300 mg) PO QD on Days 6 to 17 in Part B.
32942111|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
32942112|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
32942113|NCT05751031||European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)|Pregnant women living with HIV and their infants from 9 European cohorts and studies within the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
32942114|NCT05715463|Other|Arm 1|Arm 1 is the control arm which will receive the standard of care resource sheets.
32942115|NCT05715463|Experimental|Arm 2|Arm 2 will receive the assistance of a community resource specialist (CRS)- an individual without formal medical training with community-based expertise.
32942116|NCT05715463|Experimental|Arm 3|Arm 3 will receive the assistance of a bilingual (English and Spanish) nurse patient navigator with nursing training and additional rheumatology-specific training.
32942117|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
32942118|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
32942119|NCT05750719||Women with early triple negative breast cancer who received neoadjuvant chemotherapy.|
32942120|NCT05708365|Active Comparator|Standard-Lung Protective Ventilation|
32942121|NCT05708365|Active Comparator|Ultra-Lung Protective Ventilation|
32942122|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
32942123|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
32942124|NCT00002864|Active Comparator|Octreotide|
32942125|NCT00002864|Active Comparator|Tamoxifen|
32942126|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
33102501|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
33307291|NCT03810183|Experimental|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
33307292|NCT03810183|Placebo Comparator|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
33307293|NCT01087359|Active Comparator|LPS + melatonin night|
33307294|NCT01087359|Placebo Comparator|LPS + placebo night|
33307295|NCT01087359|Active Comparator|LPS + melatonin day|
33307296|NCT01087359|Placebo Comparator|LPS + placebo day|
33307297|NCT01087359|Experimental|LPS night|
32942127|NCT05750641||diet group|those who removed milk and dairy products under the advice of a dietician without medical treatment.
32942128|NCT05750641||free-diet group|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet.
33307298|NCT01087359|Experimental|LPS day|
33307299|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
33307300|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
33307301|NCT03962517|Experimental|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
33307302|NCT03962517|Active Comparator|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
33307303|NCT01087437|Experimental|gastrolith calcium treatment|
33307304|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
33307305|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
33307306|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
33307307|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
33307308|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
33307309|NCT01087515|Other|Blood donation|
32942129|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
32942130|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
32942131|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
33307310|NCT03571204|Active Comparator|Group 1: ART prior to 3BNC117 + 10-1074 in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
33307311|NCT03571204|Placebo Comparator|Group 1: ART prior to placebo treatment in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given normal saline intravenously. Subjects received two separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
33404378|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
32737985|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
32737986|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
32737987|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
32737988|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
32942132|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
32942133|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
32942134|NCT05750563|Placebo Comparator|Placebo|"Investigational food supplement placebo will be administered according to the same schedule provided for the active product:~From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~From day 8 to day 62: 1 tablet once a day, before breakfast"
32942135|NCT05750563|Experimental|Experimental|"The dosage will be the following:~From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~From day 8 to day 62: 1 tablet once a day, before breakfast"
33102502|NCT04597593||Control Group|No ADR, No Treatment Failure
33092053|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
32942136|NCT05693701|Other|Control group (Usual care)|This arm will receive standard notification that is usually provided by Carter describing need to review with donor's primary care physician the presence of high cholesterol
32942137|NCT05693701|Experimental|Intervention Group (Implementation strategy bundle)|Along with standard high cholesterol notification from Carter BloodCare, this arm will receive Implementation strategy bundle (educational material regarding high cholesterol levels)
32942138|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
32942139|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
32942140|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
32942141|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
32942142|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
32942143|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
32942144|NCT05690581|Experimental|CM369 Ia Dose Escalation|Dose escalation of CM369 as monotherapy
32942145|NCT05690581|Experimental|CM369 Ib Dose Expansion|Dose expansion of CM369 as monotherapy
32942146|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:~Taxotere-Administered weekly for 1 hour (6 doses)~Radiation Therapy (XRT) -5 days a week for 6 weeks~Exam under anesthesia~Neck Dissection (if indicated)"
32942147|NCT05750485||Pupilometric evaluation under procedural sedation with propofol|
32942148|NCT05750407|Experimental|Evidence based home visiting with lifestyle modules|Three lifestyle change modules will be discussed with clients: healthy eating, activity, and tracking diet and weight
32942149|NCT05750251||Ptosis patient|Undergo conventional ptosis correction surgery, including levator muscle resection surgery and Müller's muscle-conjuctival resection surgery
32942150|NCT05750251||Eyelid retraction patient|Undergo conventional ptosis correction surgery, including full-thickness anterior blepharotomy surgery
32942151|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
32942152|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
32942153|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
32942154|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
32942155|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
32942156|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
32942157|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
32942158|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
33092054|NCT00427076|Experimental|A|Cotrimoxazole
33092055|NCT00427076|Active Comparator|B|Vancomycin
33307312|NCT03571204|Experimental|Group 2: 3BNC117 + 10-1074 in HIV-1 subject|Subjects who were not on anti-retroviral therapy (ART) during primary HIV-1 infection within the past 2 years. Subjects were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
33307313|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
33307314|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
33307315|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
32746493|NCT05613621||validation cohort|For the validation cohort, the clinical and pathological information will be obtained retrospectively by TCOG and will take 6 months to identify eligible patients for the 4 sub-groups listed above.
32942159|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
32942160|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
32942161|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942162|NCT05750173||Prospective cohort|100 consecutive patients that are not already diagnosed with severe (≥50%) proximal stenosis of the left anterior descending artery (LAD) OR the left main coronary artery (LM).
32942163|NCT05750173||Retrospective cohort|"50 consecutive patients from the participating centers that already underwent CTA and ICA prior to TAVI will serve as a historical control group."
32942164|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
33307316|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
33307317|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
33307318|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
33307319|NCT00110019|Experimental|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
32942169|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942170|NCT05669599|Experimental|Cohort A: AMG 133|Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 7 dose cohorts.
32942171|NCT05669599|Placebo Comparator|Cohort A: Placebo|Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 7 dose cohorts.
32942172|NCT05669599|Experimental|Cohort B: AMG 133|Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 4 dose cohorts.
32942173|NCT05669599|Placebo Comparator|Cohort B: Placebo|Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 4 dose cohorts.
32942174|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942175|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942176|NCT05749861|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(5) - A single oral dose of 1 tablet under fasting condition"
32942177|NCT05749861|Experimental|Sequence 2|"Period 1: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
32942178|NCT05665699|Experimental|Cohort A|week 1: D-0120 low dose in combination with Allopurinol week 2-12: D-0120 increased dose in combination with Allopurinol
32942179|NCT05665699|Experimental|Cohort B|week 1: D-0120 low dose in combination with Allopurinol week 2: D-0120 increased dose in combination with Allopurinol week 3-12: D-0120 high dose in combination with Allopurinol
32942180|NCT05664061|Experimental|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals|Test (T)
33404379|NCT05076526|Active Comparator|HA|Patients will receive 2 intra-articular injections of 2mL Synolis VA (20 mg/mL HA and 40 mg/mL sorbitol), with an interval of 1 month between both injections.
33092056|NCT00460083|Active Comparator|Elidel(r)|
33092057|NCT00460083|Experimental|Epiceram(r)|
33092058|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
33092059|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
33092060|NCT00468741|No Intervention|1|subjects receive internet access and computer
33092061|NCT00468741|Experimental|2|CHESS informational services only
33092062|NCT00468741|Experimental|3|CHESS social support and informational services
33092063|NCT00468741|Experimental|4|Full CHESS
33092064|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
33092065|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
33092066|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
32942181|NCT05664061|Active Comparator|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|Reference (R)
33092067|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
33092068|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
32942182|NCT05664061|Placebo Comparator|Placebo|Placebo
32942183|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
32942184|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
32942185|NCT05663905|Experimental|Ambroxol Arm|"Amboxol arm will be receiving standard therapy as per control group with the addition of IV ambroxol hydrochloride 30mg TDS as adjunct therapy for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour. The patients will be considered as drop-outs if ambroxol is discontinued due to its side-effects, or if the patient's duration of ICU stay is less than 24 hours."
32942186|NCT05663905|Other|Control Arm|"Control arm will be receiving standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC).37 This includes antibiotics stewardship and supportive therapy."
32942187|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
32942188|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32942189|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942190|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32942191|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
33092069|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
33092070|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
33092071|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
33092072|NCT04704947|Experimental|nonselective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
33092073|NCT04704947|Experimental|cardio-selective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
33092074|NCT04704947|Placebo Comparator|Control group|Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
33102503|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
33102504|NCT00532220|Active Comparator|A|
33102505|NCT00532220|Placebo Comparator|B|
33307320|NCT00110019|Active Comparator|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
33307321|NCT03595618|Experimental|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
33307322|NCT03595618|Experimental|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
33307323|NCT03595618|Experimental|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
32799715|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
33092075|NCT04705142|Experimental|MgSO4|"MgSO4~1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.~Monitoring and Protective measures:~Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour."
33307324|NCT03595618|Placebo Comparator|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
33307325|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
33307326|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
33307327|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
33307328|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
33307329|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
33307330|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
33307331|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
33307332|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
33307333|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
33307334|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
33307335|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
33307336|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
33307337|NCT00109707|Experimental|CML-CP With Prior Imatinib Only|Imatinib-resistant / intolerant PH+ CML-CP patients
33307338|NCT00109707|Experimental|CML-AP With Prior Imatinib Onl|Imatinib-resistant / intolerant PH+ CML-AP patients
33307339|NCT00109707|Experimental|CML-CP|Imatinib-resistant / intolerant PH+ CML-CP patients
33307340|NCT00095979|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33307341|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
33307342|NCT01087593|Placebo Comparator|Control|
33307343|NCT01087671|Other|Open-lable study with one arm|
32799716|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
32799717|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
33092076|NCT04705064||AI_AKI|Adults patients undergoing non-cardiac surgery
33307344|NCT00082173|Experimental|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
33307345|NCT00082173|Placebo Comparator|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
33307346|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
33307347|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
33307348|NCT03568318|Placebo Comparator|Placebo / Upadacitinib + Topical Corticosteroids|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
33092077|NCT00460161|Active Comparator|1|true acupuncture
32942192|NCT05749549|Experimental|BR1733|25-1200 mg QD or BID
32942193|NCT05749471||Patients with chronic venous disease|Consecutive patients with chronic venous disease (CVD) that will be diagnosed, staged according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification of CVD. ASEX (Arizona Sexual Experience) questionnaire will be administered to CVD patients at time 0 of study inclusion and after treatment of CVD at intervals of 6 months and 12 months after treatment.
32942194|NCT05749393|Experimental|Low-dose group|The initial dose was 50U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
32942195|NCT05749393|Experimental|Medium dose group|The initial dose was 60U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
32942196|NCT05749393|Experimental|High-dose group|The initial dose was 70U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
32942197|NCT00381667|Experimental|GW642444M 12.5|
32942198|NCT00381667|Experimental|GW642444M 100mcg|
32942199|NCT00381667|Experimental|GW642444M 400mcg|
32942200|NCT00381667|Experimental|GW642444H 100mcg|
32942201|NCT00381667|Experimental|Placebo|
32942202|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
32942203|NCT05646979|Experimental|Experimental group|EFT application will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
32942204|NCT05646979|No Intervention|Control group|Women in the control group who will have a cesarean section at 32-38 weeks of gestation will not be interfered with.
32942205|NCT05646355|Experimental|Proactive Screening Outreach|"Participants will receive a letter from their clinic explaining CRC screening options (fecal immunochemical test (FIT) vs colonoscopy) including a FIT kit with completion and return instructions. The letter will also include information for navigation to a screening colonoscopy instead of FIT testing, if deemed to be the participant's preference.~Approximately 10-14 days after mailing the FIT kit, participants who have not completed screening will receive a telephone call (with voice message left) and text message, querying whether the FIT kit was received and reminding the participant to complete the test or request a new kit, if needed.~If the FIT kit has not been submitted after about two weeks from the reminder call/text message, the study team will mail a final letter to the participant on behalf of the clinic, reminding them to complete and return the FIT kit."
32942206|NCT05646355|Active Comparator|Usual Care|Individuals in the usual care group will not be approached or notified of their enrollment in the study.
32942207|NCT05749315|Active Comparator|Group A|Group A Speech Language Delayed Children
32942208|NCT05749315|Active Comparator|Group B|Group B Speech Language Delayed Children
32942209|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
32942210|NCT04642027|Active Comparator|Conventional|Conventional sEBRT
32942211|NCT04642027|Experimental|Hypofractionation|Hypofractionated sEBRT
32942212|NCT05749237|Active Comparator|Active group|children older than 10 years with a diagnosis of allergic asthma respiratory and relaxation exercises
32942213|NCT05749237|Placebo Comparator|Placebo group|children older than 10 years with a diagnosis of allergic asthma only relaxation exercises
32942214|NCT05639413|Other|COBRAF|"A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at the following timepoints:~At the starts of cycle 1, 2 and 3,~At 3 and 6 months after starting of each treatment line, if applicable.~At disease progression after second-line treatment with encorafenib combined with cetuximab, if applicable.~At disease progression after immunotherapy-based treatment in dMMR/MSI patients.~At most 390 mL of blood will be collected from each patient during the study."
32942215|NCT05749081|Experimental|Lacidophilin tablets group|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
32942216|NCT05749081|Placebo Comparator|Placebo group|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
32942217|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
32942218|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
32942219|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
32942220|NCT05630911||High Reinvestor Group (HRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
33092078|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
33092079|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
33092080|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
33092081|NCT00427583|Experimental|STI571|
33092082|NCT00468936|No Intervention|1|Usual medications (Cellcept)
33092083|NCT00468936|Active Comparator|2|Patients taking Myfortic
33092084|NCT00427739||CCT exam|
33092085|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
33092086|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
33092087|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
33092088|NCT00428012|No Intervention|Standard Care|
33092089|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
33092090|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
32799718|NCT04007380|Other|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
32799719|NCT04028284|Active Comparator|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
32799720|NCT04028284|Active Comparator|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
32799721|NCT05631262|Experimental|SKB264 (Cohort 1)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
32799722|NCT05631262|Experimental|SKB264 (Cohort 2)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
32799723|NCT05631262|Experimental|SKB264 (Cohort 3)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
32799724|NCT05631262|Experimental|SKB264 (Cohort 4)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
32799725|NCT05631262|Experimental|SKB264 (Part 2)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
32799726|NCT05631106|Active Comparator|Stretching, Balance, Range of Motion|Participants will engage stretching, balance, and range of motion exercises 2 days per week for 12-weeks.
32799727|NCT05631106|Experimental|High Intensity Interval Resistance Training|Participants will perform resistance training exercises at high intensity intervals 2 days per week for 12-weeks.
32799728|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
32799729|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
32799730|NCT04407130|Active Comparator|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~+ Placebo one tablet D2-5"
32799731|NCT04407130|Active Comparator|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
32799732|NCT04407130|Placebo Comparator|Placebo|"Drug: Placebo~3 Placebo tablets D1 followed by 2 tablets D2-5"
32799733|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
32799734|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
32799735|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
32799736|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
33092091|NCT00428051||All eligible patients|
33092092|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33092093|NCT04704440|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33092094|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33092095|NCT04704440|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33092096|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
33307349|NCT03568318|Experimental|Upadacitinib 15 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
33307350|NCT03568318|Experimental|Upadacitinib 30 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
33307351|NCT00108069|Experimental|GBM (Glioblastoma multiforme)|
32942221|NCT05630911||Low Reinvestor Group (LRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
32942222|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
33307352|NCT00108069|Experimental|AG (Anaplastic glioma)|
33307353|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
33307354|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
33307355|NCT00079274|Experimental|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
33307356|NCT00079274|Experimental|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
33307357|NCT00079274|Experimental|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
33307358|NCT00079274|Experimental|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
33307359|NCT00079274|Experimental|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
33307360|NCT00079274|Experimental|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
32942223|NCT05749003|Experimental|sensorimotor training program group|participants will receive Sensorimotor training exercise plus conventional physical therapy program of exercise.
33307361|NCT00079274|Other|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
33307362|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
33307363|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
32942224|NCT05749003|Other|Control group|participants will receive conventional physical therapy program of exercise.
32746494|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
32746495|NCT02444975|Other|No intervention|No intervention
32942225|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
32942226|NCT05748925|Active Comparator|study group|study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one ye
32942227|NCT05748925|Active Comparator|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
32942228|NCT05627479|Experimental|GIK Therapy|In patients randomized to the GIK Therapy Arm, a stepwise GIK infusion process will be performed. Baseline lab values that are markers of skeletal muscle injury (CPK), acute kidney injury (creatinine), and general tissue perfusion (lactate) will be obtained within the first 30 min of arrival to the ED. Subsequently, serial CPK, creatinine, myoglobin and lactate values will be obtained at regularly scheduled intervals until a minimum of 72 hours after definitive fixation or until rhabdomyolysis is resolved and/or kidney function has normalized
32942229|NCT05627479|Placebo Comparator|Placebo Control|Patients randomized to the control cohort will receive a normal saline infusion instead of GIK. Standard institutional ICU protocol will be used to monitor potassium and glucose levels per current standard-of-care practices and abnormal lab values will be treated accordingly per standard institutional protocols.
32942230|NCT05625217|Experimental|Total-body PET scan|All participants are asked to complete two study scan visits. First visit occurs before treatment and the second visit occurs 12 +/- 2 weeks after treatment. Each visit will involve a single injection of FDG, followed by three PET/CT scans that will start immediately following injection, at about 2 hours post-injection and at 5 hours post-injection, respectively and last about 60 minutes, 20 minutes and 20 minutes, respectively.
32942231|NCT05748847|Active Comparator|Pocket ICRS|Patients in this group are planned to undergo KeraRing implantation through a femtosecond laser-assisted corneal pocket creation for the management of their central keratoconus.
33092097|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
33092098|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
33092099|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
33092100|NCT00428129|Experimental|1|
33092101|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
33092102|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
33092103|NCT00428168|Experimental|Betahistine 24 mg|
33092104|NCT00428168|Placebo Comparator|Placebo|
33092105|NCT00428285|Experimental|Single Arm|
33092106|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
33092107|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
33404380|NCT05076526|Experimental|PRP-HA|Patients will receive 2 intra-articular injections of 5mL CM-PRP-HA combination (3mL of autologous PRP, 2mL of 16mg/mL HA), with an interval of 1 month between both injections.
33404381|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
33092108|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
33092109|NCT00428480|Experimental|1|Daily reinforcement of walking speed
33092110|NCT00428480|Active Comparator|2|No reinforcement of walking speed
33092111|NCT00460473|Experimental|Dexmedetomidine|
33092112|NCT00460473|Placebo Comparator|Placebo (PBO)|
33092113|NCT00428519|Placebo Comparator|1|
33092114|NCT00428519|Active Comparator|2|
33092115|NCT00428519|Active Comparator|3|
33404382|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
33092116|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
33092117|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
33092118|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
33092119|NCT01056380|Active Comparator|Nitazoxanide|
32746496|NCT04790487|Experimental|Chlorpheniramine|Chlorpheniramine (CPM)
33092120|NCT01056380|Placebo Comparator|Placebo|
33092121|NCT00460590|Experimental|1|12 adults with prior BCG
33092122|NCT00460590|Experimental|2|12 adults without prior BCG
33092123|NCT00460590|Experimental|3|12 Adolescents
33092124|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
33092125|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
32746497|NCT04790487|Placebo Comparator|Control|Saline
32746498|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
32746499|NCT04790331|Experimental|verapamil group|verapamil group who will receive verapamil 80 mg PO 3 hours preoperative
32746500|NCT04790331|Experimental|Ditiazim|Diltiazim group will receive Diltiazim 90mg PO 3 hours preoperative
32746501|NCT04790331|Experimental|placebo group|Placebo oral tablet
32746502|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
32746503|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
32746504|NCT05613465|Experimental|intervention|Codonopsis pilosula Nnannf
32746505|NCT05613465|Placebo Comparator|Control group|Placebo
32746506|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
32746507|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
32746508|NCT05472519|Other|Loeys-Dietz syndrome|Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation.
32746509|NCT05472519|Other|Healthy Group|Subjects aged ≥ 5 years.
32746510|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
32746511|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
32746512|NCT04790097|Experimental|Simultaneous In-Field Boost on FET-PET positive target volumes|
33092126|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
33092127|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
33092128|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
33092129|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
33092130|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
33092131|NCT00460668|No Intervention|Control|Control
33092132|NCT04704713|Experimental|Afamelanotide|Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
33092133|NCT04704713|Placebo Comparator|Placebo|Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
33404383|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
33092134|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
33092135|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
33092136|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
33092137|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
33092138|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
33092139|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
33092140|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
33092141|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
33092142|NCT01054976|Experimental|Galantamine|
33404384|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
33404385|NCT05076136|Experimental|Regional treatment|Group A was given regional treatment with baseline treatment protocol
33404386|NCT05076136|Active Comparator|Standard physiotherapy treatment|Group B was given standard physiotherapy treatment with baseline protocol
33404387|NCT03654482|Experimental|SuperSeton arm|
33092143|NCT00469443|Experimental|1|FOLFIRI/Avastin
33092144|NCT00469443|Experimental|2|XELIRI/Avastin
33092145|NCT00428831||1|Patients with respiratory illnesses.
33092146|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
33092147|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
33092148|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
33092149|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
33092150|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
33092151|NCT00428909|Other|Drug-Drug interaction|
33404388|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min, 8mmHg
33404389|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 20 L/min, 8mmHg
33404390|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
33404391|NCT05076058|Experimental|Treatment group|"Tablet name: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
33404392|NCT05076058|Placebo Comparator|Control group|"Tablet name: Placebo;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
33092152|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
33092153|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
33092154|NCT00460902|Experimental|Deep TMS stimulation|
33092155|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
33092156|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
33404393|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
33404394|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
33404395|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
33404396|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
33404397|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
33404398|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
32942232|NCT05748847|Active Comparator|Tunnel ICRS|Patients in this group are planned to undergo KeraRing implantation through a femtosecond laser-assisted corneal tunnel creation for the management of their central keratoconus.
32942233|NCT05617651|Active Comparator|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day~Period 3 : Ilaprazole 10mg 2Tab, one a day"
32942234|NCT05617651|Active Comparator|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day~Period 3 : Ilaprazole 20mg 1Tab, one a day"
32942235|NCT05615857|No Intervention|Colonoscopy without Endocuff|No Endocuff inserted proximally to colonoscope and use of retroflexion
32942236|NCT05615857|Experimental|Colonoscopy with Endocuff|Endocuff inserted proximally to colonoscope, no use of retroflexion
32942237|NCT05748691||Pre-implementation group|Clinical use of hs-cTnI in patients with suspected acute coronary syndrome
32942238|NCT05748691||Post-implementation group|Clinical use of hs-cTnT in patients with suspected acute coronary syndrome
32942239|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
32942240|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
32942241|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
32942242|NCT05748613|Experimental|Computerized Anxiety Sensitivity Treatment|"CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated anxiety sensitivity (AS), particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention containing video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension, introduction and practice with interoceptive exposures). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In CAST, participants are informed that the primary purpose of the presentation is to highlight healthier, more productive, and effective ways of dealing with stress. Through participation in the intervention, people learn adaptive long-term strategies for tolerating, coping with, and effectively reducing distress and negative emotions."
32942243|NCT05748613|Placebo Comparator|Health Education Control|HEC is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. To match the interactive components in the CAST condition, behavior tracking and goal-setting are included in HEC. The HEC protocol has been used in prior studies as a control condition for CAST to account for intervention modality and time. HEC is perceived positively, with high rates of acceptability. Importantly, HEC is inert with respect to the proposed mechanism of action (AS).
32942244|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
32942245|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
32942246|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
32942247|NCT05608993|Experimental|High Intensity|Community-based clinics and/or urgent care centers that are assigned to the high intensity arm will receive the high intensity intervention.
32942248|NCT05608993|Experimental|Low Intensity|Community-based clinics and/or urgent care centers that are assigned to the low intensity arm will receive the low intensity intervention.
32942249|NCT05747365||Case group|Patients with thyroid cancer diagnosis within 5 years before study enrollment
32942250|NCT05747365||Control group|Patients without clinical diagnosis of thyroid disease
32942253|NCT05745883|Experimental|Phase 1b Dose Escalation|Single ascending dose of DISC-0974
32942254|NCT05745883|Placebo Comparator|Placebo|
32942255|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
32942256|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
32942257|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
32942258|NCT04605913|Experimental|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
33092157|NCT04704206|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
33092158|NCT04704206|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
33092159|NCT00469560|Experimental|Deferasirox|
32799737|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
33092160|NCT04704167|Active Comparator|3D titanium mesh tray|3D titanium mesh tray as a method of fixation for double-barrel vascularized fibula
33092161|NCT04704167|Experimental|3D titanium miniplate|3D titanium miniplate as a method of fixation for double-barrel vascularized fibula
33092162|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
33092163|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
33092164|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
33092165|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
33092166|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
33092167|NCT00469638|Experimental|Agilis sheeth group|
33092168|NCT00469638|Active Comparator|Non-steerable sheeth group|
33092169|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
33092170|NCT00461019|Experimental|Implantation of the CardioFit system|
33092171|NCT00461058|Active Comparator|Actos|
33092172|NCT00461058|Experimental|Aleglitazar|
32799738|NCT05630950|Experimental|Smoking cessation application|
32799739|NCT05630950|Active Comparator|Written smoking cessation information|
32799740|NCT05630872|Experimental|Adults with HIV and newly diagnosed DS-TB not currently on ART|"Participants will receive daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide for 8 weeks followed by daily rifapentine-moxifloxacin plus isoniazid for 9 weeks (referred to as 2HPZM/2HPM) for anti-tuberculosis (anti-TB) therapy at study entry.~DTG-based ART at 50 mg twice daily (BID) will be started after 6 weeks of TB therapy and will be continued for 2 weeks after completion of TB therapy.~Two weeks after completion of TB therapy DTG will be reduced to standard dose 50 mg once daily (QD)."
32799741|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
32799742|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
32799743|NCT04407052|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
33092173|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
33092174|NCT02957708|Active Comparator|Control|conventional occupational therapy
33092175|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
33092176|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
33092177|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
33092178|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
33092179|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
33092180|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
33092181|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
33092182|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
33092183|NCT04704245|Experimental|epidermal growth factor (EGF) containing ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
33092184|NCT04704245|Placebo Comparator|Vehicle ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
33092185|NCT03271671|Active Comparator|PSV|Pressure support ventilation
33092186|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
33092187|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
33092188|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
33092189|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
33092190|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
33092191|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
33307364|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
33307365|NCT03960944|Experimental|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
33307366|NCT03960944|No Intervention|Control Group|Usual Activities in school
32799744|NCT04407052|Active Comparator|HCG|HCG is used to trigger ovulation
32799745|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
32799746|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
32799747|NCT01852058|Experimental|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
32799748|NCT01852058|Experimental|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
32799749|NCT01852058|Experimental|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
32799750|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
32799751|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
32799752|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
32799753|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799754|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799755|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799756|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799757|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799758|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
32799759|NCT03599128|Placebo Comparator|Placebo|Placebo
32799760|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
32799761|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
32799762|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
32799763|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
32799764|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
32799765|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
32799766|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
32799767|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
32799768|NCT03594370||control|Limbal image by OCT in normal subjects.
32799769|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
32799770|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
32799771|NCT03598972||control|teeth of children of non vitamin taking mother
32799772|NCT03598972||intervention|children teeth of vitamin taking mother
32799773|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
33092192|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
33092193|NCT03271593||All children admitted|All children admitted to hospital
33092194|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
33092195|NCT00429962|Active Comparator|B|intravitreal ranibizumab
33092196|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
33092197|NCT04703894|Experimental|AYMES 'CARDIFF'|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.
33092198|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
33092199|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
33092200|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
33092201|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
33092202|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
33092203|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
33092204|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
33092205|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
33092206|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
33092207|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
33092208|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
33092209|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
33092210|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
33092211|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
33092212|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
33092213|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
33092214|NCT00461526|Experimental|125 mg crofelemer|
33092215|NCT00461526|Placebo Comparator|placebo|
33092216|NCT00461565|Active Comparator|Part A1|
33092217|NCT00461565|Placebo Comparator|Part A2|
33092218|NCT00461565|Experimental|Part B1|
33092219|NCT00461565|Placebo Comparator|Part B2|
33092220|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
33092221|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
33092222|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
33092223|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
33092224|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
33092225|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
33092226|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
33092227|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
33092228|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
33092229|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
33092230|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
33092231|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
33092232|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
33092233|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
33092234|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
33092235|NCT00430586|Experimental|20 U NT 201|
33092236|NCT00430586|Placebo Comparator|Placebo|
33092237|NCT00430586|Experimental|10 U NT 201|
33092238|NCT00430586|Experimental|30 U NT 201|
33092239|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
33092240|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
33092241|NCT01053962|Experimental|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
33092242|NCT01053962|Experimental|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
33092243|NCT01053962|Experimental|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
33092244|NCT01053962|Experimental|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
33092245|NCT01053962|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
33307367|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
33307368|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
32799774|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
32799775|NCT05633836|Experimental|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreductive surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
32799776|NCT05633758|Placebo Comparator|SOC heart failure therapy and placebo pill (Arm A)|This group will receive all standard heart failure therapy and placebo pill.
32799777|NCT05633758|Active Comparator|SOC heart failure therapy with addition of metolazone (Arm B)|This group will receive all standard heart failure therapy with addition of metolazone.
32799778|NCT03978442|Experimental|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
32942259|NCT05595499|Experimental|Arm A (fisetin)|Patients receive fisetin PO on the trial. Patients also undergo collection of blood throughout the trial.
32799779|NCT03978442|Active Comparator|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
32799780|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
32799781|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
32799782|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
32799783|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
32799784|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
32799785|NCT04004182|Active Comparator|OGTT session|Oral Glucose Tolerance test (OGTT)
32799786|NCT04004182|Active Comparator|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
32799787|NCT04004182|Experimental|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
32799788|NCT04004182|Experimental|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
32799789|NCT04003948|Experimental|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
32799790|NCT04003948|Experimental|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
32799791|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
32799792|NCT05633368||Discontinuation of C/M-ECT|Participants with major depressive disorder who are unable to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) due to hospital restrictions during Covid-19 or due to personal preference.
32799793|NCT05633368||Continuation of C/M-ECT|Participants with major depressive disorder who are able to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) during Covid-19.
32799794|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
32799795|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
32799796|NCT03976882|Experimental|Group A：Hetrombopag|
32799797|NCT03976882|Placebo Comparator|Group B：Placebo|
32799798|NCT04747990||Baseline (Pre-Covid19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2019
32799799|NCT04747990||Pandemic (During Covid-19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2020
32799800|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
32799801|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
32799802|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
32799803|NCT02985346|Active Comparator|Control group|Patients received standard treatment
32942260|NCT05595499|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO on the trial. Patients also undergo collection of blood throughout the trial.
32942261|NCT05745571|Other|Patients with acute coronary syndrome|30 patients admitted to our hospital with the diagnosis of STEMI-type ACS and ejection fraction ≤ 35% on echocardiographic evaluation
33307369|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
33307370|NCT00079040|Experimental|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
33307371|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
32942262|NCT05745571|Other|Patients with non-ischaemic dilated cardiomyopathy|30 patients with non-ischaemic dilated cardiomyopathy and ejection fraction ≤35% on echocardiographic evaluation
32942263|NCT05745571|Other|Patients diagnosed with STEMI-type ACS|Patients diagnosed with STEMI-type ACS and ejection fraction > 50% on echocardiographic evaluation
32942264|NCT05745571|Other|Controls|Controls with normal left ventricular contractile function
32942265|NCT05592769|Experimental|HealthBeacon Injection Care Management System (ICMS) Arm|All participants enrolled will be recruited to this study arm and provided with access to the HealthBeacon ICMS.
32942266|NCT05744947||Recruited patient .|Patient previsouly recruited in the DISCO Registry (Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection. (DISCO trial - NCT02799186)) with cardiac rehabilitation following the management of acute coronary syndrome
32942267|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
32942268|NCT05744557|Experimental|num Vapocoolant|vapocoolant anesthetic spray (a spray that cools and numbs the skin) to control pain during minor surgical procedures (such as lancing boils, incisions, injections and IV placements) and minor sport injuries
32942269|NCT05743465||Ponatinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants with a ponatinib prescription identified as the index drug prior TKI use will be stratified in this cohort.
32942270|NCT05743465||Bosutinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants without ponatinib use and with bosutinib identified as the index drug prior TKI use will be stratified in this cohort.
32942271|NCT05743465||Other TKI Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants without ponatinib or bosutinib use and with imatinib, dasatinib, or nilotinib identified as the index drug after prior TKI use will be stratified in this cohort.
32942272|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
32942273|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
32942274|NCT05586373|Active Comparator|Group 1|Ibuprofen 400mg 6/6h, oral, maximum 5 days
32942275|NCT05586373|Experimental|Group 2|Dipyrone 1g 6/6h, oral, maximum 5 days
32942276|NCT05584267|Active Comparator|cohort A|Chemotherapy + immunotherapy; Every three weeks, up to four cycles of chemotherapy
32942277|NCT05584267|Experimental|cohort B|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; WBRT, 3 Gy/ time, 10 times in total
32942278|NCT05584267|Experimental|cohort C|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; HFRT, 10 Gy/ time, 3 times in total
32942279|NCT05582707|Experimental|MIPS + Pioglitazone|20 Subjects will undergo MIPS for evacuation of ICH using the BrainPath access device plus perioperative pioglitazone for 3 weeks
32942280|NCT05582707|No Intervention|MIPS Alone|This trial will compare it's subjects to subjects who have previously undergone MIPS for evacuation of ICH using the BrainPath access device as part of the ENRICH trial (NCT02880878). These subjects will be enrolled at an ENRICH trial site independent of our Institution. Deidentified patient information from 20 subjects in this group, who will be matched to those in the ENRICH-PLUS group, will be provided to the principal investigator for comparison of outcomes.
32942281|NCT00004136|Experimental|Heat Therapy|
32942282|NCT05743075|Experimental|Ensifentrine|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
32942283|NCT05743075|Placebo Comparator|Placebo|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
32942284|NCT05582161|Experimental|DAOIB|
32942285|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
32942286|NCT05741593||Patients having had a stroke|elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke
32942287|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
33404399|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
33404400|NCT05075902|Experimental|Multimorbidity Group (MULTI)|Multimorbidity group is composed of post menopausal women with two or more chronic diseases cardiometabolic (Hypertension, diabetes, dislipidemias, obesity).
32942288|NCT04207424|Experimental|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
32942289|NCT04191122|Active Comparator|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
32942290|NCT04191122|No Intervention|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
32942291|NCT00382135|Placebo Comparator|1|placebo tablet
32942292|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
32942293|NCT05519527|Experimental|Part 1 (dose escalation)|Participants of the first group will receive the lowest dose level. Participants of each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of STI-6129 is found.
32942294|NCT05519527|Experimental|Part 2 (dose expansion)|Participants will receive the dose of STI-6129 found in Part 1 of the study.
32942295|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
32942296|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
32942297|NCT04133324||Main group|One groupe in the study
32942298|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
32942299|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
32942300|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
32942301|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
32942302|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
32942303|NCT05562115|Experimental|Patients treated for an ocular malformation linked to a PAX6 mutation.|
32942304|NCT05562037|No Intervention|Treatment as usual|"Patients referred to CR or PR are initially telephoned by a RN,RC or RA who describes the program and schedules the initial intake evaluation. The intake evaluation reflects usual care practices at both BMC and Fairview Hospital. The purpose of this initial session is to obtain the data required to design an individualized effective and safe rehabilitation program. It is performed by a RN, RC, or RA and includes performing a medical history, physical examination, and testing.~Reminder telephone calls are placed prior to the initial intake and formal reassessments visits."
32942305|NCT05562037|Active Comparator|Stepped Care|"The SC arm will be offered Center Based Rehabilitation (CBR) and subsequently stepped up to transportation-subsidized CBR, home-based TR, and CHW-supported home-based TR based on prespecified non-response criteria/poor adherence.~Standard of Care. Patients meeting a non-response criterion will be stepped up to transportation-subsidized CBR.~Step 1. Transportation-Subsidized CBR. Step 2. Home-Based TR. Step 3. CHW-Supported Home-Based TR."
32942306|NCT05509543|Active Comparator|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day"
32942307|NCT05509543|Active Comparator|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day"
32942308|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
32942309|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
32942310|NCT05557591|Experimental|Phase 1: BNT116 + Cemiplimab|BNT116 is administered by intravenous (IV) injection. Cemiplimab is administered by IV infusion Q3W.
32942311|NCT05557591|Experimental|Phase 2: Cemiplimab|Arm A: Cemiplimab is administered by IV infusion Q3W
32942312|NCT05557591|Experimental|Phase 2: BNT116 + Cemiplimab|Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W.
32942313|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
32942314|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
32942315|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
32942316|NCT05508061|Experimental|Lyumjev (insulin lispro)|Administration of Lyumjev for a 30-day study period (dosage and frequency is patient-dependent)
32942317|NCT05508061|Active Comparator|Humalog (insulin lispro)|Administration of standard used Humalog for a 30-day study period and 8-day wash-out period located between the two study periods (dosage and frequency is patient-dependent)
33307372|NCT03961022|Active Comparator|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
33307373|NCT03961022|Placebo Comparator|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
32942323|NCT00384566|Experimental|1|
32942324|NCT00384566|Active Comparator|2|
32942325|NCT05501665|Experimental|Treatment (pembrolizumab, chemotherapy, radiation)|"Patients receive standard of care pembrolizumab with or without carboplatin and pemetrexed or carboplatin and nab-paclitaxel and undergo radiation therapy on day 1 of each cycle. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients receive fludeoxyglucose F-18 IV then undergo PET/CT and [18-F] (fluoropropyl)-L-glutamate (FSPG) IV then undergo PET/CT (two independent PET/CT studies) done prior to cycle 1 (within 21 days) and after cycle 3 (but before cycle 4) of therapy.~MAINTENANCE THERAPY: After 5 cycles, patients may continue receiving pembrolizumab every 21 days in the absence of disease progression or unacceptable toxicity."
32942326|NCT00384644||1|sepsis, septic shock ptients
32942327|NCT00384644||2|cardiogenic shock patients
32942328|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
32942329|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
32942330|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
32942331|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
32942332|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
32942333|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
32942334|NCT00381979|Experimental|1|set
32942335|NCT05500807|Other|Open Label Emicizumab|Emicizumab prophylaxis
32942336|NCT04472767|Experimental|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose~TACE: Within 3-4 weeks of cycle 1 day 1; may be done up to 3 times (9-12 weeks total), the intervals between each TACE treatment can vary based on investigator's discretion"
32942337|NCT00003686|Active Comparator|Pilocarpine|
32942338|NCT00003686|Placebo Comparator|Placebo|
33092246|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
33092247|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
33092248|NCT00430703|Experimental|2|Healthy volunteers
33092249|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
33092250|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
33092251|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
33092252|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
33307374|NCT00078806|Experimental|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
33307375|NCT00078806|Placebo Comparator|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
33092253|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
33092254|NCT00430820||1|30 patients
33092255|NCT00430820||2|30 patients
33092256|NCT00430820||3|30 patients
33092257|NCT00430859|Experimental|1|BIAP
33092258|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
33307376|NCT00078806|Experimental|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
33307377|NCT00078806|Experimental|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
33307378|NCT01090856|No Intervention|No pre-dilation side branch|
33307379|NCT01090856|Active Comparator|Pre-dilation side branch|
33092259|NCT03271320||systemic sclerosis|patients with systemic sclerosis
33092260|NCT03271320||control|Healthy subjects
33307380|NCT01082042||Standard Care|Individuals who attended the local falls group
33307381|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
33307382|NCT00078338|Experimental|Rebif®|
33307383|NCT00078338|Active Comparator|Copaxone®|
32799804|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
33307384|NCT01088594|Experimental|1|pioglitazone 45 mg
32799805|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
32799806|NCT05633134|Experimental|Precision preoperative embolization|60 patients with pelvic tumors will undergo arteriography and receive transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
32799807|NCT05633134|Active Comparator|Control group|60 patients with pelvic tumors will undergo arteriography and without transcatheter arterial embolization of pelvic tumors prior to surgery.
32799808|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
33092261|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
33092262|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
33092263|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
33092264|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
33307385|NCT01088594|Experimental|2|Rosiglitazone 8 mg
33307386|NCT01088594|Placebo Comparator|3|Placebo
33307387|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
33092265|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
33307388|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
33307389|NCT01090934|Experimental|high resolution EEG|
33307390|NCT01090934|Active Comparator|Stereo Electroencephalography|
33307391|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
33092266|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
33307392|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
33092267|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
33307393|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
33307394|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
33307395|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
33307396|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
33307397|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
33307398|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
32942339|NCT05495035|Experimental|Olverembatinib + APG-2575 combinational therapy|"Period 1: Olverembatinib alone period (2 weeks):~Period 2: olverembatinib in combination with APG-2575 and dexamethasone (4 weeks):"
32942340|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
32942341|NCT04438525|Active Comparator|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
32942342|NCT04438525|Active Comparator|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
32942343|NCT04438525|Active Comparator|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
32942344|NCT04438525|Other|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
32942345|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
32942346|NCT05492773|Experimental|Micro-osteoperforations|Experimental: Micro-Osteoperforations Technique(MOPs) Experimental: Micro-Osteoperforations Technique(MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
32942347|NCT05492773|Experimental|Clear aligner|Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
32942348|NCT04438057|No Intervention|Standard of Care|Patient will receive standard of care therapy.
32942349|NCT04438057|Active Comparator|Treatment Arm|Patient will receive convalescent plasma
32942350|NCT04600375|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~Survey A~Routine clinic visit~Verbal consultation only~Survey B~Verbal consultation AND Written Action Plan~Survey C"
32942351|NCT04600375|Experimental|Experimental: Written Action Plan|"INTERVENTION GROUP~Survey A~Routine clinic visit~Verbal consultation AND Written Action Plan~Survey C"
32942352|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
32942353|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
32942354|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
32942355|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
32942356|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
32942357|NCT05533333|Experimental|Self administered dual-task training|"The exercise intervention will continue for 9 months, beginning with 12 weeks of training accompanied by workshops to teach the exercises.~Experimental group: sDTT group participants will be instructed to perform 10 minutes of warm-up, 40 minutes of dual-task training and 10 minutes of cool-down exercises. The size of the workshop will be limited to 10 participants. The sDTT programme includes performing a selection of six cognitive tasks during walking, the sit-to-stand movement, heel and toe raising, stepping, tandem standing and walking and multidirectional reaching tasks. The cognitive tasks will include mental tracking, working memory, auditory cues and verbal fluency tasks. Participants will be given the freedom to mix and match the physical and cognitive tasks to make them more challenging."
32942358|NCT05533333|Active Comparator|Self-administered singletask training|Control group: The self-administered single-task training group will receive 10 minutes of warm-up, 20 minutes of physical tasks (as outlined above) and 20 minutes of cognitive tasks (as outlined above) followed by 10 minutes of cool-down exercises. Participants will be instructed to perform the exercises for the same dosage as the experimental group. After a 6-month follow-up period, the control group will receive two complimentary sessions of self-administered dual-task training.
32942359|NCT05492071|Experimental|Local Vibration Application Following Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
32942360|NCT05492071|Experimental|Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
33404401|NCT05075902|Experimental|Morbidity Group (MORB)|Morbidity group is composed of postmenopausal women with one or no chronic cardiometabolic disease (Hypertension, diabetes, dislipidemias, obesity)
32942361|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
32942362|NCT05243875|Experimental|Vaccine Concierge|The experimental group will be offered the intervention, involving COVID-19 education, testing and vaccination information, as well as scheduling appointments and arranging transportation for testing/vaccination.
32942363|NCT05243875|Other|Wait-List Control|The wait-list control group will only receive brief COVID-19 education and information about clinical guidelines for testing and the benefits of vaccination. Control group participants who have not been tested/vaccinated at 1-month follow-up will be asked about their interest in the experimental intervention.
32942364|NCT05487235|Experimental|Dose-finding Stage: GDC-1971|Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.
32942365|NCT05487235|Experimental|Expansion Stage: GDC-1971|Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
32942366|NCT05232097|Experimental|Behavioral therapy|Behavioral therapy consisting of diaphragmatic breathing exercises and physiotherapy to relax tensed abdominal and thoracic muscles
32942367|NCT05485675|Active Comparator|Stand & Move at Work|Given an evidence-based workplace program to reduce sedentary behavior and increase standing and moving using a web-based platform. The web platform has a toolkit with strategies and guides for the worksite Champions to address changes at the environmental, social, and cultural levels.
32942368|NCT05485675|Experimental|Stand & Move at Work+|This arm will receive access to the same web-based platform and toolkit as the other arm. Additionally, worksites in this arm will be assigned and expert facilitator who will meet regularly with the worksite Champions to assist with implementation.
32942369|NCT05231629|Experimental|Arm A|3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
32942370|NCT05231629|Active Comparator|Arm B|AHCT intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
32942371|NCT05231629|Experimental|Arm C|AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance in MRD positive patients
32942372|NCT05231629|Active Comparator|Arm D|AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance in MRD positive patients
32942373|NCT05231629|Other|Arm M|Induction - 6 cycles of Dara-VRd in all participants
32942374|NCT05230927||Chronic Heart Failure|
32942375|NCT05230927||Chronic Obstructive Pulmonary Disease|
32942376|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
32942377|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
32942378|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
32942379|NCT05484739|Experimental|Very hot and dry|Subjects will be exposed to 3 hours in a climate chamber set to approximately 47 deg C and 15% relative humidity, which reflects a very hot and dry heat wave condition similar to the 2018 Los Angeles heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
32942380|NCT05484739|Experimental|Hot and humid|Subjects will be exposed to 3 hours in a climate chamber set to approximately 41 deg C and 40% relative humidity, which reflects hot and humid heat wave similar to the 1995 Chicago heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
32942381|NCT05218993||Development of the new dual task test|the new two different method of dual task measurement and a traditional dual task measurement method and also, cognitive and performance measurement test will be conducted.
32942382|NCT05218993||Collecting the normative values|Better dual task measurement method (from the two methods) will be conducted at different football levels.
32942383|NCT05218993||Measurement of the athletes in return to sport stage|new dual task measurement method and other return to sport measurements will be conducted on athletes who wish to return to sport.
33307399|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
33307400|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
33307401|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
33307402|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
33307403|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
33307404|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
33307405|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
32942384|NCT04833829|Active Comparator|Clinic Patients During the Pre-implementation Period|Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
33307406|NCT03961334|Experimental|DOACs|Direct oral anticoagulants
33307407|NCT03961334|Active Comparator|Antiplatelets|Antiplatelets
33307408|NCT00077636|Experimental|1|
33307409|NCT00077636|Experimental|2|
33307410|NCT03963674|Experimental|Diacutaneous fibrolysis|
33307411|NCT03963674|No Intervention|Control|
33307412|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
33307413|NCT01088750|Experimental|CVP Chemotherapy|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
32942385|NCT04833829|Experimental|Clinic Patients During the Implementation Period|Patients visiting one of the study clinics during the Implementation period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 13 - 27.
32942386|NCT04833829|Experimental|Clinic Patients During the Maintenance Period|Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
32942387|NCT04812847||Gram negative infection, MDR present|Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
32942388|NCT04812847||Gram negative infection, MDR absent|Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
32942389|NCT05477875|Experimental|Oral cannabinoid|Oral cannabinoid
32942390|NCT05477875|Active Comparator|Oral codeine/acetaminophen|Oral codeine-acetaminophen for controlling pain
32942391|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
32942392|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
32942393|NCT05471791|Experimental|App group|Participants will use the Back2Play App to support them in following the guidelines for recovery from concussion
32942394|NCT05471791|No Intervention|Usual Care|Participants will receive usual care which often means they are provided concussion recovery guidelines in handout format and receive whatever follow up is deemed necessary by treating physician
32942395|NCT04805203|Other|blood samples|4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
32942396|NCT05467891|Experimental|Investigational Group|"The drug ribociclib will be taken orally at a dose of 600 mg daily for 21 days out of a 28-day cycle. Ribociclib will be used in combination with ET per physician choice.~Physician's choice of endocrine therapy includes:~500 mg of fulvestrant received intramuscularly. This will be taken on Day 1 and Day 15 of Cycle 1 and on Day 1 of Cycle 2 and beyond.~1 mg of anastrozole taken orally daily of the 28 day cycle.~2.5 mg of letrozole taken orally daily of the 28 day cycle.~25 mg of exemestane taken orally daily of the 28 day cycle.~Concomitant use with tamoxifen is not allowed.~Premenopausal subjects must also be treated with ovarian suppression according to institutional standards or have undergone bilateral oophorectomy."
32942397|NCT04804969||At Risk Echo Referrals|Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.
32942398|NCT05456191|Experimental|Asciminib|Participants will receive asciminib 80 mg QD
32942399|NCT05456191|Active Comparator|Nilotinib|Participants will receive nilotinib 300 mg BID
33307414|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~around 10 will be born with clubfoot and will form most of Group B,~around 5 will be born without clubfoot and will form part of group C."
33307415|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
33307416|NCT01088828||Group C|Control group of unaffected neonates (n=10)
33307417|NCT01088828||Group D|Young adults having completed treatment (n=5)
33307418|NCT01088828||Group E|Control group of young unaffected adults (n=5)
33307419|NCT03957746|Experimental|3 sets of resistance exercise|
33307420|NCT03957746|Experimental|6 sets of resistance exercise|
33307421|NCT03957746|Experimental|9 sets of resistance exercise|
33307422|NCT03957746|No Intervention|Rest|
33307423|NCT01091012|Other|Sildenafil 20mg oral|
33307424|NCT01091012|Other|Sildenafil 10mg intravenous|
33307425|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
33307426|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
33307427|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
33307428|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
33307429|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
33307430|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
33307431|NCT01091090|Active Comparator|Control|Treatment as usual
33307432|NCT03964142|Experimental|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
32942400|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
32942401|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
33092268|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
33092269|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
33404402|NCT05075668|Active Comparator|OSA support via CPAP face mask|Auto-titrated according to the settings made by sleep physicians, FiO2 0.21
33404403|NCT05075668|Active Comparator|OSA support via HFNC at 20 L/min|High flow nasal insufflation of air (FiO2 0.21) at 20 L/min
32746513|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
32942402|NCT04792099|Experimental|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) with blended oxygen delivered by binasal prongs or nasal mask.
32942403|NCT04792099|Active Comparator|Nasal Cannula|Blended oxygen delivered by nasal cannula (NC).
32942404|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
32942405|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
32942406|NCT04092842|Experimental|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
32942407|NCT04092842|Active Comparator|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
32942408|NCT04066868|Experimental|PRO active|
32942409|NCT04066868|Active Comparator|PRO not active|
32942410|NCT04712786||Group|27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
32942411|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
32942412|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
32942413|NCT05449496|No Intervention|Control|
32942414|NCT05449496|Experimental|Intervention|
33092270|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
33092271|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
33092272|NCT00431054|Experimental|Perifosine + Docetaxel|
33092273|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
33092274|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
33092275|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
33092276|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
33092277|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
33092278|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
33092279|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
33092280|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
33092281|NCT00431249|Other|one|
33092282|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
33092283|NCT00470886||Group 1|
33092284|NCT00431483|Other|Pharmaceutical counseling|
33092285|NCT00431561|Experimental|AP 12009 10 µM|
33092286|NCT00431561|Experimental|AP 12009 80 µM|
33092287|NCT00431561|Active Comparator|Chemotherapy|
33092288|NCT00431600|Experimental|1|12 healthy male subjects
33092289|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
33307433|NCT03964142|No Intervention|Conventional management|Patients with conventional management and physical activity recommendation
33404404|NCT05075668|Active Comparator|OSA support via HFNC at 30 L/min|High flow nasal insufflation of air (FiO2 0.21) at 30 L/min
33404405|NCT05075668|Active Comparator|OSA support via HFNC at 40 L/min|High flow nasal insufflation of air (FiO2 0.21) at 40 L/min
32942415|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
32942416|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
32942417|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
32942418|NCT00005006|Active Comparator|1|Alendronate alone
32942419|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
32942420|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
32942421|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
32942422|NCT00003824|Experimental|cipro|ciprofloxacin
32942423|NCT00003824|Experimental|ceph|cephalexin
32942424|NCT04791319|Placebo Comparator|Group 1: Placebo|Participants will receive subcutaneous (SC) placebo once a week (qw) through Week 15. At Week 16, participants will crossover to receive SC bermekimab Dose 2 qw through Week 31.
32942425|NCT04791319|Experimental|Group 2: Bermekimab|Participant will receive SC bermekimab Dose 1 qw from Week 0 through Week 31.
32942426|NCT04791319|Experimental|Group 3: Bermekimab|Participants will receive SC bermekimab Dose 2 qw from Week 0 through Week 15. At Week 16, participants who achieve an eczema area and severity index (EASI)-75 response (responders) will be rerandomized either to continue to receive bermekimab Dose 2 qw, or to receive bermekimab Dose 1 qw, through Week 31 and participants who do not achieve an EASI-75 response (non responders) will continue to receive bermekimab Dose 2 qw through Week 31.
32942427|NCT04791319|Active Comparator|Group 4: Dupilumab|Participants will receive a loading dose of SC dupilumab Dose 1 at Week 0, SC placebo every two week (q2w) from Week 1 through Week 15 and then dupilumab Dose 2 q2w from Week 2 through Week 14. At Week 16, participants who achieve EASI-75 response (dupilumab responders) will continue on dupilumab Dose 2 q2w through Week 30 and placebo q2w from Week 17 through Week 31. Participants who do not achieve an EASI-75 response (dupilumab non-responders) will receive placebo qw from Week 16 through Week 18 (washout period) and bermekimab Dose 2 qw from Week 19 through Week 31.
32942428|NCT04784533|Experimental|Part A, Period 1 - Low dose|8 mg BID CTP-543 for 24 weeks
32942429|NCT04784533|Experimental|Part A, Period 1 - High dose|12 mg BID CTP-543 for 24 weeks
32942430|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from low dose|Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID
32942431|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from low dose|Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID
32942432|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from high dose|Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID
32942433|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from high dose|Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID
32942434|NCT04784533|Experimental|Part B - Low dose|8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
32942435|NCT04784533|Experimental|Part B - High dose|12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
32942436|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
32942437|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
32942438|NCT05196373|Experimental|Part 1: Group 1|10ug Intrascar injection
32942439|NCT05196373|Experimental|Part 1: Group 2|20ug Intrascar injection
32942440|NCT05196373|Experimental|Part 1: Group 3|40ug Intrascar injection
32942441|NCT05196373|Experimental|Part 1: Group 4|60ug Intrascar injection
32942442|NCT05196373|Experimental|Part 1: Group 5|80ug Intrascar injection
32942443|NCT05196373|Experimental|Part 1: Group 6|100ug Intrascar injection
32942444|NCT05195437||Growth hormone treatment|Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height and who have been treated with growth hormone due to short stature.
32942445|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
33307434|NCT00095199|Experimental|Cetuximab & Pemetrexed|
33307435|NCT00095199|Active Comparator|Pemetrexed|
33092290|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
33092291|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
33092292|NCT00431678|Experimental|Arm 1|
33092293|NCT00431678|Active Comparator|Arm 2|
32799809|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
32799810|NCT05632900|Experimental|NAGI BI-FLANGED METAL STENT WITH CO-AXIAL PLASTIC STENT FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long with co Axial double pig tail stent used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
32799811|NCT05632900|Active Comparator|NAGI BI-FLANGED METAL STENT ALONE FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
32799812|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
32799813|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
32799814|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
32799815|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
32799816|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
32799817|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
32799818|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
32799819|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
32799820|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
32799821|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
32799822|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
32799823|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
32799824|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
32799825|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
32799826|NCT05632822||SBT failure|The SBT was considered to be a failure if at least one the following criteria was present: (1) blood oxygen saturation (SpO2) of <90 % with a fraction of inspired oxygen (FiO2) of≥50 %; (2) acute respiratory distress (RR≥40/min, agitation, cyanosis); (3) systolic arterial blood pressure of ≥180 mmHg; (4) cardiac arrhythmias; (5) respiratory acidosis [pH<7.32 with an arterial carbon dioxide tension (PaCO2) of ≥50 mmHg].
32799827|NCT05632822||SBT success|If none of these failure criteria was present, the SBT was considered as successfully completed.
32799828|NCT04003246|Experimental|Single Arm: Therapeutic Intervention|
32799829|NCT00218296|Active Comparator|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
33092294|NCT00471003||Arm 1|
33092295|NCT04704128||Case group|women with primary stomatodynia
33092296|NCT04704128||Control group|women without oral disease
33092297|NCT00462267|No Intervention|Usual care|
33092298|NCT00462267|Experimental|Enriched lifestyle intervention|
33092299|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
33092300|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
33092301|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
33092302|NCT04703972|Experimental|Bipolar Patients with connected devices|Patients with bipolar disorder provided with connected devices (wristwatch and wristband)
33092303|NCT04703465|Experimental|tenofovir alafenamide|tenofovir alafenamide 25mg daily for 48 weeks
32746514|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
32942446|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
32942447|NCT05454007|Experimental|Individuals with Stroke|In this single group, proof-of-principle design, all eligible participants will be assigned to a single group. These are individuals with stroke who meet inclusion and exclusion criteria. They will each undergo the same assessments and participate in a single walking training session.
32942448|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
32942449|NCT05173831|Experimental|Two MDMA-assisted Therapy Sessions|Two Experimental MDMA-assisted Therapy Sessions, and four Integrative Sessions following each Experimental Sessions.
32942450|NCT05450107|Experimental|Intervention|The intervention group is offered surgical treatment of the shaft fracture of the fifth metatarsal bone with ORIF. Depending on the type of shaft fracture this will be either lag screw fixation or plate fixation. After surgery a period of cast immobilisation with gradual increase of weight bearing will commence
32942451|NCT05450107|Active Comparator|Control|The control group (conservative treatment), will receive a period of cast immobilisation, with a gradual increase in weight bearing by protocol.
32942452|NCT05449639|Experimental|Main group|A second no-random open interventional pilot study sponsored by Relief srl. The primary objectives of the study were to assess the safety and reproducibility of the implantation of the magnetic endo-urethral sphincter, if the procedure was well tolerated by the patients, and if possible irritation symptoms due to the device presence emerged in patients with severe stress urinary incontinence where standard medical treatments failed. The device will be implanted by endoscopic procedure by a standard resectoscope. Up to 20 patients of both gender affected by severe stress urinary incontinence will be involved in the study by means of prospective enrollment.
32942453|NCT04772989|Experimental|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
32942454|NCT04772989|Experimental|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
32942455|NCT04772989|Experimental|Dose Escalation Q6W Cohort|Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
32942456|NCT04772989|Experimental|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
32942457|NCT04772989|Experimental|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
32942458|NCT04772989|Experimental|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
32942459|NCT04772989|Experimental|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
32942460|NCT04772989|Experimental|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
32942461|NCT04573231|Experimental|18F-DCFPyL PSMA-based PET/CT|"18F-DCFPyL whole body PET/CT scan~Review of relevant imaging and medical record information~Blood draw for circulating tumor cells (CTCs)~Analysis of diagnostic tissue specimens"
32942462|NCT05444569|Experimental|LY3537021 + Liraglutide (Part A)|Liraglutide administered subcutaneously (SC) followed by liraglutide in combination with LY3537021 given SC.
32942463|NCT05444569|Experimental|Liraglutide + Placebo (Part A)|Liraglutide administered SC followed by liraglutide in combination with placebo given SC.
32942464|NCT05444569|Experimental|LY3537021 + Liraglutide & Placebo + Liraglutide (Part B)|"LY3537021 administered SC followed by liraglutide administered SC in treatment period 1.~Placebo administered SC followed by liraglutide administered SC in treatment period 2."
32942465|NCT05444569|Experimental|Placebo + Liraglutide & LY3537021 + Liraglutide Part B)|"Placebo administered SC followed by liraglutide administered SC in treatment period 1.~LY3537021 administered SC followed by liraglutide administered SC in treatment period 2."
32942466|NCT05167825|Experimental|Macitentan|Participants will receive oral dose of macitentan based on age and weight through Week 52.
32942467|NCT04756765|Experimental|Talazoparib Arm|Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
32942468|NCT00004466|Experimental|Atorvastatin|
32942469|NCT00004466|Placebo Comparator|Placebo|
32942470|NCT05432011|Experimental|PENG block plus Femoral Cutaneous Nerve Block|Participants receiving PENG block combined to Lateral Femoral Cutaneous Nerve Block
32942471|NCT05432011|Active Comparator|PENG block plus Wound Infiltration|Participants receiving PENG block combined to wound infiltration
32942472|NCT00385346|Experimental|A 1|Expressive writing
32942473|NCT04742101|Experimental|S65487 with azacitidine|
33404406|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
32942475|NCT04043936|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
32942476|NCT04043936|Sham Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
32942477|NCT04043936|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
33307436|NCT00095199|Experimental|Cetuximab & Docetaxel|
32737989|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
32746536|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
32746537|NCT05472285|Active Comparator|Verum|2 capsules per day during 8 weeks
32746538|NCT05472285|Placebo Comparator|Placebo|2 capsules per day during 8 weeks
32942478|NCT04734145||Participants with an Undiagnosed Pulmonary Nodule|One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring <3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
32942479|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
32942480|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
32942481|NCT04723927||Older adults|The data for motor function and gait pattern analysis was obtained.
32942482|NCT04722991|Experimental|Runcaciguat (BAY1101042)|
32942483|NCT04722991|Placebo Comparator|Placebo|
32942484|NCT05443334||Participants with type 2 diabetes|Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
32942485|NCT04718779|Experimental|Arm A: Prospective|Participants with Gaucher's Disease 1 (GD1) transitioning from SRTs to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) in a real-world setting among adults 18 and older will be studied by observing standard patient care and by reviewing the results of tests and assessments that would be performed as part of their routine treatment.
32942486|NCT04718779|Experimental|Arm B: Retrospective|Participants with GD1 transitioning from SRT to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) previously (within the past 5 years at the time of enrollment) will be assessed retrospectively after switch to ERT for up to 12 months.
32942487|NCT04717297|Experimental|Tailored Medication Management Remote Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered remotely.
32942488|NCT04717297|Sham Comparator|Waitlist Attention Control Arm|The attention control group will receive two, 75-minute attention visits with a trained research assistant. Upon completion of waitlist period, the participants in the waitlist group will be offered the intervention in person.
32942489|NCT04717297|Experimental|Tailored Medication Management In-Person Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered in-person.
32942490|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
32942491|NCT04711915|Active Comparator|0.1 mg/kg DMT|0.1 mg/kg DMT administered intravenously
32942492|NCT04711915|Active Comparator|0.3 mg/kg DMT|0.3 mg/kg DMT administered intravenously
32942493|NCT05156983|Experimental|TAK-330 25 IU/kg|Participants will receive TAK-330, 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery) as an initial dose and an additional dose of 25 IU/kg TAK-330 can be administered during the surgery if deemed necessary by the surgeon. The total dose of TAK-330 administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller.
32942494|NCT05156983|Active Comparator|SOC 4F-PCC|Participants will receive 4F-PCC (excluding Prothromplex Total and activated 4F-PCC) as standard of care (SOC) on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
32942495|NCT00005072|Experimental|Leuvectin|Leuvectin
33092304|NCT00462618|Active Comparator|CBT|
33092305|NCT00431795|Experimental|1|Epi
33092306|NCT00431795|Experimental|2|Cael
33092307|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
33307437|NCT00095199|Active Comparator|Docetaxel|
33307438|NCT00075764|Active Comparator|Arm I|Patients receive oral anastrozole once daily on days 1-28.
33404407|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
33092308|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
33092309|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
33092310|NCT01052012|Experimental|Active: SABER-Bupivacaine|SABER-Bupivacaine
33092311|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
33307439|NCT00075764|Experimental|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
33307440|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
33307441|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
33307442|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
33307443|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
33307444|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
33307445|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
33307446|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
33307447|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
33307448|NCT03567616|Experimental|Part 1: Dose Escalation|Venetoclax (400 mg oral [PO], once daily [QD]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly [qw]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
33307449|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
33307450|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
33307451|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
33307452|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
33092312|NCT01052012|Placebo Comparator|Placebo: SABER-Placebo|SABER-Placebo
33307453|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Hispanic overweight male participants taking part in a 24 week soccer program as part of diabetes prevention.
33307454|NCT05666128|Experimental|HD-6277 100mg tab|
33307455|NCT05666128|Experimental|HD-6277 50mg tab|
33307456|NCT05666128|Placebo Comparator|Placebo|
33307457|NCT05665660|Experimental|CARE - Intervention arm for mammography education|CARE is a culturally tailored mammography education module.
33307458|NCT05665660|Experimental|CARE + COACH - Intervention arm for mammography education + a patient navigator|CARE + COACH is the CARE education module in addition to a COACH, which is access to an Apache paraprofessional women's health coach. The Coach functions like a patient navigator.
33307459|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
33307460|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
33092313|NCT00432029|Other|1|IDDM
33092314|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
33092315|NCT00432029|Other|3|age/sex matched healthy control subjects
33307461|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
33307462|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
33307463|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
33307464|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
33307465|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
33307466|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
33307467|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
33307468|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
33307469|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
33307470|NCT03726892|Active Comparator|The SYNERGY stent|
33307471|NCT03726892|Active Comparator|Xience|
32942496|NCT05138653|Experimental|Single Ascending Dose (SAD) Cohorts 1-3|In Cohorts 1 and 2, all participants will receive treatment with up to 3 single oral doses of CVL-354 and/or 1 single oral dose of placebo in a 4-period crossover design. The starting dose of CVL-354 will be 0.5 mg. Participants will be randomized to 1 of 4 treatment sequences. Cohort 3 may be used to evaluate additional doses or evaluate food effect, depending on the results from Cohorts 1 and 2.
32942497|NCT05138653|Experimental|Multiple Ascending Dose (MAD) Cohorts 1-5|All participants will receive treatment with multiple oral doses of CVL-354 (dose and regimen to be determined) or matching placebo for 14 days.
32942498|NCT05133895||Tocilizumab monotherapy|"Patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study. Clinical diagnostic criteria consist of: (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded.~Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months."
32942499|NCT04700527|Active Comparator|Short Chain Fatty Acid (SCFA)|4-6 grams of powder mixed with food and taken everyday starting 1 week prior-1 week post Radiation Therapy.
32942500|NCT04700527|Placebo Comparator|Placebo (Tapioca)|5 grams taken everyday starting 1 week prior-1 week post Radiation Therapy.
32942501|NCT04558879|Experimental|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
32942502|NCT04558879|Experimental|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
32942503|NCT04698031|Experimental|Clopidogrel|"After randomization, patients will receive clopidogrel mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
32942504|NCT04698031|Experimental|Aspirin|"After randomization, patients will receive aspirin daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 1 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
32942505|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
32942506|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
32942507|NCT05122819|Experimental|Group A|Intraligamentary Injection by Jet Injector
32942508|NCT05122819|Experimental|Group B|Intraligamentary Injection by regular Dental Anesthesia Syringe
32942509|NCT05122819|Active Comparator|Group C|Inferior Alveolar Nerve Block
32942510|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
32942511|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
32942512|NCT05122663||ED Physical Therapy|Patients in the ED physical therapy group will have been evaluated by an emergency department physical therapist for dizziness/vertigo during their index ED visit.
32942513|NCT05122663||Usual Care|Patients in the usual care group will NOT have received an evaluation by an ED physical therapist for dizziness/vertigo symptoms during their index ED visit.
32942514|NCT05421091||Asciminib|Patients prescribed with Asciminib
32942515|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
32942516|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
32942517|NCT05421013|Experimental|STP705 30ug|STP705 will be administered once weekly for 6 weeks
32942518|NCT05421013|Experimental|STP705 60ug|STP705 will be administered once weekly for 6 weeks
32942519|NCT05421013|Experimental|STP705 90ug|STP705 will be administered once weekly for 6 weeks
32942520|NCT05396833|Experimental|Part A1: M1774 and M4076|
32942521|NCT05396833|Experimental|Part B1: M1774 and Avelumab|
33307472|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
33307473|NCT00106353|Experimental|1.0|
32942522|NCT05104099|Experimental|Metvixia application for Photodynamic diagnosis|Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
32942523|NCT04648579|Experimental|Hillrom|The intervention involves an automated vital signs document system consisting of a mobile medical device for measuring vital signs (CSM / Hillrom) that collects and analyzes data acquired at the bedside to be sent to a remote data processing point (Digital Control Station), using Hillrom Connecta software.
33092316|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
33092317|NCT00432068|Experimental|Octreotide pamoate|
33092318|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
33092319|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
33092320|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
33092321|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
33092322|NCT03273231|Placebo Comparator|control group|0.9% saline solution
33092323|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
32746539|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
32942524|NCT04648579|Active Comparator|Control|Hospital usual care.
33092324|NCT00462891|No Intervention|Usual Care|
33092325|NCT00462969|Experimental|1|pre-surgical SHG
33092326|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
33092327|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
33092328|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
33092329|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
32942525|NCT04641871|Experimental|Sym021+Sym022 [ARM A] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
32942526|NCT04641871|Experimental|Sym021+Sym023 [ARM B] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
33092330|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
33092331|NCT03271359|Experimental|Progressive counting (PC) arm|
33092332|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
33092333|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
32942527|NCT04641871|Experimental|Sym021+Sym023+irrinotecan for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
32942528|NCT04641871|Experimental|Sym021+Sym023+irrinotecan for ESCC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
32942529|NCT04293055|Experimental|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
33092334|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
33307474|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
33307475|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
33307476|NCT00080301|Experimental|A|
33307477|NCT00080301|Active Comparator|B|
33307478|NCT01088061||lean women with PCOS|
33307479|NCT01088061||Obese women with PCOS|
33307480|NCT01088061||lean control women|
33307481|NCT01088061||Obese control women|
33307482|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
33307483|NCT01083927|Active Comparator|Full Graft|Surgical technique
33307484|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
33307485|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
33307486|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
33307487|NCT00079677|Experimental|1|Armodafinil 150 mg/day
32942530|NCT04293055|Active Comparator|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
33307488|NCT00079677|Placebo Comparator|2|Placebo
33307489|NCT03961425|Active Comparator|NO CO2|Traditional De Airing maneuver
33307490|NCT03961425|Active Comparator|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
32942531|NCT04280965|Experimental|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
33307491|NCT03961425|Active Comparator|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
32942532|NCT04280965|Active Comparator|Treatment As Usual (TAU)|Standard of care medications
32942533|NCT04624321|Experimental|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
33307492|NCT01088139|No Intervention|Control|
33307493|NCT01088139|Experimental|Nutritional Supplementation|
33307494|NCT03964155|Experimental|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
33307495|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
32942534|NCT04624321|Placebo Comparator|Usual care|They are followed by their ordinary healthcare provider.
32942535|NCT04623541|Experimental|Epcoritamab in R/R CLL|R/R CLL: in both dose escalation and dose expansion phases. Patients in the dose expansion phase will be treated at the RP2D defined in the dose escalation phase.
33307496|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
33307497|NCT01081353|Experimental|Arm 1|
32942536|NCT04623541|Experimental|Epcoritamab in RS|RS: only in dose expansion phase. Patients in the dose expansion phase will be treated at the RP2D defined in the dose escalation phase.
32942537|NCT05396755|Experimental|interventional|The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.
32942538|NCT05396755|No Intervention|control|The control group receives non-interventional standard of care.
32942539|NCT05394805||Participants treated with Humira (Adalimumab)|Participants prescribed Humira (adalimumab) for moderately to severely active crohn's disease (CD) in routine clinical practice.
32942540|NCT04608409|Experimental|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
32942541|NCT04608409|Experimental|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
32942542|NCT04608409|Experimental|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
32942543|NCT04608409|Experimental|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
32942544|NCT05091853|Active Comparator|Self-adhesive mesh|
32942545|NCT05091853|Active Comparator|Self-gripping mesh|
32942546|NCT04607551|Experimental|Prone positionning|
32942547|NCT04607551|Active Comparator|Supine position|
32942548|NCT04606381|Experimental|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
32942549|NCT04606381|Experimental|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
32942550|NCT04606381|Experimental|Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib|Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.
33307498|NCT01081353|Active Comparator|Arm 2|
33307499|NCT01081353|Active Comparator|Arm 3|
33307500|NCT01081353|Active Comparator|Arm 4|
33307501|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
33307502|NCT01084395|Experimental|Parent Safer Sex Intervention|
33307503|NCT01084395|Other|Adolescent Health Promotion Control|
33307504|NCT01084395|Other|Parent Health Promotion Control|
33307505|NCT00095121|Placebo Comparator|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
33307506|NCT00095121|Experimental|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
33307507|NCT01081431|Experimental|Lenalidomide|
33307508|NCT03962829|Placebo Comparator|Placebo condition|Participants receive placebo capsule
33404408|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
32942551|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)~Patients will receive questionnaires."
32942552|NCT04592731|Experimental|Gel containing Acetylated Natural Nucleotides|
32942553|NCT04592731|Placebo Comparator|Vehicle Gel|
32942554|NCT04585477|Experimental|Cohort 1 minimal residue disease positive(MRD+)|"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).~Subjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS)."
32942555|NCT04585477|Active Comparator|Cohort 2 minimal residue disease negative (MRD-)|Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment
32942556|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
32942557|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
32942558|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
32942559|NCT04567849|No Intervention|Control|No intervention control group
32942560|NCT04567849|Experimental|Nudge: call provider|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call their recent Women's Health provider (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
32942561|NCT04567849|Experimental|Nudge: call tele-nurse|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call Geisinger's nurse triage hotline (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
32942562|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
32942563|NCT04567303|Experimental|Part 1: Intravitreal Injections|RO7250284 administered in ascending dose levels through IVT injections.
32942564|NCT04567303|Experimental|Part 2: Port Delivery with High Dose|RO7250284 administered at a high dose through the PD implant.
32942565|NCT04567303|Experimental|Part 2: Port Delivery with Low Dose|RO7250284 administered at a low dose through the PD implant.
32942566|NCT04567303|Experimental|Part 3: Port Delivery with High Dose|RO7250284 administered at a high dose through the PD implant.
32942567|NCT04567303|Experimental|Part 3: Port Delivery with Low Dose|RO7250284 administered at a low dose through the PD implant.
32942568|NCT04567303|Active Comparator|Part 3: Port Delivery with Ranibizumab|100 milligrams/milliliter (mg/mL) of ranibizumab administered through the PD implant.
32942569|NCT04562467|Experimental|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
32942570|NCT04562467|No Intervention|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
32942571|NCT04713163||Health care or laboratory-based workers|Healthy individuals about to receive any approved COVID-19 vaccine
32942572|NCT04713163||Outpatients|Outpatients about to receive any approved COVID-19 vaccine
32942573|NCT04712929||Homogenous oral leukoplakia|"uniform, flat, thin, smooth/ wrinkled/corrugated surface throughout the white lesion.~Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days"
32942574|NCT04712929||Non-Homogenous oral leukoplakia|mixture of red and white lesions with a irregularly speckled/ nodular/ verrucous surface Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days
32942575|NCT04712929||Control group|30 healthy controls ( age and sex matched) would also be recruited from patients who are reporting for other routine dental problems.
32942576|NCT05082961|Other|X-ray photon therapy + biological samples|
32942577|NCT05082961|Other|Protontherapy + biological samples|
33307509|NCT03962829|Active Comparator|mCPP condition|Participants receive active (mCPP) capsule
33307510|NCT00094809|Active Comparator|Pegfilgrastim|6 mg pegfilgrastim
32942580|NCT00423254|Experimental|Low Dose Cohort|
32942581|NCT00423254|Experimental|High Dose Cohort|
32942582|NCT04552327|Experimental|Solcera|
32942583|NCT04552327|Placebo Comparator|Placebo|
32942584|NCT04552327|Active Comparator|Solaraze|
32942585|NCT04552015|Other|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
32942586|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
32942587|NCT05364541|Other|MyoVista wavECG|Single arm - subjects meeting the inclusion, exclusion and screening criteria will receive a MyoVista wavECG and a trans-thoracic echocardiogram.
33307511|NCT00094809|Placebo Comparator|Placebo|6 mg placebo
33307512|NCT03962751|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
32942588|NCT05351047|Experimental|Cohort 1|Once weekly dosing for 4 weeks (Dosing Days 1, 8, 15 and 22) OR Once weekly dosing for 6 weeks (Dosing Days 1, 8, 15, 22, 29 and 36) randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
32942589|NCT05351047|Experimental|Cohort 2|Once weekly for 6 weeks dosing on Days 1, 8, 15, 22, 29 and 36 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
33404409|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
32799830|NCT00218296|Experimental|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
32799831|NCT01824290|Experimental|Tadalafil|"Period 1: 20 mg or 40 mg administered orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to <40 kg: administered orally by tablets once a day. Light weight cohort <25 kg: administered orally by suspension once a day.~Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension)."
32942590|NCT05351047|Experimental|Cohort 3|Three times weekly for 6 weeks dosing each week on Days 1, 3, and 5 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
32942591|NCT05351047|Experimental|Cohort 4 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
32942592|NCT05351047|Experimental|Cohort 5 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
32942593|NCT04536337|Experimental|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily for up to 4 weeks
32942594|NCT04536337|Placebo Comparator|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily for up to 4 weeks
32942595|NCT04536337|Active Comparator|Entecavir in combination with ALG-000184|
32942596|NCT04534153|Experimental|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
32942597|NCT04534153|Experimental|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
32942598|NCT04534153|Experimental|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
32942599|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
32942600|NCT00382915||1|Smokers with schizophrenia
32942601|NCT00382915||2|Smokers with bipolar disorder
32942602|NCT00382915||3|Smokers without any mental illness
32942603|NCT00385502|Experimental|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
32942604|NCT04533529|Experimental|Seltorexant|Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
32942605|NCT04533529|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
32942606|NCT04524949|Experimental|IMCY-0098, low dose|The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
32942607|NCT04524949|Experimental|IMCY-0098, high dose|The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
32942608|NCT04524949|Placebo Comparator|Placebo|Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.
32942609|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
32942610|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
32942611|NCT04512235|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 79 deaths have been observed.
32942612|NCT04512235|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 79 deaths have been observed.
32942613|NCT05349721|Experimental|PTC857|"Participants will receive PTC857 during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants have the option to receive open-label PTC857 in the Long-term Extension Period for 28 weeks."
33404410|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
33404411|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
33404412|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
32942614|NCT05349721|Active Comparator|Placebo|"Participants will receive matching placebo during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants have the option to receive open-label PTC857 in the Long-term Extension Period for 28 weeks."
32942615|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
33307513|NCT03962751|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
33307514|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
32942616|NCT04504747||RH+|Prospective blood and biopsie analyses
33307515|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
32942617|NCT04504747||HER2+|Prospective blood and biopsie analyses
32942618|NCT04504747||TN|Prospective blood and biopsie analyses
32942619|NCT04489225||Observational|This single arm observational study includes all patients implanted with a Medtronic Cobalt™ XT ICD or CRT-D MRI SureScan™ (with Attain StabilityQuad™ MRI SureScan™ Model 4798 Lead (ASQ)), who are enrolled in the Medtronic CareLink (CL) Network and Product Surveillance Registry (PSR). Patients will be followed per the standard of care practices of their care provider. All patients must provide a signed informed consent.
32942620|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
32942621|NCT05040685|Experimental|Axillary mapping reverse|Application of axillary mapping reverse technique
32942622|NCT05324683||Study population (cohort)|No study arms; one patient population will be observed.
32942623|NCT05323903|No Intervention|Control Group|Postpartum Hemorrhage and Its Management course
32942624|NCT05323903|Experimental|Intervention Group 1- Telesimulation|Postpartum Hemorrhage and Its Management course, Telesimulation application
32942625|NCT05323903|Experimental|Intervention Group 2- Kahoot|Postpartum Hemorrhage and Its Management course, Kahoot game
32942626|NCT05323903|Experimental|Intervention Group 3-Telesimulation and Kahoot|Postpartum Hemorrhage and Its Management course, Telesimulation application and Kahoot game
32942627|NCT05313451|Experimental|Soluble fiber|Participants ingest 15 g daily of the experimental product for 2 months and receive the influenza vaccine at the end of the first month.
32942628|NCT05313451|Placebo Comparator|Placebo|Participants ingest 15 g daily of the placebo product for 2 months and receive the influenza vaccine at the end of the first month.
32942629|NCT05029921|Experimental|Ustekinumab|Participants will receive a single dose of ustekinumab intravenously (IV) (weight-based dose approximating 6 milligrams per kilogram [mg/kg]) at Week 0. Participants with body weight less than or equal to (<=) 55 kg will receive ustekinumab IV of 260 mg, greater than (>) 55 kg and <=85 kg will receive ustekinumab IV of 390 mg, and >85 kg will receive ustekinumab IV of 520 mg at Week 0 in induction phase followed by ustekinumab 90 mg subcutaneously (SC) in maintenance phase from Week 8 to Week 52. For participants who achieve clinical response with ustekinumab induction dosing at Week 8, will continue to receive 90 mg ustekinumab SC every 12 weeks with final dose at Week 44. If these participants meet the criteria for loss of response from Week 16 to Week 40, dose can be adjusted to 90 mg every 8 weeks (q8w). Participants who are non-responders to ustekinumab at Week 8, and achieve clinical response at Week 16, will continue to receive ustekinumab 90 mg SC q8w from Week 16 to Week 48.
32942632|NCT04456699|Experimental|Olaparib + bevacizumab|Participants will receive olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study.
32942633|NCT04456699|Experimental|Olaparib|Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
32942634|NCT04456699|Active Comparator|Bevacizumab + chemotherapy|Participants will receive investigator's choice of either bevacizumab (7.5mg/kg IV once every three weeks (Q3W)) + capecitabine (1000mg/m^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5FU (400mg/m2) can be added prior to infusional 5FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.
32942635|NCT04452955|Experimental|PRL3-zumab|All patients will receive PRL3-zumab until clinical progression per RECIST v1.1 and iRECIST criteria, or unacceptable toxicity, or withdraws consent.
32942636|NCT05305573|Experimental|COVID-19 Vaccine HIPRA 40 ug/dose|
32942637|NCT05305573|Active Comparator|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|
32942638|NCT04447807|Experimental|Group A: Metacognitive Training Intervention|"Participants of this group will undergo Metacognitive Training (MCT) in group format for the duration of 9 weeks. The intervention will be held once a week, with an estimated duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of interpersonal relations, as well as functional remediation aspects.~We estimate a total of 26 participants in this group."
32942639|NCT04447807|Experimental|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 26 participants in this group.
32942640|NCT00005774|Experimental|Early surfactant group|
32942641|NCT00005774|Active Comparator|Standard Practice group|
33307516|NCT03962751|No Intervention|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
33307517|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
33092335|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
33092336|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
33092337|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
33092338|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
33092339|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
33092340|NCT02273492|Active Comparator|Asasantin ER at fasted state|
33092341|NCT00471510|Experimental|1|NEOSH101 2%
33092342|NCT00471510|Experimental|2|NEOSH101 1%
33092343|NCT00471510|Experimental|3|NEOSH101 0.5%
33092344|NCT00471510|Placebo Comparator|4|
33307518|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
33092345|NCT02273531|Experimental|Asasantin ER, new formulation|
33092346|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
33307519|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
33307520|NCT01088373|Experimental|Azacitidine, Lenalidomide|
33307521|NCT00075218|Placebo Comparator|B|
33092347|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
33092348|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
33092349|NCT00432575|Placebo Comparator|1|
33092350|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
33307522|NCT00075218|Active Comparator|A|
33307523|NCT03963440|Experimental|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
33307524|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
33307525|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
33092351|NCT00432575|Active Comparator|3|surinabant 5 mg/day
33092352|NCT00432575|Active Comparator|4|surinabant 10 mg/day
33092353|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
33092354|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
33092355|NCT00432614|Placebo Comparator|Group 3|placebo
33092356|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
33092357|NCT01051817|Experimental|AIN457|
33092358|NCT01051817|Placebo Comparator|Placebo|
33092359|NCT04703660|Active Comparator|group A|This group will receive antero-posterior cervical mobilization at c5-6 grade III oscillation
33092360|NCT04703660|Active Comparator|group B|This group will receive lateral glide cervical mobilization at c5-6 grade III oscillation
33092361|NCT04703660|Active Comparator|group C|This group will receive postero-anterior cervical mobilization at c5-6 grade III oscillation
33092362|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
33092363|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
33307526|NCT01089140|Placebo Comparator|Saline Placebo|
33307527|NCT00094653|Active Comparator|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
33307528|NCT00094653|Experimental|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
33307529|NCT00094653|Active Comparator|3|MDX-010 (ipilimumab) + Placebo
33307530|NCT03565900|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
33307531|NCT03565900|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
33307532|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
33404413|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
33307533|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
32942642|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
33307534|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
33307535|NCT03564184|Experimental|No MT|Consists of standard care.
32942643|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
32942644|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
32942645|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
32942646|NCT05303623|Experimental|Conventional Physiotherapy|"In the intensive care unit and who had mechanical ventilation for more than 48 hours and who were extubated. Medical, physical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment.~In this group will apply only conventional physiotherapy. Conventional physiotherapy to contain breathing and,thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization. Conventional physiotherapy apply for 5 days after extubation period 1 time a day."
32942647|NCT05303623|Experimental|Conventional Physiotherapy + inspiratory muscle training|"Physical ,medical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment. In this group, inspiratory muscle training will be applied in addition to conventional physiotherapy.~Inspiratory muscle training apply for 5 days after extubation period. Inspiratory muscle training will be given with a threshold loading by giving resistance at 30-40% of the maximum inspiratory pressure measurement obtained. The subjects in this group will be given inspiratory muscle training 4 sets with 6-10 breaths per set, 1-2 minutes between each set once a day in addition to conventional physiotherapy."
32942648|NCT05303623|Experimental|Healthy Subject|In the group consisting of healthy volunteers, which will be taken to determine the normative values of the outcome measurements for diaphragmatic tissue Doppler imaging and ultrasonographic evaluation, 2 sessions a day with a threshold-loaded inspiratory muscle training device, starting at 30% of the MIP value, 5 days a week for 4 weeks. Inspiratory muscle training will be performed in 4 sets, 6-8 breaths in each set and 2 minutes rest between sets. In the second evaluation to be made after the inspiratory muscle training, the above-mentioned evaluations and measurements will be repeated.
32942649|NCT05302063|Experimental|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
32942650|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
32942651|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
32942652|NCT05006677||non-vitamin K antagonist oral anticoagulants (NOACs)|
32942653|NCT05006677||vitamin K antagonists (VKAs)|
32942654|NCT05006677||antiplatelet agents|
32942655|NCT05006677||non-antithrombotic therapy|
32942656|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
32942657|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
32942658|NCT05298085|Experimental|OXYTOCIN nasal spray|intranasal administration of Oxytocin
32942659|NCT05298085|Placebo Comparator|PLACEBO|intranasal administration of placebo
32942660|NCT04421443|Active Comparator|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
32942661|NCT04421443|Active Comparator|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
32942662|NCT04421443|Active Comparator|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
32942663|NCT05296603|Experimental|Cohort A|Duration of response time more than 6 months
32942664|NCT05296603|Experimental|Cohort B|Duration of response time between 3 and 6 months
32942665|NCT05296603|Experimental|Cohort C|Duration of response time less than 3 months
32942666|NCT04405297||Hip Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected hip joint.
32942667|NCT04405297||Knee Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected knee joint.
32942668|NCT04405297||Ankle Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected ankle joint.
32942669|NCT04405297||Shoulder Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected shoulder joint.
32942670|NCT04405297||Wrist Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected wrist joint.
32942671|NCT05294731|Experimental|Part 1a Monotherapy Dose Escalation|BGB-16673 will be orally administered
32942672|NCT05294731|Experimental|Part 1b Monotherapy Safety Expansion|BGB-16673 will be orally administered
32942673|NCT05294731|Experimental|Part 2 Monotherapy Dose Expansion|BGB-16673 will be administered at the recommended Phase 2 dose (RP2D) that was identified in Part 1
33307536|NCT05665348|Active Comparator|DOULET ATEZOLIZUMAB-BEVACIZUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab, 1 cure each 3 weeks during 24 months
32942674|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
32942675|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
32942676|NCT04995523|Experimental|Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced NSCLC|AZD2936 Intravenous (IV) monotherapy
32942677|NCT04995523|Experimental|Dose Expansion Part B: CPI experienced NSCLC|AZD2936 IV monotherapy
32942678|NCT04995523|Experimental|Dose Expansion Part C: CPI Naive NSCLC|AZD2936 IV monotherapy
32942679|NCT04995523|Experimental|Dose Expansion Part D: CPI Naive NSCLC|AZD2936 IV monotherapy
32942680|NCT05293093|Experimental|Wheelchair Skills Training Program intervention study|A one-group pretest-posttest design study will be conducted, consisting of three phases (3- or 5-week baseline phase, 4-week training phase, 4-week retention phase)
32942681|NCT04568330|Other|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
32942682|NCT04568330|Experimental|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
32942683|NCT04568330|Active Comparator|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
32942684|NCT04398433|Experimental|INO-3107|Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
32942685|NCT04569890|Experimental|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
32942686|NCT04569890|Active Comparator|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.~At 24 week, non-responders (ΔDAS28<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28<2.6). If participants have a disease flare (increased DAS28>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
32942687|NCT04569500|Experimental|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
32942688|NCT04569500|No Intervention|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
32942689|NCT04485637|Other|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
32942690|NCT04485637|Other|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
32942691|NCT04485637|Other|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
32942692|NCT04569812|Experimental|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
32942693|NCT04569812|Experimental|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
32942694|NCT04569656|Experimental|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
32942695|NCT04569578|Experimental|Policy|The policy will be implemented on preschool level.
32942696|NCT04569578|No Intervention|Regular practice|The control preschool will continue their regular practice.
32942697|NCT04379635|Experimental|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
32942698|NCT04379635|Placebo Comparator|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
32942699|NCT04569188|Experimental|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
32942700|NCT04568876|Active Comparator|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
32942701|NCT04568876|Other|Control Group|Standard therapy only
32942702|NCT04375657|Experimental|TRIIM Treatment|
32942703|NCT04375657|Active Comparator|Active Control|
32942704|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
32942705|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
32942706|NCT02210468|Placebo Comparator|Saline|
33092364|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
33092365|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
33092366|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
33092367|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
33092368|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
33092369|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
33092370|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
33092371|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
33092372|NCT01051739||Group 1|glaucoma
33092373|NCT01051739||Group 2|normal
33307537|NCT05665348|Experimental|TRIPLET ATEZOLIZUMAB BEVACIZUMAB IPILIMUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab with addition of ipilimumab for the 4 firsts cures of treatment each 3 weeks, then only treatment by the doublet atezolizumab-bevacizumab each 3 weeks. The total duration of treatment is 24 months.
33307538|NCT03726814|Experimental|EPC treatment group|
33307539|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
32799832|NCT01824290|Placebo Comparator|Placebo|"Period 1: Participants received placebo orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.~Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
32799833|NCT00217672|Experimental|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
32799834|NCT00217672|Active Comparator|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
32799835|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
32799836|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
32799837|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
32799838|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
32799839|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
32799840|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
32799841|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
32942707|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
32942708|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
32942709|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
32942710|NCT04353661|Experimental|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
32942711|NCT04353661|Active Comparator|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
32942712|NCT04353661|Active Comparator|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
32942713|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.~Treatment group with HYNR-CS inj."
33404414|NCT05068882|Experimental|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
33404415|NCT05068882|Active Comparator|High-protein diet|Oral nutrition with high-protein content
33092374|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
33092375|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33307540|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
33307541|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
33404416|NCT05068882|Active Comparator|Standard nutrition|Oral nutrition with standard ingredients
33404417|NCT05068882|No Intervention|No intervention|No intervention
33404418|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
33307542|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
33307543|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
33307544|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
33307545|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
33307546|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
33307547|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
33307548|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
33307549|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
33307550|NCT03726580||control group|regional anesthesia
33307551|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
33307552|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
33307553|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
33307554|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
33404419|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
33307555|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
33404420|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
32942717|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
32942718|NCT04569110||Negative control|Patients without pleural infection.
32942719|NCT04567472|Experimental|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
32942720|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
32942721|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
32942722|NCT04567316|Experimental|[14C]-radiolabelled BI 1358894|[14C]-radiolabelled BI 1358894 (part 1)
32942723|NCT04567316|Experimental|BI 1358894|BI 1358894 (part 2)
32942724|NCT04338061|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
32942725|NCT04338061|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
32942726|NCT04569422||ephedrine drop|
32942727|NCT04568720||Shanghai General Hospital|
32942728|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
32942729|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
32942730|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
32942731|NCT04568096|Active Comparator|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
32942732|NCT04568096|Placebo Comparator|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
32942733|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
32942734|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
32942735|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
33307556|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
33307557|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
33307558|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
33092376|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
32746540|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
32746541|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
33092377|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
33092378|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
33092379|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
33092380|NCT01051661|Experimental|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
33092381|NCT01051661|Experimental|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
33307559|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
33092382|NCT01051661|Experimental|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
33092383|NCT01051661|Experimental|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
33092384|NCT01051661|Experimental|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
33092385|NCT01051661|Experimental|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
33092386|NCT01051466|Experimental|Duloxetine|
33092387|NCT01051466|No Intervention|Healthy Participants|
33307560|NCT03560206|Experimental|Family SWaP intervention|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
33092388|NCT01051349|Experimental|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
33092389|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
33307561|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
33092390|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
33092391|NCT04444531||Ozone autohemotherapy plus standard treatment|
33092392|NCT04444531||Standard treatment alone|
33307562|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
32746542|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
32942736|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
33092393|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
33092394|NCT02894203|Experimental|Mindfulness|
33092395|NCT02894203|Active Comparator|Hatha Yoga|
33092396|NCT02894203|No Intervention|Wait-list|
33092397|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
33307563|NCT03635086|Experimental|Group A: Two MV-CHIK lyophilized low dose|Participants received two vaccinations with MV-CHIK lyophilized formulation, low dose, on day 0 and day 28.
33307564|NCT03635086|Experimental|Group B: Two MV-CHIK liquid frozen low dose|Participants received two vaccinations with MV-CHIK liquid frozen low dose formulation on day 0 and day 28.
32942737|NCT04334317|Experimental|Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)|A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1.
33307565|NCT03635086|Experimental|Group C: Two MV-CHIK liquid low dose stabilizing and protecting solution (SPS®)|Participants received two vaccinations with MV-CHIK liquid low dose SPS® formulation on day 0 and day 28.
33307566|NCT03635086|Experimental|Group D: Two MV-CHIK liquid frozen high dose|Participants received two vaccinations with MV-CHIK liquid frozen high dose formulation on day 0 and day 28.
32942738|NCT04334317|Experimental|Sentinel Cohort: Placebo (Healthy Participants)|A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1.
32942739|NCT04334317|Experimental|TAK-071 + Placebo (PD Participants)|TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2.
32942740|NCT04334317|Experimental|Placebo + TAK-071 (PD Participants)|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2.
32942741|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
32942742|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
32942743|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
32942744|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
32942745|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
32942746|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
32942747|NCT04983667|Experimental|Orange|Zinc-AA, Tablet, 30 mg. PO, Once Daily for up to one year
32942748|NCT04983667|Placebo Comparator|Green|Placebo, Tablet, 30 mg. PO, Once Daily for up to one year.
32942749|NCT04971031|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.|
32942750|NCT04971031|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.|
32942751|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
32942752|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
32942753|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
32942754|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
33092398|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~Continuous low dose chemotherapy~Intermittent ATRA"
33092399|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
33092400|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
33092401|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~3) maintenance treatment: similar to other groups"
33092402|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
33092403|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
33092404|NCT04703270||Exposed|Expectant mothers with a positive nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation regardless of antibody status.
33092405|NCT04703270||Seropositive|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation but positive IgM/IgG antibodies against SARS-CoV-2.
33092406|NCT04703270||Unexposed|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation and negative IgM/IgG antibodies against SARS-CoV-2.
33092407|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
33307567|NCT03635086|Experimental|Group E: One MV-CHIK liquid frozen high dose/placebo|Participants received one vaccination with MV-CHIK liquid frozen high dose formulation on day 0 and placebo on day 28.
33307568|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
33307569|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
33307570|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
33307571|NCT03726424||control|patients not carrying the pathogenic mutation(s)
33307572|NCT05666050|Experimental|Intervention group|The intervention group will receive mobile health intervention sending message service(SMS)
33307573|NCT05666050|No Intervention|Control group|The control group will receive the existed current health delivery approach, no mobile health sending message service
33307574|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
33307575|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
33307576|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
33307577|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
33307578|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
33307579|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
33307580|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
33307581|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
33307582|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
33307583|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
33307584|NCT00103857|Experimental|1|MK0431 100 mg q.d.
33307585|NCT00103857|Active Comparator|2|Metformin 500 mg b.i.d.
33307586|NCT00103857|Active Comparator|3|Metformin 1000 mg b.i.d.
33307587|NCT00103857|Experimental|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
33307588|NCT00103857|Experimental|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
33307589|NCT00103857|Placebo Comparator|6|Placebo/Metformin 1000 mg b.i.d.
33307590|NCT00103857|Experimental|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
33307591|NCT03587584|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
33307592|NCT03587584|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
33307593|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
32799842|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
33092408|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
33307594|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
33307595|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
33092409|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
33092410|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
33092411|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
33092412|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
33092413|NCT00463827|Active Comparator|2|Atorvastatin 40
33092414|NCT00463827|Placebo Comparator|placebo|matched placebo
33092415|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
33092416|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
33092417|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
33092418|NCT00472095|Placebo Comparator|placebo fotonovela|
33092419|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
33092420|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
33092421|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
33092422|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
33092423|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
33092424|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
33092425|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
33307596|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
33307597|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
33307598|NCT05665504|Experimental|High-Risk for Recurrence That Accept Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participants also have a special mutation on the tumor (EGFR), investigators will recommend that the participant also receive the oral anti-EGFR pill (TagrissoTM) daily for 3 years after completing the chemotherapy. The administration of standard postoperative chemotherapy is not considered part of the study. Only the results of the DetermaRx test and the potential referral to a medical oncologist are part of this study.
33092426|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
33307599|NCT05665504|Experimental|High-Risk for Recurrence That Decline Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participant declines, investigators will followup with participants periodically every 6-12 months over 5 years.
33307600|NCT05665504|Experimental|Low-Risk for Recurrence|Participants whose gene assay show that they are at a lower risk of recurrence will not be offered additional treatment after resection. Investigators will followup with participants periodically every 6-12 months over 5 years.
33307601|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
33307602|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
33092427|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
33092428|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
33092429|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
33092430|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
33092431|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
33092432|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
33092433|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
32799843|NCT00216736|Placebo Comparator|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
33092434|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
33092435|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
33092436|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
32799844|NCT00216736|Experimental|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
33092437|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
32799845|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
32799846|NCT01850030|Experimental|Dydrogesterone 30 mg|
32799847|NCT01850030|Experimental|Micronized Progesterone 600 mg|
32799848|NCT00215644|Experimental|Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab|
32799849|NCT00215644|Active Comparator|ECX Only|
32799850|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
32799851|NCT04747756|Other|Study participants|No participants will be randomized. All participants will have an opportunity to participate in the study procedures.
32799852|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
32799853|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
32799854|NCT04074616|Experimental|High Dose|
32799855|NCT04074616|Other|Control|Low dose TTNS
32799856|NCT03592732||A|Patients with atrial fibrillation
32799857|NCT03592732||B|Patients without atrial fibrillation
32799858|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
32799859|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
32799860|NCT03597334||critical ill patients|critical ill patients who admit to ICU
32799861|NCT04414839|Active Comparator|Digital Intubation (Two-finger)|
32799862|NCT04414839|Active Comparator|Video Laryngoscopy|
32799863|NCT00213148|Active Comparator|Clomiphene Citrate 50 Milligram (mg)|
32799864|NCT00213148|Active Comparator|Clomiphene Citrate 100 mg|
32799865|NCT00213148|Experimental|Anastrozole 1 mg|
32799866|NCT00213148|Experimental|Anastrozole 5 mg|
32799867|NCT00213148|Experimental|Anastrozole 10 mg|
32799868|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
32799869|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
32799870|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
32799871|NCT01715571|Experimental|Viberect treatment|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
32799872|NCT00212758|Active Comparator|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
33307603|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
33307604|NCT05665192||Cohort 1|Participants that have discontinued RUX therapy and initiated FEDR prospectively
33307605|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
33307606|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
33307607|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
33307608|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
33307609|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
32942755|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
32942756|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
32942757|NCT04566614||Part 2 Cohort|Patients with suspected advanced pancreatic or biliary tract cancer who have ctDNA via the ACCESS implementation pathway. The results must be deemed consistent with or diagnostic of pancreatic/biliary tract cancer by the molecular tumour board, discussed at central MDT and the patient cannot have a histological diagnosis.
32942758|NCT04970641|Experimental|3GT journaling group|Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
32942759|NCT04970641|No Intervention|Non-journaling group|Subjects will not participate in the evening journal activity.
32942760|NCT04566224|Experimental|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
32942761|NCT04566224|Active Comparator|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
32942762|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
32942763|NCT04958707|Experimental|Informational support group|The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.
32942764|NCT04958707|Active Comparator|Controlled group|The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information.
32942765|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment will be observed retrospectively.
32942766|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment will be observed retrospectively.
32942767|NCT04951609|Experimental|Seltorexant|Participants will receive weight based dose of Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6). Participants will continue baseline selective serotonin reuptake inhibitor (SSRI) antidepressant (Fluoxetine and Escitalopram) orally once daily.
32942768|NCT04951609|Placebo Comparator|Placebo|Participants will receive matching placebo tablets to seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
32942769|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33092438|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
33092439|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
32942770|NCT04564586|Other|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
33307610|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
32942771|NCT05264779|No Intervention|Usual Care (control)|Participants assigned to this group will proceed with usual medical care and treatment, consisting of counseling by the teams of obstetricians and/or neonatologists at the respective study sites.
32942772|NCT05264779|Experimental|Periviable GOALS DST Group|Participants randomized to the intervention will be presented with the Periviable GOALS DST and instructed to review the DST in its entirety. The participant will complete the education and values clarification components of the DST with the Recruitment RA present to confirm completion. Following completion of the GOALS DST, the Recruitment RA will repeat knowledge and decisional conflict instruments and assess acceptability.
33307611|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
33307612|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
33307613|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
33307614|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
32942773|NCT04566146|Other|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
32942774|NCT04565912|Experimental|Sage extract mouthwash|Natural product mouthwash
32942775|NCT04565912|Active Comparator|Chlorohexidine mouthwash|Synthetic mouthwash
32942776|NCT04281199|Experimental|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
32942777|NCT04565678|Experimental|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
33307615|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
33307616|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
33307617|NCT00074984|Placebo Comparator|Placebo|Patients randomized to placebo
33307618|NCT00074984|Active Comparator|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
32942778|NCT04565678|Experimental|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
32942779|NCT04565678|Experimental|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
33307619|NCT01082510|Active Comparator|BCG maintenance therapy|
33307620|NCT01082510|Experimental|UFT maintenance therapy|
32942780|NCT04565678|Experimental|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
32942781|NCT04279483|Experimental|7-11 Group|Participants visit 7-11 5 times per week during the 4-week (20 store visits total) intervention period
32942782|NCT04279483|Experimental|CVS Group|Participants visit CVS 5 times per week during the 4-week (20 store visits total) intervention period
32942783|NCT04279483|No Intervention|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
32942784|NCT02210936|Other|PDMP Data|
32942785|NCT04564352||2|Adansonia digitata (Baobab)
32942786|NCT04564430|Placebo Comparator|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
32942787|NCT04564430|Experimental|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
32942788|NCT04564118||Group 1|retrospective data on treatment from EMC
32942789|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
32942790|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
32942791|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
33307621|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
33092440|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
33092441|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
33092442|NCT00472173|Active Comparator|Calcium hydroxide|
32799873|NCT00212758|Active Comparator|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
32799874|NCT04549545|Active Comparator|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
33092443|NCT00472173|Experimental|MTA|
33092444|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
33092445|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
33092446|NCT00433706|Experimental|Control position by 3DOBI daily|
33092447|NCT00433706|Active Comparator|Standard imaging|
33092448|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
33092449|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
33092450|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
33092451|NCT03273036|Placebo Comparator|placebo injection|no injection agent
33092452|NCT03270735|Experimental|Treatment|Snake venom thrombin
33092453|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
33092454|NCT01580384||Cohort|
33092455|NCT04702841|Experimental|CAR-γδT|Infusion,iv,0.2-5 ×10^6/ kg,once.
33307622|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
33307623|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
33307624|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .~The control group were on there prescribed medications only ."
32799875|NCT04549545|Sham Comparator|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
32799876|NCT03982342|Active Comparator|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
33092456|NCT04703114|Experimental|Symptomatic|40 symptomatic patients to COVID-19 infection
33092457|NCT04703114|Experimental|Asymptomatic|40 asymptomatic patients to COVID-19 infection
33092458|NCT04053153|Experimental|Use of musical instrument|
33092459|NCT04053153|Sham Comparator|Use of sham musical instrument|
33092460|NCT04702685|Experimental|Ropivacaine|Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance
33092461|NCT04702685|Placebo Comparator|Placebo|No injection. Bandage will be placed over the presumed site of injection
33092462|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
33092463|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
33092464|NCT00472368|Experimental|LBH589|
33092465|NCT00106028|Placebo Comparator|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
33092466|NCT00106028|Experimental|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
33092467|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
33092468|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
33092469|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
33092470|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
33092471|NCT00434096|Experimental|1|
33307625|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
32942792|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
33092472|NCT00434096|Placebo Comparator|2|
33092473|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
33307626|NCT03583450|No Intervention|Control|Routine anesthetic care
33307627|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
33307628|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
33307629|NCT00074282|Experimental|Arm A (PCR)|"Treatment consisted of 6 cycles of pentostatin, cyclophosphamide, and rituximab (PCR) given every 28 days.~Rituximab administered as follows: For the first infusion, all patients receive 100 mg dose (regardless of weight/BSA). For subsequent infusions, all patients receive rituximab 375 mg/m2.~Pentostatin and cyclophosphamide administered as follows: Pentostatin given at 4 mg/m2 either as an IV push or IV over 10-30 minutes in 250 mL NS or D5W on day 1 every 4 weeks of cycles 1-6. Cyclophosphamide given at 600 mg/m2 IV over 30-60 minutes in 250 mL NS on day 1 every 4 weeks of cycle 1-6."
33404421|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
33404422|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
32942793|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
32942794|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
32942795|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
32942796|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
32942797|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
32942798|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
32942799|NCT04563962|Experimental|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
32942800|NCT04563962|Active Comparator|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
32942801|NCT04563650|Experimental|COVID-19 positive resident|
32942802|NCT04563650|Active Comparator|COVID-19 negative resident|
32942803|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
32942804|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
32942805|NCT04565444|Experimental|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
32942806|NCT04565444|Experimental|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
32942807|NCT04565444|Experimental|Protein|Carbohydrate control and 10g of whey protein.
32942808|NCT04563728|Active Comparator|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
32942809|NCT04563728|Active Comparator|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
32942810|NCT04563728|No Intervention|Usual Care|Each participant will receive educational packages about elderly community-living.
32942811|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
32942812|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
32942813|NCT04565132|Experimental|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
32942814|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 & 24 months of age.
32942815|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
33092474|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
33092475|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
32942816|NCT04564664|Other|High-flow nasal cannula oxygen therapy|
32942817|NCT04564664|Other|Standard oxygen therapy|
32942818|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
32942819|NCT04931251|Other|Financial Navigation|includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources
32942820|NCT04562636|Experimental|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
32942821|NCT04562636|Experimental|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
32942822|NCT04562636|Other|Neutral Message|Four neutral messages about checking one's credit score.
32942823|NCT04562168|Experimental|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
32942824|NCT04929847|Experimental|Group 1|All patients will receive the experimental emollient during 3 weeks.
32942825|NCT04561934|Experimental|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
32942826|NCT04561934|Active Comparator|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
32942827|NCT05252533|Experimental|Cohort 1: Juvenile Psoriatic Arthritis (jPsA)|Participants (aged greater than or equal to [>=] 5 to less than [<] 18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating health care professional (HCP).
32942828|NCT05252533|Experimental|Cohort 2: Pediatric Psoriasis (PsO)|Participants (aged >=6 to <18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating HCP.
32942829|NCT04562402|Active Comparator|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
32942830|NCT04562402|Active Comparator|Phacoemulsification alone|Cataract extraction via phacoemulsification.
32942831|NCT04231747|Experimental|CC-97540 monotherapy|Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).
32942832|NCT04561778|Active Comparator|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
32942833|NCT04561778|Active Comparator|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
32942834|NCT03606499||Inflammatory Bowel Disease (IBD) Participants with EIMs and/or IMIDs|IBD (Crohn's Disease [CD] or Ulcerative Colitis [UC]) participants with suspected extra-intestinal manifestations (EIMs) and/or one or more immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on EIMs and/or IMIDs associated with IBD (both CD and UC). Participants will receive ustekinumab at study entry (Week 0) as treatment for IBD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
32942835|NCT04563416||Patients who need undergo magnifying endoscopy|
32942836|NCT04330495|Experimental|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
32942837|NCT04330495|Active Comparator|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
32942838|NCT04181359|Experimental|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
32942839|NCT04181359|Placebo Comparator|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
32942840|NCT04563260|Placebo Comparator|Control group|Control group receives the intravenous normal saline 2 mL.
32942841|NCT04563260|Experimental|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
32942842|NCT02211170|Experimental|BIBR 796 BS, low dose|
32942843|NCT02211170|Experimental|BIBR 796 BS, high dose|
32942844|NCT02211170|Placebo Comparator|Placebo|
32942845|NCT04180189|Active Comparator|Weighted fiber blanket|Using a weighted blanket
32942846|NCT04180189|Placebo Comparator|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
32942847|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
32942848|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
32942849|NCT04175119|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
32942850|NCT04173793|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32942851|NCT04173793|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32942852|NCT04173793|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
32942853|NCT04173793|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
32942854|NCT04173793|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
32942855|NCT04561466|Experimental|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.~Befizal® 200 mg will be tested for one year"
32942856|NCT04173637|Experimental|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
32942857|NCT04173637|Experimental|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
33092476|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
33092477|NCT04702490|Experimental|MET409 A|MET409 Active (50mg)
33307630|NCT00074282|Experimental|Arm B (Alemtuzumab: CR, nPR)|Patients who achieved a confirmed CR or nPR, were registered to receive Alemtuzumab (Arm B). When the patient was registered to Arm B, the drug was administered three times a week for four weeks. The dose was 30 mg per dose. A twelve-week treatment-free period had to elapse before CAMPATH-1H began following completion of PCR for Arm B patients
32942858|NCT04173637|Experimental|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
32942859|NCT04173637|Experimental|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
32942860|NCT04173637|Experimental|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
32942861|NCT04173637|Experimental|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
32942862|NCT04173637|Placebo Comparator|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
32942863|NCT04561856|Active Comparator|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
32942864|NCT04561856|Active Comparator|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
32942865|NCT04561856|Placebo Comparator|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
32942866|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
32942867|NCT04912687|Experimental|All patients|"For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.~As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample."
32942868|NCT04909801|Experimental|Arm 1: Abatacept + Methotrexate|
32942869|NCT04909801|Experimental|Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)|
32942870|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
32942871|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
32942872|NCT04173403|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
32942873|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
32942874|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
32942875|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
32942876|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
32942877|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
32942878|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
32942879|NCT03539887|Placebo Comparator|Placebo|non-active placebo
32942880|NCT04123717|Active Comparator|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
32942881|NCT04123717|Active Comparator|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
32942882|NCT04123717|Active Comparator|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
32942883|NCT04123717|Active Comparator|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
32942884|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
32942885|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
32942886|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
32942887|NCT04094701|Placebo Comparator|Control Group|"Control Group will receive the following pain medication regimen:~- Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
32942888|NCT04094701|Experimental|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group~Tylenol extra strength (1000 mg, three times daily for 10 days following surgery)~Gabapentin (300 mg at night for 10 days following surgery)~Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
32942889|NCT04092829|No Intervention|FROZEN EMBRYO TRANSFER IN NATURAL CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
32942890|NCT04092829|Active Comparator|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol >100 pg/ml and serum progesterone < 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.
32942892|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
32942893|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
32942894|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
32942895|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
32942896|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
32942897|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
32942898|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
32942899|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
32942900|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
32942901|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
32942902|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
33092478|NCT04702490|Placebo Comparator|MET409 P|MET409 Placebo (50mg)
33307631|NCT00074282|Experimental|Arm C (Alemtuzumab: PR, <PR, PD)|For those patients not achieving a CR or nPR (thus patients either achieved PR, SD, or PD), Alemtuzumab (Arm C) was administered three times a week for eighteen weeks at a dose of 30 mg TIW. For PR, SD and PD patients, the timing of CAMPATH-1H was left to the discretion of the investigator, and treatment could begin earlier but no less than two weeks and no longer than eight weeks after the completion of the last PCR course. Patients determined to have PD during treatment with PCR did not need to complete all 6 cycles of PCR to go on to Arm C, however, completing a minimum of 2 cycles was required.
33307632|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
32942910|NCT04068103|Active Comparator|Arm I (blood stored and tested for ctDNA later)|Patients undergo active surveillance.
32942911|NCT04068103|Experimental|Arm II (blood tested for ctDNA at baseline)|"Patients are assigned to 1 of 2 groups.~GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin IV over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity at the discretion of the investigator.~GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance."
32942912|NCT04067089|Experimental|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
32942913|NCT04067089|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
32942914|NCT03351361|Experimental|Nivolumab + Ipilimumab|
32942915|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
32942916|NCT04057807|Experimental|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
32942917|NCT04057807|No Intervention|control|
32942918|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
32942919|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
32942920|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
32942921|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
32942922|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
32942923|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
32942924|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
32942925|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
33092479|NCT04702490|Experimental|MET409A +Open-Label Empagliflozin|MET409 Active (50mg) + Empagliflozin (10mg)
33092480|NCT04702490|Placebo Comparator|MET409P +Open-Label Empagliflozin|MET409 Placebo (50mg) + Empagliflozin (10mg)
33092481|NCT00464763|Experimental|Dexmedetomidine|
33092482|NCT00464763|Placebo Comparator|Placebo (PBO)|
33092483|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
33092484|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
33092485|NCT01050530|Experimental|OPC-41061|
33092486|NCT01050530|Placebo Comparator|Placebo|
33092487|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
33092488|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
33092489|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
33092490|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
33092491|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~Tab. Rilutek 50 mg PO q12hr on empty stomach.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
33092492|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
33092493|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
33092494|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
33092495|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
33092496|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
33092497|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
33092498|NCT01050062||Micombi® Combination Tablet AP|
32799877|NCT03982342|Active Comparator|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
32799878|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions~On-site supervised group exercise program (11 weeks)~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
33092499|NCT01050062||Micombi® Combination Tablet BP|
32799879|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
32799880|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
32799881|NCT03596944||Statin|History of statin use for primary prevention
33092500|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
33092501|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
33092502|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
33092503|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
33092504|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
33092505|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
33092506|NCT00464919|Experimental|A|
33092507|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
33092508|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
33092509|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
33092510|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
33092511|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
33092512|NCT00472758|Active Comparator|1|MEDI 545
33092513|NCT00472758|Placebo Comparator|2|Placebo IV
33092514|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
32799882|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
32799883|NCT04002310|Experimental|BI 754132|Single Rising Dose (SRD) part followed by a Multiple Dosing (MD) part
32799884|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
32799885|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
32799886|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
32799887|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
32799888|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
33092515|NCT01055015|Experimental|1|Q8003, Flexible dose
33092516|NCT01055015|Experimental|2|Q8003, Low dose
33092517|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
33092518|NCT00434447|Experimental|Zoledronic Acid|ZOL446
33092519|NCT00472953|Experimental|A|
33092520|NCT00472953|Active Comparator|B|
33092521|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
33092522|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
32799889|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32799890|NCT00211510|Experimental|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
32799891|NCT00211510|Active Comparator|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
32799892|NCT04549311|Active Comparator|Antibiotic 1 arm (amoxicillin + clavulanic acid)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 1 arm will receive a prescription for amoxicillin + clavulanic acid (875 mg amoxicillin and 125 mg clavulanic acid BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
32799893|NCT04549311|Active Comparator|Antibiotic 2 arm (ciprofloxacin + metronidazole)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 2 arm will receive a prescription for ciprofloxacin + metronidazole (ciprofloxacin 500 mg and metronidazole 500 mg BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
32799894|NCT04549311|No Intervention|No antibiotics|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~In the comparator arm, patients will not receive any antibiotics. Otherwise, all participants will be treated identically according to the institution's standard practices."
32799895|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
32799896|NCT03975634|Experimental|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
32799897|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
32799898|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
32799899|NCT01714947|Experimental|Alisertib|"Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
32799900|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
32799901|NCT04198636|Experimental|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
32799902|NCT04198636|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
32799903|NCT04414995|Experimental|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
32799904|NCT04414995|Experimental|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
32799905|NCT04414995|Experimental|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
32799906|NCT03975400|No Intervention|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
32799907|NCT03975400|Active Comparator|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
32799908|NCT03591718|Experimental|BI 456906|
32799909|NCT03591718|Experimental|Placebo|
32799910|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
32799911|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
32799912|NCT04198480|Experimental|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
32799913|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
32799914|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
32799915|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
32799916|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
32799917|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
32799918|NCT01849874|Experimental|MEK162|
33092523|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
33092524|NCT04702061|Active Comparator|Group E|Patients who receive general anesthesia after erector spina plane block
33092525|NCT04702061|Active Comparator|Group T|Patients who receive general anesthesia after thoracic epidural block
33092526|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
33092527|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
33092528|NCT00465153|Experimental|1|Flax oil
33092529|NCT00465153|Placebo Comparator|2|corn oil
33092530|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:~first administration intraoperatively via intraportal infusion~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
33092531|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
32799919|NCT01849874|Active Comparator|Physician's choice chemotherapy|
32799920|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
32799921|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
32799922|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
33092532|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
33092533|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
33092534|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
33092535|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
33092536|NCT00473148|No Intervention|2|
32799923|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
32799924|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
32799925|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
32799926|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
32799927|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.~Patient can receive second treatment of HSV-tk after 6 months"
32799928|NCT03981796|Active Comparator|Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab|
32799929|NCT03981796|Placebo Comparator|Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
32799930|NCT03981796|Active Comparator|Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib|
32799931|NCT03981796|Placebo Comparator|Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
32799932|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
32799933|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
32799934|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
32799935|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
32799936|NCT04588142|Experimental|Experimental group|Participants are randomized to receive probiotics for 6 weeks
32799937|NCT04588142|Placebo Comparator|Placebo group|Participants are randomized to receive placebo for 6 weeks
33092537|NCT00435032|Active Comparator|1|Early appendectomy
33092538|NCT00435032|Active Comparator|2|Interval appendectomy
33092539|NCT00465231|Active Comparator|1|Epidural
33092540|NCT00465231|Placebo Comparator|2|Epidural - saline solution
33092541|NCT00435071|Active Comparator|1|
33092542|NCT00435071|Active Comparator|2|
33092543|NCT00435149|Active Comparator|1|
33092544|NCT00435149|Active Comparator|2|
33092545|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
33092546|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
33092547|NCT00435227|Experimental|Motavizumab|Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
33092548|NCT00435227|Placebo Comparator|Placebo|Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
33092549|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
33092550|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
33092551|NCT04702334|Experimental|Hyaluronic acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.
33092552|NCT04702334|Placebo Comparator|Lidocaine|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.
33092553|NCT04702412|Experimental|Opal patient portal|Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
33092554|NCT00435266|Experimental|1|Remote ischemic preconditioning
33404423|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
32942928|NCT04866823|Experimental|Medically Tailored Meals|A series of medically tailored meals appropriate for women with gestational diabetes will be developed in partnership with chefs from a local community kitchen and catering company. Meals will create a slight caloric deficit in order to promote gradual weight loss, but with sufficient energy intake and macronutrient balance to allow breastfeeding. These meals will be roughly 40% carbohydrate, 30% protein, and 30% fat in composition. Study Team will plan up to 20 unique lunch and dinner meals for the series. Each meal will be prepared to be between 450-600 kcal and to contain 6 ounces of protein, 4 ounces of vegetable and I cup of whole grain (at a minimum). Participants will receive detailed recipe cards and nutrition information with each meal. In addition to receiving the medically tailored meals, participants will be advised to supplement their own breakfast +/- snacks to reach a total daily calorie goal determined by starting BMI category.
33404424|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
33404425|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
33092555|NCT00435266|No Intervention|2|
33092556|NCT00473460|Experimental|Arm 1|
33404426|NCT02038348|Other|PET with 18F-FDOPA|
32942929|NCT04866823|No Intervention|Usual Care Comparison Group|Participants in this group will receive written materials on self-care, nutrition, and physical activity in the postpartum period and community resources for healthy living.
32942930|NCT04863781|Experimental|Intervention|All 11 modules will include the following elements: introduction to the topic; two types of assessments (1) adherence to at-home relaxation training practice (following week 2) and (2) 3-5 topic-specific questions to tailor video-based content; a cognitive component; a relaxation component; and a wrap up that includes a brief assessment of module comprehension. Each user will view 5-7 videos per module. Videos will be tailored to user and will last between 2 and 4 minutes. Total time per module will be 20 to 30 minutes. Between modules, users will receive (based on their timing preferences) supportive texts intended to motivate continued engagement or to affirm the life experiences of African American women
32942931|NCT04863781|Active Comparator|Control|Two mobile courses: Introduction to Stress Management and Techniques for Coping with Stress. Users will be informed that the courses will be completed on their phone, that they are video-based, and that they should spend between 20 and 30 minutes each week, for the next 11 weeks, learning the material. The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
33404427|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
33404428|NCT02333812||copd patients|Adult patients with COPD
33404429|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
33404430|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
33404431|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
33404432|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
33307633|NCT03582826|Experimental|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
33307634|NCT03582826|No Intervention|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
33307635|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
33404433|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
33404434|NCT03485495|Experimental|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
33404435|NCT03485495|Placebo Comparator|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
33404436|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
33307636|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
33307637|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
33404437|NCT03652532|Experimental|Alternate Day Fasting|
33404438|NCT03652532|Experimental|Exercise|
32942940|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
32942941|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
32942942|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
32942943|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
32942944|NCT03234907|Placebo Comparator|Maintenance Phase: Induction Placebo to Placebo Q4W|Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase. Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.
32942945|NCT03234907|Experimental|Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W|Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
32942946|NCT03234907|Experimental|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W|Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.
32942947|NCT03234907|Experimental|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W|Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
32942948|NCT03980977|Other|skin and/or tumor Biopsy and blood sample|
33092557|NCT00473460|Placebo Comparator|Arm 2|
33092558|NCT00465426||1|HIV Positive men and women 18-65 years of age
33092559|NCT00465426||2|HIV negative men and women 18-65 years of age
33092560|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
33092561|NCT00473499|Active Comparator|Cypher stent|
33092562|NCT00473499|Placebo Comparator|Coroflex Blue stent|
33404439|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
33404440|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
33404441|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
33404442|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
33404443|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
33404444|NCT02330224|No Intervention|Usual Care|Control group
33404445|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
33404446|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
33404447|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
33404448|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
33404449|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
33404450|NCT02333968|Experimental|Intervention group|Self-management support
33404451|NCT02333968|No Intervention|Control group|Care as usual
33404452|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
32942949|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.~1a - Non-small cell lung cancer~1b - Small cell lung cancer~1c - Urothelial carcinoma~1d - Head and neck squamous cell carcinoma~1e - Merkel cell carcinoma~1f - Melanoma~1g - Renal cell carcinoma~1h - Gastric cancer~1i - Cervical cancer~1j - Hepatocellular carcinoma~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
33092563|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
33092564|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
33092565|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
33092566|NCT02957825|No Intervention|Control|Routine monitoring
33092567|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
33092568|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
33092569|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
33092570|NCT00435617|Experimental|A|Hand Mentor
33092571|NCT00435695|Active Comparator|GSK163090|one infusion only
33092572|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
33092573|NCT00481221||1|Screened pregnant women
33092574|NCT00435890|No Intervention|1|No triage liaison physician
33092575|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
33092576|NCT00473772|Active Comparator|Cypher Stent|
33092577|NCT00473772|Experimental|DEBlue Stent|
33092578|NCT03272165|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) infusion of placebo matched to MEDI1341 and will be followed up for 13 weeks.
33092579|NCT03272165|Experimental|Cohort 1: MEDI1341 Dose 1|Participants will receive a single IV infusion of MEDI1341 Dose 1 and will be followed up for 13 weeks.
33092580|NCT03272165|Experimental|Cohort 2: MEDI1341 Dose 2|Participants will receive a single IV infusion of MEDI1341 Dose 2 and will be followed up for 13 weeks.
33092581|NCT03272165|Experimental|Cohort 3: MEDI1341 Dose 3|Participants will receive a single IV infusion of MEDI1341 Dose 3 and will be followed up for 13 weeks.
33092582|NCT03272165|Experimental|Cohort 4: MEDI1341 Dose 4|Participants will receive a single IV infusion of MEDI1341 Dose 4 and will be followed up for 13 weeks.
33092583|NCT03272165|Experimental|Cohort 5: MEDI1341 Dose 5|Participants will receive a single IV infusion of MEDI1341 Dose 5 and will be followed up for 13 weeks.
33092584|NCT03272165|Experimental|Cohort 6: MEDI1341 Dose 6|Participants will receive a single IV infusion of MEDI1341 Dose 6 and will be followed up for 13 weeks.
33092585|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
33092586|NCT00473811|Experimental|Low-GI|a low GI dietary education
33092587|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible.
33092588|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible.
33092589|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
33092590|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
33092591|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
33092592|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
33092593|NCT00436241|Experimental|1|
33092594|NCT00481455|Experimental|1|
33092595|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
33092596|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
33092597|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
33092598|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
33092599|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
33092600|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
33092601|NCT00436358||Group A|IS case deemed children
33092602|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
33092603|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
33092604|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
33092605|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
33092606|NCT00481572|Experimental|1|Terlipressin
33092607|NCT00481572|Experimental|2|Vasopressin
33092608|NCT00481572|Active Comparator|3|titrated norepinephrine
33092609|NCT00436592|Experimental|1|
33092610|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
33092611|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
33307638|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
33307639|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
33307640|NCT01091324|Active Comparator|Dextromethorphan|
33307641|NCT01091324|Active Comparator|Silymarin|
33307642|NCT01091324|Placebo Comparator|sugar pill|
33307643|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
33307644|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
32799938|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
32799939|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
32799940|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
32799941|NCT03973294|Active Comparator|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
32799942|NCT03973294|Active Comparator|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
32799943|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
32799944|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
32799945|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
32799946|NCT04197622|Experimental|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
32799947|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
32799948|NCT03596008|Placebo Comparator|Placebo|Placebo drink
32799949|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
32799950|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
32799951|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
33092612|NCT04701554|Experimental|Qigong program|The experimental group participated in the Qigong program during 2 months, 16 sessions with a total of 16 hours.
32799952|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
32799953|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
32799954|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
33307645|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
32799955|NCT04197466|Experimental|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
32799956|NCT04197466|Experimental|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
33307646|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
32799957|NCT04197466|Experimental|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
32799958|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
32799959|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
32799960|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
32799961|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
32799962|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
32799963|NCT04197154|Experimental|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
32799964|NCT04197154|Experimental|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
32799965|NCT04197154|Experimental|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
33307647|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
33307648|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
33307649|NCT05782725||1|PCOS and SCH
33307650|NCT05782725||2|PCOH without SCH
33307651|NCT05782725||3|HPOD and SCH
33307652|NCT05782725||4|HPOD without SCH
33307653|NCT05782686|Experimental|Shaving|Subsequent to lumpectomy, a circumferential enlargement of all lumpectomy margins, including lateral, medial, superior, inferior, anterior, and posterior, approximately 5-10mm thick, will be resected.
33307654|NCT05782686|Active Comparator|No Shaving|Standard lumpectomy
33307655|NCT05782634|Experimental|subjected to immediate cortical satellite implants with immediate loading|All patients involved in this study will be subjected to immediate cortical satellite implants with immediate loading
32799966|NCT04191382|Experimental|Amcenestrant 400 mg|Participants received 4 capsules of 100 milligrams (mg) of amcenestrant once daily (QD) from Day 1 to Day 14.
33092613|NCT04701554|Active Comparator|Active comparator group|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
33307656|NCT05782621|Experimental|Acupoint focused ultrasound|the patients will receive Acupoint focused ultrasound therapy three times a week for four weeks
33307657|NCT05782621|Experimental|Laserpuncture|the patients will receive Laserpuncture therapy three times a week for four weeks
33307658|NCT05782621|Active Comparator|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
33307659|NCT05782608|Active Comparator|group (I)|
33307660|NCT05782608|Active Comparator|group (II)|
33307661|NCT05782595|Experimental|Aquatic therapy|Aquatic exercise program: Each woman in group (A) will receive aquatic exercises for 40 minutes.
33307662|NCT05782582|Experimental|Package investigation|"Resting ECG,~Evaluation of risk according to PTP-table.~Echocardiography,~Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy,~Scanning for myocardial perfusion~CAC-scoring with CT"
33307663|NCT05782582|Active Comparator|Standard investigation|"Resting ECG~Evaluation of risk according to PTP-table.~Echocardiography.~Exercise stress bicycle test.~If judged to be needed according to clinical indication sequentially completed by:~Echocardiography, Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy and/or Coronary CTA. In addition, cardiac examinations done with other modalities chosen on clinical grounds will be examined in the study.~,"
33307664|NCT05782556||Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) due to cirrhotic and non-cirrhotic portal hypertension
33092614|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
33307665|NCT05782543|No Intervention|Hypothermic machine perfusion|
33307666|NCT05782543|Active Comparator|Normothermic machine perfusion|
33307667|NCT05782530||medical stuff in obstetrics|medical doctors, nurses, midwives
33307668|NCT05782517|Experimental|I-gel|
33307669|NCT05782517|Active Comparator|Endotracheal Tube|
33307670|NCT05782504|Experimental|Treatment arm|4 treatment sessions, each lasting 60 minutes, within a 4-week perioperative period, with 2 preoperative (in the last 2 weeks before surgery) and 2 postoperative (in the first 2 weeks after surgery) sessions.
33307671|NCT05782491|Experimental|Treatment Arm|Patient in cardiogenic shock listed for Impella 5.5 placement who meets study inclusion criteria
33307672|NCT05782465||Participants with IM of OLGIM Stage 2 to 4|Participants with Intestinal Metaplasia of Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) that is evaluated to be Stage 2 to 4.
33307673|NCT05782452||Bilateral congenital cataract probands who were consecutively enrolled|
33307674|NCT05782439|Experimental|Healthy adults|Manual and instrumental evaluation to identify if there is an equal or different stiffness between the right and left ileotibial band.
33307675|NCT05782426|Experimental|paclitaxel polymeric micelles for injection, platinum combined with sindilizumab injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
33307676|NCT05782413|Experimental|Group A|The child will receive a design exercise program. The therapy was based on the principles of NDTBobath neurodevelopmental therapy.
33307677|NCT05782413|Experimental|Group B|The child will receive a design exercise program for 45 min then mechanical vestibular exercise for 15 mins.
33307678|NCT05782374||Patients diagnosed with r/r PCNSL|Adult patients diagnosed with relapsed or refractory PCNSL who in the period between August 2020 and May 2022 were candidates for treatment with ibrutinib alone or in combination with R-CHOP or R-CHOP like (in compassionate use, or off- label).
32942950|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
33092615|NCT04697745|Active Comparator|dexamethasone intrathecal|
33092616|NCT04697745|Active Comparator|dexmedetomidine intrathecal|
33404453|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
33404454|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
32942951|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
32942952|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
32942953|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
32942954|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
32942955|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
32942956|NCT03976843|Experimental|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy and lymphadenectomy
32942957|NCT03970447|Active Comparator|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
32942958|NCT03970447|Experimental|Regorafenib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
32942959|NCT03970447|Experimental|Paxalisib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles.~Recurrent GBM: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 21 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 21 days for all subsequent cycles."
32942960|NCT03970447|Experimental|VAL-083 Treatment Arm|"Newly Diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle.~Recurrent GBM: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle."
32942961|NCT03970447|Experimental|VT1021 Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. Treatment as outlined in section Experimental: VT1021 Treatment Arm with the first 6 patients receiving VT1021 at 12 mg/kg twice weekly in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities reported, the dose will be de-escalated to 9 mg/kg two times a week. 6 patients will then be receiving 9 mg/kg two times a week and observed for DLTs for 4 weeks.~Recurrent GBM: Dose Finding Phase is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
32942962|NCT03970447|Experimental|VT1021 Treatment Arm - Enhanced Safety Management (ESM)|"Experimental: VT1021 Treatment Arm - Enhanced Safety Management (ESM) Newly diagnosed MGMT Methylated and Unmethylated GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. PK and PD assessments are done for patients as a part of ESM. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.~Recurrent GBM: ESM is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
32942963|NCT03970447|Experimental|VT1021 Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and VT1021 (Dosage from: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: As confirmed through the dose finding phase) twice weekly during radiation therapy. Rest period: 2-6 weeks from last day of radiation. VT1021 dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with VT1021. After 6 cycles, VT1021 only.~Recurrent GBM: VT1021 (Dosage from: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: 12mg/kg) twice weekly."
33404455|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
32799967|NCT04191382|Experimental|Amcenestrant 200 mg|Participants received 2 capsules of 100 mg of amcenestrant QD from Day 1 to Day 14.
32799968|NCT04191382|Active Comparator|Letrozole 2.5 mg|Participants received 2.5 mg of letrozole tablet QD from Day 1 to Day 14.
32799969|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
32799970|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
33092617|NCT00436631|Experimental|diet|
33092618|NCT00481728|Experimental|Tolterodine|
33092619|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
33092620|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
33092621|NCT00436943||A|Smokers
33092622|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
33092623|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
33092624|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
33092625|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
33092626|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
33092627|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
33092628|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
33092629|NCT00482118||Cases|Non smoking women with lung cancer
33092630|NCT00482118||Controls|Non smoking women without lung cancer
33092631|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
33092632|NCT00437411|No Intervention|Control|Waiting-list control.
33092633|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
33092634|NCT04701710|Experimental|Experimental Group|"The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.~Standard biosecurity care"
33092635|NCT04701710|No Intervention|Control Group|Standard biosecurity care
33092636|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
33092637|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
33092638|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
33092639|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
33092640|NCT00437606|Experimental|1|
33092641|NCT00437606|Experimental|2|
33092642|NCT00437606|Experimental|3|
33092643|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
33092644|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
33092645|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
33092646|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
33092647|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
33092648|NCT00437723|Experimental|1|
33092649|NCT00437723|No Intervention|2|
33092650|NCT04701749||with atrial closure|
33092651|NCT04701749||without atrial occlusion|
33092652|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
33092653|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
33092654|NCT00437762|Experimental|1|Botulinum Toxin A Injection
33092655|NCT00437762|Placebo Comparator|2|Placebo injection
33092656|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
33307681|NCT05782348|Experimental|Test Group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush Cognitive behavioral intervention (CBI)
33307682|NCT05782348|Active Comparator|Control group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush
33307683|NCT05782348|No Intervention|Control group II|A commercially available fluoride toothpaste (1450 ppm F) A commercially available soft bristle toothbrush
33307684|NCT05782335||Arm 1: Abatacept Initiator|RA patients of any disease duration, 18 years or older who are starting ABA (either IV or subcutaneous at standard doses) for the first time. Concomitant non-biologic medications (for e.g., standard conventional synthetic (cs)DMARDs, one of which must be MTX as typically used in routine care, or if MTX was not tolerated leflunomide will be acceptable) will be allowed as long as the dose has been stable for at least 3 months.
33307685|NCT05782335||Arm 2: csDMARD/TNFi Treated|RA patients, 18 years or older and on stable doses of conventional DMARDs (MTX with or without hydroxychloroquine, sulfasalazine, with or without leflunomide therapy, where leflunomide therapy can be an alternate to MTX). Patient's disease activity can be controlled or near controlled (CDAI <=12) or active if a recent DMARD or TNFi has been added, though they will have been on MTX at doses of at least 15mg weekly or leflunomide 10 mg or more for 4 weeks or more. A combination of csDMARDs at stable doses for 4 or more weeks with >= MTX 10 mg weekly or ± MTX 10 mg weekly for at least 4 weeks with any dose of a conventional TNF inhibitor (stable dose + TNFi) is permitted.
33307686|NCT05782335||Arm 3. Healthy Controls|Healthy individuals over 18 y.o. without RA, SLE, juvenile arthritis, psoriasis or psoriatic arthritis or other inflammatory auto-immune rheumatic disease, who are receiving care at the HSS or volunteers from the community. Participants will be recruited to serve in the control population for this study. Given that the range of age for most RA patients is between 40-70, we will aim to recruit control volunteers in this age range, ensuring that at least 60% - 70% are female, ensuring an age range and sex that is proportionately similar to the RA population at HSS.
33092657|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
33307687|NCT05782322|Experimental|PD-RAS|training involving RAS
33307688|NCT05782322|Active Comparator|PD-noRAS|training without the aid of RAS
33307689|NCT05782322|Experimental|HC-RAS|training involving RAS
33307690|NCT05782322|Active Comparator|HC-noRAS|training without the aid of RAS
33307691|NCT05782309|Experimental|Flavanol|410 mg of flavanols twice daily
33307692|NCT05782309|Placebo Comparator|Placebo|nutrient matched control capsule
33307693|NCT05782296||Cohort|Women in active labor following rupture of membranes and placement of an IUPC and/or FSE for obstetric indications
33307694|NCT05782283|No Intervention|Usual Care Group|Primary care providers will treat subject per standard of care
33092658|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
33307695|NCT05782283|Experimental|Electrocardiogram AI Group|The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.
33307696|NCT05782257|Active Comparator|Zinc Supplementation|Those allocated in this arm will be provided with 90 capsules of gluten-free Zn gluconate 25 mg (7 mg of elemental Zn; Jamieson®) and will be instructed to take 1 tablet daily with a meal and at least 2 hrs apart from other medications, and iron or copper supplements
33307697|NCT05782257|Experimental|Zinc Optimized Diet|Instructions provided by a dietitian to establish a target of 11 mg/day (female) and 14 mg /day (male) provided by Zn-rich food sources, adjusted for dietary phytate intake.
33307698|NCT05782244|Active Comparator|Sildenafil citrate low dose|Sildenafil citrate 20 mg, oral, TID
33307699|NCT05782244|Placebo Comparator|Placebo|Placebo, oral, TID
33307700|NCT05782244|Active Comparator|Sildenafil citrate medium dose|Sildenafil citrate 40 mg, oral, TID
33307701|NCT05782244|Active Comparator|Sildenafil citrate high dose|Sildenafil citrate 80 mg, oral, TID
33307702|NCT05782231|Experimental|Experimental: GetActive+|A mind-body program focused on increasing physical and emotional function in older adults with chronic musculoskeletal pain
33307703|NCT05782218|Experimental|Almond arm|Almonds will be provided to increase the gut content in mono and poly-unsaturated fatty acids.
33307704|NCT05782218|Experimental|Coconut arm|This snack is isocaloric and almost perfectly matches the macronutrient profile of the almonds. However, despite being in the same quantity, almost all provided fatty acids will be saturated fatty acids.
33307705|NCT05782192|Experimental|SAL067|SAL067 12mg once daily
33307706|NCT05782192|Active Comparator|Alogliptin|Alogliptin 25mg once daily
33307707|NCT05782192|Placebo Comparator|placebo|placebo once daily
33307708|NCT05782179|Experimental|Cohort 1 - Active|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307709|NCT05782179|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307710|NCT05782179|Experimental|Cohort 2 - Active|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307711|NCT05782179|Placebo Comparator|Cohort 2 - Placebo|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33404456|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
32942964|NCT03970447|Experimental|Troriluzole Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. The first 6 patients will receive troriluzole at 100 mg BID for the first two weeks followed by 200 mg BID for the next two weeks in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities (DLTs) reported, the dose will be de-escalated to 100 mg in the morning and followed by 200 mg in the evening. 6 patients will receive this dose and observed for 4 weeks. If there are two DLTs reported, then this dose will be de-escalated to 100 mg BID. 6 patients will then be receiving this dose and observed for DLTs for 4 weeks.~Recurrent GBM: Rolling 6 design. The first 6 patients receiving troriluzole 100 mg twice a day (BID) for the first two weeks followed by 200 mg BID for the next two weeks in combination with lomustine. The dose de-escalation is similar to that of newly diagnosed patients during the rolling 6 design."
32942965|NCT03970447|Experimental|Troriluzole Treatment Arm - Enhanced Safety Management (ESM)|Newly diagnosed MGMT Methylated and Unmethylated GBM and Recurrent GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.
32942966|NCT03970447|Experimental|Troriluzole Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and troriluzole (Dosage from: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. Rest period: 2-6 weeks from last day of radiation. Troriluzole dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with troriluzole. After 6 cycles, troriluzole only.~Recurrent GBM: Lomustine 100 mg/m2 orally on day 1 of a 42-day cycle in combination with troriluzole (Dosage from: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. After 6 cycles, troriluzole only."
32942967|NCT03968653|Experimental|Group A: Debio 0123|"Participants will receive Debio 0123 as monotherapy (Day -3), orally, daily for 3 days during Cycle 1 then in combination with carboplatin intravenous infusion from Cycle 2 onwards.~Depending on pharmacokinetics (PK) and safety results from previous cohorts, the Debio 0123 dosing regimen may be modified for subsequent cohorts."
32942968|NCT03968653|Experimental|Group B: Debio 0123|Participants will receive Debio 0123, orally, daily, for 6 days during each cycle in combination with carboplatin IV infusion.
32942969|NCT03958747|Experimental|Ultrasound|Undergo peripheral nerve ultrasound
32942970|NCT04848883|Experimental|Advanced AMS program|Three randomily assigned primary care centres in which an infectious diseases expert will be continuously in touch with primary care practitioners.
32942971|NCT04848883|Active Comparator|Standard AMS program|Three primary care centres in which a typical AMS will be promoted.
32942972|NCT04844983|Experimental|Part 1: Arm A|STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.
32942973|NCT04844983|Experimental|Part 1: Arm B|STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.
32942974|NCT04844983|Experimental|Part 1: Arm C|STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.
32942975|NCT04844983|Other|Part 1: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
32942976|NCT04844983|Experimental|Part 2: Arm A, B or C|STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.
32942977|NCT04844983|Experimental|Part 2: Arm A or B or C|STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.
32942978|NCT04844983|Other|Part 2: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
32942979|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
32942980|NCT03155425|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion.
32942981|NCT04330027|Experimental|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
32942982|NCT04330027|Placebo Comparator|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
32942983|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
32942984|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
32942985|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
32942986|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
32942987|NCT03905941|Experimental|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
32942988|NCT03905941|Active Comparator|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
32942989|NCT03900715|Experimental|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
32942990|NCT04712617||FGIDs|Patient who were diagnosed with NERD/RH, FD, IBS and their overlaps (NERD/RH-FD, NERD/RH-IBS, FD-IBS, NERD/RH-FD-IBS)
32942991|NCT04712617||Healthy controls|Subjects who underwent GI evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during GI endoscopy
32942992|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
32942993|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
32942994|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
32942995|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
32942996|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
32942997|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
32942998|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
32942999|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
32943000|NCT03818581|Active Comparator|Treatment Group|
32943001|NCT03818581|Placebo Comparator|Placebo Responders|
32943002|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
32943003|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
32943004|NCT03811561|Experimental|Semaglutide|Participants will receive semaglutide once weekly as subcutaneous (s.c., under the skin) injection added to standard of care.
32943005|NCT03811561|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) once weekly as subcutaneous subcutaneous (s.c., under the skin) injection added to standard of care.
32943006|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
32943007|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
32943008|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
32943009|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
32943010|NCT00002923|Experimental|KRN5500|
32943011|NCT03779581|Experimental|Exercise Group|The experimental group received active self-correction exercises to restore movements in different planes as close as possible to physiologically normal.
32943012|NCT03779581|Active Comparator|Control Group|All patients were prescribed a spinal orthosis (TLSO) and got a preliminary evaluation for orthosis design and manufacturing based on the curve type categorization from Ross and Weiss during the first appointment (Rigo et al., 2010).
32943013|NCT03778957|Experimental|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
32943014|NCT03778957|Experimental|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
32943015|NCT03778957|Placebo Comparator|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
32943016|NCT03766321|Active Comparator|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
32943017|NCT03766321|Placebo Comparator|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.~Every endoscopic procedure will be performed with sedation of the patient."
32943018|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
32943019|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
32943020|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
32943021|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
32943022|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
33092659|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
33092660|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
33404457|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
32943023|NCT03736447|Active Comparator|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
32943024|NCT03736447|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
32943025|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
32943026|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
32943027|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
32943028|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
32943029|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
32943030|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
32943031|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
32943032|NCT02401789|No Intervention|control- natural healing|
32943033|NCT04329793|Experimental|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
32943034|NCT04329793|Active Comparator|Control arm|Their usual Physical Therapy.
32943035|NCT04329637|Active Comparator|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
32943036|NCT04329637|No Intervention|usual care|usual care
32943037|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
32943038|NCT03693781|Active Comparator|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
32943039|NCT03693781|Active Comparator|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
32943040|NCT03693781|Placebo Comparator|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
32943041|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
32943042|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
32943043|NCT03670849|Experimental|Patients using LapAR system|
32943044|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
32943045|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
32943046|NCT03668041|Active Comparator|Gabapentin|Participants who are assigned to take gabapentin, an active study medication.
32943047|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
32943048|NCT04329247|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
32943049|NCT04329247|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
32943050|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
32943051|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
32943052|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
32943053|NCT02263417|Sham Comparator|Placebo|Stimulation is off
32943054|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
32943055|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
32943056|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 1|Combination chemotherapy and inotuzumab ozogamicin - Dose level 1 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and 0.4 mg/m2 inotuzumab ozogamicin IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32943057|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 2|Combination chemotherapy and inotuzumab ozogamicin - Dose level 2 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.6 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33092661|NCT00482742|Other|Lifestyle counseling|
33092662|NCT00482742|Other|Metformin|
33092663|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
33092664|NCT03270176|Experimental|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion every 2 weeks.~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) of 200 mg/day (days 1-10 and 15-24 every 28 days ([q4w]) in combination with avelumab IV infusion at the standard dose unless disease progression or unacceptable toxicity occurs, as judged by investigators up to 26 cycles (each cycle is of 28 days)."
33092665|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
33092666|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
33092667|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
33092668|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
33092669|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
33092670|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
33092671|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
33092672|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
33092673|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
33092674|NCT04701125|Experimental|Study group|Players receive selective head-neck cooling after concussion
33092675|NCT04701125|No Intervention|control group|Players receive the standard sport-related concussion management
33092676|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
33092677|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
33092678|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
33092679|NCT04701086|Experimental|Cationorm Pro|Cationorm Pro is an ophthalmic sterile unpreserved eye drops emulsion (N=40) Posology: One Drop in each eye 4 times daily for 84 days
33092680|NCT04701086|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
33092681|NCT04701242|Active Comparator|Atorvastatin-Ezetimibe combination|Eligible patients randomized to this arm will receive combination of Atorvastatin 80mg plus Ezetimibe 10mg
33092682|NCT04701242|No Intervention|Atorvastatin monotherapy|Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
33092683|NCT03270267||Patients with IBD|
33092684|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
33092685|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
33307712|NCT05782179|Experimental|Cohort 3 - Active|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33404458|NCT03653468|No Intervention|Control group|No-exercise
33092686|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
33092687|NCT04701320|Experimental|Glass carbomer|Nano hydroxyapatite Reinforced Glass Ionomer that results in chemical bond formation with tooth structure mimic that of enamel tissue
33092688|NCT04701320|Active Comparator|Fuji ix|Conventional Glass Ionomer cement fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics, a wear resistant, self-adhesive
33092689|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
33092690|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
33092691|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
33092692|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
33092693|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
33092694|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
32943058|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 3|Combination chemotherapy and inotuzumab ozogamicin - Dose level 3 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32943059|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 4|Combination chemotherapy and inotuzumab ozogamicin - Dose level 4 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32943060|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 5|Combination chemotherapy and inotuzumab ozogamicin - Dose level 5 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33307713|NCT05782179|Placebo Comparator|Cohort 3 - Placebo|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307714|NCT05782179|Experimental|Cohort 4 - Active|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307715|NCT05782179|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
33307716|NCT05782166|Placebo Comparator|Betel Quid Cessation via Educational Booklet|Participants will be given only an educational booklet on screening day (Day-1) and will be followed up on Day-22 and Month-3 to assess their current chewing status and other related parameters.
32943061|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - MTD|Combination chemotherapy and inotuzumab ozogamicin - Maximum Tolerated Dose Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32943062|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
32943063|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
32943064|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
32943065|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
32943066|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
32943067|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
32943068|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
32943069|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
32943070|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
32943071|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50 Gy + boost 16 Gy. Whole breast hypofractionated RT without boost, either 40 Gy or 42.5 Gy"
32943072|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed
32943073|NCT01120249|Experimental|Arm I|Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
32943074|NCT01120249|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
32943075|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
32943076|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
32943077|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
32943078|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
32943079|NCT00003553|Experimental|1|The target for progenitor cell is >=5 x 106 CD 34/kg.
32943080|NCT00383539|Experimental|1|Lot 1
32943081|NCT00383539|Experimental|2|Lot 2
32943082|NCT00383539|Experimental|3|Lot 3
32943083|NCT00383539|Active Comparator|4|Control
32943084|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
32943085|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
32943086|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
32943087|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
32943088|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
32943089|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
32943090|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
32943091|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
32943092|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
32943093|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
32943094|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32943095|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
32943096|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
32943097|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
33404459|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
33404460|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
32943098|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
32943099|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
32943100|NCT00384631|Sham Comparator|2|
32943101|NCT00384631|Experimental|1|
32943102|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
32943103|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
32943104|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
32943105|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
32943106|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
32943107|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
32943108|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
32943109|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
32943110|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
32943111|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
32943112|NCT04097119|Other|Dietary supplement arm|Subjects to receive a specific dietary supplement
32943113|NCT04712695|Experimental|Graded Motor Imagery Group|
32943114|NCT04712695|Experimental|Mirror Visual Feedback Group|
32943115|NCT04712695|Experimental|Augmented Biofeedback Group|
32943116|NCT04712695|Sham Comparator|Diaphragmatic Breathing Group|
32943117|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
32943118|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
32943119|NCT00003787||Control|NCI-recommended diet
32943120|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
32943121|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
32943122|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
33092695|NCT00438152|Active Comparator|Invirase® tablets|
33307717|NCT05782166|Experimental|Betel Quid Cessation via Educational Booklet & Intervention Module|Participants will undergo a 5-intervention sessions which will enhance their self-efficacy o quit their chewing behaviour. During the intervention sessions, they will be guided on how to monitor their chewing triggers, the lifestyle changes that they can potentially make, how to tap on their social support system to aid in their cessation efforts and others. The intervention will last for 22 days and a follow-up session will be made on Month-3.
32943123|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
32943124|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
32943125|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
32943126|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
32943127|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
32943128|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
32943129|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
32943130|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
32943131|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
32943132|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
32943133|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
32943134|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
32943135|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
32943136|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
32943137|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
32943138|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
32943139|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
32943140|NCT04329403|Experimental|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
32943141|NCT04329403|Active Comparator|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
32943142|NCT04329403|Placebo Comparator|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
32943143|NCT00003217|Experimental|Treatment|See detailed description.
32943144|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
32943145|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
32943146|NCT00004189|Experimental|Arm I|See detailed description.
32943147|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
33307718|NCT05782153|Active Comparator|Intervention A (hearing aid self-fitting with direct adjustment)|
33307719|NCT05782153|Active Comparator|Intervention B (hearing aid self-fitting with in-situ fitting)|
32943148|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
32943149|NCT00003847|Experimental|Treatment|
32943150|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
32943151|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
32943152|NCT00003865|Experimental|Toremifene|All enrolled patients
32943153|NCT04225819|Experimental|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
32943154|NCT04225819|Placebo Comparator|Placebo|Two placebo capsules, taken daily with a meal
33307720|NCT05782140||Mayo Clinic Rochester Surgical Patients|Mayo Clinic Watch Device
33307721|NCT05782127|Experimental|Onureg + Venetoclax|"Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.~Venetoclax will be administered orally at 400 mg once daily for 14 consecutive days on days 1 to 14, beginning on Day 1 of repeated 28-day cycles.~Patients will be treated up to 4 cycles and for a maximum of 24 cycles."
33307722|NCT05782114|Experimental|The experimental Group A|"Extracorporeal Shockwave therapy (four sessions one session per week)~+Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise & strengthening exercise) (two sessions per week for 4 weeks)."
32943155|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
32943156|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
32943157|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
32943158|NCT00004285|Experimental|High dose, low flux hemodialysis|
32943159|NCT00004285|Experimental|High dose, high flux hemodialysis|
32943160|NCT00004843|Experimental|Parathyroidectomy|
32943161|NCT00004843|Active Comparator|Observation|
32943162|NCT04074343|Experimental|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
32943163|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
32943164|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
32943165|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
32943166|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
32943167|NCT00004891|Experimental|primary resectable rectal cancer|
32943168|NCT00004909||Oral chemotherapy|
32943169|NCT00004909||Parenteral chemotherapy|
32943170|NCT04069117|Active Comparator|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
32943171|NCT04069117|No Intervention|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
32943172|NCT00004933|Experimental|Homoharringtonine|
32943173|NCT00004933|Active Comparator|Hydroxyurea|
32943174|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
32943175|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
32943176|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
32943177|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
32943178|NCT00005533||Coronary Heart Disease Patients|
32943179|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
32943180|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
32943181|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
32943182|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
32943183|NCT00386191|Experimental|1|50 mg
32943184|NCT00386191|Experimental|2|75 mg
32943185|NCT00423241|Experimental|SEMPERFLO Pain Management System|
32943186|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
33092696|NCT00438152|Active Comparator|Kaletra® tablets|
33092697|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
33092698|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
33092699|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
33092700|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
33092701|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
32943187|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
33092702|NCT00474552|Experimental|1|Experimental-Placebo Comparator
33092703|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
33092704|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
33092705|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
32943188|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
32943189|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
32943190|NCT00005605||Tamoxifen group|
32943191|NCT00005605||Chemotherapy group|
32943192|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
32943193|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
32943194|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
32943195|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
32943196|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
32943197|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
32943198|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
32943199|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
32943200|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
32943201|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
32943202|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
32943203|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
32943204|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
32943205|NCT00385411|Experimental|valproate|
32943206|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
32943207|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
32943208|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
32943209|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
32943210|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
32943211|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
32943212|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
32943213|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
32943214|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
32943215|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943216|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943217|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
33307723|NCT05782114|Active Comparator|The control Group B|Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise & strengthening exercise) (two sessions per week for 4 weeks).
32943218|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943219|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943220|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943221|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943222|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943223|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943224|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943225|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943226|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943227|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943228|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943229|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943230|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943231|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943232|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943233|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943234|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
32943235|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943236|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943237|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943238|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943239|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943240|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943241|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943242|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943243|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943244|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943245|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943246|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943247|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943248|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32943249|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
32943250|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
32943251|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
32943252|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
32943253|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
32943254|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
32943255|NCT02131662|Experimental|VPR 4 mg|
32943256|NCT02131662|Experimental|VPR 2 mg|
33307724|NCT05782101||Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates whith Bronchopulmonary dysplasia and/or Retinopathy of prematurity
33307725|NCT05782101||No Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates without Bronchopulmonary Dysplasia and/or Retinopathy of prematurity
32943257|NCT02131662|Experimental|VPR 1 mg|
33092706|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
33092707|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
33092708|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
33092709|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
32943258|NCT02131662|Experimental|VPR 0.5 mg|
32943259|NCT02131662|Placebo Comparator|Placebo|
32943260|NCT04188366|Experimental|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
32943261|NCT04188366|Experimental|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
32943262|NCT05150106||Laryngeal dystonia|Patients with laryngeal dystonia (or spasmodic dysphonia)
32943263|NCT05150106||Voice tremor|Patients with voice tremor (essential or dystonic)
32943264|NCT05150106||Healthy controls|Healthy research volunteers
32943265|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
32943266|NCT05137002|Experimental|CIN-107 0.5 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
32943267|NCT05137002|Experimental|CIN-107 1 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
32943268|NCT05137002|Experimental|CIN-107 2 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
32943269|NCT05137002|Placebo Comparator|Placebo|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks
32943270|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
32943271|NCT04738812|Experimental|Intensified TB treatment|"Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks (initial phase of TB treatment).~Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to weight bands for the last 2 weeks (total duration: 6 weeks). Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.~Continuation phase: 16 weeks of RH."
32943272|NCT04738812|Active Comparator|WHO standard TB treatment|"Standard-dose of R 8-12 mg/kg daily + H 4-6 mg/kg daily + Z 20-30 mg/kg daily + E 15-20 mg/kg daily for 8 weeks.~Continuation phase: 16 weeks of RH."
32943273|NCT04737954|Experimental|Suspected VTE patients|Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws
32943274|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
32943275|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
32943276|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
32943277|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
32943278|NCT02130882|Active Comparator|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background hypereosinophilic syndrome (HES) therapy will not be tapered.
32943279|NCT02130882|Placebo Comparator|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
32943280|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
32943281|NCT02130570|No Intervention|Usual Care|Usual Care
32943282|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
32943283|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
32943284|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
32943285|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
32943286|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
33092710|NCT00438308||1|Subjects who begin therapy immediately after fracture.
33092711|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
33092712|NCT00438347||group 1|Intervention Group- aerobic exercise
33092713|NCT00438347||group 2|Control Group- stretching and toning
33092714|NCT00474981|Experimental|1|IMNCI
33092715|NCT00474981|No Intervention|2|Control
33092716|NCT00475059|Experimental|1|patients who received cimétidine
32943287|NCT05151120||Group A: Hyperthyroid|30 patients will be included and divided into three categories: A1: 10 patients with suppressed TSH, around 0.01 milli-international unit/liter (mIU/L) A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L
32943288|NCT05151120||Group B: Euthyroid|30 Patients (under treatment) with TSH values between 0.4 - 4 mIU/L will be included
32943289|NCT05151120||GROUP C: Hypothyroid|40 patients will be included and divided into two categories: C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values > 50 mIU/L up to 100 mIU/L. Even distribution (if possible).
32943290|NCT04751916|Experimental|Proprietary Essential Amino Acid Protein Supplement|Essential amino acid protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
32943291|NCT04751916|Active Comparator|Commercially-available whey protein supplement - Beneprotein®|Beneprotein® whey protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
32943292|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
32943293|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
32943294|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
32943295|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
32943296|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
32943297|NCT04736550|Experimental|Assisted Exercise and I-STOP|Participant will receive Assisted Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
32943298|NCT04736550|Experimental|Voluntary Exercise and I-STOP|Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
32943299|NCT04736550|Experimental|No Exercise (TAU) and I-STOP|Participant will receive psychotherapy for pain (I-STOP). I-STOP will be offered 1 day/week.
32943300|NCT04736550|Experimental|Assisted Exercise and No I-STOP (TAU)|Participant will receive Assisted Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
32943301|NCT04736550|Experimental|Voluntary Exercise and No I-STOP (TAU)|Participant will receive Voluntary Rate Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
32943302|NCT04736550|No Intervention|No Exercise (TAU) and No I-STOP (TAU)|Participant will receive their usual behavioral treatment offered at the residential drug treatment center and their medicated assisted treatment (MAT) as applicable.
32943303|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
32943304|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
32943305|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
32943306|NCT04736472|Experimental|DPYD/UGT1A1 pharmacogenetic testing|"All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD*2A, *5, *6, *8, *9A, *10, *12, *13, rs2297595, rs115232898, rs67376798, HapB3.~All patients will be screened for two SNPs in UGT1A1: UGT1A1*6, *28."
32943307|NCT02101554|Experimental|Embeda|One arm, open label, active
32943308|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
32943309|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
32943310|NCT02128932|Active Comparator|Insulin glargine|
32943311|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
32943312|NCT04747548|Active Comparator|Kurbo Only|Participants will receive 1-month access to the Kurbo digital program.
32943313|NCT04747548|Experimental|Kurbo + PolyRules!|Participants will receive 1-month access to the Kurbo digital program and the PolyRules! app.
32943314|NCT04751682|Experimental|BBV154: Single Dose|Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on day 0 and with placebo on day 28 via intranasal route.
32943315|NCT04751682|Experimental|BBV154: Two Dose|Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on both day 0 and on day 28 via intranasal route.
32943316|NCT04751682|Placebo Comparator|Placebo|Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via intranasal route.
32943317|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
32943318|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
32943319|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
32943320|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
32943321|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
32943322|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
32943323|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
32943324|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
32943325|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
32943326|NCT04735770|Experimental|LTAP|Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.
33307726|NCT05782088|Experimental|Single Piezocision|
33307727|NCT05782088|Experimental|Repeated Piezocision|
33102506|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
33102507|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
32943327|NCT04735770|Active Comparator|Local wound analgesia|Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.
32943328|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
32943329|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
32943330|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
32943331|NCT02146326|Active Comparator|BREATHE-Clients|
32943332|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
32943333|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
32943334|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
32943335|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
32943336|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~International Prostate Symptom Score (IPSS)."
32943337|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
32943338|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
32943339|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
32943340|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
32943341|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
32943342|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
32943343|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
32943344|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
32943345|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
32943346|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
32943347|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
32943348|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
32943349|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
32943350|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
32943351|NCT02100228|Experimental|Apixaban|
32943352|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
32943353|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
33092717|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
33307728|NCT05782049|Other|Group of case patients|"Patients with Rheumatoid Arthritis~Patients with Sjögren's Syndrome"
33307729|NCT05782049|Other|Group of control patients|Patients with Sicca, Asthenia, Polyalgia Syndrome (SAPS)
32943354|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
32943355|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
32943356|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
32943357|NCT05182944|Experimental|After 2 cycles of neoadjuvant therapy,non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel +Cisplatin and Camrelizumab maintenance treatment）
32943358|NCT05182944|Active Comparator|non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
32943359|NCT05182944|Experimental|pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
32943360|NCT05182944|Active Comparator|pCR patients adjuvant treatment(BSC)|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）
32943361|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
32943362|NCT04733040|Experimental|MOR202 Arm 1|5 doses administered on Day 1, 8, 15, 29, and 57
32943363|NCT04733040|Experimental|MOR202 Arm 2|2 doses administered on Day 1 and 15
32943364|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
32943365|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
32943366|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
32943367|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
32943368|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
32943369|NCT02122146|Experimental|PF-06664178|Experimental
32943370|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
32943371|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
32943372|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
32943373|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
32943374|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
32943375|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
32943376|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
32943377|NCT02121522|Experimental|BI 144807|twice daily
32943378|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
32943379|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
32943381|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
32943382|NCT05130216||Total Knee Arthroplasty|Patients who have undergone total knee arthroplasty post one-year.
32943383|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
32943384|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
33307730|NCT05782023|Experimental|Digital empowerment|Usual-care + preventive intervention through digital empowerment
33307731|NCT05782023|No Intervention|Usual care|Usual-care (cardiologist visit at 1, 3 and 12 months after AMI)
33307732|NCT05782010|Experimental|PexyEazy procedure|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
33307733|NCT05781958|Experimental|Cadonilimab+Gem/Cis|
33307734|NCT05781945|Experimental|probiotic +|
33307735|NCT05781945|Active Comparator|standard therapy|
33307736|NCT05781932|Experimental|Histoacryl medical tissue glue|specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4[(toluene)amino]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)
33307737|NCT05781906|Experimental|HMPL-523|HMPL-523 Tablet 300 mg QD7 days followed by a single oral dose of [14C]HMPL-523 suspension
33307738|NCT05781880|Experimental|NBO group|Normobaric hyperoxia (NBO) oxygen group will be given 100% oxgen (10L/min for 4h) via a face mask.
33307739|NCT05781880|Placebo Comparator|Control group|Control group will be given nasal oxygen (2L/min for 4h）. All other therapy measures are the same as experimental group.
33307740|NCT05781867|Placebo Comparator|control|26patients will be included in this group and will receive conventional physiotherapy in form of pursed lip breathing, diaphragmatic breathing exercise and Active Range of Motion of both upper extremities
33307741|NCT05781867|Experimental|manual therapy|26patients will be included in this group and will receive manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor and major, scaleni ) and conventional physiotherapy
33307742|NCT05781854|Active Comparator|Group P (PIEB-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive programmed intermittent epidural boluses (5 ml every 45 min with the first bolus 30 minutes after epidural initiation) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
33307743|NCT05781854|Active Comparator|Group C (CEI-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive continuous epidural infusion (5 ml/h starting immediately after the loading dose) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
33307744|NCT05781841||patients with cutaneous warts|"Under complete sterile precautions, Skin biopsy will be taken from patients with wart lesion.~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
33307745|NCT05781841||healthy volunteers|"Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches .~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
33307746|NCT05781828|Other|Laboratory investigation|Complete blood count, liver function tests, prothrombin time(PT), prothrombin concentration(PC), international normalized ratio (INR), renal chemistry and electrolytes
33307747|NCT05781815|Active Comparator|DHS|patients with trochanteric fracture treated with DHS
33307748|NCT05781815|Active Comparator|DHS with Trochanteric stabilizing plate|patients with trochanteric fracture treated with DHS with trochanteric stabilizing plate
32943385|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
32943386|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
32943387|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
32943388|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
32943389|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
32943390|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
32943391|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
33307749|NCT05781789||Patient participants|"Patient booked for elective surgery and:~Age 21 to 70 years English literacy Willing to provide signed consent Of any nationality Able to give own legal consent"
33307750|NCT05781789||Healthcare provider participants|"Criteria:~Age 21 to 70 years~Healthcare professionals comprising clinic staff (surgical outpatient clinics, PAS), clinicians (anaesthetists, surgeons), and health service managers)~working in the perioperative clinical areas"
32943392|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
32943393|NCT01627860|Active Comparator|Topiramate add-on therapy|
32943394|NCT01627860|Experimental|Topiramate monotherapy|
33404461|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
32943395|NCT04745754|Experimental|Intervention Condition|The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-36 months post-treatment for comprehensive survivorship care.
32943396|NCT04745754|No Intervention|Control Condition|Usual care for breast and colorectal cancer survivors (oncology-led model).
32943397|NCT04732494|Experimental|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab (200 milligrams [mg]) plus ociperlimab (900 mg) intravenously once every 3 weeks.
32943398|NCT04732494|Placebo Comparator|Arm B: Tislelizumab plus Placebo|Participants will receive tislelizumab (200 mg) plus placebo intravenously once every 3 weeks.
32943399|NCT01627782|Placebo Comparator|Placebo 3 times/week|
32943400|NCT01627782|Experimental|Ketamine 3 times/week|
32943401|NCT01627782|Experimental|Ketamine 2 times/week|
32943402|NCT01627782|Placebo Comparator|Placebo 2 times/week|
32943403|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
32943404|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
32943405|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
32943406|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
32943407|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
32943408|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
32943409|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
32943410|NCT04745208|No Intervention|standard discharge education|The control group will receive only the standard discharge education.
32943411|NCT04745208|Experimental|standard discharge education+Simulation based education|The intervention group will receive standard discharge education and then simulation based education will be performed
32943412|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
32943413|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
32943414|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
32943415|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
32943416|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
32943417|NCT02119104||Prevenar (13v)|
32943418|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
32943419|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
33102508|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
33404462|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
33404463|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
33092718|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
32943420|NCT04744350|Active Comparator|Surgical|Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
32943421|NCT04744350|Active Comparator|Conservative|Patients will receive individually tailored physiotherapy and analgesics if necessary.
33092719|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
33092720|NCT00475098|Active Comparator|A|
33092721|NCT00475098|Experimental|B|
33092722|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
33092723|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
32943422|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
32943423|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
32943424|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
32943425|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
32943426|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
32943427|NCT02094300|Experimental|Endovascular|
32943428|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
32943429|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
32943430|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
32943431|NCT04743492|Experimental|CBT group|cognitive behavioral therapy (CBT)+routine medical care
32943432|NCT04743492|Experimental|exercise therapy group|physiotherapy-exercise therapy+routine medical care
32943433|NCT04743492|Experimental|breathe training group|using biofeedback devices to train breathing speed+routine medical care
32943434|NCT04743492|No Intervention|usual care|accepting only routine medical care
32943435|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
32943436|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
32943437|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
32943438|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
32943439|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
32943440|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
32943441|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
32943442|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
32943443|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
32943444|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
32943445|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
32943446|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
32943447|NCT02092662||Stroke|Stroke patients at the subacute phase
32943448|NCT02092662||Healthy controls|healthy age-matched voluntiers
32943449|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
32943450|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
32943451|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
32943452|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
32943453|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
32943454|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
32943455|NCT04726020|Experimental|Intensive monitoring|Intensive phone monitoring of drug adverse events
32943456|NCT04726020|Placebo Comparator|Standard monitoring|Standard monitoring of drug adverse events
32943457|NCT01626690|Experimental|Pre-Warming|
32943458|NCT01626690|Active Comparator|Control|
32943459|NCT01626456|Experimental|ALKS 9072, Low|
32943460|NCT01626456|Experimental|ALKS 9072, High|
32943461|NCT04742166|Experimental|Side to side gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
32943462|NCT04742166|Active Comparator|Terminolateral gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
32943463|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
32943464|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
32943465|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
32943466|NCT04742088|Experimental|Orthosis group|
32943467|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
32943468|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
32943469|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
32943470|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
32943471|NCT04731558|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
32943472|NCT04731558|Other|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
32943473|NCT04183920|Active Comparator|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
32943474|NCT04183920|Active Comparator|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
32943475|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
32943476|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~placebo"
32943477|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
32943478|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
32943479|NCT04730856|Active Comparator|Tinzaparin 4500 UI/day|Procedure: Tinzaparin 4500 UI/day SC until hospital discharge.
32943480|NCT04730856|Active Comparator|Tinzaparin 100 UI/Kg/day|Procedure: Tinzaparin 100 UI/Kg/day SC until hospital discharge.
32943481|NCT04730856|Active Comparator|Tinzaparin 175 UI/Kg/day|Procedure: Tinzaparin 175 UI/Kg/day SC until hospital discharge.
32943482|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
32943483|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
33092724|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
32799971|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
32799972|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
32799973|NCT01712685|Experimental|Renal Cell Carcinoma|
32799974|NCT04195516|Experimental|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
32799975|NCT04195516|No Intervention|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
32799976|NCT05103267||Tauropace in high risk participants|"TauroPace™ is a CE marked (certified) medical device defined as a Disinfecting Solution to Eradicate Airborne Microbial Contamination on the Surface of Cardiac Impiantable Electronic Devices (CIED).~TauroPace™ is to eradicate environmental microbial contamination on the surface of any CIED during implantation or revision procedure.~TauroPace™ is intended to be used during CIED surgery procedure in any adult participant at high risk of CIED infections"
32799977|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
32799978|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
32799979|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
32799980|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
32799981|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
32799982|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
32799983|NCT04196998|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
32799984|NCT04196998|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
32799985|NCT04196998|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
32799986|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
32799987|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
32799988|NCT04196452||Arm A: participants 12 to under 18|
32799989|NCT04196452||Arm B: participants under 12|
32799990|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
32799991|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
32799992|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
32799993|NCT03956056|Experimental|Neoantigen Peptide Vaccine|The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
32799996|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
32799997|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
32799998|NCT03992950|Experimental|Cricoid pressure|Cricoid pressure is applied in the anesthetized state and during video laryngoscopy
32799999|NCT03992950|Experimental|Paratracheal pressure|Paratracheal pressure is applied in the anesthetized state and during video laryngoscopy
32800000|NCT04028206|No Intervention|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
32800001|NCT04028206|Active Comparator|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
33092725|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
33092726|NCT00475293|Experimental|1|
33092727|NCT00475371|Experimental|1|MKC253 Inhalation Powder
33092728|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
33092729|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
33092730|NCT00475410|Experimental|ASCs|
33092731|NCT00475410|Experimental|ASCs+fibrin glue|
32800002|NCT04028206|Active Comparator|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
32800003|NCT04601649|Experimental|Intervention|Participants will take part in the PrEP Talk intervention sessions.
32800004|NCT04601649|No Intervention|Control|Participants will receive standard care.
32800005|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
33092732|NCT00475410|Active Comparator|Fibrin glue|
32800006|NCT03967054|Experimental|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
33092733|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
33092734|NCT00475527|No Intervention|iron only|Only iron therapy
33092735|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
33092736|NCT00439049||A|Cocaine Dependent Subjects
33092737|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
32800007|NCT03967054|Placebo Comparator|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
32800008|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
32800009|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
32800010|NCT03590236|No Intervention|Control group|Waiting list patients
32800011|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
33092738|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
33092739|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
33092740|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
33092741|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
33092742|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
33092743|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
33092744|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
33092745|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
33092746|NCT00439322||Group 1|
33092747|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
33092748|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
33092749|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
33092750|NCT00475917|Experimental|1|
33092751|NCT00439400|Active Comparator|A|
33092752|NCT00439400|Placebo Comparator|B|
33092753|NCT00475956|Experimental|1|AZD2171 Monotherapy
33092754|NCT00475956|Experimental|2|AZD2171 + AZD0530
33092755|NCT00439439|Sham Comparator|A|Sham Procedure
33092756|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
33092757|NCT00439595|Experimental|1|Hemocue 210 meter
33092758|NCT00439595|Experimental|2|Copack HBCS
33092759|NCT00439595|No Intervention|3|Control
33092760|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
33092761|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks~Pembrolizumab will be administered through IV infusion"
33092762|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
33092763|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
33092764|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
33092765|NCT00105989|Experimental|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
33092766|NCT00105989|Placebo Comparator|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
33092767|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
33092768|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
33092769|NCT00476385|Experimental|somatropine|
33092770|NCT00476424|Active Comparator|1|400 mg EFV
33092771|NCT00476424|Active Comparator|2|600 mg EFV
33092772|NCT00439712|Experimental|Treatment Group 1|
33092773|NCT00439712|Placebo Comparator|Treatment Group 2|
33092774|NCT00476463|Active Comparator|1|AZT+FTC+EFV
33092775|NCT00476463|Active Comparator|2|TDF+FTC+EFV
33404464|NCT03697408|Experimental|Itacitinib and everolimus|
33404465|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
33404466|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
33092776|NCT00439751|Other|Immediate ADT|
33092777|NCT00439751|Other|Deferred ADT|
33092778|NCT03270891|Active Comparator|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
33092779|NCT03270891|Experimental|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
33092780|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
33092781|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
33092782|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
33092783|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
33092784|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
33092785|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
33092786|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
33092787|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
33092788|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
33092789|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
33092790|NCT03277248|Experimental|Ublituximab + Oral Placebo|Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
33092791|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
33092792|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
33092793|NCT00439907|Active Comparator|End-to-end|End-to-end repair
33092794|NCT00439907|Active Comparator|Overlap|Overlap repair
33092795|NCT03279822||Group|
33092796|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
33092797|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
33092798|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
33092799|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
33092800|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
33092801|NCT00476502||1|patients involved in structured interruption therapy
33092802|NCT00438282|No Intervention|1|Control group
33092803|NCT00438282|Experimental|2|Paraprofessional home visits
33092804|NCT00438282|Experimental|3|Nurse home visitation
33092805|NCT00440102|Active Comparator|1|ketamine
33092806|NCT00440102|Active Comparator|2|Etomidate
33092807|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
33092808|NCT00476541|No Intervention|2|No further therapy
33092809|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
33092810|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
33092811|NCT00440141|Experimental|1|
33092812|NCT00440141|Active Comparator|2|
33092813|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
33102509|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
33102510|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
33404467|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
33092814|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
33307751|NCT05781763|Experimental|HIIT-intervention group|12 weeks of structured high intensity interval training followed by 9 month of self-selected training
33307752|NCT05781763|Active Comparator|Control group|Continuing with their usual exercise habits during 12 months
33092815|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
33092816|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
33092817|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
33092818|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
33092819|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
33092820|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
33092821|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
33092822|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
33092823|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
33092824|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
33092825|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
33092826|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
33092827|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
33092828|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
33092829|NCT00438516|No Intervention|1|Control group
33092830|NCT00438516|Experimental|2|Nurse home visitation
33092831|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
33092832|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
33092833|NCT04700930|Experimental|CBD|Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
33307753|NCT05781737||Ulcerative colitis|
33092834|NCT04700930|No Intervention|Non-CBD|Patients recieve standard psychiatric care including neuroleptic medication
33092835|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
33092836|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
33092837|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
33092838|NCT00440414|Experimental|1|Alimta
33092839|NCT00440414|Experimental|2|Tarceva
33092840|NCT00440453|No Intervention|1|Normal hospital food
33092841|NCT00440453|Experimental|2|Nutritional treatment
33092842|NCT00438594|No Intervention|Control group|Control group
33092843|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
33092844|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
33092845|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
33092846|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
33307754|NCT05781737||Crohn disease|
33307755|NCT05781737||Control group|
33307756|NCT05781711|Experimental|Control Group|Control group ( Levo-dopa group, n =30 ) who will receive levodopa/carbidopa (50/250 mg) two times daily for 3 months
33307757|NCT05781711|Active Comparator|Metformin group|Patients will receive levodopa/carbidopa (50/250 mg) two times daily plus metformin 850 mg two times daily for 3 months
33307758|NCT05781698|Active Comparator|Control Group|The control group ( Mesalamine group, n =35 ) will receive 1 g mesalamine three times daily for 6 months
33307759|NCT05781698|Active Comparator|Fenofibrate group|Patients will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
33307760|NCT05781685|Experimental|Testosterone|Sublingual testosterone
33307761|NCT05781685|Placebo Comparator|Placebo|Placebo
32943484|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
32943485|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
32943486|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
32943487|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
32943488|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
32943489|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
33307762|NCT05781659|Experimental|Ultrasound elastography guided pleural biopsy group|
33307763|NCT05781659|Experimental|Traditional ultrasound-guided pleural biopsy group|
33307764|NCT05781646|Experimental|Xpert|Centrifuged CSF sent for Xpert MTB/RIF
33307765|NCT05781633|Experimental|eutidrone+ etoposide+ bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.
33307766|NCT05781620|Experimental|Vitamin D group|
33307767|NCT05781620|Placebo Comparator|Placebo group|
33307768|NCT05781607||PE|Patient education combined with drug therapy group
33307769|NCT05781607||PT|Individualized comprehensive physical therapy group
33307770|NCT05781555|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
32943490|NCT02070978|Experimental|Atacicept 75 mg|
33307771|NCT05781542|Experimental|Group 1|a total of approximately 9 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 0.4 mg, coformulated with IL-12 DNA at a dose of 0.1 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
32943491|NCT02070978|Experimental|Atacicept 150 mg|
32943492|NCT02070978|Experimental|Placebo/Atacicept 150 mg|
32943493|NCT04725630|Experimental|Subsidized Healthy Food Prescription Incentive|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider and a weekly incentive of $10.50/household member to purchase healthy foods in supermarkets for 12 months. The list of incentive-eligible foods includes whole, minimally processed foods with little to no added fat, sugar or salt from all food groups.
32943494|NCT04725630|Active Comparator|Healthy Food Prescription Comparison|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider. The pamphlet closely mimics current standard of care for patients with diabetes in Alberta (i.e., nutrition counselling).
32943495|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
32943496|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
32943497|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
33307772|NCT05781542|Experimental|Group 2|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
33307773|NCT05781542|Experimental|Group 3|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. These doses will be administered intradermally via EP of the skin on each upper arm. All participants in Group 3 will also receive 2 administrations of Trimer 4571 at a dose of 100 mcg adjuvanted with 5 mcg of 3M-052-AF + 500 mcg Alum via IM injections into the deltoid muscle at days 85 and 169
33307774|NCT05781529|Experimental|Injectable platelets rich fibrin|Injectable platelets rich fibrin was prepared where 10 ml of patient venous blood was centrifuged without anti-coagulants (plain plastic glass-coated) at 700 rpm speed for only 3 minutes, xenograft was mixed with I-PRF to make sticky bone, sticky bone was placed into extraction socket till the socket was fully filled up to the gingival margin
33307775|NCT05781529|Experimental|Hyaluronic acid|Hyaluronic acid (HA) syringe containing 1 mL of cross-linked hyaluronic at a concentration of 20 mg/ml in a saline phosphate buffer solution at sterilized content was used. HA was mixed with particulate xenograft 1:10 ratio to form a putty consistency for condensation and was placed into extraction socket till the socket was fully filled up to the gingival margin
33307776|NCT05781529|Active Comparator|Xenograft|Xenograft was mixed with saline, placed in extraction socket till the socket is fully filled up to the gingival margin
33307777|NCT05781503|Experimental|Portable Rent Subsidies + Identity Capital Intervention|Young people randomized to the intervention group will receive 12 months of: portable rent subsidies, engage in a co-designed leadership guide, and be assigned a coach (one coach/10 youth).
33307778|NCT05781503|Active Comparator|Portable Rent Subsidies Only|The control group will be offered 12 months of portable rent subsidies.
33307779|NCT05781490|Experimental|Lumentin® 44|Lumentin® 44 Powder for oral foam
33307780|NCT05781477|Experimental|Bmum GROUP|Mothers in this group were given supportive breastfeeding support with web based
33092847|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
32943498|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
32943499|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
32943500|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
33404468|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
32943501|NCT02089230|Experimental|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
32943502|NCT02089230|Experimental|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
32943503|NCT02089230|Experimental|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
32943504|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
32943505|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
32943506|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
32943507|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
32943508|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
32943509|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
32943510|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
32943511|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
32943512|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
32943513|NCT04741698|Active Comparator|Propranolol 2mg IV|"At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.~The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes."
32943514|NCT04741698|No Intervention|No intervention|At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention
32943515|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
32943516|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
32943517|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
32943518|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
32943519|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
32943520|NCT02087904|Placebo Comparator|Placebo|Placebo
32943521|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
32943522|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
32943523|NCT02087046|Other|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
32943524|NCT04729530|Active Comparator|Active|Air purifier device with standard filter cartridges installed.
32943525|NCT04729530|Placebo Comparator|Placebo|Air purifier device with placebo (non working) filter cartridges installed.
32943526|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
32943527|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
32943528|NCT04729218||Familial Mediterranean Fever group|30 participants
32943529|NCT04729218||Healthy group|30 participants
32943530|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
33092848|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
33092849|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
33092850|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
33092851|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
33307781|NCT05781477|No Intervention|control group|Mothers in the control and intervention groups were given standard care based on the Baby-Friendly Hospital Intervention Standard.
33307782|NCT05781464|Placebo Comparator|Traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) in each session which is twice daily from admission to neonatal intensive care unit till discharge
32943531|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
33092852|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
33092853|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
33092854|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
33307783|NCT05781464|Active Comparator|Prolonged slow expiration technique and traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) plus prolonged slow expiration technique in each session which is twice daily from admission in neonatal intensive care unit till discharge.
32800012|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
32800013|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
32943532|NCT04418076|Experimental|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
32943533|NCT04418076|Experimental|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
32943534|NCT04418076|Experimental|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
32943535|NCT04418076|Experimental|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
32943536|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
32943537|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
32943538|NCT04417686|Experimental|patient|
32943539|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
32943540|NCT04724694|Experimental|Brief CBT for Chronic Pain and treatment as usual|Participants will receive Brief CBT-CP in addition to usual primary care treatment. Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
32943541|NCT04724694|Other|Treatment as usual only|Participants assigned to treatment as usual will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
32943542|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
32943543|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
32943544|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
32943545|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
32943546|NCT02083926|Experimental|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
32943547|NCT02083926|Experimental|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
32943548|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
32943549|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
32943550|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
32943551|NCT02109744|Experimental|Decitabine followed by rapamycin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
33092855|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
33092856|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
33092857|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
33092858|NCT00440843|Experimental|OLZ|
33092859|NCT00440843|Active Comparator|Typicals|
33307784|NCT05781451|Experimental|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
33092860|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
33092861|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
33092862|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
33307785|NCT05781438|Experimental|In-home standing and walking intervention|Infants will participate in the in-home standing and walking intervention for 16 weeks. In addition, infants will continue with any intervention in the community recommended by their health care team.
33092863|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
33092864|NCT00438867|Experimental|1|
33092865|NCT00438867|Experimental|2|
32800014|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
33092866|NCT00438867|Placebo Comparator|3|
33092867|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
33307786|NCT05781412|Active Comparator|ASD_anodalstimulation|ASD participant, anodal stimulation on the first session, sham stimulation on the second sesion
33307787|NCT05781412|Sham Comparator|ASD_shamstimulation|ASD participant, sham stimulation on the first session, anodal stimulation on the second sesion
33307788|NCT05781412|Active Comparator|NT_anodalstimulation|Neurotypical participant, anodal stimulation on the first session, sham stimulation on the second sesion
33307789|NCT05781412|Sham Comparator|NT_shamstimulation|Neurotypical participant, sham stimulation on the first session, anodal stimulation on the second sesion
33307790|NCT05781412|Active Comparator|H-AQ_anodalstimulation|non diagnosed autistic participant,anodal stimulation on the first session, sham stimulation on the second sesion
32800015|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
32800016|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
32800017|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
32800018|NCT04196296|Active Comparator|Psychoeducation|
32800019|NCT04196296|Experimental|Psychoeducation plus Motivation Enhancement|
32800020|NCT04552743|Experimental|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
33092868|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
33092869|NCT00106002|Experimental|A|
33092870|NCT00476853|Active Comparator|1|NVP 400 mg
33092871|NCT00476853|Active Comparator|2|NVP 600 mg
33092872|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
33092873|NCT00441311|No Intervention|Service-as-Usual|Control Arm
33092874|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
33102511|NCT04687332|Experimental|plasma exchange|patients were treated with plasma exchange
33102512|NCT04687332|Experimental|immunadsorption|patients were treated with immunadsorption
33307791|NCT05781412|Sham Comparator|H-AQ_shamstimulation|non diagnosed autistic participant, sham stimulation on the first session, anodal stimulation on the second sesion
33307792|NCT05781399|Experimental|JNT-517 SAD (Part A)|Single dose of JNT-517 or placebo in fasted state.
33307793|NCT05781399|Experimental|JNT-517 MAD (Part B)|JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.
33307794|NCT05781399|Experimental|JNT-517 Suspension Then Tablet Fasted Then Tablet Fed (Part C)|Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
33307795|NCT05781399|Experimental|JNT-517 Tablet Fasted Then Tablet Fed Then Suspension (Part C)|Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
33307796|NCT05781399|Experimental|JNT-517 Tablet Fed Then Suspension Then Tablet Fasted (Part C)|Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
33307797|NCT05781399|Experimental|JNT-517 PKU (Part D)|JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.
33092875|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
33092876|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
33092877|NCT04700852|Experimental|allergic rhinitis|Puressentiel protective nasal spray
33092878|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
33092879|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
33092880|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
33092881|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
33092882|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
33092883|NCT00439101|Experimental|1|
33092884|NCT00439101|Placebo Comparator|2|Placebo
33092885|NCT00441740|Experimental|1|VG
33092886|NCT00441740|Experimental|2|DG
33092887|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
33092888|NCT00441779||1|Traumatic injury
33092889|NCT00441779||2|Elective orthopedic surgery
33092890|NCT00441779||3|Burn injury
33307798|NCT05781386|Experimental|SIM1811-03 monotherapy|All participants receive SIM1811-03 alone
33307799|NCT05781373|No Intervention|Fixed PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and fixed PEEP¨level of 6 cmH2O
33307800|NCT05781373|Experimental|Individualized PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and individualized PEEP¨level in order to achieve the lowest driving pressure
33307801|NCT05781360|Experimental|Experimental: PART ONE- Dose escalation|The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of SIM0237 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
33307802|NCT05781360|Experimental|Experimental: PART TWO- Dose expansion|Patients will be administered a recommended dose of SIM0237 established from the Dose Escalation Phase of the study.
33307803|NCT05781347|Active Comparator|Obese patients receiving Stretta|
33307804|NCT05781347|No Intervention|Obese patients receiving Conservative therapy/PPI|
33307805|NCT05781347|Active Comparator|Non-obese patients receiving Stretta|
33307806|NCT05781347|No Intervention|Non-obese patients receiving Conservative treatment/PPI|
33307807|NCT05781334|Active Comparator|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications.
33307808|NCT05781334|No Intervention|Usual Care|Usual care
33307809|NCT05781308|Other|Arm A: paclitaxel + bevacizumab|Bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
32800021|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
32800022|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
32800023|NCT03971422|Experimental|Dosage Regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
32800024|NCT03971422|Experimental|Dosage Regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
32800025|NCT03971422|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo.
32800026|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
33092891|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
33092892|NCT00477126|Active Comparator|1|start generic product cross over to reference product
33092893|NCT00477126|Active Comparator|2|start reference product cross over to generic product
33092894|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
33092895|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
33092896|NCT00439257||Group 1|
33092897|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
33092898|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
33092899|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
33092900|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
33092901|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
33307810|NCT05781308|Experimental|Arm B: paclitaxel + bevacizumab + atezolizumab|Atezolizumab 1200 mg, bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
32800027|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
32800028|NCT04021108|Other|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
32800029|NCT04021108|Experimental|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
32800030|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
32800031|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
32800032|NCT03594058|Experimental|Solabegron modified release tablets low dose|
32800033|NCT03594058|Experimental|Solabegron modified release tablets high dose|
32800034|NCT03594058|Placebo Comparator|Placebo Comparator|
32800035|NCT01712061|Active Comparator|Arm 1 PF-04634817|
32800036|NCT01712061|Placebo Comparator|Arm 2 Placebo|
32800037|NCT03591094|Active Comparator|PTI-428 dose level 1|
32800038|NCT03591094|Active Comparator|PTI-428 dose level 2|
32800039|NCT03591094|Placebo Comparator|Placebo PTI-428|
32800040|NCT03970954|Experimental|1|Low-dose IL-2
32800041|NCT03970720|Experimental|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
32800042|NCT03970720|Placebo Comparator|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
32800043|NCT03970720|Placebo Comparator|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
32800044|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
32800045|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
32800046|NCT03592186|Active Comparator|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
32943552|NCT02109744|Experimental|Decitabine followed by ribavirin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
33092902|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
33307811|NCT05781295|Experimental|TauroLock™|The patient will be followed up to a maximum of 6 months after randomization after have a Taurlock™ injected each time catheter will be used.
33092903|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
33092904|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
33307812|NCT05781295|Placebo Comparator|Physiological serum (NaCl 0.9%)|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
33307813|NCT05781269|Experimental|VLCKD-group|The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.
32943553|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~Self-directed Pedal Desk~Facilitated Pedal Desk~Facilitated Pedal Desk with Pedometer"
32943554|NCT04723602|Active Comparator|cAd3-Marburg at 1 x 10^11 Particle Units (PU)|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
32943555|NCT04723602|Active Comparator|cAd3-EBO-S at 1 x 10^11 PU vaccine|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
32943556|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
32943557|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
32943558|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
32943559|NCT02108964|Experimental|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
32943560|NCT02108964|Experimental|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
32943561|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
32943562|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
32943563|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
32943564|NCT04185402|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
33307814|NCT05781269|Experimental|r-MedDiet|The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement
33307815|NCT05781243|Experimental|Lactated Ringer solution (LR)|LR: Lactated Ringer solution. Patients in the LR treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
33307816|NCT05781243|Active Comparator|Normal saline (NS)|NS: Normal Saline. Patients in the NS treatment arm will receive fluid therapy based on normal saline for a minimum of 48 hours.
33307817|NCT05781230|Experimental|HIE program|HIE program ; High Intensity Exercises Program. 3 sets of 15 repetition
33307818|NCT05781230|Experimental|LIE Program|Low Intensity Exercises program 2 sets of 8 repetition
33307819|NCT05781217|Active Comparator|short-term ADT (6 months)|"ARM 1:~LHRH analogues for 6 months + bicalutamide 50 for 30 days"
32943565|NCT04185402|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
32943566|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
32943567|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
32943568|NCT04728360|Experimental|BAT2206|"Patients who weigh ≤ 100 kg: BAT2206 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
32943569|NCT04728360|Active Comparator|Stelara (EU-sourced)|"Patients who weigh ≤ 100 kg: EU-sourced Stelara 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
32943570|NCT02066298|Experimental|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
32943571|NCT02066298|Experimental|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
32943572|NCT02066298|Experimental|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
32943573|NCT02066298|Experimental|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
32943574|NCT02066298|Experimental|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
32943575|NCT02066298|Experimental|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
32943576|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
32943577|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
32943578|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
32943579|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
32943580|NCT04723446|Experimental|Group 1 (test group; n= up to 10 patients) - 0.2 % Chlorhexidine digluconate|Participants will be instructed to rinse their mouth with 10 ml of Corsodyl® Alcohol free mouthwash for 1 minute.
32943581|NCT04723446|Experimental|Group 2 (test group; n= up to 10 patients) - 1.5% Hydrogen peroxide|Participants will be instructed to rinse their mouth with 10 ml of Colgate® Peroxyl mouthwash for 1 minute.
32943582|NCT04723446|Experimental|Group 3 (test group; n= up to 10 patients) - Cetylpyridinium chloride|Participants will be instructed to rinse their mouth with 10 ml of Oral-B® Gum & Enamel Care mouthwashes for 1 minute.
32943583|NCT04723446|Experimental|Group 4 (control group; n= up to 10 patients) - No rinsing|Patients will be instructed to not rinse their mouth with any solution, not even water.
32943584|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
32943585|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
32943586|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
32943587|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
32943588|NCT01624974|Experimental|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
32943589|NCT01624974|Experimental|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
32943590|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
33307820|NCT05781217|Active Comparator|long-term ADT (24 months)|LHRH analogues for 24 months + bicalutamide 50 for 30 days
33307821|NCT05781191||Employees|
32943591|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
32943592|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
32943593|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
32943594|NCT01624662|Active Comparator|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
32943595|NCT01624662|Active Comparator|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
32943596|NCT01624662|Active Comparator|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
32943597|NCT01624662|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
32943598|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
32943599|NCT01624506||Fundoplication|Patients treated with laparoscopic fundoplication
32943600|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
32943601|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
32943602|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
32943603|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
32943604|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
32943605|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
32943606|NCT04707768|Experimental|Vadadustat low dose|Participants previously receiving Mircera® will receive a low dose of vadadustat for up to 52 weeks.
32943607|NCT04707768|Experimental|Vadadustat high dose|Participants previously receiving Mircera® will receive a high dose of vadadustat for up to 52 weeks.
32943608|NCT04707768|Active Comparator|Mircera®|Participants will continue to receive Mircera® for up to 52 weeks.
32943609|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
32943610|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
32943611|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
32943612|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
32943613|NCT02081196|Experimental|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
32943614|NCT02064816|Experimental|Rebif® Morning Administration|
32943615|NCT02064816|Experimental|Rebif® Evening Administration|
32943616|NCT02080260|Experimental|Single Arm|Oral Regorafenib
33307824|NCT05781152||Anti-tumor necrosis factor (TNF)|Patients newly diagnosed with pediatric-onset Crohn's disease starting anti-TNF therapy within 6 months of diagnosis
33307825|NCT05781139||Early onset Alzhiemer|before age of 65 and above age of 50
33307826|NCT05781139||Late onset Alzhiemer|Above the age of 65
33307827|NCT05781139||Vascular dementia|Any patient diagnosed with vascular dementia
33307828|NCT05781139||control group|persons who has no dementia
33307829|NCT05781100||Study Cohort|345 women will be recruited during the 3rd trimester of pregnancy, then mother-infant dyads will be assessed 1, 4, 6, 9, and 12 months postpartum. Inclusion criteria are: women with singleton, low-risk pregnancies and infants born term with no major health or feeding concerns
33307830|NCT05781087||Standard of care|Patients after ST-elevation myocardial infarction with non-culprit coronary artery disease.
32907085|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
33092905|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
33092906|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
33092907|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
33092908|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
33092909|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
33092910|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
33092911|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
33092912|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
33092913|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
33092914|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
33092915|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
33092916|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
33092917|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
33092918|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
33092919|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
33092920|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
33092921|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
33092922|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
33092923|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
33092924|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
33092925|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
33092926|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
33092927|NCT00442091|Other|10 ml of dandelion juice twice daily|
33092928|NCT00477282|Experimental|Karenitecin|
33092929|NCT00477282|Active Comparator|Topotecan|
33092930|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
33092931|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
33092932|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
33092933|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
33092934|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
33092935|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
33092936|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
33092937|NCT00439686|Experimental|Single Arm|
33092938|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
33092939|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
33092940|NCT00477360|Experimental|1|C.A.P
33092941|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
33092942|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
33092943|NCT03279744|Experimental|Single-Arm|Radion™-pdt
33092944|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
33307831|NCT05781061|Experimental|Asynchronous Screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
33307832|NCT05781048|Experimental|HRS-6209|
33307833|NCT05781035|Active Comparator|dexmedetomidine group|
33307834|NCT05781035|Active Comparator|general anesthesia group|
32943617|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
33307835|NCT05781022|Active Comparator|group (1) endoscopic group|"For patients in EG, we began with assessment of the site & size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
32943618|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
32943619|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32943620|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32943621|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32943622|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32943623|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32943624|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
32943625|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
32943626|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
32943627|NCT02077374|Placebo Comparator|Placebo|Placebo BID
32943628|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
32943629|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
32943630|NCT02047110|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
32943631|NCT02047110|Experimental|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
32943632|NCT02047110|Experimental|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
32943633|NCT02047110|Experimental|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
32943634|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
32943635|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
32943636|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
33307836|NCT05781022|No Intervention|group (2) surgical group|surgical repair of perforation after adequate drainage
33307837|NCT05781009|Active Comparator|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
32943637|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
32943638|NCT04704570|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
33092945|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
33092946|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
33092947|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
33092948|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
32943639|NCT04704570|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
32943640|NCT04704570|Other|Remotely assessment Group-Face to Face Assessment Group|First, a remote evaluation and then a face to face evaluation will be made.
32943641|NCT04704570|Other|Face to Face Assessment Group-Remotely assessment Group|First, a facet o face evaluation and then a remote evaluation will be made.
33092949|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
33092950|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
33092951|NCT00477477|Experimental|1|Low glycemic load diet
33404469|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
32943642|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
32943643|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
32943644|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
32943645|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
32943646|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
32943647|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
32943648|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
32943649|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
32943650|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
32943651|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
32943652|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
32943653|NCT04180722|Experimental|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
32943654|NCT04180722|No Intervention|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
32943655|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
32943656|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
32943657|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
32943658|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
33092952|NCT00477477|Active Comparator|2|Low fat diet
33092953|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
33092954|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
33092955|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
33092956|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
33092957|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
33092958|NCT00477516|Experimental|1|
33092959|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
33092960|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
33092961|NCT00477711|Experimental|C225+Chemotherapy|
33092962|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
33092963|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
33092964|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
33092965|NCT00439803|Active Comparator|T1|
33092966|NCT00439803|Placebo Comparator|C1|
33092967|NCT00439803|Active Comparator|T2|
33092968|NCT00439803|Placebo Comparator|C2|
33092969|NCT00439803|Active Comparator|T3|
33092970|NCT00439803|Placebo Comparator|C3|
33092971|NCT00439803|Active Comparator|T4|
33404470|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
33092972|NCT00439803|Placebo Comparator|C4|
33092973|NCT00442442|No Intervention|1|No treatment control
33092974|NCT00442442|Active Comparator|2|LLIN Nets
33092975|NCT00442442|Experimental|3|Mosquito Coils
33092976|NCT00442442|Experimental|4|Mosquito coils & LLIN
33092977|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
33092978|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
33092979|NCT00442520||2|colorectal cancer patients
33092980|NCT00442520||3|head and neck cancer patients
33092981|NCT00442520||1|lung cancer patients
33092982|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
33092983|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
33092984|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
33092985|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
33092986|NCT00442637|Experimental|1|observation
33092987|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
33404471|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
33092988|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
33092989|NCT00442676|Placebo Comparator|2|Placebo
33092990|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
33092991|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
33092992|NCT00442793|Experimental|1|
33092993|NCT00442793|Active Comparator|2|
33092994|NCT00439920|Experimental|High-dose anthracycline|
33092995|NCT00442832|Experimental|TD-1792|
33092996|NCT00442832|Active Comparator|Vancomycin|
33092997|NCT00477984|Experimental|A|alcohol and placebo
33092998|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
33092999|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
33093000|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
33093001|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
33093002|NCT00442949|Active Comparator|2|Catheterization immediate PCI
33093003|NCT00442949|Experimental|1|delayed PCI
33093004|NCT04701099||On ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.
33093005|NCT04701099||Off ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.
33093006|NCT00443027|Experimental|Vaginal Heat Wash-Out Device|
33093007|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
33093008|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
33093009|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
33093010|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
33093011|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
33093012|NCT00440154|Placebo Comparator|6|oral administration
33093013|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
33093014|NCT00478374|Experimental|1|
33093015|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
33093016|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
33307838|NCT05781009|Placebo Comparator|placebo|Patients randomly assigned to receive a placebo daily.
32943659|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
32943660|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
32943661|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
32943662|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
32943663|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
32943664|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
32943665|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
32943666|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
32943667|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
32943668|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
32943669|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
32943670|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
32943671|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
32943672|NCT01622088|Experimental|Dexpramipexole|Dexpramipexole open-label
32943673|NCT01621542|Experimental|WT2725|WT2725; injection
32943674|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
32943675|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
32943676|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
32943677|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
32943678|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
32943679|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
32943680|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943681|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943682|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943683|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943684|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943685|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943686|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943687|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943688|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943689|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
32943690|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
32943691|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
32943692|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
32943693|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
32800047|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
32800048|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
32800049|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
32800050|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
32800051|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
32800052|NCT04195282|Active Comparator|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
32800053|NCT04195282|Experimental|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
32800054|NCT04020874|No Intervention|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
32800055|NCT04020874|Experimental|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
32800056|NCT04020874|Experimental|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
32800057|NCT04029766|Experimental|HSK3486|0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
32800058|NCT04193644|Active Comparator|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
32800059|NCT04193644|Experimental|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
32800060|NCT04193644|No Intervention|TAU-Group|Participants in this group receive no intervention.
32800061|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
32800062|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
32800063|NCT04195126|No Intervention|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
32800064|NCT04195126|Active Comparator|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
32800065|NCT04190290|Experimental|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
32800066|NCT04190290|Active Comparator|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
32800067|NCT04194736|Experimental|Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
32800068|NCT04198558|Experimental|Dose Level 1|MEDI0618 or placebo
32800069|NCT04198558|Experimental|Dose Level 2|MEDI0618 or placebo
32800070|NCT04198558|Experimental|Dose Level 3|MEDI0618 or placebo
32800071|NCT04198558|Experimental|Dose Level 4|MEDI0618 or placebo
32800072|NCT04198558|Experimental|Dose Level 5|MEDI0618 or placebo
32800073|NCT04198558|Experimental|Dose Level 6|MEDI0618 or placebo
32800074|NCT04198558|Experimental|Dose Level 7|MEDI0618 or placebo
32800075|NCT04198558|Experimental|Dose Level 8|MEDI0618 or placebo
32800076|NCT04198558|Experimental|Dose Level 9|MEDI0618 or placebo
32800077|NCT04197544|Experimental|Intervention group|
32800078|NCT04197544|No Intervention|Control group|
32800079|NCT04194892|Experimental|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
32800080|NCT04194892|Experimental|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
32800081|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
32800082|NCT04197778|Experimental|group A|
32800083|NCT04197778|Experimental|group B|
32800084|NCT04028830|Experimental|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
32800085|NCT04028830|Experimental|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
32800086|NCT04028830|No Intervention|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
32800087|NCT04194658|Active Comparator|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
32800088|NCT04194658|No Intervention|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
32800089|NCT04198012|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
32800090|NCT04194502|Other|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
32800091|NCT04194580|Experimental|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
32800092|NCT04194580|No Intervention|Physical activity control|This group will not participate in the intervention
32800093|NCT04028518|Experimental|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
32800094|NCT04028518|Experimental|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
32800095|NCT04028518|Experimental|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
32800096|NCT03023956||ANF|anatomic neck fractures of proximal humerus
32800097|NCT03023956||SNF|surgical neck fractures of proximal humerus
32800098|NCT04028440|Experimental|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1~2×10e9 γδT cells (constant dose).
32800099|NCT04748068|Experimental|Glidesheath Slender|The transradial procedure will be performed using the 7-Fr glidesheath slender (studied sheath)
32800100|NCT04748068|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 7- French radial sheath (comparator sheath)
32800101|NCT04194268|Experimental|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
32800102|NCT04190212|Experimental|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
32800103|NCT04190212|No Intervention|Standard care|Participants will not participate in on-site supervised exercise sessions.
32800104|NCT04194034|Experimental|TG6002 and flucytosine (5-FC) combination|
32800105|NCT04190914|Active Comparator|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
32800106|NCT04190914|Experimental|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
32800107|NCT04190914|Experimental|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
32800108|NCT01711983|Experimental|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
32800109|NCT04027972|Experimental|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
32800110|NCT04028128|Experimental|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
33404472|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
32800111|NCT04028128|Placebo Comparator|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
32800112|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.~No Active Infection~No loss of buccal plate~ASA 1 or ASA 2 Patient~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.~Final Zirconia Crown delivered 3 month after healing.~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
32800113|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.~Active Infection~Loss of the buccal plate.~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 the same has the other group"
32800114|NCT04194112|Other|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
32800115|NCT04191928|Experimental|Apixaban dosing|Subjects to receive single dose of apixaban
32800116|NCT04193332|Experimental|Plus NIR optical imaging|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery
32800117|NCT04193332|No Intervention|Minus NIR optical imaging|Conventional identification of parathyroid glands during thyroid surgery
32800118|NCT04193722|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
32800119|NCT04193722|No Intervention|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
32800120|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score <2 (other than respiratory component)
32800121|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
32800122|NCT04193800||Rotational paramedic pilot group|
32800123|NCT04193800||Paramedic control group|
32800124|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
32800125|NCT04027582|Active Comparator|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
32800126|NCT04027582|Active Comparator|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
32800127|NCT04199884|Experimental|Active IU-focused Psychoeducation Intervention|
32800128|NCT04199884|Active Comparator|Health-focused Psychoeducation Intervention|
32800129|NCT03969706|Experimental|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
32800130|NCT04199806|Other|Questionnaire Review|
32800131|NCT04027504|Experimental|Fitabisc|Participants receiving fitabisc preoperatively
32800132|NCT04027738|Experimental|PRP injection|The patients received a single 3-ml injection of PRP.
32800133|NCT03964792|Experimental|DREPAGLOBE drug product|The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.
32800134|NCT04193488|Active Comparator|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
32800135|NCT04193488|Active Comparator|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
32800136|NCT04193488|Active Comparator|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
32800137|NCT03023098|Experimental|Drug-eluting balloon|
33404473|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
32943694|NCT04680780|Experimental|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 month
32943695|NCT04680780|Experimental|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.
32943696|NCT04680780|Placebo Comparator|Control|Patients are allowed to eat ad libitum
32943697|NCT04722354|Active Comparator|ABA group|95 ug 2x/day for 14 days
32943698|NCT04722354|Placebo Comparator|Placebo group|Corn Starch 300 mg for 14 days
32943699|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
32943700|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
32943701|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
32943702|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
32943703|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
32943704|NCT04722042|Other|Default|The default frequency filters assigned by the clinical software
32943705|NCT04722042|Experimental|Place-based|Frequency filters adjusted to align with the cochlear place frequency
32943706|NCT04721886|Experimental|Diagnostic (CEUS)|Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.
32943707|NCT04721106||Vizimpro treatment group|This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
32943708|NCT04699812|Other|COHORT 1|This will include subjects with no known history of AF
32943709|NCT04699812|Other|COHORT 2|This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)
32943710|NCT04699812|Other|COHORT 3|This will include subjects with known history of paroxysmal, persistent, or chronic AF
32943711|NCT04699812|Other|COHORT 4|Will include subjects with permanent AF
32943712|NCT04699266|Experimental|Experimental: POD F GF IOL Implantation|Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF
32943713|NCT04698252|No Intervention|Systemic therapy|Patients will receive standard of care with systemic therapy alone.
32943714|NCT04698252|Experimental|Local therapy + systemic therapy|In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.
32943715|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
32943716|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
32943717|NCT02019420|Experimental|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
32943718|NCT02019420|Active Comparator|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
32943719|NCT02019264|Experimental|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
32943720|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
32943721|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
32943722|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
32943723|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.~i. SLP will also assess the duration of successful speech during each session~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
32943724|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
33093017|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
33093018|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
32943725|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
32943726|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
33307839|NCT05780996|Active Comparator|Very high-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. In this group vHPSD (90W) will be performed. This power settings will be used for all ablation points.
33404474|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
32943727|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
32943728|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
32943729|NCT04680000|Active Comparator|Standard BCBT-CP|Brief Cognitive Behavior Therapy for Chronic Pain (BCBT-CP) is a seven-module intervention for chronic pain based on the efficacious specialty-care, ten-session version of this treatment called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP).
32943730|NCT04680000|Experimental|Standard BCBT-CP with Telephone Booster|"Participants will receive standard BCBT-CP as described in the Standard BCBT-CP arm. They will also receive telephone or video teleconference booster contacts as follows:~BCBT-CP Booster Contacts are intended to refresh BCBT-CP content without introducing new skills. To accomplish this, Booster Contacts are manualized (see appended Booster Protocol form) to cover assessment of pain since last contact, review of most recent BCBT-CP module(s) and reminder about the next BCBT-CP appointment (if one is scheduled)."
32943731|NCT02017860|Experimental|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
32943732|NCT02040870|Experimental|LDK378|daily dosing, 28-day cycle patients
32943733|NCT04697472|Experimental|Functional task practice (FTP) followed by FTP + ARC Therapy|Clinic-based functional task practice (FTP) for two months followed by FTP + ARC Therapy for an additional 2 months.
32943734|NCT04720716|Experimental|Sintilimab combined with IBI310|
32943735|NCT04720716|Active Comparator|Sorafenib|
32943736|NCT04719936|Experimental|inferior capsulotomy group|inferior capsulotomy will be conducted during posterior approach.
32943737|NCT04719936|Active Comparator|superior capsulotomy group|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
32943738|NCT04719624|Experimental|Adaptos-Si [0.5-1 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [0.5-1 mm] (synthetic bone graft material) in combination with a gelatin sponge.
32943739|NCT04719624|Experimental|Adaptos-Si [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
32943740|NCT04719624|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft) in combination with a gelatin sponge.
32943741|NCT04719624|Placebo Comparator|Empty extraction socket|Post-extraction the socket filled only by clot.
32943742|NCT04719624|Experimental|Adaptos [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
32943743|NCT04696068||Control|The patients included in this group will receive meals with the usual presentation (plastic trays) during six days. Their data will be collected at day 1 and day 6.
32943744|NCT04696068||Experimental|The patients included in this group will receive the main course in porcelain plates during six days. Their data will be collected at day 1 and day 6.
32943745|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
32943746|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
32943747|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
32943748|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
32943749|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
32943750|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
32943751|NCT02040090|Active Comparator|FDA approved HRIG product|Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.
32943752|NCT04719390|Experimental|TMI Component On|Randomized at daily time point to ON, text messaging intervention gets sent to participant at that time
32943753|NCT04719390|No Intervention|TMI Component Off|Randomized at daily time point to OFF, text messaging intervention does not get sent to participant at that time
32943754|NCT04695288||Fibromyalgia Syndrome|100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.
32943755|NCT04695288||Control subjects|60 healthy participants do not meet the exclusion criteria of the study.
32943756|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
32800138|NCT03023098|Active Comparator|Conventional PTA|
33307840|NCT05780996|Active Comparator|High-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. Ablation of the anterior aspect of the pulmonary veins will be performed with high-power short-duration (50 W) with target ablation index =550. Ablation of the posterior wall of the pulmonary veins will be performed with vHPSD (90W).
33307841|NCT05780983|Other|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
33307842|NCT05780970||Non-targeted individuals|Non-targeted children and caregivers living in the same household as the target parent/adolescent dyad. Non-targeted meaning they did not receive the TEENS+ intervention.
32800139|NCT04199650||Mild ARDS|153mmHg<PaO2/FiO2≤230mmHg
32800140|NCT04199650||Moderate ARDS|76mmHg<PaO2/FiO2≤153mmHg
33307843|NCT05780957||Firefighters who receive multi-cancer early detection (MCED) test|
33307844|NCT05780944|Experimental|Breastfeeding First, Bottle-feeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during breastfeeding. During the second visit, they will be observed during bottle-feeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
33307845|NCT05780944|Experimental|Bottle-feeding First, Breastfeeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during bottle-feeding. During the second visit, they will be observed during breastfeeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
33307846|NCT05780931||Treatment Group|This is the group of study subjects which will undergo study-related rehabilitation procedures.
33307847|NCT05780931||Control Group|This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions).
33307848|NCT05780918|Experimental|Best Case/Worst Case-ICU Communication Tool|Patients in the intervention group will receive care from a trauma team that routinely uses the Best Case/Worst Case-ICU communication tool.
33307849|NCT05780918|No Intervention|Usual Care|"Prior to implementation of the intervention, patients admitted to the trauma ICU will receive usual care. Usual care typically includes conversations focused on isolated problems, disarticulated from the patient's overall health trajectory. This is typified by the systems-base review, routinely summarizing each patient on rounds where the clinician lists each physiologic system, (e.g., neuro, cardiac, pulmonary…) with an assessment and plan to fix each abnormality with a new treatment. Deliberation about how these individual treatments align with patient preferences is typically prompted by major events like failure to liberate from a ventilator or imminent death. This pattern of usual care is well characterized and differs from daily scenario planning with the Best Case/Worst Case-ICU communication tool."
33307850|NCT05780905|Placebo Comparator|Placebo|Subjects randomized to placebo for 1 year.
33307851|NCT05780905|Active Comparator|Active|Subjects randomized to semaglutide for 1 year.
33307852|NCT05780866|Other|Video and Activity Tracker|
33307853|NCT05780853||Typically Developing Children (Control Group)|Typically developing children with no known neurodevelopmental disorder, medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
33307854|NCT05780853||Children with a Diagnosed Neurodevelopmental Disorder (Clinical Group)|Children with a diagnosed neurodevelopmental disorder including: Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder. Children must also have no known medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
32800141|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
32800142|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
33307855|NCT05780840|Experimental|Dihydroxyacetone|
33307856|NCT05780840|Placebo Comparator|Placebo|
32800143|NCT03962686||patients with diabetes mellitus (DM) treated with statin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
33307857|NCT05780827||Healthy volunteers|No symptoms and signs of oral and maxillofacial dysfunction are required
33307858|NCT05780827||Patients with temporomandibular joint disorder|Patients with temporomandibular joint disorder
33307859|NCT05780814|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|"The proposed intervention consists of 6 remotely-delivered sessions; Weeks 1, 2, 4, 6, 7, and 8, with weeks 3 and 5 being rest weeks. Session 1 will be 60-90 mins, Session 2 will be ~60 mins, and remaining visits are ~45 mins. The investigators propose a methodological innovation for CBT-I, which involves conducting 15-minute sessions every other month during the BWL intervention. Prior to these maintenance sessions, participants in the CBT-I+BWL group will complete electronic sleep diaries for one week and interventionists will use this information in sessions to sustain and enhance long-term outcomes by using MI to reinforce application of CBT-I session content."
33093019|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
33307860|NCT05780814|Placebo Comparator|Sleep Education Control (EDU)|The EDU intervention will parallel the CBT-I intervention in number, format and length of all sessions, including maintenance sessions. It provides basic information about sleep and cancer, widely available to the public. EDU content does not include any individualized behavioral instructions, sleep diary monitoring during the intervention, or behavior change counseling. Content is presented didactically only.
33093020|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
33093021|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
33093022|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
33093023|NCT00478491||1|Persons with a parent with Alzheimer's disease
33093024|NCT00478491||2|Persons whose parents survived to old age without memory problems
33093025|NCT00478491||3|Persons with diagnosed mild cognitive impairment
33093026|NCT00478491||4|Persons without memory problems
33093027|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
33093028|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
33093029|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
33093030|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
32800144|NCT03962686||patients with diabetes mellitus (DM) treated with statin plus PCSK9i|In this cohort will be enrolled 20 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by statin therapy daily (n 20) added to PCSK9i, 140 mg twice a month (n 30).
33093031|NCT03271983|Other|metronidazole gel 1|RLD gel
33093032|NCT03271983|Other|metronidazole gel 2|generic gel
33093033|NCT03271983|Other|metronidazole cream|generic cream
33093034|NCT04700982||Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).
33093035|NCT00443300||Protective environment|Participants in a Protective environment
33093036|NCT00443300||Not a protective environment|Participants not in a protective environment
33093037|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
33093038|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
33093039|NCT03272763|Experimental|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
33093040|NCT04700228|Placebo Comparator|Group C|0.25% bupivacaine at a total volume of 0.5ml/kg.
33093041|NCT04700228|Active Comparator|Group BD1|0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
33093042|NCT04700228|Active Comparator|Group BD2|0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
33093043|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
32800145|NCT04193020||steroid only group (SG)|
33093044|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
33093045|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
33093046|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
33093047|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
33093048|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
32800146|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
32800147|NCT04193020||bilogic therapy group (BTG)|
32800148|NCT04199338|Experimental|Randomized|Randomized
32800149|NCT04192864|Experimental|Lingually based triangular flap|
32800150|NCT04192864|Active Comparator|Buccally based triangular flap|
32800151|NCT04027270|No Intervention|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
32800152|NCT04027270|Experimental|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
33093049|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
33093050|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
33093051|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
33093052|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
33093053|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
33093054|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
33093055|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
33093056|NCT04700306|Experimental|Sophrology|the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
33093057|NCT04700306|No Intervention|Control|the patient must make 7 visits with interviews and questionnaires
33093058|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
33093059|NCT04700189|Experimental|Treatment with Streamline following cataract surgery|Treatment with Streamline System following phacoemulsification
33093060|NCT04700384|No Intervention|Control Group|"Control Group - Baseline Training~25 Participants allocated. Individuals receive introductory information on using the simulator and the scenario. They perform 5 simple subpial tumour resections for practice and have 5 minutes per trial. After each attempt, the student takes a 5-minute break with no assessment or feedback on their performance. On their 6th attempt they have 13 minutes to perform a different realistic scenario."
33093061|NCT04700384|Experimental|Experimental Group - Virtual Operative Assistance Training|"Experimental Group - Virtual Operative Assistance Training~25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistance Training assessment of their performance and audiovisual feedback."
33093062|NCT04700384|Experimental|Experimental Group - remote-based expert Instructor Training|25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
33093063|NCT00440622|Experimental|1|GHer
33093064|NCT00440622|Experimental|2|CapHer
33093065|NCT00443417|Placebo Comparator|1|
33093066|NCT00443417|Active Comparator|2|200mg qd
33093067|NCT00443417|Active Comparator|3|200mg bid
33093068|NCT00443417|Active Comparator|4|400mg qd
33093069|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
33093070|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
33093071|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
33093072|NCT00440739|Placebo Comparator|1|1=placebo
33093073|NCT00440739|Active Comparator|2|2= etoricoxib
33093074|NCT00440739|Active Comparator|3|3=falvoxate
33093075|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
33093076|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
33093077|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
33093078|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
33093079|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
33093080|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
33093081|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
33093082|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
33093083|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
33093084|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
33093085|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
33093086|NCT00443612|Experimental|1|"12 weeks on treatment 1~2 week washout period~12 weeks on treatment 2"
33093087|NCT00443612|Experimental|2|"12 weeks on treatment 2~2 week washout period~12 weeks on treatment 1"
33093088|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
33093089|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
33093090|NCT00443690|Placebo Comparator|2|placebo control
33093091|NCT00443690|Experimental|1|KW-3902IV
33093092|NCT00440856|No Intervention|Control|
33093093|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
33093094|NCT00443768||1|
33093095|NCT00443768||2|
33093096|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
33093097|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
33093098|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
33093099|NCT03278327|Other|Endoscopic resection|
33093100|NCT04697706|Active Comparator|"Study period Water"|Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.
33093101|NCT04697706|Experimental|"Study period Moonstone"|Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.
33093102|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
33093103|NCT00443924|Placebo Comparator|1|Arm 1
33093104|NCT00443924|Experimental|2|Arm 2
33093105|NCT00443924|Experimental|3|Arm 3
33093106|NCT00443924|Experimental|4|Arm 4
33093107|NCT00443924|Experimental|5|Arm 5
33093108|NCT00443963|Experimental|PPI|PPI Medication
33093109|NCT00443963|Experimental|H2RA|H2RA Medication
33093110|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
32943757|NCT02039856|Experimental|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
32943758|NCT02039856|Active Comparator|Routine WH-PACT Implementation|National policy guidance
33307861|NCT05780801|Experimental|Live microbiome therapeutic|Live microbiome therapeutic prepared as Allogeneic Microbiota in Glycerol (10%) (AMG)
33307862|NCT05780788|Experimental|Canine retraction arm|Canine retraction
33307863|NCT05780762|Experimental|IMPACT program - experimental group|patients followed for one or more stabilized chronic pathologies and benefiting from usual care with an Advanced Practice Nurse AND benefiting from the IMPACT program, which combines management at 3 levels: (1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and his or her care team, and incorporates evidence-based measurement tools.
33307864|NCT05780762|Sham Comparator|Usal care : control group|patients followed for one or several stabilized chronic pathology(ies) and benefiting from a usual management with a Nurse in Advanced Practice.
33307865|NCT05780749|Experimental|Active arm - DDI-IBS-001|
32943759|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
32943760|NCT02015754|Experimental|DEBIRI|
32943761|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
32943762|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
32943763|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
32943764|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
32943765|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
32943766|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
32943767|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
32943768|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
32943769|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
32943770|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
32943771|NCT04678986||ER2 participants|all participants of ER2 database will be included in the analysis
32943772|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
32943773|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
32943774|NCT04693884|Experimental|High THC, Smoked|
32943775|NCT04693884|Experimental|High THC, Vaporized|
32943776|NCT04693884|Experimental|High CBD, Smoked|
32943777|NCT04693884|Experimental|High CBD, Vaporized|
32943778|NCT04678440|Experimental|Healthy Volunteers|Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
32943779|NCT04678440|Experimental|Non-Small Cell Lung Cancer Patients (NSCLC)|Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
33093111|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
33307866|NCT05780749|Placebo Comparator|Placebo arm|
33307867|NCT05780736||Cohort 1|
33307868|NCT05780593|Experimental|Intervention Group A|Manual mobilization of lumbosacral spine along with passive stretching of the hip abductors and 01 minute of inclined board standing for 03 times a day.
33307869|NCT05780593|Experimental|Intervention Group B|Routine medications(if any) along with 01 minute of inclined board standing for 03 times a day.
33307870|NCT05780554|Active Comparator|Cyclophosphamide 50 mg/kg|
33307871|NCT05780554|Experimental|Cyclophosphamide 25 mg/kg|
33404475|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
33404476|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
32943780|NCT04678362|Experimental|Talazoparib+avelumab|"Talazoparib will be administered at the daily dose of 1 mg given orally in a 28-day cycle, except for patients with mild renal impairment (Creatinine clearance 30-59 mL/min) who will receive 0.75 mg per day.~Avelumab will be administered by intravenous (I.V.) route over 60 minutes at the dose of 800 mg on D1 and D15, in a 28-day cycle."
32943781|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
32943782|NCT04678284|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
32943783|NCT04678050|Active Comparator|group I received ketamine/propofol (ketofol) solution|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
32943784|NCT04678050|Active Comparator|group II received the Dex solution (4 µg/mL|A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
32943785|NCT04677426|Experimental|Subjects with Progressive Interstitial Lung Disease|Assess the intra-visit reliability and sensitivity to progression of 129Xe MR imaging measurements using a standardized imaging protocol in subjects with IPF and cHP.
32943786|NCT02038920|Experimental|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
32943787|NCT02038920|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
32943788|NCT02038920|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
32943789|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
32943790|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
32943791|NCT02038920|Experimental|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
32943792|NCT02038764|Placebo Comparator|Placebo|Placebo
32943793|NCT02038764|Experimental|PF-06342674|
32943794|NCT02057718|Experimental|LUM001 (Maralixibat)|Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
32943795|NCT04693260|Other|Hand-held Device Supported by Mobile Application|Insight device ETDRS measurement compared to a standard ETDRS chart
32943796|NCT04177836|Experimental|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
32943797|NCT04177836|Active Comparator|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
32943798|NCT01622868|Experimental|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
32943799|NCT01622868|Experimental|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
32943800|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
32943801|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
32943802|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
32943803|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
32943804|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
32943805|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
32943806|NCT04963452|Placebo Comparator|Group 1|Normal weight BMI 20-24.9 kg/m2
32943807|NCT04963452|Active Comparator|Group 2|Morbid Obese BMI : 40-49.9 kg/m2
32943808|NCT02037984|Experimental|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
32943809|NCT02037984|Experimental|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
33404477|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
33093112|NCT04701255|Experimental|aberration-free IOL|20 human eyes with aberration-free intraocular lens Implantation after phacoemulsification cataract surgery
32943810|NCT02037984|Experimental|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943811|NCT02037984|Experimental|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943812|NCT02037984|Experimental|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943813|NCT02037984|Experimental|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943814|NCT02037984|Experimental|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943815|NCT02037984|Active Comparator|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
32943816|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
32943817|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
32943818|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
32943819|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
32943820|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
32943821|NCT02036580|Placebo Comparator|Placebo|Placebo
32943822|NCT02014116|Experimental|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943823|NCT02014116|Experimental|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943824|NCT02014116|Experimental|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943825|NCT02014116|Experimental|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
32943826|NCT02014116|Experimental|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
32943827|NCT02014116|Experimental|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
32943828|NCT02014116|Experimental|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943829|NCT02014116|Experimental|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943830|NCT02014116|Experimental|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
32943831|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
32943832|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
32943833|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
32943834|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
32943835|NCT04676490|No Intervention|Usual Discharge Care|Usual ED discharge care
32943836|NCT04676490|Experimental|RECORD-ED Card|Usual care, plus a physical greeting card-style card with audio discharge instructions (English or Spanish) recorded on it
32943837|NCT04676490|Experimental|RECORD-ED Patient Portal|Usual care, plus access to audio-recorded discharge instructions (English or Spanish) through the patient portal
32943838|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 25mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).
32943839|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 10 mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
33093113|NCT04701255|Active Comparator|negative spherical aberration IOL|20 human eyes with negative spherical aberration intraocular lens Implantation after phacoemulsification cataract surgery
33093114|NCT00444041|Experimental|Xelox, Bev|
33307872|NCT05779709|Experimental|Urotherapy group|The purpose of urotherapy education was to teach children to empty the bladder regularly and completely. The standardized urotherapy which included instructions on daily fluid intake of at least 1,200 ml evenly distributed daily as described and voiding at 2-hour intervals until bedtime in which the voiding and defecation positions were taught not to perform avoidance maneuvers. In this training, families were given basic information about the anatomy and physiology of the lower urinary tract (LUT) and anorectum, normal voiding and defecation, fluid consumption and voiding habits of children. The children were allowed to pee whenever they wanted occasionally at any time. Children were also asked to report the number of wet days during 8 weeks
33404478|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
33404479|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
32943840|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
32943841|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28- day cycle).
32943842|NCT02036502|Experimental|Part 2:pembro 200 mg+len 10 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
32943843|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W weekly during each 28-day cycle.
32943844|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W weekly during each 28-day cycle.
32943845|NCT02036502|Experimental|Part 3:pembro 200 mg+carf 56 mg/m^2+dex 20 mg|Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg once or twice weekly (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
32943846|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
32943847|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
32943848|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
32943849|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
32943850|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
32943851|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
32943852|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
32943853|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
32943854|NCT04717050|Experimental|Progressive combine training (PCT)|"Participants will be randomly assigned to Progressive combine training (PCT) group.~Participants will have two (2) baseline tests, then begin a two phase PCT program.~Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom~Participants will receive midpoint testing, approximately week 8.~Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home~Participants will receive midpoint testing, approximately two months into phase 2.~After the two (2) 16-week phases, participants will be followed for 4 months."
32943855|NCT04717050|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to Attention Control (AC) group.~Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12."
32943856|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
32943857|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
32943858|NCT02034552|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|
32943859|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
32943860|NCT02034552|Experimental|Radium-223 with enzalutamide|
32943861|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
32943862|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
32943863|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
32943864|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
32943865|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
32943866|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
33404480|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
33307873|NCT05779709|Experimental|Reformer pilates group|The basic pilates principles were explained to the children. The diaphragmatic breathing, neutral position of the pelvis, centering and pelvic floor control were teached with appropriate language for their age. Verbal help were given to maintain centering during each movement. The exercises (30 min) were started by doing 10 repetitions in combination with diaphragm breathing, and progressed 12 repetitions after 3 weeks, 15 repetitions after 6 weeks (frog series, leg circles series, hundred series, box series, side splits series).İndividual reformer pilates training consisting of 30 minutes two days a week was given to the exercise group by an expert physiotherapist for 8 weeks.
33307874|NCT05778851|No Intervention|A1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm A2 but without an EsoGuard result and in a different order.
32943867|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
32943868|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
32943869|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
32943870|NCT04715178||Patients with suspected or confirmed pediatric solid tumors|Patients with suspected or confirmed pediatric solid tumors
32943871|NCT02034006|Experimental|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
32943872|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
32943873|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
32943874|NCT04714398|Experimental|Opt-In Recruitment|All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.
32943875|NCT04714398|Experimental|Opt-Out|All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.
32943876|NCT04714398|No Intervention|Usual Care|Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.
32943877|NCT04690998|Other|Without treatment for SMA|Patient that will not take treatment for SMA during the two years of the study.
32943878|NCT04690998|Other|Under treatment for SMA|Patient that will take treatment for SMA during the two years of the study
32943879|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
32943880|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
32943881|NCT02054520|Experimental|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
32943882|NCT02054520|Active Comparator|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
32943883|NCT02054520|Experimental|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
32943884|NCT02054520|Active Comparator|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
32943885|NCT02054520|Experimental|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
32943886|NCT02054520|Active Comparator|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
32943887|NCT04675788|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
32943888|NCT04675788|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
32943889|NCT04675788|Experimental|Men 65 years of age or older: Testosterone|Subjects will receive treatment with transdermal testosterone 1% (100 mg) every morning for 3 days
32943890|NCT04675788|Placebo Comparator|Men 65 years of age or older: Placebo|Subjects will receive treatment with transdermal placebo every morning for 3 days
32943891|NCT04675164|Active Comparator|LAISS group|Viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).
32943892|NCT04675164|Active Comparator|HOST group|Viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group).
32943893|NCT02054130|Placebo Comparator|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
32943894|NCT02054130|Experimental|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
32943895|NCT02054130|Experimental|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
32943896|NCT02054130|Experimental|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
32943897|NCT04673682|Experimental|Group 1|"Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)~Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)"
32943898|NCT04673682|Experimental|Group 2|"Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)~Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)"
32943899|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
32943900|NCT04673448|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-28 of cycle 1. Beginning cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32943901|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
32943902|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
32943903|NCT02009046|Experimental|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
32943904|NCT02009046|Active Comparator|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
32943905|NCT02052960|Experimental|CetuGEX™ plus chemotherapy|720 mg weekly administration
32943906|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
32943907|NCT02008890|Experimental|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
32943908|NCT02008890|Experimental|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
32943909|NCT02008890|Placebo Comparator|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
32943910|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
32943911|NCT02007954|Experimental|DEBDOX|
32943912|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
32943913|NCT02031432|Experimental|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
32943914|NCT02031276|Placebo Comparator|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
32943915|NCT02031276|Experimental|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
32943916|NCT02031276|Experimental|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
32943917|NCT04686864|Experimental|Parent Support Group|Support and psychoeducation in a group setting for parents who have a child or adolescent with an eating disorder.
32943918|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
32943919|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
32943920|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
32943921|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
32943922|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
32943923|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
32943924|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
32943925|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
32943926|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
32943927|NCT02006706|Experimental|MabThera/Rituxan|
33093115|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
33093116|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
33093117|NCT00478842|Experimental|1|Deep brain stimulation
33093118|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
33093119|NCT00444236|Active Comparator|1|
33093120|NCT00444236|Placebo Comparator|2|
32943928|NCT02049138|Experimental|Upadacitinib|"Participants received treatment with upadacitinib for up to 312 weeks. The starting dose was 6 mg twice a day (BID). Participants who did not achieve a 20% improvement from RCT Baseline in both Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 6 or Week 12 were up-titrated to 12 mg BID. From January 2017 participants were transitioned to a once-daily (QD) regimen of upadacitinib, either 15 mg QD (participants who were taking 6 mg BID) or 30 mg QD (participants taking 12 mg BID). Starting with Protocol Amendment 5 participants receiving 30 mg QD upadacitinib had the option to decrease the dose to 15 mg QD at the investigator's discretion.~A subset of participants who opted-in to the vaccine substudy received a single-dose of 0.5 mL intramuscular injection of pneumococcal 13-valent conjugate vaccine (PCV-13)."
32943929|NCT04686318||suspected acute pyelonephritis|All patients admitted to the emergency department with suspected acute pyelonephritis assessed by the receiving physician
33093121|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
32943930|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
32943931|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
32943932|NCT02006628|Active Comparator|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter [mL]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
32943933|NCT02006628|Placebo Comparator|Placebo|Participants received placebo (0 mL cannabidiol [CBD]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
32943934|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
32943935|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
32943936|NCT04711356|Experimental|Study Intervention|All study participants will receive an Ad26.ZEBOV vaccine at a dose of 5x10^10 vp given via IM injection
32943937|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
32943938|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
32943939|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
32943940|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
32943941|NCT02006472|Placebo Comparator|Placebo|Twice daily
32943942|NCT04672356|Experimental|Phase Ia: IBI939 in combination with Sintilimab|IBI939 10mg/kg combination with Sintilimab
32943943|NCT04672356|Experimental|Phase Ia:IBI939 in combination with Sintilimab|IBI939 20mg/kg combination with Sintilimab
32943944|NCT02005692|Experimental|DynaSense sensor|
32943945|NCT02029638|Experimental|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
32943946|NCT04710654|Other|Control|"Behavioural therapy~Exercise program"
32943947|NCT04710654|Active Comparator|connective tissue manipulation|
32943948|NCT04710654|Active Comparator|Interferential current stimulation (100 Hz frequency)|
32943949|NCT04710654|Active Comparator|Interferential current stimulation (0-100 Hz frequency)|
32943950|NCT02047734|Experimental|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
32943951|NCT02047734|Experimental|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
32943952|NCT02047734|Active Comparator|Interferon β-1a|interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.
32943953|NCT04684914|Experimental|HepTcell|Dose administered at intervals of 4 weeks for 6 doses
32943954|NCT04684914|Placebo Comparator|Placebo|Dose administered at intervals of 4 weeks for 6 doses
32943955|NCT04709016||male or transgender patients|of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers
32943956|NCT04417140|Experimental|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
32943957|NCT04417140|No Intervention|Control Arm|Patients enrolled in this arm will have routine closure.
33093122|NCT02957279||Healthy control group|Healthy volunteers.
33093123|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
33093124|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
32956076|NCT05763862|Experimental|Genetic testing|Patients randomised to testing will have blood drawn for testing of the CYP2C19 LOF mutations. Physicians of patients who test positive for an LOF mutation (intermediate and poor metabolizers) will be notified of the mutation with recommendations of possible alternative antiplatelet regimens suggested. Aspirin will be the recommended monotherapy, and aspirin in combination with ticagrelor or dipyridamole will be the recommended dual antiplatelet regimen. The decision of alternative medications used in patients with LOF mutations will be left to the discretion of the primary physician. Patients in the genotype guided antiplatelet therapy group who do not have LOF mutations will be left to continue their original intended antiplatelet regimen (this may be clopidogrel monotherapy, or in combination with aspirin).
33093125|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
33093126|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
33093127|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
33093128|NCT00441597|No Intervention|3|3 days treatment with placebo twice
33093129|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
33404481|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
33404482|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
33404483|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
33093130|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
33093131|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
33093132|NCT04701372||Obsessive-Compulsive Disorder|adults, adolescents, and children with obsessive-compulsive disorder
33093133|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
33093134|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
33093135|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
33093136|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
33093137|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
33093138|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
33093139|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
33093140|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
33404484|NCT02333266||Candidemia|0
33404485|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
33093141|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
33093142|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
33093143|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
33093144|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
33093145|NCT00444314|Experimental|A|
33093146|NCT00444314|Experimental|B|
33093147|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~Basic education about dementia (what is the disease, its course, its features etc)~Education about common behaviour problems and how they can be managed~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
33093148|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
32943958|NCT01994850|Experimental|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).~Cycle 1:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)~Cycles 2-6:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
32943959|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
32943960|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
32943961|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
32943962|NCT04671576|Active Comparator|Control Formula|A standard, milk-based, infant formula.
32943963|NCT04671576|Experimental|Investigational Formula|An organic milk-based infant formula.
32943964|NCT01994382|Experimental|Phase 1 Cerdulatinib|During Phase 1, participants will receive oral cerdulatinib on Day 1 and then starting on Day 4 at doses of 15 mg up to 100 mg QD or oral cerdulatinib at doses of 15 mg up to 45 mg BID in 28-day cycles (except Cohort 1 will have a 21-day cycle starting on Day 1) for up to 10 cycles.
32943965|NCT01994382|Experimental|Phase 2a Cerdulatinib|During Phase 2a, participants in cohorts based on cancer type will receive oral cerdulatinib at starting doses of 35, 30, or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib can be reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
32943966|NCT01994382|Experimental|Phase 2a Cerdulatinib plus Rituximab|During Phase 2a, participants in this cohort will receive oral cerdulatinib at their applicable dose and an IV injection of rituximab 375 mg/m^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.
32943967|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
32943968|NCT02027376|Experimental|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
32943969|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
32943970|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
32943971|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
32943972|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
32943973|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
32943974|NCT04667364|No Intervention|Group MED|A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
32943975|NCT04667364|Experimental|Group TENS|A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.
32943976|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
32943977|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
32943978|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
32943979|NCT02001558|Experimental|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
32943980|NCT02001558|Active Comparator|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
32943981|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
32943982|NCT04683042|Active Comparator|TENS with PT|TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
32800153|NCT04027192|Experimental|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
32800154|NCT04027192|Experimental|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
33093149|NCT04700826|Experimental|Direct Oral anticoagulants (DOAC)|Commence DOAC even with low or intermediate risk of stroke or thromboembolism, which could include currently licensed drugs apixaban, dabigatran, edoxaban or rivaroxaban; choice of drug and dose according to local practice guidelines
33093150|NCT04700826|No Intervention|No anticoagulant therapy (usual care)|Continuation of usual anticoagulant prescribing practice in patients with AF; e.g. according to National Institute for Health and Care Excellence (NICE), patients with AF should commence oral anticoagulation with a CHA2DS2-VASc score of 2 or above.
33093151|NCT04700631|Active Comparator|healthy subject|healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI
33093152|NCT04700631|Experimental|CRF patients|CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²
33093153|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
33093154|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
33093155|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
33093156|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
33093157|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
33093158|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
33093159|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
33093160|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
33093161|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
33093162|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
33093163|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
33093164|NCT04700748|Other|Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.|Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
32800155|NCT04027192|Experimental|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
32800156|NCT04027192|Experimental|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
32800157|NCT04027192|Experimental|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
32800158|NCT04027192|Experimental|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
32800159|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
32800160|NCT04406506||Group B|"receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
32800161|NCT03828292|Experimental|Part 1: Belantamab mafodotin Monotherapy|
32800162|NCT03828292|Experimental|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
32800163|NCT03828292|Experimental|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
32800164|NCT04193098|Experimental|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.
33093165|NCT00479349|Active Comparator|1|SAM 531 + placebo
33093166|NCT03279354|Experimental|Intervention group|Family Move app intervention
33093167|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
33093168|NCT02957045|Experimental|Cough|
33093169|NCT00479583|Active Comparator|A|
33093170|NCT00479583|Active Comparator|B|
33093171|NCT04699643|Experimental|EVER4010001 combination with Pembrolizumab|EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.
33093172|NCT04699916|No Intervention|Control (Usual care)|Sedation will be guided with a standard protocol based on Sedation Agitation Scale already implemented in the Intensive Care Unit
33093173|NCT04699916|Experimental|EEG-based sedation protocol|Sedation will be guided using a protocol based on 2 parameters from the EEG: Suppression Rate and Spectral Edge Frequency
33093174|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
33093175|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
33093176|NCT04699955|No Intervention|Assessment only Control|Participants received no intervention content. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments were delivered via an online survey.
33093177|NCT04699955|Experimental|Positive Message Condition|Participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
33093178|NCT04699955|Experimental|Negative Message Condition|Participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
33093179|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
33093180|NCT00444743|Active Comparator|1|
33093181|NCT00444743|Placebo Comparator|2|
33093182|NCT00479622|Experimental|1|
33093183|NCT00479622|Experimental|2|
33093184|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
33093185|NCT00444860|Experimental|1|Zostavax
33093186|NCT00479661|Experimental|1|Dexmedetomidine
32800165|NCT04192942|Experimental|intensive care management|Administration of childern with major burn in intensive care to improve out comes
33093187|NCT00479661|Active Comparator|2|Propofol
33093188|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
33093189|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
33093190|NCT04700670||Group 1|patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine
32800166|NCT04021186|Experimental|Intervention|Insulin treatment using standard measurements.
32800167|NCT04021186|No Intervention|Control|Standard care.
32800168|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
32800169|NCT04026724||Non-exposed group|Western medicine routine treatment
32800170|NCT04026802|Experimental|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
32800171|NCT04026802|Active Comparator|Standard of Care|No resistance training device
32800172|NCT04020796|Active Comparator|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
32800173|NCT04020796|Placebo Comparator|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
32800174|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
32800175|NCT04026100|Experimental|CTA101|
32800176|NCT04192552|Active Comparator|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
32800177|NCT04192552|Active Comparator|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
32800178|NCT04192552|Active Comparator|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
32800179|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
32800180|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
33093191|NCT04700670||Group 2|patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
33093192|NCT04700670||Group 3|hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
33093193|NCT04700670||Group 4|patients hospitalized in a medical non-intensive care ward.
33307875|NCT05778851|Active Comparator|A2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm A1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
32943983|NCT04683042|Other|No TENS with PT|The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
32943984|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
32943985|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
32943986|NCT04682652|Experimental|GAE Treatment|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
32943987|NCT04682652|No Intervention|Observational|"Subjects randomized to the observational group will not undergo the experimental GAE Treatment.~PI will offer subjects enrolled into the observational group to crossover to the experimental GAE Treatment group after they have completed their 6-month follow-up assessments."
32943988|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
32943989|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
32943990|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
32943991|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
32943992|NCT04862676|Experimental|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
32943993|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
32943994|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
32943995|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
32943996|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
32943997|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
32943998|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
32943999|NCT01998984|Placebo Comparator|4 days placebo|Placebo
32944000|NCT01998984|Experimental|4 days drug|Drug
32944001|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
32944002|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
32944003|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
32944004|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT)"
32944005|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
32944006|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
32944007|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
32944008|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
32944009|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
32944010|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
32944011|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
32944012|NCT01967550|Placebo Comparator|Placebo|Vehicle control
32944013|NCT01989546|Experimental|1/Talazoparib (BMN 673)|Single agent
32944014|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
32944015|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
32944016|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
33307876|NCT05778851|No Intervention|B1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm B2 but without an EsoGuard result and in a different order.
33307877|NCT05778851|Active Comparator|B2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm B1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
33307878|NCT05778851|No Intervention|C1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm C2 but without an EsoGuard result and in a different order.
33307879|NCT05778851|Active Comparator|C2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm C1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
32800181|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
32800182|NCT04192162|Experimental|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
32800183|NCT04192162|Active Comparator|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
32800184|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
32800185|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
32800186|NCT03948490|Other|Arm 1 Cohort 1: Interventional arm/In-person rehab (CLOSED)|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.~n = 20 patients"
32800187|NCT03948490|Experimental|Arm 1 Cohort 2: Interventional arm/ReMind iPad app (CLOSED)|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.~n = 20 patients"
32800188|NCT03948490|Experimental|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting (CLOSED)|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.~n = 20 patients"
32800189|NCT03948490|No Intervention|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
32944017|NCT01989468|Placebo Comparator|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
32944018|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
32944019|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
32944020|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
32944021|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
32944022|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
32944023|NCT01620762|Placebo Comparator|Placebo|Placebo
32944024|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
32944025|NCT01620528|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
32944026|NCT01620528|Experimental|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
32944027|NCT01620528|Placebo Comparator|Placebo|Placebo BID for the 6-month Treatment Period
32944028|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
32944029|NCT01965600|Experimental|Cohort 1|
32944030|NCT01965600|Experimental|Cohort 2|
32944031|NCT01996332|Experimental|Tarceva Arm|
32944032|NCT04669548||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay
32944033|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
32944034|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
32944035|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
32944036|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
32944037|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
32944038|NCT01987986|Placebo Comparator|Placebo|"Placebo~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
32944039|NCT04659018||patient|individual performing a screening colonoscopy
32944040|NCT04658940|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
32944041|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
32944042|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
32944043|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
32944044|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
32944045|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
32944046|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
32944047|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
32944048|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
32944049|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
32944050|NCT04658316||20-39Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944051|NCT04658316||40-59Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944052|NCT04658316||60-79Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944053|NCT04658316||20-39Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944054|NCT04658316||40-59Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944055|NCT04658316||60-79Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
32944056|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
32944057|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
32944058|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
32944059|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
32944060|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
32944061|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
32944062|NCT01946412|No Intervention|Observational Arm|
32944063|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~50 mg q12h for subjects 2 to <6 years of age and <14 kg,~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or~150 mg q12h for subjects ≥ 6 years of age."
32944064|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
33307880|NCT05777811|Active Comparator|Vertically Coronally advanced flap combined with connective tissue graft|
32944065|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
33307881|NCT05777811|Active Comparator|Free Gingival Graft|
33307882|NCT05776992|Experimental|balance games|virtual reality games
33307883|NCT05776992|Active Comparator|balance training|Biodex balance training
33307884|NCT05774925|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
33307885|NCT05774925|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
32944066|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
32944067|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
32944068|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
32944069|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
32944070|NCT01945710|Experimental|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2.~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
32944071|NCT01945710|Experimental|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
32944072|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
32944073|NCT01945086|Experimental|Ustekinumab 45 mg|
32944074|NCT01945086|Experimental|Ustekinumab 90 mg|
32944075|NCT01945086|Placebo Comparator|Placebo|
32944076|NCT04637802|Active Comparator|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
32944077|NCT04637802|Experimental|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
32944078|NCT04637802|Experimental|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
32944079|NCT04637802|Experimental|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
32944080|NCT04658160|No Intervention|Control|None- normal care
32944081|NCT04658160|Experimental|Intervention/Tracking|This group will have access to the longitudinal tracking and intervention platform for Medicare Advantage patients. Members of this group's care team will have access to the longitudinal data on the platform and will be able to intervene if any red flags emerge (i.e. if a patient displays signs of depression on a patient reported outcome measure/survey)
32944082|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
32944083|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
32944084|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
32944085|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
32944086|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
32944087|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
32944088|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
32944089|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
32944090|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
32944091|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
32944092|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
32944093|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
32944094|NCT01962948|Experimental|Phase 1: 100 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
32944095|NCT01962948|Experimental|Phase I: 125 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
32944096|NCT01962948|Experimental|Phase I: 150 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
32944097|NCT01962948|Experimental|Phase II: MTD/MED of ganetespib, 80 mg/m2 paclitaxel|Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at MTD/MED from Phase I on days 1, 8 and 15 of a 28-day cycle.
32944098|NCT01985334|Experimental|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
32944099|NCT01985334|Experimental|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
32944100|NCT01985334|Experimental|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
32944101|NCT01985334|Experimental|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
32944102|NCT01985334|Experimental|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
32944103|NCT01985334|Experimental|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
32944104|NCT01985334|Experimental|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
32944105|NCT01985334|Experimental|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
32944106|NCT04657770|Experimental|Telerehabilitation|Patients will receive 36 treatment sessions over 6 weeks, consisting of 3 sessions/week that are supervised rehab therapy sessions (which begin with a 30-minute videoconference with the licensed OT or PT), alternating with 3 sessions/week of unsupervised rehab therapy sessions whereby the patient follows the instructions on the screen to engage in rehab therapy. Because patients sometimes miss a session, e.g., due to a conflict, we allow up to 8 weeks for patients to complete their 36 rehab therapy sessions.
32944107|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
32944108|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
32944109|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
32944110|NCT04665648|Experimental|Treatment arm|Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
32944111|NCT04665648|Placebo Comparator|Placebo arm|Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention
32944112|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
32944113|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
32944114|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
32944115|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
32944116|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
32944117|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
32944118|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
32944119|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
32944120|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
32944121|NCT04656132|Experimental|Participants with cardiovascular disease or cardiovascular disease risk factors|Population We will recruit 59 males and females age > 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.
32944122|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
32956077|NCT05763862|No Intervention|Standard medical therapy|Patients on this arm will be placed on clopidogrel monotherapy, or in combination with aspirin, which is the original intended antiplatelet regimen.
33307886|NCT05774925|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
33307887|NCT05774652|Experimental|Diet + physical activity|Diet + physical activity Dietary advise and advise on physical activity
33307888|NCT05774652|No Intervention|Control group|No intervention
33307889|NCT05769543|Active Comparator|WATSU application|
32944123|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
32944124|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
32944125|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
32944126|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
32944127|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
32944128|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
32944129|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
32944130|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
32944131|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
32944132|NCT01983930|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
32944133|NCT04636398|Experimental|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
32944134|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
32944135|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
32944136|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
32944137|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
32944138|NCT01939548|Experimental|PF-02545920 (5mg)|
32944139|NCT01939548|Placebo Comparator|Placebo|
32944140|NCT01939548|Experimental|PF-02545920 (15mg)|
32944141|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
32944142|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
32944143|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
32944144|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
32944145|NCT04653246|Experimental|Isa-RVD|"The main study consists of 4 phases a) 28-day screening phase; b) an induction phase inclusive of two 42-day induction treatment cycles: Isatuximab (IV), Bortezomib (SQ). Lenalidomide (PO), Dexamethasone; c) Followed by stem cell mobilization (at the discretion of the Principal Investigator [PI]);d) Participants will proceed with either autologous stem cell transplant or two additional induction cycles.~- Induction will be followed by a maintenance phase that continues until disease progression."
32944146|NCT04652778|Experimental|Treatment|
32944147|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
32944148|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
32944149|NCT04663152|Experimental|INSTACARE arm|Participants in this arm will receive the INSTACARE intervention for three months.
33307890|NCT05769543|Placebo Comparator|Control|
33307891|NCT05766722|Experimental|All patients 18 years old or older undergoing uncomplicated cataract surgery.|
33307892|NCT05766501|Experimental|DOR/ISL|Participants will receive fixed dose combination (FDC) tablet of DOR/ISL (100 mg/0.25 mg) taken once daily (QD) orally from Day 1 to Week 96.
32800190|NCT03948490|No Intervention|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
32800191|NCT03948490|Other|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.~N=20"
32800192|NCT04191694|Other|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
32800193|NCT04191694|Active Comparator|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
32800194|NCT04191850|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
32800195|NCT04191850|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
32800196|NCT04191772|Experimental|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
32800197|NCT04191772|Experimental|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
32944150|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
32944151|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
32944152|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
32944153|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
32944154|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
32944155|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
32944156|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
32944157|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
32944158|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
32944159|NCT04652700|Experimental|Islatravir (ISL) Once Monthly (QM) Group|Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.
32944160|NCT04652700|Active Comparator|FTC/TDF or FTC/TAF QD Group|Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.
32944161|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
32944162|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
32944163|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
32944164|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
33093194|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
33093195|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
33093196|NCT04700592|Experimental|Gabapentin group|group which receives 600 mg of Gabapentin (two tablets) one hour prior to surgery
33093197|NCT04700592|Experimental|ketamine group|group which receives an injection of ketamine at a dosage of 0.15 mg/Kg before surgery incision
33093198|NCT04699526|Experimental|Intervention|Received UPC training, school policy and climate interventions, and Unplugged prevention program
33093199|NCT04699526|No Intervention|Control|Only implemented Unplugged prevention program
33093200|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
33093201|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
33093202|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
33093203|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
33093204|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
33093205|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
33093206|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
33093207|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
33093208|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
33093209|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
33093210|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
33093211|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
33093212|NCT00479739|Experimental|Arm 1|
33093213|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
33093214|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
33093215|NCT00442026|Experimental|1|DG
33093216|NCT00442026|Experimental|2|G
33093217|NCT00445172|Experimental|1|
33093218|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
33093219|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
33093220|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
33093221|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
33093222|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
33093223|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
33093224|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
33093225|NCT04699760|Placebo Comparator|Placebo|Nutritional supplement without fish oil
33093226|NCT04699760|Active Comparator|Fish oil|Nutritional supplement with fish oil
33093227|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
33093228|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
33093229|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
33093230|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
33093231|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
33093232|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
33093233|NCT00479973|Placebo Comparator|Placebo|
33093234|NCT00454259|Experimental|1|0,5 µg/kg
33404486|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
32944165|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
32944166|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
32944167|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
32944168|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
33404487|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
33404488|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
32944169|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
32944170|NCT04650282|Experimental|Lidocaine in SphenoCath device|One treatment will be given.
32944171|NCT04650282|Placebo Comparator|Saline Solution in SphenoCath device|One treatment will be given.
32944172|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
32944173|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
32944174|NCT01979952|Experimental|Nintedanib|150 mg twice daily
32944175|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
32944176|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
32944177|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
32944178|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
32944179|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
32944180|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:~Carboplatin* on day 1~*If a patient is allergic to carboplatin, then give~Cisplatin** on day 1~**If a patient is allergic to cisplatin and carboplatin, then give~Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
32944181|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
32944182|NCT04648644||Study population|All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
32944183|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
32944184|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
32944185|NCT01979016|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
32944186|NCT01979016|Experimental|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
32944187|NCT04648254|Experimental|Dose escalation (Q702)|Participants will receive escalating doses of Q702
32944188|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32944189|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
32944190|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
32944191|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
32944192|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
33093235|NCT00454259|Experimental|2|0,05 µg/kg
33093236|NCT00454259|Experimental|3|0,005 µg/kg
33093237|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
32800198|NCT04191772|Experimental|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
32800199|NCT04191772|Experimental|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
32800200|NCT04191772|No Intervention|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
33093238|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
33093239|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
33093240|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
33093241|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
33093242|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
33093243|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
33093244|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
33093245|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
33093246|NCT00454454||No treatment|
33093247|NCT00454493|Active Comparator|fish oil|
33093248|NCT00454493|Placebo Comparator|placebo|
33404489|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
32800201|NCT04191772|No Intervention|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
32800202|NCT04026022|Placebo Comparator|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
32800203|NCT04026022|Experimental|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
32800204|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
32800205|NCT03949270|No Intervention|Usual Care|Patients in the usual care arm will not receive any text messages.
32800206|NCT03949270|Experimental|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
32800207|NCT04020328|Experimental|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
32800208|NCT04020328|No Intervention|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
32800209|NCT04020094|Experimental|Treatment: all patients|
32800210|NCT04025476||VKH patients|acute VKH patients
32800211|NCT04025476||control|health people age/sex match to the VKH patients
32800212|NCT04025320|Experimental|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.~9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
32800213|NCT04025320|Sham Comparator|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
32800214|NCT01874288|Experimental|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
32800215|NCT01874288|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
32800216|NCT01874288|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
32800217|NCT01874288|Experimental|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
33093249|NCT00454688|Placebo Comparator|Placebo|
33093250|NCT00454688|Experimental|Asimadoline 0.15 mg|
33093251|NCT00454688|Experimental|Asimadoline 0.5 mg|
33093252|NCT00454688|Experimental|Asimadoline 1.0 mg|
33093253|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
33093254|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
33093255|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
33093256|NCT00480090|Experimental|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
33093257|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
32800218|NCT01874288|Experimental|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
33093258|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
33093259|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
33093260|NCT00454883||1 cohort of patients treated with ziprasidone|
33093261|NCT00454922|Active Comparator|1|education
33093262|NCT00454922|Placebo Comparator|2|standard of care
33093263|NCT03278652||Patient with renal colic|
33093264|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
33093265|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
33093266|NCT00455000|Experimental|Active treatment|5 possible active doses
33093267|NCT00455000|Placebo Comparator|Placebo|
33093268|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
33093269|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
33093270|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
33093271|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
33093272|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
33093273|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
33093274|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
33307893|NCT05763758||Healthy Control|Healthy participants will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. At FSU, EEG and fMRI will be simultaneously acquired. At MGH, sequential MRI and MEG/EEG will be acquired.
33307894|NCT05763758||Patients with chronic low back pain|Subjects with chronic low back pain (cLBP) patients will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. The study will only be performed at MGH, sequential MRI and MEG/EEG will be acquired.
33093275|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
33093276|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
33093277|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
33093278|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
33093279|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
33093280|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
33093281|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
33093282|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
33093283|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
33307895|NCT05762835|Experimental|Intervention (Virtual Family-Centered Rounds [FCR])|"Virtual FCR-arm parents/guardians (referred to as parents hereafter) will have the option use have the option to use telehealth for virtual rounds. Parents can participate in virtual FCR as much, or as little, as they choose. Parents also will have the option to attend FCR in person or to not attend FCR."
33307896|NCT05762835|No Intervention|Control (Usual Care)|Usual care-arm parents will receive usual care. Usual care-arm parents will have the option to attend FCR in person or to not attend FCR.
33404490|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
33404491|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
33093284|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
33093285|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
33093286|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
33093287|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Intervention: Diaphragmatic ultrasound"
33093288|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
33093289|NCT00480363|No Intervention|2|Observation
33093290|NCT00455351|Experimental|A I|Study drug
33093291|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
33093292|NCT00442806|Experimental|Treatment|ADRC's are injected
33093293|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
33093294|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
33093295|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
33093296|NCT00442923|Placebo Comparator|CTRL|
33093297|NCT00442923|Experimental|TREAT|
33093298|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
33093299|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
33093300|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
33093301|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
33307897|NCT05761639|Experimental|Telerehabilitation, Education and Telephone Monitoring.|"The effects of a physical exercise program and educational component with telephone follow-up mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression and health-related quality of life will be determined.~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
33307898|NCT05761639|Experimental|conventional rehabilitation and Education|The effects of a physical exercise program and a conventional educational component in patients with heart failure on functional capacity, depression and health-related quality of life will be determined. The development of this program will be carried out in person guided by a physiotherapist specializing in cardiac and pulmonary rehabilitation.
33093302|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
33404492|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
33404493|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
33404494|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
33093303|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
33093304|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
33093305|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
33093306|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
33093307|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
33093308|NCT01240005|Experimental|DCIK|
33093309|NCT00455897|Experimental|GMCSF-RCHOP|
33093310|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
33093311|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
33093312|NCT00443196|Experimental|Experimental|
33093313|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
33093314|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
33093315|NCT00443235|Active Comparator|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
33093316|NCT00443235|Experimental|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
33093317|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
33093318|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
33093319|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
33093320|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
32800219|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
32800220|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
32800221|NCT04020016|Experimental|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
33404495|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
33093321|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
33093322|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
33093323|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
33093324|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
32800222|NCT04020016|Experimental|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
32944193|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
32944194|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
32944195|NCT04415814|Experimental|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
32944196|NCT04415814|Active Comparator|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
32944197|NCT04411212|Active Comparator|Granulocyte colony-stimulating factor and platelet-rich plasma|
32944198|NCT04411212|Other|Control group|
32944199|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
32944200|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
32944201|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
33404496|NCT02333500|Other|control group|Rate of oxytocin of the control group
33404497|NCT05193435|Experimental|Pelvic floor exercise group|Pelvic floor exercises for muscle fiber types I and II will performed 3 days a week for 8 weeks
32944202|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
32944203|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
32944204|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
32944205|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
32944206|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
32944207|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
32944208|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
32944209|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
32944210|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
32944211|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
32944212|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
32944213|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
32944214|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
33404498|NCT05193435|Active Comparator|Stabilization exercise group|Lumbar spinal stabilization exercises will performed 3 days a week for 8 weeks
33307899|NCT05761639|Experimental|Telerehabilitation and Education|"To determine the effects of a physical exercise program and a conventional educational component mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression, and health-related quality of life~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
33307900|NCT05761509||Single arm|"200 subjects exposed to HIV, leading to prescription of 28-day doravirine based post exposure prophylaxis (PEP).~The study referred to treatments that are using routinely in the medical care of subjects under PEP. These treatments are the following:~Delstrigo®: Fixed-dose combination containing 100mg of doravirine, 245 mg of tenofovir disoproxil and 300 mg of lamivudine, one tablet to be taken orally once daily, with or without food.~Pifeltro®: doravirine dosed at 100 mg, on tablet to be taken orally once daily, with or without food, in combination with tenofovir disoproxil/emtricitabine."
33307903|NCT05758948||Patients diagnosed with de novo metastatic breast cancer|Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)
33307904|NCT05753839|Experimental|Upfront cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy, followed by induction therapy with nivolumab plus ipilimumab combination and maintenance therapy with nivolumab.
33307905|NCT05753839|Experimental|Deferred cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy after induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
33307906|NCT05753839|Active Comparator|No surgery|Induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
33307907|NCT05752487|Experimental|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants with drug refractory, paroxysmal atrial fibrillation (PAF) who are candidates for catheter ablation will be enrolled with ablation system which uses THERMOCOOL SMARTTOUCH SF (STSF) catheter and TRUPULSE generator to deliver RF or PF energy during cardiac ablation procedures.
33307908|NCT05751226|Experimental|BI 1820237 treatment group|
33307909|NCT05751226|Placebo Comparator|Placebo group|
33307910|NCT05751226|Experimental|BI 1820237 + semaglutide treatment group|
33307911|NCT05751226|Active Comparator|placebo + semaglutide group|
33307912|NCT05751226|Experimental|BI 1820237 + BI 456906 treatment group|
33307913|NCT05751226|Active Comparator|placebo + BI 456906 group|
33307914|NCT05747742|Experimental|RLRL of 50% intensity|"Participants will be treated with RLRL (50% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
33307915|NCT05747742|Active Comparator|RLRL of 100% intensity|"Participants will be treated with RLRL (100% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
33307916|NCT05747573|Active Comparator|A 100mg GB1211 tablet, fasted|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fasted conditions (n=4 per period)
33307917|NCT05747573|Active Comparator|B 100 mg GB1211 capsules, fasted|Single dose of 100 mg GB1211 as two capsules (50 mg strength) under fasted conditions (n=4 per period)
33307918|NCT05747573|Active Comparator|C 100 mg GB1211 tablet, fed|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fed conditions (n=4 per period)
33307919|NCT05747404||Functional tricuspid regurgitation|Patients with functional tricuspid regurgitation
33307920|NCT05747404||Control subjects|Healthy volunteers
33307921|NCT05744544||External Oblique Intercostal Block Group|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after EOIB. (external oblique intercostal block)
33307922|NCT05744544||modified-TAPA block|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after m-Tapa. (modified- thoracoabdominal nerves block through perichondrial approach)
33307923|NCT05743946|Experimental|Trikafta|Participants with NCFBE and one known CFTR mutation and/or mildly elevated sweat chloride measurements (i.e., 30-60 mEq/L) receiving Trikafta for four weeks.
33307924|NCT05743647||Young|40 right handed healthy subject aged between 18 and 40
33307925|NCT05743647||Old|40 right handed healthy subject aged between 41 and 75
33307926|NCT05739292|Experimental|EuMCV5|Healthy adults received 0.5mL single intramuscular dose on Day 0.
33307927|NCT05739292|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
33307928|NCT05739058|Experimental|Low Exposure to Violet-Blue Light|ID 1-7 are assigned to the low dosage group
33307929|NCT05739058|Experimental|Medium Exposure to Violet-Blue Light|ID 8-15 are assigned to the medium dosage group
33307930|NCT05739058|Experimental|High Exposure to Violet-Blue Light|ID 16-22 are assigned to the high dosage group
33307931|NCT05731141||First Degree Relatives|Siblings or parents of patients.
33307932|NCT05731141||Patients|Patients with lymphatic anomalies.
33307933|NCT05730842|Experimental|Part A - AME|Evaluation of absorption, metabolism, excretion and pharmacokinetics of a single oral dose of radiolabeled EDG-5506 in healthy male volunteers
33307934|NCT05730842|Experimental|Part B - aBA|Evaluation of bioavailability of a single oral dose of EDG-5506 followed by a single intravenous dose of radiolabeled EDG-5506 in healthy male volunteers
33307935|NCT05729984|Experimental|Paula|The patients will perform Paula exercises after cesarean delivery.
33307936|NCT05729984|Active Comparator|Gum chewing|The patients will chew gum after the cesarean delivery.
33307937|NCT05729009||heart transplantation|
33307938|NCT05727670|Experimental|main group|This group consists of patients with dental retention who will be treated using digital technologies and devices to create a place in the dentition
33404499|NCT05060536|Active Comparator|Removal of infrapatellar fat pad|When patients will have their fat pad removed.
32800223|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
32800224|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
32800225|NCT04025164|Experimental|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
32800226|NCT04025164|Active Comparator|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
33307939|NCT05725863|No Intervention|Control|No psychological intervention was offered. Postpartum mothers in the control condition were informed that they would receive MBCT after a waiting period of 2 months.
33307940|NCT05725863|Experimental|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
33307941|NCT05724043|Experimental|SmartJournal|Nursing homes in the intervention group will receive the SmartJournal intervention. They will be provided with toolboxes including tablets with SmartJournal installed, antibacterial touchscreen wipes, flashlights for monthly oral inspections, instruction video, instruction book and SmartJournal information posters. They will also receive oral hygiene equipment packages including toothbrushes for permanent teeth and prosthetic devices, dental floss, interdental brushes, toothpaste and inspection mirrors. Training, follow-up and technical support for SmartJournal usage will be provided by project staff employed at the Oral Health Centre of Expertise Rogaland. The intervention will last for 12 weeks.
33307942|NCT05724043|No Intervention|Control group|Nursing homes in the control group will also receive oral hygiene equipment packages but will, in contrast to the intervention group, continue with existing oral care routines.
33307943|NCT05721157|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
33307944|NCT05721157|No Intervention|Control|Patients randomized to control will continue routine practice.
33307945|NCT05717387|Experimental|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
33307946|NCT05717387|Experimental|the 5:2 diet|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
33307947|NCT05717387|No Intervention|Control|Participants in the control group will receive a general lifestyle counseling.
33307948|NCT05714878|Experimental|Prehabilitation arm|Patient receives prehabilitation intervention including exercise, nutrition and psychological support.
33307949|NCT05714878|No Intervention|Control arm|Patient receives regular care recommended by the WHO without supervision and support.
33307950|NCT05713916|Experimental|Intervention: Population Health Coordinator|For subject randomized to the intervention arm, population health coordinators will notify the established longitudinal specialty clinician (cardiologist or nephrologist) or the primary care provider (PCP) that their patient has a recent echocardiogram demonstrating left ventricular hypertrophy (LVH). The outpatient clinician will be notified via the electronic health record (EHR) messaging system that the finding of LVH -- in the absence of significant valvular heart disease or a previously diagnosed cardiomyopathy -- may reflect undiagnosed or untreated hypertension.
33307951|NCT05713916|No Intervention|Observation: Usual Care|Those subjects randomized to the observation arm will receive usual care and their clinicians will not be notified about the finding of LVH on a prior echocardiogram until after study completion.
33307952|NCT05710081|Active Comparator|Intervention|Bacterial Lysate - Broncho-Vaxom (OM-85) 3.5mg granules once daily for 10 days per month for 24 months
33307953|NCT05710081|Placebo Comparator|Placebo|Placebo - 3.5mg granules once daily for 10 days per month for 24 months
33307954|NCT05706805||Coronary Artery Disease (CAD)|
33307955|NCT05705271|Experimental|Finerenone|Participants will receive study treatment for 18 months ± 7 days.
33307956|NCT05703191||Nitric Oxide|Inhaled Nitric Oxide
33307957|NCT05701098|Experimental|Break Wave™ Procedure|The subject will undergo the Break Wave procedure.
33307958|NCT05694338||Major surgery for gastrointestinal cancer|Patients with gastrointestinal cancer who are scheduled for major surgery
33307959|NCT05692609||Implant overdenture group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
33307960|NCT05692609||All-on-4 group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
33307961|NCT05692479||Group 1 and Group 2|Women With and Without Premenstrual Syndrome
33307962|NCT05691530|Experimental|Flavivirus Naive|Those with <=50% neutralization at a 1:10 dilution to all four DENV serotypes, no history of flavivirus vaccination, or travel history that increases the likelihood of other flavivirus infections.
33307963|NCT05691530|Experimental|Polytypic DENV Antibody Profile|Those considered immune (a >=70% neutralization or plaques at a 1:40 dilution) to at least two serotypes.
33307964|NCT05691530|Experimental|Primary Heterotypic DENV Antibody Profile|Those who have a >=70% neutralization or plaques at a 1:40 dilution for a single serotype, either DENV1, DENV2, or DENV4.
33307965|NCT05689736|Experimental|Motivational Enhancements + Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core Essentials for Parenting (EFP) intervention and all additional engagement-focused intervention elements: motivational enhancements, simplification, gamification, and low engagement nudges.
33307966|NCT05689736|Experimental|Motivational Enhancements + Simplification + Gamification|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and gamification intervention elements.
33404500|NCT05060536|Placebo Comparator|No removal of infrapatellar fat pad|When patients will not have their fat pad removed.
33307967|NCT05689736|Experimental|Motivational Enhancements + Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and low engagement nudges as intervention elements.
32800227|NCT04021966|Experimental|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
32800228|NCT04021966|Sham Comparator|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
32800229|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
32800230|NCT04022746|Experimental|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
32800231|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
32800232|NCT01873742|Experimental|Treatment as usual|This condition will not include the use of the STIC feedback system.
32800233|NCT04024540|Experimental|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks and 1000 kcal/d for 2 months.
32800234|NCT04024540|Active Comparator|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
32800235|NCT04766242|Experimental|Intervention group|The intervention group will receive 10 healing session of 45-60 minutes as an adjunct to usual care, approximately once a week.The usual care will consist of the treatment plan made by their GP when they were diagnosed with moderate depression.
32800236|NCT04766242|Other|Control group|The control group will receive usual care as prescribed by their GP when they were diagnosed with moderate depression.
32800237|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
32800238|NCT01873586|Active Comparator|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
32800239|NCT04024774||index cases and their parents|
32800240|NCT04025398|Experimental|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
32800241|NCT04025398|Active Comparator|CONTROL GROUP|The control group involves manual activities and research computer information.
32800242|NCT04029610|Active Comparator|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
32800243|NCT04029610|Experimental|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
32800244|NCT04024852|No Intervention|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
32800245|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
32800246|NCT04026880|Active Comparator|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
32800247|NCT04026880|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks
32800248|NCT04190992|Experimental|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
32800249|NCT04190992|Other|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
32800250|NCT04191070|Experimental|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
32800251|NCT04191070|Experimental|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
32800252|NCT04024384|Experimental|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
32800253|NCT04023916|Experimental|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
32800254|NCT04023838|Placebo Comparator|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
32800255|NCT04023838|Active Comparator|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
32800256|NCT01849562|Active Comparator|Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg|Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
32800257|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg|Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
33404501|NCT04210869|Experimental|Experimental|Mixed nuts
32944215|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
32944216|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
32944217|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
32944218|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
32944219|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
32944220|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
32944221|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
32944222|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
32944223|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
32944224|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
32944225|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
32944226|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
32944227|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
32944228|NCT04645680|Experimental|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
32944229|NCT04645680|Active Comparator|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
32944230|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
32944231|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
32944232|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
32944233|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
32944234|NCT04645524|Experimental|AD182|Oral capsule administered before bed
32944235|NCT04645524|Experimental|AD504|Oral capsule administered before bed
32944236|NCT04645524|Placebo Comparator|Placebo|Oral capsule administered before bed
32944237|NCT04662216|Active Comparator|control group|Scaling and root planing
32944238|NCT04662216|Experimental|test group|"scaling and root planing + Perisolv +Hyadent BG gels."
32944239|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
32944240|NCT01931670|Placebo Comparator|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
32944241|NCT01931670|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
32944242|NCT01931670|Experimental|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
32944243|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
32944244|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
32944245|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
32944246|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
33404502|NCT04210869|No Intervention|Control|No mixed nuts
33404503|NCT04993924|Experimental|Participants|Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-6 days
33404504|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
32800258|NCT01849562|Placebo Comparator|Placebo|Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks
33093325|NCT04700943||Regional awake anesthesia|"In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage.~To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered."
32800259|NCT04023760|Experimental|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
33093326|NCT04700943||General anesthesia|"Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed.~Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium."
33093327|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
33093328|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
33093329|NCT00456248|Active Comparator|3|
33093330|NCT00480558|Active Comparator|1|Group 1: M. tb
33093331|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
33093332|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
33093333|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
33093334|NCT04700553|Experimental|Conventional physical therapy intervention plus localized muscle vibration|physical therapy intervention plus localized muscle vibration
33093335|NCT04700553|Sham Comparator|Conventional physical therapy intervention|physical therapy intervention
33093336|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
33093337|NCT04700709|Experimental|RaparoBell® Tablet|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
33093338|NCT04700709|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
33093339|NCT04698317|Experimental|beta-tricalcium phosphate plus concentrated growth factors|surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
33093340|NCT04698317|Placebo Comparator|beta tricalcium phosphate alone(control group)|surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),
33093341|NCT04700475|Experimental|Laser group|Laser group composes of thirty patients who will receive low level laser three times a week, on alternate day (48h interval) Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions
33093342|NCT04700475|Other|Control group|control group composes of thirty patients will be treated with 15mL of a 2% citric acid solution applied as a mouth rinse for 30 sec
33093343|NCT04700436|Experimental|Test group|Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
33093344|NCT04700436|Active Comparator|Control group|Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)
33093345|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
33093346|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
33093347|NCT00456482|No Intervention|No Intervention|Fellow eye
33093348|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
33093349|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
33093350|NCT04700358||Patients with Cystic Fibrosis|Patients with pulmonary Cystic Fibrosis with or without bacterial colonization
33093351|NCT04700358||Control group|Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections
33093352|NCT00456638|Experimental|Depodur|Depodur arm
33093353|NCT00456638|Active Comparator|Traditional|traditional management
33093354|NCT04700085|Experimental|ReMotion Knee|The ReMotion Knee (mechanical prosthetic knee type) was used during measurements
33093355|NCT04700085|No Intervention|Current prosthetic knee|The participant's current prosthetic knee was used during measurements
33093356|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
33093357|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
33093358|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
33093359|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
33093360|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
33093361|NCT04700397||Repeatability group 1|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 100 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
33093362|NCT04700397||Repeatability group 2|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 200 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
33093363|NCT04700397||Repeatability group 3|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 300 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
33093364|NCT04700397||pressure-recommended doses of NTG|The patient with systolic blood pressure above 100 mmHg, who will receive the nitroglycerine injection with the dose of recommendation, adjusted according to the blood pressure.
33307968|NCT05689736|Experimental|Motivational Enhancements + Simplification|Participants will receive the Core EFP intervention and motivational enhancement and simplification as intervention elements.
33307969|NCT05689736|Experimental|Motivational Enhancements + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, gamification, and low engagement nudge as intervention elements.
33307970|NCT05689736|Experimental|Motivational Enhancements + Gamification|Participants will receive the Core EFP intervention and motivational enhancement and gamification as intervention elements.
32800260|NCT04023760|Active Comparator|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
32800261|NCT04023760|Experimental|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
32800262|NCT04023760|Active Comparator|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
32800263|NCT04026490|Experimental|Immediate intervention|The student will have a conversation with an Interventionist.
32800264|NCT04026490|Active Comparator|Waitlist intervention|These students will be approached for intervention for the months following the implementation of the immediate intervention group using the same procedures.
32800265|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
32800266|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
32800267|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
32800268|NCT04025710|Other|all patients|
32800269|NCT04020952|Active Comparator|"st.st 0.019×0.025 wire"|
32800270|NCT04020952|Experimental|"st.st 0.016×0.022 wire"|
32800271|NCT04020952|Experimental|"st.st 0.017×0.025 wire"|
32800272|NCT03961750|Experimental|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
32800273|NCT04026958|Experimental|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
32800274|NCT04026958|Placebo Comparator|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
32800275|NCT04020718|Experimental|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
32800276|NCT04020718|Experimental|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
32800277|NCT04027348|Experimental|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
32800278|NCT04195204|Experimental|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
32800279|NCT04195204|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
32800280|NCT04406350|Experimental|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
32800281|NCT04023136|Other|only one arm (resected patients)|liver resection group
32800282|NCT04023214||ADPKD|ADPKD patients
32800283|NCT04023214||Controls|Healthy volunteers
32800284|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
32800285|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
32800286|NCT04023370|Experimental|BeGraft Peripheral Stent Graft System|Covered stent
33093365|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
33093366|NCT00456833|Active Comparator|erlotinib 150mg/day|
33093367|NCT04700319|Experimental|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
33093368|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
33093369|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
33093370|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
33093371|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
33093372|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
33093373|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
33093374|NCT04700241|Active Comparator|Potassium nitrate|During this experimental day, men will receive 10 mmol of potassium nitrate
33093375|NCT04700241|Placebo Comparator|Placebo|During this experimental day, men will receive an isomolar dose of potassium chloride
33093376|NCT04700046|Active Comparator|Mexiletine|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg)
33093377|NCT04700046|Placebo Comparator|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
33404505|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
33404506|NCT04904458|Experimental|Experimental group|The experimental group receives the Enfacement Illusion toward a happy emotional face through a head mounted display.
32800287|NCT04023370|Active Comparator|Bare metal stent system|bare metal stent
33093378|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
33093379|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
33093380|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
33093381|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
33093382|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
33093383|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
33093384|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
33093385|NCT00443469|Experimental|Magnetic Stimulation|
33093386|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
33093387|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
33093388|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
33093389|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
33093390|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
33093391|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
33093392|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
33093393|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
33093394|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
33093395|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
33093396|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
33093397|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
33093398|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
33093399|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
33093400|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
33093401|NCT00457496|Active Comparator|A|
33093402|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
33093403|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
33093404|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
33404507|NCT04904458|Sham Comparator|Control Group|The control group receives the exposure to a pleasant virtual environment through a head mounted display
33404508|NCT05193357|Experimental|home-based IPC device|Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
32944249|NCT04644276|Active Comparator|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
33307971|NCT05689736|Experimental|Motivational Enhancements + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement and low engagement nudge as intervention elements.
33307972|NCT05689736|Experimental|Motivational Enhancements|Participants will receive the Core EFP intervention and motivational enhancement as an additional intervention element.
33307973|NCT05689736|Experimental|Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification, gamification, and low engagement nudge as additional intervention elements.
33307974|NCT05689736|Experimental|Simplification + Gamification|Participants will receive the Core EFP intervention and simplification and gamification as additional intervention elements.
33307975|NCT05689736|Experimental|Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification and low engagement nudge as intervention elements.
33307976|NCT05689736|Experimental|Simplification|Participants will receive the Core EFP intervention and simplification as an additional intervention element.
32944250|NCT04644276|Placebo Comparator|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
32944251|NCT01931202|Placebo Comparator|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
32944252|NCT01931202|Active Comparator|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
32944253|NCT01931202|Active Comparator|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
32944254|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
32944255|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
32944256|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
32944257|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
32944258|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
32944259|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
32944260|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
32944261|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 2"
32944262|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 1"
32944263|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast SenSura and secondly test either:~Coloplast Test product 2 and thereafter Coloplast Test product 1~Coloplast Test product 1 and thereafter Coloplast Test product 2"
32944264|NCT01976364|Experimental|Tofacitinib|
32944265|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
32944266|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
32944267|NCT01929876|Experimental|Cobimetinib + Itraconazole|
32944268|NCT01975428|Other|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
32944269|NCT01975428|Active Comparator|DM Pgm + device|"Disease management (DM) program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
32944270|NCT04630236|Other|Ultrasound|
33307977|NCT05689736|Experimental|Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and gamification and low engagement nudge as additional intervention elements.
33307978|NCT05689736|Experimental|Gamification|Participants will view the Core EFP and will be exposed only to gamification as an additional intervention element.
33307979|NCT05689736|Experimental|Low Engagement Nudge|Participants will receive the Core EFP intervention and low engagement nudge as an additional intervention element.
32944271|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
32944272|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
32944273|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
32800288|NCT04023292|Experimental|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
32800289|NCT04023292|Active Comparator|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
32800290|NCT03948958|Experimental|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
32800291|NCT04198090|Other|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
32800292|NCT04199182|Experimental|Exercise|Progressive, multi-component supervised exercise training group.
32800293|NCT04199182|Active Comparator|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
32800294|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
32800295|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
32800296|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
32800297|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
32800298|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
32800299|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
32800300|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
32800302|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
32800303|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
32800304|NCT04023448|Experimental|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
32800305|NCT04023448|No Intervention|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
32800306|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
32800307|NCT02080546|Active Comparator|Cut/Coag|
32800308|NCT02080546|Experimental|V-mode|
32800309|NCT04022824||OSA|
32800310|NCT04022824||Non-OSA|
32800311|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
32800312|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
32944274|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
32944275|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
32944276|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
32944277|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
32944278|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
32944279|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
32944280|NCT01954056|Placebo Comparator|Placebo|Saline placebo
32944281|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
32944282|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
32944283|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
32944284|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
32944285|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
32944286|NCT04643886|Experimental|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.~Intervention: Biological: GEM103."
32944287|NCT04643886|Experimental|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.~Intervention: Biological: GEM103"
33307980|NCT05689736|Experimental|EFP Only|Participants will receive the Core EFP intervention and not be exposed to any additional intervention elements.
33093405|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
33093406|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
33307981|NCT05689424|Placebo Comparator|HDV-bound Lispro 0%|Subjects will receive insulin lispro with 0% bound HDV
33307982|NCT05689424|Active Comparator|HDV-bound Lispro 1%|Subjects will receive insulin lispro with 1% bound HDV
33307983|NCT05689424|Active Comparator|HDV-bound Lispro 10%|Subjects will receive insulin lispro with 10% bound HDV
33307984|NCT05689424|Active Comparator|HDV-bound Lispro 100%|Subjects will receive insulin lispro with 100% bound HDV
33307985|NCT05688852|Experimental|VTX958 Dose A|
33307986|NCT05688852|Experimental|VTX958 Dose B|
33307987|NCT05688852|Placebo Comparator|VTX958 Placebo|
33093407|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
33093408|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
33307988|NCT05687071|Experimental|ETC-1002 180mg|
33307989|NCT05685303|Experimental|Treatment|Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.
33307990|NCT05685303|Sham Comparator|Control|Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.
33307991|NCT05683366||Single Group|No interventions, single group.
33307992|NCT05682157|Experimental|Paula Method|12 weeks of the Paula Method of muscle exercises with standard care
33093409|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
33307993|NCT05682157|No Intervention|Standard Care|standard care
33307994|NCT05680779|Experimental|PNM group|Subjects were treated once time. The technique consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, with 250 μs pulse width and the maximal torelable intensity to cause an exacerbated muscle contraction during ten seconds with a rest period of another ten seconds y total number of ten times. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity)
33093410|NCT00481026|Active Comparator|active tDCS|active tDCS
33307995|NCT05680779|Other|Control group|Subjects were treated once time. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity). The needle remains in this location during 200 seconds without any electrical current.
33307996|NCT05679908|Experimental|TNX-1900 High Dose|30 IU oxytocin taken intranasally twice daily.
33307997|NCT05679908|Experimental|TNX-1900 Low Dose|30 IU oxytocin taken intranasally once daily. Placebo taken intranasally once daily.
33307998|NCT05679908|Placebo Comparator|Placebo|Placebo taken intranasally twice daily.
33307999|NCT05679882|Active Comparator|Outdoor Environment|Exposure to outdoor environmental noise
33308000|NCT05679882|Experimental|Outdoor Environment with Machine-Learning Selected Masking Sounds|Exposure to outdoor environmental noise and masking sounds
33308001|NCT05677867|Experimental|Formulation A (Reference) followed by Formulation B (Test)|
33308002|NCT05677867|Experimental|Formulation B (Test) followed by Formulation A (Reference)|
33308003|NCT05676359||Cases|Patients with rheumatic diseases from the outpatient clinic at a tertiary care level in Mexico City
33308004|NCT05676359||Controls|Two patients´ relatives of the same sex, age ± five years and who are known to be healthy
33308005|NCT05676268||Patients with oral implants supporting full ceramic fixed dental prostheses|
33308006|NCT05675670|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool
33308007|NCT05675670|No Intervention|Control|Patients randomized to control will continue routine practice.
33308012|NCT05672082|Experimental|[18F]DPA-714 PET|
33308013|NCT05671341||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
33308014|NCT05671341||Parkinson's Patients Without Motor Freezing|Individuals with Parkinson's Disease without motor freeze were included in this group.
33308015|NCT05671055||Main arm|Use of icompanion through will all assessments are performed
32944288|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
32944289|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
33308016|NCT05670990|Experimental|Equine assisted therapy|"once a week during 10 weeks the children will come to Humlamaden which is a horse farm with special trained horses and employees with specialist education in psychiatric care. During the time at the farm the child will go through a structured program that starts at the first time with just resting on the horse back under blankets"
33308017|NCT05670990|No Intervention|Control|This group will receive treatment as usual and consist of those who is randomized to control group.
33308018|NCT05669534|Active Comparator|Condition 1|Standard CHRP Intervention Components
32944290|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
32944291|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
32944292|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
33308019|NCT05669534|Experimental|Condition 2|Standard CHRP Intervention Components and Information Processing Components
33308020|NCT05669534|Experimental|Condition 3|Standard CHRP Intervention Components and Memory Components
33308021|NCT05669534|Experimental|Condition 4|Standard CHRP Intervention Components, Information Processing Components, and Memory Components
33308022|NCT05669534|Experimental|Condition 5|Standard CHRP Intervention Components, Executive Functioning Components
32944293|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
32944294|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
32944295|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
32944296|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
32944297|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
32944298|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
32944299|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
32944300|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
32944301|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
32944302|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
32944303|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
32944304|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
32944305|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
32944306|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
32944307|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
32944308|NCT05313971|Experimental|Intervention|3-week recruitment period of portuguese medical students wanting to attend the 28-hour online course
32944309|NCT05313971|No Intervention|Control|The control group was recruited in order to match the age, gender, academic year and teaching faculty variables with the intervention group and people with these characteristics were invited to participate.
32944310|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
32944311|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
32944312|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
32944313|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
32944314|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
32944315|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
32944316|NCT05314049|Experimental|Experimental Group|
32944317|NCT05314049|Active Comparator|Active Comparator Group|
32944318|NCT03935399|Other|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
32944319|NCT03935399|Placebo Comparator|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
32944320|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
32944321|NCT03993119||patients with NVAF|
32944322|NCT03988049|Active Comparator|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
32944323|NCT03988049|Active Comparator|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
32944324|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
32944325|NCT03910439|Experimental|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
32800313|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
32800314|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
33093411|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
33093412|NCT00457652|Placebo Comparator|2|7 day treatment placebo
32800315|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
32800316|NCT04022434|Placebo Comparator|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.~Meal Placebo Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
32800317|NCT04022434|Experimental|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.~Meal L-Alanine Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
32800318|NCT04196374|Experimental|FHS & JHS participants with an actionable genomic finding|Framingham and Jackson Heart Study participants who have had their genomes sequenced as part of TOPMed will be notified if an actionable genetic result in an ACMG v2.0 gene is identified and will be offered the opportunity to have their research result clinically confirmed by the study.
32800319|NCT04196686|Experimental|Ice bath Control then VR/AR|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
32800320|NCT04196686|Experimental|Ice bath with VR/AR then Control|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
32800321|NCT03957850|Experimental|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
32800322|NCT03957850|Active Comparator|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
32800323|NCT04192318|Experimental|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
32800324|NCT04192318|Experimental|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
32800325|NCT04192318|Active Comparator|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
32800326|NCT04192318|Experimental|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
32800327|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
32800328|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
32800329|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
33093413|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
33093414|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
33093415|NCT00481143|Experimental|deferasirox|
33093416|NCT00457964|Experimental|Administration of RAD001|
32800330|NCT04147390|Active Comparator|usage mycophenolate mofetil|
32800331|NCT04147390|Active Comparator|usage tacrolimus|
32800332|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
33093417|NCT01240395|Experimental|MBCT intervention|
32800333|NCT02708758|Active Comparator|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
33308023|NCT05669534|Experimental|Condition 6|Standard CHRP Intervention Components, Information Processing Components, and Executive Functioning Components
32800334|NCT02708758|No Intervention|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
32800335|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|Patients in this arm will receive entinostat at the RP2D in combination with atezolizumab
32800336|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Patients in this arm will receive placebo in combination with atezolizumab
32800337|NCT03932656||Females with borderline personality disorder|
32800338|NCT03931642|Experimental|R-CHOP- blinatumomab|"Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.~At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.~Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28."
32800339|NCT04147312|Experimental|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
32800340|NCT04147312|Placebo Comparator|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
32800341|NCT03931564|Active Comparator|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
32800342|NCT03931564|Active Comparator|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
32800343|NCT04146766|Experimental|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
32800344|NCT04146766|Experimental|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
32800345|NCT04021342|Active Comparator|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).
32800346|NCT04021342|Placebo Comparator|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
32800347|NCT04021888|Experimental|Exercise Group|
32800348|NCT04021888|Active Comparator|Control|
32800349|NCT04021420|Experimental|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
32800350|NCT03946072|Active Comparator|Transseptal Group|Transseptal Aortic Approach Catheter Ablation Procedure
32800351|NCT03946072|Active Comparator|Retrograde Group|Retrograde Aortic Approach Catheter Ablation Procedure
32800352|NCT04144582|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
32800353|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
32800354|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
32800355|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
32800356|NCT03908632||Step 1|Subjects 14 years or older diagnosed with Community Acquired Pneumonia (CAP) and positive serology for primary pulmonary coccidioidomycosis (PPC) will enroll in Step 1 within 14 days of symptom onset, n=750
32800357|NCT03908632||Step 2|Subjects with a diagnosis of primary pulmonary coccidioidomycosis (PPC) confirmed by positive serologic testing during Step 1 will enter Step 2 within 21 days of their test collection date, n=200
32800358|NCT01611974|Experimental|Maribavir 400 mg twice daily|
32800359|NCT01611974|Experimental|Maribavir 800 mg twice daily|
32800360|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
32800361|NCT04144972|Active Comparator|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
33093418|NCT01240395|No Intervention|Control group|
33093419|NCT00458081|Experimental|Rimonabant|
33308024|NCT05669534|Experimental|Condition 7|Standard CHRP Intervention Components, Memory Components, and Executive Functioning Components
33308025|NCT05669534|Experimental|Condition 8|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Executive Functioning Components
33308026|NCT05669534|Experimental|Condition 9|Standard CHRP Intervention Components and Attention Components
33308027|NCT05669534|Experimental|Condition 10|Standard CHRP Intervention Components, Information Processing Components, and Attention Components
33308028|NCT05669534|Experimental|Condition 11|Standard CHRP Intervention Components, Memory Components, and Attention Components
33308029|NCT05669534|Experimental|Condition 12|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Attention Components
33308030|NCT05669534|Experimental|Condition 13|Standard CHRP Intervention Components, Executive Functioning Components, and Attention Components
33308031|NCT05669534|Experimental|Condition 14|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
33308032|NCT05669534|Experimental|Condition 15|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
33308033|NCT05669534|Experimental|Condition 16|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, Information Processing Components, and Memory Components
33308034|NCT05667493|Experimental|Eplontersen|Eplontersen will be administered once every month by sub-cutaneous (SC) injection for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first.
33308035|NCT05664256|Experimental|policy intervention group|The group will receive the policy intervention package.
33308036|NCT05664256|No Intervention|policy control group|The group will follow the usual guidelines for food procurement policy at the canteen. After three months, the group will receive the policy intervention package.
33308037|NCT05664126|Experimental|Cohort A|"Cohort A will include haploidentical donor who is identical to the stem cell donor.~The first 5 patients will be enrolled in Cohort A. If safety criteria are met, cohort B will be open for enrollment."
33308038|NCT05664126|Experimental|Cohort B|Cohort B will include haploidentical donor who is different from the stem cell donor
33308039|NCT05662033|Experimental|Part 1 (SAD): Cohort 1|6 Healthy subjects will receive a single oral dose A of AZD6793 and 2 healthy subjects will receive placebo
33308040|NCT05662033|Experimental|Part 1 (SAD): Cohort 2|6 Healthy subjects will receive a single oral dose B of AZD6793 and 2 healthy subjects will receive placebo
33308041|NCT05662033|Experimental|Part 1 (SAD): Cohort 3|6 Healthy subjects will receive a single oral dose C of AZD6793 and 2 healthy subjects will receive placebo
33308042|NCT05662033|Experimental|Part 1 (SAD): Cohort 4|6 Healthy subjects will receive a single oral dose D of AZD6793 and 2 healthy subjects will receive placebo
33308043|NCT05662033|Experimental|Part 1 (SAD): Cohort 5|6 Healthy subjects will receive a single oral dose E of AZD6793 and 2 healthy subjects will receive placebo
33308044|NCT05662033|Experimental|Part 2 (MAD): Cohort 1|6 Healthy subjects will receive dose X of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
33308045|NCT05662033|Experimental|Part 2 (MAD): Cohort 2|6 Healthy subjects will receive dose Y of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
33308046|NCT05662033|Experimental|Part 2 (MAD): Cohort 3|6 Healthy subjects will receive dose Z of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
33308047|NCT05660109|Experimental|TPM502|
33308048|NCT05660109|Placebo Comparator|placebo|
33308049|NCT05657470|Experimental|TNK group|
33308050|NCT05657470|No Intervention|control group|
33308051|NCT05653349|Experimental|Ianalumab Lower dose|Lower dose of ianalumab administered intravenously with corticosteroids oral or parentally (if clinically justified)
33308052|NCT05653349|Experimental|Ianalumab Higher dose|Higher dose of ianalumab administered intravenously with corticosteroids oral or parentally (if clinically justified)
33308053|NCT05653349|Placebo Comparator|Placebo|Placebo administered intravenously with corticosteroids oral or parentally (if clinically justified)
33308054|NCT05653219|Experimental|Treatment arm 1|Participants will receive eltrombopag and ianalumab lower dose
33308055|NCT05653219|Experimental|Treatment arm 2|Participants will receive eltrombopag and ianalumab higher dose
33308056|NCT05653219|Placebo Comparator|Treatment arm 3|Participants will receive eltrombopag and placebo
33308057|NCT05652257|Experimental|[14C]-brensocatib|Healthy participants will receive single oral dose of [14C]-brensocatib on Day 1 under fasted conditions.
33308058|NCT05652127|Experimental|Intervention: Child play of Mightier|Ad lib child biofeedback video game play in home
33308059|NCT05651360||Abdominal Pain|Participants under evaluation for an acute abdominal condition who are referred to CT of the abdomen and pelvis.
33308060|NCT05649059|Active Comparator|Cannabidiol|300mg Cannabidiol (3mL Epidiolex), oral, single-dose
33308061|NCT05649059|Placebo Comparator|Placebo|Placebo (3mL sesame seed oil), oral, single-dose
33308062|NCT05648968|Experimental|Ianalumab low dose|Participants will receive low dose ianalumab intravenously
33308063|NCT05648968|Experimental|Ianalumab high dose|Participants will receive high dose ianalumab intravenously
33308064|NCT05648968|Placebo Comparator|Placebo|Participants will receive placebo intravenously
33308065|NCT05648552||Stroke group|Chronic subcortical stroke participants with motor dysfunction
33308066|NCT05648552||Healthy controls group|Well-matched healthy controls
33308067|NCT05643729|Experimental|Group 1: Zofin|Group 1 Treatment Arm (10 subjects): Zofin + Standard of care (SOC) Ten subjects will receive 1 mL of Zofin on Day 0, Day 4, and Day 8, containing 1-5 x 10^11 particles/ml. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside. In addition to Zofin all subjects in this trial will receive SOC throughout the study period.
33308068|NCT05643729|Placebo Comparator|Group 2: Placebo|Group 2 Control Arm (10 subjects): Placebo + SOC Ten subjects will receive placebo on Day 0, Day 4, and Day 8, containing 101 mL of sterile saline at subject's bedside. In addition to placebo all subjects in this trial will receive SOC throughout the study period.
33093420|NCT00458081|Placebo Comparator|Placebo|
32800362|NCT04144972|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
32944326|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
33093421|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
32800363|NCT04147078|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
32800364|NCT04147858|Experimental|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
32800365|NCT04147858|Experimental|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
32800366|NCT04147858|Placebo Comparator|Placebo|Placebo administered orally.
32800367|NCT04146688|Active Comparator|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
32800368|NCT04146688|Active Comparator|People with no neuropathological disease|
32800369|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
33093422|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
32800370|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
32800371|NCT04146454|Experimental|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
33093423|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
33093424|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
33093425|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
33093426|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
33093427|NCT00458159|Experimental|1|
33093428|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
33093429|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
33093430|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
33093431|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
33093432|NCT00443976|Experimental|AT9283|
33093433|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
33093434|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
33093435|NCT00444015|Experimental|Dose Escalation|
33093436|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
33093437|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
33093438|NCT00488007|Experimental|Active Hearing aids|Active
33093439|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
33093440|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
33093441|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
32800372|NCT04146454|No Intervention|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
32800373|NCT03929926|Active Comparator|Group 1 (usual care)|receive usual care
32800374|NCT03929926|Experimental|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
32800375|NCT03929926|Experimental|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
32800376|NCT04587908|Experimental|TAS-205|
32800377|NCT04587908|Placebo Comparator|Placebo|
32800378|NCT04149418|Experimental|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
32800379|NCT04149418|Experimental|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
32800380|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
32800381|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:~- Single Dose, Diltiazem (Day 1)~- Multiple Dose, Clarithromycin XL (Days 4-9)~- Single Dose, Diltiazem (Day 8)"
32800382|NCT04142632||long term evaluation of hypospadias surgery|
32944327|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
33308073|NCT05642247||CD patients who received Ustekinumab treatment|1. Inpatients with Crohn's disease diagnosed in the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022. 2.The patients were treated with Ustekinumab and followed up regularly for 20 weeks. 3. Complete pre-treatment cross-sectional imaging data (CTE/MRE and US)
33308074|NCT05640843|Experimental|Whole Foods Plant-based Diet|For 12 weeks, on the WFPBD arm, patients will receive two premade meals per day, for lunch and dinner for 6 days weekly, prepared and shipped by U.S.-based WFPBD company Plantable weekly.
33308075|NCT05640843|Experimental|Supplements|For 12 weeks on the supplement arm, patients will be given algae omega 3 supplements (QWell pharmaceuticals) and curcumin supplements (Sabinsa pharmaceuticals) twice daily.
33308076|NCT05640843|Placebo Comparator|Placebo|For 12 weeks on the placebo arm, patients will be given placebo supplements twice daily (QWell and Sabinsa pharmaceuticals).
33308077|NCT05639686|Placebo Comparator|Total Intravenous Anesthesia (TIVA)|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, and lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with propofol 150mg/kg/min, remifentanil 0.05-2µg/kg/min, and rocuronium or succinylcholine as indicated. This is standard of care for this procedure. Within 10 minutes of induction, patients in the control group will be administered a 100mL bolus of normal saline as placebo.
33308078|NCT05639686|Experimental|Transexemic Acid (TXA) and Inhalational Anesthesia|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with isoflurane 1.5-2% or sevoflurane 1-2%, as well as rocuronium or succinylcholine as indicated. Again standard of care procedure is applied. Within 10 minutes of induction, patients in the study group will be administered 15mg/kg TXA suspended in 100mL of normal saline intravenously.
33308079|NCT05639647|Experimental|ATM-AVI|ATM-AVI administered iv every 6 or 8 hours and dosed according to participant's weight and kidney function for up to 14 days depending on response. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv ATM-AVI therapy
33308080|NCT05639647|Active Comparator|Best available therapy (BAT)|BAT will be selected by the investigator and administered iv. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv BAT
32944328|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
32944329|NCT03927209|Experimental|BI 1467335 (low dose)|
32944330|NCT03927209|Experimental|BI 1467335 (high dose)|
32944331|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
32944332|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
32944333|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
32944334|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
32944335|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
32944336|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
32944337|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
32944338|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
32944339|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
32944340|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
32944341|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
32944342|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
32944343|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
32944344|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
32944345|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
32944346|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
32944347|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
33093442|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
33093443|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
33093444|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
33093445|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
33093446|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
33093447|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
33308081|NCT05638568|Experimental|Intervention arm LS guided treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as treat with surfactant or  do not treat with surfactant depending on wether the LS-ratio is under or above the cut-off ratio for treatment.~Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 > 0.30) - ie same as in control group."
32800383|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
32800384|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
32800385|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
33093448|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
33093449|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
33102513|NCT05467709|Experimental|CTP-543|Subjects will receive a single 2 mg dose of midazolam on Day 1. Starting on Day 3, 12 mg dose of CTP-543 will be administered (q12 hrs) for 14 consecutive days (up to Day 16). On Day 16, subjects will be co-administered a single 2 mg midazolam dose along with the morning dose of CTP-543. The second dose of CTP-543 will be administered as scheduled on Day 16.
32800386|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
32800387|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
32800388|NCT04149964|Active Comparator|Standard of Care arm|Standard of Care Post-operative pain medication, Acetaminophen 325 mg every 6 hours as needed for pain plus acetaminophen/hydrocodone 7.5 mg/325 mg 1 tab every 4 hours as needed for pain.
32800389|NCT04149964|Experimental|Study Arm|Acetaminophen 650 mg 1 tab every 6 hours round the clock plus Oxycodone 5 mg 1 tab every 6 hours as needed for breakthrough pain,.
33102514|NCT00532623|Active Comparator|Combination|
33308082|NCT05638568|No Intervention|Control arm - routine surfactant treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device, but result will remain blinded.~Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 > 0.30). The LS-ratio for those infants will remain blinded"
33308083|NCT05636540|Experimental|Cohort A|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental [18F]FTT PET/CT scan prior to surgery. Patients in Cohort A will undergo surgery with or without additional therapy.
33308084|NCT05636540|Experimental|Cohort B|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental [18F]FTT PET/CT scan prior to systemic therapy with radionuclide or chemotherapy. Up to 10 patients undergoing systemic therapy may undergo a second (optional) scan that will be performed approximately 1-21 days after therapy has started. The second scan is obtained to evaluate whether the initiation of systemic therapy alters [18F]FTT uptake. As this is a pilot study, only a limited number of patients are sought for the second scan.
33308085|NCT05636020|Experimental|Treatment (ICARE)|ICARE treatment consisting of 12 sessions that train affect recognition and empathic behaviors.
33308086|NCT05633576|Active Comparator|steroid eye drops|In this treatment arm, patients will self-administer the steroid eye drops three times a day for four consecutive weeks.
32800390|NCT04149496|Experimental|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
32800391|NCT04587752|Experimental|CBT for Weight Bullying|Cognitive-Behavioral Therapy (CBT) for children who have experienced weight-related bullying
32800392|NCT04140136|Active Comparator|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
32800393|NCT04140136|Placebo Comparator|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
32800394|NCT04146532|Placebo Comparator|Placebo|Single dose of a 500mg placebo tablet.
32800395|NCT04146532|Active Comparator|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
32800396|NCT03929224|Active Comparator|Bacitracin|Standard care: Bone-anchored hearing aid (BAHI) abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
32800397|NCT03929224|Experimental|Medicinal honey|Medicinal honey: Medicinal honey will be applied to the abutment site immediately after surgery. The healing cap will be placed on the BAHI site. The healing cap is removed on postoperative day 7. Patient is instructed to apply medicinal honey daily to the area for 2 weeks.
32800398|NCT04601493|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
32800399|NCT04601493|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
32800400|NCT04601493|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
32800401|NCT04601493|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
32800402|NCT03928288|Experimental|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
32800403|NCT03928288|Placebo Comparator|Placebo|Placebo capsule PO twice weekly for 6 months
32800404|NCT04146610|Experimental|Dp303c|Multiple dose grouping
32800405|NCT03925870|Experimental|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
32944348|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
32944349|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
32944350|NCT03900299|Other|oncoplastic breast surgery|
32944351|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
32944352|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
32944353|NCT04713917|Active Comparator|Gel Group|Two applications of HA gel (Mucogyne®) per week during one year.
32944354|NCT04713917|Experimental|Laser Group|Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
32944355|NCT04713917|Experimental|HA Injection Group|Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
32944356|NCT03894449|Placebo Comparator|Placebo only|
32944357|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
32944358|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
32944359|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
32944360|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
32944361|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
32944362|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
32944363|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
32944364|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
32944365|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
32944366|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
32944367|NCT03870893|No Intervention|control group|No intervention
32944368|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
32944369|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
32944370|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
32944371|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
32944372|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
33308087|NCT05633576|Placebo Comparator|Placebo|In this treatment arm, patients will self-administer the placebo eye drops three times a day for four consecutive weeks.
33308088|NCT05632484|Experimental|Newborns with a parent with HHT disease|16 newborns with one parent suffering HHT disease and carrying a mutation in the ACVRL1, ENG or SMAD4 gene will be included in this study.
33308089|NCT05631119||Diabetic Kidney Disease|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30"
33308090|NCT05631119||Chronic Kidney Disease|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am"
33308091|NCT05631119||Type 2 Diabetes|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 8 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
32944373|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32944374|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
32944375|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
32944376|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
32944377|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
32944378|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
32944379|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
32944380|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
32944381|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
32944382|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
32944383|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
32944384|NCT01340573||Genotype 1 CHC Participants|
32944385|NCT01340573||Non-genotype 1 CHC participants|
32944386|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
32944387|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
32944388|NCT01340885|Placebo Comparator|Placebo|sugar pill
32944389|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
32944390|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
32800406|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
32800407|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
32800408|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
32800409|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
32800410|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
33093450|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
33093451|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
33093452|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
33093453|NCT00444249|Active Comparator|1|White Alcon IOL
33308092|NCT05631119||Healthy Matched Controls|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 16 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
33308093|NCT05629585|Experimental|Dato-DXd in combination with Durvalumab|Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Durvalumab 1120 mg IV Q3W x 9 cycles
33308094|NCT05629585|Experimental|Dato-DXd|Arm 2: Dato-DXd 6 mg/kg IV Q3W x 8 cycles
33093454|NCT00444249|Active Comparator|2|Yellow Alcon IOL
33093455|NCT00444249|Active Comparator|3|White Hoya IOL
33093456|NCT00444249|Active Comparator|4|Yellow Hoya IOL
33093457|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
33093458|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
33093459|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
33093460|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
33093461|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
33093462|NCT03278262||36-69 letters|Baseline VA 36-69 letters
33093463|NCT03278262||<=35 letters|Baseline VA <=35 letters
33093464|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
33093465|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
33093466|NCT04698044||Healthy|Have not chronic disease
33093467|NCT04698044||Cancer|Have cancer
32800411|NCT04142710|Experimental|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
32800412|NCT04142710|No Intervention|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
33093468|NCT04698044||Non-Cancer Crhronic Disease|Have non-cancer chronic disease
33093469|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
33093470|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
33093471|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
33093472|NCT00459524||Questionnaire|AML and MDS Patients
33093473|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
33093474|NCT00459563|Placebo Comparator|Placebo|
33093475|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
33093476|NCT00459563|Active Comparator|Calcitriol|Calcitriol
33093477|NCT01242384|No Intervention|Expectant Management|
33093478|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
33093479|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
33093480|NCT00488397||1|
33093481|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
32800413|NCT04142710|Experimental|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
32800414|NCT04765930|Active Comparator|PRP Injection|Half of the face
32800415|NCT04765930|Placebo Comparator|Saline injection|Other half of the face
32800416|NCT05589922||Patients with abnormal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index smaller than 5 cm
32800417|NCT05589922||Patients with normal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index bigger than 5 cm
33093482|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
33093483|NCT00459680|Experimental|Acupuncture|
33093484|NCT00459680|Experimental|Laser Acupoint|
32800418|NCT05582044|Experimental|Heart Failure with Preserved Ejection Fraction (40 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
32800419|NCT05582044|Active Comparator|Healthy Controls (20 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
32800420|NCT03906682|Experimental|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
32800421|NCT03906682|Active Comparator|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
32800422|NCT04145518|Active Comparator|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
32800423|NCT04145518|Placebo Comparator|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
32800424|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
32800425|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
32800426|NCT04149886|Experimental|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
32800427|NCT04149886|Sham Comparator|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
32800428|NCT05584774|Placebo Comparator|PELD|
32800429|NCT05584774|Active Comparator|PELD and annuloplasty and nucleoplasty|
32800430|NCT05581654|Experimental|Junior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre. For ethical reasons, all the junior surgeons will first assist the senior surgeons in performing vNOTES salpingectomy, as first assistant in at least 15 procedures, before starting to perform them as operators.
32800431|NCT05581654|Active Comparator|Senior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre.
32800432|NCT05581576|Experimental|Pitolisant (Wakix)|Pitolisant will be titrated weekly until maximum dosage of 35.6 mg. Titration is dependent on subjects response.
32800433|NCT04145752|Experimental|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.~Drug: Ropivacaine 3 mg/kg, single-shot"
33093485|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
33093486|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
33093487|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
33093488|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
33093489|NCT00488553||Control|Participants of study from matched control group.
33093490|NCT00459719|Experimental|1|In combination with steroids
33093491|NCT00459719|Active Comparator|2|In combination with steroids
33093492|NCT00495183|Experimental|1|caffeine + placebo
33093493|NCT00495183|Experimental|2|caffeine + biperiden
33093494|NCT00495183|Placebo Comparator|3|Placebo+placebo
33093495|NCT00459797|Active Comparator|Conventional Glidescope|
32800434|NCT04145752|Active Comparator|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
32800435|NCT04149262|Active Comparator|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
32800436|NCT04149262|Active Comparator|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
32800437|NCT04145986||young ladies|Young ladies≤ 35 years old.
32800438|NCT03647800|Experimental|PART 1 Dose Escalation - 10 dose cohorts|CD123 and CD3 epsilon bispecific antibody
32800439|NCT03647800|Experimental|PART 2 Dose expansion - 5 cohorts|90 patients, 18/cohort in 5 dose expansion cohorts, will receive the recommended dose of APVO436 determined from Part 1
32800440|NCT04145908|Active Comparator|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
32800441|NCT04145908|Active Comparator|onlay mesh|patients underwent preperitoneal mesh mesh placement
32800442|NCT05581420|Active Comparator|Oral iron|"Ferrous fumarate 200mg daily for 4 weeks.~Group A1 (Normal Hb at week 4):~Ferrous fumarate 100mg daily for 12 weeks~Group A2 (Abnormal Hb at week 4):~Ferrous fumarate 200mg daily for 8 weeks~Group A2 at week 12:~Normal Hb: ferrous fumarate 100 mg daily till week 16 Abnormal Hb: intervention failure. End of study."
32800443|NCT05581420|Active Comparator|IV Iron|Dosage based on iron formulation and instructions according to recommended guidelines (weight of patient)
32800444|NCT05581264|Experimental|Self-Management Education Program|Participants received the diabetes self-management education program. The education and counseling were maintained through follow-up via phone for the intervention group
32800445|NCT05581264|No Intervention|No Intervention/Control Group|Participants received the usual medical care prescribed by the patient's attending doctor.
32800446|NCT03022474|Experimental|Intervention group|
32800447|NCT03022474|No Intervention|Control group|
32800448|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
32800449|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
32800450|NCT04149340|Other|Sufentanil sedation|3 microgram of Sufentanil IV
32800451|NCT04149340|Placebo Comparator|Placebo sedation|1 ml de NaCl 0,9%
32800452|NCT04149340|Other|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
32800453|NCT03021226|Experimental|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
32800454|NCT03021226|No Intervention|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
32800455|NCT04148794|Experimental|Intervention group|Participants who join the class of eALS
32800456|NCT05580952|Experimental|Experimental: Treatment|Device: J-Valve® valve delivery system
32800457|NCT05580874|Experimental|Massage group|"Babies in the massage group will be given a five-minute massage once a day, one hour after the morning feeding (between 9.30-11.30 am). Before, during and after the massage procedure, the video will be recorded to observe the stress behavior of the babies. Vital signs will be recorded a minute before the starting of the massage, at fifth minutes during the procedure and a minute after the end of the massage, and a video will be recorded during these processes. A saliva cortisol sample will be taken the massage five minutes before and 30 minutes after the massage. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
32830591|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
32830592|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
32830593|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
32830594|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
33093496|NCT00459797|Experimental|Single-use Glidescope|
33093497|NCT00495261|Experimental|1|
33093498|NCT00495261|Active Comparator|2|
33093499|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
33093500|NCT00459914|No Intervention|2|Pharmacological treatment alone
33093501|NCT00495339|Experimental|1|Levofloxacin
33093502|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
33093503|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
33093504|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
33093505|NCT00460226||lamotrigine|there is only one group.
33308095|NCT05629585|Active Comparator|Investigators Choice Therapy|"Arm 3: Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles~Pembrolizumab* (200 mg IV on Day 1, Q3W) for 9 cycles~Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles + pembrolizumab* (200 mg IV on Day 1, Q3W) for 9 cycles~* Only participants who have received prior pembrolizumab in the neoadjuvant setting should receive pembrolizumab as part of their adjuvant therapy on Arm 3."
33308096|NCT05628285|Experimental|Sentio 1 sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
33308097|NCT05627986||chronic shoulder impingement syndrome|Subjects with shoulder impingement more than 6 months will be included to assess pain threshold, neurophysiological measurements of scapular muscles.
33308098|NCT05627986||control group|Healthy controls without any shoulder and neck problems will be included to compare the differences in pain threshold, neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with chronic or acute shoulder impingement syndrome.
33308099|NCT05622929|Experimental|Intervention group|Real-world evidence (RWE) platform to provide data on their clinical practice + usual care + Digitally-enabled Multifaceted Quality Improvement Intervention
33308100|NCT05622929|Active Comparator|Control group|RWE platform to provide data on their clinical practice + usual care
33308101|NCT05621993||Combination therapy group|Patients who are treated with the combination therapy of Azvudine and Chinese herbal medicine will be included in this group. The combination therapy is Azvudine treatment (5 mg once a day) within 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
33308102|NCT05621993||Sequential therapy group|Patients who are treated with the sequential therapy of Azvudine and Chinese herbal medicine will be included in this group. The sequential therapy is Azvudine treatment (5 mg once a day) after 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
33308103|NCT05621993||Non-standard therapy group|Patients are treated with Azvudine combined with Chinese herbal medicine treatment. But Azvudine treatment is discontinued before the nucleic acid turns negative.
33308104|NCT05621993||The control group|Patients are treated with Chinese herbal medicine without Azvudine.
33308105|NCT05617716|Experimental|Standard dose SBRT|Participants will undergo standard dose Stereotactic Body Radiation Therapy
33308106|NCT05617716|Experimental|High dose SBRT|Participants will undergo high dose Stereotactic Body Radiation Therapy
33308107|NCT05617716|Experimental|Conventional EBRT|Participants will undergo External Beam Radiation Therapy
33308108|NCT05615935|Experimental|Get a learning material and a experiential HIV Testing|These participants in the experimental group will be provided a learning material about HIV testing, then an experiential HIV Testing, which includes HIV testing and counselling, education and discussion, and a post-test interviews will be provided.
33308109|NCT05615935|No Intervention|Get a learning material only|These participants in the control group will be provided a learning material about HIV testing only. After the post-test, the experiential HIV Testing will be provided to them.
33308110|NCT05615428||observational group|"Inclusion criteria:~GA ≤29+6, inborn at a participating centre~Age less than 45 minutes as gastric aspirate must be sampled within 45 minutes from delivery.~Exclusion criteria:~Treated with surfactant beforerandomisation and obtaining gastric aspirates~Diagnosis of major malformations (major congenital heart defects, congenital diaphragmatic hernia, gastroschisis/omphalocele, pulmonary abnormalities including pulmonary hypoplasia and trachea-oesophageal fistula~Antenatal suspicion of significant oligohydramnios and lung hypoplasia~Any intrauterine intervention except if done for genetic testing"
33308111|NCT05615402|Experimental|Training group|Group A: strength training 3x/week + nutrition optimalisation
33308112|NCT05615402|Experimental|Nutrition group|Group B: nutrition optimalisation
33308113|NCT05610657|Experimental|Mitapivat|Mitapivat tablet as a single oral dose, under fasted conditions on Day 1 to compare participants with normal hepatic function to participants with moderate hepatic function (Child-Pugh [C-P] Score B, score of 7 to 9).
33308114|NCT05610449||Testing Done Simple Antigen test in Symptomatic Subjects (Nasal swab)|
33308115|NCT05610449||Testing Done Simple Antigen test in Asymptomatic Subjects (Nasal swab)|
33308116|NCT05610358|Experimental|Intervention|Participants in the intervention group will be provided the smartphone application and they will practice application based rehabilitation for 12 weeks.
33308117|NCT05610358|No Intervention|Control|Participants in the control group will not practice rehabilitation program.
32830595|NCT03281928|Placebo Comparator|High Sodium plus placebo|
33308118|NCT05610306||Inherited ichthyosis patients|Interviews
33308119|NCT05608005|Experimental|Group 1|2 doses, 21 days apart, of Panblok H7 dose 1 + MF59
33308120|NCT05608005|Experimental|Group 2|2 doses, 21 days apart, of Panblok H7 dose 2 + MF59
33308121|NCT05608005|Active Comparator|Group 3|2 doses, 21 days apart, of Panblok H7 dose 3 unadjuvanted
33308122|NCT05607758|Experimental|App for Stress management|"Participants will:~Participate in a physical introduction to the app-based stress management program~Get access to the app-based program, and a new module every third day (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.~Receive two phone follow-up calls from study personnel (about 3 and 6 weeks after the physical introduction)"
33308123|NCT05607004|Experimental|PK Cohort|"(Z)-endoxifen capsules orally once daily for 4 weeks. Initial (Z)-endoxifen dose evaluated will be 40 mg with an option to evaluate 20 mg or 80 mg.~The PK Cohort participants may extend treatment up to 6 cycles/Week 24 based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery."
33308124|NCT05607004|Experimental|Treatment Cohort Arm 1 Initial Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks. Dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
32800458|NCT05580874|Other|Control group|"Babies in the swaddling group will form the control group. The swaddling process will be done one hour after the babies are feding (between 9.30-11.30 am). Before, during and after the swaddling procedure, the video will be recorded to observe the stress behavior of the babies. A minute before swaddling, video recording will start. Babies will be swaddling for five minutes and video recording will be continue. After this process, a minute video recording will be made while the baby is not swaddling. Vital signs will be recorded one minute before starting the swaddling at fifth minutes during the procedure, and a minute after the swaddling.~A saliva cortisol sample will be taken five minutes before and 30 minutes after the swaddling. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
33093506|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
33093507|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
33093508|NCT00460343|Experimental|max|
33093509|NCT00460343|Active Comparator|min|
33093510|NCT00495417|Active Comparator|1|
33093511|NCT00495417|Active Comparator|2|
33093512|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min Social Cognitive Theory-based counseling session delivered in STI clinic setting in Cape Town South Africa. Includes educational, motivational, and sexual risk reduction skills components delivered in a single face-to-face counseling session.
33093513|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
33308125|NCT05607004|Active Comparator|Treatment Cohort Arm 2 Initial Regimen|"Exemestane 25 mg orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant once monthly.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
33308126|NCT05607004|Experimental|Treatment Cohort Arm 1 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant once monthly. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
33308127|NCT05607004|Experimental|Treatment Cohort Arm 2 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant once monthly. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
33308128|NCT05605522|Experimental|Phase 1 Dose Escalation|
33308129|NCT05605522|Experimental|Phase 1 Dose Expansion|
33308130|NCT05604235|Experimental|Therapeutic strength exercise group|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. The protocol will be carried out in approximately 30 minutes.
33093514|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
33093515|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
32800459|NCT05580796|Experimental|TCR-T cells|TCR-T cell injection
32800460|NCT03905434||Control|A total of 15 healthy controls will be enrolled and miRNA samples will be collected
32800461|NCT03905434||Stroke|A total of 30 acute stroke patients with large vessel occlusions will be enrolled.
32800462|NCT03904498|Experimental|Tolcapone then Placebo|Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
33093516|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
33093517|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
32800463|NCT03904498|Experimental|Placebo then Tolcapone|Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
32800464|NCT04405960|Experimental|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
32800465|NCT04405960|Placebo Comparator|Control Group|Individuals in control group were given placebo once daily
32800466|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
32800467|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
32830596|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
33093518|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
33093519|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
33308131|NCT05604235|Experimental|Passive mobilization group|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulohumeral complex and neurodynamics, where mobilisations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
33093520|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
33308132|NCT05591404|Experimental|Film + TSST|Nature Film + Trier Social Stress Test (TSST)
33308133|NCT05591404|No Intervention|Film Only (No-TSST)|Nature Film Only
33308134|NCT05590234|Active Comparator|Dexmedetomidine combined with bupivacaine group (DB group)|patients received 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%,
33308135|NCT05590234|Active Comparator|bupivacaine 0.25%,|patients received 20 ml of bupivacaine 0.25%
33308136|NCT05590234|Placebo Comparator|control group (S group)|patients received 20 ml of normal saline 0.9%.
33308137|NCT05586685|Experimental|GroupA diaphragmatic release + conventional|"Group A: diaphragmatic release +conventional The patients will be positioned in the supine position. The therapist stood at the head of the patient contact thoracic cage and ask the patient to take inspiration and move laterally then ask the patient to expire.~conventional Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks: Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch the pectoral area from the supine lying position"
33308138|NCT05586685|Experimental|Group B: conventional|Group B: conventional posture correction exercises Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position
33308139|NCT05586074|Experimental|Clifutinib|Subjects received 40 mg dose orally once a day in continuous 28-day cycles, at least 2 hours before and after food. Clifutinib treatment continued until sujects met one of the treatment discontinuation criteria.
33308140|NCT05586074|Active Comparator|Salvage Chemotherapy|Subjects received chemotherapy in 28-day cycles. Subjects on Low-Dose Cytarabine (LoDAC) received 10 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10~14 days. Subjects on azacitidine received 75 mg/m^2 daily by SC for 7 days. Subjects on decitabine received 20 mg/m^2 daily by IV injection for 5 days. Subjects on LoDAC or azacitidine or decitabine treatment continued until they met discontinuation criteria. Subjects on Ara-C±IDA chemotherapy received cytarabine 1~3 g/m^2 daily by IV for 3 days and idarubicin 10 mg/m^2 daily by IV for 3 days. Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC for 6 days (days 1-6), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 1~2 g/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Subjects receiving Ara-C±IDA or FLAG-IDA received 1 cycle of therapy and were assessed for response on day 28+/-2 days.
33308141|NCT05584800|Experimental|ZGGS18|
33308142|NCT05584358|Experimental|Dry Blend|A dry blend of mycoprotein and pea protein.
33308143|NCT05584358|Experimental|Extrudate|An extruded blend of mycoprotein and pea protein
33308144|NCT05584254|Experimental|Elderly with gastrointestinal symptoms|The target group for the intervention and cohort of interest used for comparison of baseline characteristics between control groups. Went into a cross-over design with 2 yeast-derived beta-glucan supplements and a placebo.
33308145|NCT05584254|No Intervention|Senior orienteers|A model of healthy aged elderly used as a control group for the baseline characteristics.
33308146|NCT05584254|No Intervention|Young healthy adults|A cohort of young healthy adults used as a control group for the baseline characteristics.
33308147|NCT05584241|Active Comparator|Diagnostic Disclosure|"Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
33308148|NCT05584241|Experimental|Biomarker and Diagnostic Disclosure|"Participants receive information about their cognitive test results and research diagnosis. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
33308149|NCT05583630||Ligament tension measurement group|All participants will receive ligament tension measurement by the tension device during operation
33308150|NCT05580939|No Intervention|Control Grup|they receive theoretical first aid training
33308151|NCT05580939|Experimental|Intervention Grup|they receive theoretical first aid training and use web based simulation application
33308152|NCT05578781|Experimental|Music Therapy|The Music Therapy (MT) group will participate in 1 live session of music therapy with a board certified Music therapist while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
33308153|NCT05578781|Experimental|Music Medicine|The Music Medicine (MM) group will participate in 1 audio session of music while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
33308154|NCT05578781|Experimental|Music Medicine +|The Music Medicine + (MM+) group will participate in 1 audio session of music, with the board certified music therapist present while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
33093521|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
32830597|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
33093522|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
33093523|NCT00460538|Placebo Comparator|2|
33093524|NCT00460538|Active Comparator|1|
33093525|NCT00488787|Experimental|A|Intranasal ketamine low dose
33093526|NCT00488787|Experimental|B|intranasal ketamine medium dose
33093527|NCT00488787|Experimental|C|intranasal ketamine high dose
33093528|NCT00488787|Placebo Comparator|D|placebo
33093529|NCT00460616||1|Patients already receiving treatment with cabergoline.
33093530|NCT00460616||2|healthy controls sex and age-matched with the patients
33093531|NCT00495651|Active Comparator|I|Standard of care
33093532|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
33093533|NCT00495651|Experimental|III|Early Antiretroviral therapy
33093534|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
33093535|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
33308155|NCT05578781|Experimental|Control condition|the Control group will participate in 1 session of an audio of text being read to them while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
33308156|NCT05578781|Active Comparator|Control group without low back pain|This group will participate in 1 session of an audio of the music therapy session while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about the lasting effects and pain
33308157|NCT05578599|Other|Experimental Treatment|Treatment with the Swiftsure CSS device in addition to standard oral care procedures
33308158|NCT05573542||Patients with Parkinson's|Individuals with confirmed diagnosis of Parkinson's disease by neurologist.
33308159|NCT05573542||Patients with irritable bowel syndrome|Individuals with IBS according to ROME IV criterias
33308160|NCT05573542||Healthy controls|Healthy individuals lacking both IBS and Parkinson's disease, in addition to other criteras stated in the Eligibility section.
33093536|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
33308161|NCT05571566|No Intervention|Pre-implementation phase|All patients with acute appendicitis who undergo appendectomies will be eligible to participate, and families will be consented prior to surgery. The explanation of the procedure will be done verbally by the surgeon as it is the standard care at the hospital. A parental anxiety assessment will be done before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, an email from one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email again with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
33093537|NCT00460733|Experimental|1|
33093538|NCT00460733|Active Comparator|2|
33093539|NCT00488904|Experimental|a|
33093540|NCT00488904|Placebo Comparator|b|
33093541|NCT00460850|Experimental|1|
33093542|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
33093543|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
33093544|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
33093545|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
33093546|NCT00460967|Experimental|1|Rheopheresis treatment
33093547|NCT00460967|Sham Comparator|2|Sham treatment
33093548|NCT00461084||1|lymphoma follicular
33093549|NCT00461084||2|lymphoma non-follicular
33093550|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
33093551|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
33093552|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
33093553|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
33093554|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
33093555|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
33093556|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
33093557|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
33093558|NCT00495846|Other|B|Historical controls
33093559|NCT04697316|Experimental|ADHD tDCS|
33308162|NCT05571566|Active Comparator|Post-implementation phase|The education tool will be distributed to families whose child is undergoing an appendectomy. The explanation of the procedure will also be done verbally by the surgeon as it is the standard care at the hospital. The parental anxiety assessment will be done in the same way as above, before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, the email of one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
33308163|NCT05571293|Experimental|Botensilimab and balstilimab (bot/bal)|Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. A single dose of botensilimab (75 mg IV), and two doses of balstilimab (240 mg IV), will be administered on the same day. A second dose of balstilimab (240 mg IV) will be administered 14 days later (-2 +5 days). Surgical resection will occur 1-6 weeks following the second dose of balstilimab.
33308164|NCT05568615|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
33308165|NCT05565937|Experimental|BL-3100-NBR03|BL-3100-NBR03 multi-purpose solution
33308166|NCT05565937|Active Comparator|renu® Advanced Formula|renu® Advanced Formula multi-purpose solution
33308167|NCT05556837|Active Comparator|Extruded Cereal|This arm is comprised of consuming extruded cereal without beta glucan or with oat beta glucan (OBG) or with barley beta glucan (BBG) (3 different test meals on 3 different days).
33308168|NCT05556837|Active Comparator|Batch-cooked Cereal|This arm is comprised of consuming a batch-cooked cereal without beta glucan or with oat beta glucan (OBG) or with barley beta glucan (BBG) (3 different test meals on 3 different days).
33308169|NCT05554354|Experimental|Cohort I (Arm I) (fulvestrant, binimetinib)|Patients receive fulvestrant IM and binimetinib PO throughout the trial. Patients also undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
33308170|NCT05554354|Active Comparator|Cohort I (Arm II)|Patients receive fulvestrant IM throughout the trial. Patients who progress on fulvestrant alone are asked to reaffirm their willingness to enroll in cohort II. Patients not willing to transition to cohort II continue further therapy as clinically indicated. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
33308171|NCT05554354|Experimental|Cohort II (fulvestrant, binimetinib)|Patients receive fulvestrant IM and binimetinib PO throughout the trial. If the patient progressed on fulvestrant, the loading dose of fulvestrant is omitted. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
33308172|NCT05554328|Experimental|Arm I (selumetinib, olaparib)|Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
33308173|NCT05554328|Active Comparator|Arm II (selumetinib)|Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
33308174|NCT05553522|Experimental|Investigational Treatment|
33308175|NCT05552859|Experimental|Gla-300 arm|Gla-300 will be administered once daily for 24 weeks
33308176|NCT05552859|Active Comparator|IDeg-100 arm|Ideg-100 will be administered once daily for 24 weeks
33308177|NCT05552365|Experimental|Active Intervention|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder.
33308178|NCT05552365|Other|Treatment as Usual|Participants are re-directed to mental health support services. All participants given a mental health brochure which has contact details of mental health services for children.
33308179|NCT05551403|Experimental|rest-EEG, TMS-EEG/TMS-electromyography(EMG) and photic stimulation|
33308180|NCT05549453|Experimental|SNBT device use|SNBT device is used for motor cortex localization, motor threshold determination and for targeting the intracranial electric field induced by the device to the intarcranial location required for the use of the device for its intended use
33308181|NCT05548062||Hydroxyurea|Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.
33308182|NCT05548062||Ruxolitinib|Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.
33308183|NCT05547412||Cohort X|Phase 0 will include up to 20 subjects in Cohort X (TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
33308184|NCT05547412||Cohort Y|Phase 0 will include up to 20 subjects in Cohort Y (No TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
33308185|NCT05547412||Cohort A|Both Phase 1 and Phase 2 of the study will enroll Cohort A (LVO TCD). Cohort A will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
33308186|NCT05547412||Cohort B|Both Phase 1 and Phase 2 of the study will enroll Cohort B (Non-LVO TCD). Cohort B will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
33308187|NCT05547412||Cohort C|Both Phase 1 and Phase 2 of the study will enroll Cohort C (LVO No-TCD). Cohort C will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
33308188|NCT05547412||Cohort D|Both Phase 1 and Phase 2 of the study will enroll Cohort D (Non-LVO No-TCD). Cohort D will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
33308189|NCT05546996|No Intervention|Phase A:|Establish suitability of digital video recording system for quantifying CSF drainage into an EVD drainage system.
33308190|NCT05546996|Other|Phase B|Exploratory study to generate initial data on the correlation between FlowSense flow rate measurements (FlowSense Flow Rate) and: A) EVD drainage data, quantified via video recording; B) intracranial pressure (ICP) measurements
33308191|NCT05545605|Experimental|Intervention group|Subjects randomized to the trial group will receive sodium oligomannate 450mg twice daily for 24 weeks.
33308192|NCT05545605|Placebo Comparator|Control group|Subjects randomized to the control group will receive a 450mg placebo capsule twice daily for 24 weeks that has exactly the same appearance and smell as the Intervention group.
33093560|NCT04697316|Sham Comparator|ADHD Sham|
32800468|NCT04405804|Experimental|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
32800469|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
33093561|NCT04697316|Experimental|Healthy control tDCS|
33093562|NCT04697316|Sham Comparator|Healthy control Sham|
33093563|NCT00461240||acromegaly|
33093564|NCT00461240||growth hormone deficiency|
33093565|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
33093566|NCT00461279|Other|1|
33093567|NCT00461279|Other|2|
33093568|NCT04697082|Placebo Comparator|Group A|The open surgical method and a moist gauze (with saline) were applied to patients in group A
33093569|NCT04697082|Experimental|Group B|Open surgery and then PRP application were performed on patients in group B. After the cavity was filled with PRP, the wound was covered with a dry gauze.
32800470|NCT04145206||control group|not practice of flamenco dance
32800471|NCT04145128|Experimental|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
32800472|NCT03945604|Experimental|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
32800473|NCT03944434|Experimental|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
32800474|NCT05580640|Experimental|6 months + post knee surgery|: For study participation subjects need a history of unilateral knee arthroscopy or arthroplasty performed > 6 months ago with completion of post-operative rehabilitation. Subjects will be between the ages of 21 and 90 years old and the ability to walk for 5-10 minutes on level ground.
32800475|NCT05580484||Purified starch/Control group|Patients who were willing to receive purified starch at their own expense during this first surgery were included in the purified starch group, and patients who did not re-ceive purified starch or other anti-adhesion products were included in the control group.
32800476|NCT05580406|No Intervention|Usual Care|Participants assigned to usual care will not receive outreach messages (online or via telephone) by study staff.
32800477|NCT05580406|Experimental|Outreach Messaging|Participants in the outreach messaging arm will receive messages via online secure message system (embedded within the health care record) and/or telephone.
32800478|NCT04148716||patients|recruitement of 9 patients
32800479|NCT04148716||control|recruitement of 9 control person
32800480|NCT03582436||Prospective cohort|Kidney transplantation
32800481|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
32800482|NCT04406116|Experimental|patients receiving microwave therapy using the HS1 Instrument|
32800483|NCT04145050|Experimental|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
32800484|NCT04145050|Experimental|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
32800485|NCT04145050|Experimental|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
32800486|NCT03941314|Experimental|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
32800487|NCT03941314|Active Comparator|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
33093570|NCT04697082|Experimental|Group C|PRP was applied to the patients in group C after curettage of the sinus cavity. And again the wound was covered with a dry gauze.
33093571|NCT00105482|Experimental|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
33093572|NCT00105482|Placebo Comparator|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
33093573|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
33093574|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
33093575|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
33093576|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
33093577|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
33093578|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
33308193|NCT05541146|Experimental|Intraperitoneal chemotherapy|Intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis.
32944391|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
32944392|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
32944393|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
32944394|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
32944395|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
33308194|NCT05537935|No Intervention|Control|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Should a patient decline participation in the treatment plan, they will be invited to participate in a control group. They will be invited to complete the PROMIS questionnaire every 4 weeks, and the NPRS pain assessment every week from Baseline through week 12. These participants will receive follow up phone calls to confirm completion of these assessments weekly and will not have any in-person visits."
33308195|NCT05537935|Experimental|Low Dose Naloxone (LDN)|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. LDN will be given as a daytime dose."
33308196|NCT05532358|Experimental|anle138b (TEV-56286) as perpetrator (part I)|"Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days)~Victim drugs:~Caffeine 200 mg Midazolam 2 mg"
33308197|NCT05532358|Experimental|anle138b (TEV-56286) as victim (part II)|"Drug: fluvoxamine 100 mg QD for 5 days~Victim drug:~TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine"
33308198|NCT05528172|Experimental|Group A|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 4 week follow-up period with no treatment.
33308199|NCT05528172|Experimental|Group B|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 14 week follow-up period with no treatment.
33308200|NCT05528172|Placebo Comparator|Group C|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 4 week follow-up period with no treatment.
33308201|NCT05528172|Placebo Comparator|Group D|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 14 week follow-up period with no treatment.
33308202|NCT05527067||α-synucleinopathy|Participants with clinical diagnosis of α-synucleinopathy.
33308203|NCT05527067||Healthy controls|Healthy controls
33308204|NCT05525416|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
33308205|NCT05525416|Experimental|High Altitude|Participants will be assessed on a high-altitude expedition at an elevation of 3,800m.
32944396|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
32944397|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
32944398|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
32944399|NCT05313737|Experimental|Automated phone opt-in message|Audiocare message requiring Veteran to confirm that they would like to participate in screening and have consult sent
32944400|NCT05313737|Experimental|Opt-out scheduling|Consult automatically sent and Veteran called to schedule screening
32944401|NCT01298921|Active Comparator|Continous Flow Oxygen|
32944402|NCT01298921|Experimental|Oxygen Demand Valve|
32944403|NCT05313191|Experimental|Cohort 1: Central Nervous System|"Group 1 Definitive Reirradiation Phase II~Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology~Group 2 CNS Reirradiation Registry~Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary~Postop or intact setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Histologically/clinically documented recurrent CNS tumor (benign or malignant)~Glioblastoma (histologic or molecular including IDH wildtype)~Astrocytoma (molecular IDH1 mutant)~Oligodendroglioma (molecular 1p19q co deleted)~Meningioma~Ependymoma~Chordoma/chondrosarcoma"
32944404|NCT05313191|Experimental|Cohort 2: Head/Neck|"Group 1 Full Dose Reirradiation Phase II~Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT~Gross unresected disease or PORT 2/2 RF~Received at least 40 Gy overlapping w/new target region~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: surgery, HPV status, concurrent ST~Group 2 Early (<6months for prior RT) Palliative H/N ReRT Phase I~Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT~At least 30 Gy prior RT overlapping with new treatment volume~<6 month interval between RT courses~Group 3 Head/Neck ReRT Registry~Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT~Postop or definitive~Prior RT dose at least 30 Gy overlapping w/new treatment volume~Min.6 month interval b/w RT courses"
33308206|NCT05516680|Experimental|Experiment group|electro-acupuncture and MRI-navigated rTMS
33308207|NCT05516680|Active Comparator|Control group|MRI-navigated rTMS
33308208|NCT05503030||Nintedanib for CTD-associated PF-ILD patients in Greece|Connective Tissue Disease (CTD)-associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
33308209|NCT05496192|Experimental|Nivolumab IV followed by Nivolumab SC|
32944405|NCT05313191|Experimental|Cohort 3: Breast|"Group 1 Partial Breast Reirradiation (Phase II)~Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT~Node negative~Negative margins~No LVI~Lumpectomy cavity:whole breast <30%~Minimum 1 year interval between RT courses~Group 2: Regional LN and Breast/CW ReRT (Phase II)~Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN~Minimum 1 year interval between RT courses~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy~Group 3: Breast Reirradiation Registry~Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation~Some overlaps of dose with prior RT course~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy"
32944406|NCT05313191|Experimental|Cohort 4: Thoracic|"Group 1: Definitive Reirradiation for Locally Advanced Disease~Single arm, prospective, phase II study~Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field~Definitive reRT concurrent systemic therapy~Adequate pulmonary function defined as an FEV1 of >35% (with or without bronchodilator) within 90 days prior to registration~Minimum 6 month interval between RT courses~Negative metastatic workup~Group 2: Thoracic Registry Study~Registry design~Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT~Minimum 3 month interval between RT courses~Negative metastatic workup"
32944407|NCT05313191|Experimental|Cohort 5: Gastrointestinal|"Group 1 Esophagus & GEJ Reirradiation Phase II~Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended~Negative metastatic workup~Group 2 Liver Reirradiation Phase II~Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended~CTP A or B7~Excl. prev. Y 90/radioembolization~Allow prior TACE~Overlap w/50% IDL prior RT~Adequate bone marrow function~Group 3 Lower GI Reirradiation Phase II~Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy~Negative metastatic workup (PET/CT or CT C/A/P)~Group 4 GI Reirradiation Registry~•Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL"
33308210|NCT05491512|Experimental|Cohort A|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC)
33308211|NCT05491512|Experimental|Cohort B|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Participants in Cohort B will receive 1 cycle of carboplatin and Paclitaxol one week prior to the start of radiation
33308212|NCT05491512|Experimental|Cohort C|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). For participants in Cohort C where induction chemotherapy is used, additional pre-treatment 18F-FMISO PET and post induction pre radiation FMISO PET Scans will be obtained.
33308213|NCT05491512|Experimental|Cohort D|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Cohort D will just have T2N0 participants.
33308214|NCT05491200|Experimental|Prasugrel-based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy for 11 months.
33308215|NCT05491200|Active Comparator|Prasugrel based standard DAPT|Prasugrel-based DAPT for 1 year
33308216|NCT05491200|Experimental|OCT guided non-culprit lesion|Complete revascularization of non culprit lesions guided by OCT
33308217|NCT05491200|Active Comparator|Angio guided non-culprit lesion|Complete revascularization of non culprit lesions guided by Angio
32944408|NCT05313191|Experimental|Cohort 6: Genitourinary|"Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II~Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation~Min. 1 year interval b/w RT courses~Prostate gland or recurrent tumor <100 cc or 6 cm in largest dimension~No persistent grade 2+ toxicity from prior radiation~Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan~Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II~Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis)~Min.1 year interval b/w RT courses (EBRT or brachy)~No persistent grade 2+ toxicity from prior radiation~Group 3 Prostate Reirradiation Registry~Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT~No DM~Concurrent chemotherapy excl."
33308218|NCT05481177|No Intervention|Long Haul COVID|Persistent signs and/or symptoms >12 weeks post Covid-infection N = 200 evaluable subjects.
33308219|NCT05481177|No Intervention|Post COVID without LHC|No persistent signs and/or symptoms >12 weeks N = 50 evaluable subjects.
33308220|NCT05481177|Placebo Comparator|Ivabradine RCT Arms|"If POTS or IST is present for participants within either of these cohorts, then they will be assigned to one of two arms of the Ivabradine RCT [2:1 treatment:control].~RCT Arms: at least 36 evaluable subjects will be enrolled to two arms in a 2:1 ratio. More may be enrolled, depending on the number from the overall COVID-19 cohort who qualify.~IVA (Ivabradine) - at least 24 evaluable subjects Placebo - at least 12 evaluable subjects"
33308221|NCT05481034|Experimental|Simplified carbohydrate estimation first, exact carbohydrate estimation second|"In the first study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit. In the second study period, Participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals."
32944409|NCT05313191|Experimental|Cohort 7: Gynecological|"Group 1: Locally recurrent gynecological cancer within previous field~Single arm, prospective, phase II study design~Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy~At least 1 year between RT courses~No persistent grade 3+ toxicity from prior RT~Concurrent chemotherapy excluded~Uncontrolled or widely metastatic disease~Life expectancy >6 months"
32944410|NCT05313191|No Intervention|Cohort 8: Registry|"Registry design~Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts~Overlap of 50% IDL of current treatment volume with prior RT field"
32944411|NCT04331873|Experimental|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
32944412|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
32944413|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
32944414|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
32944415|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
32944416|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
32944417|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
33093579|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
33093580|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
33093581|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
32944418|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
32944419|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
32944420|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
32944421|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
32944422|NCT02708849|Experimental|Ketamine plus lamotrigine|
32944423|NCT02708849|Placebo Comparator|ketamine plus placebo|
32944424|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
32944425|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
32944426|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
32944427|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
32944428|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
32944429|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
32944430|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
32944431|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
32944432|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
32944433|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
32944434|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
32944435|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
32944436|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
32944437|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
32944438|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
33093582|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
32944439|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
32944440|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
32944441|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
32944442|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
32944443|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
32944444|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32944445|NCT03860753|Experimental|Pioglitazone|
32944446|NCT03860753|Placebo Comparator|Placebo|
33404509|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
32944447|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
32944448|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
32944449|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
32944450|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
32944451|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
32944452|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
32944453|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
32944454|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
32944455|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
32944456|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
32944457|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
32944458|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
32944459|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
32944460|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
32944461|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
32944462|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
32944463|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
32944464|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
32944465|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
33308222|NCT05481034|Experimental|Exact carbohydrate estimation first, simplified carbohydrate estimation second.|"In the first study period, participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals. In the second study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit."
33308223|NCT05477576|Experimental|Phase 1b - RYZ101|Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design. Eligible participants will be enrolled in cohorts of 6 to receive RYZ101 up to 4 infusions every 8 weeks. If the initial dose level is not tolerated, the dose will be de-escalated; up to 3 dose levels will be assessed.
33308224|NCT05477576|Active Comparator|Phase 3 - RYZ101|Actinium 225 radiolabeled somatostatin analog (SSA) for injection
33308225|NCT05477576|Active Comparator|Phase 3 - Standard of Care|Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
33308226|NCT05471492|Experimental|Treatment Group 1|PF-06480605 150 mg
33308227|NCT05471492|Placebo Comparator|Treatment Group 2|Placebo
33308228|NCT05470413|Active Comparator|SHR0302 4 mg|Drug：SHR0302
33308229|NCT05470413|Active Comparator|SHR0302 8 mg|Drug：SHR0302
33308230|NCT05470413|Placebo Comparator|Placebo|Drug: Placebo
33308231|NCT05470010|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes everyday, with a minimum of 4 days of activity in a week.
33308232|NCT05470010|Other|Control Mindfulness|No intervention and usual care for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
32944466|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
32944467|NCT03819491|Experimental|Group A|100 mg OD
32944468|NCT03819491|Experimental|Group B|100 mg BID
32944469|NCT03801473|Experimental|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
32944470|NCT03801473|Active Comparator|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
32944471|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
32944472|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
32944473|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
32944474|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
33308233|NCT05469919|Experimental|Ceralasertib monotherapy|This is a sequential group treatment/dose-escalation study with 3 cohorts with no masking.
33308234|NCT05469737|Experimental|Part I - Oral-Aza (Dose 1)|
33308235|NCT05469737|Experimental|Part I - Oral-Aza (Dose 2)|
33308236|NCT05469737|Experimental|Part II - Oral-Aza (RP3D)|RP3D: Recommended Phase 3 Dose
33308237|NCT05469737|Experimental|Part II - Placebo|
33308238|NCT05469646|Experimental|Dose Group 1: BI 1819479 (Low dose)|
33308239|NCT05469646|Experimental|Dose Group 2: BI 1819479 (Middle dose)|
33308240|NCT05469646|Experimental|Dose Group 3: BI 1819479 (High Dose)|
33308241|NCT05469646|Placebo Comparator|Placebo|
33308242|NCT05469295|Experimental|CGM_MB_1701 treatment|Subjects will be treated with the study device for about 36 minutes.
33308243|NCT05469295|Sham Comparator|Sham (CGM MB1701C) treament|Subjects will be treated with the Sham device for about 36 minutes.
33308244|NCT05462756|Experimental|Insulin Efsitora Alfa + Insulin Lispro|Participants will be given insulin efsitora alfa by subcutaneous (SC) injection along with insulin lispro
33308245|NCT05462756|Active Comparator|Insulin Glargine + Insulin Lispro|Participants will be given insulin glargine by SC injection along with insulin lispro
33308246|NCT05460325|Experimental|Lanadelumab 300 mg|Participants will receive lanadelumab 300 milligram (mg), subcutaneously, once every 2 weeks (Q2W) from Day 0 to Day 182 (26 weeks).
33308247|NCT05450731|Experimental|cardiac rehabilitation intervention group|Participants assigned to the intervention group will participate in pre-post assessments and a 12-week supervised exercise based cardiac rehabilitation program at a designated local Pulse Heart Institute Cardiac Rehabilitation program.
33308248|NCT05450731|No Intervention|control group|Participants assigned to the control group will participate in pre-post assessments and will maintain usual care and current activity levels.
33308249|NCT05449405|Active Comparator|Chlorpheniramine Malate (1%) Nasal Spray|Chlorpheniramine Malate (1%) Nasal Spray
33308250|NCT05449405|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray
33308251|NCT05448196|Experimental|Intervention|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
33308252|NCT05448196|No Intervention|Usual Care|Patients are connected to financial advocacy and social work on an ad hoc basis, rather than systematically. We hypothesize that many patients who would qualify and benefit from these services are not using them or are being referred late in their treatment course, which is contributing to their financial hardship and adversely affecting their healthcare.
33308253|NCT05447663|Experimental|Siremadlin (HDM201)|Participants with AML post allogeneic stem cell transplantation (allo-SCT) will receive siremadlin monotherapy in part 1 and siremadlin monotherapy as well as in combination with donor lymphocyte infusion in part 2
33308254|NCT05447273||Patients with penile squamous cell carcinoma.|Patients with penile squamous cell carcinoma.
33308255|NCT05442606|No Intervention|Conservative medical therapy|Patients in this group received only medication prescribed by an Ear, Nose and Throat specialist.
33308256|NCT05442606|Experimental|Medication and Physiotherapy program|Patients in this group received medication prescribed by an Ear, Nose and Throat specialist, in addition to integrated Physiotherapy program
33308257|NCT05441735|Experimental|experimental group|will have access to information on the Long-Term Care Plan 2.0 through the app-based digital care program, while the
33308258|NCT05441735|No Intervention|control group|will only have access to information on the Long-Term Care Plan 2.0 through conventional paper-based media.
33308259|NCT05438862|Experimental|Early surgery|Early surgical treatment, state of art aortic valve surgery.
33308260|NCT05438862|No Intervention|Watchful waiting|Watchful waiting strategy, regular follow-up of patients with severe valve disease. Guideline-based indication for surgery only during the follow-up.
32944475|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
32944476|NCT03823937||Control|18-70 years healthy subjects
33308262|NCT05434806|Experimental|Post menomausal women (PMW)|40g/day of Jarlsberg cheese will be given three PMW's in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new PMWs in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new PMWs in the third design level.
33308263|NCT05434806|Experimental|Men passed the age of 65 years|40g/day of Jarlsberg cheese will be given three men in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new men in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new men in the third design level.
33308264|NCT05434169|Experimental|Positive Therapeutic communication|
33308265|NCT05434169|Active Comparator|Nocebo communication|
33308266|NCT05434169|Active Comparator|Neutral communication|
33308267|NCT05433623||Vascular Surgery Admissions|Patients who present and/or are admitted to University Hospital Limerick under the care of a Vascular Consultant.
33308268|NCT05432518|Experimental|Treatment|"Patients will receive one of the 5 study drugs based on their recurrent tumor mutation profile and their recurrent organoid response to these drugs:~Afatinib~Dasatinib~Palbociclib~Everolimus~Olaparib"
33308269|NCT05430529|Experimental|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
33308270|NCT05430529|Active Comparator|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
33308271|NCT05430191||Qualitative Interviews|Conduct 15 interviews with patients diagnosed with FH. Interviews will be 30-60 minutes in length and will focus on how individuals understand cascade screening, barriers to engagement including reasons why individuals do and do not share health information with family members, and preferred approaches to engaging family members, with a focus on acceptability, appropriateness, and feasibility of the planned implementation strategies. Interviewers will also attend to structural factors such as medical mistrust and experiences of racism in health care, and ask about preferences and logistics to incorporate preference into the future clinical trial design.
32944477|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
32800488|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
33093583|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
33093584|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
33093585|NCT00489138|Experimental|1|Noradrenalin infusion
33093586|NCT00489138|No Intervention|2|No adrenalin infusion
33093587|NCT00461396||Group 1|
33093588|NCT00489177|Active Comparator|A|QuickOpt
32800489|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
32800490|NCT01700985|Experimental|122-0551|
32800491|NCT01700985|Placebo Comparator|Vehicle|
32800492|NCT04148404|Active Comparator|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
32800493|NCT04148404|Active Comparator|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
32800494|NCT04144426|Experimental|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
32800495|NCT04144426|Experimental|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
32800496|NCT03920722|Experimental|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
32800497|NCT03920722|Placebo Comparator|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
32800498|NCT05580094|Placebo Comparator|General anesthesia only.|the pediatric patients will receive general anesthesia only.
32800499|NCT05580094|Active Comparator|General anesthesia plus supraclavicular block.|the pediatric patients will receive combined supraclavicular block and general anesthesia.
32800500|NCT05589766|Placebo Comparator|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (12 weeks).
32800501|NCT05589766|Experimental|Dietary Supplement: NR 1000mg group|Nicotinamide Riboside 1000mg total daily. Administered in capsule form in doses of 500mg twice daily for the duration of the trial (12 weeks).
32800502|NCT05589766|Experimental|Dietary Supplement: NR dose escalation group|Nicotinamide Riboside dose escalation group: 1000mg NR daily in doses of 500mg twice daily (week 1 - week 4), 2000mg NR daily in doses of 1000mg twice daily (week 5 - week 8), 3000mg NR daily in doses of 1500mg twice daily (week 9 - week 12).
32800503|NCT05586100|Experimental|cetuximab in combination with toripalimab|"Participants receive toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing <50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
32800504|NCT05587270||Rock Climbers|The whole eligible population of Swedish climbers on elite- or sub-elite levels of competition will be invited to participate in the study. Participants will be both male and female, 13 years and older. There are approximately 40 climbers eligible at elite level and a minimum of 80 climbers at sub-elite level of competition.
32800505|NCT05587270||Controls|A non-athlete control group (n matched to the study group) from the general population, will be invited to participate in the study.
33093589|NCT00489177|Placebo Comparator|B|Usual care
33093590|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
33093591|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
33093592|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
33093593|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
33102515|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
33102516|NCT05467670|Experimental|ALX148 + Doxorubicin (PLD) + Pembrolizumab|"Given on Day 1 of each 21 day cycle, in the following order of administration:~200 mg IV pembrolizumab* (maximum of 2 years (approximately 35 cycles)~45 mg/kg IV ALX148~30 mg/m^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)*~*standard of care"
33093594|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
33093595|NCT04329169|Experimental|Virtual Implant Planning|
33093596|NCT00591604|Experimental|1|Vitamin D administration
33093597|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
32800506|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
33093598|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
33093599|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
33093600|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
33093601|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
33093602|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
33093603|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
32800507|NCT05585008|Active Comparator|group A|group A will receive a conventional heat-cure acrylic denture
32800508|NCT05585008|Active Comparator|group B|group B will receive a 3D printed complete denture
33093604|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
33093605|NCT04328935|Experimental|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
33093606|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:~Between 50-80 years old~Right-handed~Clinical Dementia Rating score equal to 0.5~For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders~Able to understand study requirements and give informed consent"
32800509|NCT05584852||with myosteatosis|
32800510|NCT05584852||without myosteatosis|
32800511|NCT05585086|Experimental|Experimental|Peppermint oil will be applied by diluting 1/10 in wheat oil so that it does not cause skin irritation.
32800512|NCT05585086|No Intervention|Control|Patients who underwent surgery will be monitored for the severity of nausea and vomiting after surgery. Follow-ups are 0-2, 2-6, 6-12, 12-24 and 24-48 postoperatively. hours and will be recorded without any application or intervention by the researcher.
32800513|NCT05583448||ExploR Radial Head|Subjects who have received the ExploR Radial Head Device.
32800514|NCT03904030|Experimental|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
32800515|NCT03904030|Active Comparator|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
32800516|NCT03902938|Experimental|Biodesign Otologic Graft|Graft following canal wall down mastoidectomy.
32800517|NCT03902938|Active Comparator|Autograft temporalis fascia|Graft following canal wall down mastoidectomy.
32800518|NCT05583136|Experimental|Group DD1|tACS + visuo-attentional training
32800519|NCT05583136|Active Comparator|Group DD2|Sham (placebo) tACS + visuo-attentional training
32800520|NCT05583136|Active Comparator|Group DD3|Sham (placebo) tACS + phonics training
32800521|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
32944478|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
32944479|NCT03822377|Experimental|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
32944480|NCT03822377|Active Comparator|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
33308272|NCT05430191||Penn-mediated implementation strategy|The Penn-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patients would receive text messages and/or emails containing information about FH and cascade screening from Penn Medicine. This would include a request for the patient to identify first-degree biological relatives. They would be given a choice of either contacting their family members directly or sharing their contact information so someone from Penn Medicine can contact them. If the proband chooses to contact their family members, they receive educational information to share with them. Family members would be offered FH screening at no cost by blood lipid panel.
33308273|NCT05430191||Family Heart Foundation-mediated implementation strategy|The Family Heart Foundation (FHF)-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patient would be contacted by a FHF patient navigator. The patient navigator would ask to set up a time to talk to the patient to talk about options for contacting family members, introduce them to the services they can provide to the patient and/or family members and obtain some details about the patient's family. The patient would come up with a plan to either contact their family members directly or have the patient navigator contact them. Family members will be offered FH screening at no cost by blood lipid panel. The patient and/or family members will be able to contact the patient navigator at any time with questions.
33308274|NCT05422079|Experimental|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week for four weeks.
33308275|NCT05422079|Experimental|Group motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program twice a week for four weeks.
33308276|NCT05422079|Experimental|Group motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
33308277|NCT05419037||off-spring of above|Off-spring of the women who took metreleptin during her pregnancy.
33308278|NCT05419037||Women with past pregnancy on metreleptin|Women who took metreleptin during pregnancy.
32944481|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
32944482|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
33308283|NCT05416931|Experimental|ACD440 Gel 14mg/g|Topically applied to painful neuropathic area twice daily for 7 days
33308284|NCT05416931|Placebo Comparator|Placebo Gel|Topically applied to painful neuropathic area twice daily for 7 days
33308285|NCT05415202||Remimazolam Sedation|"Patients receiving a nerve block prior to surgery or a re-block the day after surgery will receive remimazolam sedation for their nerve block.~The nerve block will then be performed under standard conditions with standard monitors. Remimazolam will be used for sedation following the guidelines on the label.~Dosing will be as follows:~Induction of Procedural Sedation For adult patients: Administer 5 mg intravenously over a 1-minute time period. For ASA* III and IV patients: Administer 2.5 mg to 5 mg intravenously over 1 minute based on the general condition of the patient.~Maintenance of Procedural Sedation (as needed) For adult patients: Administer 2.5 mg intravenously over 15 seconds. At least 2 minutes must elapse prior to administration of any supplemental dose.~For ASA III and IV patients: Administer 1.25 mg to 2.5 mg intravenously over 15 seconds.~At least 2 minutes must elapse prior to administration of any supplemental dose."
33308286|NCT05414955|Experimental|Treated|Patients implanted with neuromodulation
33308287|NCT05412706|Experimental|Treatment Arm|Treatment with Niraparib must be started after at least 2 weeks and no later than 6 weeks after the end of platinum-based induction therapy.
33308288|NCT05412628|Experimental|Esophageal cancer group|patients aged ≥ 20 years with esophageal cancer
33308289|NCT05412628|Experimental|Oropharyngeal cancer group|patients aged ≥ 20 years with oropharyngeal cancer
32944483|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
32737990|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
32737991|NCT03332381|Active Comparator|Attention training technique|
32737992|NCT03332381|Active Comparator|Mindful self-compassion|
33308290|NCT05412628|Experimental|Synchronous cancer group|patients aged ≥ 20 years with synchronous oropharyngeal cancer and esophageal cancer
33308291|NCT05412628|Placebo Comparator|Control group|patients aged ≥ 20 years with symptoms of dysphagia without cancer
33308292|NCT05411549|Experimental|Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
33308293|NCT05411549|No Intervention|No Diet Modification|Participants enrolled in group 2 will be NOT counselled by a dietician. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
33308294|NCT05407987|Experimental|Iron Therapy Arm|1000mg of IV Ferric Derisomaltose in 500mL normal saline will be administered intravenously over 1 hour.
33308295|NCT05407987|Placebo Comparator|Placebo Arm|500mL of normal saline will be administered intravenously over 1 hour between 21 and 90 days preceding surgical intervention.
33308296|NCT05407675|Experimental|Part 1: BMS-986408 Monotherapy|
33308297|NCT05407675|Experimental|Part 2: BMS-986408 in combination with nivolumab|
33308298|NCT05407675|Experimental|Part 2: BMS-986408 in combination with nivolumab and ipilimumab|
33308299|NCT05403385|Experimental|Part 1, open label|Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D).
33308300|NCT05403385|Experimental|Part 2, active treatment|Treatment with inupadenant combined with carboplatin and pemetrexed
33308301|NCT05403385|Placebo Comparator|Part 2, placebo|Treatment with matched placebo combined with carboplatin and pemetrexed
33308302|NCT05401253||Adequate physical activity group|At least 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
33308303|NCT05401253||Insufficient physical activity group|Less than 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
33308304|NCT05398510|Experimental|Treatment for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
33308305|NCT05398510|Placebo Comparator|Placebo for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
33308306|NCT05394740|Experimental|Regorafenib, Nivolumab+CapeOX/FOLFOX|Regorafenib and Nivolumab+CapeOX (Cohort A) / Nivolumab+FOLFOX (Cohort B)
33308307|NCT05390021|Experimental|PET/MRI IN ENDOMETRIAL CANCER|PET/MRI in one study visit of approximately four hours
33308308|NCT05389761|Experimental|Enzyme DAO administration|DAO enzyme supplementation for 6 months
33308309|NCT05389761|Placebo Comparator|Placebo administration|Placebo supplementation for 6 months
33308310|NCT05389033|Experimental|Active probiotic|Lactobacillus acidophilus (CUL60 and CUL21), Bifidobacterium bifidum (CUL20), Bifidobacterium animalis subs p. Lactis (CUL34), 25 billion CFU, (Proven Probiotics, United Kingdom)
33308311|NCT05389033|Placebo Comparator|Placebo|"Chicory Root Extract (Min 90% Fructo-oligosaccharides) - Providing:~100mg FOS Microcrystalline Cellulose - 137.26 mg"
33308312|NCT05388760|Experimental|Cohort 1 (6 to <12 years) - tralokinumab dose regimen A|
33308313|NCT05388760|Experimental|Cohort 1 (6 to <12 years) - tralokinumab dose regimen B|
33308314|NCT05388760|Experimental|Cohort 2 (2 to <6 years) - tralokinumab dose regimen C|
33308315|NCT05388760|Experimental|Cohort 2 (2 to <6 years) - tralokinumab dose regimen D|
33308316|NCT05388279|Experimental|JS012|
33308317|NCT05388279|Experimental|JS012 combination with chemotherapy|
33308318|NCT05375084|Experimental|Dose Escalation Level 1|Level 1 oral capsules administered in combination with nivolumab
33308319|NCT05375084|Experimental|Dose Escalation Level 2|Level 2 oral capsules administered in combination with nivolumab
33308320|NCT05375084|Experimental|Dose Escalation Level 3|Level 3 oral capsules administered in combination with nivolumab
33308321|NCT05375084|Experimental|Dose Expansion|RP2D defined dose. Oral capsules administered in combination with nivolumab
33308322|NCT05371951|Experimental|Erchonia HLS|635 nanometers (nm) laser application
33308323|NCT05371093|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV lymphodepletion chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10^8 anti-CD19 CAR T cells will be administered.
33318543|NCT02960230|Experimental|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding primary spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
32800522|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
32800523|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
33093607|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
33093608|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:~Between 50-80 years old~Right-handed~MMSE score greater than or equal to 26~Able to understand study requirements and give informed consent"
33093609|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
33093610|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
32800524|NCT05583058||Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as hormone overdose and misuse (HODM) at start of the cohorts according to the criteria established by the study.
32800525|NCT05583058||Non-Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as without hormone overdose or misuse (HODM) at start of the cohorts according to the criteria established by the study.
32800526|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
32800527|NCT04144114|Experimental|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
33093611|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
33093612|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR < 30 mL/min/1.73m2)
33093613|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR < 15 mL/min/1.73m2) with imminent initiation of RRT
32800528|NCT04144114|Active Comparator|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
32800529|NCT04144114|Placebo Comparator|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
32800530|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
33093614|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
33093615|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
32800531|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
32800532|NCT04143880|Experimental|experimental group|Progesterone
32800533|NCT04143880|Placebo Comparator|control grou|saline
32800534|NCT04144192|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
33093616|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
33093617|NCT04427800||Post-transplant|Participants post-transplant
33093618|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
33093619|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
33093620|NCT00591682|Experimental|1|MSX-122
33093621|NCT04329013|Active Comparator|Left lateral position|The patient will be in left lateral position during EGD
33093622|NCT04329013|Experimental|Prone position|The patient will be in prone position during EGD
33093623|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
33093624|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
33093625|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
33093626|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
33093627|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
33093628|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
33093629|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
33093630|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
33318544|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
33318545|NCT02864992|Experimental|Tepotinib|
33318546|NCT03817658|Experimental|SHR-1210|SHR-1210
33318547|NCT03817658|Placebo Comparator|placebo|placebo
33318548|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
33318549|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
33318550|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
33318551|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
33308324|NCT05371093|Active Comparator|Standard of Care Therapy|"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:~Rituximab plus lenalidomide (R^2) for 12 cycles (28-day cycle)~Cycle 1: lenalidomide 20 mg/day on Day 1 through Day 21; rituximab 375 mg/m^2 on Day 1, Day 8, Day 15, and Day 22~Cycle 2 through Cycle 5: lenalidomide 20 mg/day on Day 1 through Day 21; Rituximab 375 mg/m2 on Day 1~Cycle 6 through Cycle 12: lenalidomide 20 mg/day on Day 1 through Day 21~Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles (21-day cycle)~rituximab 375 mg/m^2 on Day 1~cyclophosphamide 750 mg/m^2 on Day 1~doxorubicin 50 mg/m^2 on Day 1~vincristine 1.4 mg/m^2 (maximum 2 mg) on Day 1~prednisone 40 mg/m^2 on Day 1 through Day 5~Rituximab plus bendamustine (BR) for 6 cycles (28-day cycle)~rituximab 375 mg/m^2 on Day 1~bendamustine 90 mg/m^2 on Day 1 and Day 2"
33308325|NCT05369975|Experimental|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect. The second dose can be administered within 24 hours after the first dose.
33308326|NCT05369975|Other|Non-Comparative Concurrent Reference Cohort|Patients in the non-comparative prospective concurrent reference cohort (with any grade of sensitization and negative XM) will receive medications, both pre- and post-transplant, in accordance with each clinic's routine for kidney transplanted patients.
33308327|NCT05369975|Other|Non-Comparative Historical Reference Cohort|Patients in the non-comparative historical reference cohort (with less sensitization and negative XM) randomly selected from the CTS registry have been transplanted and treated in accordance with standard-of-care for kidney transplanted patients. Patients transplanted in 2010 and onwards will be selected to optimize the probability that these patients will have received about the same maintenance immunosuppressive treatment as the patients in the current trial will receive.
33308328|NCT05366881||Cases|Cases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.
33308329|NCT05366881||Controls|Controls will include participants without known cancer at the time of enrollment.
32737993|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
32737994|NCT04443179||Infants a family history of ASD/ADHD|
33308330|NCT05363605|Experimental|Phase 1|Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered with or without pre-dosing with vofatamab.
33308331|NCT05363605|Experimental|Phase 2|Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered either with or without pre-administration of vofatamab, depending on the RP2D/regimen as determined in the phase 1 portion of the study.
33308332|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1|"Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.~A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.~Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo:~• Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID)"
33308333|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 2 will be sub-divided into 2 cohorts: Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 2a and 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID)."
33308334|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)"
33308335|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 4 will be sub-divided into 2 cohorts: Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 4a and 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)"
33308336|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 5 will be sub-divided into 2 cohorts: Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 5a and 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID)"
33308337|NCT05362227|Other|High-Volume|Patients in the group were instructed to take 4 L of solution on the day before the colonoscopy
33308338|NCT05362227|Other|Low-Volume|Patients in the group were instructed to take 2 L of solution on the day before the colonoscopy
33308339|NCT05355480||Healthy Subjects|Collection of handwriting samples
33308340|NCT05355480||Patients with Parkinson's disease|Collection of handwriting samples
32737995|NCT04443179||Infants without a family history of ASD/ADHD|
32737996|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
32737997|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
33093631|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
33093632|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
32800535|NCT04144192|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
32800536|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
32800537|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
32800538|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
32800539|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
32800540|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
32800541|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
32800542|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
32800543|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
32800544|NCT05582824||Main group|All patients included
32800545|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
32800546|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
32800547|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
32800548|NCT04147936|Active Comparator|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
32800549|NCT04147936|Active Comparator|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
32800550|NCT04147936|Placebo Comparator|Placebo 29.4 g|Dietary Supplement: Placebo
32800551|NCT03918382|No Intervention|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
32800552|NCT03918382|Experimental|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
32800553|NCT04148014|Experimental|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
32800554|NCT04143022|Active Comparator|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
32800555|NCT04143022|Active Comparator|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
32800556|NCT04143256|Experimental|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
32800557|NCT04143256|Experimental|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
32800558|NCT04143256|Experimental|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
32800559|NCT04143256|Experimental|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
32800560|NCT04143256|Experimental|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
32800561|NCT04143256|Experimental|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
33093633|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
33093634|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
32800562|NCT04143412|Active Comparator|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
32800563|NCT04143412|Active Comparator|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
32800564|NCT04143412|Active Comparator|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
32800565|NCT05582278|Experimental|HAIC+lenvatinib+tislelizumab|Hepatic Arterial Infusion Chemotherapy Combined With lenvatinib and tislelizumab
32800566|NCT05582278|Experimental|D-TACE+lenvatinib+tislelizumab|Transarterial chemoembolization with drug-eluting beads Combined With lenvatinib and tislelizumab
32800567|NCT05582122|No Intervention|Standard follow-up monitoring (16 visits over 5 years)|"Patients enrolled in the control arm will be monitored according to SFORL guidelines. Physical Examination (PE) will be carried out:~- every 2 months the 1st year, every 3 months the 2nd year, every 4 months the 3rd year, every 6 months at 4 and 5 years.~Annual chest CT scan will be performed for current smokers & for those who have quit smoking less than 15 years ago."
32800568|NCT05582122|Experimental|Lightened follow-up visits frequency (9 visits over 5 years), with HPV16 Ct-DNA dosing|"Physical Examinations (with HPV16 Ct-DNA dosing) planned at Months 4,8,12,18,24,30,36,48,60 post treatment.~Annual chest CT scan will be performed for current smokers & for those who have quit smoking less than 15 years ago.~Any patient with a normal PE but positive HPV16 ct-DNA test during follow-up period will require a confirmation test ~1-2 months later.~If HPV16 ct-DNA positivity is confirmed, an H&N MRI /PET-CT will be performed. Then:~If MRI and PET-CT are negative, the patient will be examined every 2 months (PE and HPV16 Ct-DNA dosing) and MRI/PET-CT will be repeated every 4-6 months, until HPV16 Ct-DNA becomes undetectable.~If MRI and/or PET-CT is positive, the patient will get a biopsy to confirm disease recurrence. Once confirmed, the patient will have the necessary care, as per local practices, but will continue to be followed up within this study up to 5 years after treatment."
32800569|NCT04147702|Experimental|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
32800570|NCT04147702|Active Comparator|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
32800571|NCT03902080|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
32800572|NCT03902080|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
32800573|NCT01710033|Placebo Comparator|Placebo|
32800574|NCT01710033|Experimental|CP-690,550 5 mg BID|
32800575|NCT01710033|Experimental|CP-690,550 15 mg BID|
32800576|NCT01710033|Experimental|CP-690,550 30 mg BID|
32800577|NCT04148170|Active Comparator|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
32800578|NCT04148170|Active Comparator|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
32800579|NCT01822496|Experimental|EGFR: Erlotinib|Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
32800580|NCT01822496|Active Comparator|EGFR: No Erlotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
32800581|NCT01822496|Experimental|ALK: Crizotinib|Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
32800582|NCT01822496|Active Comparator|ALK: No Crizotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
32800583|NCT03937726|Experimental|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
32800584|NCT03937726|Active Comparator|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
32800585|NCT03936088|Experimental|Intervention with Mindfulness App (Headspace)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the mindfulness (intervention) app.
32800586|NCT03936088|Active Comparator|Control with Water App (My Water Balance)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the My Water Balance (control) app and provided an in-person demonstration on how to use it.
32800587|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
32800588|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
32800589|NCT03588988|Experimental|Dexmedetomidine group|
32800590|NCT03588988|Placebo Comparator|Control group|
32800591|NCT05581888|Other|839MP group|Patients in this group were binocularly implanted with the AT LISA tri 839MP trifocal intraocular lens.
32800592|NCT05581888|Other|TFNT00 group|Patients in this group were binocularly implanted with the AcrySof IQ PanOptix TFNT00 trifocal intraocular lens.
32800593|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
32800594|NCT05580172|Experimental|Dose Level 1|RH324
32800595|NCT05580172|Experimental|Dose Level 2|RH324
32800596|NCT05580172|Experimental|Dose Level 3|RH324
32800597|NCT05587582||Observational (Family Behaviors)|"PRIMARY OBJECTIVES:~I. Use direct observation of medication administration in the home to understand common episode-level barriers and identify the most impactful behavioral parenting skills for intervention.~II. Use daily diary methods to identify contextual barriers to adherence and identify intervention components to help parents anticipate barriers and plan strategies to promote successful adherence.~OUTLINE:~Participants complete a survey over 15-20 minutes at baseline. Family behaviors before, during and after the administration of medication to the child are video-recorded over 40-45 minutes. Participants receive MEMS electronic pill bottle to use for 2 weeks and complete daily survey over 5 minutes for 14 days."
32800598|NCT05586178|No Intervention|Holdout|
32800599|NCT05586178|Experimental|Simple reminder|
32800600|NCT05586178|Experimental|Consistency reminder|
32800601|NCT05586178|Experimental|Uniqueness information reminder|
32800602|NCT05586178|Experimental|Eligibility information reminder|
32800603|NCT05586178|Experimental|Severity information reminder|
32800604|NCT05586178|Experimental|Consistency and uniqueness information reminder|
32800605|NCT01821560|Placebo Comparator|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
32800606|NCT01821560|Active Comparator|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
32800607|NCT05585164|Experimental|Engage & Connect|
32800608|NCT03896230|Active Comparator|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
32800609|NCT03896230|Active Comparator|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
32800610|NCT03896230|Active Comparator|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
32800611|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
32800612|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
32800613|NCT04607174||Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
32800614|NCT05580328|Experimental|treatment group|"Hematoporphyrin injection is a new drug for tumor photodynamic therapy approved by the State Food and Drug Administration of China. It is a representative drug of domestic photosensitizer with independent intellectual property rights developed and produced by Chongqing Huading Modern Biological Pharmaceutical Co., Ltd.~In the third phase clinical trial, the dosage of hematoporphyrin injection (5mg/kg) should be given intravenously 48-72 hours before laser irradiation for diagnosis and treatment, and skin test should be conducted before injection. Diagnostic laser wavelength is 514.5nm, power density is 10mW/cm2, therapeutic laser wavelength is 630-690nm, average output power density is 400mW/cm, and optical dose density is 200-400J/cm2 The chemical structure formula of hematoporphyrin is: C34H38N4O6, molecular weight: 598.70"
32800615|NCT04415450|Experimental|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
32800616|NCT03901300|Experimental|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
32800617|NCT03901300|Active Comparator|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
32800618|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
32800619|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
32800620|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
32800621|NCT03900286|Experimental|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
32800622|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
32800623|NCT01846442|Placebo Comparator|Placebo|
32800624|NCT01846442|Experimental|0.25% DHEA|
32800625|NCT01846442|Experimental|0.5% DHEA|
32800626|NCT01846442|Experimental|1.0% DHEA|
32800627|NCT03586570|Experimental|Aprocitentan|
32800628|NCT03586570|Placebo Comparator|Placebo|
32800629|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
32800630|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
32800631|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
33093635|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
33308341|NCT05353517||Healthy Subjects|Device: focal muscle vibration to induce spinal plasticity theta burst stimulation and paired associative stimulation to induce plasticity in M1
33308342|NCT05353517||Patients with Parkinson's disease|Device: theta burst stimulation and paired associative stimulation to induce plasticity in M1 Device: focal muscle vibration to induce spinal plasticity
33308343|NCT05350761||Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
33308344|NCT05350761||Field Cohort|includes Proband, Other carriers in family, Family Controls
33308345|NCT05344092|Experimental|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period.
33308346|NCT05343039|Experimental|Treatment Group|Participants will receive a tVNS device.
33308347|NCT05343039|Experimental|Non-Treatment Group|Participants will not receive a tVNS device.
33308348|NCT05339126|Active Comparator|Condition A|high-frequency short bursts (HFSB: 100 Hz, 160 µs pulse width, 200 msec burst)
33308349|NCT05339126|Active Comparator|Condition B|low-frequency long bursts (LFLB: 5 Hz, 160 µs pulse width, 5 sec burst)
33308350|NCT05328726|Experimental|Drug:GZR-18 administered via subcutaneous injection|For Assigned Interventions: GZR-18 administered once via subcutaneous injection at doses of 1.0 ug/kg, 5.0 ug/kg, 10.0 ug/kg, 20.0 ug/kg, 30.0 ug/kg, 40.0 ug/kg & 50.0 ug/kg
33308351|NCT05328726|Placebo Comparator|Placebo control|Commercially obtained sterile, normal saline for injection will be used as the matching placebo. Placebo will be dosed in an identical manner to active study drug. The volume of placebo will be calculated according to body weight using active drug dose for volume calculation in order to maintain the study blind.
33308352|NCT05326477|Other|Standard-of-care behavioral weight loss treatment|6-months of group-based behavioral weight loss treatment following the Centers for Disease Control and Prevention Prevent T2 curriculum.
33308353|NCT05325242|Experimental|Elbow Artery Embolization (EAE)|Patients will undergo EAE with Embozene microspheres (75 micron). The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the patient's pain.
33308354|NCT05322122|Experimental|Treatment|Side-to-side anastomosis duodeno-ileostomy diversion
33308355|NCT05322096|Experimental|RGH-706|"Part A: Dose A once daily for 4 weeks~Part B: Dose B, Dose C or Dose D once daily (depending on the randomized arm) for 13 weeks"
33308356|NCT05322096|Placebo Comparator|Placebo|"Part A: Placebo once daily for 4 weeks~Part B: Placebo once daily for 13 weeks"
33308357|NCT05318690|Experimental|PlayGait (Exoskeleton)|Experimental lower-limb device.
33308358|NCT05318690|Active Comparator|Baseline|Baseline condition without using any prescribed lower-limb orthoses.
33308359|NCT05317637||Adults with OI|"18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI.~This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded."
33308360|NCT05314647|Experimental|Lutein|5 mg lutein gummy taken daily for 180 days
33308361|NCT05314647|Placebo Comparator|Placebo|0 mg lutein gummy taken daily for 180 days
33308362|NCT05310695|Active Comparator|NSAC rapid: treatment at the NSAC at- or within 4 weeks|NSAC service delivered according to ordinary procedures, 4 weeks after referral.
33308363|NCT05310695|Active Comparator|NSAC ordinary: treatment at the NSAC after 10-14 weeks|NSAC service delivered according to ordinary procedures, 10-14 weeks after referral, by and large equivalent to current waiting time
33308364|NCT05310695|Active Comparator|NSAC - active control|Monodisciplinary examination at the NSAC close to diagnosis-specific deadline for examination as suggested by guidelines (8-26 weeks, the majority at the end of this interval)
33308365|NCT05308381|Experimental|Fasted exercise|Fasted prior to exercise
33308366|NCT05308381|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
33308367|NCT05308381|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
33308368|NCT05306743|Experimental|CONQUEST Intervention Arm|Intervention arm clusters will receive the CONQUEST quality improvement program.
33308369|NCT05306743|Other|Delayed Intervention Arm|The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
33308370|NCT05306678|Experimental|Prolonged sitting|Prolonged sitting
33308371|NCT05306678|Experimental|Breaking sitting|Breaking prolonged sitting
33308372|NCT05306613|Experimental|Prolonged sitting|Participants sat on a chair during the trial.
33308373|NCT05306613|Experimental|Breaking sitting|Participants walked regularly during the trial.
33308374|NCT05299242|Active Comparator|Arm A|Participants will receive 2 injections of adalimumab. First injection: 160mg in 3.2ml Second injection approximately 2-3 weeks later 80mg in 1.6ml
33308375|NCT05299242|Placebo Comparator|Arm B|Participants will receive 2 injections of placebo First injection: 3.2ml Second injection approximately 2-3 weeks later 1.6ml
33318552|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
33318553|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
33318554|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
33318555|NCT04535596|Experimental|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
32944484|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
32944485|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
32944486|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
32944487|NCT00378989|No Intervention|Control|Care as usual
32944488|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
32944489|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
32944490|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
32944491|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
32944492|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
32944493|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
33318556|NCT04535596|Experimental|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
32944494|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
32944495|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
32944496|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
32944497|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
32944498|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
32944499|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
32944500|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
32944501|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
32944502|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
32944503|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
32944504|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
33093636|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
33318557|NCT02856412|Experimental|Veterans Group Exercise|Exercise 3 times weekly (for 12 weeks), with each total workout lasting approximately 60 minutes. Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
33308376|NCT05296265|Experimental|Active VR treatment|Subjects assigned to the Active VR treatment will begin by selecting an avatar, with features such as gender and skin color that can be chosen according to preference. During treatment, they will participate in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects will have substantial flexibility to select games according to their interests but will be required to spend at least 30 minutes in each session in games that require forceful, large amplitude, movements of the amputated lower limb (e.g., Quest for Fire, Kick). Time spent and level of engagement as measured by movements of the avatar or, in the case of chess, checkers, solitaire, Sudoku, and internet surfing, the number of clicks produced with each leg will be recorded for each activity using custom software
33308377|NCT05296265|Experimental|Distractor VR treatment|"Subjects assigned to the Distractor VR treatment will participate in REAL i-Series immersive VR experience (REAL system), which has been demonstrated to reduce pain in several studies but lacks the hypothesized active ingredients of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects will navigate through pleasant and relaxing VR environments; they will not see any rendering of their body and make no movements with their legs"
33308378|NCT05295290|Other|myocarditis/pericarditis following COMIRNATY|myocarditis/pericarditis following COMIRNATY within 28 days of dose
33308379|NCT05295290|Other|myocarditis/pericarditis following COVID-19 or MIS-C|myocarditis/pericarditis following COVID-19 or MIS-C without exposure to COMIRNATY
32944505|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
32944506|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
33308380|NCT05288218|Experimental|Leak-free bronchoscope adapter|"The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. The intervention is considered the leak-free bronchoscope adapter."
33308381|NCT05288218|Active Comparator|Standard bronchoscope adapter|The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. This arm utilizes the standard adapter.
33308382|NCT05282823||Treatment Subjects|Subjects will be clinically indicated for pulmonary vein isolation ablation procedure (in compliance with instructions for use (IFU)/Tenpubunsyo as legally approved conditions) for the treatment of paroxysmal AF.
33308383|NCT05273996|Other|Depressed|Subjects receive FDA-approved antidepressants
32944507|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
33308384|NCT05272384|Experimental|Treatment (nivolumab, decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3 or 1-5 of each cycle and nivolumab IV over 30 minutes on day 15 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial.
33308385|NCT05267262|Experimental|Cohort 2 (Alport Syndrome Patients)|R3R01 administered orally as 200 mg tablets twice daily for the first 7 days, followed by 100 mg twice daily for the remaining 77 days
33308386|NCT05267262|Experimental|Cohort 3 (Focal Segmental Glomerulosclerosis Patients)|R3R01 administered orally as 200 mg tablets twice daily for the first 7 days, followed by 100 mg twice daily for the remaining 77 days
33308387|NCT05265767|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|Autologous gene modified peripheral blood stem cell transplantation for patients with severe hemophilia A (FVIII <1%).
33308388|NCT05264025|Active Comparator|Fexo group|
32944508|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
32944509|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
32944510|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
32944511|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
32944512|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
32944513|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
32944514|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
32944515|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
33308389|NCT05264025|Placebo Comparator|Placepo|
33093637|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
33093638|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
33093639|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
33093640|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
33093641|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
33308390|NCT05263726|Experimental|DSMP through a mobile applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
33308391|NCT05263726|No Intervention|Usual Care|Routine care
33308392|NCT05262244|Active Comparator|AMD with bevacizumab-800CW|Patients with AMD receive bevacizumab-800CW followed by angiography
33308393|NCT05262244|Placebo Comparator|AMD with vedolizumab-800CW|Patients with AMD receive vedolizumab-800CW followed by angiography
33308394|NCT05256810|Experimental|Part A: ALN-XDH|A single dose of ALN-XDH administered by subcutaneous (SC) injection.
33308395|NCT05256810|Placebo Comparator|Part A: Placebo|A single dose of placebo administered by SC injection.
33308396|NCT05256810|Experimental|Part B: ALN-XDH Single Dose|A single dose of ALN-XDH administered by SC injection.
33308397|NCT05256810|Experimental|Part B: ALN-XDH Multiple Dose|Multiple doses of ALN-XDH administered by SC injection.
33308398|NCT05256810|Placebo Comparator|Part B: Placebo|Multiple doses of placebo administered by SC injection.
33308399|NCT05256810|Experimental|Part C: ALN-XDH|A single dose of ALN-XDH administered by SC injection.
33308400|NCT05256810|Placebo Comparator|Part C: Placebo|A single dose of placebo administered by SC injection.
33308401|NCT05255991|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
33308402|NCT05255991|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
33308403|NCT05255666|Experimental|Pembrolizumab + Liposomal Irinotecan|"400 mg of pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)~50 mg/m^2 of liposomal irinotecan (Nal-IRI) intravenously every 2 weeks of each Cycle (Cycle is 42 days)"
33308404|NCT05254639|Experimental|Donepezil|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
33308405|NCT05254639|Placebo Comparator|Placebo|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
33308406|NCT05251948|Active Comparator|Atezo + CAPOX (capecitabine + oxaliplatin)|Participants in the atezolizumab plus capecitabine plus oxaliplatin in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
33308407|NCT05251948|Experimental|Atezo + CAPOX +Tir|Participants in the atezolizumab plus capecitabine plus oxaliplatin plus tiragolumab arm in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
33308408|NCT05250011||Single-cohort|Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
33308409|NCT05244213|Experimental|Sintilimab plus chemo|3 cycles of neoadjuvant Sintilimab (200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs for up to 1 year or till disease progression or unacceptable toxicity.
33308410|NCT05235178||Study group|Due to catastrophic bleeding events in patients who are anticoagulated with FXa inhibitors undergoing emergency surgery on the proximal aorta and lack of antidote (not available in Norway and most likely not compatible with heparin), the department has decided to use hemadsorber in these cases.
33308411|NCT05233956|Experimental|LNG IUS|Levonorgestrel intrauterine system
33093642|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
33093643|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
33093644|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
33308412|NCT05233956|Active Comparator|COC|Combined oral contraceptives with ferrous fumarate tables in regimen
33308413|NCT05231148|Other|infected non united fractures|patient of any age and any sex with infected non united fractures of long or short bones
33308414|NCT05228899|Experimental|Group 1: Zofin|Group 1 (15 subjects) Fifteen subjects will receive 1 mL of Zofin diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing 2-5 x 10^11 particles/ml intravenously.
33308415|NCT05228899|Placebo Comparator|Group 2: Placebo|Group 2 (15 subjects) Fifteen subjects will receive 1mL of placebo diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing sterile saline intravenously.
33308416|NCT05214768|Experimental|CC-93538|
33308417|NCT05214768|Placebo Comparator|Placebo|
33308418|NCT05212090|Other|Pre-THA|Subjects will be receiving EOS imaging prior to Total Hip Arthoplasty
33308419|NCT05212090|Other|Post-THA|Subjects will be receiving EOS imaging after Total Hip Arthroplasty
33308420|NCT05204927|Active Comparator|Standard Of Care Hormone Therapy|Abiraterone with Prednisone or Enzalutamide
33308421|NCT05204927|Experimental|Investigational Drug|177Lu-PSMA-I&T
32944516|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
33308422|NCT05202704|Experimental|Experimental: Hidden conditioning procedure + Positive Expectation|Patients with chronic low back pain will receive verbal delivered positive instructions regarding manipulative therapy. Then, after the spinal manipulative therapy they will be submitted to a hidden conditioning procedure in which the pain threshold will be surreptitiously downgrade to conditioning pain decrease to manipulative therapy (G1).
33308423|NCT05202704|Active Comparator|Active Comparator: Positive expectations|Patients with chronic low back pain will receive verbal delivered positive instructions regarding spinal manipulative therapy (G2) before the administration of a spinal manipulative therapy approach.
33308424|NCT05202704|Active Comparator|Active Comparator: Neutral Expectations|Patients with chronic low back pain will receive verbal delivered neutral instructions regarding spinal manipulative therapy (G3) before the administration of a spinal manipulative therapy approach.
33308425|NCT05198934|Experimental|Arm A: Sotorasib 960 mg once daily (QD) + panitumumab|
33308426|NCT05198934|Experimental|Arm B: Sotorasib 240 mg once daily (QD) + panitumumab|
33308427|NCT05198934|Active Comparator|Arm C : Investigator's choice|Participants will be administered trifluridine and tipiracil, or regorafenib
33308428|NCT05194072|Experimental|SGN-B7H4V|SGN-B7H4V monotherapy
33308429|NCT05185037||Caesarian Section Patient|Obstetric patient
33308430|NCT05175352|Experimental|Administration of Cendakimab and Cytochrome P450 (CYP) substrates|
33308431|NCT05169112|No Intervention|Standard of Care|Standard of Care
33308432|NCT05169112|Experimental|Standard of Care plus Androgen Deprivation Therapy (Lupron Depot)|22.5 mg intra-muscular injection of Lupron Depot every 3 months for 12 months (4 injections total)
33308433|NCT05165628|Experimental|Group 1 - CYP-006TK|Participants will receive CYP-006TK dressings
33308434|NCT05165628|No Intervention|Group 2 - Standard of Care|Participants will continue to be treated as per local standard of care
32944517|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
33308435|NCT05161689|Experimental|Mpowerment-based intervention|YMSM in this arm may be exposed to a multicomponent, multi-level, community mobilization, combination intervention to address the entire HIV Continuum of Prevention and Care.
33308436|NCT05161689|No Intervention|Standard of care|YMSM in this arm will not be exposed to the intervention.
33308437|NCT05158361|Experimental|Acupuncture|Participants will receive acupuncture.
33308438|NCT05158361|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture.
33308439|NCT05157451|Experimental|Arm I (SBRT)|Patients undergo SBRT every other day for a total of 5 days over 2 weeks.
33308440|NCT05157451|Experimental|Arm II (Y-90 radioembolization)|Patients receive Y-90 radioembolization via injection on day 1.
33308441|NCT05139420|Experimental|lifestyle intervention plus phentermine-topiramate|Participants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss
33308442|NCT05139420|Experimental|lifestyle intervention|Participants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
33308443|NCT05137223||Adolescent Only Focus Groups|20 early adolescents (ages 10-14) with physician-diagnosed persistent asthma (i.e., prescribed a controller medication) receiving care at a FQHC
32944518|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
32944519|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
32944520|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
32944521|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
32944522|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
32944523|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
32944524|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
32944525|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
32944526|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
32944527|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
32944528|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
32944529|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
32944530|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
32944531|NCT03784079|Experimental|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
32944532|NCT03784079|Experimental|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
32944533|NCT03784079|Placebo Comparator|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
33308444|NCT05137223||Caregiver Only Focus Groups|20 informal caregivers (e.g., parent, grandparent) of early adolescents with physician-diagnosed persistent asthma receiving care at a FQHC
33308445|NCT05137223||Adolescent and Caregiver Focus Groups|10 adolescents with physician-diagnosed persistent asthma receiving care at a FQHC and their caregivers (both of whom did not participate in either previous group for a total of 20 participants in the group cohort)
33308446|NCT05137184|Experimental|Methoxyflurane|3 ml inhalation Can be repeated once (3 ml) Maximum total dose of 6 ml
33308447|NCT05137184|Experimental|Fentanyl IN|100 µg IntraNasal, Patients >70 years: 50 µg IN Can be repeated Maximum total dose 500 µg IN
33308448|NCT05137184|Active Comparator|Morphine IV|0.1 mg/kg Intravenous (IV) Patients ≥ 70 years or fragile: 0.05 mg/kg IV Can be repeated Maximum total dose 0.5 mg/kg IV
33308449|NCT05133011|Experimental|Low muscle strength|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were the last 5%
33308450|NCT05133011|Experimental|Normal groups|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were greater than 5%
33308451|NCT05131347|Experimental|motor intervention|Children in the motor intervention group will receive a 8-week motor intervention program. Each week will be of 1.5-hour duration.
33308452|NCT05131347|Active Comparator|cognitive intervention|Children in the cognitive intervention group will receive a 8-week cognitive training program. Each week will be of 1.5-hour duration.
33308453|NCT05128734|Experimental|Temozolomide Arm|Temozolomide: 50 mg/m2 daily in cycles of 21 days
33308454|NCT05128734|Experimental|Temozolomide+Olaparib Arm|Temozolomide 75 mg/m2 day 1 to day 7 with Olaparib 200 mg BID, oral, day 1 to day 7 in cycles of 21 days
33308455|NCT05123300|No Intervention|A) Conventional Imaging|Conventional Imaging with NaF (sodium fluoride)-PET/CT used for staging
33308456|NCT05123300|Experimental|B) Interventional Imaging|Staging with the interventional18F-PSMA-1007 PET/CT.
33308457|NCT05117840||Lung Cancer Screening Cohort|Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.
33308458|NCT05114135|Experimental|Subject group|undergoing instrumented TLIF using investigational product as synthetic bone graft
33308459|NCT05108116||Study group|"18-30 year-old, healthy volunteers~Age: 18-30 years~BMI: <30~No previous surgery on lower limb or spine~No known developmental disorder~Without any orthopaedic complaint"
33308460|NCT05104060|Experimental|pectoralis minor intervention group|The participants in pectoralis minor group will received manual therapy for pectoralis minor by investigators, the technique including stretch and soft tissue mobilization. The participants asked to perform the scapular control exercise and shoulder strength exercise. Participants will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
33308461|NCT05104060|Active Comparator|shoulder strengthening group|The participants in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
33308462|NCT05104060|No Intervention|Healthy subject group|Healthy participants will be recruited. No Intervention will be provided. The correlation between measures of pectoralis minor length and scapular kinematics will be assessed. Measurement will be the same as pectoralis minor intervention group and shoulder strengthening group
33308463|NCT05100342||Low-risk|Low-risk:score 0-6
33308464|NCT05100342||Intermediate-risk|Intermediate-risk: score 7-13
33308465|NCT05100342||High-risk|High-risk:score 14-20
33308466|NCT05097209|Experimental|Camrelizumab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
33308467|NCT05097209|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
33308468|NCT05094622|Experimental|Physical exercise|Physical exercise program
33308469|NCT05093361|Active Comparator|Operative Treatment|Total Hip Arthroplasty
33308470|NCT05093361|Active Comparator|Conservative Treatment|Physical therapy
33308471|NCT05090904|Experimental|Brensocatib 10 mg|Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. The participants will be stratified based on cystic fibrosis transmembrane conductance regulators (CFTRs) modulator treatment.
33308472|NCT05090904|Experimental|Brensocatib 25 mg|Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
33308473|NCT05090904|Experimental|Brensocatib 40 mg|Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
33308474|NCT05090904|Experimental|Brensocatib 65 mg|Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
33308475|NCT05090904|Placebo Comparator|Placebo|Participants will be administered a placebo matching brensocatib once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
33308476|NCT05090384|Experimental|Steroid Taper|All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued
33308477|NCT05082298|Experimental|Dental Fear Intervention|All participants will receive a brief 2-step treatment for dental fear (Dental FearLess app, In-Chair Treatment)
32800632|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
33093645|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
33093646|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
33093647|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
32800633|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
32800634|NCT03588208|Experimental|Intervention Group|
33093648|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24~27+6 gestational weeks
33093649|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
33093650|NCT04698005|Experimental|Supplementation of exogenous ketones|Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.
33093651|NCT04698005|Placebo Comparator|Control group|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
33093652|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
33093653|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
33093654|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
33308478|NCT05069038|Experimental|Treatment|"The following drugs will be taken for six cycles:~Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days and 7 days off schedule (meaning: on Days 1-21 of each 28-day cycle).~Letrozole should be taken daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.~Goserelin is given as subcutaneous injection every 28 days at a dose of 3.6 mg. It is to be given on Day 1 of each cycle. Goserelin will only be administered to pre-menopausal subjects."
33308479|NCT05067998||IV Vitamin Therapy Treatments|IV vitamin infusion therapy involves inserting an IV line into a vein in your arm to administer a high concentration of liquid vitamins, antioxidants, amino acids, and minerals into your bloodstream. The therapy may be for only one vitamin or a cocktail of nutrients.
32800635|NCT03588208|Active Comparator|Control Group|
32800636|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
32800637|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
32800638|NCT01709721|Experimental|Hydromorphone Hydrochloride (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride for the duration of therapy.
32800639|NCT01709721|Active Comparator|Hydromorphone Hydrochloride Titrated Downward/Control (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride titrated downward
32800640|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
32800641|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
32800642|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
32800643|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
33093655|NCT00496899||1|Women in active labor
33093656|NCT04415710||Group|Women with diagnosed Sjogren syndrome
33093657|NCT04415437||healthy|Healthy participants
33093658|NCT04415437||mentally ill|Participants with mental disorders
33093659|NCT04415437||physically ill|Participants with organic disease
33093660|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
33093661|NCT00591877|Active Comparator|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
33093662|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
33093663|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
33308480|NCT05067998||Herbal Medicine, Tincture (Liquid Vitamins)|Tinctures are concentrated herbal extracts made by soaking the bark, berries, leaves (dried or fresh), or roots from one or more plants in alcohol or vinegar. The alcohol or vinegar pulls out the active ingredients in the plant parts, concentrating them as a liquid. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort. Herbal Medicine is type of medicine that uses roots, stems, leaves, flowers, or seeds of plants to improve health, prevent disease, and treat illness.
33308481|NCT05067998||Supplements|Dietary supplements are substances you might use to add nutrients to your diet or to lower your risk of health problems such as osteoporosis or arthritis. Dietary supplements come in the form of pills, capsules, powders, gel capsules and tablets, extracts, or liquids. Dietary supplements come in a variety of forms, including tablets, capsules, gummies, and powders, as well as drinks and energy bars. Popular supplements include vitamins D and B12; minerals like calcium and iron; herbs such as echinacea and garlic; and products like glucosamine, probiotics, and fish oils.
33308482|NCT05067998||Vitamins (Orally)|Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
33308483|NCT05065411|Experimental|Enobosarm Combination Group|"Enobosarm Combination Group will receive enobosarm 9 mg each day by mouth (QD), and abemaciclib will administered by mouth at a dose of 150 mg BID.~Stage 2 Subjects in the Enobosarm Combination Group will receive enobosarm 9 mg QD each day by mouth and abemaciclib 150 mg BID by mouth until disease progression is observed and confirmed by BICR."
33308484|NCT05065411|Active Comparator|Control Treatment Group|Control Treatment Group will receive a non-steroidal AI, a non-steroidal or steroidal (exemestane with or without everolimus), AI OR fulvestrant approved for the treatment of metastatic breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The decision of which comparator treatment will be used will be made prior to randomization.
33308485|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
33308486|NCT05058651|Experimental|Arm I (atezolizumab, platinum drug, etoposide)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
32800644|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
32800645|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
32800646|NCT03587350|Active Comparator|Interventional Treatment|
32800647|NCT03587350|No Intervention|Usual care|
32800648|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
32800649|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
32800650|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
32800651|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
32800652|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
32800653|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
32800654|NCT03897088|Experimental|Tildrakizumab|
32800655|NCT03897088|Placebo Comparator|Placebo|
32800656|NCT03897088|No Intervention|PART 3: Observational Safety Follow-up|The subjects will not receive study treatment during the follow-up period
32800657|NCT01700205|Active Comparator|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
32800658|NCT01700205|Experimental|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
32800659|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
32800660|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
32800661|NCT03589534|Other|pregnancy test|pregnancy tests
32800662|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
32800663|NCT03587194|Experimental|Otezla|Otezla BID
32800664|NCT03893500|Experimental|Initiating a new PAH medication|Participants will start a new PAH medication
33093664|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
33093665|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
33093666|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
33093667|NCT00496938|Other|1|Observational cohort using an all-comers design
33093668|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
33093669|NCT00462098|Active Comparator|Control|non-HBO comparison group
33093670|NCT00462137||1|control group
33093671|NCT00462137||2|hypnotic group
33093672|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
33093673|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
33093674|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
33308487|NCT05058651|Experimental|Arm II (atezolizumab, platinum drug, etoposide, observation)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
33308488|NCT05058651|Active Comparator|Arm III (platinum drug, etoposide, observation)|During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
33093675|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
33308489|NCT05058508|Experimental|EXER|"Just Move exercises"
33308490|NCT05058508|Experimental|SOC EXER|Standard of Care Exercise
33093676|NCT04328896|Experimental|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
33093677|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
33093678|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
33093679|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
33093680|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
33093681|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
33093682|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
33308491|NCT05050539|Active Comparator|Early Responders to Low Intensity|Early responders will include those with targeted levels of fidelity by the October assessment. They will continue to receive low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
33308492|NCT05050539|Active Comparator|Non-Responders Continue Low Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to continue receiving low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
33308493|NCT05050539|Experimental|Non-Responders Increasing to High Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to have high intensity support added (low intensity + holistic individualized facilitation, tailored educational materials).
33308494|NCT05044195|Experimental|aQIV|Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
33308495|NCT05044195|Active Comparator|Comparator QIV|Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains
33308496|NCT05042609|Experimental|TRS01|
33308497|NCT05042609|Active Comparator|Active comparator|
32944534|NCT03784079|Experimental|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
32944535|NCT03784079|Experimental|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
32944536|NCT03784079|Experimental|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
33308498|NCT05033171|Experimental|Study group|"Patients with scoliosis induced surgical indication (Cobb-degree>45).~Posterior screw-rod fixation segmentdesis~Before the implantation, right after the implantation and after the in situ bending 3D scanning of the rod using Artec Eva Spider type manual 3D scanner will be performed. Scanning is possible from a more than 60 cm distance, so that means the operational area stays sterile.~EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery (as in the actual clinical protocal)."
33308499|NCT05032105|Experimental|Intervention|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
33308500|NCT05029310|Experimental|All patients use both patiromer and tacrolimus|Pharmacokinetic investigation of tacrolimus performed in both the presence and absence of patiromer for all patients.
33308501|NCT05025293|Experimental|ZOLearly|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 5mg zoledronate (Aclasta) will be administered intravenously.~The ZOLearly group will have no further infusions during the study period."
33308502|NCT05025293|Placebo Comparator|ZOLlate|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 100ml NaCl 9mg/ml (placebo) will be administered intravenously.~3 months after hip fracture surgery (at the out-patient clinic): A single dose of 100 ml containing 5mg zoledronate (Aclasta) will administered intravenously."
33308503|NCT05024474|Experimental|Intervention: inspiratory muscle training + physical exercise|Inspiratory muscle training (IMT) twice a day for 8 weeks combined with a physical exercise program at least two times a week for 8 weeks.
33308504|NCT05024474|Active Comparator|Active control: physical exercise|A physical exercise program at least two times a week for 8 weeks.
33308505|NCT05023434||Awake Craniotomy|
33308506|NCT05023434||Healthy Volunteers|
33308507|NCT05023018|Experimental|Patients with high-grade meningioma|30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
33308508|NCT05021991|Experimental|Regimen 1|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning over 43 days: 100 mg PRAX-944~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 353 days"
32944537|NCT03784079|Placebo Comparator|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
32944538|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
33308509|NCT05021991|Experimental|Regimen 2|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 60 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 28 days of 60 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 80 mg, 36 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 353 days"
33308510|NCT05021991|Placebo Comparator|Regimen 3|"Double-blind Part: Oral dosing, once daily in the morning: 56 days of placebo~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 353 days"
33308511|NCT05021640|Experimental|Cohort 1 DCR-AUD|Single dose, subcutaneous administration of 80 mg of DCR-AUD (HV)
33308512|NCT05021640|Placebo Comparator|Cohort 1 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
33308513|NCT05021640|Experimental|Cohort 2 DCR-AUD|Single dose, subcutaneous administration of 240 mg of DCR-AUD (HV)
32944539|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
33308514|NCT05021640|Placebo Comparator|Cohort 2 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
33308515|NCT05021640|Experimental|Cohort 3 DCR-AUD|Single dose, subcutaneous administration of 480 mg of DCR-AUD (HV)
32944540|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
32944541|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
32944542|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
32944543|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
32944544|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
32944545|NCT00978419|Placebo Comparator|Placebo|Placebo
32944546|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
32944547|NCT00957827|Placebo Comparator|placebo|placebo 500mg twice a day for five days
32944548|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
32944549|NCT00962429|Placebo Comparator|Placebo|sugar pill
32944550|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
32944551|NCT00949403|Experimental|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
32944552|NCT03767153|Experimental|80 pin applicator|
32944553|NCT03767153|Active Comparator|160 pin applicator|
33308516|NCT05021640|Placebo Comparator|Cohort 3 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
33308517|NCT05021640|Experimental|Cohort 4 (OPTIONAL) DCR-AUD|Single dose, subcutaneous administration of 960 mg of DCR-AUD (HV)
32800665|NCT03893500|Active Comparator|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
32800666|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
32800667|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
32800668|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
32800669|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
32800670|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32800671|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
32800672|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
32800673|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
32800674|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
32800675|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
32800676|NCT04166799|Experimental|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
32800677|NCT04166799|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
32800678|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
32800679|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
32800680|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
32800681|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
32800682|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
32944554|NCT03766373|Active Comparator|Drug: OP0201|
32944555|NCT03766373|Placebo Comparator|Drug: Placebo|
33308518|NCT05021640|Placebo Comparator|Cohort 4 (OPTIONAL) DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
33308519|NCT05012293|Experimental|Experimental: Fatigue Manipulation|
33308520|NCT05011318|Experimental|Fatigue Manipulation|
33308521|NCT05009784|Active Comparator|Traffic Sound|600 seconds of traffic sound
33308522|NCT05009784|Experimental|Traffic and Masking Sounds|600 seconds of traffic and masking sound
33308523|NCT05009784|Active Comparator|Silence|600 seconds of no sound
33308524|NCT05004857|Experimental|Patient arm|The subject population will be newborn infants admitted to the Newborn Nursery (NN) at Tulane Lakeside Hospital. The investigators are anticipating some mothers can be recruited from the prenatal clinics who expect to deliver at Tulane Hospital during pregnancy as well.
33308525|NCT05002049|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the SEEDS project, and participants will be assessed at baseline and end-of-study.
33308526|NCT05002049|No Intervention|Control Group (No intervention)|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
33308527|NCT05001880|Experimental|Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)|Patients receive atezolizumab IV over 60 minutes, bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive atezolizumab and bevacizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
32800683|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
32800684|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
32800685|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
32800686|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
32800687|NCT03442582||Afluria|Afluria exposure in pregnancy
32800688|NCT03891706|Experimental|TCR-T cell infusion|Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy
32800689|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
32800690|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
33093683|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
33093684|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
33093685|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
33093686|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
33093687|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
33093688|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
33093689|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
33093690|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
33093691|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
33093692|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (<3months) non-specific neck pain with a neck disability index (NDI) > 8% and a Numerical Pain Rating Scale (NPRS) >3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
33093693|NCT04407637||healthy|Healthy control participants were included if they reported a NDI < 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
33093694|NCT04328545|Experimental|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
32800691|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
32800692|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
32800693|NCT05702944|Sham Comparator|Phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is taken at least 2 to 5 weeks before surgery
32800694|NCT05702944|Active Comparator|No phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is not taken before surgery
32800695|NCT03891160|Experimental|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
32800696|NCT03891160|No Intervention|Group B - Control|Group B will be the controls and will not receive a 3D model.
32800697|NCT05702866||Patients Suspected of Having Thoracic Outlet Syndrome|Patients who came for the diagnosis of TOS
32800698|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
32800699|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
32800700|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
32800701|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
32800702|NCT03586180||Dr. Clowns|they will perform shows for children and parents
32800703|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
32800704|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
32800705|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
33308528|NCT05001880|Active Comparator|Arm II (carboplatin, pemetrexed, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive bevacizumab with or without atezolizumab at the discretion of the investigator in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
33308529|NCT05001776|Active Comparator|Endovenous laser ablation without anticoagulants|Endovenous laser ablation without using of any anticoagulant
33308530|NCT05001776|Active Comparator|Endovenous laser ablation with short-term anticoagulant|Endovenous laser ablation and subsequent 7 days of subcutaneous fondaparinux sodium
33308531|NCT05001776|Active Comparator|Medical treatment|45 days of subcutaneous fondaparinux sodium
33308532|NCT05000905|Experimental|Adaptive Attention Training|Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
33308533|NCT05000905|Active Comparator|Low-dose Adaptive Attention Training|Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
33308534|NCT05000905|Other|No Contact Group (Not Randomized)|An additional thirty participants will be enrolled separately (not randomized) into the no-contact group. Participants in the no-contact group will not complete any study activities for 6-8 weeks after completing the baseline assessments. After this period, participants will be prompted to log into Nexus to complete end of study assessments (same set of assessments administered/completed at baseline).
33308535|NCT04996173|Placebo Comparator|Control|Bronchoscopic Balloon Dilation with Radial Cuts
33308536|NCT04996173|Active Comparator|Intervention|Bronchoscopic Balloon Dilation with Radial Cuts & truFreeze Spray Cryotherapy
33308537|NCT04992520|Experimental|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
33308538|NCT04992520|Experimental|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
33308539|NCT04992520|Experimental|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
33308540|NCT04992520|Experimental|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
33308541|NCT04991974|No Intervention|Usual Care (UC)|The UC Arm will include standard services from the sexual health clinic / city health department [at the time of the study, no standardized intervention for opioid use disorder treatment linkage].
33308542|NCT04991974|Active Comparator|Patient Navigation (PN)|The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
33308543|NCT04991974|Experimental|Patient Navigation + Buprenorphine Initiation (PN+BUP)|The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
33308544|NCT04991935|Experimental|Administration of CC-93538|Participants are administered CC-93538 dose subcutaneously once weekly
33308545|NCT04990895|No Intervention|Control group|Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
33308546|NCT04990895|Experimental|Intervention|Participants in the intervention group will also have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. They will be asked to complete a series of HRQOL questionnaires at baseline, at 6 months, and at completion of adjuvant chemotherapy to evaluate their HRQOL and satisfaction levels with their care. In addition, however, they will also receive an email reminder at the mid-way point between scheduled clinic visits to prompt them to enter ePROs via the REDCap online system, including measures such as the ESASr, the EORTC-QLQ C30 and EORTC-BR23 or EORTC-CR29 and specific symptom questionnaires.
33308547|NCT04981470|Experimental|Investigational Device|Subjects implanted with the baroloop device
33308548|NCT04977479|Active Comparator|Active Vaccine|Participant receives the active mRNA COVID-19 vaccine
33308549|NCT04977479|Placebo Comparator|Placebo|All participants crossover and receive active vaccine but which day placebo vs active is given is randomized and blinded.
33093695|NCT04328545|Active Comparator|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
33093696|NCT04328545|Sham Comparator|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
33308550|NCT04971473|Experimental|rhTSH+Thyroid hormone withdrawal|"rhTSH: rhTSH(0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH.Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.~Thyroid hormone withdrawal: Patients stop taking thyroid hormone for 14 days, and then monitor the level of thyroid stimulating hormone every week. When TSH>30mU/L, an ablative activity of 131I was administered.and scanning was done 48 hours after the radioiodine administration."
33308551|NCT04968236|Experimental|Deep dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a deep dry needling technique to the latent trigger point and make 10-12 incisions.
33308552|NCT04968236|Experimental|Superficial dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a superficial dry needling technique to the latent trigger point. Once the needle is placed in the subcutaneous cellular tissue, we manipulate the needle by twisting it until an unpleasant response is provoked. We keep the needle for 5 minutes
33308553|NCT04968236|Experimental|Passive muscle stretching|With the patient positioned in the supine position, the pelvis stabilized with a strap and the lower extremity where we are going to apply the rectus femoris muscle stretch placed outside the table, we perform a passive stretching technique, increasing hip extension and knee flexion until the patient feels the tension. The position is held for 60 seconds.
33093697|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
33093698|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
33093699|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
33093700|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
33308554|NCT04945733|Experimental|Amivantamab: Gastric Cancer (GC) Cohorts|Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (<) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (>=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle), followed by additional dosing based on body weight if recommended by clinical trial management team (CTMT) (amivantamab 1750 mg for body weight <80 kg and 2100 mg for body weight >=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
33308555|NCT04945733|Experimental|Amivantamab: Esophageal Cancer (EC) Cohorts|Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight <80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight >=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle) followed by additional dosing based on body weight if recommended by CTMT (amivantamab 1750 mg for body weight <80 kg and 2100 mg for body weight >=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
33308556|NCT04943588||HCV Negative|"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:~over 18 yrs old.~willing to participate~no previous history of therapy with oral medication for chronic HCV infection"
33308557|NCT04943588||HCV Positive with first-line treatment success|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.
33308558|NCT04943588||HCV positive with first-line treatment failure|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir/daclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).
33308559|NCT04943588||Cirrhotic Patients|Hepatitis C RNA positive that have cirrhosis
33308560|NCT04935489|Experimental|Patients receiving accelerated rTMS|
33308561|NCT04922554|Experimental|Omadacycline 300 mg PO|omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
33308562|NCT04922554|Placebo Comparator|Placebo PO|Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
33093701|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
33093702|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
33093703|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
33093704|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
33093705|NCT00497172|Experimental|1|drug-eluting stent
33093706|NCT00497172|Active Comparator|2|bare-metal stent
33093707|NCT03273296|Active Comparator|Amoxicillin|
33093708|NCT03273296|Active Comparator|Azithromycin|
33093709|NCT03273296|Active Comparator|Vancomycin|
33093710|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
33093711|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
33093712|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
33093713|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
33093714|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
33093715|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
33093716|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
33093717|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
33093718|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
33093719|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
33093720|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
33093721|NCT00222989|Other|no label study|1
33093722|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
33093723|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
33093724|NCT00489645|Experimental|2|Pramlintide, euglycemia
33093725|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
33093726|NCT00489645|Experimental|4|pramlintide, hyperglycemia
33093727|NCT00465686|Experimental|A|
33093728|NCT04697199|Placebo Comparator|Placebo group|patients received scaling and root planing using hand and ultrasonic instruments.
33093729|NCT04697199|Active Comparator|Probiotic group|"patients received SRP and by using blunt syringe, subgingival delivery of 1ml of probiotic suspension was applied to these sites at baseline (immediately after SRP), one, two and four weeks. Periodontal dressing was applied after placement of the drug.~After placement of the drug, patients were instructed to keep away from chewing hard or sticky food, brushing near the treated areas, or using any interdental aids for 24 hours."
33093730|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
33093731|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
33093732|NCT04697433||Myotonometry|The evaluation of myotonometry will be carried out by two independent evaluators. The first evaluator will perform the test bilaterally on the middle deltoid, upper trapezius, pectoralis major, biceps brachii, rectus femoris, anterior tibialis, triceps brachii, lumbar multifidus, biceps femoris and soleus previously marked. Immediately after, the second appraiser will perform the same measurements in the same order (Inter-rater reliability). After a 15-minute interval, the retest (intra-rater reliability) will be performed following the same procedure and order as the test step.
33308563|NCT04919824|Experimental|Bipolar Knife|ESD procedure performed with Creo Medical Speedboat RS2.
33308564|NCT04919824|Active Comparator|Monopolar Knife|ESD procedure performed with monopolar knives.
33308565|NCT04919499|Experimental|Part A: BI 765128 low dose|
33308566|NCT04919499|Experimental|Part A: BI 765128 medium dose|
33308567|NCT04919499|Experimental|Part A: BI 765128 high dose|
33308568|NCT04919499|Experimental|Part B: BI 765128|Highest safe dose from Part A
33308569|NCT04919499|Sham Comparator|Part B: Sham comparator|
33308570|NCT04917692|Experimental|empagliflozin|empagliflozin 2.5 mg daily
33093733|NCT00105443|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
33093734|NCT00105443|Placebo Comparator|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
33093735|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
33093736|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
32800706|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
32800707|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
32800708|NCT03889834|Experimental|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
32800709|NCT03889834|Experimental|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
32800710|NCT03889834|Other|Controls not transfused|no transfusion
32800711|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
32800712|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
32800713|NCT05702632|Active Comparator|Group A|
32800714|NCT05702632|Active Comparator|Group B|
32800715|NCT03585946||Cyclosporine|
32800716|NCT03585946||Intravenous Immunoglobulin|
32800717|NCT03585946||Etanercept|
32800718|NCT03585946||Steroids|
32800719|NCT03354520|Active Comparator|Tailored Videos|
32800720|NCT03354520|Active Comparator|Standard Videos|
32800721|NCT03354520|Active Comparator|OSA Treatment|
32800722|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
32800723|NCT03580642|No Intervention|Control|Habitual treatment.
32800724|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
32800725|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
32800726|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
32800727|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
32800728|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
32800729|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
32800730|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
32800731|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
32800732|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
32800733|NCT01865487|Placebo Comparator|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
32800734|NCT01865487|Experimental|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
32800735|NCT01865487|Experimental|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
32800736|NCT01865487|Experimental|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
32800737|NCT01865487|Placebo Comparator|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
32800738|NCT01865487|Experimental|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
32800739|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
32800740|NCT05702398|Experimental|Vitamin A & Nicotinamide|1,000 μg retinyl palmitate and 500 mg NAM twice a day
32800741|NCT05702398|Placebo Comparator|Placebo|Identical placebo pills twice a day
32800742|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
32800743|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
32800744|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
32800745|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
32800746|NCT01698879|Experimental|Single arm, three cohorts|Idarubicin, cytarabine, Mylotarg.
32800747|NCT02335294|Experimental|TRV130|
32800748|NCT02335294|Active Comparator|Morphine|
32800749|NCT02335294|Placebo Comparator|Placebo|
33093737|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
33093738|NCT00489840|Experimental|anecortave acetate|
33093739|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
33093740|NCT00489957||Normals|
33093741|NCT00489957||Cardiomyopathy|
33093742|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
33093743|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
33093744|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
33093745|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
33093746|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
33093747|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
33093748|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
33093749|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
33093750|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
33093751|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
33093752|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
33093753|NCT04696926||patients who underwent an aortic valve replacement|
33093754|NCT00463541|Experimental|1|
32800750|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
32800751|NCT03735628|Experimental|Dose escalation|"Copanlisib:~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
32800752|NCT03735628|Experimental|Dose expansion|"Copanlisib:~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
32800753|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
32800754|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
32800755|NCT04548297||Healthy group|Healthy individuals without chronic disease
32800756|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
32800757|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
32800758|NCT05702242|Experimental|Removal with alligator forceps|Standard of care removal with passage of an intrauterine alligator forceps under ultrasound guidance to grasp and remove the IUD. If required, multiple attempts will be performed using this technique.
32800759|NCT05702242|Experimental|Removal with manual vacuum aspiration|Intrauterine placement of an MVA under ultrasound guidance adjacent to the IUD to remove the IUD. Multiple attempts will be performed up to a maximum of 3 unsuccessful MVA attempts, after which time, the provider will switch to the alligator forceps technique, given that this is the current standard of care.
32800760|NCT01682811|Experimental|Part 1 Levulan injection|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
32800761|NCT01682811|Experimental|Part 1 Levulan painting|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
32800762|NCT01682811|Experimental|Part 1 Levulan painted twice|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
32800763|NCT01682811|Experimental|Part 1 Levulan painted twice with microneedling|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
33093755|NCT00490113|Experimental|1|
33093756|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
33093757|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
33093758|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
33093759|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
33093760|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
33093761|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
33093762|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
33093763|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
32944556|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
32944557|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
32944558|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
32944559|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
32944560|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
32944561|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
32944562|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
32944563|NCT00928499|Other|Interstim - continuous|Continuous stimulation
32944564|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
32944565|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
32944566|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
32944567|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
32944568|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
32944569|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
32944570|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
32944571|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
32944572|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
32944573|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
32944574|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
32944575|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
32944576|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
32944577|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
32944578|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
32944579|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944580|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944581|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944582|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944583|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944584|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
32944585|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
32944586|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944587|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944588|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944589|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
33093764|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
33093765|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
33093766|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
33093767|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
33308571|NCT04915248|Experimental|All patients registered in the DALYA trial|"Treatment consists of an induction phase (every 21 days) planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase (every 28 days), planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator decision."
33308572|NCT04908631|Other|tDCS during auditory training|Use of tDCS during completion of the auditory training program
33308573|NCT04903197|Experimental|Arm 1A|VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)
33308574|NCT04903197|Experimental|Arm 1B|VAY736 single agent dose expansion in patients with DLBCL
33308575|NCT04903197|Experimental|Arm 2A|VAY736 + lenalidomide dose escalation in patients with DLBCL
33308576|NCT04903197|Experimental|Arm 2B|VAY736 + lenalidomide dose expansion in patients with DLBCL
33308577|NCT04898114|Experimental|NebMag|Nebulized magnesium sulfate and oral sildenafil
33308578|NCT04898114|Placebo Comparator|Control|Nebulized placebo (isotonic saline) and oral sildenafil
33308579|NCT04893785|Experimental|Cabozantinib and Temozolomide|"All patients will receive:~Cabozantinib 40 mg os QD~Temozolomide 100 mg/m2/day seven days followed by seven days of stop (regimen one week on / one week off)."
33308580|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Daratumumab)|"Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) will receive magrolimab as per protocol and daratumumab 1800 mg subcutaneously (SC) or 16 milligrams per kilogram (mg/kg) intravenously (IV) on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)~."
33308581|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
33308582|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 20 mg/m^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
33308583|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
33308584|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Daratumumab)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)
33308585|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
33308586|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and carfilzomib 20 mg/m^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
33308587|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and bortezomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
33308588|NCT04888013|Placebo Comparator|control group|Routine care for childbirth
33308589|NCT04888013|Experimental|experimental 2|Building childbirth environment
33308590|NCT04888013|Experimental|experimental 1|Building childbirth environment and labor delivery recovery room
33308591|NCT04882579|Experimental|PoCUS group|Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
33308592|NCT04882579|No Intervention|Control group|Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
33308593|NCT04881747|Active Comparator|100 milligram (mg) Lasmiditan immediate release (IR) (Reference)|Participants received 100 mg lasmiditan as IR tablet formulation administered orally.
33308594|NCT04881747|Experimental|100 mg Lasmiditan oral disintegrating (OD) Without Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally without water.
33308595|NCT04881747|Experimental|100 mg Lasmiditan OD With Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally with water.
33308596|NCT04880434|Experimental|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
33308597|NCT04879875|Experimental|Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
33308598|NCT04879875|Experimental|Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
33308599|NCT04879329|Experimental|Cohort A - DV monotherapy for HER2-positive tumor types|Disitamab vedotin monotherapy
33308600|NCT04879329|Experimental|Cohort B - DV monotherapy for HER2-low tumor types|Disitamab vedotin monotherapy
33308601|NCT04879329|Experimental|Cohort C - Non-randomized combination therapy|Disitamab vedotin + pembrolizumab
33308602|NCT04879329|Experimental|Cohort C - Randomized combination therapy|Disitamab vedotin + pembrolizumab
33308603|NCT04879329|Experimental|Cohort C - Randomized monotherapy|Disitamab vedotin monotherapy
33308604|NCT04879329|Experimental|Cohort D - DV monotherapy (Japan only)|Disitamab vedotin monotherapy
33308605|NCT04879329|Experimental|Cohort E - DV combination therapy (Japan only)|Disitamab vedotin + pembrolizumab
33308606|NCT04874155|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation - Phase 1
33308607|NCT04874155|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation - Phase 1
33308608|NCT04874155|Active Comparator|Open-Label|Open-Label - Phase 2 lasting 4-wks, during which all subjects will receive open-label Active treatment
33308609|NCT04869943|Experimental|Enobosarm Treatment Group|Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.
33308610|NCT04869943|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization. After radiographic progression, subjects randomized to the Control Treatment Group may be crossed over to receive enobosarm 9mg.
33308611|NCT04862949||Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
33308612|NCT04862663|Experimental|Capivasertib Plus Palbociclib and Fulvestrant|Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b and Ph III)
33308613|NCT04862663|Placebo Comparator|Placebo Plus Palbociclib and Fulvestrant|Placebo Plus Palbociclib and Fulvestrant (Ph III)
33308614|NCT04862663|Experimental|Capivasertib Plus Ribociclib and Fulvestrant|Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)
33308615|NCT04862663|Experimental|Capivasertib Plus Abemaciclib and Fulvestrant|Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)
33308616|NCT04854213|Other|Liquid biopsy|Blood samples for liquid biopsy
32800764|NCT01682811|Experimental|Part 2 Dose level 1 50 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
32800765|NCT01682811|Experimental|Part 2 Dose level 2 100 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
32800766|NCT01682811|Experimental|Part 2 Dose level 3 200 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
32800767|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
32800768|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
32800769|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
32800770|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
32800771|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
32800772|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
32800773|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
32800774|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
32800775|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
32800776|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
32800777|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
32800778|NCT04765540|Active Comparator|T1: Business as Usual (BAU)|Handwashing station plus standard BRAC programming, i.e. in-person community WASH (water, sanitation and hygiene) demonstrations conducted in households/communal areas, and sticker signs/posters placed on walls in the 'catchment area' of the handwashing station, alerting people to the stations and roughly pointing the way.
32800779|NCT04765540|Experimental|T2: BAU + Low Intensity Nudges|"T1 plus a bundle of 'low-intensity' passive interventions, including:~Large mirrors installed above handwashing station sinks to attract more people to the station~7 to 8 large hand-shaped signposts pointing to the station and leading up to the station, placed on the ground in the vicinity of the station, starting from the nearest 'busy spot'"
32830598|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
33404510|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
33093768|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
33093769|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
33093770|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
33093771|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
33093772|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
33093773|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
33093774|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
33093775|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
33093776|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
33093777|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
33093778|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
33093779|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
33093780|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
33093781|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
33093782|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
33093783|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
33093784|NCT00497523|Experimental|Beclomethasone dipropionate|
33093785|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
32944590|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944591|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944592|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
32944593|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
32944594|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
32944595|NCT00850421|Other|Botulinum Toxin Type A|
32944596|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
32944597|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
32944598|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
33093786|NCT00497523|Active Comparator|Salbutamol|
33093787|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
33093788|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
33093789|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
33093790|NCT00490620|Placebo Comparator|1|blinded placebo control
33093791|NCT00490620|Active Comparator|2|Antiretroviral therapy
33093792|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
32944599|NCT04332263|Experimental|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
33093793|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
33093794|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
32944600|NCT04332263|No Intervention|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
32944601|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
32944602|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
32944603|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
32944604|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
32944605|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
33093795|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
33093796|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
33093797|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
33093798|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
33093799|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
33093800|NCT00466388|Placebo Comparator|Placebo|sugar pill
33093801|NCT00466466|Experimental|Daily dosing RAD001|
33093802|NCT00466466|Experimental|Weekly dosing RAD001|
33093803|NCT00490854|Experimental|1|
33093804|NCT00490854|Experimental|2|
33093805|NCT00463970|Active Comparator|1|Brief Intervention
33093806|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
33093807|NCT00463970|Experimental|3|Seal oil
32737998|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
32737999|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
32738000|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
32738001|NCT05024175||CARv3-TEAM-E T cells|"Eligibility to participate on this study if enrolled on study 20-532 and received infusion of CARv3-TEAM-E T~The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol~Medical History/Physical Exam~Blood Test~Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.~Tumor biopsy.~Data Collection~Biobanking"
32738002|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
32738003|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
32738004|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
32738005|NCT05023941|Active Comparator|Medicine Group|Start orally take Acetazolamide 2 days before entering the hypoxic room.
32738006|NCT05023941|Active Comparator|RIPC Group|Start RIPC training twice daily, 6 days before entering the hypoxic room.
32738007|NCT05023941|Experimental|Rapid RIPC Group|Start RIPC training forth daily, 3 days before entering the hypoxic room.
32738008|NCT05023941|Experimental|Combined Group|Medicine + Rapid RIPC
32738009|NCT05023941|No Intervention|Control Group|Subjects do not receive specific interventions before entering the hypoxic room.
32738010|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
32738011|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
32738012|NCT03332147|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
32738013|NCT03332147|Active Comparator|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
32738014|NCT03093519|Experimental|KHK6640|Intravenous administration
32738015|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
32738016|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
32738017|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
32738018|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
32738019|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
32738020|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
32738021|NCT05009433|Experimental|Pregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). The program will be also based on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise."
32738022|NCT05009433|Active Comparator|Pregnant MICT group|The moderate intensity continuous training (MICT) program will be implemented based on the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the MICT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise.
32738023|NCT05009433|Sham Comparator|Pregnant standard care group|During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to taking part in the study tests.
32746543|NCT04789629|Active Comparator|low level laser , physiotherapy|Instrumentation Diode laser device will use for biostimulation of the muscle fiber . The device has a wavelength of 808 nm and a power output 0-250 mW. parameters of laser : Wavelength 808 nm Power output 100 mW Spot size 0.0314 cm2 Power density 3,18 W/cm2 Treatment time per point 40 s Energy density per point 4,77 J/cm2 Energy per point 4 J 12 sessions for one month with traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training .)
33308617|NCT04848974|Experimental|Treatment (uproleselan, cladribine, cytarabine)|"INDUCTION THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q 12 hours on days 2-12, cladribine IV over 1-2 hours on days 1-5 and cytarabine SC BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR or CRi after cycle 1 may receive a second induction cycle.~CONSOLIDATION/MAINTENANCE THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q12 hours on days 2-1. Patients who have achieved at least CR/CRi or morphologic leukemia-free state after induction therapy receive uproleselan IV QD on days 1-12. Patients also receive cladribine IV over 1-2 hours on days 1-3 and cytarabine SC BID on days 1-10. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
33308618|NCT04848038|Active Comparator|Core and Fusion Training|150 minutes/week of Core and Fusion exercise, a mix of low impact toning, strengthening, flexibility and balance exercises.
33308619|NCT04848038|Active Comparator|Endurance Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. In addition 0-2 days of Core and Fusion control exercise will also be recommended.
33308620|NCT04848038|Active Comparator|Weight Training|Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum. In addition 3 days of Core and Fusion control exercise will also be recommended.
33308621|NCT04848038|Active Comparator|Combined Endurance and Weight Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum.
33308622|NCT04846244||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for radiographic axial spondyloarthritis (r-axSpA).
33308623|NCT04844866|Experimental|CAR T-cell MB-CART2019.1|Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight.
33308624|NCT04844866|Active Comparator|Standard of Care|Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.
32800780|NCT04765540|Experimental|T3: BAU + High Intensity Activities|"T1 plus an additional bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks provided to handwashing station users in regular giveaways at key times, along with encouragement to return to the station and to spread the word.~A 'community message board' along with encouragement to make a mark on a scoreboard at the top of the board before/after use of the station to increase commitment and as an additional social cue. This will also visually show cumulative number of uses as a persistent cue of the social norm.~General encouragement to use the stations, provided by the intervention delivery team while they are at the station. Intervention team members are equipped with a loudhailer to assist this.~In addition, village handwashing station committees will be encouraged to try out their own ideas for encouraging more people to use the stations."
32800781|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
32800782|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
32800783|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
32800784|NCT03584698|Active Comparator|control group|Misoprostol only group
32800785|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
32800786|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
32800787|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
32800788|NCT05702008|No Intervention|Control Group|The participants in this study arm were administered no intervention.
32800789|NCT05702008|Experimental|Test Group|The participants in this arm were administered the following intervention: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1&ipp=All&lang=1&level=2&sublinkid=502&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
32800790|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
32800791|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
32800792|NCT05703178|Experimental|Education + Online Pain Coping Skill Training|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects. They will also be given access to an online pain coping skills training program and asked to complete it at home over 8 to 10 weeks. This interactive, web-based program teaches cognitive and behavioral skills that research has shown can reduce pain and pain-related interference with daily activities. The program includes eight sessions that participants will complete at a rate of about 1 per week. Each session takes 35-45 minutes. Participants will be shown how to use the program and can contact the study team if they have any problems with it. Participants who do not have a device capable of accessing the program will be loaned a tablet computer for the study.
33308625|NCT04841772|Active Comparator|Vegan Protein|
32944606|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
32944607|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
33308626|NCT04841772|Placebo Comparator|Placebo|
33308627|NCT04840823|Experimental|Enoxacin 200mg twice daily|Enoxacin 200mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 1 active 200mg enoxacin tablet and 2 placebo tablets per dose.
33308628|NCT04840823|Experimental|Enoxacin 400mg twice daily|Enoxacin 400mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 2 active 200mg enoxacin tablets and 1 placebo tablet per dose.
32944608|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
33308629|NCT04840823|Experimental|Enoxacin 600mg twice daily|Enoxacin 600mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 3 active 200mg enoxacin tablets per dose.
33308630|NCT04839978|Experimental|Preventive Intervention|Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.
33308631|NCT04839978|No Intervention|Delayed Intervention Control Group|Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.
33308632|NCT04825704|Active Comparator|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
33308633|NCT04825704|Placebo Comparator|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
33308634|NCT04804917||Participants in the MindMyMind RCT|"The study participants comprise the 396 youths (and their parents) who participated in the Mind My Mind RCT. The study participants were randomized to the experimental MMM intervention (n=197) or MAU (n=199) and followed in the trial until 26 weeks after randomization, from September 7, 2017, to August 28, 2019.~The MMM consisted of 9-13 weekly, individual therapy sessions. The CBT methods were organized in modules for anxiety, depression and behavioral problems. Flowcharts described the sequencing and dosing of modules to match the problems at hand. The therapy was completed within 17 weeks, followed by a booster session after four weeks.~The MAU was enhanced by two care-coordination visits (week 2 and 17). The MAU interventions included anonymous counseling, pedagogical advice, network meetings, educational support, psychological treatment, or no treatment."
33308635|NCT04804748||Phase A|"Approximately 150 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery)~Data regarding standard of care post-operative pacing and treatment of POAF, if applicable, will be collected from time of surgery until discharge~No use of an external bi-atrial pacing device~No use of Defipace~In-hospital data will be collected for all patients~Patients that developed POAF (n=50) will be followed-up with a phone call 30 days after surgery"
33308636|NCT04804748||Phase B|"Approximately 300 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery) with planned TMA implantation~In-hospital data will be collected for all patients~Use of the DefiPace system for the treatment (low-energy cardioversion) and post-operative prevention (bi-atrial pacing) of POAF will be documented (n=100). These patients will be followed-up with a phone call 30 days after surgery"
33308637|NCT04800146||Cohort 1|patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
33308638|NCT04800146||Cohort 2|patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
33308639|NCT04800146||Cohort 3|patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
33308640|NCT04800146||Cohort 4|patients with previously untreated mature B cell tumors in watch and wait
33308641|NCT04800146||Cohort 5|patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
33308642|NCT04800146||Cohort 6|patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
33308643|NCT04800146||Cohort 7|patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
33308644|NCT04800146||Cohort 8|non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.
33308645|NCT04795622|Experimental|Treatment Ulthera System|
33308646|NCT04795622|Other|Delayed-treatment Ulthera System|
33308647|NCT04791033||Adenomyosis|Patients with adenomyosis
33308648|NCT04791033||Other benign gynecological conditions|Patients with other benign gynecological conditions (i.e: myomas, endometriosis).
33308649|NCT04787003|Experimental|Oncolytic virus (OVV-01) injection for patients with advanced solid tumors|Oncolytic virus (OVV-01) injection combined with or without immune checkpoint inhibitors in the treatment of patients with advanced solid tumors.
33308650|NCT04786691|Placebo Comparator|Black coffee first|12 oz of black coffee with no additives is the first intervention tested
33308651|NCT04786691|Active Comparator|Coffee with half and half first|12 oz of black coffee with 1 oz of half and half is the first intervention tested
32944609|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
33093808|NCT00463970|Placebo Comparator|4|Soy oil
33308652|NCT04786691|Active Comparator|Coffee with non-dairy creamer first|12 oz of black coffee with 1 oz of liquid non-dairy creamer is the first intervention tested
33308653|NCT04784871|Experimental|5waysA Intervention|The intervention, 5WaysA, is a 10 week modified web-based version of the original Five Ways to Wellbeing course. The intervention consists of a two-hour main webinar with live lecturing from a facilitator introducing the Five Ways to Wellbeing framework and teaching the participants how to implement the five health promotive activities in life, a booster session webinar four weeks later, as well as an SMS message twice a week in the six following weeks. Each SMS encourages participants to engage in one of the five activities, register activities/goals and queries about the degree of participation in the activity introduced in the previous SMS.
33308654|NCT04784871|Other|5waysA Active wait-list control|The active wait-list control group will get the same intervention as the interventions group, five months later. The active wait-list control group will be encouraged (in SMS messages) to write down an activity log once a week in ten weeks, while waiting. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
33308655|NCT04784871|Other|5waysA Inactive wait-list control|The inactive wait-list control group will get the same intervention as the interventions group, five months later. The inactive wait-list control group will not do anything specific while waiting for the intervention. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
33308656|NCT04781959|Active Comparator|5 Days of Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
33308657|NCT04781959|Active Comparator|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
33308658|NCT04777851|Experimental|Regorafenib + Nivolumab|Investigational arm: regorafenib at a dose of 90 mg orally once per day (on days 1 to 21 of a 28-day cycle), in combination with nivolumab 480 mg using 30-minutes intravenous infusion (on day 1 of a 28-day cycle, every 4 weeks).
33308659|NCT04777851|Active Comparator|Transarterial Chemoembolization (TACE)|"Control arm: Patients will be treated with transarterial chemoembolization (TACE) on-demand according to the clinical site's standards, with the goal of controlling all known liver lesions. Either conventional TACE (cTACE) or drug-eluting bead transarterial chemoembolization (DEB-TACE) may be used (as long as it is consistently applied for all patients at a given clinical site)."
33308660|NCT04757402|Active Comparator|Control arm|All eligible candidates will be receiving standard preoperative counselling as per the hospital standards and protocols. The patient will fill five-points Amsterdam Preoperative Anxiety and Information Scale (APAIS) form for anxiety evaluation and Seven-points Likert Scale form for satisfaction regarding the counselling.
33308661|NCT04757402|Experimental|NSQIP Arm|All eligible candidates will be receiving standard preoperative counselling as per the control arm PLUS the risk will be explained using the scores from the NSQIP surgical risk calculator. The anxiety and the satisfaction scores will be recorded as in the control arm.
33308662|NCT04745156|Experimental|RNS System Implantation|This is a device feasibility study, therefore participants will only be enrolled into the investigational arm and will receive the RNS System Implantation.
33308663|NCT04735575|Experimental|EMB-06|"In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.~In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D."
33308664|NCT04732026||Cases|150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
33308665|NCT04732026||Controls|450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
33308666|NCT04729608|Experimental|Batiraxcept+PAC|Combination of batiraxcept and PAC
33308667|NCT04729608|Placebo Comparator|Placebo+PAC|Placebo-controlled arm with PAC
33308668|NCT04720625|Experimental|Adapt2Quit|These participants will receive Adapt2Quit motivational messaging and quitline facilitation messaging for 6 months.
33308669|NCT04720625|Active Comparator|Control|These participants will receive quitline facilitation-only messaging for 6 months.
33308670|NCT04712903|Experimental|Durvalumab in Combination with Platinum-Etoposide|Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
33308671|NCT04710355||Chronic pain|Failed back surgery syndrome
33308672|NCT04710277|Experimental|Novel multimodal protocol group|They will receive scheduled topical ice therapy for 24 hours after surgery. It will be applied over abdominal incisions for 20 minutes every 2-3 hours. Acetaminophen and an NSAID will be scheduled for 96 hours. While inpatient, they will receive acetaminophen 975 mg every 8 hours and IV Toradol 15-30 mg every 6 hours with change to ibuprofen 800 mg every 8 hours when tolerating oral intake. They may take oxycodone 5 mg every 4-6 hours as needed (PRN) for breakthrough pain and pain score >6. They may use ice PRN after 24 hours. They will be prescribed acetaminophen 1000 mg every 8 hours and ibuprofen 800 mg every 8 hours for 96 hours postoperative. They may take them as needed after. If the participant used 0 narcotics in the first 24 hours, they will not be prescribed a narcotic. If up to 5 tablets were used, they will be prescribed 5 tablets of oxycodone 5 mg every 6 hours PRN. If more than 5 tablets were used, they will be prescribed 10 tablets of oxycodone 5 mg every 6 hours PRN.
33308673|NCT04710277|Active Comparator|Usual care protocol group|Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score >6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
33308674|NCT04709653|Experimental|Intervention Group|Occupation-based nursing program
33093809|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
33093810|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
33308675|NCT04709653|Experimental|Control Group|Routine nursing care
33093811|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
33093812|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
33308676|NCT04708470|Experimental|1/Arm 1|Dose escalation/de-escalation of entinostat and dose escalation of NHS-IL12 with fixed dose of bintrafusp alfa
33308677|NCT04708470|Experimental|2/Arm 2|RP2D of entinostat, NHS-IL12, and bintrafusp alfa
33093813|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
33308678|NCT04708470|Experimental|3/Arm3|Entinostat and NHS-IL12 (without bintrafusp alfa)
33308679|NCT04707001|Active Comparator|Ultrasound monitoring group|In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
33308680|NCT04707001|Active Comparator|Symptoms alone group|Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
33308681|NCT04705597|Experimental|BGE-175|BGE-175 tablet to be taken by mouth once a day for 14 days
33308682|NCT04705597|Placebo Comparator|Placebo|Placebo tablet to be taken by mouth once a day for 14 days
33308683|NCT04703790||Adults from the United States|Adult participants 18 years of age or older who are panelists recruited and maintained by Ipsos (KnoweledgePanel). All participants live within the United States.
33308684|NCT04702750|Experimental|Experimental group|
33308685|NCT04697628|Experimental|Tisotumab vedotin|Tisotumab vedotin monotherapy
33308686|NCT04697628|Active Comparator|Chemotherapy|Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
33308687|NCT04689568|Active Comparator|Moodkit|MoodKit is a cognitive behavioral therapy (CBT)-based app designed to provide tools for managing depressed mood, anxiety and stress.
33308688|NCT04689568|Active Comparator|Moodgym|Moodgym is an online cognitive behavioral therapy (CBT)-based program designed to prevent or reduce symptoms of depression and anxiety by helping users identify and overcome problem emotions and to develop good coping skills.
33308689|NCT04689568|Active Comparator|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey. The Toolkit offers help to people who are experiencing problems with a mood disorder as well as with stress and anxiety.
33308690|NCT04686136|Experimental|Atogepant 60 mg|Taken once daily
33308691|NCT04679636|Experimental|Experimental group|receive biofeedback training for heart rate variability for eight weeks
33308692|NCT04679636|No Intervention|Control group|receive conventional treatment
33308693|NCT04677049|Experimental|Niacin|"Niacin controlled release technology (CRT):~Niacin CRT™ is to be started 7 days before concurrent Radiation Therapy (RT)- Temozolomide (TMZ) treatment.~Chemo/Radiation Therapy:~For all patients, regardless of the phase of the study, concurrent RT and TMZ for 6 weeks followed by 6-12 cycles of monthly TMZ will be given.~Concurrent Temozolomide:~TMZ will be administered from the first to the last day of RT at 75 mg/m2 orally (PO) for a maximum of 49 days.~Monthly Temozolomide:~Cycles of chemotherapy Day 1 to Day 5 every 28 days will start 28 days (+/- 2 days) after the end of RT-TMZ. First cycle of TMZ is administered at 150 mg/m2 Day 1-Day 5 by mouth (PO) and increased to 200 mg/m2 Day 1-Day 5 PO from cycle 2 onwards if well tolerated. While 6 cycles are standard of care, the Neuro-Oncologist may continue up to 12 cycles if clinically appropriate."
33308694|NCT04671862|Experimental|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~1 Treatment pre radiotherapy~3 treatments weekly during radiotherapy"
33308695|NCT04670770|Experimental|SHR1459|SHR1459
33308696|NCT04664478||Subjects with abnormal elastogenesis|Participants with genetic variant in the connective tissue target genes
33308697|NCT04664179|Experimental|Arm A: Treatment without lymphodepletion chemotherapy|"C7R-EBVSTs~Group B will be activated if only limited expansion and clinical efficacy is observed in Group A"
33308698|NCT04664179|Experimental|Arm B: Treatment with lymphodepletion chemotherapy|C7R-EBVSTs with lymphodepletion chemotherapy
33308699|NCT04653948||Cohort Study|Women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age seeking antenatal care at Kawempe National Referral Hospital in their first and second trimesters of pregnancy will be invited to participate in the study until a sample size of at least 4000 women is achieved. They will be followed-up along with their liveborn infants until a minimum of 14 weeks post-delivery.
33308700|NCT04653948||EMR Cohort|Anonymised data from the entire maternal and infant population that attend Kawempe Hospital for antenatal and/or delivery +/- post-partum care during the two-year study period will be analysed to describe maternal, obstetric and neonatal outcomes.
33308701|NCT04653896|Experimental|Knee OA group|Individuals who are over 18 years and have medical diagnosis of Grade 3 or 4 knee OA
33308702|NCT04652245|Experimental|Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period|Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray and Placebo nasal spray
33308703|NCT04652245|Experimental|Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period|Placebo nasal spray and Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray
32944610|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
33308704|NCT04642287|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
33308705|NCT04642287|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
33308706|NCT04639167|Experimental|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
32944611|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil~taxane chemotherapy treatment alone or in combination with other agents"
32944612|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo~taxane chemotherapy treatment alone or in combination with other agents"
32944613|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
32944614|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
32944615|NCT00808769|Active Comparator|1|Zegerid®
32944616|NCT00808769|Experimental|2|Prilosec OTC®
33308707|NCT04639167|No Intervention|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
32944617|NCT00378131|Placebo Comparator|1|
32944618|NCT00378131|Experimental|2|RC-1291 50mg
33093814|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
33093815|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
32944619|NCT00378131|Experimental|3|RC-1291 100mg
32944620|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
32944621|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
32944622|NCT00379067|Placebo Comparator|2|Placebo tablet
33308708|NCT04636229|Experimental|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
33308709|NCT04636229|Placebo Comparator|Placebo|Participants receive a single IA injection of 4 mL of normal saline
32944623|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
33308710|NCT04635735|Experimental|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
32944624|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
32944625|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
32944626|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32944627|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
32944628|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
32944629|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
32944630|NCT05313503|Experimental|Ketogenic Diet|Ketogenic diet
32944631|NCT00795665|Experimental|Bevacizumab and Carmustine|
32944632|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
32944633|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
32944634|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
32944635|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
32944636|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
32944637|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
32944638|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
32944639|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
33093816|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
33093817|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
33093818|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
33093819|NCT00497913|Active Comparator|A|
33093820|NCT00497913|Placebo Comparator|B|
33093821|NCT03272360||Chronic Pelvic Pain|
33093822|NCT03272360||Elective Tubal Ligation|
33093823|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
33093824|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
33093825|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
33093826|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
33308711|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
33308712|NCT04631718||MRI based abdominal QSM|Participants with known or suspected iron overload with past serum ferritin >500 will be recruited in this study.
33308713|NCT04611334|Experimental|experimental group|HRV biofeedback
33308714|NCT04611334|No Intervention|control group|routine care
32944640|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
32944641|NCT03725033|Experimental|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
32944642|NCT03725033|Placebo Comparator|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
32944643|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
33093827|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
33093828|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
33093829|NCT00464321|Experimental|Cohort A|Dose Group
33093830|NCT00464321|Experimental|Cohort B|Dose Group
33093831|NCT00464321|Experimental|Cohort C|Dose Group
33093832|NCT00464321|Experimental|Cohort D|Dose Group
33093833|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
33093834|NCT03272984|Other|SC group|Patients will undergo the SC group.
33093835|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
33093836|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
33093837|NCT00498225|Experimental|1|Gemcitabine plus TS-1
33093838|NCT00498225|Experimental|2|TS-1
33093839|NCT00498225|Active Comparator|3|Gemcitabine
33093840|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
33093841|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
33093842|NCT01327612|Experimental|Conatumumab Monotherapy|Participants will continue to receive conatumumab every 2 weeks (Q2W) or every 3 weeks (Q3W) at the same dose and regimen as at the conclusion of the parent study.
33093843|NCT01327612|Experimental|Conatumumab + Ganitumab|Participants will receive conatumumab and ganitumab by intravenous infusion at the same dose and regimen as at the conclusion of the parent study.
33093844|NCT01327612|Experimental|Ganitumab Monotherapy|Participants will continue to receive ganitumab Q3W or every 4 weeks (Q4W) at the same dose and regimen as at the conclusion of the parent study.
33093845|NCT01327612|Experimental|Conatumumab + mFOLFOX6 ± Bevacizumab|Participants will continue to receive conatumumab by intravenous infusion in addition to modified FOLFOX6 chemotherapy with or without bevacizumab.
33093846|NCT01243281|Active Comparator|drug combination|
33093847|NCT04133545||DOAC|Direct oral anticoagulant
33093848|NCT04133545||OAC|Vitamin K anticoagulant
33093849|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33093850|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
33093851|NCT02893579|Experimental|Delayed Intervention|Wait list Control
33093852|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
33093853|NCT04402801||Standard of Care In-Person Cohort|
33093854|NCT04401592||disease and control|
33093855|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
33093856|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
33093857|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
33093858|NCT00466856|Experimental|Sir-Spheres|
33093859|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
33093860|NCT00464516|Experimental|estetrol|
33093861|NCT00464516|Placebo Comparator|placebo|
33308715|NCT04606589|No Intervention|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
33308716|NCT04606589|Experimental|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
33308717|NCT04600518||Low risk|good prognosis with surgery only and adjuvant chemotherapy patients
33308718|NCT04600518||Intermediate risk|moderate prognosis
33308719|NCT04600518||High risk|poor prognosis
33308720|NCT04595513|Experimental|Stage 1 Open Label|Phase I/II, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels are assessed at defined intervals on days 1, 7, and 14. After day 14, participants can elect to continue open-label treatment with TAVT-18 until 12 months of age. Final developmental outcomes are assessed at 24 months of age.
33308721|NCT04592237|Experimental|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33308722|NCT04592237|Experimental|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32944644|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
33308723|NCT04587531|Active Comparator|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
33308724|NCT04587531|Sham Comparator|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
33308725|NCT04576403|Active Comparator|Intervention group|Activated mittens
33308726|NCT04576403|Sham Comparator|Control group|Deactivated mittens
32944645|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
32944646|NCT05313113|Experimental|Experimental group|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
33308727|NCT04576195|Experimental|Real PENS|One single session of PENS
33308728|NCT04576195|Sham Comparator|Sham PENS|One single session of Sham-PENS
33308729|NCT04572880|Active Comparator|Trabeculectomy|
33308730|NCT04572880|Active Comparator|XEN®|
33308731|NCT04572880|Active Comparator|Preserflo®|
33308732|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum & Nathan (2001).~Exclusion criteria:~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.~Age:~- 18 - 65 years of age~Gender:~- Female and male subjects"
33308733|NCT04566783||Controls|"Inclusion criteria:~- Age and education matched healthy controls."
33308734|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
33308735|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
33308736|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
33308737|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
33308738|NCT04551430|Experimental|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
33308739|NCT04551430|Experimental|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses.
32944647|NCT05313113|No Intervention|Control Group|The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research.
32944648|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
32944649|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
32944650|NCT00746603|Experimental|A Intervention Arm|Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma
32944651|NCT05312957|Active Comparator|Group ESP|The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected and When the block needle touched the transverse process,Then, 20 ml of 0.25% bupivacaine was administered to this area, and an ESP block was applied
32944652|NCT05312957|No Intervention|Group Control|Group Control: Tramadol HCL was administered from vein with a patient-controlled analgesia device after extubation.
32944653|NCT00716807|Experimental|TMD 1|
32944654|NCT00716807|Placebo Comparator|TMD 2|
32944655|NCT00716807|Experimental|BMS 1|
32944656|NCT00716807|Placebo Comparator|BMS 2|
32944657|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
32944658|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
32944659|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
32944660|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
32944661|NCT04713683|Active Comparator|Amplatzer PFO Occluder|Patients randomized in this arm will be implanted with Amplatzer PFO Occluder.
32944662|NCT04713683|Active Comparator|Gore Cardioform Septal|Patients randomized in this arm will be implanted with Gore Cardioform Septal Occluder.
32944663|NCT05283863|Experimental|high-frequency stimulation|Patients will randomly be assigned to receive sub-threshold high-frequency spinal cord stimulation for 2 weeks.
32944664|NCT05283863|Sham Comparator|placebo stimulation|Patients will randomly be assigned to receive sham spinal cord stimulation for 2 weeks.
32944665|NCT05283863|Active Comparator|conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation for 2 weeks prior to both the high-frequency or sham stimulation.
32944666|NCT01760993|Experimental|SPD489|
32944667|NCT00669461|Experimental|Patients|
32944668|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
32944669|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
32944670|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
32944671|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
32944672|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
32944673|NCT00378365|Experimental|1|Arsenic trioxide
32944674|NCT05313425||Ectoine Eye|The right eye of the studied group will be given 2% Ectoine containig , 0.2% sodium hyaluronate eye drops(Ectohylo) hourly.
32944675|NCT05313425||Control eye|The left eye of the studied group will be give Carboxymethyl cellulose, 0.2% sodium hyaluronate eye drops(Polyfresh Extra) hourly.
32944676|NCT05600621|Experimental|Condition 1: Components 1, 2,3 and 4|"Participants will be assigned to receive all of the four intervention programs:~Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944677|NCT05600621|Experimental|Condition 2: Components 1, 2 and 3|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
32944678|NCT05600621|Experimental|Condition 3: Components 1, 2 and 4|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944679|NCT05600621|Experimental|Condition 4: Components 1 and 2|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)"
32944680|NCT05600621|Experimental|Condition 5: Components 1,3 and 4|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944681|NCT05600621|Experimental|Condition 6: Components 1 and 3|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
33308740|NCT04551430|Experimental|Crossover from Cohort A to Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Participants who cross-over from Cohort A into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day.
33308741|NCT04548752|Experimental|Arm A (olaparib, pembrolizumab)|Patients receive olaparib PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 19, patients receive olaparib PO BID on days 1-42 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
33308742|NCT04548752|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33308743|NCT04543110|Experimental|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
33308744|NCT04540497|Experimental|VIB0551|Inebilizumab administered as an IV infusion.
32944682|NCT05600621|Experimental|Condition 7: Components 1 and 4|"1.Financial Literacy Training (FLT) Workshops~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944683|NCT05600621|Experimental|Condition 8: Components 1|1.Financial Literacy Training (FLT) Workshops
32944684|NCT05600621|Experimental|Condition 9: Components 2,3 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
33308745|NCT04540497|Placebo Comparator|Placebo|Placebo administered as an IV infusion.
33308746|NCT04539938|Experimental|Single Arm|Tucatinib + trastuzumab deruxtecan
33308747|NCT04520659|Experimental|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
33308748|NCT04520659|Placebo Comparator|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
33308749|NCT04520659|Experimental|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
32944685|NCT05600621|Experimental|Condition 10: Components 2 and 3|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
32944686|NCT05600621|Experimental|Condition 11: Components 2 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944687|NCT05600621|Experimental|Condition 12: Components 2|2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)
32944688|NCT05600621|Experimental|Condition 13: Components 3 and 4|"3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
32944689|NCT05600621|Experimental|Condition 14: Components 3|3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)
32944690|NCT05600621|Experimental|Condition 15: Components 4|4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV.
32944691|NCT05600621|Experimental|Condition 16: No Components|Participants not assigned to any of the 4 components
32944692|NCT05600543|Experimental|Arm 1: Lumbar belt Lombastab® (Thuasne, Levallois Perret, France)|Low back pain patients wear Lumbar belt Lombastab® during 4 weeks according to the instructions given by the investigator of the study.
32944693|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
32944694|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
32944695|NCT01732211|Experimental|PD 0360324|
32944696|NCT01732211|Placebo Comparator|Placebo|
32944697|NCT05600309|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
32944698|NCT05600309|Active Comparator|Standard of Care (Regorafenib or TAS-102)|Participants will receive 160 mg regorafenib orally daily on Days 1-21 of each 28-day cycle. Participants will also receive 35 mg/m^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day treatment cycle.
32944699|NCT05600231|Experimental|Treatment Group: Brush Only|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
32944700|NCT05600231|Experimental|Treatment Group: Brush / Rinse (LISTERINE COOL MINT Antiseptic Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 milliliters (mL) of LISTERINE COOL MINT Antiseptic Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
33093862|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
33308750|NCT04520659|Placebo Comparator|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
33308751|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
33308752|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
33308753|NCT04507659|Experimental|Jaktinib 100mg|100 mg bid.po
32800793|NCT05703178|Active Comparator|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
32800794|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
32800795|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
32800796|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
32800797|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
32800798|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
32800799|NCT05701852||cases : patients with chronic pain|
32800800|NCT05701852||controls|
32800801|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
32800802|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
32800803|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
32800804|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
32800805|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
32800806|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
32800807|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
32800808|NCT04116723|Experimental|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
32800809|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
32800810|NCT03020134|Placebo Comparator|Placebo Group|Placebo
32800811|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
32800812|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
32800813|NCT03026062|Experimental|Arm I (sequential tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Upon progression, patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. This arm is closed to enrollment.
32800814|NCT03026062|Experimental|Arm II (combination tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
32800815|NCT05701774|Experimental|DCCR|75 - 525 mg DCCR
32800816|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
32800817|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
33308754|NCT04507659|Experimental|Jaktinib 75mg|75 mg bid.po
33308755|NCT04507659|Placebo Comparator|Placebo|Placebo bid.po
33308756|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (>28 weeks gestation)
32944701|NCT05600231|Experimental|Treatment Group: Brush / Rinse LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 mL of LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
32944702|NCT05600231|Experimental|Treatment Group: Brush / Floss|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute and floss with Reach Unflavored Waxed Dental Floss under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
32944703|NCT05600231|Experimental|Treatment Group: Brush / Floss / Rinse (LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute, floss with Reach Unflavored Waxed Dental Floss and rinse with LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds under virtual supervision once daily during the week. At home, participants will brush and rinse a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
32944704|NCT05600231|No Intervention|Healthy Reference Group|Healthy participants will enroll in this reference group and will not receive any study product nor will they receive a prophylaxis as part of their participation in this study. The healthy reference group will be used as a comparator group for microbiome.
32944705|NCT05600153|Placebo Comparator|primary breast approach|
33093863|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
33093864|NCT01243437|Experimental|ciprofloxacin|
33093865|NCT01243437|Active Comparator|doxycycline|
33093866|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
32944706|NCT05600153|Experimental|axillary approach|
32944707|NCT00652457|Experimental|Memantine|Memantine 10 mg BID for three months
32944708|NCT00652457|Placebo Comparator|Placebo|Placebo 10 mg BID for three months
33093867|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
32944709|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
32944710|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
33093868|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
33093869|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
33093870|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
33093871|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
33093872|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
33093873|NCT04328233|Experimental|Time-Restricted Eating|
33093874|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
33093875|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
33093876|NCT04396171||Probable bruxism(+)|
33093877|NCT04396171||Probable bruxism(-)|
33093878|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
33093879|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
33093880|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
33093881|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
33093882|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
33093883|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
32800818|NCT03584386|Experimental|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
32800819|NCT03584386|No Intervention|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
32800820|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
33308757|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
32800821|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
32800822|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
32800823|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
32800824|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
32800825|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
32800826|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
32800827|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
32800828|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
32800829|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
32800830|NCT05701696||Patients with fibromyalgia|Patients diagnosed with FM according to ACR 2016 criteria
32800831|NCT03153826|Other|Patients|
32800832|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
32800833|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~Lesson 2 presents different strategies to generate helpful cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors and graded exposure.~Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
32800834|NCT04405336|Active Comparator|giving tab block|giving patients tab block
32800835|NCT04405336|Active Comparator|giving PCA|Giving PCA to patients
32800836|NCT04405336|No Intervention|Patients who will not receive PCA or tab block|No tab block or PCA
32800837|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
32800838|NCT03583138||No buprenorphine|No buprenorphine
32800839|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
32800840|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
32800841|NCT03583060|No Intervention|Control|
32800842|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
32800843|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
32800844|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
33308758|NCT04490148|Active Comparator|remote PFT (rPFT) longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment.
33308759|NCT04490148|Experimental|remote PFT (rPFT) + Nurse Coaching longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment, and receive monthly coaching from an ALS nurse.
33308760|NCT04487717||Low risk|good prognosis
33308761|NCT04487717||Intermediate risk|moderate prognosis
33308762|NCT04487717||High risk|poor prognosis
33308763|NCT04487652|Placebo Comparator|Placebo spray|Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
33308764|NCT04487652|Experimental|CoQ10 spray|The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
33308765|NCT04486677|Other|Caring Cards Group|Group of Veteran card-makers.
32800845|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33308766|NCT04486677|Other|Caring Cards Recipients|Group of Veteran card-recipients.
33308767|NCT04486378|Experimental|RO7198457|Participants will receive a recommended dose of RO7198457.
33308768|NCT04486378|Other|Observational Group|Observational group will undergo watchful waiting, which is the standard of care in this setting.
33308769|NCT04486378|Experimental|Biomarker Cohort|15 patients
33308770|NCT04486378|Experimental|Exploratory Cohort|20 patients
33308771|NCT04485871|Experimental|Omega-3 fatty acids|3.6 g EPA:DHA / day (2:1)
33308772|NCT04464564|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
33308773|NCT04464564|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
33308774|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
33308775|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
33308776|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:~Infant born to a diabetic mother~Very large for gestational age (VLGA) infant with weight >97%"
33308777|NCT04456504|Experimental|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
33308778|NCT04454489|Experimental|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
33093884|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
33308779|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) <5.7% or fasting glucose <100 mg/dl.
33308780|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
33308781|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
32800846|NCT03582982|Experimental|Eccentric overload exercise|
32800847|NCT03153670|Experimental|fMRI-based programming|DBS patients will undergo fMRI scanning while on different stimulation settings. The results will be fed to the programming clinician (movement disorder neurologist) to aid the conventional programming process at the clinician's discretion.
33308782|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
33308783|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
33308784|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
33308785|NCT04447183|Experimental|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid [i.e. their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
33308786|NCT04447183|Experimental|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
33308787|NCT04444921|Active Comparator|Arm A (carboplatin, paclitaxel)|Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin IV on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33308788|NCT04444921|Experimental|Arm B (carboplatin, paclitaxel, nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 of cycle 1 and then on day 1 only of subsequent cycles, paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles for carboplatin and paclitaxel, and up to 2 years for nivolumab in the absence of disease progression or unacceptable toxicity.
33308789|NCT04432532||Neuroendocrine Tumor|
33308790|NCT04432532||Adrenal Tumor|
33308791|NCT04429334|Experimental|nangibotide|Continuous infusion of experimental agent for up to 120 hours
33308792|NCT04429334|Placebo Comparator|placebo|Continuous infusion of matched placebo for up to 120 hours
33308793|NCT04421820|Experimental|Part B - Dose Expansion - 1L Gastric Cancer (ARM I)|Arm closed to enrollment.
33093885|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
33093886|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
32800848|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
33093887|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
33308794|NCT04421820|Experimental|Part B - Dose Expansion - 2L Gastric Cancer (ARM II)|Open to enrollment.
33308795|NCT04421820|Experimental|Part B - Dose Expansion - 2L Pancreatic Cancer (ARM III)|Arm closed to enrollment.
33308796|NCT04421820|Experimental|Part B - Dose Expansion - 2L Colorectal Cancer (ARM IV)|Arm closed to enrollment.
33308797|NCT04421820|Experimental|Part B - Dose Expansion - 3L Colorectal Cancer (ARM VI)|Open to enrollment.
32800849|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
32800850|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
33093888|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
33308798|NCT04421820|Experimental|Part B - Dose Expansion - 2L Cholangiocarcinoma (ARM V)|Arm closed to enrollment.
33308799|NCT04421820|Experimental|Part A - Dose Escalation - Gastric Cancer|Arm closed to enrollment.
33308800|NCT04421820|Experimental|Part A - Dose Escalation - Pancreatic Cancer|Arm closed to enrollment.
33308801|NCT04421820|Experimental|Part A - Dose Escalation - Colorectal Cancer|Arm closed to enrollment.
33308802|NCT04421820|Experimental|Part A - Dose Escalation - Cholangiocarcinoma|Arm closed to enrollment.
33308803|NCT04408755|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
32800851|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
32800852|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
32800853|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
32800854|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
32800855|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
32830599|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
33093889|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF [mycophenolate mofetil~], prednisone)"
32830600|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
33093890|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
33093891|NCT04328428|Experimental|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
33093892|NCT04328428|Active Comparator|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
33093893|NCT04328428|Active Comparator|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
33093894|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
33093895|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
33308804|NCT04408755|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
33308805|NCT04408443|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
33308806|NCT04408443|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
33308807|NCT04405739|Experimental|EIDD-2801 twice daily (BID) for 5 days|EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
33308808|NCT04405739|Placebo Comparator|placebo (PBO) twice daily (BID) for 5 days|Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
33308809|NCT04404283|Experimental|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
33308810|NCT04404283|Active Comparator|Control Arm|Placebo + lenalidomide + rituximab
33308813|NCT04396457|Experimental|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.~500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.~*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
33308814|NCT04395521|Experimental|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
32746544|NCT04789629|Active Comparator|physiotherapy|traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training ) for one hour
33308815|NCT04395521|No Intervention|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
32944711|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
32944712|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
32944713|NCT00625703|Experimental|A|
32944714|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
32944715|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
32944716|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
32944717|NCT00616343|Active Comparator|Zonisamide|
32944718|NCT05599997|Experimental|Healthy|Age-, weight- and gender- matched control group of healthy volunteers received a single oral dose of 30 mg BAY1753011 tablet.
32944719|NCT05599997|Experimental|Mild renal impairment|Subjects with mild renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
32944720|NCT05599997|Experimental|Moderate renal impairment|Subjects with moderate renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
32944721|NCT05599997|Experimental|Severe renal impairment|Subjects with severe renal impairment received a single oral dose of 15 mg BAY1753011 tablet.
32944722|NCT05599919|Active Comparator|Patients with COVID-19 (confirmed by RT-PCR), not requiring hospitalization|Nitric oxide releasing solution delivered up to 3 times daily
32944723|NCT05599919|Placebo Comparator|COVID-19 symptoms|saline delivered up to 3 times daily morning, mid-day, and evening. Maximum volume delivered: 0.56 mL Saline @ 0.9%
32944724|NCT05599841|Active Comparator|Povidone Iodine Solution|The group whom PI solution will be used at surgery
32944725|NCT05599841|Placebo Comparator|Saline Solution|The group whom only saline solution will be used at surgery
32944726|NCT05599685||Participants with metastatic NSCLC initiated on 1L treatment with NIVO/IPI/PBC|
32944727|NCT01681745|Experimental|Cryo-Touch Treatment|Initial treatment with Cryo-Touch III and three optional re-treatments (up to 4 treatments) performed 68 days to 1 day prior to abdominoplasty.
32944728|NCT05599607|Experimental|Probiotic group|Probiotic in capsule format administered orally. This probiotic product contains a mixture of strains of lactobacillus and bifidobacteria, called BTHS21, at concentrations equal to or greater than 1x109 cfu/dose.
32944729|NCT05599607|Placebo Comparator|Placebo group|Maltodextrin, masked in an identical and indistinguishable format to that of the probiotic
32944730|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
32944731|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
32944732|NCT05599529||Pre-COVID|
32944733|NCT05599529||Peri-COVID|
32944734|NCT05270993|Active Comparator|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
32944735|NCT05270993|Experimental|I-CREST group|A 6-week home-based remote supervision cardiac rehabilitation programme with an I-CREST application and smartwatch. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
32944736|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
32944737|NCT00608465|Active Comparator|Treatment B|Ramipril
32944738|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
32944739|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
32944740|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
32944741|NCT05599373|Active Comparator|Active rTMS over bilateral dorsolateral prefrontal cortex|Active rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
32944742|NCT05599373|Active Comparator|Active rTMS over left dorsolateral prefrontal cortex|Active rTMS over left dorsolateral prefrontal cortex and sham rTMS over right dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
33308816|NCT04380740|Placebo Comparator|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
33308817|NCT04380740|Experimental|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
33308818|NCT04377204|Active Comparator|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
32944743|NCT05599373|Sham Comparator|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
33308819|NCT04377204|Active Comparator|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
33308820|NCT04376333|Active Comparator|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
32944744|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
32944745|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
32944746|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
33308821|NCT04376333|Experimental|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
32944747|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
32944748|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
32944749|NCT04706585||Youth|Young people in Indonesia between the age of 15-24 who are currently attending high school or university-level education to fill in our online survey.
32944750|NCT05597345|Experimental|Experimental: Treatment|Selinexor 40mg weekly for up to 12 cycles. Each cycle will be 28 days in length.
32944751|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
32944752|NCT00585611|Placebo Comparator|2|
32944753|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
32944754|NCT00379535|Placebo Comparator|2|Daily dose of placebo
32944755|NCT04706195|Experimental|Person-centred care|PCC in the form of a combined eHealth and structured telephone support combined with an eHealth support on top of usual care
32944756|NCT04706195|No Intervention|Usual care|Regular evidence-based treatment and care as outlined in treatment guidelines and followed as usual at their local primary care center
32944757|NCT05596253||Patients with cirrhosis who underwent TIPS|Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.
32944758|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
32944759|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
32944760|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
32944761|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
32944762|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
32944763|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
32944764|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
32944765|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
32944766|NCT01648907||SPONDYLARTHRITIS COHORT|
32944767|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
32944768|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
32944769|NCT04331951|Experimental|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.~All tissues will be sent to immunohistochemistry as a gold standard.~Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
32944770|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
32944771|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
32944772|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
32944773|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
32944774|NCT05529953|Experimental|Oleanolic acid-enriched functional olive oil|"functional olive oil elaborated enriching the control olive oil with Oleanolic acid up to 600 mg OA/kg oil.~Single oral intake of 55 mL of functional olive oil (dose equivalent to 30 mg OA)."
33308822|NCT04371900|Experimental|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
33308823|NCT04371900|No Intervention|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
33308824|NCT04367233|Active Comparator|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
33308825|NCT04367233|Experimental|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with ropivacaine 0,25% 0,2 ml/kg.
33308826|NCT04367233|Experimental|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg.
33308827|NCT04365868|Experimental|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
33308828|NCT04365868|Experimental|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
33308829|NCT04365868|Placebo Comparator|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
33308830|NCT04362475|Active Comparator|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
33308831|NCT04362475|Active Comparator|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
33308832|NCT04362475|Other|Wait-List Control|The two communities will get ESPI, upon completion of the study.
33308833|NCT04362475|Active Comparator|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
33308834|NCT04360434|Experimental|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
33308835|NCT04360434|Placebo Comparator|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.~In the OLE phase, all subjects will be administered multiple doses of NI006."
33308836|NCT04350775|Experimental|RE-IADL group|Reablement
33308837|NCT04350775|Placebo Comparator|Control group|General community rehabilitation
33308838|NCT04349267|Experimental|BMS-986315|
33308839|NCT04349267|Experimental|BMS-986315 + nivolumab|
33308840|NCT04349267|Experimental|BMS-986315 + cetuximab|
33308841|NCT04346589|Experimental|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
33308842|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
33308843|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
33308844|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
33308845|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
33308846|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
33308847|NCT04331067|Active Comparator|Arm A: Neoadjuvant chemo + nivolumab|-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
33308848|NCT04331067|Experimental|Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab|"As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given.~Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.~Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks."
33308849|NCT04329962|Experimental|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
33308850|NCT04329962|Experimental|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
33308851|NCT04329221|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
33308852|NCT04329221|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
33308853|NCT04324840|Experimental|Part A|
33308854|NCT04324840|Experimental|Part B - CC-90010 + Temozolomide (TMZ) + Radiotherapy (RT)|
33308855|NCT04324840|Other|Part B - Standard TMZ + RT|Control
33308856|NCT04316013|Active Comparator|A|Sevoflurane + intravenous lidocaine
33308857|NCT04316013|Active Comparator|B|Sevoflurane
33308858|NCT04316013|Active Comparator|C|Propofol TIVA + intravenous lidocaine
32746545|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
33308859|NCT04316013|Active Comparator|D|Propofol TIVA
33308860|NCT04313257|Active Comparator|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
33308861|NCT04313257|Experimental|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
33308862|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
33308863|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
33308864|NCT04312594|Placebo Comparator|Placebo and Basic treatment|Mimic tablets of Jaktinib Dihydrochloride Monohydrate 50mg BID and 75mg BIDand basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
33308865|NCT04295798|Experimental|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
33308866|NCT04295798|Sham Comparator|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
33308867|NCT04295798|Experimental|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
33308868|NCT04295798|Sham Comparator|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
33308869|NCT04281849|No Intervention|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
33308870|NCT04281849|Experimental|BAMS-HF Program|
32944775|NCT05529953|Active Comparator|Control olive oil|"commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.~Single oral intake of 55 mL of commercial olive oil"
32944776|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
32944777|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
32944778|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
32944779|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
32944780|NCT05231057|Experimental|experimental group|Patients in the study group received Pilates exercises plus conventional physical therapy program
32944781|NCT05231057|Experimental|control group|Patients in the control group received conventional physical therapy
32944782|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
32944783|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
32944784|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
32944785|NCT05480735|Experimental|Prehabilitation group|"The intervention group will participate in a prehabilitation program of approximately 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. A dietician will provide nutritional support and give dietary advice to increase protein intake, including a supplement containing 30 g of whey-protein daily and after supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychologist. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke.~Patients will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation."
32944786|NCT05480735|No Intervention|Control group|Patients randomized to the control group will receive care as usual according to local ERAS guideline implementation. In addition, they will receive a leaflet with the recent guidelines regarding physical activity, dietary advice, and smoking cessation. Their actual physical activity level will be obtained via questionnaire.
32944787|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
32944788|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
32944789|NCT00500045|Experimental|Treatment|Oral niacin
32944790|NCT05208359|Experimental|STRONG immediate group|Small mental health support group delivered immediately
32944791|NCT05208359|Other|STRONG delayed group|Small mental health support group delivered after a delay of approximately 3 months
32944792|NCT05404685|Experimental|Transperitoneal RAPN with AirSeal system set to 7mmH.|Patient with Low Pressure Robotic Assisted Partial Nephrectomy at 7mm Hg
32944793|NCT05404685|Active Comparator|transperitoneal RAPN with AirSeal system set to standard insufflation pressure (12mmHg)|Control arm : Patient with standard insufflation pressure of 12 mm Hg
33093896|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
33093897|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.~Local Anesthetic Injection above the serratus anterior"
33093898|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
33093899|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
33093900|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
33093901|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
32746546|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
32746547|NCT05472207||Patients with cardiovascular diseases|Recording clinical data - especially risk parameters - from patients suffering from cardiovascular diseases
33093902|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
33093903|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
33093904|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
33093905|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
33093906|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
33093907|NCT00498537|Other|1|
33093908|NCT00498537|Other|2|
33093909|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
33093910|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
33093911|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
33308871|NCT04278794|Experimental|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
33308872|NCT04278794|No Intervention|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
33308873|NCT04270474|Experimental|Active Intervention (ACT)|Pharmacist-based Deprescribing
33308874|NCT04270474|Sham Comparator|Usual Care (UC)|Usual Care
33093912|NCT00491517|Experimental|Sirolimus|
33093913|NCT00491517|Active Comparator|conventional therapy|
33308875|NCT04269902|Active Comparator|Arm I (delayed V-O)|Treatment begins once 2018 IWCLL indications are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration throughout the trial.
33308876|NCT04269902|Experimental|Arm II (early V-O)|Treatment begins as soon as eligibility criteria are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration throughout the trial.
32746548|NCT03120221||First trimester pregnant women|
32830601|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
33093914|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
33093915|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
33093916|NCT00498576||1|kidney transplant with hypertension
33093917|NCT00498576||2|hypertensive patients with native kidneys
33093918|NCT00498576||3|healthy controls
33093919|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
33093920|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
33093921|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
33093922|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
33093923|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
33093924|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
33093925|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
33093926|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
33093927|NCT00491634|Experimental|1|treosulfan
33093928|NCT04328155|Experimental|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
33093929|NCT04328155|Experimental|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
33093930|NCT04328155|Experimental|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
33093931|NCT04328155|Active Comparator|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
33093932|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
33308877|NCT04266431|Experimental|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
33308878|NCT04266431|No Intervention|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
33308879|NCT04264897|Experimental|Metformin|"The investigators use a ramp up dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
33308880|NCT04264897|Placebo Comparator|Placebo|"Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate).~The same dosing schedule will be followed as for metformin. The investigators use a ramp up dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
33093933|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
33308881|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
33308882|NCT04262713|Other|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight>~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
33308883|NCT04259281|Experimental|GTX-102 Cohort 4|3.3 mg for 3-4 monthly doses followed by a quarterly maintenance regimen (in participants 4 to < 8 years of age)
33308884|NCT04259281|Experimental|GTX-102 Cohort 5|5 mg for 3-4 monthly doses followed by a quarterly maintenance regimen (in participants ≥ 8 to 17 years of age)
33308885|NCT04259281|Experimental|GTX-102 Cohort 6|7.5 mg for 3-4 monthly doses followed by a quarterly maintenance regimen (in participants 4 to < 8 years of age)
33308886|NCT04259281|Experimental|GTX-102 Cohort 7|10 mg for 3-4 monthly doses followed by a quarterly maintenance regimen (in participants ≥ 8 to 17 years of age)
33308887|NCT04259281|Experimental|GTX-102 Cohort A|Sponsor selected dose for 3-4 monthly doses followed by a maintenance regimen (in participants 4 to < 8 years of age)
33308888|NCT04259281|Experimental|GTX-102 Cohort B|Sponsor selected dose for 3-4 monthly doses followed by a maintenance regimen (in participants ≥ 8 to 17 years of age)
33308889|NCT04259281|Experimental|GTX-102 US Cohort|2 mg for 4 monthly doses followed by a quarterly maintenance regimen
33093934|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
33093935|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
33093936|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
33093937|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
33093938|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
33093939|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
33093940|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
33093941|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
33093942|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
33093943|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
33093944|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
33093945|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
33093946|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
33093947|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
33093948|NCT04328389|Placebo Comparator|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
33093949|NCT04328389|Experimental|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
33093950|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
33093951|NCT00467207|Experimental|Resistance training|8 weeks resistance training
33308890|NCT04254107|Experimental|SEA-TGT Monotherapy (Parts A and B)|SEA-TGT
33308891|NCT04254107|Experimental|SEA-TGT + sasanlimab Combination Therapy (Part C)|SEA-TGT + sasanlimab
33308892|NCT04254107|Experimental|SEA-TGT + brentuximab vedotin Combination Therapy (Part D)|SEA-TGT + brentuximab vedotin
33308893|NCT04241315|Experimental|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
33308894|NCT04241315|Other|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
33308895|NCT04225026|Experimental|GC4419 (avasopasem manganese)|
33308900|NCT04203823|Experimental|Algorithm Testing|"The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm~The study population will be enrolled as 2 separate cohorts to test each algorithms individually"
33308901|NCT04199637|Experimental|Experimental group|Experimental group is provided therapeutic video games
33308902|NCT04199637|No Intervention|Control group|Control group is provided regular care
33308905|NCT04177108|Experimental|Cohort 1 Arm A|PD-L1 Non-Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1:1 ratio.
33308906|NCT04177108|Experimental|Cohort 1 Arm B|PD-L1 Non-Positive Participants receiving Paclitaxel, Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
33093952|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
33093953|NCT00592111|Experimental|1|
33093954|NCT00592111|Experimental|2|
33093955|NCT00592111|Experimental|3|
33093956|NCT00592150|Experimental|1|Fenoldopam infusion
33093957|NCT00592150|Placebo Comparator|2|Placebo infusion
33093958|NCT00592189|Experimental|1|Amnion tissue and blood collection
33093959|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
33093960|NCT00592228|Other|2|Routine drug-eluting stent implantation
33093961|NCT00592306|Active Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
33093962|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
33093963|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
33093964|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
33093965|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
33093966|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
32800856|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
32800857|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
32800858|NCT03582358||Verrine|Patients served verrines
32800859|NCT03582358||CNO|Patients served wrapped supplements
32800860|NCT05701540|Experimental|Tegoprazan 50mg|Tegoprazan 50mg, once daily, oral administration for two weeks
33308907|NCT04177108|Active Comparator|Cohort 1 Arm C|PD-L1 Non-Positive Participants receiving Paclitaxel, Placebo for Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
33308908|NCT04177108|Experimental|Cohort 2 Arm A|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1 ratio.
33308909|NCT04177108|Active Comparator|Cohort 2 Arm B|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Placebo for Ipatasertib. Participants will be randomised in a 1:1 ratio.
33308910|NCT04175769|Experimental|Experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
33308911|NCT04175769|Placebo Comparator|Non-experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
32800861|NCT05701540|Active Comparator|Esomeprazole 40mg or 20mg|"In case of ERD patients: Esomeprazole 40mg, qd, oral administration for two weeks~In case of NERD patients: Esomeprazole 20mg, qd, oral administration for two weeks"
32800862|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
32800863|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
32800864|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
32800865|NCT01818752|Experimental|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
32800866|NCT01818752|Active Comparator|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
32800867|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~Amor powder, each eppendorf contains 200mg Calcium~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
32800868|NCT03159754|Experimental|Early Appendectomy|
32800869|NCT03159754|Experimental|Interval Appendectomy|
32800870|NCT03159754|Experimental|No Appendectomy|
32800871|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
32800872|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
32800873|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
32800874|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
32800875|NCT05703100|Active Comparator|Control|Maximal test on a cycle ergometer
33308912|NCT04173026|Active Comparator|Provider intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
33093967|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
33093968|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
33093969|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
33093970|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
33093971|NCT04328272|Experimental|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
32800876|NCT05703100|Experimental|Hyperthermia|Maximal test on a cycle ergometer at 35º-38º C room temperature
33093972|NCT04328272|Active Comparator|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
33308913|NCT04173026|Active Comparator|Provider and Patient level intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
33308914|NCT04157608|Active Comparator|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
33308915|NCT04157608|Experimental|e-MIP|Experimental ankle-foot prosthesis
33308916|NCT04145934|Experimental|training|The subjects receive the ADSTEP intervention
33308917|NCT04145934|No Intervention|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
33308918|NCT04145115|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the study.
33308919|NCT04140513|Experimental|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
33308920|NCT04139538|Experimental|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
33308921|NCT04139538|Active Comparator|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
33308922|NCT04139343||SMA cohort|Individuals who have a diagnosis of SMA who are NOT receiving Spinraza (nusinersen).
33308923|NCT04139343||SMA Spinraza cohort|Individuals who have a diagnosis of SMA who are receiving Spinraza (nusinersen).
33308924|NCT04139343||Control cohort|Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
33308925|NCT04126161|Active Comparator|CT|Patients have standard of care CT prior to primary hip replacement
33308926|NCT04126161|Experimental|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
33308927|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
32800877|NCT05703100|Experimental|Glycogen depletion|Maximal test on a cycle ergometer after a glycogen depletion protocol
33308928|NCT04119063|Experimental|Exoskeleton Assistance|Walking with exoskeleton assistance to make walking easier.
33308929|NCT04119063|Experimental|Exoskeleton Resistance|Walking with exoskeleton resistance for functional gait training.
33308930|NCT04117347|Experimental|Light therapy A via the Re-Timer®|-15 minutes/day
33308931|NCT04117347|Experimental|Light therapy B via the Re-Timer®|-30 minutes/day
33308932|NCT04117347|Experimental|Light therapy C via the Re-Timer®|-60 minutes/day
33308933|NCT04111627|Experimental|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
33308934|NCT04111458|Experimental|BI 1701963 monotherapy|
33308935|NCT04111458|Experimental|BI 1701963 + Trametinib|
33308936|NCT04109066|Experimental|Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET|Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
33308937|NCT04109066|Placebo Comparator|Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET|Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then adjuvant (post-surgery) endocrine therapy of investigator's choice
33308938|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
33308939|NCT04104945|Experimental|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
32746549|NCT05472129||Cases|"Cases were defined, with respect to bowel, bladder or prolapse symptoms using the question: How much do your symptoms bother you? and the following choice of answers: Not applicable - I do not have symptoms, not at all, a little, quite a lot and very much."
32944794|NCT05204225|Experimental|Tablet Application|An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres. A follow-up of the use of the application will be carried out. The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
32944795|NCT05204225|Active Comparator|Conventional Treatment|Participants included in this group will receive the conventional treatment protocol usually prescribed on each recruitment centres. Participants will be asked to perform an exercise program on paper during 4 weeks at home, along with face-to-face sessions.
32944796|NCT05383547|Experimental|Glomerular disease patients|
32944797|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
32944798|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
32944799|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
32944800|NCT05299151|Experimental|Vestibular Rehabilitation Group|A vestibular rehabilitation exercise program, which is determined based on the literature and personalized according to the functional disabilities of each patient, will be applied to the participants in the experimental group. An exercise session will be performed for a total of 40 minutes, with each exercise for 1-2 minutes. Exercise training will be applied 2 days a week for 8 weeks and they will be asked to do it at home once a week.
32944801|NCT05299151|Active Comparator|Standard Neurorehabilitation Group|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises will be applied. Each training session will be 40 minutes in total. Exercise training will be done in the clinical setting 2 days a week for 8 weeks, and they will be asked to do it at home once a week.
32944802|NCT00379847|Experimental|1|Lower dose
32944803|NCT00379847|Experimental|2|Higher dose
32944804|NCT05252741|Active Comparator|Group 1: patients with psoriasis|
32944805|NCT05252741|Placebo Comparator|Group 2: age-, sex-, BMI-, and weight-matched control subjects.|
32944806|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
33093973|NCT04328272|Placebo Comparator|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
33093974|NCT04328194|Experimental|Study Group|80 patients with breast cancer
33093975|NCT04328194|Placebo Comparator|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
33093976|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
33093977|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
33308942|NCT04090710|Active Comparator|Standard of Care I/N alone|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
33308943|NCT04090710|Experimental|Standard of Care I/N plus primary disease SBRT|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
33308944|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
33308945|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
33308946|NCT04070703|Experimental|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
33308947|NCT04070703|Active Comparator|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
33308948|NCT04070703|Sham Comparator|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
33308949|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A*(1-S)*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel [GBq]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms [kg]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
33308950|NCT04069312|Active Comparator|Roflumilast arm|Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
33308951|NCT04069312|Active Comparator|Azithromycin arm|Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
33308952|NCT04064463|Active Comparator|Control Group|Standard care
33308953|NCT04064463|Experimental|Experimental Group|Standard care plus contingency management
33308954|NCT04042480|Experimental|SGN-CD228A|SGN-CD228A monotherapy
32800878|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
32800879|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
32800880|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
32800881|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
32800882|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
33093978|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
33093979|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
32800883|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
32800884|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
32800885|NCT05701462|Experimental|pleural disease|
32800886|NCT04405492|Experimental|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
32800887|NCT04405492|Experimental|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
32800888|NCT04405492|Experimental|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
32800889|NCT05701384|Experimental|Lazertinib 160mg arm|
32800890|NCT04142554|Experimental|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
32800891|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
32800892|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
32830602|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
33308955|NCT04032080|Experimental|LY3023414 + prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
33308956|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
33308957|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
33308958|NCT04023825|Experimental|experimental group|Patients will receive loco regional anesthesia
33308959|NCT04023825|No Intervention|control group|Patients will not receive loco regional anesthesia
33308960|NCT04019665|Other|SAGE and MMSE score|
33308961|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
32944807|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
33308964|NCT03983954|Experimental|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308965|NCT03983954|Experimental|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308966|NCT03983954|Experimental|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
32944808|NCT00299195|Experimental|1|sulindac
32944809|NCT00299195|Placebo Comparator|2|placebo
32944810|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
32944811|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
32944812|NCT05163275||Patients|
32944813|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
32944814|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
32944815|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
32944816|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
32944817|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
33308967|NCT03983954|Experimental|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308968|NCT03983954|Experimental|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308969|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308970|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308971|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at 15mcg/kg and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308972|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP, at the previous dose level, and durvalumab|NAP, at the previous dose level (10mcg/kg), and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308973|NCT03983954|Experimental|MTD expansion, abbreviated regimen of obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD (10 mcg/kg/day) and durvalumab (1120 mg) will be given for 6 cycles after a single dose of pre-treatment of obinutuzumab (1000 mg/day) on D-7. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
33308974|NCT03982277|Experimental|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
33308975|NCT03982277|No Intervention|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
33308976|NCT03982277|Experimental|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
33308977|NCT03982277|No Intervention|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
33308978|NCT03979443|No Intervention|Inpatient|patients staying in the hospital for 1-3 nights after surgery
33308979|NCT03979443|Active Comparator|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
33308980|NCT03955978|Experimental|TSR-042 and Brachytherapy|"Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first planned brachytherapy fraction. The second dose is given 21 (+3) days later, corresponding to the time of brachytherapy fraction #1. The third dose is given 21 (+3) days after dose 2, corresponding to the time of brachytherapy fraction #4. The fourth dose is given 21 (+3) days after dose corresponding to 1 weeks after brachytherapy fraction #6.~Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
33308981|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
33308982|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
33308983|NCT03939897|Experimental|Phase I Part A (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33308984|NCT03939897|Experimental|Phase I Part B (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33308985|NCT03939897|Experimental|Phase II, Arm I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride as in phase I. Patients also receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 1
33093980|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
33093981|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
33093982|NCT00491790|Sham Comparator|1|Sterile Water
33093983|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
32800893|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
32800894|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
32800895|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
32800896|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
32800897|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
32800898|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
32800899|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
32800900|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
32800901|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
32800902|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
32800903|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
32800904|NCT03158974|Experimental|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
32800905|NCT04142476|Experimental|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
32800906|NCT04142008|Experimental|Walk with Me app|
32800907|NCT05703022|Experimental|Early exercise training|Supervised aerobic interval training (uphill treadmill walking or cycling on an exercise bike 4x4 min at 65-85% of peak heart rate) 3 times weekly.
32800908|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
32800909|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
32800910|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
32800911|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
32800912|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
32800913|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
32800914|NCT03265366|Experimental|ABPA|15 patients with ABPA
32800915|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
32800916|NCT03158506|Experimental|[C14]-labelled HMS5552|
32800917|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
32800918|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
32800919|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
33308986|NCT03939897|Active Comparator|Phase II, Arm II (FA) (abemaciclib, fulvestrant)|Patients receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33308987|NCT03932682|Experimental|Seqirus QIVc|Cell-derived Quadrivalent Influenza Vaccine
32800922|NCT04765228|Experimental|Pegylated liposomal doxorubicin + Anlotinib|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
32800923|NCT04141540|Other|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
32800924|NCT04141540|Other|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
32800925|NCT04141462|Experimental|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
32800926|NCT04141384|Other|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
32746550|NCT05472129||Control|"Controls were identified as women answering Not applicable - I do not have symptoms or not at all, otherwise patients were defined as cases."
33093984|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
33093985|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
32746551|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~Iron study at time of diagnosis and 3 months after treatment .~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
32800927|NCT04141384|No Intervention|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
32800928|NCT04140994|Active Comparator|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
32800929|NCT04140994|Sham Comparator|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
32800930|NCT05696626|Experimental|Treatment|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
32800931|NCT05696626|Active Comparator|Reference Therapy|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
32800932|NCT03914482|Other|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
32800933|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
32800934|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
32800935|NCT05701228||day 0 of transplantation|This cohort will include 450 patients at the time of transplantation. The following number of participants will be enrolled in the cohort according to strata defined by organ-transplanted type and baseline immune status.
32800936|NCT05701228||day 0 of infection|This cohort will include 150 patients at the time of the infection: Approximatively 75 patients will be drawn from the cohort of solid-organ transplant recipients included at day 0 of transplantation. Additional 75 patients developing a CMV infection will be also included.
32800937|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
32800938|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
32800939|NCT05694052|Experimental|Multifaceted Intervention|"Lighting: a multi-channel LED Spectrum will be implemented. The spectral output covers the wavelength range from 420 nm to 730 nm. All active channels are mixed, providing a smooth (uniform in color) light with a Lambertian pattern profile.~Noise: the auditory masking system will provide a continuous background digitally generated broadband pink noise. The sound system will be placed near the head of the bed. This will be started (at 62 DB sound level) each night for 8 hours.~Nocturnal patient care activities: night-time patient care activities will be re-organized to minimize interruptions. The medication administration schedule will be organized, and the vital signs monitoring will be done continuously by medical devices without requiring to disturb the patient. Hygiene, comfort, and elective activities will be scheduled for the daytime. Emergency interventions will not be limited."
32830603|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
32830604|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
32830605|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
32830606|NCT03291444|Experimental|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
32830607|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
32830608|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
32830609|NCT03291366|Active Comparator|conventional|conventional therapy
33093986|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
33093987|NCT03272009|Experimental|Treatment A|oral EYP001a
33093988|NCT03272009|Experimental|Treatment B|oral EYP001a
33093989|NCT03272009|Experimental|Treatment C|oral EYP001a
33308988|NCT03932682|Active Comparator|Comparator|Non-influenza Comparator (NesiVac-C)
33308989|NCT03927703|Experimental|SB206 12%|SB206 12% topically once daily
33308990|NCT03927703|Placebo Comparator|Placebo Comparator|Placebo topically once daily
33308991|NCT03918499|Experimental|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
33308992|NCT03916276|Active Comparator|Cognitive Therapy (CT) Condition|Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain.
33308993|NCT03916276|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
33308994|NCT03916276|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
33308995|NCT03914443|Experimental|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
33308996|NCT03914443|Experimental|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
33308997|NCT03914443|Experimental|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
33308998|NCT03914443|Experimental|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
33308999|NCT03904602|Experimental|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
33309000|NCT03896945|Placebo Comparator|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
33309001|NCT03896945|Experimental|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
33309002|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
33093990|NCT03272009|Experimental|Treatment D|oral EYP001a
33093991|NCT03272009|Placebo Comparator|Treatment E|oral placebo
33309003|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
33309004|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
33318558|NCT02856412|Active Comparator|Illness Management and Recovery|Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
33318559|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
33093992|NCT03272009|Active Comparator|Treatment F|oral Entecavir
33093993|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
33093994|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
33093995|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
33309005|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
33093996|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
33309006|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
33309007|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
33309008|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food;~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food.~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will have a minimum of 12 months follow-up until at least December 2022.~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
33309009|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
33309010|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
33309011|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
33309012|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
33309013|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
33309014|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
33309015|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
33309016|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
33309017|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
33309018|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
33309019|NCT03846193|Experimental|GT005 Dose 1|A single dose of GT005 will be administered via subretinal injection
33309020|NCT03846193|Experimental|GT005 Dose 2|A single dose of GT005 will be administered via subretinal injection
33309021|NCT03846193|Experimental|GT005 Dose 3|A single dose of GT005 will be administered via subretinal injection
33309022|NCT03846193|Experimental|GT005 Dose 1, 2 or 3|A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
33309023|NCT03846193|Experimental|GT005 Dose 2 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
33309024|NCT03846193|Experimental|GT005 Dose 3 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
33309025|NCT03846193|Experimental|GT005 Dose 1, 2 or 3 with Orbit Subretinal Delivery Sysem|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
33309026|NCT03838549|Experimental|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
32944818|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
32944819|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
32944820|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
32944821|NCT05194007|Experimental|Experimental -Frondanol|Eligible participants will receive Frondanol capsule orally (1000 mg capsule twice daily) for 6 months
32944822|NCT05194007|Placebo Comparator|Placebo|Eligible participants will receive placebo capsule (twice daily) for 6 months
33309027|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
33309028|NCT03819829|Other|Blood sample|Blood sample
33309029|NCT03815890|Experimental|1A; LumB|Nivolumab
33309030|NCT03815890|Experimental|1B; TNBC|Nivolumab
32944823|NCT05153057||Birdshot chorioretinopathy|Patients with a diagnosis of birdshot chorioretinopathy, with confirmed HLA-A29 positivity.
32944824|NCT05099705|Experimental|Intervention Group (Access to an FSN/TSS)|40 participants will be randomly assigned to the intervention group (i.e., to receive an FSN and have access to the TSS). The FSN may meet with the participant at least twice and provide navigation support.
32944825|NCT05099705|No Intervention|Control Group (Access to Information, training and referral)|15 participants will be randomly assigned to the non-personalized comparison group (i.e., information, training, and referral).
32944826|NCT05091203|Sham Comparator|control|Control group in which vitamin D was not administrated.
32944827|NCT05091203|Active Comparator|Study group|Study group in which Vitamin D was administered
32944828|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
32944829|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
32944830|NCT00240227|Other|Placebo|Placebo no active medication
32944831|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
32944832|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
33309031|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
33309032|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
33309033|NCT03815890|Experimental|3B; TNBC, High TIL|Nivolumab and ipilimumab
33309034|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
33309035|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
33309036|NCT03802695|Experimental|Arm A|Recipients with HLA-identical or 1-allele mismatched (7/8 alleles) related or unrelated donor; with single-agent GVHD prophylaxis given
33309037|NCT03802695|Experimental|Arm B|Recipients with haploidentical-related donors; with single-agent GVHD prophylaxis given
33309038|NCT03802695|Experimental|Arm C|Recipients with an HLA-identical related or unrelated donor; no GVHD prophylaxis given
32944833|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
32944834|NCT00133679|Experimental|1|Sildenafil x 45 days
32944835|NCT00133679|Placebo Comparator|2|Placebo x 45 d
32944836|NCT04994405|No Intervention|Standard Pressure|The extremity tourniquet used during hand surgery for these participants will be the standard pressure of 250 mmHg.
33309039|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
33309040|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
33309041|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
33309042|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
33318560|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
33309043|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
33309044|NCT03794583|Experimental|Inhaled Treprostinil Solution|Inhaled treprostinil solution (0.6 milligrams per milliliter [mg/mL], 6 mcg/breath) QID during waking hours.
33309048|NCT03786952|Experimental|Stress, immediate, males|Stress immediately before learning in males
33309049|NCT03786952|Experimental|Stress, delayed, males|Stress 30 minutes before learning in males
33309050|NCT03786952|Sham Comparator|Sham control, immediate, males|Sham control immediately before learning in males
33309051|NCT03786952|Sham Comparator|Sham control, delayed, males|Sham control 30 minutes before learning in males
33309052|NCT03786952|Experimental|Stress, immediate, females|Stress immediately before learning in females
33309053|NCT03786952|Experimental|Stress, delayed, females|Stress 30 minutes before learning in females
33309054|NCT03786952|Sham Comparator|Sham control, immediate, females|Sham control immediately before learning in females
33309055|NCT03786952|Sham Comparator|Sham control, delayed, females|Sham control 30 minutes before learning in females
33309056|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
33309057|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
33309058|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
33309059|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
33309060|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
33309061|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
33309062|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
33309063|NCT03730324|Active Comparator|Standard care|Study subject will undergo sampling of plasma and urine biomarkers.
33309064|NCT03730324|Experimental|Magnetic Resonance Imaging.|Prior to biopsies a magnetic resonance imaging scan will be performed.
33309065|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
33309066|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
33309067|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
33309068|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
33318561|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
33309069|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
33309070|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
33309071|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
33309072|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
33309073|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
33309074|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
33309075|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.~Intravenous macronutrient intakes:~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
33309076|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
33309077|NCT03689543|Experimental|Arm 1|LY500307 at 25mg per day
33309078|NCT03689543|Active Comparator|Arm 2|LY500307 at 75mg per day
33309079|NCT03689543|Placebo Comparator|Arm 3|Matched placebo
33309080|NCT03682536|Experimental|Luspatercept|
33309081|NCT03682536|Active Comparator|Epoetin alfa|
33309082|NCT03681028|Other|Individualized therapy|Study treatment for a given patient will consist of a regimen chosen from agents implicated in critical molecular signaling pathways and/or from signature-based predictions of drug efficacy. All agents are listed in the current pharmacopoeia for human use, but will differ amongst individual subjects. The study treatment will consist of up to 4 FDA approved drugs that have known dosing. This study is not only looking at 4 drugs. It is selecting up to 4 drugs per patient but the drugs chosen can be any FDA-approved drug. Therefore, it is not possible to pre-specify the medications.
33309083|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
33309084|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
33309085|NCT03675893|Experimental|Cohort 1|"Abemaciclib is administered by mouth twice daily~LY3023414 is administered by mouth twice daily~Letrozole is administered by mouth once daily"
33309086|NCT03675893|Experimental|Cohort 2|"Abemaciclib is administered by mouth twice daily~LY3023414 is administered by mouth twice daily"
33309087|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily"
33309088|NCT03675893|Experimental|Cohort 3|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily~Metformin is administered by mouth once daily"
33309089|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
33309090|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
33309091|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
33309092|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
33309093|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
33318562|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
33093997|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
33093998|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
32800940|NCT05694052|No Intervention|Standard Care|"Lighting: standard lighting system currently installed in the ICU rooms provides a fix light of 300 to 400 lux during daytime, and 0 to 30 lux during night-time. Controls depends on staff to switched on and off.~Noise: The rooms do not have noise isolation and there is no protocol for reducing environmental noise. In our ICU, isolated measurements reported mean average values of 60 dB during daytime and 50 dB during nighttime, with frequent peaks over 80 to 90 dB.~Nocturnal patient care activities: There is no specific protocol for patient care activities during the night. The activities (schedules of drug administration and intravenous infusions, non-urgent examinations, and non-urgent procedures) are organized during the morning by the patient's nurse according to their own clinical criteria. Hygiene and comfort activities are carried out in standard schedules according to the rules of the ICU. Drug administration, examinations and urgent procedures are performed when necessary."
32800941|NCT04140916|Experimental|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
32800942|NCT04140916|Active Comparator|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
32800943|NCT04140760|Active Comparator|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
32800944|NCT04140760|Placebo Comparator|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
32800945|NCT01818596|Experimental|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
32800946|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
32800947|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
32800948|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
32800949|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
32800950|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
32800951|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
32800952|NCT04415216||ISR PCI with thin-DES|
32800953|NCT04415216||ISR PCI with DEB|
32800954|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
32800955|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
32800956|NCT05688280|Experimental|Colorectal Cancer (CRC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
32800957|NCT05688280|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
32800958|NCT05688280|Experimental|Soft Tissue Sarcoma (STS)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
32830610|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
32830611|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
32830612|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
33093999|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
33094000|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
33094001|NCT00491868|Experimental|1|
33094002|NCT00491868|Experimental|2|
33309094|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
33309095|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
33309096|NCT03635632|Experimental|Arm A: High-risk group of patients with lung metastases|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
33309097|NCT03635632|Experimental|Arm B: Standard risk group of all other patients|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
33094003|NCT00491868|Active Comparator|3|
33094004|NCT00491868|Active Comparator|4|
33309098|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
33309099|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
33309100|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
33309101|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
33309102|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
33309103|NCT03520660|Experimental|Phase I|Phase I treatment
33309104|NCT03520660|No Intervention|Phase II after Phase I|Participants who achieved SVR12 in Phase I
33094005|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
33094006|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
33094007|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
33094008|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
33309105|NCT03520660|No Intervention|Phase II without Phase I|Participants who achieved SVR 24 previously
33309106|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
33309107|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
33309108|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
33094009|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
33309109|NCT03493958|Experimental|Feasibility and acceptability of Sleep Healthy Using the Internet (SHUTi) for CBT-I|Individuals with alcohol use disorder (AUD) in recovery with insomnia completed six online classes that include interactive educational content and case studies about insomnia and its precipitating factors. These sessions are designed to parallel traditional (in-person) cognitive behavioral therapy for insomnia (CBT-I) sessions and are tracked and customized. New sessions are available seven days after completion of the previous session. The program includes a variety of interactive features, including goal setting, feedback based on user-identified symptoms, animations, quizzes, vignettes, and video-based expert explanations. Participants have maximum of 9-11 weeks to complete the six sessions.
33309110|NCT03486223|Experimental|Placebo then GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
33309111|NCT03486223|Experimental|GSK2256294 then Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
33309112|NCT03482024|Experimental|Tirzepatide - Control|Group 1 - Tirzepatide 5 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.
33309113|NCT03482024|Experimental|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide 5mg administered SC to participants with mild renal impairment.
32800959|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
32800960|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
32800961|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
33094010|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
33094011|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
33309114|NCT03482024|Experimental|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide 5mg administered SC to participants with moderate renal impairment.
33309115|NCT03482024|Experimental|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide 5mg administered SC to participants with severe renal impairment.
33309116|NCT03482024|Experimental|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide 5mg administered SC to participants with ESRD.
33309117|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
32800962|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
32800963|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
32800964|NCT05682664|Active Comparator|Usual care|Usual care for children with preschool wheeze consist of regular visits to the outpatient clinic every three months after starting the study, while in between these visits contact with the healthcare team is by telephone as needed. At inclusion and at every outpatient clinical visits (e.g. 3, 6, 9 and 12 months), parents/caregivers will be asked to update the healthcare team on disease symptoms by completing a digital version of Test for Respiratory and Asthma Control in Kids (TRACK) questionnaire.
32800965|NCT05682664|Experimental|Luchtbrug Junior (intervention)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
32800966|NCT04140682|Experimental|PAV+ mode|Weaning with PAV+ mode
32800967|NCT04140682|Active Comparator|PSV mode|Weaning with PSV mode
32800968|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
32800969|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
32800970|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
32800971|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
32800972|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
32800973|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
32800974|NCT04140058|Active Comparator|group O4|Patients received 4mg ondansetron.
32800975|NCT04140058|Active Comparator|group O6|Patients received 6mg ondansetron.
32800976|NCT04140058|Placebo Comparator|group C|Patients received normal saline.
32800977|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
32800978|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
32800979|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
32800980|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
32800981|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
32800982|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
32800983|NCT04142320|Experimental|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
32830613|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
32830614|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
33309118|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
33309119|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
33309120|NCT03456817|Experimental|Treatment Arm - High dose ATG, Low dose CSA|High dose ATG will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), an antipyretic (ibuprofen or acetaminophen) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. CSA (cyclosporine A) will be given from day 21. Standard dose methotrexate will be given.
33309121|NCT03456817|Other|Control Arm - Standard of care|Low dose ATG (thymoglobulin) will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.
33309122|NCT03451292|Experimental|Standard Medical Treatment + Albutein 20%|Standard Medical Treatment plus Albutein 20% administrations
33309123|NCT03451292|Active Comparator|Standard Medical Treatment|The sites will follow the Standard Medical Treatment as per their Standard of Care.
33309124|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
33309125|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
33309126|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
33309127|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
33309128|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
33309129|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
33309130|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
33309131|NCT03436485|Experimental|ODM-208 Part 1 Dose escalation|
33309132|NCT03436485|Experimental|ODM-208 Part 2 Dose expansion|
33309133|NCT03433274|Experimental|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
33309134|NCT03433274|Active Comparator|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
33309135|NCT03433274|Experimental|Non-repairable Cohort|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
33309136|NCT03433274|Experimental|Severe Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
33309137|NCT03433274|Experimental|Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
33309138|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
33309139|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
33309140|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
33309141|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
32944837|NCT04994405|Experimental|Lower Tiered Pressures|The study intervention is the inflation of the extremity tourniquet to a pressure lower than the standard pressure of 250 mmHg during hand surgery for these participants determined by tiered guidelines based on systolic blood pressure (SBP).
32944838|NCT04941833|Experimental|Desogestrel group|Desogestrel group
32944839|NCT04941833|Placebo Comparator|Control group|Placebo
32944840|NCT04890041|Experimental|Treatment group|100 subjects will be enrolled with the indicated treatment dose of TPO-RA
32944841|NCT04874909|Other|"Case Patient"|Patient with ciliopathy
32944842|NCT04874909|Other|Healthy related individual|Individual without ciliopathy but related to a patient with ciliopathy (father, mother, brother, sister)
32944843|NCT04874909|Other|"Negative Control patient"|patient without renal disease
32944844|NCT04874909|Other|"Positive Control patient"|"patient with renal disease other that ciliopathy but with a similar renal function to the ciliopathy group (case patient)"
32944845|NCT04869683|Other|MDS follow up|it is a description MDS patients study
32944846|NCT04841369|Experimental|1A|Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
32944847|NCT04841369|Active Comparator|1B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
32944848|NCT04841369|Experimental|2A|Subjects received four doses of PCV13i at 3 months of age
32944849|NCT04841369|Experimental|3A|Subject received three doses of PCV13i at 7 to 11 months of age
32944850|NCT04841369|Active Comparator|3B|Subject received three doses of PCV13 at 7 to 11 months of age
32944851|NCT04841369|Experimental|4A|Subjects received two doses of PCV13i at 12 to 23 months of age
32944852|NCT04841369|Active Comparator|4B|Subjects received two doses of PCV13 at 12 to 23 months of age
32800984|NCT04142320|Active Comparator|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
32800985|NCT04142320|Placebo Comparator|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
32800986|NCT04146298|Experimental|TCR Transduced T cell therapy|"Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine~TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11). If the participant responds to the first infusion, the second or more infusions will be considered when the disease is progressing.~Anti-PD-1 therapy: anti-PD-1 will be administered if needed."
32800987|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
32800988|NCT03156946|Experimental|Breastfeeding support program|
32800989|NCT03156946|Other|Usual or routine care|
32800990|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
32800991|NCT01670344|Other|B|Treatment with surgical standard of care
32800992|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
32800993|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
32800994|NCT04747444|Other|100% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading
32800995|NCT04747444|Other|50% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 50% full body weight loading
32800996|NCT04764760|Other|Phase 1:Study role tissue tensile strength|The tensile strength of the orifice of Frauchad was augmented by implantation of a Accordion fold shaped prosthesis.
32800997|NCT04764760|Other|Phase 2:Curative implantation of a custom designed bio-mechanically compatible Tensiflex prosthesis|The wing shaped custom designed tensiflex prosthesis in the groin was impanted as a curative technique since it provided seamless augmenation of the tensile tissue strength.
32800998|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
32800999|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
32801000|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
32801001|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
32801002|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
32801003|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
32801004|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
32801005|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
32801006|NCT01671046||Cohort|
32801007|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
32801008|NCT04577794|Experimental|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
32801009|NCT04577794|Placebo Comparator|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
32801010|NCT04551196|Active Comparator|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
32801011|NCT04551196|Active Comparator|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
32801012|NCT04536298|Active Comparator|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
32801013|NCT04536298|Placebo Comparator|Placebo|Placebo
32801014|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
32801015|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
32801016|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
33309142|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
33309143|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
33309144|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
33309145|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
32944853|NCT04841369|Active Comparator|5A|Subjects received one dose of PCV13i at 2 to 5 years old.
33309146|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
33309147|NCT03418818|Experimental|Arm A|Participants will complete FAZA PET/MRI scan and radiation therapy before surgery.
33309148|NCT03418818|Experimental|Arm B|Participants will receive pimonidazole prior to surgery. Participants in Arm B also have the option to complete a FAZA PET/MRI scan prior to surgery.
33309149|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
33309150|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
33309151|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
33309152|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
33309153|NCT03400332|Experimental|Part 1A: BMS-986253 + nivolumab|
33309154|NCT03400332|Experimental|Part 1B: BMS-986253 + nivolumab|
33309155|NCT03400332|Experimental|Part 1C: BMS-986253 + nivolumab + ipilimumab|
33309156|NCT03400332|Experimental|Part 2A: BMS-986253 + nivolumab + ipilimumab|
33309157|NCT03400332|Placebo Comparator|Part 2B: Placebo + nivolumab + ipilimumab|
33309158|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
33309159|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
33309160|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
33309161|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
32944854|NCT04841369|Active Comparator|5B|Subjects received one dose of PCV13 at 2 to 5 years old.
33309162|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
32944855|NCT04804943|Experimental|NOA-001 group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
32944856|NCT04804943|No Intervention|Standard treatment group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard therapy.
33309165|NCT03322631|Experimental|Tirzepatide|Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall.
32944857|NCT04804943|Experimental|NOA-001 group (ARDS caused by COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
32944858|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
33309166|NCT03322631|Placebo Comparator|Placebo|Participants received placebo administered into the SC tissue of the abdominal wall.
33309167|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
32944859|NCT00379925|No Intervention|Delayed intervention|Participants are assigned to a delayed intervention group and serve as a no-intervention control group.
32944860|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
32944861|NCT02221817|Active Comparator|Blind|Trochanter injection
32944862|NCT02221817|Experimental|Ultrasound|Trochanter injection
33309168|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
33309169|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
33309170|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
33309171|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
33309172|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
33309173|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
33309174|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
33309175|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
33309176|NCT03264989|Experimental|crizanlizumab 5 mg/kg|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
33309177|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
33309178|NCT03262142|No Intervention|Antibiotic-free treatment|No antibiotic treatment
33309179|NCT03250676|Experimental|H3B-6545 Arm 1: Dose escalation|
32944863|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
32944864|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
33309180|NCT03250676|Experimental|H3B-6545 Arm 2: Phase 2|
33309181|NCT03190473|Experimental|Svelte|
33309182|NCT03190473|Active Comparator|Control|
33309183|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
33309184|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
33309185|NCT03173248|Experimental|AG-120 + Azacitidine|Participants received AG-120 500 mg orally, once daily (QD) in combination with azacitidine 75 milligrams per square meter per day (mg/m^2/day) subcutaneously (SC) or intravenously (IV), on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation.
33309186|NCT03173248|Placebo Comparator|Placebo + Azacitidine|Participants received AG-120 matching placebo orally, QD in combination with azacitidine 75 mg/m^2/day SC or IV, on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation .
33309187|NCT03168750|Other|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
33309188|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
33309189|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
33309190|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
33309191|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
33309193|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
33309194|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
33309195|NCT03107546|Other|Skin graft|full thickness skin graft
33309196|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
33309197|NCT03090750|Experimental|Lavender|Lavender oil
33309198|NCT03090750|Experimental|Bergamot|Bergamot oil
33309199|NCT03090750|Placebo Comparator|Water|Water
33309200|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
32944865|NCT05239013|Experimental|Treatment Group|Subjects who receive the intervention
32944866|NCT04755647|Experimental|Nitric Oxide-Releasing Solution (NORS)|Five litre foot bath delivery NORS
33309201|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
33309202|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33309203|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
33309204|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients. The medication was dosed orally twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
33309205|NCT03012529|Active Comparator|Active drug|Patients receive oral adjunctive rifampin therapy
33309206|NCT03012529|Placebo Comparator|Placebo|Patients receive oral riboflavin
33309207|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
33309208|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
33309209|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
33309210|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
33309211|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
33309212|NCT02970500|Experimental|Methylphenidate HCl 10Mg SR|Participants of the intervention group (n=20) will receive 1 capsule of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 1 and 2 capsules of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 2.
33309213|NCT02970500|Placebo Comparator|Placebo Group|Participants of the control group (n=20) will receive 1 capsule of placebo each morning during 14 days during phase 1 and 2 capsules of placebo each morning during 14 days during phase 2.
33309214|NCT02951130|Experimental|Milrinone|Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to < 7. The maximum duration of study drug infusion is 72 hours.
33309215|NCT02951130|Placebo Comparator|5% dextrose (D5W)|An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.
33309216|NCT02924571|Experimental|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|"A total of 60, 120, or 180 mL of BMA to be aspirated. BMA is then placed into the Harvest SmartPrep® Bone Marrow Concentrate (BMAC) system and concentrated to a final volume of 10, 20, or 30 mL. The BMAC will then be combined with packed allograft cancellous bone chips using the Harvest Graft Delivery Pack. The allograft bone will be obtained routinely from the bone bank in the operating suite.~If using Harvest Graft Delivery Kit, the BMAC dosing estimate is as follows (BMAC to graft ratio will be 1:1):~1-level fusion: 10 cc of BMAC from 60 cc of BMA (roughly 10 cc of graft)~2-level fusion: 20 cc of BMAC from 120 cc of BMA~3-level fusion: 20 cc of BMAC from 120 cc of BMA~4-level fusion: 180 cc kit~5-level fusion: 240 cc kit~If not using Harvest Graft Delivery Kit:~Volume of BMAC will be slightly increased (some BMAC will not get directly into hydrating the graft as the BMAC would get lost in the hydration process and left in mixing bowls)."
33309217|NCT02924571|Active Comparator|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|"12 mL BMP will be applied at the surgical site of the interbody fusion using a collagen sponge following manufacturer's directions.~The BMP kit use per level is as follows:~1 Level Fusion: Extra small kit (1.4 cc)~2 Level Fusion: Small Kit (2.8cc)~3 Level Fusion: (4.2 cc)~4 Level Fusion: Medium Kit (5.6cc)~5 Level Fusion: (7.0 cc)"
33309218|NCT02924571|Active Comparator|Autograft|As per standard of care, the control group will receive 15cc - 45 cc of allograft with autograft and bone marrow aspirate at each level. The iliac crest is the common donor site for autograft. Using the standard technique for anterior lateral fusion, the bone graft will be laid onto the desired site of fusion.
33309219|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
33309220|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
33309221|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
33309222|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
33309223|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
33309224|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
32944867|NCT04755647|Placebo Comparator|Saline|Five litre foot bath delivery NORS
32944868|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
32801017|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
32801018|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
32801019|NCT04764838|Experimental|Intervantion|Pregnant Yoga
32801020|NCT04764838|No Intervention|Control|The clinic will receive routine care
32801021|NCT04457674|Other|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
32801022|NCT04457674|Other|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
32801023|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
32801024|NCT03155386||Standard Angiomammography (SenoBright®)|
32801025|NCT03155386||Optimized angiomammography|
32801026|NCT04417192|Experimental|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
32801027|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
32801028|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
32801029|NCT04408690|Experimental|Rehabilitation and optional delayed ACL reconstruction|
32801030|NCT04408690|Active Comparator|Immediate ACL reconstruction + rehabilitation|
32801031|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
32801032|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
32801033|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
32801034|NCT05212246|Experimental|5% Imiquimod Cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
32801035|NCT05212246|Placebo Comparator|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
32801036|NCT05196022||G1|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant but will not opt for a cochlear implant.
32801037|NCT05196022||G2|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant and receive a cochlear implant
32801038|NCT05196022||G3|Patients with a single-sided deafness in an acute setting
32801039|NCT05196022||G4|Patients with a single-sided deafness in a chronic setting
32801040|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
32801041|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
32801042|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
32801043|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
32801044|NCT04402606|Experimental|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
32801045|NCT05617768||• Cardiac anesthesiologists • Cardiac intensivists • Cardiothoracic surgeons|"Anesthesia department, Cairo university hospitals, kasr al-ainy.~Cardiothoracic thoracic surgery department, Cairo university hospitals, kasr al-ainy.~Anesthesia department, National Heart Institute.~Cardiothoracic surgery department, National Heart Institute."
32801046|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
32801047|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
32801048|NCT03154840|Experimental|Eutropin 4IU|
32801049|NCT03154840|Experimental|Eutropin AQ 12IU|
32801050|NCT03154840|Experimental|Eutropin Pen 36IU|
32801051|NCT04404790|Experimental|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
33309226|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Escalation|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
33309227|NCT02841540|Experimental|H3B-8800 (RVT-2001) MDS Expansion|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1.
33309228|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Optimization|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1, and who have not been exposed to HMA's or lenalidomide in a prior line of therapy.
33309232|NCT02821767||Participants|subjects with diagnosed or undiagnosed ocular conditions and/or their first-degree relatives
33309233|NCT02810743|Active Comparator|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.~Olaparib will be administered in Dutch centers only, as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
33309234|NCT02810743|Active Comparator|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of <100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
33309236|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
33309237|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
33309238|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
33309239|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
33309240|NCT02727270||Parkinson's - High Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported high strain/stress.
33309241|NCT02727270||Parkinson's - Low Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported low strain/stress.
33309242|NCT02727270||Controls - High Stress|Healthy controls (no neurological disease) with self-reported high strain/stress.
33309243|NCT02727270||Controls - Low Stress *FULL NOT RECRUITING|Healthy controls (no neurological disease) with self-reported low strain/stress.
33309244|NCT02727270||Huntington's - High Stress|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported high strain/stress.
33309245|NCT02727270||Huntington's - Low Stress|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported low strain/stress.
33309246|NCT02704858|Experimental|NEO100 Phase 1|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose.
33309247|NCT02704858|Experimental|NEO100 Phase 2A|Intranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose.
33309248|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
33309249|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
33309250|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One 2-hour group session will be offered once a week for 12 weeks. In addition, 30 minutes of individual training will be provided weekly by an instructor.
33309251|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
33309252|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
33309253|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
33309254|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
33309255|NCT02558491|Experimental|Decision Support System|Blinded continuous glucose monitor (CGM) data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters for each insulin pump and multiple daily injections (MDI) participant. These optimized parameters will be used during the Experimental Admission.
33309256|NCT02558491|Active Comparator|Usual Care|Insulin pump and MDI participants will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
33309257|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
33309258|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
33309259|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
33309260|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
33309261|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
33309262|NCT02458027|Experimental|40 g Hemp Protein|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
33309263|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
33309264|NCT02458027|Experimental|40 g Soybean Protein|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
33309265|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
33309266|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
33309267|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
33309268|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
33309269|NCT02417714||Body CT group|100 subjects for a body CT
33309270|NCT02417714||Chest Ct Group|100 subjects for a chest CT
33309271|NCT02411656|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab 200mg IV over approximately 30 minutes on day 1. Cycles repeat every 21 days for 8 cycles and then pembrolizumab 400mg IV every 42 days for total up to 24 months in the absence of disease progression or unacceptable toxicity
33309272|NCT02386800|Experimental|Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination|All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.
33309273|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
33309274|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
32944869|NCT05148923|Active Comparator|Rational energy algorithm|150 J, 360 J, 360 J biphasic DCCV
33309275|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
33309276|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
32944870|NCT05148923|Active Comparator|Maximum fixed energy algorithm|3x 360 J biphasic DCCV
32944871|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
32944872|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
33309277|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
33318563|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
32944873|NCT04716725|Experimental|Experimental (68Ga-PSMA-11 PET)|Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.
32944874|NCT04702607||contrast enhanced 4DCT|
32944875|NCT04618991|Experimental|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
33094012|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
33309278|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
33309279|NCT02310321|Experimental|Phase 1 Dose Evaluation Part|In the dose-evaluation part in Phase 1 part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction (42-day cycles x 2 at maximum), consolidation (28-day cycles x 3 at maximum), and maintenance (28-day cycles x 26 at maximum). The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
33309280|NCT02310321|Experimental|Phase 1 Dose Expansion Part|In the dose expansion part in Phase 1 part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
33309281|NCT02310321|Experimental|Phase 2 Part|Subjects will receive ASP2215 at the recommended dose established in Phase 1 part.
33309282|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
33309283|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
33309284|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
33309285|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
33309286|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
33309287|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
33309288|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
33309289|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
33309290|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
33309291|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
33309292|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
33309293|NCT02146378||Vyndaqel|
33309294|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
33309295|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
33309296|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
33309297|NCT01941563|Sham Comparator|Control|Sham injection
33309298|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
33309299|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
33309300|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
33309301|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
33309302|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
33094013|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
33094014|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
32944876|NCT04474145|Active Comparator|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
32944877|NCT04474145|Active Comparator|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
33309303|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
33309304|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
33309305|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
33309306|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
33309307|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
33309308|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
32944878|NCT04459013||Patient of the orthodontic consultation|
32944879|NCT00000167|Experimental|1|Laser treatment
32944880|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
32944881|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
32944882|NCT04375631|Experimental|Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)|"Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC > 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD."
32944883|NCT04300205|Experimental|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
32944884|NCT04300205|Experimental|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
32944885|NCT04251611|No Intervention|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
32944886|NCT04251611|Experimental|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
32944887|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
32944888|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
32944889|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
32944890|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
33094015|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
33309309|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
33309310|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
33094016|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
33094017|NCT00499005|Active Comparator|Primi|
33094018|NCT00499005|Active Comparator|Multi|
33094019|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.~20 patients, maximun 4 patients with diabetes."
33094020|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.~20 patients, maximun 4 patients with diabetes."
33094021|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.~20 patients, maximun 4 patients with diabetes."
33094022|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.~20 patients, maximun 4 patients with diabetes."
33094023|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15.~20 patients, maximun 4 patients with diabetes."
33094024|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
33094025|NCT04363567||Healthy|20 healthy people. Control group
33094026|NCT04327765|Experimental|Cohort 1|Single orally-inhaled dose
33309311|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
33309312|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
33309313|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
33309314|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
33309315|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
33094027|NCT04327765|Experimental|Cohort 2|Single orally-inhaled dose
33094028|NCT04327765|Experimental|Cohort 3|Single orally-inhaled dose
33094029|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
33094030|NCT03272048|Experimental|Low-Fear/Not-Temporary|
33094031|NCT03272048|Experimental|Low-Fear/Temporary|
33094032|NCT03272048|Experimental|High-Fear/Not-Temporary|
33094033|NCT03272048|Experimental|High-Fear/Temporary|
33094034|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
33094035|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
33094036|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
33094037|NCT00592462||Whole Body MRI|
33309316|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
33309317|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
33309318|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
33309319|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
33094038|NCT00592540|Experimental|Unrelated Donor BMT|
33094039|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
33094040|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
33094041|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
33094042|NCT03272594|Experimental|Breastfeeding|
33094043|NCT03272594|Active Comparator|24% oral sucrose|
33094044|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
33094045|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
33094046|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
33094047|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
33309320|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
32944891|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
32944892|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
32944893|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
33094048|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
32944894|NCT04030559|Experimental|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
32944895|NCT03967223|Experimental|Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
32944896|NCT03967223|Experimental|Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
33094049|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
33094050|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
32944897|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
32944898|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
32944899|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
32944900|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
32944901|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
32944902|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
33094051|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
33094052|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
33094053|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
33094054|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
33094055|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
33094056|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
33094057|NCT00465218||1|High dose aspirin (325 mg)
33094058|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
32944903|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
33094059|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test~Monitored through fortnightly questionnaires"
33094060|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.~non Covid Cases can become COVID cases through self report."
33094061|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.~Fortnighly questionnaire"
33094062|NCT04353349||Patients operated with an open approach|
33094063|NCT04353349||Patients operated with minimally invasive robotic approach|
33094064|NCT04353349||Patients operated with VATS approach|
33094065|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
33094066|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
33094067|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
33094068|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
33094069|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
33094070|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
33404511|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
32944904|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
33094071|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
32944905|NCT03493685|Experimental|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
32944906|NCT03493685|Active Comparator|Irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
32944907|NCT05440565|Placebo Comparator|Risk score|
33094072|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
32944908|NCT05440565|Active Comparator|Fecal immunochemical test|
33094073|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
32944911|NCT03121001|Experimental|Subject treatment|Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.
32944912|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
32956078|NCT05763732|No Intervention|Pre RAS|"After a 10-minute washout period, participants will receive the participants' optimized stimulation.~The participants will undergo assessments to measure gait parameters and patterns during stimulation ON and OFF (Pre-RAS) using the 10-meter walk (during a 2-minute walk) and MDS-UPDRS-III rating scale.~Electrophysiological activity (e.g., local field potentials, LFPs) will be collected before assessments."
32956079|NCT05763732|Experimental|During RAS|"The participants will walk to the metronome beats for four minutes (2 minutes for the same beats as baseline cadence and 2 minutes for 10% faster than baseline cadence) (RAS), and the participants' gait parameters will be recorded.~Electrophysiological activity (e.g., local field potentials, LFPs) will be collected."
33094074|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
33094075|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
33094076|NCT04327726|Placebo Comparator|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
33094077|NCT04327726|Active Comparator|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score <2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
33094078|NCT00499161|No Intervention|1|Control group received usual care
33094079|NCT00499161|Experimental|2|Received intervention New model of nursing care
33094080|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
33094081|NCT03271970||Patients with conductive hearing loss|
33094082|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
33094083|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
33094084|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
33094085|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
33094086|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
33094087|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
33094088|NCT04345354||Patient with continuous positive airway pressure treatment|
33094089|NCT04345354||without continuous positive airway pressure treatment|
33094090|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
33404512|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
33094091|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
33094092|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
33094093|NCT04327648|Active Comparator|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
33094094|NCT04327648|Sham Comparator|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
32944913|NCT03068819|Experimental|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine (or cladribine if shortage), cytarabine, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion. 5-day decitabine is an acceptable alternative for FLAG, and another standard of care salvage chemotherapy regimen, if clinically appropriate and approved by the study PI, may be used.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 106 CD3+ cells/kg) will be given fresh on day -1.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered."
32944914|NCT03068819|Experimental|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"The recipient will receive lymphodepleting chemotherapy with fludarabine (or cladribine if shortage) and cyclophosphamide beginning on day -7.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 106 CD3+ cells/kg) will be given frozen for administration on day 30.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered. The date of the second NK cell infusion will be considered a second Day 0."
32944915|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
32944916|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
32944917|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
32944918|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
32944919|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
32944920|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
32944921|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
32944922|NCT02396459|Experimental|MCT8 deficiency patients|Triac treatment
32944923|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
32944924|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
32944925|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
32944926|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
32944927|NCT00000311|Experimental|1|Methadone + CM (contingency management)
32944928|NCT00000311|Experimental|2|methadone + VC (voucher control)
32944929|NCT00000311|Experimental|3|Buprenorphine + CM
32944930|NCT00000311|Experimental|4|Buprenorphine + VC
32944931|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
32944932|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
33094095|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
32944933|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
33094096|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
33094097|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
33404513|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
33404514|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
33094098|NCT02892877||Invasive mole|
33404515|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
33404516|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
33404517|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
33094099|NCT02892877||Choriocarcinoma|
33094100|NCT02892877||Post-molar neoplasia|
33094101|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
33094102|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
33404518|NCT02330146|Placebo Comparator|Placebo|cryomedium
33404519|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
33404520|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
33404521|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
33404522|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
33404523|NCT02333344|No Intervention|blank|blank group
33404524|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
33404525|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
33404526|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
33404527|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
33404528|NCT05193201|Experimental|Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
32944934|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
32944935|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
32944936|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
32944937|NCT00000407|Placebo Comparator|Usual Care|
32944938|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
32944939|NCT00380549|Active Comparator|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
32944940|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
33094103|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
33094104|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
32944941|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
32944942|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
32944943|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
32944944|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
32944945|NCT04713761|Experimental|Toripalimab|
32944946|NCT04331327|Active Comparator|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
32944947|NCT04331327|No Intervention|Standard of care|The patients were kept on their traditional medications without any intervention
33094105|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
33094106|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
33094107|NCT02955810|Experimental|CyBorD-DARA|
33094108|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
32944948|NCT04943783|Experimental|Atorvastatin|Atorvastatin, 20mg once a day, for six months
32944949|NCT04943783|No Intervention|No drug|no drug
33309321|NCT01810913|Experimental|Arm 1 (IMRT, cisplatin)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
33309322|NCT01810913|Experimental|Arm 2 (IMRT, docetaxel)|Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up. (CLOSED AS OF 20-MAR-2020)
33309323|NCT01810913|Experimental|Arm 3 (IMRT, docetaxel, cetuximab)|Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
32944950|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
33309324|NCT01810913|Experimental|Arm 4 (IMRT, cisplatin, atezolizumab)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
33309325|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
32944951|NCT00001469||Specimens|Specimens
32944952|NCT05752643|No Intervention|Control|Participants will have 4 face-to-face quarterly follow up visits per year
32944953|NCT05752643|Experimental|Experimental|Participants will alternate face-to-face visits with online screening every three months. They will have two face-to-face and two online screenings per year
32944954|NCT05752565|Other|patients with severe HA under FVIII concentrates prophylaxis|patients with severe HA under FVIII concentrates prophylaxis
32944955|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
32944956|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
32944957|NCT00381173|Experimental|1|
32944958|NCT05752409|Experimental|Propofol + esketamin 0.5|1mg•kg-1propofol, 0.5 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
32944959|NCT05752409|Experimental|Propofol+ esketamin 0.75|1mg•kg-1propofol, 0.75 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
32944960|NCT05752409|Active Comparator|Propofol|2 mg•kg-1propofol, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
32944961|NCT04636697|Placebo Comparator|Placebo|Placebo (0.5 mL)
32944962|NCT04636697|Experimental|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
32944963|NCT05752331|Experimental|Physical activity behavioural modification|The 8-week PA behavioural modification intervention will focus on engaging participants in ADL and lowering sedentary time. Each participant will receive one semi-structured motivational interview at baseline to discuss favourite activities and barriers and facilitators to PA. Participants will produce an individualised action plan following the interview that will be followed throughout the intervention to allow an individualised approach to take place. Participants will then be provided with a low-cost pedometer and PA diary to self-monitor and record daily PA. The PA diary will provide examples of various activities that can be done in and around the house, with an emphasis placed on simple, effective movements to reduce sedentary time. Following this, a researcher will conduct weekly virtual meetings with the participant to discuss the past weeks PA levels and provide future individualised goals to promote ADL.
32944964|NCT05752331|No Intervention|Usual Care|All participants will be notified of the government 'your Covid recovery' programme (usual care) which provides details and support on managing long term symptoms of Covid-19.
32944965|NCT00381407|Experimental|1|Participants will receive organizational skills training program
32944966|NCT00381407|Experimental|2|Participants will receive contingency management program
32944967|NCT00381407|No Intervention|3|Participants will receive wait list condition
32944968|NCT02973581|Experimental|metamizol|analgesic drug
32944969|NCT02973581|Experimental|acetaminophen|analgesic drug
32944970|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
32944971|NCT02973581|Experimental|Proxymetacaine|topical analgesia
32944972|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
32944973|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
32944974|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
32956080|NCT05763732|No Intervention|Post RAS|The same assessment as the Pre-RAS will be conducted (Post-RAS).
33309326|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
33309327|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
33309328|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
33309329|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
33309330|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
33309331|NCT01725919|Experimental|Immediate CI therapy|
33309332|NCT01725919|Active Comparator|Delayed CI therapy|
33309333|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
33309334|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
32944975|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
33309335|NCT01698905|Experimental|Nilotinib|Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
33309336|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
33309337|NCT01654133|Experimental|endovascular repair TAAA|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
33309338|NCT01623167|Experimental|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
32944976|NCT04713059||patients with CPS ≥ 1 or MSI-H or TMB ≥ 10Mb/MUT|
32944977|NCT04713059||patients with CPS =0 , MSS and TMB < 10Mb/mut|
32944978|NCT04331405|Experimental|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
32944979|NCT04331405|No Intervention|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
32944980|NCT05752253|Other|Patients with Hereditary Hemorragic Teleangectasia|Patients with Hereditary Hemorragic Teleangectasia
32944981|NCT05752175|Experimental|WPV01|
32944982|NCT05752175|Placebo Comparator|Placebo|
32944983|NCT04673825|Experimental|Intervention: patient initiated care + telemonitoring|Patients in the intervention group will only have a scheduled outpatient visit at baseline and after 1 year. Patients will answer questionnaires and have routine blood tests done before every visit. At 6 months, there will be a remote monitoring check-up and results will be checked by the physician. If indicated, a telephone or video call can take place or a physical visit can be planned. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
32944984|NCT04673825|No Intervention|Control group|The standard care group will have a scheduled outpatient visit at baseline and after 1 year, and in between as usual, scheduled at the discretion of the treating rheumatologist. Prior to each visit, patients complete questionnaires in SpA-Net and have routine blood tests done. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
32944985|NCT05752019||ETI treatment group > 12 years|CF patients older than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
32944986|NCT05752019||Control group > 12 years|CF patients older than 12, whom are not eligible to receive any CFTR-modulator.
32944987|NCT05752019||ETI treatment group < 12 years|CF patients younger than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
32944988|NCT05752019||Control group < 12 years|CF patients younger than 12, whom are not eligible to receive any CFTR-modulator.
32956081|NCT05763602|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (PDI Profend) will be applied to the patients' noses 60 minutes before surgery to repair HELEF and approximately 12 hours after the first application. If the patient will have additional HELEF repair in the 6 month followup period, intranasal PVI will be applied in a similar manner for each procedure.
33309339|NCT01623167|Experimental|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
33309340|NCT01623167|Experimental|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
33309341|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
33309342|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
33309343|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
33309344|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
33309345|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
32944989|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
33309346|NCT01425892||incomplete sjogren's|patients who meet criteria as incomplete sjogren's
33309347|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
33309348|NCT01425892||secondary sjogren's|patients who meet classification criteria for secondary sjogren's
33309349|NCT01327105|Experimental|TVU|
33309350|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
33309351|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
32944990|NCT05751941|Experimental|Sipuleucel-T with NHA|Participants will continue taking New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
32944991|NCT05751941|Experimental|Sipuleucel-T without NHA|Participants will discontinue use of New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
33309352|NCT01282606|Experimental|Drug III: SI-6603 (High)|
33309353|NCT01264055||1|Adults with idiopathic bronchiectasis
33309354|NCT01233674||patients referred for standard of care MRI|
33309355|NCT01233648|Active Comparator|AF|
33309356|NCT01233648|Active Comparator|SR|
33309357|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
32944992|NCT05751785|Active Comparator|Physical Therapy (PT) Only|"Participants in the PT only arm will follow the PT program outlined above. Twice a week for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check-in Data Collection CRF). These check-ins may occur virtually or in person.~In Part 1, the physical therapy only arm requires 8 visits. The participants will complete 2 check-in visits each week (remote or in person), for three weeks. Follow-up data will be collected at 6 weeks (virtual or in-person) and at 3 months (in-person)."
33309358|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
33309359|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
33309360|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
33309361|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
32944993|NCT05751785|Active Comparator|PT + Photobiomodulation Therapy (PBMT)|"The physical therapy + photobiomodulation therapy arm will receive PBMT twice a week, for three weeks, in addition to the PT treatment described above.~A member of the study team will measure the treatment area according to a standard protocol (Appendix N PBM Dose Calculations), to calculate and determine the treatment time, approximately 5-20 minutes. PBMT will be delivered at 25W."
32956082|NCT05763602|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each participating site for subjects enrolled in the Baseline period.
32956083|NCT05763186|Experimental|Sampling|"On the PiccLine: a collection of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume~In the periphery : one 3.5ml heparin-gel tube as a reference."
32956084|NCT05763186|Experimental|Sampling and rinsing|"On the PiccLine: a 10 ml pre-rinsing with 0.9% NaCl and then a sampling of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume.~In the periphery: one 3.5 ml heparin-gel tube as a reference."
33309362|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
33309363|NCT01125228||AZT Alone|Zidovudine 200mg by mouth every 4hr
33309364|NCT01125228||AZT plus IFN|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
33309365|NCT01125228||IFN Alone|-Alpha Interferon 1 million units once a day, escalating
33309366|NCT00984321|Experimental|Psychoeducational Intervention Group|
33309367|NCT00984321|Experimental|Expressive Writing Intervention|
33309368|NCT00984321|Active Comparator|Control Group|
33309369|NCT00924196||Biologic parents of children and adults with NFI|Biologic parents of children and adults with NFI will be evaluated at one time point, using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
33309370|NCT00924196||Children and adults with NFI|Children and adults with NFI whose tumor and non tumor related manifestations will be longitudinally evaluated. Closed to enrollment
33309371|NCT00924196||Unaffected siblings of children and adults with NFI|Unaffected siblings of children and adults with NFI will be evaluated at one time point using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
33309372|NCT00634946|Experimental|I|
32801052|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
32801053|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
32801054|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
32801055|NCT04404790|Experimental|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
32801056|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
32801057|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
32801058|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
32801059|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
32801060|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
32801061|NCT04297618|Experimental|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
32801062|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
32801063|NCT01671904|Experimental|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
32801064|NCT01671904|Experimental|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
32801065|NCT01671904|Experimental|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
32801066|NCT01671982|Experimental|Tenofovir-containing HAART|
32801067|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
32801068|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
32801069|NCT03732118||Minimal hepatic encephalopathy|
32801070|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
32801071|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
32801072|NCT01672138|Active Comparator|Study I|PVAI+ scar homogenization
32801073|NCT01672138|Active Comparator|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
32801074|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
32956085|NCT05762770|No Intervention|standard ICSI|Only spermatozoa with a moving tail but no forward motion will be selected for use in ICSI.
33309373|NCT00634946|Experimental|II|
33309374|NCT00634946|Experimental|III|
33309375|NCT00634946|Placebo Comparator|IV|
33309376|NCT00594672||AREDS participants|Participants who were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
33309377|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
32801075|NCT04040452|Experimental|Treatment|"Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.~Dosage and Route of Administration:~Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.~Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
32801076|NCT04040452|Placebo Comparator|Standard of care|"Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.~Dosage and Route of Administration~Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing~Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
32801077|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
32801078|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
32801079|NCT04027894|Experimental|Rifamycin SV MMX plus ORT|Each tablet contains 200mg Rifamycin SV MMX for oral administration
32801080|NCT04027894|Placebo Comparator|Placebo tablets plus ORT|Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
33094109|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
33094110|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
33094111|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
33094112|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
33094113|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
33094114|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
33094115|NCT04327375||observational|observational
32801081|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
33094116|NCT04327453|Experimental|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
33094117|NCT04327453|Experimental|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
33094118|NCT04327453|Active Comparator|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
33094119|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
33094120|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
32801082|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
32801083|NCT03154216|Experimental|Exercise only|90 minutes of exercise
32801084|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
32801085|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
32801086|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
32801087|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
32801088|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
32801089|NCT03977272|Active Comparator|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
32801090|NCT03977272|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 200mg.
33094121|NCT04327414|Experimental|Intervention group|Implementation of standing desks in classroom. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
33094122|NCT04327414|No Intervention|Control group|No implementation of standing desks in classroom.
33094123|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
33094124|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
33094125|NCT01243710|Experimental|Taurolidine with heparin|
33094126|NCT01243710|Active Comparator|Heparin|
33094127|NCT00622843|Experimental|Group 1|PCV, 210 patients
33094128|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
32801091|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
32801092|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
32956086|NCT05762770|Experimental|PICSI (intervention)|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
32956087|NCT05762692|Experimental|HFNO Group|Intra-operative oxygenation will be administered by the high-flow nasal oxygenation device. The flow rate is 2L/kg.(upper limit 30L/min)
32956088|NCT05762679||Latent PSSP|Latent PSSP defined as focal palpable nodules that may be tender on palpation with pain rating of < 5/10 when combined with the hand-behind-neck (HBN) maneuver.
32801093|NCT03947398|Experimental|Treatment with BLIMP first|
32801094|NCT03947398|Active Comparator|Treatment with low-profile balloon first|
32801095|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
32801096|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
32801097|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
32801098|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
32801099|NCT04405258|Active Comparator|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
32801100|NCT04405258|Active Comparator|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
32956089|NCT05762679||Active PSSP|Active PSSP is defined as focal palpable nodules that are tender on palpation, reproducing the pain, and eliciting a pain rating of >= 5/10 when combined with the hand-behind-neck (HBN) maneuver.
32956090|NCT05762367|Experimental|Patients with IIH|Female patients with IIH between 20 and 40 years old
32801101|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
32801102|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
32801103|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
32801104|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
32801105|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
32801106|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
32801107|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
32801108|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
32801109|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
32801110|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
32956091|NCT05762367|Active Comparator|Healthy volunteers|Female healthy volunteers between 20 and 40 years old
32956092|NCT05762341|Experimental|EXPERIMENT GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
32956093|NCT05762341|Experimental|CONTROL GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
32956094|NCT05762315|Experimental|Audio Storytelling|15 minutes transformative audio storytelling session
32956095|NCT05761184||Steatosis grade 2-3|Subjects with Prader-Willi syndrome and with steatosis grade 2-3
32956096|NCT05761184||Steatosis grade 0-1|Subjects with Prader-Willi syndrome and with steatosis grade 0-1
32956097|NCT05761145||Cases - obese with metabolic syndrome|Obese subjects with metabolic syndrome
32956098|NCT05761145||Cases - obese without metabolic syndrome|Obese subjects without metabolic syndrome
32956099|NCT05761145||Controls|Normal weight subjects
32801111|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
33094129|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
33094130|NCT00592696||Observation|
33094131|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
33094132|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
33094133|NCT00592735||1|
33094134|NCT00592813|Experimental|1|
33094135|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
33094136|NCT01245543|Experimental|AC480IV|Dose range finding study
33094137|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
33094138|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
33094139|NCT00592930|Experimental|1|olanzapine
33094140|NCT00592930|Placebo Comparator|2|matching placebo
33094141|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
32801112|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
32801113|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
32801114|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
32801115|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32801116|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
32801117|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
32801118|NCT05067244|Experimental|MDMA assisted psychotherapy|Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
32801119|NCT05044780||Cohort 1/SARS-CoV-2 positive|Participants with molecular testing positive for SARS-CoV-2
32801120|NCT05044780||Cohort 2/SARS-CoV-2 negative|Participants with molecular testing negative for SARS-CoV-2
32801121|NCT01594281|Experimental|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
32801122|NCT01594281|Active Comparator|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
32801123|NCT01594281|Experimental|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
32801124|NCT05568004|Experimental|Combined exercise group|Aerobic plus resistance exercise intervention
32801125|NCT05568004|Experimental|Aerobic exercise group|Only aerobic exercise intervention
32801126|NCT05568004|No Intervention|Control group|
32801127|NCT05025124||Method comparison|400 samples to be compared directly against the reference method. This is to get the bias estimate.
32801128|NCT05025124||Precision|30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.
33094142|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
33094143|NCT00593047|Placebo Comparator|1|Statin + placebo
33094144|NCT00593047|Experimental|2|Statin + KB2115 dose 1
33094145|NCT00593047|Experimental|3|Statin + KB2115 dose 2
33094146|NCT00593047|Experimental|4|Statin + KB2115 dose 3
33094147|NCT00593086|Active Comparator|A|Standard of care pain management
33094148|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
33094149|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
33094150|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
33094151|NCT00593125|Experimental|1|levetiracetam
33094152|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
32801129|NCT04764526|Experimental|Protein-enriched ice cream|Two protein-enriched ice cream daily (afternoon and evening) in two days in addition to the normal menu
33094153|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
32801130|NCT04764526|No Intervention|Control|Standard menu in two days
32801131|NCT05565820|Experimental|Vamousse Spray 'n' Go|Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.
32900894|NCT05263674|Experimental|Fast sedation|Within a maximum of 60 minutes after the diagnosis of NCSE (EEG or clinical), the patient must be sedated with high-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone. After 20 hours, the sedation should be completely phased out within 3 hours.
33094154|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
33094155|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
33094156|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
33094157|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
33094158|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
33094159|NCT05654194|Experimental|AVA（Azacitidine Combined With Venetoclax and ATRA）group|(1)Inductive therapy: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles or progression; (2)Consolidate therapy:ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles or progression; (3) Maintenance therapy:ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month untill progression;
33094160|NCT05654155|Experimental|Auricular acupressure group|The AAG participants received auricular acupressure three times a day for five days every week for three weeks. Using Dr. Huang's ear reflex theory, our AAG intervention included six acupoints (i.e., shenmen, subcortex, heart, kidney, anxious, and neurasthenia points) that have been demonstrated to be effective in improving sleep and emotional stability.
33094161|NCT05654155|Sham Comparator|sham auricular acupressure group|Participants in SAG received the same protocol of auricular acupressure as the AAG, but six acupoints were used near the treated acupoints (e.g., sacroiliac, neck, stomach, wrist, tonsil, and tongue), which would have had no effects on participants' sleep and mood status.
33094162|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
33094163|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
33094164|NCT05654116|Experimental|CIP training group|Participants assigned to the CIP training group will receive either an individual 5-week CIP training or a pairwise 6-week CIP training, both with weekly sessions.
33094165|NCT05654116|No Intervention|Waiting-list control group|Participants assigned to the waiting-list control group will receive no intervention while data collection is ongoing; after data collection is finished they will also receive the CIP training.
33094166|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
32900895|NCT05263284|Experimental|Treatment (8-chloroadenosine, venetoclax)|Patients receive 8-Cl-Ado IV over 4 hours daily on days 1-5 and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32900896|NCT05214144||evaluating sources of physical function (PF)|evaluate 4 distinct modalities of sources of PF (PRO, ClinRo, PerfO and wearable device data) on Hugo Health platform in breast cancer and lymphoma patients undergoing cytotoxic chemotherapy.
33094167|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
33094168|NCT05653999||Normal Hearing|Group 1 will consist of approximately 20 infants with normal hearing. This cohort will have passed their newborn hearing screenings and will pass audiologic measurements on the day of testing. Audiologic measurements include tympanometry to determine middle ear function and otoacoustic emissions testing to determine cochlear integrity.
33094169|NCT05653999||Hearing Loss|Group 2 will consist of approximately 20 infants with diagnosed bilateral sensorineural hearing loss ranging from mild to severe. These infants will also pass audiologic measures on the day of testing (tympanometry as described in group 1), currently use bilateral air-conduction hearing aids, and are enrolled in early intervention services.
33309378|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
32900897|NCT05213442|Other|All inpatients in Vinatier psychiatric Hospital|All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.
32900898|NCT05300802|Placebo Comparator|Group A|Ringer acetate
32900899|NCT05300802|Experimental|Group B|Priming Dexmedetomidine 1 mcg/kg, Intravenous Ringer acetate
32900900|NCT05300802|Experimental|Group C|Priming Dexmedetomidine 0.5 mcg/kg, Intravenous Dexmedetomidine 0.25 mcg/kg/hour
32900901|NCT05262114||Pre-cursor text|A pre-notification text message (SMS) will be sent to eligible people informing them of their imminent invitation to participate in The Who, two days later a brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
32900902|NCT05262114||Invitation only|A brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
32900903|NCT05299476|Experimental|CAPOX combined with bevacizumab and Tislelizumab|
33404529|NCT05193201|Experimental|Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
33309379|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
33309381|NCT00385606|Active Comparator|cisplatino plus gemcitabine|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
33309382|NCT00385606|Experimental|cisplatino plus gemcitabine plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
32956100|NCT05761015|Experimental|Intervention|there is only one intervention arm and no control arm; the Bayesian analysis will be conducted under hypothetical estimates of superiority vs. control.
33309383|NCT00385606|Experimental|cisplatino plus gemcitabine 10 mg/m2/min|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
33309384|NCT00385606|Experimental|cisplatino plus gemcitabine 10 mg/m2/min plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
33309385|NCT00353782||Dyslipidemia|Dyslipidemia
33309386|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
33309387|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
33309388|NCT00339287||Healthy volunteers|Healthy adult volunteers at least 18 years of age.
33309389|NCT00109174|Other|One arm|Subjects receive the same test
33309398|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study
33309399|NCT00009243||Patients|Patients with acute stroke symptoms
33309402|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
33309406|NCT00001888||1|Asthmatics
33309407|NCT00001888||2|Research Volunteers
33309409|NCT00001813||1|Subjects with clinical and/or laboratory documentation of typical features or suggestiveclinical features of XP, CS, TTD, or overlap syndromes
33309410|NCT00001813||2|Family members of patients with XP, CS, TTD, or overlap syndromes
33309411|NCT00001813||3|Healthy volunteers
33309412|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
33309415|NCT00001405||Healthy Volunteers|Healthy Adult Volunteers
33309416|NCT00001405||Patients|Pts with PID or other blood disorder or clinical history consistent with PID or other blood disorder. Pts are able to volunteer as patient for research collection only per PI discretion.
33309419|NCT00001204||1|Longitudinal sequential cardiologic studies utilizing noninvasive techniques in homozygous patients with well-characterized LDL receptor defects
33309420|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
33309421|NCT00001186||Cohort 2|Young adults with cancer (YACers) 18-25 years of age acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
33309422|NCT00001174||Healthy Volunteers|Healthy volunteers
33309423|NCT00001174||Patients|Patients with bipolar disorder
33309424|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
33094170|NCT05653453|Experimental|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields each day~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel."
33094171|NCT05653453|Active Comparator|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel.
33094172|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
33094173|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
33094174|NCT05653375|Experimental|mindfulness-based psychoeducation program|The group in which the mindfulness-based psychoeducation program was applied.
33094175|NCT05653375|Active Comparator|control group|The group in which no intervention was made and only the pre-test and post-test were applied for comparison.
33094176|NCT05653297||Group A (Control Group)|will undergo conventional dressing daily until the wound is ready for reconstruction, Then coverage of the wound with conventional tie over for 4 days.
33094177|NCT05653297||Group B (Experimental Group)|NPWT (MEDWAY GROUP VAC) will be applied on a continuous mode between -75 & -150 mm Hg for 4 days per session for indefinite number of sessions until the wound is ready for reconstruction, Then it will be applied after coverage of the wound for 1 session.
32944994|NCT05751785|Active Comparator|PT + Shockwave Therapy (SWT)|"The physical therapy + shockwave therapy arm will receive SWT once a week for three weeks in addition to the PT treatment described above. Twice a week, for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check- in Data Collection CRF). The first check-in of the week will occur in-person after the SWT, if, however, this is not feasible, it may be conducted virtually; the second check-in of the week may occur virtually or in-person.~In total, participants will receive one SWT treatment each week (in person) and complete two check-ins each week (remote or in person), for three weeks. The SWT will take approximately 5-20 minutes."
33309425|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
33309426|NCT01589354|Experimental|Interscalene brachial plexus block|
33094178|NCT05649163||Cohort1|Cohort1: About 186 patients with histologically or cytologically confirmed gastric/gastroesophageal junction (GEJ) adenocarcinoma with HER2 overexpression who received a regimen containing Disitamab Vedotin;
33309427|NCT01589354|Experimental|Intra-articular injection|
33309428|NCT03960788|Experimental|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
33309429|NCT01583738|Experimental|V0251|
33309430|NCT01583738|Placebo Comparator|Placebo|
33309431|NCT00097370|Experimental|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
33309432|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
33094179|NCT05649163||Cohort2|Cohort2: About 80 patients with histologically or cytologically confirmed HER2-overexpressed gastric cancer /GEJ adenocarcinoma who received an investigator-selected regimen in addition to Disitamab Vedotin;
33309433|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
33309434|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
33309435|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
33309436|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
33094180|NCT05649163||Cohort3|Cohort3: Approximately 40 patients with other advanced solid tumors histologically or cytologically confirmed with HER2-overexpression and receiving a regimen containing Disitamab Vedotin.
33094181|NCT05652010|Experimental|New Coupling|
33094182|NCT05652010|Active Comparator|Comparator Device|
33094183|NCT05650684||"exclusive breastfeeding group"|Women initiating exclusive breastfeeding after birth
33094184|NCT00465491|Experimental|1|Picoplatin
33309437|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
33309438|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
33309439|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
33309440|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
33309441|NCT03960866|Experimental|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
33309442|NCT03960866|Placebo Comparator|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
33309443|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
33309444|NCT01089218|No Intervention|control|control without intervention
33309445|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
33309446|NCT03957668|Experimental|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
33094185|NCT00465491|Other|2|BSC
33094186|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
33094187|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
33094188|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
33094189|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
33094190|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
33094191|NCT00465608|Experimental|1|propranolol
33094192|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
33094193|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
33094194|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
33094195|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
33094196|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
33094197|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
33094198|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
33094199|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
33094200|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
33094201|NCT01371838|Experimental|Ceftaroline|
33094202|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
33094203|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
33094204|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
33094205|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
33094206|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
33094207|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
33094208|NCT00499629|Active Comparator|1|Arm 1: FXR 450
33094209|NCT00499629|Placebo Comparator|2|Placebo
33094210|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
33094211|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
33094212|NCT00492804|Other|Neurectomy|
33094213|NCT00492804|Other|Nerve preservation|
33094214|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
33094215|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
33094216|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
33094217|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
33094218|NCT00499668|Experimental|ARM A|
33094219|NCT00499668|Experimental|ARM B|
33094220|NCT00468611|Experimental|1|
33094221|NCT00468611|Placebo Comparator|2|
33094222|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
33094223|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
33094224|NCT00499785||patients admitted with acute leukemia|
33094225|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
33094226|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
33094227|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
33094228|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
33094229|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
33094230|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
33094231|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
33094232|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
33094233|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
33094234|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
33094235|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
33094236|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
33094237|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
32944995|NCT05751785|Active Comparator|PT + SWT and PBMT|"The PT + SWT + PBMT arm will receive both SWT and PBMT treatments in addition to PT treatment described above. Participants will receive PBMT twice a week and SWT once a week, for three weeks. The SWT visit may be combined with a PBMT visit in the same week. Up to two times each week after a treatment visit (for three weeks), a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the team member will also ensure the participant is keeping their activity/medication/pain log; the team member will also deliver the DVPRS with supplemental questions. When/if needed, these check-ins may occur virtually. (See Appendix F for check-in data collection CRF).~In Part 1, the PT+ SWT + PBMT treatment arm requires 8 visits: 3 for PBMT alone with check- ins (in person), 3 for PBMT & SWT with check-ins (in person), 6-week follow-up (virtual or in-person), and 3-month follow-up (in person)."
33309447|NCT03957668|Active Comparator|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
32944996|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
32944997|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
32944998|NCT05721989|Experimental|Ziltivekimab B (manual syringe)|Participants will receive a single subcutaneous (s.c.) injection of 15 milligram (mg) ziltivekimab B (15 milligrams per milliliter [mg/mL]) by single-use pre-filled manual syringe on Day 1.
32944999|NCT05721989|Experimental|Ziltivekimab D (manual syringe)|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
32945000|NCT05721989|Experimental|Ziltivekimab C (pen-injector)|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
32945001|NCT05751707|Experimental|NIV+/-HFNC (non invasive ventilation +/- high flow nasal cannulae) & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND High Frequency Chest Wall Oscillations
32945002|NCT05751707|No Intervention|NIV+/-HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND NO High Frequency Chest Wall Oscillations
32945003|NCT05751707|Experimental|HFNC & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
32945004|NCT05751707|No Intervention|HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
32945005|NCT05719649|Experimental|Probiotic NTU 101 Lactic Acid Bacteria Capsules|The subjects who meet the conditions of this test are randomly assigned according to the ratio of 1:1, and take the lactic acid bacteria NTU 101 (1.8 x 10 ^10 CFU) or Placebo in the test group for a total of 12 weeks of treatment. Once, after the treatment, the test physician evaluated the safety and efficacy of the subjects taking the test group lactobacillus NTU 101.
32945006|NCT05719649|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
32945007|NCT05751629|Experimental|Cohort A (Dostarlimab + Bevacizumab + Niraparib)|
33309448|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
33309449|NCT03963362|Experimental|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
32945010|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
32945011|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
32945012|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
32945013|NCT05751473|Experimental|Prolonged Exposure for Primary Care|
32945014|NCT05751473|Active Comparator|EAP Treatment as Usual (TAU)|Employee Assistance Programs standard treatment.
32945015|NCT05704049|Experimental|Cohort 1: manual administration|Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter.
32945016|NCT05704049|Experimental|Part 1 Cohort 2: manual administration|Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter.
32945017|NCT05704049|Experimental|Part 2 Randomized Cohort: OBDS to manual|Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration.
32945018|NCT05704049|Experimental|Part 2 Randomized Cohort: Manual to OBDS|Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration.
33309450|NCT03963362|Experimental|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
33309451|NCT03963362|Experimental|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
32945021|NCT05751395||Critically ill Patients in severe Multiple Organ Dysfunction|Critically ill Patients in severe Multiple Organ Dysfunction in need of a second Central Venous Catheter (CVC) for e.g. blood purification techniques
33309452|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
33309453|NCT01091402||chronic urticaria|
33309454|NCT01091402||asthma|
33309455|NCT01091402||seasonal allergic rhinitis|
33309456|NCT01091402||normal controls|
33309457|NCT03515824|Experimental|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
33309458|NCT03515824|Experimental|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
33309459|NCT03515824|Experimental|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
33309460|NCT03515824|Experimental|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
33309461|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
33094238|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
33309462|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
33309463|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
33309464|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
33309465|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
33309466|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
32900904|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
33309467|NCT04880980|Active Comparator|Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.
33309468|NCT04880980|Active Comparator|Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections
33309469|NCT01089530|No Intervention|Standard care|
33309470|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
33309471|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
33309472|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
33309473|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
32907150|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
32907151|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
32907152|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
32907153|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
32907154|NCT04375436|Active Comparator|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
32907155|NCT04375436|Placebo Comparator|Control|Placebo control
32907156|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
32907157|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
32907158|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
32907159|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
32907160|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
32907161|NCT04712669|Experimental|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
32907162|NCT04712669|Experimental|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
32907163|NCT04712669|Placebo Comparator|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
32907164|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
32907165|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
32907166|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
32907167|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
32907168|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
32907169|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
32907170|NCT05671757|Experimental|4 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
33094239|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
33094240|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
33094241|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33094242|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
33094243|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
33094244|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
33094245|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
33094246|NCT00473798||D|Health care providers.
33094247|NCT01605526|Experimental|Single Arm|
33094248|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
33094249|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
33094250|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
33094251|NCT00473954|Experimental|EGEN-001|
33094252|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
32907171|NCT05671757|Experimental|8 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
32907172|NCT05671757|Experimental|16 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
32907173|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
32907174|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
33094253|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
33094254|NCT00493077|Experimental|1|
33094255|NCT00500019||1.|Elective Cesarean sections
33094256|NCT00500019||2.|Non-elective cesarean section
33094257|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
32907175|NCT02248181||Idiopathic PD patients|
33094258|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
33094259|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
33094260|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
33309474|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
33309475|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
32907176|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
32907177|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
32907178|NCT04347590|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
32907179|NCT04347590|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
32907180|NCT05671679|Experimental|Intervention|The intervention group will use SNAQ app for the first 3 weeks (baseline to V1) of the study.
32907181|NCT05671679|Active Comparator|Control|The control group will continue estimating the carbohydrate count using their traditional methods for the first three weeks of the study (baseline to V1).
32907182|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
32907183|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
32907184|NCT03003143|Experimental|Vigabatrin treatment group|
33094261|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
33094262|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
33094263|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
33094264|NCT01605604|Experimental|recieves Buddhist mindfullness|
33094265|NCT00493116|Experimental|1|
33094266|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
33094267|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
33094268|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
33094269|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
33094270|NCT00493155|Experimental|1|
33309476|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
33094271|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
33094272|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
33094273|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
33094274|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
33309477|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
33309478|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
33309479|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
33094275|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
33094276|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
33094277|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
33094278|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
33094279|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
33094280|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
33094281|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
33094282|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
33309480|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
33309481|NCT01091636|No Intervention|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
33309482|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
33094283|NCT01350505|Experimental|All subjects|13 minutes of light at night (2 hours after bedtime)
33094284|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
33094285|NCT01605760|No Intervention|non immunotherapy treatment|
33094286|NCT01605760|Active Comparator|sublingual immunotherapy course|
33094287|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
33094288|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
33309483|NCT03511066|Experimental|CT-P27 90 mg/kg|CT-P27 will be administrated once in IV infusion.
33309484|NCT03511066|Experimental|CT-P27 45mg/kg|CT-P27 will be administrated once in IV infusion.
33309485|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
33309486|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
33094289|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
33094290|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
33094291|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
33094292|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
33094293|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
33094294|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
33094295|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
33094296|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
33309487|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
33309488|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
33309489|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
33309490|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
33309491|NCT03510910|Experimental|Percocet only|
33309492|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
33309493|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
33309494|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
33094297|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
33309495|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
33309496|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
33309497|NCT01089842|Experimental|Health coaching|
33309498|NCT01089842|No Intervention|Control|
33309499|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
33309500|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
33309501|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
33309502|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
33094298|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
33309503|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
33309504|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
33309505|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
33309506|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
33309507|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
33309508|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
33309509|NCT00072410|Experimental|Cohort 1|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 10 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
33309510|NCT00072410|Experimental|Cohort 2|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 15 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
33309511|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
33309512|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
33309513|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
33309514|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
33309515|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
33094299|NCT00493233|Experimental|1|
33094300|NCT00493233|Placebo Comparator|2|
33094301|NCT00469157|Other|1.|
33094302|NCT03270410||Neonates|Babies born in Rennes University Hospital
33094303|NCT00493272|Placebo Comparator|Placebo|Nacl
33094304|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
33094305|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
33094306|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
33094307|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
33094308|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
33094309|NCT00469235|Placebo Comparator|1|50ng dose group
32801132|NCT05565820|Active Comparator|Nix Creme Rinse Lice Treatment|During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.
33094310|NCT00469235|Placebo Comparator|2|200ng dose group
33094311|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
33094312|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
33094313|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
33094314|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
33094315|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
33094316|NCT00500409|Experimental|Drug Group|Osteoform
33094317|NCT00500409|Active Comparator|Control group|SHELCAL
33094318|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
33094319|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
33094320|NCT00469430|No Intervention|Op|traditional surgery
33094321|NCT00469430|Experimental|Ab|antibiotic treatment
33094322|NCT00500487|Experimental|1|
33094323|NCT00500487|Active Comparator|2|
33309516|NCT00072176|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33094324|NCT00500487|Active Comparator|3|
33094325|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
33094326|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
33094327|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
33094328|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
33094329|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
33094330|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
33094331|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
33094332|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
33094333|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
33094334|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
33094335|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
33094336|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~zygomatic protuberance~nostril's angle~inferior margin of tragus~lip marionette lines~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
33094337|NCT01243983|Experimental|LX211|
33094338|NCT01243983|Placebo Comparator|Placebo|
33094339|NCT00469547|Experimental|1|62% ethanol in emollient gel
33094340|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
33094341|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 150/12.5mg tablet every morning for 8 weeks.~period 3: One 300/12.5mg tablet every morning for 8 weeks.~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
33094342|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 80/12.5mg tablet every morning for 8 weeks.~period 3: One 160/12.5mg tablet every morning for 8 weeks.~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
33309517|NCT00071396|Experimental|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.~Rituximab 375 mg/m^2 IV infusion day 1, then 500 mg/m^2 on days 8, 15 + 22."
33309518|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309519|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33094343|NCT01348828|Other|Single Arm|All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.
33094344|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
33094345|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
33094346|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
33094347|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
32801133|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
32945022|NCT05698199|Experimental|Participants with Newly Diagnosed Glioblastoma (GBM)|Ten participants with histopathological diagnosis of WHO grade IV glioma (Glioblastoma; GBM) and have undergone a gross/near gross total surgical resection of tumor by analysis of residual enhancing tumor remnant on the immediate post-operative MRI
33094348|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094349|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33404530|NCT02030938|Experimental|SERI® scaffold implanted breasts|"SERI® Surgical Scaffold is a knitted, multifilament, bioengineered, silk mesh. It is mechanically strong, biocompatible, BIOSILK® purified, and long term bioresorbable. SERI® Surgical Scaffold is a sterile, single use only mesh and is supplied as a 10 x 25 cm sheet. SERI® Surgical Scaffold provides immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold like) construction of its mesh. When long term bioresorption occurs and the patient's own tissue replaces the implanted scaffold over time the mechanical integrity of the repair is maintained.~SERI® Surgical Scaffold is indicated for use as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome."
33404531|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
32945023|NCT05751083|Experimental|brisk walk+ low intensity aerobic exercises group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min of warm-up period with flexibility exercises of the knees, hips and back~30 min of walking~5 min of cool down.~General flexibility Exercises Protocol Chair Sitting exercise Standing Balance Exercises"
32945024|NCT05751083|Active Comparator|brisk walk group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min: warming up of the knees, hips and back by flexibility exercises~30 min of walking~5 min of cool down."
32945025|NCT05689307|Experimental|SIVA-MVP|Wearable cough detection device with a corresponding smartphone application and charging device.
33094350|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094351|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
33094352|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094353|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094354|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094355|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094356|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094357|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
33094358|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
33094359|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
33094360|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
32801134|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
32801135|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
32801136|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
32801137|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
32801138|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
32801139|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
32801140|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
32801141|NCT05496322|Experimental|cNIBP|Continuous non invasive blood pressure monitor (Volume clamp)
32801142|NCT05496322|Active Comparator|iNIBP|Intermittent Non Invasive Blood Pressure (Brachial Cuff)
32801143|NCT04964050|Experimental|Treatment sequence TRR|Participants will receive Capozide (T) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
32801144|NCT04964050|Experimental|Treatment sequence RTR|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by Capozide (T) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
32801145|NCT04964050|Experimental|Treatment sequence RRT|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed Capozide (T) by in period 3.
32801148|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
33094361|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
33094362|NCT00469586|Experimental|A|
32801149|NCT02386774|Other|diabetic patients|
32801150|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
32801151|NCT03526900|Experimental|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
33094363|NCT00469586|Experimental|B|
33094364|NCT00469586|Active Comparator|C|
33094365|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
32801152|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
32801153|NCT05428696|Experimental|SAD - Cohort 1|Eight participants will receive a single dose of Dose Amount 1 of ALXN2080, and 2 participants will receive placebo.
32801154|NCT05428696|Experimental|SAD - Cohort 2|Eight participants will receive a single dose of Dose Amount 2 of ALXN2080, and 2 participants will receive placebo.
32801155|NCT05428696|Experimental|SAD - Cohort 3|Eight participants will receive a single dose of Dose Amount 3 of ALXN2080, and 2 participants will receive placebo.
32801156|NCT05428696|Experimental|SAD - Cohort 4|Eight participants will receive a single dose of Dose Amount 4 of ALXN2080, and 2 participants will receive placebo.
32801157|NCT05428696|Experimental|SAD - Cohort 5|Eight participants will receive a single dose of Dose Amount 5 of ALXN2080, and 2 participants will receive placebo.
32801158|NCT05428696|Experimental|SAD - Cohort 6|Eight participants will receive a single dose of Dose Amount 6 of ALXN2080, and 2 participants will receive placebo.
32801159|NCT05428696|Experimental|MAD - Cohort 1|Eight participants will receive multiple doses of Dose Amount A of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
32801160|NCT05428696|Experimental|MAD - Cohort 2|Eight participants will receive multiple doses of Dose Amount B of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
32801161|NCT05428696|Experimental|MAD - Cohort 3|Eight participants will receive multiple doses of Dose Amount C of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
33094366|NCT01606111|Experimental|Cerebrolysin|
33094367|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
32801162|NCT05428696|Experimental|MAD - Cohort 4|Eight participants will receive multiple doses of Dose Amount D of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
32801163|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
32801164|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
32801165|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
32801166|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
32801167|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
32801168|NCT02370706|Experimental|Dose Escalation Arm 1|
32801169|NCT02370706|Experimental|Dose Escalation Arm 2|
32801170|NCT02370706|Experimental|Dose Escalation Arm 3|
32801171|NCT02370706|Experimental|Dose Expansion Arm 1|
32801172|NCT02370706|Experimental|Dose Expansion Arm 2|
32801173|NCT02370706|Experimental|Dose Expansion Arm 3|
32801174|NCT01818284|Experimental|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
32801175|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
32801176|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
32801177|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
32801178|NCT05418010|Active Comparator|Tysabri® 300mg|Tysabri® 300mg, administered via intravenous infusion in a 4 week cycle, for a total of 6 cycles
32801179|NCT05418010|Placebo Comparator|Placebo|Placebo, administered via intravenous infusion in a 4 week cycle, for 3 cycles, followed by Tysabri® 300mg, administered via intravenous infusion for a total of 3 cycles
32801180|NCT01673152|Placebo Comparator|Maltodextrin|
32801181|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
32801182|NCT05405842|Experimental|Gastroparesis|Patients diagnosed with Gastroparesis.
32801183|NCT05405842|Experimental|Functional Dsypepsia|Patients diagnosed with Functional Dsypepsia.
32801184|NCT05405842|Experimental|Healthy Controls|Healthy volunteers (without Functional Dsypepsia or Gastroparesis)
32801185|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
32801186|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
32801187|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
32801188|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
32801189|NCT04884256|Placebo Comparator|CBT-004|
32801190|NCT04884256|Experimental|0.01% CBT-004|
32801191|NCT04884256|Experimental|0.024% CBT-004|
32801192|NCT04404946|Active Comparator|phenylephrine infusion|fixed-rate phenylephrine infusion
32801193|NCT04404946|Active Comparator|norepinephrine infusion|fixed-rate norepinephrine infusion
32801194|NCT04404946|Placebo Comparator|placebo infusion|normal saline infusion
32801195|NCT01673464||High School Athletes|
32801196|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
32801197|NCT01673542|Placebo Comparator|Dexeryl|
32801198|NCT04804540|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
32801199|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
32801200|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
33094368|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
33094369|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
33094370|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
33094371|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
33094372|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
32801201|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
32801202|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
32801203|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
32801204|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
32801205|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
32801206|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
32801207|NCT02709226|Experimental|1/Radiation|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
32801208|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
32801209|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
32801210|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
32801211|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
32801212|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
33094373|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
33094374|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
33094375|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
32801213|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
32801214|NCT04587128|Experimental|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
32801215|NCT04587128|Experimental|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m^2) every 2 two weeks per standard of care"
32801216|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
32801217|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
32801218|NCT01673776|No Intervention|K group|commonly used therapy
32801219|NCT01673776|Experimental|M group|multimodal intervention
32801220|NCT01817582|Experimental|Lotemax Gel 0.5% and Restasis 0.05%|Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
32801221|NCT01817582|Experimental|Lotemax Gel 0.5%|Participants will administer lotemax gel 0.5% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
32801222|NCT01817582|Active Comparator|Restasis 0.05%|Participants will administer restasis emulsion 0.05% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
32801223|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
32801224|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
32801225|NCT04792684||Arm A.|Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
33094376|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
33094377|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
33094378|NCT01316367|Experimental|PRECEDE HPE model|
33094379|NCT01244100|Experimental|PL2200|
33094380|NCT04697888|Experimental|Overall Study|Use of Omegaven for patients with parenteral nutrition associated liver disease.
33094381|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
33094382|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
33309520|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309521|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309522|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309523|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309524|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309525|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
33309526|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
33309527|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
33309528|NCT05660590|Active Comparator|Low bandage pressure|Compression bandages applied with low pressure (20-30 mmHg)
33309529|NCT05660590|Active Comparator|high bandage pressure|Compression bandages applied with low pressure (45-55 mmHg)
33309530|NCT05664646|Sham Comparator|Without stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry without stimulation. For study 2, body core temperature and thermal comfort will be reported without stimulation.
33309531|NCT05664646|Active Comparator|With stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry with stimulation. For study 2, body core temperature and thermal comfort will be reported with stimulation.
33309532|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
33309533|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
33309534|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
33309535|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
33309536|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
33309537|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
33309538|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
33318564|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
32801226|NCT04792684||Arm B|Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy
32801227|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
32801228|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
32801229|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
32801230|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
32801231|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
32801232|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
32801233|NCT04775134||Subjects with earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
32801234|NCT04775134||Subjects WITHOUT earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
32801235|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
32801236|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
32801237|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
32801238|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
33309539|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
33309540|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
32801239|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
32801240|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
32801241|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
32801242|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
32801243|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
33309541|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
33309542|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
33309543|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
32801244|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
33094383|NCT00469781|Active Comparator|1|
33094384|NCT00469781|Other|2|
33094385|NCT01244139|Experimental|Active study drug|Treatment
33094386|NCT01244139|Experimental|Comparator|Dummy drug
33094387|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33094388|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
33094389|NCT00474695||1|Active approved treatment
33309544|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
33309545|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
33309546|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
33309547|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
33309548|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
33309549|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
32801245|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
32801246|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
32801247|NCT04604210|Experimental|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
32801248|NCT04604210|Experimental|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
32801249|NCT02081638|Active Comparator|Elite Controller|Elite controllers not on ART
32801250|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
32801251|NCT04603508|Experimental|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
32801252|NCT04603508|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association placebo, oral;~1 tablet empagliflozin , oral;~1 tablet rosuvastatin calcium, oral."
32801253|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
32801254|NCT05356546||Participants with a previous TYRX™ Absorbable Antibacterial Envelope implant|Participants who previously underwent a transvenous CIED implantation with the market released TYRX™ Absorbable Antibacterial Envelope, used for approved indications per country/region, and are returning for a CIED replacement procedure at least 12 months from the prior CIED implantation will be evaluated in this study.
32801255|NCT04748380|Experimental|CRC DA|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet.
32801256|NCT04748380|Other|Home Safety Pamphlet|Stratifying by sex, 30 will be randomized to receive the home safety information at the visit.
32945026|NCT05683457|Experimental|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
33309550|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
33309551|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
33309552|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
33309553|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
33309554|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
33309555|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
33309556|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
33309557|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
33309558|NCT03503188|Experimental|All participants|
33309559|NCT03502798|Experimental|scanning a/LCI|
33309560|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
33309561|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
33309562|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
33309563|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
33309564|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
33309565|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
33309566|NCT00066170|Experimental|Group 1.|Xyrem + Modafinil Placebo
33309567|NCT00066170|Placebo Comparator|Group 2:|Xyrem Placebo + Modafinil Placebo
33309568|NCT00066170|Active Comparator|Group 3|Xyrem Placebo + Modafinil at established dose
33309569|NCT00066170|Experimental|Group 4:|Xyrem + Modafinil at established dose
33309570|NCT03957122|Experimental|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
33309571|NCT03957122|Active Comparator|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
33309572|NCT03957122|Active Comparator|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
33309573|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
33309574|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
33309575|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
33309576|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
33309577|NCT00065468|Active Comparator|A|
33309578|NCT00065468|Experimental|B|
33309579|NCT00065468|Experimental|C|
33309580|NCT00071006|Experimental|Single arm study|
33309581|NCT00094575|Active Comparator|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
33309582|NCT00094575|Active Comparator|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
33309583|NCT01089998|Experimental|Arm 1|
33309584|NCT01089998|Experimental|Arm 2|
33309585|NCT01089998|Experimental|Arm 3|
33309586|NCT01089998|Experimental|Arm 4|
33309587|NCT00057746|Active Comparator|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
33309588|NCT00057746|Experimental|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
33309589|NCT00057746|Experimental|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
33309590|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
33309591|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
33309592|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
33309593|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
33309594|NCT00094107|Experimental|Axitinib [AG-013736]|
32801257|NCT04715074|Experimental|Develop and Pilot #iBeatCRC|"Intervention development will be informed by (1) integrating Aims 1 and 2 findings, (2) Community Action Board [CAB] input, and (3) the Behaviour Change Wheel,48 a step-by-step intervention development approach that identifies and addresses barriers using theory and evidence-based methods.~The intervention pilot may be based on a multicomponent media campaign, as endorsed by the Community Preventive Services Taskforce for promoting CRC screening among individuals ≥ age 50. #iBeatCRC may entail both outdoor mass media and online social media. #iBeatCRC will target Utah and Wisconsin hotspots and non-hotspots for comparison, with pre-post-assessment among 17 individuals in each group for both sites."
33094390|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
33094391|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
33094392|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
33094393|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
33094394|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
33094395|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
33094396|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
33094397|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
33094398|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
33094399|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
33309595|NCT00102063|Active Comparator|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
33309596|NCT00102063|Active Comparator|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
33309597|NCT00102063|Placebo Comparator|Placebo Group|Participants were given a single pill administered once daily
33309598|NCT00065156|Experimental|Lenalidomide|
33309599|NCT01092026|Experimental|cord blood transplant|Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
33309600|NCT01094210||G1|500 ppm F Test Toothpaste
33309601|NCT01094210||G2|1100 ppm F Control Toothpaste
33309602|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
32801258|NCT02235688|Experimental|aldoxorubicin|
32801259|NCT01676584|Placebo Comparator|Placebo|
33094400|NCT00501111|No Intervention|1|Placebo
33094401|NCT00501111|Active Comparator|2|donepezil
32801260|NCT01676584|Experimental|RO6811135|
32801261|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
32801262|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
33094402|NCT00501111|Experimental|3|AZD3480
33094403|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
33094404|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
33094405|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
33094406|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
33094407|NCT00501189||2|Historical group that did not get Gardasil.
33094408|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
33094409|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
33094410|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
33094411|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
33309603|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
33309604|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
33309605|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
33309606|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
33309607|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
33309608|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
33309609|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
33309610|NCT00064298|Experimental|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
33309611|NCT00064298|Placebo Comparator|Arm II - Control|Patients receive oral placebo twice daily.
32945027|NCT05683457|Placebo Comparator|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
32945028|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
33094412|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
33094413|NCT04326400||Hospital de la Princesa employees|
32945029|NCT00002633|Active Comparator|Total Androgen Blockade|
32945030|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
33094414|NCT05367778|Experimental|HS-10370（Phase 1a：Dose Escalation）|Subjects with advanced solid tumors will be enrolled in dose escalation cohorts. Dose escalation of HS-10370 will be done to determine maximum tolerated dose.
33094415|NCT05367778|Experimental|HS-10370（Phase 1b：Dose Expansion ）|Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors having a KRAS G12C mutation.
33094416|NCT05367778|Experimental|HS-10370（Phase 2 ）|Subjects with locally advanced or metastatic KRAS G12C mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10370 as monotherapy.
32945031|NCT04659005|Experimental|Nurse-led decision counseling group|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
32945032|NCT04659005|Other|Control group|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.
32945033|NCT05751005|Experimental|Collagen Supplementation 6 months|Participants were randomized into one of three treatment groups for 6 months (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides).
32945034|NCT05751005|Experimental|Collagen Supplementation 9 months|Participants were randomized into one of three treatment groups (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides) for additional 3 months after successful completion of the 6 month time point (total of 9 months).
32945035|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
33318565|NCT04384172|Experimental|Tibial e-stim followed by genital e-stim|Tibial e-stim followed by genital e-stim
32945037|NCT05750927||ASCoP (severe Aortic Stenosis with Complex PCI features)|Subjects with severe aortic stenosis undergoing transcatheter aortic valve intervention and with concomitant, complex coronary artery disease with a clinical indication for percutaneous coronary intervention
32945038|NCT05673785|Experimental|Brentuximab Vedotin + CHP|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m^2 and doxorubicin 50 mg/m^2 IV, on Day 1 of each 21-day cycle, and prednisone 100 mg tablets, orally, on Days 1 through Day 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurs first.
33318566|NCT04384172|Experimental|Genital e-stim followed by tibial e-stim|Genital e-stim followed by tibial e-stim
33318567|NCT03216850||Patients in ICU requiring parenteral nutrition|
32945041|NCT05671991|Experimental|Empagliflozin or Placebo in Acute|Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.
32945042|NCT05671991|Active Comparator|Empagliflozin in Chronic|Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks
32945043|NCT00381719|Experimental|1|3 mg
32945044|NCT00381719|Experimental|2|20 mg
32945045|NCT00381719|Experimental|3|60 mg
32945046|NCT00381719|Placebo Comparator|4|Placebo
32945047|NCT05750771|Experimental|DCB Group|Implantation of drug-coated balloons in patients with satisfactory pretreatment
32945048|NCT05750771|Experimental|DES Group|Implantation of drug-eluting stents in patients with satisfactory pretreatment
32945049|NCT05750693|Experimental|Patients who received neoadjuvant chemotherapy|Breast cancer samples of paraffin embedded tissue, obtained from the waste material of the diagnostic core-biopsy, stored at the Pathological Anatomy Service, will be used in order to analyze PIK3CA mutations status.
32945050|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
32945051|NCT05665439|Experimental|local treatment|
32945052|NCT05665439|No Intervention|observation|
32945053|NCT05750615||Quantitative phase|Pessary using women
32945054|NCT05750615||Qualitative phase|Pessary using women
33094417|NCT04697732||Adult patients age above 18 years|ASA I-IV adult patients over 18 years of age who will receive general anesthesia and are scheduled to be extubated postoperatively, who can give informed consent, have no known psychological or psychiatric problems, and who are suitable for postoperative follow-up.
33094418|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
32945055|NCT05750615||Intervention development phase|Pessary using women and pessary practitioners
32945056|NCT05750615||Pilot phase|Pessary using women
33094419|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
33094420|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
32945057|NCT05750537|Experimental|EMPACT-Us|An innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.
32945058|NCT05750537|No Intervention|Newly-enhanced usual care (EUC)|Newly-enhanced usual care (EUC)
33094421|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
33094422|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
33094423|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
33094424|NCT00469937|Experimental|Therapeutic Intervention|
32945059|NCT05750459|Experimental|Artesunate|Children with severe malaria will be treated with artesunate
32945060|NCT05750381|Active Comparator|Study Group A: Blis Q24 balm (Active)|Group A: Probiotic Micrococcus luteus Q24 balm (dose: 1e7 colony forming units per application)
32945061|NCT05750381|Placebo Comparator|Study Group B: Placebo balm (without Blis Q24)|Group A: Placebo balm
32945062|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
32945063|NCT05750303||Subacute ischemic stroke|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
32945064|NCT05750303||No ischemic stroke and no other neurological disease control group|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
32945065|NCT05750225||690AD IOL|50 eyes /patients implanted with 690AD IOL
32945066|NCT05750225||690ADY IOL|50 eyes /patients implanted with 690ADY IOL
32945067|NCT00002723|Experimental|Low dose suramin|Low dose suramin
32945068|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
32945069|NCT00002723|Experimental|High dose suramin|High dose suramin
32945070|NCT05648123|Experimental|Supportive Psychotherapy|supportive psychotherapy will be given in the form of an online group for 3 times a week with a duration of psychotherapy ranging from 1 - 2 hours per session
32945071|NCT05648123|Active Comparator|Education|education about post covid-19 syndrome will be given in the form of an online group for 3 times a week with a duration about 1 - 2 hours per session
32945072|NCT05750147||Cardiomyopathies|"Approximately 1000 participants recruited prospectively from participating sites with a diagnosis of cardiomyopathy~Participants will provide biosamples and allow access to medical scans and records for health data collection"
32945073|NCT05645393|Active Comparator|EstroGel® 0.06%|EstroGel® 0.06% (1.25 g of gel)
32945074|NCT05645393|Active Comparator|Biest cream|Biest cream (equivalent dose to EstroGel®)
32945075|NCT05643131|Experimental|Hyivy Device|Participants will receive a Hyivy device with both verbal and written instructions. Recommended use is three times per week for 12 weeks and consists of: 10 minutes of heat (37-42ºC) per session and 10 minutes of dilation per session
32945076|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
32945077|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
32945078|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
32945079|NCT05749991|Experimental|DryShield Isolation|Device: Dryshield DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time. Dryshield was used to isolate teeth that required sealant placement in the assigned participants.
32945080|NCT05749991|Active Comparator|Cotton Roll Isolation|"Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue).~Cotton roll isolation was used to isolate teeth that required sealant placement in the assigned participants.~With this technique, a high-speed evacuation of saliva and water is used."
32945081|NCT05636033||Alcohol use disorder patients|
32945082|NCT05636033||Healthy controls|
32945083|NCT00002759|Experimental|Arm I|See detailed description.
32945084|NCT05749913||Normal|"Participants living in the community.~No vision or hearing impairment.~No severe depression, or other neurological/mental disorders affecting cognitive function."
32945085|NCT05749913||Subjective Cognitive Decline, SCD|"The Montreal Cognitive Assessment (MoCA) score >22~Use two questions to screen: Compared with the previous situation, do you have memory problems?, Has your family or relatives ever thought that you have memory problems compared with the previous situation?, the answer to both questions is yes.~Geriatric Depression Scale-Short Form (GDS-S) score <8"
32945086|NCT05749913||Mild Cognitive Impairment, MCI|"MCI diagnosed by neurologists or psychiatrists: the diagnosis of MCI is mainly in accordance with the revised consensus version of the diagnostic criteria (Winblad et al., 2004), that is, memory function score is 1.5 standard deviations below the value for age- and education-related norms on the third edition of Wechsler Memory Scale.~MoCA: with a range of scores of 17-23(>17 , <23) (Trzepacz et al., 2015)~Geriatric Depression Scale-Short Form (GDS-S) score <8"
32945087|NCT05749913||Mild Dementia|"has met the criteria of dementia~at the early stages"
32945088|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (>1 line of treatment), or post-progression biopsy)
32945089|NCT05749835|Experimental|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland et al
32801263|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
32801264|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
33094425|NCT00599287|No Intervention|1|No intervention
33094426|NCT00599287|Experimental|2|Methylphenidate
33094427|NCT00599287|Experimental|3|Rivastigmine
33094428|NCT00599287|Experimental|4|Haloperidol
33094429|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~will need to obtain a complete list of medications.~will teach the patient about the medications.~will provide a medication schedule, and other papers about the medications.~will count the pills in the medication boxes.~will review all the medications with the patient and answer any question.~will check to see if the medication is working for the patient.~will work with the patient's kidney doctor to adjust medications if needed.~will give the medication boxes filled with medications to take home."
33094430|NCT00599365|No Intervention|Control|"The pharmacist:~will obtain a complete list of medications.~will count the pills in the patients' medication bottles.~will inform patients to take their medications from these bottles."
33094431|NCT00475124|Experimental|1|Home Monitoring ON
33094432|NCT00475124|Active Comparator|2|Home Monitoring OFF
33094433|NCT04326166||Group A|Patients who receive Double therapy or Insulin
33094434|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
33094435|NCT04326166||Group C|Drug-naïve patients
33094436|NCT00599443|Experimental|1|
33094437|NCT00599443|Placebo Comparator|2|
32801265|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
32801266|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
32801267|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
32801268|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
32801269|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
32801270|NCT03152812||free skin flaps|
32801271|NCT03152812||free muscle flaps|
32801272|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
32801273|NCT04746898|Experimental|Virtual Reality Training Group (VR group)|The students in the first group received basic life support practice training with virtual reality applications.
32801274|NCT04746898|Experimental|High Fidelity Simulation Training Group (HFS group)|The students in the second group received basic life support practice training with high fidelity simulators.
32801275|NCT04746898|Experimental|Low Fidelity Simulation Training Group (LFS group)|The students in the third group received basic life support practice training with the classical method, low-reality mannequin.
32801276|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
32801277|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
32801278|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
32801279|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
32801280|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
32801281|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
32801282|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
32801283|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
32801284|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
32801285|NCT03885232|Active Comparator|Control|Control-Care as usual
33094438|NCT00599482|Other|1|Far Infrared Radiation
33094439|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
33094440|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
33094441|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
33094442|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
33094443|NCT02891668||Hypothyroid|Levothyroxine treatment
33094444|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
33094445|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
33094446|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
33094447|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
33094448|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
33094449|NCT00599677|Experimental|group 3|alarm and transport points
33094450|NCT00599677|Experimental|group 4|acupoints of the other meridian
33094451|NCT00599677|Sham Comparator|group 5|non-acupoints
32801286|NCT04685980||Failed spinal anaesthesia group|Failed spinal anaesthesia: failure of anaesthetic level of blockade both sensory and motor blockage, and consequently receive general anaesthesia
32801287|NCT04685980||Control Group|Patient receiving spinal anaesthesia and successfully finish the cesarean section
32801288|NCT04764916|Experimental|Exparel/Intervention group|Will receive 10mL of standard 0.5% bupivacaine followed by 10mL of liposomal bupivacaine as adductor canal field block preoperatively
32801289|NCT04764916|Active Comparator|Standard of Care group|Will receive 20mL of standard 0.5% bupivacaine as adductor canal field block preoperatively
32801290|NCT04676386||PD1/PD-L1|Standard of Care: PD1/PD-L1 monotherapy
32801291|NCT04676386||PD1/PD-L1 + chemo|Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
32801292|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
32801293|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
33094452|NCT00599677|Active Comparator|group 6|Itopride
33094453|NCT00599716|Experimental|1|study drug
33094454|NCT00599716|Placebo Comparator|2|vehicle control
33094455|NCT00599794||1|Healty volunteers who are euvolemic.
33094456|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
33094457|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
33094458|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
33404532|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
33404533|NCT04835818|Experimental|Reporting|check point-of-care Multiplex PCR for pneumonia pathogens and report results to primary care physician
32801294|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
32801295|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
32801296|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
32801297|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
32801298|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
32801299|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
32801300|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
32801301|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
32801302|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
32801303|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
32801304|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
32801305|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
32801306|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
32801307|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
32956103|NCT05759832|Experimental|Modified HFNC oxygen therapy group|
32956104|NCT05759832|Other|Face mask group|
32956105|NCT05759637||T2D|patients with Type2 diabetes (T2D)
32956106|NCT05759637||obese without T2D|obese patients without Type 2 diabetes (T2D)
32956107|NCT05759117||Pleural effusion|All patients with pleural effusion who will undergo thoracentesis
32956108|NCT05758376|Experimental|Recovery Bridge|Open trial single arm pilot study
32956109|NCT05757570|Experimental|povetacicept 240mg|
32956110|NCT05756413|Experimental|SDT|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
32956111|NCT05756413|Other|Control|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
32956112|NCT05755568||MLD Participants|Data from medical records of participants diagnosed with late infantile or juvenile MLD at any time from 1 January 2000 to 31 December 2022 will be observed retrospectively.
32956113|NCT05754294||Coronary arteries bypass grafting with conventional cardiopulmonary bypass (cCPB)|(n=20) patients, were allocated for Conventional Cardiopulmonary Bypass (cCPB)
32956114|NCT05754294||Coronary arteries bypass grafting with Minimally invasive extracorporeal circulation (MiECC)|(n=20) patients, were allocated for Minimal invasive Extracorporeal Circulation (MiECC) type III.
32956115|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (< 60 min.)|(n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (< 60 min.)
32956116|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (>100 min.)|n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (> 100 min.)
33094459|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
33404534|NCT04835818|No Intervention|Usual Care|check point-of-care Multiplex PCR for pneumonia pathogens but do NOT report results to primary care physician. Let primary care physician provide usual standard care
33404535|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33094460|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
33094461|NCT00599911|Experimental|Lu AA24530: 5 mg|
33094462|NCT00599911|Experimental|Lu AA24530: 10 mg|
33094463|NCT00599911|Experimental|Lu AA24530: 20 mg|
33094464|NCT00599911|Active Comparator|Duloxetine: 60 mg|
33094465|NCT00599911|Placebo Comparator|Placebo|
33094466|NCT00501462|Other|Mild renal impairmnent|
33094467|NCT00501462|Other|moderate renal impairment|
33094468|NCT00501462|Other|Normal renal function|
33094469|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
33094470|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
33094471|NCT00600145|Experimental|1|Mirtazapine
33094472|NCT00600145|Placebo Comparator|2|Placebo
33094473|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
33404536|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
33404537|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
33404538|NCT04118361|Experimental|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
32801308|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
32801309|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
32801310|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
32801311|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
32801312|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
32801313|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
32801314|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
32801315|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
32801316|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
33094474|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
33094475|NCT04325971|Experimental|Healthy Subjects|All healthy subject are gathered in one arm
33094476|NCT04326127||Control|Healthy volunteers
33094477|NCT04326127||Case|Volunteers with diagnosed sleep apnea
33094478|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
33094479|NCT00600379|No Intervention|B,|Usual care
33094480|NCT05661448|Experimental|Cognitive remediation|CR was developed by Dr. Bowie (PI). Approximately 60% of CR sessions are spent on cognitive training activities, 20% on developing, monitoring, and flexibly adjusting problem-solving strategies, and 20% on transfer activities. Transfer includes discussing and role-playing how cognitive skills and strategies are applied in everyday life and teaches potential compensatory strategies for overcoming cognitive challenges. Targeted cognitive domains are processing speed, attention, memory, and executive functions, which are all commonly impaired in psychosis. The manual includes 1.5-hour sessions and uses Brain Training Pro and will be offered over an 8-week period. Zoom Health will be used for group transfer activities.
33404539|NCT05031286|Experimental|Experimental Arm|
32945090|NCT05749835|Experimental|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\her head is cradled between your body and your right forearm (when you stand at his\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
32945091|NCT05749757|Experimental|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
32945092|NCT05749757|Sham Comparator|Sham Acupuncture|Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session sham acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
32945093|NCT05624723|Experimental|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
32945094|NCT05624723|Experimental|Group 2: Mild Renal Impairment|Participants with mild levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
32945095|NCT05624723|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
32945096|NCT05624723|Experimental|Group 4: Severe Renal Impairment|Participants with severe levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
32945097|NCT05624723|Experimental|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB054707 across 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB054707.
32945098|NCT05749679|Experimental|Training|Physicians participating will receive training on renal failure in type 2 diabetes and on measures to reduce nephron loss
32945099|NCT05749679|Sham Comparator|Routine care|
32945100|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
32945101|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
32945102|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
32945103|NCT05749523|Other|Exercise|Exercise vs. non-exercise
32945104|NCT05613881|Experimental|EXPERIMENTAL GROUP|the group to be trained and then monitored by phone
32945105|NCT05613881|No Intervention|CONTROL GROUP|The individuals in this group will be given only education booklet by the researcher after the pre-tests are applied in the first face-to-face interview. 3 months after the first interview, the final tests will be applied.
32945106|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
32945107|NCT00382343|No Intervention|No prophylaxis|
32945108|NCT05749445||Nirmatrelvir-Ritonavir|Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir
32945109|NCT05749367|Active Comparator|Suprainguinal Fascia Iliaca Block Group|Patients will undergo SIFIB with ropivacaine and PENG plus LFCNB with saline solution.
32945110|NCT05749367|Experimental|PENG Block + Lateral Femoral Cutaneous Nerve Block Group|Patients will undergo SIFIB with saline solution and PENG plus LFCNB ropivacaine.
32945111|NCT05506085||Deep Brain Stimulation|Voice outcomes and Magnetic resonance imaging will be compared pre- and post-DBS (Deep brain stimulation) in patients with laryngeal dystonia and adductor laryngeal dystonia. The evaluators will be masked for analyzing the voice outcomes pre-and post-DBS
32945112|NCT05502887||Researched Group|All patients with newly diagnosed or preexistent hematological neoplasms at participating centers are intended to be registered within EndoCDO-H. Prior to inclusion, patients have to give their written informed consent.
32945113|NCT05608421|Experimental|1MoreStep Intervention|The intervention arm is 7 sessions (6 group and one individual) that meet weekly with a community health educator who is a Black woman and has experience implementing prior behavioral interventions with people who have experienced trauma and/or are LWH.
32945114|NCT05608421|Active Comparator|Equal Attention Control|The Equal Attention Control consists of 7 group-based sessions that meet weekly for 60-90 minutes. The control sessions provide equal attention and psychotherapeutic experience of a support group where participants can address issues important in their lives.
32945115|NCT05749289|Experimental|Al18F-octreotide PET/CT|Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed Neuroendocrine Tumor. The patients were injected with Al18F-octreotide and underwent PET/CT scan 20~40min after the injection.
32945116|NCT05602961|Experimental|Cohort 1 (includes GLB-COV2-043 15 μg)|12 eligible adult participants will be randomized to 15 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
32945117|NCT05602961|Experimental|Cohort 2 (includes GLB-COV2-043 30 μg)|12 eligible adult participants will be randomized to 30 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
33318568|NCT03814772||Liver transplant|"18 years to 65~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
33318569|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
33318570|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
33318571|NCT01303328|Experimental|Treatment group|
33318572|NCT01303328|Placebo Comparator|Placebo group|
33318573|NCT03817034|Experimental|Multimodal Analgesia|
33318574|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
33404540|NCT04116489|Experimental|Wildlife Immersion Activity|We will use a crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
32801317|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
32801318|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
32801319|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
32945118|NCT05602961|Experimental|Cohort 3 (includes GLB-COV2-043 60 μg)|12 eligible adult participants will be randomized to 60 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
32945119|NCT05602961|Experimental|Cohort 4 (includes GLB-COV2-043 90 μg)|12 eligible adult participants will be randomized to 90 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
32945120|NCT05749211|Experimental|Huaier granule|Huaier granule is supplied as 20-g granule. Huaier granule will be administered as 20 g orally tid x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. In the absence of intolerable toxicity, a patient may continue to receive treatment with Huaier granule until disease progression, or until 24 months have elapsed.
32945121|NCT05602727|Experimental|MK-1942 5 mg|Participants will receive a single 5 mg MK-1942 capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
32945122|NCT05602727|Experimental|MK-1942 15 mg|Participants will receive a single 8 mg MK-1942 capsule twice daily (BID), taken orally for one week. Then the dose is titrated up to 15 mg MK-1942 capsule twice daily (BID), taken orally for up to 11 weeks.
32945123|NCT05602727|Placebo Comparator|Placebo|Participants will receive a placebo capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
32945124|NCT05501249|Experimental|Aquatic Exercise Group|Aquatic class 45 minutes, 3 times a week, for 8 weeks
32945125|NCT05501249|No Intervention|Control Group|Usual care for 8 weeks and one hour education session on fall prevention.
32945126|NCT05749133|Experimental|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of Anti-GPRC5D CAR-T Cells Injection, doses of 1.0~6.0×10^6 /kg±20% CAR-T cells, after lymphodepleting therapy.
32945127|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
32945128|NCT05749055|Experimental|ENX-102|Four weeks of 2 mg of ENX-102 in capsule form plus 2 weeks of placebo in capsule form (before and/or after the ENX-102 treatment period), taken orally once daily in the evening for a 6-week total treatment period.
32945129|NCT05749055|Placebo Comparator|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period.
32945130|NCT05590481|Experimental|EG (experimental group): TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION + Behavioral Therapy|EG (experimental group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. In addition, patients will be submitted to biphasic current and surface electrodes during 12 treatment sessions, twice a week, on non-consecutive days, with a DUALPEX 961s electrical stimulation device (Quark, Brazil).
32945131|NCT05590481|Sham Comparator|GS (Sham-sham group): Behavioral therapy|GS (Sham-sham group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. Twelve sessions will be held, twice a week, on non-consecutive days. The electrodes of the DUALPEX 961 equipment will be positioned one immediately posterior to the lateral malleolus of the ankle and the other approximately 30 cm above it, where there is no stimulus for the tibial nerve.
32945132|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 1|
32945133|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 2|
32945134|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 3|
32945135|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 4|
32945136|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 5|
32945137|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 6|
32945138|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 7|
32945139|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 1|
32945140|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 2|
32945141|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 3|
32945142|NCT05490017|Placebo Comparator|Part 1: Placebo|
32945143|NCT05490017|Placebo Comparator|Part 2: Placebo|
32945144|NCT05488691|Experimental|Eye Movement Desensitization and Reprocessing therapy|8 to 10 individual 60-minutes sessions over 2 months.
32945145|NCT05488691|Active Comparator|Treatment as usual|Same periodicity as the experimental group and at the same time range.
32945146|NCT05748977|Experimental|SABA,SAMA ICS|
32945147|NCT05748977|Experimental|LABA,LAMA ICS|
32945148|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
32945149|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
32945150|NCT02972957|No Intervention|Unvaccinated|control group C
32945151|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
33094481|NCT05661448|Experimental|MetaCognitive Training|MCT, developed by Drs. Moritz (co-applicant) and Woodward (PI), is based in the theoretical foundations of CBT, but targets the biases underlying symptoms rather than symptoms directly. MCT includes eight modules targeting common cognitive errors and reasoning biases in schizophrenia that have, through decades of research, been shown to contribute to delusions (e.g., jumping to conclusions). MCT will be offered to groups of up to 8 participants over 12 sessions of 45-60 min each (two per week) through Zoom Health. Session aims include raising participants' awareness of distortions and prompting them to critically reflect on, expand upon, and change their current repertoire of problem-solving strategies.
33094482|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
33094483|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
33094484|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
33094485|NCT00600457||A,1|
33094486|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
33094487|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
33094488|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
32801320|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
32801321|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
32801322|NCT04404322|Experimental|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
32801323|NCT04404322|Active Comparator|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
32801324|NCT04404322|No Intervention|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
32801325|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
32801326|NCT01675180|No Intervention|Control|
32801327|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
32801328|NCT01675258||Control|Healthy adults above the age of 18 years
32801329|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
32801330|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
32801331|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
32801332|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
32801333|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
32801334|NCT03872206|Experimental|HPN536-2001 - Part 1 (Dose Escalation)|HPN536 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
32801335|NCT03872206|Experimental|HPN536-2001 - Part 2 (Dose Expansion)|HPN536 is IV administered once weekly for about 1 hour at the recommended phase 2 dose established in Part 1
32801336|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
32801337|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
32801338|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
32801339|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
32801340|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
32801341|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
32801342|NCT03870334|Experimental|BT-11 1,000 mg|Eligible subjects will be randomly assigned, in a centralized manner, in a 1:1 ratio to 1 of 2 treatment groups, (omilancor) BT-11 1000 mg or placebo, through an interactive web-based response system (IWRS).
33094489|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
33094490|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
33094491|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
33094492|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
33094493|NCT00600535|Experimental|Abiraterone acetate (fasting)|
33094494|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
33094495|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
33094496|NCT00600652||1|glucocorticoid-resistant patients
33094497|NCT00600652||2|glucocorticoid-sensitive patients
33094498|NCT00600652||3|normal controls
33094499|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
32801343|NCT03870334|Placebo Comparator|Placebo|Subjects in the (omilancor) BT-11 group will receive 1000 mg of BT-11 and subjects in the placebo group will receive matched placebo. Subjects will take study drug by ingesting 1 tablet per day with water.
33094500|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
33094501|NCT00623155|No Intervention|1|Control group
33094502|NCT00623155|Experimental|2|Test group
33094503|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
33094504|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
32801344|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15~Cisplatin 75 mg/m^2 on Day 1~5-FU 750 mg/m^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
32801345|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
32801346|NCT01675726|Other|quality of life|
32801347|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
32801348|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
32801349|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
32801350|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
32801351|NCT04649008|Experimental|Epilepsy patient volunteers|Patients recruited for the study with intractable epilepsy who are anticipated to undergo epilepsy surgery
32801352|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
32801353|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
33094505|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
33094506|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
33094507|NCT00600847|Active Comparator|1|desloratadine 20 mg
33094508|NCT00600847|Active Comparator|2|desloratadine 5 mg
33094509|NCT00600847|Placebo Comparator|3|
33094510|NCT04325932|Experimental|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
33094511|NCT04325932|No Intervention|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
33094512|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
33094513|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
33094514|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
33094515|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
33094516|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
33094517|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
33094518|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
33094519|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
33094520|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
33309612|NCT00078819|Placebo Comparator|Placebo|"Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
32945152|NCT05748899|Experimental|group number 1|Group number 1 will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
32945153|NCT05748899|No Intervention|group number 2|The group number 2 will not receive pranayama training, so it serves as control lupus group
33318575|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
32945154|NCT05446259||DCM group|Subjects diagnosed with degenerative cervical myelopathy.
32945155|NCT05446259||Control group|Subjects diagnosed with cervical spinal disease without myelopathic symptoms.
32945156|NCT05581043|Placebo Comparator|0 gram 3-OHB 30 minutes before an OGTT|0 gram 3-OHB 30 minutes before an OGTT
32945157|NCT05581043|Experimental|10 gram 3-OHB 30 minutes before an OGTT|10 gram 3-OHB 30 minutes before an OGTT
32945158|NCT05581043|Experimental|20 gram 3-OHB 30 minutes before an OGTT|20 gram 3-OHB 30 minutes before an OGTT
32945159|NCT05581043|Experimental|40 gram 3-OHB 30 minutes before an OGTT|40 gram 3-OHB 30 minutes before an OGTT
32945160|NCT05581043|Experimental|20 gram 3-OHB 0 minutes before an OGTT|20 gram 3-OHB 0 minutes before an OGTT
32945161|NCT05581043|Experimental|20 gram 3-OHB 60 minutes before an OGTT|20 gram 3-OHB 60 minutes before an OGTT
32945162|NCT05748743|Experimental|Glove change group|The surgical gloves were changed prior to closure of the peritoneum or closure of the abdominal fascia
32945163|NCT05748743|No Intervention|Usual care group|The surgical gloves were not changed before abdominal closure
32945164|NCT05578079|No Intervention|Control group|No music will be played to the control group.
32945165|NCT05578079|Active Comparator|Intervention 1|"The Intervention-1 group will listen to the music which determined by the researchers by examining the literature (DOI: 10.4274/jpr.24892). The music which determined by the researchers is The art of fugue by Johann Sebastian Bach."
32945166|NCT05578079|Active Comparator|Intervention 2|The Intervention-2 group will listen to lullaby.
32945167|NCT05573009|Experimental|Training Group|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~At least 3-days of the cognitive behavioral approach-based stress reduction program will be given as face to face interviews to the intervention group during hospitalisation, and the remaining sessions will be given at the bedside as long as the hospitalization continues. If the patient is discharged, the remaining 2 sessions will be completed online."
32945168|NCT05573009|No Intervention|Control Group|Routine nursing care will be provided to the control group along with a stress management manual.
32945169|NCT05748197|Experimental|ADCLEC.syn1 CAR T cells|The dose escalation cohort size of 3 patients in each cohort will be infused with escalating doses of ADCLEC.syn1 CAR T cells to inform the RP2D. There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells. After dose escalation, one or two dose levels will be selected for dose expansion cohort(s). Up to approximately 12 additional patients each if two doses are selected or approximately 16 additional patients, if one dose is selected, will be treated in the dose expansion phase to determine RP2D.
32945170|NCT05568095|Experimental|Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Domvanalimab and zimberelimab doses once every 4 weeks (Q4W) in addition to chemotherapy with FOLFOX (oxaliplatin, leucovorin, fluorouracil) once every 2 weeks (Q2W) or Domvanalimab and zimberelimab once every 3 weeks (Q3W) in addition to chemotherapy with CAPOX (capecitabine and oxaliplatin) Q3W.
32945171|NCT05568095|Active Comparator|Nivolumab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Nivolumab Q2W and FOLFOX Q2W or Nivolumab Q3W + CAPOX Q3W.
32945172|NCT05471141|Experimental|Group 1|To receive intervention during the phase 1 and will receive nothing during the phase 2, will complete the measure at the end of phase 2 as the follow-up
32945173|NCT05471141|No Intervention|Group 2|To serve as the control during phase 1 and receive intervention during the phase 2
32945174|NCT05469425|Experimental|Preoperative home-based exercise training|Patients allocated to this group will receive usual care plus a preoperative home-based exercise program consisting of aerobic and resistance exercise. In addition, a physical therapist will carry out weekly telephone supervision with all participants.
32945175|NCT05469425|No Intervention|Control Group|"Patients allocated to this group will receive usual care and must complete the outcome measures.~In addition, a physical therapist will carry out weekly telephone calls with all participants to monitor adverse events."
32945176|NCT05469191|Experimental|Group 5 STS|Group 5 STS will perform the same protocol as group 10 STS, only the number of repetitions between each set will change.
32945177|NCT05469191|Experimental|Group 10 STS|Group 10 STS will perform the same protocol as group 5 STS, only the number of repetitions between each set will change.
32945178|NCT05469191|No Intervention|Control group|Control group, no intervention.
32945179|NCT05467007|Experimental|BioFire® Respiratory Panel 2.1-EZ|EXP group will receive the BioFire RP2.1-EZ panel, designed to test for a variety of bacterial and/or viral causes for illness
32945180|NCT05467007|No Intervention|Standard of Care|Standard care procedures are essentially yes/no to patient having SARS-COV-2, the SC group will receive the standard nasal swab used in the IPCs.
32945181|NCT05462561|Experimental|Treatment (VCBA)|Patients undergo robotic VCBA transplantation.
32945182|NCT05462483|Experimental|Rice sock and instructions to heat quadriceps|Receives heating device and instructions to heat the quadriceps musculature.
32945183|NCT05462483|No Intervention|No heating device or instructions to heat quadriceps|WIll not receive heating device or instructions to heat quadriceps musculature.
32945184|NCT05460533|Experimental|Tisagenlecleucel|Patients will receive reinfusion of tisagenlecleucel on day +35-60 after their initial infusion if meeting eligibility criteria. Tisagenlecleucel is an autologous cellular immunotherapy product that is comprised of CD3+T cells that have undergone ex vivo T cell activation, gene modification, expansion, and formulation in infusible cryomedia.
33309613|NCT00078819|Experimental|Etanercept|"Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
33309614|NCT00063986|Experimental|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
33309615|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
33309616|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
33309617|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
33309618|NCT03961191||HSIL group|Patients with cervical histology of HSIL
33309619|NCT03961191||Cancer group|Patients with cervical histology of cancer
32945185|NCT05455619|Experimental|Evexomostat|Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
32945186|NCT04571333|Experimental|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
32945187|NCT05563103|Experimental|AIH + Walking Training with transcutaneous spinal stimulation (WALKtSTIM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
32945188|NCT05563103|Sham Comparator|Sham + WALKtSTIM|Sham acute intermittent hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
32945189|NCT05563103|Sham Comparator|AIH + Walking Training with sham transcutaneous spinal stimulation (WALKtSHAM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with sham transcutaneous spinal cord stimulation.
32945190|NCT05561387|Active Comparator|Arm I (VRd-Lite)|"INDUCTION CYCLES 1-9: Patients receive bortezomib SC on days 1, 8, 15, and 22 of each cycle, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32945191|NCT05561387|Experimental|Arm II (DRd-R)|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32945192|NCT05561387|Experimental|Arm III (DRd-DR):|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32945193|NCT05560763|Experimental|Completed Cases|
32945194|NCT05545319|Experimental|Nirmatrelvir/ritonavir|Participants will receive nirmatrelvir/ ritonavir 300 mg/100 mg (or 150 mg/100 mg for participants with estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) ≥30 to <60 mL/min) every 12 hours from Day 1 through Day 15
32945195|NCT05545319|Experimental|Placebo/ritonavir|Participants will receive placebo 0 mg/ritonavir 100 mg every 12 hours for 15 days.
32945196|NCT05446337||Patients and Informal Care Givers|Individuals living with diabetes who are receiving or have received care through the Diabetes Foot Care and Limb Preservation Pathway at various stages of the care pathway including screening & prevention, wound care treatment, surgery and monitoring.
32945197|NCT05446337||Healthcare Providers|Medical, Nursing, and other allied healthcare providers including chiropodists, physiotherapists, occupational therapists, social workers, and nutritionists.
32945198|NCT05446337||Stakeholders|Individuals external and internal involved in clinical care, continuity of care, and policy-making including but not limited to senior hospital leadership, decision support, and researchers and policy decision-makers.
32945199|NCT05536427|Experimental|IPM001|A neoantigen/ tumor-specific antigen sencitized autoimmune cell injection
32945200|NCT05747183|Experimental|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
32945201|NCT05747183|Active Comparator|ProTaper Gold files|Root canal preparation using ProTaper Gold files.
33094521|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
33094522|NCT00475436|Experimental|Arm 1|
33094523|NCT04326322|Experimental|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
33094524|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
33094525|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
33094526|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
32801354|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography~Perform cognitive testing of the communication tool"
32801355|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
33094527|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
33094528|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
33094529|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
33094530|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
33094531|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
33094532|NCT00601276|Experimental|1|
33309620|NCT00098865|Experimental|Thalidomide and Temozolomide|"Thalidomide:~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.~Temozolomide:~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
33309621|NCT00098787|Experimental|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
33309622|NCT00098787|Experimental|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
33309623|NCT00098787|Experimental|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
33309624|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
33309625|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
33309626|NCT01081587|Experimental|Nutritional Support Team|
33309627|NCT01081587|Active Comparator|Usual care|
33309628|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
32801356|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
32801357|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
33094533|NCT00601276|Active Comparator|2|
33094534|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
33094535|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
32801358|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
33094536|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
33094537|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
33309629|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
33309630|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
32801359|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
32801360|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
32801361|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
32801362|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
32801363|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
32801364|NCT05261386|Placebo Comparator|Placebo Comparator: CBT-008|CBT-008 vehicle ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
32801365|NCT05261386|Experimental|Experimental: 2.5% CBT-008|2.5% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
33309631|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
33309632|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
32801366|NCT05261386|Experimental|Experimental: 10% CBT-008|10% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
32801367|NCT03899805|Experimental|Liposarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
32801368|NCT03899805|Experimental|Leiomyosarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
32801369|NCT03899805|Experimental|Undifferentiated Pleomorphic sarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
32801370|NCT04617340|No Intervention|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
32801371|NCT04617340|Experimental|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
32801372|NCT03862066||Received Nivolumab|
32801373|NCT03862066||Nivolumab Naive|
32801374|NCT04768023|Other|Control group|The group after 6 weeks of the research will receive placebo treatment.
32801375|NCT04768023|Active Comparator|Control group with physical activity|The group after 6 weeks of the research will receive placebo treatment. The group will be prompt to do 3500-8000 steps per day.
32801376|NCT04768023|Placebo Comparator|Placebo group|The group will receive placebo treatment for all the time of the research.
33309633|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
33309634|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
32801377|NCT04768023|Placebo Comparator|Placebo group with physical activity|The group will receive placebo treatment for all the time of the research. The group will be prompt to do 3500-8000 steps per day.
32801378|NCT04768023|Experimental|Vitamin D3 group|The group will receive vitamin D3 supplementation.
33309635|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
32801379|NCT04768023|Experimental|Vitamin D3 group with physical activity|The group will receive vitamin D3 supplementation. The group will be prompt to do 3500-8000 steps per day.
32801380|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
32801381|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
32801382|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
32801383|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
32801384|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
32801385|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
32801386|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
32801387|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
32801388|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
32801389|NCT04764214|Experimental|3rd generation EGFR-TKI+ SBRT|
32801390|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
32801391|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
32801392|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
32801393|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
32801394|NCT01676194|No Intervention|Control|Usual care
32801395|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
32945202|NCT05526287|Experimental|Dual-Task Group|Participants will receive 8 weeks of dual-task training twice a week and home exercise program.Dual-task training will include motor-motor and motor-cognitive dual-task activities.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
32945203|NCT05526287|Active Comparator|Control Group|Participants will receive 8 weeks of home exercise program.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
32945204|NCT05526053|No Intervention|Standard|SBT: PSV 8 cmH2O, PEEP 0 cmH2O for 30 minutes and, when successful, followed by extubation with continuous suctioning.
32945205|NCT05526053|Experimental|Lung Volume Preservation|SBT: PSV 8 cmH2O, PEEP 5 cmH2O for 30 minutes and, when successful, followed by direct extubation without suctioning and connected to the ventilator with PEEP 5 cmH2O.
32945206|NCT05523869|Experimental|Intravitreal topotecan with pars plana vitrectomy with or without scleral buckle|
32945207|NCT05523869|Active Comparator|Pars plana vitrectomy with or without scleral buckle|
33309636|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
33309637|NCT04868734|Experimental|Supportive Psychotherapy|Supportive Psychotherapy do to subjects
32945210|NCT05523557|Experimental|Urban Training Group|The PA will consist of the following components: motivational interview, exercise following a dossier containing various maps of Urban Training walking trails (at least 30 minutes per day/5 days per week) and use of a Fitbit Inspire (FitBit, San Francisco) and motivational follow-up visit, in group, once per month during the follow-up period.
32945211|NCT05523557|No Intervention|Control Group|The intervention will consist of a general recommendation to perform regular physical activity .
33309638|NCT04868734|No Intervention|Casual Treatment|Do Casual Intervention
33309639|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
32945214|NCT05746325|Experimental|Treatment (TTFields, digital photos)|Patients have transducer arrays applied and digital photographs taken of placement on study. Patients wear the NovoTTF-200T portable system on study. Patients also undergo MRI and may undergo LP during screening and on study.
32945215|NCT05522465|Experimental|prednisone group|prednisone 4mg/kg.d
32945216|NCT05522465|Active Comparator|Dexamethasone|Dexamethasone 0.6mg/kg.d
32945217|NCT05736653|Experimental|Task-specific PCMS, PCMS-rest, Task-specific sham-PCMS|"During Task-specific paired corticospinal-motor neuronal stimulation (PCMS) participants will receive PCMS [Transcranial Magnetic Stimulation (TMS) + Peripheral Nerve Stimulation (PNS)] with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
32945218|NCT05736653|Experimental|Task-specific PCMS, Task-specific sham-PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
32945219|NCT05736653|Experimental|PCMS-rest, Task-specific PCMS, Task-specific sham-PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
32945220|NCT05736653|Experimental|PCMS-rest, Task-specific sham-PCMS, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
32945221|NCT05736653|Experimental|Task-specific sham-PCMS, Task-specific PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
33094538|NCT00470249|Experimental|Patients with (HER-2)-negative and anthracycline- and taxane-resistant|Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant
33094539|NCT04325893|Active Comparator|Hydroxychloroquine|
33094540|NCT04325893|Placebo Comparator|Placebo|
33094541|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
33309640|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
33094542|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
33094543|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
33094544|NCT00601471|Experimental|1|proximal tibiofibular manipulation
33094545|NCT00601471|Experimental|2|distal tibiofibular manipulation
33094546|NCT00601471|No Intervention|3|no treatment
33094547|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
33094548|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
33404541|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
32945222|NCT05736653|Experimental|Task-specific sham-PCMS, PCMS-rest, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
33094549|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
33094550|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
33094551|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
33094552|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
33094553|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
33404542|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
32945223|NCT05248997|Active Comparator|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
32945224|NCT05248997|Active Comparator|Matching Placebo|One dose of matching placebo
32945225|NCT04428047|Experimental|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
32945226|NCT05248061|Active Comparator|Group A|home exercise program
32945227|NCT05248061|Experimental|Group B|PRP+home exercise program
32945228|NCT05237297|Active Comparator|ilaprazole & naproxen|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : naproxen 500mg/tab, twice a day, 4 days and naproxen 500mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + naproxen 500mg/tab, twice a day, 5 days"
32945229|NCT05237297|Active Comparator|ilaprazole & aceclofenac|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
32945230|NCT05237297|Active Comparator|ilaprazole & celecoxib|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : celecoxib 200mg/cap, twice a day, 4 days and celecoxib 200mg/cap, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + celecoxib 200mg/cab, twice a day, 5 days"
32945231|NCT05236127|Experimental|Fasted|Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for the entire 8-day period of the study.
32945232|NCT05236127|Experimental|Pre-heading fasted|Pre-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a 4 hour eating window for a 5-day period prior to the soccer heading.
32945233|NCT05236127|Experimental|Post-heading fasted|Post-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for a 3-day period following the soccer heading.
32945234|NCT05236127|Experimental|Control|Control Group: Individuals randomly assigned to eat per usual over the course of the entire 8-day study period.
33094554|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
33094555|NCT00470405|Experimental|Therapeutic Intervention|
33094556|NCT04207372|Experimental|Whey protein isolate|
33094557|NCT04207372|Experimental|Zein|
33094558|NCT04207372|Placebo Comparator|Protein-free|
32945235|NCT05236127|Active Comparator|Subconcussive Head Impact|"All four groups undergo the same soccer heading model as described below.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by 30 second intervals."
32945236|NCT05233865|Experimental|Water condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing and walking conditions when in a pool.
32945237|NCT05233865|Active Comparator|Land condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing, and walking conditions when on land.
32945238|NCT05230277|Placebo Comparator|The experimental group is defined by the sham osteopathic treatment (SOT)|Patients will receive 3 SOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the SOT. The positions of the patient and the practitioner will be the same as in the AOT group
33094559|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
33094560|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
33094561|NCT00601861|Experimental|A|
33094562|NCT00470444|Active Comparator|1|Liberal transfusion strategy
33094563|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
33094564|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
33094565|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
33094566|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
33094567|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
32801396|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
32801397|NCT03860974|Experimental|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
32801398|NCT03860974|Active Comparator|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
32801399|NCT03860272|Experimental|3-Week Monotherapy|3+3 Dose escalation: botensilimab, every 3 weeks, starting at dose level 0.1 milligrams/kilogram (mg/kg) up to 4 mg/kg, administered intravenously (IV) for up to 2 years.
32801400|NCT03860272|Experimental|6-Week Monotherapy|3+3 Dose escalation: botensilimab, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg, administered IV for up to 2 years.
33094568|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
32801401|NCT03860272|Experimental|6-Week Combination Therapy|3+3 Dose escalation: balstilimab, every 2 weeks, at dose level 3 mg/kg in combination with botensilimab, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg, administered IV for up to 2 years. An additional cohort will investigate balstilimab, every 3 weeks, at 450 mg in combination with botensilimab every 6 weeks, at 150 mg, administered IV for up to 2 years.
33094569|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
32801402|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
32801403|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
32801404|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
32801405|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
32801406|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
32801407|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
32801408|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
32801409|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
32801410|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
32801411|NCT04781517||Short-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments less than 3 was divided into Short-segment group(200).
32801412|NCT04781517||Long-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments no less than 3 was divided into Long-segment group(200).
32801413|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
32801414|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
32801415|NCT03855280|Experimental|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
32801416|NCT01591863|Experimental|fidaxomicin|
32801417|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
32801418|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
32801419|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
32801420|NCT03851380||COVID Stress|Veterans with COVID-19-related distress
32801421|NCT03851302|Experimental|Active RIC + isometric hand exercise|Subjects will receive an active remote ischemic conditioning (200mmHg cuff pressure) before an active isometric hand exercise.
32801422|NCT03851302|Sham Comparator|Sham RIC + isometric hand exercise|Subjects will receive an sham remote ischemic conditioning (10 mmHg below the subjects' diastolic blood pressure) before an active isometric hand exercise.
33094570|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
33094571|NCT00602056|Experimental|1|Redesigned immunization card
33094572|NCT00602056|Experimental|2|Center based education to mothers/caregivers
33094573|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
33094574|NCT00602056|No Intervention|4|Standard care only
32945239|NCT05230277|Experimental|The experimental group is defined by the active osteopathic treatment (AOT)|Patients will receive 3 AOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the AOT.
33094575|NCT00602095|Experimental|1|Labour induction with misoprostol
33309641|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
33309642|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
33309643|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
33309644|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
33309645|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
33309646|NCT03495154|Experimental|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
33309647|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
33309648|NCT00077649|Active Comparator|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
33309649|NCT00077649|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
33309650|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
33309651|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
33309652|NCT03494374|Experimental|treatment group|Treatment with UCBL and exercise therapy
33309653|NCT00038948|Active Comparator|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
33309654|NCT00038948|Active Comparator|B|Continued calcineurin inhibitor therapy
33309655|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
33309656|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
33309657|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
33309658|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
33309659|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
33309660|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
33309661|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
33309662|NCT01096940|Experimental|1|AZD1656
33309663|NCT01096940|Experimental|2|Simvastatin
33309664|NCT01096940|Experimental|3|AZD1656 + simvastatin
33309665|NCT01085019|Experimental|Dietary supplement: Cinnamon|
33309666|NCT01085019|Experimental|Dietary supplement: Oregano|
33309667|NCT01085019|Experimental|Dietary supplement: Ginger|
33309668|NCT01085019|Experimental|Dietary supplement: Rosemary|
33309669|NCT01085019|Experimental|Dietary supplement: Black pepper|
33309670|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
33309671|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
33309672|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
33309673|NCT03953456|Experimental|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
33309674|NCT03953456|Placebo Comparator|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
33309675|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
33309676|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
33094576|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
33309677|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
33309678|NCT01088841|Placebo Comparator|75 g glucose|
33309679|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
33309680|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
33309681|NCT03963921|Experimental|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
32945240|NCT04835675||Cancer Arm|Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
32945241|NCT04835675||Benign Diseases Arm|Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
32945242|NCT05218187|Active Comparator|Conventional Physical Therapy (CPT) Group|CPT sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be provided using traditional over-ground walking. Additional strategies for home exercises, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided. Training will be administered 2 times per week for 40-60 minutes for six weeks.
32945243|NCT05218187|Experimental|Conventional Physical Therapy (CPT) Group with G-EO Training (CPT-GEO)|CPT-GEO sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be administered using end-effector gait training protocols (G-EO trainer). Training will be administered 2 times per week for 40-60 minutes for six weeks.
33309682|NCT03963921|Experimental|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
33309683|NCT01094600|Experimental|Secretin|Single arm (open label).
33309684|NCT02531217|Experimental|ATYR1940|ATYR1940 will be given intravenously at a dose of 3.0 mg/kg, weekly
33309685|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
32945244|NCT05217953|Experimental|Test Group|"The CGM will be integrated with the users mobile handset and all relevant measures taken will be entered. Participant will be provided with a smart watch and this will also be integrated with the users smartphone.~The user will then download and install the LovedBy mobile app. Once installed the user will set up an account and the account number will be recorded by the clinical research team to track the participant throughout the trial. The final step is to review the permissions of the mobile application and allow the mobile application to connect to the users handset"
32945245|NCT05217953|No Intervention|Control-Group|The same measurements will be taken as with the test group but here no app will be provided to the participants in this group.
32945246|NCT05215691||Group I (n=45, TAPA)|The patients who received TAPA block for postoperative analgesia are named as a Group I ( n=45). The TAPA block is performed at the rib margin where the 9th and 10th ribs meet. A linear transducer is placed at the costochondral angle in the sagittal plane. It is carried out by injecting 20 ml of Bupivacaine %0.200 between the upper and lower surface of the chondrium. All patients receive IV PCA with morphine 0.5 mg/ml.
32945247|NCT05215691||Group II (n=45, IV opioid)|The patients who did not prefer the block and preferred intravenous patient-controlled analgesia (PCA) are named as Group II (n=45). IV PCA is prepared with morphine 0.5 mg/ml.
32945248|NCT04831073||Acute type A aortic dissection|Patients who underwent surgery for acute type A aortic dissection
32945249|NCT05204381|Experimental|Theta Stimulation followed by Alpha Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
33094577|NCT00602095|Experimental|3|Labour induction with bard
33094578|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
33309686|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
33309687|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
33309688|NCT03957356|Experimental|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
33309689|NCT03956264|Experimental|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.~If Pain assessed by numerical rating scale (NRS) > 4, administration of morphine."
33309690|NCT03956264|Active Comparator|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.~If Pain NRS > 4, administration of morphine."
33309691|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
33309692|NCT00054704|Experimental|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
32801423|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
32801424|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers"
32801425|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers~Also tobacco consumption will be measured"
32801426|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers~Also Tobacco consumption will be measured"
32801427|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
32801428|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
32801429|NCT03850678|Experimental|Hearing Aid|Group of participants with hearing loss. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels, while manipulating different hearing aid parameters and also without the provision of amplification, will be assessed.
32801430|NCT03850678|No Intervention|Normal Hearing|Group of participants with normal hearing that serve as a reference group. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels will be assessed.
32801431|NCT04773639|Experimental|Multi-Modal Acceptance and Commitment Therapy (M-ACT)|M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions. The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning. The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
32801432|NCT04773639|Other|Control: Usual Care|Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request. After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
32801433|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
32801434|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
32801435|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
33094579|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
33094580|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
33094581|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
33094582|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
32801436|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
32801437|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
32801438|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
33094583|NCT00502125||Patients with oral lesions|
33094584|NCT00475592|Experimental|Capsule Endoscopy|
33404543|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
33094585|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
32801440|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
32801441|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
32801442|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
32801443|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis."
32801444|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
32801445|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:~Expectancy-neutral handout~Expectancy-neutral MP3~Acupressure bands"
32801446|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~Expectancy-enhancing handout~Expectancy-enhancing MP3~Acupressure bands"
32801447|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
32801448|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
32801449|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
32801450|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
32801451|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
32801452|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
32801453|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
32801454|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
32801455|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
32801456|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
32801457|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
32801458|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
32801459|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
32801460|NCT00003460|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32801461|NCT03646786|Experimental|visually impaired patients|
32801462|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
33094586|NCT00502281|Active Comparator|Group A|COS followed by TI
33094587|NCT00502281|Active Comparator|Group B|COS followed by IUI
32801463|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
32801464|NCT03844048|Experimental|Venetoclax|Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
33094588|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
33094589|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
33094590|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
33094591|NCT00470561|Active Comparator|Aspirin|
33094592|NCT00470561|Placebo Comparator|Placebo|
33094593|NCT00470678|Experimental|1|Ranibizumab
33094594|NCT00470756||evertors, invertors|
32801465|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
32801466|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
32801467|NCT04763122||Thyroid Cancer Cases|
32801468|NCT03838510|Experimental|Brief Counseling Intervention|
32801469|NCT03838510|No Intervention|Control Group|
32801470|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
32801471|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
32801472|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
32801473|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
32801474|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
32801475|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
32801476|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
33094595|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
33094596|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
33094597|NCT00470873||Group 1|
33094598|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
33094599|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
33094600|NCT00493623|Experimental|1|
32801477|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
32801478|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
32801479|NCT04762342|Experimental|Training Group Multiple Sclerosis|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance- and functional exercises are included from week 10."
32801480|NCT04762342|No Intervention|Control Group Multiple Sclerosis|Habitual lifestyle including standard care.
32801481|NCT04762342|Experimental|Training Group Healty Control|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance and functional exercises are included from week 10."
32801482|NCT04762342|No Intervention|Control Group Healthy Control|Habitual lifestyle
32801483|NCT04762420||Sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience.|
32801484|NCT04762420||Dose of Sugammadex determined by quantitative monitoring (QSD).|
32801485|NCT04747132|Experimental|Intervention group|Individualized geriatric medical counseling, psychological counseling, nutritional counseling and physical activity counseling through the internet
32801486|NCT04747132|No Intervention|Control group|Health guidance through standardized audiovisual educational material through Intenert
32801487|NCT03642106|Active Comparator|Unidos Se Puede|Unidos Se Puede: consists of 5-weekly Family Workshops, 6 monthly booster sessions, 10-months success coaching, adolescent group activities and will be compared to an attention placebo control.
32801488|NCT03642106|Placebo Comparator|Attention placebo control|Placebo consists of after school club for youth.
32801489|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
32801490|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
32801491|NCT03834142|No Intervention|Control|No intervention, subject receives standard of care
32801492|NCT03833674|Experimental|Adults with incomplete SCI|Adults with chronic, incomplete SCI who have >20% impairment in respiratory function, who will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks (Daily AIH Block, Sham dAIH Block, Respiratory Strength Training Block and AIH + Strength Training Block).
32801493|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
32801494|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
33094601|NCT00493623|Placebo Comparator|2|
33094602|NCT00476060|Experimental|A|
33094603|NCT00476060|Placebo Comparator|B|
33318576|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
33318577|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
33318578|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
33318579|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
32945250|NCT05204381|Experimental|Alpha Stimulation followed by Theta Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
33309693|NCT00054704|Placebo Comparator|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
33309694|NCT01097408|Experimental|AZD7295|
33309695|NCT01097408|Placebo Comparator|Matched placebo|
33309696|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
33309697|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
33309698|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
33309699|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
33309700|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
33309701|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
33309702|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
33309703|NCT01092572|Placebo Comparator|Sugar pill|
33309704|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
33309705|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
33309706|NCT03956966|Placebo Comparator|saline|bilateral quadratus lumborum block using 0.9% normal saline
32945251|NCT05204147|Experimental|Treatment (Ac225-DOTA-M5A)|Patients receive Ac225-DOTA-M5A IV over 25 minutes on day 1.
32945252|NCT04829669||Participants with Major Depressive Disorder (MDD) and Active Suicidal Ideation with Intent|Participants with MDD (moderate or severe) and active suicidal ideation with intent as defined/confirmed by healthcare team will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical chart review, carer and clinician-reported outcome measures records of each participant.
33309707|NCT03956966|Active Comparator|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
33309708|NCT03956966|Active Comparator|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
32945253|NCT04824053|Experimental|UNICLA-A2 milk and its subproducts|Participants (n=17) ingest milk and dairy products made from cows homozygous for beta casein A2 during 3 months. These products are also enriched in insaturated fatty acids and selenium. The daily intake reflects the habitual consumption habits. Recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day.
32945254|NCT04824053|Placebo Comparator|Placebo|"Participants (n=17) ingest conventional dairy products and milk daily during 3 months. As happens in the UNICLA-A2 arm, the daily intake reflects habitual dairy consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day."
32945255|NCT05190653|Experimental|Palliative and Supportive Care Intervention|Participants randomized to the intervention arm will meet (either by phone or Zoom contingent upon participant preference) with a palliative care nurse practitioner or palliative care physician. During the first meeting, pre-transplant/CAR T-cell therapy, content will focus on the provision of information and education, including: a description of palliative and supportive care, symptom management, advance care planning, prognostic and illness understanding and treatment expectations, and coping strategies. All subsequent visits will include, at minimum, these topics. All meetings will be audio-recorded using a handheld audio-recorder; the record feature of Zoom will not be utilized. Participants in the intervention arm will meet with a member of the study team (palliative care nurse practitioner or palliative care physician) one to two times weekly, or more frequently if requested by the patient and/or family caregiver, until 3 months post-transplant/CAR T-cell therapy.
32945256|NCT05190653|No Intervention|Standard Care|Standard care will involve the usual care that patients undergoing HSCT/CAR T-cell therapy would be expected to receive, including palliative care consultation as needed or upon request. Palliative care interventions beyond what are provided in the study will be tracked in both the intervention and the standard care arms.
32945257|NCT04812197|Other|Skin Biopsies|Patients undergo punch biopsies of inflamed and non-inflamed skin and a blood sample collection.
32945258|NCT04811339|Experimental|Open label BSS|All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
32945259|NCT04811339|Placebo Comparator|Randomized BSS or Placebo|The Subsequent 50 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
32945260|NCT04804631||Gastrostomy tube|Prophylactic gastrostomy placed prior to bone marrow transplant.
33309709|NCT03952988|Experimental|Probiotic|
33309710|NCT03952988|Placebo Comparator|Placebo|
33309711|NCT03953222|Experimental|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
33309712|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
33318580|NCT01303484|Placebo Comparator|MDn|Maltodextrin
33094604|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
33094605|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
33094606|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
33094607|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
33094608|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
33094609|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
33094610|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
33094611|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
33094612|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
33094613|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
33094614|NCT00470951|Active Comparator|open rectal resection|conventional open resection
33094615|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
32801495|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
32801496|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
33094616|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
33094617|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
33094618|NCT02956083|Placebo Comparator|Saline|patients use saline
32801497|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
32801498|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
32801499|NCT03833440|Experimental|Durvalumab + Monalizumab|
32801500|NCT03833440|Experimental|Durvalumab + MEDI9447|
32801501|NCT03833440|Experimental|Durvalumab + AZD6738|
32801502|NCT03833440|Active Comparator|Docetaxel|
32801503|NCT03833440|Experimental|durvalumab+savolitinib|
33318581|NCT01303484|Active Comparator|B-GOS|Prebiotic
32801505|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
32801506|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
32801507|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
32801508|NCT01695135|Experimental|Placebo plus prednisone|
32801509|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
32801510|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
32801511|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
32801512|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
32801513|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
32801514|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
32801515|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
32801516|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
32801517|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
33094619|NCT01246440|Experimental|Catumaxomab|
33094620|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
33094621|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
33094622|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
33094623|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
33094624|NCT00502632|Experimental|1|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
33094625|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
33094626|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
33094627|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
33094628|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
33094629|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
33094630|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
33094631|NCT00476255|Experimental|Motivational Intervention|Motivational interview
33094632|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
33094633|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
33094634|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
33309713|NCT03952910|Experimental|Experimental group|Online pain education program will be accessible by the intervention group
32801518|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
32801519|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
32801520|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
33094635|NCT00494052|Experimental|1|Heart to Heart intervention
33094636|NCT00494052|No Intervention|2|Usual care
32801521|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
32801522|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
32801523|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
32801524|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
32945261|NCT04804631||Nasogastric tube|Nasogastric tube placed during admission.
32945262|NCT05173961|Experimental|Supportive Care (oncpatient application, survey)|Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
32945263|NCT05168423|Experimental|Cohort 1|Cohort 1 (N = 3-6): will receive a single fixed dose of 5x107 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
32945264|NCT05168423|Experimental|Cohort -1|Cohort -1 (N = 3-6): will receive a single fixed dose of 1x107 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
33094637|NCT01246518|Active Comparator|MOB015 for 3 months|
33094638|NCT01246518|Active Comparator|MOB015 for 9 months|
33094639|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
33094640|NCT04207294|Experimental|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
33094641|NCT04207294|Placebo Comparator|Control pork|One portion of control pork
33094642|NCT04207294|Active Comparator|Vitamin D supplement|Equivocal dose of Vitamin D supplement
33094643|NCT04207294|Experimental|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
33094644|NCT04207294|Placebo Comparator|Control chicken|One portion of control chicken
33094645|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
33094646|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
33094647|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
33309714|NCT03952910|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
33309715|NCT01094678|Experimental|Stent|
33309716|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
33309717|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
33309718|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
33094648|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
33094649|NCT00476372||Parkinson's disease|Pt with parkinsons disease
33094650|NCT00471224||Patients who have received drug.|Patients who have received drug.
33094651|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
33094652|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
33094653|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
33094654|NCT00494208|Active Comparator|1|
33094655|NCT00494208|Active Comparator|2|
33094656|NCT00494208|Active Comparator|3|
33094657|NCT00494208|Active Comparator|4|
33094658|NCT00494208|Active Comparator|5|
33094659|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
33094660|NCT00502983||Interview|AML Patients & Healthy Controls
33094661|NCT00476411|Experimental|1|HBV vaccine
33094662|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
33094663|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
33094664|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
33094665|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
33094666|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
33094667|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
33094668|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
33094669|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
33094670|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
33094671|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
33094672|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
33094673|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
33094674|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
33094675|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
33094676|NCT05645653|Experimental|Educational treatment|The medication self-management intervention consists of three face-to-face education sessions and two weekly telephone follow-up over 6 weeks. Intervention components are derived from an extensive review of the literature, including the related theoretical framework and current practice. Based on the extended IMB model of medication adherence, this intervention is designed to offer information related to medication treatment, motivate patients to adhere, help build medication self-management skills, and develop adherence improvement plans. The face-to-face meeting will take place in the clinical nurse specialist counselling room in NCCCR.
33094677|NCT05645653|No Intervention|Standard Care|Participants in the control group will continue to receive standard care from Physicians, nurses, and clinical pharmacists in the NCCCR. Physicians are the primary providers and coordinators of care for patients with chronic conditions. Physicians provide patients consultations and education regarding their diseases and treatments (typically clinician-centred) at each patient visit to the chronic disease clinic.
33094678|NCT05645575|Experimental|Open-label TMS|
33094679|NCT05645497||Patient with medical device FACET FIXATION|The FACET FIXATION group include all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to FACET FIXATION from November 2017 (and having more than 2 years postop to date).
33094680|NCT05645497||Patient with medical device Pedicle Screw|The Pedicle Screw group consiste of all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to Pedicle Screw fixation from 2015 to 2016.
33094681|NCT05645458|No Intervention|Control group|Pre-tests will be applied to the caregiver before the patient is discharged, and the first data will be obtained by observing during PEG care. Then, traditional training on PEG care will be given to the patient's relatives. The tests applied after this training will be applied again. Tests and observation forms will be applied in the 1st month and 3rd month after discharge. By making home visit the participant, recording will be video-recorded so that his identity will not be seen while he is doing PEG care, and the recording will be transcribed to the observation form by 2 blinded people other than the researcher.
33309719|NCT03952676|Experimental|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
33309720|NCT03952676|Placebo Comparator|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
33309721|NCT00031694|Experimental|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32801525|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
32801526|NCT04764058|Other|Montherapy|Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours
32801527|NCT04764058|Other|Combination|Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.
32801528|NCT04763824|Active Comparator|cluster-randomized controlled trial, with delayed start control arm|Control arm/Delayed Onset
32801529|NCT04763824|Experimental|cluster-randomized controlled trial, intervention|Intervention arm
32801530|NCT03638674|Active Comparator|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
32801531|NCT03638674|Active Comparator|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
32801532|NCT03638674|Active Comparator|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
32801533|NCT03638674|Active Comparator|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
32801534|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
32801535|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
32801536|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
32801537|NCT03636022|Experimental|VR System|Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.
32801538|NCT03636022|Experimental|Control Condition|Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.
32801539|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
32801540|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
32801541|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
32801542|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
32801543|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
32801544|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
32801545|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
32801546|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
32801547|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
32801548|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
32801549|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
32801550|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
32801551|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
32801552|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
32801553|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
32801554|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
32801555|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
32801556|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
32801557|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
32801558|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
32801559|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
32801560|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
32801561|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
32801562|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
32945265|NCT05168423|Experimental|Cohort 2|Cohort 2 (N = 3-6): will receive a single fixed dose of 1x108 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
32945266|NCT05168423|Experimental|Cohort 3|Cohort 3 (N = 3-6): will receive a single fixed dose of 5x108 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
33094682|NCT05645458|Experimental|experimental group|In addition to maintaining the control group, the experimental group is monitored by installing the mobile application we have developed.
33094683|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
33094684|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
33094685|NCT04325698|Experimental|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
32945267|NCT05167409|Experimental|Evorpacept (ALX148) + cetuximab + pembrolizumab|Evorpacept (ALX148) + cetuximab + pembrolizumab. Evorpacept (ALX148) 15 mg/kg IV weekly, cetuximab 400 mg/m2 once then 250 mg/m2 weekly, and pembrolizumab 200 mg every 3 weeks
33318582|NCT00302159|Experimental|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
33094686|NCT04325698|Active Comparator|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
33094687|NCT00503100||NICU full-term early pain group|
32945270|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
32945271|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
32945272|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
32945273|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
32945274|NCT04798781|Experimental|telatinib + Keytruda|
32945275|NCT04797611|Other|Investigational Treatment 1|Investigational treatment mode (stimulation pattern) 1
32945276|NCT04797611|Other|Investigational Treatment 2|Investigational treatment mode (stimulation pattern) 2
32945277|NCT05413889|Experimental|intervention group (IG)|The IG will consist of placing the Epic 30-day unplanned readmission risk score in the story board of providers - If a patient is identified as having a high risk of readmission defined as readmission risk >20%, a link to transitional and supportive care services (TSC) will be appear in the story board
32945278|NCT05413889|No Intervention|control group (CG)|The CG will have the same transitional and supportive care services (TSC) orders available to them; however, they will not have the risk of readmission score present in their workflow
32945279|NCT04790123|Sham Comparator|Control group|
32945280|NCT04790123|Experimental|Experimental group|
32945281|NCT05409989|Other|Flow Re-Direction Endoluminal Device X|FRED™ X™ device
32945282|NCT05406713|Experimental|Experimental Group|"Cycles 1-2 (Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)~If complete response of treatment is observed then maintenance therapy will be given. All other patients will receive with standard of care local therapy (cystectomy or chemo-radiation) as per their treating physicians followed by adjuvant pembrolizumab.~Cycle 3-9 (Maintenance or Adjuvant Single agent Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)"
32945283|NCT04783415|Experimental|Treatment (ublituximab, acalabrutinib, umbralisib)|"Patients receive ublituximab IV over 90 minutes-4 hours on days 1, 8, and 15 of cycle 1 and days 1 of cycles 2-6. Patients also receive acalabrutinib PO BID and umbralisib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ublituximab IV on day 1 on cycles 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. Patients also receive acalabrutinib Po BID and umbralisib PO QD on day 1-28. Treatment repeats every 28 days for 24 cycles in the absence of disease progression of unacceptable toxicity."
32945284|NCT05406479|Experimental|BE-PEP (Bedaquiline Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Bedaquiline plus Rifampicin
32945285|NCT05406479|Active Comparator|SDR-PEP (Single-Dose Rifampicin Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Rifampicin (WHO recommendation)
32945286|NCT04781543|Experimental|HZN-825 300 mg once daily (QD)|300mg oral tablets given in the morning and placebo in the evening
32945287|NCT04781543|Experimental|HZN-825 300 mg twice daily (BID)|300mg oral tablets given in the morning and evening
32945288|NCT04781543|Placebo Comparator|Placebo|Placebo will be given orally in the morning and evening
32945289|NCT05406323|Experimental|Web-Based Fall Prevention Program Intervention|Participants in this group will receive a 6-week Web-Based Fall Prevention Program intervention, comprising of health education, exercise and safe home environment. Web-Based Fall Prevention Program will be conducted on web based (Web - Based Fall Prevention Program website)
32945290|NCT05406323|No Intervention|Control Group|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is complete.
33094688|NCT00503100||NICU premature early pain group|
33094689|NCT00503100||NICU premature control group|
33094690|NCT00503100||Soroka- full-term control group|
33094691|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
33094692|NCT01324141|Experimental|1/Chemo + Radiation|Chemo + Radiation
33094693|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
33094694|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
33094695|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
33094696|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
32945291|NCT05406011|Experimental|Age groups|Participants grouped by their age (Age group I: patients aged between 18-30, age group II: patients aged between 31-45).
33309722|NCT03953066|Active Comparator|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
33309723|NCT03953066|Active Comparator|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
32945292|NCT05406011|Experimental|Groups by toothbrush change|Half of the group change the toothbrush after scaling and the other half not.
32945293|NCT05406011|Experimental|Experimental period|"Control: Control period without sour cherry chewing gum usage, with saliva sampling on fixed appointments (between 12:00 and 14:00, 0th, 4th and 7th day of the week) of the week. At the beginning oral and basic periodontal examinations performed. Plaque and calculus index at every sampling occasions.~Prevention: After a full mouth scaling sour cherry chewing gum usage, for a week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Therapeutic: Sour cherry chewing gum usage, for one more week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Control (without sour cherry chewing gum usage), prevention and therapeutic periods takes 3 weeks together."
32945294|NCT04767347|Experimental|Fixed Work Rate|Participants will walk on a treadmill at 3 mph and the grade will be adjusted to elicit 430 W of metabolic heat production (the most common work intensity). This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios with increasing environmental heat stress (defined as Wet Bulb Globe Temperature, WBGT) at this fixed rate of metabolic heat production on kidney function.
32945295|NCT04767347|Experimental|Fixed work-to-rest ratio|This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
32945296|NCT05400473|Active Comparator|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
32945297|NCT05400473|Experimental|Therapeutic exercise group + photobiomodulation|This group will consist of 30 participants. Initially, photobiomodulation will be applied on the cervical region. A low-power infrared laser therapy unit (Therapy XT - ANVISA RDC Standard 185/2001 - DMC, São Paulo, SP, Brazil) will be used to carry out the photobiomodulation protocol. The infrared laser therapy unit to be used has the characteristics: continuous optical output of 100 mW, with a wavelength of 808 nm, beam size area of 0.028 cm2, power density 1.78 W/cm2, with 7 Joules per point, with a duration of 70 seconds of application for each point.For application, the individual will be seated. With the cervical region bare, the therapist will position the tip of the laser therapy unit perpendicularly on each of the 12 predefined points along the cervical region (6 points laterally to the right and 6 points laterally to the left).
32945298|NCT04331093|Experimental|resectable stage III-IV Acral melanoma|
32945299|NCT05142917|Experimental|fNIRS based hand motor area real stimulation|Real stimulation is applied to functional brain image-based hand function area (20 minutes) and then hand motor task (20 minutes).
32945300|NCT05142917|Active Comparator|Traditional hand motor area real stimulation|Real stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
32945301|NCT05142917|Sham Comparator|Traditional hand motor area sham stimulation|Sham stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
32945302|NCT04760873|Experimental|Cryotherapy for GAVE|Subjects will undergo cryotherapy for GAVE
32945303|NCT05130047|Experimental|Aldafermin (NGM282)|Aldafermin (NGM282) is an investigational medication. It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids. Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
32945304|NCT05130047|Placebo Comparator|Placebo|A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
32945305|NCT04758767|Experimental|Dose escalation cohort|Monotherapy CID-103. Priming dose will be given for first dose. Dose and duration of infusion dependent on dose cohort and tolerability.
32945306|NCT04758767|Experimental|Dose expansion cohort - pretreated|CID-103 monotherapy at the recommended phase 2 dose
32945307|NCT04758767|Experimental|Dose expansion cohort - Naïve|CID-103 monotherapy at the recommended phase 2 dose
32945308|NCT05124977|Experimental|Experimental group|Antimicrobial stewardship based on daily clinical assessment of clinical cure (experimental group). Discontinuation of antibiotic therapy antibiotics if criterions of clinical cure (regression of tracheal secretions, regression of temperature, improvement of PaO2/FiO2 ratio, absence of hemodynamic failure) of confirmed VAP are met. In the intervention group, intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
32945309|NCT05124977|Other|Control group|Standard management: duration of appropriate antibiotic therapy for confirmed VAP according to guidelines. In the control group, intensivists will perform clinical assessment daily, but a minimum duration of 7 days, as highly recommended of antibiotic therapy will be mandatory whatever the clinical cure.
32945310|NCT05122637|Experimental|Treatment Arm|RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.
33094697|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
32945311|NCT05122637|Other|Control Arm|Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.
33404544|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
33404545|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
33094698|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
33094699|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
33094700|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
33094701|NCT00476567|Active Comparator|control|standard antenatal care
33094702|NCT00471614|Experimental|1|NucleomaxX
33094703|NCT00471614|Placebo Comparator|2|Placebo
33094704|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
33094705|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
33094706|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
33094707|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
33094708|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
32945312|NCT05120297|Experimental|AK101|
32945313|NCT05120297|Placebo Comparator|Placebo|
32945314|NCT05116241|Experimental|BPZE1 intranasal and Placebo intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular placebo.
32945315|NCT05116241|Experimental|BPZE1 intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular Boostrix (acellular pertussis [aP] vaccine).
32945316|NCT05116241|Active Comparator|Placebo intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of placebo via the mucosal atomization device and a dose of intramuscular Boostrix (aP vaccine comparator).
32945317|NCT05106881|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
32945318|NCT05386043|Other|Baseline Imaging and Biopsy|Subjects will receive a PET-CT with the radiopharmaceuticals FET and O-15 Water (under RDRC approval for basic research) prior to their standard of care neurosurgery via stereotactic core biopsy. Research samples will be collected for analysis intraoperatively.
32945319|NCT04740359|Active Comparator|Control|Routine training; mat exercises and perturbation training
32945320|NCT04740359|Experimental|Study|Trunk training; Functional training, mat exercises and perturbation training
32945321|NCT05105555||Healthy controls|In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.
32945322|NCT05105555||Vaping teenagers|Vaping teenagers will be recruited independently from the BILD study through advertisements and visits to Bernese schools.
32945323|NCT05104541|Experimental|Intervention Arm|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein, and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
32945324|NCT04739423|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
32945325|NCT04739423|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 co-administered with matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
32945326|NCT05098145|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood cells and delivered as a single infusion with a nonmyeloablative conditioning regimen.
32945327|NCT05095727|Experimental|mRNA-3745|Participants will receive a single IV dose of mRNA-3745 on Day 1. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may receive one or more doses in subsequent cohorts (intrapatient dosing). The next dose must occur at least 21 days after the previous one.
32945328|NCT04724291|Other|MAGNET + EGD|Capsule endoscopy followed by traditional endoscopy
32945329|NCT04712825|Active Comparator|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions
32945330|NCT04712825|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis sessions
32945331|NCT05361551|Experimental|Liver ablation|The ablation procedure will be performed in 1 day
32945332|NCT04713215||Patients where MCAs are currently being used|Intervention: Patient questionnaire - Part A - patients where MCAs are currently being used
33094709|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
33094710|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
33094711|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
33094712|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
33309724|NCT03953066|Active Comparator|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
33309725|NCT03957044|Experimental|sensory integration group|This group was given the education of sensory integration with vestibular education.
33309726|NCT03957044|No Intervention|Control group|The control group was given the education of sensory integration without vestibular education.
33309727|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
33309728|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
32945333|NCT04713215||Patients where an MCA was discontinued|Intervention: Patient questionnaire - Part B - patients where an MCA was discontinued
33309729|NCT03952754|Experimental|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
33309730|NCT03952754|Active Comparator|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
33309731|NCT01097798|Experimental|Aliviador|
33309732|NCT01097798|Active Comparator|Gelol|
33309733|NCT00093795|Active Comparator|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
33309734|NCT00093795|Active Comparator|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
33309735|NCT00093795|Experimental|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
33309736|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
32945334|NCT04713215||Patients where an MCA was declined|Intervention: Patient questionnaire - Part C - patients where an MCA was declined
32945335|NCT04713215||Carers where MCAs are currently being used|Intervention: Carer questionnaire - Part A - carers where MCAs are currently being used
32945336|NCT04713215||Carers where an MCA was discontinued|Intervention: Carer questionnaire - Part B - carers where an MCA was discontinued
32945337|NCT04713215||Carers where an MCA was declined|Intervention: Carer questionnaire - Part C - carers where an MCA was declined
32945338|NCT04678271|Experimental|AFIX-OB Intervention Arm|Practices randomized to this arm will choose from a suite of quality improvement interventions that address patient, provider, and practice-level factors relating to maternal vaccination.
32945339|NCT04678271|No Intervention|Control Arm|Practices randomized to this arm will continue to provide their normal standard of care to pregnant patients at their practice.
32945340|NCT05087849|Experimental|Intralesional injection of nonavalent human papillomavirus vaccine|Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.
32945341|NCT05082857|Active Comparator|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others. The study team will collect baseline data during the first home visit and complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
32945342|NCT05082857|Experimental|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking. Young moms will participate in Group Connections for peer interactions and support. After completing the six-week course, teens will begin receiving once a month home visits, ongoing Group Connections, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to other community agencies and resources, as listed above. The study team will collect baseline data prior to the beginning of the virtual What You Do Matters program and will complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
32945343|NCT05075837|Experimental|Virus-specific T cells for the treatment of active viral infections following allogeneic HSCT.|Virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT)
32945344|NCT05350865||HDV cohort|Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI >1.5, FIB-4 > 3.25, Fibroscan > 12.5, imaging), PWID with HBV, HIV/HBV, HBV/HCV, aged 18 years and older
32945345|NCT05343455|Experimental|DFD-29|DFD-29 (40 mg) extended release capsules
32945346|NCT05343455|Active Comparator|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
32945347|NCT05343455|Placebo Comparator|Placebo|Placebo capsules matching DFD-29
33309737|NCT03952442|Active Comparator|control group|
33309738|NCT03952442|Experimental|experimental group|
33309739|NCT03467152|Experimental|Irsenontrine|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of Irsenontrine for 12 weeks.
33309740|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of Irsenontrine-matched placebo for 12 weeks.
33309741|NCT01094834|Experimental|DWP05195|
33309742|NCT01097876|Experimental|Active PF-04447943|
33309743|NCT01097876|Placebo Comparator|Placebo PF-04447943|
33309744|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
33309745|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
33309746|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
32945348|NCT05335811|Experimental|4-[18F]Fluoro-1-Naphthol|Participants will receive 1 injection of [18F]4FN
33094713|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
33094714|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
33094715|NCT00503334|Experimental|preOP booster|
33094716|NCT00503334|Placebo Comparator|preOP booster placebo|
33094717|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
33094718|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
32945349|NCT05333939|Experimental|Moringa|4 g moringa leaf powder in green capsules divided into 4 capsules twice daily x 28 days
32945350|NCT05333939|Placebo Comparator|Control|comparable weight green capsules with cornstarch divided into 4 capsules twice daily x 28 days
33094719|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
33094720|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
33094721|NCT00503451|Experimental|LBH589|
32945351|NCT04673357|Experimental|Open- Label Ustekinumab Intravenous (IV): Induction Period|All participants will receive a single IV administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
32945352|NCT04673357|Experimental|Ustekinumab Subcutaneous (SC) Every 8 Weeks (q8w): Maintenance Period|Participants will receive SC administration of ustekinumab q8w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at maintenance weeks (Weeks M)-0, M-8, M-16, M-24, M 32, and M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
32945353|NCT04673357|Experimental|Ustekinumab SC Every 12 Weeks (q12w): Maintenance Period|Participants will receive SC administration of ustekinumab q12w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
32945354|NCT05069831|Active Comparator|Abrocitinib 100mg|This arm will receive 100mg of the study drug
32945355|NCT05069831|Active Comparator|Abrocitinib 200mg|This arm will receive 200mg of the study drug
32945356|NCT05068583||Osteosarcoma|
32945357|NCT05068583||Ewing Sarcoma|
32945358|NCT05068583||Rhabdomyosarcoma|
32945359|NCT05068583||Synovial Sarcoma|
32945360|NCT05068583||Non-Rhabdomyosarcoma Soft Tissue Sarcoma|
32945361|NCT05068583||Hepatic Tumors|
32945362|NCT05068583||Renal Tumors|
32945363|NCT05068583||Thyroid Tumors|
32945364|NCT05068583||Germ Cell Tumors|
32945365|NCT05068583||Healthy Volunteers|
32945366|NCT04658849|Experimental|Pioglitazone Arm|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
32945367|NCT04658849|Placebo Comparator|Placebo Arm|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
32945368|NCT05057429|Experimental|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
32945369|NCT05057429|Experimental|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
32945370|NCT05049863|Experimental|Phase I Dose Level 1: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at 100 mg/m^2 on Days 1 and 8. Cycles are 21 days.
32945371|NCT05049863|Experimental|Phase II: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
32945372|NCT05047523|Experimental|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
32945373|NCT05047523|Active Comparator|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
32945374|NCT04652453|Experimental|Post-Intervention Group (Geriatrics Bundle)|Enrolled participants in the intervention arm will receive all 3 components of the geriatrics bundle: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
32945375|NCT04652453|No Intervention|Pre-Intervention Group (Control)|Participants in the control arm will be enrolled prior to implementation of the geriatrics bundle to gather preliminary data about the secondary outcomes.
32945376|NCT05314517|Experimental|Treatment Arm 1|Namilumab
32945377|NCT05314517|Placebo Comparator|Treatment Arm 2|Placebo
32945378|NCT05312255|Experimental|Module A (strength training, behavioral intervention)|Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.
33094722|NCT00503490|Experimental|1|Inhaled Levofloxacin
33094723|NCT00503490|Placebo Comparator|2|Placebo
33094724|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
33094725|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
33094726|NCT04696965|Experimental|Correct/recheck strategy|Patients of study arm will be asked to show how they use their two inhalers and identify errors using a device-specific checklist by research assistant. Research assistant then show the patient how to use these devices correctly and give the checklist including the steps patients did wrong. After teaching by the research assistant, patients were asked to demonstrate the correct way of wrong step(s) they made at beginning.
32945379|NCT05312255|Experimental|Module B (intermittent fasting)|Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.
33309747|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
32945380|NCT05312255|Experimental|Module C Group I (propranolol)|Patients receive propranolol PO BID for 3 months.
32945381|NCT05312255|Active Comparator|Module C Group II (propranolol)|Patients continue receiving beta-blocker regimen as per SOC for 3 months.
32945382|NCT04632485||Aim 1: Ultrasound Only|Approximately 280 asymptomatic participants will participate in ultrasound (US) studies and blood work.
32945383|NCT04632485||Aim 2: Ultrasound and MRI|A sub-group of 40 at risk volunteers determined from the clinical ultrasound scans and bloodwork from Aim 1 will be asked to participate in a longitudinal US and MRI study. Participants will be selected from a population of individuals that do not have significant atherosclerosis, but present with increased risk due to the presence of soft, lipid rich plaque that are hypoechogenic or echolucent on ultrasound B-mode images. These participants may also satisfy the current clinical guidelines of increased vessel diameter and decreased blood flow velocity with ultrasound that may result in plaque deposition for being in the at risk population. Participants will receive US, strain and shear wave imaging every 2 years after the first scan in Aim 1 and MRI Imaging in Year 1 and Year 5: separated by 4 years
32945384|NCT05043701|Experimental|Treatment|Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro
32945385|NCT05040581|Experimental|Experimental Group - 1 Day CBT|"The intervention is a 6-hour long CBT-based workshop. Cognitive behavioural therapy is a structured psychotherapy based on the cognitive theory of depression that posits that negative thoughts about the self, others and the future can lead to and perpetuate depressed mood states. CBT equips participants with skills that enable them to identify and modify distortions in their thinking that lead to depressed mood and maladaptive behavioural responses.~The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning."
32945386|NCT04281719|Experimental|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
32945387|NCT05034341|Experimental|Multimodal Prehabilitation Arm|"The Multimodal Prehabilitation group will receive:~An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to a home exercise program. Patients' compliance will be monitored by phone each week.~Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar-free.~Pain and Neuroscience Education: Per University of Florida Health Pain and Neuroscience program at Shands hospital.~Standard Clinical Care: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with a focus on preoperative cognitive assessment."
32945388|NCT05034341|Active Comparator|Standard Clinical Care Comparison Arm|"The Standard Clinical Care Comparison group will receive:~Education related to preoperative activity and home based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.~A final preoperative visit before surgery where a second set of functional assessment will be implemented"
32945389|NCT04615325|Experimental|Single Ascending Dose Stage|Participants will receive a single dose of RO7303359, in multiple escalating cohorts (A-D).
32945390|NCT04615325|Experimental|Expansion Cohort Stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
32945391|NCT04615325|Experimental|Optional Cohort E|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
32945392|NCT04615325|Experimental|Optional cohort F|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
32945393|NCT05015621|Active Comparator|study group|all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first
32945394|NCT05015621|Other|control group|FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m^2 continuously iv drip for 46～48 hours.
32945395|NCT05007509|Experimental|COVID-19 vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
32945396|NCT05007509|Active Comparator|Commercial COVID-19 vaccine|Subjects will receive 2 injections of commercial COVID-19 vaccine administered 21 days apart.
32945397|NCT04999085|Experimental|Supportive Care|
32945398|NCT04997057|Other|Probiotics mixture|Daily supplementation with a mixture of probiotics for 12 weeks
32945399|NCT05289167|Experimental|Participants with hematological malignancies|Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.
32945400|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
32801563|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
33094727|NCT04696965|Active Comparator|Usual verbal instruction|Patients of control arm will be asked to show how thy use their two inhalers and identify errors using specific check list by research assistant. The educational nurse will give verbal instruction.
33094728|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
33094729|NCT00471965|Active Comparator|B|Doxorubicin
33094730|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
33094731|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
33094732|NCT00494715|Experimental|Benazepril|
33094733|NCT00494715|Experimental|valsartan|
33094734|NCT00494715|Experimental|benazepril/valsartan|
33094735|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
33094736|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
32801564|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
32801565|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
32801566|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
32801567|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
32801568|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
32801569|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
32801570|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
32801571|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
32801572|NCT03825796|Experimental|Treatment (CPX-351, enasidenib mesylate)|See detailed description
32801573|NCT01676974||Travelers|Travelers and their family members
32801574|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
32801575|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
33094737|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
33094738|NCT01323946|Experimental|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
33094739|NCT01323946|Experimental|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
33094740|NCT01323946|Experimental|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
33094741|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
33094742|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
32801576|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
32801577|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
32801578|NCT03629470|Active Comparator|Group 1|standard conservative treatment
32801579|NCT03629470|Experimental|Group 2|nerve gliding exercises along with the standard conservative treatment.
32801580|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
32801581|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
33094743|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
33094744|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
33094745|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
33094746|NCT01246596|Active Comparator|chronic periodontitis|
33094747|NCT01246596|Active Comparator|aggressive periodontitis|
33094748|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
33094749|NCT00472121||1: AMG|
33094750|NCT00472121||2: MMG|
33094751|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
33094752|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
33094753|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
33094754|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
33094755|NCT00472160|Experimental|1|Non Invasive Ventilation
33094756|NCT00472238|Experimental|1, Training|Group for training therapy
33094757|NCT00472238|Active Comparator|2, Control|
33094758|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
33309748|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
33309749|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
33309750|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
33309751|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
33094759|NCT01323790|Experimental|1|Oral treatment
33094760|NCT01323790|Experimental|2|Oral treatment
33094761|NCT01323790|Placebo Comparator|3|Oral treatment
33309752|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
33309753|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
33309754|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
33094762|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
33094763|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
33309755|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
33309756|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
33094764|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
33094765|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
33309757|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
33309758|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
33094766|NCT01323673|Placebo Comparator|Vehicle|
33094767|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
33094768|NCT00494949|Active Comparator|Control|Ringer's lactate
33094769|NCT05645341||Eligible participants for smartphone-based ocular surface tumors diagnosis|
33094770|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
33309759|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
33309760|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
33309761|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
33309762|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
33309763|NCT00092547|Experimental|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
33094771|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
33309764|NCT00092547|Placebo Comparator|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
33309765|NCT00092547|Experimental|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
33309766|NCT03802994|Experimental|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
33094772|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
33094773|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
33094774|NCT05645302||Patients using Lidocaine Cataplasms|
33094775|NCT01323478|Experimental|Vortioxetine|
33094776|NCT04325581|Experimental|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
33094777|NCT04325581|Placebo Comparator|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
33094778|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
33094779|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
33309767|NCT03802994|Active Comparator|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
33309768|NCT03802994|Active Comparator|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
33309769|NCT03802994|Active Comparator|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
33309770|NCT03802994|Experimental|5.Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
33309771|NCT01088919|Experimental|Dosing Regimen 1|
33309772|NCT01088919|Experimental|Dosing Regimen 2|
33309773|NCT01088919|Experimental|Dosing Regimen 3|
33309774|NCT01088919|Experimental|Dosing Regimen 4|
33309775|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
33309776|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
33309777|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
32945401|NCT04330547|Active Comparator|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):~Level 1 : Non-opioid analgesics~Level 2 : Weak opioids analgesics~Level 3 : Strong opioids analgesics~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
33309778|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
33309779|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
33309780|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
33318583|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
33404546|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
33404547|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
32945402|NCT04330547|Placebo Comparator|Placebo administration|Folavit capsules will be used as a placebo
32945403|NCT04609943|Experimental|BAY1211163|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163.
32945404|NCT05286515|Experimental|Hybrid Preoperative Physical Therapy (PT)|
32945405|NCT05286515|Active Comparator|Control Standard Physical Therapy (PT)|
32945406|NCT04990427|Experimental|CLBS201|CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
32945407|NCT04987307|Experimental|Arm A: Efavaleukin alfa|Efavaleukin alfa Dose 1 administered by SC injection once every two weeks (Q2W)
32945408|NCT04987307|Experimental|Arm B: Efavaleukin alfa|Efavaleukin alfa Dose 2 administered by SC injection Q2W
32945409|NCT04987307|Experimental|Arm C: Efavaleukin alfa|Efavaleukin alfa Dose 3 administered by SC injection Q2W
32945410|NCT04987307|Placebo Comparator|Arm D: Placebo|Placebo Q2W
32945411|NCT04581785|Experimental|Dose Level 1 Part A|3 year-olds to 12 year-olds
32945412|NCT04581785|Experimental|Dose Level 1 Part B|6 month to 2 year-olds
32945413|NCT04581785|Experimental|Dose Level 1 Part C|6 month to 12 year-olds
32945414|NCT04581785|Experimental|Dose Level 2 Part A|3 year-olds to 12 year-olds
32945415|NCT04581785|Experimental|Dose Level 2 Part B|6 month to 2 year-olds
32945416|NCT04977167|Experimental|Part 1:HG146 Monotherapy, Dose-escalation Cohort|Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
32945417|NCT04977167|Experimental|Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort|"Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.~Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated."
32945418|NCT04977167|Experimental|Part 2B-1：HG146 combination Expansion Cohort 1|Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
32945419|NCT04977167|Experimental|Part 2B-2：HG146 combination Expansion Cohort 2|Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
32945420|NCT04972799|Experimental|Treatment/Placebo|treatment sequence at day 0 and placebo sequence at 6 months
32945421|NCT04972799|Experimental|Placebo/Treatment|placebo sequence at day 0 and treatment sequence at 6 months
32945426|NCT05273177||CAI group|
32945427|NCT05273177||Control group|
32945428|NCT05269355|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin 300 milligrams (mg) tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/meter squared (m^2) intravenously (IV) once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
32945429|NCT05269355|Placebo Comparator|Placebo and Dacarbazine|Participants will receive placebo matching to unesbulin tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/m^2 IV once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
33094780|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
33094781|NCT05645263|Experimental|Cola 1（3d）|The patients in intervention group 1 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 3 days.The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
33094782|NCT05645263|Experimental|Cola 2（5d）|The patients in intervention group 2 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 5 days. The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
33094783|NCT05645263|Experimental|Cola 3（7d）|The patients in intervention group 3 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 7 days. The patients will go through an endoscopy once the Coco-cola dieting therapy is over.
33094784|NCT05645263|No Intervention|Fragmentation 1|The patients who chose emergently endoscopic fragmentation was enrolled in control group 1. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
33094785|NCT05645263|No Intervention|Fragmentation 2|The patients who chose emergently endoscopic fragmentation was enrolled in control group 2. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
33094786|NCT05645263|No Intervention|Fragmentation 3|The patients who chose emergently endoscopic fragmentation was enrolled in controlled Group 3. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
33094787|NCT04325776|Experimental|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
33094788|NCT04325776|Active Comparator|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
33094789|NCT03276845|Other|1|
33094790|NCT01322386|Experimental|Oral Vancomycin|Vancocin
33309781|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
32801582|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
33094791|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
33094792|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
33094793|NCT00477308|Other|salvage therapy|Children with drug resistance were treated using the drug resistant profile
33094794|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
33094795|NCT01246908|Placebo Comparator|Placebo|
33094796|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
33094797|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
33309782|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
33309783|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
33309784|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
33309785|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
33309786|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
33309787|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
33404548|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
33094798|NCT00472472|Placebo Comparator|1|PTA
33094799|NCT00472472|Active Comparator|2|PTA with Paccocath
33094800|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
33094801|NCT00477347|Active Comparator|1|Manual administration
33309788|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
32945430|NCT04482959|Experimental|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
33309789|NCT01584050|Active Comparator|L-MTHF|
33309790|NCT01584050|Active Comparator|folic acid|
32945431|NCT04482959|Placebo Comparator|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
33309791|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
33309792|NCT01310608|Experimental|A-View|
33309793|NCT01310608|No Intervention|No A-View|
33309794|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
32945432|NCT04581395|Other|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
32945433|NCT04581395|Active Comparator|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
33309795|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
32945434|NCT04581395|Active Comparator|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
33309796|NCT03952832|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33309797|NCT01311076|Experimental|TAK-329 50 mg|
33309798|NCT01311076|Experimental|TAK-329 200 mg|
32945438|NCT04579445||TAVI patients|Consecutive, severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent TAVI; and a prospective part enrolling 50 patients undergoing TAVI)
32945439|NCT04571879|Experimental|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
32945440|NCT04571879|Experimental|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
32945441|NCT04571879|Placebo Comparator|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
32945442|NCT04563533|Experimental|adults of phase I|Healthy people aged 18-59
32945443|NCT04563533|Experimental|teenagers of phase I|Healthy people aged 6-17
32945444|NCT04563533|Placebo Comparator|elderly of phase I|Healthy people 60 years old and above
32945445|NCT04563533|Experimental|Toddler of phase I|Healthy people aged 2-5
32945446|NCT04563533|Placebo Comparator|Infants of phase I|6 weeks old-2 years old healthy person
32945447|NCT04563533|Experimental|elderly of phase II|Healthy people 60 years old and above
32945448|NCT04563533|Placebo Comparator|Toddler of phase II|Healthy people aged 2-5
32945449|NCT04563533|Experimental|Infants of phase II|6 weeks old-2 years old healthy person
32945450|NCT05255393||Standard lymphadenectomy(LND) with sentinel lymph node mapping (SLN)|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
32945451|NCT05255393||Standard lymphadenectomy(LND) alone|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
32945452|NCT05251259|Experimental|Lead-in PK Cohort (AZD5718 Dose A)|Randomised participants will receive AZD5718 dose A
32945453|NCT05251259|Experimental|Part 1: AZD5718 Dose A|Randomised participants will receive AZD5718 Dose A
32945454|NCT05251259|Experimental|Part 2: AZD5718 Dose A|Randomised participants will receive AZD5718 Dose A
32945455|NCT05251259|Experimental|Part 2: AZD5718 Dose B|Randomised participants will receive AZD5718 Dose B
32945456|NCT05251259|Experimental|Part 2: AZD5718 Dose C|Randomised participants will receive AZD5718 Dose C
32945457|NCT05251259|Active Comparator|Part 2: Montelukast Dose X|Participants will receive montelukast dose X
32945458|NCT05251259|Placebo Comparator|Lead-in PK, Part 1 and Part 2 Placebo|Randomised participants will receive placebo
32945459|NCT04330937|Experimental|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
33309799|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
33309800|NCT01311076|Placebo Comparator|Placebo|
33309801|NCT01095068|Experimental|physical exercise|Physical exercise
33309802|NCT01098656|Experimental|lenalidomide|
33309803|NCT01098656|No Intervention|Observation|
32945460|NCT04330937|Placebo Comparator|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
32945461|NCT04940039|Experimental|Paliperidone Palmitate|Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their usual clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
33309804|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
32945462|NCT04939961|Experimental|Hericium erinaceus|8 gram of mushroom Hericium erinaceus (containing 5 milligram of erinacines) per day
32945463|NCT04939961|Placebo Comparator|Placebo capsule|8 gram of allergen free corn starch per day
32945464|NCT04545515|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
32945465|NCT04358705|Experimental|Young Cigarillo User (YCU) Sample|"Aim 1: Online survey. 392 participants from the full YCU sample~Supplemental Aim 1: A sample of 196 heterosexual females from the Aim 1 survey will be compared to the SGM females~Aim 2: Eye tracking activity - A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 cigarillo users will be accrued from YCU sample participants who participated in Aim 1 and live in the Cleveland, Ohio~Aim 3: (A total of 162 participants from Aim 1 survey). Consists of the Online Electronic Tobacco Marketplace (ETM) and the aim 3 survey components in the following order:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)~A sample of 88 heterosexual females from the 162 Aim 3 participants will be compared with 88 SGM participants from supplemental Aim 1"
32945466|NCT04358705|Experimental|Sexual and Gender Minority (SGM) Female Cigarillo Users|"Supplemental Aim 1: An online convenience sample of 196 SGM females will complete the Aim 1 online survey and will be compared to sample of 196 heterosexual females from the YCU sample~Supplemental Aim 3: (88 SGM females who participated in the Supplemental Aim 1 survey). Consists of the ETM and the aim 3 survey components in the following order:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)"
32945467|NCT04358705|Experimental|Aim 2 - Non-cigarillo users|"Aim 2: (Eye tracking activity)~A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 non-cigarillo users will be accrued by means of social media posts and flyers at places that youth most likely frequent"
32945468|NCT04358705|Other|Cognitive interview|Separate population of participants (n=29) who were a mix of cigarillo users, dual e-cigarette and cigarillo users, e-cigarette users, and non-users. The cognitive interviews informed the Aim 1 survey
32945469|NCT04509791|Placebo Comparator|placebo|placebo arm
32945470|NCT04509791|Active Comparator|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
32945471|NCT04509791|Active Comparator|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
32945472|NCT04509791|Active Comparator|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
32945473|NCT04509791|Active Comparator|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
32945474|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
32945475|NCT04332107|Placebo Comparator|Placebo|Matching placebo
33094802|NCT00477347|Experimental|2|Closed-loop administration
33094803|NCT01244568|No Intervention|Usual care|
33094804|NCT01244568|Experimental|Prostate cancer treatment DESI|
33309805|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
33309806|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
33309807|NCT01093118|Experimental|TMI-358|Active treatment
33309808|NCT01093118|Placebo Comparator|MMI-467|
33309809|NCT03956108|Experimental|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
33309810|NCT03956108|Active Comparator|Systematic biopsies|PSA+systematic biopsies
33309811|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
33309812|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
33309813|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
33309814|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
33309815|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
33309816|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
33309817|NCT03963999|Experimental|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
33309818|NCT03955796|Experimental|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
33309819|NCT03955796|Experimental|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
33094805|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
33094806|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
33094807|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
33094808|NCT01244607|Placebo Comparator|Placebo|
33094809|NCT01244607|Experimental|NI-0801|
33094810|NCT00472589||1|Healthy women
33094811|NCT00472589||2|Women with breast cancer
33094812|NCT01244646||1|Patients with Diabetes Mellitus Type 2
33094813|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
33094814|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
33094815|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
33094816|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
33309820|NCT03963765|Active Comparator|Group I (Standard DL-PDT)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
32801583|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
32801584|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
33309821|NCT03963765|Experimental|Group II (DL-PDT with microneedles)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
33309822|NCT03963765|Experimental|Group III (DL-PDT with CO2 laser)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass~A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
33404549|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
33404550|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
33094817|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
33094818|NCT00472667|Experimental|1|Procalcitonin guided strategy
33094819|NCT00477581|Experimental|Sequence A|
33094820|NCT00477581|Experimental|Sequence B|
32801585|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
32801586|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
32801587|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
33094821|NCT00503802|Active Comparator|1|Active RF treatment
33094822|NCT00503802|Sham Comparator|2|Sham RF treatment
33094823|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
33094824|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
33094825|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
33094826|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
33094827|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
33094828|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
33094829|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
33094830|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
33094831|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
33094832|NCT01247142||Controls|Patients without signs of infection.
33094833|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
33094834|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
33094835|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
33094836|NCT01247181|Experimental|Mobile phone text message|
33094837|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
33094838|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
33094839|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
33094840|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
33094841|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
33094842|NCT01247259|Active Comparator|SLIT-mono|
33094843|NCT01247259|Active Comparator|SLIT-poly|
33094844|NCT00477893|Placebo Comparator|Placebo|
33404551|NCT04729192||Intervention|The patients will complete the ObsQoR-10T questionnaire on day 1 following delivery
32801588|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
33094845|NCT00477893|Active Comparator|Adalimumab|
33094846|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
33094847|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
33094848|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
33094849|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
33094850|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
33094851|NCT01247337|Experimental|Single arm chemotherapy treatment|
33094852|NCT00478049|Active Comparator|1|Docetaxel
32801589|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
32801590|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
32801591|NCT03820726|Experimental|All subjects|
33094853|NCT00478049|Experimental|2|Gefitinib
33094854|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
33094855|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
33094856|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
33094857|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
33094858|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
33094859|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
33094860|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
32801592|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
32801593|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
32801594|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
32801595|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
32801596|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
32801597|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
32801598|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
32801599|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
32801600|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
32801601|NCT04403854||Healthy Controls|Age and sex matched healthy controls
32801602|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
32801603|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
32801604|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
32801605|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
32801606|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
32801607|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
32801608|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
32945476|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32945477|NCT04328285|Experimental|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
32945478|NCT04328285|Experimental|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
32945479|NCT04308473|Experimental|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
32945480|NCT04308473|Experimental|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
32945481|NCT04308473|Experimental|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
32945482|NCT04308473|Experimental|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
32945483|NCT04928261|Experimental|De-escalated HER2 targeted treatment|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery.
32945484|NCT04925375|Experimental|Abatacept|"Pediatric subjects weighing <50 kg will be placed in an single arm with abatacept with dosing based on weight. Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26.~Pediatric dosing:~Abatacept subcutaneous every week:~10-25 kg: 50 mg; 25-50 kg: 87.5 mg; >50 kg: 125 mg~Adult dosing:~Abatacept: 125 mg subcutaneous every week"
32945485|NCT04925375|Placebo Comparator|Placebo|Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26. The composition of the placebo is the same as the active study drug without the abatacept. To maintain the blind, injection volumes will be the same as the active treatment.
32945486|NCT04920539|Experimental|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
32945487|NCT04911881|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
32945488|NCT04906187|Experimental|Arm A : Experimental group with intraoperative ANI monitoring of nociception|
32945489|NCT04906187|Other|Arm B : Control group without ANI intraoperative monitoring of nociception|
32945490|NCT04354493|Experimental|Baseline and Training|This group consists of a baseline and training conditions only.
32801611|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
32801612|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
32801613|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
32801614|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
33094861|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
33094862|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
33094863|NCT01247454|Other|academic detailing|All arms will receive this intervention
33094864|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
33094865|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
33094866|NCT00478322|Experimental|INCB013739|
32801615|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
32801616|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
32801617|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x -HCs/"
32801618|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
33094867|NCT00478322|Placebo Comparator|Matching Placebo|
32801619|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
32801620|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
32801621|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
32801622|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
32801623|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
32801624|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
32801625|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
32801626|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
32801627|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
32801628|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
32801629|NCT03807154|No Intervention|Wait-list|Wait-list control group
32801630|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
32801631|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
33094868|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
33094869|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~No history of TBI~Must have an informant (friend, spouse, child etc.)"
33094870|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
33094871|NCT00478400||US Veterans with No history of TBI|"No history of TBI~Must have an informant (friend, spouse, child etc.)"
33094872|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
33094873|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
33094874|NCT00478439|Placebo Comparator|Placebo Comparator|
33094875|NCT04325425|Experimental|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
33094876|NCT04325425|Active Comparator|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
33094877|NCT04512066|Experimental|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
32801632|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
32801633|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
33094878|NCT04512066|Experimental|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
33094879|NCT04512066|Placebo Comparator|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
33404552|NCT04696822|Experimental|Adults with seasonal allergic rhinitis|Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.
32801634|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)~All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry~6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
32801635|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
32801636|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
32801637|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
32801638|NCT00003820|Experimental|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
32801639|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
32801640|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
32801641|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
32801642|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
32801643|NCT00003910|Experimental|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
32801644|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
32801645|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
32801646|NCT01588353|Experimental|AK160 0.58 mg|
32801647|NCT01588197|Experimental|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
32945491|NCT04354493|Experimental|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
32945492|NCT04903457|Experimental|Real stimulation before motor learning training|Patients receive five sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
32945493|NCT04903457|Active Comparator|Sham stimulation before motor learning training|Patients receive five sessions of sham stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
32945494|NCT04505267|Experimental|Treatment (NBTXR3, RT)|Patients receive NBTXR3 IT or intranodally on day 1. Within 15 days, patients undergo RT 5 times weekly (Monday-Friday) over 3 weeks for a total of 10-15 fractions.
32945495|NCT04503551|Experimental|PDS Arm|Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
32945496|NCT04503551|Other|Comparator Arm|Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
32945497|NCT04888247|Experimental|Treatment|Trans-septal mitral valve replacement
32945498|NCT04487405||Group A|Symptomatic with adnexal mass
32945499|NCT04487405||Group B|Asymptomatic with adnexal mass
32945500|NCT04487405||Group C|Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant
33094880|NCT04512066|Active Comparator|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
33094881|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.~Salvage phase:~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
33094882|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
33404553|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
33404554|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
33404555|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
33404556|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
33404557|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
32801648|NCT01588197|Experimental|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
32801649|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
32801650|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
32801651|NCT00004054|Experimental|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
32801652|NCT00004054|Experimental|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin [Coumadin®]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
32801653|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
32801654|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
32801655|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: IBI305 15mg/kg IV Q3W~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W"
32801656|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
32801657|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|"Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo1 Placebo1 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
32801658|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
32801659|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
32801660|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
32801661|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
32801662|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
32801663|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
32801664|NCT03710122|Experimental|Vancomycin|
32801665|NCT03710122|Placebo Comparator|Placebo|
32801666|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
32801667|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
32801668|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
32801669|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
32801670|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
33094883|NCT05645185||Patient with Ma2 antibody|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids)."
33094884|NCT05645146|Active Comparator|Group 1: Standard Treatment|Participants will receive a connection to the Tobacco Free Florida Quitline and a 12 week supply of nicotine replacement therapy (the patch and lozenges)
33094885|NCT05645146|Experimental|Group 2: Motivation and Problem Solving (MAPS) counseling|Participants will receive a 12 week supply of nicotine replacement therapy (the patch and lozenges) along with the MAPS intervention, which consists of 6 MAPS counseling calls over 12 months, and individually tailored SMS text content driven by monthly smartphone delivered check-ins for 24 months
33094886|NCT01247532|Experimental|Waitlist|
33094887|NCT01247610||ADHD group|
33094888|NCT01247610||Control group|
33094889|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
33094890|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
33094891|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
33094892|NCT03271853||SBS II|
33094893|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
33094894|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
33094895|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
32801671|NCT03799354|Experimental|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
33309823|NCT03963765|Experimental|Group IV (DL-PDT with microdermabrasion)|"Superficial skin curettage all face with a dermatological curette~Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
33309824|NCT01081743|Experimental|Social worker|
33309825|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
32801672|NCT03799354|Active Comparator|Control group|Endurance training (ET)
32801673|NCT04763434|Active Comparator|RS group|20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone
32801674|NCT04763434|Active Comparator|RM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine
32801675|NCT04763434|Experimental|RSM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)
32801676|NCT04763668||Pregnant HIV positive women on ART|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
33094896|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
33094897|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
32801677|NCT04763668||Pregnant HIV negative women|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV negative. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
32801678|NCT04763668||Babies born to HIV positive mothers on ARTs|All babies born to pregnant HIV positive women on ARTs who were in the first arm of the study
32801679|NCT04763668||Babies born to HIV negative mothers|All babies born to pregnant HIV negative women who were in the first arm of the study.
32801680|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
32801681|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
33094898|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
33094899|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
33094900|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
33309826|NCT03962673|Experimental|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
33309827|NCT00053846|Experimental|buspirone hydrochloride|buspirone hydrochloride
33309828|NCT00053846|Placebo Comparator|Placebo|Placebo
33309829|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
33309830|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
33309831|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
33309832|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
33309833|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
33309834|NCT01099046|No Intervention|medication only|medication = anti-diuretics
33309835|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
32945501|NCT04882241|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
32945502|NCT04882241|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
32945503|NCT04882241|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
32945504|NCT04882241|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
33309836|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
33309837|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
33309838|NCT00090987|Experimental|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
33309839|NCT01085253||Parkinson|"without gait impairment~with gait and/or balance impairment~with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
33309840|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
33309841|NCT01085253||controls|age matched controls
33309842|NCT03464422|Experimental|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
33309843|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
33309844|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
33309845|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
33309846|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
32945505|NCT04874519||Participants with Fibrolamellar Carcinoma/FLC|Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
32945506|NCT04869995||Intervention|Senior abdominal and pelvic cavity surgeons (i.e., visceral surgeons, gynecologist surgeons, and urologists) having completed their robot-assisted surgery training, and commonly doing laparoscopic surgery.
32945507|NCT04481243|Experimental|Experimental|Children will receive Pneumovax 23 vaccination.
32945508|NCT04263779|No Intervention|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare & Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
33094901|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
33309847|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
33309848|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
33309849|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
33309850|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
33309851|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
33309852|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
33309853|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
33309854|NCT03543358|Experimental|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
33309855|NCT03543358|Experimental|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
33309856|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
33309857|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
32945509|NCT04263779|Experimental|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
33309858|NCT05665036|Experimental|SIG-005|SIG-005 is comprised of human native alpha-L-iduronidase enzyme (hIDUA) producing spheres
33309859|NCT00060944|Experimental|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
33309860|NCT00060944|Experimental|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
33309861|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
32945510|NCT04263779|No Intervention|Full List/Full Map/Default Video (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list, and patients will be provided the link to an introductory video presenting the SNF selection and discharge process. When only a paper printout is available, the same SNF sorting order will be presented on paper.
32945511|NCT04263779|Experimental|P-SNF List/P-SNF Map/P-SNF Video (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional introductory video will be highlighted, and the video will include sections describing the advantage of P-SNFs for care coordination. When only a paper printout is available, the same SNF sorting order will be presented on paper, with only the P-SNFs presented on the first page.
32945512|NCT04207931|Active Comparator|Topical steroid plus oral antibiotic group|Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
32945513|NCT04207931|Active Comparator|Topical steroid plus intralesional steroid injection group|Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment
32945514|NCT04437095|Experimental|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
33094902|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
33309862|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
33309863|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
33309864|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
32945515|NCT04437095|No Intervention|Control|Standard of care
32945516|NCT04431635|Experimental|Arm A: Copanlisib, Nivolumab & Rituximab|Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
32945517|NCT04421573|Experimental|BCPHD-D5W with usual care|"Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, 6 and 8 weeks.~All helpful treatment methods already underway are continued. Other new treatment methods are discouraged."
32945518|NCT04421573|Active Comparator|Waiting period with usual care|All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
32945519|NCT04183595|Experimental|Arm A: NBMI (Study Medication)|600mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours.
32945520|NCT04183595|Placebo Comparator|Arm B: Placebo|(Excipients microcrystalline cellulose, silica and magnesium stearate) capsules will be administered every 24 hours for 14 days.
32945521|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
33094903|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
33309865|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
32801682|NCT04747210|Active Comparator|Trainig workshop and Coaching one-on-one|Ten-hour training workshop that was divided into three sessions outside working hours. Coaching one-on-one in the daily routines and natural environment.
33309866|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
33094904|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
33094905|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
33094906|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
33094907|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
33094908|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
33309867|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
33309868|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
33309869|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
33309870|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
33309871|NCT03956732|Experimental|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
33309872|NCT03956732|Experimental|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
33309873|NCT03956732|Experimental|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
33309874|NCT03956732|Placebo Comparator|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
33309875|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
33309876|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
33309877|NCT01093352|No Intervention|Standard|Standard expose and bond.
33309878|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
33309879|NCT01099124|Experimental|M2ES combined with chemotherapy|
32801683|NCT04747210|Active Comparator|Trainig workshop|Assistants receive ten-hour training workshop that was divided into three sessions outside working hours.
33309880|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
33309881|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI >=30 that underwent bariatric surgery
33309882|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI >=30
33309883|NCT03461146|Experimental|MT-6548|
32801684|NCT04762966||Therapeutic|Patients with metformin blood concentration in the therapeutic ranges.
32801685|NCT04762966||Supratherapeutic|Patients with metformin blood concentration above the therapeutic ranges.
32801686|NCT03602560|Experimental|Seladelpar 5-10 mg|
32801687|NCT03602560|Experimental|Seladelpar 10 mg|
32801688|NCT03602560|Placebo Comparator|Placebo|
32801689|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
32801690|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
32801691|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
32801692|NCT03597256|No Intervention|Control Group|No treatment
32801693|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
32801694|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
32801695|NCT03797326|Experimental|Pembrolizumab + Lenvatinib (Arm 1)|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
32801696|NCT03797326|Experimental|Lenvatinib Monotherapy (Arm 2)|Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
32801697|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
32801698|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
32801699|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
32801700|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
32801701|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
32801702|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
33404558|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
33094909|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
33094910|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
33094911|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
33094912|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
33094913|NCT04519008|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
33094914|NCT04519008|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
33094915|NCT05645068|Experimental|Optical Coherence Tomography Angiography|
33094916|NCT04325347|Experimental|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
33094917|NCT04325347|No Intervention|Control|No specific intervention will be provided.
33094918|NCT00472706|Active Comparator|1|Excision
33094919|NCT00472706|Active Comparator|2|Photodynamic therapy
33094920|NCT02955459|Experimental|VNRX-5133|IV infusion
33094921|NCT02955459|Placebo Comparator|Placebo|IV infusion
33094922|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
33094923|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
33094924|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
33094925|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
33094926|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
33094927|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
33094928|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
33094929|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
33094930|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
33094931|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
33094932|NCT00478985|Experimental|1|Imatinib treatment ending
33094933|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
33094934|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
33094935|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
33094936|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
33094937|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
33094938|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
33094939|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
33094940|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
33094941|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
33094942|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
33094943|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
33094944|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
33094945|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
33094946|NCT00472862|Experimental|2|Cognitive training
33094947|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
33094948|NCT02483247|Experimental|Combo with Capecitabine|
33094949|NCT02483247|Experimental|Combo with Doxorubicin|
33094950|NCT02483247|Experimental|Combo with Nivolumab (US only)|
33094951|NCT02483247|Experimental|Combo with Pembrolizumab|
33094952|NCT02483247|Experimental|Combo with Paclitaxel|
33094953|NCT02483247|Experimental|Combo with Sunitinib|
33094954|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
33094955|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
33404559|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
33404560|NCT04567342|Experimental|Arm 1|
33404561|NCT04567342|Experimental|Arm 2|
33404562|NCT04567342|Experimental|Arm 3|
33404563|NCT04567342|Experimental|Arm 4|
32801703|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
32801704|NCT04112355||6 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provided a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
32801705|NCT04112355||12 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
32801706|NCT04112355||5 years of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
32801707|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
32801708|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
32801709|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
32801710|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
32801711|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
32801712|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
32801713|NCT04112043|Active Comparator|NR plus Walking Exercise|
33094956|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
33094957|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
33094958|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
33094959|NCT02489526|Experimental|VVZ-149 Injections|
33094960|NCT02489526|Placebo Comparator|Placebo|
33094961|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
33094962|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
33094963|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
33094964|NCT00479141|Experimental|1|HIV infected participants and their families
33094965|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
33094966|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
33094967|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
33094968|NCT00479180|Experimental|AVG1|Vascugel
33404564|NCT03985072|Experimental|Andes-1537|There will be 5 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
32801714|NCT04112043|Active Comparator|Walking Exercise plus Placebo|
33094969|NCT00479180|Placebo Comparator|AVG2|Gelfoam
33094970|NCT00479180|Experimental|AVF3|Vascugel
32801715|NCT04112043|Active Comparator|NR Alone|
32801716|NCT04111731|Active Comparator|Group one|Cryoballoon pulmonary vein isolation
32801717|NCT04111731|Active Comparator|Group two|Radiofrequency pulmonary vein isolation
32801718|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
32801719|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
32801720|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
32801721|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
32801722|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
32801723|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
32801724|NCT01585155|Experimental|TA-650|
32801725|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
33094971|NCT00479180|Placebo Comparator|AVF4|Gelfoam
33094972|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
33309884|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
33309885|NCT00031460|Experimental|Acyclovir|
33309886|NCT00031460|Placebo Comparator|Placebo|
33309887|NCT03951974|Experimental|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
33309888|NCT03951974|Other|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
33309889|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
33309890|NCT03952052|Other|Patient enrolled|Recurrent mutations determination
33309891|NCT03955562|Experimental|Intervention|Communities that receive a pedestrian footbridge.
33309892|NCT03955562|Experimental|Comparison|Communities that do not receive a pedestrian footbridge.
33309893|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
33309894|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
33309895|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
32801726|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
32801727|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
32801728|NCT04124367|Active Comparator|Verum|
32801729|NCT04124367|Placebo Comparator|Control|
32801730|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
32801731|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
32801732|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
32801733|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
32801734|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
32801735|NCT03695146|Experimental|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
32801736|NCT03695146|Active Comparator|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
32801737|NCT03695146|No Intervention|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
32801738|NCT03592264|Experimental|Dose escalation phase|OBI-3424 (1.0 mg/m^2 to 14.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.
32801739|NCT03592264|Experimental|Cohort expansion phase|OBI-3424 (12 mg/m^2) will be administered by IV infusion on Day 1 of each 21-day cycle.
32801740|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
32801741|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
32801742|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
32801743|NCT03694834|Experimental|Single Arm - Pembrolizumab|Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.
32801744|NCT03694600||men or women between 21-84|Multi-analyte blood test screening alone and as combination with multi-analyte Test and Ultrasound in subjects diagnosed with liver cirrhosis
32801745|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
33309896|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
33309897|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
33309898|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
33309899|NCT03955718|Experimental|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
32945522|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
32945523|NCT04418297|Experimental|CT-G20|
33309900|NCT03955718|Active Comparator|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
33309901|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
33309902|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
32945524|NCT04418297|Placebo Comparator|Placebo|
32945525|NCT03575195|Experimental|Intervention|Rifaximin
32945526|NCT03575195|Placebo Comparator|Placebo|Matching placebo
32945527|NCT04406441|No Intervention|Standard of Care|Participants will attend regularly scheduled well child visits (WCV) that follow standard clinical guidelines. Well child visits will include review of history, age-appropriate measurements (height/length, weight, body mass index (BMI), blood pressure), sensory and developmental screenings, physical exam, immunizations, oral health review, and anticipatory guidance (preventive counseling).
32945528|NCT04406441|Active Comparator|Patient Reported Outcome|Arm 2 builds on the standard of care WCV by adding a patient reported outcome measure, the Family Nutrition and Physical Activity risk assessment, to inform family-centered preventative counseling during clinical care.
32945529|NCT04406441|Active Comparator|Patient Reported Outcome + Food Care|Participants will receive all Arm 2 components, in addition to be referred to both the Geisinger Wellness Program for a Parent Training Program and a grocery store nutritionist for a tour aligned with the Cooking Matters program.
32945530|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
32945531|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
32945532|NCT04382963|Other|High Risk- intense coaching|"age ≥ 55 with MORE than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
32945533|NCT04382963|Other|High Risk - standard care|"age ≥ 55 with MORE than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
32945534|NCT04382963|Other|Low risk - control|"age ≥ 55 with LESS than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
32945535|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
32945536|NCT04159025|Experimental|Endobronchial ultrasound guided miniforceps biopsy|"Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.~With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
32945537|NCT04144907|Experimental|Phenylalanine intake|
32945538|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
32945539|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
33309903|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
33309904|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
33309905|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
33404565|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
33094973|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
33309906|NCT05659810|Active Comparator|Preoperative oral gabapentin before spinal anesthesia|The participants will receive 900 mg of gabapentin before surgery in 2 divided doses; 300 mg 10 hours prior to surgery and 600 mg 2 hours before surgery.
33309907|NCT05659810|Placebo Comparator|Preoperative oral placebo before spinal anesthesia|The participants will receive 1 tablet 10 hours prior to surgery, and then 2 tablets 2 hours prior to surgery
33309908|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
33404566|NCT02329288|Placebo Comparator|placebo|1ml
32945540|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
32945541|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
32945542|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
32945543|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
32945544|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
32945545|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
32945546|NCT00002921|Experimental|Suramin|
32945547|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
32945548|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
32945549|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
32945550|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
32945551|NCT04329455||Intervention group|
32945552|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
32945553|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
32945554|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
32945555|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
32945556|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
32945557|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
32945558|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
32945559|NCT03151967|Active Comparator|Applicator with LACTIN-V Treatment|Vaginal applicator containing Lactobacillus crispatus CTV-05
32945560|NCT03151967|Placebo Comparator|Applicator with Placebo|Inactive vaginal applicator without any drug
32945561|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
32945562|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
32945563|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
32945564|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
32945565|NCT04226027|Experimental|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
32945566|NCT04226027|No Intervention|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
32945567|NCT04009967|Experimental|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
32945568|NCT04000217|Active Comparator|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA & DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
33094974|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
33094975|NCT00479219|Experimental|A|
33309909|NCT03951896|Experimental|PRP|"Interventions:~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
33309910|NCT03951896|Placebo Comparator|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
33309911|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
33309912|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
32945569|NCT04000217|Active Comparator|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
32945570|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
33309913|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
33309914|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
32945571|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
32945572|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.~Completed"
32945573|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor~Completed"
32945574|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor~Completed"
32945575|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~Completed"
32945576|NCT03058289|Experimental|Cohort EC2|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC~Completed"
32945577|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.~Completed"
32945578|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|"INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.~Completed"
32945579|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|"INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.~Completed"
32945580|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|"INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.~Completed"
32945581|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Ipilimumab to be delivered at a pre-determine dose for one week~Blood Sample Collected~Standard of Care Surgery"
32945582|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Blood Sample Collected~Standard of Care Surgery"
32945583|NCT03933293|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection
32945584|NCT03933293|Placebo Comparator|placebo|Placebo, Q4W, subcutaneous injection
32945585|NCT03926741|Experimental|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
32945586|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32945587|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32945588|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32945589|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
33094976|NCT00479219|Placebo Comparator|B|
33309915|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic~According to the European Association of Urology Guidelines:~International prostate symptom score> 8 Prostate volume> 40 ml Q max <15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
33309916|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
33309917|NCT01099748|Experimental|Lersivirine + Methadone|
33309918|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
33309919|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
33309920|NCT03481816|Experimental|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
33309921|NCT03481816|Experimental|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
33309922|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
33309923|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
32945590|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32945591|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32945592|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
32945593|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
32945594|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
32945595|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
32945596|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
32945597|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
32945598|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
32945599|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
32945600|NCT02908685|Placebo Comparator|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
32945601|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
32945602|NCT02908685|Experimental|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
32945603|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.
32945604|NCT02908685|Experimental|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.
32945605|NCT04330469|Experimental|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
32945606|NCT04330469|Sham Comparator|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
32945607|NCT03911453|Experimental|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
32945608|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
32945609|NCT03905603|Experimental|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
32945610|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
32945611|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
32945612|NCT03884075|Experimental|Arm A: Steatosis|Participants with steatosis on baseline biopsy
32945613|NCT03884075|Experimental|Arm B: NASH|Participants with NASH on baseline biopsy
32945614|NCT03884075|No Intervention|Arm C: Healthy|Healthy Volunteers
32956117|NCT05753904|No Intervention|Reverse Total Shoulder Arthroplasty|For RTSA using a deltopectoral approach, the Perform glenoid and humeral components of Tornier Stryker Reverse Shoulder system will be used for all cases. The sizes and offsets of the components will be chosen based on each patient's local anatomy which will vary among patients. The subscapularis tendon will be repaired using three transosseous nonabsorbable sutures whenever there is a reparable subscapularis tendon. After definitive implantation of the prosthesis is completed, in the 'no interventional' group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
33309924|NCT01099826|Experimental|lifestyle counseling tailored|
33309925|NCT01099826|Experimental|lifestyle counseling motivational|
33309926|NCT01099826|No Intervention|control|
33309927|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
32801746|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
32801747|NCT03587740|Experimental|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
32801748|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
32801749|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
32801750|NCT03782194|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MRI data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
32801751|NCT03782194|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
33309928|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
33309929|NCT03956888|Experimental|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
32801752|NCT03691480|Experimental|simple exsufflation|
32801753|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
32801754|NCT03690700|Active Comparator|active BFRE|14 consecutive paraplegic SCI patients are block-randomized to active arm
32801755|NCT03690700|Sham Comparator|sham BFRE|14 consecutive paraplegic SCI patients are block-randomized to sham arm
32801756|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
32801757|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
32801758|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
32801759|NCT03685942|Experimental|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
32801760|NCT03685942|Placebo Comparator|placebo light therapy|People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
32801761|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
32801762|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
32801763|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
32801764|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
32801765|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
32801766|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
32801767|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a new radiological diagnosis of GBM (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.~This study arm will use 5 radiotherapy doses (6 Gy, 8 Gy, 10 Gy, 12 Gy and 14 Gy) and three treatment volumes (<30 cm3, 30-60 cm3 and >60 cm3). The study will use 6 dosing levels based on a combination of radiotherapy dose and treatment volume. The stepwise inclusion process allows for variation in tumour volume and location. The study will commence with dosing level 1: 8 Gy to <30 cm3 and 6 Gy to 30-60 cm3. In collaboration with the Clinical Trials Unit, the Trial Management Group will enter outcome data for patients at a given dose level into the CRM model. The model output will then guide dose escalation to determine the next dose level. After the single fraction of radiotherapy, patients will receive the standard treatment."
33309930|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
32801768|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
32801769|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.~Dosage level is n/a."
32801770|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
32801771|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
32801772|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
33094977|NCT04517487|Active Comparator|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:~Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}~The collected samples for VMT will be examined for bacteria,viruses and sperm.~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
33094978|NCT04517487|Placebo Comparator|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.~Before transplantation, patients will be treated with intravaginal antibiotic.~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
33094979|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
33094980|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
33094981|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
33094982|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
33094983|NCT01248312||morbidly obese|BMI >45
33094984|NCT01248312||thin patients|BMI <45
33094985|NCT01248351|Experimental|autologous stored platelets|
33094986|NCT00473174|Active Comparator|1|Ramipril on awakening
33094987|NCT00473174|Active Comparator|2|Ramipril at bedtime
33094988|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
33094989|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
33094990|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
33094991|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
33094992|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
33094993|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
33094994|NCT00479570|Experimental|Study period 1, 2 or 3|
33094995|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
33094996|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
32801773|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
33094997|NCT00473252||Hemodialysis patients|
33094998|NCT00473252||Renal transplant patients|
33094999|NCT05645029|Experimental|glass ionomer-chlorhexidine|
33095000|NCT05645029|Experimental|glass ionomer -titanium dioxide powder.|
33095001|NCT05645029|Active Comparator|glass ionomer|
33095002|NCT00479609|Placebo Comparator|1|Placebo gel
33095003|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
32801774|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
32801775|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
32801776|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
32801777|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
33095004|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
32801778|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~In case of progressive disease , patients will be considered in treatment failure."
33095005|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
33095006|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
33095007|NCT04325113|Placebo Comparator|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
33095008|NCT04325113|Active Comparator|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
33095009|NCT04325113|Active Comparator|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
33095010|NCT05644912|Experimental|All subjects|Transanal irrigation (TAI) with new catheter
33095011|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
33095012|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
33095013|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
33095014|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
33095015|NCT02275104||Ventricular arrhythmias|
33095016|NCT02275104||Persistent atrial fibrillation|
33095017|NCT05644795|Active Comparator|Active Comparator: wheat/milk free diet (W/MFD) group|Patients randomized to intervention group will go to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
33095018|NCT05644795|Placebo Comparator|Placebo Comparator: rice/turkey free diet (R/TFD) group|Patients randomized to control group will go to a 2 months elimination diet (rice and turkey's meat). After 2 months of elimination diet they will crossover to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
33095019|NCT05644717|Experimental|Ertugliflozin|Ertugliflozin 5/15mg once daily with standard of care
33095020|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
33095021|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
33095022|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
33095023|NCT00479648|Experimental|2|CSL412 formulation
33095024|NCT00479648|Experimental|3|CSL412 formulation
33095025|NCT00479648|Experimental|4|CSL412 formulation
33095026|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
33095027|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
33095028|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
33309931|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
33309932|NCT01099904|Experimental|1|Normal Renal Function
33309933|NCT01099904|Experimental|2|Mild Renal Impairment
32801779|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
32801780|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
32801781|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
32801782|NCT03774394|Experimental|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
32801783|NCT03774394|Active Comparator|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
32801784|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
32801785|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
33095029|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
33095030|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
33095032|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
33095033|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
33095034|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
33095035|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
33095036|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
33095037|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
33095038|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
33095039|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
33095040|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
33095041|NCT04697121|Placebo Comparator|Placebo|
33095042|NCT04697121|Active Comparator|Combined Bergamot Phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
33095043|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
33095044|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
33095045|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
33095046|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
33095047|NCT04325035|Experimental|Istaroxime|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
33095048|NCT04325035|Placebo Comparator|Placebo|Placebo (lactose lyophilized powder) IV infusion for 24 hours
33095049|NCT04207411|Experimental|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
33095050|NCT04207411|Sham Comparator|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
33095051|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
33095052|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
33309934|NCT01099904|Experimental|3|Moderate Renal Impairment
33095053|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
33095054|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
33095055|NCT05644483|Experimental|remimazolam group|patients who receive remimazolam-remifentanil based total intravenous anesthesia
33095056|NCT05644483|Active Comparator|propofol group|patients who receive propofol-remifentanil based total intravenous anesthesia
33095057|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:~Induction phase~Sertraline, twice daily at one of the pre-defined dose levels~Cytosine arabinoside, on days 1 and 10~Consolidation phase~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:~Allogeneic SCT and off study~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion~Maintenance phase with sertraline for cycles of 28 days in length"
33095058|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
33095059|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
33095060|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
33095061|NCT01248702|Experimental|Critical Pathway|
33095062|NCT01248702|No Intervention|Standard Practice|
33095063|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
33095064|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
33095065|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
33095066|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
33095067|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
32801786|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
33095068|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
33095069|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
32801787|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
33095070|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
33095071|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
33095072|NCT05661370|Active Comparator|Intervention|Access to educational mobile application for 8 days, diagnosing 500 digital patient-cases.
33095073|NCT05661370|No Intervention|Control|Control group receiving no intervention, continuing daily practice.
33095074|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
33095075|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
33095076|NCT00481364|Placebo Comparator|Placebo|placebo
33095077|NCT05661331||Ascites|N = A target of 88 treated patients and thereof, a maximum of ~10 subjects with a pre-TIPS LVP frequency ≥ 2 LVP per month
33095078|NCT05661331||Variceal bleeding|N = At least 88 treated patients and thereof, a maximum of ~10 subjects enrolled with Child-Pugh class C
32801788|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
33095079|NCT05661331||Other Primary Indication|Portal vein obstruction or thrombosis, pre-operative TIPS, hepatorenal Syndrome Type 1, hepatorenal Syndrome Type 2, other) N = Approximately 20 treated patients
33095080|NCT01249014|No Intervention|Control|No peri-operative warming.
33095081|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
33095082|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
33095083|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
33095084|NCT01240460|Experimental|2|Once-daily dosing XL147
33095085|NCT01240460|Experimental|3|Once-daily dosing XL765
33095086|NCT01249170|Other|First year fellow|
33095087|NCT01249170|Other|Second Year Fellow|
33095088|NCT01249209|Other|lifestyle advice|
33095089|NCT01249248||Male basketball players|
33095090|NCT01249248||Female basketball players|
33095091|NCT01249248||Baseball players|
33095092|NCT01249248||Softball players|
33095093|NCT01249248||Football players|
33095094|NCT01249248||Female vollyball players|
32801789|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
32801790|NCT03770182|Experimental|Group A|"NEUROLITH~Cycle 1: Active treatment~Cycle 2: Sham treatment"
32801791|NCT03770182|Experimental|Group B|"NEUROLITH~Cycle 1: Sham treatment~Cycle 2: Active treatment"
33095095|NCT01249248||Male soccer players|
32801792|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
32801793|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
32801794|NCT03675256|Experimental|Arm 1|immediate Cervarix, delayed MenVeo vaccine
33095096|NCT01249248||Female soccer players|
33095097|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
33095098|NCT04697537|Active Comparator|Ultrasound guided regional anesthesia|Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic block of each 15 ml ropivacaine 0,5% and 0,5 ml dexmedetomidine (100µg/ml).
33095099|NCT04697537|Active Comparator|Local infiltration analgesia|Patient will be given a local infiltration analgesia from their treating surgeon during the operation (in the OR) with 60 ml ropivacaine 0,5% and 1 ml dexmedetomidine (100µg/ml).
33095100|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
33095101|NCT01313650|Experimental|GSK573719|62.5mcg
33095102|NCT01313650|Experimental|GW642444|25mcg
33095103|NCT01313650|Placebo Comparator|Placebo|Placebo
33095104|NCT04697615||Algometry|In the test stage, pain threshold evaluations were started through the algometer in a randomized manner by two different examiners trained and experienced in the application of the test, following the same order of evaluation of the muscles (middle deltoid, upper trapezius, pectoralis major, biceps brachii , triceps, lumbar multifidus, rectus femoris, biceps femoris, tibialis anterior and soleus, bilaterally), with an interval between each assessment of five minutes in which the participants remained at rest. After the interval described, the retest stage was initiated, which had the same procedures as the test stage.
33095105|NCT00504114||1|Healthy volunteers without knee pain.
33095106|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
33095107|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
33095108|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
32801795|NCT03675256|Experimental|Arm 2|immediate Gardasil 9, delayed MenVeo vaccine
32801796|NCT03675256|Active Comparator|Arm 3|immediate MenVeo, delayed Gardasil 9 vaccine
32801797|NCT04762732|Experimental|Experimental: negative pressure wound therapy (PREVENA™ Incision Management System)|Wound of ALT donor site will be cared under PREVENA™ Incision Management System
32801798|NCT04762732|Placebo Comparator|Placebo Comparator: conventional dressing|Wound of ALT donor site will be cared by traditional dressing and care.
32801799|NCT03766750|Experimental|LIMA|
33095109|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
33095110|NCT00481481|Experimental|1|
32801800|NCT03766750|Active Comparator|Tradjenta®|
33095111|NCT05644444|Experimental|Lubricant A and Comparator A|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
33095112|NCT05644444|Experimental|Lubricant B and Comparator B|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
32801801|NCT03766750|Active Comparator|Forxiga®|
32801802|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
32801803|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
32801804|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
32801805|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
32801806|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
32801807|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
32801808|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
32801809|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
33095113|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
33095114|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
33309935|NCT03955406|Active Comparator|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
32945615|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
33095115|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
33095116|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
33309936|NCT03955406|Active Comparator|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
33309937|NCT01093664|Experimental|AFFITOPE AD02|
33309938|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
32945616|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
32945617|NCT03850067|Experimental|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
32945618|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
32945619|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
32945620|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
32945621|NCT04329689|Experimental|septal myectomy alone versus septal myectomy|"The aims of the present study is to:~Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.~Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
32945622|NCT04329845|Active Comparator|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
32945623|NCT04329845|Active Comparator|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
32945624|NCT04329611|Active Comparator|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
32945625|NCT04329611|Placebo Comparator|Placebo|Matching Placebo
32945626|NCT03763331|Sham Comparator|Sham treatment|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F was circulated through the pants for 90 minutes daily for 8 weeks..
32945627|NCT03763331|Active Comparator|Heat Therapy|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
32945628|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
32945629|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
32945630|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
32945631|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
33309939|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
33309940|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
33309941|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
33309942|NCT00050960|Experimental|bexarotene with carboplatin and paclitaxel|
33309943|NCT00050960|Experimental|carboplatin and paclitaxel|
33309944|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
33309945|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
33309946|NCT03456856|Experimental|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
33309947|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
33309948|NCT00058214|Experimental|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
33309949|NCT00097773|Placebo Comparator|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
33309950|NCT00097773|Active Comparator|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
33309951|NCT00097773|Placebo Comparator|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
33404567|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
33404568|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
33309952|NCT00097773|Active Comparator|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
33309953|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
33309954|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
33309955|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
32945634|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects
32945635|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects
32945636|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
32945637|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
32945638|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
32945639|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
32945640|NCT00003095||bone marrow transplant|bone marrow transplant
32945641|NCT00003095||standard chemotherapy|standard chemotherapy
32945642|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
33095117|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
33309956|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
33404569|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
33309957|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
33309958|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
33309959|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
33309960|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
33095118|NCT02891083|Other|Control group|Surgery alone
33095119|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
33095120|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
33095121|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
33095122|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
33095123|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
33095124|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
33095125|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
33095126|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
33095127|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
33095128|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
33095129|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
33095130|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
33095131|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
33095132|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
33095133|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
33095134|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
33309961|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
33309962|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
33309963|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
32801810|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
32801811|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
32801812|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
32801813|NCT04762810|Experimental|Cyclophosphamide and Glucocorticoids|Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
32801814|NCT04762810|Active Comparator|Glucocorticoids monotherapy|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
32801815|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
33095135|NCT05661253|No Intervention|Control group|will take general anesthesia without nerve block
33309964|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
33309965|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
33229192|NCT05753748|No Intervention|Endoscopic Surveillance|Subjects in the randomized control trial and observational cohort study, undergoing surveillance endoscopy will undergo surveillance biopsies in a 4-quadrant fashion every 1 cm throughout the extent of the Barrett's esophagus using the Seattle biopsy protocol, along with targeted biopsies from any visible lesions. For incident low grade dysplasia (newly diagnosed low grade dysplasia - within 12 months of enrollment), surveillance endoscopies will be performed every 6 months for the first year and then annually until the end of the study period. For prevalent low grade dysplasia (diagnosed >1 year prior to enrollment), surveillance endoscopies will be performed annually until the end of the study period. The number of evaluations will depend on a subject's enrollment time.
33309966|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
33309967|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
33309968|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
33309969|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
33309970|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
33309971|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
33309972|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
33309973|NCT03716986|Other|SatO2|
32801816|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
32801817|NCT04762108||Sjögren's syndrome|Sjögren's syndrome with childhood-onset
32801818|NCT04762108||Healthy control|Age matched healthy control
32801819|NCT04761952|Experimental|n-3PUFA treatment group|On the basis of routine treatment, oral supplement of n-3PUFA was given to CD patients since 2-week-postoperative till 1-year-postoperative.
32801820|NCT04761952|Placebo Comparator|Conventional treatment group|Treatment of azathioprine (daily orally) or infliximab (intravenously, at 0, 2,6 weeks with every 8-week-interval later) was given since 2-week-postoperative till 1-year-postoperative.
32801821|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
32801822|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
32801823|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
32801824|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
32801825|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
32801826|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
32801827|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
32801828|NCT03572530|Experimental|group 1|5-Azacytidine (5-AZA) group 1: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 1 will receive two 5-AZA infusions every week.
32801829|NCT03572530|Experimental|group 2|5-Azacytidine (5-AZA) group 2: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 2 will receive three 5-AZA infusions every week.
32801830|NCT03572530|Experimental|group 3|5-Azacytidine (5-AZA) group 3: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 3 will receive four 5-AZA infusions every week.
32801831|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
32801832|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
32801833|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
32801834|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
32801835|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
32801836|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
32801837|NCT00305344|Active Comparator|Cord Blood|Umbilical Cord Blood
32801838|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
32801839|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
32801840|NCT05347498|Experimental|Treatment group A|HR091506 tablets + placebo of febuxostat tablets
32801841|NCT05347498|Active Comparator|Treatment group B|febuxostat tablets + placebo of HR091506 tablets
32801842|NCT05347420||Diabetic peripheral neuropathy|Patients with diabetic peripheral neuropathy
32801843|NCT05347420||non diabetic peripheral neuropathy|Patient without diabetic peripheral neuropathy
32801844|NCT03669250|Active Comparator|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
32801845|NCT03669250|Active Comparator|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
32801846|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
32801847|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
32801848|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
32801849|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
32801850|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
32801851|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
32801852|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
32801853|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
33309974|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
33309975|NCT03718468|Experimental|GC Flu Quadrivalent|
33309976|NCT03718468|Active Comparator|Fluarix tetra|
33309977|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
33309978|NCT00049322|Experimental|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
33309979|NCT00049322|No Intervention|Arm II-chemoembolization|chemoembolization as part of standard of care
32801854|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
33309980|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
33309981|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
33309982|NCT00058058|Experimental|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
33309983|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
32801855|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
32801856|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
33309984|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
33309985|NCT01093898||No intervention|
33309986|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
33309987|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
33309988|NCT01100918|Active Comparator|1: Dyssynchrony positive|
33309989|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
33309990|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
33309991|NCT00008138|Experimental|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
33309992|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
33309993|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
33309994|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
33309995|NCT01101074||6-23 months|
33309996|NCT01101074||2-8 years|
33309997|NCT01101074||9-17 years|
33309998|NCT01101074||18-44 years|
33309999|NCT01101074||45-60 years|
33310000|NCT01101074||>60 years|
33310001|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
33310002|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
33310003|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
33310004|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
33310005|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
33310006|NCT01100216|Active Comparator|Camel Snus Frost|
33310007|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
33310008|NCT01100216|Active Comparator|Skoal Wintergreen|
33095136|NCT05661253|Active Comparator|SAP block group|After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed at the level of the midclavicular line in a sagittal plane. The second rib will be recognized at the axillary artery. The probe will be moved downward to count the ribs until the level of the ﬁfth rib in the mid-axillary line. At this time, the latissimus dorsi muscle (lying superficial) and the serratus anterior muscle (lying deep) will be clearly visualized under ultrasound . Next, A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe between the latissimus dorsi and the serratus anterior muscle. After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected superficially to serratus anterior muscle. .
33095137|NCT05661253|Active Comparator|modified SAP block group|The patient will be placed in the lateral decubitus position according to the selected site of surgical intervention. After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography ( FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed horizontally midway between tip of the scapula and posterior axillary line to identify the view of latissimus dorsi(lying superficial) and serratus anterior muscle(lying deep) over either the sixth or seventh rib. A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe from posteromedial to anterolateral direction toward posterior axillary line till reaching the interfacial plane between latissimus dorsi and serratus anterior muscle . After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected .
33310009|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
33310010|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
33310011|NCT00027560|Experimental|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
33310012|NCT03951740|Experimental|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
33095138|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
33095139|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
33310013|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
33095140|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33095141|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
33095142|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
33095143|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
33095144|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
33095145|NCT00480116|Active Comparator|1|
33095146|NCT00480116|Active Comparator|2|
33095147|NCT00480116|Active Comparator|3|
33310014|NCT03951428||All Participants|
33310015|NCT01100450|Experimental|Resistance Training|
33310016|NCT03951506|Experimental|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
33310017|NCT03951506|Experimental|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
33310018|NCT03951350|No Intervention|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
33095148|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
33095149|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
33095150|NCT00504933|Experimental|A|Bilastine
33095151|NCT00504933|Active Comparator|B|Cetirizine
33095152|NCT00504933|Placebo Comparator|C|Placebo
33095153|NCT01313299|Experimental|Dysport 500 U|
33095154|NCT01313299|Experimental|Dysport 1000 U|
33095155|NCT01313299|Placebo Comparator|Placebo|
33095156|NCT00480155|Active Comparator|1|FluMist
33095157|NCT00480155|Placebo Comparator|2|Placebo
33095158|NCT00504972|Experimental|Study Treatment|This study is a single arm study
33310019|NCT03951350|Experimental|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
33310020|NCT03951350|Experimental|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
33310021|NCT02530190|No Intervention|Control|20 minutes of supine rest
32801857|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
33310022|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
32801858|NCT03668626|No Intervention|Term infants|Healthy term infants
32801859|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
32801860|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
32801861|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
32801862|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
32801863|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
32801864|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
33310023|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
33310024|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
33310025|NCT01100684|Placebo Comparator|Placebo|Placebo
33310026|NCT03451084|Experimental|Part 1: Dose Level 1|
33310027|NCT03451084|Experimental|Part 1: Dose Level 2|
33310028|NCT03451084|Experimental|Part 1: Dose Level 3|
33310029|NCT03451084|Experimental|Part 1: Dose Level 4|
33310030|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
33310031|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
33310032|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
33310033|NCT03451006|Experimental|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
33095159|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
33095160|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
33095161|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
33095162|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
33095163|NCT04512534|Experimental|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
33095164|NCT04516512|Experimental|Investigated arm|Participants included in the study who met inclusion criteria
33095165|NCT04512495|Other|Patients with sarcoma|
33095166|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
33095167|NCT00481637||Normal|Normal volunteers
33310034|NCT03451006|Active Comparator|Placebo|Placebo by mouth every 6 to 8 hours for one year
33310035|NCT05625854|Experimental|Blow a fan to the face combine aromatherapy|
33310036|NCT05625854|Experimental|Blow a fan to the face|
33310037|NCT05625854|Placebo Comparator|Blow a fan to the feet|
33310038|NCT01327118|Placebo Comparator|Isoton sodium chloride|
33310039|NCT01327118|Active Comparator|Prostaglandin F2alpha|
33310040|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
33310041|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
33310042|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
33310043|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
33310044|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
33095168|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
33095169|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
33095170|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
32801865|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
33310045|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
33310046|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
33310047|NCT03449446|Experimental|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
33310048|NCT03449446|Experimental|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
33310049|NCT03449446|Experimental|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
33310050|NCT03449446|Experimental|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
33310051|NCT03449446|Experimental|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
32945643|NCT03713801|Experimental|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
33310052|NCT03449446|Experimental|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
33310053|NCT03449446|Experimental|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
33310054|NCT05658952|Active Comparator|Angiography-guided PCI|Patients will receive PCI according to the interpretation of angiography findings by the Interventional Cardiologist.
33310055|NCT05658952|Experimental|Microcatheter-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with microcatheter FFR performed by the Interventional Cardiologist before and after PCI.
32945644|NCT03713801|Placebo Comparator|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
32945645|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
32945646|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
32945647|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
32945648|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
32945649|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
32945650|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
32945651|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
32945652|NCT04330313|Experimental|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
32945653|NCT04330313|Experimental|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
32945654|NCT04330313|Experimental|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
32945655|NCT04330313|Experimental|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
32945656|NCT01958021|Experimental|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
32945657|NCT01958021|Placebo Comparator|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
32945658|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
32945659|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
32945660|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
33095171|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
33310056|NCT05658952|Experimental|Angiography-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with angiography-derived FFR performed by the Interventional Cardiologist before PCI. The angiography-derived FFR can be repeated after PCI to check the results and eventually apply correcting maneuvers.
33310057|NCT03435016|Other|Diagnosis|
33310058|NCT03716674|Experimental|Parkinson's Disease patients|
33310059|NCT05664958|Experimental|ESP Block|Standard of care analgesic regimen with ESP Block
33310060|NCT05664958|No Intervention|Control|Standard of care analgesic regimen
33310061|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
33310062|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
33310063|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
33310064|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
33310065|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
33310066|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
33310067|NCT03449134|Placebo Comparator|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
33310068|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
33310069|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
33310070|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
33310071|NCT05650840|Experimental|Charcoal -based whitening toothpaste|signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt
33310072|NCT05650840|Active Comparator|Calcium carbonate /perlite containing whitening toothpaste|signal whitening moonlight toothpaste Unilever Mashreq - Egypt
33310073|NCT03722914|Active Comparator|benzonatate soft capsules group|
33310074|NCT03722914|Placebo Comparator|control group|
33310075|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
33310076|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
33310077|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
33310078|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
33310079|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
33310080|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
33310081|NCT05664880|Experimental|Paricalcitol|Participants receive Paricalcitol 2mcg capsule once daily for 12 months.
33310082|NCT05664880|Placebo Comparator|Placebo|Participants receive Paricalcitol Placebo capsule matching Paricalcitol once daily for 12 months.
33310083|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
33310084|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
33310085|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
33310086|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
33310087|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
33310088|NCT03716440|Experimental|Nature group|Nature exposure intervention.
33310089|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
33310090|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
33310091|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
33310092|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
33310093|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
33310094|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
33310095|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
33310096|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
32945661|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
33095172|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
33310097|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
33310098|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
33310099|NCT03428152||Hypo|The participants with a superior hypogastric block
33310100|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
33310101|NCT05664802|Experimental|e-HERO 2.0|The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
33310102|NCT05664802|Active Comparator|e-HERO 1.0|e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
33310103|NCT03444766|Experimental|Monotherapy|administering nivolumab only
33310104|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
33310105|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
32945662|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
33310106|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
33310107|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
32945663|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
32945664|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
32945665|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
32945666|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
32945667|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
32945668|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
32945669|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
32945670|NCT01545557|Experimental|Hyaluronic acid dermal filler|One Emervel Volume injection at baseline and touch up injections 3 weeks after if needed
32945671|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
32945672|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
32945673|NCT01370447|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 50 milligrams (mg) at Day 1, 50 mg twice daily for 13 days, 100 mg on Day 15, and 100 mg twice daily until Day 28; either by mouth with a meal or via their G-tube with feeds. In the absence of clinical or laboratory indications of any safety concerns, participants will receive 100 mg EPI-743 three times daily until end of study.
32945674|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
32945675|NCT00384371|Experimental|1|Botulinum Toxin A
33310108|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
32945676|NCT00384371|Placebo Comparator|2|Placebo
32945677|NCT00423215||Patients with Type II diabetes|
33095173|NCT00481715|Experimental|1|Web-based weight loss program
33095174|NCT00481715|Experimental|2|Cash incentive weight loss program
33095175|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
33095176|NCT00481715|No Intervention|4|No intervention
33310109|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
33310110|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
33310111|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
33404570|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
33310112|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
32945678|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
32945679|NCT00003425|Experimental|Amifostine trihydrate|
32945680|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
32945681|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
32945682|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
32945683|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by a physician according to standard of care for psoriasis.
32945684|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by a physician according to standard of care for psoriasis.
32945685|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by a physician according to standard of care for psoriasis.
32945686|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
32945687|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
32945688|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by a physician according to standard of care for psoriasis.
32945689|NCT00330551|Experimental|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
32945690|NCT00330551|Active Comparator|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
32945691|NCT00001259|Placebo Comparator|Study 1, Phase 1, Assignment 1 - Placebo|As part of double Blind randomized trial, participants in Assignment 1 were randomized to 8 weeks of placebo (P) injections (1 injection per month). These participants then continued on to Study 2 after completion of 8 weeks of placebo injections.
32945692|NCT00001259|Experimental|Study 1, Phase 1, Assignment 2 - GnRH agonist injections (Lupron-L only)|As part of double Blind randomized trial, participants in Assignment 2 were randomized to 8 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Those who exhibited a remission of symptoms after 8 weeks continued on to receive one more month of GnRH agonist treatment (12 weeks total) and then entered Study 1, Phase 2.
32945693|NCT00001259|Experimental|Study 1, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
32945694|NCT00001259|Experimental|Study 1, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
32945695|NCT00001259|Experimental|Study 2, Phase 1 - GnRH agonist injections (Lupron-L only)|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
32945696|NCT00001259|Experimental|Study 2, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
33095177|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
33095178|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
33310113|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
33310114|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
33310115|NCT05664724|Experimental|Receives interdisciplinary sessions|Interdisciplinary care by a team that includes: orthopedic surgeon, physiotherapist, a patient navigator, and the patient
33310116|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
33310117|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
33310118|NCT03716128||High turnover bone disease|PTH>300 pg/ml
33310119|NCT03716128||Normal renal function|Patients under examination for prostate cancer
33310120|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
33404571|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
33095179|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
33095180|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
33095181|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~placebo orally, stopped at month 6"
33095182|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
33095183|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
33095184|NCT04513041|Experimental|Pinhole/Tunnel|Participants will receive Pinhole surgical technique for treatment of soft tissue recession at one side of the mouth and Tunnel technique for treatment of soft tissue recession at the other side of the mouth
33095185|NCT04517058||epilepsy patients with depression group|the score of HAMD-17>7
33095186|NCT04517058||epilepsy patients without depression group|the score of HAMD-17≤7
33095187|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
33095188|NCT04519788|Active Comparator|AT-301B|AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)
33095189|NCT04519788|Placebo Comparator|AT-301A|AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)
33095190|NCT04519593|Experimental|Laparoscopic myomectomy with temporary blood supply occlusion|Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
33095191|NCT04519593|Active Comparator|Conventional laparoscopic myomectomy|Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.
33095192|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
33095193|NCT04519554|Other|5FR + 7FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR
33095194|NCT04519554|Other|7FR + 5FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR
33095195|NCT04519710|Experimental|multiple sclerosis or other inflammatory neurological disease|HBV negative
33095196|NCT04519710|Experimental|systemic vasculitis|HBV negative
33095197|NCT04519710|Experimental|an autoimmune disease|HBV negative
33095198|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
33310121|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
33310122|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
33310123|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
33310124|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
33095199|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
33095200|NCT02275455|Experimental|Participants with autism|
33095201|NCT02275455|Experimental|Aged-matched controls|
33095202|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
33095203|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
33095204|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
33310125|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
33310126|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
33310127|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
33310128|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
33310129|NCT03717610|Experimental|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
33404572|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
33310130|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
33310131|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
33310132|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
33404573|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
32945697|NCT00001259|Experimental|Study 2, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
32945698|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
32945699|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
32945700|NCT00002807|No Intervention|Observation|
32945701|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
32945702|NCT04329533|Experimental|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
32945703|NCT04329533|No Intervention|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
32945704|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
32945705|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
32945706|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
32945707|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32945708|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32945709|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
32956118|NCT05753904|Experimental|Reverse Total Shoulder Arthroplasty with Conjoint Tendon Resection|RTSA in the experimental group will be identical, except for that after definitive implantation of the prosthesis is completed, in the 'experimental' group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved. As mentioned above, the control group will not receive this conjoint tendon resection. Similarly, in the experimental group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
32956119|NCT05747963|Experimental|software-delivered CBT-I|Subjects in intervention group will receive a digital CBT-I for 6 weeks. The automated software incorporates all core elements of CBT-I, tailoring content based on each participant's reported baseline sleep function and sleep progress.
33310133|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
33310134|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
33310135|NCT00090753|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
33404574|NCT02333032|Experimental|hemiplegic patient|
33095205|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
32801866|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
33095206|NCT04519398||COVID-19 patients with proved venous thrombosis|"1st group includes COVID-19 patients with proved~venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)~or arterial thrombosis (heart attacks, strokes)"
33095207|NCT04519398||Asymptomatic COVID-19 & those with mild or moderate disease|2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 > 94%
33095208|NCT04519398||Severe disease, according to Guidelines, without thrombus|3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 < 300 mmHg, or lung infiltrates >50%
33095209|NCT00482066|Active Comparator|1|Abatacept (Orencia)
33095210|NCT00482066|Placebo Comparator|2|saline placebo
33095211|NCT04519047|Experimental|Rejoint|Rejoint+PRP
33095212|NCT04519047|Active Comparator|Control|Saline+PRP
33310136|NCT00090753|Active Comparator|Comparator ESA|Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
33310137|NCT00048932|Active Comparator|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants > 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period
33310138|NCT00048932|Placebo Comparator|Double-blind Placebo|Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.
33310139|NCT00048932|Active Comparator|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
33310140|NCT01085409||Tinnitus|Patients with tinnitus
32801867|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
32801868|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
32801869|NCT03566524|Experimental|Citrulline|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 20 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
32801870|NCT03566524|Placebo Comparator|alanine|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 20 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
32801871|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
32801872|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
33310141|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
33310142|NCT01085409||Anxiety|Subjects with anxiety complaints
33310143|NCT01085409||Controls|Healthy controls
33310144|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
33404575|NCT04407988|Experimental|Pyrotinib plus Letrozole|
32801873|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
32801874|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
32801875|NCT03663400||Patients Treated with Tofacitinib|Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry
32801876|NCT03662776||retinoblastoma survivors treated with enucleation|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
32801877|NCT03662776||retinoblastoma survivors treated with intra-arteria chemo|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
32801878|NCT04403776|Experimental|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
32801879|NCT04403776|Experimental|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~Washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
32801880|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
32801881|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
32801882|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:~Training of child care providers.~Curriculum sessions for children.~Family outreach activities.~Maintenance activities."
32801883|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
32801884|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
32956120|NCT05747963|Active Comparator|online PE|Subjects in control group will receive information about insomnia and sleep health education content.
32956121|NCT05746650|Experimental|1) Electrical stimulation + growth hormone|One bout of electrical stimulation with 200 eccentric contractions. This is followed by daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
32956122|NCT05746650|Experimental|2) Electrical stimulation|One bout of electrical stimulation with 200 eccentric contractions
33095213|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
33095214|NCT04519242|Active Comparator|Patients enrolled in the ORIF group|Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.
33095215|NCT04519242|Active Comparator|Patients enrolled in the PA group|PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).
33310145|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
32956123|NCT05746650|Active Comparator|3) Growth hormone|Daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
32956124|NCT05746650|Placebo Comparator|4) Control|No intervention
32956125|NCT05745649|Experimental|Group A|Resistive exercise
32956126|NCT05745649|Active Comparator|group B|Ankle weights
32801885|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
32801886|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
32801887|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
32801888|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
32801889|NCT04762030|Experimental|Experimental Group|
32801890|NCT04761874|No Intervention|In-Person (Conventional) Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from December 1, 2019-March 15, 2020 that were evaluated, managed, and treated by the stroke care team in person.
32801891|NCT04761874|Experimental|Telestroke Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from March 16, 2020-June 29, 2020 that were evaluated, managed, and treated by the stroke care team remotely via telestroke.
32801892|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
32801893|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
33404576|NCT05192967|Experimental|Experimental 1|"The training program determined to the experimental group was applied with video. Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
32801894|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
32801895|NCT01559259|Active Comparator|Ibuprofen|
32801896|NCT01559259|Placebo Comparator|Placebo|
32801897|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
32801898|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
32801899|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
32801900|NCT03538912|Other|Routine group|patient follow the routine strategy
32801901|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
32801902|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
32801903|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
32801904|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
32801905|NCT01672762|Experimental|ASP1941 group|oral
32801906|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
32801907|NCT03534934|Experimental|Baseline|"Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
32956127|NCT05745064|Active Comparator|TL-925 Arm|For the first 7 days subjects will administer 1 drop of TL-925 followed by a 5 minute wait before administering a second drop to each eye during each dosing session. For days 8-28, subjects will administer 1 drop TL-925 OU BID.
32956128|NCT05745064|Placebo Comparator|Placebo Arm|For the first 7 days subjects will administer 1 drop of placebo followed by a 5 minute wait before administering a second drop to each eye during each dosing session. For days 8-28, subjects will administer 1 drop placebo OU BID.
32956131|NCT05744232|Experimental|Intervention- Low calorie diet/ Total diet replacement|Participants in the intervention group will be offered a dietitian-delivered intervention over 6 months, similar to the NHS pilot of low calorie diets for type 2 diabetes remission. The intervention starts with 12 weeks of low-energy total diet replacement (approx. 860 kcal/day) in a nutritionally replete package of soups, shakes, and bars. It continues with stepped food reintroduction (maximum 6 weeks) as a low-calorie, nutrient-rich diet personalised to the individual participant circumstances and preferences, and weight maintenance (6 weeks).
32956132|NCT05744232|Other|Control- usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded. Participants will be offered an invitation to a 30-45' 1:1 session with the research dietitian at the end of the study to provide help and signposting as required for the management of their diabetes.
32956133|NCT05743400|Experimental|Experimental treatment arm|Children over two years and adults undergoing a first hematopoietic stem cell transplantation will receiveThymoglobulin® as part of the conditioning.
32956134|NCT05742802|Experimental|Tozorakimab Dose 1|Injection subcutaneously Tozorakimab or placebo via pre-filled syringe.
32956135|NCT05742802|Experimental|Tozorakimab Dose 2|Injection subcutaneously Tozorakimab via pre-filled syringe.
32956136|NCT05742802|Placebo Comparator|Placebo|Injection subcutaneously with equivalent volume to Tozorakimab via pre-filled syringe.
33310146|NCT03812679|Experimental|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
33310147|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
32945710|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
32945711|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33310148|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
33310149|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
33310150|NCT01583127|No Intervention|Control|Practice as usual
33310151|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
33310152|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
32956137|NCT05735262|Experimental|DLPFC group|Active iTBS will be delivered to the left DLPFC.
33310153|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
33310154|NCT03962439|Experimental|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
33310155|NCT03962439|Active Comparator|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
33310156|NCT03962439|Placebo Comparator|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
33310157|NCT01082055||Currently receiving antiarrythmic drugs|
33310158|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
33310159|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
33310160|NCT01085487||Group 1|
33310161|NCT01085487||Group 2|
33310162|NCT01085487||Group 3|
33310163|NCT01085565|Experimental|Exablate treatment|
33310164|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS < 8 points).
33310165|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
33310166|NCT03962205|Experimental|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
33310167|NCT03962205|Placebo Comparator|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
33310168|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
33310169|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
33310170|NCT01311310|Experimental|remote ischemic preconditioning|
33310171|NCT01089387|Experimental|injection of bone marrow cells|
33310172|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
33310173|NCT01085721|Active Comparator|Dexchlorpheniramine|
33310174|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
33310175|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
33310176|NCT00006392|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
33310177|NCT00006392|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
33310178|NCT00006392|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
33310179|NCT00006392|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
33310180|NCT01089621|Experimental|Duloxetine|
33310181|NCT03951272|Experimental|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
33310182|NCT03951272|Active Comparator|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
33310183|NCT01101152|Experimental|Female|
33310184|NCT01101152|Experimental|Male|
32945712|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32945713|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
32945714|NCT04329377||platelet count in iiron overload|
33095216|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
33095217|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
33095218|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
33095219|NCT04519359|Experimental|Stop Arm|Stop NAs therapy
32945715|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
32945716|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
32945717|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32945718|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
32945719|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
32945720|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
32945721|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
32945722|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
32945723|NCT00384527|Experimental|1|
32945724|NCT00384527|Active Comparator|2|
32945725|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
33095220|NCT04519359|No Intervention|Continue Arm|Continue NAs therapy
33095221|NCT04518774|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
33095222|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
33095223|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
33095224|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
33095225|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
33095226|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
33095227|NCT04518813|Experimental|RSP-24|Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.
33095228|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
33095229|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
33095230|NCT04518852|Experimental|Treatment group|The participants will receive the combined treatment of local therapy (TACE, oxaliplatin and epirubicin), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
33095231|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
33095232|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
33095233|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
33310185|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
33310186|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
33310187|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
32945726|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
32945727|NCT00003953|Experimental|Doxorubicin and Docetaxel|
33310188|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
33310189|NCT00006164|Experimental|1|Peg-interferon alfa-2a 90 mcg/week
33310190|NCT00006164|Active Comparator|2|Standard of care followup
33318584|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
33318585|NCT03804320|Other|Patients with small renal masses|Active surveillance
32945728|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
32945729|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
32945730|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
32945731|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
32945732|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
32945733|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
32945734|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
32945735|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
32945736|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
32945737|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
32945738|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
32945739|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
32945740|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
32945741|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
32956138|NCT05735262|Experimental|DMPFC group|Active iTBS will be delivered to the left DMPFC.
32945742|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
32945743|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
33095234|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
33095235|NCT04518735||Patients on previous oral anticoagulant treatment|Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication
32945744|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
33095236|NCT04518735||Patients on previous antiplatelet therapy|Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication
32945745|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
32945746|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
32945747|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
32945748|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
32945749|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
32945750|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
32945751|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
33095237|NCT04518735||Patients without antithrombotic therapy|Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy
33095238|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
33095239|NCT04518618|Experimental|Group F|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml).
33095240|NCT04518618|Experimental|Group FN|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml) plus 20 ugs naloxone.
33095241|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
33095242|NCT01311505|Active Comparator|A|Test
33095243|NCT01311505|Active Comparator|B|Reference
33095244|NCT04518423||Elderly people over the age of 65 years|The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. The subjects will be followed up for 5 years to investigate the frailty and disability development, and survival.
32945752|NCT00004139|Experimental|Gemcitabine + Irinotecan|
32945753|NCT00004139|Experimental|Gemcitabine + Docetaxel|
32945754|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
32945755|NCT04212923|Experimental|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
32945756|NCT04212923|No Intervention|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
32945757|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly~CAT or MRI scans will be performed every 2 cycles"
32945758|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
32945759|NCT00384137|Experimental|1|
32945760|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
32945761|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
32945762|NCT00384995|Active Comparator|Saline|Standard volume expansion
32945763|NCT00003299|Active Comparator|Cisplatin + Etoposide|
32945764|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
32801908|NCT03534934|Experimental|3 year follow-up|"All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
32801909|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
32801910|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
32801911|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
32801912|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
33095245|NCT05644366|Experimental|Balance Assessment Children with Autism|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
32801913|NCT01676350|Experimental|IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
32801914|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
32801915|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
32801916|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
32801917|NCT03422770|Other|Controls|100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.
33095246|NCT05644327|Experimental|Cardiovascular training (CT)|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and, through a linear progression, will reach vigorous intensity; then, this intensity will be maintained until the end of the training period. Each session will include five minutes of warm-up and cool-down performed at the beginning and at the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool-down. CT's sessions will last approximately 45 minutes (30 to 50 minutes) and will be interspersed with 48 hours of recovery.
33404577|NCT05192967|Experimental|Experimental 2|"The training program determined to the experimental group was applied with video.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
33404578|NCT05192967|Other|Control 1|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
33404579|NCT05192967|Other|Control 2|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
33404580|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
32801920|NCT03422302|Experimental|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
32801921|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
32801922|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
32801923|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
32801924|NCT03419572||Second line therapy|Data collection
32801925|NCT03419572||Third and later line therapy|Data collection
32801926|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
32801927|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
32801928|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
32801929|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
32801930|NCT03088228||healthy pregnants|
32801931|NCT03088228||mild preeclampsia|
32801932|NCT03088228||severe preeclampsia|
32801933|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
32801934|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
32801935|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
32801936|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
32801937|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
32801938|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
32801939|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes Studies VX17-445-102 and VX17-445-103."
32801940|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
32801941|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
33095247|NCT05644327|Experimental|Resistance training (RT)|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start and end with five-minute of warm-up and cool-down, which will include exercise on a recumbent stepper and stretching, respectively. RT's sessions will last approximately 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
33095248|NCT05644327|Experimental|Multimodal training (MT)|Multimodal training (MT) will combine cardiovascular and resistance training interventions using the modalities described previously, but each component will be shortened to match the overall training duration (i.e., volume) among groups. The first part of each training session will always include three resistance exercises, which will be followed by 15-20 minutes of cardiovascular training performed on the total body recumbent stepper. Periodization will follow the same progression previously described for cardiovascular and resistance training, respectively, reaching vigorous intensity towards the end of the training period. Training sessions will include a five-minute warm-up and cool-down on the total body recumbent stepper. MT's sessions will approximately last 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
33095249|NCT05644327|No Intervention|Control condition (CON; waiting list)|The control condition (CON; waiting list) will receive no intervention (i.e., exercise) but usual care. Participants in the CON will be required to go about their normal life, maintaining their current physical activity levels until the end of the study. Then, they will be offered to join one of the training programs/condition.
32801942|NCT02402920|Experimental|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
32801943|NCT02402920|Experimental|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
33095250|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32801944|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
32801945|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
32801946|NCT02404402|Experimental|Active LED|Active LED Treatment
32801947|NCT02404402|Sham Comparator|Sham LED|Inactive (sham) LED Treatment
32801948|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
33095251|NCT04518579|Active Comparator|Group (EP)|Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
33095252|NCT04518579|Active Comparator|Group (EH)|Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
33095253|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
33095254|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
33095255|NCT04518540|Experimental|lipoic acid group|The patients will take lipoic acid by intravenous. At the same time, the patients will take take riluzole tablets orally everyday.
33095256|NCT04518540|Experimental|control group|The patients will take riluzole tablets orally everyday.
33095257|NCT01240655|Experimental|LCL161 + Paclitaxel|
33095258|NCT04518267||Civilian group|Participants with civilian status
33095259|NCT04518267||Military group|Participants with military status
33095260|NCT04518189|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
33095261|NCT04518189|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
33404581|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
32801949|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
32801950|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
32801951|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
32801952|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
32801953|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
32801954|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
32801955|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
33404582|NCT04342078||Preterm Child group|Preterm children at the age of 5 years; Born before 34 gestation weeks in 2014-2017; Cared in Oulu University Hospital
32945765|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
32945766|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
32945767|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
32945768|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
32945769|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
32945770|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
32945771|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
32945772|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
32945773|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
32945774|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
32945775|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
32945776|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32945777|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32945778|NCT04195061|Other|Cardiopulmonary exercise testing|
32945779|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
32945780|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
32945781|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
32945782|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
32945783|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
32945784|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
32945785|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
32945786|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
32945787|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
32945788|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
32945789|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
32945790|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
32945791|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
32945792|NCT00004769||Healthy controls|Healthy subjects
32945793|NCT00004769||Disease controls 1|Subjects with FSHD
32945794|NCT00004769||Disease controls 2|Subjects with CMT
32945795|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
32945796|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
32801956|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
32801957|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
32801958|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
32801959|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
32801960|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
32801961|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
32801962|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
32801963|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
32945797|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
32801964|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
33318586|NCT00302081|Active Comparator|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
33318587|NCT00302081|Experimental|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
33318588|NCT00302081|Experimental|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
33318589|NCT01060709||elective colonoscopy and requiring sedation|
33318590|NCT00302003|Experimental|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 & 2, Vincristine sulfate IV (1.4 mg/m2 [max 2.8 mg]) Days 1 & 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 & 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
32945798|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
32945799|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
32945800|NCT00423371|Experimental|EUFLEXXA™|
32945801|NCT00423371|Placebo Comparator|Placebo|
33318591|NCT00036270|Experimental|exemestane|
33318592|NCT00036270|Experimental|tamoxifen + exemestane|
33318593|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
32899687|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
32945802|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
33318594|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
33318595|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
32945803|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
32956139|NCT05735262|Sham Comparator|Sham to DLPFC group|Sham iTBS will be delivered to left DLPFC.
32956140|NCT05735262|Sham Comparator|Sham to DMPFC group|Sham iTBS will be delivered to left DMPFC.
33318596|NCT00049530|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
33318597|NCT00301067|Experimental|Cohort 1 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
32945804|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
32945805|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
32945806|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
32945807|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
32899688|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
32945808|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
32945809|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
32945810|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
32945811|NCT04172844|Experimental|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
32945812|NCT04172844|Experimental|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
32945813|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
32945814|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
32945815|NCT00005639|Experimental|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
32945816|NCT00005639|Experimental|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
32945817|NCT00005639|Experimental|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
32945818|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
32945819|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
32945820|NCT00385853|Experimental|PTK787|Single arm study of PTK787
32945821|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
32945822|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
32945823|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
33095262|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
33095263|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
33318598|NCT00301067|Experimental|Cohort 2 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
32801965|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
32801966|NCT02400736|Active Comparator|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
32801967|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
33095264|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
33095265|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
33095266|NCT00482378|Experimental|Sm 153 lexidronam|
33095267|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33095268|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33095269|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33095270|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33318599|NCT00301067|Experimental|Cohort 3 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
33318600|NCT00301067|Experimental|Expansion - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
33318601|NCT02530164|Active Comparator|real tDCS|
33318602|NCT02530164|Placebo Comparator|sham tDCS|
33318603|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
32801968|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
32801969|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
32801970|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
33318604|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
32801971|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
32801972|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
33095271|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33095272|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
33095273|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
33095274|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
33095275|NCT02275572|No Intervention|Control|Usual procedure.
33095276|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
33095277|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
33095278|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
33095279|NCT00480896|Experimental|1|
33095280|NCT00480896|Placebo Comparator|2|
33095281|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
33095282|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
33095283|NCT00482820|Experimental|1|attention training away from threat
33095284|NCT00482820|Placebo Comparator|2|placebo attention training
33095285|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
33318605|NCT03979859|Experimental|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
32801973|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
32801974|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
32801975|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
32801976|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
32801977|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
32801978|NCT02072421|Other|Non-SOS|
32801979|NCT04761861|Experimental|Vildagliptin|Vildagliptin 50 mg tablet daily
32801980|NCT04761861|Placebo Comparator|Placebo|Placebo tablet daily
32801981|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
32801982|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
32801983|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
33095286|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
33095287|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
33095288|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
33318606|NCT03979859|Placebo Comparator|Placebo|Visually matching placebo
33095289|NCT04518150|Experimental|study group|patients with placenta previa undergoing cesarean section underwent bilateral uterine artery ligation plus insertion of Bakri balloon
33095290|NCT04518150|Active Comparator|control group|patients with placenta previa undergoing cesarean section underwent insertion of Bakri balloon
33095291|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
33095292|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
33095293|NCT00482651|Experimental|UAP, SAP|
33310191|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
33310192|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
33310193|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
33310194|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
33310195|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
33310196|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
33310197|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
33310198|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
33310199|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
33310200|NCT03410992|Experimental|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
33310201|NCT00377819|Experimental|denosumab|
33310202|NCT00377819|Active Comparator|alendronate|
33310203|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
33310204|NCT00377429|Experimental|catumaxomab|
33310205|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
33310206|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
33310207|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
33310208|NCT03992963|Active Comparator|Hearing Aid without frequency lowering enabled|
33310209|NCT03992963|Experimental|Hearing Aid with frequency lowering enabled|
33310210|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
33310211|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
33310212|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
33310213|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
33318607|NCT03955458|Experimental|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
33095294|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
33095295|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
33095296|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
33095297|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
33095298|NCT04517877|Experimental|Caring Light Training|Caring Light mobile app with coping skills training.
33095299|NCT04517877|Active Comparator|Educational Training|Traditional educational program.
33095300|NCT01309243|Experimental|FTC/RPV/TDF|
33095301|NCT01309243|Experimental|EFV/FTC/TDF|
33095302|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
33095303|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
33095304|NCT04517409|Experimental|GDHT|After hepatic resection (Dynamic phase), the patients received an initial hemodynamic assessment based on PPV, CI and MAP. First, preload was optimized by fluid loading until PPV was <14% or VVS <12%, subjects were given 4 ml kg-1 boluses colloid solution every 5 minutes. At this point, the patient's individual preload optimized CI was determined and used as the hemodynamic goal until the end of surgery. Only if this value was below 2.5 L/min/(m2), inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If PPV and CI were within the target range but MAP was below 65 mmHg or PPV/VVS>1,2, vasopressors were started. After the initial assessment, patients were reassessed every 15 minutes intraoperatively to maintain values.
33095305|NCT04517409|Other|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment"
33095306|NCT01240109|Active Comparator|propofol|
33095307|NCT01240109|Active Comparator|sevoflurane|
32801984|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
32801985|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
32801986|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.~Plaque 2: No Intervention"
32801987|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
32801988|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
32801989|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
32801990|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
32801991|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
32801992|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
32801993|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
33095308|NCT04517526|Experimental|1|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles , followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites
33095309|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
33095310|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
33095311|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
33095312|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
33095313|NCT01308853|Other|Macrolane|Open label
33095314|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
33095315|NCT04517331|Active Comparator|Group S (single injection TPVB group)|Patients received bilateral single injection ultrasound-guided TPVB at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
33318608|NCT03955458|Active Comparator|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
32801994|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
32801995|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
33095316|NCT04517331|Active Comparator|Group D (double injection TPVB group)|Patients received bilateral double injection ultrasound-guided TPVB at the level of T2-T3 and T4-T5 with 10 mL bupivacaine 0.375% per injection (20 mL bupivacaine 0.375% per side as the single injection group).
33095317|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
33095318|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
33095319|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
33095320|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
32801996|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
32801997|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
32801998|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
32801999|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
33095321|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
33095322|NCT04325191|Experimental|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
33095323|NCT04325191|Placebo Comparator|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
32802000|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
32802001|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
33095324|NCT04324879|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
33095325|NCT04517292|Experimental|Eribulin,cisplatin|EP (Eribulin and cisplatin combination)
33095326|NCT04517292|Active Comparator|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
33095327|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
33095328|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
33095329|NCT01308736|Active Comparator|varenicline|
33095330|NCT01308736|Placebo Comparator|placebo pill|
33095331|NCT04517214|Experimental|Toripalimab Combined with GP Arm|Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w
33095332|NCT04517214|Active Comparator|GP Arm|Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w
33095333|NCT01240187|Experimental|Experimental 1|
33095334|NCT01240187|Experimental|Experimental 2|
33095335|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
33095336|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
33095337|NCT01240226|Experimental|A|
33095338|NCT01240226|Experimental|B|
33095339|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
33095340|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
33095341|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
33095342|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
33095343|NCT04517097||patient group|patients treated in the french anti-cancer center of the study
33095344|NCT04517097||salaried staff group|all salaried staff of the french anti-cancer center of the study
33095345|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
33095346|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
33095347|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
33095348|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
33095349|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
33095350|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
33095351|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
33095352|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
32945824|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
32945825|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
33310214|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete"
32945826|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
33095353|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
33095354|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
33310215|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
33310216|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
32945827|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
33310217|NCT05625646||Course participants|Participants will be enrolled in a quality assurance program with an online multiple-choice quiz including still-pictures and video sequences of 10 application specific POCUS examinations. Through 15-20 questions, the quiz tests participants (1) knowledge about indications for performing POCUS examinations, (2) applied knowledge of ultrasound equipment, (3) ability to optimize images, (4) ability to recognize and present structures, (5) ability to interpret images, (6) ability to describe and document findings and (7) medical decision-making. Following the quiz, the participants are offered guidance to improve their performance.
33318609|NCT03983681|Experimental|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
32945828|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
32945829|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
32945830|NCT00005807|Experimental|Treated Participants|dose escalation treatment
32945831|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
32945832|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
32945833|NCT04567433||ADRENAL study|Participants in the ADRENAL study
32945834|NCT04569929|Active Comparator|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
32945835|NCT04569929|Experimental|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
32945836|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
32945837|NCT00003653|Active Comparator|Continuous Androgen Suppression|
32945838|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
32945839|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
32945840|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
32945841|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
32945842|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
32945843|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
32945844|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
32945845|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
32945846|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
32945847|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
32945848|NCT04329143|Active Comparator|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
32945849|NCT04329143|Active Comparator|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
32945850|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
32945851|NCT00003779|Active Comparator|BCG-Connaught|
32945852|NCT00003779|Active Comparator|BCG Onko-Tice|
33310218|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
33310219|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
33310220|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
33310221|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
33310222|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
32945853|NCT05444153|Experimental|Oral semaglutide|Participants will receive once daily oral semaglutide tablet for 104 weeks in a dose escalation fashion of 3milligrams (mg), 7mg, 14 mg and 25 mg once every four weeks during the first 16 weeks and a maintenance dose of 55 mg for the rest 88 weeks.
32945854|NCT05444153|Active Comparator|Empagliflozin|Participants will receive once daily empagliflozin tablet for up to 104 weeks, starting with a dose of 10 mg for the first 8 weeks and the maintenance dose of 25 mg for the rest 96 weeks.
32945855|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
32945856|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
32945857|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
32945858|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
32945859|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
32945860|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
32945861|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
32945862|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
32945863|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
32945864|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
32945865|NCT02210663|Experimental|veliparib (ABT-888)|
32945866|NCT04568525|Active Comparator|COVID - 19 patients|
32945867|NCT04568525|Active Comparator|COVID - 19 and pneumonia patients|
32945868|NCT04568525|Active Comparator|Health patients|
32945869|NCT04568837|Experimental|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
32945870|NCT04568837|No Intervention|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
32945871|NCT04568291|Active Comparator|routine treatment|routine treatment
32945872|NCT04568291|Experimental|model treatment|model treatment
32945873|NCT04569617|Active Comparator|upper limb endurance protocol|UL endurance protocol - elbow flexion
32945874|NCT04569617|Active Comparator|upper limb strength protocol|UL strength protocol - elbow flexion
32945875|NCT04569617|Active Comparator|lower limb endurance protocol|LL endurance protocol - knee extension
32945876|NCT04569617|Active Comparator|lower limb strength protocol|LL strength protocol - knee extension
32945877|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival >28d Thromboembolic events~General data:~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure~Data records:~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
33095355|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
33095356|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
33095357|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
33095358|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
33095359|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
33095360|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
33095361|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
33095362|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
33095363|NCT04517175||Myelodysplastic syndrome (MDS) patients|MDS patients will be divided according to prognostic parameters in sub-cohorts.
33095364|NCT04517175||Acute myeloid Leukemia (AML) patients|AML patients will be divided according to prognostic parameters in sub-cohorts.
33095365|NCT04517175||Myelodysplastic syndrome/neoplasm (MDS/MPN) patients|MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
33095366|NCT04516980||Participants with ankle sprain.|Participants with ankle sprain
33310223|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
33310224|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
33095367|NCT04516980||Participants without ankle sprain|Participants without ankle sprain
33095368|NCT04516863|Active Comparator|Patients with depression|"Major depression according to DSM-V and ICD-10 (ICD F32.1, F32.2, F32.3, F33.1, F33.2, F33.3)~Hamilton Depression Rating Scale > 17"
33095369|NCT04516863|Active Comparator|Healthy controls|- Mental health
33095370|NCT04517019|Experimental|Arm A (Tracker/daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
33095371|NCT04517019|Experimental|Arm B (Tracker/no daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
33095372|NCT04517019|No Intervention|Arm C (no activity tracker)|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
33095373|NCT01241045||misoprostol|"2 groups:-~Group 1:-those with Ph<5. (n=50).~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-~Group 1A (n=25). - Group 1B (n=25).~Group 2A (n=25). - Group 2B (n=25).~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
33095374|NCT00483093|Experimental|A|
33095375|NCT00483080|Experimental|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
33095376|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
33095377|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
33095378|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
33095379|NCT04516824||Trauma,Spine cases,Arthroplasty,Arthroscopy, Miscellaneous|
33095380|NCT00483158|Placebo Comparator|A|Rising Single Dose
33310225|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
33310226|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
33310227|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
33318610|NCT03983681|Placebo Comparator|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
33095381|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
33095382|NCT00483158|Experimental|C|Open Label H. pylori cohort
33095383|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
33095384|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
33095385|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
33095386|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
33310228|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
33310229|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
33310230|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
32945878|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.~Parameters as in Group of Cytosorb recipients"
32945879|NCT04567043|Experimental|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
33310231|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
33310232|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
33310233|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
32945880|NCT04567043|Active Comparator|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
32945881|NCT04569071|Experimental|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
33318611|NCT00007020|Other|Cholic Acid|
32945882|NCT04568057|Active Comparator|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
32945883|NCT04568057|Placebo Comparator|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
32945884|NCT04568135||survey|
32945885|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
32945886|NCT04566809|Experimental|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
32945887|NCT04566809|Active Comparator|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
32945888|NCT04569305|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
32945889|NCT04569305|Active Comparator|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
32945890|NCT04567823|Experimental|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
32945891|NCT04567823|Experimental|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
32945892|NCT04567823|Placebo Comparator|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
32945893|NCT04567823|No Intervention|Control|no intervention (no smoothie, no menu plans)
32945894|NCT04568447|Experimental|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
32945895|NCT04566107|No Intervention|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
32945896|NCT04566107|Experimental|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
32945897|NCT04566107|Experimental|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
32945898|NCT04568915|Experimental|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
32945899|NCT04568915|Active Comparator|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
32945900|NCT04569227|Experimental|Active EC-18|
32945901|NCT04569227|Placebo Comparator|Placebo|
32945902|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
32802002|NCT03501082|Experimental|L. reuteri PB-W1, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
32802003|NCT03501082|Experimental|L. reuteri DSM20016T, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
32802004|NCT03501082|Placebo Comparator|Placebo, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
32802005|NCT03501082|Experimental|L. reuteri PB-W1, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
32802006|NCT03501082|Experimental|L. reuteri DSM20016T, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
32802007|NCT03501082|Placebo Comparator|Placebo, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
32802008|NCT03500458|No Intervention|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
32802009|NCT03500458|Experimental|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep.
32802010|NCT03086278|Experimental|Single Ascending Dose|
32802011|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
32802012|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
32802013|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
32802014|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
32802015|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
32802016|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
32802017|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
32802018|NCT00089284|Experimental|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
32802019|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
32802020|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
32802021|NCT00087646|Experimental|1|
32802022|NCT00087646|Experimental|2|
32802023|NCT00087646|Experimental|3|
32802024|NCT00087646|Active Comparator|4|
32802025|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
32802026|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
32802027|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
32802028|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
32802029|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
32802030|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
32802031|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
32945903|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
32945904|NCT04565639|Experimental|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
32945905|NCT04565639|Experimental|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
32945906|NCT04564235|Experimental|Indication for a genome-wide analysis in the proband|
33095387|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
33095388|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).~Part B:~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.~Part C:~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
33310234|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
33310235|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)~FFP will be provide as a solution for intravenous administration, once thawed.~The dose of the FFP will be ~ 15 mL/kg.~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
32802032|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
32945907|NCT04564001|Experimental|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
32802033|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
32802034|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
32802035|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
32802036|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
32802037|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
32802038|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
32802039|NCT00087568|Experimental|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day [(mg/day), < or >=75 kilogram (Kg) body weight, respectively], orally in divided doses for 60 weeks.
32802040|NCT00087568|Experimental|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (< or >=75 kg body weight, respectively) orally in divided doses for 36 weeks.
32802041|NCT04402216|No Intervention|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
32802042|NCT04402216|Experimental|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
32802043|NCT04402216|Experimental|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
32802044|NCT04402216|Experimental|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
32802045|NCT05346562|Experimental|Cannabidiol, then Placebo|Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks. After two week washout, participant receives Placebo for five weeks (matching Cannabidiol tablets)
32802046|NCT05346562|Experimental|Placebo, then Cannabidiol|Participant receive placebo tablets (matching Cannabidiol pills) for five weeks. After two week washout, Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks.
32802047|NCT04402762|Experimental|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
32802048|NCT04402762|Active Comparator|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
33095389|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
33095390|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
33095391|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
33095392|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
33095393|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
33095394|NCT04325152|Experimental|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
33095395|NCT04325152|Sham Comparator|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
33095396|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
33095397|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
33095398|NCT00483314|Experimental|1|
33095399|NCT04516629||Experimental|subjects with sub-health status
33095400|NCT04324918|Experimental|HCP1102|
33095401|NCT04324918|Active Comparator|HGP1408|
33095402|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
33095403|NCT00483483|Active Comparator|Attention-control group|health education & support
33095404|NCT01308424|Experimental|BTL TML HSV|
33095405|NCT01308424|Placebo Comparator|Matching Placebo|
33095406|NCT05644288|Experimental|Intervention group|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation."
33095407|NCT05644288|No Intervention|Control group|No intervention will be performed in the control group and the subjects will be contacted on the same dates as the intervention group for data collection.
33095408|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
33310236|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
33310237|NCT01324505|Experimental|One-sequence cross-over arm|
33310238|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
33095409|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
33095410|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
33310239|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
33310240|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
33310241|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
33310242|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
33310243|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
33310244|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
33310245|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
33310246|NCT01041599||Hypertensive patients|Patients with essential hypertension
33310247|NCT01041599||Healthy subjects|Healthy subjects
33310248|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
33095411|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
33095412|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
33095413|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
33095414|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
33095415|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
33095416|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
33095417|NCT00483600|Experimental|no arms/one group|
33095418|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
33310249|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
33318612|NCT03955536|Active Comparator|Group A|Routine cardiac rehabilitation program (RCRP)atient education
33095419|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
33095420|NCT04516551|Experimental|anti-CD19 allo-CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10^6/KG~3×10^6 /KG 6×10^6 /KG 1×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion."
33095421|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
33095422|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
33095423|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
33095424|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
33095425|NCT04516239|Active Comparator|LDH THA|large diameter head total hip arthroplasty
33095426|NCT04516239|Active Comparator|HR|metal-on-metalhip resurfacing
33095427|NCT00483470|Experimental|1|
33095428|NCT00483470|Active Comparator|2|
33095429|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
33318613|NCT03955536|Experimental|Group B|routine cardiac rehabilitation program + virtual reality
32945908|NCT04564001|Experimental|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
32945909|NCT04565873||P1|Primigravida in group 1
32945910|NCT04565873||M1|Multipara in group 1
32945911|NCT04565873||P2|Primigravida in group 2
32945912|NCT04565873||M2|Multipara in group 2
32945913|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
32945914|NCT04565561||DCB group|DCB group, n=20
32945915|NCT04565405|Experimental|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
32945916|NCT04565405|Experimental|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
32945917|NCT04565093|Experimental|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
32945918|NCT04565093|Placebo Comparator|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
32945919|NCT04564937|Experimental|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
32945920|NCT04564937|Experimental|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
32945921|NCT04564937|Experimental|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
32945922|NCT04564937|Experimental|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
32945923|NCT04568603|Experimental|Methadone + ISL|Methadone-maintained participants (20 to 200 mg once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9 and ISL 60 mg once on Day 2.
32945924|NCT04563689|Experimental|actve|oral rinse
32945925|NCT04563689|Placebo Comparator|placebo|distilled water,
32945926|NCT04563221|Experimental|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
32945927|NCT04563221|Experimental|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
32945928|NCT04564859|Experimental|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 ~ 16 centimeter of water Exp. Pressure ： 4 ~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：> 92% By condition, gradually tap 2~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6~10 ml/kg
32945929|NCT04564859|Active Comparator|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter > 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
33310250|NCT00165425|Experimental|Cardiac screening|"Interventions:~Participants will~meet with study cardiologist~undergo cardiac risk factors screening~undergo resting and stress echocardiogram (echo and stress echo)"
33310251|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
33310252|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
33310253|NCT04468451|Experimental|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
33310254|NCT04468451|Active Comparator|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
32945930|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
33310255|NCT04468451|Active Comparator|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
33310256|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
33310257|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
33310258|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
32945931|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
32945932|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
32945933|NCT04563299|Experimental|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
32945934|NCT04563299|Active Comparator|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
32945935|NCT04561895||control group|healthy volunteers with absence of NAFLD
32945936|NCT04561895||test group|patients with confirmed NAFLD diagnosis
32945937|NCT04561583|Other|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
32945938|NCT04561583|Other|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
32945939|NCT04561505|Active Comparator|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
32945940|NCT04561505|Active Comparator|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
32945941|NCT04561817|Active Comparator|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
32945942|NCT04561817|Active Comparator|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
32945943|NCT04561349|Experimental|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
32945944|NCT04561349|Active Comparator|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
32945945|NCT04561271|Experimental|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
32945946|NCT04561271|Sham Comparator|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
32945947|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
33095430|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
33095431|NCT04516590||autoimmune antigen negative|treated with anti-epilepsy drugs
33095432|NCT04516590||autoimmune antigen positive|whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom
33095433|NCT01307800|Experimental|80 milligrams (mg) LY2140023, BID|An 80-mg LY2140023 tablet administered orally, twice daily (BID) for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time placebo tablets identical to LY2140023 are administered orally, BID.
33095434|NCT01307800|Experimental|40 mg LY2140023, BID|A 40-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
33095435|NCT01307800|Experimental|10 mg LY2140023, BID|A 10-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
33095436|NCT01307800|Placebo Comparator|Placebo|A placebo tablet administered orally, BID for 7 weeks.
33095437|NCT04516044||Video game|Patients treated by physicians who were randomized to either play an adventure-based video game that used narrative engagement to recalibrate physician heuristics in trauma triage or a puzzle-based video game that used analogical encoding to recalibrate physician heuristics in trauma triage.
33095438|NCT04516044||Control|Patients treated by physicians who were randomized either to nothing at all or to a text-based educational program.
33095439|NCT05644210||RTX+TA group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period：Telitacicept 160mg once a week for 24 weeks Basic treatment： Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
33095440|NCT05644210||RTX group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period Basic treatment：Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
33095441|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
33095442|NCT04325074|Experimental|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
33095443|NCT04325074|Experimental|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
33095444|NCT04325074|Active Comparator|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
33095445|NCT00483834|Experimental|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
33095446|NCT04324801|Experimental|Single arm|This is a within-subject repeated-measures design.
33095447|NCT01307449|Experimental|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
33095448|NCT01307449|Experimental|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
33095449|NCT01307449|Experimental|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
33095450|NCT01307449|Experimental|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
33095451|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
33095452|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
33095453|NCT04516122||Observational (biospecimen collection, DXA scan)|Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.
33095454|NCT01307020|Placebo Comparator|Placebo|
33095455|NCT01307020|Active Comparator|Ibuprofen|
33095456|NCT01307020|Active Comparator|TRAM.HCl high dose|
33095457|NCT01307020|Active Comparator|TRAM.HCl low dose|
33095458|NCT01307020|Active Comparator|DKP-TRIS high dose|
33095459|NCT01307020|Active Comparator|DKP-TRIS low dose|
33095460|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
33095461|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
33095462|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
33095463|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
33095464|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
33095465|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
33095466|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
33095467|NCT05644132|Experimental|Thumb base joint prosthesis|
33095468|NCT04515654|Experimental|Audience participants|Community members viewed the performance (intervention) and completed pre/post stigma questionnaire
33095469|NCT04324996|Experimental|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
33095470|NCT04324996|Experimental|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
33095471|NCT04324996|Experimental|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
33095472|NCT04324996|Experimental|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
33095473|NCT04324996|Experimental|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
33095474|NCT00483951||Patients with known or suspected cardiovascular disease|Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.
33318614|NCT03955536|Experimental|Group C|RCRP + inspiratory muscle training
32802049|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
32802050|NCT03487900|Other|Clinical remission CD|
32802051|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32802052|NCT00085540|Experimental|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation two dose levels:~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2~Pharmacokinetics"
32802053|NCT00085540|Experimental|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity~Romidepsin (depsipeptide): 13.3mg/m2"
32802054|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
32802055|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
32802056|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
32802057|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
32802058|NCT01677832||ADHD/Taiwan|
32802059|NCT01677832||Control/Taiwan|
32802060|NCT01677832||ADHD/Germany|
32802061|NCT01677832||Control/Germany|
32802062|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
32802063|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
33095475|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
33095476|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
33095477|NCT04516005|Experimental|foot reflexology|Foot reflexology was performed in every participant in the foot reflexology group after resting for 5 minutes in a sitting position by the same researcher who was trained and certified by the Department of Thai Traditional and Alternative Medicine, Ministry of Health.
32802064|NCT01688739|Experimental|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
33095478|NCT04516005|No Intervention|control|The control group received conventional treatment including anti-HT medications according to the standard HT guideline's recommendations. In the end of the follow-up visit, every participants were informed to adhere to their medication and were encouraged to have healthy lifestyles including salt restriction, regular exercise, and consuming healthy diets.
33095480|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
33095481|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
33095482|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
33095483|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
32802065|NCT01688739|Placebo Comparator|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
33095484|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
33095485|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
33095486|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
33095487|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
33095488|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
33095489|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
33095490|NCT04515732|Experimental|3a (apremilast intervention)|Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
33095491|NCT04515732|No Intervention|3b (non-intervention)|Observation
33095492|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33095493|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33095494|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
33095495|NCT05644054|Experimental|Treatment (THC)|patients will receive a single dose of 0.15 mg/kg cannabis oil T10/C2 (AXIBAN).
33095496|NCT05644054|Placebo Comparator|Placebo|Placebo control
33095497|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
33310259|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
33310260|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
33310261|NCT03410056|Placebo Comparator|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).
33310262|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
33310263|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
33310264|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
33310265|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
33310266|NCT03410056|Placebo Comparator|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
33310267|NCT03410056|Experimental|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
33310268|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
33310269|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
33310270|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
33310271|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
33310272|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
33310273|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
33310274|NCT00365105|Experimental|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
33310275|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
33310276|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
33310277|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
33310278|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
33310279|NCT01041989|No Intervention|Standard health counseling at baseline|
33310280|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
32802066|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
32802067|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
32802068|NCT00084838|Experimental|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
32802069|NCT01558089||etanercept + methotrexate|
32802070|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
32802071|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
32802072|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
32802073|NCT04410003|Placebo Comparator|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
32802074|NCT04410003|Active Comparator|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
32802075|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
32802076|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
32802077|NCT00084682|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32802078|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
32802079|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
32802080|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
32802081|NCT00082888|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32802082|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
32802083|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
32802084|NCT04403152|Experimental|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
33095498|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
33095499|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
32802085|NCT04403152|Active Comparator|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
33095500|NCT04515420||Group A|"Group A for patients that will need an infusion of NA solution to meet the desired CPP.~Group A will be further divided into three sub-groups: A1 for patients that will receive NA in the dose of 0.06-0.12 μg/kg/min, A2 for patients that will receive a dose of 0.13-0.2 μg/kg/min, and A3 for patients that will receive a dose of NA > 0.2 μg/kg/min."
33095501|NCT04515420||Group B|Group B for patients that will not receive NA infusion.
33095502|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
33095503|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
33310281|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
32802086|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
32802087|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
32802088|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
32802089|NCT03084952|Experimental|1 mg/day|
32802090|NCT03084952|Experimental|4 mg/day|
32802091|NCT03084952|Experimental|8 mg/day|
32802092|NCT03084952|Experimental|12 mg/day|
32802093|NCT03084952|Active Comparator|Glucantime|
32802094|NCT03084952|Experimental|Best dose 18-MC|
32802095|NCT03084952|Experimental|Minimum effective dose 18-MC|
32802096|NCT00082810|Experimental|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*.
32802097|NCT04402918|Other|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
32802098|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
32802099|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
32802100|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
32802101|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
32802102|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
33095504|NCT00483860|Experimental|Topotecan|once a day
33095505|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
33095506|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
33095507|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
33095508|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
33095509|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
33095510|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
33310282|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
33310283|NCT03992027|Experimental|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
32945948|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
33310284|NCT03992027|Other|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
32945949|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
32945950|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
32945951|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
32945952|NCT04562909||Healthy Control Group|Age matched healthy controls
32945953|NCT04562675|Experimental|Intervention group (IG)|LHA intervention group (IG)
32945954|NCT04562675|Placebo Comparator|Control group (CG)|brochure-only control group (CG)
32945955|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
32945956|NCT04562753|Active Comparator|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
32945957|NCT04562753|Active Comparator|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
32945958|NCT04562519|Experimental|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
32945959|NCT04562519|Active Comparator|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
32945960|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
32945961|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
32945962|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
32945963|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
32945964|NCT04415970|Experimental|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
32945965|NCT04415970|Active Comparator|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
32945966|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
32945967|NCT04643808|Experimental|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
32945968|NCT04643808|Experimental|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
32945969|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
32945970|NCT04640922|Active Comparator|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
32945971|NCT04640922|Placebo Comparator|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
32945972|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
32945973|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
32945974|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
32945975|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
32945976|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
32945977|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
33310285|NCT04587479|Experimental|JAB-8263|Monotherapy, dose escalation
33310286|NCT01049711||erythropoietin|
33318615|NCT03952884|Active Comparator|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
33404583|NCT04342078||Preterm Adult group|Preterm born adults at the age of 24-25 years; Born before 34 gestation weeks in 1994-1997; Cared in Oulu University Hospital
32945978|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
32945979|NCT04628910|Active Comparator|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
32945980|NCT04628910|Experimental|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
32945981|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
32945982|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
32945983|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
32945984|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
32945985|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
32945986|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
32945987|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
32945988|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
32945989|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
32945990|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
32945991|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
32945992|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
32945993|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
32945994|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
32945995|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
32945996|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
32945997|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
32945998|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
32945999|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
32946000|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
32946001|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
32946002|NCT01972074|Experimental|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.~Placebo: Capsule"
32946003|NCT01972074|Placebo Comparator|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.~Memantine: Capsule"
32946004|NCT01972074|No Intervention|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
32946005|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
32946006|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
32946007|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
32946008|NCT01946802||Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
32946009|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
32946010|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
32946011|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
32946012|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
32946013|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
32946014|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
32946015|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
32946016|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
32946017|NCT04628832|Experimental|PMP Use Mandate|
32946018|NCT04628832|Experimental|Prescribing Information|
33310287|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
33310288|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
33310289|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
33310290|NCT00048542|Experimental|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
33404584|NCT04342078||Adult Control group|Age and gender matched term born controls for comparison of the entry assessments in the Preterm Adult group
32802103|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
32802104|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
32802105|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
32802106|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
32802107|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
32802108|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
32802109|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
32802110|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
32802111|NCT03479710|No Intervention|Control|No FMT infusion.
32802112|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
32802113|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
32802114|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
32802115|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
32802116|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
32802117|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
32802118|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
32802119|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
32802120|NCT00080938|Experimental|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
32802121|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
32802122|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
32802123|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
32802124|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
32802125|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
32802126|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
32802127|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
32946019|NCT04628832|Experimental|Prescribing Information + PMP Use Mandate|
32946020|NCT04628832|No Intervention|Control / As-Usual|
32946021|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
33310291|NCT00048542|Placebo Comparator|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
33310292|NCT00048542|Experimental|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
33310293|NCT00048542|Placebo Comparator|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
33310294|NCT00048542|Experimental|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
33310295|NCT00048542|Experimental|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
33310296|NCT00048542|Experimental|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
33310297|NCT00048542|Experimental|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
33310298|NCT03955328|Experimental|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
33310299|NCT01101230|Experimental|Almond|
33310300|NCT01101230|Placebo Comparator|Muffin|
33310301|NCT03814590|Experimental|Group Low Dose_PLAIN_A|Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
32946022|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
32946023|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
32946024|NCT04661124|Other|Adult Normal Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
32946025|NCT04661124|Other|Adult Pathology Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
32946026|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
32946027|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
32946028|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
32946029|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
32946030|NCT04416360|Experimental|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
32946031|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
32946032|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
33310302|NCT03814590|Experimental|Group Medium Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310303|NCT03814590|Experimental|Group High Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310304|NCT03814590|Placebo Comparator|Group Placebo_A|Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310305|NCT03814590|Experimental|Group Low Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33404585|NCT05192811|Experimental|probiotic K56|Probiotic capsule (lactobacillus paracasei K56 10^9CFU) 1capsule/day , for 60days
33095511|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
33404586|NCT05192811|Placebo Comparator|placebo|placebo capsule(maltodextrin, 1capsule/day, 60days
33095512|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
32802128|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
32802129|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
33095513|NCT05661136|Experimental|Warm air blower|Intra-operative lower-body forced-air warming after spinal anesthesia and co-loading 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
33095514|NCT05661136|Active Comparator|Control|Co-loading of 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
33095515|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
32946033|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
33095516|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
33095517|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
33095518|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
33095519|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
32946034|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
32946035|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
32946036|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
33095520|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
33095521|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
33095522|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
33095523|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
33095524|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :~First time measure : 1 month before the scoliosis surgery~Second time measure : 3 months after the scoliosis surgery~Third time measure : 1 year after the scoliosis surgery"
33095525|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
33095526|NCT01241175|Experimental|magnesium sulfate|
33095527|NCT01241175|Placebo Comparator|normal saline|
33229193|NCT05753748|Experimental|Endoscopic Eradication Therapy|Subjects undergoing endoscopic eradication therapy will undergo radiofrequency ablation every 2-3 months until complete eradication of intestinal metaplasia (CE-IM) is achieved or 5 treatments have been delivered, whichever is first. After achieving CE-IM, surveillance endoscopy will performed every 6 months for the first year and annually thereafter until the end of the study period. Surveillance biopsies will be obtained using a standardized protocol.
33229194|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
33229195|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
33229196|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
33229197|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
33229198|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
33229199|NCT00788554|Active Comparator|1|
33229200|NCT00788554|Active Comparator|2|
33229201|NCT00844844|Experimental|Eculizumab|
33229202|NCT04158882||Patients enrolled in differentiated service delivery models|
33229203|NCT04158882||Patients not enrolled in DSD models|
33229204|NCT05748054|Active Comparator|Study group|Children who receive a single application of 38% SDF
33229205|NCT05748054|No Intervention|Control group|Children do not receive any intervention
33229206|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
33229207|NCT00702572|Experimental|1|Phase I dose escalating scheme
33229208|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
33229209|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
33229210|NCT00913172||Control group|Directly observed treatment under general health workers
33229211|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
33229212|NCT00788632|Other|physician education|Physician web modules
33229213|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
33229214|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
33229215|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
33095528|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
33095529|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
33095530|NCT05644015|Experimental|experimental group (play group)|The experimental group played the escape room game. The experimental group played the game once in total.
33095531|NCT05644015|No Intervention|control group|No intervention was made in the control group.
33095532|NCT04324723|Experimental|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
33310306|NCT03814590|Experimental|Group Low Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310307|NCT03814590|Experimental|Group Low Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310308|NCT03814590|Experimental|Group Medium Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310309|NCT03814590|Experimental|Group Medium Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310310|NCT03814590|Experimental|Group Medium Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310311|NCT03814590|Experimental|Group High Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310312|NCT03814590|Experimental|Group High Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310313|NCT03814590|Experimental|Group High Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310314|NCT03814590|Placebo Comparator|Group Placebo_B|Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
33310315|NCT01088568|Experimental|TICL group|
33310316|NCT01088568|Active Comparator|LASIK group|
33310317|NCT01085448|Other|Low back pain|Individuals with current low back pain.
33310318|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
33310319|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
33310320|NCT01085526|No Intervention|control group|control
33310321|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
33310322|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
33310323|NCT00048074|Experimental|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
33310324|NCT00048074|Experimental|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
33310325|NCT00048074|Experimental|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
33310326|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
33310327|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
33310328|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
33310329|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
33310330|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
33310331|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
33310332|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
33310333|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
33310334|NCT03831191|Experimental|50 mg LY3375880|"Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W."
33310335|NCT03831191|Experimental|150 mg LY3375880|"Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W."
33310336|NCT03831191|Experimental|600 mg LY3375880|"Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W."
32802130|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
32802131|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
32802132|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
32802133|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
32802134|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
32802135|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
32802136|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
32802137|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
32802138|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
32802139|NCT03084094|Sham Comparator|Sham|sham stimulation
32802140|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
32802141|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
32802142|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
32802143|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
32802144|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
32802145|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
32802146|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
32802147|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
32802148|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
32802149|NCT03475264||Healthy|Healthy Participants
32802150|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
32802151|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
32802152|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
32802153|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
32802154|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
32802155|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
32802156|NCT03473782||Voiding Diary|
32802157|NCT03473782||Urodynamics Correlation Study|
32802158|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
32802159|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
32802160|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
32802161|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
32802162|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
32802163|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
32802164|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
33095533|NCT04324723|No Intervention|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
33095534|NCT05643937|Active Comparator|The control group|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
33095535|NCT05643937|Experimental|Experimental group|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
33095536|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
33095537|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
33095538|NCT05643898|Experimental|Mamá, te entiendo (Mom, I get you)|Participants assigned to this arm will receive a guided 8-week cognitive-behavioral app-based intervention for reducing postpartum depressive symptoms.
33095539|NCT05643898|No Intervention|Waitlist|Participants in the WL condition will receive the same assessments as those in the intervention condition. Participants allocated to WL may access their local mental health services during their waiting period. In Chile, patients diagnosed with depression by a general practitioner have guaranteed access to treatment at low or no cost. Treatment varies according to depression severity, with group or individual therapy, alone or combined with pharmacotherapy. After the follow-up assessment, the WL group will be offered access to the intervention.
33095540|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
33095541|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
33095542|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
33095543|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
33095544|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
33095545|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
33095546|NCT04515381|Experimental|Therapeutic touch group|Each student from the Therapeutic touch (TT) group was given TT sessions via Krieger-Kunz method in a total of 8 times in the manner of twice a week for one group (Monday - Wednesday) and another group (Tuesday - Thursday) for a duration of 1 month (4 week). TT application procedure: The procedure was explained to the student, the student person was concentrated, concentrated practitioner for TT application, the student's entire body was evaluated from head to foot with the practitioner's hands at a distance of about 2 inc, hands were moved regularly and rhythmically to prevent imbalances in the energy field, the energy field was re-evaluated from top to bottom and rebalanced if there was a blocked area, finally, the student was left to rest and response to the treatment was observed. The TT sessions of 20 minutes were applied on the students and they were given a short rest at the end of the session
33095547|NCT04515381|Placebo Comparator|Placebo group|For students in the placebo group, the similar duration (20 minutes) and frequency (2 sessions a week, total of 8 sessions) of TT was applied with hands at a certain distance from the body (approximately 5 cm) and they were moved without a specific order. The application was performed by the other researcher in a separate room to the placebo group.
33095548|NCT04515381|Other|Control group|There was no attempt being made towards the students within the control group. At the end of the 4th week, all students were asked to repeat measurements
33229216|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
32802165|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
32802166|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
32802167|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
32802168|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
32802169|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
32802170|NCT04274374|Experimental|experimental arm|In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day
33095549|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
33095550|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
33095551|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
33095553|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
33095554|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
33095555|NCT05643820|Active Comparator|Group A|Patients prescribed with topical 5% Permethrin lotion two applications seven days apart and applied overnight.
33095556|NCT05643820|Active Comparator|group B|Patients weighing greater than 15kgs prescribed with oral ivermectin 200microgram/kg two doses seven days apart
33095557|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
33095558|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
33095559|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
33095560|NCT00484263|Active Comparator|1|
33095561|NCT00484302|Experimental|CapOpus|
33095562|NCT00484302|Active Comparator|Treatment as usual|
33095563|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
33095564|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
33095565|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
33095566|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
33095567|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
33095568|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
33095569|NCT04515225||HIV-infected patients|All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination
32802171|NCT04274374|Active Comparator|control arm|the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
32802172|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
32802173|NCT03083704|Experimental|Cohort 1|
32802174|NCT03083704|Experimental|Cohort 2|
32802175|NCT03083704|Experimental|Cohort 3|
32802176|NCT03083704|Experimental|Cohort 4|
32802177|NCT03083704|Experimental|Cohort 5|
32802178|NCT03083704|Experimental|Cohort 6|
32802179|NCT03083704|Experimental|Cohort 7|
32802180|NCT03083704|Experimental|Cohort 8|
32802181|NCT03083704|Experimental|Cohort 9|
32802182|NCT03083704|Experimental|Cohort 10|
32802183|NCT03083704|Experimental|Cohort 11|
32802184|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.~Cardiovascular risk factor counseling will include:~Increased risk for atherosclerosis with chronic HCV infection~Increased risk of heart attack and stroke~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
32802185|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:~HCV infection poses an increased risk for hepatocellular carcinoma~Hepatitis C is a curable disease~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)~HCV+ individuals should reduce alcohol intake and shellfish consumption"
32802186|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
32802187|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
32802188|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
33095570|NCT04514835|Experimental|Cisplatin+Capecitabine+Sintilimab|Cisplatin+Capecitabine+Sintilimab
33095571|NCT00484211|Experimental|A|
33095572|NCT00484458|Experimental|1|Wallis Stabilization System
33095573|NCT00484458|Active Comparator|2|Total Disc Replacement
33095574|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
32802189|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
32802190|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
32802191|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
32802192|NCT04279522|Experimental|Group 1 - active stimulation|
32802193|NCT04279522|Placebo Comparator|Group 2 - sham stimulation|
32802194|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
32802195|NCT04279912|Experimental|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
32802196|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
32802197|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
32802198|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
32802199|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
32802200|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
32802201|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
32802202|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
32802203|NCT01679704|Other|Food products|Ten food products will be given to all subjects
32802204|NCT04273360|Active Comparator|Systematic use group|
32802205|NCT04273360|Experimental|Restrictive use group|
32802206|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
32802207|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
32802208|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
32802209|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
32802210|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
32802211|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
32802212|NCT01679782||control group|healthy sedentary subjects
32802213|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
32802214|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
32802215|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
32802216|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
32802217|NCT04761562|Active Comparator|Control group|Patients will be treated with a standard surgical procedure - tympanoplasty.
32802218|NCT04761562|Experimental|PVRP group|Patients will be treated with a standard surgical procedure - tympanoplasty combined with PVRP. PVRP will be applied to the reconstructed tympanic membrane.
32802219|NCT05346328|Experimental|Single Group Assignment|This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.
32802220|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
32802221|NCT04403230|Experimental|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
33095575|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
33095576|NCT00484328|Experimental|1|
33095577|NCT00484328|Experimental|2|
33095578|NCT04514640|Experimental|General Meditation|"Participants will be asked to meditate every day during the daytime for at least 10 min/session. Participants can use any general meditation including the Daily Calm which can be found on the homepage or by clicking on the meditate tab in the app. Participants will be asked to not choose any sleep meditations or Sleep Stories."
33095579|NCT04514640|Experimental|Sleep Meditation|"Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the meditate tab and then sleep. Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories."
33095580|NCT04514640|Experimental|Sleep Stories|"Participants will be asked to listen to a Sleep Story every day just before going to bed for at least 10 min/session. Participants can listen to any Sleep Story which can be found by clicking on the sleep tab. Participants will be asked to not choose any general meditations including the Daily Calm or sleep meditations."
33095581|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
33095582|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
33095583|NCT04697342|Active Comparator|NIS with pressure injury(PI) education|Clinical nurses use Nursing information system(NIS) to log in nursing records every day, and pressure injury (PI) education pops out of the NIS window for teaching
33095584|NCT04697342|Active Comparator|NIS with PI education, and microvideo|In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
33095585|NCT04697342|Experimental|NIS with PI education, and workshop|In addition to the built-in PI education in the NIS that nurses use every day, an 8-hour physical course is also provided.
33095586|NCT04514796|Experimental|40 mg/0.4 mL of SB5|100 mg/mL of SB5
33095587|NCT04514796|Active Comparator|40 mg/0.8 mL of SB5|50 mg/mL of SB5
33310337|NCT03831191|Placebo Comparator|Placebo|"Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
33095588|NCT00484367|Active Comparator|1 AGT|
33095589|NCT00484367|Active Comparator|2 TFT|
33095590|NCT00484614|Active Comparator|1 PEM|
33095591|NCT00484614|Active Comparator|2 MRI|
33095592|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
33095593|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
33095594|NCT04697108|Other|Proprioception Test (TRMOPL)|In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
33095595|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
33095596|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
33095597|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
33095598|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
33095599|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
33095600|NCT04515069|Active Comparator|Traditional technique for tooth preparation.|Tooth preparation performed directly on the tooth structure
33095601|NCT04515069|Active Comparator|Aesthetic preevaluative temporary technique|Aesthetic pre-evaluative temporary (APT) was fabricated according the planned wax-up. Once the APT was approved both aesthetically and functionally, tooth preparation was performed through the APT.
33095602|NCT00484484|Experimental|1|Ketamine
33095603|NCT00484484|Experimental|2|Ketamine
33095604|NCT04514601||Pre-Intervention Group|The verbal and written handover of these patients was observed. This included 146 general orthopaedic admissions patients and 43 trauma patients. All patient data was anonymised.
33095605|NCT04514601||Post-Intervention Group|The verbal and written handover of these patients was observed after the introduction of the intervention. This included 81 general orthopaedic admissions patients and 47 trauma patients. All patient data was anonymised.
33095606|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
33095607|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
33095608|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
33310338|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
33310339|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
33310340|NCT03955094|Experimental|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
33310341|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
33310342|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
33310343|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
33310344|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
33310345|NCT01103102|Active Comparator|Lowest Dose|
33310346|NCT01103102|Active Comparator|Intermediate Dose|
33310347|NCT01103102|Active Comparator|Highest Dose|
33310348|NCT01103102|Placebo Comparator|Placebo Control|
33310349|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
32802222|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
32802223|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
32802224|NCT03466294|Experimental|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
32802225|NCT03464500|Active Comparator|Mitopure 500mg|
32802226|NCT03464500|Active Comparator|Mitopure 1000mg|
32802227|NCT03464500|Active Comparator|Placebo|
32802228|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
32802229|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
32802230|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
32802231|NCT03435250|Experimental|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
32802232|NCT03435250|Experimental|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
32802233|NCT03435250|Experimental|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
32802234|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
32802235|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
32802236|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
32802237|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
32802238|NCT05346952|Experimental|TQB2450 injection + carboplatin + pemetrexed|TQB2450 injection：1200 mg, Intravenous drip d1； carboplatin ：Area Under Curve 5mg/mL/min，Intravenous drip d1；Pemetrexed: 500mg/m2，Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to TQB2450 injection（1200 mg, Intravenous drip d1）+Pemetrexed（500mg/m2，Intravenous drip d1）+ Anlotinib (10mg, peros every day, d1-14) . The regimen is repeated every 3 weeks until the disease progresses.
32802239|NCT05346952|Active Comparator|TQB2450 injection + Anlotinib + Pemetrexed|Tilelizumab: 200 mg, Intravenous drip d1;carboplatin : AUC 5mg/mL/min, Intravenous drip d1；Pemetrexed: 500mg/m2, Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to Tilelizumab (200 mg, Intravenous drip d1)+Pemetrexed (500mg/m2，Intravenous drip d1).The regimen is repeated every 3 weeks until the disease progresses.
32802240|NCT03089788|Other|Home-based test and skin test|
32802241|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
32802242|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
32802243|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
32802244|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
32802245|NCT04402450|Active Comparator|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
32802246|NCT04402450|Experimental|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
32802247|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
32802248|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
32802249|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
32802250|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
32946037|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
32946038|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
32946039|NCT04625790|Experimental|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
32946040|NCT04625790|Placebo Comparator|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
32946041|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
32946042|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
32946043|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
32946044|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
32946045|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
32946046|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
32946047|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
32946048|NCT04624074|Experimental|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
32946049|NCT05120154|Experimental|Intervention|Access to all the CAPACITI module materials, provided on a learning management system. The intervention group will also receive the CAPACITI program with module facilitation, namely high-facilitation and expert coaching in the coverage of module materials in four live webinars (bimonthly for the 2 month duration of the module = 4 webinars).
32946050|NCT05120154|Active Comparator|Control|Access to all the CAPACITI module materials, provided on a learning management system. The control group will not receive module facilitation (i.e., will entail self-directed learning).
32946051|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
32946052|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
32946053|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
32946054|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
32946055|NCT01919814|Active Comparator|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
32946056|NCT01919814|Placebo Comparator|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
32946057|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
32946058|NCT01968954|Placebo Comparator|Placebo|
32946059|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
32946060|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
32946061|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
32946062|NCT04615182|Experimental|OCS Preservation|
32946063|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
32946064|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
32946065|NCT01913340|Placebo Comparator|Normal saline|
32946066|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
32946067|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
32946068|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
32946069|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
32946070|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
32802251|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
32802252|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
32802253|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
33095609|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
33095610|NCT00484601|Experimental|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
33095611|NCT00484770|Other|Congestion Score Strategy|
33095612|NCT00484770|Other|BNP Strategy|
32802254|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
32802255|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
32802256|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
32802257|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
32802258|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
32802259|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
32802260|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
32802261|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
32802262|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
32802263|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
32802264|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
32802265|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
32802266|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
32802267|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
32802268|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
32802269|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
32802270|NCT03082066||Adults|Even or older 18 years
32802271|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
32802272|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
32802273|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
32802274|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
32802275|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
32946071|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
32946072|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
32946073|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
32946074|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
32946075|NCT01910298|Active Comparator|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
33095613|NCT04514718|Active Comparator|low energy holmium laser|30 watts
33095614|NCT04514718|Active Comparator|high energy holmium laser|80-100 watts
32802276|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
32802277|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
32802278|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
33095615|NCT04514406||APERTO OTW DCB|Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
33095616|NCT04514094|Experimental|Silver Diamine Fluoride|"Gross debris will be removed with cotton pellets to allow better SDF contact with denatured dentin.~Cotton rolls will be used to protect surrounding gingival tissues and mucous membranes to avoid pigmentation or irritation.~Affected tooth surfaces will be dried with a gentle flow of air.~1-2 drops only of SDF will be used for the whole visit.~SDF will then be directly applied to affected tooth surfaces only using a micro sponge brush.~At least one minute will be needed to allow drying of SDF.~Excess SDF will finally be removed with cotton rolls to minimize systemic absorption.~When possible, isolation will be continued for up to three minutes.~After 2-4 weeks: reapplication will be done only to lesions that do not appear arrested (dark and hard)."
32802279|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
32802280|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
32802281|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
32802282|NCT03394456|Experimental|Intervention|Receive diabetes group visits/diabetes program
33095617|NCT04514094|Active Comparator|Atraumatic Restorative Treatment|"Caries removal by hand instruments with care not to expose the pulp.~Maximum excavation from the periphery of lesions will be done, to minimize leakage at the restoration margins.~Cotton roll isolation will then be carried out.~Cavities will be restored by glass ionomer cement.~Hand pressure should be applied by a gloved and petroleum jelly coated finger, then, excess material will be removed."
33095618|NCT00484796||1|Patients undergoing carotid surgery
32802283|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control) for cohorts 1-4 case-matched comparisons via chart review for cohort 5
32802284|NCT05345938|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Stage 1: Subjects with R/R AML will receive one of three dose-escalation (30 mg/m^2, 36 mg/m^2, 40 mg/m^2) Mitoxantrone Hydrochloride Liposome, IV, on day 1 of each 28-day cycle (q4w).~Stage 2: Subjects with R/R AML or unfit AML will receive one dose Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 6 cycles."
33095619|NCT04514289||assesment SLND with enjection by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
33095620|NCT04514289||assesment SLND with hysterescopy by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.
33095621|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
32802285|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
32802286|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
32802287|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
32802288|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
32802289|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
32802290|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
32802291|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
32802292|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
32802293|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
32802294|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
32802295|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
32802296|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
32802297|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
32802298|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
32802299|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
32802300|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
32802301|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
33095622|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
33095623|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
33095624|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
32802302|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
32802303|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
32802304|NCT04401670|Other|Triage with different options|"Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)~ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)~Visual Inspection after Acetic Acid (VIA)"
32802305|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
32802306|NCT03088774|Experimental|Patient Handbook|Public available information.
32802307|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
32802308|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
32802309|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
32802310|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
32802311|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
32802312|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
32802313|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
32802314|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
32802315|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
32802316|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
32802317|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
32802318|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
32802319|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
32802320|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
32802321|NCT04402528|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
32802322|NCT01610336|Experimental|INC280 100 mg Cap QD Phase Ib|cap=capsule; QD=once daily
32802323|NCT01610336|Experimental|INC280 200 mg Cap QD Phase Ib|cap=capsule; QD=once daily
32802324|NCT01610336|Experimental|INC280 400 mg Cap QD Phase Ib|cap=capsule; QD=once daily
32802325|NCT01610336|Experimental|INC280 800 mg Cap QD Phase Ib|cap=capsule; QD=once daily
32802326|NCT01610336|Experimental|INC280 200 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
32802327|NCT01610336|Experimental|INC280 400 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
32802328|NCT01610336|Experimental|INC280 600 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
32802329|NCT01610336|Experimental|INC280 200 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
32802330|NCT01610336|Experimental|INC280 400 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
32802331|NCT01610336|Experimental|INC280 400 mg Cap BID Phase II|cap=capsule; BID=twice daily
32802332|NCT01610336|Experimental|INC280 400 mg Tab BID Phase II|tab=tablet; BID=twice daily
33095625|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
32946076|NCT01910298|Active Comparator|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
32946077|NCT05116878|Experimental|Omega-3 Group|Subjects will receive omega-3 supplementation (Nature's Bounty Fish Oil 1400 mg, containing 980 mg Omega-3 per capsule), to begin taking 3 days prior to surgical resection of their vestibular schwannoma. Subjects will continue to take the omega-3 supplementation for 6 weeks post-operatively.
33310350|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
32946078|NCT05116878|Placebo Comparator|Placebo Group|Subjects will receive a placebo to begin taking 3 days prior to clinical care of surgical resection of vestibular schwannoma. Subjects will continue to take the placebo for 6 weeks post-operatively.
32946079|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
33095626|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
33310351|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
33310352|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
33310353|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
32946080|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
32946081|NCT05114694|Experimental|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
32946082|NCT05114694|Placebo Comparator|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
32946083|NCT01908816|Experimental|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
32946084|NCT01908582|Experimental|Evacetrapib|"Period 1:~130 milligram (mg) evacetrapib administered orally, once on Day 1"
32946085|NCT01908582|Experimental|Evacetrapib + Rifampin|"Period 2:~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)~Evacetrapib: 130 mg administered orally once on Day 16"
32946086|NCT04621188|Experimental|Lorlatinib|100 mg once daily
32946087|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
32946088|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
32946089|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
32946090|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
32946091|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
32946092|NCT01889862|Placebo Comparator|20 mg/day Placebo|20 mg/day Placebo self-administered daily
32946093|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
32946094|NCT01889862|Placebo Comparator|40 mg/day Placebo|40 mg/day Placebo self-administered daily
33404587|NCT03143296|Experimental|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
32946097|NCT01887912|Experimental|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
32946098|NCT01887912|Placebo Comparator|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
32946099|NCT04415346|Experimental|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
32946100|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
32946101|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
32946102|NCT01887600|Experimental|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
33095627|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
33095628|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
33095629|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
33095630|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
33310354|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
33310355|NCT00005906|Experimental|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
33310356|NCT01095614||12 women with oral contraception|
33310357|NCT01095614||12 women without any contraception|
33095631|NCT01241370||Type 2 diabetic patients|
33095632|NCT01241409|Experimental|Treatment sequence ABC|
33095633|NCT01241409|Experimental|Treatment sequence ACB|
33095634|NCT01241409|Experimental|Treatment sequence BAC|
33095635|NCT01241409|Experimental|Treatment sequence BCA|
33310358|NCT03951038|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
33095636|NCT01241409|Experimental|Treatment sequence CAB|
33095637|NCT01241409|Experimental|Treatment sequence CBA|
33310359|NCT03951038|Experimental|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
33310360|NCT03949010|Experimental|Kinesiotaping with space correction technique|
33310361|NCT03949010|Experimental|Kinesiotaping with muscle inhibition technique|
33310362|NCT03949010|Active Comparator|Home exercise program|
33095638|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
33095639|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
33310363|NCT01103336|Experimental|Nicorandil in saline|
33310364|NCT01103336|Placebo Comparator|saline|
33310365|NCT03950960|Experimental|BMS-986256 +Itraconazole|
33310366|NCT03955016|Experimental|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
33310367|NCT03955016|No Intervention|Control group|Usual care
33310368|NCT03954860|Experimental|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
33310369|NCT03954860|Active Comparator|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
33095640|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
33095641|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
33310370|NCT05625698|Other|MagTrace only|Cohort 1: Clinically node negative patients undergoing neoadjuvant chemotherapy. This cN0-group will receive MagTrace injections before start of neoadjuvant chemotherapy followed standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
33310371|NCT05625698|Other|MagTrace and Magseed|Cohort 2: Clinically node positive patients undergoing neoadjuvant chemotherapy. This N+ group will receive MagTrace injection in the breast to mark sentinel nodes and Magseed will be inserted into the index metastatic node before the start of neoadjuatnt chemotherapy followed by standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace / Magseed will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
33310372|NCT03949166|No Intervention|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
33095642|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
33310373|NCT03949166|Experimental|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
33310374|NCT00066690|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
33310375|NCT00066690|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
33310376|NCT00066690|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
33310377|NCT01095692|Active Comparator|only surgery|
33310378|NCT01095692|Experimental|surgery + TOT|
33310379|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
33310380|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
33310381|NCT03949088|Experimental|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
33310382|NCT03949088|Experimental|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
33095643|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
33095644|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
33095645|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
33095646|NCT01241357||Observation only|This study has a single arm and no intervention.
33095647|NCT00485004|Experimental|Cutting balloon|Cutting balloon
33095648|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
33095649|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
33095650|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
33095651|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
33095652|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
33095653|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
33095654|NCT01242878||patients|sickle cell disease patients
33095655|NCT04514172|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
33095656|NCT04514172|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
33095657|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
33095658|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
33095659|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
33095660|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
33095661|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
33095662|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
33095663|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
33095664|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
33095665|NCT01242917|Placebo Comparator|Placebo|
33095666|NCT01242917|Experimental|CCX354-C 100mg twice daily|
33095667|NCT01242917|Experimental|CCX354-C 200mg once daily|
33095668|NCT04513704|Experimental|Oral Semaglutide A|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 2 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
33095669|NCT04513704|Experimental|Oral Semaglutide B|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 4 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
33095670|NCT04513704|Experimental|Oral Semaglutide C|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 6 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
33095671|NCT04513704|Experimental|Oral Semaglutide D|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-dose fasting time of 2 hours followed by a post-dose overnight fast.
33229217|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
33229218|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
33229219|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
33229220|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
33229221|NCT00658684|Experimental|Fesoterodine fumarate|
33229222|NCT04046146|Experimental|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
33229223|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
33229224|NCT00800098|Active Comparator|Active|AARP active arthritis cream
33229225|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
33229226|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
33229227|NCT00800332|Experimental|1|
33229228|NCT00800332|Experimental|2|
33229229|NCT00800332|Placebo Comparator|3|
33229230|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
33229231|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
33229232|NCT00800410|Experimental|Community Health Worker services|
33229233|NCT00788944|Other|1|
33229234|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
33229235|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
33229236|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
33229237|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
33229238|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
32802333|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
33310383|NCT03949088|Experimental|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
33310384|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
33095672|NCT04513704|Active Comparator|Oral Semaglutide E|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
33095673|NCT01241474|Experimental|Fish oil|
33095674|NCT01241474|Placebo Comparator|Maize (corn) oil|
33095675|NCT01242956|Experimental|Verum group|video-based training after stroke
33095676|NCT01242956|Placebo Comparator|Placebo group|non-video group
33095677|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
33095678|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
33095679|NCT00485186||1|
33095680|NCT00485186||2|
33095681|NCT04513509|Experimental|rate control|
33095682|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
33095683|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
33095684|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
33095685|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
33095686|NCT00485394|Placebo Comparator|3|vehicle placebo
33095687|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
33095688|NCT04513587|Experimental|CBT-Based Weight Loss Model|CBT- Based weight loss model
33310385|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
33310386|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
33095689|NCT04513587|Active Comparator|Control|Usual Care
33095690|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
33095691|NCT01241487|Experimental|1|valsartan/amlodipine
33095692|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
33095693|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
33095694|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
33095695|NCT00489671||pre cancerous condition (pancreatitis)|
33095696|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
33095697|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
33095698|NCT02955108|Experimental|music first then no music|
33095699|NCT02955108|Experimental|no music first then music|
33095700|NCT04513626|Other|Delayed switch|the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group).
33095701|NCT04513626|Experimental|Immediate switch|Immediate switch to doravirine/raltegravir
33095702|NCT04697303||Middle and low rectal cancer|
33095703|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
33310387|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
33095704|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
33095705|NCT04513431|Experimental|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
33095706|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles
33095707|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
33095708|NCT04513275||schizophrenia patient group|Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years
33095709|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
33095710|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
33095711|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
33095712|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
33095713|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
33095714|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
33095715|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
33095716|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
33095717|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
33310388|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
33310389|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
32802334|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
33095718|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
32802335|NCT05689138||PCA|pancreatic cancer patients
32802336|NCT05689138||NC|normal control
32802337|NCT05685550|Experimental|Treatment group|Etoposide capsules in combination with anrotinib and Emvollizumab
32802338|NCT05689060|Experimental|Group I|received mulligan straight leg raising
32802339|NCT05689060|Experimental|group II|received post facilitation stretch on hamstring muscles
32802340|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
32802341|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
32802342|NCT05688982|Other|A--general information|Patients in Arm A will receive paper handouts with general oral health and aSDoH resources
32802343|NCT05688982|Other|B--geographic information|Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources.
32802344|NCT05688982|Other|C--geographic information and navigational assistance|Patients in Arm C will receive geographically-proximate oral health and aSDoH resources plus active navigational assistance.
32802345|NCT01613222|Experimental|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
32802346|NCT05685316|Experimental|COPLA® cartilage implant|The potential subjects will be screened against inclusion and exclusion criteria. If deemed eligible, they will be consented and enrolled. The enrolled subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery with bone marrow stimulation.
32802347|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
32802348|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
32802349|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
32802350|NCT05481424|Experimental|Biodynamic Condition followed by an Active Placebo Condition.|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
32802351|NCT05481424|Experimental|Active Placebo Condition followed by Biodynamic Condition|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
32802352|NCT05345860|Experimental|TNBC with high risk or MRD+|"TNBC patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
32802353|NCT05345860|Experimental|HER2+ with high risk or MRD+|"HER2+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
32802354|NCT05345860|Experimental|ER+ with high risk or MRD+|"ER+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
32802355|NCT05345860|Experimental|TNBC with low risk and MRD-|"TNBC patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
32802356|NCT05345860|Experimental|HER2+ with low risk and MRD-|"HER2+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
32802357|NCT05345860|Experimental|ER+ with low risk and MRD-|"ER+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
32802358|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
33310390|NCT00004562|Active Comparator|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
32802359|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
32802360|NCT05688670|Active Comparator|Regional Anesthesia|Ultrasound guided blocks
32802361|NCT05688670|Active Comparator|Wound Infiltration|Surgeon-delivered wound infiltration
32802362|NCT05684848|Active Comparator|Resveratrol + CMG|Medical device: nasal spray based on resveratrol associated with carboxymethylbetaglucan in isotonic solution
32802363|NCT05684848|Placebo Comparator|Isotonic solution|Medical Device with isotonic solution
32802364|NCT03322618|Experimental|SpA HLA-B27 +,|
33095719|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
33095720|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
32802365|NCT03322618|Experimental|SpA HLA-B27-|
33310391|NCT00004562|Experimental|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
33310392|NCT00004412|Other|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
33310393|NCT00004412|Experimental|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
33310394|NCT00004412|Other|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
33310395|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
33310396|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
33310397|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
33310398|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
33310399|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
33310400|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
33310401|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
32802366|NCT03322618|Active Comparator|healthy subject|
32802367|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
32802368|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
33310402|NCT03715114|Placebo Comparator|Placebo|Oral placebo
33310403|NCT01311232||Case|Patients with HBV reactivation
33310404|NCT01311232||Control|Patients without HBV reactivation
32802369|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
32802370|NCT04761484|Experimental|Intervention|Insertion of peripheral venous catheter on admission to the NICU
32802371|NCT04761484|No Intervention|Control|Insertion of and umbilical venous catheter on admission
32802372|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
32802373|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
32802374|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
32802375|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
32802376|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
33310405|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
33310406|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
33310407|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
33310408|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
33310409|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
33310410|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
32802377|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
32802378|NCT03320512|Experimental|P3|Participants will use P3
32802379|NCT03320512|Experimental|P3+|Participants will use P3+
32802380|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
32802381|NCT05683756|Active Comparator|Brief Parent Behavioral Intervention|A brief parent behavioral intervention with evidenced based strategies for treatment of ADHD.
33310411|NCT05621200|Active Comparator|Transcranial direct current stimulation (tDCS)|Single session of anodal tDCS at 2 mA over the cerebellar hemispheres
33310412|NCT05621200|Active Comparator|Transcranial alternate current stimulation (tDCS)|Single session of gamma tACS (50 Hz) at 3 mA over the cerebellar hemispheres
33310413|NCT05621200|Sham Comparator|Placebo stimulation (sham)|Single session of sham tDCS over the cerebellar hemispheres
33310414|NCT01091610||1|all emergency medical staff having suffered an accident during work
33310415|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
33310416|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
33310417|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
33310418|NCT00004088|Experimental|HD chemotherapy followed by PBPC Rescue|Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
33310419|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
33310420|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
33095721|NCT04697511|Experimental|Midazolam and/or M2951|
33095722|NCT02274272|Placebo Comparator|Placebo Capsules|
33310421|NCT03962322|Experimental|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
33310422|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
33310423|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
33310424|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
33310425|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
33310426|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
33310427|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
33310428|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
33310429|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
33310430|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
33310431|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
33310432|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
33310433|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
33310434|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
33310435|NCT00003896|Experimental|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
33310436|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
33310437|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
33310438|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
33310439|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
33310440|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
33310441|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
33310442|NCT05624944|Experimental|Mild hepatic impairment|Patients with mild hepatic impairment will receive a single-dose of 5 mg of TS-142
33310443|NCT05624944|Experimental|Moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single-dose of 5 mg of TS-142
33310444|NCT05624944|Experimental|Normal hepatic function|Subjects with normal hepatic function will receive a single-dose of 5 mg of TS-142
33310445|NCT04826614|Experimental|optimized treatment|early adjust dose or change drug
33310446|NCT04826614|Active Comparator|routine treatment|slowly adjust dose or change drug
33310447|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
33310448|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
33310449|NCT00003830|Active Comparator|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
33310450|NCT00003830|Experimental|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
33310451|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
33310452|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
33310453|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
32802382|NCT05683756|Experimental|Sleep-Focused Parent Behavioral Intervention|A modified version of the brief parent behavioral intervention that specifically targets sleep disrupting behaviors.
32802383|NCT05683522|Experimental|Sub-omohyoidal Plane Block|Patients randomized to receive sub-omohyoid plane block.
32802384|NCT05683522|Experimental|Costoclavicular Block plus Cervical Plexus Block|Patients randomized to receive costoclavicular brachial and cervical plexus block.
33310454|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
33095723|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
33095724|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
33095725|NCT04512963|Experimental|SAD Phase including Food Interaction|Single Ascending Dose (SAD) study with up to 6 cohorts + Food interaction phase on two cohorts
33095726|NCT04512963|Experimental|MAD Phase|Multiple Ascending Dose (MAD) study with up to 2 cohorts
33310455|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
33310456|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
33095727|NCT01302067|Experimental|Fesoterodine 8mg|
33095728|NCT01302067|Experimental|Fesoterodine 4mg|
33095729|NCT01302067|Placebo Comparator|Placebo|
33095730|NCT04697147|Experimental|Intervention Group|Immediately randomized to receive the intervention for 12 weeks.
33095731|NCT04697147|No Intervention|Waitlist Control|Randomized to receive the intervention post-study.
33095732|NCT00485667|Active Comparator|Moxifloxacin tablet|
33095733|NCT00485667|Experimental|Placebo tablet|
33095734|NCT00485667|Experimental|SKY0402 300mg|
33310457|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
33310458|NCT03714646|Placebo Comparator|Placebo|
33310459|NCT03714646|Active Comparator|beta glucan|
33310460|NCT03714646|Experimental|beta glucan and Resistant Starch|
33310461|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
33310462|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
33310463|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
32802385|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
32802386|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
32802387|NCT05688514|Experimental|Innovalve TMVR System|MV replacement with Innovalve MR system
32802388|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
32802389|NCT03389230|Experimental|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
33095735|NCT00485667|Experimental|SKY0402 450mg|
33095736|NCT00485667|Placebo Comparator|Placebo injection|
33095737|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
33095738|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
33095739|NCT00485615|Experimental|1|OMEGA 3
33095740|NCT04513236|No Intervention|Control|No Airtime Incentive was given for completing the survey
33095741|NCT04513236|Experimental|Pre-survey incentive|0.1X incentive before the survey, 1X afterwards
33095742|NCT04513236|Experimental|Post-survey incentive|1X incentive after the survey
33095743|NCT00505869||1|Health & Wellness Intervention + Questionnaire
33095744|NCT00505869||2|Mood Management Intervention + Questionnaire
33095745|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
33095746|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
33095747|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
33095748|NCT01241669|Experimental|Arm 1|
33095749|NCT01241669|Experimental|Arm 2|
32802390|NCT03389230|Experimental|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
32802391|NCT03389230|Experimental|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
32802392|NCT05688436||Diroximel Fumarate (DRF)|Pregnant women with MS who were exposed to DRF 12 months prior to last menstrual period (LMP).
32802393|NCT05688436||Non-DRF|Pregnant women with MS who were exposed to disease-modifying therapies (DMTs) other than DRF 12 months prior to LMP.
32802394|NCT05688436||Non-DMT|Pregnant women with MS who were not exposed to DMTs.
32802395|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
32802396|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
32802397|NCT04401124||patients treated at surgical emergency rooms|
32802398|NCT04401124||patients receiving surgeries (both elected and emergency)|
32802399|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT Imaging with administration of [F-18] RGD-K5
33229239|NCT04854850|Experimental|Apollo|Participants will all receive Apollo devices.
33229240|NCT00826514|Experimental|Tanezumab|
33229241|NCT00826514|Placebo Comparator|Placebo|
33229242|NCT00800566|Experimental|Oral Clofarabine|
33229243|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
33229244|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
33229245|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
33229246|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
33229247|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
33229248|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
33229249|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
33229250|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
33229251|NCT00789022||1|40 subjects in a First Psychotic Episode
33229252|NCT00789022||2|20 First Degree relatives
33229253|NCT00789022||3|20 Healthy subjects
33229254|NCT00789100||1|Group provided with home-based monitor
33229255|NCT00789100||2|Group receives no home-based monitor
33229256|NCT04046458|Experimental|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
33229257|NCT04046458|Placebo Comparator|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
33229258|NCT00789178||patients with fibromyalgia|
33229259|NCT00789178||patients with active RA|
33229260|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
33229261|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
33229262|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
33229263|NCT00794014|Experimental|Conservative strategy|
33229264|NCT00794014|Experimental|Aggressive strategy|
33229265|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
33229266|NCT00800800|Placebo Comparator|2|placebo
33229267|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
33229268|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
33229269|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
33229270|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
33229271|NCT04030754|Experimental|amniotic membrane group|amniotic dressing will be applied to these patients
33229272|NCT04030754|Experimental|duoderm group|duoderm dressing will be applied to these patients as intervention
33229273|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
33229274|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
33229275|NCT04030442|Placebo Comparator|Smoked cannabidiol 0%|
33229276|NCT04030442|Active Comparator|Smoked cannabidiol 3.4%|
33229277|NCT04030442|Active Comparator|Smoked cannabidiol 12.7%|
33229278|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
33229279|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
33229280|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
33229281|NCT05603624|Active Comparator|Sterile glove|Sterile glove is usually the standard of care
33310464|NCT05472220|Experimental|Phase 1: Dose Escalation|Patients with advanced solid tumors will be adminsitered Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles.
33310465|NCT05472220|Experimental|Phase 2: Dose Expansion|Patients with HPV+ squamous cell carcinoma will be administered the recommended phase 2 dose of Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles
33310466|NCT03407482|Experimental|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
33310467|NCT00003782|Experimental|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
33310468|NCT00003782|Experimental|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
33310469|NCT00003782|Experimental|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
32802400|NCT05681962||Standard Oxygen Therapy (SOT)|Patients receiving low oxygen flow administration through nasal prongs, oxygen mask with or without reservoir, and Venturi mask.
33310470|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
33310471|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
33310472|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
33310473|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
33310474|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
33310475|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
33310476|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
33310477|NCT05625620|Experimental|Experimental: Real tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
33310478|NCT05625620|Experimental|Sham tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Sham tPCS arm will receive active tPCS. Then they will be crossed over to Real tPCS arm.
33310479|NCT05625464|Experimental|Intervention|Received SCTP monitoring and standard of care
33310480|NCT05625464|No Intervention|Control|Received standard of care only
33310481|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
33310482|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
33310483|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
33310484|NCT05621330|Experimental|QL0911|
33310485|NCT05621330|Placebo Comparator|Placebo|
33310486|NCT01095926|Experimental|Doxorubicin|
33310487|NCT05617118||Baclofen|"A cohort of patients who have not previously received baclofen will be offered a course of the drug therapy at a dosage of 10 mg according to the scheme:~1-3 days - 1 tablet per day; 4-6 days - 2 tablets per day; 7-9 days - 3 tablets per day; 10 days and then 4 tablets per day (morning and evening)."
33310488|NCT05617118||BTA|"A cohort of patients who previously received baclofen and canceled the course due to the development of side effects and/or individual intolerance, or who have contraindications to the use of this drug, will receive several injections with a total volume of 100 units. botulinum toxin type A in dilution up to 20 ml, distributed at the trigger points of the pelvic floor muscles."
33310489|NCT01103726|Experimental|Stage 1|
33310490|NCT01103726|Experimental|Stage 2|
32802401|NCT05681962||High Flow oxygen through Nasal Cannula (HFNC)|Administration of high flows (up to 60 L/min) of air/oxygen admixtures, heated (at temperatures ranging from 31 to 37°C) and fully humidified (up to 44 mg H2O/L), providing an inspired oxygen fraction ranging from 21 to 100%
32802402|NCT05681962||Continuous Positive Airway Pressure (CPAP)|application of positive end-expiratory pressure (PEEP) throughout the whole respiratory cycle by means of interfaces such as mask or helmet
33310491|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
33310492|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
32802403|NCT05681962||Non-Invasive Ventilation (NIV)|application of a PEEP by means of a mask or helmet, with an inspiratory pressure support triggered by the patient and delivered by a ventilator and through interfaces such as mask or helmet
32802404|NCT05681962||Invasive Mechanical Ventilation (iMV)|application of a ventilatory assistance in controlled or partial assisted modalities through an endotracheal or tracheostomy tube
32802405|NCT03364114|Experimental|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
32802406|NCT03364114|Active Comparator|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
32802407|NCT04401514|Experimental|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
32802408|NCT04401514|Active Comparator|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
33310493|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
32802409|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone~During hospital admissions to MGH: At least twice weekly palliative care visits"
33095750|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
33095751|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
33310494|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
33310495|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
33310496|NCT01585142|Experimental|BabyNes system formula|
32802410|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request~Standard Leukemia care"
33310497|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
33310498|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
32802411|NCT04279288|Experimental|participants enrolled with epistaxis and/or nasal fractures|
32802412|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
32802413|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
33095752|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
33310499|NCT00003590|Experimental|Hydroxyurea|
33310500|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
33310501|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
33310502|NCT01096004|Experimental|1|
33310503|NCT01096004|Placebo Comparator|2|
33310504|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
33310505|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
33310506|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
33310507|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
33095753|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
33310508|NCT00077766|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 ([methoxy polyethylene glycol-epoetin beta] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
33310509|NCT00077766|Active Comparator|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
32802414|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
32802415|NCT03386578|Experimental|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
33310510|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
33310511|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
32802416|NCT03386578|Experimental|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
32802417|NCT03386578|Experimental|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
32802418|NCT03386578|Active Comparator|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
32802419|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
32802420|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
33310512|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
33310513|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
33310514|NCT01096082|Placebo Comparator|Placebo|
33310515|NCT01096082|Experimental|Lithium Carbonate|
33310516|NCT03388138|Active Comparator|K-Lens|etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
32802421|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
32802422|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
32802423|NCT01612676|Experimental|Drug|FE 202158
32802424|NCT05688202|Active Comparator|Left face|The face's left side is treated with simultaneous combination therapy, in which fractional CO2 laser is performed immediately following subcision
33310517|NCT03388138|Placebo Comparator|Placebo Contact Lens|1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
33310518|NCT05613530|Experimental|"digital MAX néonat (intervention group or  MAX + group)"|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
33310519|NCT05613530|Active Comparator|"MAX néonat on poster/paper (control group or  MAX - group)"|Participants have no cognitive aid
33310520|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
32802425|NCT05688202|Placebo Comparator|Right face|The face's right side receives sequential combination therapy with fractional CO2 laser conducted two weeks after subcision.
32899778|NCT04236947|Experimental|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
32899779|NCT04236947|No Intervention|Control Group|The control schools will continue providing their traditional preventive actions.
33095754|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
33095755|NCT04512846||CK-SBRT with TACE group|The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.
33095756|NCT04512846||CK-SBRT group|The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.
33095757|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
33310521|NCT01327586|Active Comparator|Individual Drug Counseling|
33310522|NCT01101620|Active Comparator|Levosimendan|
33310523|NCT01101620|Placebo Comparator|Placebo|
33310524|NCT03954548|Experimental|With CB-17-08 CADe|
33310525|NCT03954548|No Intervention|Without CB-17-08 CADe|
33310526|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
33310527|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
33404588|NCT03143296|Active Comparator|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
33404589|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
32802426|NCT05424172|Experimental|Stage-I: Self Monitoring Exercise Using a Health App|Participants will be randomized into one of two groups: Group 1 (self monitoring using a non-interactive app), and Group 2 (self monitoring using an interactive app). Participants in both groups will be provided a customized exercise program to complete over the duration of the study. Within either app, participants will be able to view assigned exercises, log additional exercises completed, complete questionnaires as needed, and access additional resources. Participants will use their own smartphone to receive the health app. Participants will continue using their Stage-I app intervention for the entire duration of the study (weeks 1-24).
32899780|NCT00299000|Other|Naglazyme, 1.0 mg/kg|Dose comparison
32899781|NCT00299000|Other|Naglazyme, 2.0 mg/kg|Dose Comparison
32899782|NCT01144949|Active Comparator|silodsosin|
32899783|NCT01144949|Placebo Comparator|placebo|
32899784|NCT00215930|Experimental|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
32899785|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
32899786|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
32899787|NCT04183673|Experimental|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
32899788|NCT04183673|Active Comparator|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
32899789|NCT00230126|Active Comparator|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
32899790|NCT00230126|Experimental|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
32899791|NCT04128722|Experimental|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
32899792|NCT04128722|No Intervention|Control condition|Usual care, i.e. no intervention
32899793|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
32899794|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
32899795|NCT04071977|Active Comparator|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
32899796|NCT04071977|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
32899797|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
32899798|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
32899799|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
32899800|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
32899801|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
32899802|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
32899803|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
32899804|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
32899805|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
32899806|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
32899807|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
32899808|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
32899809|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
32899810|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
32946103|NCT01887600|Placebo Comparator|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
33310528|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
33310529|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
33310530|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
33310531|NCT05563142|Experimental|Group Perclose ProStyle closure|50 patients treated with Perclose ProStyle suture-mediated closure device to achieve hemostasis
32946104|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
32946105|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
32946106|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
33095758|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
33095759|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
33310532|NCT05563142|Active Comparator|Group manual compression|50 patients treated with manual compression and one figure of eight suture
33310533|NCT05592886|Experimental|Intervention arm|Receive SMT04 formula
33310534|NCT05592886|Placebo Comparator|Placebo arm|Receive active placebo
33310535|NCT05592340|Active Comparator|Control|Calorie labels shown on online restaurant menu
33310536|NCT05592340|Experimental|Carbon footprint labels|Carbon footprint labels shown on online restaurant menu next to every item in addition to calorie labels
33310537|NCT05533112|No Intervention|Control|Control Group, no Intervention received
33310538|NCT05533112|Experimental|Preop Stimulation|Binaural Beat Stimulation preoperatively
33310539|NCT05533112|Experimental|Postop Stimulation|Binaural Beat Stimulation postoperatively
33310540|NCT05533112|Experimental|Pre- & Postop Stimulation|Binaural Beat Stimulation pre- and postoperatively
33310541|NCT05576584|Placebo Comparator|Single Ascending Dose|Five dose groups: 5mg (group I), 15mg (Group II), 30mg (Group III), 60mg (Group IV) and 100mg (Group V). According to the safety, tolerance and PK parameters of group V, higher dose group studies (150mg and 200mg alternatively) are not excluded. There were 10 subjects in each group, of which 8 received GST-HG121 tablets and 2 received placebo.
33310542|NCT05576584|Placebo Comparator|Multiple Ascending Dose|According to the results of single dose study, it is planned to select 1-3 dose groups within the range of single dose for oral administration for 7 consecutive days. There were 12 subjects in each group, of which 10 received GST-HG121 tablets and 2 received placebo. From D 1 to d 7, take GST-HG121 tablets or placebo orally on an empty stomach every day, tentatively once a day (the specific administration frequency may be adjusted based on the results of the single dose increase test)
33310543|NCT05576584|Placebo Comparator|food affects（A）|10 subjects (8 received GST-HG121 tablets and 2 received placebo)
33310544|NCT05576584|Active Comparator|food affects（B）|8 subjects (all received GST-HG121 tablets)
33310545|NCT00045734|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study/ laboratory biomarker analysis"
33310546|NCT05513768||women who gave birth prematurely|women who had serum taken in the first trimester and gave birth earlier than 37 weeks according to the time of delivery
33310547|NCT05513768||those who gave birth on time|women who have had serum taken in the first trimester, stored and delivered on time
33310548|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
33310549|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
33310550|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
33095760|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
33310551|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
33310552|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
33310553|NCT00045110|Experimental|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~erlotinib hydrochloride given orally~Other: pharmacological study."
32946107|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
32946108|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
32946109|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
32946110|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
32946111|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
32946112|NCT04614324|Experimental|RhinAer ARC Stylus Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
32946113|NCT04613232|Experimental|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
32946114|NCT04612374|Experimental|Phase 1: Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
32946115|NCT04612374|Experimental|Phase 1: Experimental: Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
33095761|NCT01241877|Experimental|astaxanthin|
33095762|NCT01241877|Placebo Comparator|placebo|
33095763|NCT00490295||newborn cardiac surgical study group|
33095764|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
33095765|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
33095766|NCT00485784|Sham Comparator|control group|control group
33095767|NCT00485784|Experimental|prééclampsies group|prééclampsies group
33095768|NCT00485784|Experimental|RCIU group|RCIU group
33404590|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
33404591|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
33404592|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
32946116|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
33095769|NCT00485784|Experimental|MFIU group|MFIU group
33095770|NCT04512651|Experimental|Intervention Group (IG)|The GI dancers, submitted to tibiotarsal thrust manipulation
33095771|NCT04512651|Sham Comparator|Control Group (CG)|For the CG was performed the simulation of the technique, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
33095772|NCT04512417|Experimental|Combined radiotherapy group|
33095773|NCT04512417|Experimental|Immunotherapy alone group|
33095774|NCT00485888|Active Comparator|1|
33095775|NCT00485888|Placebo Comparator|2|
33095776|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
33095777|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
33095778|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
33095779|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
33095780|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
33095781|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
33095782|NCT00485940|Active Comparator|1|Prucalopride 2 mg
33095783|NCT00485940|Placebo Comparator|3|Placebo
33095784|NCT00485940|Active Comparator|2|Prucalopride 4 mg
33095785|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
33095786|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
33095787|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
33095788|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
33310554|NCT00045110|Experimental|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)~erlotinib hydrochloride given orally~Other: pharmacological study, laboratory biomarker analysis."
33310555|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
33310556|NCT04814602|Active Comparator|Control|Healthy controls Proglumide 400 mg given once by mouth
33310557|NCT04814602|Experimental|Hepatic Impaired|Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth
33310558|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
33310559|NCT00003476|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33310560|NCT00003470|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33310561|NCT03948308|Experimental|Interventional arm|blood sample before, during and after treatment for infection
33310562|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
33310563|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
33310564|NCT01104194|Experimental|Fish-oil|
33310565|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
33310566|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
33310567|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
33310568|NCT03386344|Placebo Comparator|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
33310569|NCT03386344|Experimental|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
33310570|NCT03386344|Experimental|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
33310571|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
33310572|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
33310573|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
33310574|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
33310575|NCT00073749|Experimental|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
33310576|NCT03960801|Experimental|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
33310577|NCT03960801|Active Comparator|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
33310578|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
33310579|NCT01089699|Active Comparator|Peer-led online support|
33310580|NCT01089699|Active Comparator|self-study materials|
33310581|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
33310582|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
33310583|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
33310584|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
33310585|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
33310586|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
33310587|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
33310588|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
33310589|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
33310590|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
33310591|NCT03352414|Experimental|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
33310592|NCT03352414|Placebo Comparator|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
33310593|NCT05567692||T2D group|subjects with type 2 diabetes
33310594|NCT05567692||Non-T2D group|healthy subjects
33310595|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
33310596|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
33310597|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
33310598|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
33310599|NCT03351478|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
33310600|NCT03351478|Active Comparator|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
33310601|NCT03351478|Placebo Comparator|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
33310602|NCT04572737|Experimental|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
33310603|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
33310604|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
33310605|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
33310606|NCT01042301|Active Comparator|control patients|control patients
33310607|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
33310608|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
33310609|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
33310610|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
33310611|NCT03351244|Experimental|BI 409306 50 mg|1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
33310612|NCT03351244|Experimental|BI 409306 25 mg|1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
33310613|NCT03351244|Placebo Comparator|Placebo|1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
33310614|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
33310615|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
33310616|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
33310617|NCT03712150||Healthy|"Healthy adults~- Participants will receive single session of tdcs after application"
33310618|NCT05452486|Experimental|Auditory Processing Disorder (APD) Assessment|All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order.
33310619|NCT00077610|Experimental|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
33310620|NCT00077610|Experimental|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
33310621|NCT00077610|Active Comparator|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
33310622|NCT03385564|Experimental|BI 655064 120 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
33310623|NCT03385564|Placebo Comparator|Placebo|Matching placebo were administered as solution for subcutaneous injection in a prefilled syringe once every week over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
33310624|NCT03385564|Experimental|BI 655064 180 mg|180 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
33310625|NCT03385564|Experimental|BI 655064 240 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every week (240 mg every 2 weeks) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
33310626|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
33310627|NCT05344924|Experimental|Cohort I（TACE-A-A Cohort）|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
33310628|NCT05344924|Experimental|Cohort II (A-A Cohort)|Patients will receive penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
33310629|NCT01085994||Procalcitonin-guided group|
33310630|NCT01085994||Routine practice group|
33310631|NCT03741270|Experimental|Vaccine|
33310632|NCT00066222|Experimental|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
33310633|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
33310634|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
33310635|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
33310636|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
33310637|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
33310638|NCT00066066|Placebo Comparator|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
33310639|NCT00066066|Active Comparator|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
33310640|NCT00066066|Active Comparator|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets >4mm
33310641|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
33310642|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
33310643|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
33310644|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
33310645|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
33310646|NCT00077376|Experimental|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.~NOTE: *Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33310647|NCT01088724|Experimental|chemotherapy|
33310648|NCT03957174|Experimental|Reboxetine|Single dose of 4mg
33310649|NCT03957174|Experimental|Rivastigmine|Single dose of 3mg
33310650|NCT03957174|Placebo Comparator|Placebo|Single dose of placebo
33318616|NCT03952884|Experimental|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
33310651|NCT03406156|Experimental|Obinutuzumab|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen.~After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
32802427|NCT05424172|Experimental|Stage-II: Strategy to Address Non-Adherence|After 12 weeks, the participants will be categorized as adherents or non-adherents based on their rates of adhering to the SCI exercise guidelines during Stage-I. Non-adherents (those who met the exercise guidelines <50% of the weeks) will be randomized to receive an augmented intervention of motivational interviewing-based e-coaching (2x per month or 4x per month) in addition to their Stage-I assigned app for 12 weeks (weeks 13-24) to further increase rates of exercise. All non-adherents who will be assigned to the e-coaching interventions will be asked to complete at least daily EMA surveys. A coach who is trained in motivational interviewing will review the EMA data and work collaboratively with participants to identify barriers and facilitators and develop individualized strategies to improve exercise adherence. Adherents (those who met the exercise guidelines >50% of the weeks) will continue with only their Stage-I assigned app intervention throughout Stage-II.
33310652|NCT03406156|Experimental|Obinutuzumab/bendamustine|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen.~Bendamustine (90 mg/m^2 ) was to be administered to those with nodes or nodal mass > 10 cm, or with del(11q) and > 5 cm nodes, or at the discretion of the investigator as above, via intravenous infusion over 10 minutes on Days 1 and 2 (or Days 2 and 3 at the discretion of the investigator during Cycle 1) of each 28-day cycle for up to 6 cycles during the debulking regimen. After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
33310653|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
32802428|NCT03385798|Active Comparator|Endo-GIA|
32802429|NCT03385798|Experimental|Endo-wrist|
32802430|NCT05415358||Single Arm|Biomarkers and ctDNA data generated from patients with metastatic non-small cell lung carcinoma who have completed first line pembrolizumab monotherapy or pembrolizumab-platinum doublet combination therapy, and have completed at least 85% of planned doses of pembrolizumab.
33310654|NCT00363311|Placebo Comparator|Placebo|Matching placebo
33310655|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
33310656|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
33310657|NCT00362609|Active Comparator|Low dose|
33310658|NCT00362609|Active Comparator|High dose|
33310659|NCT03991871|Placebo Comparator|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
33310660|NCT03991871|Experimental|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
32802431|NCT05688124|Other|IBI351|This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects. In a double-crossover design, subjects were enrolled and randomly divided into two test groups A and B. Group A: IBI351 was orally administered to subjects in this group on an empty stomach on Day 1, followed by a high-fat meal on Day 4. Group B: IBI351 was orally administered to subjects in this group after a high-fat meal on Day 1 followed by an empty stomach on Day 4.
33310661|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
33310662|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
32802432|NCT05688124|Other|IBI351+Esomeprazole|Enrolled subjects were orally administered IBI351 with recommended dose on an empty stomach. Esomeprazole were administered orally.
32802433|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
32802434|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
32802435|NCT05677204||Acute Achilles tendinopathy|No intervention will be given
32802436|NCT05670964|Experimental|UPLUG Arm|Patients will have regular central veinous catheter and UPLUG device for their dialysis sessions.
32802437|NCT05670964|Other|Standard Of Care Arm|Patients will have regular central veinous catheter (standard of care) for their dialysis.
32802438|NCT04602728|Experimental|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
32802439|NCT05396248|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
32802440|NCT05396248|Placebo Comparator|Placebo Control Group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
32802441|NCT05665270|Experimental|Dextenza|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8).
32802442|NCT05665270|Active Comparator|Prednisolone Acetate|Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.
32802443|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
32802444|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
32802445|NCT05687890|Experimental|SC0062 low dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
32802446|NCT05687890|Experimental|SC0062 medium dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
32802447|NCT05687890|Experimental|SC0062 high dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
32946117|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
33310663|NCT02534753|Experimental|Single Group|
32946118|NCT01881750|Experimental|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
32946119|NCT01881750|Placebo Comparator|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
32946120|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
32946121|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
32946122|NCT01863732|Experimental|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
32946123|NCT01863732|Experimental|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
32946124|NCT01863732|Experimental|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
32946125|NCT01863732|Experimental|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
32946126|NCT01863732|Experimental|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
32946127|NCT01863732|Experimental|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
32946128|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
32946129|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
32946130|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
32946131|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
32946132|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
32946133|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
32946134|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
32946135|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
32946136|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
32946137|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
32946138|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
33310664|NCT01042457|Other|Mycophenolate mofetil|
33310665|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
33310666|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
33310667|NCT00362297|Active Comparator|Standard dose|
33310668|NCT00362297|Experimental|High-dose|
33310669|NCT00065442|Placebo Comparator|APC-Placebo|
32802448|NCT05687890|Placebo Comparator|Placebo of SC0062 group|Subjects will take two capsules daily for 24 weeks during the treatment period
32802449|NCT04400266|Experimental|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
32802450|NCT04746742|Active Comparator|Tunneled femoral catheter|20 patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
32802451|NCT04746742|Active Comparator|Femoral artery-femoral arteriovenous graft|a straight or loop configuration 28patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
32802452|NCT04348162|Active Comparator|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
32802453|NCT04348162|Active Comparator|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
32802454|NCT04348162|Active Comparator|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
32802455|NCT04348162|No Intervention|Control|Normal diet for 10-12 weeks
32802456|NCT05658172|Active Comparator|Intensive Surveillance arm|Intensified surveillance. Prospective tumor marker (CA27.29, CA125, CEA), CTC and ctDNA testing of the blood samples. Abnormal findings of either marker (CA27.29 and/or CA125 and/or CEA and/or CTC and/or ctDNA) will be regarded as molecular relapse and trigger diagnostic imaging.
32802457|NCT05658172|Placebo Comparator|Standard Surveillance arm|Surveillance according to national guidelines. Blood samples will not be analyzed immediately and will therefore not trigger imaging. A biobank will be established for retrospective and translational studies. This procedure is necessary to ensure the partially double-blinded study design.
32802458|NCT05687656|Experimental|InnovaMatrix AC porcine placental ECM therapy|Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading
32802459|NCT03306316|Experimental|Experimental|Experimental Arm
32802460|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
32802461|NCT05687500|Experimental|Glibenclamide oral|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
32802462|NCT04746664|Other|Nutrition counselling|The intervention will be home-to-home-visit once per week lasting 30 minutes to one hour for one month period. The convenience day and time will be selected in the discussion.
32802463|NCT04746508||Unilateral Flat Foot (UniFF)|Participants with flat foot unilaterally (Only one foot's Calcaneal pitch angle ≤ 20 degree)
32802464|NCT04746508||Bilateral Flat Foot (BiFF)|Participants with flat foot bilaterally (Both feet's Calcaneal pitch angle ≤ 20 degree)
32802465|NCT03359356|Experimental|Dupilumab|An initial dupilumab dose of 600 mg (two 300 mg subcutaneous injections), followed by dupilumab 300 mg given every week
32802466|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
32802467|NCT05655520|Experimental|Cohort 1 (Direct Rollover)|Participants from studies 718-CIH-201 (NCT05107128)/202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 ≤7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Day 365.
32802468|NCT05655520|Experimental|Cohort 2 (Gap Rollover)|Participants from studies 718-CIH-201 (NCT05107128)/202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 after a gap of >7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Day 365.
32802469|NCT05655520|Experimental|Cohort 3 (De Novo)|Participants who were not previously included in any SAGE-718 clinical study. Participants will receive Sage-718 from Day 1 up to Day 365.
32802470|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
32802471|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
32802472|NCT05687422|Experimental|100μm laser spot diameter group|
32802473|NCT05687422|Active Comparator|200μm laser spot diameter group|
32802474|NCT05687344|Experimental|Intervention arm|Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at <140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
32802475|NCT05687344|Active Comparator|Active control arm|Active control group - a group of usual care that follows ACOG recommendations2 with Nifedipine initiation at SBP≥160 mmHg or DBP≥110 mm Hg and maintaining BP at <160/110 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
32802476|NCT04760704||Experimental group|Persons aged 65 and over, residing in an institution for dependant elderly or in a long-term care unit
32802477|NCT04760704||control group|Health and medico-social professionals between 40 and 65 years of age
32802478|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
32802479|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
32802480|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
32802481|NCT03383536||Phase 2: HC|healthy controls
32802482|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
32802483|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
32802484|NCT05687188||Retrospective Cohort|Retrospective chart review and sample analysis of both pathologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) cases and non-Cancer control cases.
32802485|NCT05687188||Prospective Cohort|Blood samples, tissue samples and data will be collected from all participants as applicable.
33095789|NCT04512027|Experimental|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class+Stand of care|Tablet chewed for 5 days along and given alongside standard of care
33095790|NCT04512027|No Intervention|Standard of Care|All patients will receive currently practiced standard of care medicines
33095791|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
33095792|NCT04511715|Active Comparator|Intravitreal Bevacizumab IVB group|
33095793|NCT04511715|Sham Comparator|undergo regular follow-up for Diabetic Retinopathy|
33095794|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
33095795|NCT00486135|Experimental|2|Continuous daily dosing
33095796|NCT00486135|Experimental|3|Continuous daily dosing
33095797|NCT04511910||Early surgery Group 1|The surgery is performed within the first 3 days
33095798|NCT04511910||Early surgery Group 2|Surgery is performed between the fourth and seventh day
33095799|NCT04511910||Early surgery Group 3|Surgery is performed more than 7 days from the onset of symptoms
33095800|NCT01241994|No Intervention|basal hemodialysis|
33095801|NCT01241994|Active Comparator|AASD|
33095802|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
33095803|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
33095804|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
33095805|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
33095806|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
33095807|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
33095808|NCT00486174|No Intervention|2|standard sepsis therapy
33095809|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|
33095810|NCT04511793|Experimental|Hepatic Artery Infusion (HAI)|The Medtronic Synchromed II pump with the Codman® Catheter will be used to create the investigational device. The Medtronic Synchromed II pump is a surgically implantable device that allows for the delivery of high doses of chemotherapy directly to the liver, in order to treat cancer. The device is surgically implanted into a subcutaneous pocket in the abdominal wall, and the catheter is inserted into the arterial system of the liver, allowing for chemotherapeutic delivery.
33095811|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
33095812|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
33095813|NCT00486395|Active Comparator|1|Mechanical ventilation
33095814|NCT00486395|Experimental|2|CPAP
33095815|NCT00490997|Active Comparator|1|Ketamine only arm
33095816|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
33095817|NCT04511949|Other|No arm|No arm
33095818|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
33095819|NCT04511637|Experimental|Test C: 15 mg ODT with water, then 15 mg film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
33095820|NCT04511637|Experimental|Test C: 15 mg film-coated tablet, then 15 mg ODT with water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
33229282|NCT05603624|Experimental|Clean glove|Clean glove is usually not used or in the event of an emergency or lack of access to sterile gloves in the United States.
33229283|NCT00801034|Placebo Comparator|1|Calcium tablets
33229284|NCT00801034|Active Comparator|2|Potassium tablets
33229285|NCT04130477|Experimental|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
33229286|NCT04130477|Active Comparator|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
33229287|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
33229288|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
33229289|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
33229290|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
33229291|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
33229292|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
33229293|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
33229294|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
33229295|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
33229296|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
33229297|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
33229298|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
33229299|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
33229300|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
33229301|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
33229302|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
33229303|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
32946139|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
32946140|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
32946141|NCT03357588|Active Comparator|Control|Standard of Care monitoring
32946142|NCT03357588|Experimental|Intervention|Intensified monitoring
32946143|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
32946144|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
32946145|NCT04611672||Controls|Healthy controls of all Ages above 18 years
32946146|NCT01880736|Experimental|IDeg OD Flexible Dose|
32946147|NCT01880736|Experimental|IDeg OD Fixed Dose|
32946148|NCT01880736|Experimental|IDeg OD Simple|
32946149|NCT01880736|Experimental|IDeg OD Stepwise|
32946150|NCT01880424|Placebo Comparator|controlled arm|
32946151|NCT01880424|Experimental|treatment arm|
32946152|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
32946153|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
32946154|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
32946155|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
32946156|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
32946157|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
32946158|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
32946159|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
32946160|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
32946161|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
32946162|NCT04415268|Experimental|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
32946163|NCT05114148|Experimental|Holmium-166 radioembolization|Individualized holmium-166 radioembolization will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
32946164|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
32946165|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
32946166|NCT01903356||Patients with T2DM|
32946167|NCT04618770|Other|Triathlon PSR Tibial Insert|Cases receiving a Triathlon Total Knee with the Triathlon PSR Tibial Insert
32946168|NCT01862796|Experimental|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
32946169|NCT01862796|Experimental|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
32946170|NCT01862796|Experimental|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
32946171|NCT01878084|Other|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)~The extraction sockets will be allocated either to the control : Extraction socket will be left empty~or~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
32946172|NCT01862640|Placebo Comparator|Placebo|Matching placebo once daily
32946173|NCT01862640|Experimental|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
32946174|NCT01862640|Experimental|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
32946175|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
32946176|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
32946177|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
32946178|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
32946179|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
32946180|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
32946181|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
32946182|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
32946183|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
32946184|NCT01901874|Experimental|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
32946185|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
33095821|NCT04511637|Experimental|Test D: 15 mg ODT without water, then 15 film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
32946186|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
33095822|NCT04511637|Experimental|Test D: 15 mg film-coated tablet, then 15 mg ODT without water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
33095823|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
33095824|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
33095825|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
33095826|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
32946187|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
32946188|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
32946189|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
32946190|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
32946191|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
33095827|NCT00486629|Experimental|Intervention|Lifestyle intervention
33095828|NCT00486629|No Intervention|Control|No intervention
33095829|NCT04511481||platinum-resistant group|
33095830|NCT04511481||platinum-sensitive group|
33095831|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
33095832|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
33095833|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
33095834|NCT04511598|Experimental|Bellus 3D Face Camera Pro|"Every single patient will be diagnosed using 3D imaging system Bellus 3D Face Camera Pro to be compared to the direct measurements obtained from direct anthropometry."
32946192|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
33095835|NCT04511598|Experimental|Planmeca ProMax 3D Proface|"Every single patient will be diagnosed using 3D imaging systems Planmeca ProMax 3D Proface to be compared to the direct measurements obtained from direct anthropometry."
33095836|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
33095837|NCT00486681||2|period II (warning activated).
33095838|NCT00486707||Patients with ovarian cancer|
33095839|NCT04510935|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
33095840|NCT04510935|Active Comparator|local anesthesia|In this group, patients will receive radiofrequency ablation under local anesthesia.
33095841|NCT04510974||Cervical SCI|Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
33095842|NCT04510974||Thoracic SCI|Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
33095843|NCT04510974||Able-bodied Control|Ages between 21-70
33095844|NCT00486746|Experimental|Lifestyle intervention|
33095845|NCT00486746|Active Comparator|General health counseling|
33095846|NCT04510896|No Intervention|Pre-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
33095847|NCT04510896|Experimental|Post-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
33095848|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
33095849|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
33310670|NCT00065442|Active Comparator|Sipuleucel-T|
33310671|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
33310672|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
33310673|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
33310674|NCT01092000||Faculty/Staff|
33310675|NCT01092000||Graduate Students|
32946193|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
32946194|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
32946195|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
33310676|NCT01092000||Undergraduate Students|
33310677|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
33310678|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
33310679|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
33310680|NCT00090402|Placebo Comparator|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
33310681|NCT00090402|Active Comparator|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
33310682|NCT00090402|Experimental|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
33310683|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
33310684|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
33310685|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
33318617|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
32946196|NCT04599660||Low Risk GISTs|This cohort include patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020.
32946197|NCT01900626|Active Comparator|single epidural catheter|
32946198|NCT01900626|Active Comparator|double epidural catheter|
32946199|NCT04414800|Placebo Comparator|Control (Placebo+ Standard of Care))|
32946200|NCT04414800|Active Comparator|Ketamine + Standard of Care|
32946201|NCT04414800|Active Comparator|Fentanyl + Standard of Care|
32946202|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
32946203|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
32946204|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
32946205|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
32946206|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
32946207|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
32946208|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
32946209|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
32946210|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
32946211|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
32946212|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
32946213|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
32946214|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
32946215|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
32946216|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32946217|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
32946218|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
32946219|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
32946220|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
33095850|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
33095851|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
33095852|NCT00486785|Experimental|1|
33095853|NCT04324411|Experimental|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
33095854|NCT04324489|Experimental|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
33095855|NCT00486876|Placebo Comparator|1|Placebo
33095856|NCT00486876|Experimental|2|100 mg BID
33095857|NCT00486876|Experimental|3|200 mg BID
33095858|NCT00486876|Experimental|4|300 mg BID
33095859|NCT05643703|Experimental|One-layered Suture|One-layered Suture in transvaginal diverticulum resection
33095860|NCT05643703|Experimental|Two-layered Suture|Two-layered Suture in transvaginal diverticulum resection
33095861|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
33095862|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
33095863|NCT05643586|Experimental|Prasugrel Group|Patient treated with 60 mg prasugrel 12 hours before the procedure
33095864|NCT05643586|Experimental|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
33095865|NCT05643430|Experimental|BioFreedom Ultra|All patients will receive the BioFreedom Ultra as per treatment.
33095866|NCT01242059|Experimental|Control Tomato Soup|
33095867|NCT01242059|Experimental|10 g of yellow pea fiber|
32946221|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
32946222|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
32946223|NCT01897896|Experimental|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
33095868|NCT01242059|Experimental|20 g of yellow pea fiber|
33095869|NCT01242059|Experimental|10 g of yellow pea protein|
33095870|NCT01242059|Experimental|20 g of yellow pea protein|
33095871|NCT05643391|Experimental|Single arm|"The treatment will include 1 preparatory angiography followed by treatment at a maximum 2 weeks interval. Dosimetry MRI will be performed just before and immediately after treatment. SPECT CT will be performed three days after treatment.~The activity of 166Ho that must be administered to a patient will depend on the tumor perfusion and absorbed dose linked to this activity.Q-SuiteTM 2.0 will be used, more precisely a dosimetry software to perform an optimal compartmental predictive dosimetry:~- minimum 150 Gy to the tumor, maximum 60 Gy to non-tumoral liver, maximum 30 Gy lung shunt fraction."
33095872|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
33095873|NCT05643235|Other|Patients initiated on Bruton tyrosine kinase inhibitors, consenting to installment of ILR|Patients free of documented arrhythmia initiating treatment with a BTK inhibitor who consent to monitoring using the Medtronic LINQ-2 implanted cardiac monitoring device (ILR) prior to initiating BTK inhibitor therapy.
33095874|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
33404593|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
33404594|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
33095875|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
33095876|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
33095877|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
33095878|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
33095879|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
33095880|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
33095881|NCT05643157||toxic maculopathy|Subjects with a history of 5+ years of Pentosan Polysulfate sodium use and with retinal findings associated with Pentosan polysulfate sodium toxicity on fundus exam
33095882|NCT01242137||Extensive metabolizers|
33310686|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
33310687|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
33310688|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
33095883|NCT01242137||Intermediate mtabolizers|
33095884|NCT01242137||Poor metabolizers|
33095885|NCT04510623||COVID-19 Patients on ARBs|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
33095886|NCT04510623||COVID-19 Patients on ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
33095887|NCT04510623||COVID-19 Patients on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
33095888|NCT04510623||COVID-19 Patients not on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
33095889|NCT05643040|Experimental|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral nerve block in patients who will have knee surgery.
33095890|NCT05643040|Experimental|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
33095891|NCT05643040|Experimental|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
33404595|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
33404596|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
33095892|NCT05367622|Experimental|Continuous glucose monitoring group|Self-regulation model of health education will be given for 1-1.5 hrs and telecommunication 10 to 15 minutes for 7 days
33095893|NCT05367622|Placebo Comparator|Self-monitoring of blood glucose group|Usual diabetes health education will be given for 1 hr.
33095894|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
33095895|NCT04510818|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
33095896|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
33095897|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
33095898|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
33095899|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
33310689|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
33310690|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
33310691|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
33310692|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
33310693|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
33310694|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
33310695|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
33229304|NCT00702728|Active Comparator|2|Standard IV saline infusion
33229305|NCT00801268|Active Comparator|emodin|
33229306|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
33229307|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
33310696|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
33310697|NCT01050335||Surgical resident or attending|
33310698|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
33310699|NCT00077064|No Intervention|Observation|Clinical observation
33310700|NCT00077064|Experimental|Captopril|Captopril
33310701|NCT01043471|Experimental|Chewing gum|
33310702|NCT01043471|Placebo Comparator|Water|
33310703|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
33310704|NCT01086072||Myocardial Infarction - STEMI|
33310705|NCT01086072||Myocardial Infarction - NSTEMI|
33310706|NCT03962010|Experimental|Dose level 1|
33310707|NCT03962010|Experimental|Dose level 2|
33310708|NCT03962010|Experimental|Dose level 3|
33310709|NCT03962010|Experimental|Dose level 4|
33310710|NCT03962010|Placebo Comparator|Placebo|
33310711|NCT03962010|Active Comparator|Dulaglutide|
33310712|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
33310713|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
33310714|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
33310715|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
33310716|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
33310717|NCT01092156|Active Comparator|Education on Infant-led latching|
33310718|NCT01092156|No Intervention|Standard education|
33310719|NCT01088880|Experimental|Canakinumab|
33310720|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
33310721|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
33310722|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
33310723|NCT01092234|Active Comparator|Traditional ward|
33310724|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
33310725|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
33310726|NCT01043549|Sham Comparator|Sham stimulation|
33310727|NCT03961230|Experimental|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
33310728|NCT03961230|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
33310729|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
33310730|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
33310731|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
33310732|NCT01086306||Patients exposed to Saxagliptin|
33310733|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
33310734|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
33310735|NCT01089036||survival|ECMO survival patients
33310736|NCT01089036||ECMO non-survival|ECMO non-survivals
33310737|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
33310738|NCT01050803|Active Comparator|Control group|
33310739|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
33310740|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
33310741|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
33310742|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
33310743|NCT03404674|Experimental|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
33310744|NCT03404674|Experimental|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
33310745|NCT03404674|Experimental|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
33310746|NCT03404674|Experimental|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
33310747|NCT03404674|Experimental|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
33310748|NCT03404674|Experimental|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
33310749|NCT00064662|Other|Burch|The Burch colposuspension
33310750|NCT00064662|Other|Sling|Pubovaginal sling, using autologous rectus fascia
33310751|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
33310752|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
33310753|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
33310754|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
33310755|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
33310756|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
33310757|NCT00394901|Placebo Comparator|Placebo|
33310758|NCT00394901|Experimental|Pregabalin 150mg/day|
33310759|NCT00394901|Experimental|Pregabalin 300mg/day|
33310760|NCT00394901|Experimental|Pregabalin 600mg/day|
33310761|NCT03349060|Experimental|PF-04965842 100 mg|
33310762|NCT03349060|Experimental|PF-04965842 200 mg|
33310763|NCT03349060|Placebo Comparator|Placebo|
33310764|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
33310765|NCT03990935|Active Comparator|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
33310766|NCT03990935|Experimental|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
33310767|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
33310768|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
33310769|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
33310770|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
33310771|NCT00064350|Experimental|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
33310772|NCT00064350|Placebo Comparator|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
33310773|NCT00064350|Other|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
33310774|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
33310775|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
33310776|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
33310777|NCT03990857|Experimental|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
33310778|NCT03990857|No Intervention|comparison group|Participants in the study that do not receive the intervention. usual care.
33310779|NCT01052597|Placebo Comparator|Placebo|
33310780|NCT01052597|Experimental|Curcumin|
33310781|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
33318618|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
33310782|NCT00076752|Experimental|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
33310783|NCT03960918|No Intervention|usual neuro-rehab training|stroke patient under usual neuro-rehab training
33310784|NCT03960918|Experimental|Novel exercise training|stroke patient under aerobic exercise training
33310785|NCT03384940|Experimental|DS-8201a Cohort A|Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
33310786|NCT03384940|Experimental|DS-8201a Cohort B|Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
33310787|NCT03384940|Experimental|DS-8201a Cohort C|Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
33310788|NCT00075582|Experimental|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
33310789|NCT00075582|Experimental|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
33310790|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
33310791|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
33310792|NCT00063258|Active Comparator|Chemotherapy + Tarceva|
33310793|NCT00063258|Active Comparator|Chemotherapy Alone|
33310794|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
33310795|NCT00088530|Experimental|Experimental Arm|Pixantrone (BBR2778)
33310796|NCT00088530|Active Comparator|Comparator Arm|To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone
33310797|NCT00359801|Experimental|Exubera|
33310798|NCT00359801|Active Comparator|Usual Diabetes Care|
33310799|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
33310800|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
33310801|NCT03990701|Experimental|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
33310802|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
33310803|NCT01051193|Experimental|TRI476|TRI476
33310804|NCT01052753||ADHD group|
33310805|NCT01052753||Control group|
33310806|NCT01051271|Active Comparator|diphenhydramine|
33310807|NCT01051271|Placebo Comparator|saline|
33310808|NCT03991637|Experimental|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
33310809|NCT03991637|Active Comparator|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
33310810|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
33310811|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
33310812|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
33310813|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
33310814|NCT00045032|No Intervention|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
33310815|NCT00045032|Experimental|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
33310816|NCT00045032|Experimental|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
33310817|NCT01052987|Experimental|Tranilast|Tranilast tablets
33310818|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
33310819|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
33310820|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
33310821|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
33310822|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
32946224|NCT01897896|Experimental|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
32946225|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
32946226|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
32946227|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
32946228|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
32946229|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
32946230|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
32946231|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
32946232|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
32946233|NCT01873950|Placebo Comparator|Placebo|Placebo
32946234|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
32946235|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
32946236|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
32946237|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
32946238|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
32946239|NCT01872078|Experimental|Placebo to match AZD4901|
32946240|NCT04618458|Experimental|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
32946241|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
32946242|NCT01856790|Experimental|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
32946243|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
32946244|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
32946245|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
32946246|NCT01896102|Experimental|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of Lenti-D Drug Product at a dose of greater than or equal to (>=) 5.0 × 10^6 CD34+ cells/kilogram (kg) (autologous CD34+ cell-enriched population that contained cells transduced with lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservative solution) on Day 0.
32946247|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
32946248|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
32946249|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
32946250|NCT04606992|Experimental|CELS resection|All patients included in the study will be in this arm
33310823|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
33318619|NCT03955224|Active Comparator|Basic Oral Care + active LLLT (experimental arm)|
33318620|NCT03955224|Placebo Comparator|Basic oral Care + inactive LLLT (control arm)|
33318621|NCT03955224|Other|Basic Oral Care (control arm)|
33318622|NCT01100970||Unipolar electric needle|
33318623|NCT01100970||Bipolar electric needle|
33310824|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
33310825|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
33310826|NCT01051505|Experimental|1|
32946251|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
32946252|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
32946253|NCT04606290|Active Comparator|Manual|Fixed dose oxygen
33310827|NCT01051505|Placebo Comparator|2|
33310828|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
33310829|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
33310830|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
33310831|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
33310832|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
33310833|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
32946254|NCT04606290|Experimental|O2matic|Automated oxygen titration
32946255|NCT04411056|Experimental|Barrier box|Participants will have a barrier box placed during intubation
32946256|NCT04411056|No Intervention|No Barrier box|Participants will have routine intubation with no barrier box
32946257|NCT01895322|Experimental|OPC-41061|
33310834|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
33318624|NCT01100970||Control|Infants who were born in a vaginal birth
33318625|NCT00300755|Active Comparator|1|Arm 1- Low Dose pantoprazole
32946258|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
32946259|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
32946260|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
32946261|NCT04605198|Experimental|Modified Mindfulness-based Stress Reduction|
32946262|NCT04605198|Active Comparator|Health Promotion Attention Control|
32946263|NCT01854918|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product [all-IP] period.
32946264|NCT01854918|Experimental|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
32946265|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
32946266|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
32946267|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
32946268|NCT04597008|Active Comparator|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
32946269|NCT04597008|Experimental|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
32946270|NCT04414878|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
32946271|NCT04596930|Experimental|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
33095900|NCT05642845|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 40 mg dose of the test product Atorvastatin (1 x 40 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 40 mg dose of the reference product Liprimar® (1 x 40 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33095901|NCT05642845|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 400 mg dose of the reference product Liprimar® (1 x 40 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 40 mg dose of the test product Atorvastatin (1 x 40 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32946272|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
33095902|NCT04510662|Experimental|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
33095903|NCT04510662|No Intervention|Control|Patients in this group will receive standard care.
33310835|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
33310836|NCT02533661|No Intervention|Usual care program|"The UCP group received:~In-hospital intervention: environmental modulation and teaching of child development skills.~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
33310837|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
33310838|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
33310839|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
33310840|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
32946273|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
32946274|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
32946275|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
33095904|NCT05642806|Experimental|Mepolizumab|Mepolizumab (100 mg) subcutaneously every 4 weeks
33095905|NCT05642806|Placebo Comparator|Placebo|Placebo 100 mg subcutaneously every 4 weeks
33095906|NCT05642767||Patients with pseudomonas aeruginosa infections|"All patients suffer from infections that can be caused by pseudomonas aeruginosa.~Clinical Data will be obtained as:~Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~Samples will be cultured on cetrimide agar.~Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI.~Molecular detection to efflux genes and some virulence genes by PCR."
33095907|NCT05642767||Patients with infections other than pseudomonas aeruginosa|"Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~Samples will be cultured on different culture media and automated identification by Vitek system."
33310841|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
33310842|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
33310843|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
32946276|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
32946277|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
32946278|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
32946279|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
32946280|NCT01892436|Experimental|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
32946281|NCT01892436|Experimental|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
32946282|NCT01892436|Experimental|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
33095908|NCT05642689|Other|1|Comparison of iron absorption from FAP to Ferrous sulfate in milk
33095909|NCT05642689|Other|2|Comparison of iron absorption from ferric pyrophosphate to Ferrous sulfate in milk
33095910|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
33095911|NCT00486915|No Intervention|Control|
33095912|NCT05642611|Experimental|Arm 1 (Cryocompression)|Patients undergo cryocompression (cooling plus moderate and low pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
33095913|NCT05642611|Experimental|Arm 2 (Continuous Compression)|Patients undergo continuous compression (moderate, steady pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
33310844|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
33310845|NCT05456594|Placebo Comparator|Conventional bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing their own conventional bra.
33310846|NCT05456594|Active Comparator|Bounceless bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Bounceless bra.
33310847|NCT05456594|Active Comparator|Shefit bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Shefit bra.
33310848|NCT05416814|Experimental|Kefir administration in critically ill adults|Critically ill subjects will receive Kefir throughout the length of their ICU course in an ascending dosing regimen
33310849|NCT05386706|Experimental|Digital Cognitive Behavioural Therapy|A mini program-based cognitive behavioral therapy.
33310850|NCT05386706|Active Comparator|Metformin|Traditional metformin monotherapy.
33310851|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
33310852|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
33310853|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
33310854|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
33310855|NCT03950882|Experimental|PXL770|PXL770 500 mg once daily (QD) for 4 weeks
33310856|NCT03950882|Placebo Comparator|Placebo|placebo once daily (QD) for 4 weeks
33310857|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
33310858|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
33310859|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
33310860|NCT01051973|Experimental|Cognitive behavior therapy|
33310861|NCT01051973|Active Comparator|Stress management|
33310862|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
33310863|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
33310864|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
33310865|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
33310866|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
33310867|NCT00356603|Experimental|Sumatriptan|Sumatriptan
33310868|NCT01052051|Experimental|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
33095914|NCT05642611|Active Comparator|Arm 3 (Low Cyclic Compression)|Patients undergo low cyclic compression (low pressure that comes and goes to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
33310869|NCT01052051|Placebo Comparator|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
33310870|NCT03948230|Active Comparator|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
33310871|NCT03948230|Active Comparator|Sodium chloride / no water|300 mg sodium chloride consumed
33404597|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
33404598|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
32802486|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
32802487|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
32946283|NCT01892436|Experimental|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
32946284|NCT04415580|Experimental|Vestibular Rehabilitation Group|
32946285|NCT04415580|Active Comparator|Conventional rehabilitation Group|
32946286|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
32946287|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
32946288|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
32946289|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
32946290|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
32946291|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
32946292|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
32946293|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
32946294|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
32946295|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
32946296|NCT04602624|Experimental|SAGE-718|Participants will receive a single dose of SAGE-718 oral tablets, once daily in the morning for 14 days.
32946297|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
32946298|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
32946299|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
32946300|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
32946301|NCT04415190||cholangiocarcinoma with early palliative care|
32946302|NCT04415190||cholangiocarcinoma without early palliative care|
32946303|NCT04595682|Experimental|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
32946304|NCT04615884|Experimental|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
32946305|NCT04615884|Placebo Comparator|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
32946306|NCT01868646|Experimental|Subetta|
32946307|NCT01868646|Placebo Comparator|Placebo|
32946308|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
32946309|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
32946310|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
32946311|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
32946312|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
32946313|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
33095915|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
33095916|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
33310872|NCT03948230|Active Comparator|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
33310873|NCT03948230|Placebo Comparator|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
33095917|NCT01300819|Placebo Comparator|Placebo|
33095918|NCT01300819|Experimental|Rotigotine|
33310874|NCT03948230|Placebo Comparator|Placebo / no water|Placebo capsule consumed
33310875|NCT03948230|Placebo Comparator|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
33310876|NCT03990155|Experimental|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR <25 bpm + pH >7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
33310877|NCT05374304|Experimental|Lead-In (BC/WC-GeriOnc)|Lead-in phase oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist and ask patients and oncologists to complete study questionnaires over one-month follow-up and one semi-structured interview about the decision-making process and communication.
33310878|NCT05374304|Experimental|Intervention (BC/WC-GeriOnc)|Intervention group oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist to understand baseline oncologist practices and communication. Patients and oncologists will be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview. For each randomized oncologist, cancer treatment decision-making discussions will be recorded with 5 patients per oncologist. Both patients and oncologists will also be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview about the decision-making process and communication. Each patient will be given the option to select 1 caregiver to participate. Caregivers will be asked to complete study questionnaires and a semi-structured interview about their decision-making experience.
33310879|NCT05374304|No Intervention|Waitlist Control|Usual care will be provided to the patients, with optional training for the oncologists at study completion.
33310880|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
33310881|NCT03948152|Active Comparator|Standard of Care|
33310882|NCT03948152|Experimental|Mask Advice Tool|
33310883|NCT01104428|Placebo Comparator|placebo|
33310884|NCT01104428|Experimental|"Drug:ziying"|
33310885|NCT05370872|No Intervention|Care-as-usual|Clients in this group will complete functional testing in the clinic using the care-as-usual approach.
33310886|NCT05370872|Experimental|Remote functional testing|Clients in this group will complete functional testing using the remote functional testing approach.
33310887|NCT05352776|Experimental|AtaCor EV-ICD Lead System|Subjects implanted with the AtaCor EV-ICD Lead Model AC-7001
33310888|NCT03947996|Experimental|Stretching|Stretching
33310889|NCT03947996|Experimental|Walking|Walking
33310890|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
33310891|NCT01104506|Active Comparator|Healthy|Healthy volunteers
33310892|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
33310893|NCT00002558|Experimental|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
33310894|NCT00002540|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
33310895|NCT00002540|Active Comparator|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
33310896|NCT03950648|Experimental|Spatial Cognitive Training|map reading and route-learning skills
33310897|NCT01101932|Experimental|(Part 1) PF-04308515|
33310898|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
33310899|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
33310900|NCT00001880|Experimental|Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors|Cyclosporin beginning day -4 then stem cells given on Day 0 followed by intravenous Methotrexate on days +1, +3, and +6.
33310901|NCT01096472|Experimental|LAS41003|Once daily
33310902|NCT01096472|Active Comparator|LAS189962|Once daily
33310903|NCT01096472|Active Comparator|LAS189961|Once daily
33310904|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
33310905|NCT05627648|Active Comparator|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
33310906|NCT05627648|Placebo Comparator|Placebo|Intracordal injection, once per week, 3 weeks
33310907|NCT05296772|Other|Dose escalation|A open-label single arm of JS014 alone or in combination with pembrolizumab
33310908|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
33310909|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
33318626|NCT00300755|Active Comparator|2|Arm 2- Medium Dose pantoprazole
33318627|NCT00300755|Active Comparator|3|Arm 3- High Dose pantoprazole
33095919|NCT05642572|Experimental|Arm A (capmatinib, osimertinib, ramucirumab)|Patients receive capmatinib PO, osimertinib PO, and ramucirumab IV on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
33095920|NCT05642572|Experimental|Arm B (capmatinib, osimertinib)|Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
33095921|NCT00486993||asuriesgo|unselected outpatient population
33310910|NCT03953924|No Intervention|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
33310911|NCT03953924|Experimental|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
33310912|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
33310913|NCT03947528|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
33310914|NCT03947528|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
33095922|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
33095923|NCT00487019||2|Same as group 1
33095924|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
33095925|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
33095926|NCT02275962|Experimental|K-877|K-877
33095927|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
33095928|NCT05642494|Experimental|SDF+NaF|Silver Diamine fluoride 38% (Applied biannually)+ Sodium Fluoride Varnish 5% (Applied every 3 months)
33095929|NCT05642494|Active Comparator|SDF|Silver Diamine fluoride 38% (Applied biannually)
33310915|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
33310916|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
33310917|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
33310918|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
33310919|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
33310920|NCT00043550|Experimental|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
33310921|NCT00043550|Active Comparator|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
33310922|NCT00043550|Placebo Comparator|3 Pill Placebo|Participants receive placebo.
33310923|NCT03950258|Experimental|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
33310924|NCT00041756|Placebo Comparator|Placebo|Placebo tablet
33310925|NCT00041756|Experimental|25 mg PG-530742|25 mg PG-530742
33310926|NCT00041756|Experimental|50 mg PG-530742|50 mg PG-530742
33095930|NCT05642455|Experimental|Afamitresgene autoleucel|
33095931|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
33095932|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
33095933|NCT05642377|Experimental|HGR4113 300 mg Single Dose|Single oral dosing of HSG4112 300 mg
33095934|NCT05642377|Placebo Comparator|Placebo 300 mg Single Dose|Single oral dosing of placebo 300 mg
33095935|NCT05642377|Experimental|HGR4113 600 mg Single Dose|Single oral dosing of HSG4112 600 mg
33095936|NCT05642377|Placebo Comparator|Placebo 600 mg Single Dose|Single oral dosing of placebo 600 mg
33095937|NCT05642377|Experimental|HGR4113 1200 mg Single Dose|Single oral dosing of HSG4112 1200 mg
33095938|NCT05642377|Placebo Comparator|Placebo 1200 mg Single Dose|Single oral dosing of placebo 1200 mg
33310927|NCT00041756|Experimental|100 mg PG-530742|100 mg PG-530742
33310928|NCT00041756|Experimental|200 mg PG-530742|200 mg PG-530742
33310929|NCT03950180|Active Comparator|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
33310930|NCT03950180|No Intervention|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
33310931|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
33310932|NCT01102244|Active Comparator|Azasite|azithromycin 1%
33310933|NCT01105208|Experimental|Arm 1|
33310934|NCT01105208|Active Comparator|Arm 2|
33310935|NCT01105286|Experimental|Calcipotriol ointment|
33404599|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
33404600|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
32946316|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~(Bolus dose can be titrated up in 25 mcg increments if necessary)~Maximum dose of 100 mcg/hr"
32946317|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes~No initial bolus and no continuous infusion~Demand dose increased 10 mcg every 12 minutes if necessary~Maximum dose of 100 mcg/hr"
32946318|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
32946319|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
32946320|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
32946321|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
32946322|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
32946323|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
32946324|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
32946325|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
33310936|NCT00041132|Experimental|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
33310937|NCT01102322||1|
33310938|NCT00040742|Placebo Comparator|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
32946326|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
32946327|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
32946328|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
32946329|NCT01849848|Experimental|SyB L-0501|
33310939|NCT00040742|Experimental|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
33310940|NCT00040742|Experimental|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
33310941|NCT00040742|Experimental|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
33310942|NCT05189210|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
32946330|NCT04594512|Other|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
33310943|NCT05189210|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
33310944|NCT05189210|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
33310945|NCT00040664|Experimental|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
33310946|NCT00040664|Experimental|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
33310947|NCT00040664|Experimental|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
33310948|NCT03953768|Experimental|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
33310949|NCT03947372|Active Comparator|OA (open Appendectomy)|Open Appendectomy
33310950|NCT03947372|Experimental|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
33404601|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
33404602|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
33404603|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
33404604|NCT05365191|Other|Multispectral near infrared imaging|The participants will be assigned to one single arm that accepted both near infrared zone I and near infrared zone II imaging during the near infrared fluorescence navigated sentinel lymph node biopsy procedure. Imaging quality will be compared between different spectrums.
33404605|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
33404606|NCT01372761|Placebo Comparator|Normal Saline|
33404607|NCT01372761|Experimental|ZGN-433|
32946331|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
32946332|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
32946333|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
32946334|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
32946335|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
32946336|NCT01832532|No Intervention|Control group|Control group
32946337|NCT04414956|Other|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
32946338|NCT04589910|Other|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
33310951|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
32946339|NCT04415112|Active Comparator|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with <10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
32946340|NCT04415112|Active Comparator|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with <10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
32946341|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
32946342|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
33310952|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
32946343|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
32946344|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
32946345|NCT01831596|Experimental|ciSNaP|
32946346|NCT01848834|Experimental|Cohort A: Triple Negative Breast Cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
32946347|NCT01848834|Experimental|Cohort B: Head & Neck Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
32946348|NCT01848834|Experimental|Cohort C: Urothelial Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
32946349|NCT01848834|Experimental|Cohort D: Gastric Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
32946350|NCT01848834|Experimental|Cohort B2: Head & Neck Cancer Expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
32946351|NCT01867008|Experimental|Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor|
32946352|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
32946353|NCT04594434|Experimental|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
32946354|NCT04594434|Active Comparator|protocol EMDR (standard).|"recommended therapy based on EMDR."
32946355|NCT04600362|Experimental|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
32946356|NCT04600362|Placebo Comparator|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
32946357|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:~Part I: participants continued on 6 g/day SA-ER for 12 weeks~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
33310953|NCT05098574|Experimental|Combined oral contraceptive (3mg drospirenone/ 0.02mg ethinyl estradiol)|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
33310954|NCT05098574|Placebo Comparator|Placebo|Continuous treatment with placebo for 12 weeks
33310955|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
33310956|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
33310957|NCT03950102|Experimental|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
33310958|NCT01096628|Experimental|Chiropractic + Exercise|
33310959|NCT01096628|Active Comparator|Exercise|
33310960|NCT03949790|Active Comparator|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
33310961|NCT03949790|Active Comparator|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
33310962|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
33310963|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
33310964|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
33310965|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
33310966|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
33310967|NCT03949712|Experimental|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
32946358|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
32946359|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
32946360|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
32946361|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
32946362|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
32946363|NCT01830816|Experimental|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
32946364|NCT01830816|Experimental|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
32956144|NCT05734040|Experimental|OVX836 480µg + Fluarix Tetra at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
33310968|NCT03949712|Experimental|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
33310969|NCT03949712|Sham Comparator|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
33310970|NCT01102400|Experimental|1|
33310971|NCT01327820||Open aortic aneurysm repair|
33310972|NCT01327820||Endovascular aortic aneurysm repair|
33310973|NCT01327820||Infra-inguinal lower limb revascularisation|
33310974|NCT05555368|Other|single group|The Qo0R-15 scale will be administered to 150 patients.
33310975|NCT04981730|Experimental|Web-based intervention|Participants in the intervention will receive both the standardized usual care and guided web-based, individually-tailored childbirth and parenting intervention program, consisting of training sessions plus weekly email, message, or video-conference contact from their assigned nurse specialist.
33310976|NCT04981730|No Intervention|Control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
33310977|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
33310978|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
33310979|NCT01108640||Elective surgical patients|
33310980|NCT01108640||Massive resuscitation patients|
33310981|NCT01108640||surgical patients on pressors|
33310982|NCT01105520||intralspinal processes|Patients with intralspinal processes
33310983|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
33310984|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
33310985|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
33310986|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
33310987|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
33310988|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
33310989|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
33310990|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
33310991|NCT01584830|Experimental|Arm 1|
33310992|NCT01584830|Placebo Comparator|Arm 2|
33310993|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
33310994|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
33310995|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
33310996|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
33310997|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
33310998|NCT03944642|Experimental|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
33310999|NCT03944642|No Intervention|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
33311000|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
33311001|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
33311002|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
33311003|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
33311004|NCT05626556|Experimental|older adults|Older adults with mild to moderate chronic illness
33311005|NCT03994172|Experimental|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
33311006|NCT03994172|Placebo Comparator|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
33311007|NCT04958096|Experimental|Prefrontal Cortex (PFC)|The Prefrontal Cortex (PFC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the PFC.
33311008|NCT04958096|Experimental|Anterior Cingulate Cortex (ACC)|The Anterior Cingulate Cortex (ACC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the ACC.
33311009|NCT04943744||String Test|Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.
33311010|NCT04940156|Other|Confirm Rx|Patient with cardiac implantable electronic devices with an atrial lead will have Confirm Rx Implantable Cardiac Monitor injected in the anterior chest wall.
33311011|NCT04940156|Other|LINQ|Patient with cardiac implantable electronic devices with an atrial lead will have LINQ Implantable Cardiac Monitor injected in the anterior chest wall.
33311012|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
33311013|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
33311014|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
33311015|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
33311016|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
33311017|NCT03907982|Experimental|DCCV + PVI|"DC cardioversion (DCCV) plus Pulmonary Vein Isolation (Cryoablation)~At end of pulmonary vein isolation, DCCV performed (if patient still in AF). An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure."
33404608|NCT03866512|Experimental|Acipimox ingestion during immobilization|Oral ingestion of Acipimox during 2 days of forearm immobilization
33311018|NCT03907982|Active Comparator|DC cardioversion (DCCV)|Acute treatment of heart rhythm by cardioversion. An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure.
33311019|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
33311020|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
33311021|NCT03949322|Experimental|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
33311022|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
33311023|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
33311024|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
33311025|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
33311026|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
33311027|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
33311028|NCT04924166|Placebo Comparator|Placebo|matching capsule PO
32946365|NCT01830816|Experimental|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
33311029|NCT04924166|Active Comparator|HCORT|180 mg capsule PO
33311030|NCT03946982|Experimental|Low thoracic patient controlled epidural analgesia|
33311031|NCT03946982|Active Comparator|Lumbar epidural patient controlled epidural analgesia|
33311032|NCT03946982|Active Comparator|Low thoracic epidural morphine|
33311033|NCT03946982|Active Comparator|Lumbar epidural morphine|
33311034|NCT03944564|Active Comparator|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
33311035|NCT03944564|Active Comparator|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
33311036|NCT03944564|Active Comparator|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
32946366|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
32946367|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
33311037|NCT04838210|Experimental|Group Prenatal Care|Group prenatal care model
33311038|NCT04838210|Active Comparator|Individual Prenatal Care|Individual prenatal care
32946368|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
32946369|NCT04589754|Experimental|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
33311039|NCT04814420|Experimental|Experimental group|The group will include 15 patients with OSA 5 with mild OSA 5 with moderate OSA 5 with severe OSA
33311040|NCT04814420|Other|Control group|This group will include 5 patients with no OSA
33311041|NCT01102712|Experimental|BTVA|
32946370|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
32946371|NCT01865448|Placebo Comparator|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
32946372|NCT01804140||Cohort|
32946373|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
32946374|NCT01803282|Experimental|Part A: ADX 200 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
33095939|NCT05642377|Experimental|HGR4113 300 mg Multiple Dose|Multiple oral dosing of HSG4112 300 mg
33095940|NCT05642377|Placebo Comparator|Placebo 300 mg Multiple Dose|Multiple oral dosing of placebo 300 mg
32946375|NCT01803282|Experimental|Part A: ADX 600 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946376|NCT01803282|Experimental|Part A: ADX 1800 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
32946377|NCT01803282|Experimental|Part B: PAC, ADX 800 mg|Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946378|NCT01803282|Experimental|Part B: LAC, ADX 1200 mg|Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946379|NCT01803282|Experimental|Part B: LSC, ADX 1200 mg|Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946380|NCT01803282|Experimental|Part B: EGC, ADX 800 mg|Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} [mFOLFOX6], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946381|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946382|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946383|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU [FOLFIRI] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946384|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946385|NCT01803282|Experimental|Part B: BRCA, ADX 800 mg|Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
32946386|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
32946387|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
32946388|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
32946389|NCT01802580|Experimental|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
32946390|NCT01802580|Experimental|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
33095941|NCT05642377|Experimental|HGR4113 600 mg Multiple Dose|Multiple oral dosing of HSG4112 600 mg
33095942|NCT05642377|Placebo Comparator|Placebo 600 mg Multiple Dose|Multiple oral dosing of placebo 600 mg
32946391|NCT01802346|Experimental|Arm I (low-calorie diet)|Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
32946392|NCT01802346|Active Comparator|Arm II (normal diet)|Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
33095943|NCT05642377|Experimental|HGR4113 1200 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg
33095944|NCT05642377|Placebo Comparator|Placebo 1200 mg Multiple Dose|Multiple oral dosing of placebo 1200 mg
33311042|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
33311043|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
33311044|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
32802488|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
32802489|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
32946393|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
32946394|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
33311045|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
33311046|NCT03766958||Registry Patients With Nodify Lung Results|Patients providing consent to have data collected to observe how Nodify Lung results were used in the clinical management of their lung nodules.
33311047|NCT03766958||Contemporaneous Group Without Nodify Lung|Contemporaneous group who did not have Nodify Lung test results for use in the clinical management of their lung nodules.
33311048|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
33311049|NCT01327898|Experimental|1|empowerment theory-based small group discussion
32946395|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
33311050|NCT01327898|Active Comparator|2|single session individual resilience counseling
33311051|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
33311052|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
32946396|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
32946397|NCT01827384|Experimental|Regimen I (veliparib, temozolomide)|Patients receive veliparib by mouth (PO) twice a day (BID) on days 1-7 and temozolomide PO every day (QD) on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33311056|NCT03989999|Experimental|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
33311057|NCT03989999|No Intervention|CONTROL Group|Mild TBI management with SFMU recommandations
33311058|NCT03946592|Placebo Comparator|Placebo group|Inject the Drug into submental fat via subcutaneous
33311059|NCT03946592|Experimental|DWJ211 group|Inject the Drug into submental fat via subcutaneous
33311060|NCT03944408|Experimental|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
33311061|NCT03944408|Other|A metal bare stent|A metal bare stent implantation
33311062|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
33311063|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
33311064|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
33311065|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
32946398|NCT01827384|Experimental|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib by mouth (PO) twice a day (BID) for 5 doses starting on day 1 and carboplatin intravenous (IV) over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32946399|NCT01827384|Experimental|Regimen III (everolimus)|Patients receive everolimus by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33095945|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
33095946|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
33311066|NCT01106144||Acute myeloid leukemia|
33311067|NCT01053377|Active Comparator|Tamiflu|
33311068|NCT01053377|Placebo Comparator|Placebo Tamiflu|
32946400|NCT01827384|Experimental|Regimen IV (trametinib)|Patients receive trametinib by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32946401|NCT01844076|Experimental|Phase I Level -2|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle"
33311069|NCT03946904|Experimental|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
33311070|NCT03946904|Experimental|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
33311071|NCT03991559|Active Comparator|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
33311072|NCT03991559|Active Comparator|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
33311073|NCT03949634|Experimental|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
33311074|NCT03949634|Active Comparator|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
33311075|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
33311076|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
32946402|NCT01844076|Experimental|Phase I Level -1|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
32946403|NCT01844076|Experimental|Phase I Level 0|Group 3: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
32946404|NCT01844076|Experimental|Phase II|"Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.~Patients will receive capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
33311077|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
33311078|NCT03944330|Active Comparator|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
33311079|NCT03944330|No Intervention|control group|All study participants were not intervened with diet
32946405|NCT01826604|Experimental|Alexis O C-section retractor|Alexis O C-section retractor will be used.
33311080|NCT04713800|Experimental|ZR-TiB|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR)
33311081|NCT04713800|Active Comparator|PFM-GA|Porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM)
33311082|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
33311083|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
32946406|NCT01826604|Other|Control- Conventional retractors|Conventional retractors for C-sections will be used.
32946407|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
32946408|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
32946409|NCT01826448|Experimental|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
32946410|NCT01826448|Experimental|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
32946411|NCT01826448|Experimental|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
32946412|NCT01826448|Experimental|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
32946413|NCT01826370||Linagliptin|
32946414|NCT01826214|Experimental|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
32946415|NCT01826214|Experimental|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
32946416|NCT04582344|Experimental|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
32946417|NCT04582344|Placebo Comparator|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
32802490|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
33095947|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
33311084|NCT03946748|Experimental|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
32802491|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
32802492|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
32802493|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
32802494|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
33311085|NCT05626166|Placebo Comparator|control group|Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.
33311086|NCT05626166|Experimental|diosmin group|Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months.
33311087|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
33311088|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
32802495|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
32802496|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
32802497|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
32802498|NCT03301636|Experimental|Nivolumab + Indoximiod|
32802499|NCT01841060|Experimental|Radiofrequency ablathermy|Percutaneous radiofrequency ablation (RFA)
32802500|NCT04414592|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
32802501|NCT04760860|Placebo Comparator|Placebo Control Arm|Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
32802502|NCT04760860|Experimental|Terazosin Arm|Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
32802503|NCT04602494|Experimental|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
32802504|NCT04602494|Placebo Comparator|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
32802505|NCT04602494|No Intervention|Monitoring only|Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support.
32946418|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
33311089|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
33311090|NCT05547724|Experimental|Virtual reality|
32802506|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
33311091|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
33311092|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
33404609|NCT03866512|Experimental|B-agonist during immobilization|Oral ingestion of salbutamol during 2 days of forearm immobilization
32802507|NCT04587050||Cohort 1|Women with perinatally acquired HIV aged 18 or over who are sexually active
32802508|NCT04587050||Cohort 2|Women with perinatally acquired HIV aged 18 or over who are not sexually active
32802509|NCT05640232|Experimental|Experimental|CDE100 The patient must take 1 pill of CDE100 association and placebo of Buscopan® Composto association, if pain, until three times a day.
32802510|NCT05640232|Active Comparator|Control|"Buscopan® Composto association.~The patient must take 1 pill of Buscopan® Composto association and placebo of CDE100 association, if pain, until three times a day."
32802511|NCT04414904||Case group|"Men 18-50 years of age~Already attending hospital for another reason~High risk of prior COVID-19 infection:~EITHER Prior positive COVID-19 PCR test result~OR history suggestive of COVID-19 illness"
32802512|NCT04414904||Control Group|"Men 18-50 years of age~Already attending hospital for another reason~Low risk of prior COVID-19 infection:~EITHER Negative positive COVID-19 PCR test result within last 4 weeks~OR no history suggestive of COVID-19 illness"
32802513|NCT05637502|Experimental|Graded Motor Imagery and Education|Participants receiving the Graded Motor Imagery programme and a therapeutic educational program
32802514|NCT05637502|Active Comparator|Education|Participants only receiving a therapeutic educational program
33404610|NCT03866512|Placebo Comparator|Placebo ingestion during immobilization|Oral ingestion of a placebo 2 days of forearm immobilization
32802515|NCT05627518|Active Comparator|Reference formulation (Treatment A)|100 mg linaprazan glurate reference formulation, fasting conditions
32802516|NCT05627518|Experimental|Test formulation (Treatment B)|100 mg linaprazan glurate reference formulation, fasting conditions
32802517|NCT05627518|Experimental|Test Formulation (Treatment C)|100 mg linaprazan glurate test formulation, fed conditions
32802518|NCT01814696|No Intervention|Control|Subjects will continue to receive usual medical care from their doctor(s).
32802519|NCT01814696|Experimental|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
32802520|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
32802521|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
32802522|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
32802523|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
32802524|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
32802525|NCT03300466|Experimental|GP0045|Treatment with GP0045
32802526|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
32802527|NCT05686954|Experimental|CSO LOW|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
32802528|NCT05686954|Experimental|CSO MID|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
32802529|NCT05686954|Experimental|CSO HIGH|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
32802530|NCT05686954|Active Comparator|CONTROL|Participants are given foods enriched with a mixture of oils and instructed on how to substitute study foods into their diet to maintain caloric balance.
32802531|NCT01868594|Experimental|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
32802532|NCT01868594|Placebo Comparator|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
32802533|NCT04348006|Experimental|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
32802534|NCT04621435|Experimental|68Ga-Dosimetry population (Cohort 1a)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
32802535|NCT04621435|Experimental|64Cu-Dosimetry population (Cohort 1b)|PET imaging will begin 60±15 minutes, 240±30 minutes after injection,and 24±2 hours after injection of 64Cu-FAP-2286. Contrast may be administered if clinically indicated.
32802536|NCT04621435|Experimental|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if clinically indicated.
32802537|NCT04621435|Experimental|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if if clinically indicated.
32802538|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
32802539|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
32802540|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
32802541|NCT05686876|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
32802542|NCT05622604|No Intervention|no intervention condition|no intervention
32802543|NCT05622604|Experimental|autonomous use condition|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
32802544|NCT05622604|Experimental|meditative prayer condition|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
32802545|NCT04171700|Experimental|Rucaparib|"Eligible patients will be enrolled in either Cohort A or Cohort B.~Cohort A: Up to 200 patients with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.~Cohort B (Exploratory): Up to 20 patients with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B."
32802546|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
32899811|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
32899812|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
33095948|NCT05642338||cohort 1 dysplastic cohort|208 BE patients referred for work up after diagnosis of LGD, HGD or earlystage cancer in the last 18 months.
32802547|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
33095949|NCT05642338||Cohort 2: non-dysplastic cohort|208 patients under standard BE surveillance without a diagnosis of dysplasia in last 18 months.
33095950|NCT05642299|Experimental|MBCI-SR|BCI based robotic rehabilitation works by detecting the motor intent of the user from Electroencephalogram signals to drive rehabilitation assisted by the soft robotics gloves.
33095951|NCT05642260|No Intervention|control group|"Patients in the control group will receive a conventional physiotherapy treatment (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital). The treatment will be delivered by four allocated physiotherapists,The treatment will be delivered by four allocated physiotherapists, and will consist of:~Blood circulation exercise (i.e., ankle pumps)~Quadriceps isometric exercises (i.e., quad sets).~Knee ROM exercises (i.e., knee flexion and extension).~Lower limb strengthening exercises (e.g., straight leg raising, short/ long arch exercises)~Stretching exercises for the hamstring and calf muscles.~Gait training (with and without the assistive device).~Parallel bars exercises (e.g., standing hip abduction/adduction, knee flexion, squatting).~Ascending/descending stairs.~Home program."
33311093|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
32802548|NCT05619718|Experimental|Treatment|Treatment group will receive Awareness, Courage, and Love Groups for loneliness.
33404611|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
32802549|NCT05619718|Active Comparator|Control|Control group will receive treatment as usual in the form of Mutual Help Meetings.
32802550|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
32802551|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
33404612|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
32802552|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
32802553|NCT05613946|Other|Microbubble contrast agent Lumason|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
32802554|NCT05613946|Other|Microbubble contrast agent Optison|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
32802555|NCT05613946|Other|Microbubble contrast agent Definity|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
32802556|NCT04401046|Experimental|Post traumatic stress and anxiety evaluation|
32802557|NCT03375892|Active Comparator|Prone Position with DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
32802558|NCT03375892|Active Comparator|Supine Position with DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
32802559|NCT03375892|Active Comparator|Prone Position with no DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
32802560|NCT03375892|Active Comparator|Supine Position with no DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
32802561|NCT05686798|Experimental|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fSRS Arm|Subjects will receive a single intratumoral injection of the Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels beginning at 1 x 1011 vp and escalating in half-log (3-fold) increments to 1 x 1012 vp, along with the same dose of fractionated stereotactic radiosurgery until unacceptable toxicity, disease progression, or withdrawal of consent.
32802562|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
32802563|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
32802564|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
32802565|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
32802566|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
32802567|NCT05686720|Experimental|SZ011 CAR-NK|
32802568|NCT04414982|Experimental|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
32802569|NCT04414982|Active Comparator|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
32802570|NCT05604742|Experimental|Low-dose group of Belimumab|Belimumab 1mg/kg com combined with conventional therapy
32802571|NCT05604742|Experimental|High-dose group of Belimumab|Belimumab 4mg/kg com combined with conventional therapy
32802572|NCT05604742|No Intervention|Control group|conventional therapy
32899813|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
32899814|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~Chlorhexidine gluconate soap applied for bathing daily.~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~Nasal mupirocin to applied inside nostrils twice daily."
32899815|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
32946419|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
32946420|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
33311094|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
33311095|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
32946421|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
32946422|NCT01799226|Active Comparator|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
32946423|NCT01799226|Experimental|Triclosan|This arm will use colgate total which contains triclosan
32946424|NCT01798992|No Intervention|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
32946425|NCT01798992|Active Comparator|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
32946426|NCT01798992|Active Comparator|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
32946427|NCT01798992|Active Comparator|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
32946428|NCT01825200|Active Comparator|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
32946429|NCT01825200|Placebo Comparator|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
32946430|NCT01824576|Experimental|ITPR|Use of the ITPR for 120 minutes.
32946431|NCT01824498|Experimental|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
32946432|NCT01824498|Experimental|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
32946433|NCT01824498|Experimental|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
32946434|NCT01824498|Experimental|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
32946435|NCT01824498|Experimental|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
32946436|NCT01824498|Experimental|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
32946437|NCT04593888|No Intervention|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
32946438|NCT04593888|Experimental|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.~The group will be followed with regular visits at the research clinic."
32946439|NCT01798134|Other|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
32946440|NCT01798056|Experimental|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
32946441|NCT01798056|Placebo Comparator|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
32946442|NCT01824342|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
32946443|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
32946444|NCT01823328|Active Comparator|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
32946445|NCT01823328|Active Comparator|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
32946446|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
32946447|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
32946448|NCT01797432|Experimental|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
32946449|NCT01797120|Active Comparator|Fulvestrant & Everolimus|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
32946450|NCT01797120|Placebo Comparator|Fulvestrant & Placebo|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
32946451|NCT01796964|Experimental|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
32946452|NCT01796964|Active Comparator|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
33311096|NCT01053455||Starting on SiPAP|randomized to SiPAP
33311097|NCT01052363|Experimental|CA4P + Avastin|
33311098|NCT01052363|Experimental|Avastin + CA4P|
32946453|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
32946454|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
33095952|NCT05642260|Experimental|intervention (treatment) group|"Patients in the experimental group will receive a comprehensive fall prevention program (described below) integrated into the conventional physiotherapy treatment. The fall prevention program will consist of:~Otago balance exercise for 12 weeks integrated with conventional physiotherapy treatment (described in the control group).~Individualized advice on assistive device usage based on the participant's Berg Balance Score (BBS) revised at the 3 data collection timepoints.~Environmental hazard checklist.~Advice on getting their eyes checked and the use of appropriate footwear to ensure the elimination of other risk factors.~Home program (consists of balance and strength training exercises).~The treatment will be delivered by four allocated physiotherapists. The physiotherapists will receive an introductory/training session on the fall prevention program prior to the commencement of the trial."
32946455|NCT01795638|Active Comparator|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
32946456|NCT01795638|Placebo Comparator|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
32946457|NCT01794780|Experimental|Indacaterol|LABA: Indacaterol, once a day, 150μg each time
32946458|NCT01794780|Experimental|Tiotropium Bromide|LAMA: Tiotropium Bromide, once a day, 18 μg
32946459|NCT01794780|Experimental|Salmeterol/Fluticasone|LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
32946460|NCT01794780|Experimental|Budesonide/ formoterol|Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
32946461|NCT01794780|Experimental|Indacaterol +Tiotropium|Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
32946462|NCT01794780|Experimental|LABA/ICS (Or budesonide/ formoterol)+ Tiotropium|Salmeterol / fluticasone Or budesonide / formoterol
32946463|NCT01794780|Experimental|Oral theophylline|
32946464|NCT01794780|Experimental|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
32946465|NCT04587726|Experimental|Intervention Group|
32946466|NCT04587726|Active Comparator|Control Group|
32946467|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
32946468|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
32946469|NCT01611792|Experimental|Stabilization|
32946470|NCT01611792|Active Comparator|Strengthening and Conditioning|
32946471|NCT01820364|Experimental|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
32946472|NCT01819506|Experimental|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length."
32946473|NCT01819506|Active Comparator|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length.
32946474|NCT01794000|Experimental|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
32946475|NCT01794000|Placebo Comparator|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
32946476|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
32946477|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 milligrams (mg) LY2140023 administered alone
32946478|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.
32946479|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
32946480|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
32946481|NCT04580472|Placebo Comparator|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
32946482|NCT04580472|Experimental|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
32946483|NCT04580472|Placebo Comparator|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
32946484|NCT04580472|Experimental|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
32946485|NCT04580472|Placebo Comparator|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
33311099|NCT03383146|Placebo Comparator|Placebo|Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
33311100|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
33311101|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
33311102|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
33311103|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
33311104|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
33311105|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
33311106|NCT01052519|No Intervention|obese control|
33311107|NCT01052519|Active Comparator|obese goal-directed|
33311108|NCT01052519|Active Comparator|non-obese goal directed|
33095953|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
33311109|NCT01053611|Active Comparator|Group 1 BIS value 30|
33311110|NCT01053611|Active Comparator|Group 2 BIS value 30|
33311111|NCT01053611|Active Comparator|Group 3 BIS value 30|
33311112|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
33311113|NCT01053611|Active Comparator|Group 1 BIS value 50|
33311114|NCT01053611|Active Comparator|Group 2 BIS value 50|
33311115|NCT01053611|Active Comparator|Group 3 BIS value 50|
33311116|NCT01053611|Active Comparator|Group 4 BIS value 50|
33311117|NCT01053611|Active Comparator|Group 1 BIS value 70|
33311118|NCT01053611|Active Comparator|Group 2 BIS value 70|
33311119|NCT01053611|Active Comparator|Group 3 BIS value 70|
33311120|NCT01053611|Active Comparator|Group 4 BIS value 70|
33311121|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
33311122|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
33311123|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
33095954|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
33095955|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
33095956|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
33311124|NCT03616964|Experimental|2 milligram (mg) Baricitinib|Participants received one 2 mg baricitinib tablet and one placebo tablet matching 4 mg baricitinib administered orally once daily (QD) for 52 weeks.
33311125|NCT03616964|Experimental|4 mg Baricitinib|Participants received one 4 mg baricitinib tablet and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
33311126|NCT03616964|Placebo Comparator|Placebo|Participants received 2 placebo tablets: one placebo tablet matching 4 mg baricitinib and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
33311127|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
33311128|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
33311129|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
33311130|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
33311131|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
33311132|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
33311133|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
33095957|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
33095958|NCT00487071|Experimental|Anal fistula plug|
33311134|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
33311135|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
33311136|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
33311137|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
32946486|NCT04580472|Experimental|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
33095959|NCT05642104||Single group assignment|Patients with invasive breast cancer who need neoadjuvant therapy.
33311138|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
33311139|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
33311140|NCT03989765|Experimental|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
33311141|NCT03989765|No Intervention|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
33311142|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
32946487|NCT01819272|Experimental|600 mg DR|600 mg delayed-release metformin once daily in the morning
32946488|NCT01819272|Experimental|800 mg DR|800 mg delayed-release metformin once daily in the morning
32946489|NCT01819272|Experimental|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
32946490|NCT01819272|Active Comparator|1000 mg XR|1000 mg extended-release metformin once daily in the evening
32946491|NCT01819272|Active Comparator|2000 mg XR|2000 mg extended-release metformin once daily in the evening
32946492|NCT01819272|Placebo Comparator|Placebo|Placebo once daily in the morning
32946493|NCT01819194|Experimental|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
32946494|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
32946495|NCT04579926|Experimental|Pinpoint App|Tablet and smartphone application.
32946496|NCT04593186|Experimental|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
32946497|NCT04579068|Experimental|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking [HED] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
32946498|NCT01818726|Experimental|Serum ferritin level ≥ 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
32946499|NCT01818726|Experimental|Serum ferritin level < 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin < 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
32946500|NCT01818336|Experimental|all subjects|"Intervention: Penicillin skin test kit~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
32946501|NCT04592640|Experimental|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
32946502|NCT01818258|Active Comparator|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
32946503|NCT01818258|Active Comparator|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
32946504|NCT01817790|Experimental|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
32946505|NCT01817790|Placebo Comparator|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
32946506|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
32946507|NCT01793610|Active Comparator|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
32946508|NCT01793610|Experimental|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
32946509|NCT01793610|Experimental|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
32946510|NCT01793142||Viviant treatment group|Viviant treatment group
32946511|NCT01792830|No Intervention|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c <7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
33095960|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
33095961|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
33095962|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
33095963|NCT02276001|Experimental|K-877|K-877
33095964|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
33095965|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
33095966|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
33095967|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
33095968|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
33095969|NCT04510155|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
33095970|NCT04510155|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
33095971|NCT00487227|Placebo Comparator|Placebo|
33095972|NCT00487227|Experimental|2.5mg caffeine|
33095973|NCT00487227|Experimental|5mg caffeine|
33095974|NCT00487227|Experimental|10mg caffeine|
33095975|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
33311143|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
33095976|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
33095977|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
33311144|NCT01055561|Experimental|Patients|
33311145|NCT01055561|Experimental|Healthy volunteers|
33311146|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
33095978|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
33095979|NCT05641987|Experimental|Healthy Workplace Participatory Program for Educators|Staff at participating schools will experience the HWPP process and complete pre- and post-intervention survey.
33095980|NCT05641987|Active Comparator|Delayed Intervention|Status quo program remains in place with new ongoing data collection, then experimental intervention as above.
33095981|NCT05641948||Low Back Pain|
33095982|NCT04510233|Experimental|Ivermectin nasal spray|Ivermectin administered as nasal spray (one ml in each nostril two times daily)
33095983|NCT04510233|Experimental|Ivermectin oral|Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
33095984|NCT04510233|Experimental|standard care|COVID-19 cases will receive standard of care [oxygen via masks or ventilators]
33095985|NCT05641909|Experimental|Remifentanil|"Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml)~+ 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 12ug/ kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
33095986|NCT05641909|Active Comparator|Fentanyl|"Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score~≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 2ug/kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
33311147|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
33311148|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
33311149|NCT03367286||Computed Tomography Perfusion (CTP)|
33311150|NCT03367286||Magnetic Resonance Perfusion (MRP)|
33311151|NCT03942926|Experimental|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
33311152|NCT03942848|Experimental|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
33311153|NCT03942848|Placebo Comparator|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
33311154|NCT05527678||5 years ICU survivors|Survivors 5 years after ICU and who participated in the Promorea1 study will be contacted to assess their quality of life.
33095987|NCT05641753|Experimental|4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment|"Treatment consists of: Evolocumab (140 mg; 2 injections, one administered at baseline visit and another self-administered 2 weeks later), and; Atorvastatin (up to 80mg dose; 1 tab per day for 30 days, starting at baseline visit post-assessment). Participants with statin intolerance will be provided with a 1-month supply of ezetimibe 10 mg to replace Evolocumab and Atorvastatin.~Additional procedures: Blood draws.~Optional procedures: Glycocalyx testing, PET/CT, or Endothelial Cell Collection."
33311155|NCT03946826|Experimental|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
33311156|NCT03946826|Experimental|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
33311157|NCT03946826|Active Comparator|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
33318628|NCT00033540|Experimental|Capecitabine + Gemcitabine|Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
32899816|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
32899817|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
32899818|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
32899819|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
32899820|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
32899821|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
32899822|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
32899823|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
32899824|NCT01174823|Placebo Comparator|Placebo|
32899825|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
32899826|NCT03011489|No Intervention|control group|This group will not receive any treatment
32899827|NCT03886649|Experimental|Copanlisib + Venetoclax|Phase Ib -> dose escalation with 2 expansion cohorts
32899828|NCT01151813|Active Comparator|Varenicline|Varenicline, oral administration for 1 week
32899829|NCT01151813|Placebo Comparator|Placebo|Placebo, oral administration for 1 week
32899830|NCT01175369|No Intervention|Usual Care|Usual asthma care
32899831|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
32899832|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
32899833|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
32899834|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
32899835|NCT03835949|Experimental|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
32899836|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
32899837|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
32899838|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
32899839|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
32899840|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
32899841|NCT01177709|Experimental|Metformin|
32899842|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
32899843|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
32802573|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
32802574|NCT05600062|Placebo Comparator|Placebo|Placebo tablet to be taken three times a day for three days
32802575|NCT05600062|Experimental|Racecadotril|Racecadotril 100 milligrams (mg) three times a day for three days
32802576|NCT05300776|Experimental|M-ROSE combined with mNGS group|The bronchoalveolar lavage fluid (BALF) of patients undergoes M-ROSE analysis and decide whether the samples are qualified, whether they indicate bacterial infection and identify pathogens, and the qualified samples are sent for mNGS analysis. The individualized anti-infection treatment is comprehensively guided according to the results of M-ROSE, mNGS and clinical examinations.
32802577|NCT05300776|No Intervention|mNGS group|BALF samples were directly sent for mNGS analysis, and anti-infective treatment was guided according to clinical examinations.
32802578|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
33095988|NCT05640700||Controls|Healthy women without HPV in their cervical and vaginal sample
33095989|NCT05640700||Women with HPV|Women with HPV, with or without cervical intraepithelial neoplasia or carcinoma
33311158|NCT03946826|Placebo Comparator|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
33311159|NCT03711136||Frozen elephant trunk surgery|
33311160|NCT03711136||Standart surgery|
33311161|NCT03946280|Other|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
33311162|NCT03946280|Experimental|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
33311163|NCT01311622|Experimental|warfarin|
33311164|NCT01311622|Experimental|warfarin and fostamatinib|
33311165|NCT04553120|Experimental|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
33311166|NCT04553120|Experimental|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
33311167|NCT04553120|Experimental|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
33311168|NCT04553120|Experimental|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
33311169|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
33311170|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
33311171|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
33311172|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
33311173|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
33311174|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
33311175|NCT05334784|Experimental|Impella ECP Device|Subjects receiving the Impella ECP.
33311176|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
33311177|NCT04542824|Experimental|arm 1: epcoritamab|In subjects with DLBCL/FL
33311178|NCT04542824|Experimental|arm 2: epcoritamab + rituximab + lenalidomide|In subjects with relapsed/refractory FL
33311179|NCT04542824|Experimental|arm 3: epcoritamab + rituximab + cyclophosphamide+ doxorubicin+ vincristine + prednisone|In subjects with previously untreated DLBCL
33311180|NCT04542824|Experimental|arm 4: epcoritamab + gemcitabine + oxaliplatin|In subjects with relapsed/refractory DLBCL
33311181|NCT04542824|Experimental|arm 5: epcoritamab maintenance|In subjects with FL in complete response (CR) or in partial response (PR) following first line or second line SOC treatment
33311182|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
33311183|NCT01106768||not disorder cohort|children without attention deficit disorder
33311184|NCT00349973|Experimental|1|Dipyridamole
33311185|NCT00349973|Active Comparator|2|Olanzapine
33311186|NCT01106924|Experimental|Probiotic|daily probiotic consumption
33311187|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
33311188|NCT03989687|Experimental|glass ionomer sealant|glass ionomer sealant
33311189|NCT03989687|Experimental|isolation|isolation type either rubber dam or cotton roll isolation
33311190|NCT03946436|Experimental|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
33311191|NCT03946436|Active Comparator|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
33311192|NCT01053923||MRI Scan|
33311193|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
33095990|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
33311194|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
33311195|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
33311196|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
33311197|NCT01109186||kidney-transplanted patients|
33311198|NCT03943004|Experimental|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
32946512|NCT01792830|Active Comparator|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
32946513|NCT01792830|Active Comparator|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
32946514|NCT01792830|Active Comparator|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
32946515|NCT01792830|Active Comparator|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c <7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
32946516|NCT01792830|Active Comparator|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
32946517|NCT01792830|Active Comparator|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c >9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
32946518|NCT01792518|Experimental|linagliptin 5mg|linagliptin 5 mg once daily
32946519|NCT01792518|Placebo Comparator|placebo|matching placebo for linagliptin dose once daily
32946520|NCT01792284|Experimental|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
33311199|NCT03946514|Experimental|losartan/hydrochlorothiazide group|
33311200|NCT03946514|Active Comparator|amlodipine/hydrochlorothiazide group|
33311201|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
33311202|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
33311203|NCT04502186|Experimental|Raising Our Spirits Together Intervention|
33311204|NCT04502186|Other|Enhanced Control Condition|
33311205|NCT03741140|Other|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
33311206|NCT03741140|Other|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
33311207|NCT03741140|Other|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
33311208|NCT03230318|Experimental|derazantinib|Oral administration
33311209|NCT03946046|Experimental|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
33311210|NCT03946046|Experimental|Ultrasonography targeting|Ultrason-guided method
33311211|NCT04464122||Neuroendocrine toumor group|30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.
33311212|NCT04464122||Control group|Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)
33311213|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
33311214|NCT03944252|Experimental|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
33311215|NCT03944252|Experimental|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
33311216|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
33311217|NCT01107158||Group 2|These patients have uterine dystocia
33311218|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
33311219|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
33311220|NCT03944174||Single Trans-sacral Screw|
32946521|NCT01792284|Experimental|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
32946522|NCT04414566|Experimental|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.
32946523|NCT04414566|Active Comparator|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
32946524|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
32946525|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
32946526|NCT01791894|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32946527|NCT04592016|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
32946528|NCT04592016|Experimental|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
32946529|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
32946530|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
32946531|NCT01836276|Experimental|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
32946532|NCT01836276|Active Comparator|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
32946533|NCT01790568|Experimental|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
32946534|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
32946535|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
32946536|NCT04587024|Other|mHealth intervention|mHealth intervention
32946537|NCT04587024|Placebo Comparator|standard of care|post-transplant standard of care
32946538|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
32946539|NCT01836198|Experimental|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
32946540|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
32946541|NCT01836198|Experimental|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
32946542|NCT01836198|Experimental|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
33311221|NCT03944174||Two Iliosacral Screws|
33095991|NCT05639179|Experimental|Assigned Interventions|Subjects who meet the enrollment conditions will receive intravenous infusion of UCAR-T Cells after lymphodepletion.
33095992|NCT05638516|Experimental|Vira Self-Care|"The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.~The Vira app can be used as a standalone product. After an initial 10-day period, during which the app assesses the relationship between the user's patterns of behavior and their day-to-day variations in mental health and wellbeing using passive mobile sensing, the user is able to access a personalized behavior change goal that is support by in app information and functionality."
33311222|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
33311223|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
33311224|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
33311225|NCT01208948|Placebo Comparator|placebo pill|
33311226|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
33311227|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
33311228|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
33311229|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
33311230|NCT01107314||trauma patient|SBP less than 90mmHg
33311231|NCT01107470||Group A1|Age 18-34y (with short protocol)
33311232|NCT01107470||Group A2|age 35-42y ( with short protocol)
33311233|NCT01107470||Group B1|age 18-34y ( with long protocol)
33311234|NCT01107470||Group B2|age 35-42y ( with long protocol)
33311235|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
33311236|NCT01109264|Experimental|Bendamustine Hydrochloride|
33311237|NCT01109264|Active Comparator|Chlorambucil|
33311238|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
33311239|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
33311240|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
33311241|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
33311242|NCT03943940|Experimental|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
33311243|NCT03943940|Other|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
33311244|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
33311245|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
33311246|NCT01107704|Experimental|Family Support Intervention|
33311247|NCT01107704|No Intervention|Control Group|
33311248|NCT01107782|Experimental|sildenafil|
33311249|NCT01107782|Placebo Comparator|Placebo control|
33311250|NCT05332678|Experimental|SLS-005|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
33311251|NCT05332678|Placebo Comparator|Placebo|"Placebo (sodium chloride injection, 0.9%, USP) will be administered as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose calculation by IV infusion once a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
33311252|NCT05520736|Experimental|Intervention|Prospectively received appointment reminders, motivational interviews and targeted vaccine drives.
33311253|NCT01107860||Group I|
33311254|NCT01107860||Group II|
33318629|NCT00300365|Experimental|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
33318630|NCT00300365|Placebo Comparator|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
33318631|NCT03980015||erythema migrans|patients with erythema migrans
32946543|NCT04590846|Experimental|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
32946544|NCT04590846|Active Comparator|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
32946545|NCT01816074|Experimental|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
32946546|NCT01816074|Experimental|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
32946547|NCT01816074|Experimental|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
32946548|NCT01816074|Experimental|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
32946549|NCT04586166|Experimental|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
32946550|NCT04586166|Experimental|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
32946551|NCT01815918|Placebo Comparator|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
32946552|NCT01815918|Active Comparator|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
32946553|NCT01789476|Experimental|CR845|Peripheral kappa opioid receptor agonist
32946554|NCT01789476|Placebo Comparator|Placebo|Matched placebo
32946555|NCT01789320|Experimental|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
32946556|NCT01815840|Experimental|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
32946557|NCT01815840|Experimental|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
32946558|NCT01774110|Experimental|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
32946559|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
32946560|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects >64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
32946561|NCT01607346|Experimental|ezogabine/retigabine|Open-label
32946562|NCT01787838|Other|health education, audit and feedback|Focused health education for staff and patients.
32946563|NCT01787760|Experimental|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
32946564|NCT01787760|Experimental|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
32946565|NCT01787760|Active Comparator|Spectacle Lenses|Control spectacle lenses worn daily.
32946566|NCT01815138|Experimental|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.~Placebo administered 35 hours after GnRH agonist trigger"
32946567|NCT01815138|Active Comparator|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
32946568|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
32946569|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
32956145|NCT05734040|Experimental|OVX836 480µg + Afluria Quad at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
32946570|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
32946571|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
32946572|NCT01772550|Experimental|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
32946573|NCT01772550|Active Comparator|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
32946574|NCT01772550|Experimental|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
32946575|NCT01787292|Experimental|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
32946576|NCT01787292|Experimental|Aerobic Exercise Intervention|B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
32946577|NCT01787292|Experimental|Self Monitoring Intervention|C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.
32946578|NCT04414644|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
32946579|NCT04414644|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
32946580|NCT01814748|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
32946581|NCT01814748|Placebo Comparator|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
32946582|NCT01814670|Experimental|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
32946583|NCT01814046|Experimental|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
32946584|NCT01814046|Experimental|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
32946585|NCT01813890|Experimental|Tapentadol IR 50 mg|
32946586|NCT01813890|Experimental|Tapentadol IR 75 mg|
32946587|NCT01813890|Placebo Comparator|Placebo|
32946588|NCT01772316|Experimental|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
32946589|NCT01813422|Placebo Comparator|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
32946590|NCT01813422|Experimental|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
32946591|NCT01786668|Experimental|Tofacitinib 2 mg|
32946592|NCT01786668|Experimental|Tofacitinib 5 mg|
32946593|NCT01786668|Experimental|Tofacitinib 10 mg|
32946594|NCT01786668|Placebo Comparator|Placebo|
32946595|NCT01786512|Placebo Comparator|Dose-escalation Cohort 1: Placebo|Participants received placebo tablets twice a day (BID) for 7 days.
32946596|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
32946597|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2|Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
32946598|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2|Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
32946599|NCT01786512|Placebo Comparator|Dose-escalation Cohort 2: Placebo|Participants received placebo tablets twice a day for 7 days.
32946600|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1|Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
32946601|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2|Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
33311255|NCT03944096|Experimental|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.~Drug: Methotrexate (MTX) Weekly methotrexate"
33311256|NCT03944096|Placebo Comparator|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.~Drug: Methotrexate (MTX) Weekly methotrexate"
33311257|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
33311258|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
33311259|NCT01107938|Experimental|10 mg ilaprazole|
33311260|NCT01107938|Experimental|15 mg ilaprazole|
33311261|NCT01107938|Active Comparator|40 mg esomeprazole|
33311262|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
33311263|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
33311264|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
32946602|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2|Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
32946603|NCT01786512|Placebo Comparator|Expansion Phase: Placebo|Participants received placebo tablets twice a day for 20 weeks.
32946604|NCT01786512|Experimental|Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
32946605|NCT01786512|Experimental|Expansion Phase: OM M-F1 PK-based Titration|All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.
32946606|NCT04414254|Experimental|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
33311265|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
33311266|NCT02812706|Experimental|Isatuximab|Isatuximab will be administered intravenously (IV) once every week (QW) for 4 weeks followed by once every other week (Q2W)
33311267|NCT05514028||Cyst Benign|100 patients
32946607|NCT04414254|Experimental|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
32946608|NCT01772160||Herpes Zoster Group|Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
32946609|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
33311268|NCT05514028||Ovarian Cancer|120 patients
32946610|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
32946611|NCT01770912|Placebo Comparator|Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
32946612|NCT01770912|Active Comparator|Triamcinolone acetonide|1 cc of triamcinolone acetonide (20 mg) injected once after the TMJ rinsing procedure.
32946613|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
32946614|NCT01811706|Experimental|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
32946615|NCT01811706|Experimental|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
32946616|NCT01811472|Placebo Comparator|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
32946617|NCT01811472|Experimental|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
33311269|NCT05514028||Borderline Ovarian Cancer|30 patients
33311270|NCT01112384|Experimental|SB939|
33311271|NCT05504590|Experimental|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
33311272|NCT05504590|Active Comparator|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
33311273|NCT04262882|Experimental|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
33311274|NCT04262882|Active Comparator|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
33404613|NCT03778606|Experimental|Potato starch supplementation|Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.
33404614|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
32802579|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
32802580|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
32802581|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
32802582|NCT03289936|Experimental|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
32802583|NCT03350386|Experimental|Single dose|Single administration of FYU-981
32802584|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
32802585|NCT04761016|Active Comparator|Control|Control group participants will receive access to the same I-POP Health resources without CHW navigation until the end of 10-months (delayed CHW navigation). The current usual care model is outlined. Participants will complete study measures at baseline, 6-months, and 10-months timepoints. Upon completion of 10-months measures, these individuals will be assigned a CHW and receive delayed navigation.
32802586|NCT04761016|Experimental|I-POP CHW Intervention|I-POP+CHW participants will be paired with a CHW at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. Participants will receive a multi-level intervention utilizing the current I-POP Health model that includes: 1) Access to health services (including oral health), 2) Access to clinical prevention services, 3) Access to education and facilities to increase physical activity and improved nutrition choices, and 4) Scheduled visits with CHWs for education and navigation. Individuals will complete study measures at baseline, 6-months, and 10-months.
32802587|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
32802588|NCT04279444|Experimental|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
32802589|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
32802590|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
32802591|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
32802592|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
32802593|NCT05345548|Experimental|Cold Pressor test|
32802594|NCT03283462|Active Comparator|Mitopure|
32802595|NCT03283462|Placebo Comparator|Placebo|
32802596|NCT05593588|Experimental|Fisetin Group|Subjects will receive the supplement, Fisetin, for 2 cycles of 2 consecutive days (first on days 0 & 1 and then repeated on days 28 & 29)
32802597|NCT05593588|Placebo Comparator|Placebo Group|Subjects will receive placebo for 2 cycles of 2 consecutive days (first on days 0 & 1 and then repeated on days 28 & 29)
32802598|NCT04400968|Experimental|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
32802599|NCT04400968|Sham Comparator|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
32802600|NCT04400968|Experimental|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
32802601|NCT04400968|Sham Comparator|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
32802602|NCT04400968|No Intervention|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
32802603|NCT05686330|Experimental|Interventional group (Apple watch)|These participants will wear a smartwatch (Apple Watch) for 6 months during 12 hours a day. The smartwatch will alarm the participant if an irregular heart rhythm is detected. When a participant receives an irregular heartbeat notification, they can record an ECG with the smartwatch. The ECG will automatically be sent to the Telecure team for evaluation.
32802604|NCT05686330|No Intervention|Control group|These participants will be following standard care alone. These participants are instructed to notify the investigators when atrial fibrillation is detected or when they have visited the emergency department during these six months. At the end of the study period the investigator will either call the participant, or their treating physician to check for these outcome measures.
32802605|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
33404615|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
33404616|NCT03111706||Intact scar|women with intact scar detected during cesarean section
33404617|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
33311275|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
32802606|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
32802607|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
32802608|NCT05310526|Experimental|Intervention Group|"Distribution of the Brazilian cardioprotective diet manual to primary health care~Training to prescribe the cardioprotective Brazilian diet. the training consists of 5 face-to-face modules lasting 4 hours each, in addition to a virtual module and group exercises.~Audit feedback"
33095993|NCT05638516|Experimental|Vira + Coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
32802609|NCT05310526|No Intervention|Control Group|Distribution of the Brazilian cardioprotective diet manual to primary health care professionals
32802610|NCT05686174|Active Comparator|MBS-217|4 ml MBS-217 twice a day for 16 weeks
32802611|NCT05686174|Placebo Comparator|Placebo|4 ml MBS-217 placebo twice a day for 16 weeks
32802612|NCT05685940|Experimental|Standard of care - risankizumab|Patients will continue to receive risankizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (2x 75mg).
32802613|NCT05567458|Experimental|Luspatercept|
32802614|NCT05567458|Placebo Comparator|Placebo|
32802615|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
33095994|NCT04510077|Experimental|Prevention (SmartQuit)|Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.
33095995|NCT02274389||Bedaquiline Patient Registry (BPR)|
33095996|NCT05637814|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters and a ML CCHD screening algorithm will be assigning a prediction every minute.
33095997|NCT05637619||Dentate Patients|Patients with natural dentition - maxilla and mandible
33095998|NCT05637619||Zirconia|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
33095999|NCT05637619||Hybrid Acrylic|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with acrylic material (hybrid acrylic)
33096000|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
33096001|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
33096002|NCT05633329|Experimental|single ESPB|single injection at level T8
33096003|NCT05633329|Experimental|dual ESB|dual injection at level T7 and T9
33096004|NCT00487422|Active Comparator|1|Prucalopride
33096005|NCT00487422|Active Comparator|2|Prucalopride
33096006|NCT00487422|Placebo Comparator|3|Placebo
33096007|NCT05628181|No Intervention|No educational tool|This arm will collect data on total standardized daily dosage of the medication classes contributing to CNS polyRx from the Electronic Medical Record (EMR).
33096008|NCT05628181|Experimental|Educational nudge intervention|Participants will be mailed the educational tool in the form of a brochure.
33096009|NCT05625529||Cohort 1: High-Risk Population|"Intraductal papillary mucinous neoplasms (IPMNs)~Family member(s) who have at least one first-degree relative (FDR) affected by pancreatic cancer,~Germline mutations in genes known to be associated with cancer, including BRCA1, BRCA2, PALB2, CDKN2A, ATM, TP53, STK11, MLH1, MSH2, MSH6, PMS2, PRSS1, EPCAM.~Personal or family history of pancreatitis~New-onset Diabetes (NOD)"
33096010|NCT05625529||Cohort 2: Clinically-suspicious PDAC or Pathologically-confirmed|"Clinical findings suspicious for early stage PDAC~Biopsy-proven, clinical stage I-IV PDAC"
33096011|NCT05620966||Patients with transient neurological symptoms and CT-negative for stroke|Patients may have transient neurological symptoms at any time point
33096012|NCT05620966||Patients with known stroke confirmed either on imaging or by stroke physician|
33096013|NCT05620966||Patients with no prior history of stroke|
33096014|NCT05620615||Intensive Drug Therapy|Dual antiplatelet therapy (DAPT) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment.
33096015|NCT00506181|Active Comparator|X|receiving probiotics
33096016|NCT00506181|Placebo Comparator|Y|
33096017|NCT00506181|No Intervention|Z|
33096018|NCT00487409|Other|Group A|Standard of Care
33096019|NCT00487409|Other|Group B|Standard of Care
33096020|NCT05620225|Experimental|Axon Therapy + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~Week 1: 3 treatments~Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
33311276|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
33311277|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
33311278|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
33311279|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
32946618|NCT01811472|Experimental|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
32946619|NCT01811238|Experimental|Oxycodone/Naloxone|Single-arm study
33311280|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
33311281|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
33311282|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
33311283|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
32946620|NCT01769508|Experimental|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
32946621|NCT04585308|Experimental|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
33311284|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
32946622|NCT04576260|Experimental|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
32946623|NCT04576260|No Intervention|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
32946624|NCT01810380|Placebo Comparator|Placebo|
32946625|NCT01810380|Experimental|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
32946626|NCT01810380|Other|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
32946627|NCT01769196|Experimental|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
32946628|NCT01769196|Placebo Comparator|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
32946629|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
32946630|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
32946631|NCT01783938|Experimental|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
32946632|NCT01783938|Experimental|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
32946633|NCT01768572|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
32946634|NCT01768572|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
32946635|NCT01768572|Active Comparator|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
32946636|NCT01783548|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
32946637|NCT01783548|Placebo Comparator|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
32946638|NCT01809210|Experimental|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
32946639|NCT01809132|Experimental|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
32946640|NCT01809132|Active Comparator|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
33311285|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
33311286|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
33311287|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
33311288|NCT03710980||Healthy Adult Volunteer|
33404618|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
33311289|NCT04252040|Experimental|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
33311290|NCT05501236|Experimental|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and second sleep study and the Grass S88 (or comparable) muscle stimulator.
33311291|NCT02624414|Other|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
33311292|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
33311293|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
33311294|NCT01585220|Experimental|Neuramis|
32946641|NCT01809132|No Intervention|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
32946642|NCT01808508|Active Comparator|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
32946643|NCT01808508|Placebo Comparator|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
32946644|NCT01808508|No Intervention|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
32946645|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
32946646|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
32946647|NCT01808196|Experimental|Losartan|Participants with eosinophilic esophagitis receive Losartan daily
32946648|NCT01808118|Experimental|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
32946649|NCT01808118|Experimental|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
32946650|NCT01808118|Placebo Comparator|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
32946651|NCT01807650|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
32946652|NCT01807650|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
32946653|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
32946654|NCT01782378|Active Comparator|Real LED Treatment Series|Participants in this group receive a series of 15 real LED treatments with the helmet and intranasal devices: Transcranial NIR, 830nm LED Helmet and two intranasal nose clips (633 nm, and 810 nm, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two NIR 870nm LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. LEDs are FDA-cleared, non-significant risk. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
32946655|NCT01782378|Sham Comparator|Sham LED Treatment Series|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing sham LEDs (no photons were emitted): Transcranial LED Helmet and two intranasal nose clips (sham LEDs, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two sham LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. These participants were offered an optional Second Real Series of identical 15 real LED treatments. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
32946656|NCT01766310|Placebo Comparator|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
32946657|NCT01766310|Experimental|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
32946658|NCT01765920|Experimental|Ergoferon (5 ml 3 times a day)|"Oral use. Dose per administration: 1 dosing spoon (5ml) without food. For best effect, the solution should be held in the mouth before swallowing.~Dosing scheme. One dose every 30 minutes for the first 2 hours, followed by three more doses spaced regularly during the rest of the day. From day 2 to 5: 1 spoon taken 3 times daily."
32946659|NCT01765920|Placebo Comparator|Placebo (5 ml 3 times a day)|Oral use. Placebo using Ergoferon scheme.
32946660|NCT01782222|Experimental|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
33096021|NCT05620225|Sham Comparator|Sham + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~Week 1: 3 treatments~Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
33096022|NCT00623662|Active Comparator|1|Glucose infusion.
33096023|NCT00623662|Placebo Comparator|2|Normal saline infusion.
33096024|NCT05609812|Experimental|Atacicept Dose|Atacicept Dose once weekly subcutaneous (SC) Injection
33096025|NCT05609812|Placebo Comparator|Placebo to match Atacicept|Placebo to match Atacicept once weekly subcutaneous (SC) injection
33096026|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
33096027|NCT04697355|Experimental|Naringenin + Beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
33096028|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
33096029|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
33096030|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
33096031|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
33096032|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
33096033|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
32802616|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
32802617|NCT03343132||Subacute SCI|
32802618|NCT03343132||Chronic SCI|
32802619|NCT03343132||Controls|
32802620|NCT04278820|Experimental|Climbing group|
32802621|NCT04278820|Experimental|Titration group|
32802622|NCT04278820|Experimental|Extension group|
32802623|NCT05305924|Other|Fulvestrant plus Abemaciclib Arm without Fulvestrant Run-In|During Cycle 1, fulvestrant at a dose of 500 mg will be administered intramuscularly (IM) into the buttocks slowly (1-2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15. Abemaciclib at a dose of 150 mg will be given p.o. BID on Days 1-28 of each cycle. After Cycle 1, fulvestrant (500 mg IM) will be administered on Day 1 of each 28-day cycle. Abemaciclib at a dose of 150 mg will be given p.o. BID on Days 1-28 of each cycle.
32802624|NCT05305924|Experimental|Fulvestrant plus Abemaciclib Arm with Fulvestrant Run-In|"A 1-month (28 days) run-in of fulvestrant will precede fulvestrant plus abemaciclib treatment. Fulvestrant at a dose of 500 mg will be administered intramuscularly (IM) into the buttocks slowly (1-2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of the run-in period.~After the fulvestrant run-in, fulvestrant plus abemaciclib will be administered in 28-day cycles until disease progression or unacceptable toxicity. Fulvestrant (500 mg IM) will be administered on Day 1 of each 28-day cycle. Abemaciclib at a dose of 150 mg will be given p.o. BID on Days 1-28 of each cycle"
32802625|NCT05685862||Group 1|All patients eligible to participate in this study.
32802626|NCT05298436||Retrospective Cohort (ICD-10)|All participants with stroke according to WHO ICD-10 definition registered on the SLSR prior to the protocol change in April 2022 will be followed up by interview at 3 months, 1 year, and 5, 10 and 15 years after stroke.
32802627|NCT05298436||Prospective Cohort (ICD-11)|All participants with stroke according to WHO ICD-11 definition registered on the SLSR following the protocol change in April 2022 will be followed up by interview at 3 months and then annually up to 5 years.
32802628|NCT05685784|Experimental|Healthy volunteer|"20 Healthy volunteers required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~15 Non-MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
32802629|NCT05685784|Experimental|People with MS|"20 patients with MS required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~15 MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
32802630|NCT05556148|Experimental|Otrivine Congestion Relief|Participants will be instructed to use the product per label and leaflet instructions: 1 spray in each nostril up to 3 times per day until resolution of symptoms or up to a maximum of 7 days, whichever occurs first.
32802631|NCT05555524|Experimental|Baby oil|"A cool commercial baby oil at a temperature between 10°C and 15°C that composed of Paraffinum Liquidum, Isopropyl Palmitate, Parfumwill be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the baby oil bottle will be stored at the refrigerator."
32802632|NCT05555524|Placebo Comparator|Placebo|"A cool distilled water at a temperature between 10°C and 15°C with added two drops of the baby oil to each 100 cc will be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the distilled water will be put at an identical bottle as the baby oil bottle and stored at the refrigerator."
32802633|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
33311295|NCT01585220|Active Comparator|Restylane®|
32802634|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
33311296|NCT03945344|Experimental|Treatment A|Tiotropium with concomitant charcoal
33311297|NCT03945344|Experimental|Treatment B|Tiotropium without concomitant charcoal.
33311298|NCT05497726|Experimental|Sentinel lymph node detection using intravenous bevacizumab-800CW|
33311299|NCT01108172|Active Comparator|Usual Care|
33311300|NCT01108172|Experimental|Virtual Ward|
33311301|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
33311302|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
33311303|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
33311304|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
33311305|NCT05494840|Experimental|Haptonomy- first experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 6 weeks (with the researcher).
33311306|NCT05494840|Experimental|Haptonomy- second experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 3 weeks (with the researcher).
33311307|NCT05494840|No Intervention|Haptonomy- Control Group|Standard of care Group The control group will not be interfered with.
33311308|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
33311309|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
33311310|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
33311311|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
33311312|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
33311313|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
33311314|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
33311315|NCT02950480|Experimental|Zafirlukast|Zafirlukast
33311316|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
33311317|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
33311318|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
33311319|NCT05494528|Experimental|Ropeginterferon alfa-2b monotherapy|Subjects will be treated with 450 µg of Ropeginterferon alfa-2b every two weeks
33311320|NCT05494528|Active Comparator|Entecavir monotherapy|Subjects will be treated with 0.5 mg of Entecavir monotherapy once per day
33311321|NCT03942380|Other|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
33311322|NCT03942380|Other|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
33311323|NCT03987815|Experimental|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
33311324|NCT04804930||patients with systemic scleroderma|
33311325|NCT04804930||healthy subject|healthy subject without systemic scleroderma or known hair or scalp disease
33311326|NCT03710902|Experimental|Intervention|
33311327|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
33311328|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
33311329|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
33311330|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
33311331|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
33311332|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
33311333|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
33311334|NCT04164290|Active Comparator|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
33311335|NCT04164290|Active Comparator|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
33311336|NCT04164290|Active Comparator|treatment group 3|Jiashen tablet,1.88g, oral, once a day
33311337|NCT04164290|Active Comparator|treatment group 4|Jiashen tablet,2.82g, oral, once a day
33311338|NCT04164290|Active Comparator|treatment group 5|Jiashen tablet,3.76g, oral, once a day
33311339|NCT04164290|Active Comparator|treatment group 6|Jiashen tablet,4.23g, oral, once a day
33311340|NCT04164290|Placebo Comparator|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
33311341|NCT04164290|Placebo Comparator|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
33311342|NCT04164290|Placebo Comparator|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
33311343|NCT04164290|Placebo Comparator|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
33311344|NCT04164290|Placebo Comparator|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
33311345|NCT04164290|Placebo Comparator|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
33311346|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
33311347|NCT03987737|Experimental|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
33311348|NCT03987737|No Intervention|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
33311349|NCT01209572|Experimental|calorimetric chamber|
33311350|NCT01209572|Experimental|Free living conditions|
32946661|NCT01782222|Experimental|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
32946662|NCT01782222|Placebo Comparator|Placebo|Placebo transdermal patches
32946663|NCT01781832|Experimental|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
33311351|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
33311352|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
33311353|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
32946664|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
32946665|NCT04584762|Sham Comparator|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
33311354|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
33311355|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
33311356|NCT03987269|Active Comparator|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
33311357|NCT03987269|Placebo Comparator|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
33311358|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
33311359|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
33311360|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
33311361|NCT01108484|No Intervention|Control|They will keep their usual way of life
33311362|NCT03945266|Experimental|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
33311363|NCT03945266|Active Comparator|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
33311364|NCT01055951|Experimental|Solo MicroPump|
33311365|NCT01056029|Experimental|G-202|
33311366|NCT03987425|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
33311367|NCT03987425|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
33311368|NCT03797144|Experimental|Fenestrated Screw System|
33311369|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
33311370|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
33311371|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
33311372|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
32946666|NCT04584762|Experimental|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
32946667|NCT01806714|Experimental|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
32946668|NCT01806714|Active Comparator|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
32946669|NCT01765764|Experimental|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
32946670|NCT01765764|Experimental|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
33311373|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
32802635|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
32802636|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
32802637|NCT04279132||INHALATION ANESTHESIA|
32802638|NCT05552248||Orthosis group 1|Use of LumbarBelt Soft 300 device during sport practice (for 12 weeks)
32802639|NCT05552248||Control group 1|Control group of the LumbarBelt Soft 300 group - no medical device used during sport practice (for 12 weeks)
32802640|NCT05552248||Orthosis group 2|Use of LumbarBelt Mid 500 device during sport practice (for 12 weeks)
32802641|NCT05552248||Control group 2|Control group of the LumbarBelt Mid 500 group - no medical device used during sport practice (for 12 weeks)
32802644|NCT03275974|Experimental|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
32802645|NCT05548582|Other|Post-operative opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, then will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)~Oxycodone 5mg every 4 hours as needed (total 12 tablets)"
32802646|NCT05548582|Active Comparator|No Opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)"
32802647|NCT04400422|Experimental|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
32802648|NCT05538754|Other|EVO ICL|STAAR EVO implantable collamer lens (ICL) for the correction or reduction of myopia or myopia with astigmatism.
32802649|NCT04278430|Experimental|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
32802650|NCT04278430|Sham Comparator|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
32802651|NCT04278430|Active Comparator|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
32802652|NCT05537974|Other|Open Suction|Endotracheal aspiration will perform after the patient disconnect from mechanical ventilation
32802653|NCT05537974|Other|Closed Suction|Endotracheal aspiration will perform without disconnection from mechanical ventilation
32802654|NCT05259046|Experimental|Intervention|Intervention treatment . Dietary supplementation with Menaquinone-7 (MK-7) tablet (333 µg/day). MK-7 (K2VITAL®DELTA) tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
32802655|NCT05259046|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablets will match the intervention treatment in both taste and appearance. Placebo tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
32802656|NCT05093374|Experimental|Cohort 1 - Quantitative|"Patients will undergo monthly follow-up visits including fluid quantification and will be retreated in case of active disease, which is defined as:~reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity compared to previous visit~new sub-retinal hemorrhage~increase >50% in IRF volume in the central 1 mm compared to month 2~increase > 50 % in SRF volume in the central 1 mm compared to month 2~in case of NO intra- and/or subretinal fluid (=less than 10nl) in visits 2 or 3, retreat if fluid in central 1mm ≥ 10nl~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator."
32802657|NCT05093374|Active Comparator|Cohort 2 - Qualitative|"Patients will undergo monthly follow-up visits. Treatment will be performed in case of active disease, which is defined as:~reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity~new sub-retinal hemorrhage~any fluid~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
32802658|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
32802659|NCT05249374|Active Comparator|Control group|10 g/ bottle (20%, 50 mL)
32802660|NCT05249374|Experimental|test group|10 g/bottle (20%, 50 mL)
32802661|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32802662|NCT05247580||Hospital staff caregivers|Necker - Enfants Malades hospital' nurses, nurses' aides, residents and, doctors of medicine.
32802663|NCT05084638|Experimental|Ofatumumab|Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
32802664|NCT05084638|No Intervention|Healthy Control|Healthy Control arm will be age- and sex-matched subjects (to the ofatumumab treated arm) and will not receive a study treatment.
32802665|NCT04278742|Experimental|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
32802666|NCT04278742|No Intervention|Control group|Traditional directive and didactic style of patient information will be provided
32802667|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
32802668|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
32802669|NCT05242510|Experimental|Patching|
32802670|NCT05242510|Experimental|Prism Adaptation|
32802671|NCT04400032|Experimental|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
33311374|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
33311375|NCT03945110|Experimental|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
33311376|NCT03945110|No Intervention|Arm B|Patients in this Arm will receive usual bladder care only.
33311377|NCT03945110|Experimental|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
33311378|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
33311379|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
33311380|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
33311381|NCT01328132|Active Comparator|Saline|
33311382|NCT01328132|Experimental|25% albumin|
33311383|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
33311384|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
33311385|NCT03942614|Experimental|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
33311386|NCT03942614|No Intervention|Control|usual daily routine and activities of daily living
33311387|NCT01666340|Experimental|high intensity aerobic training|Exercise intervention: High intensity group performing high intensity training where they are required to raise their heart rate several times during the workout and reach perceived exhaustion of 16 on a Borg scale
33311388|NCT01666340|Other|Moderate intensity training|Exercise intervention: Moderate intensity Group of people asked to perform moderate training where they exercise at a given intensity (moderate as per Borg scale) for a certain amount of time
33311389|NCT01112540|Placebo Comparator|Placebo Group|
33311390|NCT01112540|Experimental|Morphine|
33311391|NCT03986801|Experimental|PASS pharmaceutical interview|
33311392|NCT03986801|No Intervention|Usual management out of hospital|
33311393|NCT03400852|Experimental|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
33311394|NCT03400852|Experimental|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
33311395|NCT03400852|Experimental|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
33311396|NCT03986645|Experimental|4DFLOW|Acquire MR 4DFLow data.
33311397|NCT01056419|Active Comparator|Total thyroidectomy|
33311398|NCT01056419|Active Comparator|Anti-thyroid drug|
33311399|NCT04097366|No Intervention|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
33311400|NCT04097366|Active Comparator|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
33311401|NCT04097366|Active Comparator|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
33311402|NCT04097366|Active Comparator|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
33311403|NCT05304832|Experimental|AquaPlyo group|Participants in this group received the AquaPlyo training program
33311404|NCT05304832|Active Comparator|Control group|Participants in this group received the standard exercise program.
33311405|NCT01056497|Experimental|alpha lipoic acid|
33311406|NCT04097054|Experimental|Intervention|Patients in the interventional arm are operated after augmented planning of the procedure. The plan is prepared by the surgeon and made available to the study team a day prior to the procedure and on a screen in the OR during the procedure. The plan includes the current and next operative step, the used equipment and the approximate time used as well as the estimated time of when the procedure will end.
33311407|NCT04097054|No Intervention|Control|In the control cases no particular planning and distribution of operative plan is performed. The standard preparation only includes the distribution of information on the desired positioning of the patient, necessary special equipment and the overall estimated OR time.
33311408|NCT05292508|Experimental|CRP Tests in addition to Usual Standard of Care|For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample. It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes. Interpretation of CRP levels: Only red color line (No blue line): <10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: >80 mg/L. CRP levels of 40 mg/L or above will be considered as increased CRP levels. The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
33311409|NCT05292508|No Intervention|Usual Standard of Care Alone|For the clusters (health posts) in this control arm, Usual Standard of Care Alone will be provided. This usual standard of care is given to patients with febrile illness at health posts. Commonly, this involves taking a brief history and conducting a simple physical examination followed by symptomatic treatment such as paracetamol, cough medication or analgesics such as NSAIDs. Often antimicrobial treatment is also prescribed based on clinical suspicion of bacterial infection.
33311410|NCT01056575|Experimental|OC000459|
33311411|NCT04074590|Experimental|LYS006|Experimental drug
33311412|NCT04074590|Placebo Comparator|Placebo|Placebo comparator
33311413|NCT03986567|Active Comparator|control|Providing with a paper notification card to the STI diagnosed young person
33311414|NCT03986567|Experimental|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
33311415|NCT03986567|Experimental|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
33311416|NCT03398356|Other|group A|metformin dose 3 x 500 mg
33311417|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
33311418|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
33311419|NCT03945578|Active Comparator|Control Group|"This group performed a supervised Pelvic Floor Muscle Training (PFMT) protocol associated with a manual sham therapy (MST) sessions.~The PFMT protocol consisted of 20 sessions of 45-60 minutes each, twice a week, totalizing a five weeks treatment.~The MST protocol was performed once a week, during five weeks lasting approximately 15 minutes."
33311420|NCT03945578|Experimental|Experimental Group|"The experimental group performed the same PFMT protocol as the CG, but associated with a Visceral Manual Therapy (VMT) protocol.~The VMT sessions were held once a week, for five weeks. Each session lasted approximately 20 minutes."
33311421|NCT04051190|Experimental|VLED group|Participants will undergo a 10-week VLED.
33311422|NCT04051190|Experimental|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
33311423|NCT04051190|Experimental|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
33311424|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
33311425|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
33311426|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
33311427|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
33311428|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
32946671|NCT01765764|Placebo Comparator|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
32946672|NCT01806168|Active Comparator|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
33311429|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
33311430|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
33311431|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
33311432|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
33311433|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
33311434|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
33311435|NCT03940976|Experimental|Afatinib|
33311436|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
33311437|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
32946673|NCT01806168|Active Comparator|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
32946674|NCT01806168|Placebo Comparator|Sham rTMS|Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
32946675|NCT01804842|Active Comparator|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
32946676|NCT01804842|Experimental|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
32946677|NCT01804842|Experimental|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
32946678|NCT01781286|Active Comparator|High Protein|Higher Protein Soy-based Snacks
32946679|NCT01781286|Active Comparator|Low Protein|Typical, Low Protein Snacks
32946680|NCT01781286|No Intervention|No Snack|No Snack
32946681|NCT01780974|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
32946682|NCT01780974|Experimental|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
32946683|NCT01780662|Experimental|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
33311438|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
33311439|NCT00130286|Experimental|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
33311440|NCT00130286|Experimental|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
33311441|NCT00130286|Experimental|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
33311442|NCT00130286|Placebo Comparator|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
33311443|NCT03940898|Active Comparator|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
33311444|NCT03940898|Sham Comparator|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
33311445|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
33311446|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
33311447|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
33311448|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
33311449|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
33311450|NCT01211834|Placebo Comparator|Placebo+DMARDs|
33311451|NCT03941990|Experimental|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
33311452|NCT03941990|Placebo Comparator|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
33311453|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
33311454|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
33311455|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
33311456|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.~Docetaxel 60 mg/m^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
33311457|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
33311458|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
33311459|NCT03943862|Experimental|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.~Fidelity to manual is rated in each session by study staff."
33311460|NCT03943862|No Intervention|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
33311461|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
33311462|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
33311463|NCT03943472|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
33311464|NCT03943472|Experimental|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
33311465|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
33311466|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
33311467|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
33311468|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
33311469|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
33311470|NCT01114412||Patients|Patients with overactive bladder syndrome
33311471|NCT01114412||Healthy volunteers|Healthy volunteers
33311472|NCT01056887||Primary Polydip, D. insipidus|
32802672|NCT04400032|Experimental|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
32802673|NCT04400032|Experimental|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
32802674|NCT05262088||newborns|Assessment of the motor repertoire in children aged 0 to 5 months and its relationship with prenatal and perinatal factors and the results of neurological development in the second year of life.
33311473|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
33311474|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
33311475|NCT01056965|Placebo Comparator|Placebo nasal spray|
33311476|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
33311477|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
33311478|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
33311479|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
33311480|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
33311481|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
32802675|NCT05226910|Experimental|tDCS and intensive therapies|Cathodal tDCS and constraint induce movement therapy
33096034|NCT04697277|Active Comparator|Group 1|Group 1 (Prophylactic antibiotic 30 minutes before skin incision): Antibiotic diluted in 10 ml syringe 30 minutes before skin incision and after cord clamping, 0.9% NaCl in 10 ml syringe will be administered intravenously within 15 seconds.
32802676|NCT05226910|Sham Comparator|Sham and intensive therapies|Sham tDCS and constraint induce movement therapy
33311482|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
33311483|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
33311484|NCT01209806|Active Comparator|simethicone|
32802677|NCT05524948|Experimental|Experimental Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the experimental dentifrice (0.454% Stannous Fluoride with 0.3% Zinc Chloride) for 3 weeks.
32802678|NCT05524948|Active Comparator|Reference Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the reference dentifrice (Regular Fluoride Dentifrice) for 3 weeks.
32802679|NCT01839656|Experimental|Nusinersen 6 mg|
32802680|NCT01839656|Experimental|Nusinersen 12 mg|
32802681|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
32802682|NCT03335332|Active Comparator|Moderate intensity exercise|
32802683|NCT05047900|Experimental|Rapid antigen testing kit use once weekly|"Community will use rapid antigen testing kit once weekly every Monday and will be asked to conduct a weekly self-test for 3 weeks.~This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics"
32802684|NCT05047900|Experimental|Rapid antigen testing kit use twice weekly|Community will use rapid antigen testing kit twice weekly every Monday and Thursday and will be asked to conduct a twice-weekly self-test for 3 weeks This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics
32802685|NCT05047900|No Intervention|Control|Did not routinely use Rapid antigen testing kit
32802686|NCT05223868|Experimental|Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and Placebo|Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
32802687|NCT05223868|Experimental|Group 2: JNJ-77242113 Dose 2 QD and Placebo|Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
32802688|NCT05223868|Experimental|Group 3: JNJ-77242113 Dose 3 QD and Placebo|Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
32802689|NCT05223868|Experimental|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and Placebo|Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
32802690|NCT05223868|Experimental|Group 5: JNJ-77242113 Dose 3 BID and Placebo|Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
32802691|NCT05223868|Placebo Comparator|Group 6: Placebo|Participants will receive placebo BID from Week 0 through Week 16.
32802692|NCT01839188|Experimental|PR5I (V1); Pediacel® (V2); PR5I (V3)|[Vaccination 1]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. [Vaccination 2]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. [Vaccination 3]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
33311485|NCT01209806|No Intervention|no simethicone|
33404619|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
33404620|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
33311486|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311487|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311488|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311489|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311490|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311491|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
33311492|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
33311493|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
33311494|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
33311495|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
33311496|NCT03940820|Experimental|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
33311497|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
33311498|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
33311499|NCT03940274|Experimental|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
33311500|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
33311501|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
33311502|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
33311503|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
33311504|NCT03986177|Experimental|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
33311505|NCT03986177|No Intervention|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
33311506|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
33311507|NCT03986255|Experimental|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
33311508|NCT03942146|No Intervention|Control group|No information on smoking cessation
33311509|NCT03942146|Active Comparator|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
33311510|NCT03942146|Active Comparator|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
33404621|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
32946684|NCT01780584|Active Comparator|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
32946685|NCT01780584|Placebo Comparator|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
32946686|NCT01780584|Experimental|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
32946687|NCT01780506|Experimental|E/C/F/TAF (Double-Blind Phase)|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
32946688|NCT01780506|Active Comparator|E/C/F/TDF (Double-Blind Phase)|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
33311511|NCT03942146|Active Comparator|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
33311512|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
33311513|NCT00345605|Experimental|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
33311514|NCT00345605|Experimental|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
33311515|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
33311516|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
33311517|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
33311518|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
33311519|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
33311520|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
32946689|NCT01780506|Experimental|Open-Label Extension Phase|After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
32946690|NCT01779648|Active Comparator|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
32946691|NCT01779648|Active Comparator|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
32946692|NCT01762800|Experimental|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
32946693|NCT01762800|Experimental|tiotropium bromide|Randomised treatment at Visit 2
32946694|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
32946695|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
32946696|NCT01778556|Experimental|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
32946697|NCT01778556|Experimental|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
32946698|NCT04562532|Experimental|Firehawk group|Participants implant Firehawk stent(s)
32946699|NCT04562532|Active Comparator|2nd generation DES|Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)
32946700|NCT04562376|Experimental|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
32946701|NCT04562376|Active Comparator|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
32946702|NCT04562298|Experimental|LCAR-M23 Chimeric Antigen Receptor T cell|
32946703|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
32946704|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
32946705|NCT01778010|Placebo Comparator|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
32946706|NCT01778010|Experimental|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
33311521|NCT03394924|Experimental|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
33311522|NCT03394924|Experimental|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
32802693|NCT05223088|Experimental|Tislelizumab combined with apatinib and oxaliplatin plus S1|Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
33311523|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
33311524|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
32802694|NCT01838876|Experimental|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
32802695|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
32802696|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
33311525|NCT01324973|No Intervention|Control group|Care as usual
32802697|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
32802698|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
32802699|NCT03689296||Users|Person with a long-term mental disorder
32802700|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
32802701|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
32802702|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
32802703|NCT05007418|Experimental|STI-1492|Four dosing cohorts will be evaluated: Cohort 1 (1 × 10^5 donor DAR-T cells/kg); Cohort 2 (5 × 10^5 donor DAR-T cells/kg); Cohort 3 (1 × 10^6 donor DAR-T cells/kg); Cohort 4 (3 × 10^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.
32802704|NCT05509972||Columbus® DD Primary CoCr|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr)
32802705|NCT05509972||Columbus® DD Primary CoCr AS coated|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr) Advanced Surface
32802706|NCT05240170|Experimental|RIRS group|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
32802707|NCT05240170|Experimental|SWL group|The medical records of all patients who underwent SWL at our institution in the past five years will be reviewed. Patients with renal rotation or position anomalies, as defined by NCCT and/or IVU, will be included for possible study participation.
32802709|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
32946707|NCT01778010|Experimental|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
32946708|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
32946709|NCT04414176||Control|Patients with normal angiography are considered as control group.
32946710|NCT04568928|Experimental|OLTP/PE+FES|"3-5 familiarization sessions + 12 training sessions (3 blocks of 4 training sessions; 60-90 min each session, 2-3 sessions per week) of an overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).~The training sessions are divided into 3 blocks. Each block will take place over a period of approximately 2 weeks (2-3 sessions/week) and will consist of 3 training sessions with exoskeleton combined with FES and a fourth session with exoskeleton alone, without FES.~For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. FES timing and duration is already built into the device. For each participant, specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
32946711|NCT01777932||Cohort|
32946712|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
32946713|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
32946714|NCT01777776|Experimental|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
32946715|NCT01777776|Experimental|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
32946716|NCT01777776|Experimental|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
32946717|NCT01777776|Experimental|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
33311526|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be < 20%;~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of >= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
33311527|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
33311528|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
33311529|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
32802710|NCT01611194|Experimental|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
32802711|NCT01611194|Sham Comparator|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
32802712|NCT05003440|Experimental|NNC0385-0434 15 mg|15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
32802713|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 15 mg)|Oral placebo will be administered once-daily over 10 consecutive days
32802714|NCT05003440|Experimental|NNC0385-0434 40 mg|40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
32802715|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 40 mg)|Oral placebo will be administered once-daily over 10 consecutive days
32802716|NCT05003440|Experimental|NNC0385-0434 100 mg|100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
32802717|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 100 mg)|Oral placebo will be administered once-daily over 10 consecutive days
32802718|NCT05181046|Active Comparator|Standard eyedrops of 0.5% timolol maleate|Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.
32802719|NCT05181046|Experimental|Nanodropper-mediated microdrops of 0.5% timolol maleate|Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.
32802720|NCT05505448|Experimental|Cohort 1 Mid IV Dose|Randomized 3:1 for single ascending dose
32802721|NCT05505448|Experimental|Cohort 2 Mid SC Dose|Randomized 3:1 for single ascending dose
32802722|NCT05505448|Experimental|Cohort 3 High IV Dose|Randomized 3:1 for single ascending dose
32802723|NCT05505448|Experimental|Cohort 4 High SC Dose|Randomized 3:1 for single ascending dose
32802724|NCT05505448|Experimental|Cohort 5 Higher IV Dose|Randomized 3:1 for single ascending dose
32802725|NCT05505448|Experimental|Cohort 6 Highest IV Dose|Randomized 3:1 for single ascending dose
32802726|NCT05505448|Experimental|Cohort 7 Low IV Dose|Randomized 3:1 for single ascending dose
32802727|NCT05505448|Experimental|Cohort 8 Low SC Dose|Randomized 3:1 for single ascending dose
32802728|NCT01813058|Placebo Comparator|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
32802729|NCT01813058|Active Comparator|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
32802730|NCT05163262|Experimental|experimental|Addition of a sexuality questionnaire during patient follow-up within 3 months after inclusion, 6 months after and at one year
32802731|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
32802732|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
32802733|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
32802734|NCT04986514||Patients with systemic sclerosis|
32802735|NCT04415060|Experimental|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
32802736|NCT04415060|No Intervention|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
32802737|NCT04415060|No Intervention|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
32802738|NCT04601480|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
32802739|NCT04601480|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
32802740|NCT04601480|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
32802741|NCT04601480|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
33311530|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
33311531|NCT01115036|Experimental|panobinostat|
33311532|NCT01207622|Active Comparator|Atomoxetine|
33311533|NCT01207622|Placebo Comparator|Placebo|
33311534|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
33311535|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
33311536|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
33311537|NCT03942068|Experimental|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
33311538|NCT03989531|Experimental|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
33311539|NCT03989531|Placebo Comparator|Placebo on top of standard of care|100 mL saline as single dose infusion
33311540|NCT01328288||1|long-term follow-up of HIV-infected children
33311541|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
33311542|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
33311543|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
33311544|NCT01311934||HBV-infected|
33311545|NCT01311934||HCV-infected|
33311546|NCT01054469|Placebo Comparator|TAP block with placebo|
33311547|NCT01054469|Active Comparator|TAP block with ropivacaine|
33311548|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
33311549|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
33311550|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
33311551|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
33311552|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
33311553|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
33311554|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
33311555|NCT03940430|Active Comparator|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
33311556|NCT03940430|Active Comparator|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
33311557|NCT03940430|Active Comparator|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
33311558|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
33311559|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
33311560|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
33311561|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
33311562|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
33311563|NCT03940118|Active Comparator|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
33311564|NCT03940118|Experimental|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
33311565|NCT03940118|Experimental|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
33311566|NCT03940118|Experimental|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
33311567|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
33311568|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
33311569|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
33311570|NCT03942458|Experimental|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
33311571|NCT03942458|Active Comparator|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
33311572|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
33311573|NCT01210196||mild affected Fabry patients|
33311574|NCT03989375|Experimental|experiment group|
33311575|NCT03989375|No Intervention|control group|
33311576|NCT03989453|Experimental|Chi Kung group|This group receives physical training based on Chi Kung.
33311577|NCT03989453|No Intervention|Control Group|This group does not receive any treatment.
33404622|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
32802742|NCT05491330|Active Comparator|R reference (first dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
33096035|NCT04697277|Active Comparator|Group 2|Group 2 (prophylactic antibiotic after cord clamping): 30 minutes before the skin incision, 0.9% NaCl in a 10 ml injector and after the cord is clamped, the antibiotic diluted in a 10 ml syringe will be administered intravenously within 15 seconds.
33096036|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
33404623|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
33096037|NCT00506298|Active Comparator|B|bezafibrate + placebo
33096038|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
33096039|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
33096040|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
33096041|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
33096042|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
33096043|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
33096044|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
33096045|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
33096046|NCT01316354|Experimental|White bread|White bread
33096047|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
33096048|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
33096049|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
33096050|NCT01242345|No Intervention|No Intervention|Standard monitoring.
33096051|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
33096052|NCT04511364|Experimental|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
33404624|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
33404625|NCT03775785|Experimental|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
32802743|NCT05491330|Experimental|T test|Test drug (Copaxid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
32802744|NCT05491330|Active Comparator|R reference (second dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
32802745|NCT04601402|Experimental|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
32802746|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Comirnaty|Participants are already fully vaccinated with 3x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
32802747|NCT05160766|Active Comparator|Spikevax-Spikevax-Spikevax|Participants are already fully vaccinated with 3x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
32802748|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Spikevax|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
32899889|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
33096053|NCT00492011|Experimental|Ramelteon 1 mg QD|
33096054|NCT00492011|Experimental|Ramelteon 4 mg QD|
33096055|NCT00492011|Experimental|Ramelteon 8 mg QD|
33096056|NCT00492011|Placebo Comparator|Placebo|
33096057|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
33096058|NCT04518072||Control group|No prostate cancer (50)
33096059|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
33096060|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
33096061|NCT04513353|Experimental|Digital Healthcare System Rehabilitation|
33096062|NCT04513353|Active Comparator|Conventional Rehabilitation|
33096063|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
33096064|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
33096065|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
33096066|NCT00487734|Placebo Comparator|2|
33096067|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
32946718|NCT01777620|Active Comparator|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
33311578|NCT01207778||preterm ESA recipients|infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
33311579|NCT01207778||preterm controls|preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
33311580|NCT01207778||term controls|Term infants with normal delivery
33311581|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
32946719|NCT01777620|Placebo Comparator|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
32946720|NCT01777542|Active Comparator|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
33311582|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
32946721|NCT01777542|Placebo Comparator|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
32946722|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
32946723|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
32946724|NCT01759446|Placebo Comparator|Placebo taken first|Placebo powder snorted with all other arms taken crossover therafter
32946725|NCT01759446|Active Comparator|Generic H/A taken first|Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
32946726|NCT01759446|Active Comparator|Vycavert taken first|Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
32946727|NCT01759446|Active Comparator|Generic H/A plus i taken first|Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
32946728|NCT01759446|Active Comparator|Generic H/A plus p taken first|Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
32946729|NCT01777308|Experimental|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
32946730|NCT01777308|Experimental|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
32946731|NCT04571736|Active Comparator|access to the internet information platform|usual preoperative information and access to the internet information platform
32946732|NCT04571736|No Intervention|usual preoperative information|medical information delivered to the patient before any surgery
32946733|NCT01759368|Active Comparator|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
32946734|NCT01759368|No Intervention|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
32946735|NCT01777152|Active Comparator|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
32946736|NCT01777152|Experimental|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
32946737|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
33311583|NCT03940040|Active Comparator|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
33311584|NCT03940040|Experimental|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
33311585|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
33311586|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
33311587|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
33311588|NCT03989141|Experimental|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
33311589|NCT03989141|Active Comparator|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
33096068|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
33311590|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on with MSM|
33096069|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
32802749|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Comirnaty|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
33096070|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
33096071|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
33096072|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
33096073|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
33096074|NCT00487773|Active Comparator|1|budesonide
33096075|NCT00487773|Active Comparator|2|D3 vitamin
33096076|NCT00487773|Active Comparator|3|montelukast sodium
33096077|NCT00487773|Active Comparator|4|salbutamol
33096078|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
33096079|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
33096080|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
33096081|NCT00487682|Experimental|1|ASP2151 low dose
33096082|NCT00487682|Experimental|2|ASP2151 middle dose
33096083|NCT00487682|Experimental|3|ASP2151 high dose
33096084|NCT00487682|Active Comparator|4|Valacyclovir hydrochloride
33096085|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
33096086|NCT00487851|Active Comparator|2|Surgical treatment strategy
33096087|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
33311591|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on without MSM|
32802750|NCT05160766|Active Comparator|Spikevax-Spikevax-Comirnaty|Participants are already fully vaccinated with 2x Spikevax (mRNA-1273) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
32802751|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Spikevax|Participants are already fully vaccinated with 2x Comirnaty (BNT162b2) and 1x Spikevax (mRNA-1273) entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
32802752|NCT05157490|Experimental|Mindfulness training|Completion of guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
32802753|NCT05157490|No Intervention|Control|
32802754|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 10 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 10 mg/kg for up to 52 weeks.
32802755|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 20 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
32802756|NCT05156320|Placebo Comparator|Main Efficacy Population (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
33096088|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
33096089|NCT04512261|Experimental|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
33096090|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
33096091|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
33096092|NCT04519515|Experimental|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
33096093|NCT04519515|Experimental|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
33096094|NCT04517565|Experimental|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
33096095|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
33096096|NCT05149248|Other|Group 1: MSM|Arm 1: HPV vaccination in an alternative schedule for MSM of 1 dose (M0). Arm 2: HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6) Arm 3: a control group will be screened for high-risk HPV and vaccinated at 12 months
33311592|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment with MSM|
32946738|NCT01758900|Active Comparator|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
32946739|NCT01758900|Experimental|CO2 insufflation regulator|Device: CO2 insufflation regulator
33311593|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment without MSM|
33311594|NCT03939884|Active Comparator|Voltaren Emulgel|
33311595|NCT03939884|Placebo Comparator|Non-medicinal Placebo|
33311596|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
32946740|NCT01757184|Experimental|Double-blind Sebelipase Alfa|Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
32946741|NCT01757184|Placebo Comparator|Double-blind Placebo|Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
32946742|NCT01757184|Experimental|Open-label Sebelipase Alfa/Sebelipase Alfa|Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
32946743|NCT01757184|Experimental|Open-label Placebo/Sebelipase Alfa|Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
32946744|NCT01775904|Experimental|LY2886721 Capsule (water, fasting)|Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
32946745|NCT01775904|Experimental|LY2886721 ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
32946746|NCT01775904|Experimental|LY2886721 ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
32946747|NCT01775904|Experimental|LY2886721 ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
32946748|NCT01775670|Experimental|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
32946749|NCT01775670|Active Comparator|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
32946750|NCT01775124|Experimental|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
32946751|NCT01775124|Experimental|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
32946752|NCT01733316|Experimental|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
32946753|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
32946754|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
32946755|NCT01755858|Experimental|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
32946756|NCT01755858|Placebo Comparator|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
32946757|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
32946758|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
32946759|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
32946760|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
32946761|NCT01774968|Experimental|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
32946762|NCT01774968|Experimental|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
32946763|NCT01774344|Experimental|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
32946764|NCT01774344|Placebo Comparator|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
32946765|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
32946766|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
32946767|NCT01755702|Placebo Comparator|Arm 1|Placebo
32946768|NCT01755702|Active Comparator|Arm 2|paracetamol marketed forumulation
32946769|NCT01755702|Active Comparator|Arm 3|ibuprofen marketed formulation
32946770|NCT01755702|Experimental|Arm 4|experimental paracetamol + caffeine formulation
32946771|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
32946772|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
33311597|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
33311598|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
33311599|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
33311600|NCT03986411|Other|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
32946773|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
33311601|NCT01115894|Experimental|active medication + psychotherapy|
33311602|NCT01115894|Experimental|placebo + psychotherapy|
33311603|NCT01115894|Experimental|active medication+brief supportive counseling|
33311604|NCT01115894|Experimental|placebo + brief supportive counseling|
33311605|NCT03986489|Experimental|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
33311606|NCT03986489|Active Comparator|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.
33311607|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
33311608|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
33311609|NCT02533271|Experimental|TNT group|The intervention of TNT group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
33311610|NCT02533271|Other|CRT group|The intervention of CRT group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
33311611|NCT01116050|Placebo Comparator|Placebo|
32946774|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
33311612|NCT01116050|Experimental|MISOPROSTOL|
32946775|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
32946776|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
32946777|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
32946778|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
32946779|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
32946780|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
32946781|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
32946782|NCT01755546|Experimental|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
32946783|NCT04413864|Other|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
32946784|NCT04560504|Placebo Comparator|Control Group|Receive 10 sessions of 45-minute (3 sessions per week) in-office leisure activities e.g. simple non-action computer games or board games (e.g. card and chess games) and 10-20 minutes of video watching at home
32946785|NCT04560504|Active Comparator|Intervention Group|Receive 10 sessions of 45-minute office training (3 sessions per week) and 10-20 minute home training (3 sessions per week) of eye movement training
32946786|NCT01755234|Active Comparator|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
32946787|NCT01755234|Active Comparator|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
32946788|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
33096097|NCT05149248|Other|Group 2: TRANSGENDER WOMEN|Arm 1: Transgender women
33311613|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
33096098|NCT05149248|Other|GROUP 3: WOMEN AND MEN LIVING ON THE STREET|Arm 1: Women and men living on the street
33096099|NCT05149248|Other|GROUP 4: WOMEN AND MEN WHO HAVE SUFFERED RAPE|Women and men who have suffered rape
33096100|NCT05149248|Other|GROUP 5: WOMEN WHO ARE SEX WORKERS|Female sex workers
33096101|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
33096102|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
33096103|NCT04518033|Experimental|Face covering use|Participants will be provided various commercially available face coverings
33096104|NCT05149209|Experimental|Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).|ACTIVA Presto is a novel bioactive material with a mineral-enriched hydrophilic resin base and a patented rubberized component that resists abrasion and wear with high release and recharge of not only fluoride but also calcium and phosphate ions. It doesn't contain BIS-GMA, Bisphenol A, or BPA derivatives.
33096105|NCT05149209|Active Comparator|Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).|Giomer is a hybrid restorative material that contains a resin base and pre-reacted glass ionomer. S-PRG (surface reaction type) technology provides some properties of GI such as fluoride release and recharge which helps prevent recurrent caries.
32802757|NCT05156320|Experimental|Exploratory Subpopulation (Apitegromab)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
33096106|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
33096107|NCT05149170|Experimental|Inductive and concurrent anti-PD-1 antibody combined with radiotherapy|All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
33096108|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
33096109|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
33096110|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
33096111|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
33096112|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
33096113|NCT05149092|Placebo Comparator|Placebo (casein protein supplement)|
33096114|NCT05149092|Active Comparator|Chicken protein hydrolysate supplement|
33096115|NCT00492440|Experimental|CYT107 (r-hIL-7)|
33096116|NCT04518501|Experimental|study group|Fuzuloparib Capsules plus table Arsenic Trioxide po
33096117|NCT00495248|Experimental|1|
33096118|NCT00495248|Active Comparator|2|
33096119|NCT05149053|Experimental|Food Supplement|Food supplement packet taken one per day preferably in the morning for 6 months.
33096120|NCT05149053|Placebo Comparator|Control|Placebo packet taken one per day preferably in the morning for 6 months.
33096121|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
33096122|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
33096123|NCT04696185|Active Comparator|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
32802758|NCT05156320|Placebo Comparator|Exploratory Subpopulation (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
32802759|NCT01811732|Experimental|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
32802760|NCT01811732|Active Comparator|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
33096124|NCT04696185|No Intervention|Standard care|No SGLT-2 inhibitor therapy with dapagliflozin
33096125|NCT00495326|Experimental|1|Nevirapine-based ART
33096126|NCT00495326|Active Comparator|2|Efavirenz-based ART
33096127|NCT04515927|Experimental|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
33096128|NCT05148936|Experimental|At home testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker.
33096129|NCT05148936|Active Comparator|Mobile testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing.
33096130|NCT05148936|Other|Mobile testing approach 1 (Aim 2)|Mobile testing utilizing active outreach
33096131|NCT05148936|Other|Mobile testing approach 2 (Aim 2)|Mobile testing utilizing baseline outreach approaches
33404626|NCT03775785|No Intervention|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
33404627|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Telephone call"
33096132|NCT00495404|Other|Arm 1|
32946789|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
33096133|NCT00495404|Other|Arm 2|
33096134|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
33096135|NCT00495482||1|Patients receiving palliative care due to incurable illness
33096136|NCT00506805|Experimental|Single Arm|
32946790|NCT01731600|Experimental|N8-GP|
32946791|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
32946792|NCT04413942|Active Comparator|FB825|FB825
32946793|NCT04413942|Placebo Comparator|Placebo|Formulation buffer
32946794|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
32946795|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
32946796|NCT01755156|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
32946797|NCT01755156|Placebo Comparator|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
32946798|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
32946799|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
32946800|NCT01754766|Experimental|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
32946801|NCT01754766|Experimental|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
32946802|NCT01754766|Placebo Comparator|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
32946803|NCT01754376|Experimental|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
32946804|NCT01605396|Experimental|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
32946805|NCT01605396|Active Comparator|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
32946806|NCT04559802|Experimental|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
32946807|NCT04559802|Active Comparator|Submerged|Flaps will be advanced to achieve primary wound closure.
32946808|NCT01730118|Experimental|1/Part I dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at escalating doses
32946809|NCT01730118|Experimental|2/Part I dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at a next lower dose or the highest dose
32946810|NCT01730118|Experimental|3/Part 1 dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
32946811|NCT01730118|Experimental|4/Part II dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
32946812|NCT01730118|Experimental|5/Part II dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Arm 1 maximum tolerated dose (MTD)
32946813|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
32946814|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
33096137|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
33096138|NCT04510506|Experimental|Randomized substudy: Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
33096139|NCT04510506|No Intervention|Randomized substudy: Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
33096140|NCT04510506|No Intervention|Triple Label Surveillance substudy (observational arm)|Participants will remain on own baseline diabetes management (e.g. automated insulin delivery system, non-AID pump, MDI)
33096141|NCT04515693|Experimental|Maximal Assist group|Subjects with acute stroke who ambulate with Maximal assistance of 1.
33096142|NCT04515693|Experimental|Moderate Assist group|Subjects with acute stroke who ambulate with Moderate assistance of 1.
33096143|NCT04515693|Experimental|Minimal Assist group|Subjects with acute stroke who ambulate with Minimal assistance of 1.
33096144|NCT04515693|Experimental|Supervision/Modified Independence/Independence|Subjects who walk without physical assistance of a helper.
33096145|NCT00495833|No Intervention|1|
33096146|NCT00495833|Experimental|2|photo and blood pressure personalization
33096147|NCT00495833|Experimental|3|photo personalization only
33096148|NCT00495833|Experimental|4|blood pressure personalization only
33096149|NCT00495833|Experimental|5|no personalization
32946815|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
33096150|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
33096151|NCT00495833|Experimental|B|does not receive gift card in BP kit
33096152|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
33096153|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
33096154|NCT00492635|Experimental|Arm 1|
33096155|NCT00492635|Experimental|Arm 2|
33096156|NCT00492635|Placebo Comparator|Arm 3|
33096157|NCT04510311|Experimental|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
33311614|NCT03939650|Experimental|Diaana|"The patient fulfill Diaana~The resident physician reads the Diaana summary~The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
33311615|NCT03939650|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
33311616|NCT03941522|Experimental|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
33311617|NCT03941522|No Intervention|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
33311618|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
33096158|NCT04510311|Active Comparator|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
33096159|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
33096160|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
33096161|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
33096162|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
33096163|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
33096164|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
32946816|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
33096165|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
33096166|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
33096167|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
33096168|NCT00492713|Active Comparator|1|Dark chocolate
33096169|NCT00492713|Active Comparator|2|Milk chocolate 1
33096170|NCT00492713|Active Comparator|3|Milk chocolate 2
33096171|NCT00507117|Active Comparator|PSG|
33096172|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
33096173|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
33096174|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
33096175|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
33096176|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
33096177|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
33096178|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
32946817|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
33311619|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
33311620|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
33311621|NCT03941678|Experimental|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
33311622|NCT03941678|Placebo Comparator|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
33311623|NCT03941756|Experimental|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
32946818|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
32946819|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
32946820|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
32946821|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
32946822|NCT01753518|Active Comparator|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
32946823|NCT01753518|Active Comparator|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
32946824|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
32946825|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
32946826|NCT01729728|Experimental|Tapentadol|
32946827|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
32946828|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
32946829|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
32946830|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
32946831|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
32946832|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
32946833|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
32946834|NCT01752036|Other|Treatment|Post-Operative Stereotactic Radiosurgery
32946835|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
32946836|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
32946837|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
32946838|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
32946839|NCT01728246|Active Comparator|Non-Tramadol/APAP|
32946840|NCT04414020|No Intervention|Control|Control group receiving conventional treatment without progesterone
33311624|NCT03941756|No Intervention|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
33311625|NCT05282290|Experimental|Experimental group|"Lower systolic blood pressure to 90-110 mm Hg.~Blood pressure not lower than 90/60 mm Hg~Hypotensive maintenance treatment for 48 hours."
33311626|NCT05282290|Active Comparator|The control group|"Subjects with basic blood pressure(BBP) > 140/90 mm Hg should have BBP lowered to about 140/90 mm Hg.~Subjects whose BBP was less than 140/90mm Hg were kept BBP."
33404628|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
33404629|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
33096179|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
33096180|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
33096181|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
33096182|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
33096183|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
33096184|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
33096185|NCT04324450|Experimental|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
33096186|NCT04324450|Experimental|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
33096187|NCT04324450|Experimental|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
33096188|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
33096189|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
33096190|NCT02890225|Other|3|Patients in 3 days
33096191|NCT02890225|Other|10|Patients in10ys
33096192|NCT02890225|Experimental|30|Patients in10ys
33096193|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
33096194|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
33096195|NCT00492986|Experimental|Arm 1|
33404630|NCT05296239|Experimental|SimpleC Wellness Platform with Social Robot Interaction|
32802761|NCT05146648|Active Comparator|Real AMPS|AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.
32802762|NCT05146648|Sham Comparator|Sham AMPS|AMPS therapy applied to two non-specific points on both feet.
32802763|NCT04591574|Other|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
32802764|NCT04591574|Active Comparator|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
32802765|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
32802766|NCT03327064|Active Comparator|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
33096196|NCT04324528|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
33096197|NCT04324528|Other|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
33096198|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
33096199|NCT05608018|Other|Control|Participants receive a the same app as the intervention group, but the feature that notifies the teens parent when they are driving is turned off. They will self-report their smartphone communication while driving via periodic surveys.
33096200|NCT05608018|Experimental|Intervention|Participant received the app with all features turned on, so the parent gets a notification when the teen is driving before they go to send a text message to the teen. They will self-report their smartphone communication while driving via periodic surveys.
33096201|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
33096202|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
33096203|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
33096204|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
33096205|NCT04324138|Experimental|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
33096206|NCT04324138|Sham Comparator|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
33096207|NCT00493337|No Intervention|Control group|
33096208|NCT00493337|Experimental|Advanced counseling|
33096209|NCT00493337|Active Comparator|Compliance Card only|
33096210|NCT01243814|Active Comparator|supartz|active intervention arm
33096211|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
33096212|NCT01243853|Active Comparator|Alpha-galactosidase|
33096213|NCT01243853|Placebo Comparator|Placebo|
33096214|NCT01298518|Experimental|PF-04620110|
33096215|NCT01298518|Placebo Comparator|placebo|
33096216|NCT01243970|Active Comparator|phenylephrine infusion|
33096217|NCT01243970|Active Comparator|Ephedrine infusion|
33096218|NCT04515576|Experimental|LY3493269|LY3493269 administered Subcutaneous (SC).
33096219|NCT04515576|Active Comparator|Dulaglutide|Dulaglutide administered SC.
33096220|NCT04515576|Placebo Comparator|Placebo|Placebo administered SC.
33096221|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
33311627|NCT05277766|Experimental|Nal-IRI (Onivyde) - 30mg/m²|PIPAC with Onivyde (30 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
33311628|NCT05277766|Experimental|Nal-IRI (Onivyde) - 45mg/m²|PIPAC with Onivyde (45 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
33311629|NCT05277766|Experimental|Nal-IRI (Onivyde) - 60mg/m²|PIPAC with Onivyde (60 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
33096222|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
33096223|NCT00493415|Experimental|1|nitroglycerine iv
33096224|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
33096225|NCT05148741||Group 1|implanted with the C-loop haptic intraocular lens
33096226|NCT05148741||Group 2|implanted with the plate haptic intraocular lens
33311630|NCT05277766|Experimental|Nal-IRI (Onivyde) - 75mg/m²|PIPAC with Onivyde (75 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
33311631|NCT05277766|Experimental|Nal-IRI (Onivyde) - 90mg/m²|PIPAC with Onivyde (90 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
33311632|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
33311633|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
33311634|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
33096227|NCT01244009|Experimental|MK-4827|All Participants
33096228|NCT04511832|Experimental|Acupuncture to NSAIDs|
33096229|NCT04511832|Experimental|NSAIDs to Acupuncture|
33311635|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
33311636|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
33311637|NCT05270980|Experimental|Intervention Group (Cohorting)|
33311638|NCT05270980|No Intervention|Control Group (No Cohorting)|
33404631|NCT03111082||Lean|BMI less than or equal to 29.9
33404632|NCT03111082||Obese|BMI between 30.0 and 39.9
33404633|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
33096230|NCT04511832|Experimental|Combined both acupuncture and NSAIDs|
33096231|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
33404634|NCT05256459||Observation group|Those who did not deal with nodules and were closely followed up.
33404635|NCT05256459||Treatment group|Patients with liver nodules were treated by radiofrequency ablation or/and surgery and so on.
33096232|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
33096233|NCT00495950||Questionnaire|
33096234|NCT05148273||intervention|After the selection process with 1 to 1 randomization method, a personal information form and Beck anxiety scale will be applied to the women selected for the case group on the day of the initiation of treatment with assisted reproductive techniques interview. Then, within an average of 10 days, there is a treatment procedure including planned drug use, messages containing drug doses, drug use, drug administration, follicle count, reminder of the times of operations such as OPU, IUI, ET, and motivational issues. Medication use, time, date, dose, application form and motivational sentences will be sent every day through the WhatsApp application. The Beck anxiety scale will be repeated on the day of IUI and ET procedures, and the effect of telehealth practices on the anxiety levels of women undergoing infertility treatment will be evaluated. During the study, the participants will be able to reach the researcher from their mobile phones whenever they want.
33096235|NCT05148273||control|In the first interview at the beginning of the treatment protocol with assisted reproductive techniques, a personal information questionnaire and beck anxiety scale will be applied to the control group selected by the 1-to-1 randomization method. Afterwards, the Beck anxiety scale will be applied again at the end of the treatment without any intervention.
33096236|NCT01244204|Experimental|Vitamin D|
33096237|NCT01244204|Placebo Comparator|Placebo|
33096238|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
33096239|NCT00496028|Experimental|2|AZD0530 + Carboplatin
33096240|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
32802767|NCT03327064|Placebo Comparator|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
32802768|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
32802769|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
32802770|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
32802771|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
32802772|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
32802773|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
32802774|NCT05142358|Active Comparator|left-sided breast cancer|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
32802775|NCT05142358|Active Comparator|Lung SBRT|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
32802776|NCT05139004|Experimental|Treatment (90Y-basiliximab, fludarabine, melphalan, TMLI)|Patients receive cold basiliximab IV, 111In-DOTA-anti-CD25 basiliximab IV, and 90Y-DOTA-anti-CD25 basiliximab IV on day -15. Patients also receive palifermin IV on days -11 to -9, fludarabine phosphate IV on days -4 to -2, melphalan IV on day -2, and undergo TMLI on days -8 to -5 in the absence of disease progression or unacceptable toxicity. Patients then undergo AHSCT on day 0.
32802777|NCT04073992|Experimental|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
32802778|NCT01811186|Other|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
32802779|NCT01811186|Other|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
32802780|NCT04630756|Experimental|Module 1: Part A and Part B|"Participants will receive intravenous ascending doses of AZD4573 once weekly with oral acalabrutinib twice daily continuously in Part A. For Part A, cohorts 1, 2, and 3 have different target dose levels respectively.~In Part B, participants will receive the RP2D of AZD4573 from Part A."
32802781|NCT04630756|Experimental|Module 2: Part A and Part B|"Participants will receive AZD4573 as monotherapy for Period 1 and AZD4573 + acalabrutinib as combination therapy for Period 2.~Part B of Module 2 will be determined from the data emerging from Part A."
32802782|NCT04414436|Experimental|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
32802783|NCT04414436|No Intervention|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
32802784|NCT04590872|Experimental|Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)|After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
32802785|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
32802786|NCT04746196||45 ankylosing spondylitis patients.|Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
32802787|NCT04746196||35 controls|Healthy controls
32802788|NCT04399408|Experimental|Study group|Device users
32802789|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
32802790|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
32802791|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
32802792|NCT04926922||HONOR TB participants with positive IGRA and/or TST during initial phase|Adult participants who who tested positive on IGRA and or TST during initial phase and meet the study-specific eligibility criteria.
32802793|NCT04916704||CMV seropositive|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive.
32946841|NCT04414020|Active Comparator|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
32946842|NCT04559022|Other|Fat Grafting for Acne Scar Treatment|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
32946843|NCT01705236|Experimental|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
32946844|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
32946845|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
33404636|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
32946846|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
32946847|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
32946848|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
32946849|NCT01751802|Experimental|Ecopipam|Active substance being tested, orally once a day at bedtime
32946850|NCT01751802|Placebo Comparator|Placebo|Inactive substance being tested, orally once a day at bedtime
32946851|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
32946852|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
32946853|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
32946854|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
32946855|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
32946856|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
32946857|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
32946858|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
32946859|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
32946860|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
32946861|NCT04550832|Active Comparator|Arm1(D0)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will not administered~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
32946862|NCT04550832|Experimental|Arm2(D400)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 400 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
32946863|NCT04550832|Experimental|Arm3(D800-OD)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 800 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
32946864|NCT04550832|Experimental|Arm4(D1200)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 1200 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
32946865|NCT04550832|Experimental|Arm5(D800-BD)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 800 mg orally twice daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
32946866|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
32946867|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
32946868|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
32946869|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
32946870|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
32946871|NCT04166448||Group 1: High risk IUGR patients|EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
32946872|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
32946873|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
32802794|NCT04916704||CMV seronegative|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive. CMV IgG negative.
32946874|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
32946875|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
32946876|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
32946877|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
32946878|NCT01727154||Sipuleucel-T|
32946879|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
32802795|NCT04399798|Experimental|Baricitinib active treatment|Baricitinib 4 mg/day
32946880|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
32802796|NCT04897360|Experimental|Normocapnic SRT, Hypocapnic SRT, Recovery SRT|Sharpened Romberg Test
32802797|NCT04889326||patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination|
32802798|NCT04885972|Experimental|Resiniferatoxin|7.5 mcg, 10 mcg, 12.5 mcg, 15 mcg, or 20 mcg in 5 mL injected once intra-articularly
32802799|NCT04885972|Active Comparator|Zilretta|32 mg in 5 mL injected once intra-articularly
32802800|NCT04885972|Placebo Comparator|Placebo|5 mL injected once intra-articularly
32802801|NCT04884568|Experimental|Exufiber|This is an open, non-randomised , single arm study
32802802|NCT04039750|Experimental|Antibiotic irrigation with suction|Group A: You will receive antibiotic irrigation with suction if a PA is found during surgery
32802803|NCT04039750|Active Comparator|suction only|Group B: You will receive suction alone if a PA is found during surgery
32802804|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
32802805|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
32802806|NCT04606030|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
32802807|NCT04606030|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
32802808|NCT03238300|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg capsules by mouth, two pills twice daily for 10 days.
32802809|NCT03238300|Placebo Comparator|Placebo Oral Capsule|Placebo capsules by mouth, two pills twice daily for 10 days.
32802810|NCT03236428|Experimental|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
32899890|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
32899891|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
32946881|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
32946882|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
32946883|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
32946884|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
32946885|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946886|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946887|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946888|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946889|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946890|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
32946891|NCT04557930|No Intervention|Usual Care Control|The control arm occurred prior to receipt of the video game intervention. Each hospital group 'crossed over' from control to intervention at a randomized time point based on their assignment to the 'step' of the trial.
32946892|NCT04557930|Experimental|Video Game Intervention|Each hospital group 'crossed over' from control to intervention at a randomized time point. Physicians working at these hospitals, who agreed to participate in the trial, received a study iPad and were asked to play the video game loaded on the iPad for a minimum of 2 hours.
32946893|NCT01751724|Experimental|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
32946894|NCT01751724|Placebo Comparator|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
32946895|NCT01751646|Experimental|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
33311639|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
33311640|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.~From August 2020 - no placebo capsule will be administered."
33311641|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
33311642|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
33311643|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
33311644|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
33311645|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
33311646|NCT00354029|Active Comparator|S (+) Ketamine|
33311647|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
32946896|NCT01751646|Placebo Comparator|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
32946897|NCT01751568|Experimental|Cohort 1: ≥ 2 to < 6 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
32946898|NCT01751568|Experimental|Cohort 2: ≥ 6 to < 12 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
32946899|NCT01751568|Experimental|Cohort 3: : ≥ 4 weeks to < 2 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets (as a dispersible tablet), starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
32946900|NCT01751412|Experimental|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
32946901|NCT04556682||Patients who underwent Rotational atherectomy (RA)|The device contains rapidly rotating burr that is coated with microscopic diamond chips, which debulks the calcified plaque by grinding the calcified atheroma into small particles facilitating stent passage and expansion. Both transfemoral or transradial approach can be used. Regular PCI guidewire can be used to cross the often complex anatomy then switching to a rotablation dedicated guidewire over a microcatheter. Burr sizes vary from 1.25mm up to 1.75mm (in certain cases bigger calibers may also be used) aiming to achieve plaque modification .
32946902|NCT04556682||Patients who underwent Intravascular lithotripsy (IVL)|The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable. These emitters create sonic pressure waves that selectively fracture calcium and alter vessel compliance facilitating stent passage and expansion. It is available in 2.5- to 4.0-mm diameters and 12 mm in length, with an inflation pressure of 4 atm used for delivering the treatment. Every catheter can emit a maximum of 80 pulses at a rate of one pulse per second. The IVL balloon catheter is chosen based on the reference lumen of the vessel and after pre-dilatation of the lesion (preferably with a non-compliant balloon) 10-30 pulses are given, usually with interval deflation to allow distal perfusion. If the lesion exceeds the 12 mm balloon length, the balloon can be repositioned and the IVL repeated .
32946903|NCT01751178|Active Comparator|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
32946904|NCT01751178|Active Comparator|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
32946905|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
32946906|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
32946907|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
32946908|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
32946909|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
32946910|NCT01723254|Experimental|PF-06444753|
32946911|NCT01723254|Experimental|PF-06444752|
32946912|NCT01723254|Placebo Comparator|Placebo|Intramuscular
33404637|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
33096241|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
33404638|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
33096242|NCT00496067|Experimental|1|DUAO Device
33096243|NCT04516278|Experimental|Biological: bevacizumab|ONS-5010
32946913|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
32946914|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
32946915|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
32946916|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
32946917|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32946918|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32946919|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32946920|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
32946921|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
32946922|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
32946923|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
32946924|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
32946925|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
32946926|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
32946927|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
32946928|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
32946929|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
33311648|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
33311649|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
33311650|NCT03988751|Active Comparator|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
33311651|NCT03988751|Active Comparator|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
33311652|NCT01054937|Experimental|4SC-203|
32946930|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
32946931|NCT04565886|Sham Comparator|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
32946932|NCT04565886|Experimental|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
33311653|NCT01054937|Placebo Comparator|Placebo|
33311654|NCT03986099|No Intervention|Standard of care|SOC viral load
33311655|NCT03986099|Active Comparator|Near point of care|POC viral load
33311656|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
33311657|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
33311658|NCT03796676|Placebo Comparator|Placebo|Placebo
33311659|NCT03796676|Experimental|PF-04965842 100 mg QD|active
32946933|NCT04548804|Experimental|Control|Control subjects receiving body-surface potential mapping (BSPM) and CT-scan.
33311660|NCT03796676|Experimental|PF-04965842 200 mg QD|active
33311661|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
33311662|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
33311663|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
32946934|NCT04548804|Experimental|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and CT-scan. Outcome measures from these procedures will be compared to controls.
32946935|NCT01748994|Placebo Comparator|Placebo|Administration of placebo to upper- and lower-body obese women
32946936|NCT01748994|Active Comparator|Drug|Administration of pioglitazone to upper- and lower-body obese women
32946937|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
32946938|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
32946939|NCT01748760|Experimental|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
32946940|NCT01748760|Active Comparator|Treatment as Usual|Adolescent participants and parents will not receive study intervention
32946941|NCT01748292|Active Comparator|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
32946942|NCT01748292|Experimental|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
32946943|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
32946944|NCT01746732|Experimental|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods. Treatment A
32946945|NCT01746732|Experimental|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods. Treatment B
32946946|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
32946947|NCT01720524|Experimental|sildenafil|Active study drug
32946948|NCT01720446|Experimental|Semaglutide 0.5 mg|
32946949|NCT01720446|Experimental|Semaglutide 1.0 mg|
32946950|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
32946951|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
32946952|NCT01698918|Experimental|Everolimus+letrozole/exemestane (first line and second line treatment)|Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)
33311664|NCT03988673|No Intervention|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
33311665|NCT03988673|Active Comparator|decision aid with implicit VCM|decision aid with information plus an implicit VCM
33311666|NCT03988673|Active Comparator|decision aid with explicit VCM|decision aid with information plus an explicit VCM
33311667|NCT03988517|Active Comparator|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
33311668|NCT03988517|Active Comparator|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
33311669|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
32946953|NCT01746108|Experimental|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
32946954|NCT01746108|Experimental|At-risk-Primed Group|"Subjects who have been previously vaccinated~with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.~with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.~and are at an increased risk of pneumococcal infection."
32946955|NCT01746108|Active Comparator|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
32946956|NCT01746108|Active Comparator|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
32946957|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946958|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946959|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946960|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946961|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946962|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946963|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946964|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946965|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946966|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946967|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946968|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
32946969|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
32946970|NCT01745094|Experimental|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
32946971|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
32946972|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
33311670|NCT00339833|Placebo Comparator|Placebo|Placebo
33311671|NCT05444608|No Intervention|Control Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the control group. Babies in the control group will not be allowed to smell breast milk or listen to white noise.The newborn in the control group will continue to receive routine care.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
33404639|NCT05173857|Active Comparator|Drug Eluting Balloon (DEB)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Drug Eluting Balloon Technology.~Drug: Paclitaxel (PTX). Name of Device: Advance PTX"
32946973|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946974|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946975|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
32946976|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946977|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946978|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
32946979|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
32946980|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
32946981|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946982|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
32946983|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946984|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
32946985|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946986|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
32946987|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946988|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
32946989|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
32946990|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
32946991|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946992|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
32946993|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
32946994|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
32946995|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
33311672|NCT05444608|Experimental|Breast Milk Odor Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the breast milk odor group.Before the intervention, 3 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
33311673|NCT05444608|Experimental|White Noise Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the white noise listening group.Before the intervention , a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
33311674|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
32946996|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
32946997|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
33311675|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
33404640|NCT05173857|Placebo Comparator|Plain Old Balloon Angioplasty (POBA)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Plain Old Balloon Angioplasty.~Drug: None. Name of Device: Advance LP (Low Profile)"
33404641|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
32946998|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
32946999|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
32947000|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
32947001|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
32947002|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
32947003|NCT01744782|Experimental|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
32947004|NCT01744392|Experimental|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
32947005|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
32947006|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
32947007|NCT01742286|Experimental|LDK378|All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.
32947008|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
32947009|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
32947010|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
32947011|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
32947012|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
33311676|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
33311677|NCT01311856||Standard Arm (mail/telephone)|
33311678|NCT01311856||Internet Arm|
33311679|NCT01058291|Experimental|KW-6500|
33311680|NCT01058291|Placebo Comparator|KW-6500 Placebo|
33404642|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
33096244|NCT04516200|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.
33096245|NCT04516200|Placebo Comparator|traditional physical therapy program|traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months
32802811|NCT04034992||Retrospective CKD cohort|Retrospective (secondary) data refers to patient data extracted from existing electronic health records (EHRs)/registries/databases. It represents existing real-world data, regardless of reason for collection or location of storage and is analogous to those represented in the study protocol for which feasibility assessments are conducted. Retrospective data will be collected from registries, databases, and EHRs. The aim is to identify and extract clinical data retrospectively from a minimum of 100000 (no set maximum) CKD patients via existing databases/registries/EHRs across geographies. The retrospective data will be captured beginning 1 January 2008 through the most currently available data.
32802812|NCT04034992||Prospective CKD cohort|Prospective (primary and secondary) data refers to manual collection/extraction of data in a de novo manner for the purpose of addressing study objectives. Collection/extraction of patient data in the prospective cohort will be done via electronic case report form, questionnaires, and mobile phone/tablet application. The initial aim is to identify and collect/extract data from approximately 1000 (no set maximum) enrolled CKD patients until the decision to stop the study is taken, with the possibility of prospective follow-up for a minimum of approximately 1 year up to a maximum of approximately 3 years. The patient specific data in the prospective cohort will be collected by utilizing Rapid Assessment of Physical Activity (RAPA) questionnaire, Work Productivity and Activity Impairment (WPAI) questionnaire, Short Form (SF)-36 questionnaires, simple food diary, and other patient reported outcomes - including a set of questions to collect patient symptoms.
32802813|NCT03985540|Experimental|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
32802814|NCT03985540|Placebo Comparator|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
32802815|NCT03985540|Experimental|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
32802816|NCT03985540|Placebo Comparator|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
32802817|NCT04347772|Experimental|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
33096246|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
33096247|NCT01297465|Experimental|Pergoveris®|
33096248|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
33096249|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
33096250|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
33096251|NCT04511286|Experimental|Internet-delivered exposure-based treatment|Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.
33096252|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
33096253|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
33096254|NCT02276586|Experimental|Group 2|Vertical tooth preparation
32802818|NCT04347772|No Intervention|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
32802819|NCT04863352||Study group|Men who have been treated for localized or locally advanced prostate cancer with curative intent
32802820|NCT04863352||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019
32802821|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
32802822|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
32802823|NCT04858360|Experimental|Study group|
32899892|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
33096255|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
33311681|NCT03711682|Experimental|Cinnamon (Intervented)|
32802824|NCT04852822||Observational (biospecimen collection, medical record review)|"For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.~For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose."
32802825|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
32802826|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
32802827|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
33096256|NCT00496145|No Intervention|control|usual-care control group
32802828|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
32802829|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
32802830|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
32802831|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
33311682|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
33311683|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
32802832|NCT04832932||80 years of age or older|Individuals 80-89, 90-99, 100 years of age and older who received COVID-19 vaccine
32802833|NCT04832932||60-79 years of age|Individuals 60-69 and 70-79 years of age who received COVID-19 vaccine
32802834|NCT04832932||40-59 years of age|Individuals in 40-49, 50-59 age range who received COVID-19 vaccine
32802835|NCT04832932||18-39 years of age|Individuals in 18-29, 30-39 age range who received COVID-19 vaccine
32802836|NCT04832932||MEBO/PATM|Individuals with present or past MEBO/PATM symptoms who received COVID-19 vaccine
32802837|NCT04832932||Chronic Disease|Individuals with self-reported chronic health conditions who received COVID-19 vaccine
32802838|NCT04830592|Experimental|Part A|NG-641 monotherapy
32802839|NCT04830592|Experimental|Part B|NG-641 and pembrolizumab
32802840|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
32802841|NCT02984332|Experimental|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
32802842|NCT03943498|Experimental|Treatment (Fingolimod)|"Patients receive 0.5 mg dose of Fingolimod PO QD for 4 weeks.~Take your Fingolimod approximately every 24 hours"
33311684|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
33311685|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
33311686|NCT05438134|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training upon enrollment.
32802843|NCT05185024|Experimental|Ferrous Sulfate Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
32802844|NCT05185024|Experimental|>Your< Iron Forte Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
32802845|NCT05185024|Experimental|>Your< Iron Forte Liquid|35 mg of elemental iron, 0.7 mg vitamin B6 and 1.25 mcg vitamin B12 per one dosing (5 ml).
32802846|NCT01803464|Experimental|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
33311687|NCT05438134|Active Comparator|Waitlist Control Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training after the final survey time point.
33311688|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
32802847|NCT01803464|Experimental|Botox|Cerebral palsy and Botox
32802848|NCT01803464|No Intervention|Cerebral palsy control|Cerebral palsy without treatment
32802849|NCT01803464|No Intervention|Typically developing control|Typically developing
32802850|NCT03935932|Experimental|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
32802851|NCT03935932|Experimental|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
32802852|NCT04591210|No Intervention|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
33311689|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.~The sperm used in this group is considered to be enriched in non apoptotic cells."
33311690|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
33311691|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
33096257|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
33096258|NCT04518462|Experimental|EXPAREL arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
33096259|NCT04518462|Experimental|EXPAREL admix arm|subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
33096260|NCT04518462|Active Comparator|Bupivacaine HCl Arm|subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
33096261|NCT00493610|Other|1|
33096262|NCT05146908||Patients in intensive care|Ventilated intubated patients for whom enteral nutrition is planned
33096263|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
33096264|NCT04519632||Parents|Qualitative interviews
33096265|NCT04519632||Healthcare Professionals|Qualitative interviews
33096266|NCT04519632||Children|Children and young people aged 6-18 years, Qualitative interviews
33096267|NCT00496223|Experimental|1|
33096268|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
33096269|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
33096270|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
33311692|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
32802853|NCT04591210|Experimental|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
32802854|NCT04591210|Experimental|ARB treatment|The physician will initiate any ARB and dose at their discretion.
32802855|NCT01808690|Experimental|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
32802856|NCT01808690|Placebo Comparator|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
32802857|NCT03927820||Patients Using Inhalers|Adult patient admitted to Vanderbilt University Medical Center (excluding surgery services) on a long acting inhaler or prescribed a long acting inhaler during admission.
32802858|NCT04583618|Experimental|SP0202-IIb|One dose at Day 1
32802859|NCT04583618|Experimental|SP0202-VI|One dose at Day 1
32802860|NCT04583618|Experimental|SP0202-VII|One dose at Day 1
32802861|NCT04583618|Active Comparator|Prevnar 13|One dose at Day 1
32802862|NCT04583618|Active Comparator|Pneumovax 23|One dose at Day 1
32802863|NCT04591054|Active Comparator|Extended Vision IOL|Vivity
33096271|NCT02597985|Active Comparator|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
33096272|NCT02597985|Placebo Comparator|Usual care|Will receive usual care
33096273|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
33096274|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
33096275|NCT05141838|Experimental|Group 1 - Vitamin D|Patients receiving vitamin D supplements in therapy
33096276|NCT05141838|Experimental|Group 2 - Oral nutritional supplement|Patients receiving oral nutritional supplement
33096277|NCT05141838|Experimental|Group 3 - Vitamin D+Oral nutritional supplement|Patients receiving vitamin D supplements and oral nutritional supplement in therapy
33096278|NCT05141838|No Intervention|Group 4 - No intervention|Patients with dystrophic form of congenital epidermolysis bullosa who have not taken vitamin D supplements and/or oral nutritional supplement
33096279|NCT00493727|Other|1|
33096280|NCT05143788|Experimental|New surgical plan group|The investigators use monopolar stimulators to determine and retain the tumor margin within 5mm from the posterior limb of the inner capsule in type III motor area glioma patients.
33096281|NCT05143788|Active Comparator|Traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified by stimulator, the positive points are retained in order to preserve the motor function while all the non-positive points of the tumor are resected.
33096282|NCT00493766|Experimental|oral LBH589 alone|
33311693|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
33311694|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
33311695|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
33311696|NCT04782466|Experimental|Intervention|The participant receives the intervention immediately following baseline measurements.
33311697|NCT04782466|Other|Waitlist attention-control|The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
33311698|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
33096283|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
33096284|NCT05140005|Other|15 subjects testing themselves|15 subjects will use the Glow Test Kit to test themselves for Covid 19.
33096285|NCT05140005|Other|15 subjects testing someone else|15 subjects will use the Glow Test Kit to test someone else (a child) for Covid 19.
33096286|NCT00496457|Experimental|1|TRO19622
33096287|NCT00496457|Placebo Comparator|2|
33096288|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
33096289|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
33096290|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
33096291|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
33096292|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
33096293|NCT05146479||Fluoride varnish (FA group)|Application of 5% NaF varnish onto first permanent molars
33096294|NCT05146479||Fluoride varnish + dental sealant (FA+S group)|Application of 5% NaF varnish plus pit and fissure sealant onto first permanent molars
33096295|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
33096296|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
33096297|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
33311699|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
33311700|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
33096298|NCT01297270|Placebo Comparator|Placebo|
33096299|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
33096300|NCT05145621|Active Comparator|Test|Fingolimod 0.5 mg capsules - (administered as 3 x Fingolimod 0.5 mg capsules)
33311701|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
33311702|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
33096301|NCT05145621|Active Comparator|Reference|Fingolimod 0.5 mg capsules -(administered as 3 x Fingolimod 0.5 mg capsules)
33311703|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
33311704|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
33311705|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
33311706|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
32802864|NCT04591054|Active Comparator|Neutral Aspheric Monofocal IOL|enVista [MX60E]
33096302|NCT00493883|Other|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver~--------------------------------------------------------------------------------"
33096303|NCT01296568|Experimental|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 ([^14C]LY2603618).~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:~Gemcitabine 1000 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR~Pemetrexed 500 mg/m^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
33311707|NCT03828617|Active Comparator|13vPnC|13vPnC
33311708|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
33311709|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
33311710|NCT03391960|Other|Disinfecting barrier cap|"In the participating wards, disinfecting barrier cap was used on every needless connector used for accessing CVC IV lines.~Compliance with disinfecting barrier cap was observed weekly."
33311711|NCT01210430|Active Comparator|Losartan|
33311712|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
33311713|NCT01210430|Placebo Comparator|Normal Saline|
33311714|NCT05489146|Active Comparator|tRNS and FES facilitated task practice|In this arm, participants received real transcranial random noise stimulation with FES facilitated task practice
33311715|NCT05489146|Sham Comparator|sham tRNS and FES facilitated task practice|In this arm, participants received sham transcranial random noise stimulation with FES facilitated task practice
33311716|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
33311717|NCT01210586|Placebo Comparator|Placebo Patch|
33311718|NCT01210742|Experimental|Viscosupplementation with routine management|
33311719|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
33096304|NCT05140668|Active Comparator|Supraclavicular central venous catheterization approach group|supraclavicular central venous catheterization group catheter is inserted in supraclavicular fossa (an indentation immediately above the clavicle) with a long-axis in plane approach
33096305|NCT05140668|Active Comparator|Infraclavicular central venous catheterization approach group|infraclavicular central venous catheterization group catheter is inserted in infraclavicular fossa (an indentation, immediately below the clavicle, above the third rib and between the deltoid muscle laterally and medioclavicular line medially) with a short-axis out-of-plane approach
33096306|NCT00496574|Active Comparator|1|
33096307|NCT00496574|No Intervention|2|no intevention
32947013|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
32947014|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
33096308|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
33096309|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
33096310|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
33311720|NCT01113320|Placebo Comparator|Placebo|
33311721|NCT01113320|Active Comparator|Safinamide|
33311722|NCT05244304|Experimental|Tinlarebant|5 mg tablet taken orally once a day
33096311|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
33096312|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
33311723|NCT05244304|Placebo Comparator|Placebo|Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
33311724|NCT01210898|Experimental|Group 1|
33311725|NCT01210898|Experimental|Group 2|
33096313|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
33096314|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
33096315|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
33096316|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
33096317|NCT05605561|Experimental|Intervention Group (Digital Story)|The web-based digital story preparation process will be completed as a 3-5 minute short film by using pictures, videos, voiceovers and various video editing techniques by the researcher trained in storytelling. The digital story will be prepared in an appropriate format, taking into account the cognitive development and period characteristics of school children (7-12 years old).
33096318|NCT05605561|No Intervention|Standard Maintenance Group|It is the standard of care given according to the hospital's policies and procedures.
33096319|NCT05146128|Experimental|Analytic group|The participants had to perform analytic exercices for shoulder rotators and scapular stabilizing muscles
33096320|NCT05146128|Experimental|Functional group|The participants had to perform functional exercices for shoulder rotators and scapular stabilizing muscles
33096321|NCT05146128|Experimental|Mixed group|The participants had to perform both analytic and functional exercices for shoulder rotators and scapular stabilizing muscles
33311726|NCT01210898|Experimental|Group 3|
32947015|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
33096322|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
33096323|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
33096324|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
33311727|NCT01210898|Experimental|Group 4|
33311728|NCT01210898|Experimental|Group 5|
33311729|NCT01210898|Experimental|Group 6|
33311730|NCT01210898|Experimental|Group 7|
33311731|NCT01210898|Experimental|Group 8|
33311732|NCT01210898|Experimental|Group 9|
33311733|NCT01210898|Experimental|Group 10|
33311734|NCT01210898|Experimental|Group 11|
33311735|NCT01210898|Experimental|Group 12|
33311736|NCT01210898|Experimental|Group 13|
33311737|NCT01116128|Experimental|D-MP|
33311738|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
33311739|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
33311740|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
33311741|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
33096325|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
33096326|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
33096327|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
33096328|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
33096329|NCT05148429||Fetuses with abnormal positionning of mesenteric vessels|All pregnant women with abnormal positionning of mesenteric vessels during second trimester scan
33096330|NCT00496691|Experimental|1|Parent-child
33096331|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
33096332|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
33096333|NCT05145972|Active Comparator|• Group P|Ultrasound guided SHPN will be done by injecting 10 ml of Phenol 10 %.
33096334|NCT05145972|Active Comparator|• Group LP|Ultrasound guided SHPN will be done by injecting 10 ml Phenol 10 % then injecting 3 ml Lidocaine 10%.
33096335|NCT00496847|Experimental|Drug Group|PERIOGEN
33096336|NCT00496847|Active Comparator|Control group|Beta TCP alone
33096337|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
33311742|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
33096338|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
33096339|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
33096340|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
33096341|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
33096342|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
33311743|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
33311744|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
32802865|NCT04588870|Experimental|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
32802866|NCT04413734|Experimental|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
33096343|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
33096344|NCT05147883|Experimental|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks.
33096345|NCT05147883|No Intervention|Control|No intervention will be applied to the patients
33096346|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
33096347|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
33096348|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
33096349|NCT00494312|Experimental|Pioglitazone QD|
33096350|NCT00494312|Active Comparator|Glyburide QD|
33096351|NCT05145348||Down syndrome, adults|Adults and adolescents with Down syndrome >16 years old.
33096352|NCT05145348||Healthy control, adults|Healthy adults and adolescents without Down syndrome > 16 years old. Without any significant comorbidities.
33311745|NCT01210976|Experimental|levosimendan|
33311746|NCT01210976|Placebo Comparator|placebo|
33311747|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
33311748|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
33311749|NCT01109888|Active Comparator|Cetrotide|
33311750|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
33096353|NCT05145348||Down syndrome, children|Children with Down syndrome < 16 years old.
33311751|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
33311752|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
33311753|NCT01212692|Experimental|Mentally stimulating activities|
32947016|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
32947017|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
33311754|NCT01212692|Active Comparator|Mentally stimulating activities- other|
33311755|NCT01058447|Experimental|1|
33311756|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
33311757|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
33311758|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
32947018|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
33311759|NCT03708406||Children with Cleft palate|Children with Cleft palate
32947019|NCT04555512|Active Comparator|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
32947020|NCT04555512|Experimental|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
32947021|NCT04555278|Experimental|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
32947022|NCT04555278|Sham Comparator|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
32947023|NCT04555278|Experimental|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
32947024|NCT04555278|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
32947025|NCT04554420|Experimental|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
32947026|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
32947027|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
32947028|NCT01739790|Placebo Comparator|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
32947029|NCT01739790|Active Comparator|N-Acetylcysteine|1800 mg twice daily for 8 weeks
32947030|NCT04547868|Experimental|Coffee|Caffeinated coffee beverage
32947031|NCT04547868|Active Comparator|Decaffeinated coffee|Decaffeinated coffee beverage
32947032|NCT04547868|Placebo Comparator|Warm water|Warm water beverage
32947033|NCT01696032|Experimental|SGI-110 + Carboplatin|Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
32947034|NCT01696032|Experimental|SGI-110 + Carboplatin or TC|Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
32947035|NCT01695954|Experimental|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
32947036|NCT01695954|Experimental|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
32947037|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
32947038|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
32947039|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
32947040|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
32947041|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
32947042|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
32947043|NCT01693614|Experimental|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
32947044|NCT01693614|Experimental|MCL Cohort|Mantle cell lymphoma cohort
32947045|NCT01693614|Experimental|FL Cohort|Follicular lymphoma cohort
33096354|NCT05145348||Healthy control, children|Healthy children without Down syndrome < 16 years old. Without any significant comorbidities.
33096355|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
33311760|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
33311761|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
33311762|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
33311763|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
33311764|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
33311765|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
33311766|NCT01211132|Active Comparator|Cap arm|
33311767|NCT01211132|Active Comparator|Standard arm|
33311768|NCT02949934|Placebo Comparator|Placebo/rs4680 val/val|"Placebo three times per day for eight days~Individuals with the rs4680 val/val genotype"
33311769|NCT02949934|Active Comparator|Tolcapone/rs4680 val/val|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/val genotype"
33311770|NCT02949934|Placebo Comparator|Placebo/rs4680 val/met|"Placebo three times per day for eight days~Individuals with the rs4680 val/met genotype"
33311771|NCT02949934|Active Comparator|Tolcapone/rs4680 val/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/met genotype"
33311772|NCT02949934|Placebo Comparator|Placebo/rs4680 met/met|"Placebo three times per day for eight days~Individuals with the rs4680 met/met genotype"
33311773|NCT02949934|Active Comparator|Tolcapone/rs4680 met/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 met/met genotype"
33311774|NCT01055483|Experimental|LBH589|
33311775|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
33311776|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
33096356|NCT05142969|No Intervention|Control arm|Patients were daily bathed with soap and water only.
33096357|NCT05142969|Experimental|Intervention arm|Patients were daily bathed with soap and water and then receive 2% Chlorhexidine bathing (Petel Skin care wipes, Likang LtD, shanghai, China).
33096358|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
33096359|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
33096360|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
33096361|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
33311777|NCT03987971|Experimental|Deep acupuncture on GB26|
33311778|NCT03987971|Sham Comparator|Superficial acupuncture on GB26|
33311779|NCT03987971|No Intervention|waiting list|
33096362|NCT01244867|Placebo Comparator|Placebo|
33096363|NCT05141604|Experimental|Field expansion view|Various configurations of field expansion views will be additionally displayed on HMD
33096364|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
33096365|NCT02597790||Group A (HIV/HCV coinfected)|
33096366|NCT02597790||Group B (HIV monoinfected)|
33096367|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
33096368|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
33096369|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
33096370|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
33096371|NCT05147103|Experimental|Duration Trials|Six different durations (three intermittent and three continuous) of LIFU application will be tested across six study sessions. Response recorded using TMS and EMG.
33096372|NCT02276352|Experimental|Meloxicam low dose - one tablet|
33096373|NCT02276352|Experimental|Meloxicam high dose - two tablets|
33096374|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
33096375|NCT05149326|Experimental|Experimental arm|
33096376|NCT05149326|Placebo Comparator|Control arm|
33096377|NCT00497237|Experimental|1|Foster
33096378|NCT00497237|Active Comparator|2|Seretide
33096379|NCT05144061|Experimental|Single Arm|HRS2398 Tablets
33096380|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
33311780|NCT01116518|Active Comparator|physiotherapy|
33311781|NCT01116518|Active Comparator|acromioplasty|
33311782|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
33311783|NCT00338741||1|Rebif exposed pregnancies
33311784|NCT00338741||2|Non-Rebif exposed pregnancies
33311785|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
33311786|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
33096381|NCT05146440|Experimental|PM14 in monotherapy and in combination with radiotherapy in STS and other solid tumors|"Cohort A : Phase I. PM14 24-h IV 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort B: Phase I. PM14 3-h IV infusion 3 d 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort E: PM14 at RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort F: PM14 at the RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort C: Phase I: PM14 at the RP2D, 21-d cycles in combination with radiotherapy, up to PD or toxicity. Dexamethasone recommended. Radiation therapy 3Gy/f 10 d. Phase II: PM14 at RP2D with radiation therapy.~Cohort D: Phase I: PM14 at the RP2D, 3 x 21-d cycles in neoadjuvant setting, in combination with radiotherapy. Dexamethasone recommended. Radiation therapy 1.8Gy/f 25 d. Phase II: PM14 at RP2D with radiation therapy."
33096382|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
33096383|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
33096384|NCT05144178||Mild and moderated COVID -19 patient treated out side the hospital sitting|Reviewing files of such group that had been received Sotrovimab
33096385|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
33096386|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
33311787|NCT03985865|Experimental|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
33311788|NCT03985865|Experimental|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
33311789|NCT03985865|Placebo Comparator|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
33311790|NCT03985865|Experimental|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
33311791|NCT03985865|Experimental|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
33311792|NCT03985865|Placebo Comparator|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
33311793|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
33311794|NCT00351611|Experimental|Active|Active drug
33311795|NCT00351611|Placebo Comparator|Placebo|placebo comparator
33311796|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
33311797|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
33311798|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
33311799|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
33311800|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
33311801|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
33311802|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
33311803|NCT01058603|Active Comparator|D3|
33311804|NCT01058603|Experimental|D5|
33311805|NCT01116830|Placebo Comparator|Placebo|
33311806|NCT01116830|Experimental|RO4917838|
33311807|NCT03789110|Experimental|Nivolumab+Ipilimumab|"Ipilimumab is administered intravenously every 6 weeks~Nivolumab is administered intravenously every 2 weeks"
33311808|NCT00351533|Experimental|1|Enteral fish oil
33311809|NCT00351533|Placebo Comparator|2|Enteral saline
33311810|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
33311811|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
33311812|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
33311813|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
33311814|NCT03939494|Experimental|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
33311815|NCT03939494|No Intervention|Standard of Care Control|This arm will participate in their normal clinic/program routine.
33311816|NCT03939572|Active Comparator|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will simply display their accurate step count."
33311817|NCT03939572|Experimental|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display a deflated step count."
32802867|NCT04413734|Active Comparator|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
33096387|NCT05142072|Experimental|vitamin D film|Prepared intranasal films containing vitamin D3 by the investigators and administered to the right nostril with the aid of an ENT surgeon
33096388|NCT05142072|Other|control group|No devices will be added
33096389|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
33096390|NCT05140785|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional MRI sequences and biopsies in addition to the standard of care.
33096391|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
33096392|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
33096393|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
33096394|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
32802868|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
32802869|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
33096395|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
33096396|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
33311818|NCT03939572|Experimental|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display an inflated step count."
32802870|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
32802871|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
32802872|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
32802873|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
32802874|NCT04808908|Experimental|N-803|All participants will receive the intervention, N-803 treatment.
33096397|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
33096398|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
33096399|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
33096400|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
33096401|NCT05147766|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33096402|NCT05146674|Active Comparator|Tadalafil group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
33311819|NCT03939572|Experimental|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
33311820|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
33311821|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
33311822|NCT01110356|Experimental|Ferinject|
33311823|NCT01110356|Placebo Comparator|Saline|
33311824|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
33311825|NCT03941366|Other|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
32947046|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
32947047|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
32947048|NCT01713582|Experimental|AL 10 mg QD 14-21|Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
32947049|NCT01713582|Experimental|AL 20 mg QD 14-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947050|NCT01713582|Experimental|AL 40 mg QD 14-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947051|NCT01713582|Experimental|AL 20 mg BID 21-21|Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
32947052|NCT01713582|Experimental|AL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947053|NCT01713582|Experimental|AL 40 mg BID 14-21|Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
32947054|NCT01713582|Experimental|AL 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947055|NCT01713582|Experimental|AL 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947056|NCT01713582|Experimental|AL 160 mg QD 14-21|Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947057|NCT01713582|Experimental|AML de novo 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947058|NCT01713582|Experimental|AML/MDS 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947059|NCT01713582|Experimental|OHM 10 mg QD 21-21|Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947060|NCT01713582|Experimental|OHM 20 mg QD 21-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947061|NCT01713582|Experimental|OHM 40 mg QD 21-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947062|NCT01713582|Experimental|OHM 80 mg QD 21-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947063|NCT01713582|Experimental|OHM 40 mg BID 21-21|Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
32947064|NCT01713582|Experimental|OHM 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
32947065|NCT01713582|Experimental|OHM 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947066|NCT01713582|Experimental|OHM 120 mg QD 5-7|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
32947067|NCT01713582|Experimental|OHM 120 mg QD 7-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
32947068|NCT01713582|Experimental|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
32947069|NCT01739400|Experimental|Macitentan|Macitentan 10 mg tablet, once daily.
32947070|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
32947071|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
32947072|NCT01737996|Experimental|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
32947073|NCT01713036|Experimental|Pimasertib|
32947074|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
32947075|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
32947076|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
32947077|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
32947078|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
32947079|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
32947080|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
32947081|NCT01693068|Experimental|Pimasertib|
32947082|NCT01693068|Active Comparator|Dacarbazine|
32947083|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
33096403|NCT05146674|No Intervention|Control group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
33096404|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
32802875|NCT03927742|Experimental|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
32802876|NCT03927742|Active Comparator|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
32802877|NCT04808518||Bx reg group|
32802878|NCT04808518||non-Bx reg group|
32802879|NCT04805944||DTG treated (A)|80 HIV-infected adults treated with dolutegravir (as a component of their usual provider-prescribed antiretroviral regimen)
32802880|NCT04805944||BIC treated (B)|30 HIV-infected adults treated with bictegravir (as a component of their usual provider-prescribed antiretroviral regimen)
32802881|NCT04805944||DTG discontinued due to neuropsychiatric adverse event (C)|50 HIV-infected adults having stopped dolutegravir due to neuropsychiatric adverse effects (insomnia, depression, anxiety)
32802882|NCT04805944||Shifting to DTG (D)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing dolutegravir
32802883|NCT04805944||Shifting to BIC (E)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing bictegravir
32802884|NCT03906292|Experimental|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
32802885|NCT03906292|Experimental|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
32802886|NCT03906292|Experimental|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
32802887|NCT03906292|Experimental|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
32802888|NCT03906292|Experimental|Asciminib 80 mg QD monotherapy|Asciminib 80 mg QD as a single agent
32802889|NCT04399642|Active Comparator|Standard|Patients receiving single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision
32802890|NCT04399642|Experimental|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
32802891|NCT04399564|Active Comparator|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
32802892|NCT04399564|Experimental|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
32802893|NCT03672526|Experimental|device compuflo|
32802894|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
32802895|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
32802896|NCT03227926|Experimental|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
32802897|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
32802898|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
32802899|NCT03227770|Active Comparator|regular hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
32802900|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment at least once every two week
32802901|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
32802902|NCT03615742|Placebo Comparator|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
32802903|NCT03615742|Active Comparator|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
32802904|NCT03615742|Active Comparator|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
32802905|NCT03615742|Experimental|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
32802906|NCT04562194|Other|Intervention|NeVa Stent Retriever
32899893|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
33096405|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
33096406|NCT05146635|Active Comparator|Intravesical immunotherapy (BCG) group|
33096407|NCT05146635|Active Comparator|Intravesical chemotherapy (Epirubicin) group|
33096408|NCT00494741|Experimental|mycophenolate mofetil|
33096409|NCT00494741|Experimental|azathioprine|
33096410|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
33096411|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
33096412|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
33096413|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
33096414|NCT00507312|Experimental|2|Patients with risk factors for heart failure
33096415|NCT00507312|Experimental|3|Patients with heart failure
33096416|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
33096417|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
33096418|NCT05148546|Experimental|A: Neoadjuvant nivolumab|Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks
33096419|NCT05148546|Experimental|B: Neoadjuvant nivolumab + ipilimumab|Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks
33096420|NCT05148546|Experimental|C: Neoadjuvant nivolumab + relatlimab|Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks
33096421|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
33096422|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
33096423|NCT00497588|Experimental|surgery|Patients undergo surgery
33096424|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
33096425|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
33096426|NCT05143983|Active Comparator|depressed subjects, positive valence music listening at first|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to positive musical excepts (3 minutes)
33096427|NCT05143983|Other|depressed subjects, neutral valence music listening|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to neutral valence musical excepts (3 minutes)
32899894|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
33096428|NCT05143983|Other|healthy controls, positive valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to positive valence musical excepts (3 minutes)
33096429|NCT05143983|Other|healthy controls, neutral valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to neutral valence musical excepts (3 minutes)
33096430|NCT05149560|Experimental|Ticagrelor|Ticagrelor 90 mg twice daily for 12 months
33096431|NCT05148624|Experimental|Immediate ambulation|Sub-infertile women will immediately ambulate and empty her bladder after embryo transfer.
33096432|NCT05148624|Active Comparator|short time bed rest|Sub-infertile women will stay in the bed (same bed where embryo transfer was performed) after embryo transfer for a period of 5 minutes without emptying her bladder.
33096433|NCT05144919|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
33096434|NCT05144919|Experimental|Intervention|The intervention group will receive capacity building sessions on both Agriculture and Nutrition, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal.
33096435|NCT00494936||HIV/HCV|HIV and HCV coinfected
33096436|NCT00494936||HIV infected|HIV monoinfected
33096437|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
33096438|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
33096439|NCT05144568|Experimental|experimental group|Nutrition education will be given to participants with PMS in the experimental group.
33096440|NCT05144568|No Intervention|Control group|
33096441|NCT05144217|Placebo Comparator|Placebo|1 capsule twice per day
33096442|NCT05144217|Active Comparator|oral administration of 2x 140 mg per day|1 capsule twice per day
33096443|NCT05144217|Active Comparator|oral administration of 3x 280 mg per day|2 capsules three times a day
33096444|NCT05144217|Active Comparator|oral administration of 1x 1120 mg per day|8 capsules once per day
33096445|NCT05143944||Nice clinical guidelines for intrapartum care for healthy women and babies|define gold standards in intrapartum care for healthy women and babies
32947084|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
32947085|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
32947086|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
32947087|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
32947088|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
32947089|NCT01737840|Experimental|pantoprazole|Intravenous pantoprazole 40 mg flacon
32947090|NCT01737840|Active Comparator|ranitidine|Intravenous ranitidine 50 mg
32947091|NCT01691820|Experimental|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
32947092|NCT01691820|Experimental|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
32947093|NCT01691820|Experimental|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
32947094|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
32947095|NCT04547400||Healthy group|Healthy individuals without chronic disease
32947096|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
32947097|NCT01737762|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
32947098|NCT01737762|Placebo Comparator|Vehicle|Vehicle Control(fibrinogen solution & thrombin solution without cells)
32947099|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
32947100|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
32947101|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
32947102|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
32947103|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
32947104|NCT04413708|Experimental|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
32947105|NCT04413708|No Intervention|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
32947106|NCT01709838|Other|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
32947107|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
32947108|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
32947109|NCT04167618|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
33096446|NCT05143944||performance in the care provided to patients in periods of audit|measure performance in the care provided to the patients in the period of audit
33096447|NCT00495053|Experimental|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
33404643|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
33404644|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
32947110|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
32947111|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
32947112|NCT01682148|Experimental|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
32947113|NCT01682148|Active Comparator|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
32947114|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32947115|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32947116|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
32947117|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
32947118|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
32947119|NCT01681836|Experimental|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
32947120|NCT01681836|Experimental|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
32947121|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
32947122|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
32947123|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
32947124|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
32947125|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
32947126|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
32947127|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
32947128|NCT02071914|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
32947129|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
33096448|NCT00495053|Experimental|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
33096449|NCT00495053|Placebo Comparator|Placebo|Matching placebo (PBS-20% sucrose)
33096450|NCT05143554|Active Comparator|Active percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
33096451|NCT05143554|Sham Comparator|Sham percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
33096452|NCT05143515|Experimental|PACE Label group|This group used the PACE label plus calorie label to help participants to know about the number of minutes of walking or running required to burn off the calories in food and drinks.
33096453|NCT05143515|No Intervention|Calorie Label group|This group used only calorie labels to show the number of calories in food and drinks.
33096454|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
33096455|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
33096456|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
33096457|NCT05143359|Experimental|Wharfe and Pederson difficulty index|Assessment of Difficulty in third molar extraction using Wharfe and Pederson difficulty index
33096458|NCT05143359|Active Comparator|Winters difficulty index|Assessment of Difficulty in third molar extraction using Winters difficulty index
33096459|NCT05143320||Covid+|
33096460|NCT05143320||Covid-|
33096461|NCT05143281|Experimental|Dexamethasone Ophthalmic Insert|Day of surgery, in OR placement vs. Day 1 Post-Op, In-office (HOPD)
33096462|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
33404645|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
32802907|NCT04398472|Active Comparator|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19.~Hypothesis 1 (H1). There will be a reduction in the primary outcome, loneliness in participants assigned to the Nextdoor KIND Challenge groups compared to the waitlist control group post the 4-week intervention"
32802908|NCT04398472|No Intervention|Waitlist|
32899895|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
33096463|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
33096464|NCT00497900|Experimental|1|Calcium and vitamin D
33096465|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
33096466|NCT05143125|Experimental|Treatment group|Decitabine combined with NK cell infusion as post-remission therapy
33096467|NCT01244555|Experimental|Massage treatment|
33096468|NCT01244555|Experimental|Ultrasound|
33096469|NCT01244555|No Intervention|Wait-list|
33096470|NCT05143008|Experimental|SMART Intervention|Counseling sessions will be completed with a toolbox approach so that clinicians can work on topics that are of interest and relevant to each participant. SMART will focus on weight, physical activity, eating and psychosocial issues. Intervention goals will emphasize adherence to healthy behaviors rather than absolute weight goals. Specifically, women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
33096471|NCT05142930|Active Comparator|Intermittent ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Intermittent ultrasound will be used as a physical therapy agent. Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
33096472|NCT05142930|Active Comparator|Continuous ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Continuous ultrasound will be used as a physical therapy agent. Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
33096473|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
33096474|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
33096475|NCT00497978|Active Comparator|1|taurine will be given per capsule
33096476|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
33096477|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
33096478|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
33404646|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
33404647|NCT05078086||Patients undergoing cardiac surgery with CPB|>18 y/o patients who undergo cardiac surgery with cardiopulmonary bypass and with a preoperative additive EuroSCORE I≥ 6
33404648|NCT05133297|Experimental|Sequence 1|TLL018 tablets, 1piece,BID
33096479|NCT05142852|Experimental|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
33096480|NCT05142852|Active Comparator|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
33096481|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
33096482|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
33096483|NCT05141331|Experimental|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges
33096484|NCT05141331|Active Comparator|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
33096485|NCT05146557||Group Obese adolescents|BMI above the 97th percentile + 2.17 to+2.18 SDS
33096486|NCT05146557||Group Normal weight adolescents|BMI between the 10th and 90th percentile -1.64 to +1.64 SDS
33096487|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
33096488|NCT05146518|Experimental|Single-arm, pre-post|Maternity staff of health public health facilities will exposed to the intervention package (capacity building and systemic changes in the health facilities).
33096489|NCT05146401||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
33096490|NCT05146401||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
33096491|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
33096492|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
33311826|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
33311827|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
33311828|NCT01212848|Experimental|TMS|
33096493|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
33311829|NCT01212848|Sham Comparator|Sham|
33311830|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
33311831|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
33096494|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
33096495|NCT00502736|Experimental|1|
33311832|NCT03939338||Participates|
33311833|NCT03987893|Experimental|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
33311834|NCT03987893|Active Comparator|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
33311835|NCT01116908|No Intervention|Control|
33311836|NCT01116908|Active Comparator|LifeStraw Family|
33311837|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
33311838|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
33311839|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
33311840|NCT01211444|Experimental|HGNS System|
33311841|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
33311842|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
33311843|NCT01113866||heart failure|
33311844|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
33096496|NCT05146245|Experimental|Therapeutic Drug Monitoring|Physicians receive dosing advice based on measured blood levels of risperidone and 9-OH-risperidone.
33096497|NCT05146245|Active Comparator|Care As Usual|Physician decides on possible dosing changes without receiving advice based on blood levels.
32802909|NCT04558918|Experimental|LNP023 monotherapy|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
32899896|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
33096498|NCT05146089|Experimental|Hypoxia Exposure|Men and women will be exposed to acute intermittent hypoxic episodes.
33096499|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
33096500|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
33096501|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
33096502|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
33096503|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
33096504|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
33096505|NCT00498524||1|Sib who has received an ICD
33096506|NCT00498524||2|Sib who has not received an ICD
33096507|NCT02954757|Experimental|Treatment arm|HIFU treatment
33096508|NCT00502814||1|Patients with Breast Cancer.
33096509|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
33096510|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
33096511|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
33096512|NCT05147181||Participants With HAE|Participants with type 1 or type 2 HAE when treated with lanadelumab in real life in accordance with Summary of Product Characteristics (SmPC) and NDP requirements will be observed in this prospective observational study for 36 months
33096513|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
33096514|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
33096515|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
33096516|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
33096517|NCT00503048||1|foster care children
33096518|NCT00503048||2|reference children (living with families)
33096519|NCT05149287|Experimental|Experimental|The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.
33096520|NCT05149287|Placebo Comparator|Placebo|The placebo group will receive a single intravenous dose of 1% lidocaine and saline immediately postoperative in the operating room.
33096521|NCT05140980||"women aged 18 to 25 group"|"women aged 18 to 25 group: women aged 18 to 25 with or without sexual activity"
33096522|NCT00498680|Active Comparator|Viagra 100mg|
33096523|NCT00498680|Active Comparator|Levitra 20mg|
33096524|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
33096525|NCT05146011||Single stage pathway|
33096526|NCT05146011||Two stage pathway|
33096527|NCT00498719||CTP Group|One-on-one cognitive training
33096528|NCT00498719||Control Group|Standard educational support.
33096529|NCT00507390|Active Comparator|A1|n-3 PUFAs
33096530|NCT00507390|Placebo Comparator|A2|olive oil capsules
33096531|NCT05145387|Experimental|TEAMSS Intervention in the RCT|Students randomly assigned to the TEAMSS intervention will receive the 5th and 6th grade components.
33096532|NCT05145387|No Intervention|Enhanced Usual Care in the RCT|Enhanced Usual Care (EUC) will serve as the comparison group. EUC will be comprised of written materials (given all at once after randomization by study team) for parents and children that include: 1) a specialty mental health referral list; 2) a list of websites and books on child anxiety; and 3) tip sheets on successful transitions to MS. Families in this condition will not be prohibited from seeking treatment (though this will be monitored) for their children. These students will visit and meet with the 6th grade clinician in the spring of 5th grade.
33096533|NCT05145894||Asthma|Asthma patients aged 3 years and older with confirmed asthma diagnosis treated by a monotherapy ICS or ICS plus LABA or other controllers and presenting with moderate or severe disease exacerbation
33096534|NCT05145894||COPD|COPD patients aged 40 years and older with confirmed COPD diagnosis treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS and presenting with moderate or severe disease exacerbation
33096535|NCT05145543|Placebo Comparator|Group C|0.9 NaCl % (Saline) (5 ml)
33096536|NCT05145543|Active Comparator|Group L|0.25 % levobupivacaine (5 ml) will be applied.
33096537|NCT05145543|Experimental|Group LF|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
33096538|NCT05145543|Experimental|Group LD|dexamethasone plus levobupivacaine (5 ml) will be applied.
33096539|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
33096540|NCT05145504||20 obese patients, with BMI ≥ 30|
33096541|NCT05145504||20 normal weight patients with BMI between 18.5 - 24.9 inclusive|
33096542|NCT05145465|Experimental|Telerehabilitation group|"Participants will undertake the first training session in the University of Thessaly under the supervision of a specialized physiotherapist in order to precept the exercises. All the other sessions will proceed via telerehabilitation program at their home. Participants will undergo an exercise home based program 3 times/week.~The program will start with 10 minutes warm up exercise , 20 minutes continuous aerobic exercise ( 60-80% of target heart rate), 20 minutes resistance training exercise ( 30-50% 1RM), 5 minutes cool down and breathing exercises. For their safety patients will monitor glucose, blood pressure, pulse-oxygen and heart rate via, blood pressure monitor, pulse oximeter and smart-watch devices. They will be assessed at the beginning of the study and after the intervention ( at 6 weeks)"
33096543|NCT05145465|No Intervention|control group|The participants in this group will just receive the education session and they will continue their current medical therapies.They will be assessed at the beginning of the study and after the intervention ( at 6 weeks).
33096544|NCT04696107|Experimental|Intervention Group|Standard pharmacological treatment aimed at controlling mCNCP with four-week face to face psychoeducational intervention.
33096545|NCT04696107|No Intervention|Control Group|Standard pharmacological treatment aimed at controlling mCNCP without psychoeducational intervention.
33096546|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
33096547|NCT02276391|Active Comparator|Telmisartan|
33096548|NCT05145270|Active Comparator|Escitalopram|The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.
33096549|NCT05145270|Experimental|Escitalopram plus Sulforaphane|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
33096550|NCT05145270|Experimental|Escitalopram plus rTMS|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day."
33096551|NCT05149443|Experimental|Effectiveness of the Move it, Move ID app|All participants will receive the Move it, Move ID app.
33096552|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
33096553|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
33096554|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
33096555|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
33096556|NCT02276625|Active Comparator|D - IM|1x IM
33096557|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
33096558|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
33096559|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
33096560|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
33096561|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
33096562|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
33311845|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
32899897|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
32899898|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
32899899|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
32899900|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
32899901|NCT02246933|Experimental|PUFA Diet|
32899902|NCT02246933|Placebo Comparator|Control Diet|
32899903|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
32899904|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
32899905|NCT04352075|Experimental|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
33096563|NCT04695990|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given Wenyang Huoxue Decoction, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
33096564|NCT04695990|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
33096565|NCT00503321|Experimental|Arm B|S-1 plus PSK group
33096566|NCT00503321|Active Comparator|Arm A|S-1 alone
33096567|NCT05145075|Experimental|Survey group|Patients are asked to fill in a survey.
33096568|NCT05147844|Experimental|Toripalimab +Radiotherapy|
33096569|NCT05147961|Experimental|mHealth|A mHealth automated behavioral intervention via E-mail, web, and mobile phone will be developed and tested in the intervention trial trial (phase 4 of the project)
33096570|NCT05147961|Active Comparator|Standard care|Traditional recommendations (lifestyle modification) (phase 4 of the project)
33311846|NCT01113944|Active Comparator|Program 1|Program 1
33311847|NCT01113944|Active Comparator|Program 2|Program 2
33096571|NCT05144295|Experimental|Investigational Arm|"Patients will receive lubiprostone capsules (Amiprostone 8 and 24 mcg, or Lubicont 8 mcg)~Patients weighing <50 kg will be given lubiprostone at doses of 8 mcg/8 hours.~Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.~Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid."
33096572|NCT05144295|Active Comparator|Control Arm|"Subjects will receive the conventional therapy (one or a combination of the following):~Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),~Bisacodyl tablets  Bisacodyl 5 mg/tablet in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years, or~Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day."
33096573|NCT05141487||Conditional SNM|This group receives conditional sacral neuromodulation, applied intermittently based on sensor data describing bladder activity.
33096574|NCT05141487||Continuous SNM|This group receives continuous SNM, applied constantly throughout the bladder filling cycle.
33096575|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
33096576|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
33096577|NCT05147454||Trigeminal Neuralgia|Patients with a definite diagnosis of Classical or Idiopathic Trigeminal Neuralgia
33096578|NCT05147454||Persistent Idiopathic Facial Pain|Patients with a definite diagnosis of Persistent Idiopathic Facial Pain
33096579|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
33096580|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
33096581|NCT05148195|Experimental|A: Solid tumor|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
33096582|NCT05148195|Experimental|B: HCC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
33096583|NCT05148195|Experimental|D：NSCLC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）+Docetaxel(75mg/m2，Q3W)
33096584|NCT05148195|Experimental|D：CRC|Envofolimab（200mg，Q2W）+BD0801（2mg/kg，Q2W）+FOLFIRI（Irinotecan 180 mg/m2，Leucovorin 400mg/m2，5-Fluorouridine 2400 mg/m2，Q2W）
33096585|NCT04696991|Experimental|Experimental Group|The mothers in the experimental group (70) were given the postpartum discharge education with PechaKucha Method.
33096586|NCT04696991|No Intervention|Control Group|The mothers in the control group (70) were given the routine postpartum discharge education.
33096587|NCT05146869|Experimental|50 mg DBPR108 tablets|10 patients will be randomized to receive 50 mg DBPR108 tablets.
33311848|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
33311849|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
33311850|NCT01114022|Experimental|Experimental 2|conic PVC cuff
33311851|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
33096588|NCT05146869|Experimental|100 mg DBPR108 tablets|10 patients will be randomized to receive 100 mg DBPR108 tablets.
33096589|NCT05146869|Experimental|200 mg DBPR108 tablets|10 patients will be randomized to receive 200 mg DBPR108 tablets.
33096590|NCT05143827|Experimental|Senatore Cappelli pasta|
33096591|NCT05143827|Experimental|Korasan pasta|
33096592|NCT05143827|Active Comparator|Claudio pasta|
33096593|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
33096594|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
33096595|NCT05143749|Experimental|10 assistant doctors who received video training|10 assistant doctors who receive video training will be the intervention arm
33096596|NCT05143749|No Intervention|10 assistant doctors who did not receive video training|10 assistant doctors who did not receive video training will be the control arm
33096597|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
33096598|NCT05147259|Experimental|Cohort one: Low dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
33311852|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
33311853|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
33311854|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
33404649|NCT05133297|Experimental|Sequence 2|TLL018 tablets, 2pieces, BID
32802910|NCT04558918|Active Comparator|anti-C5 antibody treatment|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
33096599|NCT05147259|Experimental|Cohort two: Medium dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
33096600|NCT05147259|Experimental|Cohort three: high dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
33096601|NCT00499265|Active Comparator|Gemcitabine|
33096602|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
33096603|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
33096604|NCT05147064|Experimental|group A|randomly allocated
33096605|NCT05147064|Experimental|group B|randomly allocated
33096606|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33404650|NCT05133297|Experimental|Sequence 3|TLL018 tablets, 3pieces, BID
33096607|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
33096608|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
33096609|NCT00499382||PET/CT scan + NM cardiac scan|
33096610|NCT05148312|Experimental|AQ001S 0.125 mg/2mL single-dose|AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.
33096611|NCT05148312|Experimental|AQ001S 0.250 mg/2mL single-dose|AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.
33096612|NCT05148312|Experimental|AQ001S 0.500 mg/2mL single-dose|AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.
33096613|NCT05148312|Active Comparator|Budesonide inhalation suspension 1.0 mg/2 ml single-dose|Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.
33096614|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
32802912|NCT04764292|Experimental|Contrast-enhanced mammography|Women who meet criteria for supplemental screening MRI, but who are unable to have MRI for medical/access/cost reasons, will be invited to have screening with contrast-enhanced mammography. Women will also have standard-of-care mammography/tomosynthesis per usual clinical practice.
32802913|NCT01363297|Experimental|Inotuzumab Ozogamicin|
32802914|NCT04758598|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Direct Selective Laser Trabeculoplasty (DSLT): employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
33096615|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
33096616|NCT05142306|Experimental|COVID-HIG Intramuscular|COVID-HIG single dose administered IM
33096617|NCT05142306|Experimental|COVID-HIG Subcutaneous|COVID-HIG single dose administered SC
33096618|NCT05142306|Experimental|COVID-HIG Intravenous|COVID-HIG single dose administered IV
33311855|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
32802915|NCT04758598|Active Comparator|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
32802916|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
32802917|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin < 13g/dl undergo screening for causes and treatment as needed.
32802918|NCT04757116|Experimental|iTind arm|The iTind is a minimally invasive temporary implant
32802919|NCT04757116|Experimental|UroLift|The UroLift is a minimally invasive permanent implant
33096619|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
33096620|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
33096621|NCT05143437|Experimental|Writing Intervention|Couples will take part in three 7-minute online writing sessions over the course of four weeks.
33096622|NCT00499499|Experimental|1|
33096623|NCT05148663||blood drawing and hemorrhagic events in CCM patients|planned for three blood drawing before surgery
33096624|NCT05148663||blood drawing for age/gender/ethnicity matched controls|Blood draw from Control patients with no inflammation
33311856|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
33404651|NCT05133297|Active Comparator|Sequence 4|TOFA tablets, 1pieces, BID
33096625|NCT04696341|Experimental|Matrix Rhythm Therapy|Group I (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound, conventional massage and Matrix Rhythm Therapy were applied. Home-based exercise program and recommendations were also given to patients.
33096626|NCT04696341|Experimental|Control|Group II (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound and conventional massage were applied. Home-based exercise program and recommendations were also given to patients.
33096627|NCT05147025|Experimental|Revasularization|Revascularization of failed previously revascularized younge permenant inciors
33311857|NCT03938714|Active Comparator|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
33311858|NCT03938714|Experimental|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
33311859|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
33311860|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
33311861|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
33311862|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
33311863|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
33311864|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
33311865|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
33311866|NCT01117142||Healthy Volunteers|Healthy Volunteers
33311867|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
33311868|NCT01117142||MCL|Mantle Cell Lymphoma
33311869|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
33311870|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
33311871|NCT01213160|Experimental|AZD4547|
33311872|NCT03938636|Experimental|Subjects Free of Inflammatory Disease|The first arms is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
33311873|NCT03938636|Experimental|RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
33311874|NCT03938636|Experimental|Candidates for Initiation of, or Change to,|The third arm is designed to assess the efficacy of TUV global in clinically diagnosed subjects with active RA who are candidates for initiation of, or change to, a new anti-TNFα bDMARD therapy.
33311875|NCT04774120||Young Patients (Patients aged 18 to 65 years.)|Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
33311876|NCT04774120||Elderly patients (Patients aged 65 to 85 years. )|Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
33311877|NCT01110512|Experimental|Flavonid|
33311878|NCT01110512|Active Comparator|Daflon|
33311879|NCT03707704||SCI patients in primary rehabilitation|
33311880|NCT01117220|Placebo Comparator|2|
33311881|NCT01117220|Active Comparator|1|
32802920|NCT04756804|Experimental|70% Isopropyl Alcohol novel preoperative skin antiseptic|70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation
32947130|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
32947131|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
33311882|NCT03707626||LAD with collaterals with and without wellens sign|
32947132|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
32947133|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
33311883|NCT05236972|Experimental|Sintilimab|Sintilimab 200mg iv drip Q3W for 8 courses
33311884|NCT05236972|Experimental|XELOX|Patients receive chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 or 8 courses
33311885|NCT03941054|No Intervention|Control arm|No intervention
33311886|NCT03941054|Experimental|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
33311887|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
33311888|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
33311889|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
33311890|NCT01110590|Experimental|Arm 1|
33311891|NCT01110590|Experimental|Arm 2|
32947134|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
32947135|NCT04116840|Experimental|MT1002 for Injection|Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects
32947136|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32947137|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32947138|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32947139|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32947140|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
32947141|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
32947142|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
32947143|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
32947144|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
32947145|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
32947146|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
32947147|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
32947148|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
32947149|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
32947150|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
32947151|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
33311892|NCT01110590|Experimental|Arm 3|
33311893|NCT01110590|Placebo Comparator|Arm 4|
33404652|NCT05078008|Placebo Comparator|Group 1 - Physiotherapy modalities|
33404653|NCT05078008|Experimental|Group 2 - Physiotherapy modalities + Balneotherapy modalities|
33311894|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
33311895|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
32947152|NCT01593696|Experimental|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
32947153|NCT01593696|Experimental|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
32947154|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
32947155|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
32947156|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
32947157|NCT03901014|Active Comparator|Baseline diet|1 week baseline diet
32947158|NCT03901014|Experimental|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
32947159|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
32947160|NCT04768374|Experimental|VR group|Enrolled into 12 week VR intervention with Microsoft Kinect (twice a week, for 45 minutes) and conventional occupational therapy.
32947161|NCT04768374|Active Comparator|Control group|Control group only received conventional occupational therapy for 12 weeks
32947162|NCT01592370|Experimental|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
32947163|NCT01592370|Experimental|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
32947164|NCT01592370|Experimental|Nivolumab + Lirilumab|"Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort"
32947165|NCT01592370|Experimental|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants > 75 years old~Weeks with daratumumab dosing:~20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants > 75 years old~Enrollment is closed for this cohort"
32947166|NCT01592370|Experimental|Daratumumab vs. Nivolumab + Daratumumab|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1"
32947167|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
32947168|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
32947169|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
32947170|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
32947171|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
32947172|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
32947173|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
32947174|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
32947175|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
32947176|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
32947177|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
32947178|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
33311896|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
33096628|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
33096629|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
33096630|NCT05148975||Mild ARDS due to Covid- 19 pneumonia|Adults with SARS-CoV-2 PCR positivity in the last 21 days on mechanical ventilation for Covid-19 pneumonia, fulfilling criteria for mild acute respiratory distress syndrome (ARDS) definition.
33096631|NCT01246934|No Intervention|COMPLICATION|
33311897|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
33311898|NCT03938948|Experimental|Treatment Arm|62 participants shall be enrolled
33311899|NCT01117298|Experimental|Tadalafil|
33096632|NCT01247012|Active Comparator|Lipid minimization|
33096633|NCT01247012|Experimental|Omegaven|
33096634|NCT03454191|Experimental|Erector spinae plane block|
33096635|NCT03454191|Placebo Comparator|Placebo|
33311900|NCT01117298|Placebo Comparator|Placebo|
32899906|NCT04352075|Experimental|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
32899907|NCT04352075|Experimental|Microfat|microfat (5 ml) and saline solution (5 ml)
32899908|NCT05410080||good perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
32899909|NCT05410080||poor perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
32899910|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
32899911|NCT04388774|Experimental|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
32899912|NCT01602666|Experimental|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
32899913|NCT01552356|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
32899914|NCT04423380|Experimental|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
32899915|NCT05442060|Active Comparator|Erlotinib|Erlotinib (150 mg daily)
32899916|NCT05442060|Experimental|Erlotinib + OBI-833/OBI-821|Erlotinib (150 mg daily) + 30 μg OBI-833/100 μg OBI-821
32899917|NCT05441982|Active Comparator|Acesulfame Potassium|Controlled feeding study. Dosage of acesulfame potassium will follow 50% of the acceptable daily intake (equivalent to 7.5 mg/kg). This amount represents 450 mg/day of acesulfame potassium for a 60 kg adult.
32899918|NCT05441982|Active Comparator|Saccharin|Controlled feeding study. Dosage of saccharin will follow 50% of the acceptable daily intake (equivalent to 7.5 mg/kg). This amount represents 450 mg/day of saccharin for a 60 kg adult.
32899919|NCT05441982|Placebo Comparator|No NNS|controlled feeding study with no non-nutritive sweeteners
32899920|NCT05441592|Experimental|Irrigation that contains tranexamic acid (TXA)|
32899921|NCT05441592|Other|No additional irrigation usual care|
32899922|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
32899923|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
32899924|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
32899925|NCT04259970|Experimental|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
32899926|NCT04259970|Experimental|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
33311901|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
33311902|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
33311903|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
32947179|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
32947180|NCT04873050|Experimental|Semaglutide Pen Injector (Ozempic)|Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)
32947181|NCT04873050|Sham Comparator|Placebo|Weekly injections of placebo for 8 months total
32947182|NCT04871568|Active Comparator|Right subclavian vein catheterization|The temporary central dialysis catheter is placed in the right subclavian vein.
32947183|NCT04871568|Active Comparator|Right internal jugular vein catheterization|The temporary central dialysis catheter is placed in the right internal jugular vein.
32947184|NCT01590888|Experimental|PBT2 250mg|
32947185|NCT01590888|Experimental|PBT2 100mg|
32947186|NCT01590888|Placebo Comparator|Sugar pill|
32947187|NCT01565928|Experimental|MDV3100|
32947188|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
32947189|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
32947190|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
32947191|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
32947192|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
32947193|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
32947194|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
32947195|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
32947196|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
32947197|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
32947198|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
32947199|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
32947200|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
32947201|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
32947202|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
32947203|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
32947204|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
32947205|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
32947206|NCT04410354|Active Comparator|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
32947207|NCT04410354|Placebo Comparator|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
32947208|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
32947209|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
32947210|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
32947211|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
32947212|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
32947213|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
33311904|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
33311905|NCT01110668|Experimental|Nilotinib|
33311906|NCT03938558|Experimental|Dance intervention group|"Dancers at beginners level~Dancers at advanced level"
33311907|NCT03938558|Active Comparator|Art intervention group|"Paint artists~Word artists~Film artists~Photographers"
33311908|NCT01114178||claudicants|patients referred for a treadmill test
33311909|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
33311910|NCT01110824|No Intervention|Control|Control arm without intervention
33311911|NCT03936140|Experimental|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
33311912|NCT03936140|Experimental|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
33311913|NCT03936140|Placebo Comparator|Distilled water|"Distilled water~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
33311914|NCT03938090|Placebo Comparator|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
33311915|NCT03938090|Active Comparator|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
33311916|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
33311917|NCT01117532|No Intervention|No Treatment|
33311918|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
33311919|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
33311920|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
33311921|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
33311922|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
33311923|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
33311924|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
33311925|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
33311926|NCT01111136|Experimental|stress intervention|Stress intervention.
33311927|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
33311928|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
33311929|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
33311930|NCT05422690|Experimental|gemcitabine, cisplatin and nab-paclitaxel chemotherapy with Yittrium-90|single arm - Induction Gemcitabine, Cisplatin and Nab-Paclitaxel Triplet Chemotherapy followed by Gemcitabine, Cisplatin and yttrium-90 (Y-90) Radioembolization
33311931|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
33311932|NCT01117922|Other|Usual Care Group|This group will receive usual care.
33311933|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
33311934|NCT01213394|Experimental|CellCept optimization|
33311935|NCT01213394|Active Comparator|Control|
33311936|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
33311937|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
33311938|NCT03938012||Lung and head and neck tumours|"Age 18 years or older~Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region~No other active malignancy within the past 24 months~Refractory disease"
33311939|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
33311940|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
32947214|NCT04103814|Active Comparator|Mg-CBDa cream|Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
33311941|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
33311942|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
33311943|NCT03937934|Experimental|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
33311944|NCT03368170|Experimental|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
33311945|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
33311946|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
33311947|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
33311948|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
33311949|NCT03937856|Experimental|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
32947215|NCT04103814|Placebo Comparator|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
32947216|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
32947217|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
32947218|NCT04114344|Active Comparator|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
32947219|NCT04114344|Experimental|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
32947220|NCT01563354|Experimental|Pasireotide LAR|Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
32947221|NCT01563354|Experimental|Everolimus|Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
32947222|NCT01563354|Experimental|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1
32947223|NCT01588548|Active Comparator|AZD1208|
32947224|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
32947225|NCT01587924|Experimental|2 mg GSK1278863|once daily
32947226|NCT01587924|Experimental|5 mg GSK1278863|once daily
32947227|NCT01587924|Active Comparator|rhEPO|as required
32947228|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
32947229|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
32947230|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
32947231|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
32947232|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
32947233|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
32947234|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
32947235|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
32947236|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
32947237|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
32947238|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
33311950|NCT03937856|No Intervention|Control group|Usual care participants.
33311951|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
33311952|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
33311953|NCT01213550|Experimental|Chlorhexidine|
33311954|NCT01213550|Placebo Comparator|Placebo mouthrinse|
33311955|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
33311956|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
33311957|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
33096636|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
33096637|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
32802921|NCT04756804|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation
33096638|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
33096639|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
33096640|NCT03450096|Active Comparator|Treatment group|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
33096641|NCT03450096|No Intervention|Control group|Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand
33096642|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
32802922|NCT04398394|Experimental|Group 1|Individuals with healthy retina, 18 to 50 years old.
32802923|NCT04398394|Experimental|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
32802924|NCT04398394|Experimental|Group 3|Individuals with healthy retina, over the age of 50.
32802925|NCT04398394|Experimental|Group 4|Patients with early and intermediate AMD, over the age of 50.
32802926|NCT04398394|Experimental|Group 5|Patients with other retinopathies than AMD, over the age of 18.
32802927|NCT04740268|Other|Patiant without treatment|Non-Randomized patients with atrophic acne skin conditions
32802928|NCT04740268|Other|Straberi Microneedling Treatment|Non-Randomized treatment for patients with atrophic acne skin conditions using the Straberi Microneedling device.
32802929|NCT03829462|Experimental|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
32802930|NCT03829462|Active Comparator|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
32802931|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
32802932|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
32802933|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
32802934|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
32802935|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
32802936|NCT04398940|Experimental|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
32802937|NCT04632199|Experimental|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
32802938|NCT04632199|Experimental|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
32802939|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
32802940|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
32802941|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
32802942|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
32802943|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
32802944|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
32802945|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
32802946|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
32802947|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
32802948|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
32802949|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
32802950|NCT04746430|Experimental|Intervention|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
32802951|NCT04746430|No Intervention|Control|Only remote monitoring
32802952|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
32802953|NCT03781414|Experimental|Arm 2|CFZ533 dose A + MMF + Corticosteroids
32802954|NCT03781414|Experimental|Arm 3|CFZ533 dose B + MMF + Corticosteroids
32802955|NCT04277650|Active Comparator|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
32802956|NCT04277650|Experimental|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
32802957|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
32802958|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
33096643|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
33096644|NCT05146830||Participants with Cystinosis Disease|This is a long-term follow-up study of participants who previously received AVR-RD-04 (single dose administration). No investigational product will be administered in this study.
33096645|NCT00499733|Experimental|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
33311958|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~Group II - Control: Routine follow-up with the health team in the reference institution."
33311959|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
33311960|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
33311961|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
33311962|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
33311963|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
33311964|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
32802959|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
32802960|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
32802961|NCT04277494|Experimental|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
32802962|NCT03642028|Experimental|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
32802963|NCT03642028|Placebo Comparator|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
32802964|NCT04458220||difficult airway|C-L≥Ⅲ grade
32802965|NCT04458220||none difficult airway|C-L<Ⅲgrade
32802966|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
32802967|NCT05166460|Experimental|Surgery utilizing the Kidney Skinn cooling device|All patients in Part A, and those randomized to the Kidney Skinn arm in Part B, will receive transplant surgery in the traditional fashion with the exception that the renal allograft will be placed in the cooling device at the initiation of the vascular anastomosis. Cold saline irrigation flowing through the device will be used to maintain renal hypothermia for the duration for the vascular anastomosis. After the vascular clamps are released, the device will be removed.
32802968|NCT05166460|No Intervention|Standard transplant surgery practice|Standard transplant surgery per site practice
32802969|NCT04430842|Experimental|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
32802970|NCT04428580|Experimental|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
32802971|NCT04428580|Active Comparator|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
32802972|NCT04691986|Experimental|NR Supplementation|Participants in this group will receive NR supplementation at 1000 mg per day (given as 2x250mg capsules morning and 2x250mg at night).
32802973|NCT04691986|Placebo Comparator|Placebo supplementation|Participants in this group will receive placebo given as 2 pills in the morning and 2 pills at night. Placebo pills contain micro cellulose which is likewise found in NR containing capsules.
33096646|NCT03452202|Experimental|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
33404654|NCT03417999|Experimental|Cohort 1|"Cohort 1A:~Dexmedetomidine 2 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~Dexmedetomidine 2 μg/kg~Under sedation with a natural airway~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
33404655|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo"
32802974|NCT04686838|Experimental|READyR II A|Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
32802975|NCT04686838|Active Comparator|READyR II B (comparison)|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
32802976|NCT04684264|Experimental|Pharmacist-directed collaborative practice|Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention.
32802977|NCT04684264|No Intervention|Usual care|Participants will receive usual care with their primary care physician.
32802978|NCT04677010|No Intervention|Run-in period, patients with cerebral palsy or muscular dystrophy|10 weeks of no exercise
32802979|NCT04677010|Active Comparator|Exercise period, patients with cerebral palsy or muscular dystrophy|10 weeks of exercise
32802980|NCT04277806|No Intervention|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
32802981|NCT04277806|Experimental|Intervention group|The preterm infants in this group would be fed according to the new process.
32802982|NCT04407442|Experimental|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in absence of disease progression or unacceptable toxicity.~INDUCTION (CYCLES 1-2): Patients receive azacitidine IV on days 22-26, dexamethasone IV or orally (PO), and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity~MAINTENANCE (CYCLES 7+): Patients receive azacitidine IV on days 1-5, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity"
32802983|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
32802984|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
32802985|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
32802986|NCT04402138|Experimental|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
32802987|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
32802988|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
32802989|NCT04391062|Experimental|intraoperative PDT 400J/cm²|
32802990|NCT04391062|Experimental|intraoperative PDT 600J/cm²|
32802991|NCT04391062|Experimental|intraoperative PDT 800J/cm²|
32802992|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
32802993|NCT04384276|Experimental|Prospective Weigh Easy|"Patients enrolled onto this arm of the study will use the Weigh Easy system for weight tracking in the first three months of life. Weights will be measured in home using the Weigh Easy scale and transmitted to the study team via the Weigh Easy eClipboard message. A notification scheme will be activated for weights found to have plateaued or decreased to ensure that the infant's standard of care nutritionist and provider are able to follow up and recommend additional interventions to counteract the weight change.~After three months, families will complete a satisfaction survey to determine if the Weigh Easy system was preferable or if there are any improvements that could be made.~All other aspects of the patients' care will follow the standard of care for cleft and craniofacial diagnoses and will be guided by the nutritionists specializing in cleft and craniofacial care."
32802994|NCT04384276|Other|Retrospective Control Arm|Patients enrolled onto the control arm will have retrospectively presented to the Cleft and Craniofacial Clinic from January 1, 2016 to December 31, 2018 as infants. These patients were treated with the standard of care for cleft and craniofacial diagnoses and were followed by the nutritionists specializing in cleft and craniofacial care.
32802995|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
32802996|NCT01808612|Experimental|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
32802997|NCT01808612|Experimental|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
32802998|NCT01808612|Placebo Comparator|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
32802999|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
32803000|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
33096647|NCT03452202|Sham Comparator|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
33096648|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
33096649|NCT00503594|Active Comparator|bras conventional|bras conventional
33096650|NCT04696302|Experimental|Focus of attention in individuals post chronic stroke during seated lateral weight shifting|Feasibility study
33096651|NCT04696302|Experimental|Focus of attention in individuals post acute stroke during seated lateral weight shifting|Feasibility study
33096652|NCT05146791||Inlay Bristow Group|Inlay Bristow procedure
33096653|NCT05146791||Onlay Bristow Group|Onlay Bristow procedure
33096654|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
33096655|NCT05146752|Experimental|Extremely low frequency electromagnetic fields|After parental permission for participation was obtained, the preterm newborns were enrolled and divided into the experimental group, which received ELF-EMF therapy after a pretest in addition to regular medical care, and the control group, which received regular medical care only, using a random number table.
33096656|NCT05146752|Other|control group|routine care
33096657|NCT03451422|Experimental|Efavaleukin Alfa|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
33096658|NCT03451422|Placebo Comparator|Placebo|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
33096659|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
33096660|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
33096661|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
33096662|NCT05146713|Experimental|Propolis nanoparticles extract solution|
33096663|NCT05146713|Active Comparator|sodium hypochlorite|
33096664|NCT00503789|Active Comparator|1|cow-milk based infant formula
33311965|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
33311966|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
33311967|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
33311968|NCT01118234|No Intervention|Observation|Observation for 24 months
33311969|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
33311970|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
33311971|NCT03937544|Experimental|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
33311972|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
33096665|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
33096666|NCT00503789|Other|3|human milk reference group
33096667|NCT05149989|Experimental|Proning|Proned on standard and proning pillows
33096668|NCT05149950|Experimental|Increased therapist contact.|The patient gets access to the internet treatment via a secure login to 1177 The care guide-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
33096669|NCT05149950|Other|Less therapist contact.|The feedback from the therapist will largely be general and not individually tailored. The general feedback is based on responses to the participants in the previous pilot study. No physical or digital meetings between patient and therapist take place during treatment.
33096670|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
33096671|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
33311973|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
33311974|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
33311975|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
33311976|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
33311977|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
33311978|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
33311979|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
32947239|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
32947240|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
32947241|NCT04112316|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
32947242|NCT04112316|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
32947243|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
32947244|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
32947245|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
32947246|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
32947247|NCT04767828|Experimental|One arm exploratory research|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition. Pyrrotini: 400 mg once a day, oral within 30 minutes after breakfast for 21 days. Cassitabine: twice a day, 800 mg / m2 orally within 30 minutes after each meal (one morning and one night, 12 hours apart, equivalent to a daily dose of 1600 mg / m2, one dose in the morning and one dose in the morning)
32947248|NCT01585584|Experimental|Boceprevir|
32947249|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
32947250|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
32947251|NCT04111536|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
32947252|NCT04111536|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
32947253|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
32947254|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
32947255|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
32947256|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
32947257|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
32947258|NCT01585194|Experimental|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
32947259|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
32947260|NCT03028116|Placebo Comparator|Placebo|Water for Injection
32947261|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
32947262|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
32947263|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
32947264|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
32947265|NCT01560234|Experimental|AZD8848|
32947266|NCT01560234|Placebo Comparator|Placebo|
32947267|NCT04124328|Active Comparator|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
32947268|NCT04124328|Active Comparator|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
32947269|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
32947270|NCT01584648|Experimental|Dabrafenib + Trametinib|Dabrafenib and Trametinib combination
32947271|NCT01584648|Active Comparator|Dabrafenib + Placebo|Dabrafenib and Trametinib placebo
32947272|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
32947273|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
33096672|NCT05149677|No Intervention|Standard of Care for labor pain|Standard of Care of Care for labor pain
33096673|NCT05149677|Experimental|Music therapy intervention + Standard of Care for labor pain|Music therapy intervention + Standard of Care for labor pain
33096674|NCT03455478|Experimental|corrected refractive error|
33096675|NCT03455478|No Intervention|uncorrected refractive error|
33096676|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
33096677|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
33096678|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
32947274|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
33311980|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
33311981|NCT03983369|Experimental|"preventive treatment with LLLT (Laser group)"|
33311982|NCT03983369|Placebo Comparator|control group with a placebo intervention|
33311983|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
32947275|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.~Survey of clinicians will be sent via e-mail."
32947276|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
32947277|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
32947278|NCT01583166|Active Comparator|Bupivacaine + epinephrine|
32947279|NCT01583166|Placebo Comparator|Saline + epinephrine|
32947280|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
32947281|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
32947282|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
32947283|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
32947284|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
32947285|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
32947286|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
32947287|NCT04102644||Pregnant Women|Up to 15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
32947288|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
32947289|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
32947290|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
32947291|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
32947292|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
32947293|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
32947294|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
32947295|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
32947296|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
32947297|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
32947298|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
32947299|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
32947300|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
32947301|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
32947302|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
32947303|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
32947304|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
32947305|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
33096679|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
33311984|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
33311985|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
33311986|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
33311987|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
32947306|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
33311988|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
33404656|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
32947307|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
32947308|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
32947309|NCT04410510|Placebo Comparator|Control group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
32947310|NCT04410510|Experimental|Intervention group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
32947311|NCT04767672|Experimental|Test product|Food ingredient containing non digestible carbohydrates, in shape of powder
32947312|NCT04767672|Placebo Comparator|Placebo|Food ingredient containing containing 95% of maltodextrin
32947313|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
32947314|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
32947315|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
32947316|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
32947317|NCT04758234|Experimental|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
32947318|NCT04758234|Experimental|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
32947319|NCT04758234|Placebo Comparator|Placebo|Placebo administered orally.
32947320|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
32947321|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
32947322|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
32947323|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
33096680|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
33096681|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
33096682|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
33096683|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
33096684|NCT00500006|Other|A|Arm A: Drug and comparator
33096685|NCT00500006|Other|B|Arm B: Drug and comparator
33404657|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
32947324|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
32947325|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
32947326|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
32947327|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
32947328|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
32947329|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
32947330|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
32947331|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
32947332|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
32947333|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
32947334|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
32947335|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
32947336|NCT01580670|Experimental|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~PCDAI score on the evaluation day exceeds 30"
32947337|NCT04748484|Other|KCC active or inactive|The medical device KCC will be active, or inactive. Randomization will define when and how long time the medical device will be active, and when and how long time the medical device will be inactive. The patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
32947338|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
32947339|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
32947340|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
32947341|NCT01579812|Experimental|Metformin|
32947342|NCT01533714|Experimental|CDP6038 (olokizumab)|CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).
32947343|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
32947344|NCT01579578|Experimental|1|
32947345|NCT01579578|Placebo Comparator|2|
32947346|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
32947347|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
32947348|NCT01532934|Placebo Comparator|Standard Care|standard care
32947349|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
32947350|NCT01532388|No Intervention|Control group|Untreated control group
32947351|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
32947352|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
32947353|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
32947354|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
32947355|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
32947356|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
32947357|NCT01554618|Experimental|EQW|Exenatide once weekly
32947358|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
32947359|NCT04108728|Experimental|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
32947360|NCT04108728|Other|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
32947361|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
32947362|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
33096686|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
33096687|NCT01247051|Experimental|Precoating|
32947363|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
32947364|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
32947365|NCT01553136|Placebo Comparator|Sugar pill|
32947366|NCT01553136|Active Comparator|Varenicline|
32947367|NCT04836468|Experimental|Experimental group|Application of Magnetic Tape transversely over the vertebral levels of L4 and L5
32947368|NCT04836468|Placebo Comparator|Placebo group|Application of kinesiology tape transversely over the vertebral levels of L4 and L5
32947369|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
32947370|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
32947371|NCT01552902|Placebo Comparator|Placebo|
32947372|NCT03923790|Experimental|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is < 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
32947373|NCT03923790|Active Comparator|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
32947374|NCT04102254|Experimental|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
32947375|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
32947376|NCT01529346|Experimental|PF-05089771 1600 mg|
32947377|NCT01529346|Experimental|PF-05089771 450 mg|
32947378|NCT01529346|Experimental|PF-05089771 150 mg|
32947379|NCT01529346|Active Comparator|Ibuprofen 400 mg|
32947380|NCT01529346|Placebo Comparator|Placebo|
32947381|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
32947382|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
32947383|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
32947384|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
32947385|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
32947386|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
32947387|NCT01551420|Active Comparator|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
32947388|NCT01551420|Active Comparator|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
32947389|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
33096688|NCT01247051|Active Comparator|Standard priming|
33096689|NCT00506727|Experimental|Adderall XR|
33096690|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
33096691|NCT01247168|Experimental|1|
33096692|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~Step 2. All patients will receive 6 courses of the VR combination.~Step 3. After 6 courses of VR combination:~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
33096693|NCT00500162|Active Comparator|1|
33096694|NCT00500162|Active Comparator|2|
33096695|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
33096696|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
33096697|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
33096698|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
33096699|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
33096700|NCT01247246|Placebo Comparator|Placebo|
32803001|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
32803002|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.~Subjects withdrawn from the study for any reason will be replaced."
32803003|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.~Subjects withdrawn from the study for any reason will be replaced."
33096701|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
33096702|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
33096703|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
33096704|NCT04696536|Experimental|Group 1: Listerine Cool Mint Mouth Rinse (Marketed product)|Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
33096705|NCT04696536|Experimental|Group 2: Negative Control (5 Percent (%) Hydroalcohol Mouth Rinse)|Participants will receive negative control mouth rinse (5% Hydroalcohol mouth rinse) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
33311989|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
33311990|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
33096706|NCT04696536|Experimental|Group 3: Flossing Performed by Dental Hygienist|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Dental hygienist will floss participant's teeth at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
33096707|NCT04696536|Experimental|Group 4: Flossing under Supervision|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Participants floss their teeth under supervision at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
33096708|NCT03459651|Experimental|ANS training|
33096709|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
33096710|NCT01245881|Active Comparator|Control group|
33096711|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
33096712|NCT05149404||ERAS group|
33096713|NCT05149404||Conventional group|
33096714|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
33096715|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
33096716|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
33311991|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
33311992|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
33311993|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
33096717|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
33096718|NCT00508170||Patients with Oropharyngeal Cancer|
33096719|NCT00508170||Patients with Non-Oropharyngeal Cancer|
32803004|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
32803005|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
33096720|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
33096721|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
33096722|NCT01247519|No Intervention|observation|
33096723|NCT01247519|Experimental|Intervention|
33096724|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
33096725|NCT00500513|Experimental|Implanted Markers + CT + RT|
33096726|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
33096727|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
33096728|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
33096729|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
33096730|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
33096731|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
33096732|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
33096733|NCT00500591||Obese Women|
33096734|NCT02954289|Other|Dietary intervention|Dietary intervention
32803006|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
32803007|NCT01773122|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
33096735|NCT04696913||Pulmonary Embolism Positive|As determined by CT Pulmonary Angiogram
33096736|NCT04696913||Pulmonary Embolism Negative|As determined by CT Pulmonary Angiogram
32803008|NCT01773122|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
32803009|NCT01773122|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
32803010|NCT01773122|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
32803011|NCT04377100||Adults 18 and over|Adults 18 and over
32803012|NCT01808534|Experimental|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32803013|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
32803014|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
32803015|NCT01808222|Experimental|FACBC|Participants receiving a bolus of anti-[18F]FACBC injected with PET-CT detection of cancer recurrence.
33096737|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
33096738|NCT00500669|Experimental|Betadine|
33096739|NCT00500669|Active Comparator|Saline|
33096740|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
33096741|NCT01247636|Experimental|Home-exercise|
33096742|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
33096743|NCT00508248|Placebo Comparator|A2|
33096744|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
33096745|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
33096746|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
33096747|NCT00507663|No Intervention|routine care|routine clinical care
33096748|NCT00508287|Experimental|A|
33096749|NCT00508287|Active Comparator|B|
33096750|NCT00508287|Placebo Comparator|C|
33096751|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
33096752|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
33096753|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
33096754|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
33096755|NCT01247753|Experimental|Intervention|
33096756|NCT01247753|No Intervention|Control|
33096757|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
33096758|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
33096759|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
33096760|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
33096761|NCT00500786|Placebo Comparator|Placebo Hypertensives|
33096762|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
33096763|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
33096764|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
33096765|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
33096766|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
33096767|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
33096768|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
33096769|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
33096770|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
33096771|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
33096772|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
33096773|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
33096774|NCT01316393|Experimental|XER2020|mucoprotective product
33096775|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
33096776|NCT01316393|Placebo Comparator|XER2020 placebo|
33311994|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
33311995|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
33311996|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
33311997|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
33311998|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
33311999|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
33312000|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
33312001|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
33318632|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
33096777|NCT00508560|Experimental|Arm 1|Experimental
33096778|NCT00508560|Active Comparator|Arm 2|Active Comparator
33096779|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
33096780|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
33096781|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
33096782|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
33096783|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
33096784|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:~Sham~motor M1 area~motor M1 + Dorsolateral Prefrontal cortex~Dorsolateral Prefrontal cortex.~The tDCS condition will be randomized and double blinded"
33096785|NCT01247948|Experimental|navigation assisted spine surgery|
33312002|NCT03935828|Experimental|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
33312003|NCT03935828|Active Comparator|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
33312004|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
33312005|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
33312006|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
33312007|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
32947390|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
32947391|NCT04748328||ACL Reconstruction Group|This group received reconstruction treatment in Gatot Subroto Hospital, Jakarta
32947392|NCT04748328||Rehabilitation Group|This group received rehabilitation treatment with optional delayed reconstruction in Arifin Achmad Hospital, Pekanbaru
32947393|NCT01528254|Active Comparator|Vilda 50mg bid + metformin|Metformin + vildagliptin
32947394|NCT01528254|Experimental|Placebo + metformin|Metformin + Placebo of vildagliptin
32947395|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
32947396|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
32947397|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
32947398|NCT01526928|Experimental|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose <900 mg twice a day (BID)
32947399|NCT01526928|Experimental|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
32947400|NCT01526928|Experimental|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
32947401|NCT01526928|Experimental|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
32947402|NCT01526928|Experimental|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
32947403|NCT01526928|Experimental|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
32947404|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
32947405|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
32947406|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
32947407|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
32947408|NCT01574274|Active Comparator|SC-PEG (Arm A)|Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV SC-PEG was administered every 3 weeks (for a total of 10 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
32947409|NCT01574274|Active Comparator|Oncaspar (Arm B)|Patients in this arm were randomized to receive IV Oncaspar 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV Oncaspar was administered every 2 weeks (for a total of 15 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
32947410|NCT01526148|Active Comparator|Lithium|
32947411|NCT01526148|Active Comparator|Quetiapine|
32947412|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
32947413|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
32947414|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
32947415|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
33312008|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
32947416|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
32947417|NCT04749966||Emergency services staff|Emergency Services staff recruited from the Ambulance, Police, and Fire and Rescue Services.
32947418|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I&D will be followed according to protocol using topical and local anesthetic."
33312009|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
33312010|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
32947419|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I&D will be followed according to protocol using topical and local anesthetic."
32947420|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
32947421|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
32947422|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
32947423|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
32947424|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
32947425|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
32947426|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
32947427|NCT01572792|Placebo Comparator|5|Placebo
32947428|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
32947429|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
32947430|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
32947431|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
32947432|NCT01547286|Experimental|Allergic asthmatic|
32947433|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
32947434|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
32947435|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
32947436|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
32947437|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
32947438|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
32947439|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
32947440|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
32947441|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
32947442|NCT01524900||nevirapine extended release|
32947443|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
32947444|NCT04410120||Asthma with recent (<4/52) asthma attack|
32947445|NCT04121676|Experimental|2-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
32947446|NCT04121676|Experimental|3-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
32947447|NCT04121676|Experimental|4-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
32947448|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
32947449|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
32947450|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
32947451|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
33096786|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
32803016|NCT04660435||Women with ER+/Her2 negative metastatic breast cancer|Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice
33096787|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
33096788|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
33096789|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
33096790|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
33096791|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
33096792|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
33096793|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
33096794|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
33096795|NCT01248026|Experimental|Buttermilk|
33096796|NCT01248026|Placebo Comparator|Placebo|
33096797|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
33096798|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
33096799|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
33096800|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
33096801|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
33096802|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
33096803|NCT00508014|Active Comparator|Control|usual care
33096804|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
33096805|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
33096806|NCT00508053|Active Comparator|1|Mass closure
33096807|NCT00508053|Experimental|2|Small stitches
33096808|NCT00508092|Active Comparator|A|lanz incision appendectomy
33096809|NCT00508092|Active Comparator|B|lanz incision appendectomy
32803017|NCT01772576|Experimental|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
32803018|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
33096810|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
33096811|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
33096812|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
33096813|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
33096814|NCT00508131|Placebo Comparator|B|Milk not fortified
33096815|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
33096816|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
33096817|NCT00508950|Other|All subjects|All subjects
33096818|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
33096819|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
33096820|NCT00501215|Experimental|Parathyroidectomy + Observation|
33096821|NCT00501215|Other|Observation Alone|
33096822|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
33096823|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
33096824|NCT00509301|Experimental|1|1.5 mCi/cc
33096825|NCT00509301|Experimental|2|2.0 mCi/cc
33096826|NCT00509301|Experimental|3|2.5 mCi/cc
33096827|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
33096828|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
33096829|NCT01248377||Cephalosporins allergic patients|
33096830|NCT01246154||EXERCISE TOLERANCE|
33096831|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
33096832|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
32803019|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
33096833|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
33096834|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
33096835|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
33096836|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
33096837|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
33096838|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
33096839|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
33096840|NCT01246271||Sub urethral sling|
33096841|NCT01246271||sus with anterior vainal wall repair|
33096842|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
33312011|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
33312012|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
33312013|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
33312014|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
33312015|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
33312016|NCT01118936|No Intervention|Washout|
33312017|NCT01118936|Active Comparator|Mablet|
33312018|NCT01118936|Placebo Comparator|Placebo|
33312019|NCT01119014|Experimental|Aripirazole|
33312020|NCT01119014|Experimental|Quetiapine prolong|
33312021|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
33312022|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
32803020|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
32803021|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
32803022|NCT01802216|No Intervention|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
32803023|NCT01802216|Active Comparator|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth >=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
32803024|NCT04760158|Experimental|Taping group|A new star taping technique and exercises were applied to participants.
32803025|NCT04760158|Sham Comparator|Sham Taping Group|Sham patellar taping and exercises were applied to participants.
33096843|NCT00509418|Active Comparator|B|Controlled diet and exercise
33096844|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
33096845|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
33096846|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
33096847|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
33312023|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
33312024|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
33312025|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
33312026|NCT01219244|Experimental|Caloric restriction|
33312027|NCT01219244|Experimental|omega-3 supplementation|
33312028|NCT01219244|Experimental|resveratrol supplementation|
33312029|NCT01219244|Placebo Comparator|placebo|
33312030|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
32803026|NCT04760158|Other|control group|Only exercises were applied to participants.
32803027|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
33312031|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
32947452|NCT04121364|Experimental|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
32947453|NCT01523886|Active Comparator|Deep neuromuscular blockade|
33312032|NCT01119170|Placebo Comparator|control starter formula|
33312033|NCT01119170|Experimental|D-lactate probiotics|
32803028|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
32803029|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
32803030|NCT04330378||Hospital-at-home|All patients who are enrolled into the NUHS@Home Programme will be recruited into this arm. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
32803031|NCT04330378||Usual in-hospital care|Patients who would otherwise be eligible for NUHS@Home but are not able to be enrolled due to capacity will be recruited into this arm. They will receive usual care in the wards that they are already in until they are discharged.
32947454|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
33312034|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
33312035|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
33312036|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
33312037|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
33312038|NCT01119404||Control|80 physically active men
33312039|NCT03937232|Active Comparator|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
33312040|NCT03937232|Active Comparator|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
33312041|NCT03937232|Experimental|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
33312042|NCT03937232|Active Comparator|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
33312043|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
33312044|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
33312045|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
33312046|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
33312047|NCT03937388|Experimental|Cochlear implant recipients|
33404658|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
33404659|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
32947457|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
32947458|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
32947459|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
32947460|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
32947461|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
32947462|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
32947463|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
32947464|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
32947465|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
32947466|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
32947467|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
32947468|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
32947469|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
32947470|NCT01522404|Experimental|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
32947471|NCT01522404|Placebo Comparator|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
32947472|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
32947473|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
32947474|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
32947475|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
32947476|NCT04120584|Experimental|Forma Eye treatment|
32947477|NCT03911466|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
32947478|NCT03911466|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
32947479|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
32947480|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
32947481|NCT04119414|Experimental|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S&S program followed by the LFLS Program.
32947482|NCT01518192|Active Comparator|1Doxycycline|
32947483|NCT01518192|Active Comparator|2 Cefuroxime axetil|
32947484|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
32947485|NCT04099056|Active Comparator|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS/ TI
32947486|NCT04099056|Active Comparator|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS/TI
32947487|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
32947488|NCT04099992|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
33404660|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
33096848|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
33096849|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
33096850|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
33096851|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
33096852|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
33404661|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
33096853|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
33096854|NCT02275091||Healthy|Healthy children 12-21 years old
33096855|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
33096856|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
33404662|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
33404663|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
33096857|NCT00501332|Active Comparator|2|
33096858|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
32947489|NCT04099992|Active Comparator|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
33404664|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
32947490|NCT04099992|Experimental|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
32947491|NCT04099992|Active Comparator|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
32947492|NCT04099992|Experimental|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
33096859|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
33096860|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
33096861|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
33096862|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
33096863|NCT00509652|Active Comparator|Arm 2|Phlebotomy
33096864|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
33096865|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
33096866|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
33096867|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
33096868|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
33096869|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
33404665|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
32947493|NCT04099992|Active Comparator|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
32947494|NCT04714710|Experimental|Potassium canrenoate|Potassium canrenoate 200mg diluted in SODIUM CHLORIDE SOLUTION 0.9%
32947495|NCT04714710|Placebo Comparator|Placebo (SODIUM CHLORIDE SOLUTION 0.9%)|SODIUM CHLORIDE SOLUTION 0.9%
32947496|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
32947497|NCT01569438|Experimental|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
32947498|NCT01569438|Placebo Comparator|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
32947499|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
32947500|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
32947501|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
32947502|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
32947503|NCT04098354|Active Comparator|home-based BP telemonitoring|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
32947504|NCT04098354|Placebo Comparator|usual care|Patients in the control arm will also follow the same BP measurement protocol as the 'active comparator (intervention) group, however, there will be no interactions with the case manager; they will share their BP readings with their primary care physicians or nurse practitioners at scheduled visits.
32947505|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
32947506|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
32947507|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
32947508|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
32947509|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
32947510|NCT01516008|Experimental|Tapentadol IR 50 mg|
32947511|NCT01516008|Experimental|Tapentadol IR 75 mg|
32947512|NCT01516008|Placebo Comparator|Placebo|
32947513|NCT01489254|Experimental|GTR|Drug
32947514|NCT01489254|Active Comparator|Copaxone®|Drug
32947515|NCT01489254|Placebo Comparator|Placebo|Drug
32947516|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
32947517|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
32947518|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
32947519|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
33096870|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
33312048|NCT03935672|Other|All trial participants|"Baseline plasma and saliva tests for future translational analysis~Baseline planning FDG PET CT scan~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
33312049|NCT01216592||COPD|
33312050|NCT03338998|Experimental|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
32803032|NCT04330378||Rejected cohort|Patients who were offered but declined enrolments inot the NUHS@Home programme will be approached for consent to be in the rejected cohort. There will be no change to the patient's clinical management.
33312051|NCT03338998|Placebo Comparator|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
33312052|NCT03935984|Experimental|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
33096871|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
33096872|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
33312053|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
33312054|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
33096873|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
33312055|NCT05683132|Experimental|Trauma-Informed CBT-I|This intervention includes trauma-informed adaptations to standard treatment for insomnia, CBT-I
33312056|NCT05683132|Active Comparator|PTSD Psychoeducation|This intervention includes psychoeducation about PTSD symptoms modeled after usual care in a VA Women's Health Clinic.
33312057|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
33312058|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
33312059|NCT04760548||Train dataset|This group is dedicated to developing an automated algorithm
33312060|NCT04760548||Test dataset|This group is dedicated to testing the performance of an automated algorithm
33096874|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
33096875|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
33312061|NCT04760548||Clinical Validation|This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort
33312062|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
32803033|NCT01808144|Experimental|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
32803034|NCT01808144|Experimental|lesinurad 200 mg + febuxostat 80 mg|
32803035|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
32803036|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
33096876|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
33096877|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
33312063|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
33096878|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
33096879|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions~Interventions include:~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
33096880|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
33096881|NCT00509691|Experimental|Single arm study|
33096882|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
33096883|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
33096884|NCT00501527|Placebo Comparator|C|
32803037|NCT01808066|Experimental|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab & Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
32803038|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
32803039|NCT01604343|Experimental|Sirukumab 100 mg|
32803040|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
32803041|NCT01801436|Experimental|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
32803042|NCT01771250|Experimental|Insulin Peglispro|Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
32803043|NCT01771250|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SC once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
32803044|NCT01770860|Active Comparator|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
32803045|NCT01770860|Active Comparator|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
32803046|NCT01770860|Active Comparator|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
32803047|NCT01770860|Placebo Comparator|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
32803048|NCT01770860|No Intervention|0000|"Device: 0000~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.~Other Names:~Sheer Strips~BAND-AID® with QuiltVent™ Pad Technology~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
32803049|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
32803050|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
32803051|NCT04305106|Experimental|Bevacizumab|Bevacizumab 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including dexamethasone 6mg/day no more than 10 days, therapeutic dose of anticoagulant (low molecular weight heparin or ordinary heparin), and supportive care if necessary.
32803052|NCT04305106|Placebo Comparator|Placebo|Placebo (inactive excipient) 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including dexamethasone 6mg/day no more than 10 days, therapeutic dose of anticoagulant (low molecular weight heparin or ordinary heparin), and supportive care if necessary.
32803053|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
32803054|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
33096885|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
33096886|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
33096887|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
33096888|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
33096889|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
33096890|NCT01248494|Experimental|BEZ235 + Letrozole|
33096891|NCT01248494|Experimental|BKM120 + Letrozole|
33096892|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
33096893|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
33096894|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
33096895|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
33096896|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
33096897|NCT03459963|Experimental|group C|indwelling urinary catheter
32803055|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
32803056|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
33312064|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
33312065|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
32803057|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
32803058|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
32803059|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
32803060|NCT01770392|Active Comparator|Test|multiple doses of Rifampicin + single dose of Nintedanib
33096898|NCT03459963|No Intervention|group N|Non cathetrized patients
32803061|NCT01770392|Experimental|Reference|single dose of Nintedanib
32803062|NCT02020564|Experimental|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32803063|NCT02020564|Placebo Comparator|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32803064|NCT01603641|Experimental|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
33096899|NCT01248572|Experimental|Softec HD IOL|
32803065|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
32803066|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
32803067|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
32803068|NCT04397380||ED Patients|Patients Presenting in Emergency Department
32803069|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
32803070|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
32803071|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
32803072|NCT04397458|Sham Comparator|Sham Control|20 milliliters (mL) 0.9% saline on each side
32947520|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
32947521|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
33312066|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
33312067|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
32947522|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
32947523|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
32947524|NCT01514682|Placebo Comparator|Placebo|Placebo pills to be assigned using a permuted randomization system
32947525|NCT01514682|Experimental|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
32947526|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
32947527|NCT01514370|Experimental|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
32947528|NCT01514370|Placebo Comparator|IFN beta 1a 44 mcg TIW + placebo|
32947529|NCT04705974|Experimental|Fascia iliaca block|ultrasound-guided fascia iliaca block with predetermined dose of 0.4% ropivacaine will be performed.
32947530|NCT04705974|Experimental|Femoral nerve block|ultrasound-guided ultrasound-guided femoral nerve block with predetermined dose of 0.4% ropivacaine will be performed.
32947531|NCT04705974|Experimental|Pericapsular nerve group block (PENG block)|ultrasound-guided ultrasound-guided pericapsular nerve group block with predetermined dose of 0.4% ropivacaine will be performed.
32947532|NCT03868410|Active Comparator|cPMD rTMS + Training|New Approach
32947533|NCT03868410|Active Comparator|iM1 rTMS + Training|Conventional Approach
32947534|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
32947535|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
32947536|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
32947537|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
32947538|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
32947539|NCT04705038|Experimental|Educational Intervention|Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
32947540|NCT04705038|No Intervention|No Intervention|"Participants that decline the education session will continue with routine care of their cancer.~They will also be asked to complete questionnaires."
32947541|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
32947542|NCT01518972|Experimental|Prazosin|Prazosin medication
32947543|NCT01518972|Placebo Comparator|Placebo|Placebo medication
32947544|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
32947545|NCT01513590|Experimental|IDegAsp BID|
32947546|NCT01513590|Active Comparator|BIAsp 30 BID|
32947547|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
32947548|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
32947549|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
32947550|NCT04672512|Experimental|SAD Cohort A CORT125329|Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1
32947551|NCT04672512|Experimental|SAD Cohort B CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.
32947552|NCT04672512|Experimental|SAD Cohorts C through H CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
32947553|NCT04672512|Placebo Comparator|SAD Cohorts A through H Placebo|Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.
32947554|NCT04672512|Experimental|MAD Cohorts A through D CORT125329|Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
32947555|NCT04672512|Placebo Comparator|MAD Cohorts A through D Placebo|Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.
33096900|NCT02953080|Active Comparator|Call for Life Mobile phone support|"The intervention is Call for life mHealth adherence support tool  through basic mobile phone-based interactive voice response."
33096901|NCT02953080|No Intervention|Standard of Care|No call for life Uganda: Patients are randomized to standard of Care
33312068|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
33312069|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
33312070|NCT05210530|Experimental|VCTX210A combination product|Up to ten (10) units will be implanted
33312071|NCT05683054|Active Comparator|Standard dosing group|In the standard based arm, patients will continue to receive adalimumab according to the standard dosing schedule of 40 mg every other week (maintenance phase).
32947556|NCT04672512|Experimental|Pharmacodynamic (PD) Effect Cohort|Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.
33312072|NCT05683054|Active Comparator|Dose tapering group|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab at three consecutive measurements.
33312073|NCT03937076|No Intervention|intercostal block|patients will get intercostal block at the end of the surgery, control group
32947557|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
33312074|NCT03937076|Experimental|PECS II block|patients with get PECS II block at the end of the surgery, research group
33312075|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
33312076|NCT01120106|Placebo Comparator|placebo|saline infusion
33312077|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
32947558|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
32947559|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
32947560|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
32947561|NCT01512108|Experimental|Liraglutide + an OAD therapy|
32947562|NCT01512108|Active Comparator|Two OADs combination therapy|
32947563|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
32947564|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
32947565|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
32947566|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
32947567|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
32947568|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
32947569|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
32947570|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
32947571|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
32947572|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
32947573|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
32947574|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
32947575|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
32947576|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
32947577|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
32947578|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
33096902|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
33312078|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
32947579|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
33312079|NCT03935516|Experimental|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
33312080|NCT03935516|Experimental|Extended Elbow|The second will be placed in a cast with the elbow straight.
33312081|NCT03933644|Other|Ambu Aura Gain TM with gastric tube|
32947580|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
32947581|NCT04655352||Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention
32947582|NCT04700280|Experimental|GLPG3970|Participants will receive GLPG3970 tablet, orally, once daily for 12 weeks.
32947583|NCT04700280|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
32947584|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
32947585|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
32947586|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
32947587|NCT01510158|Placebo Comparator|Placebo + allopurinol|
32947588|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
32947589|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
32947590|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
32947591|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
32947592|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
32947593|NCT03027336|Placebo Comparator|placebo|placebo tablets
32947594|NCT01485120|Other|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
32947595|NCT03027258|Experimental|Intervention|mHealth intervention
32947596|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
32947597|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
32947598|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
32947599|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
32947600|NCT04097340|Active Comparator|Attentional Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
32947601|NCT04097340|Placebo Comparator|Control Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
32947602|NCT01509846|Experimental|Cohort 1|Received one oral dose of 2.6±0.8 x 10^8 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
32947603|NCT01509846|Experimental|Cohort 2|Received three oral doses of 2.6±0.8 x 10^9 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
32947604|NCT01509846|Experimental|Cohort 3|Received three oral doses of 2.6±0.8 x 10^10 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
32947605|NCT01509846|Experimental|Cohort 4|Received three oral doses of 2.6±0.8 x 10^11 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
32947606|NCT01509846|Placebo Comparator|Placebo|Received oral dose of placebo concurrent with Cohort 1 (one dose), 2, 3, or 4 (3 doses).
32947607|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
32947608|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
32947609|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
32947610|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
32947611|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
32947612|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
32947613|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
32947614|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
33312082|NCT03933644|Other|Ambu Aura Gain TM without gastric tube|
33312083|NCT01214096|Placebo Comparator|placebo|
33312084|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
33312085|NCT03933800|Experimental|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
33312086|NCT03933800|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
33312087|NCT03935438|Experimental|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
33312088|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
33312089|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
33312090|NCT01122368|Experimental|1 Micafungin|IV
33312091|NCT01122368|Placebo Comparator|2 Placebo|IV
33312092|NCT03338062|Experimental|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
33312093|NCT03338062|No Intervention|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
33312094|NCT01216826|Experimental|Everolimus|
32947615|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
32947616|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
32947617|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
32947618|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
32947619|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
32947620|NCT01462110|Experimental|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
32947621|NCT01462110|Sham Comparator|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
32947622|NCT04087590|Experimental|PT003 treatment|
32947623|NCT04078854|Experimental|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
32947624|NCT04078854|Active Comparator|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
32947625|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
32947626|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
32947627|NCT04096014|Active Comparator|Ensure Enlive|
32947628|NCT04096014|Placebo Comparator|Standard of Care|
32947629|NCT01508130||Cohort|
32947630|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
32947631|NCT04087512|Experimental|Instrumented perturbation-based balance training|
32947632|NCT04087512|Experimental|Conventional perturbation-based balance training|
32947633|NCT04087512|No Intervention|Control|
32947634|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
32947635|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
32947636|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
32947637|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
33096903|NCT01248611|Experimental|fentanyl|cancer patients with pain
33096904|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
33312095|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
33312096|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
33312097|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
33312098|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
33312099|NCT01328912|Placebo Comparator|Control|
33312100|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
33312101|NCT01120340|Placebo Comparator|placebo|
33312102|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
33312103|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
33312104|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
33312105|NCT05682976||AD patient treated by Tralokinumab|AD patient treated by Tralokinumab
33312106|NCT01214408|Experimental|GRP-A|
33096905|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
33096906|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
33096907|NCT00501761||1: Endometrial Cancer Survivors|
33096908|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
33096909|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
33096910|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
33312107|NCT01214408|Experimental|GRP-B|
33312108|NCT01214486|Experimental|Raltegravir|
33312109|NCT05412550|Experimental|Exercise self-management|The EXP intervention will integrate conventional telehealth care with exercise self-management training and include structured 1:1 sessions (six) with an interventionist, peer group sessions (six), real-time step count feedback throughout the 18 months using a wrist-worn Fitbit with an LED interface, and tailored messaging with text messages designed using six key behavior-change techniques promoting exercise self-management.
33312110|NCT05412550|Active Comparator|Attention control|The CTL intervention will incorporate the annual multidisciplinary team telehealth sessions, 12 attention-control telehealth sessions (six individual, six peer-group), and general health education text message prompts to match the timing and duration of the EXP group.
33312111|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
33312112|NCT03710512||Control|patients not receiving hydroset at osteotomy site
33312113|NCT03936842|Experimental|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
33312114|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
33312115|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
33312116|NCT01219478||control|0 metabloil risk
33312117|NCT01219478||1|1 metabloil risk
33312118|NCT01219478||2|2 metabloil risk
33312119|NCT01219478||3|3 metabloil risk
33312120|NCT01214564|Experimental|1|Up to three days of treatment
33312121|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
33312122|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
33312123|NCT01216904|Placebo Comparator|Placebo patch|
33312124|NCT01216904|Active Comparator|Nicotine patch|
33312125|NCT05682898||More than 7 weeks|Timing of colorectal cancer surgery is more than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
33312126|NCT05682898||Less than 7 weeks|Timing of colorectal cancer surgery is less than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
33312127|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
33312128|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
33312129|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
33312130|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
33312131|NCT03935204|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
33312132|NCT03935204|Placebo Comparator|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
33312133|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
33312134|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
33312135|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
33312136|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
33312137|NCT03936764|Other|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
33312138|NCT03936764|Other|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
33312139|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
33312140|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
32947638|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
32947639|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
32947640|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
32947641|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
33312141|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
33312142|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
33312143|NCT05176444|Experimental|Music therapy intervention|Music therapy
32947642|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
32947643|NCT01507896|Experimental|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
32947644|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
33312144|NCT05176444|No Intervention|Control group - standard care|Standard care for residents with cognitive impairment. Staff will not receive music therapy training.
33312145|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
33312146|NCT01125254|Placebo Comparator|Controls|placebo
33312147|NCT01214876||Children 1-5 years old|
33312148|NCT01214876||Children 6-10 years old|
33312149|NCT01214876||Adults 25 years and above|
33312150|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
33312151|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
33312152|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
33312153|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
33312154|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
33312155|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
32947645|NCT01507662|No Intervention|Control|Those who received usual care
32947646|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
32947647|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
32947648|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
32947649|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
32947650|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
32956146|NCT05734040|Active Comparator|Fluarix Tetra at commercial dose + Placebo|"Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
33312156|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
33312157|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
33312158|NCT01120574|No Intervention|1|Oxygen therapy group.
33312159|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
33312160|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
33312161|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
33312162|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
33312163|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
33312164|NCT05682820||Patients with ACL tear|Patients with ACL tear- MRIs will be assessed
33312165|NCT05682820||Patients without ACL tear|Patients without ACL tear - MRIs will be assessed
33312166|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
33096911|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
32803073|NCT04397458|Experimental|Quadratus Lumborum Block|20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side
33312167|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
33312168|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
33312169|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
32803074|NCT04397146|Experimental|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
33312170|NCT05682586|No Intervention|standard therapy|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
33312171|NCT05682586|Active Comparator|Paxlovid treatment|Participants will receive paxlovid treatment on the basis of standard therapy.
33312172|NCT05682586|Experimental|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment.
33312173|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
32803075|NCT04398316|Experimental|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
33312174|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
33312175|NCT03710356|Experimental|Danazol|Danazol
33312176|NCT01125332|Placebo Comparator|group gel KY|
33312177|NCT01125332|Experimental|group gel lidocaine|
33312178|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
32803076|NCT04398316|Active Comparator|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
33312179|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
32803077|NCT01576575|Experimental|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.~Sessions 1&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)~Sessions 3&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine~Sessions 6&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
32803078|NCT05051566|Experimental|LY3502970 Prototype (Part A)|Multiple doses of LY3502970 prototype administered orally.
32803079|NCT05051566|Experimental|LY3502970 Reference (Part A)|Multiple doses of LY3502970 reference administered orally.
32803080|NCT05051566|Experimental|LY3502970 Prototype (Part B)|Multiple doses of LY3502970 prototype administered orally.
32803081|NCT05051566|Experimental|LY3502970 Reference (Part B)|Multiple doses of LY3502970 reference administered orally.
32803082|NCT05051566|Active Comparator|Esomeprazole (Part B)|Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.
32803083|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
32803084|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
32803085|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
32803086|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
32803087|NCT04276090|Experimental|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan, or panitumumab if KRAS/NRAS wild type)
32803088|NCT04276090|Experimental|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
32803089|NCT03451630|Active Comparator|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
32803090|NCT03451630|Active Comparator|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
32803091|NCT03451630|Active Comparator|Usual Care|Delivered via Health Plan support and resources within 14 days of an initial home or telephonic visit.
33312180|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
33312181|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
33312182|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
33312183|NCT03361228|Experimental|INCB001158 + Epacadostat|
33312184|NCT03936686|Active Comparator|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
33312185|NCT03936686|Active Comparator|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
33312186|NCT03936686|Active Comparator|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
33312187|NCT03936686|Active Comparator|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
33312188|NCT03936686|Active Comparator|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
33312189|NCT05175898||VA-ECMO|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
33312190|NCT05175898||ECMELLA|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
33312191|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
33312192|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
33312193|NCT05677438|Experimental|Test Group1|
33312194|NCT05677438|Experimental|Test Group2|
32803092|NCT04247464|No Intervention|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
32803093|NCT04247464|Experimental|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
32803094|NCT04241224|Experimental|Excimer Laser Photoablation|"Device: DABRA Laser System~Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System."
32803095|NCT04226248|Active Comparator|Active (Rivastigmine)|Rivastigmine Transdermal Patches
32803096|NCT04226248|Placebo Comparator|Placebo|Placebo Matched Transdermal Patches
33312195|NCT05677438|Experimental|Test Group3|
32803097|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
32803098|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
32803099|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
32803100|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
33312196|NCT05677438|Placebo Comparator|Placebo Group|
33312197|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
33312198|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
32803101|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
32803102|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
32803103|NCT04398004|Experimental|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
32803104|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
32803105|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
32803106|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
32803107|NCT03577990|Experimental|Interactive Technology Enhanced Coaching (ITEC)|Fitbit Plus monitoring will include BP, weight measurements, daily food intake, self-report medication-taking, and physical activity plus weekly Interactive Technology-Enhanced Coaching (ITEC) for 3 months, then biweekly ITEC for 3 months, followed by another 3 months with no coaching to assess for sustainability.
32803108|NCT03577990|Active Comparator|Interactive Technology-No Coaching (IT)|Participants will receive usual care for 3 months followed by 6 months of only Fitbit Plus monitoring (with no ITEC) of BP, weight measurements, daily food intake, self-report medication-taking, and physical activity to be used for comparative data with the treatment arm.
32803109|NCT04181320|No Intervention|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
32803110|NCT04181320|Experimental|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
32803111|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
32803112|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
32803113|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
32803114|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
32803115|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
32803116|NCT01801358|Experimental|Arm A|AEB071 and MEK162 combined
32803117|NCT01801358|Experimental|Arm B|MEK162 alone
32803118|NCT01807598|Experimental|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
32803119|NCT01801280|Active Comparator|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) b.i.d. every 12 hours for 2 weeks.
32803120|NCT01801280|Other|Mycophenolate mofetil+Pantoprazole (C+P)|Mycophenolate mofetil b.i.d and Pantoprazole o.m. for 2 weeks.
32803121|NCT01801280|Other|Mycophenolate sodium (M)|Mycophenolate sodium (M) b.i.d. every 12 hours for 2 weeks.
32803122|NCT01801280|Other|Mycophenolate sodium+Pantoprazole (M+P)|Mycophenolate mofetil b.i.d and Pantoprazole 40mg o.m. for 2 weeks.
32803123|NCT01769456|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
32803124|NCT01769378|Placebo Comparator|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
32803125|NCT01769378|Experimental|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
32803126|NCT01807520|Experimental|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
32803127|NCT01807520|Experimental|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
32803128|NCT01807520|Placebo Comparator|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
32803129|NCT01806896|Experimental|20 mg Arm Cohort A|
32803130|NCT01806896|Placebo Comparator|Placebo Arm Cohort A|
32803131|NCT01806896|Experimental|5 mg Arm Cohort B|
32803132|NCT01806896|Placebo Comparator|Placebo Arm Cohort B|
32803133|NCT01768676|Experimental|avanafil|100 mg
32803134|NCT01768676|Placebo Comparator|Placebo|placebo
32803135|NCT01555125|Experimental|secukinumab 150 mg|Drug
32803136|NCT01555125|Experimental|secukinumab 300 mg|Drug
32803137|NCT01555125|Placebo Comparator|placebo|
32803138|NCT01768286|Experimental|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
32803139|NCT01768286|Experimental|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
32803140|NCT01768286|Experimental|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
32803141|NCT01768286|Experimental|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
32803142|NCT01800968|Active Comparator|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
33312199|NCT05677048|No Intervention|Group 1 (Standard of Care Group)|Participants (probands, those with a hereditary cancer syndrome) are sent a family letter to share with relatives. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing.
32947651|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
32947652|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
33096912|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
33312200|NCT05677048|Experimental|Group 2 (Free genetic testing and counseling group)|Enrolled relatives receive a letter with information to access telegenetic counseling and genetic testing at no cost to the participant
33312201|NCT05677048|Experimental|Group 3 (IGNITE-TX Group)|"Enrolled relatives receive a letter with information to access the IGNITE-TX online educational Hub and access services of a family genetic navigator."
33312202|NCT05677048|Experimental|Group 4 (IGNITE-TX and free genetic testing and counseling group)|"Enrolled relatives receives a letter with information to access telegenetic counseling and genetic testing at no cost to the participant and information to access the IGNITE-TX online educational Hub as well as access to assistance from a family genetic navigator."
33312203|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
32947653|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
32947654|NCT01505868|Experimental|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
32947655|NCT01505868|Experimental|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
32947656|NCT01505634|Experimental|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
33312204|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
32947657|NCT01505634|Experimental|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
32947658|NCT01505634|Placebo Comparator|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
32947659|NCT04409730|Experimental|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
32947660|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
32947661|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
32947662|NCT04581798||Non-OSA|Patients without OSA aged 35-65
32947663|NCT01480596|Experimental|Belimumab|10mg/kg
32947664|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
32947665|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
32947666|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
32947667|NCT04409028|Active Comparator|indirect restoration|
32947668|NCT04409028|Active Comparator|direct restoration|
32947669|NCT04559334|Other|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
32947670|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
32947671|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
32947672|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
32947673|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
32947674|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
33312205|NCT03933488|Experimental|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
33312206|NCT03933488|Experimental|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
32947675|NCT01505010|Other|Control group|Standard antihypertensive drug treatment
32947676|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
32947677|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
33312207|NCT03933488|Experimental|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
33312208|NCT03933488|Experimental|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
33312209|NCT03933488|Experimental|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
32947678|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
32947679|NCT01458366|Experimental|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m^2 Ofatumumab, Carboplatin, and Etoposide
33312210|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
32947680|NCT01458366|Experimental|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m^2 Ofatumumab, Carboplatin, and Etoposide
32947681|NCT01458366|Experimental|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m^2 Ofatumumab, Carboplatin, and Etoposide
32947682|NCT01458366|Experimental|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m^2 Ofatumumab, Carboplatin, and Etoposide
32947683|NCT01458366|Experimental|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
32947684|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
32947685|NCT01478958|Active Comparator|high saturated fat diet|
32947686|NCT01478958|Experimental|high monounsaturated fat diet|
32947687|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
32947688|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
32947689|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
32947690|NCT01457352|Experimental|SPARC0921|
32947691|NCT01457352|Placebo Comparator|Placebo0921|
32947692|NCT01457118|Experimental|NKTR-102|
32947693|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
32947694|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
32947695|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
32947696|NCT01501110|No Intervention|no intervention|No intervention
32947697|NCT01500720|Experimental|Cabazitaxel|
32947698|NCT01500720|Active Comparator|Topotecan|
32947699|NCT04408872|Active Comparator|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
32947700|NCT04408872|Experimental|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
32947701|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
32947702|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
32947703|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
33096913|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
33096914|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
33096915|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
33096916|NCT00510549|Active Comparator|2, HD|Hemodialysis
33096917|NCT00510588|Other|1|regular physical exercise training
33096918|NCT00510588|Other|2|regular physical exercise training + metformin
33096919|NCT00510588|Other|3|regular physical exercise training + glitazon
33096920|NCT00510588|No Intervention|4|Control
33096921|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
33096922|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
33096923|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
33312211|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33312212|NCT05682508|Experimental|Education group|The training planned four step. In the first interview, a pre-test will be applied by the researcher. The patient will then be trained and given a training booklet. The second interview will take place 30 days after the end of the first training. The topics will be summarised and the benefits of adherence to diet and fluid control will be emphasised. The third interview will be held 30 days after the second interview. In this interview, the patient's questions will be answered and the necessary training sections will be explained again for patient. The issues that prevent the patient from complying with fluid and diet control will be discussed with the patient and positive developments in the patient prognosis will be reinforced. The last interview will be held 30 days after the third interview. In all interviews, data will be collected with data collection tools and clinical parameters of the patient will be recorded.
33312213|NCT05682508|No Intervention|Control grup|No training will be given to the control group. In the first interview will be applied data collection tools and will be recorded clinical parameters. Last interview with control group will be held 90 days after first interview. Data collection tools will be applied and clinical parameters will be recorded in last interview. The training booklet will be given also to patients in control group at the end of the research.
33096924|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
33096925|NCT02953236|Experimental|Instrumented massage|
33096926|NCT02953236|Active Comparator|Manual massage|
33096927|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
33096928|NCT00502034|No Intervention|B-follow-up|Wait-and-see
33096929|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
33096930|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
33096931|NCT00510666|Experimental|3|Premedication of Tramadol
33312214|NCT01219556||Group 1|
33312215|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
33312216|NCT01217528|Active Comparator|Group A|"Group A:~VT zone: 350ms~VF zone: 280ms"
33096932|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
33096933|NCT00510705|Other|1|Regular physical exercise training alone
33096934|NCT00510705|Other|2|Regular physical exercise training + metformin
33096935|NCT00510705|Other|3|Regular physical exercise training + glitazone
33312217|NCT01217528|Experimental|Group B|"Group B:~VT zone: 320ms~VF zone: 250ms"
32803143|NCT01800968|Placebo Comparator|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
33096936|NCT00510705|No Intervention|4|Control
33096937|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
33096938|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
33096939|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
33096940|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
33096941|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
33096942|NCT00502112|Experimental|1|lintuzumab and lenalidomide
33096943|NCT04695912|Other|Initial activity tracker with feedback followed by control period|Initial activity tracker with feedback followed by control period
33096944|NCT04695912|Other|Initial control period followed by activity tracker with feedback|Initial control period followed by activity tracker with feedback
33096945|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
33096946|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
33096947|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
33096948|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
33096949|NCT01249079||Schizophrenia Family|
33096950|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
33096951|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
33096952|NCT00502229|Active Comparator|Group A|Continuing treatment
33096953|NCT00502229|Active Comparator|Group B|Gonadotrophins
33096954|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
33096955|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
33096956|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
33096957|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
33096958|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
33096959|NCT01249196|Placebo Comparator|Placebo|
33096960|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
32947704|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
32947705|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
32947706|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
32947707|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
32947708|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
32947709|NCT04767438||Pregnant women|All singleton pregnancies that present to the 12-week scan in the Obstetrics Unit of the participant hospitals. Singleton pregnancies; Gestational age less than 14 weeks, estimated according to Crown-Rump Length (CRL); Blood sample between 8 and 14 weeks of pregnancy; Patients who accept to participate in the study and sign the informed consent.
32947710|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
32947711|NCT01455012|Placebo Comparator|Placebo|Placebo
32947712|NCT01454934|Experimental|Arm A|
32947713|NCT01454934|Active Comparator|Arm B|
32947714|NCT04408716|Experimental|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
32947715|NCT04408716|Active Comparator|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
32947716|NCT01454778|Experimental|Paclitaxel|
32947717|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
32947718|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
32947719|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
32947720|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
32947721|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
32947722|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
32947723|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
32947724|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
32947725|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
32947726|NCT01453374|Experimental|VIVITROL|380 mg IM injection
33096961|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
33096962|NCT01249196|Other|Donepezil|
32803144|NCT01799720|Experimental|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
32803145|NCT01799720|Experimental|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
32803146|NCT01799720|Experimental|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
32803147|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
32803148|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
32803149|NCT01806740|Experimental|Gadoterate meglumine|there is one single arm of patients (no comparative arm)
32803150|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
32803151|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
32803152|NCT01968967|Placebo Comparator|Placebo|
32803153|NCT01554579|Placebo Comparator|Sugar pill|
32803154|NCT01554579|Experimental|Gefapixant|
32803155|NCT01806662|Experimental|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
32803156|NCT01806662|Placebo Comparator|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
32803157|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
32803158|NCT01930123|Active Comparator|Health controls|15 healthy controls for comparison with NAFLD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
32803159|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
32803160|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
32803161|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
32803162|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
32803163|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
32803164|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
32803165|NCT04631263|Experimental|Treatment Group|
32803166|NCT04631263|No Intervention|Control Group|
33096963|NCT00510081|Experimental|1|subjects will receive filler injections
33096964|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
33096965|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
33312218|NCT05388838|Active Comparator|Negative control|uveitis patients with a diagnosis other than ocular diagnosis other than ocular lymphoma and without cerebral lymphoma (15 patients),
32947727|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
32947728|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
32947729|NCT01453140|Experimental|Cyclophosphamide and Sirolimus|cyclophosphamide and sirolimus combo
33312219|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvementand never treated|patients with primary ocular lymphoma without brain involvement and never treated (5 patients),
33312220|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvement and treated|patients with primary ocular lymphoma without brain involvement, treated and considered in remission (5 patients),
33312221|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvement in relapse|patients with primary ocular lymphoma without brain involvement, considered in relapse (5 patients),
33312222|NCT05388838|Active Comparator|Positive control|patients with cerebral lymphoma with or without ocular involvement and without uveitis (15 patients).
33312223|NCT01121198|Experimental|ASP1941 single arm|
33312224|NCT01121198|Experimental|ASP1941 repeated arm|
33312225|NCT01121198|Placebo Comparator|placebo single arm|
33312226|NCT01121198|Placebo Comparator|placebo repeated arm|
33312227|NCT05675488||Trigger Finger Patients|
33312228|NCT05675488||Healthy individuals|
33312229|NCT01121276|Experimental|NN1218, formulation A|
33312230|NCT01121276|Experimental|NN1218, formulation B|
33312231|NCT01121276|Experimental|NN1218, formulation C|
32947730|NCT01453140|Experimental|Lowdose IL-2, Cytoxan + Sirolimus|Low dose IL-2 with Cytoxan + Sirolimus Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
32947731|NCT01453140|Experimental|Lowdose IL-2, Vidaza, cyclophosphamide & Sirolimus|Lowdose IL-2, Vidaza, cyclophosphamide (Cytoxan) & Sirolimus Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).
32947732|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
32947733|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
32947734|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
32947735|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
32947736|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
32947737|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
32947738|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
32947739|NCT01496976|Experimental|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
32947740|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
32947741|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
32947742|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
32947743|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
32947744|NCT01475370|Experimental|OCV-501|
32947745|NCT04091646|Active Comparator|ARQ-154 foam 0.3%|active
32947746|NCT04091646|Placebo Comparator|ARQ-154 foam Vehicle|placebo
33312232|NCT01121276|Experimental|NN1218, formulation D|
33312233|NCT01121276|Active Comparator|insulin aspart|
33312234|NCT05682430|Active Comparator|Heart rate-based HIIT|12 weeks heart-rate based HIIT intervention.
33312235|NCT05682430|Experimental|VIFT speed-based HIIT with mechanical work|12 weeks VIFT speed-based HIIT with mechanical work.
33312236|NCT01214954|Active Comparator|Control group|Standard rehabilitation
33312237|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
33096966|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
33096967|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
33096968|NCT00510120|Active Comparator|2|Participants will receive parent management training.
33096969|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
33096970|NCT00502502||Symptom-Related Cytokines Questionnaire|
33096971|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
33096972|NCT01249391|No Intervention|Control|Observation and usual treatment only.
33096973|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
33096974|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
33096975|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
33096976|NCT05653973|Experimental|assessment of microvascular function|The investigators use intradermal microdialysis to deliver acetylcholine, acetylcholine + L-NAME, endothelin-1, endothelin-1 + BQ-788, and endothelin-1 + BQ-123 to the cutaneous microvasculature.
33096977|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
33096978|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
33096979|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
33096980|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
33096981|NCT00502541|Active Comparator|Standard of Care|Standard of care
33096982|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
33096983|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
33096984|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
33096985|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
33096986|NCT02955914||Optimism|Based on quality of life assessment
33096987|NCT02955914||Pessimism|Based on quality of life assessment
33096988|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
33096989|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
33096990|NCT00510978|Placebo Comparator|3|Placebo
33096991|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
33096992|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
33096993|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
33096994|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
33096995|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
33096996|NCT00510315||Women treated with SCT/TBI|
33096997|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
33096998|NCT02955992|No Intervention|standard of care|
33096999|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:~Preparation for the death : Prepare the relative for the patient's imminent death~During the dying and death process: The physician enters the patient's room at least once to check on the relatives~After the patient's death: the physician and the nurse meet the relative"
33097000|NCT00511017|Experimental|Doxercalciferol|
33097001|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
33097002|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
33097003|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
33097004|NCT00510354|Experimental|RAD001 + Imatinib|
33097005|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
33097006|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
33312238|NCT05175508|Experimental|Azacytidine Combined With ARTA|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle with ATRA 20mg tid by po on days 1-21 of every cycle 28 days
33312239|NCT05175508|Experimental|Azacytidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle
33312240|NCT01125410|Experimental|Dequalinium chloride 10mg|
33097007|NCT04695951|Experimental|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
33097008|NCT04695951|Placebo Comparator|Control|A total of 35 patients treated with the study product Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
33097009|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
33097010|NCT00510393|Experimental|1|drug eluting stent
33097011|NCT00510393|Placebo Comparator|2|Bare Metal Stent
33097012|NCT01249547|Experimental|axitinib arm|
33097013|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
33097014|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
33097015|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
33097016|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
33097017|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
33097018|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
33097019|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
33312241|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
33312242|NCT05646550|Experimental|Dose Escalation Part|In the dose escalation part, up to 7 dose cohorts will be included depending on occurrence of dose-limiting toxicity (DLT). Each dose cohort has a predefined day 3 dose level (DL): cohort 1, 78µg; cohort 2, 110µg; cohort 3, 150µg; cohort 4, 210µg; cohort 5, 300µg; cohort 6, 400µg; cohort 7, 600µg. Each dose cohort will consist of at least three patients evaluable for DLT. Maximum tolerated dose (MTD) is defined on at least six patients
33312243|NCT05646550|Experimental|Dose Expansion Part|CC-1 is administered as a 3-hour short-term intravenous infusion started at the MTD dose level identified in the dose escalation part of the study or based on the discretion of the sponsors delegate and DSMB recommendation supported by preliminary safety and efficacy data to constitute a modified MTD, e.g. to be one or more dose levels lower than the MTD determined. Patients can be treated simultaneously during the dose expansion phase. Patients must be hospitalized during step dosing, i.e. from day 1-4 (last dosing on day 3) of the first cycle. Thereafter inpatient treatment (overnight stay) depends on the discretion of the investigator, an outpatient treatment is preferred.
33312244|NCT03933332||Ventilator length of use|measured in days
33312245|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
33097020|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
33312246|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
33097021|NCT00504686|Active Comparator|2|therapeutic exercise
33097022|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
33097023|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
33097024|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
33097025|NCT00511368|Placebo Comparator|1|placebo
33097026|NCT00511368|Experimental|2|Bevirimat
33097027|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
33097028|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
33097029|NCT00511407|Experimental|I|RAD Treatment
33097030|NCT00511407|No Intervention|II|Conventional CVVHD
33097031|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
33097032|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
33097033|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
33312247|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
33312248|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
33097034|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
33097035|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
33097036|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
33097037|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
33097038|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
33097039|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
33097040|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
33097041|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
33097042|NCT01249781||resilience in caregivers whose child with ALL|
33097043|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
33097044|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
33097045|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
33097046|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
33312249|NCT05097820||Cisgender patients|All cisgender patients in which one or two testicular prostheses are to be implanted for various reasons.
33312250|NCT05097820||Transgender patients|All transgender patients in which one or two testicular prostheses are to be implanted for gender reassignment surgery.
33312251|NCT01121354|Experimental|Cefazolin 2g (Test)|
33312252|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
33312253|NCT01122602|Experimental|Arm 1|
33312254|NCT01122602|Active Comparator|Arm 2|
33312255|NCT01122602|Placebo Comparator|Arm 3|
33312256|NCT03935048|Experimental|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
33312257|NCT03935048|Active Comparator|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
33312258|NCT03935048|Placebo Comparator|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
33097047|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
33097048|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
33097049|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
33097050|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
33097051|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
33097052|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
33097053|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
33097054|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
33097055|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
33097056|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
33097057|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
33097058|NCT01249859||Signet ring cell carcinoma|
33097059|NCT01249859||non signet ring cell adenocarcinoma|
33097060|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
33097061|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
33312259|NCT03359590|Experimental|Sitagliptin arm|Sitagliptin 100 mg
33312260|NCT03359590|Placebo Comparator|Placebo arm|Placebo comparator
33097062|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
33097063|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
33097064|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
33097065|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
32803167|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg(milligrams per kilogram) initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
32803168|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
32803169|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
32803170|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
33097066|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
33312261|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
33097067|NCT00512967||sarcoidosis|21 onset patients, non-treated
33097068|NCT00512967||IPF|15 IPF patients, partially treated
33097069|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
33097070|NCT00512967||controls|25 healthy controls, matched for age and gender
33097071|NCT04519073|Placebo Comparator|Placebo|0.5 mL of diluent (phosphate buffer)
32803171|NCT01806584|Active Comparator|SRM003|
33097072|NCT04519073|Experimental|V-306 low dose|V-306 at 15 µg
33097073|NCT04519073|Experimental|V-306 intermediate dose|V-306 at 50 µg
33097074|NCT04519073|Experimental|V-306 high dose|V-306 at 150 µg
32803172|NCT01806584|Other|Participating Site's standard practice|
33312262|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
33312263|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
33312264|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
32803177|NCT01798706|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
32803178|NCT01798706|Placebo Comparator|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
32803179|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
32803180|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
33097075|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
33097076|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
33097077|NCT00504296|Experimental|SB939|
33097078|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
33097079|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
33097080|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
33097081|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
33097082|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
33097083|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
33097084|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
33097085|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
33097086|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
33097087|NCT04516577||Nanjing Drum Tower Hospital|The Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital has been focusing on the research of rare pulmonary diseases for many years.
33097088|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
33097089|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
33097090|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
33097091|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
33312265|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
33312266|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
32803181|NCT04397926|Experimental|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
32803182|NCT01767194|Experimental|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
32803183|NCT01767194|Experimental|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
33312267|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
32803184|NCT03091192|Experimental|Savolitinib|See: intervention description
33312268|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
33312269|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
33312270|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
33312271|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
33312272|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
33312273|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
33312274|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
33312275|NCT05378464|Experimental|T-Cell therapy dose level 1|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8, IL-7 and Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8.
32803185|NCT03091192|Active Comparator|Sunitinib|See: intervention description
32803186|NCT04398784|Other|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
32803187|NCT04398784|Other|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
32803188|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
32803189|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
32803190|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
32803191|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
32803192|NCT04135066|Other|Refined grain breakfast|white bread (100g) + milk powder (25g)
32803193|NCT04135066|Other|Whole grain breakfast|plain oats (70g) + milk powder (25g)
32803194|NCT04276636|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
32803195|NCT04276636|No Intervention|Control|The other group do not interfere.
32803196|NCT04397224||CRT responder|
32803197|NCT04397224||CRT non-responder|
32803198|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
32803199|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
32803200|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
32803201|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
32803202|NCT04277026|Experimental|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
32803203|NCT04277026|No Intervention|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
32803204|NCT00002644|Experimental|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
32803205|NCT00002644|Placebo Comparator|Placebo|Placebo 20 mg/day for 5 years
32803206|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
32803207|NCT04120402|Experimental|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
32803208|NCT04120402|Placebo Comparator|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
32803209|NCT03921801|No Intervention|Control|14-week control period.
32803210|NCT03921801|Experimental|Intervention|14-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
32803211|NCT03921801|No Intervention|Young adults - control|Outcome measures obtained at a single time point. The data is used to compare outcome measured between older and young adults.
32803214|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
33312276|NCT05378464|Experimental|T-Cell therapy dose level 2|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9.
33312277|NCT05378464|Experimental|T-Cell therapy dose level 3|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9.
33312278|NCT05378464|Experimental|T Cell therapy dose expansion|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with CD4 treated t-cells at the maximum tolerated dose determined.
33312279|NCT01121432||Mediastinal lymphadenopathy|
33312280|NCT03936062||2nd Generation SUs|Reference group
33312281|NCT03936062||Sitagliptin|Exposure group
33312282|NCT05682274|Active Comparator|Group I|Partial restoration with the apical border at the level of CEJ in combination with CAF+CTG
33312283|NCT05682274|Active Comparator|Group II|Partial restoration with the apical border within 1 mm apical to the CEJ.
33312284|NCT01215266|Active Comparator|Sorafenib|
33312285|NCT01215266|Placebo Comparator|Placebo|
32738024|NCT05009433|Experimental|Nonpregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
32803215|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
32803216|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32803217|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
32803218|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
32803219|NCT04112758|Experimental|Exercise group|The group will receive twice a week for 5 week
32803220|NCT04112758|No Intervention|Control group|The group will be maintained their normal after school activities
32803221|NCT04087642|Experimental|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.~In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly."
32947747|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
32947748|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
32947749|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
32947750|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
32947751|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
32947752|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
32947753|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
32947754|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
32947755|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
32947756|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
32947757|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
32947758|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
32947759|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
32947760|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
32947761|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
32803222|NCT04087642|Active Comparator|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.~In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly."
33097092|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
33312286|NCT05682196|Experimental|Rituximab plus standard of care (RTX)|Rituximab i.v of two perfusions (375 mg/m²) administered in a 14 day-interval added to a standard of care treatment
33312287|NCT05682196|Active Comparator|Standard of care treatment (Control)|Standard of care treatment
33312288|NCT03936374|Experimental|BMS-986205 + Omeprazole|
33312289|NCT05366920|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
33097093|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
33312290|NCT05366920|Active Comparator|5 mm suction irrigation blunt dissection|Laparoscopic cholecystectomy made with 5mm suction irrigation blunt dissection starting from gallbladder fundus Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
33312291|NCT01219790|Experimental|irradiation + zometa|
33312292|NCT05682040|Other|Active|
33312293|NCT03936296|Active Comparator|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
33312294|NCT03936296|Other|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
33097094|NCT00513045|No Intervention|Waiting list|Waiting list
33097095|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
33097096|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
33097097|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
33097098|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
33097099|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
33312295|NCT05085964|Other|QR421a RNA antisense oligonucleotide for intravitreal injection|There is only one treatment arm in the PQ-421a-002 study; All participants that are eligible to be dosed will receive QR-421a in an open label fashion.
33097100|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
33097101|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
33097102|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
33097103|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
33097104|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
33097105|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
33097106|NCT01244438|Experimental|FP-1039|FP-1039
33097107|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
33097108|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
33312296|NCT01215500|Experimental|Radiation therapy|
33312297|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
33312298|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
33312299|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
33312300|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"HMBD-002 administered as a 60-minute IV infusion at escalating doses in combination with pembrolizumab. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle."
33312301|NCT05082610|Experimental|Part 2 - Dose Expansion (Monotherapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion as a monotherapy in patients with TNBC or NSCLC.
33097109|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
33097110|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
33097111|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
33097112|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
33097113|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
33097114|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
33097115|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
33097116|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
33312302|NCT05082610|Experimental|Part 2 - Dose Expansion (Combination Therapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose in patients with TNBC or NSCLC.
33312303|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
33312304|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
33312305|NCT01215656|Active Comparator|Control|follow on formula without probiotics
33312306|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
33312307|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
33312308|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
33312309|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
33312310|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
33312311|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
32947762|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
32947763|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
33312312|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
32947764|NCT01475136|Experimental|LY2140023|A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.
32947765|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
32947766|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
33312313|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
33312314|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
32947767|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
32947768|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
32947769|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
32947770|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
32947771|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
32947772|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
32947773|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
32947774|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
32947775|NCT04074798|Active Comparator|Patients with low back pain|
32947776|NCT04074798|Sham Comparator|Healthy controls|
32947777|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
32947778|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
32947779|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
32947780|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
32947781|NCT01473732|Experimental|Everolimus (Zortress)|
32947782|NCT01473732|Active Comparator|Reduced dose Tacrolimus (Prograf)|
32947783|NCT01450098|Experimental|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
32947784|NCT01450098|Experimental|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
32947785|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
32947786|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
32947787|NCT01449630|Experimental|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
32947788|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
32947789|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
32947790|NCT01493778|Experimental|turoctocog alfa|
32947791|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
32947792|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
32947793|NCT04674774|Experimental|tegoprazan based bismuth quadruple therapy group|tegoprazan based bismuth quadruple therapy group
32947794|NCT04674774|Active Comparator|PPI based bismuth quadruple therapy group|PPI based bismuth quadruple therapy group
32947795|NCT01492686|Experimental|Arm 1|
33097117|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
33097118|NCT02951871||LP: Lymphoma Progression|
33097119|NCT02951871||TRM: Treatment Related Mortality|
33097120|NCT02951871||NHM: Non hematologic malignancy|
33097121|NCT02951871||OC: Other Cause|
32803223|NCT04746352|Experimental|BES-SMFR group|Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs. (b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs. (c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
32803224|NCT04746352|Active Comparator|BES group|"A standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.~Patients were required to participate in intensive training regarding myofascial release techniques. (I) Pressing: press directly on a specific MTrP with gentle, slow pressures (2kg/cm2) using a flat palpation, the pressure was sustained until the participant perceived the pain decreased and taut band released, and then gradually increased to previous level of MTrPs tension and maintained until a reduction of pain again. The process was usually 3 to 5 repetitions for 90 sec. (II) Stretching: stretch in parallel to the direction of the myofascial to facilitate elongation of a contracted muscle. (III) Strumming: stroking and strumming the affected muscles region with the fingertips to aid in MTrPs tension release, the initial pressure was small and increased gradually until the patients adapted."
32803225|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
32803226|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
32947796|NCT01492686|Placebo Comparator|Arm 2|
33097122|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
33097123|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
33097124|NCT01243658|Experimental|Oxytocin|Oxytocin
33097125|NCT01243658|Placebo Comparator|Placebo|Placebo
32947797|NCT04409496|Experimental|Intervention group|Chat-based instant messaging support + Self-help booklet
32947798|NCT04409496|Active Comparator|Control group|SMS message support + Self-help booklet
32947799|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
32947800|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
32947801|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
32947802|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
32947803|NCT04085172|Experimental|Part A: Guanfacine hydrochloride (TAK-503)|Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet once daily (QD) for 52 weeks.
32947804|NCT04085172|Active Comparator|Part A: Atomoxetine hydrochloride|Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 52 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 52 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
32947805|NCT04085172|Placebo Comparator|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for first 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of first 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
33312315|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
33312316|NCT05577988|No Intervention|Control arm|Standard of Care : Systematic de-escalation to a high potency antiplatelet single therapy
32803227|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
33312317|NCT05577988|Other|Intervention arm|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
33312318|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
32803228|NCT03164122|Experimental|Intra-articular injection|
33312319|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
33312320|NCT01222052|No Intervention|Observation|
33312321|NCT05174416|Experimental|Mavacamten|Mavacamten Capsules
33312322|NCT05174416|Placebo Comparator|placebo|Matching Placebo Capsules
33312323|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
33312324|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
33312325|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
33312326|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
33312327|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
33312328|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
32803229|NCT04397770|Experimental|Camre+Apa+TMZ|
32803230|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
32803231|NCT03213418|Experimental|Contingency management|
32803232|NCT02929810|Experimental|sleep extension|
32803233|NCT02929810|Active Comparator|sleep maintenance|
32956147|NCT05734040|Active Comparator|Afluria Quad at commercial dose + Placebo|"Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
32956148|NCT05734040|Placebo Comparator|OVX836 480µg + Placebo|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
32956149|NCT05734040|Placebo Comparator|Placebo + Placebo|Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
32956150|NCT05733689|Experimental|Neoadjuvant chemotherapy with ctDNA testing|"The patients will be treated with one of the standard neoadjuvant protocols (FLOT or FOLFOX.) If no decline in ctDNA detected after 4 cycles, treatment will be switched to a different chemotherapy backbone (e.g. irinotecan based regimen, or taxane based if not used upfront).~ctDNA will be re-evaluated after 3 cycles (if a 21 day regimen) or 4 cycles (if a 14 day regimen) of the 2nd line regimen. If ctDNA is lower than the previous measurement, then the same regimen continues for 3-4 more cycles (depending on 14 day or 21 day cycle), followed by gastrectomy. Adjuvant treatment is given based on the investigator's discretion."
32956153|NCT05731726|Experimental|Serplulimab+CAPEOX+celecoxib|articipants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w and celecoxib, 200mg, PO, BID, day1-21, q3w. Treatment repeats every 3 weeks for 6-8 cycles followed by surgery (total mesorectal excision, TME).
32956154|NCT05730829|Experimental|Pain Informed Movement and pain neuroscience education|Participants will receive a twice weekly, 8 week in-person group exercise program, consisting of exercise instruction (75 minutes) and pain neuroscience education (PNE) videos (20 to 30 minutes/week for the first 4 weeks). During the exercise sessions, the educational components and concepts such as mindfulness, muscle tension regulation, and breathing techniques will be applied by the instructor. A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component will be delivered by an experienced yoga teacher that has been extensively trained. The PNE video component will cover the following topics: The purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
33097126|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.~Amoxicillin 250 mg , three times daily for five days."
33097127|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
33097128|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
33097129|NCT01249664|Experimental|Arm 1|
33097130|NCT01249664|Sham Comparator|Arm 2|
33097131|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
33097132|NCT04513418|Experimental|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion during the neoadjuvant chemoradiotherapy. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
33097133|NCT04513418|No Intervention|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
32803234|NCT05249764|Active Comparator|Exercise|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
33097134|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
33097135|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
33097136|NCT04510727|Experimental|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
33097137|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
33097138|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
33097139|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
33097140|NCT00513396|Experimental|1|
32803235|NCT05249764|Active Comparator|Control|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
32803236|NCT05247034|Experimental|Intervention group|Diet for patients with diabetes + 4 capsules of cocoa powder, 500 mg each, daily for 12 weeks.
32803237|NCT05247034|Placebo Comparator|Control group|Diet for patients with diabetes + 4 capsules of methylcellulose 500 mg each, daily for 12 weeks.
32803238|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
32803239|NCT04276324|Active Comparator|Control Group|Only testing sessions
32803240|NCT04276324|Experimental|Resistance training group|Ten weeks of resistance training
33097141|NCT00513396|Active Comparator|2|
32803241|NCT05240482|Placebo Comparator|Conventional treatment group|Patients in the placebo group will receive bilateral ST36 injection with normal saline 1ml/point
32803242|NCT05240482|Experimental|ST36 acupoint injection group|Patients in the experimental group will receive bilateral ST36 injection with anisodamine 1ml/point
32803243|NCT05249998|Experimental|Interventional group|"Patients will receive the usual care, with the intervention of the multidisciplinary team which defines with the patient the objectives of the stay and the inter-stay period, without specific therapeutic education on adapted physical activity, nutrition and eating behaviour."
32803244|NCT05249998|No Intervention|Standard care group|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
32803245|NCT04746118|No Intervention|CONTROL|During routine clinical visits the patients will receive a written standard general guidelines for diet and physical activity.
33097142|NCT00513396|Placebo Comparator|3|
33097143|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
33097144|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
33097145|NCT00512304|Experimental|Preoperative chemoradiotherapy|
33097146|NCT00512304|Experimental|Postoperative chemoradiotherapy|
33097147|NCT04695834|Active Comparator|Conservative treatment|"Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached.~If necessary, cross-over can occur after primary endpoint is reached.~Conservative treatment is considered standard of care."
33097148|NCT04695834|Active Comparator|Surgical treatment|"Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days).~Neurolysis is considered standard of care."
32803246|NCT04746118|Experimental|DIET CHANGE|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive a written general guidelines for exercising without supervision.
32803247|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision.
32803248|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY + INTEGRATIVE PRACTICES|"In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision and submitted to orientated mind-fullness, auriculotherapy and laying on of hands approaches that belong to health integrative practices."
32803249|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT) Group|Participants undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
33097149|NCT04695756||People who require liver transplant|We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
33097150|NCT00512382||A|Babies and small children 1-24 months
33097151|NCT00512382||B|Children 2-18 years old
33097152|NCT00512421||A|navigation technique
33097153|NCT00512421||B|conservative surgery
33097154|NCT00512421||C|Historical control
33097155|NCT00512460|Experimental|RTA 744|
33312329|NCT05082220|Experimental|10 ml ESPB group|ESPB group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
33312330|NCT05082220|Experimental|20 ml ESPB group|ESPB group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
33312331|NCT01122758||COPD cohort|"Inclusion criteria:~Patients ≥ 35 years.~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).~Being in a stable phase of disease (8 weeks without exacerbation).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Recent exacerbation (<8 weeks).~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
33312332|NCT01122758||Control cohort|"Inclusion criteria:~Patients ≥ 35 years.~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
33312333|NCT05681806|Experimental|Treatment High Dose|Subjects consuming 1000mg LMP Creatine + 500mg Carnipure crystalline 1x/day
33312334|NCT05681806|Experimental|Treatment Low Dose|Subjects consuming 500mg LMP Creatine + 500mg Carnipure crystalline 1x/day
33312335|NCT05681806|Active Comparator|Active Control|Subjects consuming 5g creatine monohydrate 1x/day
33312336|NCT01219868|Experimental|Physician-nurse team|
33312337|NCT05160142|Experimental|Intervention|Participate in the DICE program, which entails culinary and diabetes educational programming delivered weekly for 10 consecutive weeks.
33312338|NCT03932006|Experimental|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
33312339|NCT03932006|Experimental|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
33312340|NCT03932006|Active Comparator|Imrecoxib|Imrecoxib 0.1g twice a day,orally
33312341|NCT04737226|Experimental|Basketballers|
33312342|NCT04737226|Experimental|Volleyballers|
33312343|NCT04737226|Experimental|Runners|
33312344|NCT01222364|Active Comparator|Standard Cord Clamping|
33312345|NCT01222364|Experimental|Delayed Cord Clamping|
33312346|NCT05155540|Active Comparator|Direct mechanical thrombectomy|Direct mechanical thrombectomy performed within 4.5 of stroke onset without giving intravenous recombinant tissue plasminogen activator.
33312347|NCT05155540|Active Comparator|Bridging therapy|Mechanical thrombectomy performed within 4.5 of stroke onset after giving intravenous recombinant tissue plasminogen activator at a dose of 0.9 mg/Kg
33312348|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
33312349|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
33312350|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
33312351|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
33312352|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
33312353|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
33312354|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
33312355|NCT05155384|Experimental|biopsychosocial model-based treatment|Biopsychosocial model-based management will be applied including pain neuroscience education, functional exercises, and relaxation training.
33312356|NCT05155384|Active Comparator|Conventional physiotherapy|Conventional physiotherapy will be applied including standard exercises and electrical stimulation.
33312357|NCT03933176|Experimental|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
33097156|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
33097157|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
32803250|NCT02783716|Active Comparator|Control Group|Participants undergoing device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
32803251|NCT03145168|Experimental|High Target Mean Arterial Pressure|
32803252|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
32803253|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
32803254|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
32803255|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
32803256|NCT02397226|Active Comparator|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
32803257|NCT02397226|Active Comparator|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
32803258|NCT05249140|Experimental|Active Repetitive Transcranial Magnetic Stimulation|rTMS parameters are intensity 110% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations), targeting the right DLPFC. To target the dorsolateral prefrontal cortex (DLPFC) for rTMS treatment we will use the traditional method (i.e. the 5cm rule; George et al., 1995, 1996; Herwig et al., 2001, 2003; MacMaster et al., 2019), in which the TMS coil is placed 5 cm anterior to the participant's motor cortex along a line to the nasion. Treatments will occur on weekdays at the same time of day for 4 weeks (20 total).
32803259|NCT05249140|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|For the sham rTMS group, a sham coil is used: this sham method does not emit any magnetic field, and therefor does not affect brain activity, but it does produce auditory sensations that is indistinguishable from active rTMS in naïve subjects
32803260|NCT05249920|Experimental|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
32803261|NCT05249920|Placebo Comparator|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days.
32803262|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
32803263|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
32803264|NCT05241808|No Intervention|Control|No-treatment group that only participates in pre- and post-testing.
32803265|NCT05241808|Experimental|Experimental|Experimental group participants will receive the 8-week Girls Can...Move! program.
32803266|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
32803267|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
32803268|NCT01609790|Experimental|Arm I (bevacizumab and trebananib)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32803269|NCT01609790|Active Comparator|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
32803270|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32803271|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
32803272|NCT01574703|Experimental|placebo|
32803273|NCT01574703|Experimental|varenicline|
32803274|NCT01574703|Experimental|bupropion|
32803275|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
32803276|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
32803277|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
32803278|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
32803279|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
33312358|NCT03933176|Active Comparator|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
32803280|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
32803281|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
33097158|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
33097159|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
33097160|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
33097161|NCT00504959|Experimental|1|ranibizumab
33097162|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
33097163|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
33097164|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
33097165|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
33097166|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
33097167|NCT04695561|Experimental|Self Myofascial Relaxation|In addition to the exercises applied to the participants in the control group, the participants in this group used Foam Roller, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
33097168|NCT04695561|Experimental|Instrument Assisted Soft Tissue Mobilization|In addition to the exercises applied to the participants in the control group, the participants in this group used Instrument Assisted Soft Tissue Mobilization, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
33097169|NCT04695561|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the hip flexors, hip extensors and iliotibial band were shown to the participants in the control group for 6 weeks every day of the week.
33097170|NCT04512794|Other|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
33097171|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
33097172|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
33097173|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
32803282|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
32803283|NCT04545723|No Intervention|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
33097174|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
33312359|NCT05154526|Experimental|Exercise Group|Exercise Program only
33312360|NCT05154526|Active Comparator|Manual Therapy Group|Manual Therapy only
33312361|NCT05154526|Active Comparator|Manual Therapy and Exercise Group|Manual Therapy + exercise program
33312362|NCT05360758||Patients diagnosed with CLL with treatment criteria, first line or relapsed/refractory.|
33312363|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
32803284|NCT04545723|Active Comparator|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
32803285|NCT04413669|Experimental|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history> 400 years).Biopsy was taken for abnormal bronchial mucosa.
32803286|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
33312364|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
33312365|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
32947806|NCT04085172|Experimental|Part B: Guanfacine hydrochloride (TAK-503)|Participants from Part A roll over into Part B, where participants received placebo in Part A will roll over after first 18 weeks and participants received TAK-503 or atomoxetine will roll over after 52 weeks of Part A. During Part B all the participants will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
33097175|NCT00512655|No Intervention|2|Usual care.
33097176|NCT00505037|Experimental|ASP1585 dose #1|
33097177|NCT00505037|Experimental|ASP1585 dose #2|
33097178|NCT00505037|Experimental|ASP1585 dose #3|
33097179|NCT00505037|Placebo Comparator|Placebo|
32947807|NCT04748406|Active Comparator|Peloid Therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week(16).
32947808|NCT04748406|Active Comparator|ESWT(Extracorporeal Shock Wave Therapy)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied(4).
32947809|NCT04083534|Experimental|REGN5459|Cohorts of multiple REGN5459 dose levels
32947810|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
32947811|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
32947812|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
32947813|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
32947814|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
32947815|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
32947816|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
32947817|NCT01490814|Active Comparator|Cryoballoon ablation|
32947818|NCT01490814|Active Comparator|Radiofrequency ablation|
33097180|NCT00505037|Active Comparator|Sevelamer hydrochloride|
32947819|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
32947820|NCT01490580|Experimental|Atropine + Propofol|
32947821|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
32947822|NCT01490190|Experimental|NuvaRing|
32947823|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
32947824|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
32947825|NCT01445886|Experimental|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
32947826|NCT01445886|Active Comparator|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
32947827|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
32947828|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
32947829|NCT01445730|Experimental|After fructose feeding|After 3 month fructose diet 75 g/day
32947830|NCT04073706|Experimental|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG) (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
32947831|NCT04073706|Active Comparator|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
32947832|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
32947833|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
32947834|NCT04073316|Experimental|"Intervention group"|
32947835|NCT04073316|Active Comparator|"Control group"|
33097181|NCT00513552|Experimental|Antibiotics|Antibiotics
33097182|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
33097183|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
33097184|NCT00513591||1|Women with lupus
33097185|NCT00513591||2|Health women who are matched to women with lupus by age and race
33097186|NCT00513591||3|Women with other autoimmune diseases
33097187|NCT00513630|Active Comparator|metformin|
33404666|NCT05077930|Experimental|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Centro de Hematologia e Hemoterapia do Paraná - Hemepar following national blood donation guidelines and Brazilian Health Regulatory Agency (ANVISA) criteria. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined. Participants will receive the standard of care treatment and a single unit of convalescent plasma (volume=200 mL or 400 mL).
33404667|NCT05077930|Active Comparator|Standard of care|Standard of care treatment according to the institutional protocol.
33097188|NCT00513630|Active Comparator|glipizide|
33097189|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
33097190|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
33097191|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
33097192|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
33097193|NCT04696679||Very preterm children group|
33097194|NCT04696679||Control group|
32803287|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
32803288|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
33097195|NCT04515719|Experimental|Belimumab 2mg/kg|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
33097196|NCT04515719|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
33404668|NCT05077696||Patients with progressive motor neuron disease without definite diagnosis|Patients with progressive motor neuron disease without definite diagnosis
33404669|NCT05077618||patients with Alzheimer's disease|47 cases (patients with Alzheimer's disease)
32803289|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
32803290|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
32803291|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
33404670|NCT05077618||patients without Alzheimer's disease|47 patients without Alzheimer's disease
32803292|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
32803293|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
32803294|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
32803295|NCT03180034|Experimental|Arm I (Gardasil, DTaP)|Participants receive Gardasil IM at month 0 and DTaP IM at month 6.
32803296|NCT03180034|Experimental|Arm II (Cervarix, DTaP)|Participants receive Cervarix IM at month 0 and DTaP IM at month 6.
32803297|NCT03180034|Active Comparator|Arm III (Gardasil)|Participants receive Gardasil IM at month 0 and 6.
32803298|NCT03180034|Active Comparator|Arm IV (Cervarix)|Participants receive Cervarix IM at month 0 and 6.
32803299|NCT03180034|No Intervention|Arm V (epidemiologic survey)|A concurrent epidemiologic survey for HPV status among two groups of unvaccinated women. Survey participants are followed for two study visits six months apart to determine their HPV DNA status, with no further follow-up. These women will be offered HPV vaccination (Cervarix) at the two study visits.
32803300|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
32803301|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
32803302|NCT03141424|No Intervention|Group A|Usual care. Unchanged asthma medication during the entire study period.
32803303|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
32803304|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
32803305|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
32803306|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
32803307|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
32803308|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
33097197|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
33097198|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
33097199|NCT04516070|Experimental|Treatment (SRS)|Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
33097200|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
33097201|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
33097202|NCT04518254|Experimental|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
33097203|NCT04518254|Experimental|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
33097204|NCT04518254|Experimental|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
33097205|NCT04518254|Experimental|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
33097206|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
33097207|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
33097208|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
33097209|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
33097210|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
33097211|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
33097212|NCT00512850|Other|Placebo|Placebo pill once per day
33097213|NCT04695522|Experimental|Group of subjects undergoing cell transplantation|
33097214|NCT04695522|Sham Comparator|Group of subjects undergoing sham operation|
33097215|NCT00512889|Experimental|Cohort 1|Different dose of CTL
33097216|NCT00512889|Experimental|Cohort 2|Different dose of CTL
33097217|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
33097218|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
33097219|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
33097220|NCT04695405||Treatment-Resistant Depression|Patients, who previously received intravenous ketamine, will be asked to provide genetic samples in order to assess relationships between response and genetic markers.
33097221|NCT02951442|Experimental|Renal Transplant|
33097222|NCT04696523|Active Comparator|Air/Oxygen|Control arm: air/oxygen with standard of care
33097223|NCT04696523|Experimental|xenon|Xenon arm: xenon inhalation in air/oxygen with standard of care
33097224|NCT00505154|Placebo Comparator|2|Placebo tablets
33097225|NCT00505154|Active Comparator|1|rosuvastatin
33097226|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
33097227|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
33097228|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
33097229|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
33097230|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
33097231|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
33097232|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
33097233|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
33097234|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
33097235|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
33097236|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
33097237|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
33097238|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
33312366|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
33097239|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
33097240|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
33097241|NCT00514059|Other|1|
33097242|NCT00514761|Active Comparator|1|Xeloda
32803309|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
33097243|NCT00514761|Experimental|2|AZD6244
33097244|NCT04514315||Minimally invasive aortic valve surgery|Patients undergoing minimally invasive aortic valve surgery
33097245|NCT04514315||Minimally invasive mitral valve surgery|Patients undergoing minimally invasive mitral valve surgery
33097246|NCT04514315||Conventional aortic valve surgery|Patients undergoing conventional aortic valve surgery
33097247|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
33097248|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
32803310|NCT04276480|Experimental|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
32803311|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
32803312|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
33097249|NCT04695600|Experimental|Botulinum toxin arm|100 units of botulinum toxin (Botox, Allergan, CA) diluted in 2.5 mL of normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Botulinum toxin will be injected into the muscle in four aliquots into each quadrant using 23 G needle (160cm). Post procedure patient will be observed for an hour for any untoward adverse event
33097250|NCT04695600|Placebo Comparator|Placebo arm|2.5 mL of Normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Post procedure patient will be observed for an hour for any untoward adverse event
33097251|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
33097252|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
33312367|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
33312368|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
33312369|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
33312370|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
32803313|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
32803314|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
32803315|NCT04276402|Experimental|Right side of the maxilla|
32803316|NCT04276402|No Intervention|Left side of the maxilla|
32803317|NCT01574157|Active Comparator|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
32803318|NCT01574157|Placebo Comparator|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
32803319|NCT04276246|Experimental|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
33097253|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
33097254|NCT00514800|Active Comparator|Control|
33097255|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
33097256|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
33404671|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
33404672|NCT05387512||Camrelizumab treatment group|The primary treatment is Camrelizumab combined with Pemetrexed and Platinum, secondary treatment with standard chemotherapy after progression. Reference regimen of Camrelizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
33097257|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
33097258|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
33097259|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
33097260|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
33097261|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
33097262|NCT01245062|Experimental|GSK1120212|MEK inhibitor
33097263|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
33097264|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
33097265|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
33097266|NCT04695717|Placebo Comparator|Vaccine|Received two doses of IVACFLU-S vaccine intramuscularly in children aged 6 months to under 9 years old and one dose of IVACFLU-S vaccine in children from 9 years old to under 18 years old adult over 60 years old
33097267|NCT04695717|Other|Placebo|Received two doses of placebo intramuscularly in children aged 6 months to under 9 years old and one dose placebo in children from 9 years old to under 18 years old adult over 60 years old
33097268|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
33097269|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
33097270|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
33097271|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
32803320|NCT04276246|Experimental|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
32803321|NCT05247892|Active Comparator|Fluoroscopic-guided S1 Radiofrequency stimulation|
32803322|NCT05247892|Experimental|Ultrasound-guided S1 Radiofrequency stimulation|
32803323|NCT05245708|Experimental|oxytocin|a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
32803324|NCT05245708|Experimental|placebo|a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
32803325|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
32803326|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
32803327|NCT05249686|Experimental|Manual Therapy + Dry Needling|
32803328|NCT05249686|Active Comparator|Manual Therapy|
32803329|NCT05249686|No Intervention|Control|The control group received only the dentist´s usual advice after endodontic surgery.
33097272|NCT04695483|Experimental|Corifollitropin alpha group|Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
33312371|NCT05073874|Other|Functional Near-Infrared Spectroscopy (fNIRS)|"Subjects will be guided to walk at a normal pace while maintaining the required attentional focus:~no instructions about the attentional focus~internal focus on their feet movements,~external focus on two lines drawn on the floor,~divided attention (walking while performing an arithmetic task).~A fNIRS system will be used for the prefrontal cortex activation evaluation and connected soles for gait analyses."
32947836|NCT04089852|Experimental|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
33312372|NCT05681728|Experimental|Pembrolizumab combined with chemotherapy|
33312373|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
33312374|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
33312375|NCT03931850|Experimental|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
33312376|NCT03931850|Active Comparator|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
33312377|NCT05535166|Experimental|Stratum S-2|"Patients with Sonic Hedgehog subgroup 2 (SHH-2), 0-2.99 years, or M0 and 3-4.99 years, will receive systemic high-dose methotrexate (HD-MTX) and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
33312378|NCT05535166|Experimental|Stratum S-1|"Patients with SHH-1, SHH-3, SHH-4, or SHH-Not otherwise specified (NOS), 0-2.99 years, will receive intraventricular methotrexate (IVT-MTX) in parallel with systemic HD-MTX and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
32947837|NCT04089852|Placebo Comparator|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
32947838|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
32947839|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
32947840|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
32947841|NCT03026244|Placebo Comparator|Placebo product|placebo product
33312379|NCT05535166|Experimental|Stratum N|"Patients with Medulloblastoma (MB) group 3 or group 4 (G3/G4) or MB [including Non-WNT non-SHH medulloblastoma (NWNS) NOS or otherwise indeterminate cases] (0-2.99 years) will receive systemic HD-MTX and conventional chemotherapy only for radiation delaying purposes. At 3 years of age, these patients will receive risk-stratified craniospinal irradiation (CSI).~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Radiation"
33312380|NCT03931538|Active Comparator|Culture Only|Physician receives only culture result
33312381|NCT03931538|Active Comparator|Guidance 4.0 PCR test only|Physician receives Guidance report only
33312382|NCT03931538|Active Comparator|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
33312383|NCT03931538|Active Comparator|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
33312384|NCT03931928|No Intervention|Control group (Group 1)|All patients receive Placebo
33312385|NCT03931928|Experimental|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
33312386|NCT03931928|Experimental|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
33312387|NCT05523310||Training group|The training group will be used to develop the prediction model, based on their reported daily questionnaire. Participants in the training group will not be included in the Validation group
33312388|NCT05523310||Validation group|"The validation group will be used only for validation (test) of the prediction model (Naïve group). Participants in the validation group could not be recruited from the training group"
33312389|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
33312390|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
33312391|NCT05681572|Experimental|Premedication Group (Midazolam)|Midazolam (0,5 mg/kg; max 10 mg), oral administration, 45 minutes prior entering in the operating room
33404673|NCT05387512||Control treatment group|The primary treatment is Pemetrexed and Platinum plus anti-angiogenic drugs, Secondary treatment is standard chemotherapy regimens after progression. Reference regimen of Carilizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
33097273|NCT04695483|Active Comparator|FSH group|Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
33404674|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
33404675|NCT05077462|Experimental|Sequence A|Period 1: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
33404676|NCT05077462|Experimental|Sequence B|Period 1: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
33404677|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
33404678|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
33404679|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
33404680|NCT02328508|No Intervention|Control|The control group received only routine care.
33404681|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
33404682|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
33097274|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
33097275|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
33097276|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
33097277|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
33097278|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
33097279|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
33097280|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
33097281|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.~No radiation therapy will be given."
33097282|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention~Radiation Therapy:~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.~Dose Prescription:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
33097283|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
33097284|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
33097285|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
33097286|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
33097287|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
33097288|NCT04695639||cohort group|A convenient sample of children with spastic hemiparetic CP of both genders will participate in this study. To avoid type II error, sample size calculation was performed prior to the study, based on data of pilot study, using G*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany) [Exact tests- correlational study, α=0.05, β=0.2, and effect size = 0.4] and revealed that the appropriate sample size for this study is N=46.
33097289|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
33097290|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
33097291|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
33097292|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
33097293|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
32803330|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
33312392|NCT05681572|Experimental|Premedication Group (Dexmedetomidine)|Dexmedetomidine (2 µg/kg), oral administration, 45 minutes prior entering in the operating room
32803331|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
32803332|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
32803333|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
33312393|NCT05681572|Placebo Comparator|Placebo Group|grenadine syrup (3 mL), oral administration, 45 minutes prior entering in the operating room
33312394|NCT05514730|Experimental|Experimental Treatment|The experimental treatment is Phase-Based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children, an innovative intervention demonstrating promise in preliminary testing.
33312395|NCT05514730|Active Comparator|Control Treatment|The Control Treatment will utilize a Treatment-as-Usual (TAU) condition designed to mimic the types of treatment generally provided in the community for mental health concerns of children.
33312396|NCT05133310|No Intervention|Standard Care Group|Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.
33312397|NCT05133310|Experimental|Simvastatin Treatment Group|Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.
33312398|NCT01217918|Experimental|Cohort 1|PH-797804
33312399|NCT01217918|Experimental|Cohort 2|PH-797804
33312400|NCT01217918|Experimental|Cohotr 3|PH-797804
33312401|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
33312402|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
33312403|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
33312404|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
33312405|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
33312406|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
33312407|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
33312408|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
33312409|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
33312410|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
33312411|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
33312412|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
33312413|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
33312414|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
33312415|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
33312416|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
33312417|NCT01222988|Other|very low calorie diet program|
33312418|NCT03932864|Placebo Comparator|Single Ascending Dose of MGTA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
33312419|NCT03932864|Placebo Comparator|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
33312420|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
33312421|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
33312422|NCT03931694||All patients with chronic pain follow in pain clinic|
33312423|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
33312424|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
33312425|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
33312426|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
33312427|NCT05500924|Experimental|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
33312428|NCT05500924|Experimental|Control group|5 sets of functional activities each will be repeated for 3 times: Sit to stand Squat Stand to sit Stairs stepping Bridging
33312429|NCT03934580|Experimental|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
33312430|NCT03934580|Active Comparator|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
33312431|NCT05494216|Active Comparator|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Individual bound sperm selection is done followed y ICSI
32803334|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
32803335|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
33312432|NCT05494216|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for ICSI.
33312433|NCT01312168|No Intervention|Healthy non-OSA control|
33312434|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
32803336|NCT04396990|Experimental|Group A Dextenza|
33312435|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
33312436|NCT03934502|Experimental|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
33312437|NCT03934502|Experimental|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
33312438|NCT03934502|Experimental|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
32803337|NCT04396990|Active Comparator|Group B Topical Prednisolone|
32803338|NCT04397068|Other|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
33312439|NCT03934502|Experimental|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
33312440|NCT05287282|Experimental|TECAR application|
32803339|NCT04396678|No Intervention|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
32803340|NCT04396678|Experimental|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
33312441|NCT05287282|Active Comparator|selected abdominal exercises program|
33312442|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
33312443|NCT01123226|Active Comparator|Trigger point pressure release|
32803341|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
32803342|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
32803343|NCT04545489|Experimental|Intervention group|Participants randomized to the intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the interventionist (nurse or pharmacist), with additional BP monitoring support and medication management for 12 months.
32803344|NCT04545489|Active Comparator|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
32803345|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
32803346|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
32803347|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
32803348|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
32803349|NCT04496830|Experimental|Relapsing Remitting Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
32803350|NCT04496830|Experimental|Progressive Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
32803351|NCT04496830|Experimental|Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
32803352|NCT04496830|Experimental|Other Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
32803353|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
32803354|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
33312444|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
33312445|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
33312446|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
33097294|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
33097295|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
33097296|NCT01243268||Patients with essential hypertension|
33097297|NCT00514995|Experimental|1|
33097298|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
33097299|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
33097300|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
33097301|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
33097302|NCT00515151|Active Comparator|Oct/Alc|
33097303|NCT00515151|Active Comparator|Alc|
33097304|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
33097305|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
33097306|NCT00514332|Experimental|A|primary surgery group
33097307|NCT01241786|Experimental|response to Vidaza + Revlimid|response to combination of azacitidine + lenalidomide A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
33097308|NCT00514410|Experimental|Folic Acid|
33097309|NCT00514410|Placebo Comparator|Placebo|
33097310|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
33312447|NCT05268562|Active Comparator|Anesthesia induction with Ketamine|Subjects will receive Ketamine to begin anesthesia for their cardiac surgery.
33312448|NCT05268562|Active Comparator|Anesthesia induction with Propofol|Subjects will receive Propofol to begin anesthesia for their cardiac surgery.
33312449|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
33404683|NCT03111004||Comparator Group|The comparator group receives usual care
33312450|NCT02529332|No Intervention|Control Group|
33312451|NCT05245552|Experimental|Safety group|PhaseⅠ,30 subjects will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
33312452|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) on the immunization schedule of day 0,28.
33312453|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
33097311|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
33097312|NCT00514527|Experimental|1|
33097313|NCT00514527|Experimental|2|
33097314|NCT00514527|Experimental|3|
33097315|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
33097316|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
33097317|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
33097318|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
33312454|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) on the immunization schedule of day 0,28.
33312455|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) on the immunization schedule of day 0,28.
33312456|NCT03932942|Experimental|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
33312457|NCT03932942|No Intervention|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
33097319|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
33097320|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
33097321|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
33097322|NCT04695015||Melanoma and Nevus|Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
33097323|NCT04695015||Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma|Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
33097324|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
33097325|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
33097326|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
33097327|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
33097328|NCT04695249|Experimental|Exposure intervention|Eleven individual sessions.
33404684|NCT02039986||all subjects|all subjects enrolled in same cohort
33097329|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
33097330|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
33097331|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
32947842|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
32947843|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
32947844|NCT01470144|Experimental|Treatment|Single arm, open-label
32947845|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
33404685|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
33404686|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
32947846|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
32947847|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
32947848|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
32947849|NCT01439880|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product [all-IP] period.
32947850|NCT01439880|Experimental|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
32947851|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
32947852|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
32947853|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
32947854|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
32947855|NCT01439568|Active Comparator|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
32947856|NCT04072380|Experimental|SUVN-G3031 2mg|Orally taken once daily for 14 days
32947857|NCT04072380|Experimental|SUVN-G3031 4mg|Orally taken once daily for 14 days
32947858|NCT04072380|Placebo Comparator|Placebo|Orally taken once daily for 14 days
32947859|NCT01469052|Experimental|Cohort 1|
32947860|NCT01469052|Experimental|Cohort 2|
32947861|NCT01469052|Experimental|Cohort 3|
32947862|NCT01469052|Experimental|Cohort 4|
32947863|NCT01469052|Experimental|Cohort 5|
32947864|NCT01469052|Experimental|Cohort 6|
32947865|NCT01442688|Experimental|Amoxicillin + MMX placebo|
32947866|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
32947867|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
32947868|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
32947869|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
32947870|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
32947871|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
33404687|NCT05077306|Experimental|music therapy group|Patients receive an individual single session of receptive music therapy in presence.
32803355|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
32803356|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
32803357|NCT00638404||1|Elective Cesarean Sections-this portion completed
32803358|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
32803359|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
32803360|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
32803361|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
32803362|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
33312458|NCT05233930|Experimental|TKR with augmented reality-based navigation system.|This technology offers the orthopedic surgeon intraoperative assistance in positioning the implants with the help of a pair of augmented reality glasses. The cutting planes are oriented with respect to the mechanical axes calculated according to anatomical landmarks acquired with a pointer. The connected glasses calculate precisely the 3D coordinates of the instruments thanks to the analysis of their specific markers (QR-Code), filmed by the integrated camera. The navigation information is displayed in the surgeon's field of vision, who interacts with the application thanks to the glasses' accelerometers.
33312459|NCT05233930|Active Comparator|TKR with traditional mechanically aligned technique.|TKR with traditional mechanically aligned technique will be performed according to local practice and standard guidelines.
32803363|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
32803364|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
32803365|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
32803366|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
32803367|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
33312460|NCT03931382|Experimental|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
33312461|NCT03931382|Active Comparator|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
33312462|NCT03931382|Active Comparator|Booklet|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
33312463|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
33312464|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
33312465|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
33312466|NCT05485168|Experimental|Sequential Variety, Small Portion|3 different foods served in a small portion in 3 successive courses
33312467|NCT05485168|Experimental|Sequential Variety, Large Portion|3 different foods served in a large portion in 3 successive courses
33312468|NCT05485168|Experimental|Single-Food, Small Portion|1 food served in a small portion in 3 successive courses
33312469|NCT05485168|Experimental|Single-Food, Large Portion|1 food served in a large portion in 3 successive courses
32803368|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
32803369|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
33312470|NCT05482516|Experimental|Atezolizumab plus Bevacizumab|atezolizumab 1200 mg and bevacizumab 15 mg/kg given intravenously on Day 1 of each 21-day cycle (every 3 weeks [Q3W]) for a maximum of 12 months.
33312471|NCT05681416|Other|Healthy men with familial risk|≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age <60
33312472|NCT05681416|Other|healthy men with genetic risk|BRCA1/2 Germline mutation
33312473|NCT05681416|Other|Men with PCA and genetic oder familial risk|familial risk = ≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age <60 genetic risk= BRCA1/2 Germline mutation
32947872|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
33312474|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
33312475|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
33312476|NCT05452408|Experimental|Antitumor B KAC|ATB will be administered on an outpatient basis.
33312477|NCT01125878|Active Comparator|Starch Composite B|fiber mixture
33312478|NCT01125878|Active Comparator|Starch Composite C|fiber mixture
33312479|NCT01125878|Active Comparator|Starch Composite D|fiber mixture
33312480|NCT01125878|Placebo Comparator|Placebo|Placebo
33312481|NCT04955314|Experimental|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
33312482|NCT04955314|Experimental|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
33312483|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
33404688|NCT05077306|No Intervention|Control group|Patients receive standard care
32947873|NCT01467960||Group I|Healthy Subjects aged 20-40
32947874|NCT01467960||Group II|Healthy Subjects aged 40-65
32947875|NCT01467960||Group III|Healthy Subjects aged more than 65
32947876|NCT01467960||Group A|Patients at Stage I, H&Y classification
33097332|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
33097333|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
33097334|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
33097335|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
33097336|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
33097337|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
33312484|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
32803370|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
32803371|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
32803372|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
32803373|NCT05240950|Experimental|MRD or positive ctDNA patients to inject anti-CEA CAR-T cells|Patients with liver metastasis of colorectal cancer after R0 surgery and adjuvant chemotherapy could not clear MRD (including patients with MRD still positive after the intermediate and final evaluation of adjuvant chemotherapy, and patients with MRD positive again after the end of adjuvant chemotherapy), and no measurable lesions or tumor remnants were found on imaging after surgery.
32803374|NCT05241574|Experimental|radiotherapy dose escalation|Additional two fractions of endorectal high dose rate iridium brachytherapy boost, 10 Gy each.
32803375|NCT05241574|Experimental|chemotherapy dose escalation|Additional three cycles of consolidation chemotherapy consisted of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4).
32803376|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
32803377|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
32803378|NCT05241106|Experimental|HYML-122 treatment|HYML-122 tablets, 200mg spec, 28 days for each cycle. The first eligible three enrolled subjects will be administrated with 600mg bid dose regimen for 28 consecutive days ( 1 treatment cycle). The Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of these three subjects and make decision whether the regimen need to be adjusted (increasing/decreasing administration dosing or adjusting dosing frequency).
32803379|NCT05241028|Experimental|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
32803380|NCT01572909|Active Comparator|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
32803381|NCT01572909|Placebo Comparator|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
32803382|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
32803383|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
32803384|NCT01550289|Experimental|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
32803385|NCT01550289|Placebo Comparator|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
32803386|NCT04108143|Experimental|Intervention|MonitorMe device
32803387|NCT04107519|Experimental|Immediate GRIT (ImT) training intervention|
32803388|NCT04107519|No Intervention|Delayed Training (DeT) control|
32803389|NCT04107285||Neurocognitive evaluation prior to and following CART|
32803390|NCT04122183|Experimental|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
32803391|NCT04122183|No Intervention|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
32803392|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
32803393|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
32803394|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
32803395|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
32803396|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
32803397|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
33312485|NCT04473742|Experimental|Patients exposed to silica|
33312486|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
32803398|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
32803399|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
33097338|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
33097339|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
33097340|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
33097341|NCT01240382|Experimental|3% DE-089|
33097342|NCT01240382|Active Comparator|0.1% HA|
32803400|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
32803401|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
32803402|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
32803403|NCT03911739|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
32803404|NCT03911739|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
33097343|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
33097344|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
33097345|NCT01243346|Experimental|Crenolanib (CP-868,596)|
33097346|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
33312487|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
33312488|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
33312489|NCT04459156|Experimental|Healthy Participants|healthy control subjects
33312490|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
33312491|NCT04459156|Experimental|Healthy Young Participants|healthy young subjects with age 18-30 years old
33312492|NCT01223300||Osteoporosis|
33312493|NCT04427488|Experimental|Morning Chronotype (MC) Group|In the MC group, exercises were applied in the morning hours for the first 6 weeks and in the evening hours for the next 6 weeks.
33312494|NCT04427488|Experimental|Evening Chronotype (EC) Group|The EC exercises were applied in the evening hours for the first 6 weeks and in the morning hours for the next 6 weeks
33312495|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
33312496|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
33312497|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
33312498|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
33312499|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
33312500|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
33312501|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
33312502|NCT01220336|Experimental|Health Coaching|
33312503|NCT05149534|Experimental|Active TMS/WET|Active repetitive transcranial magnetic stimulation completed prior to written exposure therapy
32803405|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
33312504|NCT05149534|Sham Comparator|Sham TMS/WET|Sham repetitive transcranial magnetic stimulation completed prior to written exposure therapy
33312505|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
33312506|NCT04395586||Culture-proven infected patients|
32803406|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
32803407|NCT04106115|Experimental|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
33312507|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
33312508|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
32803408|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32803409|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
32803410|NCT01907737|Active Comparator|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
32803411|NCT01907737|Other|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
32803412|NCT01907737|Other|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
32803413|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
32947877|NCT01467960||Group B|Patients at Stage II, H&Y classification
33312509|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
33312510|NCT05437198||Chronic Obstructive Pulmonary Disease (COPD)|Patients with chronic obstructive pulmonary disease will be recruited from the pulmonology or occupational pathology department. They are either active smokers or ex-smokers. They are over 18 years old
33312511|NCT05437198||NO-Chronic Obstructive Pulmonary Disease|"The no-COPD are controls followed in chi créteil for another pathology. They are between 18 and 30 years old and 45 and 70 years old.~They are either:~Ex-smoker~Active smoker~Non-smoker"
33312512|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
33312513|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
33312514|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
33312515|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
33312516|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
33312517|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
33312518|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
33312519|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
33312520|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
33312521|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
33312522|NCT01127750|Experimental|FTY720|
33312523|NCT05419024|Experimental|ATI|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
32947878|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
32947879|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
32947880|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
33312524|NCT05419024|No Intervention|Continue ART|Participants will continue on their pre-study ART throughout the trial.
32947881|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
33312525|NCT05177224|Experimental|Participants with dual mobility cup|
32947882|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
32947883|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
33312526|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
33312527|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
33312528|NCT05185180||Males with Category III Chronic Pelvic Pain Syndrome|Category III is subdivided into inflammatory (IIIa) and noninflammatory (IIIb) subtypes, based on the presence of white blood cells in expressed prostatic secretions (EPS). Category III prostatitis or chronic pelvic pain syndrome (CPPS) is the most common prostatitis observed in medical practice with a prevalence rate in the general population from 5% to 14.2%. CPPS is a poorly understood entity characterized by pelvic or perineal pain, irritative voiding symptoms, and sexual dysfunction.
33312529|NCT05185180||Control Group|The control group will consist of men with no history of Chronic Pelvic Pain or any underlying condition.
33312530|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
32947884|NCT01441440|Placebo Comparator|Placebo|
32947885|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
32947886|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
32947887|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
32947888|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
32947889|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
32947890|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
32947891|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
32947892|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
32947893|NCT04066764|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
32947894|NCT04066764|Active Comparator|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
32947895|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
32947896|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
32947897|NCT01440972|Active Comparator|Exercise without PBFR|
32947898|NCT01440972|Experimental|exercise with PBFR|
32947899|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
32947900|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
32947901|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
32947902|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
32947903|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
32947904|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
32947905|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
32947906|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
32947907|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
32947908|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
32947909|NCT01418352|Placebo Comparator|Matching Placebo|Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
32947910|NCT01418352|Experimental|Aripiprazole 52.5 mg|Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
32947911|NCT01418352|Experimental|Aripiprazole 77.5 mg|Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
32947912|NCT01418352|Experimental|Aripiprazole 110 mg|Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
32947913|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
32947914|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
33312531|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
33312532|NCT05681338|Experimental|the medium intensity coughing technique|Immediately before the subcutaneous heparin injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
32947915|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
32947916|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
32947917|NCT01465464|Experimental|Orantinib|
33312533|NCT05681338|No Intervention|the standard injection technique|During the subcutaneous heparin injection, patients were not asked to perform any action, and the injection was given by the standard technique.
32947918|NCT01465464|Placebo Comparator|Placebo|
32947919|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
32947920|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
32947921|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32947922|NCT04082364|Experimental|Chemotherapy-free arm|margetuximab plus retifanlimab
32947923|NCT04082364|Experimental|Margetuximab, retifanlimab, and chemotherapy arm|"margetuximab plus retifanlimab plus investigator choice of chemotherapy options.~Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)"
32947924|NCT04082364|Experimental|Margetuximab, tebotelimab and chemotherapy arm|margetuximab plus tebotelimab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
32947925|NCT04082364|Experimental|Margetuximab and chemotherapy arm|margetuximab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
32947926|NCT04082364|Active Comparator|Trastuzumab and chemotherapy arm|Trastuzumab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
32947927|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
32947928|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
32947929|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
32947930|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
32947931|NCT04048668|Active Comparator|Anodal tDCS|2mA for 20 minutes
32947932|NCT04048668|Sham Comparator|Sham tDCS|30 second ramp-up / ramp-down for 20 minutes
32947933|NCT04500132|Experimental|EC-18 Arm|EC-18 QD
32947934|NCT04500132|Placebo Comparator|Placebo Arm|Placebo EC-18 QD
32947935|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
33097347|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
32947936|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
33312534|NCT05168488|Experimental|All participants|There is only one study arm consisting of all participants.
33312535|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
32947937|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
32947938|NCT01435356|Placebo Comparator|Placebo|MAGE-A3 positive patients treated with placebo
32947939|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
32947940|NCT04048122|Active Comparator|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
32947941|NCT04048122|Experimental|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
32947942|NCT01434810|Experimental|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
32947943|NCT01434810|Active Comparator|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
32947944|NCT01393626|Placebo Comparator|Placebo BID|
32947945|NCT01393626|Experimental|5mg BID|
32947946|NCT01393626|Experimental|10mg BID|
32947947|NCT04059666|Active Comparator|Control|
32947948|NCT04059666|Experimental|Investigational|
32947949|NCT04059666|No Intervention|Mother's-own Breast Milk|
32947950|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
32947951|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
32947952|NCT04059276||Patients with stroke|
32947953|NCT04059276||Healthy subjects|
32947954|NCT01393158|Experimental|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
32947955|NCT01393158|Experimental|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
32947956|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
32947957|NCT01413204|Experimental|TA-7284 Low|
32947958|NCT01413204|Experimental|TA-7284 High|
32947959|NCT01413204|Placebo Comparator|Placebo|
32947960|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
32947961|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
32947962|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
32947963|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
32947964|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
32947965|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
32947966|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
32947967|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
33312536|NCT03931304||Control group|Cytoreductive surgery alone
33312537|NCT05031832||HIV-negative|
33312538|NCT05031832||HIV-positive|
33312539|NCT01123304|Experimental|MORAb 028|
32803414|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
33312540|NCT05381350|Experimental|Experimental group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
33312541|NCT05381350|Active Comparator|Control Group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
32803415|NCT01570491|Placebo Comparator|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
33312542|NCT05381350|Experimental|Experimental group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
33312543|NCT05381350|Active Comparator|Control Group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
33097348|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
33097349|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
33097350|NCT00516204||Patients at very high risk|
33097351|NCT00516204||Patients at high risk|
33312544|NCT05381350|Experimental|Experimental group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
33312545|NCT05381350|Active Comparator|Control Group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
32803416|NCT04118517|Experimental|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
32803417|NCT04117425|Other|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
33312546|NCT05381350|Experimental|Experimental group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
33312547|NCT05381350|Active Comparator|Control Group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
32803418|NCT01929109|Experimental|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
32803419|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
32803420|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
32803421|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
32803422|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
32803423|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
32830749|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
33097352|NCT00516204||Patients at medium risk|
33097353|NCT00516204||Patients at low risk|
33097354|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
33097355|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
33097356|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
32947968|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
32947969|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
32947970|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
32947971|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
32947972|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
32947973|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
32947974|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
32947975|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
32947976|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
32947977|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
32947978|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
32947979|NCT04767204|Experimental|Peer support service|Peer support workers co-lead and assist workplace problem-solving and care skills training in an extended vocational rehabilitation program
32947980|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
32947981|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
32947982|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
32947983|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
32947984|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
32947985|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
32947986|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
32947987|NCT01410474|Experimental|2-18 years|
32947988|NCT04037592|Experimental|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
32947989|NCT04037592|Experimental|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
32947990|NCT04037592|Sham Comparator|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
32947991|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
32947992|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
32947993|NCT04046094|Experimental|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
32947994|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
32947995|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
32947996|NCT01409928|Experimental|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
33312548|NCT05381350|Active Comparator|Historical control group|Backup serum samples will be selected from 250 healthy adult subjects aged 26-45 years who received two doses of inactivated COVID-19 vaccine(CZ strain)from clinical trial of lot-to-lot consistency of an inactivated SARS-CoV-2 Vaccine(Pro-NCOV-4001) to detect neutralizing antibodies against the CZ, Delta and Omicron strains.
32947997|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
33312549|NCT03934736|Experimental|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
33312550|NCT05176834|Experimental|B-Cure laser pro|In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.). In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
33097357|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
33097358|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
33097359|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
33097360|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
33097361|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
33097362|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
33097363|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
33097364|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
33097365|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
33312551|NCT01223768|Experimental|Acetyl-L-carnitine|
33312552|NCT01223768|Placebo Comparator|placebo|
33312553|NCT04759066|Experimental|Experimental|Participants will wear HEALiX device
33097366|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
33097367|NCT04512131||Intermittent hemodialysis|patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination
33097368|NCT04512131||continuous renal replacement therapy|patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample
33097369|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
33097370|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
33097371|NCT04511117|Active Comparator|Control Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by composite restorations.
33097372|NCT04511117|Experimental|Endocrown Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by endocrown restorations.
33097373|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
33097374|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
33097375|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
33312554|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
33312555|NCT05024032|Experimental|Tirzepatide Dose 1|tirzepatide administered subcutaneously (SC) once a week.
33312556|NCT05024032|Experimental|Tirzepatide Dose 2|tirzepatide administered SC once a week.
33312557|NCT05024032|Placebo Comparator|Placebo|placebo administered SC once a week.
32947998|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
32947999|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
32948000|NCT04055220|Experimental|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
33312558|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
33312559|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
33312560|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
33312561|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
33312562|NCT04724668|Other|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
33312563|NCT04724668|Other|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
33312564|NCT03934424|Experimental|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
33312565|NCT03934424|Other|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
33312566|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
33312567|NCT05358808|Experimental|γδ T cells (IMP, TCB008)|"After inclusion, all patients will receive lymphodepleting chemotherapy with fludarabine 30mg/m2 Day -6 to Day -3 [total 120 mg/m2] and cyclophosphamide 0.5g/m2 [total 1.5 g/m2) Day -5 to Day -3,]. This will be followed by a rest day (Day -2).~TCB008 treatment (consisting initially of one dose of 7 X 10^7 or 7 X 10^8 cells ) is administered on Day 0"
33312568|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
32830750|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
32830751|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
32830752|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
32830753|NCT00047853|Experimental|Acoustic startle|loud noises with MEG only
32830754|NCT00047853|Experimental|Threat of shock|threat of electric shock
32830755|NCT02459340|Experimental|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
32830756|NCT02459340|No Intervention|healthy control group|passive control group
32830757|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
32830758|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
32830759|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
32830760|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
32830761|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
32830762|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
32830763|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
32830764|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
32830765|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
32830766|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~In a complete remission rate of leucocytes with ≥ 2G / L~Affiliated to social security person or beneficiary of such a scheme."
32830767|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~Having a rate of circulating lymphocytes ≥ 1 G / L~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~The statutes CMV and EBV are known (positive or negative).~Affiliated to social security person or beneficiary"
32830768|NCT00026559|Experimental|Threat Conditions|threat of shock and auditory startle
32830769|NCT04168866|Experimental|Surgery|Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
32830770|NCT04168866|Active Comparator|Non-operative management|If a patient chooses non-operative management and if an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
32830771|NCT04168398|Experimental|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
32830772|NCT04168398|Experimental|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
32830773|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
32830774|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
32830775|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
32830776|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
32830777|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
33312569|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
32948001|NCT04055220|Placebo Comparator|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
32948002|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
33312570|NCT05156944|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including two exercises for daily self-guided therapy.
33312571|NCT05156944|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
33312572|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
33312573|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
33312574|NCT05309980||Without Shock Team|Before January 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device without involvment of a dedicated shock team
33312575|NCT05309980||With Shock Team|After April 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device following a collegial meeting of a shock team (cardiac surgeon, cardiologist, intensivist) using a common algorythm.
32948003|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
32948004|NCT01390584|Experimental|ABVD + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks."
33312576|NCT03930992|Experimental|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
33312577|NCT03930992|Active Comparator|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
33312578|NCT03930992|Experimental|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
33312579|NCT03930992|Active Comparator|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
33312580|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
33312581|NCT05235880|Experimental|study group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
32948005|NCT01390584|Experimental|ABVD + BEACOPP + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks."
33312582|NCT05235880|Active Comparator|control group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
32948006|NCT01431534|Experimental|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
32948007|NCT01431534|Experimental|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
32948008|NCT01431534|Experimental|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
32948009|NCT04053582|Active Comparator|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
32948010|NCT04053582|Active Comparator|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
32948011|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
32948012|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
32948013|NCT01408914|No Intervention|RIF 600|
32948014|NCT01408914|Experimental|RIF 900|
32948015|NCT01408914|Experimental|RIF 1200|
32948016|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
32948017|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
33097376|NCT04512092|Experimental|CMT-C group|Compassion Mind Training for Caregivers (CMT-C) is a 12-session structured program to be delivered in a group format, aiming to cultivate a compassionate-self and compassionate care practices in residential youth care.
33097377|NCT04512092|No Intervention|Control group|This group did not receive any mind training or group intervention during the study.
33097378|NCT04513301|Active Comparator|Sintilimab alone|Sintilimab (200 mg q3w ×2cycle)
33097379|NCT04513301|Experimental|Sintilimab+Radiotherapy|Sintilimab (200 mg q3w ×2cycle)+RT 50-60Gy/25-30f
33097380|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
33097381|NCT04516421|Experimental|Experimental group|The experimental group will receive a 12-weeks intervention, with each day a pack of supplementation containing 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
33097382|NCT04516421|Placebo Comparator|Control (Placebo) group|The control (placebo) group will receive a 12-week oat drink, with each day a pack of oat tea containing 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
33312583|NCT03931148|Experimental|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :~Geriatric Assessment with specific neuropsychologic tests of decision making~fRMI~EEG High Resolution~Qualitative interview"
32803424|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
32803425|NCT01906489|Experimental|AKB-6548|
33312584|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
33312585|NCT01223924|Placebo Comparator|Placebo|placebo contract
33312586|NCT05229640|Other|Fibroscan|One study visit for fibroscan measurement of the liver.
32803426|NCT01906489|Placebo Comparator|Placebo|
32803427|NCT04620343|Active Comparator|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).~This is the reference treatment against which the other methods will be measured."
32803428|NCT04620343|Experimental|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
32803429|NCT04620343|Experimental|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
32803430|NCT04620343|Experimental|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
32803431|NCT04620343|No Intervention|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
32803432|NCT04620343|Experimental|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
32803433|NCT04620343|Experimental|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
32803434|NCT04620343|Experimental|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
32803435|NCT04620343|No Intervention|Phase3, Group 3|Non-surgery control group
32803436|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
32803437|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
32803438|NCT01517373|Experimental|PF-04937319 10 mg|
32803439|NCT01517373|Experimental|PF-04937319 50 mg|
32803440|NCT01517373|Experimental|PF-04937319 100 mg|
32803441|NCT01517373|Active Comparator|Glimepiride|
32803442|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
32803443|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
32803444|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
32803445|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
32803446|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
32803447|NCT04104321|Experimental|Aramchol|Aramchol 300 mg oral tablet
32803448|NCT04104321|Placebo Comparator|Placebo|Placebo matching oral tablet
32803449|NCT04104165|Active Comparator|Intermittent catheterization|women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours
32803450|NCT04104165|Active Comparator|Continous catheterization|women which will have an indwelling catheter inserted for 24 hours
32830778|NCT03280212|No Intervention|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
32830779|NCT01264185||Asia--Thailand; S. America--Brazil|
32830780|NCT01264185||Africa--Zambia|
33097383|NCT04512014||major liver surgery|Patients undergoing major liver surgery
32830781|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
32830782|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
33097384|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
33097385|NCT04519970|Active Comparator|Highest Tier of Case Management (Piggyback) and Biktarvy|The most intensive tier of case management. Includes three appointment reminders; check ins twice per week; travel compensation; housing support; food insecurity support; follow ups for missed appointments and off pill counts; connections with substance use programs; meetings with the benefits department for health insurance needs; childcare support to make appointments; mental healthcare referrals; open pool appointments as back-up options in case of rescheduling needs; late doctor's appointments and prescription pick up for those working during the day; meetings with the health educators to discuss HIV and ART; and re-motivation of HIV treatment every 3 months.
33097386|NCT04519970|Active Comparator|Middle Tier of Case Management (Got Your Back) and Biktarvy|The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
33097387|NCT04519970|Active Comparator|Lowest Tier of Case Management (Backbone) and Biktarvy|The top tier (Backbone) will need the least amount of support and also have a CORE Center case manager for a majority of the support in housing, food, insurance, transportation, childcare, substance use, and mental healthcare. The retention specialist will still provide an appointment reminder; check ins every other week; text checkups after missed appointments or off pill counts; support with scheduling for appointments or prescription pick up for limited availability; and re-motivation of treatment for HIV at the 9 month mark of study participation.
33312587|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
32830783|NCT04784169|Experimental|free middle turbinate flap group|A free middle turbinate flap is used to repair the leakage
33312588|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
33312589|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
33312590|NCT03930758|Experimental|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
33312591|NCT03930758|Experimental|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
33312592|NCT03930758|Experimental|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
33312593|NCT03930758|Experimental|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
33312594|NCT03930758|Sham Comparator|Sedentary trial|A trial with no exercise
33312595|NCT04682860|Placebo Comparator|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
33312596|NCT04682860|Active Comparator|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
33312597|NCT05125822|Experimental|Meal Replacement and Lifestyle Therapy|Participants in this study will have an 8-week meal replacement therapy period in which they are asked to reduce their BMI by 5% by following a prescribed eating regimen consisting of meal replacement shakes and/or frozen meals for breakfast and lunch. For dinner they will consume a pre-packaged frozen entree to be consumed with two servings of fruit and three servings of vegetables per day. Participants will also have lifestyle/behavioral modification counseling every 2 weeks throughout the entire study.
33312598|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
33312599|NCT04458766|Experimental|Interventions|"All subjects in this trial will receive the following interventions:~Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).~Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.~Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
32830784|NCT04784169|Active Comparator|vascularized nasoseptal flap|A vascularized nasoseptal flap is used to repair the leakage
32830785|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
32830786|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
32830787|NCT05279157|Experimental|ADASCs Group|5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment
32830788|NCT05279157|Experimental|Acellular laminas group|5 patients, who will receive decellularized corneal laminas as treatment medication
32830789|NCT05279157|Experimental|ADASCs recellularized laminas group|5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention
32830790|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
32830791|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
33097388|NCT04697043|Experimental|systemic therapy followed by surgery|"ُThe main intervention is surgery. After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
32803451|NCT04103775|Experimental|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
32803452|NCT04103775|Active Comparator|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
32803453|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
32803454|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
32803455|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
32803456|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
32803457|NCT04767867|Experimental|Facemask oxygen (FM)|100% oxygen administered via facemask through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'breathe normally'
32803458|NCT04767867|Active Comparator|High-flow nasal oxygen (HFNO)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Participant instructed to 'keep the mouth closed and breathe normally'
32803459|NCT04767867|Active Comparator|High-flow nasal oxygen plus mouthpiece oxygen (HFNO+MP)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Additionally, 100% oxygen administered via mouthpice through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'keep the mouth closed and breathe normally'.
32803460|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
32803461|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
32803462|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
32803463|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
32803464|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
32803465|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
32803466|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
32803467|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
32803468|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
32803469|NCT00637156|Experimental|PRESTIGE LP Device|
32803470|NCT00637156|Other|ATLANTIS Cervical Plate System|
32803471|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
32803472|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
32803473|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
32803474|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
32803475|NCT04767399|Experimental|Single visit|root canal treatment will be done in one visit
32803476|NCT04767399|Experimental|multiple visit|root canal treatment will be done in multiple visit
32803477|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
32803478|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
32803479|NCT01546155|Experimental|healthy controls|
32803480|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
32830792|NCT04784325|Experimental|Women recruited from a general population subject to I/E criteria|All study participants will administer three blood collection modalities (2 TAP II, 1 ADx card, and phlebotomist-performed venipuncture).
33312600|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
33312601|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
33312602|NCT04918654||Study Subjects|
33312603|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
33312604|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
33312605|NCT05309824||Atrial fibrillation|
33312606|NCT05309824||Left ventricular hypertrophy|
33312607|NCT05309824||Pulmonary hypertension|
33312608|NCT05309824||Coronary atherosclerotic heart disease|
33312609|NCT05309824||Heart failure with retained ejection fraction|
33312610|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
33312611|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
33312612|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
33312613|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
33312614|NCT05193916|Experimental|Chiglitazar low dose|3 tablets of drug and 1 tablet of placebo p.o. per day
33312615|NCT05193916|Experimental|Chiglitazar high dose|4 tablets p.o. per day
33312616|NCT05193916|Placebo Comparator|control group|4 placebo tablets p.o. per day
33312617|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
33312618|NCT05320822|Active Comparator|Progressive Return to Activity (Group 1)|The current practice, Progressive Return to Activity (PRA) based on Traumatic Brain Injury Center of Excellence (TBICoE) protocols, provides a framework for activity progression based on participant symptom reports and recovery. PRA TBICoE includes a graded approach for clinicians to return participants to pre-injury activities based on the severity of the participant symptoms with and without physical exertion.
33312619|NCT05320822|Experimental|Active Rehab (Group 2)|"Active Rehab includes an adaptive paradigm based on personal characteristics, symptom presentation, and duty requirements that integrate with current progressive return to activity (PRA TBICoE) guidelines. Activity progressions consider the initial presentation and changes in participant status during treatment, with the goal of safely accelerating recovery. Severity and presence of symptoms will guide progression as reported by the participant.~The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and military duty specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements."
33312620|NCT03930914|Other|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
33312621|NCT03930914|Other|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
33312622|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
33312623|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
33312624|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
33312625|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
33312626|NCT03933098|Experimental|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
33312627|NCT03933098|Experimental|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
33312628|NCT03933098|Experimental|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
33312629|NCT03933098|Active Comparator|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
33097389|NCT04697043|No Intervention|Systemic therapy|"After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
33097390|NCT04511975|Experimental|IBI188 + azacitidine|Participants will receive IBI188 in combination with azacitidine
33312630|NCT05111314|Experimental|Diagnostic (embolization, 68Ga-PSMA, PET/CT)|Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.
32803481|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
32803482|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
32803483|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
33097391|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
33097392|NCT04511663|Active Comparator|intervention group|The intervention group received assertive community treatment, in which the team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers.
33097393|NCT04511663|Other|control group|The control group received basic public health services which is regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge.
33312631|NCT01123772|Placebo Comparator|Control|Vehicle control
33312632|NCT01123772|Experimental|INO-8875|Active drug
33097394|NCT04519931|Experimental|Stress ball|
33097395|NCT04519931|No Intervention|Control group|
33097396|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
33097397|NCT04511936|Active Comparator|i-Lumen AMD Active|
33097398|NCT04511936|Sham Comparator|i-Lumen AMD Sham|
33097399|NCT01249794|No Intervention|Best available treatment|
33097400|NCT01249794|Experimental|non invasive ventilation|
33097401|NCT04519736|Active Comparator|Harmony Dye-VL 500-600nm|The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
33097402|NCT04519736|Active Comparator|Palomar MaxG|Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
33097403|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
33097404|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
33097405|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
33097406|NCT04511897|Experimental|Experimental group|oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.
33097407|NCT04511897|No Intervention|Control group|No experimental durgs used.
33097408|NCT04695093||London (intervention)|1606 children aged 6-9 yrs old, recruited in 44 London primary schools (years 2-4) within the Central London ULEZ area
33097409|NCT04695093||Luton (comparison)|1706 children aged 6-9 yrs old, recruited in 41 Luton and Dunstable primary schools (years 2-4)
33097410|NCT04519463|Experimental|Xylocaine|30 patients who receive Xylocaine 10% nasal spray
33097411|NCT04519463|Placebo Comparator|Saline|30 patients who receive saline nasal spray
33097412|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
33097413|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
33097414|NCT04519424|Experimental|CSL324|CSL324 administered intravenously
33097415|NCT04519424|Placebo Comparator|Placebo|Normal saline administered intravenously
33097416|NCT04696770|Experimental|Mindfulness Intervention|"Four face-to-face direct coachings on Mindfulness technique at weekly intervals. The following will be the broad theme of each coaching session~Week 1 - On the first encounter, the mothers will learn how to practice an introductory mindfulness technique to develop the awareness of any sensations felt in the body while holding their baby.~Week 2 - On the second encounter, the mothers will learn how to practice a second mindfulness technique to create positive feelings in the body while holding their baby.~During the third and fourth weekly encounters, the mothers will have a chance to ask their questions and explore further both mindfulness techniques as needed."
33097417|NCT04696770|No Intervention|Control|Standard of care will be offered to all mothers in the control group which includes kangaroo care but does not involve any mindfulness practices.
33097418|NCT04511780||Caregivers|• Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak
33097419|NCT04696848|Experimental|CKD-516 plus Durvalumab|Stage 1 : dose escalation durvalumab (1500 mg Q4W) plus CKD-516 at dose levels (9, 11, or 13 mg/m2) Stage 2 : durvalumab (1500 mg Q4W) plus CKD-516 at recommended phase 2 dose
33097420|NCT04511585|Experimental|GLMC experimental arm|GLMC experimental arm receiving a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice
33097421|NCT04511585|No Intervention|the control arm|the control arm that do not receive any intervention
33097422|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
33097423|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
33097424|NCT04519346|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with migraine pain
33097425|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
33312633|NCT05309746||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation. Pre-surgery assessment will be done while the child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove the child's ovary is called laparoscopy. It is not required for the treatment of the child's cancer or other medical condition. Laparoscopic surgery is done under general anesthesia (the child will be asleep during the surgery) in the operating room.
33312634|NCT03930836|Active Comparator|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
33312635|NCT03930836|Experimental|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
33312636|NCT00323609|Active Comparator|Kyphoplasty|
33312637|NCT00323609|Active Comparator|Vertebroplasty|
33312638|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
33312639|NCT04918420|Experimental|Flow Diverter (Tonbridge)|Treatment with Flow Diverter (Tonbridge)
33312640|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
33312641|NCT01220804||Control Population|Healthy volunteers
33312642|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
33312643|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
33312644|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
33312645|NCT05125510||Hospitalized ICU Cohort|COVID-19+ patients over age 16 who are critically ill and admitted to an ICU and/or required mechanical ventilation (MV) in participating hospitals will be invited to participate. Patients who were hospitalized prior to study start up will be invited to participate in CANCOV.
33312646|NCT05125510||Hospitalized non-ICU Cohort|COVID-19+ patients over age 16 admitted to acute care hospitals, GIM/other wards of participating hospitals will be invited to participate. Patients who were hospitalized prior to this study start up (from January 25, 2020 to study start up) will be invited to participate in this study.
33312647|NCT05125510||Non-Hospitalized Cohort|Individuals who are community dwelling, over the age of 16, are COVID-19+ and never hospitalized for their COVID-19 infection are included. These individuals may be diagnosed by participating hospital emergency rooms / in-person assessment centres / virtual clinics. In addition, we will include individuals who were diagnosed from January 25, 2020 within 6 months of study start up.
33312648|NCT05125510||Caregiver Cohort|Up to 500 family caregivers of patients admitted to the GIM wards and ICUs of participating hospitals will be invited to participate.
33312649|NCT05125510||Antibody Negative/Presumed COVID-19 comparator cohort|Approximately 500 individuals who do not have a positive COVID-19 test (nasal swab, serological antibody assay, etc.) but who have experienced COVID-19 symptoms and have strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case) will be invited to participate.
33312650|NCT01128140|Experimental|Motivational Enhancement Therapy|
33312651|NCT01128140|Active Comparator|Education|
33312652|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
33312653|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
33312654|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
33312655|NCT04975438|Experimental|Group 1: Biologic Naïve participants receiving GSK1070806|
33312656|NCT04975438|Placebo Comparator|Group 1: Biologic Naïve participants receiving Placebo|
33312657|NCT04975438|Experimental|Group 2: Dupilumab inadequate responders receiving GSK1070806|
33312658|NCT04975438|Placebo Comparator|Group 2: Dupilumab inadequate responders receiving Placebo|
33312659|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
33312660|NCT01224470|Placebo Comparator|saline|
33312661|NCT04406428|Experimental|NKI followed by EBD|
33312662|NCT04406428|No Intervention|Standard EBD|
33312663|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
33312664|NCT05052502|Experimental|reactive focal mass drug administration (rfMDA)|Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
33312665|NCT05052502|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
32948018|NCT04044846|Experimental|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
32948019|NCT04044222|Experimental|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
32948020|NCT04044222|Experimental|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
32948021|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
32948022|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
32948023|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
32948024|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
32948025|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
32948026|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
32948027|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
32948028|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
32948029|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
32948030|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
32948031|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
32948032|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
32948033|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
32948034|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
32948035|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
32948036|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
32948037|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
32948038|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
32948039|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
32948040|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
32948041|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
32948042|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
32948043|NCT01390272|Experimental|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
32948044|NCT01390272|Active Comparator|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
32948045|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
32948046|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
32948047|NCT01406652|Active Comparator|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
32948048|NCT01406652|Experimental|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
32948049|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
32948050|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
32948051|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
32948052|NCT01405950|Experimental|Dose Level 1|
32948053|NCT01405950|Experimental|Dose Level 2|
33097426|NCT04519112|Experimental|Remote magnetic navigation group|PVC ablation with RMN
32948054|NCT01405950|Experimental|Dose Level 3|
33097427|NCT04519112|Active Comparator|Mannual control navigation group|PVC ablation with mannual navigation
33097428|NCT01249950||adolescents|adolescents with morbid obesity
32948055|NCT01405950|Experimental|Dose Level 4|
32948056|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
32948057|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
32948058|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
32948059|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
32948060|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
32948061|NCT01389882|Experimental|ventilator assist|
32948062|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%~followed by~Treatment A2: ACT-246475"
32948063|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin~followed by~Treatment B2: ACT-246475"
32948064|NCT04031742|Experimental|Part 1: IBI306|Participants receive open-label IBI306 150 mg subcutaneously Q2W or 450 mg Q4W for 12 weeks.
32948065|NCT04031742|Experimental|Part 2: IBI306|Participants receive open-label 450 mg Q4W subcutaneously for 12 weeks.
32948066|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
32948067|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
32948068|NCT04051320|Experimental|Women with a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
32948069|NCT04051320|Experimental|Women without a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
32948070|NCT04050774|Experimental|Age group 1|6-9 years old
32948071|NCT04050774|Experimental|Age group 2|15-17 years old
32948072|NCT04050774|Experimental|Age group 3|18 - 24 years old
32948073|NCT04050774|Experimental|Age group 4|65-80 years old
32948074|NCT01426386|Experimental|5.2 µg|
32948075|NCT01426386|Experimental|6.9 µg|
32948076|NCT01426386|Experimental|8.6 µg|
32948077|NCT01426386|Experimental|10.3 µg|
32948078|NCT01426386|Experimental|12.1 µg|
32948079|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
32948080|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
32948081|NCT01403610|Experimental|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
32948082|NCT01403610|Experimental|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
32948083|NCT01403610|Experimental|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
32948084|NCT01403610|Experimental|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
32948085|NCT01403064|Experimental|Open Label ALD518|
32948086|NCT01403064|Experimental|ALD518 Dose 1|
32948087|NCT01403064|Experimental|ALD518 Dose 2|
32948088|NCT01403064|Placebo Comparator|Placebo|
32948089|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
32948090|NCT04408014||CORAS|Refugees living in the city of São Paulo
32948091|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
32948092|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
32948093|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
32948094|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
32948095|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
32948096|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
32948097|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
32948098|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
32948099|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
32948100|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
32948101|NCT01402908|Experimental|PI-88|Arm 1
32948102|NCT01402908|Placebo Comparator|Placebo|Arm 2
32948103|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
33097429|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
33097430|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
33097431|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
33097432|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
33097433|NCT04511351|Experimental|RT+GDP+Chidamide|IMRT followed by GDP chemotherapy with chidamide during radiation and chemotherapy phase
33312666|NCT01128218|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
33312667|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33312668|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
33312669|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
33312670|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
33097434|NCT04511351|No Intervention|RT+GDP|IMRT followed by GDP chemotherapy without chidamide during radiation and chemotherapy phase
33097435|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
33312671|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
33312672|NCT01124084||Health Care Providers|
33097436|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
33097437|NCT04519268||Elective Surgical Adult Patients|Adult patients scheduled for an elective general surgical operation.
33097438|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
33097439|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
33097440|NCT04511507||liver failure|patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
33097441|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
33097442|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
33097443|NCT04511546|Experimental|BPET Scan|
33097444|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
33097445|NCT04511390|Experimental|Transparent, reusable respirator|Transparent, reusable elastomeric respirator that has been designed to fit multiple different face sizes and shapes.
33097446|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
33097447|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
33097448|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
33097449|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
32803484|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
33097450|NCT04519151|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
33097451|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
32803485|NCT05240404|Other|Arm A|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation alone.
33097452|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
33097453|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
33097454|NCT04511000|Experimental|Experimental group|
33097455|NCT04511000|Active Comparator|Comparator group|
33312673|NCT03933956|Experimental|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
33097456|NCT04519385|Experimental|Tocilizumab|Tocilizumab
33097457|NCT04519385|Active Comparator|Dexamethasone|Dexamethasone therapy
33097458|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
33097459|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
33097460|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
33097461|NCT04518800|Experimental|Jin Youli(PEG-rhG-CSF)|PEG-rhG-CSF Secondary Prevention：patients with pancreatic cancer who met the eligibility criteria were given secondary prophylactic administration of the Jin Youli(PEG-rhG-CSF).
33097462|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
33312674|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
33312675|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
32803486|NCT05240404|Experimental|Arm B|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation and adjuvant immunotherapy with toripalimab.
32803487|NCT01923376|Other|Lactulose|per standard of care
32803488|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
32803489|NCT05246566||Subjects covered for suspected or SE diagnosis|"Patients covered for suspected or SE diagnosis defined by one of the following:~a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.~a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.~a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.~an absence-type crisis that lasts longer than 10 to 15 minutes.~a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.~a coma with an epileptic cause diagnosed on an EEG."
32803490|NCT05245786|Experimental|Treatment (64Cu labeled M5A antibody and imaging)|Patients receive 64Cu labeled M5A antibody IV over 5 minutes on day 0 pre standard of care chemo/radiotherapy and on day 0 post chemo/radiotherapy. Patients also undergo 64Cu-M5A PET scan on day 1 pre chemo/radiotherapy and on day 1 post chemo/radiotherapy.
32803491|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
32803492|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
32803493|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
32803494|NCT04396054|Active Comparator|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
32803495|NCT04396054|Active Comparator|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
32803496|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
32803497|NCT00634114|Experimental|2|Esomeprazole
32803498|NCT00634036|Active Comparator|1|
32803499|NCT00634036|Placebo Comparator|2|
33097463|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
33097464|NCT04510883|Experimental|PACO|Participants are asked to use the intervention for eight weeks.
33097465|NCT04510883|Other|Waiting list + PACO|Participants receive the same intervention, but only after a waiting period of four weeks.
33097466|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
32948104|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
32948105|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
32948106|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
33404689|NCT05077150||PCP cases|"Any allogeneic HSCT recipient who, during the 1-year study period, underwent a BAL from the day of transplant, and whose BAL fluid was positive for PcP: either by qPCR alone, or positive cytology or IF, irrespectively of clinical presentation, imaging, co-infection and PcP treatment. Only first episode of PcP will be included (incident cases).~Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP."
33404690|NCT05077150||Controls|Controls are matched to case on Centre and HSCT date and if possible on gender and date of birth.
32948107|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
32948108|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
32948109|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
32948110|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
32948111|NCT04030338||Prostate cancer|Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
32948112|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
32948113|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
32948114|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
32948115|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
32948116|NCT04029714|Active Comparator|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
32948117|NCT04029714|Experimental|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
32948118|NCT01424670|Experimental|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
32948119|NCT01424670|Placebo Comparator|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
32948120|NCT04028700|Experimental|G6PD Deficient Red Blood Cell Transfusion, then Non-G6PD deficient Red Blood Cell Transfusion|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity.
32948121|NCT04028700|Active Comparator|Non-G6PD deficient Red Blood Cell Transfusion, then G6PD Deficient Red Blood Cell Transfusion,|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity
32948122|NCT01424514|Experimental|SB-705498|
32948123|NCT01424514|Placebo Comparator|Placebo|
32948124|NCT04028310|Experimental|Phonological group|
32948125|NCT04028310|Experimental|visual-attention group|
32948126|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
32948127|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
32948128|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
33097467|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
33097468|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
32803500|NCT05241496|Experimental|Marina Ramsis|In the other group, 70 women will be randomly assigned for ibuprofen; participants will take 1 tablet (400mg) immediately & clinicians will wait at least 45 minutes before inserting the copper IUD
32803501|NCT05243602|Experimental|Switch to B/F/TAF|Participants in this arm will switch from their current ARV regimen to the study drug B/F/TAF. This is an oral drug administered once daily for the duration of the study.
32803502|NCT05243602|Active Comparator|Continue current regimen|Participants in this arm will be maintained on their pre-enrollment ARV regimen for the duration of the study.
32803503|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
33097469|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
33097470|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
33097471|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
33097472|NCT04510961|Active Comparator|Paraffin baths therapy (PBT) :group A|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
33097473|NCT04510961|No Intervention|Control group (B)|receive routine skin care program ; lifestyle change, emollients and moisturizers
33097474|NCT04510649|Experimental|Surufatinib and Rabeprazole (Part A)|Part A: Surufatinib 300 mg on study days 1 and 11 Rabeprazole 40 mg on study days 5 - 11
33097475|NCT04510649|Experimental|Surufatinib and Rifampin (Part B)|Part B: Surufatinib 300 mg on study days 1 and 12 Rifampin 600 mg on study days 5-15
33097476|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
33097477|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
33097478|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
32803504|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
32803505|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
32803506|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
33097479|NCT05653947|Experimental|Vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
33097480|NCT05653947|Other|Non-vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
33404691|NCT02624128|Experimental|valproic acid plus cisplatin and cetuximab|
32803507|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
32803508|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);~Subgroups:~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)~Please answer:~Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)~Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
32803509|NCT05242978|Experimental|Impact of GT, coffee, OJ, PGJ, milk, SSB on exercise induced oxidative stress&inflammation|single consumption of one cup of green tea (GT), coffee, orange juice (OJ), pomegranate juice (PGJ), milk and sugar sweetened beverage (SSB) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
32803510|NCT05242978|Experimental|Impact of choc, bcc, tomato, walnuts, r&w bread on exercise induced oxidative stress&inflammation|single consumption of one proportion of dark chocolate (choc), broccoli (bcc), tomatoes, walnuts, white bread and whole grain bread (r = refined & w = whole grain) 2 hours prior to a 30-min-HIIT resistance circuit exercise in healthy human subjects
32803511|NCT05242978|Experimental|Impact of r&p meat, cheese, eggs, tofu, salmon, on exercise induced oxidative stress&inflammation|single consumption of one proportion of red meat (r meat), full fat cheese, eggs, tofu, salmon and processed meat (p meat) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
32803512|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
32803513|NCT01539837|Placebo Comparator|Placebo|Drug excipient
32803514|NCT01539837|Active Comparator|Deferiprone 20mg|20mg/kg/day deferiprone
32803515|NCT01539837|Active Comparator|Deferiprone 30mg|30mg/kg/day Deferiprone
32803516|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
32803517|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
32803518|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
32803519|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
32803520|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
32803521|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
32803522|NCT04410081|Experimental|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
32803523|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
32803524|NCT03153124|No Intervention|Control|No intervention
32803525|NCT01923610|Experimental|Main|MVA HIV-B
32803526|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
32803527|NCT05248672|Experimental|150 mg QD|CT1812 150 mg QD
32803528|NCT05248672|Experimental|150 mg BID|CT1812 150 mg BID
32803529|NCT05248672|Experimental|300 mg QD|CT1812 300 mg QD
32803530|NCT05246410|Experimental|Spot stent system|A system that loaded multi low radial force stents on one catheter.
32803531|NCT05246410|Active Comparator|Self-Expanding peripheral stent system|A conventional stent system that commonly used.
32803532|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
32803533|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
32803534|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
32803535|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
32803536|NCT03128164|Experimental|Six arm including in dose expansion stage by following:|"Arm A: patients with MZL (subtype including nodal, extra-nodal and splenic) who received ≥ 1 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm B: patients with CLL/SLL who received ≥ 1 previous line of systematic treatment and at least one of which included purine-based regimen or CD20-directed regimen~Arm C: patients with FL (grade 1, 2, and 3a) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm D: patients with MCL who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm E: patients with DLBCL (including GCB and non-GCB, Richter' transformation) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm F: patients with PTCL who received ≥ 2 previous line of systematic treatment"
32803537|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
32803538|NCT00633022|Placebo Comparator|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
32803539|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
32803540|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
32803541|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
32803542|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
32803543|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
32803544|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
32803545|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
33312676|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
32803546|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
32803547|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
32803548|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
32803549|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
32803550|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
32803551|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
33312677|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
32803552|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
32803553|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
32803554|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
32803555|NCT00630838|Experimental|1|VSL#3 probiotic
32830793|NCT05228184|Experimental|Treatment|Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.) at the following strengths: 25, 37.5, 44, 50, 62.5, 75, 88, 100 mcg.
33312678|NCT00323297|Placebo Comparator|placebo|
33312679|NCT00323297|Experimental|Active|
33312680|NCT01126658||All subjects act as their own contral|
33312681|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
33312682|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
33312683|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
33312684|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
33312685|NCT01224860|Experimental|Telmisartan|
33312686|NCT01224860|Experimental|Losartan|
33312687|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
33312688|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
33312689|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
33312690|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
33312691|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
33312692|NCT03930368|Experimental|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
33312693|NCT03983057|No Intervention|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
33312694|NCT03983057|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 3mg/kg
33312695|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
33312696|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
33312697|NCT01329302|Active Comparator|Group A: Direct aspiration|
33312698|NCT01329302|Active Comparator|Follicular Flushing|
33312699|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
33312700|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
33312701|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
33312702|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
33312703|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
33318633|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
32948129|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
32948130|NCT01388166||Patients with COPD|
32948131|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
32948132|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
32948133|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab. This Phase 1b portion of the study has been completed.~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) of 15 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of every 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
32948134|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
32948135|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
32948136|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
32948137|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
32948138|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
32738025|NCT05009433|Active Comparator|Nonpregnant MICT group|"The moderate intensity continuous training program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
32738026|NCT05009433|Sham Comparator|Nonpregnant standard care group|During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests.
32738027|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
32738028|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
32948139|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
32738029|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
32948140|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
32948141|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
32948142|NCT04413786|Experimental|oxytocin group|male subjects with oxytocin treatment
32948143|NCT04413786|Placebo Comparator|placebo group|male subjects with placebo treatment
32948144|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
32948145|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
32948146|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
32948147|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
32948148|NCT01387230|Experimental|GSK573719|active drug
32948149|NCT01387230|Placebo Comparator|Placebo|no active drug
32948150|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
32948151|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
32948152|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
32948153|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
32948154|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
32948155|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
32948156|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
32948157|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
32948158|NCT01397448|Experimental|E3810 5 mg|
32948159|NCT01397448|Experimental|E3810 10 mg|
32948160|NCT01397448|Active Comparator|Teprenone 150 mg|
32948161|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
32948162|NCT05366010|Experimental|Intervention|Intervention time period, during which all subjects receive OLE therapy as their airway clearance intervention
32948163|NCT05365932|Experimental|TMD Pain group|Arm included patients with TMD Pain intensity >3 on a VAS scale and with diagnosis of myofascial pain, either alone or in combination with arthralgia, headache attributable to TMD or with disc displacement with reduction. Participants had to be 18 years of age or older. All subjects had to wear the device for 6 months and it should not be used for more than 23 hours in a 24-hour period
33318634|NCT01095588|Experimental|Avanafil|
33312704|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
33312705|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
33312706|NCT01047605|Experimental|PP1|Neurapas balance
32948164|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
32948165|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
32948166|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
32948167|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
32948168|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
32948169|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
33312707|NCT01047605|Experimental|PP2|Pascoflair 425 mg
33312708|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
33312709|NCT03934346|Other|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
33312710|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
33312711|NCT01329068|Active Comparator|Individual consult|regular individual consult
32948170|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
33312712|NCT01329068|Active Comparator|group medical consult|regular group medical consult
32948171|NCT01396434||Prevenar 13 patients|
33312713|NCT01061489|Experimental|sensory-cognitive training|
32948172|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
32948173|NCT05365698||Cohort I|randomly assigned 12 health facilities (treatment/intervention group) that will have access to CHN program components
33312714|NCT01061489|Experimental|physical fitness|
33312715|NCT01061489|No Intervention|waiting list (control group)|
33312716|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
33312717|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
33312718|NCT03930212|Experimental|Progesterone|received rectal progesterone suppositories 400 mg once daily
32948174|NCT05365698||Cohort II|randomly assigned 12 health facilities that will serve as a control for the first year of the program implementation and then transition into the intervention/treatment group
32948175|NCT05365464|Active Comparator|Progesterone|Women receive prometrium 200 mg qhs for up to 8 weeks
32948176|NCT05365464|Active Comparator|hCG|A single shot of hCG (ovidril 250 ug) will be given as a subcutaneous injection 1 week after ovulation
33312719|NCT03930212|Placebo Comparator|Control group|received placebo suppositories rectally once daily.
33312720|NCT01128374|Experimental|intervention|Therapy
33312721|NCT03932474|Experimental|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
33312722|NCT03932474|Placebo Comparator|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
33312723|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
33312724|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
33312725|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
33312726|NCT01221038||group 1|young women not using OC
33312727|NCT01221038||group 2|young women using OC
33312728|NCT01221038||group 3|young men (database)
33312729|NCT01124318|Active Comparator|Lactofiltrum|
33312730|NCT01124318|Placebo Comparator|Placebo|
32948177|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
32948178|NCT04766736||Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
33312731|NCT03930134|Experimental|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
33312732|NCT03930134|Active Comparator|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
33312733|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
33312734|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
33312735|NCT03929744|Experimental|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
33312736|NCT03929744|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally.
33312737|NCT03929744|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
32948179|NCT04766736||Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
33312738|NCT03929744|Placebo Comparator|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
33312739|NCT03929744|Experimental|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
33312740|NCT03929744|Experimental|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
33312741|NCT03929744|Placebo Comparator|Placebo (Part D)|Single dose of placebo administered orally.
32948180|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
33312742|NCT03929744|Experimental|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
33312743|NCT03929744|Experimental|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
33312744|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
33312745|NCT01225406||third line experienced|children who are on third line regimen
33312746|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
33312747|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
33312748|NCT01126814|Experimental|one|
32948181|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
32948182|NCT01396278|Experimental|BI 54903 low dose|patient to receive Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoroalkane (HFA) metered dose inhaler (MDI)
32948183|NCT01396278|Experimental|BI 54903 medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
32948184|NCT01396278|Experimental|BI 54903 high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
32948185|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|Fluticasone HFA MDI containing 440 mcg ICS plus placebo matching Respimat inhaler
32948186|NCT01396278|Active Comparator|Fluticasone propionate 88 mcg BID|Fluticasone HFA MDI containing 88 mcg ICS plus placebo matching Respimat inhaler
32948187|NCT05365152|Experimental|Meal replacement intervention group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight * 25/kcal (BMI > 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2. The meal replacement intervention group replaced the daily meal with meal replacement on the basis of the conventional diabetic diet. About 400kcal calories in carbohydrates."
33312749|NCT03929510|Experimental|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
33312750|NCT03929510|Experimental|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
33312751|NCT03929276|Experimental|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
33312752|NCT03929276|Placebo Comparator|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
33312753|NCT03929276|Active Comparator|control - exercises only group|exercise program
33312754|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
33312755|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
33312756|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
33312757|NCT03929354|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.~The 12-week programme will consist of 12 sessions of 2.5 hours each per week.~Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.~The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
33312758|NCT03929354|Active Comparator|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
33312759|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
33312760|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
32948188|NCT05365152|No Intervention|diabetes diet group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight * 25/kcal (BMI > 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2."
32948189|NCT05365074||chloroprocaine anesthesia for arthroplasty|patients having predicted uncomplicated surgery for total or unicompartment knee arthroplasty of anterior access total hip arthroplasty, operated under spinal anesthesia with 50 mg of chloroprocaine
32948190|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
32948191|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
32948192|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
32948193|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
32948194|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
32738030|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
32948195|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
32948196|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
32948197|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
32948198|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
32948199|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
32948200|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
32948201|NCT04040244|Experimental|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
32948202|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
32948203|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
32948204|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
32948205|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
32948206|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
32948207|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
32948208|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
32948209|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
32948210|NCT01395810|Experimental|On-demand|
32948211|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
32948212|NCT05366166|Experimental|Single Arm|The participants will receive neoadjuvant and adjuvant pembrolizumab and olaparib combination plus standard of care (chemoradiation therapy) as defined in the protocol.
32948213|NCT05363358||Ig-naive (New-to-class) Cohort|Participants who initiate GGL or one of the comparator IVIG products who have no record of previous use of any Ig product (Ig naive) for at least 6 months before study initiation will be include in this cohort.
32948214|NCT05363358||Ig-experienced (New-to-drug) Cohort|Participants who initiate either GGL or a comparator IVIG product with no record of previous use of that specific IVIG product but with previous use of any other Ig product (Ig experienced) in all available study data will be included in this cohort.
32948215|NCT05369598|Active Comparator|ABF fitting followed by standard fitting|
32948216|NCT05369598|Active Comparator|Standard fitting followed by ABF fitting|
33312761|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
33312762|NCT03928496|Experimental|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
33312763|NCT03928496|Placebo Comparator|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
33404692|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
32948217|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32948218|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32948219|NCT04013256|Experimental|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
32948220|NCT04013256|Active Comparator|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
32948221|NCT04013256|Active Comparator|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
32948222|NCT04013256|Sham Comparator|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
32948223|NCT01395030|Experimental|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
32948224|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
32948225|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
32948226|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
32948227|NCT01394952|Placebo Comparator|Placebo|Administered once weekly, subcutaneously
32948228|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
32948229|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
32948230|NCT04012710|Active Comparator|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
32948231|NCT04012710|Active Comparator|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
32948232|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
32948233|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
32948234|NCT01380990|Experimental|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
32948235|NCT01380990|Other|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
32948236|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
32948237|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
32948238|NCT04407702|Experimental|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
32948239|NCT04407702|Experimental|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
32948240|NCT04407702|Experimental|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
32948241|NCT04407702|Experimental|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
32948242|NCT04766658|Other|Water Swallow Intervention First|Subjects will complete voice recordings after water swallows and then perform voice recordings after gargle phonation.
32948243|NCT04766658|Other|Gargle Phonation Intervention First|Subjects will complete voice recordings after gargle phonation and then perform voice recordings after gargle phonation.
32948244|NCT05360940||A|100 positive stool samples for H.pylori
32948245|NCT05360940||B|100 negative stool samples for H.pylori
32948246|NCT05369676|Experimental|SSD8432 dose 1|SSD8432 dose 1/ritonavir or placebo
32948247|NCT05369676|Experimental|SSD8432 dose 2|SSD8432 dose 2/ritonavir or placebo
32948248|NCT04407468||COVID|Patients with or without prone position
32948249|NCT05363046||Group A|Participants will complete the PD diary on 3 consecutive days in 1 week.
33318635|NCT01095588|Placebo Comparator|Placebo|
33404693|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
32948250|NCT05363046||Group B|Participants will complete the PD diary on 2 consecutive days in each of 2 consecutive weeks.
32948251|NCT05368740||median IPI group|IPI score level was between 5-7
32948252|NCT05368740||high IPI group|IPI score level was between 8-10
33404694|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
33404695|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
32738031|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
32738032|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
32948253|NCT05361330|Experimental|The experimental group: Shuganjieyu capsule|Shuganjieyu capsule combined with Fluoxetine
32948254|NCT05361330|Placebo Comparator|The control group: Shuganjieyu capsule simulator|Fluoxetine monotherapy
32948255|NCT05364060||patients followed in psychiatry|Quantitative questionnaires
32948256|NCT00214968|Experimental|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
32948257|NCT00210522|Experimental|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
32948258|NCT03999216|Active Comparator|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
32948259|NCT03999216|Active Comparator|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
32948260|NCT00214422|Experimental|Arm 1- 5040cGy to the lymph nodes|5040Gray (cGy) to the lymph nodes
32948261|NCT00214422|Experimental|Arm 2 - 5400cGy to the lymph nodes|5400Gray (cGy) to the lymph nodes
32948262|NCT00214422|Experimental|Arm 3 - 5900cGy to the lymph nodes|5900Gray (cGy) to the lymph nodes
32948263|NCT05367180|No Intervention|Reference Arm|no preventive action
32948264|NCT05367180|Experimental|Vivre avec le Soleil|"Use of existing validated program vivre avec le soleil"
32948265|NCT05367180|Experimental|Vivre avec le Soleil + program of MISOLRE association|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association"
32948266|NCT05367180|Experimental|Vivre avec le Soleil + program of MISOLRE association + sun protections|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association and with the distribution of caps, sunscreens and sunglasses"
32948267|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
32948268|NCT03997968|Experimental|CYT-0851 dose escalation|Part A: CYT-0851 administered orally in rising doses QD or BID for 28 day cycles
32948269|NCT03997968|Experimental|CYT-0851 dose expansion|Part B: CYT-0851 administered orally at the selected Phase 2 dose for 28 day cycles
32948270|NCT03997968|Experimental|CYT-0851 and rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab on Day 1 and bendamustine on Days 1 and 2 of each 28 day cycle
32948271|NCT03997968|Experimental|CYT-0851 and gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine on Day 1, 8 and 15 of each 28 day cycle
32948272|NCT03997968|Experimental|CYT-0851 and capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine on Days to 14 of each 21 day cycle
32948273|NCT05368194|Experimental|Isocaloric Arm|Participants within the isocaloric arm will be provided with food provisions in accordance with their nutrition needs. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
32948274|NCT05368194|Experimental|Excess Calorie Arm|Participants within the excess calorie arm will be provided with food provisions in accordance with their nutrition needs plus an additional 500 kilocalories per day. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
32948275|NCT05367804|Experimental|Isolated plant protein|Visit 1 to 8 participants will collect faecal samples. Visits 4 to 8 in addition to the faecal sample, urinary samples (24 h urine collection) will be collected by themselves, and blood sample will be collected at the hospital. For the visits with blood collection (visits 4 to 8), subjects will come to the study centre after 10 hours of overnight fast. Subjects will have anthropometry measurements taken in the visits 4, 5, 6, and 7 using a Tanita® full body composition. Subjects will respond to questionnaires about their physical activity (once a week), Gastrointestinal Symptom rating scale (GSRS - once a week) and track their intestinal habits using Bristol scale (every day). Subjects' diet will be assessed using a web-based 24-hour diet recall (interviewed so the participants learn how to use the tool regardless of where they are) followed by multiple day records (3 times a week).
32948276|NCT05363280|Experimental|OBD finding cohort at low dose|Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
32948277|NCT05363280|Experimental|OBD finding cohort at middle dose|Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
33404696|NCT03639233|Other|Arm 1|Intervention access
32948278|NCT05363280|Experimental|OBD finding cohort at high dose|Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
32948279|NCT05362968|No Intervention|Control arm|Each participants on usual diet and lifestyle for 12 weeks
32948280|NCT05362968|Experimental|Strawberry intervention|Each participants will consume freeze-dried strawberry powder (32g/day) for 12 weeks
32948281|NCT05362578|Experimental|Treatment group|Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
32948282|NCT05362578|Sham Comparator|Sham group|Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
32948283|NCT03997422|Experimental|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
32948284|NCT05364528||clinical pregnancies with direct catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using direct technique.
32948285|NCT05364528||clinical pregnancies with afterload catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using afterload technique.
32948286|NCT04263090|Experimental|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
33404697|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
33404698|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
32948287|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
32738033|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
32948288|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
32948289|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
32948290|NCT03997266|Active Comparator|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
32948291|NCT03997266|Placebo Comparator|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
32948292|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
32948293|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
32948294|NCT05630508|Experimental|interactive mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application
32948295|NCT05630508|Sham Comparator|Sham group - app access only|Receiving standard care, LIVEN educational material and access to the application
32948296|NCT05630508|No Intervention|Control group - Standard care|Receiving Standard care only
32948297|NCT05368818||All patients|Included all patients prescribed an on-label secukinumab dose
32948298|NCT05368818||Patients with Psoriatic Arthritis (PsA)|Included patients classified as having a concomitant PsA diagnosis, if it was declared in the Baseline table
32948299|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
32948300|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
32948301|NCT03995082|Experimental|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
32948302|NCT03995082|No Intervention|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
32948303|NCT04021914|Experimental|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
32948304|NCT03994770|Other|STR|Older people who have suffered a stroke
32948305|NCT05630274|Experimental|Selpercatinib (Dose level 1)|Selpercatinib administered as single dose orally.
32948306|NCT05630274|Experimental|Selpercatinib (Dose level 2)|Selpercatinib administered as single dose orally.
32948307|NCT05630274|Active Comparator|Moxifloxacin|Moxifloxacin administered as single dose orally.
32948308|NCT05630274|Placebo Comparator|Placebo|Placebo administered orally.
32948309|NCT05630040|Experimental|Non-invasive Vagus Nerve Stimulation|Participants in the Non-Invasive Vagus Nerve Stimulation arm will have devices calibrated to a therapeutic setting.
32948310|NCT05630040|Sham Comparator|Sham Vagus Nerve Stimulation|"Participants in the sham VNS arm will be asked to use the VNS device daily on a sham setting for six weeks and will be given the opportunity to crossover into the active VNS arm once they have completed the sham arm."
32830794|NCT05228184|Active Comparator|Control|Crushed levothyroxine sodium tablets
33097481|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
33097482|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
33097483|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
33097484|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
33097485|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
33097486|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
33097487|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
33097488|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
33097489|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
33097490|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
33097491|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
33097492|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
33097493|NCT04518956|Experimental|Inter maxillary fixation and exposure to shockwave therapy|
32738034|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
32738035|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
32738036|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
32738037|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
32738038|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
32738039|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
32738040|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
32738041|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
32738042|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
32738043|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.~Drug: Capecitabine"
32738044|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.~Drug: Capecitabine"
32738045|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
32738046|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
32738047|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
32738048|NCT03092973||Epistaxis Group|
32738049|NCT03092973||Control Group|
32738050|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32738051|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32738052|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32803556|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
33312764|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
33312765|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
32803557|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
33312766|NCT01128998|Experimental|S-1 and Sorafenib|
33312767|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
33312768|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
33312769|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
33312770|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
33312771|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
33312772|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
33312773|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
33312774|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
33312775|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
33312776|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
33312777|NCT03928340|Active Comparator|combined metformin and insulin|
33312778|NCT03928340|Other|Insulin only|
33312779|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
33312780|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
33312781|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
33312782|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
33312783|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
33312784|NCT03929198|Experimental|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
33312785|NCT03929198|No Intervention|Control|This group did not receive any intervention.
33312786|NCT03982823|Experimental|Hand-Sewn Sleeve Gastrectomy|
33312787|NCT03982823|Active Comparator|Stapled Sleeve Gastrectomy|
33312788|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
33312789|NCT01128920|Experimental|Assessment-Only Condition|
33312790|NCT03928886|Experimental|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
33312791|NCT03928886|Active Comparator|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
33312792|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
33312793|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
33312794|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
33312795|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
33312796|NCT00321737|Placebo Comparator|Placebo|
33312797|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
33312798|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
33312799|NCT03924674|Active Comparator|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
33312800|NCT03924674|Active Comparator|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
33312801|NCT03924674|Active Comparator|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
33312802|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
33312803|NCT01325363|Experimental|Control|Neurotypical subjects
32948311|NCT04407624|Experimental|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
32948312|NCT04407624|Active Comparator|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
33312804|NCT01126892|Experimental|Nilotinib|
33312805|NCT01061645|Experimental|MOC31-PE|
33312806|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
33312807|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
33312808|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
33312809|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
33312810|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
33312811|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
32948313|NCT05632692|Experimental|Intervention|A menthol solution is going to be formulated by crushing and dissolving one noncalorific menthol candy drop (15 mg) in 150 ml of warm water, in order to obtain a solution with a concentration of 0.01%. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each participant on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
32948314|NCT05632692|Placebo Comparator|Placebo|A placebo beverage is going to be prepared using noncaloric berry-flavored sweetener consisting of sucralose candy drops, which will be crushed and dissolved in 150 ml of warm water. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each athlete on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
32948315|NCT05632614|Active Comparator|High-intensity IMST|Participants who will be trained with high-intensity IMST
32948316|NCT05632614|Sham Comparator|Low-intensity IMST|Participants who will be trained with low-intensity IMST
32948317|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
32948318|NCT04407312|Experimental|CILO group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
32948319|NCT04407312|Placebo Comparator|Placebo group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
32948320|NCT03993444|Experimental|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
32948321|NCT03993444|Active Comparator|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
32948322|NCT04009668|Experimental|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
32948323|NCT04020276|Experimental|MRI-Guided SBRT Dose Escalation|"Treatment on MRI Linac with SBRT in 5 fractions with adaptive planning, maximum dose 80 Gy~Dose Escalation Bowel Pathway, V34 < 0.5cc Dose Escalation Liver Pathway, 700 cc < 16 Gy~Subsequent Phase 1B: CRC only for Safety and Local Control, dosage informed by Phase 1A"
32948324|NCT04326738|Placebo Comparator|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
32948325|NCT04326738|Active Comparator|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
32948326|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
32948327|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
32948328|NCT04347486|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
32948329|NCT04347486|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
32948330|NCT04347486|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
33312812|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
33312813|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
33312814|NCT03983135|Experimental|Study group|Patients who undergo revisional bariatric surgery
33312815|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
33312816|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
33312817|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
33312818|NCT03982667|Experimental|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
32948331|NCT04347486|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
32948332|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
32948333|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
32948334|NCT03598608|Experimental|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
32948335|NCT03598608|Experimental|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
32948336|NCT03598608|Experimental|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
32948337|NCT03598608|Experimental|Part B: cHL-Combination Therapy|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the recommended Phase 2 dose (RP2D) of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
33312819|NCT03982667|No Intervention|Standard-of-care group|
33312820|NCT01226498|Experimental|Fresh blood auto-transfusion|
33312821|NCT01226498|Experimental|Old blood auto-transfusion|
32948338|NCT03598608|Experimental|Part B: DLBCL-Combination Therapy|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
32948339|NCT03598608|Experimental|Part B: iNHL-Combination Therapy|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
33312822|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
33312823|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
33312824|NCT03740594|Active Comparator|KMC 60 min group|
32948340|NCT03598608|Experimental|Part B: Randomized cHL-Monotherapy|Participants with cHL receive either pembrolizumab by IV infusion or the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).
32948341|NCT03992196|Experimental|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
32948342|NCT04407234|Experimental|Tirzepatide + Acetaminophen|Tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.
32948343|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
32948344|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
32948345|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
32948346|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
32948347|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
32948348|NCT05632458|Experimental|double stent retriever|
32948349|NCT05632458|Active Comparator|single stent retriever|
32948350|NCT05632224|Active Comparator|Aprepitant|Substance P inhibitor chemotherapeutic and also useable for prevention of postoperative nausea and vomiting
33312825|NCT03740594|Active Comparator|KMC 120 min group|
33312826|NCT03740594|Active Comparator|control group|
33312827|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
33312828|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
33312829|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
33312830|NCT01129232|Placebo Comparator|Placebo|
33097494|NCT04518956|Experimental|Inter maxillary fixation and exposure to low intensity pulsed|
33097495|NCT04518956|Active Comparator|Inter maxillary fixation only|
33312831|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
33312832|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
33312833|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
33312834|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
33312835|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
33312836|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
33312837|NCT01127048|Experimental|Prospan Hustenzäpfchen|
33312838|NCT01127048|Placebo Comparator|Placebo|
33312839|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
33312840|NCT03928574||Conventional|Conventional Block
33312841|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
33312842|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
33312843|NCT03924830|Active Comparator|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
33312844|NCT03924830|Experimental|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
33312845|NCT03924830|Experimental|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
33312846|NCT03924596|Experimental|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
33312847|NCT03924596|Active Comparator|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
33312848|NCT03924596|Experimental|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
33312849|NCT03924596|Active Comparator|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
33312850|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
33312851|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
33312852|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
33312853|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
33312854|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
33312855|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
33312856|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
33312857|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
33312858|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
33312859|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.
33312860|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously on the day of randomization.
33312861|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
33312862|NCT03928106|Other|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
33312863|NCT03928106|Other|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
33312864|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
33312865|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
33312866|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
33312867|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
33312868|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
33312869|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
33312870|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
33312871|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
33312872|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
33312873|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
33312874|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
33312875|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
33312876|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
33312877|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
33312878|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
33312879|NCT03923816|Experimental|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
33312880|NCT03923816|Experimental|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
33312881|NCT03927872||cardioembolic stroke|
33312882|NCT03927872||non cardioembolic stroke|
33312883|NCT01129466|Active Comparator|Supplement A followed by supplement B|
33312884|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
33312885|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
33312886|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
33312887|NCT03992573|Experimental|Study group|
33312888|NCT03992573|No Intervention|Control group|
33312889|NCT03928028|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
33312890|NCT03928028|Experimental|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
33312891|NCT03928028|Experimental|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
33312892|NCT03923894|Experimental|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
33312893|NCT03923894|Placebo Comparator|Placebo|Placebo 2.07 g/day for 8 weeks.
33312894|NCT03923660|Experimental|Concentric-eccentric|Concentric-eccentric
33312895|NCT03923660|Experimental|Eccentric-concentric|Eccentric-concentric
33312896|NCT01221818|Experimental|1|
33312897|NCT01221818|Experimental|2|
33312898|NCT01221818|Experimental|3|
33312899|NCT01221818|Experimental|4|
33312900|NCT01221818|Experimental|5|
33312901|NCT01221818|Experimental|6|
33312902|NCT01228604|Experimental|Methylphenidate|
33312903|NCT03932084|Experimental|Control group|"During hospitalization:~Monitor subjects' blood glucose;~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
33312904|NCT03932084|Experimental|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
33312905|NCT01228682||Patients who are treated with Samsca.|
33097496|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
33097497|NCT04510610|Experimental|Camrelizumab plus decitabine|Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.
33097498|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
33097499|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
33312906|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
33312907|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
33097500|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
33097501|NCT04518878|Experimental|Fixed Low-dose Eltrombopag and rhTPO|Fixed Low-dose Eltrombopag and rhTPO
33097502|NCT04518371|Experimental|Indirect Restoration|Milled Resin Composite Block, Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments (inorganic pigments such as ferrous oxide or titanium dioxide).
33097503|NCT04518371|Active Comparator|Direct Restoration|"3M™ Filtek™ One Bulk Fill Restorative is a visible light activated, restorative composite optimized to create fast and easy restorations.~It is composed of fillers which are a combination of a non-agglomerated/non-aggregated 20 nm silica filler, 4 to 11 nm zirconia filler, zirconia/silica cluster filler and ytterbium trifluoride filler consisting of 100nm particles. The inorganic filler loading is about 76.5% by weight (58.5% by volume)."
33097504|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
33312908|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
33312909|NCT03923114|Other|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
33312910|NCT03923114|Other|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
33312911|NCT03923192|Other|ICDAS II|Visual tactile examination based on ICDASII scoring system
33312912|NCT03923348|Experimental|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
33097505|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
33097506|NCT01244490|Placebo Comparator|Placebo|
33097507|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
33097508|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
33097509|NCT00506090|Sham Comparator|C|dynamic cooling device
33097510|NCT04510376|Experimental|Test article|
33097511|NCT04510376|Active Comparator|Histamine Positive Skin Test Control|
33097512|NCT04510376|Placebo Comparator|Aqueous Negative Control|
33097513|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
33097514|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
33097515|NCT04518488|Active Comparator|Prehabilitation group|The prehabilitation group will receive a set of exercises designed to strengthen both limbs. The exercises will be taught and illustrated by a trained physiotherapist and are to be done daily during the period prior to surgery. The participant will be coached and supported for the exercise program, twice a week during the pre-operative period.
33097516|NCT04518488|Other|Informational support group (control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period. The intervention will be in the form of telephone or video calls by a trained health professional. These calls will be scheduled twice a week during the pre-operative period.
33097517|NCT04510571|Active Comparator|Protaper Next|Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
33312913|NCT01228760|Experimental|Dose level 1|
33312914|NCT01228760|Experimental|Dose level 2|
33312915|NCT01228760|Experimental|Dose level 3|
33312916|NCT01228760|Experimental|Dose level 4|
33312917|NCT01228760|Experimental|Dose level 5|
33312918|NCT01228760|Experimental|Dose level 5A|
33312919|NCT01228760|Experimental|Dose level 6|
33312920|NCT01228760|Experimental|Dose level 7|
33312921|NCT01228760|Experimental|Dose level 8|
33312922|NCT01228760|Experimental|Dose level 9|
33312923|NCT01228760|Experimental|Chemotherapy-naïve subjects|
33312924|NCT01228760|Experimental|Chemotherapy exposed subjects|
33312925|NCT03927404|Experimental|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
33312926|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
33312927|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
33312928|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
33312929|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
32803558|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
32803559|NCT03126136|Experimental|Pregnant women|
32803560|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
32803561|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
32803562|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
33312930|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
33312931|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
33312932|NCT03927560|Experimental|Robotic Assisted Percutaneous Coronary Intervention|
33312933|NCT01226966||A|
33312934|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
33312935|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
33312936|NCT01228838|Placebo Comparator|Placebo liquid|
33312937|NCT03922412|Active Comparator|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
33312938|NCT03922412|Active Comparator|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
33312939|NCT03919838|Active Comparator|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
33312940|NCT03919838|Placebo Comparator|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
33312941|NCT01129700|Experimental|short-course CRT-5FU|
33312942|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
33312943|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
33312944|NCT03919916|Experimental|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
33312945|NCT03919916|Active Comparator|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
33312946|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
33312947|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
33312948|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
33312949|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
33312950|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
33312951|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
33312952|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
33312953|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
33312954|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
33312955|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
33312956|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
33312957|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
33312958|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
33312959|NCT03922178|Experimental|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
33312960|NCT01131650||diabetic retinopathy|
33312961|NCT01131650||diabetica retinopathy prevalence|
33312962|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
32948351|NCT05632224|Active Comparator|Granisetron|5- HT3( 5-hydroksitriptamine 3) antagonist drug for prevention of postoperative nausea and vomiting
32948352|NCT05632146|Active Comparator|Patients with hollow viscus perforation|
32948353|NCT05632146|Active Comparator|Patient with hollow viscus perforation|
33312963|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
33312964|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
33312965|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
33312966|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
33312967|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
33312968|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
33312969|NCT03927170|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
33312970|NCT03927170|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
33312971|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
33312972|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
33312973|NCT03922022|Experimental|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
33312974|NCT03921632|Experimental|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
33312975|NCT01227356|Experimental|imatinb + pegIntron|
33312976|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
33312977|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
33312978|NCT03922100|Experimental|Dose Escalation and Expansion (Phase I)|Dose escalation will be applied until one patient experiences first cycle DLT (Dose Limiting Toxicity) or 2 patients at any dose level experience non-DLT NCI CTCAE Grade ≥2 drug-related toxicity during the first cycle. Once the Maximum Tolerated Dose (MTD) is identified, a maximum of 10 additional patients will be enrolled (dose expansion).
33312979|NCT03922100|Experimental|AML FLT3 mutated (Phase II)|Cohort of AML FLT3 mutated patients. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
33312980|NCT03922100|Experimental|CMML (Phase II)|Cohort of patients with CMML. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
33312981|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
33312982|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
33312983|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
33312984|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
33312985|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
33312986|NCT03927326|Experimental|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
33312987|NCT03927326|Experimental|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
33312988|NCT03919682|Experimental|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
33312989|NCT03919682|Experimental|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
33312990|NCT03919682|No Intervention|Control|6 health centers served as controls and did not receive training during the study period
33312991|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
33312992|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
33404699|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
33312993|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33312994|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
32948354|NCT05632068|Experimental|Xian-Hua-Cha (XHC) group|Xian-Hua-Cha (XHC) 520 mL, twice a day will be given with diet education/monitoring program for this group for 3 months, followed by one-month wash-out period and a 3-month period with diet education/monitor program alone.
33312995|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
32948355|NCT05632068|No Intervention|Control group|Diet education/monitoring program (500 kcal lower than estimated total energy expenditure of each subject) will be given to each subject for 3 months first, followed by one month wash-out period and a 3-month period of Xian-Hua-Cha (XHC) 520 mL, twice a day, intervention course.
32948356|NCT05366322||Cohort A: mRNA-1273 COVID Vaccine|Participants who have received 2 doses of the mRNA-1273 vaccine at least 14 days apart.
32948357|NCT05366322||Cohort B: BNT1262b2 COVID Vaccine|Participants who have received 2 doses of the BNT1262b2 vaccine at least 14 days apart.
32948358|NCT05631912|Experimental|Autologous TRAC locus-inserted CD19-targeting STAR-T cells|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous targeting CD19 synthetic T-cell receptor antigen receptor T cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
32948359|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
32948360|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
32948361|NCT05366088|Experimental|Mindfulness-Based Cognitive Therapy|Group sessions 2 hours/week, for 8 weeks, based on the manualized protocol developed by co-I Dr. Segal and will be delivered by social workers (or equivalent) with ≥3 years of experience delivering MBCT and training for official certification from the Center for Mindfulness Studies (Toronto).
32948362|NCT05366088|Active Comparator|Health Enhancement Program|Group sessions 2 hrs/week for 8 weeks, and amount of home practice (~30 mins/day, 6 days/week). HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin.
33312996|NCT03921710|Active Comparator|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
33312997|NCT03921710|Active Comparator|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
33312998|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
33312999|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
33313000|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
33313001|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
33313002|NCT03921398||Healthy individuals|Healthy individuals
33313003|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
33313004|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
33313005|NCT03921086|Other|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
33313006|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide~Type: Yellow granule stick~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
33313007|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
33313008|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
33313009|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
33313010|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
33313011|NCT01132742||hospitalised children|
32803563|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
32803564|NCT00630058|Experimental|Group A (MP-424 High)|
32803565|NCT00630058|Experimental|Group B (MP-424 Low)|
32803566|NCT01925794|Experimental|COBRA PzF Stent|Single Arm study
32803567|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
32803568|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
32803569|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
32803570|NCT01927198|Placebo Comparator|Placebo|Placebo group
32803571|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
32803572|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
32803573|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
32803574|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
32803575|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
32803576|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
32803577|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
32803578|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
32803579|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
32803580|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
32803581|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
32803582|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
32803583|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
32803584|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
32803585|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
32803586|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
32803587|NCT00981448|Experimental|Zinc supplement|
32803588|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
32803589|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
32803590|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
32803591|NCT04395820||Cystic Fibrosis|
32803592|NCT04395820||Healthy|
32803593|NCT04395742||Coffee:1,3,7-trimethylxanthine|
32803594|NCT04395742||Tea and hot chocolate with milk|
32803595|NCT00989950|Experimental|Daytrana 9 hr wear|
32803596|NCT00989950|Experimental|Daytrana 10 hr wear|
32803597|NCT00989950|Experimental|Daytrana 11 hr wear|
32803598|NCT00989950|Experimental|Daytrana 12 hr wear|
32803599|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
32803600|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
32803601|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
32803602|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
32830795|NCT04784403||Students and workers at the University of Barcelona|"The study population will be randomly selected from the different groups of the University:~Students from the different centers and type of studies (undergraduate / graduate).~Administrative and service personnel.~Teaching and Research Staff."
33313012|NCT03927248|Experimental|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
33313013|NCT03926780|Active Comparator|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
33313014|NCT03926780|Experimental|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
33313015|NCT01585532||TB suspects with alternative final diagnosis|
33313016|NCT01585532||Confirmed tuberculosis patients|
32830796|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
32830797|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
32830798|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
33313017|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
33313018|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
32830799|NCT04783623||Non-recurrence group|
33313019|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
33313020|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
33313021|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
33313022|NCT03920930|Experimental|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
33313023|NCT03920930|Active Comparator|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
33313024|NCT01585610|Experimental|DVD Program|
33313025|NCT01585610|Active Comparator|Standard Care Printed Materials|
33313026|NCT03919448|Active Comparator|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
33313027|NCT03919448|Active Comparator|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
33313028|NCT03919448|Active Comparator|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
33313029|NCT03926936|Experimental|Low-grade uterine sarcoma|
33313030|NCT03926936|Experimental|low-grade endometrial carcinoma|
33313031|NCT03926936|Experimental|sex cord stromal tumors|
33313032|NCT03926936|Experimental|low-grade serous ovarian cancer|
33313033|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
33313034|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
32830800|NCT04783623||Recurrence group|
32830801|NCT01679457|Experimental|ACT-Focused ERP|One Session.
32830802|NCT01679457|Active Comparator|TAU-ERP|One Session.
32830803|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
32830804|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
32830805|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32830806|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
32830807|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
33097518|NCT04510571|Active Comparator|Reciproc Blue|Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
33097519|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
33097520|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
33097521|NCT04518527|Active Comparator|true taping+ exercise|The true taping method was applied to the first group according to the method determined by Kase. According to this method, a 2-inch (5 cm) wide beige-colored Kinesio tape (Kinesio® Tex Gold FP) was measured from the second-third metacarpal base to the lateral epicondyle while the elbow was extended and the wrist was in the neutral position and the tape was applied in the shape of a 'Y'. In a position where the wrist-ankle extensors were most tense (wrist-ankle extension - forearm pronation), the anchor point of the tape was applied to the insertion of the muscle without creating any tension. Then, the tape was applied to the medial and lateral edges of the wrist extensors by applying a 15-25% tension towards the origin of the muscle. Both ends of the Y-shaped tape were terminated without tension on the lateral epicondyle.
33097522|NCT04518527|Placebo Comparator|sham taping+exercise|In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
33313035|NCT03920618|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
33313036|NCT03920618|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
33313037|NCT03920618|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
33097523|NCT00516438|Experimental|1|Topotecan + KU-0059436
33313038|NCT03920852|Experimental|Ruxolitinib cream|
33313039|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
33313040|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
33313041|NCT03919058|Active Comparator|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
32803603|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
32803604|NCT04276012|Experimental|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
32803605|NCT04276012|No Intervention|Control group|Usual clinical care
32803606|NCT03121456|Experimental|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
32803607|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
32803608|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
32803609|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
32803610|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
33097524|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
33097525|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
33097526|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
33097527|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
32803611|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
32803612|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
33097528|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
33097529|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
33097530|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
33313042|NCT03919058|Experimental|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
33313043|NCT03919058|Experimental|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
32803613|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
33313044|NCT03919058|Experimental|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
33313045|NCT03920540|Experimental|GC1111|All subjects should receive the GC1111 for 52 weeks.
33313046|NCT03920540|Active Comparator|Comparator|All subjects should receive the comparator for 52 weeks.
33313047|NCT01229540|No Intervention|Lifestyle counseling|
33313048|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
33313049|NCT01227746||Tumor biopsies|
32803614|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
32803615|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
32803616|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
33313050|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
33313051|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
32803617|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
32803618|NCT04629703|Active Comparator|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
32803619|NCT04629703|Placebo Comparator|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
32803620|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
32803621|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
33313052|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
33313053|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
32803622|NCT04629625|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
32803623|NCT04629625|Active Comparator|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
32803624|NCT04629625|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
32803625|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
32803626|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
32803627|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
32803628|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
32803629|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
32803630|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
32803631|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
32803632|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
32803633|NCT00988858|Experimental|LY2603618 and Pemetrexed|
32803634|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
32803635|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
32803636|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
32803637|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
32803638|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
32948363|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
32948364|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
32948365|NCT03595644|Experimental|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
32948366|NCT03595644|Active Comparator|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
32948367|NCT05631678|Experimental|the effect of oral rifampicin on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 160mg in fast condition；Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASK120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
32948368|NCT05631678|Experimental|effect of oral itraconazole on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 80mg in fast condition；Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
32948369|NCT05631600|Experimental|Manuka honey|The intervention in this study was conducted in a split-mouth design, meaning that after completing the NSPT for each subject, Manuka honey was administered as an adjunct to the periodontal treatment in two randomly selected quadrants of the oral cavity around the teeth with a specially designed cannula. The cannula reached the bottom of the periodontal pocket and moved circumferentially around the tooth at 6 sites, and Manuka honey was extruded until the excess of the material was observed in the sulcus.
32948370|NCT05631522|Experimental|foot reflexology group|Patients who will receive foot reflexology before and throughout the MCDR procedure.
32948371|NCT05631522|No Intervention|control group|Patients who will receive the routine ICU care during the MCDR procedure.
32948372|NCT05631444|Placebo Comparator|Placebo group|Placebo group (n=10), which consisted of 15 injections of 1 mL of vehicle (1 mL saline solution with 2% of autologous serum) on periadventitial arteries in one dose at day 0.
32948373|NCT05631444|Experimental|Auto-BM-MNC|Auto-BM-MNC (n=7) were obtained from diabetic patients. Fifteen injections of 7.197x106 ± 2.984x106 cells/mL each with 2% of autologous serum were periadventitial arteries administrated in one dose at day 0.
32948374|NCT05631444|Experimental|Allo-WJ-MSCs|Allo-WJ-MSCs (n=7) were obtained from culturing the WJ from healthy cordon umbilical donors unrelated to the patient. Fifteen injections of 1.333x106 cells/mL each with 5% of human serum albumin serum were periadventitial arteries administrated in one dose at day 0.
32948375|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
32948376|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
32948377|NCT03990012|Experimental|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
32948378|NCT03980418|Experimental|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
32948379|NCT03979404|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
32948380|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
32948381|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
32948382|NCT03599700||myeloproliferative neoplasms|"history taking~physical examination~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
32948383|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
32948384|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
32948385|NCT05631288||Cases|Periodontally compromised patients attending the Periodontology Department during periodontal diagnosis appointments at the point of first diagnosis.
32948386|NCT05631288||Controls|Periodontally healthy patients attending the remaining specialty departments ath the same clinic at the point of first diagnosis.
32948387|NCT03595410||Recurrence laryngeal cancer|
32948388|NCT03595410||No recurrence laryngeal cancer|
32948389|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
32948390|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
32948391|NCT05631210|No Intervention|Normal privacy agreement|This group was the control. They were given a normal privacy agreement to read and interpret.
32948392|NCT05631210|Experimental|Pictogram privacy agreement|This group was given the same privacy agreement of the control group, but with the addition of pictograms that summarized the information.
32948393|NCT05631132|Other|BAL + NIV|
32948394|NCT05631132|Other|BAL without NIV|
33313054|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
33097531|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
33097532|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
33097533|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
33097534|NCT02275988|Experimental|K-877|K-877
33097535|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
33097536|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
33097537|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
33097538|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
33097539|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
33313055|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
33313056|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
33313057|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
33313058|NCT03920228|Experimental|Open label period|
33313059|NCT03920228|Placebo Comparator|Randomized period - Dosing A|
33313060|NCT03920228|Experimental|Randomized period - Dosing B|
33313061|NCT03920228|Experimental|Randomized period - Dosing C|
33313062|NCT03920150|Active Comparator|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
33313063|NCT03920150|Active Comparator|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
33313064|NCT03920150|Active Comparator|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value [nmol/l] x body weight [kg] / 24'000 IU.
32830808|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
33097540|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
33097541|NCT04694625|Experimental|Structured rehabilitation program|Structured rehabilitation program & conventional physical therapy
33097542|NCT04694625|Active Comparator|conventional physical therapy|conventional physical therapy
33097543|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
33097544|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
33313065|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
33313066|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
33313067|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
33313068|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
33313069|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
33313070|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
33313071|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
33313072|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
33313073|NCT01229774|Experimental|Etoricoxib|
33313074|NCT01229774|Active Comparator|Diclofenac|
33313075|NCT03918590|Active Comparator|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
33313076|NCT03918590|Other|Patching|A light pressure patch applied for two hours
33313077|NCT03918590|Placebo Comparator|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
33313078|NCT01231724|Active Comparator|Allstate Nasal Spray|
33313079|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
33313080|NCT01130402||Neck masses|Patients with previously untreated neck masses
33313081|NCT03918746|Experimental|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
33097545|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
33097546|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
33097547|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
33097548|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
33097549|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
33097550|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
33097551|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
33097552|NCT04510415|Experimental|Olmutinib 600mg|HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)
33097553|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
33097554|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
33097555|NCT04517942|Experimental|EVERYbody Project: Peer facilitator version|"This dissonance-based body image program was created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and piloted in an initial randomized-controlled trial. Based on the Body Project (Stice et al., 2006), it retains key dissonance activities while adapting exercises to have a more inclusive focus (e.g., expanding the gender focus, exploring diversity characteristics within appearance ideals, adjusting activities to be inclusive of diversity).~Around 10% of the original EVERYbody Project manual was modified to create the Peer Facilitator version for the current trial. Changes focused on adding individual exercises to draw out the critique of diversity in cultural ideals, refining prompts to be more suitable for peer facilitation, and flagging sections of the manual for more expert peer facilitation.~Peer facilitators received 16 hours of training on the EVERYbody Project manual and peer facilitation guidelines (e.g., group management, handling problems, etc.)."
33097556|NCT04517942|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists (2015 ), and (2) The Mask You Live In (2015). Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
32803639|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
33097557|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
33404700|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
33404701|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
33404702|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
33404703|NCT00069238|Experimental|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
33404704|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
33404705|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
33404706|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
33404707|NCT03143140|Other|tumor ablation|ablation of tumor directly
33404708|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
33404709|NCT03639155|Experimental|Regimen B|vadadustat test tablets
32803640|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
32803641|NCT04275622|Experimental|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
32803642|NCT04275622|No Intervention|Control|Control group receives regular surveillance.
33097558|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
33313082|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
33313083|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
33313084|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
33313085|NCT03926390|No Intervention|Non bovine colostrun|Preterm received preterm formula
33313086|NCT03926390|Active Comparator|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
33313087|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
33313088|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
32803643|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
32803644|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
32803645|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
32803646|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
32803647|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
32803648|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
32803649|NCT04275466|Experimental|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
32803650|NCT04275466|No Intervention|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
32803651|NCT01904773|Placebo Comparator|Placebo|
32803652|NCT01904773|Experimental|low dose AZD5213|
32803653|NCT01904773|Experimental|high dose AZD5213|
32803654|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
32803655|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
32803656|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
32803657|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
32803658|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
32803659|NCT00986440|Experimental|CS-7017|
32803660|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
32803661|NCT01904383||Trazenta|
32803662|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
32803663|NCT01920880||Healthy controls|Healthy controls
32803664|NCT04390672|Experimental|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
32803665|NCT04390672|Active Comparator|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
32803666|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
32803667|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
32803668|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
32803669|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
32803670|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
32803671|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
32803672|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
32803673|NCT04629547|Experimental|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
32803674|NCT04629547|Placebo Comparator|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
33313089|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
32948395|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
32948396|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
32948397|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)~Fitbit 24/7~Phone/videoconference (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)"
32948398|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
32948399|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
32948400|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
32948401|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
33313090|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
33313091|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
32948404|NCT03987672|Other|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
32948405|NCT03986970|No Intervention|Arm 1: Control|No PrEP.
32948406|NCT03986970|Experimental|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
32948407|NCT03986970|Experimental|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
32948408|NCT03986970|Experimental|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
32948409|NCT03986970|Experimental|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
32948410|NCT03986970|Experimental|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
32948411|NCT03986970|Experimental|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
32948412|NCT03986970|Experimental|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
32948413|NCT03986970|Experimental|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
32948414|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
32948415|NCT03985800|Active Comparator|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
32948416|NCT03985800|Active Comparator|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
32948417|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
32948418|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
32948419|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
32948420|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
32948421|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
32948422|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
32948423|NCT03599076||Manifest HD|
32948424|NCT03599076||Premanifest HD|
32948425|NCT03599076||Control|
32948428|NCT05633784|Experimental|Intervention group|At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
32948429|NCT05633784|Active Comparator|Control group|At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
32803675|NCT00986362|Experimental|Ocriplasmin|
32948430|NCT03598764|Other|Classic head extraction group|
33313092|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
33313093|NCT03926312|Experimental|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
33313094|NCT03926312|No Intervention|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
33313095|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
33313096|NCT03926546|Experimental|Individual ERP|Individual Exposure and Response Prevention for OCD
33313097|NCT03926546|Experimental|Group ERP|Group Exposure and Response Prevention for OCD
33313098|NCT01134302|Active Comparator|Arm 1|Hybrid Management
33313099|NCT01134302|Active Comparator|Arm 2|Norwood Management
33313100|NCT05402618||minimally invasive surgery|
33313101|NCT05402618||open surgery|
33313102|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
33313103|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
33313104|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
32803676|NCT00986362|Placebo Comparator|Placebo|
32803677|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
32803678|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
32803679|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
32803680|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
32803681|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
32803682|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
32803683|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
32803684|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
32803685|NCT03092284|Placebo Comparator|Placebo|Saline
32803686|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
32803687|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
32803688|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
32803689|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
32803690|NCT00985504|Experimental|Duloxetine|
32803691|NCT00985504|Active Comparator|Escitalopram|
32803692|NCT03115840||Adults (≥18 years old) with critical illness|
32803693|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
32803694|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
32803695|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
32803696|NCT01921192|Placebo Comparator|Sugar pill|
32803697|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
32803698|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
32803699|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
32803700|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
32830809|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
33097559|NCT04510220|Experimental|Subjects diagnosed with relapsing forms of multiple sclerosis|We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using [F-18] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
32948431|NCT03598764|Other|External Pop out group|
33097560|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
33097561|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
32803701|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
33097562|NCT04510337|Active Comparator|Standard rocuronium|patients received rocuronium 0.6mg/kg
33097563|NCT04510337|Experimental|Magnesium|patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes
33097564|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
33097565|NCT04510259|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthesize the whole upper limb.
33097566|NCT04694898|Other|Control|Households in the control arm receive standard/national nutrition specific interventions, i.e. growth monitoring, vaccination, vitamin A supplementation and deworming
32803702|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
32803703|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
33097567|NCT04694898|Experimental|SURE Intervention|"Households in the intervention group with children younger than 2 years benefit from:~Interpersonal contacts to provide counselling on infant and young child feeding practices (IYCF) and nutrition-sensitive agriculture advice to mothers and fathers of children under 24 months, inclusive of pregnant women and fathers-to-be, jointly delivered by the local health and agriculture extension workers during routine household visits~Men's and women's group dialogues targeting all men and women in a given community network, facilitated also by the local health and agriculture extension workers~Media campaign to reinforce IYCF and dietary diversity messages"
32803704|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
32803705|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
33097568|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
32803706|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
32803707|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.~Dosage form: tablet~Dosage frequency: daily~Duration: 12 weeks total"
33097569|NCT00516867|Active Comparator|UVB 0.5%|
33097570|NCT00516867|No Intervention|Controls|
33097571|NCT00516867|Active Comparator|UVB 1.4%|
32803708|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy~12 individual 50-minute appointments over the course of up to 14 weeks~According to Fairburn, Marcus, and Wilson (1993)"
32803709|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
32803710|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
32803711|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
32803712|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
32803713|NCT00985426|Experimental|HEPLISAV-B|0.5 mL HEPLISAV-B and 0.5 mL Placebo
32803714|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
32803715|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
32803716|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
32803717|NCT03392662||Hemopatch Sealant Use with General Surgery|
32803718|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
32803719|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
32803720|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
32803721|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
32803722|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
32803723|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
32803724|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon during CS~this group in which prevention of uterine atony is made by intrauterine misoprostol plus the usual syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
32803725|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon during cesarean section~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
32803726|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
33097572|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
33097573|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
33097574|NCT04694664||Pregnant Women|Pregnant women who are 18 years of age or older.
33097575|NCT04694664||Post-partum women|Women who have at least one child younger than 18 years of age.
33097576|NCT04518176|Experimental|study group|patients with twin pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
33097577|NCT04518176|Active Comparator|control group|patients with twin pregnancy undergoing cesarean section received oxytocin only.
32803727|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
32803728|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
32803729|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
32803730|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
32803731|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
32803732|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
32803733|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
32803734|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
32803735|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
32803736|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
32803737|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
32803738|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
32803739|NCT04395976|No Intervention|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
32803740|NCT04395976|Experimental|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
32803741|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
32803742|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
32803743|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
32803744|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
32803745|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
32803746|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
33097578|NCT04694859||Symptomatic Severe Aortic Valve Stenosis|Patients >18 years old with symptomatic severe aortic valve stenosis.
33097579|NCT04510064|Experimental|Treatment group|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every two weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
33097580|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
33097581|NCT04694703||Covid-19 group|Patients diagnosed with COVID-19 will be enrolled in this group.
33097582|NCT04694742||ARDS COVID-19|Patients who meet Berlin's ARDS diagnostic criteria, with confirmed SARS-CoV-2 infection, requiring invasive mechanical ventilation.
33097583|NCT04510181|Experimental|Amino acid-based blend|The amino acid-based blend will be administered PO daily for the study duration
32803747|NCT00984256|Placebo Comparator|Control -no prophylaxis|
32803748|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
32803749|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
32803750|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
32803751|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
32803752|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
32803753|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
32803754|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
32803755|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
32803756|NCT01890265|Experimental|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
32803757|NCT01890265|Placebo Comparator|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
32803758|NCT01890265|Active Comparator|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
32803759|NCT01890265|Placebo Comparator|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
32803760|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
32803761|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
32803762|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
32803763|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
32803764|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
32803765|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
32803766|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
32803767|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
32803768|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
32803769|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
32803770|NCT03110926|Experimental|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
32803771|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
32803772|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
32803773|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
32803774|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
32803775|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
32830810|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
32948432|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
32948433|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
32948434|NCT03976908|Experimental|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
33313105|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
33313106|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
33313107|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
32948435|NCT03976908|Experimental|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
32948436|NCT05633238|Experimental|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
33313108|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
33313109|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
33313110|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
33313111|NCT01231880|Experimental|Monthly IPT|IPT given every month
33313112|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
32948437|NCT03594006|Other|Cancer patients on active therapy|
32948438|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
32948439|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
32948440|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
32948441|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
32948442|NCT05633082|Active Comparator|Lens 1|Subjects will wear Lens 1 for the first period of 15 minutes and Lens 2 for the second period of 15 minutes.
32948443|NCT05633082|Experimental|Lens 2|Subjects will wear Lens 2 for the second period of 15 minutes.
32948444|NCT03976362|Experimental|Pembrolizumab + Carboplatin + Taxane + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until centrally verified progressive disease, physician decision or intolerable toxicity."
32948445|NCT03976362|Active Comparator|Pembrolizumab + Carboplatin + Taxane + Olaparib Placebo|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS matching maintenance olaparib placebo twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib placebo until centrally verified progressive disease, physician decision or intolerable toxicity."
32948446|NCT04747782||COVID positive|Patients admitted to the ICU with respiratory distress found to be COVID19 positive.
33313113|NCT05402306|Experimental|Treatment group|A two-week intensive group treatment with MCT mainly focusing on attention training. The participants will be allocated into treatment in groups of six. Group sessions will be conducted two times a day for approximately 60 minutes.
33313114|NCT05402306|No Intervention|Waitlist control group|Cohorts of 12 included patients will be randomly assigned to active treatment or waitlist for two weeks. The waitlist patients will receive the same treatment immediately after four-week waiting period.
33313115|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
33313116|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
32803776|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
32803777|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
32803778|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
32803779|NCT03108976|Sham Comparator|Control group|Children with a typical development.
32803780|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
32803781|NCT01926808||Vitamin D supplementation|
32803782|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
32803783|NCT00982930|Experimental|Tobramycin Inhalation Powder (TIP)|Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
32803784|NCT03091816|Experimental|Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
32803785|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
32803786|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
32803787|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
32803788|NCT03069664|No Intervention|Control group|control group
32803789|NCT05602168|Experimental|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate, and buccal swab
32803790|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
32803791|NCT05602090|Experimental|Growth Hormone adjuvant treatment|Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
32803792|NCT05602090|No Intervention|control|standard controlled ovarian stimulation
32803793|NCT00981682|Experimental|SER120 (desmopressin)|
32803794|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
32803795|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
32803796|NCT00981292|Active Comparator|135mg EGCG|
32803797|NCT00981292|Active Comparator|270mg EGCG|
32803798|NCT00981292|Placebo Comparator|0mg EGCG|
32803799|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
32803800|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
32803801|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
32803802|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
32803803|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
32803804|NCT01927510|No Intervention|Control|Standard care
32803805|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
32803806|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
32803807|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
32948447|NCT04747782||COVID negative|Patients admitted to the ICU with respiratory distress found to be COVID19 negative
32948448|NCT04747782||COVID positive delayed|Patients admitted to the ICU for an indication other than respiratory distress, found to be COVID19 positive.
32948449|NCT04747782||never-ICU|Patients admitted to the internal medicine ward with respiratory distress found to be COVID19 positive.
32948450|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
32803808|NCT03049306|Placebo Comparator|Placebo Oral Tablet|"Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.~This visit is part of both the PROSAT 1.0 and PROSAT 2.0 study."
33404710|NCT05080426|Experimental|Intervention Group|"Mangers in the intervention group will be asked to:~1. Complete an online survey. 2. Take the Family Supportive Supervisor Training online (FSST). 3. Take the Supervisor Support for Leave Use module 4. Track their behaviors for two weeks 5. Participate in a webinar 7. Complete a post-training survey. 8. 8-10 managers will participate in the focus group.~Employees in the intervention group will be asked to:~1. Complete an online survey twice over the course of 6 months."
33404711|NCT05080426|No Intervention|Control Group|"Managers and employees in the control group will be asked to:~1. Complete an online survey twice over the course of 6 months."
33404712|NCT05080348|Active Comparator|Ropivacaine iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.25% Ropivacaine with 1:400,000 epinephrine in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
32803809|NCT03049306|Active Comparator|Propranolol Oral Tablet|"Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.~This visit is part of both the PROSAT 1.0 and PROSAT 2.0 study."
32803810|NCT03049306|Active Comparator|CPAP|"Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.~This visit part of the PROSAT 1.0 study."
32803811|NCT05601934|Experimental|Neurophysiological Facilitation Techniques|
33404713|NCT05080348|Sham Comparator|Normal Saline iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.9% Normal Saline in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
32803812|NCT05601934|Experimental|Respiratory exercises|
32803813|NCT05601700|Experimental|Experimental arm|Letrozole 2.5 mg daily, per os, until progression or up to 60 months, whichever comes first
32803814|NCT05601700|Active Comparator|Control arm|Carboplatin AUC 5 + Paclitaxel 175 mg/mq, IV, on day 1 every 21 days, for 6-8 cycles.
32803815|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
32803816|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
32803817|NCT05601466|Experimental|QN-023a|QN-023a in adult subjects with r/r AML
32803818|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
32803819|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
32803820|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
32803821|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
32803822|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
32803823|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
32803824|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
32803825|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
32803826|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
32803827|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
32803828|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
32803829|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
33097584|NCT04510103|Other|Regression Group|The Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then entered a 2-week regression period (no moisturizer usage).
32803830|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
32803831|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
32803832|NCT05601310||Control group|in the group, the participants exhibited negative results or <50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease and diabetes
32803833|NCT05601310||T2DM group|in the group, the participants exhibited negative results or <50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease but have type 2 diabetes mellitus.
32948451|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
32948452|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
32948453|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
32948454|NCT05632848|Experimental|Treatment arm|Chidamide and Zimberelimab
32948455|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
33404714|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
33404715|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
33404716|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
32803834|NCT05601310||T2DM+AMI group|In the group, we eventually recruited 30 adult patients who were firstly diagnosed ST-elevation myocardial infarction (STEMI) within 12 hours of appearance chest pains or other AMI symptoms and had no previous history of coronary artery disease (CAD). Peripheral venous blood samples were drawn from subjects on admission or prior to coronary revascularization.
32803835|NCT01927900|Active Comparator|HMO1|HMO diluted in water
32803836|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
32803837|NCT01927900|Active Comparator|HMO2|HMO diluted in water
32803838|NCT01927900|Active Comparator|HMO3|HMO diluted in water
32803839|NCT01927900|Active Comparator|HMO4|HMO diluted in water
32803840|NCT01927900|Active Comparator|HMO5|HMO diluted in water
32803841|NCT01927900|Active Comparator|HMO6|HMO diluted in water
32803842|NCT01927900|Active Comparator|HMO7|HMO diluted in water
32803843|NCT01927900|Active Comparator|HMO8|HMO diluted in water
32803844|NCT01927900|Active Comparator|HMO9|HMO diluted in water
32803845|NCT04274920|Experimental|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
32803846|NCT04274920|Active Comparator|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
32803847|NCT04274842|Other|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
32803848|NCT04274608|Experimental|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
32803849|NCT04274608|Active Comparator|Control Arm|Patients will undergo a 12-week weight management program.
32803850|NCT01927978||esophageal cancer, 18F-FDG PET|
32803851|NCT05601076|Experimental|The drainage tube in the experimental group was fixed with the triple-buffer system|
32803852|NCT05601076|Active Comparator|that in the control group was fixed using the conventional lifting platform method|
32803853|NCT05600998|Experimental|Camrelizumab+Anlotinib|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
32803854|NCT05607940|Experimental|blood volume loss based blood transfusion|intraoperative blood transfusion begin once blood volume loss over 400ml
32803855|NCT05607940|Active Comparator|hemoglobin concentration based blood transfusion|intraoperative blood transfusion begin once hemoglobin concentration below 70g/L
32803856|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
32803857|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
32803858|NCT05607706|No Intervention|Control|families were not allowed to enter the NICU
32803859|NCT05607706|Active Comparator|Maternal Odor|Babies compared only to the mother's odor
32803860|NCT05607706|Active Comparator|Kangaroo care|Babies given kangaroo care
32803861|NCT05607628|Active Comparator|Low-Calorie Control Group|"The control group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of animal proteins (~20g), a portion of vegetables, and a portion of starch (rice/ noodles) per meal. The group will also receive a mid-morning beverage in the form of a malted drink (~150 kcal and ~5g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of individual participants by ~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
33404717|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
32948456|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
32948457|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
32948458|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
32948459|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
32948460|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
32948461|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
32948462|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
32948463|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
32948464|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
32948465|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
32948466|NCT04407078|Experimental|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
32948467|NCT04407078|Placebo Comparator|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
32948468|NCT04003116|Experimental|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
33404718|NCT05080114|Experimental|Modified technique (MT)|All the steps of the laparoscopic hysterectomy were performed according to conventional standard technique until the colpotomy step. Instead, the modified Bakay technique was used for later on.
32948469|NCT04003116|No Intervention|Standard medical therapy|Standard management.
32948470|NCT00218634|Experimental|CBT-AD|Cognitive behavioral therapy for adherence and depression
32948471|NCT00218634|Active Comparator|ETAU|Enhanced treatment as usual
32948472|NCT00217620|Experimental|sorafenib|sorafenib
32948473|NCT00217464|Experimental|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
32948474|NCT00214500|Experimental|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.~Treatment Period:~Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).~Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).~Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).~Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).~Extension Period:~Migalastat 25 mg BID for Weeks 12 through 48.~Migalastat 50 mg QD for Weeks 48 through 96."
32948475|NCT04002726|Active Comparator|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
32948476|NCT04002726|Active Comparator|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
32948477|NCT04002726|Active Comparator|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
32948478|NCT04002726|Active Comparator|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
32948479|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
32948480|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
32948481|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
32948482|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
32948483|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
32948484|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
32948485|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
32948486|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
32948487|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
32948488|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
32948489|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
32948490|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
32948491|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
32948492|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
32948493|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
32948494|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
32948495|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
32948496|NCT04002414|Active Comparator|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
32948497|NCT04002414|Experimental|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
32948498|NCT04002414|Experimental|Usually Insufficiently Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
32948499|NCT04002414|Active Comparator|Usually Insufficiently Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
32948500|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
32948501|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
32948502|NCT00211536|Experimental|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
32948503|NCT00211536|No Intervention|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
32948504|NCT04001088|Experimental|Probiotic|Probiotics in a capsule.
32948505|NCT04001088|Placebo Comparator|Placebo|Non active ingredients in a capsule.
32948506|NCT03976128|Experimental|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
32948507|NCT03976128|Active Comparator|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
32948508|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
32948509|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
32948510|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32948511|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32948512|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
32948513|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
32948514|NCT04199286|Active Comparator|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
32948515|NCT04199286|Active Comparator|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
32948516|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
33404719|NCT05080114|Active Comparator|Standard technique (ST)|The conventional standard total laparoscopic hysterectomy technique was used in this control group.
33313117|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
33313118|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
33313119|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
33313120|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
33313121|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
33313122|NCT01232036|Active Comparator|A|Reference
33313123|NCT01232036|Experimental|B|Test
33313124|NCT01232036|Placebo Comparator|C|Placebo
33313125|NCT05401994|Active Comparator|conventional Erich's arch bar|• Patients will receive conventional Erich's arch bar
33313126|NCT05401994|Experimental|Screw Retained Arch Bar|patients will receive modified screw retained arch bar.
33313127|NCT01130480|Experimental|A|
33313128|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
33313129|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
33313130|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
33313131|NCT04363138||bacterial infection|Patients with bacterial infection
33313132|NCT04363138||No bacterial infection|Patients without bacterial infection
33313133|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
33313134|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
33313135|NCT03926156|Experimental|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
33313136|NCT03926156|Active Comparator|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
33313137|NCT03926078|Other|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
33313138|NCT03926078|Other|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
33313139|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
33313140|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
33313141|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
33313142|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
33313143|NCT01134692|Placebo Comparator|Propranolol + Placebo|
33404720|NCT05079958|Experimental|Stage2 - cognitive-behavioral education|A quasi-experimental design will be used to determine the effects of a four-week cognitive-behavioral education course related to smoking cessation on the participants' smoking cessation behavior, smoking decision-making, and self-efficacy in smoking cessation.
33313144|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
33313145|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
33313146|NCT01134848|Active Comparator|Morphine-neostigmine|
33313147|NCT01134848|Active Comparator|Secretin|
33313148|NCT03926000|Active Comparator|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
33313149|NCT03926000|Placebo Comparator|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
33313150|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~Insertion of finished dentures."
33313151|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~Initial impression and the obtainment of custom trays;~Final impression with border molding using compound;~Facebow transfer;~Determination of maxillomandibular relationship;~Try-in of anterior teeth;~Try-in of posterior teeth;~Insertion of finished dentures."
33313152|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
33313153|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
33313154|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
33313155|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
32948517|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
32948518|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
32948519|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
32948520|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
32948521|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
33313156|NCT05401604|Experimental|Moderate probiotic beer consumption|1 can of 330ml (3.5-5% alcohol) probiotic beer. Ingredients: water, grains, raspberry puree, yeast, and lactic acid bacteria (Lactobacillus paracasei Lpc-37®, or Lactobacillus paracasei LAFTI®L26).
33313157|NCT05401604|Placebo Comparator|Moderate normal beer consumption|1 can of 330ml (3.5-5% alcohol) normal beer. Ingredients: water, grains, raspberry puree, and yeast.
32948522|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
32948523|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
32948524|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
32948525|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
32948526|NCT03759522|Experimental|Healthy Controls|
32948527|NCT03759522|Experimental|Fibromyalgia Subjects|
32948528|NCT03759522|Experimental|Chronic Fatigue Syndrome Subjets|
32948529|NCT03759522|Experimental|Multiple Sclerosis Subjects|
32948530|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
33313158|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
33313159|NCT03918200||Study|Women with unexplained infertility
33313160|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
33313161|NCT04307056|Experimental|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
33313162|NCT04307056|Active Comparator|Prostatectomy|Patients Treated by Radical Prostatectomy
33313163|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
33313164|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
33313165|NCT05043532|Active Comparator|Two passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of two passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
33313166|NCT05043532|Active Comparator|Three passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of three passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
33313167|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
33313168|NCT01228136|Active Comparator|Tranexamic acid|
33313169|NCT01228136|Placebo Comparator|Placebo|
33313170|NCT04259164|Active Comparator|QMF149|Mometasone furoaat / Indacaterol
33313171|NCT04259164|Experimental|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
33313172|NCT03918356|Experimental|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
33313173|NCT03918356|Experimental|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
33313174|NCT03918356|Placebo Comparator|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
33313175|NCT01133054|Experimental|low FFR|FFR<0.75
33313176|NCT01133054|No Intervention|high FFR|FFR > 0.75
33313177|NCT05401448|Placebo Comparator|Placebo|sterile 0.9% NaCl
33313178|NCT05401448|Experimental|Influenza|Influenza (tetravalent vaccine)
33313179|NCT05401448|Experimental|MMR|measles, mumps, and rubella vaccine
32948531|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
33313180|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
33313181|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
32948532|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
32948533|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
32948534|NCT04198038|Experimental|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
32948535|NCT03968328||Observational (interview, survey)|Patients respond to a survey and participate in an interview with study staff about their fever and when they started feeling unwell.
32948536|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
32948537|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
32948538|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
32948539|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
32948540|NCT03596190|Other|Assessment arm|
32948541|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
32948542|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
32948543|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
32948544|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
32948545|NCT04197570|Active Comparator|Opioid-based anesthetic|"Premedication~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist~Induction~Fentanyl 2-4 mcg/kg IV bolus~Propofol 1-3 mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy & aortic cannulation~Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula~Dexmedetomidine 0.4 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
32948546|NCT04197570|Experimental|Opioid-free anesthetic|"Premedication~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist~Induction~Dexmedetomidine 1mcg/kg IV~Propofol 1-3mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~May add propofol infusion if clinically indicated~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
33097585|NCT04510103|Other|Non-Regression Group|The Non-Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then underwent a physical insult (tape stripping) on the lower legs and continued using the moisturizer for 4 additional days.
33097586|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
33313182|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
33313183|NCT01130714|No Intervention|Control|Usual care.
33313184|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
33313185|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
33313186|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
33313187|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
33313188|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
32803862|NCT05607628|Active Comparator|Low-Calorie Treatment Group|"The treatment group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of plant proteins (~25g), a portion of vegetables, and a portion of starch (rice/noodles) per meal. The group will also receive a mid-morning beverage, in the form of a soy-based, plant protein beverage (~120 kcal and 13g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of participants by ~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
32803863|NCT05607472|Other|All patient with Dengue prognostic purpose|blood samples for bio collection clinical exam : Fitzpatrick phototype classification , Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation)
32803864|NCT04759378|Experimental|IBS patients who have upper GIT symptoms|
32803865|NCT04219696|Active Comparator|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session. Participants will also complete 5 45-minute 'traditional' balance training sessions.
32803866|NCT04219696|Experimental|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session. Participants will also complete 3 45-minute 'traditional' balance training sessions.
32803867|NCT04219696|Experimental|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
32803868|NCT05607160||Cohort 1|Type 2 diabetes patients >= 75 years
32803869|NCT05606770|Other|Structured exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity, in keeping with recent guidelines on secondary stroke prevention. Classes will include a full body warm up followed by a circuit of eight strengthening exercises completed for between one and three sets of 12 repetitions. Participants will be encouraged to exercise to fatigue on the 12th repetition of each set. This will be repeated for increasing sets and adding resistance through the use of resistance bands. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
32803870|NCT05606770|Other|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
32803871|NCT01927861|Experimental|0.033 mg/kg/day|
32803872|NCT01927861|Experimental|0.066 mg/kg/day|
32803873|NCT05606536|Experimental|10 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 15 ml/kg/h~infusion rate after 20 minutes: 2,6 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 16 ml/kg/h~infusion rate after 20 minutes: 0,8 ml/kg/h"
32803874|NCT05606536|Experimental|20 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 26 ml/kg/h~infusion rate after 20 minutes: 3,4 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 28 ml/kg/h~infusion rate after 20 minutes: 1,6 ml/kg/h"
32803875|NCT05606536|Experimental|30 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 38 ml/kg/h~infusion rate after 20 minutes: 5,1 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 44 ml/kg/h~infusion rate after 20 minutes: 2,4 ml/kg/h"
32803876|NCT05606536|No Intervention|Standart care|Infusion rate based upon the standard care.
32803877|NCT05600218||Cohort 1|Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
33313189|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
33313190|NCT05401370|Active Comparator|MB group|Mb group will undergo surgeries with methylene blue staining
33313191|NCT05401370|No Intervention|Control group|Control group will undergo surgeries without methylene blue staining
33313192|NCT03917888|Experimental|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
33313193|NCT03917888|No Intervention|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
33313194|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
33313195|NCT01130792|Placebo Comparator|Inulin|
33313196|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
33313197|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
33313198|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
33313199|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
33313200|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
33097587|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
33313201|NCT05401292|Active Comparator|Iodine or Chlorhexidine Preparation|Standard of care with only skin preparation of iodine or chlorhexidine solution prior to sterile draping before surgery.
33313202|NCT05401292|Active Comparator|Iodine or Chlorhexidine Scrub Brush Pre-Scrub with Isopropyl Alcohol and Chlorhexidine Soap|"In addition to standard of care skin preparation with iodine or chlorhexidine solution prior to sterile draping, patients will also receive an additional pre-scrub with isopropyl alcohol and chlorhexidine soap. The operative extremity will be scrubbed for 2 minutes with chlorhexidine soap with a scrub brush until the entire extremity is covered. Isopropyl alcohol will then be wiped onto the skin with a gauze and allowed to evaporate (dry)."
33313203|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
33313204|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
32738053|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32738054|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32803878|NCT05601232|Experimental|Boron Neutron Capture Therapy (BNCT)|
32803879|NCT05603572|Experimental|Oral experimental arm|Oral administration (KAT-101) taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Each cycle is 28 days. Treatment will continue for up to 12 cycles until progressive disease (PD), unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
33313205|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
33313206|NCT05401136||Participants|Consecutive people who use drugs and visit the addiction care centre
33313207|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
33313208|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
32803880|NCT05603572|Experimental|IT experimental arm|IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or computed tomography (CT) guidance once a week (on Day 1 weekly). Each cycle is 28 days. Treatment will continue for up to 2 cycles until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
32803881|NCT05603572|Experimental|Oral + IT experimental arm|Once optimal oral and IT dose are determined, oral + IT will be administered as follows: oral administration (KAT-101) will be taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Treatment will continue for up to 12 cycles (each cycle 28 days). IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or CT guidance once a week (on Day 1 weekly). Treatment will continue for up to 2 cycles (each cycle 28 days) until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
32803882|NCT05603182|Experimental|SAD Cohorts 1-8 Experimental Arm|Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format
32803883|NCT05603182|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|Subjects will receive a single intravenous or subcutaneous dose of placebo
33313209|NCT01232192|No Intervention|Antenatal model|
33313210|NCT01232192|Experimental|Antenatal Model|
33313211|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
33313212|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
33313213|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
33313214|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
33313215|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
33313216|NCT01135940|Active Comparator|2|Standard staple closure
32803884|NCT05603182|Experimental|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three subcutaneous or intravenous doses of PRA052, one dose every 2 weeks, in a dose escalation format
32803885|NCT05603182|Placebo Comparator|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three subcutaneous or intravenous doses of placebo, one dose every 2 weeks
33313217|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
33313218|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
33313219|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
33313220|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
33313221|NCT01136018||intentional lateral caudal approach|
33313222|NCT01133366|Active Comparator|warfarin alone|
33313223|NCT01133366|Experimental|warfarin with mipomersen|
33313224|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
33313225|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
33313226|NCT01232270|Active Comparator|fentanyl|
33313227|NCT01232270|Placebo Comparator|saline|
33313228|NCT05400902|Experimental|HAIC Combined with Sintilimab and Bevacizumab|
33313229|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
33097588|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
33313230|NCT01233206|Placebo Comparator|Control group|Placebo
33313231|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
33313232|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
33097589|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
33097590|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
33313233|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
33313234|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
33313235|NCT01232348||Symbicort|Those with an exposure
33313236|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
33313237|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
33313238|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
33313239|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
33313240|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
33313241|NCT05608772|Active Comparator|RYGB procedure arm 1|After failed sleeve, the patients will get a revisional procedure. The RYGB
33313242|NCT05608772|Active Comparator|OAGB procedure arm 2|After failed sleeve, the patients will get a revisional procedure. The OAGB
33313243|NCT05608772|Active Comparator|SADI-S procedure arm 3|After failed sleeve, the patients will get a revisional procedure. The SADI-S
33313244|NCT00319553|Experimental|Adacel® Vaccine Group|
33313245|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
33313246|NCT05606198||COVID|641,407 patients with a SARS-CoV-2 infection in the year 2020.
33313247|NCT05606198||Non-COVID|Matched patients with no SARS-CoV-2 infection during the study period.
33313248|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
33313249|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
33313250|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
33313251|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
33313252|NCT03917732|Experimental|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
33313253|NCT03917732|Active Comparator|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
33313254|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
33313255|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
33313256|NCT05476562||First-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
33313257|NCT05476562||Second-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
33313258|NCT05476562||Third-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
32948547|NCT04197882|Experimental|treatment|"This study consisted of 3 stage of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 intratumoral injection in combination with Toripalimab infusion. Toripalimab : 3 mg/kg, IV infusion: Once every 2 weeks for 6 doses ; OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks for 6 doses ; Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Toripalimab infusion. Toripalimab 3 mg/kg intravenously given every 3 weeks (every 3 weeks per cycle) for up to 1 year (the one-year duration will be counted from 1st dose in neoadjuvant treatment)."
32948548|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
32948549|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
33313259|NCT05476562||Fourth-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
33313260|NCT01136252|Experimental|Adalimumab|
33313261|NCT03917498|Experimental|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
33313262|NCT05597462|Experimental|DFD-29|DFD-29 (minocycline hydrochloride) capsules, 40 mg will be administered orally once daily for 16 weeks.
32948550|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
32948551|NCT04197492|Experimental|HSRT With Anlotinib|"Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.~Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
33313263|NCT05597462|Placebo Comparator|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
33313264|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
33313265|NCT01136564|Active Comparator|Paricalcitol|
33404721|NCT05079958|Experimental|Stage 3- 12-week brisk walking|"Subjects who are at the preparation  and action stage will be recruited and randomly divided into experimental or control group to identify the effect of a 12-week brisk walking on improving the participants' immediate (short-term), three-month, and six month (long-term) health status."
32948552|NCT04197648|Experimental|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
32948553|NCT04197648|No Intervention|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
32948554|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
32948555|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
32948556|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
32948557|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
32948558|NCT04197024|Experimental|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
32948559|NCT04197024|Experimental|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
32948560|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
32948561|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
32948562|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
32948563|NCT03024138||Repeat CT|
32948564|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
32948565|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
32948566|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
32948567|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
32948568|NCT03981744|Experimental|Group 1: Ustekinumab + Placebo|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
32948569|NCT03981744|Placebo Comparator|Group 2: Placebo + Ustekinumab|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
33097591|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
33097592|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
33097593|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
33313266|NCT01136564|Placebo Comparator|Placebo|
32803886|NCT05602948|Experimental|'Run, Jump & Fun' intervention|"The Run, jump & fun intervention consists of four 30 minutes sessions per week for one school year. Activities are mostly conducted as whole class activities. Head of schools and teachers/school pedagogues are involved in an initial intervention establishing process, guided by Active School personnel. The aim is to create a local plan for the intervention tailored to the particular school. Examples are movement band, structured activities during recess with older students (13-15 years olds), etc. Activities are created to be fun, motivating and with moderate to high intensity PA."
32803887|NCT05602948|Experimental|'Move & Learn' intervention|"This intervention is implemented as PA for 30 min in two Mathematics and two Danish lessons each week for one school year. Activities are conducted at whole-class level.~The physical activities in Move & Learn are closely linked to the Mathematic curriculum and the Danish curriculum. The way the body is integrated in the learning task can vary. Examples are bodily or motor-skill demanding activities or less vigorous activities, e.g. standing up miming, using hand gestures or facial expressions. An important aspect of the interventions is that movements should be task relevant. The intervention is developed based on the embodied learning theory."
32803888|NCT05602948|No Intervention|Control|Control schools will continue their usual practice.
32803889|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
32803890|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
32803891|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
32803892|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
32803893|NCT05602870|Experimental|Psychiatric patient|All patients having psychiatric disorders and hospitalised in a Psychiatry Unit of CHU Montpellier will have an non invasive evaluation of liver fibrosis after giving their consent
32803894|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
32803895|NCT05602792|Experimental|T3011 Herpes Virus Injection|
32803896|NCT04629469|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
32803897|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
32803898|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
32803899|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
32803900|NCT05602558|Experimental|LYB001|
32803901|NCT05602558|Placebo Comparator|Placebo|
32803902|NCT04173169|Active Comparator|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|For those who agree to be randomized, subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who do not want to be randomized while choose elagolix.
32803903|NCT04173169|Other|Pre-IVF Treatment with 60 day course of Placebo or SOC IVF|For those who agree to be randomized, subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who want to continue their ongoing or planned IVF and follow standard of care (SOC) (SOC IVF) if they do not want to delay the IVF procedure.
32803904|NCT04394338|Active Comparator|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
32803905|NCT04394338|No Intervention|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
32803906|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
32803907|NCT05602402|Active Comparator|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule beforebreakfast (preferably with milk/butter/ghee)
32803908|NCT05602402|Placebo Comparator|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
32803909|NCT05602324|Experimental|Lauric Acid and Berberine|Participants in this arm of the trial will receive 15 ml lauric acid and 1000 mg berberine daily (via feed tube) for the duration of time that they are receiving enteral feeding, up to a maximum time of 14 days
32803910|NCT05602324|No Intervention|No-intervention|participants in this arm will receive no additional intervention, beyond standard of care
32803911|NCT05600608|Experimental|Oesophago- gastric adenocarcinoma patients|"Oesophagogastric adenocarcinoma (OG) cancer patients (who are neoadjuvant chemotherapy treatment naïve) will receive 120mls of a sterile oral stimulant drink (OSD) (manufactured by Ingenza ltd), which is an ISO accredited laboratory. The active component of the drink is iron sulphate (5g/l), pH 5-6.~Breath will be taken following an optimised methodology designed by the VOC laboratory at Imperial college London at baseline and then at 30, 60 and 90 minutes following consumption of the drink.~Participants will be nil by mouth for 6 hours prior to the breath test, they can have water up to 2 hours before the breath test."
33097594|NCT04510025||Non-COVID|We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects ( no serological evidence of previous infection or active symptoms).
33097595|NCT04510025||COVID-19|Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
33097596|NCT00517062|Active Comparator|A|Growth hormone
33097597|NCT00517062|Placebo Comparator|B|Placebo
32948570|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
32948571|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
32948572|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
32948573|NCT03595800|Experimental|haploidentical related donors|
32948574|NCT03595800|Active Comparator|Matched unrelated donor|
32948575|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
32948576|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
32948577|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
32948578|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32948579|NCT04196946|Experimental|Group I|25 mcg fentanyl intrathecally
32948580|NCT04196946|Experimental|Group II|250 mcg alfentanil intrathecally
32948581|NCT04194528|Experimental|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
32948582|NCT04193202|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
32948583|NCT04193202|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
32948584|NCT04199208|Active Comparator|Standard Care Arm|Standard perioperative care is given.
32948585|NCT04199208|Experimental|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
32948586|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
32948587|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
32948588|NCT04194918|Experimental|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
32948589|NCT04747938|Experimental|Energy accumulator|Energy Accumulator was a portable handheld device invented for local heat therapy for healthcare purpose. All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts.
32948590|NCT04747938|Experimental|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
32948591|NCT04196556|Experimental|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
32948592|NCT04196556|Active Comparator|Control group|"Usual care:~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Cartera de Servicios Estandarizados de Atención Primaria de Madrid, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
32948593|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
32948594|NCT03967002|Experimental|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
32948595|NCT03967002|No Intervention|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
33097598|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
33097599|NCT04517981||Drug intervention|Antidepressant
33097600|NCT04517981||Psychological intervention|Cognitive behavior therapy, sand table therapy
33097601|NCT04517981||Comprehensive intervention|Psychological intervention, community intervention combined with drug intervention
32803912|NCT05600608|Active Comparator|Benign healthy control patients|Age, gender and demographic matched patients who have had a negative oesophagogastroscopy within 1 year which is negative for adenocarcinoma will be recuited into the comparison arm. Patients will be given the same OSD and breath will be sampled at the same time points as the experimental arm.
32803913|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
33097602|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
33097603|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
33097604|NCT00506246|Experimental|1|Propofol MCT/LCT
33097605|NCT00506246|Active Comparator|2|Propofol LCT
33097606|NCT00517335||1|Women who are healthy controls
33097607|NCT00517335||2|Women who have recovered from bulimia
33097608|NCT00517335||3|Women who have recovered from anorexia
32803914|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
32803915|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
32803916|NCT05609734||Patients with an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
32803917|NCT05609734||Patients without an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
32803918|NCT05609422|Active Comparator|control group|Received the designed physical therapy program.
32803919|NCT05609422|Experimental|study group|Received a designed physical therapy program in addition to scooter bord activities.
32803920|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
32803921|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
32803922|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
32803923|NCT05609344|Experimental|SBIRT|Each intervention barbershop, will hold screening days, where a trained community health worker will be onsite to provide Screening, Brief Intervention, and Referral to Treatment (SBIRT).
32803924|NCT05609344|Other|Usual-care|Six months after completion of Time 1, barbershops in the usual-care arm will receive the intervention.
32803925|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
32803926|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
32803927|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants~Standard of Care practice is used"
32803928|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
33097609|NCT04517708|Experimental|Intervention group|"Regarding the intervention group, patients were treated with the intervention regimen, which consisted of:~Nutritional counseling~Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months."
33097610|NCT04517708|No Intervention|Control group|Patients had diets based on their demands
32803929|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
32803930|NCT04168372|Experimental|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
32803931|NCT04168372|Experimental|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
32803932|NCT04168372|Experimental|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
32803933|NCT04168372|Experimental|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
32803934|NCT05609032|Experimental|Intervention (App Arm)|Participants randomized to the intervention arm will receive access to the Sense2Quit App (A multi-component intervention that links a smartphone app to a smartwatch to provide real-time quit reminders to curtail relapses and avoid potential triggers), standard smoking cessation counseling, and nicotine replacement therapy.
33097611|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
33097612|NCT00517452||Standard Wound Care|Group was treated as per standard care
33097613|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
33097614|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
33097615|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
33097616|NCT00517491|Experimental|1|
33097617|NCT00517569|Experimental|1|GX-12 combined with HAART
33097618|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
33097619|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
32803935|NCT05609032|No Intervention|Control|Participants randomized to the control arm will receive standard smoking cessation counseling and referral to quitline.
32803936|NCT05608720|Experimental|study group|Information Booklet prior to the dental visit
32803937|NCT05608720|No Intervention|control group|no information prior to the dental visit
32803938|NCT05608642|Active Comparator|Group given intravenous hydration|The first group consists of patients given 500 cc intravenous saline for 1 hour.
32803939|NCT05608642|Active Comparator|Group given intravenous prednisolone|Second group; consists of patients who were given 80 mg of intravenous prednisolone for the first 4 days and then given gradually decreasing doses of prednisolone in the following days.
32803940|NCT05608642|Active Comparator|Group given intravenous lidocaine|Third group; includes patients given 2 mg/kg intravenous lidocaine by 1-hour infusion.
32803941|NCT05608564|Experimental|Local antibiotic group|A combination of Piperacillin and Tazobactam in gel form is applied using a syringe and a flexible blunt needle into the periodontal pockets 24 hours after the non-surgical periodontal therapy. After administration, the dry field should be maintained for 5 minutes and the patient should not rinse the oral cavity for 15 minutes.
32803942|NCT05608564|Active Comparator|Systemic antibotic group|Amoxicillin (500mg, 3 times a day, 14 days) and Metronidazole (400mg, 3 times a day, 14 days) per os at the beginning of non-surgical treatment.
32803943|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
32803944|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
32803945|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
32803946|NCT05608096||Hemoperfusion|ICU septic patients treated with hemoperfusion
32803947|NCT05608096||non-hemoperfusion|ICU septic patients non treated with hemoperfusion
32803948|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
32803949|NCT05604898|Experimental|Part 1：608 40 mg|Randomized in a 6:2 ratio to 608 40mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 40mg or placebo 4-weekly.
32803950|NCT05604898|Experimental|Part 1：608 80 mg|Randomized in a 10:2 ratio to 608 80mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 80mg or placebo 4-weekly.
32803951|NCT05604898|Experimental|Part 1：608 160 mg|Randomized in a 10:2 ratio to 608 160mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 160mg or placebo 4-weekly.
32803952|NCT05604898|Experimental|Part 2：608 160 mg W0+80 mg Q2W+80 mg Q4W|Participants will receive starting dose of 160 mg 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period. During the maintenance period, participants will receive 80mg 608 once every four weeks (Q4W).
32803953|NCT05604898|Experimental|Part 2：608 160 mg Q2W+160 mg Q4W|Participants will receive 160mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period followed by 160mg 608 once every four weeks (Q4W) during maintenance period.
32803954|NCT05604898|Experimental|Part 2：608 160 mg Q4W+160 mg Q8W|Participants will receive 160mg 608 once every four weeks (Q4W) by subcutaneous injection during induction period followed by 160mg 608 once every eight weeks (Q8W) during maintenance period.
32803955|NCT05604898|Placebo Comparator|Part 2：Placebo|Participants will receive Placebo by subcutaneous injection.
32803956|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
32803957|NCT01544595|Experimental|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
32803958|NCT05600842||De-escalated radiotherapy|
32803959|NCT05606692|Active Comparator|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
32803960|NCT05606692|Experimental|Propofol group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
32803961|NCT04759534|Experimental|Treatment group 1|Received abdominal subcutaneous injection of IBI306 150 mg Q2W
32803962|NCT04759534|Experimental|Treatment group 2|Received abdominal subcutaneous injection of IBI306 150 mg Q4W
32803963|NCT04759534|Placebo Comparator|Placebo Group 1|Received a subcutaneous injection of placebo Q2W in the abdomen
33097620|NCT00506363|Sham Comparator|C|dynamic cooling device
33097621|NCT01242111|Experimental|BMN 110|
33097622|NCT04517591|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
33097623|NCT04517591|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels and health nutrition.
33097624|NCT04517630||Severe pneumoniae|Evaluate the progression to AKI during first 30 days of recruitment
33097625|NCT04517201|Experimental|AI group|iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)
33313267|NCT05568758|Experimental|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
33313268|NCT05568758|Experimental|exercises|Stretching exercises (hamstring stretch-lower back stretch) Strenghening exercises(abdominal curl up-supine bridging-trunk extension)
33313269|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
33313270|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
33097626|NCT04517201|Active Comparator|Control group|iGMS+routine treatment group (Physicians decided insulin titration group)
33097627|NCT01241604|Active Comparator|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
33313271|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
33313272|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
33313273|NCT04973254|Experimental|Cohort 1- HIV injection at a community-based site|CAB-RPV LA administered to patients in an alternative community-based site
33313274|NCT04973254|Active Comparator|Cohort 2- HIV injection at a HIV clinic|CAB-RPV LA administered to patients in the HIV clinic
33097628|NCT01241604|Active Comparator|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
33097629|NCT04515524||ROP patients from VGFTe-ROP-1920|Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.
33097630|NCT04519775|Experimental|HOBSCOTCH-V (virtual)|"Participants will receive the HOBSCOTCH intervention consisting of 1:1 sessions delivered once per week, including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)~Participants will also receive 3 booster sessions, via webcam or telephone, once per month."
33097631|NCT04519775|Other|Control|Participants will be wait listed and will receive HOBSCOTCH-V (above) following a 6 month wait period.
33097632|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
33097633|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
33313275|NCT04973254|Active Comparator|Cohort 3- Standard of care for HIV|Individuals who share characteristics of cohort 1 and are engaged in standard of care
33313276|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
33313277|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
33313278|NCT05309356|Active Comparator|Usual care (Control)|Routine COPD patient care.
33313279|NCT05309356|Experimental|ACCEPT Decision Intervention|Clinical prediction model (ACCEPT)-based treatment recommendations: The ACCEPT tool will display the predicted risk of exacerbations, and the corresponding treatment recommendations to the physicians. These recommendations will be provided in a non-mandatory 'directive' format where the physician can override the recommendation, but is required to provide a justification (pre-set choices and a free text).
33313280|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
33313281|NCT04956952|Other|Enhanced External Counterpulsation (EECP)|1 hour of treatment with EECP
33313282|NCT05004376|No Intervention|Non-adherent control|Control subjects will receive no text intervention and a 150 day follow-up phone call.
33313283|NCT05004376|Experimental|Non-adherent intervention|Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
33313284|NCT04752904|Experimental|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
33313285|NCT04752904|No Intervention|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
33313286|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
33313287|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
33313288|NCT01137734|Experimental|Valtech Cardinal Mitral Annuloplasty Ring|All subjects enrolled in the study are implanted with the Valtech Cardinal Mitral Annuloplasty ring.
33097634|NCT04696406||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours
33097635|NCT04696406||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation.
33097636|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
33097637|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
33097638|NCT04516850||Patients tested for COVID-19|The nasopharyngeal swabs taken from patients tested for Covid-19 who resulted infected and non-infected will be analyzed to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2.
33097639|NCT04516850||Patients with mild-moderate and severe SARS-CoV-2 infection|Formalin-fixed paraffin will be analysed to determine the association between polymorphism of the HSD3B1 gene and outcomes in COVID-19 affected patients
33097640|NCT00517725|Active Comparator|Carvedilol|
33097641|NCT00517725|Active Comparator|Bisoprolol|
33097642|NCT00517725|Active Comparator|Nebivolol|
33097643|NCT04512248|Experimental|Quit and Stay Quit Monday Model|
33313289|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
33313290|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
33313291|NCT04235374|Experimental|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT [(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
33313292|NCT04235374|Placebo Comparator|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
33313293|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
33313294|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
32803964|NCT04759534|Placebo Comparator|Placebo Group 2|Received a subcutaneous injection of placebo Q4W in the abdomen
33097644|NCT04512248|No Intervention|Usual Care|
33313295|NCT04749628|Placebo Comparator|Ora-sweet SF|
33097645|NCT04516889|Experimental|Intervention|The intervention arm will undergo the modified sutured SFIOL technique with double Prolene sutures instead of a single Prolene suture
33097646|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
33313296|NCT04749628|Experimental|400mg cannabidiol|
33097647|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
33097648|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
33097649|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
33097650|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
33313297|NCT04749628|Experimental|800mg cannabidiol|
33313298|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
33313299|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
33313300|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
33313301|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
33313302|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
33313303|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
33313304|NCT03917576|Active Comparator|Normoglicamic group|Control normoglycaemic participants
33313305|NCT03917576|Active Comparator|Hyperglicaemic group|Control hyperglicaemic group
33313306|NCT03917576|Experimental|Experimental group|Experimental Type 2 Diabetes Mellitus Group
33313307|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
33313308|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
33313309|NCT01136720||patients injected with the Halifax produced 18-FDG|
33313310|NCT05557760|Experimental|Cognitive Control Training Group|
33313311|NCT05557760|Experimental|Cognitive Control Training + Booster Sessions Group|
32803965|NCT05606614|Experimental|Cohort 1|"Participants will be randomized to treatment with TSHA-102 or delayed treated control at the starting dose.~Dose Level 1"
32803966|NCT05606614|Experimental|Cohort 2|"Participants will be randomized to treatment with TSHA-102 or delayed treated control at the higher dose.~Dose Level 2"
33313312|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
33313313|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
33313314|NCT03917420|Experimental|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
33313315|NCT00369629|Experimental|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
32803967|NCT05606224|Experimental|iMIED+TAU: internet-based mindfulness intervention for emotional distress plus treatment as usual|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
32948596|NCT03966768|Experimental|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
32948597|NCT03966768|Experimental|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
32948598|NCT03966768|Experimental|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
33313316|NCT00369629|Experimental|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
33313317|NCT00369629|Experimental|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
33313318|NCT00369629|Experimental|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
33313319|NCT04744090|Experimental|Roflumilast add-on|Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
33313320|NCT04744090|Placebo Comparator|Placebo control|Eligible patients will take placebo plus standard of care.
32948599|NCT03956238|Experimental|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
32948600|NCT03956238|Placebo Comparator|Males and Placebo Control|Men assigned to placebo control arm
33313321|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
32948601|NCT03956238|Experimental|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
32948602|NCT03956238|Experimental|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
32948603|NCT03956238|Experimental|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
32948604|NCT03956238|Placebo Comparator|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
32948605|NCT04406922|Experimental|Intervention group|Cold exposure in the morning and evening.
32948606|NCT04196010|Experimental|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
32948607|NCT03591198|Experimental|Qigong Training|
32948608|NCT03591198|Active Comparator|Cognitive Training|
33313322|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
33313323|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
33313324|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
33313325|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
33313326|NCT03917264|Active Comparator|Tooth-borne treatment|Titanium curettes
33313327|NCT03917264|Experimental|Implant-specific treatment|Implant brush
33313328|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
33313329|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
33313330|NCT04719910|Experimental|Study group|The study group will watch 15 minute long videos of cooking and preparing the food of the patient's preferred type of food prior to be taken to the operating room.
33313331|NCT04719910|Placebo Comparator|Placebo group|The control group will watch 15 minute long non-food related videos.
33313332|NCT03917342|Active Comparator|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
33313333|NCT03917342|Active Comparator|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
33313334|NCT03917342|Active Comparator|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
33313335|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
33313336|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
33313337|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
33313338|NCT05435222|Experimental|male-specific psychotherapeutic program (MSPP)|In this treatment group, eugonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting.
33313339|NCT05435222|Active Comparator|cognitive behavioral therapy (CBT)|In this treatment group, depressed men will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting.
33404722|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
32948609|NCT04196400|Active Comparator|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
32948610|NCT04196400|No Intervention|Control Group|
32948611|NCT04021758|Experimental|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
32948612|NCT04021758|No Intervention|Wait list|
32948613|NCT04196322||Controlled|
32948614|NCT04196322||Uncontrolled|
32948615|NCT04196088|Active Comparator|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
32948616|NCT04196088|Placebo Comparator|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
32948617|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
32948618|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
32948619|NCT03591042|Experimental|cervical length screening|cervical length screening
32948620|NCT03591042|No Intervention|no screening|no screening
32948621|NCT04195932|Experimental|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
32948622|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
32948623|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
32948624|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
32948625|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
32948626|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
32948627|NCT03742986|Experimental|HER2-positive, independent of HR status|
32948628|NCT04020978|Other|Patients with GUC|Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
32948629|NCT03972774|Other|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
32948630|NCT03972774|Other|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
32948631|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
32948632|NCT04020042|Experimental|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
32948633|NCT04020042|Active Comparator|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
32948634|NCT04026594|Experimental|Mindfulness Based Stress Reduction (MBSR)|"306 participants will be randomized in the MBSR program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a MBSR recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability.."
33313340|NCT05435222|No Intervention|Waitlist|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP.~As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality."
32803968|NCT05606224|No Intervention|TAU-only: treatment as usual|In the current study, TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therapy.
33313341|NCT05435222|Experimental|male-specific psychotherapeutic program (MSPP) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
33313342|NCT05435222|Active Comparator|cognitive behavioral therapy (CBT) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men (blood testosterone ≤ 12.1 nmol/l) will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
32803969|NCT05605288|Experimental|Distal transradial artery access|Vascular access after cannulation of distal transradial artery through anatomical snuffbox for coronary angiography and interventions
32803970|NCT05605288|Active Comparator|Conventional transradial artery access|Vascular access after puncturing on the conventional transradial artery for performing coronary angiography and interventions
33313343|NCT05435222|No Intervention|Waitlist + testosterone treatment (TT)|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality.~Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection."
33313344|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
33313345|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
33313346|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
32803971|NCT04392700|Experimental|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
32803972|NCT04392700|Active Comparator|group B|drugs：entecavir dose： 0.5 mg/d
32803973|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
32803974|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
32803975|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
32803976|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
32803977|NCT04274452|Experimental|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
32803978|NCT04274452|Placebo Comparator|placebo|Patients receiving an intravenous infusion of placebo
32803979|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
32803980|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
32803981|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
32803982|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus~Dosage of prograf will be determined by trough levels and adjusted accordingly"
32803983|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
32803984|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
32803985|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
32803986|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
32803987|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
32803988|NCT02958280|Experimental|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development & Open Pilot) will consist of: 1) development of the Fit&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery.~Phase 2: RCT of the Fit&Sober app with 160 patients with AUD"
32803989|NCT02958280|Active Comparator|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
32803990|NCT01513551|Experimental|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
32803991|NCT01513551|Active Comparator|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
32803992|NCT01513551|Active Comparator|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
32803993|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
32803994|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
32803995|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
32803996|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
32803997|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
32803998|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
32803999|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
32804000|NCT03827200|Experimental|Ambrisentan|Ambrisentan
32804001|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
32804002|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
32804003|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
32804004|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
32804005|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
32804006|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
32804007|NCT04346368|Experimental|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
32804008|NCT04346368|Placebo Comparator|Placebo|Conventional treatment plus placebo
32804009|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
32804010|NCT03826810|Experimental|ART group|In this group, only ART was performed.
32804011|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
32804012|NCT03826654|Placebo Comparator|control|daily intake of plain oil
32804013|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading dose of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
32804014|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
32804015|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
32804016|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
32804017|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
32804018|NCT03826420|No Intervention|Control Group|
32804019|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
32804020|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
32804021|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
32804022|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
32804023|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
32804024|NCT03825250|No Intervention|Group A: Control|Standard of care
32804025|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
32804026|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
32804027|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
32804028|NCT04105179|Experimental|Implant Groups|Group will receive the Smith & Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
32804029|NCT04105179|No Intervention|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
32804030|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
32804031|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
32830811|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
32830812|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
33313347|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
33313348|NCT05528666||Overall cohort|Included all patients
33313349|NCT05528666||Previous Non-HET|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
33313350|NCT05528666||Previous HET|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
33313351|NCT05524220|Active Comparator|Group A: Standard care with a facemask.|
33313352|NCT05524220|Experimental|Group B: SuperNO2VA™EtCO2|
33313353|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
32948635|NCT04026594|Active Comparator|Progressive Muscle Relaxation Training (PMRT)|"306 participants will be randomized in a relaxation program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a relaxation recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability"
32948636|NCT04025424||Skin melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;~2) The availability of basic clinical information about the patient and the course of his illness;"
32948637|NCT04025424||Hodgkin disease, retrospective|"1) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);~2) The availability of basic clinical information about the patient and the course of his illness;"
32948638|NCT04025424||Uveal melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);~2) The availability of basic clinical information about the patient and the course of his il"
32948639|NCT04025424||Skin melanoma, proscpective|"1) Clinically and morphologically verified diagnosis of metastatic melanoma;~2) The availability of basic clinical information about the patient and the course of his illness;"
32948640|NCT04025424||Lung cancer, procpective|"1) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;~2) The availability of basic clinical information about the patient and the course of his illness;~3) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;"
32948641|NCT04023396|Experimental|ABX464 50mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
32948642|NCT04195464|Experimental|DN|
32948643|NCT04195464|Sham Comparator|Sham-DN|
32948644|NCT04195464|No Intervention|Control|
32948645|NCT04195386|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
32948646|NCT04195386|Active Comparator|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
32948647|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
32948648|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
32948649|NCT04195074|Experimental|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
32948650|NCT04195074|Experimental|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
32948651|NCT04195074|Experimental|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
32948652|NCT04194762|Experimental|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
32948653|NCT04194762|Active Comparator|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
32948654|NCT03971838|Experimental|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
32948655|NCT04029792|Experimental|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
32948656|NCT04029792|Placebo Comparator|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
32948657|NCT04029948|Active Comparator|laser ERBT|Laser En Bloc Resection Of bladder Tumor
32948658|NCT04029948|Active Comparator|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
32948659|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
32948660|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
32948661|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
32948662|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
32948663|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
33313354|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
33313355|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
33313356|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
33313357|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
33313358|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
32804032|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
32804033|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
33097651|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
33097652|NCT04517045|Sham Comparator|Conventional treatment group|Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.
33097653|NCT04517045|Experimental|Conventional treatment plus L92 group|Conventional treatment combined with L92
32804034|NCT03057184|Experimental|Intervention group|behavioral intervention program
32804035|NCT03057184|No Intervention|Usual care|Usual care
33097654|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction group|Conventional treatment combined with Dachengqi Decoction
33097655|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction plus L92 group|Conventional treatment combined with L92 and Dachengqi Decoction
33097656|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
33097657|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
33097658|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
33097659|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
32804036|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
32804037|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
32804038|NCT02948842|Experimental|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
32804039|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
32804040|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
32804041|NCT04392466||Healty individuals|Healty individuals
32804042|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
32804043|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
32804044|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
32804045|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
32804046|NCT03824392|Experimental|Cohort 1|ATYR1923 1.0 mg/kg or placebo
32804047|NCT03824392|Experimental|Cohort 2|ATYR1923 3.0 mg/kg or placebo
32804048|NCT03824392|Experimental|Cohort 3|ATYR1923 5.0 mg/kg or placebo
32804049|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
32804050|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
32804051|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
32804052|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
32804053|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
32804054|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
33097660|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
33097661|NCT04513028|Experimental|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.~Pembrolizumab: 200 mg/100mL IV in three week intervals~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
33097662|NCT04516382|Experimental|Intravenous|PTG-300 Intravenous
33097663|NCT04516382|Experimental|Subcutaneous Low Concentration|PTG-300 Subcutaneous Low Concentration
33097664|NCT04516382|Experimental|Subcutaneous High Concentration|PTG-300 Subcutaneous High Concentration
33097665|NCT04516382|Experimental|Intramuscular|PTG-300 Intramuscular
33097666|NCT04517123|No Intervention|Control - Usual Care|Usual Care
33097667|NCT04517123|Experimental|Intervention - Prone Positioning|Prone Positioning
32948664|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
33313359|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
33313360|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
32948665|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
33313361|NCT05502224|Other|Specific fatigue management program|
33313362|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
33313363|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
33313364|NCT01137266|Active Comparator|random|3) a random stimulation site.
32948666|NCT04029558|Experimental|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
32948667|NCT04029558|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
32948668|NCT04194684|Experimental|Assigned Interventions|Nab-paclitaxel
32948669|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~Demonstrate negative drug screens done randomly during their hospitalization.~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
32948670|NCT04194294|Active Comparator|Liocaine|Group Lid
32948671|NCT04194294|Active Comparator|Na CL 0.9%|group C
32948672|NCT04029324|Active Comparator|Immediate implant placement|Implants are placed immediately after extraction
32948673|NCT04029324|Placebo Comparator|Early implant placement|Implants are placed 4-8 weeks after extraction
32948674|NCT04029090|Experimental|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
32948675|NCT04029090|Experimental|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
32948676|NCT04029090|Experimental|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
33404723|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
32948679|NCT04194216|Active Comparator|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
32948680|NCT04194216|Active Comparator|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
32948681|NCT04193982|Experimental|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
32948682|NCT04193982|Experimental|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
32948683|NCT04193982|Experimental|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
32948684|NCT04193982|Active Comparator|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
32948685|NCT04028778|Experimental|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
32948686|NCT04028778|Placebo Comparator|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
32948687|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
32948688|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
32948689|NCT03594474|No Intervention|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
32948690|NCT03594474|Experimental|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
33313369|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
32804055|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
32804056|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
32804057|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
32804058|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
32804059|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
32804060|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
32804061|NCT03823924||Psoriatic arthritis|
32804062|NCT03823924||Healthy volunteers|
32804063|NCT04273906|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
32804064|NCT04273906|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
32804065|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
32804066|NCT02834104|Experimental|Myocardial fibrosis|
32804067|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
32804068|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
32804069|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
32804070|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
32804071|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
32804072|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
32804073|NCT02933008|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
32804074|NCT02933008|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
32804075|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
32804076|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
32804077|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
32804078|NCT02790424|Experimental|Patients|Imaging devices
32804079|NCT02738398|Experimental|PET imaging|PET imaging
32804080|NCT02735902|Experimental|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant"
32804081|NCT02735902|Active Comparator|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant Intervention: Aspirin"
32804082|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
32804083|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
32804084|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
32804085|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
32804086|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
32804087|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
32804088|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
32804089|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
32804090|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
32804091|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
32830813|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
32948691|NCT04028544|Experimental|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
32948692|NCT04028544|Placebo Comparator|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
32948693|NCT04406220|Active Comparator|Small clog size|
32948694|NCT04406220|Active Comparator|Large clog size|
32948695|NCT04193592|Experimental|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
32948696|NCT04193670|Experimental|Atopic dermatitis classical form|15 patients
32948697|NCT04193670|Experimental|Atopic dermatitis with atopic prurigo type|10 patients
32948698|NCT03964272|Experimental|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
32948699|NCT03963102|Active Comparator|Control Group 3 hours|Application of Ameluz for 3 hours.
32948700|NCT03963102|Experimental|Trial Group 4 hours|Application of Ameluz for 4 hours.
32948701|NCT03933384|Active Comparator|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
32948702|NCT03933384|Active Comparator|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
32948703|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
32948704|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
32948705|NCT04193358|Experimental|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
32948706|NCT04193358|Placebo Comparator|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
32948707|NCT04193436|Experimental|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
32948708|NCT04193436|Experimental|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
32948709|NCT04193436|Experimental|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
32948710|NCT04193436|Experimental|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
32948711|NCT04193748|Active Comparator|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
32948712|NCT04193748|Experimental|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
32948713|NCT04193748|Experimental|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
32948714|NCT04028466|Experimental|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
32948715|NCT04028466|Active Comparator|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
32948716|NCT04028154|Experimental|ESP Block|
32948717|NCT04028154|Active Comparator|TLIP Block|
32948718|NCT04028076|Experimental|Peers LEAD|8-week educational behavioral intervention
32948719|NCT04027764|Experimental|Toripalimab Combined With S1 and Albumin Paclitaxel|
32948720|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
32948721|NCT04027842|Experimental|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
32948722|NCT04027842|No Intervention|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
32948723|NCT04192890|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
32948724|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
32948725|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
32948726|NCT04027530|Experimental|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
32948727|NCT04027530|Placebo Comparator|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
32948728|NCT04199754|Experimental|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
32948729|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
32948730|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
33097668|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
33097669|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
33097670|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
33097671|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
33097672|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
33097673|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
33097674|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
33313370|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
33313371|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
33313372|NCT01140542|Placebo Comparator|Placebo|
33313373|NCT01234610|Experimental|Exercise|Exercise
32804092|NCT04273282|Active Comparator|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
32804093|NCT04273282|Active Comparator|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
32804094|NCT04391530|Experimental|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
32804095|NCT04391530|Experimental|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
32804096|NCT04391530|No Intervention|Control group|No intervention was made to the students in the control group.
33313374|NCT01234610|No Intervention|Control|No exercise
33313375|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
32804099|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
32804100|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
32804101|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
32804102|NCT01454206|No Intervention|Treatment as Usual|
32804103|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
32804104|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
32804105|NCT01454440|Placebo Comparator|Placebo|
32804106|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
32804107|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
32804108|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
32804109|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
32804110|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
32804111|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
32804112|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
32804113|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
32804114|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
32804115|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
32804116|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
32804117|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
32804118|NCT01455142|Experimental|Formulation 1|
32804119|NCT01455142|Experimental|Formulation 2|
32804120|NCT01455298|Other|Transient elastography and fibrotest|
32804121|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
32804122|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
32804123|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
32804124|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
32830814|NCT03284190||ASDH Copenhagen, Denmark|
32830815|NCT03284190||ASDH Odense, Denmark|
32830816|NCT03284190||ASDH Århus, Denmark|
32830817|NCT03284190||ASDH Ålborg, Denmark|
33097675|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
33313376|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
33313377|NCT05320094|Experimental|Mavacamten|
32948731|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
32948732|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
32948733|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
32948734|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
32948735|NCT04192812|Experimental|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
32948736|NCT04192812|Placebo Comparator|no GnRHa|NO TREATMENT
32948737|NCT04199910||Liver cirrhosis with spironolactone|
32948738|NCT04199910||Liver cirrhosis with rifaximin|
32948739|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
33313378|NCT05320094|Experimental|Mavacamten and activated charcoal with sorbitol - Dose A|
32948740|NCT04199910||Pneumonia|
32948741|NCT04199910||Crohn's disease|
32948742|NCT04199910||Ulcerative colitis|
32948743|NCT04192578|Experimental|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948744|NCT04192578|Experimental|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948745|NCT04192578|Experimental|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948746|NCT04192578|Experimental|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948747|NCT04192578|Experimental|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948748|NCT04192578|Experimental|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948749|NCT04192578|Experimental|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948750|NCT04192578|Experimental|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
32948751|NCT04407000|Experimental|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
32948752|NCT04407000|Active Comparator|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
32948753|NCT04192656|Experimental|PAP plus medication|patients treated by both PAP and medication
32948754|NCT04192656|Active Comparator|medication|patients treated by medication only
32948755|NCT04191954|Active Comparator|Fasudil eye drops (concentration 0.5 percent)|twice daily
32948756|NCT04191954|Placebo Comparator|receive artificial tears drop with the same frequency|
32948757|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
32948758|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
32948759|NCT04192032|Experimental|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
32948760|NCT04192032|Active Comparator|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
32948761|NCT04192032|Experimental|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
32948762|NCT04192032|Experimental|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
32948763|NCT04192032|Experimental|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
32948764|NCT04027062|Other|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
32948765|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
32948766|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
32948767|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
32948768|NCT04026516|Experimental|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
33313379|NCT05320094|Experimental|Mavacamten and activated charcoal with sorbitol - Dose B|
32948769|NCT04192188||ART-Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
32948770|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
33097676|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
33097677|NCT04516460|Experimental|PuraStat|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection
33097678|NCT00504543|Active Comparator|Neoral|
33097679|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
33097680|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
33097681|NCT02949570|Experimental|Treatment|
33097682|NCT04518995|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
33097683|NCT04518995|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
33097684|NCT04518995|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
33097685|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
33097686|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
33097687|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
33097688|NCT04516343|Experimental|User testing|Two sessions of user-centric testing.
33097689|NCT04516343|Experimental|Therapist-guided training|Therapist-guided gait training with the RAAD.
33097690|NCT04516343|Experimental|Assistance training|Assistance training with the RAAD
33097691|NCT04516343|Experimental|Therapist supervised resistance training|Resistance training with the RAAD under therapist supervision.
33097692|NCT04516343|Experimental|Parent supervised resistance training|Resistance training under parent supervision.
33097693|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
33097694|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
33097695|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
33097696|NCT04516265|Active Comparator|NGT Group|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
33097697|NCT04516265|Active Comparator|Video-based training group|Trunk training will be done with games developed for the use of children with cerebral palsy.
33097698|NCT04516265|Active Comparator|Video-based training group with theratogs|Video-based trunk training (45 minutes) will apply with Theratogs to the group
33097699|NCT00517803|Experimental|1|
33097700|NCT00517803|Placebo Comparator|2|
32948771|NCT04191408|Experimental|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
32948772|NCT04191564|Experimental|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
32948773|NCT04191564|Experimental|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
32948774|NCT04195620|Experimental|Low loneliness, low self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
32948775|NCT04195620|Experimental|Low loneliness, high self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
32948776|NCT04195620|Experimental|high loneliness, low self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
32948777|NCT04195620|Experimental|high loneliness, high self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
32948778|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
32948779|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
33313380|NCT03917030|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
32804125|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
32804126|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
32804127|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
33097701|NCT04517435|Experimental|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
33097702|NCT01243125|Experimental|NVC-422|
32804128|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
33097703|NCT01243125|Placebo Comparator|Saline|
33097704|NCT04516304|Placebo Comparator|Placebo|Placebo
33097705|NCT04516304|Experimental|Experimental|S-equol
32804129|NCT01455688|Experimental|Early antiviral therapy|
32804130|NCT01455688|Active Comparator|Conventional therapy|
32804131|NCT01455844|Experimental|CaPre 1.0g|
32804132|NCT01455844|Experimental|CaPre 2.0g|
32804133|NCT01455844|Placebo Comparator|Placebo|
32804134|NCT01455922|Experimental|ITCA 650 60 mcg/day|
32804135|NCT01455922|Active Comparator|glimepiride|
32804136|NCT01456156|Experimental|hepatectomy plus radiotherapy|
32804137|NCT04391140|Experimental|Experimental|Combination of prone position and HFNC
32804138|NCT04391140|No Intervention|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
32804139|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
32804140|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
32804141|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
32804142|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
32804143|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
33097706|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
32804144|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
32804145|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
32804146|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
32804147|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
32804148|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
33097707|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
33097708|NCT04516226|Experimental|Vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
33097709|NCT04516226|No Intervention|No vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
33097710|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
33097711|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
33097712|NCT04516031|Active Comparator|Mesh-only repair|
33097713|NCT04516031|Active Comparator|Transversus Abdominis Muscl|
33097714|NCT04515758|Experimental|Exercise and Cognitive Training|Each participant (in a group setting) completes 30 minutes of cognitive training and 1 hour of exercise two days/week.
33097715|NCT04515758|Active Comparator|Exercise Training Only|Each participant (in a group setting) completes 1 hour of exercise two days/week (separate days than the experimental group).
33097716|NCT01241214|Experimental|Investigational drug - Dose 1|
33097717|NCT01241214|Experimental|Investigational drug - Dose 2|
33097718|NCT01241214|Experimental|Investigational drug - Dose 3|
33097719|NCT01241214|Experimental|Investigational Drug - Dose 4|
33097720|NCT01241214|Other|Active Matching Reference|
33097721|NCT01241214|Placebo Comparator|Matching Placebo|
33313381|NCT03917030|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
32804149|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
32804150|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
32804151|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
32804152|NCT01456624|Active Comparator|Megace / Fed condition|800mg
32804153|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
32804154|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
32804155|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
32804156|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
32804157|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
32804158|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
32804159|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
32804160|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
32804161|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
32804162|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
32804163|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
32804164|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
32804165|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
32804166|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
32804167|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
32804168|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
32804169|NCT01457560|Experimental|Group A|
32804170|NCT04758442|Experimental|Vancomycin|Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.
32804171|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
32804172|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
32804173|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
32804174|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
32804175|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
32804176|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
32804177|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
32804178|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
32804179|NCT04391218|Experimental|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
32804180|NCT04391218|No Intervention|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
32804181|NCT04391296|Experimental|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
32804182|NCT04391296|Active Comparator|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
32804183|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
32804184|NCT01458028|Experimental|Arm 1|
32804185|NCT01458028|Placebo Comparator|Arm 2|
32804186|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
32804187|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
32804188|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
32804189|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
32804190|NCT01458496|Experimental|Health Coaching|
32804191|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
32804192|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
32804193|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
32948780|NCT03951870|Experimental|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.~anatomical masks: VTA (Midbrain): -4 -24 -10 *see below Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).~* 23/08/22: Due to VTA complex contours, it was not restricted according to Oldham et al as mentioned above, but via more accurate VTA mask (Murty et al. 2014, NeuroImage). This was mistakenly left out of the original preregistration. It is noteworthy that, to date (23/8/22), ROI analyses haven't been performed.~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
32948781|NCT03951870|Active Comparator|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):~Motor Imagery (Hétu, Sébastien, et al. Neurosci. & Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
32948782|NCT03951870|Other|Natural history|"No brain manipulation (Assesment of natural history immune response).~Hepatitis B vaccination: subjects (n=17) will receive vaccination against Hepatitis B."
32948783|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
32948784|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
32948785|NCT04192110|Experimental|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
32948786|NCT04025736|Experimental|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
33097722|NCT04515836|Experimental|Treatment Arm|Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.
33313382|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
33313383|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
32830818|NCT03284190||ASDH Lund, Sweden|
32830819|NCT03284190||ASDH Linköping, Sweden|
32948787|NCT04025736|Placebo Comparator|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
32948788|NCT04766112|Experimental|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training which consist of 10 positions
32830820|NCT03284190||ASDH Gothenburg, Sweden|
32830821|NCT03284190||ASDH Stockholm, Sweden|
32830822|NCT03284190||ASDH Uppsala, Sweden|
32830823|NCT03284190||ASDH Umeå, Sweden|
32830824|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
32830825|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
32830826|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
32948789|NCT04766112|Active Comparator|Group II|Group B will receive yang style Tai chi exercise which consist of 10 positions
32948790|NCT04190940|Experimental|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
32948791|NCT04190940|Experimental|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
32948792|NCT04195230|Experimental|Computerized Cognitive Training (Breakfast Game)|"Participants will undergo a pilot training protocol where they will have to perform two tasks concomitantly, in a multi-tasking fashion. The tasks are related to everyday activities as cooking and setting tables."
32948793|NCT04199598|Experimental|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
32948794|NCT04199598|Experimental|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
32948795|NCT04199598|Experimental|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
32948796|NCT04199598|Experimental|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
33313384|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
33313385|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
32948797|NCT04190784|Experimental|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
32948798|NCT04190784|Experimental|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
32948799|NCT04190784|Experimental|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
32948800|NCT04190784|Placebo Comparator|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
32948801|NCT04190784|Placebo Comparator|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
32948802|NCT04190784|Placebo Comparator|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
32948803|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
32948804|NCT04190316|Other|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
32948805|NCT03961854|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
32948806|NCT03961854|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
32948807|NCT04190160|Experimental|6 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
32948808|NCT04190004|Experimental|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
32948809|NCT04190004|Placebo Comparator|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
33097723|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
33097724|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
32948810|NCT04406298|Experimental|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
32948811|NCT04406298|Active Comparator|Large Volume Paracentesis|Large Volume Paracentesis > 5 litres
32948812|NCT03949764|Experimental|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
32948813|NCT03949764|No Intervention|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
32948814|NCT04025892|Experimental|Tracking group|Participants will be asked to track weight daily for six weeks
32948815|NCT04406376|Active Comparator|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
32948816|NCT04406376|Active Comparator|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
32948817|NCT04025268|Active Comparator|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
32948818|NCT04025268|Active Comparator|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
32948819|NCT04025346|Active Comparator|Capsimax|
32948820|NCT04025346|Placebo Comparator|Placebo|
32948821|NCT03948984|Experimental|Therapeutic Music Session|
32948822|NCT04025034|Experimental|Study Group|Use of SONOPET(R) to orbital surgery.
32948823|NCT04025112|Experimental|Armeo|Patients group (54 patients) for robotic therapy.
32948824|NCT04025112|Active Comparator|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
32948825|NCT04024722|Experimental|Single ovary treatment|
32948826|NCT04024722|Experimental|Dual ovary treatment|
32948827|NCT04024800|Experimental|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
32948828|NCT04199520|Experimental|surgery combined with systemic therapy|surgery combined with systemic therapy
32948829|NCT04199520|Active Comparator|systemic therapy|systemic therapy
33097725|NCT04513769|Experimental|Study participants|This is a single-arm study so all participants receive the same intervention.
33097726|NCT04515368|Experimental|Fendrix|Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
33097727|NCT04515368|Experimental|Bexsero|Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.
33097728|NCT04515368|Experimental|Fluad|Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
33097729|NCT04515368|Experimental|Seasonal Trivalent Influenza Vaccine|Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.
33097730|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32804194|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
32804195|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
32804196|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
32804197|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
32804198|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
32804199|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
32804200|NCT01459042||primary aldosteronism|
32804201|NCT01459042||essential hypertension|
33097731|NCT04515446|Other|TROD + PCR diagnosis|For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.
33313386|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
32804202|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
32804203|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
32804204|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
32804205|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
32804206|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
32804207|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
32804208|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
32804209|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
32804210|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
32804211|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
32804212|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
32804213|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
32804214|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
32804215|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
32804216|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
32804217|NCT01459432||Follow-on blood sample from previous study|
32804218|NCT01459510|Experimental|multi media intervention|Play Nicely Program
32804219|NCT01459510|No Intervention|Routine primary care|Routine primary care
32804220|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
32804221|NCT04390984|Experimental|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
32804222|NCT01459822||Survival Group|
32804223|NCT01459822||Death Group|
32804224|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
32804225|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
32804226|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
32804227|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
32804228|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
33097732|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
33097733|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
33097734|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
33097735|NCT00506402|Experimental|1|
33097736|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
33097737|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
33097738|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
33097739|NCT04515641|Experimental|Moderate Hepatic Impairment|Participants receive a single dose of ISL 60 mg.
33097740|NCT04515641|Experimental|Healthy Controls|Participants receive a single dose of ISL 60 mg.
33097741|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
33313387|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
33313388|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
33313389|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
33313390|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
32804229|NCT02878408|Other|TOC|blood sampling and data collection (only one visit)
32804230|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
32804231|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
32804232|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
32804233|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
32804234|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
32804235|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
32804238|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
32804239|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
32804240|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
32804241|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
32804242|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost~Intervention:~Implantation of two iStent inject micro-bypass stents~Tobramycin~Dexamethasone"
32804243|NCT01890382|Placebo Comparator|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
32804244|NCT01890382|Experimental|whey protein|
32804245|NCT01890382|Experimental|soy protein|
32804246|NCT01890382|Experimental|leucine supplementation|
32804247|NCT01890382|Experimental|whey plus creatine|
32804248|NCT01890382|Experimental|creatine|
32804249|NCT01890616||Motility|This arm will ingest the SmartPill.
32804250|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
32804251|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
32804252|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
32804253|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
32804254|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
32804255|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
32804256|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
33313391|NCT05298878|Experimental|Virtual home-based rehabilitation plus usual outpatient care|An 8-week home-based virtual rehabilitation program consisting of exercises and education plus usual care.
33313392|NCT05298878|No Intervention|Usual outpatient care|The control group will receive usual outpatient care which consists of any medical outpatient follow-up visits. The participants will receive a set of written generic instructions on how to manage symptoms and engage in physical activity after critical illness.
33313393|NCT03917108|Active Comparator|retraction cord|
33097742|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
33313394|NCT03917108|Other|subgingival clamp|
33313395|NCT05298644|Experimental|Dose finding ≥5 to <12 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
33097743|NCT04515992|Experimental|High Intensity Body-weight Circuit (HIBC)|The at home HIBC intervention program involved the use of both bodyweight and suspension training equipment (TRX® Fit System) with modified movements. The TRX® system was used to modify squats and rows while attached to the top of a door frame.
33097744|NCT04515602|Experimental|Part 1 Arm I (low/medium tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
33313396|NCT05298644|Experimental|Dose finding ≥2 to <5 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
33313397|NCT05298644|Other|Confirmatory ≥5 to <12 years|Day 1: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: Active Comparator
33313398|NCT05298644|Other|Confirmatory ≥2 to <5 years|Day 1: Active Comparator Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose)
33313399|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
33313400|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
33313401|NCT01231100|No Intervention|Standard care|
33313402|NCT04725266|Experimental|family-based intervention plus routine care|This group of participants including drug abusers and their families will be receiving family-based intervention which is a well-designed intervention with group sessions and routine care provided by professional social workers in local social service center.
33313403|NCT04725266|Active Comparator|routine care|The group of participants will receive routine care which is widely used in social service providers and mainly includes individual counselling service for drug abusers.
33313404|NCT03917186|Active Comparator|Group sevoflurane|Administration under labelling conditions
33313405|NCT03917186|Experimental|Group desflurane|Administration under labelling conditions
33313406|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
33313407|NCT04713098|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
33313408|NCT04713098|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
33313409|NCT04676594||Diagnosis of Pulmonary Fibrosis on Chest CT|Retrospective chart review of patients with a diagnosis of pulmonary fibrosis on chest CT.
33313410|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
33313411|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
33313412|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
33313413|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
33313414|NCT03916952||Healthy older|All participants > 65 years of age that completed the test
33313415|NCT01138670||Cardiac device group|
33313416|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, >=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by >= 2 ED visits, >= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
33313417|NCT04657250|Experimental|Smoking cessation + quitline linkage text messages|Text messaging for smoking cessation + text messages with proactive linkage to quitline
33313418|NCT04657250|Placebo Comparator|Passive quitline referral|Single text message with contact information for the Quitline
33313419|NCT01231178|Active Comparator|Alginate based beverage|
33313420|NCT01231178|Placebo Comparator|Control beverage|
33313421|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
32948830|NCT04198662|Active Comparator|Cryoneurolysis|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
32948831|NCT04198662|Sham Comparator|Sham|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
32948832|NCT03969654|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA
32948833|NCT03969654|Active Comparator|Conventional TKA|Conventional TKA
32948834|NCT04198272|Experimental|Facilitated|"Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to the following:~-Peer facilitation of the CyberRwanda platform at the school-based cyber clubs that will house an online tablet with the educational components of CyberRwanda with a facilitator."
32948835|NCT04198272|Active Comparator|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:~Availability of the fully functional online CyberRwanda web portal through school-based cyber clubs;~SMS-based ordering of contraceptives and SMS-based FAQs Online (through web portal on computer or smartphone) ordering of contraceptives;~Facility finder: A list of the closest health centers and pharmacies where youth can get contraceptives and other FPRH services;~Promotion of the CyberRwanda program through school launch events; and~Access to Youth Centers (1 per district) that will house tablets with the fully functional online CyberRwanda web portal"
32948836|NCT04198272|No Intervention|Control|Schools in this arm will not receive any intervention
32948837|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
32948838|NCT04406610|Experimental|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
32948839|NCT04406610|No Intervention|Control|With no medical intervention
32948840|NCT04024176|Experimental|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
32948841|NCT04024332|Experimental|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
32948842|NCT04024332|Experimental|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
32948843|NCT04023864|Experimental|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
32948844|NCT04023864|Placebo Comparator|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
32948845|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
32948846|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
32948847|NCT04023786|Experimental|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
32948848|NCT04023630|Experimental|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
32948849|NCT04023630|Active Comparator|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
32948850|NCT04023474|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
32948851|NCT04023474|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
32948852|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
32948853|NCT04022928|Experimental|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
32948854|NCT04147104|Active Comparator|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
32948855|NCT04147104|Experimental|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
32948856|NCT04147182|Experimental|Patient with low grade TCC|"Patients of 18 years or older able to sign informed consent~A previous diagnosis of low grade bladder cancer~A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion~Serum creatinine levels ≤ 2.0 mg/dl~Serum sodium levels <146 mg/ml~Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months~Patient is candidate for TURBT"
32948857|NCT04147260|Experimental|BI 730357 low dose|
32948858|NCT04147260|Active Comparator|Ciprofloxacin|
32948859|NCT04147260|Experimental|BI 730357 high dose|
32948860|NCT04147260|Placebo Comparator|Placebo|
32948861|NCT04146792|Experimental|body acceptance program|
32948862|NCT04146792|Active Comparator|writing creativity program|
32948863|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
32948864|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
32948865|NCT04022304|Experimental|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
33097745|NCT04515602|Active Comparator|Part 1 Arm II (low/medium tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
33097746|NCT04515602|Experimental|Part 2 Arm I (high tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
33097747|NCT04515602|Active Comparator|Part 2 Arm II (high tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
33097748|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
33097749|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
33097750|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
33097751|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
33097752|NCT04518605|Experimental|Low protein breakfast|Subject will eat a low protein breakfast and maintain their habitual physical activity.
33097753|NCT04518605|Experimental|High protein breakfast|Subject will eat a high protein breakfast and maintain their habitual physical activity.
33097754|NCT04518605|Experimental|Low protein breakfast and exercise training|Subject will consume a low protein breakfast (bread, jam, juice) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
33097755|NCT04518605|Experimental|High protein breakfast and exercise training|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr) with oats) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
33097756|NCT00518310|Placebo Comparator|0|Placebo
33097757|NCT00518310|Active Comparator|1|Azathiprine Prednisone
33313422|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
32804257|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
32804258|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
32804259|NCT04272112|Active Comparator|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
32804260|NCT04272112|Active Comparator|Zirconia|30 dental crowns of high translucent zirconia
32804261|NCT04272112|Active Comparator|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
32804262|NCT04272346|Experimental|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
32804263|NCT04272346|Experimental|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
32804264|NCT04272346|Placebo Comparator|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
32804265|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
32804266|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
32804267|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
33097758|NCT04510532||Patients with Breast Cancer who use pyrotinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
33097759|NCT04510532||Patients with Breast Cancer who use apatinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
33097760|NCT04510532||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
33097761|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
33097762|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
33097763|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
33097764|NCT04519814|Experimental|all eligible patients|A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.
33097765|NCT00518427|Experimental|1|insulin glargine
32948866|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
32948867|NCT04022304|Experimental|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
32948868|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
32948869|NCT04022304|Experimental|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
32948870|NCT04022304|Experimental|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
32948871|NCT04022382|Experimental|Restylane Defyne recipient|
32948872|NCT04021446|Active Comparator|Exercise|Will receive the exercise intervention
32948873|NCT04021446|No Intervention|Attention Control|Will not receive the exercise intervention
32948874|NCT03930654|Experimental|iPrEP Intervention|"iPrEP Intervention:~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
32948875|NCT03930654|Active Comparator|Usual Care|"Control Intervention:~Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
32948876|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children <18 years, admitted for a general anesthesia.
32948877|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
32948878|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
32948879|NCT04405986|Experimental|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
32948880|NCT03929640|Placebo Comparator|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
32948881|NCT03929640|Active Comparator|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
32948882|NCT03928626|Active Comparator|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
32948883|NCT03928626|Placebo Comparator|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
32948884|NCT04021992|Experimental|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
32948885|NCT04022070|Other|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
32948886|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
33097766|NCT04515173|Experimental|Artificial intelligence group|On the basis of conventional drug therapy combined with psychotherapy robot psychotherapy, the corresponding intelligent psychotherapy module and intensity were recommended according to the results of intelligent psychological evaluation. Each module was set once a week, 50 minutes each time, a total of 12 times.
33313423|NCT04630730|Experimental|Recombinant intravesical BCG|"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.~4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine.~After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles."
33313424|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
32948887|NCT04406532|Experimental|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
32948888|NCT04406532|Active Comparator|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
32948889|NCT04021836|Other|3d evaluation of naso labial changes using alar cinch suture|
32948890|NCT04021836|Other|3d evaluation of nasolabial change without Alar cinch|
32948891|NCT03926130|Experimental|Mirikizumab|"Mirikizumab given intravenously (IV) and subcutaneously (SC).~Participants in the open-label adolescent addendum will be given mirikizumab IV and SC."
32948892|NCT03926130|Active Comparator|Ustekinumab|Ustekinumab given IV and SC.
32948893|NCT03926130|Placebo Comparator|Placebo|Placebo given IV and SC.
32948894|NCT04020588|Active Comparator|Celecoxib|Celecoxib 200 mg twice a day
32948895|NCT04020588|Active Comparator|Minocycline|Minocycline 100 mg twice a day
32948896|NCT04020588|Placebo Comparator|Placebo|Placebo capsules twice a day
32948897|NCT04146402|Experimental|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
32948898|NCT04146402|Active Comparator|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
32948899|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
32948900|NCT04146480|Experimental|Cardiac amyloidosis patients|
32948901|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
32948902|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
32948903|NCT04020354|Experimental|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
32948904|NCT04020354|Active Comparator|Usual Care|A two weeks period of usual customary care
32948905|NCT03907410|Experimental|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
32948906|NCT03907410|Active Comparator|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
32948907|NCT03907410|No Intervention|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
32948908|NCT04145544|Experimental|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.~Post operation the subject will stay at the hospital according to site standards and physician discretion."
32948909|NCT04145544|Active Comparator|Control|"Same procedure as for the treatment arm but using a commercial suturable dural substitute.~Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
32948910|NCT04146558|Experimental|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
32948911|NCT04146558|Active Comparator|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
32948912|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
32948913|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
32948914|NCT04146246||Neonate|Neonates gestational age >35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
32948915|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
32948916|NCT04145856|Placebo Comparator|Placebo|- Control arm
32948917|NCT04145856|Experimental|Probiotic|- Arm with active probiotic alone
32804268|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
32804269|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
32804270|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
32804271|NCT01891474|No Intervention|control|conventional treatment
32804272|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
32804273|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
32804274|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
32804275|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
32804276|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
32804277|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
32804278|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
32804279|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
32804280|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
32804281|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
32804282|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
32804283|NCT01892332|Other|lidocaine with fentanyl 75ug|
32804284|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
32804285|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
32804286|NCT04390204|Experimental|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
32804287|NCT04390204|No Intervention|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
32804288|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
32804289|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
32804290|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
32804291|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
32804292|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
32804293|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
32804294|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
32804295|NCT01892878|Other|Single Arm Study|All patients will receive treatment
32804296|NCT01892956||Healthy volunteers|
32804297|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
32804298|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
32804299|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
32804300|NCT02804230|Experimental|Exablate Neuro System Treatment|MR-Guided Focused Ultrasound will be used to ablate epileptic foci up to 8 cm3 in size.
32804301|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
32804302|NCT01925989|Experimental|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
32804303|NCT01925989|Active Comparator|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
32804304|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
32804305|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
32804306|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
32804307|NCT02798536|Experimental|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
32804308|NCT02798536|Experimental|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
32804309|NCT02798536|Experimental|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
32804310|NCT02798536|Experimental|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
32804311|NCT01893268||Cohort|
32804312|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
32804313|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
32804314|NCT04758286|Active Comparator|Successful outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
32804315|NCT04758286|Active Comparator|Complicated outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
32804316|NCT04757896|Active Comparator|Costoclavicular block lateral aproach|An 80-100 mm needle will be directed from the lateral to the medial with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
32804317|NCT04757896|Active Comparator|Costoclavicular block medial aproach|An 80-100 mm needle will be directed from the medial to the lateral with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
32804318|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
32948918|NCT04145856|Experimental|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
32948919|NCT04145778||Patient|
32948920|NCT04145778||Control|
32948921|NCT04146090|Active Comparator|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
32948922|NCT04146090|Placebo Comparator|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
32948923|NCT03925038|Active Comparator|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
32948924|NCT03925038|Experimental|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
32948925|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
32948926|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
32948927|NCT04149522|Active Comparator|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
32948928|NCT04149522|Active Comparator|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
32948929|NCT04140786|Experimental|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
32948930|NCT04140786|Experimental|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
32948931|NCT04147650|Experimental|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
32804319|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
32948932|NCT04147650|Experimental|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
33313425|NCT04626284|Experimental|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
33313426|NCT04619654|Experimental|Cataract Surgery with concurrent MIGS|
32804320|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months."
32804321|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months.~Apalutamide 240 mg, once daily, orally for 3 months."
32804322|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
32804323|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
32804324|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
32804325|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32804326|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
33313427|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
32804327|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
32804328|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
32804329|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
32804330|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
32804331|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
32804332|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
32804333|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
32804334|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.~Patients in the study will receive an annual monitoring as recommended, independently of the study."
32804335|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
32804336|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
32804337|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
32804338|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
32804339|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
32948933|NCT04147650|Experimental|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
32948934|NCT04147650|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
32948935|NCT04023942|Active Comparator|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
33313428|NCT01138748|Experimental|Radiation therapy|
32804340|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
32804341|NCT02773732|Experimental|Ciprofloxacin Dose Level 0|
32804342|NCT02773732|Experimental|Ciprofloxacin Dose Level +1|
32804343|NCT02773732|Experimental|Ciprofloxacin Dose Level -1|
32804344|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
32830827|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
32830828|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
32830829|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
32830830|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
32830831|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
32830832|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
32830833|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
32830834|NCT01252719|Active Comparator|IV Vancomycin|
32830835|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
32830836|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
32830837|NCT01233531|Other|B--No cash transfers|No cash transfers.
32830838|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
32830839|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
32830840|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
32830841|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
32830842|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
32830843|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
32830844|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
32830845|NCT03271866|Other|metformin treatment|
32830846|NCT03271866|No Intervention|non-metformin treatment|
32830847|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
32830848|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
32830849|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
32830850|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
32830851|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
32830852|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
32830853|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
32830854|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
32830855|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
32830856|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
32830857|NCT04389723|Other|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
32830858|NCT04389723|Other|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
32830859|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
32830860|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
32948936|NCT04023942|Active Comparator|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
32948937|NCT04023942|Active Comparator|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
32948938|NCT04023942|Active Comparator|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
32948939|NCT04022226|Active Comparator|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
32948940|NCT04022226|Experimental|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
32948941|NCT04029012|Experimental|Penthrox|methoxyflurane inhaler (Penthrox) to be used 5 minutes (+/- 1 minutes) before procedure, and continuously breathing in the inhaler throughout the procedure.
32948942|NCT04025658|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948943|NCT04025658|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948944|NCT04025658|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948945|NCT04025658|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948946|NCT04025658|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948947|NCT04025658|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
32948948|NCT04020744|Active Comparator|healthy elderly participants receiving feedback from the hippocampus|This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.
32948949|NCT04020744|Sham Comparator|healthy elderly participants receiving feedback from another area|This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.
32948950|NCT04020744|Experimental|patients with MCI receiving feedback from the hippocampus|This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.
32948951|NCT04020744|Sham Comparator|patients with MCI receiving feedback from another brain area|This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.
32948952|NCT05588856||Patients with Chronic Lung Disease|
32948953|NCT05588856||Healthcare professionals|
32948954|NCT05588466|Active Comparator|CDS alone|This arm will only receive the CDS.
32948955|NCT05588466|Active Comparator|CDS plus practice facilitation|This arm will receive the CDS and practice facilitation.
32948956|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
32948957|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
32948958|NCT03924180|Experimental|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
32948959|NCT03924180|Active Comparator|Control -Amino acids mixtures|Mixtures of conventional amino acids.
32948960|NCT04027296||suspected COPD|Patients aged ≥ 35yo and ≥10Pack.Year
32948961|NCT05581680|Experimental|patients with facial palsy|
32948962|NCT05581680|Active Comparator|healthy volunteers|
32948963|NCT04023240|Experimental|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
32948964|NCT05588700|Active Comparator|Control group|
32948965|NCT05588700|Experimental|Intervention group|
32948966|NCT05586438|Experimental|blood draws|All patients enrolled will have PK blood samples obtained around a colistin dosing
32948967|NCT05581524|Experimental|VELEX|Treatment of varicose veins of lower limbs by means of chemical ablation or empty-vein sclerotherapy
32948968|NCT03922932||Group A: PDR|This group will consist of 30 subjects with active proliferative diabetic retinopathy (PDR) and 30 subjects with treated PDR.
32948969|NCT03922932||Group B: NPDR|This group will consist of 60 subjects with severe non-proliferative diabetic retinopathy (NPDR), 60 subjects with moderate NPDR, and 60 subjects with mild NPDR.
32948970|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
32948971|NCT03922932||Group C: DM without Retinopathy|This group will consist of 60 subjects with diabetes mellitus (DM) who do not have retinopathy.
32948972|NCT03922932||Group D: Healthy Controls|This group will consist of 50 subjects with healthy eyes who do not have diabetes.
32948973|NCT04765878|Experimental|Humidification|
32948974|NCT04025814|Experimental|dHealth tool and BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will use a digital Health (dHealth) tool in daily life contexts while receiving BPT, aimed to improve parent adherence sustained use of evidence-based parenting strategies. They will also participate in focus groups and discussions to facilitate the build, design, and use of the dHealth.
32948975|NCT04025814|Experimental|BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will be receiving BPT without the use of a digital Health (dHealth) tool.
32948976|NCT03921294|Experimental|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
33404724|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
33404725|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
32948977|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
32948978|NCT04144764|Experimental|Workplace-based exercise group|
32948979|NCT04144764|Sham Comparator|Control group|
32948980|NCT04029246|No Intervention|Letter only|
32948981|NCT04029246|Active Comparator|Letter plus phone call|
32948982|NCT04029246|Active Comparator|Letter plus incentive|
32948983|NCT04144920|Other|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
32948984|NCT04144920|Other|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
32948985|NCT04144920|Other|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
32948986|NCT04144920|Other|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
32948987|NCT04144920|Other|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
32948988|NCT04144920|Other|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
32948989|NCT04027452|Experimental|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
32948990|NCT04027452|Placebo Comparator|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
32948991|NCT04144452|Active Comparator|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
32948992|NCT04144452|Experimental|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
32948993|NCT03947190|Experimental|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
32948994|NCT03947190|Experimental|Group 2|Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
32948995|NCT03947190|Experimental|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
32948996|NCT03947190|Experimental|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
32948997|NCT04144374|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
32948998|NCT04144374|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
32948999|NCT04026282|Experimental|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
32949000|NCT04026282|Active Comparator|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
32949001|NCT04144296|Other|Study Arm|All patient will be included in this arm
32949002|NCT04144218|Placebo Comparator|Control group|
32949003|NCT04144218|Experimental|Experimental group|
32949004|NCT05580900|Experimental|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
32949005|NCT05580900|Experimental|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
32949006|NCT03905538|Experimental|[18F]FLT-PET/CT Arm|The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
32949007|NCT04021602|Active Comparator|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
33404726|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
32804345|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
32804346|NCT04390126||Register of haematological malignancies|
32804347|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
32804348|NCT04390126||Giant Cell Arteritis Cohort|
33313429|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
33313430|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
33313431|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
33404727|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
32804349|NCT04390126||AMD and Macular Edema Cohort|
32804350|NCT04390126||Multiple Sclerosis Cohort|
32804351|NCT04390126||Myocardial Infarction Observatory RICO|
32804352|NCT04390126||Heart Failure Cohort|
32804353|NCT04390126||Hemophilia Cohort|
32804354|NCT02771236||Participants with cataracts|Participants with cataracts
32804355|NCT02771236||Participants with corneal dystrophies|Participants with corneal dystrophies
32804356|NCT02771236||Participants with glaucoma|Participants with glaucoma or other anterior chamber anomalies
33097767|NCT04515173|Other|General group|The subjects in this group only received routine drug therapy and routine outpatient follow-up evaluation
33313432|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
33313433|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
32804357|NCT02771236||Participants with lens refractive errors|Participants with lens refractive errors including myopia and hyperopia
33313434|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
33313435|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
33313436|NCT01139060|No Intervention|Usual Care|
33313437|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
33313438|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
33313439|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region abdomen|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
33313440|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region upper arm|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
33313441|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region thigh|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
33313442|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
33313443|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
33313444|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
33313445|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
33313446|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
33313447|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
33313448|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
32804358|NCT02771236||Participants with retinal degenerations|Participants with retinal degenerations
33097768|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
33313449|NCT05290142|Active Comparator|Self-Guided Digital Training (DT)|"Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available online on a smartphone app as well as a website that can be accessed through an internet-enabled device.~Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface."
33313450|NCT05290142|Experimental|Digital Training with Coaching (DT-C)|In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. Participants will also be able to send text messages to coaches.
33313451|NCT05280314|Experimental|Cohort A - Melanoma|"Cutaneous resectable Stage IIIB, IIIC, or IIID melanoma or oligometastatic IV melanoma.~Neoadjuvant Treatment (6 weeks): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) weekly, and intravenous Pembrolizumab 200mg Q3W × 2.~Adjuvant Treatment (12 months): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) every 3 weeks (Q3W) for the first 18 weeks, followed by every 6 weeks (Q6W), and intravenous Pembrolizumab 400mg Q6W."
33313452|NCT05280314|Experimental|Cohort B - SCCHN|"Squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity, oropharynx, hypopharynx, or larynx, HPV+/-, T1N1-N2b or T2-4N0-N2b.~Neoadjuvant Treatment (6 weeks): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) weekly, and intravenous Pembrolizumab 200mg Q3W × 2.~Adjuvant Treatment (12 months): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) every 3 weeks (Q3W) for the first 18 weeks, followed by every 6 weeks (Q6W), and intravenous Pembrolizumab 400mg Q6W."
33313453|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
33313454|NCT05403008|Other|Zirconomer improved|a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
33313455|NCT05403008|Active Comparator|Nano hybird resin composite|Resin composite (RC) is the gold standard esthetic restoration in proximal cavities due to their high aesthetic properties, increased mechanical durability and enhanced adhesion to tooth structure.
33313456|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
33313457|NCT02446912|Placebo Comparator|Placebo|Placebo
33313458|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
33313459|NCT04563026|Experimental|DUR-928 (larsucosterol, 30 mg)|
33313460|NCT04563026|Experimental|DUR-928 (larsucosterol, 90 mg)|
33313461|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
33313462|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
33313463|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
33313464|NCT04528082|Experimental|Apremilast|Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
33313465|NCT04528082|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.
33313466|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
33313467|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
33313468|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
33313469|NCT04708600|Experimental|Group 1|Sham therapy Intervention 1: PET Intervention 2: ART
33313470|NCT04708600|Experimental|Group 2|Sham therapy Intervention 1: ART Intervention 2: PET
33313471|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
33313472|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
33313473|NCT05402852|Experimental|Drug：EuBone® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
33313474|NCT05402852|Placebo Comparator|control：placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
33313475|NCT05308966||Patient presenting MPS treated with nivolumab and ipilimumab|Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
33313476|NCT01134224|Experimental|NN5401 - low dose|
33313477|NCT01134224|Experimental|NN5401 - medium dose|
33313478|NCT01134224|Experimental|NN5401 - high dose|
33313479|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
33313480|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
33313481|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
33313482|NCT05308888|Experimental|Intervention|All patients will have to undergo an 18F-FDG PET-CT.
33313483|NCT04502732||Observational|NSSM and GEBT
33313484|NCT01312636||A|
33313485|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
33313486|NCT04703920|Experimental|Talozoparib in combination with Belinostat|Patients will receive Talozoparib in combination with Belinostat
33313487|NCT01233830|Experimental|1|
33313488|NCT01233830|Placebo Comparator|2|
33313489|NCT04849234||New born|New born population aged 37 Weeks of Amenorrhea (SA) to 42 Weeks of Amenorrhea (SA) will be included. Their cries will be longitudinally registered.
33313490|NCT01231490|Experimental|Active|
33313491|NCT01231490|Placebo Comparator|Placebo|
32804359|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
32804360|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
32949008|NCT04021602|Active Comparator|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
32949009|NCT04021602|Placebo Comparator|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
32949010|NCT05580822|Experimental|intra-arterial TNK infusion (0.4mg/min) via support/access catheter, over 15 minutes|
32804361|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
32804362|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
32804363|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
32804364|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
32804365|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
32804366|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
32804367|NCT02752750||HC_GROUP|Healthy controls
32804368|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
32804369|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
32804370|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
32804371|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
32804372|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
32804373|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
32804374|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
32804375|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
32804376|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
32804377|NCT02734888|Other|E-cigarette user|Will undergo PET scan
32804378|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
32804379|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
32804380|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 224
32804381|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
32804382|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
32804383|NCT02720068|Experimental|Part A: Favezelimab Dose A|Participants receive favezelimab Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.
32804384|NCT02720068|Experimental|Part A: Favezelimab Dose B|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle.
32804385|NCT02720068|Experimental|Part A: Favezelimab Dose C|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle.
32804386|NCT02720068|Experimental|Part A: Favezelimab Dose D|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle.
32804387|NCT02720068|Experimental|Part A: Favezelimab Dose E|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle.
32804388|NCT02720068|Experimental|Part A: Favezelimab Dose A+Pembro|Participants receive favezelimab Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804389|NCT02720068|Experimental|Part A: Favezelimab Dose B+Pembro|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804390|NCT02720068|Experimental|Part A: Favezelimab Dose C+Pembro|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804391|NCT02720068|Experimental|Part A: Favezelimab Dose D+Pembro|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804392|NCT02720068|Experimental|Part A: Favezelimab Dose E+Pembro|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32949011|NCT05580822|Experimental|intra-arterial TNK infusion (0.25mg/min) via support/access catheter, over 15 minutes|
32949012|NCT05580822|Placebo Comparator|intra-arterial placebo infusion via support/access catheter, over 15 minutes|
32949013|NCT05580744|Active Comparator|Traditional occupational therapy|Traditional occupational therapy delivered skill training related to daily living tasks.
32804393|NCT02720068|Experimental|Part B: Favezelimab Monotherapy Dose|Participants receive favezelimab monotherapy dose IV infusion on Day 1 of each 21-day cycle.
32804394|NCT02720068|Experimental|Part B: Favezelimab Dose F+Pembro|Participants receive favezelimab Dose F IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804395|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
33097769|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
33097770|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
33097771|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
33313492|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
33313493|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
32804396|NCT02720068|Experimental|Part B: Favezelimab Dose H+Pembro|Participants receive favezelimab Dose H IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
32804397|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+mFOLFOX7|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and fluorouracil [5-FU] 2400 mg/m^2 IV over 46 to 48 hours every 2 weeks [Q2W]).
32804398|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+FOLFIRI|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and 5-FU 2400 mg/m^2 IV over 46 to 48 hours Q2W).
32804399|NCT02720068|Experimental|Part B: Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (favezelimab and pembrolizumab administered as a co-formulation) IV infusion on Day 1 of each 21-day cycle.
32804400|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+Lenvatinib|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21 day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib (20 mg) each day of 21-day cycle.
32804401|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
32804402|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
32804403|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
32804404|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
32804405|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
32804406|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
32804407|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
32804408|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
32804409|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
32830861|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
32830862|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
32830863|NCT04058769|Other|Software first|Patients that are pre-operatively assessed first software-guided and then traditional
33313494|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
33313495|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
33313496|NCT04065334|Experimental|low dose training|
32949014|NCT05580744|Active Comparator|Mirror therapy using a mirror box|Exercise of mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using a mirror box .
32949015|NCT05580744|Experimental|Augmented reality-based mirror therapy|"Exercise of augmented reality-based mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using an augmented reality mirror therapy system~."
32949016|NCT04026126|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
32949017|NCT04024254|Experimental|Folic Acid|Folic Acid supplement 1 mg by mouth daily
32949018|NCT04024254|No Intervention|No Supplementation|
32949019|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
33313497|NCT04065334|Active Comparator|high dose training|
33313498|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33313499|NCT04011748|Experimental|Hair regrowth by SCE|AA subjects will receive Stem Cell Educator therapy. Hair regrowth will be evaluated during six-month follow-up studies.
33313500|NCT04011748|Experimental|Minoxidil therapy|Control subjects will receive treatment with topical 5% minoxidil
33313501|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
33313502|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
33313503|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
33313504|NCT04003636|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
33313505|NCT04003636|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
33313506|NCT05402774|Other|point-of-care ultrasound group|
33313507|NCT05402774|No Intervention|Control group|
33313508|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
33313509|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
33313510|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
33313511|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
33313512|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
33313513|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
33313514|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
33313515|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
33313516|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
33313517|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
33313518|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
33313519|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
32804410|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone~Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
32804411|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
32804412|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
32804413|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
32804414|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
32804415|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
32830864|NCT04058769|Other|Traditional|Patients that are first pre-operatively assessed in the traditional way and then with aid of the software
33313520|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
33313521|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
33313522|NCT01235312||Healthy subjects|
33313523|NCT01235312||Patients suffering from Diabetes mellitus|
33313524|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
33313525|NCT01719640|Experimental|MSC+MC|infusion of BMMSC+BMMNC and insulin injection
33313526|NCT01719640|Active Comparator|MC|infusion of BMMNC and insulin injection
33313527|NCT01719640|Active Comparator|Insulin|insulin injection
33313528|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
33313529|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
33313530|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
33313531|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
33313532|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
33313533|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
33313534|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
33313535|NCT04660396||Outpatients following discharge for treatment of heart failure|Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.
33313536|NCT01141868|Experimental|Internet Intervention|
33313537|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
33313538|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
33313539|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
33313540|NCT05191394|Other|Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.|"Assessment of the possible variation of anti-SARS-CoV-2 antibody titer in adult patients regularly treated with therapeutic plasma exchange.~For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session."
33313541|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
33313542|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
33313543|NCT04908514|Experimental|ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.|
33313544|NCT01142024|Placebo Comparator|saline|saline hydration
33313545|NCT01142024|Experimental|Glutathione|
33313546|NCT04895098||combination therapy group|750 Subjects in the statin and ezetimibe combination therapy group
33313547|NCT04895098||monotherapy group|250 Subjects in the statin monotherapy group
33313548|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
33313549|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
33313550|NCT04303676|Active Comparator|Virtual Practice Facilitation with e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content
33313551|NCT04303676|Active Comparator|Virtual Practice Facilitation without e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules
33313552|NCT04646044|Experimental|Bempegaldesleukin IV + Standard of Care|
33313553|NCT04646044|Placebo Comparator|Placebo + Standard of Care|
33313554|NCT01235390|Experimental|5 g of walnuts|
33313555|NCT01235390|Experimental|40 g of walnuts|
33313556|NCT01142102|Experimental|Arm 1|Radiation Therapy
33097772|NCT04518020|Active Comparator|Short implant|Short implant 6 mm installed
33313557|NCT04628962||Asthma-COPD Overlapped (aCOPD)|50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
32949020|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
32949021|NCT05580666|Experimental|Oral Azithromycin 250 mg once daily|Active Azithromycin tablet
33313558|NCT04628962||Non-Exacerbator COPD (neCOPD)|50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
33313559|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
33313560|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
33313561|NCT04628962||Asthma patients (AST)|200 subjects affected by asthma comparable by age and sex with the other recruited subjects
33313562|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
33313563|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
33313564|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
32949022|NCT05580666|Placebo Comparator|Oral matching placebo, once daily|Matching placebo tablet
32949023|NCT05580588|Experimental|SPH4336|400 mg (2 - 200 mg tablets) PO QD
32949024|NCT05580354|Experimental|Arm 1|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
32949025|NCT04144062|Active Comparator|Zirconia crowns|
32949026|NCT04144062|Active Comparator|CAD/CAM crowns|
32949027|NCT04143906|Experimental|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
32949028|NCT04143906|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
32949029|NCT04143750|Experimental|[14C]Vicagrel|
32949030|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
32949031|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
32949032|NCT05580276||Study group|Adolescent with headache, 10-18 ages
32949033|NCT05580276||Control group|Adolescent without headache
32949034|NCT02708004|Experimental|ACT-132577|3 different dose levels
32949035|NCT02708004|Placebo Comparator|Placebo|Matching active drug
32949036|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
32949037|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
32949038|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided hydrodilatation with hyaluronic acid plus physical therapy
32949039|NCT02708706|Active Comparator|physical therapy only|patient received physical therapy only
32949040|NCT04143672|Experimental|study group|"The following tests will be performed on the study subjects.~Pain catastrophizing scale~Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)~Pain sensitivity questionnaire~Pain pressure threshold using electronic digital pressure algometer"
32949041|NCT04143828|Experimental|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
32949042|NCT04143828|No Intervention|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
32949043|NCT05587608|Active Comparator|ultrasound-guided thoracic segmental spinal group|given ultrasound-guided thoracic segmental spinal heavy Marcaine plus 25 ug fentanyl at the level of T10 interlaminar space.
32949044|NCT05587608|No Intervention|General anesthesia group|General anesthesia (control)
32949045|NCT02703714|Experimental|Pembrolizumab and GM-CSF|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
32949046|NCT05583552|Experimental|Single-arm imetelstat|
32949047|NCT05583474|Experimental|subject receive OPC-1085EL solution|OPC-1085EL group ，one drop for each eye, once per day for 8 weeks
32949048|NCT05583474|Active Comparator|subject receive 0.005% latanoprost ophthalmic solution|0.005% latanoprost ophthalmic solution group ，one drop for each eye, once per day for 8 weeks
32949049|NCT03919578|Experimental|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
32949050|NCT03919578|Experimental|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
32949051|NCT03919578|Experimental|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
32949052|NCT03919578|Active Comparator|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
32949053|NCT03945864|Experimental|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
32949054|NCT03945864|Active Comparator|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
32949055|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
33313565|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
32949056|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
32949057|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
32949058|NCT03904446|Experimental|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
32949059|NCT03904446|Placebo Comparator|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
32949060|NCT04143984|Active Comparator|Arm-C|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE).
32949061|NCT04143984|Experimental|Arm-CC|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.
32949062|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
32949063|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
32949064|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
32949065|NCT05583318||Part 1: Patients diagnosed with non-Hodgkin's lymphoma|Diagnosis period 2010-2018, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
32949066|NCT05583318||Part 2: Patients diagnosed with live non-Hodgkin's lymphoma after vital status update|Update of vital status in December 2022
32949067|NCT05582772|Active Comparator|GA+M Intervention|"GA+M intervention arm All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol.~Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C. Monthly telephone follow-up by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed."
32949068|NCT05582772|Active Comparator|RSM Intervention|RSM Intervention All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. Symptom monitoring will continue for 6 months or discontinuation of treatment.
32949069|NCT05582772|Active Comparator|GA+RSM intervention|GA+RSM Combination Participants will receive both strategies as detailed above, with a GA at baseline.
32949070|NCT05582772|No Intervention|Control|Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.
32949071|NCT03902652|Experimental|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
33313566|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
33313567|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
33313568|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
33097773|NCT04518020|Other|Conventional implant + bone augmentation|Standard length implant 13 mm in conjunction with maxillary sinus floor augmentation serves as a control group
33097774|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
33097775|NCT04518761||Prospective group|
33097776|NCT04518761||Retrospective group|
33097777|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
33097778|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
33097779|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
33097780|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
33097781|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
33097782|NCT04694508|Experimental|Group A|Headphones (Disok, Alicante, España)
33097783|NCT04694508|No Intervention|Group B|Without music therapy
33097784|NCT04515056|Experimental|Papain dosage|In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).
33097785|NCT04515056|Experimental|Papain SPT|Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
33097786|NCT04514900|Active Comparator|Video Chat +Personalized Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
33097787|NCT04514900|Active Comparator|Video Chat + Basic Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive basic feedback weekly on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
33097788|NCT04514900|Active Comparator|Discussion Board for Social Support + Basic Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly basic feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
33097789|NCT04514900|Active Comparator|Discussion Board for Social Support+Personalized Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
33097790|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
33097791|NCT00519792|Experimental|1|Omega DUROS: Dose 25
33097792|NCT00519792|Experimental|2|Omega DUROS: Dose 50
33097793|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
33097794|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
33097795|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
33313569|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
33313570|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
33313571|NCT04119440|Experimental|Low Dose|Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
33313572|NCT04119440|Experimental|High Dose|Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
33313573|NCT04119440|Placebo Comparator|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
33313574|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)~1 antigen or allele mismatched (mismatch at A or B or DRB1)~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
33313575|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~Haploidentical match~2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
33313576|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
32804416|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
32804417|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
32804418|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
32804419|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
32804420|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
32804421|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
32804422|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
32804423|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
32804424|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
32804425|NCT02684578|Experimental|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 18 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
32804426|NCT02684578|No Intervention|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
32804427|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
32804428|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
32804429|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
32804430|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
32804431|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
32804432|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
32804433|NCT01614925|Experimental|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
32804434|NCT01614925|Active Comparator|Periodontal Surgery|Periodontal surgery alone
33313577|NCT04734652|Experimental|BIC arm|The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.
32804435|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
32804436|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
32804437|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
32804438|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
32804439|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.~The placebo regimen is identical to the vitamin D3 regimen."
33313578|NCT04734652|Active Comparator|DTG Arm|Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)
33313579|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
33313580|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
33313581|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
33313582|NCT01142258|Placebo Comparator|Placebo|Inert pill
33313583|NCT04043312|Sham Comparator|Control|Patients will receive one hour of sham stimulation.
33313584|NCT04043312|Experimental|Active|Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
33313585|NCT05152940|Active Comparator|Ertugliflozin then Placebo|Treatment with Ertugliflozin for one month, washout period for one month, and then with Placebo for one month
33313586|NCT05152940|Active Comparator|Placebo|Treatment with matching placebo for one month, washout period for one month, and then Ertugliflozin for one month
33313587|NCT01139606|Experimental|Vibration trainig|
33313588|NCT03764072|Placebo Comparator|Placebo|Participants received placebo matched to VX-150 for 2 days.
33313589|NCT03764072|Experimental|VX-150 - Dose Level 1|Participants received VX-150 1500 milligrams (mg) as first dose, followed by VX-150 750 mg every 12 hours (q12h) for 2 days.
33313590|NCT03764072|Experimental|VX-150 - Dose Level 2|Participants received VX-150 1000 mg once daily (qd) for 2 days.
33313591|NCT03764072|Experimental|VX-150 - Dose Level 3|Participants received VX-150 500 mg q12h for 2 days.
33313592|NCT03764072|Experimental|VX-150 - Dose Level 4|Participants received VX-150 500 mg as first dose, followed by VX-150 250 mg q12h for 2 days.
32949072|NCT03902652|Active Comparator|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
32949073|NCT03916692|Experimental|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
32949074|NCT03916692|Experimental|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
32949075|NCT03916692|Active Comparator|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
33313593|NCT03764072|Experimental|VX-150 - Dose Level 5|Participants received VX-150 250 mg qd for 2 days.
32949076|NCT03916068|Experimental|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
32949077|NCT03916068|Active Comparator|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
33313594|NCT05133830|Experimental|Treatment Arm 1|Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration
33313595|NCT05133830|Experimental|Treatment Arm 2|Participants will receive OCA at dose level 2 along with linerixibat
32949078|NCT04142970|Active Comparator|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)
32949079|NCT04142970|Active Comparator|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)
33313596|NCT05133830|Experimental|Treatment Arm 3|Participants will receive OCA at dose level 1 along with linerixibat
32949080|NCT04142970|Active Comparator|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)
33313597|NCT05133830|Experimental|Treatment Arm 4|Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration
33313598|NCT01233986||Case group - Large artery atherosclerosis|
33313599|NCT01233986||Control group-Small vessel occlusion|
33313600|NCT01139684|Experimental|Exercise|
32949081|NCT04765332||Included patients|Fill patient questionnaires at inclusion visit, around 3 months and 12 months
33313601|NCT01234064|Active Comparator|Graduated Compression Stockings|
33313602|NCT01234064|Other|No Graduated Compression Stockings|
33313603|NCT05069324||Acromegaly patients not adequately controlled by any kind of SSAs monotherapy|Acromegaly patients not adequately controlled by any kind of SSAs monotherapy, requiring PEG in combination with SSAs or PEG monotherapy
33313604|NCT05069324||Acromegaly patients adequately controlled by medical treatment|Acromegaly patients adequately controlled by medical treatment, by any kind of SSAs or by PEG
32949082|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
32949083|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
32949084|NCT04142346|No Intervention|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
33097796|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
33097797|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
33097798|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
33313605|NCT03333928|Active Comparator|HTD1801 500 mg BID|
33313606|NCT03333928|Active Comparator|HTD1801 1000 mg BID|
33313607|NCT03333928|Placebo Comparator|Placebo BID|
33313608|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
33313609|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
33313610|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
33313611|NCT01139840|Active Comparator|vitamin D2|
33313612|NCT01139840|Active Comparator|vitamin D3|
33313613|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
33313614|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
33313615|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
33313616|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
33313617|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
33313618|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
33313619|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
33313620|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
33313621|NCT01142960|Active Comparator|Placebo|Starch
33313622|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
33313623|NCT03727724|Experimental|Afatinib plus cetuximab|"Afatinib, 40 mg once daily, orally.~Cetuximab, 500 mg/m² intravenously, every 2 weeks.~Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
33313624|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
33313625|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
33313626|NCT05032508|Experimental|xylocaine|
33313627|NCT05032508|Placebo Comparator|Placebo|
33313628|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
32830865|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
33313629|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
32949085|NCT04142346|Experimental|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
32949086|NCT04142112|Experimental|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
33313630|NCT04578652|Active Comparator|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
33313631|NCT04578652|Active Comparator|FIBER|Fiber supplementation [35g fiber daily] + MET placebo po bid
32830866|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
32830867|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
32830868|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
32830869|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
32949087|NCT04142112|Active Comparator|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
32830870|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
32949088|NCT04143282|Experimental|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
32949089|NCT04143282|Other|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
32949090|NCT04142190||ELONVA|Patients stimulated with Elonva
32949091|NCT04142190||PUREGON|Patients stimulated with Puregon
32949092|NCT04149678|Experimental|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
32949093|NCT04149678|Experimental|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
32949094|NCT05582070|Experimental|actigraphy|Patient with nasal obstruction
32949095|NCT05581992|Experimental|AMG 510 + Omeprazole|Participants will receive AMG 510 on Day 1, daily doses of omeprazole on Days 4 to 8, and a single dose of both omeprazole and AMG 510 on Day 9.
32949096|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
32949097|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
32949098|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
32949099|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
32949100|NCT05581914|Experimental|Treatment group|Care as Usual and the MY LIFE treatment
32949101|NCT05581914|Active Comparator|Waitinglist Control group|Care as Usual
32949102|NCT05581758|Experimental|Treatment Sequence AB|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment A) - AMG 510 under fasted conditions. Period 2 (treatment B) - AMG 510 under fed conditions."
32949103|NCT05581758|Experimental|Treatment Sequence BA|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment B) - AMG 510 under fed conditions. Period 2 (treatment A) - AMG 510 under fasted conditions."
32949104|NCT05580198||BRH+|Acute ischemic stroke patients with brainstem raphe hypoechogenicity.
32949105|NCT05580198||BRH-|Acute ischemic stroke patients without brainstem raphe hypoechogenicity.
32949106|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
32949107|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
33313632|NCT04578652|Experimental|FIBER + MET|Fiber supplementation [35g fiber daily] + MET 850 mg po bid
33313633|NCT03674138|Active Comparator|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
33313634|NCT03674138|Active Comparator|Clinical management|Clinical management
33313635|NCT04823026||Group 1|"70 young infants with proven bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
33313636|NCT04823026||Group 2|"70 young infants with non-bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
33313637|NCT04823026||Group 3|"30 young infants without infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
33313638|NCT05010512|Other|DT1, then Infuse|Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
33313639|NCT05010512|Other|Infuse, then DT1|Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
33313640|NCT03913442|Placebo Comparator|Placebo|Placebo in capsule identical to study drug
33313641|NCT03913442|Experimental|Colchicine|"0.6 or 0.8 mg orally once daily.~Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses."
33313642|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
33313643|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
33097799|NCT04694937||metabolic healthy obese|Demographic, clinical laboratory and heart rate variability assesment
33097800|NCT04694937||metabolic unhealthy obese|Demographic, clinical laboratory and heart rate variability assesment
33313644|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
32830871|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
32830872|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
32830873|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
32830874|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
32830875|NCT03271398||Adult victims of sexual assault|
32830876|NCT03271398||Children who have been exposed to domestic abuse|
32830877|NCT03271398||Women with perinatal emotional complications|
32830878|NCT03271398||Teens with behavior problems and histories of abuse|
32830879|NCT03271398||Veterans with military-related trauma|
32830880|NCT03271398||Survivors of intimate partner violence|
32830881|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
32830882|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
32830883|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
32830884|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
32830885|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
32830886|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
32830887|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
32830888|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
32830889|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
32830890|NCT01963078|Placebo Comparator|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
33313645|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
33313646|NCT03670628|Active Comparator|720 shockwave therapy Group|Participants in this group will receive a total of 5 daily sessions of shockwave therapy within a week. Each therapy session will consist of 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
33313647|NCT03670628|Sham Comparator|Sham shockwave therapy|Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
33313648|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
32949108|NCT03645408|Experimental|Exenatide then Placebo|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
33313649|NCT01236482|Active Comparator|Oxytocin|
33313650|NCT01236482|Experimental|Oxytocin - ergometrine|
32949109|NCT03645408|Experimental|Placebo then Exenatide|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
32949110|NCT04141722|Experimental|Sleep|
32949111|NCT04141722|Experimental|Wake|
32949112|NCT04141488|Experimental|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
32949113|NCT04141488|Other|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
32949114|NCT04141254|Experimental|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
32949115|NCT04141254|Other|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
32949116|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy> 3 segments, duodeno cephalic pancreatectomy
33313651|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
33313652|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
32949117|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
32949118|NCT04141098|Experimental|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
32949119|NCT05586204|Experimental|Facilitate action narrowly|
33313653|NCT03992651|Experimental|Experimental group|One single group of healthy subjects
33313654|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
32949120|NCT05586204|Experimental|Facilitate action broadly|
32949121|NCT05586204|Experimental|Boost intentions only|
32949122|NCT05586204|Experimental|Boost intentions and facilitate action narrowly|
32949123|NCT05586204|Experimental|Boost intentions and facilitate action broadly|
32949124|NCT05586204|No Intervention|Holdout|
33313655|NCT03629678|No Intervention|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
33313656|NCT03629678|Active Comparator|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
33313657|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
33313658|NCT01236014||Eltrombopag & standard of care|
33313659|NCT01236014||Romiplostim & standard of care|
32949125|NCT04149834|Active Comparator|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
32949126|NCT04149834|Other|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
33313660|NCT01236014||Standard of care|
33313661|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
32949127|NCT04140474|Experimental|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
33313662|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
33313663|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
33313664|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
33313665|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
33313666|NCT03963154|Experimental|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
33313667|NCT03958474|Experimental|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
33313668|NCT03958474|Experimental|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
33313669|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
33313670|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
33313671|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
33313672|NCT04566484|Experimental|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
33313673|NCT04566484|Placebo Comparator|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
33313674|NCT04956692|Experimental|Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy|Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
33313675|NCT04956692|Active Comparator|Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy|Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
33313676|NCT02145208|Experimental|Medi-Tate iTind|TIND System
33313677|NCT01234142|Experimental|Cohort 1|
33313678|NCT01234142|Experimental|Cohort 2|
33313679|NCT01234142|Experimental|Cohort 3|
32804440|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
32804441|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
32804442|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
32804443|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
32804444|NCT02377258||2|with on-going anti-TNF monotherapy
32804445|NCT02377258||3|with thiopurines monotherapy
32804446|NCT02377258||4|with on-going combination therapy
32804447|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
32804448|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
32804449|NCT02375854||Preterm infants|Less than 32 weeks' gestation
33313680|NCT01234142|Experimental|Cohort 4|
33313681|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
33313682|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
33313683|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
33313684|NCT03579680|Experimental|ADT ORDER CHECK ATTESTATION (OR)|"Experimental: ADT ORDER CHECK ATTESTATION (OR) Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior. Study staff will place a health factor structured data element in the EMR of patients whose clinic visits study staff have confirmed to be targets for ADT de-implementation. This health factor combined with a low PSA level will trigger the ADT Order Check Attestation Intervention (Or) when the provider places an order for ADT."
33313685|NCT03579680|Experimental|PROVIDER SCRIPT (SC)|"Experimental: PROVIDER SCRIPT (SC) The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior. Study staff will enter a pre-populated CPRS EMR progress note 1 business day prior to a target clinic visit. The note includes talking points for the provider to help with a discussion. It can be edited and cosigned by the provider, giving a quick and simple way to document the discussion. The progress note template asks providers to indicate whether patient prefers to continue or discontinue low-value ADT. Appropriate documentation of the decision will be tracked for fidelity. We will also have a patient handout entitled: Living well with prostate cancer: Is hormone therapy still right for you? as a patient engagement and information resource."
33313686|NCT01143194|Experimental|oréVida™ 60mg/day|
33313687|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
33313688|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
33313689|NCT01143194|Placebo Comparator|Placebo|
33313690|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
33313691|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
32804450|NCT01898923|Experimental|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
32804451|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
33313692|NCT04911452|No Intervention|Control|Standard Neonatal Intensive Care Unit (NICU) care
33313693|NCT04911452|Experimental|Calmer|Calmer placed and left in infant incubator for the 3-week study period. Calmer treatment provided for minimum total of 3 hours/day (can be discontinuous).
33313694|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33313695|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32804452|NCT04251442|Experimental|Study Group|The study group will have soft tissue balance performed with the use of IOS.
32804453|NCT04251442|No Intervention|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
33313696|NCT05397392||acute kidney injury|Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
33313697|NCT05397392||chornic kidney disease|Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease
33313698|NCT03503864|Experimental|ATO-combined chemotherapy|Patients receive combined induction chemotherapy with arsenic trioxide.
33313699|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
33313700|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
33313701|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
32949128|NCT05583864|Active Comparator|CONDUIT Porous Titanium Spinal Cage|Solid titanium spinal cage, infused with microscopic, porous canals to allow for adhesion and proliferation of bone graft factors contributing to spinal ossification, and ultimately, spinal fusion between vertebrae demonstrating instability.
33097801|NCT04514978|Experimental|Blood donation and transfusion|Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
33097802|NCT04514978|No Intervention|Control group|Blood samples collected with same frequency as described in the intervention arm.
33097803|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
33097804|NCT04512599|Experimental|Single Arm|Open-label consumption of prebiotic bar(s); 1 bar for 3 days; followed by 2 bars for 7 days
33097805|NCT04514861|Other|Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2|Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
33097806|NCT04514666|Experimental|Liver/kidney transplant|The breath of patients undergoing liver or kidney transplant will be sampled and analysed
33097807|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
33097808|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
33097809|NCT04511234|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
33097810|NCT04511234|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
33097811|NCT04514822|Other|N0 stage|patients without malignant lymph nodes
33097812|NCT04514822|Other|Non-N0 stage|patients with malignant lymph nodes
33097813|NCT04514588|Other|caffeine consumption and metabolism|Participants will take part in two trials. Each trial will last one day at least one week apart. During the first trial half of the participants will consume caffeine (5mgr/kgr) and the rest only water. During the second trial a crossover design will be applied
33097814|NCT04514588|Other|control|Control group will consume only water (not coffee) and the same parameters will be recorded as previously
33097815|NCT00519987|Experimental|Treatment A|intranasal ketamine
33097816|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
33097817|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
33313702|NCT04700176|Experimental|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
33313703|NCT04700176|Experimental|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
33097818|NCT04514939||Group A - Leg elevation|Patients will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
33097819|NCT04514939||Group B- Non Leg elevation|Patients will lie in their hospital bed without leg elevation
33097820|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
33097821|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
33097822|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
33097823|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
33097824|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
33097825|NCT00520026|Active Comparator|1|Lithium treatment
33097826|NCT00520026|Placebo Comparator|2|Placebo treatment
33097827|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
33097828|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
33097829|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
33097830|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
33097831|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
33097832|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
33097833|NCT00518895|Experimental|A|Dacarbazine with Genasense
33097834|NCT00518895|Active Comparator|B|Dacarbazine with placebo
33097835|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
33097836|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
33097837|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
33097838|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
33097839|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
32804454|NCT04557436|Other|Standard of care|"Follow-up period:~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m~Physical examination, ECOG~Laboratory tests~Vital signs (temperature, BP, HR, respiratory rate, weight)~Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)~Chimerism and MRD in blood and bone marrow (if sampled)~Adverse events~Concomitant treatments"
32804455|NCT04551586|Experimental|Sequence 1|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
32804456|NCT04551586|Experimental|Sequence 2|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
32804457|NCT04551586|Experimental|Sequence 3|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
33097840|NCT00520065|Experimental|#1|Diabetes specific enteral product
33097841|NCT00520065|Active Comparator|#2|Standard enteral feeding
33097842|NCT00520104|Experimental|A|intranasal ketamine
33097843|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
33097844|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
33097845|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
33097846|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
33097847|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
33097848|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
33097849|NCT00520182|Active Comparator|1|ADA 2003 diet
33097850|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
33097851|NCT00520182|Active Comparator|3|MUFA diet
33097852|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
33097853|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
33097854|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
33097855|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
33097856|NCT04514237|Experimental|Part 1: Regimens AB(CD)|Participants received 50 milligrams (mg) BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 1, followed by 50 mg BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
33097857|NCT04514237|Experimental|Part 1: Regimens BA(CD)|Participants received 50 milligrams (mg) BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 1, followed by 50 mg BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
33097858|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
33097859|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
33097860|NCT04514354|Experimental|GEST Visit|As described in the detailed study description, the GEST Visit included measures of cardiovascular health at Hartford Hospital. These measures included BMI, waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), HRV, resting BP, the GEST, and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers.
33097861|NCT04514354|No Intervention|CONTROL Visit|On either Visit 3 or 4, subjects performed the CONTROL Visit. Resting auscultatory blood pressure was measured according to AHA standards. At the conclusion of CONTROL, subjects were fitted for the ABP monitor. Subjects were instructed to proceed with normal activities, not to exercise, and to keep their arm still and extended at their side when each ABP measurement was being taken. Subjects carried a standard journal, recording activities performed during each measurement, any unusual physical or emotional events, and sleep and wake times. The following morning, subjects detached the monitor and returned it that day to the study investigators.
33097862|NCT00520338|Placebo Comparator|2|"placebo~celecoxib"
33097863|NCT00520338|No Intervention|1|1 placebo
33313704|NCT05397080|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
33404728|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
32949129|NCT05583864|Active Comparator|PROTI 360 Titanium-Coated PEEK Spinal Cage|Spinal cage composed primarily of a medical-grade polymer: poly-ether-ether-ketone (PEEK), with a titanium coating that is etched, but lacking porous features. These design features also attempt to stimulate spinal vertebrae fusion through bone-graft ossification and enhance vertebral stability.
32949130|NCT04149444|Experimental|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
32949131|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
32949132|NCT03020706|No Intervention|Control|No intervention
32949133|NCT04149366||group 1 (Wrapround retainer)|
32949134|NCT04149366||Group 2 (Essix retainer 1mm)|
32949135|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
32949136|NCT04149366||Group 3 (Essix retainer 2mm)|
32949137|NCT04148976|Placebo Comparator|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
32949138|NCT04148976|Experimental|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
32949139|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
32949140|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
32949141|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
32949142|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user >1 month), non-user of any kind of tobacco product (never or former user >1 month), and other household members should not be users of tobacco products or e-cigarettes
32949143|NCT03900624|No Intervention|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
32949144|NCT03900624|Experimental|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
32949145|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
32949146|NCT03908892|Experimental|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
32949147|NCT03908892|Active Comparator|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
32949148|NCT04140318|Experimental|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
32949149|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
32949150|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
32949151|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
32949152|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
32949153|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
32949154|NCT04140006|Active Comparator|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
32949155|NCT04140006|Active Comparator|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
32949156|NCT04140006|Active Comparator|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
32949157|NCT04140006|Sham Comparator|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
32949158|NCT04140084|No Intervention|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
32949159|NCT04140084|No Intervention|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
32949160|NCT04140084|Experimental|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
32949161|NCT04140084|No Intervention|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
32949162|NCT04140084|No Intervention|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
32949163|NCT04140240|Experimental|İntervention group|Experimental: İntervention group
32949164|NCT04140240|No Intervention|Control group|Control group: No intervention
32949165|NCT04149288|Active Comparator|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
32949166|NCT04149288|Active Comparator|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
32949169|NCT04144608|Experimental|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
32949170|NCT04140396|Placebo Comparator|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
32949171|NCT04140396|Active Comparator|Active Comparator|Participants will receive a lidocaine infusion
32949172|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
32949173|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
32949174|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
32949175|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
32949176|NCT03585582||PARDS survivors|"Children <18 years~diagnosed with PARDS, as defined by PALICC~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
32738055|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
33097864|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
33097865|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
33097866|NCT04694391||Recurrence|The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
33097867|NCT04694391||No recurrence|The period was more than 3 years after radiotherapy and no recurrence signs were observed.
33097868|NCT00520377|Experimental|1|MD05
33097869|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
33097870|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
33097871|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
33097872|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
33097873|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
33097874|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
33097875|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
33097876|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
32738056|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
32738057|NCT05017467|Experimental|vss|Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery
32738058|NCT05017467|Experimental|QuickDASH , VAS|, Quick Disabilities of Arm Shoulder and Hand functional score (QuickDASH) and Visual Analogue Scale (VAS) test was used to determine overall hand function, activities of daily living, work performance, pain, aesthetics, and satisfaction with hand function
32738059|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
32738060|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
32738061|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
33097877|NCT02597075|Active Comparator|Arm B:|Standard therapy
33097878|NCT04694118|Experimental|15 hemiparetic cerebral palsy,walking back group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
33097879|NCT04694118|Experimental|15 hemiparetic cerebral palsy,rebound therapy group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
33097880|NCT02597738|Experimental|Lung/ Head and Neck Cancer Group|Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
33097881|NCT02597738|Experimental|Chronic inflammatory disease|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
33097882|NCT02597738|Experimental|At risk for lung cancer|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
33097883|NCT02597738|Experimental|Healthy people who exercise|Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
33097884|NCT02597738|Experimental|Lung cancer with planned resection|"Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.~Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded."
33097885|NCT02597738|Experimental|Solid tumor cancer w/ radiation therapy|Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
33097886|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
33097887|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
33097888|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
33097889|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
33097890|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
33097891|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
33097892|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
33097893|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
33097894|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
33097895|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
33097896|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
33097897|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
33097898|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
33097899|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
33097900|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
33097901|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
33097902|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
33097903|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
33097904|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
33097905|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
33097906|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
33097907|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
33097908|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
33097909|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
33097910|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
33097911|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
32804458|NCT04554004|Experimental|Study group|All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).
32804459|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
32804460|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
32804461|NCT04553848|Experimental|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
32804462|NCT04553848|Active Comparator|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
32804463|NCT04553848|Active Comparator|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
32804464|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
32804465|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
32804466|NCT04552990|Experimental|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
33097912|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
33097913|NCT04514432||When music was available|3 month period during which music was available to patients experiencing agitation
33097914|NCT04514432||When music was not available|3 month period during which music was not available to patients
33097915|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
33097916|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
33097917|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
33097918|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
33313705|NCT05397080|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
33097919|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
33097920|NCT04514081|Experimental|Chidamide+Decitabine+Camrelizumab|
33097921|NCT04514081|Active Comparator|Decitabine+Camrelizumab|
33097922|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
33097923|NCT02948517|No Intervention|Control|No intervention
33097924|NCT04514120|Experimental|Stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and/or with Allergic Fungal Rhinosinusitis and stable condition
33097925|NCT04514120|Experimental|Non-stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and with Allergic Fungal Rhinosinusitis who are experiencing an exacerbation
33097926|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
33313706|NCT05397080|Active Comparator|TAU + multicomponent treatment VIRTUAL + 4 face-to-face sessions|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session will be added to solve doubts and emphasize the most important points of therapy
33097927|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
32804467|NCT04552990|Experimental|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
32804468|NCT04550650|No Intervention|Controll|No intervention
32804469|NCT04550650|Experimental|Training grp|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
32804470|NCT04550650|Experimental|PNF|2 years long, You have only treated patients with the PNF technique.
32804471|NCT04550650|Experimental|Spinning group|Patients developed endurance for 2 years. They worked using a spinning bike.
32804472|NCT04550650|Experimental|Balance|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance
32804473|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
33097928|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
32804474|NCT04559386|Experimental|Overall trial|People who complete the questionnaire.
32804475|NCT04395118|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
32804476|NCT04395118|Active Comparator|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
32804477|NCT04628065|Experimental|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
33097929|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
33097930|NCT04514042|Active Comparator|Standard procedure|Patients with Zenker's diverticulum treated with flexible endoscopy septotomy.
33097931|NCT04514042|Experimental|Investigational procedure|Patients with Zenker's diverticulum treated with peroral endoscopic myotomy.
33097932|NCT00519246|Placebo Comparator|I|No drug was delivered.
33097933|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
33097934|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
33097935|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
33097936|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
33097937|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
33313707|NCT05396300|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
33313708|NCT05396300|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
33097938|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
33097939|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
33097940|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.~Participants continue daily meditation practice and some other short exercises at home."
33313709|NCT04390750|No Intervention|Treatment Group 1|Treatment Group 1 will receive a standard educational booklet, a clinical oral health evaluation and a smart electronic toothbrush with no instruction on oral hygiene technique. The study coordinator will download the toothbrush data for data collection. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided. The hygienist will provide basic instruction on proper use of the smart electronic toothbrush.
33313710|NCT04390750|Experimental|Treatment Group 2|Treatment Group 2 will receive a standard educational booklet, a smart electronic toothbrush, a clinical oral health evaluation with tailored instruction on oral hygiene technique and care partner coaching. The study coordinator will download the toothbrush data for data collection. The dental hygienist and interventionist will work together to fulfill the following intervention components: tailored instruction and coaching.
32949177|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
32949178|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
32949179|NCT03586128||HIV serodiscordant couples|
32949180|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
32949181|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
32949182|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
32949183|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
32949184|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
32949185|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
32949186|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
32949187|NCT03589872||Study Group|patients with parkinson disease
32949188|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
32949189|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
32949190|NCT03022188||Observational|Observational
32949191|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
32949192|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
32949193|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
32949194|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
32949195|NCT04148742|Experimental|daily dose of DZD9008|daily dose of DZD9008
32949196|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
32949197|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
33097941|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
33313711|NCT04390750|No Intervention|Control Group|The Control group will receive a standard educational booklet and a clinical oral health evaluation with no instruction on oral hygiene technique. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided.
32804478|NCT04393870|Experimental|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
32804479|NCT04393870|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
32804480|NCT05602480|Experimental|1A|Subjects received one dose of PCV13 at 18 years of age and above.
32804481|NCT05602480|Experimental|2A|Subjects received one dose of PCV13 at 6~17 years of age.
32804482|NCT05602480|Experimental|3A|Subjects received one dose of PCV13 at 2~5 years of age.
32804483|NCT05602480|Experimental|4A|Subjects received two doses of PCV13 at 12~23 months of age.
32804484|NCT05602480|Experimental|5A|Subjects received three doses of PCV13 at 7~11 months of age.
32804485|NCT05602480|Experimental|6A|Subjects received four doses of PCV13 at 3 months of age.
32804486|NCT05602480|Experimental|6B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
32804487|NCT05602480|Active Comparator|6C|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
32804488|NCT05602480|Experimental|7A|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
32804489|NCT05602480|Active Comparator|7B|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
32804490|NCT05600296|Active Comparator|Ilioinguinal/iliohypogastric nerve block (IINB)|evaluate the postoperative analgesic effects with using ultrasound-guided ilioinguinal/iliohypogastric nerve block (IINB) in children scheduled for elective open inguinal herniotomy.
32804491|NCT05600296|Active Comparator|IINB+ Spermatic cord block|evaluate the postoperative analgesic effects with using ultrasound-guided IINB + spermatic cord block (SCB) in children scheduled for elective open inguinal herniotomy.
32804492|NCT05604586|Experimental|N-acetylcysteine|Intervention: Dietary Supplement: N-acetylcysteine Participants will undergo two exercise tests and daily supplementation with N-acetylcysteine orally in three doses a day for seven consecutive days.
32804493|NCT05604586|Placebo Comparator|Placebo|Supplement: Placebo Participants will undergo two exercise tests and daily supplementation with placebo orally in three doses a day for seven consecutive days.
32804494|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.~Pembrolizumab 200mg Intravenously.~Cyclophosphamide 50mg Twice daily orally."
32804495|NCT05604430||Ventilator patients|Patients being ventilated by the ZOLL 731 Series ventilator in accordance with device labeling and Agency protocols in a pre-hospital setting.
32804496|NCT05604352|Experimental|Main study|Study to investigate the safety and clinical efficacy of the DiaSole insole.
32804497|NCT05604118|Experimental|Aspirin supplemented|
32804498|NCT05604118|No Intervention|Off aspirin|
32804499|NCT05603884|Experimental|treatment arm|2 cycles of VCA regimens followed by 2 cycles of D-MAG regimens, and then repeat the above four courses of treatment once
32804500|NCT05603650|Placebo Comparator|Water rinse|rinse twice daily for 1 min with water
32804501|NCT05603650|Experimental|Lumineux Oral Essentials rinse|rinse twice daily for 1 min with Lumineux Oral Essentials rinse
32804502|NCT05603650|Experimental|Listerine rinse|rinse twice daily for 1 min with Listerine rinse
32804503|NCT03030274|Experimental|Occlutech AFR Device|Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial
32804504|NCT04760080||Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine.|"Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression a treatment by dabrafenib/trametinib and hydroxychloroquine"
32804505|NCT04760080||Patients with a metastatic melanoma treated by cytotoxic chemotherapy.|"Patients with a metastatic melanoma treated by cytotoxic chemotherapy after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression under dabrafenib/trametinib a treatment by cytotoxic chemotherapy"
32804506|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
32804507|NCT04124848||Somali Descent|Study participants who are of Somali origin.
32804508|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
33097942|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
33097943|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
33097944|NCT00519324|Experimental|RAD001|
33097945|NCT04514471|Experimental|Unventilated Filter Cigarette|Conventional cigarette with approximately 6-7% (non-menthol) and 5-6% filter ventilation (menthol).
32804509|NCT04129060|Experimental|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
32804510|NCT04129060|Experimental|Placebo Challenge|One of the two study days will be the oral placebo.
33097946|NCT04514471|Active Comparator|Ventilated Filter Cigarette|Conventional cigarette with approximately 22-26% (non-menthol) and 35-38% filter ventilation (menthol).
33097947|NCT04513535|Experimental|manual therapy combination 1|Cervical manipulation, Thoracic manipulation
33097948|NCT04513535|Experimental|manual therapy combination 2|Cervical manipulation, glenohumeral mobilization
32738062|NCT05024019|Experimental|Study group|The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
32738063|NCT05024019|No Intervention|Control group|The control group received radiotherapy alone.
32738064|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
32738065|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
32738066|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
32738067|NCT05017077|Experimental|Telemonitoring|To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients
32738068|NCT05464979|Experimental|Esketamine intubation group|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation. The Richmond Agitation Sedation Scale (RASS) was used to assess the sedation of patients every 1 hour and maintains a RASS score of -2 to 0.
32738069|NCT05464979|Placebo Comparator|Conventional intubation group|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score. The RASS score was assessed every 1 h and maintained at -2 to 0.
32738070|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
32738071|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
32738072|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
32738073|NCT05008731|Experimental|Group 1|botulinum toxin: 100 units (0.5ml) in 1 injection
32738074|NCT05008731|Placebo Comparator|Group 2|Placebo: 0.5 ml in 1 injection
32738075|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
32738076|NCT03331523|Active Comparator|Taclonex®|
33097949|NCT04513535|Experimental|manual therapy combination 3|cervical manipulation, sleeper stretch
33097950|NCT04513535|Experimental|manual therapy combination 4|thoracic manipulation, glenohumeral mobilization
33097951|NCT04513535|Experimental|manual therapy combination 5|thoracic manipulation, sleeper stretch
32738077|NCT03331523|Placebo Comparator|Placebo|
32738078|NCT05023863|Active Comparator|Alpha Lipoic Acid Group (intervention group)|35 patients will receive radiation therapy with or without platinum-based chemotherapy in addition to alpha lipoic acid 600 mg tablets twice daily (throughout the radiotherapy period). .
32738079|NCT05023863|Placebo Comparator|Control Group|35 Patients will receive radiation therapy with or without platinum-based chemotherapy in addition to placebo tablets twice daily (throughout the radiotherapy period)
32738080|NCT05463809|Experimental|Experimental group: Ropivacaine-controlled analgesia pump|A single injection of 0.375% Ropivacaine 15 milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Than，a catheter was placed in the gastrocnemius plane, and a 0.125% ropivacaine-controlled analgesic pump was applied.(The formulation was 0.125% ropivacaine at 300 milliliters, with a background dose of 3 milliliters/hours, a patient-controlled analgesia(PCA) dose of 8 milliliters, and a locking time of 25 minutes.）
32804511|NCT04126096|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
32804512|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
32804513|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
32804514|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
33097952|NCT04513535|Experimental|manual therapy combination 6|glenohumeral mobilization, sleeper stretch
33097953|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
32804515|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
32804516|NCT04393792|Active Comparator|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
32804517|NCT04393792|Placebo Comparator|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
32804518|NCT04120714|Experimental|Active tDCS group|Active tDCS
32804519|NCT04120714|Placebo Comparator|Placebo tDCS group|Inactive tDCS
32804520|NCT04129762|Experimental|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
32804521|NCT04129762|Active Comparator|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
32804522|NCT04129762|Experimental|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
32804523|NCT04129762|Active Comparator|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
32804524|NCT04129684|Experimental|Test group|SRP+BioGaia Prodentis oil drops and lozenges
32804525|NCT04129684|Placebo Comparator|Control group|SRP+subgingival delivery of placebo and placebo lozenges
32804526|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
32804527|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
32804528|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
32804529|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
32804530|NCT03026764|Experimental|Outpatient|Patients in the outpatient group (same day discharge following THA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
32804531|NCT03026764|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following THA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
32804532|NCT04129606|Other|TURBT|Transurethral resection of bladder tumour
32804533|NCT04129372|Experimental|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
32804534|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
32804535|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
32804536|NCT04128826|Experimental|Partial Range of Motion (PROM)|
32804537|NCT04128826|Experimental|Full Range of Motion (FROM)|
32804538|NCT04128826|No Intervention|Control (CON)|
32804539|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
32804540|NCT04128202|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
32804541|NCT04128202|Experimental|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
32804542|NCT04128592|Other|Wheezing|
32804543|NCT04128592|Other|Rattling|
32804544|NCT04128280|Experimental|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
32804545|NCT04128280|Active Comparator|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
33097954|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
33097955|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
33097956|NCT02591030|Placebo Comparator|GEMCIS|
33097957|NCT02591030|Experimental|mFOLFIRINOX|
32804546|NCT04127812|Experimental|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
32804547|NCT04127890|Experimental|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
32804548|NCT04127890|Placebo Comparator|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
32804549|NCT04128046|Experimental|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
32804550|NCT04128046|Placebo Comparator|Saline|Hemi-face injected with saline.
32804551|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
32804552|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
32804553|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.~A- The questionnaire will contain the following items:~symptoms related to the breast.~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~breast tender point(s).~breast nodularity.~nipple discharge.~weight, height, body mass index (BMI).~C- bilateral breast ultrasonography for all patients.~D- breast biopsy when clinically indicated as per hospital policy."
32804554|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.~A- The questionnaire will contain the following items:~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~1- weight, height, body mass index (BMI)."
32804555|NCT04393714|Experimental|autogenous dentin graft treated with nitric acid|
32804556|NCT04393714|Active Comparator|autogenous dentin graft treated with hydrochloric acid|
32804557|NCT04127500|Experimental|DEX group|use DEX
32804558|NCT04127500|No Intervention|control group|use placebo
32804559|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
32804560|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
32804561|NCT04127344|Experimental|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
32804562|NCT04127344|No Intervention|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients allocated to Non-Music Therapy Intervention received standard treatment."
32804563|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
32804564|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
32804565|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
32804566|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
32804567|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
32804568|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
33313712|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
33313713|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
33313714|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
33313715|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
33313716|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
32804569|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
32804570|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
32804571|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
32804572|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
32804573|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
32804574|NCT04126876|Experimental|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
32804575|NCT04126876|Placebo Comparator|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
32804576|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
32804577|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
32804578|NCT04126564|Experimental|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
32804579|NCT04126564|Active Comparator|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
32804580|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Elderly|
32804581|NCT04126330|Placebo Comparator|Placebo- Elderly|
32804582|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Obese|
32804583|NCT04126330|Placebo Comparator|Placebo- Obese|
32804584|NCT04126720|Active Comparator|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
32804585|NCT04126720|Placebo Comparator|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
32804586|NCT04126252|Experimental|Group A|This arm received pharmacotherapy for erectile dysfunction.
32804587|NCT04126252|Experimental|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
32804588|NCT04126252|Experimental|Group C|This arm received combined treatment approach.
32804589|NCT04126252|Placebo Comparator|Group D|This arm acted as a control group and received placebo or no intervention.
32804590|NCT04125940|Placebo Comparator|Placebo-controlled Arm|Placebo - 12oz water with food coloring
32804591|NCT04125940|Active Comparator|1 serving Resync Arm|12oz water + 7.5g Resync
32804592|NCT04125940|Active Comparator|2 servings Resync Arm|12oz water + 15g Resync
32804593|NCT04125940|Active Comparator|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
32804594|NCT04125862|Other|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
32804595|NCT04125862|Other|Healthy Controls|20, matched healthy controls
32804596|NCT04125628|Experimental|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
32949198|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
32949199|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
32949200|NCT03588390|Experimental|Dose Group 1|
32949201|NCT03588390|Experimental|Dose Group 2|
32949202|NCT03588390|Experimental|Dose Group 3|
32949203|NCT03588390|Experimental|Dose Group 4|
32949204|NCT03588390|Experimental|Dose Group 5|
32949205|NCT03588390|Experimental|Dose Group 6|
32949206|NCT03588390|Experimental|Dose Group 7|
32949207|NCT03588390|Experimental|Dose Group 8|
32804597|NCT04125628|Active Comparator|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
32804598|NCT04393480|Active Comparator|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
32804599|NCT04393480|Sham Comparator|Conventional therapy|Conventional rehabilitation
32804600|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
32804601|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
32804602|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
32804603|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
32804604|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
32804605|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
33313717|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
33313718|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
33313719|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
33313720|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
33313721|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
33313722|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
33313723|NCT04882150|Experimental|Part A: SAD|SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
33313724|NCT04882150|Experimental|Part B: MAD|MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.
33313725|NCT04882150|Experimental|Part C: FE/Formul.|FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.
33313726|NCT01234298|Experimental|SPD489 Low-Dose|
33313727|NCT01234298|Experimental|SPD489 High-Dose|
33313728|NCT01234298|Placebo Comparator|Placebo|
33313729|NCT05308342|Experimental|UC-MSCs+hormone replacement group|Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).
33313730|NCT05308342|Active Comparator|hormone replacement group|Group B was the hormone replacement group (control group).
33313731|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
33313732|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
33313733|NCT04369846|Experimental|Test drug group|The arm applies the test drug of GM-XANTHO
33313734|NCT04369846|Placebo Comparator|Placebo group|The arm applies the placebo
33313735|NCT05385224|Experimental|PillSense (Active)|This is a single-arm, non-randomized study.
33313736|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
33313737|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
33404729|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
33313738|NCT03417284|Experimental|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
33313739|NCT03417284|Experimental|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
33313740|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
33313741|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
33313742|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
32804606|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
32804607|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
32804608|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
32804609|NCT04125706|Experimental|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
32949208|NCT04148898|Experimental|osimertinb group|Osimertinib 80 mg oral daily
32949209|NCT04148898|Experimental|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
32949210|NCT04148820|Experimental|Once daily drug administration|Patients will be given cardiovascular drugs once daily
32949211|NCT04148820|Experimental|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
32949212|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
32949213|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
32949214|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
32949215|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
32949216|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
32949217|NCT04148586|Experimental|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
32949218|NCT04148586|Experimental|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
32949219|NCT04148586|Active Comparator|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
32949220|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
32949221|NCT03589248||US score|assess the AGI by ultrasonography(US) score
32949222|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
32949223|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
32804610|NCT04125706|Experimental|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
32804611|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
32804612|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
32804613|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
32804614|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
32804615|NCT04125394|Experimental|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
32804616|NCT04125004|Experimental|virtual reality|Patients will use virtual reality headset during procedure
32804617|NCT04125004|No Intervention|general anesthesia|Patients will undergo general anesthesia for their procedure
32804618|NCT04125082|Other|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.~Participants will wear CMG throughout the study.~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
32804619|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
32804620|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
32804621|NCT04393246|Active Comparator|Standard of care|Standard of care
32804622|NCT04393246|Experimental|EDP1815|1.6 x 10^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
32804623|NCT04393246|Experimental|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
32804624|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804625|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804626|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804627|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804628|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
32804629|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804630|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
32804631|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804632|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
32804633|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
32804634|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
32804635|NCT04124302|Active Comparator|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
33097958|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
33097959|NCT02955017|Active Comparator|Traditional follow-up|
33097960|NCT02955017|Experimental|"Distance follow-up new technologies"|
32804636|NCT04124302|Experimental|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
32804637|NCT03004144|Other|FLOAT-Support|
32804638|NCT04123990|Experimental|IBD|
32804639|NCT04124068|Experimental|GLO Science Professional Chairside Teeth Whitening|
32804640|NCT04124068|Experimental|GLO Science Professional At-Home Teeth Whitening Device|
32804641|NCT04124068|Experimental|GLO Brilliant At-Home Teeth Whitening Device|
32804642|NCT04124068|Experimental|GLO Lit At-Home Teeth Whitening Device|
32804643|NCT04124068|Experimental|GLO Lit Whitening GLO Vials|
32804644|NCT04411069|No Intervention|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
32804645|NCT04411069|Other|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
32804646|NCT04123912|Experimental|KT-FMPT group|
32804647|NCT04123912|Placebo Comparator|Control group|
32804648|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
32804649|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
32804650|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
32804651|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
32804652|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
32804653|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
32804654|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
32804655|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
32804656|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
32804657|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
32804658|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
32804659|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
32804660|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
32804661|NCT04123288|Experimental|Test drug formulation|Test drug 60 mg single dose
32804662|NCT04123288|Active Comparator|Reference drug formulation|60 mg single dose
32804663|NCT04392934|Experimental|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
32804664|NCT04392934|Experimental|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
32804665|NCT04392934|Experimental|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
32804666|NCT04123210|Experimental|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
32804667|NCT04123210|Placebo Comparator|Placebo|Subjects receive an oil placebo containing no vitamin A
32804668|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
32804669|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
32804670|NCT04123132||Patients with metabolic syndrome|
32804671|NCT04123132||Healthy controls|
32804672|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
32804673|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
32804674|NCT04122664|Active Comparator|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
32804675|NCT04122664|Active Comparator|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
32804676|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT~."
32804677|NCT04122586|No Intervention|health control group|
32804678|NCT04122586|Experimental|Tongxieyaofang granule group|
32804679|NCT04122820|Other|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
32804680|NCT04122820|Other|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
32949227|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
32949228|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
32949230|NCT03941808|Experimental|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
32949231|NCT03941808|Placebo Comparator|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
32804681|NCT04121884|Experimental|ART Treatment|A broad patient representation of male and female adults; aged > 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
32804682|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
32804683|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
32804684|NCT04121494|Experimental|Group A|BCG-vaccinated, 1x10^9 vp, aerosol
32804685|NCT04121494|Experimental|Group B|BCG-vaccinated, 5x10^9 vp, aerosol
32804686|NCT04121494|Experimental|Group C|BCG-vaccinated, 1x10^10 vp, aerosol
33313743|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
33313744|NCT04872842||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
33313745|NCT04872842||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
33313746|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
33313747|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
33313748|NCT04867850|Active Comparator|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice. Usual care for clinicians includes a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm.
32804687|NCT04121494|Experimental|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
32804688|NCT04121494|Experimental|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
32804689|NCT04121494|Experimental|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
33313749|NCT04867850|Experimental|Clinician Nudge|Clinicians receive a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm as well as performance feedback compared to peers.
33313750|NCT04867850|Experimental|Patient Nudge|Patients receive a nudge consisting of a normalizing message prompting patients to complete an electronic questionnaire designed to prime patients towards having an SIC.
33313751|NCT04867850|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
33313752|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
33313753|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
33313754|NCT01234376||Control patients|
33313755|NCT01234376||Patients with eosinophilic esophagitis|
33313756|NCT03867916|Experimental|Health services research (Patient COUNTS)|Patients attend focus groups to help develop patient portal and navigation program. Patients use in-person navigation program. Patients also complete data collection and surveys over 15 minutes via web portal at baseline, 3 months, and 6 months and user experience survey at end of program participation.
32804690|NCT04121416|Experimental|Oxycodone group|
32804691|NCT04121416|Experimental|Sufentanil group|
33313758|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
32804692|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
33097961|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
33313759|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
33313760|NCT04828538|Active Comparator|1 - Vitamin D, Omega 3, Vitamins B, C, Zinc|"Vitamin D of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~[60 days]"
33313761|NCT04828538|Active Comparator|2 - Vitamin D, Omega 3|"Vitamin D of F1 Omega 3 of F2 Placebo of F3~[60 days]"
33313762|NCT04828538|Active Comparator|3 - Vitamin D, Vitamins B, C, Zinc|"Vitamin D of F1 Placebo of F2 Vitamins B, C, Zinc of F3~[60 days]"
33313763|NCT04828538|Active Comparator|4 - Vitamin D|"Vitamin D of F1 Placebo of F2 Placebo of F3~[60 days]"
33313764|NCT04828538|Active Comparator|5 - Omega 3, Vitamins B, C, Zinc,|"Placebo of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~[60 days]"
33313765|NCT04828538|Active Comparator|6 - Omega 3|"Placebo of F1 Omega 3 of F2 Placebo of F3~[60 days]"
33313766|NCT04828538|Active Comparator|7 - Vitamins B, C, Zinc|"Placebo of F1 Placebo of F2 Vitamins B, C, Zinc of F3~[60 days]"
33313767|NCT04828538|Placebo Comparator|8 - No Interventions|"Placebo of F1 Placebo of F2 Placebo of F3~[60 days]"
33313768|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
33313769|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
33313770|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
33313771|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
33313772|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
33313773|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
33313774|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
32804693|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
32804694|NCT04121338|Experimental|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
32804695|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
32804696|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
32804697|NCT04121104|Experimental|SCS off|
32804698|NCT04121104|Experimental|SCS on|
32804699|NCT04120792|Experimental|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
32804700|NCT04120792|Active Comparator|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
32804701|NCT04120792|Active Comparator|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
32804702|NCT04120792|Active Comparator|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
32804703|NCT04393012|Experimental|Noddle Group|Patients who received noddle to allow access to the nurse call system.
32804704|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
33313775|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
33313776|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
32804705|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
32804706|NCT04120090|Active Comparator|Low dose|
32804707|NCT04120090|Experimental|High dose|
32804708|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
32804709|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
32804710|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
32804711|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
32804712|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
32804713|NCT04125238|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at five time points in the future (1 day, 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
32804714|NCT04125238|Sham Comparator|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
32804715|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
32804716|NCT04129996|Experimental|camrelizumab in combination with nab-paclitaxel and famitinib|
33313777|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
33313778|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
33313779|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
33313780|NCT03729544|No Intervention|No Alert|No provider notification
32804717|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
32804718|NCT04129216|Experimental|Tamoxifen arm|for premenopausal patients
32804719|NCT04129216|Experimental|Letrozole arm|for postmenopausal patients
32804720|NCT04129216|Experimental|Exemestane arm|for postmenopausal patients
32804721|NCT04125784||Lipid-profile|The cohort includes male and female patients diagnosed and confirmed HIV diagnosis who receive HIV related treatment in an extramural setting. All patients are adults (older than 18 years old) and have participated in the original study in 2014.
33097962|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
33097963|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
33097964|NCT04696211|Experimental|Experimental group|The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
33097965|NCT04696211|No Intervention|Control group|The participants in the control group will continue to receive their usual care and receive a one-page pain management pamphlet.
33097966|NCT00520689|Active Comparator|1|
33097967|NCT00520689|Active Comparator|2|
33097968|NCT00520689|Active Comparator|3|
33097969|NCT00520689|Active Comparator|4|
32804722|NCT04124614|Experimental|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32804723|NCT04124614|Experimental|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32804724|NCT04124614|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32804725|NCT04122274|Sham Comparator|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
32804726|NCT04122274|Experimental|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
33097970|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
33097971|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
33097972|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
33097973|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
33097974|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
32804727|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
32804728|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
32804729|NCT04393168|Experimental|Patients with unilateral arm or leg lymphedema|
32804730|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
32804731|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
32804732|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
32804733|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
32804734|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
33097975|NCT00519519|Active Comparator|2|regular dose versus high dose
33097976|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
33097977|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
33097978|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
33097979|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
32804735|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
33097980|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
33097981|NCT00505739|Experimental|Mifepristone|
33097982|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
33097983|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
33097984|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
32804736|NCT03824080|Experimental|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles without a treatment-free period in between.~Responding patients (as per criteria of European LeukaemiaNet and International MDS working Group (2006)) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
32804737|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
32804738|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
32804739|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
32804740|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
32804741|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
32804742|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
32804743|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
32804744|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Neratinib will be taken post radiation at a daily oral pre-determine dose"
32804745|NCT02977780|Experimental|QBS10072S|"Daily Radiation for a maximum of 49 days.~QBS10072S will be administered on Day 1 of Radiation Treatment~QBS10072S will be administered post- radiation for up to 6 cycles"
32804746|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
32804747|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
32804748|NCT02974738|Experimental|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
32804749|NCT02974738|Experimental|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
32804750|NCT02972398|Experimental|NAC group|"Participants of NAC group receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
32804751|NCT02972398|Placebo Comparator|Placebo group|"Participants of Placebo group receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
32804752|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
32804753|NCT04392778|No Intervention|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
32804754|NCT04392778|Sham Comparator|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
32804755|NCT04392778|Experimental|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
33097985|NCT00519597|No Intervention|IV|Non-OSA
33097986|NCT05142800||Target Therapy Drug-Stand Care|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
32804756|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
32804757|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
32804758|NCT04758910|Active Comparator|High Flow Oxygen Therapy|Tracheostomized patients will undergo a spontaneous breathing trial with high flow oxygen therapy.
32804759|NCT04758910|Active Comparator|T-piece|Tracheostomized patients will undergo a spontaneous breathing trial with T-piece as a standard of care.
32804760|NCT03829072|Experimental|cooking Education and adapted physical activity|
32804761|NCT03828916|Other|NuShield|
32804762|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
32804763|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
32804764|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
33313781|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
33313782|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
33313783|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
33313784|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
33313785|NCT04943302|Experimental|Isatuximab + bendamustine|Bendamustine will be administered by IV at a dose of 70mg/m2 on cycle days 1 and 8 for up to 6 cycles. Isatuximab will be administered by IV at a dose of 10mg/kg on cycle 1 days 1, 8, 15, and 22; cycle 2-6 days 1,8; and cycle 7-12 day 1.
33313786|NCT04786210|Experimental|Site A of keloid scar|One half of keloid scarring on a single subject
33313787|NCT04786210|Experimental|Site B of keloid scar|One half of keloid scarring on a single subject
33313788|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
33313789|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
33313790|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
33313791|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
33313792|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
33313793|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
33313794|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
32804765|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~In this arm the subjects receives as in standard care no pericardial lavage."
33097987|NCT05142800||Target Therapy-Early or Metastatic Breast Cancer|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
32804766|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
33313795|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
33097988|NCT05149820|Active Comparator|Nudge Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
33097989|NCT05149820|Active Comparator|Nudge Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
33097990|NCT05149820|Active Comparator|Preference Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
33097991|NCT05149820|Active Comparator|Preference Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
33097992|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
33097993|NCT04513457||Liver resection and Neoadjuvant chemotherapy|Liver resection and Neoadjuvant chemotherapy
33097994|NCT04513457||Liver resection and Adjuvant chemotherapy|Liver resection and Adjuvant chemotherapy
33313796|NCT03711370|Experimental|Opaque Bottle Group|This group will be given a set of opaque bottles that are to be used during infant feedings for a full 12-week period.
33313797|NCT03711370|Active Comparator|Clear Bottle Group|This group will be given a set of clear bottles that are to be used during infant feedings for a full 12-week period.
33313798|NCT03379844|Experimental|Holmium-166 radioembolization|
33313799|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33313800|NCT04939636|Active Comparator|Vitamin D3 capsules 4000IU/100µg|Get Vitamin D3 capsules 4000IU/100µg.
33313801|NCT04939636|Active Comparator|Vitamin D3 capsules 600IU/15µg|Get Vitamin D3 capsules 600IU/15µg.
33313802|NCT03621124||Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
33313803|NCT03621124||Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
33313804|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
33313805|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
33313806|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
32804767|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
33097995|NCT04513457||Liver resection, Neoadjuvant and Adjuvant chemotherapy|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy
33097996|NCT04513457||Liver resection|Liver resection
32804768|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following~De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
32804769|NCT04613713|Experimental|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
32804770|NCT04613713|Active Comparator|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
33097997|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
32804771|NCT03483649|Experimental|HLX04|
32804772|NCT03483649|Active Comparator|United States (US) Avastin®|
33097998|NCT00520962||1,2,3|"First degree relatives of patients with type 2 diabetes~Patients with cardiovascular disease and stroke~patients with heart valve disease"
33313807|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
33097999|NCT00520962||4|Healthy controls
33098000|NCT04696601|Experimental|Olfactory test|The result of the olfactory test will be compared to the result of the RT-PCR test.
33098001|NCT04513730|Experimental|pelvic suspension device|A device will be built with the function of keeping the user in position of pelvic suspension promoting lumbar traction that will consist of a structure of pvc pipes and connections and padded material.
33098002|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
33098003|NCT04694235|No Intervention|Observational cohort (control group)|In the observational cohort, pregnant mothers in the 2nd trimester (n=500) will be recruited and they will be followed up until their children are 24 months old. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives (Polindes) or Puskesmas (IFA tablet, calcium tablet, nutrition counselling).
33098004|NCT04694235|Experimental|Intervention group|The intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
33313808|NCT04652674|Experimental|Group I|Patients who will undergo telemedicine visit approximately 1 week postoperatively, then an in-person clinic visit approximately 4 weeks postoperatively
33313809|NCT04652674|Active Comparator|Group II|Patients who will undergo in-person clinic visit approximately 1 week postoperatively, then a telemedicine visit approximately 4 weeks postoperatively
33313810|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
33313811|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
33313812|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
33313813|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
33313814|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
33313815|NCT03634540|Experimental|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
33313816|NCT03634540|Experimental|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
33313817|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
33313818|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
33313819|NCT03621670|Experimental|MenB+PCV Group|Approximately 800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age.
33313820|NCT03621670|Placebo Comparator|Placebo+PCV Group|Approximately 400 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age.
32804773|NCT03483649|Active Comparator|European Union (EU) Avastin®|
32804774|NCT03483649|Active Comparator|China (CN) Avastin®|
32804775|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
32804776|NCT04612933|Experimental|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
32804777|NCT04612933|No Intervention|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.~Patients will receive their usual treatment."
32804778|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
32804779|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
32804780|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
32804781|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
32804782|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
32804783|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
33313821|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
33313822|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
33313823|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
33313824|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
33313825|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
33313826|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
33313827|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
33313828|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
33313829|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
33313830|NCT03526588|Experimental|Autologous umbilical cord blood|
33313831|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
33313832|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
33313833|NCT05272280|Active Comparator|External oblique intercostal (EOI) block|
33313834|NCT05272280|Active Comparator|Erector spinae plane block (ESPB)|
33313835|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
33313836|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
33313837|NCT04239274|Sham Comparator|No Stimulation|
33313838|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
33313839|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
33313840|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
33313841|NCT05207228|No Intervention|Treatment as usual|After completing the inpatient care (at discharge of inpatient care), patients randomized to TAU will receive day-care / outpatient treatment.
33313842|NCT05207228|Experimental|Treatment as usual + CBT4CBT|After completing the inpatient care (at discharge), the patients randomly assigned to the experimental condition will receive the TAU + CBT4CBT a web-based treatment which has been tested on individuals with cocaine use disorder in America by the team of Dr. K.M. Carroll.
33313843|NCT01313104|Experimental|Screening|See Detailed Description
33313844|NCT01238744|Placebo Comparator|Study I: control drink|
33313845|NCT01238744|Experimental|Study I: flaxseed drink|
33313846|NCT01238744|Active Comparator|Study II: flaxseed drink|
33313847|NCT01238744|Experimental|Study II: flaxseed tablets|
33313848|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
33313849|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
33313850|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
33313851|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
33313852|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
33313853|NCT05173688|Experimental|Low maintenance dose propofol group|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h
33313854|NCT05173688|Experimental|High maintenance dose propofol group|The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
33313855|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
33313856|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
33313857|NCT03813836|Experimental|pembrolizumab + best supportive care|Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
33313858|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
33313859|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
33313860|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
33313861|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
33313862|NCT01312714|Active Comparator|Cholecalciferol|
33313863|NCT01312714|Placebo Comparator|Placebo|
33313864|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
33313865|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
32949232|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
32949233|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
32949234|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
32949235|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
32949236|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tissue biopsy at the end of cycle 1, collection of blood samples on C1D1, at the end of cycle 1, and at the end of treatment. In addition, patients undergo CT, MRI, or PET scans at baseline, at the end of cycles 2, 4, and 6, and then every 8 weeks until disease progression.
32949237|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
33313866|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
33313867|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
33313868|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
33313869|NCT03523000|Active Comparator|Active Solution followed by Inactive Placebo Solution|"Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml~6 hour washout followed by~Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline"
33098005|NCT04513340|Experimental|Treatment A|Treatment A will be given under fed conditions by intra-oral single dose administration
33313870|NCT03523000|Placebo Comparator|Inactive Placebo Solution followed by Active Solution|"Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline~6 hour washout followed by~Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml"
33313871|NCT01143740|Experimental|Single Arm|
33313872|NCT04705480|Experimental|Pregabalin|
33313873|NCT04705480|Experimental|Gabapentin|
33313874|NCT04705480|Active Comparator|Neither Pregabalin nor Gabapentin|
33098006|NCT04513340|Experimental|Treatment B|Treatment B will be given intra-orally and orally under fed conditions by single dose administration
33313875|NCT01238978|Experimental|Vildagliptin|
33313876|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
33313877|NCT01239134|Experimental|TRX518|
33313878|NCT03327220|Experimental|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
33313879|NCT03327220|No Intervention|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
33313880|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
33313881|NCT01245608|No Intervention|Control|Only 6-monthly visits
33313882|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
33313883|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
33313884|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
33313885|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
33313886|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
33313887|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
33313888|NCT05139914|Experimental|Dapagliflozin then Placebo|Participants in this arm will receive dapagliflozin and then placebo with a 2 week wash out period in between.
33313889|NCT05139914|Placebo Comparator|Placebo then dapagliflozin|Participants in this arm will receive placebo and then dapagliflozin with a 2 week wash out period in between.
33313890|NCT04648696|Active Comparator|continuous infusions (CI) group|CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge
33313891|NCT04648696|Active Comparator|Intermittent infusion (II) group|Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
33313892|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
33098007|NCT04513340|Experimental|Treatment C|Treatment C will be given orally under fed conditions by single dose administration
33098008|NCT04513340|Experimental|Treatment D|Treatment D will be given orally under fasting conditions by single dose administration
33313893|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
33313894|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
33313895|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
33313896|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
33313897|NCT04154800|Experimental|Part A:SAD|Single Ascending Dose
33313898|NCT04154800|Experimental|Part B: MAD|Multiple Ascending Dose
33313899|NCT04154800|Experimental|Part C: DDI|Drug-Drug Interaction
33313900|NCT04154800|Experimental|Part A (SAD) Placebo|
33313901|NCT04154800|Experimental|Part B (MAD) Placebo|
33313902|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
33313903|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
33313904|NCT01048229|Experimental|Rasagiline|
33313905|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
33313906|NCT04703296|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session.
33313907|NCT04703296|No Intervention|No-training control (NTC) group|Receives 4 weeks of no mindfulness training followed by a testing session.
33313908|NCT05058950||Phenotyped in Research Objectively: Cognitively Normal|"Participants with age ≥50 years and with a label of cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
33313909|NCT05058950||Phenotyped in Research Objectively: MCI|"Participants with age ≥50 years, with a label of MCI or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
33313910|NCT05058950||Phenotyped in Research Objectively: Exploratory Biomarker|"Participants with age ≥50 years, with documented positive result for an Alzheimer's disease biomarker, and with a label of subjective cognitive complaints or cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
33313911|NCT05058950||Aging Across Adulthood: MCI|Participants with age ≥50 years, with a diagnosis of MCI, mild neurocognitive disorder (MND), or cognitively impaired, not demented (CIND) will be enrolled virtually from the community.
33313912|NCT05058950||Aging Across Adulthood: Subjective Cognitive Complaint|Participants with age ≥50 years and positive screen result from Cognitive Function Instrument (CFI) will be enrolled virtually from the community.
33313913|NCT05058950||Aging Across Adulthood: Cognitively Normal With Risk Factor For Dementia|Participants with age ≥60 years and self-reported history of a minimum of 2-4 risk factors for cognitive decline will be enrolled virtually from the community.
33098009|NCT05144945|Experimental|RIV4|RIV4 single injection at Day 1
33313914|NCT05058950||Aging Across Adulthood: Cognitively Normal Without Risk Factors For Dementia|Participants with age ≥60 years having missing descriptor of minimal risk factors for cognitive decline will be enrolled virtually from the community.
33313915|NCT05058950||Aging Across Adulthood: Cognitively Normal|Participants with age 21 to 59 years will be enrolled virtually from the community.
33313916|NCT04770376||Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab|Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
33098010|NCT05144945|Active Comparator|IIV4|IIV4, single injection at Day 1
33098011|NCT04513379|Experimental|Trial|EFV 400mg
33313917|NCT04770376||Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)|Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
33098012|NCT04513379|Active Comparator|Control|EFV 600mg
33313918|NCT05291026|No Intervention|control group|Type 2 diabetes patients, 18 years old and above, enrolled in the out-patient, diabetes clinic of the tertiary health facility, receiving only standard of care, and who gave their informed consent
33313919|NCT05291026|Experimental|intervention group|type 2 diabetes patients, 18 years old and above, enrolled in the out-patient diabetes clinic of the tertiary health facility, receiving standard of care in addition to a mobile phone - based health education and follow-up messaging on a frequency of once a day corresponding to how often they are expected to take their medications (that is every day), and who gave their informed consent.
33313920|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
33313921|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
33313922|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
33404730|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
33098013|NCT05142839|Experimental|EUS-CD|EUS-guided choledochoduodenostomy
32804784|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
33098014|NCT05142839|Experimental|EUS-GEA|EUS-guided gastroenterostomy
33098015|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
33098016|NCT00521157|No Intervention|2|waiting list control
33098017|NCT04694352|Experimental|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side
33098018|NCT04694352|Active Comparator|Conventional|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping."
33098019|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
33098020|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
33098021|NCT04513262||Video-assisted surgery|Patients undergoing video-assisted major abdominal surgery (VAS) in Trendelenburg position. The decision regarding the type of VAS was made by the attending surgeon prior to study inclusion. Twenty-five consecutive patients undergoing classic laparoscopic surgery and twenty-five patients undergoing robotic-assisted surgery will be included in the study.
33098022|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
33098023|NCT00521391|No Intervention|B|
33098024|NCT05144633||Acute Respiratory failure|Patients presenting to the Emergency Department in acute respiratory failure. These patients may or may not have a diagnosis of chronic lung disease.
33098025|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
33098026|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
33098027|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
33098028|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
33098029|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
33098030|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
33098031|NCT05146778|Active Comparator|Opioid-free anesthesia group|OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
33098032|NCT05146778|Active Comparator|Conventional anesthesia group with opioid|Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
33098033|NCT04694430||Severe exacerbation of COPD|N = 250
33098034|NCT04694430||Mild and moderate exacerbations of COPD|N = 250
33098035|NCT05143385|No Intervention|Control|"The variables to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: Mississippi Aphasia Screening test, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfreiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16., Will be performed on all patients who are part of the trial.~Those patients where conventional rehabilitative treatment is performed will be:~Physiotherapy sessions~Speech therapy sessions~Neuropsychology sessions~Occupational therapy sessions"
33098036|NCT05143385|Experimental|Intervention Group|The variables are to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: MAST, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfeiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16.The beginning of the intervention will be once you have completed 15 calendar days from your admission.The intervention will be carried out once a week with a duration of 20 min with one of the games chosen by the patient together with the physiotherapist.The completion of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions carried out in order to participate in the study.A registration table will be executed where the number of sessions of each patient and the type of session are quantified like a control group.
33098037|NCT04694274||group 1|patients with temporomandibular disorders
33098038|NCT04694274||group 2|healthy control
33098039|NCT05145764|Experimental|Suvorexant|Nightly dosing of suvorexant
33098040|NCT05145764|Placebo Comparator|Placebo|Nightly dosing of placebo
33098041|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33404731|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
33404732|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
33404733|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
33313923|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
33313924|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
33313925|NCT03326518|Experimental|Lumentin® 44|Contrast agent
33313926|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
33313927|NCT03326518|Active Comparator|Movprep®|Contrast agent
33313928|NCT04017832|Experimental|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
33313929|NCT04017832|Experimental|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
33313930|NCT04017832|Experimental|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
33313931|NCT04017832|Experimental|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
33313932|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
33313933|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
33313934|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
33313935|NCT03620812|Active Comparator|soy protein|
33313936|NCT03620812|Placebo Comparator|no protein|
33313937|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
33313938|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
33313939|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
33313940|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
32804785|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
32804786|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
32804787|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
32804788|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
32804789|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
33313941|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
33313942|NCT03985787|Experimental|All Participants|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
33313943|NCT03981965|Experimental|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
33313944|NCT03981965|Active Comparator|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
33313945|NCT03981965|No Intervention|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
33313946|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
33313947|NCT01058759|Experimental|Arm B: Enoxaparin|
33313948|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
33313949|NCT01239368|Experimental|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
33313950|NCT01239368|Experimental|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
33313951|NCT03985709|Experimental|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
32804790|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
32804791|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
32804792|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
32804793|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
32804794|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
32804795|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
32804796|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
32804797|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
32804798|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
32804799|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
32804800|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
32804801|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
32804802|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
32804803|NCT04274062||peri partum integrated nursing care of placenta previa|"Part (1) personal data:~Part (2) baseline and characteristics of the patients participants:~Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.~Part (1) pre-operative: includes assessment of :~patients general condition~investigation~reserved blood~Hemoglobin level~Impact of hysterectomy option. -9-~Part (2) Intra-operative:~Includes assessment of :-~Investigation~Vital signs~Hypothermia~Blood loss~I.V fluid~Blood gases~Fetal condition and APGAR score.~Part (3) Post-operative: Includes:~maternal complication~fetal complication~psychological satisfaction"
32804804|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
32804805|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
32804806|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
32804807|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
32804808|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
32804809|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
32804810|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
32804811|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
32804812|NCT03821350|No Intervention|Control Group|The control group was given verbal information
32804813|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
32804814|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
32804815|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
32804816|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
32804817|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
32804818|NCT03821194|Active Comparator|control group|give hot pack for the subjects
32804819|NCT03820570|Experimental|lichtenstein|hernia repair
32804820|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
32804821|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
32804822|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
32804823|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
32804824|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
32804825|NCT03820336|Experimental|Extra Virgin Olive Oil|
32804826|NCT03820336|Placebo Comparator|Control Oil|
32804827|NCT04391998|Active Comparator|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
32804828|NCT04391998|Active Comparator|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
32804829|NCT04391998|Active Comparator|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
32804830|NCT03828448|Experimental|ublituximab + umbralisib|"Ublituximab: 900 mg administered through Cycle 12, via IV infusion~Umbralisib: 800 mg administered through Cycle 24, via daily oral tablet"
33313952|NCT03985631|Experimental|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
32804831|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
32804832|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
32804833|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
32804834|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
32804835|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
32804836|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
32804837|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
32804838|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
32804839|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
32804840|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
32804842|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
32804843|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
32804844|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
32804845|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
32804846|NCT01894243|Other|Normal hepatic function|"Patients with:~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
32804847|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
32804848|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
32804849|NCT03822832|Experimental|Spesolimab|i.v.
32804850|NCT03822832|Placebo Comparator|Placebo|i.v.
32804851|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
32804852|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
32804853|NCT01450150|Experimental|Active tDCS|
32804854|NCT01450150|Sham Comparator|Sham tDCS|
32804855|NCT01450228|Placebo Comparator|Placebo KI1001|
32804856|NCT01450228|Experimental|KI1001|
32804857|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32804858|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
32804859|NCT01450462|Placebo Comparator|Placebo|
32804860|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
32804861|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
32804862|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
32804863|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
32804864|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
32804865|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
32804866|NCT01450774|Experimental|CHF 1535 50/6µg|
32804867|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
32804868|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
32804869|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
32804870|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
32804871|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
33098042|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
33098043|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
33098044|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
33098045|NCT00521508|Other|3|Healthy volunteers
33098046|NCT05141123||Preloaded Fenestrated Stent-graft Designs for Endovascular Aortic Procedures|Patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type B dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone)
33098047|NCT00506012|Experimental|1|T2000
33098048|NCT04693728|Active Comparator|Behavioral Intervention|The study intervention arm was a behavioral treatment that consisted of training resilient intrinsic self-regulation strategies to help alleviate chronic pain.
33098049|NCT04693728|No Intervention|Wait-list with no treatment|The control comparison arm consisted of a wait-list condition in which participants received no treatment during a time interval comparable to the intervention arm.
33098050|NCT04512872|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in PFS
33098051|NCT04512872|Active Comparator|EU-approved Prolia|60 mg/mL single dose administration, Solution for injection in PFS
32804872|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
33098052|NCT05144867|Active Comparator|Arm 1|The WBRT dosage schedule will be 30 Gy in 10 fractions over 2 weeks. For Arm 1, Treatment planning is to be done using CT simulation or conventional simulation (fluoroscopy). Simple beam arrangements, such as parallel opposed beams, will be favoured wherever possible.
33098053|NCT05144867|Experimental|Arm 2|Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
33098054|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
33098055|NCT05144672||Patient Group|The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.
33098056|NCT05144672||Control Group|control group will include 30 apparently healthy age-matched and sex-matched individuals.
33098057|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
33098058|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
33098059|NCT04512950|Active Comparator|Ringer's lactate|administered as infusions or boluses as per the treating physician
33098060|NCT04512950|Active Comparator|0.9% Saline|administered as infusions or boluses as per the treating physician
33098061|NCT04694040||healthy adult volunteers showing no signs of temporomandibular disorders|
33098062|NCT05144594||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2013-2017, identified by ICD-code K.58.
33098063|NCT04694469||Group Day|operated at 07:30 AM - 06:30 PM
33098064|NCT04694469||Group Night|operated at 06:30 PM - 07:30 AM
33313953|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
32804873|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
32804874|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
32804875|NCT01451242||brain injury|
32804876|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
32804877|NCT01451710|Experimental|Prednisone or Prednisolone|
32804878|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
32804879|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
32804880|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
32804881|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
32804882|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
32804883|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
32804884|NCT01451944|Experimental|asthma education and case management|asthma education and case management
32804885|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
32830891|NCT01963078|Experimental|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
33098065|NCT04512638|Active Comparator|Conservative treatment|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minor debridement. Primary wound closure is not part of this treatment strategy.
33098066|NCT04512638|Experimental|Minimally invasive approach + LPRF|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
33098067|NCT04512638|Experimental|Primary surgical management|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
33098068|NCT04693923|Experimental|Group A (rapid fluid challenge)|Patients will receive a rapid fluid challenge (4ml/kg of crystalloids in 5 minutes using a syringe of 60 mL and a timer in the multiparameter monitor).
33098069|NCT04693923|Active Comparator|Group B (standard fluid challenge)|Patients will receive a standard fluid challenge (500 ml of crystalloids in 30 minutes).
33098070|NCT05144516|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
33098071|NCT00523185|Active Comparator|2|
33098072|NCT00523185|Active Comparator|1|
33098073|NCT04512443||1|42 women (treated with Daflon 1000 mg (study group))
33098074|NCT04512443||2|41 women (placebo (control group))
33313954|NCT05288608||Simple palliation|Treatment of patients who are referred for palliative radiotherapy to uncomplicated metastases.
33098075|NCT04512404||hypercholesterolemia|"3-hydroxy-3-methylglutaric acid coenzyme A (HMG Co-A) reductase inhibitor Types of drug, dosage and frequency is according to the treating physician. This is an observational study.~Duration of treatment: 3-5 months"
33098076|NCT04693962||Partial Nephrectomy (PN)|Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
33313955|NCT05288608||Complex palliation|Treatment of patients who require treatment to a site of previous radiation, patients undergoing concurrent systemic therapy, and those requiring a radiation dose exceeding 8 Gy.
33313956|NCT04700722||Parkinson's disease|Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
33313957|NCT04700722||Multiple System Atrophy|Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
32804886|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
32804887|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
33098077|NCT04693962||Hemicolectomy (HC)|Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
32804888|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
32804889|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
32804890|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
32804891|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
32804892|NCT02637934|Experimental|Biodistribution|"The Biodistribution cohort will include up to 4 patients who will undergo a series of vertex to mid-thigh biodistribution [18F]FTT PET/CT scans over a period of approximately 4 hours.~Up to 10 subjects were initially planned for this cohort, however, the first 4 subjects have been enrolled and initial data analysis for these completed. The decision was made to close enrollment for this cohort as we do not believe that we need to complete the up to 10 subjects originally planned for this cohort as the initial data shows consistent and repeatable data that we do not believe would change significantly with the addition of 6 more subjects."
33313958|NCT04700722||Dementia with Lewy bodies|Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
33313959|NCT04700722||Pure Autonomic Failure|Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
33313960|NCT04700722||Healthy Controls|No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
32804893|NCT02637934|Experimental|Dynamic|The Dynamic cohort will include up to 36 patients who will undergo 1 static skull base to mid-thigh scans imaging post injection of [18F]FTT.
32804894|NCT01452334|Experimental|Arm 1: BMS-936559|
32804895|NCT01452490|Experimental|Diode Laser Treatment|
32804896|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
32804897|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
32804898|NCT01452646|Experimental|MRD-directed therapy|
32804899|NCT01452724|Experimental|TAK-438 20 mg QD|
33098078|NCT04693962||Nephrolithotomy (NL)|Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
33098079|NCT05149118|Experimental|PDRN injected group|The participants in treatment group had received two consecutive injections of PDRN one day and two days after the surgery. A total 1mL of PDRN was injected along the suture line at distance of 1cm in each session.
33313961|NCT05632172||maxillary group|implant insertion
33313962|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
33313963|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
32949238|NCT03941496|Experimental|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:~5 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~15 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~30 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~50 mg/m^2 SQ once daily x 5 days for 8 individuals~75 mg/m^2 once daily x 5 days for 8 individuals"
32949239|NCT03895476|Active Comparator|control group|palatal wound will not be protected with any material
32949240|NCT03895476|Active Comparator|group 1|palatal wound will be protected with Platelet rich Fibrin
32949241|NCT03895476|Active Comparator|group 2|wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
32949242|NCT03895476|Active Comparator|group 3|wound will consist of collagen protection with the application
32949243|NCT03940560|Experimental|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
32949244|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
32949245|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
32949246|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
32949247|NCT04406064|Experimental|Viral Specific T-cells (VSTs)|
32949248|NCT04405752||12-mm diameter metallic billiary stent|
32949249|NCT04405752||10-mm diameter metallic billiary stent|
32949250|NCT03894150|Experimental|F0002-ADC|
32949251|NCT05702892|Experimental|periodontitis|
32949252|NCT05702892|Experimental|gingivitis|
32949253|NCT05702892|Experimental|periodontal healthy|
32949254|NCT04148664|Active Comparator|Standard Catheter Settings|Group 1 - Standard RF ablation settings
32949255|NCT04148664|Experimental|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
32949256|NCT04765410||Patients with solid pancreatic masses|Patients with solid pancreatic masses
32949257|NCT04765254||control group|COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
32949258|NCT04765254||diabetic group|COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs
32949259|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
32949260|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
32949261|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
32949262|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
32949263|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
32949264|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
32949265|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
32949266|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
32949267|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
32949268|NCT02985060|Other|Control group|Stroke care based on international guidelines
32949269|NCT03587454|Experimental|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
32949270|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
32949271|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
32949272|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
32949273|NCT03587298||Group 2|Control group: matched age; no NAFKL
32949274|NCT04148196|No Intervention|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
32949275|NCT04148196|Experimental|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises twice a week for 8 weeks. Each PMR exercise was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
33098080|NCT05149118|No Intervention|Control group|The participants in control group were left untreated.
33313964|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
32804900|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
32804901|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
32804902|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
32804903|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
32804904|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
32804905|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
32804906|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
32804907|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
32804908|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
32804909|NCT01453270|Active Comparator|Usual care|
32804910|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
32804911|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
32804912|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
32804913|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
32804914|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
32804915|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
32804916|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
32804917|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
32804918|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
32804919|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
32804920|NCT01544127|Experimental|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
32804921|NCT01544127|Experimental|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
32804922|NCT01544127|Other|TAU Alone|Treatment as usual
32804923|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
32804924|NCT01453504|Placebo Comparator|Placebo-DHAP|
32804925|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
32804926|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
32804927|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
32804928|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
32804929|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
32804930|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
32804931|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
32804932|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
32804933|NCT04272892|Experimental|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
32804934|NCT04272892|Active Comparator|Sleep hygiene information|Leaflet of sleep hygiene information
32804935|NCT04273204|Experimental|UCP Group|
32804936|NCT04273204|Other|Control Group|
32804937|NCT01458340|Experimental|TD-9855 Dose 1|
32804938|NCT01458340|Experimental|Placebo|
32804939|NCT01458340|Experimental|TD-9855 Dose 2|
32804940|NCT04844554|Experimental|Group 1 - 3.0 mA active HD-tDCS|HD-tDCS with 3.0 milliamperes (mA) of intensitive
32804941|NCT04844554|Experimental|Group 2 - Sham HD-tDCS|Sham HD-tDCS
32804942|NCT04841590|Experimental|Experimental Group|The experimental group (EG) will receive treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
32804943|NCT04841590|Sham Comparator|Control Group|The control group (CG) will not receive any treatment
32804944|NCT04841590|Placebo Comparator|Placebo Group|Subjects belonging to this group will receive the application of off ultrasound applied to the abdominal region for approximately 10 minutes.
32804945|NCT04849000|Experimental|SHR-1209|
32804946|NCT04849000|Placebo Comparator|SHR-1209 Placebo|
32804947|NCT04846270|Experimental|Investigational Device|TENA SmartCare Change Indicator
32804948|NCT04845568|No Intervention|Video|This is the control condition, which views a short video and online interactive game with psychoeducational material on healthy eating and consideration of future consequences.
33098081|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
33098082|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
33098083|NCT05144399|Experimental|Accelerated antibiotic treatment|Patients are treated shorter than usual
33098084|NCT05144399|Other|Standard length of antibiotic treatment|Patients are receiving the standard length of antibiotic treatment
33098085|NCT00521703|Experimental|1|group treated
33098086|NCT00521703|Placebo Comparator|2|control group
33098087|NCT05144321||All pregnant women delivering a twin pregnancy|All pregnant women delivering a twin pregnancy
33313965|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
33313966|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
33098088|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
33098089|NCT05144282||premature baby without ROP (Group 1)|ROP: retinopathy of prematurity
33098090|NCT05144282||ROP without treatment (Group 2)|ROP: retinopathy of prematurity
33098091|NCT05144282||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity
33098092|NCT05144282||ROP with laser photocoagulation treatment (Group 4)|ROP: retinopathy of prematurity
33098093|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
33098094|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
33098095|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
33098096|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
33098097|NCT05144204|Experimental|Irritable Bowel Syndrome Patients|
33098098|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
33098099|NCT05144126|Experimental|i-Factor Arm|All patients undergoing spine fusion surgery will be treated with i-FACTOR
33098100|NCT00521820|Experimental|Pioglitazone QD|
33098101|NCT00521820|Active Comparator|Glyburide QD|
33098102|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
33098103|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
33098104|NCT04696328|Experimental|Group of subjects undergoing cell transplantation|Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation (only once)
33098105|NCT00521859|Experimental|Cloretazine + Fludarabine|
33098106|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
33098107|NCT00521898|Experimental|DMEK|DMEK as intervention
32804949|NCT04845568|Experimental|Virtual Reality|This is the intervention condition, which participates in the virtual reality experience; the experience includes psychoeducational material on healthy eating and consideration of future consequences.
32804950|NCT04847206|Experimental|MDMA (100 mg MDMA-hydrochloride)|MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)
33098108|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
33098109|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
33098110|NCT00521937|Experimental|A|Dermagen®
33098111|NCT00521937|Active Comparator|B|Conventional treatment
33098112|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
33098113|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).~10 milliliter of blood are collected from these donors"
33098114|NCT04693611|Experimental|Intervention Group|"Participants who meet the inclusion criteria will be randomised to the CS intervention group or to the control group that will maintain their usual treatment.~Participants in the intervention group will participate in two CS sessions per 12 weeks besides their treatment as usual."
33098115|NCT04693611|No Intervention|Control Group|Participants in the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed dementia-specific medication.
33098116|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
33098117|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
33098118|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
33098119|NCT02954744|Experimental|Treatment arm|HIFU treatment
33098120|NCT00523380|Experimental|A|
33098121|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
33098122|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
33098123|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
33313967|NCT01245842|No Intervention|Usual care|
33313968|NCT01245842|Experimental|Exercise group|
33313969|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
33313970|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
33313971|NCT02924324|Active Comparator|Propofol First, then Propofol & Ropivacaine|1st Bone Marrow procedure (BM) Intervention A: propofol first. Then second BM procedure with propofol & ropivacaine
33313972|NCT02924324|Experimental|Propofol and Ropivacaine First, then Propofol|1st BM procedure: Intervention B: propofol & ropivacaine first. Then second BM procedure with propofol
33313973|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
33313974|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
33098124|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
33098125|NCT05143580|Experimental|Cognitive Therapy Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
33098126|NCT05143580|Placebo Comparator|Routine Care Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
33098127|NCT00522054|Other|A|Single group study
33098128|NCT00506987|Experimental|SCH 486757|
33098129|NCT00506987|Placebo Comparator|Placebo|
33098130|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
33098131|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
33098132|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
33098133|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
33098134|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
33098135|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
33098136|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
33098137|NCT00507065|Experimental|Adderall XR (10 mg)|
33098138|NCT00507065|Experimental|Adderall XR (20 mg)|
33098139|NCT00507065|Experimental|Adderall XR (30 mg)|
33098140|NCT00507065|Experimental|Adderall XR (40 mg)|
33098141|NCT00507065|Placebo Comparator|placebo|
33098142|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
33098143|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
33313975|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
33313976|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
33313977|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
33313978|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
33313979|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
33313980|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
33313981|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
33313982|NCT05137574|Active Comparator|Group P|Patients sedated with propofol
33098144|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
33098145|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
33098146|NCT05143151|Experimental|Treatment group|CD276 targeted chimeric antigen receptor cells treatment
33098147|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
33098148|NCT00523536|No Intervention|2|Usual clinical care
33098149|NCT00523575|No Intervention|C|Usual nurse and dietetic care
33098150|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
33098151|NCT05143112|Experimental|Treatment group|Allogeneic CD19 CR-T cell infusion
33098152|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
33098153|NCT05148767|Experimental|Neoadjuvant chemoradiotherapy based on irinotecan|Locally advanced rectal cancer patients who were treated with irinotecan-based neoadjuvant chemoradiotherapy regimen can be enrolled in this group.
33098154|NCT00522288|Experimental|Contact Lens|Soft contact lenses
33313983|NCT05137574|Active Comparator|Group K|Patients sedated with ketamine
33313984|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
33313985|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
33313986|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
33313987|NCT05018546|Experimental|Gravity Irrigation|RIRS under Gravity irrigation
33313988|NCT05018546|Experimental|Pressure Irrigation|RIRS under Pressure irrigation.
33313989|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
33313990|NCT01239602||Normal control|
32949276|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
32949277|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
33098155|NCT00522288|Active Comparator|Spectacle|Spectacles
33313991|NCT01239602||with Stem cell therapy plus G-CSF|
33313992|NCT01239602||G-CSF along|
33313993|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
33313994|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
33313995|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
32738081|NCT05463809|Experimental|Control group: oxycodone-controlled analgesia pump|No treatment was given preoperatively, and postoperative oxycodone patient-controlled intravenous analgesia(PCIA). After awakening, intravenous oxycodone was titrated according to numerical rating scale(NRS) score, providing analgesia without background dose of oxycodone patient-controlled intravenous analgesia(PCIA) pump (single dose 1 milligram, locking time 5 minutes, 14 hours limit 12 milligrams)
32949278|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
32949279|NCT04148040|Experimental|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
32949280|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
32949281|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
32949282|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
32949283|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
32949284|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
32949285|NCT05702658|Experimental|experimental arm|Individuals who receive CAPS
32949286|NCT05702658|No Intervention|control|Individuals who receive treatment as usual
32949287|NCT04147572|Experimental|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
32949288|NCT04147572|Experimental|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
32949289|NCT04147572|Placebo Comparator|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
32949290|NCT04147572|Experimental|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
32949291|NCT04147572|Placebo Comparator|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
32949292|NCT04147806|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
32949293|NCT04147806|Experimental|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
32949294|NCT05702580|Experimental|Standard thoracentesis followed by pre-aspiration fluid agitation|Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique
32949295|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
32949296|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
32949297|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
32949298|NCT03934944|Experimental|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
32949299|NCT03934944|Other|Usual care|Participants will have Podiatry care and education.
32949300|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
32949301|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
32949302|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
32949303|NCT05702424|Experimental|IGM-7354 Single-Agent Dose Escalation|IGM-7354 will be administered intravenously as a single agent.
33313996|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
33313997|NCT04971746|Experimental|GLPG4716 and pirfenidone|
33313998|NCT04971746|Experimental|GLPG4716 and nintedanib|
33313999|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
33314000|NCT02779244|Active Comparator|Standard Treatment Cam boot|
32738082|NCT03331445|Experimental|160 ppm Nitric Oxide|
32949304|NCT05702424|Experimental|IGM-7354 Single-Agent Dose Expansion Serial Biopsy|IGM-7354 will be administered intravenously as a single agent and patients will undergo pre-treatment and on-treatment biopsies.
32949305|NCT03586752|Experimental|On-line group|On-line program course
33098156|NCT05142956||Smokers|Current smokers are defined as cigarettes smoking within one year before surgery.
33098157|NCT00522327|Experimental|1|remote simult med interpret
33098158|NCT00522327|Active Comparator|2|Usual & Customary
33098159|NCT00522327|Other|3|comparison group
33098160|NCT05148728|No Intervention|Active surveillance|After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
33098161|NCT05148728|Active Comparator|endoscopic fulguration|After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
33098162|NCT00523692|Experimental|1|Intensive therapy
33098163|NCT00523692|Active Comparator|2|Standard therapy
33098164|NCT05148689|Experimental|test product|Oxymetazoline Cream, 1%
33098165|NCT05148689|Active Comparator|reference|Rhofade™ (oxymetazoline) cream, 1%
32949306|NCT03586752|Active Comparator|Standard group|Standard program course
33098166|NCT05148689|Placebo Comparator|placebo|Vehicle of Test product
33098167|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
32949307|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
33098168|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
33098169|NCT05148650|Experimental|Crystalloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of a balanced crystalloid solution (Optilyte®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
32949308|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
32949309|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
32949310|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
32949311|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
32949312|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.~Inclusion:~Prevalent haemodialysis patient (more than 3 months)~Active on the supportive care register with anticipated death in the subsequent 12 months~Able to give informed consent~Consent to donation of heart for research following death~Able to understand written and verbal explanations in English~Exclusion:~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)~Unable to give informed consent~Unable to understand written and verbal explanations in English"
32949313|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
32949314|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree~distance between on table and acromion ≥ 2.5 cm"
32949315|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree~distance between on table and acromion < 2.5 cm"
32949316|NCT03586206||Mild-moderate C.difficile infection|
32949317|NCT03586206||severe C.difficile infection|
32949318|NCT03586206||severe complicated/fulminant C.difficile infection|
32949319|NCT05697588||MCI progression|MCI-P (Compared with the baseline, MMSE score declined > 4 points per year)
32949320|NCT05697588||MCI stabilization|MCI-S (Compared with the baseline, MMSE score decreased < 4 points per year）
32949321|NCT05702346|Experimental|Intervention|Participants will receive the EPA intervention.
32949322|NCT05702346|Active Comparator|Control|This is the control group who will receive written information about health.
32949323|NCT05695872|Active Comparator|subtarsal approach|
32949324|NCT05695872|Active Comparator|conventional transconjunctival approach|
32949325|NCT05695872|Active Comparator|transconjunctival approach with Y- modification|
32949326|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
32949327|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~Sociodemographic~Morbid~Pharmaco-therapeutic~Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
32949328|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
33098170|NCT05148650|Experimental|Colloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of gelatin 26,500 Da (Geloplasma®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
33314001|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
33404734|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
32949329|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
32949330|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
32949331|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
32949332|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
32949333|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
32949334|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
32949335|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
32949336|NCT03589326|Experimental|Cohort A: Ponatinib 30 milligram (mg)|Ponatinib 30 mg, tablets, orally, once daily (QD), with vincristine 1.4 mg/m^2 intravenous(IV), on Days 1 and 14 and dexamethasone 40 mg(<60 years [yrs]) and 20 mg (>=60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 for up to 3 cycles (each cycle will be of 28-days) in induction phase followed by ponatinib last dose of induction phase tablets, orally, QD, with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (<60 yrs) and 250 mg/m^2 every 12 hours (>=60 yrs), IV on Days 1, 3, and 5 of Cycles 2, 4, and 6, (cytarabine dose will be reduced/ discontinued in case of impaired renal function) and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (>=60 yrs), IV infusion, on Day 1 of cycles 1, 3, and 5 in consolidation phase followed by ponatinib last dose of consolidation phase, tablets, orally, QD, with vincristine 1.4 mg/m^2, IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (>=60-69 yrs) and 50 mg(>=70 yrs) on Days 1 to 5 for up to 11 cycles in maintenance phase.
32949337|NCT03589326|Active Comparator|Cohort B: Imatinib 600 mg|Imatinib 600 mg,tablets, orally,QD,along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Days 1 and 14 and dexamethasone 40 mg (<60 yrs) and 20 mg (≥60 yrs),orally,once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle up to 3 cycles in induction phase followed by imatinib 600 mg,tablets,orally,QD, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (<60 yrs) and 250 mg/m^2 every 12 hours (≥60 yrs), IV on Days 1,3, and 5 of each 28-day even cycles (Cycles 2,4,and 6), (cytarabine dose reduced/discontinued for participant with impaired renal function) and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (≥60 yrs),IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1,3,and 5) in consolidation phase followed by imatinib 600 mg,tablets,orally,QD, along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each 28-day cycle up to 11 cycles in maintenance phase.
32949338|NCT05684640|Experimental|Rodatristat ethyl|Part One: is 600 QD
32949339|NCT05684640|Placebo Comparator|Placebo|Part Two: Placebo match for Rodatristat ethyl
32949340|NCT05701956|Experimental|Intravenous tenecteplase+aspiration thrombectomy alone|patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) and a direct aspiration first pass
32949341|NCT05701956|Experimental|Intravenous tenecteplase+ stent retriever alone or combined contact aspiration and stent retriever|patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) and stent retriever alone or combined contact aspiration and stent retriever as first pass.
32949342|NCT05701956|Experimental|no intravenous tenecteplase+aspiration thrombectomy alone|patients will not receive intravenous thrombolysis, and will receive a direct aspiration first pass
32949343|NCT05701956|Active Comparator|no intravenous tenecteplase+stent retriever alone or combined contact aspiration and stent retriever|patients will not receive intravenous thrombolysis, and will receive stent retriever alone or combined contact aspiration and stent retriever as first pass. pass
32949344|NCT03886584|Experimental|Patients with with neuropsychiatric conditions|"In this arm, five groups :~Patients with DFT, diagnosed according Racovsky criteria~Patients with Lewi Body dementia, diagnosed according McKeith criteria~Patients with pre-demential Alzheimer, diagnosed according Dubois criteria~Patients with Alzheimer, diagnosed according MMSE~Patients with bipolar disorder, diagnosed according DSM 5"
33404735|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
33404736|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
33404737|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
33098171|NCT05148416|Experimental|Laser group|"1. Experimental group (A) the laser group (n=20) which received~high intensity laser therapy(HILT)~knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
33098172|NCT05148416|Sham Comparator|the sham group group( B)|"the Sham group (n= 20) which received~sham HILT~knee osteoarthritis conventional exercises program previously mentioned .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
32949345|NCT03886584|Active Comparator|Healthy subjects|Healthy controls appaired in age, sex and educational level
32949346|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
33098173|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
33098174|NCT05148182||low risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.
32949347|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
32949348|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
32949349|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
33098175|NCT05148182||medium risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.
33098176|NCT05148182||high risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.
32949350|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
32949351|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
32949352|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
32949353|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
32949356|NCT05701878|Experimental|Intervention (App) Group|Participants in this group will be given access to a COVID-19 self-testing app (SMARTest). Access to the app, given exclusively to this group, will be in addition to the 12 COVID-19 self-test kits participants receive.
32949357|NCT05701878|No Intervention|Control (No App) Group|Participants in this group will not be given access to the COVID-19 self-testing app (SMARTest). Participants will only receive the 12 COVID-19 self-test kits.
32949358|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
32949359|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
32949360|NCT03585426|Experimental|Vancomycin 1g q12h|
32949361|NCT03585426|Experimental|Vancomycin 1g q8h|
32949362|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
32949363|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure~."
32949364|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
32949365|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
32949366|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
32949367|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
32949368|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
32949369|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
32949370|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
32949371|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
32949372|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
33098177|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
32804951|NCT04847206|Experimental|MDA (93.9 mg MDA-hydrochloride)|MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)
33098178|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
32804952|NCT04847206|Experimental|lysine-MDMA (171.7mg lysMDMA dihydrochloride|lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)
33098179|NCT00522444|Experimental|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
33098180|NCT00522444|Placebo Comparator|normal saline nebulization|standard of care
33098181|NCT05148143|Experimental|RALOX|Raltitrexed combined with oxaplatin
33098182|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
33098183|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
33098184|NCT00522561|Other|1|healthy volunteers
33098185|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
33098186|NCT05145218|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 21 days, 1200mg each time, intravenous infusion. The longest administration time should not exceed 24 months.~Anlotinib Hydrochloride capsules: once a day, 12mg each time, oral administration on an empty stomach before breakfast for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment."
33098187|NCT05145218|Active Comparator|Paclitaxel injection|80mg/m2, intravenous drip, once a week (D1, D8, D15 of 21 days), 21 days as a course of treatment.
33098188|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
33098189|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
32804953|NCT04847206|Experimental|lysine-MDA (165.6 mg lysMDA dihydrochloride;|lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)
32804954|NCT04847206|Placebo Comparator|Placebo|Placebo
32804955|NCT04844008|Experimental|Nanobubble|Sports drink nanobubble drink
33098190|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
33098191|NCT05140850||PRES group|PE or E with PRES
32804956|NCT04844008|Placebo Comparator|control|Flavoured drink- no active ingredients
32804957|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
33098192|NCT05140850||non-PRES group|PE or E without PRES
33098193|NCT00522717|Experimental|1|
33098194|NCT00522717|Active Comparator|2|
33098195|NCT05142098|Active Comparator|Dexamethasone|Dexamethasone 4mg will be injected intramuscularly into the pterygomandibular space after achieving effective inferior dental block.
33098196|NCT05142098|Experimental|Etoricoxib|2 tablets 60mg each would be given orally one hour prior to the surgery.
33098197|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
32804958|NCT04848142||Primary Group (parent-child)|parents (i.e., guardians/caregivers) and children age ≥ 8 years,will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years with P/LP variant and aware of results, or their parent)
32804959|NCT04848142||Parent Only Group|parents of children age < 8 years, will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment.
32804960|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
32804961|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
32804962|NCT04840264|Experimental|1st Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
32804963|NCT04840264|Experimental|2nd Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
32804964|NCT04840264|Experimental|3rd or later Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
32804965|NCT04272814|Experimental|Compression therapy|compression therapy
32804966|NCT04272814|Active Comparator|Standard treatment|standard treatment
32804967|NCT04841434|Experimental|Dose escalation|Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
32804968|NCT04272580|Sham Comparator|Control group|No preload was given before spinal anesthesia
32804969|NCT04272580|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
32804970|NCT04272580|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
32804971|NCT04272580|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
33098198|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
33098199|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
33098200|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
33098201|NCT05141669||Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
33404738|NCT05762796|No Intervention|Healthy Controls|Never-concussed age-and gender-matched healthy controls will not receive any intervention. Behavioral and neuroimaging measurements will be administered only once, at the initial visit.
32949373|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
32949374|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
33314002|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
33314003|NCT01246388||Chronic Liver Disease|
33314004|NCT01143974|Experimental|PC Regimen|
32949375|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
33314005|NCT01239836|Experimental|Self-management|
32949376|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
33314006|NCT01239836|Sham Comparator|General Health Lecture|
32949377|NCT05701722|No Intervention|Routine Care|Women with recurrent BV who are randomly assigned to the Routine Care (control) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will be treated with appropriate antibiotics or antifungals in case of BV or yeast infection, respectively, but otherwise will not receive any treatment. They may engage in any vulvovaginal hygiene of their choosing except for using products made by Good Clean Love.
32949378|NCT05701722|Experimental|Flourish HEC|Women with recurrent BV who are randomly assigned to the Flourish HEC (intervention) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will receive routine care as needed (see Routine Care arm). In addition, they will use the Flourish HEC Vaginal Care System regularly for the 24-week duration of the study. Briefly, they will use Balance intimate wash daily with regular bathing; BioNourish vaginal moisturizing gel every other day; and BiopHresh homeopathic vaginal suppository with probiotics every 3rd day. They will use no other products (except menstrual hygiene products) in the vulvovaginal area during the study.
33314007|NCT01239836|Experimental|Combined workshop and self-management|
33314008|NCT01239836|Experimental|Workshop|
33314009|NCT04904042|Experimental|Use of plasma of neutral argon|Use of plasma of neutral argon in the eradication of tumor implants at the mesentery level, with different doses (established according to the percentage of energy used) and distances of application and time. It will also be compared in-vivo with control therapy of Monopolar electrofulguration at a power of 100 in cut mode with ball-tip terminal.
33314010|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
33314011|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
33314012|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
33314013|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
32949379|NCT04405050|Active Comparator|Restrata|Treated with Restrata
33314014|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
33314015|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
32949380|NCT04405050|Active Comparator|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
33314016|NCT01247480||Breast cancer patients|
33314017|NCT00337571|Experimental|A1|5 mg
33314018|NCT00337571|Experimental|A2|10 mg
32949381|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.~Melphalan: 140 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)~TBI: 200 cGy Day: -1.~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):~Melphalan: 70 mg/m2/day IV on Day -6.~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~TBI: 200 cGy; Days -1."
32949382|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
32949383|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
32949384|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
32949385|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
32949386|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
32949387|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
33314019|NCT00337571|Experimental|A3|15 mg
33314020|NCT00337571|Placebo Comparator|B1|
33314021|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
33314022|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
33314023|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
33098202|NCT05141669||Non-fingolimod Disease Modifying Treatment (DMT)|All patients with ≥ 1 medical or pharmacy claim for a DMT other than fingolimod. Among patients included in the study that those with ≥ 1 pharmacy or medical claim for any MS DMT during pre-index would be excluded.
32804972|NCT04390438|Experimental|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
33098203|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
32804973|NCT04390438|Experimental|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
32804974|NCT04390438|Active Comparator|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
32804975|NCT04843852|Experimental|Intervention - vaccination|"HEPLISAV-B is available in pre-filled, single-dose 0.5 mL vials. Each dose contains 20 μg of HBsAg and 3,000 μg of 1018 adjuvant. HEPLISAV-B is administered as an intramuscular injection in the deltoid region.~Study subjects randomized to the vaccine group will receive a total of 2 injections, each administered at least 4 weeks apart - the same dosing schedule recommended for hepatitis B prevention.~Once enrolled, participants will have study visits on days 0 (first injection), 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196."
32804976|NCT04843852|No Intervention|No vaccination|Participants randomized to the control group will have study visits on days 0, 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196.
32804977|NCT04840342|Experimental|Eplerenone Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
32804978|NCT04840342|Experimental|Amlodipine Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
32804979|NCT04390516|Other|COViage|Machine learning intervention
32804980|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
32804981|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;~Intervention:~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Intradermal injections of hair loss"
32804982|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Stem/Stromal Cell Isolation~Intradermal injections of hair loss"
32804983|NCT05027230|Experimental|Consecutive doses of low-dose of STSP-0601|
32804984|NCT05027230|Experimental|Consecutive doses of high-dose of STSP-0601|
32804985|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
32804986|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
32804987|NCT05028790|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
32804988|NCT05028790|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
32949388|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
32949389|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
32949390|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
33098204|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
33098205|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
33098206|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
33098207|NCT04693845|Active Comparator|Treatment as Usual|Community Mental Health Center Next Day Appointment clinic
33098208|NCT04693845|Experimental|Experimental|Collaborative Assessment and Management of Suicidality (CAMS)
33098209|NCT05141240||Ribociclib|Participants who initiated CDK4/6i therapy
33314024|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
33098210|NCT05141240||Palbociclib|Participants who initiated CDK4/6i therapy
32804989|NCT05025358|Experimental|LP-118|"The classic 3+3 design at dose levels of 50mg, 100mg, 200mg, 300mg, 400mg and 500mg will be implemented in this study."
32804990|NCT05021926|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 26
32804991|NCT05021926|Experimental|Comparator product|Juvéderm Voluma™ with lidocaine (Allergan, Inc)
32804992|NCT05026528|Experimental|Digital DSME/S|Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.
32804993|NCT05026528|No Intervention|Standard care|Control group continuing with regular standardized care.
32804994|NCT05024188|Experimental|Antibiotics + FMT|7 days of antibiotics- Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).
32804995|NCT05024188|Placebo Comparator|Placebo|7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).
32804996|NCT05029960|Experimental|Experimental|Brivaracetam at a dose of 50 mg twice daily for 6 months
32804997|NCT05028868||Large artery atherosclerosis(LAA)|
32804998|NCT05028868||Cardiogenic stroke(CS)|
32804999|NCT05028868||Penetrating artery disease(PAD)|
32805000|NCT05028868||Other etiology(OE)|
32805001|NCT05028868||undetermined etiology(UE)|
32805002|NCT05023876|Experimental|IASTM group|
32805003|NCT05023876|Experimental|Control Group|
33098211|NCT05141240||Abemaciclib|Participants who initiated CDK4/6i therapy
33098212|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
33098213|NCT00522912|Active Comparator|B|Regular epilation by another person
32805004|NCT04390594|No Intervention|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
32805005|NCT04390594|Experimental|Standard of Care + Nafamostat mesilate|"The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~Nafamostat mesilate"
32805006|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
32805007|NCT02843386|Other|B : Surveillance|Intensive surveillance
33098214|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
33098215|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
33098216|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
33098217|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
33098218|NCT05145803||College Students|"Collegiate students tested positive for SARS-CoV-2 by a molecular reference test (PCR test or antigen test) (index patients).~Collegiate students known to be contacts of the index patients."
33098219|NCT04694079|Experimental|Group 1, CMR-guided VT ablation|"Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
33098220|NCT04694079|Experimental|Group 2, CMR-aided VT ablation|"Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
33098221|NCT04694079|Active Comparator|Group 3, Electroanatomical guided ablation|Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.
33098222|NCT05146076|Experimental|telemedicine supervised group|physical training supervised by telemonitoring
33098223|NCT05146076|Active Comparator|institutional training|institutional training supervised by physiotherapist
33098224|NCT04693572||Parturients undergoing repeated caesarean sectiona|
33098225|NCT04696367||Patients with acute intra-abdominal pathology|Patients admitted to hospital with acute intra-abdominal pathology
33098226|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
33314025|NCT02528396|Experimental|BioChaperone insulin lispro|
33314026|NCT02528396|Active Comparator|Humalog®|
33314027|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
33098227|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
33098228|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
33098229|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
32805008|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
33314028|NCT03985319|Experimental|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
33098230|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
33098231|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
33098232|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
32805009|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
32805010|NCT05022082|Experimental|Chest Physiotherapy- Aspiration- Inhaler drugs group|The study group (n=21) will first receive chest physiotherapy (tapotement or vibration) and aspiration, followed by inhaler drug therapy.
32805011|NCT05022082|Other|Inhaler drugs- Chest Physiotherapy- Aspiration group|The control group (n=21) will be administered the inhaler drug routinely administered in the intensive care unit where the study is conducted and then receive chest physiotherapy (tapotement or vibration), then nasopharyngeal and oropharyngeal aspiration
32805012|NCT05026996|Experimental|Mild hepatic impairment patients|Participants with mild hepatic impairment
32805013|NCT05026996|Experimental|Healthy participants|Matched healthy participants with normal hepatic function
33098233|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
33098234|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
33098235|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
33098236|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
33098238|NCT05145998|Active Comparator|Control - Glucola|Glucola control beverage
33098239|NCT05145998|Experimental|Whole peas|Whole cooked peas in a 50 gram carbohydrate meal dose
33098240|NCT05145998|Experimental|Pea Flour|Pea flour in a 50 gram carbohydrate meal dose
33098241|NCT05145998|Experimental|Whole lentils|Whole cooked lentils in a 50 gram carbohydrate meal dose
33098242|NCT05145998|Experimental|Lentil flour|Lentil flour in a 50 gram carbohydrate meal dose
33098243|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
33098244|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
33314029|NCT03985319|Active Comparator|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
33314030|NCT01237028|Experimental|oral calcitriol|Calcio®
32805014|NCT05024422|Active Comparator|Administration of Cabergoline|one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
32805015|NCT05024422|Active Comparator|Administration of Vitamin B6|200 mg X 3 per day for a week
32805016|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
32805017|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
32805018|NCT05021614|Experimental|Treatment|Transcatheter Mitral Valve Repair with Valveclip®
32805019|NCT04272502|Experimental|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
32805020|NCT04272502|Experimental|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
32805021|NCT04272502|Experimental|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
33314031|NCT01237028|No Intervention|placebo|
32805022|NCT04758130|Experimental|App Group|Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
32805023|NCT04758130|Placebo Comparator|Placebo Group|Patients in this group are not provided with the clinic link to the application.
32805024|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)~Three weeks of washout to avoid additive effects on treatments to follow."
33098245|NCT05148377|Experimental|Sodium heparin (Heptar)|Sodium heparin (Heptar®) produced by Eurofarma Laboratory,
33098246|NCT05148377|Active Comparator|Liquemine®|Roche Lab's Liquemine®
33098247|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
33098248|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
33098249|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
33098250|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
33098251|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
33098252|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
33098253|NCT00524238|No Intervention|2|10 healthy controls
33314032|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
33314033|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
33314034|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app with motivational messages (A)|After study entry and baseline assessments, subjects will attend the one-month IDEA group sessions aimed at promoting physical activity and exercise. Participants randomly assigned to this study arm will use the smart band and the app with the motivation set enabled, allowing participants to receive the messages according to their compliance and adherence to the personalised prescriptions. After group sessions (week 4), study subjects will start receiving motivational messages up until the end of the trial (8 consecutive months).
33314035|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app without motivational messages (B)|Subjects will follow the same procedure as intervention A, with the difference that the app will have the motivation set disabled, therefore participants will not receive any messages regarding their compliance. After group sessions, study subjects will be expected to continue using the smart band and app up until the end of the trial (8 consecutive months).
32805025|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
32805026|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.~Three weeks of washout to avoid additive effects on treatments to follow."
32805027|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
32805028|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
32805029|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
32805030|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
32805031|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)~Three weeks of washout to avoid additive effects on treatments to follow."
32805032|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.~Three weeks of washout to avoid additive effects on treatments to follow."
32805033|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
32949391|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
32949392|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
32949393|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
32949394|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
32949395|NCT05701644|Experimental|C1K 150mg|Subcutaneous Administration C1K 150mg single or multi dose
32949396|NCT05701644|Experimental|C1K 300mg or placebo|Subcutaneous Administration C1K 300mg or placebo single or multi dose
32949397|NCT05701644|Experimental|C1K 600mg or placebo|Subcutaneous Administration C1K 600mg or placebo single or multi dose
32949398|NCT05701644|Experimental|C1K 900mg or placebo|Subcutaneous Administration C1K 900mg or placebo single or multi dose
32949399|NCT05701644|Experimental|C1K 1200mg or placebo|Subcutaneous Administration C1K 1200mg or placebo single or multi dose
33098254|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
33098255|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
33314036|NCT04857944|Sham Comparator|Fitness tracker + app without motivational messages (CG)|After study entry and baseline assessments, all patients assigned to the control group will receive both the app and the smart band, but the motivation set will be disabled. Study subjects will be expected to use the smart band and app up until the end of the trial.
33314037|NCT04831658|Experimental|Orelabrutinib combined with PD-1 and fotemustine|To observe the efficacy and safety of a new generation of BTK inhibitor abutinib combined with PD-1 and formustine in the treatment of newly-treated patients with primary central nervous system lymphoma (PCNSL)
33098256|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
33314038|NCT01240850|Active Comparator|Prednisone|
33098257|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
33098258|NCT05145920|Experimental|Pilot testing of an education program promoting effective parenting habit|Parents will receive a series of 5 short videos via Whatsapp
33098259|NCT04696250||Adverse Events associated with Antineoplastic and Immunomodulating Agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by anticancer drugs, with a chronology compatible with the drug toxicity
33098260|NCT05145842|Active Comparator|floroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
33098261|NCT05145842|Experimental|ultrasound+fluoroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
33098262|NCT00524433|Experimental|1|tezosentan
33098263|NCT00524433|Placebo Comparator|2|
33098264|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
33098265|NCT05142878|Experimental|Experimental: Static air support devices (Ultracore Repose®)|"Residents will be placed on a static air foam hybrid mattress during 14 days:~• Ultracore Repose® Mattress"
33098266|NCT05145647|Experimental|Add-on Brachytherapy|The evaluation for feasibility of surgery takes place 5-6 weeks after CCRT. Any subject whose tumor status is resectable at evaluation but declines surgical proposal will be eligible to be enrolled in the following study phase.
33098267|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
33098268|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
33314039|NCT01240850|Experimental|Methotrexate+Prednisone|
33314040|NCT04813016|Active Comparator|Early tramal/bupivacaine|patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.
33098269|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
33098270|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
33098271|NCT05141747|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
33098272|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
32805034|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
33314041|NCT04813016|Active Comparator|Late tramal/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
33098273|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
33098274|NCT05146154|Experimental|Pharmacokinetic cohort|After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
33098275|NCT05146154|Experimental|Safety cohort|After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
33098276|NCT00524667|Experimental|1|
33098277|NCT05145686|Experimental|Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis|The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
33314042|NCT04813016|Active Comparator|Early dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.
32738083|NCT05008029|Experimental|In situ immobilization|Immobilization without reducing the radius fracture and above-elbow casting.
32805035|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
32805036|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
32805037|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil~Three weeks of washout to avoid additive effects on treatment following."
32805038|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)~Three weeks of washout to avoid additive effects on treatments to follow."
32805039|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
32805040|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
32805041|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
32805042|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
32805043|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
32805044|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
32805045|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)~Three weeks of washout to avoid additive effects on treatments to follow."
32805046|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
32805047|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
32805048|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
32805049|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
32805050|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
32805051|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil~This is followed by a 3 week wash out period, to neutralize any additive effects."
32805052|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
32805053|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
32805054|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
32805055|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
33314043|NCT04813016|Active Comparator|Late dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
32805056|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
32805057|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
33098278|NCT05145686|Active Comparator|Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments|In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
33098279|NCT05145179|Experimental|HER2-expressing Solid Tumors|SSGJ-705 Administered via intravenous (IV) infusion
33098280|NCT04692987|Experimental|Intervention|Participants will receive decision-aid video
33314044|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
33098281|NCT04692987|No Intervention|Usual care|Participants will receive usual care
33098282|NCT05147870||Irrigation group|
32805058|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
32805059|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
33098283|NCT05147870||Suction only group|
33314045|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
33314046|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
33314047|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
33314048|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
33314049|NCT01237106|Experimental|In Vitro Maturation (IVM)|
33314050|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
33314051|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
33314052|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
33098284|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
33098285|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
33098286|NCT05142644||Early / growth restriction|Intrauterine growth restriction with onset before 32 weeks of gestation
33098287|NCT05142644||Late growth restriction|Intrauterine growth restriction with onset after 32 weeks of gestation
33098288|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
33098289|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
33098290|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
33098291|NCT05147519||Step 1|Step 1 will enroll participants aged 15-55 years who are vulnerable to contracting HIV. They will be evaluated every 12 weeks for HIV and other sexually transmitted infections (STIs).
33098292|NCT05147519||Step 2|Participants who are diagnosed with HIV will proceed to Step 2, with evaluation of viral load and other HIV-related tests every four weeks for 12 weeks and then every 12 weeks for a total of 48 weeks.
33314053|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
33314054|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
33314055|NCT04792112|Experimental|Guideline + decision support tool|A decision support tool summarizing harms and benefits of late preterm antenatal corticosteroids will be integrated into the clinical practice guideline available to clinicians in the hospitals in the experimental arm.
33314056|NCT04792112|No Intervention|Guideline only|Clinicians in the hospitals in the 'no-intervention' arm will have access to the standard guideline only (without the integrated decision support tool).
33314057|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
33314058|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
33314059|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
33314060|NCT01242410|No Intervention|Expectant Management|
33314061|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
33314062|NCT04770662|Other|research group|patients who are willing to participate in the study
32949400|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
33314063|NCT04742582|Active Comparator|Preterm Infants - fed fermented formula|Feeding infants with fermented formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
33314064|NCT04742582|Placebo Comparator|Preterm Infants - fed standard formula|Feeding infants with standard formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
33314065|NCT04742582|Other|Reference Group: Pre-term Infants - breastfed|The breastfeeding infants were the reference group
33314066|NCT01146392||1|Primary care patients with COPD diagnosis
33314067|NCT02655692|Placebo Comparator|Placebo|Saline dose
33314068|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
32949401|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
32949402|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
33314069|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
33314070|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
32738084|NCT05008029|Active Comparator|Reduction under general anesthesia|Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.
32949403|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
33314071|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
33314072|NCT01146470|Experimental|RGC 200 mg|
33314073|NCT01146470|Experimental|RGC 400 mg|
33314074|NCT01146470|Placebo Comparator|Placebo|
33314075|NCT04696640|Experimental|Remote Patient Monitoring|All participants who have successfully established remote data-sharing from their glucose monitors to the research team's Glooko account by conclusion of the one-month baseline period will advance to the six-month intervention period.
33314076|NCT04663100|Experimental|Pharmacist Coordinated care Oncology Model|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.
33314077|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
33314078|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
33314079|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
32949404|NCT03027414|Experimental|Substudy 1 Active and Sham|HVs that receive TMS over the right dlPFC
32949405|NCT03027414|Experimental|Substudy 2 Active and Sham|HVs that receive TMS over the right dlFPC
32949406|NCT03027414|Experimental|Substudy 3 Active and Sham|HVs will receive offline TMS to the lest IPS (FPN)
32949407|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
32949408|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
32949409|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
32949410|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
32949411|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
32949412|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
32949413|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
32949414|NCT05701566|Experimental|virtual reality group|unsedated colonoscopy using virtual reality headset.
32949415|NCT05701566|Active Comparator|colonoscopy with standard sedation|standard sedated colonoscopy.
32949416|NCT04764786|Experimental|EVOO+POLY|Acute test meal
32949417|NCT04764786|Active Comparator|OO-POLY|Acute test meal
32949418|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
32949419|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
32949420|NCT03583476||Concomitant therapy|Patients with concomitant therapy
32949421|NCT03583476||Sequential therapy|Patients with sequential therapy
32949422|NCT03583398||TAVI TAo|
32949423|NCT03583398||TAVI TF|
32949424|NCT03583398||AVR|
32949425|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
33098293|NCT05147519||Step 3|Participants who achieve and maintain viral suppression in Step 2 will proceed to Step 3 for continued HIV monitoring every 24 weeks to document maintenance of viral suppression and maintain engagement with the study site for potential future recruitment into interventional studies, including clinical trials of novel strategies to achieve HIV remission.
33098294|NCT05144360|Experimental|Atenas association|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Atenas, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan + amlodipine placebo, oral."
32805060|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
32805061|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
32805062|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
32805063|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
32805064|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
32805065|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
32805066|NCT05586646|No Intervention|control group|100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations
32805067|NCT05586646|Experimental|alanyl-glutamine group|100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).
32805068|NCT05586568|Experimental|XZP-3621 tablet and itraconazole oral liquid|
32805069|NCT05586568|Experimental|XZP-3621 tablet and Rifampicin capsules|
32805070|NCT05586568|Experimental|XZP-3621 tablet and esomeprazole tablet|
32805071|NCT01893814|Active Comparator|Probiotics|
32805072|NCT01893814|Placebo Comparator|Control|
32805073|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
32805074|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
32805075|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
32805076|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
32805077|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
32805078|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
32805079|NCT02651662|Experimental|Open label (cemiplimab)|Experimental cohorts will consist of multiple dose levels of cemiplimab administered intravenously (IV) every 2 weeks (Q2W)
32805080|NCT02651662|Experimental|Open label (cemiplimab and REGN1979)|Experimental cohorts will consist of a single dose level of cemiplimab administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)
32805081|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
32805084|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]) may continue on maintenance therapy and receive daily treatment with AG-120.
32805085|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
32805086|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
32805087|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
32805088|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
32805089|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
32805090|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
32805091|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
33098295|NCT05144360|Active Comparator|Empagliflozin + telmisartan + amlodipine|"The patient must take 3 tablets once a day, as follows:~1 tablet Atenas placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan + amlodipine, oral."
33098296|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
33098297|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
33098298|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
32805092|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
32805093|NCT02621476|Experimental|Usual care|Usual care
32805094|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
32805095|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
32805096|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
32805097|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
32805098|NCT02614534|Experimental|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
32805099|NCT02614534|Active Comparator|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
32805100|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
32805101|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
32805102|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
32805103|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
32805104|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
32805105|NCT02291848|Experimental|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
32805106|NCT02291848|Experimental|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
32805107|NCT02291848|Experimental|Group C|Patients with high risk MGUS or smoldering myeloma receiving a fixed dose TAA-Specific CTLs
33098299|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
33098300|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
33098301|NCT00525993|Experimental|A|
33098302|NCT00525993|Active Comparator|B|
33098303|NCT05147753|Experimental|Group|0.6 mg moxonidine daily
32805108|NCT05586412|Experimental|exercise therapy group|Exercise therapy group; joint range of motion exercises including the upper extremity, strengthening, stretching, isometric and posture exercise program will be given. These exercises are in the form of a home program and will be asked to do 2 sets a day, 5 days a week, and 10 repetitions of each movement for 4 weeks.
32805109|NCT05586412|Experimental|vagus stimulation group|To the patients in the vagus stimulation treatment group; Auricular vagus nerve stimulation in the physical therapy and rehabilitation unit, 20 sessions in total, 5 days a week, and 30 minutes each session. will be applied. Patients will be treated in the form of daily arrival and departure. Vagus nerve stimulation will be performed using a TENS device with specially designed ear-shaped surface electrodes, the size of which can be selected according to any size ear. The electrodes will be placed on the inner and outer surface of the tragus and the concha. Waveform biphasic asymmetrical, pulse duration less than 500 microseconds and frequency of 10 hertz for 30 minutes. been applied continuously throughout and the amplitude will be adjusted according to the sensory threshold level.
32805110|NCT05586412|Experimental|exercise-vagus stimulation group|Exercise and vagus stimulation treatment group; Both the applications made to the patients in the vagus stimulation group and the same exercises given to the patients in the exercise therapy group will be given as a home program. Patients in all groups will be evaluated with different parameters twice, before and after the treatment.
32805111|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
32805112|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
32805113|NCT04757818|Experimental|0.07% cetylpyridinium chloride (CPC) in mouthwash|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
32805114|NCT04757818|Placebo Comparator|Distilled water with the same colorant as the experimental product|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
32805115|NCT04758052|Experimental|simultaneous tracheostomy with gastrostomy (TSG)|This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
32805116|NCT04758052|No Intervention|non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)|"This arm include the patients who proceed with usual care placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard."
32805117|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
32805118|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
32805119|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
32805120|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
32805121|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
32805122|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
32805123|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
32805124|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
32805125|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
32805126|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
32805127|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
32805128|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
32805129|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
32805130|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
32805131|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
32805132|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
32805133|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
33098304|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
33098305|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
32805134|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
32805135|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
32805136|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
32805137|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
32805138|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
32738085|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
32738086|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
32805139|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
32805140|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
32805141|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.~- Lenalidomide Oral, Daily for 21 days of each cycle"
32805142|NCT02514382|Experimental|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32805143|NCT04271800|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
33098306|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
33098307|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
33098308|NCT05140967|Experimental|High Intensity Interval Training (A)|Exercise training with intermittent bouts of high intensity
33098309|NCT05140967|Experimental|Moderate Intensity Continous Training (B)|Exercise training with constant workload
33098310|NCT02947815|Experimental|NABOTA|Single-dose
33098311|NCT02947815|Active Comparator|BOTOX|Single-dose
33098312|NCT05147285|Experimental|Stabilization group|Only stabilization exercises in patients with cystic fibrosis
33098313|NCT05147285|Experimental|combined group|stabilization exercise and aerobic exercise training in patients with cystic fibrosis
33098314|NCT05147285|Experimental|control group|physical activity recommendations in patients with cystic fibrosis
33098315|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
33098316|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
33098317|NCT04693299||Study cohort|"Inclusion criteria:~Outpatient and hospitalized patients, adults, candidates for colonoscopy for any pathology, as part of the normal care process, with the need to repeat bowel preparation due to inadequate cleansing.~Exclusion criteria:~Emergency regime~Inability to obtain consent~Refusal of the patient"
33098318|NCT00507260|Experimental|Control Group|Control Group (Food Record)
33098319|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
33098320|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
33098321|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
33098322|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
33098323|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
33098324|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
33098325|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
33098326|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
33098327|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
33098328|NCT05140031|Active Comparator|Usual care|Participants will initially undergo 2 weeks of usual care.
33098329|NCT05140031|Experimental|PNE4Adults|Participants will undergo 2 sessions (1-2 weeks) where they will be introduced to the PNE4Adult board.
33098330|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
33098331|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
33098332|NCT05147012||control group|
33098333|NCT05147012||focus group|
33098334|NCT04693104|Experimental|PVA Hydrogel|PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection
33098335|NCT04693104|Active Comparator|Synvisc-One®|Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection
32805144|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
32805145|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
32805146|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
33098336|NCT05146934||Hormone sensitive group|Prednisone, 0.5mg/kgqd, 3-6months
33098337|NCT05146934||Hormone insensitivity group|Prednisone, 0.5mg/kgqd, 3-6months
33098338|NCT05146895|Experimental|Local Hyperthermia at 44℃ for falt warts|Local hyperthermia at 44℃ for 30 mins on one lesion region, at days of 1,2,3, 15, 16, 21 and 28.
32805147|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
32805148|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32805149|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32805150|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32805151|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
32805152|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
32805153|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
32805154|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
32805155|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
32805156|NCT04757974|Experimental|Part 1: Treatment sequence ABC|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
32805157|NCT04757974|Experimental|Part 1: Treatment sequence BCA|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
32805158|NCT04757974|Experimental|Part 1: Treatment sequence CAB|Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
32805159|NCT04757974|Experimental|Part 1: Treatment sequence ACB|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
32805160|NCT04757974|Experimental|Part 1: Treatment sequence BAC|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
32805161|NCT04757974|Experimental|Part 1: Treatment sequence CBA|Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
32805162|NCT04757974|Experimental|Part 2: Treatment sequence DE|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.
32805163|NCT04757974|Experimental|Part 2: Treatment sequence ED|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.
32805164|NCT04757506|Placebo Comparator|Placebo|cellulose-filled capsule
32805165|NCT04757506|Experimental|Naltrexone|single 50 mg oral dose naltrexone (capsule)
32805166|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
33098339|NCT05146895|Active Comparator|Imiquimod for Flat Warts|Miquimod treatment: 3 times a week for 1 month
33098340|NCT02947776|Active Comparator|USUAL|Usual care
33098341|NCT02947776|Experimental|PEER|Usual care + peer-befriending
33098342|NCT05143073|No Intervention|No educational materials|No educational materials will be provided.
33098343|NCT05143073|Active Comparator|Alcohol use disorder and strategies to reduce risk|The information provided to participants will be related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies. The content is based on information from National Institute of Alcohol Abuse and Alcoholism websites, Mayo Clinic websites, and the National Survey on Drug Use and Health.
32805167|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
33098344|NCT05143073|Active Comparator|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk|The information provided to participants will explain polygenic risk scores by discussing genetic variation, risk variants, how polygenic scores are created, and how they can be interpreted. The participants will also receive the same information related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies.
32738087|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
32805168|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
32805169|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
32805170|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
32805171|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
33098345|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
33098346|NCT05146856||Control|Residents in control group have a usual day with clinical activity before night shift
33098347|NCT05146856||Intervention|Residents in intervention group have a day off clinic before night shift (i.e day off or day with university activity)
33098348|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
33098349|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
33098350|NCT05148338|Experimental|Risk intervention group|Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea.
33098351|NCT05148338|Active Comparator|Control group|Standard of care. Treatment by cardiologist conform existing guidelines.
33098352|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
33098353|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
33098354|NCT00524823||2|10 patients with benign growth
33098355|NCT00524823||3|10 health volunteers
33098356|NCT00524823||4|10 patients diagnosed with other cancer
33098357|NCT05144243|Experimental|Venetoclax in Combination with Azacitidine|Participants will receive oral tablet venetoclax dose ramp-up only in Cycle 1 Days 1-3 until target dose is reached. Particpants will then receive oral tablet venetoclax at the target dose every day (QD) on Cycle Days 1 - 28 plus Azacitidine through subcutaneous injection (SC) QD on Cycle Days 1 - 7 (28-day cycle).
33098358|NCT00524862|Other|1|
33098359|NCT00524862|Other|2|
33098360|NCT05146817|Active Comparator|Traditional oral care in long-term mechanical ventilation ICU patients|Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
33098361|NCT05146817|Experimental|Original oral care protocol in long-term mechanical ventilation ICU patients|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine .
33098362|NCT02946450||Not applicable-observational study|Not applicable-observational study
33098363|NCT05149703|Experimental|Mezieres Group|This intervention includes a total of three postures of the Mézières therapy. Specifically, the postures maintained for 12 weeks consist of: supine dancer; in supine position with the upper extremities abducted 120 °; and dancer in a sitting position.
33098364|NCT05149703|Active Comparator|Isostretching Group|This study aims to follow a total of 6 isostretching postures, the most similar to the Mezieres method. In each of the isostretching positions, if it is symmetric, 3, 6 or 9 repetitions will be performed and if it is asymmetric, 2, 4, or 8 repetitions.
33098365|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
33098366|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
33098367|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
33098368|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
33098369|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
33098370|NCT04692792|Placebo Comparator|Placebo drink|
33098371|NCT04692792|Experimental|Dai Dai flower drink|
33098372|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
33098373|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
33098374|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
33098375|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
33098376|NCT05148104||Patients receiving shoulder arthroplasty|Patients receiving shoulder arthroplasty that have an intact glenoid prior to the procedure. Ideally the glenoid surface should be visible and intact during imaging.
33098377|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
33098378|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
33098379|NCT00524979||Mentally healthy|People who have no mental disease
33098380|NCT05145608|Active Comparator|Test- Lamotrigine ER Tablets USP 50mg|Single dose of Test- Lamotrigine ER Tablets USP 50mg will be administered
32805172|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
32805173|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
32805174|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
32805175|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
32805176|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
32805177|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
32805178|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Randomization (1:1)~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
32805179|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
32805180|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
32805181|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805182|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805183|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805184|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805185|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805186|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
33098381|NCT05145608|Active Comparator|Reference- Lamictal® XRTM ER tablet 50mg|Single dose of Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg will be administered
33098382|NCT05143034|Experimental|TCI66207 Essence|Essence
33098383|NCT05143034|Placebo Comparator|Placebo Essence|
33098384|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
33098385|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
33098386|NCT05146349|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
33098387|NCT05146349|No Intervention|Control|The control group does not receive the full set of RETAIN intervention activities.
33098388|NCT05146232|Active Comparator|Opioid free group|After induction of aesthesia, anesthesia maintained by sevoflurane and continuous unfusion of lidocaine, ketamine, dexmeditomedine and Paracetamol.
33098389|NCT05146232|Active Comparator|Opioid based group|After induction of aesthesia, anesthesia maintained by continuous remifentanyl infusion
33098390|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
33098391|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
33098392|NCT05142176|Placebo Comparator|control group|will receive general anesthesia with bilateral sham erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg normal saline on each side.
33098393|NCT05142176|Active Comparator|Erector spinae plane block group|will receive bilateral ultrasound-guided erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg.
33098394|NCT00525213|Active Comparator|A|
33098395|NCT00525213|Active Comparator|B|
33098396|NCT00525213|Active Comparator|C|
33098397|NCT00525213|Placebo Comparator|D|
33098398|NCT05149664|Experimental|VibratoSleeve TUS|Subjects will receive 30 TUS treatments, each one lasting 90 minutes on the calf of a leg with peripheral arterial disease.
33098399|NCT04693026|Experimental|Group A: Remdesivir + Baricitinib treatment group|"Remdesivir (Injectable solution):~A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Baricitinib (oral tablet form):~Baricitinib tablets 4 mg/day for 2 to 4weeks"
33098400|NCT04693026|Active Comparator|Group B: Remdesivir + Tocilizumab treatment group|"Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Tocilizumab (Injectable solution):~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
33098401|NCT05140889||Group 1|Children with severe asthma
32805187|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
33314080|NCT03913676|Experimental|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
33314081|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
32805188|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
32805189|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
33098402|NCT05140889||Group 2|Children who undergo chest CT scan for other reasons than asthma
33314082|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
33314083|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
33314084|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
33314085|NCT03913520|Other|Congenital Heart Disease|Undergoing evaluation at 30 days
33314086|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
33314087|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
33314088|NCT01147484|Experimental|Foretinib|
33314089|NCT00316589|Experimental|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
33314090|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
33314091|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
33314092|NCT03913364|Experimental|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
33314093|NCT03913364|Placebo Comparator|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
33314094|NCT03913364|Experimental|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
33314095|NCT03913364|Placebo Comparator|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
33314096|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
33314097|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
33314098|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
33314099|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
33314100|NCT03916640|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
33314101|NCT03916640|Active Comparator|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
33314102|NCT03916640|Active Comparator|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
33314103|NCT03916250|Experimental|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314104|NCT03916250|Experimental|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314105|NCT03916250|Experimental|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314106|NCT03916250|Experimental|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314107|NCT03916250|Experimental|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314108|NCT03916250|Experimental|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
33314109|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
33314110|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
33314111|NCT03916328|Active Comparator|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
33314112|NCT03916328|Experimental|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
33314113|NCT03916328|Experimental|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
33314114|NCT03916562|Experimental|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
33314115|NCT03916562|Experimental|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
33314116|NCT03916406|Experimental|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
32738088|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
32738089|NCT05008263||Patients with viral chronic liver disease at primary diagnosis|Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.
32738090|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
33314117|NCT03916406|Experimental|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
33314118|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
33314119|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
33314120|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
33314121|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
33314122|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
33314123|NCT03916172|Experimental|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
33314124|NCT03916172|No Intervention|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
33314125|NCT03912974|Active Comparator|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
33314126|NCT03912974|Placebo Comparator|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
33314127|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
33314128|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
33314129|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
33314130|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
33314131|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
33314132|NCT03912896|Experimental|Children with autism spectrum disorder|
33314133|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
33314134|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
33314135|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
33314136|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
33314137|NCT00316199|Experimental|A|
33314138|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
33314139|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
33314140|NCT01573208|Experimental|Register|Register
33314141|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
33314142|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
33314143|NCT03985553|Other|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
33314144|NCT03913052|Experimental|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
33098403|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
33098404|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
33098405|NCT05143970|Experimental|IPH5301 administration|"Part I- Dose escalation:~Escalating dose levels of IPH5301 will be evaluated.~Part II-Cohort Expansion:~IPH5301 will be administrated in combination with trastuzumab and paclitaxel"
33098406|NCT05149625|Experimental|Dexcom G6|
33098407|NCT05149625|No Intervention|Traditional self-blood glucose measurement|
33098408|NCT00526266|Experimental|1|
33098409|NCT00526266|Placebo Comparator|2|
33098410|NCT00526266|No Intervention|3|No Treatment
33098411|NCT04692753||Pre-intervention|baseline data prior to training and education of health care workers. Intervention: intensive training and education of workers for maintenance of venous access devices.
33314145|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
33314146|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
33098412|NCT04692753||Post intervention|observation after training and education of health care workers
33314147|NCT03916016|Experimental|Intervention Group|The intervention group received enhanced integrated behavioral health care.
33314148|NCT03916016|Active Comparator|Control Group|The control group received care as usual only.
33314149|NCT03915938|Experimental|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
33314150|NCT03915938|Placebo Comparator|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
32738091|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
33314151|NCT03915782|Experimental|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
33314152|NCT03915782|Sham Comparator|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
33314153|NCT01237496|Experimental|1|
33314154|NCT03915704|Experimental|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
33314155|NCT03915704|Experimental|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
33314156|NCT03915704|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
33098413|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
33098414|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
33314157|NCT01251458|Experimental|Torisel|
33314158|NCT01416428|Experimental|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
33314159|NCT01416428|Experimental|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
33314160|NCT00316121|Experimental|1|
33314161|NCT00316121|Active Comparator|2|
33314162|NCT03912740|Active Comparator|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
32738092|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
32738093|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
33314163|NCT03912740|Active Comparator|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
33314164|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
33314165|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
32738094|NCT05016375||T2DM|Individuals with T2DM.
32738095|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
32738096|NCT03325049|Active Comparator|Control Arm|Usual Care
32805190|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
32805191|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
32805192|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
32805193|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
33314166|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
33314167|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
33314168|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~day 0~when leaving intensive care unit~month 3~month 12"
33314169|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
33314170|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
33314171|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
33314172|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
32805194|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32805195|NCT02420314|Experimental|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
33314173|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
33314174|NCT03912116|Experimental|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
32805196|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
32805197|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
32805198|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
32805199|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
32805200|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
33314175|NCT03912116|Placebo Comparator|Saline Injection|8cc saline
33314176|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
33314177|NCT01144832|Placebo Comparator|placebo capsule|
33314178|NCT01144832|Active Comparator|ebastine|
33314179|NCT01147952|Experimental|12 week exercise training|
32805201|NCT01539291|Experimental|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
32805202|NCT01539291|Experimental|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
32805203|NCT04746040|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
33314180|NCT01147952|No Intervention|Conventional Care|
33314181|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
33314182|NCT01251848|Active Comparator|Treatment A|
33314183|NCT01251848|Active Comparator|Treatment B|
33314184|NCT01251848|Experimental|Treatment C|
33098415|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
33314185|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
33098416|NCT05147090|Active Comparator|Empagliflozin group|Empagliflozin 10mg daily for 156 weeks
33098417|NCT05147090|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 156 weeks
33098418|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
33098419|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
33098420|NCT05149391|Experimental|C-CAR039|Autologous C-CAR039 administered by intravenous (IV) infusion
33098421|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
33098422|NCT05146193||All subjects are diagnosed of having a spinal deformity|Routine care of patients with spinal deformities
32805204|NCT04746040|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
33098423|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
33098424|NCT05149274|Active Comparator|Part1|DWP14012 Tablet A : single/multiple dose, 1 group, 2 period study
33098425|NCT05149274|Active Comparator|Part2|DWP14012 Tablet A 4T vs DWP14012 Tablet B 1T
33314186|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
33314187|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
33314188|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
33314189|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
32805205|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
33314190|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
33314191|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
33314192|NCT03911804|Experimental|Bolus group|
32805206|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
32805207|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32805208|NCT02398240|Experimental|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
33098426|NCT02947464|Active Comparator|Control|Standard clinical practice
33098427|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
33098428|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
33314193|NCT03911804|Active Comparator|Infusion group|
33098429|NCT00525291|Active Comparator|EMG-biofeedback alone|
33098430|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
33098431|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
33098432|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
33098433|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
33098434|NCT04696016|Experimental|Skin conductance guided|Sufentanil is titrated by the intensive care team to maintain skin conductance in target
33098435|NCT04696016|Active Comparator|Standard care|Sufentanil is titrated at the discretion of the intensivist
33098436|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
33314194|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
33314195|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
33314196|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
33098437|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
33098438|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
33098439|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
33098440|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
33314197|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
32805209|NCT02398240|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
32805210|NCT02398240|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
32805211|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
32805212|NCT02022280|Placebo Comparator|Vitamin pill|
32805213|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
32805214|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
32805215|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
32805216|NCT02364310|No Intervention|Best medical care|Best medical care
32805217|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
32805218|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
32805219|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
32805220|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
32805221|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
32805222|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
32805223|NCT01543503||Cohort|
32805224|NCT01511055|Experimental|Folate-FITC|
32805225|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
32805226|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
32805227|NCT02362438|Experimental|10X|Highest dose in the escalation scheme
32805228|NCT02362438|Experimental|1X|Lowest dose in the escalation scheme
32805229|NCT02362438|Experimental|3.3X|2nd dose increase in escalation scheme
32805230|NCT02362438|Experimental|5X|3rd dose increase in escalation scheme
32805231|NCT02355340||DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
32805232|NCT02347540||Women with a history of preeclampsia (cases)|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
32805233|NCT02347540||Women with a history of uncomplicated pregnancy (controls)|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
32805234|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
32805235|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
32805236|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
32805237|NCT02315716|Active Comparator|Autologous Stem Cell Transplant (ASCT)|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
32805238|NCT04757428|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
32805239|NCT04757428|Active Comparator|Hybrid nanoceramic|The intervention will be: Prosthetic endocrown
32805240|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
32805241|NCT01537887|Experimental|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
32805242|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
33314198|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
33314199|NCT01148030||Single|3M Skin and Nasal Antiseptic
33314200|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
33314201|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
33314202|NCT01252160|Experimental|QUTENZA|Cutaneous patch
33314203|NCT00337103|Experimental|1|
33314204|NCT00337103|Active Comparator|2|
33314205|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
33314206|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
33314207|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
33314208|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
33314209|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
33314210|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
33314211|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
33314212|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
33314213|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
33314214|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
33314215|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
33314216|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
33314217|NCT03915080|Other|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
33314218|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
33314219|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
33314220|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
33314221|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
33314222|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant
33314223|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group C)|Patients receiving CTLs following allogeneic stem cell transplant
33314224|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
33314225|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
33314226|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
33314227|NCT00075504|Experimental|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
33314228|NCT01092390|Experimental|Lovaza|4 grams per day
33314229|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
33314230|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
33314231|NCT01092624|Experimental|Pessary and solifenacin|
33314232|NCT01092624|Placebo Comparator|Pessary and placebo|
33314233|NCT03957096|Experimental|SGN-CD47M|
33314234|NCT00087438|Experimental|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
33314235|NCT00321464|Active Comparator|zoledronic acid|
33314236|NCT00321464|Experimental|denosumab|
33314237|NCT02889796|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
33314238|NCT02889796|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
33314239|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
33314240|NCT02889796|Experimental|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
33314241|NCT02889796|Experimental|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
33314242|NCT02889796|Placebo Comparator|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
33314243|NCT03911258|Experimental|Nasal flora in CF patient|
32949426|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
32949427|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
32949428|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
32949429|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
33314244|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
33314245|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
33314246|NCT03911024|Active Comparator|HIV|
33314247|NCT03911024|Placebo Comparator|General Health|
33314248|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
33314249|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
33314250|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
33314251|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
33314252|NCT03911180|Experimental|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
33314253|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
33314254|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
33314255|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
33314256|NCT01252394||Hemodialysis patients|
33314257|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
33314258|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
33314259|NCT03910790|Experimental|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
33314260|NCT03908762|Experimental|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose <70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
33314261|NCT03908762|Active Comparator|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured <70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
33314262|NCT03910634|Experimental|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
33314263|NCT03910634|Placebo Comparator|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
33314264|NCT03910712|Experimental|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32805243|NCT04757350||cataract|Research subjects should meet the following criteria: Signed and dated informed consent form Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research 18-90-year-old cataract patients or patients after cataract surgery
32805244|NCT04757194|Experimental|Intervention|Calculation of risk assessment score by machine learning algorithm and display of risk assessment information to dispatch nurses. Staff encouraged but not required to comply with suggested ranking.
32805245|NCT04757194|No Intervention|Control|Ambulance dispatch per standard of care
32805246|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
33314265|NCT03910712|Active Comparator|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
33314266|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
33314267|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
33314268|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
33314269|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
33314270|NCT02528474|Experimental|Pantera Lux|
33314271|NCT02528474|Active Comparator|SeQuent Please|
33314272|NCT03908606|Experimental|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
33314273|NCT03908606|Experimental|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
33314274|NCT03908606|No Intervention|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
33314275|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
33314276|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
33314277|NCT03344458|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
33314278|NCT03914924|Active Comparator|Exercise Program|Ex: The participants will be submitted to only exercise sessions for 12 weeks.
33314279|NCT03914924|Experimental|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to exercise sessions and education classes for 12 weeks.
33314280|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
33314281|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
33314282|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
33314283|NCT03910322|Placebo Comparator|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
33314284|NCT03910322|Experimental|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
33314285|NCT03910322|Experimental|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
33314286|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
33314287|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
33314288|NCT01148186|No Intervention|Wait-list group|
33314289|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
33314290|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
33314291|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
33314292|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
33314293|NCT03768544|Experimental|Self-help guided by a lay provider|
33314294|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
33314295|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
33314296|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
33314297|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
33314298|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
32830892|NCT01963078|Placebo Comparator|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
32830893|NCT01963078|Experimental|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
33098441|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
33098442|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
33098443|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
33098444|NCT05148221|Experimental|A three-week tailored, virtual exercise intervention.|A three-week tailored, virtual exercise intervention.
32830894|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
33098445|NCT00526344||1|Subjects with complete remission of asthma
33098446|NCT00526344||2|Subjects with symptomatic remission of asthma
33098447|NCT00526344||3|Subjects with asthma
33098448|NCT00526344||4|Healthy controls
33098449|NCT05143268||A|In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion. Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
33098450|NCT05143268||B|In the standard arm (arm B), patients will be treated with standard of care treatment.
33098451|NCT00526383|Experimental|A|antidepressant versus medical dispositive
33098452|NCT00526383|Placebo Comparator|B|
33098453|NCT05145257|Other|Elix Cycle Balance|Elix Cycle Balance supplement
33098454|NCT00525408|Experimental|2|Docetaxel+Mw
33098455|NCT00525408|Active Comparator|1|Docetaxel
33098456|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
33098457|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
33098458|NCT00525447|Experimental|1|
33098459|NCT05149976|Experimental|Experimental group|Patients scheduled for VFSS testing
33098460|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
33098461|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
33098462|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
33098463|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
33098464|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
33098465|NCT03452813||ischemic stroke or intracerebral hemorrhage patients|patients discharged from hospital to home or discharged to rehab will be called at 30 day and 90 day to monitor their transition of care outcomes.
33098466|NCT00525564|Placebo Comparator|A|Placebo diskus
33098467|NCT00525564|Active Comparator|B|Salmeterol diskus powder
33098468|NCT03453710|Active Comparator|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
33098469|NCT03453710|Active Comparator|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
33098470|NCT04693143|Other|Parenteral Nutrition for Critically Ill Children|Total Parenteral Nutrition for critically ill children
33098471|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
33098472|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
33098473|NCT04692909|Active Comparator|Active|Active dTMS
33098474|NCT04692909|Placebo Comparator|Placebo|Placebo dTMS
33098475|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
33098476|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
33098477|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
33098478|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
33098479|NCT00525642|Experimental|A|six cycles of adjuvant TAC
33098480|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
33098481|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
33314299|NCT03910010|Experimental|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
33314300|NCT03910010|No Intervention|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
33314301|NCT03910010|No Intervention|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
33314302|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
33314303|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
32949430|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
33314304|NCT04689880||XLIF Decade Plate|
33314305|NCT03914768|Experimental|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
33314306|NCT03915236|Experimental|Group 1: MON4STRAT Strategy|
33314307|NCT03915236|Active Comparator|Group 2: Conventional treatment|
33314308|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
33314309|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
33314310|NCT03914690|Experimental|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
32949431|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
32949432|NCT05701488|Experimental|Durvalumab + Tremelimumab (Arm A)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~Cycle 1:~Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~Day 28 of 28 Day cycle: Pre-determined dose of Durvalumab~Participants will undergo surgery on day 49 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
32949433|NCT05701488|Experimental|Durvalumab + Tremelimumab + SIRT (Arm B)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~Cycle 1:~Day 3 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~Day 31 of 28 Day Cycle: Pre-determined dose of Durvalumab~Day 1 of 28 Day Cycle: Yttrium-90~Participants will undergo surgery on Day 52 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
32949434|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
32949435|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
32949436|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
32949437|NCT05701410|Experimental|Study group|Patients with a history of lumbar spinal stenosis.
32949438|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
32949439|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
32949440|NCT05703126|Other|The study group|The study group will include patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom in the course of chemotherapy treatment after the next course of treatment a decrease in global longitudinal strain of 15% or more relative to the initial values will be revealed.
32949441|NCT05703126|Other|The control group|The control group will consist of patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom no signs of myocardial disease will be detected during chemotherapy. and endothelial dysfunction.
32949442|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
32949443|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
33314311|NCT03914690|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
33314312|NCT03914456|Experimental|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
33314313|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
33314314|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
33314315|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
32830895|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
32830896|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
32830897|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
32830898|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
32830899|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
32830900|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
32830901|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
32830902|NCT05234892||EVAR group|All consecutive eligible patients submitted to EVAR by Alto Endovascular AAA implantation will be included in analysis. Patients will be submitted to EVAR procedures on the basis of their own preferences, anatomical features, and operators experience.
32830903|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
32830904|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
32830905|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
32830906|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
32830907|NCT04349176|Experimental|Group A 100U|
32830908|NCT04349176|Experimental|Group A 155U|
32830909|NCT04349176|Experimental|Group B 100U|
32830910|NCT04349176|Experimental|Group B 155|
32949444|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
33098482|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
32830911|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
32830912|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
32830913|NCT04329546||Cases|Cases are patients with COVID-19.
32830914|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
32830915|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Long axis, in-plane needle:~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
33314316|NCT04612738|Active Comparator|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.~Other names; previously name My Gift of Grace"
32949445|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
32949446|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
32949447|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
32949448|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
32949449|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
32949450|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
32949451|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
32949452|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
32949453|NCT03159234|Other|Diabetic pregnant women|
32949454|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
32949455|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
32949456|NCT05628246|Active Comparator|In-person|Face to face at OPD
32949457|NCT05628246|Experimental|Telemedicine|Telemedicine
32949458|NCT05701332|Experimental|BCG|6 doses of intravesical BCG
32949459|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
32949460|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
32949461|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
32949462|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
32949463|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
32949464|NCT05622006|Experimental|Control condition|Control condition: Sitting from 8 am until 3pm.
32949465|NCT05622006|Experimental|Condition 1|Condition 1: 35 minutes of treadmill walking followed by sitting until hour 7 is reached
32949466|NCT05622006|Experimental|Condition 2|Condition 2: 2.5 minutes of treadmill walking for every 30 minutes until hour 7 is reached.
32949467|NCT05622006|Experimental|Condition 3|Condition 3: 5 minutes of treadmill walking every 60 minutes, until hour 7 is reached.
32949468|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
32949469|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
32949470|NCT03154866|Placebo Comparator|Placebo|
32949471|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
32949472|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
32949473|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
32949474|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
32949475|NCT05703048|Experimental|dexmedetomidine group|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
32949476|NCT05703048|Active Comparator|Esmolol group|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
32949477|NCT05702970|Active Comparator|Ferric Carboxymaltose|Control Group
32949478|NCT05702970|Experimental|Sucrosomial iron|Experimental arm 1
32949479|NCT05702970|Experimental|Sucrosomial iron and vitamin D|Experimental arm 2
32949480|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
32949481|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
32949482|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
32949483|NCT05701176|Experimental|[18F]F-AraG PET procedures|All patients will undergo a total of 3 [18F]F-AraG PET scanning procedures at T=0, T=2 weeks and T=6 weeks.
32949484|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
32949485|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
32949486|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
32949487|NCT03028740|Placebo Comparator|Placebo|Participants received cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
32949488|NCT03028740|Experimental|Cenicriviroc 150 mg|Participants received cenicriviroc, 150 milligrams (mg), tablet, orally, once daily for up to approximately 40 months.
32949489|NCT03733626|Active Comparator|ViviGen® Cellular Bone Matrix|20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system
32949490|NCT03733626|Placebo Comparator|Local Bone Autograft|20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system.
32949491|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
32949492|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
32949493|NCT05701020|Experimental|Adult women with an abnormal pap test|
32949494|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
32949495|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
32949496|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
32949497|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
32949498|NCT05252520|Experimental|JNJ-77474462|Participants will receive a single subcutaneous (SC) Dose 1 of JNJ-77474462 on Day 1 in Cohort 1, a single SC Dose 2 of JNJ-77474462 on Day 1 in Cohort 2 and a single SC Dose 3 of JNJ-77474462 on Day 1 in Cohort 3.
32949499|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
32949500|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
32949501|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
32949502|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
32949503|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
32949504|NCT01670994|Experimental|ALT-801|
32949505|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
32949506|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
32949507|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
32949508|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
32949509|NCT05608902||DOCTOBA cohort|Patients > 18 years of age with suspected basal cell carcinoma requiring biopsy or skin resection in the dermatology department
32949510|NCT03154398||1|case control
32949511|NCT03156972|Active Comparator|Group a|
32949512|NCT03156972|Active Comparator|Group b|
32949513|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
32949514|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
32949515|NCT05238324|Experimental|HMI-203 Low Dose Level Cohort 1|
32949516|NCT05238324|Experimental|HMI-203 Intermediate Dose Level Cohort 2|
32949517|NCT05238324|Experimental|HMI-203 High Dose Level Cohort 3|
32949518|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
32949519|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
32949520|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
32949521|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
33098483|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
32949522|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
32949523|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
32949524|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
32949525|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
32949526|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
32949527|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
32949528|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
32949529|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
32949530|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
32949531|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
32949532|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
32949533|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;~no blood transfusion requirement;~base deficit < 5 mEq/L;~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
32949534|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
32949535|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
32949536|NCT01671774|Experimental|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
32949537|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
32949538|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
32949539|NCT01671774|Active Comparator|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
32949540|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
32949541|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
32949542|NCT05564208|Experimental|Elafibranor Fasting then Elafibranor fed|Participants will receive Elafibranor 80 mg in Fasting State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fed State on Day 1 of Period 2.
32949543|NCT05564208|Experimental|Elafibranor Fed then Elafibranor fasting|Participants will receive Elafibranor 80 mg in Fed State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fasting State on Day 1 of Period 2.
32949544|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
32949545|NCT01672086||Stelkast Surpass Patients|
32949546|NCT01672164||Liver Transplant Recipients|
32949547|NCT04529070|Experimental|Intervention + Standard of care|Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.
32949548|NCT04529070|Active Comparator|Standard of care|Standard of Care Sleep Hygiene handout alone.
32949549|NCT04472598|Experimental|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
32949550|NCT04472598|Active Comparator|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
32949551|NCT05153304|Experimental|anti-PD1 and personalized vaccine|
32949552|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
32949553|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
32949554|NCT05547750|Experimental|vitamin K2 arm|The vitamin K2 arm takes vitamin K2 180 μg/day at bedtime for 8 weeks.
32949555|NCT05547750|Placebo Comparator|Placebo|The placebo group takes a placebo at bedtime for 8 weeks.
32949556|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
32949557|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
32949558|NCT04370106|No Intervention|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
33098484|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
33098485|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
33098486|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
33098487|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
33098488|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
33098489|NCT04692636||Total study cohort|Patients with dysfunctional hemodialysis vascular access referred for PTA or patients who received maintenance hemodialysis will be prospectively enrolled.
33098490|NCT02955095|Experimental|Current cigarette smoker|
33098491|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
32949559|NCT04370106|Other|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
33314317|NCT04612738|Active Comparator|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
32949560|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
33314318|NCT04612738|Placebo Comparator|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
32949561|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
32949562|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
32949563|NCT04317612|Active Comparator|Active berry product|Once daily consumption over the period of the study
32949564|NCT04317612|Placebo Comparator|Reference product|Once daily consumption over the period of the study
32949565|NCT05463198|Experimental|Blood Loss|
32949566|NCT04296006|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
32949567|NCT04296006|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
32949568|NCT04244682|Other|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
32949569|NCT04200768|Other|Standard|Standard of care
32949570|NCT04105842|Experimental|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
32949571|NCT04404816|Experimental|Group 1|premature infants born < 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 <0.4
32949572|NCT04404816|Experimental|Group 2|premature infants born < 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
32949573|NCT04077372|Experimental|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
32949574|NCT04077372|Active Comparator|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
32949575|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
32949576|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
32949577|NCT01672398|No Intervention|Usual Care Group|Usual Care
32949578|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
33098492|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
33098493|NCT00508313||With Lung Cancer|Patients with lung cancer.
33098494|NCT00508313||Healthy Participants|Healthy participants without cancer.
33098495|NCT02945982|Placebo Comparator|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
33098496|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
33098497|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
33098498|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
33098499|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
33314319|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
32830916|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach~Short axis, out-of-plane needle:~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
33314320|NCT03914534|Experimental|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
33314321|NCT03914534|Active Comparator|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
32830917|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Oblique axis, in-plane needle:~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
32830918|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
32830919|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
32830920|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)<25 kg/m^2 in the baseline study
32830921|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI>25kg/m^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
32830922|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI>25kg/m^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
32830923|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
32830924|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
32830925|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
32830926|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
32830927|NCT03264612|No Intervention|Non swimming group|no intervention
32830928|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
32830929|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
32830930|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
32830931|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
32830932|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
32830933|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
32830934|NCT03264846||Group 1|PCOS participants with periodontitis
32830935|NCT03264846||Group 2|PCOS participants with periodontally healthy
32830936|NCT03264846||Group 3|systemically healthy participants with periodontitis
32830937|NCT03264846||Group 4|systemically and periodontally healthy participants
32830938|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
32830939|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
32830940|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
32830941|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
32830942|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
32830943|NCT02458872|No Intervention|Control Arm|Usual care.
33314322|NCT03913988|Active Comparator|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
32949579|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
32949580|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
32949581|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
32949582|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
32949583|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
32949584|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
32949585|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
32949586|NCT05067582|Placebo Comparator|Placebo Capsules|1 capsule twice daily
32949587|NCT05067582|Experimental|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
32949588|NCT05033808|Placebo Comparator|Placebo|Administration of NaCl i.v. as placebo once.
32949589|NCT05033808|Experimental|Epirubicin Phase I|Administration of epirubicin i.v. 3.75 mg/m2 once.
32949590|NCT05033808|Experimental|Epirubicin Phase II|Administration of epirubicin i.v. 7.5 mg/m2 once.
32949591|NCT05033808|Experimental|Epirubicin Phase III|Administration of epirubicin i.v. 15 mg/m2 once.
32949592|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
32949593|NCT04026984|Experimental|Rifamycin SV MMX plus ORT|One tablet contains 50 mg Rifamycin SV-MMX® plus standard of care Oral Rehydration Therapy (ORT). Two 50mg tablets will be administered twice daily.
32949594|NCT04026984|Placebo Comparator|Placebo tablets plus ORT|Matching placebo tablets plus standard of care Oral Rehydration Therapy (ORT)
32949595|NCT04019340|No Intervention|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
32949596|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
32949597|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
32949598|NCT03989466|Experimental|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
32805247|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
32805248|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
32805249|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
32805250|NCT05585944|Active Comparator|control|healthy participants
32805251|NCT05585944|Active Comparator|cases|cases of immune thrombocytopenic purpura
32805252|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
32805253|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
32805254|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
32805255|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
32805256|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
33314323|NCT03913988|Active Comparator|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
32805257|NCT02290366|Experimental|Focal Therapy|
32805258|NCT05585866||Sevoflurane|The group of patients which received sevoflurane as randomized anesthetic modality.
32805259|NCT05585866||Propofol|The group of patients which received propofol as randomized anesthetic modality.
32805260|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
32805261|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
32805262|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
32805263|NCT01928134|Active Comparator|B|Vit K2+CaCO3
32805264|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
32805265|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
32805266|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
32805267|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
32805268|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
32805269|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
32805270|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
33314324|NCT03913988|Active Comparator|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
33314325|NCT03914222|Other|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
33314326|NCT03910400|Experimental|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
33098500|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
33098501|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
33098502|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
33098503|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
33098504|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
33098505|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
33098506|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
33098507|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
33098508|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
33098509|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
33098510|NCT02947074|No Intervention|Control|Waiting list
33098511|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
33098512|NCT00526500|Experimental|P-T|
33098513|NCT00526500|Experimental|P- SAH|
33314327|NCT03910400|Experimental|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
33314328|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
33314329|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
32805271|NCT01928212||healthy control|Sex- and agematched healthy subjects
32805272|NCT01928212||Parkinson group|Patients with Parkinson's disease
32805273|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
32805274|NCT01928368|Active Comparator|Experimental Arm|
32805275|NCT01928368|Placebo Comparator|Placebo Arm|
32805276|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
32805277|NCT04756882|Experimental|study group|6 patients received 12.5 speywood unit/cm (SU/cm) Dysport intramuscular & intradermal injections, within the first 5 postoperative days of the trauma
32805278|NCT04756882|No Intervention|control group|of 6 patients that acted as the control group and received no treatment
33098514|NCT00526500|Experimental|P- A|
33098515|NCT00526500|Experimental|Control|
33098516|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
33098517|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
33098518|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
33098519|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
33098520|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
33098521|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
33098522|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
33098523|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
33098524|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
33098525|NCT00508430|Experimental|1|Low dose group
33098526|NCT00508430|Experimental|2|Middle dose group
33098527|NCT00508430|Experimental|3|High dose group
33098528|NCT00508430|Placebo Comparator|4|
33314330|NCT03910088|Placebo Comparator|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
33098529|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
33098530|NCT04693065||Ponseti|Patients treated by ponseti method
33098531|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
33098532|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
33098533|NCT04693455|Experimental|Experimental: Cohort 1, Dose 1 of ZD03 or Placebo|Dose 1 of ZD03 or matching Placebo capsules by mouth
33098534|NCT04693455|Experimental|Experimental: Cohort 2, Dose 2 of ZD03 or Placebo|Dose 2 of ZD03 or matching Placebo capsules by mouth
33098535|NCT04693455|Experimental|Experimental: Cohort 3, Dose 3 of ZD03 or Placebo|Dose 3 of ZD03 or matching Placebo capsules by mouth
33098536|NCT04693455|Experimental|Experimental: Cohort 4, Dose 4 of ZD03 or Placebo|Dose 4 of ZD03 or matching Placebo capsules by mouth
33098537|NCT04693455|Experimental|Experimental: Cohort 5, Dose 5 of ZD03 or Placebo|Dose 5 of ZD03 or matching Placebo capsules by mouth
33098538|NCT04693455|Experimental|Experimental: Cohort 6, Dose 6 of ZD03 or Placebo|Dose 6 of ZD03 or matching Placebo capsules by mouth
33098539|NCT04693455|Experimental|Experimental: Cohort 7, Dose 7 of ZD03 or Placebo|Dose 7 of ZD03 or matching Placebo capsules by mouth
33098540|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
33098541|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
33098542|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
33314331|NCT03910088|Active Comparator|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
33098543|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
33098544|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
33098545|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
33098546|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
33098547|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
33098548|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
33314332|NCT03910088|Active Comparator|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
32805279|NCT02271256|Experimental|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
33314333|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
33314334|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
33314335|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
32805280|NCT02271256|No Intervention|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
32805281|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
32805282|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
32805283|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
32805284|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
32805285|NCT01894126|No Intervention|Control|
32805286|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
32805287|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
32805288|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
32805289|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
32805290|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App~Behavioral: Mind-Games"
33098549|NCT04692948|Experimental|TAA6 cell injection|"Drug: TAA6 cell injection（Targeting CD276 autologous chimeric antigen receptor T cells）~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells.Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
33098550|NCT00508508|Experimental|1|Behavioral: IVR
33098551|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
32805291|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games~Behavioral: TherAppy Language App"
33314336|NCT03908372|Experimental|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
33314337|NCT03908372|Active Comparator|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
33098552|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
33098553|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
33098554|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
33098555|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
33098556|NCT00508040|Active Comparator|B|
33098557|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
33098558|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
33098559|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
33098560|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
33098561|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
33098562|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
33098563|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
33098564|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
33098565|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
33098566|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
33098567|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
33098568|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
33098569|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
33098570|NCT02954120||(PCOS+CP+)|PCOS participants with CP
33098571|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
33098572|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
33098573|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
33098574|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
33098575|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
33098576|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
33098577|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
33098578|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
33098579|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
33098580|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
33314338|NCT03322462|Experimental|Flortaucipir PET Scan|
33314339|NCT03908138|Active Comparator|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
33314340|NCT03908138|Active Comparator|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
33314341|NCT05617664|Placebo Comparator|patients with primary nocturnal enuresis will be followed up with behavioral therapy alone.|
33314342|NCT05617664|Active Comparator|patients with primary nocturnal enuresis will take desmopressin 120 mcg oral tablets.|
33314343|NCT05617664|Active Comparator|patients with PNE will take mirabegron 25 mg oral tablets.|
32805292|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
33314344|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
33314345|NCT03909776|Active Comparator|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
33314346|NCT03909776|Sham Comparator|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
32805293|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
33098581|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
33098582|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
33098583|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
32805294|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
33098584|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
33098585|NCT02953730|Experimental|PEG-rhG-CSF|
33098586|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
32805295|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
33098587|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
33098588|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
33314347|NCT01253096|Experimental|L19IL2|
33314348|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
33314349|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
33314350|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
33314351|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
33314352|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
33314353|NCT01148264|Experimental|olanzapine|
33314354|NCT01148264|Active Comparator|metoclopramide|
32805296|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
32805297|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
32805298|NCT01536795|Experimental|WR279,396 with Tegaderm dressing|24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
32805299|NCT01536795|Experimental|WR279,396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
32830944|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
32805300|NCT04767633|Active Comparator|group A (PMC standard-dose)|Group A (PMC standard-dose): patients will receive two oral doses of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 17:00 and 4 hours later in the evening prior to the colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
32805301|NCT04767633|Active Comparator|Group B (PMC split-dose)|Group B (PMC split-dose): patients will receive the first oral doses of PMC diluted in 150 ml of water (Picoprep; Ferring Italia, Milan, Italy) at 19:00 of the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
32805302|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine) Ph1|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32805303|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine) Ph2|Patients receive 50mg ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32805304|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
32805305|NCT01894750|No Intervention|usual care|
32805306|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung nodule lesion in the chest (based on local CT result);~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
32805307|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung cancer lesion in the chest (based on local CT result);~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
32805308|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
32805309|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
32805310|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
32805311|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
32805312|NCT05585554|Experimental|Ablative MRIdian SMART|Induction Chemotherapy + MRIdian SMART 50 Gy in 5 fractions
32805313|NCT05585554|No Intervention|No ablative MRIdian SMART|Induction chemotherapy alone
32805314|NCT05583760|Experimental|Experimental: Osteopathic manipulation TUG for scaphoid bone|
32805315|NCT05583760|Sham Comparator|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|
32805316|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
32805317|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
32805318|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
32805319|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
32805320|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
32805321|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
32805322|NCT01928992||3D|Subjects that undergo 3D mammography
32805323|NCT01928992||2D|Subjects that undergo 2D mammography
32805324|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
32805325|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
32805326|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
32805327|NCT04389736|Experimental|SIT|Sitting
32805328|NCT04389736|Experimental|STAND|Standing
32805329|NCT04389736|Experimental|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
32805330|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
32805331|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
33098589|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
32805332|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
32805333|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet~R1 -> T2 -> R2 -> T1"
32805334|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
32805335|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
32805336|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
32805337|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
32805338|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
32805339|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
32805340|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
32805341|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
33098590|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
33098591|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
33314355|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
33314356|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
33314357|NCT03907358||cataract in old age|
33314358|NCT03907358||cataract in young age|
33314359|NCT03909308|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 45 min.
33098592|NCT02953613||Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
33314360|NCT03909308|Experimental|Beach Tennis session|The participants performed a beach tennis training session throughout 45 min.The session started with a standardized 5-minute warm-up consisting of basic techniques (i.e., serve, volley, forehand, and backhand) followed by three 12-minute beach tennis matches with 2-minute intervals between the games. We used regular beach tennis rules in the game, which was played on a regular beach tennis court (i.e., 16 m long by 8 m wide and net 1.70 m high).
33314361|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
33314362|NCT00086580|Experimental|Combination Arm (FluCAM)|
33314363|NCT00086580|Active Comparator|Fludarabine Alone|
33314364|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
33314365|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
32805342|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
32805343|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
32805344|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
32805345|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
32805346|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
32805347|NCT02236312|Placebo Comparator|Placebo|I.M. injection
32805348|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
32805349|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
32805350|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
33314366|NCT03908996|Experimental|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
33314367|NCT03908840|Experimental|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
32805351|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
32805352|NCT01916278|Experimental|Emervel Lips Lidocaine|
32805353|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
33314368|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
33314369|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
33314370|NCT03908918|Experimental|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
33314371|NCT03908918|Other|Waitlist control|Waitlist control - receiving the app after 6 months
33314372|NCT03908528|Experimental|Chemotherapy plus Placebo for six Months|• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.
33314373|NCT03908528|Experimental|Chemotherapy plus alpha lipoic acid for six Months|• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
33314374|NCT04850170|Experimental|Experimental group|"The first ten subjects will be enrolled in a pilot study. The following sixty subjects will be separated randomly to experimental group and control group.~The first ten subjects and the experimental group will be arranged manual therapy and rehabilitation for six months."
33314375|NCT04850170|Active Comparator|Control group|The control group will be arranged rehabilitation.
33314376|NCT03903458|Experimental|Tinostamustine and Nivolumab|Experimental drug combination arm
33314377|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
33314378|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
32805354|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
32805355|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
32805356|NCT03084640|Experimental|Part 1: Dose-Escalation - CMP-001 (SC) and Pembrolizumab|Participants will receive up to 7 escalating dose levels (5 milligrams [mg], 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, and 20 mg) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
32805357|NCT03084640|Experimental|Part 1: Dose-Expansion - CMP-001 (SC) and Pembrolizumab|Participants will receive RP2D (as determined in Part 1 dose-escalation phase) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
32830945|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
33314379|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
33314380|NCT00086502|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg
33314381|NCT00086502|Placebo Comparator|Placebo|Placebo
33314382|NCT03903302|Active Comparator|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
33314383|NCT03903302|Active Comparator|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
33314384|NCT03903302|Active Comparator|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
33314385|NCT03903302|Active Comparator|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
32805358|NCT03084640|Experimental|Part 2: CMP-001 (SC and IT) and Pembrolizumab|Participants will receive CMP-001 via SC injection once weekly for 2 weeks, then IT injection once weekly for 4 weeks, and SC injection once weekly for every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule. CMP-001 planned IT dose level in Part 2 will be up to 10 mg and the SC dose will be the RP2D determined from Part 1 dose-escalation phase of the study.
32805359|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
32805360|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
32805361|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
32805362|NCT01895686||Narrow angle|patients diagnosed with narrow angles
32805363|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
33314386|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
32805365|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
32805366|NCT04409691|Active Comparator|prednison group|
32805367|NCT04409691|Experimental|prednison+sirolimus group|
33314387|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
33314388|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
33314389|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
33314390|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
33314391|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
33314392|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
32805368|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
32805369|NCT04096989|No Intervention|Control group|Routine care.
32805370|NCT04096989|Experimental|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
32805371|NCT04096989|Sham Comparator|Sham comparator group|The participants accept mobile health application intervention.
32805372|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
32805373|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
32805374|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
32805375|NCT04756960|Experimental|CHF6001|single dose of CHF6001 DPI co-administered with an intravenous microdose of [14C]-labelled CHF6001
33314393|NCT03907592|Experimental|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
33314394|NCT03907592|Experimental|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
33314395|NCT03907592|Experimental|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
32805376|NCT04757038|Experimental|Hyalodisc injection|"• Group 1: One single X-ray-guided intradiscal injection (25 gauge) of 8 mg/mL of HYALODISC combined with PEP. The investigator will use one syringe for each involved disc, up to a maximum of three discs.~The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided. Both groups (Group 1 and Group 2) will be treated with PEP according to a standardized protocol."
32805377|NCT04757038|No Intervention|Physical exercise program (PEP)|Group 2: PEP alone
33314396|NCT01313338||Acute coronary syndrome|
33314397|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
32805378|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
32805379|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
32805380|NCT04389970|Experimental|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
32805381|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
32805382|NCT01485627|No Intervention|Control|Patients will receive usual care
32805383|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
33314398|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
33314399|NCT03907436|Sham Comparator|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
32805384|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
32805385|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
32805386|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
32949599|NCT03945240|Experimental|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
32949600|NCT03945240|Experimental|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
32949601|NCT03945240|Experimental|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
33314400|NCT03907436|Experimental|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
33314401|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
33314402|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
33314403|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
33314404|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
33314405|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
33314406|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
33314407|NCT03898622|Active Comparator|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
32805387|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
32805388|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
32805389|NCT01515904||Control|Approximately 50% of attendees choose not to book into the STOMP program, for reasons including difficulty attending the frequent appointments due to distance or inability to leave work early. This population will serve as the control group for the evaluation. Control participants will be recruited from the community through posters in the hospital
32805390|NCT01515904||STOMP|12-17 yrs. Patients in the program have severe complex obesity defined as children and youth who have a BMI >95th %ile for their age and gender in addition to one of the following: at least one significant obesity-related co-morbidity requiring specialty care (e.g. type 2 diabetes), other co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant), or a BMI ≥99th percentile for their age and gender
32805391|NCT02203240|Experimental|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
32805392|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage consumed per day.
32805393|NCT01508325|Experimental|Bisoprolol|
32805394|NCT01508325|Active Comparator|Metoprolol|
33314408|NCT03898622|Placebo Comparator|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention."
33314409|NCT03907514|Experimental|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
33314410|NCT03907514|No Intervention|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
33314411|NCT00086190|Active Comparator|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
33314412|NCT00086190|Active Comparator|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
32805395|NCT01514344|Experimental|intralesional rituximab|
33314413|NCT00086190|Placebo Comparator|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
33314414|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
33314415|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
33314416|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
33314417|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
33314418|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
33314419|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
33314420|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
33314421|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
33314422|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
33314423|NCT01760291|Experimental|WATCHMAN|WATCHMAN LAA Closure Technology
32805396|NCT01506856|Active Comparator|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
32805397|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
32805398|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
32805399|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
32805400|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
32805401|NCT01496014||severe open fractures of the tibia bone|
32805402|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
32805403|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
33314424|NCT03903224|Active Comparator|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
33314425|NCT03903224|Active Comparator|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
33314426|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
33314427|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
33314428|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
33314429|NCT03275350|Active Comparator|TAU|Treatment as usual
33314430|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
33314431|NCT04783714|Experimental|Active Group|"Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols.~Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols.~The intervention will be administered for 4 months (112 days)."
33314432|NCT04783714|Placebo Comparator|Placebo|3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
32805404|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
32805405|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
32805406|NCT02195206||Healthy|Adult
32805407|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
32805408|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
32805409|NCT01872208|Experimental|Human Acellular Vessel (HAV)|HAV implantation to study participants.
32805410|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
32805411|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
32805412|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
32805413|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
32805414|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
32805415|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
32805416|NCT04725825|Experimental|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
32805417|NCT04725825|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
32805418|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
32805419|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
32805420|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
32805421|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
32805422|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
32805423|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
32805424|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
32805425|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
32805426|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
32805427|NCT01860898|Other|Skin Biopsy|
33314433|NCT03903146|Experimental|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
33314434|NCT03903146|No Intervention|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
33314435|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
33314436|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
33314437|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
32949602|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
32949603|NCT03153618|No Intervention|Control|Current standard of care will be followed
32949604|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
32949605|NCT04404348|Experimental|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
33314438|NCT01150370|Experimental|Males undergoing circumcision|
33314439|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
33314440|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
33314441|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
32949606|NCT04404348|Placebo Comparator|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
32949607|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
32949608|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
32949609|NCT03153228||Control|29 healthy volunteers.
32949610|NCT03805932|Experimental|1 - Dose Escalation|Moxetumomab Pasudotox-tdfk + Rituximab
32949611|NCT03805932|Experimental|2- Dose Expansion|Moxetumomab Pasudotox-tdfk + Ruxience
32949612|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
32949613|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
32949614|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
32949615|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
32949616|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
32949617|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
32949618|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
32949619|NCT03670524|No Intervention|Control Group|No intervention
32949620|NCT04764396|Experimental|Heparin priming biopsies|
32949621|NCT04764396|Active Comparator|Standard of care (saline)|
33098593|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
33098594|NCT02953574|No Intervention|usual nursing care|
33098595|NCT00508703||CT Scan + IMRT Radiation Therapy|
33098596|NCT00526773|Other|1|Telephone management plus a motivational intervention
33098597|NCT00526773|Other|2|Telephone management with standard patient education
33098598|NCT02953496|Experimental|vonapanitase|
33098599|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
33098600|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
32805428|NCT05581108|Experimental|Juice PLUS+® OMEGA|The Juice Plus+®Omega Blend capsules contain the following ingredients: DHA and EPAenriched oil of the micro algae Schizochytrium sp., pomegranate seed oil, coating agent: pullulan; raspberry seed oil, sea buckthorn oil 9, release agent: silicon dioxide; high oleic safflower seed oil, tomato seed oil, orange oil, vanilla oil, antioxidant: rosemary extract.
32805429|NCT05581108|Placebo Comparator|Matched placebo|Placebo capsules consist of medium chain triglycerides oil+ excipients like silicon dioxide aerosil, lecithin, vanilla flavor, orange oil, water and hypromellose(shell).
32805430|NCT01535235|Active Comparator|ACE Inhibitor|Active group
32805431|NCT01535235|Placebo Comparator|Placebo|Placebo group
32805432|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
32805433|NCT04748211|Experimental|Infraclavicular Block|Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
32805434|NCT04748211|Experimental|Interscalen Block|Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
32805435|NCT04748289|Experimental|NICU patients|All patients admitted to the Neurointensive Care Unit (NICU)
32805436|NCT04095429|Experimental|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
32805437|NCT04095429|Active Comparator|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
32805438|NCT02168686|Experimental|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
32805439|NCT02168686|Experimental|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
32805440|NCT02168686|Experimental|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
32805441|NCT02168686|Experimental|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
32805442|NCT02168686|Experimental|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
32805443|NCT04756336|Experimental|LTX-109 treatment|Patients are treated with LTX-109 gel, 3% w/w twice daily (morning- evening) by application on active hidradenitis lesions during the intervention period of 6 weeks
32805444|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
32805445|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
32805446|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
32805447|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
32805448|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
32805449|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
32805450|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
33098601|NCT00508859|Experimental|Active, 1|sertraline
33098602|NCT00508859|Placebo Comparator|Placebo|placebo
33098603|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
33098604|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
32805453|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
33098605|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
33314442|NCT03898466|Experimental|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
33314443|NCT03898466|Placebo Comparator|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
33314444|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
33098606|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
33314445|NCT03907124|Experimental|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
33314446|NCT03907124|No Intervention|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
33314447|NCT04531384|Experimental|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
33314448|NCT04531384|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
33314449|NCT02870530|Experimental|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
33314450|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
33314451|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
33314452|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
33314453|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
32805454|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
33314454|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
32830946|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
32830947|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
33314455|NCT01150604|Experimental|Self-help course|
33314456|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
33314457|NCT01256606||Positive for fetal aneuploidy|
33314458|NCT01256606||Negative for fetal aneuploidy|
33314459|NCT01254812||Bilateral dual TAP-block|
33314460|NCT01254812||Placebo Bilateral dual TAP-block|
33314461|NCT03902834|Experimental|Intervention|
33314462|NCT03304522|Experimental|VX-150|
33314463|NCT03304522|Placebo Comparator|Placebo|
33314464|NCT03902990|Experimental|Dual task|Treadmill training + cognitive tasks + standard exercise programme
33314465|NCT03902990|Active Comparator|Single task|Treadmill training + standard exercise programme
33314466|NCT03902990|Active Comparator|Control|Standard exercise programme
33314467|NCT03907202|Active Comparator|KBP-089|"Three cohorts:~Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg~Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg~Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
32830948|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
32830949|NCT03970356|Experimental|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
33314468|NCT03907202|Placebo Comparator|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
32830950|NCT03970356|No Intervention|control|Usual care
33098607|NCT00508937|Active Comparator|1|
33314469|NCT03903068|Experimental|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
33314470|NCT03903068|Sham Comparator|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
33314471|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
33314472|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
33314473|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
33314474|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
33314475|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
33314476|NCT01149200|Experimental|TC-6499|
33314477|NCT01149200|Placebo Comparator|Placebo|
33314478|NCT04613050|Active Comparator|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
33314479|NCT04613050|Active Comparator|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
33314480|NCT04613050|No Intervention|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
33314481|NCT03902678|Experimental|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
33314482|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
33314483|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
32949622|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
32949623|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
32949624|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
32949625|NCT03024528||CAM-ICU (+)|Delirious patients.
32949626|NCT03024528||CAM-ICU (-)|Non-delirious patients
32949627|NCT04903314|Experimental|Cohort I|Xcopri to be administered to ages 12 to < 18 years not to exceed 400 mg/day.
32949628|NCT04903314|Experimental|Cohort IIa|Xcopri to be administered to ages 6 to < 12 years not to exceed 400 mg/day.
32949629|NCT04903314|Experimental|Cohort IIb|Xcopri to be administered to ages 4 to < 6 years not to exceed 400 mg/day.
32949630|NCT04903314|Experimental|Cohort III|Xcopri to be administered to ages 2 to < 4 years not to exceed 400 mg/day.
32949631|NCT03021954|Experimental|Platelet rich plasma|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
32949632|NCT03021954|No Intervention|Control|No intervention given, patient will only get local anesthesia injection before perineoraphy
32949633|NCT03153072|Other|A child with supraventricular tachycardia|
32949634|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
32949635|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
32949636|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
32949637|NCT05394948|Experimental|Group receiving dietary recommendations including experimental nutraceutic.|Experimental group will consume experimental nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
32949638|NCT05394948|Active Comparator|Group receiving dietary recommendations including control nutraceutic.|Experimental group will consume control nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
32949639|NCT04843332|No Intervention|Usual Oncology Care|This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
33098608|NCT00508937|Experimental|2|
33098609|NCT00508937|Experimental|3|
33098610|NCT00508937|Experimental|4|
33098611|NCT00508937|Experimental|5|
33098612|NCT04692558|Experimental|HYALURONIC ACID|CAF+CTG+HA
33098613|NCT04692558|Active Comparator|WITHOUT HYALURONIC ACID|CAF+CTG
33098614|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
33098615|NCT00526968|Experimental|1|EVT 101 8 mg capsule
33098616|NCT00526968|Experimental|2|EVT 101 15 mg capsule
33098617|NCT00526968|Placebo Comparator|3|Matching placebo capsule
33098618|NCT00527007|Experimental|A|
33314484|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
33314485|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
33314486|NCT03897686|Experimental|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
33314487|NCT03897686|Placebo Comparator|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
33314488|NCT03897842|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
33404739|NCT05762796|Experimental|tDCS in Youth with mild traumatic brain injury|"Behavioral as well as neuroimaging measurements will be administered at the final post-anodal transcranial direct current stimulation (tDCS), final post-sham tDCS, and at 30-day follow-up visits.~tDCS will be administered after the initial behavioral and neuroimaging testing. Ten sessions of 1.5 mA real tDCS and 10 sessions of sham tDCS will be administered using Neurocom (Germany) DC stimulator and two 5x7 electrodes, moistened in saline solution, to 10 participants with mTBI following a cross-over design with a 2-week washout period. The location of the brain regions will be determined using either the Transcranial Magnetic Stimulation Neuronavigation or Brainsight Neuronavigation system. The anode will be placed over pre-determined brain regions, whereas the cathode will be placed either over Fp2 (contralateral supraorbital) or other suitable reference areas."
33404740|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
33404741|NCT02327962||Control|Hemodynamic measurements with PWV
33404742|NCT02602314|Experimental|Imatinib + Nilotinib|
33314489|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
33314490|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
33098619|NCT00527007|No Intervention|B|
33314491|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
33314492|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
33098620|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
33314493|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
33314494|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
33314495|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
33314496|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
33314497|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
33314498|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
33314499|NCT03906734|Experimental|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
33098621|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
33098622|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
33314500|NCT03906734|Active Comparator|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
33314501|NCT00085644|Experimental|Adalimumab|
33314502|NCT00085644|Placebo Comparator|Placebo|
33314503|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
33314504|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
33314505|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
33314506|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
32805455|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
32805456|NCT05395078|Experimental|Group A|Thoracic extension exercises
32805457|NCT05395078|Experimental|Group B|Thoracic Stabilization exercises
32805458|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
33404743|NCT02602314|Experimental|Nilotinib|
32805459|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
32805460|NCT05577442|Experimental|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|for the HR+/HER2+MBC will be treated with Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy. Endocrine drug be determined by physician depend on the history.
32805461|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
32805462|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
32805463|NCT05392036|Experimental|Group A|shockwave therapy
32805464|NCT05392036|Other|Group B|therapeutic ultrasound
32805465|NCT04756102||FBS lower than 80|Those pregnant patients with FBS less than 80 mg/dl
32805466|NCT04756102||FBS 80-120|Those pregnant patients with FBS between 80-120
32805467|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
32805468|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
32805469|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
32805470|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
32805471|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
32805472|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
32805473|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
32805474|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
32805475|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
32805476|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
32805477|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
32805478|NCT02138734|Experimental|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
32805479|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
32805480|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
32805481|NCT02138344||Healthy control subjects|
32805482|NCT02138344||Subjects with peripheral nerve diseases|
32805483|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
32805484|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
32805485|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
32805486|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
32805487|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
32805488|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
32805489|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
32805490|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
32805491|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
32805492|NCT05376358|Active Comparator|Usual Care|Participants in this arm will receive no intervention and access treatment as usual per their mental health services provider. A mobile application (AWARE) which is not interactive and is only for purposes of data collection will be downloaded on the adolescents' smartphone.
32805493|NCT05376358|Experimental|MoodRing|Adolescent participants in this arm will download two mobile applications - a data collection non-interactive app to collect passive sensing data (AWARE) and the MoodRing (MR) mobile application with which they can visualize their data about their mood, sleep, activity, enter their own mood score, and access psychoeducational resources including links to a research-based website, SOVA. Their parents will download a parent MoodRing application which provides them with parenting resources and articles and a weekly report of their adolescents' mood as predicted by passive sensing. Clinical providers will receive access to a web portal where they can view their adolescent patients' data who are enrolled in the study.
32805494|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
32805495|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
32805496|NCT01406548|Experimental|BPS804 dosing frequency 1|Subjects dosed 20mg/Kg BPS804 monthly
32805497|NCT01406548|Placebo Comparator|placebo dosing frequency 1|Subjects dosed with matching placebo to 20mg/Kg BPS804 monthly
32805498|NCT01406548|Experimental|BPS804 dosing frequency 2|Subjects dosed with 20mg/Kg BPS804 quarterly
32805499|NCT01406548|Placebo Comparator|placebo dosing frequency 2|Subjects dosed with matching placebo to 20mg/Kg BPS804 every 3 months
32805500|NCT01406548|Experimental|BPS804 dosing frequency 3|Subjects dosed with 20mg/Kg BPS804 weekly
32805501|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|Subjects dosed with matching placebo to 20mg/Kg BPS804 weekly
32805502|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
32805503|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
32805504|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
33404744|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
33314507|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
33314508|NCT01256996|Experimental|Low-abrasive powder|
33314509|NCT03897764|Experimental|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
33314510|NCT03897764|Placebo Comparator|placebo controlled group|The group which placebo used
33098623|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
33098624|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
33098625|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
33098626|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
33098627|NCT04692480|Experimental|Breastfeeding Video Education|"Participants will view a breastfeeding educational video entitled Breastfeeding in the First Hour, It's in Your Hands."
33098628|NCT04692480|Other|Control|Participants will view a PDF of breastfeeding education materials available for inclusion in standard discharge paper work.
33098629|NCT00508976|Experimental|3|
33098630|NCT00508976|Experimental|2|
33098631|NCT00508976|Experimental|4|
33098632|NCT00508976|Active Comparator|1|
33098633|NCT04692285|Active Comparator|Patients with focal dystonia treatment first placebo second|Zolpidem 5 mg single dose
33098634|NCT04692285|Placebo Comparator|Patients with focal dystonia placebo first treatment second|Placebo 5 mg single dose
33098635|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
33314511|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
33314512|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
33314513|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
33314514|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
33314515|NCT03906812|Active Comparator|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
33314516|NCT03906812|Active Comparator|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
33314517|NCT03961932|Experimental|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m^2)
33314518|NCT03961932|Experimental|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m^2)
33314519|NCT03961932|Experimental|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m^2)
33314520|NCT03961932|Experimental|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m^2), not on hemodialysis
33314521|NCT03961932|Experimental|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
33314522|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
33314523|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
33404745|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
33098636|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
33098637|NCT04692246|Experimental|Test Group|Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
33098638|NCT04692246|Placebo Comparator|Control Group|Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
33098639|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
33098640|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and minimal care.
33098641|NCT03459560|No Intervention|Control|Only minimal care
33098642|NCT00527085|Experimental|AMG 073|
33098643|NCT00527085|Placebo Comparator|Placebo|
33098644|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
33098645|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
33098646|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
33098647|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33098648|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33098649|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33098650|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33098651|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33098652|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
33314524|NCT03906500|Experimental|Intervention|"The intervention consist of three main components.~School environmental component~The component targeting the high school environment consisted of two separate elements:~Revision of school alcohol policy~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student components~The Student components consisted of three main elements:~Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee~Pocket movie campaign~Social norms campaign~Parent components~The parent component consisted of three separate elements:~Parent Information Meeting~Parent Information Folder~Parent Information Website"
33314525|NCT03906500|No Intervention|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
33098653|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
33098654|NCT00509405|Placebo Comparator|Potassium citrate|
33098655|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
33098656|NCT00509444|Active Comparator|Educational materials|
33098657|NCT00509444|Experimental|Educational materials, plus patient navigation|
33098658|NCT00528138||1|Simple appendicitis
33314526|NCT04597918|Experimental|Faricimab|
33098659|NCT00528138||2|Perforated appendicitis
32830951|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
33098660|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
33098661|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
33098662|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
33098663|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
32949640|NCT04843332|Experimental|Community Health Worker Intervention|This arm is the treatment group. Patients randomized into the intervention will be assigned a community health worker who will contact the patient to begin the intervention. They will receive usual oncology care from their regular oncologist and care team but will also receive supplemental support and health education from a community health worker. The lay health worker will assist patients in ensuring that patients discuss the following with their cancer care teams: 1) precision medicine 2) cancer diagnosis and treatment plan 3) adherence to treatments and 3) goals of care and 4) symptom burden. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
32949641|NCT01673412|Experimental|interventional arm|Psychological tests
32949642|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
33314527|NCT04177992|Experimental|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
33314528|NCT04177992|No Intervention|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
33314529|NCT01150994|No Intervention|Treatment as Usual|
33314530|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
33314531|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
33314532|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
33314533|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
33314534|NCT01149278|Active Comparator|high pressure|
33314535|NCT01149278|Placebo Comparator|normal pressure|
33314536|NCT00314795|Experimental|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
33314537|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
33314538|NCT03902522|Experimental|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
33314539|NCT01092858|Experimental|Arm 1|
32949643|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
32949644|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
32949645|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
33314540|NCT01092858|Placebo Comparator|Arm 2|
33314541|NCT03902756|Experimental|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
33404746|NCT05079880|Experimental|GC group|received 300 mg of caffeine citrate infusion
32949646|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
32949647|NCT04765098|Active Comparator|Etoposide|
32949648|NCT04765098|Experimental|Tamoxifen|
32949649|NCT01673880|Other|E2006 2.5 mg|
32949650|NCT01673880|Other|E2006 10mg|
32949651|NCT01673880|Other|E2006 25 mg|
32949652|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
32949653|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
32949654|NCT04777032||Liver transplant recipients|All liver transplant recipient in Denmark aged 18-100 years will be eligible for inclusion in the DACOLT study. Inclusion requires the individual to be able to understand the study information in either Danish or English and to be able to provide an informed consent.
32949655|NCT04777032||Control group 1_CGPS|The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area > 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
32949656|NCT04777032||Control group 1_CCHS|The Copenhagen City Heart Study (CCHS) includes a random population sample included from the greater Copenhagen area. Health surveys have been repeated 5 times between 1976 and 2015. Almost 4000 participants were randomly selected for echocardiography.
32949657|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
32949658|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
32949659|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
33098664|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
33098665|NCT00509561|Active Comparator|Chemo-radiotherapy|
33098666|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
33098667|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
33314542|NCT03902756|Active Comparator|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
33098668|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
33098669|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
33098670|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
33098671|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
33098672|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
33098673|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
33098674|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
33098675|NCT00528255|Experimental|1|
33314543|NCT01529879|Experimental|New abutment connection implant|Implant with new abutment connection
33314544|NCT01529879|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
33314545|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
33314546|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
33314547|NCT03985397|Experimental|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
33314548|NCT03985397|No Intervention|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
33314549|NCT03902288|Experimental|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
33314550|NCT03902288|Active Comparator|Healthy individuals|Healthy individuals match age and gender to the experimental group
33098676|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
33098677|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
33098678|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
33098679|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
33098680|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
33098681|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
33098682|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
33098683|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
33098684|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
33098685|NCT00509717|Experimental|experimental|
33098686|NCT00509717|Active Comparator|control|
33098687|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
33098688|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
33098689|NCT00509756|Active Comparator|1|Drug: FXR-450
33098690|NCT00509756|Placebo Comparator|2|Placebo
33098691|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
33098692|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
33098693|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
33098694|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
33314551|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
33314552|NCT03897218|Placebo Comparator|Group 1|Patients consuming placebo (millet flakes) each day
33314553|NCT03897218|Experimental|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
33314554|NCT03897218|Experimental|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
33314555|NCT03897452|Experimental|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.~This is not an RCT with several arms."
33314556|NCT03906032|Experimental|Intra-medullary hip Nail|Surgery
33314557|NCT03906032|Active Comparator|Sliding hip screw|Surgery
33314558|NCT01151072|Experimental|IDeg i.m. thigh|
33314559|NCT01151072|Experimental|IDeg i.v.|
33314560|NCT01151072|Experimental|IDeg s.c. abdomen|
33314561|NCT01151072|Experimental|IDeg s.c. deltoid|
33314562|NCT01151072|Experimental|IDeg s.c. thigh|
33314563|NCT03906266|Active Comparator|nutric score|> 5 indicates high risk for malnutrition < 4 indicates low risk for malnutrition
33314564|NCT03906266|Placebo Comparator|adductor pollicis|< 20 mm indicates high high risk for malnutrition > 20 mm indicates low risk for malnutrition
32805505|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
32805506|NCT01393522|Active Comparator|Milnacipran|Oral Milnacipran titration was Day 1-2 - 12.5mg/d; Day 3-6 - 12.5mg bid; Day 7-14 - 25mg bid; Day 15 and on - 50mg bid. After the first 30 days, patients did not continue to increase the dose beyond the dose they have achieved at 30 days. At study completion medication taper as follows: patients who at their completion visit were taking 50mg bid decreased to 25mg bid for 4 days, then decreased to 12.5mg bid for 2 days, then 12.5mg once a day for one day and then stopped. Patients on 25mg bid, decreased to 12.5mg bid for 2 days, 12.5mg once a day for one day and then stopped.
32805507|NCT01393522|Placebo Comparator|Placebo|Sugar Pill No active ingredients
32805508|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
32805509|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
32805510|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
32805511|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
32805512|NCT02119702||Uninfected Cohort|HIV-uninfected participant at or beyond their 18th birthday at enrollment. May have horizontally-acquired HIV infection.
32805513|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
32805514|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
32805515|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
32805516|NCT02118922||Healthy volunteers|Volunteers with normal corneas
32805517|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
32805518|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
32805519|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
32805520|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
32805521|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
32805522|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
32805523|NCT01787500|Experimental|Treatment (vemurafenib, cetuximab, irinotecan hydrochloride)|Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32805524|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
32805525|NCT01782820||no dexamethasone|no dexamethasone during measurements
32805526|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
32805527|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
32805528|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
32805529|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
32805530|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
32805531|NCT01374412||osteoporosis|patients with benign osteoporosis
33098695|NCT00527202|Experimental|botulinum toxin A|active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart
33314565|NCT03906266|Placebo Comparator|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
33314566|NCT03906266|Placebo Comparator|NRS 2002 score|> 3 indicates high risk for malnutrition
33404747|NCT05079880|Placebo Comparator|GS group|Equivalent saline infusion
32949660|NCT04348578|No Intervention|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
32949661|NCT04348578|Experimental|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
33404748|NCT05021146|Experimental|Standard care and CEO treatment with standard 20% concentration Copaiba oil|
32949662|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
32949663|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
32949664|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
32949665|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
32949666|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
32949667|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
32949668|NCT02980692|Experimental|SUNPG1623 dose I|low range dose
32949669|NCT02980692|Experimental|SUNPG1623 dose II|mid range dose
32949670|NCT02980692|Experimental|SUNPG1623 dose III|mid range dose
32949671|NCT02980692|Experimental|SUNPG1623 dose IV|mid range dose to high dose
32949672|NCT02980692|Placebo Comparator|Placebo|mid range dose to high dose
32949673|NCT04747392|Other|Sequence A|The test drug (SAL001) is administrated once by subcutaneous injection in the first period, and the reference drug (FORSTEO) is administrated once by subcutaneous injection in the second period.
32949674|NCT04747392|Other|Sequence B|The reference drug (FORSTEO) is administrated once by subcutaneous injection in the first period, and the test drug (SAL001) is administrated once by subcutaneous injection in the second period.
32949675|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
32949676|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
32949677|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
32949678|NCT03728712||Never smokers|Participants with no history of cigarette smoking
32949679|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
32949680|NCT02821806||Cohort 1|Healthy Volunteers
32949681|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
32949682|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
32949683|NCT01674270|Experimental|Degarelix|Degarelix Alone
32949684|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
32949685|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
32949686|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
32949687|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
32949688|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
32949689|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
32949690|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
32949691|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
32949692|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
32949693|NCT01674582|Other|MRI, Neuropsychological testing|
32949694|NCT05353062|Active Comparator|Standard therapy|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
32949695|NCT05353062|Experimental|Bipolar hemostatic forceps|Endoscopic therapy with bipolar hemostatic forceps
32949696|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
32949697|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
32949698|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
32805532|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
32805533|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
32805534|NCT02114086||breast cancer|observation of intraoperative radiotherapy
33098696|NCT00527202|Placebo Comparator|placebo|saline injection with the same dosages injected using the same procedure as botulinum toxin A
33098697|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
33098698|NCT00527241|Experimental|1: A|
33098699|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
33098700|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
33314567|NCT03897140|Experimental|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
33314568|NCT01253876|Experimental|Soy milk|
33314569|NCT01253876|Experimental|Caw's milk|
33314570|NCT03896906|Experimental|Group N|pre-oxygenation with High-flow nasal cannula
33314571|NCT03896906|Active Comparator|Group M|pre-oxygenation with simple mask
33314572|NCT01257386|Experimental|Asacol®|Import Mesalazine
33314573|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
32805535|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
33314574|NCT03896672|Experimental|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
33314575|NCT01257464|Active Comparator|Sitagliptin|
33314576|NCT01257464|Placebo Comparator|Placebo|
33314577|NCT01257620|Placebo Comparator|Placebo|Placebo
33314578|NCT01257620|Experimental|Probiotic|Life Start Two
33314579|NCT01255046|Active Comparator|Donepezil plus STA-1|
33314580|NCT01255046|Placebo Comparator|Donepezil plus placebo|
33314581|NCT02528006|Other|Titanium Bridges|Surgery
33314582|NCT03902054|Experimental|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
33314583|NCT03902054|Experimental|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
33314584|NCT03902054|Experimental|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
32805536|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
32805537|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
32805538|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
32805539|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
32805540|NCT01895218|Active Comparator|Standard medical Care|
32805541|NCT02100904||Women undergoing radiofrequency ablation.|Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
32805542|NCT02100904||Women undergoing myomectomy|About 25% of women in the trial will be in the group who receive treatment with myomectomy.
32805543|NCT02095288||Healthy volunteers|Blood draw
32805544|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
32805545|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
32805546|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
32805547|NCT01507545|Active Comparator|MORAb-004|
32805548|NCT01507545|Placebo Comparator|Placebo|
32805549|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
33098701|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
33098702|NCT00527280|Experimental|1|
33098703|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection~Up to 3 fresh tumor tissue core biopsies~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
33314585|NCT03902054|Active Comparator|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
33314586|NCT03902054|Active Comparator|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
33314587|NCT03901976|Other|Bed Exit Detection On|prevention of fall by a true bed exit detection
33404749|NCT05021146|Experimental|Standard care and CEO treatment with 40% concentration Copaiba oil|
33404750|NCT05021146|Placebo Comparator|standard care and placebo treatment with coconut oil|
33404751|NCT05021146|Active Comparator|Standard care|
33404752|NCT05018338||The study cohort|The study will enroll 10 subjects meeting the eligibility criteria, with the expectation to obtain complete data from at least 6 subjects.
32805550|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
32805551|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Spectacles~Galyfilcon A Plus~Polymacon~Galyfilcon A"
32805552|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Galyfilcon A~Lotrafilcon A~Polymacon~Spectacles"
32805553|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Polymacon~Galyfilcon A Plus~Spectacles~Lotrafilcon A"
32805554|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Lotrafilcon A~Polymacon~Galyfilcon A Plus~Galyfilcon A"
32805555|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Galyfilcon A~Spectacles~Galyfilcon A Plus~Lotrafilcon A"
32805556|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Galyfilcon A Plus~Polymacon~Lotrafilcon A~Spectacles"
32805557|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Spectacles~Galyfilcon A~Lotrafilcon A~Galyfilcon A Plus"
32805558|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Lotrafilcon A~Galyfilcon A~Spectacles~Polymacon"
32805559|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Galyfilcon A Plus~Spectacles~Galyfilcon A~Polymacon"
32805560|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Polymacon~Lotrafilcon A~Galyfilcon A~Galyfilcon A Plus"
32805561|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
32805562|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
32805563|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
32805564|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
32805565|NCT02986035|Experimental|Intervention|
32805566|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
32805567|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
32805568|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
32805569|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
32805570|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
32805571|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
32805572|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
32805573|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
32805574|NCT01759186||None interventional|
32805575|NCT01758796|Experimental|Non-operative|Non-operative treatment with six weeks in a below-the-knee cast. Partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bearing as tolerated for the remaining two weeks.
32805576|NCT01758796|Active Comparator|Surgery|Open reduction and internal fixation with 1/3 semitubular plate and screws. Post-operatively, surgically treated ankles are placed in a below-the-knee cast for six weeks. They are advised to carry out partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bear as tolerated for the remaining two weeks.
32805577|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
32805578|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
32805579|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
32805580|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
32805581|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
32805582|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
32805583|NCT04389502|Experimental|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
32805584|NCT04389502|Active Comparator|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
32805585|NCT01719562|Experimental|ADDENDUM: Physical Activity Intervention|Participants will be offered one to two training sessions per week at onsite rehab facilities and 1-2 sessions per week at home consisting of slow 15 minute aerobic warm-up followed by 20 minutes of strength training, 15 minutes of progressive intensity aerobic exercise and 10 minute cool down.
32805586|NCT01719562|Experimental|ADDENDUM: Healthy Living Instruction Group (Control Arm)|Organized various health workshops lasting for 60 minutes to match the number of visits to the rehab centers for participants in Arm 1 with 2 sessions offered per month onsite and remaining sessions offered over the phone for 6 months. .
32805587|NCT01719562|Experimental|MRI (Diagnostic)|Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
32805588|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
32805589|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
32805590|NCT02056756|Experimental|CBD|
32805591|NCT01299532|Experimental|Macrolane VRF30|
32805592|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
32805593|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
32805594|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
32805595|NCT01276600|Experimental|Arm 4|One tablet orally daily
32805596|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
32805597|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
32805598|NCT04756180|Experimental|Omacor|Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks
32805599|NCT04756180|Placebo Comparator|Placebo|Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks
32805600|NCT04745806|Experimental|ActiGraft|Whole blood clot (WBC) gel
32805601|NCT04755868|Experimental|Maintenance therapy with talazoparib|Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
32805602|NCT04755868|Active Comparator|Maintenance therapy with placebo|Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
32805603|NCT04772638|Experimental|PLAY intervention|The PLAY intervention with educators, parents and children
32805604|NCT04772638|Placebo Comparator|Wait list control|
32805605|NCT05567926|Experimental|Experimental condition, receiving beetroot juice supplement|Participants will receive beetroot juice intervention in the experimental condition.
33314588|NCT03902210|Experimental|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
32805606|NCT05567926|Placebo Comparator|Placebo condition|Participants will receive placebo (blackcurrant juice) in the placebo condition
32805607|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
32805608|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
32805609|NCT05228314|Experimental|Standard dose SCB-2020S with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-2020S with CpG/alum adjuvant
32805610|NCT05228314|Experimental|Low dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with low dose squalene based adjuvant
33404753|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
32805611|NCT05228314|Experimental|Low dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with standard dose squalene based adjuvant
32805612|NCT05228314|Experimental|Standard dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with low dose squalene based adjuvant
32805613|NCT05228314|Experimental|Standard dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with standard dose squalene based adjuvant
32805614|NCT05228314|Active Comparator|Standard dose SCB-2019 with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-20219 with standard CpG/alum adjuvant
32805615|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
32805616|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
32805617|NCT01682980|No Intervention|Control group|The control group will do as usual.
32805618|NCT01659658|Experimental|IXAZOMIB 4 mg + Dexamethasone 20 mg/day|IXAZOMIB 4 mg, capsules, orally, once on Days 1, 8, and 15; plus dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Participants may continue to receive treatment until Progressive Disease (PD) or unacceptable toxicity, whichever comes first.
32805619|NCT01659658|Active Comparator|Physician's Choice|"Participants will receive one of the following treatment options as selected by the physician:~Dexamethasone 20 mg/day: dexamethasone 20 mg/day, orally, on Days 1-4, 9-12 and 17- 20 of each 28-day cycle.~Dexamethasone 20 mg/day + Melphalan 0.22 mg/kg: dexamethasone 20 mg/day, orally, on Days 1-4 of each 28-day cycle; plus melphalan 0.22 mg/kg, orally, on Days 1-4 every 28 days.~Dexamethasone 20 mg/day + Cyclophosphamide 500 mg: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 every 28 days.~Dexamethasone 20 mg/day + Thalidomide 200 mg/day: dexamethasone 20 mg/day, orally, weekly Days 1, 8, 15 and 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day, orally.~Dexamethasone 20 mg/day+ Lenalidomide 15 mg/day: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus lenalidomide 15 mg/day, orally, for 21 days every 28 days."
32805620|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
32805621|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
33098704|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
33098705|NCT00527358|No Intervention|2|Business as usual.
33098706|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
33098707|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
33098708|NCT00510965|Experimental|A|
33098709|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
32805622|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33098710|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
33098711|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
33098712|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
33098713|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
33098714|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
33098715|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
33098716|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
33098717|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
33098718|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
33098719|NCT04695782|Experimental|Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily|
33314589|NCT03902210|Placebo Comparator|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
33314590|NCT03902132|Experimental|Core Stability exercises group|Core Stability exercises
33314591|NCT03902132|Active Comparator|Traditional low back physical therapy group|Traditional low back physical therapy management
32805623|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32805624|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32805625|NCT01639690|Experimental|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
33098720|NCT04695782|Experimental|Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily|
33098721|NCT00527436|Other|Dietary Supplement|Fish oil pill
33098722|NCT00527436|Placebo Comparator|Placebo|Placebo matched corn oil pill
33098723|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
33318636|NCT03951246|Experimental|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.~Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.~Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.~NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
32805626|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
32805627|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
33098724|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
33098725|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks~adaptive, therapeutic cueing during visuo spatial tasks"
33098726|NCT02945592|No Intervention|Control|- unspecific neglect treatment
33098727|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
33098728|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
32949699|NCT04675710|Experimental|Treatment (dabrafenib, trametinib, pembrolizumab)|Patients receive 21-day cycles of dabrafenib 150 mg orally (PO) twice daily from Days 1-21, trametinib 2mg PO once daily from Days 1-21, and pembrolizumab 200mg intravenously (IV) on Day 1 of each cycle.
32949700|NCT02315898|Experimental|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
32738097|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
32738098|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
32949701|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
32949702|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
32949703|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
32949704|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
32949705|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
32949706|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
32949707|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
32949708|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
32949709|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
32949710|NCT01674894||Group 1|Women treated with Menopur
32949711|NCT01674894||Group 2|Women treated with Menopur and Bravelle
32949712|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
32949713|NCT01674972||Control|Matched healthy control subjects
32949714|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
32949715|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
32949716|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
32949717|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
32949718|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
32949719|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
32949720|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
32949721|NCT01059786|Experimental|Arm 1|Rituximab + bendamustine at 70 mg/m2 for initial tolerability study (closed)
32949722|NCT01059786|Experimental|Arm 2|Rituximab +bendamustine at 90 mg/m2 for initial tolerability study (closed)
32949723|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine (at the tolerated dose)
32949724|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
32949725|NCT04747080|Experimental|TAC and HD-DXM|"Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).~Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks."
32949726|NCT04747080|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14) .
32949727|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
32949728|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
32949729|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
32805628|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
33314592|NCT03901898|Experimental|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
33314593|NCT03901898|Other|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
32738099|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
32738100|NCT03325829||Patients with colonic diverticula|No interventional study
32738101|NCT05016063|Experimental|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR T cells
32738102|NCT03325751||Healthy subjects|
32738103|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
32738104|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
32738105|NCT04493957|Experimental|educational intervention|"Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods."
32738106|NCT04493957|Active Comparator|Control group|"Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness."
32738107|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
32738108|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
32738109|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
32738110|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
32738111|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
32738112|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
32738113|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
32738114|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
32738115|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
32738116|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
32738117|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
32738118|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
32738119|NCT05015907|Experimental|Selective supraclavicular nerve block|After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
32738120|NCT05015907|Active Comparator|Control|The nerve block is not performed in the control group.
32738121|NCT05015595|Active Comparator|Memantine|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of Memantine up to 20mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Memantine will be reduced at 10mg/day due to safety reasons before the end of treatment (T5)."
32738122|NCT05015595|Placebo Comparator|Placebo|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of placebo 20 mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Placebo will be reduced at 10mg/day, following the study protocol, before the end of treatment (T5)."
32805629|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
32805630|NCT00580996|Experimental|1|16 oz water in AM
32805631|NCT00580996|Active Comparator|2|water 1 oz in AM
32805632|NCT04755556|Other|Experimental group|Intensive bimanual training with routine physical therapy
32805633|NCT04755556|Other|control group|routine physical therapy
32805634|NCT01245712|Experimental|Treatment (APBI)|Within 10 weeks of last breast cancer surgery, patients undergo APBI delivered with proton radiation BID for 5 days.
32805635|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
32805636|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
32805637|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
32805638|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
32805639|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
32805640|NCT00530062|Experimental|Albuterol-HFA-BAI|Participants will receive single actuation of albuterol 90 micrograms (mcg), administered using BAI in treatment period 1 or 2.
32805641|NCT00530062|Active Comparator|Albuterol-HFA-MDI|Participants will receive single actuation of albuterol 90 mcg, administered using MDI in treatment period 1 or 2.
32805642|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
32805643|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
32805644|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
32805645|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
32805646|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
32805647|NCT05090722|Experimental|The PureWick Urine Collection System|The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
32805648|NCT05080192||Fenofibrate recipients|Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
32805649|NCT05080192||Placebo recipients|Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
32805650|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
32805651|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
33314594|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
33314595|NCT03906188|Experimental|LitEmotion group|This group will play to LitEmotion video game.
33314596|NCT03906188|No Intervention|Control group|This group will no do receive any intervention with the video game
32805652|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
32805653|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
32805654|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
32805655|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
32805656|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
32805657|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
32805658|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
33314597|NCT03901742|Active Comparator|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
33314598|NCT03901742|Active Comparator|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
33318637|NCT03951246|No Intervention|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
32805659|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
32805660|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
32805661|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
32805662|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
32805663|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
32805664|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
32805665|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
32830952|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
32949730|NCT01675362|Placebo Comparator|Control group|They will receive placebo
32949731|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
32949732|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
32949733|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
32949734|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
32949735|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
32949736|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
32949737|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
32949738|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
32949739|NCT01675440||2 or More Conditions|2 or more of the listed conditions
32949740|NCT01675518|Experimental|Part-1 dose 1|
32949741|NCT01675518|Experimental|Part-1 dose 2|
32949742|NCT01675518|Experimental|Part-1 dose 3|
32949743|NCT01675518|Experimental|Part-1 dose 4|
32949744|NCT01675518|Experimental|Part-1 dose 5|
32949745|NCT01675518|Experimental|Part-1 dose 6|
32949746|NCT01675518|Placebo Comparator|Part-1 placebo|
32949747|NCT01675518|Experimental|Part-2 fed|
32949748|NCT01675518|Experimental|Part-2 fasted|
32949749|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
32949750|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
32949751|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
32949752|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
32949753|NCT04404738|Experimental|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
32949754|NCT04404738|Active Comparator|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
32949755|NCT03885024|Active Comparator|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
32830953|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
33314599|NCT03901742|Active Comparator|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
32830954|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
32830955|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
32830956|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
32830957|NCT04023084|Experimental|Atopic Dermatitis Group|Receive crisaborole intervention
32830958|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
32830959|NCT05075460|Experimental|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
32830960|NCT05075460|Active Comparator|CHOP|CHOP
32830961|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
32830962|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
32830963|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
32830964|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
32830965|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
32830966|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
32830967|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
32830968|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
32830969|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
32830970|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
32830971|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
32830972|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
32830973|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
32830974|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
32830975|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
32830976|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
32830977|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
32830978|NCT05075304|Experimental|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
32830979|NCT05075304|Experimental|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
32830980|NCT05075304|Experimental|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
32830981|NCT03269058|Experimental|Patients not treated with statins|
32830982|NCT03269058|Experimental|Patients treated with statins|
32830983|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
32830986|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
32830987|NCT05074836|Experimental|Formula Milk|"Formula milk designed for young children aged over 3 years;~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
32830988|NCT05074836|Active Comparator|Regular milk|"Regular milk (pure milk);~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
32830989|NCT05074836|Other|Control foods|"Grain foods: e.g., bread;~Dosage: 20-40 g/time;~Frequence: 2 times /day;~Duration: 12 months"
32830990|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
32830991|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
32830992|NCT05074602|Experimental|SHR8008|
32949756|NCT03885024|No Intervention|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
32949757|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
32949758|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan. Dose-Escalation, which enrolled a total of 12 patients at MSK, is completed. Phase 1 of this study determined that the highest and safest dose of DS-3201b in patients was 100 mg daily.
32949759|NCT03878316|Active Comparator|Intranasal Oxytocin|Oxytocin, 35 IU per dose, intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL. The total daily dose of oxytocin will be 70 IU/mL.
32949760|NCT03878316|Placebo Comparator|Instrasal Placebo|Identically matched placebo administered intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL.
32949761|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
32949762|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
32949763|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
32949764|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
32949765|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
32949766|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
32949767|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
32949768|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
32949769|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
32949770|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
32949771|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
32949772|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
32949773|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
32949774|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
32949775|NCT01670058||CNIs at transplantation|
32949776|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
32949777|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
32949778|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
32949779|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
32949780|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
32949781|NCT01676142||Patients with NTM pulmonary infection|
32949782|NCT01676142||Patients with other pathogen related lung infection|
32949783|NCT01676142||Patient with NTM pulmonary colonization|
32949784|NCT03861390|Active Comparator|Prednisone, then Placebo|
32949785|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
32949786|NCT04747002|Active Comparator|Administration Group|Patients who are injected with DSP-7888.
32949787|NCT04747002|No Intervention|Non-administration Group|Patients who are only under observation.
32949788|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
32949789|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
33098729|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
33098730|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
33098731|NCT05648487|Experimental|Gastric Cancer With Peritoneal Metastasis, HIPEC, Anti-PD-1 Antibody|"Surgical exploration, if PCI≤20, then we perform this study.~HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration;~Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). After the surgery, HIPEC for three cycles, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy.~After the surgery, continue to use standard adjuvant chemotherapy."
33098732|NCT04695665|Active Comparator|Cervical pain|Only patients with positive Cervical pain syndrome.
33098733|NCT04695665|Active Comparator|Thoracic pain|Only patients with positive Thoracic pain syndrome.
33098734|NCT04695665|Active Comparator|Lumbar pain|Only patients with positive Lumbar pain syndrome.
33098735|NCT00527553|Experimental|A|daily consumption of a regular egg
33098736|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
33098737|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
33098738|NCT00527553|Experimental|D|daily egg product from enriched eggs
33098739|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
33098740|NCT00511082|Experimental|Treatment group|
33098741|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
33098742|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
33098743|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
33098744|NCT00511160|Active Comparator|C|Routine cardiology group
33098745|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
33318638|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
32805666|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
32805667|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
32805668|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
32805669|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
32830993|NCT05074602|Active Comparator|Fluconazole|
33098746|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
33098747|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
33098748|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
33098749|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
33098750|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
33098751|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
33098752|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
33098753|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
32949790|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
32949791|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
32949792|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
32949793|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
32949794|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
32949795|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
32949796|NCT03872778|Experimental|Phase I Cohort VII|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 2 cycles (q6w)"
32949797|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
32949798|NCT03872310|Active Comparator|Active comparator|Within group
32949799|NCT03872310|Sham Comparator|Sham comparator|Within group
32949800|NCT04404426|Experimental|L-citrulline|Administration of citrulline enterally for 7 days
32949801|NCT04404426|Placebo Comparator|Placebo|Administration of placeboenterally for 7 days
32949802|NCT04764084|Experimental|Treatment group|Niraparib-Anlotinib combination therapy
32949803|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
32949804|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
32949805|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
32949806|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
32949807|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
32949808|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
32949809|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
32949810|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
32949811|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
32949812|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
32949813|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
32949814|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
32949815|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
32949816|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
32949817|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
32949818|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
32949819|NCT03870048|Experimental|All Study Participants/tDCS or SHAM|"tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.~Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes."
32949820|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
32949821|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
32949822|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm~maximal number of doses: 6~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
32949823|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration~If AROM cannot be performed- oxytocin infusion will be initiated at first.~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
32949824|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
32949825|NCT03866538|No Intervention|Continued Budesonide|Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
32949826|NCT03866538|Experimental|Withdrawal of Budesonide|Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial
32949827|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
32949828|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
32949829|NCT03865212|Experimental|Group A (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1.
33098754|NCT04692051|Experimental|Nab-paclitaxel + Cisplatin|Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
32805670|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
32805671|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
32805672|NCT02317042|Active Comparator|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
32805673|NCT02317042|Experimental|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
32805674|NCT02317042|Active Comparator|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
32805675|NCT04205266|Experimental|IV Iron|Will receive 2 infusions of 510mg of ferumoxytol, administered over 15 minutes, 3-8 days apart
32805676|NCT04205266|Active Comparator|Oral Iron|Will receive 325mg ferrous sulfate tablets daily for 60 days
32805677|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
32805678|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
32805679|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
32805680|NCT01125436|Placebo Comparator|placebo|Weekly placebo plus 800 calcium daily
32805681|NCT01113658|Experimental|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
32805682|NCT04755322|Active Comparator|hydroxychloroquine group|hydroxychloroquine 400 mg+ Folic Acid 5 mg+ Low-dose aspirin 75 mg
32805683|NCT04755322|Placebo Comparator|Placebo group|Folic Acid 5 mg+ Low-dose aspirin 75 mg+ Placebo oral tablet
32805684|NCT04755478||Lung lobectomy via open thoracotomy|participants scheduled for lung lobectomy via open thoracotomy
32805685|NCT04755478||Lung lobectomy via VATS|participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery
32805686|NCT04755400|Active Comparator|Potassium Nitrate|4 days treatment with 24 mmol potassium nitrate capsules
32805687|NCT04755400|Placebo Comparator|Potassium Chloride|4 days treatment 24 mmol potassium chloride capsules
32805688|NCT04777942|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
32805689|NCT04777942|Active Comparator|surgery alone|hepatic resection remove the liver tumors
32805690|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
32805691|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
32805692|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
32805693|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
32805694|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
32805695|NCT00412594|Experimental|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
32805696|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
32805697|NCT04778098|Experimental|SMS group|"After postoperative standard discharge education was provided to the patients in the SMS group, they were given an individualized written Postoperative Medication Reference Chart. The patient/relative, whose contact information was received, was informed that they would be reminded via text message (SMS). SMS reminders which were individualized according to the patient based on the doctor's directive, were sent to the patients in the SMS group by the researcher clinical nurse (A. Ş). SMS sending started on postoperative day 1 and ended on day seven.~SAI was applied again to all patients who came to the outpatient clinic for control on postoperative day seven. Unlike the control group, the Patient Satisfaction Form, which was prepared for the use of SMS reminders, was applied to the patients in the SMS group. Confirmation was obtained from the patients and their relatives that SMS reminders were received every day."
32830994|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
32830995|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
32830996|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
33314600|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33314601|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33314602|NCT03905954||Parkinson's Diagnosis|Usual care
33314603|NCT01148576|Other|control group|patients only with chronic hepatitis B
33314604|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
33314605|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
33314606|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
33314607|NCT01253954||ICU patients with IFI|1
33314608|NCT03901586|Experimental|Patients who had Richter intervention|
33314609|NCT03901508|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
33314610|NCT03901508|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
33314611|NCT03901352|Experimental|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to < 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
33314612|NCT03901352|Placebo Comparator|Placebo|Placebo (14-weeks)
33314613|NCT03905486|Active Comparator|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
33314614|NCT03905486|Active Comparator|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
33314615|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
33314616|NCT03901040|Other|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
33314617|NCT03901118|Experimental|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
33314618|NCT03901118|Experimental|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
33314619|NCT03900962|Experimental|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
32830997|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
32830998|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
32830999|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
32831000|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
32831001|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
32831002|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
32831003|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
32831004|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
32831005|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
32831006|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
32831007|NCT05074368|Active Comparator|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
32831008|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
32831009|NCT05074368|Active Comparator|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
32831010|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
32831011|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
32831012|NCT03263754|Experimental|Intervention|
32831013|NCT03263754|Active Comparator|Control|
32831014|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
32831015|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
32831016|NCT03263910|Experimental|NPO-11|
32831017|NCT03263910|Placebo Comparator|Placebo|
33404754|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
32831018|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
32831019|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
32831020|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
32949830|NCT03865212|Experimental|Group B (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1. Cycle 1 continues for 28 days, with subsequent cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity.
33098755|NCT04692051|Active Comparator|Gemcitabine + Cisplatin|Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
32831021|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
32831022|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
32831023|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
32831024|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
32831025|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
32831026|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
32831027|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
32831028|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
32831029|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
32831030|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
32831031|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
32831032|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
32831033|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
32831034|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
32831035|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
32831036|NCT05045586|Experimental|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
32831037|NCT05045586|Active Comparator|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
33404755|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
33404756|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
33314620|NCT03900962|Experimental|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
33314621|NCT03896594|Experimental|HL237 200mg|HL237 100mg 1 tablet twice a day
33314622|NCT03896594|Experimental|HL237 400mg|HL237 100mg 2 tablets twice a day
32805698|NCT04778098|No Intervention|Control group|the Patient Identification Form and SAI were applied to patients in the control on the day of surgery (postoperative day 0). Routine discharge education was provided to all patients by clinical nurses. During the discharge of the patients in the control group, they were informed about the change of dressing on the next day (postoperative day one) and control in the outpatient clinic on postoperative day seven. The patients were given an individualized written Postoperative Medication Reference Chart indicating the dosage and application time of eye drops they must follow for seven days at home.
32805699|NCT04777786|Experimental|Physical Therapy Intervention|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning ~4 weeks after surgery (x̄=10 visits).
32805700|NCT04777786|No Intervention|Usual Care|The usual care group will be instructed to continue with their typical daily activities.
32805701|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
32805702|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
33314623|NCT03896594|Experimental|HL237 800mg|HL237 400mg 1 tablet twice a day
33314624|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
32805703|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
32805704|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
32805705|NCT03783052|Other|Healthy volunteers|11 Healthy volunteers
32805706|NCT03783052|Other|Obese volunteers|11 Obese Volunteers
32805707|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
32805708|NCT03783052|Other|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
32805709|NCT03783052|Other|Volunteers with obesity|6 obese volunteers
32805710|NCT04634578|Experimental|Bevacizumab- 0.063 mg|Participants will receive a single intravitreal injection of 0.063 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
32805711|NCT04634578|Experimental|Bevacizumab- 0.25 mg|Participants will receive a single intravitreal injection of 0.25 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
32805712|NCT04564612|Experimental|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
32805713|NCT04564612|Experimental|Part 1B|Participants will be randomized to receive single oral or 2 oral doses for divided daily doses of BIIB091 on Day 1 of Period 1, in fasted state or single oral dose of BIIB091 on Day 1 of Period 1, in fed state. Participants will receive single oral dose of BIIB091 on Day 1 of Period 2, in fasted state. Participants will receive single or two divided oral dose(s) of BIIB091 on Day 1 of Periods 3 and 4, in fasted or fed state. There will be a minimum 7-day washout between Day 1 of each study period.
32805714|NCT04564612|Experimental|Part 2|Participants will receive single oral dose of BIIB091 on Day (D) 1 of Period (P) 1 in fasted/fed state; then itraconazole 100 milligram (mg) capsules (cap), orally, twice daily (BID) for 1 day (D -4) of P2, in fed state; then itraconazole 100 mg cap, orally, once daily (QD) for 2 days (D -3, -2) of P2, in fed state; then itraconazole 100 mg cap, orally, QD for 1 day (D -1) of P2, in fasted/fed state; then combination of itraconazole 100 mg cap, orally and BIIB091, orally on 5th day (D 1) of P2, in fasted/fed state; then itraconazole 100 mg cap, orally on 6th day (D 2) of P2, in fed state; then rabeprazole 20 mg tablets (tab), orally, BID for 3 days (D -3, -2, and -1) of P3 in fed state; then combination of rabeprazole 20 mg tab, orally and BIIB091, orally, on 4th day (D 1) of P3 in fasted/fed state. Minimum 7-day washout between dose of BIIB091 in P1 and 1st dose of itraconazole in P2; minimum 10-day washout between final dose of itraconazole in P2 and 1st dose of rabeprazole in P3.
32805715|NCT04564612|Experimental|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
32805716|NCT04778254|Active Comparator|conventional obturator|conventional group received conventional clasp-retained obturators with metallic framework (Control group).
32805717|NCT04778254|Experimental|metallic attachment retained obturator|metal group received an attachment-retained obturator with metallic framework
32805718|NCT04778254|Experimental|PEEk attachment retained obturator|PEEK group received attachment-retained obturators with milled PEEK framework,
32805719|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy~Infants of HIV-infected women exposed to TDF during pregnancy"
32805720|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding~Infants of HIV-infected women exposed to TDF while breastfeeding"
32805721|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy~Infants of HIV-infected women not exposed to TDF during pregnancy"
32805722|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding~Infants of HIV-infected women not exposed to TDF during breastfeeding"
32805723|NCT04777552||Fixed-schedule|Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.
33314625|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
33314626|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
32805724|NCT04777552||CIWA-Ar|Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.
32805725|NCT04777318|Experimental|Conventional physiotherapy|The individuals in the control group will be included in a total of 12 sessions of conventional physiotherapy program for 4 weeks, 3 days a week.
32805726|NCT04777318|Experimental|Muscle Energy Technique (MET)|In addition to the conventional physiotherapy program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the second group.
32805727|NCT04777318|Experimental|Cervical Mobilization Techniques (CMT)|In the third group, cervical mobilization techniques will be applied in addition to the conventional physiotherapy program for a total of 12 sessions for 4 weeks, 3 days a month.
32805728|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m^2 QD Days 1 through 5 in each 28-day cycle.
32805729|NCT01506609|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
32805730|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
33314627|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
33314628|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
33314629|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
33314630|NCT03896282|Active Comparator|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
33314631|NCT03896282|Active Comparator|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
33314632|NCT03895892|Placebo Comparator|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
33314633|NCT03895892|Experimental|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
33314634|NCT03895892|Experimental|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
33314635|NCT03896204|Experimental|telephone-supported group|
33314636|NCT03896204|Experimental|Other group|
33314637|NCT01151306|Placebo Comparator|Lactose tablet|
33314638|NCT01151306|Active Comparator|Simvastatin 20mg|
33098756|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
33314639|NCT05590364|Experimental|Profhilo® Body treatment group|"1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage.~Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol).~Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire.~Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire."
33314640|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
33314641|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
33314642|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
33314643|NCT05543720|No Intervention|Control|Control groups will be compared to 350 patients who received standard of care via propensity-matched controls from the ICES provincial database.
33314644|NCT05543720|Experimental|Telemonitoring (Medly MCC)|Medly is a smartphone application allows patients with heart failure, diabetes, depression, hypertension, and/or COPD to measure and record their daily self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
33314645|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
33314646|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
33314647|NCT05114876|No Intervention|Standard of Care|Standard of care
33314648|NCT05114876|Active Comparator|Intervention|Multicomponent delirium-risk prevention bundle
33314649|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
33314650|NCT01149590|No Intervention|No CT Scan|No CT Scan
33318639|NCT03951168|Other|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
33318640|NCT03951168|Experimental|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
33404757|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
33404758|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
33404759|NCT03687060|Other|Organization Level|
33404760|NCT03687060|Other|Provider Level|
33404761|NCT03687060|Other|Patient Level|
33404762|NCT05017324|Experimental|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an individualised RR-TB treatment recommendation
33404763|NCT05017324|No Intervention|Standard of Care|Standard of care diagnosis of the drug resistance profile and individualised treatment
32949831|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
33404764|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
32949832|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
32949833|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
32949834|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
32949835|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
32949836|NCT03661086|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
32949837|NCT03661086|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
32949838|NCT03658668|Experimental|active tDCS+PA|
32949839|NCT03658668|Sham Comparator|sham tDCS+PA|
32949840|NCT03658512||TUEDID cohort|
32949841|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
32949842|NCT03749460|Experimental|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
32949843|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
32949844|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
32949845|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
32949846|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
32949847|NCT03748134|Experimental|Sintilimab + chemotherapy|"Sintilimab in combination with investigator's choice of chemotherapy~TP regimen: Cisplatin + paclitaxel~or~CP regimen: Cisplatin + fluorourcil"
32949848|NCT03748134|Active Comparator|Placebo + chemotherapy|"Placebo in combination with investigator's choice of chemotherapy~TP regimen: Cisplatin + paclitaxel~or~CP regimen: Cisplatin + fluorourcil"
32949849|NCT03747432|Experimental|Propofol|Procedural sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
32949850|NCT03747432|Experimental|Dexmedetomidine|Procedural sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
32949851|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
32949852|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
32949853|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
32949854|NCT01345656|Experimental|Arm 1|
32949855|NCT01345656|Experimental|Arm 2|
32949856|NCT01345656|Experimental|Arm 3|
32949857|NCT01345656|Experimental|Arm 4|
32949858|NCT01345656|Placebo Comparator|Arm 5|
32949859|NCT01345656|Active Comparator|Arm 6|
32949860|NCT01676922||Cohort|
32949861|NCT03744624|Experimental|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
32949862|NCT03744624|Active Comparator|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
33098757|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
32949863|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
32949864|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
32949865|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
32949866|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
32949867|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
32949868|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
32949869|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
32949870|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
32949871|NCT03851406|Active Comparator|5% Hypertonic Saline|Subjects will inhale 5% hypertonic saline
32949872|NCT03851406|No Intervention|No Treatment|No inhaled treatment
32949873|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
32949874|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
32949875|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
32949876|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
32949877|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: Normal Saline Normal saline is safe for perineural injection."
32949878|NCT04763460|Active Comparator|Baseline CRT programming|The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
32949879|NCT04763460|Experimental|Electrocardiography-guided optimal CRT programming|The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.
32949880|NCT04763616|Experimental|Isatuximab and Cemiplimab combined therapy|"Drug : Isatuximab~1 cycle : 10mg/kg IV every week. It is administered on Day 2, Day 9, Day 16, Day 23.~2~6 cycle : 10mg/kg every 2 weeks . It is administered on Day 2, Day 16.~7th cycle and beyond : 10mg/kg IV every 3 weeks. It is administered on Day 2.~Drug : Cemiplimab~1st - 6th cycle : 250mg IV every 2 weeks. It is administered on Day 1, Day 15.~7th cycle and beyond : 350mg every 3 weeks. It is administered on Day 1."
32949881|NCT04747158|Experimental|Convalescent plasma|COVID-19 convalescent plasma
32949882|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine"
32949883|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
32949884|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine"
32949885|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine"
32949886|NCT03650244||Patients fitted with REMEEX|
32949887|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
32949888|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
32949889|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
32949890|NCT00003468|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32949891|NCT03647358|Experimental|Lesion Dosimetry With Iodine-124|Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.
33098758|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
33314651|NCT03900494|Active Comparator|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
33314652|NCT03900494|Active Comparator|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
32949892|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
32949893|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
33314653|NCT03900572|Experimental|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
33314654|NCT03900572|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
33314655|NCT05528120|Experimental|KG|
33314656|NCT05528120|Experimental|GK|
33404765|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
32949894|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
32949895|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
32949896|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
32949897|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
32949898|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
32949899|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
32949900|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
32949901|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
32949902|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
32949903|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
32949904|NCT03645096|Experimental|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
32949905|NCT03645096|Experimental|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
32949906|NCT03645096|Experimental|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
32949907|NCT03645096|Experimental|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
32949908|NCT03645096|Experimental|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
32949909|NCT03645096|Experimental|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
32949910|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
32949911|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
32949912|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
32949913|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
32949914|NCT03732300|No Intervention|TAU|Treatment as usual
32949915|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
32949916|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
32949917|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
32949918|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
33314657|NCT05570786|Experimental|Gestrinone|Subdermal implant-bioabsorbable gestrinone pellet (85 mg) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
33314658|NCT05570786|Placebo Comparator|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
33314659|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
33314660|NCT01255202||twin preganacies|
33314661|NCT05561894|Placebo Comparator|A (control)|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 12%.
33314662|NCT05561894|Active Comparator|B|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 16%.
33314663|NCT03895970|Experimental|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
33314664|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
33314665|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
33314666|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
33404766|NCT05079646|No Intervention|Group 1, subgroup A (blue color coded)|Normal teeth with no cavity preparation and no endodontic procedure.
32805731|NCT04777162|Experimental|tislelizumab+anlotinib|patients will be administrate with dual drugs, tislelizumab plus anlotinib.
32805732|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
32805733|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
32805734|NCT04776772|Placebo Comparator|Soccer player placebo|Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
32805735|NCT04776772|Experimental|Soccer player synbiotic|Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
32805736|NCT04776772|Placebo Comparator|Sedentary individuals placebo|Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
32805737|NCT04776772|Experimental|Sedentary individuals synbiotic|Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
32805738|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
32805739|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
32805740|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
32805741|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
32805742|NCT04389580|Active Comparator|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
32805743|NCT04389580|Active Comparator|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
32805744|NCT04389580|No Intervention|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
32805745|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
32805746|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
32805747|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
32805748|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
32805749|NCT03856437|Experimental|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
32805750|NCT03856437|Experimental|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
32805751|NCT03856437|Active Comparator|Control messages|Participants in this arm receive non-framed HPV vaccination messages.
32805752|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
32805753|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
33314667|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
33098759|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
33098760|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
33098761|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
33098762|NCT03459326||control group|men in relation
33098763|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
33098764|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
33098765|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
33098766|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
33098767|NCT01580514|Placebo Comparator|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
33098768|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
33098769|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
33098770|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
33098771|NCT00510185|Sham Comparator|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
33098772|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
33098773|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
33098774|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
33098775|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
33098776|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
33314668|NCT03905564|Experimental|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
33098777|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
33098778|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
33098779|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
33098780|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
33098781|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
33098782|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
33098783|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
33314669|NCT03905564|Active Comparator|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
33314670|NCT03895424|Experimental|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
33314671|NCT03895424|Experimental|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
33314672|NCT03895424|Active Comparator|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
33314673|NCT01151384|Experimental|LE-DT|
33314674|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
33314675|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
33314676|NCT01254110||1|Enterally fed with leucine
33314677|NCT01254110||2|Enterally fed with glutamine
33314678|NCT01254110||3|Enterally fed with protein powder
33314679|NCT03895190|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
32805754|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
32805755|NCT00199108|Experimental|Only 1 arm|
32805756|NCT04776538|Experimental|Stem cell group|60 patients will be randomized to receive adipose-derived allogeneic stem cells
32949919|NCT04762524|Experimental|Initiation on CVVH|Patients in this arm were initiated on CVVH, rather than CVVHD
32805757|NCT04776538|Placebo Comparator|Placebo group|60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
32805758|NCT01504971||Gastroesophageal reflux disease (GERD)|
32805759|NCT04776616|Sham Comparator|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
32805760|NCT04776616|Experimental|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
32805761|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
32805762|NCT00954226|Experimental|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
32805763|NCT00954226|Experimental|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
32805764|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
32805765|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
32805766|NCT04776304|Other|qEEG Art Therapy|Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.
32805767|NCT04753918|Experimental|Novel light delivery methods for photodynamic therapy|High refraction-index contrast medium: Lipiodol injected in the bronchial tree can enhance the treatment extension of the photodynamic therapy
32805768|NCT04161664|Experimental|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
32805769|NCT04753606|Placebo Comparator|Placebo|once-daily placebo
32805770|NCT04753606|Experimental|obicetrapib 5 mg|once-daily obicetrapib
32805771|NCT04753606|Experimental|obicetrapib 10 mg|once-daily obicetrapib
32805772|NCT04755946|Experimental|roflumilast arm|
32805773|NCT04755946|Placebo Comparator|placebo arm|
32805774|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
32805775|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
32805776|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
32805777|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
32805778|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
32805779|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
32805780|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
32805781|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
32805782|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
32805783|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32805784|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32805785|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32805786|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32805787|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
32805788|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32949920|NCT04762524|Active Comparator|Initiation on CVVHD|Patients in this arm were initiated on CVVHD, rather than CVVHDH
33404767|NCT05079646|Experimental|Group 1, subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu).
32805789|NCT04776226|No Intervention|Patients without depression|This group included patients without depression during enrollment of the cases.
32805790|NCT04776226|Experimental|Depressive patients with treatment|This group included patients wit depression but with treatment during enrollment of the cases.
32805791|NCT04776226|No Intervention|Depressive patients wihout treatment|This group included patients without depression but withou treatment during enrollment of the cases.
32805792|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as prescribed below.~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~Leucovorin: 200 mg/m2 IV bolus over 2 hours~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
32805793|NCT00910312|Experimental|Breast Fibroadenoma|
32805794|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
32805795|NCT00885664|Other|Truvada/Kaletra CD4<100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4<100 cells/cu mm
32805796|NCT00885664|Other|Truvada/Kaletra CD4>/=100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4>/=100 cells/cu mm
32805797|NCT04775992||preemptive group|patients in this group will receive preoperative gabapentoids
32805798|NCT04775992||control group|patients in this group will not receive gabapentoids
32805799|NCT04775758|Experimental|Atypical facial pain group|Patients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
32805800|NCT04775758|Active Comparator|Maxillofacial fracture pain group|Patients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
32805801|NCT04775602|Experimental|18F-PSMA PET/CT|Patients with evidence of biochemical recurrence of prostate cancer radically treated, with negative results to traditional diagnostic methods or doubtful imaging of 18F- Fluoro Methyl Choline (18F-FMC) PET/CT will perform a 18F-PSMA PET/CT as a tool for searching and location of recurrence.
32805802|NCT04784104|Experimental|Supraclaviculer block|The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
32805803|NCT04784104|Experimental|Infraclaviculer block|The lateral sagittal infraclavicular block will be applied to the second group with ultrasound guidance using a 22G 100 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.). Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
32805804|NCT00880594|Experimental|Open label desipramine|
32805805|NCT04783870|Experimental|Dapagliflozin|Dapagliflozin 10 mg PO QD
32805806|NCT04783870|Placebo Comparator|Control|Placebo PO QD
32805807|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
32805808|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
32805809|NCT04783636|Other|A|After a single administration of PT105R (leuprorelin acetate 3.75mg), a single administration of PT105 (leuprorelin acetate 3.75mg)
32805810|NCT04783636|Other|B|After a single administration of PT105 (leuprorelin acetate 3.75mg), a single administration of PT105R (leuprorelin acetate 3.75mg)
32805811|NCT04784026||Healthy Control Group|Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.
32805812|NCT04784026||Case Group|The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.
32805813|NCT03510208|Experimental|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
32805814|NCT03510208|Experimental|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
32805815|NCT03510208|Experimental|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
32805816|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
32805817|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
32805818|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
32805819|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
32805820|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
32805821|NCT03371368|Other|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
32805822|NCT03371368|Other|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
32805823|NCT03371368|Active Comparator|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
32805824|NCT03371368|No Intervention|Obese Control Group|Non-diabetic obese subjects
32805825|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
32805826|NCT03364348|Experimental|Cohort 1A (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 1B).
32805827|NCT03364348|Experimental|Cohort 1B (trastuzumab + utomilumab)|Utomilumab 100 mg IV + trastuzumab 6 mg/kg IV every 3 weeks.
32805828|NCT03364348|Experimental|Cohort 2A (ado-trastuzumab emtansine + utomilumab)|Utomilumab 20 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
32805829|NCT03364348|Experimental|Cohort 2B (ado-trastuzumab emtansine + utomilumab)|Utomilumab 100 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
32805830|NCT04445116|Experimental|Endeavor™ Action Video Game Treatment|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
32805831|NCT04775290|Experimental|Arm Yoga (YG)|Patients assigned to the YG arm participate in yoga classes
32805832|NCT04775290|No Intervention|Arm control (CG)|Patients assigned to the CG arm will follow the normal course of radiotherapy.
32805833|NCT04783558|Experimental|Adapted NAS tool Intervention|Pregnant women in this condition will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth.
32805834|NCT04783558|No Intervention|Treatment-as-Usual (TAU)|Pregnant women in this condition will receive care as usual that involves continued enrollment in OAT and continued obstetric care. We will also provide them with a printed handout containing information on NAS and local resources. Participants in the TAU condition will not receive iPads with accompanying modules, however the handout constitutes more information than they normally receive.
32805835|NCT04782622||Apatinib+Camrelizumab|treated with apatinib+camrelizumab
32805836|NCT04775212|Active Comparator|desflurane|patients to be anesthetized with desflurane
32805837|NCT04775212|Active Comparator|sevoflurane|patients to be anesthetized with sevoflurane
32805838|NCT04306900|Experimental|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
32805839|NCT04306900|Experimental|Combo 2|TTX-030 plus budigalimab plus docetaxel
32805840|NCT04306900|Experimental|Combo 3|TTX-030 plus mFOLFOX6
32805841|NCT04306900|Experimental|Combo 4|TTX-030 plus pembrolizumab
32805842|NCT04306900|Experimental|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
32805843|NCT04306900|Experimental|Combo 6|TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
32805844|NCT04306900|Experimental|Combo 7|TTX-030 plus nab-paclitaxel + gemcitabine
32805845|NCT04306900|Experimental|Combo 8|Budigalimab plus mFOLFOX6
32805846|NCT03355066|Experimental|Part 1A: Dose Escalation|Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.
33314680|NCT03895190|Experimental|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
33314681|NCT03905408|Experimental|50 mL Dextrose|50 mL of 50% dextrose
33314682|NCT03905408|Experimental|100 mL Dextrose|100 mL of 50% dextrose
33314683|NCT03905408|Experimental|150 mL Dextrose|150 mL of 50% dextrose
33098784|NCT02951091|Experimental|biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
33098785|NCT02951091|Active Comparator|control group|Patients will be randomized to the biomarker vs control group (standard of care; paclitaxel) as 4:1 ratio.
33314684|NCT03905408|Experimental|200 mL Dextrose|200 mL of 50% dextrose
33314685|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
33314686|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
33314687|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
33314688|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
33314689|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
33314690|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
33314691|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
33314692|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
33314693|NCT03900260|Other|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
33314694|NCT03900104|Experimental|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
33314695|NCT03900104|Active Comparator|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
33314696|NCT05667272||Pancreatic fistula group|no intervention(s)
33314697|NCT05667272||non-pancreatic fistula group|no intervention(s)
33314698|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
33314699|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
33314700|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
33314701|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
33314702|NCT05526404|Experimental|Mobile application-based Bristol stool scale|Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application
33314703|NCT03905018|Experimental|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
33314704|NCT03905018|Placebo Comparator|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
33314705|NCT01589588|Experimental|Mask 1|
33314706|NCT01589588|Experimental|Mask 2|
33314707|NCT01589588|Experimental|Mask 3|
33314708|NCT01589588|Placebo Comparator|Mask 3, placebo|
33314709|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
33314710|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
33314711|NCT03894722|Placebo Comparator|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
33314712|NCT03894722|Experimental|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
33314713|NCT03894722|Experimental|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
33314714|NCT03894722|Experimental|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
32949921|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
32949922|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
32949923|NCT03642210|Experimental|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months
32949924|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
32949925|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
32949926|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
32949927|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
32949928|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
32949929|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
32949930|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
32949931|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
32949932|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
32949933|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
32949934|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
32949935|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
32949936|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
32949937|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
32949938|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
32949939|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
32949940|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
32949941|NCT04403958|Experimental|PRC|Total wrist arthrodesis with PRC and dorsal plate
32949942|NCT04403958|Active Comparator|TWA|Total wrist arthrodesis with dorsal plate
32949943|NCT04763850|Experimental|Walking decline|Walking decline on an instrumented treadmill under 3 different conditions
32949944|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
32949945|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.~Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
32949946|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
33098786|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
32805847|NCT03355066|Experimental|Part 1B: Dose Finding|Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.
32805848|NCT03355066|Experimental|Part 2: Expansion|"Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 3 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC (two biomarker selection cohorts) and NSCLC for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll up to 20 subjects.~Approximately 10 subjects of the total enrolled in Part 2, irrespective of cohort, will be included in a food-effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502."
32805849|NCT04774900||Standardised|The procedures will be observed with standardized equipment placement.
32805850|NCT04774900||Modified|The procedures will be observed with modified equipment placement - placement according to older methodology or custom.
32805851|NCT04774978|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE continuously with ProbeFix
32805852|NCT04774822||Sequential Enrollment|Enrollment based on default inclusion criteria listed below
32805853|NCT04774822||Enrichment Enrollment|Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution
32805854|NCT04782934|Experimental|YANG system group|
32805855|NCT04782388|Experimental|Staccato alprazolam|Study participants will receive Single dose of Staccato alprazolam on Day 1 of the Treatment Period.
32805856|NCT04782388|Placebo Comparator|Staccato placebo|Study participants will receive placebo on Day 1 of the Treatment Period.
32805857|NCT04782076|Experimental|Dabigatran + Selpercatinib|Dabigatran as single dose administered orally on Day 1 followed by a single dose of dabigatran coadministered with a single dose of selpercatinib on Day 8 orally.
32805858|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
32805859|NCT04782310|Experimental|Group Pregabalin|Patients will receive oral Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
32805860|NCT04782310|Experimental|Group Duloxetine|Patients will receive oral duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
32805861|NCT04782310|Experimental|Group Pregabalin& Duloxetine|Patients will receive single dose of Pregabalin 75mg + duloxetine 30mg two hour preoperatively, 75mg pregabalin 12 hour postoperative and then will continue pregabalin twice per day +duloxetine once after breakfast for one week.
32805862|NCT04781998|Experimental|liraglutide 3 mg (Saxenda®) once-daily|
33404768|NCT05079646|Experimental|Group 1, subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent)
32805865|NCT04781764||glioma patients|glioma patients with routine surgery
32805866|NCT04774432|Active Comparator|GM-CSF group|"Patients will be randomly allocated to intervention group with GM-CSF added to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
32805867|NCT04774432|Active Comparator|Control group|"Patients will be randomly allocated to control group without the addition of GM-CSF to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
32805868|NCT04774588|Other|Using VSI Streamer and Telemedicine Study|Using the real time streaming of input from video capture devices to a head mounted display during interventional radiology procedures
32805869|NCT04774588|Placebo Comparator|Not using VSI Streamer and Telemedicine Study|Not using real time streaming of input from video capture devices to a head mounted display and just using current standard imaging in the Interventional Suite.
32805870|NCT04774510|Other|Optimized C-ARM CBCT|An optimized C-arm CBCT evaluation with a different acquisition geometry and a novel software for the rapid, quality improved and less-artefacts assessment of brain parenchyma and angiogram.
32805871|NCT04774276||Group with occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They will have the cardiac rehabilitation protocol (4 weeks) with occupational therapist as usual practice. The inclusion in this group will be prospective, from January 2021.
32805872|NCT04774276||Group without occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They have done the cardiac rehabilitation protocol (4 weeks) without occupational therapist until december 2020. The inclusion in this group will be retrospective,
32805873|NCT04774042|Placebo Comparator|Placebo|Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
32805874|NCT04774042|Experimental|HAC|Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
32805875|NCT04774042|Experimental|Infloran|Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
32805876|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
32805877|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
32805878|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
32949947|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
32949948|NCT03621306||Men and women aged 18+|Men and women over the age of 18
32949949|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
33314715|NCT03894800|Active Comparator|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
32949950|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
32949951|NCT00003816|Experimental|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
32949952|NCT00003816|Experimental|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
32949953|NCT00003816|Experimental|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
32949954|NCT00003816|Experimental|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
32949955|NCT00003816|Experimental|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
32949956|NCT00003816|Experimental|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
32949957|NCT00003816|Experimental|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
32949958|NCT00003816|Experimental|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
32949959|NCT00003816|Experimental|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
32949960|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
32949961|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
32949962|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
32949963|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
32949964|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~abutment or encasement of the celiac axis~involvement of lymph nodes outside the area of resection"
32949965|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
32949966|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
32949967|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
32949968|NCT03717402|Other|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
32949969|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
32949970|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
32949971|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
32949972|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
32949973|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
33098787|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
33314716|NCT03894800|Active Comparator|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
33318641|NCT00048048|Experimental|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
32949974|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
32949975|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
32949976|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
32949977|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
32949978|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
32949979|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
32949980|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
32949981|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
32949982|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~rTMS: System Mag Pro (Magventure, Denmark)~Neuronavigation system: Syneika One (Syneika, France)"
32949983|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
32949984|NCT04763070|Other|Ciprofloxacin|
32949985|NCT04763694|Experimental|Treatment arm|Subjects wore multifocal soft contact lenses for 12 months.
32949986|NCT04762914||Prehabilitation (PH)|Patients who underwent prehabilitation prior to colorectal cancer resection
32949987|NCT04762914||Non-Prehabilitation (NPH)|Patients who did not undergo prehabilitation prior to colorectal cancer resection
32949988|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
32949989|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
32949990|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
32949991|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
32949992|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
32949993|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
32949994|NCT03828318|Experimental|Patient Activation Arm|
32949995|NCT03828318|No Intervention|Standard Care Arm|
32949996|NCT03609060|Experimental|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
32949997|NCT04762992|Experimental|Intervention group, enoxaparin|Enoxaparin subcutaneous injections
32949998|NCT04762992|Placebo Comparator|Placebo, normal saline|Normal saline subcutaneous injections
32949999|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
32950000|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
32950001|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
33314717|NCT03894800|Active Comparator|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
33314718|NCT03894800|Placebo Comparator|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
32950002|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
32950003|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
32950004|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
32950005|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.~Venetoclax is given daily by mouth per assigned dose level."
33314719|NCT03894644|Experimental|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
33314720|NCT03894644|Active Comparator|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
33314721|NCT03900182|Active Comparator|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
32950006|NCT00004092|Experimental|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
32950007|NCT00004092|Active Comparator|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
32950008|NCT00004146|Experimental|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.~Other: pharmacological study, radiation therapy"
32950009|NCT00004500|Experimental|Lucinactant|Lucinactant via bronchoaveolar lavage
32950010|NCT00004500|Other|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
32950011|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
32950012|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
32950013|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
32950014|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
32950015|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
32950016|NCT03604692|Experimental|Cohorts of escalating dose levels of SNDX-6352|"Escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).~Intravenous (IV) infusion; SNDX-6352 at a dose of 0.15 milligrams (mg)/kilogram (kg) to 3 mg/kg."
32950017|NCT03604692|Experimental|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.~IV infusion; SNDX-6352 at a dose of 1 mg/kg."
32950018|NCT03602976|No Intervention|Observation|
32950019|NCT03602976|Experimental|UDCA at Month 6|
32950020|NCT03701724|Experimental|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
32950021|NCT03701724|Experimental|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
32950022|NCT03701724|Sham Comparator|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
32950023|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and~Patients who receive PO or IV voriconazole for more than 3 days"
32950024|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
32950025|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
33314722|NCT03900182|Sham Comparator|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
33098788|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
33098789|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
33098790|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
33098791|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
33098792|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
33098793|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
33098794|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
33098795|NCT00515307|Experimental|A|
33098796|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
33098797|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
33098798|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
33098799|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
33098800|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
33098801|NCT02952638||Healthy|BMI is between 20 and 25
32805879|NCT03249844|Experimental|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
32805880|NCT03249844|No Intervention|control group|Children will be treated by standard of care alone
32805881|NCT04755166|Experimental|100:0|100 % bone substitute, 0% autogenous bone
32805882|NCT04755166|Experimental|90:10|90% bone substitute, 10% autogenous bone
32805883|NCT00684580||Observational Group|Data Collection
32805884|NCT04781608|Experimental|Intervention group|Gains access to the digital intervention program
32805885|NCT04781608|No Intervention|Wait-list- control group|Does not gain access to the intervention (until end of study)
32805886|NCT00637624|Active Comparator|1|N-Acetylcysteine
32805887|NCT00637624|Placebo Comparator|2|Placebo
32805888|NCT04754620|No Intervention|Standard face to face visit|This group will receive a traditional outpatient visit
32805889|NCT04754620|Experimental|Online visit|This group will receive a smartphone-based real-time video conference visit
32805890|NCT04773964|Experimental|MET642 high dose|
32805891|NCT04773964|Experimental|MET642 low dose|
32805892|NCT04773964|Placebo Comparator|MET642 Placebo|
32805893|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
32805894|NCT01479465|Experimental|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
32805895|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
32805896|NCT01479465|Experimental|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
32805897|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
32805898|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32805899|NCT04773574|Experimental|Normal pregnant women with high myopia|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA) were performed in each trimesters and at 6 weeks after childbirth.
32805900|NCT04773496||Balance evaluation|patient's balance is evaluated with instrumental posturography
32805901|NCT04773886|Sham Comparator|MTA GROUP|Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
33098802|NCT02952638||Overweight|BMI is between 25 and 30
33098803|NCT02952638||Obese|BMI is between 30 and 40
33098804|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
33314723|NCT03900026|Placebo Comparator|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
33314724|NCT03900026|Experimental|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
32805902|NCT04773886|Sham Comparator|BIODENTINE GROUP|Vital Pulpotomy will be done using Biodentine as pulp capping agent.
32805903|NCT04773886|Active Comparator|PRF + MTA GROUP|Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
32805904|NCT04773886|Active Comparator|PRF+ BIODENTINE GROUP|Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
32805905|NCT04781686|Experimental|First-line treatment|"First-line treatment: Apatinib plus Camrelizumab combined with Docetaxel and S1 for six cycles.~Maintenance treatment: Apatinib and Camrelizumab"
32805906|NCT04781920||Patients having undergone an Anterior Cruciate Ligament (ACL) reconstruction|Patients having undergone an ACL reconstruction will be included.
32805907|NCT02390284|No Intervention|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
32805908|NCT02390284|Experimental|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.~Drugs could be:~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
32805909|NCT02390284|No Intervention|Normal|Patients with a normal PERG test that will go through the study under observation.
32805910|NCT05605132|Experimental|Proprioceptive Training Group|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation gaze stability eye follow saccadic eye movement head and eye coordination"
32805911|NCT05605132|Experimental|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
32805912|NCT05605132|Sham Comparator|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
32805913|NCT04781218||Participants enrolled in the registry|Participants enrolled in the registry will include school community members including students, parents, staff, etc.
32805914|NCT04780906|Sham Comparator|Sham first (group 1)|Performs the first round of test with the sham comparator than with the experimental wrist taping
32805915|NCT04780906|Experimental|Wrist taping first (group 2)|Performs the first round of test with the experimental wrist taping than with the sham comparator
32805916|NCT03996460|Placebo Comparator|Placebo powder|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo powder orally once daily for 12 weeks (90 days).
32805917|NCT03996460|Active Comparator|192 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally once daily for 12 weeks (90 days).
32805918|NCT03996460|Active Comparator|384 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive the 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) orally once daily for 12 weeks(90 days).
32805919|NCT04780594||Pre-pandemic COVID-19 group (PreCOVID)|All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
33314725|NCT01149668|Experimental|PCI-24781|
33314726|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
33314727|NCT01586234|Active Comparator|Standard DSAEK|
33314728|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
33314729|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
33314730|NCT01149824|Other|Dose Escalating|
33314731|NCT03904940|Experimental|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
33314732|NCT03904940|Sham Comparator|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
33314733|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
33314734|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
33314735|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
33404769|NCT05079646|Active Comparator|Group 1, subgroup D (black color coded) positive control group|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson)
33314736|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
33314737|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
33314738|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
33318642|NCT00048048|Experimental|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
32950026|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
32950027|NCT03825120||Women from original OVA cohort|
32950028|NCT03824106|Experimental|Arm1.Control|Participants randomized to the control arm will not receive any of the Frailty Rehabilitation Interventions. Participants in the control arm will receive Vitamin D.
32950029|NCT03824106|Experimental|Arm2.Group Exercise|Participants will attend the exercise program, twice-weekly, for 4-months with supplemental home exercise.
32950030|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2.~Nutrition, protein supplementation, and a medication review will also be implemented."
32950031|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32950032|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
32950033|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
32950034|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
32950035|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
32950036|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
32950039|NCT03690648||Saliva collection|"Clinical examination;~Quality of life survey;~Saliva collection for genetical analysis"
32950040|NCT03690648||Saliva and Blood collection|"Clinical examination;~Quality of life survey;~Saliva and blood collection for genetical analysis"
32950041|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
32950042|NCT03689634|No Intervention|Standard Preoperative Care Group|
32950043|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
32950044|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
32950045|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
32950046|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
32950047|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
32950048|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
32950049|NCT03817320|Experimental|Ixazomib Dose Level 1 (Stratum A)|Patients will be treated on ixazomib at 1.6 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm is the starting Dose Level for patients being enrolled.
32950050|NCT03817320|Experimental|Ixazomib Dose Level 2 (Stratum A)|Patients will be treated on ixazomib at 2.0 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Patients will be treated at this arm Dose Level once patient accrual at Dose Level 1 has been completed and dose escalation is allowed as defined by the 3+3 design.
32950051|NCT03817320|Experimental|Ixazomib Dose Level -1 (Stratum A)|Patients will be treated on ixazomib at 1.2 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm Dose Level -1 is needed only if de-escalation from Dose Level 1 is required.
33098805|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
33098806|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
33098807|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
33098808|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
33098809|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
33098810|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
33098811|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
33098812|NCT00510263|Experimental|1|
32805920|NCT04780594||Pandemic COVID-19 group (COVID)|All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.
33098813|NCT00510263|Experimental|2|
33098814|NCT00510263|Experimental|3|
33404770|NCT05079646|No Intervention|Group 2, Subgroup A (Blue color coded) negative control group|Normal teeth with no cavity preparation and no endodontic procedure.
33404771|NCT05079646|Experimental|Group 2, Subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu) by using tofflemire retainer and matrix band.
33098815|NCT00510263|Placebo Comparator|4|
33098816|NCT00515385|Experimental|1a|Cohort 1 completed
33098817|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
33098818|NCT00515385|Experimental|2a|Cohort 2 completed completed
33098819|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
33098820|NCT00515385|Experimental|3a|Cohort 3 active
33404772|NCT05079646|Experimental|Group 2, Subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent) by using tofflemire retainer and matrix band.
33404773|NCT05079646|Active Comparator|Group 2, Subgroup D (black color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson) by using tofflemire retainer and matrix band.
33098821|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
33098822|NCT00515385|Experimental|4a|Cohort 4 active
33098823|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
33404774|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
32805921|NCT04780750|Active Comparator|Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
32805922|NCT04780750|Active Comparator|Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks|Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\m2 every 3 weeks)
32805923|NCT04780672|Active Comparator|Molixan|30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products
32805924|NCT04780672|Placebo Comparator|Placebo|"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.~ATC: B05CB01 Sodium chloride"
32805925|NCT04780984|Placebo Comparator|Placebo|Placebo, 2mL
32805926|NCT04780984|Experimental|Group 1 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~8 µg, 2.0 mL, 4 µg/mL"
32805927|NCT04780984|Experimental|Group 2 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~16 µg, 2.0 mL, 8 µg/mL"
32805928|NCT04780984|Experimental|Group 3 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~24 µg, 2.0 mL, 12 µg/mL"
32805929|NCT04780984|Active Comparator|Spiriva Respimat|5 ug, 2 actuations, 2.5 µg/actuation
32805930|NCT04773340||DBT intervention|Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
32805931|NCT02090374|Experimental|Poly ICLC dose escalation|Poly ICLC nasal challenge dose escalation 10ug, 100ug, 500ug
32805932|NCT02090374|Experimental|Poly ICLC highest dose|Poly ICLC nasal challenge single dose of 1000ug
32805933|NCT02090374|Experimental|Poly I:C single dose|Poly I:C nasal challenge single dose 500ug
32805934|NCT02090374|Experimental|R848 high dose|R848 nasal challenge 10ug
32805935|NCT02090374|Experimental|R848 low dose|R848 nasal challenge low dose 1-2ug (0.02ug/kg)
32805936|NCT02090374|Experimental|Grass pollen|Timothy grass pollen nasal challenge
32805937|NCT02090374|Experimental|Vitamin D supplementation|Vitamin D 4000U orally daily
32805938|NCT02090374|Experimental|Tuberculin|Tuberculin PPD nasal challenge
33098824|NCT00515385|Experimental|5a|Cohort 5 active
33098825|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
33098826|NCT00511628||001|Risperidone As prescribed
33098827|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
33098828|NCT00529425|Active Comparator|Ropivacaine|
33098829|NCT00529425|Placebo Comparator|Saline|
33098830|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
33098831|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
33098832|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
33098833|NCT00510341|Active Comparator|1|CMP program
33098834|NCT00510341|No Intervention|2|Control group
33098835|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
33098836|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
33098837|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
33098838|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
33098839|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
33098840|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
33098841|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
33098842|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
33098843|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
33098844|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
32805939|NCT04772794|Active Comparator|hyperoxygenation group|Intraoperative administration of a mixture of 80% oxygen and 20% air
32805940|NCT04772794|Placebo Comparator|control group|intraoperative administration of 30% oxygen and 70% air
32805941|NCT04773028||PATİENT GROUP(GROUP 1)|This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
32805942|NCT04773028||CONTROL GROUP(GROUP 2)|This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
32805943|NCT04772950||Healthy adults|
32805944|NCT04772950||Patients with non-specific low back pain|
32805945|NCT04772872||Group A:Naturally conceived singleton|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
32805946|NCT04772872||Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
32805947|NCT04772872||Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
32805948|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
32805949|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
32805950|NCT04752982|Active Comparator|c-SIGHT intervention|Grasp, lift and balance three wooden rods of different lengths.
32805951|NCT04752982|Sham Comparator|c-SIGHT attentional control|Grasp and lift three wooden rods of different lengths from one end only (no attempt to balance rods).
32805952|NCT04780360|Experimental|Cayanoacrylate tissue adhesives|thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds
32805953|NCT04780360|Active Comparator|Silk suture material|interrupted knots
32805954|NCT04780438|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following catheter ablation.
32805955|NCT04780438|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following catheter ablation.
32805956|NCT04779814||Cohort 1|Demipulse®/Aspire HC® (30 adult subjects)
32805957|NCT04779814||Cohort 2|Demipulse®/Aspire HC® (30 pediatric subjects)
32805958|NCT04779814||Cohort 3|Aspire SR® (30 adult subjects)
32805959|NCT04779814||Cohort 4|Aspire SR® (30 pediatric subjects)
32805960|NCT04779814||Cohort 5|SenTiva® (30 adult subjects)
32805961|NCT04779814||Cohort 6|SenTiva® (30 pediatric subjects)
32805962|NCT04780126||COVID-19 pneumonia patients|Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
32805963|NCT04779892|Experimental|CMAB008|
32805964|NCT04779892|Active Comparator|Remicade|
32805965|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
32805966|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
32805967|NCT04771780|Experimental|KHK7791|"During the dosing period, subjects administer KHK7791 twice daily just before meals.Subjects will be underwent tests at scheduled visits at least weekly until Week 12, at least once every 2 weeks after completion of Week 12 test.~KHK7791 and phosphate binders are adjusted with the goal of controlling serum phosphorus concentration within a certain range based on the dose adjustment criteria described in the study protocol.It should be considered that phosphorus adsorbent should be switched to KHK7791 whenever feasible."
33404775|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
33404776|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
33098845|NCT00510380||growth-restricted Chinese pregnancies|
33098846|NCT00510380||appropriately-grown Chinese pregnancies|
33098847|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
33098848|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
33098849|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
33098850|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
33098851|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
33404777|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
33404778|NCT03142672|Active Comparator|Control group|Tooth filling
33404779|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
33314739|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).~SBT Failure is defined by one or more of the following criteria occurring during the SBT:~loss of ≥ 2 points of Glasgow Coma Scale~respiratory rate/ tidal volume ≥105 breaths/min/L~arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH <7.32 or a decrease in pH ≥0.07 units at the end of the SBT~systolic Blood Pressure <90 mmHg or ≥180 mmHg or increased by ≥20%~Heart Rate >140 beats/min or increased by 20%~onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia~Respiratory Rate ≥35 breaths/min or increased by ≥50%~increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
33314740|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
33314741|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:~Respiratory Rate >25 breaths/min for 2 hours~Heart Rate >140 beats/min or sustained increase or decrease >20%~clinical signs of respiratory muscle failure~arterial partial pressure of oxygen (PaO2) <80 mmHg on inspired oxygen fraction (FiO2) ≥50%~Arterial partial pressure of carbon dioxide >45 mmHg with pH <7.33"
33314742|NCT02527928||desoxycholate|Amphotericin B desoxicholate
33314743|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
33314744|NCT02527928||ABLiposomal|Amphotericin B liposomal
33314745|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
33314746|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
33314747|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
33314748|NCT03899714|Active Comparator|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
33314749|NCT03899714|Active Comparator|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
32805970|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
32805971|NCT04389268||Control group|Age and sex matched with patients
32805972|NCT04771702|Experimental|Edmon arm|
32805973|NCT04771546|Experimental|Intervention (Colpofix)|Intravaginal gel with Carboxymethyl-β-glucan and Polycarbophil
32805974|NCT04771546|No Intervention|Control|No intervention (standard of care)
32805975|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
32805976|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
32805977|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
32805978|NCT04779346||Outpatient cancer patients|Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)
32805979|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
32805980|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
32805981|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
32805982|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
32805983|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
32805984|NCT04389346|Active Comparator|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
32805985|NCT04389346|Placebo Comparator|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
32805986|NCT04771390|Experimental|Part 1: Group A|Participants will receive 3 single doses of selitrectinib in adult tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
32805987|NCT04771390|Experimental|Part 1: Group B|Participants will receive 3 single doses of selitrectinib in pediatric tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
32805988|NCT04771390|Experimental|Part 2 (Group A): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
32805989|NCT04771390|Experimental|Part 2 (Group A): Dose B-C-A-D|Participants will receive dose B, C, A and D sequentially. The washing-out period between each dose is at least 3 days
32805990|NCT04771390|Experimental|Part 2 (Group A): Dose C-A-B-D|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
32805991|NCT04771390|Experimental|Part 2 (Group B): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
32805992|NCT04771390|Experimental|Part 2 (Group B): Dose B-D-A-C|Participants will receive dose B, D, A and C sequentially. The washing-out period between each dose is at least 3 days
33314750|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
33314751|NCT03644186|Active Comparator|Paclitaxel plus trastuzumab and pertuzumab|Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
33314752|NCT03644186|Experimental|Palbociclib plus letrozole plus trastuzumab and pertuzumab|Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
33314753|NCT03893708|Experimental|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
33314754|NCT03893708|Active Comparator|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
33314755|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
33314756|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
32950052|NCT03817320|Experimental|Ixazomib Dose Level 1 (Stratum B)|Patients will be treated on ixazomib at 1.6 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Leucovorin PO/IV at 5 mg/m^2/dose X 2 doses given 24 and 30 hours after IT Methotrexate or Triple IT will also be given on this arm. This arm is only for patients with Down syndrome (Stratum B).
32950053|NCT03684018|Experimental|IgPro10 (dose level 1)|
32950054|NCT03684018|Experimental|IgPro10 (dose level 2)|
32950055|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
32950056|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
32950057|NCT03680586|Experimental|Treatment (low-dose radiation therapy)|Patients undergo low-dose radiation therapy over 2 fractions for 2 consecutive days in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease at 12-16 weeks post-treatment, or persistent disease at 1 year may undergo higher-dose radiation therapy at the discretion of treating physician.
32950058|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
32950059|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 Continuous Glucose Monitor (CGM) for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of sensor-augmented pump (SAP) in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
32950060|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
32950061|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
32950062|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
32950063|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
32950064|NCT03589794|Experimental|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
32950065|NCT03589794|Experimental|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
32950066|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
32805993|NCT04771390|Experimental|Part 2 (Group B): Dose C-A-D-B|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
32805994|NCT04771390|Experimental|Part 2 (Group B): Dose D-C-B-A|Participants will receive dose D, C, B and A sequentially. The washing-out period between each dose is at least 3 days
32805995|NCT04771468||Sovratentorial ischemic stroke|
32805996|NCT05579548||Pregnant Women with PKU|This study will enroll pregnant women diagnosed with PKU who have been treated with pegvaliase from 2 weeks prior to LMP or at any time during pregnancy.
32805997|NCT05570578|Active Comparator|HD-tDCS|high-density transcranial direct current stimulation (HD-tDCS) over Broca's area
32805998|NCT05570578|Sham Comparator|sham-tDCS|sham transcranial direct current stimulation. The same setup will be used as in the HD-tDCS arm, except that the current will be ramped up for 30 seconds and then switched off. This does not lead to neural effects, but the patients have a similar sensation.
32805999|NCT04779502|Experimental|oregano|oregawash mouthwash was used twice times daily for 7 days
32806000|NCT04779502|Placebo Comparator|placebo|distilled water was used twice times daily for 7 days
32806001|NCT04779502|Active Comparator|chlorhexidine|Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days
32806002|NCT05480956|Experimental|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
32738123|NCT05023785|Experimental|Cardio-Oncology Rehabilitation (CORE)|Participants in the CORE group will have (1) 2 HIIT sessions (1 facility- and 1 home-based) and 1 home-based MICT session, (2) CV risk factor management, and (3) behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories. CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period. After the supervised 6 month exercise period, participants will be asked to maintain a PAI Score of ≥100 for the remainder of the study period via the PAI Health App.
32806003|NCT05480956|Experimental|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
33314757|NCT01258322|Experimental|pioglitazone|
33314758|NCT01148732||Patient needed intubation in emergency department|
32738124|NCT05023785|No Intervention|Standard of Care 1 (CON1)|Participants in the CON1 group will receive standard medical care only.
32738125|NCT05023785|Active Comparator|PAI Group (PAI)|Participants in the PAI group will be asked to download the same PAI Health application as CORE participants and be challenged to meet and maintain a weekly PAI Score ≥100 throughout the 24-month follow-up period.
32738126|NCT05023785|Active Comparator|Exercise Guidelines for Cancer Survivors (ExGL)|Participants in the ExGL group will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated weekly physical activity guidelines for cancer survivors (i.e. 90-150 minutes of moderate to vigorous-intensity physical activity).
32806004|NCT05480956|Experimental|SIRI Checklist + Enhanced Peer Recovery Coach|"A standardized checklist of clinical items to review by the attending hospitalist with participants.~Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month."
33314759|NCT03893786|Experimental|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
33314760|NCT03893786|Active Comparator|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
33314761|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
33314762|NCT03899558|Experimental|Intervention|HNHF device (intervention) + usual care
33314763|NCT03899558|No Intervention|Control|Usual care alone
33318643|NCT00048048|Experimental|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
33318644|NCT00048048|Experimental|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
32806005|NCT05480956|No Intervention|Standard of Care|Participants will receive the stand hospital care while in-patient.
32806006|NCT05411380|Experimental|Tucidinostat+Metronomic Capecitabine+Endocrine Therapy|This arm is divided into two groups. The main difference of this two groups lies in the selection of endocrine therapy. One is supposed to choose aromatase inhibitor, and the other is fulvestrant. The principle of making choice is based on the history of endocrine drug use.
32950067|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
32950068|NCT03816228||Experimental Flortaucipir|
32950069|NCT03810768||Intensive Care Patients|Postoperative high-risk patients who have been admitted to intensive care after surgery
33314764|NCT03904706|Experimental|Audits only|"Formalized audit teams with monthly meetings at each facility.~Audit Intervention phases:~Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.~Training of identified audit leaders (main investigator is typically a physician)~a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation~Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)~Establishing and launching the audit cycle (monthly meetings)~Annual re-certification of audit leaders"
33314765|NCT03904706|Experimental|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
33314766|NCT03904706|No Intervention|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
33318645|NCT00048048|Experimental|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
32738127|NCT05023785|No Intervention|Standard of Care 2 (CON2)|Participants in the CON2 group will receive standard medical care only.
32738128|NCT05007795|No Intervention|Programmatic MDR TB treatment regimen|Conventional MDR-TB laboratory tests. Sputum culture (and smear microscopy) will be evaluated monthly during the treatment period (and 6 monthly during the follow-up period) for the conventional arm.
32738129|NCT05007795|Experimental|Sequence based resistance testing and individualized treatment|Sputum extracted for targeted sequencing and drug resistance profile provided to clinician for individualized treatment.
32738130|NCT05023239|Sham Comparator|control group|patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.
32738131|NCT05023239|Experimental|UG-SZM Group|The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine
32738132|NCT05015517|Active Comparator|ESPB Group|This group will receive ultrasound-guided erector spinae plane block and subarachnoid block.
32738133|NCT05015517|Active Comparator|FIB Group|This group will receive supra-inguinal fascia iliaca block and subarachnoid block .
32738134|NCT05015829||Classical low-flow low-gradient aortic stenosis|LVEF<50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
32738135|NCT05015829||Paradoxical low-flow low-gradient aortic stenosis|LVEF>50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
32738136|NCT05022537|Experimental|Treatment (retrograde nephrostomy)|
32738137|NCT05022537|Active Comparator|Control Group ( antegrade nephrostomy)|
32738138|NCT05015673|Experimental|SEP-363856 25mg|SEP-363856 25 mg given orally
32738139|NCT05015673|Experimental|SEP-363856 50mg|SEP-363856 50mg given orally
32738140|NCT05015673|Placebo Comparator|Placebo|Placebo given orally
32738141|NCT05015361|Experimental|Treatment group A/B|Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate
32738142|NCT05015361|Active Comparator|Treatment group C|Treatment group C: Propofol Injection.
32738143|NCT01375075|Experimental|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
32738144|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
32738145|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
32738146|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
32738147|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
32738148|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
32738149|NCT05022381|Other|Preoperative and Postoperative Pain Level|The preoperative pain level, hip function and quality of life of patients who underwent radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerve in chronic hip pain will be compared with the postoperative pain level, hip function and quality of life of these patients.
32738150|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
32738151|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
32738152|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
32738153|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
32738154|NCT05022303|Placebo Comparator|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
32738155|NCT05022303|Experimental|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
32738156|NCT05021445|Experimental|plates based exercise|This will consists of 12 elderly participants who receive intervention protocol of Plates- based exercises program in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
32950070|NCT03810768||Operative Control patients|Elective operative patients where control blood samples and muscle ultrasound will be measured.
32950071|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
32950072|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
32950073|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
32950074|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
32950075|NCT03581214|Active Comparator|Room air|Room air (no mask)
32950076|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
32950077|NCT03581136|Experimental|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.~If PTV >100cc or if dose constraints cannot be met on higher dose prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis."
32950078|NCT00006156|Experimental|Control|Control for FSH stimulation test
32950079|NCT00006156|Experimental|Drug: FSH|FSH Stimulation Test
32950080|NCT03677778|Placebo Comparator|Placebo group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This control group will have no normal saline injected into their nerve catheter (no intervention). Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
32950081|NCT03677778|Active Comparator|Treatment group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This group will then have 30ml of normal saline injected into their nerve catheter. Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
32950082|NCT03675126|Experimental|SRP-5051|Patients will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
32950083|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
32950084|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
32950085|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
32950086|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
32950087|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
32950088|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
32950089|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
32950090|NCT05347914|Experimental|Mindfulness|
32950091|NCT05347836||Children diagnosed to have T1DM with a minimum duration of five years|
32950092|NCT05347836||Healthy children|
32950093|NCT05347758|Experimental|Group A|Drug: HRS-7535
32950094|NCT05347758|Placebo Comparator|Group B|Drug: Placebo
32950095|NCT05347680|Active Comparator|intubating laryngeal Tube Suction|Fiberoptic Intubation through intubating laryngeal Tube Suction
32950096|NCT05347680|Active Comparator|Ambu AuraGain Laryngeal Mask|Fiberoptic Intubation through Ambu AuraGain Laryngeal Mask
32950097|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
33404780|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
33314767|NCT03899480|Experimental|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy & colonoscopy to obtain ileal & rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets & measure frequencies of HIV RNA & DNA. On Day -1, the donor will undergo apheresis & donor cells will be obtained & incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 & 12 hrs after. Subjects will return on Days 2, 4, 7, 10, & 14 for blood draw. Subjects will return Days 21 & 42 for blood work & to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam & laboratory evaluations on Days 2, 4, 7, 10, 21, & 42. On day 49, we will perform lymph node biopsy & colonoscopy to obtain ileal & rectal tissues. The patient will then be followed until day 100 post infusion.
32950098|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
32950099|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
33404781|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
32950101|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
32950102|NCT03580356|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
32950103|NCT03580356|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
32950104|NCT03580356|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
32950105|NCT03580356|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
32950106|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
32950107|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
32950108|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing treatment with oXiris will be prospectively observed.
32950109|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
32950110|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
32950111|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
32950112|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
32950113|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
32806007|NCT04779580|Experimental|Intervention Group (Only Group)|"Only one group in this study. 10 participants to have intervention.~Lateral femoral cutaneous nerve block and evaluation:~Routine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.~After 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.~The above will then be repeated for the subcostal nerve block.~The total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia."
32806008|NCT03925480|Experimental|Azithromycin|A single 2g dose of Azithromycin
32806009|NCT03925480|Placebo Comparator|Placebo|Matching Placebo
32806010|NCT04771312|Active Comparator|Information-only intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the information-only condition could respond to daily questions in a diary.
32806011|NCT04771312|Experimental|Social support network intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the social support condition could use an online chatting tool where they can send messages to their own network.
32806012|NCT04770844||premature child|300 premature child will be included. They will have three acquisitions during hospitalization.
32806013|NCT05403658|Experimental|Family Navigation + Usual Care|Participants assigned to this arm will receive the Family Navigation (FN) intervention in addition to standard pediatric obesity management (Usual Care).
32806014|NCT05403658|Active Comparator|Usual Care|Participants assigned to this arm will standard pediatric obesity management only.
32806015|NCT04770688|Experimental|Osimertinib + Anlotiib|Escalating doses and expanding doses of Anlotinib administered with Osimertinib
32806016|NCT05399758||ICU sedated patients|Critical patients sedated with propofol and fentanyl The values obtained with the use of the NOL® index will be recorded and compared with the standard measurements of pain assessment (Behavioral Pain Scale (BPS) and/or CPOT)
32806017|NCT05390476|Experimental|Tucidinostat and metronomic capecitabine group|
32806018|NCT05390476|Active Comparator|metronomic capecitabine group|
32806019|NCT04770298|Experimental|Halliwick Assessment Group|8 children with GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM (GMFCS) I, 13 children with GMFCS II, 7 GMFCS III children, 8 GMFCS IV children and 4 children with GMFCS V. Intervention in water environment (Halliwick Concept), 1 times/week- 1 intervention on land/week, 9 months duration.
32806020|NCT04770298|Experimental|Bobath Assessment Group|7 children with GMFCS I, 12 children with GMFCS II, 8 children with GMFCS III, 6 children with GMFCS IV and 2 children with GMFCS V. Intervention on land ( Bobath), 2 times/week, 9 months duration.
32806021|NCT04770298|No Intervention|No intervention group|1 children with GMFCS I, 1 child with GMFCS III, 1 child with GMFCS IV and 2 GMFCS V children. No intervention.
32806022|NCT05379088|Experimental|Additional Follow-up|In addition to receiving an ActiGraph activity monitor, participants will complete weekly phone/zoom calls with research staff for a more in-depth monitoring of their activity level.
33314768|NCT03899246|Experimental|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
33314769|NCT03893552|Experimental|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
33314770|NCT03893864|Experimental|Intervention Group (CoQ10)|Runner athletes > 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
33314771|NCT03893864|Active Comparator|Control Group|Runner athletes > 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
33314772|NCT03893474|Other|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
32806023|NCT05379088|No Intervention|Activity Level Monitoring|Participants receive an ActiGraph activity monitor to track their activity level over a 6-week period.
33314773|NCT03893474|Other|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
33314774|NCT03893084|Experimental|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
33314775|NCT03893084|No Intervention|Control|The women in the control group were not given training, and routine practice was performed.
33314776|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
32806024|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
33314777|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
33314778|NCT03904394|Placebo Comparator|Placebo Mouthwash|
32806025|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
32806026|NCT04779034|Experimental|Group 1|Basketball players
33314779|NCT03904394|Active Comparator|Antibacterial Mouthwash|
33314780|NCT03899168|Experimental|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
33314781|NCT03899168|Experimental|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
32950114|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
32950115|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
32950116|NCT03806244|No Intervention|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
32950117|NCT03806244|Experimental|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
33314782|NCT03899168|Experimental|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
33314783|NCT03899324|Experimental|Group 1: Experimental Bumetanide|bumetanide with a titration period
32950118|NCT03575052|Experimental|Drug - Pimavanserin|
32950119|NCT03575052|Placebo Comparator|Placebo|
32950120|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
32950121|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
32950122|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
32950123|NCT04762056||COVID-19 patients after ICU discharge|Patients who suffered COVID-19 pneumonia and stayed in ICU and discharged
32950124|NCT04761900||participants were followed for the incidence of T2DM in a cohort study|performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.
32950125|NCT04761900||participants were followed for the incidence of hypertension in a cohort study|performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.
32950126|NCT04761900||participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study|performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.
32950127|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
32950128|NCT03804138||Patient|patient with COPD
32950129|NCT03804138||control group|patient without COPD
32950130|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
32950131|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
32950132|NCT03570918|Experimental|MGD014 0.1 micrograms/kilogram (mcg/kg)|a single 2-hour infusion
32950133|NCT03570918|Experimental|MGD014 0.3 mcg/kg|a single 2-hour infusion
32950134|NCT03570918|Experimental|MGD014 1.0 mcg/kg|a single 2-hour infusion
32950135|NCT03570918|Experimental|MGD014 3.0 mcg/kg|a single 2-hour infusion
32950136|NCT03570918|Experimental|MGD014 10.0 mcg/kg|a single 2-hour infusion
32950137|NCT03570918|Experimental|MGD014 30.0 mcg/kg|a single 2-hour infusion
32950138|NCT03570918|Experimental|MGD014 100.0 mcg/kg|a single 2-hour infusion
32950139|NCT03570918|Experimental|MGD014 300.0 mcg/kg|a single 2-hour infusion
32950140|NCT03570918|Experimental|MGD014 300.0 mcg/kg multiple doses|2-hour infusion every 2 weeks for 3 infusions
32950141|NCT03570372|Experimental|Intervention group|18 week internet-based CBT with therapist support. Regular online group discussions.
32950142|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
32950143|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
32950144|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
32950145|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
32950146|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
32950147|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
32950148|NCT05347524||Case arm - Gastric cancer with peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants with peritoneal metastasis.
33314784|NCT03899324|Placebo Comparator|Group 2: Placebo comparator|placebo intake identically to group 1
33314785|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
33314786|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
32950149|NCT05347524||Control arm - Gastric cancer without peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants without peritoneal metastasis.
32950150|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
32950151|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
32950152|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
32950153|NCT04403724|Active Comparator|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
32950154|NCT04403724|Active Comparator|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
32950155|NCT04403646|Experimental|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
32950156|NCT04403646|Placebo Comparator|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
32950157|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
32950158|NCT04403568|Experimental|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
32950159|NCT04403568|Experimental|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
32950160|NCT04403568|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
32950161|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
32950162|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
32950163|NCT03552276|Experimental|SUNPG18_07 q4 weeks, high dose|
32950164|NCT03552276|Experimental|SUNPG18_07 q12 weeks, high dose|
32950165|NCT03552276|Experimental|SUNPG18_07 q12 weeks, low dose|
32950166|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
32950167|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
32950168|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
32950169|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
32950170|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
32950171|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
32950172|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
32950173|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
32950174|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
32950175|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
32950176|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
32950177|NCT03541512|Active Comparator|Education only|Educational materials only
32950178|NCT04762134|Experimental|STI PrEP arm|doxycycline capsules 100mg orally daily for 12 months. Though the usual treatment dose of doxycycline is 100mg twice daily
32950179|NCT04762134|Experimental|STI PEP arm|doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
32950180|NCT04762134|No Intervention|Control/Standard of care arm|routine STI screening and care, which for sexually active gbMSM would not include any chemoprophylaxis for STI, as no clinical guidelines currently recommend its use
32950181|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
32950182|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
32950183|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
32950184|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
33314787|NCT05520086|Experimental|Single dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells
33098852|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
33098853|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
33098854|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
33098855|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
33098856|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
33098857|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
33098858|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
33098859|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
33098860|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
33098861|NCT00513032||methylene blue|
33098862|NCT00513032||C|
33098863|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
33098864|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
33098865|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
33098866|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
33098867|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
33098868|NCT00529854||1|Observational evaluation of current billing and documentation practices
33314788|NCT05520086|Experimental|Double dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14
33314789|NCT05507996|Experimental|A single-arm study of recombinant adeno-associated virus|An open, single-arm study of recombinant adeno-associated virus
33314790|NCT03893006|Experimental|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
33314791|NCT03893006|Experimental|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, & Hoc, 2007; Suzuki & Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, & Reyes, 2002).
33314792|NCT03893006|Experimental|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths & Gillespie, 2005; Mulder, Abbink, & Boer, 2012) as well as longitudinal (Adell, Várhelyi, & Hjälmdahl, 2008).
33314793|NCT03893006|Experimental|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
33314794|NCT03893006|Experimental|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
33098869|NCT00529854||2|Use of SIC-IR Billing Module
33098870|NCT00511745||001|
33098871|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
33098872|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
33098873|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
33098874|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
33098875|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
33098876|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
33098877|NCT02945124|Experimental|Normal children with K Tape|
33098878|NCT02945124|No Intervention|Normal children without K Tape|
33098879|NCT02945124|Experimental|DCD with K Tape|
33098880|NCT02945124|No Intervention|DCD without K Tape|
33098881|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
33098882|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
33098883|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
33314795|NCT03893006|Experimental|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
33314796|NCT01254500||patients with brain lesions|
33314797|NCT01254500||young normal controls|
32950185|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
33314798|NCT01254500||old normal controls|
33314799|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
32950186|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
32950187|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.~Incline treadmill walking Decline treadmill walking"
32950188|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
32950189|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
32950190|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
32950191|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
32950192|NCT03797898|No Intervention|Control|usual care well child care
32950193|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
32950194|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
32950195|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
32950196|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
32950197|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
32950198|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
32950199|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
32950200|NCT03794700|No Intervention|Control|
32950201|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
32950202|NCT04403412|Experimental|Left atrial appendage closure group|
32950203|NCT04403412|Experimental|Radiofrequency ablation group|
32950204|NCT04403412|Experimental|LAAC combined with radiofrequency ablation group|
32950205|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
32950206|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
32950207|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
32950208|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
32950209|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
32950210|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days between.
32950211|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
32950212|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days.
33314800|NCT01258556|Experimental|Probiotic yogurt|
32950213|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
32950214|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
33314801|NCT01258556|Placebo Comparator|Placebo yogurt.|
32950215|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
32950216|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
32950217|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
32950218|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
32950219|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
32950220|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
32950221|NCT03528408|Experimental|Nivolumab and Ipilimumab|All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
32950222|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
32950223|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
32950224|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
32950225|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
32950226|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
32950227|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
32950228|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
32950229|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
32950230|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
32950231|NCT03525288|Active Comparator|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
32950232|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
32950233|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
32950234|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
32950235|NCT05346822|Experimental|integrated rehabilitation program for total knee arthroplasty|the intervention was performed in one KMUH affiliated facility
32950236|NCT05346822|No Intervention|normal total knee arthroplasty clinical pathway|no integrated rehabilitatoin program for total knee arthroplasty patients with our conventional clinical pathway
32950237|NCT03524898|Experimental|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
32950238|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
32950239|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
32950240|NCT03524508|Active Comparator|5FU/LV|dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
32950241|NCT03524118|Experimental|Panel A: Pre-term clesrovimab Dose 1|Pre-term infants will receive clesrovimab Dose 1 via intramuscular (IM) injection and will be followed for up to 365 days.
32950242|NCT03524118|Experimental|Panel B: Pre-term clesrovimab Dose 2|Pre-term infants will receive clesrovimab Dose 2 via IM injection and will be followed for up to 365 days.
32950243|NCT03524118|Experimental|Panel C: Pre-term clesrovimab Dose 3|Pre-term infants will receive clesrovimab Dose 3 via IM injection and will be followed for up to 365 days.
32950244|NCT03524118|Experimental|Panel D1: Pre-term clesrovimab Dose 4|Pre-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
32950245|NCT03524118|Experimental|Panel D2: Pre-term clesrovimab Dose 4|Pre-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
32950246|NCT03524118|Experimental|Panel E1: Full-term clesrovimab Dose 4|Full-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
32950247|NCT03524118|Experimental|Panel E2: Full-term clesrovimab Dose 4|Full-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
32950248|NCT03524118|Placebo Comparator|Placebo|Pre-term infants will receive placebo via IM injection.
32950249|NCT03522168||Risperidone group|Rispridone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
33314802|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
33314803|NCT01258634|Other|Pre-op treatment|
33314804|NCT03904628|Experimental|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
33314805|NCT03904628|Experimental|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
33314806|NCT03904628|Experimental|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
33314807|NCT01258712|Experimental|1|
33314808|NCT01258712|Placebo Comparator|2|
32950250|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
32950251|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
32950252|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
32950253|NCT03782610||Primary Study Cohort|450 Infants
33314809|NCT03904160|Sham Comparator|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
33314810|NCT03904160|Experimental|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
32950254|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
33314811|NCT03904160|Experimental|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
33314812|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
33314813|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
33314814|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
33404782|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
33404783|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
32950255|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
32950256|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
32950257|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
32950258|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
32950259|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
32950260|NCT04270266|Experimental|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
32950261|NCT04270266|Active Comparator|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
32950262|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
32950263|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
32950264|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
32950265|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
32950266|NCT04403334|Experimental|Intracameral levofloxacin|0.5% unpreserved solution
32950267|NCT04403334|Experimental|Intracameral moxifloxacin|0.5% unpreserved solution
32950268|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
32950269|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
33314815|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
33314816|NCT03898700|Active Comparator|coaching face to face|10, 1 hour sessions of face to face strength based coaching sessions
33314817|NCT03898700|Active Comparator|phone coaching|10, 1 hour sessions of strength based coaching via phone.
32950270|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
32950271|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )~Non squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
32950272|NCT03503058|Experimental|Group 1|N=124 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given on day 1, 8 and 29.
32950273|NCT03503058|Placebo Comparator|Group 2|N=62 will receive normal saline; three doses of NS administered by DVI given on day 1, 8 and 29.
33314818|NCT03892850|Experimental|nurse prescription|experimental group receiving pharmacological nurse prescription
32950274|NCT03503058|Experimental|Group 3|"N=124 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
33314819|NCT03892850|Active Comparator|medical prescription|control group receiving medical prescription
33314820|NCT01152008||healthy volunteers|
33314821|NCT03904082|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
32950275|NCT03503058|Placebo Comparator|Group 4|"N=62 will receive normal; three doses of NS administered by DVI given on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
33314822|NCT03904082|Active Comparator|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
33314823|NCT03904082|Placebo Comparator|Control Group|The Control group receive no intervetion ( Group III).
33314824|NCT03892928|Placebo Comparator|Propofol group|2-5 mg/kg.h propofol during the whole colonoscopy
33314825|NCT03892928|Other|Dexmedetomidine group|0.1mcg/kg continuous infusion for 15min, 0.7-1mcg/kg.h during the whole colonoscopy
33314826|NCT05667194|Experimental|KH617 dose 1|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
33314827|NCT05667194|Experimental|KH617 dose 2|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
33314828|NCT05667194|Experimental|KH617 dose 3|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
33314829|NCT05667194|Experimental|KH617 dose 4|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
33314830|NCT05667194|Experimental|KH617 dose 5|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
33314831|NCT03903926|Experimental|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
33314832|NCT03903926|No Intervention|Cohort two|10000 unvaccinated volunteers (6-35 months)
33314833|NCT03903926|No Intervention|Cohort three|500 unvaccinated volunteers (36-71 months)
33314834|NCT03903848|Experimental|Exercise session|One session of physical exercise
33314835|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
33314836|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
33314837|NCT03904238|Experimental|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
33318646|NCT00048048|Experimental|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
33314838|NCT03904238|Experimental|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
33314839|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
33314840|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
33314841|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
32950276|NCT03500016|Experimental|Acute exercise and high intensity interval training|Euglycemic-hyperinsulinemic clamp, IVGTT, DXA scan, VO2max, plasma samples, fat and muscle biopsies before and after 8 weeks supervised high intensity interval training (HIIT). Before the 8 weeks HIIT-protocol the participants will also perform an 1-h acute exercise with plasma samples and musce samples before and immediately after the exercise bout and 4 hours into recovery
32950277|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
32950278|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
33314842|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
33314843|NCT03315130|Placebo Comparator|Placebo|
33314844|NCT01152164||rectal cancer patients|
33314845|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
33314846|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
33314847|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
33314848|NCT01152242|Active Comparator|Part 1|Part I of the trial
33314849|NCT01152242|Active Comparator|Part 2|Part II of the trial
33314850|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
33314851|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
33314852|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
33314853|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
33314854|NCT03903770|Experimental|Intervention|Upper extremity rehabilitation
33314855|NCT01152320|No Intervention|Standard of Care|
33314856|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
32950279|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
32950280|NCT05347134|Active Comparator|SKB264|5 mg/m2, IV (in the vein) on day 1 and Day 15 of each 28 day cycle.
32950281|NCT05347134|Active Comparator|Eribulin or Capecitabine or Gemcitabine or Vinorelbine|"Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21day cycle.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle."
32950282|NCT05346744|Experimental|Zirconia|10 crowns made of zirconia from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950283|NCT05346744|Experimental|Celtra Duo|10 crowns made of Celtra Duo from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950284|NCT05346744|Experimental|e.max CAD|10 crowns made of e.max CAD from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950285|NCT05346744|Experimental|Lici UPCERA|10 crowns made of Lici from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950286|NCT05346744|Experimental|Enamic|10 crowns made of Enamic from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950287|NCT05346744|Experimental|Runci UPCERA|10 crowns made of Runci from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
32950288|NCT00089778|Experimental|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
32950289|NCT00089778|Experimental|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
33314857|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
33314858|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
33314859|NCT01152398|Experimental|MVA-BN-HER2|
33314860|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
32950290|NCT00089778|Experimental|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
33404784|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
32806027|NCT04778956|Experimental|Toripalimab plus salvage surgery|"Toripalimab: Toripalimab treatment before and after salvage surgery.~Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node."
32806028|NCT04778956|Active Comparator|Salvage surgery alone|1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.
32806029|NCT04778800|Experimental|almonertinib 110mg PO once daily|
32806030|NCT04778800|Experimental|almonertinib 160mg PO once daily|
32806031|NCT04778800|Experimental|almonertinib 220mg PO once daily|
32806032|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
32806033|NCT05369806|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages. The NLP model will be applied to messages and will highlight those determined to be urgent.
32806034|NCT05324332|Experimental|68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.
32806035|NCT04779190|Experimental|Low-level laser therapy|In the low-level laser therapy group, each patient are going to receive low-level laser therapy and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
32806036|NCT04779190|Experimental|Therapeutic ultrasound|In the therapeutic ultrasound group, each patient are going to receive therapeutic ultrasound and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
32806037|NCT04779190|Active Comparator|Control|Participants are going to perform a home-based exercise program and receive cold-pack therapy 5 times a week, once a day for 15 sessions.
32806038|NCT04769908|Experimental|Systemic Chemotherapy, Lenvatinib Plus Sintilimab|
32806039|NCT04769986|Experimental|Mobile Mindfulness-Based Relapse Prevention (mMBRP)|Participants will complete the Mindfulness Coach app program that is enhanced with additional modules containing MBRP content.
32806040|NCT04769986|Active Comparator|Active control|Participants will complete a course of an exercise/healthy eating app program that is matched in time and effort to the intervention condition app.
32806041|NCT05324254|Experimental|Heavier blanket|A heavier blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
32806042|NCT05324254|Experimental|Lighter blanket|A lighter blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
32806043|NCT05324254|No Intervention|Waitlist control|No blanket will be provided until the end of the study; participants will sleep with their normal bedding.
32806044|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
32806045|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
32806046|NCT04778488|Other|NIRS diagnostics|NIRS measurement
33404785|NCT01374321|Placebo Comparator|Placebo|
32806047|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
32806048|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
32806049|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
32806050|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
32806051|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
32806052|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
33098884|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
33098885|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
33098886|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
33314861|NCT03903614|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
33098887|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
33098888|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
33098889|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
33314862|NCT03903614|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
33314863|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
33314864|NCT01256138||transplantation|
33314865|NCT01256138||control|
33314866|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
33314867|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
33098890|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
33098891|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
33314868|NCT01152476|Active Comparator|group SR|
33314869|NCT01152476|Active Comparator|group S|
33314870|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
33314871|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
33314872|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
33314873|NCT03903380|Active Comparator|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
33314874|NCT03903380|Experimental|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.~The same manual therapy protocol will be used for both groups.~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
33314875|NCT05482412|Experimental|T3 Subgroup|"Two T3 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 3 SI Marker (Sexual Incitation) note: incitation/stimulation"
33098892|NCT02952482||newborns testing for ALD|newborns testing for ALD
33098893|NCT00511940|Experimental|1|acamprosate
33098894|NCT00511940|Placebo Comparator|2|sugar pill
33098895|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
33098896|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
33098897|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
33098898|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
33098899|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
33314876|NCT05482412|Experimental|T5 (Young Adult) Subgroup|"Two T5 Subgroups Age-Play Subgroup (APSI):~Paraphilia with androphilic or gynephilic Tanner 5 SI Marker (Sexual Incitation)"
33314877|NCT05482412|Sham Comparator|Sham Comparator|Medical Device Sham Comparator taVGN (Cranial Ten - Vagus Nerve) Selection of Random Participants In Any Subgroup Class Androphilic or gynephilic SI Marker (Sexual Incitation)
33314878|NCT05482412|Experimental|T2 Subgroup|"Two T2 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 2 SI Marker (Sexual Incitation)"
33404786|NCT01374321|Experimental|TRO40303|
33098900|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
33098901|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
33098902|NCT02952326|Experimental|XP Endo Finisher|
33098903|NCT02952326|Active Comparator|Conventional needle irrigation|
33314879|NCT05482412|Experimental|T4 Subgroup|"Two T4 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 4 SI Marker (Sexual Incitation)"
33314880|NCT03891758|Experimental|BK1310|
33314881|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
33314882|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
33314883|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
33314884|NCT01259180|No Intervention|Control group|observation.
33098904|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
33098905|NCT04695938|Other|MRI|MRI examination
33098906|NCT04691778|Active Comparator|CTO PCI using antegrade wiring strategy starting with the Gladius guidewire|Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.
33098907|NCT04691778|Other|CTO PCI using standard antegrade wire escalation strategy|Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.
33314885|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
33314886|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
33098908|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
33098909|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
33098910|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
33314887|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
33314888|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
33314889|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
33314890|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
33314891|NCT01152632|No Intervention|waiting list|
33314892|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
33314893|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
33314894|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
33314895|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
33314896|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
33314897|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
33314898|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
33314899|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
33314900|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
33314901|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
33314902|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
33314903|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
33314904|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
33314905|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
33314906|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
33314907|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.~OCT (investigation) before and after cataract extraction"
33098911|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
33098912|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
33098913|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
33098914|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
32950291|NCT00089544|Experimental|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
33314908|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
33314909|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
33314910|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
33314911|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
33314912|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
33314913|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
33314914|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
33314915|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
33314916|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
33314917|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
33314918|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
33314919|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
33314920|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
33314921|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
33314922|NCT03886298|Experimental|radiofrequency splanchnic denervation|
33314923|NCT03886298|Active Comparator|retrocrural celiac denervation|
33314924|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
33314925|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
33314926|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
33314927|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
33314928|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~<150 mg/dl: 0 units of insulin~150-220 mg/dl: 2 units of insulin~201-250 mg/dl: 4 units~251-300 mg/dl: 6 units~301-350 mg/dl: 8 units~351-400 mg/dl: 10 units~> 400 mg/dl: inform the MD on call"
33314929|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
33314930|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
33314931|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
33314932|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
33314933|NCT01260116||1|Ziprasidone,Zeldox capsule
32950292|NCT00089544|Experimental|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
32950293|NCT00089076|Experimental|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
32950294|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
33098915|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
33098916|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
33098917|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
33098918|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
33098919|NCT04695821|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
33098920|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
33098921|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
33098922|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
33098923|NCT04695470|Experimental|Fruquintinib with Sintilimab|Patients who met the eligibility criteria took fruquintinib 5mg qd for 2 weeks on and 1 week off Q3w plus Sintilimab 200mg iv, Q3w.
33098924|NCT04691973||Access to tool|Access to the digital tool. Participants use the tool at their own in addition to usual care and do the different themes that are available. They are recommended to use it at least every other week.
33098925|NCT04691973||No access to tool|Participants are followed by their ordinary healthcare provider and are not exposed to the tool.
33098926|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
33098927|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
33098928|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
33098929|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
33098930|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
33098931|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
33098932|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
33098933|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
33098934|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
33098935|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
33098936|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
33098937|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
33314934|NCT03271528|Experimental|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
33404787|NCT04960150|Experimental|Acupuncture group|Intervention of press tack needle acupuncture
33098938|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
33098939|NCT00513734|Active Comparator|2|Lacrilube ointment
33098940|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
33098941|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
33098942|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
33098943|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
33098944|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
33098945|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
33098946|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
33098947|NCT00530127|Placebo Comparator|A|Placebo solution
33098948|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
33098949|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
33098950|NCT00530127|Placebo Comparator|D|Placebo solution
33098951|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
33404788|NCT04960150|Placebo Comparator|Control group|Intervention of placebo acupuncture
33404789|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
33404790|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
32950295|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
32950296|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
32950297|NCT00088374|Experimental|Von Hippel-Lindau (VHL) associated renal tumors|
32950298|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
33314935|NCT03271528|Placebo Comparator|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
33314936|NCT01262144||Case group|
33314937|NCT01153412|No Intervention|Control Group|Control group no intervention
33314938|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
33314939|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
33314940|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
33314941|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
33314942|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
33314943|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
33314944|NCT03889184|No Intervention|Usual care|the control group will receive usual care
33314945|NCT04480372|Experimental|NSCLC (cohort 1) and inoperable MPM (cohort 2)|"Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.~Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).~The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start."
32950299|NCT03773250|Other|Control|An active placebo control intervention was designed which did not apply evidence-based lifestyle recommendations effective in weight loss and focused on vegetable education.
32950300|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
32950301|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
32950302|NCT03772548||Patients with spinal cord injury|
32950303|NCT03772548||Healthy subjects|
32950304|NCT00087594|Experimental|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
32950305|NCT00087594|Experimental|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
32950306|NCT03770286|Active Comparator|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
32950307|NCT03770286|Experimental|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
32950308|NCT03770286|Experimental|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
32950309|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
32950310|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
32950311|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
33098952|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
33314946|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
33314947|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
33314948|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
33314949|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
33314950|NCT04472260|Other|Sequence 1: PP->PP->V->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
32950312|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
32950313|NCT05347056||Vertebral Body Tethering Group|Vertebral Body Tethering applied to the lumbar region, with or without fusion to the thoracic region
32950314|NCT05347056||Selective Thoracic Fusion Group|selective thoracic fusion was applied, no intervention was applied to the lumbar region
32950315|NCT00087516|Active Comparator|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
32950316|NCT00087516|Active Comparator|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
32950317|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
32950318|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
32950319|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
32950320|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
32950321|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
32950322|NCT00087126|Experimental|Topotecan|Topotecan weekly
32950323|NCT03490968|Other|Healthy Subjects|
32950324|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
32950325|NCT03490968|Active Comparator|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
32950326|NCT03767946||Group 1|"Children both genders according to age:~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
32950327|NCT03767946||Group 2|"Children both genders according to age:~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
32950328|NCT03767946||Group 3|"Children both genders according to age:~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
32950329|NCT03767946||Group 4|"Children both genders according to age:~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
32950330|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
32950331|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
32950332|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
32950333|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
32950334|NCT04763382|Other|Experimental grups: Training of caregivers|"Application of data collection:~Tools as pre-test, post-test and retention test to participants in the experimental group,~Education:It includes the training given to the caregivers in the experimental group, delivery of the guide booklet at the end of the training~Android phone application: Installing on the phones of the caregivers in the experimental group of the android application, which includes the frequency of CIC application, the CIC application process steps and hospital appointments, created by the nurse for the caregivers in the experimental group and the software is made by the computer engineer.~One home visit and three phone calls were made in order to solve the problems that the caregivers in the experimental group experienced with the use of CIC or android use.~Urinalysis for children who are inserted and put into the study:All participants in the study were asked to give urine tests three times with an interval of one month after discharge."
32950335|NCT04763382|Other|Control: Control grups|"As in the experimental group, the caregivers in the control group were pre-tested and post-tested using data collection tools.~No intervention was made to the caregivers in the control group.~However, caregivers in the control group performed urinalysis three times with an interval of one month after discharge."
32950336|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
32950337|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
33314951|NCT04472260|Other|Sequence 2: PP->V->V->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
33314952|NCT04472260|Other|Sequence 3: V->PP->PP->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
33404791|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
32950338|NCT04763304|Active Comparator|PPE-G (gown) followed by PPE-C (coverall)|"Placement of PPE-G (personal protective equipment including a gown for body protection) fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning."
32950339|NCT04763304|Active Comparator|PPE-C (coverall) followed by PPE-G (gown)|"Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-G (personal protective equipment including a gown for body protection), fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning."
33404792|NCT04926454|Experimental|TAP block|patients will receive general anesthesia followed by Tap block at the end of the operation.
32950340|NCT00086346|Active Comparator|A|
32950341|NCT00086346|Active Comparator|B|
32950342|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
32950343|NCT00085566|Experimental|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
32950344|NCT00085098|Experimental|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
32950345|NCT00085098|Experimental|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
32950346|NCT00084864|Experimental|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
32950347|NCT00084864|Experimental|Stage 1, Arm II|No study drugs before surgery.
32950348|NCT00084864|Experimental|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
32950349|NCT00084864|Experimental|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
32950350|NCT03487302||cCHD|
32950351|NCT03487302||CONTROLS|
32950352|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
32950353|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
32950354|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
32950355|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
32950356|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management~100 participants"
32950357|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation~35 participants"
32950358|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
32950359|NCT03487224||Healthy Controls|Adults without mental illness
33098953|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
32950360|NCT05346978|Experimental|Nasturtium (NT)|5g freeze-dried nasturtium leaf powder ; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
32950361|NCT05346978|Placebo Comparator|Placebo (PLC)|3g collagen colored with green pigment used in the food industry; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
32950362|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When one antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
32950363|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSI-L).
32950364|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
32950365|NCT00084318|Experimental|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
32950366|NCT00084318|Experimental|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
32950367|NCT00084084|Experimental|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
32950368|NCT00084084|Experimental|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
32950369|NCT00083616|Experimental|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
32950370|NCT04402710|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
32950371|NCT04402710|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
32950372|NCT00083226|Experimental|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
32950373|NCT05346510|Experimental|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS.
32950374|NCT05346510|Experimental|pALND Group|pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.
32950375|NCT05346510|Experimental|SLNB Group|SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
32950376|NCT00082758|Experimental|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV"
32950377|NCT00082758|Experimental|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV"
32950378|NCT00082758|Experimental|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV"
32950379|NCT03483012|Experimental|Atezolizumab + Stereotactic radiosurgery (SRS)|"Atezolizumab administered intravenously once every 3 weeks~Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
32950380|NCT01678014|Experimental|Anorexia|Anorexia patients
32950381|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of > 40 % in either hip over a follow-up period of three years.
32950382|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of > 40 % on either hip over a follow-up period of three years
33098954|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
33098955|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
33098956|NCT00513851|Experimental|1|Once Daily Dosing
33098957|NCT00513851|Experimental|2|Twice Daily Dosing
33098958|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
33098959|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
33098960|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
33098961|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
33098962|NCT00512057|Experimental|1|
33098963|NCT00512057|Placebo Comparator|2|
33098964|NCT00531141||A|examination twice by examiner 1
33098965|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
32950383|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
32950384|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
33098966|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
33098967|NCT00531141||D|examination performed twice by examiner 2
33098968|NCT00513929|Experimental|X: Zinc sulphate|
33098969|NCT00531180|Experimental|4-DCT Ventilation Validation|
33098970|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
33098971|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
33098972|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
33404793|NCT04926454|Experimental|Caudal block|patients will receive general anesthesia followed by caudal block at the beginning of the operation.
32950385|NCT03424200|Other|Routine Care|Participants will receive the routine care
32950386|NCT03438318|Experimental|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
33098973|NCT00513968|Active Comparator|II|Adefovir
33098974|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
33098975|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
33098976|NCT00514007|Experimental|OSI-906 QD|Once per day
33098977|NCT00514007|Experimental|OSI-906 BID|Twice per day
33098978|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
33098979|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
33098980|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
33098981|NCT00514085|Experimental|Recombinant human interleukin-21|
33098982|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
33098983|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
33098984|NCT04691349|Experimental|Chimeric antigen receptor T cell|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells
33098985|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
33098986|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
33098987|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
33098988|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
33098989|NCT00531258|Active Comparator|1|
32806053|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
32806054|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
32806055|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
32806056|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
32806057|NCT05606458|No Intervention|Control Group|The baby who met the inclusion and exclusion criteria underwent routine heel blood sampling at the hospital. First of all, the foot of the baby, who was taken to an open bed under a radiant heater, was warmed in the nurse's hand for one minute, the area where the baby's heel blood would be taken was determined, the baby's heel was wiped with 70% alcohol with the help of a sponge and waited for it to dry, then heel lance was performed. The procedure was completed after the relevant sections on the pre-prepared heel blood sheet were filled with blood. A light touch was provided if necessary for routine comfort of the infant for ethical reasons.
32806058|NCT05606458|Experimental|İntervention Group|"Their mothers gave a multisensory stimulus to the newborns in the mother's room.~Stimulus: Breast milk, breastfeeding (sense of taste)~Stimulus : Maternal touch (sense of touch)~Stimulus: Mother's voice (hearing sense)~Stimulus: Maternal eye contact (sense of sight)~Stimulus: Mother skin smell (sense of smell)"
32806059|NCT05297734|Active Comparator|Technology-based supportive cancer care|Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.
32806060|NCT05297734|Experimental|Redesigned team-based supportive cancer care|Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.
32806061|NCT05606380|Experimental|HLX60 Group|The initial dose of HLX60 is 0.5mg/kg, and 5 dose levels are designed: 2mg/kg, 5mg/kg, 15mg/kg and 25mg/kg (Q3W). Patients will receive the treatment until without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first)
32806062|NCT05606302||Piperacillin group|Blood samples for hemolytic anemia in patients treated with piperacillin were screened for the production of drug antibodies.
32806063|NCT05606302||Amoxicillin group|Blood samples for hemolytic anemia in patients treated with amoxicillin were screened for the production of drug antibodies.
32806064|NCT05606302||Cefazolin group|Blood samples for hemolytic anemia in patients treated with cefazolin were screened for the production of drug antibodies.
32806065|NCT05606302||Cefuroxime group|Blood samples for hemolytic anemia in patients treated with cefuroxime were screened for the production of drug antibodies.
32806066|NCT05606302||Ceftriaxone group|Blood samples for hemolytic anemia in patients treated with ceftriaxone were screened for the production of drug antibodies.
32806067|NCT05606302||Cefoxitin sodium group|Blood samples for hemolytic anemia in patients treated with cefoxitin sodium were screened for the production of drug antibodies.
32806068|NCT05606302||Vancomycin group|Blood samples for hemolytic anemia in patients treated with vancomycin were screened for the production of drug antibodies.
32806069|NCT00054028|Experimental|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
32806070|NCT04753060|Active Comparator|Waxing|Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.
32806071|NCT04753060|No Intervention|Standard care|Standard wound preparation
32806072|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
33314953|NCT04472260|Other|Saquence 4: V->V->PP->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
33314954|NCT01153490|Placebo Comparator|Placebo|
33314955|NCT01153490|Active Comparator|Quetiapine ER|
33314956|NCT04462276|Experimental|Arm A: Atezolizumab + thoracic radiotherapy|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W) Thoracic radiation therapy (TRT), 30 Gy in 10 fractions
33314957|NCT04462276|Experimental|Arm B: Atezolizumab|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
33314958|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
33314959|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
33404794|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
33404795|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
33404796|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
33314960|NCT04461262|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
32950387|NCT03438318|Experimental|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
33314961|NCT04461262|Other|Standard Care|Foley catheter, uncoated
33404797|NCT04875988|Active Comparator|POCUS-assisted IV placement|using ultrasound to help with placement
33314962|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
33404798|NCT04875988|Active Comparator|Traditional IV placement|Standard of care
33404799|NCT03411863|Active Comparator|Participants without neurological disease|Participants without neurological disease. All subjects undergo the same full protocol.
32950388|NCT03087942|Experimental|Group 1|ESRD patients
32950389|NCT03087942|Experimental|Group 2|healthy volunteers
32950390|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
32950391|NCT03087942|Experimental|Group 4|mild renal impaired patients
32950392|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
32950393|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
32950394|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
32950395|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
32950396|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
32950397|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
32950398|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
32950399|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
32950400|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
32950401|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
32950402|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
32950403|NCT00087984|Experimental|MB-002-003|
32950404|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
32950405|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
32950406|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
32950407|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
32950408|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
32950409|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
32950410|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
32950411|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
33098990|NCT00531258|Placebo Comparator|2|
33098991|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
33314963|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
33314964|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
32950412|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.~The majority are female (62 %)~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~All subjects demonstrated a reduction in lesion count.~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~The Percent of responders is similar for males & females and similar for cheeks & front."
32950413|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
32950414|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
32950415|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
32950416|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
32950417|NCT00081510|Experimental|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
32950418|NCT00081510|Active Comparator|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
32950419|NCT00088452|Active Comparator|Ethosuximide|"Ethosuximide~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup~Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)"
32950420|NCT00088452|Active Comparator|Lamotrigine|"Lamotrigine~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets~Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower)."
32950421|NCT00088452|Active Comparator|Valproic acid|"Valproic acid~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.~Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)"
32950422|NCT04278534|Experimental|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
32950423|NCT04278534|Active Comparator|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
32950424|NCT04278534|Active Comparator|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
32950425|NCT04278534|Active Comparator|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
32950426|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.
32950427|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.
32950428|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
32950429|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
32950430|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
32950431|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
32950432|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
33314965|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
33314966|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
32950433|NCT04403100|Active Comparator|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
32950434|NCT04403100|Active Comparator|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
32950435|NCT04403100|Active Comparator|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days~Plus~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
32950436|NCT04403100|Placebo Comparator|Placebo|"Placebo~Twice a day from day 1 through day 10."
32950437|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
32950438|NCT03087318|Experimental|Private sport club|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
32950439|NCT03087318|Experimental|Sport association|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
32950440|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
32950441|NCT04761276||Lucidis Intra-ocular lens (IOL)|Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens
32950442|NCT03473730|Experimental|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
32950443|NCT03473730|Experimental|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
32950444|NCT01679262|Other|Optimal size of OPAs|
32950445|NCT02984748||Cochlear Implant Recipients|
32950446|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
32950447|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
32950448|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
32950449|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
32950450|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
32950451|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
32950452|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
32950453|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
32950454|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
33314967|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
33314968|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
33314969|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
33314970|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
33314971|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
33098992|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
33098993|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
33098994|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
33098995|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
33098996|NCT00531297|Experimental|Treatment arm|endoscopic posterior mesorectal resection
33098997|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
33098998|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
33098999|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
33099000|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
33314972|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
33314973|NCT03885752|Active Comparator|the control group|
33314974|NCT03885752|Placebo Comparator|the gum group|
32806073|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
32806074|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
33404800|NCT03411863|Experimental|Participants with ALS|Participants with ALS. All subjects undergo the same full protocol.
33404801|NCT04262726|Experimental|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
32806075|NCT05274334|Experimental|intervention group|Assessment of de novo lipogenesis non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.
32806076|NCT00058240|Experimental|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
32806077|NCT05606146|Experimental|Treatment|IUB SEAD procedure
32806078|NCT05606068|Experimental|Cancer patients|Cancer patients will undergo limb cryocompression based on the established optimal temperature and pressure from previous studies over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
32806079|NCT05605990|Experimental|Nurse group|Using an innovative tourniquet (Acusense Nonpneumatic tourniquet) for the standard of care
32806080|NCT01502631|Active Comparator|SUN13837|
32806081|NCT01502631|Placebo Comparator|Placebo|
32806082|NCT00060346|Experimental|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
32806083|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
32806084|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
32806085|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
32806086|NCT05262946|Active Comparator|control|control arm: usual care and foot care education.
32806087|NCT05262946|Experimental|experimental|experimental arm: sensorimotor training, foot care education and usual care
32806088|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
32806089|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
32806090|NCT00060424|Experimental|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
32806091|NCT05256316||Previously admitted COVID-19 patients in intensive care units|Infectious Diseases Physicians from participating hospitals will identify patients with COVID-19 admitted to their hospital who had an intensive care unit stay during the first 60 days after hospital admission.
32806092|NCT05253040|Experimental|Intervention group|"The experimental group will receive:~Online education modules Online group discussions facilitated by Specialist Physiotherapist"
32806093|NCT05253040|Active Comparator|Control Group|The comparator for this study is usual care pathway. Under the usual care pathway, participants will receive education booklets on exercise by Parkinson's UK.
32806094|NCT05247346|Experimental|probe-based endoscopic Raman and scattering measurements of GI tissue|probe-based integrated Raman spectroscopy and scattering measurements of BE and colorectal tissue during GI endoscopy
32806095|NCT05215522|Experimental|The BCI-FES Intervention|The BCI-FES device will be used by all participants.
32806096|NCT00062764|Experimental|Pioglitazone|
32806097|NCT00063622|Active Comparator|1|Pioglitazone
32806098|NCT00063622|Active Comparator|2|Vitamin E
32806099|NCT00063622|Placebo Comparator|3|Placebo Pioglitazone or Placebo Vitamin E
32806100|NCT05605912|Experimental|Myosuit intervention|Participants perform Myosuit training sessions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home for six weeks and a recommendation for physical activity at home.
32806101|NCT05605912|Active Comparator|Control|Participants perform conventional training sessions. After the clinical training program, participants receive a recommendation for physical activity at home. After the conventional training program the control group will receive the Myosuit intervention.
32806102|NCT05185726|Experimental|Mini-KIDS|Mini-KIDS is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. The program for 4-6-year old children consists of four stages: Stage 1 = desensitization, Stage 2 = modification, Stage 3 = identification and Stage 4 = generalization. The program for 2-4-year old children does not include stage 3. Speech therapist and parent(s) are the speech model for the child. They add normal dysfluencies to their speech. Later on in treatment and if necessary, children learn to recognise and alter their stuttering moments.
32806103|NCT05185726|Experimental|Social-Cognitive Behaviour Treatment|The social cognitive behaviour therapy contains 5 treatment phases: (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training (Boey, 2010). This treatment is not directed at the speech of the children, but rather at the cognitive and emotional aspects that surround the stuttering.
32806104|NCT05185726|Active Comparator|Lidcombe Program|The Lidcombe Program (LP) is an operant program that directly provides verbal feedback to the child's stutter-free speech (mainly) and the child's stuttering (occasionally). The program comprises two stages: Stage 1 in which (near) zero levels of stuttering are achieved and Stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. The LP usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of Stage 1, i. e. (near) zero levels of stuttering.
32806105|NCT00153166|Experimental|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
32806106|NCT00153166|Active Comparator|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
32806107|NCT00153166|Active Comparator|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
32806108|NCT00156910|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
32806109|NCT00156910|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
32806110|NCT02188108|Experimental|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
32806111|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
32806112|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
32806113|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
32806114|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
32806115|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
32806116|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
32806117|NCT00065806|Experimental|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
32806118|NCT00065806|Placebo Comparator|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
32806119|NCT05152888|Experimental|Evolocumab|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.
32806120|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
32806121|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
32806122|NCT01530087|Experimental|Treatment|CASTLE Barrier
32806123|NCT00068770|Active Comparator|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm"
32806124|NCT00068770|Active Comparator|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm"
33404802|NCT04262726|Active Comparator|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
33404803|NCT04813354|Experimental|Sequence arm A: ELLIPTA followed by BREEZHALER/ Questionnaire version 1|
33099001|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
33099002|NCT00514163|Experimental|1|gemcitabine + S-1
33099003|NCT00514163|Active Comparator|2|S-1
33099004|NCT04691466||HIP_R|Patients undergoing hip replacement surgery
33099005|NCT04691466||KNEE_R|Patients undergoing knee replacement surgery
33099006|NCT04695548|Experimental|Concentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
33099007|NCT04695548|Experimental|Isometric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
33099008|NCT04695548|Experimental|Eccentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
33099009|NCT04695548|Experimental|Analytic passive stretching.|After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
33099010|NCT04691388|Experimental|Amlotinib+Sindili|Patients will be treated with amlotinib hydrochloride combined with Sindili monoclonal antibody
33318647|NCT00048048|Experimental|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
33404804|NCT04813354|Experimental|Sequence arm B: ELLIPTA followed by BREEZHALER/ Questionnaire version 2|
33099011|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
33099012|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
33099013|NCT04695743|Experimental|Intervention|Attendance at online CST groups
33099014|NCT04695743|No Intervention|Control|Treatment as usual
33099015|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
32806125|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
32806126|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
33404805|NCT04813354|Experimental|Sequence arm C: BREEZHALER followed by ELLIPTA/ Questionnaire version 1|
32806127|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
32806128|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
32806129|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
32806130|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
32806131|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
32806132|NCT00069160|Experimental|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
32806133|NCT00069160|Experimental|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
32806134|NCT00071890|Active Comparator|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
32806135|NCT00071890|Active Comparator|Control group|HAART alone
32806136|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
32806137|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
32806138|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
32806139|NCT00072514|Experimental|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
32806140|NCT00074308|Experimental|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32806141|NCT00159250|Experimental|Low dose|Low dose of AVI-4658
32806142|NCT00159250|Experimental|High dose|High dose of AVI-4658
32806143|NCT00165958|Experimental|Punch excision|
32806144|NCT00165958|Active Comparator|Traditional excision|
32806145|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
32806146|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
32806147|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
32806148|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
32806149|NCT00166036|Experimental|Atorvastatin 10MG|
32806150|NCT00166036|Experimental|Pravastatin 80mg|
32806151|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
32806152|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
32806153|NCT00167206|Experimental|HSCT Patients|Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
32806154|NCT01475097|Active Comparator|Active Arm|
32806155|NCT01475097|Active Comparator|Comparator Arm|
32806156|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
32806157|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
32806158|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
32806159|NCT02094586|Experimental|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
32806160|NCT02094586|Experimental|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
32806161|NCT02094586|Experimental|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
32806162|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
32806163|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
32806164|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
32806165|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
32806166|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
32806167|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
32806168|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
32806169|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
32806170|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
32806171|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
32806172|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
32806173|NCT00168298|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
32806174|NCT00168298|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
32806175|NCT00168298|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
32806176|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
32806177|NCT00075088|Experimental|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
32806178|NCT00075088|Other|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
32806179|NCT00076258|Experimental|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
33099016|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
33099017|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
33099018|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
33099019|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
33099020|NCT00512408||A|
33099021|NCT00512408||B|
33099022|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
33099023|NCT00530400|Placebo Comparator|2|intravenous placebo
33099024|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
33099025|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
33099026|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
33099027|NCT00512486|Active Comparator|1|MEDI-563
33099028|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
33099029|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
33099030|NCT00512525|Placebo Comparator|2|
33099031|NCT00531492|Experimental|A|
33099032|NCT00531492|Active Comparator|B|
33099033|NCT00512564||1|Patients suffering from Sickle cell disease
33099034|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
33099035|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
33099036|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
33099037|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
33099038|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
33099039|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
33099040|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
33099041|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
33099042|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
33099043|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
33099044|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
33099045|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
33099046|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
32806180|NCT00076258|Experimental|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
32806181|NCT00078286|Experimental|Sertraline|Participants will take sertraline for 12 weeks
32806182|NCT00078286|Placebo Comparator|Placebo|Participants will take placebo for 12 weeks
32806183|NCT00078754|Experimental|A|Participants will to receive treatment with fluoxetine for 12 weeks
32806184|NCT00078754|Experimental|B|Participants will to receive treatment with divalproex for 12 weeks
32806185|NCT00078754|Placebo Comparator|C|Participants will to receive treatment with placebo for 12 weeks
32806186|NCT00080470|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
32806187|NCT00080470|Sham Comparator|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
32806188|NCT00081328|Experimental|1|Metformin alone
33099047|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
33099048|NCT00514358||gestational age|
33099049|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
33099050|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
33099051|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
33099052|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
33099053|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
33099054|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
33099055|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
33099056|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
33099057|NCT00530868|Experimental|Letrozole + Avastin|50 evaluable patients received the combination therapy of 2.5 gm daily oral Letrozole and Avastin 15 mg/kg IV every 3 weeks for 24 weeks.
33099058|NCT00530868|Experimental|Letrozole alone|25 evaluable patients received daily oral 2.5 mg letrozole as a single agent
32806189|NCT00081328|Experimental|2|Metformin + Rosiglitazone
32806190|NCT00081328|Experimental|3|Metformin + Lifestyle Program
33099059|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
33099060|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
33099061|NCT02951663|No Intervention|Control|Control group
33099062|NCT00530985|Experimental|1|Benefits Counseling
33099063|NCT00530985|Active Comparator|2|VA Orientation
33099064|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
33099065|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
33099066|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
32806191|NCT04756570|Active Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose Mini-Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale (SSQOL) assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
32806192|NCT04756570|Active Comparator|Robotic 1|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
32806193|NCT04756570|Active Comparator|Robotic 2|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
32806194|NCT00082342|Active Comparator|real transcranial direct current stimulation (tDCS)|
32806195|NCT00082342|Sham Comparator|sham transcranial direct current stimulation (tDCS)|
32806196|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
32806197|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
32806198|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
32806199|NCT00083122|Experimental|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32806200|NCT00083122|Experimental|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32806201|NCT01474239|Experimental|Calibration Arm|
32806202|NCT01474239|Experimental|Investigational Arm|
32806203|NCT03026829|Experimental|CART sound therapy|
32806204|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
32806205|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
32806206|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
32806207|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
32806208|NCT00168454|Placebo Comparator|Placebo|Placebo (normal saline) injected into detrusor on Day 1
32806209|NCT00168454|Experimental|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
32806210|NCT00168454|Experimental|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
32806211|NCT00168454|Experimental|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
32806212|NCT00168454|Experimental|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
33099067|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
33099068|NCT00531726|Sham Comparator|B|
33099069|NCT00531726|Experimental|A|
33099070|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
33099071|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
33099072|NCT00512837|Active Comparator|2|
33314975|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
32806213|NCT00168454|Experimental|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
32806214|NCT00175006||Tophi Participants|
32806215|NCT04737772|Active Comparator|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
32950455|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
32806216|NCT04737772|Experimental|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
32950456|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
32806217|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
32806218|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
32806219|NCT00176800|Experimental|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
32806220|NCT00176878|Experimental|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
32806221|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
32806222|NCT02338336|Placebo Comparator|Placebo|Placebo
32806223|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
32806224|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
32806225|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
32806226|NCT04672174|Other|Effect of hearing loss on dementia|Effect of hearing loss on dementia, collected with a standardized questionnaire
32806227|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
32806228|NCT01499043|Experimental|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
32806229|NCT00087022|Experimental|Arm I|Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.
32806230|NCT00087022|Placebo Comparator|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
32806231|NCT00179998|Active Comparator|Recombinant Human DNase (Pulmozyme) then Placebo|once daily nebulized rhDNAse
32806232|NCT00179998|Placebo Comparator|Placebo (Nebulized Saline) then rhDNase|once daily nebulized vehicle
32806233|NCT02191306||HIV Positive Patients (Study Group)|
32806234|NCT02191306||Non HIV Positive Patients (Control)|
32806235|NCT02164942||Single Arm|Specimen Collection
32806236|NCT00181168|Experimental|Euthyroid Group|Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
32806237|NCT00181168|No Intervention|Hypothyroid Group|Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
32806238|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
32806239|NCT00089752|Active Comparator|Active Treatment|Continuous Positive Airway Pressure Treatment
32806240|NCT00089752|Placebo Comparator|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to <1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
32806241|NCT02119468|Experimental|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32950457|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
32950458|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
33314976|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
33314977|NCT01153568|Placebo Comparator|Placebo|placebo
33314978|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
33314979|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
33314980|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
33314981|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
32950459|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
32950460|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
32950461|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
32950462|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
32950463|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
32950464|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
32950465|NCT05346198|Experimental|Subjects will receive CART-BCMA|"Biological: CART-BCMA Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CART-BCMA.~During CART-BCMA production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CART-BCMA product, subjects will receive treatment with CART-BCMA therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CART-BCMA administered by intravenous (IV) injection."
32950466|NCT01679730||irritable bowel syndrome patients|
32950467|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
32950468|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
32950469|NCT03464760|Placebo Comparator|Placebo|
32950470|NCT03464760|Experimental|Spirulina-Silicon supplementation|
32950471|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
32950472|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
32950473|NCT04761744|Experimental|Nivolumab|
32950474|NCT01679886|Experimental|Rubidium PET|Rubidium PET
32950475|NCT04402476|Experimental|Device and Control|"Device:~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive Control:~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
32950476|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
32950477|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
32950478|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
32950479|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
32950480|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
32950481|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
32950482|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
32950483|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
33099073|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
33099074|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
33099075|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
33099076|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
33099077|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
32806242|NCT02119468|Experimental|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33099078|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
33099079|NCT02943330||Hemodialysis|Hemodialysis patients
33099080|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
33099081|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
33099082|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
33099083|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
33099084|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
33099085|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
33099086|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
33314982|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
33314983|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
33099087|NCT02943681|No Intervention|Control|Nothing
33099088|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
33314984|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
32806243|NCT00090844|Experimental|triptorelin|GnRH analogue (triptorelin) during chemotherapy
32806244|NCT00090844|No Intervention|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
32806245|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
32806246|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
33099089|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
33099090|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
33099091|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
33099092|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
32806247|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
32806248|NCT01498887|Experimental|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
32806249|NCT01498887|Experimental|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
32806250|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
32806251|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
32806252|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
32806253|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
32806254|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
32806255|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
32806256|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
32806257|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
32806258|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
32806259|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
32806260|NCT01528605|Experimental|Low lutein|low lutein group
32806261|NCT01528605|Experimental|High lutein|high lutein group
32806262|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
32806263|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
32806264|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
32806265|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
32806266|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
33099093|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
32806267|NCT01527357|Experimental|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
32806268|NCT01527357|Active Comparator|Gelatin Sponge|Single application of gelatin sponge alone.
32806269|NCT00093964|Experimental|Cilengitide 500 Milligram (mg)|
32806270|NCT00093964|Experimental|Cilengitide 2000 mg|
32806271|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
32806272|NCT01526889|Active Comparator|Conventional Therapy|
32806273|NCT00181714|Experimental|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
32806274|NCT04643626|Experimental|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
32806275|NCT04643626|No Intervention|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
32806276|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
32806277|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
32806278|NCT00185692|Experimental|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
32806279|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
32806280|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
32806281|NCT00094900|Experimental|IL-1 Trap|
32806282|NCT00096460|Active Comparator|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
32806283|NCT00096460|Active Comparator|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
32806284|NCT00006178|Experimental|Sirolimus and Thymoglobulin|Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.
32806285|NCT00098956|Experimental|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
32806286|NCT01472757|Placebo Comparator|Placebo|
32806287|NCT01472757|Active Comparator|Dose 1|
32806288|NCT01472757|Active Comparator|Dose 2|
32806289|NCT01472757|Active Comparator|Dose 3|
32806290|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
32806291|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
32806292|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
32806293|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
32806294|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
32806295|NCT02197156|Placebo Comparator|Placebo|Matching placebo
32806296|NCT00187720|Experimental|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
32806297|NCT00187720|Experimental|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
32806298|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
32806299|NCT00006244|Experimental|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
32806300|NCT00187876|Active Comparator|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
32806301|NCT00187876|Experimental|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
32806302|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
32806303|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
32950484|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
32950485|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
32950486|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
32950487|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
32950488|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
32950489|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
32950490|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
32950491|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
32950492|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
32950493|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
32950494|NCT04402164|Active Comparator|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
32950495|NCT04402164|Active Comparator|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
32950496|NCT03395184|Experimental|PF-06700841 or placebo|
32950497|NCT03395184|Experimental|PF-06651600 or placebo|
32950498|NCT03080532||european population|
32950499|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
32950500|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
32950501|NCT03080298|Experimental|Treatment with BP101|
32950502|NCT03080298|Placebo Comparator|Treatment with placebo|
32950503|NCT04401618||Class V RMGI Restorations|Resin-modified glass ionomer (RMGI - Fuji 2 LC) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
32950504|NCT04401618||Class V Glass ionomer - GIC Restorations|Glass ionomer (GI - Fuji 9) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
32950505|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
32950506|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
32950507|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
32950508|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
32950509|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
32950510|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
32950511|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
32950512|NCT04761354||University Medical Center Utrecht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950513|NCT04761354||University Medical Center Groningen|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950514|NCT04761354||Vu University Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950515|NCT04761354||University Medical Center Maastricht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950516|NCT04761354||Academic Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950517|NCT04761354||Istituto di Semeiotica Chirurgica Roma|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950518|NCT04761354||University of California San Francisco|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950519|NCT04761354||Northwestern Memorial Hospital|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950520|NCT04761354||Weill Cornell Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950521|NCT04761354||Columbia University Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950522|NCT04761354||University of Chicago Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950523|NCT04761354||M.D. Anderson Cancer Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950524|NCT04761354||Boston Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32806304|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
32806305|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
32806306|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
32806307|NCT04409613|Active Comparator|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
32806308|NCT04409613|No Intervention|Standard care group|that will receive standard medical care
32806309|NCT01525641||Patient with Parkinson's Disease|
32806310|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
32806311|NCT00006400|Active Comparator|Hydroxyurea|Participants will receive hydroxyurea.
32806312|NCT00006400|Placebo Comparator|Placebo|Participants will receive placebo.
32806313|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
32806314|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
32806315|NCT04633096|Experimental|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
32806316|NCT04633096|Experimental|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
32806317|NCT04633096|No Intervention|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
32806318|NCT00189436|Active Comparator|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
32806319|NCT00189436|Active Comparator|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
32806320|NCT04082637|Experimental|MABT* + Medication Treatment|Mindful Awareness in Body-oriented Therapy + Medication Treatment
32806321|NCT04082637|No Intervention|Treatment as Usual|Treatment as Usual is medication for the treatment of opioid use disorder
32806322|NCT04091607|Active Comparator|Music Therapy Intervention Group|listen to preferred choice of music during the Lumbar Medial Branch Block procedure.
32806323|NCT04091607|No Intervention|Control Group|No music will be provided but will be provided earbuds. The sound environment will be standard for procedures by closing procedure room door and minimizing extraneous sounds.
32806324|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
33099094|NCT04695353|Experimental|Study group|These patients will receive telemedicine by using Telecommunication Platform videoconferences/messages.
33099095|NCT04695353|No Intervention|Control group|The patients will receive in-office clinical care
33314985|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
33314986|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
33314987|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
33314988|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
33314989|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
33099096|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
33314990|NCT03890042|Active Comparator|Dienogest group|
33314991|NCT03890042|Active Comparator|Gynera group|
33404806|NCT04813354|Experimental|Sequence arm D: BREEZHALER followed by ELLIPTA/ Questionnaire version 2|
32806325|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
32806326|NCT01471197|Experimental|Arm 1: Ipilimumab|
32806327|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
32806328|NCT04408989|Experimental|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
32806329|NCT04408989|Experimental|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
32806330|NCT04408989|Active Comparator|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
32806331|NCT00011986|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
32950525|NCT04761354||University Health Network Toronto|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950526|NCT04761354||Montreal General Hospital - McGill University|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950527|NCT04761354||University of Sydney|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
32950528|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
32950529|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
32950530|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
32950531|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
32950532|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
32950533|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
32950534|NCT03083886|Active Comparator|Usual PCP led care|
32950535|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
32950536|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
32950537|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
32950538|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
32950539|NCT03088956||Healthy|Healthy Participants (n=10)
32950540|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
32950541|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
32950542|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
32950543|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
32950544|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
32950545|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
32950546|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
32950547|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
32950548|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
32950549|NCT03088488||Periodontally healthy subjects|
32950550|NCT03088488||Chronic periodontitis patients|
32950551|NCT05685420|Experimental|open-label|Herombopag plus standard of care
32950552|NCT05685342|Experimental|Preemptive administration group|Preemptive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes at the end of induction of anesthesia.
32950553|NCT05685342|Active Comparator|Preventive administration group|The preventive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes when surgical site closure starts.
32950554|NCT04279080||1|rectal cancer patients
32950555|NCT04279080||2|ovarian cancer patients
32950556|NCT05684718|Experimental|BV100 Plus Itraconazole|A total 2 doses of BV100 and 14 doses of itraconazole will be administered to each participant per specified dosing schedule
32950557|NCT05689086||Program Participants|"Patients with HFrEF (LVEF<40%) & NYHA class II-III who are referred to and consent to participate in the Virtual Heart Failure Optimization Program"
32950558|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
32950559|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
32950560|NCT05689008|No Intervention|control|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
32950561|NCT05689008|Experimental|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment on the basis of standard treatment.
32950562|NCT05688930|Experimental|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk.
32950563|NCT05688930|Active Comparator|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
32950564|NCT05684484|Active Comparator|conventional treatment group|Group 1 (n=26): Patients will receive conventional treatment only of ulcerative colitis for 3 months.
32950565|NCT05684484|Experimental|experimental treatment group|Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months
32950566|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
32950567|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
33314992|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
33314993|NCT03299686|Experimental|CJM112|Study treatment
33314994|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
33314995|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
32950571|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
32950572|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
32950573|NCT04401696|Experimental|Group A|Use of Bubble CPAP for management of respiratory distress
32950574|NCT04401696|Active Comparator|Group B|Use of Oxygen via nasal cannula for respiratory distress
32950575|NCT05680428|Experimental|early feeding group|after stoma reversal in patients in this group oral feeding was started with in 12 hrs after surgery
32950576|NCT05680428|Active Comparator|conventional feeding group|after stoma reversal in patients in this group oral feeding was started 48hrs after surgery
32950577|NCT05688618|Active Comparator|Experimental group|
32950578|NCT05688618|Placebo Comparator|Control group|
32950579|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
32950580|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
32950581|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
32950582|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
32950583|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
32950584|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
32950585|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
32950586|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
32950587|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
33314996|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
33314997|NCT03889964||patients with stable COPD|
33314998|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 8-12 of cycle 6"
33314999|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 15-19 of cycle 6"
33315000|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
33315001|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
33315002|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
33315003|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
33315004|NCT03884738|Active Comparator|Concentric|Leg Curl Training
33315005|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
33315006|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
33315007|NCT01153256|Experimental|group M|
33315008|NCT01153256|Placebo Comparator|Group R-0.6|
33315009|NCT01153256|Placebo Comparator|Group R-0.9|
33315010|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
33315011|NCT01153334|Placebo Comparator|Conventional statin therapy|
33315012|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
32950588|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
32950589|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
32950590|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
32950591|NCT05679492|Experimental|Meplazumab|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
32950592|NCT05679492|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
32950593|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
32950594|NCT03362424|Active Comparator|Control group|rotator cuff repair
32950595|NCT04401462|Active Comparator|Operative group|tension band wiring or plate fixation
32950596|NCT04401462|Active Comparator|Non-operative group|conservative treatment
32950597|NCT05688540|Experimental|e book|a multi-media model through e-book for preoperative care of CIED intervention.
32950598|NCT05688540|Experimental|traditional education booklet|traditional education booklet of CIED intervention.
32950599|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
32950600|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
32950601|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
32950602|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
32950603|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
32950604|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
32950605|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
32950606|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
32950607|NCT05667324|Experimental|Group 1: Ropivacaine plus Dexamethasone|The group 1 injection procedure will be performed as follows: after preparation of the skin using appropriate skin preparation solution and using aseptic technique, a small-gauge spinal needle will be advanced into the pterygopalatine fossa under ultrasound guidance. Once the needle is properly positioned, 0.5% ropivacaine will be administered at a dose of 20 mg plus 4 mg dexamethasone and the needle will be removed. This procedure will be performed bilaterally
32950608|NCT05667324|Active Comparator|Group 2: Placebo plus Dexamethasone|In group 2 the same procedure will be performed, but the injectate will consist of 5 mL of a balanced crystalloid intravenous solution (4 ml of normal saline) plus 4 mg dexamethasone (each side). This procedure will be performed bilaterally.
32950609|NCT03086148|Experimental|ketamine group|
32950610|NCT03086148|Placebo Comparator|normal saline group|
32950611|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
32950612|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
32950613|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
32950614|NCT04272138|Experimental|Calm Meditation|Participants in the intervention group will be exposed to 10 minutes per day of meditation via a smartphone application for 4 weeks. Participants will log their meditation participation in an online weekly log.
32950615|NCT04272138|Active Comparator|Educational Podcast Control|Participants in the control group will be exposed to 10 minutes per day of health education podcasts via a smartphone application for 4 weeks. Participants will log their podcast participation in an online weekly log.
32950616|NCT05345808|Other|Formulated Posterior Sub Tenon Triamcinolone|All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.
32950617|NCT04401228||covid ICU patients|
32950618|NCT04401228||covid conventionnal ward|
32950619|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
32950620|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
32950621|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
32950622|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
32950623|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
32950624|NCT04760886||Urban trauma cohort|All paediatric trauma admissions in an urban, MTC treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
32950625|NCT04760886||Rural trauma cohort|All paediatric trauma admissions in a rural district general, treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
32950626|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
32950627|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
32950628|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
32950629|NCT05688072|Active Comparator|study group (A)|
32950630|NCT05688072|Active Comparator|Study group (B)|
32950631|NCT04401306|Experimental|Self-regulated simulation training|
32950632|NCT04401306|Active Comparator|Instructor-regulated simulation training|
33315013|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with modified visual input."
33315014|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with no modified visual input."
32950635|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
32950636|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
32950637|NCT04746690|Active Comparator|Slider neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch on one nerve end and slackness on the other end.
32950638|NCT04746690|Active Comparator|Tensioner neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch of both nerve ends.
32950639|NCT04746690|Active Comparator|Stretching exercises of back extensors, hamstrings and gastrocnemius muscles|Stretching exercises of back extensors, hamstrings and gastrocnemius to relief the pressure on the nerve.
32950640|NCT03085446|Experimental|PDM nutritional intervention|
32950641|NCT03085446|Experimental|control|General information on nutrition and health
32950642|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
32950643|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
32950644|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
32950645|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
32950646|NCT05638932||Interleukin-6 receptor inhibitor (IL6Ri) initiators vs Janus kinase inhibitor (JAKi) initiators|Hospitalized patients who initiate an IL6Ri versus JAKi in addition to a corticosteroid of interest
33315015|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
33315016|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
32950649|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
32950650|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
32950651|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
32950652|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
32950653|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
32950654|NCT05687760|Active Comparator|calcium hydroxide arm|intracanal medication of calcium hydroxide paste
32950655|NCT05687760|Experimental|bromelain arm|intracanal medication of bromelain paste (Bromelain powder with enzymatic activity of 2400 Gelatin digestion unit per Gram was mixed with saline in 1:1 proportion 1 g powder was mixed with 1 ml distilled water)
32950656|NCT05687682|Experimental|Level -1|0.1 mg/kg
32950657|NCT05687682|Experimental|Level 1|0.3 mg/kg (Stating Dose)
32950658|NCT05687682|Experimental|Level 2|1 mg/kg
32950659|NCT05687682|Experimental|Level 3|3 mg/kg
32950660|NCT05687682|Experimental|Level 4|6 mg/kg
32950661|NCT05687682|Experimental|Level 5|10 mg/kg
32950662|NCT05687682|Experimental|Level 6|15 mg/kg
32950663|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
32950664|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
32950665|NCT05687604|Active Comparator|STELLAR Program|STELLAR arm participants will receive goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
33315017|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
33315018|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
33315019|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
33315020|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
33315021|NCT01260428||healthy active subjects|with and without high altitude intolerance
33404807|NCT05200143|Experimental|Cabozantinib + Ipilimumab + Nivolumab|Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg IV every 3 weeks + Cabozantinib 40 mg PO daily for 4 cycles followed by Nivolumab 480 mg IV every 4 weeks + Cabozantinib 40 mg PO daily for up to 24 months.
32950666|NCT05687604|No Intervention|Enhanced Usual Care|Patients in the EUC group will receive informational packets about their risk behaviors - obesity, physical inactivity, and/or smoking. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months
32950667|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
32950668|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
32950669|NCT05687526|Experimental|Telitacicept 2.5 mg/kg|Telitacicept 2.5 mg/kg
32950670|NCT05626686|Experimental|CLINY reusable catheter 28 days|The investigation is designed as an open-labelled, single-arm investigation, in which the reuse CLINY catheter will be compared to single use catheters at baseline.
33404808|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
32950672|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
32950673|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
32950674|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
32950675|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
32950676|NCT05619432|Experimental|Group A: Clinic Setting|Participants will complete their virtual reality (VR) visual training program by visiting a local clinic and using the head-mounted display (HMD) provided. Participants will receive initial training on using the device and software and are expected to complete their 6-weeks of visual training independently at the clinic. Additional training and FAQ materials will be available on site for participants to use as reference.
32950677|NCT05619432|Experimental|Group B: Home Setting|Participants will complete their virtual reality (VR) visual training program from their own homes using a head-mounted display (HMD) that is on loan for the study. Participants will receive initial training on using the device and software at the clinic and will take home the HMD to complete their 6-weeks of visual training independently from home. Additional training and FAQ materials will be given to participants to use as reference.
32950680|NCT05345730||Mitral valve insufficiency patients undergoing mitral valve repair surgery|The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria. These patients will undergo a cardiac MRI scan 2 weeks prior to surgery and 3 months after surgery.
32950681|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
32950682|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
32950683|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
32950684|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
32950685|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
32950686|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
32950687|NCT05613660|Experimental|VEGCOL™️ (Veg Collagen Peptide)|"Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water~VEGCOL helps in providing the necessary nutrition needed for the body to produce collagen. Vegan collagen gives a lighter feel on consumption compared to any other collagen and increases the elasticity of the skin and makes skin supple. VEGCOL has more amino acids than animal derived Collagen which makes it very ideal to consume not only in Vegetarian populated countries like in India but around the world. Pepsin, a digestive enzyme, is added to help structure the building blocks into collagen molecules with the exact structure of human collagen."
32950688|NCT05613660|Experimental|PROCOL (Bovine Collagen Peptide)|"Bovine collagen is a naturally occurring protein present in the connective tissue, bones, cartilage, and hides of cows.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
32950689|NCT05613660|Experimental|"AQUACOL (Fish | Marine Collagen Peptide)"|"Marine Collagen is made from Fish Skin which delays the signs of aging such as wrinkles, Joint issues and weakness.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
33318648|NCT00048048|Experimental|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
32806332|NCT00011986|Experimental|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
32806333|NCT00011986|Experimental|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
32806334|NCT00011986|Experimental|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
32806335|NCT00011986|Experimental|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
32806336|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
32806337|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
32806338|NCT01524783|Placebo Comparator|Placebo + BSC|Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
32806339|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
32806340|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
32806341|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
32806342|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
32806343|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
32806344|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
32806345|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
32806346|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
32806347|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
32806348|NCT04409223|Experimental|Famitinib|
32806349|NCT04409223|Active Comparator|Sunitinib|
32806350|NCT04748367|Experimental|Intervention group|Children wear VR headset during immunisation
32806351|NCT04748367|No Intervention|Control group|Children did not wear VR headset during immunisation( usual care)
32806352|NCT00012298|Experimental|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
32806353|NCT00193258|Experimental|Intervention|"In the phase I portion:~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course~Erlotinib 150 mg orally daily~Imatinib 300 mg orally daily or 400 mg orally daily~In the phase II portion:~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle~Erlotinib 150 mg orally daily~Imatinib 400 mg orally daily"
32806354|NCT00029536|Experimental|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
32806355|NCT00029536|Placebo Comparator|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
32806356|NCT00029536|Experimental|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
32806357|NCT00029536|Placebo Comparator|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
32806358|NCT00193492|Active Comparator|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
32806359|NCT00193492|Experimental|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
32806360|NCT00194116|Experimental|Divalproex Sodium ER|
32806361|NCT00194116|Placebo Comparator|Placebo|
32806362|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
32806363|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
32806364|NCT00194896|Active Comparator|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
32806365|NCT00194896|Active Comparator|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
32806366|NCT00197392|Experimental|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
32806367|NCT00197392|Active Comparator|Standard EVD Catheter|Standard External Ventricular Device system
32806368|NCT04348474|Experimental|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
32806369|NCT04318834|Experimental|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
32806370|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
32806371|NCT04300816|Experimental|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
32806372|NCT04300816|Active Comparator|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
32806373|NCT04300816|No Intervention|TAU|Participant continues with their lives as they normally would.
32806374|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
32806375|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
32806376|NCT04290286|Experimental|intervention group|TGD people (n = 82) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
32806377|NCT04290286|No Intervention|waiting group|TGD people (n = 82) wait 4 months until they are offered regular care (waiting group), which can include video consultation
32806378|NCT00107536|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32806379|NCT04389190|Active Comparator|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
32806380|NCT04389190|Experimental|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
32806381|NCT04389190|Experimental|Customized Protocol|This will have varying settings based on three weight based groups. Small (<60 kg), medium (60-85 kg), large (>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
32806382|NCT00108550|Experimental|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
32806383|NCT00108550|Sham Comparator|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
32806384|NCT00109876|Experimental|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature > 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
32806385|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
32806386|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
32806387|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
32806388|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
32806389|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
32806390|NCT00200902|Active Comparator|MED|"For medication treatment, three different types were utilized and assigned specifically to each subject depending on their condition:~MED 1: Venlafaxine XR. MED 2: Duloxetine (Cymbalta) MED 3: Escitalopram (Lexapro)"
32806391|NCT00200902|Placebo Comparator|Placebo (PBO)|Subjects enrolled will receive interpersonal clinical interaction (ICI) along with a placebo treatment (Interaction and assessment as in ICI plus double blinded treatment with placebo tablets).
32806392|NCT00200902|Other|Interpersonal Clinical Interaction (ICI)|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
32806393|NCT00201448|Active Comparator|Placebo (hepatitis A)|Placebo group
32806394|NCT00201448|Experimental|Towne vaccine|Towne vaccine given at 3000 pfu/subject
32806395|NCT00201760|Experimental|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
32806396|NCT00201760|Active Comparator|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
32806397|NCT00201838|Experimental|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
32806398|NCT00201838|Active Comparator|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
32806399|NCT00040846|Experimental|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
32806400|NCT00041938|Active Comparator|aspirin|Aspirin: 325 mg per day
32806401|NCT00041938|Active Comparator|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
32806402|NCT00202930|Other|Rituximab|Single Arm
32806403|NCT00044044|Experimental|Lurasidone 20 mg|Lurasidone 20 mg tablets
32806404|NCT00044044|Experimental|Lurasidone 40 mg|Lurasidone 40 mg tablets
32806405|NCT00044044|Experimental|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
32806406|NCT00044044|Active Comparator|Haloperidol 10mg|Haloperidol 10mg tablets
32806407|NCT00044044|Placebo Comparator|Placebo|Matching Placebo to Lurasidone and Haloperidol
32806408|NCT00112918|Active Comparator|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Observation only."
32806409|NCT00112918|Experimental|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
32806410|NCT00112918|Experimental|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
32806411|NCT00046228|Experimental|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
32806412|NCT00046228|Experimental|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
32806413|NCT00046228|Experimental|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
32806414|NCT00205504|Active Comparator|Obese women with metabolic syndrome|
33404809|NCT04256876|Active Comparator|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
32806415|NCT00205504|Active Comparator|Obese women without metabolic syndrome|
32806416|NCT00205504|Active Comparator|lean women without metabolic syndrome|
32806417|NCT00205660|Other|Stayers|Subjects are randomized to stay on their current antipsychotic.
32806418|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
32806419|NCT00113230|Experimental|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
32950690|NCT05613660|Experimental|CALCOL (Chicken Collagen Peptide)|"Chicken collagen is used to treat joint pain associated with many types of arthritis and surgery, as well as back pain, neck pain, and pain following injury. Chicken collagen works by causing participants' body to produce substances that fight inflammation and pain. It also contains chondroitin and glucosamine, two compounds that help rebuild cartilage. That's why chicken collagen can provide some amazing benefits for participants' gut, immune system, skin, and more.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
32950691|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
32950692|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
33404810|NCT04256876|Sham Comparator|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.~Home therapy: Daily stimulation during 60 minutes."
32950693|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
32950694|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
32950695|NCT03084276|Experimental|High-fat meal|
32950696|NCT03084276|Active Comparator|Low-fat meal|
32950697|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
32950698|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
32950699|NCT05687136|Experimental|Treatment (peposertib, tuvusertib)|Patients receive peposertib PO in combination with tuvusertib PO on study. Patients undergo tumor biopsy and blood sample collection during screening and on study. Patients also undergo PET, CT, and MRI during screening and on study.
32950700|NCT05345574|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
32950701|NCT05345574|Active Comparator|remifentanil infusion group|remifentanil of 0.05 ㎍/kg/h during induction, followed by remifentanil infusion (0.05-0.3 ㎍/kg/h) during the surgery
32950702|NCT03084198|Active Comparator|Control group|Standard care for ALF
32950703|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
32950704|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
32950705|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
32950706|NCT05598606|Experimental|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
32950707|NCT05598606|Active Comparator|zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months.
32950708|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
32950709|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
32950710|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
32950711|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
32950712|NCT05597358|Active Comparator|High Intensity Laser Therapy (HILT)|Active high intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
32950713|NCT05597358|Sham Comparator|Sham High Intensity Laser Therapy|Sham high-intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
32950714|NCT05686902|Experimental|PH 5.5 BABY SHAMPOO GROUP|Distilled water+Ph 5.5 baby shampoo for stoma care of patients in the first group
32950715|NCT05686902|Active Comparator|SERUM PHYSIOLOGIC GROUP|0.9% saline solution for stoma care of patients in the second group
32950716|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
32950717|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
32950718|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
32950719|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
32950720|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
32950721|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
32950722|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
32950723|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
32950724|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
32950725|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
32950726|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
32950727|NCT03084042||Healthy controls|Demographically matched healthy controls.
32950728|NCT03406884|Experimental|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
32950729|NCT03406884|Active Comparator|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
32950730|NCT03406884|No Intervention|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) Stage II BDCPA operation without the injection of harvested c-kit+ cells.
32950731|NCT05686824||Midwives and student midwives at one Trust|No intervention - this is an exploratory case study
32950732|NCT04400916|Experimental|Topical tranexamic acid|
32950733|NCT04400916|Placebo Comparator|Topical BSS|
32950734|NCT05582538|Experimental|TNBC patients treated with ceralasertib, durvalumab e nab-paclitaxel|"Patients will be assessed for eligibility during the 28-day screening period prior to enrollment. Enrolled patients will be treated with:~Ceralasertib at 240 mg administered orally, twice daily on Days -6 to 0 prior to Day 1 Cycle 1 and thereafter on Days 22 to 28 (priming period) of Cycle 1 and every subsequent cycle;~Durvalumab at 1500 mg administered via IV infusion on Day 1 of every 28-day cycle; Nab-paclitaxel at 100 mg/m2 administered via IV infusion on Days 1,8 and 15 of every 28- day cycle.~A safety run-in phase will be carried out at the start of the present study using a 3+3 de-escalating schema down to -2 ceralasertib dose level. Nab- paclitaxel or durvalumab doses will not be de-escalated. Once the definitive dose for ceralasertib is established, treatment will be continued until progression or unacceptable toxicity, which ever come first."
32950735|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
32950736|NCT03406104|Experimental|GS010|Lenadogene nolparvovec Intravitreal occular unilateral Injection
32950737|NCT03406104|Sham Comparator|Sham|Sham Intravitreal occular unilateral Injection
32950738|NCT05571072|Active Comparator|Standard Opioid Prescription|Patients will be given a prescription for opioid pain medication to use for acute postoperative pain as would be typical for the attending surgeon performing the surgery.
32950739|NCT05571072|Experimental|Opioid Calculator Prescription|Patients will be a given a prescription for opioid pain medication based on the opioid calculator.
32950740|NCT04761042|Experimental|Wilderness program|A one-week (8 days) wilderness program, 3-month online support, and a follow-up visit for four days.
32950741|NCT04761042|Other|Holiday program (Attention control)|A one-week (8 days) holiday program, 3-month online contact, and a follow-up visit for four days.
32950742|NCT04400526|Other|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
32950743|NCT04400526|Other|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
33404811|NCT04808284|Experimental|tDCS-SMA|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.
32950744|NCT04400526|Other|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
32950745|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
32950746|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
32950747|NCT05686746|Experimental|Baricetinib 4 mg|4 mg oral tablet daily
32950748|NCT05686746|Experimental|Baricetinib 2 mg|2 mg oral tablet daily
32950749|NCT05686746|Active Comparator|MMF|MMF 500 mg tablet twice daily
32950750|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
32950751|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
32950752|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
32950753|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
32950754|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
32950755|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
32950756|NCT04400760|Other|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
32950757|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
32950758|NCT05686668||AASP|
32950759|NCT05686512|Experimental|Step-by-Step treatment|Stepped care cognitive behavioral therapy
32950760|NCT05686512|Experimental|Cool Kids treatment|Cognitive behavioral therapy
32950761|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
32950762|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
32950763|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
32950764|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
32950765|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
32950766|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
32950767|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
32950768|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
32950769|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
32950770|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
32950771|NCT03083418|Experimental|Control group|No EDP treatment.
32950772|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
32950773|NCT05553132|Experimental|CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects|Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier.
32950774|NCT05548920||Ultrasound guided Superior Vena Cava Collapsibility Index (SVC - CI)|Preoperative ultrasound guided Superior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
32950775|NCT05548920||Ultrasound Guided Inferior Vena Cava Collapsibility Index (IVC -CI)|Preoperative Ultrasound guided Inferior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
32950776|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
32950777|NCT05547984|Experimental|Dual Mobility Cup|dual mobility articulation
32950778|NCT05547984|Active Comparator|Standard Acetabular component|standard articulation with polyethylene + vitamin E inlay and metal head
32950779|NCT04279938|Other|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
32950780|NCT05534256|Experimental|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
32950781|NCT05534256|No Intervention|Control Group|The control group will receive usual medical care and American Heart Association's Healthy Living booklet
32950782|NCT05686434|Experimental|Osimertinib adjuvant therapy group|Patients must be enrolled within 10 weeks of complete surgical excision and receive oral Osimertinib at a dose of 80 mg once a day for a planned duration of 3 years (156 weeks).
32950783|NCT05686356|Experimental|Arm 1 (S1200BP)|Sutezolid 1200mg QD plus bedaquiline and pretomanid for 4 months
32950784|NCT05686356|Experimental|Arm 2 (S1600BP)|Sutezolid 1600mg QD plus bedaquiline and pretomanid for 4 months
32950785|NCT05686356|Experimental|Arm 3 (S1600BPN)|Sutezolid 1600mg QD plus bedaquiline pretomanid and N-acetyl cysteine for 4 months
33315022|NCT05499338|Experimental|Experimental group|The experimental group received a lecture session explaining what stretching is, its advantages and the importance of stretching in injury prevention. The specific intervention programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
32950786|NCT05686356|Active Comparator|Arm 4 (HRZE)|Rifafour (2HRZE/4HR)
32950787|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
32950788|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
32950789|NCT05686278||Hip hemiarthroplasty with BiPolar i and cemented stems (Meije or Oceane+)|Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices
32950790|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
32950791|NCT03338244|Active Comparator|Azithro|Communities will receive four rounds of biannual mass azithromycin.
32950792|NCT03338244|Placebo Comparator|Placebo|Communities will receive four rounds of biannual mass placebo.
32950793|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
32950794|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
32950795|NCT05686122|Experimental|PainPac|4 behavioral cancer pain intervention sessions delivered by mobile application. Patient-focused intervention. PainPac uses Social Cognitive Theory to promote behaviors to improve pain, self-efficacy for pain management, and pain-related quality of life indices. It also uses real-time data to personalize the intervention and messaging to participants. The app also has interactive components to improve coping skills engagement.
32950796|NCT05686122|No Intervention|PCST-Video|4 behavioral cancer pain intervention sessions delivered by videoconferencing by a pain therapist in the medical center to the patient in their natural environment (e.g., home). Sessions will be scheduled weekly for 45-60 min and mimic in person sessions. PCST-Video session content is matches the PainPac skills modules. PCST-Video participants will complete assessments at the same intervals as PainPac participants.
32950797|NCT03083028|Active Comparator|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
32950798|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
32950799|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
32950800|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
32950801|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
32950802|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
32950803|NCT05685888||The Ursodeoxycholic acid (UDCA) group|The Ursodeoxycholic acid (UDCA) group was defined as individuals who have received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed COVID-19 infection (The frequency and dosage of UDCA were also recorded). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
32950804|NCT05685888||The non-Ursodeoxycholic acid (non- UDCA) group|The non-Ursodeoxycholic acid (non- UDCA) group was defined as individuals who didn't received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed as COVID-19 infection. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
32950805|NCT05525676|Experimental|Brief Relationship Checkup (BRC)|Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but has not been explored in Veterans with ongoing mental health issues and has not been compared to an active treatment.
32950806|NCT05525676|Active Comparator|Co-Located Collaborative Care (CCC)|The comparison condition will be three sessions of Co-Located Collaborative Care (CCC) offered to the Screened Veteran only. This reflects the current standard of care in VA Primary Care Mental Health.
33315023|NCT05499338|No Intervention|Control group|The control group performed the initial and final assessments and continued to perform their team's standard/habitual stretches. To record whether they performed the stretches prescribed by the club, the researchers went to the end of the training unknown sessions and recorded whether the players performed them or not.
33315024|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
32950807|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
32950808|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
32950809|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
32950810|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
33315025|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
33315026|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
32950811|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
32950812|NCT04348188|Experimental|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
32950813|NCT04348188|Active Comparator|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
32950814|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
32950815|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
32950816|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
32950817|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
32950818|NCT04348344|Experimental|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
32950819|NCT04348344|No Intervention|control group|health education of pulmonary rehabilitation
32950820|NCT05512962|Experimental|Suprachoroidal Triamcinolone acetonide 2.4mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 2.4mg/60µl Triesence® will be applied.
32950821|NCT05512962|Experimental|Suprachoroidal Triamcinolone acetonide 4.0 mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 4.0mg/100µl Triesence® will be applied.
32950822|NCT05505864|Experimental|Intervention Group|"Participants in the intervention group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~Participants in the intervention group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 app at week 0, 2, 4, 6, and 12.~Participants in the intervention group will receive a one-on-one behavioural counselling session online through zoom at week 0 to create personalized action plans and coping strategies to reduce and break up sedentary behaviour. The participant will update these action plans and coping strategies at the end of week 2 and 4 on the SEMA3 app.~Participants in the intervention group will receive tailored text messages the day after receiving their one-on-one counselling session for a 6-week period.~Participants in the intervention will receive one-on-one qualitative interview on zoom at week 6 to explore participants overall experience engaging in the intervention."
32950823|NCT05505864|No Intervention|Control Group|"Participants in the control group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~Participants in the control group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 mobile app at week 0, 2, 4, 6, and 12."
32950824|NCT05685576|Experimental|Ridge splitting and osseodensification with simultaneous implant placement|
32950825|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
33315027|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
32806420|NCT00049036|Experimental|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
32806421|NCT00049036|Experimental|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
32806422|NCT00212446|Experimental|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
32806423|NCT00049504|Experimental|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
32806424|NCT00050986|Experimental|Temozolomide and R115777|
32806425|NCT04499950|Experimental|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave [as per the Food and Drug Administration (FDA) recommended administration] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
32806426|NCT04499950|Active Comparator|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
32806427|NCT00214786|Experimental|Islet Cell Transplantation|Allogenic islet cell transplantation
32806428|NCT00118144|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
32806429|NCT00118378|Experimental|Modafinil|Participants will take modafinil for 4 weeks.
32806430|NCT00118378|Placebo Comparator|Placebo|Participants will take placebo for 4 weeks.
32806431|NCT00217438|Experimental|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
32950826|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
32950827|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
32950828|NCT05498454|Active Comparator|Breathworks Mindfulness for Health|an 8-week, online, protocol based mindfulness course designed to manage chronic pain and chronic health conditions
32950829|NCT05498454|Active Comparator|Breathworks Mindfulness for Stress|an 8-week, online, protocol based mindfulness course designed to manage stress
32950830|NCT05498454|No Intervention|Waiting list|The Waiting list will be for the whole sample of participants (acting as a waiting list control). From this, participants will be randomly allocated to one of the Arms above
32950831|NCT05454228||Delirium|
32950832|NCT05454228||Non-delirium|
32950833|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
32950834|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
32950835|NCT05453370|Experimental|CALMA app|the arm will receive CALMA app and continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study. In the first interview, the CALMA application will be downloaded to the participant's smartphone. In each follow-up interview (30-days and 60-days), the use of the app will be reinforced.
32950836|NCT05453370|Other|Treatment As Usual (TAU)|the arm will not receive the app and will continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study.
32950837|NCT05498220|Experimental|Single Arm|The subjects with diffuse large B-cell lymphoma were relapsed or refractory after the first treatment and receiving the study protocol treatment.
32950838|NCT04401852|Active Comparator|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
32950839|NCT04401852|Placebo Comparator|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
32950840|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
32950841|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
32831038|NCT04975620|Experimental|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
32831039|NCT04975620|Experimental|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
32831040|NCT04957134|Experimental|Electro-acupuncture with lifestyle intervention|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.While the intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
32831041|NCT04957134|Placebo Comparator|Sham electro-acupuncture with lifestyle intervention|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.The intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
32831042|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
32831043|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
32831044|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
32831045|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
32831046|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
32831047|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
32831048|NCT03263676|Experimental|Icon reusable underwear|
32831049|NCT03263676|Placebo Comparator|Disposable pad|
32831050|NCT04736862|Experimental|Continuous monitoring group|
32831051|NCT04736862|Active Comparator|Intermittent monitoring group|
32831052|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
32831053|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
32831054|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
32831055|NCT04706598|Experimental|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
32831056|NCT04706598|Active Comparator|Intravenous therapy group|Camrelizumab(SHR-1210) is administered on the first day (D1) of each treatment cycle (21 days) at a dose of 200 mg by 30-min intravenous infusion(the allowable error in infusion time is -5 min, +10 min). The maximum duration of dosing is 2 years.
32831057|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
32831058|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
32831059|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
32831060|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
32831061|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
32831062|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
32831063|NCT03970746|Experimental|Cohort A1|PDC*lung01 Low Dose
32831064|NCT03970746|Experimental|Cohort A2|PDC*lung01 High Dose
32831065|NCT03970746|Experimental|Cohort B1|PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
32831066|NCT03970746|Experimental|Cohort B2|PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
32831067|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
32831068|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
32831069|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
32831070|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
32950842|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
32950843|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
32950844|NCT03318900|Experimental|Treatment (T-cell infusion, aldesleukin, utomilumab)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV on day -2, CD8-positive T-lymphocyte via infusion on day 0, and aldesleukin SC every 12 hours for 14 days. Beginning 24 hours after CD8-positive T-lymphocyte, patients also receive utomilumab IV over 90 minutes on days 1, 29, 57, 85, 113, and 141 in the absence of disease progression or unacceptable toxicity.
32950845|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
32950846|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
32950847|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
32950848|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
32950849|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
32950850|NCT03318120|No Intervention|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
32950851|NCT05337228|Experimental|IN-C006 Peri inj.|IN-C006 Peri inj. 1904 mL
32950852|NCT05337228|Active Comparator|RPN301|RPN301 2020 mL
32950853|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30mg/kg load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
32950854|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
32950855|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
32950856|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
32950857|NCT03314922|Experimental|Parsaclisib|
32950858|NCT03081780|Experimental|FATE NK-100|
32950859|NCT04278612|Experimental|Intervention|"Provision of comprehensive care including the following:~Baby:~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -~Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks~Nevirapine for the baby for six weeks~Mother:~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)~HIV Care:~HIV positive mothers - provide ART for the mother and adherence support~HIV negative mothers- HIV test every three months while breastfeeding"
32950860|NCT04278612|Active Comparator|Control|Routine maternal and child care service delivery
32950861|NCT05430282|Active Comparator|Vestibular rehabilitation|Patients in the vestibular rehabilitation group will be asked to do vestibular exercises 3 times a day for 20 minutes, every day for one month.
32950862|NCT05430282|Experimental|Cervical exercise in addition to vestibular rehabilitation|Patients in this group will receive the same vestibular exercise program and will be asked to do additional neck exercises and they will be asked to do these exercises twice a day for ten minutes.
32950863|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
32950864|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
32950865|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
32950866|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
32950867|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
32950868|NCT05422638|Experimental|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
32950869|NCT05422638|Active Comparator|PCT|8-week health promotion group focused on providing support and facilitating problem solving
32950870|NCT05422326|Experimental|Group 1|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive two aH5N6c vaccinations, 3 weeks apart
33099097|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
33099098|NCT04695509|Experimental|moderate sedation|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with moderate propofol sedation
33099099|NCT04695509|Experimental|deep sedation|Arm Description: patients with American Society of Anesthesiologists (ASA I-II), Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with deep propofol sedation
33404812|NCT04808284|Experimental|tDCS- DLPFC|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.
32950871|NCT05422326|Experimental|Group 2|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive an aH5N6c vaccination on Day 1 and saline placebo on Day 22
33099100|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
33099101|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
33099102|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
33099103|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
33099104|NCT00531765|Active Comparator|1|hydration with normal saline
33099105|NCT00531765|Experimental|2|hydration with sodium bicarbonate
33099106|NCT00515996||2|paroxetine treatment group vs. normal control group
33099107|NCT00531804|Experimental|1|
33099108|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
33099109|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
32950872|NCT05422326|Experimental|Group 3|Eligible subjects who received placebo in the parent study V89_18 receive two aH5N6c vaccinations, 3 weeks apart.
32950873|NCT05418192|Experimental|Group A|Intervention Given: Enriched Environment (age-appropriate) + NDT + Therapeutic Dosing
32950874|NCT05418192|Other|Group B|Traditional Physical Therapy consisting of NDT
32950875|NCT05096598|Experimental|ZP8396|Up to 10 single dose cohorts are planned with 8 subjects in each; 6 participants in each cohort will receive active treatment.
32950876|NCT05096598|Placebo Comparator|Placebo (ZP8396)|In each of the 10 single dose cohorts, 2 subjects will receive placebo.
32950877|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
33099110|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
32950878|NCT03081624||Term Preschoolers|Term children who haven't attend school.
32950879|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
32950880|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
32950881|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
32950882|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
32950883|NCT05345964|Active Comparator|Single-dose experimental group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
32950884|NCT05345964|Placebo Comparator|Single-dose control group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
33099111|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
33099112|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
33099113|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
33099114|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
33315028|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32950885|NCT05345964|Active Comparator|Multi-dose experimental group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
32950886|NCT05345964|Placebo Comparator|Multi-dose control group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
32950887|NCT05345964|Active Comparator|Food Impact Study Group A|According to the results of the SAD, it is planned to select 1 dose group，10 subjects(8 received GST-HG151 and 2 received placebo， randomly assigned)，two cycles, crossover
32950888|NCT05345964|Active Comparator|Food Impact Study Group B|According to the results of the SAD, it is planned to select 1 dose group，8 subjects，two cycles, crossover
32950889|NCT04399824|Experimental|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
32950890|NCT04399824|Experimental|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
32950891|NCT05410392|Experimental|Combined physical and cognitive exercise intervention|Participants will receive both the physical exercise intervention and the cognitive exercise intervention for 3 months.
32950892|NCT05410392|Experimental|Physical exercise intervention|Participants will receive the physical exercise intervention for 3 months.
32950893|NCT05410392|Experimental|Cognitive exercise intervention|Participants will receive the cognitive exercise intervention for 3 months.
32950894|NCT05410392|Active Comparator|Control group|Participants will receive health education for 3 months.
32950895|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
32950896|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
32950897|NCT05397210||Infinity-Lock™ Button System|Participants diagnosed with acute or chronic Grade Ill-VI ACJ dislocation who require treatment with an Infinity-Lock Button System who meet the inclusion criteria and none of the exclusion criteria.
32950898|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
32950899|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
32950900|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
32950901|NCT05393076|Experimental|Cohort 1 (Moderate hepatic impairment participants)|Eligible participants to receive single dose of linerixibat.
32950902|NCT05393076|Experimental|Cohort 2 (Matched healthy control participants)|Eligible participants to receive single dose of linerixibat
32950903|NCT05386992|Experimental|Anthropometric study of children's feet and healthy standard last design:|"An anthropometric study of the feet of the subjects included in the sample will be carried out. The variables of interest used in this work are collected by digitizing the foot and ankle of each person, as well as through an anonymous questionnaire, which the study volunteers and their parents or legal guardians fill out and deliver.~From the data collected, 5 models of healthy standard last will be produced that are adapted to the anthropometric characteristics of our study population: sports last, boot last, sandal last, ballerina last and moccasin last."
32950904|NCT05385510|Experimental|Group 1 - children with HIV|100 5-36 month old children with confirmed HIV infection.
32950905|NCT05385510|Experimental|Group 2 - children without HIV|20 5-36 month old children without HIV infection.
32950906|NCT05381220|Experimental|early mobilization in stroke patients|"The first day is to elevate the head of the bed and sit for 5 minutes The second day is to elevate the head of the bed for 10 minutes and sit on the edge of the bed for 5 minutes.~The third day, sit on the edge of the bed for 10 minutes, get out of bed and stand for 10 minutes, and standing still for 5 minutes. The activity time is about 25 minutes each time, and the activity frequency is 2 times a day for 3 days."
32950907|NCT05381220|No Intervention|usual care in stroke patients|usual care
32950908|NCT05378958||Caregivers|Any health professional (medical or paramedical profession) practicing therapeutic education in distance mode by videoconferencing, regardless of the programs concerned
32950909|NCT05378958||Participants|"Patient's caregivers or parents who have taken part in a therapeutic education session by videoconference (individual or collective) as part of a program, regardless of their age, sex or the pathology concerned by education program~Patients: from 10 years old and only if the therapeutic education session was intended for them, regardless of gender or pathology"
32950910|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
32950911|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
32950912|NCT05059704|Experimental|Circuit Class Training|Patients will participate in a total of 1.5hour/day for 8 weeks with a 1:3 (therapist to patient). The circuit will be divided into 5 specific stations, 5 to 10 minutes for warm-up tasks and 15 to 20 minutes on each station as tailored to the patient's activity level
32950913|NCT05059704|Active Comparator|Individual Task specific training|Patients will participate in a total of 1.5hour/day for 8 weeks with 1:1 (therapist to patient) ratio. During each session, all patients will perform 5 to 10 minutes warm-up tasks, then practiced the selected tasks for the rest of the time.
32950914|NCT05034042|Experimental|Fezolinetant: low dose|Participants will receive low dose of fezolinetant once daily for 12 weeks.
32950915|NCT05034042|Experimental|Fezolinetant: high dose|Participants will receive high dose of fezolinetant once daily for 12 weeks.
32950916|NCT05034042|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 12 weeks.
32950917|NCT03244722|Other|Obese - Very low energy diet (VLED)|Participants will adopt a very-low energy diet
32950918|NCT03244722|Other|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
32950919|NCT03244722|Other|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
32950920|NCT05026710|Experimental|Silicone (Coloplast Imajin Hydro) ureteral stent|
32950921|NCT05026710|Experimental|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
32950922|NCT05019144|Active Comparator|Face-to-face arm|Standard face-to-face burn care.
32950923|NCT05019144|Experimental|TOBI arm|A novel smartphone application for burn wound care, called the Telemedicine Optimized Burn Intervention (TOBI), was recently developed to enable burn experts to direct burn wound care while the patient and caregiver are home through text messaging and video-conferencing. The app was designed to bring expert wound care directly to the patient's home to address barriers to healthcare, including high cost burden and time commitment (e.g., geographic limitations, transportation to burn centers, parking, lodging, meals, time away from school and work), particularly for patients/families in rural and medically underserved communities. TOBI is synced with a portal used by providers, as an adjunct to standard therapy. This burn app provides education through frequently asked questions, instructional burn dressing change videos in addition to direct communication between patient and burn expert through store-and-forward pictures and videoconferencing.
32950924|NCT05015478|Active Comparator|Active Tailored Rhythmic Lighting|1 hour intervention period where active lighting is experienced by participants.
32950925|NCT05015478|Placebo Comparator|Inactive Placebo Rhythmic Lighting|1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.
32950926|NCT05374590|Experimental|Efgartigimod|Patients receiving efgartigimod IV treatment
32950927|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
32950928|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
32950929|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
32950930|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
32950931|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
32950932|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
32950933|NCT05006352|Experimental|DNL343 (High Dose)|
32950934|NCT05006352|Experimental|DNL343 (Low Dose)|
32950935|NCT05006352|Placebo Comparator|Placebo|
32950936|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
32950937|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
32950938|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
32950939|NCT04760574||Case group|HIV infected men who have sex with men
32950940|NCT04760574||Control group|HIV non-infected men
32950941|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32950942|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
32950943|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
32950944|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
32950945|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
32950946|NCT05328804|Experimental|rhTPO|rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days.
32950947|NCT05328804|Experimental|Herombopag|Herombopag will be taken orally at 5 mg daily for 28 days.
32950948|NCT05328804|Experimental|Herombopag in combination of rhTPO|Herombopag will be taken orally at 5 mg daily for 28 days，while rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days
32950949|NCT05348850||Study Group|"Athletes with patellofemoral pain syndrome will be selected Muscle contractile properties and functional performance will be assessed for athletes with patellofemoral pain syndrome .~Data will be collected from all athletes regarding age, gender, training intensity running experience and previous injuries.~By the end of the assessment it will be detected if muscle contractile properties of vastus medialis and vastus lateralis is a determinant factor that influence functional performance in runners with patellofemoral pain syndrome."
32950950|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
32950951|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
32950952|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
32950953|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
32806432|NCT00217438|Active Comparator|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
32806433|NCT04480450|Active Comparator|IVIg/SCIg < 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
32806434|NCT04480450|Active Comparator|IVIg/SCIg > 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
32806435|NCT00217594|Experimental|Alemtuzumab|Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days
32806436|NCT00118534|Experimental|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
32806437|NCT00118534|Active Comparator|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
32806438|NCT00052078|Active Comparator|Sertraline|Participants received sertraline for 12 weeks.
32806439|NCT00052078|Active Comparator|CBT|Participants received cognitive behavioral therapy for 12 weeks
32806440|NCT00052078|Active Comparator|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
32806441|NCT00052078|Placebo Comparator|Placebo|Participants received a placebo pill for 12 weeks.
32806442|NCT00119158|Placebo Comparator|placebo|Placebo cream
32806443|NCT00119158|Active Comparator|pimecrolimus cream|
32806444|NCT00119392|Experimental|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
32806445|NCT04752280|Experimental|Arm A: Proton irradiation|Irradiation applied with protons
32806446|NCT04752280|Active Comparator|Arm B: Photon IMRT|Photon irradiation applied as intensity-modulated radiotherapy
32806447|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
32806448|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
32806449|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
32806450|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
32806451|NCT00218062|Experimental|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
32806452|NCT00218062|Experimental|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
32806453|NCT00218062|Experimental|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
32806454|NCT00218062|Placebo Comparator|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
32806455|NCT00121186|Experimental|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m^2 on days -6 to -2 and melphalan 70 mg/m^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m^2 on days 1, 3, and 7.
32806456|NCT00121810|Experimental|1|
32806457|NCT00121810|Active Comparator|2|
32806459|NCT00053014|Experimental|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
32806460|NCT00123604|Experimental|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
33315029|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
32806461|NCT00123604|Active Comparator|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
32806462|NCT00123682|Experimental|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
32806463|NCT00123682|Experimental|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
32806464|NCT00123682|Experimental|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
32806465|NCT00123682|Experimental|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
32806466|NCT00125788|Experimental|investigational product|L-glutamine
32806467|NCT00125788|Placebo Comparator|placebo|maltodextrin
32806468|NCT00221338|Experimental|Gabapentin|Double blind, placebo controlled
32806469|NCT00221338|Placebo Comparator|Placebo|Double blind
32806470|NCT00223678|Active Comparator|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
32806471|NCT00223678|No Intervention|2|Patient will remain on calcineruin inhibitor
32806472|NCT04752436|Experimental|Supra high intensity interval training|The experimental group will engage in the high intensity interval training.
32806473|NCT00053482|Experimental|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
32806474|NCT00053482|Experimental|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
32806475|NCT00053482|Experimental|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
32806476|NCT00053482|Experimental|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
32806477|NCT00053482|Active Comparator|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
32806478|NCT00130780|Active Comparator|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
32806479|NCT00130780|Active Comparator|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
32806480|NCT04752748||Woman with Early Rheumatoid Arthritis|
32806481|NCT00041392|Active Comparator|Magnesium|100 mg/kg magnesium
32806482|NCT00041392|Placebo Comparator|0.9 % saline|100 mg/kg 0.9 % saline
32806483|NCT02091778|Experimental|Fast Gelling Dressing|
32806484|NCT04752046|Active Comparator|obturator group|patients with resected maxillary defects were managed with surgical obturator
32806485|NCT04752046|Active Comparator|scapular flap group|
32806486|NCT04752202|Experimental|Test group (group A)|The women were randomly assigned to group A. Test group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
32806487|NCT04752202|Other|Control group (group B)|The women were randomly assigned to group B. Control group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
32806488|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
32806489|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
32806490|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
32806491|NCT00225784|Experimental|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
32806492|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
32806493|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
32806494|NCT00132964|Active Comparator|Immobilizaton device|Below Knee walking cast
32806495|NCT00132964|Experimental|Immobilization device|Removable ankle brace
32806496|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
32806497|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
32806498|NCT00133978|Experimental|Glutamine|Glutamine supplementation
32806499|NCT00133978|Experimental|Antioxidants|Antioxidant supplementation
32806500|NCT00133978|Experimental|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
32806501|NCT00133978|Placebo Comparator|Placebo|Non-isonitrogenic, iso-caloric placebo solution
32806502|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
32831071|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
32831072|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
33404813|NCT04808284|Sham Comparator|tDCS- SHAM|Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).
33404814|NCT05197803|Experimental|Hearing aid model|Unaided, Unitron RIC and Unitron BTE hearing aid styles during one-time visit.
32950954|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
32950955|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
32950956|NCT05341128||Pediatric Participants With CPP|Pediatric participants who have been diagnosed with CPP per criteria set in the 2015 version of The Consensus on the Diagnosis and Treatment of Central Precocious Puberty and have received treatment or medical services in China between 07 August 2015 and 31 December 2024 will be assessed retrospectively using the Chinese CPP Big Data Platform database.
32950957|NCT05340348|Other|Patient library|All the patients are included in one arm. They will undergo various type of samples.
32950958|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
32950959|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
32950960|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
32950961|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
32950962|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
32950963|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
32950964|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
32950965|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
32950966|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
32950967|NCT04400136|No Intervention|GROUP A - no PPI|no PPI treatment (control group)
32950968|NCT04400136|Experimental|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
32950969|NCT04400136|Experimental|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
32950970|NCT04990284|Experimental|50 mg opicapone once-daily|
32950971|NCT04990284|Experimental|100 mg of L-DOPA|
32950972|NCT04983654|Experimental|Patients with limb ulcer|Patients with sickle cell disease and suffering from limb ulcer
32950973|NCT04983654|Experimental|Patients without limb ulcer|Patients with sickle cell disease without any limb ulcer
32950974|NCT04962126|Experimental|Treatment naive advanced follicular lymphoma|All consenting participants will be receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (PR or SD) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg IV) q8/52 for up to 12 cycles.
33404815|NCT04054700|Experimental|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
33404816|NCT04054700|Other|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
33404817|NCT05387044|Experimental|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
32950975|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
32950976|NCT04941066|Experimental|Active neurofeedback|Receiving feedback signals from the rumination-related brain functional connectivity.
32950977|NCT04941066|Sham Comparator|Sham neurofeedback|Receiving artificially generated feedback signals.
32950978|NCT04938336||expert healthcare professionals|Delphi Procedure
32950979|NCT04938336||healthcare professionals, patients and informal carers|interviews
32950980|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
32950981|NCT04932252|Experimental|A4368 - Dose 1|Single dose of A4368 or placebo tablet, orally administered
32950982|NCT04932252|Experimental|A4368 - Dose 2|Single dose of A4368 or placebo tablet, orally administered
32950983|NCT04932252|Experimental|A4368 - Dose 3|Single dose of A4368 or placebo tablet, orally administered
32950984|NCT04932252|Experimental|A4368 - Dose 4|Single dose of A4368 or placebo tablet, orally administered
32950985|NCT04932252|Experimental|A4368 - Dose 5|Single dose of A4368 or placebo tablet, orally administered
32950986|NCT04932252|Experimental|A4368 - Dose 6|Single dose of A4368 or placebo tablet, orally administered
32950987|NCT04932252|Experimental|A4368 - Dose 1 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
32950988|NCT04932252|Experimental|A4368 - Dose 2 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
32950989|NCT03233646|Experimental|Case|500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease
32950990|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.
32950991|NCT04278300||case|patient with age-related exudative macular degeneration
32950992|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
32950993|NCT05270694|Experimental|COVID-19 Testing|The cohort participants will be exposed to a public health messaging campaign and provided with at-home tests to improve acceptability and access to COVID-19 testing.
32950994|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
32950995|NCT05266014|Experimental|tinlarebant|Daily, oral administration of one tinlarebant.
32950996|NCT05338086|Experimental|MB09-MB09|Subjects randomised into MB09-MB09 group will receive MB09 (60 mg in 1 mL) SC injection every 6 months.
32950997|NCT05338086|Active Comparator|Prolia-MB09|Subjects randomised into Prolia- MB09 group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
32950998|NCT05338086|Active Comparator|Prolia-Prolia|Subjects randomised into Prolia-Prolia group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
32950999|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
32951000|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
32951001|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants were given the LIITA3H app, which is a combination product consisting of 3 main features that tracked their visits to fast food restaurants (using the ELI feature), sent tailored text messages to prompt healthy choices when they were in a fast food restaurant (using the POP feature), and allowed them to submit pictures of their food (using the SNAP feature).
32951002|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) and they submitted pictures of their food (using the SNAP feature). However, they did not receive tailored text messages.
32951003|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) but they did not receive tailored messages or submit pictures of their food.
32951004|NCT04902768||Adults with congenital heart disease|
32951005|NCT02984670|Experimental|Behavior Therapy|
32951006|NCT02984670|Experimental|Cognitive Therapy|
32951007|NCT02984670|Other|Waitlist|
32951008|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
32951009|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
32951010|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
32951011|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
32951012|NCT05323110|Experimental|Part A - Cohort 1A|Single dose cohort
32951013|NCT05323110|Experimental|Part A - Cohort 2A|Single dose cohort
32951014|NCT05323110|Experimental|Part A - Cohort 3A|Single dose cohort
32951015|NCT05323110|Experimental|Part A - Cohort 4A|Single dose cohort
32951016|NCT05323110|Experimental|Part A - Cohort 5A|Single dose cohort
32951017|NCT05323110|Experimental|Part A - Cohort 6A|Single dose cohort
32951018|NCT05323110|Experimental|Part A - Cohort 7A|Single dose cohort
32951019|NCT05323110|Experimental|Part A - Cohort 8A|Single dose cohort
32951020|NCT05323110|Experimental|Part B - Cohort 1B|Multiple dose cohort
32951021|NCT05323110|Experimental|Part B - Cohort 2B|Multiple dose cohort
33099115|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
33099116|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
33099117|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
33099118|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
33099119|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
33099120|NCT00531921||Kidney transplants|patients from 5 specific sites
33099121|NCT00531921||Liver transplants|patients from 5 specific sites
33099122|NCT00531921||Heart transplants|patients from 5 specific sites
33099123|NCT00531921||Lung transplants|patients from 5 specific sites
33099124|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
33099125|NCT05318235||Children|Children between 6 weeks and 4 years of age who have a older sibling or attend day care
33099126|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
33099127|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
32806503|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
32806504|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
32806505|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
32806506|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
32806507|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
32806508|NCT01897948|Active Comparator|Milk-based beverage without DHA|
32806509|NCT00253708|Experimental|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
32806510|NCT00253708|Active Comparator|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
32806511|NCT00253708|No Intervention|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
32806512|NCT00254410|Experimental|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
32806513|NCT00254488|Experimental|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
32806514|NCT00254488|Experimental|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
32806515|NCT00255970|Experimental|Regenafil graft|Regenafil
32806516|NCT00255970|Active Comparator|DFDBA|Demineralized Freeze Dried Bone Allograft
33099128|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
33099129|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
33315030|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
33315031|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
33315032|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
33315033|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
32951022|NCT05323110|Experimental|Part A - Cohort 3B|Multiple dose cohort
32951023|NCT04858854|Active Comparator|BSE group (Broccoli sprout group)|The BSE Group will receive 50 µmmol/day of sulforaphane administered by BSE (Lantmännen®) from week 0 to week 4. If no side-effects are reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.
32951024|NCT04858854|Placebo Comparator|Control group|The Control Group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for 12 weeks.
32951025|NCT04857840|Experimental|Arm A: Investigational Product /Period 1,2 and 3 if any (open label)|Firibastat 1000 mg tablets QD - 12 weeks
32951026|NCT04857840|Placebo Comparator|Arm B: Placebo/Period1 only|Placebo tablets QD 12 weeks in Period 1 only, followed by open label Period 2 and 3 if any.
32951027|NCT04582968|Experimental|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
32951028|NCT04834284||Helicopter Emergency Medical Services (HEMS)|Patients transported to the comprehensive stroke centre at least in some part by a HEMS unit
32951029|NCT04834284||Ground Emergency Medical Services (GEMS)|Patients transported to the comprehensive stroke centre solely by an ambulance
32951030|NCT04833894|Experimental|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
32951031|NCT04563468|Experimental|Strength inspiratory muscle training group|Strength IMT
32951032|NCT04563468|Sham Comparator|Endurance inspiratory muscle training group|Endurance IMT
32951033|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
32951034|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
32951035|NCT05296902||SILKAM®|SILKAM® is a non-absorbable sterile suture material made from braided silk fibrils. It is available either undyed (white) or dyed black with hematein and is coated with refined paraffin wax or beeswax.
32951036|NCT05295732|Experimental|TMB-001 0.05%|TMB-001 0.05% ointment: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Maintenance therapy for additional 12 weeks randomized QD vs BID
32951037|NCT05295732|Placebo Comparator|Vehicle|Matching vehicle ointment with no action isotretinoin: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Cross over to 12 weeks TMB-001 0.05% BID.
32951038|NCT05295732|Experimental|Maximal use|Optional Parallel Arm to evaluate the systemic exposure and safety of TMB-001 0.05% under conditions of maximal use.
32951039|NCT05293470||Piqray|Patients prescribed with Piqray
32951040|NCT05292612|Experimental|Standard therapist-guided iCT-SAD vs. Waitlist|"to examine if standard iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C&W) for SAD under the guidance of trained therapist."
32951041|NCT05292612|Experimental|Guided self-help iCT-SAD vs. Waitlist|"to examine if guided self-help iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C&W) for SAD under the guidance of trained coaches."
32951042|NCT05292612|Experimental|Standard therapist-guided iCT-SAD vs. Guided self-help iCT-SAD|"to examine if guided self-help iCT-SAD is noninferior to standard iCT-SAD.~participants would be randomised into two groups. one group of participants would receive iCBT(C&W) for SAD under the guidance of trained therapist while the other group of participants would receive iCBT(C&W) for SAD under the guidance of trained coaches."
32951043|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
32951044|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
32951045|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
32951046|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
32951047|NCT04277364|Active Comparator|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
32951048|NCT04277364|Active Comparator|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
32951049|NCT04277364|Placebo Comparator|Placebo|750mg of corn starch per day for 8 weeks
32951050|NCT05277168|Experimental|Single Arm|Single Arm : SHR-A1904
32951051|NCT05276778||People with type 2 diabetes|People diagnosed with type 2 diabetes age 18-70
32951052|NCT04557228|Placebo Comparator|Placebo|Study participants will receive 4 weeks of supplementation with 400mg placebo supplements
33315034|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
33315035|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
33315036|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
33315037|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
33315038|NCT01155674||Sepsis patients|Patients presenting sepsis
33315039|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
33315040|NCT01155674||Healthy subjects|Healthy blood donors
33315041|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
33315042|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~30 patients with a quiescent lupus~30 patients with an active lupus"
33315043|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
32806517|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
32806518|NCT00231868|Experimental|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
33315044|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
33315045|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
33315046|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
33315047|NCT01262378|Active Comparator|HF knife|
32806519|NCT00257686|Experimental|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
32806520|NCT00257686|Active Comparator|Pravastatin 10 mg|Pravastatin 10 mg once daily
32806521|NCT00257686|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
32806522|NCT00257686|Active Comparator|Pravastatin 20 mg|Pravastatin 20 mg once daily
32806523|NCT00257686|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
32806524|NCT00257686|Active Comparator|Pravastatin 40 mg|Pravastatin 40 mg once daily
32806525|NCT00234286|Experimental|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
32806526|NCT01469013|Placebo Comparator|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
32806527|NCT01469013|Experimental|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
32806528|NCT01469013|Experimental|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
32806529|NCT01469013|Experimental|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
32806530|NCT01469013|Experimental|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
32806531|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
32806532|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
32806533|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
32806534|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
32806535|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
32806536|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
32806537|NCT02985567||Safety of sedation|"Documentation of:~The need for repeat dosing of chloral hydrate.~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge~Interventions required for the patient including administration of oxygen, and need for intubation."
32831073|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
33099130|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~Raltegravir 400 mg twice daily for the last 14 days of the study."
33099131|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
33099132|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|
32951053|NCT04557228|Experimental|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 400mg phosphatidylserine supplements.
32951054|NCT04278378|Active Comparator|Riboflavin|1.6 mg riboflavin / day for 24 weeks
32951055|NCT04278378|Experimental|Folic Acid|0.4 mg folic acid/ day for 24 weeks
32951056|NCT04278378|Experimental|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
32951057|NCT04278378|Placebo Comparator|Placebo|
32951058|NCT04399512|Active Comparator|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
32951059|NCT04399512|Active Comparator|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
32951060|NCT04399278|Other|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
32951061|NCT04399278|Other|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
32951062|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
32951063|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
32951064|NCT04523376|Experimental|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
32951065|NCT04523376|Experimental|Beta Thalassemias Major|Patients with Beta Thalassemias Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
32951066|NCT04801758|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 704/HPTN 085 (NCT02716675).
32951067|NCT04797468|Experimental|HLX23|HLX23 administered IV.
32951068|NCT04785924|Other|Observation Treatment Group|All patients observed while treated with IMI/REL.
32951069|NCT04774380|Experimental|Durvalumab - (cisplatin or carboplatin) - Etoposide|Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
32951070|NCT04514562|Other|Intervention|NeVa Stent Retrievers
32951071|NCT04509180|Experimental|Catheter ablation group|Patients undergoing catheter procedure will be put under conscious sedation and local anesthesia. Pulmonary vein isolation and posterior wall isolation will be performed with a radiofrequency ablation catheter (20-45W, open-tip irrigation). Ablation index will be used for the lesion formation guidance (450-500 on anterior aspects; 350-400 on the posterior aspects). A wide antral circumferential ablation will be performed for pulmonary veins and a box lesion set for the posterior left atrial wall. Voltage mapping and signal analysis performed by the operator will be used to assess electrical isolation of the pulmonary veins and posterior wall and to identify gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
32951072|NCT04509180|Active Comparator|Convergent group|Patients undergoing convergent procedure will be put under general anesthesia. A minimally invasive epicardial radiofrequency ablation (30W, 90s) of posterior wall will be performed through a subxiphoid window. Monitoring of the esophageal temperature will be performed with an esophageal temperature probe set at 38°C. Next, an endocardial radiofrequency ablation (20-40W, open-tip irrigation; ablation index 450-500 anteriorly and 350-400 posteriorly) of pulmonary veins in a wide antral circumferential fashion will be performed. Voltage mapping and signal analysis performed by the operator will be used to assess the electrical isolation of the pulmonary veins and posterior wall and to identify the gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
32951073|NCT04509024|Experimental|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
32951074|NCT04509024|Active Comparator|explicit training|Participants undergo traditional explicit language learning.
32951075|NCT04348110|Placebo Comparator|Placebo tablets|
32951076|NCT04348110|Experimental|Blueberry Chewable Tablets|
32951077|NCT04506294|Experimental|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
32951078|NCT04506294|No Intervention|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (~12 weeks)
32951079|NCT05251818|Active Comparator|Acupressure grubu|"The first thing after the operation is to apply the thumb tool for approximately seven minutes, with 15 seconds of preparation and 1.5 minutes of application at each point of the LI4 and TH6 acupuncture points (the equivalent of working each point).The second application will be repeated three hours after the first application, with the same procedure.~By the researcher, hourly monitoring will be done until the bowel sounds of the puerperant are heard, and the puerperant will be followed up until the gas and defecation output. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
33099133|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|
33099134|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
33315048|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
33315049|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
33315050|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
32951080|NCT05251818|Active Comparator|Control Group|"No application will be made to the control group.. From the first postoperative hour, the researcher will follow the bowel sounds every hour until the first bowel sounds of the patient are heard.~Postpartum women will be followed until gas and defecation are released. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
32951081|NCT04498806|Experimental|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
33315051|NCT05080166|Experimental|Clinicians Interviews|Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
32951082|NCT04498026|Experimental|Adherus Dural Sealant System|Device: Adherus Dural Sealant, In situ polymerizing sealant
33315052|NCT05080166|Experimental|Lymphoma Survivors Field Test|A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
32806538|NCT01609556|Experimental|Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)|Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks [Q3W]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
32951083|NCT04498026|Active Comparator|DuraSeal Exact Dural Sealant System|Device: DuraSeal Exact (P080013b)
32951084|NCT04398810|Experimental|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
32951085|NCT04398810|Experimental|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
32951086|NCT05221320|Experimental|Stage 1 - 5 baskets included, based on primary disease|"Ulixertinib: 450mg twice daily (BID), orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
32951087|NCT05221320|Experimental|Stage 2 - basket expansion based on Stage 1|"Ulixertinib: 450mg BID, orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
32951088|NCT04737720||1|This is an expanded use protocol for a named subject.
32951089|NCT05167734|No Intervention|Control (Standard of Care) Group|Subjects will receive standard clinical care for the treatment of anemia while in the ICU.
32951090|NCT05167734|Experimental|Anemia Treatment Bundle|The intervention arm is multi-faceted with 3 primary components: 1) Optimized phlebotomy, defined by minimal volume draws and closed-loop blood sampling, all performed by a dedicated phlebotomy team independent from the treatment team; 2) Decision support aids, including visual and electronic alerts reminding the care team to minimize non-essential laboratory testing and mitigate patient-specific bleeding risk; and 3) Pharmacologic anemia treatment with a single dose of IV iron and/or subcutaneous erythropoietin (given immediately following enrollment) targeted to 2 broad groups: 1) anemias responsive to iron supplementation alone (i.e. acute blood loss, iron deficiency) and 2) anemias requiring erythropoietic stimulation (e.g. anemia of inflammation, anemia of renal disease).
32951091|NCT04722666|Experimental|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
32951092|NCT04722666|Experimental|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
32951093|NCT04722666|Experimental|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
32951094|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
32951095|NCT04722666|Placebo Comparator|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
32951096|NCT04722666|Experimental|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
32951097|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
32951098|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
32951099|NCT04760418|Experimental|4 week baseline|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
32951100|NCT04760418|Experimental|6 week baseline|Participants in this arm are randomized to a 6-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
32951101|NCT04478370|Experimental|An. minimus|"This arm will be divided into 2 groups; the low-exposure groups and the high-exposure group.~In the low-exposure group, participants will be exposed to 5 mosquito bites at weekly intervals from day 14 to day 56 (seven challenges with 5 mosquito bites/challenge over six weeks, yielding a total of 35 mosquito bites).~In the high-exposure group, participants will be exposed to 5 mosquito bites on day 14 and then to 50 mosquito bites at weekly intervals from day 21 to day 56 (one challenge with 5 mosquito bites and six challenges with 50 mosquito bites/challenge over 6 weeks, yielding a total of 305 mosquito bites)."
32951102|NCT04478370|Experimental|An. maculatus|Same as above
32951103|NCT04478370|Experimental|An. dirus|Same as above
32951104|NCT04478370|Experimental|Ae. aegypti|Same as above
32951105|NCT04478370|Experimental|Ae. albopictus|Same as above
32951106|NCT04277520|Active Comparator|Continous rotation|instrumentation was done in continuous rotation motion
32951107|NCT04277520|Active Comparator|Reciprocation|instrumentation was done in reciprocation motion
32951108|NCT04277520|Active Comparator|Adaptive motion|instrumentation was done in adaptive motion
32951109|NCT04466358|Experimental|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
32951110|NCT04466358|Active Comparator|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
32951111|NCT04399902|Experimental|Study blanket|Two standard warmed hospital blankets will be placed on top of the patient and the study blanket on top of the standard warmed blankets, covering as much of the patient as possible, at the discretion of the care team. At all times, clinicians should ensure that the study blanket does not touch the patient's bare skin.The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
32951112|NCT04277754||two-year-old children with typical development|
32951113|NCT04451772|Experimental|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
32951114|NCT04451772|Experimental|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
32951115|NCT04451772|Experimental|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
32951116|NCT04451772|Experimental|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
32951117|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
32951118|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
32951119|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
32951120|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
32951121|NCT05173740|Experimental|Individually tailored rehabilitation intervention|The intervention is based on a multidisciplinary rehabilitation team approach (psychologists, physiotherapists, social workers, physicians within social medicine and occupational medicine and psychiatrists). A comprehensive neurocognitive assessment will be conducted to inform the individually tailored intervention plan. The intervention plan will be evaluated monthly by the multidisciplinary rehabilitation team. Core intervention elements are; 1) providing strategies to lessen impact for the individual cognitive findings (e.g. problems regarding fatigue, executive functions or attention), 2) educating patients and relatives about the impact of a heart attack 3) Work preparation, including establishment of routines and opportunities to practice work skills and 4) collaboration with employers to plan, support and monitor the graded RTW.
32951122|NCT05173740|Active Comparator|Usual care|In Denmark, medical treatment and rehabilitation services are provided by the public healthcare system in an up-front tax paid welfare system. Medical treatment is provided by hospitals and rehabilitation is provided by the 98 municipalities. Hence, after hospital medical treatment is complete, survivors of OHCA are referred to rehabilitation in their municipality. Before discharge from the hospital, the physician is required to assess the survivors of OHCA rehabilitation needs and if a rehabilitation potential is identified the individual have the right to be referred to the municipality, and from then the responsibility for the rehabilitation, and the content, is the municipality's. The rehabilitation organisation and the content of the intervention offered to survivors of OHCA have been investigated through registry data and suggest that there are no consensus on the organisation or content of what a rehabilitation intervention consist of.
32951123|NCT05172102|Experimental|study group|"Will receive diaphragmatic breathing with pursed lips as (breathing exercise), They will instruct to perform 3 different conditions will be registered: (1) 6 min of quiet breathing (3 sets of 2 min each), defined as spontaneous breathing pattern; (2) 6 min of diaphragmatic breathing (3 sets of 2 min each); and (3) 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).~For aerobic exercises: Will include the following exercises: walking, cycling, running and intermittent running. The exercises will perform for 18-60 minutes for 1-2 sets per week.~For resistance exercises: Will include the following 8 exercises: shoulder press, biceps curl, triceps curl, bench press, leg squats, leg press, leg curl and toe raise. The exercises will perform for 60 minutes for 2-3 sets per week."
32951124|NCT05172102|No Intervention|control group|not receiving any exercises
32951125|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
32951126|NCT04704024|Experimental|Pregnant Women - Tenofovir|Women will be randomized to early initiation (enrollment at 14-28 weeks pregnant) vs standard initiation (at 28 weeks pregnant) of tenofovir disoproxil fumarate (TDF) 300 mg daily oral medication until delivery.
32806539|NCT01609556|Experimental|Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)|Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
32806540|NCT01609556|Experimental|Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)|Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose [MTD]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
32806541|NCT01609556|Experimental|Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)|Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
32806542|NCT01806506|Experimental|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
32806543|NCT01806506|Experimental|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
32806544|NCT01766336|Experimental|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
32806545|NCT01766336|Experimental|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
32806546|NCT01797536|Experimental|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
32806547|NCT01797536|Experimental|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
32806548|NCT01797536|Experimental|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
32806549|NCT01797536|Experimental|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
32806550|NCT01797302|Active Comparator|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
32806551|NCT01797302|Active Comparator|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
32806552|NCT01797302|Placebo Comparator|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
32806553|NCT01805180|Other|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
32806554|NCT01805180|Other|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
32806555|NCT04413968|Experimental|Interventional|nasopharyngeal and blood sample
32806556|NCT01804946|Experimental|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
32806557|NCT01804946|Active Comparator|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
32806558|NCT01737398|Active Comparator|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
32806559|NCT01737398|Active Comparator|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
32806560|NCT01795898|Experimental|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
32806561|NCT01736696|Experimental|5 mg BID|5 mg BID for 13 days and once on Day 14
32806562|NCT01736696|Experimental|10 mg BID|10 mg BID for13 days and once on Day 14*
32806563|NCT01736696|Experimental|20 mg BID|20 mg BID for 13 days and once on Day 14
32806564|NCT01736696|Experimental|30 mg BID|30 mg BID for 13 days and once on Day 14
32806565|NCT01736696|Experimental|60 mg QD|60 mg QD for 14 days
32806566|NCT01736696|Experimental|50 mg BID|50 mg BID x 13 days and once on day 14
32806567|NCT01736540|Other|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
32806568|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
32806569|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
33315053|NCT05080166|Experimental|UPLYFT Pilot|Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.
32806570|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
32806571|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
32806572|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
32806573|NCT01764854|Experimental|AZD1722- in patient|Tenapanor administered in a clinical pharmacology unit
32806574|NCT01764854|Placebo Comparator|Placebo- in patient|Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
32806575|NCT01764854|Experimental|AZD1722 out-patient|Tenapanor
32806576|NCT01764854|Experimental|Placebo out-patient|Placebo
32806577|NCT01764464|Other|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
32806578|NCT01764464|Other|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
32806579|NCT01764386|Experimental|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
32806580|NCT01764386|Other|Usual Care|"Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
32806581|NCT01763996|Experimental|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
32806582|NCT01763996|Experimental|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
32806583|NCT01763918|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
32806584|NCT01763918|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
32806585|NCT01763918|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
32806586|NCT01763918|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
32806587|NCT01763684|Active Comparator|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
32806588|NCT01763684|Active Comparator|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
32806589|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
32806590|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
32806591|NCT01761266|Active Comparator|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
32806592|NCT01761266|Active Comparator|Sorafenib|Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
32806593|NCT01760954|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
32806594|NCT01760954|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
32806595|NCT01760876|Experimental|Biofreedom stent|Coronary intervention
32806596|NCT01759862|Experimental|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.~Theophylline drug levels will be monitored daily for 4 days."
32806597|NCT01759862|Placebo Comparator|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.~Drug levels will be monitored daily for 4 days."
32806598|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
32806599|NCT04579874|Experimental|LIVERFASt validation|blood draw for LIVERFASt
32806600|NCT01793792|Other|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
32806601|NCT01790984|Experimental|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
32806602|NCT01790984|Experimental|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
32806603|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
32806604|NCT01735994|Other|Brochure wait list|Brochure wait list control group
32806605|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
32806606|NCT01790594|Active Comparator|Immunosuppression without Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
32806607|NCT01790594|Experimental|Immunosuppression Including Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Belatacept~Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
32806608|NCT01790516|Experimental|Cisplatin|Cisplatin
32806609|NCT01790516|Experimental|Cetuximab|cetuximab
32806610|NCT01790438|Experimental|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
32806611|NCT01790438|Active Comparator|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
32806612|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
32806613|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
32806614|NCT01790126|Active Comparator|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
32806615|NCT01790126|Active Comparator|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
32806616|NCT01790126|Active Comparator|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
32806617|NCT01734902|Experimental|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
32806618|NCT01734902|Experimental|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
32806619|NCT01790048|Experimental|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
32806620|NCT01790048|Active Comparator|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
32806621|NCT01789970|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
32806622|NCT01789970|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
32806623|NCT01734434||Pregnant women|24 weeks or more of gestation
32806624|NCT01788566|Experimental|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.~Gemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.~Cisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
32806625|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
32806626|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
32806627|NCT01732874|Other|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
32806628|NCT01732874|Other|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
32806629|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
32806630|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
32806631|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
32806632|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
32806633|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
32806634|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
32806635|NCT01786148|Active Comparator|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
32806636|NCT01786148|Experimental|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
32806637|NCT04560686|Experimental|Treatment (bintrafusp alfa, surgical resection)|Patients receive bintrafusp alfa IV on days 1, 15, and 29 in the absence of unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may receive chemotherapy or undergo radiation therapy at the discretion of the treating physician.
32806638|NCT04576676||Essential Tremor|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
32806639|NCT04576676||Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Parkinson's Disease~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
32806640|NCT04576676||Healthy Individuals|"Healthy individuals living within 3 hours of UTSW~Subjects must be 50 years of age or older~You are healthy and have not being diagnosed with any neurological disease~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
32806641|NCT04576676||Essential Tremor and Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
32806642|NCT01785602|Experimental|QAW039|Participants received QAW039 450 mg daily by mouth.
32806643|NCT01785602|Placebo Comparator|Placebo|Participants received matching placebo to QAW039.
32806644|NCT01785524|Experimental|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
32806645|NCT01785524|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
32806646|NCT01757288|Active Comparator|PACLITAXEL (Phase II, Arm A)|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
32806647|NCT01757288|Experimental|NAB-PACLITAXEL (Phase II, Arm B)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
32806648|NCT01757288|Experimental|NAB-PACLITAXEL (Phase I)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
32806649|NCT01756898|Experimental|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
32806650|NCT01756898|Experimental|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
32806651|NCT01756898|Experimental|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
32806652|NCT01756898|Placebo Comparator|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
32806653|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
33099135|NCT05319912|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099136|NCT05319912|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099137|NCT05319912|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099138|NCT05319912|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099139|NCT05319912|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099140|NCT05319912|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33099141|NCT05319834|Active Comparator|Progesterone with asprin|The included women will be randomly allocated to prophylactically receive either vaginal progesterone at a dose of 200 mg (prontogest 200mg every 12 hr) combined with oral aspirin at a dose of 100mg once daily both at the same time (group1),
33099142|NCT05319834|Placebo Comparator|Progesterone and placebo|vaginal progesterone (prontogest 200mg every 12 hr) and oral placebo (manufactured in a standard way to have the same size and shape of asprin tablet) also at the same time (group 2).
33099143|NCT04695587||TakoTsubo|Patients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
33099144|NCT02943018||anovaginal distance variation|3 measurements
33099145|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
32806654|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
33099146|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
33099147|NCT02942940|Active Comparator|mobile app|
33099148|NCT02942940|Active Comparator|in-person|
33099149|NCT04695197|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine, standard 3-day antimalarial treatment regimen.
33099150|NCT04695197|Experimental|Pyronaridine-artesunate|Pyronaridine-artesunate, standard 3-day antimalarial treatment regimen.
33099151|NCT05317962||COVID-19 positive patients admitted to hospital|
33099152|NCT05319678||Cochlear implant users|Pre-or perilingual patients aged 6 to 17 years old, and postlingual adults who underwent cochlear implantation from 2000 to January 2023 at La Paz University Hospital
33099153|NCT05319678||Normal hearing subjects|Control group is set up with the normal hearing peers of cochlear implant users
32806655|NCT01731470|Experimental|Liposomes|Liposomes
33099154|NCT05319600|Experimental|Intervention|This arm will complete an intervention delivered remotely via an online website and online communication from the research team across the 12-week intervention period. This intervention has two parts, taking place simultaneously over the 12 weeks. First, participants will complete 8 web-delivered online behavior-change skills learning sessions which include reading and activities. Second, participants will be given daily and weekly personalized physical activity goals to meet, which will be tracked via their Garmin activity tracker and weekday text and if indicated video support. They have the opportunity to win money each week for meeting activity goals.
33315054|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
32806656|NCT01756352|Experimental|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
32831074|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
33099155|NCT05319600|No Intervention|Treatment as usual - Control|This arm will not complete an intervention. Participants will be instructed to wear a Garmin activity tracker but will be given no other specific instructions, other than to continue to follow their normal daily diabetes care plan.
33099156|NCT05319366||Stable angina|50 patients with stable angina will be included and tissue samples from balloon cathether and blood samples will be collected
33099157|NCT05319366||Unstable angina/non-ST-segment elevation myocardial infarction|50 patients with unstable angina/non-ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
33099158|NCT05319366||ST-segment elevation myocardial infarction|50 patients with ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
32806657|NCT01756274|Experimental|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
32806658|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
32806659|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
32806660|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
32806661|NCT04559984|Experimental|JUVÉDERM VOLUX®|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator.
32806662|NCT04559984|Other|Control- No treatment|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
32806663|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
32806664|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
32806665|NCT01783886|Active Comparator|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
32806666|NCT00234832|Experimental|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
32806667|NCT00234832|Placebo Comparator|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
32806668|NCT00234832|Experimental|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
32806669|NCT00259090|Active Comparator|1|Anastrozole Monotherapy
32806670|NCT00259090|Experimental|2|Fulvestrant Monotherapy
32806671|NCT00259090|Experimental|3|Anastrozole + Fulvestrant
32806672|NCT00235456|Active Comparator|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
32806673|NCT00235456|Placebo Comparator|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
32806674|NCT00236938|Experimental|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
32806675|NCT00236938|Active Comparator|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
32806676|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
32806677|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
32806678|NCT00260962|Placebo Comparator|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
32806679|NCT00260962|Experimental|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
32806680|NCT00261040|Active Comparator|Minimally Invasive Surgery (MIS)|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
32806681|NCT00261040|Sham Comparator|Standard Surgery|The standard way an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision
32806682|NCT00237718|Active Comparator|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
32806683|NCT00237718|Placebo Comparator|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
32806684|NCT00238108|Experimental|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
32806685|NCT00238108|Placebo Comparator|2|Placebo
32806686|NCT01899196|Other|no Arm|
32806687|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
32806688|NCT04752124|Active Comparator|HIIT+CT|HIIT combined with conventional rehabilitation.
32806689|NCT04752124|Placebo Comparator|Conventional therapy|Conventional rehabilitation will be provided to this group of patients.
32806690|NCT00266110|Experimental|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
32806691|NCT00240526|Experimental|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
32806692|NCT00240526|Experimental|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
32806693|NCT00240526|Experimental|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.
32806694|NCT00240526|Experimental|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.
32806695|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
32806696|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
32806697|NCT00242632|Experimental|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
32806698|NCT00242632|Experimental|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
32806699|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
32806700|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
32806701|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
32806702|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
32806703|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
32806704|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
32806705|NCT00245518|Experimental|Isoflavone|Isoflavone
32806706|NCT00245518|Placebo Comparator|Placebo|
32806707|NCT00267670|Experimental|Pentoxifylline|400mg PO TID
32806708|NCT00267670|Placebo Comparator|Placebo|1 pill PO TID
32806709|NCT00247624|Experimental|A|Participants will receive treatment with eszopiclone and fluoxetine
32806710|NCT00247624|Active Comparator|B|Participants will receive treatment with placebo and fluoxetine
32806711|NCT00248560|Experimental|Gemcitabine, docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
32806712|NCT00248638|Active Comparator|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
32806713|NCT00248638|Placebo Comparator|standard|Participants given standard nutrition without glutamine dipeptide
32806714|NCT00249496|Active Comparator|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
32806715|NCT00249496|Experimental|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
32806716|NCT00268762|Experimental|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
32806717|NCT00252382|Experimental|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
32806718|NCT00270634|Active Comparator|Low Dose Voclosporin|Low dose voclosporin
32806719|NCT00270634|Active Comparator|Mid Dose Voclosporin|Mid Dose Voclosporin
32806720|NCT00270634|Active Comparator|High Dose Voclosporin|High Dose Voclosporin
32806721|NCT00270634|Active Comparator|Tacrolimus|Standard Dose Tacrolimus
32806722|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
32806723|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
32831075|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
33099159|NCT05319366||Controls|50 patients without corornary arthery-related treatment will be included and tissue samples from balloon cathether and blood samples will be collected
33099160|NCT05319366||Vascular surgery|25 patients who undergo will be included and tissue samples and blood samples will be collected
33099161|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
33099162|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
33099163|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
33099164|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
33099165|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
33099166|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
33099167|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
33099168|NCT00515450|Experimental|1|
33099169|NCT00515450|Active Comparator|2|
32738157|NCT05021445|Active Comparator|conventional treatment|this will consists of 12 elderly participants who will receive intervention protocol of Conventional balance training exercises in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
32738158|NCT05015205|Experimental|MET Group|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The exercises were performed 3 times per week for 4 weeks.
32738159|NCT05015205|Experimental|Control Group|Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. The exercises were performed 3 times per week for 4 weeks.
32738160|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
32738161|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
32738162|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
32738163|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
32738164|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
32738165|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
32738166|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
32738167|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
32738168|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
32738169|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
32738170|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
32738171|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
33099170|NCT02941848|Experimental|Group1|"C → A + B~A : HGP0816 B : HGP1404 C : HCP1306"
32738172|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
33099171|NCT02941848|Experimental|Group2|"A + B → C~A : HGP0816 B : HGP1404 C : HCP1306"
32738173|NCT03078699|Experimental|stereotactic body radiation therapy|
32738174|NCT05007171|Experimental|Very low calorie diet|Use of very low calorie diet in hospital for 3 weeks
32738175|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
33099172|NCT00515489||001|Risperidone as prescribed
33099173|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
33099174|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
33099175|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
33099176|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
33099177|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
33099178|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
32738176|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
32738177|NCT04463043|Experimental|SelfBACK app|The selfBACK app in addition to usual care
33099179|NCT05319210|Experimental|Buzzy application|It is fixed on the right upper arm area of the child one minute before the procedure. After cleaning the skin with the appropriate solution, venous catheter placement will be performed. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
33099180|NCT05319210|Experimental|Virtual Reality Glasses|A dinosaur movie suitable for the 7-12 age group will be watched 2-3 minutes before the venous catheter insertion. In this process, after cleaning the skin with the appropriate solution, a venous catheter will be inserted. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
32831076|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
32831077|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
33099181|NCT05319210|No Intervention|No intervention|The routine venous catheter placement protocol in the institution where the study is conducted will be applied. An evidence-based non-pharmacological method is not used to reduce pain during venous catheter insertion in children in the institution. A venous catheter is inserted by attaching a tourniquet to the child. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
33099182|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
33099183|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
33099184|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
33099185|NCT02941809|Experimental|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
33099186|NCT02941809|No Intervention|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
33099187|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
33099188|NCT02951000|Active Comparator|no platysma suture|no platysma suture
32831078|NCT05219058||Patients undergoing abdominoperineal excision|
33099189|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:~Baseline evaluation session with a Pediatrician for initial screening;~Appointment with a Dietitian;~A brochure with physical activity guidelines for youth with examples of physical exercises."
33099190|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;~Physical activity consultation (Physical activity behavior change);"
33099191|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;~Physical activity consultation;~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
33315055|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
32831079|NCT05219058||Patient undergoing pelvic exenteration|
32831080|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery~Immediately after the transvaginal US, US/PAI imaging will be performed~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
32831081|NCT03263052||Tacrolimus XR|
32831082|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
32738178|NCT04463043|Active Comparator|e-Help webpage|The e-Help webpage in addition to usual care
32738179|NCT04463043|Active Comparator|Usual care|Usual care only
32738180|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
32738181|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
32738182|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
32738183|NCT04466007|Placebo Comparator|Control arm|0.9% physiological saline
32738184|NCT04466007|Experimental|Low dose treatment arm|Low dose allogeneic mesenchymal stem cells derived from adipose tissue
32738185|NCT04466007|Experimental|High dose treatment arm|High dose allogeneic mesenchymal stem cells derived from adipose tissue
32738186|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over~With solid cancer irrespective of the stage~Pre-screened or screened for at least one ongoing clinical trial in the center~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~Social security affiliation"
32738187|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
32951127|NCT04704024|Placebo Comparator|Newborn Infants - Lamivudine|Infants exposed to HBV at birth will be randomized to receive oral lamivudine post-exposure prophylaxis or matching placebo. Medication will be administered twice daily for 6 months.
32951128|NCT04439994|Active Comparator|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
32951129|NCT04439994|Placebo Comparator|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
32951130|NCT03256656|Experimental|Healthy subjects|
32738188|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
32951131|NCT03256656|Active Comparator|Patients with SCI|
32951132|NCT04686084|Experimental|CT scan|CT scan (MDCT, standard of care) and DE-CBCT (Investigational)
32951133|NCT05156112|Experimental|PAP Treatment on SARRTP Unit|Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.
32951134|NCT05156112|No Intervention|Waitlist Control|Veterans will not receive PAP device until after 3-month Follow Up.
32951135|NCT04434066|Experimental|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
32951136|NCT04434066|Experimental|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
32951137|NCT04433988|Placebo Comparator|Control group|100 patients will receive standard treatment plus placebo
32951138|NCT04433988|Experimental|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
32951139|NCT04425408|Experimental|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
32951140|NCT04425408|Experimental|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
32951141|NCT04685538|Experimental|Chloroprocaine 3%|All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
32951142|NCT04685538|Active Comparator|Tetracaine 0.5%|All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
32951143|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
32951144|NCT04674384|Active Comparator|Intermittent Low Energy Diet (ILED)|
32951145|NCT04674384|Active Comparator|Continuous Low Energy Diet (CLED)|
32951146|NCT04673760|Experimental|Arm 1: Structured specialized palliative home care|Eligible specialist palliative home care teams provide ambulant specialised palliative care as usual
32951147|NCT04673760|No Intervention|Arm 2: No care of specialist palliative home care teams at study inclusion|No care from specialist palliative home care teams at study inclusion
32951148|NCT04746222|Experimental|Treatment|Single dose of 30 oral capsules containing FMT from a stool bank
32951149|NCT04746222|Placebo Comparator|Placebo|Single dose of 30 oral placebo capsules
32951150|NCT03252756|Placebo Comparator|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
32951151|NCT03252756|Experimental|Phytocannabinoid cannabidiol (CBD)|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
32951152|NCT04746768|Experimental|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
32951153|NCT05130606|Experimental|Video Arm|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles."
32951154|NCT05130606|Active Comparator|FORCE Fact Sheet|Participants in the FORCE Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.
32951155|NCT05121246|Experimental|MB05 (Proposed palivizumab biosimilar)|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1.
32951156|NCT05121246|Active Comparator|EU-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
32951157|NCT05121246|Active Comparator|US-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
32951158|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
32951159|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
32951160|NCT04344678|Placebo Comparator|Control group|Escitalopram 20 mg tablet plus one placebo tablet
32951161|NCT04344678|Experimental|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
32951162|NCT04075110|Placebo Comparator|Control group|50 patients will receive metformin up to 2000mg/daily (Control group)
33099192|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
33099193|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
33099194|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
33099195|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
33099196|NCT02950376||Group1：amphetamine abusers|
33099197|NCT02950376||Group2: health control|
33099198|NCT02950376||Group3: norm of assessment system|
33099199|NCT00515645|Experimental|1|
33099200|NCT02950220|Experimental|Arm 1|
33099201|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
32806724|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
33099202|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
33099203|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
32806725|NCT04110340|Active Comparator|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days."
33099204|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
33099205|NCT05317767|Experimental|Flu-M|300 children that will be vaccinated with a single dose of the Flu-M vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
33099206|NCT05317767|Active Comparator|Ultrix|300 children that will be vaccinated with a single dose of the Ultrix® vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
32806726|NCT04110340|Other|Control arm|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
32806727|NCT00270790|Experimental|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
32806728|NCT00271570|Active Comparator|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
32806729|NCT00271570|Experimental|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
32806730|NCT00273364|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
32806731|NCT00273364|Active Comparator|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
32806732|NCT05237596||Prescription-grade Crystalline Glucosamine Sulfate Group (pCGS Group)|pCGS Group includes patients treated with pCGS (Dona®, VIATRIS), in sachets of powder for oral solution, at the dose of 1500 mg glucosamine sulfate once daily, for a total period of 6 consecutive months according to the approved indication for knee OA, in addition to conventional therapy for HOA.
32806733|NCT05237596||Control Group|Control Group includes patients treated with conventional therapy alone for at least 6 consecutive months.
32831083|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
33099207|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
33099208|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
33099209|NCT04695158||COVID-19 group (Group I)|Patients diagnosed with COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatment according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020.
33315056|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
33315057|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
33099210|NCT04695158||Type II Diabetes Mellitus and COVID-19 group (Group II)|Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
33099211|NCT04695158||Control group (Group III)|Healthy volunteers will be in this group. No intervention will be applied in this group.
33099212|NCT05317650|No Intervention|Control group|Control group, no exercise was performed, and the measurements were repeated at the end of 4 weeks.
33099213|NCT05317650|Experimental|M-Gravity group|Intervention group performed the exercise with the M-Gravity, 2 sessions per week, for 4 weeks, at the Outpatient Clinic of Department of Physical Therapy, Baskent University, one session for 60 minutes.
33099214|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
33099215|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
33099216|NCT04691310|Active Comparator|Kinesio taping study|Kinesio tex gold tape was applied to neck localised lymphedema as stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
33099217|NCT04691310|Sham Comparator|Kinesio taping sham|Kinesio tex gold tape was applied to neck localised lymphedema as no-stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
33099218|NCT00515762|Experimental|1: scalp cooling|scalp cooling
33404818|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
32806734|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
32806735|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
32806736|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
32806737|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
32806738|NCT00273754|Placebo Comparator|Placebo|Saline
32806739|NCT00273754|Active Comparator|Caffeine|Caffeine benzoate
32806740|NCT04751344|Experimental|Liposomal Bupivacaine|The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
32806741|NCT04751344|Active Comparator|Bupivacaine HCl|The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
32806742|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
32806743|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
32806744|NCT05211232|Experimental|GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for eight cycles after radiotherapy
32806745|NCT05211232|Placebo Comparator|GP combine with Placebo neoadjuvant therapy+CCRT+Placebo adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and Placebo(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with Placebo(200mg) every three weeks for eight cycles after radiotherapy
32806746|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
32806747|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
32806748|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
33099219|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
33099220|NCT00515801|Placebo Comparator|B|placebo capsules
33099221|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
33315058|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
33404819|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
33404820|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
33315059|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
33404821|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
32951163|NCT04075110|Experimental|Montelukast group|50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
32951164|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
32951165|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
32951166|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
32951167|NCT04056312|Experimental|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
32951168|NCT04056312|Placebo Comparator|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
32951169|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
32951170|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
32951171|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
32951172|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
32951173|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
32951174|NCT05180136|Experimental|Rice bran extract group|This group takes rice bran extract for 8 weeks.
32951175|NCT05180136|Placebo Comparator|Control group|This group takes a placebo for 8 weeks.
32951176|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
32951177|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
32951178|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
32951179|NCT04054596|Experimental|STEM|The treatment group (TX) will complete 8 sessions of STEM (2 sessions per week for 4 weeks), Sessions are approximately 30-45 minutes long.
32951180|NCT04054596|No Intervention|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
32951181|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134."
32951182|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
32951183|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5~Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 17 cycles (approximately 1 year)."
32951184|NCT03246828|Experimental|Omission of gliclazide|
32951185|NCT04336644|Experimental|Continuous patch monitoring system|"Participants will receive standard of care treatment with either arsenic trioxide or capecitabine. They will have continuous patch monitor system (BodyGuardian Heart) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.~Twelve-lead ECGs are routinely performed in patients receiving arsenic trioxide at baseline and twice weekly during the first 4 weeks of therapy. These ECGs (total of up to 9) will be accessed for the purposes of this study. Patients who receive capecitabine do not routinely have ECGs performed after baseline, but for the purposes of this study, two serial ECGs will be conducted on Day 14 and Day 28 of Cycle 1 of treatment (total of 5 including baseline)."
32951186|NCT04746300||Group 1: no sequencing|Participants in this group, for which DNA sequencing could not be reported due to a variety of (quality/technical) reasons, will be treated with standard of care therapy. This group is therefore comparable to patients treated outside the Radboudumc.
32951187|NCT04746300||Group 2: no druggable aberration|Participants in this group received a DNA sequencing report identifying no biomarkers to which a logical treatment option can be connected. These participants will also receive standard of care therapy.
32951188|NCT04746300||Group 3: allocated to personalized treatment|Participants in this group received a DNA sequencing report which identified presence of a biomarker allowing the participant to be treated with a personalized therapy. This therapy could range from immunotherapy, or PARP inhibitors, to other medication.
32951189|NCT02476812|Experimental|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
32831084|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
32831085|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
32831086|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
32831087|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
32831088|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
32831089|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
32831090|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
32831091|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
32831092|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
32831093|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
32831094|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
32831095|NCT03262506|Experimental|Cognitive Training|
32831096|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
32831097|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
32831098|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
32831099|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
32831100|NCT05234814|Active Comparator|Control group|The control group was given the Traditional Chinese Medicine auricular acupuncture point buried seeds therapy.
32831101|NCT05234814|Experimental|Observation group|The observation group was given the auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
32831102|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
32831103|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
32831104|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
32831105|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
32831106|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
32831107|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
32831108|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
32831109|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
32831110|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
32831111|NCT02456766||F0|Liver Steatosis Grade: <5%
32831112|NCT02456766||F1|Liver Steatosis Grade: 5-33%
32831113|NCT02456766||F2|Liver Steatosis Grade: 34-66%
32831114|NCT02456766||F3|Liver Steatosis Grade: > 66%
32831115|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
32831116|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
32831117|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
32831118|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
32831119|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
32831120|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
32831121|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
32831122|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
33099222|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
33099223|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
33099224|NCT05317611|Active Comparator|Intraperitoneal instillation of ondansetron and bupivacaine (group A)|Patients will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % and (4 mg) 2 ml ondansetron through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
33099225|NCT05317611|Active Comparator|Intravenous ondansetron and intraperitoneal instillation of bupivacaine (group B)|Patient will receive intravenous (4 mg) 2 ml ondansetron and intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
33099226|NCT05317611|Sham Comparator|Intraperitoneal instillation of bupivacaine (group C)|patient will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
33099227|NCT04695314|Experimental|Glaucoma Group|Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
33099228|NCT04695314|Experimental|Ocular Hypertension Group A|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again."
33099229|NCT04695314|Active Comparator|Ocular Hypertension Group B|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again."
33099230|NCT05317572|Active Comparator|Group 1|Group 1: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 80 mcg intrathecal morphine) + iv Fentanyl-PCA
33099231|NCT05317572|Active Comparator|Group 2|Group 2: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 120 mcg intrathecal morphine) + iv Fentanyl-PCA
33099232|NCT05317572|Active Comparator|Group 3|Group 3: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 160 mcg intrathecal morphine) + iv Fentanyl-PCA
33099233|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
33099234|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
33099235|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
33099236|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
33099237|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
33315060|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
32831123|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
32831124|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
32831125|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
32831126|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
32831127|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
32831128|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
32831129|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
32831130|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
32831131|NCT02456454|Experimental|Risperidone|Risperidone, PO 0.25-2 mg/day
32831132|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
32831133|NCT02456454|Placebo Comparator|Placebo|Liquid placebo PO matched for color and taste.
32831134|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
32831135|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
32831136|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
32831137|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
32831138|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
32831139|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
33404822|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
33404823|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
33404824|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
32951190|NCT02476812|No Intervention|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
32951191|NCT04316442|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
32951192|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
32951193|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
32951194|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
32951195|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
32951196|NCT03175302||Control|Non-surgery matched peers with the same testing.
32951197|NCT03175224|Experimental|Single-Arm|APL-101 Oral Capsules
32951198|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
32951199|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
32951200|NCT05061966|Active Comparator|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
32951201|NCT05061966|Experimental|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
32951202|NCT03987126|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
32951203|NCT03987126|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
32951204|NCT03959904|Active Comparator|Small Stitch|Small stitch for wound closure
32951205|NCT03959904|Active Comparator|Large Stitch|Large Stitch for wound closure
32951206|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
32951207|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
32951208|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
32951209|NCT04277052|Experimental|Group 1|Muscle disorders
32951210|NCT04277052|Experimental|Group 2|Disc displacements
32951211|NCT04277052|Experimental|Group 3|Other common joint disorders
32951212|NCT04277052|Experimental|Group 4|Mix type
32951213|NCT04277052|Experimental|Group 5|Healthy individuals
32951214|NCT03918798|Experimental|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
32951215|NCT03918798|Experimental|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
32951216|NCT03909282|Active Comparator|Surgical Excision|Surgical excision of ductal carcinoma
32951217|NCT03909282|Experimental|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
32951218|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
32951219|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
32951220|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
32951221|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
32951222|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
32951223|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
32951224|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
33315061|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
33315062|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
32951227|NCT02008656|Experimental|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
32951228|NCT02008656|Experimental|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
32951229|NCT04300140|Experimental|Phase 1b: Batiraxcept + cabozantinib|Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated.
32951230|NCT04300140|Experimental|Phase 2 Part A: batiraxcept + cabozantinib|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated.
32951231|NCT04300140|Experimental|Phase 2 Part B: batiraxcept + cabozantinib + nivolumab|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab.
32951232|NCT04300140|Experimental|Phase 2 Part C: batiraxcept alone|One dose level of batiraxcept administered Q2W will be evaluated.
32951233|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
32951234|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
32951235|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
32951236|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
32951237|NCT04285476|Experimental|Signature of microRNA|Signature of miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5
32951238|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
32951239|NCT03592368|Active Comparator|Active IBT, Out of MRI|
32951240|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
32951241|NCT03592368|Active Comparator|Active IBT, In MRI|
32951242|NCT03592368|Sham Comparator|Sham IBT, In MRI|
32951243|NCT04271904|Sham Comparator|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
32951244|NCT04271904|No Intervention|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
32951245|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
32951246|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
32951247|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
32951248|NCT01812252|Other|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
32951249|NCT01812252|Other|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
32951250|NCT05005806|Active Comparator|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
32951251|NCT05005806|Placebo Comparator|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
33315063|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
33315064|NCT03884582||HealthyVolunteers|
33315065|NCT05075486|Experimental|Intervention group|Group who recieve collaborative quality improvement during study period.
32951252|NCT04233528|Experimental|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and <25 kg / m2) without any IDF criteria for metabolic syndrome
32951253|NCT04233528|Experimental|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
32951254|NCT04233528|Experimental|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
32951255|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
32951256|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
32951257|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
32951258|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
32951259|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
32951260|NCT04398186||Control group|Do not have PCOS
32951261|NCT04217694|Experimental|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
32951262|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
32951263|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
32951264|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
32951265|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
32951266|NCT03817632||A Standard|Computer assisted primary total knee replacement with OrthoPilot FS 101 navigation system and Software 5.1
32951267|NCT03817632||B Elite|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
32951268|NCT04398108|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
32951269|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
32951270|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
32951271|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
32951272|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
32951273|NCT04277130|Experimental|Intervention group|Intervention with active video games
32951274|NCT04277130|No Intervention|Control group|No intervention
32951275|NCT01583322|Experimental|vargatef/Nintedanib|
32951276|NCT01583322|Placebo Comparator|placebo|
32951277|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
32951278|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
32951279|NCT03796962|Experimental|25 mg XEN1101|Capsule filled with 25 mg XEN1101
32951280|NCT03796962|Experimental|20 mg XEN1101|Capsule filled with 20 mg XEN1101
32951281|NCT03796962|Experimental|10 mg XEN1101|Capsule filled with 10 mg XEN1101
32951282|NCT03796962|Placebo Comparator|Placebo|Placebo capsule
32951283|NCT04204122|Experimental|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
32951284|NCT04204122|Placebo Comparator|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
32951285|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
32951286|NCT03197922|No Intervention|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
32951287|NCT03197922|Experimental|MIE Treatment for One Week|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for one week. This study arm was discontinued in October 2019.
32951288|NCT05158062|Experimental|pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib|Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
33315066|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
33404825|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
32806749|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
32806750|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
32806751|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
32806752|NCT05167396|Experimental|Healthy Controls (HC)|n=90
32806753|NCT05167396|Experimental|Clinical High Risk of Psychosis (CHRP)|n=30
32806754|NCT05167396|Experimental|First Episode Psychosis (FEP)|n=30
32806755|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
32806756|NCT00274768|Experimental|Capecitabine|26 patients received the pre-defined starting dose of capecitabine of 3,000 mg orally daily given in two divided doses. Two thirds of the patients received either the same dose or a 500 mg lower dose compared to what would have been administered with a commonly used body surface area (BSA)-dosing schedule (2,000 mg/m2 with rounding down to nearest 500 mg multiple).
32806757|NCT00280384|Active Comparator|E2014 (Botulinum toxin type B)|
32806758|NCT00280384|Placebo Comparator|E2014 (Botulinum toxin type B) Placebo|
32806759|NCT05161546|Experimental|patients with bipolar disorder (BD)|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit.~Between day 23 and day 28 (after the second visit), patients will be offered to assess the retinal structure and microvascularization using Spectral Domain Optical Coherence Tomography (SD-OCT) and OCT-Angiography (OCT-A)."
32806760|NCT05161546|Active Comparator|healthy volunteers|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit."
32806761|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
32806762|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
32806763|NCT01790542|Other|A|Iron fortified cereal
32806764|NCT01790542|Other|B|Iron fortified cereal with fruit
32806765|NCT01790542|Other|C|Meat
32806766|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
32806767|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
32806768|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
32806769|NCT04511338|Experimental|Sequence AB: circuit A follow by circuit B|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
32806770|NCT04511338|Experimental|Sequence BA: circuit B follow by circuit A|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
32806771|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
32806772|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
32806773|NCT04480528|Experimental|BFRT Group|This group will receive physical therapy plus active BFRT.
32806774|NCT04480528|Sham Comparator|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
32806775|NCT04054180|Experimental|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
32806776|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
32806777|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
32806778|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
32806779|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
32806780|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
32806781|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
32806782|NCT04445662|Active Comparator|Control (n=200)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with fixed payments ($10) regardless of results"
32806783|NCT04445662|Experimental|Financial incentives (n=200)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with escalating payments ($25-70) for levels <30 ng/ml"
32806784|NCT00283504|Experimental|all patients received Xolair/active drug|One arm:active drug
32806785|NCT04407676|Experimental|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
32806786|NCT04407676|Placebo Comparator|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
32806787|NCT04370236|Placebo Comparator|Placebo + Standard of Care|Patients will receive placebo + standard medical care
32806788|NCT04370236|Experimental|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
32806789|NCT00283816|Active Comparator|1|metformin
32806790|NCT00283816|Placebo Comparator|0|placebo
32806791|NCT00284518|Experimental|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
32806792|NCT00284518|Experimental|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
32806793|NCT00284518|Experimental|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
32806794|NCT00284518|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
32806795|NCT04339426|Experimental|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
32806796|NCT01899898|Experimental|Simplified Modified Atkins Diet|
32806797|NCT01899898|Active Comparator|Antiepileptic drugs alone|
32806798|NCT00286078|Experimental|Treatment|Active occipital nerve stimulation (stimulation on)
32806799|NCT00286078|Sham Comparator|Control|Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
32806800|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
32806801|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
32806802|NCT04169074|Experimental|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days).
32806803|NCT00287716|Active Comparator|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
32806804|NCT00287716|Active Comparator|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
32806805|NCT00287716|Placebo Comparator|placebo|Placebo equivalent.
32806806|NCT00287872|Experimental|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
32806807|NCT00288574|Experimental|fluoxetine|fluoxetine up to 80 mg per day
32806808|NCT00288574|Placebo Comparator|Placebo|Placebo
32806809|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
32806810|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
32806811|NCT00288886|Experimental|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
32806812|NCT00288886|Active Comparator|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
32806813|NCT00289120|Experimental|Cola beverage|Subjects will be given 500cc of Cola twice daily.
32806814|NCT00289120|Placebo Comparator|Deionized water|Subjects will be given 500cc of deionized water.
32806815|NCT04079218|Experimental|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
32806816|NCT04079218|No Intervention|No treatment|No intervention
32806817|NCT04061590|Experimental|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
32806818|NCT04061590|Experimental|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
32806819|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32806820|NCT00289744|Experimental|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
32806821|NCT00289744|Experimental|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
32806822|NCT00289744|Experimental|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
33315067|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
33315068|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
33315069|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
33315070|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
33315071|NCT00075270|Experimental|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
33315072|NCT00075270|Placebo Comparator|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
33315073|NCT01155752|Experimental|PULMOZYME|active drug
33315074|NCT01155752|Placebo Comparator|placebo|cross over to placebo
33315075|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
33315076|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
33315077|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
32951289|NCT01176474|Experimental|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
32951290|NCT01176474|Experimental|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
32951291|NCT01076868|Experimental|Primaquine|Primaquine 14 days
32951292|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
32951293|NCT05151432|Experimental|Pulsed US + Exercise Group|Twenty subjects will receive PUT, plus an exercise program.
32951294|NCT05151432|Experimental|Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PEMF, plus an exercise program.
32951295|NCT05151432|Experimental|Pulsed US + Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PUT, PEMF, plus an exercise program.
32951296|NCT05151432|Experimental|Sham + Exercise group|Twenty subjects will receive sham PEMF and sham PUT plus exercises program.
32951297|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection~Combined Chemotherapy~Etoposide Injection +Methotrexate Tablet + HYCAMTIN - Topotecan Capsule~Usual Approach Group"
32951298|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule~Combined Chemotherapy~Etoposide Capsule + Methotrexate Tablet + HYCAMTIN - Topotecan Capsule~Study Approach Group"
32951299|NCT04199052|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-Virtual Peer Navigator (PN) supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment. It is important to note that the case management approach is self-guided versus intensive virtual PN assistance.
32951300|NCT04199052|Experimental|LinkPositively Intervention|Women assigned to the LinkPositively intervention arm will have access to all four components of the LinkPositively app. Women will be scheduled for a session with staff to inform them of their assigned virtual Peer Navigator (PN). Staff will train participants on how to download the app, explain the five components, using each component, and contacting their PN. Within the first week after, virtual PNs will complete a one-on-one, in-person or phone intake session with the participant, based on the participant's preference. During this intake session, the PN will conduct a participant needs assessment to connect her to HIV medical care via local health clinics and identify other areas of need, services of need, and assisted referrals (domestic violence services, mental health care, substance abuse treatment, housing and legal support, etc.). PNs will provide trauma-informed emotional and informational support, including guidance on accessing information about referred services.
32951301|NCT04198116|Experimental|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
32951302|NCT04198116|Active Comparator|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
33315078|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
33315079|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
33315080|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
32806823|NCT00291226|Experimental|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
32806824|NCT00291226|Placebo Comparator|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
32806825|NCT01791166|Experimental|Pulmonary transplant|
32806826|NCT00291694|Active Comparator|1|Oral Celecoxib 400 mg twice daily for 12 months
32806827|NCT00291694|Placebo Comparator|2|Matched blinded placebo twice daily for 12 months
32806828|NCT00292162|Active Comparator|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
32806829|NCT00292162|Active Comparator|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
32806830|NCT00296296|Active Comparator|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
32806831|NCT00296296|Active Comparator|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
32806832|NCT03880786|Experimental|PNE test lead|
32806833|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
32806834|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
32806835|NCT00298090||StO2 values|StO2 monitoring
32806836|NCT03962452|Other|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
32806837|NCT00298558|Active Comparator|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
32806838|NCT00298558|Active Comparator|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
32806839|NCT00298558|Active Comparator|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
32806840|NCT00298558|Placebo Comparator|Control|This group did not complete any cognitive training interventions
32806842|NCT00300430|Active Comparator|A|20 mg drug and ABT-335
32806843|NCT00300430|Active Comparator|B|40 mg drug and ABT 335
32806844|NCT00300430|Active Comparator|C|40 mg drug and ABT-335
32806845|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
32806846|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
32806847|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
32806848|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
32806849|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
32806850|NCT03587272|Experimental|SUN regimen|"Alemtuzumab intravenously, low dose total body irradiation, Sirolimus~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
32806851|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
32806852|NCT03895450|Experimental|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
32806853|NCT03895450|Placebo Comparator|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
32806854|NCT04271722|Experimental|Mifepristone|Mifepristone 200mg 24hours before the induction day
32806855|NCT04271722|Active Comparator|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
32806856|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
33099238|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
33099239|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
33099240|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
33099241|NCT00515918||1|Iron deficient
32806857|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
32806858|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
32806859|NCT00300742|Experimental|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
32806860|NCT00301756|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32806861|NCT00302068|Experimental|1|Supervised aerobic exercise, three times per week for 16 weeks.
32806862|NCT00302068|Active Comparator|2|Sertraline (Zoloft), for 16 weeks.
32806863|NCT00302068|Placebo Comparator|3|Placebo control, for 16 weeks.
32806864|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
32806865|NCT00302848||Users of Drospirenone (DRSP)|
32806866|NCT00302848||Users of Levonorgestrel (LNG)|
32806867|NCT00302848||Users of other oral contraceptives (OCs)|
32806868|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
32806869|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
32806870|NCT00138034|Active Comparator|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
32806871|NCT00138034|Other|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
32806872|NCT00303862|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
32806873|NCT00304096|Experimental|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
32806874|NCT00304096|Experimental|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
32806875|NCT05267392|Experimental|Durvalumab|All subjects enrolled in the study will receive open-label neoadjuvant durvalumab 1500 mg followed by standard of care RT/RCT
32806876|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
32806877|NCT00140842||Normal-weight girls|
32806878|NCT00142168|Experimental|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
32806879|NCT02611570||Non-smokers at risk for lung cancer|"Non-smoking subjects with lung cancer family history~Non-smoking subjects with a given lung cancer risk other than lung cancer family history"
32806880|NCT02578732|Experimental|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
32806881|NCT02501434|No Intervention|Control|Standard of Care
32806882|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
32806883|NCT02247232|Placebo Comparator|Placebo|
32806884|NCT02247232|Experimental|Z-100|
32806885|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
32806886|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
32806887|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
32806888|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
32806889|NCT05267314|No Intervention|standard therapy|standard therapy
32806890|NCT05267314|Experimental|exerciser and standard therapy|exerciser and standard therapy
32806891|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
32806892|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
32806893|NCT00147082||COPD|Patients with COPD - no intervention
32806894|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
32806895|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
32951303|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
33315081|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
33315082|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
33315083|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
32951304|NCT04193826|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
32951305|NCT04180020|Active Comparator|TAU|Treatment as Usual (TAU).
32951306|NCT04180020|Experimental|ID/LAB|Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
33315084|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
33315085|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
33315086|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.~Counseling is considered about physical activity, diet, smoking, and medication compliance."
33315087|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
33315088|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
33315089|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
33315090|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
33315091|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
33315092|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
32951307|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
33315093|NCT01157624|Active Comparator|oxygen|
33315094|NCT01157624|Placebo Comparator|air supplement|
33315095|NCT00074958|Experimental|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
33315096|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
33315097|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
32951308|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
32951309|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL (milliliter) of water. (180mg)
32951310|NCT03217422|Experimental|Arm 1|VAY736 Dose 1
32951311|NCT03217422|Experimental|Arm 2|VAY736 Dose 2
32951312|NCT03217422|Experimental|Arm 3|VAY736 Dose 3
32951313|NCT03217422|Placebo Comparator|Arm 4|Placebo
32951314|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
33099242|NCT00515918||2|Iron sufficient
32951315|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
32951316|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
32951317|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
32951318|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
32951319|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
32951320|NCT03667404|Experimental|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
32951321|NCT03667404|Placebo Comparator|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
32951322|NCT04276662|Experimental|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
32951323|NCT04276662|Experimental|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
32951324|NCT04276662|Experimental|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years [y]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
32951325|NCT04130802|Experimental|OCS-01 1.5% mg/mL QD|eye drops
32951326|NCT04130802|Experimental|OCS-01 1.5% mg/mL BID|eye drops
32951327|NCT04130802|Placebo Comparator|Placebo (Vehicle) BID|eye drops
32951328|NCT04276350|Experimental|Acupuncture|"Acupuncture Regime:~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
32951329|NCT04276350|Active Comparator|Best medical therapy|"Best Medical Therapy Regime:~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
32951330|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
32951331|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
32951332|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
32951333|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
32951334|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
32951335|NCT04110522|Experimental|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
32951336|NCT04110522|Experimental|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
32951337|NCT04110522|No Intervention|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
32951338|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
32951339|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or the MECTA Sigma devices.
32951340|NCT03190590|Active Comparator|Transcranial direct current stimulator (tDCS)|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
32951341|NCT03190590|Active Comparator|Transcranial magnetic stimulation (TMS)|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability.]
32951342|NCT03190590|Placebo Comparator|Sham-tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
32951343|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
32951344|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
32951345|NCT03166098||Diagnosis of Schizophrenia|
32951346|NCT03166098||Diagnosis of Bipolar Disorder|
32951347|NCT03166098||Unaffected siblings of the SZ groups|
32951348|NCT03166098||Unaffected siblings of the BP group|
32951349|NCT03166098||Healthy control (HC) comparison group|
32951350|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
32951351|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
32951352|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
32951353|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
32951354|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
32951355|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
33099243|NCT02942667||Subjects undergoing high quality MRI Scans|
32951356|NCT04103892|Experimental|CLE-100 (oral esketamine)|"Part A: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 1 week.~Part B: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 4 weeks."
32951357|NCT04103892|Placebo Comparator|placebo|"Part A: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 1 week.~Part B: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 4 weeks."
32951358|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
32951359|NCT04397328|Experimental|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
32951360|NCT04397328|Placebo Comparator|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
32951361|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
32951362|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
32951363|NCT04100538|Experimental|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
32951364|NCT04100538|No Intervention|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
32951365|NCT04098744|Experimental|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
32951366|NCT04098744|Placebo Comparator|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.
32951367|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
32951368|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
32951369|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
32951370|NCT04398576|No Intervention|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
32951371|NCT04398576|Active Comparator|Training and support|"All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
32951372|NCT04398576|Active Comparator|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
32951373|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
32951374|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
32951375|NCT04084314|Experimental|Erenumab|70 mg and 140 mg Erenumab
32951376|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
32951377|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
32951378|NCT04083612|Other|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
33315098|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
33315099|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
32806896|NCT00147316|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
32806897|NCT00148798|Experimental|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
32806898|NCT00148798|Active Comparator|Chemotherapy alone|cisplatin + vinorelbine alone
32806899|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
32806900|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
32806901|NCT00149734|Experimental|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
32806902|NCT00149734|Experimental|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
32806903|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
32806904|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
32806905|NCT00305578|Placebo Comparator|Placebo|Placebo daily
32806906|NCT00305578|Active Comparator|Memantine|Daily dose Memantine
32806907|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
32806908|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
32806909|NCT01492101|Experimental|NKTR-102|
32806910|NCT01492101|Active Comparator|Physician's Treatment of Choice|
32806911|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
32806912|NCT00306202|Experimental|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
32806913|NCT00306202|Experimental|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
32806914|NCT00306202|Experimental|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
32806915|NCT05267002|Experimental|Suture removal at 1 week|Cutaneous nylon suture removal of half of the split-scar at one week.
32806916|NCT05267002|Experimental|Suture removal at 2 weeks|Cutaneous nylon suture removal of half of the split-scar at two weeks.
32806917|NCT00308230|Placebo Comparator|Normal Heart|Control Group with Normal Heart
32806918|NCT00308230|Active Comparator|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
32806919|NCT00308230|Active Comparator|Heart Failure|Left ventricular heart failure, no congestive heart disease
32806920|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
32806921|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
32806922|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
32806923|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
32806924|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
32806925|NCT05266690|Experimental|Sequence 1|Roquette Glucidex 40 - Roquette Glucidex 2 - Pharmacosmos Dextran 10 - Promitor 70
32806926|NCT05266690|Experimental|Sequence 2|Roquette Glucidex 2 - Promitor 70 - Roquette Glucidex 40 - Pharmacosmos Dextran 10
32806927|NCT05266690|Experimental|Sequence 3|Promitor 70 - Pharmacosmos Dextran 10 - Roquette Glucidex 2 - Roquette Glucidex 40
32806928|NCT05266690|Experimental|Sequence 4|Pharmacosmos Dextran 10 - Roquette Glucidex 40 - Promitor 70 - Roquette Glucidex 2
32806929|NCT00328042|Experimental|Self-Management Workshop|
32806930|NCT00328042|Active Comparator|Information Only|
32806931|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
32806932|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
32806933|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
32806934|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
32806935|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
32951379|NCT05243628|Experimental|Afrezza + Automatic Insulin Delivery|Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.
32951380|NCT05243628|Experimental|Afrezza + Insulin Degludec|Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
32951381|NCT05243628|Active Comparator|AID Control|Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).
32951382|NCT05249478|Active Comparator|epidural catheter inserted before spinal anesthesia.|"As for the epidural analgesia, it will be performed under complete aseptic precautions, by introducing a needle between the lumbar vertebrae at level of L3-L4 or L4-L5 and injecting anesthetic medication into the epidural space, via the epidural catheter inserted through the needle into the epidural space.~A small amount of air (1 to 2 mL) may be injected into the epidural space, avoid injecting larger amounts of air as this may contribute to patchy anesthesia."
32951383|NCT05249478|Active Comparator|ultrasound guided femoral nerve catheter inserted before spinal anesthesia.|"As for the femoral nerve block, it will be performed under complete aseptic precautions, using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed on the femoral crease to obtain the images of the femoral nerve & artery.~The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, Once the femoral nerve is visualized, the needle will be inserted in-plane in a lateral to medial orientation and advanced towards the nerve. Once the tip placed adjacent to the nerve, the catheter is introduced through it, then the needle is removed, the location of the catheter can be confirmed by visualization of the catheter and spread of local anesthetic (LA)."
32951384|NCT05249478|Active Comparator|ultrasound guided adductor canal block inserted before spinal anesthesia.|As for the adductor canal block,using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed perpendicular to the thigh at the midpoint between the anterior superior iliac spine and the base of the patella,The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, the saphenous nerve is identified as it lies adjacent proximally lateral then distally superior to the femoral artery. Saphenous nerve is followed distally as it becomes more superficial, traveling with an arterial branch just deep to the sartorius muscle. Using an in-plane approach, after negative aspiration, the tip of the needle is placed deep to the sartorius muscle, at the lateral border of the artery, Once the needle is in position, the catheter is introduced through it, then the needle is removed.
32951385|NCT04083222|Placebo Comparator|Placebo|Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
32951386|NCT04083222|Experimental|ISIS 757456|Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
32951387|NCT04080648|Other|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
32951388|NCT05249946|Experimental|Intervention group|"increasing provision of vegetables and sustainable fish in food offered in early childhood education and care (ECEC) and adjusting intake of meat and milk to reasonable levels to meet recommendations~advancing food education, reducing food waste and assessing the climate and financial impacts of the shift towards a more plant-based diet"
32951389|NCT05249946|No Intervention|Control group|Food supply and food education continue as usual.
32951390|NCT04276506|Experimental|information booklet group|information session before the coronary angiography
32951391|NCT04276506|Experimental|music group|music session before the coronary angiography
32951392|NCT04276506|No Intervention|control group|No information or music session before the coronary angiography
32951393|NCT03148080||Observational|Participants complete a Current Medical Conditions Form, the CogState web-based cognitive assessment, and a Self-Report Questionnaire administration over 45-60 minutes containing measures of work ability and other work-related measures, cognitive, physical, and psychosocial symptoms, and characteristics of workplace environment. Self-report measures of individual and family characteristics, resources, and demands are also included.
32951394|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
32951395|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
32951396|NCT05246124|Experimental|Intervention group|This study used Zumba dance exercise done 3 times a week during 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
32951397|NCT05246124|No Intervention|Control group|No intervention during 2-week self-isolation period
32951398|NCT05244252|Experimental|Group A|Two drugs dexmeditomidine and bupivacaine will be given in TAP block
32951399|NCT05244252|Active Comparator|Group B|One drug bupivacaine will be given in TAP block
32951400|NCT05249790|Experimental|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
32951401|NCT05249790|Active Comparator|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
32951402|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32951403|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
32951404|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
32951405|NCT03304314|Experimental|Control|
32951406|NCT03286842|Experimental|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
32951407|NCT03269994|Active Comparator|Cefoxitin|
32951408|NCT03269994|Experimental|Piperacillin-tazobactam|
32951409|NCT05243784|Experimental|Intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of 8 weeks and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
32951410|NCT05243784|No Intervention|Control|Students in the control group (CG) will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT program once the interventions are completed.
32951411|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
32951412|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
32951413|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
32951414|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
32951415|NCT05247060||Hypertensive Patients Hospitalized in Internal Medicine|Clinical data will be collected from all consecutive patients diagnosed with arterial hypertension hospitalized in Internal Medicine and able to assume the erect station
32951416|NCT05245188|Experimental|Experimental Product 1|Consumption of 200 ml of product 1. Subjects will take this amount only on the day of the visit that they are to consume this product.
32951417|NCT05245188|Experimental|Experimental Product 2|Consumption of 200 ml of product 2. Subjects will take this amount only on the day of the visit that they are to consume this product.
33315100|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
33315101|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
32951418|NCT05245188|Experimental|Experimental Product 3|Consumption of 200 ml of product 3. Subjects will take this amount only on the day of the visit that they are to consume this product.
32951419|NCT05245188|Experimental|Experimental Product 4|Consumption of 200 ml of product 4. Subjects will take this amount only on the day of the visit that they are to consume this product.
32951420|NCT05240274|Active Comparator|Metformin|metformin 500mg OD
32951421|NCT05240274|Placebo Comparator|Placebo|placebo 500mg OD
32951422|NCT05240196|No Intervention|Control|participant will receive standard care only
32951423|NCT05240196|Other|Binaural music|Participants will listen to binaural music whilst having a routine mammogram
32951424|NCT05240196|Other|Non-binaural music|Participants will listen to non-binaural music whilst having a routine mammogram
32951425|NCT05240586|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
32951426|NCT05240586|Active Comparator|acupuncture therapy|The physicians will choose the type and number of acupuncture therapy according to participants' conditions.
32951427|NCT05240586|Active Comparator|physical therapy, medication(prn)|The physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
32951428|NCT05244018|Active Comparator|Group 1(Treatment group)|
32951429|NCT05244018|Active Comparator|Group 2(Control group)|
32951430|NCT03190200||MRI|Subjects with healthy knees
32951431|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
32951432|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
32951433|NCT04396314|Experimental|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
32951434|NCT04396314|Active Comparator|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
32951435|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
32951436|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
32951437|NCT04276818|Active Comparator|PRP group|Second-degree superficial burn group treated with PRP
32951438|NCT04276818|Active Comparator|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
32951439|NCT04396392|Experimental|VR-based training|receiving only VR intervention
33315102|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
33315103|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
33315104|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
33315105|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
33315106|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
33315107|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
33315108|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
33315109|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
33315110|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
33315111|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
33315112|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
33315113|NCT03884192|No Intervention|Observation Arm|Observation
32806936|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
32806937|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
32806938|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
32806939|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
32806940|NCT05266534|Active Comparator|intramyometrial Terlipressin injection in women undergoing open myomectomy|intramyometrial Terlipressin injection
32806941|NCT05266534|Active Comparator|intramyometrial Carbetocin injection in women undergoing open myomectomy|intramyometrial Carbetocin injection
32806942|NCT05266534|Placebo Comparator|intramyometrial saline injection in women undergoing open myomectomy procedure|intramyometrial saline injection in women
32806943|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
32806944|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
32806945|NCT01783496|Active Comparator|Framed Tip|Treatment with Thermage CPT Framed Tip
32806946|NCT01783496|Experimental|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
32806947|NCT01783496|Experimental|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
32806948|NCT01783496|Experimental|Total Tip|Treatment with the Thermage CPT Total tip
32806949|NCT01783496|Experimental|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
32806950|NCT01783496|Experimental|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
32806951|NCT04559750|Experimental|Internet-delivered behavior therapy (I-BT|10 weeks of (I-BT) delivered via the Internet.
32806952|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
32806953|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
32806954|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
32806955|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
32806956|NCT00331162|Active Comparator|1|Alemtuzumab
32806957|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
32806958|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
32806959|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
32806960|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
32806961|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
32806962|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
32806963|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
33315114|NCT03880838|No Intervention|No contact control|Participants are not contacted.
33315115|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
33315116|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
33315117|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
33315118|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
33315119|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
33315120|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
33315121|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
33315122|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
33315123|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
33315124|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
32951440|NCT04396392|Active Comparator|text-based training|receiving only text-based intervention
32951441|NCT04396392|Experimental|VR- and text-based training|receiving both VR intervention and text-based intervention
33315125|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
32951442|NCT04396392|No Intervention|waiting list|waiting list in phase 1 and text-based training after 3 weeks
32951443|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
32951444|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
32951445|NCT04397640|Other|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
32951446|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
32951447|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
32951448|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
32951449|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
32951450|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
32951451|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
32951452|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
32951453|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Study 2 receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
32951454|NCT03037476|Other|Assessment Only|The Assessment Only group receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6-month follow-up, and 12-month follow-up in Study 2.
32951455|NCT04276896|Experimental|pathogen-specific DC and CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
32951456|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
32951457|NCT04276428|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
32951458|NCT04276428|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
33315126|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
33315127|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
33315128|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
32951459|NCT05248932|Active Comparator|infusion|patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline
33315129|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
33315130|NCT01264250|Experimental|1|
33315131|NCT01264250|Placebo Comparator|2|
33315132|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
33315133|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
33315134|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
32951460|NCT05248932|Active Comparator|bolus|patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to <80% of the baseline value.
32951461|NCT05246826|Experimental|Clinical Pilates Exercises|Pilates exercises will be performed 3 days a week, for a total of 18 sessions for 6 weeks.
32951462|NCT05246826|Experimental|Clinical Pilates Exercises and Conventional Treatment|In addition to Pilates exercises, conventional treatment will be performed 3 days a week, for 6 weeks, a total of 18 sessions.
32951463|NCT05240352|Experimental|active tDCS|
32951464|NCT05240352|Sham Comparator|sham tDCS|
32951465|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
32951466|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
32951467|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
32951468|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
32951469|NCT05247528|Placebo Comparator|Placebo Comparator|"Subjects randomized to the placebo arm, will receive a single subcutaneous injection each morning daily.~Intervention: Placebo"
32951470|NCT05247528|Experimental|MANP|"Subjects randomized to the experimental arm, will receive a single subcutaneous injection each morning daily. (multiple ascending dose cohorts)~Intervention: Drug: MANP"
32951471|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
32951472|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
32951473|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
32951474|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
32951475|NCT03007758|Active Comparator|robotic ventral hernia repair (VHR)|Robotic VHR
32951476|NCT03007758|Active Comparator|open ventral hernia repair (VHR)|Open VHR
32951477|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
32951478|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
32951479|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
33099244|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
33315135|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
33315136|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
33315137|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
32951480|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
32951481|NCT04396938|Experimental|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
32951482|NCT04396938|Placebo Comparator|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
32951483|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
32951484|NCT03139266|Other|Control Group|Treatment-as-usual
32951485|NCT00639678|Experimental|1|
32951486|NCT00639678|Experimental|2|
32951487|NCT00639678|Placebo Comparator|3|
32951488|NCT00639678|Placebo Comparator|4|
32951489|NCT02914158|Experimental|Ovarian Suppression and aromatase inhibitors|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
32951490|NCT02914158|Active Comparator|Ovarian Suppression and tamoxifen|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~Tamoxifen: 20mg oral for every day, for 5 years."
32951491|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
32951492|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
32951493|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
32951494|NCT05241210|Experimental|Testing of degree of mucosal inspection|AI provides real-time feedback related to circumferential views during endoscope removal
32951495|NCT05241210|Experimental|Testing of clearing of fecal debris|AI provides real-time feedback related to removal of remaining fecal debris
32951496|NCT05241132|Experimental|BMCUP treated with Tislelizumab and chemotherapy|"Patients with bone metastases from cancer of unknown primary (BMCUP) diagnosed according to the criteria defined in the 2015 European Society of Medical Oncology (ESMO) clinical Practice Guidelines and with bone metastases confirmed by imaging and histology that cannot be completely resected~Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
32951497|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
32951498|NCT05241054|Active Comparator|Bupivacaine|Patients will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
32951499|NCT05241054|Active Comparator|Nitroglycerine|Patients will receive an infusion of Nitroglycerine (TNG) (0.2-1μg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65 mmHg.
32951500|NCT05240820|Placebo Comparator|Vicryl+Prolene|wound closure using polyglactin 910 (Vicryl®, Ethicon, Johnson and Johnson Ltd., NJ, USA) and polypropylene (Prolene®, Ethicon)
32951501|NCT05240820|Active Comparator|PDS+Dermabond|wound closure using polydioxanone (StratafixTM Spiral PDS® Plus) and combination of 2-octyl cyanoacrylate and polyester mesh (Dermabond Prineo®)
32951502|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
32951503|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
32951504|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
32951505|NCT05240430||stem cell application; Group I disease 0-7. days,|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,
32951506|NCT05240430||stem cell application; Group II; 8-14 days of the disease. days|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days
32951507|NCT05240430||stem cell application; Group III; those applied on the 15th day and after.|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after.
32951508|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
32951509|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
32951510|NCT00637806|Placebo Comparator|3|
32951511|NCT05240118||HFmrEF Group|"HFmrEF (Heart failure with mildly reduced ejection fraction): ESC Guideline heart failure 2021: patients with LVEF 41-49%.~non-cardiac events group versus cardiac events (cardiac death or heart failure-related rehospitalization) group"
32951512|NCT04396782|Experimental|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
32951513|NCT04396782|Active Comparator|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
32951514|NCT03180216|Experimental|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
32951515|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
33315138|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.~12 weeks, 5 days/week, 15 minutes/day."
33315139|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
32951516|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
32951517|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
32951518|NCT00637728|Placebo Comparator|2|Placebo suspension
32951519|NCT01922466|Experimental|Bee Venom Acupuncture|
32951520|NCT01922466|Experimental|Loxoprofen|
32951521|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
32951522|NCT05248074|Other|Fasting group|"Period 1 : Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast~Peroid 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)"
32951523|NCT05248074|Other|Fed group|"Peroid 1: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)~Period 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast"
32951524|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
32951525|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
32951526|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
32951527|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
32951528|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
32951529|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
32951530|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
32951531|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
32951532|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
32951533|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
32951534|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
32951535|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
32951536|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
32951537|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
32951538|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
32951539|NCT04506918|Experimental|IVR survey|Participants will receive an IVR survey
32951540|NCT04506918|Experimental|SMS survey|Participants will receive an SMS survey
32951541|NCT04499508|Experimental|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
32951542|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
32951543|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
33099245|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
32806964|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
32806965|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
33099246|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
33099247|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
33099248|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
33099249|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
32806966|NCT00332644|Experimental|1|nicotine patch alone treatment
33099250|NCT04694690|Experimental|RelyX U200 Automix Self Adhesive Resin Cement|Self Adhesive Resin Cement
33099251|NCT04694690|Active Comparator|G-Cem LinkForce Resin Cement|Resin Cement system used after surface treatment
33099252|NCT05318820|Experimental|HMPL-523-TRR|Three cycle dose: TRR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
33099253|NCT05318820|Experimental|HMPL-523-RTR|Three cycle dose:RTR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
33099254|NCT05318820|Experimental|HMPL-523-RRT|Three cycle dose:RRT Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
33099255|NCT05305170||HF|Patients with heart failure.
33099256|NCT05305170||Controls|Controls without heart failure.
33099257|NCT00516581||no HAART|Patients that no received HAART
33099258|NCT00516581||with HAART|Patients that received HAART
33099259|NCT05302947||Baricitinib|group included patients received Baricitinib in addition to standard of care therapy
33099260|NCT05302947||Tocilizumab|group included patients received Tocilizumab in addition to standard of care therapy
33099261|NCT05302947||Netakimab|group included patients received Netakimab in addition to standard of care therapy
32806967|NCT00332644|Experimental|2|nicotine lozenge alone treatment
32806968|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
32806969|NCT00332644|Experimental|4|bupropion alone treatment
32806970|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
32806971|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
32806972|NCT01755416|Placebo Comparator|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
32806973|NCT01755416|Active Comparator|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
32806974|NCT01755026|Active Comparator|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
32806975|NCT01755026|Experimental|4 gram Dose|4 gram dose of pre-operative prophylaxis
32806976|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
32806977|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
32806978|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|Ventana Fenestrated Stent Graft System
32806979|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
33099262|NCT05302947||Control|group included patients received only standard of care therapy at the time of hospital admission according to the corresponding COVID-19 Russian guidelines 2020.
33099263|NCT04694573||POST-TX Covid-19 Serum Study Case|Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2
33099264|NCT04694573||POST-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection after TX; matching according to~age (18-34, 35-59, 60-75 years)~sex~type of transplantation~time after transplantation (0-180, 181-365, 366-1095, 1096-2555, >2555 days after TX)"
33099265|NCT04694573||PRE-TX Covid-19 Serum Study Case|Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2
33099266|NCT04694573||PRE-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection prior to TX; matching according to~age(18-34, 35-59, 60-75 years)~sex~type of transplantation"
33099267|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
33099268|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
33099269|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
33099270|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
33099271|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
33099272|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
33315140|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
32951544|NCT00636636|Placebo Comparator|Placebo|Sugar pill
33315141|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
33315142|NCT01154582|Experimental|Egg|
33315143|NCT01154582|Experimental|Cottage cheese|
33315144|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
32951545|NCT05244954|Experimental|Intermittent Screening and Treatment (IST)|Students will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
32951546|NCT05244954|Experimental|Intermittent Preventive Treatment (IPT)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
32951547|NCT05244954|No Intervention|Control|Students will not receive preventive treatment.
33315145|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
33315146|NCT01264328|Experimental|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
32951548|NCT00635778|Experimental|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951549|NCT00635778|Experimental|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951550|NCT00635778|Experimental|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951551|NCT00635778|Experimental|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951552|NCT00635778|Experimental|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951553|NCT00635778|Experimental|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951554|NCT00635778|Experimental|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
32951555|NCT04396470|Experimental|tVNS treatment|
32951556|NCT04396470|Sham Comparator|tVNS sham treatment|
32951557|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
32951558|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
32951559|NCT04275960|Experimental|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
32951560|NCT04275960|Experimental|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
32951561|NCT04275960|Experimental|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
32951562|NCT04276038|Active Comparator|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
32951563|NCT04276038|Sham Comparator|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
32806980|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
32806981|NCT00333814|Sham Comparator|3|Sham
32806982|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
33099273|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
33315147|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
33099274|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
33099275|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
33315148|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
33315149|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
33315150|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
33315151|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
33315152|NCT01157936|Active Comparator|Allopurinol treatment|
33315153|NCT01157936|Placebo Comparator|Placebo|
33315154|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
33315155|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
33315156|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
33315157|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
33315158|NCT01260818|Experimental|Tranexamic Acid|
33315159|NCT01260818|Placebo Comparator|control group|
32806983|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
32806984|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
32806985|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
32806986|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
32806987|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
33315160|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
33315161|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
32806988|NCT05266144||atrial fibrillation|Atrial fibrillation patients who underwent radiofrequency ablation in Peking Union Medical College Hospital.
32806989|NCT05265988|Experimental|Meridian|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
32806990|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
32806991|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
32806992|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
32806993|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
32806994|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
32806995|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
32806996|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
32806997|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
32806998|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
32806999|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
32807000|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
32807001|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
32807002|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
32807003|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
33099276|NCT05299983|Experimental|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
33099277|NCT05299983|Active Comparator|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
33099278|NCT04694963||Subaute Cough|N=500
33099279|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
33099280|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
33099281|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
33099282|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
33099283|NCT05286879|Other|Patient Navigator|Navigators will assist linking study participants to appropriate community service providers
33099284|NCT05286879|Other|Mobile Health Unit|Study participants will be linked to a MHU within their community
33099285|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
33099286|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
33099287|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
33099288|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
33099289|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
33099290|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
33099291|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
33099292|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
33099293|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
33315162|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
33315163|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
33315164|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
33315165|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
33315166|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
33099294|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
33099295|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
33099296|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
33099297|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
33099298|NCT04694612|Placebo Comparator|Mild condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive the same quantity of Placebo.~Duration of treatment : 5 days in each group"
33099299|NCT04694612|Active Comparator|Moderate condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive Inj Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily.~Duration of treatment : 10 days in Favipiravir group & 5 days in Remdesivir group"
33315167|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
33315168|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
33315169|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
33315170|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
32807004|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
32807005|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
32807006|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
32807007|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
32807008|NCT01754402|Experimental|Cohort 1: benda 120mg + pom 3mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
32807009|NCT01754402|Experimental|Cohort 2: benda 120mg + pom 4mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
32807010|NCT01754402|Experimental|Expansion|"Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
32807011|NCT01783418|Experimental|Mindfulness intervention|
32807012|NCT01783418|Active Comparator|Wait-list control|
32807013|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
32807014|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
32807015|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
32807016|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
32807017|NCT01782872|Active Comparator|Interscalene Block (ISB) - Systemic Control|
33315171|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
32807018|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
32807019|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
33315172|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
33315173|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
32807020|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
32807021|NCT01728194|Other|Control|Non-psychiatric comparison participants.
32807022|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
32807023|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
33315174|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
33315175|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
33315176|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
33315177|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
33315178|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
33315179|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
33315180|NCT01260974|Experimental|Caspofungin|Study group
33315181|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
33315182|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
33315183|NCT03883958|Active Comparator|TPVB|
33315184|NCT03883958|Experimental|ESPB|
33315185|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
32807024|NCT01782482|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
33315186|NCT01262690|Experimental|Dose|6 treated, 3 placebos
33315187|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
33315188|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
33315189|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
33315190|NCT01155986|Active Comparator|Lidocaine Plaster|
33315191|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
33315192|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
33315193|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
33315194|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
33315195|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
33315196|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
33315197|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
33315198|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
32951564|NCT04275804|Active Comparator|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
32951565|NCT04275804|Experimental|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
33315199|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
33315200|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
33315201|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
33315202|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
32951566|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
32951567|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
32951568|NCT01923012|Experimental|Vitamin K2|
32951569|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
32951570|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
32951571|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
32951572|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
32951573|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
32951574|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
32951575|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
32951576|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
32951577|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
32951578|NCT04396548|Active Comparator|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
32951579|NCT04396548|Placebo Comparator|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
32951580|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
32951581|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
32951582|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
33315203|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
33315204|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
33315205|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
33315206|NCT03887156|Other|Arm 1|One arm
33315207|NCT01154660|Experimental|Neutral|
33315208|NCT01154660|Active Comparator|Trendelenberg|
33315209|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
32807025|NCT01782482|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
33315210|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
33315211|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
32807026|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
32807027|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
32807028|NCT01753856|Experimental|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
32807029|NCT01753856|Active Comparator|Denosumab|"60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
32807030|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
32807031|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
32807032|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
32807033|NCT04559204|Experimental|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
32807034|NCT04559204|Active Comparator|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
32807035|NCT04559204|Active Comparator|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
32807036|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
32807037|NCT01753310|Active Comparator|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
32807038|NCT01753310|Placebo Comparator|Placebo|Placebo, up to 2mL
32807039|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
32807040|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
32807041|NCT04100577|Experimental|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
32807042|NCT04100577|No Intervention|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
32807043|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
32807044|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
32807045|NCT01521117|Experimental|Donepezil, Then Placebo|Donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6. After a washout period of 4 weeks, placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.
32807046|NCT01521117|Experimental|Placebo, Then Donepezil|"Placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.~After a washout period of 4 weeks, donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6."
32807047|NCT04100109|Active Comparator|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
32807048|NCT04100109|Active Comparator|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
32807049|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
32807050|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
32951583|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
33315212|NCT01586546|Experimental|Online MBM Skills Group|
33315213|NCT01586546|Other|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
33404826|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
32807051|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
32807052|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
32807053|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
32807054|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
32807055|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
32807056|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
32807057|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
32807058|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
32807059|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
32807060|NCT01753076|Experimental|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
32807061|NCT01753076|Placebo Comparator|Placebo|Normal saline by IV route. Treatment period - 48 weeks
32807062|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
32807063|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
32807064|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
32807065|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
32807066|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
32807067|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
32807068|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
32951584|NCT01923246|No Intervention|Control group|Untreated Control Group.
32951585|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
32951586|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
32951587|NCT01923402||Exclusive cigarette smokers|
32951588|NCT01923402||Exclusive moist snuff consumers|
32951589|NCT01923402||Non-tobacco consumers|
32951590|NCT04395456|Experimental|AMY-101|
32951591|NCT04395456|Placebo Comparator|Placebo|
32951592|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
32951593|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
32951594|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
32951595|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
32951596|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
32951597|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
32951598|NCT04395690|Active Comparator|Inferior Alveolar Block Nerve (IABN)|Inferior Alveolar Block Nerve (IABN) anesthesia technique before posterior mandibular implant placement.
32951599|NCT04395690|Experimental|Infiltration (INF)|Infiltration (INF) anesthesia technique before posterior mandibular implant placement.
32951600|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
32951601|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
32951602|NCT04395612|Experimental|Treatment arm1|niraparib 200mg/day and brivanib 400mg/day
32951603|NCT04395612|Experimental|Treatment arm2|niraparib 200mg/day and toripalimab 240mg/21 days
32951604|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
32951605|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
32951606|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
32951607|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
32951608|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
32951609|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
32951610|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
32951611|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
32951612|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
32951613|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
32951614|NCT01922076|Experimental|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
32951615|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
32951616|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
32951617|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
32951618|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
32951619|NCT00633750|Experimental|Tarceva|
32951620|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
32951621|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
32951622|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
32951623|NCT00633360|Placebo Comparator|Placebo|
32951624|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
32951625|NCT00988260|Experimental|Ganirelix 0.125 mg|
32951626|NCT00988260|Experimental|Ganirelix 0.25 mg|
32951627|NCT00988260|Experimental|Ganirelix 0.5 mg|
32951628|NCT00633126|Experimental|A|ceftaroline
32951629|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
32951630|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
32951631|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
32951632|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
32951633|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
32951634|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
32951635|NCT03492060||Variant in a hnRNP gene|Individuals with a variant in any hnRNP gene who present with neurodevelopmental abnormalities are eligible for the study.
32951636|NCT03492060||Variant in other gene|Individuals with a confirmed variant in other genes who present with neurodevelopmental abnormalities are eligible for the study.
32951637|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
32951638|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
32951639|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
32951640|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
32951641|NCT01924026||Unaffected Siblings|With normal Phe levels
33099300|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
33099301|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
33099302|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
33099303|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
33099304|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
33099305|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
33099306|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
33099307|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
33099308|NCT02949713|Experimental|Text messaging-motivational interviewing|Participants will register their phone numbers into an automated SMS software (provided by WelTel.org). Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, 10, 14, and 24. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
33099309|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
33099310|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
33099311|NCT04694729|Experimental|study group|Videoconference-based
33099312|NCT04694729|Experimental|control group|Video-based
33099313|NCT05318742|Active Comparator|Fewer Laser Spots|Group A patients underwent endolaser PRP with a range of 200-300 shots during PPV
33099314|NCT05318742|Active Comparator|Higher Laser Spots|Group B patients underwent endolaser PRP with a range of 500-600 shots during PPV
32807069|NCT04079751|Active Comparator|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
32807070|NCT04079751|Active Comparator|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
32807071|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
32807072|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
32807073|NCT01465191|Experimental|50 micrograms (mcg) spinal morphine|Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
32807074|NCT01465191|Experimental|100 micrograms spinal morphine|Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
32807075|NCT01465191|Experimental|150 micrograms spinal morphine|Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
32807076|NCT01519947|Active Comparator|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
32807077|NCT01519947|Active Comparator|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
32807078|NCT01519947|Experimental|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
32807079|NCT01519947|Experimental|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
32807080|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
32807081|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
32807082|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
32807083|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
32807084|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
33099315|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
33099316|NCT05267574|Experimental|REN001|100 mg once daily
33099317|NCT00518258||1|Patient Group
33099318|NCT00518258||2|Control Group
33099319|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
33404827|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
32951642|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
32951643|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
32951644|NCT03100656|Other|Controls|Healthy control women
32951645|NCT00989196|Experimental|Human-cl rhFVIII|
33404828|NCT03033693|Other|The deep anesthesia group|
33404829|NCT03033693|Other|The light anesthesia group|
32951646|NCT00989196|Active Comparator|Kogenate FS|
32951647|NCT04288362|Experimental|Intervention Group|
32951648|NCT04288362|Active Comparator|Control Group|
32951649|NCT03100110|Experimental|NeuroCognitive Communicator|
32951650|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
32951651|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
32951652|NCT00632424|Experimental|1|
32951653|NCT00631488|Experimental|MK-0893 + Sitagliptin|
32951654|NCT00631488|Experimental|MK-0893 + Metformin|
32951655|NCT00631488|Active Comparator|Sitagliptin + Metformin|
32951656|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
32951657|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
32951658|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
32951659|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
32951660|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
32951661|NCT03098862||1|Direct EBOV exposure risk controls
32951662|NCT03098862||2|EVD fatal cases
32951663|NCT03098862||3|EVD survivor cases
32951664|NCT03098862||4|No known EBOV exposure population controls
32951665|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
32951666|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
32951667|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
32951668|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
32951669|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
32951670|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
32951671|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
32951672|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
32951673|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
32951674|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
32951675|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
32951676|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
32951677|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
32951678|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
32951679|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
32951680|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
32951681|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
32951682|NCT04594824||Term neonates|
32951683|NCT04594824||Preterm neonates|
32951684|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
32951685|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
32951686|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
32951687|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
32951688|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
32951689|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
32951690|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
32951691|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
32951692|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
32951693|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
32951694|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
32807085|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
32807086|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
32807087|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
32807088|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
32807089|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
32807090|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
32807091|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
32807092|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
32807093|NCT04078191|Experimental|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
32807094|NCT01782326|Experimental|QVA149|QVA149 (110/50 μg) once daily
32807095|NCT01782326|Active Comparator|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
32807096|NCT01439373|Experimental|GSK2336805|Study Part 1
32807097|NCT01439373|Placebo Comparator|Placebo|Study Part 1
32807098|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
32807099|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
32807100|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
32807101|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
32807102|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
32807103|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
32807104|NCT01461369|Placebo Comparator|Placebo Capsule|
32807105|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|
32807106|NCT04414124|Other|Self Supportive Care (SSC) Alone|
32807107|NCT04575662|Experimental|STAR Treatment|Patients performing STAR treatment
32807108|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
32807109|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
32807110|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
33315214|NCT01586546|Other|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
32807111|NCT04583306||Healthy Subjects|40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
32807112|NCT04583306||COVID-19 Positive|40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
32807113|NCT04583306||COVID-19 Negative|40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
32807114|NCT01781390|Placebo Comparator|Placebo|Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.
32807115|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 12.5 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.
32807116|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 25 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0.
32807117|NCT01781234|Experimental|Intranasal Insulin|Intranasal Insulin
32807118|NCT01781234|Placebo Comparator|Placebo|Placebo
32807119|NCT01752842|Experimental|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
32807120|NCT01752842|Placebo Comparator|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
32951695|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
32951696|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
33315215|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary radial artery access during TAVI"
32951697|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
32951698|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
32951699|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
32951700|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
32951701|NCT00635934|Experimental|A-MAV™disc|
32951702|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
32951703|NCT00630552|Experimental|AMG 655 + Gemcitabine|
32951704|NCT00630552|Experimental|AMG 479 + Gemcitabine|
32951705|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
33315216|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
33315217|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
33315218|NCT01264796|No Intervention|delyed intervention|control group
33315219|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
33315220|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
32951706|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
32951707|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
32951708|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
32951709|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
32951710|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
32951711|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
32951712|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
32951713|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
32951714|NCT01920126|Placebo Comparator|Saline group|Saline group
32951715|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
32951716|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
32951717|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
32951718|NCT04347720||Acetaminophen Arm|Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
32951719|NCT04347720||Control group|Infants <29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
32951720|NCT04347720||Reference group|Infants <29 weeks GA who were never diagnosed with PDA
32951721|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
32951722|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
32951723|NCT01925118|Experimental|High-dose IL-2|
32951724|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
33315221|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
33315222|NCT01264874|Placebo Comparator|placebo|matched placebo
33315223|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
33315224|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
33315225|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
33315226|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
33315227|NCT01586468|Placebo Comparator|NaCl Solution|
33315228|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
33315229|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
32807121|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
32807122|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
32807123|NCT01460901|Experimental|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
32807124|NCT04584801||Part A|"Development Phase Any adult (≥18 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator <0.70)~Cohort A (N=50): COPD stage 1~Cohort B (N=50): COPD stage 2~Cohort C (N=50): COPD stage 3~Cohort D (N=50): COPD stage 4~Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)"
32807125|NCT04584801||Part B|"Validation Phase~Cohort A (N=50): COPD stage 1~Cohort B (N=50): COPD stage 2~Cohort C (N=50): COPD stage 3~Cohort D (N=50): COPD stage 4~Cohort E (N=50): Suspected COPD"
32807126|NCT04567407|Experimental|Bilateral erector spinae blocks|All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).
32807127|NCT01519635|Active Comparator|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
32807128|NCT01519635|Active Comparator|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
32807129|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
32807130|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
32807131|NCT01519245|Placebo Comparator|Placebo|Normal saline
32807132|NCT01519167|Experimental|Dexmedetomidine|
32807133|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
32807134|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
32807135|NCT00318136|Experimental|Treated with Bevacizumab|
32807136|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
32807137|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
32807138|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
32807139|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
32807140|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
32807141|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
32807142|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
32807143|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
32807144|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
33404830|NCT05079490|No Intervention|Baseline|All children will receive outcome measures.
33404831|NCT05079490|Experimental|Intervention phase|Children in the experimental group will receive intervention for 12 weeks while children in the control group remain their regular activities.
33404832|NCT05079490|No Intervention|Follow up phase|All children will be followed after the end of intervention phase and receive outcome measures at 3- and 6-month after the completion of intervention.
33315230|NCT01262924|Experimental|Group A|dTPa vaccine
33404833|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
33404834|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
33404835|NCT05079100|Active Comparator|group of intervention (counseling)|the group will receive the contraception counseling
33404836|NCT05079100|No Intervention|group of control (no counseling)|this group will not receive any counseling
33404837|NCT05053347|Experimental|Flaxseed oil|Flaxseed oil capsule, 5g/d(ALA2.5g/d)
33404838|NCT05053347|Placebo Comparator|Corn oil|Corn oil capsule, 5g/d
33404839|NCT05079022|Experimental|Furmonertinib|ctDNA-MRD positive participants received 3 years of furmonertinib once daily as adjuvant therapy after radical surgery until disease progression or unacceptable toxicity occurs.
32951725|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
32951726|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
32951727|NCT03095352|Experimental|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
32951728|NCT03095352|Experimental|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32951729|NCT01925430||Comparative product|A device which monitors sleep/wake states
32951730|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
32951731|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32951732|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32951733|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
32951734|NCT00984204|Experimental|Treatment arm|
32951735|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
32951736|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
32951737|NCT04508010|Experimental|IVR survey|Participants will receive an IVR survey
32951738|NCT04508010|Experimental|CATI survey|Participants will receive a CATI survey
32951739|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
32951740|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
32951741|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
32951742|NCT04275258|Experimental|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:~A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.~PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
32951743|NCT04275258|No Intervention|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
32951744|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
32951745|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
32951746|NCT03474744|Experimental|Experimental Arm|"Induction Phase:~Cycle 1-6 (28 days cycle):~Copanlisib: 60 mg i.v. fixed dose days 1, 8, 15. Rituximab: 375 mg/m2 day 1 i.v.~Maintenance:~Start 2 months after start of the last induction cycle for patients at least achieving a stable response after induction.~Copanlisib: 60 mg i.v. fixed dose day 1 and day 15 every 4 weeks for a maximum of 12 cycles or until progression or study drug-related intolerable toxicity (month 2 to month 13 after end of induction).~Rituximab: 375 mg/m2 i.v. day 1 every 8 weeks for a maximum of 12 infusions or until progression or study drug-related intolerable toxicity (month 2 to month 24 after end of induction)"
32951747|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
32951748|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
32951749|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
32951750|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
33315231|NCT01262924|Experimental|Group B|Pa vaccine
33315232|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
32951751|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
32951752|NCT01925898|Experimental|Ketamine|Oral ketamine
32951753|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
32951754|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
32951755|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
32951756|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
32951757|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
32951758|NCT00982878|Experimental|Maraviroc|
32951759|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
32951760|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
32951761|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
32951762|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
32951763|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
32951764|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
32951765|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
32951766|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
32951767|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
32951768|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
32951769|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
32951770|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
32951771|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
32951772|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
32951773|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
32951774|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
32951775|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
32951776|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
32951777|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
33099320|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
33315233|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
33315234|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
33404840|NCT05078788|Experimental|Laser uretherotomy|Using Holmium laser uretherotomy only in the treatment of bulbar uretheral stricture
32951778|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
32951779|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
32951780|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
32951781|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
32951782|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
32951783|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
32951784|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
32951785|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
32951786|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
32951787|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
32951788|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
32951789|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
32951790|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
32951791|NCT03117816|Experimental|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
32951792|NCT03117816|Other|surveillance arm B|"This is an open-label study with a surveillance group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment."
32951793|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
32951794|NCT03115086||New User|First-time initiators of Cholbam
32951795|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
32951796|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
32951797|NCT04275492|Experimental|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
32951798|NCT04275492|Experimental|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
32951799|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
32951800|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
32951801|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
32951802|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
32951803|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
32951804|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
32951805|NCT01926600||PO|administrated by per oral
32951806|NCT01926600||IV|Administrated by intravenous
32951807|NCT01926600||SL|administrated by sublingual
32951808|NCT01921530|Active Comparator|Interbody Fusion|
32951809|NCT01921530|Active Comparator|Posterolateral Fusion|
32951810|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
32951811|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
32951812|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
32951813|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
32951814|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
32951815|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
32951816|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
32951817|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
32951818|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
32951819|NCT01926912||Participants with schizophrenia|
32951820|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
32951821|NCT03385512|Experimental|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
32951822|NCT03385512|Experimental|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
32951823|NCT03385512|Experimental|ASK Poster|Participants in this arm will experience the ASK intervention.
32951824|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
32951825|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
32951826|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
32951827|NCT00983814|Placebo Comparator|Placebo|Placebo
32951828|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
32951829|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
32951830|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
32951831|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
32951832|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
32951833|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
32951834|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
32951835|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
32951836|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
32951837|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
32951838|NCT04275414|Experimental|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
32951839|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
32951840|NCT04395144|Experimental|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
32951841|NCT04395144|Active Comparator|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
32951842|NCT04395768|Experimental|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;~Plus Active Comparator treatment:~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
32951843|NCT04395768|Active Comparator|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
32951844|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
32951845|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
32951846|NCT04396158|Experimental|intervention|
32951847|NCT01927146||Resectable gastric cancer|No intervention
32951848|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
32951849|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
32807148|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
32807149|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
32807150|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
32807151|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
32807152|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
32807153|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
32807154|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
32807155|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
32807156|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
32807157|NCT03793114|Active Comparator|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
32807158|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
32807159|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
32807160|NCT00348946|Active Comparator|Oxandrolone|Androgen oxandrolone: Oxandrolone, 0.6 > mg/kg/day, orally, for 2 years.
32807161|NCT00348946|Placebo Comparator|Placebo|An inactive substance.
32807162|NCT00349336|Experimental|1|
32807163|NCT00349336|Experimental|2|
32807164|NCT04888468|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
32807165|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32807166|NCT04751188|Experimental|Bezafibrate and Ursodeoxycholic acid|Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
32807167|NCT04751188|Placebo Comparator|Placebo and Ursodeoxycholic acid|Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
32807168|NCT00352612|Placebo Comparator|cephalexin|
32807169|NCT00352612|Active Comparator|clindamycin|
32807170|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
32807171|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
32807172|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
32807173|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
32807174|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
32807175|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
32807176|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
32807177|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
32807178|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
32807179|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
32807180|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
32807181|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
32807182|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
32807183|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
32807184|NCT04559932|Experimental|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
32951850|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
32951851|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
33099321|NCT00518297|Active Comparator|1|
33099322|NCT00518297|Active Comparator|2|
33099323|NCT00518297|Active Comparator|3|
32807185|NCT04559932|No Intervention|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
32807186|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
32807187|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
32807188|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
32807189|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
32807190|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
32807191|NCT01519089|Experimental|CP-690,550 10 mg BID|
32807192|NCT01519089|Experimental|CP690,550 5 mg BID|
32807193|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
32807194|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
32807195|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
32807196|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
32807197|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
33315235|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
33315236|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
33315237|NCT01158638|No Intervention|Usual Care|Usual Care
33315238|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
33315239|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
33315240|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
33315241|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
32807198|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
32807199|NCT01518699|Experimental|HA44 Abametapir Lotion|Study drug plus positive-control placebo.
32807200|NCT01518699|Placebo Comparator|Placebo|Placebo plus positive-control placebo.
32807201|NCT01518699|Active Comparator|Moxifloxacin|Placebo plus positive control
32807202|NCT04556266|Experimental|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^4 cells/kg"
32807203|NCT04556266|Experimental|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^5 cells/kg"
32807204|NCT04556266|Experimental|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 2 x 10^5 cells/kg"
32807205|NCT04556266|Experimental|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 4 x 10^5 cells/kg"
32807206|NCT01792648|Active Comparator|Standard Reference Diet|
32807207|NCT01792648|Experimental|Almond Supplemented Diet|
32807208|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
32807209|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
32951852|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
33315242|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
32951853|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
32951854|NCT04556370|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
32951855|NCT04556370|Experimental|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
32951856|NCT04556370|Experimental|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
32951857|NCT04556370|Experimental|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
32951858|NCT04396080|Experimental|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
32951859|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
32951860|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
32951861|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
32951862|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
32951863|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
32951864|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
32951865|NCT04554576|Experimental|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
32951866|NCT04554576|Active Comparator|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
32951867|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
32951868|NCT03060642||Controls|Non-BE endoscopic controls
32951869|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
32951870|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
32951871|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
32951872|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
32951873|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
32951874|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
32951875|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
32951876|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
32951877|NCT04552782|Experimental|Alcohol Cognitive Bias Modification (CBM) + PTSD CBM|
32951878|NCT04552782|Experimental|Alcohol CBM + PTSD Sham|
32951879|NCT04552782|Experimental|Alcohol Sham + PTSD CBM|
32951880|NCT04552782|Sham Comparator|Alcohol Sham + PTSD Sham|
32951881|NCT04552470|Placebo Comparator|Placebo|
32951882|NCT04552470|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
32951883|NCT04552470|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
32951884|NCT04552470|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
32951885|NCT04550130|Experimental|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
32951886|NCT04550130|Experimental|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
33315243|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
33315244|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
33315245|NCT03879668||eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
33315246|NCT03879668||Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
33315247|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
33315248|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
33315249|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
33315250|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
33315251|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
33315252|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
33315253|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
33315254|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
33315255|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
33315256|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
33315257|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
33315258|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
33315259|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
33315260|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
33315261|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
33315262|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
33315263|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
33315264|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
33315265|NCT01261364|Active Comparator|Treatment as Usual|
33315266|NCT01261364|Experimental|Pharmacogenetic guided treatment|
33315267|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
33315268|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
33315269|NCT01261442||Diabetic patients with DSPN|
33315270|NCT01261442||Diabetic patients without DSPN|
33315271|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
33315272|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
33315273|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
33315274|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
33315275|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
33315276|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
33315277|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
33315278|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
33315279|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
33315280|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
33315281|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
33315282|NCT01265342|Placebo Comparator|Placebo|
33315283|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
33315284|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
33315285|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
32951887|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
32951888|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
32951889|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
32951890|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
32951891|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
32951892|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
32951893|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32951894|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32951895|NCT04274946|Active Comparator|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
32951896|NCT04274946|Experimental|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
32951897|NCT04274946|Experimental|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
32951898|NCT04274946|Experimental|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
32951899|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
32951900|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
32951901|NCT04323774|No Intervention|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.~The research study procedures include:~Using and reviewing AYA-RISE~Participating in audio-recorded, 30-minute interviews"
32951902|NCT04323774|Experimental|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).~The activities involved in this part of the study are:~Baseline Questionnaire~Using and reviewing AYA-RISE~Follow-up Questionnaire~Brief interviews to get feedback on AYA-RISE"
32951903|NCT04323774|Active Comparator|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
32951904|NCT04323774|Experimental|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~Using the study intervention, AYA-RISE~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
32951905|NCT04323774|No Intervention|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
32951906|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
32951907|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
32951908|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
32951909|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
32951910|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
32951911|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
32951912|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
32951913|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
32951914|NCT04550520|Experimental|study part 1: healthy adult volunteers|22 Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
32951915|NCT04550520|Experimental|study part 2: adult patients with primary polydipsia or central diabetes insipidus|If results of study part 1 suggest that glucagon stimulates copeptin (proof of concept),10 patients with primary polydipsia and 10 patients with central diabetes insipidus will be additionally included (study part 2): The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
32951916|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
32951917|NCT04759482||Patients with sleep apnea|We selected 150 patients recorded by polysomnography between january 2019 and june 2020 in the Center for Sleep Medecine and Research in Nancy.
32951918|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
32951919|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
32951920|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
32951921|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
32951922|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
32951923|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
32951924|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
32951925|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
32951926|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
32951927|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
32951928|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
32951929|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
32951930|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
32951931|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
32951932|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
32951933|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
32951934|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
32951935|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
32951936|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
32951937|NCT05602662|Experimental|Music therapy during mechanical ventilation in the iCU.|Headphones with music.
32951938|NCT05602662|Sham Comparator|Comparator|Headphones only.
32951939|NCT05600868|Active Comparator|EMDR+dual attention|.Processing the trauma with exposition and dual attention.
32951940|NCT05600868|Active Comparator|EMDR + fixed point|Processing the trauma with exposition and fixed point.
32951941|NCT05600868|Active Comparator|EMDR + exposition|Processing the trauma with exposition.
32951942|NCT05600790|Experimental|the MIED+TAU group|Intervention description: provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
32951943|NCT05600790|No Intervention|the TAU-only group|TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therap
32951944|NCT04558554|Experimental|Pharmacy-based PrEP delivery|Participants in this experimental arm (which includes all participants) will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at community pharmacies in Kenya. During Phase Two of the study, participants will also have the option to initiate post-exposure prophylaxis (PEP) at the 12 study pharmacies, and in a subset of four study pharmacies, participants will have the option to undergo STI testing.
32951945|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
32951946|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
33315286|NCT01159496|Experimental|Active|
33315287|NCT01159496|Placebo Comparator|Placebo|
32807210|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
32807211|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
32807212|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
32807213|NCT01419717|Experimental|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
32807214|NCT04748133|Active Comparator|acupuncture|"Patients in the acupuncture group will receive a standardised treatment with 12 needles (sharp tip, stainless steel needles, size 0.3 X 40 mm) at 7 acupuncture points Du 26 and Ren 17 (on the middle body line), and bilateral LI 4, HE 7, LV 3, ST 36 and PC 6). Application of the needles is performed by a licensed medical acupuncturist.~The needles will be inserted after endotracheal intubation and mechanical ventilation and will be removed immediately before patient extubation."
32807215|NCT04748133|Placebo Comparator|placebo|no treatment
32807216|NCT01458951|Experimental|tofacitinib 10 mg BID|
32807217|NCT01458951|Placebo Comparator|Placebo BID|
32807218|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
32807219|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
32807220|NCT01437423|Experimental|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
32807221|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
32807222|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
32807223|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
32807224|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
32807225|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
32807226|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
32807227|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
32807228|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
32807229|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
32807230|NCT01458171|Experimental|IgPro20|
32807231|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
32807232|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
32807233|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:~BMI ≥30 kg/m2~History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
32807234|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2~History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
32807235|NCT04445428|Experimental|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
32807236|NCT04445428|Other|Control|Information regarding prevention of COVID-19
32807237|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
32807238|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
32807239|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
32807240|NCT00357214|Active Comparator|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
32807241|NCT00357214|Active Comparator|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
32807242|NCT00357214|Active Comparator|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
32951947|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
32951948|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
32951949|NCT04554888|Experimental|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
32951950|NCT04554888|Experimental|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
32951951|NCT04553016|Experimental|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.~At week 4,1.0 x 10^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
32951952|NCT04553016|Placebo Comparator|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
32951953|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
32951954|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
33315288|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
33315289|NCT01265576|Experimental|Sorafenib plus VT-122|
33315290|NCT01261676||Caesarean section|
33315291|NCT01261676||Vaginal birth (control)|
33315292|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
33315293|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
33315294|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
33315295|NCT01261754|Active Comparator|Healthy Volunteers|
33315296|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
33315297|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
33315298|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
33315299|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
33315300|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
33315301|NCT03883022|Experimental|Vancomycin (V Group)|
33315302|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
33315303|NCT01159652|Placebo Comparator|Bedtime Placebo|
33315304|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
33315305|NCT01159652|Experimental|Zolpidem|
33315306|NCT01159652|Experimental|Zaleplon|
33315307|NCT01159730|Experimental|Multiple doses of VB-201|
33315308|NCT01159730|Placebo Comparator|Placebo|
33315309|NCT01159808|Experimental|INX-08189|
33315310|NCT01159808|Placebo Comparator|Placebo|
33315311|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
33315312|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
33315313|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
33315314|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
33315315|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
33315316|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
33315317|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
33315318|NCT03883178|Experimental|Neurolysis|
33315319|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
33315320|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
33315321|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
32951955|NCT04553406|Experimental|SPR720 low dose|SPR720 500 mg administered orally once daily for 28 days.
32951956|NCT04553406|Experimental|SPR720 high dose|SPR720 1000 mg administered orally once daily for 28 days.
32951957|NCT04553406|Placebo Comparator|Placebo|Placebo administered orally once daily for 28 days
33404841|NCT05078788|Experimental|Laser uretherotomy with intralesional steroids|Using holmium laser uretherotomy with injection of 80 mg of triamcinolone (diluted with normal saline to 10 ml) in the treatment of bulbar uretheral stricture
32807243|NCT00357214|Placebo Comparator|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
32807244|NCT01418937|Experimental|HPV Group|
32807245|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
32807246|NCT02076321|Other|Acetaminophen|control group
32807247|NCT02076321|Other|NSAID (Ibuprofen)|Study group
32807248|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
32807249|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
32807250|NCT01417377||Cohort|Mircera
32807251|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
32807252|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
32807253|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
32807254|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
32807255|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
32807256|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
32807257|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
32807258|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
32807259|NCT00397150|No Intervention|No intervention|No intervention
32807260|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
32807261|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
32807262|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
32807263|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
32807264|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
32807265|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
32807266|NCT00397462|No Intervention|Control|No change to usual behavior
32807267|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
32807268|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
32807269|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
32807270|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
32807271|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
32807272|NCT01437111|Experimental|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
32807273|NCT04767477|Other|Face-to-face rehabilitation and Telerehabilitation|The Face-to-face rehabilitation and Telerehabilitation protocol will consist of flexibility exercises, aerobic and resistance training, with two sessions per week.
32807274|NCT04065555|Experimental|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
32807275|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
32807276|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
32807277|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
32807278|NCT04388800|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
33099324|NCT05240742||Dutch COVID-19 patients|"The study population consists of Dutch (former) COVID-19 patients who have been included in one of the cohorts and categorized in various subgroups:~Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward.~Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU.~Patients who suffered from (confirmed or suspected) COVID-19 at home.~Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU)."
33099325|NCT05240742||Dutch controls who did not experience COVID-19|One of the cohorts, the POPCOrn cohort, is a community-based cohort which partly consists of controls who did not experience COVID-19
32807279|NCT04388800|Experimental|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
32807280|NCT04388800|No Intervention|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
32807281|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
32807282|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
33099326|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
33099327|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
33099328|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
32807283|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
32807284|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
32807285|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
32807286|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
32807287|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
32807288|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
32807289|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
32807290|NCT00399880|No Intervention|Usual care|
32807291|NCT04316494|Experimental|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
32807292|NCT04316494|Placebo Comparator|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
32807293|NCT04309942|Experimental|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
32807294|NCT04309942|No Intervention|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
32807295|NCT04239196|Experimental|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
32807296|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
33099329|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
33099330|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
33315322|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
32807297|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
32807298|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
32807299|NCT00362440|Experimental|Leptin|Leptin replacement therapy
32807300|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
32807301|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
32807302|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
32807303|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
32807304|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
32807305|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
32807306|NCT00401986||Alair Treatment|Alair Treated subjects from PREDECESSOR STUDY (NCT00214539).
32807307|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
32807308|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
32807309|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
32807310|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
32807311|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
32807312|NCT01794286|Active Comparator|Control Group|Trigger alerts only
32807313|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
33315323|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
33315324|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
33315325|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
33315326|NCT01154894|Experimental|Placebo-controlled trial|
33315327|NCT03886376|Experimental|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
33315328|NCT03886376|Active Comparator|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
32807314|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
32807315|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
33315329|NCT03886376|No Intervention|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
33315330|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
32807318|NCT00368290|Experimental|1|modafinil plus CBT
32807319|NCT00368290|Placebo Comparator|2|placebo plus CBT
33315331|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
33315332|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
33315333|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
33315334|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
32807320|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
32807321|NCT01416441|Experimental|Aripiprazole|Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
32807322|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
32807323|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
32807324|NCT04050579|Other|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
32807325|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
32951958|NCT04553406|Active Comparator|Standard of Care (SOC)|Standard of Care regimen per the Investigator's discretion.
33315335|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
33315336|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
32807326|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
32807327|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
32807328|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
32807329|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
32807330|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
32807331|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
32807332|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
32807333|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
32807334|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
32807335|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
32807336|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
32807337|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
32807338|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
32807339|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
32807340|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
32807341|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
32807342|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
32807343|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
32738189|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
32744232|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
32807344|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
32807345|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
32807346|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
32807347|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
32807348|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
32807349|NCT02110108|Experimental|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
32807350|NCT02110108|Experimental|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
32951959|NCT04552704|Experimental|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
32807351|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
32807352|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
32807353|NCT05287438|Active Comparator|Group A - Culture|Following local standard of care, treatment will be based on standard culture
32807354|NCT05287438|Experimental|Group B - NGS|Treatment will be based on NGS results reviewed by an infectious disease doctor
33404842|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
33404843|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
33404844|NCT04750486|No Intervention|Control|No intervention, the patient will be provided routine care at time of epidural placement without use of sequential compression devices.
32807355|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
32807356|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
32807357|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
32807358|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
32807359|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
32807360|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
32807361|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
32807362|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
32807363|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
32807364|NCT03303898|Other|asymptomatic carriers|
32807365|NCT03303898|Other|uninfected patient|
32807366|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
32807367|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
32807368|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
32807369|NCT05286970|Experimental|0.5mg AK115 SC|
32807370|NCT05286970|Experimental|1mg AK115or placebo SC|
32807371|NCT05286970|Experimental|3mg AK115or placebo SC|
32807372|NCT05286970|Experimental|10mg AK115or placebo SC|
32807373|NCT05286970|Experimental|30mg AK115or placebo SC|
32807374|NCT05286970|Experimental|60mg AK115or placebo SC|
32807375|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
32807376|NCT00414700|Experimental|ChondroCelect|
32807377|NCT00414700|Active Comparator|Microfracture|
32807378|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
32807379|NCT00415870|Experimental|PACE|Received text messages and counseling calls
32807380|NCT00415870|No Intervention|Control|
32807381|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
32807382|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
32807383|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
32807384|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
32807385|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
32807386|NCT00416494|Experimental|Initial Cohort|
32807387|NCT00416494|Experimental|Second cohort|
32807388|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
32807389|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
32951960|NCT04552704|Experimental|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
33099331|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
33099332|NCT00518453|Experimental|Arm 1: Fluvirin|
33099333|NCT05318664|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
33099334|NCT05318664|No Intervention|Control|20 minutes of rest
33099335|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
33099336|NCT04694924||Localized and locally advanced prostate cancer|Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
33099337|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
33099338|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
33315337|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
33315338|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
33315339|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
33099339|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
33315340|NCT03607838|Experimental|SI-6603|
33315341|NCT03607838|Sham Comparator|Sham injection|
33315342|NCT03606512|Experimental|Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)|Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5*10^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.
33315343|NCT03606512|Placebo Comparator|Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)|RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29 and 57. Placebo can be replaced with Nimenrix on Day 57 in countries where applicable.
33315344|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
33315345|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
33315346|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
33315347|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
33315348|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
33315349|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
33315350|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
33315351|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
33315352|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
33315353|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
33315354|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
33404845|NCT04750486|Experimental|Lower Extremity Compression|Patients will have sequential compression devices prior to epidural placement, and maintained for at least one hour following procedure.
32807390|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
32807391|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
32807392|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
32807393|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
32807394|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
32807395|NCT04271644|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
32807396|NCT04271410|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
32807397|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
32807398|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
32807399|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
32807400|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
32807401|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
32807402|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
32807403|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
32807404|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
32807405|NCT04750564|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
32807406|NCT04750564|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
32807407|NCT01793428||Injured patient admitted in vital emergency unit|
32807408|NCT04749940|Experimental|Hospitalized burn patients|Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
32807409|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
32807410|NCT04750096||Esophagectomy post enhanced recovery after surgery|Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.
32807411|NCT05286346|Experimental|Experimental group|Tenolid Tab
32807412|NCT05286346|Active Comparator|Control group|Viread Tab
32807413|NCT05286268||Study group|Patients with confirmed COVID-19 disease
32807414|NCT05286268||Control group|Healthy volunteers without any of the exclusion criteria
32807415|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
32807416|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
32807417|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
32807418|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
32807419|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
32807420|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
32807421|NCT01388920|Placebo Comparator|Placebo|Placebo
32807422|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
32807423|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
32807424|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
32807425|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
32807426|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
32807427|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
32807428|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
32807429|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
32807430|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
32807431|NCT00424840|Experimental|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
32807432|NCT00424840|Experimental|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
32807433|NCT00424840|Experimental|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
33404846|NCT04737694|Experimental|Ketone + Carbohydrate|573 mg/ kg body weight ketone ester + 110 g glucose
32807434|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
32807435|NCT05286034|Experimental|Intervention group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test, with access to a decision aid tool tailored to those with low education levels. This tool will be available via Chatbot platforms.
32807436|NCT05286034|No Intervention|Control group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test (Standard care)
32807437|NCT04345978|Placebo Comparator|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
32807438|NCT04345978|Experimental|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
32807439|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
32807440|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
32807441|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
32807442|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
32807443|NCT05281588|Experimental|Micro-osteoperforations|Micro-osteoperforations- assisted upper incisors retraction
32807444|NCT05281588|No Intervention|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
32807445|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
32807446|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
32807447|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
32807448|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
32807449|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
32807450|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
32807451|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
32807454|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
32807455|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
32807456|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
32807457|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
32807458|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
32807459|NCT00428584|Experimental|1|interferon beta-1a
32807460|NCT00428584|Active Comparator|2|interferon beta-1b
32807461|NCT00428974|Experimental|CF101 1 mg|
32807462|NCT00428974|Experimental|CF101 2mg|
32807463|NCT00428974|Experimental|CF101 4mg|
32807464|NCT00428974|Placebo Comparator|Placebo|
32807465|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
32807466|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
32807467|NCT00373360|Experimental|1|
32807468|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
32807469|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
32807470|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
32807471|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
32807472|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
32807473|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
32807474|NCT00455650|Active Comparator|Control, Mecamylamine|
32807475|NCT00455650|Active Comparator|Control, Varenicline|
32807476|NCT00455650|Placebo Comparator|Control, placebo|
32807477|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
32807478|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
33099340|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
33099341|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
33099342|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
33099343|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
33099344|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
33099345|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
33099346|NCT00517088|Other|Other|Group Description
33099347|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
33099348|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
33099349|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
33099350|NCT05190588|No Intervention|Exercise|Quadriceps Strength 10 repetition in three-set, 5 times a week
33099351|NCT05190588|Active Comparator|Mesotherapy|Group 2: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used. One time a week for a total of 3 times.
33099352|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
33099353|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
33099354|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
33099355|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
33099356|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
33099357|NCT05174130|Experimental|Patients undergoing mechanical ventilation in stable phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
33099358|NCT05174130|Experimental|Patients undergoing mechanical ventilation in weaning phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
33099359|NCT00518648|Experimental|I|Multifactorial fall prevention program
33099360|NCT00518648|Other|II|Usual care
33099361|NCT03458208|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
33099362|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
33099363|NCT00517166||A|Individuals on whom tourniquet was used.
33099364|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
33099365|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
33099366|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
33099367|NCT02940834||patients with sodium imbalance|
33099368|NCT02940834||patients without sodium imbalance|
33099369|NCT00517244||A|Primary anxiety disorder
33099370|NCT00517244||B|Primary obsessive compulsive disorder
33099371|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
33099372|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
33099373|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
33099374|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
33099375|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
33099376|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
33099377|NCT00518726|Experimental|Arm 1|
33404847|NCT04737694|Active Comparator|Carbohydrate|Isocaloric amount of glucose to match ketone + carbohydrate
33099378|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
33315355|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
33315356|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
33315357|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
32951961|NCT04552704|Placebo Comparator|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
32951962|NCT04759638||Rectal Cancer|Rectal Cancer
32951963|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
32951964|NCT04124796|Experimental|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
32951965|NCT04124796|Active Comparator|health care team|the health care team managing these patients
32951966|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9
32951967|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
32951968|NCT03246126|Experimental|Valiant™Thoracoabdominal Stent Graft System|The implantation of the Valiant™ Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance
32951969|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
32951970|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
32951971|NCT05605002|Active Comparator|Waiting list group|This group will include 30 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
32951972|NCT05605002|Sham Comparator|SIA+SSRIs group|This group will include 30 patients with MDD who will be treated with sham intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
32951973|NCT05605002|Experimental|AIA+SSRIs group|This group will include 30 patients with MDD who will be treated with active intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
32951974|NCT05604924|Experimental|Participants who received virtual reality training|
32951975|NCT05604924|Placebo Comparator|Participants who received similar contents in a standard PowerPoint presentation on a laptop|
32951976|NCT05604846|Experimental|Probiotic group|Probiotic group: 0,5 g per day of ProPrems®, including a combination of Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million and Streptococcus thermophilus (TH-4®) 350 million. Mixed with 3 mills of breastmilk
32951977|NCT05604846|Placebo Comparator|Control group|Control group receives 3 mills of breastmilk without additives
32951978|NCT05604768||Normal parturient group|20 normal parturients who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
32951979|NCT05604768||Pregnant women with threatened premature delivery group|20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
32951980|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
32951981|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
32951982|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
32951983|NCT04124484|Experimental|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
32951984|NCT04124484|Experimental|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
32951985|NCT04124484|Experimental|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
32951986|NCT04124484|Placebo Comparator|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
32951987|NCT04124016|Experimental|Inulin|Inulin_ extract of chicory fermentable fiber
32951988|NCT04124016|Experimental|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
32951989|NCT04124016|Experimental|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
32951990|NCT04124016|Experimental|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
32951991|NCT05601804||Food Insecure Women with Obesity|4 focus groups with 6-8 participants each
32951992|NCT05601804||Food Secure Women with Obesity|2 focus groups with 6-8 participants each
32951993|NCT04124094|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
32951994|NCT04124094|Active Comparator|SERETIDE DISKUS 100/50|reference Product
32951995|NCT05604612|Experimental|Experimental|
32951996|NCT05604612|No Intervention|Active Comparator|
32951997|NCT05601336|Active Comparator|metformin monotherapy|Glucophage 1000 once daily
32951998|NCT05601336|Active Comparator|Dapagliflozin monotherapy .|Farxiga once per day
32951999|NCT05601336|Active Comparator|metformin and dapagliflozin combined therapy|Xigduo once daily
32952000|NCT05601336|No Intervention|control group.|placebo
33099379|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
32952001|NCT03343236||Patients with head and neck cancer|All patients with newly diagnosed and untreated head and neck cancer. Exclusion criteria: previous treatment for malignant disorder except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish
32952002|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32952003|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32952004|NCT05604378||EBV-positive gastric cancers|
32952005|NCT05604378||EBV-negative gastric cancers|
32952006|NCT04123782|Active Comparator|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
32952007|NCT04123782|Placebo Comparator|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
32952008|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
32952009|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
32952010|NCT04275024|Experimental|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
32952011|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
32952012|NCT04123392|Experimental|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32952013|NCT04123392|Active Comparator|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32952014|NCT03371706|Experimental|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
32952015|NCT03371706|Active Comparator|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
32952016|NCT04393038|Experimental|ABX464|ABX464 - Capsules + Standard of Care (SOC)
32952017|NCT04393038|Placebo Comparator|Placebo|Placebo - Capsules + Standard of Care (SOC)
32952018|NCT05601258||patients with higher lipase level|patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
32952019|NCT05601258||Control|patients with normal lipase levels in the course of SARS-CoV-2 infection
32952020|NCT05601180|Active Comparator|Stadard of care|standard treatment that is prescribed by the treating physician.
32952021|NCT05601180|Experimental|Standard of care + Respicure®|standard treatment that is prescribed by the treating physician in addition to Respicure®
32952022|NCT04760262||Group Propofol|anesthesia was maintained with TIVA (intravenous 125-250 µg/kg/min propofol + 0.1-0.25 µg/kg/min remifentanil infusion)
32952023|NCT04760262||Group Sevoflurane|anesthesia was maintained with inhalation (sevoflurane concentration of 1-2% in 50-50% O2-air mixture).
32952024|NCT04127292|Experimental|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
32952025|NCT04127292|No Intervention|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
32952026|NCT04127292|Sham Comparator|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
32952027|NCT04127292|No Intervention|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
32952028|NCT04123002|Experimental|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
32952029|NCT04123002|No Intervention|Comparison group|They would use only tooth brush and paste
32952030|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
33099380|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
33099381|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
33404848|NCT04734886|Active Comparator|L. reuteri DSM 17938|Probiotic compound
33404849|NCT04734886|Placebo Comparator|Placebo|Placebo compound
33404850|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
32807479|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
32807480|NCT01794988|Active Comparator|No TIVR|Control - no intervention
32807481|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
32807482|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
32807483|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
32807484|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
32807485|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
32807486|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
32807487|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
32807488|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
32807489|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
32807490|NCT04388176|Experimental|C21 followed by placebo|
32807491|NCT04388176|Experimental|Placebo followed by C21|
32807492|NCT01796704||healthy and mild heart failure|diversity of patients
32807493|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
32807494|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
32807495|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
32807496|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
32807497|NCT00434278|Placebo Comparator|Placebo|
32807498|NCT00434278|Experimental|Dornase alfa|
32807499|NCT00434356|Experimental|1|
32807500|NCT00434356|Placebo Comparator|2|
32807501|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
32807502|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
32807503|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
32807504|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
32807505|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
32807506|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
32807507|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
32807508|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
32807509|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
32807510|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
32807511|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
32807512|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
32807513|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
32807514|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
32807515|NCT00457366|Active Comparator|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
32807516|NCT00457366|Active Comparator|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
32807517|NCT00457366|Active Comparator|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
32807518|NCT00457366|Active Comparator|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
32807519|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
32807520|NCT00461734|Active Comparator|RV Apex|
32807521|NCT00461734|Experimental|RV High Septum|
32807522|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
32807523|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
32807524|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
32807525|NCT00438880|Experimental|Arm I|See Detailed Description
32807526|NCT00462124|Other|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
32807527|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
32807528|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
32807529|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
32807530|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
32807531|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
32807532|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
32807533|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
32807534|NCT00440050|Experimental|1.|DHA
32807535|NCT00440050|Placebo Comparator|2.|Placebo
32807536|NCT00440596|Experimental|Mindfulness based stress reduction|Mindfulness based stress reduction
32807537|NCT00440596|Active Comparator|Progressive Muscle Relaxation|Progressive Muscle Relaxation
32807538|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32807539|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
32807540|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
32807541|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
32807542|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
32807543|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
32807544|NCT00464464|No Intervention|2|standard medical care
32807545|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
32807546|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
32807547|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
32807548|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
32807549|NCT00381862|Experimental|Aprepitant and Palonosetron|
32807550|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
32807551|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
32807552|NCT00465088|Experimental|1|
32807553|NCT00465088|Experimental|2|
32807554|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
32807555|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
33099382|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
33099383|NCT00517322|Experimental|1|treatment with ramipril
32807556|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
32807557|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
32807558|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
32807559|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
32807560|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
32807561|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~Each cycle will last 21 days."
33099384|NCT00517322|Experimental|2|treatment with irbesartan
33099385|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
33099386|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
33099387|NCT00517400|Active Comparator|Exposure-Stimulation|
33099388|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
33099389|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
33099390|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
33099391|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
32807562|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
32807563|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
32807564|NCT00467038|No Intervention|Healthy Controls|Healthy controls
32807565|NCT00467350|Active Comparator|enema|Rectal enema containing mixture of milk and molasses
32807566|NCT00467350|Active Comparator|PEG 3350|Medication to be taken orally once each day for three consecutive days
32807567|NCT00444028|Experimental|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
32807568|NCT00444028|Experimental|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
32807569|NCT00444028|Experimental|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
32807570|NCT00444028|Experimental|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
32807571|NCT00444028|Experimental|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
32807572|NCT00444964|Experimental|Primary Cohort|Nutropin AQ
32807573|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
32807574|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
32807575|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
32807576|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
32831140|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
33099392|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
33099393|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
33099394|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
33099395|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
33099396|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
33099397|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
32952031|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
32952032|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
32952033|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
32952034|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
32952035|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
32952036|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
32952037|NCT04122846|Experimental|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
32952038|NCT05607810||No Intervention - Subjects who received ADVM-022 in prior clinical study|
32952039|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
33099398|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
33099399|NCT02939391|Placebo Comparator|Placebo|Oral administration
33315358|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
33404851|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
32952040|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
32952041|NCT04126278|Experimental|Barbotage Injection|Subjects receiving barbotage with saline injection
32952042|NCT04126278|Active Comparator|Barbotage with Cortisone Injection|Subjects receiving barbotage with cortisone injection
32952043|NCT04394910|Experimental|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
32952044|NCT04394910|Placebo Comparator|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
32952045|NCT05607654|Active Comparator|active iTBS|The active group of TRD will receive the accelerated intermittent TBS(iTBS).The iTBS cycles including 10 bursts of three pulses at 50 Hz were delivered in 2-second trains. Each iTBS session comprised 60 x 2 second trains, with an 8-second intertrain interval and total duration of 10-minutes.Treatment sessions were administered hourly 10 times a day totaling 18,000 pulses/day. Patients received this treatment protocol for 5 consecutive days (90,000 pulses in total).
32952046|NCT05607654|Sham Comparator|sham rTMS|The sham group of TRD will receive sham rTMS stimulation.
32952047|NCT04127682||Physicians|Physicians dealing with cases of pediatrics' acute URIs at PHC units either urban or rural, insurance hospitals or Assiut university hospitals.
32952048|NCT05607576|Experimental|Uncovered|Dexcom G6 CGM will be uncovered during standard of care radiologic procedures.
32952049|NCT04122144|Experimental|Intervention|ENHANCED-SPS intervention implemented
32952050|NCT04122144|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
32952051|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
32952052|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
32952053|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
32952054|NCT05607264|Experimental|Kinsiotaping|patients who received kinesiotaping plus conventional treatment for chronic shoulder impingement syndrome.
32952055|NCT05607264|Experimental|Virtual Reality training|patients who received VR training plus conventional treatment for chronic shoulder impingement syndrome.
32952056|NCT05607264|Active Comparator|conventional treatment|patients who received conventional treatment for chronic shoulder impingement syndrome only.
32952057|NCT04122300|Experimental|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
32952058|NCT04122300|Placebo Comparator|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
33315359|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
33315360|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
33315361|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
33315362|NCT01266356||Experimental Group|
33315363|NCT01266356||Control Group|
33315364|NCT03882710|Experimental|metoprolol XR capsule|
33315365|NCT03882710|Placebo Comparator|placebo capsule|
33315366|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
33315367|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
33315368|NCT01161602|Experimental|0.2mg Pumosetrag|
32952059|NCT04121910|Experimental|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
32952060|NCT04274478|Other|Single group|
33315369|NCT01161602|Experimental|0.5mg Pumosetrag|
33315370|NCT01161602|Experimental|0.8mg Pumosetrag|
32952061|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
33315371|NCT01161602|Placebo Comparator|Placebo|
33315372|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
33315373|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
32952062|NCT04274634||Age-matched with normal axial lengths|
32952063|NCT04274634||Age-matched with extreme axial lengths|
32952064|NCT04274634||Intraocular lens|
32952065|NCT04274634||Pre- and post- cataract surgery|
32952066|NCT04274634||Normals|
32952067|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
32952068|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
32952069|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
32952070|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
32952071|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
32952072|NCT04393818|Experimental|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
32952073|NCT04393818|Sham Comparator|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
32952074|NCT04393896|Experimental|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
32952075|NCT04393896|No Intervention|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
32952076|NCT04129788|Experimental|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
32952077|NCT04129788|Placebo Comparator|placebo|tablet, once a day on three consecutive days
32952078|NCT03831126||betamethasone treatment|
32952079|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
32952080|NCT05607108|Experimental|ZEN003694|All patients enrolled on the study will undergo treatment with ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle.
33315374|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
33315375|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
33315376|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
33315377|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
33099400|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
33099401|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
33099402|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
33099403|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
33315378|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
32807577|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
32807578|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
32807579|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
32807580|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
32807581|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
32807582|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
32807583|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
32807584|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
32807585|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
32807586|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
32807587|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
32807588|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
32807589|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
32807590|NCT04388488|Experimental|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
32807591|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
32807592|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
32807593|NCT00388414|Placebo Comparator|Placebo - sugar pill|
32807594|NCT00388414|Experimental|Duloxetine|
32807595|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
32807596|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
33099404|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
33099405|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
33099406|NCT00517673|Experimental|GSK945237|Active Study Drug
33099407|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
33315379|NCT05051306|Experimental|High-load resistance exercise|4 high-load resistance exercises that target all major muscle groups.
33315380|NCT05051306|Experimental|Low-load resistance exercise|4 low-load resistance exercises that target all major muscle groups.
33315381|NCT05051306|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
33099408|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
33099409|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
33099410|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
33099411|NCT02949245||Groups/Cohorts|"Surgical treatment~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
33099412|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
33099413|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
33099414|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
32807597|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
32807598|NCT04388410|Experimental|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
33099415|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
33099416|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
33099417|NCT02941068|No Intervention|Empirical group|
32807599|NCT04388410|Placebo Comparator|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
32807600|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
32807601|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
32807602|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
32807603|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
32807604|NCT01795066|Experimental|EUS-FNB with 25-gauge|
32807605|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
33099418|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
32807606|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
32807607|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
32807608|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
32807609|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
32807610|NCT03286114|Experimental|Pembrolizumab|
32807611|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
32807612|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
32807613|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
32807614|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
32807615|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
32807616|NCT01436175|Experimental|SPD489 + Antidepressant|
33099419|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
33099420|NCT00518843|Experimental|FBT-BN|Family-based treatment
33099421|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
33099422|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
33099423|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
33099424|NCT00518921|Experimental|Arm 1|
33099425|NCT00518921|Experimental|Arm 2|
33099426|NCT00518921|Experimental|Arm 3|
33099427|NCT00518921|Placebo Comparator|Arm 4|
33099428|NCT04694183|Experimental|Camrelizumab combined with chemotherapy|The enrolled patients will be administered in two ways according to the difference between peritoneal metastasis and liver metastasis
33099429|NCT05030571|Experimental|Intervention|Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.
33315382|NCT01266434|Experimental|simvastatin|
33315383|NCT01266434|Placebo Comparator|B1-6-12|
33404852|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
32807617|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
32807618|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
32807619|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
32807620|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
32807621|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
32807622|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
32807623|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
32807624|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
32807625|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
32807626|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
32807627|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
32807628|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
32807629|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
32807630|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
32807631|NCT04076241|Experimental|Combined intervention|Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients. Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
32807632|NCT04076241|Active Comparator|Osteopathic manipulative treatment|OMT group consisted of 16 PAH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
32807633|NCT04076241|No Intervention|Control|Control group also consisted of 16 PAH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
32807634|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
32807635|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
32807636|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
32807637|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
32807638|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
32807639|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
32807640|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
33099430|NCT05030571|Active Comparator|Standard care|Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017
33099431|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
33099432|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
33099433|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
33099434|NCT04998240|Experimental|Prime BBIBP-CorV, Boost Ad26.COV2.S (A1)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of Ad26.COV2.S vaccine (A1).
33099435|NCT04998240|Experimental|Prime BBIBP-CorV, Boost BBIBP-CorV (A2)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (A2).
33099436|NCT04998240|Experimental|Prime Ad26.COV2.S, Boost BBIBP-CorV (B1)|The randomized study participants will receive Prime Ad26.COV2.S vaccine followed by Booster dose of BBIBP-CorV vaccine (B1).
33099437|NCT04998240|Experimental|Prime Placebo, Boost Ad26.COV2.S (B2)|The randomized study participants will receive Prime Placebo vaccine followed by Booster dose of Ad26.COV2.S (B2).
33099438|NCT02949401|No Intervention|Standard of Care|"No research intervention to be administered.~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
33099439|NCT02949401|Experimental|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
33099440|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
33099441|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
33099442|NCT04988685||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.
33099443|NCT04690920|No Intervention|Control|
33099444|NCT04690920|Experimental|Tocilizumab|
33099445|NCT04690920|Experimental|Remdesivir|
33099446|NCT04690920|Active Comparator|Standard Treatment|
33099447|NCT00519038|Experimental|1|Patients treated according to clinical pathways
33099448|NCT00519038|Other|2|Patients treated according to usual care
33099449|NCT04691895||Patients admitted to hospital for COVID19 disease (case group)|"The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive COVID19 confirmed patients (COVID +ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
33099450|NCT04691895||Patients admitted to hospital in absence of COVID19 disease (control group)|"The study cohort will be composed by consecutively enrolled COVID19 negative patients hospitalized for other reasons (controls group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive hospitalized COVID19 negative patients (COVID -ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
33099451|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
33315384|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
33315385|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
33315386|NCT05049590|Experimental|Intervention Group|Perform blood conservation in the operating room (OR).
33315387|NCT05049590|No Intervention|Control Group|Blood conservation will not be performed in the OR.
33315388|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
33315389|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
33099452|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
33099453|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
33099454|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
33099455|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
33099456|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
33099457|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
33315390|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
32952081|NCT04073784|Experimental|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
32952082|NCT05606796|Experimental|Preserved latanoprost|"Benzalkonium chloride (BAK) preserved latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
32952083|NCT05606796|Experimental|Preservative-free latanoprost|"Preservative-free (Benzalkonium chloride-free) latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
32952084|NCT04121208|Active Comparator|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
32952085|NCT04121208|Placebo Comparator|Placebo|Non-active study drug
32952086|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
33315391|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
33315392|NCT05046002||Prospective (cases)|Patients who develop new symptoms of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath, or pain with breathing; palpitations; diaphoresis or sudden death. The symptoms can also be non-specific, including fatigue, abdominal pain, dizziness or syncope, edema, cough or irritability, vomiting, poor feeding, tachypnea or lethargy in young children
33315393|NCT05046002||Prospective (Control Positive)|Family members/relatives who have been vaccinated in a similar timeframe with the participant and had similar reactions
33315394|NCT05046002||Prospective (Control Negative)|"Family members/relatives who have been vaccinated in a similar timeframe with the participants but did not experience myocarditis side-effects.~If a relative is not available, then a voluntary control who has received the same COVID-19 vaccine in a similar time frame can be recruited."
33315395|NCT05046002||Retrospective|Identified patients, previously diagnosed with the condition, at participating centers
33315396|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
33315397|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
33315398|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
33315399|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
33315400|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
32952087|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
32952088|NCT05606640||Haemophilia|Adult males with severe or moderate haemophilia A or B
33315401|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
33318649|NCT00048048|Experimental|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
33318650|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
33318651|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
32952089|NCT04129710|Experimental|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
32952090|NCT04129710|Experimental|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
32952091|NCT04129710|Active Comparator|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
32952092|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
32952093|NCT05603598|Placebo Comparator|Placebo|IV infusion of saline, approximately 5.5 hours
32952094|NCT05603598|Experimental|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5.5 hours
32952095|NCT04121130|Active Comparator|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
33318652|NCT03953118|Placebo Comparator|Placebo|
33099458|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
33099459|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
33099460|NCT00518141|Experimental|1|FER
33099461|NCT00518141|No Intervention|2|FER
33099462|NCT00518141|Experimental|3|SET
33315402|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
33315403|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
33315404|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
33315405|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
33315406|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
33315407|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
33315408|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
33315409|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
33315410|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
33315411|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
33315412|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
33315413|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
33315414|NCT01156688|Active Comparator|Sublingual Misoprostol|
33315415|NCT01156688|Active Comparator|Buccal misoprostol|
33315416|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
33315417|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
33318653|NCT03953118|Active Comparator|Azithromycin|
33099463|NCT00518141|No Intervention|4|SET
33099464|NCT00518141|Experimental|5|DET
33099465|NCT00518141|No Intervention|6|DET
33099466|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
33099467|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
33099468|NCT00519701|Experimental|1|hydroxyurea
33099469|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
33099470|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
33099471|NCT00519155|Experimental|1|Open flap debridement + MD05
33099472|NCT00519155|Active Comparator|2|Open flap debridement
33099473|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
33099474|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
33315418|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
33315419|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
33315420|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
33315421|NCT03878732||Caucasian female|
33315422|NCT03878732||Hispanic female|
33315423|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
33315424|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
33315425|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
33315426|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
33315427|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
33404853|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
32952096|NCT04121130|Placebo Comparator|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
32952097|NCT04129476|Experimental|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
32952098|NCT04129476|No Intervention|Control|We provide routine care for these people during pregnancy
32952099|NCT05603520||healthy volunteers|
32952100|NCT05603520||patients with aortic stenosis|
32952101|NCT05603520||patients with aortic aneurysms|
32952102|NCT04128852|Other|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
32952103|NCT04129008|Experimental|Indobufen|
32952104|NCT04129008|Active Comparator|Aspirin|
32952105|NCT04121052|Experimental|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952106|NCT04121052|Experimental|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952107|NCT04121052|Experimental|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952108|NCT04121052|Experimental|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952109|NCT04121052|Experimental|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952110|NCT04121052|Experimental|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952111|NCT04121052|Experimental|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952112|NCT04121052|Experimental|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32807641|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
32807642|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
32807643|NCT01415349|Experimental|SSP-002358 alone|
32807644|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
32807645|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
32807646|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
32807647|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
32807648|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
32807649|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
32807650|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
32807651|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
32807652|NCT04048863|Active Comparator|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
32807653|NCT04048863|Other|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
32807654|NCT04048863|Other|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
32807655|NCT04048863|Other|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
32807656|NCT04522557|Experimental|Experimental: Participants with breast cancer enrolled in grou|
32807657|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
32807658|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
32807659|NCT04767321|Experimental|LTX-109 treatment|Nasal application of LTX-109 gel 3% (w/w), 250 mikroliters in each nostril, 4 times in one day, every two hours.
32807660|NCT04767321|Experimental|Placebo|Nasal application of placebo, 250 mikroliters in each nostril, 4 times in one day, every two hours.
32807661|NCT01452789|Experimental|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
32807662|NCT01452789|Active Comparator|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
32807663|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
32807664|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
32807665|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
32807666|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
32807667|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
32807668|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
32807669|NCT04048551|No Intervention|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
32807670|NCT04048551|Experimental|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
32807671|NCT04048551|Active Comparator|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
32807672|NCT04048551|Experimental|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
32807673|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
32807674|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
32807675|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
32807676|NCT04490044|Active Comparator|1|Participants in Arm 1 will be posted the Under & Over study pack (1) and asked to complete the Under & Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
32807677|NCT04490044|Active Comparator|2|Participants in Arm 2 will be posted the Under & Over study pack (2) and asked to complete the Under & Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
32952113|NCT04121052|Experimental|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
33099475|NCT04691076|Experimental|Propofol/Esketamine sedation|Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.
33099476|NCT04691076|Active Comparator|Propofol/Fentanyl sedation|Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.
32952114|NCT04121052|Experimental|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952115|NCT04121052|Experimental|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952116|NCT04121052|Experimental|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
33099477|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
33099478|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
33099479|NCT02949323||children with urinary stones|children with urinary stones
33099480|NCT02949323||children without urinary stones|children without urinary stones
33099481|NCT04690959|Experimental|Neural gliding mobilization|Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
33099482|NCT04690959|Experimental|Neural tensioning mobilization|Tensioning will be performed with the subject lying supine. The investigator will perform the upper limb neurodynamic test as reported by Butler (2000): shoulder depression; 110 of shoulder abduction; external shoulder rotation; wrist and fingers extension; forearm supination and then elbow extension. The final test position will be defined as either i) end of joint amplitude or ii) the joint amplitude that provokes pain, paresthesia or numbness. In this case, a decrease of 5 to 10 of range of motion (elbow extension) will be allowed for symptoms to disappear and from this end position the investigator will perform repetitive movements of approximately 10 of elbow flexion/extension while maintaining the test end position for all the other joints. For tensioning, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series will be performed. After each cycle of 10 repetitions, the position will be held for 10 seconds.
33099483|NCT04690959|Sham Comparator|Control|Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
33099484|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
33099485|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
33099486|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
33099487|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
33099488|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
33099489|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
32952117|NCT04121052|Experimental|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952118|NCT04121052|Experimental|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952119|NCT04121052|Experimental|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952120|NCT04121052|Experimental|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
32952121|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
32952122|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
32952123|NCT04120896|Experimental|Karate group|
32952124|NCT04120896|Active Comparator|Kung Fu group|
32952125|NCT05603286|Experimental|Home-monitoring arm|After inclusion, participants will skip one regular 3-monthly control visit and instead complete an online EQ-5D-Y-5L and JAMAR questionnaire. 5-7 months after inclusion, participants will be followed-up at the hospital and complete a questionnaire about their experiences with home-monitoring.
32952126|NCT04128930|Experimental|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:~After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O~After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
32952127|NCT04128930|Active Comparator|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
32952128|NCT04128462|Experimental|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:~Loading dose: 20 g infused over 6 hours~Intermediate dose: 15 g infused over 18 hours~Maintenance dose: 15 g infused over 24 hours for up to 4 days"
32952129|NCT04128462|Placebo Comparator|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
32952130|NCT04394520|No Intervention|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
32952131|NCT04394520|Experimental|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
32952132|NCT04394520|Experimental|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
32952133|NCT04394520|Experimental|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
32952134|NCT04394520|Experimental|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
32952135|NCT04128618|Experimental|Active NMES|
32952136|NCT04128618|Sham Comparator|Modified NMES sham|
32952137|NCT03309306|No Intervention|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
32952138|NCT03309306|Active Comparator|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
33099490|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
33099491|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
33315428|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
33315429|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
33315430|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
32952139|NCT03309306|Experimental|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
32952140|NCT04120662|Active Comparator|Group A: Surgery group|Surgical procedure according to the injury type
32952141|NCT04120662|Active Comparator|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
32952142|NCT04120506|Experimental|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
33315431|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
33315432|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
32952143|NCT04120350|Experimental|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
32952144|NCT04128306|Experimental|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:~In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.~In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
33315433|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
33315434|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
33315435|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
33315436|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
33315437|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
33315438|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
33315439|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
33315440|NCT01162148|Experimental|1|conventional
33315441|NCT01162148|Experimental|2|sham IMT
33315442|NCT01162148|Experimental|3|Conventional plus threshold IMT
32952145|NCT04128306|Active Comparator|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
32952146|NCT04394598|Experimental|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
33315443|NCT01162148|Experimental|4|threshold IMT alone
32952147|NCT04394598|Placebo Comparator|CRT with Placebo|"Placebo: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
32952148|NCT04120194|Experimental|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
32952149|NCT04120194|Active Comparator|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
32952150|NCT04120272||Delirium group|Group of patients with postoperative delirium
32952151|NCT04120272||Non delirium group|Group of patients without postoperative delirium
33099492|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
33099493|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
33099494|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
33099495|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
33099496|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
33099497|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
33099498|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
33099499|NCT05135052|Experimental|Treatment arm|Treatment with Rhenium-SCT, Single treatment.
33099500|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
33099501|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
33315444|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
32807678|NCT04490044|Placebo Comparator|3|Participants in Arm 3 will be posted the Under & Over study pack (3). For the first three months of the study they will be asked to complete the c9HPT 5 days a week. After three months, they will be able to complete the Under & Over tool daily for as long or short as they choose. Similar to Arm 2, They will be asked to do this 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to
32807679|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
32807680|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
33099502|NCT05108454||Intervention group|Pregnant women who received MMS from the SMC program
33099503|NCT05108454||Comparison|Pregnant women who did not receive MMS
33099504|NCT04694222|Other|Control Group|scaling and root planning (SRP) was applied.
33315445|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
33315446|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
32807681|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
32807682|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
32807683|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
32807684|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
32807685|NCT01434693|Experimental|TSO 500|
32807686|NCT01434693|Experimental|TSO 2500|
32807687|NCT01434693|Experimental|TSO 7500|
32807688|NCT01434693|Placebo Comparator|Placebo|single dose
32807689|NCT04046991|Active Comparator|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
32807690|NCT04046991|Sham Comparator|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
32807691|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
32807692|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
32807693|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
32807694|NCT01451541|Placebo Comparator|Placebo|
33315447|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
33315448|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
33315449|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
33315450|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
33315451|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
33315452|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
33315453|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
33315454|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
33315455|NCT01162226|Experimental|training program|
33315456|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
32952152|NCT04394832|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
33315457|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
33315458|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
33315459|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
33315460|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
33315461|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
32952153|NCT04127760|No Intervention|control|Follow-up at several time frames
32952154|NCT04127760|Experimental|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
32952155|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
32952156|NCT04127370|Experimental|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
32952157|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
32952158|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
32952159|NCT04129086|Experimental|Ketamine plus Usual care|
32952160|NCT04129086|Active Comparator|Usual care|
32952161|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
32952162|NCT04122690|Experimental|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
33099505|NCT04694222|Active Comparator|LANAP Group|After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
33099506|NCT04694222|Active Comparator|LLLT Group|after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
33099507|NCT04694222|Active Comparator|LANAP+LLLT Group|after scaling both LANAP and LLLT were applied.
33315462|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
33315463|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
33315464|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
33315465|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
33315466|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
33315467|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
32952163|NCT04122690|Active Comparator|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
32952164|NCT04127526|Active Comparator|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
33315468|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
33315469|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
33315470|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
33315471|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
33315472|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
33315473|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
33315474|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
33315475|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
32952165|NCT04127526|Active Comparator|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
32952166|NCT04127526|Active Comparator|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
32952167|NCT05602506|Active Comparator|BETAF OD arm|one tablet taken orally once daily
32952168|NCT05602506|Experimental|BETAF 3W arm|one tablet taken orally 3 days per week : Mondays, Wednesdays, and Fridays
32952169|NCT05602506|Experimental|BETAF 2W arm|one tablet taken orally 2 days per week : Mondays, and Thursdays
32952170|NCT05602506|Experimental|BETAF 1W arm|one tablet taken orally 1 days per week : Mondays
32952171|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
32952172|NCT05602428|Experimental|The observation group A|The use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block. The patients were subjected to local anesthesia and punctured through the left radial artery for invasive arterial blood pressure monitoring. Anesthesia induction: the observation group followed by intravenous injection of ketamine 0.2mg/kg, sufentanil 0.3μg/kg, Cyclophenol 0.3mg/kg, midazolam 2mg, rocuronium 0.6mg/kg. After the onset of the drug endotracheal intubation, connect anesthesia machine control breathing. Anesthesia was maintained with 1%~2% sevoflurane inhalation, remifentanil infusion rate was 0.2~0.3 μg/kg·min, sevoflurane was stopped 30 min before the end of the operation. Patient-controlled intravenous analgesia pump (PCIA) was given for postoperative analgesia. PCIA formula: sufentanil 100ug+ondansetron 8mg+ketorolac tromethamine 60mg+saline to 100ml, pump speed 2ml/h, automatic single dose 3ml, lock time 20min.
32952173|NCT05602428|Active Comparator|the control group B|Esketamine subanesthetic dose combined with lumbar plexus block was used. The patient was placed in the healthy lateral decubitus position and ultrasound-guided puncture was performed 4 cm beside the 3rd and 4th lumbar vertebrae (Figure 1B、C). The frequency of the ultrasound probe was 2-5 MHz, and the probe was adjusted until the images below the transverse processes of the 3rd to 5th lumbar vertebrae and the psoas muscle were clearly displayed, and the needle was inserted close to the probe and retracted in the lumbar plexus, and sufentanil 0.5 μg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg were injected after no blood extraction. General anesthesia was then performed using a subanesthetic dose of esketamine and the same maintenance and postoperative analgesic measures were used as in group A.
32952174|NCT05602428|Active Comparator|the control group C|general anesthesia was performed with esketamine subanesthetic dose. The same maintenance and postoperative analgesia measures were used as in group A.
32952175|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
32952176|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
33315476|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
33315477|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
33315478|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
33315479|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
33404854|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
32952177|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
32952178|NCT03022968|Experimental|Benson disease|[18F]T807 PET
33315480|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
33315481|NCT01162460|Active Comparator|Carbamazepine controlled release|
33315482|NCT01162460|Experimental|Eslicarbazepine acetate|
33315483|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
32952179|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
32952180|NCT04129944|Placebo Comparator|Placebo|
33315484|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
33315485|NCT01267214|Other|Osteotomy alone|
33315486|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
33315487|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
33315488|NCT03877874||Non-Asthmatic children|no intervention
32952181|NCT04129944|Experimental|UBX0101 0.5 mg|
32952182|NCT04129944|Experimental|UBX0101 2.0 mg|
32952183|NCT04129944|Experimental|UBX0101 4.0 mg|
32952184|NCT05602350|Experimental|Treatment|Survey respondents will self-administer three survey sections in a tablet: (1) antisocial behaviors, (2) depression symptoms, and (3) anxiety symptoms
32952185|NCT05602350|Placebo Comparator|Control|Survey respondents will have the survey questions on the three sections administered by an enumerator
32952186|NCT04127994|Experimental|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
32952187|NCT04127994|Experimental|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
32952188|NCT04124172|Active Comparator|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
32952189|NCT04124172|Sham Comparator|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
32952190|NCT04393194|Experimental|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
32952191|NCT04393194|Placebo Comparator|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
32952192|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
32952193|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
32952194|NCT04127058|Other|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
32952195|NCT04127058|Other|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
32952196|NCT05602194|Experimental|Arm A (levocarnitine, standard of care chemotherapy)|Patients receive levocarnitine PO or IV prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
32952197|NCT05602194|Active Comparator|Arm B (standard of care chemotherapy)|Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
32952198|NCT05602194|Experimental|Arm C (rescue levocarnitine)|Patients in Arms A and B who develop conjugated hyperbilirubinemia > 3 mg/dL during induction may receive levocarnitine rescue PO or IV supplementation until resolution of conjugated hyperbilirubinemia =< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).
32952199|NCT05600010||Study group|Detection of microplastics/nanoplastics in heart tissue and the blood of patients undergoing cardiac surgery
32952200|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|3 days of placebo
32952201|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
32952202|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
33315489|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
33315490|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
32952203|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
32952204|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
32952205|NCT04120974|Experimental|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
32952206|NCT05609838|Experimental|Experimental group|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.Data collection tools were applied at the 5th minute, 1st hour and 2nd hour after the hot water footbath and the gas output was questioned.
32952207|NCT05609838|No Intervention|Control Group|The control group was given routine post-cesarean care without any intervention and data collection tools were applied at the same time as the experimental group.
33315491|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
32952208|NCT04392882|Experimental|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
32952209|NCT04392882|No Intervention|Usual diet group|"Maintaining usual diet~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
32952210|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
32952211|NCT05609604|Active Comparator|active tDCS|This group will receive 30 minutes of active stimulation from tDCS
32952212|NCT05609604|Placebo Comparator|sham tDCS|This group will receive 30 minutes of sham (placebo) stimulation from tDCS
32952213|NCT04126668|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
32952214|NCT04126668|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
32952215|NCT04126434|Sham Comparator|no masking|not wearing facemask
32952216|NCT04126434|Active Comparator|masking|wearing facemask
32952217|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
32952218|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
32952219|NCT02979678|Experimental|Questionnaire|Breast cancer
32952220|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
32952221|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
32952222|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
32952223|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
32952224|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
32952225|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~The same procedure will be ask to do again about one and a half month later."
33315492|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
32952228|NCT05609448|Experimental|MRI-guided radioembolization|Study patients will receive radioembolization with holmium microspheres in an MRI guided setting.
32952229|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
32952230|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
32952231|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
32952232|NCT04758936|Experimental|Clonidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (clonidine) will be administered as soon as possible, The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
33315493|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older~Cough as chief complaint~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~pH testing for standard of care purposes"
33315494|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older~No history of chronic or acute cough and throat clearing~Ability to read a 5th grade script written in English for approximately 20 minutes"
33315495|NCT01162616|Other|Iron absorption|
33315496|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
33315497|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
33315498|NCT01160666|Experimental|1: Belilumab|
33315499|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
33315500|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
32952233|NCT04758936|Experimental|Dexmedetomidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (dexmedetomidine) will be administered as soon as possible. The α-2 agonist treatment that will be started will depend on the allocation of the previously randomized unit. The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
32952234|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
32952235|NCT04126044|Active Comparator|Reference: bevacizumab - EU|
32952236|NCT04126044|Experimental|Test: PF-06439535 (CN)|
32952237|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough >1%.
32952238|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
32952239|NCT03822390||Patients|Patients older than 18 years undergoing colonoscopy in one the participating centres.
32952240|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
32952241|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
32952242|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
32952243|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
32952244|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
32952245|NCT03829800|Active Comparator|Glicolab®|Glucose solution
32952246|NCT04125810|Experimental|Probiotic|Probiotic
32952247|NCT04125810|Placebo Comparator|Placebo|Placebo
32952248|NCT04758858|Active Comparator|VLCHF (Very Low CHO High Fat) Diet|10% of energy from CHO, 15% proteins, and 75% lipids
32952249|NCT04758858|Active Comparator|Low-CHO Diet|30% of energy from CHO, 15% proteins and 55% lipids
32952250|NCT04758858|Placebo Comparator|Control Diet|50% of energy from CHO, 15% proteins and 35% lipids
32952251|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
32952252|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
32952253|NCT04759092|Experimental|Treatment with tDCS|Home based treatment with tDCS for four months
32952254|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
32952255|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
33315501|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
33315502|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
33315503|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
33315504|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
33315505|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
33315506|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
33315507|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
33315508|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
33315509|NCT01268228||Residual ic ECG ST elevation in SB|
33315510|NCT01268228||Residual ic ECG ST elevation in MB|
33315511|NCT01161056||Healthy Control Group|
33315512|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
33315513|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
33315514|NCT01161212|Other|Control group|
33315515|NCT01161212|Other|Intervention group|
33315516|NCT03874442|No Intervention|Controls|
33315517|NCT03874442|Experimental|CliniPup|
33315518|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
33315519|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
33315520|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
33315521|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
33315522|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
33315523|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
33315524|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
33315525|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
33315526|NCT03874598|Experimental|Ear acupuncture|
33315527|NCT03874598|Active Comparator|Psychoeducation|
33315528|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
33315529|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
33315530|NCT01269476|Experimental|SNX-001|
33315531|NCT01269476|Placebo Comparator|Placebo|
33315532|NCT05417126|Experimental|Experimental-vMCO-010|Participants receive 1.2E11gc/eye of vMCO-010
33315533|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
33315534|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
32952256|NCT05609136|Experimental|Bobath+ Scapular Stabilization Group|In addition to the Bobath approach, which is one of the neurophysiological treatment methods for the upper extremity, 5 sessions a week for 6 weeks, scapular stabilization exercises will be applied to this group for an additional 6 weeks from the beginning of the treatment. Scapular Stabilization Exercises will be performed with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
32952257|NCT05609136|Active Comparator|Bobath Group|The Bobath approach, one of the neurodevelopmental treatment methods for the upper extremities, was applied to all participants included in the study for 6 weeks, 5 sessions per week. Before starting the Bobath exercises, preparation was made with 10 minutes of stretching and upper extremity mobilization. The Bobath approach included functional exercises that patients could perform at home. Bobath program; shoulder flexion, protraction, abduction and extranal rotation; It included extension of the elbow and wrist, extension and opposition of the fingers. After these exercises, task-specific functional upper extremity exercises were performed with or without an object that could help the treatment. These tasks are; required reaching, grasping, or lifting objects such as a cup, pen, cylindrical box, etc., in different body positions. Each session lasted for 1 hour and at the end of each session, patients were given a home exercise program.
32952258|NCT04394208|Placebo Comparator|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
32952259|NCT04394208|Experimental|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
32952260|NCT05608980|Active Comparator|Treatment arm|0.01%hypochlorous acid group
32952261|NCT05608980|Placebo Comparator|Placebo|eyelid wipes
32952262|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
32952263|NCT03933306|Placebo Comparator|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
32952264|NCT03933306|Experimental|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
32952265|NCT03933306|Experimental|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
33315535|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
33315536|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
33315537|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
33315538|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
33315539|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
33315540|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
33315541|NCT05415410|Experimental|Apraglutide Low Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
33315542|NCT05415410|Experimental|Apraglutide High Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
33315543|NCT05415410|Experimental|Apraglutide Standard Dose|Apraglutide SC injections, once weekly, for subjects with body weight between 40.0 kg to 49.9 kg.
33315544|NCT01269554||Children with diarrhea in Bissau|
33315545|NCT01269554||Children without diarrhea in Bissau|
33315546|NCT01269554||Children without diarrhea in Finland|
33315547|NCT01269554||Children with diarrhea in Finland|
33315548|NCT01269554||Adults without diarrhea in Finland|
32952266|NCT03933306|Experimental|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
32952267|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
32952268|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
32952269|NCT04125576||Healthy controls|age and sex matched healthy controls
32952270|NCT04125654|Experimental|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
32952271|NCT04394442|Experimental|Hydroxycholoroquine group|
32952272|NCT04394442|No Intervention|Control group|
32952273|NCT04125264|Experimental|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
32952274|NCT04125264|No Intervention|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
32952275|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
32952276|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
32952277|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
32952278|NCT05608590|Experimental|Direct HSG during fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) incorporated in the fertility work-up
32952279|NCT05608590|Active Comparator|Delayed HSG 6 months after completing fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) after a 6 months waiting period after completion of fertility work-up
32952280|NCT04393584|Experimental|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
32952281|NCT04393584|Active Comparator|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
32952282|NCT03005418|Experimental|Human Acellular Vessel (HAV)|Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, will be implanted with the Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
32952283|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
32952284|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
32952285|NCT03037632|Experimental|Communication Tool|
32952286|NCT03037632|No Intervention|No Communication Tool|
32952287|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
32952288|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
32952289|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
32952290|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
32952291|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
32952292|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
32952293|NCT02965950|Experimental|TP53 mutated, MBC, first line|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide first line metastatic disease
32952294|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
32952295|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
32952296|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
32952297|NCT04125108|Experimental|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
32952298|NCT04125108|No Intervention|control group|The control group was to participate in a 12-week conventional rehabilitation program.
33315549|NCT01269554||Adults with diarrhea in Finland|
33315550|NCT01269554||Adults without diarrhea in Bissau|
32807695|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
32807696|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
32807697|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
32807698|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
32807699|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
32807700|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
32807701|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
32807702|NCT00484354|Active Comparator|1|Bicarbonate administration
32807703|NCT00484354|Placebo Comparator|2|Normal saline administration
32807704|NCT00485836|Sham Comparator|Sham injection|
32807705|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
32807706|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
32807707|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
32807708|NCT04283188|Experimental|Adolescents with bipolar disorder|25 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
32807709|NCT04249024|Experimental|Laser treatment|Laser treatment with diode laser 970nm and settings 1.2W in intervals of max 20s, until satisfactory removal of diseased epithelium and granulation tissue.
32807710|NCT04249024|Active Comparator|Mucosal flap surgery|Conventional mucosal flap surgery of affected dental implant.
32807711|NCT04200508|Experimental|Intervention|Targeted gown and glove use for high risk care activities in high risk residents
32807712|NCT04200508|No Intervention|Baseline|Standard of Care
32807713|NCT00488488||A|
32807714|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
32807715|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
32807716|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
33315551|NCT01269554||Adults with diarrhea in Bissau|
32807717|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
32807718|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
32807719|NCT04149574|Experimental|Arm A: nivolumab + Bacillus Calmette-Guérin (BCG)|
32807720|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
32807721|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
32807722|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
32807723|NCT04126486|Other|Zio®XT Monitor Arm|
32807724|NCT04126486|No Intervention|Usual Care Arm|
32807725|NCT04059237|Experimental|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
32807726|NCT04126018||Mitral Valve Regurgitation|Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
32807727|NCT04126018||Aortic Valve Regurgitation|Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
32807728|NCT04126018||Aortic Stenosis|Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
32807729|NCT04126018||Patients referred for CRT Implantation|Patients who meet clinical guideline criteria for CRT implantation with EF < 40%
32807730|NCT04075539|Experimental|Home-based cycling program associated to usual care|
32807731|NCT04075539|Other|Outpatient physiotherapy|
32807732|NCT04015804|Other|Clinical database|
32807733|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
32807734|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
32807735|NCT00491374|Experimental|MFNS|
32807736|NCT00491374|Placebo Comparator|Placebo|
33315552|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
33315553|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
33315554|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
33315555|NCT01163006|Experimental|polydextrose|
32807737|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
32807738|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
32807739|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
32807740|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
33315556|NCT01163006|Experimental|soluble glucofibre|
32807741|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
32807742|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
32807743|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
32807744|NCT00539656|Experimental|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
32807745|NCT01433991|Experimental|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
32807746|NCT01433991|Experimental|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
32807747|NCT01433991|Experimental|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1*4 mg capsule + 2*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
32807748|NCT01433991|Experimental|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
32807749|NCT01433991|Experimental|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
32807750|NCT04057833|Experimental|E-CEL UVEC|"Patients will receive an injection of the Cell therapy vehicle into their supraspinatus muscle and tendon at the time of rotator cuff repair.~E-CEL UVEC cells suspended in autologous plasma and combined with thrombin at the implantation site (tendon delivery).~E-CEL UVEC cells suspended in 6.0% Dextran 40 and 10.0% human serum albumin (HSA) (infusion solution) (muscle delivery)."
32807751|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
32807752|NCT01433055|Active Comparator|Minocycline|
32807753|NCT01433055|Placebo Comparator|Sugar Pill|
32807754|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
32807755|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
32807756|NCT04075149|Experimental|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
32807757|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2~Carboplatin area under curve (AUC)2 (IV)~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
32807758|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
32807759|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
32807760|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
32807761|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
32807762|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
32807763|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
32807764|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
32807765|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
33315557|NCT01163006|Placebo Comparator|isocaloric dietary control|
33315558|NCT01163006|Placebo Comparator|full caloric control|
33315559|NCT01268462|Experimental|Heliox + PEP (Group 1)|
33315560|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
33315561|NCT01268462|Experimental|Heliox ( Group 3)|
33315562|NCT01268462|Active Comparator|Oxygen (Group 4)|
33315563|NCT01269632|Other|HIV infected|young adult infected by HIV
33315564|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
33315565|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
33315566|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
33315567|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
33315568|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
33315569|NCT01268618|Experimental|Probiotic|
33315570|NCT01268618|Placebo Comparator|Placebo|
33315571|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
33315572|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
33315573|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
33315574|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
33315575|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
33315576|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
33315577|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
33315578|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
33315579|NCT01167062|Placebo Comparator|Placebo|
33315580|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
33315581|NCT01268696||control group|healthy volunteers
33315582|NCT01268696||Metabolic group|Patients with metabolic syndrome
33315583|NCT01165190||Pioglitazone group|
33315584|NCT01280240|Active Comparator|Monofer 500 mg|
33315585|NCT01280240|Active Comparator|Monofer 250 mg|
33315586|NCT01163240||pediatric|
33315587|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
33315588|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
33315589|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
33315590|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
33315591|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
32807766|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
33315592|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
33315593|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
33315594|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
33315595|NCT01280396||SGAs|patients receiving SGAs
33315596|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
33315597|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
33315598|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
33315599|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
33315600|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
33315601|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
33315602|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
33315603|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
33315604|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
33315605|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
33315606|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
33315607|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
33099508|NCT04690608|Experimental|resistant diabetic macular edema and central retinal vein occlusion|"Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.~The study will be conducted from January 2021 to June 2021.~For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.~Cases with recent onset central retinal vein occlusion less than 2 months duration will be included"
33099509|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
32807767|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
32807768|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
32807769|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
33099510|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
33099511|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
33315608|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
33315609|NCT01269788|Active Comparator|pH positive-omeprazole|
32807770|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
32807771|NCT04408053|Experimental|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
33315610|NCT01269788|Placebo Comparator|pH positive-placebo|
32807772|NCT04408053|No Intervention|No fixation|
32807773|NCT01431963|Experimental|Lamotrigine|No comparison.
32807774|NCT01447407|Active Comparator|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
32807775|NCT01447407|Active Comparator|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
32807776|NCT01447407|Placebo Comparator|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
32807777|NCT01447407|Active Comparator|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
32807778|NCT04056819|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
32807779|NCT04055025|Other|Sleeve gastrectomy operated patients|Six test days in a randomized, patient-blinded, cross-over design
32807780|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
32807781|NCT04046523|Experimental|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
32807782|NCT04046523|Experimental|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
32807783|NCT04046523|Experimental|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
32807784|NCT04046445|Experimental|Cohort 1a|6 patients with stage IV CRC who failed SoC therapies
32807785|NCT04046445|Experimental|Cohort 1b|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
32807786|NCT04046445|Experimental|Cohort 2a|5 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
32807787|NCT04046445|Experimental|Cohort 2b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
32807788|NCT04046445|Experimental|Cohort 2c|19 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
32807789|NCT04046445|Experimental|Cohort 3|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
32807790|NCT04046445|Experimental|Cohort 4a|24 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
32807791|NCT04046445|Experimental|Cohort 4b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
32807792|NCT00540982|Experimental|Normal Liver Function|
32807793|NCT00540982|Experimental|Mild Liver Dysfunction|
32807794|NCT00540982|Experimental|Moderate Liver Dysfunction|
32807795|NCT00540982|Experimental|Severe Liver Dysfunction|
32807796|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
32807797|NCT00542620|Experimental|Mixed injection|
32807798|NCT00542620|Active Comparator|Separate injection|
32807799|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
32807800|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
32807801|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
32807802|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
32807803|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
32807804|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
32807805|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
32807806|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
32807807|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
32807808|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
32807809|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
32807810|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
32807811|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
32807812|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
32807813|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
32807814|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
32807815|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
32807816|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
32807817|NCT03837496|Experimental|STRIDE Run-In|"Stride is delivered as a Five weekly one-hour virtual (videophone) or in-person sessions in small groups with a trained clinician~Two 15-minute check-in phone calls later in the study~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment and 3-months post- enrollment"
32807818|NCT03837496|Experimental|STRIDE|"Stride is delivered as six weekly one-hour virtual (videophone) sessions in small groups with a trained clinician (or individually, in the rare instance in which scheduling doesn't allow for groups and the participant is approaching the 12-week assessment window)~Two 15-minute check-in phone calls later in the study~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment, 12-weeks, and 24-weeks post-enrollment"
32807819|NCT03837496|Active Comparator|Medication Monitoring Control|"Medication monitoring plus standard care~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment, 12-weeks and 24-weeks post-enrollment"
32807820|NCT04750018||COVID-19 2019|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
32807821|NCT04750018||COVID-19 2020|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
32807822|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
32807823|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
32807824|NCT04750174|Active Comparator|Kinesiotape Group|In active group, KT was applied with stretching to the suprahyoid muscles with right method.
32807825|NCT04750174|Sham Comparator|Sham Kinesiotape Group|In sham group, KT was applied without stretching to the suprahyoid region and not including the origins of mylohyoid and digastric muscles
32807826|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
32807827|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
32807828|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
32807829|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
32807830|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
32807831|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
32807832|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
32807833|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
32807834|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
32807835|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
32807836|NCT04749706|Active Comparator|Normal weight|the normal weight women will receive the 12-week physical activity intervention and serve as a control group.
32807837|NCT04749706|Experimental|constitutionally lean women - Physical training only|women will receive the 12-week physical activity intervention
32807838|NCT04749706|Experimental|constitutionally lean women - Physical training + proteins|women will receive the 12-week physical activity intervention in addition to a protein supplementation
32807839|NCT04749472|Experimental|Study Group|Participants received intervention.
32807840|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
32807841|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
32807842|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
32807843|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
32807844|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
32807845|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
32807846|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
32807847|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
32807848|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
32807849|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
32807850|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
32807851|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
32807852|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
32807853|NCT00499408|Experimental|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
32807854|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
32807855|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
32807856|NCT03021928|Experimental|96 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 96 hours correlates to starting treatment on Day 4, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
32807857|NCT03021928|Experimental|132 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 96 hours correlates to starting treatment on Day 4, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
32807858|NCT03021928|Experimental|228 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 96 hours correlates to starting treatment on Day 4, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
32807859|NCT03021928|Experimental|324 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 96 hours correlates to starting treatment on Day 4, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
32807860|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
32807861|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
33315611|NCT01269788|Active Comparator|pH positive-fluoxetine|
33315612|NCT01269788|Active Comparator|pH negative-omeprazole|
33315613|NCT01269788|Active Comparator|pH negative-fluoxetine|
33315614|NCT01269788|Placebo Comparator|pH negative-placebo|
32807862|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
33315615|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
33315616|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
33315617|NCT01280708||Capture data|
32831141|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
33315618|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
33315619|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
33315620|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
33315621|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
33315622|NCT01280786|Experimental|Elesclomol Sodium|
33315623|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
33315624|NCT01163708|Experimental|Prophecy and Navigation validation|
33315625|NCT01280864||Interstitial Cystitis Alone|
33315626|NCT01280864||Irritable Bowel Syndrome Alone|
33315627|NCT01280864||Healthy Controls|
33315628|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
33315629|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
33315630|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
33315631|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
33315632|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
33315633|NCT05388422|Experimental|Severe cerebral palsy (GMFCS IV and V)|This study included patients with severe cerebral palsy (GMFCS IV and V)
33315634|NCT05387642|Experimental|Double-blind Sequence 1|Double-blind treatment sequence of 10 mg, 20 mg, and placebo in the morning
33315635|NCT05387642|Experimental|Double-blind Sequence 2|Double-blind treatment sequence of 20 mg, placebo, and 10 mg in the morning
33315636|NCT05387642|Experimental|Double-blind Sequence 3|Double-blind treatment sequence of placebo, 10 mg, and 20 mg in the morning
33315637|NCT05387642|Experimental|Open-label Period PRAX-114|Open-label extension period - 10 mg or 20 mg PRAX-114 once daily in the morning for 28 days
33315638|NCT05382026|Experimental|1% chocolate milk|250 ml of 1% chocolate milk consumed immediately after resistance training sessions + 250 ml of chocolate milk consumed 1 hour after resistance training sessions
33315639|NCT05382026|Active Comparator|Pea-based beverage|250 ml of pea beverage consumed immediately after resistance training sessions + 250 ml of pea beverage consumed 1 hour after resistance training sessions
33315640|NCT05382026|Placebo Comparator|Placebo: Low protein plant-based beverage|250 ml of placebo beverage consumed immediately after resistance training sessions + 250 ml of placebo beverage consumed 1 hour after resistance training sessions
33315641|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
33315642|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
33315643|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
33315644|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
33315645|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
33315646|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
33315647|NCT03871400|Other|NanoMetalene/PEEK|
33315648|NCT03871400|Other|NanoMetalene/Allograft|
33315649|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
33315650|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
33315651|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
33315652|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
33315653|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
33315654|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
33315655|NCT00313781|Active Comparator|B|
33315656|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
33315657|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
33315658|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.~Injected at the start of every Mohs excision stage"
33315659|NCT01281332|Active Comparator|Menopod device|Menopod®
33315660|NCT01281332|Sham Comparator|Sham device|Inactive device.
33315661|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
33315662|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
33315663|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
33315664|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
33315665|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
33315666|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
33315667|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
32952299|NCT05608356|Experimental|intervention group|"Intervention group subjects will receive injectable platelet rich fibrin (i-prf) . The (i-prf) will be injected in the periodontal ligament of maxillary anterior teeth during en masse retraction.The injection sites will be the sites of bone compression to target the surfaces of the bone where osteoclastogenesis and bone resorption occurs during en masse retraction.~Considering that the obtained (i-prf) after centrifuging would be 4 ml, 1 ml will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. The study group will receive i-PRF intraligamentally in the periodontal ligament space of the maxillary six anterior teeth three times as follow, just before anterior teeth retraction, and after 21 days of the retraction, and after 42 days of the retraction. Before each time of injection, an anesthetic solution will be administered for pain control."
32952300|NCT05608356|Sham Comparator|control group|Subjects in the control group will only receive sham (placebo) injection three successive times with and interval of 21days between each injection, similar to the timepoints of (i-prf) injection in the intervention group. Also the sites of injection will be similar to the sites of injection of the intervention group; 1 ml of the placebo agent will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. An anesthetic solution will be administered for pain control before the administration of the sham injections.
32952301|NCT05608200|Experimental|Len-Sin|Lenvatinib Plus Sintilimab
32952302|NCT05608200|Active Comparator|Len|Lenvatinib alone
32952303|NCT03142308||Surgeons|Young surgeons in all surgical specialities
33315668|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
33315669|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
33315670|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
32952304|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
32952305|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
32952306|NCT04394364||BIS monitor group|Patients under monitoring of BIS
32952307|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
32952308|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
32952309|NCT05608122||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
32952310|NCT05608122||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
32952311|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
32952312|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
32952313|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
32952314|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
32952315|NCT05604300|Active Comparator|Vitamin E incorporated oat|Oral vitamin E incorporated oat supplementation
32952316|NCT05604300|Placebo Comparator|Placebo|Oral oat supplementation
32952317|NCT05604300|No Intervention|Control|Control
32952318|NCT02923206|Experimental|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
33315671|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
33315672|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
33099512|NCT04690881|Experimental|Psychodrama group psychoteraphy|Psychodrama is not just a training but also a treatment technique where an individual is offered a potential cure, as well as improvement and awareness for his or her ongoing relationships within the group. In psychodrama, the participant is given an opportunity to re-experience of earlier incidents for a second time so that the person could be free from the impacts of that earlier experience. All of this happens simultaneously with joy, tears, laughter, and depth of feeling.Prenatal psychodrama is held by psychodrama psychotherapists in individual and group therapy sessions. In these sessions the pregnant mother encounters herself, her baby, her partner, her mother, her fear of childbirth and the moment of birth; she may act as protagonist in some scenes and in this way she closes any unfinished business from the past and rehearses the future in a safe therapeutic environment. In this study, 90-minute psychodrama practice was conducted in addition to pregnancy training for 6 weeks.
33099513|NCT04690881|No Intervention|Childbirth-antenatal education|Childbirth is one of the most significant events in a parent's life and has the potential to be an exhilarating and fulfilling experience for some or a frightening anxiety provoking experience for others. Structured antenatal classes have developed worldwide as traditional methods of information sharing have declined and expectant parents look for strategies to prepare for childbirth. In this study, routine pregnancy training was conducted for 6 weeks.
33099514|NCT00519233|Experimental|1.AGS-1C4D4|
33099515|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
33099516|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
33099517|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
33099518|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
33099519|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
33099520|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
33099521|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
33099522|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
33099523|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
33099524|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
33099525|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
33099526|NCT04690647|Placebo Comparator|Opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
33099527|NCT04690647|Experimental|Regional anaesthesia, opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
33099528|NCT04690647|Experimental|Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.
32807863|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
32807864|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
32807865|NCT02888860||Group 1|Patients with candidemia
32807866|NCT02888860||Group 2|Patients without colonization during follow up
32807867|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
32807868|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
32807869|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
32807870|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
32807871|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
32807872|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
32807873|NCT01430559|Other|Meloxicam|
32807874|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
33099529|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
33099530|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
33099531|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
33099532|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
33099533|NCT00519350||I|Liver surgery
33099534|NCT00519350||II|Colon surgery
33099535|NCT00519350||III|Femur Fracture
33099536|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
33099537|NCT04974684|Experimental|Interventional group|
33099538|NCT04974684|No Intervention|Control group|
33099539|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
33099540|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
33099541|NCT00520169|Active Comparator|A|oral ketamine
33099542|NCT00520169|Experimental|B|intranasal ketamine
33099543|NCT00520169|Active Comparator|C|intravenous ketamine
33099544|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
33099545|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
33099546|NCT04932681||Qualitative group|Interview about the use of Complementary and Alternative Medecine
33099547|NCT04932681||Quantitative group|Questionnaire about the use of Complementary and Alternative Medecine
33099548|NCT00519545|Experimental|1|scripted prayer group (intervention group)
33099549|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
32807875|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
32952319|NCT02923206|Experimental|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
32952320|NCT02923206|Experimental|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
32952321|NCT02921256|Active Comparator|Arm I (mFOLFOX6, RT, capecitabine)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
32952322|NCT02921256|Experimental|Arm II (mFOLFOX6, RT, capecitabine, veliparib)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
32952323|NCT02921256|Experimental|Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab)|ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32952324|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
32952325|NCT03827928|No Intervention|Wait list|A wait list control period.
32952326|NCT04392414|Experimental|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
33099550|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
33099551|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
33099552|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
33099553|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
33099554|NCT05044065|Experimental|Exercise group|The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress, and protein supplementation to ensure adequate protein intake.
33099555|NCT05044065|No Intervention|Usual care|The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.
33099556|NCT00520325|Other|0.5 mg/kg|
33099557|NCT00520325|Other|1.0 mg/kg|
33099558|NCT04925466|Experimental|Treatment with CPAP at 10cmH2O|Patients with OSA will be treated with CPAP at 10cmH2O during sleep.
33099559|NCT04925466|Experimental|Treatment with CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
33099560|NCT00520364||History of chemotherapy|IVF after chemotherapy
33099561|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
33099562|NCT04894656|Experimental|Gastroparesis patients|
33099563|NCT04894656|Active Comparator|Healthy volunteers|
33099564|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
33099565|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
33099566|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
33099567|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
33099568|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
33099569|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
33099570|NCT04880694|Experimental|Cohort 1: STC3141 58.3mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72 hours) N=10
33099571|NCT04880694|Experimental|Cohort 2: STC3141 87.5mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72 hours) N=10
33099572|NCT04880694|No Intervention|Cohort 3: Comparator|Only to receive appropriate standard of care N=5
33099573|NCT00520442|Experimental|Ibuprofen|
33099574|NCT00520442|Active Comparator|acetamin w codeine|
33099575|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
33099576|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
33099577|NCT04870320|Experimental|Arm I (Endeavor)|Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
33099578|NCT04870320|Active Comparator|Arm II (Words!)|Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
33099579|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
33099580|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
33315673|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
32807876|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
33099581|NCT02948738|Experimental|Interactive Education|Interactive asthma education
33099582|NCT02948738|Active Comparator|Standard Education|Standard asthma education
33099583|NCT03457974|Experimental|congenital heart disease|42 patients
33099584|NCT03457974|Other|helathy children|42 children
33099585|NCT02938572|Experimental|NNC0143-0406|
33099586|NCT02938572|Active Comparator|Insulin aspart|
33099587|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:~diarrhea~nocturnal diarrhea~body weight loss (>5%)~abdominal pain~perianal lesions."
33099588|NCT02940093||Stem cell transplant recipient|
33099589|NCT02940093||Stem cell donor|
33099590|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
33315674|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
33315675|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
32807877|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
32807878|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
32807879|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
32807880|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
32807881|NCT01409811|Experimental|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.~zoledronic acid: Given IV~laboratory biomarker analysis: Correlative studies~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
33099591|NCT04691193||study and control group|The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.
33099592|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
33099593|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
33099594|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
33099595|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
33099596|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
33099597|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
33315676|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
33315677|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
33099598|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
33099599|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
33099600|NCT04866303|Experimental|Active delivery|For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
33099601|NCT04866303|Experimental|Passive delivery|Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.
33099602|NCT04694417|Experimental|Compression stocking|Compression stockings are mainly used for the prevention and reduction of lower limb oedema or venous thrombosis. There are three compression classes used in health care. The compression stocking group of the study will receive CE-marked stockings within the compression class of 1 (25-40 mmHg compression). The correct size for the compression stockings will be defined by the reported circumference of the participant's ankle and calf. The participants will be given instructions to put the stockings on immediately after getting out of bed in the morning and to take them off before going to bed in the evening for the last four weeks of the study. Stockings within the mild compression class have no harmful effects on individuals when the exclusion criteria are considered. The participants will be instructed to communicate with a dedicated research assistant via e-mail or phone in case of any problems or questions.
33099603|NCT04694417|Active Comparator|Magnesium|"Magnesium is a mineral substance which regulates many biochemical reactions in the body, for example protein synthesis and the function of the muscles and nerves. It has a significant role in controlling blood sugar, blood pressure, energy generation and the formation of the bones. The recommended dietary allowance for magnesium is 420 mg for males and 320 mg for females over 50 years old. Dark green vegetables, leguminous plants, nuts, seeds and wholegrains are good sources of magnesium (11,12).~In the average Finnish diet, the recommendation is usually exceeded, and excessive amounts of magnesium in the body are extremely rare. The magnesium arm of the study will take oral tablets containing 620 mg of magnesium hydrochloride daily for the last four weeks of the study, which is equivalent to 250 mg of pure magnesium per day. The magnesium tablets for this study were manufactured and analysed by the Pharmia pharmaceutical company in Finland."
33099604|NCT04694417|Placebo Comparator|Placebo|The placebo tablets will consist of microcrystalline cellulose, magnesium stearate (anti-caking agent) and silicon dioxide. The placebo tablets were manufactured and analysed by the Pharmia pharmaceutical company in Finland. The placebo arm will receive placebo tablets to be taken daily for the last four weeks of the study. The participants will not know whether they are randomised into the magnesium arm or the placebo arm. The packaging and the appearance of the placebo and magnesium tablets are identical.
33099605|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
33099606|NCT04864158|Experimental|RSA-group|Surgery
33099607|NCT04864158|Experimental|Exercise-group|Exercise
33099608|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
33099609|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
33099610|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
33099611|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
33099612|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
33099613|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
32807882|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
33099614|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
33099615|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
33099616|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
33099617|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
33099618|NCT00521495|Active Comparator|C|
33099619|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
33099620|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
33099621|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
33099622|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
33315678|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
32807883|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
32807884|NCT00501592|Active Comparator|25 mg INT-747|
32807885|NCT00501592|Active Comparator|50 mg INT-747|
33315679|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
33315680|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
33315681|NCT01165580|Experimental|Single Arm|
33315682|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
33315683|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
32807886|NCT00501592|Placebo Comparator|Placebo|
33315684|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
33315685|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
33315686|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
33315687|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
32807887|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
32807888|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
32807889|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
32807890|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
32807891|NCT03191266|Active Comparator|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
32807892|NCT03191266|Sham Comparator|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
32807893|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
32807894|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
32807895|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
32807896|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
32807897|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
32952327|NCT04392414|Placebo Comparator|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
32807898|NCT00545974|Experimental|1|Memantine 10mg BID
32807899|NCT00545974|Placebo Comparator|2|Placebo condition
32807900|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
32807901|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
32807902|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
32807903|NCT00548470|Experimental|varenicline|open label varenicline 2mg/day
32807904|NCT02732704|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
33315688|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
32807905|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
32807906|NCT02675452|Experimental|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
32807907|NCT02675452|Experimental|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
32807908|NCT02675452|Experimental|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
32807909|NCT02675452|Experimental|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
33315689|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
33315690|NCT01586858||RAVE subjects|
33315691|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
33315692|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
33318654|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
32807910|NCT02675452|Experimental|AMG 176 - Part 3d|Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.
32807911|NCT02675452|Experimental|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
32807912|NCT02675452|Experimental|AMG 176 - Part 5|Part 5 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion at the maximum tolerated combination dose from Part 4, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
32807913|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
32807914|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
32807915|NCT00508300|Other|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
32807916|NCT00508300|Other|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
32807917|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy or stenting (endovascular) for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy or stenting due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
32807918|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
32807919|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
32807920|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
32807921|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule or equivalent age-appropriate oral formulation, daily dosage
32807922|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
32807923|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
32807924|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
32807925|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
32807926|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
32807927|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
32807928|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
32807929|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
32807930|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
32807931|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
32807932|NCT00557284|Experimental|1|Montelukast
32807933|NCT00557284|Placebo Comparator|2|
32807934|NCT00551746|Active Comparator|1|Grape Juice
32807935|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
32807936|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
32807937|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
32807938|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
32807939|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
32807940|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
32807941|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
32807942|NCT00558844|Active Comparator|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
32807943|NCT00558844|Placebo Comparator|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
32807944|NCT00558844|Active Comparator|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
32807945|NCT00558844|Active Comparator|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
32807946|NCT00558844|Placebo Comparator|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
32807947|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
32807948|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
32807949|NCT01445535|Experimental|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
32807950|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
32807951|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
32807952|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
32807953|NCT04072887|Experimental|QBW251 450 mg|QBW251 was orally administered 450 mg b.i.d for 24 weeks
32807954|NCT04072887|Experimental|QBW251 300 mg|QBW251 was orally administered 300 mg b.i.d for 24 weeks
32807955|NCT04072887|Experimental|QBW251 150 mg|QBW251 was orally administered 150 mg b.i.d for 24 weeks
32807956|NCT04072887|Experimental|QBW251 75 mg|QBW251 was orally administered 75 mg b.i.d for 24 weeks
32807957|NCT04072887|Experimental|QBW251 25 mg|QBW251 was orally administered 25 mg b.i.d for 24 weeks
32807958|NCT04072887|Placebo Comparator|Placebo|Placebo was orally administered b.i.d for 24 weeks
32807959|NCT01409031|Experimental|Intravenous Sildenafil|
32807960|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
32807961|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
32807962|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
32807963|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
32807964|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
32807965|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
32807966|NCT01408641|Experimental|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
32807967|NCT01408641|Placebo Comparator|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
32807968|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
32807969|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
32807970|NCT01428453|Experimental|250mg rilapladib|Experimental drug
32807971|NCT01428453|Placebo Comparator|placebo|Placebo comparator
32807972|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
32807973|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
32807974|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
32807975|NCT04069923|Experimental|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
32807976|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
32807977|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
32807978|NCT04407975|Experimental|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
32807979|NCT04407975|Placebo Comparator|Placebo|Patients will receive an equivalent volume of normal saline
32807980|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
32807981|NCT04069767|Experimental|ICoreDIST|The intervention starts with an assessment by the physiotherapist to identify the patient's movement problems in order to choose among the 48 exercises in the intervention. Each session lasts for 60 minutes + exercises 5-10 minutes outside of therapy and is performed 5-6 days/per week in the rehabilitation units, and 3 sessions/week + home exercises 30 minutes 3 days per week in home based or outpatient treatment during the 12 weeks period.To allow for individualisation, each exercise contains five levels of difficulty. All exercises demand enhancement of dynamic trunk stability and functional movements.
32807982|NCT04069767|Active Comparator|Standard Care|Consists of standard inpatient rehabilitation, home-based and outpatient-based physiotherapy with the same dose as the intervention group.
32807983|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
32807984|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
32807985|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
32807986|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
32807987|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
32807988|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
32807989|NCT00513370|Experimental|1|
32807990|NCT00559468|Experimental|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
32807991|NCT00559468|Experimental|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
32807992|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
32807993|NCT00560560|Experimental|1|Single arm study
32807994|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
32807995|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
32807996|NCT00514852|Active Comparator|2|Carboxymethylcellulose
32807997|NCT00555880|Experimental|1|
32807998|NCT00555880|Placebo Comparator|2|
32807999|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
32808000|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
32808001|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
32808002|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
32808003|NCT05560828||Zio Cohort|Patients who have been prescribed Zio
32808004|NCT05560828||Holter Cohort|Patients who have been prescribed Holter
32808005|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
32808006|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
32808007|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
32808008|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
32808009|NCT05622682||Children, adolescents, and young adults who recently completed ALL treatment|This cohort of participants who recently completed leukemia therapy will be assessed for infection incidence during the year following treatment and give blood samples to be measured for antibodies to vaccine-preventable diseases. A small subset will also have their blood samples tested for B and T cell recovery.
32808010|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
32808011|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
32808012|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
32808013|NCT05560672|Experimental|Experimental group|Cord blood mononuclear cell transplantation is performed at the same time as medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, regulation of intestinal flora, etc.
32808014|NCT05560672|No Intervention|Control group|Medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, and regulation of intestinal flora are given.
32808015|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
32808016|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
32808017|NCT05560516|Experimental|Patients with chemotherapy-induced peripheral neuropathy who receive Qutenza|
32808018|NCT05560516|Active Comparator|Patients with chemotherapy-induced peripheral neuropathy who receive Duloxetine|
32808019|NCT05622526|Experimental|Group 1 or Experimental group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months (4 maintenance doses).
32808020|NCT05622526|Placebo Comparator|Group 2 or Control group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months for 12 months (4 maintenance doses)
32808021|NCT05560438|Experimental|Technorehab|Rehabilitation using Tyromotion Amadeo and Armeo Senso
32808022|NCT05622448|Active Comparator|RPD with metallic framework|removable partial denture with cobalt chromium framework
32808023|NCT05622448|Experimental|RPD with PEEK framework|removable partial denture with poly ether ether ketone framework
32808024|NCT05559268|Experimental|Denosumab|
32808025|NCT05559268|Placebo Comparator|Placebo|
32952328|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
32808026|NCT02338960|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
32808027|NCT02338960|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
32808028|NCT05622214|Experimental|Plant based nutrition|Plant based nutritional formula based on almond and buckwheat
32808029|NCT05621980|Experimental|FES + AVK group|This group will use the AVK system in combination with targeted FES to provide training of independent movement of each digit of the paretic hand. This training has two modes: Key Combination and Song. In the Key Combination mode, the subject will attempt to play the discrete key or key combinations specified on the computer screen to practice difficult movements and combinations. In the Song mode, sequential, rhythmic movements will be practiced as the participant is guided to play a series of keys, specified as falling keys, constituting five-note songs. Key Combination will be employed at the beginning and end of each training session to practice discrete movements that proved troubling during the current or previous session. Most of the session will be spent in the Song mode to emphasize the transitions from one movement to the next. In both modes the AVK system will trigger FES for the finger matching the desired key and signal the PneuGlove to resist movement of other digits.
32808030|NCT05621980|Active Comparator|OT Group|An occupational therapist will provide therapy of matching duration to the OT subject group. This will consist of 10 minutes of stretching of the finger muscles, particularly of the extrinsic finger flexors. This stretching will be followed by two 20-minute sessions of therapy focused on active task practice, object manipulation, and individuated movement of the digits. The Canadian Occupational Performance Measure (COPM) will be administered to identify goals that incorporate dexterous use of the paretic hand. Part of each training session will be used to practice these tasks, while the remainder will be used to practice component skills. Active practice will be followed by a final 10 minutes of stretching of muscles of the digits.
32808031|NCT05621902|Experimental|Weekly symptom monitoring|Web-based weekly symptom monitoring in addition to standard follow-up
32808032|NCT05621902|No Intervention|Standard care|Standard follow-up according to guidelines
32808033|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
32808034|NCT01441635|Experimental|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
32808035|NCT01441635|Experimental|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
32808036|NCT01441635|Placebo Comparator|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
32808037|NCT01441635|Experimental|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
32808038|NCT01441635|Placebo Comparator|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
32808039|NCT01441635|Placebo Comparator|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
32808040|NCT01441635|Experimental|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
32808041|NCT01441635|Experimental|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
32808042|NCT01441635|Experimental|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
32808043|NCT01441635|Experimental|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
32808044|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
32808045|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
32808046|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
32808047|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
32808048|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
32808049|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
32808050|NCT01920061|Experimental|Arm A|
32808051|NCT01920061|Experimental|Arm B|
32808052|NCT01920061|Experimental|Arm C|
32808053|NCT01920061|Experimental|Expansion Arm 1|
32808054|NCT01920061|Experimental|Expansion Arm 2|
32808055|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
32808056|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
32808057|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
32808058|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
32808059|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
32808060|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
32808061|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808062|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808063|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808064|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808065|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808066|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
32808067|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
32808068|NCT04415983|Experimental|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
32808069|NCT04415983|Active Comparator|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
32808070|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
32808071|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
32808072|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
32808073|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
32808074|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
32808075|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
32808076|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: None|Comparator arm first phase: baseline community-based HIV and multi-disease testing; ART by country standard of care
32808077|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
32808078|NCT04415593|Experimental|high dose of peanut|20 patients
32808079|NCT04415593|Active Comparator|low dose of peanuts|20 patients
32808080|NCT01393899|Placebo Comparator|Placebo BID|
32808081|NCT01393899|Experimental|5mg BID|
32808082|NCT01393899|Experimental|10mg BID|
33404855|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
32808085|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
32808086|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
32808087|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
32808088|NCT01405911|Placebo Comparator|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
33099623|NCT04811196|Experimental|Metronomic dosing|"This Arm is an open-label, non-randomized, phase 1 study of metronomic dosing of selinexor in patients with locally advanced or metastatic MPNST, ESS, LMS. Up to seven dose levels of Selinexor will be investigated.~Patients will undergo 3+3 based dose escalation to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Selinexor.~Escalating doses of selinexor will be given starting with 2.5 mg (taken orally 4 days in a row followed by 3 days break from treatment, repeating this weekly as part of a 28-day cycle). The first dose for the first 2 patients at each dose level will be staggered by 7 days. Minimum number of patients treated in this trial arm is 18 patients, and maximum 36 patients.~Schedule:~Selinexor flat dosing with dose levels (DLs) of 2.5mg (DL1), 5mg (DL2), 7.5mg (DL3), 10mg (DL4), 12.5mg (DL5), 15mg (DL6), 17.5mg (DL7). A DL-1 (1.25 mg) is also incorporated."
33099624|NCT04811196|Experimental|Split dosing|The second arm of the study is an open-label, non randomized, phase 1b study of selinexor in patients with any histological subtype of STS administered orally one day per week, 40mg in the morning, 20mg in the afternoon and 20mg at night as part of a 28 day cycle. Twenty patients will be accrued to this arm.
33099625|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
33099626|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
33099627|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
33099628|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
33099629|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
33099630|NCT00521534||A|CRT programmed to VDD pacing mode
33099631|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
33099632|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
33099633|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
33099634|NCT00520949|Experimental|Quadruple Therapy|
33099635|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:~Receive a personalized physical exercise program~Receive nutritional counselling with whey protein isolate powder~Receive relaxation techniques"
32808089|NCT01405911|Experimental|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
32808090|NCT01405911|Experimental|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
32808091|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
32808092|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
32808093|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
32808094|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
32808095|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
32808096|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
32808097|NCT03025503|Experimental|nipple stimulation|
32808098|NCT03025503|No Intervention|no intervention|
32808099|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
32808100|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
32808101|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
32808102|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
32808103|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
32808104|NCT01424397|Experimental|SB-705498|Experimental
32808105|NCT01424397|Active Comparator|Fluticasone Propionate|Active Comparator
32808106|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
32808107|NCT01424397|Experimental|SB-705498+FP|Experimental
32808108|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
32808109|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
32808110|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
32808111|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
32808112|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
32808113|NCT01405053|Active Comparator|Rufinamide|
32808114|NCT01405053|Active Comparator|Any other approved AED|
32808115|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
32808116|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
32808117|NCT01423617|Active Comparator|Zenoctil|
32808118|NCT01423617|Placebo Comparator|Placebo|
32808119|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
32808120|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
32808121|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
32808122|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
32808123|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
32808124|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
32808125|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
32808126|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
32808127|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
32808128|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
32808129|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
32808130|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
32808131|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
32808132|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
32808133|NCT01391793|Active Comparator|Adjuvant dexamethasone|
32808134|NCT01391793|Placebo Comparator|Placebo|
32808135|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
32808136|NCT04037943|Experimental|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
32808137|NCT04037943|Experimental|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
32808138|NCT04037943|No Intervention|Control group|Control group will received non-edible gifts during the study period of 6 months.
32808139|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
32808140|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
32808141|NCT04558736|Experimental|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.~Cells for infusion are prepared using the CliniMACS System."
32808142|NCT01422213|Placebo Comparator|Placebo|
32808143|NCT01422213|Experimental|Vortioxetine 10 mg|
32808144|NCT01422213|Experimental|Vortioxetine 20 mg|
32808145|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
32808146|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
32808147|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
32808148|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
32808149|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
32808150|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
32808151|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
32808152|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
32808153|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
32808154|NCT01421667|Experimental|Brentuximab vedotin|
32808155|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
32808156|NCT01891669|Experimental|Part 1|
32808157|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
32808158|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
32952329|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
32952330|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
32952331|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
32952332|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
32952333|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
32952334|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
32952335|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
32952336|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
32952337|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32952338|NCT04274244|Experimental|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.~Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth >5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
32952339|NCT04274244|Active Comparator|Enamel Matrix Proteins|"SCALE AND ROOT PLANING~REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
32952340|NCT04274244|No Intervention|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
32952341|NCT04274322||Cohort 1|High NUTRIC score
32952342|NCT04274322||Cohort 2|low NUTRIC score
32952343|NCT04273698|Experimental|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
32952344|NCT04274166|Experimental|Experimental|2 s.c. secukinumab 150 mg injections
32952345|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
32952346|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
32952347|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
32952348|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
32952349|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
32952350|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
32952351|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
32952352|NCT03821922||Control|Those healthy pregnant women
32952353|NCT05607732|Experimental|MyCog Paradigm|The MyCog paradigm establishes a protocol for implementing our self-administered assessment in the clinic whenever a patient or involved family member reports a concern. The MyCog test can be completed either in the exam room or the waiting room. The MyCog app, on an iPad, can be readily linked to the electronic health record, so once the two tests are completed, results are securely transmitted and will populate within discrete, fields that can be queried found in the patient record; specifically: 1) in a screening tab, under 'cognitive abilities', 2) a flow sheet to capture trend with future repeated tests - informing physicians of a patient's relative vs. normative cognitive decline. Both a binary, objective classification of 'impairment detected or suspected' or 'no impairment detected' will populate in the record, as well as a summary score to further guide the clinician by clarifying the extent to which a patient's performance falls outside a normal threshold.
32952354|NCT05607732|No Intervention|Usual Care Arm|At Oak Street Health, cognitive assessments included when concerns are reported by patients or family members, if a clinician suspects a concern, or during Annual Wellness Visits (AWVs) are limited to the Mini-Cog©, and are variably administered, particularly outside of AWVs. Oak Street practices vary by clinician in terms of making referrals, how results are documented, what diagnosis code, placement in problem list or visit diagnosis, and any follow-up plans. While we will not make any explicit recommendations to usual care practices regarding their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to a data field that can be queried in the EHR, and 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will be provided to each clinical leadership.
32952355|NCT02959086||1|Patients were diagnosed since January 2002.
32952356|NCT05606952|Active Comparator|Group (C)|patients with BMI less than 35
32952357|NCT05606952|Active Comparator|Group (O)|patients with BMI more than 35
32952358|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.~DCS = d-cycloserine~Dosage: 100mg~Dosage form: Pill, administered orally~Frequency: Daily for four weeks"
32952359|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
32952360|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
32952361|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
32952362|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
32952363|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
32952364|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
32952365|NCT05603988|Placebo Comparator|Placebo group|• Mock laser application (Placebo group): The fiber optic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated
32952366|NCT05603988|Other|Diode Laser group|Intracanal Diode laser application
32952367|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
32952368|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
32952369|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
32952370|NCT02956590|Active Comparator|Pitavastatin|Study Drug
32952371|NCT02956590|Placebo Comparator|Placebo|Placebo
32952372|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
32952373|NCT02675244|Active Comparator|MVS Alone|Participants will undergo mitral valve surgery alone.
32952374|NCT02675244|Active Comparator|MVS + TV Annuloplasty|Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
32952375|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
32952376|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
32952377|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
32952378|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
32952379|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
32952380|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
32952381|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
32952382|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
32952383|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
32952384|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
32952385|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
32952386|NCT01453842|Experimental|Diet oil|
32952387|NCT01453842|Active Comparator|Olive oil|
32952388|NCT01453842|Placebo Comparator|Carrot|
32952389|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
32952390|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
32952391|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
32952392|NCT04392648|Experimental|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
32952393|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
33099636|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
33099637|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
33099638|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
32808159|NCT04612231|Active Comparator|T-STEP Intervention|The T-STEP is a comprehensive 12-week transition program that will be delivered in a community college setting. The curriculum includes 36 hours of group-based instruction delivered within a traditional school academic semester (i.e., 24 ninety-minute classes across 12 weeks). Students also participate in a weekly community-based internship to practice the skills learned in the intervention group (2 hours per week for 12 weeks). In addition, students participate in 12 hours of manualized individual counseling services that are traditionally available on a college campus (e.g., job exploration/career counseling, academic counseling, and self-advocacy counseling).
32808160|NCT04612231|Active Comparator|Counseling Only Intervention|Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
32808161|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
32808162|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
32808163|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
32808164|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
32808165|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
32808166|NCT04035447|Experimental|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention provides systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive defusion, relaxation training) delivered over the course of 8 sessions (12 therapy hours). By employing these strategies, participants learn to adjust their behaviors and emotions as well as interact differently with their thoughts in the service of better managing symptoms.
32808167|NCT04035447|Active Comparator|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
32808168|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
32808169|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
32808170|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
32808171|NCT04033575|Sham Comparator|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
32808172|NCT04033575|Active Comparator|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
32808173|NCT04767009|Experimental|SBRT for oligoprogressive NSCLC|
32808174|NCT04767087|Active Comparator|Honey and Nigella sativa Arm|0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
32808175|NCT04767087|Placebo Comparator|Placebo Arm|empty capsule with sugar water
32808176|NCT03842085|Experimental|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
32808177|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~Visit 1 (Baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
32808178|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
32808179|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
32808180|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
32808181|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
32808182|NCT04016415|Experimental|Mindfulness Based Stress Reduction|
32808183|NCT04016415|Active Comparator|Stress Management Education|
32808184|NCT03025347|Experimental|Control|Experimental day where participants rest.
32808185|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
32808186|NCT05365815|Experimental|MGMC Intervention Group|"In the MGMC (intervention) group, pregnant women will participate in group prenatal care and have ~2-hour visits with the same two co-facilitators, a Black midwife and a Black care coordinator, along with 8-12 other Black women at a similar stage of pregnancy, for all prenatal and one postnatal care visits.~The care coordinator will proactively engage with women throughout pregnancy and up to 12 months postpartum. The care coordinator helps women make appointments, sends reminders, and follows-up to ensure care was received, understood, and was appropriate. In the 3rd trimester, women in MGMC will be introduced to a community-based postpartum doula. The doula will make home visits once before birth and within the first 2 weeks postpartum; they will have approximately 50 contact hours available for 12 months postpartum for primarily in-person support, but they will be available by phone and text."
33099639|NCT02938260||Diltiazem|
33099640|NCT02938260||Metoprolol|
33099641|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
33099642|NCT00520988|No Intervention|2|Usual care
33315693|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
33318655|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
32952394|NCT04392648|Experimental|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
32952395|NCT04392648|Experimental|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
32952396|NCT04392648|Experimental|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
32952397|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
32952398|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
32952399|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
32952400|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
32952401|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
32952402|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
32952403|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
32952404|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
32952405|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
32952406|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
32952407|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
32952408|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
32952409|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
32952410|NCT03123198|Experimental|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
32952411|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
32952412|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
32952413|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
32952414|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
32952415|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
32952416|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 6mg total
33099643|NCT04781244|Active Comparator|EndWarts® FREEZE in Soft keratin|EndWarts® FREEZE were treated to 11 patients with wart at soft keratin
33318656|NCT03953352|Other|Radiotherapy treatment|
33318657|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
33318658|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
33318659|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
33318660|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
32952417|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
33315694|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
33315695|NCT03982121|Experimental|A|FOLFOX IV + NIVOLUMAB IV
33315696|NCT03982121|Experimental|B|FOLFOX IV + GLA IT
33315697|NCT03982121|Experimental|C|FOLFOX IV + IPILIMUMAB IT
33315698|NCT03982121|Experimental|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
32952418|NCT02952222|Active Comparator|Propofol (Group P)|Propofol only
32952419|NCT02952222|Active Comparator|Propofol with Dexmedetomidine (Group DP)|Propofol with Dexmedetomidine
32952420|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
32952421|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
32952422|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
32952423|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
32952424|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
32952425|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
32952426|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
32952427|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
32952428|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
32952429|NCT04391790|Active Comparator|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
32952430|NCT04391790|Experimental|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
32952431|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
32952432|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
32952433|NCT04391478|Active Comparator|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
32952434|NCT04391478|Active Comparator|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
32952435|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
32952436|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
32952437|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
32952438|NCT04346706|Experimental|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
32952439|NCT04346706|Experimental|Delayed implantation|Implant inserted in a healed socket with immediate temporization
32952440|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
32952441|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
32952442|NCT03826134|Experimental|[11C]-PXT012253|
32952443|NCT01454154|Experimental|Glyburide|Glyburide delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
32952444|NCT01454154|Placebo Comparator|Placebo|Matching placebo delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
32952445|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
32952446|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
32952447|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
32952448|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
33315699|NCT03982121|Experimental|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
33315700|NCT03982121|Experimental|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
33315701|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
33099644|NCT04781244|Active Comparator|EndWarts® FREEZE in Hard keratin|EndWarts® FREEZE were treated to 11 patients with wart at hard keratin
33099645|NCT04781244|Active Comparator|Liquid nitrogen in Soft keratin|Liquid nitrogen were treated to 11 patients with wart at soft keratin
33099646|NCT04781244|Active Comparator|Liquid nitrogen in Hard keratin|Liquid nitrogen were treated to 11 patients with wart at hard keratin
32952449|NCT02951598||MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
32952450|NCT02951598||Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
32952451|NCT02951598||MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
32952452|NCT02951598||Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
32952453|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~Baseline~6 month follow-up"
32952454|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~Baseline~Post 6 month follow-up"
32952455|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
32952456|NCT04391868|Active Comparator|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
32952457|NCT04391868|Experimental|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
32952458|NCT04391868|Experimental|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
32952459|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
32952460|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
32952461|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
32952462|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
32952463|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
32952464|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
32952465|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
32952466|NCT01454310|Experimental|Acellular skin substitute|
32952467|NCT01454310|Active Comparator|Autologous skin graft|
32952468|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
32952469|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
32952470|NCT03829332|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
32952471|NCT03829332|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
33099647|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
33099648|NCT00521027|Other|Control|Conventional surgical debridement techniques
33099649|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
33099650|NCT00521066||1|Prosima Pelvic Floor Repair System
32808187|NCT05365815|No Intervention|Usual Care|In the usual care (comparator) group, pregnant women attend individually scheduled visits with a midwife or obstetrician for a physical assessment and counseling. Although this can vary by provider, continuity of care is rare and racial concordance is not a consideration. Referrals for medical or social services are given to the patient to complete in both prenatal and postnatal care.
32808188|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
32808189|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
32808190|NCT05365113|Active Comparator|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
32808191|NCT05365113|Active Comparator|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
32808192|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
32808193|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
32808194|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808195|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808196|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808197|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808198|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808199|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
32808200|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
32808201|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
32808202|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
32808203|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
32808204|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
32808205|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
32808206|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
32808207|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
32808208|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
32808209|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
32808210|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
32808211|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
32808212|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
32808213|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
32808214|NCT04590781|Experimental|Part A: XmAb18087 Monotherapy|Part A, will enroll subjects with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
32808215|NCT04590781|Experimental|Part B: XmAb18087 + pembrolizumab|Part B, will enroll subjects with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
32808216|NCT04590781|Experimental|Part C: XmAb18087 monotherapy|Part C will enroll subjects with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
32808217|NCT01862029|Experimental|Roflumilast|
32808218|NCT01835431|Experimental|Insulin degludec/insulin aspart|
32808219|NCT01835431|Active Comparator|Insulin detemir|
32808220|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
32808221|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
32808222|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
32808223|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
32808224|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
32808225|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
32808226|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
32808227|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
32808228|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
32808229|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
32808230|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
32808231|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
32808232|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
32808233|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
32808234|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
32808235|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
32808236|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
32808237|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
32808238|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
32808239|NCT01779440|Other|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
32808240|NCT01779440|Placebo Comparator|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
32808241|NCT01750346|Active Comparator|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
32808242|NCT01750346|Active Comparator|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
32808243|NCT01750346|Placebo Comparator|Placebo|Participants in the Placebo arm received the placebo.
32808244|NCT01750268|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
32808245|NCT01750268|Placebo Comparator|Placebo|Placebo capsules daily - up 300 mg
32808246|NCT01880437|Experimental|Vismodegib|
32808247|NCT01861717|Experimental|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
32808248|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
32808249|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
32808250|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
32808251|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
32808252|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
32808253|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
32808254|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
32808255|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
32808256|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
32808257|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
32808258|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
32952472|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
32952473|NCT03825666|No Intervention|Control|control group following standard guidelines
32952474|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
32952475|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
32952476|NCT03069924|Active Comparator|No NRT - Unframed Messaging|Unframed smoking cessation materials, but no NRT and no gain-framed messaging.
32952477|NCT03069924|Experimental|NRT plus Gain-framed Messaging|Gain-framed messaging plus NRT.
32952478|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
32952479|NCT01454388|No Intervention|PEG without breakfast|
32952480|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
32952481|NCT01454388|No Intervention|picosalax without breakfast|
32952482|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
32952483|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
32952484|NCT01454544|Placebo Comparator|Placebo|
32952485|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
32952486|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
32952487|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
32952488|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
32952489|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
32952490|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
32952491|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
32952492|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
32952493|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
32952494|NCT01454622|Experimental|Treatment Sequence AB|
32952495|NCT01454622|Experimental|Treatment Sequence BA|
32952496|NCT01450332|Experimental|study|
32952497|NCT01454856||Surgical cancer patients|No modification of the treatment
32952498|NCT01454856||Non-surgical cancer patients|No modification of the treatment
33099651|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
32808259|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
32808260|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
32808261|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
32808262|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
32808263|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
32808264|NCT04408131|Experimental|Homeless people|Blood sample
32808265|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
32808266|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
32808267|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
32808268|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
32808269|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
32808270|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
32808271|NCT01388361|Experimental|IDeg (non-randomised)|
32808272|NCT01388361|Experimental|IDeg + IAsp|
32808273|NCT01388361|Experimental|IDeg + liraglutide|
32808274|NCT04028895|Other|Experimental|
32808275|NCT05368935|Experimental|Healthy Control Match (RF ≥ 90 mL/min)|500 mg Twice Daily for 7 days
32808276|NCT05368935|Experimental|Mild Renal Impairment (RF ≥ 60 to < 90 mL/min)|500 mg Twice Daily for 7 days
32808277|NCT05368935|Experimental|Moderate Renal Impairment (RF ≥ 30 to < 60 mL/min)|500 mg Twice Daily for 7 days
32808278|NCT05368935|Experimental|Severe Renal Impairment (RF < 30 mL/min and not on dialysis)|500 mg Twice Daily for 7 days
32808279|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
32808280|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
32808281|NCT04015791||Match Group|Surgery conducted at the disc level corresponding with the highest level of NOCISCORE value in the subject and that is classified as either NOCI + or NOCI mild
32808282|NCT04015791||Miss Group|Surgery conducted at a disc that: (a) corresponds with a low relative NOCISCORE value in the subject and that is classifies as NOCI - or (b) excludes the disc level with the highest NOCISCORE value in the subject and that is classifies as NOCI+ or NOCI mild
32808283|NCT04026633|Experimental|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
32808284|NCT04026633|Placebo Comparator|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
32808285|NCT01399047|Active Comparator|Mycophenolate Mofetil|
32808286|NCT01399047|Placebo Comparator|Placebo liquid|
32808287|NCT05369169|Experimental|Resonance paced breathing|Active resonance breathing task consisting of synchronizing breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
32808288|NCT05369169|Active Comparator|Low demand vanilla control|"A low-demand cognitive vanilla task wherein different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles"
32808289|NCT04025931|Experimental|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;~240 mg of toripalimab (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
32808290|NCT01387737|Experimental|TA-7284-Low|
32808291|NCT01387737|Experimental|TA-7284-High|
32808292|NCT05367141|Active Comparator|CDSS|patient management with aid of CDSS
32808293|NCT05367141|No Intervention|standart care|patient management with standard care according to guidelines
32808294|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
32808295|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
32808296|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to <18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
32808297|NCT04012827|Experimental|Apatinib Mesylate Combined With Doxorubicin and Ifosfamide|A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
33099652|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
32808298|NCT01859923|Experimental|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
33099653|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
32808299|NCT01859923|Experimental|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
32808300|NCT01859923|Experimental|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
32808301|NCT01859923|Experimental|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:~Participants >10 kilograms (kg) received DPF 10 mg BID plus OBR~Participants >8 kg and ≤10 kg received DPF 5 mg BID plus OBR~Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits [Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)]."
32808302|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
32808303|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
32808304|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
32808305|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
32808306|NCT04766619||Staff and stakeholders|For the longitudinal process evaluation - staff and stakeholders who have had direct contact or involvement with and have an understanding of OptmiseRx and/or PINCER will be invited to take part in an interview or focus group, an observation and/or complete a questionnaire. For the consolidated learning exercise - those who are in a position to influence the wider adoption of these interventions will be invited to take part in an interview or development workshop.
32808307|NCT04766619||Patients|Patients registered with a practice who have attended a consultation (or other related activity) for the PINCER intervention OR selected by their clinical care team OR attached to a patient group within a Clinical Commissioning Group (CCG) or practice OR patients identified through social media who have a long-term health condition and/or are taking any medication that requires them to have regular blood tests and have had a medication review in the past six month will be invited to take part in an interview or focus group.
32808308|NCT04766619||Public and patient representatives|For the consolidated learning exercise - patient and public representatives who have an understanding of the related medicines management issues in primary care will be invited to take part in an interview or workshop.
32808309|NCT05364333|Sham Comparator|Sham RIPC|Control patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.
32808310|NCT05364333|Experimental|RIPC|Patients in the intervention group will be submitted to 3 cycles of RIPC. For each cycle of RIPC, a blood pressure cuff will be inflated at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time.
32808311|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
32808312|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
32808313|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
32808314|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
32808315|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
32808316|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
32808317|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
32808318|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
32808319|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
32808320|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
32808321|NCT01878097|Active Comparator|Control|Awareness Eduation
32952499|NCT01454856||Surgical non-cancer patients|No modification of the treatment
32952500|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
33315702|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
33315703|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
33315704|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
33315705|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
33315706|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
33315707|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
33315708|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
33315709|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
33315710|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
33315711|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
33315712|NCT01164176|Experimental|RAD001 group|
33315713|NCT01164332|Other|Method A|First experimental detection method
33315714|NCT01164332|Other|Method B|Second experimental detection method
32952501|NCT01450410|Active Comparator|Nicotinic Acid|
32952502|NCT01450410|Placebo Comparator|Placebo|
32952503|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
32952504|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
32952505|NCT03824418||Chromoendoscopy follow-up|
32952506|NCT03824418||Autofluorescence follow-up|
32952507|NCT04391712|Experimental|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
32952508|NCT04391712|Active Comparator|Control Group|Participants will receive regular inpatient medical care.
32952509|NCT04391634|Other|Mechanical ventilation|Preterm infants on mechanical ventilation
32952510|NCT02905110|Experimental|Methotrexate / Etoposide Infusion|12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.
32952511|NCT01450488|Experimental|masitinib 3 mg/kg/day|
32952512|NCT01450488|Experimental|masitinib 6 mg/kg/day|
32952513|NCT01450566|Experimental|Lidocaine|Use of lidocaine
32952514|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
32952515|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
32952516|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
32952517|NCT02947386|Experimental|Treatment (nivolumab, nimotuzumab)|Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32952518|NCT03043014|Experimental|Mifépristone group|
32952519|NCT03043014|Active Comparator|misoprostol group|
32952520|NCT03824184|Active Comparator|manipulation of endometrium|Manipulation of endometrium with saline
32952521|NCT03824184|No Intervention|control group|Control group : No intervention
32952522|NCT02978118||Group A|Subjects in Group A (patients with metastatic renal cell carcinoma starting immune therapy) will have PBMC, plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and upon disease progression. Urinary specimens will be collected at baseline, 4 weeks, 12 weeks, and disease progression. Fecal specimens will be collected at baseline (within 3 days of cycle 1 day 1), 4 weeks, and upon disease progression.
32952523|NCT02978118||Group B|Subjects in Group B (patients with metastatic urothelial carcinoma) will have PBMC and plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and disease progression. Urinary specimens will be collected at baseline, 4 weeks, 12 weeks, and disease progression. Fecal specimens will be collected at baseline (within 3 days of cycle 1 day 1), 4 weeks, and upon disease progression.
32952524|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
32952525|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
32952526|NCT01455168||No treatment|Capsular tension ring is not used in the group.
32952527|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
32952528|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
32952529|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
32952530|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
32952531|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
32952532|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
32808322|NCT01750190|Experimental|Roxadustat|Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing <70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
32808323|NCT01750190|Placebo Comparator|Placebo|Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing <70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.
32808324|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
32808325|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
32808326|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
32808327|NCT01749800|Experimental|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
32808328|NCT01749800|Active Comparator|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
32808329|NCT01749800|Sham Comparator|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
32808330|NCT04556396|Experimental|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
32808331|NCT04556396|No Intervention|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
32808332|NCT04414891|Experimental|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is <12cm H20 and PEEP requirement is <5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
32808333|NCT04414891|Active Comparator|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to <8 cm of H2O, and the respiratory rate is < 28 breaths per minute and patient is able to maintain SpO2 > 90% at FiO2< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
32808334|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
32808335|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
32808336|NCT01748552|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
32808337|NCT01748552|Experimental|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligrams [mg]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
32808338|NCT01748552|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
32808339|NCT01748552|Experimental|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
32808340|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
32808341|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
32952533|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
32952534|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
32952535|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
32952536|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
32952537|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
32952538|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
32952539|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
32952540|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
32952541|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
32952542|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
32952543|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
32952544|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
32952545|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
32952546|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
32952547|NCT01451112|Experimental|Treated|
32952548|NCT02910648|Experimental|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
32952549|NCT02910648|Sham Comparator|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
32952550|NCT02910648|Sham Comparator|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
32952551|NCT01455480|Experimental|RPh201|
32952552|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
32952553|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
32952554|NCT01451190|Experimental|Treated|
32952555|NCT01451268|Experimental|Panobinostat Arm A|
32952556|NCT01451268|Experimental|Panobinostat Arm B|
32952557|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
32952558|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
32952559|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
32952560|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
32952561|NCT01455558|Experimental|Cilostazol|
32952562|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
32952563|NCT02884908|Experimental|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
32952564|NCT02884908|Experimental|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
32952565|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
32952566|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
32952567|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
32952568|NCT01451658|Experimental|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
32952569|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
32952570|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
32952571|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
32952572|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
32952573|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
32952574|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
32952575|NCT02861898|Experimental|Intra-arterial Cetuximab after BBBD|Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2
32952576|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
32952577|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
32952578|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
32952579|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
32952580|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
32952581|NCT02936466|Experimental|Interventional group|Bipolife group
32952582|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
32952583|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
32952584|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
32952585|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
32952586|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
32952587|NCT01452204|Experimental|Pulsed Electromagnetical Field|
32952588|NCT01452204|Placebo Comparator|Placebo|
32952589|NCT01452282||Ankle Brachial Index|
32952590|NCT01452360||Collection of CKD patient group|
32952591|NCT01452360||Collection of CKD high-risk group|
32952592|NCT01452360||Collection of healthy control group|
32952593|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
32952594|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
32952595|NCT01452750|Experimental|TAK-438 10 mg QD|
32952596|NCT01452750|Experimental|TAK-438 20 mg QD|
32952597|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
32952598|NCT04273308|Experimental|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
32952599|NCT01452828|Experimental|Renal Impairment Nondialyzed|
32952600|NCT01452828|Experimental|Renal Impairment Dialyzed|
32952601|NCT01452828|Experimental|Matched Control|
32952602|NCT01452906|Experimental|PA21 and Omeprazole with food|
32952603|NCT01452906|Experimental|No PA21; Omeprazole with food|
32952604|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
32952605|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
32952606|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
32952607|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
32952608|NCT01453218|Active Comparator|ATeGe-Fresenius|
32952609|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
32952610|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
32952611|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
32952612|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
32952613|NCT02781090|Experimental|Positively Smoke Free on the Web+|Subjects will be assigned to the PSFW+ website and social network. They will also be offered a three-month supply of nicotine patches.
32952614|NCT02781090|Placebo Comparator|American Heart Assoc Getting Healthy|Subjects will be assigned to the AHA Getting Healthy website. They will also be offered a three-month supply of nicotine patches.
32952615|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
32952616|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
32952617|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
32952618|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
32952619|NCT03823092||Normal|phakic participants with no evidence of eye disorders
32952620|NCT03823092||Cataract|participants with cataract
32952621|NCT03823092||AMD|participants with age related macular degeneration
32952622|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
32952623|NCT03823092||other macula|participants with macular ddisorders other than AMD
32952624|NCT03823092||DR|participants with diabetic retinopathy
32952625|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
32952626|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
32952627|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
32952628|NCT03822624|Experimental|Probiotic group|
32952629|NCT03822624|Placebo Comparator|Placebo group|
32952630|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
32952631|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
32952632|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
32952633|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
32952634|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
32952635|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
32952636|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
32952637|NCT04273152||children with allergy|children with allergies
32952638|NCT04273152||healthy control|healthy control (non allergic children)
32952639|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
32952640|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
32952641|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
32952642|NCT01453686|Experimental|Hydrocortisone 1%|
32952643|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
32952644|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
32952645|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
32952646|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
32952647|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
32952648|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.~Device: InTENsity MicroCombo"
32952649|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
32952650|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
32952651|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.~Device: InTENsity MicroCombo"
32952652|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.~Device: InTENsity MicroCombo"
32952653|NCT01459926|Experimental|Dose 1|
32952654|NCT01459926|Experimental|Dose 2|
32952655|NCT01459926|Experimental|Dose 3|
32952656|NCT01459926|Experimental|Placebo|
32952657|NCT01456182|Other|Dose arm 1|
32952658|NCT01456182|Other|Dose arm 2|
32952659|NCT01456182|Other|Dose arm 3|
32952660|NCT01456182|Other|Dose arm 4|
32952661|NCT01456182|Other|Dose arm 5|
32952662|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
32952663|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
32952664|NCT01456260|Experimental|TAK-438 10 mg QD|
32952665|NCT01456260|Experimental|TAK-438 20 mg QD|
32952666|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
32952667|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
32952668|NCT04842786|Experimental|Coconut oil at 5 mg/Kg body weight twice daily|Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
32952669|NCT04842786|No Intervention|No intervention|Subjects assigned to this arm will have their skin gently stroked twice daily for the time that would be required to apply an oil. This will simulate the stroking received by the intervention arm subjects. This will occur from enrollment until discharge, or until day of life 28, whichever occurs first.
32952670|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
32952671|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
32952672|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
32952673|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
32952674|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
32952675|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
32952676|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
32952677|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
32952678|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
32952679|NCT04849806||COPD patients (n=60)|"The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).~OSA severity.~Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;~Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis;~Assessment of systemic inflammation"
32952680|NCT04849806||Controls (n=20)|(and in a group of healthy controls [3:1] matched for age, sex and BMI).
33099654|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
32952681|NCT04844658|Experimental|standard treatment + NASAFYTOL®|"Minimum 25 patients will receive NASAFYTOL® as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days"
32952682|NCT04844658|Active Comparator|standard treatment + FULTIUM® - D3 800|"Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days"
32952683|NCT04841538|Experimental|Cohort 1|ES101 is administered via intravenous infusion, 0.3mg/kg，once every 14 days, every 28 days as a treatment cycle.
32952684|NCT04841538|Experimental|Cohort 2|ES101 is administered via intravenous infusion, 1mg/kg，once every 14 days, every 28 days as a treatment cycle.
32952685|NCT04841538|Experimental|Cohort A1|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
32952686|NCT04841538|Experimental|Cohort A2|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
32952687|NCT04841538|Experimental|Cohort B|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
32952688|NCT04841538|Experimental|Cohort C|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
32952689|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
32952690|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
32952691|NCT04849650|Experimental|Renal Impairment Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
32952692|NCT04849650|Experimental|Healthy Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
32952693|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
32952694|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
32952695|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
32952696|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
32952697|NCT05587140|Experimental|Acupuncture like TENS|The study would use acupuncture like TENS for 30 minutes
32952698|NCT05587140|Experimental|Conventional TENS|The study would use conventional TENS for 30 minutes
32952699|NCT05587140|Experimental|Sham TENS|The study would use sham TENS for 30 minutes
32952700|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
32952701|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
32952702|NCT04272372||Group 1|Complete Decongestive Therapy
32952703|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
32952704|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
32952705|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
32952706|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
32952707|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
32952708|NCT01891266|Experimental|Non-tourniquet assisted TKA|
32952709|NCT01891266|Other|Tourniquet assisted TKA|
32952710|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
32952711|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
32952712|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
32952713|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab|Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
32952714|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab +/- pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab ± pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab ± pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
32952715|NCT02862132|Experimental|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
32952716|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
33404856|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
33404857|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
32952717|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
32952718|NCT04273074|Other|preoperative sonographic assessment group|preoperative sonographic assessment to airway
32952719|NCT04843722|Experimental|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
32952720|NCT04843722|Experimental|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
32952721|NCT04844268|Experimental|Cohort 1|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
32952722|NCT04844268|Experimental|Cohort 2|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 5 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
32952723|NCT04844268|Experimental|Cohort 3|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 25 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
32952724|NCT04844268|Placebo Comparator|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride). Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
32952725|NCT04842552|Active Comparator|Hydralazine hydrochloride 25mg|Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
32952726|NCT04842552|Placebo Comparator|Placebo|Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
32952727|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
32952728|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
32952729|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
32952730|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
32952731|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
32952732|NCT04390932|Experimental|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
32952733|NCT04390932|Active Comparator|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
32952734|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
32952735|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
32952736|NCT04842630|Experimental|SHR-1916|
32952737|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
32952738|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
32952739|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
32952740|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
32952741|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
32952742|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
32952743|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
32952744|NCT04389996||Patients with cancer|Survey
32952745|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
32952746|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
32952747|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
32952748|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
32952749|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
32952750|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
32952751|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
32952752|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
32952753|NCT02809716||Ancillary-Correlative (blood and tumor tissue collection)|Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo and tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
32952754|NCT04840914|Experimental|LY3461767|LY3461767 administered subcutaneously (SC).
32952755|NCT04840914|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC).
32952756|NCT04840836||Telehealth-supported LARC provision|"Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a reproductive health visit, which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR."
32952757|NCT04840602|Active Comparator|Arm I (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive ibrutinib, rituximab, and venetoclax as in Arm II for up to an additional 24 cycles.
32952758|NCT04840602|Experimental|Arm II (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24, rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5, and venetoclax PO QD on days 1-28 of cycles 2-24. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32952759|NCT04272684|Experimental|Interventional|Driving Assessment
32952760|NCT01457664|Placebo Comparator|Placebo|
32952761|NCT01457664|Experimental|RO4995819|
32952762|NCT04390464|Active Comparator|Standard of care|Standard of care
32952763|NCT04390464|Experimental|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
32952764|NCT04390464|Experimental|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
32952765|NCT04390542|Experimental|Psychoeducation intervention|Psychoeducatoinal intervention
32952766|NCT04390542|No Intervention|Usual care|Information from healthcare providers
32952767|NCT04845750|Experimental|Rodeo Micro Mapping Catheter|Determination of pulmonary vein isoation during cryoablation procedure
32952768|NCT04844424|Experimental|Part 1A: Treatment Sequence ABC|Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952769|NCT04844424|Experimental|Part 1A: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952770|NCT04844424|Experimental|Part 1A: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952771|NCT04844424|Experimental|Part 1A: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952772|NCT04844424|Experimental|Part 1A: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952773|NCT04844424|Experimental|Part 1A: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
33099655|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
33318661|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
33318662|NCT01095744||young controls|under 65
33315715|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
33315716|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
33315717|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
32952774|NCT04844424|Experimental|Part 1B: Treatment Sequence DEF|Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952775|NCT04844424|Experimental|Part 1B: Treatment Sequence EFD|Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952776|NCT04844424|Experimental|Part 1B: Treatment Sequence FDE|Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952777|NCT04844424|Experimental|Part 1B: Treatment Sequence DFE|Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952778|NCT04844424|Experimental|Part 1B: Treatment Sequence EDF|Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952779|NCT04844424|Experimental|Part 1B: Treatment Sequence FED|Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952780|NCT04844424|Experimental|Part 2A: Treatment Sequence GH|Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
32952781|NCT04844424|Experimental|Part 2A: Treatment Sequence HG|Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
32952782|NCT04844424|Experimental|Part 2B: Treatment Sequence IJ|Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
32952783|NCT04844424|Experimental|Part 2B: Treatment Sequence JI|Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
32952784|NCT04844424|Experimental|Part 3A: Treatment Sequence KLM|Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952785|NCT04844424|Experimental|Part 3A: Treatment Sequence LMK|Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952786|NCT04844424|Experimental|Part 3A: Treatment Sequence MKL|Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952787|NCT04844424|Experimental|Part 3A: Treatment Sequence KML|Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952788|NCT04844424|Experimental|Part 3A: Treatment Sequence LKM|Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952789|NCT04844424|Experimental|Part 3A: Treatment Sequence MLK|Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
33099656|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
33318663|NCT01095744||old controls|over 65
32952790|NCT04844424|Experimental|Part 3B: Treatment Sequence NOP|Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952791|NCT04844424|Experimental|Part 3B: Treatment Sequence OPN|Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952792|NCT04844424|Experimental|Part 3B: Treatment Sequence PNO|Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952793|NCT04844424|Experimental|Part 3B: Treatment Sequence NPO|Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952794|NCT04844424|Experimental|Part 3B: Treatment Sequence ONP|Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952795|NCT04844424|Experimental|Part 3B: Treatment Sequence PON|Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952796|NCT04844424|Experimental|Part 4 A: Treatment Sequence QRS|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952797|NCT04844424|Experimental|Part 4A: Treatment Sequence RSQ|Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952798|NCT04844424|Experimental|Part 4A: Treatment Sequence SQR|Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952799|NCT04844424|Experimental|Part 4A: Treatment Sequence QSR|Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952800|NCT04844424|Experimental|Part 4A: Treatment Sequence RQS|Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952801|NCT04844424|Experimental|Part 4A: Treatment Sequence SRQ|Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952802|NCT04844424|Experimental|Part 4B: Treatment Sequence TU|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952803|NCT04844424|Experimental|Part 4B: Treatment Sequence UT|Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952804|NCT04844424|Experimental|Subpart 4A: Treatment Sequence VW|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
32952805|NCT04844424|Experimental|Subpart 4A: Treatment Sequence WV|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
32952806|NCT04844424|Experimental|Part 5: Treatment Sequence XYZ|Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
33099657|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
33315718|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
33315719|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
32952807|NCT04844424|Experimental|Part 5: Treatment Sequence YZX|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952808|NCT04844424|Experimental|Part 5: Treatment Sequence ZXY|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952809|NCT04844424|Experimental|Part 5: Treatment Sequence XZY|Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
33315720|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
33315721|NCT01586936||eptacog alpha users|
33315722|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
33315723|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
33315724|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
33318664|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
32952810|NCT04844424|Experimental|Part 5: Treatment Sequence YXZ|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952811|NCT04844424|Experimental|Part 5: Treatment Sequence ZYX|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
32952812|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
32952813|NCT04840680||Participants With MM|Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years 11 months.
32952814|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
32952815|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.~Device: Terumo IMUFLEX WB-SP collection bag system"
32952816|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
32952817|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
32952818|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
32952819|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
32952820|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
32952821|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
32952822|NCT01892826|Experimental|hCG group|
32952823|NCT01892826|No Intervention|LH pic|
32952824|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
32952825|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
32952826|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
32952827|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
32952828|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
33099658|NCT00521183|Experimental|CldC + H4U|
33099659|NCT02937987||Group 1|non-obese type 2 DM
33099660|NCT02937987||Group 2|obese type 2 DM
33099661|NCT02938026|No Intervention|Control|Usual care
33099662|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
33315725|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
33315726|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
32808342|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
32808343|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
32808344|NCT01747772|Experimental|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
33099663|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
33099664|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
33099665|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
33099666|NCT00521612|Experimental|A|Sevoflurane group, experimental group
33099667|NCT00521612|Active Comparator|B|Isoflurane group, control group
33099668|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
33099669|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
33099670|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
33099671|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
33099672|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
33099673|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
33099674|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
33099675|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
33099676|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
33099677|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
33099678|NCT02931825|No Intervention|Control|No intervention (what is done currently)
33099679|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
33099680|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
33315727|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
33315728|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
33099681|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
33099682|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
33099683|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
33099684|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
33099685|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
32952829|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
32952830|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
32952831|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
32952832|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
32952833|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
32952834|NCT02344290|Experimental|Pitavastatin|Participants will receive pitavastatin once a day for the entire time they are enrolled in the study.
32952835|NCT02344290|Placebo Comparator|Placebo|Participants will receive placebo for pitavastatin once a day for the entire time they are enrolled in the study.
32952836|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
32952837|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
32952838|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
32952839|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
32952840|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Dose level 1: 1 mg/kg~Dose level 2: 3 mg/kg"
32952841|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 1.0 mg/kg~Dose level 3: 3.0 mg/kg"
32952842|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 0.6 mg/kg~Dose level 3: 1.0 mg/kg"
32952843|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
32952844|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
32952845|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
32952846|NCT01457820|Experimental|Allopurinol High dose|
32952847|NCT01457820|Experimental|Allopurinol Low dose|
32952848|NCT01457820|Placebo Comparator|Placebo|
32952849|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
32952850|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
32952851|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
32952852|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
32952853|NCT01457898|Experimental|VPAP II®|VPAP II® Group
32952854|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
32952855|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
32952856|NCT04758156|Experimental|CleanViewAL|1L polyethylene glycol+ascorbic acid split dose
32952857|NCT04758156|Placebo Comparator|SUPREP|Oral sulfate solutiom
32952858|NCT01457976||Members of the US public, non-probability sample|
32952859|NCT01457976||Members of the German public, non-probability sample|
32952860|NCT01457976||Members of the US public, probability sample|
32952861|NCT02309580|Experimental|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
32952862|NCT02794428|Active Comparator|Eflornithine|
32952863|NCT02794428|Placebo Comparator|Eflornithine Placebo|
32952864|NCT05020782|Experimental|Intervention Arm|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
32952865|NCT05029986|Experimental|All participants|This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
32952866|NCT05022342||HR-positive HER2-negative ABC/MBC|Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) patients
32952867|NCT05022342||PIK3CA mutation positive|Patients with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) gene mutation positive
32952868|NCT05028582|Active Comparator|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
32952869|NCT05028582|Placebo Comparator|ARQ-154 Vehicle|ARQ-154 Vehicle
32952870|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
32952871|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
32952872|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
32952873|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
32952874|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
32952875|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
33099686|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
33099687|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
33099688|NCT04694027|Active Comparator|group a|will receive omega 3 plus vitamin E
33099689|NCT04694027|Active Comparator|Group b|will receive vitamin E
33099690|NCT04694027|No Intervention|Group c|no intervention just reassurance and analgesics on need
33099691|NCT00521807|No Intervention|A 1|
33099692|NCT00521807|Experimental|A 2|Treatment group
33099693|NCT04577274|Experimental|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
33099694|NCT04577274|Experimental|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
33099695|NCT04577274|Active Comparator|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
33099696|NCT04693988|Experimental|Case management|Patient receives case management while in hospital.
33099697|NCT04693988|No Intervention|Usual Care|This control condition does not receive intervention of case management
33099698|NCT02937675|Experimental|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
33099699|NCT02937675|Experimental|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
32808345|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
32808346|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
33099700|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
33099701|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
33099702|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
33099703|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
33099704|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
33099705|NCT00521963|Experimental|E|
33099706|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
33099707|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
33315729|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
33315730|NCT01168154|Active Comparator|Lactobacillus Reuterii|
33315731|NCT01168154|Placebo Comparator|Placebo|
33315732|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
33315733|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
33315734|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
33315735|NCT01168388||Movement disorder|
33315736|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
33315737|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
33315738|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
33315739|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
33315740|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
33315741|NCT01164488|Experimental|1|
33099708|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
33099709|NCT04693871||high-flow rate group|
33099710|NCT04693871||low-flow rate group|
33099713|NCT02948348|Experimental|Nivolumab & Ipilimumab(Only Cohort D)|chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
33099714|NCT02937480|Experimental|Experimental group|Task-specific training
33099715|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
33099716|NCT04693910|Experimental|Multimedia information group|The experimental group received a weekly multimedia hormone therapy information program for 6 weeks.
33099717|NCT04693910|No Intervention|Routine care group|The control group will receive routine care.
33099718|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
33099719|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
33099720|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
33099721|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
33099722|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
33099723|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
33099724|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
33099725|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
33404858|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
32808347|NCT04611295|Experimental|Teleneurological evaluation and support|teleneurological evaluation using a medical device certified as telemedicine system
32808348|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
32808349|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
32808350|NCT01614067|Experimental|Delayed Start|Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
32808351|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
32808352|NCT01777490|Active Comparator|Arm 1: Control - Caregiver|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home.
32808353|NCT01777490|Experimental|Arm 2: HI FIVES - Caregiver|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
32808354|NCT01777490|Active Comparator|Arm 1: Control - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
32808355|NCT01777490|Experimental|Arm 2: HI-FIVES - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
32808356|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
32808357|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
32808358|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
33099726|NCT00522197|Active Comparator|ACAPHA|
33099727|NCT00522197|Placebo Comparator|Sugar Pill|
33099730|NCT00522236|Experimental|Arm 1|
33099731|NCT02931123|No Intervention|standard|
33099732|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
33099733|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
33099734|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
33099735|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
33099736|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
33099737|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
33099738|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099739|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099740|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099741|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099742|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099743|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
33318665|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
33315742|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
32952876|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
32952877|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
32952878|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
32952879|NCT05024916|Experimental|Intervention|Participants will receive the dietary intervention. Participants will take 1 serving of blueberries/day.
33315743|NCT01272362|Experimental|Indacaterol|
32952880|NCT05024916|Active Comparator|Control|Participants will receive a placebo. Participants will take 1 serving of placebo/day.
32952881|NCT05028270||Balloon technology|The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. The common carotid artery and internal carotid artery will be received laterally. After whole-body heparinization, micro-catheter and guide wire technology are used. In the figure below, the proximal end of the 4mm super-form occlusion ball is marked far away from the eye, plugged and sealed, and the guide tube is pushed around in the internal carotid artery. When the occlusion is finished, the internal carotid artery and the ophthalmic artery are not accompanied far away, and the plot is good. The guiding catheter drives the injection of drugs, topotecar, and topotecan for 5 minutes (the suction balloon is opened and blocked, and the infusion is continuous) to complete the infusion.
32952882|NCT05028270||Microcatheter technology|The tip of the Marathon microcatheter is placed at the opening of the ophthalmic artery. After the contrast agent is confirmed by hand, the chemotherapeutic drugs The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. Maphalan, carboplatin, and topotecan are injected sequentially for 30 minutes. Make sure that the tip position of the catheter is not maintained during the injection process. verb: move. After the operation is completed, the blocking balloon is pulled out under the guidance of the guide wire, the arterial sheath is removed, and the femoral artery puncture point is pressed to stop bleeding.
32952883|NCT05026554||CHE|Adults with moderate to severe chronic hand eczema
32952884|NCT05026554||Healthy Volunteers|Healthy adults
32952885|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
32952886|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
32952887|NCT05029518|Experimental|Treatment A: SMP-100 dissolved in water administered under fasting conditions|12 subjects，For Treatment A, SMP-100 will be dissolved in a total of 240 mL of water and administered orally to each subjects, and a hand and mouth check will be performed to ensure consumption of the medication. Subjects will be required not to wear dentures or mouth piercing at the time of dosing. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
32952888|NCT05029518|Experimental|Treatment B: SMP-100 tablets administered under fasting conditions|12 subjects，For Treatment B, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
32952889|NCT05029518|Experimental|Treatment C: SMP-100 tablets administered under fed conditions|"12 subjects，For Treatment C, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL.~After a supervised fast of at least 10 hours, subjects will be served a high-fat, high-calorie meal of approximately 800 to 1000 calories (approximately 50% of total caloric content of the meal derived from fat). This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Subjects should start the meal approximately 30 minutes prior to drug administration. Subjects will be required to completely eat the meal in 30 minutes or less. No food will be allowed until at least 4 hours post-dose."
32952890|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
32952891|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
32952892|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
32952893|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
32952894|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
32952895|NCT05027100|Experimental|exploratory research|Anlotinib 10mg QD with 2W stop 1W tiselizumab injection 200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
32952896|NCT05024214|Experimental|Phase Ib arm|Subjects with advanced or metastatic solid tumor (excluding hepatocellular carcinoma and thyroid cancer) with disease progression or intolerance or no effective treatment after standard therapy
32952897|NCT05024214|Experimental|Phase II cohort1-NSCLC|Subjects with non-small cell lung cancer, resistant after previous treatment with PD-(L)1 inhibitors
32952898|NCT05024214|Experimental|II Phase cohort1-RCC|Subjects with renal cell carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
32952899|NCT05024214|Experimental|Phase II cohort1-HCC|Subjects with hepatocellular carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
32952900|NCT05024214|Experimental|Phase II cohor2-experiment group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
32952901|NCT05024214|Experimental|Phase II cohort2-control group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
32952902|NCT02778750||Stable Group|
32952903|NCT02778750||Rapid Decliner Group|
33315744|NCT01282034|Active Comparator|Marrow stimulation|
33315745|NCT01282034|Experimental|Medical device: MaioRegen|
33315746|NCT00312845|Experimental|Bortezomib + Rituximab|
33315747|NCT00312845|Active Comparator|Rituximab|
33315748|NCT01282190|Experimental|Motivational interview|
33315749|NCT01282268|Active Comparator|Arbaclofen|
33315750|NCT01282268|Placebo Comparator|Placebo|
33315751|NCT01165736|Active Comparator|Intravenous: PF-05186462|
33315752|NCT01165736|Active Comparator|Oral: PF-05186462|
33315753|NCT01165736|Active Comparator|Intravenous: PF-05089771|
33315754|NCT01165736|Active Comparator|Oral: PF-05089771|
32952904|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
32952905|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
33315755|NCT01165736|Active Comparator|Intravenous: PF-05150122|
33315756|NCT01165736|Active Comparator|Oral: PF-05150122|
33315757|NCT01165736|Active Comparator|Intravenous: PF-05241328|
33315758|NCT01165736|Active Comparator|Oral: PF-05241328|
33315759|NCT03870308|Experimental|Deep Brain Stimulation subjects|
33315760|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
33315761|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
32952906|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
32952907|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
32952908|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
32952909|NCT05027568|Experimental|Drug: IOA-289 single dose|Single oral dose of IOA-289 liquid filled capsule formulation - ascending doses
32952910|NCT05027568|Placebo Comparator|Placebo single dose|Single oral dose of placebo liquid filled caspule formulation
32952911|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
32952912|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
32952913|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
32952914|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
32952915|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
32952916|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
32952917|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
32952918|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
32952919|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
32952920|NCT02765880|Experimental|Healthy volunteer|
32952921|NCT02765880|Experimental|Patients with schizophrenia|
32952922|NCT02765880|Experimental|Patient with bipolar disorder|
32952923|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
32952924|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
32952925|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
32952926|NCT04272528|Experimental|experimental group|Nurses provide uniform care to patients according to the quality standards.
32952927|NCT04272528|Placebo Comparator|control group|Nurses provide the routine care to patients.
32952928|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
32952929|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
32952930|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
32952931|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
32952932|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
32952933|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
32952934|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
32952935|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
32952936|NCT02828904||Users of Chlormadinone Acetate (CMA) combined with Ethinylestradiol (EE)|"CMA/EE users are defined as~aged 15 to 49 years~Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~COC new user (starters, switchers, and re-starters)"
32952937|NCT02828904||Users of Levonorgestrel (LNG) combined with Ethinylestradiol (EE)|"LNG/EE users are defined as~aged 15 to 49 years~Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~COC new user (starters, switchers, and re-starters)"
33315762|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
33315763|NCT03985241|Experimental|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
33315764|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
33315765|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
33315766|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
33315767|NCT00368069|Placebo Comparator|Placebo|placebo
33315768|NCT01165814|Active Comparator|Tramadol at fixed intervals|
33315769|NCT01165814|Active Comparator|Tramadol on request|
33315770|NCT01165814|Active Comparator|Naproxen at fixed intervals|
33315771|NCT01165814|Active Comparator|Naproxen on request|
33315772|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
32952938|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
32952939|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
32952940|NCT02761746|Experimental|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
32952941|NCT02761746|No Intervention|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
32952942|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
32952943|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
32952944|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
32952945|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
32952946|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
32952947|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
32952948|NCT01458834|Experimental|Active attention training condition|
32952949|NCT01458834|Placebo Comparator|Control condition|
32952950|NCT05025852||Metformin exposed in utero|Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial.
32952951|NCT05025852||Placebo exposed in utero|Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial.
32952952|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
32952953|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
32952954|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
33315773|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
33315774|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
33315775|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
33315776|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
33315777|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
33315778|NCT05666804|Experimental|Personalized regimen arm|1~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T&E) regimen up to Week 56
33315779|NCT05666804|Active Comparator|Standard regimen arm|3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
33315780|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
33315781|NCT00367835|Placebo Comparator|Placebo|
33315782|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
33099744|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099745|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
33099746|NCT00522314|Active Comparator|1|NIV & ACBT
33099747|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
33099748|NCT04690062|Experimental|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
33099749|NCT04694495||volunteers from health examination center|volunteers(n = 50/center) doing gynecologial examination recruited from health examination center, who shows no symptoms and signs in reproductive tract and are potentially regarded as the healthy controls
33099750|NCT04694495||volunteers from gynecology outpatient|volunteers(n = 150/center) recruited from gynecology outpatient, who show abnormal symptoms and signs in reproductive tract and are potentially regarded as the cases with conditions in reproductive tract
33099751|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
33099752|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
32808359|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
33099753|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
33099754|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
33099755|NCT00522353|Active Comparator|1|Oligofructose
33099756|NCT00522353|Placebo Comparator|2|Placebo
33099757|NCT04690296|Experimental|US group|a group underwent real time USG-SCV catheterization
33099758|NCT04690296|Experimental|LM group|a group in whom anatomical LM method was used
33099759|NCT04689789||Patients with RAP|Patients with previous diagnosis of retinal angiomatous proliferation
33099760|NCT04689789||Patients with reticular pseudodrusen|Patients with previous diagnosis of reticular pseudodrusen
33099761|NCT04689789||Control group|Healthy eyes without actual and previous ocular diseases
33099762|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);~total or free T levels above the reference interval and/or excessive facial hair, acne;~transvaginal ultrasound with polycystic ovaries.~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
33099763|NCT02937090||Control|Women matched for age and BMI.
33099764|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
33099765|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
33099766|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
33099767|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
33099768|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
33099769|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
33099770|NCT00522587|Experimental|7|Fixed remifentanil dose 1
33099771|NCT00522587|Experimental|8|Fixed remifentanil dose 2
33099772|NCT00522587|Experimental|9|Fixed remifentanil dose 3
33099773|NCT00522587|Experimental|10|Fixed remifentanil dose 4
33099774|NCT00522587|Experimental|11|Fixed remifentanil dose 5
33099775|NCT00522587|Experimental|12|Fixed remifentanil dose 6
33099776|NCT04689633|Active Comparator|Quadratus lumborum block|received bilateral ultrasound-guided Quadratus lumborum block using 20 ml bupivacaine 0.25% on each side
33099777|NCT04689633|Active Comparator|Erector spinae block|received bilateral ultrasound-guided erector spinae block using 20 ml bupivacaine 0.25% on each side
33099778|NCT04689633|No Intervention|Control|didn't received any block
33099779|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
33099780|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
33099781|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
33099782|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
33099783|NCT00522743|Experimental|1|GH & GNRHa treatment
33099784|NCT00522743|Active Comparator|2|GH treatment
33099785|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
33099786|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
33099787|NCT04694456|Experimental|Facioscapulohumeral muscular dystrophy|Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
33099788|NCT00522782|Active Comparator|A|Nebulized budesonide
33099789|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
33099790|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
33404859|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
32952955|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
32952956|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
32952957|NCT02743728||All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
32952958|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
32952959|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
32952960|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
32952961|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
32952962|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly~Phase II~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
32952963|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
32952964|NCT05026632|Experimental|Single NPI-002 Intravitreal Implant|one NPI-002 implant inserted at the time of vitrectomy
32952965|NCT05026632|Experimental|Double NPI-002 Intravitreal Implant|two NPI-002 implants inserted at the time of vitrectomy
32952966|NCT05026632|No Intervention|Control|No implant inserted at time of vitrectomy
32952967|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
32952968|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
32952969|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
32952970|NCT05020158|Experimental|Family Talk intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
32952971|NCT05028894||IPF|Participants diagnosed with idiopathic pulmonary fibrosis
32952972|NCT05025774||Case|Adolescent or young adult acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant
32952973|NCT05025774||Control|14-25 years old healthy individuals who are ambulatory without assistance. We may enroll younger subjects but we wish to subjects to match our patient population
32952974|NCT05024136|Active Comparator|Placebo|Subjects take 30 mins aromatherapy of Limon essential oil per time, a total of 3 times for the month.
32952975|NCT05024136|Experimental|Experimental|Subjects take 30 mins aromatherapy of vetiver essential oil per time, a total of 3 times for the month.
32952976|NCT05026398|Experimental|Fenfluramine|Drug: Fenfluramine - 15mg twice daily oral solution for seven days
32952977|NCT05026398|Placebo Comparator|Placebo|Placebo - 15mg twice daily oral solution for seven days
32952978|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
32952979|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
32952980|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
32952981|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
32952982|NCT05586828||different controlling nutritional status score|
32952983|NCT05586750|Experimental|STAREE Statin group|
32952984|NCT05586750|Placebo Comparator|STAREE Placebo group|
32952985|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
33099791|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
33099792|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
33099793|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
33315783|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
32952986|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
32952987|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
32952988|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
32952989|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
32952990|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
32952991|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
32952992|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
32952993|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
32952994|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
32952995|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
32952996|NCT04346004|Placebo Comparator|Control group|Participants in this group are administered N/S.
32952997|NCT04346004|Experimental|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside & Vitamin B12.
32952998|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
32952999|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
32953000|NCT05586672||ASD group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks at several times.
32953001|NCT05586672||Control group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks in inclusion visit.
32953002|NCT02707692|Other|Pneumococcal, then Influenza, then Placebo vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
32953003|NCT02707692|Other|Pneumococcal, then Placebo, then Influenza vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
32953004|NCT02707692|Other|Influenza, then Pneumococcal, then Placebo vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
32953005|NCT02707692|Other|Influenza, then Placebo, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
32953006|NCT02707692|Other|Placebo, then Pneumococcal, then Influenza vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
32953007|NCT02707692|Other|Placebo, then Influenza, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
32953008|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
32953009|NCT02705196|Experimental|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.~The following LOAd703 doses will be evaluated:~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment"
33315784|NCT01168778|No Intervention|Control|
33315785|NCT01168778|Experimental|Intervention|
33315786|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
33315787|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
33315788|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
33315789|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
33315790|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
33099794|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
33099795|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
32808360|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
33099796|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
33099797|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
33099798|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
33099799|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
33099800|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
33099801|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
33099802|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
33099803|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
33099804|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
33099805|NCT02931006|Placebo Comparator|control|
33099806|NCT02931006|Active Comparator|experimental|
33099807|NCT02936856|Experimental|After Hepatic Arteriography|
33099808|NCT02936856|Active Comparator|Before Hepatic Arteriography|
33099809|NCT04763772|Experimental|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
33099810|NCT04763772|Placebo Comparator|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
33099811|NCT04763772|Experimental|Patient Provided|Report provided directly to the patient.
33099812|NCT04763772|Placebo Comparator|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
33099813|NCT04694105|Active Comparator|dexmedetomidine|Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
33404860|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
33404861|NCT05078710|Experimental|Telitacicept arm|Telitacicept 160mg once a week for 24 week as an add-on treatment regimen.
32808361|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
32808362|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
32808363|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
33099814|NCT04694105|Active Comparator|dexamethasone|Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)
33099815|NCT04694105|Placebo Comparator|control group|Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline
33099816|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
33099817|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
33099818|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
33099819|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
33099820|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
33099821|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
33099822|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
33404862|NCT05078632||Healthy volunteers|healthy volunteers
33099823|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
33099824|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
33099825|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
33099826|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
33099827|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
32808364|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
33099828|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
33099829|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
33099830|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
32808365|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
32808366|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
33099831|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
33099832|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
33315791|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
33315792|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
33099833|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
33099834|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
33315793|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
33315794|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
33315795|NCT01169012|Other|Single Arm Trial|Single Arm Trial
33315796|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
33315797|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
33315798|NCT01169090|Experimental|SK-0403 100 mg QD|
32808367|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
32808368|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
32808369|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
32831142|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
33315799|NCT01169090|Experimental|SK-0403 200 mg QD|
33315800|NCT01169090|Experimental|SK-0403 400 mg QD|
33315801|NCT01169090|Experimental|SK-0403 200 mg BID|
33315802|NCT01169090|Sham Comparator|Placebo|
33315803|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
33315804|NCT01282502|Experimental|Midostaurin with chemoradiation|
33315805|NCT01169246||Paradym VR, DR and CRT models|
33099835|NCT04761081||South Asians who are lean|"The south Asian group who are lean will be of south Asian ethnicity and a waist circumference <90cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
33315806|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
33315807|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
33315808|NCT01269242|Experimental|bindarit 600 mg|
33315809|NCT01269242|Experimental|bindarit 1200 mg|
32808370|NCT04766775|Other|Application of Silver Diamine Fluoride onto the carious teeth surfaces|The patients will receive Silver Diamine Fluoride (SDF) treatment to the carious primary teeth. These are teeth with no sign or symptom, radiographically the deepest layer of the caries lesion does not involve the pulp, the inter-radicular area appears normal). Procedure: apply vaseline, isolate the tooth with a cotton roll, remove the food debris, and gross plaque on the tooth cavity with a spoon excavator, dry the tooth, apply the SDF (a clear, colorless solution) onto the tooth cavity. This application lasts for one minute. Take the urine and hair sample to assess the silver and fluoride levels. Take the urine sample before the SDF treatment, in the first and second 24 hours after the SDF treatment. Take the hair samples before the SDF treatment, followed by days 7,14,30,60,75, and 90 after the SDF treatment. Send the hair and urine samples to the laboratory to assess the silver and fluoride levels. If caries remains active, restore the SDF treated after the day 90 review.
32808371|NCT01777334|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
32808372|NCT01777334|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
32808373|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
32808374|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
32808375|NCT05369013||A|Biosimilar Teriparatide
32808376|NCT05369013||B|Original Teriparatide
33099836|NCT04761081||South Asians with central obesity|"The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
33099837|NCT04761081||White Europeans who are lean|"The white European group who are lean will be of white European ethnicity and a waist circumference <94cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
33099838|NCT04761081||White Europeans with central obesity|"The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
33099839|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
33099840|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
33099841|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
33099842|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
32808377|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
32808378|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
32808379|NCT05368467||1|All consecutive consenting patients diagnosed with PH according to specific hemodynamic criteria at participating institutions.
32808380|NCT05369637|Experimental|Non-pharmacological Intervention|Participants in the intervention group will receive a multidomain non-pharmacological program, including cognitive training, physical exercise, nutrition education, psychoeducation, and diagnosis and correction of hearing impairment.
32808381|NCT05369637|No Intervention|Control group|Control group will receive the usual standard of care provided to these clinical diseases.
32808382|NCT05368545|Active Comparator|usual care lipid lowering|Usual care: atorvastatin 40 mg
32808383|NCT05368545|Experimental|Intensive lipid lowering|Intensive: rosuvastatin 40 mg + ezetimibe 10 mg
32953010|NCT02705196|Experimental|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.~Patients will be assigned to the following LOAd703 doses:~Dose level 1: 1 X 10^11 viral particles per treatment Dose level 2: 5 X 10^11 viral particles per treatment"
32953011|NCT02703948|Other|Restylane Silk with Lidocaine|
32953012|NCT01459536||Rotator Cuff Tear-surgical|
32953013|NCT01459536||Health Older Adult Control|
32953014|NCT01459536||Rotator cuff tear - non surgical|
33315810|NCT01269242|Placebo Comparator|placebo|
33315811|NCT01164878||Before|ELBW infants before change of feeding policy
32953017|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
32953018|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
32953019|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32953020|NCT02666742|Experimental|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
32953021|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
32953022|NCT04390776|Experimental|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
32953023|NCT04390776|Experimental|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
32953024|NCT04390776|Experimental|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
32953025|NCT04390776|Experimental|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
32953026|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
32953027|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
32953028|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
32953029|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
32953030|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
32953031|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
32953032|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
32953033|NCT02686320||Rheumatoid arthritis >65 years old|
32953034|NCT02686320||Rheumatoid arthritis <50 years old|
32953035|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
32953036|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
32953037|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine > 1.5 men, > 1.5 women), liver enzymes > 2.5x normal, pregnant at the time of screening will be excluded
32953038|NCT04391010|Other|Health care providers with beard|
33315812|NCT01164878||After|ELBW infants after change of feeding policy
33315813|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
32953039|NCT04391010|Other|Health care providers without beard|
32953040|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
32953041|NCT05586516|Experimental|IOA-289 in combination with gemcitabine/nab-paclitaxel|
32953042|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
33315814|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
32953043|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
32953044|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
32953045|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
32953046|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
32953047|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
32953048|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
32953049|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
32953050|NCT01459770|Active Comparator|control|"usual care for hospital discharge:~CKD group~ESRD group"
32953051|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention~CKD group~ESRD group"
32953052|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
32953053|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
32953054|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
32953055|NCT02639988||rheumatoid arthritis and type 2 diabetes|
32953056|NCT02639988||osteoarthritis and type 2 diabetes|
32953057|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
32953058|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
32953059|NCT04390854|Active Comparator|Induced blood clot scaffold|
32953060|NCT04390854|Experimental|Induced blood clot scaffold combined with Platelet rich fibrin|
32953061|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Docetaxel~Drug: Cisplatin"
32953062|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Vinorelbine~Drug: Cisplatin"
32953063|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
32953064|NCT02630316|Active Comparator|Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
32953065|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
32953066|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
32953067|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
32953068|NCT02359968|Active Comparator|FOLFOX|"Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days~Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1~Folinic acid 200 mg/m² 2-hr IV infusion on day 1~3 cycles, q14"
32953069|NCT02359968|Experimental|CarboP-pacliT|"Carboplatin (carboP) AUC=2, given by intravenous infusion~Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion~on days 1, 8, 15, 22 and 29"
32953070|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
32953071|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
32953072|NCT04757376|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
32953073|NCT04757376|Active Comparator|US-licensed Prolia|60 mg/mL single dose administration, Solution for injection in PFS
32953074|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
32953075|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
32953076|NCT02624544|Active Comparator|Group B|desonide
32953077|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
32808384|NCT05365035|Experimental|cladribine, cytarabine, venetoclax, and azacitidine|Participants will receive cladribine, cytarabine, and venetoclax for 2 cycles and then azacitidine and venetoclax for 2 cycles. Participants will repeat this pattern of 2 cycles each for up to a total of 18
32808385|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
32808386|NCT01396395|Other|Standard treatment|
32808387|NCT05365347|No Intervention|Treatment as Usual|
32808388|NCT05365347|Experimental|Cognitive enhancement therapy (CET)|Cognitive enhancement therapy with an aim to reduce alcohol consumption
32808389|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
32808390|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
32808391|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
32808392|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
32808393|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
32808394|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
32808395|NCT05630625|Experimental|Drinking Dashboard|Day-level feedback on alcohol use and consequences
32808396|NCT05630625|No Intervention|Assessment Only|Daily assessment control group
32808397|NCT01396083|Experimental|Ranibizumab|
32808398|NCT01396083|Active Comparator|Standard of Care|
32808399|NCT04345263|Active Comparator|MTA pulpotomy|Tooth will receive MTA & resin composite restoration
32808400|NCT04345263|Active Comparator|Biodentine pulpotomy|Tooth will receive Biodentine & resin composite restoration
32808401|NCT04345263|Active Comparator|Bioceramic pulpotomy|Tooth will receive Bioceramic & resin composite restoration
32808402|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
32808403|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
32808404|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
32808405|NCT01776554|Experimental|aH5N1c-High dose|
32808406|NCT01776554|Experimental|aH5N1c-Low dose|
32808407|NCT01776008|Experimental|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32808408|NCT01746368|Experimental|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
32808409|NCT01746368|Active Comparator|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
32808410|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
32808411|NCT01381575|Active Comparator|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
32808412|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
32808413|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
33315815|NCT01274702|Experimental|Visual Reconstitution Therapy|
32808414|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
32808415|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
32808416|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
32808417|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
32808418|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
32808419|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
32808420|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
32953078|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
32953079|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
32953080|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
33315816|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
33315817|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
32953081|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
32953082|NCT02612454|Experimental|Body weight ≥60 kg|Administered every two weeks (Q2W)
32953083|NCT02612454|Experimental|Body weight 30 kg to <60 kg|Administered Q2W
32953084|NCT02612454|Experimental|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
32953085|NCT02612454|Experimental|Body weight 5 kg to <15 kg|Administered Q4W
32953086|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
32953087|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
32953088|NCT02603328|Active Comparator|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
32953089|NCT02603328|Placebo Comparator|Placebo|Identically looking capsules containing no active ingredient
33315818|NCT01169324|Experimental|DBS on|baseline settings
32953091|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
32953092|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
32953093|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
32953094|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
32953095|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
32953096|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
32953097|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
32953098|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
32953099|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
32953100|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
32953101|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
32953102|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
32953103|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
32953104|NCT01451736|Experimental|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
32953105|NCT01451736|Active Comparator|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
32953106|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
32953107|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
32953108|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
32953109|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
32953110|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
32953111|NCT04757844|Experimental|Young healthy voluntary adults|30 young healthy voluntary adults
32953112|NCT04758000|Experimental|Metformin|"Metformin will be administrated according with patients body mass index (BMI). The study is divided into 2 groups.~Group 1: Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy).~Group 2: Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse."
33315819|NCT01169324|No Intervention|DBS off|DBS off
33318666|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
33318667|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
33404863|NCT05078632||intensive care patient|patient hospitalized in intensive care unit
32808421|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
32808422|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
32808423|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
32808424|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
32808425|NCT01877083|Experimental|Lenvatinib|
32808426|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
32808427|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
32808428|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
32808429|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
32808430|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
32808431|NCT03796689|Experimental|Smartphone-linked|
32808432|NCT03796689|Active Comparator|Standard|
32808433|NCT05630079||Metaneb®|"Patients admitted for severe acquired brain injury (sABI) in Neurological Rehabilitation Unit of IRCCS Santa Maria Nascente - Fondazione Don Gnocchi received the MetaNeb® system treatment. It consist of simultaneous combination of positive pressure, continuous high frequency oscillations and aerosol delivery"
32808434|NCT05630079||IPV®|Patients with severe acquired brain injury from Neurological Rehabilitation Unit of IRCCS Fondazione Don Gnocchi, S.M. Nascente received the IPV® treatment. The principle of IPV® is to open collapsed airways and mobilize intrabronchial secretions through the delivery of small tidal volume at high frequency. IPV® adjusts the percussions to the changes in the mechanical properties of the patient's respiratory system: in case of high resistance, it produces small tidal volume at high pressure and low frequency; vice versa in case of low resistance, it produces large tidal volume at low pressure and high frequency
32808435|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
32808436|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
32808437|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (> 18 years of age, BMI> 40 or > 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
32808438|NCT05632653|Experimental|CTO-PCI|
32808439|NCT05632653|No Intervention|non-CTO-PCI|
32808440|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
32808441|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
32808442|NCT05368623||Sequential Enrollment|Patients aged 22yrs or older who have diabetes will be recruited from primary care settings.
32808443|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
32808444|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
32808445|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
32808446|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
32808447|NCT04304469||women|women consulting for domestic violence
32808448|NCT05632575|Other|Single Arm: Virtual Promotoras Intervention|Single-arm study. Pre and post intervention. Observational. Behavioral
32808449|NCT05367999||Patients presenting with TLOC|A concurrent nested qualitative-quantitative design is used. Patients first presenting to an ED with TLOC (and witnesses) who have contributed to the quantitative part of this project will be offered participation in a qualitative interview study after completion of the iPEP during the initial study procedure. Capturing variation based on diagnosis, gender, age and participant/witness role, a purposive sample of participating participants and witnesses will be invited to semi-structured interviews in which they will be prompted to discuss their experiences of using the iPEP and their views on the accuracy in describing their peri-episodal experiences.
32808450|NCT04407273||with statins|Covid-19 infected patients with statins
32808451|NCT04407273||without statins|Covid-19 infected patients without statins
32808452|NCT05632497||Anorexia patients|Hospitalized anorexia patients with body mass index < 15.
32808453|NCT05632497||Healthy controls|Health volunteers: 18 years or older with body mass index between 18.5 and 25.
32808454|NCT05363553|Experimental|infant formula based on whole goat milk|
32808455|NCT05363553|Active Comparator|Infant formula based on cow milk proteins|
33404864|NCT05078398|Experimental|POINT-B|Patients will receive perioperative counseling on opioid consumption following breast surgery, both preoperatively and postoperatively. Upon discharge, patients will be asked whether they would like to be discharged with narcotic pain medication or not.
32808456|NCT05363553|No Intervention|Predominantly breastmilk|
32808457|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
32808458|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
32808459|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
32808460|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
32808461|NCT04000347|Active Comparator|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
32808462|NCT04000347|Active Comparator|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
32808463|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
32808464|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
32808465|NCT05360745|Experimental|Experimental arm|ARACOMPLEX® (food supplement). 2 tablets per day, during 6 months.
32808466|NCT05360745|Placebo Comparator|Control arm|Placebo. 2 tablets per day, during 6 months.
32808467|NCT00211185|Experimental|Denileukin diftitox in combination with CHOP|Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle, pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles, participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles, with a maximum of 8 cycles.
32808468|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
32808469|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
32808470|NCT05632185|No Intervention|Control group|standard regular treatment modalities
32808471|NCT05632185|Active Comparator|Equine assisted intervention|patients will receive weekly equine-assisted therapy sessions over a period of 8 weeks in addition to their standard regular therapy
32808472|NCT05632029|Active Comparator|laser (active laser)|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
32808473|NCT05632029|Sham Comparator|laser (sham laser)|32 lupus prediabetic women will receive laser acupuncture (sham . i.e power of the device will be zero) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
32808474|NCT05631873|Experimental|Intervention|
32808475|NCT05631873|No Intervention|Control|
32808476|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
32808477|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
32808478|NCT00219297|Experimental|Single Arm|
32808479|NCT05631795|Experimental|Alpelisib + fulvestrant|Alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28 day cycle.
32808480|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
32808481|NCT00216255|Experimental|Pagoclone|.15mg, .30mg, .60mg
32808482|NCT00216255|Placebo Comparator|Placebo|Placebo
32808483|NCT01745120|Experimental|LentiGlobin BB305 Drug Product|
32808484|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
32808485|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
32808486|NCT01828567|No Intervention|Control|Usual care
32808487|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
32808488|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
32808489|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
32808490|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
32808491|NCT04610905|No Intervention|Control group|This group will be asked to maintain their daily routine.
32808492|NCT04610905|Experimental|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
32953113|NCT04758078|Experimental|Corticosteroids|Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)
32953114|NCT04758078|Placebo Comparator|Placebo|Patients will receive nebulized 0.9% saline
32953115|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
32953116|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
32953117|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
32953118|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
32953119|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
32953120|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
32953121|NCT01453530|Placebo Comparator|No reversal agent|No treatment
32953122|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
32953123|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
32953124|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
32953125|NCT02019654||1|Mild or moderate TBI within the past 30 days
32953126|NCT05585892|Other|Intervention items 1-15|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group B.
32953127|NCT05585892|Other|Intervention items 16-30|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group A.
32953128|NCT05585814|Experimental|Pembrolizumab+ Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles;~Pembrolizumab：Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles"
32953129|NCT02567292|No Intervention|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
32953130|NCT02567292|Experimental|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
32953131|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
32953132|NCT02566122||muscle strength ,muscle mass|
32953133|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
32953134|NCT02013648|Active Comparator|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
32953135|NCT02013648|Experimental|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
32953136|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
33099843|NCT04506216|Experimental|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
32808493|NCT04610905|Experimental|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
32808494|NCT05631639|Experimental|PillSense System|The device is composed of an orally ingested sensor capsule and a wireless handheld receiver for real-time display of sensor data. The capsule contains a measuring slot for blood entry. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
32808495|NCT04610515||Symptomatic Individuals with infection with SARS-COV2 (ie exposed cohort)|Symptomatic Individuals test positive for SARS-COV2. Participants will be enrolled soon after infection and followed to assess for long term outcomes.
32808496|NCT04610515||Symptomatic Individuals without infection with SARS-COV2 (ie unexposed cohort)|Symptomatic Individuals test negative for SARS-COV2. Participants will be enrolled soon after testing and followed to assess for long term outcomes.
32808497|NCT05366517|Other|Group|LiST active treatment group
32808498|NCT05631483|Experimental|DAISe|DAISe Thrombectomy Device
32808499|NCT01775930|Experimental|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
32808500|NCT01856569||observational|
32808501|NCT03999021|Experimental|Experimental Arm|All participants to receive study intervention.
32808502|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
32808503|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
32808504|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
32808505|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
32808506|NCT01721408|Experimental|Group A|
32808507|NCT01721408|Active Comparator|Group B|
33315820|NCT05343494|Experimental|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
33315821|NCT01169402|Experimental|Fluconazole|
32808508|NCT03998709|Other|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
32953137|NCT02555280|Other|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
33315822|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
33315823|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
33315824|NCT01274780|Experimental|Darunavir / Ritonavir|
33315825|NCT01274780|Experimental|Atazanavir / Ritonavir|
33315826|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
33315827|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
33315828|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
33315829|NCT01169948||Patients awaiting cardiac surgery|
33315830|NCT01282658||Colorectal cancer|
33315831|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
33315832|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
33315833|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
33315834|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
33315835|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
33315836|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
32808509|NCT03998709|Other|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
32808510|NCT05366439|Experimental|AT-752|AT-752 administered orally for 14 days
32808511|NCT05366439|Placebo Comparator|Placebo|Matching placebo administered orally for 14 days
32808512|NCT05366361||Patients Undergoing Clinically-Indicated Maze Surgery|This group includes patients with persistent AF who will be undergoing clinically-indicated Maze surgery.
32808513|NCT05366361||Patients Undergoing Clinically-Indicated Ablation|This groups includes patients with persistent AF who will be undergoing clinically-indicated ablation.
32808514|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
32808515|NCT03025191|Experimental|Prison Connect|
32808516|NCT01744496|Experimental|Rotigotine|Rotigotine Transdermal Patches
32808517|NCT01744496|Placebo Comparator|Placebo|Placebo Transdermal Patches
32808518|NCT05631405|Placebo Comparator|Placebo|
32808519|NCT05631405|Experimental|Intervention|
32808520|NCT04007055|Experimental|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
32808521|NCT04007055|No Intervention|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
32808522|NCT05366205|Experimental|Oral nutritional supplements|Patients in this arm will receive oral nutritional supplements 24-48 hours after admission，which is enteral nutrition emulsion(TPF-T).
32808523|NCT05366205|Sham Comparator|nutrition consultation|Patients in this arm will receive nutrition consultation was given in addition to basic treatment.
32808524|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
32808525|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
32808526|NCT05366127||Patient with bullous pemphigoid|IGA score and BPDAI score will be assessed to patient with bullous pemphigoid
32808527|NCT05631015||Artificial Intelligence support decision group|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
32808528|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
32808529|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
32808530|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
32808531|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
32808532|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
32808533|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
32808534|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
32808535|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
32808536|NCT04254159|Experimental|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
32808537|NCT04254159|Active Comparator|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
33315837|NCT01282892||patients with NAFLD|
33315838|NCT01282892||excess of visceral fat|
33315839|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
33315840|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
33315841|NCT03873350|Experimental|Living kombucha|
33315842|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
33315843|NCT03873350|No Intervention|Water|
33315844|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
33315845|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
33315846|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
33315847|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
33315848|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
33315849|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
32808538|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
32808539|NCT03978585|Experimental|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
32808540|NCT03978585|Active Comparator|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
32808541|NCT05634057|Experimental|anisodamine hydrobromide|The dosage of anisodamine hydrobromide is 1.2-4.0mg/ (kg·d) according to the condition, and the micropump will be used at constant speed. After circulation stabilization and withdrawal of vasoactive drugs, the dosage will be reduced and gradually discontinued.
32808542|NCT05634057|Experimental|heparin|The dosage of heparin is determined by the condition, 3000-6000U subcutaneous injection once a day; After circulation stabilization and withdrawal of vasoactive drugs, the dosage will be reduced and gradually discontinued.
32808543|NCT05634057|Experimental|Anisodamine hydrobromide combined with heparin|The dosage of anisodamine hydrobromide is 1.2-4.0mg/(kg·d) according to the condition, and the micropump will be used at constant speed. The dosage of heparin, depending on the condition, is 3000-6000U subcutaneous injection once a day; After circulation stabilization and withdrawal of vasoactive drugs, the dosage will be reduced and gradually discontinued.
32808544|NCT05634057|No Intervention|conventional therapy|Conventional treatment includes antishock therapy, elimination of the cause, active treatment of the primary disease, replenishing blood volume, correcting acid-base imbalance, blood pressure maintenance with vasoactive drugs, and advanced life support, including advanced organ support such as ventilators and bedside hemofiltration, when the condition requires it.
32808545|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
32808546|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
32808547|NCT04004403|Experimental|Alternate day fasting|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
32808548|NCT04004403|Experimental|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
32808549|NCT04004403|Experimental|Combination alternate day fasting plus exercise|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax."
32808550|NCT04004403|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
32808551|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
32808552|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
32808553|NCT03996135|Experimental|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
32808554|NCT03996135|No Intervention|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
32808555|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
32808556|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
32808557|NCT03995511|Experimental|Bilateral sagittal split|
32808558|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
32808559|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
32808560|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
32808561|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
32808562|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
32808563|NCT05633667|Experimental|Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)|ZIM 360 mg and DOM 1200 mg on Day 1 of each 21-day cycle, up to 35 treatment cycles, plus SG 10 mg/kg on Days 1 and 8 of each 21-day cycle, until disease progression (PD) or unacceptable toxicity.
32808564|NCT05633667|Experimental|Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)|ZIM 360 mg plus DOM 1200 mg on Day 1 each 21-day cycle up to 35 treatment cycles and ETRUMA 150 mg, daily in each 21-day cycle, until PD or unacceptable toxicity.
32808565|NCT05633667|Experimental|Substudy 01: ZIM + ETRUMA|ZIM 360 mg on Day 1 of each 21-day cycle up to 35 treatment cycles plus ETRUMA 150 mg, daily in each 21-day cycle, until PD or unacceptable toxicity.
32831143|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
33315850|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
33315851|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
33315852|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
33315853|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
32831144|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
32831145|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
33315854|NCT01172756|Experimental|Arm 1|
33315855|NCT01172756|Experimental|Arm 2|
33315856|NCT01172756|Experimental|Arm 3|
33315857|NCT01172756|Placebo Comparator|Arm 4|
33315858|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
33315859|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
33315860|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
33315861|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
33315862|NCT01172834|Experimental|Lifestyle counseling|
33315863|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO)~Day 1 : CDDP 60mg/m2/day IVF 2hours~Day 15~21 : Rest"
33315864|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
33315865|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
33315866|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
33315867|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
33315868|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
33315869|NCT01166204|Experimental|Single group|
33315870|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
33315871|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
33315872|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
33315873|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
33315874|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
33318668|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
32831146|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
32831147|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
32831148|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
32831149|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
32831150|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
32831151|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
32831152|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
32831153|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
33099844|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
33099845|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
33099846|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
33099847|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
33099848|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
32808566|NCT05633667|Active Comparator|Substudy 01: ZIM + Platinum Based Chemotherapy|"Expansion Stage Only: ZIM 360 mg on Day 1 of each 21-day cycle for a maximum of 35 treatment cycles plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Participants with non-squamous histology will receive:~Cisplatin 75 mg/m^2 or carboplatin area under the curve (AUC) 5 plus pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle. Cisplatin/carboplatin will be administered for a maximum of 4 treatment cycles. Pemetrexed continued 4 cycles until PD or unacceptable toxicities.~OR,~Participants with squamous histology will receive:~Carboplatin AUC 6 with paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle or nab-paclitaxel 100 mg/m^2 on Days 1, 8 and 15 of each 21-day cycle. Carboplatin, paclitaxel, and nab-paclitaxel will be administered for a maximum of 4 treatment cycles."
33099849|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
33099850|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
33099851|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
33099852|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
33099853|NCT04502667|Experimental|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
33099854|NCT04502667|No Intervention|Control|No intervention
33099855|NCT00524498|Experimental|A|FAIT
33099856|NCT00524498|Active Comparator|B|BST
33099857|NCT04492917|Experimental|Cranial Technique CV4|"All subjects received a combination of the active technique (CV4) and the corresponding sham technique (shamCV4).~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.~ShamCV4: sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch"
33099858|NCT04492917|Active Comparator|Sacral Technique ST|"All subjects received a combination of the active technique (ST) and the corresponding sham technique (sST).~ST: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.~ShamST: sham intervention was performed by placing the hands in the same position of the corresponding active technique, applying a light touch"
33099859|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
33099860|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
33099861|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
33315875|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
32808567|NCT05633667|Experimental|Substudy 02: SG + ZIM + ETRUMA|ZIM 360 mg on Day 1 of each 21-day cycle up to 35 treatment cycles plus SG 10 mg/kg on Days 1 and 8 in each 21-day cycle, and ETRUMA 150 mg, daily until PD or unacceptable toxicity.
32808568|NCT05633667|Active Comparator|Substudy 02: Either Docetaxel or SG (Monotherapy Only)|Expansion Stage Only: Either SG 10 mg/kg on Day 1 and Day 8 of each 21-day cycle or Docetaxel 75 mg/m^2 on Day 1 of each 21-day cycle, until PD or unacceptable toxicity.
32808569|NCT04588363||SARS-CoV-2 positive children|"Individuals less than 21 years of age who fulfill one or more of the following criteria:~SARS-CoV-2 detection from a respiratory specimen, and/or~Meets criteria for MIS-C, and/or~Meets criteria for MIS-C, except has involvement of only 1 organ system"
32808570|NCT05633589|Experimental|Experimental: Sc610 cell injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: Sc610 cell injection.
33099862|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
33099863|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
33099864|NCT00524615|Placebo Comparator|2|placebo oraly once daily
33099865|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
33099866|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
33315876|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
33099867|NCT03458819||Control|Patients on neither active Vitamin D or a statin
32808571|NCT04003779|Other|Participant stability with various room configurations|Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room.
32808572|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
32808573|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
32808574|NCT03994653||Cases|Participants diagnosed with ovarian cancer
32808575|NCT03994653||Controls|Participants without ovarian cancer
32808576|NCT05633199|Experimental|cytoreduction surgery followed by chemotherapy|
32808577|NCT05633199|No Intervention|chemotherapy alone|
32808578|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
32808579|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
32808580|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
32808581|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks~Osimertinib 80 mg once daily, orally, continuous~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
32808582|NCT01827943|Experimental|Temsirolimus|Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.
32808583|NCT03594201||group1|A+B grade sperm count after treatment=0
32808584|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
32808585|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
32808586|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
32808587|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
32808588|NCT04609813||Screening population|Participants underwent opportunistic endoscopic screening for esophageal cancer in high-risk regions in China will be enrolled in this study. Esophageal cell specimen will be collected by esophageal sponge cell collection device (Esoheal 1.0) prior to endoscopic examinations.
32808589|NCT05633043||16-18 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32808590|NCT05633043||16-18 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32831154|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
32831155|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
32831156|NCT03261882||Foreign-born Mexican-Americans|
32831157|NCT03261882||US-born Mexican-Americans|
32831158|NCT03261882||non-Hispanic Whites|
33099868|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
33404865|NCT05078398|Active Comparator|Usual Care|Patients will receive equivalent of 5 tabs of Norco 5/325 mg upon discharge routinely
32808591|NCT05633043||18-25 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32808592|NCT05633043||18-25 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32808593|NCT05633043||25-45 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32808594|NCT05633043||25-45 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
32808595|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
32808596|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
32808597|NCT05632887||Control|The population who do not use eyeliner.
32808598|NCT05632887||Eyeliner|The population who using eyeliner and the duration and frequency are appropriate。
32808599|NCT05632731|Other|Double Cleavage-stage Embryos transfer|In group A, two embryos at cleavage stage were transplanted on the third day after oocyte retrieval.
33315877|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
33315878|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33315879|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33315880|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33315881|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33318669|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
33318670|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
33318671|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
33318672|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
32808600|NCT05632731|Other|Single Blastocyst Stage Embryos transfer|Group B was graded by Gardner blastocyst grading method, and one blastocyst was transplanted on the 5th or 6th day after oocyte retrieval.
32808601|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
32808602|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
32808603|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
32808604|NCT00212121|Experimental|2|high boost (26 Gy)
32808605|NCT00217971|Active Comparator|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
32808606|NCT00217971|Placebo Comparator|Placebo|placebo
32808607|NCT03976323|Experimental|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
32808608|NCT03976323|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m^2 on Day 1 of each 21-day cycle. In the Maintenance Phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
32808609|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
32808610|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
32808611|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
32808612|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
32808613|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
32808614|NCT03991923|Experimental|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
32808615|NCT03991923|Active Comparator|Ischemic cold static storage (ICSS)|Standard preservation technique
32808616|NCT00217581|Experimental|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
32808617|NCT03991455|Other|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
32808618|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
32808619|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
32808620|NCT00217425|Experimental|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 [max. 2 mg]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
32808621|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
32808622|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
32808623|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
32831159|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
32831160|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
32831161|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing~SR stimulation and Sensory integration testing"
33099869|NCT03458819||Statin|Patients on a statin but not active Vitamin D
33099870|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
33099871|NCT04689750||Allogeneic HSCT recipients and donors|
32808624|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
33099872|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
33099873|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
33099874|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
33099875|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
33315882|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33315883|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
33099876|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
33099877|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
33099878|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
33099879|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
33099880|NCT04690725|Experimental|TQB3525 arm|3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
33099881|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
33099882|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
33099883|NCT02947919|Experimental|Intervention|Music in the perioperative period
33099884|NCT02947919|No Intervention|Control|Usual treatment
33315884|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
33315885|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
33315886|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
33315887|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
33315888|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
33315889|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
33315890|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
32808625|NCT00215943|Active Comparator|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
32808626|NCT00215943|Active Comparator|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
32808627|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
32808628|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
32808629|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
33315891|NCT03866876||Hôpital Femme Mère Enfants births|
33315892|NCT04590430|Experimental|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
33315893|NCT04590430|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
32953138|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
32953139|NCT02279550||hip fracture|aged >65 with hip fracture
33315894|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
33315895|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
33315896|NCT05276440||General Anesthesia|
33315897|NCT05276440||Erector Spinae Plane Block|
33315898|NCT05276440||Rhomboid Block|
33315899|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
33315900|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
33315901|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
33315902|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
33315903|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
33315904|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
33315905|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
33315906|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
33315907|NCT04435444|Experimental|Masterful supportive care|This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
33315908|NCT04435444|Active Comparator|Attention control supportive care|This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
32953140|NCT05585736|Other|Cycloplegic refraction|All refractions were measured before and after cycloplegic addition to the eye.
33315909|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
33315910|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
33315911|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
33315912|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
32953141|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
32953142|NCT01989780|Experimental|Arm B|"endocrine therapy* + bevacizumab then back to weekly paclitaxel + bevacizumab therapy~(*Letrozole, Anastrozole, Exemestane, Fulvestrant, LHRH Analogs + Aromatase inhibitors.)"
32953143|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
32953144|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
33099885|NCT04690569||Infectious|Eligible pediatric and adult patients from ED\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.
33099886|NCT04690569||Healthy|For the purpose of establishing a normal reference range.
33099887|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
32808630|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
32808631|NCT04608877|Placebo Comparator|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
32808632|NCT04608877|Experimental|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
32808633|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
32808634|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
32808635|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
32808636|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
33404866|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
33404867|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
33404868|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
32808637|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
32808638|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
32808639|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~expanded community health worker services;~home blood pressure self-monitoring; and~a storytelling intervention."
32808640|NCT03990207|Experimental|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
32808641|NCT01827163|Experimental|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.
32808642|NCT00215553|Experimental|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
32808643|NCT00215553|Experimental|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
32808644|NCT00215553|Experimental|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
32831162|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing~SR stimulation and Sensory integration testing"
33404869|NCT02046096|Experimental|Cook Celect® Vena Cava Filters|Cook Celect® Vena Cava Filters
33404870|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
33404871|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
33404872|NCT05124678|Experimental|Fast/intermediate acetylators|"Participants in this arm have fast/intermediate acetylator status from NAT2 genotyping.~In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 10mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
33404873|NCT05124678|No Intervention|Slow acetylators|"Participants in this arm have a slow acetylator status from NAT2 genotyping. They will receive the standard of care. In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 5mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
33404874|NCT04668820|Experimental|Children who admit to Pediatric Rehabilitation outpatient clinic|Children who admit to Pediatric Rehabilitation outpatient clinic of the Department of Physical Medicine and Rehabilitation will be evaluated by face to face and virtually by using zoom application via video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
32808645|NCT00215553|Experimental|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
32808646|NCT00215553|Experimental|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
32808647|NCT00215553|Experimental|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
32808648|NCT00215553|Other|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care [SOC]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
32808649|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
32808650|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
32808651|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
32808652|NCT00214461|Placebo Comparator|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
32808653|NCT00214461|Experimental|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
32808654|NCT00214461|Experimental|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
32808655|NCT00214461|Experimental|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
32808656|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
32808657|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
32808658|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
32808659|NCT04407351|Other|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
32808660|NCT04407351|Other|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
32808661|NCT00214383|Experimental|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
32808662|NCT00214383|No Intervention|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
32808663|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
32808664|NCT00212355|Experimental|NPC-02|zinc acetate
32808665|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
32808666|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
32808667|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
32808668|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
32808669|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
32808670|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
32808671|NCT00211887|Active Comparator|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate~Interferon b-1a (IFN) intramuscularly weekly"
32808672|NCT00211887|Active Comparator|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate~Glatiramer acetate 20mg daily"
32808673|NCT00211887|Active Comparator|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
32808674|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
32808675|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
33315913|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
33315914|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
33315915|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
33315916|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
33315917|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
33315918|NCT01283750|No Intervention|Augmented Usual Care|
33315919|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
33315920|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
32953145|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~Cisplatin or carboplatin may be given at the discretion of the investigator.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
32953146|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
33315921|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
32953147|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
33315922|NCT01585688|Experimental|hLL1-DOX|
33315923|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
33315924|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
33315925|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
32953148|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
32953149|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
32953150|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
32953151|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
32953152|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
33315926|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
33315927|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
33315928|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
33315929|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
32953153|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
32953154|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
32953155|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
32953156|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
32953157|NCT01894464|No Intervention|Control Group|
32953158|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
32953159|NCT02260362||HTAP of Congenital Heart Disease|
32953160|NCT05585580|Experimental|Serplulimab, lenvatinib and paclitaxel|Patients will be treated with serplulimab combined with lenvatinib and paclitaxel for 6 cycles, followed by serplulimab combined with lenvatinib maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of treatment consent.
32953161|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
32953162|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
33315930|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
33315931|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
33315932|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
33315933|NCT00312377|Active Comparator|1|Docetaxel monotherapy
33315934|NCT00312377|Experimental|2|Vandetanib + Docetaxel
33315935|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
33315936|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
33315937|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~one sample prior to treatment initiation~one sample after completion of treatment~one sample every 6 to 8 weeks during follow up visits~one sample at the time of Relapse"
33315938|NCT01173536|Active Comparator|A|
33315939|NCT01173536|Active Comparator|B|
33315940|NCT01173536|Experimental|C|
33315941|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
33315942|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
33315943|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
33315944|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
33315945|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
33315946|NCT05285696|Experimental|[68Ga]-NOTA-hGZP (CSB-111) Injection|Eligible participants will receive a single IV injection of CSB-111 up to 40 micro grams
33315947|NCT01059383|Experimental|VECAM 40/300|
33315948|NCT01059383|Active Comparator|Esomeprazole 20 mg|
33315949|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
33315950|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
33315951|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
33315952|NCT01173614||Normal subjects|Subjects with two normal eyes.
33315953|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
33315954|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
33315955|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
33315956|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
33315957|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
33315958|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
33315959|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
33315960|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
33315961|NCT01285154||Modified Triple Osteotomy|Modified technique
33315962|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
33315963|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
33315964|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
33315965|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
33315966|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
33315967|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
33315968|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
33315969|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
33315970|NCT01173770|Experimental|Cohort 6: ADC3680B|
33315971|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
33315972|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
33315973|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
33315974|NCT01166594|Experimental|Bevacizumab|Tested Drug
33315975|NCT01166594|Placebo Comparator|Control|Control - BSS
33315976|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
33315977|NCT01170338|Placebo Comparator|sugar pill|
33099888|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
33099889|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
33099890|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
33099891|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
33099892|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
33099893|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
33315978|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
33315979|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
33315980|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
33315981|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
33315982|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
33315983|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
33315984|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
33315985|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
32808676|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
32808677|NCT04002297|Experimental|zanubrutinib plus rituximab|
32808678|NCT04002297|Active Comparator|bendamustine plus rituximab|
32808679|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
32808680|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
32808681|NCT04199013|Active Comparator|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
32808682|NCT04199013|Active Comparator|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
32808683|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
32808684|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
33099894|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
33099895|NCT04748172||Study Group: Women who are planning to be vaccinated|Women that are planning to be vaccinated, before receiving the first shot of the vaccine
33099896|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
33099897|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
33099898|NCT04690803|Active Comparator|treatment with forced-air cooling|comparing treatment with and without forced-air cooling in a comparative lower extremity model
33099899|NCT04690803|No Intervention|treatment without forced-air cooling|comparing treatment without forced-air cooling in a comparative lower extremity model
33099900|NCT00523757|Experimental|1|Spironolactone
33099901|NCT00523757|Placebo Comparator|2|
33099902|NCT00524693|Active Comparator|1|4mg Singulair© sachets
33099903|NCT00524693|Placebo Comparator|2|
33099904|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
33099905|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
33099906|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
33099907|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
32953163|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
32953164|NCT04756986|Experimental|malic acid group|patients will receive a topical spray containing 1% malic acid
33315986|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
33315987|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
33315988|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
33315989|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
33315990|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
33315991|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
33315992|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
32953165|NCT04756986|No Intervention|placebo group|patients will receive a topical placebo spray
32953166|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
32953167|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
32953168|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
32953169|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
32953170|NCT02283996|Experimental|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
32953171|NCT02283996|Experimental|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
32953172|NCT05586282||Patients with a circulatory failure|All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
32953173|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
32953174|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
32953175|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
32953176|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
32953177|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
32953178|NCT04390152|Experimental|Mesenchymal stem cell|WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
32953179|NCT04390152|Active Comparator|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
32953180|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
32953181|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
32953182|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
32953183|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
32953184|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
32953185|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
32953186|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part A|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
32953187|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part B|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after modified myeloreductive conditioning including increased monitoring and rescue treatment
32953188|NCT04756674||Control Group|"Non-Covid -19 associated community acquired pneumonia with oxygen therapy required.~n=12"
32953189|NCT04756674||Oxygen Therapy|"Confirmed COVID-19 infection via PCR swab, with a new oxygen therapy requirement. NB the researchers will not be involved in the clinical decision of if the participant requires oxygen, this will be the clinical-teams decision.~n=12"
33099908|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
33099909|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
33099910|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
33099911|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
33099912|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
33315993|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
33099913|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
33099914|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32808685|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
32808686|NCT03989895|Experimental|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
32808687|NCT04747665||Patients|Patients who have undergone or refused to undergo colonoscopy
32808688|NCT04747665||Endoscopists|Endoscopists who perform or are training to perform colonoscopy
32808689|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
32808690|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
33099915|NCT02936700|Other|Control group|Add on relaxation group
33099916|NCT02936700|Experimental|Therapy ACT|Add on ACT group
33099917|NCT04693481|Experimental|experimental group: 5 seconds for each photo|receive the intervention, which is viewing each nature photo for 5 seconds
33099918|NCT04693481|Experimental|experimental group: 15 seconds for each photo|receive the intervention, which is viewing each nature photo for 15 seconds
33099919|NCT04693481|Experimental|experimental group: 30 seconds for each photo|receive the intervention, which is viewing each nature photo for 30 seconds
33099920|NCT04693481|No Intervention|control group|not receive the intervention, which is viewing each nature photo for 0 seconds.
32808691|NCT04198935|Experimental|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
32808692|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
32808693|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
32808694|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
32808695|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
33099921|NCT02930382|Experimental|BAROREFLEX|
33099922|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
33099923|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
33099924|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
33099925|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
33099926|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
33099927|NCT00523835||Normal|Normal men Age matched to KS patients
33099928|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33099929|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33099930|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
33099931|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
33099932|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
33099933|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
33099934|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
33315994|NCT01173926|Experimental|IAsp|
33315995|NCT01173926|Experimental|IDeg|
33315996|NCT01173926|Experimental|IDegAsp|
33315997|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
33315998|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
33315999|NCT03349268|Active Comparator|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
33316000|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
32808696|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
32808697|NCT04198389|Experimental|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
32808698|NCT03989115|Experimental|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
32808699|NCT03989115|Experimental|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
32808700|NCT04198467|Experimental|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
32808701|NCT04198467|Placebo Comparator|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
32808702|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
32808703|NCT04198155|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
32808704|NCT03024333||Healthy subjects|"Healthy subjects are:~Between 19-60 years old~Able to sign the informed consent after the whole study is explained to them~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery~Able to sit upright with or without back support of chair~No other diseases affect swallowing function"
32808705|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
32808706|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
32808707|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
32808708|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
32808709|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
32808710|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
32808711|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
32808712|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
32808713|NCT04198233|Experimental|Diazepam group|Rectal Diazepam suppository
32808714|NCT04198233|Placebo Comparator|Placebo group|Placebo suppository
32808715|NCT04216563|Experimental|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
32808716|NCT03968445|Experimental|Recent Myocardial Infarction|
32808717|NCT03968445|Experimental|undergoing elective percutaneous coronary intervention|
32808718|NCT04197375|Experimental|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
32808719|NCT04197375|Sham Comparator|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
32808720|NCT03987711|Experimental|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
32808721|NCT03987711|Active Comparator|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
32808722|NCT03987711|Active Comparator|No oral anticoagulation|Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
32808723|NCT03986853|Experimental|Blood sample|Blood sampling Under general anesthesia
32808724|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
32808725|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
32808726|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
32808727|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
32808728|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
32953190|NCT04756674||Non-Invasive ventilation therapy|"Confirmed COVID-19 infection via PCR Swab, with a clinical need for non-invasive ventilation.~NB the researchers will not be involved in the clinical decision if the participant requires non-invasive ventilation, this will be the clinical-teams decision.~n=12"
33316001|NCT01170494|Active Comparator|D2 2000 IU daily|
33316002|NCT01170494|Active Comparator|D3 2000 IU daily|
33316003|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
33099935|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
33099936|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
33099937|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
33099938|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
33099939|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
33316004|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
33316005|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
33099940|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
33099941|NCT00523952|Experimental|1|
33099942|NCT04693676|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
33099943|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
33099944|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
33099945|NCT00524810|Experimental|Caelyx - Taxotere|
33099946|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
33099947|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
32808729|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
32808730|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
33099948|NCT02936154|Experimental|300 mg|
33099949|NCT02936154|Placebo Comparator|placebo|
33316006|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
33316007|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
33099950|NCT00524888|Active Comparator|1|suturing lacerations of the hand
33099951|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
33099952|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
33099953|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
33099954|NCT00524927|Active Comparator|A|
33099955|NCT00524927|Placebo Comparator|B|
32808731|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
33099956|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
33099957|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
33316008|NCT01170494|Placebo Comparator|placebo daily|
33316009|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
33316010|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
33316011|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
33316012|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
33316013|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
33316014|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
33316015|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
33316016|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
33316017|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
33316018|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
33316019|NCT03865550|Placebo Comparator|Placebo|
33316020|NCT03865550|Active Comparator|Ketamine|
33316021|NCT02965690|Active Comparator|Zimmer Biomet NexGen CR|Patients receive a Zimmer Biomet NexGen Total Knee Replacement
32808732|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
33099958|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
33099959|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
33316022|NCT02965690|Active Comparator|Medacta International GMK Sphere|Patients receive a Medacta International, GMK Sphere Total Knee Replacement
33316023|NCT01285388|Experimental|MB12066 10mg|
33316024|NCT01285388|Active Comparator|MB12066 30mg|
33099960|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
33099961|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
33099962|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
33316025|NCT01285388|Active Comparator|MB12066 100mg|
33316026|NCT01285388|Active Comparator|MB12066 150mg|
33099963|NCT04693442||Burn patients|with the condition
33099964|NCT04693442||Control group|without the condition (blood sampling only for adults) and children undergoing general anaesthetic procedures that involve skin resections (blood sampling and excised skin)
33099965|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
33099966|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
33099967|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
33099968|NCT04693208|Experimental|Laser|Laser light will be applied to the surgery site after tonsils excision.
33099969|NCT04693208|No Intervention|Standard care|
33099970|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
32808733|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
33316027|NCT01285388|Active Comparator|MB12066 200mg|
33316028|NCT01285388|Placebo Comparator|placebo|
32808734|NCT01610791|Experimental|Single Arm|
32808735|NCT03832491|Other|Control Group|"Home Based Therapy: 16 patients with PCD~Airway clearence techniques, everday of the week, during eight weeks"
33099971|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
33099972|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
33099973|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
33099974|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
33099975|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.~Phase II: maximum tolerated dose. given as a 1 hour infusion~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
33099976|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
33316029|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
33316030|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
33316031|NCT01285466|Experimental|BEZ235 + paclitaxel|
33316032|NCT01285466|Experimental|BKM120 + paclitaxel|
33316033|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
33316034|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
33316035|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
33316036|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
33316037|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
33316038|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
33316039|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
33316040|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
33316041|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
32808736|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 16 patients with PCD~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.~Airway clearence techniques, everday of the week, during eight weeks"
32808737|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
32808738|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
32808739|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
32808740|NCT01876381|Experimental|OPC-41061|
32808741|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
32808742|NCT03984513|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
32808743|NCT03984513|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
32808744|NCT01855399|Experimental|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
32808745|NCT01855399|Active Comparator|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
32808746|NCT04210557|Experimental|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
32808747|NCT04210557|Experimental|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
32808748|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
32808749|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
33316042|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
33316043|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
33316044|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
33316045|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
33316046|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
33316047|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
33316048|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
33316049|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.~Conventional surgery"
33316050|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.~Complete mesocolic excision with central vascular ligation"
33316051|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
33316052|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
33316053|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
33099977|NCT04442178|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
33099978|NCT04442178|Placebo Comparator|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
33099979|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
33099980|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
33099981|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
33099982|NCT02946749||Shanghai First Maternity and Infant Hospital|
33099983|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
33099984|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
33099985|NCT02946749||The Sixth people's hospital of Shanghai|
33099986|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
33099987|NCT00525200|Active Comparator|A|
33099988|NCT00525200|Experimental|B|
33099989|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
33099990|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
33099991|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
33099992|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
33099993|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
33099994|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
33099995|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
33099996|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
33099997|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
33099998|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
33099999|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
33100000|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
33100001|NCT02947568||CKD|chronic kidney disease
33100002|NCT02947568||DM|diabetes mellitus
33100003|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
33100004|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
33100005|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
33100006|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
33100007|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
33100008|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
33100009|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.~chart review"
33316054|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
33100010|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
33100011|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
32808750|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
32808751|NCT04203927|Active Comparator|Empagliflozin + insulin infusion|vascular measurements in overnight fasted state and during insulin infusion
32808752|NCT04203927|Active Comparator|Empagliflozin + mixed meal|vascular measurements in overnight fasted state and 2 hours after mixed meal 10kcal/kg body weight ( 55% Cho, 30%Fat, 20% Pro)
32808753|NCT04196985|Experimental|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
33100012|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
33100013|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
33100014|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
33100015|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
33100016|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
33100017|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
32808754|NCT04201431|Experimental|Group 1|Up to 12 volunteers in Group 1 will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at 1, 2 and 12-18 months prior to blood-stage CHMI 2-4 weeks after the third vaccination.
32808755|NCT04201431|Experimental|Group 2|If fewer than 8 volunteers complete the study in Group 1, then new volunteers will be recruited into Group 2, to make up a total of 10 to 12 volunteers who complete 3 vaccinations and CHMI between Groups 1 and 2. Group 2 volunteers will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at monthly intervals, prior to blood-stage CHMI 2-4 weeks after the third vaccination.
32808756|NCT04201431|Experimental|Group 3|Up to 6 volunteers from Group 1 will receive a fourth dose of PvDBPII 50ug/Matrix M1 50ug, at 5 months post the third dose, prior to a second CHMI 2-4 weeks later.
32808757|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
32808758|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
32808759|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
32808760|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
32808761|NCT04196829|Experimental|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
32808762|NCT04196829|Active Comparator|silver diamine fluoride|38% silver diamine fluoride
32808763|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
32808764|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
32808765|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
32808766|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
32808767|NCT01825837|Experimental|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
32808768|NCT01825837|Experimental|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
32808769|NCT01825837|Experimental|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
32808770|NCT01825837|Experimental|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
33100018|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
33316055|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
33100019|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
33100020|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
33100021|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
33100022|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
33100023|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
33100024|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
33100025|NCT04693052||Patients receiving mental health care prior to and during the COVID-19 pandemic|
33100026|NCT02929914|Experimental|Control|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, dentin washed with sodium 0.9% saline, sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
33100027|NCT02929914|Experimental|PDT+CH|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, disinfect the remaining dentin with antimicrobial photodynamic therapy (DENFOTEX PADplus), sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
33100028|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
33316056|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
33100029|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
33100030|NCT04417725||Chronic kidney disease|
33100031|NCT04417725||Type 2 diabetes mellitus|
33100032|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|
33100033|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
33100034|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
33100035|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
33100036|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
33100037|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
33100038|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
33100039|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
33100040|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
33100041|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
33100042|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
33100043|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
33100044|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
33316057|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
33316058|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
33316059|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
33316060|NCT03865160|Experimental|Arm A, Interventional group|Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months
33316061|NCT03865160|Experimental|Arm B, Control group|Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months
33316062|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
33316063|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
33100045|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
33316064|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
33316065|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
33316066|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
33100046|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
33100047|NCT04325685|Placebo Comparator|Control group|
33100048|NCT04325685|Active Comparator|Antiseptic (Octenisept) group|
33100049|NCT04325685|Experimental|Bacteriophage (Sextaphag) group|
33100050|NCT04693559|Other|autogenous iliac bone graft (group A)|autogenous iliac bone graft will be used to fill the alveolar defect
33100051|NCT04693559|Other|Nano crystalline Hydroxyapatite (group B)|Nano crystalline Hydroxyapatite will be used to fill the alveolar defect
32808771|NCT04197063|Experimental|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
33100052|NCT04323150|Experimental|Closed suction systems|
33100053|NCT04323150|Other|Open (conventional) suction|control group
33100054|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
33100055|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
33100056|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
33100057|NCT00526019||Healthy controls|Healthy controls
33100058|NCT00525434|Experimental|A|
33100059|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
33100060|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
33100061|NCT04310475|Experimental|Active Treatment|This is a case series
33100062|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
33100063|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
33100064|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
33100065|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
33100066|NCT02929446|Experimental|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
33100067|NCT02929446|No Intervention|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
33100068|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
33100069|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
33100070|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
33100071|NCT00525551|Active Comparator|1|
33100072|NCT00525551|Placebo Comparator|2|
32808772|NCT04197063|Experimental|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
33100073|NCT04288323|Experimental|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
33100074|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
33100075|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
33100076|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
33100077|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
33100078|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
33100079|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
33316067|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
32808773|NCT04197063|Experimental|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with </= 16 oz. SSB portion sizes with the option to purchase refills
32808774|NCT04197063|Experimental|</= 16 oz. SSB portions plus free refills|Offered a menu with </= 16 oz. SSB portion sizes plus free refills
32808775|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
32831163|NCT03938532|Active Comparator|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
33316068|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
33316069|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
33316070|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
32953191|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
33316071|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
33316072|NCT03992105|Other|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
33316073|NCT01286246|Experimental|Vaginal progesterone|
33316074|NCT01286246|Placebo Comparator|Placebo|
33316075|NCT01324817||Hopitalized|Patients admitted to the hospital
33316076|NCT05275660|Experimental|HFB30132A|Participants will receive HFB30132A administered across 2 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
33316077|NCT05275660|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
33316078|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
33316079|NCT03753542|No Intervention|Control|The Control group will receive routine care
33316080|NCT03981887|Experimental|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
33316081|NCT03981887|Placebo Comparator|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
32953192|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
32953193|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
32953194|NCT02502162|Placebo Comparator|Placebo|Sugar pill
32953195|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
32953196|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
32953197|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
32953198|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
32953199|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
32953200|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
32953201|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
32953202|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
32953203|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
32953204|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
32953205|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
32953208|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
32953209|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
32953210|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
32953211|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
32953212|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
32953213|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
32953214|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
33100080|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
33100081|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
32808776|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
33316082|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
33100082|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
33316083|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
32808779|NCT04196673|Experimental|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
33100083|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
33100084|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
32808780|NCT04196673|Experimental|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
32808781|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
32808782|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
32808783|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
32808784|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
32808785|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
32808786|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
32808787|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
32808788|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
32808789|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
32808790|NCT04196517|Experimental|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
32808791|NCT04196517|Experimental|Arm 2 - WebMD|WebMD.com
32808792|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
32808793|NCT03590067||Heamodialysis group|
32808794|NCT03590067||Kidney transplantation group|
32808795|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
32808796|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
32808797|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
32953215|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
32953216|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
32953217|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
33100085|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
32953218|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
32953219|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
32953220|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
32953221|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
32953222|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
32953223|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
32953224|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
32953225|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
32953226|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
32953227|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
32953228|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
32953229|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
32953230|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
32953231|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
32953232|NCT02461446||Controls|Healthy control group
32953233|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
32953234|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
32953235|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
32953236|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
32953237|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
32953238|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
32953239|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
32953240|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
32953241|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
32953242|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
32953243|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
32953244|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
32953245|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
32953246|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
32953247|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
32953248|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
32953249|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
32953250|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
32953251|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
32953252|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
32953253|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
32953254|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~OXINIUM heads on polyethylene liners or~Ceramic heads on ceramic liners (all uncemented components)"
33316084|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
32808798|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
32808799|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
32808800|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
32808801|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
32808802|NCT03591159|Active Comparator|Membrane Sweeping Group|
32808803|NCT03591159|No Intervention|Control Group|
32808804|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
32808805|NCT01824979|Experimental|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
32808806|NCT01824979|Active Comparator|Other CPAP mask|Other CPAP mask during CPAP titration
32808807|NCT04195971|Experimental|Liver CT with dual arterial phase|
32808808|NCT01824823|Experimental|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
32808809|NCT01824823|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
32808810|NCT04196205|Experimental|Anti-CD19 CAR-T|Anti-CD19 CAR-T
32808811|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
32808812|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
32808813|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
32808816|NCT03598569||lung cancer|
32808817|NCT03598569||other lung diseases|
32953255|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
32953256|NCT02153580|Experimental|Group I (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
32953257|NCT02153580|Experimental|Group II (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
32953258|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
32953259|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
32808818|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
32808819|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
32808820|NCT04766307|Experimental|experimental group|"Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
33100086|NCT04693091|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
33100087|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
33100088|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
32808821|NCT04766307|Active Comparator|Control regimen group|"The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
33100089|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
33100090|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
32808822|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
32808823|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
33100091|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
33100092|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
33100093|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
33100094|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
33100095|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
33100096|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
33100097|NCT02946281|Experimental|Intervention|
32808824|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
32808825|NCT04190823|Experimental|RC98|
32808826|NCT04195191|Placebo Comparator|Placebo|The usual practice by community pharmacies
32808827|NCT04195191|Experimental|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
32808828|NCT01875367|Experimental|Arm A: T-IV + T-SC vial + T-SC device|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
32808829|NCT01875367|Experimental|Arm B: T-IV + T-SC device + T-SC vial|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
32808830|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
33100098|NCT02946281|No Intervention|Care as usual|
33100099|NCT02929290|Experimental|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
33100100|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
32808831|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
32808832|NCT04197999|Experimental|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
32808833|NCT04191057|Experimental|Healthy twin|Free light chains of twins compared to non-twin siblings
32808834|NCT04190589|Experimental|Robotic CME|Robot-assisted extended right colectomy
32808835|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
32808836|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
32808837|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
32808838|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
32808839|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
32808840|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
32808841|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
32808842|NCT04194957|Experimental|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
32808843|NCT04194957|Experimental|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G>A or c.2846A>T of these SNPs
32808844|NCT04194957|Experimental|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs
32808845|NCT04191135|Experimental|pembrolizumab + carboplatin and gemcitabine|Participants receive both carboplatin Area Under The Curve (AUC) 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will continue to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
32953260|NCT02152956|Experimental|Flotetuzumab dose escalation:|Participants will be assigned sequentially to escalating doses of flotetuzumab, up to the maximum tolerated dose (MTD).
32953261|NCT02152956|Experimental|Flotetuzumab dose expansion|Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation.
32953262|NCT02152956|Experimental|Flotetuzumab and ruxolitinib|Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation in combination with one of two escalating doses of ruxolitinib.
32953263|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
32953264|NCT02146950||LCS12|New users of LCS12
32953265|NCT02146950||Mirena|New users of Mirena
32953266|NCT02146950||Copper IUD|New users of copper IUDs
32953267|NCT02146950||Kyleena|New users of Kyleena
32953268|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
32953269|NCT05578950|Active Comparator|group A pulse therapy of itraconazole|patients with pulse therapy group recieved oral itraconazole 100 mg, two capsules twice daily for 7 days a month
32953270|NCT05578950|Active Comparator|group B continous therapy of terbinafine|patients with continous therapy group , recieved continous oral 250 mg terbinafine once daily for 12 weeks continously
32953271|NCT05586126||Sevoflurane|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by using sevoflurane
32953272|NCT05586126||Control|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by means of intravenous medication, such as propofol, midazolam, esketamine of fentanyl
32953273|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
32953274|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
32953275|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
32953276|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
32953277|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
32953278|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
32953279|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32953280|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
32953281|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
32953282|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
32953283|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
32953284|NCT02983110||Cohort E|Group E will be HIV infected men
32953285|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
32953286|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
33100101|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
33100102|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
33100103|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
33100104|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
33100105|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
33100106|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
33100107|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
33100108|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
33100109|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
33100110|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
33100111|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
33100112|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
33404875|NCT03463577||Exposed cohort women-on or after 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) on or after the 1st day of the 27th week of pregnancy during the period January 1, 2018 to January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
33100113|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
33100114|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
33100115|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
32808846|NCT04191135|Experimental|pembrolizumab + olaparib|Participants receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
32808847|NCT04194645|Experimental|BI 474121|
32808848|NCT04194645|Placebo Comparator|Placebo|
33100116|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
33100117|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
33100118|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
32808849|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
32808850|NCT03598101|Experimental|Test group|
32808851|NCT04194567|Experimental|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
32808852|NCT04194567|Experimental|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
33100119|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
33100120|NCT00525707|Placebo Comparator|2|
33100121|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
32808853|NCT04177797|Experimental|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
33100122|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
33100123|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
33100124|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
33100125|NCT02928744|Experimental|COPD|
33100126|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
33100127|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
33100128|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
33100129|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
32808854|NCT04194255|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
32808855|NCT04194255|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
32808856|NCT04194255|Experimental|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
33316085|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
33316086|NCT03984773|No Intervention|Control|Clinicians will receive current standard communications regarding serious illness performance.
33316087|NCT03984773|Experimental|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
33316088|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
33316089|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
33316090|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
33316091|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
33316092|NCT03984929|Experimental|Localized Information Resource Intervention|
32808857|NCT04194255|Experimental|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
33316093|NCT03984929|Active Comparator|Generic Information Resource Intervention|
33316094|NCT03865004|Placebo Comparator|Placebo|
33316095|NCT03865004|Active Comparator|Paracetamol|
33316096|NCT03865004|Active Comparator|Dexketoprofene|
33316097|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
33316098|NCT03292432|Active Comparator|Standard of Care (SOC)|Standard of Care for adherence support at Site
33316099|NCT03292432|Experimental|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
33316100|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
33316101|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
33316102|NCT01063205|Placebo Comparator|Placebo|
33316103|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
32808858|NCT04171167|Active Comparator|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
32808859|NCT04171167|Active Comparator|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score < 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
32808860|NCT04171167|Active Comparator|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
32808861|NCT04171167|No Intervention|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
32808862|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
32808863|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
32808864|NCT03983577|Experimental|Point of service delivery model|After the informed consent is signed, the participant will watch a standardized video on the principles of genetic testing. At the end of the video, the provider will return to answer any remaining questions. The participant will receive pre- and post- surveys for evaluation of the delivery model.
32808865|NCT04406883|Active Comparator|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
32808866|NCT04406883|Active Comparator|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
32808867|NCT04199949|No Intervention|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
32808868|NCT04199949|Experimental|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (~ 20%) to match the reduction in energy expenditure induced by inactivity
32953287|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
32953288|NCT05585970|Active Comparator|healthy Control individuals|
33404876|NCT03463577||Unexposed historical cohort women|This group consisted of women matched to Exposed cohort women-on or after 1st day of 27th week of pregnancy group and pregnant at least one day during the historical period between January 1, 2012-December 31, 2014 and did not receive any Tdap vaccine during the pregnancy.
32808869|NCT04194177|Experimental|protective|
32808870|NCT04194177|Active Comparator|conventional|
32808873|NCT04199559|Experimental|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
32808874|NCT04199325|Experimental|Intervention group|
32808875|NCT04199325|Placebo Comparator|Control group|
32808876|NCT03952299|Active Comparator|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
32808877|NCT03952299|Experimental|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
32808878|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
32808879|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
32808880|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
32808881|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
32808882|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
32808883|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
32808884|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
32808885|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
32808886|NCT03597477||Control|Patients with no developmental diagnoses
32808887|NCT04199715|Experimental|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
32808888|NCT04193319|Other|Single arm|
32808889|NCT03962985|Other|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
32808890|NCT04192851|Experimental|Tent Pole Grafting Technique|"Bone graft [NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.~PRF membrane is prepared by:~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
32808891|NCT03957135|Experimental|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
32808892|NCT03957135|Active Comparator|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
32808893|NCT03956979|Experimental|JM-010 group A|Group A (JM-010 dose fixed combination drug(tablet)) +Placebo 2
32808894|NCT03956979|Experimental|JM-010 group B|Group B (JM-010 8/0.8mg dose fixed combination drug(tablet)) + Placebo 1
32808895|NCT03956979|Placebo Comparator|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
32808896|NCT04190901|Experimental|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
32808897|NCT04190901|Experimental|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
32808898|NCT04190901|Experimental|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
32808899|NCT04190901|Experimental|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
32808900|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
32808901|NCT03597321|No Intervention|Arm B- No intervention|
32808902|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
32808903|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
32808904|NCT04193007|Experimental|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
32953289|NCT05585970|Active Comparator|CKD patients|
32953290|NCT05585970|Active Comparator|ESRD on regular hemodialysis|
32953291|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
32953292|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
32953293|NCT02137122|Experimental|Cognitive Training|Participants will undergo 60 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The training control will be the same tasks set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
32953294|NCT02137122|Placebo Comparator|Training Control|Participants will undergo 60 hours of training control. Training control will involve the same computerized games as in the cognitive training condition but are set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
32953295|NCT04757220|Experimental|Patients with schizophrenia|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
33316104|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
33316105|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
33316106|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
32953296|NCT04757220|Experimental|Patients with depression|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
32953297|NCT04757220|Active Comparator|Healthy controls|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
32953298|NCT04757064|Experimental|Standard Rehabilitation Group|"Standard Rehabilitation Group: will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion <60_ MUA contraindicated.~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is < 60 degrees at six months after surgery."
33316107|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
33316108|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
32953299|NCT04757064|Experimental|Supervised Rehabilitation Group|Supervised Rehabilitation Group: will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour.
32953300|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
33316109|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
33316110|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
33316111|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
33316112|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
32953301|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
32953302|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
32953303|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
32953304|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
32953305|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
32953306|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
32953307|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
32953308|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
32953309|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
32953310|NCT02414178||Experimental F 18 T807|
33100130|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
32808905|NCT04193007|Experimental|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
32808906|NCT04190355|Active Comparator|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
32808907|NCT04190355|Active Comparator|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
32808908|NCT04193163||Patients receiving ESOP 2 stem|
32808909|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
32808910|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
32808911|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
32808912|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
32808913|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
32808914|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
32808915|NCT04192617|Experimental|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
32808916|NCT04192617|Experimental|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
32808917|NCT04192617|Placebo Comparator|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
32808918|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
32808919|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
32808920|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
32808921|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
32808922|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
32808923|NCT04192539|Active Comparator|Control|
32808924|NCT04192539|Active Comparator|Inflammation|
32808925|NCT04192539|Active Comparator|Benign group|
32808926|NCT04192539|Active Comparator|Malignant group|
32808927|NCT04192383||Cyberknife|
32808928|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
32808929|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
32953311|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
32953312|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
32953313|NCT02408952|No Intervention|Usual Care|Care is administered as usual
32953314|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
32953315|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
32953316|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
32953317|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
32953318|NCT01894932|No Intervention|normal|normal, no intervention.
32953319|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
32953320|NCT04757532|Experimental|Bupropion|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.
32953321|NCT04757532|Experimental|Anastrozole|Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.
32953322|NCT04757532|Experimental|Testosterone cyclopentylpropionate|Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.
32953323|NCT04757532|Experimental|Danazol|Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.
32953324|NCT04757532|Experimental|Chlorthalidone|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.
33100131|NCT02928939||Multimorbid patients|
32808930|NCT04026867|Active Comparator|Clinician Referral Only|"The Clinician Referral arm will serve as an active control and baseline standard of care. All individuals who test positive for HCV antibodies or are identified with untreated, active HCV will be informed of their result and receive the following information from their clinical care teams in the ED: (a) explanation of process and rationale for follow-up RNA testing; (b) delivery of simple posttest counseling (e.g., risk for liver disease, risks of transmission); and (c) provision of a list of insurance enrollment resources, as needed, along with (d) a list of HCV treatment providers and their contact information as provided in aftercare instructions. For new HCV diagnoses, patients will be instructed to access their electronic patient portal (MyChart) for their RNA test results or to call a designated results line. Post-testing counseling messages and follow-up instructions will be included on the patient discharge papers."
32808931|NCT04026867|Experimental|Clinician Referral + Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS). Individuals randomized to this intervention will be contacted by a linkage navigator either during the ED visit (if during business hours) or the following business day (if during non-business hours). If the navigator does not contact the patient at the time of ED visit, they will offer to meet with the patient in person or over the phone. For all individuals in this arm, a structured linkage navigation process will include motivational interviewing and (a) reiteration of posttest counseling messages, (b) assessment of the patient's needs for medical insurance and substance abuse treatment, c) assistance scheduling and/or rescheduling appointments for HCV treatment, and d) follow-up phone call after the first HCV treatment appointment and thereafter as needed up to 6 months after ED visit.
32808932|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
32808933|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
33100132|NCT04692935||Asian lung adenocarcinoma|Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
33100133|NCT04692935||Caucasian lung adenocarcinoma|Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations
33100134|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
33100135|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
33100136|NCT04693013|Experimental|Interventional|use of virtual reality (VR)
33100137|NCT04693013|No Intervention|Control|no use of VR
32808934|NCT04022343|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
32808935|NCT04192149|Experimental|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
32808936|NCT04192149|Experimental|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
32808937|NCT04192149|Experimental|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
32808938|NCT04192149|Experimental|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
32808939|NCT04192149|Experimental|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
32808940|NCT04192071|Active Comparator|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
32808941|NCT04192071|Active Comparator|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
32808942|NCT04192071|Sham Comparator|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
33100138|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
33100139|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
33100140|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
33100141|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.~Operative procedure of by RI approach:"
33316113|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
33316114|NCT01063361|Active Comparator|High Cereal Fibre Diet|
33404877|NCT03463577||Exposed cohort women-before 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) before the 1st day of the 27th week of pregnancy during the period January 1, 2018-January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
32808943|NCT04020471||Experimental|All subjects who have completed their standard of care total knee arthroplasty will undergo pharmacogenomics testing and will complete a daily pain and medication diary for 30 days post discharge from the hospital. Subjects will be offered a consultation visit with a member of the Pharmacogenomics Team to discuss results.
32808944|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
32808945|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
32808946|NCT04191525|Experimental|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
32808947|NCT04191525|Placebo Comparator|Placebo|1 capsule/day
32808948|NCT03954171|Other|Patients treated with platinum based-chemotherapy|
32808949|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
32808950|NCT04029987|Active Comparator|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
32808951|NCT04029987|Active Comparator|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
32808952|NCT04029987|Placebo Comparator|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\ k.g every 6 hours, and naluphin 0.1 mg \kg on demands
32808953|NCT04191837|Experimental|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
32808954|NCT04191837|Active Comparator|Knee health education|A course regarding knee health will be offered to the subjects in this group.
32953325|NCT01901562|Experimental|Ductoscopic papillomectomy|Ductoscopic papillomectomy to treat pathological nipple discharge
32953326|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
32953327|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
32953328|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
32953329|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admission.
32953330|NCT02392572|Experimental|Arm A (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every 3 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32953331|NCT02392572|Experimental|Arm B (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32953332|NCT02392572|Experimental|Arm C (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on the first two consecutive days of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32953333|NCT02392572|Experimental|Arm D (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32953334|NCT02392572|Experimental|Arm E (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO twice weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32953335|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
32953336|NCT02069730|Experimental|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
32953337|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
32808955|NCT04191759|Experimental|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
32808956|NCT03596463||Group A|Patients treated according to suggestions of tumor board
32808957|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
32808958|NCT04191603|Active Comparator|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
32808959|NCT04191603|Active Comparator|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
32808960|NCT04029909|Experimental|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
32808961|NCT04029909|Experimental|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
32808962|NCT04029909|Experimental|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
32808963|NCT04190979|Experimental|Single arm|TrackCath
32808964|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
32808965|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
32808966|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
32808967|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
32808968|NCT04406337|Experimental|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
32808969|NCT04406337|Active Comparator|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
32808970|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
32808971|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
32808972|NCT04766151|Experimental|Transdermal glyceryl trinitrate patches|
32808973|NCT04766151|Placebo Comparator|Transdermal placebo patches|
32808974|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
32808975|NCT04191213|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
32808976|NCT04191213|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age & two-gram-dose for children above 5 years of age
32808977|NCT04029129|No Intervention|High exposure|Ambient air was allowed freely into the room.
32808978|NCT04029129|Experimental|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
32808979|NCT04029129|Experimental|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
32808980|NCT03024177|Experimental|Vapendavir 528 mg|
32808981|NCT03024177|Placebo Comparator|Placebo|
32808982|NCT01874431|Experimental|Finerenone (BAY94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
32808983|NCT01874431|Experimental|Finerenone (BAY94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
32808984|NCT01874431|Experimental|Finerenone (BAY94-8862)(5 mg)|5 mg dose oral once daily for 90 days
32808985|NCT01874431|Experimental|Finerenone (BAY94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
32808986|NCT01874431|Experimental|Finerenone (BAY94-8862) (10 mg)|10 mg dose oral once daily for 90 days
32808987|NCT01874431|Experimental|Finerenone (BAY94-8862) (15 mg)|15 mg dose oral once daily for 90 days
33404878|NCT03463577||Exposed cohort infants-on or after 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to Exposed cohort women-on or after 1st day of 27th week of pregnancy group.
32808988|NCT01874431|Experimental|Finerenone (BAY94-8862)(20 mg)|20 mg dose oral once daily for 90 days
32808989|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
33100142|NCT02928510||Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
33100143|NCT04692974|Experimental|Intervention Group|Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
33100144|NCT04692974|No Intervention|Control Group|For the control group, they will wear the wearables as a tracking device for the period of the study (6 months). No prompts will be given and the mobile application will only be installed but not used for this group.
33100145|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
33100146|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
33100147|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
33316115|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
33316116|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
33316117|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
32808990|NCT04028817|Experimental|group treatment|This group will receive laser treatment combined with low intensity exercises
32808991|NCT04028817|Placebo Comparator|group control|This group will receive placebo laser treatment combined with low intensity exercises
32808992|NCT04190511|Experimental|Prebiotic-containing dairy intervention group|
32808993|NCT04190511|Active Comparator|Dietary intervention group|
32808994|NCT04190511|No Intervention|Conventional care group|
32808995|NCT04028739|Experimental|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
32808996|NCT04028739|Experimental|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
32808997|NCT04028739|Experimental|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
32808998|NCT04028661|Experimental|Intervention group|use of 3D printed Modified Twin Block Appliance.
32808999|NCT04028661|No Intervention|Untreated control group|No treatment phase of 8 months.
32809000|NCT04028583|Experimental|PIM-Check group|
32809001|NCT04028583|Active Comparator|STOPP/START group|
32809002|NCT04028505|Experimental|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
32809003|NCT04028505|Active Comparator|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
32809004|NCT01824355|Experimental|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:~At least 60% of subjects were younger than 65 years of age.~At least 20% had type 1 diabetes.~At least 50% with type 2 diabetes were insulin users."
32809005|NCT04042623|Experimental|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
32809006|NCT04190745|Experimental|The control group|
32809007|NCT04190745|Experimental|The experimental group|
32809008|NCT01823341|Active Comparator|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
32809009|NCT01823341|No Intervention|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
32809010|NCT04028427|Experimental|Participants randomly assigned to VGI|
32809011|NCT04028427|Experimental|Participants randomly assigned to MBI|
32809012|NCT04190121|Experimental|GROUP A|
32809013|NCT04190121|No Intervention|GROUP B|
32809014|NCT04028349|Experimental|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
32809015|NCT01853137|Experimental|FLMGM Treatment Group|
32809016|NCT01853137|No Intervention|Untreated Class II Control Group|
32809017|NCT04028271|Experimental|experimental|local anesthesia applyed with Comfort in system
32809018|NCT04028271|Active Comparator|conventional injection|local anesthesia applyed with conventional syringe
32809019|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
32809020|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
33316118|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
33316119|NCT05275348|Experimental|Tele-EF|Remote delivery of Enhance Fitness.
33316120|NCT05275348|Active Comparator|In-person EF|In-person delivery of Enhance Fitness.
33316121|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
33316122|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
33316123|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
32809021|NCT01823107|Experimental|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
32809022|NCT04190277|Experimental|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
32809023|NCT04190277|Active Comparator|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
32809024|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
32809025|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
32809026|NCT04198623|Other|Montelukast (Singulair)|Montelukast(Singulair) 10mg to be taken in addition to standard institutional premedication
32809027|NCT01873729|Experimental|Naltrexone|Naltrexone
32809028|NCT04197297|Other|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
32809029|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
32809030|NCT04028037|Experimental|FTPG treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. In Test group, the harvest of palatal graft was performed using FTPG technique. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
32809031|NCT04028037|Active Comparator|Sub-epithelial connective tissue graft (SCTG) treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. To ensure an effective randomization only at this stage the patients were assigned to the test and to the control group.In control group trap door technique was used to obtain connective palatal graft. SCTG was adapted to recipient site in way that the first mm upon cementoenamel junction (CEJ) was covered , the flap is stabilized with interrupted sutures. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
32809032|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
32809033|NCT04027959|Experimental|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
32809034|NCT04027959|Experimental|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
32809035|NCT04027959|Experimental|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
32809036|NCT04195503|Other|liver transplantation|Surgical Intervention - Liver transplantation
32809037|NCT04027569|Active Comparator|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
32809038|NCT04027569|Experimental|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
32809039|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
32809040|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
32809041|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
33100148|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
33100149|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
32809042|NCT04027413|Placebo Comparator|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
32809043|NCT04027413|Experimental|Intervention group|Participants in this group will receive high protein product
32809044|NCT04344951|Experimental|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
32809045|NCT01822561|Experimental|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
32809046|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
32809047|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
32809048|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
32809049|NCT04027491|Experimental|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).~Each intervention session lasts 45 minutes."
32809050|NCT04027491|No Intervention|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
32809051|NCT04596241|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
33316124|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
32809052|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
32809053|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
32809054|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
32809055|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
32809056|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
32809057|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
32809058|NCT04406493|Experimental|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization each patient will undergo this examination twice a day until discharged.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
32809059|NCT04021251|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
32809060|NCT04021251|Experimental|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
32809061|NCT04021251|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
32809062|NCT04021251|Experimental|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
32809063|NCT03961581|Experimental|car|Children who will use cars to go from the double-door entrance of the block to the operative room.
32809064|NCT03961581|No Intervention|bed|Children who will use bed to go from the double-door entrance of the block to the operative room.
32809065|NCT04021407|Active Comparator|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
32809066|NCT04021407|Active Comparator|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
32809067|NCT04021173|Experimental|Anfibatide|
32809068|NCT04021173|Placebo Comparator|Placebo|
32809069|NCT04027881|Experimental|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
33316125|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
33316126|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
32809070|NCT04027881|No Intervention|STAR - waitlist control|No intervention for the 15 weeks after pretest.
32809071|NCT04027335|Experimental|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
32831164|NCT03938532|Experimental|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
33100150|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
32809072|NCT04027725|Experimental|Sensorimotor neurofeedback training group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.~The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
32809073|NCT04027725|No Intervention|Control Group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours~The psychopedagogical care: each session will be organized using the same video material"
32809074|NCT01852045|Experimental|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
32809075|NCT01852045|Experimental|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
32809076|NCT01852045|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
32809077|NCT04027257|Experimental|STAR|Receive 15-week STAR intervention immediately after pretest.
32809078|NCT04027257|No Intervention|Waitlist Control|No intervention for the 15 weeks after pretest.
32809079|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
32809080|NCT03960957|Placebo Comparator|Placebo|
32809081|NCT03960645|Experimental|B/F/TAF|B/F/TAF for up to approximately 38 weeks
32809082|NCT04020939|Experimental|Patients undergoing intestinal resections|"Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence~Drug:~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
32809083|NCT04027179|Experimental|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
32809084|NCT04027179|Placebo Comparator|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
32809085|NCT04027179|Active Comparator|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
32809086|NCT04199169|Experimental|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
32809087|NCT04199169|Placebo Comparator|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
32809088|NCT04199169|Experimental|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
32809089|NCT04199169|Experimental|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
32809090|NCT04199169|Placebo Comparator|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
32809091|NCT04199169|Experimental|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
32809092|NCT04199169|Experimental|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
32809093|NCT04199169|Experimental|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
32809094|NCT04199169|Placebo Comparator|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
32809095|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
32809096|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
32809097|NCT04021095|Experimental|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
32809098|NCT04026789|Active Comparator|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
32809099|NCT04026789|Active Comparator|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
32809100|NCT04191291|Experimental|Shortened lunch period|The amount of seated lunch time will be 10 minutes.
32809101|NCT04191291|Experimental|Longer lunch period|The amount of seated lunch time will be 20 minutes.
32809102|NCT04199871|Experimental|Group1|dichoptic 3D movies
32809103|NCT04199871|Sham Comparator|Group 2|dichoptic standard movies
32809104|NCT04026555|Active Comparator|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
33100151|NCT02946944|Experimental|double drug therapy|
33100152|NCT02946944|Active Comparator|mono drug therapy|
33100153|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
33100154|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
32809105|NCT04026555|Placebo Comparator|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
32809106|NCT03952377|Placebo Comparator|0.9% Sodium Chloride for Injection|
33100155|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
33316127|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
33316128|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
33316129|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
33316130|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
32809107|NCT03952377|Experimental|12.5 mg SX600|Low Dose
32809108|NCT03952377|Experimental|25.0 mg SX600|High Dose
32809109|NCT04026321|Experimental|SQ-001 125mL/day|
32809110|NCT04026321|Experimental|SQ-001 250mL/day|
32809111|NCT04026321|Experimental|SQ-001 500mL/day|
32809112|NCT04026321|Experimental|SQ-001 625mL/day|
32809113|NCT04026321|Placebo Comparator|saline(0.9% NaCl injection)|
32809114|NCT04026243|Active Comparator|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
32809115|NCT04026243|Active Comparator|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
32809116|NCT01821937|Experimental|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
32809117|NCT01821937|Experimental|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
32809118|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
32809119|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
32809120|NCT01821625|Experimental|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
32809121|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
32809122|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
32809123|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
32809124|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
32809125|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
32809126|NCT04020783||Observation group|sequential
32809127|NCT01821391|Experimental|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
32809128|NCT01821391|Experimental|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
33100156|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
32809129|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
33100157|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
33100158|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
32809130|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
32809131|NCT04020705|Experimental|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
32809132|NCT04020705|Placebo Comparator|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
32809133|NCT04020627|Experimental|BiPAP Group|Bilevel Positive Airway Pressure
32809134|NCT04020627|Experimental|CPAP Group|Continuous Positive Airway Pressure
32809135|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
32809136|NCT04025697|Placebo Comparator|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
32809137|NCT04025697|Active Comparator|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
32809138|NCT03934827|Experimental|Part A|"Open label, preliminary phase~20 participants"
32809139|NCT03934827|Experimental|Part B|"Randomised, double blinded phase~100 participants"
32809140|NCT03950427|Active Comparator|game-based Physical Activity Group|"The game-based physical activity group, will play active games using the Kinect for Xbox 360 game system or outdoors in a public park. Each game group will be facilitated by the study coordinator, the principal investigator or other study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
32809141|NCT03950427|Placebo Comparator|Sedentary Videogame Group|"The sedentary videogame group will play games while seated using the Xbox 360 game system (without the Kinect sensor) or seated outdoors in a public park. Each sedentary videogame group will be facilitated by study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
32809142|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.~Oral dose for 12 weeks"
32809143|NCT04025385|No Intervention|Control Group|Patients will participate in regular training units
32809144|NCT04025385|Active Comparator|HIIT Group|Patients will participate in high intensity interval training
32809145|NCT03947931||General group|Patient with extremely severe ulcerative colitis
32809146|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
32809147|NCT01871545|No Intervention|Healthy Controls|
32809148|NCT04020315|Experimental|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
32809149|NCT04020549|Experimental|Intervention|
32809150|NCT04020549|Sham Comparator|Study Skills Control|
32809151|NCT03933657|Experimental|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
32809152|NCT03932643|Experimental|ONC201 treatment|A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
32809153|NCT04020237|No Intervention|Observational arm|General counselling to particulate matter practice score.
32809154|NCT04020237|Other|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
32809155|NCT04025307|Experimental|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
32809156|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
32809157|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
32809158|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
32809159|NCT03932097|Experimental|Parenting Now|Preventive Parenting Now digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
32809160|NCT03932097|Active Comparator|Active Control Materials|SAMHSA alcohol prevention materials for parents
32809161|NCT04025619|Experimental|treatment group|the data is collected from the same participant after the intervention.
32809162|NCT04025619|No Intervention|Control group|The Collect the data from the same participant before the intervention as control
32809163|NCT01850641|Experimental|PA21|
32809164|NCT04020081|Experimental|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
32809165|NCT04020081|No Intervention|COPD patients lung functions without yoga excercises.|Control group
32809166|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
32809167|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
32809168|NCT04147299||Elite Athletes|Endurance athletes
32809169|NCT01850563|Other|HBO feasibility|
32809170|NCT03931473|Experimental|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
32809171|NCT03931473|Experimental|Royal Guard|Pyriproxyfen/alpha-cypermethrin
32809172|NCT03931473|Active Comparator|Interceptor|Alpha-cypermethrin
32953338|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
32953339|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
32953340|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
32953341|NCT04756830|Other|Vaccination|All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
32953342|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
32953343|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
32953344|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
32953345|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
32953346|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
32953347|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
32953348|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
32953349|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
32953350|NCT05435040|Experimental|self-comparison|"The patient will be fitted with proprioceptive knee brace and with no knee brace.~the patient will perform tests (Y Balance Test, test with Weinstein monofilaments, and Joint Position Sense test) and complete visual analog scales with and without the proprioceptive knee brace in a randomized order.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
32953351|NCT04389528|Experimental|tDCS active arm|
33316131|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
33316132|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
33404879|NCT03463577||Unexposed historical cohort infants|This group consisted of infants whose mothers belong to the Unexposed historical cohort women group.
32953352|NCT04389528|Placebo Comparator|tDCS placebo|
32953353|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
32953354|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
32953355|NCT05413356|Experimental|treatment group|Ruxolitinib twice daily treatment, combined with steroids 1mg/kg/day for two weeks, and tampering 0.25 mg/kg/day every week
32953356|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
32953357|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
32953358|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
32953359|NCT00599118||atrial fibrillation|Atrial fibrillation
32953360|NCT00599118||Control|Control subjects with no atrial fibrillation
32953361|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
32953362|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
32953363|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
32953364|NCT04293666|Experimental|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
32953365|NCT04293666|Placebo Comparator|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
32953366|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
32953367|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
32953368|NCT00556218|Other|Tibetan Meditation|
32953369|NCT00556218|Other|No Meditation|
32953370|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
32953371|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
32953372|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
32953373|NCT00508794|Experimental|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
32809173|NCT03930771|Experimental|All Patients|"All subjects will receive:~Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.~Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.~After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity)."
32809174|NCT04027101|Experimental|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
32809175|NCT04027101|Placebo Comparator|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
32809176|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
32809177|NCT04024683||Control group|Realization of a para-vertebral catheter
32809178|NCT04024527|Active Comparator|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
32809179|NCT04024527|Experimental|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
32809180|NCT01819129|Experimental|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
32809181|NCT01819129|Active Comparator|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
32809182|NCT04147065|Experimental|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
32809183|NCT04147065|Active Comparator|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
32809184|NCT04024137|Experimental|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
32809185|NCT04024137|Experimental|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
32809186|NCT04024137|Experimental|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
32809187|NCT04024137|Placebo Comparator|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
32809188|NCT04146831|Experimental|Sintilimab|Sintilimab is administered in this arm.
32809189|NCT04146285|Experimental|BAT4406F|
32809190|NCT04025775|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days~The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
32809191|NCT04025775|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
32809192|NCT03926481|Experimental|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
32809193|NCT03926481|Experimental|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
32809194|NCT04028193|Other|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
32809195|NCT04028193|Other|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
32809196|NCT04406181|Other|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
32809197|NCT04406181|Other|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
32809198|NCT04406181|Other|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
32831165|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
32953374|NCT00508794|Experimental|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
32809199|NCT04026477|Experimental|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Universal Trauma-Informed Care and Cultural Humility Training. After video and workshop training, staff will have ability to recognize trauma and racism and its impact on school procedures, practices, and children themselves. Staff will be able to apply core principles of cultural humility. Staff will examine their own cultural identity and how it influences their interactions and relationships with students of diverse cultural backgrounds (Principle 1). Staff will learn ways that privilege and oppression relate to their cultural identity and identify ways to flatten power hierarchies between themselves and students, including handling misbehavior from a trauma-informed, culturally humble perspective (Principle 2). Staff will problem-solve ways for their schools to be accountable for equitable discipline practices (Principle 3).
32809200|NCT04026477|Active Comparator|Waitlist Universal Trauma-Informed Care and Cultural Humility Training|All staff from waitlisted schools will receive Universal Trauma-Informed Care and Cultural Humility Training at the end of the waitlist period.
33316133|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
32809201|NCT04765917|Active Comparator|Selected Physical Therapy group|The Control group will receive a selected physical therapy program for 60 minutes, 3 times/week for 3 successive months including the following exercises
32809202|NCT04765917|Experimental|Motor imagery training|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 30 min in addition to 30 minutes motor imagery training program
32809203|NCT04023903|Experimental|RTA 402 5mg 3cap at fasting|
32809204|NCT04023903|Experimental|RTA 402 5mg 3cap after meal|
32809205|NCT04023981|No Intervention|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
32809206|NCT04023981|Experimental|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
32809207|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
32809208|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
32809209|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
32809210|NCT04146675|Experimental|TRICOT JERSEY VANISE DOUBLE FACE|
32809211|NCT04146675|Placebo Comparator|TRICOT JERSEY SIMPLE|
32809212|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
32809213|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
32809214|NCT04023279|Experimental|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
32809215|NCT04023279|Experimental|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
32809216|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
32809217|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
32809218|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
32809219|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
33316134|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
33316135|NCT05275270|Active Comparator|Group A|patients were treated with an active gel containing oxytocin
33316136|NCT05275270|Placebo Comparator|Group B|patients were treated with placebo gel without oxytocin
33316137|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
32809220|NCT04146519|Experimental|Study group|Autologous MMSC
32809221|NCT04146519|Placebo Comparator|control group|
32809222|NCT04022811|Experimental|Artificial tears|0.1% bromfenac VS Artificial tears
32953375|NCT00508794|Other|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
32953376|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
32809223|NCT04022889|Experimental|Stage 1|The study will be performed in two stages. Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled based on either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control. With agreement from the FDA (BQ200481, July 8, 2020), completion of Stage 1 is not required.
32809224|NCT04022889|Experimental|Stage 2|Stage 2 is a single arm design. Test platelets from 24 healthy subjects, stored for 7 days, will be prepared for radiolabeling following the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Stage 1 subjects with evaluable Variant 1 method data will contribute to the requirement of the 24 subjects for Stage 2.
32809225|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
32809226|NCT04146129|Experimental|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
32809227|NCT04146129|Placebo Comparator|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
32809228|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
32809229|NCT04022577|Experimental|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
32809230|NCT04022577|Placebo Comparator|control group|The control group received routine care
32809231|NCT04145583|Experimental|HSK3486|0.4 mg/kg
32809232|NCT04145583|Experimental|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
33316138|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
32809233|NCT04022421|Experimental|hydroxychloroquine arm|
32809234|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
32809235|NCT04022031||Non-exposed group|Western medicine routine treatment
33316139|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
32809236|NCT03947151|Other|one arm|one arm
32809237|NCT04023045|Active Comparator|Habitual Prosthesis|Participant's prescribed prosthesis
32809238|NCT04023045|Experimental|Assist-Knee|Experimental knee prosthesis
32809239|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
32809240|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
32809241|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
32809242|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
32809243|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
33316140|NCT01048931|Experimental|single-port LAVH|single port LAVH
33316141|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~The study coordinator will provide the decision aid for the parent/clinician dyad.~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
33316142|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
33316143|NCT03868124|Experimental|Implant Group 1|G2TR intraocular implant containing Travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
32809244|NCT04145739|Experimental|Mastectomy group|Patients undergoing mastectomy
32809245|NCT04145739|Experimental|Quadrantectomy group|Patients undergoing quadrantectomy
32809246|NCT04145661|Experimental|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
32809247|NCT04145661|Experimental|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
32809248|NCT03923673|Experimental|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
32809249|NCT04021953|Experimental|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
33316144|NCT03868124|Experimental|Implant Group 2|G2TR intraocular implant containing Travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
32953377|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
33100159|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
33316145|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
32809250|NCT04021953|Active Comparator|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
32809251|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
32809252|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
32809253|NCT04145193|Active Comparator|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
32809254|NCT04145193|Experimental|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
32809255|NCT04145193|Experimental|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
32809256|NCT04145193|Experimental|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
32809257|NCT04021563|Experimental|SR419|Ascending single and multiple doses of SR419 orally
32809258|NCT04021563|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
32809259|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
32809260|NCT04765839|Experimental|Intervention Arm - Receives COVID-19 Vaccine messages|Group to receive COVID-19 Vaccine messages during the first two weeks of the study.
32809261|NCT04765839|Experimental|Delayed Intervention Arm|Group to receive COVID-19 Vaccine messages during the last two weeks of the study.
32809262|NCT04144569|Experimental|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
32809263|NCT04141215|Experimental|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
32809264|NCT04141215|Active Comparator|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
32809265|NCT04141059|Experimental|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
32809266|NCT04141059|Placebo Comparator|Placebo|Placebo group that will intake 250 mg of Maltodextrin
32809267|NCT04146909|Active Comparator|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
32809268|NCT04146909|Active Comparator|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or < 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
32809269|NCT04142697|Active Comparator|Healthy subjects|
32809270|NCT04142697|Active Comparator|Vestibular Disease patients|
32809271|NCT03022227|Experimental|group A start with the remote session followed by on site|
32809272|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
32809273|NCT04747743||Egyptian dental practitioners|170 dental practitioners in Egypt (professionals both academic and nonacademic).
32809274|NCT04144335|Active Comparator|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
32809275|NCT04144335|Experimental|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
32809276|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
32809277|NCT02707497|Placebo Comparator|placebo|The control group will not use any platelet-increased drugs.
32809278|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
32809279|NCT02702895||Phase 1|Former ASPIRE participants
32809280|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
32809281|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
32809282|NCT04144257|Experimental|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
32809283|NCT04147845|Experimental|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
32831166|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
32809284|NCT04147845|Experimental|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
32809285|NCT04147845|Experimental|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
32809286|NCT04147845|Experimental|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
32809287|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA > 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
32809288|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|< 50 copies/mL under treatment for at least 12 months
32809289|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads < 400 copies /ml)
32809290|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
32809291|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
32809292|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
32809293|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
32809294|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
32809295|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
32809296|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
32809297|NCT01817959|Experimental|Reparixin group|Continuous iv infusion
32809298|NCT01817959|Placebo Comparator|Placebo group|Continuous iv infusion
32809299|NCT01817725|Experimental|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for >20 years old and 20μg for < or =20 years old
32809300|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
32809301|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
32809302|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
32809303|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
32809304|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
32809305|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
32809306|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
32809307|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
32809308|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
32809309|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
32809310|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
32809311|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
32809312|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
32809313|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
32809314|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
32809315|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
32809316|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
32809317|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
32809318|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
32809319|NCT05558878|Experimental|Ambroxol (intervention arm)|40 patients will receive conventional therapy for diabetic neuropathy in addition to ambroxol 450 mg/day divided into 3 doses (each dose consists of 2 75mg capsules) daily for 3 months.
32809320|NCT05558878|No Intervention|Control arm|40 patients will receive conventional therapy for diabetic neuropathy for 3 months.
32809321|NCT04874584|Experimental|CTNSM Group|Culturally Tailored Nurse Symptom Management group (CTNSM) - participants in the CTNSM group will receive one in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message during the first 12 weeks of standard of care chemotherapy. In addition, participants can receive standard of care chemotherapy education.
32809322|NCT04874584|Active Comparator|Standard of Care (control) Group|Participants in the control group will only be receiving the standard of care chemotherapy education.
32809323|NCT05621668|Experimental|Part A: Dose Findings (MTD)|The dose of attIL2-T cell therapy the participants will receive will depend on when the participants joined this study. The first group of participants will receive the lowest dose level of attIL2-T cell therapy.
32809324|NCT05621668|Experimental|Part B: Osteosarcoma Dose Expansion|Participants will receive attIL2-T cell therapy at the recommended dose that was found in Phase 1.
32809325|NCT01846741|Other|Model 106 VNS Therapy System|
32809326|NCT05621590|Experimental|mlc-901 group|
32809327|NCT05621590|Placebo Comparator|placebo group|
33404880|NCT03463577||Exposed cohort infants-before 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to the Exposed cohort women-before 1st day of 27th week of pregnancy group.
33404881|NCT04667884|Experimental|Group A|a mixture of Xylooligosaccharides, Stachyose, Fructooligosaccharides, and Water-soluble Dietary Fiber, 12 g/d, 4 weeks
32809330|NCT05554042||Instruments Followed By SCID|Participants will complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually. Participants will then complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5.
32809331|NCT05554042||SCID Followed By Instruments|Participants will complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5. Participants will then complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually.
32809332|NCT05621434|Experimental|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
32809333|NCT05621356||allergen-specific immunotherapy (AIT)|Adults with birch pollen allergy, who are treated with allergen-specific immunotherapy (AIT)
32809334|NCT05621356||control|Adults with birch pollen allergy, who are treated with immunosuppressive medication
32809335|NCT04415203|Experimental|TAES plus usual care|TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); Usual Care: usual medicine treatment for PVCs.
32809336|NCT04415203|Placebo Comparator|Sham-TAES plus usual care|"Sham-TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.~Usual Care: usual medicine treatment for PVCs."
32809337|NCT05621278||Children|Grade 5 and grade 6 students (aged 9-12) in primary school.
32809338|NCT05621278||Adolescent|Grade 7 to grade 12 students (aged 12-18) in middle school and high school.
32809339|NCT05621278||Students' teachers|School Teachers
33404882|NCT04667884|Experimental|Group B|a mixture of Fructooligosaccharide, water-soluble dietary fiber, polydextrose, and isomalt oligosaccharide, 12 g/d, 4 weeks
33404883|NCT04667884|Experimental|Group C|a mixture of Polydextrose, wheat fiber, and Seed shell of Plantago rotundifolia, 12 g/d, 4 weeks
33404884|NCT04667884|Experimental|Group D|a mixture of Fructooligosaccharides, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001, 3 g/d, 4 weeks
33404885|NCT04667884|Placebo Comparator|Group E|Maltodextrin， 3 g/d, 4 weeks
32809340|NCT05621278||Students' parent|Parents of students mentioned above.
32809341|NCT04741204|Experimental|White women|White women on metformin Extended release 750 mg BID
32809342|NCT04741204|Experimental|Black women|Black women on metformin Extended release 750 mg BID
32809343|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
32809344|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
32809345|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
32809346|NCT01816477|Active Comparator|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
32809347|NCT01816477|Experimental|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
32809348|NCT05517148|Experimental|Mindfulness-based Stress Reduction by Therapeutic VR|Two departments randomized and allocated to this treatment group. Participants received an immersive multimodal, skills-based, pain self-management VR program, called EaseVRx (AppliedVR), that incorporates evidence-based principles of CBT, mindfulness, and pain neuroscience education. The program content trains users on mindfulness-based stress reduction via immersive and enhanced biofeedback experiences. EaseVRx combines biopsychosocial education, diaphragmatic breathing training, relaxation response exercises that activate the parasympathetic nervous system, and executive functioning games to provide a mind-body approach toward relaxing better with anxiety. The standardized 8-week program delivers a multifaceted combination of anxiety relief training through a prescribed sequence of daily immersive experiences. Each VR experience is 30 minutes in length.
32809349|NCT05517148|Other|Mindfulness-based Stress Reduction|Received the same mindfulness therapy training audio as the other set, but did not watch the 3D scene on the VR device. At the end of the study, we will compensate them and let them use VR for relaxation training according to their wishes.
32809350|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
32809351|NCT05615038|Experimental|Contact aspiration first line thrombectomy|Patients will have the mechanical thrombectomy by first-line contact aspiration
32809352|NCT05615038|Active Comparator|Stent retriever first line thrombectomy|Patients will have the mechanical thrombectomy by first-line stent retriever
32809353|NCT05613790|Experimental|Active HD-tDCS|Participants in the active arm will receive 20 min of real High-Definition transcranial direct current stimulation. Additional ramp-up and ramp-down phases at the beginning and the end of stimulation will last for 30 s.
32809354|NCT05613790|Experimental|Sham HD-tDCS|During the sham session, the montage will be identical, however, the current amplitude will ramp up for 30 seconds, and for the remaining stimulation time, the current flow will terminate and will be kept to zero. Ramp-down phase at the end of stimulation will last for 30 s.
32809355|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
32809356|NCT04699240|Active Comparator|Clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
32809357|NCT04699240|Active Comparator|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
32809358|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
32809359|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
32809360|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
32809361|NCT05493982|Experimental|Receives Stanford vaping prevention curriculum|Stanford vaping prevention curriculum in administered.
32809362|NCT05493982|No Intervention|Does not receive Stanford vaping prevention curriculum|Receives another curriculum or no vaping prevention education.
32809363|NCT04478500|Active Comparator|Minocycline Group|Subjects will be randomized to receive Minocycline 100mg twice daily
32809364|NCT04478500|Placebo Comparator|Placebo Group|Subjects will be randomized to receive placebo.
32809365|NCT01816243|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
32809366|NCT05607784||Adolescent Advisory Board Male|This board will consist of 8 male adolescents recruited from the schools.
32809367|NCT05607784||Adolescent Advisory Board Female|This board will consist of 8 female adolescents recruited from the schools.
32809368|NCT05607784||Health Education Professionals Panel (HEPP)|This panel will consist of 8 health teachers and other school health professionals such as nurses and counselors. They will be recruited at each participating school.
32809369|NCT04604899|Experimental|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
32809370|NCT05484778|Other|Case Group|This group consists of athletes whose are between the ages of 14-30 and are still active at high school or university level in sports involving sudden changes of direction and jump physically and who have a history of injury to only one lower extremity before.
33316146|NCT05275192|Experimental|Videoscope-assisted periodontal regeneration minimally invasive surgery|Videoscope-assisted periodontal regeneration minimally invasive surgery - Test group
32809371|NCT05484778|Other|Control Group|This group consists of athletes whose age range is 14-30, and who are still active at high school or university level in sports involving sudden changes of direction and jump physically and who do not have a history of lower extremity injuries.
32809372|NCT05576896|Experimental|Treatment (Hydroxychloroquine)|
32809373|NCT01845805|Experimental|Arm A: CC-486|CC-486 (oral azacitidine), 300 mg total, taken daily on days 1-21 (of a 28 day cycle) for up to 12 cycles. Upon disease recurrence, subjects will start on a first-line chemotherapy.
32809374|NCT01845805|Active Comparator|Arm B: observation|Observation until disease recurrence. Upon disease recurrence, subjects will start on a first-line chemotherapy.
32809375|NCT05575804|Experimental|experimental group|Patients will receive the recommended phase 2 dose of GQ1001 determined in phase I. GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity.
32809376|NCT05575804|Active Comparator|control group|Patients will receive pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
32809377|NCT04415125|Experimental|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
32809378|NCT05440318||mRNA Vaccines Recipients|Participants will wear 2 devices during the specified monitoring period. They will wear both a small patch on their chest that captures continuous electrocardiogram (ECG), accelerometry, and temperature data, and a modified smartwatch measuring continuous photoplethysmography (PPG) and accelerometry data.
32809379|NCT04371094|Active Comparator|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
32809380|NCT04371094|Active Comparator|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
32809381|NCT04343716|Experimental|White women|White women aged 65-75 with knee OA
32809382|NCT04343716|Experimental|Black women|Black women aged 65-75 with knee OA
32809383|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
32809384|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
32809385|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
32809386|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
32809387|NCT04257760|No Intervention|Standard care|These ALS patients and their caregivers will receive standard care.
32809388|NCT04257760|Experimental|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
32809389|NCT04242940|Experimental|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
32809390|NCT04233424|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
32809391|NCT04233424|Other|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
32809392|NCT04211740|Active Comparator|OCH-NCNP1 3 mg|
32809393|NCT04211740|Placebo Comparator|Placebo|
32809394|NCT04185610|Experimental|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
32809395|NCT04164004|Experimental|Routine Collection of Patient-Reported Health Status (KCCQ-12 Arm)|Patients in the KCCQ-12 arm will undergo KCCQ-12 assessment of patient-reported heart failure health status in the electronic health record at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians in the electronic health record when making treatment decisions during each clinic visit.
32809396|NCT04164004|Active Comparator|Usual Care|Patients in the usual care arm will not complete KCCQ-12 assessments in the electronic health record with clinic visits. They will complete a KCCQ-12 assessment at baseline that will not be available to the treating clinician.
32809397|NCT05534932|Active Comparator|Treatment Arm|35 Subjects will be placed in the sub-study treatment arm. These subjects will receive the remote patient monitoring program therapy offered by the University of Chicago heart failure program.
32809398|NCT05534932|No Intervention|Observational Arm|35 Subjects will be placed in the sub-study Obervational arm. These subjects will not reveive the remote patient monitoring program and will continue with thier standard of care treatment for the duration of the study.
32809399|NCT05367856|Experimental|Chi-BEAM|Patients in this arm will receive Chidamide Combined With BEAM(Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.
32809401|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
32809402|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
33316147|NCT05275192|Active Comparator|Periodontal regeneration minimally invasive surgery|Periodontal regeneration minimally invasive surgery - Control Group 1
32809403|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
32809404|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
32809405|NCT04148872|Active Comparator|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
32809406|NCT04148872|Active Comparator|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
32809407|NCT04129294|Experimental|NS-089/NCNP-02|NS-089/NCNP-02
32809408|NCT05328856|Active Comparator|Vital shower|Participants receive the installation of a shower prototype from Hansgrohe and training including a handout. After installation, participants are asked to shower daily for four weeks according to a predefined shower protocol with alternating warm and cold water application.
32809409|NCT05328856|No Intervention|Regular shower|Participants are advised not to change their showering behaviour; at the end of the study, the participants receive an offer of a shower head for free.
32809410|NCT05310994|Placebo Comparator|Placebo drink|
32809411|NCT05310994|Experimental|Wasabi Leaf Extract Drink|
32809412|NCT05293522|Experimental|NTX-001|Solution #1, Solution #2 Active, Solution #3
32809413|NCT05293522|No Intervention|Standard of Care|Standard neurorrhaphy
32809414|NCT05272306|Active Comparator|Sedation and Analgesia|A standardized sedation and analgesia will be administered by an experienced anesthesiologist. After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 minutes), patients will be induced with propofol and fentanyl via intravenous route at doses calculated according to ideal body weight. Anesthesia was maintained with propofol infusion. Repetitive intravenous boluses of propofol will be administered, if required. Patients will be received oxygen (100%, 3 L/min) through a nasal cannula during sedation and analgesia.
32809415|NCT05272306|Active Comparator|Gastro-laryngeal Tube|After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 min), patients will be induced with propofol and fentanyl. After induction of anesthesia, supraglottic airway device named Gastro-laryngeal Tube (GLT) will be inserted. Patients will be ventilated mechanically with a tidal volume of 6-8 mL/kg based on ideal body weight and a frequency of 12-14 breaths/min after inserting the GLT. Repetitive intravenous boluses of propofol will be administered, if required.
32809416|NCT05072236|Placebo Comparator|normal saline|intravenous normal saline 5 mL 1 minute before bronchoscope insertion
32809417|NCT05072236|Active Comparator|lidocaine|intravenous lidocaine 1.5 mg/kg 1 minute before bronchoscope insertion
32809418|NCT05072236|Experimental|alfentanil|intravenous alfentanil 10 ug/kg 1 minute before bronchoscope insertion
32809419|NCT05007964|Experimental|Spatz4 subjects|Subjects will be studied in an open label multi-center center study which will examine the usability of the adjustment process and success of the process. .
32809420|NCT04997668|Active Comparator|SOLTIVE Thulium Fiber Laser|SOLTIVE Thulium Fiber Laser group (laser A)
32809421|NCT04997668|Active Comparator|Ho:YAG Laser|Ho:YAG Laser group (laser B)
32809422|NCT05193994|Experimental|Dolutegravir/Abacavir/Lamivudine|"Combination of Dolutegravir, Abacavir and Lamivudine in a single product/capsule.~4 capsules to be taken orally once daily (all 4 at the same time, each capsule is Dolutegravir 12.5mg, Abacavir 150mg and Lamivudine 75mg). Maximum duration is 24months"
32809423|NCT05193994|Placebo Comparator|Placebo|4 capsules to be taken orally once daily (all 4 at the same time). Maximum duration is 24months
32809424|NCT04876456|Experimental|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
32809425|NCT04847440|Experimental|ATI-2173 and Viread|ATI-2173 + Tenofovir disoproxil fumarate (Viread)
32809426|NCT04847440|Active Comparator|Placebo and Viread|ATI-2173 Placebo + Tenofovir disoproxil fumarate
32809427|NCT04847440|Experimental|ATI-2173, Viread and AB-729|ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729
32809428|NCT04847440|Active Comparator|Placebo, Viread and AB-729 Placebo|ATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo
32809429|NCT04812106||Participants with LC-FAOD|
32809430|NCT04807660||Prospective cohort|Middle ear fluid sample for each enrrolled children
32809431|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
32809432|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
32809433|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
32809434|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
32809435|NCT03667846|Placebo Comparator|Placebo|Placebo
33100160|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
32809436|NCT03667846|Experimental|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
32809437|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
32809438|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
32809439|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
32809440|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
32809441|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
32809442|NCT05180110|Experimental|Symptoms of inflammation, Infection, tissue injury|Venous blood draw of up to 24mL and up to 6 capillary fingersticks
32809443|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
32809444|NCT05174650|Experimental|Combined treatment with Atezolizumab and Derazantinib|Treatment with Atezolizumab 1200 mg i.v. every 3 weeks and Derazantinib 300 mp p.o. once daily for a maximum of 96 weeks or until disease progression or unacceptable toxicity or study termination
32809445|NCT01870297|Experimental|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
32809446|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
32809447|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
32809448|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
32809449|NCT04719988|Experimental|Experimental|"Induction treatment~Modified DCF: every 2 weeks for 8 cycles Docetaxel (40 mg/m², day 1), Cisplatin (40 mg/m², day 1) , 5-FU (1200 mg/m²/day for 2 days)~Ezabenlimab: 240 mg intravenous, every 3 weeks for 3 cycles~In case of tumor response:~Two additional cycles of mDCF and one additional cycle of Ezabenlimab (Q3W).~Hypofractionated radiotherapy~Ezabenlimab: 240 mg intravenous, every 3 weeks for 7 cycles~In absence of tumor response:~o Chemoradiotherapy (Intensity-Modulated Radiation Therapy [IMRT]) treatment: Chemoradiotherapy using IMRT will begin 3-4 weeks following the last cycle of induction phase, in the absence of toxicities of grade 1 and/or management of toxicities. It will last 7 weeks and will consist of:~• Standard dose of 45 Gy in 25 fractions over 5 weeks followed by a sequential boost of 14.4 Gy in 8 sessions,~Concomitantly given with:~Capecitabine (825 mg/m²/orally twice daily) from Monday to Friday,~Mitomycin C (10 mg/m² Day 1)"
32809450|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
32809451|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
32809452|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
32809453|NCT04602949|Experimental|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
32809454|NCT04602949|Other|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
32809455|NCT04717726|Experimental|MT|Participants in the MT group will be supplemented with Milk Thistle extract for 12 weeks
32809456|NCT04717726|Experimental|LAC|Participants in the LAC group will be supplemented with Lactobacillus Gassri for 12 weeks
32809457|NCT04717726|Experimental|EX|Participants in the EX group will perform aerobic exercise, 5 days per week for 12 weeks
32809458|NCT04717726|Experimental|MT + EX|Participants in the MT + EX group will be supplemented with Milk Thistle extract and exercise for 12 weeks
32809459|NCT04717726|Experimental|LAC + EX|Participants in the LAC + EX group will be supplemented with Lactobacillus Gassri and exercise for 12 weeks
32809460|NCT04717726|Placebo Comparator|CON|Participants in the CON group will be supplemented with maltodextrin pills made to look like the pills received by the MT and LAC groups for 12 weeks
32809461|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
32809462|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
32809463|NCT05141110|Experimental|NVP-1705|Tablet formulation for oral administration, single dose of NVP-1705 at Day 1
32809464|NCT05141110|Active Comparator|NVP-1705-R|Tablet formulation for oral administration, single dose of NVP-1705-R at Day 1
32809465|NCT04616248|Experimental|Cohort A (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
32809466|NCT04616248|Experimental|Cohort B (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
32809467|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
32809468|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
33100161|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
33100162|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
32809469|NCT01798030||Vitamin D|Specimen analysis
32809470|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
32809471|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
32809472|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
32809473|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
32809474|NCT01814371|Active Comparator|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
32809475|NCT01814371|Active Comparator|Household Approach|All members of the household will perform the decolonization regimen.
32809476|NCT05124652|No Intervention|Focus Group Testing|Focus group testing of key-fob device to control adjusting socket system
32809477|NCT05124652|Experimental|In-Lab, Crossover Study|Testing of auto-adjusting algorithm in-lab. Participants will carry out a structured protocol wearing the socket in all modes. Order will be randomly assigned.
32809478|NCT05124652|Experimental|Out-of-Lab Crossover Study|Evaluate socket performance in user free-living environments. Participants will use the prosthesis in all modes by end of study, order will be randomly assigned.
32809479|NCT05054998|Experimental|Diagnostic (fludeoxyglucose F-18, PET/MRI)|Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
32809480|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
32809481|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
32809482|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
32809483|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
32809484|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
32809485|NCT01814137|Experimental|IDegAsp BID + IAsp OD|
32809486|NCT01814137|Experimental|IDeg OD + IAsp TID|
32809487|NCT04084288|Experimental|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
32809488|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
32809489|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
32809490|NCT05037526|Active Comparator|Dexcom G System|The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
32809491|NCT05037526|Active Comparator|Standard care of gestational diabetes with self monitoring blood glucose (SMBG)|SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily.
32809492|NCT04008160||healthy persons|
32809493|NCT04008160||individuals with paraplegia|
32809494|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
32809495|NCT04934800||Cladribine|
33100163|NCT02928276|Experimental|All patients|All eligible patients
33100164|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
33316148|NCT05275192|Active Comparator|Guided tissue regeneration surgery|Guided tissue regeneration - Control Group 2
33316149|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
33100165|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
33316150|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
33316151|NCT05253898|Active Comparator|Pelvic Floor Physical Therapy|"Group 1 includes a training program about correctly using pelvic floor muscles. At the first session, an educational program will be given to all women about the anatomy and function of the pelvic floor muscles. Then, the pelvic floor muscles contractions will be controlled by vaginal palpation for approximately 10 minutes.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of fast and slow pelvic floor muscles contractions in different positions, and 10 minutes of abdominal breathing, general relaxation, stretching, and cool-down exercises.~It is planned to teach contractions with internal palpation for 10 minutes before the first session to ensure that the patients' pelvic floor contractions are performed correctly. PFT treatment will be given as two sessions per week, 45 minutes, and 8 weeks as group sessions."
33316152|NCT05253898|Active Comparator|Therapeutic Yoga Training|"Group 2 program includes therapeutic yoga training. It will begin with education about the positive effects of yoga on the body and pelvic floor.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of different asanas coordinated with breathing, and 10 minutes of yogi breathing and cool-down exercises.~Also, a home exercise program will be given based on yoga sessions. Participants will receive a detailed description of the home program."
33316153|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
33316154|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
33316155|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
33316156|NCT00311363|Placebo Comparator|Placebo|Placebo
32809496|NCT01813357|Placebo Comparator|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
32809497|NCT01813357|Experimental|Rosuvastatin|Rosuvastatin 20mg daily
32809498|NCT01812655|Experimental|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
32809499|NCT01812655|Active Comparator|Passive distraction|watching a movie
32809500|NCT01812655|No Intervention|UC provided by the nurses|
32809501|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~Blood Tests~CT scan~Bone scan~FACBC PET/MRI in a subset of participants"
32809502|NCT01812109|Experimental|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
33100166|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
32809503|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 12 weeks (84 days)
32809504|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 12 weeks (84 days)
32809505|NCT02016430|Experimental|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet
32809506|NCT02016430|Experimental|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet
32809507|NCT02016430|Experimental|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported
32809508|NCT03944902|Experimental|Cohort 1: Dose Escalation using Niraparib and CB-839|The first phase will be a 3+3 design, 3 participants will be enrolled in the first cohort with a fixed dose of Niraparib and CB-839, 600 mg. If there are no dose limiting toxicities (DLT), 3 additional participants will be enrolled in the next cohort (CB-839, 800mg). If 1 of the 3 in the first cohort experiences DLT's, then the additional participants will be enrolled in the same cohort (CB-839, 600mg).
32809509|NCT03944902|Experimental|Cohort 2: Dose Escalation using Niraparib and CB-839|If there are no DLT's, 3 additional participants will be enrolled in the next cohort with a fixed dose of Niraparib and CB-839, 800mg.
32809510|NCT03944902|Experimental|Cohort 3: Expansion with Maximum Tolerated Dose (MTD)|Patients in this expansion cohort will continue study treatment with the MTD until they experience disease progression, unacceptable toxicity or withdraw consent. Patients who discontinue study treatment for reasons other than Progressive-Free Survival (PFS) will continue to have PFS follow-up visits every 2 months for the first 6 months after treatment, and every 3 months until disease progression, death, or start of another anticancer therapy.
32809511|NCT01811953|Experimental|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
32809512|NCT01811953|Experimental|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
32809513|NCT01811953|Experimental|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
32809514|NCT01811953|Experimental|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
33100167|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
32953378|NCT04271046|Experimental|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:~self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;~one orientation phone visit with a coach;~ongoing support from the coach via telephone and secure messaging in the web-portal.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
33100168|NCT00526370||B|Women with only normal PAP-smears
33100169|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
33100170|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
33316157|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
33316158|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
33316159|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
33316160|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
33316161|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
33316162|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
33316163|NCT00333983|Experimental|Arm 1|Robot Exercise Group
33316164|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
32953379|NCT04271046|Active Comparator|Control|"One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
32953380|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
32953381|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
32953382|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
32953383|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
32953384|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
32953385|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
32953386|NCT04755738|Experimental|Almonertinib plus Microwave ablation group|Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
32953387|NCT04755738|Active Comparator|Almonertinib group|Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.
32953388|NCT04755270|Experimental|vr-supported hypnofertility|Relaxation, visualization, imagination and affirmation and techniques based on the hypnofertility philosophy were applied to women in the experimental group in four stages
32953389|NCT04755270|No Intervention|Control|Any initiative was not applied to the control group
32953390|NCT04755504|Experimental|EEG evaluation|All patients will be evaluated during 1 night by standard polysomnography and additionally EEG will be evaluated by 2 electrodes behind each ear connected to a recording device (Sensor Dot)
32953391|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
32953392|NCT01490502|Active Comparator|Low-dose vitamin D3|
32953393|NCT01490502|Active Comparator|High-dose vitamin D3|
32953394|NCT01895712||Orsiro|
32953395|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
32953396|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
32953397|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
32953398|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
32953399|NCT01428024|Experimental|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
33100171|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
33316165|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
33316166|NCT01171430|Experimental|MRI WHOLE BODY|
33316167|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
33316168|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
33316169|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
33316170|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
33316171|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
33316172|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
32953400|NCT01428024|Experimental|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
33316173|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
33316174|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
33316175|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
32953401|NCT05049174|Experimental|Intensive intervention|
32953402|NCT05049174|Active Comparator|Low-threshold intervention|
32953403|NCT01424982|Experimental|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
32953404|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
32953405|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
32953406|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
32953407|NCT01412190|Other|Untreated|
32953408|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
32953409|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
32953410|NCT01895868|No Intervention|Control|Clinical training alone.
32953411|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
32953412|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|TeleCareOhio Monitor (Honeywell HomeMed) system provides in-home medical monitoring for patients with chronic disease such as heart failure.
32953413|NCT01393314|No Intervention|Usual care|These participants receive usual care which consists of usual home-care with educational package.
32953414|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
32953415|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
32953416|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
32953417|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
32953418|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
32953419|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
32953420|NCT04969302|Experimental|Intervention Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 37°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the warm group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
33100172|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
33100173|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
33100174|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
33100175|NCT04692090|Experimental|Yoga Group|Hatha yoga will be practiced twice a week for 10 weeks
33100176|NCT04692090|No Intervention|Control group|This group will not have any intervention.
33100177|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
32809515|NCT01811953|Experimental|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
33100178|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
32809516|NCT01811953|Experimental|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
32809517|NCT03926728|Experimental|Cohort A - 85µg CTH522-CAF01|Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
32809518|NCT03926728|Experimental|Cohort B - 85µg CTH522-CAF01+ TO CTH522|Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
32809519|NCT03926728|Experimental|Cohort C - 85µg CTH522-CAF01+ID CTH522|Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
33100179|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
33316176|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
33316177|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
33316178|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
33316179|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
33316180|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
33316181|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
32809520|NCT03926728|Experimental|Cohort D - 15µg CTH522-CAF01|Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
32809521|NCT03926728|Experimental|Cohort E - 85µg CTH522-CAF09b|Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
32809522|NCT03926728|Placebo Comparator|Cohort F - Placebo|Cohort F will receive only placebo in form of 0.9% NaCl saline.
32809523|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
32809524|NCT03895762||Abstral Oral Disintegrating Tablet (ODT)|Abstral Oral Disintegrating Tablet (ODT)
32809525|NCT01811563|Active Comparator|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
32809526|NCT01811563|Active Comparator|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
32809527|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
32809528|NCT04907890||Cases|All survivor patients hospitalised for COVID-19 and previously recruited in the CORIST study
32809529|NCT04907890||Controls 1|Individuals who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms.
33316182|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
33316183|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
33316184|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
32809530|NCT04907890||Controls 2|Individuals who was never diagnosed for SARS-Cov-2 infection
33316185|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
32809531|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
33100180|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
33100181|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
33316186|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
33316187|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
33100182|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
33100183|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
33100184|NCT04692545||A|patients receiving immunonutrition supply
33100185|NCT04692545||B|patients receiving standard dietary advice
33100186|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
33100187|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
33100188|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
33100189|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
33100190|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
32809532|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
33100191|NCT04692506|Active Comparator|Low dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
33100192|NCT04692506|Active Comparator|High dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
33100193|NCT04692506|Placebo Comparator|Placebo Sachet|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
33100194|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
33100195|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
33100196|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
33100197|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
33100198|NCT00526487|Other|1|Endovascular Repair
33100199|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
33100200|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
32809533|NCT01811485|Experimental|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
32809534|NCT01811485|Experimental|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
32809535|NCT01811485|Placebo Comparator|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
32809536|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
32809537|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
32809538|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
32809539|NCT05246644|Experimental|Intravenous Acetaminophen|subjects will receive IV acetaminophen and a placebo oral acetaminophen starting immediately after surgery and for 8 doses
32809540|NCT05246644|Active Comparator|Oral acetaminophen|subjects will receive a placebo for IV acetaminophen and active oral acetaminophen starting immediately after surgery and for 8 doses
32809541|NCT03832036|Experimental|Patients with lumbar disc herniation|
32809542|NCT01810939|Active Comparator|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
32809543|NCT01810939|Placebo Comparator|Placebo|Placebo was administered twice a day as a powder mixed with water.
32809544|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
32809545|NCT00565084|Active Comparator|1|Ibuprofen
32809546|NCT00565084|Placebo Comparator|2|Placebo 1
32809547|NCT00565084|Placebo Comparator|3|Placebo 2
32809548|NCT01810783|Experimental|Brexpiprazole|
32809549|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
32809550|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
32809551|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
32809552|NCT01808209|Experimental|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
32809553|NCT01808209|Active Comparator|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
32809554|NCT05246332|Experimental|Patient receive grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The grounding group use a grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
32809555|NCT05246332|Sham Comparator|Patient receive sham-grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The sham-grounding group use a sham grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
32809556|NCT05246254||Prefrailty group|According to the frailty index(FI) and FI =0.12~0.25
32809557|NCT05246254||Frailty group|According to the frailty index(FI) and FI≥ 0.25
32809558|NCT05246254||Nonfrailty group|According to the frailty index(FI) and FI<0.12
32809559|NCT04585009|Experimental|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
32809560|NCT04585009|Experimental|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
32809561|NCT04585009|Experimental|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
32809562|NCT04585009|Experimental|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
32809563|NCT04585009|Experimental|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
32809564|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
32809565|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
32809566|NCT04585009|Experimental|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
32809567|NCT04585009|Experimental|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
32809568|NCT04585009|Experimental|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
32809569|NCT04585009|Experimental|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
32809570|NCT05246176|Experimental|Cases|group of patient with inoperable malignant obstructive jaundice with failed internal drainage.
32809571|NCT04170283|Experimental|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
32809572|NCT04170283|Experimental|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
32831167|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
33404886|NCT05761002|Experimental|treatment group|"All patients will be subjected to:~A thorough history taking and proper dermatological examination.~Skin sampling from anogenital wart lesions: skin sterilization followed by injection of local anesthesia at the base of lesions, then the part of wart above skin surface will be removed using shave biopsy technique.~DNA extraction of skin samples.~Conventional PCR for low-risk HPV genotypes (6,11) and RT-PCR for high-risk HPV genotypes.~Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions."
33404887|NCT03424824|Experimental|BP1.3656 low dose|administration of BP1.3656 at 30 µg
33404888|NCT03424824|Experimental|BP1.3656 intermediate dose|administration of BP1.3656 at 60 µg
33404889|NCT03424824|Placebo Comparator|Placebo|administration of placebo
32809573|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
32809574|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
32809575|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
32809576|NCT05246020|Experimental|NHIPEC|Treatment: Four tubes will be placed via the laparoscopic ports and HIPEC will be given within 24 hours after laparoscopic evaluation.
32809577|NCT05246020|Active Comparator|Intravenous NACT|Drug:Three cycles of intravenous NACT will be given in this group. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin area under curve(AUC) 5 for a 21-day cycle.
32809578|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
32809579|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
32809580|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
32809581|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
32809582|NCT05245630||Robotic arm assisted PET/CT guided biopsy|"In this group, participants were recruited for robotic-assisted PET/CT guided biopsy from the FDG avid lung lesions.~biopsies were done using an automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) to guide the needle for biopsy. It is a robotic arm with a four-ax guide arm and a planning console. Pre-interventional fused PET/CT images from Biograph mCT 16 scanner were sent via LAN cable to the device (MAXIO-EX) console."
32809583|NCT05245630||PET fused CT-Fluoroscopy guided biopsy|"In this group, participants were recruited for PET fused CT-Fluoroscopy guided biopsy from the FDG avid lung lesions.~A biopsy needle was placed to the target lesion on PET/CT under CT fluoroscopy"
32809584|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
32809585|NCT05363410|Experimental|MagnéVie B6®|Each film coated tablet contains 100mg magnesium citrate and 10mg pyridoxine hydrochloride.
32809586|NCT05363410|Placebo Comparator|Placebo|Each identical film coated tablet contains inert materials.
32809587|NCT05363332||COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS secondary to COVID-19.
32809588|NCT05363332||Non COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS not secondary to COVID-19.
32809589|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
32809590|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
32809591|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
32809592|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
32809593|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
32809594|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
32809595|NCT05363098||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
32809596|NCT05362942|Experimental|venetoclax + Hypomethylation agent + low-dose cytarabine treatment group|patients treated with venetoclax combined with decitabine/azacytidine and low-dose cytarabine
32809597|NCT01798654||Antithrombotic agents|
32809598|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
32809599|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)~tauroursodeoxycholic acid (250 mg / TID)"
32809600|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
32809601|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
32809602|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
32809603|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
32809604|NCT05362708|Experimental|Experimental group - VRH|Patients will receive VRH during port-a-cath (Port) placement
32809605|NCT05362708|No Intervention|Control Group|Patients who do not want to receive the VRH but who accept to answer the questionnaires will be considered as a control group.
32809606|NCT04602169|Active Comparator|PVI only group|Patients allocated to this group will receive PV re-isolation alone
32809607|NCT04602169|Active Comparator|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
32809608|NCT05204368|Experimental|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg ,q6h(0.5h infusion)
32809609|NCT05204368|Active Comparator|Meropenem|Meropenem 1g ,q8h (0.5h infusion)
32809610|NCT03394846|Experimental|Test of Existing MI Products|We will test the impact of three widely available MI products (GoNoodle, Take10, ABC for Fitness) on students' physical activity with 60 elementary classroom teachers.
32809611|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
32809612|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
32809613|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
32809614|NCT05362240|Experimental|Four corner fusion|Scaphoid excision and fusion between lunate , capitate , hamate and triquetrum using k.wires
32809615|NCT05362240|Experimental|Three corner fusion without triquetrum excision|Scaphoid excision with fusion between lunate , capitate and hamate with preservation of triquetrum
32809616|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
32809617|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
32809618|NCT05162482|Active Comparator|Heterologous 1|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809619|NCT05162482|Active Comparator|Heterologous 2|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809620|NCT05162482|Active Comparator|Heterologous 3|"CanSinoBIO (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809621|NCT05162482|Active Comparator|Heterologous 4|"CanSinoBIO (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809622|NCT05162482|Active Comparator|Heterologous 5|"AstraZeneca ChAdOx (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV(0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809623|NCT05162482|Active Comparator|Heterologous 6|"AstraZeneca ChAdOx (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
32809624|NCT05162482|Active Comparator|Homologous 7|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
32809625|NCT05162482|Active Comparator|Homologous 8|"CanSinoBIO (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
32809626|NCT05162482|Active Comparator|Homologous 9|"AstraZeneca ChAdOx (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
32809627|NCT04414969|Experimental|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
32809628|NCT04817098|Experimental|Journey of Life Intervention Group|Community members (caregivers, teachers, and community leaders) will participate in group workshops for a period of 6 weeks.
32809629|NCT04817098|Other|Waitlist Control Group|The waitlist control group will not receive the intervention during the first 6 months of implementation in order to assess the effects of the intervention compared to the control group. However, following intervention completion in the experimental group, the control group will receive 6 months of the intervention.
32809630|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
32809631|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
32809632|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
32809633|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
32809634|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
32809635|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
32809636|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
32809637|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
32809638|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
32809639|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
32809640|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
32809641|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
32809642|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
32809643|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
32809644|NCT03099850||Chronic Pancreatitis|
33316188|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
33316189|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
33316190|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
33316191|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
33316192|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
33316193|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
33100201|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
33316194|NCT01283984|Experimental|1|AZD2115
33316195|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
33316196|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
33316197|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
33404890|NCT03424824|Experimental|BP1.3656 high dose|administration of BP1.3656 at 90 µg
32809645|NCT05361850|Active Comparator|Awake Extubation|Removal of the endotracheal tube while the patient is no longer under general anesthesia
32809646|NCT05361850|Active Comparator|Deep Extubation|Removal of the endotracheal tube while the patient is under general anesthesia
32809647|NCT05361772|Experimental|low-dose colchicine group|colchicine 0.5mg per day for 24 months
33100202|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
32809648|NCT05361772|Placebo Comparator|placebo group|placebo 0.5mg per day for 24 months
32809649|NCT05360368|Experimental|HLX07|"This study uses the 3+3 design to investigate the safety and determine the MTD of HLX07. Four dose levels of 800 mg, 1200 mg, 1500 mg and 1800 mg are planned for dose finding. Enrollment will continue until a maximum of 24 patients are enrolled."
32809650|NCT04810702||patients with von Willebrand disease|
32809651|NCT04810702||case control|
32809652|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
32809653|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
32809654|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
32809655|NCT04794478|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
32809656|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
32809657|NCT04760938|Experimental|Outdoor Behavioral Healthcare (OBH)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
32809658|NCT04760938|Experimental|Cognitive Behavioral Therapy (CBT)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
32809659|NCT01803607|Experimental|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
32809660|NCT01803607|Placebo Comparator|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
32809661|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
32809662|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
32809663|NCT04388722|No Intervention|Control Arm|
32809664|NCT04388722|Experimental|Investigational Arm|
32809665|NCT04667260|Placebo Comparator|Bone substitue|Bone augmentation with bone substitute
32809666|NCT04667260|Experimental|Coagulum|Bone augmentation with coagulum
32809667|NCT05290168|Experimental|Normal children|normal children undergoing simple surgery
32809668|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
32809669|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
32809670|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
32809671|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
32809672|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
33316198|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
33404891|NCT04661956|Experimental|Transbronchial cryobiopsy|Transbronchial cryobiopsy was performed in the patiens of pulmonary peripheral nodule
32953421|NCT04969302|No Intervention|Control Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 20°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the room heat group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
32953422|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
32953423|NCT04912830||20 years follow-up after TVT surgery|Women who had tension free vaginal tape surgery during January 2001-December 2002 in Norway, identified in the National Incontinence Registry
32953424|NCT04912830||10 years follow-up after TVT surgery, age 42 or younger|Women who had tension free vaginal tape surgery and aged < 42 years at the time of surgery during 2011-2012 in Norway, identified in the National Incontinence Registry
32953425|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intramuscular|Low Dose SC-Ad6-1, I.M., single-dose (Day 1)
32953426|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intramuscular|Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)
32953427|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intramuscular|High Dose #1 SC-Ad6-1, I.M., single-dose (Day 1)
32953428|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intramuscular|High Dose #2 SC-Ad6-1, I.M., single-dose (Day 1)
32953429|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intramuscular|Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)
32953430|NCT04839042|Experimental|SC-Ad6-1 High Dose #3 Intramuscular Booster|High Dose #3 SC-Ad6-1, I.M., single-dose booster (Day 1)
32953431|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intranasal|Low Dose SC-Ad6-1, I.N., single-dose (Day 1)
32953432|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intranasal|Medium Dose SC-Ad6-1, I.N., single-dose (Day 1)
32953433|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intranasal|High Dose #1 SC-Ad6-1, I.N., single-dose (Day 1)
32953434|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intranasal|High Dose #2 SC-Ad6-1, I.N., single-dose (Day 1)
32953435|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intranasal|Multiple Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 22)
32953436|NCT04839042|Experimental|SC-Ad6-1 High Dose #3 Intranasal Booster|High Dose #3 SC-Ad6-1, I.N., single-dose booster (Day 1)
32953437|NCT04839042|Experimental|SC-Ad6-1 High Dose #4 Intranasal Booster|High Dose #4 SC-Ad6-1, I.N., single-dose booster (Day 1)
32953438|NCT01862718|Experimental|1|Ablation plus radiation
32953439|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
32953440|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
32953441|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
32953442|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
32953443|NCT04755894|Experimental|group A|
32953444|NCT04755894|Active Comparator|group B|
32953445|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
32953446|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
32953447|NCT00273624|Placebo Comparator|placebo|Placebo
32953448|NCT00262470|Experimental|1|Acetazolamide
32953449|NCT00262470|Experimental|2|Atomoxetine
32953450|NCT00262470|Experimental|3|NO Drug
32953451|NCT00262470|Experimental|4|Clonidine
32953452|NCT00262470|Experimental|5|Entacapone
32953453|NCT00262470|Experimental|6|Indomethacin
32953454|NCT00262470|Experimental|7|Isosorbide Dinitrate
32953455|NCT00262470|Experimental|8|Mecamylamine
32953456|NCT00262470|Experimental|9|Memantine
32953457|NCT00262470|Experimental|10|Melatonin
32953458|NCT00262470|Experimental|11|Midodrine
32953459|NCT00262470|Experimental|12|Modafinil
32953460|NCT00262470|Experimental|13|Octreotide
32953461|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
32953462|NCT00262470|Experimental|15|Propranolol
32953463|NCT00262470|Experimental|16|Sertraline
32953464|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
32953465|NCT00262470|Experimental|18|Drinking Water
32953466|NCT00262470|Experimental|19|Dead Space Breathing Device
32953467|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
32953468|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
33404892|NCT04661956|Other|Transbronchial lung biopsy|Transbronchial lung biopsy was performed in the patiens of pulmonary peripheral nodule
32809673|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
32809674|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
32809675|NCT04621630|Experimental|Single Dose|Single dose administration
32809676|NCT04621630|Experimental|Multiple Dose|Multiple dose administration
32809677|NCT04621630|Experimental|Solid Dose Comparison|Solid dose administartion
33404893|NCT05060172|Experimental|Bloomlife MFM-Pro|
33404894|NCT04983927||Ischemic stroke positive|Patients diagnosed with acute ischemic stroke after a brain CT scan
33404895|NCT04983927||Ischemic stroke negative with other brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan, but has been diagnosed with other brain diseases.
32809678|NCT05242900||At-risk for lymphedema|Participants at-risk for leg lymphedema
32809679|NCT05242900||With lymphedema|Participants with leg lymphedema
32809680|NCT05242900||With lymphedema undergoing complete decongestive therapy (CDT)|Participants with leg lymphedema undergoing routine complete decongestive therapy (CDT)
33100203|NCT02928003|Experimental|Lung Surgery|
33404896|NCT04983927||Ischemic stroke negative and no brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan and has not been diagnosed with other brain diseases.
32809681|NCT04572022|Experimental|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
32809682|NCT04572022|No Intervention|Control group|Control group receive proximal humerus fracture standard care only.
32809683|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
32809684|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
32809685|NCT05238298|Experimental|rTMS Group|Participants will receive continuous theta burst stimulation (cTBS) for a 10-day period (10 sessions). If feasible for the participant, all stimulation sessions will be held at the same time of the day.
32809686|NCT05236894|Experimental|Aim 1: Arm I (lower dose nicotine pouch)|Patients receive lower dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
32809687|NCT05236894|Experimental|Aim 1: Arm II (higher dose nicotine pouches)|Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
32809688|NCT05236894|Active Comparator|Aim 1: Arm III (cigarette smoking)|Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
32809689|NCT05236894|Experimental|Aim 2: Arm I (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
32809690|NCT05236894|Experimental|Aim 2: Arm II (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
32809691|NCT05236894|Experimental|Aim 2: Arm III (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
32809692|NCT05231824|Active Comparator|BWL-S|1 year of remote gold standard, small group-based behavioral weight loss treatment with an MS-level clinician.
32809693|NCT05231824|Experimental|BWL-AI|1 year of remote weight loss treatment made up of a combination of (1) remote small group-based behavioral weight loss sessions, (2) 12-minute individual video calls, (2) automated text messages. An MS-level clinician will deliver the group treatment. Most video calls will be delivered by a paraprofessional coach, but some by an MS-level clinician. Each week the AI system will select one of the interventions for each participant based on which treatment the participant has responded to the best, within certain time constraints.
32809694|NCT04559230|Experimental|Sacituzumab govitecan|Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
32809695|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
32809696|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
32809697|NCT05183854|Experimental|Arm I (PCV13, PPSV23)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 and pneumococcal polyvalent vaccine IM on day 60 in the absence of disease progression or unacceptable toxicity.
32809698|NCT05183854|Experimental|Arm II (PCV13, PPPSV23)|Patients who have received or are receiving venetoclax therapy, receive pneumococcal 13-valent conjugate vaccine IM on day 1 and pneumococcal polyvalent vaccine IM on day 60 in the absence of disease progression or unacceptable toxicity.
33404897|NCT04651270|Experimental|SurroundScope|For laparoscopic camera system, the SurroundScope. 270-degree angle videoscope (270Surgical, Israel) was used
33404898|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
32809699|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
32809700|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
32809701|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
32809702|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
32809703|NCT04505566|Experimental|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
33404899|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
33404900|NCT01374399|Experimental|resistance and endurance exercise|
33404901|NCT01374399|Active Comparator|relaxation|
33100204|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
33100205|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
33100206|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
33100207|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
33100208|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
33100209|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
33100210|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
33100211|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
33100212|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
33100213|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
33100214|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
33100215|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
33100216|NCT04692623|Experimental|Moxfloxacin Group|In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
33100217|NCT04692623|Experimental|Gemifloxacin Group|In this arm 30 healthy volunteers were selected and they were given Gemifloxacin
33100218|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
33100219|NCT02927730||negative retainted placenta histology|
33100220|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
33100221|NCT04692402|Other|open label|open label prospective feasibility trial.
33100222|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
32809704|NCT04505566|Placebo Comparator|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
33100223|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
33100224|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
33100225|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
33100226|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
33100227|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
33100228|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
33100229|NCT00526643|Experimental|Arm B|combination chemotherapy
33100230|NCT00526643|Active Comparator|Arm A|monochemotherapy
33100231|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
33100232|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
33100233|NCT00526682|Active Comparator|1|Comparison of actives for synergy
33100234|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
33100235|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
33100236|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
33100237|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
33100238|NCT00526760|Experimental|Dexmedetomidine|
33100239|NCT00526838|Experimental|1|once-weekly dosing
33100240|NCT00526838|Experimental|2|twice-weekly dosing
32953469|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
32953470|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
32953471|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
32953472|NCT04767282|Other|Fruit and Vegetable Prescription|Each program participant will receive a fruit and vegetable prescription that is written by pediatricians to exchange for $15 of fresh produce. Prescriptions will be distributed during pediatric office visits and are redeemable at a local farmers' market and mobile market.
33100241|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
32953473|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
32953474|NCT04756284||Bladder Tumor Positive|Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.
32953475|NCT04756284||Bladder Tumor Negative|Patients with no suspected bladder tumor.
32953476|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
32953477|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
32953478|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
32953479|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
32953480|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
32953481|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
32953482|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
32953483|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
32953484|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
32953485|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
32953486|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
32953487|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
32953488|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
32953489|NCT04389606|Experimental|Study Formula (SF)|New infant formula for term infants
32953490|NCT04389606|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
32953491|NCT04389606|No Intervention|Human Milk Reference Group|Human milk
32953492|NCT01812174|Experimental|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
32953493|NCT01812174|Experimental|23mm On-X Mitral Heart Valve|"Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.~Enrollment into the 23mm On-X mitral arm has been terminated."
32953494|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
32953495|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
32953496|NCT00055224|Experimental|Threat conditions|acoustic startle and shock device
32953497|NCT00033774||1|Eligible healthy volunteers 18 and older
32953498|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
32953499|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
32953500|NCT04705662|Other|Ferrous Sulphate|This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
32953501|NCT04687020|Other|Non-interventional (United States) / Low-interventional (Canada) : Viltolarsen|Patients will receive viltolarsen (recommended dose 80mg/kg/week) during a treatment period up to 120 months.
33100242|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
33100243|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
33100244|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
33404902|NCT04598386|Experimental|PR Lotion Topical Solution|Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
33404903|NCT04598386|Placebo Comparator|Placebo Lotion Topical Solution|Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
33404904|NCT05056350|Other|Assessment of the feasibility and impact of a back-to-work support program|questionnaires, back to work coaching
33404905|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
33404906|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
33100245|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
33100246|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
33100247|NCT00527033|Experimental|1|Oral
33100248|NCT00527033|Experimental|2|Oral
33100249|NCT00527033|Experimental|3|Oral
33404907|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
32953502|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
32953503|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
32953504|NCT04784286|Active Comparator|Telemedicine 30-day follow-up visit|"The Center for Connected Care will arrange for 30-day post-op telemedicine visits via a secured video application. When there is a telemedicine visit, the Center of Connected Care will connect the patient and then page the midlevel provider and dietitian after the electronic rooming process is complete & the patient is ready.~A survey about post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-op care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for care outside of the direct medical costs, along with an open question asking for comments & feedback about their overall experience with their follow-up appointment."
32953505|NCT04784286|Active Comparator|In-person 30-day follow-up visit|"Standard practice of having bariatric surgery patients follow up with the bariatric surgery midlevel providers as well as with dietitians within 30-days after their bariatric procedure. The bariatric surgery midlevel providers are staffed and supported by our bariatric surgeons in case if they have questions or concerns.~Participants will be contacted via telephone and will be surveyed about their post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-operative care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for their care outside of the direct medical costs, along with an open question that will ask patients to provide comments and feedback about their overall experience with their follow-up appointment."
32953506|NCT05391984|Experimental|Activity oriented|Activity-oriented therapy will be given to 15 patients which will train the structures around the shoulder in different activities of daily life.
32953507|NCT05391984|Experimental|Structural oriented|Structural-oriented therapy will be given to 15 patients including a fixed sequence of physiotherapy techniques.
32953508|NCT04783818||One Stage Reconstruction With Adjuvant Radiotherapy|
32953509|NCT04783818||Two Stage Reconstruction With Adjuvant Radiotherapy|
33100250|NCT00527033|Placebo Comparator|4|Oral
33100251|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
33100252|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
33100253|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
32953510|NCT04783818||Autologous Reconstruction With Adjuvant Radiotherapy|
32953511|NCT04783818||One Stage Reconstruction Without Adjuvant Radiotherapy|
32953512|NCT04783818||Two Stage Reconstruction Without Adjuvant Radiotherapy|
32809705|NCT04505566|Other|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
32809706|NCT04505566|Other|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
32809707|NCT04505566|Other|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
32809708|NCT04387864|Experimental|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
32831168|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
32953513|NCT04783818||Autologous Reconstruction Without Adjuvant Radiotherapy|
32953514|NCT04783038|Active Comparator|Distance Reiki|Subjects will be scheduled for once a week session of distance Reiki for 4 weeks.
32953515|NCT04783038|Sham Comparator|Sham Reiki|Subjects will be scheduled for once a week session of Sham distance Reiki for 4 weeks.
32953516|NCT04783038|No Intervention|Standard of Care|Subjects will not receive any Reiki treatment
32953517|NCT04783116|Experimental|Plant stanols (3g/day)|Consumption of plant stanol chews
32953518|NCT04783116|Placebo Comparator|Control|Consumption of placebo chews (without plant stanols)
32953519|NCT04782960|Active Comparator|20 patients receive Subconjunctival bupivacaine of the end of the surgery|20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score
32953520|NCT04782960|Placebo Comparator|20 patients receive Subconjunctival placebo in the end of operation|20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score
32953521|NCT01075230|Active Comparator|Standard TKA|Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
32953522|NCT01075230|Active Comparator|Standard TKA with PRP|Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma
32953523|NCT04634604|Active Comparator|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
32953524|NCT04634604|Experimental|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
32953525|NCT04480242||Asthma Research in Children and Adolescents - Spanish Cohort|Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring
32953526|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
32953527|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
32953528|NCT02088216|Other|Control group|Participants received as-needed therapy.
32953529|NCT04782882|Experimental|intervention group|In the first session of the researcher (S.K.), the participants were explained the effects of anxiety and stress on the treatment in simple terms for 5 min. Then, information was given about the effects of laughter therapy and progressive muscle relaxation on the body. Laughter therapy was applied for 15-20 min. Then, the lights were turned off and progressive muscle relaxation exercises were performed for 15-20 min under candlelight and accompanied by music. The procedures were received as a group (2-6 people) in 3-4 face-to-face sessions.
32953530|NCT04782882|No Intervention|Control group|The control group then received routine care
32953531|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
32953532|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
32953533|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
33316199|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
33316200|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
33316201|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
33316202|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
33316203|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
33316204|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
33316205|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
33316206|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
32953534|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
32953535|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
32953536|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
32953537|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
32953538|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
32953539|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32953540|NCT00960102|Active Comparator|bilateral cochlear implant|
32953541|NCT00960102|Active Comparator|cochlear implant and hearing aid|
32953542|NCT00960102|Active Comparator|bilateral hearing aid|
32953543|NCT04782024|Placebo Comparator|Placebo|
32953544|NCT04782024|Experimental|7-Keto 50mg|
32953545|NCT04782024|Experimental|7-Keto 25mg|
32953546|NCT04389762|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
32953547|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
32953548|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
32953549|NCT04346160||Healthy control group|group of healthy patients considered as controls
32953550|NCT04755348|Experimental|Product usage order ABFCED|Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session
32953551|NCT04755348|Experimental|Product usage order BCADFE|Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session
32953552|NCT04755348|Experimental|Product usage order CDBEAF|Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session
32953553|NCT04755348|Experimental|Product usage order DECFBA|Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session
32953554|NCT04755348|Experimental|Product usage order EFDACB|Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session
32953555|NCT04755348|Experimental|Product usage order FAEBDC|Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session
32953556|NCT04754958|Experimental|VR|In addition to standard care during MRI scan, patient receives VR intervention.
32953557|NCT04754958|No Intervention|No VR|Standard of care during MRI scan.
32953558|NCT04754880||non-CTO|This group was defined as no chronic obstruction, except for non-critical stenosis, who underwent coronary angiography with the diagnosis of stable angina pectoris.
32953559|NCT04754880||CTO|This group was defined as the presence of complete occlusion in one artery and no critical lesions (> 50%) in the other arteries undergoing coronary angiography with the diagnosis of stable angina pectoris.
32953560|NCT04781868|Experimental|Multi-nutrient supplement|
32953561|NCT04781868|Placebo Comparator|Placebo supplement|
32953562|NCT04781634|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
32953563|NCT04756050|Experimental|corner pocket|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
32953564|NCT04756050|Experimental|corner+intracluster|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
32953565|NCT04756050|Experimental|multi|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
33316207|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
33316208|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.~Table 1: PEELP framework:~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
33316209|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
33316210|NCT03288142|Experimental|Intervention: Hypertension Coaching Application and Home Monitor:|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
33404908|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~Complete 9 follow-up phone calls to assess for relapse."
32953566|NCT00909012|Placebo Comparator|1|
33404909|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline and 2 month time points.~Complete MRI brain imaging data collection at the baseline and 2 month time points."
33404910|NCT05761860|Active Comparator|Oral oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
32953567|NCT00909012|Experimental|2|
32953568|NCT00909012|Experimental|3|
32953569|NCT00909012|Experimental|4|
32953570|NCT00909012|Experimental|5|
32953571|NCT00877500|Experimental|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32953572|NCT00877500|Active Comparator|Group II (standard of care)|Participants receive standard of care for 18 weeks.
32953573|NCT00875004|Experimental|Erythropoietin beta|
32953574|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
32953575|NCT04781790||Patients with Bone marrow failure|Standard of care of patients with bone marrow failure
32953576|NCT05320692|Experimental|Treatment group|TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib).
32953577|NCT05320692|Active Comparator|Control group|TACE Alone.
32953578|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
32953579|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
32953580|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
32953581|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
32953582|NCT04754724|Experimental|GIMate|Individuals with suspected lactose intolerance who start with GIMate use first
32953583|NCT04754724|Active Comparator|H2 Check|Individuals with suspected lactose intolerance who start with H2 Check use first
32953584|NCT04780854|Active Comparator|Metformin group|1 gm metformin tablet administered twice daily for 3 months
32953585|NCT04780854|Placebo Comparator|Metformin-free|1 placebo tablet administered twice daily for 3 months
32953586|NCT01896258||Regional emergency centers|
32953587|NCT01896258||Local emergency centers|
32953588|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
32953589|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
32953590|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
32953591|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
33316211|NCT03288142|Active Comparator|Control:Tracking Application and Home Monitor:|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
33316212|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
33316213|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
33316214|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
33316215|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
33316216|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
33316217|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
33316218|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
33316219|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
33316220|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
32953592|NCT04381416|Experimental|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
33316221|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
32953593|NCT04381416|Experimental|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
32953594|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
32953595|NCT01753830|Experimental|Durolane|Single intraarticular injection of Durolane
32953596|NCT01753830|Placebo Comparator|PBS|Single intraarticular injection of PBS
32953597|NCT04314492|Experimental|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
32953598|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
32953599|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
32953600|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
32953601|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
32953602|NCT01745250|Experimental|Emervel Lips|Emervel Lips
32953603|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
32953604|NCT03969420|Experimental|Lead-In Cohort: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
32953605|NCT03969420|Experimental|Lead-In Cohort: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
32953606|NCT03969420|Experimental|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
32953607|NCT03969420|Experimental|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
32953608|NCT00760812|Experimental|ESI--Individual PII First Condition|This group will first receive the Early Social Interaction (ESI) model individual parent-implemented intervention (PII) for 9 months, followed by the ESI model group information, education, and support (IES) intervention for 9 months.
32953609|NCT00760812|Experimental|ESI--Group IES First Condition|The group will first receive ESI group IES condition for 9 months, followed by ESI individual PII for 9 months.
32953610|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
32953611|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
32953612|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
32953613|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
32953614|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
32953615|NCT00747396|Experimental|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
32953616|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
32809709|NCT04387864|No Intervention|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
32809710|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
32809711|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
32809712|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
32809713|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
32809714|NCT05122936||SOWI Group|Obesity Cohort undergoing SRXPY-based Obesity Wellness Intervention
32809715|NCT05076292|Experimental|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise and placebo will be administered after exercise.
32809716|NCT05076292|Experimental|2*75 ug glucagon before exercise and after exercise|75 ug glucagon will be administered subcutaneously just before exercise and another 75 ug of glucagon will be administered immediately after exercise.
32809717|NCT05076292|Active Comparator|Saline as placebo|Saline as placebo will be administered in the same amount as glucagon before and after exercise.
32809718|NCT01798420||Corticosteroid|
32809719|NCT01798420||non-corticosteroid group|
32809720|NCT04815070||Diabetic|A group of diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
32809721|NCT04815070||Non-Diabetic|A group of non-diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
32809722|NCT04789330|Active Comparator|Norepinephrine|Norepinephrine continuous infusion as the first line vasopressor
32809723|NCT04789330|Active Comparator|Phenylephrine|Phenylephrine continuous infusion as the first line vasopressor
32809724|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
32809725|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
32809726|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
33316222|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
33316223|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
32809727|NCT04497298|Experimental|One COVID-19 vaccine candidate (TMV-083/V-591) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
32809728|NCT04497298|Placebo Comparator|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
32953617|NCT04780386|Experimental|NVP-1805|NVP-1805
33316224|NCT01060397|Experimental|Control|Usual care
33316225|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
33316226|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
33316227|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
33316228|NCT01063673||Active runners|Observational follow-up study on 39 runners
33316229|NCT01177748||Patients on the Stroke Unit|
33316230|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
33316231|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
33316232|NCT02747498|Experimental|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
33316233|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
33316234|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
33316235|NCT01177826||Group 1|Cases
33316236|NCT01177826||Group 2|Controls
33316237|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
33316238|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
33316239|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
33316240|NCT02940886|Active Comparator|Iron sucrose|Administered IV
33316241|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
33316242|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
33316243|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
33100254|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before laparoscopic partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
33100255|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before robot assisted partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
33100256|NCT04692896|Experimental|0.1% lidocaine|
33100257|NCT04692896|Experimental|0.2% lidocaine|
33100258|NCT04692896|Experimental|0.3% lidocaine|
33316244|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
33316245|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
33316246|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
33404911|NCT05761860|Active Comparator|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
32809729|NCT04483102|Experimental|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
32809730|NCT04483102|Active Comparator|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
32809731|NCT04418830||Base Interfixated System|
32809732|NCT04418830||Brigade Interfixated System|
32809733|NCT04418830||Coalesce Thoracolumbar Interbody|
32809734|NCT04418830||Cohere XLIF Interbody System|
32809735|NCT04418830||CoRoent Ti PLIF Interbody System|
32809736|NCT04418830||CoRoent Ti TLIF Interbody System|
32809737|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
32809738|NCT04418830||Modulus TLIF Interbody System|
32809739|NCT04418830||Modulus XLIF Interbody System|
32809740|NCT04418830||TLX Interbody System|
32809741|NCT04418830||XLX ACR Interbody System|
32809742|NCT04418830||CoRoent Ti XLIF Interbody System|
32809743|NCT04418830||Cohere TLIF|
32809744|NCT04418830||Modulus ALIF|
32809745|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
32809746|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
32809747|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
32809748|NCT04509622|Experimental|Venetoclax + Low-Dose Cytarabine (LDAC)|Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.
32809749|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
32809750|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
32809751|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
32809752|NCT02137486||sequential ballooning|include BMS or DES
32809753|NCT02137486||final kissing ballooning|include BMS or DES
32809754|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
32809755|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
32809756|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
32809757|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
32953618|NCT04780386|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1 and NVP-1805-R2
32953619|NCT04780308||1 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire
33316247|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
33316248|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
33316249|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
33316250|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
33404912|NCT05761860|Active Comparator|Oral placebo + intranasal oxytocin (48 IU)|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
32953620|NCT04780308||1 medial 2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire
32953621|NCT04780308||2 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire
32953622|NCT04780308||2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire
32953623|NCT04780308||3 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire
32953624|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
32953625|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
32953626|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
32953627|NCT04780152|Experimental|tDCS arm|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
32953628|NCT04780152|Placebo Comparator|Control arm|Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
32953629|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
32953630|NCT04779840||period 2011|
32953631|NCT04779840||period 2018|
32953632|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
32953633|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
32953634|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
32953635|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
32953636|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
32953637|NCT00641316|Experimental|2- FDBA/TCP|
32953638|NCT00641316|Experimental|3 FDBA/TCP+PRP|
32953639|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
32953640|NCT04779762|Experimental|Group 1|Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)
32953641|NCT04779762|Active Comparator|Group 2|Standard induction regimen of Ustekinumab as above without diet
32953642|NCT04779684|Experimental|ACP by proxy pilot intervention group|All participants are included in the intervention group
32953643|NCT01728402||Blood Draw|
32953646|NCT04778202||first group (control group)|25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
32953647|NCT04778202||Second group (breast cancer patient group)|25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
32953648|NCT04778280||Group A|1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
32953649|NCT04778280||Group B|2- Group B(Cases group with positive Giardia lamblia )96 sample
32953650|NCT04777968|No Intervention|Control Group (A) : RMGI restoration without SDF and KI.|• RMGI restoration without SDF and KI.
32953651|NCT04777968|Experimental|Intervention Group (B): Pretreatment with SDF and KI prior to RMGI restoration.|• Pretreatment with SDF and KI prior to RMGI restoration.
32953652|NCT04779606|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min ± 15 sec interval.
32953653|NCT04779606|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min ± 15 sec interval.
32953654|NCT05295654|Experimental|Kinect validation|Kinect measurements will be compared with the vicon measurements to validate the kinect system.
32953655|NCT01722708|Experimental|clindamycin|
32953656|NCT01722708|Experimental|metronidazole|
32953657|NCT04779450|Experimental|Synchronous Telemonitoring|The sessions will be supervised by a therapist and conducted via video call using the WhatsApp® application, lasting 50 minutes, 3 times a week, for 6 consecutive weeks, the exercises will basically consist of active stretching, mobilization and scapular stabilization, and active shoulder exercises with gradual range of motion.
32809758|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
32809759|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5
32809760|NCT04228978|Experimental|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
32809761|NCT04228978|Active Comparator|Exercise alone (EX)|Home based walking exercise (EX)
32809762|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
32809763|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
32809764|NCT04327336|Active Comparator|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
32809765|NCT04327336|Active Comparator|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
32809766|NCT04309864|No Intervention|Focus group-Veteran|Veterans will inform study staff regarding desired device design refinements
32809767|NCT04309864|No Intervention|Focus group-Clinicians|Clinicians will inform study staff regarding desired app design changes
32809768|NCT04309864|Other|Usability-inpatients|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
32809769|NCT04309864|Other|Usability-in-home|The Veteran will use the CMAP system at home for two weeks to use in their daily routines, along with wearing the acti-graph one week prior, two weeks during and one week after CMAP usage.
32809770|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
32809771|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
32809772|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
32809773|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
32809774|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
32809775|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
32809776|NCT00575146|Experimental|1|ketogenic diet
33100259|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
32809777|NCT04095520|Active Comparator|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
32809778|NCT04095520|Experimental|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
32809779|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
32809780|NCT03934840|Experimental|Carboplatin, Cabazitaxel and Abiraterone|
32809781|NCT04259398|Experimental|TIVA|propofol infusion targeting bispectral index 40-60
32809782|NCT04259398|Active Comparator|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
32809783|NCT04251520|No Intervention|Control Group|Standard care by Palliative Medicine physician
32809784|NCT04251520|Experimental|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
32809785|NCT04251520|Experimental|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
32809786|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
32809787|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
32809788|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
33100260|NCT00528008|Active Comparator|A|povidone-iodine
32809789|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
32809790|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
32809791|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
32809792|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
32809793|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
32809794|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
32809795|NCT00605644|Placebo Comparator|Placebo|Placebo
32809796|NCT00605644|Experimental|150 mg|MOA-728
32809797|NCT00605644|Experimental|300 mg|MOA-728
32809798|NCT00605644|Experimental|450 mg|MOA-728
32809799|NCT00605644|Experimental|600 mg|MOA-728
32809800|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
32809801|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
32809802|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
33100261|NCT00528008|Active Comparator|B|chlorhexidine gluconate
33100262|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
32953658|NCT04779450|Experimental|Asynchronous Telemonitoring|An explicative schedule with the exercises to be performed asynchronously during the week will be delivered weekly via e-mail and WhatsApp®. The exercises will be the same as those performed by the synchronous telemonitoring group, and the participant will be free to ask any questions about the protocol to the therapist at any time via text message or e-mail.
32953659|NCT04779450|Active Comparator|Control Group|Will receive only a booklet of usual guidelines for women after breast cancer, such as skin care, return to activities, upper limb functionality, self-care, lymphedema and physical activity practice.
32953660|NCT04777890|Active Comparator|suboccipital inhibition technique group|
32953661|NCT04777890|Experimental|INYBI group|Participants in this group will be treated with the INYBI, an instrument designed for treating the suboccipital area, in a more precise way than the manual technique.
32953662|NCT04777890|Experimental|combined treatment group|Participants in this group will be first treated with the INYBI and then receive an upper cervical manipulation
32953663|NCT04778124|Other|Patients with hemorrhoidal disease undergoing HAL-RAR|This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.
32953664|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
32953665|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
32953666|NCT03726528|Experimental|Experimental intervention|
32953667|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
32953668|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
32953669|NCT04777578|Experimental|DN|
32953670|NCT04777578|No Intervention|Control|
32953671|NCT04754568|Experimental|Virtual reality instructional design|Completion of virtual reality simulation of an outpatient physical therapy evaluation.
32953672|NCT04754568|Active Comparator|Role-playing instructional design|Completion of traditional role-playing of a scripted outpatient physical therapy evaluation
32953673|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
32953674|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
32953675|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
32953676|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
32953677|NCT04756206|Active Comparator|Dutasteride|Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
32953678|NCT04756206|Placebo Comparator|Placebo|same form and color of Dutasteride tablet was given at the same regimen to act as a placebo
32953679|NCT04777500|Experimental|taVNS Group1|This group will receive taVNS for 4 weeks.
32953680|NCT04777500|Experimental|taVNS Group 2|This group will receive taVNS for 4 weeks.
32953681|NCT04777188|Experimental|Hypertrophic Obstructive Cardiomyopathy|Left ventricular systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
32953682|NCT04777266|Experimental|Experimental Musictherapy Group|experimental group receiving the MT programme in addition to their usual treatment (pharmacological and psychosocial) (TAU + MT)
32953683|NCT04777266|Active Comparator|Control Non Musictherapy Group|Group with usual treatment only (TAU).
32953684|NCT04745598||Control group: Dental model|Patients diagnosed with periodontal disease stage I/II/III
32953685|NCT04745598||Computer-assisted teaching format group|Patients diagnosed with periodontal disease stage I/II/III
32953686|NCT04745598||Plaque-disclosing group|Patients diagnosed with periodontal disease stage I/II/III
32953687|NCT04745598||Intra-oral Camera group|Patients diagnosed with periodontal disease stage I/II/III
32953688|NCT04779060|Active Comparator|fentanyle group|
32953689|NCT04779060|Active Comparator|dexamethasone group|
32953690|NCT04779060|Placebo Comparator|control group|
32953691|NCT04778826|Active Comparator|Lung Lobectomy with standard ipsilateral lymphadenectomy|Lung lobectomy with ipsilateral lymphadenectomy
33100263|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
32953692|NCT04778826|Active Comparator|Lung Lobectomy with VAMLA|Lung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
32953693|NCT04778514|Other|Sequence 1|This arm is a single, over-encapsulated DPP containing PrEP (200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]) and a COC (30 mcg of ethinyl estradiol [EE], 150 mcg of levonorgestrel [LNG]) taken once daily for three 28-day cycles followed by PrEP (FTC/TDF) and a COC (EE/LNG) taken daily for three 28-day cycles.
32953694|NCT04778514|Other|Sequence 2|This arm is two separate tablets (PrEP [FTC/TDF] and COC [EE/LNG]) taken once daily for three 28-day cycles followed by single, over-encapsulated DPP containing PrEP (FTC/TDF) and a COC (EE/LNG) taken once daily for three 28-day cycles.
33404913|NCT05761860|Active Comparator|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
33404914|NCT05761860|Active Comparator|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
33404915|NCT05761860|Sham Comparator|Oral placebo + intranasal placebo|Serves as the control.
32953695|NCT04777110|Experimental|Esketamine injection group (0.25mg/kg)|The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5 mg/kg) for 30 s
32953696|NCT04777110|Sham Comparator|Saline injection group(0.05ml/kg)|The main anesthesiologist standing on the right side of the patient sequentially injects normal saline (0.05ml/kg), and 1 minute later injects propofol (1.5 mg/kg), the injection time is 30 seconds
32953697|NCT04776876|Experimental|Treatment (retifanlimab, telotristat ethyl)|Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32953698|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
32953699|NCT04776642||MARK_AF|MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery
32953700|NCT04776642||INDICO AF|Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.
32953701|NCT04776642||PREDICT AF|PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery
32953702|NCT04776642||WEIGHTLOSS AF|The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.
32953703|NCT04776642||MAD AF|(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.
32953704|NCT04776642||Adapt Biobank - AF surgery|Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.
32953705|NCT04776642||Adapt Biobank - blood|Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.
32953706|NCT05291208|Experimental|Treatment group|This group will receive a cognitive training intervention combined with alternating current electrical stimulation (i.e., treatment).
32953707|NCT05291208|Sham Comparator|Control group|This group will receive a traditional cognitive training intervention with sham electrical stimulation.
32953708|NCT04776486|Experimental|Critically ill patients with augmented renal clearance|ICU patients with estimated renal clearance over 130ml/min/1.73m2
32953709|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
32953710|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
32953711|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
32953712|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
32953713|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
32953714|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
32953715|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
32953716|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
32953717|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
32953718|NCT04753944|Active Comparator|Probiotic group|Patients will be introduced for 5 weeks with probiotic therapy (in the study group). They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains). The treatment will be administered two times a day, during breakfast and supper. The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp. z o. o. sp. k
32953719|NCT04753944|Placebo Comparator|Placebo group|Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily (one capsule). The treatment will be administered two times a day, during breakfast and supper.
32953720|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
32953721|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
32953722|NCT04754178||Down syndrome|Down syndrome patients and their parents
32953723|NCT04754178||Control group|Healthy children and their parents
32953724|NCT04753866|Experimental|Rehabilitated|Initial lip support condition of the patient when presents himself/herself at the office with indication for full arch implant rehabilitation. Then, the patient is facially scanned before and after the implant surgery.
32953725|NCT05605626||Simulator training before|group exposed directly to simulator training without knowing the topic of obstetric emergency
32953726|NCT05605626||lesson before simulation training|group undergoing formal lecture before the vacuum delivery simulation on mannequin
32953727|NCT04753554|Active Comparator|Conventional group|The patient group that whose oxygenation will be managed by blood gas analysis.
32953728|NCT04753554|Experimental|ORI group|The patient group that whose oxygenation will be managed by ORI values
32953729|NCT05272098|Experimental|Group A|myofascial release therapy
32953730|NCT05272098|Active Comparator|Group B|endurance training of the trunk extensor muscles
32953731|NCT04753476|Experimental|Secretome-MSCs (n=24)|This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome
32953732|NCT04753476|Other|Control (n=24)|This group will receive standard Covid-19 therapy with the best supportive care
32953733|NCT05605392|Experimental|Deinstitutionalization|
32953734|NCT05171946|Experimental|Cohort 1|Low-Dose, 1mg, 3 doses 21 days apart
32953735|NCT05171946|Experimental|Cohort 2|Mid-Dose, 2 mg, 2 doses 21 days apart
32953736|NCT05171946|Experimental|Cohort 3|High-Dose, 4 mg, 2 doses 21 days apart
32953737|NCT05605314||pSS-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028. The pSS-DED patients further accepted the diagnosis of rheumatology department. All enrolled DED participants met the criterion of TFOS DEWS II Definition and Classification Report and pSS-DED group also met 2016ACR/EULAR pSS diagnosis and classification consensus.
32953738|NCT05605314||nss-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028.
32953739|NCT04776330|Experimental|BCMA targeted prime CAR-T cells treat|Patients will be be treated with BCMA targeted prime CAR-T cells
32953740|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
32953741|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
32953742|NCT04775940|Experimental|Perforated collagen membrane|
32953743|NCT04775940|Active Comparator|Occlusive collagen membrane|
32953744|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
32953745|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
32953746|NCT04775862|Experimental|RAS wild type; investigator choice re-challenge with anti EGFR Rx|
32953747|NCT04775862|Active Comparator|RAS mutant; investigator choice of SOC third line Rx|
32953748|NCT05605158|Active Comparator|Group 1 (Pioglitazone group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 30mg/day pioglitazone for 24 weeks.
32953749|NCT05605158|Active Comparator|Group 2 (Empagliflozin group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 10mg/day empagliflozin for 24 weeks.
32953750|NCT05605080|Experimental|Gelfoam as hemostatic agent after surgery|Use Gelfoam as hemostatic agent after surgery.
32953751|NCT05605080|Active Comparator|Gauze with Bosmin as hemostatic agent after anal surgery|Use gauze with Bosmin as hemostatic agent after anal surgery
32953752|NCT01653678|Active Comparator|Vitamin D + fish oil|
32953753|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
32953754|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
32953755|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
32953756|NCT01896648||Type 2 diabetic women|
32953757|NCT05602116|Experimental|1 x 1000000 C2C_ASCs/kg body weight|Trial participant 1 - 5 will be treated with 1 x 1000000 C2C_ASCs/kg body weight
32953758|NCT05602116|Experimental|2 x 1000000 C2C_ASCs/kg body weight|Trial participant 6 - 10 will be treated with 2 x 1000000 C2C_ASCs/kg body weight
32953759|NCT05598762|Active Comparator|Children with mild atopic dermatitis|"age 1-8 years old~mild degree of atopic dermatitis"
32809803|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
32809804|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
32809805|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
32809806|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
32809807|NCT00579280|Placebo Comparator|Placebo|placebo
32809808|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
32809809|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
32809810|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
32809811|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
32809812|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
32809813|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
32809814|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
32809815|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
32809816|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
32809817|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
32809818|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
32809819|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
32809820|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
32809821|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
32809822|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
32809823|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
32809824|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
32809825|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
32809826|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
32809827|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
32809828|NCT00607126|Active Comparator|2|resistive training using weights and therabands
32809829|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
32809830|NCT01866319|Experimental|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
32809831|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
32809832|NCT01866319|Active Comparator|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
32809833|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
32809834|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
32809835|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
32809836|NCT01802515|Active Comparator|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
32809837|NCT01802515|Active Comparator|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
32809838|NCT01802515|Placebo Comparator|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
32831169|NCT03741582||Control - San Cristobal|"1000 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
32831170|NCT03741582||Intervention - Ciudad Bolviar|1000 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
32953760|NCT05598762|Active Comparator|Children with moderate-severe atopic dermatitis|"age 1-8 years old~moderate or severe degree of atopic dermatitis"
33404916|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
33404917|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
33404918|NCT05081830|Experimental|transdiagnostic intervention via the Internet|Treatment provided in eight individual sessions of 60 min., Once a week by videoconference. The integrity of the treatment will be controlled through the therapist's manual (Barlow et al., 2011) adapted for the Mexican population and to the online modality.
33404919|NCT05081830|Active Comparator|TCC intervention via the Internet|The TCC intervention program is short, with active, focused and directive participation, in 8 individual weekly sessions of one hour by videoconference.
33404920|NCT05081830|No Intervention|waiting list control.|Participants in the control group on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic intervention.
32809839|NCT01802437|Experimental|Talk Therapy 4-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 4 weeks of therapy, participants with at less than a 20% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy frequency or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy
32809840|NCT01802437|Experimental|Talk Therapy 8-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 8 weeks of therapy, participants with at less than a 40% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy.
32809841|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
32809842|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
32809843|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
32809844|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
32809845|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
32809846|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
32809847|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
32809848|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
32809849|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
32809850|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
32809851|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
32809852|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
32809853|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
32809854|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
32809855|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
32809856|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
32809857|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
32809858|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
32809859|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
32809860|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
32809861|NCT00610480|Active Comparator|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
32809862|NCT00610480|Active Comparator|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
32809863|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
32809864|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
32809865|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
32809866|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
32809867|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
32809868|NCT00582400|Experimental|I|
32809869|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
32809870|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
32809871|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
32809872|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
32809873|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
32809874|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
32809875|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
32809876|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
32809877|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
32809878|NCT04583215|Active Comparator|Active PAS|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
32809879|NCT04583215|Sham Comparator|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
32809880|NCT04583215|No Intervention|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. They will not complete the 10-session course of PAS or follow-up assessments.
32809881|NCT01801735|Experimental|Meloxicam Test Capsules|One Capsule QD
32809882|NCT01841359|No Intervention|Baseline|"Baseline Arm/Phase 1, is comprised of study visits 1 and 2. Visit 1: Screening visit. Eligible individuals who provided informed consent were asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms, concurrent with a 3 day period of blinded (masked) continuous glucose monitoring device wear.~Visit 2: a baseline mixed meal tolerance test was performed. Glucose, hormonal responses, and satiety were assessed. Glucose and symptom logs were reviewed."
32809883|NCT01841359|Experimental|Pramlintide|"At the end of Visit 2 (following the baseline mixed meal tolerance test), pramlintide was prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During the treatment phase (8 weeks), the participants were asked to keep record of all hypoglycemic symptoms and blood glucose measurements..~Visit 3: (week 4 of treatment) focused on evaluation of symptoms and side effects. Participants again completed a food and glucose diary for 3 days with concurrent wear of a blinded (masked) continuous glucose monitoring device.~Visit 4: (week 8 of treatment), participants received a dose of pramlintide 15 minutes prior to undergoing a repeat mixed meal tolerance test. (the dose administered was the maximally tolerated dose of pramlintide used during the 8 week outpatient treatment phase)."
32809884|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
32809885|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
32809886|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
32809887|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
32809888|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
32809889|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
32809890|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
33100264|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
32953761|NCT05598762|Active Comparator|Children with food allergy and moderate-severe atopic dermatitis|"age 1-8 years old~moderate or severe degree of atopic dermatitis~IgE mediated food allergy"
32953762|NCT05598762|Active Comparator|Adult with atopic dermatitis|"age 18-60 years old~mild-severe atopic dermatitis"
32953763|NCT05598762|Active Comparator|Healthy|"age 1-60 years old~no history of atopic diseases"
32953764|NCT05598762|Active Comparator|Healthy with Asthma|"age 1-8 years old~doctor diagnosed asthma~no history of chronic or chronic relapsing eczema"
32953765|NCT05598684||Cohort|Patient being treated with Humira® in whom the investigator has decided, with the patient's agreement and prior to enrolment, to replace Humira® with FK adalimumab
32953766|NCT01053234|Experimental|Insulin aspart|
32953767|NCT01053234|Experimental|NPH insulin|
32953768|NCT04775784||Adult neurosurgical patients|Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
32953769|NCT02090088||All Subjects|All Subjects
32953770|NCT05162820|Experimental|Smoker Solarplast|Smoker's assigned to solarplast
32953771|NCT05162820|Placebo Comparator|Smoker Placebo|Smoker's assigned to placebo
33316251|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
33316252|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
33316253|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
33316254|NCT03863444|Active Comparator|Control Group|Routine Care
33316255|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
33316256|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
33316257|NCT01172054|Placebo Comparator|Placebo|one IM injection
33316258|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
32953772|NCT05162820|Experimental|Non-smoker Solarplast|Non-smoker assigned to solarplast
33316259|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
33316260|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
33316261|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
33316262|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
33316263|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
32953773|NCT05162820|Placebo Comparator|Non-smoker Placebo|Non-smoker assigned to placebo
32953774|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
32953775|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
32953776|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
32953777|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
32953778|NCT04775238|Active Comparator|Group 1 (Staphylococcus aureus)|Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
32953779|NCT04775238|Active Comparator|Group 2 (Pseudomonas aeruginosa )|Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
32953780|NCT05595798||Geriatric population|patient with ages above 65-yr
32953781|NCT05595798||Pediatric population|patient with ages between 4-8 year old
32953782|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
32953783|NCT01896882|No Intervention|Control|Standard treatment.
32953784|NCT05580978|Experimental|GEM + CGM + Activity Monitor|GEM plus CGM and Activity Monitor (FitBit)
32953785|NCT05580978|Active Comparator|Routine Care|Usual care already being received for prediabetes as treated by their care team.
32953786|NCT05580042|Experimental|Patients with Granuloma Annulare|4-week treatment and 2-week follow-up period (without treatment)
32953787|NCT05579652||Patients with open abdomen|All non-pregnant adults with an open abdomen who are consentable or who have a legally authorized representative will have the tension on each side of their abdominal wall measured using a tensiometer at each abdominal exploration
32953788|NCT04775160|No Intervention|Control group|The control group will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and will receive treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
33100265|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
33316264|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
33316265|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
33316266|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
33316267|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
33316268|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
32953789|NCT04775160|Experimental|Intervention group|The intervention group will receive an Ecological Momentary Intervention called SmartSafe, will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and their treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
32953790|NCT03404388|Experimental|Experimental|Balance Training
33316269|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
33316270|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
33316271|NCT05216614|Experimental|Fluvoxamine|"This arm will be given the active treatment, oral fluvoxamine capsules of 25 mg each.~The first six weeks will be gradual titration (weeks 1 & 2 25mg BID, weeks 3 & 4 75mg BID, weeks 5 & 6 100mg BID).~The following six weeks will be fixed dose of 100mg TID.~The last two weeks will be a taper down (first week 50mg BID and second week 25mg BID)~There will be 14 weeks of active treatment and assessments will be conducted after completion of week 12, prior to beginning taper down period."
33316272|NCT05216614|Placebo Comparator|Placebo|"Placebo capsules that look, smell, and taste like fluvoxamine capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule BID during the first six weeks following the titration schedule and one capsule TID during the next six weeks for the fixed-dose period.~Subjects will then taper-down placebo to imitate the fluvoxamine arm for two weeks.~Assessments will be conducted at 12 weeks following completion of fixed-dose period, prior to starting taper down period."
33316273|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.~The day they receive their HCG trigger,~The day of transvaginal oocyte retrieval (TVOR) and~The day of embryo transfer (ET)."
33404921|NCT05081674|Active Comparator|ALK-translocated|"st line Alectinib~nd line Carboplatin pemetrexed~rd line Docetaxel"
32953791|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
32953792|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
32953793|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
32953794|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
32953795|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
32953796|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
32953797|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
32953798|NCT04774770|Experimental|HED-Start Intervention arm|Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
32953799|NCT04774770|No Intervention|Standard care arm|Participants assigned to the standard care arm will proceed with routine standard care.
32953800|NCT01614990|Active Comparator|Macimorelin|
32953801|NCT01614990|Placebo Comparator|Placebo|
32953802|NCT05433558|Experimental|Experimental group|enter the experiment directly
32953803|NCT05433558|Experimental|Waiting group|enter the experiment after waiting eight weeks
32953804|NCT04774614|Experimental|VITA ENAMIC multiColor anterior laminate veneers|
32953805|NCT04774614|Active Comparator|IPS e.max CAD anterior laminate veneers|
32953806|NCT05074134|Experimental|[14C]-TNP-2092|
32953807|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
32953808|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
32953809|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
32953810|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
32953811|NCT05421546|Active Comparator|Spermidine arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive Spermidine supplements 6mg/day and oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
32953812|NCT05421546|Placebo Comparator|Placebo arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive placebo oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
32953813|NCT05415774|Active Comparator|S Stimulation|Standard STN DBS defined as high frequency at 130Hz stimulation
32953814|NCT05415774|Experimental|C1 Stimulation|Combined high frequency stimulation of the STN and SNr using an interleaved pulses at 125Hz
32953815|NCT05415774|Experimental|C2 Stimulation|Combined low frequency stimulation of the SNr at 60Hz and high frequency stimulation of the STN
32953816|NCT05390970|Experimental|Platelet-rich Plasma|These subjects will have the active PRP injected into their anterior vaginal wall.
32953817|NCT05390970|Placebo Comparator|Placebo (saline)|These subjects will have a saline placebo injected into the anterior vaginal wall.
32809891|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
32809892|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
32809893|NCT01429168|Experimental|Part 2: Etoricoxib|
32809894|NCT01429168|Placebo Comparator|Part 2: Placebo|
32809895|NCT00771160|Experimental|1|MK0476 5mg
32809896|NCT00771160|Experimental|2|MK0476 10mg
32809897|NCT00756418|Experimental|1|
32809898|NCT00756418|Active Comparator|2|
32809899|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
32809900|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
32809901|NCT00615784|Experimental|A|
32809902|NCT00755794|Experimental|1|Montelukast
32809903|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
32809904|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
32809905|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
32809906|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
32809907|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
32809908|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
32809909|NCT04345900|Experimental|20 mg/m^2 Plinabulin|Docetaxel + 20 mg/m^2 Plinabulin
33100266|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
33100267|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
33404922|NCT05081674|Active Comparator|EGFR-mutant|"st line Erlotinib~nd line Carboplatin pemetrexed~rd line Docetaxel"
33404923|NCT05081674|Active Comparator|PD-L1 >= 50%|"st line Pembrolizumab~nd line Carboplatin pemetrexed~rd line Docetaxel"
33100268|NCT04692740|Experimental|Chlorambucil|
33100269|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
33100270|NCT04692857|Experimental|group 30|participants received a supra inguinal fascia iliaca compartment block with 30 ml of 0.2% ropivacaine
33100271|NCT04692857|Experimental|group 40|participants received a supra inguinal fascia iliaca compartment block with 40 ml of 0.2% ropivacaine
33100272|NCT04692857|Experimental|group 50|participants received a supra inguinal fascia iliaca compartment block with 50 ml of 0.2% ropivacaine
33404924|NCT05081674|Active Comparator|PD-L1< 50%|"st line Carboplatin pemetrexed~nd line nivolumab~rd line Docetaxel"
32809910|NCT04345900|Experimental|10 mg/m^2 Plinabulin|Docetaxel + 10 mg/m^2 Plinabulin
32809911|NCT04345900|Experimental|5 mg/m^2 Plinabulin|Docetaxel + 5 mg/m^2 Plinabulin
32809912|NCT04345900|Active Comparator|6 mg Pegfilgrastim|Docetaxel + 6 mg Pegfilgrastim
33100273|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
33404925|NCT05150535|Active Comparator|Hypofractionation control arm|Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.
32809913|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
32809914|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
32809915|NCT05247424|Experimental|Early unfractionated heparin|Administration of UFH at a dose of 100 IU/kg body weight at first medical contact. Addition of UFH before coronary intervention according to ACT measurement after coronary angiography before coronary intervention.
32809916|NCT05247424|No Intervention|Control - Unfractionated heparin for coronary intervention only|Control arm with administration of UFH at a dose of 100 IU/kg body weight after coronary angiography before coronary intervention.
32809917|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
32809918|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
32809919|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
32809920|NCT05246956|Experimental|Intradialytic exercise in hemodialysis patients ( Experimental Group)|Intradialytic exercise group
32809921|NCT05246956|No Intervention|Control Group|No intervention
32809922|NCT05246800|Experimental|Experimental group|a structured 8-week mHealth mindfulness program.
33100274|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
32953818|NCT05390580|Experimental|Stimulation with Transcutaneous Auricular Vagal Nerve Stimulator|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period, the investigator will stimulate the auricular branch of the vagus nerve. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
32953819|NCT05390580|Sham Comparator|Control - Transcutaneous Auricular Vagal Nerve Stimulator - Sham|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period. Patients assigned to the controls arm will have electricity applied to the the great auricular nerve (cervical nerve branch), the lobule of the ear. The investigator will stimulate the lobule of the ear. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
32953820|NCT05390502|Experimental|Integrated|Participants will have their home blood pressure readings sent directly to their participating health systems. Participants will also receive a wrap-around intervention.
32953821|NCT05390502|Active Comparator|Manual|Participants will record their own blood pressures and report them to their health care system as per usual care.
32953822|NCT05371002|Experimental|Online group nonviolent communication (NVC) interventions|"Rosenberg's Nonviolent Communication: A Language of Life: Life-changing Tools for Healthy Relationships and Raising Children Compassionately: Parenting the Nonviolent Communication Way will be used as reference guides. Six 1.5-hour weekly online group sessions (10-14 participants in each group) will be delivered by NVC professionals to the intervention group, including (1) introduction to four key principles of NVC, communication that blocks compassion, and distinguishing observations from evaluations, (2) identifying and expressing feelings, providing a list of words to express feelings and four steps to express anger, (3) taking responsibility for feelings (needs), distinguishing between an outside event and the met or unmet needs behind the feelings, (4) using positive action language to make requests, (5) review and summary, and (6) experience sharing and suggestions for further practice. Group discussion will be used to sustain the participants' engagement."
32953823|NCT05371002|Active Comparator|Waitlist control group|The participants in WL group will not be provided any materials or training content between baseline (T1) and immediate post assessment (T2). Once the participants completed the T2 assessments, they will be delivered one 1.5-hour online session about physical activity (completely different from NVC training content). In the session, the participants will be introduced the concept of Zero-time exercise and provided video demonstrations of exercise. Six 1.5-hour weekly NVC training sessions (the same as those in intervention group) will be delivered to participants as soon as they have completed the final assessment at T3 (three months after T2).
32953824|NCT04773756|Other|Sofosbuvir / Daclatsvir|A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
32953825|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
32953826|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
32953827|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting the Trauma memories~Processing the trauma memories~In vivo Exposure homework~*Use of a brief pre-exposure trauma memory retrieval trial~Exposure to video clips related to the patient's trauma~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
32953828|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting of the Trauma memories~Processing the trauma memories~Breathing retraining~In vivo Exposure homework"
32953829|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
32953830|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
32953831|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
32953832|NCT04773990|Other|Experimental Group|Group (A) twenty-five patients will receive biodex balance training
33316274|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.~The day we coordinate with embryologist (day of progesterone +/-1)~The day of embryo transfer (ET)."
33316275|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
32953833|NCT04773990|Other|Controlled Group|twenty-five patients will receive a physical therapy exercise protocol
32953834|NCT05051202|Experimental|25g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 25 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
32953835|NCT05051202|Active Comparator|25g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 25 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
32953836|NCT05051202|Experimental|35g Sugars From Fiber per day|Administered in 50 g Flapjack containing 35 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
32953837|NCT05051202|Active Comparator|35g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 35 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
32953838|NCT05051202|Experimental|45g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 45 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
32953839|NCT05051202|Active Comparator|45g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 45 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
32953840|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
33404926|NCT05150535|Experimental|. Ultrahypofractionation experimental arm|Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\4 fractions).
33404927|NCT00138372||Adult Repeat Cross-Sectional study (ARCS)|This group will be enrolled from the sub-location of Kanyawegi, Kisumu District, Nyanza Province.
33404928|NCT00138372||Prospective Infant Cohort study (PIC)|will be a clinic-based study recruiting infants attending Chulaimbo Rural Health Training Center (CRHTC), Maseno Division, Kisumu District, Nyanza Province for routine immunizations.
33404929|NCT00138372||Normal volunteers|will be recruited from the CWRU/UHCMC area as well as general local community.
33404930|NCT05081440||patients diagnosed with hypertension or diabetes|Age ≥18 years; Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for ≥ 3 months; The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded
32953841|NCT05290974|Active Comparator|In-person group|Conventional in-person standardized teaching
32953842|NCT05290974|Experimental|Online group|Independent learning with online educational material
32953843|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
32953844|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
32953845|NCT04773132|Experimental|Low Protein Diet|All subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
32953846|NCT01565382|Experimental|Independent, blinded reader trainees|Seven practicing nuclear medicine physicians with no prior training in reading scans from florbetapir-PET, or other amyloid imaging agents.
32953847|NCT05283564|Other|Administration of Percussive ventilation breathhold (PVB) technique in healthy volunteers|The healthy patient will execute the Percussive ventilation breathhold technique
32953848|NCT05283564|Other|Administration of the PVB-SABR in lung cancer patients|Lung cancer patients will execute a PV breathhold and a verification cone-beam CT scan.
32953849|NCT04773444|Experimental|Eccentric cycling training|Moderate intensity cycling training in eccentric type
32953850|NCT04773444|Experimental|Concentric cycling training|Moderate intensity cycling training in concentric type (intensity matched the eccentric training)
32953851|NCT04773444|No Intervention|Control group|without receiving any exercise training
32953852|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
32953853|NCT05217108|Other|Fit Bit (Study Groups)|Participants wear a Fitbit every day for 8 weeks to record the number of steps you take
32953854|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
32953855|NCT01895556|Placebo Comparator|Control|Control
32953856|NCT05208450|Experimental|Intervention Group|
32953857|NCT05208450|No Intervention|Usual care (UC) Group|
32953858|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
32953859|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
33316276|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
33316277|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
33316278|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
33316279|NCT05666648||Sixty patients completed trial in two groups|
33316280|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
33316281|NCT03285646|Experimental|Placebo|SC every 4 weeks
33316282|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
32953860|NCT05208138|Experimental|Intervention|Bariatric operation with the Senhance surgical system
32953861|NCT05204706|Active Comparator|Intervention arm|Women who meet study inclusion criteria and consent to study participation will be randomised using sealed envelope randomisation and online database for clinical trials to one of two groups in a 1:1 ratio.
32953862|NCT05204706|No Intervention|Control arm|Women allocated to the control arm will receive standard care and no digital intervention. This includes self-monitoring blood glucose and lifestyle advice (diet, physical activity, optimal body weight) by a multidisciplinary team.
32953863|NCT04772976||Patient group|Patients with Ankylosing Spondylitis
32953864|NCT04772976||Healthy controls|Healthy controls
32953865|NCT00054756|Experimental|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
32953866|NCT04772430|No Intervention|Control group|The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure
32953867|NCT04772430|Experimental|Experimental group|The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
32953868|NCT04772508|Sham Comparator|Group A|15 sites received only scaling and root planing
32953869|NCT04772508|Active Comparator|Group B|15 sites received scaling and root planing with subgingival placement of amnion membrane
32953870|NCT04772508|Active Comparator|Group C|15 sites received scaling and root planing with subgingival placement of amnion membrane hydrated with Taurine
32953871|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
32953872|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
32953873|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
32953878|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
32953879|NCT03013998|Experimental|BAML-16-001-S2 (Closed)|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
32953880|NCT03013998|Experimental|BAML-16-001-S3 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
32953881|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
32809923|NCT05246800|No Intervention|Control group|The control group was suggested to read the information about stress and burnout on the website of the TV-programme.
32809924|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
32809925|NCT00588406|Placebo Comparator|P|Placebo plus standard care
33316283|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
33316284|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
33316285|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
33316286|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
33316287|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
33316288|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
33316289|NCT03867656|Placebo Comparator|Placebo|Saline
33316290|NCT01172210||Bulimia Nervosa|
33316291|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
33316292|NCT01172210||Healthy Controls|
33316293|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
33316294|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
33316295|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
33316296|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
33316297|NCT01284218||Aripiprazole cohort|
33316298|NCT01284218||Other atypical cohort|
33316299|NCT01284218||Other antidepressant cohort|
33316300|NCT01284218||Mood stabilizer cohort|
33316301|NCT01284218||Stimulant cohort|
33316302|NCT03860324|No Intervention|Control-group|No peripheral nerve block
33316303|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
33316304|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
33316305|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
33316306|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
33316307|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
33316308|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
33316309|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
33316310|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
33316311|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
33316312|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
33316313|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
33316314|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
33316315|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
33316316|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
33316317|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
33316318|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
33316319|NCT01178372|Active Comparator|probiotics|
32809926|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
32809927|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
32809928|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
32809929|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
32809930|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
32809931|NCT00669214|Experimental|Efalizumab|
32809932|NCT00669214|Placebo Comparator|Placebo|
32809933|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
32809934|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
32809935|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
32809936|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
32809937|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
32809938|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
32809939|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
32809940|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
32809941|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
32809942|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
32809943|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
32809944|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
32809945|NCT00623506|Active Comparator|1|Pregnenolone
32809946|NCT00623506|Placebo Comparator|2|Placebo
32809947|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
32809948|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
32809949|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
32809950|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
32809951|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
32809952|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
32809953|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
32809954|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
32809955|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
32809956|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
32809957|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
32809958|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
32809959|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
32809960|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
32809961|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
32809962|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
32809963|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
33100275|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
33100276|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
33100277|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
33100278|NCT00528047|Experimental|PRLX 93936|
33100279|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
33100280|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
33100281|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
33100282|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
33100283|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
33100284|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
33100285|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
33100286|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
33100287|NCT04692272|No Intervention|CONTROL group|The CONTROL group did not exercise.
32809964|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
33316320|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
32809965|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
32809966|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
32809967|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
32809968|NCT00673114|Other|Transplant Recipients|
32809969|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
32809970|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
32809971|NCT00594256|Experimental|Sodium oxybate|Active treatment
32809972|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
32809973|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
32809974|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
32809975|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
32809976|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
32809977|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
32809978|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
32809979|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
32809980|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
32809981|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
32809982|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
32953882|NCT03013998|Experimental|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
32953883|NCT03013998|Experimental|BAML-16-001-S6 (Closed)|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
32953884|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
32953885|NCT03013998|Experimental|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
32953886|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
32953887|NCT03013998|Experimental|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
32953888|NCT03013998|Experimental|BAML-16-001-S14 (Closed)|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
32953889|NCT03013998|Experimental|BAML-16-001-S18 (Closed)|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
33316321|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
33316322|NCT00074490|Experimental|Arm IVD cohort 1 (Th2 DLI)|Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
33316323|NCT00074490|Experimental|Arm IVD cohort 2 (conventional DLI)|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
33316324|NCT00074490|Experimental|Arm IVD cohort 3 (multiple Th2 DLI)|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
33316325|NCT00074490|Experimental|Arm IVA (12-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
33404931|NCT05037942|Experimental|Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)|Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
32809983|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
32809984|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
32809985|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
32809986|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
32809987|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
32809988|NCT00596440||1|Relatives of Cancer Patients
32809989|NCT00596440||2|Relatives of Orthopedic Patients
32809990|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
32809991|NCT00632632|Experimental|D-Cycloserine (DCS)|
32809992|NCT00632632|Placebo Comparator|Placebo|
32809993|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
32809994|NCT00633256|Sham Comparator|Placebo|Matched placebo
32809995|NCT00634270|Experimental|Sirolimus|"Design~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~Disease status will be evaluated using volumetric MRI analysis at regular intervals.~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~Pain reduction and quality of life outcomes will also be assessed.~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
32809996|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
32809997|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
32809998|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
32809999|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
32810000|NCT00678418|Experimental|VIVITROL® 380 mg|
32810001|NCT00678418|Placebo Comparator|Placebo|
32810002|NCT00678496|Experimental|1|CBT software delivered at home or in a primary care facility (n=12)
32810003|NCT00678496|Other|2|Treatment as usual (n=12)
32810004|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
32810005|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
33404932|NCT05037942|Experimental|Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)|Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
32810006|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
32810007|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
32810008|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
32810009|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
32810010|NCT00635830|Experimental|1|Open Label
32810011|NCT00600340|Active Comparator|A Bev+Pac|Bevacizumab plus Paclitaxel
32810012|NCT00600340|Active Comparator|B Bev+Cap|Bevacizumab plus Capecitabine
32810013|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
32810014|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
32810015|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
32810016|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
32810017|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
32810018|NCT00636220||A, Observational|
32810019|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
32810020|NCT00638014|Active Comparator|1|Conventional wires only
32810021|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
32810022|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
32953890|NCT03013998|Experimental|BAML-16-001-S17|This is an open-label Phase 1b dose escalation and expansion clinical trial to determine the safety and recommended dose of SNDX-5613 combined with azacitidine and venetoclax in newly diagnosed, untreated AML patients age ≥ 60 years who are not candidates or do not wish to pursue intensive induction therapy and who have NPM1 mutated/FLT3-ITD and FLT3-TKD wild type or MLL-rearranged disease. After determination of the recommended dose of SNDX-5613, the study will have an expansion cohort to be treated at the recommended dose in combination with azacitidine and venetoclax in the same patient population.
32953891|NCT03013998|Active Comparator|BAML-16-001-S12 (Arm A)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
32953892|NCT03013998|Experimental|BAML-16-001-S12 (Arm B)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
32953893|NCT00055692|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
32953894|NCT05048316|Experimental|eHealth|Weekly video conference groups led by a trained facilitator
32953895|NCT05043012|Experimental|Group 1|will have an mpMRI scan with a flexible AIR coil.
32953896|NCT05043012|Experimental|Group 2|will have an mpMRI scan with an endorectal coil
32953897|NCT04772352|Experimental|Experimental group: Lifestyle intervention + febuxostat (40mg, once a day, orally)|participants accept febuxostat treatment in addition to lifestyle intervention for 0-48 week.
32953898|NCT04772352|Active Comparator|Control group: Lifestyle intervention|participants receive lifestyle intervention for 0-24 week. If the results of the 0-24 week study showed that the liver fat content of subjects in the experimental group was significantly lower than that in the control group, control group will accept febuxostat treatment in addition to lifestyle intervention in the next 25-48 week.
32953899|NCT00056472|Active Comparator|olanzapine/sertraline combination|sertraline plus olanzapine
32953900|NCT00056472|Placebo Comparator|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
32953901|NCT00056550|Experimental|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level > 80% and < 120% of normal.
32953902|NCT04752930|Experimental|ctDNA monitoring|ctDNA monitoring will be performed at protocol-specified intervals and requirement
32953903|NCT04752930|Active Comparator|Imageology (SOC)|Imaging examination will be performed at protocol-specified intervals and requirement
32953904|NCT04771728|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
32953905|NCT04771728|Experimental|Metronidazole vagianl and Probiotics(Umeta-mimi)|Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）
32953906|NCT04271826|Experimental|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
32953907|NCT04271826|Experimental|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
32953908|NCT04771884||Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)|The use of antimicrobial agents depends on the clinical practice.
32953909|NCT04880850|Experimental|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
32953910|NCT04880850|Active Comparator|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
32953911|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
32953912|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
32953913|NCT00060528|Experimental|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
32953914|NCT00060528|Experimental|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
32953915|NCT00060528|Experimental|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
32953916|NCT00060528|Experimental|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
32953917|NCT02255838|Experimental|Disposable bronchoscope first (aScope IV), then Reusable bronchoscope (Storz 8402 2x)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
32953918|NCT02255838|Active Comparator|Reusable bronchoscope first (Storz 8402 2x), then Disposable bronchoscope (aScope IV)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
33404933|NCT05037942|No Intervention|Control for BFR-40|Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
33404934|NCT05037942|No Intervention|Control for BFR-80|Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.
32953919|NCT04696224|Active Comparator|INTRAVENOUS|30 patients who will receive 15mg / kg of TXA intravenous in 100ml salina solution (0,9%), after anesthetic induction and before incising the skin (administered in 10 minutes). For masking purposes, these patients will also receive at the end of the surgery, and before performing the plan closure, a compress soaked in 80ml of saline solution (0.9%), which will fill all the plans of the incision, and will be kept for 5 minutes.
33404935|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
33404936|NCT05003076|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
33404937|NCT05003076|Experimental|Methamphetamine Then Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
33404938|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
33404939|NCT05002374|Experimental|Experimental Group|
33404940|NCT05002374|Active Comparator|Control Group|
33404941|NCT05081050||10-year Patients|Clinical and image examination to assess single crowns on short (6-mm) implants in the posterior region of the maxilla and mandible, according to functional, biological and technical variables, patient's satisfaction and quality of life.
33404942|NCT04986930|Experimental|SBRT+mFOLFIRINOX|"Stereotactic body radiotherapy: 3500 cGy (5 fractions)~mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2"
33404943|NCT04986930|Active Comparator|mFOLFIRINOX|-mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
33404944|NCT05080894|Experimental|Virtual reality|Daily 20-minute sessions of virtual reality based rehabilitation for the first 4 weeks post-operatively + standard rehabilitation protocol
33404945|NCT05080894|No Intervention|Standard intervention|Standard rehabilitation protocol only
33404946|NCT05762640|Experimental|Ruxolitinib|
33404947|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
33404948|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
33404949|NCT04949022|Experimental|Hybrid closed loop system|Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
33404950|NCT05762562||Telerehabilitation with OS platforms|Patients with Parkinson's Disease were divided into three subgruops based on their residual motor skills.
33404951|NCT04457752|Active Comparator|Dual Layer Amniotic Membrane (DLAM) + SOC|DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).
33404952|NCT04457752|No Intervention|Standard of Care|Standard of Care: sharp debridement, offloading, and proper moisture balance.
33404953|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
32810023|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
32810024|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
32810025|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
32810026|NCT01478542|Active Comparator|Favourable Prognosis F-A - Recruitment completed|Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
32810027|NCT01478542|Experimental|Favourable F-B - Arm Closed|Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,4 mg/sqm (max. 2mg absolute), Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
32810028|NCT01478542|Active Comparator|Less Favourable LF-A - Recruitment completed|Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.
32810029|NCT01478542|Experimental|Less Favourable LF-B - Recruitment completed|Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed. Recruitment completed.
32810030|NCT01478542|Experimental|Less Favourable LF-C - Recruitment completed|Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed. Recruitment completed.
33316326|NCT00074490|Experimental|Arm IVB (6-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
33316327|NCT00074490|Experimental|Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
32810031|NCT01478542|Experimental|Less Favourable LF-D - Recruitment completed|Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed. Recruitment completed.
32810032|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
33316328|NCT01286636|Experimental|artificial neural network|
33316329|NCT01286636|Active Comparator|Polysomnogram|
33316330|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
33316331|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
33316332|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
33316333|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
33404954|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
33404955|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
32810033|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
32810034|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
32810037|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
32810038|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
32810039|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
32810040|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
32810041|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
32810042|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
32810043|NCT00683332||A|
32810044|NCT00683410||1|
32810045|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
32810046|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
32810047|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
32810048|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
32810049|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
32810050|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
32810051|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
32810052|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
32810053|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
32810054|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
32810055|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
32810056|NCT02998294|Experimental|Respiratory monitoring group|
32810057|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
32810058|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
32810059|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
32810060|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
32810061|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
32810062|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
32810063|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
32810064|NCT00645970||Group 1|
32810065|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
32810066|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
32810067|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
32953920|NCT04696224|Active Comparator|LOCAL|30 patients who, at the end of the surgery, and before the suture in layers, will receive a compress soaked in a solution of 1.5 g of tranexamic acid (six ampoules of Transamin®, Zydus Nikkho) diluted in 50 ml of saline solution (0.9 %) (total volume of 80ml), which will fill all the plans of the incision and will be maintained for 5 minutes. For masking purposes, these patients will also receive 100ml of saline solution (0.9%) after anesthetic induction and before incising the skin.
32953921|NCT04696224|Placebo Comparator|PLACEBO|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2.
32953922|NCT04693494|Experimental|Intervention group|"Four training sessions (before the baby is 1 month old, at 3 months, at 6 and at 9 months old) teaching the main motor milestones to get in the next 3 months and how to help infants with the correct stimuli, positions or plays; triptychs containing the main points explained at the session and links to short videos about the given advices.~Two evaluations of motor milestones at the age of 9 and 12 months old"
32953923|NCT04693494|No Intervention|Control group|Two evaluations of motor milestones at the age of 9 and 12 months old
32953924|NCT04690452|Experimental|Intervention condition|Intervention group that receive a standardized 8 weeks Compassion Cultivation Training from a faculty member certified CCT© instructor (https://www.compassioninstitute.com/about-us/teacher-directory/)
32953925|NCT04690452|Other|Waitlist control condition|"The participants assigned to the waitlist control will fill in the same questionnaires as the intervention group at the different time points (i.e., pre, post, 2-month and 6-month follow-ups).~Two months after finishing the intervention, will become participants of a CCT© program themselves given by the same faculty member certified CCT© teacher as for the experimental group."
32953926|NCT04689438||Healthy control groups|clinically healthy gingiva BOP score less than 10%
32953927|NCT04689438||Gingivitis groups|BOP score of 10% or greater
32953928|NCT04689438||Periodontitis groups|interdental AL ≥5 mm, PD≥6 mm
32953929|NCT04688580|Experimental|XW10172|
33316334|NCT03961152|Experimental|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
33316335|NCT03961152|No Intervention|Control group|The control group received usual care.
33316336|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
33316337|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
32953930|NCT04753008|Experimental|Dopamine group|Cardiac surgery patients receiving dopamine to support their cardiac function (as part of the routine post-operative care).
32953931|NCT04753008|No Intervention|Control group|Cardiac surgery patients receiving no positive inotrope drug.
33316338|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
33316339|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
33316340|NCT01288508|Active Comparator|Supra Fiber|
33316341|NCT01288508|Active Comparator|Psyllium|
33316342|NCT03960762|Active Comparator|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
33316343|NCT03960762|Active Comparator|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
33316344|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
33316345|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
33316346|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
33316347|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
33316348|NCT01286714|Experimental|clips OST|
33316349|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
33316350|NCT03859778||pharmacy students|
33316351|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
32953932|NCT04771494|Experimental|Trained|Participants with at least 6 months of training with unstable devices
32953933|NCT04771494|Experimental|Untrained|Participants with no previous instability experience
32953934|NCT04771104|Active Comparator|Allocated to intervention at first experimental day|
32953935|NCT04771104|Placebo Comparator|Allocated to intervention at second experimental day|
32953936|NCT00060606|Experimental|Prenatal Surgery Group|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
32953937|NCT00060606|Active Comparator|Postnatal Surgery Group|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
32953938|NCT04771338|Experimental|Treatment group|Job interview training protocol for 12 sessions
32953939|NCT04771338|No Intervention|Control group|No participation in any intervention protocol
32810068|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
32810069|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
32810070|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
32810071|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
33316352|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
33316353|NCT02525276|Experimental|training + HT|training + HT
32810072|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
32810073|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
33316354|NCT02525276|Experimental|training - HT|training - HT
32810074|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
32810075|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
33316355|NCT02525276|Placebo Comparator|-training + HT|-training + HT
32810076|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
32810077|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
32810078|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
32810079|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
32810080|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
32810081|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
32810082|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
32810083|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
33316356|NCT02525276|No Intervention|- training - HT|- training - HT
33316357|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
33316358|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
33316359|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
33316360|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
33316361|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
33316362|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
33316363|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
33316364|NCT01176110|Active Comparator|no specific thermal management|
33316365|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
33316366|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
33316367|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
33316368|NCT01178684||1: HIV-pos on d4T with neuropathy|
33316369|NCT01178684||2: HIV-pos on d4T without neuropathy|
33316370|NCT01178684||3: HIV-neg without peripheral neuropathy|
33316371|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
33316372|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
33316373|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
33316374|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
33316375|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
33316376|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
33316377|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
33316378|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
33316379|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
33316380|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
33316381|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
33316382|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
33316383|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
33316384|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
33316385|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
33316386|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
32810084|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
32810085|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
32810086|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
32810087|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
32810088|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
32810089|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
32810090|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
32810091|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
32810092|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
32810093|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
32810094|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
32810095|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
32810096|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
32810097|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
32810098|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
32810099|NCT00690274|Placebo Comparator|Placebo|Volunteers are given Placebo, up to 20mg per day
32810100|NCT00690274|Active Comparator|BF2.649|Volunteers are given BF2.649, up to 20mg per day
32810101|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
32810102|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
32810103|NCT04582201|Experimental|Dosage and Cohorts|"Cohort 1: 100 × 10^6 iNKT cells; Cohort 2: 300 × 10^6 iNKT cells; Cohorts 3 to 4: 1000 × 10^6 iNKT cells~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion."
32810104|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
32810105|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
32810106|NCT01184950|Experimental|Trainer Curriculum|
32810107|NCT01184950|No Intervention|No Curriculum|
32810108|NCT02997748|No Intervention|Observational group|No intervention, standard care
33100288|NCT04692272|Experimental|XBOX group|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
33100289|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
33316387|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
33316388|NCT01180868||healthy subjects|
33100290|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
33100291|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
33100292|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
33100293|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
33100294|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
33100295|NCT00528125|Active Comparator|A|Active laser acupuncture
33100296|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
33316389|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
33316390|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
32810109|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
32810110|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
32810111|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
32810112|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
32810113|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
32810114|NCT00654784|Experimental|1|
32810115|NCT00654784|Placebo Comparator|2|
32810116|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
32810117|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
32810118|NCT01799824|Experimental|Active|ANT-1403
32810119|NCT01799824|Placebo Comparator|Vehicle|Vehicle
32810120|NCT04387396|Experimental|Physiotherapy|Exercise intervention will be applied to this arm.
32810121|NCT04387396|No Intervention|Control|No intervention will be made to this arm, only evaluations will be made.
32810122|NCT01801111|Experimental|Alectinib|Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
32810123|NCT00691600|Active Comparator|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
32810124|NCT00691600|Placebo Comparator|placebo|Placebo after incision and drainage of abscess less than 5 cm.
32810125|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
32810126|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
32810127|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
32810128|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
32810129|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
32810130|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
32810131|NCT01773967|Experimental|LGG|LGG 10^10 cfu PO bid x 5 days
32810132|NCT01773967|Placebo Comparator|Placebo|micro-crystalline cellulose PO bid x 5 days
32810133|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
32810134|NCT01773889|Experimental|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
32810135|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
32810136|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
32810137|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
33100297|NCT02945696|No Intervention|Local port site injection|
33100298|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
33316391|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
32953940|NCT04771026|No Intervention|Control|Receiving routine conduct of general anaesthesia for supraglottic airway device
33316392|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
32953941|NCT04771026|Experimental|Dexamethasone|Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
32953942|NCT00063570|Experimental|A|
32953943|NCT00063570|Experimental|B|
33316393|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
33316394|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
33316395|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
33316396|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
33316397|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
32953944|NCT04770714|Other|Breast MRI|Patients in this arm will be randomized to receive a Breast MRI in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
32953945|NCT04770714|Other|Contrast Enhanced Mammography|Patients in this arm will be randomized to receive a Contrast Enhanced Mammograph in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
32953948|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
32953949|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
32953950|NCT04770792|Experimental|Experimental group|2% chlorhexidine gluconate with mineral trioxide aggregate.
32953951|NCT04770792|Active Comparator|Control group|Mineral trioxide aggregate.
32953952|NCT00064038|Experimental|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32953953|NCT00064038|Active Comparator|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
32953954|NCT04770558|Experimental|Exergame group|The exergame group will receive exergame training for 12 weeks, 2 times a week and 60 min per session.
32953955|NCT04770558|No Intervention|Control group|The control group will not receive any intervention and maintain their lifestyle for 12 weeks.
32953956|NCT04770948|Experimental|19G|19 gauge EBUS-TBNA needle
32953957|NCT04770948|Active Comparator|22G|22 gauge EBUS-TBNA needle
32953958|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
32953959|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
32953960|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
32953961|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
32953962|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
32953963|NCT01897350||CMR following ST segment myocardial infarction|
32953964|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
32953965|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
32953966|NCT04389372|Experimental|Mindfulness by Smartphone|mindfulness therapy by smart phone
32953967|NCT04753632||Cerebral palsy patients and caregivers|Cerebral palsy patients and caregivers
32953968|NCT04753632||Healthy people and their caregivers|Healthy people and their caregivers
32953969|NCT04770168|Experimental|CBT Curriculum - First Cohort|Students will receive the 3-month cognitive behavioral therapy curriculum in the first half of the academic year.
32953970|NCT04770168|Experimental|CBT Curriculum - Second Cohort (Waitlist Controls)|Students will receive the current school board curriculum as usual for the first half of the academic year, serving as wait-list controls. Since this is a stepped wedge trial, the winter cohort will receive the identical intervention as the fall cohort in the second half of academic year.
32953971|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
33316398|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
33316399|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
32810138|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
32810139|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
32810140|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
32810141|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
32810142|NCT02997046||Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
32810143|NCT02997046||Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation~6 week US fistula arm~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
32810144|NCT02997046||Mapping & surveillance (for graft)|"US vascular mapping before graft creation~6 week US graft arm~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
32810145|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
32810146|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
32810147|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
32810148|NCT00695188|Other|Standard dose|Escalating dose
32810149|NCT00695188|Active Comparator|High dose|25 mg
32810150|NCT00658138|Experimental|Adhesive A|
32810151|NCT00658138|Active Comparator|Adhesive B|
32810152|NCT00706264|No Intervention|1|Expectant management
32810153|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
32810154|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
32810155|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
32810156|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
32810157|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
32810158|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
32810159|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
32810160|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
32810161|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
32810162|NCT00695578|Experimental|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
32810163|NCT00695578|Experimental|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
32810164|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
33316400|NCT03859232|Active Comparator|Cotton Padding Group|
33316401|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
33316402|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
33316403|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
32810169|NCT00699010|Active Comparator|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
32810170|NCT00699010|Active Comparator|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
32810171|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
32810172|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
32810173|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
32810174|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
32810175|NCT00661570|Experimental|Early feasability arm|
32953972|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
32953973|NCT05606562|Experimental|Dental treatment|All participants will be offered dental treatment for free.
32953974|NCT00067236|Experimental|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
33100299|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
32810176|NCT00706810|Experimental|All participants|
33100300|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
33100301|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
33100302|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
32953975|NCT00067236|Placebo Comparator|Placebo tablet|Placebo tablet taken twice daily for 90 days
33100303|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
33100304|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
33100305|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
33100306|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
33316404|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
33316405|NCT01289366||Patients with IBD|
32810177|NCT00661960|No Intervention|1|HIV Negative volunteers
32810178|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
33316406|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
32810179|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
32810180|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
32953976|NCT04753398|Experimental|Telemonitoring group|Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology
32953977|NCT04753398|No Intervention|Control group|usual care, without telemonitoring
32953978|NCT04617678|Active Comparator|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
32953979|NCT04617678|No Intervention|Prospective Control|Prospectively enrolling patients to a control arm with no intervention.
32953980|NCT00007644|Other|Radical Prostatectomy|Surgical removal of the prostate
32953981|NCT00007644|No Intervention|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
32953982|NCT00068718|Experimental|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
32953983|NCT00024102|Active Comparator|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU~OR~Cyclophosphamide + doxorubicin"
32953984|NCT00024102|Experimental|Capecitabine|Treatment with capecitabine
32953985|NCT05606250|No Intervention|Physical therapy protocol|The physiotherapy protocol is based on manual therapy (passive joint mobilization), myofascial work, active exercise, high intensity neuromuscular electrical stimulation and cryotherapy.
32953986|NCT05606250|Experimental|Ultrasound-Guided Percutaneous Neuromodulation|"Ultrasound-guided percutaneous neuromodulation (e-NMP) is the electrical stimulation by means of a needle with ultrasound guidance of a peripheral nerve at some point in its course or of a muscle at a motor point, with a therapeutic purpose.~The application of the stimulation is carried out with a puncture needle accompanied by a low or medium frequency electrical current.~In e-MPN, a sensory and/or motor response is sought when the peripheral nerve is stimulated, and a motor response is achieved by stimulating the motor point (uncontrolled exaggerated response that normalizes after the application of the technique)."
32953987|NCT05606016|Experimental|Facilitated Self-Sampling Intervention (FSSI)|Participants in the FSSI arm will receive education on COVID-19 testing and be provided with rapid antigen tests. Participants will also receive pre and post surveys.
32953988|NCT05606016|Experimental|Testing Navigation Intervention (TNI).|Participants in the TNI arm will receive COVID-19 testing education and be navigated to PCR testing sites. Participants will also receive pre and post surveys.
32953989|NCT05606016|Active Comparator|Control|Participants in the Control Group arm will receive a CDC-designed COVID-19 testing brochures, and pre and post surveys only.
32953990|NCT00074802|Experimental|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
33316407|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
33316408|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
33316409|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
33316410|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
33316411|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
32953991|NCT00074802|Experimental|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
32953992|NCT02505750|Active Comparator|EBRT 45 Gy/capecitabine + EBRT boost|"3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W)."
32953993|NCT02505750|Experimental|EBRT 45 Gy/capecitabine + CXB boost|"Arm B divided in 2 subgroups depending on the tumour diameter:~B1: If the tumour is < 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.~B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice."
32953994|NCT05605938|Experimental|Tenoten for children|1 tablet 3 times daily for 12 weeks. Route of administration: sublingual, the tablet should be held in the mouth until completely dissolved.
32953995|NCT05605938|Placebo Comparator|Placebo|As per the Tenoten for children dosing regimen.
32953996|NCT05605782||Participants initiating treatment with ozanimod|
32953997|NCT05605782||Participants initiating an sphingosine-1 phosphate (S1P) modulator|
32953998|NCT05605782||Participants initiating other non-S1P-receptor modulators disease modifying treatments (DMTs)|
32953999|NCT00156390|Experimental|1|echo-guided LV lead placement
32954000|NCT00156390|Other|2|LV lead placement as per standard of care (without echo-guidance)
32954001|NCT00029172|Experimental|Nurse Case management|
32954002|NCT04592562|Experimental|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
32954003|NCT00030264|Experimental|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
32954004|NCT00036738|Experimental|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
32954005|NCT00038610|Experimental|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, & 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 & 11; & Dexamethasone 40 mg IV or orally daily days 1-4 & 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
32954006|NCT00156936|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
32954007|NCT00156936|Experimental|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
32954008|NCT00076050|Experimental|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
32954009|NCT00076050|Placebo Comparator|2|Participants will receive placebo daily over 2 years.
32954010|NCT00046566|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
32954011|NCT00046566|Experimental|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
32954012|NCT00046566|Placebo Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
32954013|NCT00077922|Experimental|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
32954014|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
32954015|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
33100307|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
33100308|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
33100309|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
33100310|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
32810181|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
32810182|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
33316412|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
32810183|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
32810184|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501: Phase 2|pemetrexed, cisplatin and CBP501
32810185|NCT00700336|Active Comparator|Pemetrexed and Cisplatin: Phase 2|pemetrexed and cisplatin
32810186|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501:Phase 1|MTD, which was equal to recommended dose for the Phase II part, was determined by 6 patients (3+3)
32810187|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
32810188|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
33100311|NCT02926599|No Intervention|Control|"No particular training.~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
32810189|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
32810190|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
32810191|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
33100312|NCT02924532||Patients with total thiroidectomy|
33100313|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
32810192|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
32810193|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
33316413|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
33316414|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
33316415|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
32810194|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
32810195|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
32810196|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
33316416|NCT03862508|Experimental|Experimental|Five Plyometric exercises
33316417|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
33316418|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
33316419|NCT03859310||Glaucoma|diagnosis of glaucoma
32810197|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
32810198|NCT01839487|Experimental|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
32810199|NCT01839487|Active Comparator|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
32810200|NCT01839487|Experimental|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
32810201|NCT01839487|Active Comparator|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
32810202|NCT01839487|Experimental|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
32810203|NCT01839487|Active Comparator|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
32810204|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
32810205|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
32810206|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
32810207|NCT00666406|Experimental|1|Advate rAHF-PFM
32810208|NCT00666406|Active Comparator|2|Recombinate rAHF
32810209|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
32810210|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
32810211|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
33316420|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
33316421|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
33316422|NCT01287026|Experimental|1|Open Label
33316423|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
33316424|NCT01176188|Active Comparator|Usual Care|
33316425|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
32810212|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
32810213|NCT02996188||Patients with refractory tense ascites|
32810214|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
32810215|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
33316426|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.~AND consenting to be part of the study"
33316427|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
32810216|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
32810217|NCT01799941|Other|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
32810218|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
32810219|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
32810220|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
32810221|NCT00667186|Active Comparator|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
32810222|NCT01799239|Experimental|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.~After cross-over the subject test SenSura which is CE-marked and commerical available."
32810223|NCT01799239|Active Comparator|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
32810224|NCT02995798||Group A|T-score ≥-1
32810225|NCT02995798||Group B|-2.5<T-score<-1.0
32810226|NCT02995798||Group C|T-score≤-2.5
32810227|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
32810228|NCT02649868|Experimental|2|Treatment of hepatic tumors using bead embolization
32810229|NCT00713284|Other|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
32810230|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
32810231|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
32810232|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
32810233|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
32810234|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
32810235|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
32810236|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
32810237|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
32810238|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
32810239|NCT02995486|Experimental|Intervention|Post-discharge exercise group
32810240|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
32810241|NCT04387006|Experimental|Osteopatic Manipulative Treatment (OMT)|
32810242|NCT04387006|Placebo Comparator|Manual Placebo (MP)|
33316428|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
32810243|NCT04386772|Experimental|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
32810244|NCT04386772|Active Comparator|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
32810245|NCT02995330|Experimental|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.~Subjects will receive GVHD prophylaxis consisting of:~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning [dose adjusted to maintain trough level of 5-15 ng/mL] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
32810246|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
32810247|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
32810248|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
32810249|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
32810250|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
32810251|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
32810252|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
32810253|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
32810254|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32810255|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
32810256|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare System
32810257|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
32810258|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
32810259|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
32810260|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
32810261|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
32810262|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
32810263|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
32810264|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
32810265|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
32810266|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
32810267|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
32810268|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
32810269|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
32810270|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
32810271|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
32810272|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
32810273|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
32810274|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
32810275|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
32810276|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
32810277|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
32810278|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
32810279|NCT04270162|Experimental|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
32810280|NCT04270162|Active Comparator|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
32810281|NCT04270162|Active Comparator|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
32810282|NCT04387630|Experimental|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
32810283|NCT04387630|Placebo Comparator|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
32810284|NCT04270318|Active Comparator|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
32810285|NCT04270318|Experimental|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
32810286|NCT04270318|Active Comparator|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
32810287|NCT04270318|Experimental|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
32810288|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
32810289|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
32810290|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
32810291|NCT04386382|Experimental|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:~Optical scanning of the dental casts was done using Ceramill map 400~The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
32810292|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
32810293|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
32810294|NCT02999542|Experimental|Music|Children will receive music via headphones
32810295|NCT02999542|Experimental|No music|Children will listen to silence via headphones
32954016|NCT00161382|Experimental|Intervention Group|HIV, STD, and pregnancy prevention curriculum
32954017|NCT00161382|Experimental|Control Group|Standard sexual education curriculum
32954018|NCT00079326|Experimental|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33404956|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
32810296|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
32810297|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
32810298|NCT04270708|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
32810299|NCT04270708|Active Comparator|Triclofos|Oral Triclofos Sodium 50mg/kg
32810300|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
32810301|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
32810302|NCT02999308|Experimental|single arm|
32810303|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
32810304|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
32810305|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
32810306|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
32810307|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
32810308|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
32810309|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
32810310|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
32810311|NCT02995408|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
32810312|NCT02995408|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
32810313|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
32810314|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
32810315|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'~standard code for item: 200005689~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
32810316|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
32810317|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
32810318|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
32810319|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
32810320|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
33404957|NCT05080816|Active Comparator|Parenteral nutrition|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
33404958|NCT05080816|Active Comparator|Enteral nutrition|Oral nutrition drink. 2 * 200 ml on the night before operation. 1* 200 ml on the morning of operation day.
32810321|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
32810322|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
32810323|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
32810324|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
32810325|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
32810326|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
32810327|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
32810328|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
32810329|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
32810330|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
32810331|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
32810332|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
32810333|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
32810334|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
32810335|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
32810336|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
32810337|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
32954019|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
32954020|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
32954021|NCT04531176|Experimental|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
32954022|NCT04531176|Experimental|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
32954023|NCT04531176|Active Comparator|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
32954024|NCT00051168|Experimental|Travatan|Travoprost (0.004%)
32954025|NCT00083382|Experimental|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
32954026|NCT04526730|Experimental|Neoadjuvant Treatment|"Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion).~Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist.~Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase."
32954027|NCT04506840|Experimental|Training group|Participants will participate in a program of physical exercise during the adjuvant chemotherapy treatment
32954028|NCT04506840|No Intervention|Not training group|Participants will not do any intervention, they only will be perform the pre and post-tests.
32954029|NCT00167388|No Intervention|group 1|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
32954030|NCT00167388|Active Comparator|group 2|Babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
32954031|NCT00167388|No Intervention|group 3|All babies >1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
32954032|NCT00167388|Experimental|group 4|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
32954033|NCT00167544|Experimental|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
32954034|NCT00167544|Placebo Comparator|2|2. Identical-appearing saline placebo
32954035|NCT00167934|Placebo Comparator|Placebo|50% of participants will receive placebo
32954036|NCT00167934|Experimental|Experimental|50% of participants will receive Depakote ER
32954037|NCT00168324|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
32954038|NCT00168324|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
32954039|NCT00168324|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
32954040|NCT00084552|Active Comparator|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
32954041|NCT00084552|Experimental|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
32954042|NCT02091882|Experimental|Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System|"Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours.~Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System."
32954043|NCT00085254|Experimental|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Doses of cilengitide: 500mg, 1000mg and 2000mg~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
32954044|NCT00085254|Experimental|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
32954045|NCT00085254|Experimental|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
32954046|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
32954047|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
32954048|NCT00253890|Active Comparator|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
32954049|NCT00253890|Placebo Comparator|Placebo|1-3 capsules at bedtime for 90 days
32954050|NCT00254592|Experimental|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
32954051|NCT00255684|Experimental|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
32954052|NCT00256776|Experimental|Thal + Dex + Velcade|
32954053|NCT00256776|Active Comparator|Thal + Dex|Standard treatment
32954054|NCT00257322|Experimental|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m^2 SQ QD with a cap of 500mcg SQ QD
32954055|NCT00258180|Experimental|severe autoimmune enteropathy|Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
32954056|NCT01899222||fundus imaging|retinal photograph obtained at visit
33404959|NCT05080816|Placebo Comparator|control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
32810338|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32810339|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32810340|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
32810341|NCT01270594|Other|Usual Care|
32810342|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
32810343|NCT01276132||Subjects who are designated to receive same-day PCI|
32810344|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
32810345|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
32810346|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
32810347|NCT01276210|Experimental|Treatment|See Detailed Description
32810348|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
32810349|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
32810350|NCT00709696|Placebo Comparator|1|Placebo Varenicline
32810351|NCT00709696|Active Comparator|2|Varenicline
32810352|NCT01270906|Experimental|CHIR-258 (TKI258)|
32810353|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
32810354|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
32810355|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
32810356|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
32810357|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
32810358|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
32810359|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
33100314|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
33404960|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
32810360|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
32810361|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
32810362|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
32810363|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
32810364|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
32810365|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
32810366|NCT02992912|Experimental|Cohort 1: metastatic colorectal cancer|
32810367|NCT02992912|Experimental|Cohort 2: metastatic non-small lung cancer|
32810368|NCT02992912|Experimental|Cohort 3: metastatic renal cell carcinoma|
32810369|NCT02992912|Experimental|Cohort 4: metastatic sarcoma|
32810370|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
32810371|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.~There is one visit:~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
32810372|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
32810373|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
32810374|NCT01271140|Experimental|Insulin/dextrose clamp|
33100315|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
33100316|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
33100317|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
33100318|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
33100319|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
33100320|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
33100321|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
33100322|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
33100323|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
33100324|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
33316429|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
33316430|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
33100325|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
33100326|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
33100327|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
33100328|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
33100329|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
32810375|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
32810376|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
32810377|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
32810378|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
32810379|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
32810380|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
32810381|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
32810382|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
32810383|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
33100330|NCT00527267|Experimental|AMG 073|AMG 073
33100331|NCT00527267|Placebo Comparator|Placebo|Placebo
32810384|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
32810385|NCT01271530|Experimental|Exercise|
32810386|NCT01271530|No Intervention|Control|
32810387|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
32810388|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
32810389|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
32810390|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
32810391|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
32810392|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
32810393|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
32810394|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
32810395|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
32810396|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
32810397|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
32810398|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
32810399|NCT01277068|Active Comparator|the adjustable gastric banding|
32810400|NCT01277068|Active Comparator|the sleeve gastrectomy|
32810401|NCT01277068|Active Comparator|the gastric bypass|
32810402|NCT01271764|No Intervention|endometrial cancer|
32810403|NCT01277146|Experimental|OMP-59R5|
32810404|NCT00711022|Experimental|OsseoSpeed|
32810405|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
32810406|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
32810407|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
32810408|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
32810409|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
32810410|NCT04270006|Experimental|Exosomes|
32810411|NCT01271998|Experimental|healthy volunteer|healthy volunteers
32810412|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%~artificial tears"
32810413|NCT00798226|Active Comparator|1|n-3 fatty acid
32810414|NCT00798226|Placebo Comparator|2|Olive oil
32810415|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
32810416|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
32810417|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
32810418|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
32810419|NCT01277380||Experimental Group|
32954057|NCT00176202|Active Comparator|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
32810420|NCT01277380||Control Group|
32810421|NCT01277380||Negative control group|
32810422|NCT01277458||Non white HIV positive men who have sex with men|
32810423|NCT01277536||hospitalization >24 hours|
32810424|NCT04275310|Experimental|Microeconomic intervention|
32810425|NCT04275310|No Intervention|Waitlisted control|
32810426|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
32810427|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
32810428|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
32810429|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
32810430|NCT01277614|Placebo Comparator|Health Literature|
32810431|NCT04385602|Placebo Comparator|CON group|placebo
32810432|NCT04385602|Active Comparator|DT group|Intratracheal dexmedetomidine
32810433|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
32810434|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
32810435|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
32810436|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
32810437|NCT00719134|Placebo Comparator|2|
32810438|NCT00719134|Experimental|3|
32810439|NCT00719134|Placebo Comparator|4|
32810440|NCT00719134|Experimental|5|
32810441|NCT00719134|Experimental|6|
32810442|NCT04146363|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50."
32954058|NCT00176202|Active Comparator|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
32954059|NCT00176592|Active Comparator|Betaseron|Betaseron 250 micrograms SQ every other day and Triple-Dose Gadolinium at each MRI
32954060|NCT00176592|Active Comparator|Copaxone|Copaxone 20 mg daily SQ and Triple-Dose Gadolinium at each MRI
32954061|NCT00176826|Experimental|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
32954062|NCT00176904|Experimental|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
32954063|NCT00179478|Experimental|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
32954064|NCT00179478|Active Comparator|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
32954065|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
32954066|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
32954067|NCT00182754|Experimental|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
32954068|NCT00182754|Placebo Comparator|Arm II|Patients receive placebo SC once on day 1.
32954069|NCT00183456|Experimental|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
33316431|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
32954070|NCT00183456|Active Comparator|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
33316432|NCT02525042||Comparator 1|family controls
33316433|NCT02525042||Comparator 2|population controls
33316434|NCT01179542||first trimester|first trimester
33316435|NCT01179542||third trimester|third trimester
33316436|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
32954071|NCT00183456|No Intervention|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
32954072|NCT00183456|No Intervention|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
33316437|NCT01179542||preeclampsia|preeclampsia
33316438|NCT01179620|Experimental|Certoparin|
32954073|NCT00184548|Experimental|rFVIIa, Blunt Trauma|
32954074|NCT00184548|Placebo Comparator|Placebo, Blunt Trauma|
32954075|NCT00184548|Experimental|rVIIa, Penetrating Trauma|
32954076|NCT00184548|Placebo Comparator|Placebo, Penetrating Trauma|
32954077|NCT00085410|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
32954078|NCT00186498|Placebo Comparator|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
32954079|NCT00186498|Experimental|memantine|Patients receive memantine starting the day before ECT begins and while receiving ECT
32954080|NCT00265200|Experimental|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
32954081|NCT00087672|Experimental|CC-5013|
32954082|NCT00265512|Active Comparator|Telephone Case Monitoring Aftercare|Telephone Case Monitoring Aftercare
32954083|NCT00265512|Active Comparator|Continuing Care as Usual|Continuing Care as Usual
32954084|NCT00265980|No Intervention|Weight initial|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.
32954085|NCT00265980|Placebo Comparator|Weight -10% placebo|Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.
33316439|NCT01179698|Other|Stryker navigation system|
33316440|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
33316441|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
33316442|NCT01181024|Experimental|A: HV ascending dose|
33316443|NCT01181024|Experimental|B: HV food effect|
33316444|NCT01181024|Experimental|C: Hepatitis C|
33316445|NCT01181180|Experimental|balance treatment|
32954086|NCT00265980|Experimental|Weight -10% leptin|Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.
32954087|NCT00187200|Active Comparator|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
32954088|NCT00187200|Active Comparator|Sequential VV Pacing|Programmed to sequential biventricular pacing
32954089|NCT00088218|Active Comparator|Clofarabine|Clofarabine intravenous (IV) 30 mg/m^2 daily times 5 days
33316446|NCT00057330|Experimental|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
33316447|NCT00057330|Experimental|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
32954090|NCT00088218|Active Comparator|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m^2 daily times 5 days + Ara-C 20 mg/m^2 subcutaneously daily times 14 days.
32954091|NCT00189228|Experimental|xolair|This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.
32954092|NCT00091260|Experimental|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
32954093|NCT00193128|Experimental|Cohort 1|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
32954094|NCT00193128|Experimental|Cohort 2|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
32954095|NCT00193596|Experimental|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1~Carboplatin area under the curve (AUC) 6.0 IV, day 1~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10~Regimen A was repeated at a 21-day interval"
32954096|NCT00193596|Experimental|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8~Gemcitabine 1000 mg/m2 IV, days 1 and 8~Regimen B was repeated at a 21-day interval"
32954097|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
32954098|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
32954099|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
32954100|NCT01899378|No Intervention|control|
32954101|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
32954102|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
32954103|NCT00091962|Experimental|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
32954104|NCT00091962|Active Comparator|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
32954105|NCT00091962|No Intervention|Non-Depressed Control Group|Non-depressed control group
32954106|NCT00194532|Experimental|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
32954107|NCT00194532|Active Comparator|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
32954108|NCT00194610|Experimental|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
32954109|NCT00194610|Placebo Comparator|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
32954110|NCT00093756|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
32954111|NCT04176666|Experimental|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
32954112|NCT04176666|No Intervention|Control group|The control group will receive the intervention after study completion.
32954113|NCT04389138|No Intervention|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
32954114|NCT04389138|Experimental|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
32954115|NCT04145154|Experimental|Plasma|Subjects to whom platelet rich plasma is applied
33316448|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
33316449|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
32954116|NCT04145154|No Intervention|Advanced cure|Subjects to whom advanced healing is performed
32954117|NCT04118556|Experimental|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
32954118|NCT04118556|Active Comparator|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
33316450|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
32954119|NCT00267696|Experimental|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
32954120|NCT00267774|Experimental|FFR guided PCI|
32954121|NCT00267774|Active Comparator|Angio-guided PCI|
32954122|NCT00195624|Experimental|Relapsed severe aplastic anemia|Subjects diagnosed with relapsed severe aplastic anemia
32954123|NCT00195624|Experimental|Refractory severe asplastic anemia|Subjects diagnosed with refractory severe aplastic anemia
32954124|NCT00195624|Experimental|Relapse after Alemtuzumab|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.
32954125|NCT00195702|Experimental|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
32954126|NCT00195702|Experimental|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
32954127|NCT00195702|Placebo Comparator|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
32954128|NCT00195702|Experimental|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
32954129|NCT00195702|Experimental|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
32954130|NCT00195702|Experimental|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
32954131|NCT00196716|Experimental|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
32954132|NCT00197184|Experimental|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
32954133|NCT00197184|Active Comparator|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
32954134|NCT00198042|Experimental|Surgical Reconstruction of the ACL|
32954135|NCT00201240|Experimental|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
32954136|NCT00098670|Experimental|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
32954137|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|Participants had an Abdominal Sacral Colpopexy without Burch colposuspension for treatment of pelvic organ prolapse
32954138|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|Participants had an Abdominal Sacral Colpopexy with Burch colposuspension for treatment of pelvic organ prolapse
33100332|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
33316451|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
33316452|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
33316453|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
33316454|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
33316455|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
32810443|NCT04146363|Experimental|Lebrikizumab 250 Q2W|"Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection Q2W until Week 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18."
32954139|NCT04098588|Experimental|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
32954140|NCT04098588|Active Comparator|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
32954141|NCT00100230|Experimental|1.|Oral Docosahexaenoic acid, dosage based on body weight
32954142|NCT00100230|Placebo Comparator|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
32954143|NCT00201864|Experimental|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
32954144|NCT00202722|Active Comparator|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
32954145|NCT00100698|Active Comparator|1|recombinant human growth hormone subcutaneously once a day
32954146|NCT00100698|Placebo Comparator|2|placebo subcutaneously once a day
32954147|NCT00103116|Experimental|Autologous dendritic cell cancer vaccine|Open label nonrandomized
32954148|NCT00205374|Active Comparator|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
32954149|NCT00205374|Placebo Comparator|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
32954150|NCT04751448||Observational|All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.
32954151|NCT04751526|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
32954152|NCT04751526|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
32954153|NCT00103194|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32954154|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
32954155|NCT00278538|Experimental|Hematopoietic Stem Cell Transplant Regimen 2|Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen
32954156|NCT00208026|Experimental|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
32954157|NCT00208494|Active Comparator|A|Ceramic-on-metal total hip implant
32954158|NCT00208494|Active Comparator|B|Metal-on-metal total hip implant
32954159|NCT00106392|Experimental|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
32954160|NCT00106392|Placebo Comparator|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
32954161|NCT00211692|Active Comparator|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
32954162|NCT00211692|Experimental|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
32810444|NCT04146363|Experimental|Lebrikizumab 250 Q4W|"Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two placebo injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~Two placebo injections on Week 18"
32810445|NCT04146363|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.~For participants who received placebo in the Induction Period, the loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.~For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm."
32810446|NCT01272154|Experimental|Primary cervical dystonia Patients|
32810447|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
32810448|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
32810449|NCT01272154|Other|Healthy volunteers|
32810450|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
32810451|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
32810452|NCT01773421|Experimental|Part A|
32810453|NCT01773421|Experimental|Part B|
32810454|NCT00721162|Experimental|Ramucirumab|
32810455|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
32810456|NCT01773109|Experimental|Eligible patients will receive etirinotecan pegol at a dose of|single-arm, open-label study is designed to investigate the efficacy and safety of etirinotecan pegol in patients with metastatic or recurrent NSCLC after failure of 2nd line therapy. Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Patients will be followed clinically every week for the first cycle with laboratory parameters (section 6.2.1) and physical exam. Response will be determined with RECIST version 1.1 after 2 cycles of therapy. Patients with Stable disease (SD), partial response (PR) or complete response (CR) will continue on additional therapy for up to six cycles. In the absence of disease progression in subjects completing six full cycles, further treatment beyond cycle #6 will be left to the discretion of the treating physician and his/her staff. Patients with progressive disease will be taken off study and will be followed for OS
32810457|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
32810458|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
32810459|NCT01772719|Experimental|Study Arm|Study Arm
32810460|NCT05582265|Experimental|Neoadjuvant Tislelizumab + Reduction of Cycles of Chemotherapy (Arm A)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
32810461|NCT05582265|Experimental|Neoadjuvant Tislelizumab + Chemotherapy (Arm B)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
32810462|NCT05582265|Other|Up-front Surgery (Arm C)|Following surgical resection, high risk participants receive chemoradiotherapy as adjuvant therapy. Low risk participants receive radiotherapy as adjuvant therapy.
32810463|NCT01798927|Other|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
32810464|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
32810465|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
32810466|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
32810467|NCT04144101|Experimental|Etoricoxib|Etoricoxib 60 mg QD
32810468|NCT04144101|Experimental|Aceclofenac|Aceclofenac 100 mg BID
32810469|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
32810470|NCT01278004|Experimental|Drug|
32810471|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
32810472|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
32810473|NCT01278238|Active Comparator|Phenylephrine|
32810474|NCT01278238|Active Comparator|Lower limb compression|
32810475|NCT01278238|Placebo Comparator|Placebo|
32810476|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
32810477|NCT04279834|Active Comparator|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
32810478|NCT04279834|Active Comparator|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
32810479|NCT05580705|Active Comparator|ROUTINE PHYSICAL THERAPY GROUP|This group will receive routine physical therapy including strength training intervention. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
32810480|NCT05580705|Experimental|VIBRATION THERAPY|This group will receive routine physical therapy and vibration therapy. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
32810481|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
32810482|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
32810483|NCT04143867|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
32810484|NCT01272310|Experimental|Combination therapy|
32810485|NCT05586477|Other|Intervention Order (Placebo - Diphenhydramine)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~25°C and 50% relative humidity
32810486|NCT05586477|Other|Intervention Order (Diphenhydramine -Placebo)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~25°C and 50% relative humidity
32810487|NCT01272466|Experimental|peptides from antiapoptotic proteins|
32810488|NCT04143789|Experimental|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
32810489|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
32810490|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
32810491|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
32810492|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
32810493|NCT02991742||Iodixanol|Iodixanol contrast media
32810494|NCT02991742||Ioxaglate|Ioxaglate contrast media
32810495|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
32810496|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
32810497|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
32810498|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
32810499|NCT04386850|Experimental|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
32810500|NCT04386850|Experimental|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
32810501|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
32810502|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
32810503|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
32810504|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
32810505|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
32810506|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
32810507|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
32810508|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
32810509|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
32810510|NCT01272856|Experimental|Open Label Abatacept|
32810511|NCT01273090|Experimental|Treatment|
32810512|NCT04386694|Experimental|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
32954163|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
32954164|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
33316456|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
33316457|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
32954165|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
33316458|NCT01583946||Male low past-oriented SWB|
33316459|NCT01583946||Male high past-oriented SWB|
33316460|NCT01583946||Female low past-oriented SWB|
33316461|NCT01583946||Female high past-oriented SWB|
32954166|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
32954167|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
32954168|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
33316462|NCT01583946||Black Female high past-oriented SWB|
32954169|NCT00214890|Active Comparator|Tenofovir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
32954170|NCT00214890|Active Comparator|Abacavir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
33316463|NCT01583946||Black Female low past-oriented SWB|
33316464|NCT01583946||Black male low past-oriented SWB|
33316465|NCT01583946||Black male high past-oriented SWB|
33316466|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
33316467|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
32954171|NCT00216060|Experimental|Experimental Arm|Daily oral risedronate combined with androgen deprivation
32954172|NCT00216060|Placebo Comparator|Placebo Arm|daily oral placebo combined with androgen deprivation
32954173|NCT00106938|Active Comparator|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
32954174|NCT00106938|Active Comparator|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
32954175|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
32954176|NCT00110136|Experimental|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
32954177|NCT00282672|Sham Comparator|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
32954178|NCT00282672|Active Comparator|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
32954179|NCT00282672|Sham Comparator|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
32954180|NCT00282672|Active Comparator|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
32954181|NCT00282828|Experimental|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
32954182|NCT00282828|Experimental|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
32954183|NCT00282828|Experimental|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
32954184|NCT00112242|Experimental|1. Melan-A ELA|500 mcg Melan-A ELA analog peptide + 1 ml Montanide ISA-51
33316468|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
33316469|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
33316470|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
33316471|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
33316472|NCT01313806|Placebo Comparator|Placebo|
33316473|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
33316474|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
33316475|NCT03748706|Experimental|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
33316476|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
33316477|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
32810513|NCT04386694|Placebo Comparator|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator."
32810514|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
32810515|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
32810516|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
32810517|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
32810518|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
32810519|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
32810520|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
32810521|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
32810522|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
32810523|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
32810524|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
32810525|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
32810526|NCT04345276|Experimental|Danoprevir+Ritonavir group|
32810527|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
32810528|NCT01278628|Experimental|Lifestyle modification|
32810529|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
32810530|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
32810531|NCT01273324||ADM|ADM Cup
32810532|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
32810533|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
32810534|NCT02991274||T790M mutation test|genomic testing of T790M mutation
32810535|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
32810536|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
32810537|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
32810538|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
32810539|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
32810540|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
32810541|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
32810542|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
32810543|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
32810544|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
32810545|NCT01278706|No Intervention|no treatment|
32810546|NCT01278706|Experimental|one biopsy, proliferative phase|
32810547|NCT01278706|Experimental|one biopsy, secretory phase|
32810548|NCT01278706|Experimental|two biopsies|
32810549|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
32810550|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
32810551|NCT01278784|Experimental|Healthy volunteer|
32810552|NCT04386226|Experimental|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
32810553|NCT04386226|Experimental|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
32810554|NCT04386226|Active Comparator|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
32810555|NCT04386226|Active Comparator|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
32810556|NCT04386226|Placebo Comparator|Placebo|4 grams Maltodextrin daily for 8 weeks
32810557|NCT04386070|No Intervention|Control (normal practice)|Treatment without the trial intervention. Patients will be treated as per hospital routine practice. The control arm may change over the course of the trial and will be monitored by the TMG and DMC
32810558|NCT04386070|Experimental|RESP301|RESP301 is administered quickly (8-10 minutes) via an easy-to-use, vibrating mesh nebuliser. The recommended nebulisers used to administer this intervention are available in all participating countries. The intervention will be administered using a nebuliser according to standard local practice; where permitted for patients to self-administer, a member of the clinical team will ensure that the patient has viewed the intervention administration training video, and will also oversee the patient for the first trial dose to ensure proper administration.
32810559|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
32810560|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
32810561|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
32810562|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
32810563|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
32810564|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
32810565|NCT01273792||Patients with Susac syndrome|
32810566|NCT01273792||Matched healthy controls|
32810567|NCT02702271|Experimental|WATCHMAN FLX - M|WATCHMAN FLX Main Cohort
32810568|NCT02702271|Experimental|WATCHMAN FLX - R|WATCHMAN FLX Roll-In Cohort
32810569|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
32810570|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
32810571|NCT05582889|Experimental|Experimental: Immediate Fitbit Intervention|Participants randomized to this arm receive the 12-week Fitbit intervention; participants then crossover and are observed (no health coaching) for an additional 12-weeks. The Fitbit intervention includes a Fitbit activity tracker, the free Fitbit smartphone app, and 6 Health Coaching calls.
32810572|NCT05582889|Active Comparator|Comparator: Delayed Fitbit Intervention|Wait-listed; participants maintain their usual physical activity for 12-weeks; participants then crossover and receive the full 12-week Fitbit intervention.
32810573|NCT04143633|Experimental|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
32810574|NCT04143633|Experimental|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
32810575|NCT04143633|Active Comparator|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
32810576|NCT05581563|Active Comparator|tourniquet use|knee replacement surgery with the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
32810577|NCT05581563|Sham Comparator|without tourniquet use|knee replacement surgery without the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
32810578|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
32810579|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
32810580|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
32810581|NCT04143555||endoscopic submucosal injection of indocyanine green|
32810582|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention~Four sessions in total:~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
32810583|NCT03021603|Experimental|Control Group|"Standard care:~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
32810584|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
33100333|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
32810585|NCT05581329|Experimental|Group A: acupoints on the left hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
32810586|NCT05581329|Experimental|Group B: acupoints on the right hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
32810587|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
32810588|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
32810589|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
32810590|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
32810591|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
32810592|NCT04148937|Experimental|Cohort A LY3475070|LY3475070 administered orally.
33100334|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
32810593|NCT04148937|Experimental|Cohort B LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered intravenously (IV).
32810594|NCT04148937|Experimental|Cohort C1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
32810595|NCT04148937|Experimental|Cohort C2 LY3475070|LY3475070 administered orally.
32810596|NCT04148937|Experimental|Cohort D1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
32810597|NCT04148937|Experimental|Cohort D2 LY3475070|LY3475070 administered orally.
32810598|NCT04148937|Experimental|Cohort E LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
32810599|NCT05581095|Active Comparator|Mindful Eating Self-Help Book Only|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May & Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
32810600|NCT05581095|Experimental|Mindful Eating Self-Help Book + Smartphone App|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May & Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. In addition, participants will be asked to use the companion Am I Hungry? Mindful Eating Virtual Coach smartphone application three times daily. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
32810601|NCT03021057|Experimental|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
32810602|NCT00734500|Experimental|Treatment|Treatment
32810603|NCT03919929|Active Comparator|Diet Intervention|Weight loss with dietary intervention
32810604|NCT03919929|Experimental|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
32810605|NCT04148391|Placebo Comparator|Placebo|Matching placebo Capsules
32810606|NCT04148391|Experimental|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
32810607|NCT00734734|Experimental|1|
32810608|NCT04143321|Experimental|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
32810609|NCT04143321|Placebo Comparator|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
32810610|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
32810611|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
32810612|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
32810613|NCT03918837|Sham Comparator|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
32810614|NCT03918837|Active Comparator|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
32810615|NCT04143399|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
32810616|NCT04143399|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
32810617|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
32810618|NCT04143165|Active Comparator|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
32810619|NCT04143165|No Intervention|control group|patients did not receive injection
32810620|NCT04143087||Withdrawal TKIs|
32810621|NCT04143087||halve TKIs|
32810622|NCT00533182||Immunocompromised|Immunocompromised individuals
32810623|NCT00533182||Non-Immunocompromised|Non-immunocompromised individuals
32810624|NCT00533182||Pregnant|Pregnant women
32810625|NCT03917043|Experimental|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level.
32810626|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
33100335|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
33100336|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
33100337|NCT02924415|Active Comparator|Control group|Standard care
33316478|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32810627|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
32810628|NCT04765605|Experimental|WeFlow-Tbranch Stent Graft System|Participants will be treated with WeFlow-Tbranch Stent Graft System
32810629|NCT00735826|Experimental|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
32810630|NCT03916341|Experimental|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
32810631|NCT03916341|Experimental|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
32810632|NCT03916341|Experimental|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
32810633|NCT04765995|Experimental|HZBio1 0.96mg/kg|Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.
32810634|NCT04765995|Experimental|HZBio1 3mg/kg|Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.
32810635|NCT04765995|Experimental|HZBio1 6mg/kg|Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.
32810636|NCT04765995|Experimental|HZBio1 9mg/kg|Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.
32810637|NCT04765995|Experimental|HZBio1 12mg/kg|Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.
32810638|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
32810639|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
32810640|NCT05580627|Experimental|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
32810641|NCT05580627|Experimental|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
32810642|NCT01798849|Experimental|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, 14 mg or 2.0 mg fed, and 2 participants received placebo. Dosing periods will alternate with Panel B.
32810643|NCT01798849|Experimental|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods will alternate with Panel A.
32810644|NCT01798849|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
32810645|NCT05580471|Experimental|Use 4DryField|One group use 4DryField before wound closure.
32810646|NCT05580471|No Intervention|Not Use 4DryField|One group do not use 4DryField before wound closure.
32810647|NCT04405947|Other|deltopectoral|deltopectoral surgical approach
32810648|NCT04405947|Other|antero-superior|antero-superior approach
32810649|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
32810650|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
32810651|NCT04143243|Active Comparator|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
32954185|NCT00112242|Experimental|2. Melan-A ELA + NY-ESO-1b + MAGE-A10|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51
32954186|NCT00112242|Experimental|3. Melan-A ELA + NY-ESO-1b + MAGE-A10 + CpG|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 + 2.5 mg CpG-7909/PF-3512676
32954187|NCT00112242|Experimental|4. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676"
33100338|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
33100339|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
33316479|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
33316480|NCT01289054||Cohort 2 - Interrupted TKI|
33316481|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
33316482|NCT01179776|Placebo Comparator|Placebo|
33316483|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
32954188|NCT00112242|Experimental|5. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG+ IL-2|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2"
32954189|NCT00284154|Experimental|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
32954190|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
32954191|NCT04083144|Active Comparator|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
32954192|NCT04083144|Sham Comparator|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
32954193|NCT01899924|Experimental|Event Related Potentials|
32954194|NCT00223236|Active Comparator|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
32954195|NCT00223236|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
32954196|NCT00223704|Experimental|HOE 140|Bradykinin receptor antagonist
32954197|NCT00223704|Active Comparator|Aminocaproic Acid|Antifibrinolytic
32954198|NCT00223704|Placebo Comparator|Placebo|Placebo
32954199|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
32954200|NCT00225420|Other|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
32954201|NCT00225498|Experimental|1|ziprasidone
32954202|NCT00225498|Active Comparator|2|risperidone or olanzapine
32954203|NCT00225732|Active Comparator|intravenous ibuprofen|
32954204|NCT00225732|Placebo Comparator|normal saline|
32954205|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
32954206|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
32954207|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
32954208|NCT00113022|Experimental|Org 24448|Blinded, active experimental compound
32954209|NCT00113022|Placebo Comparator|Placebo|Blinded placebo
32954210|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
32954211|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
32954212|NCT04752306||residents|"10 residents~Minimum 1x > 1week had experience with incontinence material~MMSE score >23~good verbal communication"
33316484|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
33316485|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
33316486|NCT01179854|Placebo Comparator|Placebo|Placebo
33316487|NCT00062010|Experimental|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
33316488|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
33316489|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
32954213|NCT04752306||healthcare workers|8 healthcare workers working in setting, no exclusion criteria
32954214|NCT04752306||policymakers|2 policymakers responsible for the purchase of incontinence material
32954215|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
33316490|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
32954216|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
32954217|NCT00113334|Experimental|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
32954218|NCT00286182|Experimental|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
32954219|NCT00286182|Placebo Comparator|Placebo|Placebo consists of saline injections.
32954220|NCT00286728|Experimental|Arm 1|Intensive referral to dual-focused self-help groups
32954221|NCT00286728|No Intervention|Arm 2|Usual care
32954222|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
32954223|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
32954224|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
33316491|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
33316492|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
32954225|NCT00226590|Experimental|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
33316493|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
32954226|NCT00114114|Experimental|Group 1: 0 g/day|Zoladex plus Placebo Testosterone (T) gel
33316494|NCT01093170|Experimental|RNA-144101|
33316495|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
33316496|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
33316497|NCT01094340|Other|Thalidoide|CSF
33316498|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
33316499|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
33316500|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
32954227|NCT00114114|Experimental|Group 2: 1.25 g/day|Zoladex plus 1.25 g/day T gel
32954228|NCT00114114|Experimental|Group 3: 2.5 g/day|Zoladex plus 2.5 g/day T gel
32954229|NCT00114114|Experimental|Group 4: 5 g/day|Zoladex plus 5 g/day T gel
32954230|NCT00114114|Experimental|Group 5: 10* g/day|Zoladex plus 10* g/day T gel. *Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial
32954231|NCT00114114|Experimental|Group 6: Placebo/Placebo (PBO/PBO)|Placebo Zoladex plus Placebo T gel (controls)
32954232|NCT00227760|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32954233|NCT00227994|Experimental|Galantamine|Galantamine for 12 weeks
32954234|NCT00227994|Experimental|Donepezil|Donepezil for 12 weeks
32954235|NCT04250454|No Intervention|Control|Elsass Standard Care
32954236|NCT04250454|Active Comparator|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
32954237|NCT00114504|Experimental|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
32954238|NCT00114504|No Intervention|Control group|Patients FDG-positive plaque who received diet therapy alone
32954239|NCT04247802|Experimental|Backwards Walking (BW) programme|This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
32954240|NCT04247802|Active Comparator|Usual Care|This group will undertake a routine course of one to one out-patient physiotherapy over 12 weeks. To allow comparison between the two groups the control group will also have up to four review appointments where their home exercise programme can be progressed or regressed. The physiotherapy treatments will be not be restricted (apart from no BW programme) to allow for a pragmatic approach based on the treating clinician's clinical judgement, however their content will be recorded on treatment logs.
32954241|NCT00118248|Experimental|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32954242|NCT04245384|Experimental|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
32954243|NCT04245384|Active Comparator|Standard treatment|Dietetic treatment with physical meetings
32954244|NCT00230022|Experimental|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
32954245|NCT00230022|No Intervention|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
32954246|NCT00230100|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
33316501|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
33316502|NCT00056862|Experimental|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
33316503|NCT00056862|Active Comparator|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
33316504|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
33316505|NCT01287182|Placebo Comparator|Placebo|
33316506|NCT01287182|Active Comparator|Ateronon|
32810652|NCT04143243|Placebo Comparator|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
32810653|NCT04142931|Active Comparator|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
32810654|NCT04142931|Active Comparator|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
32810655|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
32810656|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
32810657|NCT04140825||Group 1|Subjects>=18 years old will measure as a minimum FOT and spirometry.
32810658|NCT01797835|Placebo Comparator|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
32810659|NCT01797835|Experimental|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
32810660|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
32810661|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
32810662|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
32810663|NCT04581733|Experimental|Single Arm|Male and female Participants <18 years
32810664|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
32810665|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
32810666|NCT05580237||Severe aortic valve stenosis|
32810667|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
32810668|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
32810669|NCT05580159|Experimental|SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
32810670|NCT05580159|Active Comparator|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration Intramuscular : injection Intramuscular
32810671|NCT01838551|Experimental|Levoketoconazole DL0|Levoketoconazole Tablets Dose Level 0 Once Daily
32810672|NCT01838551|Experimental|Levoketoconazole DL1|Levoketoconazole Tablets Dose Level 1 Twice Daily
32810673|NCT01838551|Experimental|Levoketoconazole DL2|Levoketoconazole Tablets Dose Level 1 Twice Daily
32810674|NCT01838551|Experimental|Levoketoconazole DL3|Levoketoconazole Tablets Dose Level 3 Twice Daily
32810675|NCT01838551|Experimental|Levoketoconazole DL4|Levoketoconazole Tablets Dose Level 4 Twice Daily
32810676|NCT01838551|Experimental|Levoketoconazole DL5|Levoketoconazole Tablets Dose Level 5 Twice Daily
33100340|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
32810677|NCT01838551|Experimental|Levoketoconazole DL6|Levoketoconazole Tablets Dose Level 6 Twice Daily
32810678|NCT01838551|Experimental|Levoketoconazole DL7|Levoketoconazole Tablets Dose Level 7 Twice Daily
32810679|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
32810680|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
32810681|NCT04142853|Experimental|Persons with MS, dance group|
32810682|NCT04142853|Active Comparator|Persons with MS, art group|
32810683|NCT05580081|Experimental|i-CAN|18 weeks of access to the online consulting platform
32810684|NCT05580081|No Intervention|waitlit control|No offered support or consultation
32810685|NCT05587413|Experimental|treatment group|
32810686|NCT05587413|No Intervention|control group|
32810687|NCT04144413|Experimental|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
32810688|NCT04144413|Experimental|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
33100341|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
33100342|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
33100343|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
33100344|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
33100345|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
33100346|NCT00527345||1|children riding retrofitted school buses or private cars
33100347|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
33100348|NCT00527345||3|children who ride old diesel buses through the study
33316507|NCT00056316|Experimental|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
33316508|NCT00056316|Active Comparator|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
33316509|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
32810689|NCT04144413|Other|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
32810690|NCT04143477|Experimental|Peficitinib 50 mg|Participants will receive a single dose of 50 milligrams (mg) under fasted condition Day 1, followed by multiple doses of 50 mg under fed condition once daily in the morning from Day 8 till Day 13.
32810691|NCT04143477|Experimental|Peficitinib 100 mg|Participants will receive a single dose of 100 mg under fasted condition Day 1, followed by multiple doses of 100 mg under fed condition once daily in the morning from Day 8 till Day 13.
32810692|NCT04143477|Experimental|Peficitinib 150 mg|Participants will receive a single dose of 150 mg under fasted condition Day 1, followed by multiple doses of 150 mg under fed condition once daily in the morning from Day 8 till Day 13.
32810693|NCT04142463|No Intervention|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
32810694|NCT04142463|Experimental|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
32810695|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
32810696|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
32810697|NCT05586009|Active Comparator|Group 1|(n=25): receive cisplatin with hydration 1000mg magnesium (8 Meq) intravenous infusion ( IVI ).
32810698|NCT05586009|Active Comparator|Group 2|(n=25): receive cisplatin with hydration 2000mg magnesium (16 Meq) ( IVI ).
32810699|NCT05586009|Active Comparator|Group 3|(n=25): receive cisplatin with hydration 3000 mg magnesium (32 Meq) ( IVI ).
32810700|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
32810701|NCT04142151|Active Comparator|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.~Drug: Aspirin or Clopidogrel"
32810702|NCT04142151|Placebo Comparator|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).~Drug: Aspirin or Clopidogrel"
32810703|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
32810704|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
33100349|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
33100350|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
33100351|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
33100352|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
33100353|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
33100354|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
32954247|NCT00230100|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
32954248|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
32954249|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
32954250|NCT04243902|Experimental|1 - standard manual valve (without leg-bag)|"The valve will initially be tested in 8 participants who currently use a standard manual valve (without leg-bag).~This first group will include a safety cohort of participants (n=4). All safety data will be reviewed from the initial 4 participants before further participants can undergo the study investigation."
32954251|NCT04243902|Experimental|2 - drainage bag with free drainage|The valve will then be tested with participants (n=8) who currently use a drainage bag with free drainage.
32954252|NCT04236180|Active Comparator|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
32954253|NCT04236180|No Intervention|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
32954254|NCT00230802|Active Comparator|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
32954255|NCT00230802|Active Comparator|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
32954256|NCT00288366|Active Comparator|1|aripiprazole (Abilify)
32954257|NCT00288366|Active Comparator|2|ziprasidone (Geodon)
32954258|NCT00288600|Experimental|Experimental group|Intravenous Immunoglobulin
32954259|NCT00288600|Placebo Comparator|CONTROL GROUP|Normal Saline solution
32954260|NCT00290472|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
32954261|NCT04752852|Experimental|Dexamethasone|Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
32954262|NCT04752852|Placebo Comparator|Placebo|Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.
32954263|NCT00291876|Experimental|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
32954264|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
33316510|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
32954265|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
32954266|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
32954267|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
32954268|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
32954269|NCT00234078|Experimental|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
32954270|NCT00234078|Experimental|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
32954271|NCT00234078|Experimental|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
32954272|NCT00234078|Placebo Comparator|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
32954273|NCT00118404|Experimental|1|Participants received acute phase and continuation phase cognitive therapy
32954274|NCT00118404|Placebo Comparator|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
32954275|NCT00118404|Active Comparator|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
32954276|NCT00121836|Experimental|1|
32954277|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
32954278|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
32954279|NCT00237666|Experimental|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
32954280|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
32954281|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
32954282|NCT00297102|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
32954283|NCT00297102|Placebo Comparator|Placebo|once daily
32954284|NCT00123162|Experimental|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
32954285|NCT00123162|Placebo Comparator|Placebo|A single vaginal dose of placebo.
32954286|NCT01897818|Experimental|ALS patients|
32954287|NCT04751838||Survivor cohort; Non-survivor Cohort|All patients were categorized according to the state of departure from the hospital, named survivor or non-survivor.
32954288|NCT04751838||Training Cohort, Validation Cohort|the eligible patients randomly (7:3) into training cohort and validation cohort. The training cohort were used to build nomogram model, while the validation cohort validated the model.
32954289|NCT00123630|Placebo Comparator|placebo|placebo group
32954290|NCT00123630|Experimental|omalizumab|Xolair group
32954291|NCT00124176|Experimental|1|Nebulized levalbuterol 10mg/hr given continuously
32954292|NCT00124176|Active Comparator|2|Racemic albuterol 20mg/hr given continuously
32954293|NCT00240162|Experimental|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
32954294|NCT00299988|Experimental|IVIG|ivig
33316511|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
33404961|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
32954295|NCT00299988|Placebo Comparator|Placebo|
32954296|NCT04226352|Experimental|Dose 1|60 mg DXM a day for 28 days
32954297|NCT04226352|Experimental|Dose 2|300 mg DXM every 2 weeks for 28 days.
32954298|NCT04226352|Experimental|Dose 3|300mg DXM once, with 60mg DXM daily afterwards
32954299|NCT00300456|Active Comparator|A|ABT-335 + 20 mg simvastatin
32954300|NCT00300456|Active Comparator|B|ABT-335 + 40 mg simvastatin
32954301|NCT00300456|Placebo Comparator|C|ABT-335 monotherapy
32954302|NCT00300456|Placebo Comparator|D|20 mg simvastatin monotherapy
32954303|NCT00300456|Placebo Comparator|E|40 mg simvastatin monotherapy
32954304|NCT00300456|Placebo Comparator|F|80 mg simvastatin monotherapy
32954305|NCT00125034|Experimental|Cetuximab Plus FOLFOX-4|
32954306|NCT00125034|Active Comparator|FOLFOX-4 Alone|
32954307|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
32954308|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
32954309|NCT00241176|Experimental|Aripiprazole|
32954310|NCT02129244|Active Comparator|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
32954311|NCT02129244|No Intervention|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
32954312|NCT00125658|Active Comparator|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
32954313|NCT00125658|Experimental|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
32954314|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
32954315|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
32810705|NCT04142229|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
33316512|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
33316513|NCT01289132|Placebo Comparator|Placebo|
33316514|NCT01289132|Experimental|Azilsartan 5 mg QD|
33316515|NCT01289132|Experimental|Azilsartan 10 mg QD|
33316516|NCT01289132|Experimental|Azilsartan 20 mg QD|
32810706|NCT04142229|Active Comparator|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
33316517|NCT01289132|Experimental|Azilsartan 40 mg QD|
32810707|NCT04149951|Experimental|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
32810708|NCT04149951|Placebo Comparator|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
32810709|NCT04149873|Placebo Comparator|Control group|Control group' has the treatment with [Physical chest care ]
32810710|NCT04149873|Placebo Comparator|Experimental group-A|'Experimental group-A' has the treatment with [Mechanical-Insufflation- Exsufflation]
32810711|NCT04149873|Experimental|Experimental group-B|'Experimental group-B' has the treatment with [Mechanical-Insufflation- Exsufflation] and [Physical chest care]
32810712|NCT05583591|Experimental|Combined cataract surgery with Hydrus microstent|
32810713|NCT05583591|Active Comparator|Combined cataract surgery with iStent Inject W|
32810714|NCT03904329||Obese Patients with non valvular AF|Obese Patients with non valvular AF using oral anti coagulants
32810715|NCT04141995|Experimental|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
32810716|NCT05583435|Experimental|One-on-one professional coaching|"One-on-one professional coaching (N=30). Six one-on-one coaching sessions via Zoom with one of two private professional coaches every other week for 3 months.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health)."
32954316|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
32954317|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
32954318|NCT00242502|Experimental|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
32954319|NCT04389060|Active Comparator|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
32954320|NCT04389060|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
32954321|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
32954322|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
32954323|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
32954324|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
32954325|NCT00244140|Experimental|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
32954326|NCT00244140|Experimental|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
32954327|NCT00126750|Other|Arm 1|
32954328|NCT00127062|Experimental|Asthma|Asthma patients ranging from mild to severe
32954329|NCT00127062|Other|Healthy Non-Smokers|
32954330|NCT00127218|Experimental|1|any statin plus niacin
32954331|NCT00127218|Placebo Comparator|2|any statin plus placebo
32954332|NCT00127530|Placebo Comparator|Placebo- sugar pill|Placebo control
32954333|NCT00127530|Experimental|Fampridine-SR|10 milligram (mg) tablet b.i.d.
32954334|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
32954335|NCT00250926|Experimental|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
32954336|NCT00251238|Experimental|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
32954337|NCT00251238|Placebo Comparator|Placebo|Receiving daily placebo
32810717|NCT05583435|Experimental|Small-group professional coaching with coach-guided activities/behavioral internventions|"Coach-facilitated small group professional coaching sessions and coach-guided activities/behavioral interventions (N=30). Six small-group coaching sessions via Zoom with one of two private professional coaches and three physician participants in each group, every other week for 3 months. Group 2 includes coach-guided activities/behavioral interventions in addition to small group coaching sessions. These activities will be sent by coaches to participates throughout the 3 month period and include, but are not limited to: Wheel of Life, visioning exercise, one page miracle: core values, purpose, and goals, buckets and mental models.~The professional coaching method is similar to those receiving 1:1 professional coaching. The primary difference in this intervention group is that coaching sessions will be group-based with 3 physician participants and they will also be receiving behavioral interventions/activities in between group sessions, sent by coaches directly to participants."
32810718|NCT05583435|Experimental|Delayed-entry group (placebo then one-on-one professional coaching)|"Delayed-Entry Group 3 (N=30). No intervention during the 90 day study period. Note: once participation in the pilot study has been completed for Groups 1 and 2, physicians participating in Group 3 will be offered to participate in six one-on-one sessions with a private professional coach over a 3 month period.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health)."
32810719|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
32810720|NCT04149483|Experimental|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
32810721|NCT04149483|Placebo Comparator|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
32810722|NCT04149639|Experimental|NeuroQ|Directions: take 2 capsules at the same time daily
32810723|NCT04141371|Active Comparator|Molar Sodium Lactate|
32810724|NCT04141371|Placebo Comparator|physiological serum|
32810725|NCT04141449|Experimental|Potlako intervention|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation~Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.~Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program~Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
32810726|NCT04141449|Active Comparator|Enhanced Care|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
32810727|NCT04140981||group 1|difficult intubation according to antropometric measurements
32810728|NCT04140981||group 2|not difficult intubation according to antropometric measurements
32810729|NCT04140981||group 3|difficult intubation according to ultrasound measurements
32810730|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
32810731|NCT04149327|Experimental|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
32810732|NCT04149327|Active Comparator|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
32810733|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
32810734|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
32954338|NCT00251862|Experimental|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
32954339|NCT00251862|Experimental|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
32954340|NCT00251862|Sham Comparator|III|Standard care
32954341|NCT00303966|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33100355|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
33404962|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
32810735|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
32810736|NCT05582733|Experimental|Cervical spine manipulation|In spinal manipulation, the velocity, magnitude and direction of the impulse are controlled to encourage relaxation and comfort of muscle and connective tissue.
32810737|NCT05582733|Experimental|traction|aimed to relieve pressure on the spine
32810738|NCT05582655|Experimental|ONLINE|"This strategy will primarily include self-directed family access to the online JASPER modules developed for this project. The online modules follow a stepped hierarchy beginning with foundational concepts (e.g., engagement states) and systematically adding new concepts and strategies each week (e.g., balancing imitation and modeling, play routines). Access to the modules will be paired with a weekly brief (20 minute) check-in call provided by a community interventionist. The call is designed to create a space for the caregiver to ask questions about the week's content and to provide basic troubleshooting for implementation.~Slower responders to phase 1 ONLINE intervention will intensify to receive COACH in phase 2."
32810739|NCT05582655|Experimental|ONLINE + COACH|"Families randomized to add coaching will receive access to the ONLINE intervention program as described above. However, every second check in call will be shifted to a 45-minute live coaching session with their community interventionist. The coaching session will begin with a brief check-in and review of the target content for the session. This will be followed by support to set up the environment. The child will then join the interaction and the interventionist will provide real time coaching supports for the caregiver to practice the intervention strategies with their child. The session will end with a short discussion to debrief on the practice session.~Slower responders to phase 1 ONLINE + COACH intervention will intensify in phase 2 where check in calls are modified to include video feedback and review."
32810740|NCT05582577|Experimental|Simultaneous intravitreal bevacizumab injection with subthreshold micropulse laser|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A subthreshold micropulse laser will be performed after the third injection in group A. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
32810741|NCT05582577|Active Comparator|Intravitreal bevacizumab injection alone|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A sham laser will be performed after the third injection in group B. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
32810742|NCT04149015|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
32810743|NCT04149171|Experimental|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
32810744|NCT04149171|Active Comparator|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
32810745|NCT04140591|Placebo Comparator|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
32810746|NCT04140591|Active Comparator|Propranolol+Proton-pump inhibitor|"Propranolol:~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)~PPI: Pariet EC 20 mg/QDAC"
32810747|NCT03945669|Active Comparator|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access above the patella, through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
32831171|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: A permanent resin restoration is placed on top of the remained caries."
33100356|NCT04692038||Treatment Group|The subjects would receive forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
33100357|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
32810748|NCT03945669|Experimental|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
32810749|NCT03909321|No Intervention|Control group|The Control group will not be submitted to intervention and will be instructed not to engage in any kind of structured physical exercise training and to keep the life activities identified at baseline.
32810750|NCT03909321|Experimental|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
32810751|NCT05582109|Experimental|Envafolimab, Lenvatinib Combined With TACE|Envafolimab, Lenvatinib Combined With TACE
32810752|NCT04140123|Experimental|ZSP1601-Dose 1|ZSP1601-50mg once daily
32810753|NCT04140123|Experimental|ZSP1601-Dose 2|ZSP1601-50mg twice daily
32810754|NCT04140123|Experimental|ZSP1601-Dose 3|ZSP1601-100mg once daily
32810755|NCT04140123|Placebo Comparator|Placebo|Placebo
32810756|NCT05581953|Experimental|Omnivorous|Animal protein-lean pork
32810757|NCT05581953|Other|Vegetarian|Lacto-ovo-vegetarian without any meat
32810758|NCT03901833|Experimental|Telemedicine Support|Weekly telemedicine breastfeeding support visits for four weeks, delivered via telemedicine
32810759|NCT03901833|Placebo Comparator|Control|Standard of care
32810760|NCT04140201|Active Comparator|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
32810761|NCT04140201|Active Comparator|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
32810762|NCT04140201|Active Comparator|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
32810763|NCT04140201|No Intervention|Receive oral hypoglycemic only|Standard treatment only
32810764|NCT05581875|Experimental|Part 1 : Dose finding|"Belantamab mafodotin will be administered by intravenous infusion as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose for Part 1:~Cohort 1: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Cohort 2: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Daratumumab 1800mg SC (fixed dose) on:~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Pomalidomide: 4 mg/d on days 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years."
32810765|NCT03945513|Experimental|LPRI424|
32810766|NCT03945045|Experimental|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
32810767|NCT03945045|Experimental|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
32810768|NCT04148469|Experimental|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
32810769|NCT04148469|Placebo Comparator|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
32810770|NCT04148469|Experimental|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
32810771|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
32810772|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
32810773|NCT04140045|Experimental|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
32810774|NCT04140045|Experimental|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
32810775|NCT05587881||donor with vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT but whose donors receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
32810776|NCT05587881||donor without vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT but whose donors don't receive COVID-19 vaccine before stem cell collection.
32810777|NCT05587881||donor with vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT and whose donors also receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
32810778|NCT05587881||donor without vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT and whose donors also don't receive COVID-19 vaccine before stem cell collection.
32810779|NCT05586165|No Intervention|Holdout|
32810780|NCT05586165|Experimental|Simple Reminder|
32810781|NCT05586165|Experimental|Flu Tag Along|
32810782|NCT05586165|Experimental|Covid-19 Booster + Flu Bundle|
32810783|NCT03944265|Experimental|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
32810784|NCT04148547|Experimental|transcranial direct current stimulation|
32810785|NCT04148547|Placebo Comparator|Sham transcranial direct current stimulation|
32810786|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
32810787|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
32810788|NCT03941847|Experimental|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
32810789|NCT03941847|No Intervention|silence|The control group will have a usual care.
32810790|NCT05583669|Experimental|DS-2325a SC|Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 300 mg).
32810791|NCT05583669|Experimental|Placebo SC|Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
32810792|NCT05582421|Sham Comparator|calcium hydroxide|calcium hydroxide will be placed as intracanal medication between visits.
32810793|NCT05582421|Active Comparator|diclofenac sodium|diclofenac sodium will be placed as intracanal medication between visits
32810794|NCT05581407|Active Comparator|Licensed seasonal influenza vaccine|
32810795|NCT05581407|Experimental|1/5th of licensed seasonal influenza vaccine plus 1 mg LiteVax Adjuvant|
32810796|NCT05581407|Experimental|1/5th of licensed seasonal influenza vaccine plus 4 mg LiteVax Adjuvant|
32810799|NCT03898167|Active Comparator|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
32810800|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
32810801|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
32810802|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level was performed preoperatively to patients in the ESP group (Group I).
32810803|NCT03897933||non- blocked Group|consists of the patient group without any procedure
32810804|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
32810805|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
32810806|NCT03897621|Experimental|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
32810807|NCT03897621|Placebo Comparator|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
32810808|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
32810809|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
32810810|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
32810811|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
32810812|NCT03581487|Experimental|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32810813|NCT03581487|Experimental|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32810814|NCT04148859|Experimental|pregnant women|women who have to undergo amnioreduction due to TTTS
32810815|NCT04148703|Experimental|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
32810816|NCT04148703|Active Comparator|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
32810817|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
32899927|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~Infusion of minimally manipulated unlicensed UCB units:~vital signs Monitoring during and after UCB infusion:~Management of infusion reactions~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
32954342|NCT00304512|Experimental|Migalastat Low Dose 50 mg|Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
32954343|NCT00304512|Experimental|Migalastat Middle Dose 150 mg|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
32954344|NCT00304512|Experimental|Migalastat High Dose 250 mg|Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
32954345|NCT00304746|Active Comparator|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
32954346|NCT00304746|Placebo Comparator|placebo gel|Placebo gel
32954347|NCT05267808||Obstructive sleep apnea patients eligible for DISE|Patients with obstructive sleep apnea (AHI>=5) will be included in the study. Subjects should be eligible for drug-induced sleep endoscopy as the next step in their clinical path.
32954348|NCT05267730|Experimental|Modern board and card games group|"Conectar Jugando Game Program: The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games).~All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation"
32954349|NCT05267730|No Intervention|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the postintervention evaluation, the Conectar Jugando Game Program will be implemented under the same conditions as the experimental group.
32954350|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 alone|The participant received automated nasal oxygen titration administered by a closed loop system (FreeO2) during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). The objective of this system is maintain SpO2 a the pre-specified target level (94% in this study) with an automatic adjustment of oxygen flow second by second.
32954351|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 with high-flow nasal O2 therapy|In addition to nasal oxygen titration administered by a closed loop system (FreeO2), the participant received high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula during the 3-min CSST and endurance shuttle walking test.
32954352|NCT05267418|Active Comparator|Fixed-flow oxygen therapy|The participant received oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). In patients already on home oxygen, the O2 flow during exercise was set at 1 L/min above the usual flow used at home .
32954353|NCT00134004|Experimental|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
32954354|NCT00135798|Experimental|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
32954355|NCT00135798|No Intervention|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
32954356|NCT00135798|Experimental|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
32954357|NCT00136812|No Intervention|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
32954358|NCT00136812|Experimental|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
32954359|NCT00137280|Experimental|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
32954360|NCT00137280|No Intervention|Usual Care|Usual Care
32954361|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
32954362|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
32954363|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
32954364|NCT00138294|Experimental|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
32954365|NCT00138294|Active Comparator|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
32954366|NCT02103114|Experimental|Anti-thrombin III|
32954367|NCT02103114|Placebo Comparator|Placebo|
32954368|NCT00140244|Active Comparator|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
32954369|NCT00140244|Placebo Comparator|Placebo|SubQ once daily
33100358|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
33100359|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
33100360|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
33100361|NCT00528515|Active Comparator|1|propofol
33100362|NCT00528515|Experimental|2|desflurane
33100363|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
33100364|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
33100365|NCT00528554|Active Comparator|A|Active laser acupuncture
33100366|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
33100367|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
33100368|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
33100369|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
33316518|NCT01289132|Experimental|Azilsartan 80 mg QD|
33316519|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
32810818|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
32810819|NCT03940521||HIV-A infected patients|
32810820|NCT03897309|Experimental|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
32810821|NCT03897309|Experimental|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
32810822|NCT03897309|Experimental|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
32810823|NCT03897309|Placebo Comparator|Placebo|Placebo tablets
32810824|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
32810825|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
32810826|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
32810827|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
32810828|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
32810829|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
32810830|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
32810831|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
32810832|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
32810833|NCT03580161||99mTc MDP/HDP Bone Scan|Patients receiving routine diagnostic scan
32810834|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
32810835|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
32810836|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
32810837|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
32810838|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
33100370|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
33100371|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
33100372|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
33100373|NCT00528593|Active Comparator|1|
33100374|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) <18Years old
33100375|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) >18Years old
33100376|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
33100377|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
33316520|NCT01287260|Experimental|Arm1|
33316521|NCT01287260|Active Comparator|Arm 2|
33316522|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
33316523|NCT01181570|Experimental|Adalimumab|
33316524|NCT01181570|Placebo Comparator|Placebo|
33318673|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
33100378|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
32810839|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
32810840|NCT03585465|Experimental|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
32810841|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
32810842|NCT03585465|Experimental|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)~This arm is applicable to second stage, and 43 patients are expected"
33100379|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
33100380|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
32810843|NCT03585465|Experimental|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab~This arm is applicable to second stage, and 43 patients are expected"
32810844|NCT03940209|No Intervention|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
32810845|NCT03940209|Experimental|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
32810846|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
33100381|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
33100382|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
33100383|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
33100384|NCT00528710|Placebo Comparator|P|Placebo Control Group
33100385|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
33316525|NCT05200312|Experimental|Treatment-naive DLBCL|Treatment-naive high-risk DLBCL patients will be enrolled. R/R2-CHOP were allowed in cycle 1 due to poor physical condition or liver and renal failure caused by lymphoma progression. Patients achieving Complete Remission (CR) or Partial Remission (PR) after 2 cycles will receive another 2 cycles. Patients achieving CR or PR after 4 cycles will finish 6 cycles. Patients achieving CR after 6 cycles with double-hit/triple-hit/double-expression/median to high risk aaIPI will undergo Autologous Stem Cell Transplantation (ASCT). Other patients will be administered rituximab for another 2 cycles and then turn to follow-up. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for another 3 years. Patients achieving Stable Disease (SD) or PD (Progression Disease) after 2 or 4 cycles will quit the study. After 6 cycles, patients achieving SD or PD will quit the study and patients achieving PR will receive second-line therapy.
33316526|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
33316527|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
33316528|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
33316529|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
33316530|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
32810847|NCT03938649|Experimental|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday"
32810848|NCT03938649|Experimental|SBRT|"RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)~5 fractions of weekly treatment. Once fraction per week."
32810849|NCT04747821|Experimental|First group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval
32810850|NCT04747821|Experimental|Second group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval
32810851|NCT04747821|Experimental|Third group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval
32810852|NCT04747821|Experimental|Fourth group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval
32810853|NCT03588195|Experimental|Education Group|
32810854|NCT03588195|Active Comparator|Control Group|
32899928|NCT05415618|Active Comparator|Kontrol group|
32810855|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
32810856|NCT03588819|Experimental|2-fraction SABR|
32810857|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
32810858|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810859|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810860|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810861|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810862|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810863|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810864|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810865|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
32810866|NCT03545607|Experimental|MultiStem|1.2 billion cells
32810867|NCT03545607|Placebo Comparator|Placebo|
32810868|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
32810869|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
32810870|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
32810871|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
32810872|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
32810873|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
32810874|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
32810875|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
32810876|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
32810877|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
32810878|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
32810879|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
32810880|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
32810881|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
32810882|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
32810883|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
32810884|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
32954370|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
32954371|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
32954372|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
32954373|NCT01790412|Experimental|Exercise group|"Three sessions per week:~Supervised exercise program"
32954374|NCT01790412|No Intervention|Control|Sedentary pregnant women
32954375|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
32954376|NCT05267028||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
32954377|NCT05267028||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
32954378|NCT00140556|Experimental|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
32954379|NCT05215392|Experimental|Smartphone Application|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app.
32954380|NCT05215392|Active Comparator|Treatment As Usual|Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
33316531|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
33316532|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
32954383|NCT00142116|Experimental|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
32954384|NCT05201430|Experimental|A: FOLFOXIRI|Neoadjuvant chemotherapy with 3-4 cycles of FOLFOXIRI regimen, followed by surgery
32954385|NCT05201430|Experimental|B: CapeOX|Neoadjuvant chemotherapy with 2-3 cycles of CapeOX regimen, followed by surgery
32954386|NCT05188560|Experimental|AOT+MI|participants who, in addiction to standard rehabilitation program after surgery, underwent a single pre-operative training session of action observation therapy associated with motor imagery.
32954387|NCT05188560|No Intervention|Control group|Participants who was not subjected to any pre-operative activity. They received standard rehabilitation program after surgery too.
32954389|NCT00142506|Active Comparator|1|radiotherapy with hormones, questionaire assessments
32954390|NCT00142506|Placebo Comparator|2|radiotherapy without hormones, questionaire assessments
32954391|NCT05266794|No Intervention|Control|25 hemodialysis patients who received their routine therapy only.
32954392|NCT05266794|Active Comparator|Selenium|23 hemodialysis patients who received Selenium 200µg once daily with their routine therapy just after the dialysis sessions for 3 months.
32954393|NCT05266794|Active Comparator|Alpha Lipoic acid|20 hemodialysispatients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
32954394|NCT00142818|Experimental|Naltrexone plus modafinil|Nal + Mod
32954395|NCT00142818|Experimental|Naltrexone|Nal
32954396|NCT00142818|Experimental|Modafinil|Mod
32954397|NCT00142818|Placebo Comparator|Placebo|Placebo
32954398|NCT05266716|Experimental|Primary Arm|The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform
32954399|NCT00147030|Active Comparator|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
32954400|NCT00147030|No Intervention|non-cooled|Standard intensive care
32954401|NCT05266560|Active Comparator|Propofol injection group (1.5mg/kg)|The patients in the propofol group were given intravenous injection of propofol 1.5 mg/kg and succinylcholine 1 mg/kg in turn, and the interval between each drug administration was 1 minute, and electroconvulsive therapy was performed after the patients were anesthetized.
32954402|NCT05266560|Experimental|Ciprofol injection group(0.4mg/kg)|The patients in the ciprofol group were given intravenous injection of ciprofol 0.4 mg/kg and succinylcholine 1 mg/kg in turn. The interval between each drug administration was 1 minute, and the patients received electroconvulsive therapy after anesthesia.
32954406|NCT05117034|Experimental|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
32954407|NCT05117034|Placebo Comparator|Placebo|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
33100386|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
33100387|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
33100388|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
33100389|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
33100390|NCT00528827|Placebo Comparator|1|
33100391|NCT00528827|Experimental|2|5 mcg
33316533|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
33316534|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
33100392|NCT00528827|Experimental|3|2.5
33100393|NCT00528827|Experimental|4|0.5
33316535|NCT05131672|Experimental|Operative reduction w/ fixation|open reduction and internal fixation (ORIF)
33316536|NCT05131672|Active Comparator|Non-operative immobilization|immobilization in a cast without reduction
33100394|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
33100395|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
33100396|NCT04691765|Experimental|100 mg SC|100 mg of Kineret (anakinra) will be administered sub-subcutaneously once a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
33100397|NCT04691765|Experimental|100 mg SC BID|100 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
33100398|NCT04691765|Experimental|200 mg SC BID|200 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
33100399|NCT04689204|Experimental|Administration of CTA30X|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
33100400|NCT04691687|No Intervention|Standard of Care (Group 1)|Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
33100401|NCT04691687|Placebo Comparator|IV Placebo Infusion|Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
33316537|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
33316538|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
32810885|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
32810886|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
32810887|NCT03896763|Experimental|Supine / CMV|Supine positioning and conventional mechanical ventilation
32810888|NCT03896763|Experimental|Prone / CMV|Prone positioning and conventional mechanical ventilation
32810889|NCT03896763|Experimental|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
32810890|NCT03896763|Experimental|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
32810891|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
32810892|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
32810893|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
32810894|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
32810895|NCT01797445|Experimental|E/C/F/TAF (Double-Blind)|"E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
32810896|NCT01797445|Active Comparator|E/C/F/TDF (Double-Blind)|"E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
32810897|NCT01797445|Experimental|Open-Label E/C/F/TAF|After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
32810898|NCT03935451|Placebo Comparator|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
32810899|NCT03935451|Experimental|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
32810900|NCT03935295|Experimental|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
33316539|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
33316540|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
33316541|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
33316542|NCT04696198|Experimental|Range of motion|Treatment is based on a set diagnostic and therapeutic protocol and carried out by registered health care professionals that are additionally trained in manual therapy intervention. 30 minutes of treatment will be given once a week over a period of two months
33316543|NCT04696198|Other|Standard care|Standard care
32810901|NCT03935295|Placebo Comparator|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
32810902|NCT04765683||Patients|Attending surgical outpatients
32810903|NCT04765683||Surgeons|Running surgical outpatients
32810904|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
32810905|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
32810906|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
32810907|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
32810908|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
32810909|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
32810910|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
32810911|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
33316544|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
32810912|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
32810913|NCT04147767|Experimental|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
32810914|NCT04147767|Placebo Comparator|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
32810915|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
32810916|NCT04147377|Experimental|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
32810917|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
32810918|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
32810919|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
32899929|NCT05415618|Experimental|Treatment group|
32899930|NCT05415462|Experimental|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
33100402|NCT04691687|Experimental|IV Furosemide Infusion|The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP <80 mmHg or symptoms of presyncope).
33100403|NCT04110327||Claudication|Subjects presenting with claudication, identified as Rutherford category 1, 2, or 3
33100404|NCT04110327||Critical Limb Ischemia|Subjects presenting with rest pain (Rutherford category 4) or minor tissue loss (Rutherford category 5)
33100405|NCT04110327||Critical Limb Ischemia with major tissue loss|Subjects presenting with major tissue loss (Rutherford 6)
33316545|NCT05046418||Hypoallergenic formula containing synbiotics|Infants (aged <13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.
33316546|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
33316547|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
33316548|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
33316549|NCT01287338|Experimental|Lower Puncta Delivery|
33316550|NCT01287338|Experimental|Double Puncta Delivery|
33316551|NCT01289288|Experimental|Mailed printed materials and in-office training|
33316552|NCT01289288|No Intervention|Control|Usual care
32810920|NCT01796197|Experimental|Treatment Arm|"Run in: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg (Day 1 Week 1)~Pre-Op:~Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly (beginning on Day 8 Week 2) x 16 doses.~Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above, add Pertuzumab 420 mg IV x 3 weeks. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued x 3 weeks until surgery Modified Radical Mastectomy~Post-Op:~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV x 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg x 3 weeks to complete 12 months of HER2-directed therapy Post-mastectomy radiation to the chest wall / regional lymph nodes and endocrine therapy by standard of care."
33316553|NCT01180322|Active Comparator|Arm A|Standard Therapy
33316554|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
32810921|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
32810922|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
32810923|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
32810924|NCT01795495|Active Comparator|Remifentanil|This arm will receive remifentanil alone as is the current practice.
32810925|NCT01795495|Experimental|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
32810926|NCT01795495|Experimental|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
32810927|NCT04765527|Experimental|Turmeric|Dietary supplement, Turmeric Strength for Joint, containing turmeric root extract (with 350 mg curcumin), black pepper extract, boswellia gum resin extract, devil's claw root extract, and ginger root; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
32810928|NCT04765527|Placebo Comparator|Placebo|Placebo tablets; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
32810929|NCT04570111|Active Comparator|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
32810930|NCT04570111|Experimental|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
32810931|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
32810932|NCT04170907|Other|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
32810933|NCT04170907|Other|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
32810934|NCT04170907|Other|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
32810935|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
32899931|NCT05415462|Active Comparator|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
33100406|NCT04107675|Experimental|L-CsA 10 mg plus Standard of Care|Liposomal Cyclosporine A 10 mg bid for 12 weeks
33100407|NCT04107675|Experimental|L-CsA 5 mg plus Standard of Care|Liposomal Cyclosporine A 5 mg bid for 12 weeks
33316555|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
33316556|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
33316557|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~Care managers: Screening, Adherence support, psychoeducation and communication.~Psychiatric Consultation"
33316558|NCT01287494|No Intervention|Care as Usual|
32954408|NCT05081934|Active Comparator|Treatment as usual, TAU|TAU: Interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial.
32954409|NCT05081934|Experimental|TAU + A-CRA|"Behavioral: A-CRA, a 12-14 weekly sessions long behavioral treatment for youth (ages 12-25) suffering from substance use disorder and co-occurring problems, i.e. criminal behavior. The aim is to increase constructive behavior that reduces the need of substances and creates a context where it is rewarding to stay sober. Individual functional analyses, goals and needs guides treatment planning and interventions.~TAU: interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial."
33316559|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
33316560|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
33316561|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
33316562|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
33316563|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
32954410|NCT00147966|Experimental|ritxumab|all patients get treatment
32954411|NCT04528212|Experimental|Group I|Glimepiride (4 mg) per Day
33316564|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
33316565|NCT05666570||Avelle NPWT|Avelle Negative Pressure Wound Therapy administered as indicated by the IFU.
33316566|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
32954412|NCT04528212|Experimental|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
32954413|NCT04528212|Experimental|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
32954414|NCT04456140|Experimental|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
32954415|NCT05265936|Active Comparator|Guidewire through DJ stent|Patients who underwent lithotripsy after guidewire insertion through a previously placed double j stent.
32954416|NCT05265936|Sham Comparator|DJ stent remove + guidewire|Patients who underwent lithotripsy after double j stent removal and guidewire placement.
32954417|NCT05265858||Patients with hip osteoarthritis|Patients with hip osteoarthritis who will undergo total hip arthroplasty
32954418|NCT00148668|Active Comparator|Arm 1|Herceptin/navelbine
32954419|NCT00148668|Active Comparator|Arm 2|Taxotere/carboplatin/herceptin
32954420|NCT05265780|Experimental|kinesiotape|kinesiotaping group
32954421|NCT05265780|Sham Comparator|control|sham group
32954422|NCT00149838|Experimental|Active prefrontal rTMS phase1|Phase I participants receiving rTMS
32954423|NCT00149838|Placebo Comparator|Sham rTMS phase 1|Phase I participants receiving sham stimulation
32954424|NCT00149838|Experimental|rTMS extension|rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
32954425|NCT00149838|Experimental|Open label antidepressant regimen|All patients who met remission who were then transitioned to medications after the TMS trial was completed.
32954428|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
32954429|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
32954430|NCT04046796||Healthy twin|
32954431|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
32954432|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
32954433|NCT00151320|Experimental|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
32810936|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
33100408|NCT04107675|Placebo Comparator|Liposomal Placebo plus Standard of Care|Liposomal Placebo 2.5 mL bid for 12 weeks
33100409|NCT04093167|Experimental|Pembrolizumab|200mg (or 2mg/kg) IV every 3 weeks for cycles 1-3 then as per standard of care for patients with PD-L1+ EGFR/ALK-NSCLC
33100410|NCT03458624||Not applicable-observational study|Not applicable-observational study
33100411|NCT04049175|Experimental|Treatment A|Administration of CHF 6532 Dose #1
33100412|NCT04049175|Experimental|Treatment B|Administration of CHF 6532 Dose #2
33100413|NCT04049175|Experimental|Treatment C|Administration of CHF 6532 Dose #3
32810937|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
32810938|NCT01794949|Experimental|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
32810939|NCT01794949|Experimental|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
33100414|NCT04049175|Placebo Comparator|Treatment D|Administration of CHF 6532 Placebo
33316567|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
32810940|NCT04414501|Active Comparator|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
33316568|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
33316569|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
33316570|NCT01181882|Experimental|Fish Oil and Aspirin|
32810941|NCT04414501|Active Comparator|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
32810942|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
32810943|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
32810944|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
32810945|NCT05702775|No Intervention|Non-endoscopic treatment group (Group NE)|Antibiotic treatment will start from the moment of diagnosis in both arms of the study. Following the recommendations of the Clinical Practice Guideline for the Management of Acute Cholecystitis of Tokyo 2018, CAL will be classified into three groups according to severity (I,II,III) and empirical antibiotic treatment will be started according to the recommendations of said guideline
32810946|NCT05702775|Experimental|Endoscopic treatment group (EUS-GBD Group)|The procedure will be performed after at least 6 hours of fasting The placement of the drain will be performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy.
33100415|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
33100416|NCT04692311|Experimental|Persons with central nervous system diseases|Persons with central nervous system diseases received additional training with i-ACT during 6 weeks. After final training, a semi-structured interview was performed. And at six weeks follow-up, a final assessment took place.
33100417|NCT04692311|Other|Occupational therapists|Occupational therapists were invited to a semi-structured interview to gather information about their professional opinion regarding i-ACT.
33100418|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
33100419|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
33100420|NCT00528905|Placebo Comparator|1|Placebo
33100421|NCT00528905|Experimental|2|AZD3480 oral
33100422|NCT00528905|Experimental|3|AZD3480 oral dose
33100423|NCT02923791|Experimental|Filgrastim Hospira|
33100424|NCT02923791|Active Comparator|US-Approved Neupogen|
33100425|NCT02926092||Arm 1|Observation of progression of disease over time.
33100426|NCT04033419|Experimental|Memantine|
33100427|NCT04689243|Experimental|ALA-PDT|
33100428|NCT04689243|Other|red light|
33100429|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
33100430|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
33100431|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
33316571|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
33316572|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
33316573|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
33100432|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
33316574|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
33316575|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
33316576|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
32810947|NCT05702697|Experimental|F-ESWT|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
32810948|NCT05702697|Sham Comparator|Sham-ESWT|sham ESWT by using the focused shockwave device and placing the shocking head in the same muscle positions as performed in the intervention group with 0.01 mJ/mm2 intensity and 6 Hz frequency in 2,000 shocks/session/week for 3 weeks.
32810949|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin TEVA 850 mg (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin TEVA 850 mg (1-3 times daily) on top of usual care."
32810950|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
32810951|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
32810952|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
32810953|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~57FePP (95.8%) 3.49 mg~Aspergillus oryzae (unenriched) 0.025 mg~FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
32810954|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~ASP-p (8% Fe; natural abundance) 3.516 mg~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~4.2 total mg of Fe"
32810955|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~Aspergillus oryzae (unenriched) 0.027 mg~57FeSO4 (95.4%) 3.18 mg~4.2 total mg of Fe"
32810956|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
32810957|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
32810958|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
32810959|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
32810960|NCT05702619||Arm 1|Arm 1 - De novo, treatment-naïve metastatic prostate cancer
32810961|NCT05702619||Arm 2|Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
32810962|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
32810963|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
32810964|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
32810965|NCT01770379|Experimental|Secukinumab 75 mg|Secukinumab 75 mg s.c.
32810966|NCT01770379|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c.
33316577|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
33316578|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
32810967|NCT01770379|Placebo Comparator|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
32810968|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
32810969|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
32810970|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
33316579|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
33316580|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
32954434|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
32954435|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
32954436|NCT04332198|Experimental|ALS patients|
32954437|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
32954438|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
33316581|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
33316582|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
33316583|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
32954439|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
33316584|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
33316585|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
33316586|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
33316587|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
32954440|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
32954441|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
32954442|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
33316588|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
33316589|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
32954443|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
33100433|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
33316590|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
33316591|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
33316592|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
33316593|NCT04994444|Experimental|Preloading|Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks.
32954444|NCT05105568|Experimental|Process-based therapy|
32954445|NCT04281654|Experimental|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
32954446|NCT04281654|Experimental|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
32954447|NCT04281654|Active Comparator|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
32954448|NCT04952376|Active Comparator|Short message service (SMS)|Subjects will receive vaccine availability and appointment information via SMS.
32954449|NCT04952376|Experimental|Personalized text message|Subjects will receive vaccine availability and appointment information via a personalized message text from the primary care provider (PCP).
32954450|NCT04952376|Experimental|Interactive or 2-way SMS|Subjects will receive vaccine availability and appointment information via interactive 2-way SMS options.
32954451|NCT04248192|Experimental|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
32954452|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
32954453|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
32954454|NCT04177680|Experimental|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
32954455|NCT04177680|Active Comparator|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
33316594|NCT04994444|Active Comparator|Standard treatment|Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks.
33316595|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
33316596|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
33316597|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
33316598|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
33316599|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
33100434|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
33100435|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
33100436|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
33100437|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
33100438|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
33100439|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
33100440|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
33100441|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
33100442|NCT00527696|Active Comparator|TVT SECURE|sling
32810971|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
33100443|NCT00527696|Active Comparator|TVT O|sling
33100444|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
33100445|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
33100446|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
33100447|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
33100448|NCT00529139|Active Comparator|A|
33100449|NCT00529139|Active Comparator|B|
33100450|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
33100451|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
33100452|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
33100453|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
33316600|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
33316601|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
32810972|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
32810973|NCT04592653|Experimental|Cohort 1: Tumor Microenvironment (TME) Nemvaleukin and Pembrolizumab|Nemvaleukin will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of nemvaleukin
32810974|NCT04592653|Experimental|Cohort 2 Part A: Less Frequent IV Dosing Nemvaleukin|
32810975|NCT04592653|Experimental|Cohort 2 Part B: Less Frequent IV Dosing Nemvaleukin and Pembrolizumab|
32810976|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
32810977|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
32810978|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
32810979|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
32810980|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
32810981|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
32810982|NCT01770145|Experimental|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
32810983|NCT05702385|No Intervention|Standard Practice|The control group treats their simulated patients using standard practice and has no introduction to the new diagnostic test.
32810984|NCT05702385|Experimental|Intervention Group 1 - Test Results Given|Intervention Group 1 will receive information regarding the test and will be given the test results, whether selected or not, in Round 2 of CPV administration.
32810985|NCT05702385|Experimental|Intervention Group 2 - Test Results Optional|Intervention Group 2 will receive information regarding the test and will be given the test results if selected in Round 2 of CPV administration.
32810986|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
33100454|NCT00527774||A|HCV(+) maintenance hemodialysis patients
33100455|NCT00527774||B|HCV(-) maintenance hemodialysis patients
33100456|NCT02925780|Experimental|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
33100457|NCT02925780|Active Comparator|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
33100458|NCT00527813|Experimental|A|prone position for at least 16 hours per day
33316602|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
33316603|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
32810987|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
32810988|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
32810989|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
32810990|NCT05702307|Experimental|Glucose as reference food|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32810991|NCT05702307|Experimental|Tagliatelle Control|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32810992|NCT05702307|Experimental|5% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32810993|NCT05702307|Experimental|16% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32899932|NCT05415384|Experimental|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy plus CRYOABLATION|Adding Cryoablation of levels 3-8, in addition to patients that undergo SSRF for multiple rib fractures.
32899933|NCT05415384|Active Comparator|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy|Standard surgical treatment of patients with multiple rib fractures plus Multimodal Pain Therapy
33100459|NCT00527813|No Intervention|B|semi-recumbent position
33100460|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
33100461|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
33100462|NCT04692428|Experimental|FIBSI group|ultrasound supra inguinal Fascia iliaca block
33100463|NCT04692428|Experimental|FNB group|ultrasound femoral nerve block
33100464|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
33100465|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
33316604|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
33100466|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
33100467|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
33100468|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
33316605|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
33100469|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
33100470|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
33100471|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
33100472|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
33100473|NCT02923518||Control group|Those without a positive score on the two scores listed above.
33100474|NCT02945189||Peri menopausal|Participants aged 41-55 years
33100475|NCT02945189||post menopausal|participants aged 56-65 years
32899934|NCT00300482|Active Comparator|A|ABT-335 + 10 mg rosuvastatin
33100476|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation by ARBOT device"
33100477|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation performed by physiotherapist~Specific ankle rehabilitation by Biodex System 3 dynamometer~Specific ankle rehabilitation by ProKin PK254 platform."
33100478|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
33316606|NCT01290770||obese men|obese men with chest pain like angina
33316607|NCT03307252|Experimental|Treatment Reference 1|
33316608|NCT03307252|Experimental|Treatment Reference 2|
33316609|NCT03307252|Experimental|Treatment Reference 3|
33316610|NCT03307252|Experimental|Treatment 1|
32899935|NCT00300482|Active Comparator|B|ABT-335 + 20 mg rosuvastatin
32899936|NCT00300482|Placebo Comparator|C|ABT-335 monotherapy
32899937|NCT00300482|Placebo Comparator|D|10 mg rosuvastatin monotherapy
33316611|NCT03307252|Experimental|Treatment 2|
33316612|NCT03307252|Experimental|Treatment 3|
33316613|NCT03307252|Experimental|Treatment 4|
33316614|NCT03307252|Experimental|Treatment 5|
33316615|NCT03307252|Experimental|Treatment 6|
32899938|NCT00300482|Placebo Comparator|E|20 mg rosuvastatin monotherapy
32899939|NCT00300482|Placebo Comparator|F|40 mg rosuvastatin monotherapy
32899940|NCT05440812|Experimental|Care As Usual plus STAIRS|Care as usual added with a eight week STAIRS-training
32899941|NCT05440812|No Intervention|Care As Usual|Care as usual added with three information letters
32899942|NCT05439876|Experimental|Melatonin|Melatonin
32899943|NCT05439876|Placebo Comparator|Placebo|Placebo
32899944|NCT05439252|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening, and record exercise snacking compliance data in a log book
32899945|NCT01791062|Experimental|HYTOP®|
32899946|NCT05404308|Experimental|Weekly follow-up by a medical radiography technician and weekly follow-up by the radiotherapist|
32899947|NCT05404308|Active Comparator|Standard weekly follow-up by the radiotherapist only|
33100479|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
33100480|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
33100481|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
33100482|NCT00529256|No Intervention|2|No intervention
33100483|NCT04231968|Experimental|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
33100484|NCT04231968|Placebo Comparator|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
33100485|NCT00529295|Experimental|1|Titrated oral misoprostol
33100486|NCT00529295|Active Comparator|2|Vaginal misoprostol
33100487|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
33100488|NCT04218903|Experimental|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
33100489|NCT04218903|Active Comparator|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
32810994|NCT05702307|Experimental|16% sunflower penne|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32810995|NCT05702307|Experimental|16% sunflower fusilli|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32810996|NCT01609543|Experimental|Single Arm|
32810997|NCT03888105|Experimental|FL|Follicular lymphoma grade 1-3a cohort
32810998|NCT03888105|Experimental|DLBCL|Diffuse large B-cell lymphoma cohort
32810999|NCT03888105|Experimental|MCL|Mantle Cell Lymphoma cohort
32811000|NCT03888105|Experimental|MZL|Marginal Zone Lymphoma cohort
32811001|NCT03888105|Experimental|Other B-NHL|Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed
32811002|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
32811003|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
32811004|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
32811005|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
32811006|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
32811007|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
32811008|NCT04405089|Experimental|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
33100490|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
33100491|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
33100492|NCT04210206|Experimental|Diet|
33100493|NCT04210206|No Intervention|Control|
33100494|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
32811009|NCT04405089|Sham Comparator|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
32811010|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
32811011|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
32811012|NCT03887715|Active Comparator|Active|Group will have VNS activated 2 weeks post implant.
32811013|NCT03887715|Sham Comparator|Control|Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
32811014|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, [F-18]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
32811015|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
32811016|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
32811017|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
32811018|NCT05702151|Active Comparator|Morphine infusion|IV morphine 50mcg/kg/h infusion with Patient Controlled Analgesia extra bolus on demand of 1mg (lockout interval 20 minutes), and paracetamol 1g every 8 hours.
32811019|NCT05702151|Experimental|ESP Block analgesia|"After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed.~An infusion of ropivacaine 0.16% at 10ml/h is started in the operating room. Patient Controlled Analgesia pump will be connected with 1mg IV morphine bolus on demand, and paracetamol 1g every 8 hours, is also delivered."
32811020|NCT05702073|Experimental|INS068|
32811021|NCT05702073|Active Comparator|IGlar|
32811022|NCT01986647|Experimental|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
32811023|NCT01986647|Active Comparator|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
32811024|NCT01986647|Active Comparator|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
32811025|NCT01986647|Active Comparator|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
32811026|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
32811027|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
32811028|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
32811029|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
32811030|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
32811031|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
32811032|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
32811033|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
32811034|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
32811035|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
32811036|NCT05701995|Experimental|Deucravacitinib|
32811037|NCT05701995|Placebo Comparator|Placebo then Deucravacitinib|
33316616|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
32811038|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
32811039|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
32811040|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
32811041|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
32811042|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
32811043|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
32811044|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
32811045|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
32811046|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
32811047|NCT03584841|Active Comparator|Healthy volunteers|
32811048|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
32811049|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
32811050|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
32811051|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
32811052|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
32811053|NCT03587337||Prophylaxis|
32811054|NCT03587337||Antibiotic tp|
32811055|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
32811056|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
32811057|NCT04765215||Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine|
32811058|NCT04765215||Healthy volunteers who received two doses of coronavac vaccine|
32811059|NCT04764981|Experimental|Experimental Group 1: Essences Oils|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.
32811060|NCT04764981|No Intervention|Experimental Group 2: Clinical follow-up|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.
32811061|NCT04764981|No Intervention|Control Group|The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.
32811062|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
32811063|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
32811064|NCT04405245|Experimental|AKB-9778 QD + Latanoprost|• AKB-9778 QD (AM) and placebo for AKB-9778 ophthalmic solution QD (PM) plus latanoprost QD (PM) for 28 days
32811065|NCT04405245|Experimental|AKB-9778 BID + Latanoprost|• AKB-9778 BID (AM & PM) plus latanoprost QD (PM) for 28 days
32811066|NCT04405245|Placebo Comparator|Placebo BID + Latanoprost|• Placebo for AKB-9778 ophthalmic solution BID (AM & PM) plus latanoprost QD (PM) for 28 days
32811067|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
32811068|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
32811069|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
32811070|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
32811071|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
32811072|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
32811073|NCT00724984|Experimental|1|
32811074|NCT03583983|Other|Personalized Health Recommendations|
32811075|NCT03583983|Other|No Health Recommendations|
32811076|NCT05703165|Experimental|subjects with stress burden and animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
32811077|NCT05703165|Active Comparator|subjects with stress burden and without animal-assisted intervention|Study participants only observe the natural environment.
32899948|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
32811078|NCT05703165|Active Comparator|subjects without stress burden and with animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
32811079|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
32811080|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
32811081|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
32811082|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:~1g of tranexamic acid by slow intravenous injection~1g of tranexamic acid by syringe pump during 8 hours"
32811083|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:~10 mL of 0.9% sodium chloride by slow intravenous injection~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
32811084|NCT03020277|Other|ASD children families|
32811085|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
32811086|NCT02753751|No Intervention|Usual Care|No alert will be fired.
32811087|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
32811088|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
32811089|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
32811090|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
32811091|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
32811092|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
32811093|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
32811094|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
32811095|NCT01275196|Experimental|Nilotinib|
32811096|NCT01275196|Active Comparator|Imatinib|
32811097|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
32811098|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
32811099|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
32811100|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
32811101|NCT03153579|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
32811102|NCT03153579|Other|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
32811103|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
32811104|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
32811105|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
32811106|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
32811107|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
32811108|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
32811109|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
32811110|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
32811111|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
32811112|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
33100495|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
33100496|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
33100497|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
33100498|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
33100499|NCT00529412|No Intervention|control|no Seprafilm
33100500|NCT00529412|Active Comparator|Seprafilm|
33100501|NCT04204668|Active Comparator|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
33102517|NCT04687488|Other|Fluorescein|"Fluorescein dye and ultraviolet (UV) light are used to assess the aerosol contamination during endonasal investigations. We will dilute medical fluorescein vials (FLUORESCEINE 10% Faure; SERB, 40 Avenue George V, 75008 Paris, France) to a concentration of 1% fluorescein in 10ml of normal saline solution. Next, we swab the nasal cavity with a compress soaked (15 droplets with a pipette) in fluorescein and we apply 5 droplets into the nasal cavity and nasopharynx at the beginning of the investigation.~After coating the nose with fluorescein, the patient will wear a surgical nose-mouth mask and will be positioned in the bed used for HRiM or MII-pH probe insertion. As the MII-pH probe is removed 24h after placement of the probe, prior to this activity the same fluorescein application method (fluorescein drops and a cotton swab) will be used."
32811113|NCT03155607|No Intervention|Standard Care|
32811114|NCT03155607|Experimental|Virtual Reality Distraction|
32811115|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
32811116|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
32811117|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
32811118|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
32811119|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
32811120|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
32811121|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
32811122|NCT05647161|Experimental|Treatment Group|"Participants undergo 1st open heart surgery (first operation), and before closing the chest BAX602 will be sprayed on the surface of the heart and large vessels. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
32811123|NCT05647161|Active Comparator|Non-Treatment Group|"Participants undergo 1st open heart surgery (first operation) and the chest will be closed without spraying BAX602. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
32811124|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
32811125|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m^2 and then 250 mg/m^2 IV weekly + irinotecan IV, 180 mg/m^2 once every two weeks, during ≥1 42-day treatment cycle(s).
32811126|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
32811127|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
32811128|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
32811129|NCT04664933|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
32811130|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
32811131|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
32811132|NCT04438187|Other|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
32811133|NCT04438187|Other|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
32811134|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
32811135|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
32811136|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
32811137|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
32811138|NCT01793935|Experimental|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
32811139|NCT01793935|Placebo Comparator|Placebo|Placebo
32811140|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
33100502|NCT04204668|Active Comparator|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
33100503|NCT04204668|Active Comparator|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
33100504|NCT00529490|Experimental|HL|Hypertonic lactate group
33100505|NCT00529490|Active Comparator|RL|Ringer's lactate
33100506|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
32811141|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
33316617|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
32811142|NCT04405011|Experimental|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
32811143|NCT04405011|Active Comparator|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
32811144|NCT04405011|No Intervention|Control|Control group does not receive prophylactic ETV
33100507|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
33100508|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
33316618|NCT05668520||weight stable|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
32811145|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
33100509|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
33100510|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
33100511|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
33100512|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
33100513|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
33100514|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
33100515|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
33100516|NCT02923050|No Intervention|Waitlist control|
33100517|NCT02923050|Experimental|10-week family meals program|
33100518|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
33100519|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
33100520|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
33100521|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
33100522|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
33100523|NCT00529607||2|- 30 patients with stable CAD (control group 1)
32811146|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
32811147|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
32811148|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
32811149|NCT01768117|Experimental|rLP2086|
32811150|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
32811151|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
32811152|NCT01767493|Experimental|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
32811153|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
32811154|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
32811155|NCT04569799|Other|group-1|Following treatment, patients will receive their standard CT or MRI, as routinely ordered in the post-TACE setting. This imaging will be per standard protocol, as directed by hepatology or oncology services, often 2 to 4 months after the treatment. At the same visit, patients will also receive a one-time additional contrast-enhanced ultrasound (CEUS),
32811156|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
32811157|NCT01274182|Experimental|GP2013|
32811158|NCT01274182|Active Comparator|MabThera|
32811159|NCT01274182|Active Comparator|Rituxan|
32811160|NCT04591093|Active Comparator|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
32811161|NCT04591093|Active Comparator|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
32811162|NCT05615649|Experimental|Study procedure|This single-arm, repeated-measures study includes study visits at baseline, surgery, device activation, and at 1, 3, 6, and 12 months post-activation.
32811163|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
32899949|NCT00301028|Experimental|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m^2 intravenous (IV), and 250 mg/m^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m^2 for 6 courses.
33100524|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
33100525|NCT02922972|Experimental|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
33100526|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
33100527|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
33316619|NCT05668520||weight loss|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
33316620|NCT01184534||Questionnaires + Video|
33316621|NCT01184534||Questionnaires|
33316622|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
33316623|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
32811164|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
32811165|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
33316624|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
32811166|NCT03582735|No Intervention|Control|No intervention according to current practice.
32811167|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
32811168|NCT01835899|Experimental|Placebo to BI 1015550|placebo
32811169|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
33316625|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
32811170|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
32811171|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
32811172|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
32811173|NCT05701449||Patients applying a prediction model for postoperative pulmonary complications|
32811174|NCT05701449||Patients non-applying a prediction model for postoperative pulmonary complications|
32811175|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
32811176|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
32811177|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
32811178|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
32811179|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
32811180|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
32811181|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
32811182|NCT01766401|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
32811183|NCT01766401|Experimental|Vilazadone|Vilazadone tablets, oral administration
32811184|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
32811185|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
32811186|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
32811187|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
32811188|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
32899950|NCT05404230|Active Comparator|Fish oil|"4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day.~4 capsules per day for 8 months"
33316626|NCT05275556|No Intervention|Colonoscopy (Standard of Care)|The control arm is colonoscopy with High Definition White Light Endoscopy (HD-WLE) per standard of care.
33100528|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
33316627|NCT05275556|Experimental|CADe Device|The intervention arm is colonoscopy with HD-WLE per standard of care plus the CADe Device.
33316628|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
33100529|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
33316629|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
33316630|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
32811189|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
32811190|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
32811191|NCT01272934|Placebo Comparator|Placebo|
32811192|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
32811193|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
32811194|NCT01279252|Experimental|Antibiotic regimen|
32811195|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
32811196|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
32811197|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
32811198|NCT01279330|Experimental|Co-signed Letter|
32811199|NCT05701293||LEAD patients undergoing endovascular treatment with implantation of Renzan stent|
32811200|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
32811201|NCT00739336|No Intervention|A, 2|Wait-List Control
32811202|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
32811203|NCT04385836|Active Comparator|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
32811204|NCT04385836|Placebo Comparator|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
32811205|NCT05701215|Experimental|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months after stop of TKI
32811206|NCT04385524|Other|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
32811207|NCT03154905||Control|Healthy controls
32811208|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
32811209|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
32811210|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
32811211|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
32811212|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
32811213|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
32811214|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
32811215|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
33100530|NCT04689321||Phase 1|Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
33100531|NCT04689321||Phase 3|Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
33100532|NCT04689555|Experimental|Novel method without manual compression|
33100533|NCT04689555|Active Comparator|Standard method with manual compression|
33100534|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
33100535|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
32811216|NCT05610111|Active Comparator|CLC, then CLC+BAM, then CLC+ABC|Participants will be using closed loop control (CLC) for 2 weeks. Participants will then use closed loop control (CLC) with behavioral adaption module (BAM) for 4 weeks, followed by closed loop control (CLC) adaptive biobehavioral control (ABC) for 16 weeks.
32811217|NCT05610111|Active Comparator|CLC+ABC, then CLC+BAM, then CLC|Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
32811218|NCT04405713|Active Comparator|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
32811219|NCT04405713|Active Comparator|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
32811220|NCT04405713|Active Comparator|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
32811221|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
32811222|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
32811223|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
32811224|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
32811225|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
32811226|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
32811227|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
32811228|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
32899951|NCT05404230|Placebo Comparator|Corn oil|"4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day.~4 capsules per day for 8 months.~Corn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine."
32899952|NCT00301418|Experimental|Tarceva (Erlotinib)|
32899953|NCT05414994||Cohort A|normal eyes with no ocular disease
33100536|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
33100537|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
33100538|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
33100539|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
33100540|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
33100541|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
33100542|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
33100543|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
33100544|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
33100545|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
33100546|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
33100547|NCT02944292|Experimental|All enrolled patients|"Study population:~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
33100548|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
32811229|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
33100549|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
33100550|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
33100551|NCT00529919|Active Comparator|1|MCT oil consumption
33100552|NCT00529919|Placebo Comparator|2|Olive oil consumption
33100553|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
33100554|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
33100555|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
32811230|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
32811231|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
32811232|NCT01998893|Experimental|MabThera/Rituxan|
32811233|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
33100556|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
33100557|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
33102518|NCT05467631|Active Comparator|Plain Tea Tree Oil Control|Topical application of 20% tea tree oil in almond oil base as a carrier twice daily for 2 weeks.
33102519|NCT05467631|Experimental|Verum|Therapeutic mixture applied topically twice daily for two weeks
32899954|NCT05414994||Cohort B|primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months
32811234|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
32811235|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
32811236|NCT04664621|Experimental|HepQuant Testing|
32811237|NCT04176497|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
32811238|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
32811239|NCT01998737||Women under osteoporosis suspicion|
32811240|NCT01998737||Healthy women|
32811241|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
32811242|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
32811243|NCT05703087|No Intervention|Standard information video before primary total knee arthroplasty|Information video (about procedure, complications, rehabilitation) shown to the participants before TKA in the OLVG.
32811244|NCT05703087|Experimental|Positive cueing in the information video before a primary total knee arthroplasty|"The information video was adapted from the existing standard information video used in OLVG. The concept of positive cueing was applied to the standard video by an expert team including a psychiatrist and clinical psychologist. Illustrations which were incomprehensible or with negative associations were removed.~Four rules were followed to use positive cueing:~make patients aware that they are able to influence their own recovery process,~be descriptive in explanations; objectively describe the performed procedure, name equivalent, not negatively charged feelings,~explain why specific steps and actions during the procedure are performed, so the patients understand what is going to happen,~do not use medical langue, but use accessible, understandable language instead."
32811245|NCT01791517|Other|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
32811246|NCT01791517|Other|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
32811247|NCT01791517|Other|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
32811248|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
32811249|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
32811250|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
32811251|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
32811252|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
32811253|NCT05601453||redo-TAVI patients|Patients with severe aortic stenosis (sAS) treated with TAVI developing SVD and thus an indication for redo-TAVI procedure
32811254|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
32811255|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
32811256|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
32811257|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
32811258|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
32811259|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
32811260|NCT01983293|Experimental|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
32811261|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
32811262|NCT05701059||Semi-Constrained Nuvasive Simplify|This group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core.
32811263|NCT05701059||Unconstrained Biomet Zimmer Mobi-C|This group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design.
32811264|NCT04765293|Experimental|Gravity group|"GRAVITY® system exercise is conducted on a machine. The tasks were non-weight bearing, and the only external load was the body mass of the trainee. The degree of unloading (the level of exercise) was chosen depending on the patient's body mass, their current health and the difficulty of the exercise. The machine allowed for exercising any chosen muscle group at chosen setting of the bench, platform and ropes. GRAVITY® system exercise aimed at general posture improvement and at strengthening the desired movement path, along with strengthening the deep spinal and abdominal muscles.~GRAVITY therapy group had therapy twice a week for 4 weeks for 40 minutes that made 2x40 minx 4 weeks=320 minutes."
32811265|NCT04765293|Active Comparator|Control group|Control group had standard, two weeks ambulant every day physical therapy sessions ( laser therapy, cryotherapy, magnetotherpy, TENS and interference currents), 5 times a week 30 min, that is 10 sessions 30 min x10=300 min.
32811266|NCT05576337|Experimental|Strict vegetarians|Strict vegetarians women
32811267|NCT05576337|Experimental|non vegetarians|Non vegetarians women
32811268|NCT05703009|Experimental|Treatment|Subjects will be randomized to take active treatment, sacrosidase, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
32811269|NCT05703009|Placebo Comparator|Placebo|Subjects will be randomized to take placebo treatment, sacrosidase placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
32811275|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
32811276|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
32811277|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
32811278|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
32811279|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
32811280|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
32811281|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
32811282|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
32811283|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
32811284|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
32811285|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
32811286|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
32811287|NCT03013491|Experimental|CX-072|Monotherapy CX-072
32811288|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
32811289|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
32811290|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
32811291|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
32811292|NCT01272232|Experimental|Lira 3.0 mg|
32811293|NCT01272232|Experimental|Lira 1.8 mg|
32811294|NCT01272232|Experimental|Placebo|
32811295|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
32811296|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
32811297|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
32811298|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
32811299|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
32811300|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
32811301|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
32811302|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
32811303|NCT01670643||Video camera magnifier|
32811304|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
32811305|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
32811306|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
32811307|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
32811308|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
32811309|NCT03157245||participant|
32811310|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
32811311|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
32811312|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
32811313|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
32811314|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
32811315|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
32811316|NCT00739960|Other|Abatacept|
32811317|NCT05537181|Experimental|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
32811318|NCT05522751|Experimental|AUD DBS|This is a single arm study. Participants will undergo baseline medical and psychiatric assessments, cognitive and behavioral testing, and positron emission tomography (PET) imaging. One to two weeks later, participants will undergo neurosurgical implantation of DBS electrodes in the limbic pallidum and a neurostimulator. Four weeks after DBS system implantation, the DBS system will be turned ON and the stimulation parameters optimized. Participants will be followed biweekly then monthly for repeat comprehensive assessments.
32811319|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
32811320|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
32811321|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
32811322|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
32811323|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
32811324|NCT01274806|No Intervention|Usual care|
32811325|NCT01274806|Experimental|Physical therapy|
32811326|NCT05480943||Hospitalized non-alcoholic veterans|Any veteran with full admission to the VA Sierra Nevada Healthcare System Hospital.
32811327|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
32811328|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
32811329|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
32811330|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
32811331|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
32811332|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
32811333|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
32811334|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
32811335|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
32811336|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
32811337|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
32811338|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
32811339|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
32811340|NCT01271920|Experimental|AUY922 + Trastuzumab|
32811341|NCT05479149|Experimental|Experimental: Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
32811342|NCT05479149|Active Comparator|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
32811343|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
32811344|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
32811345|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
32811346|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
32811347|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
32811348|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
32811349|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
32811350|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
32811351|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
32811352|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
32811353|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
32811354|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
32811355|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
32811356|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
32811357|NCT04539483|Experimental|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
32811358|NCT04539483|Placebo Comparator|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
32811359|NCT00746122|Other|Open repair|Immediate Open Surgery
32811360|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
32811361|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
32811362|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
32811363|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
32811364|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
32811365|NCT03153267|Active Comparator|EM-7 days doxycycline|
32811366|NCT03153267|Active Comparator|EM-14 days doxycycline|
32811367|NCT03153267|Placebo Comparator|Controls|
32811368|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
32811369|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
32811370|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
32811371|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
32811372|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
32811373|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
32811374|NCT05409027|Experimental|Single Arm|"Each subject will receive between 1 to 15 mg SPI-62 QD PO for up to 14 days.~Each subject will receive up to 12 mcg cortisone-d8 SC during each of one or more study visits."
32811375|NCT01275742|No Intervention|Usual Care|
32811376|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
32811377|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
32811378|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
32811379|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
32811380|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
32811381|NCT03153423|Other|Basic intermittent exotropia patients|
32811382|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
32811383|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
32811384|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
32811385|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
32811386|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
32811387|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
32811388|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
32811389|NCT00752908||Obese patients|Obese patients
32811390|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
32811391|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
32899955|NCT05414994||Cohort C|non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)
32899956|NCT05414994||Cohort D|Dry AMD (age related macular degeneration)
32899957|NCT05414994||Cohort E|Wet AMD
32899958|NCT05414994||Cohort F|diabetic retinopathy
32811392|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
32811393|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
32811394|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
32811395|NCT04669691|Experimental|Lowest dose, less-adjuvanted vaccine|Two consecutive intramuscular (IM) administrations (Day 1 and Day 22)
32811396|NCT04669691|Experimental|Low dose, less-adjuvanted vaccine|Two consecutive (IM) administrations (Day 1 and Day 22)
32811397|NCT04669691|Experimental|Mid dose, less-adjuvanted vaccine|Two consecutive (IM) administrations (Day 1 and Day 22)
32811398|NCT04669691|Experimental|Lowest dose, adjuvanted vaccine|Two consecutive (IM) administrations (Day 1 and Day 22)
32811399|NCT04669691|Experimental|Low dose, adjuvanted vaccine|Two consecutive (IM) administrations (Day 1 and Day 22)
32811400|NCT04669691|Experimental|Mid dose, adjuvanted vaccine|Two consecutive (IM) administrations (Day 1 and Day 22)
32811401|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
32811402|NCT00753142|Active Comparator|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
32811403|NCT00753142|Active Comparator|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
32811404|NCT00753142|Active Comparator|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
32811405|NCT00762424|Active Comparator|Tamsulosin|
32811406|NCT00762424|Placebo Comparator|Placebo|
32811407|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
32811408|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
32811409|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
32811410|NCT01279876|Active Comparator|Melatonin|
32811411|NCT01279876|Placebo Comparator|Placebo|
32811412|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
32811413|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
32811414|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
32811415|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
32811416|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
32811417|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
32811418|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
32811419|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
32811420|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
32811421|NCT04276948|Experimental|Active1|312 mg dose of active
32811422|NCT04276948|Experimental|Active2|812 mg dose of active
32811423|NCT04276948|Placebo Comparator|Placebo|placebo
32811424|NCT01279954|Experimental|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
32811425|NCT01279954|Experimental|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
32811426|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
32811427|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
32811428|NCT04278118|Experimental|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
32811429|NCT04278118|Experimental|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
32811430|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
32811431|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
32811432|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
32811433|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
32899959|NCT05414994||Cohort G|maculopathy
33100558|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
32738190|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
32738191|NCT03228511|Experimental|Formerly Arm Label|
32738192|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
32738193|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
32738194|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
32738195|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
32738196|NCT05021523|Experimental|HEAT group|Participants are doing passive and active heat exposures
32738197|NCT05021523|Sham Comparator|CON group|Participants are doing sham altitude exposures
32738198|NCT03239821|Sham Comparator|Placebo - deflated balloon|
32738199|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
32738200|NCT03239821|Active Comparator|Codeine - delfated balloon|
32738201|NCT03239821|Active Comparator|Codeine - inflated balloon|
32811434|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
33102520|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
32738202|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
32738203|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
32738204|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
32738205|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
32738206|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
32738207|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
32738208|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
32738209|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
32738210|NCT05021367|Experimental|TQB3823 tablets|Subjects receive TQB3823 in the first cycle for a total of 28 days , a single dose on Day 1. Day 2 to Day 7 are the elution period, and the continuous doses are from Day 8 to Day 21. From the second cycle, continuous treatment for 28 days is as a treatment cycle.
32738211|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
32738212|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
32738213|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
32738214|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
32738215|NCT05463653|Experimental|Experimental telemedicine|Patient's rehabilitation and compliance with the standard exercices will be guided and monitored through an ad hoc device developed specifically for this trial.
32738216|NCT05463653|Active Comparator|Control|Patient's rehabilitation and compliance with the standard exercices will be monitored in the usual manner, at the monthly visits to the physical therapy clinic
32738217|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
32738218|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
32738219|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
32738220|NCT04493879|Experimental|Bioptron Light Therapy (BLT) group|Received Bioptron Light Therapy (BLT) ten minutes every day for one month plus the routine medical treatment of oral mucositis(Analgesics, anti-inflammatory medication and antimicrobial therapy for any new mouth infections
32738221|NCT04493879|Experimental|Routine medical care group|Received only the routine medical care of oral mucositis for one month this consists of analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections
32744233|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
33100559|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
33100560|NCT02925624|Experimental|CLOSE guided PVI and insertable cardiac monitor|
33100561|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
33100562|NCT00531167|Experimental|A|combination therapy
33100563|NCT00531167|Active Comparator|B|entecavir
33100564|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
33100565|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
33100566|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
33100567|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
33100568|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
33100569|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
33100570|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
33100571|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
33100572|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
32811435|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
32811436|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
32811437|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
32811438|NCT00160732|Experimental|Transplant|
32811439|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
32811440|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
32811441|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
32811442|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
32811443|NCT01996241|Experimental|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
32811444|NCT01996241|No Intervention|Control Village Clusters|No multi-level, structural and norms-based intervention
32811445|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
32811446|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
32811447|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
32811448|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
32899960|NCT05414838|Experimental|Curcumin, Omega-3 and Vitamin-D (COD)|
33100573|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
33102521|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
33102522|NCT00532337|Placebo Comparator|P|
33102523|NCT00532337|Experimental|E1|
32811449|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
33404963|NCT05080582|Experimental|Mother-Scented Simulated Hand|The neonates received the same standard care of the NICU, while they wrapped with a warm Mother-Scented Simulated Hand as follow; simulated hand was scented with mothers' body odor by placing it on the mothers' bare chest or behind the neck for one hour. Then, the MSSH was placed under a radiant warmer for a couple of minutes to reach the mothers' unique warm touch. Inside the incubator, the mechanically ventilated neonates were placed in a side-lying flexed fetal position, where they encircled with the two warm simulated human hand to contain them. Where the palm of one MSSH cupped the neonates' head, and the palm of the other hand cupped the lower part of body and extremities. The neonates were kept in such a position throughout the mentioned invasive procedures, as shown in Figure 2. Neonates' physiological response, comfort, distress, and pain levels were assessed the same way as the first day.
33404964|NCT05080582|Active Comparator|NICU Standard Care|The neonates were provided with standard care, which entailed maintaining a quiet environment with minimal stimulation, uninterrupted periods of sleep, containment. Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture. This position was maintained during the performance of the invasive procedures.
32811450|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
32811451|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
32811452|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
32811453|NCT00248794|Experimental|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
32811454|NCT00248794|Experimental|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
32811455|NCT00248794|Experimental|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
32811456|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
32811457|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
32811458|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
32811459|NCT01995539|Experimental|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
32811460|NCT01835587|Experimental|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
32811461|NCT01736917|Experimental|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.~Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).~Acute emesis prophylaxis:~Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.~Dexamethasone 20mg PO (orally) daily, D1 and 2~Fosaprepitant 150mg IV on day 3~Delayed emesis prophylaxis:~Fosaprepitant 150mg IV on D5~Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8~PRN antiemetics allowed at the discretion of the treating investigator~No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
32899961|NCT00302042|Experimental|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
33100574|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
32811462|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
32811463|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
32811464|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
32811465|NCT04414579|No Intervention|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
32811466|NCT04414579|Active Comparator|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
33100575|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
33100576|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
33100577|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
33100578|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
33316631|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
33316632|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
33100579|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
33100580|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
33100581|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
33100582|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
32811467|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
32811468|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
32899962|NCT00302042|Active Comparator|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
33100583|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
33100584|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
33100585|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
33316633|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
33100586|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
33100587|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
33100588|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
33100589|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
33100590|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
33100591|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
33100592|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
33102524|NCT00532337|Experimental|E2|
33102525|NCT00532337|Experimental|E3|
33102526|NCT00532337|Active Comparator|A|
33316634|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
32811469|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
32811470|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
32811471|NCT04731623|Experimental|ION904|Single ascending dose of ION904 will be administered by SC injection on Day 1.
32811472|NCT04731623|Placebo Comparator|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.
32811473|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
32811474|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
32811475|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
32811476|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
32811477|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
32811478|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
32811479|NCT04659707|Experimental|COVID-19 Survivors|Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
32811480|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
32811481|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
32811482|NCT01967537|Experimental|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
32811483|NCT01967225|Experimental|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
32811484|NCT01967225|Active Comparator|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
32811485|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
32811486|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
32811487|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
32811488|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
32811489|NCT01790503|Experimental|Phase 1b dose escalation - 600mg/day PLX3397 cohort|600mg/day PLX3397, Radiation Therapy, and Temozolomide
32811490|NCT01790503|Experimental|Phase 1b dose escalation - 800mg/day PLX3397|800mg/day PLX3397, Radiation Therapy, and Temozolomide
32811491|NCT01790503|Experimental|Phase 1b dose escalation - 1000 mg/day PLX3397 cohort|1000 mg/day PLX3397, Radiation Therapy, and Temozolomide
32811492|NCT01790503|Experimental|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397 (800mg/day), Radiation therapy, and Temozolomide
32811493|NCT01790113|Active Comparator|Univer™ II|Univers™ II Total Shoulder Replacement
32811494|NCT01790113|Experimental|Eclipse™|Eclipse™ Total Shoulder Replacement
32811495|NCT01789567|Other|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
32811496|NCT01765543|Experimental|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
32899963|NCT05400408|Experimental|Colorectal Cancer|Subjects who were diagnosed as Colorectal Cancer patients by colonoscopy.
32899964|NCT05400408|Experimental|Pancreatic Cancer|Subjects who were diagnosed as Pancreatic Cancer patients by Endoscopic Retrograde Cholangio Pancreatography.
32899965|NCT05400408|Other|Healthy volunteers|Subjects who were found with no Colorectal or Pancreatic malignancies, by either colonoscopy or by Endoscopic Retrograde Cholangio Pancreatography.
33316635|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
32811497|NCT01765153|Experimental|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
32811498|NCT01765153|Experimental|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
32811499|NCT00248170|Experimental|Letrozole|2.5 mg by mouth (p.o.) once daily
32811500|NCT00248170|Active Comparator|Anastrozole|1 mg p.o. once daily
32811501|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
32811502|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
32811503|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
32811504|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
32811505|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
32811506|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
32811507|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
32811508|NCT00246376|Placebo Comparator|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
32811509|NCT00246376|Experimental|2|Diet, exercise, and two placebos
32811510|NCT00246376|Experimental|3|Diet, exercise, Niaspan, and placebo
32811511|NCT00246376|Experimental|4|Diet, exercise, placebo, and Tricor
32811512|NCT00246376|Experimental|5|Diet, exercise, Niaspan, and Tricor
32811513|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
32811514|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
32811515|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
32811516|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
32811517|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
32811518|NCT04385914||COVID positive patients|
32811519|NCT04385914||COVID negative patients|
32811520|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
32811521|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
32811522|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
32811523|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
32811524|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
32811525|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
32811526|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
32811527|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
32811528|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
32811529|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
32954456|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
32954457|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
32954458|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
32954459|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
32954460|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
32954461|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
32954462|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
32954463|NCT00333606|Experimental|Verum acupuncture|Acupuncture of specific acupuncture points
32954464|NCT00333606|Sham Comparator|Sham acupuncture|Acupuncture of non-specific acupuncture points
32954465|NCT04947852|Experimental|Investigation Mask|Bi Level CPAP Mask
32954466|NCT04947852|Active Comparator|Comparator Mask|Bi Level CPAP Mask
32954467|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
32954468|NCT00335478|Experimental|Daptomycin|
32954469|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
32954470|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
32954471|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
32954472|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
32954473|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
32954474|NCT04870164|Experimental|ensovibep dose 1 (infusion)|
32954475|NCT04870164|Experimental|ensovibep dose 2 (infusion)|
32954476|NCT04870164|Experimental|ensovibep dose 3 (infusion)|
32954477|NCT04870164|Placebo Comparator|placebo (infusion)|
32954478|NCT04870164|Experimental|ensovibep dose 4 (IV bolus)|
32954479|NCT04870164|Experimental|ensovibep dose 5 (IV bolus)|
32954480|NCT04870164|Experimental|ensovibep dose 6 (SC injection)|
32954481|NCT04870164|Experimental|ensovibep dose 7 (SC injection)|
32954482|NCT04870164|Experimental|ensovibep dose 8 (SC injection)|
32954483|NCT04870164|Experimental|ensovibep dose 9 (SC injection)|
32954484|NCT04870164|Experimental|ensovibep dose 10 (IM injection)|
32954485|NCT04870164|Experimental|ensovibep dose 11 (IM injection)|
32954486|NCT04870164|Experimental|ensovibep dose 12 (IM injection)|
32954487|NCT04870164|Experimental|ensovibep dose 13 (IM injection)|
32954488|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
32954489|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
32954490|NCT04345926|Experimental|Dose-response|"- Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).~- Patients will be intubated and remifentanil will be decreased to 4 ng/mL.~- Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).~- Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
32954491|NCT03974646|Experimental|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
32954492|NCT03974646|No Intervention|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
32954493|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
32954494|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
32954495|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
32954496|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
32954497|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
32954498|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
32954499|NCT04724304|Experimental|Healthy adults|Healthy adults will have blood flow to the heart evaluated using s Real-Time Myocardial Echocardiography (RTMPE) and magnetic resonance image (MRI) to the heart.
32954500|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
32954501|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
32811530|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
32811531|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
33102527|NCT05341167|Active Comparator|Intervention group:|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
32811532|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
32811533|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
32811534|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
32811535|NCT01764841|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
32811536|NCT01764841|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
32811537|NCT01764841|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
32811538|NCT01764841|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
32811539|NCT03806842|Experimental|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
32811540|NCT00245050|Experimental|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
32811541|NCT00245050|Placebo Comparator|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
32811542|NCT04345588|Active Comparator|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
32811543|NCT04345588|Active Comparator|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
32811544|NCT00778648|Experimental|Juice Plus|
32811545|NCT00778648|Placebo Comparator|Placebo|
32811546|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
32811547|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
32811548|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
32811549|NCT00763360|Active Comparator|Healon|Healon
32811550|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
32811551|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
32811552|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly SCOPP-CW educational modules delivered via WeChat.~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
32811553|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
32811554|NCT00756106|Experimental|Temozolomide and Radiation Therapy|
32811555|NCT00243412|Experimental|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
32811556|NCT00243412|Experimental|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
32811557|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
32811558|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
32811559|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
32811560|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
32811561|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
32811562|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
33100593|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
33100594|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
33100595|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
33100596|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
33316636|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
33316637|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
32811563|NCT03805750|Experimental|CBD/THC|Treatment arm consisting of Tetrahydrocannabinol (5mg/capsule) and Cannabidiol (100mg/capsule).
32811564|NCT03805750|Placebo Comparator|Placebo|Matched placebo capsule with no active ingredients.
32811565|NCT04385446|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
32811566|NCT04385446|No Intervention|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
32811567|NCT03804268|Placebo Comparator|Vehicle|Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
32811568|NCT03804268|Experimental|Pilocarpine HCl Ophthalmic Solution|Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
32811569|NCT00765856|Experimental|Oxymorphone ER|
32811570|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
32811571|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
32811572|NCT00756496|Experimental|1|
32811573|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
32811574|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
32811575|NCT00243022|Experimental|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
32811576|NCT00243022|Active Comparator|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
32811577|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
32811578|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
32811579|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
32811580|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
32811581|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
32899966|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
33100597|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
33100598|NCT02922387|Active Comparator|Behavioral support|behavioral support
33100599|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
32954502|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
32954503|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
32954504|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
32954505|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
32954506|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
32954507|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
32954508|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
32954509|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
32954510|NCT04271592|Experimental|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
32954511|NCT04271592|Placebo Comparator|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
32954512|NCT04271592|Experimental|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
32954513|NCT04271592|Placebo Comparator|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
32954514|NCT04271592|Experimental|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
32954515|NCT04271592|Placebo Comparator|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
32954516|NCT04271592|Experimental|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
32954517|NCT04271592|Placebo Comparator|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
32954518|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
32954519|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
32954520|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
32954521|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
32954522|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
32954523|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
32954524|NCT01791192|Experimental|FTY720|Fingolimod
32954525|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
32954526|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
32954527|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
32954528|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
33316638|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
32954529|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
33100600|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
33100601|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
32811582|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
32811583|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
33100602|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
33100603|NCT04691882|Experimental|Diaphragmatic contraction|
33100604|NCT04691882|Active Comparator|Diaphragmatic relaxation|
33316639|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
33316640|NCT01184768||participants in the 6th tromsø study|
33316641|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
33316642|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
32811584|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
32811585|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
32811586|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
32811587|NCT03800758|Experimental|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
32811588|NCT03800758|Active Comparator|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
32811589|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
32811590|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
32811591|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
32811592|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
32811593|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
32811594|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
32811595|NCT04384666|Experimental|LY03003|LY03003 28 mg
32811596|NCT04384666|Active Comparator|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
32811597|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
32811598|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
32811599|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
32811600|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
32811601|NCT04384588|Experimental|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
32811602|NCT04384588|Experimental|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
33100605|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
33100606|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
33100607|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
33100608|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
33100609|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
33100610|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
33100611|NCT02944253|Experimental|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
33100612|NCT02944253|Experimental|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
33100613|NCT02944253|Experimental|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
33100614|NCT04689126|Experimental|intervention|diagnosis and treatment plan before and after cone beam computed tomography scan
33100615|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
33100616|NCT02925585||Pre/post pelvic floor surgery imaging|
33100617|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
33100618|NCT04015011|Experimental|Low Calorie Diet (LCD) diet intervention|In person or video conference
33100619|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.~3 successive blocks are realized at 1 week interval."
33316643|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
33316644|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
33316645|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
33316646|NCT04922866||elderly patients following hepatectomy|elderly patients (aged ≥65 years) scheduled for any type of liver resection
33316647|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
32811603|NCT04384588|Experimental|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
32811604|NCT04384588|Experimental|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
32811605|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
32811606|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
32811607|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
32811608|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
32811609|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
32811610|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
32811611|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
32811612|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
32811613|NCT04278586|Experimental|Live-Online Mindful Recovery OUD Care Continuum|Live-Online Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed for patients with OUD prescribed buprenorphine to be delivered in a live-online environment. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. The live-online M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then a mindfulness maintenance check-in support group.
32811614|NCT04278586|Active Comparator|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
32811615|NCT04275076|Experimental|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
32811616|NCT04275076|Experimental|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
32811617|NCT03803332|Active Comparator|Exposure Therapy|Participants receive 10 90-minute exposure therapy sessions for PTSD following the treatment procedures as outlined in the standard Prolonged Exposure therapy manual.
32811618|NCT03803332|Active Comparator|Interpersonal Psychotherapy|Participants receive 14 weekly 50-minute Interpersonal Psychotherapy sessions focused on the interpersonal sequelae of trauma in current daily life.
32811619|NCT03809572|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
32811620|NCT03809572|No Intervention|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
32811621|NCT04274218|Experimental|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
32811622|NCT04274218|Experimental|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
32811623|NCT05744284||Sex, age, kind of disease in relation to the organ affected|Sex, age, kind of disease in relation to the organ affected and type of surgical procedure and related incision have been investigated. Patients with diabetes mellitus, coagulation disorders and those submitted to a treatment of steroids and anticoagulant; patients previously operated with scar in the site of the second operations, or with anemia or with active source of infection in any part of the body where excluded from the study.
32811624|NCT04275700|Experimental|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
32811625|NCT05744206|Experimental|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
32811626|NCT04345432|Experimental|Gabapentin|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
32811627|NCT04345432|Placebo Comparator|Placebo|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
32811628|NCT05744128|Other|Single Arm|"Eligible subjects will receive up to two zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 2.0 mCi ± 20% and 3.0 mg API) as an IV infusion or slow bolus injection.~PET/CT imaging is performed 24hrs ± 3hrs post administration. The two scans are performed a minimum 2 weeks apart."
32811629|NCT03809884|Experimental|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
32811630|NCT03809884|Active Comparator|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
32811631|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
32811632|NCT03807076|Placebo Comparator|Placebo|Saline
32811633|NCT05744050|Experimental|Low energy density|The meal served at lunch time to participants will have a low energy density of ~1.1kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
32811634|NCT05744050|Experimental|Medium energy density|The meal served at lunch time to participants will have a low energy density of ~1.7kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
33316648|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
33316649|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
33316650|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for up to 96 weeks.
33316651|NCT01176734|Experimental|active t-VNS|active t-VNS
33316652|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
33316653|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
32811635|NCT05744050|Experimental|High energy density|The meal served at lunch time to participants will have a low energy density of ~3kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
32811636|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
32811637|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
32811638|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
32811639|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
32811640|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
32811641|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
32811642|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
32811643|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
32811644|NCT01736683|Experimental|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
32811645|NCT01736683|Experimental|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
32811646|NCT01736683|Experimental|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
32811647|NCT01736683|Experimental|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
32811648|NCT01736683|Experimental|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
32811649|NCT01736683|Experimental|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
32811650|NCT05743972|Experimental|CEUS-guided core biopsy group|
32811651|NCT05743972|Active Comparator|US-guided core biopsy group|
32811652|NCT01788943||Slow metabolizers|Individuals with an NMR <0.26 will be classified as slow metabolizers.
32811653|NCT01788943||Normal metabolizers|Participants with an NMR >= 0.26 will be classified as normal metabolizers.
32811654|NCT00757822|Experimental|Arm 1|dronabinol
32811655|NCT00757822|Active Comparator|Arm 2|ondansetron
32811656|NCT04561765|Experimental|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
32811657|NCT04561765|Experimental|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
32811658|NCT04561765|No Intervention|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
32811659|NCT01788163|Other|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
32811660|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
32811661|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
32811662|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
32811663|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
32811664|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
32811665|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
32811666|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
32811667|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
32811668|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
32811669|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
32811670|NCT00784030|Other|Healthy Patients|
32811671|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
32811672|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
32811673|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
32811674|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
32811675|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
33404965|NCT05230576||Deep learning training cohort|2/3 of the enrolled patients and their corresponding carotid artery dynamic scan images and expert diagnosis results were randomly selected as the training cohort for deep learning.
33404966|NCT05230576||Deep learning validation cohort|The carotid artery dynamic scan images and expert diagnosis results of the remaining 1/3 patients were used as a validation cohort to evaluate the overall diagnostic accuracy of the deep learning model.
33404967|NCT05077072|Experimental|ARM I (CHAT)|Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.
33404968|NCT05077072|Experimental|ARM II (NFB)|Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.
32811676|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
32811677|NCT01787461|Experimental|Imedeen|Imedeen is the study product
32811678|NCT01787461|Placebo Comparator|Placebo|
32811679|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
32811680|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.~dosage: 6 drops a day for three months period."
32811681|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.~dosage: 6 drops a day for three months period."
32811682|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
32811683|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
32811684|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
32811685|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
32811686|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
32811687|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
32811688|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
32811689|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
32811690|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
32811691|NCT04384432|Experimental|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
33404969|NCT05077072|Active Comparator|ARM III (SOC)|Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.
33404970|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
33404971|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
33404972|NCT05071456|Experimental|Atopic dermatitis patients|
33404973|NCT05071456|Experimental|Patient with oily acne skin|
33404974|NCT05071456|Active Comparator|Control group of patient without facial dermatosis|
33404975|NCT04370002||No Intervention|This is an observational study. There is no active treatment that is examined.
33404976|NCT04353934||Respondents|All adults aged 18 or older who elect to respond to the online survey
33404977|NCT02926950|Experimental|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
33404978|NCT02926950|Placebo Comparator|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
33404979|NCT03410693|Experimental|Rogaratinib|"Rogaratinib treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
33404980|NCT03410693|Active Comparator|Chemotherapy|"Chemotherapy treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
33404981|NCT02039752||Multivessel|from 1995
33404982|NCT05203198|No Intervention|1. No adolescent modules + no parent modules|No adolescent nor parent modules will be offered to the participant.
33404983|NCT05203198|Experimental|2. Adolescent behavioral activation modules only|Adolescent behavioral activation modules only
32811692|NCT04384432|Active Comparator|Routine Physical Therapy|Routine Physical Therapy exercise
32811693|NCT01786993|Experimental|Multi-point pacing arm|MultiPoint Pacing
32811694|NCT01786993|Active Comparator|Biventricular arm|Traditional Biventricular Pacing
32811695|NCT00769600|Active Comparator|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
32811696|NCT00769600|Active Comparator|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
32811697|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
32811698|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
32811699|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
32811700|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
32811701|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
32811702|NCT05743738|Other|Presence of thrombosis|Doppler ultrasound D8, D15, D30, D45, D60 and D90
32811703|NCT05743738|No Intervention|Absence of thrombosis|
32811704|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
32811705|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
32811706|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
32811707|NCT03809260|Experimental|Part 2|Metformin
32811708|NCT01763905|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
32811709|NCT01763905|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
32811710|NCT01763905|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
32811711|NCT01763905|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
32811712|NCT05743504|Experimental|Immunotherapy with CCRT before surgery|Tiragolumab and Atezolizumab with CCRT before surgery
32811713|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
32811714|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
32811715|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
32811716|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
32811717|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
32811718|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
32811719|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
32811720|NCT04730999|Experimental|Single Arm|"Induction phase (6 cycles, 21 days duration): carboplatin, etoposide, bevacizumab and atezolizumab.~Maintenance phase (12 cycles, 21 days duration): bevacizumab and atezolizumab"
32811721|NCT00759772|Active Comparator|Teriparatide|
32811722|NCT00759772|Placebo Comparator|Placebo|
32811723|NCT01763203|Experimental|Care Management+Community Health Worker|Care management
32811724|NCT01763203|Active Comparator|Usual Care|Written materials
32811725|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
32811726|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
32811727|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
32811728|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
32811729|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
32811730|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
32811731|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
32811732|NCT01763047|Active Comparator|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
32811733|NCT01763047|Active Comparator|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
32899967|NCT05414682|Experimental|MIND+SOUL Diet|The MIND+SOUL diet is an adapted brain-healthy soul food diet. Participants follow the diet for 12 weeks.
32899968|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
32899969|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
33100620|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.~3 successive blocks are realized at 1 week interval."
33100621|NCT04013763|Experimental|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
33100622|NCT04013763|Experimental|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
33100623|NCT04013763|Experimental|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
33316654|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
32811734|NCT04384120|Experimental|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
32811735|NCT04384120|Active Comparator|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
33316655|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
33316656|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
33316657|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
33316658|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
32811736|NCT04569097|Experimental|Patient group|lingual strengthening
32811737|NCT04569097|No Intervention|Healthy controls|Healthy normal swallow
32811738|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
32811739|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
32811740|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
32811741|NCT01762345|Experimental|pessary device|pessary (disposable intra-vaginal device)
32811742|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
32811743|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
32811744|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
32811745|NCT05743270|Experimental|LA Cohort: RP3 in combination with CCRT followed by nivolumab in Locally Advanced SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
32811746|NCT05743270|Active Comparator|LA Cohort: concurrent chemoradiation therapy in Patients With Locoregionally Advanced SCCHN|standard-of-care CCRT (defined as intensity-modulated radiation therapy [IMRT] and cisplatin
32811747|NCT05743270|Experimental|R/M Cohort:RP3 in combination with carboplatin, paclitaxel and then nivolumab in R/M SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
32811748|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
32811749|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.~fractional flow reserve and SPECT detection before and after intervention."
32811750|NCT01761565|Experimental|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
32811751|NCT04385056|Experimental|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
32811752|NCT04385056|Experimental|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
32811753|NCT04385056|Experimental|High Dose MSCTC-0010|Participants will receive high-dose cell administration
32811754|NCT04576741|Experimental|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
33100624|NCT04013763|Experimental|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
33100625|NCT04013763|No Intervention|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
33100626|NCT04013763|No Intervention|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
33316659|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
32811755|NCT04576741|Experimental|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
32811756|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
32811757|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
32811758|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
32811759|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
32811760|NCT04384900|Experimental|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
32811761|NCT04384900|Active Comparator|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) < 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
32811762|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
32811763|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
32811764|NCT05743192||Before group|Group of patients with a positive urine culture for Enterococcus faecalis before the procedure consisting of systematically performing an antibiotic susceptibility test.
32811765|NCT05743192||After group|Group of patients with a positive urine culture for Enterococcus faecalis after the procedure consisting of systematically performing an antibiotic susceptibility test.
32811766|NCT05743114|Experimental|Sleep Onset Latency Crossover|Arm 1 is a crossover arm in which participants receive one block of active stimulation (experimental) and a second block in which the device is worn and actively recording, but not delivering phase-locked auditory stimulation (sham). The order of blocks is randomized for each participant.
32811767|NCT05743114|Experimental|Wake After Sleep Onset|This arm tests active stimulation during sleep onset, as well as additional stimulation if participants wake up during the night. One of 4 possible conditions are randomized for each stimulation even (within subject and within nights): Stimulation locked to alpha peak phase, stimulation locked to alpha trough phase, white noise (active sham), and no sound (control).
32811768|NCT01786603|Experimental|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
32811769|NCT01786603|Placebo Comparator|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
32811770|NCT00786916|Placebo Comparator|Group A|Saline
32811771|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
32811772|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
32811773|NCT03802708|Other|control|control
32811774|NCT04414267|Experimental|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
32811775|NCT04414267|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
32811776|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
32811777|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
32811778|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
32811779|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
32811780|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
32811781|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
32811782|NCT01735279|Placebo Comparator|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
32811783|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
32811784|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
32811785|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
32811786|NCT04663061|Experimental|High intensity medical weight loss (HIWL)|Participants randomized to the HIWL treatment group will be placed on a meal replacement-based weight loss protocol. Participants will consume a minimum of 80 grams of protein daily in 4-5 servings of meal replacement. Participants will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-24, caloric prescriptions will be between 1100 to 1600 calories a day, using a combination of meal replacements and food, for continued weight loss. Beyond week 25, caloric intake will be individually tailored to achieve continued gradual weight loss or maintenance of body weight based on individual weight loss goals. We will recommend continued use of at least 1 serving of meal replacement per day for maintenance of weight loss.
32899970|NCT05414604||PV group|Patients who had a spine CT
32899971|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
32899972|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
32811787|NCT04663061|Active Comparator|Diabetes self-management education (DSME)|"The DSME intervention will be administered and delivered at the Wake Forest Baptist Health Diabetes Center, located next to the Weight Management Center, by a team of certified diabetes educators, nurses, and nutritionists in group and individual settings.~The diabetes education program is accredited by the American Diabetes Association in recognition of meeting national standards for diabetes self-management education. The goal of the program is to provide participants with information to make informed decisions about how to best integrate diabetes management strategies into their daily lives. Assessment, planning, implementation, and evaluation are the basic components of the diabetes education process."
32811788|NCT04663061|Experimental|High intensity medical weight loss (HIWL) plus continuous glucose monitoring (CGM)|Participants randomized to the HIWL + CGM treatment group will be placed on a meal replacement-based weight loss protocol as described in the HIWL arm. In addition, the participants in this arm will receive a supply of continuous glucose monitors to use throughout the trial. The CGM we provide will give the patient instant feedback on blood glucose levels and be readable using a mobile phone device or an associated CGM reader. The data from the CGM will be integrated into the Carium app and used to help guide the patient's actions based on defined care pathways.
32811789|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
33316660|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
33316661|NCT05268224||Dense Breast|Women mammographically categorized as having either heterogeneously dense or extremely dense breast tissue.
32811790|NCT01759381|No Intervention|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
32811791|NCT01759381|Experimental|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
32811792|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
33316662|NCT01176812||Dermal Fillers|Facial Wasting
32811793|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
33316663|NCT03856892|Experimental|Active intervention|Intensive breath-based Hatha yoga program (more breath, more hours of practice)
33316664|NCT03856892|Active Comparator|Active Control|Less intensive practice on body (not breath) based yoga practices
32811794|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
32811795|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
32811796|NCT04662671|Experimental|RD-X19 Device|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
32811797|NCT04662671|Sham Comparator|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
32811798|NCT01758523|Experimental|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
32811799|NCT01758523|Placebo Comparator|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
32811800|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
32811801|NCT00773422|Experimental|varenicline|varenicline 2mg
32811802|NCT00773422|Placebo Comparator|placebo|placebo control
32811803|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
32811804|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
32811805|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
32811806|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
32811807|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
32811808|NCT01757821|Experimental|6-Hz Priming|real 6-Hz primed low-frequency rTMS
32811809|NCT01757821|Sham Comparator|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
32811810|NCT01757821|Active Comparator|Real 1-Hz rTMS only|real 1-Hz rTMS only
32811811|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
32811812|NCT00774202|Active Comparator|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
32811813|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
32811814|NCT01735201|Experimental|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
32811815|NCT01735201|Experimental|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
32811816|NCT01735201|Experimental|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
32811817|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
32811818|NCT01735201|Experimental|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
32811819|NCT01735201|Experimental|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
32811820|NCT01735201|Experimental|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
32811821|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
32811822|NCT05742880|No Intervention|Without Facemask|
32811823|NCT05742880|Active Comparator|Wearing a Facemask|
32811824|NCT05742880|Active Comparator|Wearing a FFP2-Mask|
32811825|NCT03808324|Experimental|Heart transplant recipients|
32811826|NCT01734811|Placebo Comparator|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
32811827|NCT01734811|Experimental|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
32811828|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
32811829|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
32811830|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
32811831|NCT03802162|Experimental|CKD-355A|
32811832|NCT03802162|Experimental|CKD-355B|
32811833|NCT03802162|Active Comparator|D797, D324|
32811834|NCT01757275|Experimental|Esomeprazole|
32811835|NCT01757275|Active Comparator|Cimetidine|
32811836|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
32811837|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
32811838|NCT01757197|Experimental|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
33404984|NCT05203198|Experimental|3. Adolescent cognitive-behavioral therapy modules only|Adolescent cognitive-behavioral therapy modules only
32811839|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
32811840|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
32811841|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
32811842|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
32811843|NCT01784965|Placebo Comparator|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
32811844|NCT01784965|Active Comparator|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
32811845|NCT05742724|Experimental|THC/CBD|Oral THC 0.1mg/kg and CBD 2.5mg/kg
32811846|NCT01784419|Experimental|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
32811847|NCT01784419|Experimental|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
32811848|NCT03801850|Experimental|observational cohort|
32811849|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
32811850|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
32811851|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
32811852|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
32811853|NCT01784029|Experimental|Low Dose|"VItamin D3 1,000 IU~1 x day, 8 weeks"
32811854|NCT01784029|Experimental|Weekly High Dose|"Vitamin D3 50,000 IU~1x week, 8 weeks"
32811855|NCT01784029|Experimental|Daily High Dose|"Vitamin D3 5,000 IU~1x day, 8 weeks"
32811856|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
32811857|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
32811858|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
32811859|NCT05742646|Active Comparator|MATADORS app basic information|
32811860|NCT05742646|Experimental|MATADORS app to include basic information and expanded educational features|
32811861|NCT01783483|Active Comparator|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
32811862|NCT01783483|Experimental|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
32811863|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
32811864|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
32811865|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
32811866|NCT05742568|Experimental|High-dose dual therapy|Esomeprazole Enteric Tablets 40mg, 3 times/day; Amoxicillin Capsules 1000mg, 3 times/day.The course of all drugs is two weeks.
32811867|NCT05742568|Active Comparator|Bismuth Quadruple Therapy|Esomeprazole Enteric Tablets 40mg, 2 times/day; Amoxicillin Capsules 1000mg, 2 times/day; Clarithromycin Tablets 500mg, 2 times/day; Colloidal Bismuth Tartrate Capsules 220mg, 2 times/day.The course of all drugs is two weeks.
32811868|NCT01607593||sertraline (Zoloft)|
32811869|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
32811870|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
32811871|NCT01755637|Experimental|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
32811872|NCT01755637|Active Comparator|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
32811873|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
33404985|NCT05203198|Experimental|4. Adolescent interpersonal therapy modules only|Adolescent interpersonal therapy modules only
33404986|NCT05203198|Experimental|5. Adolescent behavioral activation modules + cognitive-behavioral therapy modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules
33404987|NCT05203198|Experimental|6. Adolescent behavioral activation modules + interpersonal therapy modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules
33404988|NCT05203198|Experimental|7. Adolescent cognitive-behavioral therapy modules + interpersonal therapy modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
33404989|NCT05203198|Experimental|8. Full Adolescent program only|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
33404990|NCT05203198|Experimental|9. Parent program modules only|Parent program modules
32811874|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
32811875|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
32811876|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
32811877|NCT04567693|Experimental|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
32811878|NCT04567693|Experimental|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
32811879|NCT04567693|No Intervention|Usual Care|Do not advance to spaced-out appointments during study period
32811880|NCT05742412|Experimental|Intervention Group|"Intervention group: EMS dispatcher using video-based communication in emergency calls.~In the intervention arm, the EMS Dispatchers are requested to use video in all emergency calls during the 4-month study period."
32811881|NCT05742412|Active Comparator|Control Group|"Control group: EMS dispatcher using telephone-only (audio-only) communication in emergency calls.~In the control arm, the EMS Dispatchers continue using standard telephone communication (usual care)."
33100627|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
33100628|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
33100629|NCT02917785|No Intervention|Control|
33100630|NCT04000854|Active Comparator|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
33100631|NCT04000854|Active Comparator|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
32811882|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
32811883|NCT05620342|Experimental|iC9.GD2.CAR.IL-15 T Therapy|Experimental: Single Arm Subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy will receive iC9.GD2.CAR.IL-15 T cells were manufactured from their collected blood sample.
32811884|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
33100632|NCT03994614|Experimental|the TEAS intervention group|Patients in this group will be given TEAS treatment for 12 weeks prior to COS.
33100633|NCT03994614|No Intervention|No intervention group|Patients in this group will not be given any interventions for 12 weeks prior to COS.
33100634|NCT04689165|Experimental|Experimental Vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
33100635|NCT04689165|Active Comparator|Active Comparator Vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
33100636|NCT04689087|Experimental|Second line conventional treatment|
33316665|NCT03856892|No Intervention|Passive control|No intervention is followed other than daily duties while in the same environment as both of the active groups.
33100637|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
32811885|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
33100638|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
33100639|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with hypothyroidism:~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die~Dosage in adults:~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
33100640|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with acquired hypothyroidism:~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area~Dosage in adults:~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
33404991|NCT05203198|Experimental|10. Adolescent behavioral activation modules + parent program modules|Adolescent behavioral activation modules Parent program modules
33404992|NCT05203198|Experimental|11. Adolescent cognitive-behavioral therapy modules + parent program modules|Adolescent cognitive-behavioral therapy modules Parent program modules
32811888|NCT05741398|Experimental|Demaod VR system tratment|Non-invasive light pulse generated by a non-contacting device for treating the symptoms of dry eyes and MDG.
32811889|NCT05739838|Experimental|Periodontally compromised patients subjected to low level laser therapy|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment subjected to low-level laser of 940 nm will be applied at day one after start of treatment , weekly during the first month, then monthly.
32811890|NCT05739838|No Intervention|Periodontally compromised patients|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment.
32811891|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
32811892|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
32811893|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
32811894|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
32811895|NCT05596708|Experimental|Telitacicept treated group|
33100641|NCT02917824|Experimental|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
33100642|NCT02917824|Active Comparator|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
33100643|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
33100644|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
33316666|NCT03855254|Experimental|Positive communication|
33316667|NCT03855254|No Intervention|Control (neutral communication)|
33316668|NCT03855254|Experimental|Negative communication|
33316669|NCT01291082||Breast cancer patients|Breast cancer patients
33404993|NCT05203198|Experimental|12. Adolescent interpersonal therapy modules + parent program modules|Adolescent interpersonal therapy modules Parent Program
33100645|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
33100646|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
33100647|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
33100648|NCT03950817|Active Comparator|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
33316670|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
32811896|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
32811897|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
32811898|NCT04383964|Experimental|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.~The prepared disc is to be wide enough to fit the upper portion of the distrcator.~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
32811899|NCT05593978|Experimental|Culinary Medicine|Those in this group will receive culinary medicine, which includes cooking videos and educational videos to help educate on ways to increase protein intake through lean ground beef.
32811900|NCT05593978|Other|Control|This group will only receive recipes containing lean ground beef to help increase protein intake.
32811901|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
32811902|NCT01755091|Placebo Comparator|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
32811903|NCT01755091|Experimental|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
32811904|NCT01755091|Experimental|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
32811905|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
33102528|NCT05341167|Other|Control group:|Hypotensive episodes will be treated with vasoactive agents and fluids according to the standard clinical practice. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
33316671|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
33316672|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
33316673|NCT01185314|Other|1|EGFR mutation testing
33316674|NCT01182584||Graves' disease|
33316675|NCT01182584||Healthy volunteers|
33316676|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
32811906|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
32811907|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
32811908|NCT04567225|Experimental|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
32811909|NCT04567225|Active Comparator|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
32811910|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
32811911|NCT01754467|Experimental|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
32811912|NCT01753999|Active Comparator|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
32811913|NCT01753999|Active Comparator|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
32811914|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
32811915|NCT05574712|Experimental|Open-Label Treatment Group|Participants will be treated with neoadjuvant therapy for a total of 3 months (12 weeks) prior to prostatectomy. Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan.
32811916|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
32811917|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
32811918|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
33316677|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
33316678|NCT01176890|Experimental|Healthy controls|Healthy control subjects
33316679|NCT03257410|Experimental|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
33100649|NCT03950817|Active Comparator|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
33100650|NCT03950817|Active Comparator|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
33100651|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
33100652|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
33316680|NCT03257410|Active Comparator|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
33316681|NCT02524574|Experimental|cardiac Rehabilitation|
33100653|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
33100654|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
33100655|NCT04688892|Active Comparator|Intervention Group|The type of cupping therapy will be dry-cupping with moving-cupping (dynamic cupping therapy). The participants will remain in the supine position on a massage table (Posturarte® Olympic), without inclination. Cupping therapy will be performed with a plastic suction cup (5.08 cm in diameter) (K.S. Choi Corp®) and with a pistol for dosing pumps (K.S. Choi Corp®). Prior to the cupping therapy, a small amount of massage cream (ATL®) will be applied throughout the median nerve pathway in order to facilitate the sliding of the suction cup. The cupping therapy will performed with the suction cup sliding with a slow rhythm, insufflation of the suction cup with two pumps for 5 minutes along the median nerve path.
33404994|NCT05203198|Experimental|13. Adolescent behavioral activation + cognitive-behavioral therapy + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Parent program modules
32811919|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
32811920|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
32811921|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
32811922|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
32811923|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
32811924|NCT05567770|Active Comparator|Cohort 1|
32811925|NCT05567770|Active Comparator|Cohort 2|
32811926|NCT05730166|Experimental|Mechanical stimulation at moderate pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
32811927|NCT05730166|Active Comparator|Mechanical stimulation at mild pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
32811928|NCT05730166|Active Comparator|Painless mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 0/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
32811929|NCT01782859|Placebo Comparator|Placebo|Control group
32811930|NCT01782859|Active Comparator|Prednisone/hydrocortisone|"Steroid group will receive the following:~20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital~100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
32811931|NCT05723536|Experimental|PLAI (Partial Left Atrial Isolation)|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
32811932|NCT05723536|Active Comparator|CA (Catheter Ablation)|Conventional catheter ablation of persistent atrial fibrillation.
32811933|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
32811934|NCT05562778|Experimental|Chatbot|Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.
32811935|NCT05562778|No Intervention|Usual Care|Personal and family cancer history will be collected by the clinician during the subject's visit. Clinicians will evaluate the patient's personal/family history according to National Comprehensive Cancer Network (NCCN) high-risk criteria. For subjects recognized by the clinician as meeting NCCN criteria, the clinician will complete genetic counseling and recommend genetic testing. For subjects interested in genetic testing, the clinician will order genetic testing.
32811936|NCT05718622|Experimental|real EECP|
32811937|NCT05718622|Sham Comparator|sham EECP|
32811938|NCT05718622|No Intervention|Health Control|
33316682|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
33316683|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
33316684|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
33316685|NCT00056160|Experimental|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
32811939|NCT05714254|Active Comparator|MEDI0618|A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)
32811940|NCT05714254|Placebo Comparator|Placebo|Histidine/histidine HCl, sucrose and polysorbate
32811941|NCT05555290|Experimental|Treatment A (PT027) [experimental], then Treatment B (PT007) [active comparator] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10-14 days. At Visit 3, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge.
32811942|NCT05555290|Experimental|Treatment B (PT007) [active comparator], then Treatment A (PT027) [experimental] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10 to 14 days. At Visit 3, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge.
32811943|NCT01782313|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32811944|NCT04575259|Experimental|ANAVEX2-73 Active|Oral capsules
32811945|NCT04574947|Active Comparator|Intravenous lidocaine|
32811946|NCT04574947|Experimental|Topical lidocaine|
32811947|NCT04574947|Placebo Comparator|Placebo|
32811948|NCT00790192|Experimental|Lurasidone 80mg|
33316686|NCT00056160|Experimental|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
33404995|NCT05203198|Experimental|14. Adolescent behavioral activation + interpersonal therapy + parent program modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules Parent program modules
32811949|NCT00790192|Experimental|Lurasidone 160mg|
32811950|NCT00790192|Active Comparator|Quetiapine XR|
32811951|NCT00790192|Placebo Comparator|Placebo|
32811952|NCT01781611|Experimental|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
32811953|NCT01781611|Active Comparator|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
32811954|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
32811955|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
32811956|NCT01781299|Active Comparator|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
33404996|NCT05203198|Experimental|15. Adolescent cognitive-behavioral therapy + interpersonal therapy + parent program modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
32811957|NCT01781299|Active Comparator|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
32811958|NCT03802084|Experimental|vactosertib/imatinib combination|
32811959|NCT01732471|Experimental|Kuvan®|
32811960|NCT00790270|Active Comparator|Cyclobenzaprine|
32811961|NCT00790270|Active Comparator|Ibuprofen|
32811962|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
32811963|NCT01780987|Experimental|Apixaban|
32811964|NCT01780987|Active Comparator|UFH/Warfarin|
32811965|NCT00790738|Experimental|1|liothyronine (T3)
32811966|NCT00790738|Placebo Comparator|2|placebo
32811967|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
32811968|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
32811969|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
32811970|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
32811971|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
32811972|NCT05535478|Other|STRIDE Intervention|Educational intervention for clinicians
32811973|NCT05521984|Experimental|Dapagliflozin + Standard of Care carmustine chemotherapy (Ages 6-10)|"Dapagliflozin will be initiated by mouth once daily at the same time as standard of care carmustine chemotherapy.~Dapagliflozin 5 mg by mouth once daily on days 1-84 (duration of study)~All patients will stop taking dapagliflozin after 12 weeks of treatment, corresponding to 2 cycles of carmustine.~Carmustine chemotherapy dose adjustments will be made per oncologist's judgement."
32899973|NCT05414214||Elderly|Elderly patients who are scheduled for elective surgeries under general anesthesia with endotracheal intubation accomplished using conventional laryngoscopy will be included.
32899974|NCT01898858||HYPOXIA|
32899975|NCT01898858||HYPERCAPNIA|
33404997|NCT05203198|Active Comparator|16. All adolescent + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
32811974|NCT05521984|Experimental|Dapagliflozin + Standard of Care carmustine chemotherapy (Ages 11-21)|"Dapagliflozin will be initiated by mouth once daily at the same time as standard of care carmustine chemotherapy.~Dapagliflozin will be initiated at 5 mg by mouth once caily, days 1-4 (2 weeks)~Dapagliflozin will be escalated to 10 mg by mouth once daily for the remaining 10 weeks~Dose adjustment will need to be approved by endocrinologist Dr. Sprague/or another attending MD diabetologist at SLCH/WUSM on the HRPO-approved study team. This dose is reflective of current clinical practice for diabetes and heart failure.~All patients will stop taking dapagliflozin after 12 weeks of treatment, corresponding to 2 cycles of carmustine.~Carmustine chemotherapy dose adjustments will be made per oncologist's judgment."
32811975|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
32811976|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
32811977|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
32811978|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
32811979|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
32811980|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
32811981|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
32811982|NCT05709184|Experimental|Lyophilized fecal microbiome transfer (Lyo-FMT)|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 5 days (day 1 - initiation of therapy by the clinical team), followed by a loading dose of oral Lyo-FMT capsules on day 6 (15 capsules). On days 7-10, patients will receive 10 Lyo-FMT capsules per day. A total of 55 capsules, derived from ~30-40g of the original material, will be administered throughout 5 days. Prior to each Lyo-FMT administration, patients will be asked to fast for 8 hours. Bowel preparation or proton pump inhibitor use will not be required per protocol. The loading dose will be administered under medical supervision, while further dosing can be administered at the patient's home/institute, after training and guidance
32811983|NCT05709184|Active Comparator|Vancomycin monotherapy|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 10 days (day 1 - initiation of therapy by the clinical team, not from randomization).
32811984|NCT05521126||high risk/ACL repair cohort|The high risk cohort will be subjects who have had an ACL reconstruction procedure 9-24 months prior to enrollment.
32811985|NCT05521126||control group|The control group will be individuals who have not had an ACL reconstruction procedure.
32899976|NCT01898858||HYPOXIA + HYPERCAPNIA|
32899977|NCT05413668|Experimental|RVP-001 group|will receive RVP-001
33100656|NCT04688892|No Intervention|Control Group|The participants will remain at rest in a supine position on a massage table (Posturarte® Olympic) without inclination for 5 minutes.
33100657|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
33100658|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
33100659|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
33100660|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
33100661|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
33100662|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
33100663|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
33100664|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
33100665|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
33100666|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
33100667|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
33100668|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
32899978|NCT05413668|Placebo Comparator|Placebo group|will receive placebo
32899979|NCT01791140||Cohort|
33100669|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
33100670|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
33100671|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
33100672|NCT00531674|Experimental|2|Nutritional supplementation for children
33404998|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
32811986|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
32811987|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
32811988|NCT01753297|Active Comparator|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
32811989|NCT01753297|No Intervention|Active surveillance|Active surveillance after radical prostatectomy (RP)
32811990|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
33100673|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
33100674|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
33316687|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
33100675|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
33100676|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
33100677|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
33100678|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
33316688|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
33316689|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
33316690|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
33316691|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
33316692|NCT01177124|Experimental|MBSR 6 Weeks Program|
33316693|NCT01177124|No Intervention|Usual Care (UC)|
33316694|NCT00061932|Experimental|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
33100679|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
33100680|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
33100681|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
32811991|NCT03831100|Experimental|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
32899980|NCT05014230|Other|Treatment as Usual|Opioid medication, as prescribed in routine care
33100682|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
33100683|NCT00531713|No Intervention|1|Usual T4 dose is given
33100684|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
33100685|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
33100686|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
33100687|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
33316695|NCT00061932|Experimental|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
33316696|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
33316697|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
33316698|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
33316699|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
33316700|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
33316701|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
33316702|NCT01177202|Placebo Comparator|Group G|Saline
33100690|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
33100691|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
33100692|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
33100693|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
33100694|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
33100695|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
33100696|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
33100697|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
33100698|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
33100699|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
33100700|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
33100701|NCT02917707||liver metastasis tissues|liver metastasis tissues
32811992|NCT03831100|Placebo Comparator|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
32811993|NCT05517382|Experimental|supportED group|Participants in this group will engage with the digital game for one session (~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
32811994|NCT05517382|Other|Control group|Participants in this group will engage with a non-health-related game for one session (~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
32811995|NCT05688904|Active Comparator|Imipramine|Topical 4% Imipramine
32811996|NCT05688904|Placebo Comparator|Vehicle|Vehicle
32811997|NCT05681884|Experimental|Group 1|"Subjects will be administered intravitreal faricimab 6 mg every 4 weeks (defined as every 28 days + 7 days and at least 21 days between injections) through week 48. Starting at Week 48, subjects will be treated every 16 weeks (weeks 48, 64 & 80) with an end of study visit at week 96.~Rescue: At any visit after Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
32899981|NCT05014230|Experimental|Open Label Placebo + Treatment as Usual|Opioid medication, as prescribed in routine care + Honest placebos
33100702|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
33100703|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
33100704|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
33100705|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
33100706|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
33100707|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
33100708|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
33100709|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
33100710|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
33100711|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
33100712|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
32899982|NCT00237770|Placebo Comparator|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
32899983|NCT04228484|Placebo Comparator|Placebo|Placebo infusion
33100713|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
33100714|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
33100715|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
33100716|NCT02943239|Experimental|Panel G|REGN2477 (Regimen 7) or placebo
33316703|NCT01177202|Active Comparator|Group H|H1N1
33316704|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
33316705|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
32811998|NCT05681884|Experimental|Group 2|"Subjects are seen and observed every 16 weeks. Starting at Week 48, subjects will be administered intravitreal faricimab 6 mg every 4 weeks from week 48 to week 92, (defined as every 28 days ± 7 days and at least 21 days between injections) with an end of study visit at week 96.~Rescue: At any visit before Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
32811999|NCT04843774||COVID-negative Multiple Sclerosis patients treated with ocrelizumab|
33100717|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
33100718|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
33100719|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)~1 drop b.i.d at 12 hour interval for 12 weeks"
33100720|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo~1 drop b.i.d at 12 hour interval for 12 weeks"
33100721|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
33100722|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
33100723|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
33100724|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
33100725|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
32812000|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
32812001|NCT04818268|Experimental|Auditory Sensory Memory|Auditory Sensory Memory
32812002|NCT04818268|Experimental|Somatosensory Sensory Memory|Somatosensory Sensory Memory
33100726|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
32812003|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback + cTBS to 46v|Adaptation to Altered Auditory Feedback + cTBS to 46v
32812004|NCT04818268|Experimental|Sensory Memory + cTBS to 46v|Sensory Memory + cTBS to 46v
32812005|NCT05680948||Enrolled patients exiting the ISS T-003 EF-UP study|No intervention - No intervention is foreseen in this Observational Study
32812006|NCT04383652||Adult cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age 16 years or older~Have provided informed consent~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
32812007|NCT04383652||Paediatric cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age less than 16 years~Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
32812008|NCT05647798|Active Comparator|Usual care glycemic management arm|Blood glucose will be checked every 2 hours during labor and glucose target will be 75-110 mg/dl
32812009|NCT05647798|Active Comparator|More liberalized glycemic management arm|Blood glucose will be checked every 4 hours during labor and glucose target will be 70-126 mg/dl
33100727|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
33100728|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
33100729|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
33100730|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
33100731|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
33100732|NCT00531791|Active Comparator|1|
33100733|NCT00531791|Experimental|2|
33100734|NCT00531830||1|Preschool children with PDD
33100735|NCT00531830||2|Preschool children without PDD
33100736|NCT03313011||Progressive Apraxia of Speech|
33316706|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
33316707|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
33316708|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
33316709|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
33316710|NCT03280264|Experimental|KHK7580|oral administration
33316711|NCT01094418||IGT group|IGT diagnosed by endocrinologist
33316712|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
32899984|NCT04228484|Active Comparator|GIP receptor antagonization|GIP(3-30)NH2 infusion
32899985|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
33404999|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
33405000|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
33405001|NCT04255810||Women with breast implants and self-reported symptoms of BII|Women undergoing elective breast implant removal without replacement who self-report systemic symptons associated with BII
32899986|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
32899987|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
32899988|NCT02536404|Experimental|Etrasimod 2 mg|
32899989|NCT02536404|Active Comparator|Placebo|
32899990|NCT04271618|Active Comparator|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
32899991|NCT04271618|Experimental|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
32899992|NCT05438160|Other|Schizophrenia treated with digital therapeutics app CT-155|Single group of People with Schizophrenia to be treated with digital therapeutics app CT-155
32899993|NCT05435820|Experimental|BCW group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: continuous wave iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
32899994|NCT05435820|Experimental|BPW-1 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 10 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
32899995|NCT05435820|Experimental|BPW-2 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 40-50 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
32899996|NCT05435820|Sham Comparator|SHAM group|"NIR-TLT dose:~i. Treatment site(s): none ii. Temporal format: none iii. Average radiance: 0 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 0 kJ"
32899997|NCT03954990|Placebo Comparator|Control Arm|Placebo tablets oral, 4 tablets once.
32899998|NCT03954990|Active Comparator|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
32899999|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
32900000|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
32900001|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
32900002|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
32900003|NCT00239642|Experimental|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
32900004|NCT00239642|Experimental|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
32900005|NCT00239642|Experimental|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
32900008|NCT04041830|Experimental|NW (Normal Weight)|20 to 55 years old lean adults
32900009|NCT04041830|Experimental|OBESE|20 to 55 years old adults with obesity
32900010|NCT01351896|Experimental|Arm A (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.
32900011|NCT01351896|Experimental|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity.
32900012|NCT04271462||Study group|Patients undergoing surgery (>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
32900013|NCT05267522|Experimental|Egg Diet|Egg diet, contains 2 eggs per day and limits saturated fat to 6% of energy intake. Cholesterol intake is 600mg/day. Protein and carbohydrate levels will be maintained at 20% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
32900014|NCT05267522|Active Comparator|Egg-free Diet|Egg-free diet, limits cholesterol to 300 mg/day (no eggs) with saturated fat intake at 12% of energy intake. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
32900015|NCT05267522|Active Comparator|Control Diet|Comparator diet based on the average Australian diet, limited to 1 egg per week, with saturated fat intake at 12% of energy intake. Cholesterol intake is 600 mg/day. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
32900016|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
32812010|NCT04795336|Active Comparator|Knee cohort|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
32812011|NCT04795336|Placebo Comparator|Knee cohort control|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
32812012|NCT04795336|Active Comparator|Hip cohort|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
32812013|NCT04795336|Placebo Comparator|Hip cohort control|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
32812014|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
32812015|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
32812016|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
32812017|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
32812018|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
33316713|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
32812020|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
32812021|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
32812022|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
32812023|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
32812024|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
33316714|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
33316715|NCT01089348|Experimental|Lactofiltrum|
32812025|NCT04382716||PANS participants|
32812026|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
32812027|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
32812028|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
32812029|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
32812030|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
32812031|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
32812032|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
33316716|NCT01089348|Active Comparator|Control|
33316717|NCT01291316|Experimental|clobazam|
33316718|NCT01291316|Active Comparator|clonazepam|
33100737|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
32812033|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
32812034|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
32812035|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
32812036|NCT01752985|Experimental|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
32812037|NCT01752985|Experimental|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
32812038|NCT01752985|Placebo Comparator|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
32812039|NCT01751113|Active Comparator|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
32812040|NCT01751113|Active Comparator|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
32812041|NCT01751113|Active Comparator|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
32812042|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
33316719|NCT01291316|Placebo Comparator|tolterodine|
32812043|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
32812044|NCT04761406|Experimental|Phaeosol group|Daily supplementation of Phaeosol softgel capsule (218mg/d), active ingredients of Microphyt. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
32812045|NCT04761406|Placebo Comparator|Placebo group|Daily supplementation of placebo softgel capsule (218mg/d of 100% sunflower oil) with the same appearance and packaging than experimental product. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
32812046|NCT04753294|Experimental|Avance Solo NPWT System|Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.
32812047|NCT04753294|Experimental|Avance Solo Adapt NPWT System|Treatment with negative pressure wound therapy for Pressure ulcers.
32812048|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
32812049|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
32812050|NCT01750879|Active Comparator|Peanut Flour|Oral Immunotherapy with peanut flour.
32812051|NCT01750879|Placebo Comparator|Oat Flour|Oral Immunotherapy with oat flour.
32812052|NCT01719380|Experimental|LGX818 + cetuximab|
32812053|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
32812054|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
32812055|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
32812056|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
32812057|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
32812058|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
32812059|NCT05640778|Experimental|neoadjuvant endocrine therapy|CDK4/6 inhibitor combined with aromatase inhibitor
32812060|NCT05640778|Active Comparator|neoadjuvant chemotherapy|anthracycline-cyclophosphamide followed by taxane
32812061|NCT01743560|Experimental|Everolimus and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
32812062|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
32812063|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
32812064|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
32812065|NCT01743092|Other|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
32812066|NCT01743092|Experimental|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
32812067|NCT05627362|Experimental|Double-Blind Period: Elafibranor 80 mg|Participant will receive two tablets per day (one tablet of elafibranor 80 mg + 1 tablet of placebo matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
32812068|NCT05627362|Experimental|Double-Blind Period: Elafibranor 120 mg|Participant will receive 2 tablets per day (one tablet of elafibranor 120 mg + 1 tablet of placebo matching the 80 mg sized tablet) over the 12 weeks in Double-blind period.
32812069|NCT05627362|Placebo Comparator|Double-Blind Period: Placebo|Participant will receive 2 placebo tablets per day (one matching the 80 mg sized tablet + one matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
32812070|NCT05627362|Experimental|Open-Label Extension Period: Elafibranor 120 mg|Participant will receive one tablet per day (elafibranor 120 mg) over the 96 weeks in Open-Label extension period.
32812071|NCT04383886||Emergency department staff|
32812072|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
32812073|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
32812074|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
32812075|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
32812076|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
32812077|NCT01780831|Experimental|Cohort 1|"HIV-1-exposed full-term infants. Infants received two single doses of RAL: first dose within 48 hours of birth and second dose at 7-10 days of life:~RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life.~RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life."
32812078|NCT01780831|Experimental|Cohort 2|"HIV-1-exposed full-term infants. Daily RAL through 6 weeks of life with first dosing within 48 hours of birth and between 12-60 hours of birth for in utero RAL-naive and RAL-exposed infants, respectively.~Daily RAL through 6 weeks of life: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life."
32812079|NCT05449132|Experimental|RTX-GRT7039|Participants will receive a single intra-articular injection of RTX-GRT7039 during the 52-week double-blind treatment period.
32812080|NCT05449132|Placebo Comparator|Placebo|Participants will receive a single intra-articular injection of placebo matching RTX-GRT7039 during the 52-week double-blind treatment period.
32812081|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
32812082|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
32812083|NCT04572139||Young participants|18-45 years old
32812084|NCT04572139||Old participants|55-80 years old
32812085|NCT04572139||Oldest old participants|over 80 years old
32812086|NCT04571749|Experimental|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
32812087|NCT04382170|Active Comparator|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
33100738|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
33100739|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
33100740|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
33100741|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
32812088|NCT04382170|Experimental|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
32812089|NCT01778023|Experimental|hGH:12months treatment|
32812090|NCT01778023|Active Comparator|hGH: 6 month un-treatment + 6 month treatment|
32812091|NCT04929496|No Intervention|Angiographical guidance only|Standard of care
32812092|NCT04929496|Experimental|Post-PCI FFR guidance|Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement
32812093|NCT04920370|Experimental|ALXN1720 Single Dose SC|Participants will receive a single dose of ALXN1720 SC.
32812094|NCT04920370|Experimental|ALXN1720 Multiple Dose SC|Participants will receive multiple doses of ALXN1720 SC.
32812095|NCT04920370|Experimental|ALXN1720 Single Dose SC + rHuPH20|Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.
33100742|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
33100743|NCT02921217|Placebo Comparator|Control|Control
33100744|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
32812096|NCT04920370|Experimental|ALXN1720 Single Dose IV|Participants will receive a single dose of ALXN1720 IV.
32812097|NCT04920370|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
32812098|NCT01777321|Experimental|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
32812099|NCT01777321|Active Comparator|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
32812100|NCT04718350|Active Comparator|Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia|in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
32812101|NCT04718350|Active Comparator|Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia|in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
32812102|NCT04646902||HTN_OSA|"Patients with hypertension* with obstructive sleep apnea**~* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values >= 140 mmHg and/ or diastolic blood pressure values >= 90 mmHg.~** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:~an apnea-hypopnea index > 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR~an apnea-hypopnea index > 15 events per hour, AND~no significant changes in health, medications, or lifestyle since the polysomnography."
32812103|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
32812104|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
32812105|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
32812106|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
32812107|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
33405002|NCT04255810||Women with breast implants and no self-reported BII|Women undergoing elective breast implant exchange or removal without self-reported symptoms of BII
33405003|NCT04255810||Women undergoing elective mastopexy (breast lift)|Women undergoing an elective mastopexy (breast lift) without breast implants or soft tissue support
32812110|NCT01776541|Experimental|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
32812111|NCT01776541|Experimental|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
32812112|NCT05440708|Experimental|Cohort A: TTI-101 as a Single Agent|"Cohort A Phase 1b: Participants will receive up to 3 dose levels of TTI-101 as a single agent to determine the RP2D.~Cohort A Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 as a single agent."
32812113|NCT05440708|Experimental|Cohort B: TTI-101 in Combination with Pembrolizumab|"Cohort B Phase 1b: Participants will receive up to 3 dose levels of TTI-101 in combination with pembrolizumab to determine the RP2D.~Cohort B Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with pembrolizumab."
32812114|NCT05440708|Experimental|Cohort C: TTI-101 in Combination with Atezolizumab and Bevacizumab|"Cohort C Phase 1b: Participants will receive up to 3 dose levels of TTI-101 in combination with atezolizumab and bevacizumab to determine the RP2D.~Cohort C Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with atezolizumab and bevacizumab."
32812115|NCT05434156|Experimental|Cohort 1 (Part 1)|A single 10-minute intravenous infusion of 0.25 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
32812116|NCT05434156|Experimental|Cohort 2 (Part 1)|A single 10-minute intravenous infusion of 0.75 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
32812117|NCT05434156|Experimental|Cohort 3 (Part 1)|A single 10-minute intravenous infusion of 2.0 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
32812118|NCT05434156|Experimental|Cohort 4 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
32812119|NCT05434156|Experimental|Cohort 5 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
32812120|NCT05434156|Experimental|Cohort 6 (Part 2)|A single TBD minute intravenous infusion of TBD mg ELE-101
32812121|NCT05414500|Experimental|Cohort|Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin
32812122|NCT05408572|Experimental|Single Dose Level 1|6 healthy adults dosed with SON-1010 (Level 1) + 2 healthy adults dosed with Placebo
32812123|NCT05408572|Experimental|Single Dose Level 2|6 healthy adults dosed with SON-1010 (Level 2) + 2 healthy adults dosed with Placebo
32812124|NCT05408572|Experimental|Single Dose Level 3|6 healthy adults dosed with SON-1010 (Level 3) + 2 healthy adults dosed with Placebo
32812125|NCT05408572|Experimental|Single Dose Level 4|6 healthy adults dosed with SON-1010 (Level 4) + 2 healthy adults dosed with Placebo
32812126|NCT05408572|Experimental|Single Dose Level 5|6 healthy adults dosed with SON-1010 (Level 5) + 2 healthy adults dosed with Placebo
32812127|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
32812128|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
32812129|NCT00811798|Experimental|Cervarix Group|
32812130|NCT05394298|Experimental|Short-treatment of any active antibiotic regimen|7 days from the initiation of an appropriate antimicrobial therapy and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
32812131|NCT05394298|Active Comparator|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
32812132|NCT04520776|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
32812133|NCT04520776|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
32812134|NCT01742078|Experimental|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
33405004|NCT04254172||Single cohort|There is no randomization or stratification in this study. All subjects will complete the same study assessments.
33316720|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
33316721|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
33316722|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
33316723|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
32812135|NCT01742078|Experimental|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
32812136|NCT01742078|Experimental|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
32812137|NCT01742078|Experimental|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
32812138|NCT01742078|Experimental|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
32812139|NCT01742078|Experimental|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
32812140|NCT01742078|Placebo Comparator|Placebo|Single dose of placebo administered IV or SC
32812141|NCT01742078|Experimental|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
32812142|NCT01742078|Experimental|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
32812143|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
32812144|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
32812145|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
32812146|NCT01776307|Experimental|BBI608 in combination with cetuximab|
32812147|NCT01776307|Experimental|BBI608 in combination with panitumumab|
32812148|NCT01776307|Experimental|BBI608 in combination with capecitabine|
32812149|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
32812150|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
32812151|NCT01775995|Experimental|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
32812152|NCT01775995|Other|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
32812153|NCT01741532|Experimental|Deferiprone|Deferiprone 80 mg/mL oral solution
32812154|NCT01741532|Placebo Comparator|Placebo|Matching placebo solution
32812155|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
32812156|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
32812157|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
32812158|NCT01717976|No Intervention|Control|usual care
32812159|NCT01740440|Other|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
32812160|NCT01740128|Experimental|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
32812161|NCT01740128|Active Comparator|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
32812162|NCT01976741|Experimental|Rogaratinib total dose escalation|Participants with any type of solid tumor received escalating doses of Rogaratinib oral solution or tablet. The actual dose-escalation cohorts were 100 mg (50 mg BID), 200 mg (100 mg BID), 400 mg (200 mg BID), 800 mg (400 mg BID), 1200 mg (600 mg BID), and 1600 mg (800 mg BID). The participants in the 100 mg and 200 mg dose-escalation cohorts received oral solution and the participants in all the subsequent dose-escalation cohorts received tablet. And as an exception, on C1D-3 in the 200 mg dose-escalation cohort, the participants received tablet instead of oral solution.
32812163|NCT01976741|Experimental|Rogaratinib dose expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.~(1600 mg/day) in 21-days cycles."
32812164|NCT01976741|Experimental|Rogaratinib dose expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
32812165|NCT01976741|Experimental|Rogaratinib dose expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
32812166|NCT01976741|Experimental|Rogaratinib dose expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
32812167|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
32812168|NCT04658927|Experimental|Dexamethosone intracanalicular insert|All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
32812169|NCT04658927|Active Comparator|Group 1: Prednisolone actetate 1%|15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
32812170|NCT04658927|Sham Comparator|Group 2: Sham dilation|"15 fellow eye will undergo ILux and receive punctal sham dilation (control eye)."
32812171|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
33100745|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
33100746|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
33100747|NCT03792282|Active Comparator|Usual care|Participants in this group will receive a general lifestyle counseling.
32812172|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
32812173|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
33316724|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
33316725|NCT00060840|Active Comparator|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
33316726|NCT00060840|Placebo Comparator|Nitrogen|Nitrogen (N2) administered at 40 ppm.
33316727|NCT03854864||Oncologists|French oncologists
33316728|NCT01185860|Active Comparator|A|
33316729|NCT01185860|Experimental|B|
32812174|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
32812175|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
32812176|NCT01775137|Experimental|TBM100|TIP 112 mg/b.i.d
32812177|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
32954530|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
32812178|NCT04661579|Experimental|Group 1: Positive baseline parasitemia, antimalarial treatment, RTS,S/AS01E vaccine|Group 1 subjects have detectable P. falciparum parasitemia at baseline measured by PCR. Anti-malarial treatment with Dihydroartemisinin-piperaquine (DHA/Pip) to clear asexual stage and young gametocyte parasites plus low dose primaquine (LD PQ) to clear mature gametocytes will be given 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of Artemether/lumefantrine (A/L) plus Primaquine will be administered to clear infection. Rationale for administration of A/L is its preferred shortened half-life allowing for evaluation of vaccine efficacy thereby excluding any confounder effect due to prolonged anti-malarial effect of drug.
32812179|NCT04661579|Experimental|Group 2: Negative baseline parasitemia, antimalarial prophylaxis, RTS,S/AS01E vaccine|Group 2 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment. It is proposed to initiate anti-malarial chemoprevention to subjects (prophylaxis effect) with DHA/Pip plus LD PQ 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of A/L plus Primaquine will be administered to clear infection.
32954531|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
32954532|NCT04019418|Placebo Comparator|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
32954533|NCT04019418|Active Comparator|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
32954534|NCT04019418|Active Comparator|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
33100748|NCT02917434|Active Comparator|Patients with PsA and obesity|Very Low Energy Diet (VLED)
33100749|NCT02917434|Other|Patients with obesity|Very Low Energy Diet (VLED)
33316730|NCT01185860|Placebo Comparator|C|
33316731|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
33316732|NCT01089426|Experimental|Omegaven™|
33316733|NCT01290302|Experimental|Luitpold Azacitidine|
33316734|NCT01290302|Active Comparator|Vidaza®|
33316735|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
33316736|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
33316737|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.~intervention is watching informative video."
33316738|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
33316739|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
33316740|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
33316741|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
33316742|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
33316743|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
33316744|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
33100750|NCT05319899|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33100751|NCT05319899|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33100752|NCT05319899|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33100753|NCT05319899|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
32812180|NCT04661579|Experimental|Group 3: Positive baseline parasitemia, RTS,S/AS01E vaccine|Group 3 subjects have detectable P. falciparum parasitemia at baseline measured by PCR but will not receive any anti-malarial medications to clear PCR-positive parasites. This group includes 35 subjects and is included only for immunological assessment and not for vaccine efficacy. Subjects in Group 3 will be administered RTS,S/AS01E three times on a 0, 1, 7 month schedule.
32812181|NCT04661579|Placebo Comparator|Group 4: Positive baseline parasitemia, antimalarial treatment, rabies vaccine|Group 4 subjects have detectable P. falciparum parasitemia at baseline measured by PCR (note any positive result from PCR will be considered positive for purposes of group selection and study endpoints as with Group 1) and will receive DHA/Pip , Primaquine, and A/L on the same schedule as subjects in group 1. Subjects in Group 4 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
33316745|NCT01185938|Active Comparator|Rosuvastatin|
33316746|NCT01185938|No Intervention|Control|
33316747|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
33316748|NCT00059202|Placebo Comparator|Placebo|Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.
33316749|NCT00059202|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid 28-30 mg/kg/day
33316750|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
32812182|NCT04661579|Placebo Comparator|Group 5: Negative baseline parasitemia, antimalarial prophylaxis, rabies vaccine|Group 5 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment and will receive DHA/Pip, Primaquine, and A/L on the same schedule as subjects in group 2. Subjects in Group 5 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
32812183|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
32812184|NCT04175639|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
33316751|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
33316752|NCT01584102|Experimental|Group 1|
33316753|NCT01584102|Active Comparator|Group 2|
33316754|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
33316755|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
33316756|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
33316757|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
32812185|NCT04175639|No Intervention|mHealth-Education (mHealth-Ed)|mHealth-Education (mHealth- Ed): Participating in mHealth will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic with a nurse about cancer care.
33316758|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
33100754|NCT05319899|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33316759|NCT03956472|Experimental|Osteopathic group|LCS Drainage before altitude exposure
33316760|NCT03956472|Experimental|PEEP 10 cmH2O|10 min at rest
33100755|NCT05319899|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
33100756|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
33316761|NCT03956472|Sham Comparator|Control group|Sham PEEP and fake osteopathic protocol
33316762|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
33316763|NCT01182740||glidescope|
33316764|NCT01182740||storz c-mac|
32812186|NCT04807907|Experimental|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
33316765|NCT01182740||mcgrath vl|
33316766|NCT01182740||ambu pentax aws|
33316767|NCT01182740||macintosh laryngoscope|
32812187|NCT04807907|No Intervention|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
33316768|NCT01182740||others|
33316769|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
33405005|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
32812188|NCT04739657||Participants|Subjects whose clinical conditions require stent implantation, and the interventional procedure of which needs the guidance of IVUS imaging.
32812189|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
32812190|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).~Goal: 50 patients"
32812191|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.~Goal: 50 Patients"
32812192|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
32812193|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
32812194|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
32812195|NCT01963403|Placebo Comparator|Placebo|Placebo
32812196|NCT04416503|Experimental|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
32812197|NCT04416503|No Intervention|Control group|Usual follow-up was done to the control group.
32812198|NCT01973387|Experimental|Treatment Arm A|
32812199|NCT01973387|Experimental|Treatment Arm B|
32812200|NCT04657445||home-quarantined patients|home-quarantined patients
32812201|NCT04657445||inhospitalized patients|inhospitalized patients
32812202|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
32812203|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
32812204|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
32812205|NCT04656275|Experimental|BI 1323495 treatment group (part 1)|Part 1
32812206|NCT04656275|Experimental|BI 1323495 treatment group (part 2)|Part 2
32812207|NCT04656275|Placebo Comparator|Placebo group|Placebo
32812208|NCT04174391|Experimental|Mediterranean diet supplemented with extra-virgin olive oil|
32812209|NCT04174391|Active Comparator|Low-fat diet|
32812210|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
32812211|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
32812212|NCT04640974|Experimental|Cingal|
32812213|NCT05356468|Experimental|Structured pain neuroscience education|Pain neuroscience education will be given to both groups. Group A will receive Structured Pain Neuroscience Education along with therapeutic , balance exercises and Postural training.
32900017|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
32812214|NCT05356468|Active Comparator|Conventional treatment|"Group B will receive Pain Neuroscience Education along with therapeutic, balance exercises. The treatment will continue for 6 weeks. Three sessions will be given in a week. Assessment would be done on baseline and at the end of every third week.~Each session will be of 45 minutes. 15min electrotherapy, 15 min conventional treatment, 15 min PNE education."
32812215|NCT04382950|Experimental|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
32812216|NCT04382950|No Intervention|No Intervention: Control group|Standard of care; no placebo
32812217|NCT04382560|Experimental|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
32812218|NCT04382560|No Intervention|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
32812219|NCT04537156|Experimental|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
32812220|NCT04537156|Active Comparator|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
32812221|NCT01961609|Experimental|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
32812222|NCT01961609|Experimental|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
32812223|NCT04468672|Active Comparator|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
32812224|NCT04468672|Active Comparator|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
32812225|NCT04387162|Experimental|Immediate|Participants will enter treatment after one week baseline
32812226|NCT04387162|Experimental|Delayed|Participants will enter treatment after two week baseline
32812227|NCT04267978|Experimental|glioblastoma|
32812228|NCT04267978|Experimental|lower-grade glioma|
32812229|NCT04267198|Active Comparator|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
32812230|NCT04267198|Active Comparator|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
32812231|NCT03991156|Experimental|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|
32812232|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
32812233|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
32812234|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
32812235|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
32812236|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
32812237|NCT04383418|Experimental|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
32812238|NCT04383418|Experimental|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
32812239|NCT04383418|Placebo Comparator|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
32812240|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
32812241|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
32812242|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
32812243|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
32812244|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
32812245|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
32812246|NCT05287204||AKI-RRT|Adults admitted to the ICU with AKI requiring CRRT with study enrollment within 48 hours of CRRT initiation.
32812247|NCT05287204||Historical Controls|The controls for the ICU phase will be 41 critically ill adults without AKI-RRT in whom similar measurements of muscle size, quality, and function were collected in a recent prior study [PubMed ID: 33148301]. The controls for the recovery phase will come from an ongoing prospective observational study being performed at the University of Kentucky, which will include outpatient functional assessments performed on 200 ICU survivors (NCT05537298).
32812248|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
32812249|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
33100757|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
33100758|NCT05319782|Experimental|Experimental arm|
33100759|NCT05319743||Medicaid expansion states|Eight Medicaid expansion states: (experimental group): Arizona, California, Illinois, Massachusetts, New Jersey, Ohio, Washington
33100760|NCT05319743||Non-Medicaid expansion states|Five states that did not expand Medicaid (control group): Florida, Georgia, North Carolina, Texas, Virginia
32812250|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
32812251|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
32812252|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
32812253|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
33100761|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
33100762|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
33100763|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
33100764|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
33100765|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
33100766|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
33100767|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
33100768|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
32812254|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
32812255|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
33100769|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
32812256|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
32812257|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
33405006|NCT04944849||digital gamer group|Individuals with computer use more than 14 hours a week were included in this group.
33405007|NCT04944849||player group|Individuals with computer use less than 14 hours a week were included in this group.
33405008|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
32812258|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
32812259|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
32812260|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
32812261|NCT03906526|Experimental|Monotherapy Arm 1: Nivolumab|Nivolumab IV every 2 weeks
32812262|NCT03906526|Experimental|Monotherapy Arm 2: Motolimod|Motolimod IT injection weekly
32812263|NCT03906526|Experimental|Combination Arm 3: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod IT injection weekly
32812264|NCT03906526|Experimental|Combination Arm 4: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod SC injection weekly
32812265|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
32812266|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
32812267|NCT05265754|Experimental|Experimental group|In the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
32812268|NCT05265754|No Intervention|control group|A questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
32812269|NCT05250778|Experimental|Nudge Group|Encounters in this group will be nudged
32812270|NCT05250778|No Intervention|Control Group|Encounters in this group will not receive a nudge.
32812271|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
32812272|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
32812273|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
32954535|NCT04019418|Experimental|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
32954536|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
32954537|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
32954538|NCT04714866|Experimental|Interventional group|Cognitive behavioral therapy for ADHD
32954539|NCT04714866|No Intervention|waiting list group|No Intervention for the waiting list group
32954540|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
32954541|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
32954542|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
32954543|NCT01791348|Other|d2 test of attention|
32954544|NCT03962400|Active Comparator|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
32954545|NCT03962400|Experimental|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
33100770|NCT05319704|Active Comparator|Test of effort, sub-maximal, progressive, carried out in eccentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
33316770|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
33316771|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
33316772|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
33316773|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
32812274|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
32812275|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
33100771|NCT05319704|Placebo Comparator|Test of effort, sub-maximal, progressive, carried out in concentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
32812276|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
32812277|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
32812278|NCT05206942|Experimental|Ultrasound|Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.
32812279|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
32812280|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
32812281|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
32812282|NCT03836482|Experimental|Selective Cytopheretic Device|
32812283|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
32812284|NCT03834922||Sternotomy|Patients undergoing sternotomy
32812285|NCT03834922||Breast|Patients undergoing breast surgery
32812286|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
32812287|NCT05172232||Primary care patients with melanoma suspicious skin lesion(s)|Patients seeking primary care, having one or more skin lesion that the primary care physician cannot by certainty can rule out as being a possible melanoma.
32812288|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
32812289|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
33316774|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
32812291|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
32812292|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
32812293|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
32812294|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
33316775|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
33316776|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
33316777|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
33316778|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
33316779|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
33316780|NCT04902976|Active Comparator|CPC+Zn|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride associated with 0.28% zinc lactate solution.
33316781|NCT04902976|Active Comparator|CPC|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride solution.
33316782|NCT04902976|Placebo Comparator|Negative Control|patients submitted to mouth rinse with distilled water.
33316783|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
33316784|NCT05571436|Experimental|Intervention group|iCan Diabetes Self-Management and Prevention Program
32954546|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
32954547|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
32954548|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
32954549|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
32954550|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
33316785|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
33316786|NCT01287806|Sham Comparator|blank control group|
33316787|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
33316788|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
33316789|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
33316790|NCT03861182|Other|Adult Healthy Volunteers|
33316791|NCT03861182|Other|Neonates|
33316792|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
33316793|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
33316794|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
33316795|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
32954551|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
32954552|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
33316796|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
32954553|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
32954554|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
33316797|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
32954555|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
32954556|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
32954557|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
32954558|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
32954559|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
32954560|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
32954561|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
33316798|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
33316799|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
33316800|NCT03860870|Placebo Comparator|Placebo|Subjects ingest placebo tablets
33316801|NCT01588262|Other|Stressmanagement counselling|
33316802|NCT01588262|No Intervention|Control|
33316803|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
33316804|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
33316805|NCT00073008|Other|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
33316806|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
33316807|NCT01182974|Active Comparator|paracetamol treatment|
33316808|NCT01182974|Active Comparator|control- dypirone treatment|
32812297|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
33316809|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
32812298|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
32812299|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
32812300|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
32812301|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
32812302|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
32812303|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
32812304|NCT01774981|Placebo Comparator|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
32812305|NCT01774981|Experimental|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
32812306|NCT01774981|Experimental|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
32812307|NCT01774981|Experimental|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
32812308|NCT01774981|Placebo Comparator|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
32812309|NCT01774981|Experimental|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
32812310|NCT01774981|Experimental|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
32812311|NCT01774981|Experimental|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
32812312|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
32812313|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
32812314|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
32812315|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
32812316|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
32812317|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
32812318|NCT01774903|Experimental|TTS-fentanyl|
32812319|NCT01774591|Active Comparator|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
32954562|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
32954563|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
32954564|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
32954565|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
32954566|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
32954567|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
32954568|NCT00353652|Active Comparator|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
33100772|NCT05319704|Active Comparator|Kinetic in eccentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
33100773|NCT05319704|Placebo Comparator|Kinetic in concentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
33100774|NCT05318456|Experimental|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
33100775|NCT05318456|Active Comparator|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
33100776|NCT05318456|Placebo Comparator|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
33100777|NCT05319665|No Intervention|Control|The control group will have the standard-of-care treatment.
33100778|NCT05319665|Experimental|Interventional|The interventional group will have a head-mounted display whilst still in the operating theatre airing a live video of their newborn filmed by a 2D 360° camera to enable a visual and auditory contact.
33100779|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
33100780|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
33316810|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
33316811|NCT03960684|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System
33316812|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
33316813|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
33316814|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
33316815|NCT03741192|Experimental|Treatment Group|SPEAC System
33316816|NCT03741192|No Intervention|Standard of Care|
32812320|NCT01774591|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
32812321|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
32812322|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
33316817|NCT03856346||Phaco-vitrectomy|
32812323|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
32812324|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
32812325|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
32812326|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
32812327|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
32812328|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
32812329|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
32812330|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
32812331|NCT01708057|Placebo Comparator|5|Single dose of placebo
32812332|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
32812333|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
32812334|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
32812335|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
32812336|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
32812337|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
32812338|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
32812339|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
32812340|NCT01747915|Experimental|Study Drug Level 1|
32812341|NCT01747915|Experimental|Study Drug Level 2|
32812342|NCT01747915|Placebo Comparator|Placebo|
32812343|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
32812344|NCT04656041|Experimental|FOLFOX/ nal-IRI|"Treatment will be administered on an outpatient basis.~FOLFOX with nal-IRI for eight two-week cycles (16 weeks total)~Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks~Surgery"
33316818|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
33316819|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
33100781|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
32812345|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.~They will follow their usual care path as provided by their local NHS"
32812346|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.~The system is composed by:~a touch-screen pc for the administration of daily questionnaires~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
33316820|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
33316821|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
33316822|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
33316823|NCT01183052|Other|Training|20 sessions of training
32812347|NCT01747837|No Intervention|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
32812348|NCT01747837|Experimental|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.~Ablation arm"
32812349|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
32812350|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
32812351|NCT04174703|Experimental|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
32812352|NCT04174703|No Intervention|Control condition|
32812353|NCT04654325|Other|Patients attending to the COVID19 screening facility|Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
32812354|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
32812355|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; < 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of bucindolol was 6.25 mg BID with weekly dose titrations to the weight-based target dose or to the maximum tolerated dose. The starting dose assigned was based on the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
32812356|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; < 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of metoprolol was 25 mg QD with weekly dose titrations to the target dose or to the maximum tolerated dose. The starting dose assigned was based upon the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
32812357|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
32812358|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
32812359|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
32812360|NCT01969721|Experimental|T+O FDC dosage 2|High dose
32812361|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
32812362|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
33100782|NCT05319470||Study Group|100 patients with diagnosed glaucoma receiving travoprost without preservatives
33100783|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
33316824|NCT01327014|Placebo Comparator|Placebo group|
33316825|NCT01327014|Experimental|1,200 mg/day of XZK group|
33316826|NCT01327014|Experimental|2,400 mg/day of XZK group|
33316827|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
33316828|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
33316829|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)~n-3 Polyunsaturated fat (experimental)~monounsaturated fat"
32954569|NCT00353652|Active Comparator|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
32954570|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
32954571|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
32954572|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
32954573|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
33316830|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
33316831|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
33316832|NCT03955848|Experimental|ARM 1|NK cell infusion
33316833|NCT03955848|No Intervention|ARM 2|Follow up without treatment
33316834|NCT01089738|Experimental|Dosing|Ascending Doses
32954574|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
32954575|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
32954576|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
32954577|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
32954578|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
32954579|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
32954580|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
32954581|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
32954582|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
32954583|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
32954584|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
32954585|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
32954586|NCT03921840|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
33100784|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
33316835|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
33316836|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
33100785|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
33100786|NCT05319392||Patients with Gastric Adenocarcinoma|Patients with origin of tumor in distal part of stomach who underwent total or partial gastrectomy after biopsy examination with availability of follow-up and archived FFPE tissue will be considered for this study.
33100787|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
33100788|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
33100789|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
33100790|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
33100791|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
33100792|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
33100793|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
33100794|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
33100795|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
33316837|NCT03956160|Experimental|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
32812363|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
32812364|NCT01968707|Active Comparator|ChloraPrep Hi-Lite Orange|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32812365|NCT01968707|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32812366|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5 mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32812367|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
32812368|NCT04650191||Mild COVID-19 infection|Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
32812369|NCT04650191||Moderate COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
32812370|NCT04650191||Severe COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
32812371|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
32812372|NCT01746901|Placebo Comparator|Treatment A|
32812373|NCT01746901|Experimental|Treatment B|
32812374|NCT01746901|Experimental|Treatment C|
32812375|NCT01746901|Active Comparator|Treatment D|
32812376|NCT01746901|Experimental|Treatment E|
32812377|NCT01746901|Active Comparator|Treatment F|
32812378|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
32812379|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
32812380|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
32812381|NCT01707992|Placebo Comparator|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
32812382|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
32812383|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
32812384|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
32812385|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
32812386|NCT01707992|No Intervention|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
33100796|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
33100797|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
33100798|NCT02917200|Other|CTRL|Negative control, tid, 7 days
33100799|NCT05318144||PCR (-) symptomatic|control group, pregnant women with negative COVID-19 Polymerase Chain Reaction (PCR) test
33100800|NCT05318144||PCR (+) asymptomatic|Pregnant women who have a positive COVID-19 PCR test and have had the infection without symptoms
32812387|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
32812388|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
32812389|NCT04649411|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.
32812390|NCT04649411|Active Comparator|Standard of care|Participants aged 12 to <18 years and 6 to <12 years will receive standard of care treatment for 24 weeks.
32812391|NCT01707667|Experimental|Prucalopride|
32812392|NCT01707667|Active Comparator|PEG 3350|
32812393|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
32812394|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
32812395|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
32812396|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
32812397|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
32812398|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
32812399|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
32812400|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
32812401|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
32812402|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
32812403|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
32812404|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
32812405|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
32812406|NCT04413721|Experimental|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
32812407|NCT04413721|Active Comparator|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
32812408|NCT04413565|Experimental|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
32812409|NCT04413565|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
32954587|NCT03921840|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
32954588|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
32954589|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
32954590|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
32954591|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
32954592|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
32954593|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
32954594|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
32954595|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
32954596|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
32954597|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
32954598|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
32954599|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
32954600|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
32954601|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
32954602|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~Combined phase: continues ERP while making explicit links to the cognitive targets.~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
32954603|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
32954604|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~learn why this doubt is 100% irrelevant here and now~learn the inferential confusion process~have to recognize that the doubt originates from him/her~have to identify/describe the narrative leading him/her to the doubt~have to identify the cross-over point when he/she leaves reality~learn to be aware of the reasoning devices~learn how personal themes dictate the idiosyncratic nature of the person's obsession~explore and reinforced an alternative self-view~be trained to use properly his/her senses in the face of obsessional triggers situations"
32954605|NCT04194060|Experimental|Enhanced recovery after surgery group|"ERAS GROUP~Tracheal intubation.~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
32954606|NCT04194060|Active Comparator|Conventional group|"CONVENTIONAL GROUP~Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics.~I"
33316838|NCT03956160|No Intervention|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
33316839|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
33316840|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
33316841|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
32954607|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
32954608|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
32954609|NCT01792596|Other|pasta|1. Plain pasta
32954610|NCT01792596|Other|pasta with protein|Pasta with protein
32954611|NCT01792596|Other|pasta with fiber|Pasta with Fiber
32954612|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
32954613|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
32954614|NCT03138096|Experimental|Group 1 - five Pb(PfCS@UIS4)-infected mosquitoes|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
32954615|NCT03138096|Experimental|Group 2 - 25 Pb(PfCS@UIS4)-infected mosquito bites|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
32954616|NCT03138096|Experimental|Group 3 - 75 Pb(PfCS@UIS4)-infected mosquito bites|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
32954617|NCT03138096|Other|Group 4 - Infectivity control group of Phase 1|Infectivity control group of Phase 1
32954618|NCT03138096|Other|Group 5 - Infectivity control group of Phase 2|Infectivity control group of Phase 2
32954619|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
32954620|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
32954621|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
32812410|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:~Previous (within 3 years) eGFR >45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND~Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND~Increasing creatinine >= 27μmol/L above index value within 48 hours"
32812411|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR > 60).~This group will be recruited contemporaneously with, and matched to, AKI participants by:~Age (± 5 years)~Sex~AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
32812412|NCT01705717||cohort|
32812413|NCT01744483|Active Comparator|PVC ETT|Polyvinylchloride cuff endotracheal tube
32812414|NCT01744483|Experimental|PUC ETT|Polyurethane cuff endotracheal tube
32812415|NCT01744483|Experimental|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
32812416|NCT01744093|Active Comparator|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
32812417|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
32812418|NCT04565509|Active Comparator|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
32812419|NCT04565509|Active Comparator|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
32812420|NCT04565509|Active Comparator|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
32812421|NCT04565509|Active Comparator|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
32812422|NCT04565041|Experimental|Social Support|
32812423|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
32812424|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
32812425|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
32812426|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
32812427|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
32812428|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
32812429|NCT04558567|Other|Open-Label|
32812430|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
32812431|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
32812432|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
32812433|NCT04166552|Experimental|EHP-101 low dose once a day|
32812434|NCT04166552|Experimental|EHP-101 low dose twice a day|
32812435|NCT04166552|Experimental|EHP-101 high dose once a day|
32812436|NCT04166552|Experimental|EHP-101 high dose twice a day|
32812437|NCT01717040|Experimental|Pioglitazone|
32812438|NCT01717040|Placebo Comparator|Placebo|
32812439|NCT04552262|Experimental|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
32812440|NCT04552262|Experimental|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
32812441|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
32812442|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
32812443|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
32812444|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
32812445|NCT01743469|Experimental|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
32812446|NCT01743469|Experimental|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
32812447|NCT01743469|Experimental|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
32812448|NCT01743469|Experimental|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
32812449|NCT01743001|Experimental|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
32812450|NCT01743001|Placebo Comparator|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
32812451|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
32812452|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
32812453|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
32812454|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
32812455|NCT04564963|Experimental|Cryotherapy|Cold therapy
32812456|NCT04564963|No Intervention|No cryotherapy|Standard practices for pain management
32812457|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
32812458|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
32812459|NCT04557787|Active Comparator|Intermittent catheter; SpeediCath® Standard female|Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
32812460|NCT04557787|Experimental|New intermittent catheter Variant 1 for females|Participants underwent two catheterizations with the new intermittent catheter variant 1 for females: The first was performed by a trained nurse, the second by the participant later the same day.
32812461|NCT04557787|Experimental|New intermittent catheter Variant 2 for females|Participants underwent two catheterizations with the new intermittent catheter variant 2 for females: The first was performed by a trained nurse, the second by the participant later the same day.
32812462|NCT05103358|Experimental|Arm A: Pathogenic inactivating TSC1 alterations|Patients with pathogenic inactivating TSC1 alterations.
32812463|NCT05103358|Experimental|Arm B: Pathogenic inactivating TSC2 alterations|Patients with pathogenic inactivating TSC2 alterations.
32812464|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
32812465|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
32812466|NCT04550143||Septic Shock|
32812467|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
32812468|NCT04556695||Accelerometer study|A purposive sample of questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour. Some participants will also be asked to complete a further online survey, while wearing the accelerometer, regarding their health, wellbeing, burnout and fatigue.
32812469|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
32812470|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
32812471|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
32812472|NCT04556383|Experimental|GB004 Dose A|GB004 dose A for oral administration for 36 weeks
32812473|NCT04556383|Experimental|GB004 Dose B|GB004 dose B for oral administration for 36 weeks
32812474|NCT04556383|Placebo Comparator|Placebo|Placebo for oral administration for 36 weeks
32812475|NCT04556383|Experimental|Open-Label GB004 Dose A|GB004 dose A for oral administration for 24 weeks
32812476|NCT01724359|Experimental|Paliperidone ER|
32812477|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
32812478|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
32812479|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
32954622|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
32812480|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
32812481|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
32812482|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
32812483|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
32812484|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
32812485|NCT05098600||Cases|Patients with a confirmed histologic/dermatoscopic diagnosis of Alopecia areata within the study period will be included for analysis.
32812486|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
32812487|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
32812488|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
32812489|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
32812490|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
32812491|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
32812492|NCT00823966||Delavirdine Mesilate|Patients administered.
32812493|NCT04135261|Experimental|Part 1: Dose escalation|"QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
32812494|NCT04135261|Experimental|Part 2: Dose expansion|Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
32812495|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
32812496|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
32812497|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
32812498|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
32812499|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
32812500|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
32812503|NCT04549129|Experimental|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
32812504|NCT04549129|Active Comparator|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
32812505|NCT01739803|Experimental|Intervention Group|Behavioral contract intervention
32812506|NCT01739803|No Intervention|Control Group|No intervention
32812507|NCT00824434|Experimental|Experimental Stent|
32812508|NCT01739335|Experimental|Mifepristone|'Mifepristone Oral Tablet [Korlym] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
32812509|NCT01739335|Placebo Comparator|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
32812510|NCT00824512|Experimental|EGb 761® 120 mg|
32812511|NCT00824512|Placebo Comparator|Placebo|
32812512|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
32812513|NCT01702363|Experimental|GSK573719|125mcg
32812514|NCT05049928|Experimental|Experimental arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
32812515|NCT05049928|No Intervention|Control arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
32812516|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
32812517|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
32812518|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
32812519|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
32812520|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
32812521|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
32812522|NCT05039632|Experimental|Cohort I (NBTXR3, Abscopal, ipilimumab, ipilimumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and ipilimumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
32812523|NCT05039632|Experimental|Cohort II (NBTXR3, RadScopal, ipilimumab, nivolumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo RadScopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
32812524|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
32812525|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
32812526|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
32812527|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
32812528|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
32812529|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
32812530|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
32812531|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
32812532|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
32812533|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
32812534|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
32812535|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
32812536|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
32812537|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
32812538|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
32812539|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
32812540|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
32812541|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
32812542|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
32812543|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
32812544|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
32812545|NCT05038852|Other|Group 1 smartphone applications|app is designed to help you learn relaxation skills
32812546|NCT05038852|Other|Group 2 smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
32812547|NCT01701193|Placebo Comparator|Physiological saline- Laparoscopic|Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
32812548|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparoscopic|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
32812549|NCT01701193|Placebo Comparator|Physiological saline- Laparotomy|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
32812550|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparotomy|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
32812551|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
32812552|NCT05035654|Experimental|Treatment Arm A: LYR-220 Design 1|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
33100801|NCT05318144||PCR (+) mild-moderate|Pregnant women with positive COVID-19 PCR test and mild to moderate symptoms and inpatient treatment
33100802|NCT05318144||PCR (+) severe COVID-19|Pregnant women with positive COVID-19 PCR test and severe symptoms
33100803|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
33316842|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
33100804|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
33100805|NCT05319275|Experimental|Acetyllevocarnitine Hydrochloride Tablets|
33316843|NCT03856034|Experimental|Fetoscopic repair|
33100806|NCT05319275|Placebo Comparator|Placebo|
33100807|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
33100808|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
33100809|NCT02920515|No Intervention|blank group|without therapy
33100810|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
33100811|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
32812553|NCT05035654|Experimental|Treatment Arm B: LYR-220 Design 2|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
32812554|NCT05035654|Sham Comparator|Treatment Arm C: Bilateral sham procedure control|Bilateral sham procedure control
32812555|NCT05024968|Experimental|Treatment (sintilimab)|The study drug is sintilimab. The first dose of study treatment should start on Day 1 of Cycle 1. For the rest of the treatment cycles, the study treatment can be administered 3 day before or 3 days after the scheduled day of administration. Treatment can be delayed for up to 1 week if the administration day is on a holiday or if the subject is otherwise unavailable.
32812556|NCT04382092|Experimental|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
32812557|NCT00827944|Active Comparator|1|Parietex ProGrip
32812558|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
32812559|NCT05014438|Placebo Comparator|Placebo|
32812560|NCT05014438|Experimental|Treatment BMS-986166 Dose 1|
32812561|NCT05014438|Experimental|Treatment BMS-986166 Dose 2|
32812562|NCT05014438|Experimental|Treatment BMS-986166 Dose 3|
32812563|NCT05014438|Experimental|Treatment Branebrutinib|
32812564|NCT02153710|Experimental|Phonomotor therapy|Experimental group
32812565|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
32812566|NCT04989556|Active Comparator|Arm I (standard symptom management)|Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
32812567|NCT04989556|Experimental|Arm II (weekly provider-initiated remote contact)|Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
32812568|NCT04989556|Experimental|Arm III (weekly provider-initiated remote contact)|Patients in Phase I non-immunotherapy clinical trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact once a week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
32812569|NCT04955626|Experimental|10 µg dose|1 dose
32812570|NCT04955626|Placebo Comparator|Placebo|1 dose
32812571|NCT04955626|Experimental|30 µg dose|1 dose
32812572|NCT04955626|Experimental|60 µg dose|1 dose
32812573|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
33100812|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
33100813|NCT05319119||1.CT-FFR Related Group|Coronary diseased artery CTFFR>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI
33100814|NCT05319119||Coronary Angiography Related Group|Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.
33100815|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
33100816|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
32812574|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
32812575|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
32812576|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
32812577|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
32812578|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
32812579|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
32812580|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
32812581|NCT01959035|Experimental|Aripiprazole once-monthly|
32812582|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
32812583|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
32812584|NCT04637087|Experimental|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
32812585|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
32812586|NCT01738477|Experimental|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
32812587|NCT01738477|Active Comparator|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
32812588|NCT00829738||Group 1|All patients enrolled
32812589|NCT01737931|Experimental|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
32812590|NCT01737931|Experimental|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
32812591|NCT01737931|No Intervention|No-treatment|No treatment to the application sites after the patch removal
33100817|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
33100818|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
33100819|NCT02920632|Experimental|Online cognitive training 1 (N=70)|Eight-week, three times a week during 45 minutes cognitive training
33100820|NCT02920632|Active Comparator|Online cognitive training 2 (N=70)|Eight-week, three times a week during 45 minutes cognitive activities
32812592|NCT04564261|Experimental|myPlan Teen Group|Personalized Healthy Relationship and Safety Planning Tool.
32812593|NCT04564261|Active Comparator|Usual Care Teen Control Group|Usual Care Teen Relationships and Health Resource.
32812594|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
32812595|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
32812596|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
32812597|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
32812598|NCT04564183||Full Cohort|Entire study population
32812599|NCT04564183||Sub-Cohort|Randomly selected sub-cohort from the larger group of all participants
32812600|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.
32812601|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
32812602|NCT00830362|Active Comparator|Propranolol 40mg|
32812603|NCT00830362|Placebo Comparator|Placebo|
33100821|NCT02920632|No Intervention|Healthy control subjects (N=30)|Reference group to compare cognitive training effects to
33100822|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
33100823|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
33100824|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
33100825|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
33100826|NCT05319002|Experimental|Group EMDR|Participants in the experimental group will undergo a 3-week group EMDR intervention with weekly 60-minute group sessions.
33100827|NCT05319002|No Intervention|Control|The control group will follow routine daily school activities
33100828|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
33100829|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
33316844|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
33316845|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
33316846|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
33316847|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
33316848|NCT01287962|Placebo Comparator|Placebo|
33316849|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
33316850|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
32812604|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
32812605|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
32812606|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
32812607|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
32812608|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
32812609|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
32812610|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
32812611|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
32812612|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
32812613|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
32954623|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
32954624|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
32954625|NCT02816580|Experimental|elderly subjects|
32954626|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
32954627|NCT04182516|Experimental|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
32954628|NCT04182516|Experimental|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer.
32954629|NCT04182516|Experimental|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
32954630|NCT04182516|Experimental|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
32954631|NCT04182516|Experimental|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).
32954632|NCT04182516|Experimental|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
32954633|NCT01794234||Cohort|
32954634|NCT02485860|No Intervention|standard dressings|
32954635|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
32954636|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32954637|NCT04011072|Active Comparator|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
32954638|NCT04011072|No Intervention|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
32954639|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
32954640|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
32954641|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
32954642|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
32954643|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
32954644|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
33100830|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
33100831|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
33100832|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
33100833|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
33405009|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
33405010|NCT05202600||Incidental appendectomy (IA)|Group IA will include adult patients operated on for colon tumors who have data on age, sex, data on a previously diagnosed colon tumor, data on incidental appendectomy, and a PHD finding for a removed vermiform appendix.
33100834|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
33100835|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
33100836|NCT02941874||Healthy volunteers IRAP measurement|
33100837|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
33100838|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
33100839|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
33100840|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
33100841|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
33100842|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
32812614|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
32812615|NCT04646057|Experimental|Treatment Arm|
32812616|NCT04646057|No Intervention|Historical Control Arm|
32812617|NCT04645589||Myfortic|Oral administration
32812618|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
32812619|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
32812620|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
32812621|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
32812622|NCT04548661|Experimental|Povidone-iodine solution|
32812623|NCT04548661|Placebo Comparator|Saline|
32812624|NCT04548661|No Intervention|No irrigation|Standard incision management
32812625|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
32812626|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
32812627|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
32900020|NCT00241904|Active Comparator|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
33100843|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
33100844|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).~A Manual is created and trained with the Music Therapists, which distinguishes between~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,~Essential but not Unique Principles,~Acceptable but not necessary Principles,~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
33100845|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
33100846|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
33100847|NCT02920437|Other|Control group|Usual government pamphlets.
33100848|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
33318674|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
32812628|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
33100849|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
33100850|NCT02920359|Experimental|LEUPRORELIN ACETATE|
33100851|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
33100852|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
33100853|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
33100854|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
33100855|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
33100856|NCT02941796|Experimental|Sequence 1|"T → R~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
33100857|NCT02941796|Experimental|Sequence 2|"R → T~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
33100858|NCT05318963|Experimental|LCAR-AIO cells product|Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level.
33318675|NCT01095900||LIS group)|
33318676|NCT01095900||BT group|
32954645|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
32954646|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
32954647|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
32954648|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
32954649|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
32954650|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
32954651|NCT03984240|Experimental|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
33318677|NCT03954912|Active Comparator|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
33318678|NCT03954912|Active Comparator|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
33318679|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
33318680|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
32954652|NCT03984240|Active Comparator|control group|Healthy volunteers without intracranial diseases.
32954653|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
32954654|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
32954655|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
32954656|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
32954657|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
32954658|NCT01552590|Active Comparator|Tolvaptan|Tablet, QD, 2 weeks
32954659|NCT01552590|Placebo Comparator|Placebo|Tablet, QD, 2 weeks
32954660|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
32954661|NCT01105884|Active Comparator|Group 1|
32954662|NCT01105884|Active Comparator|Group 2|
32954663|NCT01105884|Active Comparator|Group 3|
32954664|NCT01105884|Active Comparator|Group 4|
32954665|NCT01105884|Active Comparator|Group 5|
32954666|NCT00549978|Other|1|Two compartments with cross-over and parallel
32954667|NCT00549978|Other|2|Two compartments with cross-over and parallel
32954668|NCT03983226|Experimental|Surgery|"Intervention:~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
32954669|NCT03983226|Active Comparator|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
32954670|NCT04346082|Experimental|online mindfulness group|
32954671|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
32954672|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
32954673|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
32954674|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
32954675|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
32954676|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
32954677|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
32954678|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
32954679|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
32954680|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
32954681|NCT00362466|Active Comparator|B|200-800 mg QD
32954682|NCT00305682|Active Comparator|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
32954683|NCT00305682|Active Comparator|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
32954684|NCT00305682|Active Comparator|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
32954685|NCT00305682|Active Comparator|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
33100859|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
33100860|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
33100861|NCT02916576|Experimental|Blood glucose measurement|
33100862|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
33100863|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
33100864|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
33100865|NCT05318924|Experimental|Ghrelin infusion|To achieve approximately stable elevated ghrelin levels during the infusion procedure, the investigators will use a loading dose of 1 mcg/kg as well as an infusion rate of 0.051 mcg/kg/min in line with recent studies (Farokhnia, Grodin, Lee et al., 2017) and general recommendations (Garin, Burns, Kaul et al., 2013).
33100866|NCT05318924|Placebo Comparator|Placebo infusion|Saline
33100867|NCT05318924|No Intervention|Patients with MDD|Patients with major depressive disorder will be enrolled for comparison to healthy participants on the reward task battery, but not randomized to the ghrelin vs. saline infusion.
33100868|NCT02920398|Experimental|N8-GP pivotal|
33100869|NCT02920398|Active Comparator|N8-GP commercial|
33316851|NCT00058422|Experimental|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
33316852|NCT01183286|Active Comparator|CFFONE|
33100870|NCT05318885|Experimental|Forward leaning position|The children in asthma attacks were administered nebulization three times, during which the study group children were placed in the forward-leaning position.
33100871|NCT05318885|No Intervention|Fowler position|The children in asthma attacks were administered nebulization three times, during which the control group children in the routine Fowler's position.
32812629|NCT04644809|Experimental|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
33316853|NCT01183286|Placebo Comparator|CF website|
33100872|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
32812630|NCT04644809|Experimental|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
32812631|NCT04644809|Experimental|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
32812632|NCT04644809|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered SC.
32812633|NCT00805948|Experimental|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
32812634|NCT00805948|No Intervention|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
32812635|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
32812636|NCT00807586|Experimental|Steroid|
32812637|NCT00807586|Placebo Comparator|Placebo|
33100873|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
33100874|NCT05318846|Experimental|Treatment group A|
33100875|NCT05318846|Placebo Comparator|Treatment group B|
33100876|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
33100877|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
33100878|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
33100879|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
33100880|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
33100881|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
33100882|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
33100883|NCT02920320|No Intervention|Waiting control group|
32954686|NCT00305682|Active Comparator|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
32954687|NCT00305682|Active Comparator|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
32954688|NCT00305760|Experimental|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
32954689|NCT03839394|Experimental|Educational pamphlets + telephone|
33316854|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
33318681|NCT03954600|Other|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
32954690|NCT03839394|Active Comparator|Educational pamphlets|
32954691|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
32954692|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
32954693|NCT00310050|Experimental|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
32954694|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
32954695|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
32954696|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
32954697|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
32954698|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
32954699|NCT03723798|Experimental|Group 1|SA001 Low dose
32954700|NCT03723798|Experimental|Group 2|SA001 Mid dose
32954701|NCT03723798|Experimental|Group 3|SA001 High dose
32954702|NCT03723798|Placebo Comparator|Placebo|Placebo
32954703|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
32954704|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
32954705|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
32954706|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
32954707|NCT00310362|Experimental|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
32954708|NCT00310362|Experimental|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
32954709|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
32954710|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
32954711|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
32954712|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
32954713|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
32954714|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
32954715|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
32954716|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
32954717|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
32954718|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
33100884|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
33100885|NCT03458468|Placebo Comparator|Group B|Saline injection
33316855|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
33316856|NCT03956628|Experimental|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
33316857|NCT03956628|No Intervention|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
33316858|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
33316859|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
33316860|NCT01089816||All|Anyone presenting with influenza-like-illness
32812638|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
32812639|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
32812640|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
32812641|NCT01957787|Experimental|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
32812642|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
32812643|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
32812644|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
32812645|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
32812646|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
32812647|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
32812648|NCT00832390|Experimental|1|sitagliptin
32812649|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
32812650|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
32812651|NCT04644029|Experimental|ISL QM|ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily during Part 1.
32812652|NCT04644029|Active Comparator|FTC/TDF QD|FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) administered once daily in Parts 1, 2, and 3. Placebo to ISL (islatravir) also administered once monthly during Part 1.
32812653|NCT00807664|Experimental|1|Biatain Ag dressing
32812654|NCT00807664|Active Comparator|2|Biatain dressing
32812655|NCT04636619|Experimental|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
32812656|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
33100886|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
33316861|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
33316862|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
33316863|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
33316864|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
33316865|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
33318682|NCT03954600|Other|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
33318683|NCT03954600|Other|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
32812657|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
32812658|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
32812659|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
32812660|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
32812661|NCT01940939|Sham Comparator|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
32812662|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2~Finally the all subject test Coloplast Test 3"
32812663|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1~Finally the all subject test Coloplast Test 3"
32812664|NCT01940705|Active Comparator|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
32812665|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
32812666|NCT01940705|Experimental|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
32812667|NCT01940705|Experimental|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
32812668|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
32812669|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
32812670|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
32812671|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
32812672|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
32812673|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
32812674|NCT00844090|Experimental|Arm 2|methylphenidate tablets
32812675|NCT00844714|Experimental|Rituxan|
32812676|NCT01956773|Experimental|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
32812677|NCT01956773|Experimental|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
32812678|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
32812679|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
32812680|NCT00834808|Experimental|1: Tramadol HCl 100mg|
32812681|NCT00834808|Experimental|2: Tramadol HCl 200mg|
32812682|NCT00834808|Experimental|3: Tramadol HCl 300mg|
32812683|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
33100887|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
33100888|NCT02941679|Experimental|HCP1202|Test
33100889|NCT02941679|Active Comparator|HGP1011|Control
33100890|NCT02941679|Active Comparator|HCP0910|Control
33100891|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
33100892|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
33100893|NCT02942537|Experimental|Intervention|Microwave treatment
33100894|NCT02942537|Active Comparator|Control|Uterine artery embolization
33100895|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
33100896|NCT05317793||Professionals|150 knowledge workers from three Finnish companies.
33316866|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
33316867|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
33316868|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
33316869|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
32812684|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
32812685|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
32812686|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
32812687|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
32812688|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
32812689|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
32812690|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
32812691|NCT05125289|Experimental|experimental intervention group 1|Graston technique group
32812692|NCT05125289|Experimental|Experimental :interventional group II|Active release technique group
32812693|NCT05125289|Experimental|experimental group III|Proprioceptive Neuromuscular Facilitation stretching group
32812694|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
32812695|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
32812696|NCT04636073|Experimental|Leaflex™ Performer|
32812697|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
32812698|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
32812699|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
32812700|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
32812701|NCT00835900|Experimental|varenicline|drug plus counseling.
32812702|NCT00835900|Active Comparator|placebo|placebo plus counseling
32812703|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
32812704|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
32812705|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
32812706|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
32812707|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
32812708|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
33100897|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
33100898|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
33100899|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
33100900|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
33100901|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
33100902|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
33100903|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
32812709|NCT04635761|Experimental|Prevention (AIR Program)|Participants complete the Roswell Awareness, Information and Resources for Lung Cancer Screening (AIR) Program over 45 minutes and then receive the High-Risk Lung Cancer Tip Sheet..
32812710|NCT04634045|Experimental|Web-Based Treatment|A web-based treatment for pediatric overweight or obesity will be piloted with 10 caregiver and child pairs. Assessments will take place pre (0 months), post intervention (3.5 months) and at six months post-intervention (9.5 months) to evaluate patient outcomes, acceptability and feasibility.
32812711|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
32812712|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
32812713|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
32812714|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
32812715|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
32812716|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
32812717|NCT00836758|Experimental|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
32812718|NCT03770260|Experimental|Treatment (ixazomib citrate, pevonedistat)|Patients receive ixazomib citrate PO QD on days 1, 8, and 15 of each cycle and pevonedistat IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32812719|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
32812720|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
32812721|NCT01952015|Experimental|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.~No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.~Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
32812722|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
32812723|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
33316870|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
32812724|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
32812725|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
32812726|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
32812727|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
32812728|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
32812729|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
32812730|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
32812731|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
32812732|NCT00853606|Experimental|avanafil|
32812733|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
32812734|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
32812735|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
32812736|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
32812737|NCT01737697|Experimental|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
32812738|NCT01737697|Placebo Comparator|Placebo (acute phase)|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
32812739|NCT01737697|Experimental|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
32812740|NCT01737697|Placebo Comparator|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
32812741|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
32812742|NCT00841828|Experimental|Experimental|Epirubicin + Cyclophosphamide -> Docetaxel + Lapatinib
32812743|NCT00841828|Active Comparator|Control|Epirubicin + Cyclophosphamide -> Docetaxel + Trastuzumab
32812744|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
32812745|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
32812746|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
32812747|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
32812748|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
32812749|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
33316871|NCT03960528|Active Comparator|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
33316872|NCT03960528|Sham Comparator|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
33318684|NCT03954600|Other|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
33318685|NCT03954600|Other|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
32812750|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
32812751|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
32812752|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
32812753|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
32812754|NCT00856414|Experimental|1|botulinum toxin Type A 20U
32812755|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
32812756|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
32812757|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
32812758|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
32812759|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
32812760|NCT03696784|Experimental|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)~-1 1 x 10^5~1 x 10^6~2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
32812761|NCT03696784|Experimental|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
32812762|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
32812763|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
32812764|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
32812765|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
32812766|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
32812767|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
32812768|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
32812769|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
32812770|NCT02453620|Experimental|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32812771|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Plasma Therapy (PlasmaDerm)"
32812772|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
32812773|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
32812774|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Plasma Therapy (PlasmaDerm)"
32812775|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
33405011|NCT05202600||Acute appendectomy (AA)|Group AA will include adult patients who have been operated due to clinical suspicion of acute appendicitis and have data on age, sex, data on the diagnosis of acute appendicitis and accompanying PHD findings of the performed appendectomy.
32812776|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812777|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812778|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812779|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812780|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812781|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812782|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
32812783|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
32812784|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
32812785|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
32812786|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
32812787|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
33318686|NCT03954600|Other|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
32812789|NCT04400890|Active Comparator|Resveratrol with Vitamin D3|Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1
32812790|NCT04400890|Placebo Comparator|Placebo with Vitamin D3|Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1
32812791|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
32812792|NCT04351438||Centrifuge TPE with citrate|These participants were undergoing centrifuge TPE using citrate anticoagulant
32812793|NCT04351438||Filter TPE with heparin|These participants were undergoing filter TPE using filter-based heparin anticoagulant
32812794|NCT04351438||Filter TPE with citrate|These participants were undergoing filter TPE using filter-based citrate anticoagulant
32812795|NCT04330846|Experimental|EBD group|"Post-procedural admission in the Short Stay Unit (SSU).~Superficial sedation by endoscopist or anesthesiologist depending on the center.~Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.~A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.~Dilation failure will be considered if > 2 dilations are required."
32812796|NCT04330846|Experimental|SEMS group|"Post-procedural admission in the Short Stay Unit (SSU).~Superficial sedation by endoscopist or anesthesiologist depending on the center.~Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist~Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.~Removal time of the prosthesis 4 weeks."
32812797|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
32812798|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
32812799|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
32812800|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
33100904|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
32812801|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
32812802|NCT04135027||CD group|no interventions
32812803|NCT04548193|Experimental|Arm A (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM A: Patients receive mailed educational materials about the importance of consuming cruciferae, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
33405012|NCT04904601|Active Comparator|Experimental Group: Kale|This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
32954719|NCT00313560|Experimental|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
32954720|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
32954721|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
32954722|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
32954723|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
32954724|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
32954725|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
32954726|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
32954727|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
32954728|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
32954729|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
32954730|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
32954731|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
32954732|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
32954733|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
32954734|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
32954735|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
32954736|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
32954737|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
32954738|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
32954739|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
32954740|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
32954741|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
32954742|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
32954743|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
32954744|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
32954745|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
32954746|NCT00316524|Experimental|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
32954747|NCT00316524|Experimental|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
32954748|NCT00316524|Placebo Comparator|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
32954749|NCT00316524|Experimental|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
32954750|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
32954751|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
32954752|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
32954753|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
32954754|NCT05288010|Other|Active Group|Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.
33316873|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
33316874|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
33316875|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
33316876|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
33316877|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
33316878|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
33316879|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
33318687|NCT00300053|Experimental|CLBS14: Low-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 1 x 10^5 (=100000) cells/kg bodyweight
32954755|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
32954756|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
32954757|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
32954758|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
32954759|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
32954760|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
32954761|NCT05287854|Experimental|Local anesthesia + Virtual Reality|In addition to local standard anaesthesia, patients benefit from a virtual reality session during the operation using a virtual reality headset
32954762|NCT05287854|No Intervention|Local anesthesia alone|Patients benefit only from a local anaesthesia is provided according to the standard procedure
32954763|NCT05287776|Experimental|15 patients with vitiligo subjected to NB-UVB|Patients will be subjected to NB-UVB sessions 3 times weekly. The UVB dosing scheme in the patients receiving only NB-UVB treatment entailed initial dosing at 0.5 J/cm2 with increasing increments by 0.3 J/cm 2 every other session until faint erythema occurs.
32954764|NCT05287698|Experimental|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600a-ultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
32954765|NCT05287698|No Intervention|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service.
32954766|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~Lab values: D-Dimer, IL-6, CRP~APACHE II Scores Day 1 and after TH (day 4)~Length of stay in the ICU and hospital~Prevalence of infections~28-day mortality~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
32954767|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
32954768|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
32954769|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
32954770|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
32812804|NCT04548193|Active Comparator|Arm B (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM B: Patients receive mailed educational materials about general fruit and vegetable intake, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
32812805|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
32812806|NCT04311112|Placebo Comparator|ZA placebo|
32812807|NCT04311112|Active Comparator|ZA low dose|
32812808|NCT04311112|Active Comparator|ZA high dose|
32812809|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
32812810|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
32812811|NCT00814138|Active Comparator|1|Methotrexate
32812812|NCT00814138|Placebo Comparator|2|Placebo
32812813|NCT00860938|Active Comparator|Budesonide|
32812814|NCT00860938|Placebo Comparator|Placebo|
32812815|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
32812816|NCT04266730|Experimental|PANDA-VAC combined with pembrolizumab|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing <5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
32812817|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
32812818|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
32812819|NCT01718509|Placebo Comparator|Placebo|
32812820|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
32812821|NCT04547959|Experimental|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in Titane is used
32812822|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
32812823|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
32812824|NCT00862810|Other|Received HPV vaccine first|
32812825|NCT00862810|Other|Received concomitant vaccines first|
32812826|NCT01143532||Kidney transplant donor of black African descent.|Kidney transplant donor of black African descent.
32812827|NCT01143532||Kidney transplant recipient of black African descent|Kidney transplant recipient of black African descent.
32812828|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
32812829|NCT00488878||Observational (electronic health record review)|Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
32812830|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
32812831|NCT00815698|Experimental|Suture|Suture for mesh fixation
33318688|NCT00300053|Experimental|CLBS14: High-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 5 x 10^5 (=500000) cells/kg bodyweight
32812832|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
32812833|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
32812834|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
33318689|NCT00300053|Placebo Comparator|Placebo injection|10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma
32812835|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
32812836|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
32812837|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
32812838|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
32812839|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
32812840|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
32812841|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
32812842|NCT04250350|Experimental|Lebrikizumab 250 mg|Participants received two subcutaneous (SC) injections of 250 milligram(mg) Lebrikizumab at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 up to (but not including) Week 52.
33318690|NCT01097928||Patients undergoing Pulmonary Embolectomy|
33318691|NCT01098084|Experimental|Decitabine|
32812843|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
32812844|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
32812845|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
32812846|NCT00005398||1; no experimental groups in this study|Observational cohort study
32812847|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
32812848|NCT04228042|Experimental|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
32812849|NCT03536884|Experimental|Bimekizumab dosage regimen 1|"Subjects randomized to this arm will receive bimekizumab dosage regimen 1 (BKZ 1).~At Week 16 subjects will be re-randomized and continue to receive BKZ 1 or to switch to bimekizumab regimen 2 (BKZ 2).~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
32812850|NCT03536884|Experimental|Bimekizumab dosage regimen 2|"Subjects randomized to this arm will receive bimekizumab dosage regimen 2 (BKZ 2) starting at Week 16 after initial treatment on bimekizumab regimen 1 (BKZ 1) for 16 weeks.~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
32812851|NCT03536884|Active Comparator|Secukinumab|"Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 (BKZ 1) or bimekizumab dosage regimen 2 (BKZ 2).~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
32812852|NCT00815776|Experimental|1|Treatment group receiving the CID
32812853|NCT00815776|Active Comparator|2|Group assigned a mouth splint
32812854|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
32812855|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
32812856|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
32812857|NCT04209790|Other|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
32812858|NCT05317234|Experimental|children with cerebral palsy|Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
32812859|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
32812860|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
32900021|NCT00241904|Active Comparator|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
33100905|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
33405013|NCT04904601|Placebo Comparator|Placebo Group: Green Peas|This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
33100906|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
32954773|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative (Recruitment Closed)|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
33100907|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
33100908|NCT02920086|No Intervention|Usual Care|No intervention
33100909|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
33100910|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
33100911|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
33100912|NCT05318807|Experimental|Personalised prehabilitation|A personalised plan of diet, exercise and emotional support for patients having chemotherapy or radiotherapy treatment for lung cancer.
33405014|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
33100913|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
33100914|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
33100915|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 14 days between the each period."
33100916|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
33100917|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
33100918|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
33100919|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
33100920|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
33100921|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
33100922|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
33100923|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
33100924|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
33100925|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
33100926|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
33100927|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
33100928|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
33100929|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
33100930|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
32954774|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
33100931|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE+G-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
32812861|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
32812862|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
32812863|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
32812864|NCT01697449||Cohort|
32812865|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
32812866|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
32812867|NCT01696279|Experimental|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
32812868|NCT01696279|Active Comparator|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
32812869|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
32812870|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
32812871|NCT01716559||Cohort|
32812872|NCT04555759|Experimental|Patient with spinal cord injuries|
32812873|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
32812874|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
32812875|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
32812876|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
32812877|NCT04642235|Experimental|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
32812878|NCT04642235|Experimental|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
32812879|NCT04642235|Experimental|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
32812880|NCT04642235|No Intervention|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
32812881|NCT04641611|Active Comparator|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
32812882|NCT04641611|Experimental|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.~This technique is not routinely used in CABG operations."
32812883|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
32812884|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
32812885|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
32812886|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
32812887|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
32812888|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
32812889|NCT04547803|Experimental|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
32812890|NCT04547803|Active Comparator|Standard of Care|Participants will participate in standard of care for discharged patients.
32812891|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
32812892|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
32812893|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
32812894|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
32812895|NCT02986321|Placebo Comparator|Matched placebo|placebo control
32812896|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
33100932|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE+G-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
33100933|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
33100934|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
33316880|NCT00072384|Experimental|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
33316881|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
32812897|NCT04554667|Experimental|Exercise Intervention|Single exercise arm
32812898|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
33316882|NCT01183442|Placebo Comparator|Placebo|placebo drops
33100935|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
33100936|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
33316883|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
32812899|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
32812900|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
32812901|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
32812902|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
32812903|NCT04410601|Active Comparator|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication~*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
32812904|NCT04410601|Experimental|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
32812905|NCT04410601|Experimental|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
32812906|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
32812907|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
32812908|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
32812909|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
32812910|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
32812911|NCT00867100|Placebo Comparator|Placebo|Placebo treatment
32812912|NCT00867100|Experimental|140 mg SC|140 mg SC PsO
32812913|NCT00867100|Active Comparator|350 mg SC|350 mg SC PsO
32812914|NCT00867100|Experimental|700 mg IV|700 mg IV PsO
32812915|NCT05310292|Experimental|Subjects diagnosed with IKH|10 patients, diagnosed with IKH
32812916|NCT05310292|Experimental|Healthy control subjects|10 subjects, healthy, matched for gender, BMI, age
32812917|NCT05310214|Experimental|Acupuncture treatment (ACP)|The experimental group will be treated with acupuncture
32812918|NCT05310214|Active Comparator|Laser acupuncture treatment (LACP)|The active comparator group will be treated with laser acupuncture
32812919|NCT00817804|Experimental|V60 then Conventional|Study device first
32812920|NCT00817804|Experimental|Conventional then V60|Conventional device first
32812921|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
32812922|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
32812923|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
32812924|NCT00868348|Placebo Comparator|Saline|
32812925|NCT00868348|Active Comparator|Ketorolac|
32900022|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
32900023|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
32954775|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Letrozole: daily oral dose of 2.5 mg."
32954776|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy~Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
32954777|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab or endocrine therapy (Aromatase Inhibitor, Fulvestrant or Tamoxifen) in combination with trastuzumab.
32954778|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
32954779|NCT02422446|No Intervention|Control|Control group will not receive EPA
32954780|NCT05287386|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
32954781|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
32954782|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
32954783|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
32954784|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
32954785|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
32954786|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
32954787|NCT05287230|Experimental|Intervention|
32954788|NCT05287230|Other|Control|
32954789|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
32954790|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
32954791|NCT05286606||Focus groups|Health Care Professionals (HCP), facilitators, participants in the exercise program will be invited to participate in focus groups to comment on usability/acceptability.
32954792|NCT05286606||App users|Users of the exercise program with musculoskeletal conditions have been referred to the exercise program via the charities, all will be participating in a three-month program using the beta version of the app. They will be invited to participate in the program evaluation
32954793|NCT05286606||Facilitators|Facilitators of the exercise program: The facilitators for the virtual groups have been recruited equally by the charities and are working for GoodBoost to facilitate the exercise program for the app users. They will be invited to participate in the program evaluation
32954794|NCT04271670|Experimental|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
32954795|NCT04271670|Experimental|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
32954796|NCT04271670|Active Comparator|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
32954797|NCT04750746|Active Comparator|Control Group|Control group will get conventional treatment.
32954798|NCT04750746|Experimental|Experimental Group|This group will get base line treatment with exer gaming.
32954799|NCT04750668|Experimental|Multisensory Balance Training Group|Multisensory balance training manipulate sensory inputs of vision, vestibular and proprioception.
32954800|NCT04750668|No Intervention|Control Group|Participants in control group maintain their regular activity without any intervention.
32954801|NCT04750590|Experimental|en bloc resection group|Patients scheduled for laser en bloc tumor resection with subsequent morcellation of exophytic part of the tumor
32954802|NCT04750590|Experimental|piecemeal resection group|Patients scheduled for piecemeal bladder tumor TUR with subsequent removing of tissue using the instrument loop or Janet's syringe.
32954803|NCT04750200|No Intervention|Control Arm|Patients randomized to the control arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH.
32954804|NCT04750200|Experimental|Interventional Arm|Patients randomized to the interventional arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH as per the standard of care in the institution. These patients will then undergo EMMA within 48 hours after finishing the surgical drainage. The embolic agent and use of general anesthesia vs conscious sedation will be left to operators' preference and the institutional protocol. All patients will be followed as per the institutional standard of the care. Any peri-procedural complications and change in clinical status will be recorded.
32954805|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32954806|NCT04751292||Lowlanders|People living at low (<1500 m) altitude
32954807|NCT04751292||Highlanders|People living at high (>2500 m) altitude
32954808|NCT04751136|Active Comparator|Intervention Arm|infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
32954809|NCT04751136|No Intervention|Non-intervention Arm|No medication was given
32954810|NCT04750980||Food allergy|Childen with food allergy
32954811|NCT04750980||Respiratory allergy|Children with respiratory allergy
32954812|NCT04750980||Healthy controls|Healthy subjects
32954813|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
32954814|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
33316884|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
33316885|NCT01183598|Experimental|Single Arm|
33316886|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
33316887|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
33316888|NCT01187108|Placebo Comparator|Placebo pills|
33316889|NCT01187108|Active Comparator|Acetazolamide alone|
33316890|NCT01187108|Active Comparator|N-acetylcysteine alone|
33316891|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
33316892|NCT01187888|Active Comparator|Rasagiline|
33316893|NCT01187888|Placebo Comparator|Sugar pill|
33316894|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
32954815|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
32954816|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
32954817|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
32954818|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
32954819|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
32954820|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954821|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954822|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954823|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954824|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954825|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954826|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954827|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
32954828|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
32954829|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
32954830|NCT04388982|Experimental|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
32954831|NCT04388982|Experimental|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
32954832|NCT04388982|Experimental|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
32954833|NCT05286216|Experimental|Experimental group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale will be applied before the intervention. The training will be in two modules and two different sessions. The effectiveness of the training will be evaluated by re-applying the scales 12 weeks and 24 weeks after the training."
33316895|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
33316896|NCT00054132|Experimental|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33316897|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
33316898|NCT01291550||Controls|
33316899|NCT01291550||ADHD|Subjects diagnosed with ADHD
33316900|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
33316901|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
33316902|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
33100937|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
33100938|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
33100939|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
32738222|NCT04485169|Experimental|TPE Arm|In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery
32738223|NCT04485169|No Intervention|NON TPE arm|Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone
33316903|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
33100940|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
33316904|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
33316905|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
33316906|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
33316907|NCT03854084|Sham Comparator|control group|Control group
33316908|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
32738224|NCT04493723||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
33316909|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
33316910|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32738225|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
32738226|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
32738227|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
32738228|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
32738229|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
32738230|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
32738231|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
32738232|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
32738233|NCT05006469|Experimental|BAd treatment|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
32738234|NCT04485247|Active Comparator|Conventional group|conventional laparoscopic appendectomy with 3-ports
32738235|NCT04485247|Experimental|TULAA group|An operator extracts and ligates appendix through umbilical port.
32738236|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
32738237|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
33100941|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
33100942|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
32954834|NCT05286216|No Intervention|Control group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale in the first evaluation, 12 weeks and 24 weeks later, the scales were re-applied and the education was improved. effectiveness will be evaluated."
33316911|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32954835|NCT00638898|Experimental|Arm I|See Detailed Description
32954836|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
32954837|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
32954838|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
32954839|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
32954840|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
32954841|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
32954842|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
32954843|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
32954844|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32954845|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
32954846|NCT05220462|Experimental|Remimazolam|"White to off-white lyophilised powder, presented in a 12 mL clear glass vial with a grey bromobutyl stopper, fitted with an aluminium crimp and a blue plastic flip-off cap. Each 20 mg vial of remimazolam, will be reconstituted with sterile 0.9% NaCl solution to yield a 2.5 mg/mL solution for injection.~An initial dose of 5mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 2.5mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 2.5mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly, at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum dose of 40mg of remimazolam (16mL) will be set."
32954847|NCT05220462|Active Comparator|Midazolam|"Midazolam will be presented as a solution in a 5 mL ampoule. Each ampoule will contain 5 mg of midazolam, yielding a 1 mg/mL solution for injection.~Dosing of midazolam was based on local formulary and standard of care / local guidance. An initial dose of 2mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 1mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 1mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum of dose of 16mg of midazolam (16mL) will be set."
32954848|NCT05215938||Study I: Multi-organ sodium imaging with B1 field correction|"The scan will be performed in four area of interests (AOFs) to acquire sodium level signal form the thigh, heart, kidneys, and brain. Between each AOF the sodium receive coil will be moved to cover the specific organ. Determination of the sodium imaging method robustness is performed with a series of MRI sequences.~The scans at the four AOFs are repeated to evaluate repeatability. The scan time with repositioning of coils is approximately 15 min per station (total scan time 2 hours).~If needed the participants are able to have a break between scan stations."
32954849|NCT05215938||Study II: Circadian sodium level variation in the kidney measured with MRI|"Participation requires one full day at the MR Centre. MRI scans will be performed three times at the same day within the following time periods: 6.30-8.00 am. (before breakfast), 12.30-14-00 pm. (after lunch) and 21.00-22.00 pm. (after dinner). The scan time is expected to be 30-40 min at each scan (three scans are performed on one examination day), which requires a total scan time ~1½ hours.~Participants are not allowed to perform excessive physical exercise the day before and during the study day. Lighter physical exercise as walking, biking etc. is accepted. Alcohol consuming is not allowed the day before and during the study day. The participants can drink and eat as usual, but all fluid intake and urinations shall be documented in a liquid urination schedule. Blood pressure will be measured at each scan session and urine samples are collected just after each scan session to assess the osmolarity."
32954850|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
32954851|NCT05154552|Experimental|group A/ routine physical therapy and PNF|"In group A, PNF based gait training (15 minutes) and conventional physical therapy (45 minutes) will be performed.~PNF exercises involved PNF pelvic patterns (pelvic interior elevation and posterior depression), PNF lower extremity D1 Flexion and PNF lower extremity D1 extension (Unilateral during 1st to 3rd week and bilateral from 4th week onwards). Exercises will progress from rhythmic initiation and then progress to slow reversal and agonistic reversal up to 6th week of therapy and continues until 12th week. Each exercise will be repeated for 10 to 20 times.~Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson's disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
32954852|NCT05154552|Active Comparator|group B/ routine physical therapy|"Conventional physical therapy (45 minute session) will be performed in group B.Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
32954853|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
32954854|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
32954855|NCT01795404|No Intervention|Control group|Waited-list control
32954856|NCT04271124|Active Comparator|PR|
32954857|NCT04271124|Experimental|PR+ET|
32954858|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
32954859|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
32954860|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
32954861|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
33316912|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
33316913|NCT01183754||patients receiving drug-eluting stents|
33316914|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
33316915|NCT00071760|Experimental|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
33316916|NCT00071760|Experimental|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
33316917|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
33316918|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
33316919|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
32954862|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
32954863|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
32954864|NCT04270890|Experimental|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
32954865|NCT00374244|Placebo Comparator|1|placebo pimozide
32954866|NCT00374244|Active Comparator|2|active pimozide
32954867|NCT04270812|Experimental|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
32954868|NCT00377832|No Intervention|1|
32954869|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
32954870|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
32738238|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
32954871|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
32954872|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
32954873|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
32954874|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
32954875|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
32954876|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
32954877|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
32954878|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
33100943|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
33100944|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
33100945|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
33100946|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
33100947|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
32738239|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
33100948|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
33100949|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
33100950|NCT02941016|Experimental|Lipid lowering|
32738240|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
32738241|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
32738242|NCT05021211||Low Egg Consumers|Participants who consume fewer than 1 whole egg per week
32738243|NCT05021211||Moderate Egg Consumers|Participants who consume 5-9 whole eggs per week
32738244|NCT05021211||High Egg Consumers|Participants who consumes great than or equal to 14 whole eggs per week
32738245|NCT03228355|Active Comparator|Levcromakalim|
32738246|NCT03228355|Placebo Comparator|Saline|
32738247|NCT05232617||Rheumatological rehabilitation training|
32738248|NCT05021289|Experimental|Guided İmagery|• participants were given one session of guided imagery.
32738249|NCT05021289|No Intervention|control group|No intervention was applied on the control group patients.
32738250|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
32738251|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
33100951|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
32738252|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
32738253|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
32738254|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
33100952|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
32738255|NCT03325361|Experimental|TD|
33100953|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
33100954|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
33100955|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
33100956|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
32738256|NCT03325361|No Intervention|NTD|
32738257|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
32738258|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
32738259|NCT03229993|Experimental|OCT guided PCI|
32738260|NCT03229993|Experimental|OCT guided medicine|
32738261|NCT03229993|No Intervention|SPECT guided PCI|
33100957|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
33100958|NCT05220722|Experimental|SD-101|Three weekly doses of SD-101 given over two cycles via HAI using the PEDD method of administration.
33100959|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
33100960|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
33100961|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
33100962|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
32954879|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
32954880|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
32954881|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
32954882|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
32954883|NCT00405522|Experimental|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
32954884|NCT00405522|Experimental|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
32954885|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
32954886|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
32954887|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
32954888|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
32954889|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
32954890|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
32954891|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
32954892|NCT00382824|Active Comparator|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
32954893|NCT00382824|Placebo Comparator|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
32954894|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
32954895|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
32954896|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
32954897|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
32954898|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
32954899|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
32954900|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
32954901|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
32954902|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
32954903|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
32954904|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
32954905|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
32954906|NCT00384774|Experimental|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
32954907|NCT00384774|Placebo Comparator|Placebo|Participants received intravenous infusion of placebo solution.
32954908|NCT00410280|Other|1|
32954909|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
32954910|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
32954911|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
32954912|NCT00385008|Other|Arm 1|open-label active drug
32954913|NCT00385008|Other|Arm 2|open-label active drug
32954914|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
32954915|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
32954916|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
33100963|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
33100964|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
33100965|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
33100966|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
33316920|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
32738262|NCT03229993|No Intervention|SPECT guided medicine|
32738263|NCT05006547||Young adults|18<age<35
32738264|NCT05006547||Middle aged adults|50<age<65
33102529|NCT05467436|Experimental|Experimental group|"Subject will receive standard prescription for local anesthetics, IV sedation drugs and analgesics at the time of first surgery.~Subject will receive individually tailored-prescription for local anesthetics, IV sedation drugs and analgesics, based upon pharmacogenomic assessment at the time of second surgery."
32738265|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
32738266|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
33102530|NCT00533637|Experimental|1|NLA Nasal Spray
33102531|NCT00533637|Active Comparator|2|
32738267|NCT03324425|Experimental|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
32738268|NCT05020431|Experimental|One arm|One arm nonrandomized clinical trial
32738269|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
32738270|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
32738271|NCT05006157|Experimental|ViaOne device|ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac
32738272|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
32738273|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
32738274|NCT05006001||Case|Cases were defined as patients with an event of renal impairment during follow-up, such as acute kidney injury.
32738275|NCT05006001||Control|Cases were defined as patients without an event of renal impairment during follow-up, such as acute kidney injury.
32738276|NCT05006001||Exposure|Exposure was defined as patients with colchicine and NSAIDs combination therapy.
32738277|NCT05006001||Non-Exposure|Non-Exposure was defined as patients with other gout therapy.
32738278|NCT03227965|Other|ELITE|
32738279|NCT04493489|Placebo Comparator|BCG|After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
32738280|NCT04493489|Experimental|Propranolol plus BCG|After TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
32738281|NCT05005923|No Intervention|Periodontal healthy|
32738282|NCT05005923|Active Comparator|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
32738283|NCT05005923|Active Comparator|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
32738284|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
32738285|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
32738286|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
32738287|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
32738288|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
32738289|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
32738290|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision. NOL and hemodynamic responses will be recorded during the entire duration of surgery."
32738291|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
32738292|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
33100967|NCT04688619|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by receiving activities to do with their children, given to the adolescents during the scool program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
33316921|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
33316922|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
33100968|NCT04688619|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
33100969|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
33100970|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
33100971|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
33316923|NCT05170178|Experimental|Women with parental experience caring for infants|Women parent of a child under 2 years old
33100972|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
33100973|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
33100974|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
33100975|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
32812926|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
33100976|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
33100977|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
33102532|NCT00533637|Placebo Comparator|3|
32812927|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
33102533|NCT05467358||Patients with preendoscopic ppi order|Patients receiving 80 mg esomeprazole loading and 8 mg esomeprazole infusion per hour before endoscopic treatment
33316924|NCT05170178|Experimental|Men with parental experience caring for infants|Men parent of a child under 2 years old
32812928|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
32812929|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
32812930|NCT04640441|No Intervention|Control group|Participants in the control group received usual care.
32812931|NCT04640441|Experimental|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
32812932|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
32812933|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
32812934|NCT05317468|Experimental|Video|Patients will complete contraceptive counseling using a video-based platform. Patients and counselors will have an audio and video connection.
32812935|NCT05317468|Experimental|Telephone|Patients will complete contraceptive counseling on a telephone call. Patients and counselors will have an audio connection only.
32812936|NCT05318170||Women affected by gynecological cancer|Women affected by gynecological cancer (cervical, endometrial, ovarian and vulvar cancer)
32954917|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
32954918|NCT00411684|Experimental|CDB-2914|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
32954919|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
32954920|NCT00386256|Experimental|Telephone outpatient|
32954921|NCT00386256|Experimental|health buddy inpatient|
32954922|NCT00386256|Experimental|telephone inpatient|
32954923|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
32954924|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
32954925|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
32954926|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
32954927|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
32954928|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
32954929|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
32954930|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
32954931|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
32954932|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
33316925|NCT05170178|Experimental|Women with professional experience in caring for infants|Women in daily contact with infants in professional circle (e.g., nannies, pediatricians, midwives, maternity nurses) without dependent children under 2 years old
32954933|NCT00413166|Experimental|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
32954934|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
33316926|NCT00057954|Experimental|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
32954935|NCT00413166|Experimental|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
32954936|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
32954937|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
32954938|NCT00413400|Placebo Comparator|Placebo|
32954939|NCT00413400|Active Comparator|Etanercept|
32954940|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
32954941|NCT00413634|Experimental|Younger Participants (18-50 years)|
32954942|NCT00413634|Experimental|Elderly Participants (≥65 years)|
32954943|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
32954944|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
32954945|NCT00467844|Experimental|1|1 mg GTx-024
32954946|NCT00467844|Experimental|2|3 mg GTx-024
32954947|NCT00467844|Placebo Comparator|3|Placebo
32954948|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
33316927|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
33316928|NCT05167682||Prehabilitation|25 patients scheduled for tumor-esophagectomy (Ivor-Lewis) who are capable and have given consent to participate in a smartphone-based prehabilitation program.
33316929|NCT05167682||Historical Cohort|Patients ≥ 65 years of age who have undergone tumor-related esophagectomy at the University Hospital of Cologne between 05/2016 and 04/2020, who have not participated in any form of prehabilitation procedures
32738293|NCT05014035|Experimental|Exercise Intervention|
32954949|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
32954950|NCT04388904|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
32954951|NCT04388592|Experimental|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
32954952|NCT04388592|No Intervention|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
32954953|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
32954954|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
32954955|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
32954956|NCT00470106|Other|Skills Training|control training
32954957|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
32954958|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
32954959|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
32954960|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
32954961|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
32954962|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
32954963|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first cycle of induction are eligible for a second cycle, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during cycle 1, and cytarabine IV every 12 hours on days 1-6 of cycles 2-3. Treatment repeats every month for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
32954964|NCT00389532|Experimental|1|aged 19 to 59 years
32954965|NCT00389532|Experimental|2|aged ≥ 60 years
32954966|NCT03520686|Experimental|Cohort A (Experimental)|
32954967|NCT03520686|Experimental|Cohort B (Experimental)|
32954968|NCT03520686|Experimental|Cohort C (Experimental)|
32954969|NCT03520686|Active Comparator|Cohort A (Control)|
32954970|NCT03520686|Active Comparator|Cohort B (Control)|
32954971|NCT03520686|Active Comparator|Cohort C (Control)|
32954972|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32954973|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
32954974|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
32954975|NCT00475878|Placebo Comparator|placebo|
32954976|NCT00475878|Active Comparator|escitalopram|
32954977|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
32954978|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
32954979|NCT01796886|Experimental|patient's neurological status|
32954980|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
32954981|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
32954982|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
33102534|NCT05467358||Patients with preendoscopic cannot be ppi order|patients who could not get ppi before endoscopy
33316930|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
33316931|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
32954983|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
32954984|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
32954985|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
32954986|NCT04270656|Experimental|Insulin pump therapy|
32954987|NCT04270656|Active Comparator|Multi-injection treatment ( MDI ).|
32954988|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
32954989|NCT00424554|Experimental|Temozolomide treatment|
32954990|NCT00424554|No Intervention|No treatment|
32954991|NCT02117310|Experimental|ICG|Angiography with administered ICG
32954992|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
32954993|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
33316932|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
33316933|NCT01188044||Study group|Healthy children
33316934|NCT00057876|Active Comparator|Gemcitabine|
32954994|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
32954995|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
33316935|NCT00057876|Experimental|Gemcitabine + Radiation|
33316936|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
32954996|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
32954997|NCT00531882|Experimental|2-simvasatin|Simvastatin
32954998|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
32954999|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
32955000|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
32955001|NCT00486018|Sham Comparator|Sham injection|
32955002|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
32955003|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
32955004|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.~."
32955005|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
32955006|NCT04388514|Experimental|Blood ozonization|Blood ozonization plus BAT
32955007|NCT04388514|No Intervention|Standard of Care|"BAT only~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
32955008|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
33316937|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
33316938|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
33316939|NCT01588574|Experimental|MT10109|
32955009|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
32955010|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
32955011|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
32955012|NCT00533910|Experimental|Drug|
32955013|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
32955014|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
32955015|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
32955016|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
33316940|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
33316941|NCT05234684|Experimental|Orelabrutinib+ R-CHOP|Participants will receive 150 mg of oral orelabrutinib once daily with R-CHOP on day 1 of each cycle (21 days).
33316942|NCT05234684|Placebo Comparator|Placebo+ R-CHOP|Participants will receive 150 mg placebo once daily with R-CHOP on day 1 of each cycle (21 days).
33316943|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
33316944|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
33316945|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
33316946|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
33316947|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
32955017|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
32955018|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
32955019|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
32955020|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
32955021|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
32955022|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
32955023|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
32955024|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
32955025|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
32955026|NCT00535392|Experimental|Levetiracetam|
32955027|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
32955028|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
32955029|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
32955030|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
32955031|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
32955032|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
32955033|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
32955034|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
32955035|NCT00537576|Experimental|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
32955036|NCT00537576|Experimental|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
32812937|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
32812938|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
32812939|NCT01932437|Experimental|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
32812940|NCT01932437|Experimental|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
32812941|NCT01932437|Experimental|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
32812942|NCT01932437|Experimental|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
32955037|NCT00537576|Experimental|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
32955038|NCT00537576|Placebo Comparator|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
32955039|NCT00537576|Placebo Comparator|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
32955040|NCT00537576|Placebo Comparator|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
33316948|NCT03853382|No Intervention|Treatment As Usual|
33316949|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
32955041|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
33316950|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
32955042|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
32955043|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
32955044|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
32955045|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
32955046|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
32955047|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
32955048|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
32955049|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
32955050|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
32955051|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
32955052|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
32955053|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
32955054|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
32955055|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
32955056|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
32955057|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
32955058|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
32955059|NCT00539526|Experimental|1|bimatoprost 0.03%
32955060|NCT00539526|Active Comparator|2|travoprost 0.004%
32955061|NCT00539526|Active Comparator|3|latanoprost 0.005%
32955062|NCT01796106|Experimental|Icon|The study clinician will provide Icon treatment to all study participants randomized to study arm 1 after the radiograph and visual exam.
32955063|NCT01796106|Active Comparator|control|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish) to all study participants randomized to study arm 2 after the radiograph and visual exam.
32955064|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
32955065|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
32955066|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
32955067|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
32955068|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
32955069|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
32955070|NCT00439296|Experimental|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955071|NCT00439296|Experimental|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955072|NCT00439296|Experimental|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955073|NCT00439296|Experimental|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955074|NCT00439296|Experimental|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955075|NCT00439296|Experimental|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955076|NCT00439296|Experimental|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
32955077|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
33316951|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
33316952|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
33316953|NCT01188122|Experimental|AnapnoGuard|
32955078|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
32955079|NCT03117660|No Intervention|Control|Subjects will receive no treatment
32955080|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
32955081|NCT00439374|Placebo Comparator|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
32955082|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
32955083|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
32955084|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
32955085|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
32955086|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
32955087|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
32955088|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
32955089|NCT04749888|Experimental|Targeted nurse-led home visiting|The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
32955090|NCT04749888|No Intervention|Control group|The control group will receive existing maternal and child health services (usual care) except for the targeted nurse-led home visits.
32955091|NCT04750122|Experimental|Neoadjuvant therapy base on PTC drug screenning|Patients will receive neoadjuvant therapy including trastuzumab, pertuzumab, and chemotherapy based on PTC drug screening.
32955092|NCT04749576|Active Comparator|Low dose saffron|healthy, mild-moderate ulcerative colitis for low dose
32955093|NCT04749576|Active Comparator|High dose Saffron|healthy, mild-moderate ulcerative colitis for high dose
32955094|NCT04749576|Placebo Comparator|Placebo|healthy, mild-moderate ulcerative colitis for placebo
32955095|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
32955096|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
32955097|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
32955098|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
32955099|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
32955100|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
32955101|NCT00502944|Experimental|Counselor-based HIV screening|
32955102|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
32955103|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
32955104|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
32955105|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
33316954|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
33316955|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
33316956|NCT01187654|Active Comparator|control|injection of autologous serum
33316957|NCT04938284|Experimental|PAS and VNS|
33316958|NCT04938284|Active Comparator|PAS and sham VNS|
32955106|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
32955107|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
32955108|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
32955109|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
32955110|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
32955111|NCT00447330|Experimental|1|
32955112|NCT04388280|Other|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
32955113|NCT04388280|No Intervention|Observation|No imaging for the estimation of coronary artery disease
32955114|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
32955115|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
32955116|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
32955117|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
32955118|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
32955119|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
32955120|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
32955121|NCT00546390|Experimental|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
32955122|NCT00546390|No Intervention|No Cuff|No rIP
32955123|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
32955124|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
32955125|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
32955126|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
32955127|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
33100978|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
33100979|NCT02919501|Experimental|IV vortioxetine|
33100980|NCT02919501|Placebo Comparator|IV placebo|
33100981|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
33100982|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
33100983|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
33100984|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
33316959|NCT04938284|Active Comparator|PAS|
33316960|NCT04938284|Active Comparator|VNS|
33316961|NCT01290458|Experimental|Vitamin|
33316962|NCT01290458|Placebo Comparator|Control|
33316963|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
33316964|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
33316965|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
33316966|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
32812943|NCT01932437|Experimental|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
32812944|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
32812945|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
32812946|NCT01694485|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32812947|NCT01694485|Experimental|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32812948|NCT01694485|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32812949|NCT01694485|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32812950|NCT01694485|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
32812951|NCT01931735|Experimental|Randomized Meniscectomy|This group will have a partial meniscectomy
32812952|NCT01931735|Active Comparator|Randomized Lavage|This group will have arthroscopy and lavage
32812953|NCT01931735|Other|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
32812954|NCT01931735|Other|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
32812955|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
32812956|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
32812957|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
32812958|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
32812959|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
32812960|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
32812961|NCT04638725||HER2 positive breast cancer treated only with trastuzumab|
32812962|NCT04638725||HER2 positive breast cancer treated with pertuzumab|
32812963|NCT04638725||HER2 positive breast cancer treated with neratinib|
32812964|NCT04638725||HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)|
32812965|NCT04638725||HER2 positive breast cancer treated with TDM1 and neratinib|
32812966|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
32955128|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
33316967|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
33316968|NCT01188200|Active Comparator|Regular standard meal|standard meal
33316969|NCT01291628|Experimental|socks containing copper-oxide fibers|
33316970|NCT04934462|Other|non-surgical treatment|All participants will undergo 6 months of non-surgical treatment.
33316971|NCT04934462|Other|arthroscopic treatment|Those participants with failed non-surgical treatment at 6 months will undergo arthroscopic treatment.
33316972|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
33316973|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
33316974|NCT00053898|Active Comparator|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
33316975|NCT00053898|Experimental|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
33316976|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
33316977|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
33316978|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
33316979|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
32955129|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
32955130|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
32955131|NCT00511992|Experimental|Avastin|
32955132|NCT00451698|Placebo Comparator|3|acyanotic placebo
32955133|NCT00451698|Experimental|4|acyanotic erythropoietin
32955134|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
32955135|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
32955136|NCT01796340|Experimental|Food cue exposure|
32955137|NCT01796340|Active Comparator|Psycho-education|
32955138|NCT00548652|No Intervention|1|standard nutrition counselling
32955139|NCT00548652|Experimental|2|MOVE -weight loss intervention
32955140|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
32955141|NCT00548652|Experimental|4|MOVE plus methylphenidate
32955142|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
32955143|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
32955144|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
32955145|NCT00549042|Experimental|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
32955146|NCT00549042|Placebo Comparator|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
32955147|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
32955148|NCT00453336|Experimental|Single Arm|
32955149|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
32955150|NCT00550290|Active Comparator|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
32955151|NCT00550290|Experimental|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
32955152|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
32955153|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
32955154|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
32955155|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
32955156|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
32955157|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
32955158|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
32955159|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
32955160|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32955161|NCT04591392|Experimental|Device|ASD closure with the reSept ASD Occluder
32955162|NCT00552786|Experimental|Acetin|
32955163|NCT00552786|Placebo Comparator|Glucose|
32812967|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
32955164|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
32955165|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
32955166|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
32955167|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
32955168|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
33100985|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
33100986|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
33100987|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
33100988|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
33100989|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
33100990|NCT05317676|Active Comparator|Palmitoylethanolamide|300 mg PEA twice a day for a total of 600 mg PEA daily 2-month supply upon discharge
33100991|NCT05317676|Placebo Comparator|Placebo|1 placebo tablet twice a day for a total of 2 tablet placebo daily 2-month supply upon discharge
32955169|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
32955170|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
32955171|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
32955172|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
32955173|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
32955174|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
32955175|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
33100992|NCT04688697|Experimental|Prepectoral Group|Prepectoral implant-based reconstruction applied for patients in this group
33100993|NCT04688697|Active Comparator|Subpectoral Group|Subpectoral implant-based reconstruction applied for patients in this group
33100994|NCT02940821|Active Comparator|Whitening and Dentifrice|
33100995|NCT02940821|Active Comparator|Whitening Dentifrice|
33100996|NCT02940821|Active Comparator|Dentifrice|
33100997|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
33100998|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
33100999|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
33101000|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
33101001|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
33101002|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
33101003|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
33101004|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
33101005|NCT04691453|Active Comparator|QM-C Hysterectomy|QM-C Hysterectomy
33101006|NCT04691453|Experimental|QM-B Hysterectomy|QM-B Hysterectomy
33101007|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
33101008|NCT02940743|Active Comparator|Education (Edu)|
33101009|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
33101010|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
33101011|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
32812968|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
32812969|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
32812970|NCT01930175|Placebo Comparator|Placebo|single dose iv of Placebo
32812971|NCT01930175|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
32812972|NCT01930175|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
32812973|NCT04124965|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
32812974|NCT04124965|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
32812975|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
32812976|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
32812977|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
32812978|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
32812979|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
32812980|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
32812981|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
32812982|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
32812983|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
32812984|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
32812985|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
32812986|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
32812987|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
32812988|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
32812989|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
32812990|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
32812992|NCT04124809|Experimental|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
32812993|NCT04124809|No Intervention|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
32812994|NCT04553263|Experimental|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
32812995|NCT04553263|Experimental|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
32812996|NCT04553263|No Intervention|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
32812997|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
32812998|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
32812999|NCT04768075|Experimental|Camrelizumab group|"subject will receive Camrelizumab intravenously(IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by Camrelizumab ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
32813000|NCT04768075|Placebo Comparator|placebo group|"subject will receive placebo intravenously (IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by placebo ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
32813001|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32813002|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
33101012|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
33101013|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
32813003|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
33101014|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.~Size: R40 (40/0.06)"
33101015|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.~Size: 25/0.06"
33101016|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
33316980|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
32813004|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
32813005|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
32813006|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
32813007|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
32813008|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
32813009|NCT04546867|Other|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
32813010|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
32813011|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
32813012|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
32813013|NCT04625231|Experimental|Shared-Decision Making Tool Group|
32813014|NCT04625231|No Intervention|Standard of Care Group|
32955176|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
32955177|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
32955178|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
32955179|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
32955180|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
32955181|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
32955182|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
32955183|NCT00520884|Placebo Comparator|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
32955184|NCT00520884|Placebo Comparator|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
32955185|NCT00520884|Active Comparator|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
32955186|NCT00520884|Active Comparator|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
32955187|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
32955188|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
32955189|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
32955190|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
32955191|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
32955192|NCT00523614||1: Cases|
32955193|NCT00523614||2: Controls|
32955194|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
32955195|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
32955196|NCT00524940|Experimental|Study Group|
32955197|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
32955198|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
32955199|NCT04384848|Experimental|Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
32955200|NCT04166916|Active Comparator|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
32955201|NCT04166916|Sham Comparator|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
32955202|NCT04166916|Active Comparator|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
32955203|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
32955204|NCT04146714|Experimental|Substance use screening|Participants complete a substance use questionnaire (=intervention).
32813015|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
32813016|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
32813017|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
32813018|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
32813019|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
32813020|NCT01689337|Placebo Comparator|Placebo|
32813021|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
32813022|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
32813023|NCT04624139|Experimental|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
32813024|NCT04624139|Active Comparator|Active control group, group 2|Physiotherapy only
32813025|NCT04881409|Experimental|nasal high-flow|Patient with AECOPD is treated with NHF.
32813026|NCT04881409|Active Comparator|non-invasive ventilation|Patient with AECOPD is treated with NIV
32813027|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
32813028|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
32813029|NCT04871503|Experimental|HIFEM+RF (HR)|The HR group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with mild heating of the muscles.
32813030|NCT04871503|Experimental|HIFEM (H)|The H group will receive a treatment with the intensities of the magnetic field just below the patient's tolerance threshold without the use of radiofrequency.
32813031|NCT02986009|Experimental|Parenting|To receive the parenting intervention
32813032|NCT02986009|Experimental|Information|To receive the information intervention
32813033|NCT02985931||Suspected CAD subjects|
32813034|NCT00891436|Placebo Comparator|Placebo nasal spray|
32813035|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
32813036|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
32813037|NCT04381546|Experimental|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
32813038|NCT00820534|Experimental|Penciclovir|Penciclovir
32813039|NCT00820534|Placebo Comparator|Placebo|Placebo
32813040|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.
32813041|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.
32813042|NCT00820612|Active Comparator|1|Indomethacin suppository
32813043|NCT00820612|Placebo Comparator|2|Placebo suppository
32813044|NCT01928927|Experimental|Arm A: Telmisartan|
32813045|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
32813046|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
32813047|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
32813048|NCT05315518|Experimental|single shade universal resin composite (omnichroma) with blocker|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
32955205|NCT04146714|Active Comparator|Physical activity screening|Participants complete a physical activity questionnaire (=control).
32955206|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
32955207|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
32813049|NCT05315518|Active Comparator|single shade universal resin composite(GC solare sculpt) with chameleon effect|One-shade universal resin composite (GC solare sculpt) gives very natural appearance, High gloss retention over time, time saving regarding to layering technique, wide shade matching range (chameleon effect) and delivering lifelike aesthetic restorations. These features can be offered by supra-nano spherical filler which have controlled refractive index, records excellent esthetic properties in small and medium class IV restorations.
32813050|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
32813051|NCT05310448|Experimental|Treatment (tumor treating fields)|After completion of standard of care radiation therapy, patients wear the Optune device for 18 hours per day for 12 months in the absence of disease progression or unacceptable toxicity.
32813052|NCT05318404|No Intervention|Conventinal feeding group|Start oral feeding 5-7 days after esophagectomy and discharge with soft blended diet as major energy source
32813053|NCT05318404|Experimental|Delayed feeding group|Start clear liquid fluid diet 5-7 days after esophagectomy and discharge with jejunostomy feeding as the major energy source. Start oral feeding at postoperative 1st visit
32813054|NCT05317546|Experimental|Cannabidiol, Then Placebo|
32813055|NCT05317546|Experimental|Placebo, Then Cannabidiol|
32813056|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
32813057|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
32813058|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
32813059|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
32813060|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
32813061|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
32813062|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
32813063|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
32813064|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
32813065|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
32813066|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
33316981|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
32813067|NCT05312320|Active Comparator|Information film|Randomized to receive a short information film online.
32813068|NCT05312320|No Intervention|Standard care|No film, only questionnaire.
32813069|NCT05310760|Active Comparator|Vitamin C receiving|Therapeutic doses of Vitamin C are added to rachitic children treatment
32813070|NCT05310760|No Intervention|Non Vitamin C receiving|The traditional treatment of nutritional rickets
32813071|NCT05236504|Experimental|Supplement|Melatonin and magnesium-containing pod
32813072|NCT05236504|Placebo Comparator|Placebo|Placebo pod
32813073|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
32813074|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
32813075|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
32813076|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
32813077|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
32813078|NCT00875836|Experimental|Buspirone|Buspirone
32813079|NCT00875836|Placebo Comparator|Placebo|Placebo
32813080|NCT05235802||Patients with traumatic brain injury about 10 years ago|Patients that had suffered a TBI and being managed at the Neurosurgical Department at the Karolinska University Hospital between 2007 and 2015.
32813081|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
32813082|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
32813083|NCT05312476|Experimental|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)
32813084|NCT05312398|Experimental|single arm|"This is an open-label phase II study investigating the efficacy and safety of a bio-marker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. Based on dynamic and longitudinal liquid biopsy assessment of RAS/BRAF status, that will be prospectively performed before each line of treatment, mCRC patients will be treated with cetuximab in combination with chemotherapy throughout three lines of therapy, as follows:~FOLFIRI plus cetuximab (first line);~FOLFOX plus cetuximab (second line);~irinotecan plus cetuximab (third line).~If at progression after the first line or after the second line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with FOLFOX plus bevacizumab as second line of therapy, or with regorafenib or with trifluridine-tipiracil (investigator's choice) as third line therapy."
32955208|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
32955209|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
32955210|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
32955211|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
32955212|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
32955213|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
32955214|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
32955215|NCT00556140|Experimental|Major Depression with Psychotic Features|
32955216|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
32955217|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
32955218|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
32955219|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
32955220|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
32955221|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
32955222|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
32955223|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
32955224|NCT04043598|Active Comparator|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
32955225|NCT04043598|Active Comparator|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
32955226|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
32955227|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
32955228|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~postoperative day 1 to 10: 1 placebo capsule x 3"
32955229|NCT01797510|Experimental|Coaching|Interventional web based coaching study
32955230|NCT01797510|No Intervention|Usual Care|
32955231|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
32955232|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
32955233|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
32955234|NCT05622630|Active Comparator|Four-cell bathroom|Four-cell bath:Treatment with direct current
32955235|NCT05622630|Active Comparator|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
32955236|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
32955237|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
33316982|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff~A web-based self-management education (I-Can-Manage Cancer) for patients~Telephone-based, nurse-led health coaching~Optional end of study patient interview (sub-study)"
32955238|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
33101017|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
32955239|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
33316983|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
33316984|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
33316985|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
32955240|NCT04747704|Experimental|Intervention|Participants receiving Three-Principles Counseling
33316986|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
32955241|NCT05622552|Active Comparator|active group|"tDCS stimulation, which was performed once a day sessions of active anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
33316987|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
33316988|NCT01293734|Active Comparator|Western medicine control group|
33316989|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
33316990|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
33316991|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
33316992|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
33316993|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
33316994|NCT03138538|Experimental|M8891 7 mg|Participant received M8891 at dose of 7 milligrams (mg) orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33316995|NCT03138538|Experimental|M8891 12 mg|Participant received M8891 at dose of 12 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33316996|NCT03138538|Experimental|M8891 20 mg|Participant received M8891 at dose of 20 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33316997|NCT03138538|Experimental|M8891 35 mg|Participant received M8891 at dose of 35 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33316998|NCT03138538|Experimental|M8891 60 mg|Participant received M8891 at dose of 60 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33316999|NCT03138538|Experimental|M8891 80 mg|Participant received M8891 at dose of 80 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
33317000|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
32955242|NCT05622552|Sham Comparator|sham group|"tDCS stimulation, which was performed once a day sessions of sham anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
32955243|NCT03572790|Experimental|Prucalopride|
32955244|NCT03572790|Placebo Comparator|Placebo|
33317001|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
33317002|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
32955245|NCT05622474|Experimental|IC plus CC plus IMRT|Induction chemotherapy followed by Intensity-modulated radiotherapy plus concurrent chemotherapy
33317003|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
33317004|NCT04325230|Experimental|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
33317005|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
33317006|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
33317007|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
33405015|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
32744260|NCT04391517|Experimental|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
32744261|NCT04877769|Experimental|AT-527 Group A|n=8
32744262|NCT04877769|Experimental|AT-527 Group B|n=8
32744263|NCT04877769|Experimental|AT-527 Group C|n=8
32744264|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
32744265|NCT03049059|Active Comparator|4% hydroquinone cream alone|
32744266|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
32744267|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
32744268|NCT03048591|Experimental|Electroacupuncture group|
32744269|NCT03048591|No Intervention|control group|
32744270|NCT04885413|Experimental|study arm|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
32744272|NCT04386993|Experimental|IMRT|-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy.
32744273|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
32744274|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
32744275|NCT04872075|Experimental|Experimental|People at the concert
32744276|NCT04872075|Active Comparator|Control|People staying at home
32744277|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
32744278|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
32744279|NCT04411017|Active Comparator|1L PEG|
32744280|NCT04411017|Active Comparator|2L PEG|
32744281|NCT04411017|Active Comparator|2L sodium picosulfate|
32744282|NCT04410705|Experimental|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
32744283|NCT04368507|Experimental|YYB101+Irinotecan|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
32744284|NCT04147533|Experimental|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
32744285|NCT04871841||Sputnik V Vaccinees|Participants (healthy adults aged >=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.
32744286|NCT04871685||Covid Center UOC Vanvitelli, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744287|NCT04871685||Covid Center Cotugno Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744288|NCT04871685||"Covid Center Del Mare Hospital, Naples"|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744289|NCT04871685||Covid Center Santa Maria delle Grazie Hospital, Pozzuoli|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744290|NCT04871685||Covid Center Monaldi Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744291|NCT04871685||Covid Center Vannini Hospital, Rome|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744292|NCT04871685||Covid Center Bassini Hospital, ASST Milano Nord|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744293|NCT04871685||Covid Center Melfi Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744294|NCT04871685||Covid Center Messina University Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
32744295|NCT04870983||SAE group|SAE was defined as cerebral dysfunction in the presence of sepsis or septic shock and the absence of any of the exclusion criteria. For patients undergoing sedation during the ICU stay, the GCS scores were evaluated before sedation; for patients who have been sedated prior to ICU admission, the assumed GCS scores, i.e., the scores measured before any administration of sedative/relaxant drug were used for analysing; for postoperative patients, the GCS scores measured before surgery was used. The CAM-ICU was assessed daily by the nurse or the physician in charge of the patient during the ICU stay. For patients who were sedated, spontaneous awakening trials were performed daily; the longest evaluate time after withdrawal of sedation was 24 h during the trials. In this evaluation period, patients should be awake to evaluate their consciousness, and they were diagnosed of SAE if the patients were not awake.
33101018|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
33101019|NCT02919540|No Intervention|control group|routine care will be implemented
33101020|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
33101021|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
33101022|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
33101023|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
33101024|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~Direct thrombin inhibitor: Dabigatran or~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
33101025|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~antiplatelet drug(s) or~no antithrombotic drugs."
33101026|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
33101027|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
33317008|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
33317009|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
33317010|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
32744296|NCT04870983||non-SAE group|The patient was diagnosed with sepsis or septic shock but could not be diagnosed with SAE
32744297|NCT05257395|Experimental|XZP-3287+ Letrozole/Anastrozole|
32744298|NCT05257395|Placebo Comparator|Placebo + Letrozole/Anastrozole|
32744299|NCT05257317|Experimental|Intervention|It will consist of osteopathic manual therapy techniques applied to the occipital and temporal bones.
32744300|NCT05257317|Placebo Comparator|Placebo|It consists of a light contact applied to the cranial vault (frontal and parietal bones) where circular movements will be induced.
32744301|NCT05257161|Active Comparator|Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))|183 Carotid stenting (Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))
32744302|NCT05257161|Experimental|MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS)|183 Carotid stenting (MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS))
32744303|NCT05256771|Active Comparator|Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF)|Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
32744304|NCT05256771|Active Comparator|Arm B: EMS/RF Arm (EMS + RF/PEMF)|Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
32744305|NCT05256771|Active Comparator|Arm C: EMS Arm (EMS only)|Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).
32744306|NCT05256693|Experimental|Vancomycine|Oral vancomycine 125 mg twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
32744307|NCT05256693|Placebo Comparator|Placebo|Vancomycine placebo, twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
32744308|NCT04871139|Experimental|Diagnostic (iodine-based contrast, CEM)|Patients receive iodine-based contrast agent IV and the undergo CEM over 10-15 minutes.
32744309|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
32744310|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
32744311|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
32744312|NCT04877925|Active Comparator|Standard Group|Patients with 2 standard chest tubes
32744313|NCT04877925|Experimental|Coaxial Group|Patients with 1 coaxial tube
32744314|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
32744315|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
32744316|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
32744317|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
32744318|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
32744319|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
32813085|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
32813086|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
33317011|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
33317012|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
33317013|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
33317014|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
33317015|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
33317016|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
33317017|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
33317018|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
32744320|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
32744321|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
32744322|NCT04871373|Experimental|Experimental group|A trained periodontist delivered oral hygiene instructions and motivational interviewing sessions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
32744323|NCT04871373|Active Comparator|Control group|A trained periodontist delivered only oral hygiene instructions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
32744324|NCT05256147|Experimental|Intervention group|There is one group in this study and they will receive ibuprofen 400 mg before their narrow band UVB phototherapy session which occurs two to three times weekly. The treatment dose of NBUVB will start off at 150 mJ/cm2 and will be increased 10% as tolerated til the patient reaches 700 mJ/cm2. They will receive ibuprofen before each phototherapy session.
32744325|NCT04877067|Active Comparator|WJ-MSC combine witf rEMS|WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
32744326|NCT04877067|Active Comparator|Only rEMS|rEMS applications were repeated 10 times with a 1-week interval.
32744327|NCT04877067|Active Comparator|Only WJ-MSC|WJ-MSC was applied only one time for both eyes.
32744328|NCT04877145|Experimental|single drill|one drill to place the implants 3.25mm diameter stainless steel drill was used.
32744329|NCT04877145|Active Comparator|sequential drills|For the control group, four drills (2.2mm, 2.75mm, 3.25mm and 4mm diameter),
32744330|NCT04870749||lower urinart tract syptoms|Lower urinary tract symptoms (LUTS) are common in older men and one of the main reasons for this is the enlargement in prostate gland volume caused by hormonal changes.
32744331|NCT04877301|Experimental|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter.
32744332|NCT04877301|Active Comparator|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter.
32744333|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
32744334|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
32744335|NCT05255913|Experimental|group 1|
32744336|NCT05255913|Active Comparator|group 2|
32744337|NCT05255835|Active Comparator|Semiconductor knee-sleeves|Knee-sleeves containing semiconductor elements within the fabric constitute the intervention arm.
32744338|NCT05255835|Placebo Comparator|Placebo knee-sleeves|Cotton knee-sleeves constitute the placebo arm.
32744339|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
32744340|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
32744341|NCT05214417|Experimental|KAP (Ketamine-assisted Psychotherapy) Recipients|Two separate IM ketamine injection sessions, with possible multiple doses administered at each session not to exceed 100 mg IM ketamine total for the session.
32744342|NCT05214417|Other|Naturalistic Comparator|Pre-existing conventional treatment will continue for this group during the study period.
32744343|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
33317019|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
33317020|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
33317021|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
32813087|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
32813088|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
32813089|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
32813090|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
32813091|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
32813092|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
32813093|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
32813094|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
32813095|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
32813096|NCT04545229|Experimental|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
32813097|NCT04545229|Experimental|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
32813098|NCT04545229|No Intervention|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
32813099|NCT01589653|Experimental|Subject-driven titration|
32813100|NCT01589653|Experimental|Investigator-driven titration|
32813101|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
32813102|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
32813103|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
32813104|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
32813105|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
32813106|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
32813107|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
32813108|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
32813109|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
32813110|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
32813111|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
32813112|NCT04624061|Experimental|Intervention|"The integrated HIV/HTN care model with the following components;~Training and capacity building on the INTEGRATED HIV/HTN model and NCD care~Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.~HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.~SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
32813113|NCT04624061|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
32813114|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
32813115|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
32813116|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
32813117|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
32813118|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
32813119|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
32813120|NCT04415723|Experimental|intervention group|supportive care management programme
32813121|NCT04415723|No Intervention|control group|receive the usual care provided by the health care system of Cyprus
32813122|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
32813123|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
32813124|NCT01927055|Placebo Comparator|Placebo|Placebo
32813125|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
32813126|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
32813127|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
32813128|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
32813129|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
32813130|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
32813131|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
32813132|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
32813133|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
32813134|NCT04415879|Active Comparator|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
32813135|NCT04415879|Experimental|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
32813136|NCT04415879|Experimental|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
32813137|NCT01925417|Experimental|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
32813138|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
32813139|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
32813140|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
32813141|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
32813142|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
32813143|NCT01910519|Experimental|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
32813144|NCT01910519|Experimental|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
32813145|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
32813146|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
33317022|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
33101028|NCT05317598|Experimental|Intervention group|Students in the intervention group will be given a 5-week positive psychotherapy-based kindness and honesty psychoeducation.
33101029|NCT05317598|No Intervention|control group|Students in the control group will not receive any intervention during the 5-week period.
33101030|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
32813147|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
32813148|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
32813149|NCT01910129|Placebo Comparator|sham gammaCore|Inactive stimulation treatment
32813150|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
32813151|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
32813152|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
32813153|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
32813154|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
32813155|NCT04622423||Primary non-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
32813156|NCT04622423||Healthy volunteers|Negative control for the clinical study.
32813157|NCT04622267|Active Comparator|Standard suture|Standard antimicrobial suture (vicryl) - control arm
32813158|NCT04622267|Experimental|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
32813159|NCT04171895||Enhanced Usual Care (EUC)|
32813160|NCT04171895||Communication Training|
32813161|NCT04621877|Experimental|"Volunteer-delivered Behavioral Activation - Do More, Feel Better"|"Do More, Feel Better (DMFB) is a streamlined, simplified version of Behavioral Activation (BA) delivered by lay volunteers to depressed senior center clients."
32813162|NCT04621877|Active Comparator|Master's Level Clinician-delivered Behavioral Activation|Traditional Behavioral Activation (BA) delivered by master's level mental health clinicians
32813163|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
32813164|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
32813165|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32813166|NCT01923389|Placebo Comparator|Placebo|
32813167|NCT01923389|Experimental|100 mg PF-05231023|
32813168|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
32813169|NCT04620161|Experimental|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
32813170|NCT04620161|Experimental|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
32813171|NCT04620161|Placebo Comparator|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
32813172|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
32813173|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
32813174|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
32813175|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
32813176|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
32813177|NCT01589185|Experimental|Placebo|KBSA301-placebo
33101031|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
32813178|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
33101032|NCT04688970||Acute stroke with affection of the upper extremity|"Subject is 18 years or above.~Subject has an acute stroke affecting one UE (FMA less than 50).~Subject or caregiver understands the study and its procedures and gives informed consent.~If the subject is not able to give informed consent:~The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.~The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points."
33317023|NCT03955926|No Intervention|Control group|kept fasted from midnight until surgery
33317024|NCT03955926|Experimental|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
33317025|NCT05571358|No Intervention|Control Group|Following clinical practice guidelines, subjects in the control group will receive multidisciplinary rehabilitation programmes with coordinated delivery of supervised exercise therapy, cognitive behavioural therapy (education on pain), as well as therapeutic massage to relieve low back pain during pregnancy.
33317026|NCT05571358|Experimental|Virtual Reality (Nature Trek)|"Subjects in the experimental group will receive the same treatment described for the control group.~Subjects in the experimental group will receive an additional Virtual Reality Intervention (VRi)."
33317027|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
33317028|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
33317029|NCT01191164|Experimental|Study Arm|
33317030|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
33317031|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
33317032|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
32813179|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
32813180|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
33317033|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
33317034|NCT03852446|Experimental|Part 1: Single Ascending Dose|
33317035|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions~Single dose of Indoximod HCL (F2) formulation under fed conditions~Single dose of Indoximod base formulation under fasting conditions"
32813181|NCT04863313|Experimental|Group receiving the probiotic capsules|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
32813182|NCT04863313|Placebo Comparator|Group receiving the placebo capsules|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
32813183|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
32813184|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
32813185|NCT01588405|Experimental|UT-15C SR|
32813186|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
32813187|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
32955246|NCT05622474|Active Comparator|CC plus IMRT|Intensity-modulated radiotherapy plus concurrent chemotherapy alone
32955247|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
32955248|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
32955249|NCT03379194|No Intervention|Control|No intervention
32955253|NCT04429542|Experimental|BCA101 Monotherapy|Route: IV Infusion Frequency: QW Current Dose: 1500mg
32955254|NCT04429542|Experimental|BCA101 + pembrolizumab|Route: IV Infusion Frequency: Q3W Dose: 200mg
32955255|NCT04428528||Neoadjuvant Chemotherapy Monitoring|
32955256|NCT04428528||Breast Mass Characterization|
32813188|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
32813189|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
33317036|NCT05117710|Active Comparator|Ebselen|The intervention will be 7-10 days administration of ebselen 600 mg twice daily taken orally. Ebselen has been manufactured to Good Manufacturing Practice (GMP) standards and will be provided by Sound Pharmaceuticals Inc. in 200 mg capsules.
33317037|NCT05117710|Placebo Comparator|Placebo|The intervention will be 7-10 days administration of placebo 600 mg twice daily taken orally.Identical placebo capsules have been manufactured and formulated in the same facilities as the active treatment.
32813190|NCT01603615|Experimental|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
32813191|NCT04626947|Other|Open label|Single arm
32813192|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
32813193|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
32813194|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
32813195|NCT04416113|Active Comparator|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.~The laser device:~Laser watched applied at the wrist on the radial artery.~Laser acupuncture"
32813196|NCT04416113|Active Comparator|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.~0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to~After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).~The session will be done twice per week~Laser watched applied at the wrist on the radial artery."
32813197|NCT04416113|Active Comparator|positive control|This group will include patients who are subjected to conventional treatment
32813198|NCT04619615|Experimental|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
32813199|NCT04619615|Active Comparator|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional ~7.5 hours in total).
32813200|NCT01904903|Other|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
32813201|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
32813202|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
32955257|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
33317038|NCT01293890||COPD patients with hospital admission for exacerbation|
32813203|NCT01921205|Experimental|Lacosamide|
32813204|NCT01921205|Placebo Comparator|Placebo|
32813205|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
32813206|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
32813207|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
32813208|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
32813209|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
32813210|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
32813211|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
32813212|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
32813213|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
32813214|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
32813215|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
32813216|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
32813217|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
32813218|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
32813219|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
32813220|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
32813221|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
32813222|NCT05312086|Other|patients with X-linked hypophosphatemic|Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment
32813223|NCT05312086|Other|healthy volunteers|control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex
32813224|NCT04129138||Observational (survey)|Participants complete a survey over 30 minutes.
32813225|NCT00878878|Experimental|Arm A|
32813226|NCT00878878|Experimental|Arm B|
32813227|NCT05311696||Residential Cohort|Those completing the program in a residential context
32813228|NCT05311696||Online Cohort|Those completing the program online
32813229|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
32813230|NCT04089202|Active Comparator|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.~Surveys will be administered to measure patient burden and self efficacy."
33317039|NCT05111236|Active Comparator|RPT Group|"Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies. This whole regimen will be practiced fives times a week for a period of twelve weeks.~Other Names:~• Routine Physical Therapy"
32813231|NCT04089202|Experimental|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.~Surveys will be administered to measure patient burden and self efficacy."
32813232|NCT04088890|Experimental|R/R ALL|"Relapsed/refractory ALL~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10"
32813233|NCT04088890|Experimental|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.~Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)"
32813234|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
33101033|NCT05317559|Experimental|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux).
33101034|NCT05317559|No Intervention|dim light|The dim light condition (n=10) included two consecutive nights of sleep in dim light.
33317040|NCT05111236|Experimental|Massage Group|"Traditional massage of thirty minutes duration ( five minutes of massage will be provided to all four limbs, front and back of trunk area) prior to routine physical therapy. Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies.~Other Names:~• Routine physical therapy and Traditional massage"
33317041|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
33405016|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
32813235|NCT00879190|Active Comparator|Ampicillin/gentamicin|
32813236|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
33405017|NCT05202444|Experimental|Osteotomy using piezoelectrical device|
32813237|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32813238|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
32813239|NCT01709149|Experimental|CK-2017357|125 mg tablets
32813240|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
32813241|NCT05216926|Experimental|Hypoglycemia predicition and preventive treatment|
32813242|NCT05216926|Other|Corrective hypoglycemia treament (at hypogylcemia)|
32813243|NCT05214196|Experimental|Hypochlorous acid group|The effect of 0.02% Hypochlorous acid solution on viral load was investigated by using 25 COVID-19 patients as an oral antiseptic for 30 seconds.
32813244|NCT05214196|Active Comparator|Povidone-iodine group|The effect on viral load was investigated by using 0.5% Povidone-iodine solution as an oral antiseptic for 30 seconds in 25 COVID-19 patients.
32813245|NCT05214196|Placebo Comparator|Saline group|The effect on viral load was investigated by using 0.9% isotonic saline solution as a placebo for 30 seconds in 25 COVID-19 patients.
32955258|NCT03271554||Alectinib|Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
32955259|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
32955260|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
32955261|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
32955262|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
33405018|NCT05202444|Active Comparator|Osteotomy using surgical saw|
33405019|NCT01374633|Experimental|1:patient with severe traumatic brain|
33405020|NCT03652922|Experimental|Propranolol|
33405021|NCT03652922|Placebo Comparator|Placebo|
33405022|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
32813246|NCT05213026||Apexification|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling is sufficient for the MTA,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
32813247|NCT05213026||Regenerative|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
32813248|NCT01568593|Experimental|T2750|
32813249|NCT01568593|Active Comparator|Vismed|
32813250|NCT05311228|Experimental|Intervention group|Intervention group will give azithromycin for 14 days, 7 days 10 mg/body weight/24 hours, 7 days 5 mg/bw/hours
32813251|NCT05311228|No Intervention|Control group|No intervention
32813252|NCT04382014|Experimental|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
32813253|NCT04382014|Active Comparator|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
32955263|NCT05622162|Experimental|Interventional and Comparator|The subject participation in the study consists from performing of one non-contrast enhanced PET/CT with Investigational Product (18F-JK-PSMA-7) and of one PET/CT with Comparator (18F-Fluorocholine) This sequence of administration is established in advance as the organizational model, linked to the availability and management of the radiopharmaceutical, not allow to perform a randomization.
32955264|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
32955265|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
32955266|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
32955267|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
32955268|NCT04069572|Experimental|Vibrotactile Stimulation|
32955269|NCT04069572|Sham Comparator|Sham Stimulation|
32955270|NCT04049994|Experimental|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
32955271|NCT04049994|Placebo Comparator|Placebo|Oral placebo tablet once daily for 90 days.
32955272|NCT04039074|Experimental|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
32955273|NCT04039074|Active Comparator|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
32955274|NCT04039074|Active Comparator|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
32955275|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
32955276|NCT04005378|Other|Usual Care|Usual care provided by CSC center
32955277|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
32955278|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
32955279|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
32955280|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
32955281|NCT05621928||Case|Individuals aged 18 years or older, with a suspected clinical picture of COVID-19 virologically confirmed, that is, with positive RT-PCR for SARS-CoV-2 in a respiratory secretion sample collected in the first 7 days of the onset of symptoms , who did not have a positive RT-PCR result for SARS-CoV-2 in the 90 days preceding enrollment in the study.
32955282|NCT05621928||Control|Individuals residing in the vicinity of the case, aged 18 years or older, without a suspected clinical picture of COVID-19 and with RT-PCR negative for SARS-CoV-2 in a respiratory secretion sample collected at the time of inclusion, followed by confirmation of the absence of signs and symptoms suggestive of COVID-19 within the next 7 days.
32955283|NCT05621928||immunogenicity analyzes|a convenience sample composed of all cases exposed or not to vaccination and 200 controls, 100 vaccinated and 100 unvaccinated, for analysis of humoral response.
32955284|NCT05621928||assessment of cellular immunity|a sample of 100 vaccinated cases and 100 unvaccinated cases followed prospectively, and 100 vaccinated controls 100 unvaccinated controls assessed spot-on at enrollment.
32955285|NCT05621928||analysis of potential genetic risk factors for the occurrence of severe forms of COVID-19 (SRAG)|a total of 50 cases
32955286|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
32955287|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
32955288|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
32955289|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
32955290|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
32955291|NCT03884634||Dabir Microsurface Overlay Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned ON (in addition to standard operating room table mattress and heating/cooling gel pad).
32955292|NCT03884634||Control Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned OFF (in addition to standard operating room table mattress and heating/cooling gel pad).
33317042|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
33405023|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
32955293|NCT05621694|Experimental|Qigong/Tai Chi Intervention|"Tai chi and Qigong combined into a simplified, standard practice, Tai Chi Easy"
32955294|NCT03718494|Experimental|Follow up|Subjects will receive F-18 Florbetapir PET
32955295|NCT03718494|Experimental|Follow up - Mayo Clinic Sites only|Subjects will receive F-18 AV-1451 PET and F-18 Florbetapir PET
32955296|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
32955297|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
32955298|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
32955299|NCT04388202|Experimental|Sertraline|Sertraline 100-200 mg daily for 8 weeks
32955300|NCT04388202|Active Comparator|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
32955301|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
32955302|NCT02128230|Experimental|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
32955303|NCT05621538|Experimental|Neurofeedback-active + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
32955304|NCT05621538|Active Comparator|Neurofeedback-active + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
32955305|NCT05621538|Active Comparator|Neurofeedback-sham + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
32955306|NCT05621538|Sham Comparator|Neurofeedback-sham + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
32955307|NCT05621538|No Intervention|Check-In Only|4 sessions of: Completing typical pre-TMS/MRI procedures Being prompted to reflect on outside treatment (TAU)
32955308|NCT03416244|Experimental|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
32955309|NCT03416244|Experimental|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
32955310|NCT05560776|Experimental|2 passes per target on EBUS|
32955311|NCT05560776|Experimental|3 passes per target on EBUS|
32955312|NCT05560620|Experimental|Sleep Deprivation and Caffeine Intervention|Participants randomized into the sleep deprivation group and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
32955313|NCT05560620|Sham Comparator|Sleep Deprivation and no Caffeine intervention|Participants randomized into the sleep deprivation group and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
32955314|NCT05560620|Active Comparator|Control and Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
32955315|NCT05560620|Sham Comparator|Control and No Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
32955316|NCT04388124|Placebo Comparator|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
32955317|NCT04388124|Experimental|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
32955318|NCT05560386|Experimental|Text messaging program|Enrolled participants received the pilot text messaging program.
32955319|NCT05560386|Experimental|Virtual peer education|Enrolled participants received a virtual peer education diabetes prevention program.
32955320|NCT05621460|Experimental|500mL carbonated water first, then 500mL of still water, then 50mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 500mL still water on the second test day, then 50mL still water on the third day.
32813254|NCT04382014|Active Comparator|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
32813255|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
32813256|NCT01683565|Placebo Comparator|Canola Oil Placebo|
32813257|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
32813258|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
32813259|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
32813260|NCT04416035|Experimental|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
32813261|NCT04416035|Active Comparator|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
32813262|NCT04381858|Experimental|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
32813263|NCT04381858|Active Comparator|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
32813264|NCT04381390|Experimental|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
32813265|NCT04381390|Experimental|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
32813266|NCT04088422||B-cell lymphoma|
32813267|NCT05117086|Experimental|Dietary Intervention Arm|Subjects will receive the active intervention of nutrition education and medical nutrition therapy counseling for dietary and behavioral lifestyle changes. The focus will be on DASH diet implementation and adherence for management of heart failure. The subjects will have 4 study visits with a Registered Dietitian over 6 months (visits at 1, 2, 3, and 6 months). Outcome measures will be assessed at baseline, 3 and 6 months.
32813268|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
32813269|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
32813270|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
32813271|NCT00883168|Placebo Comparator|placebo|
32813272|NCT00883168|Active Comparator|azelastine Hcl|
32813273|NCT00883168|Active Comparator|fluticasone propionate|
32813274|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
32813275|NCT01616693|Experimental|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
32813276|NCT01616693|Active Comparator|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
32813277|NCT01616693|Active Comparator|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
32813278|NCT01616693|Placebo Comparator|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
32813279|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
32813280|NCT04415645|Experimental|VVZ-149 Injections|
32813281|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
33101035|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
33405024|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
33101036|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
33101037|NCT05316194||Participation in digital OA treatment|All participants that have participated in a digitally delivered first-line treatment program (Joint Academy) for hip or knee OA until May 2022.
33101038|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
33101039|NCT02915718|No Intervention|control group|non intervention
32813282|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
33101040|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
33101041|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
32813283|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
33317043|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
33317044|NCT04318366||COVID-19 patients|
33317045|NCT00071058|Experimental|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
33317046|NCT05012410|Experimental|Immediate treatment group with High-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive telephone and email prompts.
33317047|NCT05012410|Experimental|Immediate treatment group with Low-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive email prompts only.
32813284|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
33317048|NCT05012410|Experimental|Waitlist Control after three months with high-Intensity prompts|After three months, caregivers will receive WeCareAdvisor and telephone and email prompts.
33317049|NCT05012410|Experimental|Waitlist Control after three months with Low-Intensity Prompts|After three months, caregivers will receive WeCareAdvisor and email prompts only.
32813285|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
32813286|NCT05086354|Experimental|One group that all receive the intervention of jumping rope.|All participants will be in one group. Every participant receives the same intervention.
32813287|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
32813288|NCT04964440||PURE EP Guided Procedures|Redo AF procedures guided by Pure EP System during an AF Ablation
32813289|NCT04964440||Standard Recording System Guided Procedures|Redo AF procedures guided by the Standard Recording System during an AF Ablation
33101042|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
33101043|NCT05302388|Experimental|Experimental group|Drug: SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine Starting from the lowest dose, when the former dose does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD).
33101044|NCT05302388|Placebo Comparator|Placebo control group|Placebo control: The same volume of placebo as SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine The rule and dose of placebo were the same as SIBP-R002.
33101045|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
33101046|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
33101047|NCT05296616|Experimental|MSQSLHRV|The group in which the mindfulness-based stress reduction intervention will be implemented.
33101048|NCT05296616|No Intervention|Control|The group to which mindfulness-based stress reduction intervention will not be applied
33317050|NCT01089972||20 gauge group|
33317051|NCT01089972||22 gauge group|
33317052|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
33317053|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
33317054|NCT04285372|Experimental|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
33317055|NCT04285372|Active Comparator|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
33405025|NCT04053920|Experimental|Low load|Training at 30-40% one-repetition maximum (1RM)
32955321|NCT05621460|Experimental|500mL still water first, then 500 mL carbonated water, then 50mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 500mL carbonated water on the second test day, then 50mL still water on the third day.
32955322|NCT05621460|Experimental|500mL carbonated water first, then 50mL of still water, then 500mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 50mL still water on the second test day, then 500mL still water on the third day.
32955323|NCT05621460|Experimental|500mL still water first, then 50mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 50mL still water on the second test day, then 500mL carbonated water on the third day.
32955324|NCT05621460|Experimental|50mL still water first, then 500mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL carbonated water on the second test day, then 500mL carbonated water on the third day.
32955325|NCT05621460|Experimental|50mL still water first, then 500mL carbonated water, then 500 mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL still water on the second test day, then 500mL still water on the third day.
32955326|NCT05560152|Experimental|Experimental group|"Experimental: Experimental group Subjects will receive Yiqihuayu Decotion, combined with guidelines-based standard care.~Interventions:~Drugs: Yiqihuayu Decotion Other: Standard care (e.g. antiplatelet drugs and statins)"
32955327|NCT05560152|No Intervention|Control group|"No Intervention: Control group Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care (e.g. antiplatelet drugs and statins)"
32955328|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
32955329|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
33317056|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:~Clinical Evaluation;~Fine Needle Aspiration Cytology;~Multiparametric Magnetic Resonance Imaging.~Postoperative Collection of Final Histopathological Diagnosis"
33317057|NCT05571280|Active Comparator|Standard Intervention (CONTROL Arm)|"The Standard package includes a series of actions carried out by the Community and Health Development Agents (ADECOS), who improves access to primary health care practices and promotes well-being behaviors at community levels. ADECOS has the potential to facilitate improvements in the health state and quality of life in rural communities. Activities performed by ADECOS can be grouped into two blocks:~Health awareness-raising, and promotion activities at the community level (against malnutrition and promoting adequate nutrition).~Preventive community activities involving the promotion of treatment against malnutrition at the community level and direct referral to local health facilities when necessary."
32955330|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
32955331|NCT03115788|Active Comparator|No Intervention Game play|The person will be instructed how to hold the iPad and how to play the game.
32955332|NCT03115788|Experimental|Thermal pain and ipad performance|Interventions: Cold induced pain and heat induced pain. The whole group gets thermal heat (n=40) and half (n=20) get cold water foot immersion and half (n=20) get body temperature foot emersion. The person will be instructed how to hold the iPad and how to play the game. The person will then be allowed to play the game until the number of trials is completed or until the person no longer wishes to play.
32955333|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
32955334|NCT03033420|No Intervention|Control group|Treatment-as-usual
32955335|NCT01798212|Other|full thickness gastroplication|
33101049|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
33317058|NCT05571280|Experimental|Standard Intervention plus nutritional supplementation (CONTROL+NUT Arm)|"In addition to the services performed by the ADECOS, it is included a supply of complementary food rations (individual + family) at the relative level, being:~One individual portion composed by nutritional lipid supplements in small quantities (SQ-LNS)~One complementary family portion composed by local foods."
32813291|NCT05319262|No Intervention|Control|Single study night with no noise exposure, to determine normal baseline sleep
32813292|NCT05319262|Experimental|Traffic noise|Single study night with traffic noise events, to determine consequences of sleep disturbance by traffic noise
32813293|NCT05319262|Experimental|Pink noise|Single study night to measure the effects of a non-pharmacological intervention to promote sleep, pink noise.
32813294|NCT05319262|Experimental|Traffic noise + pink noise|Single study night with concurrent traffic noise events and continuous pink noise sound exposure. Night is used to determine attenuation of sleep disturbance by traffic noise due to introduction of pink noise.
32813295|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
32813296|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
32813297|NCT05310682|Experimental|DIPH-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the comparison arm based on health system performance and distance. The DIPH intervention is implemented at the district health administration office level.
32813298|NCT05310682|No Intervention|Non-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the DIPH intervention arm based on health system performance and distance.
33101050|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
33101051|NCT05291078|Experimental|Experimental Group A|Tinnitus patients(n=12 people)
33101052|NCT05291078|Experimental|Experimental Group B|Tinnitus patients(n=12 people)
32813299|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
33101053|NCT05291078|Sham Comparator|Control Group|Tinnitus patients(n=12 people)
33101054|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101055|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101056|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101057|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101058|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101059|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101060|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33102535|NCT05467319|Experimental|Ferric derisomaltose|1000mg of intravenous Ferric derisomaltose/Iron isomaltoside in 100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
33405026|NCT04053920|Experimental|High load|Training at 65-75% one-repetition maximum (1RM)
33405027|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
33405028|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
32813300|NCT03397966|Experimental|BNP infusion|Subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32)) for 240 minutes.
32813301|NCT03397966|Placebo Comparator|saline infusion (control)|Subjects will receive an IV infusion of normal saline for 240 minutes. The volume of saline delivered will be equivalent to the volume of saline that the subject receives during the BNP infusion visit.
33101061|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
33101062|NCT02941406||Healthy subjects|"Men and Women aged 18 and older~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
33101063|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
33101064|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
33101065|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
33101066|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
33317059|NCT05571280|Experimental|Standard Intervention plus money transfers (CONTROL+TM Arm)|In addition to the services performed by the ADECOS, it will be delivered a total of 14,000.00 Kz per month and per relative with 4 or more people living in the same household by the end of the study. It will be delivered a total of 11,000.00 Kz per month and per relative with 3 or fewer people living in the same household by the end of the study. The monetary value will be delivered in cash with unconditional format, and it will not be determined by the investigator team the use and the destination of said amount and nothing will be requested in return.
33317060|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
32813302|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
33317061|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
32813303|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
32813304|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
32813305|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
32813306|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
32813307|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
32813308|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
32813309|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
32813310|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
32813311|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
32813312|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
32813313|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
32813314|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
32813315|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
32813316|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
32813317|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
32813318|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
32813319|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
32813320|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
32813321|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
32813322|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
32813323|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
32813324|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
32813325|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
33317062|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
33317063|NCT00053352|Experimental|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes & etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 & 6).~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, & 16."
33317064|NCT00053352|No Intervention|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.~Observation only for recurrence or development of an SMN"
33317065|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
33317066|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
33317067|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
33317068|NCT01193816|Experimental|loxapine|loxapine
33317069|NCT01193816|Placebo Comparator|Placebo|Placebo
33317070|NCT05571202||Anorectal surgery patient under general anesthesia plus local infiltration|Anorectal surgery patient under general anesthesia plus local infiltration
33317071|NCT05571202||Anorectal surgery patient under spinal anesthesia|Anorectal surgery patient under spinal anesthesia alone
33317072|NCT03847688||Treatment resistant Major Depressive Disorder|
33317073|NCT05671250|Experimental|PRP gel and SOC-treatment|platelet-lysate loaded lyophilized gel in addition to standard of care
33317074|NCT05671250|Experimental|Trigel and SOC-treatment|Erythropoietin/isosorbide dinitrate loaded cryogel scaffold in addition to standard of care
33317075|NCT05671250|Active Comparator|standard of care alone|sharp debridement, saline washing and saline dressing
33317076|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
33317077|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
33317078|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
33317079|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
33317080|NCT01291940|No Intervention|Adult Control|No intervention.
33317081|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
33317082|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
33317083|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
33317084|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
33317085|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
33317086|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
33317087|NCT00052962|Other|Arm 1 Surgery + post op chemotherapy|"Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
33405029|NCT04053686|Experimental|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
32813326|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32813327|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33317088|NCT00052962|Other|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy~Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin~post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m^2 and paclitaxel 125 mg/m^2~post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
33317089|NCT01193894|Experimental|Profermin|
33317090|NCT01193894|Active Comparator|Fresubin|
33317091|NCT05571124|Experimental|Therapeutic exercise and pain education|"It consists of implementing active breaks at the workstation through a web application, in which they will perform strength and mobility exercise sessions through general low-moderate intensity movements.~In this arm, daily short-form content also is given on pain and the relationship of musculoskeletal pathologies with sedentary lifestyles and maintained postures. The type of online application will depend on the results obtained in the qualitative phase, as we will adapt to the workers' preferences to facilitate accessibility to the content and make the experience as satisfactory as possible for them."
33317092|NCT05571124|Active Comparator|Therapeutic exercise only|Workers in this arm Will receive the same procedure as Group 1 without the short-form content of pain education. Once the intervention is finished, this content will be added in an infographic or audio-visual format pain education information, giving the same access to the participants.
33101067|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
33317093|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
33317094|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
32813328|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
32813329|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
33317095|NCT01194050||Cohort|
33317096|NCT05571046|Active Comparator|Glucocorticoid injection|Intramuscular glucocorticoid (5 mg betamethasone dipropionate and 2 mg betamethasone sodium phosphate)
33317097|NCT05571046|Placebo Comparator|Placebo injection|Intramuscular saline (%0.9 isotonic sodium chloride)
33317098|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
33317099|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
33317100|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
33317101|NCT04226794|Experimental|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
33317102|NCT04226794|Active Comparator|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
33317103|NCT04226794|Active Comparator|a-tDCS|a-tDCS
33317104|NCT04226794|Active Comparator|Nutritional counseling|Nutritional counseling
32813330|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
33317105|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
33317106|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
33317107|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
33317108|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
33317109|NCT04190524|Other|Intervention/Control|Each subject will serve as their own control. The esophagus diameter will be measured on each subject, then cricoid pressure will be applied and the esophagus diameter will again be measured.
33317110|NCT00051636|Experimental|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
33317111|NCT00051636|Active Comparator|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
33101068|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
33317112|NCT01188590||Patients undergoing heart surgery|
33317113|NCT01294826|Experimental|AUY922 plus Cetuximab|
33317114|NCT03956004|Experimental|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
33317115|NCT03956004|Active Comparator|Control|Education component of the decision aid only.
33317116|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
33317117|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
33317118|NCT03955770|Experimental|HFOT first then LFOT|
33317119|NCT03955770|Experimental|LFOT first then HFOT|
33101069|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
33101070|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
32813331|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
33101071|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
33101072|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
33317120|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
32813332|NCT03215446|Active Comparator|propofol|
32813333|NCT03215446|Experimental|sevoflurane|
32813334|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
33101073|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
33317121|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
32813335|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
32813336|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
33317122|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
32813337|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
32813338|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
32813339|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
32813340|NCT03219346|Experimental|Oral hygiene|
32813341|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
32813342|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
32813343|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
32813344|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
32813345|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
32813346|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
32813347|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
32813348|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
32813349|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
33317123|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
33317124|NCT01096758||PKU patients|
32813350|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
32813351|NCT02639260|Experimental|Cohort A|3,000 mg/day
32813352|NCT02639260|Experimental|Cohort B|10,000 mg/day
32813353|NCT04381234|Experimental|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
32813354|NCT04381234|Active Comparator|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
32813355|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
32813356|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
32813357|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
32813358|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
32813359|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
32813360|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
32813361|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
32813362|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
32813363|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
33101074|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
33317125|NCT01096758||healthy controls|
32813364|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
33405030|NCT05202288|Active Comparator|Single vaccination|"The control arm (vaccination alone) will serve as a comparator of vaccine response.~r-VSV-ZEBOV vaccine will be administered at inclusion (D0)"
32813365|NCT04380844|Active Comparator|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
32813366|NCT04380844|No Intervention|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
33405031|NCT05202288|Experimental|Simoultaneous vaccination|Mabs and r-VSV-ZEBOV vaccine will be administered the same day, at inclusion (D0), one hours appart
32813367|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
33101075|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
33101076|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
33101077|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
33101078|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
33101079|NCT05268731||Extrahepatic bile duct obstruction and failed ERCP|"Patients with extrahepatic bile duct obstruction and obstructive jaundice have received a percutaneous transhepatic biliary drainage.~The choice between an insertion of an external or an external/internal drainage has been made during the procedure depending on whether the guide wire could be accessed to the jejunum/duodenum or not.~The choice between internal/external drainage or a primary metal stent has been made by the investigators preference or was made on the basis of an existing malign bile duct obstruction or not."
33101080|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
33101081|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
33405032|NCT05202288|Experimental|Early vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 3 weeks later
32813368|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
32813369|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
32813370|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
32813371|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
32813372|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
32813373|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.~."
32813374|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
33101082|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
33101083|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
33405033|NCT05202288|Experimental|Intermediate vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 6 weeks later
33405034|NCT05202288|Experimental|Late vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 12 weeks later
33101084|NCT05238545|Experimental|PD gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
33101085|NCT05238545|No Intervention|PD gluten-containing diet group|Subjects with PD on regular, gluten-containing diet, i.e. no restrictions during eating.
33101086|NCT05238545|Experimental|MSA gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
33101087|NCT05238545|No Intervention|MSA gluten-containing diet group|Subjects with MSA on regular gluten-containing diet, i.e. no restrictions during eating.
32813375|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
32813376|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
32813377|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
32813378|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
32813379|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
32813380|NCT04415801|Experimental|Implant abutments|implant abutments
32813381|NCT04626401|Placebo Comparator|Control diet during immobilisation|A 2 day controlled dietary intervention.
33101088|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
32813382|NCT04626401|Experimental|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
32813383|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
32813384|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
33102536|NCT05467319|Placebo Comparator|Placebo|100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
33102537|NCT04590300|Other|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
33405035|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
32813385|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
32813386|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
32813387|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
32813388|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
32813389|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
32813390|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
32813391|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
32813392|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
32813393|NCT04615247|Experimental|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
32813394|NCT04615247|Active Comparator|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
32813395|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
32813396|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
32813397|NCT01900691|Experimental|Evolution® Esophageal Stent|
32813398|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
32813399|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
33102538|NCT04590300|Other|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
33317126|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
32813400|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
32813401|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
32813402|NCT04381780|Experimental|Assessing clinical outcomes|Nutritional support with Recovery Factors
32813403|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
32813404|NCT03218332||Healthy controls|Active Comparator
32813405|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
32813406|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
32813407|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
32813408|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
32813409|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
32813410|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
32813411|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
32813412|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
32813413|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
32813414|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
32813415|NCT03217630||Diabetic patients|
32813416|NCT03217630||Non-diabetic patients|
32813417|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
32813418|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
32813419|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~The Mologic Biomarker Panel~PCT~CRP~Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
32813420|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~Patients being managed for potential infection~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
32955336|NCT05560074|Experimental|Buzzy|Buzzy®: It is a 8x5x2.5 cm sized, noninvasive device used for pain control in adults and children, developed by the pediatrician Ammy Baxter, with a plastic battery and vibration motor. A cold ice pack is placed under Buzzy. It has a local cold application and vibration effect. It is placed 3~5 cm above the injection site for 15~30 sec before and during the procedure, making local cold application and vibrations. One should be sure about the definite contact of Buzzy® with the skin. The ice pack is kept in a deep freezer and placed in the device before the procedure. After the procedure is completed, the ice pack is wiped with 70% alcohol, and kept and chilled again in the deep freezer. http://www.buzzy4shots.com/)
32955337|NCT05560074|Experimental|DistractionCards|"DistrACTION® Cards consisted of visual cards of 5 cm × 8 cm, covered with various pictures and shapes. In this method, the children first carefully examine the cards. Then, the PhD-qualified nurse researcher asks some questions about those cards to be answered by the children, such as How many ladybugs are there in the picture? How many apes are there in the picture? or Can you see the comet? The distraction procedure via distraction cards begin just before the venous blood specimen collection and continue until the end of the blood specimen collection"
32955338|NCT05560074|No Intervention|Control|Controll group: Venous blood will be taken as usual on the blood collection room without applying an intervention to the children in the Control group. Children will follow the standard blood draw procedure.
32955339|NCT05618886|Active Comparator|control group|Education given to all participants included before randomization. Information about UI, PFM and PFMT, together with lifestyle advices such as using the 'knack' (pre-contracting the PFM before coughing and sneezing), maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure. The education session will last 30 minutes, and include a video (https://www.youtube.com/watch?v=XsDpfq10JMI) and a leaflet containing the information given.
32955340|NCT05618886|Experimental|intervention group|Along with education session, twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participants will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary
32955341|NCT05559996|Experimental|Hyaluronic acid injection|Hyaluronic acid injection
32955342|NCT05559918||Preloading with clopidogrel|
32955343|NCT05559918||In-hospital loading with clopidogrel|
32955344|NCT05559840|Active Comparator|Group I|The control group (Group I) will be treated with condom catheter tamponade by inflating the condom with saline according to national protocol.
32955345|NCT05559840|Experimental|Group II|The study group (Group II) will receive condom catheter that will be inflated with air
32955346|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.~Diuretic renography to measure the cortical transit time"
32955347|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
32955348|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
32955349|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
32955350|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
32955351|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
32955352|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
32955353|NCT05559762||Day Shift|Nurses regularly working 12hr day shifts
32955354|NCT05559762||Night Shift|Nurses regularly working night shift
32955355|NCT05559684|No Intervention|Control|"Patients in this group will receive fentanyl infusion at a dose of (0.5 μg/kg/h) all through the whole operation; in addition to~1μg/kg during skin incision, sternotomy, aortic cannulation and increase in MBP or HR more than 20% of the baseline readings."
32955356|NCT05559684|Active Comparator|Erector Spinae Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
32955357|NCT05559684|Experimental|Transversus Thoracis Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus ultrasound guided bilateral TTPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
32955358|NCT05559528||Public health system|Group with patients treated in the public health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
32955359|NCT05559528||Private health system|Group with patients treated in the private health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
32955360|NCT05559450|Experimental|Blinatumomab arm|On the 1st to 3rd day, Blinatumomab should be continuous intravenous use for 24 hours with 9ug/ day for those whose weight are equal to or greater than 45kg, and 5ug/ m2 / day for those whose weight are less than 45kg (maximum dosage is 9ug/ day) per 24 hours. On the 4th to 14th day, for the patients who are equal to or greater than 45kg, they will receive Blinatumomab at the dose of 28ug/ day with continuous intravenous administration, and those below 45kg are given a 24h continuous infusion of 15ug/ m2 / day (maximum dose is 28ug/ day). Bucy-based myeloablative conditioning regimen will be performed on the 15th day.
32955361|NCT05559450|Other|Conventional therapy|Bucy-based myeloablative conditioning regimen will be given to those patients are enrolled into control group.
32955362|NCT05559372|Experimental|Nutrabolt C4 Energy Drink Carbonated|16 oz
32955363|NCT05559372|Active Comparator|Monster Energy Original|16 oz
33101089|NCT04691336|Experimental|PIMAGroup|All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
33101090|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
33405036|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
32813421|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
33101091|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
33101092|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
33101093|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
32813422|NCT00903448|Experimental|A|Prilosec OTC
32813423|NCT00903448|Active Comparator|B|Prevacid
32813424|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
32813425|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32813426|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32813427|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
32813428|NCT01830712||Chart review|
32813429|NCT01830868||Zonisamide tablets|
32813430|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
32813431|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
32813432|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
32813433|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
32813434|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
32813435|NCT03213808||anaphylaxis|anaphylaxis
32813436|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
32813437|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
32813438|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
32813439|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
32813440|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
32813441|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
32955364|NCT05559372|Placebo Comparator|Placebo|16 oz carbonated placebo
32955365|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
32955366|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
32955367|NCT05615844|Experimental|Antibiotic Cement Bead Pouch|"The antibiotic cement bead pouch involves placing temporary non-absorbable antibiotic-laden cement beads into the open fracture wound and sealing the wound with a large occlusive dressing for prophylaxis against bacteria.~The antibiotic beads used will be prepared intraoperatively by the surgical team. The bead recipe will be comprised of a ratio of 2 grams of vancomycin, 2.4 grams of tobramycin, and 40g (one bag) of PMMA cement. The beads will be handmade and approximately 10-mm in diameter. The number of beads placed in the wound will be at the discretion of the treating surgeon based on recipient wound size. As commonly practiced, the antibiotic beads may be exchanged for new beads at each subsequent irrigation and debridement surgery. The number of beads, the number of replaced beads, and the removal of the antibiotic beads will be recorded."
33101094|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
33101095|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
33101096|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
33101097|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
33101098|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
33101099|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
33101100|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
33101101|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
33405037|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
32813442|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
32813443|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
32813444|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
32813445|NCT01831024|Experimental|Treatment Group|Dignicap System
32813446|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
32813447|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
32813448|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
32813449|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
32813450|NCT01831102||Mexican American|Mexican American ancestry
32813451|NCT01831180||Premenopausal women 19-25 yrs|
32813452|NCT01831180||Postmenopausal 60 yrs +|
32813453|NCT01739348|Experimental|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|[Part I] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
32813454|NCT01739348|Experimental|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
33101102|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
33405038|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
33405039|NCT04054388|Experimental|300 Randomized to re-education group|LINE re-education of colon preparation
33405040|NCT04054388|No Intervention|300 Randomized to control group|education of colon preparation 1 time in hospital
32813455|NCT01739348|Experimental|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
32813456|NCT01739348|Placebo Comparator|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|[Part I] Placebo once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
32813457|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
32813458|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
32813459|NCT03213730|No Intervention|Control group|Standard care alone
32813460|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
32813461|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
32813462|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
32813463|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
32813464|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
32813465|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
32813466|NCT01738646|Experimental|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
32813467|NCT01831336||Orsiro DES|
32813468|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
32813469|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
32813470|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
32813471|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
32813472|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
32813473|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
32813474|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
32813475|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
32813476|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
32813477|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
32813478|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
32813479|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
32813480|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
32813481|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
32813482|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
32813483|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
32813484|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
32813485|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
32813486|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
32813487|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
33101103|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
33101104|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
32813488|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
33101105|NCT02939417|Active Comparator|without uing grape seed extract|
33101106|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
32813489|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
32813490|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
32813491|NCT01831882||Major Depressive Disorder|
32813492|NCT01831882||Healthy Control|
32813493|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
32813494|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
32813495|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
32813496|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
32813497|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
32813498|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
32813499|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
32813500|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
32813501|NCT04380532|Experimental|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
32813502|NCT00906958|Experimental|Nexus Flow Generator|Participants were randomised to Nexus Flow Generator group for one night.
32813503|NCT00906958|Active Comparator|VPAP Flow Generator 25|Participants were randomised to VPAP Flow Generator 25 group for one night.
32813504|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
32813505|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
32813506|NCT03212872|Other|Endoscopy|
32813507|NCT01832194|Experimental|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
32813508|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
32813509|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
33101107|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports~Patient proficiency training"
33101108|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports~Patient proficiency training~PCP & cardiologist training of using Web-based analytics~Proactive and interactive care by PCPs and cardiologists"
33101109|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
33101110|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
33101111|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
33101112|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
33101113|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
32813510|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
32813511|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
32813512|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
32813513|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
32813514|NCT01839760||Inpatient cohort|Patients admitted to general wards
32813515|NCT01839760||ICU cohort|Patients admitted to ICU
32813516|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
32813517|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
32813518|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
32813519|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
32813520|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
32813521|NCT00908908|Experimental|1|
32813522|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
32813523|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
32813524|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
33101114|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
33101115|NCT05034536|Experimental|Pembrolizumab + Infliximab|"Participants will be randomly assigned to receive pembrolizumab and infliximab.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Infliximab will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
33101116|NCT05034536|Experimental|Pembrolizumab + Placebo|"Participants will be randomly assigned to receive pembrolizumab and placebo.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Placebo. will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
32813525|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
32813526|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
32813527|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
32813528|NCT03837106|No Intervention|No intervention|Control group, no intervention
32813529|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
32813530|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
33101117|NCT05018351|Active Comparator|Treatment as Usual-Integrated Care (TAU-IC)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.
33101118|NCT05018351|Experimental|Peer Navigator Program (PNP)|"Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~scheduling and attending healthcare appointments;~partnering with participant on tasks that arise from appointments;~health-related goal setting; and~taking action-steps toward health-related goals."
33101119|NCT02918643|Active Comparator|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
32813531|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
32813532|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
32813533|NCT03211780|Experimental|Ultrasound|
32813534|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~PEEP 4 cmH2O~Use ultrasound"
32813535|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~PEEP titrated~Use ultrasound~Impedance tomography~Best PEEP for less collapse"
32813536|NCT01830400||Eslicarbazepine Acetate tablets|
32813537|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
33101120|NCT02918643|Sham Comparator|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
33101121|NCT05012891||Study Population|Fifty (n=50) consecutive patients with lower-extremity disability or chronic pain (unilateral or bilateral), undergoing a rehabilitation course in a Day-Care Center setting.
33101122|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
33101123|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
33101124|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.~All participants receive the same dose of Capecitabine.~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.~All participants receive the same dose of Capecitabine."
33101125|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
33101126|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
33101127|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
33101128|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
33101129|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
33101130|NCT02939222|Other|Routine implant placement|No comparison needed
33101131|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
33101132|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
32738294|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
33101133|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
32813538|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
32813539|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
32813540|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
32813541|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
32813542|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
32813543|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
32813544|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
32813545|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
32813546|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
32813547|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
32813548|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
32813549|NCT04426695|Experimental|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
32813550|NCT04426695|Experimental|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
32813551|NCT04426695|Experimental|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
32813552|NCT04426695|Experimental|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
32813553|NCT01838200|Experimental|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
32813554|NCT01838200|Experimental|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
33101134|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
33101135|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
33101136|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
32813555|NCT01838200|Experimental|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
32813556|NCT01838200|Experimental|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
32813557|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
33101137|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
33101138|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
32813558|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
32813559|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
32813560|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
32813561|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
32813562|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
32813563|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
32813564|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
32813565|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
32813566|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
32813567|NCT03211468|No Intervention|Control Group|No participation in intervention program.
32813568|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
32813569|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
32813570|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
32813571|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
32813572|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
32813573|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
32813574|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
32813575|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
32813576|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
32813577|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
32813578|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
32813579|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
33101139|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
33101140|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
33101141|NCT01295827|Experimental|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
33101142|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
33317127|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
33317128|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
32813580|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
32813581|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
33317129|NCT01096836|Experimental|exercise training|
33317130|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
33317131|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
33317132|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
33317133|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
32813582|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
32813583|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
32813584|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
32813585|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
32813586|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
32813587|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
32813588|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
32813589|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
32813590|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
32813591|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
32813592|NCT01671969|Experimental|very low calorie diet|
32813593|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
32813594|NCT04294641|Experimental|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
32813595|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
32813596|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
32813597|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
32813598|NCT05189457|Experimental|First Strike then Second Strike|"The first part of the study treatment or first strike involves 12-18 weeks of combined therapy with LHRH analog and one of the new hormonal agents (NHAs). Participants will complete the first strike at week 13 if their PSA has reduced >90%; otherwise they will complete a total of 18 weeks of therapy. The second part of the treatment or second strike involves 4 cycles docetaxel and LHRH analog. The second strike will start immediately after the first strike. MRI guided prostate biopsy will be performed after second strike. For patients with positive prostate biopsy or detectable PSA, the second strike will be consolidated with 4-6 additional cycles of docetaxel plus 6 doses of tislelizumab at 200 mg, given IV once every 3 weeks. For patients with undetectable PSA at year 3 from study enrollment, LHRH analog can be discontinued."
32955368|NCT05615844|Active Comparator|Negative Pressure Wound Therapy (NPWT)|"The NPWT system is a sealed dressing placed over the open fracture wound that includes an occlusive plastic wound dressing connected to a vacuum pump, tubing, and a canister to collect fluid. The pump creates a vacuum seal and exerts negative pressure on the wound to remove fluid and maintain a sealed environment. NPWT promotes wound healing through four primary mechanisms: 1) wound shrinkage or macrodeformation; 2) microdeformation at the foam-wound surface interface; 3) fluid removal; and 4) stabilization of the wound environment.~125 mmHg continuous negative pressure is the recommended NPWT device setting; however, the treating surgeon will be allowed to adjust these settings as clinically necessary.~The frequency and timing of NPWT changes will also be at the surgeon's discretion but is expected to primarily coincide with the timing of repeat debridement, typically every 24-72 hours until definitive management has occurred."
33317134|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
33317135|NCT03847532|Other|Control sample|Patients who did not have colon polyps
33317136|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
33317137|NCT03953430||control group|healthy children of employees of our hospital
33317138|NCT01194284||High-grade osteosarcoma patients|
33317139|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
33317140|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
32955369|NCT05559294|Experimental|Professional development|"The intervention consists of a nine months long professional development program with an interchange between three e-learning modules and three group workshops starting with an e-learning module and ending with a workshop. Each workshop is 3 hours with approximately 100 participants. The e-learning modules are completed individually by ECEC staff. Between workshops, each day nursery and/or kindergarten center will receive a two-hour supervisory visit from UCL staff to support professional development. The daily leader at the day nursery and/or kindergarten center sets the theme for each supervisory visit to enhance development as much as possible.~The intervention is being designed as a collaboration between UCL and Odense municipality"
33101143|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
33317141|NCT03960450|Experimental|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
33317142|NCT03960450|Placebo Comparator|Part A: Vehicle cream|Daily application of vehicle cream
33317143|NCT03960450|Experimental|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
33317144|NCT03960450|Placebo Comparator|Part B: Vehicle cream|Daily application of vehicle cream
33317145|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
33317146|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
33317147|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
33317148|NCT03847298||Pacemaker|
33317149|NCT03847298||Control|
33317150|NCT03955692|Active Comparator|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
33317151|NCT03955692|Sham Comparator|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
33317152|NCT01194518|Experimental|Lifestyle Intervention Program|
33317153|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
33317154|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
33317155|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
33317156|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
33317157|NCT03960294|Experimental|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
33317158|NCT01294904||renal transplant patients|Patients undergoing transplantation
33317159|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
33317160|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
33317161|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
33317162|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
33101144|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
33101145|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
33101146|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
32813599|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
32813600|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
32813601|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
32813602|NCT04405323|Experimental|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
32813603|NCT04405323|Experimental|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
32813604|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
32813605|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
32813606|NCT01672047|Experimental|Treament|Intervention Vitamin D2
32813607|NCT01672047|No Intervention|Control|Not take Vitamin D2
32813608|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
32813609|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
32813610|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
32813611|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
32813612|NCT01672125||healthy women|healthy women adjusted in age and BMI
32813613|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
32813614|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
32813615|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
32813616|NCT04170543|Experimental|Group 1|MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
32813617|NCT04170543|Experimental|Group 2|MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
32813618|NCT04170543|Experimental|Group 3|MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
32813619|NCT04170543|Experimental|Group 4|MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
32813620|NCT04170543|Placebo Comparator|Group 5|Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
32813621|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
32813622|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
32813623|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
32813624|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
32813625|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
32813626|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
32813627|NCT01720732|No Intervention|TAU|Treatment as Usual
32813628|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
33317163|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
33317164|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
33101147|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
33101148|NCT01295827|Experimental|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
33101149|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
33101150|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
33317165|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
33317166|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
33101151|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
33101152|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
33101153|NCT04985942|Experimental|Lumateperone 42 mg|
33101154|NCT04985942|Placebo Comparator|Placebo|
33101155|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
33101156|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
33101157|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
32813629|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
32813630|NCT04380376|Experimental|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
32813631|NCT04380376|Other|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
33101158|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
33101159|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
33101160|NCT04983368|Experimental|Xanamem® 5 mg|Oral Xanamem® capsules 5 mg, to be administered once daily
33101161|NCT04983368|Experimental|Xanamem® 10 mg|Oral Xanamem® capsules 10 mg, to be administered once daily
33101162|NCT04983368|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
33101163|NCT02918604|Other|B : veinsite access|infrared technology vein access
32813632|NCT04380298|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
32813633|NCT04380298|Active Comparator|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
33101164|NCT02918604|Active Comparator|A: control group|conventional vein access
33101165|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
33101166|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
33101167|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
33101168|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
32813634|NCT04164849|Experimental|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
33101169|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
33101170|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
33101171|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
33101172|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
33101173|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
33101174|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
33101175|NCT04690517|Other|Tracheal ultrasound|The patients in cardiopulmonary arrest should be performed tracheal ultrasound when tube is passed through the trachea or esophagus.
32813635|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
33101176|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
33317167|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
32813636|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
32813637|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
32813638|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
32813639|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
32813640|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
32813641|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
32813642|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
32813643|NCT05384691|Other|Luspatercept|Single-arm design: All patients are treated with 1.75 mg Luspatercept per kg body weight subcutaneously on day 1 of each 21 day cycle for up to 24 weeks and in case of response for up to 1.5 years.
32813644|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
32813645|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
32813646|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
32813647|NCT01672281|Experimental|vibrox training|
32813648|NCT01672281|Experimental|resistance training|
32813649|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
32813650|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
32813651|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
32813652|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
32813653|NCT05620888|Experimental|Tailored messages (TM)|"Participants assigned to this arm receive a daily tailored message on the benefits of taking at least 7000 steps daily. Tailoring concerns change-related expectations, risk perception, planning, retention capacity, resilience, and coping skills and is based on the responses provided by participants at baseline evaluation.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring).In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
32813654|NCT05620888|Experimental|Non tailored messages (NTM)|"Participants assigned to this arm receive a daily non-tailored message on the emotional benefits of taking at least 7000 steps daily.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
32813655|NCT05620888|No Intervention|No messages (NM)|Participants assigned to this arm receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section.
32813656|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
32813657|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
32813658|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
32813659|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
32813660|NCT05382975|Other|Wedge 1 includes Schools 1 and 2.|
32813661|NCT05382975|Other|Wedge 2 includes Schools 3, 4, and 5.|
33101177|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
33101178|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
33101179|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
33101180|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
33317168|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
33317169|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
33101181|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
33101182|NCT04690712|No Intervention|Socio-Demographic Characteristics of Students|When the socio-demographic characteristics of the students are examined according to the pre-test findings; It was seen that 27% were in the first grade, 20.9% in the second grade, and 25.7% in the third grade. When the age groups were evaluated, it was determined that 47.8% were in the 7-8 age group, 51.5% were in the 9-10 age group and 50% of them were female students and 50% were male students. It was observed that 27.6% of the students had a bad income and 59.3% had a medium level of income. When the father's education status was questioned, it was determined that 17.6% of them did not finish primary school, 55.4% of them were primary school graduates, 2.6% of them were high school graduates. On the other hand, 55% of their mothers did not complete primary school, 43.5% were primary school graduates and 1.5% were secondary school graduates
33317170|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
33317171|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
33101183|NCT04690712|Experimental|Comparison of Students' Pretest and Posttest Development Screening Average|According to the results of height and weight screening at the pre-test stage; the average height of the students is 127.0 ± 9.11; It was determined that the average weight was 26.1 ± 6.19, the average height was 130.61 ± 8.83 and the average weight was 29.92 ± 6.39 in the final test stage. A significant difference was found between pre-test and post-test screening results
33101184|NCT04690712|Experimental|Comparison of Pre-Test and Post-Test Screening Results of Students|In the statistical evaluation, it was found that there was no significant difference between pre-test and post-test screening results
33317172|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
33101185|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
33101186|NCT02914704|Experimental|Patients treated with MRI-HIFU|
33101187|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
33101188|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
33317173|NCT01296464|Placebo Comparator|Placebo|
33317174|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
33317175|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
33317176|NCT05146466|Other|E-MATVR (intervention)|
33317177|NCT05146466|Other|E-MATEE (control)|
32813662|NCT05382975|Other|Wedge 3 includes Schools 6, 7, and 8.|
32813663|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
32813664|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
32813665|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
32813666|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
32813667|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
32813668|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~Mother consents to her infant receiving trial infant formula for 12 months"
32813669|NCT02563431|Active Comparator|SP-ED|Classic use
32813670|NCT02563431|Experimental|4P-ED|Literature update
32813671|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
32813672|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
32813673|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
32813674|NCT03956277||Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
32813675|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
32813676|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
32813677|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
32813678|NCT05119413|Experimental|New traitement|Thiamidol, retinoid, topical steroid preparation
32813679|NCT05119413|Other|Kligman's trio|Application once a day for 12 weeks
32813680|NCT01834378|No Intervention|No intervention|
32813681|NCT01834378|Experimental|Low intensity intervention|
32813682|NCT01834378|Experimental|High intensity intervention|
33101189|NCT04690751|Experimental|Types of Cenobamate|"Treatment A: Oral Dose of cenobamate administered as a single 200 mg tablet under fasted conditions~Treatment B: Oral Dose of cenobamate administered as a single 200 mg/20 mL suspension under fasted conditions~Treatment C: Oral Dose of cenobamate administered at a single 200 mg/20 mL suspension under fed conditions"
33101190|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
33101191|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
33101192|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
33101193|NCT03458078|Placebo Comparator|Group C|Control group
33101194|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
33101195|NCT03458078|Active Comparator|Group MDZ|Midazolam group
33101196|NCT02914860|Experimental|Volunteers|Healthy volunteers
33101197|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
33101198|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
33317178|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
33101199|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
32813683|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
32813684|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
32813685|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
33101200|NCT04690556|Active Comparator|Lucentis (ranibizumab)|Intravitreal injection
33101201|NCT04690556|Experimental|LUBT010 (proposed ranibizumab biosimilar)|Intravitreal injection
33101202|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
33101203|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
33101204|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
33101205|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
33101206|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
33317179|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
33317180|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
32813686|NCT05381181|Experimental|CD19-UCART|All patients will be treated with at least 1 injection of CD19- UCART. A dose of 5x10^6/kg BW of CD19-UCART will be evaluated. If > 1/6 of DLT occurred, the dose would be reduced to 2.0x10^6/kg BW.
32813687|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
32813688|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
32813689|NCT03938415|Experimental|Acupuncture|Acupuncture
32813690|NCT03938415|Active Comparator|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
32813691|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
33101207|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
33101208|NCT04972331|Active Comparator|CONTROL|Arthroscopic Partial menisectomy
33101209|NCT04972331|Experimental|INTERVENTION|Platet- Rich-Plasma
33101210|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
33101211|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
33101212|NCT04927169|Experimental|CYT107|IM administration of CYT107 / Interleukin-7
33101213|NCT04927169|Placebo Comparator|PLACEBO|IM administration of Saline at the same volume
33101214|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
33101215|NCT02914626|Sham Comparator|Control|Standard of care therapy
33405041|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
32813692|NCT05112315|Experimental|Predigraft|Subjects will have a clinical follow-up based on site standard of care and benefit from follow-up using Predigraft in addition of the standard of care: the investigator will receive an alert every time there is a subject's instability, instability based on the following criteria: allograft survival assessed by iBox decreased by at least 5% in the last 12 months.
33101218|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
33101219|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
33101220|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
33101221|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
33101222|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
33101223|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
33101224|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
32813693|NCT05112315|No Intervention|Standard of Care|Subjects will have a clinical follow-up based on site standard of care.
32813694|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
32813695|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
32813696|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
32813697|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
32813698|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will continue to receive placebo capsules through Week 100, and will not receive capsules during a 12-week off-treatment period between Weeks 100 and 112."
32813699|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
32813700|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
32813701|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
33101225|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
33101226|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
33101227|NCT02938715|Experimental|Feedback group (teledermatology)|
33101228|NCT02938715|No Intervention|Control group (phone only)|
33101229|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
33101230|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
33101231|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
33101232|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
33101233|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
33101234|NCT01294462|Active Comparator|2|Clopidogrel
33101235|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
33101236|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
33101237|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
33101238|NCT01294423|Experimental|1|Dapagliflozin 5 mg
33101239|NCT01294423|Experimental|2|Dapagliflozin 10 mg
33101240|NCT01294423|Placebo Comparator|3|
33101241|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
33101242|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
33101243|NCT04845074|Experimental|TSA-group|Surgery
33101244|NCT04845074|Experimental|Exercise-group|Exercise
32813702|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
32813703|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
32813704|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
32813705|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
33101245|NCT04841798|Other|Duloxetine|Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.
32813706|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
32813707|NCT05079321|Experimental|Coated Scleral Lens|Participants wear a lens coated with Hydra-PEG.
32813708|NCT05079321|Placebo Comparator|Uncoated Scleral Lens|Participants wear an uncoated (control) lens.
32813709|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
32813710|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
32813711|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
32813712|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
32813713|NCT05372991|Active Comparator|0.025% atropine sulphate|The comparator formulation of 0.025% atropine sulfate monohydrate in normal saline will be prepared by diluting commercial 1% atropine sulphate solution with physiologic saline.
32813714|NCT05372991|Placebo Comparator|vehicle|CBT-009 vehicle formulation is a proprietary sterile ophthalmic solution that does not contain CBT-009 drug substance.
32813715|NCT05372991|Experimental|CBT-009, Low Dose|CBT-009 low dose formulation is a proprietary sterile ophthalmic solution that contain low dose of CBT-009 drug substance.
32813716|NCT05372991|Experimental|CBT-009, Mid Dose|CBT-009 mid dose formulation is a proprietary sterile ophthalmic solution that contain mid dose of CBT-009 drug substance.
32813717|NCT05372991|Experimental|CBT-009, High Dose|CBT-009 high dose formulation is a proprietary sterile ophthalmic solution that contain high dose of CBT-009 drug substance.
32813718|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
32813719|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
32813720|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
32813721|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
32813722|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
33101246|NCT04841798|Other|Rasagiline|Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.
33101247|NCT04841798|Other|Tranylcypromine|Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.
33101248|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
33101249|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
33101250|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
33101251|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
33101252|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
33101253|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
33101254|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
33101255|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
33101256|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
33101257|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
33101258|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:~Decision aid~YouTube video~Group information session"
33101259|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
33101260|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
33101261|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
33101262|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
33101263|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
33317181|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days. Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
32813723|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
32813724|NCT01722058|Experimental|peptide application|
32813725|NCT04764825|Experimental|Methadone, induction|"Patients receive methadone 0.15-0.2 mg/kg ideal bodyweight 10 minutes prior to surgery start (Syringe A).~45 minutes before expected extubation patients will receive saline (syringe B)."
32813726|NCT04764825|Experimental|Methadone, end of surgery|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive methadone 0.15-0.2 mg/kg ideal bodyweight (syringe B).
32813727|NCT04764825|Active Comparator|Morphine|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive morphine 0.15-0.2 mg/kg ideal bodyweight (syringe B).
32813728|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
32813729|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
32813730|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
32813731|NCT03863379||Control group|Able bodied persons
32813742|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
32813743|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
32813744|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
32813745|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
32813746|NCT01834534|No Intervention|Usual care|Usual medical care.
32813747|NCT04764279|Experimental|OPTIFAST Arm|Participants in the intervention group will be given OPTIFAST® meal replacement shakes, 4 per day to achieve 900kcal/day, for the first 12 weeks of the study. The second phase will consist of partial meal replacement and food reintroduction over a 4 week period. When the intervention group begins to reintroduce foods, all study participants will be provided a workbook, created for the study, to explain optimal lifestyle changes for DMII management. The third phase will be a 8-month follow-up of participants on continued healthy lifestyle as described in the workbook.
33101264|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
33101265|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
33101266|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
33101267|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
33101268|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
33101269|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
32813748|NCT04764279|No Intervention|Control/Usual Care Arm|Usual Care : A gift card will be offered to participants in the control group to stabilize the incentive of the intervention. Participants in the control group will receive usual diabetes care based on the current Canadian Diabetes Association guidelines by their family physician. Participants in the control group will receive the same workbook as the intervention group at 16 weeks into the study.
32813749|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
32813750|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
32813751|NCT04404621|Experimental|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
32813752|NCT04404621|Experimental|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
32813753|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
32813754|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
32813755|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
32813756|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
32813757|NCT04764435||Patients receiving dialysis at a physician-owned dialysis facility|All adults with Medicare fee-for-service in 2017 who received dialysis at a physician-owned dialysis facility. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
32813758|NCT04764435||Patients receiving dialysis at a dialysis facility not owned by a physician|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility not owned by a physician. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
32813759|NCT04764435||Patients receiving dialysis at a facility owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
32813760|NCT04764435||Patients receiving dialysis at a facility NOT owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility NOT owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
32813761|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
32813762|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
32813763|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
32813764|NCT01722448|Experimental|Choline|Phosphatidyl choline
32813765|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
32813766|NCT01834768|Experimental|A|Eplerenone
32813767|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
32813768|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
32813769|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
32813770|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
32813771|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
32813772|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
32813773|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
32813774|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
32813775|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
32813776|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
32813777|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
32813778|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
33101270|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
32813779|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
33101271|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
33101272|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
32813780|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
32813781|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
32813782|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
33101273|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
32813783|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
33101274|NCT03077685|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
33101275|NCT03077685|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
33101276|NCT03077685|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
33101277|NCT03077685|Experimental|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
32813784|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
32813785|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
32813786|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
32813787|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
32813788|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351,~Regimen B injections every week between D15 and D351"
32813789|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351~Regimen B injections every week between D15 and D351"
32813790|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
32813791|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
32813792|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
32955370|NCT05559294|Active Comparator|Usual professional development|Education and Care as Usual entails a standing offer from the municipality of Odense for Usual Competence development within the area of nature, outdoor life and natural phenomena visits from a learning consultant to support the ECEC staff's work with digital technology at the day nursery and/or kindergarten center. It is up to the day nursery and/or kindergarten center if the use the offer or not. This offer is extended to all day nursery and/or kindergarten centers.
32955371|NCT05559138||hemodialysis patients with omicron infection|hemodialysis patients with omicron infection
32955372|NCT05559138||non-hemodialysis patients with omicron infection|non-hemodialysis patients with omicron infection
32955373|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
32955374|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
32955375|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
32955376|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
32955377|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
33101278|NCT03077685|Experimental|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
32813793|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
32813794|NCT01722760||Term and preterm infants|Term and preterm infants
32813795|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
32813796|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
32813797|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
32813800|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
32813801|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
32813802|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
32813803|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
32813804|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
32813805|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
32813806|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
32813807|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
32813808|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
32813809|NCT03243669|Active Comparator|Fujinon standard|
32813810|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
32813811|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
32813812|NCT03243669|Active Comparator|Olympus standard|
32813813|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
32813814|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
32813815|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
32813816|NCT03243669|Active Comparator|Pentax standard|
32813817|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
32813818|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
32813819|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
32813820|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
32813821|NCT04937127||Experimental Group|The experimental group will be made up of patients from nursing homes whose carers have received I-Learn training.
32813822|NCT04937127||Control Group|The control group will consist of nursing homes patients whose caregivers have not received I-Learn training and will continue their usual care, regardless of the practices already implemented.
32813823|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
32813824|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
32813825|NCT05324943|Experimental|FLT201|FLT201 is an advanced therapy investigational medicinal product (ATIMP) administered as a single intravenous infusion.
32813826|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
32813827|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
32813828|NCT01673139|Experimental|Moderate exercise|Moderate exercise
32813829|NCT01673139|Experimental|Control|Control group
32813830|NCT01673139|Experimental|Interval exercise|interval exercise
32813831|NCT01725880||No treatment|Observation
32813832|NCT04379362|Experimental|Low or intermediate grade prostate cancer|
32813833|NCT03153969|Experimental|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
32813834|NCT03153969|Active Comparator|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
32813835|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
32813836|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
32813837|NCT03079323|Experimental|PART-trial|External beam radiotherapy
32813838|NCT01835860|Other|Embolization|Prostate artery embolization
32813839|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
32813840|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
32813841|NCT04883073|Experimental|Endo App use|use of Endo App during trial
32813842|NCT04883073|No Intervention|control|no use of Endo App during trial
32813843|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
32813844|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
32813845|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
32813846|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~Dose level (DL) 1 = 50 mg / day,~Dose level (DL) 2 = 100 mg / day, and~Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
32813847|NCT01835938|Placebo Comparator|placebo|
32813848|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
32813849|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
32813850|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
32813851|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
32813852|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
32813853|NCT04378816|Experimental|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
32813854|NCT04378816|No Intervention|Usual care group|No intervention, just continue using usual care
32813855|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
32813856|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
32813857|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
32813858|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
32813859|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
32813860|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
32813861|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
32813862|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
32813863|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
32813864|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
32813865|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
32813866|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
32813867|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
32813868|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
32813869|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
33101279|NCT04324216|Experimental|Experimental group|3D virtual reality and hands-on aromatherapy
32813870|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
32813871|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
32813872|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
32813873|NCT04378894|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
32813874|NCT04378894|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
32813875|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
32813876|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
32813877|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
32813878|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
32813879|NCT01836406|Experimental|Keromin Group|
32813880|NCT01836406|Placebo Comparator|Placebo Group|
32813881|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
32813882|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
32813883|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
32813884|NCT01836484||Surgically staged endometrial and cervical carcinoma|
32813885|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
33101280|NCT04324216|No Intervention|Control group|No intervention
33101281|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
32813886|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
32813887|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
32813888|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
32813889|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
32813890|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
32813891|NCT01836796|Placebo Comparator|Placebo|
32813892|NCT01726894|Experimental|Irreversible Electroporation|
32813893|NCT00915538|Other|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
33101282|NCT05660551|No Intervention|Control Group|
33101283|NCT05660551|Experimental|Demonstration group|
33101284|NCT05660551|Experimental|Telesimulation Group|
33101285|NCT05660551|Experimental|Kahoot Game Group|
33101286|NCT04832516|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
33101287|NCT04832516|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
33101288|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
33101289|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
33101290|NCT04817072|Other|Chronic inflammatory rheumatic disease|Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
33101291|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
33101292|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
33101293|NCT04817033|Active Comparator|High risk OSA Dexmedetomidine|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
33101294|NCT04817033|Active Comparator|High risk OSA Midazolam|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
33101295|NCT04817033|Active Comparator|Low&Medium OSA Dexmedetomidine|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
33101296|NCT04817033|Active Comparator|Low&Medium OSA Midazolam|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
33101297|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
32813894|NCT00915538|Experimental|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
32813895|NCT01836874||Topiramate|
32813896|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
32813897|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
32813898|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
32813899|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
32813900|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
32813901|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
32813902|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
32813903|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
32813904|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
32813905|NCT01727050|Active Comparator|Mechanical stapling|
32813906|NCT01727050|Active Comparator|Fibrin sealant spray|
32813907|NCT03836716|Experimental|Arimoclomol|Arimoclomol, capsule
32813908|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
32813909|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
32813910|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
32813911|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
32813912|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
32813913|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
32813914|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
32813915|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
32813916|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
32813917|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
32813918|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
33101298|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
33101299|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
32813919|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
32813920|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
32813921|NCT01836952||Infants|Infant born via vaginal delivery
32813922|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
32813923|NCT01724242|Placebo Comparator|Placebo|
32813924|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
32813925|NCT01837030|Other|Oral Iron|
32813926|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
32813927|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
32813928|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
32813929|NCT01727596|Experimental|1|
32813930|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
32813931|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
32813932|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
32813933|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
32813934|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
32813935|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
32813936|NCT01837186||EFP|Empyema following pneumonectomy
32813937|NCT01837186||nEFP|No empyema following pneumonectomy
32813938|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
32813939|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
32813940|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
32813941|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
32813942|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
32813943|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
32813944|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
32813945|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
32813946|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
32813947|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
32813948|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
32813949|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
32813950|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
32813951|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
32813952|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
32813953|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
32813954|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
32813955|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
32813956|NCT01727986|Experimental|RoActemra/Actemra|
32813957|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
33101300|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
33101301|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
33101302|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
33101303|NCT03457883|Experimental|group A|accepted herniamesh mesh
33101304|NCT03457883|Experimental|group B|accepted biological graft of cook
33101305|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
33101306|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
32813958|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
32813959|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
33101307|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
32813960|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
32813961|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
32813962|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
33101308|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
33101309|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
33101310|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
33101311|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
33101312|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
32813963|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
33317182|NCT00038142|Active Comparator|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days, Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin).
33101313|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
33101314|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
33317183|NCT04859842|Active Comparator|Pulse Electromagnetic Field Group|Pulse Electromagnetic Field Therapy (PEMF) will be applied to patients' low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to PEMF therapy.
33317184|NCT04859842|Active Comparator|Interferential Current Group|Interferential current will be applied to patients' low back pain region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to Interferential current.
33317185|NCT04859842|Sham Comparator|Sham Group|Sham electrodes will be placed on the low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to sham therapy.
33317186|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
32813964|NCT01705574|Active Comparator|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
32813965|NCT01705574|Experimental|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
32813966|NCT04378660|Experimental|Intervention arm|Colonoscopy with AI
32813967|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
32813968|NCT04378738|Other|Cohort|the healthy people who accepted to participate in the study
32813969|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
32813970|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
33317187|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
33317188|NCT01090128|Experimental|All patients|All participants enrolled.
33101315|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
33101316|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
33101317|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
33101318|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
33101319|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
33101320|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
33101321|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
33101322|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
33101323|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
33317189|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
33317190|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
33317191|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
33317192|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~Hemophilia, Normal Vitamin D - no intervention - observation only"
32813971|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
32813972|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
32813973|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
32813974|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
32813975|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
32813976|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
32813977|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
32813978|NCT01737710|Experimental|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
32813979|NCT01737710|Experimental|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
32813980|NCT01737710|Active Comparator|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
32813981|NCT01737710|Active Comparator|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
32813982|NCT01737710|Experimental|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
32813983|NCT01724944|Experimental|Systematic Lymphadenectomy|
32813984|NCT04381000|No Intervention|Control Group|The control group will not participate in any exercise program.
32813985|NCT04381000|Experimental|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
32813986|NCT04379674|Experimental|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
33101324|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
33101325|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
33101326|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
33101327|NCT05600179||patients with diabetic macular edema|
33101328|NCT05600179||healthy patients|
33101329|NCT05599945|Experimental|Single Dose 1: NNC0581-0001 10 milligram (mg)|Participants will receive a single dose of NNC0581-0001 10 mg or matching placebo injection subcutaneously.
33101330|NCT05599945|Experimental|Single Dose 2: NNC0581-0001 30 mg|Participants will receive a single dose of NNC0581-0001 30 mg or matching placebo injection subcutaneously.
33101331|NCT05599945|Experimental|Single Dose 3: NNC0581-0001 90 mg|Participants will receive a single dose of NNC0581-0001 90 mg or matching placebo injection subcutaneously.
33101332|NCT05599945|Experimental|Single Dose 4: NNC0581-0001 250 mg|Participants will receive a single dose of NNC0581-0001 250 mg or matching placebo injection subcutaneously.
33101333|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
33101334|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
33101335|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
33101336|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
33101337|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
33101338|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
33101339|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
33101340|NCT04687956|Experimental|LYMPHA|LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
33101341|NCT04687956|Active Comparator|Control|No LYMPHA procedure is performed
33101342|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
32813987|NCT04379674|Experimental|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
32813988|NCT04379674|Placebo Comparator|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
32813989|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
32813990|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
32813991|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
32813992|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
32813993|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
32813994|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
32813995|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
32813996|NCT04378348|Experimental|Motivational Interview|
32813997|NCT04378348|Experimental|Participatory Group Activity|
32813998|NCT04378348|Placebo Comparator|Control Condition|
32813999|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
32814000|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
32814001|NCT01725178|No Intervention|Standard care|No intervention besides usual care
32814002|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
32814003|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
33101343|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
33101344|NCT04324060|Active Comparator|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
33101345|NCT04324060|Placebo Comparator|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
33101346|NCT01290718|Experimental|Single Arm|
33101347|NCT04324294|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
33101348|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
33317193|NCT05570890|Experimental|Sham stimulation on stable surface|The participant will not receive stimulation and will stand on flat ground.
33317194|NCT05570890|Experimental|Noise stimulation on stable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on flat ground.
32955378|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
32955379|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
32955380|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
33317195|NCT05570890|Experimental|Sham stimulation on unstable surface|The participant will not receive stimulation and will stand on foam.
32955381|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
32955382|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
32955383|NCT05609526|No Intervention|1.Group (Compression Therapy)|"The patient will be placed in the supine position. Short stretch bandages of 6, 8, 10 and 12 cm will be applied to the extremity in a multi-layered and special way. Starting with the finger bandage, the pressure will be reduced as it goes distally. The patient's gait and circulation will be checked after bandaging is finished.~will be."
32955384|NCT05609526|Experimental|2.Group (Inspiratory muscle training)|"Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time 30 minutes per day will be. On the first day, the MIP levels of the participants will be evaluated and the training workload will be determined as 30% of the MIP. For IMT, after a nose clip was inserted from the participants They will be asked to sit on the mouthpiece of the device and close their lips tightly. With the device in this position, the device for four to five breath rests after every 10 breathing cycles.~mouth, and repeat the cycle for 15 minutes."
32955385|NCT05609526|Experimental|3.Group (Calf muscle exercise training)|A strengthening treatment program will be applied to the calf muscles. CMET will consist of static stretching exercise for the dorsiflexors and plantar flexors, isotonic resistance exercise with elastic resistance bands, heel and toe lift in both feet, followed by toe raising and lowering without heel raising. An isotonic exercise (mini squat) will be performed for ankle pumping exercise and knee flexion in sitting position. Patients will begin strength training with elastic resistance bands using red bands (lowest resistance). Green and blue bands by increasing the number of sets and repetitions will start to be used (increased resistance). (31.32)
32955386|NCT05609526|Experimental|4.Group (Inspiratory and calf muscle training)|All applications made in 3 groups will be made in this group.
32955387|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
32955388|NCT04346316|Active Comparator|SHR0302 Dose#1|
32955389|NCT04346316|Active Comparator|SHR0302 Dose#2|
32955390|NCT04346316|Active Comparator|SHR0302 Dose#3|
32955391|NCT04346316|Placebo Comparator|Placebo|
32955392|NCT05567328|Experimental|Adult patient (age > 18 y.o) followed for a liver disease, all etiologies combined|Adult patients followed in the Hepatology or Endocrinology department for a liver disease, all etiologies combined.
32955393|NCT00567840|Experimental|1|PA-824 200 mg/qd
32955394|NCT00567840|Experimental|2|PA-824 600 mg/qd
32955395|NCT00567840|Experimental|3|PA-824 1000 mg/qd
32955396|NCT00567840|Experimental|4|PA-824 1200 mg/qd
32955397|NCT00567840|Active Comparator|5|Rifafour e-275 mg
32955398|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
32955399|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
32955400|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
32955401|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
32955402|NCT03830970|Experimental|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
32955403|NCT03830970|Experimental|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
32955404|NCT03830970|Other|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
32955405|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
32955406|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
32955407|NCT05547048|Experimental|Athena Strategy|Virtual care model that includes direct synchronous videoconferencing with a provider, telephone/ texting communication, electronic health records, e-prescribing for the purposes of delivering PrEP and medications for opioid use disorder. This is combined with a decision aid for PrEP
32955408|NCT05547048|Active Comparator|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
32955409|NCT05508750|Experimental|New Infant Formula|New infant formula for healthy term infants
32955410|NCT05508750|Active Comparator|Commercial Infant Formula|Standard, commercially available infant formula for healthy term infants
32955411|NCT05508750|No Intervention|Human Milk|Breastfed infants serve as a reference group
32955412|NCT05363202|Experimental|Fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd.)|
32955413|NCT05363202|Active Comparator|FLOVENT HFA|
32955414|NCT05363202|Placebo Comparator|Placebo of Fluticasone propionate inhalation aerosol 44 mcg|
32955415|NCT05537064|No Intervention|Control|Control arm exposed only to usual care, which consists of the passive decision support functionality Health Maintenance flag that is the current decision-support tool in the EMR.
32955416|NCT05537064|Experimental|Non-visit Based Intervention|In this arm the investigators will evaluate a non-visit-based nudge to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Practices will be randomized to usual care versus the non-visit-based nudge. The non-visit-based nudge will consist of an EPIC In-basket message sent to each provider that identifies their patients eligible for but not prescribed high- or moderate-intensity statins and notifies them that pended orders for a referral to centralized pharmacy services for statin management will be entered for these patients unless the provider opts out. At the time the in-basket message is sent out, PCPs will also have the opportunity to opt out of participating in the trial entirely.
32955417|NCT05537064|Experimental|Visit-Based Intervention|In this arm the investigators will evaluate a visit-based nudge to refer to centralized pharmacy services to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Physicians in a single practice will be randomized to usual care versus visit-based nudge. The visit-based nudge will consist of an interruptive Best Practice Advisory (BPA) in the EMR that will trigger during non-acute patient visits and will prompt the provider to refer the patient to a centralized pharmacy service for statin initiation and management.
32955418|NCT05461092|Active Comparator|Standard of Care Anesthesia without Thoracolumbar Interfascial Plane (TLIP) Block of bupivicaine.|Subjects will receive standard of care anesthesia without TLIP Block of bupivicaine.
32955419|NCT05461092|Experimental|Standard of Care Anesthesia with Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivacaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
32955420|NCT05442840|No Intervention|Control Arm|The participants in this arm will receive standard of care from their physician as they would have been doing previously. This still may involve blood work, referrals to other health providers (except pharmacist) and medication adjustments driven by the pharmacist.
32955421|NCT05442840|Active Comparator|Pharmacist Intervention Arm|The participants in this arm will receive standard of care from their physician in addition to pharmacist intervention. The pharmacist or pharmD intern leads the diabetes care for the patient typically, conducting a medication review, recommending medication changes, frequent follow up and requesting blood work and providing referrals to other health care providers as needed,which is standard care
32955422|NCT05421780|Placebo Comparator|Control biscuits group|For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.
32955423|NCT05421780|Experimental|autoclaved BSG-containing group|For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.
32955424|NCT05421780|Experimental|bio-transformed BSG-containing group|For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.
32955425|NCT05394012|Experimental|RQ3013|
32955426|NCT05394012|Active Comparator|Comirnaty|
32955427|NCT02129478|Experimental|Olanzapine|
32955428|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
32955429|NCT05362500|Active Comparator|Group A 70% Glycolic acid|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing to stop peeling
32955430|NCT05362500|Active Comparator|Group B intradermal tranexamic acid|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
32955431|NCT05161806|Experimental|SOK583A1 (40 mg/mL)|participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study
32955432|NCT05362188|Experimental|Topical Nicotinamide 2%|will receive topical nicotinamide 2%
33317196|NCT05570890|Experimental|Noise stimulation on unstable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on foam.
33317197|NCT01296620|Experimental|Experimental 1|
32738295|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
32738296|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
32738297|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
32955433|NCT05362188|Experimental|Topical Nicotinamide 4%|will receive topical nicotinamide 4%
32738298|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
32738299|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
32955434|NCT05362188|Placebo Comparator|Placebo|Subjects will receive only cream/gel base without API for control
32955435|NCT01798368|Experimental|PBASE system 2.0|
32955436|NCT05355168|Experimental|Neoadjuvant treatment|Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab
32955437|NCT05353374|Experimental|Sodium fusidate ointment|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, sodium fusidate ointment was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
32955438|NCT05353374|Placebo Comparator|Petrolatum|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, petrolatum was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
32955439|NCT05352594||Chronic Low Back Pain|The participants whose low back pain intensity score ≥2 by numeric pain rating scale at 24-week follow-up.
32955440|NCT05352594||Recovered Low Back Pain|The participants whose low back pain intensity score <1 by numeric pain rating scale at 24-week follow-up.
32955441|NCT05293236|Placebo Comparator|Placebo|Nine COVID-19 patients (three from each treatment-group) treated with saline intravenous infusion
32955442|NCT05293236|Experimental|Dose 1|Seven COVID-19 patients treated with ApTOLL (0.05mg/kg) intravenous infusion
32955443|NCT05293236|Experimental|Dose 2|Seven COVID-19 patients treated with ApTOLL (0.1mg/kg) intravenous infusion
32955444|NCT05293236|Experimental|Dose 3|Seven COVID-19 patients treated with ApTOLL (0.2mg/kg) intravenous infusion
32955445|NCT05292300|No Intervention|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
32955446|NCT05292300|Experimental|Cornelian Cherry Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 20 g/day Cornelian Cherry powder.
32955447|NCT05292300|Experimental|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
32955448|NCT05292300|Experimental|Cornelian Cherry and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
32955449|NCT05249088|Experimental|Protocolised reduction of non-resuscitation fluids|Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.
32955450|NCT05249088|Other|Usual Care|Participants receive non-resuscitation fluids according to local routines.
32955451|NCT05239494|Experimental|Dailies Total1|All participants will be asked to wear Dailies Total1 for the duration of this study.
32955452|NCT05214222|Experimental|group A|Penpulimab plus chemotherapy with Anlotinib
33317198|NCT01296620|Experimental|Experimental 2|
33317199|NCT01296620|Placebo Comparator|Placebo|
33317200|NCT04728646|Experimental|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
33317201|NCT04728646|Other|Dissolvable intracanalicular plug|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
32814004|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
32814005|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
32814006|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
32814007|NCT04378036|Active Comparator|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
32814008|NCT04378036|Active Comparator|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
32814009|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
32814010|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
32814011|NCT04378192|Active Comparator|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
32814012|NCT04378192|Active Comparator|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
32814013|NCT01725412|Experimental|Thiamine Supplementation|
32814014|NCT01725412|Placebo Comparator|Placebo|
32814015|NCT01838356||No treatment.|
32814016|NCT01725490|Experimental|metformin 500mg daily (arm A)|
32814017|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
32814018|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
33317202|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
33317203|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
32814019|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
32814020|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
32814021|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
32814022|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
32814023|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
32814024|NCT01728610|Active Comparator|Active high|Probiotic, high dose
32814025|NCT01728610|Active Comparator|Active low|Probiotic, low dose
32814026|NCT01728610|Placebo Comparator|Placebo|Placebo
33317204|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
33317205|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
33317206|NCT04674826|Experimental|TR (Test-Reference)|Treatment period 1: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T) Treatment period 2: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R)
33317207|NCT04674826|Experimental|RT (Reference-Test)|Treatment period 1: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R) Treatment period 2: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T)
32814027|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
32814028|NCT04553666|Experimental|Intervention Group|Four 200mg EGCG pills and one 250mg Vitamin C pill taken one time each day
32814029|NCT04553666|No Intervention|Usual Care Group|No study pills
32814030|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
32814031|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
32814032|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
32814033|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
32814034|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
33101349|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
33101350|NCT04688424|Experimental|FES + Cycling|Functional electrical stimulation cycling group
33405042|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
33405043|NCT05762484|Experimental|Intervention group, laser hair removal therapy|Patients will undergo 6 monthly laser hair removal treatments with de Nd:YAG laser. After 6 months, a 6 follow up will start, using clindamycin 1% lotion if needed.
32814035|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
32814036|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
32814037|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
32814038|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
32814039|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
32814040|NCT04377646|Active Comparator|Hydroxychloroquine & Zinc|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Zinc 15 mg at daily dose up to 2 months"
32814041|NCT04377646|Active Comparator|Hydroxychloroquine|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Placebo of Zinc"
32814042|NCT04377646|Placebo Comparator|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
32814043|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
32814044|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
32814045|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
32814046|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
32814047|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
32814048|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
32814049|NCT01838746||PCI|Patients undergoing PCI
32814050|NCT01838746||CABG|Patients undergoing CABG
32814051|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
32814052|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
32955453|NCT05214222|Experimental|group B|Penpulimab plus chemotherapy
32955454|NCT05211180|Active Comparator|Vida Sana|Vida Sana is a cultural-adaption of Group Lifestyle Balance, a 12-month intervention that targets at least 5% weight loss and at least150 minutes per week of moderate-to-vigorous physical activity. Health coaches will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
32955455|NCT05211180|Experimental|Vida Sana y Completa|Vida Sana y Completa is an obesity intervention with integrated treatment for food insecurity. This arm includes all the activities described for the active comparator arm (Vida Sana) as well as a weekly food box delivery for the first 12 weeks of the intervention. The food box will contain approximately 40 pounds of food including proteins and dairy, whole grains, and produce. Just like the Vida Sana active comparator arm, the Vida Sana y Completa group will include health coaches who will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
32955456|NCT05195268|Active Comparator|Group 1 - PVI + PWI|These patients will receive pulmonary vein isolation and posterior wall isolation.
32955457|NCT05195268|Other|Group 2 - PVI only|These patients will receive pulmonary vein isolation only.
32955458|NCT05290740|Active Comparator|group A|
32955459|NCT05290740|Active Comparator|group B|
32955460|NCT05118204|Experimental|BUP microdose induction|Participants in this arm will receive a novel BUP microdose induction protocol.
32955461|NCT05118204|Active Comparator|Treatment As Usual (TAU)|Participants in this arm will receive standard BUP induction protocol.
32955462|NCT04991454|Other|end-stage pulmonary hypertension .|subjects with end-stage PH that currently on the waitlist for lung transplant
32955463|NCT04991454|Other|following pulmonary arterial hypertension subjects|Following pulmonary arterial hypertension subjects upto 24 months
33405044|NCT05762484|Active Comparator|Control group, clindamycin 1% lotion if needed, standard care|Patients will use clindamycin 1% lotion of needed for 1 year.
32814053|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
32814054|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
32814055|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
32814056|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
32814057|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
32814058|NCT03409822|Other|Placenta previa|
32814059|NCT03401086|Active Comparator|Study group|Kinesio Taping
32814060|NCT03401086|No Intervention|Control group|No intervention
32814061|NCT04553432|Experimental|Omnigen + OmniLenz|Omnigen amniotic membrane 17mm disk with 6mm central aperture place under 18mm OmniLenz bandage contact lens
32814062|NCT04553432|Active Comparator|OmniLenz|Bandage contact lens alone
32814063|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
32814064|NCT04551014|Experimental|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
32814065|NCT04551014|Experimental|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
32814066|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
32814067|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
32814068|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
32814069|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
32814070|NCT01729078|Experimental|high carb/low fat|Habitual diet
32814071|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
32814072|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
32814073|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
32814074|NCT03400696|Experimental|Randomized- Higher fiber diet|
32814075|NCT03400696|Experimental|Randomized- Exercise focused|
32814076|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
32814077|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
32814078|NCT03400696|Experimental|Participant chooses- Exercise focused|
32814079|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
32814080|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
32814081|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
32814082|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
32814083|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
33101351|NCT04688424|Active Comparator|Cycling only|Volitional cycling group (no electrical stimulation)
33101352|NCT04688424|No Intervention|Control|control group
32814084|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
32814085|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
32814086|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
32814087|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
32814088|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
32814089|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
32814090|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
32814091|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
32814092|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
32814093|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
32814094|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
32814095|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
32814096|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
32814097|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
32814098|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
32814099|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
32814100|NCT04550468|Experimental|Low-Carb High-Fat Breakfast|Participants will follow a daily low carbohydrate high fat breakfast intervention for 3 months.
32814101|NCT04550468|Active Comparator|"Low fat Standard Care Control Breakfast"|"Participants will follow a daily low fat standard care control breakfast intervention for 3 months."
33101353|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
32814102|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
33405045|NCT03462641|Experimental|Sequence A - (Flumazenil at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the first visit as treatment. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
32814103|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
32814104|NCT04376788|Experimental|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
32814105|NCT04376788|Experimental|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
32814106|NCT04376788|Experimental|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
32814107|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
32814108|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
33101354|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
33101355|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.~No treatment for negative HBe Ag women"
33101356|NCT04688229|Experimental|Hummingbird intervention group|10 one-hour sessions of focused hand training (affected or dominant hand) using the Hummingbird device in addition to standard of care inpatient rehabilitation
33101357|NCT04688229|Active Comparator|Comparison (sham) group|10 one-hour sessions of activity focused on playing games or puzzles gaged to the ability of the subject in addition to Standard of care inpatient rehabilitation
33101358|NCT04688073|Experimental|Downhill running|Running at 60% VO2max on -15% slope for 30 min on a treadmill
33101359|NCT04688073|Experimental|Level running|Running at 60% VO2max on level surface for 30 min on a treadmill
33101360|NCT04688073|Placebo Comparator|Control|Rest 30 min
33101361|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
33317208|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
32814109|NCT01729702|Other|single group - consecutive patients|
32814110|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
32814111|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
32814112|NCT03400072|No Intervention|Usual care|Usual care
32814113|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
32814114|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
32814115|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
32814116|NCT03409744|Experimental|evinacumab|
33101362|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
33101363|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
33317209|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
33405046|NCT03462641|Experimental|Sequence B - (Placebo at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the first visit as treatment. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
32814117|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
32814118|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
32814119|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
32814120|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
32814121|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
33317210|NCT04650568|Experimental|Mesenchymal Stem Cell Recipient|Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
33101364|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
33101365|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
33101366|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
33317211|NCT04650568|Placebo Comparator|Control Sham Incision|Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care.
33317212|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
33317213|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
33317214|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
33317215|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
32814122|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
32814123|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
33317216|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
33317217|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
32814124|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
32814125|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
32814126|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
32814127|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
32814128|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
33317218|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
32814129|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
33317219|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
33317220|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
33317221|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
32814130|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
32814131|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
32814132|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
32900905|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
33101367|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
33101368|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
33101369|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
33101370|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
33101371|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
33101372|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
33317222|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
32955467|NCT05198232|No Intervention|Control Group|This group will complete normal daily activities. The participants will complete pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher, the control group will participate in normal activities as part of their community day program.
32955468|NCT05198232|Experimental|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
32955469|NCT05198232|Experimental|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
32955470|NCT05175690||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
32955471|NCT04961658|Experimental|Treatment Arm - Low Dose|Participants will receive a single dose of GEM00220 at 15 million cells
32955472|NCT04961658|Experimental|Treatment arm - Mid dose|Participants will receive a single dose of GEM00220 at 60 million cells
32955473|NCT04961658|Experimental|Treatment arm - High dose|Participants will receive a single dose of GEM00220 at 150 million cells
32955474|NCT05048550|No Intervention|A (control)|First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
32955475|NCT05048550|Experimental|B1 (intervention)|First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
32955476|NCT05048550|Experimental|B2 (intervention)|First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
32955477|NCT04932018|Experimental|Interventional|The intervention group will participate in a round table educational session with a study facilitator/mentor farmer and occupational health nurse plus receive an invitation to participate in an interactive virtual community providing ongoing resources and support from community farmers and agriculture experts.
32955478|NCT04932018|Sham Comparator|Attention Control|The second group (attention control) will receive an invitation to participate in the virtual community without mentor interaction.
33317223|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
33101373|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
33101374|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
33101375|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
33101376|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
33317224|NCT04647604|Active Comparator|Omega|Omegaven® (2 mL/kg/day, equivalent to 6 g Docosahexaenoic Acid (DHA)+Eicosapentaenoic Acid (EPA) in a 70 kg individual) once daily for 5 days
33317225|NCT04647604|Placebo Comparator|Sodium chloride (NaCl)|2 mL/kg/day) once daily for 5 days
33317226|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
33317227|NCT01188824|Placebo Comparator|placebo|"Placebo~1 tablet, bid p.o."
33317228|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
33317229|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
33317230|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
33317231|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
33317232|NCT04600180||Palliative treatment with immunotherapy|
33317233|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
33317234|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
33317235|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
33317236|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
33317237|NCT01060631||patients with frontal or frontotemporal brain tumor.|
33317238|NCT01060631||patients without supratentorial brain tumor.|
33101377|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
33101378|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
32814133|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
33101379|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
33101380|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
33101381|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
33317239|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
33317240|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
32814134|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
32814135|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
33317241|NCT03851978|Experimental|Pharmacist Vaccine Education|
33317242|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
33317243|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
33317244|NCT01188902|No Intervention|control|
33317245|NCT00037830|Active Comparator|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
32814136|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
32814137|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
33317246|NCT00037830|Placebo Comparator|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
33317247|NCT00037830|No Intervention|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
33317248|NCT05282810||cartilage tympanoplasty|use cartilage in tympanoplasty for recuurent perforation
32814138|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
32814139|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
32814140|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
32814141|NCT04549922|Placebo Comparator|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
32814142|NCT04549922|Active Comparator|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
33317249|NCT05282810||temporalis fascia graft in tympanoplasty|use temporalis fascia as a graft in tympanoplasty for recuurent perforation
33317250|NCT05179642||Control group|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group."
32814143|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
32814144|NCT01681628|Other|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
32814145|NCT04377958|Other|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
32814146|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
32814147|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
32955479|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
32955480|NCT05035056||CT Coronary Angiogram with quantitative characterization of plaque|Participants (150 from Intensive Medical Therapy [IMT] and 150 from the Usual Care [UC] group in the WARRIOR trial) will undergo CTA at the Year 3 follow-up visit at their respective enrollment study sites. Quantitative characterization of plaque analysis will be conducted at Cedars-Sinai Medical Center using Autoplaque plaque analysis software.
32955481|NCT04747236|Experimental|AZA and ROMI|Oral Azacytidine (AZA) (300 mg daily on days 1-14) plus Romidepsin (ROMI) (14 mg/m2 as an intravenous infusion over 4 hours on days 8, 15 and 22 of a 35-day cycle.
32955482|NCT04747236|Active Comparator|Investigator's Choice|Investigator's choice to include: ROMI, 14 mg/m2 IV infusion on days 1, 8, and 15 of a 28 day cycle, belinostat,1000 mg/m2 IV infusion on days 1-5 every 21 days, pralatrexate, 30 mg/m2 IV push once weekly for 6 weeks of a 7-week treatment cycle, or gemcitabine, 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle.
32955483|NCT05040204|Experimental|Experimental Supplement 1|6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks
32955484|NCT05040204|Experimental|Experimental Supplement 2|6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks
32955485|NCT05040204|Experimental|Experimental Supplement 3|20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks
32955486|NCT05040204|Placebo Comparator|Placebo Comparator 1|6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks
33317251|NCT05179642||Tool OPTIM-EHPAD|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
33317252|NCT05568862||spinal cord injury|patient with spinal cord injury
33317253|NCT05568862||no spinal cord injury|patient without spinal cord injury
33317254|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
33317255|NCT03953196|Experimental|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
32955487|NCT05040204|Placebo Comparator|Placebo Comparator 2|6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks
32955488|NCT04742946|Experimental|TR Group|Personalized digital physiotherapy program 4 weeks. One session per day. Web and mobile application. Auto-Exercise
32955489|NCT05017194|Experimental|Emodepside 5 mg|
32955490|NCT05017194|Experimental|Emodepside 10 mg|
32955491|NCT05017194|Experimental|Emodepside 15 mg|
32955492|NCT05017194|Experimental|Emodepside 20 mg|
32955493|NCT05017194|Experimental|Emodepside 25 mg|
32955494|NCT05017194|Experimental|Emodepside 30 mg|
32955495|NCT05017194|Active Comparator|Albendazole|
32955496|NCT05017194|Placebo Comparator|Placebo|
32955497|NCT04993248|Experimental|Intervention|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
32955498|NCT04993248|No Intervention|Control|Usual intervention
32955501|NCT04853394|Experimental|MASLIHAT peer education|A peer educator prevention intervention program consisting of five weekly 2-hour small group sessions.
32955502|NCT04853394|Sham Comparator|TANSIHAT health education|A health education program consisting of five weekly 2-hour sessions small group sessions.
32955503|NCT04850820|Experimental|Novel essential amino acid supplementation (EAA+)|Arm will investigate the effect of a novel essential amino acid-based formula (essential amino acids enriched with active botanical compounds; EAA+) developed by Iovate Health Sciences International Inc. on post-exercise anabolism. The formulation was recently granted a Natural Product Number (NPN: 80087022) and approved by the Natural and Non-prescription Health Products Directorate of Health Canada.
32955504|NCT04850820|Active Comparator|Branched-chain amino acid supplementation (BCAA)|Arm will used a branched-chain amino acid supplement developed by Iovate Health Sciences International Inc. to compare with the experimental arm after exercise.
32955505|NCT04850820|Placebo Comparator|Isocaloric carbohydrate supplementation|Carbohydrate supplement that is isocaloric to the EAA+ supplement and designed to function as a placebo to the experimental arm after exercise.
32955506|NCT04850820|Other|Rested control|Carbohydrate supplement that is isocaloric to the EAA+ supplement but consumed at rest to serve as the baseline control
32955507|NCT04778748||Obstructive Sleep Apnea|Participants will be provided with a Withings sleep monitor and instructed to begin using it. Effective data collection via the Withings unit should be confirmed for at least 7 consecutive nights, and the WatchPAT device will be used during one of those same 7 nights.
32814148|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
32814149|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
32814150|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
32814151|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
32814152|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
32814153|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
32814154|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
32814155|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
32814156|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
32814157|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
32814158|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
32814159|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
32814160|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
32814161|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
32814162|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
32814163|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
32814164|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
32814165|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
32814166|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
32814167|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
32814168|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
32814169|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
32814170|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
32814171|NCT04377178|Experimental|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
32814172|NCT04377178|Active Comparator|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
32814173|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
32814174|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
32814175|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
32814176|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
32814177|NCT03405142|Experimental|T1 or T2 stage and node-negative|T1 or T2 stage primary tumor and node-negative (ie, cN0)
32814178|NCT03405142|Experimental|Any T stage and node-positive|Any T stage tumor and node-positive (ie, cN+)
32814179|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
32814180|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
32814181|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
32814182|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
32814183|NCT00016354|Experimental|benzoylphenylurea|
32814184|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
32814185|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
32814186|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
32814187|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
32814188|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
32814189|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
32814190|NCT01681472|Experimental|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
32814191|NCT01681472|Experimental|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
32814192|NCT01727518||Reference Population|No Intervention
32814193|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
33101382|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3"
33101383|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
33101384|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
33101385|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
33101386|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
33101387|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
33101388|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
33101389|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)~Group 2 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
33317256|NCT03953196|Experimental|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
33317257|NCT03953196|Experimental|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
33317258|NCT03953196|Experimental|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
33317259|NCT03953196|Experimental|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
33317260|NCT05179564|Experimental|iohexol plasma clearance|"a weight-dependent dose of iohexol will be injected as an intravenous bolus in 100 patients~2,5 -9kg = 1ml; 10-19kg = 2ml; 20-29kg = 3ml; 30-39kg = 4ml; ≥ 40kg = 5ml"
33317261|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
33317262|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
33317263|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
33317264|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
33317265|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
33317266|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
33317267|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
33317268|NCT05179252|Experimental|SFI intervention group|shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
33317269|NCT05179252|Sham Comparator|Control group|same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
33317270|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
33317271|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
33317272|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
33317273|NCT04502914|Experimental|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
33317274|NCT04502914|Other|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
33317275|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
33317276|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
33317277|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
33317278|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
33317279|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
33317280|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
32814194|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
32814195|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
32814196|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
32814197|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
32814198|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
32814199|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
32814200|NCT00915928|Active Comparator|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
32814201|NCT00915928|Placebo Comparator|Placebo|patients randomized to this arm will be treated with placebo after surgery
32814202|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
32814203|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
33317281|NCT05565040|Experimental|Phallopexy group|phallopexy only
32814204|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
32814205|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
32814206|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
32814207|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
32814208|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
32814209|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
32814210|NCT01049308||Heart Failure|veteran population with documented heart failure
32814211|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
32814212|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
32814213|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
32814214|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
32814215|NCT03407092||Stentriever Cohort|
32814216|NCT03407092||ADAPT cohort|
32814217|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
32814218|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
32814219|NCT01047436|Active Comparator|Intravenous Quinine|
32814220|NCT02240446|Experimental|Active tDCS|Active tDCS
32814221|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
32814222|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
32814223|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
32814224|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
32814225|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
32814226|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
32814227|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
32814228|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
32814229|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
33101390|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)~Group 4 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
32738300|NCT04434339|Experimental|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
33101391|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
33101392|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
33101393|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
33101394|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
33101395|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
33101396|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
33101397|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
33101398|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
33317282|NCT05565040|Experimental|Dartos excision group|complete circumferential dissection and excision of dartos fascia only
33317283|NCT05565040|Experimental|Combined phallopexy and dartos excision group|phallopexy as in patients of group A but after complete dissection and excision of dartos fascia
33317284|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
33317285|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
33317286|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
33317287|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
32738301|NCT04434339|Experimental|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
32738302|NCT04434339|No Intervention|group 3|"the control group, Patients will not receive any block."
32738303|NCT04493801||with nasoseptal flap|patient who undergo a pituitary gland surgery with nasoseptal flap
32738304|NCT04493801||without nasoseptal flap|patient who undergo a pituitary gland surgery without nasoseptal flap
32738305|NCT03120169|Active Comparator|treadmill endurance training|
32738306|NCT03120169|Active Comparator|cycling endurance training|
32738307|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
32738308|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
32738309|NCT05013723||Intervention|Patients who received casirivimab-imdevimab antibody infusion
33317288|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
33317289|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
32738310|NCT05013723||Control|Matched control group who did not receive MAb, matched on diagnosis date, age, gender and Utah COVID-19 Risk Score
32738311|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
32738312|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
32738313|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
32738314|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
32738315|NCT05020041|Experimental|Intervention|"The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers, or manipulation of objects to maintain COVID-19 sanitary and safety protocols.~The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers."
32738316|NCT05020041|No Intervention|Control|The schools participating in the control group will receive an online educational talk aimed at promoting healthy habits and the benefits of physical activity inside and outside the school environment.
32738317|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
32738318|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
32738319|NCT03227887|Active Comparator|Good chewing ability|
32738320|NCT03227887|Experimental|Impaired chewing ability|
32738321|NCT03323957||Patients|all infants admitted for care
32738322|NCT05020119|Experimental|Low dose of neoantigen-based cell therapy (N=3+3)|(1±20%) × 109cells/200 mL every 14 days for 10 doses
32738323|NCT05020119|Experimental|Medium dose of neoantigen-based cell therapy (N=3+3)|(3±20%) × 109cells/200 mL every 14 days for 10 doses
33101399|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
33101400|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
33101401|NCT02978391|Experimental|UI-EWD Hemostatic system|Patients with upper gastrointestinal bleeding treated with UI-EWD
33101402|NCT02978391|Active Comparator|epinephrine|Patients with upper gastrointestinal bleeding treated with submucosal epinephrine injection
33101403|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
33101404|NCT02936882|Other|Preoperative gastric ultrasonography|
32738324|NCT05020119|Experimental|High dose of neoantigen-based cell therapy (N=3+3)|(9±20%) ×109cells/400 mL every 14 days for 10 doses
33101405|NCT01290094|Experimental|Single Arm|
33317290|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
32738325|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
32738326|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
32738327|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
32738328|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
32738329|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
32738330|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
32738331|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
32738332|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
32738333|NCT05013489|Experimental|Mindfulness, compassion and intercare based Intervention|An Eight week mindfulness and intercare group online program.
32738334|NCT05013489|No Intervention|Waiting list|Psychological support if needed. No other intervention.
32738335|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
32738336|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
32738337|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
32738338|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
32738339|NCT04434183|Active Comparator|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
33101406|NCT04688346|Placebo Comparator|Control|Saline Pellet
33101407|NCT04688346|Experimental|Intervention|Racemic Epinephrine Pellet
33317291|NCT01188980||NoBE (control)|
33317292|NCT01188980||BE without dysplasia|
33317293|NCT01188980||BE with dysplasia|
32738340|NCT04434183|Active Comparator|home exercise|The group(home exercise group, n=25) was given home exercise program.
32738341|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
32738342|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
32738343|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
32738344|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
32738345|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
32738346|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
32738347|NCT04485091|Experimental|Group A: 20% TCM and PBM|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with photobiomodulation (PBM) with red spectrum LED (660nm) on the back of the hands.
32738348|NCT04485091|Placebo Comparator|Group B: 20% TCM and PBM placebo|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with simulated photobiomodulation on the back of the hands.
32738349|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
32738350|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
32738351|NCT03323645||Patients with penile prostheses|
32738352|NCT04434105|Experimental|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
32738353|NCT04434105|Active Comparator|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
32738354|NCT04434105|Placebo Comparator|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
33317294|NCT04222426|Experimental|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
32814230|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
32814231|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
32814232|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
32814233|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
32814234|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
32814235|NCT01046110|Experimental|IDeg OD|
32814236|NCT01046110|Experimental|DPP-IV inhibitor|
32814237|NCT04549688|Experimental|Focal therapy|
32814238|NCT01713530|Experimental|IDegAsp BID+/-OADs|
32814239|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
32814240|NCT01045798|Experimental|Caspofungin|caspofungin acetate
32814241|NCT01045798|Placebo Comparator|Placebo|normal saline
32814242|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
32814243|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
32814244|NCT04377256|Experimental|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
33317295|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
33317296|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
32814245|NCT04377256|Experimental|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
32814246|NCT02240914||Vascular USG and IVUS imaging diagnosis|
32814247|NCT03406234||A group of participants|
32814248|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
32814249|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
32814250|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
32814251|NCT04377568|Experimental|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
32814252|NCT04377568|No Intervention|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
32814253|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
32814254|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
32814255|NCT02241070|No Intervention|waiting-list control|passive control group
32814256|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
32814257|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
32814258|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
32814259|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
32814260|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
32814261|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
32814262|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
32814263|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
32814264|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
32814265|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
32814266|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
32814267|NCT04377412||Albania|
32814268|NCT04377412||Australia|
32814269|NCT04377412||Czech Republic|
32814270|NCT04377412||France|
32814271|NCT04377412||Germany|
32814272|NCT04377412||Hong Kong|
32814273|NCT04377412||Israel|
32814274|NCT04377412||Italy|
32814275|NCT04377412||Lebanon|
32814276|NCT04377412||Norway|
32814277|NCT04377412||Poland|
32814278|NCT04377412||Russia|
32814279|NCT04377412||Spain|
32814280|NCT04377412||Sweden|
32814281|NCT04377412||Taiwan|
32814282|NCT04377412||Ukraine|
32814283|NCT04377412||United States|
32814284|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
32814285|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
32814286|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
32814287|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
32814288|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
32814289|NCT04376710||Surgeons|
32814290|NCT04376710||Patients|
32814291|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
32814292|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
32814293|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
32814294|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
32814295|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
32814296|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
32814297|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
32814298|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
32814299|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
32814300|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
32814301|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
32814302|NCT01712516|Placebo Comparator|Placebo|b.i.d.
32814303|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
32814304|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
32814305|NCT04166240|Experimental|SAFER TRACKS Intervention|Each cluster starts receiving the intervention in sequence per cluster randomized control trial designs. Each cluster will participate in attending monthly coaching calls and compare their data on test results from pre-intervention to receiving the intervention.
32814306|NCT04166240|No Intervention|Non-intervention period|When the cluster is not in active intervention, they are in the non-intervention period. The amount of time that each site contributes to the intervention depends on which cluster they belong to.
32814307|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
32814308|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
32814309|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
32814310|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
32814311|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
32814312|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
33101408|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
32814313|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
32814314|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
32814315|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
32814316|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
32814317|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
32814318|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
32814319|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
32814320|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
32814321|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
32814322|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
32814323|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
32814324|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
32814325|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
32814326|NCT01712438|Experimental|Human cl rhFVIII|
32814327|NCT03405376|Experimental|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
32814328|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
32814329|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
32814330|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
32814331|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
32814332|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
32814333|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
32814334|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
32814335|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
32814336|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
32814337|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
32814338|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32814339|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33101409|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
33317297|NCT04200196|Experimental|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
32814340|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
32814341|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
32814342|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
32814343|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
32814344|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
32814345|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
32814346|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
32955508|NCT04773834|Experimental|Experimental group|Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.
32955509|NCT04773834|Other|Control group|Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team
32955510|NCT04520100|No Intervention|MRI without intervention|No hypnosis during MRI and care by regular MR technologist
32955511|NCT04520100|Active Comparator|MRI with clinical hypnosis and regular MR tech|Hypnosis during MRI and care by regular MR technologist
32955512|NCT04520100|Active Comparator|MRI with care by MR Tech trained in empathic communication|No hypnosis during MRI and care by MR technologist who have been trained in emphatic communication
32955513|NCT04504344|Experimental|Active tDCS|Active tDCS
32955514|NCT04504344|Sham Comparator|Sham tDCS|Sham tDCS
32955515|NCT04501380|Experimental|1st regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
33317298|NCT04200196|Active Comparator|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
33317299|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
33317300|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
32955516|NCT04501380|Experimental|2nd regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
32955517|NCT04465734|Experimental|A (treatment group)|HLX10 in combination with HLX04
33317301|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
33317302|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
33317303|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
33317304|NCT01295372|Experimental|Zicronapine|
33317305|NCT01295372|Active Comparator|Risperidone|
32955518|NCT04465734|Sham Comparator|B (control group)|sorafenib
32955519|NCT04448808|Experimental|BX-1 (dronabinol)|BX-1
32955520|NCT04448808|Placebo Comparator|Placebo|Placebo of BX-1
32955521|NCT04388358|Other|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
32955522|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
32955523|NCT04392960|Experimental|18F-florbetaben PET-CT scans|
32955524|NCT04954872|Active Comparator|Training as usual|Standard Problem Management Plus training.
32955525|NCT04954872|Experimental|Equip-based training|Training that uses the Equip platform to assess competencies and incorporate this information into trainers and supervisors activities.
32955526|NCT04170426|Experimental|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
32955527|NCT04170426|Active Comparator|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
32955528|NCT04170426|Placebo Comparator|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
32955529|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
32738355|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
32955530|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
32955531|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
32955532|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
32955533|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
32955534|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed parkinsonian disorder
32955535|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
32955536|NCT04020198||Normal Pressure Hydrocephalus|Subjects who are prescribed a lumbar puncture to treat normal pressure hydrocephalus
33317306|NCT05179174||patients with uveal melanoma|51 patients with a diagnosed with uveal melanoma; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, diseases kidney, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
33317307|NCT05179174||healthy controls|51 age sex matched controls, patients with diagnosed with cataracts; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, kidney diseases, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
33317308|NCT05179096|Experimental|Mindfulness|Participants in the experimental group will undergo an 8-week mindfulness training program with weekly 60-minute group sessions
33317309|NCT05179096|No Intervention|Control|The control group will follow routine daily school activities
33317310|NCT05283278|Active Comparator|Lactoferrin Bovine group|Group A (20 preterm neonates) which will receive lactoferrin (100mg/day)
33317311|NCT05283278|Active Comparator|Lactoferrin Bovine with probiotics group|Group B (20 preterm neonates) which will receive lactoferrin (100mg/day) in combination with the probiotic
33317312|NCT05283278|Placebo Comparator|Placebo group|Group C (40 preterm neonates) which is a placebo group.
33317313|NCT05179018||SLE patients group|The study will include 50 patients suffering from SLE, all patients with SLE should fulfill 2012 SLICC criteria
32738356|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
32738357|NCT02488421||Patient treated with Apixaban|
32955537|NCT03907644|Experimental|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
32955538|NCT03907644|Sham Comparator|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
32955539|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
32955540|NCT01798524||Kidney allograft recipients|
32955541|NCT03869814||Non-cancer|3,250 asymptomatic individuals without prior history of cancer
32955542|NCT03869814||Cancer|3,250 individuals with confirmed malignancy
32955543|NCT03869034|Experimental|A, Combination group (HAIC+PD-1)|HAIC+PD-1
32955544|NCT03869034|Experimental|B, HAIC group (HAIC only)|HAIC
32955545|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
32955546|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
32955547|NCT03821142|Experimental|Calistar S|Single arm cohort trial
32955548|NCT04286178|Experimental|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
32955549|NCT04286178|Placebo Comparator|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
32955550|NCT04655976|Experimental|Participants receiving cobolimab+dostarlimab+docetaxel|
32955551|NCT04655976|Experimental|Participants receiving dostarlimab+docetaxel|
32955552|NCT04655976|Active Comparator|Participants receiving docetaxel|
32955553|NCT04256460|Experimental|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
32955554|NCT04256460|No Intervention|Control arm|Receiving regular care and follow up in Community health centers
32955555|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
32955556|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
32955557|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
32955558|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
32955559|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
32955560|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
32955561|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
32955562|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
32955563|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
32955564|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
32955565|NCT00604890|Experimental|1|Active cream, 3% AM & PM
32955566|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
32955567|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
32955568|NCT00604890|Placebo Comparator|4|Placebo AM and PM
32955569|NCT03714048||Perioperative|
32955570|NCT03714048||Cardiogenic shock minus arrest|
32955571|NCT03714048||Cardiogenic shock plus arrest|
32955572|NCT03714048||Preventive|
32955573|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
32955574|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
32955575|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
32955576|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
32955577|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
32955578|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
32955579|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
32955580|NCT03642366|Active Comparator|Active Arm 1|
32955581|NCT03642366|Active Comparator|Active Arm 2|
33317314|NCT05179018||Healthy control group|Control group of 40 healthy volunteers with age and gender-matched with SLE patients.
33317315|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
33317316|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
32738358|NCT02488421||Patient treated with Rivaroxaban|
32955582|NCT03642366|Sham Comparator|Sham Arm|
32955583|NCT05246592||Preponderant lymphatic reflux group|high ratio of axillary lymphatic reflux to axillary vein reflux
32955584|NCT05246592||Preponderant venous reflux group|low ratio of axillary lymphatic reflux to axillary vein reflux
32955585|NCT05246436|Active Comparator|warm saline|Patients who used warm saline as a distention media in office hysteroscopy
32955586|NCT05246436|Sham Comparator|room temperature saline|Patients who used room temprature saline as a distention media in office hysteroscopy
32955587|NCT05246358|Experimental|ChroniSense Polso Respiratory Rate|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
32955588|NCT00604968|Experimental|Caelyx|
32955589|NCT00605202|Active Comparator|Licorice|
32955590|NCT00605202|Active Comparator|Licorice and HCTZ|
32955591|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
32955592|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
32955593|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
32955594|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~an evaluation~referral to a local mental health provider~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
32955595|NCT03508752|Experimental|Radiation|Stereotactic Radiosurgery
32955596|NCT05245578|Experimental|KX01 ointment and Placebo ointment|
32955597|NCT00605826|Experimental|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
32955598|NCT00605826|Sham Comparator|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
32955599|NCT00605826|Other|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
32955600|NCT05219448|Experimental|Education and self-efficacy coaching|This arm will receive education, behavior change support in the form of self-efficacy coaching, and introduction of sugar-free water enhancers.
32955601|NCT05219448|No Intervention|Comparison|This arm will have the outcomes assessed but will not receive the intervention (education, behavior change support, and introduction of sugar-free water enhancers) until the end of the study.
32955602|NCT05216562|Experimental|Intervention group|Group participants who receive injection of EXOSOME-MSC as adjuvant
32955603|NCT05216562|Placebo Comparator|Control group|Group participants who receive injection of Placebo (NaCL) as adjuvant
32955604|NCT03381300|Other|Single cohort|
32955605|NCT03324360|Experimental|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
32955606|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
32955607|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
32955608|NCT05216094|Experimental|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected upper limb or bilateral arm movement for 12 weeks
32955609|NCT05216094|Active Comparator|conventional group|stroke subjects receive conventional rehabilitation home program for 12 weeks
32955610|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
33317317|NCT05178394|Experimental|Male recreational weightlifters|
33317318|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
32955611|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
32955612|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
32955613|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
32955614|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
33317319|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
33317320|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
32955615|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
32955616|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
32955617|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
32955618|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
32955619|NCT05194488|Experimental|Low level laser therapy|
32955620|NCT05194488|Experimental|Botulinum toxin type A|
32955621|NCT05194488|Active Comparator|Anterior repositioning appliance|
32955622|NCT05175768|Active Comparator|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
32955623|NCT05175768|Active Comparator|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
32955624|NCT05175768|Placebo Comparator|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
32955625|NCT05097846|Experimental|Group1: Vonoprazan Fumarate + amoxicillin + doxycycline|
32955626|NCT05097846|Experimental|Group2: Vonoprazan Fumarate + furazolidone + doxycycline|
32955627|NCT05097846|Experimental|Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|
32955628|NCT05097846|Experimental|Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|
33317321|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
33317322|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
33317323|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
33317324|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
32738359|NCT02488421||Patient treated with Dabigatran|
32738360|NCT02488421||Patient treated with vitamin K antagonists|
32738361|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
32738362|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
32738363|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
32738364|NCT03320291|Experimental|Regjoint|
32738365|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
32738366|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
32738367|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
32738368|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
32738369|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
32738370|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
32738371|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
32738372|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
32738373|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
32738374|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
32738375|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
32738376|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
32738377|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
32738378|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
32738379|NCT04410861|Active Comparator|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120~."
32738380|NCT04410861|Experimental|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
32738381|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
32738382|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
32738383|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
32738384|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
32738385|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
32738386|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
33101410|NCT04324333|Experimental|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
33101411|NCT04688268||deep neuromuscular blockade|patients who underwent surgery with deep neuromuscular blockade
33101412|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
33101413|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
33317325|NCT01297088|Experimental|Arm 1|
33317326|NCT03846908|Experimental|MCT|subjects start with MCT fat load
33317327|NCT03846908|Experimental|SFA|subjects start with SFA fat load
32814347|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
32814348|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
33317328|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
32814349|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
32814350|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
32814351|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
32814352|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
32814353|NCT02241694||survey|
32814354|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
32814355|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
32814356|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
32814357|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
32814358|NCT02241850|Other|High intensity training|9 weeks of supervised training
32814359|NCT04413656|Experimental|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
32814360|NCT04413656|Experimental|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
32814361|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
32814362|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
32814363|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
32814364|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
32814365|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
32814366|NCT04377022|No Intervention|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
32814367|NCT04377022|Experimental|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
32814368|NCT03401710|Experimental|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
32814369|NCT03401710|No Intervention|Group 2|No recombinant human erythropoietin will be administered to this group
32814370|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
33317329|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
33101414|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
33101415|NCT04762589|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
33101416|NCT04762589|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
33101417|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
33101418|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
33101419|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
33101420|NCT03457844|Experimental|Anlotinib|
33101421|NCT02971956|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
32814371|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
33101422|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
33317330|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
33317331|NCT01295528||Blood Pressure, Heart Rate, Monitor|
32814372|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
32814373|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
32814374|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
32814375|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
32814376|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
32814377|NCT02993523|Placebo Comparator|Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax-matching placebo, orally, every day (QD), from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, subcutaneously (SC) or intravenously (IV), QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
32814378|NCT02993523|Active Comparator|Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, on Day 3 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
32814379|NCT02993523|Active Comparator|Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2|Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
32814380|NCT01701362|Active Comparator|pregabalin|
32814381|NCT01701362|Placebo Comparator|placebo|
32814382|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
32814383|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
32814384|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
32814385|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
32814386|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
32814387|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
32814388|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
32814389|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
32814390|NCT04375540|Experimental|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
32814391|NCT04375540|Experimental|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
33101423|NCT04690283|Placebo Comparator|Placebo-control group|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and placebo treatment twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
33317332|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
33317333|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
33317334|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
33101424|NCT04690283|Experimental|Treatment group I|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Huangqi Guizhi Wuwu granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
33101425|NCT04690283|Experimental|Treatment group II|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Danggui Sini granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
33101426|NCT04747418||Study Group: Women with low segment uterine scar following cesarean delivery|Women with low segment uterine scar following cesarean delivery, with no other abnormalities observed during diagnostic hysteroscopy
33101427|NCT04747418||Cohort Group: Women with no uterine scar|Women with no uterine scar, with no other abnormalities observed during diagnostic hysteroscopy
32814392|NCT04375540|No Intervention|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
33101428|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
33101429|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
32814393|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
32814394|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
32814395|NCT04375618|Experimental|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
32814396|NCT04375618|Active Comparator|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
32814397|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
32814398|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
32814399|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
32814400|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
32814401|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
32814402|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
32814403|NCT01710020|Experimental|CP-690,550|
32814404|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
32814405|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
32814406|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
32814407|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
32814408|NCT01700348|Experimental|Airflosser|Use of Airflosser
32814409|NCT01700348|Active Comparator|Manual Floss|Normal Routine
32814410|NCT02242162||neuromuscular diseases|
32814411|NCT04413890|Active Comparator|Classical administration|One prostaglandin vaginal gel every 24 hours
32814412|NCT04413890|Experimental|Experimental administration|One prostaglandin vaginal gel every 12 hours
32814413|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
32814414|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
32814415|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
32814416|NCT02242240|Experimental|Tiotropium with Placebo|
32814417|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
32814418|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
32814419|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
32814420|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
32814421|NCT02242318|Placebo Comparator|Placebo|
32814422|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
32814423|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
32814424|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
32814425|NCT00924118|No Intervention|Open Control|Standard therapy
32814426|NCT02242396||Hypertensive patients|
32814427|NCT03403816|Active Comparator|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.~."
32814428|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
32814429|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
33101430|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
33317335|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
33101431|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33101432|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
33101433|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
33101434|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
33101435|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
33101436|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
33101437|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
33101438|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
33101439|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
33101440|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
33101441|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
33101442|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
33101443|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
32814430|NCT03403738|Experimental|BBN|Bounce Back Now intervention
32814431|NCT04374994|Active Comparator|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
32814432|NCT04374994|Placebo Comparator|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
32814433|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
32814434|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
32814435|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
32814436|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
32814437|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
32814438|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
32814439|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
32814440|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
32814441|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
32814442|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
32814443|NCT04374916|Experimental|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
32814444|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
32814445|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
32814446|NCT04878315|Experimental|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
32814447|NCT04878315|Experimental|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
32814448|NCT04878315|Experimental|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
33101444|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
33317336|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
32814449|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
32814450|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
32814451|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
32814452|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
32814453|NCT01651533|Experimental|Experimental: Mental Practice Group|
32814454|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
32814455|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
32814456|NCT03403348|Experimental|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
32814457|NCT03403348|Experimental|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
32814458|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
32814459|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
32814460|NCT03403348|Experimental|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
32814461|NCT03403348|Experimental|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
32814462|NCT04867395|No Intervention|Usual Care|75 participants will receive standard care, consisting of verbal discharge counseling given by doctors and nurses supplemented by written instructions (all unstandardized).
32814463|NCT04867395|Experimental|Intervention group|75 participants will be randomized to receive behavioral intervention, consisting of discharge counseling using the health literacy-informed discharge instructions
32814464|NCT02242786|Experimental|EBRT|
32814465|NCT01673451|Placebo Comparator|Placebo comparator|
32814466|NCT01673451|Experimental|E2006|
32814467|NCT02242864||Patients with hypertension and diabetes mellitus|
32814468|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
32814469|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
32814470|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
32814471|NCT02243098|Experimental|Semaglutide|
32814472|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
32814473|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
32814474|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
32814475|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
32814476|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
32814477|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
32814478|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
32814479|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
33317337|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
32814480|NCT04374292|Experimental|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
32814481|NCT04374292|Active Comparator|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
32814482|NCT05289063|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP who are randomized to receive atorvastatin 10 mg daily.
32814483|NCT05289063|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP who are randomized to receive placebo daily.
32814484|NCT04374526|Experimental|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
33101445|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
33101446|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
33101447|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
32814485|NCT04374526|No Intervention|Standard therapy|Patients receive standard therapy alone
33101448|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
33101449|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
33101450|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
33101451|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
33101452|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
33101453|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
33317338|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
33317339|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
32814486|NCT05284305||Patients with history of pregnancy|Patients with DT diagnosed during pregnancy; patients with DT with macroscopic disease in situ at the time of pregnancy (including previous partial resection, recurrent disease, primary disease followed with active surveillance); resected DT without clinical evidence of residual or recurrent disease at the onset of pregnancy.
32814487|NCT05284305||Patients without history of pregnancy|Patients with DT without history of pregnancy
32814488|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
32814489|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
32814490|NCT02590809|Experimental|Treatment group|20 patients
33101454|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
33101455|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
33101456|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
33101457|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
33101458|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
32814491|NCT02590809|Placebo Comparator|Placebo group|20 patients
32814492|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814493|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814494|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814495|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814496|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814497|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
32814498|NCT01709318|Active Comparator|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol [ENG-EE] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33101459|NCT02936336|No Intervention|Control|without exercise intervention
33101460|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
33317340|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
33317341|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
33317342|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
33317343|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
33101461|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
33101462|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
33101463|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
33101464|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
33101465|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
33101466|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
33317344|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
33317345|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
33317346|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
33317347|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
32814499|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
32814500|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
32814501|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
32814502|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
32814503|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
32814504|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
32814505|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
32814506|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
32814507|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
32814508|NCT01673841||Relative + absolute cerebral oxygen saturation.|
32814509|NCT04374214|Active Comparator|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
32814510|NCT04374214|Active Comparator|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
32814511|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
32814512|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
32814513|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
32814514|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
32814515|NCT04373824|Experimental|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
32814516|NCT04373824|No Intervention|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
32814517|NCT01676571|Experimental|Lu AA21004|
32814518|NCT04373980|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
32814519|NCT04373980|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
33101467|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
33101468|NCT01289041|Experimental|All Patients|
33101469|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
33317348|NCT01195142||PCOS-CSAT|Women with PCOS
33317349|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
33317350|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
33317351|NCT01292720|Experimental|Vitamin D|
33317352|NCT05601596||Control Participant|Having No symptoms of Endo. Provide Menstrual samples.
33317353|NCT05601596||Symptomatic participant|Having symptoms of Endo and heading to diagnostic surgery as part of their standard of care (referred).
33317354|NCT05671172|Experimental|Group H1|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 750 IU hyaluronidase as an adjuvant in each side after closing skin.
33317355|NCT05671172|Experimental|Group H2|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 1500 IU hyaluronidase as an adjuvant in each side after closing skin.
33317356|NCT05671172|Placebo Comparator|Group C|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline without any adjuvant in each side after closing skin.
32814520|NCT04373980|No Intervention|Control group|
32814521|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
32814522|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
32814523|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
32814524|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
32814525|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
32814526|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
32814527|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
32814528|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
32814529|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
32814530|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32814531|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
32955629|NCT04388046|Experimental|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
32955630|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
32955631|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
32955632|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
32955633|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
32955634|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
32955635|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product
32955636|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
32955637|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
32955638|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
32955639|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
32955640|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
32955641|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
32955642|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
33101470|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Old plasma exchange over a course of 3 consecutive days after stroke onset.~Patients will receive usual care and drug use in hospital."
33101471|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
33101472|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
33101473|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
33101474|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
33101475|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
33101476|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
33101477|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
33101478|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
33101479|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
33101480|NCT04323982|Experimental|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
33101481|NCT04323982|Active Comparator|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
33101482|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
33101483|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
33101484|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
33101485|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
33101486|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
33101487|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
33101488|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
33101489|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
32955643|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
33101490|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
33101491|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
33101492|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
33101493|NCT01287754|Experimental|Single Arm|
33101494|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.~Operators were blinded to all other results for a sample upon data entry."
33101495|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
33101496|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
33101497|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
33101498|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
33101499|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
33101500|NCT02912637||CF patients|Hyperpolarized Xenon MRI
33101501|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
33101502|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
33101503|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
33317357|NCT05671406|Experimental|Sensor-controlled digital game|The intervention group will receive a sensor-controlled digital game (SCDG) app and physical activity tracker.
33317358|NCT05671406|Active Comparator|Sensor-only|The control group will receive only the physical activity tracker.
33317359|NCT01193036||Interview|
32814532|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
32814533|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
32814534|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
32814535|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
32814536|NCT04548518|Active Comparator|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
32814537|NCT04548518|Active Comparator|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
32814538|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
32814539|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
32814540|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
32814541|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
32814542|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
32814543|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
32814544|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
32814545|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
32814546|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
32814547|NCT02243566||Essential hypertension|
32814548|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
32814549|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
32814550|NCT04373590|Experimental|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
32814551|NCT04373590|No Intervention|Treatment as usual (TAU)|Treatment as usual without the DA
32814552|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
32814553|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
32814554|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
32814555|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
32814556|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
32814557|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
32814558|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
32814559|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
32814560|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
32814561|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
32814562|NCT04373278||description of infection of free fibula flap reconstruction|
32814563|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
32814564|NCT04373356|Experimental|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
32814565|NCT04373356|Active Comparator|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
32814566|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
32814567|NCT01745757||Cohort|first line treatment for metastatic breast cancer
32814568|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
32814570|NCT03402178|Experimental|E2082|E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
32814571|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
32814572|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
32814573|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
32814574|NCT04764201|Other|Sequence 1|Period 1: HGP2001, Period 2: HIP2001
32814575|NCT04764201|Other|Sequence 2|Period 1: HIP2001, Period 2: HGP2001
32814576|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
32814577|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
32814578|NCT04764123||AVNRT Cohort|"Patients admitted for electrophysiological study and ablation due to AVNRT tachycardia.~During the study and before the ablation high density electroanatomical mapping will be performed."
32814579|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
32814580|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
32814581|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
32814582|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
32814583|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
32814584|NCT03906422|Experimental|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
32814585|NCT03906422|Experimental|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
32814586|NCT03906422|Experimental|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
32814587|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
32814588|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
32814589|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
32814590|NCT04764045|Active Comparator|Ropivacaine injection in trigger points|Ropivacaine injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
32814591|NCT04764045|Placebo Comparator|Placebo injection in trigger points|Saline injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
32814592|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
32814593|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
33101504|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
33101505|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
33317360|NCT01193036||Symptom Inventory Assessment|
32814594|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
32814595|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
32814596|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
32814597|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
32814598|NCT04404855|Other|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
32814599|NCT04404855|Other|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
32814600|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
32814601|NCT04376866|Experimental|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
32814602|NCT04376866|No Intervention|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
32814603|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
32814604|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
32814605|NCT01674387|Experimental|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral cervical Jiaji (EX-B2),and two trigger points.Bilateral Jianzhongshu (SI15) and Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
32814606|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
32814607|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
32814608|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
32814609|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
32814610|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
32814611|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
32814612|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
32814613|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
32814614|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
32814615|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
32814616|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
33317361|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
33317362|NCT05601518||Single Group Assignment|
33317363|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
33317364|NCT05178160|Active Comparator|Group A|All the patients undergo to helmet-CPAP setting PEEP at 10 cmH2O and performing a blood gas analysis after 2 hours
33101506|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
33101507|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
33101508|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
33317365|NCT05178160|Experimental|Group B|All the patients undergo to helmet-CPAP. PEEP was increased from 5 to 7.5 and 10 cmH20 in 30-minute steps during which lung ultrasound and blood gas analyses were repeated. The best PEEP was setted as the PEEP value before the appearance of lung pulse and with a PaO2/FiO2 levels stable or major than 20% in comparison to the basal value
33317366|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
32738387|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
32955644|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
32738388|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
32738389|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
32738390|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
32955645|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
32738391|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
32738392|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
32738393|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
32738394|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
32738395|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
32738396|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
32738397|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
32814617|NCT04692597|Experimental|Group 1 (LLLT)|"Group 1: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes affected per hand.~The protocol for each group will involve one minute of LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
32814618|NCT04692597|Sham Comparator|Group 2 (LLLT Sham)|"Group 2: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes affected per hand.~The protocol for each group will involve one minute of sham LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
32814619|NCT01698008|Experimental|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
32814620|NCT01698008|No Intervention|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
32814621|NCT04548206|Experimental|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
32814622|NCT04548206|Placebo Comparator|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
32814623|NCT04372810|Experimental|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
32814624|NCT04372810|Sham Comparator|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
32814625|NCT01674543|Experimental|Resistance training|
32814626|NCT01674543|Experimental|Concurrent training|
32814627|NCT01674543|Sham Comparator|Control Group|
32814628|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
32814629|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
32814630|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
32814631|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
32814632|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
32814633|NCT03877653|Experimental|Interventional|Single arm, active stimulation
32814634|NCT03877653|Placebo Comparator|Placebo|"When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.~Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives."
32814635|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
32814636|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
32814637|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
32814638|NCT03876717|Experimental|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
32814639|NCT03876717|Placebo Comparator|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
32814640|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
32814641|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
32738398|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
32738399|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
32738400|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
32738401|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
32738402|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
32738403|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
32738404|NCT04492709|Experimental|Treatment|The subjects will receive oral midazolam solution of 2 mg as a single dose on 2 occasions, 6 days apart (Days 1 and 7). The first dose will be prior to dosing with oral AZD5718 tablet and the second dose after five administrations of AZD5718 under fasted conditions.
32738405|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~Respiratory rate (RR): 10-12 breath/minute."
32738406|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~Patient's height in cm..~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~Minimum and maximum Pressure Support (PS) :8-16~Respiratory rate :10-12 breath/min."
32738407|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
32738408|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
32738409|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
32738410|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
32738411|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
32738412|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
32738413|NCT05006235|Active Comparator|Salbutamol Group|included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline
32738414|NCT05006235|Active Comparator|Epinephrine Group|included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline
32738415|NCT05006235|Placebo Comparator|Saline Group|include babies who had received nebulized 0.9% saline
32738416|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
32738417|NCT05005611|Placebo Comparator|Placebo|
32738418|NCT05005611|Experimental|Probiotics-1|
32738419|NCT05005611|Experimental|Probiotics-2|
32738420|NCT05005611|Experimental|Probiotics-3|
32738421|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
32738422|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
32738423|NCT03207919|Experimental|Lullaby Project|
32738424|NCT03207919|No Intervention|Control Group|
32738425|NCT03323333|Experimental|Intervention|
32738426|NCT04961151|Experimental|Conductive Wrap Warming|Esophageal warming will be discontinued first
32738427|NCT04961151|Experimental|Esophageal Warming|Conductive wraps will be discontinued first
32738428|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
32738429|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
33101509|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
33101510|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
33101511|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
33101512|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
33101513|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
33101514|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
33101515|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
33101516|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
33101517|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
33101518|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
33101519|NCT02935868||Control Group|Patients without systemic diseases
33101520|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
33101521|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
33101522|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
33101523|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
33101524|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
32814642|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
32814643|NCT01674855|Experimental|DA-3031|PEG-G-CSF
32814644|NCT01674855|Active Comparator|Leucostim®|G-CSF
32814645|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
32814646|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
32814647|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
32814648|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
32814649|NCT03852693||Retrospective Group|
32814650|NCT03852693||Prospective Group|
32814651|NCT04373044|Placebo Comparator|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
32814652|NCT04373044|Experimental|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
33405047|NCT04150796|Experimental|Enhanced-view Totally Extraperitoneal (eTEP) Hernia Repair|Initial access into the retromuscular space is achieved using an optical trocar. Insufflation of CO2 is performed under direct visualization. Multiple assistant ports will be placed medial to the semilunar line to continue developing the retromuscular space. The medial insertion of the posterior rectus sheath will be incised to enter the preperitoneal plane and facilitate reduction of hernia contents. The contralateral posterior rectus sheath will be incised and the contralateral retrorectus space will be matured. Suture will be used to close any defect in the hernia sac. The defect will be measured, as will be the retrorectus space. The fascial defect will be closed with suture. Non-barrier coated mesh will be placed in the retrorectus space and flat positioning will be confirmed. Ports will be removed under direct visualization, and the abdomen desufflated. Anterior fascia of any larger ports (8mm or greater) will be closed.
33101525|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
33101526|NCT02912442||Infertile women study 1|
33101527|NCT02912442||Infertile women study 2|
33101528|NCT02912442||Repeated pregnancy loss|
32814656|NCT03874299||Kidney Transplant Receipients|
32814657|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
32814658|NCT03851991|Placebo Comparator|control|two capsules, three times per day, for 2-5 Days.
32814659|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
32814660|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
32814661|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
32814662|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
32814663|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
32814664|NCT03850431|Experimental|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
32814665|NCT03850431|Experimental|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
32814666|NCT03850431|Experimental|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
32814667|NCT03850431|Experimental|Combination of all Nudges|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
32814668|NCT03850431|No Intervention|Usual Care|An appointment reminder that includes basic appointment information on date, location, and phone number(s) for scheduling changes.
32814669|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
32814670|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
32814671|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
32814672|NCT04764903||LUTS/Nocturia|Patients with LUTS / Nocturia
32814673|NCT04404543|Experimental|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
32814674|NCT04404543|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
32814675|NCT03849807|Experimental|Experimental group|Chiropractic care
32814676|NCT03849807|Active Comparator|Control group|Usual health care
32814677|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
32814678|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
32814679|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
32814680|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
32814681|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
32814682|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
32814683|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
32814684|NCT03028454|Experimental|Ginger Root Capsule|
32814685|NCT03028454|Placebo Comparator|Placebo Capsule|
32814686|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
32814687|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
32814688|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
32814689|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
32814690|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
32814691|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
32814692|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
32814693|NCT04410068|Experimental|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
32814694|NCT04410068|Experimental|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
32814695|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
32814696|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
32814697|NCT03848325|Experimental|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
32814698|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
32814699|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
32814700|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
32814701|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
32814702|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
32814703|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
32814704|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
32814705|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
32814706|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
32814707|NCT01676025|Experimental|LA|Persons who get LA surgery.
32814708|NCT04640259||EGFR|
32814709|NCT04640259||ROS1|
32814710|NCT04640259||ALK|
32814711|NCT04640259||KRAS|
32814712|NCT04640259||NSCLC Other|
32814713|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
32814714|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
32814715|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
32814716|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
32814717|NCT01569074|Experimental|Dosing A regimen|Oral treatment
32814718|NCT01569074|Experimental|Dosing B regimen|Oral treatment
32814719|NCT01569074|Experimental|Dosing C regimen|Oral treatment
32814720|NCT01569074|Experimental|Dosign D regimen|Oral treatment
32814721|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
32814722|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
32814723|NCT03842475||Control|Healthy volunteers with normal body mass index
32814724|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
32814725|NCT03842241||Without foot orthoses|Other: without foot orthoses
32814726|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
32814727|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
32814728|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824|
32814729|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824|
32814730|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824|
32814731|NCT03840915|Experimental|Cohort D: Docetaxel + M7824|
32814732|NCT03839121||single arm: CRT-DX|
32814733|NCT03752775|Experimental|subacute device assisted group|
32814734|NCT03752775|Active Comparator|subacute conventional group|
32814735|NCT03752775|Other|chronic device assisted group|
32814736|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
32814737|NCT03751371|Other|Usual Care|Usual Care
32814738|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814739|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814740|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814741|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814742|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814743|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814744|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814745|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814746|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814747|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
32814748|NCT03748953|Experimental|Ixazomib|"Ixazomib 3 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which if the participants have tolerated the initial dose, the dose may be escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26, or until documented PD or intolerable toxicity, whichever occurs first.~Participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will have the opportunity to cross over to ixazomib maintenance."
32814749|NCT04348773|Experimental|Dehydration|
32814750|NCT04348773|Experimental|Rehydration|
32814751|NCT04403685|Experimental|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
32814752|NCT04403685|No Intervention|Control arm|Best supportive care.
32814753|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
32814754|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
32814755|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
32814756|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
32814757|NCT04404231|Sham Comparator|No infrared light therapy|This arm does not receive any phototherapy
32814758|NCT04404231|Active Comparator|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
32814759|NCT04404231|Experimental|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
32814760|NCT04404231|Experimental|random frequency|A wavelength between 650-1100nm which is picked at random
32814761|NCT04413578|Experimental|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
32900906|NCT04239534|Other|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
32900907|NCT05299398|Experimental|Trazodone|Trazodone once daily for 24 weeks.
32814762|NCT04413578|Placebo Comparator|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
32814763|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
32814764|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
32814765|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
32814766|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
32814767|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
32814768|NCT03744975|Placebo Comparator|Placebos|Control Intervention will be 1 Placebo Capsule given orally, one time
32814769|NCT03744975|Active Comparator|LCZ 696|1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
32814770|NCT03657459|No Intervention|usual care group|Usual care consists of patient's receiving a Heart Failure Handbook before hospital discharge + verbal education delivered by multiple care providers (including a group education class at 1 site). The handbook is consistent; however, verbal education may vary between care providers based on their knowledge and time available, and perceived patient needs
32814771|NCT03657459|Active Comparator|video education group|"Will receive usual care, plus will watch 2 short Wellflix, Inc. Danger Signs of Heart Failure videos (via iPAD) on dyspnea, fatigue + a Danger Sign edema video, when applicable. Each video describes how to recognize if the sign/symptom is new or worsening and how to self-manage at home (via diet, fluid management and activity instructions)"
32814772|NCT01697462||Cohort|
32814773|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
32814774|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
32814775|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
32814776|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
32814777|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
32814778|NCT03743025|Experimental|Dulaglutide Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
33101529|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
33101530|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
33101531|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
33101532|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
33101533|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
32814779|NCT03743025|Placebo Comparator|Placebo Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
32814780|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
32814781|NCT04124432|Experimental|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
32814782|NCT04124432|Experimental|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
32814783|NCT04124432|Experimental|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
32814784|NCT04124432|Experimental|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
33101534|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
33101535|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
33101536|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
32814785|NCT04124432|Experimental|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
32814786|NCT04124432|Experimental|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
32814787|NCT04124432|Experimental|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
33101537|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
33101538|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
32814788|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
32814789|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
32814790|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
33101539|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
32814791|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
33101540|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
33101541|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
33101542|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
33101543|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
33101544|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
33101545|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
32814792|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
33101546|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
33101547|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
33101548|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
33101549|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
33101550|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
33101551|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
33101552|NCT02912130|No Intervention|Control|No Intervention
33101553|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
32814793|NCT04116710|Experimental|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
32814794|NCT03653013|Active Comparator|Control Group|Usual standard of care from their diabetes care team
33101554|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
33101555|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
33101556|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
33101557|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
33101558|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
33101559|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
33101560|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
33101561|NCT02934815|No Intervention|Control group|No intervention
33101562|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
33101563|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
32814795|NCT03653013|Experimental|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
32814796|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
32814797|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
32814798|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
32814799|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
32814800|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
32814801|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
32814802|NCT03649581|Active Comparator|healthy volunteers|
32814803|NCT03741777|Active Comparator|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
32814804|NCT03741777|Active Comparator|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
32814805|NCT03741777|Active Comparator|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
32814806|NCT03741777|Active Comparator|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
32814807|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
32814808|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
32814809|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
32814810|NCT00003459|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
32814811|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
32814812|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
33317367|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
32814814|NCT04747041|Experimental|Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol|Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
33101564|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
33101565|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
33317368|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
33317369|NCT05177926|Other|antiviral prophylaxis with Tenofovir Alafenamide Fumarate (TAF)|All participants will receive oral Tenofovir Alafenamide Fumarate 25mg, daily, at gestational 27-29 week until delivery.
32814815|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
32814816|NCT04763811||Older 65 people|Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews.
32814817|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
32814818|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
32814819|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
32814820|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
32814821|NCT04403997|Active Comparator|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
32814822|NCT04403997|Experimental|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
32814823|NCT00925054|Experimental|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
33317370|NCT03848390|Experimental|Modified Time-restricted Feeding|
33317371|NCT03848390|Active Comparator|Conventional diet|
32814824|NCT00925054|Experimental|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
32814825|NCT00925054|Experimental|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
32814826|NCT00925054|Experimental|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
32814827|NCT00925054|Experimental|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
32814828|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
32814829|NCT03827967|Experimental|1x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
32814830|NCT03827967|Experimental|2x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
32814831|NCT03827967|Experimental|4x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
33101566|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
33101567|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
33317372|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
33317373|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
33317374|NCT01313962|Experimental|Flufirvitide-3|
32814832|NCT03827967|Experimental|8x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
32814833|NCT00925756|Experimental|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:~150 mg twice daily with strong CYP3A4 inhibitors, including:~Protease inhibitors (except tipranavir/ ritonavir)~Delavirdine~ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin~Darunavir/r + etravirine~300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:~Tipranavir/ ritonavir~Nevirapine~All NRTIs~Enfuvirtide~600 mg twice daily with strong CYP3A4 inducers, including:~Efavirenz, etravirine~rifampin"
32814834|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
32814835|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
32814836|NCT04372966|Active Comparator|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
32814837|NCT04372966|Active Comparator|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
33317375|NCT01313962|Placebo Comparator|Placebo|
32814839|NCT04372654|Experimental|Radial group|Use of Electroducer Sleeve on radial route
32814840|NCT04372654|Experimental|femoral group|Use of Electroducer Sleeve on femoral route
32814841|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
32814842|NCT03731013|Experimental|Physical activity (PA)|
32814843|NCT03731013|Experimental|Mediterranean diet and physical activity|
32814844|NCT03731013|No Intervention|Control|
32814845|NCT04372888|Other|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
32814846|NCT04372888|Other|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
33317376|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
33101568|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
33101569|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
33101570|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
33101571|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
33101572|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
33101573|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
33101574|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
33101575|NCT04690088||Manual infusion (control) group|
33101576|NCT04690088||TCI (case) group|
33317377|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
33317378|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
33317379|NCT01189214|Experimental|Memantine|
33101577|NCT04690244|Experimental|Tai Chi Chuan group|"Fifteen healthy elderly subjects participated in 10 weeks of Tai Chi Chuan practice. Inclusion criteria were:~aged 60 years and older;~sedentary behavior for at least 6 months;~no previous experience of Tai Chi Chuan practice;~good physical health determined by Physical Activity Readiness Questionnaire as - confirmed by medical history;~no cognitive impairments determined by baseline Mini-Mental State Examination score of ≥ 45.~All participants were asked to not perform any sports activities while the research was ongoing."
33101578|NCT04690244|No Intervention|Control group|In the control group, fifteen subjects also had to meet the same criteria and did not perform any exercises or make changes in their daily living life.
33101579|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
33317380|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
33317381|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
32814847|NCT03728985|Active Comparator|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
32814848|NCT03728985|Experimental|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
32814849|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
32814850|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)~3-3-4 mix was administered"
32814851|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
32814852|NCT03728673|Experimental|escitalopram|
33317382|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
33317383|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
33317384|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
33317385|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
33317386|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
33317387|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
32814853|NCT04347382|Experimental|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)~along with standard medical care"
32814854|NCT04347382|Placebo Comparator|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
32814855|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
32900908|NCT05299398|Placebo Comparator|Placebo|Placebo once daily for 24 weeks
33101580|NCT04690166||Cancer Patients|"In outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
33317388|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
33317389|NCT05599802|Experimental|1A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
33317390|NCT05599802|Experimental|1B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
33317391|NCT05599802|Experimental|2A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
33101581|NCT04690166||Healty Control|"In outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
33101582|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
33101583|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
32814856|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
32814857|NCT04372342|Experimental|nalbuphine|
32814858|NCT04372342|Placebo Comparator|remifentanil|
32814859|NCT04372264|Experimental|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
32814860|NCT04372264|Experimental|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
32814861|NCT04372264|Experimental|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
32814862|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
32814863|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
32814864|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
32814865|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
32814866|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
32814867|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:~Diet A: Fasted conditions~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
32814868|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
32814869|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
32814870|NCT03723681|Experimental|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
32814871|NCT03723681|Experimental|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
33101584|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
33101585|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
33101586|NCT02935608|Experimental|BIIB074 low dose|Administered BID
33101587|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
32814872|NCT04366180|Experimental|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).
32814873|NCT04366180|Placebo Comparator|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
32814874|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
32814875|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
32814876|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
32814877|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
32814878|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
32814879|NCT04372420|Active Comparator|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
33317392|NCT05599802|Experimental|2B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
33317393|NCT05599802|Experimental|3A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
33317394|NCT05599802|Experimental|3B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
33317395|NCT00051558|Experimental|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
33317396|NCT00051558|Active Comparator|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
33317397|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
33317398|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
33405048|NCT04150796|Active Comparator|Intraperitoneal Onlay Mesh (IPOM) Hernia Repair|Access is achieved using an optical trocar. Insufflation of CO2 is performed. Two additional trocars are placed on the left side along the anterior axillary line. If necessary, auxiliary ports may be placed on the right side. When present, hernia contents are reduced using graspers. Adhesions between abdominal contents and the abdominal wall are lysed. The hernia defect is identified and measured internally with a sterile plastic ruler with the abdomen insufflated. Defect closure is performed using nonabsorbable suture. Mesh repair is performed using polypropylene mesh with an absorbable hydrogel barrier. Mesh is chosen to achieve a minimum 3 to 5-centimeter overlap from the edges of the closed defect. Inside the abdomen, the mesh is unrolled and positioning against the anterior abdominal wall is confirmed. Mesh edges are fixed circumferentially with permanent fixation. Ports are removed and the abdomen is desufflated. The anterior fascia of the 12mm port is closed.
33405049|NCT04858152|Experimental|Experimental Arm: Transplantation of hair follicles to non-hair bearing areas affected by vitiligo|Punch biopsies will be used to extract hair follicles from area on participant's body that is not affected by vitiligo and has hair growth. The follicles will then be transplanted into an area of the body affected by vitiligo that is hairless.
33405050|NCT04858074|Experimental|Active medication- PECKO-D|Participants will be randomly allocated to experimental drug
33405051|NCT04858074|Placebo Comparator|Placebo|Corn-Starch will be administered as placebo agent
33405052|NCT04856202|Active Comparator|Intervention|A trained facilitator will schedule two facilitated Respecting Choices interviews with the patient and preferably, if the patient agrees, in the presence of a caregiver or relative.
33405053|NCT04856202|No Intervention|Control|Care as usual
33405054|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
33405055|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
33405056|NCT04814316||Study group|Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.
33405057|NCT04814316||Control group|Healty volunteers who will not use lansoprazole.
33405058|NCT04113122|Experimental|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
32955646|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
32955647|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
32955648|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
32955649|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
32955650|NCT04955340|Experimental|[14C]-resminostat|single dose of 400 mg [14C]-resminostat
32955651|NCT04815330||Patient dyspnea under veno-arterial extracorporeal circulation|"Relief of dyspnea will be carried out by the clinician in charge of the patient. He will have complete control of his behaviour. He will carry out this test according to the practices in force in the department.~If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.~In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved."
32955652|NCT04736940||Patients|Patients followed or currently treated for a solid or haematological neoplasia
32955653|NCT04736940||Doctors|Medical oncologist or haematologist
32955654|NCT04736940||Paramedical staff|Nurses or assistant nurses
32955655|NCT04736940||Oncopsychologist|Psychologist specialised in the care of patients with cancer
32814880|NCT04372420|Placebo Comparator|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
32814881|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
32814882|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
32814883|NCT02244190|Experimental|new Tipranavir + Ritonavir|
32814884|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
32814885|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
32814886|NCT00926380|Experimental|denosumab ONLY|
32814887|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
32814888|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
32814889|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
32814890|NCT04366414|Active Comparator|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
32814891|NCT04366414|Active Comparator|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
32814892|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
32814893|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
32814894|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
32814895|NCT04366492|Other|persons in prison|
32814896|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
32814897|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
32814898|NCT04365946||Controls|Healthy subjects
32814899|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.~All social network members will be asked about intervention exposure at 6- and 15-month followups."
32814900|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
32814901|NCT03823131|Experimental|Arm A: Tavo-EP, pembrolizumab, epacadostat|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
32900909|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
33101588|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
33101589|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
33101590|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
33101591|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
33101592|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
32814902|NCT03823131|Experimental|Arm B: Tavo-EP, pembrolizumab|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
32814903|NCT03823131|Experimental|Arm C: Tavo-EP, pembrolizumab, CORVax|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30-minute IV infusion at a dose of 200 mg every 3 weeks. CORVax will be administered at a total dose of 0.2 mg of (S) protein plasmid in 120 microliter (uL) per lesion intratumorally into a maximum of 4 lesions of at least 0.3 mm in diameter for a total plasmid dose of 0.8 mg on treatment days 1 and 29 of cycle 1 followed by electroporation of the plasmid solution in infiltrated regions. On days when both tavo and CORVax is administered to the same lesions, tavo and CORVax will each be injected into the lesion followed by electroporation.
33317399|NCT05671640|Experimental|DragonFly-T Transcatheter Tricuspid Valve Repair System|The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
33317400|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
33317401|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
33317402|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
33317403|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
33317404|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
33317405|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
32814904|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
32814905|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
32814906|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
32814907|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
32814908|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
32814909|NCT03630315|Experimental|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
32814910|NCT03630315|Experimental|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
32814911|NCT00929344|Experimental|Duloxetine|
32814912|NCT00929344|Experimental|Pregabalin|
32814913|NCT00929344|Placebo Comparator|Placebo|
32814914|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
32814915|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
32814916|NCT04371874|No Intervention|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
32814917|NCT04371874|Experimental|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
33101593|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
33101594|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
33101595|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
33101596|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
33101597|NCT02934464|Experimental|ARM A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
33101598|NCT02934464|Active Comparator|ARM B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
33101599|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
33101600|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
33317406|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
32814918|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
32814919|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
32814920|NCT04371796|Experimental|Sintilimab injection|"Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.~Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
32814921|NCT02244346||Benign prostatic hyperplasia patients|
32814922|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
32814923|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
32814924|NCT04365712|Active Comparator|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
33101601|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
33101602|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
32814925|NCT04365712|Experimental|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
32814926|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814927|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814928|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814929|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814930|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
32814931|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814932|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
32814933|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
32814934|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
32814935|NCT03720717|Experimental|Opioid Tolerant - baclofen|
32814936|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
32814937|NCT03720717|Experimental|Opioid Naive - baclofen|
32814938|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
32814939|NCT04376554|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
33101603|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
33101604|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
33317407|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
33101605|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
33101606|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
33101607|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
33101608|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
33101609|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
33101610|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
33317408|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
32814940|NCT04376554|Active Comparator|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
32814941|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
32814942|NCT04371718|Experimental|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
32814943|NCT04371718|Experimental|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
32814944|NCT04371718|Experimental|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
32814945|NCT04371718|Placebo Comparator|Placebo|Matched placebo, daily for 104 weeks
32814946|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
32814947|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
32814948|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
32814949|NCT04376164|No Intervention|control group|was treated without laser intervention
32814950|NCT04376164|Experimental|laser group|received low level laser therapy
32814951|NCT04365322||Severe COVID-19 infection|
32814952|NCT04365322||Light to moderate COVID-19 infection|
32814953|NCT04365322||Cancer patients with COVID-19 infection|
32814954|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
32814955|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
32814956|NCT03818217|Other|Tablet group|Tablet training
32814957|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
32814958|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
32814959|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
32814960|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
32814961|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
32814962|NCT02244658|No Intervention|control|no thrombopoietic agents
32814963|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
32814964|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
32814965|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
32814966|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
32814967|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
32814968|NCT04403841|Other|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
32814969|NCT04403841|Other|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
32814970|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
32814971|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
32814972|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
32814973|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
32814974|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
32814975|NCT03816111|Experimental|TEACH-PD Training Curriculum|All patients at sites randomized to this arm will receive the TEACH-PD Training Curriculum
33317409|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
33317410|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
33317411|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
32814976|NCT03816111|Active Comparator|Current Standard PD Training|All patients at sites randomized to this arm will receive the unit's current PD training materials and plan
32814977|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
33101611|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
33101612|NCT02934308|Experimental|ICU patients|
33405059|NCT04113122|Experimental|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
33101615|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
33101616|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
33101617|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
33317412|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
32814978|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
32814979|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
32814980|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
32814981|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
32814982|NCT04371484||children from 0 to 5 years old, hospitalized|
32814983|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
32814984|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
32814985|NCT02244736||Diabetics|Subjects with abnormal OGTT
32814986|NCT04371016|Experimental|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :~insertion of an esophageal balloon catheter (Nutrivent®, Sidam)~installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)~insertion of a Swan-Ganz catheter~continuous recording of digital and analogic data~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
32814987|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
32814988|NCT04371406|Experimental|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
32814989|NCT04371406|Sham Comparator|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
32814990|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
32814991|NCT04370938|Experimental|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
32814992|NCT04370938|No Intervention|Control|No additional requests will be made of individuals in the control arm.
32814993|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
32814994|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
32814995|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
32814996|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
32814997|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
32814998|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 2: Patients randomized to conservative plaster treatment"
32814999|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 3: Patients randomized to operative treatment (ORIF)"
32815000|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
32815001|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
32815002|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
32815003|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
32815004|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
32815005|NCT04365010|Experimental|Sodium Bicarbonate Ringer's Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
32900910|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
32955656|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
33317413|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
33317414|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
33317415|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
32955657|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
33317416|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
32955659|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
32955660|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
32955661|NCT00610116|Other|LV lead electronically repositioning|Single arm study
32955662|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
32955663|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
32955664|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
32955665|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
32955666|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
32955667|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
32955668|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
32955669|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
32955670|NCT02226432|Sham Comparator|surgery|"- Surgery:~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
32955671|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
32955672|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
32955673|NCT04470180|Experimental|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
32955674|NCT04470180|Active Comparator|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
32955675|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
32955676|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
32955677|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
32955678|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
32955679|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
32955680|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
32955681|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
32955682|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
32955683|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
32955684|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
32955685|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
32955686|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
33101618|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
33101619|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
33317417|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
33317418|NCT05671328||Patients with suspected ventilator-associated pneumonia|
33317419|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
33317420|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
33317421|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
33317422|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
33317423|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
33317424|NCT01296308||type 2 diabetics with neuropathy|
33317425|NCT01189682|Active Comparator|Tegaderm HP|
33317426|NCT01189682|Placebo Comparator|Tegaderm|
32955687|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
32955688|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
33317427|NCT01189682|Active Comparator|Tegaderm CHG|
33317428|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
33317429|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
32955689|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
32955690|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
32955691|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
33317430|NCT01196780||Cohort|
33317431|NCT03845972|No Intervention|before SSFTB|
33317432|NCT03845972|Experimental|after SSFTB|
33317433|NCT05391698|Experimental|Parent Training - Child Training (Group PC)|Parents of families who will be randomized in Group PC will first take part in behavioral parent training. After the completion of the parent training program and the assessment (Time 2 assessment), their children will take part in the individualized child training program.
33317434|NCT05391698|Experimental|Child Training - Parent Training (Group CP)|Children of families who will be randomized in Group CP will first take part in the individualized child training program. After the completion of the child training program and the assessment (Time 2 assessment), parents will take part in the behavioral parent training program.
33317435|NCT05388266|Experimental|Paratracheal pressure|After the induction of anesthesia, paratracheal pressure is applied during mask ventilation.
32955692|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
32955693|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
32955694|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
32955695|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
32955696|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
32955697|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
32955698|NCT04405908|Placebo Comparator|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
32955699|NCT04405908|Placebo Comparator|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
32955700|NCT04405908|Placebo Comparator|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
32955701|NCT04405908|Placebo Comparator|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
32955702|NCT04405908|Placebo Comparator|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955703|NCT04405908|Placebo Comparator|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
32955704|NCT04405908|Placebo Comparator|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
32955705|NCT04405908|Placebo Comparator|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
32955706|NCT04405908|Placebo Comparator|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
33101620|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
33101621|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
33405060|NCT04113122|Other|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
33405061|NCT05201352|Experimental|Experimental arm|trifluridine/tipiracil + XB2001
33405062|NCT05201352|Placebo Comparator|Control arm|trifluridine/tipiracil + placebo
32815006|NCT04365010|Active Comparator|0.9% Sodium Chloride Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
33101622|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
33101623|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
33101624|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
33101625|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
32815007|NCT03609801|Experimental|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
32815008|NCT03609801|Active Comparator|The Duluth Model|The Duluth Model Men's Nonviolence Classes is the most widely used BIP. The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model's Men's Nonviolence Classes (The Duluth Model for short) help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
32815009|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
32815010|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
32815011|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
32815012|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
32815013|NCT03707691|Experimental|Control Participants|
32815014|NCT02156908|Experimental|D-serine|D-serine
32815015|NCT04763265|Active Comparator|Group A (n=100): BoNT/A-DP (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures..~A volume of 0.5 mL of the properly reconstituted BoNT/A-DP should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
32815016|NCT04763265|Active Comparator|Group B (n=100): Botox Cosmetic (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures.~A volume of 0.5 mL of the properly reconstituted Botox Cosmetic should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
32815017|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
32815018|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
32815019|NCT00004143|Experimental|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
32815020|NCT00004143|Experimental|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
32815021|NCT04364542|Experimental|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
32815022|NCT04364542|Active Comparator|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
32815023|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
32815024|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
33101626|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
33101627|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
33101628|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
33101629|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
33101630|NCT02935296|No Intervention|Control|Standard of Care
33101631|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
33101632|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
33101633|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
33101634|NCT02934113|No Intervention|Control|
33101635|NCT02934113|Experimental|iOTA and HWPP|
33101636|NCT02934113|Experimental|HWPP|
33101637|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
33101638|NCT02933996|Experimental|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.~GA: general anesthesia"
33101639|NCT02933996|Sham Comparator|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
33101640|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
33101641|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
33101642|NCT02933918|Experimental|Probiotics|
33101643|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
33101644|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
33101645|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
33101646|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
33101647|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
33101648|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
33101649|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
32955707|NCT04405908|Placebo Comparator|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
32955708|NCT04405908|Placebo Comparator|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
32955709|NCT04405908|Placebo Comparator|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955710|NCT04405908|Placebo Comparator|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
32955711|NCT04405908|Placebo Comparator|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
32955712|NCT04405908|Placebo Comparator|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
32955713|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 16|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg.
32955714|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 17|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg with AS03 adjuvant.
32955715|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 18|SARS-CoV-2 Seropositive subjects receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
32955716|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 19|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955717|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 20|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
32955718|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 21|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955719|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 22|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
32955720|NCT04405908|Placebo Comparator|Alum Only Adjuvant Group 23|Subjects receive SCB-2019 9 µg with Alum adjuvant only.
33317436|NCT05388266|Active Comparator|No pressure|After the induction of anesthesia, no pressure is applied during mask ventilation.
33317437|NCT05671016||Patient aged 65 or older receiving radiotherapy treatment for a newly diagnosed GBM|Patients aged 65 or older who have been newly diagnosed with a Glioblastoma (either through histological confirmation or confirmed by a consultant radiologist in a multidisciplinary team meeting setting) who are planned to be treated with radiotherapy. There is only 1 arm in this study, there is no randomisation. All participants will undertake questionnaires (as described in detail elsewhere in the form) and if the required MRI sequences are not available on their diagnostic imaging then they will undertake a trail specific MRI scan.
33317438|NCT05519696|Experimental|Intervention|This group will receive a 10-week group-based intervention program.
33317439|NCT05519696|Active Comparator|Comparison|The group will receive a 10-week group-based comparison program.
33317440|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
32955721|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 24|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955722|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 25|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
32955723|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 26|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
32955724|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 27|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
33317441|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
33317442|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
32955727|NCT04333368|Experimental|MSC|
32955728|NCT04333368|Placebo Comparator|NaCl|
32955729|NCT04331496|Experimental|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
32955730|NCT04331496|Active Comparator|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
32955731|NCT04304274|Experimental|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
32955732|NCT04304274|Placebo Comparator|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
32955733|NCT04253496||Prospective|
32955734|NCT04253496||Retrospective|
32955735|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of docosahexaenoic acid (DHA).
32955736|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
32955737|NCT00612924|Experimental|Anaconda|
32955738|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
32955739|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
32955740|NCT00614406|Experimental|1|
32955741|NCT00614406|Placebo Comparator|2|
32955742|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
32955743|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
32955744|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
33317443|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
33317444|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
33101650|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
33101651|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
33101652|NCT04689971|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily (experimental group).
33101653|NCT04689971|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
33317445|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
33317446|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
32815025|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
33317447|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
32815026|NCT04370782|Experimental|Experimental Arm 1|"Hydroxychloroquine~Azithromycin~Zinc sulfate"
32815027|NCT04370782|Experimental|Experimental Arm 2|"Hydroxychloroquine~Doxycycline~Zinc sulfate"
32815028|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
32815029|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
32815030|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
32815031|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
32815032|NCT04376320|Active Comparator|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
32815033|NCT04376320|Active Comparator|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
32815034|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
32815035|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
32815036|NCT04376086|Active Comparator|General anesthesia|Patients will receive general anesthesia
32815037|NCT04376086|Experimental|Epidural anesthesia|Patients will receive epidural anesthesia
32815038|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
32815039|NCT04375852|Experimental|1|consecutive cases diagnosed with APS-1associated keratitis
32815040|NCT03805659|Experimental|HD-tDCS, then Sham|Subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
32815041|NCT03805659|Experimental|Sham, then HD-tDCS|Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
32815042|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1.~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
33101654|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
33101655|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
33101656|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
33101657|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
33101658|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
33101659|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
33101660|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
33101661|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
33317448|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
33317449|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
33317450|NCT01197014|Experimental|Amlodipine plus Losartan|
33317451|NCT01197014|Active Comparator|Amlodipine, Losartan|
33101662|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
33101663|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
33101664|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
32815043|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1."
32815044|NCT04370314|Experimental|Zirconia implant-supported crown|Full zirconia implant-supported crown
32815045|NCT03803397|Experimental|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
32815046|NCT04364464|Experimental|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) >80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
32815047|NCT04364464|Experimental|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
32815048|NCT04364464|Experimental|Riociguat, moderate renal impairment|Participants with CLCR 30-<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
32815049|NCT04364464|Experimental|Riociguat, severe renal impairment|Participants with CLCR <30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
32815050|NCT04364386|Experimental|InPress|Treatment with InPress Device for Postpartum Hemorrhage
32815051|NCT04746885|Other|Group A|(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
33101665|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
33101666|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
33101667|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
33101668|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
33317452|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
33317453|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
33317454|NCT01197092|Active Comparator|Verum|
33317455|NCT01197092|Experimental|Control|
33317456|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine~Period 2: New insulin glargine formulation~Period 3: New insulin glargine formulation~Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
33317457|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
33317458|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
33317459|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
33317460|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).~The daily dose administrated is 15 grams."
33317461|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).~The daily dose administrated is 15 grams."
33317462|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
33317463|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
32815052|NCT04746885|Other|Group B|(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.
32815053|NCT04375774|Other|FFP2|
32815054|NCT04375774|Other|Facial mask|
32815055|NCT04375774|Other|Modified full-face snorkeling|
32815056|NCT03700047|Experimental|GAL1704 (needle)|Subjects randomized (2:1) to GAL1704 or Control for cheek augmentation and the correction of midface contour deficiencies.
32815057|NCT03700047|Experimental|GAL1704 (cannula/needle)|GAL1704 treatment using a split face design - one cheek treated using cannula and the other cheek treated using needle.
33317464|NCT01187966|Experimental|High Dose (100mg/day)|
33317465|NCT01187966|Experimental|Low dose (50mg/day)|
33317466|NCT01292954|Active Comparator|Low dose blueberry|
33317467|NCT01292954|Active Comparator|medium dose blueberry|
33317468|NCT01292954|Active Comparator|high dose blueberry|
33317469|NCT01292954|Placebo Comparator|control|
33317470|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
33317471|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
33317472|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
32815058|NCT03700047|Active Comparator|Juvederm Voluma|Subjects randomized to control.
33317473|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
32815059|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
32815060|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
32815061|NCT04363996|Experimental|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
32815062|NCT04363996|Active Comparator|Resin Modified Glass Ionomer|Fuji II
32815063|NCT04763031|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy - IORT
32815064|NCT04363918|Active Comparator|intervention (IG1)|
32815065|NCT04363918|Active Comparator|intervention (MyoStim group)|
32815066|NCT04363918|Sham Comparator|control (CG)|
32815067|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
32955745|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
32955746|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
32955747|NCT04159974|Experimental|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
32955748|NCT04159974|Experimental|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
32955749|NCT04142502|Active Comparator|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3~1.0 mg/ml using target concentration infusion Bispectral index 60~80
32955750|NCT04142502|Active Comparator|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60~80
32955751|NCT00615420|Experimental|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
32955752|NCT00615420|Placebo Comparator|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
32955753|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
32955754|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
32955755|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
32955756|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
32955757|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
32955758|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
32955759|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
32955760|NCT00616200|Experimental|A|
32955761|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
32955762|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
32955763|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
32955764|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
32955765|NCT03930732|Experimental|Dupilumab|Dupilumab administered every 2 weeks
32955766|NCT03930732|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
32955767|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
32955768|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
32955769|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
32955770|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
32815068|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
32815069|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
32815070|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
32815071|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) every three weeks (Q3W). Carboplatin area under the plasma concentration (AUC) 5, Day 1 (D1) of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
32815072|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
32815073|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles; Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
32815074|NCT04357912|Experimental|Experimental group|
32815075|NCT04357912|Active Comparator|Control Group|
32815076|NCT05620654|Experimental|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|Patients with ovarian cancer receive hyperthermic intraperitoneal paclitaxel combined with a fixed dose of cisplatin (75mg/m2)
32815077|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
32815078|NCT04357834||Smartwatch group|
32815079|NCT04357522|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
32815080|NCT04357522|Active Comparator|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
32815081|NCT03801369|Experimental|Arm I (olaparib, durvalumab)|Patients receive olaparib PO BID on days 1-28 of each cycle and durvalumab intravenously (IV) over 1 hour on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
32815082|NCT03801369|Experimental|Arm II (olaparib, selumetinib)|Patients receive olaparib PO BID on days 1-28 of each cycle and selumetinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
32815083|NCT03801369|Experimental|Arm III (olaparib, capivasertib)|Patients receive olaparib PO BID on days 1-28 of each cycle and capivasertib PO BID 4 days on and 3 days off of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
32815084|NCT03801369|Experimental|Arm IV (ceralasertib)|Patients receive ceralasertib PO BID on days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
32815085|NCT03801213|Active Comparator|Urinary catheterization|
32815086|NCT03801213|Experimental|manual bladder stimulation Technique|
32815087|NCT00937378|Experimental|SER120|
32815088|NCT00937378|Placebo Comparator|Placebo|
32815089|NCT00005901|Active Comparator|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
32815090|NCT00005901|Active Comparator|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
32815091|NCT04369768|Active Comparator|direct composite restorations|
32815092|NCT04369768|Active Comparator|preformed metal crowns|
32815093|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
33317474|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
32815094|NCT04369534|Active Comparator|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
32815095|NCT04369534|Active Comparator|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
32815096|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
32815097|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~family history (first degree relative) one or more neurological and/or psychiatric conditions;~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
32815098|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
32815099|NCT04369456|Other|Covid-19 kidney transplant patients with moderate symptoms|
32815100|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
32815101|NCT04115306|Experimental|PMD-026|Oral PMD-026 (dose: 25 - 1000 mg), given daily until disease progression or unacceptable toxicity
32815102|NCT04363762|Experimental|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
32815103|NCT04363762|Active Comparator|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
32815104|NCT04763187|Active Comparator|Control group|Lower molar extraction and filling of post-extraction alveolus with hemostatic sponge containing gentamicin.
32815105|NCT04763187|Experimental|PRGF group|Post-extraction alveolus is filled with PRGF.
32815106|NCT04763187|Experimental|PRF group|Post-extraction alveolus is filled with PRF.
32815107|NCT03685773|Experimental|MRI: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
32815108|NCT03685773|Placebo Comparator|MRI: Non-diabetic transplant (Placebo)|Taste-matched placebo for diazoxide
32815109|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
32815110|NCT03685773|Placebo Comparator|MRI: T2D transplant (Placebo)|Taste-matched placebo for diazoxide
32815111|NCT03685773|Experimental|Clamp: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
32815112|NCT03685773|Placebo Comparator|Clamp: Non-diabetic transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
32815113|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
32815114|NCT03685773|Placebo Comparator|Clamp: T2D transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
32815115|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study
32815116|NCT03685773|Experimental|Clamp: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study
32815117|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg)
32815118|NCT03685773|Experimental|MRI: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide)
32815119|NCT04363450|Experimental|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
32815120|NCT04363450|Placebo Comparator|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
32815121|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
32815122|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
32815123|NCT04370080|Experimental|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
32815124|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
32815125|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
32815126|NCT01591616|Other|Oraqix for tooth extraction|
32815127|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
32815128|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
32815129|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
32815130|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
32815131|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
32815132|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
32815133|NCT00938314|Placebo Comparator|Saline Placebo|
32815134|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
32815135|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
32815136|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
32815137|NCT03681015||Cohort 1 - Parkinson's Disease Participants|Volunteers will be women and men with early, untreated Parkinson disease.
32815138|NCT03681015||Cohort 2 - Control Participants|Participants will be women and men without PD.
32815139|NCT04370392|Active Comparator|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
32815140|NCT04370392|Experimental|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
32815141|NCT04370392|Experimental|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
32815142|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
32815143|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
32815144|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
32815145|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
32815146|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
32815147|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
32815148|NCT04369378|Experimental|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
32815149|NCT04369378|No Intervention|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
32815150|NCT03798327|Experimental|Home Palliative Care|Randomized to Intervention Arm
32815151|NCT03798327|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.
32815152|NCT04357678|Experimental|Qi Gong Programme|Qi Gong Programme
32815153|NCT04357678|Experimental|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
32815154|NCT03585153||T1D|Individuals with type 1 diabetes
32815155|NCT03585153||Control|Individuals without type 1 diabetes
32815156|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
32815157|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
32815158|NCT04357444|Experimental|1: ILT101|ILT-101 in Subcutaneous route
32815159|NCT04357444|Placebo Comparator|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
32815160|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
32815161|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
32815162|NCT04369144|Experimental|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
32815163|NCT04369144|Placebo Comparator|Control|The dynamic scapular recognition exercise + placebo taping
32815164|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
32815165|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
32815166|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
32815167|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
32815168|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
32815169|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
32815170|NCT04363294|Other|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
32815171|NCT01591460|Experimental|Dual Combination Therapy|
32815172|NCT01591460|Experimental|Triple Combination Therapy|
32815173|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
32815174|NCT03584295|Experimental|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (22-24Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-1.75 L/min.
32815175|NCT04363216|Experimental|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
32815176|NCT04363216|No Intervention|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
32815177|NCT04363372|Experimental|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10^9 to 4 x10^10 colony forming units.
32815178|NCT04363372|Placebo Comparator|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
32815179|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
32815180|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
32815181|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
32815182|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain. Ibuprofen would be ordered 6 hours following the last dose after the last study drug.
32815183|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 6 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room or post-operative care unit.
32815184|NCT04363060|Experimental|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
32815185|NCT04363060|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
32815186|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
32815187|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
32815188|NCT04362904|Experimental|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
32815189|NCT04362904|No Intervention|control|No intervention was applied to the control group.
32815190|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
32815191|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
32815192|NCT04362982|Experimental|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
32815193|NCT04362982|Active Comparator|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
32815194|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
32815195|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
32815196|NCT00931996|Experimental|Antipsychotic|Antipsychotic
32815197|NCT04348305|Experimental|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
32815198|NCT04348305|Placebo Comparator|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
32815199|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
32815200|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
32815201|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
32815202|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
32815203|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
32815204|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
33317475|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
32815205|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
32815206|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
32815207|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
32815208|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
32815209|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
32815210|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
32815211|NCT05347875|No Intervention|Control Group|Activities of Daily Living App
32815212|NCT05347875|Experimental|Experimental Group|ICanWALK© App
32815213|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
32815214|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
32815215|NCT04362358|Experimental|7 sessions of the online CBT programme|
32815216|NCT04362358|Active Comparator|Bibliotherapy|
32815217|NCT03791619|Active Comparator|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
32815218|NCT03791619|Active Comparator|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
32815219|NCT04356508|Experimental|Intervention (n=10)|Nivolumab + best supportive care
32815220|NCT04356508|No Intervention|Non-intervention (n=5)|Best supportive care
32815221|NCT04362280|Experimental|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
32815222|NCT04362280|Active Comparator|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
32815223|NCT04362202|Experimental|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
32815224|NCT04362202|Active Comparator|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
32815225|NCT04762641|Experimental|ABL503|ABL503 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
32815226|NCT01543087|Other|One group of subjects|
32815227|NCT04368598|Experimental|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
32815228|NCT05347641|Experimental|Penpulimab combined with RMA was used for first-line treatment of PCNSL|One course of treatment was performed every 21 days. After 3 courses, patients underwent cranial MR+ whole-body enhanced CT for disease assessment. Patients who did not achieve partial response (PR) were withdrawn, and patients who achieved PR or complete response (CR)/uncertain CR (CRu) were given 3 courses of treatment.
32815229|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
32815230|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
32815231|NCT04368520|Placebo Comparator|Placebo|
32815232|NCT04368520|Experimental|Low dose vitamin D3|
32815233|NCT04368520|Experimental|High dose vitamin D3|
32815234|NCT04762797||Non-neoplastic group|"Gallbladder polyps with pathological diagnosis of cholesterol polyps or inflammatory polyps are classified into Non-neoplastic group."
32815235|NCT04762797||Neoplastic group|"Gallbladder polyps pathologically diagnosed as adenocarcinoma, adenoma, adenomyosis, or other malignancies are classified into Neoplastic group."
32815236|NCT04762563|Experimental|Experimental: Study Group|Patients in the IASTM group were asked to lie face down on a stretcher, exposing the entire lumbar region. IASTM was applied to all paraspinal muscles for a total of 5 minutes after massage cream was applied. Immediately afterwards, the same application was performed for the right and left hamstring muscles from the gluteal line to the bottom of the popliteal fossa for 3 minutes after massage cream was applied. IASTM application was performed vertically, horizontally and diagonally using instruments of different sizes and shapes at an angle of 45 degrees to the skin surface.
32815237|NCT04762563|Active Comparator|Active Comparator|"KT application (Kinesio Tape® Tex Gold) was performed using the muscle technique. In lumbar region application, while the patient was standing, the tape was cut as a Y-strip with a base of 5 cm."
32815238|NCT04356820|Experimental|acupressure|
32815239|NCT04356820|Experimental|music|
32815240|NCT04356820|No Intervention|control|
32815241|NCT04356274|Experimental|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
32815242|NCT04356274|Experimental|Audit and Feedback (AF)|12 clinics assigned to AF
32815243|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
32815244|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 20 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for approximately 4 months. Patients that benefit from this treatment will remain on medication through an extension phase of the study.
32815245|NCT04795076|Placebo Comparator|Standard formula|Feeding the infant or child with the regular formula which is prepared with standard concentrations
32815246|NCT04795076|Active Comparator|Nutrient-dense formula|Feeding the infant or child with the nutrient-dense formula which is prepared by concentrating regular formula.
32815247|NCT04368286|Experimental|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
32815248|NCT04368286|No Intervention|Conventional medical group|Conventional medical treatment
32815249|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
32815250|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
32815251|NCT04347148|Experimental|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
32815252|NCT04347148|Placebo Comparator|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
32815253|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
32815254|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
32815255|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
32815256|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
32815257|NCT04362124|Experimental|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
32815258|NCT04362124|Placebo Comparator|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
32815259|NCT04361968|Experimental|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
32815260|NCT04361968|Experimental|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
32815261|NCT04361968|Experimental|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
32815262|NCT04361968|Other|Control condition|Participants in this condition will receive no intervention.
33317476|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
33101669|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
32815263|NCT04356118|Experimental|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.~Targeted drugs for non-small cell lung cancer:~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
32815264|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
32815265|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
32815266|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
32815267|NCT04361578||Patients|All patients enrolled in the study will be in this group.
32815268|NCT04361812|Experimental|HS632|HS632 150mg for a single subcutaneous injection
32815269|NCT04361812|Active Comparator|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
32815270|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
32815271|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
32815272|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
32815273|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
32815274|NCT04368052|Other|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
32815275|NCT04355962|Experimental|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
32815276|NCT04355962|Active Comparator|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
32815277|NCT03781167|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 52 weeks.
32815278|NCT04367662|Experimental|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
32815279|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
32815280|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
32815281|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
32815282|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
32815283|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
32815284|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
32815285|NCT04361890|Other|Women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
32815286|NCT03779139|Active Comparator|Intrahepatic islets alone|
32815287|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
32815288|NCT03779139|Sham Comparator|Normal Volunteers|
32815289|NCT04361500||COVID-19 patients with Seraph 100 therapy|
32815290|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
32815291|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
32815292|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
32815293|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
32815294|NCT00704769||1|Children with a history of perennial allergic rhinitis
32815295|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
32815296|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
32815297|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
32815298|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
33317477|NCT05670860||Anti-epileptic prophylaxis|The first group consists of patients treated between January 2019 and late 2020 who were given systematic prophylaxis
32815299|NCT04361188|Experimental|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
32815300|NCT04361188|Active Comparator|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
32815301|NCT00003453|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32815302|NCT04367818|Active Comparator|Peri-anal local anaesthetic infiltration|Patients in this group will receive the prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline) in a syringe will be connected to 22_ gauge short, beveled needle. The technique of the block will be done guided by Nystrom et al.
32815303|NCT04367818|Active Comparator|caudal anaesthesia|Patients in this group will receive caudal block using 22_gauge short, beveled cannula or needle, The prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline).
32815304|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
32815305|NCT01677273|Active Comparator|Intact casein|Intact casein
32815306|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
32815307|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
32815308|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
32815309|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
32815310|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
32815311|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
32815312|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
32815313|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
32815314|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
32815315|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
32815316|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
32815317|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
32815318|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
32815319|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
32815320|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
32815321|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
32815322|NCT03665337|Active Comparator|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
32900911|NCT05299086|Placebo Comparator|As needed INCs|"Use placebo everyday, and INCs as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
33317478|NCT05670860||NO Anti-epileptic prophylaxis|Patients from the second group were treated between 2021 and 2022 and did not receive any prophylaxis
33317479|NCT05382572||Patients|An individual diagnosed with PF or ILD, including those who are post lung transplant.
33317480|NCT05382572||Family Members|A family member (defined as biological parent, full or half-sibling, or biological child) of an individual with PF or ILD.
33317481|NCT05382572||Caregivers|An individual who has cared (currently or in the past) for an individual with PF or ILD.
33317482|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
32815323|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
32815324|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
32815325|NCT04361422|Active Comparator|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
32815326|NCT04361422|Sham Comparator|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
32815327|NCT04361422|Active Comparator|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
32815328|NCT04355338||0-9 years|Participants aging 0-9 years
32815329|NCT04355338||10-19 years|Participants aging 10-19 years
32815330|NCT04355338||20-29 years|Participants aging 20-29 years
32815331|NCT04355338||30-39 years|Participants aging 30-39 years
32815332|NCT04355338||40-49 years|Participants aging 40-49 years
32815333|NCT04355338||50-59 years|Participants aging 50-59 years
32815334|NCT04355338||60-69 years|Participants aging 60-69 years
32815335|NCT04355338||70-79 tears|Participants aging 70-79 years
32815336|NCT04355338||80+ years|Participants aging 80 years or more
32815337|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
32815338|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
32815339|NCT03575403|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules one time daily.
32815340|NCT03575403|Experimental|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
32815341|NCT03575403|Experimental|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
32815342|NCT04367428|Experimental|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
32815343|NCT04367428|No Intervention|No probiotics|Patients will not receive probiotics
32815344|NCT04367272|Active Comparator|First Knee|The first knee is the knee where the surgery will begin to be applied.
32815345|NCT04367272|Experimental|Second Knee|The second knee is the knee where the surgeon will apply secondly.
32815346|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
32815347|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
32815348|NCT04367194|Experimental|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
32815349|NCT04367194|Experimental|BPPV Epley|Only Epley training.
32815350|NCT04367194|Experimental|BPPV Optocinetic|Only Optocinetic training.
32815351|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
32815352|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
32815353|NCT04355416|Experimental|curcumin oral gel|
32815354|NCT04355416|Other|subgingival scaling and root planing|
32815355|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
32815356|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
32815357|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
32815358|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
32815359|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
32815360|NCT04355260|Experimental|Hypertrophic Obstructive Cardiomyopathy|
32815361|NCT04347304|Experimental|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
32815362|NCT04347304|Placebo Comparator|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
32815363|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
32815364|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
32815365|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
32815366|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.~The participation in the study will consist in:~Plasmatic collection at the time of AIS, for study of plasma biomarkers~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
32815367|NCT00934024|Other|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was abstinent after 5 weeks of varenicline treatment.."
32815368|NCT00934024|Other|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
32815369|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
32815370|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
32815371|NCT04360954||US Controls|Human samples pre-COVID.
32815372|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
32815373|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32815374|NCT04361032|Experimental|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
32815375|NCT04361032|Active Comparator|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
32815376|NCT04747119|Experimental|study group|received the conventional selected exercise program in addition to muscle energy technique
32815377|NCT04747119|Experimental|control group|received the conventional selected exercise program
32815378|NCT04360798|Experimental|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
32815379|NCT04360798|Experimental|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
32815380|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
32815381|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
32815382|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
32815383|NCT04355026|Experimental|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
32815384|NCT04355026|Active Comparator|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
32815385|NCT04762485|Experimental|CD38 positive relapsed or refractory acute leukemia|Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5- 10)x10^6 CD7 CAR-T cells/kg
33317483|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
32815386|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
32815387|NCT04762173|Experimental|Online self-help intervention|Participants are provided access to two online self-help programs provided by SilverCloud Health. One program is designed to support general stress resilience using principles and techniques from positive psychology and cognitive-behavioral therapy. The other program is designed to support coping with pandemic-related stressors using psychoeducation and cognitive-behavioral therapy and grief therapy principles. Participants have access to both programs and can proceed through them in the order and pace of their choosing. The online self-help intervention is fully self-guided.
32815388|NCT04762173|No Intervention|Care as usual|Participants are provided information about how to contact the counseling center at their college and/or in the local community using the phone number and website of their counseling center (if available), as well as the Substance Abuse and Mental Health Services Administration treatment locator.
32815389|NCT04762329|Experimental|Patient group using Manage My Pain (MMP) digital application for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits, on the Manage My Pain (MMP) digital application
32815390|NCT04762329|No Intervention|Patient group using paper format for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits on paper format or phone interviews.
32815391|NCT04367038|Experimental|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
32815392|NCT04367038|Experimental|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
32815393|NCT04367038|Experimental|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
32815394|NCT04367038|No Intervention|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
32815395|NCT03549507|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
32815396|NCT04360642|Other|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
32815397|NCT04403451|Experimental|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
32815398|NCT04403451|Experimental|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
32815399|NCT04403451|Experimental|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
32815400|NCT04360564||Recurrent pregnancy loss|All women with >/=2 pregnancy loss before 20 weeks gestational age
32815401|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age before the first birth
32815402|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
32815403|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
33317484|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
32815404|NCT04360408|Experimental|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
32815405|NCT04360408|No Intervention|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
32815406|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
32815407|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
32815408|NCT00939562|Experimental|doxycycline monohydrate tablet|
32815409|NCT00939562|Active Comparator|doxycycline carragenate tablet|
32815410|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
32815411|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
32815412|NCT04355104|Experimental|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
32815413|NCT04355104|Active Comparator|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
32815414|NCT03543735|Experimental|Wisepill+SMS|
32815415|NCT03543735|Active Comparator|Wisepill-only|
32815416|NCT03543735|No Intervention|Disulfiram-only|
32815417|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
32815418|NCT03542175|Experimental|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
32815419|NCT04359862|Experimental|SEVOFLURANE Group|
32815420|NCT04359862|Active Comparator|PROPOFOL Group|
32815421|NCT03568383|Experimental|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
32815422|NCT03568383|Experimental|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
32815423|NCT04366726|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide.
32815424|NCT04354948|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
32815425|NCT04354948|Placebo Comparator|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
32815426|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
32815427|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
32815428|NCT04354714|Experimental|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
32815429|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
32815430|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
32815431|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
32815432|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
32815433|NCT04360876|Experimental|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
32815434|NCT04360876|Placebo Comparator|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
32815435|NCT03771417|Experimental|Resistance Exercise|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week.
33317485|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
33317486|NCT01197404|Active Comparator|General Health Promotion|
33317487|NCT01197404|Experimental|Affect Management|
32815436|NCT03771417|Experimental|RE plus Low Intensity Physical Activity|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week and regular unsupervised low intensity physical activity breaks in sedentary time 5 days per week [6x10 min breaks/d at 2 metabolic equivalents (METS) or ~30-40% peak oxygen consumption (VO2 peak), ~500 kcal/wk above resting metabolism].
32815437|NCT03771417|Active Comparator|RE plus Moderate IntensityExercise|Exercise Intervention: Participants will be asked to complete supervised RE 2 days per week and supervised calorically matched moderate intensity physical activity 3 days per week (50 min/session at 4 METS (~60-75% VO2 peak), ~500 kcal/week above resting metabolism).
32815438|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
32815439|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
32815440|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
32815441|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
32815442|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
32815443|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
32815444|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
32815445|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
32815446|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
32815447|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
32815448|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
32815449|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
32815450|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
32815451|NCT04403529|Experimental|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
32815452|NCT04403529|Placebo Comparator|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
32815453|NCT04354324|Experimental|The test group|Oral administration of 30mci once on an empty stomach.
32815454|NCT04354324|Active Comparator|The control group|Oral administration of 100mci once on an empty stomach.
32815455|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
32815456|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
32815457|NCT04403373|Placebo Comparator|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
32815458|NCT04403373|Experimental|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
32815459|NCT04403373|Experimental|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
32815460|NCT05620264||Keratitis Group|Patients with clinically suspected bacterial or fungal keratitis
32815461|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
32815462|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
32815463|NCT04354636|Experimental|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
32815464|NCT04354636|Active Comparator|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
32815465|NCT04354090|Experimental|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
32815466|NCT04354090|Experimental|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
32815467|NCT04354090|Experimental|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
32815468|NCT04354090|Experimental|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
32815469|NCT04354090|Experimental|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
32815470|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
33317488|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
32815471|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
32815472|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
32815473|NCT04359550|Experimental|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
32815474|NCT04359550|Placebo Comparator|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
32815475|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
32815476|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
32815477|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
32815478|NCT04354480|Experimental|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
32815479|NCT04354480|Placebo Comparator|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
32815480|NCT03567603||opioid exposed neonates|prenatal opioid exposure
32815481|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
32815482|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
32815483|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
32815484|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
32815485|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
32815486|NCT02084511|Experimental|Placebo reference|Placebo reference
32815487|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
32815488|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
32815489|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
32815490|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
32815491|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
32815492|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
32815493|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
32815494|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
32815495|NCT04697758|Experimental|Low Dose|AXT107 0.1 mg/eye
32815496|NCT04697758|Experimental|Mid Dose|AXT107 0.25 mg/eye
32815497|NCT04697758|Experimental|High Dose|AXT107 0.5 mg/eye
32815498|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
32815499|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
32815500|NCT05620186|Other|Original PROSPECT|Original, distributed PROSPECT where trainees learn at their own pace in between, before/after clinical activities
32815501|NCT05620186|Other|Massed PROSPECT|Massed, bootcamp-style training form of PROSPECT where trainees are exempt from clinical duties
32815502|NCT04359082|Placebo Comparator|Placebo|Placebo for 8 straight days
32815503|NCT04359082|Experimental|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
32815504|NCT04359316|Experimental|Azithromycin|
32815505|NCT04359316|Active Comparator|Hydroxychloroquine|
32815506|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
32815507|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
32815508|NCT03762135|Experimental|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
32815509|NCT03762135|Active Comparator|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
32815510|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
32815511|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
32815512|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
32815513|NCT00939874|Experimental|Raltegravir|
32815514|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
32815515|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
32815516|NCT04359160|Experimental|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
32815517|NCT04359160|Active Comparator|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
32815518|NCT03557385|Other|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
32815519|NCT04644172|Experimental|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
32815520|NCT04644172|Other|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
32815521|NCT03528213|Sham Comparator|Normal saline|at physician discretion
32815522|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
32815523|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
32815524|NCT05620030|Experimental|Univentricular Heart|All patients with univentricular hearts
32815525|NCT04601350|Experimental|Remimazolam 1|
32815526|NCT04601350|Experimental|Remimazolam 2|
32815527|NCT04601350|Experimental|Remimazolam 3|
32815528|NCT04601350|Other|Control|
32815529|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
32815530|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
32815531|NCT05346861|Active Comparator|Trastuzumab plus chemotherapy|
32815532|NCT05346861|Experimental|Pyrotinib in combination with Trastuzumab plus chemotherapy|
32815533|NCT04358614|Active Comparator|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
32815534|NCT04358614|Other|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
32815535|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
33317489|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
33317490|NCT05516966|Experimental|Group A|Participants receive low dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
33317491|NCT05516966|Experimental|Group B|Participants receive medium dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
33317492|NCT05516966|Experimental|Group C|Participants receive high dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
33317493|NCT05516966|Active Comparator|Group D|Participants receive Dulaglutide 1.5 mg by multiple subcutaneous injection
33317494|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
32815539|NCT04761705|Experimental|Randomized Part 2, Arm 1|Dose 1 selected in Part I
32815540|NCT04761705|Experimental|Randomized Part 2, Arm 2|Dose 2 selected in Part I
32815541|NCT04761705|Active Comparator|Randomized Part 2, Arm 3|
32815542|NCT04358692|Experimental|Surgical Aortic Valve Replacement|Patients with aortic stenosis
32815543|NCT04358692|Other|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
32815544|NCT04403217|Experimental|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
32815545|NCT04358926|Active Comparator|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
32815546|NCT04358926|No Intervention|Control|Standard of care
32815547|NCT03520179||SMA TYPE 1|genetically confirmed SMA
32815548|NCT03520179||SMA TYPE 2|genetically confirmed SMA
32815549|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
32815550|NCT04358770|Experimental|Test|Clocortolone Pivalate Cream, 0.1%
32815551|NCT04358770|Active Comparator|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
32815552|NCT04402983|Experimental|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
32815553|NCT04402983|No Intervention|Control group|Information and exercise brochure will be provided
32815554|NCT04564300|Experimental|Oral contraceptive users|
32815555|NCT04564300|Active Comparator|Non-oral contraceptive users|
32815556|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815557|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815558|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
32815559|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815560|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815561|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
32815562|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815563|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815564|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
32815565|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815566|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
32815567|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
32815568|NCT04533022|Experimental|C21|
32815569|NCT04525144|Experimental|Tebonin Forte|Treatment: 120mg, twice a day, 52 weeks
32815570|NCT04525144|No Intervention|Control|No Treatment
32815571|NCT05619484|No Intervention|Participant's prescribed ankle-foot orthosis|
32815572|NCT05619484|Experimental|Smart AFO|
32815573|NCT05618470|Experimental|Wumeiwan Jiawei Fang|This group will take Wumei pill granule orally.
32815574|NCT05618470|Active Comparator|botulinum toxin A|In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.
32815575|NCT04490512|Experimental|FluBHPVE6E7|Multiple administration of FluBHPVE6E7
32815576|NCT04490512|Placebo Comparator|Placebo|Multiple administration of buffer solution
32815577|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
32815578|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
32815579|NCT04358146|Experimental|Test|new thickened infant formula containing fibres
32815580|NCT04358146|Active Comparator|Control|infant formula thickened with locust bean
32815581|NCT05620498|Experimental|tislelizumab+lenvatinib+GMOX|"tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd,) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd for maintained treatment until disease progression or toxicity became intolerable."
32815582|NCT05620498|Active Comparator|tislelizumab+GEMOX|"tislelizumab 200mg, Q3W, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W for maintained treatment until disease progression or toxicity became intolerable."
32815583|NCT04468126|Active Comparator|standard oxygen group|In order to maintain SpO2 between 92 and 96%
32815584|NCT04468126|Experimental|high-flow nasal cannula oxygen group|At least 50 L/min adjusted in order to maintain SpO2 between 92 and 96 %
32815585|NCT04456816|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
32815586|NCT04456816|Experimental|Placebo|Placebo. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
32815587|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
32815588|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
32815589|NCT04432090|Experimental|MBX-2982 first then placebo- Volunteers with Type 1 diabetes|This will be followed by a second study period in which they will be crossed over to the other treatment.
32815590|NCT04432090|Active Comparator|Healthy Volunteers|this group will not receive any medication. It will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
32815591|NCT04432090|Experimental|Placebo first then MBX-2982- Volunteers with Type 1 diabetes|
32815592|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
32815593|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
32815594|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
32815595|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
32815596|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
32815597|NCT01675479|Experimental|wavefront-guided LASIK|
32815598|NCT05613244||Patients with Orbital Solitary Fibrous Tumors|
32815599|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
32815600|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
32815601|NCT01678755|Placebo Comparator|Placebo|Placebo
32815602|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
32815603|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
32815604|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
32815605|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
32815606|NCT04358302|Experimental|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
33317495|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
32815608|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
32815609|NCT05574244|Experimental|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
32815610|NCT05574244|Experimental|Partial surgery preserving the prostatic apex|Patients randomised to the partial endoscopic resection group will undergo surgical treatment that preserves the apex area of the prostate (tissue located 1 cm around the veru montanum).
32815611|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
32815612|NCT02404935|Other|Arm B observation|observation until progression
32815613|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
32815614|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
32815615|NCT03511131|Other|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
32815616|NCT03511131|Other|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
32815617|NCT03511131|Other|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
32815618|NCT03511131|Other|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
32815619|NCT03511131|Other|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
33317496|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
32815620|NCT03511131|Other|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
32815621|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
32815622|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
32815623|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
32815624|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
32815625|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
32815626|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
32815627|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
32815628|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
32815629|NCT04317118||Neurodevelopmental|Individuals between 8 and 17 years old with neurodevelopmental disorders
32815630|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
32815631|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
32815632|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
32815633|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over~Treatment D: AL-3778 2×300-mg tablets (fasted) once.~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
32815634|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
32815635|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
32815636|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
32815637|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
32815638|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
32815639|NCT03420963|Experimental|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
32815640|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
32815641|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
32815642|NCT05489614|Experimental|Single Dose Olpasiran Renal Impairment|Participants will be enrolled in 1 of 5 renal function groups based on their renal impairment status, as determined by estimated glomerular filtration rate (eGFR). All participants will receive a single dose of olpasiran on Day 1.
32815643|NCT05489614|Experimental|Single Dose Olpasiran Normal Renal Function|Participants with normal renal function will be enrolled and will receive a single dose of olpasiran on Day 1.
32815644|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
32815645|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
32815646|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
32815647|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
32815648|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
32815649|NCT03502707|Placebo Comparator|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
32815650|NCT03502707|Experimental|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
32815651|NCT03502707|Placebo Comparator|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
32815652|NCT03502707|Experimental|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
32815653|NCT03502707|Experimental|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
32815654|NCT03502707|Placebo Comparator|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
32815655|NCT03502707|Experimental|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
32815656|NCT03502707|Placebo Comparator|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
32815657|NCT03502707|Experimental|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
32815658|NCT03502707|Experimental|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
33317497|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
32815659|NCT03502707|Experimental|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
32815660|NCT03502707|Experimental|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
32815661|NCT03502707|Experimental|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
32815662|NCT03502707|Experimental|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
32815663|NCT03502707|Experimental|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
32815664|NCT03502707|Experimental|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
32815665|NCT03502707|Experimental|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
33317498|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
32815666|NCT03502707|Placebo Comparator|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
32815667|NCT03502707|Experimental|C3 G19: Selected Regimen (SR)|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
32815668|NCT03502707|Experimental|C3 G20: SR + Placebo for SR|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and Month 24, and a placebo at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a placebo at Month 12.
32815669|NCT03502707|Placebo Comparator|C3 G21: Placebo for SR|If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.
32815670|NCT04182490|Active Comparator|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 14 days (n=21)
32815671|NCT04182490|Placebo Comparator|Placebo cohort|Placebo, six 500-mg capsules orally three times daily for 14 days (n=21)
32815672|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
32815673|NCT02245438|Experimental|TPV/RTV low dose|
32815674|NCT02245438|Experimental|TPV/RTV high dose|
32815675|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
32815676|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
32815677|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
32815678|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
33317499|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
33317500|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
33405063|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
32815679|NCT02401815|Experimental|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815680|NCT02401815|Experimental|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815681|NCT02401815|Experimental|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815682|NCT02401815|Experimental|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815683|NCT02401815|Experimental|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815684|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815685|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815686|NCT02401815|Experimental|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815687|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815688|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
32815689|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
32815690|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
33405064|NCT04804332|Experimental|EXPECTANT MANAGEMENT|No treatment will be offered.
32815693|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
32815694|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
32815695|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
32815696|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
32815697|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
32815698|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
32815699|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
32815700|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
32815701|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
32815702|NCT00948298|Placebo Comparator|Placebo|
32815703|NCT00948298|Experimental|Vitamin D|
32815704|NCT05346783|Experimental|TJO-083 [Part 2]|1 drop 3 times a day
32815705|NCT05346783|Placebo Comparator|Placebo of TJO-083 [Part 2]|1 drop 6 times a day
32815706|NCT05346783|Active Comparator|Diquas-s Ophthalmic solution 3% 0.4mL [Part 2]|1 drop 6 times a day
32815707|NCT00948610|Placebo Comparator|Placebo|Placebo-participant will receive placebo saline solution via IV route.
32815708|NCT00948610|Active Comparator|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
32815709|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
32815710|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
32815711|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
32815712|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
32815713|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
32815714|NCT04097002|Experimental|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10*11 viral particles.~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
32815715|NCT04097002|Experimental|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10*11 viral particles.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
32815716|NCT04097002|Experimental|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10*12 viral particles.~Group of 3 subjects.~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
32815717|NCT04097002|Experimental|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.~Group of 12 subjects."
32815718|NCT04053166|Experimental|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
32815719|NCT04053166|Active Comparator|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
32815720|NCT04007536||Part 1|Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
32815721|NCT04007536||Part 2|Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical assessments are optional in Part 2.
32815722|NCT04007536||Part 3|Participants <8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
32815723|NCT04007536||Part 4|Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
32815724|NCT03995212|Active Comparator|CR845 1.0 mg|Oral CR845 1.0 mg tablet administered twice daily
32815725|NCT03995212|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
32815726|NCT05430958|Experimental|Group 1|Single injection of 0.8 mg of INO-4800 followed by EP administered at Day 0
32815727|NCT05430958|Experimental|Group 2|Single injection of 0.8 mg of INO-4800 plus 0.05 mg of INO-9112 followed by EP administered at Day 0
32815728|NCT05430958|Experimental|Group 3|Single injection of 0.8 mg of INO-4800 plus 0.10 mg of INO-9112 followed by EP administered at Day 0
32815729|NCT05430958|Experimental|Group 4|Single injection of 0.8 mg of INO-4800 plus 0.20 mg of INO-9112 followed by EP administered at Day 0
32815730|NCT05430958|Experimental|Group 5|Two injections of 0.8 mg (1.6 mg total) of INO-4800 followed by EP administered at Day 0
32815731|NCT05430958|Experimental|Group 6|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.05 mg (0.1 mg total) of INO-9112 followed by EP administered at Day 0
32815732|NCT05430958|Experimental|Group 7|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.1 mg (0.20 mg total) of INO-9112 followed by EP administered at Day 0
32815733|NCT05430958|Experimental|Group 8|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.20 mg (0.40 mg total) of INO-9112 followed by EP administered at Day 0
32815734|NCT03915652|Experimental|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
32815735|NCT03915652|Experimental|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
32815736|NCT03915652|Experimental|BWH iCMP to Rheum iCMP|100 lupus patients within the Partners system who are already enrolled in BWH iCMP will have their iCMP nurse trained in lupus-specific care
32815737|NCT05428930|Experimental|CKDB-501B|
32815738|NCT05428930|Active Comparator|Botox® 50U|
32815739|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
32815740|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
33405065|NCT04804332|Experimental|OPERATIVE HYSTEROSCOPY|Operative hysteroscopy using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) is performed.
33405066|NCT04788576||Patients with heart failure with preserved ejection fraction (HFpEF)|Subject with preserved ejection fraction (ejection fraction > 50%) and with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
33405067|NCT04737876|Experimental|BX002-A|BX002-A: 1 mL liquid for multiple dose oral administration
33405068|NCT04737876|Placebo Comparator|Placebo|Placebo: 1 mL liquid for multiple dose oral administration
33405069|NCT04128956|Experimental|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
32815745|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
32815746|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
32815747|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
32815748|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
32815749|NCT05421754|Experimental|ANNE Sleep|After consent, subjects will wear the ANNE Sleep system with HST for 1 night and 3 nights with ANNE sleep system alone.
32815750|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
32815751|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
32815752|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
32815753|NCT00944710|Active Comparator|Control|Weekend atropine 1%
32815754|NCT00945100|Active Comparator|Control|2 hours daily patching
32815755|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
32815756|NCT05384236|Experimental|kinesiology taping|Application of a neuromuscular bandage on the plantar fascia
32815757|NCT05384236|Active Comparator|taping or Low-dye taping|Application of a taping on the plantar fascia
32815758|NCT03861130||Kawasaki disease|Kawasaki disease affected children
32815759|NCT03861130||parent of Kawasaki disease affected child|
32815760|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
32815761|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
32815762|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
32815763|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
32815764|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
32815765|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
32815766|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
32815767|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
32815768|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
32815769|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
32815770|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
32815771|NCT05354752|Experimental|VC005 Tablets Dose escalation groups|VC005 Tablets groups Repeat doses
32815772|NCT05354752|Placebo Comparator|VC005 Tablets Placebo groups|VC005 Tablets Placebo groups Repeat doses.
32815773|NCT05330182|Experimental|Sentinel Cohort|
32815774|NCT05330182|Active Comparator|LMN-201|
32815775|NCT05330182|Placebo Comparator|Placebo|
32815776|NCT03854032|Experimental|Arm I (BMS986205, nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.
32815777|NCT03854032|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.
32815778|NCT03850912|No Intervention|Activity 1: Stakeholder Feedback|"Obtain stakeholder feedback to inform eSyM finalization and implementation from:~patient advisory councils~health system leaders~clinicians~clinic support staff/administration~IT/Informatics"
32815779|NCT03850912|No Intervention|Activity 2: eSym Build|"Build and deploy eSyM~Finalize training materials based on findings from stakeholder engagement"
32815780|NCT03850912|Experimental|Activity 3: Pilot Test eSyM App|"Pilot testing of the eSyM app will include:~Activity 3a (eSyM app usage by patients)~Activity 3b (User acceptability testing)~Activity 3c (Medical record abstraction)"
32815781|NCT03850912|Experimental|Activity 4: eSyM+ Participants|"These patients (and/or proxy) will report their symptoms in eSyM~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM+ version or eSyM-Non-Responder version)~A medical record abstraction will be completed for ALL eSyM+ patients"
32815782|NCT03850912|Experimental|Activity 4: eSyM- Participants|"These patients (and/or proxy) will NOT report their symptoms in eSyM~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM- version)~A medical record abstraction will be completed for ALL eSyM- patients"
32815783|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
32815784|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
32815785|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
32815786|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
32815787|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
32815788|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
32815789|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
32815790|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
32815791|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
32815792|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
32815793|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
32815794|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
32815795|NCT05328700|Experimental|kinesiotaping|
32815796|NCT05328700|Placebo Comparator|Tape|
32815797|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
32815798|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
32815799|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
32815800|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
32815801|NCT05320042|Experimental|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
32815802|NCT05320042|Active Comparator|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
32815803|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
32815804|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
32815805|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
32815806|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
32815807|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
32815808|NCT05258734|Experimental|COVOS app|
32815809|NCT05258734|Active Comparator|Control Group|
32815810|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
32815811|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
32900912|NCT05299086|Active Comparator|Regular INCs|"Use INCs everyday, and placebo as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
32815812|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
32815813|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
32815814|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
32815815|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
32815816|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
32815817|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
32815818|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
32815819|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
32815820|NCT03656536|Experimental|Pemigatinib|
32815821|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
32815822|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
32815823|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
32815824|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
32815825|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
32815826|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
32815827|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
32815828|NCT03493581|Experimental|NSCLC patients|
32815829|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
32815830|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
32815831|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
32815832|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
32815833|NCT05198908|Experimental|VR group|VR (virtual reality glasse) group
32815834|NCT05198908|Experimental|skin to skin group|skin to contact group
32815835|NCT05198908|No Intervention|Control group-none|Women in this group will not be subjected to any treatment other than the routine hospital protocol. Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary.
32815836|NCT05153590||Reimbursed|The reimbursed cohort includes only patients who received Saxenda® through mandatory basic insurance
32815837|NCT05153590||Non reimbursed|The non reimbursed cohort includes patients who received Saxenda® through additional private insurance or self-pay
32815838|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
32815839|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
32815840|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
32815841|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
32815842|NCT03030898|Other|respiratory variation of the right internal jugular vein|
32815843|NCT00089973|Experimental|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
32815844|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
32815845|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
32815846|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
32815847|NCT04402203|Experimental|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
32815848|NCT04402203|Placebo Comparator|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
32815849|NCT05100862|Experimental|Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab|Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
32815850|NCT05100862|Active Comparator|Follicular Lymphoma Arm B: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
32815851|NCT05100862|Experimental|Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab|Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
32815852|NCT05100862|Active Comparator|Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
32815853|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
32815854|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
32815855|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
32815856|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
32815857|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
32815858|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
32815859|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
32815860|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
32815861|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
32815862|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
32815863|NCT03090880|No Intervention|Control|usual care,
32815864|NCT03090880|Experimental|Experimental|tinzaparin sodium
32815865|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
32815866|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.~During this 12 months period, practice facilitation will end in the Group A arm."
32815867|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
32815868|NCT02245594||Gl motility and sleep pattern|
32815869|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
32815870|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
32815871|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
32815872|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
32815873|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
33405070|NCT04128956|No Intervention|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
32815874|NCT05099848|Experimental|CAHAIC group|Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib
32815875|NCT05097976|Experimental|Methylprednisolone taper|Methylprednisolone taper - 21 x 4mg tablets beginning on POD 1
33405071|NCT05206578|Experimental|AGT2, AGZ|
32815876|NCT05097976|Placebo Comparator|Placebo taper|2.Placebo taper - 21 sugar tablets beginning on POD 1 with standard management
32815877|NCT05092126|Active Comparator|6MST VO2|Completion of 6MST exercise protocol
32815878|NCT05092126|Active Comparator|DASI VO2|Completion of DASI fitness activity questionnaire
32815879|NCT05060380|Experimental|Exercise training|The exercise training group will receive progressive muscle resistive exercise, 10 sets of exercises for 2 times per week for a total of 6 months.
32815880|NCT05060380|No Intervention|Control|The control group will be asked to maintain their normal lifestyle and will be advised to continue their standard care of treatment.
32815881|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
32815882|NCT03030430|Experimental|BAT1706|BAT1706 injection
32815883|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
32815884|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
32815885|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
32815886|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),~50 patients with Parkinson's disease dementia (PDD),~50 patients with Dementia with Lewy Bodies (DLB) and~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
32815887|NCT03030586||Healthy Controls|200 healthy subjects
32815888|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly-confirmed SCA7
32815889|NCT00089661|Experimental|AMG 162 / Denosumab|
32815890|NCT00089661|Placebo Comparator|Placebo|
32815891|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
32815892|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
32815893|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
32815894|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
32815895|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
32815896|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
32815897|NCT05056792|Experimental|Participants in this group will receive isometric strength training.|Isometric strength training of the quadriceps femoris muscle for 8 weeks.
32815898|NCT05056792|Sham Comparator|Participants in this group will receive plyometric training.|Participants in this group will receive plyometric training for 8 weeks.
32815899|NCT01597414|Active Comparator|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
32815900|NCT01597414|Experimental|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
32815901|NCT05056246|Experimental|Group 1: Japanese participants - AMG 133 low dose|Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.
32815902|NCT05056246|Experimental|Group 2: Japanese participants - AMG 133 medium dose|Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
32815903|NCT05056246|Experimental|Group 3: Japanese participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
32815904|NCT05056246|Experimental|Group 4: Caucasian participants - AMG 133 medium dose|Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
32815905|NCT05056246|Experimental|Group 5: Caucasian participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
32815906|NCT04984330|Experimental|selinexor/ dexamethasone (Sd)|"Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity~Dexamethasone~• 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23"
32815907|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
32815908|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
32815909|NCT04951102|Experimental|Group A Patients who receive SDM intervention|Group A patients will complete a pre-visit electronic Asthma SDM App. They may also receive educational information regarding asthma, medication management, smoking cessation, COVID-19 and COVID-19 vaccines.
32815910|NCT04951102|Active Comparator|Group B Patients who receive standard care|Group B patients will receive standard care.
32815911|NCT04951102|Experimental|Group A Physicians who receive SDM training and electronic Asthma SDM App data|Group A physicians will view an SDM Physician Training Video and receive the patients' reported data from the pre-visit asthma SDM App prior to the patients' visits.
32815912|NCT04951102|Active Comparator|Group B Physicians who provide standard care|Group B physicians will provide standard care.
32815913|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
32815914|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
32815915|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
33405072|NCT05206578|Active Comparator|AGT2|
33405073|NCT05206578|Experimental|AGT4, AGZ|
33405074|NCT05206578|Active Comparator|AGT4|
32815916|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
32815917|NCT00265798|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32815918|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
32815919|NCT04933942|Active Comparator|Control group|Lomustine alone
32815920|NCT04933942|Experimental|Experimental group|Lomustine plus Romiplostim
32815921|NCT04930822|Active Comparator|Table Top Visual Intervention|Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator.
32815922|NCT04930822|Experimental|Bioness Integrated Therapy System Visual Intervention|Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator.
32815923|NCT00089583|Experimental|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
32815924|NCT00089583|Experimental|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
32815925|NCT04902664|Experimental|Intervention Arm|Intervention arm physicians will receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals, along with physician-facing education materials. This email will be sent before each patient study visit for all patients in the study. Participating patients of intervention arm physicians will receive patient education materials one to two days before their study visit.
32815926|NCT04902664|Placebo Comparator|Control Arm|Control arm physicians receive an email with information on the general visit preparation tips that their patients will receive. Participating patients of control arm physicians will receive general visit preparation tips one to two days before their study visit.
32815927|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
32815928|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
32815929|NCT04893226|No Intervention|Control|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). There will be no intervention.
32815930|NCT04893226|Experimental|Time-Restricted Feeding (TRF) Group|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). Subjects in this group will be educated about the health benefits of time-restricted feeding (TRF). Then each subject in the TRF group will self-select a 10-h window during which she will consume all daily calories for 16 weeks.
32815931|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
32815932|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
32815933|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
32815934|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
32815935|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
32815936|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
32815937|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
32815938|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
32815939|NCT05346705|Experimental|Tongue/soft palate muscle control function training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
32815940|NCT05346705|Experimental|Soft palate muscle group vocal resistance training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
32815941|NCT05346705|Placebo Comparator|Simple tongue extension, cheek drumming/voice training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
33317501|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
32815942|NCT04832230||Healthy individuals|This group is composed of healthy individuals without previous noise exposure.
32815943|NCT04832230||Acute acoustic trauma patients|This group is composed of patients suffering from acute acoustic trauma.
33405075|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
32815944|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
32815945|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
32815946|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
32815947|NCT04402047|Experimental|Electroacupuncture group|
32815948|NCT04402047|Active Comparator|Topical DSG group|
32815949|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
32815950|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
32815951|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
32815952|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
32815953|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
32815954|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
32815955|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
32815956|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
32815957|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
32815958|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
32815959|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
32815960|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:~Maximal PACU VAS pain score (per nursing charts)~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)~POD 24 and 48 hours and 4 weeks Respiratory complications"
32815961|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
32815962|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
32815963|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
32815964|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
32815965|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
32815966|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
32900913|NCT05285930|Experimental|group A|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
32815967|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
32815968|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
32815969|NCT03034486|Experimental|A single sequence, 3-period|
32815970|NCT00088881|Experimental|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
32815971|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
32815972|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
32815973|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
32815974|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
32815975|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
32815976|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
32815977|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
32815978|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
32815979|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
32815980|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
32815981|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
32815982|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
32815983|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
32815984|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
32815985|NCT04353544|Active Comparator|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
32815986|NCT04353544|Experimental|delayed cord clamping|when the cord stopped pulsing, or five minutes
32815987|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
32815988|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
32815989|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
32815990|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
32815991|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
32815992|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
32815993|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
32815994|NCT00953212|Active Comparator|Group D|Beta Blockers alone
32815995|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
32815996|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
32815997|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping~regular OT rehabilitation program for 3 weeks"
32815998|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises~regular OT rehabilitation program for 3 weeks"
32815999|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
32816000|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
32816001|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
32816002|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
32816003|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
32816004|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
32816005|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
32816006|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
32816007|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
32816008|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
32816009|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
32816010|NCT00087555|Experimental|2|Sodium oxybate 6.0 g per day.
32816011|NCT00087555|Placebo Comparator|3|Placebo (one of two doses matching active treatment by volume).
32816012|NCT00087555|Experimental|1|Sodium oxybate 4.5 g per day.
32816013|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
32816014|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
32816015|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
32816016|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
32816017|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
32816018|NCT03033940||ATTUNE TM subjects|
32816019|NCT03033940||PFC Sigma subjects|
32816020|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
32816021|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
32816022|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
32816023|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
32816024|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
32816025|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
32816026|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
32816027|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
32816028|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
32816029|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
32816030|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
32900914|NCT05285930|Experimental|group B|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
33405076|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
33405077|NCT05206032||healthy participants|healthy participants
33405078|NCT05206032||acute aortic dissection (AAD)|acute aortic dissection (AAD)
32816031|NCT05346549|Experimental|High energy|"Child will be given a high energy drink: sugar free ribena squash (2kcal/100ml) plus a weighed amount of super soluble maxijul. Super Soluble Maxijul is a powdered carbohydrate energy source, which can be mixed with sweet or savoury foods/ liquids. It is safe for use in both children and adults that require fortification with a high or readily available carbohydrate. It is flavourless and tasteless offering little to no change in taste, flavor and texture of food being added to. It supplies 380 kcal energy per 100g powder. The amount given will supply 10% of the child's daily energy requirements per Kg - for example a 3-year old child weighing about 16 kg requires approximately 1300 kcal/day. Hence the high energy drink will supply the child with 130kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat standardized weighed buffet lunch of known energy content suitable for their age, chosen in consultation with the parents."
32816032|NCT05346549|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink: sugar free ribena squash containing 2kcal per 100ml.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of weighed buffet foods as above."
32816033|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
32816034|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
32816035|NCT00086619|Experimental|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
32816036|NCT00086619|Experimental|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
32816037|NCT00945958|Experimental|SPARC0913|
32816038|NCT00085917|Active Comparator|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
32816039|NCT00085917|Experimental|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
32816040|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
32816041|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
32816042|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
32816043|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
32816044|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
32816045|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
32816046|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
32816047|NCT03479697|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
32816048|NCT03479697|Other|Continued Current Care|Participants will continue their current care.
32816049|NCT00084747|Experimental|bortezomib|
32816050|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
32816051|NCT04402671|Active Comparator|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
32816052|NCT04402671|Active Comparator|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
32816053|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
32816054|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
32816055|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
32816056|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
32816057|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
32816058|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
32816059|NCT00946270|Experimental|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
32816060|NCT00946270|Experimental|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
32816061|NCT00946270|Experimental|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
32816062|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
32816063|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
33405079|NCT05206032||acute myocardial infarction (AMI)|acute myocardial infarction (AMI)
32816064|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
32816065|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
32816066|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
32816067|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
32816068|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
32816069|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
32816070|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
32816071|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
32816072|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
32816073|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
32816074|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
32816075|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
32816076|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
32816077|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
32816078|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
33405080|NCT05206032||pulmonary embolism (PE)|pulmonary embolism (PE)
33405081|NCT05206032||angina|angina
33405082|NCT05201274|Experimental|Baduanjin sequential therapy|
32816082|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
32816083|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
33405083|NCT05201274|Active Comparator|Aerobic exercise|
32816084|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
32816085|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
32816086|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
32816087|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
32816088|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
32816089|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
32816090|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
32816091|NCT03445221|Active Comparator|Group I|Patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
32816092|NCT03445221|Active Comparator|Group II|Patients will continue preoperative oral conventional diet.
32816093|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
32816094|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
32816095|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
32816096|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
32816097|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
32816098|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
32816099|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
32816100|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
32816101|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
32816102|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
32816103|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
32816104|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
32816105|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
32816106|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
32816107|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
32816108|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
32816109|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
32816110|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
32816111|NCT00081159|Experimental|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
32816112|NCT00081159|Experimental|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
32816113|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
32816114|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
32816115|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
32816116|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
32816117|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
32816118|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
32816119|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
32816120|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
32816121|NCT01679067||HIV-GALT|
32816122|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine;"
32816123|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine;"
32816124|NCT03414567||Control Group|Non-smoker
32816125|NCT03414567||Study Group|Smoker
32816126|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
32816127|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
32816128|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
32816129|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts [2,660 were enrolled].~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018 [1,525 were enrolled]."
32816130|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~High flow rate: 40-50 L/min without additional oxygen~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~High flow rate: 40-50 L/min with FiO2 of 28%"
32816131|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
32816132|NCT03033082||Normal males|Questionnaire sheets.
32816134|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
32816135|NCT03033160|No Intervention|Observation|Observation
32816136|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
32816137|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
32816138|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
32816139|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
32816140|NCT04348539|Experimental|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
32816141|NCT04348539|Experimental|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
32816142|NCT04348539|Experimental|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
32816143|NCT04348539|No Intervention|Control group|control group: who will receive educational lectures on health, walking and aging.
32816144|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
32816145|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
32816146|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
32816147|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
32816148|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
32816149|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
32816150|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32816151|NCT03032926||Open Trial|N/A - Open Trial
32816152|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
32816153|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
32816154|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
32816155|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
32816156|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
32816157|NCT00080223|Experimental|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
32816158|NCT03472443|Experimental|Sinew Acupuncture|
32816159|NCT03472443|No Intervention|Waitlist|
33317502|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
33317503|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
32816160|NCT01679223||<40 years|subjects aged less than 40 years
32816161|NCT01679223||40-60 years|subjects aged 40-60years
32816162|NCT01679223||> 60 years|subjects aged greater than 60 years
32816163|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
32816164|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
32816165|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
32816166|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
32816167|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
32816168|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
32816169|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
32816170|NCT05346471|Other|Acute posterior fossa lesions|Subjects will receive additional multimodal infratentorial neuromonitoring
32816171|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
32816172|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
32816173|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
32816174|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
32816175|NCT03085485|Placebo Comparator|Placebo|matching placebo
32816176|NCT03085251|Experimental|Blood glucose measurement|
32816177|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
32816178|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
32816179|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
32816180|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
32816181|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
32816182|NCT04278573|Experimental|Vitamin D3 Treatment Group|Subjects will receive a Vitamin D3 injection into their wart
32816183|NCT04278573|Placebo Comparator|Placebo Group|Subjects will receive a placebo injection into their wart
32816184|NCT03088059|Experimental|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
32816185|NCT03088059|Experimental|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
32816186|NCT03088059|Experimental|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
32816187|NCT03088059|Experimental|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
32816188|NCT03088059|Experimental|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
32816189|NCT03088059|Experimental|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
32816190|NCT03088059|Experimental|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
32816191|NCT03088059|Experimental|Patient Cohort I3|Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
32816192|NCT03084549|Experimental|Ropivacaïne|
32816193|NCT03084549|Placebo Comparator|Placebo|
32816194|NCT04761549|Other|Adolescent Idiopathic Scoliosis|
32816195|NCT03085719|Experimental|High Dose Radiation + Pembrolizumab|"High dose radiation will be given in 3 fractions~Pembrolizumab administered intravenously on day one of each cycle."
32816196|NCT03085719|Experimental|High Dose + Low Dose Radiation + Pembrolizumab|"High Dose radiation will be given in 3 fractions~Low Dose Radiation will be given in 2 fractions~Pembrolizumab administered intravenously on day one of each cycle."
32816197|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
32816198|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
32816199|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
32816200|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
32816201|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
32816202|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
32816203|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
32816204|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
32816205|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
32816206|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
32816207|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
32816208|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
32816209|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
32816210|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
32816211|NCT03701763|Placebo Comparator|Administration of Placebo|Placebo tablet Twice Daily (BID)
32816212|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
32816213|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
32816214|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
32816215|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
32816216|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
32816217|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
32816218|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
32816219|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
32816220|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
32816221|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
32816222|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
32816223|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
32816224|NCT03089775|Experimental|BBI-2000|Cohort A
32816225|NCT03089775|Placebo Comparator|Vehicle|Cohort A
32816226|NCT03089775|Other|Multiple treatments|Cohort B
32816227|NCT04401735|Experimental|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
32816228|NCT04401735|Experimental|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
32816229|NCT04401735|Placebo Comparator|Placebo|Placebo (Normal saline)
32816230|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
32816231|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
32816232|NCT03089463||Observation group|The entire participants in this study will be included in this group.
32816233|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
32816234|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
32816235|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
32816236|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
32816237|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
32816238|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
32816239|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
32816240|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
32816241|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
32816242|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
32816243|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, but the Parasym was not turned on and the subject did not receive any stimulation. The clip was switched to the other ear every 4 hours for a total of 48 hours.
32816244|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, and the subject received continuous stimulation for 48 hours. The clip was switched to the other ear every 4 hours.
32900915|NCT05285930|Sham Comparator|group C|received a noncontact low-frequency pulsed ultrasound delivered through only plain gel without BV gel at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
32816245|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
32816246|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
32816247|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
32816248|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
32816249|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
32816250|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
32816251|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
32816252|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
32816253|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
32816254|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~Developing attentional stability and clarity of the mind (Mindfulness)~Cultivating insight into the nature of mental experience~Cultivating self-compassion~Developing impartiality~Developing appreciation and affection for others~Developing empathy and realizing engaged compassion"
32816255|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
32816256|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
32816257|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
32816258|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
32816259|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
32816260|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
32816261|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
32816262|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
32816263|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
32816264|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
32816265|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
32816266|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
32816267|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
32816268|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
32816269|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
32816270|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
32816271|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
32816272|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
32816273|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
32816274|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
32816275|NCT01008280|Placebo Comparator|Placebo|placebo given tid
32900916|NCT00407420|Experimental|Mandometer|Active intervention - one meal eaten per day off Mandometer
32900917|NCT00407420|Active Comparator|Control|Nutritional and activity advice alone
33317504|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
32816276|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
32816277|NCT03084159|Experimental|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
32816278|NCT03084159|No Intervention|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
32816279|NCT04279665|Experimental|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
32816280|NCT05689047|Experimental|Part A: Safety Run-in Cohort M5717+Pyronaridine|M5717 and pyronaridine once daily in a single day treatment regimen at low dose of 330 milligrams (mg) and 360 mg respectively.
32816281|NCT05689047|Experimental|Part B: Dose escalation cohort; M5717+Pyronaridine|After completion of Part A, if dose will be considered safe and well tolerated, the Internal Data Monitoring Committee (IDMC) will have the option to recommend dose adjustments. M5717 and pyronaridine once daily will be administered in an escalated dose in a single day or 2-day treatment regimen.
32816282|NCT05689047|Active Comparator|Pyronaridine-artesunate|Pyronaridine-artesunate (Pyramax) once daily in a 3-day treatment regimen.
32816283|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
32816284|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
32816285|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
32816286|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
32816287|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
32816288|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
32816289|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
32816290|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
32816291|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
32816292|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
32816293|NCT05688969|Active Comparator|Early Biopsy|"We will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: we will not be assigning volunteers to a specific osteoporosis therapy, though we will randomize volunteers to either the early or late second biopsy."
32816294|NCT05688969|Active Comparator|Late Biopsy|"We will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: we will not be assigning volunteers to a specific osteoporosis therapy, though we will randomize volunteers to either the early or late second biopsy."
32816295|NCT05688813|Experimental|Caudal block group|An echogenic block needle (22 Gauge 50 mm) was then advanced into the sacral canal through the sacrococcygeal membrane while a longitudinal position was used, continuing with the in-plane technique. After ensuring that there is no blood or cerebrospinal fluid with aspiration, 0.5 ml/kg 0.25% bupivacaine was administered while observing caudal epidural space dilation or turbulent flow with Doppler.
32816296|NCT05688813|Experimental|Sacral erector spinae block|Following antiseptic preparation of block site linear ultrasound probe was placed longitudinally to midline just above the sacrum. After the median sacral crests and erector spinae were identified, a 22G, 50 mm block needle was advanced from the cranial to the caudal direction until it touched the top of the 4th median sacral crest with the in-plane technique. After hydrodissection was achieved with 1 ml of saline, 0.5 ml/kg of 0.25% bupivacaine was administered after negative aspiration.
32816297|NCT03425643|Experimental|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, IV; given on cycle day 1]."
32900918|NCT05299008||Infants with diagnosis of tracheobronchomalacia treated with bethanechol|Infants with a diagnosis of tracheobronchomalacia by dynamic computed tomography and showing > 50% cross-sectional diameter collapse at 40 to 60 post menstrual age
32816298|NCT03425643|Placebo Comparator|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1] in combination with platinum doublet NAC, consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1]."
32816299|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
32816300|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
32816301|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
32816302|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
32816303|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
32816304|NCT05688657|Experimental|Monthly Replacement Toric Silicone Hydrogel Contact Lens A|Subjects will wear Monthly Replacement Toric Silicone Hydrogel Contact Lens A for the first period of 15 minutes and Daily Disposable Toric Silicone Hydrogel Contact Lens B for the second period of 15 minutes.
32816305|NCT05688657|Active Comparator|Daily Disposable Toric Silicone Hydrogel Contact Lens B|Subjects will wear Daily Disposable Toric Silicone Hydrogel Contact Lens B for the second period of 15 minutes.
32816306|NCT05688579|Experimental|Spironolactone|Participants will treat with spironolactone (dose 20-40mg/ day) in addition to the original antihypertensive drugs for 48 months.
32816307|NCT05688579|Active Comparator|Finerenone|Participants will treat with finerenone (dose 10-20mg/ day) in addition to the original antihypertensive drugs for 48 months.
32816308|NCT05688579|Placebo Comparator|Blank Control|Participants will be given a placebo(dose 20-40mg/ day) in addition to the original antihypertensive drugs for 48 months.
32816309|NCT04401657|Experimental|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
32816310|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
32816311|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
32816312|NCT04401501|Experimental|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
32816313|NCT04401501|Active Comparator|Exercise Group|Only exercises for cervicogenic headache
32816314|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
32816315|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
32816316|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
32816317|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
32816318|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
32816319|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
32816320|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
32816321|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
32816322|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
32816323|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
32816324|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
32816325|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
32816326|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
32816327|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
32816328|NCT05685537||Levosimendan - Interventional|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have received Levosimendan preoperatively
32816329|NCT05685537||Non Levosimendan - Control|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have not received Levosimendan preoperatively
32816330|NCT04279509|Experimental|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
32816331|NCT04401189||Breast cancer patients|
32816332|NCT04401189||Healthy controls|
32816333|NCT04353622|Active Comparator|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
32816334|NCT04353622|Active Comparator|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
32816335|NCT05685459|Experimental|Intervention|The students involved in the intervention group were divided into subgroups, and the simulation was carried out using standardized patients. Each subgroup consisted of two students. Students were asked to practice supine and lateral recumbent positions in each scenario.
32816336|NCT05685459|No Intervention|Control|The students in the control group were divided into subgroups and practised the supine position and the lateral recumbent position with a high-fidelity manikin. Each subgroup consisted of two students. The applications lasted 5-10 minutes for each group, and after the applications, the debriefing phase was conducted, which lasted 20 minutes.
32816337|NCT04400721|No Intervention|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
32816338|NCT04400721|Active Comparator|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin [Ropivacaine])
32816339|NCT04400721|Active Comparator|IC block arm|3 ml of 0.5% solution of Naropin [Ropivacaine] per intercostal space, up to a maximum of 30ml
32816340|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
32816341|NCT05688423|Experimental|SIRI Team|"The study intervention (SIRI Team) consists of a hospital-based multidisciplinary (ID/SUD consult) team that will provide intensive, integrated care for participants' ID and SUD both during the hospital stay and post-discharge for up to four months post-randomization. The SIRI Team will provide low barrier access to medications and harm reduction services for SUD; streamline ID/SUD treatment; provide longitudinal care with familiar providers; leverage different areas of expertise between physicians, advance practice providers, and patient navigators; and create patient-centered treatment plans, tailored to the individual, and informed by each patient's social circumstances, substance use, and personal goals/desires."
32816342|NCT05688423|Active Comparator|Treatment as Usual|Treatment as Usual (TAU) will consist of the current healthcare landscape at each participating hospital site.
32816343|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
32816344|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
32816345|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
32816346|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
32816347|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
32816348|NCT04353700|Active Comparator|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
32816349|NCT04353700|No Intervention|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
33317505|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
32816350|NCT04353466|Experimental|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
32816351|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
32816352|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
32816353|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
32816354|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
32816355|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
32816356|NCT03387579|Experimental|Smoflipid 20%|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
33317506|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
32816357|NCT03387579|Experimental|Intralipid 20% Reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
32816358|NCT03387579|Other|Intralipid 20% Historic|Patients who retrospectively received soy-based lipid (Intralipid) at standard dosing of 2-3 g/kg/day were eligible for inclusion. Patients in this group were matched to prospective patients based on diagnosis, gestational age, and length of lipid therapy.
32816359|NCT01012336|Experimental|Aprepitant|
32816360|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
32816361|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
32816362|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
32816363|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
32816364|NCT05688345|Active Comparator|Remimazolam|Maintenance doses of remimazolam is administered for sedation
32816365|NCT05688345|Active Comparator|Propofol|Propofol is administered for sedation through target-controlled infusion
32816366|NCT05688345|Active Comparator|Dexmedetomidine|Loading and maintenance doses of dexmedetomidine are administered for sedation
32816367|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
32816368|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
32816369|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816370|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816371|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816372|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816373|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816374|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
32816375|NCT04353232||DANCAVAS I and II trials|Enrolment started September 2014 and ended in February 2019. Approx. 24 000 were invited, and approx. 15 000 were examined.
32816376|NCT04353232||VIVA screening trial|Enrolment started October 2008 and ended January 2011. In all, 18 749 men were screened.
32816377|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
32816378|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
33101670|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
33101671|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
33101672|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
32816379|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
32816380|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
32816381|NCT04348461|No Intervention|Control|Patients receiving regular respiratory distress treatment
32816382|NCT04348461|Experimental|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
32816383|NCT04348617|Experimental|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
32816384|NCT04348617|Experimental|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
32816385|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
32816386|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
32816387|NCT04761237|Experimental|Group 1|(H-P) : Pcv-aCO2≥6mmHg between T base and T 0h.;
32816388|NCT04761237|Experimental|Group 2|(L-P) : Pcv-aco2< 6mmHg at T base and≥6mmHg at T 0h
32816389|NCT03018262||Healthy Volunteers - Sub-study 1|Healthy Volunteers
32816390|NCT03018262||Healthy Volunteers - Sub-study 2|Healthy Volunteers
32816391|NCT03018262||Healthy Volunteers - Sub-study 3|Healthy Volunteers
32816392|NCT05684835||Vagus nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the vagus nerve
32816393|NCT05684835||Sympathetic nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the sympathetic nerve
32816394|NCT05684835||Cervical spinal nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the cervical spinal nerve
32816395|NCT05688267|Experimental|Experimental group|The continuous mobility training adopted grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists. The five stages are half-lying on the bed, sitting at the bedside, sitting on the chair, standing and marching on spot.
32816396|NCT05688267|Placebo Comparator|Control group|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training. The physicians assessed the participants and appropriately adjusted the settings of the mechanical ventilation modules to gradually reduce the participants' dependence on mechanical ventilation. Hand bicycle training was conducted by nurse practitioners once a day. The participants' bedhead was raised, and the participants held the cycle ergometer with both hands once they could tolerate upright positions for 15-20 minutes. Training intensity was targeted at the level of symptom limitation, on the basis of a modified Borg scale rating of 3-5. Intermittent and short-term periods of rest were allowed for participants to achieve the goal of a total of 15-20 minutes exercise session.
32816397|NCT04401345|Experimental|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
32816398|NCT04401345|Placebo Comparator|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
32816399|NCT00968344|Experimental|Leucine|3-4 g Leucine added to daily meals during bed rest
32816400|NCT00968344|Placebo Comparator|Placebo|3-4 g Alanine added to daily meals during bed rest
32816401|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
32816402|NCT05684679|Experimental|IS Group|"• Patients were instructed to utilize an incentive spirometer in the sitting or half lying position as taught preoperatively.~3 to 5 consecutive breath with the spirometer were interspersed between period of quite breathing.~Duration 10-15 minutes/session."
32816403|NCT05684679|Experimental|DBE Group|"• Patients were advised to do diaphragmatic breathing exercise in the sitting or half lying position as taught preoperatively.~3 to 5 consecutive deep breath were interspersed between period of quite breathing.~Duration 10-15 minutes/session."
32816404|NCT04761003|Active Comparator|Group I (Cryobiopsy group):|patients where patients will be subjected to thoracoscopic cryobiopsy.
32816405|NCT04761003|Active Comparator|Group II (Forceps group)|patients where patients will be subjected to thoracoscopic forceps biopsy.
32816406|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
32816407|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
32816408|NCT05684055|Active Comparator|Intervention villages|"CC-VHWs provide screening, diagnosis and first-line treatment for aHT at community-level. They are equipped with a tablet where the ComBaCaL app guides them to provide first-line antihypertensive SPCs to individuals found to have aHT. In addition, the CC- VHW offers lifestyle counselling and -for participants at high CVD risk- lipid-lowering treatment. Trained, supervised and mentored by chronic care nurses (CC nurses) and guided by the ComBaCaL app they follow-up persons with aHT to monitor adherence, life-style changes, treatment response and side-effects.~TwiC 1: enrols individuals with uncomplicated aHT with baseline BP values above treatment targets.~TwiC 2: enrols individuals with uncomplicated pharmacologically controlled aHT.~In case of complicated disease (i.e. if treatment targets are not reached under first-line SPC) or presence of clinical alarm signs or symptoms, participants will be referred to the closest health facility for further investigation."
32816409|NCT05684055|Active Comparator|Control villages|"Control villages will follow the standard of care in the ComBaCaL cohort study. CC-VHWs will also receive tablets with the ComBaCaL app installed. They are trained, supervised and equipped to screen and diagnose aHT with subsequent referral to facility-based follow-up and care. In control villages the ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/ provision of antihypertensive or lipid-lowering medication.~TwiC 1: enrols individuals with uncomplicated aHT with baseline BP values above treatment targets.~TwiC 2: enrols individuals with uncomplicated pharmacologically controlled aHT.~In case of complicated hypertension or presence of clinical alarm signs or symptoms, participants will be immediately referred to the closest health facility for further investigation."
32816410|NCT05688033|Experimental|experimental arm|peritoneal space V15<850cc，pelvic bone V10<80% and normal dosimetric limitation
32816411|NCT05688033|No Intervention|control arm|normal dosimetric limitation
32816412|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
32816413|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
32816414|NCT05683353||Patients with SARS-CoV-2 positive hematologic tumors|Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems.
32816415|NCT05683353||People with SARS-CoV-2 positive without underlying diseases|People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems.
32816416|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
33101673|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
33101674|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
33405084|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
33405085|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
33405086|NCT05762406|Experimental|Wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask
33405087|NCT05762406|No Intervention|Not wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities in basal conditions
33405088|NCT05761704|Experimental|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
33405089|NCT05761704|Experimental|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
33405090|NCT05205798|Experimental|Participants|Food consumption using plates with a diameter of 23 cm first then using plates with a diameter of 31 cm
33405091|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
33405092|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
33405093|NCT05205642|Experimental|Patients recovering from COVID-19|Pediatric and adult patients recovering from COVID-19 with or without complaints.
33405094|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
33405095|NCT04656678|Experimental|DynaCAD / UroNAV|This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
33405096|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
33405097|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
33405098|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
33405099|NCT05762328|No Intervention|Standard of care|Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
33405100|NCT05762328|Other|Interventional|Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
33405101|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
33405102|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
33405103|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
33405104|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
33405105|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
33405106|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
33405107|NCT04629378|Active Comparator|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
33405108|NCT04615806|Experimental|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
33405109|NCT04615806|No Intervention|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
33101675|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
33101676|NCT02934867|Experimental|CONTARM|Protocol phone advice
33101677|NCT02934867|Other|CONTHAB|Usual phone advice
33101678|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
33101679|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
33101680|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
32816417|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
32816418|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
32816419|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
32816420|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
32816421|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
32816422|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
32816423|NCT05687955|Experimental|Hip Exercise Program|A 12-week strength exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance.
32816424|NCT05680623||study population|"Subgroups based on the ISGPS diagnostic criteria and the grading system of PPAP:~Without PPAP or POH: Patients without POH nor imaging consistent with AP.~POH: sustained postoperative serum hyperamylasemia neither clinically relevant nor consistent imaging~PPAP: requiring the fulfilment of three criteria:~POH: sustained serum hyperamylasemia greater than the institutional upper limit of normal persisting on postoperative days 1 and 2;~macroscopic radiologic features of AP~clinically relevant complications. PPAP severity will be classified into grades B and C, with progressive clinical deterioration."
32816425|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330~IPs for Period 2: CKD-330 + D086"
32816426|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: CKD-330"
32816427|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: D086~IPs for Period 2: CKD-330 + D086"
32816428|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: D086"
32816429|NCT05687643||Diabetic Foot Ulcer (DFU) group|"Inclusion criteria:~Age >18~A diagnosis of diabetes mellitus~A diagnosis of diabetic peripheral neuropathy~Recently healed plantar ulcer (within the last 3 months)"
32816430|NCT05687643||Low risk group|"Inclusion criteria:~Age >18~A diagnosis of diabetes mellitus~Low risk for DFU according to the NG19 guidelines (no risk factors for ulceration except callus alone)"
32816431|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
32816432|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
32816433|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
32816434|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
32816435|NCT05687565|Placebo Comparator|Control group|Dietary supplementation
32816436|NCT05687565|Experimental|Experimental group 1|1.5 grams once daily during 48 weeks
32816437|NCT05687565|Experimental|Experimental group 2|3 grams once daily during 48 weeks
32816438|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
32816439|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
32816440|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
32816441|NCT03083223||lung disease|Patients with lung disease
32816442|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
33101681|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
33405110|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
32816443|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
32816444|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
32816445|NCT05687409|Experimental|A 10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group|"10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group:Adults with histologically confirmed stable cirrhosis and BMI < 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
32816446|NCT05687409|Placebo Comparator|A 10-g packet of glucose oral solution and three capsules of starch+entecavir group|"A 10-g packet of glucose oral solution and three capsules of starch+entecavir group:Adults with histologically confirmed stable cirrhosis and BMI < 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
32816447|NCT01016938||Group I|This is a pilot study and there is only one group.
32816448|NCT05679063|Experimental|Therapeutic Exercise and Pain Neurophysiology Education|"Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, and prevent risk factors for solid and optimized overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and decrease the threatening meaning of pain."
32816449|NCT05679063|Sham Comparator|Sham Comparator|Talks about healthy habits
33405111|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
33405112|NCT04594980|Other|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
32816452|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
32816453|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
32816454|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
32816455|NCT05678673|Experimental|XL092 + Nivolumab|Subjects with advanced or metastatic nccRCC will receive XL092 + nivolumab
32816456|NCT05678673|Active Comparator|Sunitinib Malate|Subjects with advanced or metastatic nccRCC will receive an active comparator of sunitinib
32816457|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
32816458|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
32816459|NCT05687331||Patients with hemarthrosis|10 patients that sustained a knee trauma and have hemarthrosis during knee arthrocentesis (red color of the synovial fluid)
32816460|NCT05687331||Patients without hemarthrosis|10 patients that sustained a knee trauma and do not have hemarthrosis during knee arthrocentesis (yellow color of the synovial fluid)
32816461|NCT05678439|Experimental|sesame extract|"Dietary supplement: sesame extract (contains sesamin 37-56mg per capsule)~This group will be given supplements for 8 weeks."
32816462|NCT05678439|Placebo Comparator|placebo|Placebo treatment ( identical capsules containing Lactose, Silica, Magnesium Stearate, Gelatin)
32816463|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
32830615|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
32830616|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
32900919|NCT05258526|Experimental|Home-based exercise program|This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
32900920|NCT05258292||Women with type 1 diabetes|
33405113|NCT04594980|Other|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
33405114|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
32816464|NCT05677815||patients with COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
32816465|NCT05677815||patients without COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
33317507|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
33317508|NCT05355584|Active Comparator|10-minute Cryotherapy Application|A cold application will be made on the shoulder for 10 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
33317509|NCT05355584|Active Comparator|15-minute Cryotherapy Application|A cold application will be made on the shoulder for 15 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
33317510|NCT05355584|Active Comparator|20-minute Cryotherapy Application|A cold application will be made on the shoulder for 20 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
32816466|NCT05672823|Experimental|Minimally invasive, upper extremity|Radial artery for pigtail catheter and pacing over the Left Ventricular (LV) stiff wire OR radial artery for pigtail catheter and brachial vein for temporary pacemaker when not pacing over the LV stiff wire.
32816467|NCT05672823|Active Comparator|Lower extremity|Femoral artery for pigtail catheter and pacing over the LV stiff wire OR femoral artery for pigtail catheter and femoral vein for temporary pacemaker when not pacing over the LV stiff wire.
32816468|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
32816469|NCT03082443|Experimental|Therapeutic group|
32816470|NCT03082443|No Intervention|Control group|
32816475|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
32816476|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
32816477|NCT05687253|Experimental|BX1000 0.15 mg/kg|BX1000 0.15 mg/kg IV Bolus
32816478|NCT05687253|Experimental|BX1000 0.25 mg/kg|BX1000 0.25 mg/kg IV Bolus
32816479|NCT05687253|Experimental|BX1000 0.35 mg/kg|BX1000 0.35 mg/kg IV Bolus
32816480|NCT05687253|Active Comparator|Rocuronium 0.6 mg/kg|Rocuronium bromide 0.6 mg/kg IV Bolus
32816481|NCT05687175||Neuropathic pain|Questionnaire administration and socio-demographic data collection
32816482|NCT05687175||Nociceptive pain|Questionnaire administration and socio-demographic data collection
32816483|NCT04746651|Experimental|Guided Self Help|"Four guided self-help booklets were used; Why do I feel so bad? covered formulation/understanding feelings, I can't be bothered doing anything centred on activity scheduling, Why does everything always go wrong? focused on thought-challenging, and How to fix almost everything incorporated problem solving. Linked worksheets were adapted following feedback from Prison Officers."
32816484|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
32816485|NCT05687097||Individuals without sleep apnea after spinal cord injury|No significant sleep apnea is defined as an apnea-hypopnea index (AHI) < 5 events per hour of sleep
32816486|NCT05687097||Individuals with mild sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep, but an AHI <15 events.
32816487|NCT05687097||Individuals with moderate sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep but an AHI <15 events.
32816488|NCT05687097||Individuals with severe sleep apnea after spinal cord injury|Severe sleep apnea is defined as an apnea-hypopnea index (AHI) > 30 events per hour of sleep.
32816489|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
32816490|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
32816491|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
32816492|NCT00417664||Dexmedetomidine|
32816493|NCT00417664||Propofol|
32816494|NCT00417664||Midazolam|
32816495|NCT05687019|Experimental|Patient undergoing prostate enucleation by Holmium Laser|It is based on a pulsed laser at a wavelength of 2140 nm, which penetrates the tissues over a very short distance. The prostate tissue must therefore be in contact with the laser fiber to be cut or vaporized, and hemostasis will take place nearby. The procedure lasts approximately one hour.
32816496|NCT03400059|Experimental|Active Treatment|
32816497|NCT03400059|Sham Comparator|Sham Treatment|
32816498|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
32816499|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
32816500|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
32816501|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
32816502|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
32816503|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
32955771|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
32955772|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
33101682|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
33317511|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
32816504|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
32816505|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
32816506|NCT03082365||pre-dialysis|
32816507|NCT03082365||end stage renal disease|
32816508|NCT05657613|Experimental|CYP450 Cocktail and Transporter Substrates with Pacritinib|This is the first part of the study which is an open-label, single-center, 1-way DDI study designed to assess the effect of pacritinib 200 mg BID at steady state on the systemic exposure of a cocktail of cytochrome P450 (caffeine, midazolam, and omeprazole) and transporter substrates (digoxin, rosuvastatin, and metformin) in 18 healthy male subjects.
32816509|NCT05657613|Experimental|CYP450 3A4 inducer (Bosentan) with Pacritinib|The second part of the study comprises of 2 arms. This is the first arm Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of bosentan 125 mg BID (approximately 12 hours apart) All the doses will be administered with approximately 240 mL of water.
32816510|NCT05657613|Experimental|CYP450 3A4 inhibitor (Fluconazole) with Pacritinib|"This is the second arm of Part 2 of the study:~Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of fluconazole 200 mg QD"
32816511|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
32816512|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
32816513|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
32816514|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
32816515|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
32816516|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
32816517|NCT05686941||Healthy Volunteers|Employees of the Host organisation in the Respiratory Team who meet the inclusion criteria
32816518|NCT05686941||Patients with suspected Inducible laryngeal Obstruction (ILO)|Patients referred to a Tertiary referral centre who are suspected of having ILO
32816519|NCT03358563|Experimental|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
32816520|NCT03358563|Experimental|DegarelixSC + bicalutamide + docetaxel + Ferumoxytol enhanced MRI|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
32816521|NCT05634837|Experimental|Decision Support System counseling|In the Intervention group (CDSS group), women receive a personalised daily dietary plan based on the Mediterranean diet and according to participant's needs, habits and preferences.
32816522|NCT05634837|Other|Standard nutritional counseling|Participants of the Control group did not have access to CDSS and only received general lifestyle guidelines.
32816523|NCT01018420|Experimental|Colchicine|
33317512|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
33317513|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
33317514|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
33405115|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
32816524|NCT01018420|Active Comparator|Moxifloxacin|
32816525|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
32816526|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
33317515|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
32816527|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
32816528|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
32816529|NCT05686785||Chronic viral hepatitis|
32816530|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
32816531|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
33405116|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
32816532|NCT03082131|Experimental|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
32816533|NCT03082131|Experimental|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
32816534|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
32816535|NCT00974350|Experimental|Group 1: SABER-Bupivacaine|2.5 mL SABER-Bupivacaine/Once
32816536|NCT00974350|Experimental|Group 2: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
32816537|NCT00974350|Placebo Comparator|Group 3: SABER-Placebo|2.5 mL or 5.0 mL SABER-Placebo/Once
32816538|NCT05633901|Placebo Comparator|Standard of Care|Standard verbal counseling provided to patients by clinic nurse about post-operative expectations
32816539|NCT05633901|Active Comparator|Educational Video|An educational video to aid standard counseling packet on post-operative expectations
32816540|NCT05633511|Experimental|All Participants|Participants will receive the CTG procedure on one side and the PRF procedure on the other. Both are standard of care soft tissue grafting methods and a split mouth design is standard of care.
32816541|NCT05395702|Experimental|Drug: Interferon Gamma|Antibacterial therapy + IFN-G administered intramuscularly 100,000 IU once a day daily for 5 days
32816542|NCT05395702|No Intervention|Control: No intervention|Only antibacterial therapy
32816543|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
32816544|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
32816545|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
32816546|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
32816547|NCT01023178|Active Comparator|Estrace|17beta Estradiol
32816548|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
32816549|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
32816550|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
32816551|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
32816552|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
32816553|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
32816554|NCT05623995|Experimental|Treatment arm|Participants will receive PCSK9 inhibitors added to guideline recommended statin therapy.
32816555|NCT05623995|Active Comparator|Control arm|Patients will continue to taking guideline recommended statin therapy.
32816556|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.~The psychological intervention will consist of four sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly"
32816557|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
32816558|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
32816559|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
32816560|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
33405117|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
32816561|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
32816562|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
32816563|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
32816564|NCT04761471|Experimental|TI stimulation|Temporal interference (TI) stimulation is a type of low-intensity transcranial electrical stimulation with alternating current (tACS). In case of TI stimulation, 2 electric fields in kHz range are delivered to 4 electrodes, which are placed on the surface of the skull, to modulate neural oscillations.
32816565|NCT05395546|Experimental|dCBT-I treatment group|
33405118|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
32816566|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
32816567|NCT05623683|Active Comparator|Intermittent Walking|Intermittent walking on the treadmill
32816568|NCT05623683|Active Comparator|Continuous Walking|Continuous walking on the treadmill
32816569|NCT05620719|Active Comparator|Clinic-based Cognitive Behavioral Therapy (CCBT)|CCBT provides CBT for posttraumatic headache through 8 face-to-face, in-clinic sessions.
32816570|NCT05620719|Active Comparator|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|TCBT provides 8-sessions of CBT for posttraumatic headache using telemedicine technology rather than attending in-office sessions. Additionally, TCBT includes instructions for each session specific to the mechanics of a telehealth encounter (e.g., asking participant for name, location, and accessible phone number for location in case of technical failure or crisis). All TCBT participants must be enrolled at the MTF or VA from which they were recruited, and the treatment facility will be notified that they are receiving TCBT in case a crisis arises and needs to be managed by the site.
32816571|NCT05620719|Active Comparator|Treatment As Usual|Participants will continue to engage in clinical care as usual for 8 weeks. Research staff will call the TAU participants weekly to assess for adverse events. Research staff at each site will be trained on standardized assessment of usual care activities using forms adapted from our single-site trial.
32816572|NCT05395234|Experimental|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura & McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction & flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
32816573|NCT03371667|Experimental|Methotrexate|"5mg/Kg/day methotrexate for 4 weeks then 3 mg/m2 every two weeks for 12 weeks~2mg/kg/day PO prednisone prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each MTX administration"
32816574|NCT03371667|Placebo Comparator|Placebo|"Once a week placebo for 4 weeks then every two weeks for 12 weeks~2 mg/kg/day PO prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each placebo administration"
32816575|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
32816576|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
32816577|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
32816578|NCT05613153|Experimental|Peppermint Oil|Peppermint oil will be provided free of charge to participants under the trademark Pepogest produced by the maker Nature's Way® (dosage 0.2 mL, 181 mg peppermint oil).
32816579|NCT04279041|Experimental|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
32816580|NCT04279041|Active Comparator|manual K-files|manual K-files
32816581|NCT05686473|Experimental|Patient group|Single arm study. The family with child with FASD will act as its own control in the period before intervention starts.
32816582|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
32816583|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
32816584|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
32816585|NCT05686395|Active Comparator|group 1 Ultrasound-guided Interscalene Block group|In this group, ultrasound-guided ISB will be done using 10 ml of bupivacaine 0.25%.
32816586|NCT05686395|Active Comparator|group 2 Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|, ultrasound-guided SHAC block will be done using 10 ml of bupivacaine 0.25% injected in the interfacial plane between deltoid and subscapular muscle and 10 ml of bupivacaine 0.25% injected in the pericapsular space. Ultrasound-guided SSN block will be done using 10 ml of bupivacaine 0.25% injected at sub omohyoid space.
32816587|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
32816588|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
32816589|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
32816590|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
32816591|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
32816592|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
32816593|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
32816594|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
32816595|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
32816596|NCT05609487|Other|Control group|"Step in control group This stepped wedge study does not use two parallel treatment arms. The stepped wedge design allows each center to be its own control group and then, after implementation of the practice by the research team, to become a intervention group.~The characteristics of these two phases are detailed below. Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period."
32816597|NCT05609487|Other|Protection plan group|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
32816598|NCT04278963|Experimental|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
32816599|NCT04278963|Placebo Comparator|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
32816600|NCT04278963|Active Comparator|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
32816601|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
32816602|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
32816603|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
32816604|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
32816605|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
32816606|NCT05686239|Experimental|RL-007 20 mg|oral dosing three times per day (TID)
32816607|NCT05686239|Experimental|RL-007 40 mg|oral dosing three times per day (TID)
32816608|NCT05686239|Placebo Comparator|Placebo|oral dosing three times per day (TID)
32816609|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
32816610|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
32816611|NCT05686161|Experimental|A single 25 μg dose mRNA vaccine SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
32816612|NCT05686161|Active Comparator|A third dose of COVID-19 Inactivated vaccine|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration: injection Intramuscular
32816613|NCT05686161|Active Comparator|A single 30μg dose mRNA vaccine Pfizer(BNT162b2)|Type :mRNA COVID -19 vaccine - Pfizer(BNT162b2) Dose :Formulation mRNA Unit Dose Strength(s) :30ug; Dosage Level(s) :0.3ml; Route of Administration: injection Intramuscular
32816614|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
32816615|NCT03368313|No Intervention|Control arm|No compression
32816616|NCT05686083|Active Comparator|12.5 g of C6 ketone di-ester|Low dose of C6 ketone di-ester.
32816617|NCT05686083|Active Comparator|12.5 g of novel ketone di-ester|Low dose of novel ketone di-ester.
32816618|NCT05686083|Active Comparator|25 g of novel ketone di-ester|High dose of novel ketone di-ester.
32816619|NCT05686005|No Intervention|Control|No intervention
32816620|NCT05686005|Active Comparator|Oral tranexamic|The participants will receive 4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
32816621|NCT05686005|Active Comparator|Intravenous tranexamic|The participants will receive 15 mg/kg in a 20ml syringe slowly tranexamic acid during induction.
32816622|NCT05685927||Non-obese participants with dysregulated type 1 diabetes|
32816623|NCT05685927||Non-obese participants with dysregulated type 2 diabetes|
32816624|NCT05685927||Obese participants with type 2 diabetes|
32816625|NCT05685927||Obese participants without type 2 diabetes|
32816626|NCT05685927||Healthy control participants|
32816627|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
32816628|NCT04279743|Experimental|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
32816629|NCT04279743|Experimental|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
32816630|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
32816631|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
32738430|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
33101683|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
33405119|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
33405120|NCT03651440|Experimental|PNF training|PNF training exercises
32738431|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
32955773|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
33405121|NCT03651440|Experimental|physical therapy|HP,TENS US
32738432|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
32738433|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
32738434|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
32738435|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
32738436|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
32738437|NCT03091569|Active Comparator|Vitamin K|
32738438|NCT03091569|Placebo Comparator|Control|
32738439|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
32738440|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
32738441|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
32738442|NCT05005767|Placebo Comparator|Placebo group|ten patients with sites suffering from mild chronic periodontitis sites will be treated with scaling and root planing (SRP) only
32738443|NCT05005767|Active Comparator|test group|Ten patients with sites suffering from mild chronic periodontitis. sites will be treated with scaling and root planing (SRP) and subgingival application of Frankincense extract gel
32738444|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
32738445|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
32738446|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
32738447|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
32738448|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
32738449|NCT04948749|Experimental|Drug-eluting stent implantation with aggressive medical treatment group|DES implantation (The Maurora ® Sirolimus Eluting Stent System) combined with aggressive medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 6 months); management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
32738450|NCT04948749|Active Comparator|Standard medical treatment group|Standard medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 3 months after enrolment), management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
32738451|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
32738452|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
32738453|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
32738454|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
32738455|NCT05019807|Other|WhatsApp group|The arm receives education information about diabetes and its complications, diet and physical activities through WhatsApp.
32738456|NCT05019807|Other|Control group|The arm does not received any education information.
32738457|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
32738458|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
32738459|NCT05012553|No Intervention|no education about self and peer assesment|Stoma care skills of the group who did not receive self- and peer-assessment training will be evaluated.
32816632|NCT05685849||Trial group|A total of 200 pregnant women in the first trimester (gestational age of 6-13 weeks+6 days), who had cardiovascular disease and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 10 centers, with 20 cases in each center.
32816633|NCT05471349|Active Comparator|Hope message|Participants will view a hope-based video message and flyer.
32816634|NCT05471349|Active Comparator|Fear message|Participants will view a fear-based video message and flyer.
32816635|NCT05471349|Placebo Comparator|Control message|Participants will view a water advertisement video and flyer.
32816636|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
32816637|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
32816638|NCT05457933|Experimental|Dapagliflozin group|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
32816639|NCT05457933|Active Comparator|Basal-bolus group|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
32816640|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
32816641|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
32816642|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
32816643|NCT03321981|Experimental|Cohort 1 doublet|
32816644|NCT03321981|Experimental|Cohort 1 triplet|
32816645|NCT03321981|Experimental|Cohort 2|
32816646|NCT05450133||R-ax-Spa|Radiographic axial spondyloarthritis
32816647|NCT05450133||nR-ax-Spa|Non-radiographic axial spondyloarthritis
32816648|NCT05450133||Control|Healthy Controls
32816649|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
32816650|NCT05685693|Active Comparator|Conventional TKA|Conventional TKA, with no patient-specific instrumentation or robotic assistance
32816651|NCT05685693|Experimental|Robotic-assisted TKA|ROSA Knee System assisted TKA
32816652|NCT05685615|Experimental|BV100 (200 mg) plus Polymyxin B|BV100 (200 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
32816653|NCT05685615|Experimental|BV100 (300 mg) plus Polymyxin B|BV100 (300 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
32816654|NCT05685615|Active Comparator|Best Available Therapy|Best Available Antibiotic Therapy to Treat CRAB
32816655|NCT05685615|Experimental|Part B: BV100 plus BAT|BV100 (300 mg q12h) infused over 2 hours plus Best Avaialble Therapy to Treat Colistin resistant CRAB
32816656|NCT01027468|Experimental|group 1|bevacizumab intravitreal injection
32816657|NCT05237349|Experimental|envafolimab plus chemotherapy|Envafolimab:300mg,sc,d1,Q3W; Chemotherapy:SOX(Oxaliplatin，130mg/m2, iv,d1,Q3W + S-1，40mg/m2, op,bid,d1-14,Q3W).
32816658|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
32816659|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
32816660|NCT05102799||Anoctaminopathies|Anoctaminopathies including Limb Girdle Muscular Dystrophy R12, Miyoshi distal Muscular Dystrophy type 3 and asymptomatic hyperCKemia
32816661|NCT05395156|Experimental|sham acupoint|Control group: (placebo group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on sham acupoint (the acupoint selection site was 1 inch away from the acupoint selection in the study group) daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months
32816662|NCT05395156|Experimental|Electroacupuncture|Study group: (Electroacupuncture group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months.
32816663|NCT03320343||Patients recruited for pelvic imaging examination|
32816664|NCT05395000|Experimental|"Parents group"|Parent or primary caregiver of a child or adolescent (<18 years old) diagnosed with type 1 diabetes.
32816665|NCT05395000|Experimental|"School workers group"|"Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, facilitators, teacher candidates, etc.). This individual must not meet the criteria for the parent group."
32816666|NCT04278807|Experimental|PENG-group|Ultrasound-guided PENG-block - 30 patients
32816667|NCT04278807|Experimental|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
32816668|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
32816669|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
32816670|NCT03344757|Experimental|C-CBSM|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
32816671|NCT03344757|Active Comparator|CBSM|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
32900921|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
32900922|NCT05297760|Active Comparator|Polvac|Polvac Grass+Rye
32816672|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
32816673|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
32816674|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32816675|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32816676|NCT04400565|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
32816677|NCT04400565|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
32816678|NCT05394454|Experimental|Experimental Group|"Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~Genital area will be cleaned.~Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~After the maneuvers are started, the infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
32816679|NCT05394454|No Intervention|Control Group|"Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~Genital area will be cleaned.~Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~Bladder stimulation technique will not be applied.~Infants will be observed for 3 minutes. Infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
32816680|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
32816681|NCT03274401|No Intervention|Control Arm|Standard of care
32816682|NCT05086107|Experimental|Group 1|subjects with mild renal impairment (eGFR: 60 to 89 mL/min)
32816683|NCT05086107|Experimental|Group 2|subjects with moderate renal impairment (eGFRr: 30 to 59 mL/min)
32816684|NCT05086107|Experimental|Group 3|subjects with severe renal impairment (eGFR: 15-29 mL/min)
32816685|NCT05086107|Experimental|Group 4|subjects with normal renal function (eGFR: ≥ 90 mL/min)
32816686|NCT05086107|Experimental|Group 5|subjects with end stage renal disease (ESRD) eGFR: <15 mL/min requiring dialysis (with BV100 dosing and PK during the dialysis-free interval)
32816687|NCT05086107|Experimental|Group 6|subjects with ESRD (eGFRr: <15 mL/min) requiring dialysis (with BV100 dosing and PK on the day of dialysis)
32816688|NCT05085015|Experimental|Functional Exercise Training Group|A program including stretching, aerobics, strengthening and balance training will be implemented under the supervision of a physiotherapist with the instructions of the physiotherapist.They will apply a total of 24 sessions of exercise program for 60-80 minutes, 3 days a week, 8 weeks.
32816689|NCT05085015|Experimental|Home Exercise Training Group|Individuals in the home exercise training program will be asked to follow the program in accordance with the home exercise brochure given for 8 weeks, 3 days a week. The program will include stretching, aerobics, strengthening and balance training. The home exercise program will consist of a brochure prepared from a program similar to a functional exercise program.
32816690|NCT05075109|Experimental|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
32816691|NCT05075109|Experimental|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
32816692|NCT05075109|Active Comparator|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
32816693|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
32816694|NCT03317535|Other|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
32816695|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
32816696|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
32816697|NCT05552235|Experimental|Orthosis group|Use of Elbow Soft 300 device during sport practice
32816698|NCT05552235|Other|Control group|No medical device used during sport practice
32816699|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
32816700|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
32816701|NCT05066997|Experimental|Active treatment arm: OCS-01|"In Stage 1: Active treatment arm: OCS-01 - dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~In Stage 2, subjects will receive the dosing regimen determined from Stage 1 for OCS-01 for 52 weeks."
32816702|NCT05066997|Placebo Comparator|Vehicle placebo arm|"In stage 1: Vehicle: dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~In Stage 2, subjects will receive the matched dosing regimen for Vehicle for 52 weeks."
32816703|NCT05345535|Experimental|Study group|Participants of study group will perform 45 minutes of trampoline exercises. Evaluations are going to be done immediately before and after trampoline session.
32816704|NCT05345535|Experimental|Control group|Participants of control group will perform 45 minutes of walking. Evaluations are going to be done immediately before and after walking session.
32816705|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
32816706|NCT05025033|Experimental|PD-1 antibody combined with apatinib and chemotherapy|PD-1 antibody: 200mg intravenous drip every 3 weeks; Apatinib: 250mg/day; Chemotherapy: Irinotecan: 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel: 150mg/m2, intravenous drip once every 3 weeks.
32816707|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
32816708|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
32816709|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
32816710|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
32816711|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
32816712|NCT00980746|Placebo Comparator|Placebo|Placebo
32816713|NCT05424783|Experimental|Genomic Prostate Score assay and multi-parametric MRI of the prostate|Men with newly diagnosed NCCN very low to favorable intermediate risk prostate cancer will be enrolled at their post biopsy urologist visit. Once enrolled, participants will have their prostate tissue sent off for their Genomic Prostate Score assay and men will undergo a prostate MRI to evaluate for potentially missed clinically significant prostate cancer. In a subsequent urologist visit, participants will choose their treatment choice. Men who choose active surveillance for their primary treatment choice will be monitored per clinical routine by PSA, digital rectal exam, and active surveillance prostate biopsy in 12-18 months. After month 6, men will be followed through their electronic medical records system to track adherence to their 12-18 month active surveillance prostate biopsy.
32816714|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
32816715|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
32816716|NCT05201157|Active Comparator|Acupressure group|Acupressure will be applied to ST36, LI4 and SP6 points.The Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled by women once on the post-op 0th day and once on the post-op 2nd day, a total of 2 times.
32816717|NCT05201157|Active Comparator|Control Group|No application will be made to this group, and the Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled in 2 times in total, once on the post-op 0th day and once on the post-op 2nd day.
32816718|NCT00981214|Experimental|EUR-1008 (APT-1008)|
32816719|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
32816720|NCT03308877|Active Comparator|Standard Care (SC)|
32816721|NCT03308565|Experimental|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
32816722|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
32816723|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
32816724|NCT05415657|Experimental|Denosumab|Denosumab 60 mg were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
32816725|NCT05415657|Placebo Comparator|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
32816726|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
33405122|NCT03651440|Sham Comparator|control|NO APPLİCATİON
32816727|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
32816728|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
32816729|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
32816730|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
32816731|NCT05409807|Experimental|Classic Ultrasound Guided|Ultrasound guided interscalene nerve block
32816732|NCT05409807|Experimental|Smart Glasses Assisted|Ultrasound guided smart glasses assisted interscalene nerve block
32816733|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
32900923|NCT05297760|Placebo Comparator|Placebo|Saline
32900924|NCT05256264||Control group|Sevoflurane
32816734|NCT05404893||Fibromyalgia without gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with no abdominal pain, constipation, diarrhea, tenesmus, abdominal cramps
32816735|NCT05404893||Fibromyalgia with gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with abdominal pain and constipation and/or diarrhea and/or tenesmus and/or abdominal cramps
32816736|NCT05404893||Healthy controls|Healthy controls, no gastrointestinal symptoms
32816737|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
32816738|NCT05538585|Experimental|Part 1: Navocaftor with food|Participants will receive navocaftor administered with food
32816739|NCT05538585|Experimental|Part 1: Navocaftor without food|Participants will receive navocaftor administered without food
32816740|NCT05538585|Experimental|Part 2: Galicaftor with food|Participants will receive galicaftor administered with food
32816741|NCT05538585|Experimental|Part 2: Galicaftor without food|Participants will receive galicaftor administered without food
32816742|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
32816743|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
32816744|NCT05537571|Experimental|SLN360 Dose 1|SLN360 for subcutaneous injection
32816745|NCT05537571|Experimental|SLN360 Dose 2|SLN360 for subcutaneous injection
32816746|NCT05537571|Experimental|SLN360 Dose 3|SLN360 for subcutaneous injection
32816747|NCT05537571|Placebo Comparator|Placebo Dose 1|Sodium chloride for subcutaneous injection
32816748|NCT05537571|Placebo Comparator|Placebo Dose 2 and 3|Sodium chloride for subcutaneous injection
32816749|NCT05343195|Active Comparator|Control group|"Conventional physiotherapy was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program:~1-2 week: 20 min. of active exercise in lying position (e.g.: hip flexion, extension, abduction) with the goal to improve hip range of motions, strengthen muscles. Various equipment was used (slippery base, elastic bands, foam roller, gymnastic ball etc.). + gait training exercise within the bars (10 min);~3 week: 20 min. of active exercise in lying position + stationary bicycle / treadmill (10 min)."
32816750|NCT05343195|Experimental|Task oriented exercise group|"Task oriented exercise program was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program included:~1 week: active exercise in lying position (15 min) + task-oriented exercise (15 min);~2 week: active exercise in lying position (10 min) + task-oriented exercise (20 min);~3 week: stationary bicycle / treadmill (10 min) + task-oriented exercise (20 min).~Task oriented exercise included:~walking backwards, sideways, high kneels (on the instable bases);~walking with alternate speed (physiotherapist give the instruction when to walk faster / slower);~Sit and stand from the chair (standing up to reach for the ball held by the physiotherapist);~step onto the step (after stepping to reach the ball held by the physiotherapist);~walk with the obstacles (obstacle course);~Catch and throw the ball while standing on an unstable base."
32816751|NCT01899053|Experimental|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
32816752|NCT01899053|Experimental|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
32816753|NCT01899053|Experimental|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
32816754|NCT01899053|Experimental|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
32816755|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
32816756|NCT05396235|Experimental|MT-3921|Intravenous (IV)
32816757|NCT05396235|Placebo Comparator|Placebo|Intravenous (IV)
32816758|NCT05532423|Experimental|Metabolic Syndrome Older Adult|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
32816759|NCT05532423|Experimental|Metabolic Syndrome Older Adult - Placebo juice condition|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
32816760|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
32816761|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
32816762|NCT04975581|Experimental|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
32816763|NCT04975581|Active Comparator|Rotator cuff repair surgery|Open Rotator cuff repair surgery
32816764|NCT05525949|Experimental|VIVID Brain|VIVID Brain, 5 times a week for 12 weeks
32816765|NCT05525949|Other|No-treatment Control|No-treatment is administered during control period.
32900925|NCT05256264||Low dose ketamine group|Sevoflurane + 3µg/kg/min ketamine infusion
32900926|NCT05256264||High dose ketamine group|Sevoflurane + 6µg/kg/min ketamine infusion
32955774|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
32816766|NCT04957095||Parkinson's disease patients|This group consists of Parkinson's disease patients who are undergoing deep brain stimulation surgery for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation and / or inhaled levodopa medication, Inbrija. Stimulation will be applied at the previously determined therapeutic frequency. Two capsules (84 mg) of Inbrija will be administered.
32816767|NCT04957095||Essential Tremor patients|This group consists of essential tremor patients who are undergoing deep brain stimulation for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation. Stimulation will be applied at the previously determined therapeutic frequency.
32816768|NCT05391945||goiter|Patients referred for partial/total thyroidectomy for goiter
32816769|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
32816770|NCT04399707|Active Comparator|Active TENS Unit|
32816771|NCT04399707|Placebo Comparator|Placebo TENS Unit|
32816772|NCT04399707|No Intervention|No TENS Unit|
32816773|NCT05393986|Experimental|Experimental: CAR-CLDN18.2 T-Cells (CT048)|The subjects will be initially enrolled in the lymphodepletion cohort. Subsequent subjects will be enrolled in the non-lymphodepletion cohort after reviewing the data in the lymphodepletion cohort.
32816774|NCT05500599|No Intervention|midazolam (Group M)|receive 0.5 mg/kg midazolam orally approximately 30 min before the induction of anaesthesia
32816775|NCT05500599|Active Comparator|fentanyl (Group F)|receive 10 μg/kg fentanyl orally approximately 30 min before the induction of anaesthesia
32816776|NCT05390944|Experimental|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
32816777|NCT05390944|Experimental|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
32816778|NCT04911309|Active Comparator|Group 1: 12 weeks functional exercise training followed by standard therapy|"12 weeks functional exercise training twice per week, each session lasting 60 min, additionally to standard therapy. Training sessions will be performed in a group-setting consisting of minimum 4 and maximum 8 participants and coached by experienced sport scientists with the supervision of a medical doctor. The exercises will be individually pants and constantly recorded in order to allow a progression over the course of the 12 week-period. The motor tasks and exercises will be tailored to individual capacity by experienced and trained sport scientists and coaches, therefore insuring the participants' safety and a continuous and progressive monitoring of training load.~After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks."
32816779|NCT04911309|Active Comparator|Group 2: 12 weeks standard therapy / treatment followed by 12 weeks functional exercise training|"12 weeks standard therapy / treatment; the standard therapy group receives no additional exercise sessions. After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks.~After 12 weeks the groups will switch the intervention method. Group 2 will perform the same intervention which Group 1 received over the first course of 12 weeks."
32816780|NCT04909437|Experimental|Mycobiotic group|
32816781|NCT04909437|Placebo Comparator|Placebo group|
32816782|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
32816783|NCT04278339|Experimental|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
32816784|NCT04278339|Experimental|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
32816785|NCT04278261|Experimental|Focal therapy|Using focal therapy(high-frequency Irreversible electroporation) to treat patients with localized Prostate cancer
32816786|NCT04278261|Active Comparator|Radical prostatectomy|Using laparoscopic radical prostatectomy to treat patients with localized Prostate cancer
32816787|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
32816788|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
32816789|NCT04278105|Experimental|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
32816790|NCT04278105|Sham Comparator|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
32816791|NCT03266055|Experimental|Blueberry powder|
32816792|NCT03266055|Placebo Comparator|Blueberry placebo powder|
32816793|NCT04278027|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
32816794|NCT04278027|No Intervention|Treatment as usual|Treatment as usual
32816795|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
32816796|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
32816797|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
32816798|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
32816799|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
32816800|NCT04895241|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC) every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
32816801|NCT04895241|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
32816802|NCT04895241|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
32816803|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
33317516|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
32816804|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
32816805|NCT05377827|Experimental|Part A Cohort A: Dose Escalation WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
32816806|NCT05377827|Experimental|Part A Cohort B: Dose Escalation WU-CART-007 AML|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
32816807|NCT05377827|Experimental|Part B Cohort A: Dose Expansion WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
32816808|NCT05377827|Experimental|Part B Cohort B: Dose Expansion WU-CART-007 AML|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
32816809|NCT05334459||Intervention|"Operable, postmenopausal ER/PR positive and Her2 neu (-), oligometastatic dnMBC patients~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc)~o ER / PR /Her2 /Ki67 study~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
32816810|NCT05373615|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate
32816811|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory~On 2 randomly selected days, the participants will wear a light meter during wake time"
32816812|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
32816813|NCT04352920|Experimental|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
32816814|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
32816815|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
32816816|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
32816817|NCT00988000|Other|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
32816818|NCT00988000|Other|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
32816819|NCT00988000|Other|Comparator|Choose and book
32816820|NCT05343117||Palbociclib based-therapy as initial endocrine therapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy as initial endocrine therapy from August 1, 2018 to December 31, 2023.
32816821|NCT05343117||Palbociclib based-therapy after chemotherapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy after chemotherapy from August 1, 2018 to December 31, 2023.
32816822|NCT05340322|Experimental|HPV+ Pap smear|Visualization of cervix and if abnormalities are present treat with SOC thermocoagulation.
32816823|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
32816824|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
32816825|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
32816826|NCT04348071|Experimental|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
32816827|NCT05242666|Other|DCM1: MRI Spinal Cord|3T MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
32816828|NCT05242666|Other|DCM2: MRI Brain and Spinal Cord|3T MR Imaging of the brain and cervical spinal cord, before and at 3-6 months after surgery. A subset will also be invited to undergo 7T MRI Brain and Spinal Cord Imaging.
32816829|NCT05242666|Other|DCM3: [11C]-PIB MR/PET Cervical Spinal Cord|[11C]PIB PET/MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
32816830|NCT05242666|Other|Healthy Volunteer: MRI Brain and Spinal Cord|Age-Matched Healthy Controls will undergo MRI Brain and Spinal Cord. A subset will also be invited to undergo interval imaging at 3-6 months.
32816831|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
32816832|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
32816833|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
32816834|NCT04352998|Active Comparator|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
32816835|NCT04352998|Active Comparator|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
32816836|NCT04352998|Placebo Comparator|Placebo condition|One dose/serving of a placebo was administered to the subjects.
32816837|NCT04883619|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) from Week 0 through Week 50 along with standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE) until unblinding of the study.
32816838|NCT04883619|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
32816839|NCT04883619|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
32816840|NCT05593744||Thyroid dysfunction|Patients had thyroid dysfunction during anti-PD-1 therapy.
32816841|NCT05593744||No thyroid dysfunction|Patients didn't have thyroid dysfunction during anti-PD-1 therapy.
32816842|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
32816843|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
32816844|NCT04881903|Experimental|MIST intervention followed by MIRA intervention|These are both mobile interventions that use interpretation bias modification (IBM) techniques to reduce cognitive biases. The MIST app targets suicidal cognitions and the MIRA app targets hostile interpretation bias (which contributes to anger). The MIRA application has already been developed, but the MIST application is newly developed based on the same procedures. All participants will complete the MIST intervention and provide feedback so that we can refine it. We will also be collecting EMA data on to examine how changes to suicide cognitions and hostile interpretation bias (by use of the two apps) affects suicidal ideation and functioning.
32816845|NCT04353076|Experimental|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
32816846|NCT04353076|Experimental|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
32816847|NCT04353076|Experimental|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
32816848|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
32816849|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
32816850|NCT04415411|No Intervention|Control group|Routine nursing care
32816851|NCT04415411|Experimental|Intervention group|Nursing care based on the Theory of Human Caring
32816852|NCT05184478|Experimental|Group A (MC then placebo)|Group A will receive medicinal cannabis during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive placebo during Treatment Period 2 (70 days).
32816853|NCT05184478|Experimental|Group B (placebo then MC)|Group B will receive placebo during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive medicinal cannabis during Treatment Period 2 (70 days).
32816854|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
32816855|NCT01887353|Active Comparator|Ranolazine|
32816856|NCT01887353|Placebo Comparator|Placebo|
32816857|NCT05352711|Experimental|active assisted exercise with Oculus Quest virtual reality (VR) group|This group includes 30 patients suffered from pain and loss of shoulder flexion ROM, The patients will treated with active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand controller ) for 30 min. 2 times per week for 4 weeks The ROM will be assessed by mobile goniometer application and Smart phone version of visual analogue scale (VAS) to assess pain and The Quality-of-Life Scale for Children to assess the psychometric properties after the 1st session, day 14 and day 28.
32816858|NCT05352711|Active Comparator|active assisted range of motion exercise group|This group includes 30 patients suffering from pain and loss of shoulder flexion ROM. Patients will recieve active-assisted ROM physical therapy 2 sessions per week for 4 weeks.
32816859|NCT05495997|Experimental|Mental Imagery|
32816860|NCT05495997|Active Comparator|Psychoeducation|
32816861|NCT03263091|Experimental|Roxadustat|"Open-label, lead-in: Participants will receive sequential escalating roxadustat doses (1.5 milligrams/kilograms [mg/kg], 2.0 mg/kg and 2.5 mg/kg), three times a week (TIW) based upon their actual weight at the randomization visit to identify the starting dose for double-blind period.~Double-blind: Participants will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks.~Open-label: Participants with high serum erythropoietin levels (>400 milli-international units [mIU]/milliliter [mL] mIU/mL) will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks."
32816862|NCT03263091|Placebo Comparator|Placebo|Double-blind: Participants will receive placebo matching to roxadustat for a duration of 52 weeks.
32816863|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
32816864|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
32816865|NCT03331341|Experimental|Treatment (APVD)|"PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles."
32816866|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
32816867|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
32816868|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
32816869|NCT01896869|Experimental|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
32816870|NCT01896869|Experimental|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
32816871|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
32816872|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
32816873|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
32816874|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
32816875|NCT03329001|Experimental|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
32816876|NCT03329001|Experimental|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
32816877|NCT04872465|Active Comparator|Experimental|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
32816878|NCT04872465|Placebo Comparator|Sham Comparator|Participants will receive sham (placebo) TBS treatment the same as experimental group
32816879|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
32816880|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
32816881|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
32816882|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
32816883|NCT04864665|Experimental|Formula fed|0 - 6 months: a formula with prebiotics and milk fat (Stage 1); >6 - 12 months: a formula with prebiotics and milk fat (Stage 2); >1 - 2 years: a formula with prebiotics and milk fat (Stage 3)
32816884|NCT05492799|Experimental|single arm|AX 250 300 mg - open label
32816885|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
32900927|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
32738460|NCT05012553|Experimental|education of self and peer assesment|Stoma care skills of the group who received self and peer assessment training will be evaluated.
32738461|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
32738462|NCT05012709|Experimental|intervention group|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
32738463|NCT05012709|No Intervention|control group|The TAU group received usual routine care.
32738464|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
32738465|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
32738466|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
32738467|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
32738468|NCT04946253|Active Comparator|DOCC with standard implementation (No TEAM or LEAD)|Practices in this arm will receive DOCC materials/training and technical support, but will not receive care team coaching/consultation (TEAM) or practice leadership facilitation (LEAD) after the training phase.
32738469|NCT04946253|Experimental|DOCC with TEAM implementation|Practices in this arm will receive DOCC training and materials and one type of implementation support after the training: coaching/consultation for the provider care team (TEAM).
32738470|NCT04946253|Experimental|DOCC with LEAD implementation|Practices in this arm will receive DOCC training and materials and only one type of implementation support after the training: facilitation for practice leadership (LEAD).
32738471|NCT04946253|Experimental|DOCC with TEAM + LEAD implementation|Practices in this arm will receive DOCC training and materials and both types of implementation support after the training: coaching/consultation for the provider care team (TEAM) and facilitation for practice leadership (LEAD).
32738472|NCT03207217|Experimental|Phase I Knowledge Assessment|
32738473|NCT03207217|Experimental|Phase II Efficacy|
32738474|NCT03207217|Experimental|Phase II Acceptability|
32738475|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron sulfate 1 tbl daily until birth"
32738476|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron polymaltose 1 tbl daily until birth"
32738477|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
32738478|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
32738479|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
32738480|NCT04942041||local thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the local center
32738481|NCT04942041||distant thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the distant center
32738482|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
32738483|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
32738484|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
32738485|NCT04940871|Experimental|Favipiravir HU + SOC|Favipiravir HU + SOC
32738486|NCT04940871|Placebo Comparator|Placebo HU + SOC|Placebo HU + SOC
32738487|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
32738488|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
32738489|NCT04939935|Experimental|Intervention|"Participants randomised to the intervention group receive Metformin XR plus standard of care for 104 weeks.~Dosage will depend on individual participant's level of tolerance to Metformin XR as well as their estimated glomerular filtration rate (eGFR). The dosage will be between 1000-2000mg/day."
32738490|NCT04939935|Placebo Comparator|Control|Participants randomised to the control group receive placebo plus standard of care for 104 weeks.
32738491|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
32738492|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
32738493|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
32738494|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
32738495|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
32738496|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
32816886|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
32816887|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
32816888|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
32816889|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
32816890|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
32816891|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
32816892|NCT05485779|Experimental|Part A (SAD): Group A1|Single dose of AQ280, 3 mg or placebo
32816893|NCT05485779|Experimental|Part A (SAD): Group A2|Single dose of AQ280, dose to be determined (TBD) or placebo
32816894|NCT05485779|Experimental|Part A (SAD): Group A3|Single dose of AQ280, dose TBD or placebo
32816895|NCT05485779|Experimental|Part A (SAD): Group A4|Single dose of AQ280, dose TBD or placebo
32816896|NCT05485779|Experimental|Part A (SAD): Group A5|Single dose of AQ280, dose TBD or placebo
32816897|NCT05485779|Experimental|Part B (MAD): Group B1|AQ280 dose TBD or placebo, once daily (QD) for seven days
32816898|NCT05485779|Experimental|Part B (MAD): Group B2|AQ280 dose TBD or placebo, once daily (QD) for seven days
32816899|NCT05485779|Experimental|Part B (MAD): Group B3|AQ280 dose TBD or placebo, once daily (QD) for seven days
32816900|NCT05095012|Other|Clinical Pathway Participation|Patients that are seen in an emergency department participating in the clinical pathway will not be aware of any changes, other than be given a specific education handout at discharge and be advised to visit the recoverconcussion.ca web portal. Specialty referrals for high risk patients will automatically be made during the emergency visit, through the clinical pathway.
32816901|NCT03262779|Experimental|combination nivolumab and ipilimumab - primary|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with primary resistance.
32816902|NCT03262779|Experimental|combination nivolumab and ipilimumab - acquired|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with acquired resistance.
32816903|NCT05593120||CT-FFR|All patients will be assessed and managed according to the results of CT-FFR test, assuming they have no prespecified contraindications to CT coronary angiography. The result of the CT-FFR will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
32816904|NCT05593120||Routine care|All patients will be assessed and managed exactly as they are usually treated by the investigator and the institution's heart team according to routine practice in Wuhan Asia Heart Hospital.
32816905|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
32816906|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
32816907|NCT05199441|Experimental|Dihydroxydibutylether group|This group takes dihydroxydibutylether for 8 weeks.
32816908|NCT05199441|Placebo Comparator|Control group|This group takes placebo for 8 weeks.
32816909|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
32816910|NCT05592730||Study Group|Patients with Unexplained İnfertility
32816911|NCT05592730||First Control Group|Healthy Multiparous Women
32816912|NCT05592730||Second Control Group|A: Patients with male infertility B: Patients with tubal factor
32816913|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
32816914|NCT05031754||Infants with atopic dermatitis|Infants with atopic dermatitis
32816915|NCT05031754||Infants without atopic dermatitis|Infants without atopic dermatitis
32816916|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
32816917|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
32816918|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
32816919|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
32816920|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
32816921|NCT05022394|Experimental|Treatment (sapanisertib, nivolumab)|Patients receive PO QD on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32816922|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
32816923|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
32816924|NCT05005936||Ancillary-Correlative (ABUS, WBUS)|Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).
32816925|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
32816926|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
32900928|NCT05256108|Experimental|Cebranopadol 600 µg|Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo
32900929|NCT05256108|Experimental|Cebranopadol 1000 µg|Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo
33101684|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
32816927|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
32816928|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
32816929|NCT04976686|Experimental|All study participants|All participants will undergo sample collection during their regular diet and after modification of their diet to a low carbohydrate diet
32816930|NCT05592652||simple post-traumatic stress disorder|Patients suffering from PTSD according to DSM-5 diagnostic features
32816931|NCT05592652||complex post-traumatic stress disorder|Patients suffering from CPTSD according to CIM-11 diagnostic features
32816932|NCT05592652||volonteer trauma +|non clinical volunteer with traumatic exposure
32816933|NCT05592652||volonteer trauma -|non clinical volunteer without traumatic exposure
32816934|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
32816935|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
32816936|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
32816937|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
32816938|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
32816939|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
32816940|NCT04889248|Experimental|Intervention|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
32816941|NCT04889248|No Intervention|Control|Without inspiratory muscle training. Treatment as usual.
32816942|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
32816943|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
32816944|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
32816945|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
32816946|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
32816947|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
32816948|NCT04618211|Other|Low dose/placebo|Single low dose of PHA-022121 or placebo
32816949|NCT04618211|Other|Medium dose/placebo|Single medium dose of PHA-022121 or placebo
32816950|NCT04618211|Other|High dose/placebo|Single high dose of PHA-022121 or placebo
32816951|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
32816952|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
32816953|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
32816954|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
32816955|NCT04695808|Experimental|intervention group|Yoga practice will be done two days a week for 10 weeks.
32816956|NCT04695808|No Intervention|control group|no intervention
32816957|NCT04525456|Experimental|Reduxium|1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days
32816958|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
32816959|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
32816960|NCT04434040|Experimental|Atezolizumab and Sacituzumab govitecan|"Patients will receive the following treatment:~Atezolizumab and Sacituzumab govitecan treatment will continue for 6 cycles (18 total weeks).~Atezolizumab intravenously (IV) at a pre-determined dose on day 1 in a 21-day cycle~Sacituzumab govitecan: intravenously (IV) at a pre-determined dose on days 1 and 8 in a 21-day cycle"
32816961|NCT05535088|Experimental|Virtual reality|Virtual reality
32816962|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
32816963|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
32816964|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
32816965|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
32816966|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
32816967|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
32816968|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
32816969|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
32816970|NCT04263610|Experimental|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
32816971|NCT04263610|Experimental|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
32816972|NCT04263610|Experimental|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
32816973|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
32816974|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
32816975|NCT04225390|Experimental|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
32816976|NCT05507164|Other|Temporo-masseteric Nerve Block Administration|Non-randomized administration of the TMNB injection (unilateral) followed by bite force distribution and surface EMG assessment of the temporalis and masseter muscles on the side of the injection
32816977|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
32816978|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
32816979|NCT04201132|Experimental|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
33101685|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
33101686|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
32816980|NCT05495776||Patients with colorectal cancer|Patients with colon adenocarcinoma who have not previously received antitumor treatment (chemo/radiation therapy) for a currently detected tumor
32816981|NCT04160650|Experimental|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of~healthy diet~malnutrition, its prevalence and consequences for patients with CRC undergoing CT~side effects impairing nutrition intake during CT treatment.~prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
32816982|NCT04160650|No Intervention|Standard care|"Patients in control group receive standard care, information of~general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation~side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT~weight control~taste alteration~cold sensitivity~variable diet~dietary supplements~available dietitian services~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
32816983|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
32816984|NCT04159012|Experimental|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
32816985|NCT04159012|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
32816986|NCT04148482|Active Comparator|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
32816987|NCT04148482|Placebo Comparator|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
33101687|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
33101688|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
33101689|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
32816988|NCT04101838|Active Comparator|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
32816989|NCT04101838|Active Comparator|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
32816990|NCT04101838|Active Comparator|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
32816991|NCT04101838|Active Comparator|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
32816992|NCT04101838|Active Comparator|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
32816993|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 1|Phase 2 / Part A: ensovibep active treatment arm 1
32816994|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 2|Phase 2 / Part A: ensovibep active treatment arm 2
32816995|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 3|Phase 2 / Part A: ensovibep active treatment arm 3
32816996|NCT04828161|Placebo Comparator|Phase 2 / Part A, Placebo|Phase 2 / Part A: Placebo
32816997|NCT04828161|Experimental|Phase 3/ Part B, ensovibep active treatment arm 4|Phase 3/ Part B: ensovibep active treatment. Part B was not initiated.
32816998|NCT04828161|Placebo Comparator|Phase 3/ Part B, Placebo arm|Phase 3/ Part B: Placebo. Part B was not initiated.
32816999|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
32817000|NCT04399629|Active Comparator|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
32817001|NCT04399629|Experimental|Parenting Wisely|Online parenting training
32817002|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
33101690|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
33101691|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
33101692|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
33317517|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
32817003|NCT03260361|Other|usual practice|physiopathology and treatments
32817004|NCT04606797|Experimental|Nicotine Replacement Therapy|
32817005|NCT04606797|No Intervention|Control|
32817006|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
32817007|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
32817008|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
32817009|NCT04795167||FlowTriever Arm|
32817010|NCT04795167||Context Arm|
32817011|NCT04795167||Prior Therapy Arm|
32817012|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
32817013|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
32817014|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
32830617|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
33317518|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
32817015|NCT04604067|Experimental|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (>2log10 reduction of ctDNA)) results:~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).~Follow up: Patients off treatment will be followed for 5 years."
32817016|NCT04771611|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
32817017|NCT04771611|Placebo Comparator|Placebo|Subjects will receive placebo
32817018|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
32817019|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
32817020|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
32817021|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
32817022|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
32817023|NCT05440396||Patient|"Patients will be recruited independently in each of the centers participating in the study, according to the specific organization of each service (hospital and home). Patients will be selected based on the study inclusion/non-inclusion criteria. The included patients will receive oral information about the study. The informed consent will be obtained before any investigation.~Each photograph will focus on the intravascular catheter. The investigators will respect the main non-inclusion criterion: not to show any peripheral identification sign close to the insertion point of the catheter that cannot be masked when the photograph is taken. In this context, jewellery, clothing, tattoos, scars, and birthmarks represent identifying features. Individual access accounts with secure, randomly generated passwords will be provided to investigators.~The photographs will be anonymous, and any identification of the person concerned will be impossible."
32817024|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
32817025|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
32817026|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
32817027|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
32817028|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
32817029|NCT05417620|No Intervention|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
32817030|NCT05417620|Experimental|Enhanced social media campaign|Social media campaign which will be disseminated on Facebook, Instagram, and WhatsApp with targeted ads/promotion of materials in intervention districts.
32817031|NCT05417620|Experimental|Enhanced social media campaign + PrEP champions|Venue-based peers who will provide PrEP information, share personal experiences with PrEP, and refer young women to TB HIV Care to receive PrEP if interested in addition to the enhanced social media campaign.
32817032|NCT05417620|Experimental|Enhanced social media campaign + Community mobilization|Peers will work within wards to organize and attend community meetings to share PrEP information and facilitate discussions with young women, male partners, family members, and other community members in addition to the enhanced social media campaign.
32817033|NCT05417620|Experimental|Enhanced social media campaign + PrEP champions + Community mobilization|Clusters in this arm will receive both the PrEP champion and community mobilization interventions in addition to the enhanced social media campaign.
32817034|NCT05322993|Active Comparator|With artificial intelligence (AI)|Use of GI Genius artificial intelligence device during colonoscopy.
32817035|NCT05322993|Active Comparator|Without artificial intelligence|Use of standard colonoscopy equipment without GI Genius.
32817036|NCT04021264|Active Comparator|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
32817037|NCT04021264|Sham Comparator|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
32817038|NCT03233139|Experimental|Cemiplimab|Part 1
32817039|NCT03233139|Experimental|Cohort A|Part 2
32817040|NCT03233139|Experimental|Cohort B|Part 2
32817041|NCT03233139|Experimental|Cohort C|Part 2
32817042|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
32817043|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
32817044|NCT05387980||Patients receiving CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
32817045|NCT05311839|Experimental|Thera band exercises group|received graded Thera band exercises for 5 days per week for eight weeks in addition to the conventional physical therapy program.
32817046|NCT05311839|Experimental|conventional physiotherapy program group|received a conventional physical therapy program.
32817047|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
32817048|NCT04763343|Experimental|Ketamine Treatment + CAMS Therapy|
32817049|NCT04763343|Placebo Comparator|Saline Placebo Treatment + CAMS Therapy|
32817050|NCT04759365|Experimental|ASN51|ASN51 will be administered as an oral capsule
32817051|NCT04759365|Placebo Comparator|Placebo|Placebo will be administered as an oral capsule
32817052|NCT05364112|Experimental|Compreflex|Patients recruited for the study will be given one unit of Compreflex (study device) to be worn on the studied leg with a venous ulcer. Once the wound is covered by dressing, the subjects were instructed to wear the study device for 24 hours over the study period. Subjects were allowed to take off the study device during a shower. Subjects were asked to visit the clinic for follow-up purposes at 3 assessment time points after being recruited at the first visit: V2 (3-week), V3 (12-week) and V4 (26-week). Subjects' wound area, leg circumferences were measured and calculated. Patient-centred questionnaires were given to the subjects to assess their compliance and satisfaction with the study device.
32817053|NCT04757571|Experimental|Paroxetine|Paroxetine 20 mg daily plus standard therapy
32817054|NCT04757571|Placebo Comparator|Placebo|Placebo tablet daily plus standard therapy
32817055|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
32817056|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
32817057|NCT04746183|Experimental|CST-2 EIDD-2801 Phase Ib|EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.
32738497|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
32738498|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~The Patient Navigation Program include~Education,~Appointment reminders,~Help with insurance,~Transportation,~Navigating the Cancer Center,~Assisting in finding appropriate child care,~Interpreting,~Connecting the patient to psychosocial and/or palliative care teams,~Physically escorting the patient to appointments"
32817058|NCT04746183|No Intervention|CST-2 Control|Phase 1b only (standard of care)
32817059|NCT04746183|Placebo Comparator|CST-2 Placebo|Phase II placebo blinded controlled
32817060|NCT04746183|Experimental|CST-3A Nitazoxanide|Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
32817061|NCT04746183|Experimental|CST-5 VIR-7832 Phase I|Phase I: Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
32817062|NCT04746183|Active Comparator|CST-5 VIR-7831 Phase II|Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
32817063|NCT04746183|Placebo Comparator|CST-5 Placebo Phase I|Phase I: placebo blinded controlled
32817064|NCT04746183|Experimental|CST3B Nitazoxanide|Phase II experimental arm.
32817065|NCT04746183|No Intervention|CST3B Control|Standard of care
32817066|NCT04746183|Experimental|CST6 IV Favipiravir|IV Favipiravir twice daily for 7 days. Starting dose 600 mg twice daily. Dose escalation to 1200 mg twice daily, 1800 twice daily, 2400 twice daily.
32817067|NCT04746183|No Intervention|CST6 Control|Standard of care
32817068|NCT04746183|Experimental|CST-2 EIDD-2801 Phase II|"EIDD-2801 (also known as MK-4482, molnupiravir).~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
32817069|NCT04746183|Experimental|CST-8 Phase I Molnupiravir + Paxlovid®|Molnupiravir 800mg Twice a day (BD) in combination with Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required. The dose of Paxlovid® will be fixed for all cohorts.
32817070|NCT04746183|No Intervention|CST-8 Phase I Molnupiravir + Paxlovid® Control|Standard of care
32817071|NCT04746183|Active Comparator|CST-5 VIR-7832|Phase II: 500 mg dose of VIR-7832 will be given by IV infusion.
32817072|NCT04746183|Placebo Comparator|CST-5 Placebo Phase II|Phase II: placebo blinded controlled
32817073|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
32817074|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
32830618|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
32900930|NCT05256108|Active Comparator|Oxycodone 40 mg|Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo
33101693|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
32817075|NCT04745325|Experimental|Smartphone app - full access|"A smartphone app containing 5 modules: 1) personalized feedback on alcohol use (containing normative feedback by age and sex for those located in the Canada), 2) self-monitoring and goal setting tool, 3) tool to choose a designated driver, 4) blood alcohol content (BAC) calculator, and 5) educational information on alcohol use and its consequences (i.e. fact sheets)."
32817076|NCT04745325|Active Comparator|Smartphone App - education only|"A version of the Smartphone app containing only the module with the educational information on alcohol use and its consequences (i.e. fact sheets)."
32817077|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~sFlt1/PlGF ratio >38: pre-eclampsia risk~sFlt1/PlGF ratio >85: pre-eclampsia~ISSHP pre-eclampsia definition + ratio >210: severe PE~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
32817078|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
32817079|NCT04740255|Other|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Straberi Epistamp needling.
32817080|NCT04740255|Other|No Treatment|Non-Randomized patients with Postinflammatory Hyperpigmentation (PIH)
32817081|NCT04738071||Sex|Female and male patients
32817082|NCT04738071||Age >60 years of age|Patients younger or oder than 6o years of age
32817083|NCT04738071||World region|Patients from different world regions: North America, Europe, Asia, Latin America
32817084|NCT04738071||Stroke vs. TIA|Index event: stroke vs. TIA
32817085|NCT04738071||Neurocardiology Teams|Patients assessed by a neurocardiology team
32817086|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
32817087|NCT01004770|Experimental|1 (AH113111 Injection)|
32817088|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
32817089|NCT04399317|Experimental|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
32817090|NCT04399317|No Intervention|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
32817091|NCT03230877|Experimental|Group A|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
32817092|NCT03230877|Experimental|Group B|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
32817093|NCT04469374|Experimental|Jumping exercise|10 rest-inserted jumps performed three times per week
32817094|NCT04469374|Sham Comparator|Balance exercise|Single-leg balances for 60 seconds on each leg
32817095|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
32817096|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
32817097|NCT05221294|Experimental|MDN group|will receive modified Del Nido cardioplegia solution
32817098|NCT05221294|Experimental|C group|will receive Custodiol cardioplegia
32817099|NCT04720209|Experimental|Circuit-style aerobic and resistance Exercise(CARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months.~-16 weeks of circuit-style aerobic and resistance exercise"
32817100|NCT04720209|Experimental|Traditional Aerobic Resistance Exercise (TARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months~- 16 weeks of traditional aerobic and resistance exercise"
32817101|NCT04720209|Active Comparator|Home-Based Stretching|"Attention Control for 16 weeks home-based stretching~-structured home-based stretching program, participants will be asked to maintain their current activity level for the 4-month study duration, and will be offered the CARE program upon study completion"
32817102|NCT04614311|Active Comparator|Intervention|Intra-articular corticosteroid injections into active joints
33101694|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
32817103|NCT04614311|No Intervention|Comparator|No intra-articular injections
32817104|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
32830619|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
32817105|NCT03922204|Experimental|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
32817106|NCT04717791|Other|Procedure|Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.
32817107|NCT04713579||Premature infants|Infants born prematurely requiring a stoma for condition such as necrotizing enterocolitis (NEC) or spontaneous intestinal perforation (SIP).
32817108|NCT04713579||Term Infants|Infants born closer to term requiring a stoma e.g. for congenital causes of bowel obstruction such as intestinal atresia, gastroschisis or meconium ileus
32817109|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
32817110|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
32817111|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
32817112|NCT04418206|Other|Samples With DNA|Nasopharyngal swab and blood samples
32817113|NCT04579029|Experimental|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
32817114|NCT04579029|No Intervention|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
32817115|NCT03761446|Experimental|Older adults with pre-diabetes or type 2 Diabetes|Male and female older adults between the ages 60-80 with pre-diabetes or type 2 diabetes
32817116|NCT03761446|Experimental|Older adults without pre-diabetes or Type 2 Diabetes|Male and female older adults between the ages 60-80 without pre-diabetes or type 2 diabetes
32817117|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
33317519|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317520|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317521|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317522|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317523|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317524|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317525|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
32817118|NCT03285321|Experimental|Arm 2|Nivolumab 240mg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
33101695|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
32900931|NCT05256108|Active Comparator|Tramadol 600 mg|Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets
32738499|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
32738500|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
32738501|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
32738502|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
32738503|NCT04433793|Experimental|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
32738504|NCT04433793|No Intervention|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
32738505|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
32738506|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
32738507|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
32738508|NCT03080415|Experimental|Combined Therapy SOF and DCV|
32738509|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
32738510|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
32738511|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
32738512|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
32738513|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
32738514|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
32738515|NCT05410925|Experimental|r-SAK group|intravenous injection of single-bolus 5 mg r-SAK in 3 min
32738516|NCT05410925|Placebo Comparator|placebo group|intravenous injection of placebo in 3 min
32738517|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
32738518|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
32738519|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
32738520|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
32738521|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
32738522|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
32738523|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
32738524|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
32738525|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated~Treat cohort with Dabrafenib~Analysis~Treat cohort with Dabrafenib"
32738526|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~Treat cohort with Dabrafenib and Trametinib~Analysis~Treat cohort with Dabrafenib and Trametinib"
32738527|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~KRAS or NRAS mutated~Treat cohort with Trametinib~Analysis~Treat cohort with Trametinib"
32738528|NCT04493255|Experimental|E7090|Participants will receive 100 microcurie (μCi) of [14C]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.
32738529|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
32738530|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
32738531|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
32817119|NCT04366258|Experimental|t-PBM at Low Irradiance, then t-PBM at Middle Irradiance, then t-PBM at High Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32817120|NCT04366258|Experimental|t-PBM at Low Irradiance, then t-PBM at High Irradiance, then t-PBM at Middle Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32817121|NCT04366258|Experimental|t-PBM at Middle Irradiance, then t-PBM at High Irradiance, then t-PBM at Low Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32830620|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
33317526|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
33317527|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
33317528|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
32900932|NCT05256108|Placebo Comparator|Placebo|Single oral dose of 6 capsules containing placebo
33317529|NCT03254420|Active Comparator|Image-guided radiation therapy (IGRT) with standard margins|moderate hypofractionation during 4 weeks
33317530|NCT03254420|Experimental|Calypso tracking system with margin reduction|moderate hypofractionation during 4 weeks after calypso beacon implant 10 days before
33317531|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
33317532|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
33317533|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
33317534|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
33317535|NCT03898648|Experimental|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
33317536|NCT03898648|Experimental|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
33317537|NCT05124548||Post-COVID condition|
33317538|NCT05124548||Healthy controls|
33317539|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
33317540|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
33317541|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
33317542|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
33317543|NCT03660280|Experimental|Probiotics|
33317544|NCT03660280|Placebo Comparator|Placebo|
33317545|NCT05670626|Other|non comparative interventional study|patients with high refractive error will do phakic ICL after preoperative assessment of anterior segments parameters and post-operative ICL vault will be measured using pentacam
33317546|NCT03631654|Placebo Comparator|Control|
33317547|NCT03631654|Experimental|Intervention|
33317548|NCT03477916|Other|Control (Placebo FMT and cellulose)|
33317549|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
33317550|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
33317551|NCT03477916|Experimental|FMT + prebiotic fiber|
33317552|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
33317553|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
33317554|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
33317555|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
33317556|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
33317557|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33317558|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
33317559|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
32817122|NCT04366258|Experimental|t-PBM at Middle Irradiance, then t-PBM at Low Irradiance, then t-PBM at High Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32817123|NCT04366258|Experimental|t-PBM at High Irradiance, then t-PBM at Low Irradiance, then t-PBM at Middle Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32817124|NCT04366258|Experimental|t-PBM at High Irradiance, then t-PBM at Middle Irradiance, then t-PBM at Low Irradiance, then Sham|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: Sham irradiance dose of 0 mW/cm2"
32955775|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
32955776|NCT00574236|Experimental|A|
32955777|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
32955778|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
32955779|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
32955780|NCT00574704|Experimental|1|
32955781|NCT00574704|Placebo Comparator|2|
32955782|NCT00574704|Experimental|3|
32955783|NCT00574704|Placebo Comparator|4|
32955784|NCT04309630|Active Comparator|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
32955785|NCT04309630|Experimental|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
32955786|NCT01168219|Experimental|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
32955787|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
32955788|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
32955789|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
32955790|NCT01107886|Experimental|Saxagliptin|
32955791|NCT01107886|Placebo Comparator|Placebo|Placebo
32955792|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
32955793|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
32955794|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
32955795|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
32955796|NCT01107457|Placebo Comparator|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
32955797|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
32955798|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
32955799|NCT05767008|Experimental|Static and water immersion SPF evaluation|
32955800|NCT05766969|Experimental|CBD/PEA|Subject will receive a 42-day supply of 10/50 mg CBD/PEA sublingual tablets to be taken 3 times a day for 42 days.
32955801|NCT05766969|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 42 days.
32955802|NCT05766930|Experimental|The genital itching and one treatment|Participants with itching genitalia will receive one treatment with the device and complete the questionnaire.
32817125|NCT04366258|Experimental|t-PBM at Low Irradiance, then t-PBM at Middle Irradiance, then Sham, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817126|NCT04366258|Experimental|t-PBM at Low Irradiance, then t-PBM at High Irradiance, then Sham, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance doses of 300 mW/cm2"
32817127|NCT04366258|Experimental|t-PBM at Middle Irradiance, then t-PBM at Low Irradiance, then Sham, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817128|NCT04366258|Experimental|t-PBM at Middle Irradiance, then t-PBM at High Irradiance, then Sham, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817129|NCT04366258|Experimental|t-PBM at High Irradiance, then t-PBM at Middle Irradiance, then Sham, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817130|NCT04366258|Experimental|t-PBM at High Irradiance, then t-PBM at Low Irradiance, then Sham, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: Sham irradiance dose of 0 mW/cm2~Visit 4: t-PBM at irradiance dose of 300 mW/cm2"
32817131|NCT04366258|Experimental|t-PBM at Low Irradiance, then Sham, then t-PBM at Middle Irradiance, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817132|NCT04366258|Experimental|t-PBM at Low Irradiance, then Sham, then t-PBM at High Irradiance, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 50 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: t-PBM at irradiance dose of 300 mW/cm2"
32817133|NCT04366258|Experimental|t-PBM at Middle Irradiance, then Sham, then t-PBM at Low Irradiance, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817134|NCT04366258|Experimental|t-PBM at Middle Irradiance, then Sham, then t-PBM at High Irradiance, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 300 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817135|NCT04366258|Experimental|t-PBM at High Irradiance, then Sham, then t-PBM at Middle Irradiance, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817136|NCT04366258|Experimental|t-PBM at High Irradiance, then Sham, then t-PBM at Low Irradiance, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: t-PBM at irradiance dose of 770 mW/cm2~Visit 2: Sham irradiance dose of 0 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: t-PBM at irradiance dose of 300 mW/cm2"
32955803|NCT05766904|Experimental|Intervention|Intramuscular injection of 2 doses of 0.5mL 4CMenB vaccine 1 month apart
33101696|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
33101697|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
32817137|NCT04366258|Experimental|Sham, then t-PBM at Low Irradiance, then t-PBM at Middle Irradiance, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817138|NCT04366258|Experimental|Sham, then t-PBM at Low Irradiance, then t-PBM at High Irradiance, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 50 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: t-PBM at irradiance dose of 300 mW/cm2"
32817139|NCT04366258|Experimental|Sham, then t-PBM at Middle Irradiance, then t-PBM at Low Irradiance, then t-PBM at High Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: t-PBM at irradiance dose of 770 mW/cm2"
32817140|NCT04366258|Experimental|Sham, then t-PBM at Middle Irradiance, then t-PBM at High Irradiance, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 300 mW/cm2~Visit 3: t-PBM at irradiance dose of 770 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817141|NCT04366258|Experimental|Sham, then t-PBM at High Irradiance, then t-PBM at Middle Irradiance, then t-PBM at Low Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: t-PBM at irradiance dose of 300 mW/cm2~Visit 4: t-PBM at irradiance dose of 50 mW/cm2"
32817142|NCT04366258|Experimental|Sham, then t-PBM at High Irradiance, then t-PBM at Low Irradiance, then t-PBM at Middle Irradiance|"Participants undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose, including a sham dose, once over the 4 treatment visits.~Schedule of interventions:~Visit 1: Sham irradiance dose of 0 mW/cm2~Visit 2: t-PBM at irradiance dose of 770 mW/cm2~Visit 3: t-PBM at irradiance dose of 50 mW/cm2~Visit 4: t-PBM at irradiance dose of 300 mW/cm2"
32817143|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
32817144|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
32817145|NCT04705545|No Intervention|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
32817146|NCT04705545|Experimental|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
32817147|NCT04705545|Experimental|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
32817148|NCT05066698|Experimental|ST266|Topical ocular application: one drop in the study eye four times a day for 8 weeks
32817149|NCT05066698|Placebo Comparator|Placebo|Topical ocular application: one drop in the study eye four times a day for 8 weeks
32817150|NCT04277793|Experimental|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
32817151|NCT05058742|Experimental|Nervus vagus stimulation|Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.
32817152|NCT05058742|No Intervention|Control|There is no Nervus vagus stimulation.
32817153|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
32830621|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
32830622|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
32830623|NCT03286296|Experimental|LZM009|
32955804|NCT05766904|Placebo Comparator|Control|Intramuscular injection of 2 doses of 0.5mL placebo 1 month apart
32738532|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
32738533|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
32738534|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
32738535|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
32738536|NCT05019573|Experimental|Black tea group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.
32738537|NCT05019573|Placebo Comparator|Placebo group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.
32738538|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
32738539|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
32738540|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
32738541|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
32738542|NCT05005377|Experimental|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
32738543|NCT05005377|Experimental|Socket Preservation with Freeze-Dried Bone Allograft|the extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
32738544|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
32738545|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
32738546|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
32738547|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
32738548|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
32738549|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
32738550|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
32738551|NCT03078153|No Intervention|Control|No intervention
32738552|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
32738553|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
32738554|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
32738555|NCT05012319|Experimental|treatment arm|"Nitric Oxide Nasal Spray Enovid"
32738556|NCT05012319|Placebo Comparator|Placebo|Placebo
32738557|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
32738558|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
32738559|NCT05011773|Experimental|Deep brain stimulation|"All patients have already undergone deep brain stimulation. Results compared on and off stimulation."
32738560|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
32738561|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
33101698|NCT04634240|Experimental|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of ≥70% in vessels ≥2.5mm in diameter.
32817154|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
32817155|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
32817156|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
32817157|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
32817158|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
32817159|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
32817160|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
32817161|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
32817162|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
32817163|NCT04334980|Experimental|bacTRL-Spike|"Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);~Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;~Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;~Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.~Group 5 (n=12): DSMB-defined prime and boost doses of bacTRL-Spike delivered with a 28-day intervening interval."
32817164|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
32817165|NCT05003908|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
32817166|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
32817167|NCT04323748|Experimental|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
32817168|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
32817169|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
32817170|NCT04296838|Experimental|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
32817171|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
32817172|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
32817173|NCT03397108||Women with IBD|This group is composed of breastfeeding women aged over 18 years and in their first 4-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
32817174|NCT03397108||Healthy breastfeeding women|This group is composed of healthy breastfeeding women aged over 18 years and in their first 4-month postpartum period.
32817175|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
32817176|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
32817177|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
32817178|NCT04704999|Active Comparator|Low dose tafenoquine (5mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range Low dose~>21-25 kg 200 mg~26-40 kg 200 mg~41-50 kg 300 mg~51-60 kg 400 mg~61-80 kg 400 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
32900933|NCT05209776|Experimental|Patients|Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
32817179|NCT04704999|Active Comparator|Medium dose tafenoquine (9mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range Medium dose~>21-25 kg 200 mg~26-40 kg 300 mg~41-50 kg 400 mg~51-60 kg 500 mg~61-80 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
32817180|NCT04704999|Active Comparator|High dose tafenoquine (12.5mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range High dose~>21-25 kg 300 mg~26-40 kg 400 mg~41-50 kg 600 mg~51-60 kg 600 mg~61-80 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
32817181|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
32817182|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
32817183|NCT04197310|Experimental|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Cabozantinib will be administered at a dose of 40mg orally, once daily~Nivolumab will be given at a dose of 240mg every 14 days, intravenously~Retreat Phase (Optional)~Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.~Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.~This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
32817184|NCT04760457|Active Comparator|IL-FLS|Immediate loading (IL) and Flapless surgery (FLS)
32817185|NCT04760457|Active Comparator|IL-FPS|Immediate loading (IL) and Flapped surgery (FPS)
32817186|NCT04760457|Active Comparator|DL-FLS|Delayed loading (DL) and Flapless surgery (FLS)
32817187|NCT04760457|Active Comparator|DL-FPS|Delayed loading (DL) and Flapped surgery (FPS)
32817188|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
32817189|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
32817190|NCT05330247|Experimental|Therapeutic Diet: CRHP Diet|Carbohydrate-reduced high-protein (CRHP) dietary intervention. Intervention: Therapeutic Diet: CRHP Diet.
32817191|NCT05330247|Active Comparator|Therapeutic Diet: CD Diet|Conventional diabetes (CD) dietary intervention. Intervention: Therapeutic Diet: CD Diet.
32817192|NCT04898296||Patients over 55 Years with coronary heart disease|Questionnaire and semistructured Interview 45 -60 minutes
32817193|NCT04898296||physical therapists working with patients with coronary heart disease|Focus group 60 -90 minutes
32817194|NCT04550013|Active Comparator|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
32817195|NCT04550013|Experimental|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
32817196|NCT04894162|Other|Sequential recruitment of all inpatients|"Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a questionnaire about research preferences.~This is not part of standard care and results do not contribute to usual care - thus is an 'interventional' study."
32817197|NCT04134520||Generally healthy subjects with no known cancer disorder|
32817198|NCT04134520||Subjects with a pathological diagnosis of cancer|
32817199|NCT05320731|Active Comparator|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
32817200|NCT05320731|Active Comparator|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
32817201|NCT04823650||Ages 3-5|
32817202|NCT04823650||Ages 6-11|
32817203|NCT04823650||Ages 12-17|
32817204|NCT04685655|No Intervention|COVID-19 therapy according to center standard alone|
32817205|NCT04685655|Active Comparator|Therapeutic plasma exchange and COVID-19 therapy according to center standard|
32817206|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
32817207|NCT04683393||Healthy Subjects|To compare the markers of frailty (MoF) in patients with multiple myeloma (MM) with the healthy subjects.
32817208|NCT04683393||MM Patients|Patients with multiple myeloma (MM), the aim is to assess if any of the proposed parameters and markers of frailty (e.g. biomarkers of cellular senescence and organ damage, inflammatory markers, physical tests such as gait speed and hand grip test) are associated with frailty status, defined according to the GA, at baseline.
32955805|NCT05766891|Experimental|Group 1|Participants will receive hypnosedation before and during surgery as well as local anesthesia and pain/nausea medications during surgery
33101699|NCT04634240|No Intervention|Medical Therapy Alone|No revascularization of coronary artery lesions.
33101700|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
32817209|NCT04545177|Experimental|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
32817210|NCT02709616|Experimental|Personalized cellular vaccine|DC based cellular vaccine
32817211|NCT04534881|Active Comparator|progesterone|subjects on active drug (progesterone)
32817212|NCT04534881|Placebo Comparator|placebo|subjects on placebo
32817213|NCT02468752|Sham Comparator|Air|Normobaric air breathing
32817214|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
32817215|NCT04817956|Experimental|Atezolizumab|Atezolizumab used outside of current indication, based on biomarkers
32817216|NCT04817956|Experimental|Atezilizumab combined with bevacizumab|Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers
32817217|NCT04817956|Experimental|Phesgo (trastuzumab og pertuzumab)|Phesgo used outside of indication, based on biomarkers.
32817218|NCT04817956|Experimental|Alectinib|Alectinib used outside of indication, based on biomarker
32817219|NCT04817956|Experimental|vismodegib|vismodegib used outside of indication, based on biomarker
32817220|NCT04817956|Experimental|entrectinib|entrectinib used outside of indication, based on biomarker
32817221|NCT04817956|Experimental|Zelboraf + Cotellic|Zelboraf + Cotellic used outside of indication, based on biomarker
32817222|NCT04817956|Experimental|Alpelisib|Alpelisib used outside of indication, based on biomarker
32817223|NCT04817956|Experimental|Dabrafenib + trametinib|Used outside of indication, based on biomarker
32817224|NCT04817956|Experimental|Melfalan|Melfalan used outside ofcurrent indication
32817225|NCT04817956|Experimental|Pemazyre|Pemazyre used outside ofcurrent indication
32817226|NCT04817956|Experimental|Selpercatinib|used outside ofcurrent indication
32817227|NCT04817956|Experimental|Olaparib|Used outside of current indication, for patients with bi-allelic BRCA-inactication
32817228|NCT04817956|Experimental|Capmatinib|Used outside of current indication,
32817229|NCT04817956|Experimental|Imatinib|Used outside of current indication,
32817230|NCT04817956|Experimental|Bortezomib|Used outside of current indication,
32817231|NCT04817956|Experimental|Actinomycin D|Used outside of current indication,
32817232|NCT04672239|Experimental|SiS|"Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking."
32817233|NCT04672239|Active Comparator|QG|"Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking."
32817234|NCT04672239|Other|CTA|"Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking."
32817235|NCT01894919|Experimental|2H3H511_V|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
32817236|NCT01894919|No Intervention|2H3H511_NV|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
32817237|NCT01894919|Experimental|3H5_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
32817238|NCT01894919|No Intervention|3H5_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
33101701|NCT04630886|Experimental|Tranexamic acid|The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
32817239|NCT01894919|Experimental|68_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
32817240|NCT01894919|No Intervention|68_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
32817241|NCT01894919|Experimental|02_2_5_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
32817242|NCT01894919|No Intervention|02_2_5_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
32817243|NCT01894919|Experimental|02_6_10_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
32817244|NCT01894919|No Intervention|02_6_10_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
32817245|NCT01894919|Experimental|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
32817246|NCT01894919|Experimental|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
32817247|NCT01894919|Experimental|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
32900934|NCT05209776|Experimental|Control case|Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
32817248|NCT04130698|Experimental|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.~Module 1: Orientation & ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
32817249|NCT04130698|Active Comparator|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
32817250|NCT04667949|Experimental|Fingolimod|Fingolimod 0.5 mg capsule taken orally once daily
32817251|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
32817252|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
32817253|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
32817254|NCT05306223|Experimental|Bedaquiline-containing Short-course Regimen (SCR)|Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid [LZD] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.
32817255|NCT05306223|Experimental|Non-bedaquiline-containing Short-course Regimen (SCR)|Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.
32817256|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
32817257|NCT03016000|Other|Observation|Observation
32817258|NCT04130152|Experimental|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
32817259|NCT05304819||AchilloCordPLUS|End to end repair for acute Achilles tendon rupture with AchilloCordPLUS
32817260|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
32817261|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
32817262|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
32817263|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
32817264|NCT04106674|No Intervention|Non-surgical|No surgery
32817265|NCT04106674|Active Comparator|Surgical|Surgeons preference
32817266|NCT05304507|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
32817267|NCT05304507|Active Comparator|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
32817268|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
32817269|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
32817270|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
32817271|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
32817272|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
32817273|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
32817274|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
32817275|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
32817276|NCT03982888|Experimental|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
32817277|NCT04399395|Active Comparator|Lifestyle and naltrexone/bupropion|
32817278|NCT04399395|Other|Lifestyle|
32817279|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
32817280|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
32817281|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
32817282|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
32817283|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
32817284|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
32817285|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
32817286|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
32817287|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator~Photon SBRT will be given during TAS-102 dosing~TAS-102 dosing occurs on days 1 through 5 and 8 through 12~TAS-102 tablets should be taken twice a day orally"
32817288|NCT04613297|Other|COVID-19 uninfected patients|Patient with negative PCR result
32817289|NCT04613297|Other|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
32817290|NCT04613297|Other|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
32817291|NCT05168865|Experimental|PCOS women will receive letrozole ovarian stimulation.|Polycystic ovarian disease (PCOS) women undergoing frozen embryo transfer (FER) will use Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
32817292|NCT05168865|Active Comparator|PCOS women will receive Estradiol and Progesterone (hormonal endometrial preparation).|PCOS women will use daily Cetorelix acetate 0.25 mg injections for 5 days from day 1-3 of the menstrual follow or after progesterone (P4) withdrawal bleeding. They will commence daily oral Estradiol Valerate (E2) 2 mg twice daily for 5 days starting from day 3 of the menstrual flow or after P4 withdrawal bleeding, then-after three times daily. When endometrial thickness reaches 7 mm or more, the dose of E2 will be reduced to 4 mg/ day. Women will start using vaginal micronized P4 100 mg three times daily starting from 8PM. After 48 hours of starting the vaginal P4, oral Dydrogesterone 10 mg three times daily will commence.
32817293|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
32817294|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
32817295|NCT04654143|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
33101702|NCT04630886|Active Comparator|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
33317560|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
32817296|NCT04654143|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
32817297|NCT04654143|Experimental|Food Effect|This cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo. Each participant will receive a single oral dose of BVL-GSK098 or placebo administered after the participant eats a high-fat, high calorie breakfast.
32817298|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
32817299|NCT04648761|Experimental|OPTIMAL group|This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm
32817300|NCT04648761|No Intervention|Control group|This group will continue their treatment with anti IL 5 biologics unchanged
32817301|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
32817302|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
32817303|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
32817304|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
32817305|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
32817306|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
32817307|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
32817308|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
32817309|NCT04460235|Other|Vaccination|All patients will be vaccinated according to national guidelines
32817310|NCT04643769|Experimental|25 mg ORIN1001 (Active)|25 mg ORIN1001
32817311|NCT04643769|Experimental|50 mg ORIN1001 (active)|50 mg ORIN1001
32817312|NCT04643769|Experimental|100 mg ORIN1001 (active)|100 mg ORIN1001
32817313|NCT04643769|Placebo Comparator|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
32817314|NCT04643769|Placebo Comparator|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
32817315|NCT04643769|Placebo Comparator|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
32817316|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
32817317|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
32817318|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
32817319|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.~Plus (all patients):~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
32817320|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
32817321|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
32817322|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
32817323|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
32817324|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
32817325|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
32817326|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
32817327|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
32817328|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
32817329|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
32817330|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
32817331|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
32817332|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
32817333|NCT04073823|Active Comparator|Flexitouch Plus|
32817334|NCT04073823|Experimental|Flexitouch Plus with SW|
32817335|NCT04049955|Experimental|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
32817336|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
32817337|NCT04046601|Experimental|Impedance|every resected tissue will measured by an impedance probe
32817338|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
32817339|NCT04024917|Experimental|Coherence cardiac|
32817340|NCT04024917|Active Comparator|Standard care|
33317561|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
32817341|NCT02981446|Experimental|DE-117 ophthalmic solution|
32817342|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
32817343|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
32817344|NCT04023435|Experimental|PNE education|All subjects will be tested before and after receiving PNE education
32817345|NCT05263947|Experimental|Arm A|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Icotinib 250 mg tablets shall be administered orally 3 times every day at least one hour before or two hours after the ingestion of food.
32817346|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
32817347|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
32817348|NCT04723576|Experimental|Stress First Aid|"The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. SFA sites will implement SFA through a train-the-trainer model."
32817349|NCT04723576|No Intervention|Usual Care|The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. UC sites will not implement SFA during the study period but will be given full access to all implementation materials following the conclusion of their participation.
32817350|NCT05256537|Experimental|Open Arm|Omission of the drug mycophenolate mofetil
32817351|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
32817352|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
32817353|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
32817354|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
32817355|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
32817356|NCT04399005|Experimental|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
32817357|NCT04399005|Experimental|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
32817358|NCT04760301|Experimental|local tranexamic acid injection to cervix|1 gr of Tranexamic acid diluted in 10 ml saline
32817359|NCT04760301|Placebo Comparator|local normal saline injection to cervix|20 ml of saline
32817360|NCT04760301|Experimental|IV 1 g tranexamic acid|1 gr of Tranexamic acid diluted in 100 ml saline- IV
32817361|NCT04760301|Placebo Comparator|IV 1 g normal saline|100 ml saline- IV
32817362|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
32817363|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
32817364|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
32817365|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
32817366|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
32817367|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
32817368|NCT04400097|Experimental|hidden-knot group|
32817369|NCT04400097|Active Comparator|two-knot group|
32817370|NCT04400097|Active Comparator|multi-knot group|
32817371|NCT04678648|Experimental|RSC-1255 Treatment|Single Arm Study. All study participants receive RSC-1255.
32955806|NCT05766891|Experimental|Group 2|Participants will receive hypnosedation before surgery and standard general anesthesia during surgery.
33317562|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
33317563|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
32817372|NCT04018053|Experimental|18F-fluciclovine|"18F-fluciclovine will be administered via slow push over 10 seconds through a peripheral intravenous line~Immediately after the injection of the radiopharmaceutical, dynamic PET/CT images of the pelvis will be obtained for 15 minutes~Subsequently, PET/CT images will be obtained from the pelvis to the base of skull."
32817373|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
32817374|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
32817375|NCT04392375|Active Comparator|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
32817376|NCT04392375|Placebo Comparator|Placebo|Matching placebo group q24hrs until delivery
32817377|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
32817378|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
32817379|NCT04760379|Active Comparator|Conventional Therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
32817380|NCT04760379|Experimental|Vibration Therapy|Focal muscle vibrator (FMV) (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
32817381|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
32817382|NCT03014908||NMR-C|non-diabetic children and adolescents
32817383|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.
32817384|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
32817385|NCT04387617|Experimental|CBD Oil Group|
32817386|NCT04387617|Placebo Comparator|Control Group|
32817387|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
32817388|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
32817389|NCT05237193||malignant biliary obstruction|Pre-surgery patients with malignant biliary obstruction will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology.
32817390|NCT05237193||Benign biliary obstruction|Patients being treated for other biliary diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
32817391|NCT04527406|Experimental|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
32817392|NCT04527406|Active Comparator|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
32817393|NCT04277403|Experimental|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
32817394|NCT04277403|Active Comparator|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
32817395|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
32817396|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
32817397|NCT04365465|Experimental|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
32817398|NCT04365465|Sham Comparator|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
32817399|NCT04365465|Active Comparator|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
32817400|NCT04398615|Experimental|Intervention|Single arm, receiving the experimental device
32817401|NCT01055704|Experimental|Methylnaltrexone|
32817402|NCT01055704|Experimental|Codeine|
32817403|NCT01055704|Experimental|Methylnaltrexone + codeine|
32817404|NCT01055704|Placebo Comparator|Placebo|
32817405|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
32817406|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
32817407|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
32817408|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
32817409|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
32817410|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
32817411|NCT05236491|Active Comparator|Trajectory A|"Participants who have received 3 doses of an mRNA vaccine, will be offered a choice between a fourth dose of an mRNA vaccine and a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID)~For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
32817412|NCT05236491|No Intervention|Trajectory B|Participants who have already received a 4 doses or more of COVID-19 vaccine in the community at inclusion and do not wish to receive a 5th dose of vaccine in the study.
32817413|NCT05236491|Active Comparator|Trajectory B5|"Participants who have received 4 doses of an mRNA vaccine at inclusion and wish to receive a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID) as a fifth dose.~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
32817414|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
32817415|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
32817416|NCT04400019|No Intervention|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
32817417|NCT04400019|Experimental|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
32817418|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
32817419|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
32817420|NCT05225805|Experimental|Group A|Group A will receive one dose of 150 mg lefamulin IV followed by one dose of 600 mg lefamulin oral
32817421|NCT05225805|Experimental|Group B|Group B will receive one dose of 600 mg lefamulin oral followed by one dose of 150 mg lefamulin IV
32817422|NCT01056016|No Intervention|Wait-list control|Wait-list control group
32817423|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
32817424|NCT03915405|Experimental|KHK2455 in Combination with Avelumab|
32817425|NCT03913611|Other|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
32817426|NCT03913611|Experimental|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
32817427|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
32817428|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
32817429|NCT04358913|Experimental|MR Imaging on the Alberta linac-MR P3 system|All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
32817430|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
32817431|NCT04351581|Experimental|A: COVID+ Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
32817432|NCT04351581|Experimental|B: Covid+ Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
32817433|NCT04351581|Experimental|C: COVID% Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose.
32817434|NCT04351581|Experimental|D: COVID% DIscontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
32817435|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
32817436|NCT01057888|Experimental|Letters|Mailed reminder letters
32817437|NCT01057888|No Intervention|Controls|Controls
32817438|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
32817439|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
32817440|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
32817441|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
32817442|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
32817443|NCT04344873|Experimental|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
32817444|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
32817445|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
32817446|NCT04760145|Experimental|Intervention Group|Multicomponent exercise with blood flow restriction
32817447|NCT04760145|Active Comparator|Control Group|Multicomponent exercise without blood flow restriction
32817448|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
32817449|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
32817450|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
32817451|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
32817452|NCT03867201|Experimental|Erenumab|Administered by pre-filled syringe
32817453|NCT03867201|Placebo Comparator|Placebo|Administered by pre-filled syringe
32817454|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
32817455|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
32817456|NCT03279393|Active Comparator|PTSD Subjects|
32817457|NCT03279393|Active Comparator|Trauma Control Subjects|
32817458|NCT03279393|Placebo Comparator|Healthy Control Subjects|
32817459|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
32817460|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
32817461|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
32817462|NCT04333407|Experimental|Active Arm|
32817463|NCT04333407|No Intervention|Control Arm|
32817464|NCT05207943|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and and in the popliteal fossa.
32817465|NCT05207943|Sham Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and in the popliteal fossa.
32817466|NCT05207943|No Intervention|Control|Participant will maintain the conventional rehabilitation treatment
32817467|NCT05206617||Limb Girdle Muscular Dystrophy type 2L|At baseline, 1- and 3-year follow up will the outcome measures be assessed. There will be no intervention.
32817468|NCT04398225|Experimental|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
32817469|NCT04398225|Experimental|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
32817470|NCT04398225|Experimental|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
32817471|NCT04398225|Experimental|Cohort 4 (6-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
32955807|NCT05766891|Experimental|Group 3|Participants will receive standard general anesthesia alone. You will not receive hypnosedation.
32817472|NCT04398225|Experimental|Cohort 5 (4-5 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
32817473|NCT04398147|Experimental|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
32817474|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
32817475|NCT04398147|Experimental|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
32817476|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817477|NCT04398147|Experimental|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
32817478|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
32817479|NCT04398147|Experimental|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
32817480|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817481|NCT04398147|Experimental|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
32817482|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
32817483|NCT04398147|Experimental|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
32817484|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817485|NCT04398147|Experimental|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
32817486|NCT04398147|Placebo Comparator|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
32817487|NCT04398147|Experimental|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
32817488|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817489|NCT04398147|Experimental|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
32817490|NCT04398147|Placebo Comparator|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
32817491|NCT04398147|Experimental|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
33101703|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
33101704|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
33317564|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
32738562|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
32738563|NCT05019183|Experimental|Experimental arm|Patients in the experimental arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) during which they will be able to move freely in a virtual environment.
32738564|NCT05019183|Other|Control arm|Patients in the control arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) without being exposed to a virtual environment.
32738565|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
32738566|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
32738567|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
32738568|NCT03226327|Experimental|hypertension patients|
32738569|NCT05019417|Experimental|Glycerol phenylbutyrate treatment|"Name of the Investigational Medicinal product: Glycerol phenylbutyrate [GPB] (Ravicti oral liquid 1.1 gr/1 ml; manufacturer Horizon Pharma USA).~Dosage of GPB will follow the dosage in use for children with urea cycle disorder.~Initial dose: 5.0 gr (4.5 ml)/ meter square divided by three time a day. An escalating schedule dose of GPB will be used until normal serum T3 levels are reached.~Initial dose: 5 gr/square meter body surface area (BSA). Second visit: 10 gr/square meter BSA~The dose raising will be stopped if one of the following condition is reaches:~Clinically significant side effects~Reaching the PAA serum toxic threshold of 500 µg/ml~Reaching the maximal dose of GPB that is in use in urea cycle disorder: 12.4 gr (11.2 ml)/ meter square BSA divided by three times a day.~Duration of study: 4 months"
32738570|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
32738571|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
32738572|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
32738573|NCT05011695|Active Comparator|1. Group ESWT treatment|"6000 SWT Easy device will be used for ESWT treatment. The plantar fascia of the patients will be applied once a week for 3 weeks. In each application, 2400 beats, 2.0 bar pressure and 12 frequency doses of ESWT will be applied"
32738574|NCT05011695|Active Comparator|2. Group transverse friction massage|Transverse friction massage will be applied to the plantar fascia of the patients for 3 weeks, 3 days a week, on Mondays, Wednesdays, and Fridays, with a break for 1 day and 15 minutes each. Transverse friction massage, when the patient is in the supine semi-lying position, the big toe will be dorsiflexed and in this position, it will be applied in the direction that will be transverse to the plantar fascia.
32738575|NCT05011695|Active Comparator|3. Group exercise group|Stretching the plantar fascia and gastrocsoleus muscles of the patients, towel picking exercises with the foot intrinsic muscles, heel drop exercises will be given. All stretching and exercises will be applied once a day, 5 days a week, for 3 weeks. Plantar fascia stretching exercises will be performed with a physiotherapist; While the patient is lying in the supine position, 30 seconds of stretching will be performed using the windlass (windlass) mechanism (toes are brought to dorsi flexion). This stretch will be repeated 3 times. Gastrocsoleus stretching exercises will be studied with a physiotherapist. In the supine position, the gastrocsoleus muscles will be stretched for 10 seconds and stretching will be performed with 10 repetitions. Towel collection exercises for the foot intrinsic muscles will be practiced in 3 sets, 15 repetitions per day. Heel drop exercise will be applied in 3 sets of 15 repetitions per day.
32738576|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
32738577|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
32738578|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
32738579|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
32738580|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
32738581|NCT05011227|Experimental|Camrelizumab and chemotherapy combined with endoscopic surgery|Camrelizumab and chemotherapy combined with endoscopic surgery
32738582|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
32738583|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
32738584|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
32738585|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
32738586|NCT03226171|Experimental|Dose-adjusted SK-1403|
32738587|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
32738588|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
32738589|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
32738590|NCT05018715||coronary heart disease|A total of 300 patients with CHD WHO were hospitalized in the First Affiliated Hospital of Xinjiang Medical University from August 2021 to February 2022 were selected, all of whom met the DIAGNOSTIC criteria of CHD formulated by the World Health Organization (WHO) and excluded diseases such as highly severe valvular disease and congenital heart disease
32738591|NCT05018715||Healthy person|.A total of 300 healthy subjects from the First Affiliated Hospital of Xinjiang Medical University during the same period were selected as controls.
32738592|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
32738593|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
32817492|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817493|NCT04398147|Experimental|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
32817494|NCT04398147|Placebo Comparator|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
32817495|NCT04398147|Experimental|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
32817496|NCT04398147|Placebo Comparator|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
32817497|NCT04398147|Experimental|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
32817498|NCT04398147|Placebo Comparator|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
32817499|NCT04398147|Experimental|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
32817500|NCT04398147|Placebo Comparator|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
32817501|NCT04328181|Experimental|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
32817502|NCT04398927|Experimental|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
32817503|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
32817504|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
32817505|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
32817506|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
32817507|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
32817508|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
32817509|NCT05195073|Active Comparator|3 D laparoscopy group|salpingectomy will be performed by using Storz image 1 S 3D laparoscopy system (Karl Storz, Tuttlingen, Germany) which is comprised of a 10 mm scope with 2 full HD sensors at the tip of the scope and a 3 D control unit plus a 3 D display
32817510|NCT05195073|Active Comparator|2 D laparoscopy group|salpingectomy will be performed by using a conventional 2 D laparoscopy system.
32817511|NCT05194059|Experimental|Experimental Group|Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet
32817512|NCT05194059|No Intervention|Control Group|Participants will follow a personalized activity pacing program for 16 weeks without any other support
32817513|NCT01059682|Experimental|Dalcetrapib|
32817514|NCT01059682|Placebo Comparator|Placebo|
32817515|NCT04398693|No Intervention|Normotensive Patients|40 normotensive patients with systolic BP (SBP) < 140 mmHg and diastolic BP (DBP) < 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP < 130/80 mmHg) and the exclusion of possible masked hypertension.
32817516|NCT04398693|No Intervention|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP < 130 mmHg and DBP < 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
32817517|NCT04398693|Active Comparator|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
32817518|NCT04399083|Experimental|Single Arm|
32817519|NCT01892345|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams [mg]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
32817520|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
32817521|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
32817522|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
32817523|NCT05179551|Experimental|Proximal Medial Gastrocnemius Recession Surgery|Patients will be operated with Proximal Medial Gastrocnemius Recession Surgery (PMGR) ad modum Barouk.
32817524|NCT04399785|Experimental|Arm 1|
32817525|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
32817526|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
32817527|NCT01059994|Placebo Comparator|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
32817528|NCT01059994|Experimental|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
32817529|NCT01059994|Placebo Comparator|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
32817530|NCT01059994|Experimental|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
32817531|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
32817532|NCT04207203|Other|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
32817533|NCT03819465|Experimental|A1|Durvalumab
32817534|NCT03819465|Experimental|A2|Durvalumab + danvatirsen
32817535|NCT03819465|Experimental|A3|Durvalumab + oleclumab
32817536|NCT03819465|Experimental|A4|MEDI5752
32817537|NCT03819465|Experimental|B1|Durvalumab + Investigator's choice of chemotherapy
32817538|NCT03819465|Experimental|B2|Durvalumab + Investigator's choice of chemotherapy + danvatirsen
32817539|NCT03819465|Experimental|B3|Durvalumab + investigator's choice of chemotherapy + oleclumab
32817540|NCT03819465|Experimental|B4|MEDI5752
32817541|NCT03819465|Experimental|A5|AZD2936
32817542|NCT03819465|Experimental|B5|AZD2936 + chemotherapy
32817543|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
32817544|NCT04398303|Experimental|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
32817545|NCT04398303|Experimental|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
32817546|NCT04398303|Placebo Comparator|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
32817547|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
32817548|NCT03772743|Other|Culprit-only revascularization|All patients randomized to culprit only revascularization must not undergo percutaneous coronary intervention (PCI) any lesion except from the culprit lesion already treated at the moment of the randomization. Staged procedures are considered protocol violation.
32817549|NCT03772743|Other|Complete functionally-guided revascularization|Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
32817550|NCT01111318|Experimental|BI 10773|50 mg single dose
32817551|NCT05165433|Experimental|All cohorts|NG-350A and pembrolizumab
32817552|NCT04760067||Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
32817553|NCT04760067||Artificial Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
32817554|NCT04760067||Wood Parquet|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
32817555|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
32817556|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
33405123|NCT05200728|Experimental|SIM1910-09|"This trial includes of 2 parts, Part A-single ascending doses and Part B- multiple ascending doses.~Part A, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~Part B, there are 3 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
32817557|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817558|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817559|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817560|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817561|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
32817562|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817563|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
32817564|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
32817565|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
32817566|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
32817567|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
32817568|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
32817569|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
32817570|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
32817571|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
32817572|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
32817573|NCT05155137|Experimental|Riskometer + Polypill|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
32817574|NCT05155137|Placebo Comparator|Riskometer + Placebo|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use placebo polypill
32817575|NCT05155137|Experimental|No Riskometer + Polypill|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
32817576|NCT05155137|No Intervention|No Riskometer + Placebo (Usual Care)|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the placebo polypill = usual care
32817577|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
32817578|NCT04179981|Active Comparator|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
32817579|NCT05154201|Experimental|Dose escalation of ORIN1001 as a single agent|"Single-agent dose escalation in Chinese patients with advanced solid tumors. Nine dose groups: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 650 mg, 900 mg, 1200 mg, and 1500 mg orally in 21-day cycles.~A total of 27-54 evaluable patients are expected to be enrolled. However, the dose in the escalation phase is not limited to these dose groups, and the number of enrolled patients is not limited to 27-54."
32817580|NCT05154201|Experimental|Dose escalation of ORIN1001 in combination with Standard of Care|ORIN1001 will be administered daily as a tablet in combination with standard of care. This arm of the study will be carried out in 8 different cancer indications, including advanced triple-negative breast cancer received ≥ 3 lines of treatment, postmenopausal ER+/HER2-advanced breast cancer received the 1 line of treatment, advanced hepatocellular carcinoma received 1/2 line of treatment, chemotherapy-naive castrate-resistant prostatic cancer, advanced pancreatic cancer received 1/2 line of treatment, platinum-resistant/refractory advanced ovarian cancer received ≥ 2 lines of treatment, non-small cell lung cancer received ≥ 2 lines of treatment, and esophageal cancer received ≥ 2 lines of treatment.
32817581|NCT05154201|Experimental|Dose expansion of ORIN1001 as a single agent or in combination with Standard of Care|"After the recommended phase 2 dose of single-agent ORIN1001 is determined, a single-agent efficacy expansion study for advanced esophageal cancer, as well as a single-agent efficacy expansion study for advanced solid tumors with failure of standard treatments or no effective standard treatment.~After the recommended phase 2 dose of the combination treatment is determined, the efficacy expansion study of the combination treatment will be conducted in the corresponding 8 different indications."
32817582|NCT05153343|Experimental|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
32817583|NCT05153343|Experimental|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
32817584|NCT05153343|Experimental|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
32817585|NCT05153343|Experimental|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
32817586|NCT05153343|Experimental|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
32817587|NCT05153343|Experimental|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
32817588|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
32817589|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
32817590|NCT04165473||Intervention Group|Study participants having finished the following course in the past will be assigned to the intervention group: During a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
32817591|NCT04165473||Control Group|Individuals without intervention
32817592|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
32817593|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
32817594|NCT04611815|Active Comparator|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
32817595|NCT04611815|Active Comparator|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
32817596|NCT04156347|Experimental|Phase I Open Label Study|Phase I Single Arm
32817597|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
32900935|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
32738594|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
32738595|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
32738596|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
32738597|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
32738598|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
32738599|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
32738600|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
32738601|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
32738602|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
32738603|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
32738604|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
32738605|NCT04493177|Experimental|Gestational diabetes intervention|All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
32738606|NCT04493177|Experimental|No diabetes intervention|Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
32738607|NCT04493177|Active Comparator|No diabetes no intervention|Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
32738608|NCT03079479||Two Years Group|
32738609|NCT03079479||Five Years Group|
32738610|NCT03079479||Ten Years Group|
32738611|NCT03079479||Control Group|
32738612|NCT03206125||Controls|Controls
32738613|NCT03206125||ESCC Cases|ESCC Cases
32738614|NCT04493021|Experimental|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
32738615|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
32738616|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
32738617|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
32738618|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
32738619|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
32738620|NCT04955223|Experimental|Yinhu Qingwen Granule|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
32738621|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
32738622|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
32738623|NCT04493099|Experimental|Treatment (decitabine, alvocidib hydrochloride, venetoclax)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10, or 1-14, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive decitabine IV over 1 hour on days 1-5, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10 or 1-14, and venetoclax PO QD on days 1-10. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
32738624|NCT05004909|Active Comparator|1 Fingertip Unit 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
32817598|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
33405124|NCT05200728|Placebo Comparator|Placebo|"This trial Includes of 2 parts, Part A-single ascending dose and Part B- multiple ascending dose.~Part A, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~Part B, there are 3 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
32817599|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
32817600|NCT05145309|Experimental|Potassium Magnesium Citrate (KMgCit) first then Placebo|Patients will be asked to take KMgCit ( Sterling Pharmaceutical Services) first for 4 weeks. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day. Then, subjects will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
32817601|NCT05145309|Experimental|Placebo first then KMgCit|Patients will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks. Then, subjects will be asked to take KMgCit (Sterling Pharmaceutical Services, Dupo, IL) after dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
32817602|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
32817603|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
32817604|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
32817605|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
32817606|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
32817607|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
32817608|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
32817609|NCT04152837|Experimental|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
32817611|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
32817612|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
32817613|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
32817614|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
32817615|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
32817616|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
32817617|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
32817618|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
33101705|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:~Lupron / Flutamide~Zoladex/ Flutamide~Lupron/ Casodex~Zoladex/ Casodex~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
32817619|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
32817620|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
32817621|NCT04126551||Overweight/obese nondiabetic|Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
32817622|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
32817623|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
32817624|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
32817625|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
32817626|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
32817627|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
32817628|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
32817629|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
32817630|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
32817631|NCT04616963|Other|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
32817632|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
32817633|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
32817634|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
32817635|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
32817636|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
32817637|NCT04616651|Active Comparator|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
32817638|NCT04616651|Experimental|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
32817639|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
32817640|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
32817641|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
32817642|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
32817643|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
32817644|NCT04123197|Other|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
32817645|NCT03306706|Experimental|whole yellow pea|2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
32817646|NCT03306706|Experimental|split yellow pea|2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
32817647|NCT03306706|Placebo Comparator|wheat-PPGR|2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
32817648|NCT03306706|Placebo Comparator|wheat-satiety|"2 muffins containing wheat flour to match the calories in the whole and split pea muffins.~Intervention: Wheat muffins"
32817649|NCT05132907|Experimental|Cohort 1 (previously vaccinated, two dose recipients)|Cohort 1 will include individuals with vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
32817650|NCT05132907|Experimental|Cohort 2 (previously vaccinated, single dose recipients)|Cohort 2 will include individuals with vaccination against COVID-19 who will receive a one-dose schedule of HDT-301. Dose will be escalated from low to mid to high according to predefined safety parameters.
32817651|NCT05132907|Experimental|Cohort 3 (previously unvaccinated)|Cohort 3 will include 21 individuals with no history of vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
32817652|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
32817653|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
32817654|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
32817655|NCT05117229|Experimental|MetaWear Sensor on radiograph|subjects being considered for surgical orthopedic surgery will have a MetaWear sensor added to their standard of care lateral sit to stand radiograph
32817656|NCT05117151||Observation|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
32817657|NCT01067716|Experimental|Refractive Error|
32817658|NCT05116761|Placebo Comparator|Treatment Arm 1|Normal Saline 100 mL
32817659|NCT05116761|Experimental|Treatment Arm 2|Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV
32817660|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
32817661|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
32817662|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
32817663|NCT05113641|Experimental|Alkalizing Fruit and Vegetables|Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
32817664|NCT05113641|Active Comparator|Sodium Bicarbonate|Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level >22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
32817665|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
32817666|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
32817667|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
32817668|NCT03279081|Experimental|Cx601|Cx601 eASCs 120 million cells (5 million cells per milliliter [mL]) will be administered once by intralesional injection.
32817669|NCT03279081|Placebo Comparator|Placebo|CX601 placebo-matching eASCs cells will be administered once by intralesional administration.
32817670|NCT04611191|Experimental|Team Sports|Elderly men and women performing team sports in local sports clubs
32817671|NCT04611191|Experimental|Control|Elderly men and women continue their normal lifestyle
32817672|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
32817673|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
32817674|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
32817675|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
32817676|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
32817677|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
32817678|NCT05111145|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
32817679|NCT04352842||Non-survivors|Patients deceased during the study period
32817680|NCT04352842||Survivors|Patients survived during the study period
32817681|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
32817682|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
32817683|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
32817684|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
32817685|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
32817686|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
32817687|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
32817688|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
32817689|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
32817690|NCT03517917||Arm 1|Tumour tissue, blood and leukapheresis collection to enable a manufacturing process for immunotherapies to be developed.
32817691|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
32817692|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
32817693|NCT01069510|Placebo Comparator|Placebo|Patients will receive placebo
32817694|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
32817695|NCT04398069|No Intervention|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.
32817696|NCT04398069|Experimental|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI < 1,2.
32817697|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
32817698|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
32817699|NCT04746261|Experimental|ASSIP plus treatment as usual|ASSIP according to manual. Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
32817700|NCT04746261|Active Comparator|Treatment as usual|Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
32817701|NCT04278495|Active Comparator|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK),"
32817702|NCT04278495|Placebo Comparator|Placebo|to receive either placebo
32817703|NCT04276545|Experimental|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
32817704|NCT04276545|Active Comparator|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
32817705|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
32817706|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
32817707|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
32817708|NCT01118338|Experimental|Redesigned Purevision Contact Lens|Redesigned Bausch & Lomb PureVision contact lens
32817709|NCT01118338|Active Comparator|PureVision Contact Lens|Bausch & Lomb PureVision contact lens
32817710|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
32817711|NCT03013036|Other|Group I|Patients between 1 and 2 years
32817712|NCT03013036|Other|Group II|patients between 3 and 5 years
32817713|NCT03013036|Other|Group III|patients between 6 and 8 years
32817714|NCT03364803||Participants with Cushing's Syndrome|
32817715|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
32817716|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
32817717|NCT01072006||PTSD Group|PTSD (not TBI)
32817718|NCT01072006||TBI Group|TBI (no PTSD)
32817719|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
32817720|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
32817721|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
32817722|NCT04352686|Active Comparator|Buspirone|Buspirone 20 mg per oral
32817723|NCT04352686|Placebo Comparator|Placebo|Placebo
32817724|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
32817725|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
32817726|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
32817727|NCT04275687|Experimental|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
32817728|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
32817729|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
32817730|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
32817731|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
32817732|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
32817733|NCT03831633|Experimental|AKYNZEO|
32817734|NCT03831633|Active Comparator|Standard of Care|
32817735|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
32817736|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
32817737|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
32817738|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
32817739|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
32817740|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
32817741|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
32817742|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
32817743|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
32817744|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
32817745|NCT02393079|Experimental|Active helmet LED|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
32817746|NCT02393079|Sham Comparator|Sham group|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
32817747|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
32817748|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
32817749|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
32817750|NCT02817958|Experimental|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
32817751|NCT02817958|Experimental|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
32817752|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
32817753|NCT01120834|Experimental|all subjects|
32817754|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
32817755|NCT04346836|Experimental|Metabolic Syndrome|"Elderly women with Metabolic Syndrome~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
32817756|NCT04346836|Experimental|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
32817757|NCT02798224|Experimental|e-assist: Colon Health (treatment arm)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
32817758|NCT02798224|Active Comparator|Healthwise Educational Program (active control)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
32817759|NCT02798224|No Intervention|Usual care control (observational only)|There will be no participant contact in this arm. We will use existing data sources only (e.g., EHRs) to obtain information on participants in this arm (i.e., an observational data review only).
32817760|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
32817761|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
32817762|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 6 weeks.
32817763|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing regimen of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
32817764|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
32817765|NCT03012958||Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
32817766|NCT03012958||Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
32817767|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817768|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817769|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817770|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817771|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817772|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817773|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817774|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817775|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817776|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32955808|NCT05766852|Experimental|Intervention Group|Participants assigned to Intervention First Group will complete all pre-, 1-week post-intervention, and 1-month assessments and participate in the 3 two-hour intervention classes over the first nine weeks of the study. The pre- and post-assessments will require participants to complete a 20-25-minute survey and provide blood samples and the 1-month post-assessment only requires participants to complete a 20-25-minute online survey.
32817777|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817778|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817779|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817780|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817781|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
32817782|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
32817783|NCT01122316|Experimental|Metformin|
32817784|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
32817785|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
32817786|NCT01076686||Bupivacaine and low dose SKY0402|
32817787|NCT01076686||Bupivacaine and high dose SKY0402|
32817788|NCT01076686||Bupivacaine|
32817789|NCT01076686||High dose SKY0402|
32817790|NCT03049449|Experimental|Chimeric Antigen Receptor (CAR)+ T cells|All patients will be receiving starting dose: 0.3x10^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
32817791|NCT03187353|Active Comparator|Lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
32817792|NCT03187353|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
32817793|NCT04396431|Other|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
32817794|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
32817795|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
32817796|NCT02393625|Experimental|Dose Escalation|
32817797|NCT02393625|Experimental|Dose Expansion|
32817798|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
32817799|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.~Panitumumab: 6 mg/kg, intravenously, Q2W"
32817800|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
32817801|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
32817802|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
32817803|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32817804|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
32817805|NCT04397523|Other|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
32817806|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
32817807|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
32817808|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
32817809|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
32817810|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
32817811|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
32817812|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
32817813|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
32817814|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
32817815|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
32817816|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
32817817|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
32817818|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
32817819|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
32817820|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
32817821|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
32817822|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
32817823|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
32817824|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
32817825|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
32817826|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
32817827|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
32817828|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
32817829|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
32817830|NCT02989857|Active Comparator|AG-120|Participants received AG-120 500 mg, tablet, orally, once a day (QD) in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.
32817831|NCT02989857|Placebo Comparator|Placebo|Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.
32817832|NCT02989857|Experimental|After Cross over to AG-120|Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 32 months.
32817833|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
32817834|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
32817835|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
32817836|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
32817837|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
32817838|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
32900936|NCT05297604|Active Comparator|Non-Invasive Intravascular Laser Irradiation Of Blood Group|Participants in this group will receive low-intensity laser that is attached to a bracelet that has been developed so that the light beam is transported transcutaneously over the radial artery. They will receive 2 sessions per week for 12 weeks.
32817839|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
32817840|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
32817841|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
32817842|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
32817843|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
32817844|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
32817845|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
32817846|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
32817847|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
32817848|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
32817849|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
32817850|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
32817851|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
32817852|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
32817853|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
32817854|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
32817855|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
32817856|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
32817857|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
32817858|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
32817859|NCT02861391|Sham Comparator|Sham laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
32817860|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
32817861|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
32817862|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
32817863|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
32817864|NCT01876901|Experimental|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|Patients treated with 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.
32817865|NCT01876901|Experimental|Colo-anal anastomosis (CAA)|Patients operated with colo-anal anastomosis (CAA) in centers who routinely performing this intervention.
32817866|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
32817867|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
32817868|NCT01876511|Experimental|Cohort A: MSI Positive Colorectal Cancer|
32817869|NCT01876511|Experimental|Cohort B: MSI Negative Colorectal Cancer|
32817870|NCT01876511|Experimental|Cohort C: MSI Positive Non-Colorectal Cancer|
32830624|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
32817871|NCT01993719|Experimental|Arm 1N -Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants without prior treatment pembrolizumab or nivolumab Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
32817872|NCT01993719|Experimental|Arm 1P - Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants previously treated with pembrolizumab or nivolumab.~Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
32817873|NCT01993719|Experimental|Arm 2/Foll By Arm 1P-Low dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Decreased Chemo Prep Regimen+Retreat. Young TIL+High Dose Interleukin-2, Decreased Chemo Preparative Regimen. Young TIL+High Dose Interleukin-2, Standard Chemo (Retreat). Lower dose preparative regimen + Young TIL Cells. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days. Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 300 mg/m^2 IV over 60 minutes. Young TIL: Day 0: Cells will be infused IV. Retreatment: Standard Chemo Prep Regimen. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide: 60 mg/kg/day X 2 days IV. Young TIL: Day 0: Cells will be infused IV.
32817874|NCT01993719|Experimental|Arm 2- Low Dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Decreased Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2 Lower Dose preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 30 mg/kg IV over 60 minutes for 2 days.~Young TIL: Day 0: Cells will be infused intravenously (IV)"
32817875|NCT01993719|Experimental|Arm 1P/Foll By Arm-1P/R-Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Standard Chemo Prep Regimen(SCPR)+Retreat. Young TIL+High Dose(HD) Interleukin-2, SCPR. Young TIL+HD Interleukin-2, SC(Retreat). SCPR+Young TIL Cells retreatment with SCPR+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kgIV every eight hours (+/-1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back(IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL:Day 0: Cells will be infused IV. Retreatment with standard preparative regimen+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL: Day 0:Cells will be infused IV. Pembrolizumab:2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
32817876|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
32817877|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
32817878|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
32817879|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
32817880|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
32817881|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
32817882|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
32817883|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
32817884|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
32817885|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
32817886|NCT01848171|No Intervention|blank|No intervention
32817887|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
32817888|NCT03182907|Experimental|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
32817889|NCT03182907|Placebo Comparator|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose
32817890|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
32817891|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment~ROS1, ALK non-gene fusion molecular alterations~Oral entrectinib (RXDX-101)"
32817892|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment~molecular alterations, including gene fusions~Oral entrectinib (RXDX-101)"
32817893|NCT02650401|Active Comparator|Neuroblastoma|"Arm closed for further enrollment~Oral entrectinib (RXDX-101)"
32817894|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment~harboring - NTRK1/2/3, ROS1, ALK gene fusions~Oral entrectinib (RXDX-101)"
32817895|NCT02650401|Active Comparator|Any participant unable to swallow capsules|"Arm closed for further enrollment~Any participant who otherwise meet all other eligibility criteria~Oral entrectinib (RXDX-101)"
32817896|NCT02650401|Active Comparator|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions~Oral entrectinib (RXDX-101)"
32817897|NCT02650401|Active Comparator|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions~Oral entrectinib (RXDX-101)"
32817898|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
32817899|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
32817900|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
32817901|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
32817902|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
32817903|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
32817904|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
33101706|NCT04623983|Experimental|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
33101707|NCT04623983|Experimental|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
33101708|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
33101709|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
32817905|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
33101710|NCT04690049|Experimental|Neuromuscular resistance exercise group|Subjects will develop an innovator program consisting in the performance of exercises of increasing difficulty, with movements based on functional tests to analyze the subjects' neuromuscular capacities. Participants will attend to 80 individual, face-to-face physiotherapy sessions, including both supervised and semi-supervised monitoring. From the total, a minimum of 15 sessions will be supervised, including 6 sessions to teach and monitor the exercises, and 9 sessions to perform the tests in order to quantify the load; 37 sessions will be semi-supervised, where subjects will perform the exercises independently, but with the presence of an instructor; additionally, the remaining 28 sessions will consist in non-supervised aerobic work at a 70-80% from maximum heart rate, obtained according to the methodology of Tanaka et al.
33101711|NCT04690049|Active Comparator|Control exercise group|This program will be based on a home exercise protocol considering painful sensation and self-perceived stability as progression criteria: regarding pain management, exercises will be planned in a way that increased pain after their performance reverts to before-exercise levels prior to the next session; regarding self-perceived stability, participants will be asked to maintain a constant sensation of joint stability and control during the execution of the exercises. Participants will perform shoulder rotations (external and internal) and abduction up to 30º by using elastic bands. The resistance of the band will be adjusted by the physiotherapist so that participants perceive the exercises as demanding enough but not too unpleasant, being able to complete the 10 repetitions before taking the rest. Likewise, exercises will progress until a maximum of 90º of shoulder abduction.
33101712|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
33101713|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
33101714|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
33101715|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
32817906|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
33101716|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
32817907|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
32817908|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
32817909|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
32817910|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
32817911|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
32817912|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
32817913|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
32817914|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
32817915|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
32817916|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
32817917|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
32817918|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
32817919|NCT01080976||Primary Care Physicians|
32817920|NCT01080976||Diabetologists|
32817921|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
32817922|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
32817923|NCT05307796|Experimental|Semantic Feature Analysis plus metacognitive strategy training|Participants attend three treatment sessions per week for eight weeks. Treatment sessions include: strategy education (participants learn about anomia, circumlocution, and circumlocution's purpose), Semantic Feature Analysis plus strategy application (participants build self-awareness and practice circumlocution), and strategy debriefing (participants reflect and receive feedback on their performance, and generate scenarios in which they could use the strategy in everyday life).
32817924|NCT05307718||The basic cohort|The subjects with the newly indicated indication for use: NOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins
32817925|NCT05307718||Cases|"Cases will be subjects who have observed ADRs during follow-up: bleeding that meets the criteria of major or non-major, clinically relevant bleeding (for anticoagulants and platelet aggregation inhibitors); muscle or liver lesions (for statins); any other serious ADR."
32817926|NCT05307718||Controls|Controls will be subjects in whom no ADRs were observed during the study
32817927|NCT05307562|Active Comparator|Training program|Global intervallic exercise using cyclometer and analytical strength exercises
32817928|NCT05307562|Experimental|Training program + Inspiratory muscle traioning (IMT)|Global intervallic exercise using cyclometer and analytical strength exercises + inspiratory muscles training
32817929|NCT05307484|Experimental|Serious game group|Participants in the intervention group installed a mobile application, 'Sam's Mozzie Adventure'. This is a locally designed serious game which was co-created between SingHealth Polyclinics and AI Innovation Labs (AI2 Labs) Private Limited, specifically for this study. The principal investigator reviewed existing publicly available information on dengue prevention, including those on the National Environmental Agency (NEA) 'Stop Dengue' website, and provided the relevant content and pedagogical knowledge to the team of app developers from AI2 Labs. After creating the syllabus, the developers deployed their technological knowledge to integrate the dengue prevention information into the serious game. The participants were instructed to complete playing this serious game within 2 weeks.
32817930|NCT05307484|Active Comparator|Dengue prevention website group|The control group accessed the NEA 'Stop Dengue' website which contained dengue prevention information in the forms of online articles, posters and video. The participants were instructed to complete reading the online resources within 2 weeks.
32817931|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
32817932|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
32817933|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
32817934|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
32817935|NCT05307016||MAP patients|All pregnancies complicated with any degree of Placenta previa anterior, posterior or centralis undergoing pre-labor CS at gestational age (36+0 to 40+0)
32817936|NCT01082380|Experimental|1|
32817937|NCT01083628|Experimental|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
32817938|NCT01083628|Active Comparator|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
32817939|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32817940|NCT03014128||Inspection and Packaging|self-descriptive
32817941|NCT03014128||Grinding, Polishing and Matting|self-descriptive
32817942|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
32817943|NCT01035346|Experimental|A|
32817944|NCT01035346|Placebo Comparator|B|
32830625|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
32817945|NCT05306626|Experimental|The BEAM program group|The BEAM Program is delivered via mobile application and weekly group telehealth sessions. BEAM includes approximately 20 minutes of weekly asynchronous video modules on parenting and mental health. Mental Health videos will provide information and emotion-regulation strategies that draw from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication will also be central focuses of the mental health content. Supportive parenting videos will provide parents with emotion-focused parenting strategies and help parents understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow participants to discuss content and ask questions, with the purpose of increasing a sense of community and social support. The online community forum will provide a space for participants to reflect on their learned skills and connect with other participants in the program.
32817946|NCT05306626|No Intervention|Treatment as usual group|The treatment as usual (TAU) control arm of the study is designed to account for the potential effects of time on depression symptoms.
32817947|NCT05306392|Experimental|Moderate Hypothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of moderate hypothermia during 48 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
32817948|NCT05306392|Sham Comparator|Control - Normothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
32817949|NCT05306314||TREATAPROST 0 mL( BID- 10mL*2) PO|Treataprost 10 mL ( 5 mL 2*1- PO ) 42 days Generic Name : Treatarost Advance Dosage Form: Suspension, vials of 250 mL Dosage : 250 mL Frequency : 2*1 (BID) Duration: 42 days (6 weeks) Administration:Oral administration before meals 30 minutes as 20 mL(10mL*2)
32817950|NCT05306314||Antibiotic Treatment (1*1) PO + NSAID (PRN) PO ya da SUPP|"Levolon 500 mg ( 1*1 -PO) 28 daANTIBIOTIC TREATMENT Levolon 500 mg ( 1*1 - PO) 28 days (4 weeks) Dosage Form:Film-coated tablet Dosage : 500 mg Frequency : 1*1 Duration: 28 days (4 weeks) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals.~NSAID Diclomec 75 mg ( PRN- PO )- 28 days (4 weeks) Dosage Form:Tablet Dosage : 75 mg Frequency : PRN Duration: 28 days (4 weeks as per needed) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals."
32817951|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
32817952|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
32817953|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
32817954|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
32817955|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
32817956|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
33101717|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
33317568|NCT05668286|Active Comparator|posterior intra-articular steroid injection under USG guidance|Intra-articular steroid injection will be performed to the glenohumeral joint from the posterior, 2cm inferior and 2cm medial of the acromion posterolateral corner, under the guidance of USG.
33317569|NCT05668286|Active Comparator|anterior extra-articular steroid injection under USG guidance|Steroid injection will be performed from the anterior, immediately lateral to the coracoid process, to the CHL localization, to the extra-articular area under the guidance of USG.
33317570|NCT03992261|Experimental|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
33317571|NCT05324930|Placebo Comparator|Control group|After conventional therapy consisting of debridement, infection control and offloading, patients received a saline-moistened gauze dressing (control group) for wound care.
32830626|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
33101718|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
33317572|NCT05324930|Experimental|Experimental group|After conventional therapy consisting of debridement, infection control and offloading, patients received the piscean collagen dressing (the study group) for wound care.
33317573|NCT05292404|Experimental|Early PCSK9 inhibitor treatment group|
33317574|NCT05292404|Other|conventional treatment group|
33317575|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33317576|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
32817957|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
32817958|NCT05306236|Experimental|LLL therapy and postural correction ex (study group)|study group will be treated by low level laser therapy and postural correction exercises
32817959|NCT05306236|Experimental|postural correction ex (control group)|control group will be treated by postural correction exercises only
32817960|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
32817961|NCT01037452|Active Comparator|PPI alone|Lansoprazole
32817962|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
32817963|NCT01037452|Placebo Comparator|Placebo|Placebo
32817964|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
32817965|NCT05289856|Experimental|combination of Avelumab and Cabozantinib|800 mg Avelumab every 2 weeks and 40 mg Cabozantinib daily
32817966|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
32817967|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
32817968|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
32817969|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
32817970|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~AC sensitive patients [>60% probability of response to AC]~TC sensitive patients [>60% probability of response to TC]~Patients sensitive to neither AC nor TC; randomized to AC or TC"
32817971|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~In patients randomly assigned to AC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC~In patients randomly assigned to TC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC"
32817972|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
32817973|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
32817974|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
32817975|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
32817976|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
32817977|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
32817978|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
32817979|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
32817980|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
32817981|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
32817982|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
32817983|NCT01588119||Dabigatran|in atrial fibrillation
32817984|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
32817985|NCT01588119||Apixaban|in atrial fibrillation and VTE
32817986|NCT01588119||Edoxaban|in atrial fibrillation and VTE
32817987|NCT01088464|Experimental|Cohort 1|
32817988|NCT01088464|Experimental|Cohort 2|
32817989|NCT01088464|Experimental|Cohort 3|
32817990|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
32817991|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
32817992|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
32817993|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
32830627|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
32817994|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
32817995|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
32817996|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
32817997|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
32817998|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
32817999|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
32818000|NCT04395885||control group|age matched group of non-health worker individuals.
32818001|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
32818002|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
32818003|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
32818004|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
32818005|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
32818006|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
32818007|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
32818008|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
32818009|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
32818010|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
32818011|NCT01092364|No Intervention|Advice only|Advice only control group.
32818012|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
32818013|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
32818014|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
32818015|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
32818016|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
32818017|NCT05289622|Experimental|Polyurethane expandable valve stent implant surgery|Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.
32818018|NCT05273320|Experimental|Open Label|"Titration: Nabilone p.o., increased in 0.25 mg increments every 2 days to a maximum of 1 mg b.i.d.~Open label: Nabilone p.o. at maximum dose tolerated for 28 days Tapering: Nabilone p.o. decreased in 0.25 decrements per day"
32818019|NCT05271994||Endoscopic biliary drainage|Patients with distal malignant biliary obstruction, who need endoscopic biliary drainage
32818020|NCT05190640|Experimental|Intervention arm|The dietary supplement (Asystems) is designed, and marketed commercially to be taken in servings of one gummy: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies.
32818021|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
32818022|NCT05106244|Experimental|family self-nursing mode|
32818023|NCT05106244|No Intervention|hospital nursing mode|
32818024|NCT05088148||Group 1: FGR group|Estimated fetal weight <10th percentile
32818025|NCT05088148||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
32818026|NCT01039792|Placebo Comparator|Placebo|Placebo
32818027|NCT01039792|Experimental|Active|Active Methyl B12
32818028|NCT03013816|Experimental|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
32818029|NCT03013816|Experimental|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
32818030|NCT03013816|Experimental|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
32830628|NCT04443504|Experimental|Intervention Group|
32830629|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
32955809|NCT05766852|Other|Control Group|Participants assigned to the Intervention Second Group will act as the control group and will not receive intervention during the first half of the study (Session 1). Although the Intervention Second Group participants will not participate in the intervention alongside Intervention First Group participants, they will still be asked to complete the pre- and post-assessments, which includes providing blood samples and completing of a 20-25-minute survey. Their post-assessment will be compared to the pre-assessment to assess improvements and benefits of the intervention, which will be provided in session 2. The Intervention Second Group participants will then participate in the three two-hour intervention classes, followed by a post-assessment survey and provide blood sample. The Intervention Second Group participants will complete a final post-assessment survey 1-month post the intervention.
32955810|NCT05766839|Experimental|Patiromer|"Cohort A (2 to < 6 years old): Pharmacodynamics (PD)/dose-ranging period duration is 4 weeks~Cohort B (0 to < 2 years old): Pharmacodynamics (PD)/dose-ranging period duration is 4 weeks"
32955811|NCT05766826|Experimental|Treatment Arm|After enrollment over a phone call, they receive a SMS text message with an ID number to receive their coupons at the health facility. Those coupons can be used to redeem WaterGuard 150mL dilute chlorine. Participants in this group will receive a packet of coupons that ensure a monthly supply of a150ml bottle of dilute chlorine solution for at least the next 12 months. These coupons are redeemable in health facilities and other sites registered for the study.
32955812|NCT05766826|Experimental|Control Arm|After enrollment over a phone call, they will not be contacted.
32955813|NCT05766813|Experimental|Lenrispodun 30 mg|Lenrispodun 30 mg tablets administered orally, once-daily.
32955814|NCT05766813|Placebo Comparator|Placebo|Matching tablets administered orally, once daily.
32955815|NCT05766787|Other|LID022821/AOHP|Serafilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
32955816|NCT05766787|Other|AOHP/LID022821|Senofilcon A contact lenses worn first, with serafilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
32955817|NCT05766774|Experimental|Low-added sugar, high-fat diet Arm|Patients will receive a low-added sugar, high-fat diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation.Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
32955818|NCT05766774|Active Comparator|Typical CF diet Arm|Patients will receive a high-added sugar, high-fat CF diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation. Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
32955819|NCT05766748|Experimental|Treatment Group|"Azeliragon will be orally administered to 3 groups of 6 subjects, with escalation of dosing occurring with each subsequent group.~Dose Level 1 consists of a loading dose of 15mg once daily for 6 days, followed by a continuous dose of 5mg once daily for the remainder of the study.~Dose Level 2 consists of a loading dose of 15mg twice daily for 6 days, followed by a continuous dose of 10mg once daily for the remainder of the study.~Dose Level 3 consists of a loading dose of 30mg twice daily for 6 days, followed by a continuous dose of 20mg once daily for the remainder of the study.~Escalation will continue until stopping rules are met or the highest defined dose level is reached. The trial will be closed to accrual if the first dose level is deemed intolerable."
32955820|NCT05766735|Active Comparator|Medication Management (MM)|Participants will be actively working with their personal physician during the study and will attend appointments with their physician as needed. The study team will monitor their progress at the scheduled Assessment Visits. The participants should discuss any concerns they have, including side effects or cost, in order to adjust the medication regime with their primary care team. Their physician/clinician may recommend additional things, like weight loss, exercise programs and/or diabetes education programs.
32955821|NCT05766735|Experimental|Glucose Excursion Minimization (GEM)|GEM is an individualized, person-centered, empowerment program, not a behavior modification program. GEM provides individuals with personally relevant information to make choices that will help them achieve their diabetes goals. It focuses on techniques - eating low glycemic load foods, increasing moderate and vigorous exercise, and monitoring blood glucose (BG) to educate individuals about the impact of high glycemic load nutrients and vigorous exercise. The emphasis is on minimizing glucose excursions by any practical means, e.g., nutrient selection, timing and combinations of nutrient intake, time restricted eating, eating carbohydrates after protein and fat, post prandial physical activity, whatever is personally affirmed by BG feedback.
32955825|NCT05766696|Experimental|Atraumatic Restorative Treatment (ART)|GIC restorations placed using ART in a class room.
33101719|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
32818031|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
32818032|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
32818033|NCT05023720||Regorafenib group|Patients were given only regorafenib orally
32818034|NCT05023720||Joint group|The patient was treated with regorafenib orally and in combination with other medications
32818035|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
32818036|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
32818037|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
32818038|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
32818039|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
32818040|NCT04988386|Experimental|AG10|Open-label study all participants will receive AG10 during this study.
32818041|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
32818042|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
32818043|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
32818044|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
32818045|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
32818046|NCT01401699|Experimental|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
32818047|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
32818048|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
32818049|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
32818050|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
32818051|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
32818052|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
32818053|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
32818054|NCT04906018||volunteer group - BMI less than 30|Each subject with a BMI less than 30 will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
32818055|NCT04906018||volunteer group - BMI of 30 and above|Each subject with a BMI of 30 and above will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
32818056|NCT04880668|No Intervention|Control - No aerosol box|Participants will perform the AGMP without an aerosol box
32818057|NCT04880668|Experimental|Intervention - Aerosol box|Participants will perform the AGMP with an aerosol box
32818058|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
32818059|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
33101720|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
33101721|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
32818060|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
32818061|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
32818062|NCT04801810|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
32818063|NCT04801810|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
32818064|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
32818065|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
32818066|NCT04510090|Experimental|EP547 Single Dose|Single doses of EP547
32818067|NCT04510090|Experimental|EP547 Multiple Doses|Multiple doses of EP547
32818068|NCT04510090|Placebo Comparator|Placebo Single Dose|Single doses of placebo
32818069|NCT04510090|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo
32818070|NCT04447534|Experimental|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine alone
32818071|NCT04447534|Experimental|Chloroquine or hydroxychloroquine with zinc|Chloroquine or hydroxychloroquine with zinc
32818072|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
32818073|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
32818074|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
32818075|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
32818076|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
32818077|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
32818078|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
32818079|NCT04365478|Experimental|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
32818080|NCT04365478|Active Comparator|Control group|conventional physiotherapy
32818081|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
32818082|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
32818083|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
32818084|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
32818085|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
32830630|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
32830631|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
32830632|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
32955826|NCT05766696|Active Comparator|Conventional Cavity Preparation|GIC restorations placed using conventional cavity preparation in a mobile clinic.
32818086|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
32818087|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
32818088|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
32818089|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
32818090|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
32818091|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
32818092|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
32818093|NCT04229992|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
32818094|NCT04229992|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
32818095|NCT04229992|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
32818096|NCT04229992|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
32818097|NCT04224766|Experimental|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
32818098|NCT04224766|Active Comparator|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
32818099|NCT04210882|Experimental|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
32818100|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
32818101|NCT03012256|No Intervention|Control|Home care (standard of care)
32818102|NCT04185298|Active Comparator|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
32818103|NCT04185298|Experimental|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
32818104|NCT04184362|Experimental|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
32818105|NCT04184362|Sham Comparator|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
32818106|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
32818107|NCT01049776|Experimental|Pazapanib (GW786034)|
32818108|NCT04118062|Other|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
32818109|NCT04118062|Other|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
32818110|NCT04118062|Other|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
33317577|NCT05276804|Experimental|Sugammadex|Prospective cohort of patients undergoing laparoscopic inguinal hernia repair will receive Sugammadex. Sugammadex will be used for reversal of their neuromuscular blockade. The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
32818111|NCT04118062|Other|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
32818112|NCT04118062|Other|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
32818113|NCT04118062|Other|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
32818114|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 1.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.
32818115|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 3.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818116|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818117|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 20.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818118|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once weekly for the first 12 weeks and once every 2 weeks starting Week 13 in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818119|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, Post-platinum Doublet|Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818120|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, First Line|Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818121|NCT01772004|Experimental|Primary Expansion Cohort: Metastatic Breast Cancer|Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818122|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who progressed on or after first line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818123|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Non Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818124|NCT01772004|Experimental|Secondary Expansion Cohort: Colorectal Cancer|Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818125|NCT01772004|Experimental|Secondary Expansion Cohort: Castrate-resistant Prostate Cancer|Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818126|NCT01772004|Experimental|Secondary Expansion Cohort: Adrenocortical Carcinoma|Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818127|NCT01772004|Experimental|Secondary Expansion Cohort: Melanoma|Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818128|NCT01772004|Experimental|Secondary Expansion Cohort: Mesothelioma|Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818129|NCT01772004|Experimental|Secondary Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818130|NCT01772004|Experimental|Secondary Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818131|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)|Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818132|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)|Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32955829|NCT05766670|Other|Intramedullary calcium sulfate antibiotic depot prior to Intramedullary nailing (IMN) placement (CS)|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
32955830|NCT05766670|Other|Standard of care intramedullary nail (SN)|Standard of care intramedullary nail
32955831|NCT05766657|Experimental|Intervention group|Children with obesity or T1D will be randomized into this group. An individualized dietary approach will be used in this group of children.
32955832|NCT05766657|Placebo Comparator|Control Group|children assigned to the control group will receive generic advice based on European dietary guidelines for obesity or follow their usual diet in the case of children with T1D.
32955833|NCT05766644|No Intervention|Control|Usual care, with no guide on app use. Surveys are administered via Short Message Services links.
32818133|NCT01772004|Experimental|Efficacy Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818134|NCT01772004|Experimental|Efficacy Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818135|NCT01772004|Experimental|Efficacy Expansion Cohort: GC/ GEJC, Third Line|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818136|NCT01772004|Experimental|Efficacy Expansion Cohort: HNSCC|Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
32818137|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
32818138|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
32818139|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
32818140|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
32818141|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
32818142|NCT04352218|Active Comparator|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
32818143|NCT04352218|Experimental|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
32818144|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
32818145|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
32818146|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
32818147|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
32818148|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
32818149|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
32818150|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
32818151|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
32818152|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
32818153|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
32818154|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
32818155|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
32818156|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
32818157|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
32818158|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
32818159|NCT02550886||Patient/Caregiver Dyad|
32818160|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
32818161|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
32818162|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
32818163|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
32818164|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
32818165|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
32818166|NCT01668082|Experimental|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.~--------------------------------------------------------------------------------"
32818167|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
32818168|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
32818169|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
32818170|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
32818171|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
32818172|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
32818173|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
33317578|NCT05276804|No Intervention|Retrospective cohort|Retrospective cohort of patients who did not receive Sugammadex
32818174|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
32818175|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
32818176|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
32818177|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
32818178|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
32818179|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
32818180|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
32818181|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
32818182|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
32818183|NCT05389566||Type 1 diabetes|People with type 1 diabetes above 40 years
32818184|NCT05389566||People with type 2 diabetes|People with type 2 diabetes above 50 years
32818185|NCT05389566||Healthy controls|Healthy controls without diabetes
32818186|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
33101722|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
33101723|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
33101724|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
32818187|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
32818188|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
32818189|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
32818190|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
32818191|NCT03469362|Experimental|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
32818192|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
32818193|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
32818194|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
32818195|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
32818196|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
32818197|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
32818198|NCT05166330|Active Comparator|ketofol 1:1|0.15-0.2 mL/kg from of 5 mg/mL propofol and 5 mg/mL ketamine mixture
33101725|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
33101726|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:~stretching, strengthening and/or mobilization;~functional training of the affected muscles;~functional training of the paretic limb."
32818199|NCT05166330|Active Comparator|ketofol 1:3|0.15-0.2 mL/kg from of 7.5 mg/mL propofol and 2.5 mg/mL ketamine mixture
32818200|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
32818201|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
32818202|NCT03344250|Experimental|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
32818203|NCT03344250|Experimental|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
32818204|NCT01130740|No Intervention|Arm 1|usual care
32818205|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
32818206|NCT05397288|Experimental|Resistance-Aerobic-Education (RAE)|"Participants first receive 6 months of resistance exercise, then 6 months of aerobic exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A) Behavioral: Healthy lifestyle education (E)"
32818207|NCT05397288|Experimental|Aerobic-Resistance-Education (ARE)|"Participants first receive 6 months of aerobic exercise, then 6 months of resistance exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Aerobic exercise (A) Behavioral: Resistance exercise (R) Behavioral: Healthy lifestyle education (E)"
32818208|NCT05397288|Experimental|Education-Resistance-Aerobic (ERA)|"Participants first receive 6 months of education program on healthy lifestyle, then 6 months of resistance exercise, and finally 6 months of aerobic exercise.~Behavioral: Healthy lifestyle education (E) Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A)"
32818209|NCT04453644|Experimental|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
32818210|NCT04453644|Experimental|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
32818211|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
32818212|NCT05166174||Pregnant women who underwent previous cesarean section with barbed suture|"This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed by using barbed suture (Fish-bone suture)."
32818213|NCT05166174||Pregnant women who underwent previous cesarean section with conventional smooth suture|This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed conventional smooth suture.
32818214|NCT05396976|Experimental|Yoga Group|Yoga practice will be done two days a week for 10 weeks.
32818215|NCT05396976|No Intervention|control group|no intervention
32818216|NCT05396976|Experimental|Muscle Relaxation Exercise Practices Group|Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
32818217|NCT05396976|Experimental|Yoga and Muscle Relaxation Exercise Practices Group|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
32818218|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
32818219|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
32818220|NCT03687138||Control 1|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
32818221|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the controls populations.
32818222|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
32818223|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
32818224|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
32818225|NCT05389410|Experimental|Revision Hip surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
32818226|NCT05389410|Active Comparator|Revision knee surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
32818227|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
33317579|NCT03981419|Experimental|GRF6021|"Subjects will receive GRF6021 per the following schedule:~On the day before surgery~On the day of surgery within 4 hours before surgery start (first incision)~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)~On the day after surgery"
33317580|NCT03981419|Placebo Comparator|Placebo|"Subjects will receive Placebo per the following schedule:~On the day before surgery~On the day of surgery within 4 hours before surgery start (first incision)~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)~On the day after surgery"
33317581|NCT05266352|Experimental|Supervised exercise group|The group received the supervised exercise program
33317582|NCT05266352|Active Comparator|Home exercise group|The group received the home exercise program
32818232|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
32818233|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
32818234|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
32818235|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
32818236|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
32818237|NCT05396742|Experimental|Cohort 1|Participants received a single dose of ravulizumab SC 400 (milligrams) mg .
32818238|NCT05396742|Experimental|Cohort 2|Participants received a single dose of ravulizumab SC 500 mg/rHuPH20 10000 units.
32818239|NCT05396742|Experimental|Cohort 3|Participants received a single dose of ravulizumab SC 1000 mg/rHuPH20 20000 units.
32818240|NCT05396742|Experimental|Cohort 4|Participants received a single dose of ravulizumab SC 2000 mg/rHuPH20 40000 units.
32818241|NCT05396742|Experimental|Cohort 5|Participants received a single dose of ravulizumab intravenously (IV) 400 mg.
32818242|NCT01171924|Experimental|Arm A: 5 days/week schedule|
32818243|NCT01171924|Experimental|Arm B: 3 days/week schedule|
32818244|NCT05396664|Experimental|Intervention|The ATWA LSE program will be implemented following a joint curricula development process with approval from the government in each of the three countries. The 'dose' of the intervention are once-weekly hour-long sessions for both in-school adolescents (session facilitated by teachers) and out-of-school adolescents (sessions facilitated by community leaders) over the course of the academic year (roughly 9 months), or roughly 30 sessions of exposure to the in-depth LSE curriculum.
32818245|NCT05396664|No Intervention|Control|"Control groups are comprised of adolescents (10-19) attending schools where the ATWA Life Skills Education (LSE) program has not been implemented, as well as out-of-school adolescents (10-19) who have not received the ATWA LSE program in their communities. Control groups receive standard of care educational opportunities. Standard of care in the case of this trial translate to the provision of standard Ministry of Education-sanctioned sexuality education, as already available in the adolescents' schools and communities."
32818246|NCT05389254|Experimental|real-time CGM group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. According to the real-time CGM blood glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
32830633|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
33317583|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
33317584|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
33317585|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
33317586|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
33317587|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
32818247|NCT05389254|Other|Capillary blood glucose monitoring group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. But these patients will be blind to the CGM data. They'll receive 8-point capillary blood glucose monitoring simultaneously, which are 6am, 9am, 11am, 1pm, 4pm, 7pm, 9pm, 2am. According to the 8-point glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
32818248|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
32818249|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
32818250|NCT05389176|Experimental|Group A|Esmolol is used 6 to 24 hours after onset of septic shock in patients with fluid optimization to control heart beats between 70-100bpm.
32818251|NCT05389176|Experimental|Group B|Esmolol is used 24 hours after onset of septic shock in patients to control heart beats between 70-100bpm.
32818252|NCT05389176|No Intervention|Group C|patients received conventional therapy in accordance with septic shock guidelines 2021
32818253|NCT05396508|Active Comparator|physical therapy|physical therapy
32818254|NCT05396508|Active Comparator|physical therapy + interfacial injection|physical therapy + interfascial injection
32818255|NCT01132690|Experimental|30 units/kg|
32818256|NCT01132690|Experimental|60 units/kg|
32818257|NCT05396430|Experimental|Urinary catheter 8 hours|The urinary cathter is to be removed at 8 hours after the end of surgery
32818258|NCT05396430|Experimental|Urinary catheter 10 hours|The urinary cathter is to be removed at 10 hours after the end of surgery
32818259|NCT05396430|Active Comparator|Urinary catheter 12 hours|The urinary cathter is to be removed at 12 hours after the end of surgery
32818260|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
32818261|NCT05396352|Experimental|Right cerebellum|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the right posterolateral cerebellum (lobule VII). All participants will receive anodal, cathodal and sham tDCS.
32818262|NCT05396352|Experimental|Posterior vermis|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the posterior cerebellar vermis. All participants will receive anodal, cathodal and sham tDCS.
32818263|NCT05380830|No Intervention|Control|The group will be only submitted to evaluations (body composition, hematological, lipid and cytokines profile, food intake, and maximal effort under treadmill and deep-water running) at the beginning and the end of the study.
32818264|NCT05380830|Experimental|Group Hypoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, but during the rest they will be under hypoxia (FiO2=13%).
32818265|NCT05380830|Placebo Comparator|Group Normoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, and during the rest they will keep under normoxia (FiO2=20%).
32818266|NCT05396274|Active Comparator|standard nasal therapy|"nasal oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
32818267|NCT05396274|Active Comparator|high flow nasal cannula|"High Flow Nasal Oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
32818268|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
32818269|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
32818270|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
32818271|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
32818272|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
32818273|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
32818274|NCT05378802|Experimental|NAVA mode|"st select a NAVA level that gives peak pressure about 9-10 cm H2O assist keep NAVA level for 15 minutes, do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM~nd increase NAVA level by 50% and repeat the protocol when patient's breathing has stabilized (only one increase) Do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM"
32818275|NCT05378802|Experimental|N- PSV mode|"st PS level of 8-10 cmH2O, keep PS level for 15 minutes, do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM At the end of protocol (minute 15) do one end-inspiratory hold-maneuver and one end-expiratory occlusion.~nd increase PS by 50% and repeat protocol when patient's breathing has stabilized (only 1 increase). Do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM"
32818276|NCT05378802|Active Comparator|VCV mode|"no spontaneous breathing Set Vt, Ti and RR to match the breathing pattern observed during NAVA. Make sure each change in level does not increase the pressure by more than 1 cmH2O.~Mode PCV no spontaneous breathing-do ZAM after each PS level Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures."
32818277|NCT05378802|Active Comparator|PCV mode|"Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures The idea is not to have pressures as high as 20 cmH2O, it is important to have high enough VCV & PCV flow rates so we can match the flow rates during spontaneous breathing. You might find that 15 or 16 cmH2O is enough to generate flow rates that match the maximum flow rate you saw during spontaneous breathing."
32818278|NCT05396196|Active Comparator|Pre-Tape|
32818279|NCT05396196|Experimental|With Tape 1|
32818280|NCT05396196|Experimental|With Tape 2|
32818281|NCT05396196|Experimental|Post-Tape|
32818282|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
32818283|NCT05165784|Active Comparator|V technique|Researcher will perform the V tecnique on the patient's inguinal area
32818284|NCT05165784|Active Comparator|palpation tecnique|Researcher will perform the V tecnique on the patient's inguinal area
32818285|NCT05165706|Experimental|Mediterranean Low Carbohydrate Diet|
32818286|NCT05165706|Experimental|Standard Low Carbohydrate Diet|
32818287|NCT05165706|Experimental|Low Fat, Healthy Carbohydrate Diet|
32818288|NCT04215900|Experimental|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
32818289|NCT04215900|No Intervention|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
32818290|NCT01133158|Experimental|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
32818291|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
32818292|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
32818293|NCT05396118|Experimental|Experimental|Injection of 18F-FDG and injections of hyperpolarized [1-13C]Pyruvate and subsequent PET/MRI/MRS scan
32818294|NCT01133860|Experimental|eltrombopag|
32818295|NCT04455516||repair group|The first operation in these patients was meniscus repair
32818296|NCT04455516||nonfailure group|These patients had a successful first operation
32818297|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
32818298|NCT04099836|Experimental|atezolizumab and bevacizumab|Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
32818299|NCT02184208||Device utlization following extubation|
32818300|NCT02184208||Pulmonary mechanics|
32818301|NCT05372406||training group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
32818302|NCT05372406||external validation group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
32818303|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
32818304|NCT04819074||Patients with unruptured brain aneurysms|"We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.~No intervention."
32818305|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
32818306|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
32818307|NCT04815798|Experimental|Bacteriophage-loaded Microcapsule Spray with Standard of Care|Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
32818308|NCT04815798|Placebo Comparator|Placebo with Standard of Care|Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.
32818309|NCT05388240|Active Comparator|Education Group|"The Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery and will be advised to continue with their normal activities of daily living (ADL). They will have access to the standard education and resources tabs on the mobile app. Shoulder specific exercises tab on the app will be available to them upon their completion of the study (eight weeks post-intervention)."
32818310|NCT05388240|Experimental|Education plus Exercise Group|"The Exercise plus Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery. Participants in this group will have access to the education and resources tabs on the app."
32818311|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
32818312|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
32818313|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
32818314|NCT01174030|Placebo Comparator|Vehicle Gel QD|
32818315|NCT01174030|Placebo Comparator|Vehicle Gel BID|
32818316|NCT04092894|Active Comparator|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
32818317|NCT04092894|Placebo Comparator|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
32818318|NCT04697004|Experimental|SMR Stemless Reverse|
32818319|NCT04697004|Active Comparator|SMR Reverse Shoulder System|
32818320|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
33317588|NCT05559892|Experimental|Diabetes-Tailored CCTs (DM-CCT) Intervention|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions). Therefore, they will only receive cash transfer payments if they attend two sessions per month.
33317589|NCT05559892|Active Comparator|Unconditional Cash Transfer-UCTs Intervention|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
33317590|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
33317591|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
33317592|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
32818321|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
32818322|NCT01174576|Experimental|Water|200 mL, control intervention
32818323|NCT04641936||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
32818324|NCT04641936||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
32818325|NCT01134328|Experimental|AC-150 Combo|
32818326|NCT01134328|Active Comparator|AC-150A 0.1%|
32818327|NCT01134328|Active Comparator|AC-150B 0.005%|
32818328|NCT01134328|Other|Vehicle|
32818329|NCT05165004|Experimental|Kangaroo Mother Care|Researchers contacted the mother a day before applying KMC, and advised her to take shower and abstain from using perfumes before attending to the NICU. On days of KMC application, the researchers asked the mother to remove the upper clothes in a private room and put on an open-front gown and mask. The mother was assisted to sit in a comfortable chair with a soft backrest and footrest to prevent fatigue. Then, the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation. The mother was instructed to support the neonate's bottom with the right hand while supporting the head and neck with the other hand.
32818330|NCT05165004|Experimental|Hammock Positioning|Researchers made a hammock by using a rectangular cotton cloth with ropes that passed through the circular openings of the incubator and tied on the upper part of it. After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed.
32818331|NCT05165004|Active Comparator|NICU Routine Care|The preterm neonates in the control group received the routine care of the NICU, which entails; encircling the neonate in a fetal position using rolled towel inside the incubator.
32818332|NCT04622124|Placebo Comparator|Part 1 Single Ascending Dose (SAD) study|The single ascending dose trial set up 7 dose groups of 2.5, 5, 10, 20, 40, 60 and 80 mg. The 2.5 mg dose group was the exploratory part with open label, while the other dose groups were double-blind. 8 subjects were randomly enrolled in each dose group, 6 of whom received FCN-207 tablets and 2 of whom received placebo. This part of the study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic studies of single dose FCN-207 tablets in healthy volunteers.
32818333|NCT04622124|Experimental|Part 2 Food-effect study|Twelve subjects were enrolled and randomly divided into two groups. The subjects were given FCN-207 tablets after fasting and high-fat diet with double Cross experiment , and feces samples were collected for metabolism/excretion characteristics study.
32818334|NCT04622124|Placebo Comparator|Part 3 Multiple Ascending Dose (MAD) study|A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
32818335|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
33317593|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
32818337|NCT04590222||Female, BMI≥30, mild|"Females:~Obese BMI≥30 With Mild infection n = 10"
32818338|NCT04590222||Female, BMI≥30, severe|"Females:~Obese BMI≥30 With severe infection n = 10"
32818339|NCT04590222||Female, BMI<30, mild|"Females:~Non-Obese BMI<30 With Mild infection n = 10"
32818340|NCT04590222||Female, BMI<30, severe|"Females:~Non-Obese BMI<30 With severe infection n = 10"
32818341|NCT04590222||male, BMI≥30, mild|males: Obese BMI≥30 With Mild infection n = 10
32818342|NCT04590222||male, BMI≥30, severe|males: Obese BMI≥30 With severe infection n = 10
32818343|NCT04590222||male, BMI<30, mild|males: Non-Obese BMI<30 With Mild infection n = 10
32818344|NCT04590222||male, BMI<30, severe|males: Non-Obese BMI<30 With severe infection n = 10
32818345|NCT04590222||Healthy donors from the EFS (Etablissement Français du Sang, St Louis)|Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
32830634|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
33317594|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
33317595|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
32818346|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
32818347|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
33405125|NCT05762250|Experimental|Auricular Acupuncture|"Intervention group: Ear acupressure is performed on both ears with permanent pellets according to the NADA (National Acupuncture Detoxification Association) protocol over a period of 8 weeks (presentation at the study center 1x/week, application of the acupressure patches there; these remain on both ears for 5 days and should be massaged 3x/day by the patients themselves according to the instructions provided).~In addition, patients receive a 30-minute psychoeducational talk at the first treatment appointment to promote their own health competence."
33405126|NCT05762250|No Intervention|Waitlist|Control group: standard treatment / waiting list Patients in the control group will also receive a one-time 30-minute psychoeducational interview at baseline.
32818350|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
32818351|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
32818352|NCT04691232|Experimental|Regulatory T cells|Intravenous infusion of a single dose of 0.5x10e6, 1x10e6, 2x10e6, 5x10e6 or 10x10e6 Treg/kg body weight
32818353|NCT05384730|Experimental|Intervention Arm|This group will receive the weekly group exercise and nutrition support which will be delivered online by trained volunteers. The duration of the intervention is 12 weeks.
32818354|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
32818355|NCT03892980|Experimental|Nipple Sparing Mastectomy|
32818356|NCT01216683|Experimental|Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)|"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
32818357|NCT01216683|Experimental|Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)|"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D."
32818358|NCT01216683|Experimental|Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)|"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
32818359|NCT05379114|Experimental|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
32818360|NCT05379114|Active Comparator|COMPARATOR DEVICE|dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®
32818361|NCT05164848|Experimental|Cohort A|"JMT101 combined with two dose levels of afatinib will be tested according to the 3 + 3 dose-escalation design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
32818362|NCT05164848|Experimental|Dose Expansion Cohort|Once the safe and effective dose has been determined, an expansion cohort will be recruited to further evaluate the efficacy and safety of the selected dose.
32818363|NCT04663074||IVUS Group|Patients treated by BEVAR/CHEVAR/FEVAR due to a thoracoabdominal aneurysm.
32818364|NCT05164770|Experimental|Zanubrutinib+R+chemotherapy|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
32818365|NCT05164770|Active Comparator|R+chemotherapy|R-CHOP; R-DA-EPOCH; R-HD MTX
32818366|NCT05374668|Experimental|Video-based Yoga|video-based yoga (n=40) given for patients in post-covid-19 status for 8 weeks
32818367|NCT05374668|Experimental|Home-based postur exercises|Home exzercises were given for 8 weeks
32818368|NCT05164692|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
32830635|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
32818369|NCT05164692|Experimental|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billions CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
32818370|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
32818371|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
32818372|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
32818373|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
32818374|NCT05090982||Patients with Atopic dermatitis|150 patients with Atopic dermatitis
32818375|NCT05370222|Experimental|Experimental group|
32818376|NCT00634569|Experimental|Flebogamma 5% DIF|
32818377|NCT04247100|Experimental|Active Stimulation (8)|"Participants will receive active auricular microstimulation via TENS unit for 8 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks."
32818378|NCT04247100|Sham Comparator|Sham Stimulation (4), Active (4)|"Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS)."
32818379|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
32818380|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
32818381|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32818382|NCT04246554|Experimental|Control|Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
32818383|NCT04246554|Experimental|Ketorolac|Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control
32818384|NCT01922817|Active Comparator|Saxagliptin|5mg once daily in addition to insulin therapy
32818385|NCT01922817|Placebo Comparator|Placebo|Crossover Placebo once daily
32818386|NCT04275765|No Intervention|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
32818387|NCT04275765|Active Comparator|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
32818388|NCT04275765|Active Comparator|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
32818389|NCT05697432|Experimental|Education|The children with special needs will receive a complete oral examination and then their parent/guardian will be subjected to education about oral hygiene, brushing and dietary guidance.
32818390|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
32818391|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
32818392|NCT04275609|Experimental|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
32818393|NCT04275609|Active Comparator|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
32818394|NCT05351268|Experimental|3DPCT and CT guided RISI|All patients were treated with clinical routine treatment: 3DPCT combined with CT guided radioactive seed implantation. Collect patient information and treatment information for analysis.
32818395|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
32818396|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
32818397|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
32818398|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
32818399|NCT04275921|Experimental|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
32818400|NCT04275921|Experimental|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
32818401|NCT04397289|Experimental|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
32818402|NCT04397289|Experimental|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
32818403|NCT04397289|Sham Comparator|Control group|No preventive intervention measures.
32818404|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
32818405|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
32818406|NCT05349552||Chest Wall Type|The lesion is directly adjacent (less than 1cm) or overlapped with the chest wall.
32818407|NCT05349552||Peripheral Type|The lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree.
32818408|NCT05349552||Central Type|The lesion is less than 2cm away from the bronchial tree.
32818409|NCT05349552||Ultral-central Type|The lesion is directly adjacent or overlapped with the mediastinal structure.
32818410|NCT04396275|Experimental|Cooked whole navy beans|A meal consisting of cooked navy beans
32818411|NCT04396275|Experimental|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
32818412|NCT04396275|Experimental|Cooked rice (control)|A meal consisting of cooked rice
32818413|NCT05697354|Experimental|Tablet group|The Tablet group will carry out the exercises using the Khymeia VRRS Home Tablet.
32818414|NCT05697354|Experimental|App group|The App group will perform the exercises on their smartphone using the Khymeia Medico Amico App.
32818415|NCT01137370||Patients with TB|
32818416|NCT01137370||People without TB|
32818417|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
32818418|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
32818419|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
32818420|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
32818421|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
32818422|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
32818423|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
32818424|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
32818425|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
32818426|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
32818427|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
32818428|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
32818429|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
32818430|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
32818431|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
32818432|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
32818433|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
32818434|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
32818435|NCT03877926|Experimental|AV7909 Lot 1|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
32818436|NCT03877926|Experimental|AV7909 Lot 2|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
32818437|NCT03877926|Experimental|AV7909 Lot 3|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
32818438|NCT03877926|Active Comparator|BioThrax|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax® vaccine will be administered, per the study visit schedule.
32818439|NCT01181674|Experimental|Group 1 (short)|
32818440|NCT01181674|Experimental|Group 2 (long)|
32818441|NCT01181674|Other|Standard care|
32818442|NCT05697198||Cohort lung cancer|
32818443|NCT05697198||Gyn malignancies|
32818444|NCT05697198||Gastrointestinal malignancies Cohort|
32818445|NCT05697198||Melanoma Cohort|
32818446|NCT05697198||Breast cancer Cohort|
32818447|NCT05697198||Head and neck cancer Cohort|
32818448|NCT05697198||Sarcoma and soft tissue cancer cohort|
32818449|NCT05697198||Prostate cancer|
32818450|NCT05221866|No Intervention|Control|UControlPain App with only data collection function. No provider-facing prescription intervention.
32818451|NCT05221866|Active Comparator|UControlPain educational app only|UControlPain app with education components. No provider-facing prescription intervention.
32818452|NCT05221866|Active Comparator|UControlPain app AND provider facing tool|UControlPain app with education components and provider-facing prescription intervention.
32818453|NCT05221866|Active Comparator|Provider facing tool only|UControlPain App with only data collection function. Provider-facing prescription intervention.
32818454|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
32818455|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
32818456|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
32818457|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
32818458|NCT05219136|Active Comparator|Conventional Fasting Group|In this parallel group, subjects are performed a conventional fasting protocol which requires 6-8h fasting for solid, 2h for clear liquids.
32818459|NCT05219136|Experimental|Modified Fasting Group|"In this test group, a new protocol of 4h fasting for rice porridge, 2h for clear liquids is applied to subjects.~The rice porridge is commercially available (New Rice Porridge®, Charm Kitchen Food Co., Ltd., Q/NBBD0001S). The volume is 300ml, with the energy as 105kJ per 100g, and it can be eaten after being heated or at room temperature."
32818460|NCT03188172|Experimental|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
32818461|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
32818462|NCT05340036|Active Comparator|Group I (Conventional plates)|"Digital intermediate and final interocclusal wafer splints will be designed to guide the maxilla and mandible in the desired position using CAD software (3-matic 11.0; Materialise NV, Leuven, Belgium).~The designed splints will be then exported in stereolithography (STL) file format to the additive CAM machine (FORMIGA P 110 printer; EOS e-manufacturing solutions, Munich, Germany) and manufactured in white polyamide (PA2200; EOS e-manufacturing solutions, Munich, Germany) using fused deposition modelling (FDM) technology.The splints will be cold sterilized by overnight immersion in 2% glutaraldehyde.~2.0 conventional mini plates will be used for fixation of maxilla and mandible in the new position."
32818463|NCT05340036|Experimental|Group II (Patient specific plates)|"The cutting guides will be designed on the maxilla and mandible to orient the osteotomy and mark reference holes to be used later for the repositioning/ fixation plate, using CAD software.~The designed guide will be then exported in stereolithography (STL) file format to the additive CAM machine and manufactured in white polyamide using fused deposition modelling (FDM) technology. No finishing or polishing was done in order to maintain accuracy. The guides will be cold sterilized by overnight immersion in 2% glutaraldehyde.~The patient-specific osteosynthesis plates will be designed to fix the maxilla and mandible in the desired position making use of the previously established reference holes. The designed plates will be exported in STL file format to be manufactured in grade 5 titanium alloy utilizing selective laser sintering (SLS) technology on an additive CAM machine."
32818464|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
32818465|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
32818466|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
32818467|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
32818468|NCT05672550|Experimental|Bayesian based dose adjustment|"Optimization of the enoxaparin dose using a bayesian program in order to prevent patients from complications due to the renal transplantation.~A first recommended dose of enoxaparin (50 IU/kg) is administered subcutaneously during transplantation or within the first 24 hours.~Then, in the experimental group, the dose is adjusted following a bayesian program integrated in the electronic Case Report Form which is based on each patient's data as the Anti-Xa activity"
32818469|NCT05672550|Active Comparator|Treatment as usual (empirical dose adjustment)|Anti-Xa activity is measured and twice-daily enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers
32818470|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
32818471|NCT05282706|Experimental|Pain Symptoms Arm|Subjects who will receive physical or occupational therapy experiencing pain prior to therapy session.
32818472|NCT05282706|Experimental|Nausea Symptom Arm|Subjects who will receive physical or occupational therapy experiencing nausea prior to therapy session.
32818473|NCT05282706|Placebo Comparator|Placebo Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session.
32818474|NCT05282706|No Intervention|Standard of Care Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session that decline the option to use an aromatherapy patch.
32818475|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
32818476|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
32818477|NCT05263596|Other|No Sarcopenia (Control Group)|healthy participants
32818478|NCT05263596|Other|Sarcopenia is probable|"Low muscle strength (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
32818479|NCT05263596|Other|Sarcopenia is confirmed|"Low muscle strength + low muscle quantity (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
32818480|NCT05199168|No Intervention|Thoracoscopic esophagectomy without IONM|
32818481|NCT05199168|Experimental|Thoracoscopic esophagectomy with IONM|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
32818482|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
32818483|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
32818487|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
32818488|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
32818489|NCT05194800|Experimental|Unilateral upper extremity amputees|Unilateral upper extremity amputees suffering from chronic phantom limb pain > 1 yr will be recruited from a hospital based outpatient Physical Medicine and Rehabilitation Amputee Clinic at UAB.
32818490|NCT05190822||Students|
32818491|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
32818492|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
32818493|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
32818494|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
32818495|NCT05439954||Case group|（a）patients fulfilling the Diagnostic Criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition（DSM-V); (b)age:14 and under 14 years old; (c)first clinic visit, never-treated; (d)without injury to head and other diseases of the nervous system.
32818496|NCT05439954||Control Group|（a）healthy subject of same ages;(b)without injury to head and diseases of the nervous system; (c)without family history of mental disorders; (d)without other somatic illness.
32818497|NCT05439798|Active Comparator|Group OD (Group ondansetron+dexamethasone)|The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg-1).
32818498|NCT05439798|Active Comparator|Group PD (Group palonosetron+dexamethasone)|The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).
32818499|NCT05439798|Placebo Comparator|Group D (Group Dexamethasone)|The patients in Group D (Group Dexamethasone) will be given intravenous (iv) dexamethasone (0.5 mg.kg-1).
32818500|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
32818501|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
32818502|NCT05439720|Experimental|Exercise and ketone|Ketone ester is provided
32818503|NCT05439720|Placebo Comparator|Exercise and placebo|Placebo is provided
32818504|NCT05439720|Placebo Comparator|Non-exercise and placebo|Placebo is provided
32818505|NCT05439642|Other|Hemophilia|Evaluation of quality of life of children with hemophilia in Turkey
32818506|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
32818507|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
32830636|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
32830637|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
32818508|NCT05309460|Active Comparator|Nifedipine|Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
32818509|NCT05309460|Active Comparator|Labetalol|Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.
32818510|NCT03261804||Group I:internal vaginal douching users|
32818511|NCT03261804||Group II: none internal vaginal douching users|
32818512|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
32818513|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
32818514|NCT05301426|Experimental|Passive hamstring stretch.|Manual stretching of the hamstring muscles using the technique proposed by Henri Neiger.
32818515|NCT05301426|Experimental|Longitudinal slippage of the sciatic nerve.|Neurodynamic technique described by David Butler and Michael Shacklock.
32818516|NCT05301426|Active Comparator|Passive upper limb mobilisations.|Control group. Passive mobilisation of the upper limbs.
32818517|NCT04455360|Experimental|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
32818518|NCT04455360|No Intervention|Standard care|Patients will receive standard post-hospital discharge care.
32818519|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
32818520|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
32818521|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
32818522|NCT05439486|Active Comparator|100% oxygen|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
32818523|NCT05439486|Placebo Comparator|ordinary room oxygen|ED patients in this group exposed to normal air oxygen concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
32818524|NCT01143688|Active Comparator|albuterol inhaler|albuterol
32818525|NCT01143688|Placebo Comparator|placebo inhaler|placebo
32818526|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
32818527|NCT04455594|Experimental|Almonertinib|Almonertinib 110mg QD
32818528|NCT04455594|Active Comparator|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
32818529|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
32818530|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
32818531|NCT05439408|Experimental|XS004 - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
32818532|NCT05439408|Active Comparator|SPRYCEL - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
32818533|NCT05439408|Experimental|XS004 - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
32818534|NCT05439408|Active Comparator|SPRYCEL - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
32818535|NCT05439408|Experimental|XS004 - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
32818536|NCT05439408|Active Comparator|SPRYCEL - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
32818537|NCT05439408|Experimental|XS004 - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
32830638|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
32830639|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
32830640|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness*~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
33101727|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
33101728|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
33101729|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
33101730|NCT04690257|Experimental|TICK-B group as Intervention group|"Experimental: TICK-B group~-Pediatric patients received TICK-B as a distraction in the TICK-B group"
33405127|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
32818538|NCT05439408|Active Comparator|SPRYCEL - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
32818539|NCT05261880|Experimental|Neural mobilization|Neural mobilization will be given for 15 minutes with 3 repetitions. After mobilization, Kinesio taping will be applied and it will bandage till the next session.
32818540|NCT05261880|Experimental|Scaphoid, hamate mobilization|Scaphoid and hamate mobilization for 20 minutes, at the end of session kinesio taping will bandage till the next session.
32818541|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
32818542|NCT04453800|Experimental|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
32818543|NCT04453800|Experimental|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
32818544|NCT04453800|Experimental|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
32818545|NCT04453800|Placebo Comparator|Group D: placebo group|Saline was administered intravenously
32818546|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
32818547|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
32818548|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
32818549|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
32818550|NCT05438784|Active Comparator|Group A (patient specific titanium implant)|(reconstruction with patient specific titanium implant)
32818551|NCT05438784|Active Comparator|Group B (preformed plate bended on stereolithographic model)|(reconstruction with preformed titanium plate preoperatively bended on stereolithographic model)
32818552|NCT02522754|Placebo Comparator|Placebo|Placebo
32818553|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
32818554|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
32818555|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
32818556|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
32818557|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
32818558|NCT01188694|Other|Delayed Psychotherapy|
32818559|NCT04453566||Elite Athletes|Elite Athletes
32818560|NCT05182866|Experimental|Single Arm|ASP-1929 640 mg/m^2 treatment by intravenous (IV) infusion followed approximately 24 hours later by illumination (also termed as photoimmunotherapy [PIT]) of tumor(s) using the PIT690 Laser System with a 690 nm light dose of 50 J/cm^2 for superficial illumination and 100 J/cm of fiber length for interstitial illumination.
32818561|NCT04454112|Experimental|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
32818562|NCT04454268|Other|hydatid cyst|
32738625|NCT05004909|Experimental|2 Fingertip Units 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
32738626|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
32738627|NCT03119545|No Intervention|Comparison group|This Group will have standard care
32738628|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
32738629|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
32738630|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
32738631|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
32738632|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
32738633|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
32738634|NCT03206359||Patients|Patients with SLE
32738635|NCT03206359||Healthy subjects|
32738636|NCT04463121|Experimental|Acute CNT pacing signals testing|"Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.~Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.~A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions."
32738637|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
32738638|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
32738639|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
32738640|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
32738641|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
32738642|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
32738643|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
32738644|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
32738645|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
32738646|NCT05010447|Experimental|Study Group|Participants receive the Virtual Coach App for one week at the beginning of their therapy and one week towards the end of their therapy.
32738647|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
32738648|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~PS mode~IPAP according to clinical and hemodynamic tolerance~EPAP according to air trapping~RR around 12/ min.~LOT for SaO2 > 90%~Monitoring with capnometry for settings validation"
32738649|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
32738650|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
32738651|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
32738652|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
32738653|NCT03077217|Active Comparator|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
32738654|NCT03077217|Active Comparator|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
32738655|NCT03077217|Placebo Comparator|the control group|The control group didn't receive rifaximin treatment
32738656|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
32738657|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
32738658|NCT05001243|Experimental|Experimental PBOHB|Pilocarpine, brimonidine, Oxymetazoline combined with Hyaluronic Acid and Bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
32738659|NCT05001243|Active Comparator|Pilocarpine 5 mgs|Pilocarpine was instilled in the other oye.
32738660|NCT05001243|Active Comparator|Brimonidine 0.5 mgs|Brimonidine was instilled in the other eye.
32738661|NCT05399537|Experimental|Prismocitrate 18|
32738662|NCT04492631|Experimental|Probiotic|Powdered probiotic with a carrier.
33317596|NCT05253248|Experimental|Healthy adults|"We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days. Supplementation will provide the daily dietary recommendations of micronutrients, as these are established by the Department of Health, on top of the participant's free diet. Supplementation aims to correct any subclinical deficiencies the participants might have particularly those which are common in the general community. In the UK, a typical example is Vitamin D, due to lack of sunshine and selenium (a geochemical) whose content in the UK soil is depleted and therefore intake is often below the recommendations.~Fasted blood and urine samples will be collected before, and again two-to-three days, post-supplementation."
33317597|NCT05489354|Experimental|mHealth psychoeducational intervention|The intervention group will receive six weeks mHealth psychoeducational intervention (mPEI) delivered through a mobile application.
33317598|NCT05489354|No Intervention|Control Group|No psychoeducational intervention will be given.
33317599|NCT04337554||Older healthy|Individuals over 40 years of age
33317600|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
33317601|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
33317602|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
33317603|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
33317604|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
33317605|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
33317606|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
33317607|NCT05559814|Experimental|Peppermint oil|1.6% peppermint oil solution 50 ml(Peppermint oil plus simethicone and tween)
33317608|NCT05559814|Placebo Comparator|Placebo|Placebo solution 50ml(Simethicone plus tween)
33317609|NCT01293188||Biopresthetic aortic valve replacement.|
33317610|NCT03963622|Active Comparator|Control|Standard ventilation strategy.
32818563|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
32818564|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
32818565|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
33317611|NCT03963622|Experimental|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
32738663|NCT04492631|Placebo Comparator|Placebo|Carrier only.
32738664|NCT05005143||Paroxysmal AF ablation|Patients with standard indications to paroxysmal AF ablation
32738665|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
32738666|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
32738667|NCT05397899|Experimental|AHT group|This group will receive Abdominal hypopressive exercises. Each AHT will be repeated 3-5 times with 1 min rest between exercises (shift to new posture, lying,sitting and standing). Between 6 and 15 hypopressive exercises (HEs) will be performed within each session based on the participant's mastery of the exercises and readiness to progress, for 6 weeks.
32738668|NCT05397899|Active Comparator|General exercise group|This group will receive general exercises (Bridging, knee to chest, Straight leg rise) these will be repeated 3-5 times with 1 min rest between exercises. Between 6 and 15 repetitions will be performed within each session based on the participant's mastery of the exercises and readiness to progress. Each exercise to be repeated 3-5 times per set, and participants will be asked to perform technique once daily for 6 weeks
32738669|NCT05010135||Healthy Subject|Aged 60 and over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
32738670|NCT05010135||Vertebral fracture subjects|"Aged 60 or over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.~Have been diagnosed by doctors to have the vertebral fracture"
32738671|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
32738672|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
32738673|NCT05009745|Experimental|Intervention|"The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.~Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles."
32738674|NCT05009745|No Intervention|Control arm|Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
32738675|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
32738676|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
32818566|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
32818567|NCT05171244|Experimental|Experimental group|
32818568|NCT05171244|Sham Comparator|Control group|
32818569|NCT05438706|Experimental|Arm 1|chidamide in combination with camrelizumab and capecitabine
32818570|NCT05438706|Experimental|Arm 2|chidamide in combination with camrelizumab and carboplatin
32818571|NCT05438472||healthcare professionals with COVID-19 mRNA vaccine booster|Consecutive individuals that received a COVID-19 mRNA vaccine booster and undergo a systematic approach to detect myocarditis at the University Hospital Basel. The project population includes mainly healthcare workers, aged between 16-65, most of them with presumable no comorbidities. Baseline characteristics include age, divided in several groups (16-20 years, 21-25 years, 26-30 years, 31-35 years, 36-40 years, 41-45 years, 46-50 years, 51-55 years, 56-60 years, 61-65 years).
32818572|NCT05167344|Experimental|Healthy Relationships Program-Enhanced (HRP-E)|Youth participating in the HRP-E and facilitators delivering in the program
32818573|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
32818574|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
32818575|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
32818576|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
32818577|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
32818578|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
32818579|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
33101731|NCT04690257|No Intervention|Standard care provided group as control group|-Pediatric patients received standard care (routine care) in the control group.
32818580|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
32818581|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
32818582|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
32818583|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
32818584|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
32818585|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
32818586|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
32818587|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
32818588|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
32818589|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
33101732|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
32818590|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
32818591|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
32818592|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
32818593|NCT03462186|No Intervention|Control|No intervention
32818594|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
32818595|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
32818596|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
32818597|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
32818598|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
32818599|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
32818600|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
32818601|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
32818602|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
32818603|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
32818604|NCT04722822|Experimental|Providers recommending HPV vaccine at age 9-10 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 9-10 years of age.
32818605|NCT04722822|Active Comparator|Providers recommending HPV vaccine at age 11-12 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 11-12 years of age.
32818606|NCT05434182|Experimental|Intradermal Suture Group|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
32818607|NCT05434182|Active Comparator|Metallic Staples|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with metallic stapling using Visistat® (Weck®) 35W skin stapler.
32818608|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
32818609|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
32818610|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
32818611|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
32818612|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
32818613|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
32818614|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
32818615|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
32818616|NCT04712994|Experimental|PrEP Optimization Strategies|Up to 16 facilities will be assigned one of four intervention groups (4 facilities per group). One of the intervention groups is pre-identified (PrEP video counselling, HIV Self-Testing, and optimized delivery and prescription processes), however the other 4 strategies have no yet been identified but will be through other activities in the PrEPARE study.
32818617|NCT04712994|No Intervention|Comparator|Up to 4 facilities will be assigned to the comparator group.
32818618|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
32818619|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
32818620|NCT04703322|Experimental|Pexidartinib|Participants with TGCT who will receive oral pexidartinib 800 mg (400 mg twice daily [BID]).
32818621|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
32818622|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
32818623|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
32818624|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
32818625|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
32818626|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
32818627|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
32830641|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
32818628|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
32818629|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
32818630|NCT05432700|No Intervention|Control group: usual clinical practice.|"The women will receive an initial Health Literacy Survey (HLS-EU-Q16) via the email account registered on the platform. From this point until birth, no further notifications will be sent.~Subsequently, reminders will be planned via email to obtain information on EBF follow-up, avoiding providing any extra information on BF and, where appropriate, referring to the EBF support services available in their area, following a standard clinical practice. During pregnancy, the pregnancy programme of the local and national government provides parenting education and breastfeeding workshops, with various manuals published.~Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
32818631|NCT05432700|Experimental|Intervention group: LactApp|"From the initial registration in LactApp during the third trimester, women will be able to consult all the information available in the application. The women will receive an initial Health Literacy Survey (HLS-EU-Q16), from this point until birth, no further notifications will be sent. A reminder schedule will be made via email to obtain information on the follow-up of the EBF.~LactApp® works as a self-administered questionnaire based on decision trees constructed with questions and answers developed by professional breastfeeding experts, supported by scientific evidence and updated official health recommendations. In addition, the app will remind them of the topics according to the estimated date of birth provided. Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
32818632|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
32818633|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
32818634|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
32818635|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
32818636|NCT05431920|Experimental|Experimental|Vitamin D3: single 50,000 IU loading dose + 4,000 IU daily dose for three months
32818637|NCT05431920|Active Comparator|Active control|Vitamin D3: 2,000 IU daily dose for three months
32818638|NCT05430360|Experimental|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
33317612|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33317613|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
32818639|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
32818640|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
32818641|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
32830642|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
33317614|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
32955834|NCT05766644|Experimental|Education|Enrolled in a mobile app-based education program, with guidance from a healthcare professional. All educational materials and surveys are provided via the app.
32955835|NCT05766631|Active Comparator|Methadone Treatment-as-Usual|Participants randomized to the Methadone Treatment-as-Usual (TAU) Condition will receive treatment-as-usual at the community methadone clinics, which will include daily medication, individual and group addiction counseling, and outpatient or intensive outpatient behavioral health services, depending on the clinic and the needs of the patient. After randomization into the TAU arm, participants will complete the program's psychosocial and medical intake, methadone dose induction and adjustment, and provide urine tests and receive medication take-homes per the program's policies and methadone treatment regulations.
32955836|NCT05766631|Experimental|DynamiCare Plus Methadone Treatment-as-Usual|DynamiCare Plus Methadone Treatment-as-Usual (DCM+TAU) participants will receive the same services as TAU participants, plus access to the DynamiCare Health smartphone app for 48 weeks. After randomization, the research assistant (RA) will download the DynamiCare Health app onto their smart phone (or provide them with a smartphone with the app already installed). Participants will get oral fluid testing kits and a Next Step debit card. Participants will be trained in use of the app and oral fluid test kits and will practice until they can produce two valid tests in a row without aid of the research staff. Participants will earn $40 for successful completion of the orientation and training. DCM+TAU participants will then use the app to complete remote random drug screenings, prove attendance to appointments and medication pickups, interact with modules designed to improve substance use reductions, and other treatment-related activities.
32955837|NCT05766618|Experimental|injection site|it is the arm where the patients will receive the PRF injection intraligamentally in distobuccal, and distopalatal areas of the distal surface of the canine also submucosal injection will be given buccally and palatially (0.25mm) for each side in either the right or left side of the arch.
32955838|NCT05766618|No Intervention|control site|it is the arm where the patients will not receive any injection with the same method of retraction as the intervention side.
32955839|NCT05766605|Experimental|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.
32955840|NCT05766605|Active Comparator|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.
32955841|NCT05766579|Experimental|K1, 18-21 mmHg|Use of elastic stockings at 18-21 mmHg after endovenous thermal ablation
32955842|NCT05766579|Experimental|K2, 23-32 mmHg|Use of elastic stockings at 23-32 mmHg after endovenous thermal ablation
32955843|NCT05766553|Experimental|Interventional Group|"Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week).~Patients will then have a visit at day 90 and day 180."
32955844|NCT05766553|Active Comparator|Control group|"Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90.~Patients will then have a visit at day 90 and day 180."
32955845|NCT05766540|Experimental|Aripiprazole|This group will receive Aripiprazole 10 mg/day for 6 months along with Clozapine and Metformin
33317615|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
33317616|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
32955846|NCT05766540|Placebo Comparator|Treatment as usual|This group will receive Clozapine and Metformin.
32955847|NCT05766527|Experimental|KM602 monotherapy|Dose escalation and expansion
32955848|NCT05766514|Experimental|Arm A (investigational arm): cladribine, cytarabine, and decitabine|
32955849|NCT05766514|Active Comparator|Arm B (control arm): azacitadine with venetoclax or decitabine with venetoclax|
32955850|NCT05766488|Experimental|Continuous Glucose Monitoring Arm|Participants in this arm will use a Freestyle Libre 2 monitoring device for 6 months to track their blood glucose levels while receiving usual patient care within an interprofessional primary care team.
32955851|NCT05766488|Active Comparator|Traditional Glucometer Arm|Participants in this arm will use a traditional glucose monitoring device (glucometer) to self-monitor their blood glucose for 6 months while receiving usual patient care within an interprofessional primary care team.
32955852|NCT05766475|Active Comparator|In-Person Delivery of Group Preventative Intervention (ROSE)|The Reach Out, Stay Strong, Essentials for New Mothers Program (ROSE), is an established Interpersonal Therapy (IPT)-oriented group intervention for postpartum depression. ROSE is a brief (5-session) program and its content addresses social support, role transition to motherhood, communication skills, and psychoeducation on PPD. ROSE consists of four 90-minute, weekly in person group sessions and one individual booster session. The first four sessions of ROSE will be delivered in groups of 6 to 20, and conducted in both English and Spanish. For the in-person groups, transportation via Uber will be provided to Denver Health Medical Center to reduce barriers to attendance.
32955853|NCT05766475|Experimental|Virtual Delivery of Group Preventative Intervention (ROSE)|In parallel to ROSE delivered in person, virtual ROSE consists of four 90-minute, weekly group sessions conducted via Zoom and one individual booster session.
32818642|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
32818643|NCT03466788|Other|Patients treated with chemotherapy|
32818644|NCT03466788|Other|Patients not treated with chemotherapy|
32818645|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
32818646|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
32818647|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
32818648|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
32818649|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
32818650|NCT04018092|Experimental|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.~Total amount of sessions:~16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.~AND~44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
32818651|NCT04018092|Sham Comparator|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
32818652|NCT04009122|Experimental|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
32818653|NCT04009122|Placebo Comparator|Placebo|a sachet after each meal, preferably (3 sachets per day)
32818654|NCT04009122|No Intervention|group C|standard treatment
32818655|NCT03466554|Experimental|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
32818656|NCT03466554|No Intervention|Control-follow up|"The standard of care of psychological and mediational support .~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
32818657|NCT03461562|Experimental|Experimental|
32818658|NCT03461562|Active Comparator|Control|
32818659|NCT05348928||With oral ascorbic acid|1 g ascorbic acid orally
32818660|NCT05348928||Without oral ascorbic acid|No oral ascorbic acid is taken
32818661|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
32818662|NCT01144624|Placebo Comparator|2|
32818663|NCT05339334|Experimental|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days to adult Chinese healthy volunteers
32818664|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
32818665|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
32818666|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
32818667|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
32818668|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
32818669|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
32818670|NCT04453254|Active Comparator|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
32818671|NCT04453254|Active Comparator|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
32818672|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
32818673|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
32818674|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
32818675|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
32818676|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
32818677|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
32818678|NCT03466320|Experimental|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
32818679|NCT03466320|Experimental|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
32818680|NCT03466320|Experimental|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
32818681|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
32818682|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
32818683|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
32818684|NCT03013270|Active Comparator|AT/RT group|Aerobic-Resistance
32818685|NCT03013270|Active Comparator|AT/IMT group|Aerobic-Inspiratory
32818686|NCT03013270|Active Comparator|AT group|Aerobic Training
32818687|NCT03461250||HCV serology negative in HD|Risk factors
32818688|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
32818689|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
32818690|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
32818691|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
32818692|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
32818693|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
32818694|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
32818695|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
32818696|NCT03466008|No Intervention|Usual treatment arm|usual care
32818697|NCT05324280|Experimental|Acupuncture Group|"Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture. The needles will be stimulated manually and will remain for 20 minutes.~Body acupuncture needles (diameter 0.3mm, length 30 mm) will be placed on the following positions:~On the lower abdomen and back within Th11 and L1~Kidney 13 and 14; alternately unilaterally~Ren2 and 3 (midline) On classical acupuncture points on the extremities and the head~Stomach 36, Spleen 6; bilaterally~Large intestine 4, Liver 3; Bladder 60 bilaterally~Du 20 (midline)~Ear acupuncture:~Ear acupuncture needles (diameter 0,2 mm, length 20mm) will be used:~Veg. I (Sympathetic), lower pelvis, hypogastric plexus, Heart,Thalamus, genital system (combining Chinese and French ear acupuncture)~For point detection an electric potentiometer will be used. Ear points are punctured according to their generally accepted positions."
32818698|NCT05324280|No Intervention|Waiting list Group|Participants allocated to the waiting list control group may continue previously initiated standard therapy, but must not initiate any new treatment. They will be asked not to undergo acupuncture treatment for any condition within the next 3 months. After this period they are offered 10 acupuncture treatments over a period of 3 months.
32818699|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
32818700|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
32818701|NCT01190878|Experimental|ISV-303 BID|
32818702|NCT01190878|Experimental|ISV-303 QD|
32818703|NCT01190878|Active Comparator|Xibrom BID|
32818704|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
32818705|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
32818706|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
32818707|NCT01146496|No Intervention|Control|
32818708|NCT05301816|Experimental|IPG Activated|The group of participants who have had a successful trial (>50% pain relief) during the trial phase
32830643|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
32818709|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
32818710|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
32818711|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
32818712|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
32818713|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
32818714|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
32818715|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
32818716|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
32818717|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
32818718|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
32818719|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
32818720|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
32818721|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
32818722|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
32818723|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
32818724|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
32818725|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
32818726|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
32818727|NCT03460938|Experimental|RIPC|
32818728|NCT03460938|No Intervention|Control|
32818729|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
32818730|NCT03460860|Placebo Comparator|Placebo|
32818731|NCT05215236|Experimental|Opiate Sparing|Standard icing and elevation therapy Acetaminophen 1000 milligrams by mouth every 8 hours for five days then as needed every 8 hours for pain control Gabapentin 100 milligrams by mouth three times per day for 14 days Celecoxib 100 milligrams by mouth two times per day for 5 days Esomeprazole 20 milligrams by mouth once per day for 14 days Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone Oxycodone 5 milligrams by mouth every 6 hours as needed for pain control unresponsive to other medications
32818732|NCT05215236|Active Comparator|Opiate Based|Standard icing and elevation therapy Oxycodone 5-10 milligrams by mouth every 4 to 6 hours as needed for pain control Acetaminophen 1000 milligrams by mouth every 8 hours as needed for pain control Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone
32818733|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
32818734|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
32818735|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
32818736|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
32818737|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
32818738|NCT01191736|Experimental|Brief video; assessed 2 months later|
32818739|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
32818740|NCT05192148|Experimental|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
32818741|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
32818742|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
32818743|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
32818744|NCT01192828|Experimental|Taurine|Treatment with Taurine
32818745|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
32818746|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
32818747|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
32818748|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
32818749|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
32818750|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
32818751|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
32818752|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
32818753|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
32818754|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
32818755|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
32818756|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
32818757|NCT04453488|Experimental|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
32818758|NCT04453488|Placebo Comparator|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
32818759|NCT05678244|Active Comparator|Comparator|"Standard of care + IV acetaminophen:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of IV acetaminophen every 4 or 6 hours at weight-appropriate doses based on the patient's gestational age."
32818760|NCT05678244|Placebo Comparator|Placebo|"Standard of care + placebo:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of an IV saline placebo every 4 or 6 hours at a rate which would mimic their dose of acetaminophen."
32818761|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
32818762|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
32818763|NCT05159388|Experimental|PRS-344/S095012|PRS-344/S095012
32818764|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
32818765|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
32818766|NCT03460548|Experimental|Remogen|
32818767|NCT03460548|Active Comparator|Cationorm|
32818768|NCT05115006||Cohort 1|Participants diagnosed with stage II and stage III melanoma who have undergone surgery
32818769|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
32818770|NCT01149616|Placebo Comparator|Placebo|placebo
32818771|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
32818772|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
32818773|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
32818774|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
32818775|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
32818776|NCT03465306|Experimental|Intensive digital CBT|
32818777|NCT03465306|Active Comparator|Standard digital CBT|
32818778|NCT01101100|Experimental|AMG 827|AMG 827
32818779|NCT05072574|Experimental|Experimental: nutritional education program|Specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
32818780|NCT05072574|No Intervention|Control Group|Dietary and general lifestyle recommendations
32818781|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
32818782|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
32818783|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
32818784|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
32818785|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
32818786|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
32818787|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
32818788|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
32818789|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
32818790|NCT05201118|Experimental|CT103A combined with Selinexor|All subjects will be assigned to two Selinexor dose groups of 20 mg/week and 40 mg/week after receiving a single dose infusion of CT103A.
32818791|NCT05012436|Experimental|YHD1119 75mg, 150mg NF|CLcr (mL/min/1.73m2) >= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF
32818792|NCT05012436|Experimental|YHD1119 75mg|60 > CLcr (mL/min/1.73m2) >= 30 Period 1 : YHD1119 75 mg Period 2 : NA
32818793|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
32818794|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
32818795|NCT03460080||Hepatic hemangioma patients|
32818796|NCT04989972|Experimental|Intervention arm|participants will take the active intervention PSIL428
32818797|NCT04989972|Experimental|placebo arm|participants will take the intervention 1 mg Oyster mushrooms
32818798|NCT04989972|Experimental|open label|all participants will take the active intervention PSIL428
32818799|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
32818800|NCT04978038|Experimental|Pfizer-BioNtech mRNA- COVID-19|Eligible participants will be vaccinated with the Pfizer-BioNtech mRNA- COVID-19. A 0.3ml dose of the vaccine will be administered intramuscularly.
32818801|NCT04978038|Active Comparator|Pneumococcal Prevnar-13|Eligible participants will be vaccinated with Pfizer Prevar-13 (pneumococcal vaccine) in a blinded manner such that the vaccination with Pfizer-BioNtech mRNA- COVID-19 will be mimicked. That is, a 0.5ml dose of the vaccine will be administered intramuscularly. After completion of the study participants in the control arm will be given a fourth dose of Pfizer-BioNtech mRNA- COVID-19.
32818802|NCT04958694|Experimental|CEDARS|Using an adapted stress-reduction intervention called the CEDARS, we will pilot the intervention in adolescents (N=50) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
32818803|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
32818804|NCT01194466|Experimental|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
32818805|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
32818806|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
32818807|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
32818808|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
32818809|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
32818810|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
32818811|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
32818812|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
32818813|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
32818814|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
32955854|NCT05766462||PLR group|The pacemaker lower rate of PLR group will be set as 75 bpm and might be adjusted according to physician diagnosis based on patients situation.
32818815|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
32818816|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
32818817|NCT04352374|Experimental|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
32818818|NCT04352374|Active Comparator|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
32818819|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
32818820|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
32818821|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
32818822|NCT04488978|Experimental|Irbesartan low/Amlodipine low|Irbesartan low & Amlodipine low, once daily for 8 weeks
32818823|NCT04488978|Experimental|Irbesartan low/Amlodipine high|Irbesartan low & Amlodipine high, once daily for 8 weeks
32818824|NCT04488978|Experimental|Irbesartan high/Amlodipine low|Irbesartan high & Amlodipine low, once daily for 8 weeks
32818825|NCT04488978|Experimental|Irbesartan high/Amlodipine high|Irbesartan high & Amlodipine high, once daily for 8 weeks
32818826|NCT04488978|Active Comparator|Amlodipine low|Amlodipine low, once daily for 8 weeks
32818827|NCT04488978|Active Comparator|Amlodipine high|Amlodipine high, once daily for 8 weeks
32818828|NCT04488978|Active Comparator|Irbesartan low|Irbesartan low, once daily for 8 weeks
32818829|NCT04488978|Active Comparator|Irbesartan high|Irbesartan high, once daily for 8 weeks
32818830|NCT04464486|Experimental|COVID-19 Symptom Augmented SCH Intervention|The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
32818831|NCT04464486|No Intervention|Enhanced Usual Care|Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.
32818832|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
32818833|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
32818834|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
32818835|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
32818836|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
32818837|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
32818838|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
32818839|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~Radiation within 3-5 weeks of surgery~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~Temozolomide at a dose of 150 mg/m^2 on Days 1-7~Bevacizumab 10 mg/kg on Day 8 and Day 22~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
32818840|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
32818841|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
32818842|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
33101733|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
32818843|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
32818844|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
32818845|NCT04947150|Experimental|LOCATION TRIGGERED MESSAGING|Weekly message is triggered when arriving at grocery store.
32818846|NCT04947150|Experimental|COACH MONITORING|Coaches view grocery purchases via web portal, send weekly messages about purchases they observe, and conduct three brief phone calls to discuss purchases.
32818847|NCT04947150|Experimental|BENEFITS OF CHANGE|Attend an extra workshop session and three phone calls to identify and reflect on benefits of dietary change. Content added to standard weekly messages about benefits of change.
32818848|NCT04947150|Experimental|HOUSEHOLD SUPPORT|An adult household member attends one workshop session and three phone calls with the index participant. This household member receives weekly text messages for 20 weeks about program goals and ways to support the index participant.
32818849|NCT04453332|Active Comparator|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
32818850|NCT04453332|Active Comparator|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
32818851|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
32818852|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
32818853|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
32818854|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
32818855|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
32818856|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
32818857|NCT04920318|Experimental|active TDCS|During intervention excitatory/anodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period
32818858|NCT04920318|Sham Comparator|sham TDCS|The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
32818859|NCT04906434|Experimental|ABSK011 60mg cohort|60mg cohort：1 patient will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, the patient will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
32818860|NCT04906434|Experimental|ABSK011 120mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
32830644|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
33101734|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
33101735|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
33101736|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
33101737|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
32818861|NCT04906434|Experimental|ABSK011 180mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
32818862|NCT04906434|Experimental|ABSK011 240mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
32818863|NCT04906434|Experimental|ABSK011 320mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
32818864|NCT04906434|Experimental|ABSK011 400mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
32818865|NCT04904250|Experimental|Emboshield NAV6|using Emboshield NAV6 distal embolism protection device during CAS
32818866|NCT04904250|Active Comparator|SpiderFX|using SpiderFX distal protection device during CAS
32818867|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
32818868|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
32818869|NCT04453098|Experimental|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
32818870|NCT04453098|Experimental|rE group|moderate-resistance (30%) - high-Endurance (70%)
32818871|NCT04453098|Experimental|re group|moderate-resistance (30%) - moderate-endurance (30%).
32818872|NCT04453098|No Intervention|control group|no intervention
32818873|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
32818874|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
32818875|NCT04452864|Experimental|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
32818876|NCT04452864|Active Comparator|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
32818877|NCT04452864|Other|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
32818878|NCT05203224|Experimental|Intravenous Dornase alfa (DNase)|Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, or 0.5mg/kg in escalating tiers), administered as a bolus over ~30 seconds.
32818879|NCT03464838|Experimental|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
32818880|NCT03464838|Sham Comparator|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
32818881|NCT04870554|No Intervention|Continuous Feeding|Enteric feeding will be given continuously.
32818882|NCT04870554|Experimental|Timed Feeding|Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
32818883|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
32818884|NCT03468348|Placebo Comparator|placebo group|
32818885|NCT03468348|Active Comparator|duloxetine 30|
32818886|NCT03468348|Active Comparator|duloxetine 60|
32818887|NCT03468348|Active Comparator|duloxetine 90|
32818888|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
32818889|NCT03464682|Experimental|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
32818890|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
32818891|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
32818892|NCT03464682|Active Comparator|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
32818893|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
32818894|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
32818895|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
32818896|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
32818897|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
32818898|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
32818899|NCT04336878|Experimental|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice & purchasing, portion size, eating behaviour & keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
32818900|NCT04336878|No Intervention|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
32818901|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
32818902|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
32818903|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
32818904|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
32818905|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
32818906|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
32818907|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
32818908|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
32818909|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
32818910|NCT03453996|Other|Control|Usual care.
32818911|NCT04862052|Active Comparator|Xience chromium-cobalt everolimus eluting stent|The Xience chromium-cobalt everolimus eluting stent will be evaluated in prior implanted coronary drug eluting stent restenosis.
32818912|NCT04862052|Experimental|Emperor paclitaxel coated balloon|The Emperor paclitaxel coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
32818913|NCT04862052|Experimental|Magic Touch sirolimus coated balloon|The Magic Touch sirolimus coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
32818914|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
32818915|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
32818916|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
32818917|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
32818918|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
32818919|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
32818920|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
32818921|NCT04854018|Experimental|Single Arm|Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
32818922|NCT04815096|Experimental|[18F]F-AraG|"Radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
32818923|NCT04803786||Transition from Xyrem to Xywav|
32818924|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
32818925|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
32955855|NCT05766462||control group|The pacemaker lower rate of control group will be set as 60 bpm.
32955856|NCT05766436|Active Comparator|group D|will receive placebo ODF and nebulized dexmedetomidine (Precedex™ rxlist)
32955857|NCT05766436|Active Comparator|group M|will receive placebo nebulizer and ODF melatonin (metacyst ™ nerhadou)
32955858|NCT05766436|Placebo Comparator|group C|will receive placebo ODF and placebo 0.9% normal saline nebulizer
33317617|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~Pars plana vitrectomy~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
32818926|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
32818927|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
32818928|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
32818929|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
32818930|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
32818931|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
32955859|NCT05766423|No Intervention|Usual Care|"Usual care includes:~The normal standard clinical practices at the participating practice.~No specific materials to promote PATTERN, and no materials that include routine adherence assessments or care alert notifications."
32955860|NCT05766423|Active Comparator|The PATTERN Intervention|"The intervention components include:~Routine adherence assessments completed by participants.~Care alert notifications directed to a nurse pool and/or member of the clinical care team."
32955861|NCT05766397|Other|Health volunteer|Health volunteers will follow a standard protocol for inhalation of methoxyflurane while the off-gassing will be captured.
32955862|NCT05766384||Normal Lung Function|Participants with FEV1 > 85% predicted and no respiratory symptoms as determined at the baseline visit for the Lung Health Cohort
32818932|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
32818933|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
32818934|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
32818935|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
32818936|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
32818937|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
32818938|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
32955863|NCT05766384||Low Normal Lung Function|Participants with FEV1 < 85% predicted as determined at the baseline visit for the Lung Health Cohort
32955864|NCT05766384||Respiratory Symptoms|Participants with respirator symptoms as determined at the baseline visit for the Lung Health Cohort.
32955865|NCT05766371|Experimental|Pembrolizumab, 177Lu-PSMA-617|Participants will receive an infusion of 7.4 gigabequerel (GBq) (+/- 10%) of 177Lu-PSMA-617 on Cycle 1 Day 1 (of a 28 day cycle), and at every PSA progression for up to a maximum of 6 doses. Beginning Cycle 2 Day 1 (Day 29), participants will receive 400 mg of Pembrolizumab every 6 weeks.
32955866|NCT05766358||Placebo|
32955867|NCT05766358||Tirzepatide|
32955868|NCT05766345|Experimental|BCG vaccine|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331 0.1ml (=0.0075mg) One-time vaccination intradermally
32955869|NCT05766345|Placebo Comparator|Placebo vaccine|0.9% NaCl placebo 0.1ml One-time vaccination intradermally
32955870|NCT05766332||Observational (clinical evaluation, record review)|Patients undergo a clinical evaluation consisting of a six-minute walk test, hand grip strength test, and gait speed test on study. Patients' medical records are also reviewed for a year on study.
32955871|NCT05766319|Experimental|Patients receiving the ICU-recover box containing home monitoring devices|"Treatment of subjects on the ICU will be state of the art, conform current practice, protocols and guidelines.~Patients discharged from the ICU will receive an ICU-Recover Box on one of the clinical wards of the LUMC filled with several devices after they have given informed consent. These devices are listed below and are described in further detail in section 6 of this protocol.~The ICU-Recover Box contains the following devices and tools:~Withings BPM Connect~Withings Body weight scale~Withings ScanWatch, from which the following features will be used:~Measurement of SpO2~Automatic recording of heart rate~Automatic recording of activity (step count)"
32955872|NCT05766306|Experimental|Probiotic|Participants will be randomized to receive the probiotic blend for 56 days.
32955873|NCT05766306|Placebo Comparator|Placebo|Participants will be randomized to receive the placebo for 56 days
32955874|NCT05766293|Active Comparator|Shockwave treated group|Effect of Extracorporeal shockwaves on Fibroblast cell proliferation and cell viability
32955875|NCT05766293|Placebo Comparator|No shockwave group|Fibroblast cell lines assessed for proliferative rate and viability without shockwave exposure.
32818939|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
32818940|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
32818941|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
32818942|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
32818943|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
32818944|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
32818945|NCT05163444|Experimental|Rolling can|Gait analysis with rolling cane
32818946|NCT05163444|Active Comparator|Quadripod can|Gait analysis with quadripod cane
32818947|NCT03451734||treatment cohort|in sub-project 1, participants are randomized into olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups, we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
32818948|NCT03451734||adjunctive group|Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
32818949|NCT03451734||metformin and lifestyle intervention for MetS|Participants who develop MetS at the last visit in sub-project 1 and sub-project 2 are recruited in this trial. Patients are randomized into low-dose metformin (1000 mg/d), high-dose metformin (1500 mg/d), low dose metformin plus lifestyle intervention group (1000 mg/d), high dose metformin plus lifestyle intervention (1500 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
32818950|NCT03451734||metformin and lifestyle prevention for high risk of MetS|Participants who are at a high risk of MetS are recruited in this trial. Participants are randomized into low dose metformin (750 mg/d), high dose metformin (1000 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
32818951|NCT03451734||validation cohort|in sub-project 2, there are1,800 first-episode schizophrenia patients recruited from 19 hospitals, and six groups as with sub-project 1. The assessments (timepoint and content) are conducted as in sub-project 1.
32818952|NCT04304508|Experimental|BAY2433334 high dose|
32818953|NCT04304508|Experimental|BAY2433334 medium dose|
32818954|NCT04304508|Experimental|BAY2433334 low dose|
32818955|NCT04304508|Placebo Comparator|BAY2433334 matching placebo|
32818956|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
32818957|NCT03467880||Healthy subjects|Healthy subjects.
32818958|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
32818959|NCT03467880||Asthma|Patience with asthma.
32818960|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
32818961|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
32818962|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
32818963|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
32818964|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
32818965|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
32818966|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
32818967|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
32818968|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
32818969|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
32818970|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
32818971|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
32818972|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
32818973|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
32818974|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
32818975|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
32818976|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
32818977|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
32818978|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
32818979|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
32818980|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
32818981|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
32818982|NCT05322486||Primary tumour resection group.|Surgical resection of the primary tumour followed by chemotherapy +/- targeted therapy regime.
32818983|NCT05322486||Chemotherapy group.|Chemotherapy +/- targeted therapy alone.
32818984|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
32818985|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
32818986|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
32818987|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
32818988|NCT01199146|Experimental|Abiraterone acetate|
32818989|NCT05322252|Experimental|Simulatenous mifepristone and misoprostol|Participants will receive a dose of 200mg oral mifepristone at time of induction with misoprostol
32818990|NCT05322252|Active Comparator|Misoprostol alone|Participants will have labor induced with misoprostol alone
32818991|NCT01199848|Placebo Comparator|Placebo|Pbo
32818992|NCT01199848|Experimental|10G STRB powder|Dose 1
32818993|NCT01199848|Experimental|20G STRB powder|Dose 2
32818994|NCT01199848|Experimental|40G STRB powder|Dose 3
32818995|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
32818996|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
32818997|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
32818998|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
32818999|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
32819000|NCT04778592|Experimental|ETX-018810|Drug: ETX-018810 bid
32819001|NCT04778592|Placebo Comparator|Placebo|Matching Placebo bid
32819002|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
32819003|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
32819004|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
32819005|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
32819006|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
33317618|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~Descemet Stripping Endothelial Keratoplasty (DSEK)~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~Descemet Membrane Endothelial Keratoplasty (DMEK)~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~Conjunctival and/or corneal lesion excisions~Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
32819007|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
32819008|NCT05321862|Experimental|[68Ga]Ga-PentixaFor|
32819009|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
32819010|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
32819011|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
32819012|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
32819013|NCT03463200|No Intervention|Control group|It will not apply any tape.
32819014|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
32819015|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
32819016|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
32819017|NCT04212780|Active Comparator|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
32819018|NCT04212780|Active Comparator|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
32819019|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
32819020|NCT04163094|Experimental|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
32819021|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
32819022|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
32819023|NCT01107730|Active Comparator|Placebo|
32819024|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
32819025|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
32819026|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
32819027|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
32819028|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
32819029|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
32819030|NCT03463044|Placebo Comparator|Placebo|
32819031|NCT03463044|Experimental|MOTREM 1|
32819032|NCT03463044|Experimental|MOTREM 2|
32819033|NCT03463044|Experimental|MOTREM 3|
32819034|NCT03463044|Experimental|MOTREM 4|
32819035|NCT03463044|Experimental|MOTREM 5|
32819036|NCT03463044|Experimental|MOTREM 6|
32819037|NCT03463044|Experimental|MOTREM 7|
32819038|NCT03463044|Experimental|MOTREM 8|
32819039|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
32819040|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
32819041|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
32819042|NCT01107964|Placebo Comparator|Corn oil capsule|
32819043|NCT05684172|Active Comparator|endovascular thrombectomy|For patients randomized to the control group, EVT has to be completed within 24 hours of stroke onset. The choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
32819044|NCT05684172|Experimental|endovascular thrombectomy+intra-arterial tenecteplase|For patients randomized to the endovascular treatment arm, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the lenticulostriates branches. The administration of TNK will be infused for 15 seconds.
32819045|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
32819046|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
32819047|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
32819048|NCT04772820|Other|Primary Aim|Brief Behavioral Activation coaching will be delivered by telephone and other remote technology by trained coaches. Over 10 sessions, the coaches will help people to find meaningful activities to decrease loneliness, increase physical activity and improve nutrition.
32819049|NCT01200160||Lipid abnormalities|Niacin
32819050|NCT04771650|Experimental|CAMI/CAMI booster|Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
32819051|NCT04771650|No Intervention|Control|Assessment plus standard care. Participants will complete an assessment, including measures on drinking and drug use. They will also receive standard care in a primary care setting.
32819052|NCT04908228|Experimental|Ibrutinib + obinutuzumab|Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).
32819053|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
32819054|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
32819055|NCT04452786|Other|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
32819056|NCT04452786|Other|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
32819057|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
32819058|NCT05321628|Experimental|iCBT + Decision Support Tool|Internet-based Cognitive Behavioural Therapy where therapists have traditional clinical routines and supervision and also use a clinical decision support tool.
32819059|NCT05321628|Active Comparator|Traditional iCBT|Internet-based Cognitive Behavioural Therapy with traditional clinical routines and supervision.
32819060|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
32819061|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
32819062|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
32819063|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
32819064|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
32819065|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
32819066|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
32819067|NCT04701450||conventional|consent for anaesthesia is obtained as part of a conversation with physical attendance
32819068|NCT04701450||telephonic|consent for anaesthesia is obtained telephonically
32819069|NCT04701450||digital|a digital survey and video information is used to inform the patient about the anaesthetic procedure
32819070|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
32819071|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
32819072|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
32819073|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
32819074|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
32819075|NCT03462732|Active Comparator|Group II|Endotracheal tube
32819076|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
32819077|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
32819078|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
32819079|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
32819080|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
32819081|NCT04639752|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
32819082|NCT04639752|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
32819083|NCT03848754|Experimental|Pracinostat 45 mg with Gemtuzumab Ozogamicin|"Gemtuzumab Ozogamicin Induction: GO 3 mg/m^2 on Day 1, 4, and 7~Pracinostat Induction: 45 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles. We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is < 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
32830645|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
32830646|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
32830647|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
32830648|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
32830649|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
32819084|NCT03848754|Experimental|Pracinostat 60 mg with Gemtuzumab Ozogamicin|"Gemtuzumab Ozogamicin Induction: GO 3 mg/m^2 on Day 1, 4, and 7~Pracinostat: 60 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is < 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
32819085|NCT03848754|Experimental|Gemtuzumab Ozogamicin Monotherapy Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~**Gemtuzumab Ozogamicin Maintenance: 2 mg/m^2 intravenous administration on day 1, in a 28-day cycle."
32819086|NCT03848754|Experimental|Pracinostat with Gemtuzumab Ozogamicin Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~Gemtuzumab Ozogamicin Maintenance: 2 mg/m^2 intravenous administration on day 1, in a 28-day cycle.~Pracinostat Maintenance: (In addition to GO, only if induction dose escalation occurs) 45 mg orally 3 days a week with 48 hours between dosing, for three consecutive weeks, followed by 1 week of rest, in a 28-day cycle."
33101738|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
33101739|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
32819087|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
33101740|NCT02911194|Experimental|Treatment|a2 milk intervention period
33101741|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
32819088|NCT01155154|Active Comparator|cepahlexin|
32819089|NCT01155154|Placebo Comparator|Placebo|
32819090|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
32819091|NCT04614714|Experimental|NR First|Mothers will receive NR during the first 7 days of intervention, then placebo for the 7 days following washout.
32819092|NCT04614714|Experimental|Placebo First|Mothers will receive placebo during the first 7 days of intervention, then NR for the 7 days following washout.
32819093|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
32819094|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
32819095|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
32819096|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
32819097|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
32819098|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
32830650|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
33101742|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
33101743|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
33101744|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
33101745|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
33101746|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
33101747|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
33101748|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
33101749|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
32738677|NCT05010057|Experimental|New Zealand blackcurrants (NZBC)|1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.
32738678|NCT05010057|Placebo Comparator|Placebo (PLA)|1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.
32738679|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
32738680|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
32738681|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
32738682|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
32738683|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
32738684|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
32738685|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
32738686|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
32738687|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
32738688|NCT05001087||Patients registry|"Non-interventional, multicentre, retrospective and prospective registry. In order to increase the sample size and the validity of the Registry, patients who were diagnosed with myeloma since 1st January 2019 will also be included retrospectively, once their informed consent has been obtained by the enrolling centre. Being a registry, patients will be enrolled consecutively according to their appointments at the centre, at the discretion of their doctor and only once the patient has signed the informed consent form.~Also patients participating in interventional or other observational studies can be enrolled. In case of patients enrolled in interventional trials, only baseline and survival data can be collected for the period in with the patient is in interventional trial.~The data will be collected using an electronic data capture (EDC) platform. Hospital visits are planned every 6 months."
32738689|NCT03205735||normal DPD result group|patients group with a normal DPD result
32738690|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
32738691|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HF meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HP meals for 4 weeks"
32738692|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HP meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HF meals for 4 weeks"
32738693|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
32738694|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
32738695|NCT05000775|Experimental|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
32738696|NCT05000775|Placebo Comparator|Placebo|Placebo
32738697|NCT02490449|Experimental|Exprerimental group|medication after diet
32738698|NCT02490449|Active Comparator|control group|medication before diet
32738699|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
32738700|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
32738701|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
32738702|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
32738703|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
32738704|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
32738705|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
33405128|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
32819099|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
32819100|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
32819101|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
32819102|NCT04604184|Experimental|BI 764198 treatment group|
32819103|NCT04604184|Placebo Comparator|Placebo|
32819104|NCT04604106||Patient group|Infant aged 12 months (± four weeks) with a history of general anesthesia exposure
32819105|NCT04604106||Healthy subject group|Infant aged 12 months (± four weeks) without a history of general anesthesia
32819106|NCT04569708|Experimental|Children and adolescents with epilepsy and controls|Closed loop auditory stimulation during nap
32819107|NCT04549272||Patients with Patent Foramen Ovale|
32819108|NCT04542720|Experimental|Randomized: Decompression|
32819109|NCT04542720|Active Comparator|Randomized: Extension Fusion|
32819110|NCT04542720|Experimental|Observational: Decompression|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are still eligible for the study and may be enrolled under observational arms. This arm refers to the decompression alone observational study arm. All study procedures are identical to the randomized decompression alone study arm.
32819111|NCT04542720|Active Comparator|Observational: Extension Fusion|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are still eligible for the study and may be enrolled under observational arms. This arm refers to the decompression with extension of fusion study arm. All study procedures are identical to the randomized decompression with extension of fusion study arm.
32819112|NCT04507464|Experimental|Ecological Momentary Intervention|Participants will receive real time physical activity notifications via a wearable activity tracker and smartphone application.
32819113|NCT04507464|No Intervention|Physical Activity Guidelines|Participants will be sent general guidelines for disruption of sedentary time.
32819114|NCT04504266|No Intervention|Control Arm|Recommendations to follow Mediterranean diet and exercise regularly before surgery.
32819115|NCT04504266|Experimental|Prehab|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
32819116|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
32819117|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
32819118|NCT03449394|Active Comparator|Delusions (Tx)|
32819119|NCT03449394|No Intervention|Delusions (TAU)|
32819120|NCT03449394|Active Comparator|Depression (Tx)|
32819121|NCT03449394|No Intervention|Depression (TAU)|
32819122|NCT05320848|Experimental|Treatment group|the patients treated with cardiac rehabilitation intervention.
32819123|NCT05320848|No Intervention|Control group|the patients treated without cardiac rehabilitation intervention.
32819124|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
32830651|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
32830652|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
32830653|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
33101750|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
32819125|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
32819126|NCT05320536|Experimental|Experimental group|Guilingji capsule Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days.
33101751|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
33101752|NCT02932124||1|manual chest compressions
32819127|NCT05320536|Placebo Comparator|Control group|Placebo Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days
33101753|NCT02932124||2|mechanical chest compression
33101754|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
33101755|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily sham stimulation sessions"
33101756|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
33101757|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
33101758|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
32819128|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid."
33101759|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.~Study subjects: Subjects with established primary (adrenal) AI"
33101760|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
33317619|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~Ahmed valve~Ahmed valve with cataracts~Trabeculectomy~Trabeculectomy with cataracts~Baerveldt~Baerveldt with cataracts~Endocyclophotocoagulation~Endocyclophotocoagulation with cataracts~Istent~Cataracts with istent~Kahook~Cataracts with kahook~Cypass~Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
32819129|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
32819130|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
32819131|NCT04369638|Experimental|3D NAM|
32819132|NCT04369638|Active Comparator|Traditional NAM|
32819133|NCT05320458|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation program will be applied 3 days a week at 40-60% of submaximal heart rate for a total of 8 weeks. Diaphragmatic breathing, pursed lips and segmental breathing exercises will be applied to the patients in the presence of a physiotherapist. Walking and aerobic exercise training will be given.
32819134|NCT05320224|Other|Patient-Oriented Music Intervention (POMI) followed by No Music - Sequence AB|Patient participants will first receive 20-30 minutes of the patient-oriented music intervention (POMI) first, followed by no music, with a minimal washout period of four hours
32819135|NCT05320224|Other|No Music followed by Patient-Oriented Music Intervention (POMI) - Sequence BA|Patient participants will first receive no music first, followed by 20-30 minutes of the patient-oriented music intervention (POMI), with a minimal washout period of four hours
32819136|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
32819137|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
32819138|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
32819139|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
32819140|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
32819141|NCT05308134|Active Comparator|Standard fortification|
32819142|NCT05308134|Experimental|Target fortification|
32819143|NCT05308134|Experimental|BUN adjustable fortification|
32819144|NCT05307900|Experimental|All patients requiring intubations|All intubated patients with feeding tube
32819145|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
32819146|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
32819147|NCT03449238|Other|pembrolizumab and SRS|Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
32819148|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
32819149|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
32819150|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
32819151|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
32819152|NCT04169100|Experimental|Prednisone Group|These patients have CTD and QTc over 500 msec. Prednisone is administered as a preventative measure against arrhythmia via QTc shortening.
32819153|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
32819154|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
32819155|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
32819156|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
32819157|NCT04155996||data collection|20 patients
32819158|NCT05239806|Experimental|SCTV01C|Participants will receive one dose of SCTV01C on Day 0 and one dose of SCTV01E on Day 180.
32819159|NCT05239806|Experimental|SCTV01E|Participants will receive one dose of SCTV01E on Day 0 and one dose of SCTV01E on Day 180.
32819160|NCT05239806|Active Comparator|Sinopharm inactivated COVID-19 vaccine|Participants will receive one dose of Sinopharm inactivated COVID-19 vaccine on Day 0 and one dose of SCTV01E on Day 180.
32819161|NCT05239806|Active Comparator|Comirnaty|Participants will receive one dose of Comirnaty on Day 0 and one dose of SCTV01E on Day 180.
32819162|NCT01155778|Experimental|10 mg rhHNS|10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
32819163|NCT01155778|Experimental|45 mg rhHNS|45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
32819164|NCT01155778|Experimental|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months
32819165|NCT04155840|Experimental|Treatment (copanlisib, rituximab, bendamustine)|Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
32819166|NCT03448848|Experimental|study|
32819167|NCT03448848|Placebo Comparator|control|
32819168|NCT05086770|Experimental|Test group|The test group will be administered 300-500 ㎛ range of Gelatin microsphere (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.
32819169|NCT05086770|Active Comparator|Control group|The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.
32819170|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
32819171|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
32819172|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
32819173|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
32819174|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
32819175|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
32819176|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
32819177|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
32819178|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
32819179|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
32819180|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
32819181|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
32819182|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
32819183|NCT01872312|Other|treatment|Loading IBV® Valve System
32819184|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
32819185|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
32819186|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
32819187|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
32819188|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
32819189|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
32819190|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
32819191|NCT02948712|Experimental|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
32819192|NCT04114656|Placebo Comparator|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
32819193|NCT04114656|Experimental|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
32819194|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
32819195|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
32819196|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
32819197|NCT03443388|Active Comparator|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
32819198|NCT03443388|No Intervention|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
32819199|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
32819200|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
32819201|NCT03955614|Experimental|St Marys Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
32819202|NCT03955614|Experimental|University College Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
32819203|NCT03955614|Experimental|Chelsea and Westminster Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
32819204|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
32819205|NCT03943836|Experimental|Music Group|Patients listen to music
32819206|NCT03943836|No Intervention|No Music group|Patients do not listen to music
32819207|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
32819208|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
32819209|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
33317620|NCT05484440|Experimental|Group cognitive-behavioral intervention plus individual Motivational Interviewing|Group participants will participate in six individual sessions based on Motivational Interviewing techniques (60 minutes each) and then in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
32819210|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
32819211|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
32819212|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
32819213|NCT04983732|Experimental|FL-101-IV|FL-101 single IV infusion over 60-minutes
32819214|NCT04983732|Experimental|FL-101-SC|FL-101 single SC injection
32819215|NCT04452396|Experimental|patients|patients undergoing CGM monitoring
32819216|NCT04452552|Experimental|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
32819217|NCT04452552|Experimental|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
32819218|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
32819219|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
32819220|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
32819221|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
32819222|NCT04968210||Pulmonary arterial hypertension (PAH)|Patients that have been clinically diagnosed with pulmonary arterial hypertension and fall under the category of WHO group 1 PAH.
32819223|NCT04963530|Experimental|Wear of antagonist teeth to monolithic zirconia restorations|Evaluate enamel wear antagonist to monolithic zirconia restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
32819224|NCT04963530|Experimental|Wear of antagonist teeth to lithium disilicate restorations|Evaluate enamel wear antagonist to lithium disilicate restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
32819225|NCT04963530|Experimental|Wear of antagonist teeth to metalceramic restorations|Evaluate enamel wear antagonist to metal ceramic restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
32819226|NCT04963530|Experimental|Wear of natural enamel|Evaluate physiological enamel wear (control group) monitoring the short short and medium-term volume loss and assessing the factors that may influence this wear.
32819227|NCT01158820|Placebo Comparator|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
32819228|NCT01158820|Active Comparator|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
32819229|NCT03707028|Experimental|Rivoceranib with Paclitaxel|Participants will receive oral daily doses of rivoceranib per 28-day cycle (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on Day 1, Day 8, and Day 15 of the 28-day cycle.
32819230|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
32819231|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
32819232|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
32819233|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
32819234|NCT04956042|Experimental|Cohort 1 - Fosciclopirox only|An initial 14 study participants will be enrolled in Cohort 1a and will be treated with fosciclopirox. If there is a disease response, an additional 14 study participants will be enrolled into Cohort 1 (Cohort 1b).
32819235|NCT04956042|Experimental|Cohort 2 - Fosciclopirox + Cytarabine|To be implemented if a disease response is not seen in Cohort 1a. Cohort 2a will have an initial 14 study participants treated with fosciclopirox and cytarabine. If a disease response is seen, an additional 14 study participants will be enrolled (Cohort 2b).
32819236|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
32819237|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
32819238|NCT04945278|Other|Patients|"Both patients and healthy volunteers arms will undergo the double mirror test within a day.~But the patients arm will additionally respond to the EASE test."
32819239|NCT04945278|Other|Healthy volunteers|Both patients and healthy volunteers arms will undergo the double mirror test within a day.
32819240|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
32819241|NCT04937790|Experimental|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
32819242|NCT04937790|Experimental|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
32819243|NCT04937790|No Intervention|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
32819244|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
32819245|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
32819246|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
32819247|NCT01226914|Placebo Comparator|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
32819248|NCT01226914|Experimental|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
32819249|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 26 weeks. At Week 12, if participants has HbA1c >=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 26.
32819250|NCT03499704|Active Comparator|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin >=500 mg, tablet, orally, twice a day, for up to Week 26.
32819251|NCT01158976|Experimental|DHA supplementation|
32819252|NCT01158976|Placebo Comparator|Soybean Oil|
32819253|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
32819254|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
32819255|NCT04937556|Active Comparator|Probiotic: Lactobacillus salivarius + Vit D + Zinc|Lactobacillus strain during 28 days, approximately 1*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
32819256|NCT04937556|Placebo Comparator|Placebo|Placebo supplement in 1 capsule per day during 28 days.
32819257|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
32819258|NCT05183880|Active Comparator|Crystalline vitamin C supplementation|1000 mg of vitamin C ingested in crystalline form
32819259|NCT05183880|Experimental|Phosphatidylcholine-lipid encapsulated vitamin C supplementation|1000 mg of vitamin C ingested in phosphatidylcholine-lipid encapsulated form
32819260|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
32819261|NCT05175846||Normal volunteers|Participants with negative COVID-19 test
32819262|NCT05175846||COVID-19|Participants with positive COVID-19 test and severe symptoms of disease
32819263|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
32819264|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
32819265|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
32819266|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
32819267|NCT04452006|Experimental|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
32819268|NCT04452006|Experimental|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
32819269|NCT04452006|Experimental|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
32819270|NCT04452006|Experimental|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
32819271|NCT04452006|Experimental|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
33101761|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.~Study subjects: Subjects with suspected PHA."
33101762|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.~Study subjects: Adult subjects with established clinical and biochemical GHD."
33101763|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
33101764|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
33101765|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
33101766|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
33101767|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
33317621|NCT05484440|Experimental|Group cognitive-behavioral intervention|Group participants will participate in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
33317622|NCT05484440|No Intervention|Treatment as usual (TAU)|Group participants will receive the usual treatment delivered by different institutions (e.g., correctional services, probation services, child protection services) as the participants of this study are justice-involved individuals (i.e., perpetrators of intimate partner violence).
33317623|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
33317624|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
33317625|NCT01196546|Experimental|Vildagliptin/metformin|
33317626|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
33317627|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
32819272|NCT04452006|Experimental|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
32819273|NCT04452006|Experimental|Part B - B1-3, ACT-541478 low or high dose|
32819274|NCT04452006|Experimental|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
32819275|NCT04452006|Experimental|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
32819276|NCT04452006|Experimental|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
32819277|NCT04452006|Experimental|Part C (Elderly) E1, ACT-541478, fasted|
32819278|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
32819279|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
32819280|NCT03071328|Experimental|Bone metastatic site|
32819281|NCT03071328|Experimental|Liver metastatic site|
32819282|NCT03071328|Experimental|Lymph node metastatic site|
32819283|NCT03071328|Experimental|Soft tissue metastatic site|
32819284|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
32819285|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
32819286|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
32819287|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
32819288|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
33101768|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
33101769|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
33101770|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
33101771|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
33101772|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
33101773|NCT02934594||Group A|Motor function intact group: received palliative decompression
33317628|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
32819289|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
32819290|NCT05173818|Experimental|HBO at 1.5 Atmosphere absolute|Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
32819291|NCT05173818|Sham Comparator|Sham control initially at 1.2 then changed to 1.0 ATA|Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
32819292|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
32819293|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
32819294|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
32819295|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
32819296|NCT03010696||Healthy subjects|Normal kidney function
32819297|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
32819298|NCT04923984|Experimental|Embolization of Middle Meningeal Artery for Subdural Hematoma|All patients with CSDH will undergo embolization of Middle Meningeal artery
32819299|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
32819300|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
32819301|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
32819302|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
32819303|NCT02521740||controls|someone who lives with an healthy elderly
32819304|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
32819305|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
32819306|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
32819307|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
33101774|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
33101775|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
33101776|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
33101777|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
33101778|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
33101779|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
33317629|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
33317630|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
33317631|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
33317632|NCT05671562|Experimental|Lycopene|Capsules containing 7mg of lycopene. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to placebo capsule.
33317633|NCT05671562|Placebo Comparator|Placebo|Placebo capsules containing an inactive ingredient. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to lycopene capsule.
33317634|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
33101780|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
33101781|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
32819308|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
32819309|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
32819310|NCT04901208|Active Comparator|Users of Juul|Individuals who use Juul devices to vape nicotine
33101782|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
32819311|NCT04901208|No Intervention|Controls|Healthy non-smokers
32819312|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
32819313|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
32819314|NCT02768766|Experimental|Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.
32819315|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
32819316|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
32819317|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
32819318|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
32819319|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
32819320|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
32819321|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
32819322|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
32819323|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
32819324|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
32819325|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
32819326|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
32819327|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
32819328|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
32819329|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
32819330|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
32819331|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
32819332|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
32819333|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
32819334|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
32830654|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
32830655|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
32830656|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
32830657|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
32830658|NCT04755309|Experimental|Typical development infants - experimental|Children without familial risk for language disorders, who participate to the rhythmic intervention.
33317635|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
33317636|NCT03246646|Experimental|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
33317637|NCT03246646|Other|Treatment as usual|Treatment as usual matched comparison
33317638|NCT05475002|Experimental|Intervention group|care empowerment program
33317639|NCT05475002|Active Comparator|Control group|dementia education
33317640|NCT03948646|Experimental|Active|Sofpironium bromide, 15% gel, once per day
33317641|NCT03948646|Placebo Comparator|Vehicle|Vehicle gel, once per day
33317642|NCT05474066||Pre and Post Training|A sample will be recruited from a group of 20 CAF SOF personnel ages 18-65 will be assessed twice: pre and post-special forces military training. All members enrolled in this training will be invited to participate in the study. Testing periods will be about 4 weeks apart, with post training testing within 1 week of conclusion of the exercise. Patients will be recruited from within the Canadian Special Operation Forces community. Recruitment and study will take place starting in September 2022 and continue until complete which is estimated to be approximately 12 months. Participants will be made aware of the study through recruitment letter sent as part of their training package (Appendix A). They will be allowed questions prior to enrollment or at any point during participation.
32819335|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
32819336|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
32819337|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
32819338|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
32819339|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
32819340|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
32819341|NCT04900584|Experimental|Intervention group|The intervention group is managed by applying all three types of intervention.
32819342|NCT04900584|No Intervention|non-Intervention group|Non-intervention group is managed by conventional heart failure treatment.
32819343|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
32819344|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
32819345|NCT01192776|Active Comparator|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
32819346|NCT01192776|Experimental|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
32819347|NCT01192776|Experimental|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
32819348|NCT01192776|Experimental|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
32819349|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
32819350|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
32819351|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32819352|NCT05161182|Experimental|High fat, low carbohydrate diet|
32819353|NCT05161182|Experimental|Low fat, high carbohydrate diet|
32819354|NCT04609865|Experimental|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
32819355|NCT04609865|Placebo Comparator|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
32819356|NCT05139498|Experimental|Conservative Management for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
33317643|NCT01198340|Active Comparator|With basal local anesthetics|
33317644|NCT01198340|Experimental|Without basal local anesthetics|
32819357|NCT05139498|Active Comparator|Hysterectomy at time of delivery for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
32819358|NCT04608695|No Intervention|Control ovary|
32819359|NCT04608695|Experimental|Punctured ovary|
32819360|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
32819361|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
32819362|NCT05138250|Experimental|Treatment arm (all participants, not randomised)|All participants will be treated with mepolizumab, a 100mg dose every 4 weeks for 1 year (13 doses)
32819363|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
32819364|NCT01140594|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
32819365|NCT01140594|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
32819366|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
32819367|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
32819368|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
32819369|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
32819370|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
32819371|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
32819372|NCT01876043|Experimental|plitidepsin|plitidepsin
32819373|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
32819374|NCT05128032|Experimental|Sequence A: Standard microcatheter for Mapping #1 and PEDD device for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using a standard microcatheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using the PEDD device catheter will be done just prior to the treatment.
32819375|NCT05128032|Experimental|Sequence B: PEDD device for Mapping #1 and standard microcatheter for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using the PEDD device catheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using a standard microcatheter will be done just prior to the treatment.
32819376|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
32819377|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
32819378|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
32819379|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
32819380|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
32830659|NCT04755309|No Intervention|Typical development infants - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
32819381|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
32819382|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
32819383|NCT04891614|Experimental|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
32819384|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
32819385|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
32819386|NCT00493896|Experimental|Fondaparinux|Fondaparinux treatment - one standard of care option
32819387|NCT00493896|Active Comparator|2|Enoxaparin
32819388|NCT04597619|No Intervention|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
32819389|NCT04597619|Experimental|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
32819390|NCT00388908|Experimental|A|Multifaceted intervention
32819391|NCT00388908|Active Comparator|B|Usual Care
32819392|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
32819393|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
32819394|NCT04890834|Active Comparator|Arm I (Standard of care)|Patients and caregivers receive standard care including education pertaining to symptom management, prophylactic dental hygiene and possible extraction, speech pathology for baseline swallowing assessment and prophylactic treatment, and dietary services for regular nutrition consults during CRT. Psychiatry, social work, interventional radiology and supportive care services are consulted as needed.
32819395|NCT04890834|Other|Arm II (exercise, yoga sessions)|Patients and caregivers receive standard care as in arm I. Patients and caregivers also participate in yoga sessions 3 times per week over 60 minutes each for a total of 15 sessions.
32819396|NCT04885920||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who initiated or are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for at least 12 months.
32819397|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
32819398|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
32819399|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
32819400|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
32819401|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.~1g Ceftriaxone IV was given.~Incision-- Subcoronal, circumferential & degloving.~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.~All patients were discharged from hospital within 24 hours."
32819402|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.~In an ambulatory setting, surgery was done 7 - 10 days later.~1g Ceftriaxone IV was given.~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.~Incision--- 2 - 3cm localized incision over the site of the rolling sign.~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
32819403|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
32819404|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
32819405|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
32819406|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
32819407|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
32819408|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
32819409|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
32819410|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
32819411|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
32819412|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
32819413|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
32819414|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
32819415|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
32819416|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
32819417|NCT01857869|Experimental|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
32819418|NCT01857869|Experimental|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
32819419|NCT01857869|Experimental|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
32819420|NCT05092542|No Intervention|Random Sample of Latinx Immigrants|random sample comparison group of Latinx immigrants who are NOT randomly assigned to a treatment condition
32819421|NCT05092542|Experimental|Refugee & Immigrant Well-being Project (RIWP) Intervention|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
32819422|NCT05092542|No Intervention|Treatment-as-usual Waitlist Control Group|participants recruited from community-based organizations receive usual services from community-based organizations and may participate in RIWP intervention in Year 3
33317645|NCT05670548||Abnormal postpartum glucose metabolism|GDM with positive OGTT results at 6-12 weeks postpartum
32819423|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
32819424|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
32819425|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
32819426|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
32819427|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
32819428|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
32819429|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
32819430|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
32819431|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
32819432|NCT03445572|Experimental|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
32819433|NCT03445572|Experimental|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
32819434|NCT03445572|Active Comparator|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
32819435|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
32819436|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
32819437|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
32819438|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
32819439|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
32819440|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
32819441|NCT05088408|Active Comparator|Control|Bowel preparation as usual. Colonoscopy.
32819442|NCT05088408|Experimental|Dietary supplement|"Bowel preparation as usual plus two bottles of the dietary supplement Resource® Energy Apricot.~Colonoscopy."
32819443|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
32819444|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
32819445|NCT05086068|Other|Arthrosamid Inj|Single arm study - no comparator
32819446|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
32819447|NCT04452318|Experimental|REGN10933 + REGN10987|
32819448|NCT04452318|Placebo Comparator|Placebo|
32819449|NCT04632576|Experimental|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing electrodes on acupoint and electrical stimulation is given.
32819450|NCT04632576|No Intervention|Control|Electrodes are placed on same acupoints as the experimental group, but no electrical stimulation is given.
32819451|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
32819452|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
32819453|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
32819454|NCT04621578|Experimental|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
32819455|NCT04621578|Sham Comparator|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
32819456|NCT04573764|Active Comparator|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
32819457|NCT04573764|Placebo Comparator|Placebo|
32819458|NCT04571190|Experimental|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
32819459|NCT04571190|No Intervention|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
32819460|NCT03010618|Other|Study Group|
32819461|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
32819462|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
32819463|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
32819464|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
32819465|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
32819466|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
32819467|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
32819468|NCT03438084|Active Comparator|Saturated fat control|Butter. 50g fat
32819469|NCT04807764|Experimental|Real transspinal stimulation delivered during standing followed by locomotor training|Transspinal tonic stimulation of the thoracolumbar region will be delivered at a frequency of 30 Hz during standing with as needed body weight support (BWS) in a standing frame or in the Lokomat to ensure safety.
32819470|NCT04807764|Experimental|Real transspinal stimulation delivered while lying supine followed by locomotor training|Transspinal tonic stimulation will be delivered at a frequency of 30 Hz while lying supine.
32819471|NCT04807764|Sham Comparator|Sham transspinal stimulation delivered during standing followed by locomotor training|One sham group will be receiving transspinal stimulation during standing at an intensity where sensation is absent.
32819472|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
33317646|NCT05670548||Control|GDM with negative OGTT results at 6-12 weeks postpartum
32819473|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
32819474|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
32819475|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
32819476|NCT04560660|Experimental|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
33317647|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
33317648|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
33317649|NCT05572450|Experimental|Infectious Titre 1|Dose Arm 1 (Part A): Approximately 10^5.5 TCID50/mL (titre may be adjusted based on stock titre)
32819477|NCT04560660|Placebo Comparator|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
32819478|NCT04542018|Experimental|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
32819479|NCT03437850||South African cohort|
32819480|NCT03437850||Swedish Cohort|
32819481|NCT03437772||CBT with mindfulness|
32819482|NCT03437772||Treatment as Usual: Barkley therapy|
32819483|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
32819484|NCT01214980|Active Comparator|Control arm|Standard of care treatment
32819485|NCT03445338|Experimental|Cohort 1|
32819486|NCT03445338|Experimental|Cohort 2|
32819487|NCT03445338|Experimental|Cohort 3|
32819488|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
32819489|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
32819490|NCT01232920|Active Comparator|Methotrexate|
32819491|NCT01232920|Active Comparator|Mycophenolate mofetil|
32819492|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
32819493|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
32819494|NCT03010540|Experimental|Morphine Plus Fentanyl|
32819495|NCT03010540|Active Comparator|Fentanyl only|
32819496|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
32819497|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
33101783|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
32819498|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
32819499|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
32819500|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
32819501|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
32819502|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
32819503|NCT01162096|Experimental|Transplantation|
32819504|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
32819505|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
32819506|NCT04801290||TIPS insertion|
32819507|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
32819508|NCT05665686|Experimental|Device Group|Sexual Information and Advice to Individuals Individuals in both groups will be given training on sexuality. Male and female sexual situation, orgasm, male and female anatomical structures will be explained. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
32819509|NCT05665686|Active Comparator|home exercise|A home exercise program including pelvic floor relaxation exercises in different positions will be created for individuals in both groups and self-myofascial massages will be taught. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
32819510|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
32819511|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
32819512|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
32819513|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
32819514|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
32819515|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
32819516|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
32819517|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
32819518|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
33317650|NCT05572450|Experimental|Infectious Titre 2|Dose Arm 2 (Part A): Approximately 10^4.5 TCID50/mL (titre may be adjusted based on stock titre)
33317651|NCT05572450|Experimental|Infectious Titre 3|Optional Dose Arm 3 (Part B): to be determined (TBD), depending on outcome of Part A
33317652|NCT05572450|Experimental|Infectious Titre 4|Optional Dose Arm 4 (Part B): TBD, depending on outcome of Part A
33317653|NCT05572372|Experimental|ACT group|Psychological intervention will consist in an 8-session individual on line-delivered ACT-based treatment.
33317654|NCT05083598||Adult patients undergoing major surgery|Patients aged 70 or older undergoing major non cardiac surgery, with expected surgical duration > 2 hours.
33317655|NCT05572216|No Intervention|conventional group|Robot-Assisted Partial Nephrectomy without 3D navigation
33317656|NCT05572216|Experimental|3D IGRAPN GROUP|Robot-Assisted Partial Nephrectomy with 3D navigation
32819519|NCT03444636|Experimental|Ropivacaine/Fentanyl|
33317657|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
33317658|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
33317659|NCT00308711|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
32819520|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
32819521|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
32819522|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
32819523|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
32819524|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
32819525|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
32819526|NCT04796454|Active Comparator|CisGem/GemOx|"Cisplatin/Gemcitabine (3-week cycle):~Cisplatin IV 25 mg/m² d1 and day8~Gemcitabine 1000 mg/m² d1 and d8~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years.~In case of unacceptable toxicity the CisGem regimen can also be switched to a GemOx regimen (4-week cycle):~Oxaliplatin IV 100 mg/m² d1 and day15~Gemcitabine 1000 mg/m² d1 and d15"
32819527|NCT04796454|Experimental|PamTMZ|"Pamiparib + temozolomide (4-week cycle):~Pamiparib 60 mg PO twice a day d1-d28 Temozolomide 60 mg PO daily d1-d7~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years."
33317660|NCT00308711|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
33317661|NCT00308711|Active Comparator|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
33317662|NCT05487586||ceftazidime avibactam group|Receive ≥1 dose of ceftazidime avibactam in routine practice; Aged ≥ 18 years old at the time of the informed consent signature.
33317663|NCT05170568|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
33317664|NCT04057456|Placebo Comparator|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
33317665|NCT04057456|Active Comparator|Placebo diet and Nabilone capsules|Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
33317666|NCT04057456|Active Comparator|Anti-inflammatory diet and placebo capsules|This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
33317667|NCT04057456|Active Comparator|Anti-inflammatory diet and Nabilone capsules|"Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.~This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc)."
33317668|NCT05156762|Experimental|Bariatric surgery group|Participants randomized to the bariatric surgery arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass to achieve a BMI ≤ 40 kg/m2.
33317669|NCT05156762|Experimental|Medical weight loss group|Participants randomized to the medical weight loss study arm will attempt to lose weight through diet, exercise, and potentially pharmacotherapy an effort to lower their BMI to ≤ 40 kg/m2.
33317670|NCT05156762|Other|"Usual Standard of Care"|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics."
33317671|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
33317672|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
33101784|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
33101785|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
33101786|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
33101787|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
33317673|NCT04655716|Experimental|Sodium bicarbonate|Intravenous sodium bicarbonate infusion
33101788|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
33101789|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
33101790|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
33101791|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
32819528|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
33101792|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
33101793|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
33101794|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
33101795|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
33101796|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
33101797|NCT02925026|Placebo Comparator|Placebo|rice flour
32819529|NCT05113680|Experimental|compassion|compassion focused group based on CFT
32819530|NCT05113680|Active Comparator|emotional competencies|emotional competencies group (based on emotional intelligence)
32819531|NCT05113680|No Intervention|control|control group
32819532|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
32819533|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
32819534|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
32819535|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
32819536|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
32819537|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
32819538|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
32819539|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
32819540|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
33101798|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
33101799|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
33101800|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
33101801|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
33317674|NCT04655716|No Intervention|Standard care|Standard of care by the clinical team
33317675|NCT03981263|Other|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
33317676|NCT03981263|Other|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
33317677|NCT01198418|Experimental|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
33317678|NCT01198418|No Intervention|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
33317679|NCT04653688|Experimental|Parkinsonian syndromes patients|
32819541|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
32819542|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
32819543|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
32819544|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
32819545|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
32819546|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
32819547|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
32819548|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
32819549|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
32819550|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
32819551|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
32819552|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
32819553|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
32819554|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
32819555|NCT04793412|Experimental|AHL/SSD|Children with asymmetric hearing loss or single-sided deafness
32819556|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
32819557|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
32819558|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
32819559|NCT04788420||Sorafenib group|Patients assigned to this group received sorafenib post-transplantation.
32819560|NCT04788420||Control group|Patients assigned to this group did not receive sorafenib or any other FLT3 inhibitor post-transplantation until reaching the primary outcome.
32819561|NCT04766190|Other|Group 1: Usual Care|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study."
32819562|NCT04766190|Other|Group 2: The DISCO App|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study."
32830660|NCT04755309|Active Comparator|Typical development infants - control|Children without familial risk for language disorders, who are exposed to passive auditory stimulation.
32830661|NCT04755309|Experimental|Infants at familial risk - experimental|Children with familial risk for language disorders, who participate to the rhythmic intervention.
32830662|NCT04755309|No Intervention|Infants at familial risk - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
32830663|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
32819563|NCT04766190|Other|Group 3: The DISCO App + Booster|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app."
32819564|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
32819565|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
32819566|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
33101802|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
33101803|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
32819567|NCT03440346|Experimental|Few-foods diet intervention|
33101804|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
33101805|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
33101806|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
33101807|NCT04687995|Active Comparator|Tragal preichondrium graft|Tragal perichodrium graft for endoscopic myringoplasty as a reference graft
33101808|NCT04687995|Active Comparator|pretragal ( SMAS) fascia graft|pretragal ( SMAS) fascia graft for endoscopic myringoplasty as a new graft
33101809|NCT02925104|Experimental|INC280|
33101810|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
33101811|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
33101812|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
33317680|NCT04653688|Sham Comparator|healthy subjects|
33101813|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
33101814|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
33101815|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
33101816|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
33317681|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
33317682|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
32819568|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
33101817|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
33101818|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
33101819|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
33101820|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
33101821|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
33101822|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
33317683|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
33317684|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
33317685|NCT05157100|Experimental|Ingrezza|Participants will receive Ingrezza orally once daily for 12 weeks.
32819569|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
32819570|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
32819571|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
32819572|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
32819573|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
32819574|NCT03437070|Experimental|TDO Dose Level|Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
32819575|NCT04346446|Experimental|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
32819576|NCT04346446|Active Comparator|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
32819577|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
32819578|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
33317686|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
33317687|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.~At this time, cord clamping will be made."
33317688|NCT00308555|Other|Cannabis|
32819579|NCT04487262|Active Comparator|Day O chest tube removal|"Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:~blood loss through chest tubes less than 200 ml during the last four hours~no air leak~the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period"
32819580|NCT04487262|Active Comparator|Day 1 chest tube removal|"Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:~blood loss through chest tubes less than 200 ml during the last four hours~no air leak~the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment."
32819581|NCT04478058|Experimental|e-CBT|Weekly e-CBT sessions will occur through Online Psychotherapy Tool (OPTT) and consist of slides and interactive therapist videos. Content and format mirrors live CBT. Slides will highlight a different topic each week and include general information, overview of skills, and homework. Homework will be submitted through OPTT and reviewed by administrators with personalized feedback within three days. Weekly homework submission will be mandatory before beginning the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment. After each cycle of e-CBT, patients and healthcare providers involved in e-CBT will be recruited for focus groups once they have completed their 12-week program. Qualitative data will be gathered through 10 focus groups. The focus group prompts will pertain to experience and expectations of service. Patients will be contacted six months after treatment to complete DASS 21 and Q-LES-Q-SF questionnaires.
32819582|NCT04478058|Active Comparator|Live CBT|The content and format of live CBT will be mirrored by the e-CBT group over the course of 12 weeks. The sessions will highlight a different topic each week and include general information, an overview of skills, and homework on that topic. Live CBT homework will be reviewed by the CBT group organizer and provided at the beginning of the next CBT session. Weekly homework submission for feedback will be mandatory before being eligible for the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment for both live and e-CBT. All live and e-CBT patients will be contacted six months after the completion of their CBT to complete final DASS 21 and Q-LES-Q-SF questionnaires. This will allow for the examination of the longevity of e-CBT compared to live CBT.
32819583|NCT01284244|Experimental|Uresta|
32819584|NCT01284244|Sham Comparator|Silastic vaginal ring|
32819585|NCT04469088|Experimental|Dry Needling Group|
32819586|NCT04469088|Active Comparator|Manual Therapy Treatment|
33101823|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
33317689|NCT05153044|Other|sickle cell children group|sickle cell children group
32819587|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
32819588|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
32819589|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
32819590|NCT04450290|Experimental|single arm - treatment|All subjects will be implanted with the investigational device.
32819591|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
32819592|NCT00633477|Placebo Comparator|Placebo|
32819593|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
32819594|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
33317690|NCT05153044|Other|sickle cell adult group|sickle cell adult group
33317691|NCT05153044|Other|control children group|control children group
32819595|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
32819596|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
32819597|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
32819598|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
32819599|NCT05054868|Active Comparator|Group 1 (Control group) - Oxycodone only|Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).
32819600|NCT05054868|Experimental|Group 2 (Treatment group) - Oxycodone and Ketorolac|Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.
32819601|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
32819602|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
32819603|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
32819604|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
32819605|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
32819606|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
32819607|NCT00340899||Pregnant women|Pregnant women with gestational age between 6 and 22 weeks
32819608|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
32819609|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
32819610|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
32819611|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
32819612|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
32819613|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
32819614|NCT04396002||Control|Participants with healthy eyes.
32819615|NCT04377360|Experimental|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
32819616|NCT04752228|Experimental|ACE Screen|"At the initial visit, the Philadelphia ACE Survey, a validated ACE questionnaire, will be administered by a research coordinator. A Lifestyle Assessment package will also be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire. Patients who test positive for ACE will receive a 3-page printed ACE Resource Pack.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
32819617|NCT04752228|Other|Lifestyle Assessment|"At the initial visit, no Philadelphia ACE Survey will be administered. The Lifestyle Assessment packaged will be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
32819618|NCT04369014|Experimental|etomidate|
32819619|NCT04369014|Experimental|propofol|
32819620|NCT03436914|Experimental|PPI|Esomezol®
32819621|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
32819622|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
32819623|NCT04749030|Other|Faecal microbiota transplantation (FMT)|Donor faeces is obtained from thoroughly screened healthy blood donors and processed in compliance with the European Tissue and Cells Directive.
32819624|NCT04749030|Placebo Comparator|Placebo|Placebo capsules will be identical in terms of visual appearance, weight, and vials and number
32819625|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
32819626|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
32819627|NCT04723056|No Intervention|Control Group (TAU only)|Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.
32819628|NCT04723056|Experimental|Experimental (TAU plus CBT)|Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).
32819629|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
32819630|NCT04708938|Experimental|Treatment group|High voltage electrical stimulation + exercise therapy
32819631|NCT04708938|Active Comparator|Control group|Exercise therapy
33317692|NCT05153044|No Intervention|Vaccinated patients|Vaccinated patients
32819632|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
32819633|NCT03436524||Validation cohorts|Cohorts of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
32819634|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
32819635|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
32819636|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
32819637|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
32819638|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
32819639|NCT04327518|Experimental|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
32819640|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical Practice: is the execution of the motor action."
32819641|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
32819642|NCT04760223|Experimental|Video intervention 1|We presented a 100-second video to study participants to reduce stigma towards depression (a boy presenter). The protagonist discussed his own depression and how getting help assist him.
32819643|NCT04760223|Experimental|Video intervention 2|We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
32819644|NCT04760223|Placebo Comparator|control video 1|A 100-second video presenting a boy without depression
32819645|NCT04760223|Placebo Comparator|control video 2|A 100-second video presenting a girl without depression
32819646|NCT05017974|Experimental|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement (MBSR+PS)|The study intervention is standard mindfulness-based stress reduction (MBSR), which will be delivered through 8 weekly 2.5-hour sessions via video conferencing to groups of 20-30 pregnant and non-pregnant people. MBSR also consists of a 2.5-hour orientation session, a 30-minute private interview with the instructor, and an all-day retreat, all conducted via video conferencing. The supplemental prenatal sleep content will be delivered through 6-8 30-minute sessions via video conferencing either individually or to small groups, and draws material from mindfulness-based therapy for insomnia, mindfulness-based childbirth and parenting program, and cognitive behavior therapy for prenatal insomnia.
32819647|NCT05017974|Other|Treatment as Usual|The control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy, with the exception of asking participants to refrain from participating in non-study mindfulness practice. Use of non-study treatment will be tracked.
32819648|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
32819649|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
32819650|NCT00244101|Active Comparator|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
32819651|NCT00244101|Experimental|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
32819652|NCT00244101|Experimental|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
32819653|NCT04959708|Active Comparator|Control group|Participants in the control group will have the same exposure in time as the intervention group and will be asked to maintain their lifestyle during the whole study and to refrain from starting any new regular physical activity. In case they can not maintain the same lifestyle during the study period, they will be asked to inform the researchers at any of the assessments.
32819654|NCT04959708|Experimental|Intervention group|The intervention group will consist of the Ínsula method. Insula method will be developed twice a week for 12 weeks online form through videoconference platform. The intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
32819655|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
32819656|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
32819657|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
32819658|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
32819659|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
32819660|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
32819661|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
32819662|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the wrist during active video games playing|In one session the accelerometer will place on the dominant wrist Individuals will instructed not to remove and instruct them to wear the device during the session.
32830664|NCT04264962|Placebo Comparator|Routine medical care|
32819663|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the hip during active video games playing|"In one session the accelerometer will place on a flexible belt by attaching to the hip area at the intersection of the dominant wrist and axillary line.~Individuals will instructed not to remove and instruct them to wear the device during the session."
32819664|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
32819665|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
32819666|NCT04276389|Active Comparator|OCT-guided arm|
32819667|NCT04276389|Placebo Comparator|Angiography-guided arm|
32819668|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
32819669|NCT01923441||Highschool athletes|
32819670|NCT01923441||midschool athletes|
32819671|NCT03128814||Elite (pre)adolescent tennis players|
32819672|NCT03128814||Age- and gender-matched controls|
32819673|NCT03128619|Experimental|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
32819674|NCT03128619|Experimental|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32819675|NCT03128619|Experimental|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
32819676|NCT03128619|Experimental|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32819677|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.~Procedures:~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
32819678|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
32819679|NCT03433092||Jing Huang et. al, 2017|
32819680|NCT03433092||Max Leenders et. al,2014|
32819681|NCT03433092||Yusuke Okuyama et. al,2014|
32819682|NCT03433092||GC Kabat et. al,2012|
32819683|NCT03433092||Christina Persson et. al,2008|
32819684|NCT03433092||M Jenab et. al,2006|
32819685|NCT03433092||Kenji Wakai et. al,2005|
32819686|NCT03433092||Christian C. Abnet et. al,2003|
32819687|NCT03433092||N Malila et. al,2002|
32819688|NCT03433092||G Pappalardo et. al,1997|
32819689|NCT04451538|Experimental|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g [12 spoon, 500 kcal]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoon, 440 kcal]/day, twice a day).
32819690|NCT04451538|Placebo Comparator|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
32819691|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
32819692|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
32819693|NCT04923672|No Intervention|Control group|Participants will be asked to wear an Apple watch through about 30 days after surgery and will be asked to maintain their current activity level.
32819694|NCT04923672|Active Comparator|Moderate continuous training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of continuous moderate intensity exercise prior to surgery."
32819695|NCT04923672|Active Comparator|High intensity interval training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery."
32819696|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
32819697|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
32819698|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
32819699|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
32819700|NCT04678908|Experimental|HB0025|HB0025 IV every 2 weeks (q2w)
32819701|NCT03999606|Active Comparator|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
32819702|NCT03999606|Experimental|Music Training|Participants in the experimental group will be assigned to a online based choir program.
32819703|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
32819704|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
32819705|NCT03435900|Experimental|Intervention group|
32819706|NCT03435900|Active Comparator|Control group|
32819707|NCT04283448|Experimental|Lentil|0.66 cups lentils
32819708|NCT04283448|Sham Comparator|Control|0.0 cups lentils
32819709|NCT00632931|Experimental|A|Arm A: Drug/Placebo
32819710|NCT00632931|Experimental|B|Arm B: Placebo/Drug
32819711|NCT04666974|Experimental|Phase 3: iCBT + Treatment As Usual|CWs in the iCBT group, will be assigned to one the six therapy modules, based on their gender and diagnosis (i.e. Female/Male * GAD, MDD or PTSD). Each CW will be assigned a specific clinician (a trained psychiatrist/psychologist/ social worker) who would be their care liaison through the study. Each week, the clinician would send one session of the 12-session curriculum to the CW on a pre-determined day of the week. Each weekly session consists of 20-30 slides followed by a homework assignment. It usually takes 40-60 minutes for a participant to complete one weekly session which they have to complete by a specific day of the week. The clinician will review the CW's assignments and provide feedback on their performance. The clinician feedback is structured and takes approximately 15 minutes to complete. The clinician will then send the content for the next session along with the feedback.
32819712|NCT04666974|No Intervention|Phase 3: Treatment as Usual|Participants will complete clincally validated questionnaires to measure symptoms while continuing with their regular daily activities and treatments (if any) (i.e., exercise, diet, medications, etc.)
32819713|NCT04666974|Experimental|Phase 4: iCBT + Treatment as Usual|Participants will be randomly assigned to this group and take part in the iCBT module program from phase 3.
32819714|NCT04666974|Active Comparator|Phase 4: In-Person CBT + Treatment as Usual|Participants will be randomly assigned to this group and complete in-person CBT with similar content, homework, and feedback as in the iCBT + TAU group. All in-person CBT will be delivered by a trained professional and each session will take approximately 60-75 minutes.
32819715|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
32819716|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
32819717|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
32819718|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
32819719|NCT03513939|Experimental|T1D Cell Pouch Recipients|Eligible Type 1 Diabetes Mellitus (T1D) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch intervention
32819720|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
32819721|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
32819722|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle~Ipilimumab will be administered intravenously once per cycle~Radiation Therapy will be administered per hospital standard"
32819723|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
32819724|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
32819725|NCT00055731|Experimental|Chemotherapy|
32819726|NCT00055731|Active Comparator|Without Chemotherapy|
32819727|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
32819728|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
32819729|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
32819730|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
32819731|NCT03975504|Other|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
32819732|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
32819733|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
32819734|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
32819735|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
32819736|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
32819737|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
32819738|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
32819739|NCT04451148||Obese subjects|Subjects with obesity
32819740|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
32819741|NCT04451148||Healthy controls|Otherwise healthy subjects
32819742|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
32819743|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
32819744|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
32819745|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
32819746|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
32819747|NCT04607681|Experimental|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;~On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices,~In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.~After 6 weeks of training, second data will be collected on the web in the intervention group."
32819748|NCT04607681|No Intervention|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices, Second data after 6 weeks will be collected in the control group via Google form or phone call"
32819749|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
32819750|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
32819751|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
32819752|NCT03432468|Active Comparator|postmenopausal hypertensive women|
32819753|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
32819754|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
32819755|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
32830665|NCT01751841||Spinal fusion patients with MIS surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
32830666|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
32819756|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
32819757|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 or 25 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
32819758|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
32819759|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
32819760|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
32819761|NCT03435432|Placebo Comparator|Water|50 ml water
32819762|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
32819763|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
32819764|NCT03439098|Placebo Comparator|Placebo|Placebo
32819765|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.~(Plastic stent anchoring)"
32819766|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
32819767|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
32819768|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
32819769|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
32819770|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
32819771|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
32819772|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
32819773|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
33405129|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
32819774|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
32819775|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
32819776|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
32819777|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
32819778|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
32819779|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
32819780|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
32819781|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
32819782|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
32819783|NCT00632463|Experimental|1|Dose regimen 1
32819784|NCT00632463|Experimental|2|Dose regimen 2
32819785|NCT00632463|Placebo Comparator|3|Placebo
33405130|NCT05761548||mature|
33405131|NCT05761548||preterm|
32819786|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
32819787|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
32819788|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
32819789|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
32819790|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
32819791|NCT05666310|Active Comparator|Zoledronic Acid|
32819792|NCT05666310|Active Comparator|Denosumab|
32819793|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
32819794|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
32819795|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
32819796|NCT01923675|Experimental|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
32819797|NCT01923675|Other|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
32819798|NCT01923675|Other|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
32819799|NCT01923675|Other|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
32819800|NCT03435042|Experimental|Children with cancer + their siblings|
32819801|NCT03435042|Experimental|Parents of children with cancer|
32819802|NCT04446507|Experimental|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
32819803|NCT04446507|Experimental|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 10 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
32819804|NCT03431922|Experimental|endovascular denervation|endovascular denervation
32819805|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
32819806|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
32819807|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
32819808|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
32819809|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
32819810|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
32819811|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
32819812|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
32819813|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
32819814|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
32819815|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
32819816|NCT01923831|Experimental|Magnesium group|
32819817|NCT01923831|Active Comparator|Dexamethasone group|
32819818|NCT03940950|Experimental|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
32819819|NCT03940950|Placebo Comparator|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
32819820|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
33405132|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
32819821|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
32819822|NCT03434886|Experimental|CF View|
32819823|NCT03434886|Active Comparator|CF Educational videos|
32819824|NCT03434886|Active Comparator|CF View and videos|
32819825|NCT03434886|No Intervention|Usual standard of care|
32819826|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
32819827|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
32819828|NCT04450602|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
32819829|NCT04450602|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
32819830|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
32819831|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
32819832|NCT04892940|Experimental|Virtual Reality group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
32819833|NCT04892940|Active Comparator|Control group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
32819834|NCT04885218|Experimental|Cohort 1：SHR-1209 / placebo|
32819835|NCT04885218|Experimental|Cohort 2：SHR-1209 /placebo|
32819836|NCT04885218|Experimental|Cohort 3：SHR-1209 / placebo|
32819837|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
32819838|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
32819839|NCT04875078|Experimental|UVA-1 Treated hand|This hand will be treated with UVA-1 phototherapy.
32819840|NCT04875078|No Intervention|The untreated hand|This hand will be gloved when the patient undergoes UVA-1 phototherapy treatments.
32819841|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
32819842|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
32819843|NCT04866342|Experimental|Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
32819844|NCT04866342|Active Comparator|Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
32819845|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
32819846|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
32819847|NCT04450446||cerebral hemorrhage|
32819848|NCT04450446||thromboembolism|
32819849|NCT04450446||no thromboembolism and cerebral hemorrhage|
32819850|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
32819851|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
32819852|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
32819853|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
32819854|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
32819855|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
32819856|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
32819857|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
32819858|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
32819859|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
32819860|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
32819861|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
32819862|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
32819863|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
32819864|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
32819865|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
32819866|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
32819867|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
32819868|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
32819869|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
32819870|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
32819871|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
32819872|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
32819873|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
32819874|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
32819875|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
32819876|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
32819877|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
32819878|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
32819879|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
32819880|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
32819881|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
32819882|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
32819883|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
32819884|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
32819885|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
32819886|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
32819887|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
32819888|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
32819889|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
32819890|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
33405133|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
32819891|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
32819892|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
33405134|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
32819893|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
32819894|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
32819895|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
32819896|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
32819897|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
32819898|NCT03537963|Experimental|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
32819899|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.~Individualized functional movement control training is 60 min/week~Aerobic exercise is 60 min/week"
32819900|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.~Frequency: 2 times/ week~Duration: 60min/ time"
32819901|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
32819902|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
32819903|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
32819904|NCT01924143|Experimental|TD-9855|
32819905|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
32819906|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
32819907|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
32819908|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
32819909|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
32819910|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
32819911|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
32819912|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
32819913|NCT03179904|Experimental|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
32819914|NCT03179904|Experimental|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
32819915|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
32819916|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
32819917|NCT01241344|Active Comparator|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
32819918|NCT01241344|Placebo Comparator|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
32819919|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
32819920|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
32819921|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
32819922|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
32819923|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
32830667|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
32819924|NCT03098277|Experimental|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
32819925|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
32819926|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
32819927|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
32819928|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
32819929|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
32819930|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
32819931|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
32819932|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
32819933|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
32819934|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
32819935|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
32819936|NCT04450134|Placebo Comparator|Placebo|6 weeks high-intensity interval training + placebo intake
32819937|NCT04450134|Experimental|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
32819938|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
32819939|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
32819940|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
32819941|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
32819942|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
32819943|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
32819944|NCT05248503||Nurse|Pediatric nurses taking charge of the care of patients with epidermolysis bullosa at Necker Hospital
32819945|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
32819946|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
32819947|NCT04450056||Mother-infant pairs|Mothers with a term-born (>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
32819948|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
33405135|NCT00641420|Experimental|Fractional Laser 10mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
33405136|NCT00641420|Experimental|Fractional Laser 40mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
32819949|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
32819950|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
32819951|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
32819952|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
32819953|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
32819954|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
32819955|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
32819956|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
32819957|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
32819958|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
32819959|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
32819960|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
32819961|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
32819962|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
32819963|NCT01925313|Experimental|CJ-30044|
32819964|NCT01925313|Active Comparator|TALION TAB. 10mg|
32819965|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
32819966|NCT05249751||mild-moderate|Cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, CORAD 1-5, and oxygen saturation (SpO2 92 percent),
32819967|NCT05249751||Severe|severe cases met the following criteria: fever and respiratory symptoms, CORAD 4-5, and oxygen saturation (SpO2 92 percent).
32819968|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
32819969|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
32819970|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
32819971|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
32819972|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
32819973|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
32819974|NCT02197078||Glitazones|
32819975|NCT02197078||Linagliptin|
32819976|NCT02197078||Sulfonylurea|
32819977|NCT02197078||Within-class comparators|
32819978|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
32819979|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
32819980|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
32819981|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
32819982|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
32819983|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
32819984|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
32819985|NCT00633789|Experimental|1|
32819986|NCT00633789|Placebo Comparator|2|
32819987|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
32819988|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
32819989|NCT00630201|Experimental|Probuphine|buprenorphine implant
32819990|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
32819991|NCT05241483||fever|Remote patient monitoring. fever values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
32819992|NCT05241483||pulse|Remote patient monitoring. pulse values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
32819993|NCT05241483||blood pressure|Remote patient monitoring. Blood pressure values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
32819994|NCT05241483||oxygen saturation|Remote patient monitoring. oxygen saturationvalues recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
32819995|NCT05241483||glucose|Remote patient monitoring. glucose values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
32819996|NCT01288534|Experimental|Radiation Treatment|
32819997|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
32819998|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
32819999|NCT04395807|Active Comparator|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
32820000|NCT04395807|Active Comparator|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
32820001|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
32820002|NCT03122301|Sham Comparator|Saline|Saline injection
32820003|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
32820004|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
32820005|NCT05247645||Rare diseases with predominantly skeletal involvement|The group comprises all patients affected rare diseases with predominantly skeletal involvement
32820006|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
32820007|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
32820008|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
32820009|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
32820010|NCT03161067|Experimental|Surgical implantation of BiCNS|
32820011|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
32820012|NCT04347837|Experimental|Investigational device|The investigational device will be used for all participants
32820013|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
32820014|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
32820015|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
32820016|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
32820017|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
32820018|NCT01920633||People with Down syndrome|
32820019|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
32820020|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
32820021|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
32820022|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
32820023|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
32820024|NCT05247723|Experimental|SIVCA|Aspirating testicular tissue using a standard IV cannula with applied negative pressure.
32820025|NCT05247723|Active Comparator|Micro-TESE|Extracting testicular tissue surgically
32820026|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
32820027|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
32820028|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
32820029|NCT01926405|Other|Control patients with no sleeping disorder|
32820030|NCT01920945|Experimental|OnabotulinumtoxinA|
32820031|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
32820032|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
32820033|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
32820034|NCT01926717||Pancreaticoduodenectomy|
32820035|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
32820036|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
32820037|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
32820038|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
32820039|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
32820040|NCT01926873||Healthy volunteers|
32820041|NCT04395417|Experimental|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
32820042|NCT04395417|Active Comparator|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
32820043|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
32820044|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
32820045|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
32820046|NCT02199652|Placebo Comparator|placebo|placebo pill
32820047|NCT02199652|Experimental|prazosin|prazosin pill
32820048|NCT05241561|Experimental|Cabozantinib|
32820049|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
32820050|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
32820051|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
32820052|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
32820053|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
32820054|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
32820055|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
32820056|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
32820057|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
33405137|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
32820058|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
32820059|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
32820060|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
32820061|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
33405138|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
32820062|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
32820063|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
32820064|NCT01246258||Test group|Standard tests of balance function
32820065|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
32820066|NCT01927107|Active Comparator|Control|Standard diet therapy
32820067|NCT03087591|Experimental|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
33101824|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
33101825|NCT04673136|Experimental|Colonoscopy assisted by GI-GENIUS|
33405139|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
32820068|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
32820069|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
32820070|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
32820071|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
32820072|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
32820073|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
32820074|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
32820075|NCT04275453|Experimental|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
32820076|NCT04275453|Experimental|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
32820077|NCT04275453|Experimental|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
32820078|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
32820079|NCT05248425|No Intervention|Usual Care|All participants will answer questionnaires at specified time points. This arm will receive usual care and their questionnaire responses will not be reviewed.
32820080|NCT05248425|Experimental|Monitored|All participants will answer questionnaires at specified time points. The monitored arm will have their responses reviewed for new or worsening symptoms which will be assessed and managed by a study nurse in addition to usual care.
32820081|NCT05246865|Experimental|Women with PCOS|Women with polycystic ovary syndrome
32820082|NCT05246865|Experimental|Age and BMI-matched healthy volunteers|Otherwise healthy women without PCOS but matching in age and body mass index to the above group
32820083|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
32820084|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
32820085|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
32820086|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
32820087|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
32820088|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
32820089|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
32820090|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
32820091|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
32820092|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
32820093|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
32820094|NCT05244525|Experimental|Treatment|
32820095|NCT05244525|Active Comparator|Control Group|
32820096|NCT01927263|Experimental|NI-071|
32820097|NCT01927263|Active Comparator|Infliximab|
32820098|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:~Without taking any St John's wort~After 3 weeks pretreatment with St John's wort~Minimum 6 weeks after last St John's wort ingestion"
32820099|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
32820100|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
32820101|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
32820102|NCT01921959||Partners of no intervention women|Partners of women randomized to control
32820103|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:~memory complaint~normal general cognition~normal activities of daily living~not demented"
32820104|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:~relatively focal executive dysfunction~Within reference range on tests of memory, language and visuospatial skills~normal general cognition~normal activities of daily living~not demented"
32820105|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:~Age and gender matched healthy subjects without significant neuropsychiatric disorder~Able to understand and provide signed informed consent"
32820106|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
32820107|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
32820108|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
32820109|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
32820110|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
32820111|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
32820112|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
32820113|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
32820114|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
32820115|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
32820116|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
32820117|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
32820118|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
32820119|NCT04397055|Experimental|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
32820120|NCT04397055|Active Comparator|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
32820121|NCT04396743|Active Comparator|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
32820122|NCT04396743|Active Comparator|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
32820123|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
32820124|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
32820125|NCT01247974|No Intervention|Control|No Pericardial Closure
32820126|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
32820127|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
32820128|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
32820129|NCT01922193|Experimental|Test Group|
33101826|NCT04673136|Placebo Comparator|Standard colonoscopy|
32820130|NCT01922193|Active Comparator|Control Group|
33101827|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
33101828|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
33101829|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
32820131|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
32820132|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
32820133|NCT01928121|No Intervention|Usual care|
33405140|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
33405141|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
32820136|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
32820137|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
32820138|NCT05240235|Active Comparator|Education, compression and exercise therapy|Patients will be given exercise therapy every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do home exercise at home for 10 minutes.
32820139|NCT05240235|Active Comparator|Education, compression,exercise therapy and manual lymph drainage|Patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
32820140|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
32820141|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
32820142|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
32820143|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
32820144|NCT04754529|Experimental|Supportive care (yoga)|Patients receive online yoga intervention QW for 12 weeks.
32820145|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
32820146|NCT01928355||metabolically healthy|
32820147|NCT01928355||Unhealthy|
32820148|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
32820149|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
32820150|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
32820151|NCT05241327|Active Comparator|Active|Beetroot Juice (Nitrate, 400 mg)
32820152|NCT05241327|Placebo Comparator|Placebo|Beetroot Juice (Nitrate, 0 mg)
33101830|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
32820153|NCT05241249|Experimental|Bethanechol|Patients with borderline resectable pancreatic cancer and no contraindication to bethanechol therapy will receive bethanechol on day 1 and continue until 2 days prior to scheduled surgery for a minimum of 2 months.
32820154|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
32820155|NCT05241171|Experimental|Fitbit plus Feedback Intervention|Participants who were randomized to the provider-feedback intervention arm received goal setting, and feedback graphs and charts,
32820156|NCT05241171|Active Comparator|Fitbit alone|Participants in self-managed control group were provided access to the Fitbit website or app but did not receive any feedback on their activity level from the study team.
32820157|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
32820158|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
32820159|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
32820160|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
33405142|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
32820163|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
32820164|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
32830668|NCT01748175||Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
33101831|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
33405143|NCT03650504|Experimental|Above Artery Group|
33405144|NCT03650504|Active Comparator|Between Artery and Vein Group|
33405145|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
33405146|NCT03650426|Experimental|Inlay patellar resurfacing technique|
33405147|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
33405148|NCT03462563|Experimental|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
32820165|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
32820166|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
32820167|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
32820168|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
32820169|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
32820170|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
32820171|NCT02977494|Experimental|Daratumumab Bortezomib|
32820172|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
32820173|NCT04217850|Experimental|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
32820174|NCT05241093|Experimental|HYML-122 plus cytarabine|"The first three eligible enrolled patients will be treated with initial dosing of HYML-122 400mg bid daily and cytarabine 100mg/m2 intravenously by using 3+3 escalating design to explore RP2D. the Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of the phase 1 subjects and establish the combined regimen recommended dose. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgement of the investigator, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria, whichever occurs first."
32820175|NCT04178460|Experimental|Assigned Interventions|Niraparib combined with MGD013
32820176|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
32820177|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
32820178|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
32820179|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
32820180|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
32820181|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
32820182|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
32820183|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
32820184|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
32820185|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
32820186|NCT03433560||Korean female breast cancer patients|
32820187|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
32820188|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
32820189|NCT04395183|Active Comparator|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
32820190|NCT04395183|Active Comparator|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
32820191|NCT04395183|Active Comparator|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
32820192|NCT04395183|Placebo Comparator|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
32820193|NCT04085406|Experimental|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
32820194|NCT04085406|Sham Comparator|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
32820195|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
32820196|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
32820197|NCT01928979||Group 1|
32820198|NCT04075734|Experimental|Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
33101832|NCT02924675|Experimental|pregabalin group|
33101833|NCT02924675|Placebo Comparator|Placebo group|
32820199|NCT04075734|No Intervention|Usual Care|Participants are not receiving the tested intervention. They continue to receive standard or routine psychosocial or transition care available to them as part of the normal practice
32820200|NCT05240859||Geleli|RA patients treated with Geleli
32820201|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~300 participants with an isolated cognitive complaint and an age of 60 years or more."
32820202|NCT04395105|Experimental|High dose Dexamethasone|Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
32820203|NCT04395105|No Intervention|Usual care - low dose Dexamethasone|Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial
32820204|NCT04072770|Experimental|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
32820205|NCT04072770|Active Comparator|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
32820206|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
32820207|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
32820208|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
32820209|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
32820210|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
32820211|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
32820212|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
32820213|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
32820214|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
32820215|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
32820216|NCT01929213|Experimental|Udenafil|
32820217|NCT01929213|Experimental|Bosentan|
32820218|NCT01929213|Experimental|Udenafil/Bosentan|
32820219|NCT03785730|Experimental|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
32820220|NCT03785730|Active Comparator|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
32820221|NCT05607615|Experimental|Experimental|Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks
32820222|NCT05607615|Placebo Comparator|Placebo|Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks
32820223|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
32820224|NCT03749538|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
32820225|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session.
32820226|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
32820227|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.~The splint will be subsequently delivered to the patient with the relative indications of use.~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
32820228|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.~The cycle will consist of 10 sessions distributed over 3 months."
32820229|NCT05604651||dry eye disease|Dry eye disease was diagnosed according to the Tear Film and Ocular Surface Society (TFOS) DEWS II criteria: (1) Ocular Surface Disease Index (OSDI) score ≥ 13 and (2) one of these signs; fluorescein tear breakup time (TBUT) <10 sec; abnormal ocular surface staining (>5 corneal spots or > 9 conjunctival spots).
32820230|NCT05604651||control|The controll group enrolled healthy participants without ocular and systemic diseases.
32820231|NCT03712098|Experimental|Smoking Cessation Counseling & Liraglutide|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of the medication liraglutide. Liraglutide comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which follows FDA guidelines and is documented to be safe and well-tolerated in prior clinical studies, will begin at 0.6 mg and increase weekly by 0.6 mg until the recommended dose of 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
32820232|NCT03712098|Active Comparator|Smoking Cessation Counseling & Placebo|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
32820233|NCT05240625|Experimental|Computer-aided colonoscopy|The subject will receive the standard colonoscopy procedure simultaneously with a computer-aided detection (CADe) analysis software designed to automatically detect and highlight potential polyps on colonoscopy images in a real-time manner during colonoscopy procedures.
32820234|NCT05240625|Active Comparator|Standard colonoscopy|The subject will receive the standard colonoscopy procedure.
32820235|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
32820236|NCT05240313|Experimental|keepin' it REAL (kiR)|The standard keepin' it REAL intervention, adapted for an online format. This includes 10 one-hour small group sessions focused on helping youth to develop drug refusal skills and improve decision making, risk assessment, and emotion regulation. Additionally, short videos highlight various aspects of the program (refuse, explain, avoid, leave). All materials are available in Spanish and English.
32820237|NCT05240313|Experimental|kiR + aggression|The standard keepin' it REAL intervention, adapted for an online format, plus content on interpersonal aggression
32820238|NCT05240313|Active Comparator|Stress Management|A single session focused on stress management skills.
32820239|NCT02938806||Obese/overweight children with T1D|No intervention
32820240|NCT02938806||Normal weight children with T1D|No intervention
32820241|NCT02938806||Obese/overweight children, no diabetes|No intervention
32820242|NCT02938806||Healthy, normal weight children|No intervention
32820243|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
32820244|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
32820245|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
32820246|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
32820247|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
32820248|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
32820249|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
32820250|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
32820251|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
32820252|NCT03430362|Placebo Comparator|Control group|Group B, will receive 2 ml of normal saline single intravenous dose
32820253|NCT05240079|Experimental|Patients|
32820254|NCT03430284|Experimental|Integrated Treatment|
32820255|NCT03430284|Other|General Treatment|
32820256|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
32820257|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
32820258|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
32820259|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
32820260|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
32820261|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
32820262|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
32820263|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
32820264|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
32820265|NCT05076396|Experimental|PM14|Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
32820266|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
32820267|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
32820268|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
32820269|NCT05069298|Experimental|INTERVENTION|Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.
32820270|NCT05069298|Placebo Comparator|CONTROL|Similar treatment regimen, but with a placebo.
32820271|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
32820272|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
32820273|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
32820274|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
32820275|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
32820276|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
32820277|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
32820278|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
32820279|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
32820280|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
32820281|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
32820282|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
32820283|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
32820284|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
32820285|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
32820286|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
32820287|NCT05601999|Experimental|GNR-060|Main group (122 patients) - GNR-060
32820288|NCT05601999|Active Comparator|Metalyse|Control group (122 patients) - Metalyse
32820289|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
32820290|NCT03423576|No Intervention|Control|Standard care
32820291|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
32820292|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
32820293|NCT05249829|Experimental|Part 1: mRNA-1273.529|"Phase A: Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
32820294|NCT05249829|Active Comparator|Part 1: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
32820295|NCT05249829|Experimental|Part 2: mRNA-1273.214|"Phase A: Participants will receive 1 IM dose of mRNA-1273.214 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
32820296|NCT05249829|Active Comparator|Part 2: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
32820297|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
32820298|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
32820299|NCT04351282|Experimental|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
32820300|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
32820301|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
32820302|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
32820303|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
32820304|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
32820305|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
32820306|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
32820307|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
32820308|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
32820309|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
32820310|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
32820311|NCT03657732||Normal control group|Normal cognitive control people
32820312|NCT05248113|Experimental|Intraoperative electrical stimulation of cochlear nerve|Electrical stimulation of the cochlear nerve will be tested intraoperatively in patients undergoing vestibular schwannoma resection.
32820313|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
32820314|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
32820315|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
32820316|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
32820317|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
32820318|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
32820319|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
33405149|NCT03462563|Placebo Comparator|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
32820320|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
32820321|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
32820322|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
32820323|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
32820324|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
32820325|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
32820326|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
32820327|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
32820328|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
32820329|NCT03423108|No Intervention|Control|Participants randomized to this group will perform monthly cohabitation meetings.
32820330|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
32820331|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
32820332|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
32820333|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
32820334|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
32820335|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
32820336|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
32820337|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
32820338|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
32820339|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
32820340|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
32820341|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
32820342|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
32820343|NCT03427242|Experimental|treatment arm|oral apatinib
32820344|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
32820345|NCT01252732|Active Comparator|IV Vancomycin|
32820346|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
32820347|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
32820348|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
32820349|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
32820350|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
32820351|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
32820352|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
32820353|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
32820354|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
32820355|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
32820356|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
32820357|NCT04396977|Other|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
32820358|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
32820359|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
32820360|NCT05242185||COVID-19 survivors|All patients age 18years and more who have SARS-CoV-2 infection confirmed by reverse-transcriptase polymerase-chain-reaction assay (RT-PCR) following their discharge from Dhaka hospital or outpatient clinic or inpatient wards of BSMMU
32820361|NCT03429660||Cohort|"Data to be collected are :~- Medical information on Immune Thrombocytopenia treatment"
32820362|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
32820363|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
32820364|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
32820365|NCT05601843|Experimental|TENS Arm|Participants randomized to receive treatment with TENS in addition to standard care.
32820366|NCT05601843|No Intervention|Control Arm|Participants randomized to not receive treatment with TENS. These participants receive standard care only.
32820367|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 & 3 for 24 weeks
32820368|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
32820369|NCT05601609||young colorectal cancer (yCRC)|"histologically confirmed cases of adenocarcinoma in the colon and rectum~the age at the time of diagnosis should be ≤ 40 years"
32820370|NCT05601609||elderly colorectal cancer (eCRC)|"histologically confirmed cases of adenocarcinoma in the colon and rectum~the age at the time of diagnosis should be ≥ 70 years"
32820371|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
32820372|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
32820373|NCT04449354|Other|Quality of Life assessment|HidraWear AX Garment
32820374|NCT00988533|Experimental|0.5% Ivermectin Cream|
32820375|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
32820376|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
32820377|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
32820378|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
32820379|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
32820380|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
32820381|NCT05601375||Pregnancy with a healthy fetus|3 times echocardiography in pregnancy once echocardiography after birth
32820382|NCT05601375||Pregnancy with a fetus with a structural heart disease|3 times echocardiography in pregnancy once echocardiography after birth
32820383|NCT05601375||Pregnancy with a fetus with a fetal growth restriction|3 times echocardiography in pregnancy once echocardiography after birth
32820384|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
32820385|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
32820386|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
32820387|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
32820388|NCT03154749|Experimental|DCb|Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
32820389|NCT03154749|Active Comparator|EC-D|Epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles
32820390|NCT05242497|Experimental|pharmacopuncture group|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
32820391|NCT05242497|Active Comparator|conservative treatment group|The physicians will choose the type and time of physical therapy and if needed, pharmacological treatment according to participants' conditions.
32820392|NCT03633396|Placebo Comparator|Placebo|Participants will receive placebo administered by subcutaneous injection on Day 1 followed by monthly doses of placebo by subcutaneous injection on Days 29, 57, and 85.
32820393|NCT03633396|Experimental|imsidolimab|Participants will receive 200 mg imsidolimab by subcutaneous injection on Day 1 followed by monthly doses of 100 mg imsidolimab by subcutaneous injection on Days 29, 57, and 85.
32820394|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
32820395|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
32820396|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
32820397|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
32820398|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
32820399|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
32820400|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
32820401|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
32820402|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
32820403|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
32820404|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
32820405|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
32820406|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
32820407|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
32820408|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
32820409|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
32820410|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
32820411|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
32820412|NCT01351090|Placebo Comparator|Placebo|
32820413|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
32820414|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
32820415|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
32820416|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
32820417|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
32820418|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
32820419|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
32820420|NCT04274907|Experimental|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
32820421|NCT04274907|Experimental|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
32820422|NCT04274907|Active Comparator|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
32820423|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
32820424|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
32830669|NCT04261764|Experimental|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
32830670|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
32820425|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
32820426|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
32820427|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
32820428|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
32820429|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
32820430|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
32820431|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
32820432|NCT01256944||Control|The normal reproductive-aged women
32820433|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~Oligo- or anovulation~Clinical and/or biochemical signs of hyperandrogenism~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
32820434|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
32820435|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
32820436|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
32820437|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
32820438|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
32820439|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
32820440|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Each 28-day cycle is repeated on Day 29/Day 1.~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
32820441|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
32820442|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
32820443|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
32820444|NCT03426930|Experimental|The reference treatment with the virtual reality|
32820445|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
32820446|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
32820447|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
32820448|NCT05246709|Active Comparator|Control Group|This group will be received the current standard of care (SOC) dressing method for PICC lines.
32820449|NCT05246709|Experimental|Cyanoacrylate Glue Group|This group will receive a few drops of cyanoacrylate glue on PICC line site prior to application of usual standard film dressing over the PICC line site.
32820450|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
32820451|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
32820452|NCT05245461||Anterior Cruciate Ligament Reconstruction|Patients who had remnant-preserving anterior cruciate ligament reconstruction
32820453|NCT05245461||Healthy Group|People who had no knee surgery or injury
32820454|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
32820455|NCT03426852||Control Group|Individuals with lumbar back pain
32820456|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
32820457|NCT05601063||Psychiatric patient group|"Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.~Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder~Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder~(Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder~Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder~Personality disorder - borderline personality disorder~Attention-Deficit Hyperactivity Disorder"
32820458|NCT05601063||Healthy controls|Healthy comparison subjects with no known psychiatric diagnosis
32820459|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820460|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820461|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820462|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820463|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820464|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820465|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820466|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
32820467|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
32820468|NCT00986349|Experimental|Diabetes|Single Arm
32820469|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
32820470|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
32820471|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
32820472|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
32820473|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
32820474|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
32820475|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
32820476|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
32820477|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
32820478|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
32820479|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
32820480|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
33101834|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
32820481|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
32820482|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
32820483|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
32820484|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
32820485|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
32820486|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
32820487|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
32820488|NCT04448730||overweight PCOS|38 cases
32820489|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
32820490|NCT04449120|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
32820491|NCT04449120|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
32820492|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
32820493|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
32820494|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
32820495|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
32820496|NCT03483324|Experimental|Experimental|Unmanipulated umbilical cord blood plus AB-110
32820497|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
32820498|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
32820499|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
32820500|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
32820501|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
32820502|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
32820503|NCT02053584|Experimental|Dario BGMS|
32820504|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
32820505|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
32820506|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
32820507|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
32820508|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
32820509|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
32820510|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
32820511|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
32820512|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
32820513|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
32820514|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
32820515|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
32820516|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
32820517|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
32820518|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
32820519|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
32820520|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
32820521|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
32820522|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
32820523|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
32820524|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
32820525|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
32820526|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
32820527|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
32820528|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
32820529|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
32820530|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
32820531|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
32820532|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
32820533|NCT03421002|Experimental|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
32820534|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
33101835|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
32820535|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
32820536|NCT03420924|Experimental|Thermal suit|
32820537|NCT03420924|Active Comparator|Conventional hospital clothes|
32820538|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
32820539|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
33317693|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
33317694|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
32820540|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
32820541|NCT03420846|No Intervention|Control arm|Standard MMS is performed
32820542|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
33317695|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
32820543|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
32820544|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
32820545|NCT03416478||ctDNA test group|
33101836|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
33101837|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
33101838|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
33101839|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
33101840|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
33101841|NCT03847545|Experimental|Intervention|The participants receive Fampridine treatment (10 mg x 2 daily) for 14 days. They are testet prior to treatment and following the 14 days of treatment.
33101842|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
33101843|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
33101844|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
33101845|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
33101846|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
33101847|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
33101848|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
33101849|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
33101850|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
33317696|NCT05137834|Experimental|"Exercise with a peanut ball."|"The rehabilitation program consists of mobility- and functional training exercises with a peanut ball."
32820546|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
32820547|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
32820548|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
32820549|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
33101851|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
32820550|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
32820551|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
32820552|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
32820553|NCT05607849|Experimental|Decisional aid for organised cancer screening|Eligible women will receive an invitation letter for a mammography accompanied by a leaflet mentioning the existence of the DA and encouraging them to consult their GP to initiate the DMP. The GPs will receive a letter informing them of the letter sent to their patients inviting them to make use of the DA, of the DA itself, and presenting the different stages in the DMP with encouragement to implement it.
32820554|NCT05607849|No Intervention|Standard organised cancer screening|Eligible women will receive only invitation letters, in line with national standard practice
32820555|NCT00985725|Experimental|Active|SPD489
32820556|NCT00985725|Placebo Comparator|Placebo|Placebo
32820557|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32820558|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
32820559|NCT05602701||Patients awaiting TKA|Patients awaiting unilateral total knee arthroplasty due to end-stage knee osteoarthritis.
32820560|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
32820561|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
32820562|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
32820563|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
32820564|NCT05607069||COVID-19 previous infection|
32820565|NCT04348149|Experimental|Intervention group|
32820566|NCT04348149|No Intervention|Wait-list|
32820567|NCT05607693|Experimental|SHR3680|
32820568|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
32820569|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
32820570|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
33317697|NCT05137834|Active Comparator|"Exercise without peanut ball"|"The rehabilitation program consists of standard mobility- and functional training exercises without a peanut ball."
32830672|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
32830673|NCT03280758|No Intervention|Control group|No exercise training.
33317698|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
32820571|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
32820572|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
32820573|NCT05607537|Experimental|Part 1: E7386 40 mg Tablet + (14C)E7386|Participants will be administered a single oral dose of E7386 40 mg tablet on Day 1 followed by an intravenous infusion containing a microdose solution of [14C]E7386 (100 mcg) with not more than (NMT) 7.4 kilobecquerel (kBq) (0.20 microcurie [mcCi]), starting approximately 25 minutes post oral dose administered as 5 milliliter (mL) over 5 minutes to coincide with the time at which the highest drug concentration occurs (tmax) for E7386 after an oral dose.
32820574|NCT05607537|Experimental|Part 2: (14C)E7386 40 mg Capsule|Participants will be administered a single oral dose of E7386 40 mg capsule radiolabeled with approximately 2.96 megabecquerel (MBq) (80 mcCi) (14C)E7386 (final dose to depend on the specific activity of [14C]E7386) in the morning on Day 1 after an overnight fasting.
32820575|NCT01352182|Experimental|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
32820576|NCT01352182|No Intervention|Normal standard care|Normal standard care control group
32820577|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
32820578|NCT00984867|Placebo Comparator|2|Matching placebo tablet
32820579|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
32820580|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
32820581|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
32820582|NCT04759521||Group 1|Inactive HBsAg carriers were patients with HBsAg positivity for more than 6 months
32820583|NCT04759521||Group 2|Patients diagnosed with chronic hepatitis B were patients with HBsAg positivity for more than 6 months
32820584|NCT04759521||Group 3|The control group was composed of healthy individuals who were not infected with hepatitis B virus and did not fit any exclusion criteria.
32820585|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
32820586|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
32820587|NCT05607303||Cases|MTF youth who will begin taking estrogen clinically in < 6 months with or without headache
32820588|NCT05607303||Controls|Cisgender males with or without headache
32820589|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
32820590|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
32820591|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
32820592|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
32820593|NCT05604963|Active Comparator|Group 1: Two-stage Completion Thyroidectomy|Patients randomised to this arm will undergo a 2nd operation to remove the remaining thyroid lobe.
32820594|NCT05604963|No Intervention|Group 1: Surveillance|Patients randomised to this arm will have no 2nd surgery and proceed directly to follow-up visits.
32820595|NCT05604963|Experimental|Group 2: Hemi-thyroidectomy|Patients randomised to this arm will have a single HT operation to remove thyroid lobe with the tumour.
32820596|NCT05604963|Active Comparator|Group 2: Total Thyroidectomy|Patients randomised to this arm will have a single TT operation to remove the entire thyroid gland.
32820597|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
32820598|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
32955876|NCT05766267|Experimental|2BMZRb/2 BMRb|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus rifabutin (Rb), followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily x 56 days; Rifabutin (Rb): 300 mg once daily"
32955877|NCT05766267|Experimental|2 BMZD/2 BMD|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus delamanid (D or DLM) followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily x 56 days; Delamanid (D):300 mg once daily"
32955878|NCT05766267|Active Comparator|2RHZE/4RH|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily~study drug doses: Rifampin (R), 600 mg daily; Isoniazid (H), 300 mg daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily ; Ethambutol, 15 mg/kg once daily rounded up to nearest 400 mg dose"
32955879|NCT05766254|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined prefrontal target for a total of 1000 pulses. Within each of the two TMS sessions, two targets will be stimulated.
32955880|NCT05766254|Sham Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
32955881|NCT05766241|Experimental|Program group|Participants in this group will receive five weekly sessions of Sensory Strategies Training (SST), facilitated by a trained clinician or graduate/post-graduate student in a health-related field.
32955882|NCT05766241|No Intervention|Waitlist control group|Participants in the waitlist control group will not receive SST or any other PTSD or sensory-processing treatments for the duration of the study.
32955883|NCT05766228|Experimental|Experimental|Web-Based Intercultural Midwifery Training
32955884|NCT05766228|No Intervention|Control|without any intervention
32955885|NCT05766215|Experimental|Therapeutic patients education|3 sessions of structured therapeutic patient education (TPE) in which diet, exercise, alcohol abuse and insulin or pharmacological treatment management advise is given.
32955886|NCT05766189|Experimental|Intervention arm|Receives communications on level of SARS-CoV-2 as identified in the wastewater
32955887|NCT05766189|No Intervention|Comparison arm|
32955888|NCT05766176||Health worker|A health worker who received a second dose of booster COVID19 vaccine
32955889|NCT05766163|Active Comparator|DaVinci system|Robot-assisted radical prostatectomy is carried out through daVinci platform.
32955890|NCT05766163|Experimental|Hugo system|Robot-assisted radical prostatectomy is carried out through Hugo platform.
32955891|NCT05766163|Experimental|Versius system|Robot-assisted radical prostatectomy is carried out through Versius platform.
32955892|NCT05766150||Patients with no oral malignant disease|
32955893|NCT05766150||Patients with oral premalignant disease|
32955894|NCT05766150||Patients with oral malignant disease|
32955895|NCT05766137|Experimental|Ridge preservation by filling the socket with autogenous partially demineralized dentin graft|2% HNO3 partial demineralization for 10 minutes
32955896|NCT05766137|Experimental|Ridge preservation by filling the socket with autogenous completely demineralized dentin graft|0.6N HCl for 30 minutes for complete demineralization
32955897|NCT05766137|Active Comparator|Ridge preservation by filling the socket with autogenous whole-tooth graft (AWTG).|After cleaning the tooth, it will be ground using bone mill and AWTG particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection , then washed twice in saline and dried using sterile gauze.
32955898|NCT05766124|Experimental|Low dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 2.5mg
32955899|NCT05766124|Active Comparator|Standard dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 10mg
32955900|NCT05766098||Patients with papillary thyroid cancer|
32955901|NCT05766085||hypertension|Those patients suffering from arterial hypertension
32955902|NCT05766085||no hypertension|Those patients without arterial hypertension
33317699|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
33317700|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
33317701|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
32955903|NCT05766072|Active Comparator|Intervention arm|"Youth in this arm received the intervention over 10 weeks during one semester (recruiting children over 6 semesters in total), children meeting in groups of approx. seven children. The groups were led by school health nurses.~At the same time parents met for 7 group sessions, with the children participating in four of these"
32955904|NCT05766072|No Intervention|Control arm|The youth in the control condition received treatment as usual, e.g. talks with school health nurses or no intervention
32955905|NCT05766059|Experimental|[Phase 1] Stroke patients with upper-limb hemiparesis|
32955906|NCT05766059|Experimental|[Phase 2] Patients with phantom limb pain (PLP)|
32955907|NCT05766033|Experimental|Novel etchent paste|
32955908|NCT05766033|Active Comparator|Phosphoric acid 37%|
32820599|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
32820600|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
32820601|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
32820602|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
32820603|NCT05604729|Experimental|BoNT A (botulinum neurotoxin type A)|Botulinum neurotoxin, 25 units (U) into each masseter at three sessions.
32820604|NCT05604729|Placebo Comparator|Placebo|Saline solution
32820605|NCT05604729|Placebo Comparator|Control|Saline solution, no tooth wear
32820606|NCT05606913|Experimental|IBI362 6.0mg|①2mg, SC, once a week* 4weeks; ②4mg, SC, once a week* 4weeks；③6mg, SC, once a week* 20weeks.
32820607|NCT05606913|Experimental|dulaglutide|1.5mg, SC, once a week* 28weeks
32820608|NCT05606913|Experimental|IBI362 4.0mg|2mg, SC, once a week* 4weeks; ②4mg, SC, once a week* 24weeks.
32820609|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
32820610|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
32820611|NCT05606211||Long COVID|Individuals who have been infected with the corona virus and developed Long COVID
32820612|NCT05606211||No Long COVID|Individuals who have been infected with the corona virus and fully recovered.
32820613|NCT03033927||Participants with Stage IV Pancreatic Cancer|
32820614|NCT03032835||Study participants|No intervention
32820615|NCT05603559|Experimental|177Lu-P17-087 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
32820616|NCT05603559|Experimental|177Lu-P17-088 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
32820617|NCT05604573||pancreatic cancer|patients with pancreatic cancer
32820618|NCT05604573||control|patients without any malignancy
32820619|NCT02984319|Active Comparator|Cherry|Cherry concentrate
32820620|NCT02984319|Placebo Comparator|Placebo|Placebo concentrate
32820621|NCT05604495||Adult patients with bronchiectasis (unknown cause)|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of hemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualization of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
32820622|NCT05604417|Experimental|PHASE 1: ZANDELISIB + TAZEMETOSTAT|"Phase 1 study (3+3 design), followed by a phase 2 expansion component~For phase 1 portion, which follows the same dosing schedule as Arm A, there will not be any randomization.~Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles. There will be 2 dose levels of tazemetostat."
32820623|NCT05604417|Experimental|Arm A: COMBINATION ZANDELISIB + TAZEMETOSTAT|"Participants randomized into Arm A of the phase 2 component will receive~Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles"
32820624|NCT05604417|Experimental|Arm B: Zandelisib and Tazemetostat|"Participants randomized into Arm B of the phase 2 component will receive~Zandelisib oral, daily on predetermined days (Cycles 1-2) and predetermined days of cycle 3 and onwards up to 14 cycles.~Tazemetostat, oral, twice daily on predetermined days of each cycle. This will begin on cycle 3 and will continue for up to 12 cycles."
32820625|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
32820626|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
32820627|NCT05604261|Experimental|Anaprazole sodium 40 mg QD|
32820628|NCT05604261|Experimental|Anaprazole sodium 60 mg QD|
32820629|NCT05604261|Active Comparator|Rabeprazole sodium 20 mg QD|
32820630|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 500mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
32820631|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
32820632|NCT05604105||Sample of the Egyptian population|"Participants of Giza residents.~Inclusion criteria:~• Adult individuals (Age>18 years).~Exclusion criteria:~Dental students or dental practitioners; as awareness of the disease is an integral part of their profession.~Oral cancer patients: Individuals who experience currently or previously having oral cancer.~Individuals with mental or communication disabilities."
32820633|NCT04759287|Active Comparator|VS group|include patients undergoing awake intubation using the C-MAC VS
32820634|NCT04759287|Placebo Comparator|FOB group|will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
32820635|NCT05603013|Experimental|Vinorelbine Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
32820636|NCT05602935|Experimental|Camrelizumab+SOX|The patients in the experimental arm will receive camrelizumab concurrently with SOX(S-1 and oxaliplatin).
32820637|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
33317702|NCT05073848||BfitBwell Participants|Individuals in the BfitBwell Cancer Exercise Program complete a FACIT-Fatigue questionnaire at their baseline assessment. This will be screened for all incoming BfitBwell participants and those meeting the inclusion criteria of a score of 48 or less will be approached for interest in participating. The primary research activities beyond recruitment, screening, and informed consent are the collection of EMA fatigue assessments via smartphone application and PA assessment via actigraphy.
32820638|NCT05602857|Experimental|Balance Training|Participants will follow a home-based BT intervention specifically designed by the investigators to improve postural control and balance in children. The BT program will consist of training sessions every other day (3 days a week) and a total of up to 45 minutes of balance exercises per week (15 minutes or less per session), addressing static balance (i.e., standing on one foot) and dynamic balance (i.e., balancing a book on your head while walking).
32820639|NCT05602857|Active Comparator|Music Training|Participants will follow a home-based MT intervention designed to provide enjoyable experiences to the child participants. The sessions will occur every other day (3 days a week) for a total of up to 45 minutes per week (15 minutes or less per session) for 12 weeks. The MT program will consist of a different selection of music videos each week, including a mix of familiar and new tunes.
32820640|NCT05602857|No Intervention|Business as usual|Children assigned to this control group will follow their usual activities during the 12 weeks between initial assessment and the second assessment.
32820641|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
32820642|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
32820643|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
32820644|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
32820645|NCT05603715|Other|Pyridostigmine Bromide|Open Label
32820646|NCT04394793|Experimental|Study Arm|
32820647|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
32820648|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
32820649|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
32820650|NCT05602779|Experimental|tVNS Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
32820651|NCT05602779|Experimental|Phone App Program|Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.
32820652|NCT05602779|Experimental|tVNS and Phone App Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
32820653|NCT05602779|Sham Comparator|Enhanced Treatment as Usual|Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.
32820654|NCT00981747|Experimental|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
32820655|NCT05602545|Experimental|Test-1|patients with peri-implantitis
32820656|NCT05602545|Experimental|Test-2|patients with peri-implant mucositis
32820657|NCT05602545|Other|control|patients with peri-implant health
32820658|NCT04394403|Experimental|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
32820659|NCT04394403|No Intervention|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
32820660|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
32820661|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
32820662|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
32820663|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
32820664|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
32820665|NCT05600751|Experimental|Radiosurgery of Ganglion Stellatum|Patients will undergo radiosurgery of the ganglion stellatum (left one or both)
32820666|NCT04275219|Experimental|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
32820667|NCT04275219|Placebo Comparator|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
32820668|NCT05602389|Experimental|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
32820669|NCT05602389|Experimental|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
32820670|NCT05602389|Placebo Comparator|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
32820671|NCT05601765|Active Comparator|Standard communication pathways after discharge|"Patients who need contact within 72 hours of discharge are advised to call the bed section, from where they were discharged. Telephone counseling can be provided by the nurses available at the time of calling (e.g., questions for medical treatment, precautions after surgery etc.).~If deemed relevant, the patient may be asked to appear in person at the ward (e.g., for the examination of wounds).~If more serious conditions are suspected, a doctor or emergency department will be contacted by the nurse for assessment, triage and possibly readmission.~Patients who need contact after 72 hours of discharge are advised to call the outpatient clinic, if they have planned attendances here, or alternatively their own general practitioner or home care nurse.~Standard communication pathways between healthcare professionals across sectors are electronic correspondences and telephone inquiries."
32820672|NCT05601765|Experimental|Digital team-based communication after discharge|"Patients will be given access to digital communication with their healthcare team across sectors who are involved in their treatment and care after hospital discharge (eDialogue). They will be set up in a messenger-like tool on the day of discharge, and relevant healthcare professionals will be connected. Individually, the patients will define who they would like to involve, and consent is given digitally. The minimum participants for each patient will be the patient and/or their closest relative, the orthopaedic surgeon, a nurse from the outpatient clinic and a secretary. Patients will have access to eDialogue for 60 days after discharge, and the response rate is set to be 24 hours on weekdays. On weekends and public holidays, patients are informed that they cannot expect a response. If the primary healthcare professional is registered to be on vacation or other absence, substitutes within the respective health professional groups will be included."
32820673|NCT05609955|Experimental|MgSO4|The treatment group received intravenous magnesium sulfate therapy with a 20% magnesium sulfate regimen, 39mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously.
32820674|NCT05609955|Placebo Comparator|Placebo|The treatment group who received intravenous placebo therapy with a regimen of 100 ml NaCl in 1 hour intravenous
32820675|NCT04129905|Experimental|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
32820676|NCT04129905|Active Comparator|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
32820677|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
32820678|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
32820679|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
32820680|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
32820681|NCT01258582|Experimental|Oral HIV testing|
32820682|NCT01258582|Active Comparator|Fingerstick HIV testing|
32820683|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
32820684|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
32820685|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
32820686|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
32820687|NCT01353196||stenosis|carotid stenosis
32820688|NCT01353196||no stenosis|no stenosis
32820689|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
32820690|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
32820691|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
32820692|NCT01354444|Placebo Comparator|Placebo|Non active substance
32820693|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
32820694|NCT01259440|Placebo Comparator|Usual Care|Usual Care
32820695|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
32820696|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:~24-35.9 kg: Two tablets~36-59.9 kg: Three tablets~60-79.9 kg: Four tablets~≥80 kg: Five tablets"
32820697|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
32830674|NCT04755387|Other|Ticagrelor 90mg|Standard strategy group receive ticagrelor 90mg twice daily
32820698|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
32820699|NCT01354990||Participants treated with sitagliptin|
33405150|NCT05285618|Experimental|Predicting the perceptual experience of retinal prosthesis patients|This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
32820700|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
32820701|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
32820702|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
32820703|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
32820704|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
32820705|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
32820706|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
32820707|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
32820708|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
32820709|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
32820710|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
32820711|NCT01856309|Experimental|Sirukumab 100 mg|
32820712|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
32820713|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32820714|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32820715|NCT01355458|Experimental|CD07805/47 gel|
32820716|NCT01355458|Placebo Comparator|Placebo|
32820717|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
32820718|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
32820719|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
32820720|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
32820721|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
32820722|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
32820723|NCT01299454|Active Comparator|Normal|
32820724|NCT01299454|Active Comparator|Mild|
32820725|NCT01299454|Active Comparator|Moderate|
32820726|NCT01299454|Active Comparator|Severe|
32820727|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
32820728|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
32820729|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
32820730|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
32820731|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
32820732|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
32820733|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
32820734|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
32820735|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
32820736|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
32820737|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
32820738|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
32830675|NCT04755387|Experimental|Ticagrelor 60/45mg|De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight <60kg, or age >75 years old.
32830676|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
32820739|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
32820740|NCT04352062|Experimental|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
32820741|NCT04352062|Placebo Comparator|Placebo|1 tablet twice daily (period 6 months)
32820742|NCT04352062|Other|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
32820743|NCT01302808|Experimental|Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
32820744|NCT01302808|Experimental|Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
32820745|NCT01302808|Experimental|Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
32820746|NCT01302808|Experimental|Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
32820747|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32820748|NCT01357564|Experimental|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
32820749|NCT01357564|Active Comparator|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
32820750|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
33317703|NCT03980873|Experimental|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
32820751|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
32820752|NCT01357720|Experimental|Quinvaxem|
32820753|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
32820754|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
32820755|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
32820756|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
32820757|NCT01358266|Active Comparator|Ophthalmic solution low dose|
32820758|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
33317704|NCT03980873|No Intervention|Control|Three-month waitlist
33317705|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
33317706|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
33317707|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
33317708|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
33317709|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
33317710|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
32820759|NCT01358266|Active Comparator|Ophthalmic solution high dose|
32820760|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
32820761|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
33317711|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
33317712|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
33317713|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
32820762|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
32820763|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
32820764|NCT01267864|Active Comparator|Valproate|1gm IV
32820765|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
32820766|NCT04415255|Experimental|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
32820767|NCT04415255|Active Comparator|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
32820768|NCT04414709|Experimental|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
32820769|NCT04414709|Active Comparator|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
32820770|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
32820771|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
32820772|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
32820773|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
32820774|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
32820775|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
32820776|NCT03009448||Late onset depression|
32820777|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
32820778|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
32820779|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion~Planned doses are:~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
32820780|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
32820781|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
32820782|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
32820783|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
32820784|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
32820785|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
32820786|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
32820787|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
32820788|NCT01269736|No Intervention|Control|Usual in-service education for nurses
32820789|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
32820790|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
32820791|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
32820792|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
32820793|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
32820794|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
32820795|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
32820796|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
32820797|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
32820798|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
32820799|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
32820800|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
32820801|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
32820802|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32820803|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32820804|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32820805|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32820806|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
32820807|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
32820808|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
33317714|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
33317715|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
32820809|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
32820810|NCT04605809|Experimental|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
32820811|NCT04605809|Active Comparator|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
32820812|NCT04605809|Active Comparator|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
32820813|NCT04605809|No Intervention|no intervention control group.|No intervention control group will maintain habit and daily activity.
32820814|NCT04605731|Experimental|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
32820815|NCT01307098|Experimental|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
32820816|NCT01307098|Experimental|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
32820817|NCT01307098|Experimental|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
32820818|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
32820819|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
32820820|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
32820821|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
32820822|NCT01272388|Active Comparator|Tadalafil|
32820823|NCT01272388|Placebo Comparator|Placebo|
33317716|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
33317717|NCT05431556|Experimental|Virtual mind-body group exercise classes (VMB)|Will be provided with the schedule and links to the web-based mind-body exercises offered by MSK in real-time via the Zoom video conferencing platform. Each session is led by a licensed clinician (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting.
33317718|NCT05431556|Active Comparator|Enhanced usual care (EUC)|Pre-recorded self-care videos.
33317719|NCT05572060|Active Comparator|Group C: (n=25) control.|patients will receive standardized protocol without receiving metformin.
33317720|NCT05572060|Active Comparator|Group D: (n=25) diabetic patients.|diabetic patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 140-180 in diabetic patients.
33317721|NCT05572060|Active Comparator|Group ND: (n=25) non-diabetic patients.|patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 100-140 in non diabetic patients.
33317722|NCT05431244|Other|Antiviral treatment in combination with low-dose gemcitabine|"For 1st & 2nd cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D8-28 Valganciclovir 900mg qd Every 4 weeks~For 3rd ~ 6th cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D1-28 Valganciclovir 900mg qd Every 4 weeks"
33317723|NCT05571982|Experimental|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
33317724|NCT05571982|Active Comparator|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
33317725|NCT05428982|Experimental|Postoperative Modified Trendelenburg group|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours
33317726|NCT05428982|No Intervention|Control|Patients underwent the laparoscopic hysterectomy were positioned in a neutral position
32955912|NCT05766007||Risperidone|Pregnant or breastfeeding women receiving the long acting injectable form of Risperidone and their babies
32955913|NCT05766007||Paliperidone palmitate|Pregnant or breastfeeding women receiving Paliperidone palmitate and their babies
33317727|NCT01314040|Other|Run in|
33317728|NCT01314040|Experimental|High meat protein diet|
33317729|NCT01314040|Experimental|High dairy protein diet|
33317730|NCT01314040|Experimental|High grain protein diet|
33317731|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
33317732|NCT05425888||Hemophilia group|Group of adult patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy
33317733|NCT05425888||Control group|Group of healthy subjects with sociodemographic characteristics similar to patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy.
33317734|NCT04923308||Intervention group|
33317735|NCT04923308||Control group|
33317736|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:~Power point presentation on the following topics as it relates to medication reconciliation:~Communication skill (with patients and also with other members of the healthcare team)~Documentation of pharmaceutical care activities~Medication history taking~Drug therapy problems~Medication reconciliation practice~Case studies on medication reconciliation~Role plays on medication reconciliation"
33317737|NCT03182972|No Intervention|Control arm|Control group
33317738|NCT05571826||telerehabilitation|Assessments, no specific intervention
33317739|NCT03172754|Experimental|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
33317740|NCT03172754|Experimental|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
33317741|NCT03172754|Experimental|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
33317742|NCT04046536|Active Comparator|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
33317743|NCT04046536|Sham Comparator|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
32955914|NCT05766007||Flupentixol decanoate|Pregnant or breastfeeding women receiving the Flupentixol decanoate and their babies
32955915|NCT05766007||Zuclopenthixol decanoate|Pregnant or breastfeeding women receiving the Zuclopenthixol decanoate and their babies
32955916|NCT05766007||Fluphenazine decanoate|Pregnant or breastfeeding women receiving the Fluphenazine decanoate and their babies
32955917|NCT05765994||ICU patients|Adult ICU patients on mechanical ventilation
32955918|NCT05765981|Experimental|Aromatic L-amino acid decarboxylase (AADC) deficiency|This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.
32955919|NCT05765929|Experimental|Non-operative treatment|Non-operative treatment based on weightbearing radiographs
32955920|NCT05765916|Experimental|Online mindfulness and acceptance intervention|Participants of the intervention group will receive an intervention manual and videos. The duration of the intervention will be six weeks. Participants will be asked for a minimum time investment of 60 min per week. The intervention will be delivered via WeChat video call. The intervention will be conducted following the intervention manual to ensure consistency of intervention content that delivered.
32955921|NCT05765916|No Intervention|Standard of care|Participants of the control group will be received usual follow-up care including regular medical checkups, which may include a physical exam, blood tests, and imaging tests.
32820824|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
32820825|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
32820826|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
32820827|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
32820828|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
32820829|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
32820830|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
32820831|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
32820832|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
32820833|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
32820834|NCT04351594|Experimental|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
32820835|NCT04351594|Placebo Comparator|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
32820836|NCT04603469||Trisomy 21 patients|Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
32820837|NCT04596293|Experimental|BBT-401-1S (800mg)|
32820838|NCT04596293|Experimental|BBT-401-1S (1,600mg)|
32820839|NCT04596293|Placebo Comparator|Placebo|
32820840|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
32820841|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
33317744|NCT04046536|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
33317745|NCT04046536|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
32820842|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
32820843|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
32820844|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
32820845|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
32820846|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
32820847|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
32820848|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
32820849|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
32820850|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
32820851|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
32820852|NCT01367080|Experimental|A Group|"1st administration - DWETR10~2nd administration - DWETR25"
32820853|NCT01367080|Experimental|B Group|"1st administration - DWETR25~2nd administration - DWETR10"
32820854|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
33317746|NCT03709264|Experimental|Amino Acids infusion|
32820855|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
32820856|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
32820857|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
32820858|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
32820859|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
32820860|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
32820861|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
32820862|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
32820863|NCT04595279|Experimental|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
32820864|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
32820865|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
32820866|NCT01369108|Experimental|Flowable composite|Flowable composite
32820867|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
32820868|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
32820869|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
32820870|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
32820871|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
32820872|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
32820873|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
32820874|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
32820875|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
32820876|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
32820877|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
32820878|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
32820879|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
32820880|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
32820881|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
32820882|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
32820883|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
32820884|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
32820885|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
32820886|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
32820887|NCT04602221|Experimental|Treatment sequence: T1-T2-R|"Treatments:~T1: Lamotrigine T2: BI 409306 T3: BI 425809 R: Placebo"
32820888|NCT04602221|Experimental|Treatment sequence: T1-R-T2|
32820889|NCT04602221|Experimental|Treatment sequence: T1-T3-R|
32820890|NCT04602221|Experimental|Treatment sequence: T1-R-T3|
32820891|NCT04602221|Experimental|Treatment sequence: T2-T1-R|
32820892|NCT04602221|Experimental|Treatment sequence: T2-R-T1|
32820893|NCT04602221|Experimental|Treatment sequence: T2-T3-R|
32820894|NCT04602221|Experimental|Treatment sequence: T2-R-T3|
32820895|NCT04602221|Experimental|Treatment sequence: T3-R-T1|
33317747|NCT03709264|Placebo Comparator|Placebo|
32820896|NCT04602221|Experimental|Treatment sequence: T3-T1-R|
32820897|NCT04602221|Experimental|Treatment sequence: T3-T2-R|
32820898|NCT04602221|Experimental|Treatment sequence: T3-R-T2|
32820899|NCT04602221|Experimental|Treatment sequence: R-T1-T2|
32820900|NCT04602221|Experimental|Treatment sequence: R-T2-T1|
32820901|NCT04602221|Experimental|Treatment sequence: R-T1-T3|
32820902|NCT04602221|Experimental|Treatment sequence: R-T3-T1|
32820903|NCT04602221|Experimental|Treatment sequence: R-T2-T3|
32820904|NCT04602221|Experimental|Treatment sequence: R-T3-T2|
32820905|NCT01309906|Experimental|Investigational lens|Bausch & Lomb investigational silicone hydrogel lens
32820906|NCT01309906|Active Comparator|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
32820907|NCT04415099|Experimental|One group|Only one group was assessed before and after performing muscle fatigue protocol.
32820908|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
32820909|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
32820910|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
32820911|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
32820912|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
32820913|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
32820914|NCT01279564|Sham Comparator|Control|Endotracheal tube
33405151|NCT04528134|Experimental|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
33405152|NCT04528134|Experimental|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
33405153|NCT04528134|Active Comparator|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
33405154|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
33405155|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
33405156|NCT04504422|Experimental|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
32820915|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
32820916|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
32820917|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
32820918|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
32820919|NCT01403584|Experimental|AutoVPAP with addition of AutoEPAP|This arm will receive conventional device modified to enable algorithm for automatically applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
32820920|NCT01403584|Active Comparator|AutoVPAP without addition of AutoEPAP|This arm will receive conventionally applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
32820921|NCT01374490|Experimental|Crofelemer|
32820922|NCT01374802|Experimental|BI 201335|capsule for oral administration
32820923|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
32820924|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
32820925|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
32820926|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
32820927|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
32820928|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
32820929|NCT01849289|Experimental|Insulin Degludec|
32820930|NCT01849289|Experimental|Insulin Glargine|
32820931|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
32820932|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
32820933|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
32820934|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
32820935|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
32820936|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
32820937|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
32820938|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
32820939|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
32820940|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
32820941|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
32820942|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
32820943|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
32820944|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
32820945|NCT02201212|Experimental|Everolimus|"Everolimus~Fixed doses orally once a day per each 28 day cycle~Participants will stay on study as long as they do not progress for a maximum of 24 months.~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
32820946|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
32820947|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
32820948|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
32820949|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
32820950|NCT01312948|Experimental|Prototype mask|
32820951|NCT04346680|Experimental|Experimental group|
32820952|NCT01962792|Experimental|Phase 1 - Dose Finding|Ibrutinib PO 560mg + Carfilzomib IV 20/27mg/m2 + Dexamethasone PO 20mg
32820953|NCT01962792|Experimental|Phase 2b - Main Study|Ibrutinib PO 560mg + Carfilzomib IV 20/36mg/m2 + Dexamethasone PO 20mg
32820954|NCT01962792|Experimental|Phase 2b - Sub-study|Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg
32820955|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
32820956|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
32820957|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
32820958|NCT03420690||Family of patient|
32820959|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
32820960|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
32820961|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
32820962|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
32820963|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
32820964|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
32820965|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
32820966|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
32820967|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
32820968|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
32820969|NCT03420612||validation|The validation cohort was used to verify the IDS
32820970|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
32820971|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
32820972|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
32820973|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
32820974|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
32820975|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
32820976|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
33317748|NCT05072288|Experimental|Remote activity program|Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
33317749|NCT03905356|Experimental|Exercise|"The exercise intervention will utilize the Moving Through Cancer: A Guide to Exercise for Cancer Survivors framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises)."
33317750|NCT04916912||CABG-1|A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
33317751|NCT04916912||CABG-2|A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
33317752|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
33317753|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
33317754|NCT01199432|Experimental|Group B(CEF)|
33317755|NCT01199432|Experimental|Group A(CEFci)|
33317756|NCT01199432|Active Comparator|Group C(EC)|
33317757|NCT05064020||Polypharmacy|"Polypharmacy: patient is using five or more medications will be considered polypharmacy.~Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
33317758|NCT05064020||Nonpolypharmacy|"Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy~Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
33317759|NCT05058560|Experimental|BACE+Tislelizumab|BACE was performed on the first day of the first cycle, and the first 200 mg of tislelizumab was given 3-5 days later.
33317760|NCT01293422|Experimental|Rifampicin|
33317761|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
32820977|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
32820978|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
32820979|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
32820980|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
32820981|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
32820982|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
32820983|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
32820984|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
32820985|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
32820986|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
32820987|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
33317762|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
33317763|NCT03850262||patients with posterolateral corner trauma of the knee|
33317764|NCT01198886|Placebo Comparator|Successful Aging Program|
33317765|NCT01198886|Experimental|Exercise-Nutrition Program|
32820988|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
32820989|NCT01407094|Placebo Comparator|Placebo|Placebo control
32820990|NCT01407094|Active Comparator|Bupropion|BupropionXL
32820991|NCT01867307|Experimental|Healthy Controls|healthy controls
32820992|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
32820993|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
32820994|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
32820995|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
32820996|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
32820997|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
32820998|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
32820999|NCT01866917|Experimental|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
32821000|NCT01866917|Placebo Comparator|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
32821001|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
32821002|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
32821003|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
32821004|NCT01316302|Placebo Comparator|Placebo|Matching placebo
32821005|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
32821006|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
32821007|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
32821008|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
32821009|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
32821010|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
32821011|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
32821012|NCT01316770|Placebo Comparator|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
32821013|NCT01316770|Experimental|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
32821014|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
32821015|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
32821016|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
32821017|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
32821018|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
32821019|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
32821020|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
32821021|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
32821022|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
32821023|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
32821024|NCT04351516|Experimental|hydroxychloroquine|
32821025|NCT04351516|Placebo Comparator|Placebo|
32821026|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
32821027|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
32821028|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
32821029|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
32821030|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
32821031|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatinib or dasatinib
32821032|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
32821033|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
32821034|NCT04346758|Other|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
32821035|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
32821036|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
32821037|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
32821038|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
32821039|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
32821040|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
32821041|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
32821042|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
32821043|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
32821044|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
32821045|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
32821046|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
32821047|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
32821048|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
32821049|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
32821050|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
32821051|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
32821052|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
32821053|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
32821054|NCT03420378|Experimental|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
32821055|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
32821056|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
32821057|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
32821058|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
32821059|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
32821060|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
32821061|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
32821062|NCT03425448|Active Comparator|Heparin group|
32821063|NCT03425448|Experimental|Neotrolin Group|
32821064|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
32821065|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
32821066|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
32821067|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
32821068|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
32821069|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
32821070|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
32821071|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
32821072|NCT03425214|Experimental|control group (healthy subjects)|fMRI
32821073|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
32821074|NCT04855812|Experimental|MyoPro|Receiving MyoMo training in-clinic and at home for 6-weeks
32821075|NCT04855812|Active Comparator|Myo-SB|Receiving MyoMo training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
32821076|NCT04855812|Active Comparator|Control|Receiving conventional therapy/training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
32821077|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
32821078|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
32821079|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
32821080|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
32821081|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
32821082|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
32821083|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
32821084|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
32821085|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
32821086|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
32821087|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
32821088|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
32821089|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
32821090|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
32821091|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
32821092|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
32821093|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
32821094|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
32821095|NCT03424902||group1|patients with no or mild paravalular leakage
32821096|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
32821097|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
32821098|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
32821099|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
32821100|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
32821101|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
32821102|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
32821103|NCT04590521|Experimental|Intervention|A standard 3-dose schedule (0, 2 and 6 months) of licensed HPV vaccine (Gardasil®, Merck) will be administered to all participants intramuscularly.
32821104|NCT04448496|Experimental|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
32821105|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
32821106|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
32821107|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
32821108|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
32821109|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
32821110|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
32821111|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
32821112|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
32821113|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
32821114|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
32821115|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
32821116|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
32821117|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
32821118|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
32821119|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
32821120|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
32821121|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
32821122|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
32821123|NCT01412866|Experimental|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
32821124|NCT01412866|Active Comparator|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
32821125|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
32821126|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
32821127|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
32821128|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
32821129|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
32821130|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
32821131|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
32821132|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
32821133|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
32821134|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
32821135|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
32821136|NCT04351672|Experimental|Early Time-Restricted Feeding|
32821137|NCT04351672|Experimental|Late Time-Restricted Feeding|
32821138|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
32821139|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
32821140|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
32821141|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
32821142|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
32821143|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
32821144|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
32821145|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
32821146|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
32821147|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
32821148|NCT03414528||Patients with PID|
32821149|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
32821150|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
32821151|NCT03424278|Active Comparator|Motor Control|
32821152|NCT03424278|Experimental|Resistance Training|
32821153|NCT03414294|Experimental|K-755 Part A (SAD)|
32821154|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
32821155|NCT03414294|Experimental|K-755 Part B (MAD)|
32821156|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
32821157|NCT03414294|Experimental|K-755 Part C (FE)|
32821158|NCT03414294|Experimental|K-755 Part D (FE)|
32821159|NCT03414294|Experimental|K-755 Part E (MAD)|
32821160|NCT03414294|Placebo Comparator|Placebo Part E (MAD)|
32821161|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
32821162|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
33101852|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
33101853|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
33101854|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
33101855|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
33101856|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
32821163|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
32821164|NCT02879604|Experimental|Compensatory cognitive training|Compensatory cognitive training
32821165|NCT02879604|Placebo Comparator|usual treatment|usual treatment for shizophrenai
32821166|NCT02853474|Sham Comparator|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment"
32821167|NCT02853474|Experimental|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment~Early palliative care visits"
33101857|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
33101858|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
33101859|NCT04323865||Study 2. Repeatability of FHRV|
33101860|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
33101861|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
33317766|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
33317767|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
33317768|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
32821168|NCT02813226|Other|Imaging|Molecular Imaging
32821169|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
32821170|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
32821171|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
32821172|NCT01389856|Experimental|1|Bosentan
32821173|NCT01389856|Placebo Comparator|2|Matching placebo
33101862|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
33317769|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
32821174|NCT04448964|Experimental|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
33317770|NCT01566734|No Intervention|Control|
33317771|NCT00050778|Active Comparator|Interferon Beta-1a|
33317772|NCT00050778|Experimental|Alemtuzumab 12 mg|
33317773|NCT00050778|Experimental|Alemtuzumab 24 mg|
32821175|NCT04448964|Experimental|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821176|NCT04448964|Experimental|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821177|NCT04448964|Experimental|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821178|NCT04448964|Experimental|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821179|NCT04448964|Experimental|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821180|NCT04448964|Experimental|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821181|NCT04448964|Experimental|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
32821182|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
32821183|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
32821184|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
32821185|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
32821186|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
32821187|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
32821188|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
32821189|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
32821190|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
32821191|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
32821192|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
32821193|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
32821194|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
32821195|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
32821196|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
32821197|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
32821198|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
32821199|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
32821200|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
32821201|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
32821202|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
32821203|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
32821204|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
32821205|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
32821206|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
32821207|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
32821208|NCT04634916|Experimental|EndoAVF|
32821209|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
32821210|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
32821211|NCT04631952|Experimental|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
32821212|NCT04631952|Active Comparator|SMS message|SMS messages on encouraging active lifestyle
32821213|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
32821214|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
32821215|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
32821216|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
32821217|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
32821218|NCT04447794|Active Comparator|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
32821219|NCT04447794|Experimental|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
32821220|NCT04447794|No Intervention|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
32821221|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
32821222|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
32821223|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
32821224|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
32821225|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
32821226|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
32821227|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
32821228|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
32821229|NCT01842581|Experimental|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
32821230|NCT01842581|Experimental|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
32821231|NCT04448028|Placebo Comparator|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
32821232|NCT04448028|Active Comparator|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
32821233|NCT04447950|Experimental|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
32821234|NCT04447950|Placebo Comparator|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
32821235|NCT04414553|Experimental|Community-AHF|Participants in this arm will receive the Community Active and Healthy Families Intervention
33317774|NCT05670392|Active Comparator|Arm 1: laser and HITS treatment|Laser and magnetic chair Treatment
32821236|NCT05169996|Experimental|Real Food|Participants are exposed to a tangram game with puzzle pieces from chocolate.
32821237|NCT05169996|Experimental|Real Nonfood|Participants are exposed to a tangram game with puzzle pieces from wood.
32821238|NCT05169996|Experimental|Virtual reality Food|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate.
32821239|NCT05169996|Experimental|Virtual reality Nonfood|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) wood.
32821240|NCT05169996|Experimental|Virtual reality Food Branded|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate. In the background of the puzzle, a brand is shown.
32821241|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
32821242|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
32821243|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
32821244|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
32821245|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
32821246|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
32821247|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
32821248|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
32821249|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
32821250|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
32821251|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
32821252|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
32821253|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
32821254|NCT05169528|Other|Colorectal Cancer Prehabilitation Program|This is a before-after trial. The same group of participants will have a series of outcome measures taken at baseline, which will then be compared to these same outcome measures when repeated after undergoing prehabilitation and at 3 months' post-operatively
32821255|NCT01841567|Other|dressing|
32821256|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
32821257|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
32821258|NCT05169450|Experimental|Diterpene ginkgolides meglumine injection|The intervention group received daily single infusions of 25 mg diterpene ginkgolides meglumine injection (DGMI) diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
32821259|NCT05169450|Active Comparator|Ginaton|The control group received once or twice a day infusion of 35-60mg Ginaton diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
32821260|NCT04593407|Active Comparator|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
32830677|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
32830678|NCT00186147||Graft recipients and donors|
32830679|NCT04046328|Experimental|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID (twice daily) as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
32821261|NCT04593407|Experimental|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (<2%) when margins are tumor-free.
32821262|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
32821263|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
32821264|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
32821265|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
32821266|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
32821267|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
32821268|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
32821269|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
32821270|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
32821271|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
32821272|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
32821273|NCT01833065|Placebo Comparator|PLCBO|Placebo
32821274|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
32821275|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
32821276|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
32821277|NCT03417414||B-CLL|Patients with B-Cell CLL
32821278|NCT03417414||B-NHL|Patients with B-Cell NHL
32821279|NCT04860102|Experimental|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
32821280|NCT04860102|No Intervention|hands off|standard of care
32821281|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
32821282|NCT03413046||Control|30 healthy children
32821283|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
32821284|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
32821285|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
32821286|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
32821287|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
32821288|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
32821289|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
32821290|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
32821291|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
32821292|NCT04839744|Experimental|TG103 produced by the modified manufacturing process|A single dose of TG103 (15mg) produced by the modified manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
32821293|NCT04839744|Active Comparator|TG103 produced by the original manufacturing process original manufacturing process|A single dose of TG103 (15mg) produced by the original manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
32821294|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
32821295|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
32821296|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
32821297|NCT05169294|Experimental|Intervention|
32821298|NCT05169294|Active Comparator|Control|
32830680|NCT04046328|Experimental|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID (twice daily) as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
32821299|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
32821300|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
32821301|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
32821302|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
32821303|NCT03412656|Experimental|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
32821304|NCT03412656|Other|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
32821305|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
32821306|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
32821307|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
32821308|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
32821309|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
32821310|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
32821311|NCT01417780|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride)
32821312|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
32821313|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
32821314|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
32821315|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
32821316|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
32821317|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
32821318|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
32821319|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
32821320|NCT05171400|Sham Comparator|Control Group (CG)|The palatal wound area will not receive any treatment
32821321|NCT05171400|Experimental|Blank Film Group (BF)|The palatal wound area will receive silk fibroin film as a dressing
32821322|NCT05171400|Experimental|Insulin-loaded film (IF)|The palatal wound area will receive an insulin-loaded silk fibroin film as a drug delivery system
32821323|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
32821324|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
33317775|NCT05670392|Other|Arm 2: laser (without HITS treatment)|Laser treatment
32821325|NCT05169138|Placebo Comparator|massage group with lavender essential oil|Pregnant women (n:37) who participated in this group were given an intense massage for at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
32821326|NCT05169138|Placebo Comparator|group of inhalations with lavender essential oil|Pregnant women (n:44) who participated in this group were administered inhalation with lavender oil at an intensity of at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
32821327|NCT05169138|No Intervention|control group|No application was made to the pregnant women (n:40) who participated in this group in each phase of the first phase of labor. Despite this, the Visual Analog Pain Scale and McGill Melzack Pain Questionnaire, which were applied at the beginning of each phase in order to increase the reliability of the results, were re-evaluated 30 minutes after the measurements, even though there was no application, and the process was completed with a total of 6 measurements.
32821328|NCT04593329|Experimental|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet Tiradentes association, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
32821329|NCT04593329|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet Tiradentes association placebo, oral;~1 capsule tramadol placebo, oral."
32821330|NCT04593329|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet Tiradentes association placebo, oral."
32821331|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
32821332|NCT04447482|Experimental|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
32821333|NCT04447482|Active Comparator|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
32821334|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
32821335|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
32821336|NCT05168904|Experimental|Phase I Dose escalation|Phase 1 = fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4-week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
32821337|NCT05168904|Experimental|Phase 2|Recommended fadraciclib phase 2 dose and schedule administered orally in 28-day cycles.
32821338|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
32821339|NCT05168436||Cohort 1|Participants with renal cell carcinoma (RCC) treated with nivolumab
32821340|NCT05168436||Cohort 2|Oncologists with expertise in renal cancer from Spain and Portugal
32821341|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
32821342|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
32821343|NCT04681794|Experimental|MayoP4 Group|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, hopping/jumping, and movement-based mindfulness.
32821344|NCT04681794|No Intervention|Control Group|No intervention
32821345|NCT04667442||EUA RT-PCR positive|
32821346|NCT04667442||EUA RT-PCR negative|
32821347|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
32821348|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
32821349|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
32821350|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
32821351|NCT04656522|Experimental|Participatory Comic Intervention|This is a pre-test/post-test trial, therefore all participants will participate in the participatory comic intervention.
32821352|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
32821353|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
32821354|NCT01417936|Experimental|Sym004|
32821355|NCT05170932|No Intervention|open flap + mechanical debridement|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement only.
33317776|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
32821356|NCT05170932|Experimental|open flap +CHX gel 2 % + 24% EDTA|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement before treating root and bony walls of the pocket surfaces by application of 24% EDTA etching and washing with saline, then application of 2% chlorhexidine gel on root surface.
32821357|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
32821358|NCT05168358|No Intervention|Control group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours.
32821359|NCT05168358|Experimental|OCD group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours, in addition to placing an overnight catheter to drain the urinary bladder during night.
32821360|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
32821361|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
32821362|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
32821363|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
32821364|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
32821365|NCT05170620|Experimental|Patients|Patients with squamous intraepithelial lesions of the lower anogenital tracts will receive laser ablation.
32821366|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
32821367|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
32821368|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.~Intervention: Questionnaire"
32821369|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
32821370|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
32821371|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
32821372|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
32821373|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
32821374|NCT04632966|Experimental|PTP-001 - Low Dose (100 mg)|intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
32821375|NCT04632966|Experimental|PTP-001 - High Dose (200 mg)|intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
32821376|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
32821377|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
32821378|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
32821379|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
32821380|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
32821381|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
32821382|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
32821383|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
32821384|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
32821385|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
32821386|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
32821387|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
32821388|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
32821389|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
32821390|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
32821391|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
32821392|NCT03406806|Experimental|GaitBox|
32821393|NCT03406806|Active Comparator|Sprint System device|
32821394|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
32821395|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
32821396|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
32821397|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
32821398|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
32821399|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
32821400|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
32821401|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
32821402|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
32821403|NCT04588818|Experimental|Adalimumab plus Methotrexate|
32821404|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
32821405|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
32821406|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
32821407|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
32821408|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
32821409|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
32821410|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
32821411|NCT04544358|Experimental|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
32821412|NCT04544358|No Intervention|Control|Randomized to wait list, received BAILAMOS© program after data collection.
32821413|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
32821414|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
32821415|NCT05170542|Experimental|Camrelizumab+S-1|
32821416|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
32821417|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
32821418|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
32821419|NCT04447326|Experimental|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
32821420|NCT04447326|Active Comparator|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
32821421|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
32821422|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
32821423|NCT01426360|Placebo Comparator|control dentifrice|
32821424|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
32821425|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
32821426|NCT05167890|Active Comparator|Coffee Arm|Patients in coffee arm receive 1 cup of coffee 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
32821427|NCT05167890|Active Comparator|Orange Arm|Patients in orange arm receive 1 cup of orange juice 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
32821428|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
32821429|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
32821430|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
32821431|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
32821432|NCT03396354|Experimental|Integrated robotic surgery|
32821433|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
32821434|NCT05167812||Prospective cohort of couples with RPL|
32821435|NCT05167812||Retrospective cohort op couples with RPL|
32821436|NCT04390620||MUCODA|DAFILON - sterile, monofilament, non-absorbable surgical suture material produced from Polyamide
32821437|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)|Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
32821438|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (SAD)|Participants will receive andecaliximab 1.0 mg/kg on Day 1.
32821439|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (SAD)|Participants will receive andecaliximab 2.5 mg/kg on Day 1.
32821440|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (SAD)|Participants will receive andecaliximab 5.0 mg/kg on Day 1.
32821441|NCT01831427|Placebo Comparator|Placebo Pooled (SAD)|Participants will receive placebo on Day 1.
32821442|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)|Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
32821443|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (MAD)|Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
32821444|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (MAD)|Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
32821445|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (MAD)|Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
32821446|NCT01831427|Experimental|Andecaliximab 150 mg SC (Adaptive MAD)|Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
32821447|NCT01831427|Placebo Comparator|Placebo Pooled (MAD)|Participants will receive placebo on Days 1, 15, and 29.
32821448|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
32821449|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
32821450|NCT05167422|Experimental|Trusted Messenger|"The trusted messenger patient intervention will involve training a small number of staff trusted messengers to engage patients informally and assist with building vaccine confidence in brief one- on-one sessions, supported by trusted messengers weekly consultations with a content expert who can answer specific vaccine related questions that patients have over a 3-week period. Trusted messengers will be full time unit employees, selected with the assistance of the nursing supervisor for having excellent rapport with patients (assessed with the Nurse Coordinator Questionnaire) and for having been vaccinated. Mental health workers or nurses may serve in this role. Both inpatient units involved in this study will be grouped into the same vaccination cohort within the hospital, to provide patients in the intervention and the wait list similar opportunities to be vaccinated."
32821451|NCT05167422|No Intervention|Standard Care|After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
32821452|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
32821453|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
32821454|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
32821455|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
32821456|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
32821457|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
32821458|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
32821459|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
32821460|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
32821461|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
32821462|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
32821463|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
32821464|NCT05215002|Experimental|Telephone call|Patient will receive a telephone call in the evening of the day of the surgery or one day after surgery
32821465|NCT05215002|Experimental|No telephone call|Patient will not receive a telephone call in the evening of the day of the surgery or one day after surgery
32821466|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
32821467|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
32821468|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
32821469|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
32821470|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
32821471|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
32821472|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
32821473|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
32821474|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
32821475|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
32821476|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
32821477|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
32821478|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
32821479|NCT03404310|Experimental|Treatment|Zinc Sulfate 220mg twice daily for three months.
32821480|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
32821481|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
32821482|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
32821483|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
32821484|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
32821485|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
32821486|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
32821487|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
32821488|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
32821489|NCT04589897|Experimental|Experimental|Manuka honey sinus rinse
33317777|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
32821490|NCT04589897|Active Comparator|Standard|Standard sinus rinse
32821491|NCT04290000||hematological malignancies|hematological malignancies treated with CAR-T Cells
32821492|NCT04447560|Experimental|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
32821493|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
32821494|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
32821495|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
32821496|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
32821497|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
32821498|NCT01427296|Active Comparator|OsmoPrep Tablets|
32821499|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
32821500|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
32821501|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
32821502|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
32821503|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
32821504|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
32821505|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
32821506|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
32821507|NCT05166642|Active Comparator|Bandgrip Micro-Anchor Skin Closure|
32821508|NCT05166642|Active Comparator|Standard of Care wound closure|Standard Monocryl suture closure
32821509|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
32821510|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
32821511|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
32955922|NCT05765890||Hepatologists|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
33317778|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
33317779|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
32821512|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821513|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821514|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821515|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821516|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821517|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
32821518|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
32821519|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821520|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
32821521|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
32821522|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
32821523|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
32821524|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
33317780|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
33317781|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
33317782|NCT04153682|Active Comparator|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
33317783|NCT04153682|Experimental|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
33317784|NCT04855370|Experimental|Patients diagnosed with Pulmonary Embolism|Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
33317785|NCT01199120|Experimental|Omega 3|
33317786|NCT00050622|Placebo Comparator|No Treatment|No Medication, No Behavior Modification (BMOD)
33317787|NCT00050622|Active Comparator|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
33317788|NCT00050622|Active Comparator|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
33317789|NCT00050622|Active Comparator|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
33317790|NCT00050622|Active Comparator|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
33317791|NCT00050622|Active Comparator|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
32821525|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821526|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
32821527|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
32821528|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
32821529|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
32821530|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.~After surgery gabapentin 2 times per day for 3 days."
32821531|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.~After surgery placebo 2 times per day for 3 days."
32821532|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
32821533|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
32821534|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
32821535|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
32821536|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
32821537|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
32821538|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
32821539|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
32821540|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
32821541|NCT04447092|Experimental|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
32821542|NCT04447092|Experimental|FOLFIRINOX|FOLFIRINOX + pembrolizumab
32821543|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
32821544|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
32821545|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
32821546|NCT04589741|Experimental|toripalimab combined with CAV / IE regimen|toripalimab combined with CAV / IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
32821547|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
33317792|NCT00050622|Active Comparator|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
32821548|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
32821549|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
32821550|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
32821551|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
32821552|NCT01334086|Experimental|Aprepitant|
32821553|NCT03399474|Active Comparator|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
32821554|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
32821555|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
32821556|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
32821557|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
32821558|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
32821559|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
32821560|NCT05166408|Other|Buccinator myomucosal flap for primary cleft repair|Study group
32821561|NCT05166408|Other|Bardach two flap palatoplasty for primary cleft repair|Control group
32821562|NCT05097768|Active Comparator|Dexamethasone|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive Dexamethasone 0.5 mg.
32821563|NCT05097768|Active Comparator|Ketorolac|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ketorolac 10 mg.
32821564|NCT05097768|Active Comparator|Meloxicam|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive meloxicam 7.5 mg.
32821565|NCT05097768|Active Comparator|Ibuprofen|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ibuprofen 600 mg.
32821566|NCT05097768|Placebo Comparator|Placebo|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive placebo.
32821567|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
32821568|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
32821569|NCT03393312|Experimental|Bifrontal tDCS|"20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).~The stimulation will be applied before or during task performance, depending on the condition assignment."
32821570|NCT03393312|Sham Comparator|Sham tDCS|"Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.~The stimulation will be applied before or during task performance, depending on the condition assignment."
32821571|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
32821572|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
32821573|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
32821574|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
32821575|NCT03395496|Experimental|Biodentine|Dental materials
32821576|NCT03395496|Experimental|ProRoot MTA|Dental Materials
32821577|NCT04592549|Experimental|Cohort 1: 150 mg IM injection of active drug or placebo|"Subjects in cohort 1 will receive a 150 mg dose IM injection of either active drug or placebo.~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
32821578|NCT04592549|Experimental|Cohort 2: 300 mg IM injection of active drug or placebo|"Subjects in cohort 2 will receive 300 mg IM injection of either active drug or placebo.~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo."
32821579|NCT04592549|Experimental|Cohort 3: 300 mg IM injection of active drug or placebo|"Subjects in cohort 3 will receive 300 mg IM injection of either active drug or placebo.~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
32821580|NCT04592549|Experimental|Cohort 4: 300 mg IM injection of active drug or placebo|"Subjects in cohort 4 will receive 300 mg IM injection of either active drug or placebo.~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
32821581|NCT04592549|Experimental|Cohort 5: 600 mg IM injection of active drug or placebo|"Subjects in cohort 5 will receive 600 mg IM injection of either active drug or placebo.~Cohort 5 will dose 8 subjects to active drug and 2 subject to placebo"
32821582|NCT05040282|Other|Etonogestrel 68 mg implant|Women will be subjected to etonogestrel 68 mg implant insertion (Implanon NXT; Organon, USA Inc) according to manufacture instructions. The insertion will be within the first 5 days of the menstrual cycle
32821583|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
32821584|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
32821585|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
32821586|NCT04982172|Experimental|Interventional arm|Model-informed precision dosing of infliximab (intravenously administered) using a Bayesian forecasting software tool. Doses and dosing intervals will be derived from the software tool, aiming to maintain adequate exposure (trough concentration target 5 mg/L).
32821587|NCT04982172|Active Comparator|Historical control arm|The treating physician adjusted the intravenously administered infliximab doses and dosing intervals without being guided by a model-informed precision dosing software tool. The primary objective was to extend the dosing interval. Therefore, dose de-escalation (interval extension with/without dose adjustment) were performed following a scheme at the treating physician's discretion.
32821588|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
32821589|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
32821590|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
32821591|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
32821592|NCT04944186|Active Comparator|Intervention Group|Patients in the experimental group will receive structured pressure injury patient education. It is consists of 2 sessions followed by biweekly follow-up for 8-week. The first session lasts for two days; the duration is 80 minutes (40 minutes /day for two days). Method of delivery is face to face, one to one with the aid of PowerPoint presentation and booklet. In the second session, the duration remains the same (80 minutes; 40 minutes/day for 2 days). The method of delivery also the same but teaching aid video presentation will be used. Three videos with a duration of approximately 2 - 3 minutes. In the second session, participants will be given a task to perform and document in the booklet given to monitoring its adherence. Upon completion of the two sessions, the patient will be follow-up biweekly and monitored their progress.
32821593|NCT04944186|Other|Control group|Patients in this group shall continue with the standard patient education in the ward. Standard patient education routinely delivers through an informal verbal method after wound dressing is done.
32821594|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
32821595|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
32821596|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
32821597|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
32821598|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
32821599|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
32821600|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
32821601|NCT03395262|Placebo Comparator|Placebo|Dextrose
32821602|NCT03852888|Experimental|mtugroup|All patients managed for rheumatoid arthritis (according to the ACR / EULAR 2010 criteria) in the Rheumatology Department of the University Hospital of Reims and treated with methotrexate monotherapy.
32955923|NCT05765890||Metabolically-Focused HCPs|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
32821604|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
32821605|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
32821606|NCT04770012|Placebo Comparator|placebo|
32821607|NCT04770012|Active Comparator|clopidogrel|
32821608|NCT04770012|Active Comparator|aspirin|
32821609|NCT04755972|Active Comparator|N-acetylcysteine|Inhalation of 5 ml-s of N-acetylcysteine every 12 hours.
32821610|NCT04755972|Active Comparator|Hypertonic saline|Inhalation of 5 ml-s of 5% sodium chloride every 12 hours.
32821611|NCT04755972|Active Comparator|Bicarbonate|Inhalation of 5 ml-s 8.4% sodium bicarbonate every 12 hours.
32821612|NCT04755972|No Intervention|Control group|No preventive inhalation.
32821613|NCT01828073||Cohort 1: Full term infants exposed in utero to maternal RAL|Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
32821614|NCT01828073||Cohort 2: LBW infants exposed in utero to maternal RAL|Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
32821615|NCT04697693|Experimental|Treatment with escitalopram or duloxetine|Participant will be begun on either escitalopram 10mg or duloxetine 30mg. The default medication will be escitalopram. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the Hamilton Rating Score for Depression (HRSD) >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study. Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg of duloxetine for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study
32821616|NCT03819114|Experimental|A: LNG 1.5 mg among participants on EFV-based ART (randomized)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
32821617|NCT03819114|Experimental|B: LNG 3.0 mg among participants on EFV-based ART (randomized)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
32821618|NCT03819114|Experimental|C: LNG 1.5 mg among participants on DTG-based ART (assigned)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
32821619|NCT03819114|Experimental|D: LNG 3.0 mg among participants on RIF-INH TB Therapy (assigned)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
32821620|NCT01827839|Experimental|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
32821621|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
32821622|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
32821623|NCT05239416|Experimental|Fat grafting combined with compression therapy|"Fat grafting + compression bandages/stockings~Fat grafting:~For the purposes of this study, the standard technique will be used for all patients~General or local anaesthesia.~Performed under the supervision of a plastic surgeon.~Harvest site will be either abdomen or lower limb.~After harvesting fat by liposuction, the lipoaspirate (which contains the ASCs) will be injected at the base of the healed venous ulcer within the same aseptic operative setting.~Compression therapy:~compression bandages / stockings as per routine practice"
32821624|NCT05239416|No Intervention|Compression therapy only|"Compression therapy:~compression bandages / stockings as per routine practice"
32821625|NCT04722120|Active Comparator|Conventional liver CT|Underwent conventional liver CT on HCC high-risk patient
32821626|NCT04722120|Experimental|Double low dose CT|Underwent double low dose liver CT with 30% lower radiation dose and 20% contrast media on HCC high-risk patient
32821627|NCT04709250|Active Comparator|group A: receive ultrasound-guided interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine consistent with the overall local anaesthetic dosing of less than 2.5 mg/kg. will be injected with low pressures to avoid intraneural injection.
32821628|NCT04709250|Active Comparator|group B: receive ultrasound-guided selective nerve block|The patient will be put in the sitting position, a linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to obtain a view of the suprascapular nerve a 22 G, 8 cm needle will be advanced in-plane and a total of 5-8 mL of 0.25% bupivacaine is injected then the arm adducted the linear probe will be placed at the junction of the pectoralis major muscle and the biceps muscle such that the axillary artery will be visualized in cross-section The probe will be moved towards the biceps muscle (laterally) until the musculocutaneous nerve is visualized and8 ml of 0.25% bupivacaine will be injected
32821629|NCT05107050|Active Comparator|Normal saline wash and an amorphous gel (NSS-HG)|Normal Saline Wash and Amorphous Gel
32821630|NCT05107050|Experimental|synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG)|"Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel."
32821631|NCT01827371|Experimental|Arm C|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
32821632|NCT01827371|Experimental|Arm B|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
32821633|NCT01827371|Experimental|Arm A|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
32821634|NCT01827371|Experimental|Arm D|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
32821635|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
32821636|NCT03399006||Normal pregnancy|women with normal blood presure
32821637|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
32821638|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
32821639|NCT05056116|Experimental|Biliary Tract Cancer|Surufatinib 250mg/Toripalimab 240mg
32821640|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
32821641|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
32821642|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
32821643|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - Not applicable for this cohort."
32821644|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
32821645|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
32821646|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
32821647|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
32821648|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
32821649|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
32821650|NCT05238402||on statins|patients who received a statin
32821651|NCT05238402||not on statins|patients who not received a statin
32821652|NCT03395106|Experimental|Parent source + intuitive story content|
32821653|NCT03395106|Experimental|Doctor source + intuitive story content|
32821654|NCT03395106|Experimental|Parent source + deliberative content|
32821655|NCT03395106|Experimental|Doctor source + deliberative content|
32821656|NCT03394950|Experimental|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
32821657|NCT03394950|Active Comparator|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
32821658|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
32821659|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
32821660|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
32821661|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
32821662|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
32821663|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
32821664|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.~Surface EMG, Q angle measurement were administered to the control group."
32821665|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
32821666|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
32821667|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
32821668|NCT04617444|Experimental|Intervention group|
32821669|NCT04617444|Active Comparator|Control group|
32821670|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
32821671|NCT04586634|Active Comparator|Peristeen|Subjects to use newly developed Peristeen cone catherter device
32821672|NCT04586634|No Intervention|Standard of care|subjects continue with their standard of care treatment
32821673|NCT04567992|Experimental|SCPB|
32821674|NCT04567992|Placebo Comparator|Control|
32821675|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
32821676|NCT01335724|Placebo Comparator|placebo gel|
32821677|NCT01476202|Experimental|Nicotine mouth strip|single dose
32821678|NCT01476202|Active Comparator|nicotine lozenge|single dose
32821679|NCT01476202|Active Comparator|nicotine gum|single dose
32821680|NCT01539694|Experimental|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
32821681|NCT01539694|Active Comparator|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
32821682|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
32821683|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
32821684|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
32821685|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
32821686|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
32821687|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
32821688|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
32821689|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
32821690|NCT01478854|Experimental|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
32821691|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
32821692|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
32821693|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
32821694|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
32821695|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
32821696|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
32821697|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
32821698|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
32821699|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
32821700|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
32821701|NCT01439854|Placebo Comparator|Placebo|this arm is control
32821702|NCT01439854|Experimental|Dapagliflozin|Interventional arm
32821703|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
32821704|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
32821705|NCT04409262|Experimental|Remdesivir + Tocilizumab (RDV+TCZ)|Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
32821706|NCT04409262|Active Comparator|Remdesivir + Placebo (RDV+Placebo)|Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
32821707|NCT01481740|Experimental|Phenylephrine bolus|
33317793|NCT00050622|Active Comparator|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
33317794|NCT00050622|Active Comparator|High Intensity BMOD Only|Placebo, High Intensity BMOD
33317795|NCT00050622|Active Comparator|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
33317796|NCT00050622|Active Comparator|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
33317797|NCT00050622|Active Comparator|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
33317798|NCT00308087|Active Comparator|Rituximab|
33317799|NCT00308087|Experimental|Rituximab + Sargramostim|
33317800|NCT04942184|Experimental|Group 1- 15 Mild AD and 15 MCI due to AD|In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.
33317801|NCT04942184|Active Comparator|Group 2- 15 Mild AD and 15 MCI due to AD|"In Group 2, for the first 2 weeks participants will be reminded to try hard to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4."
33317802|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
33317803|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
33317804|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
33317805|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
33317806|NCT00307931|Experimental|Certolizumab pegol|certolizumab pegol 400 mg
33317807|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
33317808|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
33317809|NCT01097226|Experimental|Apple flavanols|
32821708|NCT01481740|Experimental|Phenylephrine infusion|
32821709|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
32821710|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
32821711|NCT04331964|Active Comparator|Mineral Trioxide Aggregate (MTA)|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The exposed pulp tissues will be directly capped with a 3mm of MTA (Pro Root MTA) layer.
32821712|NCT04331964|Experimental|MTA with platelet rich fibrin (PRF).|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The PRF membrane obtained after centrifugation of the patient's own blood is going to be placed over the exposed pulp. Then, a 3mm of MTA (Pro Root MTA) will be placed over the PRF membrane.
32821713|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
32821714|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
32821715|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
32821716|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
32821717|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
32821718|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
33317810|NCT05670080|Experimental|The Motor Imagery (MI) Group|"MI training will be prepared using the Microsoft PowerPoint program which includes written, visual and audio materials, as well as features that can be sent to participants ' phones/tablets/computers. The MI training will allow the participant to perform visual and kinesthetic imagery with visual and audible notifications and will include 6 exercises for the muscles around the shoulder, 3 exercises for strengthening, and dynamic stabilization for the muscles around the scapula. In each presentation, verbal cues will be given to explain how to imagine the movement while a visual of the motor movement is displayed on the screen. During MI exercises, participants will be called once a week and their MI practices will be followed up.~After the first four weeks of MI training, the MI group will also participate in a four-week physical therapy program."
33317811|NCT05670080|Experimental|Physical Therapy (PT) Group|"Following the preoperative evaluations, both groups will be shown remedial exercises (pumping exercises that activate the circulation), flexion, and extension wrist exercises, which they should do for four weeks.~After a 4-week immobilization period, participants in the PT Group will begin a physical therapy program that includes routine electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder."
33317812|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
33317813|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
33317814|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
33317815|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
32821719|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
32821720|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
32821721|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
32821722|NCT01483378|No Intervention|Subjects who declined the vaccine|
32821723|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
32821724|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
32821725|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
32821726|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
32821727|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
32821728|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
32821729|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
32821730|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
32821731|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
32821732|NCT04305912|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to verofilcon A daily disposable lenses for one week.
32821733|NCT04305912|Active Comparator|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
32821734|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
32821735|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
32821736|NCT04303260|Active Comparator|Interventional arm|"Patients in the interventional arm will be asked to complete 3 different videos repeatedly, as many days a week as possible. This repetition is to be maintained even if a patient missed one day of training.~The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation."
32821737|NCT04303260|Placebo Comparator|controled arm|"Patients in the controled arm will also be asked to practice generally recommended exercises in 3 different videos repeatedly, as many sets as possible..~The control arm will practice generally recommended exercises, without particular attention to the abdomen."
32821738|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
32821739|NCT03391830|Placebo Comparator|Placebo|Placebo
32821740|NCT04139616||No ECG changes in patients without pre-existing RBBB|Patients with no new conduction disturbances on the ECG performed immediately post-TAVR (and no episodes of HAVB/CHB during the procedure) have a very low risk of developing HAVB/CHB or any conduction disturbance within the hours-days following the procedure. In these cases, temporary pacing will be discontinued at the end of the procedure. However, continuous ECG monitoring until hospital discharge is recommended. A 12-lead ECG is recommended 24 hours after the procedure. If no arrhythmic episodes and no ECG changes occur within the 24 hours post-procedure, the patient can be safely discharged (the day after TAVR) with no other monitoring measures in case of otherwise uneventful clinical course (absence of other TAVR related adverse events). If the patient has to remain hospitalized because of other reasons or TAVR complications, telemetry would be recommended (but no strictly required) for the detection of post-TAVR tachyarrhythmias or late ECG changes.
32830681|NCT04045470|Experimental|Initial Cohort|"Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
32955924|NCT05765877|Experimental|WX-0593|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 2 years. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
33317816|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
32821741|NCT04139616||Patients with pre-existing RBBB|A temporary pacing wire is recommended to be maintained for 24 hours (or at least overnight) in all patients with prior RBBB, along with telemetry and daily ECG during the entire hospitalization period (minimum of 2 days). If any ECG changes occur during the initial 2-3 days, patients can be managed according to the proposed strategy (see management strategies for groups 3 and 5). If no ECG changes or significant bradyarrythmias occur within the 2-3 days following the procedure, the patient can be discharged. Considering that the increased risk of life threatening bradyarrhythmias in these patients may extend beyond the hospitalization period, the use of continuous ECG monitoring systems (minimum of 48 hours, up to 4 weeks) may be considered.
32821742|NCT04139616||ECG changes in patients with prior conduction disturbances|"Any significant increase in PR or QRS interval will indicate to continuing the temporary pacing for 24 hrs, with daily ECG and telemetry for 1-2 days. If the ECG changes regress in <24 hrs, an earlier removal of the temporary pacing may be considered. Also, a strategy of multiple ECGs during the first 24 hrs may be considered. If ECG changes regress or no further changes occur the patient can be discharged with no PPM at 2 days post-TAVR.~If 24 hrs post-TAVR, the PR and QRS interval remain stable but >240 or >150 ms, respectively, and ≥20 ms longer than baseline, maintaining the temporary pacing wire for another 24 hrs is recommended. If no decrease in the PR or QRS duration occurs at day 2, the patient can be considered at risk for more advanced conduction disturbances requiring PPM. The use of an EP study may be a reasonable option for deciding PPM in those patients with prior conduction disturbances with worsening of ECG changes post-TAVR"
32821743|NCT04139616||New-onset LBBB|"Temporary pacing for 24 hrs is recommended, in all patients with new-onset LBBB post-TAVR. Earlier removal of the temporary pacing and discharged at day 1 can be considered if LBBB resolves in <24 hrs.~If LBBB persists but no further progression of the duration of the QRS or PR interval is observed at day 1, temporary pacing can be discontinued. If no further ECG changes are observed up to day 2-3 post-TAVR, the patient can be discharged. These patients are however at increased risk of HAVB/CHB requiring PPM, and continuous ECG monitoring and/or EP studies may be considered.~If further prolongation of the QRS or PR interval is observed at day 1, the temporary pacing is recommended for an additional 24 hrs. If the prolongation of the QRS or PR intervals continues at day 2, evaluation with EP studies or PPM implantation may be considered.~The occurrence of any episode of HAVB/CHB following TAVR in a patient with new-onset LBBB will be considered an indication for PPM"
32821744|NCT04139616||HAVB/CHB during the periprocedural period|"Maintaining temporary pacing in patients with procedural persistent HAVB/CHB, and monitoring in intensive care unit are recommended. If HAVB/CHB persists at 24 hrs, PPM is recommended. If HAVB/CHB recovers the day after TAVR, the temporary pacing can be removed and the patient can remain hospitalized for 1 day. If another episode of HAVB/CHB occurs, PPM is recommended. If no other episode of HAVB/CHB occurs, and no other features potentially justifying PPM exist the patient can be discharged.~Temporary pacing is recommended for 24 hrs in patients with transient HAVB during the procedure, with telemetry and daily ECG for 2 days. Discontinuing temporary pacing may be considered in those cases with brief episodes of HAVB/CHB and normal ECG. If no recurrent episodes of HAVB/CHB occur, and the patient has no other potential indications for PPM the patient can be discharged at day 2. PPM would be indicated if any recurrent episode of HAVB/CHB occurs during the hospitalization period."
32821745|NCT04033770|Active Comparator|Air-charged measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS but using an air-charged instead of a water-filled measurement system."
32821746|NCT04033770|Active Comparator|Water-perfused measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS."
32821747|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
32821748|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
32821749|NCT01441570|Active Comparator|Nebivolol|
32821750|NCT01441570|Active Comparator|Metoprolol Succinate|
32821751|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
32821752|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
32821753|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
32821754|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
32821755|NCT05238012|Experimental|Xuezhikang Capsule|Experimental drug: Xuezhikang Capsule, specification: 300mg / capsule.
32821756|NCT05238012|Active Comparator|Atorvastatin Calcium Tablets|Control drug: Atorvastatin Calcium Tablets, specification: 20mg / tablet.
32821757|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32821758|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
32821759|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
32821760|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
32821761|NCT04446936||Random flaps|Patients who undergone random flap surgery
32821762|NCT03394638|Active Comparator|Conventional group|"Treatment includes:~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.~Additional visits if necessary~No further access to the BePATIENT website"
32821763|NCT03394638|Experimental|Online group|"Treatment includes:~Added to conventional group: Continuation of access to the BePATIENT website with:~eLearning programs~Informative videos~Patient network~Video consulting"
32821764|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are~Weight Scale~Blood Pressure~Oximeter~Activity Tracker"
33101863|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
32821765|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
32821766|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
32821767|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
32821768|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
32821769|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
32821770|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
32821771|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
32821772|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
32821773|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
32821774|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
32821775|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
32821776|NCT05237778|Experimental|TMR group|Patients will receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound during REM sleep.
32821777|NCT05237778|Active Comparator|Control group|Patients will not receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will receive the same sound as the experimental group during REM sleep under the same conditions.
32821778|NCT05237700||Trendelenburg with lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg with lithotomy positioning on the operating table.
32821779|NCT05237700||Trendelenburg without lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg without lithotomy positioning on the operating table.
32821780|NCT05237544||leftover dried blood spot material|All samples used will be leftover dried blood spot material from the Newborn Screening Lab at Great Ormond Street Hospital.
32821781|NCT05237544||anonymous known SMA positive blood spots|The anonymous known SMA positive blood spots will be provided by an external company (Biogen),
32821782|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
32821783|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
32821784|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
32821785|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
32821786|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
32821787|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
32821788|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
32821789|NCT02520336|No Intervention|Routine care|
32821790|NCT04006002||Endoscopic Sleeve Gastrectomy|This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
32821791|NCT04006002||Laproscopic Sleeve Gastrectomy|This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss
32821792|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
32821793|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
32821794|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
32821795|NCT04446546||Cold Stored Allograft Vascular Access|
32821796|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
32821797|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
32821798|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
32821799|NCT03398772|No Intervention|Control|Guideline-based usual care
32821800|NCT04446624|No Intervention|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
32821801|NCT04446624|Experimental|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
32821802|NCT01443442|Active Comparator|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
32821803|NCT01443442|Active Comparator|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
32821804|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
32821805|NCT03389646|No Intervention|Control|Control without CERAMENT device
32821806|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
32821807|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
32821808|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
32900937|NCT05297604|Placebo Comparator|Placebo group|Participants will be treated in the same way as the active group. The person in charge of the ILIB application will simulate the irradiation with the equipment kept off, so that the participant does not identify the group to which he belongs, and the device activation sound (beep) will be turned on at the time of application. They will receive 2 sessions per week for 12 consecutive weeks.
32821809|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
32821810|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
32821811|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
32821812|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
32821813|NCT03994146|Experimental|Remifentanil tapering / Placebo abrupt cessation|Syringe one contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1 and Syringe two contains 40 ml NaCl 9 mg.ml-1 at an identical infusion rate. According to randomisation syringe one will then be tapered towards the end of surgery and syringe two abruptly stopped.
32821814|NCT03994146|Placebo Comparator|Placebo tapering / Remifentanil abrupt cessation.|Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
32821815|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
32821816|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
32821817|NCT03391752||Royal Alexandria|Administrative records
32821818|NCT03391752||Pasqua Regional hospital|Administrative records
32821819|NCT03391752||Concordia Hospital|Administrative records
32821820|NCT03391752||Niagara General Hospital|Administrative records
32821821|NCT03391752||Hospital 6|Administrative Records
32821822|NCT03391752||Hospital 7|Administrative Records
32821823|NCT03391752||Hospital 8|Administrative Records
32821824|NCT03391752||Hospital 9|Administrative Records
32821825|NCT03391752||Hospital 10|Administrative records
32821826|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
32821827|NCT03391674|No Intervention|Observational|Observational
32821828|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
32821829|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
32821830|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
32821831|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
32821832|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
32821833|NCT02797314|Other|Non-diabetic control population|Bone biopsies
32821834|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
32821835|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
32821836|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32821837|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
32821838|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
32821839|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
32821840|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
32821841|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
32821842|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
32821843|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
32821844|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
32821845|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
32821846|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
32821847|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
32821848|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
32821849|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
32821850|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
32821851|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
32821852|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
32821853|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
32821854|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
32821855|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
32821856|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
32821857|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
32821858|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
32821859|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
32821860|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
32821861|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
32821862|NCT03398226||Control group|
32821863|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
32821864|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
32821865|NCT01490788|Experimental|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
32821866|NCT01490788|Experimental|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
32821867|NCT01490788|Active Comparator|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
32900938|NCT05297604|No Intervention|Control group|Composed of individuals who will not receive any type of intervention.
32900939|NCT05484492|Experimental|demineralized and mineralized combination putty bone allograft|Fifteen test patients will receive an intrasocket demineralized and mineralized combination putty allograft (MinerOss Putty, BioHorizons) with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
32821868|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
32821869|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
32821870|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
32821871|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
32821872|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:~Delivery of a positive rule-in diagnosis of functional neurological disorder~Individuals are provided with educational materials on functional neurological disorders~Referred to physical therapy and/or occupational therapy as clinically indicated~FND related cognitive behavioral therapy (CBT) referral when appropriate~Psychotropic medication management based on standard psychiatric care"
32821873|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
32821874|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
32821875|NCT02559726|Other|healthy volunteers|20 healthy volunteers
32821876|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
32821877|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
32821878|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
32821879|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
32821880|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
32821881|NCT03391050|Experimental|APR-246 + Dabrafenib|
32821882|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
32821883|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
32821884|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
32821885|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
32821886|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
32821887|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
32821888|NCT01254474|Experimental|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
32821889|NCT04929600|Experimental|Experimental|One pill of sacubitril/valsartan (200mg tablet) + one pill of matching placebo of amlodipine daily. If possible, dosage titration should be conducted.
32821890|NCT04929600|Active Comparator|Comparator|One pill of amlodipine (5mg tablet) + one pill of matching placebo of sacubitril/valsartan daily. If possible, dosage titration should be conducted.
32821891|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
32821892|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
32821893|NCT00782184|Experimental|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
32821894|NCT00782184|Active Comparator|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
32821895|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
32821896|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity"
32821897|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
32821898|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
32821899|NCT03397914|Experimental|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
32821900|NCT03397914|Experimental|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
32821901|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
32821902|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
32821903|NCT04924140|Experimental|Aducanumab Intravenous|Participants will receive aducanumab as body weight-based dose, via IV infusion for approximately 1 hour on Day 1.
32821904|NCT04924140|Experimental|Aducanumab Subcutaneous|Participants will receive aducanumab as fixed dose, via SC injection on Day 1.
32821905|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
32821906|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
32821907|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
32821908|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
32821909|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
32821910|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
32821911|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
32821912|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
32821913|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
32821914|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
32821915|NCT03390582||healthy controls|healthy controls are all from normal volunteers
32821916|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
32821917|NCT03390582||treated GD|GD patients treated by Methimazole Pill
32821918|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
32821919|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
32821920|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
32821921|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
32821922|NCT03938298|Experimental|Intervention group|
32821923|NCT03938298|Active Comparator|Control group|
32821924|NCT01913574|Experimental|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
32821925|NCT01913574|Active Comparator|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
32821926|NCT03125850|Experimental|day-ward group|
32821927|NCT03125850|Active Comparator|inpatient group|
32821928|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Monthly Dilution Schedule Dilution of mite extract~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
32821929|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Intervention: Placebo - Immunotherapy allergen diluent"
32821930|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
32821931|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
32821932|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
32821933|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
32821934|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
32821935|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
32821936|NCT01856868|Experimental|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
32821937|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
32821938|NCT03125694|Active Comparator|Sitagliptin|
32821939|NCT03125694|Active Comparator|Pioglitazone|
32821940|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
32821941|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
32821942|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
32821943|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
32821944|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
32821945|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
32821946|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
32821947|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
32821948|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
32821949|NCT01491490|Placebo Comparator|Placebo|
32821950|NCT03816852|Experimental|High dose group|Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml
32821951|NCT03816852|Experimental|Medium dose group|Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml
32821952|NCT03816852|Experimental|Low dose group|Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml
32821953|NCT03008200||RDS +|postpartum RDS developed group
32821954|NCT03008200||RDS -|postpartum RDS undeveloped group
32821955|NCT03812016|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device. Test the device one time ( duration: 30-120 mins/each time) and 3 times within 3 months.~Intervention: using the magnetic device"
32821956|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
32821957|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
32821958|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
32821959|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
32821960|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821961|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821962|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821963|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821964|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821965|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
32821966|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
32821967|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
32821968|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
32821969|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
32821970|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
32821971|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
32821972|NCT01495858|Active Comparator|DPH 50 mg|
32821973|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
33101864|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
32821974|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
32821975|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
32821976|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
32821977|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
32821978|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
32821979|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
32821980|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
32821981|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
32821982|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
32821983|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
32821984|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
32821985|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 2)|
32821986|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 3)|
32821987|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 2)|
32821988|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 3)|
32821989|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
32821990|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
32821991|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
32821992|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
32821993|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
32821994|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
32821995|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
32821996|NCT01557322||Biologic|
32821997|NCT01557322||non-biologic DMARD|
32821998|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
32821999|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
32822000|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
32822001|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
32822002|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
32822003|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
32822004|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
32822005|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
32822006|NCT01504672|Experimental|Medication review|
32822007|NCT01504672|No Intervention|Usual care|
32822008|NCT01557790|Experimental|Proton RT|Subjects receive proton radiation for seminoma
32822009|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
32822010|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
32822011|NCT01559506|No Intervention|No device|Subject does not receive ABS system
32822012|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
32822013|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
32822014|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
32822015|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
32822016|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
33317817|NCT03955380|Active Comparator|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
32822017|NCT02209948|No Intervention|Without treatment|
32822018|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
32822019|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
32822020|NCT01560286|Experimental|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
32822021|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
32822022|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
32822023|NCT01464190|Experimental|PA21|
32822024|NCT01464190|Active Comparator|Sevelamer carbonate|
32822025|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
32822026|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
32822027|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
32822028|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
32822029|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
32822030|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
32822031|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
32822032|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
32822033|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
32822034|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
32822035|NCT01468012|Placebo Comparator|Placebo|placebo
32822036|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
32822037|NCT03730662|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
32822038|NCT03730662|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
32822039|NCT03730662|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
32822040|NCT03730662|Active Comparator|Insulin Glargine|"Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.~The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG <100 mg/dL, following a treat-to-target (TTT) algorithm."
32822041|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
32822042|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
32822043|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
32822044|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
32822045|NCT01509586|No Intervention|cigarette group|
32822046|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
33405157|NCT04504422|Experimental|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
32822047|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
32822048|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
32822049|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
32822050|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
32822051|NCT01564654||iTotal KRS|
32822052|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
32822053|NCT03390036|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
32822054|NCT03390036|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
32822055|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
32822056|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
32822057|NCT03389880|Active Comparator|Patellar denervation|
32822058|NCT03389880|Experimental|Non-patellar denervation|
32822059|NCT04446234|Experimental|Risperidone|Risperidone tablet
32822060|NCT04446234|Experimental|Aripiprazole|Aripiprazole tablet
32822061|NCT04446234|Experimental|Ziprasidone|Ziprasidone tablet
32822062|NCT04446234|Experimental|Amisulpride|Amisulpride tablet
33405158|NCT04504422|Experimental|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
33405159|NCT04504422|Sham Comparator|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
32822063|NCT04446234|Experimental|Quetiapine|Quetiapine tablet
32822064|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
32822065|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
32822066|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
32822067|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
32822068|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
32822069|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
32822070|NCT03388086||Onabotulinum 300 units|
32822071|NCT03388086||Onabotulinum 200 units|
32822072|NCT01511068|Experimental|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
32822073|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
32822074|NCT03612336|Experimental|Intervention group|
32822075|NCT03612336|Active Comparator|Control group|
32830682|NCT04045470|Experimental|Expansion Cohort|"Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)~Participants will receive standard of care therapy and clinical course followed~Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study~Participants will not be assigned any treatment intervention"
33405160|NCT05180214|Active Comparator|bupivacaine|
33405161|NCT05180214|Active Comparator|bupivacaine and ketorolac|
33405162|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
33405163|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-1 trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
33405164|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
32830683|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
32830684|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
32822076|NCT05174286|Experimental|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|"1a) SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~1b) We will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
32822077|NCT05174286|Active Comparator|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
32822078|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
32822079|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
32822080|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
32822081|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
32822082|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
32822083|NCT05565976|Experimental|Dapagliflozin|10mg PO q24h for 12 months plus standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
32822084|NCT05565976|Active Comparator|Standard treatment|Standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
32822085|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
32822086|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
32822087|NCT03185832||CRT-D Cohort|Number of participants with first appropriately treated ventricular arrhythmia
32822088|NCT03185832||ICD Cohort|Number of participants with first appropriately treated ventricular arrhythmia
33317818|NCT03955380|Active Comparator|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
33317819|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
32822089|NCT03185832||Pacing (PM / CRT-P) Cohort|All cause mortality
32822090|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
32822091|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
32822092|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
32822093|NCT05565664|Active Comparator|Ketamine group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg."
32822094|NCT05565664|Active Comparator|Magnesium group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV magnesium sulphate in a dose of 40 mg/kg."
32822095|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
32822096|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
33101865|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
33405165|NCT05177172|Placebo Comparator|Control|White wheat flour bread
32822097|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
32822098|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
32822099|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
32822100|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
32822101|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
32822102|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
32822103|NCT05565586|Experimental|High-Fiber Diet (HFD) Intervention|Participants are expected to eat only the study meals and snacks provided
32822104|NCT05565586|Experimental|Prebiotic Food-Enriched Diet (PreFED) Intervention|Participants are expected to incorporate study snacks and meal components provided into your usual diet.
32822105|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
32822106|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
32822107|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
32822108|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
32822109|NCT05565508|Experimental|new laparoscopic access technique|in which we used our new laparoscopic access
32822110|NCT05565508|Experimental|Hasson's technique|in which we used the well-known Hasson's technique for primary laparoscopic access
32822111|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
32822112|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
32822113|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
32822114|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
32822115|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
32822116|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
32822117|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
32822118|NCT05174208||CD|
32822119|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
32822120|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
32822121|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
32822122|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
32822123|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
32822124|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
32822125|NCT05565274|Experimental|Tramadol plus Paracetamol|2ml of 100mg of intramuscular tramadol plus 2ml of 600mg of intramuscular paracetamol unlabeled
32822126|NCT05565274|Active Comparator|Pentazocine plus placebo|2ml of 30mg of pentazocine plus 2 ml of water for injection will be administered intramuscularly during labour
32822127|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
32822128|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
32822129|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
32822130|NCT05173662|Experimental|Intervention Group|"To the mothers in this group; At least 12 hours before the heel blood collection (guthrie screening test), training was given, lasting 25 minutes, on average, through the training brochure on non-pharmacological pain management prepared by the researcher. The training was carried out in a language that the mother could understand, in the form of direct lectures and questions and answers, using the visuals in the brochure. In the training content; There are five non-pharmacological methods. These;~Expressed breast milk~Wrapping~Skin-to-skin contact~Cuddling~They are methods of making calming sounds."
32822131|NCT05173662|No Intervention|Control Group|In the control group, as in the clinical routine, the heel stick procedure was performed in the newborn's own bed next to his mother. No other action has been applied.
32822132|NCT05173584|Experimental|Levalbuterol Arm|
32822133|NCT05173584|Active Comparator|Albuterol Arm|
32830685|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~Fracture confirmed radiographically~No head trauma~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
33101866|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
33405166|NCT05177172|Experimental|High betaglucans|White wheat flour bread included beta glucans with the highest amounts in this study
33317820|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
33317821|NCT01199666|Experimental|Text message reminders|
33317822|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
32822134|NCT05173194|Experimental|Telematic Exercise|A remotely supervised resistance exercise program will be carried out for 8 weeks, with three weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness. The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises.
32822135|NCT05173194|No Intervention|Control|Control group will follow routine recommendations from the multidisciplinary CF team.
32822136|NCT03387306||Patient group|This grup included 38 patients with NTG.
32822137|NCT03387306||Control group|This group included 38 healthy controls.
32822138|NCT04671030|Experimental|Treatment group|Subjects are screened by criteria, intravenous and transdermal iontophoresis then undergo the study during which they will be administered the placebo alternating with real drug without being aware of which is being given.
32822139|NCT04671030|Placebo Comparator|Placebo group|Placebo will be given without the subject being aware of the time in advance.
32822140|NCT04660890|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants will receive all 3 doses of ALXN2050 in a multiple-ascending fashion over 3 periods:~Treatment A (Period 1): ALXN2050 Dose 120 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): ALXN2050 Dose 240 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): ALXN2050 Dose 360 mg and moxifloxacin-matching placebo."
32822141|NCT04660890|Placebo Comparator|Control Arm (DEF)|"Treatment Sequence DEF - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment D (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment E (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin.~Treatment F (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin-matching placebo."
32822142|NCT04660890|Placebo Comparator|Control Arm (GHI)|"Treatment Sequence GHI - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment G (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin.~Treatment H (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment I (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin."
32822143|NCT04632264|Experimental|Pre-placental group|"Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our intervention group. Saline placebo will be initiated post placenta delivery (within 15 seconds)."
32822144|NCT04632264|Other|Post-placental group|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).
32822145|NCT04607928|Placebo Comparator|Placebo|No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment
32822146|NCT04607928|Experimental|Treatment|Pirfenidone
32822147|NCT03610386|Active Comparator|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
32822148|NCT03610386|Experimental|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
32822149|NCT03384420|Experimental|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
32822150|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
32822151|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
32822152|NCT04569786|Experimental|V590 5.00x10^5 pfu (Panel A)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel A) will receive a single dose of V590 5.00x10^5 pfu or placebo on Day 1.
32822153|NCT04569786|Experimental|V590 2.40x10^6 pfu (Panel B)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel B) will receive a single dose of 2.40x10^6 pfu or placebo on Day 1.
32822154|NCT04569786|Experimental|V590 1.15x10^7 pfu (Panel C)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel C) will receive a single dose of 1.15x10^7 pfu or placebo on Day 1.
32822155|NCT04569786|Experimental|V590 5.55x10^7 pfu (Panel D)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel D) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
32822156|NCT04569786|Experimental|Part 2: 5.00x10^5 pfu (Panel E)|Participants in this ≥ 55 years old SARS CoV-2 seronegative cohort (Panel E) will receive a single dose of V590 5.00x10^5 pfu or placebo on Day 1.
32822157|NCT04569786|Experimental|Part 2: 2.40x10^6 pfu (Panel F)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel F) will receive a single dose of 2.40x10^6 pfu or placebo on Day 1.
32822158|NCT04569786|Experimental|Part 2: 1.15x10^7 pfu (Panel G)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel G) will receive a single dose of V590 1.15x10^7 pfu or placebo on Day 1
33317823|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
33317824|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
33317825|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
32822159|NCT04569786|Experimental|Part 2: 5.55x10^7 pfu (Panel H)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel H) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
32822160|NCT04569786|Experimental|Part 3: 5.55x10^7 pfu (Panel I)|Participants in this 18 to 54-year-old SARS-CoV-2 seropositive cohort (Panel I) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
32822161|NCT04485624||Attendees at Paediatric Emergency Department 1 (PED1)|"These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large district general hospital.~There was going to be a second group recruited but COVID meant that the site was not able to support non-COVID studies by the time the necessary approvals were in place."
32822162|NCT04447170||Laparoscopic repair|Patients undergoing laparoscopic treatment
32822163|NCT04447170||Open repair|Patients undergoing open treatment
32822164|NCT05172804|Experimental|Nursing students receiving progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement [11].
32822165|NCT05172804|Experimental|Nursing students receiving guided imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin [11].
32822166|NCT05172804|Experimental|Nursing student receiving mindfulness meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) [11]."
32822167|NCT05172804|Active Comparator|control Group|Participants in the control condition will be instructed to sit with their eyes closed during the intervention periods. Participants in the control group will follow an identical time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
32822168|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
32822169|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
32822170|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
32822171|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
32822172|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
32822173|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
32822174|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
32822175|NCT05172570|No Intervention|No Gabapentin|Patients will not receive any gabapentin postoperatively after open thoracotomy
32822176|NCT05172570|Active Comparator|300 mg Gabapentin 3X per day|Patients will receive 300mg gabapentin 3x a day after open thoracotomy
32822177|NCT05172570|Active Comparator|300 mg Gabapentin once per day at night|Patients will receive 300mg gabapentin once a day at night after open thoracotomy
32822178|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
32822179|NCT03380286||Coronary Stenosis|
32822180|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
32822181|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
32822182|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
32822183|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
32822184|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
32822185|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
32822186|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
32822187|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
32822188|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
33101867|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
32822189|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
32822190|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
32822191|NCT03384264|Experimental|TG|
32822192|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
32822193|NCT03384186|Experimental|Danicopan Modified Release Prototype Tablets|"Participants received danicopan once each period as a single oral dose as follows:~Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.~There was a washout period of at least 14 days between each danicopan dosing."
32822194|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
32822195|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
32822196|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise intervention"
32822197|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
32822198|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention~Intervention #2: no further intervention (rest)"
32822199|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
32822200|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
32822201|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
32822202|NCT03379896||Control|Age-matched healthy control
32822203|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
32822204|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
32822205|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
32822206|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
32822207|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
32822208|NCT03383796|Experimental|open approach|Open resection for pCCA
32822209|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
32830686|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~Non-penetrating head trauma manifesting one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Altered mental status~Focal neurologic deficits, seizure~GCS> 12~No abnormalities on CT other than contusion~No operative Lesions~Length of hospital stay < 48 hrs~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
32830687|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
32830688|NCT03285672|Experimental|Arm 1|FP-101
32822210|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
32822211|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
32822212|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A
32822213|NCT03386058|Experimental|Intervention|Temporary device deactivation
32822214|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
32822215|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Optimal Medical Treatment/OMT"
32822216|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
32822217|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
32822218|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
32822219|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
32822220|NCT04316754|No Intervention|Control group|No music will be played to the control group.
32822221|NCT04316754|Active Comparator|Intervention 1|During angiography, the Intervention-1 group will listen to the music that the child wants to listen.
32822222|NCT04316754|Active Comparator|Intervention-2|"The Intervention-2 group will listen to the music which determined by the researchers. The music which determined by the researchers is The art of fugue by Johann Sebastian Bach. The music to be played has been decided by examining the literature. (DOI: 10.4274/jpr.24892)"
32822223|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
32822224|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
32822225|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
32822226|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
32822227|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
32822228|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
32822229|NCT05172180||The control group|The control group consisted of 54 patients who received Ringer's solution at an average daily dose of 8.1 ml/kg/day as the main infusion solution from the time of transfer to the intensive care unit
32822230|NCT05172180||The test group|Fifty one patients in the test group received the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate) at an average daily dose of 8.3 ml/kg/day for the same purpose
32822231|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
32822232|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
32822233|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
32822234|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
32822235|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
32822236|NCT04446312|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
32822237|NCT04446312|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
32822238|NCT05564884||Unvaccinated, Prior natural COVID-19 infection|Unvaccinated, Prior natural COVID-19 infection
32822239|NCT05564884||Vaccinated, No prior natural COVID-19 infection|Vaccinated, No prior natural COVID-19 infection
32822240|NCT05564884||Vaccinated, Prior natural COVID-19 infection|Vaccinated, Prior natural COVID-19 infection
32822241|NCT04445922|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
32822242|NCT04445922|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
32822243|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
32822244|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
32822245|NCT01518868|Experimental|Investigational contact lens|multifocal high add soft contact lens
32822246|NCT01518868|Active Comparator|PureVision contact lens|Multi-focal contact lens
32822247|NCT04287348|Other|Beovu (Brolucizumab)|Prospective, one-treatment-arm, monocentre study
32822248|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
32822249|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
32822250|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
32822251|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
32822252|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
33317826|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
32822253|NCT05171790|Experimental|QL1706 injection|This clinical trail is a single arm study, all the patients that meet the entry criteria will receive treatment until disease progression occurs or meet other criteria for the discontinuation of treatment. QL1706 will be administered by intravenous infusion, 5 mg/kg, Q3W.
32822254|NCT04445376|Experimental|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
32822255|NCT04445376|Experimental|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
32822256|NCT01573702|Other|Stereotactic Radiosurgery Followed by Erlotinib|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
32822257|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
32822258|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
32822259|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
32822260|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
32822261|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
32822262|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
32822263|NCT03093246|Placebo Comparator|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
32822264|NCT03093246|Experimental|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
32822265|NCT03000426|Sham Comparator|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
32830689|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
33101868|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
33101869|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
32822266|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
32822267|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
32822268|NCT05171634|Experimental|Colonoscopy assisted by DiscoveryTM|
32822269|NCT05171634|Active Comparator|Virtual Colonoscopy with iSCAN|
32822270|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
33101870|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
32822271|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
32822272|NCT02969928|Active Comparator|Amoxicillin and Metronidazole|In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
32822273|NCT02969928|Experimental|Clarithromycin|In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
32822274|NCT05171556||RV4942A arm|RV4942A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
32822275|NCT02968446|Placebo Comparator|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
32822276|NCT02968446|Experimental|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
32822277|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
32822278|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
32822279|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
32822280|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
32822281|NCT03383250|Experimental|Meal ingestion|
32822282|NCT03378960|Other|omeprazole|omeprazole 20 mg
32822283|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.~Reading EEG."
33405167|NCT05177172|Experimental|Low beta glucans|White wheat flour bread included beta glucans with the lowest amounts in this study
33101871|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
33101872|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
33101873|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
33101874|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
33101875|NCT02924012|Other|walking|An walking lasting 40 minutes
32822284|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.~Reading EEG."
32822285|NCT02907996||Sofosbuvir|Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to <18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens
33101876|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
33101877|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
33101878|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
33101879|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
33101880|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
33101881|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
33405168|NCT05177172|Experimental|Low beta glucans + low polar lipids|White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids
33405169|NCT05177172|Experimental|low polar lipids|White wheat flour bread included polar lipids
32822286|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
32822287|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
32822288|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
32822289|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
32822290|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
32822291|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
32822292|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
32822293|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
32822294|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
32822295|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
32822296|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
32822297|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
32822298|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
32822299|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
32822300|NCT05137938|Experimental|Intranasal Ketamine (IN)|Ketamine will be administered intranasally (IN) using an atomizer (MAD300 by Teleflex, North Carolina, USA).
32822301|NCT03378648|Experimental|CHF6366 active|
32822302|NCT03378648|Placebo Comparator|CHF6366|
32822303|NCT03378648|Active Comparator|Comparator|
32822304|NCT04039542|Experimental|Compassion focused therapy (CFT)|A group programme of CFT running for 10 sessions lasting 90 minutes per session.
32822305|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
32822306|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32822307|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
32822308|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
32822309|NCT01519570|No Intervention|Standard medical care from their primary care physician|
32822310|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
32822311|NCT01519648||Allo- or auto- transplant recipients|
32822312|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
32822313|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
32822314|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
32822315|NCT05562856|Experimental|surface pre-reacted glass filler coating material|surface pre-reacted glass filler coating material used to remineralize WSLs
32822316|NCT05562856|Active Comparator|micro-invasive resin infiltration technique (Icon)|micro-invasive resin infiltration technique (Icon) in the ability to improve caries lesion state (LF scores) and making the WSLs
32822317|NCT05562856|Experimental|Permaseal resin|Permaseal composite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
32822318|NCT05562856|Experimental|Optiguard resin|Optiguardcomposite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
32822319|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
32822320|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
32822321|NCT05550376||HHT1|Mutations in the ENG (endoglin) gene
32822322|NCT05550376||HHT2|Mutations in the ALK-1 (activin receptor-like kinase) gene
32822323|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
32822324|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
32822325|NCT01576276|Experimental|Morphine condition|
32822326|NCT01576276|Experimental|Ketorolac condition|
32822327|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
32822328|NCT01826981|Experimental|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
32822329|NCT01826981|Experimental|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
32822330|NCT01826981|Experimental|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
32822331|NCT01826981|Experimental|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
32822332|NCT01826981|Experimental|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
32822333|NCT01826981|Experimental|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
32822334|NCT01826981|Experimental|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
32822335|NCT01826981|Experimental|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
32822336|NCT01826981|Experimental|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
32822337|NCT01826981|Experimental|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
32822338|NCT01826981|Experimental|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
32822339|NCT01826981|Experimental|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
32822340|NCT01826981|Experimental|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
32822341|NCT01826981|Experimental|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
32822342|NCT01826981|Experimental|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
32822343|NCT02247154|Experimental|Vigam® Liquid|
32822344|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
32822345|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
32822346|NCT01523704|Experimental|Home Monitoring(HM)|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
32822347|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
33405170|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
32830690|NCT01725165|Experimental|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
32830691|NCT01725165|Active Comparator|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
32822348|NCT02728752|Placebo Comparator|Placebo|Subjects randomized to placebo will receive 4 infusions of placebo every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to Octagam 10%. After response assessment at Week 16, all subjects with no confirmed deterioration and subjects switched to Octagam 10% due to confirmed deterioration but without further confirmed deterioration during the First Period will continue to receive 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to placebo and switched to Octagam 10% due to confirmed deterioration, who deteriorate also during Octagam 10% treatment at 2 consecutive visits will drop-out after response assessment at Week 16 and will not enter the Extension Period.
32822349|NCT02728752|Experimental|Octagam10%|Subjects randomized to Octagam will receive 4 infusions of 2.0 g/kg Octagam 10% every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to the alternate treatment. After response assessment at Week 16, all subjects with no confirmed deterioration during the First Period will continue receiving 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to Octagam and switched to the alternate treatment due to confirmed deterioration will drop-out after response assessment at Week 16 and will not enter the Extension Period.
32822350|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
32822351|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
32822352|NCT01578772|Experimental|Telmisartan|Open label
32822353|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
32822354|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
32822355|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
32822356|NCT01804049|Placebo Comparator|Placebo|60 participants will be randomized to placebo pills.
32822357|NCT01804049|Active Comparator|Metformin|60 enrolled participants will be randomized to metformin.
32822358|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
32822359|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
32822360|NCT02556762|Experimental|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
32822361|NCT02556762|Active Comparator|Standard dose RT|Standard dose radiotherapy
32822362|NCT02383992|Active Comparator|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
32822363|NCT02383992|Active Comparator|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
32822364|NCT02346630|Active Comparator|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
32822365|NCT02346630|Placebo Comparator|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
32822366|NCT01826825||Clock in the box|Those patients with and without probable cognitive impairment based on the Clock-in-the-box assessment.
32822367|NCT01826825||Mini-Cog|Those patients with and without probable cognitive impairment based on the Mini-Cog assessment.
32822368|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
32822369|NCT01803737|Active Comparator|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
32822370|NCT01803737|Experimental|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
32822371|NCT03994848|No Intervention|Control|
32822372|NCT03994848|Experimental|Spirometry Group|
32822373|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
32822374|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
32822375|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).~And follow up for 3 years to identify of the correlation with PAD outcome."
32822376|NCT01826201|Experimental|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
32822377|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
32822378|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
32822379|NCT04947072|Experimental|Erector Spinae Plane Block|Patient will receive single-shot ultrasound-guided erector spinae plane block at the level of T9 on the side which will be operated on.
32822380|NCT04947072|Active Comparator|Spinal Anesthesia|Patient will receive spinal anesthesia at the level of L3-L4 or L4-L5
32822381|NCT04942158|Experimental|CTZ group|Non-instrumentation endodontic treatment and use of a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste)
32822382|NCT04942158|Active Comparator|ZOE group|Endodontic treatment with instrumentation and filling with Zinc Oxide and Eugenol paste (ZOE paste)
32822383|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
32822384|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
32822385|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
32822386|NCT03375450||Observation|Cohort of patients with COPD
32822387|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
32822388|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
32822389|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
32822390|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
32822391|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
32822392|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
32822393|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
32822394|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
32822395|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
32822396|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
32822397|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
32822398|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
32822399|NCT03947112||Norwegian population with Duchenne Muscular Dystrophy (DMD)|Boys with DMD.
32822400|NCT03396666|Experimental|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
32822401|NCT03396666|No Intervention|No intervention|Regular follow-up with advice on physical activity and nutrition
32822402|NCT03387774|Experimental|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;~Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
32822403|NCT03387774|Active Comparator|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
32822404|NCT04377594|Experimental|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
32822405|NCT04377594|Active Comparator|Pulmonary vein isolation|Pulmonary vein isolation
32822406|NCT03382392||ALS|
32822407|NCT03382392||control 1|
32822408|NCT03382392||control 2|
32822409|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
32822410|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
32822411|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
32822412|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
32822413|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
32822414|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
32822415|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
32822416|NCT03124524|No Intervention|Control group|33 healthy controls
32822417|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
32822418|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
33101882|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
32822419|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
32822420|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
32822421|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
32822422|NCT03377322|Active Comparator|Treatment|Probiotics capsules
32822423|NCT03377322|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
32822424|NCT03382236|Experimental|Real osteopathy|
32822425|NCT03382236|Placebo Comparator|Sham osteopathy|
32822426|NCT01803269|Active Comparator|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32822427|NCT01803269|Experimental|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32822428|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
32822429|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school"
32822430|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
32822431|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
32822432|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
32822433|NCT01802879|Experimental|Panobinostat - 10 to 40 mg/day TIW QoW|10 to 40mg/day TIW QoW (3 times/week every other week) as per parent protocol design
32822434|NCT03145038|Experimental|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
32822435|NCT03145038|Experimental|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
32822436|NCT03145038|Experimental|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
32822437|NCT03145038|Active Comparator|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
32822438|NCT03145038|Experimental|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
32822439|NCT03145038|Experimental|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
32822440|NCT01825577|Experimental|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
32822441|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
32822442|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
32822443|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
32822444|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
32822445|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
32822446|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
32822447|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
32822448|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
32822449|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
32822450|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
32822451|NCT01802411|Active Comparator|EXPAREL 266 mg|Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg [6.6 mL] to each of three nerve segments)
32822452|NCT01802411|Placebo Comparator|Placebo|Intercostal nerve block using single total administration of 20 mL normal saline (6.6 mL to each of three nerve segments)
32822453|NCT03374982|Experimental|DentalVibe On|DentalVibe will be turned on during local anesthetic injection at one appointment.
32822454|NCT03374982|No Intervention|DentalVibe Off|DentalVibe will be be turned off during local anesthetic injection at one appointment.
32822455|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
32822456|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
32822457|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
32822458|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
32822459|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
32822460|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
32822461|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
32822462|NCT03381690||Epidural (ED) emergent C-sec|
32822463|NCT03381690||Non-ED emergent C-sec|
32822464|NCT03381690||Non-ED elective C-sec|
32822465|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
32822466|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
32822467|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
32822468|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
32822469|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
32822470|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
32822471|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
32822472|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
32822473|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
32822474|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
32822475|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
32822476|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
32822477|NCT02963610|Experimental|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
32822478|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
32822479|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
32822480|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
32822481|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
32822482|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
32822483|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
32822484|NCT03376854|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
33317827|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
32822485|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
32822486|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
32822487|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
32822488|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
32822489|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
32822490|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
32822491|NCT01580098|No Intervention|Control group|treatment as usual
32822492|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
32822493|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
32822494|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
32822495|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
32822496|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
32822497|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
32822498|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
32822499|NCT03007654|No Intervention|No treatment|standard treatment for surgery
32822500|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
32822501|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
32822502|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
32822503|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
32822504|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
32822505|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
32822506|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
32822507|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
32822508|NCT03381456|Experimental|Healthy subject|LICI
32822509|NCT03381456|Experimental|Dystonic subject|LICI
32822510|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
32822511|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
32822512|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
32822513|NCT01526356|Placebo Comparator|Placebo|Cream only
32822514|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
32822515|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
32822516|NCT03812094|Active Comparator|Basic Bladder advice|Basic bladder advice as given from a pre-specified document, study nurse
32822517|NCT03812094|Active Comparator|Alarm|Alarm Enurad 400
32822518|NCT03812094|No Intervention|No treatment|No treatment during study period.
32822519|NCT04838964|Experimental|MRG003|MRG003 will be administrated via IV infusion at 2.0 mg/kg on Day 1 of every 3 weeks (21-day cycle).
32822520|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
32822521|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
32822522|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
32822523|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
32822524|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
32822525|NCT02903160|Experimental|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
33101883|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
32822526|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
32822527|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
32822528|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
32822529|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
32822530|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
32822531|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
32822532|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.~Pain score, withdrawal movement score and hemodynamic response was recorded."
32822533|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
32822534|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
32822535|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
32822536|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
32822537|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
32822538|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
32822539|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
32822540|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
32822541|NCT03376230||Control patients|
32822542|NCT03376230||Crohn's disease patients|
32822543|NCT03376230||Ulcerative colitis patients|
32822544|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
32822545|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
32822546|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
32822547|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
32822548|NCT03380988|Active Comparator|Corn pasta|Acute test meal
32822549|NCT03374046|No Intervention|Control Group|Standard care
32822550|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula~If 0-2 years: 3L/min NC of 100% FiO2~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
32822551|NCT03630666|Active Comparator|IADT|one injection of IADT. The overall duration of IADT will be six months.
32822552|NCT03630666|Experimental|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
32822553|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
32822554|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
32822555|NCT02814786|Experimental|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.~Interventions: MRI scanner and gait analysis"
32822556|NCT02814786|Experimental|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.~Interventions: MRI scanner and gait analysis"
32822557|NCT04764552|Experimental|Yeahhh Baby Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
32822558|NCT04764552|Placebo Comparator|Placebo Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
32822559|NCT02647242|Experimental|Patients with parkinson's disease|Patients with parkinson's disease
32822560|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
32822561|NCT03376074|Active Comparator|Conventional cold storage|
32822562|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
32822563|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
32822564|NCT03370146||TKA patients - Experimental Group|
32822565|NCT03370146||TKA patients - Control Group 1|
32822566|NCT03370146||Healthy subjects - Control Group 2|
32822567|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
32822568|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
33101884|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
32822569|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
32822570|NCT02606136|Experimental|Pamrevlumab|Participants will receive pamrevlumab 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 2 weeks for a minimum of 104 weeks.
32822571|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
32822572|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
32822573|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
32822574|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
32822575|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
32822576|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
32822577|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
32822578|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
32822579|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
32822580|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
32822581|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
32822582|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
32822583|NCT03369990|Experimental|Botulinum toxin type A|DWP450
32822584|NCT03369990|Placebo Comparator|Placebo|Normal Saline
32822585|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
32822586|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
32822587|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
32822588|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
32822589|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
32822590|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
32822591|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
32822592|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
32822593|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
32822594|NCT03369912|Experimental|Active|CSJ148
32822595|NCT03369912|Placebo Comparator|Placebo|5% dextrose
32822596|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
32822597|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
32822598|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
32822599|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
32822600|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
32822601|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
32822602|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
32822603|NCT01531738||Control|Normal weight healthy volunteers
32822604|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
32822605|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
32822606|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
32822607|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
32822608|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
32822609|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
32822610|NCT01584388|Experimental|Rituximab|
32822611|NCT03007108|Experimental|healthy infants|
32822612|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
33101885|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
32822613|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32822614|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32822615|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32822616|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32822617|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
32822618|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
32822619|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
32822620|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
32822621|NCT01532830|Experimental|Active|n-VNS active therapy
32822622|NCT01802333|Experimental|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
32822623|NCT01802333|Experimental|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
32822624|NCT01802333|Experimental|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
32822625|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
32822626|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
32822627|NCT01585324|Experimental|Single Arm|
32822628|NCT01586026||Group A|Maintenance flushes at days 1-28
32822629|NCT01586026||Group B|Maintenance flushes at days 29-56
32822630|NCT01586026||Group C|Maintenance flushes at days 57+
32822631|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
32822632|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
32822633|NCT03006640|Placebo Comparator|Control group|
32822634|NCT03006640|Active Comparator|NTG group|
32822635|NCT01586962|Experimental|Upper Respiratory Infections|
32822636|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
32822637|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
32822638|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
32822639|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
32822640|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
32822641|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
32822642|NCT00980655|Experimental|1|
32822643|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
32822644|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
32822645|NCT04129437|Active Comparator|NSAID|Ibuprofen, 800 mg, one time dose
32822646|NCT04129437|Active Comparator|OMT/NSAID|Ibuprofen, 800 mg, one time dose
32822647|NCT04129437|Active Comparator|OMT alone|low velocity osteopathic manipulative medicine
32822648|NCT05609799|Other|Healthy females|One blood sample is collected on healthy females in reproductive age. The sample will be analyzed for volumen of leucocyte subsets.
33405171|NCT05761470|Experimental|Camrelizumab, Fluzoparib and Nab-paclitaxel|Participants who confirmed pathogenic or likely pathogenic HRR gene mutation received Camrelizumab and Fluzoparib with nab-paclitaxel from the second cycle followed by nab-paclitaxel for one cycle.
32822649|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
32822650|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
32822651|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
32822652|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
32822653|NCT05609721||Patients with antithromotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
32822654|NCT05609721||Patients without antothrombotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
32822655|NCT04588259|Experimental|Faster aspart|4 daily injections of faster aspart given with insulin degludec and with or without metformin
32822656|NCT04588259|Active Comparator|Insulin aspart|4 daily injections of insulin aspart given with insulin degludec and with or without metformin
32822657|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
32822658|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
32822659|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
32822660|NCT01801865|Experimental|MRI for Neonates|All participants will receive an MRI in the NICU scanner in the GE OPTIMA 1.5T MRI at CCHMC.
32822661|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
32822662|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
32822663|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
32822664|NCT01801475|Active Comparator|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
32822665|NCT01801475|Active Comparator|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
32822666|NCT01801475|No Intervention|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
32822667|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
32822668|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
32822669|NCT03063021|Experimental|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.
32822670|NCT03063021|Experimental|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
32830692|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
32830693|NCT03280680|Experimental|Female+male group sessions|
32830694|NCT03280680|Experimental|Female group sessions|
32830695|NCT03280680|Other|No group sessions|
32830696|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
33101886|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
33101887|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
33317828|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
33317829|NCT04133792|Experimental|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
32822671|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
33317830|NCT04133792|Placebo Comparator|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
33317831|NCT01204034|Other|Inuvair|
33317832|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
33317833|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
33317834|NCT05670314|Placebo Comparator|Placebo arm|The participants in the placebo/control arm (N=30) will be required to take 10g of maltodextrin for the same period of 6 weeks.
33317835|NCT05670314|Experimental|Diet only Arm|The participants in the dietary intervention arm will be required to take 20g of inulin (N=30) for a period of 6 weeks.
33405172|NCT05205096|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
32822672|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
32822673|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
32822674|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
32822675|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
32822676|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
32822677|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
32822678|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
32822679|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
32822680|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
32822681|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
32822682|NCT03042975||Laryngeal Dystonia|Patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
32822683|NCT03042975||Unaffected relatives of laryngeal dystonia patients|Unaffected relatives of patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
32822684|NCT03042975||Voice tremor|Patients with voice tremor will undergo an MRI of the brain and a blood draw.
32822685|NCT03042975||Muscle tension dysphonia|Patients with muscle tension dysphonia will undergo an MRI of the brain and a blood draw.
32822686|NCT01822925|Experimental|DA-9801 300mg|DA-9801 will be administered in tablet form, 100mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
32822687|NCT01822925|Experimental|DA-9801 600mg|DA-9801 will be administered in tablet form, 200 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
32822688|NCT01822925|Experimental|DA-9801 900mg|DA-9801 will be administered in tablet form, 300 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
32822689|NCT01822925|Placebo Comparator|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
32822690|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
32822691|NCT03041415|Active Comparator|ALED Alone Physical Activity Program|"The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.~Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
33101888|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
33405173|NCT05759598|Other|Control group (CTRL)|
33405174|NCT05759598|Experimental|Experimental group (RMT)|
33101889|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
33405175|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
33405176|NCT05131542||Down Syndrome|Children with down syndrome
32822692|NCT03041415|Experimental|ALED + Our Voice PA Program|"The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.~Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
32822693|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
32822694|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
32822695|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
32822696|NCT03061539|Experimental|Nivolumab & Ipilimumab - Cohort 1|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
32822697|NCT03061539|Experimental|Nivolumab & Ipilimumab - Cohort 2|Patients will receive Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses followed by a 3 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
32822698|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
32822699|NCT05609253|Active Comparator|Itraconazole in capsule form|Participants in this arm will receive the capsule form of itraconazole
32822700|NCT05609253|Active Comparator|Itraconazole in solution form|Participants in this arm will receive the solution form of itraconazole
32822701|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
32822702|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
32822703|NCT05609097|Experimental|PRIME + COMBO|PRIME training (Phase 1), followed by 8 weeks of progressive whole-body COMBO training.
32822704|NCT05609097|Other|COMBO only|4 weeks of standard progressive whole-body aerobic plus resistance training (COMBO) followed by 8 weeks continued COMBO training.
32822705|NCT01801007|Other|Flow Re-Direction Endoluminal Device|
32822706|NCT05609019|Experimental|SYHX2005|"Stage1 dose-escalation: Patients with advanced solid tumors will receive escalating doses of SYHX2005 as monotherapy.~Stage2 dose-expansion: Patients with advanced solid tumors will receive SYHX2005 monotherapy at recommended dose (1 or 2 ) in Stage 1 (dose escalation) to evaluate the preliminary antitumor activity of SYHX2005."
32822707|NCT04120545|Experimental|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
32822708|NCT04120545|Placebo Comparator|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
32822709|NCT01822691|Experimental|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
32822710|NCT01822535|No Intervention|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room."
32822711|NCT01822535|No Intervention|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
32822712|NCT01822535|Experimental|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
32822713|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
32822714|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
32822715|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
32822716|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
33101890|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
33101891|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
32822717|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
32822718|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
32822719|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
32822720|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
32822721|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
32822722|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
32822723|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
32830697|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
32822724|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
32822725|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
32822726|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
32822727|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
32822728|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
32822729|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
32822730|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
33405177|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
33101892|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
33101893|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
32822731|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
32822732|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
32822733|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
32822734|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
32822735|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
32822736|NCT01799993|Experimental|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
32822737|NCT01799993|Placebo Comparator|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
32822738|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
32822739|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
32822740|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
32822741|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
32822742|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
32822743|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
32822744|NCT01822223|Experimental|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
32822745|NCT01822223|Active Comparator|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
32822746|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
32822747|NCT01593748|Experimental|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
32822748|NCT01593748|Active Comparator|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
33101894|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
32822749|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
32822750|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
32822751|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
32822752|NCT01594528|Experimental|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
32822753|NCT01594528|Experimental|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
32822754|NCT01594528|Experimental|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
32822755|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
32822756|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
32822757|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
32822758|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
32822759|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
32822760|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
32822761|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
33101895|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
33101896|NCT01286779|Experimental|BAX 326|
33101897|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
33101898|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
32822762|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
32822763|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
32822764|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
32822765|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
32822766|NCT02228382|Experimental|Bosutinib|
32822767|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
32822768|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
32822769|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
32822770|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
32822771|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
32822772|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
32822773|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
33101899|NCT04137770|No Intervention|control|Patients will receive routine post-operative analgesics
33101900|NCT04137770|Experimental|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
32822774|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
32822775|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
32822776|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
32822777|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
32822778|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
32822779|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
32822780|NCT03369834|Active Comparator|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
32822781|NCT03369834|Placebo Comparator|Sham Group|LED device off.
32822782|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
32822783|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
32822784|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
32822785|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
32822786|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
32822787|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
32822788|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
32822789|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
32822790|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
32822791|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
32822792|NCT05510596|Other|Patients with CAR-T Cell treatment|Single arm All patient will undergo an MRI with contrast injection, a blood withdrawal and a neurological consultation with neuropsychological tests
32822793|NCT03375606|Experimental|CSL730|
32822794|NCT03375606|Placebo Comparator|Placebo|
32822795|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
32822796|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
32822797|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
32822798|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
32822799|NCT03369522||Construction|100 recordings that will be used for the algorithm development
32822800|NCT03369522||Validation|100 recordings for the validation of the algorithm
32822801|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
32822802|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
32822803|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
32822804|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
32822805|NCT03363594||1|Diabetes Mellitus
32822806|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
32822807|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
32822808|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
32822809|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
32822810|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
32822811|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
33101901|NCT05594797|Experimental|Human BCMA Targeted T Cells Injection|Single administration：6.0×10^6 CAR+T/kg
32822812|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
32822813|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
32822814|NCT05566834|Experimental|Open-label, dose-escalation, safety, Pharmacodynamic, pharmacokinetic study.|One
32822815|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
32822816|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
32822817|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
32822818|NCT03363438||martinique|
32822819|NCT03363438||guadeloupe|
32822820|NCT02980900|Placebo Comparator|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
32822821|NCT02980900|Active Comparator|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
32822822|NCT02980900|Active Comparator|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
32822823|NCT02980900|Active Comparator|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
32822824|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
32822825|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
32822826|NCT05566522||Experimental Group|Those between the ages of 20-75, Those with musculuskeletal disorders, choronic and neurological disease
32822827|NCT05566522||Control Group|Healty group
32822828|NCT03369132|Experimental|Angiflash|
32822829|NCT03369132|Placebo Comparator|Placebo|
32822830|NCT05488600||Team Sports|30 elite athletes between the ages of 20-30 who are interested in team sports
32822831|NCT05488600||Individual Sports|30 elite athletes between the ages of 20-30 who are interested in individual sports
32822832|NCT05488600||Control Group|30 healthy individuals between the ages of 20-30 who are not interested in sports
32822833|NCT05566366|Other|population who lost a loved one during the COVID19 health crisis|"Analyze the grieving process of people who have lost a close first degree relative, understand the impact of death conditions on this process and model a theory of mourning in the context of the actual epidemic health crisis."
32822834|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
32822835|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
32822836|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
32822837|NCT01900002|Experimental|Treatment (sorafenib tosylate, TheraSphere)|Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32822838|NCT03005314|Other|Surgery|Postoperative chemotherapy group
32822839|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
32822840|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
32822841|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
32822842|NCT03123510|Placebo Comparator|placebo|sugar pills
32822843|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
32822844|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
32822845|NCT04526964|Other|Intervention Group (IGr)|Participants of the intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum during the inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up and a supplementary app.
32822846|NCT04526964|No Intervention|Control Group (CGr)|Participants in the control group (CGr) receive the standard follow-up procedures (care as usual).
32822847|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
32822848|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
32822849|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
33101902|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
32822850|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
32822851|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
32822852|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
32822853|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
32822854|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
32822855|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
32822856|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
32822857|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
32822858|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
32822859|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
32822860|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
32822861|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
32822864|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
32822865|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
32822866|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
32822867|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
32822868|NCT05067556|Experimental|Intervention|Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)
32822869|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
32822870|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
32822871|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
32822872|NCT03368976||Interscalene|
32822873|NCT03368976||Supraclavicular|
32822874|NCT03368976||Infraclavicular|
32822875|NCT03368976||Transversus Abdominus Plane|
32822876|NCT03368976||Paravertebral Space|
32822877|NCT03368976||Fascia Iliaca|
32822878|NCT03368976||Femoral Nerve|
33101903|NCT04061135|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
32822879|NCT03368976||Saphenous Nerve via Adductor Canal|
32822880|NCT03368976||Popliteal Sciatic Nerve|
32822881|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
32822882|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
32822883|NCT04525560|Experimental|PEG-ELS-S|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
32822884|NCT04525560|Active Comparator|PEG-ELS-L|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
32822885|NCT05460130|Other|Study Participants|Persons infected with the hepatitis C virus who meet the study inclusion criteria and do not meet one or more of the exclusion criteria.
32822886|NCT03363048|Experimental|Restricted|
32822887|NCT03363048|Experimental|Restriction plus Incentive|
32822888|NCT03363048|No Intervention|Control|
32822889|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
33101904|NCT04061135|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
33101905|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
33101906|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
32822890|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
33101907|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
33101908|NCT01286311|No Intervention|Control|
33101909|NCT03783195|Experimental|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
33101910|NCT03783195|Experimental|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
33101911|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
33101912|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
33101913|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
33101914|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
33101915|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
33101916|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
33101917|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
33101918|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles~Consolidation therapy:~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
32822891|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
32822892|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
32822893|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
32822894|NCT05064670|Experimental|Exercise|The intervention group will, in addition to routine clinical care according to (inter-) national guidelines, receive an exercise program of resistance and aerobic exercise delivered live online by an upskilled exercise professional in group exercise classes twice weekly for 3 months
32822895|NCT05064670|No Intervention|Control|The control group will receive routine clinical care according to (inter-) national guidelines
32822896|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.~* Standard care for sepsis and PAD"
32822897|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.~* Standard care for sepsis"
32822898|NCT04525482|No Intervention|Control Group|No intervention was implemented
32822899|NCT04525482|Experimental|Intervention Group|Early goal-directed sedation programs was implemented
32822900|NCT05035888|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
32822901|NCT05035888|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
32822902|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
32822903|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
32822904|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
32822905|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
32822906|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
32822907|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
33101919|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
33101920|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
33101921|NCT04689152|No Intervention|Control group|Best Supportive care
33101922|NCT04689152|Experimental|Injection group: Cellgram-LC|Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
33101923|NCT03749655|No Intervention|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
33101924|NCT03749655|Experimental|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
32822908|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
32822909|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
32822910|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
32822911|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
32822912|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
32822913|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
32822914|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
32822915|NCT05004454|Experimental|Bacillus subtilis BS50|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
32822916|NCT05004454|Placebo Comparator|Placebo|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
32822917|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
32822918|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
32822919|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
32822920|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
32822921|NCT02518776|Other|Neuropsychological tests|
32822922|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
32822923|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
32822924|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
32822925|NCT03000556|Experimental|experience|
32822926|NCT03000556|No Intervention|control|
32822927|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:~Education about depression and the cognitive-behavioral therapy model;~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;~Coaching as participants fully engage emotional and behavioral strategies."
33101925|NCT05590936|Active Comparator|Dimenydrinate|Preoperative per os administration of 50 mg dimenydrinate
33101926|NCT05590936|Other|Ondasentron|Intraoperative intravenous administration of 4 mg ondansetron
33101927|NCT04689464||mild covid|
33101928|NCT04689464||moderate covid|
33101929|NCT04689464||severe covid|
33101930|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
33101931|NCT05587192|Experimental|18F-PSMA-1007 PET/CT based on USTC diagnostic model|Patinets will complete the 18F-PSMA-1007 PET/CT based USTC diagnostic model firstly. If clinically significant prostate cancer is considered by 18F-PSMA-1007 PET/CT. Patinets will receive radical prostatectomy directly or undergo prostate biopsy according to patients own decisions, patients with negative results in prostate biopsy will be asked to complete rebiopsy after 3 months.
33101932|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
32822928|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
32822929|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
32822930|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
32822933|NCT03368508|Experimental|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
32822934|NCT03368508|Active Comparator|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
32822935|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
32822936|NCT03371862|Experimental|Test group|
32822937|NCT03004378|No Intervention|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
32822938|NCT03004378|Experimental|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
32822939|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
32822940|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
32822941|NCT04986046|Active Comparator|Fruit and vegetable prescription|Fruit and vegetable incentive program
32822942|NCT04986046|Experimental|Fruit and vegetable prescription + Home Plate Lite|Fruit and vegetable incentive program + asynchronous, electronic resources delivered over six weeks
32822943|NCT04986046|Experimental|Fruit and vegetable prescription + Virtual Home Plate|Fruit and vegetable incentive program + 45-minute, virtual, small-group classes twice weekly for six weeks
32822944|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
32822945|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
32822946|NCT04946656|Experimental|SPG block|The sphenopalatine ganglion will be blocked with bipuvacaine for this study
32822947|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
32822948|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
32822949|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
32822950|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
32822951|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
32822952|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
32822953|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
32822954|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
32822955|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
32822956|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
32822957|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
32822958|NCT03371628|No Intervention|Group O2|Oxygen therapy
32822959|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
32822960|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
32822961|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
32822962|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
32822963|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
32822964|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
32822965|NCT03362268|Experimental|Ilaprazole|
32822966|NCT03362268|Active Comparator|omeprazole|
32822967|NCT04901962|Experimental|JOBST® Confidence compression garments|The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.
32822968|NCT04523844|Active Comparator|Brinzolamide-brimonidine fixed combination|One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection
32822969|NCT04523844|No Intervention|No topical IOP-lowering medication|No IOP-lowering drops are instilled before the intravitreal injections
32822970|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
32822971|NCT03362034|Active Comparator|single transfer tray|
32822972|NCT03362034|Experimental|double transfer trays|
32822973|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
32822974|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
32822975|NCT03361878|Active Comparator|Metformin Tolerant|
32822976|NCT03361878|Active Comparator|Metformin Intolerant|
32822977|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
32822978|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
32822979|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
32822980|NCT05369260|Experimental|Cervical and scapular stabilization group|In this arm cervical and scapular stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
32822981|NCT05369260|Experimental|Cervical and core stabilization group|In this arm cervical and core stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
32822982|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
32822983|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
32822984|NCT04523532|Experimental|Group 1: Folate + hazelnut oil|Group 1 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of vegetables rich in folate - 191µg and additionally received 01 capsule containing 25 mg hazelnut oil per day.
32822985|NCT04523532|Placebo Comparator|Group 2: Folate|Group 2 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of folate-rich vegetables - 191 µg and 01 placebo capsule.
32822986|NCT04523532|Experimental|Group 3: Moderate folate + hazelnut oil|Group 3 = in this group, individuals received, during the period of 08 weeks daily, with 300 g of vegetables containing 94 µg of folate and 01 capsule containing 25 mg of hazelnut oil per day.
32822987|NCT04523532|No Intervention|Group 4: Control|Group 4 = in this group, individuals received weekly visits during the 08 week period to maintain their eating habits.
32822988|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
32822989|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
32822990|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
32822991|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
32822992|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
32822993|NCT04636528|Experimental|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
32822994|NCT04636528|Active Comparator|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
32822995|NCT05365438|Experimental|Atmeg with Omethyl Cutielet|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg) Omethyl Cutielet: Omega-3 2000mg (920mg as EPA ethyl ester, 760mg as DHA ethyl ester) once daily
32822996|NCT05365438|Active Comparator|Atmeg|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg)
32822997|NCT05365438|Active Comparator|ezetimibe/atorvastatin 10/20|1 tablet once daily (atorvastatin 20mg with ezetimibe 10mg)
32822998|NCT05360290|Active Comparator|CTC positive|
32822999|NCT05360290|Other|CTC negative|
32823000|NCT05290558|Placebo Comparator|Placebo|Patients in this arm will be given a placebo pill that resembles the actual Bu Shen Yi Jing Pill.
32823001|NCT05290558|Active Comparator|Bu Shen Yi Jing Pill|Patients in this arm will be given the BSYJ Pill.
32823002|NCT05264506|Experimental|Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A)|The NOMAC-E2 COC active tablets contain 2.5 mg NOMAC and 1.5 mg E2 and will be used in a 24/4 regimen, i.e., 28-day cycles with 24 days of active tablet intake followed by 4 days of placebo tablet intake.
32823003|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
32900940|NCT05484492|Active Comparator|calcium phosphosilicate putty alloplast graft|The positive control group of fifteen patients will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft (NovaBone, Osteogenics) covered with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
32823004|NCT05132998|Experimental|Cardiac Rehabilitation Program (CRP) Group|"Baseline consultation with physiatrist specialized in CRP - addressing CVRF control, comorbidities and disabilities; case-by-case discussion with a cardiologist specialized in CR will be undertaken, for tailoring exercise prescription. Nutritional individualized plan addressing dietary goals. Psychological management addressing psychosocial outcomes and motivation for healthy lifestyle habits~Multidisciplinary team educational meeting: periodic group sessions with health education purposes~Exercise intervention - 2 times/week sessions at CR facilities, supervised by a physiatrist, conducted by physiotherapist. Heart rate (HR) continuously monitored during each session by remote electrocardiographic monitoring or HR monitor. Exercise intensity estimated according to CR guidelines, determined after CV risk stratification, using CPET results."
32823005|NCT05132998|Active Comparator|Community Exercise Group|"a) Besides standard medical and supportive care, psychological and nutritional individual support will be offered on demand, in hospital setting, according to the attending physician standard clinical assessment and usual care.~Exercise intervention - Performed at a community-based facility, comprising 2 sessions/week, prescribed according to current physical activity guidelines for cancer survivors. Exercise intervention will be conducted by an exercise physiologist, internationally certified in exercise for cancer patients"
32823006|NCT05672914|Experimental|Tablet-based Sustained Care|Intervention to support sustained smoking cessation.
32823007|NCT05672914|No Intervention|Usual Care|Standard hospital care: : A brief (5-10 min.) tobacco education session from a hospital nurse, along with educational materials about quitting and a quitline brochure.
32823008|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
32823009|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
32823010|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
32823011|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
32823012|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
32823013|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
32823014|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
32823015|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
32823016|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
32823017|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
32823018|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
32823019|NCT03003208|Other|Pulmonary rehabilitation|
32823020|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
32823021|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
32823022|NCT02248168||Idiopathic Parkinson's disease patients|
32823023|NCT03002740||NVAF patients newly prescribed apixaban|
32823024|NCT03002740||NVAF patients newly prescribed rivaroxaban|
32823025|NCT03002740||NVAF patients newly prescribed dabigatran|
32823026|NCT03002740||NVAF patients newly prescribed VKA|
32823027|NCT05672680|Placebo Comparator|Placebo|"Normal Saline:~For patients weighing <100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received."
32823028|NCT05672680|Experimental|Experimental|0.25% bupivacaine: For patients weighing <100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received.
32823029|NCT02248402|Experimental|Vax-DC/MM|
32823030|NCT05672602||LONG COVID patients|Measurement of ncRNAs and cytokines in patients with new diseases or intermittent or permanent symptoms after COVID-19 at the moment of the recruitment
32823031|NCT05672602||Controls|Measurement of ncRNAs and cytokines in Individuals who have never suffered from COVID-19 at the moment of the recruitment
32823032|NCT05672602||Asymptomatic LONG COVID patients|Measurement of ncRNAs and cytokines in patients who have never suffered from LONG COVID symptoms or with only resolved symptoms at the moment of the recruitment
32823033|NCT05672524|Experimental|Participant with Rectal Adenocarcinoma|Participants will have HER2-positive locally advanced rectal adenocarcinoma.
32823034|NCT05672446|Experimental|Experimental|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients.
32823035|NCT05672446|No Intervention|Control|No attempt was made to the students in the control group.
32823036|NCT05672368|Experimental|Device feasibility (da Vinci SP1098 robotic system)|Patients undergo surgery using the da Vinci SP1098 robotic system on study.
32823037|NCT05672290|Experimental|Group 1|Group 1 will be applied external electric stimulation three days per week
32823038|NCT05672290|Active Comparator|Group 2|Group 2 will be applied external electric stimulation one day per week
32823039|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
32823040|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
32823041|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
32823042|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
32823043|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
32823044|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
32823045|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
32823046|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
32823047|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
32823048|NCT04398706|Experimental|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
32823049|NCT04398706|Experimental|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
33101933|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
33101934|NCT04016402||Study Group|All participants enrolled in the study
33101935|NCT05579743|No Intervention|Standard care|Patients randomized to receive standard of care will be provided with a wound care plan at the time of enrollment, and then follow-up in clinic on a biweekly basis (week 2, 4, 6, 8, 10, 12) for a wound check and care plan update as needed.
33101936|NCT05579743|Experimental|Remote wound monitoring technology|Enrolled patients (and their caregivers, if applicable) are given an in-person training on how to use the smartphone app to self-assess their wound during regular dressing changes. Wound assessments are electronically transmitted to a secure, dedicated portal up to once a week for remote review by the study doctors. In-person follow-up is monthly (at the time of enrollment, week 4, week 8, and week 12).
33101937|NCT04323826|Experimental|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
33101938|NCT04323826|Experimental|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
33101939|NCT04323826|Experimental|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
33101940|NCT04323826|Experimental|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
33101941|NCT04690140|Active Comparator|modified coronally advanced tunnel technique|Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
33101942|NCT04690140|Active Comparator|epithelialized free gingival graft|A partial-thickness flap was elevated (blade #15c) with horizontal incisions at the cemento-enamel junction level of the adjacent teeth. Then, two vertical incisions extending to the apical were made from two ends of the horizontal incision. The epithelium in the framed region was removed with a scalpel and the underlying connective tissue was exposed. To achieve the best vascularization from the recipient site, bed preparation was completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region.
33101943|NCT05578183|Experimental|high dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
33101944|NCT05578183|Experimental|low dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
33101945|NCT05578183|Sham Comparator|high dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
33101946|NCT05578183|Sham Comparator|low dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
33101947|NCT02923817|Experimental|Treatment|
33101948|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
32823050|NCT04398706|Experimental|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
32823051|NCT04398706|Active Comparator|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
32823052|NCT04398706|Experimental|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
32823053|NCT04398706|Experimental|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
32823054|NCT04398706|Experimental|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
32823055|NCT04398706|Active Comparator|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
32823056|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
32823057|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
32823058|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
32823059|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
32823060|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
32823061|NCT02225860|No Intervention|Control|Continue with usual diet
32823062|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
32823063|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
32823064|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
32823065|NCT04930198|Other|Social Incentive|"For the social incentive, the mHealth application will track the participant's individual adherence score (% of doses taken), track the top scorers (leaderboard), and provide a figure highlighting the proportion of their peers with poor (<80%), medium (80-94%), or high (>94%) adherence scores. The display of the individual's adherence score relative to peer scores is considered a descriptive norm and is meant to portray what most people are doing, as young people often inaccurately estimate behaviors for their peer groups. Participants will also receive an injunctive norm, or an indication of what they ought to be doing. This will come in the form of an emoji or congratulatory vs. motivating text for those with high or low adherence scores, respectively. When coupled with descriptive norms, injunctive norms have counteracted regression to the mean for individuals who demonstrate desirable behaviors relative to their peers."
32823066|NCT04930198|Other|Social Plus Financial Incentive|"For the financial incentive, the top 5 scorers in the PEER+ arm will be eligible win a lottery prize each month of the 24 week pilot of 1000 Nigerian Naira (NGN) of data that can be directly loaded onto the winner's phone. Behavioral economics theory tells us that individuals are more averse to losses than rewarded by gains, so that even incentives/prizes should be framed in terms of losses. Accordingly, participants in the financial incentive arm will receive weekly motivating messages such as take your dose today or you lose the chance of winning the lottery."
32823067|NCT05672134|Experimental|Experimental arm|Patients will receive 13 weeks of experimental treatment, followed by a 7 week wash-out period, continuing with 13 weeks of placebo as per crossover design.
32823068|NCT05672134|Placebo Comparator|Placebo arm|Patients will receive 13 weeks of placebo treatment, followed by a 7 week wash-out period, continuing with 13 weeks of experimental treatment as per crossover design.
32823069|NCT05672056|Experimental|Intervention|The intervention will be modifying stock reconstruction plates to mimic patient specific plates in mandibular reconstruction with free fibula flaps
32823070|NCT05671822|Experimental|Arm 1A: SHR-A1811 and SHR-1701|
32823071|NCT05671822|Experimental|Arm 1B: SHR-A1811 and capecitabine|
32823072|NCT05671822|Experimental|Arm 1C: SHR-A181,SHR-1701,and capecitabine|
32823073|NCT05671822|Experimental|Arm 1D: SHR-A1811,capecitabine,and oxaliplatin|
32823074|NCT05671822|Experimental|Arm 2A: SHR-A1811 and SHR-1701|
32823075|NCT05671822|Experimental|Arm 2B: SHR-A181,SHR-1701,and capecitabine|
32823076|NCT05671822|Experimental|Arm 2C: SHR-A1811,capecitabine,and oxaliplatin|
32823077|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
32823078|NCT05671744|Other|Blood samples from pregnant women|Samples of peripheral blood collected from pregnant women undergoing CVS or genetic amniocentesis
32823079|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
33101949|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
33101950|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
33101951|NCT03441477|Experimental|Adults 18 years old or older|Nidek Tonoref III
32738706|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~tumor (RS) = 1.5~Late rectal and bladder complications = 3.0~early rectal and bladder complications = 10.0."
32738707|NCT04993521|Active Comparator|bilateral superficial cervical plexus block (BSCPB)|Analgesia obtained by a ultrasound guided cervical plexus block using lidocain
32738708|NCT04993521|Active Comparator|local wound infiltration (LWI)|Analgesia obtained by local wound infiltration of lidocain
32738709|NCT03318263|Other|experimental|
32738710|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
32738711|NCT02452177|Placebo Comparator|Placebo|
32738712|NCT05000697|Experimental|Arm 1 - 5FU + Oxaliplatin|1) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
32738713|NCT05000697|Active Comparator|Arm 2 - 5FU Only|2) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
32738714|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
32738715|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
32738716|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
32738717|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
32738718|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
32738719|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
32738720|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
32738721|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
32738722|NCT04992819|No Intervention|Control Group|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. Experiment is about labeling breast milk by time of day before giving it to babies. There is no extra intervention during feeding. The breastmilk of the control group patients will be given without matching according to the clinical routine practice.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
32738723|NCT04992819|Experimental|Chronobiological Approach Nutrition Model|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. The milk of the intervention group patients will be matched circadian and given to the babies. Intervention group's breast milk is labeling by time of day before the each feeding. In the intervention group, a label containing the time of expressed breastmilk will be affixed. Circadian matched milk will be provided at each feeding.~intervention is;n the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
32738724|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
32738725|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
32738726|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
32738727|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
32738728|NCT05004753|Experimental|Artemisinin 500mg|The dose regimen will be in cycles. In a cycle a subject will receive Artemisinin 500 mg capsule once daily plus SOC on Day 1 to Day 5 followed by 5 days off (no dosing of Artemisinin) or SOC alone. A subject can have a total of consecutive 3 cycles maximum. Here SOC is Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)
32738729|NCT05004753|Active Comparator|Standard of Care|Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Mild Patients: HYDROXYCHLOROQUINE Moderate Patients: Dexamethasone - OD for 05
32738730|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
32738731|NCT02486471|Other|Observational approach|Wait and see
32738732|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
32823080|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
32823081|NCT03371394||median 1|
32823082|NCT03371394||median 2|
32823083|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
32823084|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
32823085|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
32823086|NCT03371238|Experimental|Floorball|
32823087|NCT03371238|No Intervention|Control|
32823088|NCT05671666|Other|Healthy controls|
32823089|NCT04527120|Other|Model A first and then B|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
32823090|NCT04527120|Other|Model B first and then A|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
32823091|NCT05670028|Experimental|CA-guided BP|The upper and lower limits of autoregulation determined by ICM+ software are used to guide the range of blood pressure control, but no more than 40% above or below the usual BP. From when the upper or lower limit of autoregulation appeared in ICM+ software to 48h after revascularization, the total time of actual BP beyond the CA range will be no more than two hours through drug intervention.
32823092|NCT05670028|Active Comparator|Fixed target BP|After randomization to 48h after endovascular therapy, the target of BP was determined by clinicians according to current guidelines, i.e. <180/105mmHg.
32823093|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
32823094|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
32823095|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
32823096|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
32823097|NCT05669872|Experimental|patient blood management group|"before surgery (within 2-6 weeks before surgery)~- 7 ≤ Hb < 12 g/dL : ferric carboxymaltose 1000mg~during surgery~- In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~after surgery (POD #1)~7 ≤ Hb < 12 g/dL : ferric carboxymaltose 1000mg~Hb <7 g/dL : pRBC 2 packs transfusion"
32823098|NCT05669872|Active Comparator|conventional management group|"before surgery (within 2-6 weeks before surgery)~8 ≤ Hb < 10 g/dL: pRBC 1 pack transfusion~Hb < 8 g/dL: pRBC 2 packs transfusion * Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)~during surgery~- In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~after surgery (POD #1)~8 ≤ Hb < 10 g/dL: pRBC 1 pack transfusion~Hb < 8 g/dL: pRBC 2 packs transfusion * Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)"
32823099|NCT04877860|Experimental|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Access to the PaiNEd system.
32823100|NCT04877860|Active Comparator|Multimodal rehabilitation program + traditional biomedical information|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
32823101|NCT04877860|Active Comparator|Control group|Information dossier with recommendations on pain control and dysfunction improvement.
32823102|NCT04526808|Experimental|FODMAP diet|
32823103|NCT04861948|Experimental|Cohort A|
32823104|NCT04861948|Experimental|Cohort B|
32823105|NCT04861948|Experimental|Cohort C|
32823106|NCT04861948|Experimental|Cohort D|
32823107|NCT04526496|Experimental|Single Ascending Doses|50mg-600mg
32823108|NCT04526496|Experimental|Multiple Ascending Doses|dose to be determined
32823109|NCT04856956|Experimental|Intervention (Use of diagnostic decision support software)|Trainee or nurse practitioner sees patient and uses diagnostic decision support software in developing their differential diagnosis and plan
32823110|NCT04856956|No Intervention|Control (Current process)|Trainee or nurse practitioner sees patient but doesn't use diagnostic decision support software in developing their differential diagnosis and plan
32823111|NCT04526184|Active Comparator|healthy group|25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.
32823112|NCT04526184|Active Comparator|patient group|25 individuals will be selected randomly from 103 patients with COPD from hospital records.
32823113|NCT04526262|Experimental|BBB disruption|All participant in this arm will undergo 2 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 3 months.
32823114|NCT04526028||Palbociclib combined with Fulvestrant|
32823115|NCT04526028||Fulvestrant|
32823116|NCT04812184|Experimental|Surgical Tape to bridge of nose|placed a piece of tape to the bridge of the nose, adhering a face mask to the patient's face
33101952|NCT02923622||Traditional Chinese and Western medicine combined group|
32823117|NCT04812184|No Intervention|Standard of care|Patients given a mask with no intervention to the mask
33101953|NCT02923622||Traditional Chinese medicine group|
33405178|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
32823118|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
32823119|NCT04143490|Experimental|UC Patients|Patient group
32823120|NCT04143490|Active Comparator|Healthy controls|Control group
32823121|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
32823122|NCT04799470|Experimental|PD with DBS|Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
32823123|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
32823124|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
32823125|NCT04765462|Experimental|Allogeneic γδ T cell Group|Enrolled patients will be administered allogeneic γδ T cells with or without the combinations of traditional therapies, including chemotherapy, targeted therapy, radiotherapy, immune checkpoint inhibitors and others.
32823126|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
32823127|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
32823128|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
32823129|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
32823130|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
32823131|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
32823132|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
32823133|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
32823134|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
32823135|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
32823136|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
32823137|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
32823138|NCT04737460|Experimental|AAV9/CLN7|"AAV9/CLN7 is an intrathecally administered AAV9-based gene therapy vector that expresses the fully functional form of MFSD8 under the control of a synthetic promoter. AAV9/CLN7 is designed to achieve stable, potentially life-long expression of MFSD8 in non-dividing cells.~The first participant will receive a low dose of 5X1014 vg, subsequent participants will receive a higher dose of 1x1015 vg of the AAV9/CLN7 agent."
32823139|NCT04666558|No Intervention|Standard Care|The standard of care response to COVID. Educational materials will be provided to patients via email. The package will include a combination of personalized exercises, and nutrition information for healthy eating. Participants will also receive a Garmin watch to track their activity over the intervention.
32823140|NCT04666558|Experimental|App-Based, Personnel-Light Care|"An app-based, personnel-light approach to virtual care with a focus on support through group-based interactions with the Trainers, Dietitians and other participants. The patient's personalized 12-week home based exercise program will be enabled in the app after a baseline exercise specialist appointment. The 10-week nutrition program will be enabled at week 3 after a virtual dietitian assessment in week 2 (~1 hour). The home programs will auto-progress. Participants will also receive a Garmin watch to track their activity over the intervention."
32823141|NCT04666558|Experimental|App-Based, Personnel-Intensive Care|"An app-based, personnel-intensive approach to virtual care with support through a combination of group-based interactions with Trainers, Dietitians and other participants, as well as one-on-one support with Exercise Trainers and Dietitians. In addition to Group 2 features, patient interaction with Trainers will be via live group classes AND 1-to-1 sessions: up to seven 1-to-1 consultations with an exercise specialist and three 1-to-1 consultations with a dietitian to review progress and goals and make any necessary modifications to programming. Participants will also receive a Garmin watch to track their activity over the intervention."
32823142|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
32823143|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
32823144|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
32823145|NCT05664490|No Intervention|Standard-of-Care Mental Health Services|Participants randomized to this group will receive standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
33405179|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
33405180|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
32823146|NCT05664490|Experimental|Youth Friendship Bench SA + Standard-of-Care|Participants randomized to this group will receive the Youth Friendship Bench SA intervention in addition to standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
32823147|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
32823148|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
32823149|NCT05651620||Calorie Restriction (CR)|Individuals in the CR group were prescribed a 25% reduction from their baseline energy intake during the two-year CALERIE trial.
32823150|NCT05651620||Ad Libitum (AL)|Individuals in the AL group were asked to continue their usual dietary intake during the two-year CALERIE trial.
32823151|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
32823152|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
32823153|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
32823154|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
32823155|NCT04129528|Active Comparator|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
32823156|NCT04129528|Placebo Comparator|Placebo|Similar in appearance to active study drug
32823157|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
32823158|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
32823159|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
32823160|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
32823161|NCT05626816|Experimental|All interventions, Sham applied first|These participants will have all interventions applied, but will be randomly designated to have sham stimulation applied before effective stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
32823162|NCT05626816|Experimental|All interventions, effective stim applied first|These participants will have all interventions applied, but will be randomly designated to have effective stimulation applied before sham stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
32823163|NCT03361332||Healthy subjects|
33405181|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
32823164|NCT03361332||Patients with Gilles de la Tourette Syndrome|
32823165|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
32823166|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
32823167|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
33101954|NCT02923622||Western medicine group|
33405182|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
33405183|NCT04425720|Active Comparator|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
33405184|NCT04425720|Experimental|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
33405185|NCT05285228|Active Comparator|Control group: allocation to specific taste of fluoride varnish|allocation to specific taste of fluoride varnish
32823168|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
32823169|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
32823170|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
32823171|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:~Impact of ALS in Guadeloupe and Martinique~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study~The distribution of ALS various phenotypes in our population of patients.~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease~Search for possible environmental factors"
32823172|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
32823173|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
32823174|NCT04073056|Active Comparator|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
32823175|NCT04073056|Active Comparator|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
32823176|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
32823177|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
32823178|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
32823179|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
32823180|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
32823181|NCT03367494|Other|Healthy Volunteers|Diagnostic
32823182|NCT04051294|Experimental|Intervention group 1: commercial kombucha|8oz
32823183|NCT04051294|Experimental|Intervention group 2: brewed kombucha|8oz
32823184|NCT04051294|Active Comparator|Control group 1: tea|8oz
32823185|NCT04051294|Placebo Comparator|Control group 2: water|8oz
32823186|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
32823187|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.~Intervention: Dietary Supplement: Placebo"
32823188|NCT04508998|Experimental|Patients with microvascular angina|Patients with clinical features of microvascular angina screened for the main PRIZE trial however not possessing the PHACTR1 GG minor allele single nucleotide polymorphism
32823189|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
32823190|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
32823191|NCT05594290|Experimental|Preoperative arm|"Patients will be treated with one cycle of chemo-immunotherapy with retifanlimab (500 mg day 1), cisplatin (25 mg/sqm i.v. day 1, 2 ) or carboplatin (AUC 4 i.v., day 1 - in patients unsuited or unfit for cisplatin) and etoposide (100 mg/sqm iv. day 1, 2, 3).~After receiving the short-course preoperative chemo-immunotherapy study regimen, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant radiation therapy if indicated"
32823192|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.~This program will take place within 6 months after biologic treatment initiation."
32823193|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
32823194|NCT04031950||test group|Test group will wear PSG
32823195|NCT04031950||Novel wearable device|THis group will wear the novel device
32823196|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
32823197|NCT05579704|Active Comparator|My Viva Plan Access|Participants will receive access to a web-based platform called My Viva Plan® (MVP, www.myvivaplan.com). Interactions with the platform will be fully self-guided (without weekly group video conferencing sessions health professionals).
32823198|NCT05579704|Experimental|My Viva Plan Access with Health Professional Support|Participants will receive access to a web-based platform called My Viva Plan® (MVP, www.myvivaplan.com). In addition to MVP access, participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, psychologist, and exercise specialist). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
32823199|NCT04525170|Experimental|HPT treated|daily wear Hexafocon A rigid contact lens treated with Hydra PEG surface coating
33101955|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
32823200|NCT04525170|Experimental|untreated|daily wear Hexafocon A rigid contact lens
32823201|NCT03995368|Experimental|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
32823202|NCT03995368|Experimental|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
32823203|NCT03995368|Experimental|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
32823204|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
32823205|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
32823206|NCT03367338|Active Comparator|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
32823207|NCT03367338|Active Comparator|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
32823208|NCT04523610|Experimental|Program Users - Quantitative|The Telehealth Intervention Program (TIP-OA) for older adults was created during the COVID-19 pandemic to support the health of older adults who are isolated or have mental health/cognitive issues. Within the TIP-OA program, trained volunteers provide friendly phone calls once a week to older adults (age 60+). 200 participants will be recruited for the quantitative component of the study.
32823209|NCT04523610|Other|Program Users - Qualitative|Interviews will be conducted with 25 participants regarding their perceptions and experiences in the TIP-OA program.
32823210|NCT04523610|Other|Volunteers - Qualitative|15 volunteers taking part in the semi-structured interviews and 16 volunteers participating in the focus groups. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
32823211|NCT04523610|Other|Stakeholders - Qualitative|18 stakeholders (clinicians, community partners, TIP-OA team members) will participate in focus groups and interviews. Specifically, 10 clinicians will participate in one focus group and 8 community partners/team members will participate in interviews. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
32823212|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
32823213|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
32823214|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
32823215|NCT03360630|Active Comparator|Anti-PD-1 alone|
32823216|NCT03965104|Experimental|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
32823217|NCT03965104|No Intervention|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
32823218|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.~A group is the patients with non-overlapping range"
32823219|NCT03358446||S group|S group is the patients without non-overlapping range
32823220|NCT04414540|Experimental|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
32823221|NCT04414540|Experimental|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
32823222|NCT04413994|Active Comparator|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
32823223|NCT04413994|Active Comparator|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
32823224|NCT04413994|No Intervention|Term control group|Term-born controls as a reference group for outcome parameters
32823225|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
32823226|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
32823227|NCT05568160|Experimental|Intervention|
32823228|NCT05568160|Active Comparator|Control|
32823229|NCT04525248|Active Comparator|High resection|Laparoscopic total colectomy + High resection of rectum
32823230|NCT04525248|Experimental|Low resection|Laparoscopic total colectomy + Low resection of rectum
32823231|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, three additional cohorts (A, B and C) of patients will be evaluated.
32823232|NCT03367182||Weekly paclitaxel + bevacizumab|
32823233|NCT03367182||Topotecan + bevacizumab|
32823234|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
33101956|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
33101957|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
32823235|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
32823236|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
32823237|NCT05561764|Experimental|Imipenem/cilastatin/relebactam|Adult participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with the current prescribing information and according to estimated renal function. Adolescent participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with Phase I data [37.5 (15/15/7.5) mg/kg, up to a maximum dose of 1.25g]. Each dose will be infused over 30 minutes.
32823238|NCT04119180|Experimental|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
32823239|NCT04119180|Other|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
33317836|NCT05670314|Experimental|Exercise only arm|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises. The intervention also includes educational sessions integrated into the programme covering the basics of OA, its treatment, self-managing symptoms of OA and the benefits of maintaining a healthy lifestyle. The exercise intervention focuses on core stability and performance, neuromuscular leg strengthening and balance enhancement.
33405186|NCT05285228|Experimental|Test group: child chooses taste of fluoride varnish|child chooses taste of fluoride varnish before dental treatment
32823242|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
32823243|NCT04521816|Experimental|Intervention--PACT Intensive Management|"The intervention is the PACT Intensive Management Program (PIM) provides a standardized menu of services, ranging from chart review assessment or in-home assessment, to a time limited intensive care management intervention. The following PIM features are standardized across the PIM demonstration sites:~A) Chart review assessment template in the EMR; B) Comprehensive assessment template of unmet needs and modifiable risk factors in EMR; C) Transitions in care process (eligibility criteria, clinical protocols); D) Diagnostic home visits process (eligibility criteria, clinical protocols); E) Core risk stratification/Triage process; F) Discharge criteria and note template in EMR; G) Standardized interdisciplinary team (IDT) meeting note procedure and template in EMR."
32823244|NCT04521816|No Intervention|Usual care|High-Risk patients receiving care in PACT.
32823245|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
32823246|NCT04040400|Experimental|Treatment Arm|intraoperative radiotherapy (IORT) arm
32823247|NCT04334668|Active Comparator|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
32823248|NCT04334668|Placebo Comparator|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
32823249|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
32823250|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
32823251|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
32823252|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
32823253|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
32823254|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
32823255|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
32823256|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
32823257|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
32823258|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
32823259|NCT04256980|Experimental|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
32823260|NCT04522050|Other|Induction chemotherapy + IMRT and concurrent gemcitabine|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m²,d1) every 3weeks for 2 cycles before radiotherapy, and then receive intensity modulated radiotherapy (IMRT) concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. Patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
32830698|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
33101958|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
32823261|NCT04222270|Experimental|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
32823262|NCT04222270|No Intervention|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
32823263|NCT04522128|Active Comparator|Feedback Intervention|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the feedback intervention will then be provided with graphs showing WHOQOL COMBI facet scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important."
32823264|NCT04522128|Experimental|Extended Intervention|"All participants will complete an online questionnaire (as described above).~Participants randomly allocated to the extended intervention will then be provided with graphs to highlight differences between their actual WHOQoL COMBI scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important.~Participants will then receive an online intervention that will provide them with behaviour change techniques to help them address the discrepancies in the relevant quality of life domains."
32823265|NCT04522128|Other|Waitlist Control|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the waitlist control group will then receive their WHOQoL COMBI scores only, with no information about differences between quality of life and importance or intervention materials."
32823266|NCT04521894||Primary PCa without metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies.
32823267|NCT04521894||Primary PCa with metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies. And the 18F-PSMA-PET/CT scan confirmed metastases.
32823268|NCT04521894||Oligometastatic PCa group|"Oligometastaticis a subgroup of metastatic patients with a limited number of secondary lesions (threshold ranging from 3 to 5) in one or few organs."
32823269|NCT04521894||Biochemical recurrence Group|Proven biochemical recurrence after radical therapy (PSA >0.2 ng/mL after radical prostatectomy, PSA ≥2 ng/mL above the nadir after external-beam radiotherapy) or persisting PSA after radical treatment with rising PSA values.
32823270|NCT04521894||Control Group|Prostate cancer benign prostatic hypertrophy or normal prostate.
32823271|NCT04190680|Experimental|Kokkerelli Learning Street|The classes included in this group will participate in the Kokkerelli Learning Street; a school-based nutrition education programme included classroom-based lessons, a visit to a grower's farm and a cooking workshop.
32823272|NCT04190680|No Intervention|Control group|The classes included in this group will not participate in the Kokkerelli Learning Street and will continue with their regular curriculum.
32823273|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
32823274|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
32823275|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
32823276|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
32823277|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
32823278|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
32823279|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
32823280|NCT04160806|Active Comparator|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
33405187|NCT03649568|Experimental|Pork|1 ounce lean pork
33405188|NCT03649568|Active Comparator|Egg|1 large whole egg
32823281|NCT04160806|Sham Comparator|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
32823282|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution~bioelectrical impedance Analysis~blood draw~transient elastography (FibroScan)~ataxia score~Five-Times-Sit-to-Stand Test"
32823283|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
32823284|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
32823285|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
33101959|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
33101960|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
33101961|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
33405189|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
32823286|NCT03357900|Experimental|Orthotopic liver transplantation|
32823287|NCT03360006|Experimental|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
32823288|NCT03360006|Experimental|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
32823289|NCT04525326|Experimental|standard chemotherapy plus Cetuximab|
32823290|NCT04525326|Experimental|standard chemotherapy plus Bevacizumab|
32823291|NCT02247622||Healthy control|
32823292|NCT02247622||IBD|patients with inflammatory bowel disease, study group
32823293|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
32823294|NCT03367104||Normal healthy controls|
32823295|NCT03367104||Heart failure patients|
32823296|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
32823297|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
32823298|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
32823299|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
33101962|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
33101963|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
33101964|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
33101965|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
33405190|NCT03649568|Experimental|Almonds|1 ounce almonds
33405191|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
33101966|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
33101967|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
33101968|NCT02933853|Experimental|Faster Aspart|
33101969|NCT02933853|Active Comparator|Insulin Aspart|
33101970|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
33101971|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
33101972|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
33101973|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
33101974|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
32823300|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
32823301|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
32823302|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
32823303|NCT05445934|Experimental|FB2001 group|FB2001 will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
32823304|NCT05445934|Placebo Comparator|Placebo group|Placebo will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
32823305|NCT03359772|No Intervention|Group 1|Exercise Only Group
32823306|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
32823307|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
32823308|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
32823309|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
32823310|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
32823311|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
32823312|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
32823313|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
32823314|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
32823315|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
32823316|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
32823317|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.~No drugs treatment in this group."
32823318|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
32823319|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
33405192|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
33405193|NCT04075526|Experimental|Povidone iodine and vancomycin powder|
33405194|NCT04075526|Experimental|Povidone iodine alone|
33405195|NCT04075526|Active Comparator|Vancomycin powder alone|
33405196|NCT04075526|Active Comparator|Conventional|neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation
33405197|NCT05204628|Experimental|XZP-3621|Participants will receive XZP-3621 tablets orally at a dose of 500 mg QD with food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
33405198|NCT05204628|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
33405199|NCT05078190||Doxorubicin|Patients treated with doxorubicin (Adriamycin) for breast cancer
33405200|NCT05078190||Trastuzumab|Patients treated with trastuzumab (Herceptin) for breast cancer
33405201|NCT05078190||Doxorubicin and Trastuzumab|Patients treated with both doxorubicin (Adriamycin) and trastuzumab (Herceptin) for breast cancer
33405202|NCT05285072||Vascular graft infection|Patients with confirmed vascular graft infection according to current syndromic criteria.
33405203|NCT05285072||Vascular graft without infection|Patients with no clinical evidence of infection and CRP less than 5.
33405204|NCT03459443|Experimental|Danicopan|Danicopan was to be administered to participants with C3G or IC-MPGN at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then the dosage was to be increased to 200 mg TID for the remainder of the study.
32823320|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
33405205|NCT05204394|Experimental|VM-1500A-LAI 600mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 600mg i / m Q4W injections with the background of oral 2NRTIs QD.
32823321|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
32823322|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
32823323|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
32823324|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
32823325|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
32823326|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
32823327|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
32823328|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
32823329|NCT04113382|Experimental|Participants aged 2 to <4 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (½ bottle [approximately 80 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL."
32823330|NCT04113382|Active Comparator|Participants aged 2 to <4 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 4 ounce (oz) for every 30 minutes, one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
32823331|NCT04113382|Experimental|Participants aged 4 to <9 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (1 bottle [approximately 160 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum."
32823332|NCT04113382|Active Comparator|Participants aged 4 to <9 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 8 oz for every 30 minutes one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
32823333|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
32823334|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
32823335|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
32823336|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
32823337|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
32823338|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
32823339|NCT04041310|Experimental|Cohort A - Dose-escalation|"Phase I. Part 1. Dose escalation cohort. Subjects treated with low dose or with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors."
32823340|NCT04041310|Experimental|Cohort B - Expansion Cohort Phase I|"Phase I. Part 1. Expansion cohort at RP2D. Subjects treated with RP2D dose of GAd20-209-FSP prime and MVA-209-FSP boosts, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic dMMR or MSI-H CRC, gastric, or G-E junction tumors."
32823341|NCT04041310|Experimental|Cohort C - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment. Subjects will be randomized with an allocation ratio 2:1 to Nous-209 vaccine plus pembrolizumab combination therapy versus pembrolizumab monotherapy.
33405206|NCT05204394|Experimental|VM-1500A-LAI 900mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 900mg i / m Q4W injections with the background of oral 2NRTIs QD.
33405207|NCT05204394|Other|Standard or Care|Any approved 1st line oral HIV treatment regimen
32823342|NCT04041310|Experimental|Cohort D - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who have had radiographic progression (PD) after having a best response of stable disease (SD) or better on/after anti-PD1 treatment. Nous-209 vaccine plus pembrolizumab combination therapy.
32823343|NCT03357354|Experimental|Obese Children in precarious situations|
32823344|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
32823345|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
32823346|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
32823347|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
32823348|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
32823349|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
32823350|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
32823351|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
32823352|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
32823353|NCT03359382|No Intervention|control|
32823354|NCT03359382|Experimental|exercise|
32823355|NCT03855904|Experimental|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
32823356|NCT03855904|Active Comparator|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
32823357|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32823358|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32823359|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
32823360|NCT04524936||obese patient with non-alcoholic fatty liver disease|
32823361|NCT04524936||obese patient without non-alcoholic fatty liver disease|
32823362|NCT04524936||control group|
32823363|NCT03819478|Placebo Comparator|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
32823364|NCT03819478|Active Comparator|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
32823365|NCT03819478|Active Comparator|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
32823366|NCT04524780|Experimental|left atrial appendage radiography|
32823367|NCT04524780|Experimental|intracardiac echocardiography guidance|
32823368|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
32823369|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
32823370|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
32823371|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
32823372|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
32823373|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
32823374|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
32823375|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
32823376|NCT04521660|Experimental|Intervention group|Patients in the intervention group will wear virtual reality glasses during coronary angiography.
33405208|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
33405209|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
32823377|NCT04521660|No Intervention|Control group|Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.
32823378|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
32823379|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
32823380|NCT04521504|Experimental|Biofeedback|Patients were treated with an experimental rehabilitation protocol, based on shoulder kinematic biofeedback.
32823381|NCT04521504|No Intervention|Control|Patients were treated with a standard rehabilitation protocol, based on hospital guidelines.
32823382|NCT05180500|Active Comparator|Q-GRFT Nasal Spray|Q-Griffithsin (Q-GRFT) nasal spray (7.5mg/mL). Two metered doses of 100μL into each nostril, total of 3mg Q-GRFT per administration, administered once daily for 14 consecutive days.
32823383|NCT05180500|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray. Two metered doses of 100μL into each nostril, administered once daily for 14 consecutive days.
32823384|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
33405210|NCT05065398|Experimental|HLX208|
32823385|NCT03366402||Influenza A|
32823386|NCT03366402||Influenza B|
32823387|NCT05159518|Experimental|PRT2527|PRT2527 will be administered by intravenous infusion
32823388|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
32823389|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
32823390|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
32823391|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
32823392|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
32823393|NCT04521192|Experimental|TR sequence group|
32823394|NCT04521192|Experimental|RT sequence group|
32823395|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
32823396|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
32823397|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
32823398|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
32823399|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
32823400|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
32823401|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
32823402|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
32823403|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
32823404|NCT04521036|Experimental|Convalescent plasma|Standard of care plus 500 mL of convalescent plasma from COVID-19 recovered donors
32823405|NCT04521036|No Intervention|Standard of care|Standard of care (Supportive care, oxygen, antibiotics, no convalescent plasma)
32823406|NCT04524624|Experimental|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.~Classification of stroke subtypes and mechanisms.~Evidence-based alerts and guidelines for early stroke management.~Guideline-recommended secondary stroke prevention strategies."
32823407|NCT04524624|No Intervention|Usual Care|Usual Care
32823408|NCT03366090||IBD patients|Biopsies for immunological analyses
32823409|NCT03366090||healthy controls|Biopsies for immunological analyses
32823410|NCT01624168|Placebo Comparator|Anxiety Management Education|
32823411|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
32823412|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
32823413|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
32823414|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
32823415|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
32823416|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
32823417|NCT03677128|No Intervention|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
32823418|NCT03365856||RA patients|As routinary clinical practice and observational study
32823419|NCT03642574|Experimental|PIMT methylation|Subjects will have blastocyst biopsy and whole genome DNA methylation sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. Only embryos with euploid chromosome will be transfered to the uterus. The outcome of all euploids transfers within 1 year will be followed up. During study, every subject will have at most one live birth.
32823420|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
32823421|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
32823422|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
32823423|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
32823424|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
32823425|NCT04520958|Experimental|Mindfulness of Breath|
32823426|NCT04520958|Experimental|Mindfulness of Pain|
33101975|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
32823427|NCT04520958|Active Comparator|Cognitive-Behaviorally Based Pain Psychoeducation|
32823428|NCT04520646|Experimental|empagliflozin|empagliflozin is added on the basis of the original treatment
32823429|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
32823430|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
32823431|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
32823432|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
32823433|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
32823434|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
32823435|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
32823436|NCT04520568|Active Comparator|HFNC group|For HFNC group, F&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
32823437|NCT04520568|Placebo Comparator|control group|induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
32823438|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
32823439|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
32823440|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
32823441|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
32823442|NCT04523064|Active Comparator|SGLT2i (empagliflozin)|Empagliflozin 25 mg 1 time day for three months
32823443|NCT04523064|No Intervention|Standard of care|Standard care treatment of diabetes patients in our center
32900962|NCT05250050|Experimental|Phenotypic resistance guided therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to phenotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
32823444|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~Written plan from sites detailing plans to change processes of care."
32823445|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
32823446|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
32823447|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
32823448|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
32823449|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
32823450|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
33405211|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
32823451|NCT04520880||Critically ill SARS-Cov2 patients|Critically ill patients with acute hypoxemic respiratory failure defined as those admitted to ICU and receiving mechanical ventilation (invasive or non-invasive) or high-level supplemental oxygen (via a high-flow nasal cannula or non-rebreathing face mask at a flow rate of 15 L per min or greater), at or during hospitalization
32823452|NCT04520880||Hospitalized non-critically ill SARS-Cov2 symptomatic patients|Hospitalized non-critically ill SARS-Cov2 symptomatic patients
32823453|NCT04520724|Experimental|Study group|"30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (ca. 300 kcal; no less than 12 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (12 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
32823454|NCT04520724|Placebo Comparator|Placebo group|"30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (ca. 300 kcal; no less than 6 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (6 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
33405212|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
33405213|NCT05065008|Experimental|Cranberry juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) of cranberry juice daily for 3 weeks.
32823455|NCT03477604|Experimental|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
32823456|NCT03477604|Active Comparator|Standard PTA|
32823457|NCT04520802||POCD|Patients with postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
32823458|NCT04520802||no POCD|Patients without postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
32823459|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
32823460|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
32823461|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
32823462|NCT03365466||Group D|Patients who did not receive any treatment.
32823463|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
33405214|NCT05065008|Experimental|Apple juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) apple juice with matching sugar and calories daily for 3 weeks.
32823464|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
32823465|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
32823466|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
32823467|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
32823468|NCT04522752||Gastric Polyp|The included subjects were patients with benign epithelial gastric polyps confirmed by gastroscopy and biopsy pathology. The size and pathology type of polyps were identified. Gastroscopy and biopsy were followed up six, twelve and eighteen months later to observe the relationship between the size, pathology types of polyps and the development of gastric polyps. Other factors including the relationship between helicobacter pylori infection and polyp type were also observed.
32823469|NCT04522830|Experimental|BTL-TML-COVID|BTL-TML-COVID
32823470|NCT04522830|Placebo Comparator|Placebo|Placebo
32823471|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
32823472|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
32823473|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
32823474|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
32823475|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
32823476|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
32823477|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
32823478|NCT04522986|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
32823479|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
32823480|NCT04522362|Sham Comparator|Control task-|The Control Task was implemented to ensure the specificity of the psychological stress effects had on study outcomes. Therefore, the Control Task had a similar procedure and the same duration of the TSST, lacking except for only the psychologically stressful component. The control task consisted of (a) Participants had a 5-min a preparation section and anticipation phase (5 min ), (b) a reading task where they had to. Then, all participants had to be read a simple text in a low voice (5 min), and (c) an arithmetic section where they were asked to perform an easy mathematical calculation (5 mins).
32900963|NCT05250050|Active Comparator|Empiric therapy|Esomeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g bid (no penicillin allergy) OR tetracycline 0.5g qid (penicillin allergy) for 14 days
33317837|NCT05670314|Experimental|Diet + exercise intervention arm|The participants in this arm will be required to take 20g of inulin (N=30) for a period of 6 weeks and doing exercise at the same time.
33317838|NCT04717388|Experimental|impact of tinnitus on executive cognitive functioning|
33317839|NCT04717388|Experimental|impact of tinnitus on reorganization of functional/ structural brain connectivity maps|
33317840|NCT05670002|Other|Intervention|Taking milk supplement
33317841|NCT01204190|Experimental|Arm 1|
33317842|NCT01204190|Experimental|Arm 2|
33317843|NCT01204190|Experimental|Arm 3|
33317844|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
33317845|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
33317846|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
33317847|NCT02965898|Active Comparator|Vitamin D 100ug|The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.
33317848|NCT02965898|Placebo Comparator|Vitamin D 10ug|Placebo dose. Minimal recommended dose
33317849|NCT03843866|Active Comparator|Suture & steri-strips|
33317850|NCT03843866|Active Comparator|Adhesive Glue|
33317851|NCT01204346|Experimental|MBT group|mentalization based treatment program
32823481|NCT04522362|Experimental|Experimental Task- Trier Social Stress Task|"The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, & Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about their dream job in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible."
32823482|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
32823483|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
32823484|NCT03365232|Experimental|non custom base attachment|
32823485|NCT03365232|Active Comparator|custom base attachment|
32823486|NCT04444986|Experimental|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
32823487|NCT04444986|Experimental|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
32823488|NCT04444596|Other|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
32823489|NCT04444674|Experimental|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
32823490|NCT04444674|Placebo Comparator|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
32823491|NCT04444674|Experimental|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
32823492|NCT04444674|Placebo Comparator|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
32823493|NCT04444674|Experimental|Group 2b- IP|Participants will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
32823494|NCT04444674|Placebo Comparator|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
32823495|NCT04444674|Experimental|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
32823496|NCT04444674|Placebo Comparator|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
32823497|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
32823498|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
32823499|NCT02519166|Other|Patients with chronic wounds|
32823500|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
32823501|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
32823502|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
32823503|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
32823504|NCT03364998|Experimental|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
32823505|NCT03364998|Experimental|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
32823506|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
32823507|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
32823508|NCT04520022|Experimental|FURESTEM-CD Inj|
32823509|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
32823510|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
32823511|NCT03364920||normal level of serum maresin-1|
32823512|NCT03364920||abnormal level of serum maresin-1|
32823513|NCT04509102|Active Comparator|Active|Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
32823514|NCT04509102|Placebo Comparator|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.
32823515|NCT04520334|Other|Zhineng Qigong|Zhineng Qigong intervention
32823516|NCT04508946|Active Comparator|Hydrocortisone Monotherapy|Hydrocortisone Monotherapy
32823517|NCT04508946|Experimental|triple therapy regimen (vitamin c - thiamine- hydrocortisone)|triple therapy regimen (vitamin c - thiamine- hydrocortisone)
32823518|NCT03364842|Experimental|F group|Furosemide group
32823519|NCT03364842|No Intervention|C group|Control group
32823520|NCT04443972|Experimental|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
32823521|NCT04443972|Experimental|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
32823522|NCT03356184|Experimental|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
32823523|NCT03356184|Active Comparator|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
32823524|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
32823525|NCT04524858|Experimental|ATI-450|Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
32823526|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
32823527|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
32823528|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
32823529|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
32823530|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
32823531|NCT04518696|Experimental|suprachoroidal buckling treatment group|suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
32823532|NCT04517916||Zephyr Valve treatment|Patients undergoing the Zephyr Valve treatment for emphysema/COPD
32823533|NCT04509258|Placebo Comparator|control group|this group will have the standard and routine therapy of treatment of acute Aluminium Phosphide poisoning immediately after admission according to PCCA guidelines
32823534|NCT04509258|Active Comparator|N- acetyl cysteine grouo|N-acetyl cysteine will be given at dose of 300mg/kg/d IV in the first day then 150 mg/kg/d IV in addition to standard of care according to PCCA guidelines
32823535|NCT04509258|Active Comparator|Acetyl L-carnitine group|Acetyl L-carnitine will be given at dose of 50 mg/kg IV once to be followed by additional doses of 15 mg/kg IV q4hr infused over 30 min. standard of care according to PCCA guidelines will also be provided
32823536|NCT04509258|Active Comparator|Medicated paraffin oil group|Gastric decontamination with sodium bicarbonate (NaHCO3; 44 mEq, orally) and medicated paraffin oil (200 mL) will be administered in addition to standard of care according to PCCA guidelines
32823537|NCT03364530|Other|Gemcitabine-Oxaliplatin Regimen|
32823538|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
32823539|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
32823540|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
32823541|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
32823542|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
32823543|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
32823544|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
32823545|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
32823546|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
32823547|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
32823548|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
32823549|NCT03364374||Controls|Healthy controls with no history of stroke
32823550|NCT03364218|Experimental|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
33101976|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
33101977|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
32823551|NCT03364218|No Intervention|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
32823552|NCT04444284|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
32823553|NCT04444284|Placebo Comparator|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
32823554|NCT04444284|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
32823555|NCT04444284|Placebo Comparator|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
32823556|NCT04444284|Experimental|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
32823557|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
32823558|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
32823559|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s~180-second phase of rest between stimuli~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT~120-s check after the stimuli"
32823560|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.~180 second phase of rest between stimuli~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT~120-s check after the stimuli"
32823561|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
32823562|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
32823563|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
32823564|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
32823565|NCT04508868|Experimental|Brief Behavioral Activation with Mental Imagery|Four weekly sessions of Brief Behavioral Activation with Mental Imagery.
32823566|NCT04508868|Placebo Comparator|Minimal Attention Control Intervention|Four weeks with weekly follow-up calls.
32823567|NCT04524468||hemodialysis patients|end-stage renal disease patients on hemodialysis
32823568|NCT04524468||peritoneal dialysis patients|end-stage renal disease patients on peritoneal dialysis
32823569|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
32823570|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
32823571|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
32823572|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
32823573|NCT04444206|Experimental|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
32823574|NCT04444206|No Intervention|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
32823575|NCT04524078|Experimental|Intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
32823576|NCT04524078|No Intervention|Non intensive integrated intervention care program|
32823577|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
32823578|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
32823579|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
32823580|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
32823581|NCT04508400|Experimental|a single dose of fosaprepitant|Participants received a single dose of fosaprepitant (age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
32823582|NCT04508400|Placebo Comparator|a single dose of matched placebo|Participants received a single dose of matched placebo for fosaprepitant administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
32823583|NCT04508478|Experimental|Aerobic training|
32823584|NCT04508478|Active Comparator|Resistance training|
32823585|NCT04508478|Placebo Comparator|Control|
32823586|NCT04524312|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
32823587|NCT04524312|Active Comparator|K-Mod|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Bioimplanti K-MOD prosthesis
32823588|NCT04524156|Active Comparator|COVIS 19 positive|
32823589|NCT04524156|Sham Comparator|COVID 19 negative|
32823590|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
32823591|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
32823592|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
32823593|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
32823594|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
32823595|NCT04516356|Experimental|Intervention Arm|Korean hand acupressure will be applied to the experimental group 30 minutes before the induction of anesthesia. After determining the pressure / therapy points associated with nausea and vomiting on the patient's hand, a massage will be made for 3-5 minutes with a diagnostic stick. The seeds will then be fixed at these points with a paper patch. Seeds will not be removed for 24 hours. It will be massaged for 3-5 minutes by pressing the seeds every 3-4 hours and making a curling motion at the same time. At the end of the 24th hour, the application will be terminated.
32823596|NCT04516356|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
32823597|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
32823598|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
32823599|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
32823600|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
32823601|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
32823602|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
32823603|NCT04515966|Active Comparator|Ultrasound-guided steroid injection|Participants with CTS who meet the inclusion criteria are randomized to two groups. One group (or arm) will receive an ultrasound-guided steroid injection in the vicinity of the median nerve within the carpal tunnel. A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine is injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
32823604|NCT04515966|Active Comparator|Wrist splint|Participants in this arm are treated with a wrist splint.
32823605|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32823606|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
32823607|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33317852|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
32823608|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32823609|NCT03355404|Experimental|"Standing Patient"|
32823610|NCT03355404|No Intervention|"Standardized management in stretcher"|
32823611|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
32823612|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
33317853|NCT03841604|Experimental|Experimental|Safinamide methanesulfonate film coated tablets once daily
32823613|NCT04504656||1|open surgery
32823614|NCT04504656||2|minimally invasive surgery
32823615|NCT04507932|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
32823616|NCT04504110|Experimental|Epithelial ovarian cancer|68Ga-FAPI-04 and 18F-FDG PET/CT
32823617|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
32823618|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
32900964|NCT05500248|Experimental|Leave-In-Situ Arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
32823619|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
32823620|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
32823621|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
32823622|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
32823623|NCT04515108||Group 1 (Pregnants with COVID-19)|Study group included pregnant women with clinically confirmed COVID-19.
32823624|NCT04515108||Group 2 (Pregnants without COVID-19)|Control group consisted of healthy pregnant women in the same number and same gestational week with the Study group.
32823625|NCT04513470|Experimental|COVID-19|Five subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
32823626|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
32823627|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
32823628|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
32823629|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
32823630|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
32823631|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
32823632|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
32823633|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
32823634|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
32823635|NCT03350178|Experimental|treated patients|Treated wit FMT
32823636|NCT04513392|Active Comparator|KTP laser treatment|All participants will complete a paper Voice Handicap Index-10 (VHI-10) questionnaire and laryngeal stroboscopy examination at baseline. Local anesthesia will be administered as per standard of care for in-office laryngeal procedures. KTP laser will be utilized to ablate the lesion of interest. Immediately following the procedure, participants will complete a VAS pain scale on paper. Participants will be asked to exercise 3 days of absolute voice rest following the procedure. All patients will have follow-up clinic appointments on POD 7, POD 30, and POD 90 after surgery. At each of the follow-up visit, the patients will fill out a paper VHI-10 questionnaire and undergo stroboscopic examination to assess vocal fold vibratory properties and closure, as well as residual lesions. During the first week post procedure, the participants will continue to complete a daily VAS at home for pain assessment.
32823637|NCT04513392|Experimental|BL laser treatment|The only difference in study procedures between the experimental arm and the control arm is that the experimental arm will use the BL laser. The post-operative instructions and follow-up schedule are identical.
32823638|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
33101978|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
33101979|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
32823639|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
32823640|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria~Type of procedure~Age~ASA score~BMI~Duration of procedure (as percentile for this procedure)~Diabetes~Sex"
33101980|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
32823641|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
32823642|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
32823643|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
33101981|NCT02923154|Experimental|MT-3995|
33101982|NCT02923154|Placebo Comparator|Placebo|
33101983|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
33101984|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
32823644|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
32823645|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
32823646|NCT04512612|Active Comparator|Dye based Chromoendoscopy|The patients enrolled in this group will undergo pan-colonic chromoendoscopy evaluation.
32823647|NCT04512612|Active Comparator|High Definition White Light Endoscopy|The patients enrolled in this group will undergo high definition white light endoscopy based evaluation
32823648|NCT04513158|Experimental|Treatment Arm|Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.
32823649|NCT01629784|Other|CLE and sun counseling|
32823650|NCT03350022|Experimental|Sham Feeding|
32823651|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
32823652|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
32823653|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
32823654|NCT02230696|Active Comparator|Reference Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
32823655|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
32823656|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
32823657|NCT03353454|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
32823658|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
32823659|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
33101985|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
33101986|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
32823660|NCT04507620||cervical neck collar|
32823661|NCT04507620||head blocks strapped on the backboard|
32823662|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
32823663|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
32823664|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
32823665|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
32823666|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
32823667|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
32823668|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~Moderate or severe neonatal encephalopathy~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
32823669|NCT03122808||Control|"The inclusion criteria will be:~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~Admission to the neonatal unit~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
32823670|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
32823671|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
32823672|NCT02509546|Experimental|Treatment (8-chloro-adenosine)|Patients receive 8-chloro-adenosine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32823673|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
32900965|NCT05500248|Active Comparator|Standard arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
32900966|NCT05499390|Experimental|AK112|Subjects receive AK112 monotherapy intravenously (IV), selected dose.
33101987|NCT03292419|Other|Topography guided LASI|
32823674|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
32823675|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
32823676|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
32823677|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
32823678|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
32823679|NCT04503798|Experimental|Online Goal Management Training (GMT)|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
32823680|NCT04503798|No Intervention|Treatment-as-usual control group|Participants randomized to this arm will receive no additional information or access to the intervention program. They will continue to receive treatment-as-usual from their care providers.
32823681|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
32823682|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
32823683|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
32823684|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
32823685|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
32823686|NCT03354780||non endometriosis|Survey on first pregnancy
32823687|NCT04443894|Active Comparator|PECS block|
32823688|NCT04443894|Active Comparator|local infiltration|
32823689|NCT03353142|Experimental|Equal Breathing|
32823690|NCT01631110|Experimental|Elderly subjects aged over 60 years|
32823691|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
32823692|NCT04507698|Experimental|Supervised Exercise Arm|If participants are placed in the Supervised Exercise Group, they will attend supervised group exercise sessions, which are individually tailored to the participants physical condition, at least once a week, every week for the first year of the study. They will be asked to exercise 3 times a week.
32823693|NCT04507698|No Intervention|Self-Directed Exercise Arm|If Participants are placed in the Self-directed Exercise Group, they will receive usual medical care (standard of care) and be asked to follow their usual exercise and lifestyle routine. They will receive supportive care in the form of newsletters, covering a variety of topics including pain management, bone health, goal setting, taking control of life, and more.
32823694|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
32823695|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up"
32823696|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
33101988|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
33101989|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
33101990|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
33101991|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
33101992|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
33101993|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
33317854|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily
32823697|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
33101994|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
33101995|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
33101996|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
33317855|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
33317856|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
32823698|NCT04503876|Active Comparator|Decremental PEEP titration following an ARM|PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.
32823699|NCT04503876|Active Comparator|Incremental PEEP titration without any previous ARM|PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.
32823700|NCT04507542|Experimental|Enriched Music-Supported Therapy group|Participants in the eMST-group will follow a 10-week program of Enriched Music-Supported Therapy. The program comprises 3 individual self-training sessions and 1 group session per week (total program duration: 40 hours).
32823701|NCT04507542|Active Comparator|Control group|Participants in the control intervention group will follow the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009). They will be asked to complete 4 weekly one-hour session for 10 weeks (total program duration: 40 hours).
32823702|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
32823703|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
32823704|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
32823705|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
32823706|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
32823707|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
32823708|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
32823709|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
32823710|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
32823711|NCT02000284||General ASD|150 general ASD children
32823712|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
32823713|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
32823714|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
32823715|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
32823716|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
32823717|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
32823718|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
32823719|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
32823720|NCT01636102|Experimental|Arm 1|
32823721|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
32823722|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
32900967|NCT05499390|Active Comparator|Pembrolizumab|Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.
33405215|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
32823723|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
33317857|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
33317858|NCT02798042||Patient population|Patients undergoing bariatric surgery
32823726|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
32823727|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
32823728|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 1, 14 and 30 after stroke to assess the non heme iron levels on MRI.~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
32823729|NCT04507386|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
32823730|NCT04507386|No Intervention|Control|The control group will receive regular medical care and advice on healthy lifestyle, including physical activity and healthy eating recommendations
32823731|NCT03349554|Experimental|"standardized meditation technique body-scan"|
32823732|NCT04506996|Experimental|Intervention Group - Receiving Text Messages|"The 16-weeks text-messaging intervention centered around 8 goal topics: eating only when hungry, increasing PA, eating a lower fat diet, eating less sugar and reducing calories from beverages, exercising more, eating a balance diet, portion control, and making healthier food choices in social situations.~Messaging~Sun evening: asked to pick 1 of 3 goal topics~Mon morning: received a goal to focus on for the week~Mon evening: asked whether plans were made to reach the goal~Wed morning: received a tip to help reach goal~Wed evening: reminded that if having cravings, text tip to automatically receive a tip~Fri morning: received end of the week congratulations, encouragement to keep goals in mind over the weekend~Fri evening: asked for weight, congratulated if lost weight, or encouraged if no weight lost"
32823733|NCT04506996|Active Comparator|Control Group - Written Messages|"Participants in the control group, received a printed copy of the same messages that the intervention group received. However, the first eight-weeks' worth of messages and craving tips were given after the baseline assessment, and the rest were given after the first follow-up assessment (~ 8 weeks post randomization).~The messages for each week were clearly laid out and labeled. Participants were given spaces to record their answers (i.e. to which goal they were selecting for each week). The study staff reviewed the first week's messages together with the study participants to get the participants comfortable with the format that the printed messages were presented in."
32823734|NCT04509882|Experimental|bear bile pill|Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).
32823735|NCT04509882|Placebo Comparator|placebo|Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).
32823736|NCT04509960|No Intervention|proseal laryngeal mask insertion|no intervention
32823737|NCT04509960|Experimental|proseal laryngeal mask insertion with laryngoscope|with the help of direct laryngoscopy
32823738|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
32823739|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
32823740|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
32823741|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
32823742|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
32823743|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
32823744|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
32823745|NCT03349398|Active Comparator|the group of Roux-en-Y|
32823746|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
32823747|NCT01585402|Experimental|Etidronate Treatment for Arterial Calcifications due to Deficiency in CD73 (ACDC)|Participants diagnosed with Arterial Calcifications due to Deficiency in CD73 (ACDC) will receive Etidronate. Etidronate will be administered orally at total dose of 20mg/kg daily x 14 days, followed by 10 weeks off study drug (12 weeks = one cycle). Participants may receive up to 12 cycles of etidronate.
33317859|NCT02796170|Active Comparator|Dapagliflozin|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
33317860|NCT02796170|Active Comparator|Placebo|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
33317861|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
33317862|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
33317863|NCT02725658|Other|DOSI|
33317864|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
32823748|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
32823749|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
32823750|NCT01636414|Active Comparator|Hemovac drain|
32823751|NCT01636414|Active Comparator|Re-infusion drain|
32823752|NCT01636414|Active Comparator|Tranexamic drain|
32823753|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
32823754|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
32823755|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
32823756|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
32823758|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
32823759|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
32823760|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
32823761|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
32823762|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
32823763|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
32823764|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
32823765|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
32823766|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
32823767|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
32823768|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
32823769|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
32823770|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
32823771|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
32823772|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
32823773|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
32823774|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
32823775|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
32823776|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
32823777|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
32823778|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
32823779|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
32823780|NCT01640548||Cohort|
32823781|NCT04502628|Experimental|HBOT group|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished.
32823782|NCT05473338||CRPS (Complex Regional Pain Syndrome)|Participants with CRPS (Complex Regional Pain Syndrome))
32823783|NCT05473338||Healthy|Healthy individuals
33101997|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
32823784|NCT04443270|Experimental|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
32823785|NCT04443270|No Intervention|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
32823786|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
32823787|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
32823788|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
32823789|NCT01598350|Experimental|Orthotic|Orthotic Use
33317865|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
32823791|NCT01598428|Other|cataract|
32823792|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
32823793|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
32823794|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
32823795|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
32823796|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
32823797|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
32823798|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
32823799|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
32823800|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
32823801|NCT01598740|Experimental|CLP with spironolactone|
32823802|NCT01598740|Experimental|CLP without spironolactone|
32823803|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
32823804|NCT05419050|Experimental|treatment|treatment arm
32823805|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
32823806|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
32823807|NCT04503642||Intervention Group|The intervention consisted in the closure of the abdominal wall and skin by a second surgical team which included a board-certified surgeon and a resident.
32823808|NCT04503642||Baseline Group|During the baseline period, closure of the abdominal wall was performed by the main surgical team, the same team that performed the whole surgery.
32823809|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
32823810|NCT01600222|Experimental|LEO 90100|
32823811|NCT05062096|Other|Group 1: BRAF-mutated metastatic patients treated with 1st line targeted therapy|BRAF-mutated metastatic patients treated with 1st line targeted therapy
33317866|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
32823812|NCT05062096|Other|Group 2: Metastatic patients treated with 1st line immunotherapy|Metastatic patients treated with 1st line immunotherapy
32823813|NCT05062096|Other|Group 3: BRAF-mutated patients treated with adjuvant targeted therapy|BRAF-mutated patients treated with adjuvant targeted therapy
32823814|NCT05062096|Other|Group 4: Patients treated with adjuvant immunotherapy|Patients treated with adjuvant immunotherapy
32823815|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
32823816|NCT00709098|Experimental|iloprost power 15|iloprost power 15
32823817|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
32823818|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
33405216|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
32823819|NCT04506450|Active Comparator|Peripheral nerve block|The participant will receive a combination of lumbar plexus block, sciatic nerve block, lateral femoral cutaneous nerve block and lateral branch of iliohypogastric nerve block
32823820|NCT04506450|Active Comparator|Spinal anesthesia|The participant will receive a combination of spinal anesthesia and lumbar plexus block
32823821|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
32823822|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
32823823|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
32823824|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
32823825|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
32823826|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
32823827|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
32823828|NCT05281692||Positive|Enhanced Preservation Media (EPM-IX)
32823829|NCT05281692||Control|Med Schenker's STM viral media
33317867|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
33317868|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
33317869|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
33317870|NCT04702724|Experimental|Experimental group|
33317871|NCT03841994||Preterm infant cohort|Preterm infants who were born <28 weeks of gestational age
33317872|NCT04681274||patient with hepatocellular carcinoma|Phenotype signature database building Image features extraction and clustering
32823830|NCT04505904|Experimental|Syntocinon First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
32823831|NCT04505904|Placebo Comparator|Placebo First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.
32823832|NCT04505982||Tocilizumab intravenous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, intravenous
32823833|NCT04505982||Tocilizumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, subcutaneous
32823834|NCT04505982||Sarilumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with sarilumab, subcutaneous
32823835|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
32823836|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
32823837|NCT04505514|Experimental|Intravenous Iron Group|
33317873|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
33317874|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus enhanced transition services.
33317875|NCT00049842|Experimental|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
33317876|NCT00049842|No Intervention|Untreated Control|
33317877|NCT00307151|Experimental|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
33317878|NCT00307151|Experimental|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
32823838|NCT04505514|Active Comparator|Oral Iron Group|
33317879|NCT00307151|Experimental|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
33317880|NCT00307151|Experimental|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
33317881|NCT03979157|Experimental|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
33317882|NCT03978923||the drill-inserted implants (G1)|
33317883|NCT03978923||the ultrasonic device- inserted implants (G2)|
33405217|NCT05031624|Experimental|CDX-0159|Subjects will receive a single dose of CDX-0159
33405218|NCT05031624|Placebo Comparator|Normal Saline|Subjects will receive a single dose of normal saline
32823839|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
32823840|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
32823841|NCT05256732|Experimental|AT-527|
32823842|NCT05256732|Placebo Comparator|Placebo|
32823843|NCT05256732|Experimental|AT-527 BID|
32823844|NCT05256732|Experimental|AT-527 single dose fasted/fed|
32823845|NCT05208918|Active Comparator|Epidural steroid group|Transforaminal steroid application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
32823846|NCT05208918|Active Comparator|PRF plus steroids group|Pulsed radiofrequency plus Depo-Medrol (steroid) application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
32823847|NCT03348384|Experimental|Cocaine use disorders|PET scan
32823848|NCT03348384|Experimental|Controls|PET scan
32823849|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
32823850|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
32823851|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
32823852|NCT04505748|Experimental|Self-transfusion group|Patients to whom a self-transfusion device has been used after total knee arthroplasty.
32823853|NCT04505748|No Intervention|Control group|Patients to whom conventional drains have been used after total knee arthroplasty.
32823854|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
32823855|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
32823856|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
32823857|NCT05585502|Experimental|Training group|T2D patients and controls in the experimental group will undergo 50 telemedicine MOS sessions (15 minutes/day, 5 days/week, 10 weeks). Before the training period all subjects will participate to three different experimental sessions: during the first session a blood sample will be withdrawn and a skin biopsy will be taken; during the second session, muscle-tendon stiffness and muscle function will be evaluated; during the third session, the energy cost of walking will be determined at different speeds. After the training period and 5 weeks after the end of the training period, all subjects will repeat the second and the third sessions.
32823858|NCT05585502|No Intervention|Control group|T2D patients and controls in the control group will not perform any specific training. However, they will participate to the same three sessions as the experimental group.
32823859|NCT04503330|Experimental|Patients with iatrogenic PUJO|patients with iatrogenic PUJO or long segment ureteric stricture disease for safety and efficacy of using buccal graft for repair
32823860|NCT05585424|Experimental|Experimental Group|Patients in the experimental group were paired so that each patient with MCI faced a patient with ModCI. During the sessions, two therapists performed the upper limb activities that only the MCI patients could see and they performed them by imitation
32823861|NCT05585424|No Intervention|Control group|The CG was assessed at baseline and after one month and continued with their usual activities in the nursing home.
32823862|NCT05139732||control|Healthy participants
32823863|NCT05139732||Functional Neurological Disorder (FND)|People with the subtype functional paralysis
32823864|NCT05139732||Spinal Cord Injury (SCI)|Incomplete and complete paralysis with the ability to hold a pen
32823865|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
32823866|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
32823867|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
32823868|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
32823869|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
32823870|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
32823871|NCT04505202|Experimental|Experimental group|0.12% chlorhexidine gluconate
32823872|NCT04505202|Placebo Comparator|Placebo group|sodium bicarbonate
32823873|NCT04505124|Experimental|FutureMe|"Participants use the FutureMe app for 12 weeks. The app has the following functionality:~Opportunity to personalize one's avatar~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~Feedback on health behaviors represented through a Future-self avatar (consequential and visual feedback)~Individualized shopping tipps"
32823874|NCT04505124|Active Comparator|Control|"Participants use the a control app for 12 weeks. The control app has the following functionality:~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~Feedback on health behaviors represented through conventional dashboards (numeric & text feedback)~Individualized shopping tipps"
32823875|NCT04504890||Adults - Diagnosis|Adults seeking treatment for an attention-related disorder
32823876|NCT04504890||Adults - Prescribed|Adults who have been diagnosed with ADHD and prescribed medication treatment for the disorder
32823877|NCT04504890||Children - Diagnosis|Children seeking treatment for an attention-related disorder
32823878|NCT04504890||Children - Prescribed|Children who have been diagnosed with ADHD and prescribed medication treatment for the disorder
32823879|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
32823880|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
32823881|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
32823882|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
32823883|NCT03122028|Experimental|LAmbre closure system|
32823884|NCT05585346|Experimental|PBMT Group|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
32823885|NCT05585346|Active Comparator|Control Group|Control group were received prednisolone acetate treatment, took prednisolone acetate 24 mg once a day for 1 week.
32823886|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
32823887|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
32823888|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
32823889|NCT05098704|Experimental|clopidogrel|
32823890|NCT05098704|Placebo Comparator|placebo|
32823891|NCT05585268|Active Comparator|MedSafer-supplemented medication reconciliation|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
32823892|NCT05585268|No Intervention|Standard of care medication reconciliation|This unit will serve as the control unit where standard of care will be provided and no deprescribing reports nor brochures will be delivered. MedSafer reports will be generated but withheld from the clinical team. This will serve as a comparator to determine if the intervention unit was more successful in deprescribing compared to this control unit.
32823893|NCT05584956|Active Comparator|Group 1|n=22): Patients will receive traditional treatment and L- carnitine 50mg/kg/day orally (maximum dose 3g per day)
32823894|NCT05584956|Active Comparator|Group 2|n=22): Patients will receive traditional treatment and Sildenafil 0.25mg/kg/dose every 6 h orally (maximum dose 60 mg per day)
32823895|NCT04502004|No Intervention|Control Group (CG)|"Receive the recommendations of the Clinical Practice Guidelines which consist of: advice on smoking cessation smoking, leaflet with information (tobacco components, treatments to reduce withdrawal syndrome).~Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
32823896|NCT04502004|Experimental|Experimental Group (EG)|"Receive codes to download the App NoFumo+ . Is a mHealth that offer a CBT program. Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
32823897|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
32823898|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
32823899|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
32823900|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
32823901|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
32823902|NCT04504578|Experimental|patients with progressive keratoconus with thin corneas|patients with progressive keratoconus with thin corneas , with thickness less than 400 micron ,will do conventional cross linking but with putting contact lens over the cornea ( will receive Contact lens assisted corneal cross liking )
32823903|NCT01797965|Experimental|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
32823904|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
32823905|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
32823906|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
32823907|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
32823908|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
32823909|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
32823910|NCT05584878|Experimental|Group I|
32823911|NCT05584878|Experimental|Group II|
32823912|NCT05584878|Active Comparator|Group III|
32823913|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
32823914|NCT01601860|Active Comparator|Control|Active Comparator: Control Group Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
32823915|NCT01601860|Experimental|Intervention Group|Experimental: Intervention Group Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: Walking (with cervical dilation between 4 and 5 cm) Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm) Shower (with dilation> 7 cm);
32823916|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
32823917|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
32823918|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
32823919|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
32823920|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
32823921|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
32823922|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
32823923|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
32823924|NCT04966338|Experimental|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
32823925|NCT04966338|Active Comparator|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
32823926|NCT05046496|No Intervention|Observational arm|Patients recruited to this arm will undergo no intervention.
32823927|NCT05046496|Active Comparator|Interventional arm|Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement
32823928|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
32823929|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
32823930|NCT05584644||Palbociclib plus hormonal treatment - first line treatment|Patients who initiated Palbociclib + hormonal therapy in the first line treatment
32823931|NCT05584644||Palbociclib plus hormonal treatment - second line treatment|Patients who initiated palbociclib plus hormonal treatment in the second line treatment
32823932|NCT04892706|Experimental|IDP-126 Gel|
32823933|NCT04892706|Placebo Comparator|IDP-126 Vehicle Gel|
32823934|NCT04892706|Active Comparator|Epiduo® Forte Gel|
32823935|NCT04884594|Experimental|AAV8-hCocH Low dose: 2e12 vg/kg|Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
32823936|NCT04884594|Experimental|AAV8-hCocH Medium dose: 6e12vg/kg|Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
32823937|NCT04884594|Experimental|AAV8-hCocH High dose: 2e13 vg/kg|Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
32823938|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
32823939|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
32823940|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
32823941|NCT01821677|Experimental|Low Dose Danazol|Capsules, 0.5 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
32823942|NCT01821677|Experimental|High Dose Danazol|Capsules, 1.0 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
32823943|NCT01821677|Placebo Comparator|Placebo|Gelatin capsules, identical in appearance to the active capsules, filled with pharmaceutical grade lactose and magnesium stearate.
32823944|NCT04794582|Active Comparator|ProGrip® Mesh reinforcement|Once the closure has been completed in 2 muscle-aponeurotic planes with continuous synthetic suture (Monomax® USP 0), the closure will be completed by placing the ProGrip® macroporous polypropylene monofilament mesh in supra-aponeurotic position using the surface with the polylactic acid microgrips, which act as Velcro, in direct contact with the superficial aponeurotic plane constituted by the aponeuroses of the greater oblique muscle and the crescentic line of the anterior rectus abdominis muscle. The polylactic acid microgrips provide immediate fixation, making additional fixation with stitches unnecessary, which makes the technique very easy to use and systematize among the different surgeons of the transplant team. The procedure is completed with the placement of a low caliber round Jackson-Pratt subcutaneous drain (10F) connected to a vacuum system that will be removed on post-transplant day 2 or 3
32900968|NCT04243044|Experimental|Intensity 1 (0.8x reflex threshold, continuous, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
32900969|NCT04243044|Experimental|Intensity 2 (0.8x reflex threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at two sites at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
33317884|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
33317885|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
33317886|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Subjects > 75 years old:~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
33317887|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects > 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~Decadron~Dexamethasone Intensol~Dexpak~Taperpak"
33317888|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
33317889|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
32823945|NCT04794582|No Intervention|Monomax® USP 0 2 planes closure|The control group will proceed according to standard clinical practice with closure using the technique in 2 muscle-aponeurotic planes with very long-term (3 months) absorbable synthetic continuous suture of poly(4-hydroxybutyrate), monofilament, elastic (Monomax® USP 0) according to the small-bites technique. In order to achieve masking of the participating subject, a small-bore (10F) Jackson-Pratt drain connected to a vacuum system will be placed in the subcutaneous space at the end of the procedure in a manner similar to the intervention group. In both treatment groups, the subcutaneous drain will be removed on post-transplant day 2 or 3.
32823946|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
32823947|NCT01797731|Active Comparator|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
32823948|NCT01797731|Experimental|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
32823949|NCT05651958|Experimental|Pranayma Breathing Technique|Pranayma Breathing Technique protocol includes 15 breaths in the morning and 15 breaths in evening for atleast weeks.
32823950|NCT05651958|Active Comparator|Conventional Treatment|Long-acting beta-2 agonist, nebulizers and long acting anti-mucosic drugs.
32823951|NCT04785456|Experimental|Active TBS|"Daily, 4-week, 5-days per week treatment sessions, each consisting of:~First, intermittent TBS (iTBS) over the L-DLPFC: triplet 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, (600 pulses per session, total duration of 3 min 9 s), then continuous TBS (cTBS) over the R-DLPFC as 40 s uninterrupted bursts (600 pulses). Intensity at 120% resting motor threshold (RMT)."
32823952|NCT04785456|Sham Comparator|Sham TBS|Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
32823953|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
32823954|NCT02922816|Placebo Comparator|Control arm|The control arm will participate in the bowel preparation and stool or perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive microbiota restoration transplant (MRT) for up to two cycles, as necessary (Cycles 1 and 2).
32823955|NCT02922816|Experimental|Fecal Microbiota Transplant (FMT)|The experimental arm will participate in the bowel preparation, stool or perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).
32823956|NCT00709722|Experimental|1|NKT-01
32823957|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
32823958|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
32823959|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|Placebo control with PBS, 1% sucrose and 4% mannitol
32823960|NCT01645306|Active Comparator|40 mg Revacept|low dose Revacept 40mg in PBS, 1% sucrose, 4% mannitol
32823961|NCT01645306|Active Comparator|120 mg Revacept|high dose revacept 120mg in PBS, 1% sucrose, 4% mannitol
32823962|NCT05584488||Inherited diseases of allergic inflammation or immune dysregulation|Patients and blood relatives with disorders of allergic inflammation and immune dysregulation.
32823963|NCT01820585|Placebo Comparator|Placebo|Tablets
32823964|NCT01820585|Active Comparator|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
32823965|NCT01820585|Active Comparator|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
32823966|NCT01820585|Active Comparator|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
32823967|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
32823968|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
32823969|NCT04741776|Experimental|Resilience Enhancement Skills Training|video-based family therapy
33317890|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
32823970|NCT04741776|Active Comparator|Standard of care|video-based individual therapy
32823971|NCT01797263|Experimental|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
32900970|NCT04243044|Experimental|Intensity 3 (0.8x reflex threshold, burst, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
33317891|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
32823972|NCT01797263|Active Comparator|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
32823973|NCT05584332|Placebo Comparator|Placebo|
32823974|NCT05584332|Experimental|4vHPV Vaccine|
32823975|NCT01602172|Experimental|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
32823976|NCT01602172|Active Comparator|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
32823977|NCT01602172|Active Comparator|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
32823978|NCT04733742|Experimental|Conbined treatment group|intravenous tenecteplase bridging with endovascular treatment
32823979|NCT04733742|Active Comparator|Endovascular treatment alone group|endovascular treatment alone
32823980|NCT05030272|Experimental|"Quit on the Go (formerly Learn to Quit)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum). Participants also receive technical smartphone coaching for the first 4 weeks of the study.
32823981|NCT05030272|Other|Brief Advice (Standard of Care)|Brief Advice and Combined Nicotine Replacement Therapy (patches and gum or lozenges) has been recommended by the US Clinical Practice Guidelines for patients with psychiatric illness. Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt. The intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum).
32823982|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.~rituximab and methotrexate"
32823983|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
32823984|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.~methotrexate and methylprednisolone"
32823985|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
32823986|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
32823987|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
32823988|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
32823989|NCT04500990||Single agent PD-1/PD-L1 inhibitor|Patients will receive single agent PD-1/PD-L1 inhibitor in a predefined group.
32823990|NCT04500990||Combined immunotherapy|Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
32823991|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
32823992|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
33317892|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
33317893|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
32823993|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
32823994|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
32823995|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
32823996|NCT05645484||18F-PFPN PET imaging|For clinically suspected or confirmed melanoma patients, targeted melanin-specific imaging 18F-PFPN PET/MR was performed. CT was instead when MRI was contraindicated. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
32823997|NCT05645484||18F-FDG PET imaging|For clinically suspected or confirmed melanoma patients, general metabolic imaging 18F-FDG PET PET/CT was performed. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
32823998|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
32823999|NCT04551300|Experimental|VS-505 500mg|VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
32824000|NCT04551300|Experimental|VS-505 750mg|VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
32824001|NCT04551300|Experimental|VS-505 1500mg|VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
32824002|NCT04551300|Experimental|VS-505 2250mg|VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
32824003|NCT04551300|Active Comparator|Sevelamer Carbonate 1600mg|Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
32824004|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
32824005|NCT04448262||G1 Asthma|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
32824006|NCT04448262||G2 Diabetes|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
32824007|NCT04448262||G3 Asthma plus diabetes|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
32824008|NCT04437186|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
32824009|NCT04437186|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
33317894|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
32824010|NCT04974580|Experimental|CoachingOnlyArm|Phone Coaching; no Digital Coaching, no NRT: This arm will receive only the two phone counseling calls which all other arms will receive.
32824011|NCT04974580|Experimental|DigitalArm|Phone Coaching + Digital Coaching; no NRT: This arm will receive digital content (text messages with links to online materials) in addition to to the two phone counseling calls which all arms will receive.
32824012|NCT04974580|Experimental|CoachingNRTArm|Phone Coaching + NRT; no Digital Coaching: This arm will receive Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
32824013|NCT04974580|Experimental|DigitalNRTArm|This arm will receive digital content (text messages with links to online materials) AND Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
32824014|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
32824015|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
32824016|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
32824017|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
32824018|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
32824019|NCT01797185|Experimental|SPARC1104 group 1|
32824020|NCT01797185|Experimental|SPARC1104 group 2|
32824021|NCT01797185|Experimental|SPARC1104 group 3|
32824022|NCT04231734|Experimental|All Subjects|Low tumor burden, treatment-naïve MCL
32824023|NCT04501848||Study|parents of obstructive sleep disordered breathing (OSDB) children before and after surgical treatment
32824024|NCT04501848||Control|A group of parents to healthy children comprised the control group.
33317895|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
33317896|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
33317897|NCT04614844|Experimental|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
33317898|NCT04614844|Active Comparator|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
33317899|NCT02618408|Experimental|Low dose SPN-810 (18 mg)|Oral
33317900|NCT02618408|Experimental|High dose SPN-810 (36 mg)|Oral
33317901|NCT02618408|Placebo Comparator|Placebo|Oral
32824025|NCT04501770|Experimental|M802|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
32824026|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
32824027|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
32824028|NCT04501692|Experimental|VivaSight|Intubated with a VivaSight-SL endotracheal tube.
32824029|NCT04501692|Active Comparator|Conventional|Intubated by videolaryngoscopy.
32824030|NCT04501068||Ambu AuraGain|Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.
32824031|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
32824032|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
32824033|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
32824034|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
32824035|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
32824036|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
32824037|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
32824038|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
32824039|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
32824040|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
32824041|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
32824042|NCT03346200|Active Comparator|20 mg tamoxifen|
32824043|NCT03346200|Experimental|10 mg tamoxifen|
32824044|NCT03346200|Experimental|5 mg tamoxifen|
32824045|NCT03346200|Experimental|2.5 mg tamoxifen|
32824046|NCT03346200|Experimental|1 mg tamoxifen|
32824047|NCT03346200|Placebo Comparator|0 mg tamoxifen|
32824048|NCT05584176|Experimental|Subject 14-65+ years of age|Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the Rapid SARS-CoV-2 Antigen Test.
32824049|NCT05584176|Experimental|At least 30 children between 2 and 13 years of age|Participants 2-13 years of age will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The parent or legal guardian of the child will collect an anterior nasal swab sample from the child and perform the Rapid SARS-CoV-2 Antigen Test.
32824050|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
32824051|NCT01691950||Healthy volunteers|Healthy volunteers for control
32824052|NCT04501458|Experimental|Functional community health units|Community health units with active community health workers.
32824053|NCT04501458|No Intervention|Non functional community health units|Community health units without active community health workers.
32824054|NCT04501458|Experimental|Health facilities with oxygen capacity|Health facility with regular oxygen capacity.
32824055|NCT04501458|No Intervention|Health facilities without oxygen capacity|
32824056|NCT01819727|Active Comparator|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
33317902|NCT05343286|Experimental|APAP group: adapted and personalized physical activity|12 weeks of adapted and personalized physical activity
33317903|NCT05343286|Active Comparator|APA group: adapted physical activity|12 weeks of generic physical activity
33317904|NCT05343286|Sham Comparator|Control group: no physical activity|no physical activity
33317905|NCT04572646|Other|NRT proposition and exhaled CO measurement|
33317906|NCT05307874|Experimental|Dose Level 1 ICT01 + Low dose SC IL-2|c
32824057|NCT01819727|Active Comparator|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
32824058|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
32824059|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
32824060|NCT05584020|Experimental|ACL Repair|Patients under surgical anterior cruciate ligament repair
32824061|NCT05584020|Other|ACL Reconstruction|Patients under surgical anterior cruciate ligament reconstruction
32824062|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
32824063|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
32824064|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
32824065|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
32824066|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
32824067|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
32824068|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
32824069|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
32824070|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
32824071|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
32824072|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
32824073|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
32824074|NCT05583240|Experimental|Essential Oils|
32824075|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
32824076|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
32824077|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
32824078|NCT02517216|Other|parabolic flight and MRI scans|
32824079|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
32824080|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
32824081|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
32824082|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
32824083|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
32824084|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
32824085|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
33317907|NCT05307874|Experimental|Dose level 2 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
33317908|NCT05307874|Experimental|Dose Level 1 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824086|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
32824087|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
32824088|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
32824089|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
32824090|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
32824091|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
32824092|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
32824093|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
32824094|NCT01650298|No Intervention|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
32824095|NCT01650298|Experimental|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
32824096|NCT01795937|Experimental|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
32824097|NCT01795937|Experimental|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
32824098|NCT04139382|Experimental|Intervention|Telephone Consultation for women requesting abortion
32824099|NCT04139382|Active Comparator|Control|Face-to-face consultation for women requesting abortion
32824100|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
32824101|NCT05581368||Chronic Cannabis Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~age: 19 to 80~males and females~all ethnicities~cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group)~no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users:~that ingest cannabis containing cannabidiol (CBD)~that are unable to provide a receipt for the cannabis product(s) they ingest~that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
32824102|NCT05581368||Control Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~age: 19 to 80~males and females~all ethnicities~patients who do not use cannabis~no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants:~that ingest cannabis~that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
32824103|NCT04501224|Experimental|switch to tenofovir alafenamide fumarate|Patients will switch to tenofovir alafenamide fumarate treatment, 25mg，once a day
32824104|NCT04501224|Active Comparator|Continue with the original regimen|Patients will continue with the original regimen treatment, entecavir, 0.5mg once a day, or tenofovir disoproxil fumarate 300mg once a day
32824105|NCT02517060||Healthy participants|Male or female healthy participants
32824106|NCT01817777|Experimental|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
32824107|NCT01817777|Experimental|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
32824108|NCT05576844|Experimental|Interpersonal and social rhythm intervention|
32824109|NCT05576844|Active Comparator|Controlled group|
32824110|NCT05617170||Group 1 experimental group will subject to implanted rehabilitation programme|50 case of acute cerebrovascular stroke patients will subject to implanted rehabilitation programme based on telemedicine if avilable .
32824111|NCT05617170||Group 2 control group will subject to ordinary rehabilitation techniques|50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques .
32824112|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
32824113|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
32824114|NCT04013568|Active Comparator|Group 1 - Agree to Exercise Program|12-week exercise program
32824115|NCT04013568|No Intervention|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline, after 12 weeks and annually) however they will not participate in the exercise sessions
32824116|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
32824117|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
32824118|NCT01795547|Experimental|Aripiprazole and aripiprazole once-monthly|
32824119|NCT01795547|Active Comparator|Paliperidone and paliperidone palmitate|
32824120|NCT05642676|Experimental|Interventions clinics to be remodeled|
32824121|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
32824122|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
32824123|NCT03923556|Experimental|Sugammadex|Sugammadex
32824124|NCT03923556|Active Comparator|Neostigmine|Neostigmine
32824125|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
32824126|NCT03920826|Experimental|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
32824127|NCT03920826|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
32824128|NCT01794923|Experimental|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
32824129|NCT01794923|Placebo Comparator|Placebo topical gel BID|Placebo BID (Treatment B)
32824130|NCT01794923|Experimental|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
32824131|NCT01794923|Placebo Comparator|Placebo topical gel TID|Placebo TID (Treatment D)
32824132|NCT03863184|Experimental|ALR in Combination|Acalabrutinib, lenalidomide, and rituximab in combination
32824133|NCT02517138|Other|Measurements of eye movements and perception|
32824134|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
32824135|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
32824136|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
32824137|NCT02516904|Placebo Comparator|Placebo|normal saline
32824138|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
33405219|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
32824139|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
32824140|NCT04502940||Mild pancreatitis|Patients with mild acute biliary pancreatitis according to Atlanta classification
32824141|NCT04502940||Moderate Pancreatitis|Patients with moderate acute biliary pancreatitis according to Atlanta classification
32824142|NCT04502940||Severe pancreatitis|Patients with severe acute biliary pancreatitis according to Atlanta classification
32824143|NCT04502940||Control|Healthy volunteers
32824144|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
32824145|NCT01794845|Experimental|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
32824146|NCT01794689|Experimental|Morphine US then Morphine FA|Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
32824147|NCT01794689|Placebo Comparator|Placebo US then Placebo FA|Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
32824148|NCT01794689|Experimental|Morphine FA then Morphine US|Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
32824149|NCT01794689|Placebo Comparator|Placebo FA then Placebo US|Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
32824150|NCT01794299|Experimental|ATIR|
32824151|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
32824152|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
32824153|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
32824154|NCT04587089|Experimental|Conventional Treatment + Guedes-Pinto Paste Group|In this group, the conventional endodontic treatment will be made, the canals will be irrigated and filled with Guedes-Pinto paste.
32824155|NCT04587089|Experimental|Irrigation + Guedes-Pinto Paste Group|In this group, the canals will be irrigated and filled with Guedes-Pinto paste.
32824156|NCT04587089|Experimental|Irrigation + aPDT + Guedes-Pinto Paste Group|In this group, the canals will be irrigated, antimicrobial photodynamic therapy will be performed and the canals will be filled with Guedes-Pinto paste.
32824157|NCT04587089|Experimental|Irrigation + CTZ Paste Group|In this group, the canals will not be instrumented and the filling will be performed with CTZ paste (Chlorophenicol, Tetracycline and Zinc Oxide and Eugenol).
32824158|NCT04587089|Experimental|Irrigation + aPDT + CTZ Paste Group|In this group, the root canals will not be instrumented, only irrigated, antimicrobial photodynamic therapy will be performed and the canals will be filled with CTZ paste.
32824159|NCT04580225|Active Comparator|Group A: Partial Wrist Arthrodesis without Triquetral Excision|Four-Corner Arthrodesis
32824160|NCT04580225|Active Comparator|Group B: Partial Wrist Arthrodesis with Triquetral Excision|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
32824161|NCT01817075|Experimental|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
32824162|NCT01817075|Active Comparator|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
32824163|NCT01816763|Experimental|tablet based NRS pain one week, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain one week'
32824164|NCT01816763|Experimental|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
32824165|NCT01816763|Experimental|DVPRS, followed by nurse pain screen|Defense Veterans Pain Rating Scale on tablet followed by usual nursing staff documented pain screening with NRS pain now
32824166|NCT04578353|Experimental|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
32824167|NCT01816685|Experimental|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
32824168|NCT01816685|No Intervention|Routine Care|
32824169|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32824170|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
32824171|NCT00708552|Placebo Comparator|Placebo|
32824172|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
32824173|NCT00708552|Active Comparator|Donepezil|
32824174|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
32824175|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
32824176|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
32824177|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
32824178|NCT03347526|Active Comparator|Vigabatrin|
32824179|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
32824180|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
32824181|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
32824182|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
32824183|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
32824184|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
32824185|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
32824186|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
32824187|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
32824188|NCT02516124||NISSC|Autologous HSCT
33317909|NCT05307874|Experimental|Dose level 2 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824189|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
32824190|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
32824191|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
32824192|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
32824193|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:~Finally, RQ was calculated according to the following equation:~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene~∆∆ Ct = ∆ Ct sample - Ct control gene~RQ = 2-(∆∆Ct)"
32824194|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
32824195|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
32824196|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
32824197|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
32824198|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
32824199|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
32824200|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
32824201|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
32824202|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
32824203|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
32824204|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
32824205|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
32824206|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
32824207|NCT04500522|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (INH) 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
32824208|NCT04500522|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
32824209|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
32824210|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
32824211|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
33317910|NCT05307874|Experimental|Dose level 3 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824212|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
32824213|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
33317911|NCT05307874|Experimental|Dose level 3 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824214|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
32824215|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
32824216|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
32824217|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
32824218|NCT04500444|Experimental|Blood-Flow Restriction Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The blood flow restriction protocol will be applied to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. Before the first application, patients will be evaluated by a specialist physician using ultrasonography and it will be ensured that the arterial blood flow is not restricted as the blood flow restriction restricts only venous blood flow. The pressure threshold at this point is the level to be used in subsequent training sessions and the same person (physician) will be bandaging in the same way during all subsequent training sessions.
32824219|NCT04500444|Sham Comparator|Control Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The sham blood flow restriction protocol will be applied which consists of loose bandaging to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. The same person (physician) will be bandaging in the same way during all subsequent training sessions. The pressure feeling of the patient must correspond to level 0 -not tight at all- before starting the exercise training.
32824220|NCT04498338|Experimental|Neural mobilization and conventional physical therapy|Neural mobilization combined with conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) were performed three times/week for 6 successive weeks.
32824221|NCT04498338|Active Comparator|Conventional physical therapy program|Conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) was performed three times/week for 6 successive weeks.
32824222|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
32824223|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
32824224|NCT01609348|Placebo Comparator|Sugar pill|
32824225|NCT04500678|Experimental|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
32824226|NCT04500678|No Intervention|Observation|Observed without metformin
32824227|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
32824228|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.~The implant fixture will be inserted in the empty socket by conventional manner.~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
32824229|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
32824230|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
32824231|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
32824232|NCT02512770|Experimental|dilatation|esaphageal dilatation group
32824233|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
32824234|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
32824235|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
32824236|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
32824237|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
33101998|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
33101999|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
32824238|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
32824239|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
32824240|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
32824241|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
32824242|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
32824243|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
32824244|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
32824245|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
32824246|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
32824247|NCT02512536|Experimental|Experimental|"Intervention:~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.~Drug: Dysport 300 units im. One single injection over course of study."
32824248|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
32824249|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
32824250|NCT02512614|No Intervention|Comparison|Hand hygiene education.
32824251|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
32824252|NCT04500054|Experimental|Music Intervention Group|The music intervention group listened to the music by the researchers for the duration of 15 minutes one hour before the surgery as well as the standard care.
32824253|NCT04500054|No Intervention|No Intervention Group|The control group patients received standard care only.
32824254|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
32824255|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
32824256|NCT04497558|Experimental|ERA group|In the experimental group, those patients undergo endometrial receptivity array. According to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out.
32824257|NCT04497558|No Intervention|Control group|In the control group, those patients do not receive any treatment before next cycle of transfer. In the control group, no intervention will be performed.
32824258|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
32824259|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
32824260|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
32824261|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
32824262|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
32824263|NCT02506686|Experimental|Meropenem|Meropenem i.v.
32824264|NCT02515500|Active Comparator|Gradual Cessation|
32824265|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
33405220|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
32824266|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
32824267|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
32824268|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
32824269|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.~Intervention: colonoscopy."
32824270|NCT04497792|Experimental|Treatment group|The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.
32824271|NCT04497792|Other|Control group|patients continue previously prescribed medication intake
32824272|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
32824273|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
32824274|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
32824275|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
32824276|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
32824277|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~3 mg/kg, single dose IV administration of 10-1074"
32824278|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~10 mg/kg, single dose IV administration of 10-1074"
32824279|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
32824280|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
32824281|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals~3 mg/kg, single dose IV administration of 10-1074"
32824282|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals~10 mg/kg, single dose IV administration of 10-1074"
32824283|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
32824284|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
32824285|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
32824286|NCT02506218|Active Comparator|30 g protein breakfast|
32824287|NCT02506218|Active Comparator|10 g protein breakfast|
32824288|NCT03345264|Experimental|Cancer patients, survivors, and partners|
32824289|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
32824290|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
32824291|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
32824292|NCT04497714||Cervical lymph nodes tuberculosis|The patients with Cervical lymph nodes tuberculosis
33405221|NCT03713177||Interns|Dental interns of Cairo University
32824293|NCT04497714||Cervical lymphoma|The patients with
32824294|NCT04497714||Cervical lymph node metastasis|The patients with
32824295|NCT04497714||Cervical Reactive hyperplasia|The patients with
32824296|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
32824297|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
32824298|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
32824299|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
32824300|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
32824301|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
32824302|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
32824303|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening~General Practitioners allocated to the intervention group (A) will receive:~a nominative list of their patients who were not compliant to colorectal cancer screening.~a document providing general information about colorectal cancer screening"
32824304|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening~General Practitioners allocated to group (B) will receive:~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
32824305|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
32824306|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol~Groups will be compared for:~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)~glycaemic response to standard DPPIV inhibitor therapy"
32824307|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
32824308|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
32824309|NCT02515188|Experimental|propacetamol group|
32824310|NCT02515188|Placebo Comparator|placebo group|
32824311|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
32824312|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
33317912|NCT05307874|Experimental|Dose level 4 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824313|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
32824314|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
32824315|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
32824316|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
32824317|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
32824318|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
32824319|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
32824320|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
32824321|NCT02228824|Experimental|Very low nicotine content cigarettes|
33317913|NCT05307874|Experimental|Dose level 4 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
32824322|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
32824323|NCT02505828|Other|Septic arthritis|with bacteriological identification
32824324|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
32824325|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
33317914|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
32824326|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
32824327|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
32824328|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
32824329|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
32824330|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
33102000|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
32824331|NCT04443036|Experimental|Albumin-bound Paclitaxel Combined With Toripalimab|"Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W~Toripalimab：240 mg，IV d1，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
32824332|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
32824333|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
32824334|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
32824335|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
32824336|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
32824337|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
32824338|NCT02511210|Active Comparator|general anesthesia|intubated patients
32824339|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
32824340|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
32824341|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
32824342|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
32824343|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
32824344|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
32824345|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
32824346|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
32824347|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
32824348|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
32824349|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
32824350|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
32824351|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
32824352|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
32824353|NCT04497480|Experimental|experimental group|
32824354|NCT04497480|No Intervention|controlled group|
32824355|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
32824356|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
32824357|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
32824358|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
32824359|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
32824360|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
32824361|NCT04499118|Experimental|Arm a(HR+/HER2-,HRD-）|Participants receive AT regimen for neoadjuvant therapy
32824362|NCT04499118|Experimental|Arm b(TNBC, HRD-)|Participants receive TP regimen for neoadjuvant therapy
32824363|NCT04499118|Experimental|Arm c(HER2-,HRD+)|Participants receive AT regimen for neoadjuvant therapy
32824364|NCT04499118|Experimental|Arm d(HER2-, HRD+)|Participants receive TP regimen for neoadjuvant therapy
33102001|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
32824365|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
32824366|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
32824367|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
32824368|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
32824369|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
32824370|NCT02514564||Control|This group will not perform exercise.
32824371|NCT04499898|Experimental|carvedilol|Carvedilol
32824372|NCT04499898|Active Comparator|Band Ligation|Band Ligation
32824373|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
32824374|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
32824375|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
32824376|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
32824377|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
32824378|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
32824379|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
32824380|NCT02505516|Placebo Comparator|metformin|metformin 500mg
32824381|NCT02505516|No Intervention|not on metformin|
32824382|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
32824383|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
32824384|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
32824385|NCT04499586|Experimental|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7).Radiation: 45-55Gy/25-30Fx
32824386|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
32824387|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
32824388|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
32824389|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
32824390|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
32824391|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
32824392|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
32824393|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
32824394|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
32824395|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
32824396|NCT01816295|Placebo Comparator|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
32824397|NCT01816295|Experimental|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
32824398|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
32824399|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
32824400|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
32824401|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
32824402|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
32824403|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
32824404|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
32824405|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
32955925|NCT05765851|Experimental|Dose Escalation: DS-1103a + T-DXd|Participants with HER2-expressing or HER2-mutant advanced metastatic solid tumors who will receive an intravenous (IV) infusion of DS-1103a (starting dose of 100 mg) every 3 weeks (Q3W) starting on Cycle 1 Day 1. Starting on Cycle 2 Day 1 and on Day 1 of each subsequent cycle, participants will also receive T-DXd Q3W at a dose of 5.4 mg/kg.
32955926|NCT05765851|Experimental|Dose Expansion: DS-1103a + T-DXd|Participants with HER2-low expressing breast cancer who will receive an IV infusion of DS-1103a at the recommended dose for expansion (RDE) in combination with T-DXd 5.4 mg/kg Q3W starting on Cycle 1 Day 1.
33102002|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
32738733|NCT05004519|Experimental|Opioid free anesthesia|"Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
32738734|NCT05004519|Experimental|Multimodal anesthesia|"magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
32738735|NCT03224689|Experimental|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
32738736|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
32738737|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
32738738|NCT04926597|Experimental|Intervention group: individualized nutritional support|Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed
32738739|NCT04926597|Other|Control group: general information on healthy food habits|Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up
32738740|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
32738741|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
32738742|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
32738743|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
32738744|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
32738745|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
32738746|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
32738747|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
32738748|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
32738749|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
32738750|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
32824406|NCT03344796||Focus Group|"32 subjects~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities."
32824407|NCT03344796||Usability testing|"10 subjects~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week."
33102003|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
32824408|NCT03344796||Cohort Study 1|"60 subjects~First cohort study: It is expected that each of 60 melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment) or submit a free text description of their strategy (unstructured goal attainment)."
32824409|NCT03344796||Structured Interviews|50 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days.
32824410|NCT03344796||Cohort Study 2|Second cohort study: 40 young adults will wear the sensor and transmit data for 28 days in summer 2020.
32824411|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
32824412|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
32824413|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
32824414|NCT03343782|Experimental|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
32824415|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
32824416|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
32824417|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
32824418|NCT01793051|Experimental|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
32824419|NCT01793051|Placebo Comparator|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
32824420|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
32824421|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
32824422|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
32824423|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
32824424|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
32824425|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
32824426|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
32824427|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
32824428|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
32824429|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
32824430|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
32824431|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
32824432|NCT01816061|Experimental|Experimental - COMPASS|Goal-setting sessions
32824433|NCT01816061|Active Comparator|Control - COMPASS|Informative phone calls
32824434|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
32824435|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
32824436|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
32824437|NCT03121482|Active Comparator|HFNC alone|Control group
32824438|NCT03121482|Experimental|HFNC and NIV|
32824439|NCT01662778|Active Comparator|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
32824440|NCT01662778|Active Comparator|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
32824441|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
32824442|NCT01662778|Active Comparator|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
33102004|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
32824443|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
32824444|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
32824445|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
32824446|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
32824447|NCT01792115|Active Comparator|Vit E 200 IU/d|Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
32824448|NCT01792115|Active Comparator|Vitamin E 400|Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
32824449|NCT01792115|Active Comparator|Vitamin E 800|Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
32824450|NCT02505126|Experimental|Active tDCS group|Active tDCS
32824451|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
32824452|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
32824453|NCT01791803|Experimental|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
32824454|NCT01791803|Experimental|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
32824455|NCT01791803|Experimental|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
32824456|NCT01791803|No Intervention|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
32824457|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
32824458|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
32824459|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
32824460|NCT01791725|Experimental|ELND005 BID|ELND005 250 mg BID
32824461|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
32824462|NCT01791725|Placebo Comparator|Placebo|Placebo BID
32824463|NCT04499976|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily dose, 900 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
32824464|NCT04499976|Placebo Comparator|Placebo Comparator|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
32824465|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
32824466|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
32824467|NCT01791413|Active Comparator|depot medroxyprogesterone acetate|
32824468|NCT01791413|No Intervention|No depot medroxyprogesterone acetate|
32824469|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
32824470|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
32824471|NCT01614574|Experimental|Investigational|velaglucerase alfa
32824472|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
32824473|NCT01610063|No Intervention|Unguided|Treatment as usual
32824474|NCT04499040|Experimental|patients with SD/THE|
32824475|NCT04499040|Placebo Comparator|control group|
32824476|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
32824477|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
32824478|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
32824479|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
32824481|NCT01813721||Group 1|All patients enrolled
32824482|NCT02509728|Active Comparator|standard nutrition|standard nutrition
32824483|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
32824484|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
32824485|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
32824486|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
32824487|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
32824488|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
32824489|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
32824490|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
32824491|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
32824492|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
32824493|NCT01790633|Active Comparator|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
32824494|NCT01790633|Experimental|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
32824495|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
32824496|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
32824497|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
32824498|NCT01788215|Active Comparator|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
32824499|NCT01788215|Placebo Comparator|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
32824500|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
32824501|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
32824502|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
32824503|NCT01787825|Other|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
32824504|NCT01787825|Other|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
32824505|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
32824506|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
32824507|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
32824508|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
32824509|NCT01813019|Experimental|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)~*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
32824510|NCT01813019|Placebo Comparator|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) *patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
32824511|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
32824512|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
32824513|NCT01787591|Experimental|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
32824514|NCT01787591|Experimental|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
32824515|NCT01787591|Experimental|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
32824516|NCT01787591|Experimental|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
32824517|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
32824518|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
32824519|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
32824520|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
32824521|NCT01812707|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
32824522|NCT01812707|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
32824523|NCT01812707|Experimental|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
32824524|NCT01812707|Placebo Comparator|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
32824525|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
32824526|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
32824527|NCT04497090|Active Comparator|Fixed-EPAP|EPAP was kept fixed at the prescribed level throughout the night
32824528|NCT04497090|Experimental|Auto-EPAP|EPAP was continuously adjusted using the experimental approach aimed at abolishing tidal expiratory flow limitation
32824529|NCT04585607|Experimental|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
32824530|NCT04585607|Active Comparator|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
32824531|NCT01787279|Experimental|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
32824532|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
32824533|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
32824534|NCT04576793|Experimental|Cognitive impairment|"Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties~Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties~Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
32824535|NCT04576793|Active Comparator|No cognitive impairment|Healthy controls
32824536|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
32824537|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
32824538|NCT01811225|Experimental|Low-Dose Contraceptive, then High-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the high dose progesterone, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM)."
32824539|NCT01811225|Experimental|High-Dose Contraceptive, then Low-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the high progesterone dose, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM)."
32824540|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
32824541|NCT01809197|Experimental|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
32824542|NCT01809197|Active Comparator|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
32824543|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
33102005|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
33102006|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
32824544|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
32824545|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
32824546|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
32824547|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
32824548|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
32824549|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.~Note: this is a crossover study."
32824550|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.~Note: this is a crossover study."
32824551|NCT01786109|Experimental|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
32824552|NCT01786109|Experimental|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
32824553|NCT01786109|Placebo Comparator|Placebo|One dose of placebo was taken orally with water.
32824554|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
32824555|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
32824556|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
32824557|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
32824558|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
32824559|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
32824560|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
32824561|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
32824562|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
32824563|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
32824564|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
32824565|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
32824566|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
32824567|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
32824568|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
32824569|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
32824570|NCT04496778|Active Comparator|low level laser plus exercise|acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
32824571|NCT04496778|Placebo Comparator|sham laser plus exercise|placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
32824572|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
32824573|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
32824574|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
32824575|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
32824576|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
32824577|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
32824578|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
32824579|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
32824580|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
32824581|NCT04498962|Experimental|chronic stable angina|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with chronic stable angina will be treated by Danzhu Fuyuan Granule in addtion to routine care
32824582|NCT04498962|Experimental|Vascular Dementia|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Vascular Dementia will be treated by Danzhu Fuyuan Granule in addtion to routine care
32824583|NCT04498962|Experimental|Idiopathic Membranous Nephropathy|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Idiopathic Membranous Nephropathy will be treated by Danzhu Fuyuan Granule in addtion to routine care
32824584|NCT04498962|No Intervention|Healthy population|Comparator: Healthy population with no treatment
32824585|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
32824586|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
32824587|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
32824588|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.~Envarsus® tablets will be administered orally once daily in the morning"
32824589|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.~Advagraf® capsules will be administered orally once daily in the morning"
32824590|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
32824591|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
32824592|NCT02500290||Acute coronary syndrome|
32824593|NCT04496934|Experimental|Intervention|Exercise intervention
32824594|NCT04496934|Active Comparator|Control|The control group is a waiting list group. The participants will receive exercise intervention after twelve weeks of treatment as usual.
32824595|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
32824596|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
32824597|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
32824598|NCT02503176|Experimental|KCT-0809|
32824599|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
32824600|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
32824601|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
32824602|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
32824603|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
32824604|NCT02249338|Experimental|BIIL 284 BS|
32824605|NCT02249338|Placebo Comparator|Placebo|
32824606|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
32824607|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
32824608|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
32824609|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
32824610|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
32824611|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
32824612|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
32824613|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
32824614|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
32824615|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
32824616|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32824617|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
32824618|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
32824619|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
32824620|NCT04496856|Experimental|Collagen|Participants of this arm are going to consume 30 g of collagen peptides daily for 30 days
32824621|NCT04496856|Experimental|Whey Protein|Participants of this arm are going to consume 30 g of whey protein daily for 30 days
32824622|NCT04498884|Experimental|Rinsulin® mix 30/70|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
32824623|NCT04498884|Active Comparator|Humulin® M3|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
32824624|NCT04498494||myocarditis|The diagnosis of acute myocarditis was confirmed by a recent history of gastrointestinal/upper respiratory tract infection and/or complaints of cardiac symptoms and increasing cardiac markers and/or presentation with a new abnormality of the 12-lead ECGcombined with at least one of the following: ⅰ) Active or borderline biopsy according to the Dallas criteria (13); ⅱ) positive infectious origin of ventricular dysfunction; ⅲ) delayed enhancement on cardiac MRI consistent with myocarditis; or ⅳ) serological tests, ECGs, ultrasonic cardiogram (UCG), coronary angiography and ventriculography to exclude acute myocardial infarction (AMI), stress cardiomyopathy, congenital heart disease, myocarditis secondary to sepsis, valve disease, hyperthyroidism, autoimmune disease and rheumatic fever
32824625|NCT04498494||fulminant myocarditis|In patients with acute myocarditis, a diagnosis of FM was determined upon identification of one or more of the following: Haemodynamic instability due to cardiogenic shock or arrhythmia; left ventricular dysfunction and low cardiac output syndrome requiring inotropes or mechanical circulatory support; mechanical ventilation; and/or cardiac arrest (CA)
32824626|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
32824627|NCT01621672|No Intervention|No further treatment|No treatment control.
32824628|NCT05504070|Experimental|GSV/SSV|Incompetent Great and Small Saphenous Veins
32824629|NCT05504070|Experimental|IPV|Incompetent Perforator Veins
32824630|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
32824631|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
32824632|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
32824633|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
32824634|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
32824635|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
32824636|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
32824637|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
32824638|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
32824639|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
32824640|NCT04496622|Experimental|Whole Body Vibration Technique|WBV training with the frequency of 16-25 Hz along with conventional treatment.
32824641|NCT04496622|Active Comparator|WBV Technique|WBV training with the frequency of 26-35 Hz along with conventional treatment.
32824642|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
32824643|NCT02499432|No Intervention|Standard training|Training as usual
32824644|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
32824645|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
32824646|NCT04496700|Experimental|Group 1 - Shooting test|All participants in this group were tested for shooting abilities before and after blood donation. No variation within the group.
32824647|NCT04496700|Experimental|Group 2 - VO2max|"All participants in this group were tested for physical abilities before and after blood donation. Method: Bruce protocol.~No variation of protocol within the group."
32824648|NCT04496700|Experimental|Group 3 - Feasability|"All participants in this group were tested for feasability before and after blood donation. Method: Hiking uphill with 20 kg backpack.~No variation of method within the group."
32824649|NCT04495140|Experimental|Oral [14C]PF-06882961, 50 mg|In this arm, a single oral dose of [14C]PF-06882961, 50 mg will be administered as a liquid formulation.
32824650|NCT04495140|Experimental|Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug|In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961, 100 ug, will be administered via intravenous infusion.
32824651|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
32824652|NCT03343548|Placebo Comparator|Group II|control group (C)
32824653|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
32824654|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
32824655|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
32824656|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
32824657|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
32824658|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
32824659|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
32824660|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
32824661|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
32824662|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
32824663|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
32824664|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
32824665|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
32824666|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
32824667|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
32824668|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
32824669|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
32824670|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
32824671|NCT03343002|Active Comparator|fentanyl at end of surgery|
32824672|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
32824673|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
32824674|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
32824675|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
32824676|NCT04496388|Experimental|Aerobic exercise|Aerobic exercise is lasting for nearly 50 minutes each time, including warm-up and stretching for 10 minutes after exercise.
32824677|NCT04496388|Experimental|Aerobic exercise combined with resistance exercise|Aerobic exercise is lasting for nearly 20 minutes each time, and add resistance exercise for 20 minutes. Additional warm-up 10 minutes and stretching for 5 minutes.
32824678|NCT04496388|Experimental|Aerobic exercise combined with interval training|Aerobic exercise is lasting for nearly 20 minutes each time, and add moderal intensity interval training for 10 minutes. Additional warm-up 10 minutes and stretching for 15 minutes.
32824679|NCT04496388|Placebo Comparator|Placebo|No exercise intervention.
32824680|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
32824681|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
32824682|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
32824683|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
32824684|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
32824685|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
32824686|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
32824687|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
32824688|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
32824689|NCT04494984|Active Comparator|Active|Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
32824690|NCT04494984|Placebo Comparator|Placebo|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
32824691|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
32824692|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
32824693|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
32824694|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
32824695|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
32824696|NCT04498260|Experimental|Local steroid-triamcinolone acetonide|Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.
32824697|NCT04498260|Active Comparator|Oral steroid-predonisolone|(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.
32824698|NCT02507544|Experimental|TRX-818|
32824699|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
32824700|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
32824701|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
32824702|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
33102007|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
32824703|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
32824704|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
32824705|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
32824706|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
32824707|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
32824708|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
32824709|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
32824710|NCT02502708|Experimental|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
32824711|NCT02502708|Experimental|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
32824712|NCT02502708|Experimental|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
32824713|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
32824714|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily"
32824715|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
32824716|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
32824717|NCT05473182|Other|Single arm: All participants receive the intervention|All participants receive power wheelchair skills training using the IndieTrainer system.
32824718|NCT02728596|Active Comparator|Clinic group 1 (clinics with existing automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.
32824719|NCT02728596|Active Comparator|Clinic group 2 (clinics with no automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.
32824720|NCT02728596|Experimental|Clinic group 3 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.
32824721|NCT02728596|Experimental|Clinic group 4 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.
32824722|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
32824723|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
32824724|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
32824725|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
32824726|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
32824727|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
32824728|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
32824729|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
32824730|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
32824731|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
32824732|NCT01709032|Experimental|Deferasirox and deferiprone|
32824733|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
32824734|NCT04495998|Other|Motor Neurological Soft Signs|motor test and an interview for the participants
32824735|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
32824736|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
32824737|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
32824738|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
32824739|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
32824740|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
32824741|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
32824742|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
32824743|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
32824744|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
32824745|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
32824746|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
32824747|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
32824748|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
32824749|NCT01669096|Experimental|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
32824750|NCT05363020|Experimental|S-Adenosyl-L-Methionine (SAMe)|Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
32824751|NCT05363020|Placebo Comparator|Placebo|Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
32824752|NCT05341336|Experimental|Surgical excision|complete surgical excision of the scalp AVMs after identifying feeding arteries, vein and high flew shunts to perform a complete devascularization of the AVM.
32824753|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
32824754|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
32824755|NCT05711290|Experimental|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles will be provided as a drink first. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the placebo will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
32824756|NCT05711290|Placebo Comparator|Placebo First|"In this arm, the placebo will be provided as a drink first. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the oxygen nanobubbles will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
32824757|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
32824758|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
32824759|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
32824760|NCT05711134|Experimental|Serial In-Person Feedback|Providers are given recurring individualized in-person feedback on their practice patterns.
32824761|NCT05711134|Experimental|In-Person Feedback with Serial Electronic Feedback|Providers are given one-time individualized in-person feedback on their practice patterns, followed by recurrent individualized electronic feedback.
32824762|NCT05711134|No Intervention|Control|Providers are not given any feedback on their practice patterns.
32824763|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
32824764|NCT01670110|Placebo Comparator|placebo injection|
32824765|NCT05711056|Experimental|Sociobehavioral program Group|A novel sociobehavioral collaborative program that will improve the health of individuals in rural areas by expanding access to MOUD through an ED- based telemedicine strategy. Researchers will prospectively study a poison center OUD consultation and peer recovery coach (PRC) intervention as it is rolled out at each site, collecting participant-level data at baseline, one week post intervention and 30 days post intervention.
32824766|NCT05711056|No Intervention|Control Group|Patients who are seen at a participating hospital prior to the initiation of the intervention will be considered controls.
32824767|NCT05710978|Experimental|Work Heat Stress|Each participant will complete three consecutive days of heavy intensity aerobic work in a hot environment.
32824768|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
32824769|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
32824770|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
32824771|NCT05710900|Experimental|Low-calorie diet group|A low-calorie diet involving will involve a commercial weight loss program (pre-packaged foods from Ideal Protein, select lean protein sources, non-starchy vegetables) and be led by the pharmacist and registered dietitian (RD) involving in-person and virtual appointments.
32824772|NCT05710900|Experimental|Low-carbohydrate diet group|The low-carbohydrate diet will involve an individualized whole-food diet (30-130 grams carbohydrate per day) led through virtual visits with a registered dietitian.
32824773|NCT01674478|Experimental|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
32824774|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
32824775|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
32824776|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
32824777|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
32824778|NCT02245360|Placebo Comparator|Placebo|Placebo
32824779|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
32824780|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
32824781|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
32824782|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
32824783|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
32824784|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
32824785|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
32824786|NCT05710744|No Intervention|Family Members of patients in the ICU|Family members will join routine meetings with the physicians treating with their critically ill loved ones.
32824787|NCT05710744|Other|ICU Physicians|Physicians will view a tip sheet containing information about best practices of shared decision making with diverse individuals. Physicians will then conduct routine meetings with families of patients with acute respiratory failure.
32824788|NCT05710666|Experimental|T-DXd|
32824789|NCT05147038|Experimental|Intervention group|Participants allocated into the intervention group will be coached for 12 weeks by a tele-coaching mobile App containing tips for PA increase and for number of steps recording (visual feedback for the patient).
32824790|NCT05147038|No Intervention|Control group|Participants in the control group will receive usual care (including regular visits) together with the educational information.
32824791|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
32824792|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
32824793|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
32824794|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
32824795|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
32824796|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
32824797|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
32824798|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
32824799|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
32824800|NCT05710588|Experimental|M-DTT group|This group has motor-motor dual task training-balance related tasks as primary task (e.g. marching, stepping) and motor tasks as secondary task (e.g. touching wall, popping a fidget toy).
32824801|NCT05710588|Experimental|C-DTT group|This group has motor-cognitive dual-task training-balance related tasks as primary task (e.g. marching, stepping) and cognitive tasks as secondary task (e.g. repeating tongue twisters, counting backwards from 100).
32824802|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
32824803|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
32824804|NCT02249806||PH target therapy|Patients receiving PH target therapy
32824807|NCT05118490|Experimental|Group 1: People living with HIV infection without active TB|
32824808|NCT05118490|Experimental|Group 2: HIV-negative household contacts of adults with rifampicin-sensitive pulmonary TB|
32824809|NCT05710510|Active Comparator|Local Care + Model|Quarterly clinic visits with a local primary care provider
32824810|NCT05710510|Active Comparator|Team Care Model|An intensive group lifestyle intervention led by a lifestyle coach via Zoom, paired with quarterly clinic visits with a local primary care provider and the lifestyle coach, the coach joining via telemedicine.
32824811|NCT05710432|Experimental|Quasi-Isometric Neck Flexion|"On minimal mechanical ventilation support (unassisted/assisted spontaneous breathing) via tracheostomy.~Quasi-Isometric Neck Flexion will be performed during mechanical ventilation. Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction. 30% will be the target intensity level for neck flexion. The patient will perform 2 sets of 6-10 quasi-isometric neck flexions."
32824812|NCT05710432|Experimental|Inspiratory Muscle Training|Perform 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load). The training device will be set at 30% of the highest value of three MIP maneuvers. A two-minute rest period with MV support will be provided between each set.
32824813|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
32824814|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
32824815|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
32824816|NCT05710120||Before Period (January 2022 to October 2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients who are eligible to be screened for hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
32824817|NCT05710120||After Period (January 2023 to October 2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients who are are eligible to be screened for hepatitis C infection will be disseminated to healthcare providers and clinic staff.
32824818|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
32824819|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
32824820|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
32824821|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
32824822|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
32824823|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
32824824|NCT02249416|Experimental|TPV/RTV low + ZDV|
32824825|NCT02249416|Experimental|TPV/RTV high + ZDV|
32824826|NCT01685242|Experimental|AC-170 0.24%|
32824827|NCT01685242|Placebo Comparator|AC-170 0%|
32824828|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
32824829|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
32824830|NCT05709964||Study group|All patients included in this study. Investigators will record both self-reported and measured height, weight, and neck circumference in all of these patients.
32824831|NCT04937296|Placebo Comparator|Usual care|
32824832|NCT04937296|Experimental|Physical activity|
32824833|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
32824834|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
32824835|NCT04930042|Experimental|AVT04 45 mg SC|Test Product: AVT04 (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
32824836|NCT04930042|Active Comparator|EU Stelara 45 mg SC|Comparator ref product: EU Stelara (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
32824837|NCT04915768|Experimental|Treatment|CH505 TF chTrimer plus adjuvants administered at months 0, 2, 4, 8 and 12.
32824838|NCT04898920|Placebo Comparator|Control Group|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
32824839|NCT04898920|Experimental|Dexamethasone Group|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
32824840|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
32824841|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
32824842|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
32824843|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
32824844|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
32824845|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
32824846|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
32824847|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
32824848|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
32824849|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
32824850|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
32824851|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
32824852|NCT02498262|Experimental|Virtual Reality Training System|
32824853|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
32824854|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
32824855|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
32824856|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
32824857|NCT01687036|Other|Cryoablation|Cryoablation
32824858|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
32824859|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
32824860|NCT04496154|Experimental|Omega-3 fatty acids|3 oral softgels (600 mg EPA and 300 mg DHA / softgel), Triple Strength Omega-3 from Webber Naturals
32824861|NCT01687114|Experimental|cranberry juice|27% cranberry juice
32824862|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
32824863|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
32824864|NCT05709730||Women aged 26-80 with atypical glandular cell (AGC) cytology result|Women in the capital region of Sweden with AGC, a concomitant human papillomavirus (HPV) analysis, and a histopathology.
32824865|NCT04495920|Experimental|Test product|
32824866|NCT01687972|Active Comparator|Sutures|
32824867|NCT01687972|Active Comparator|Insorb Staples|
32824868|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
32824869|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
32824870|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
32824871|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
32824872|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
32824873|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
32824874|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
32824875|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
32824876|NCT04869592|Experimental|Phase 1 low-dose group|
32824877|NCT04869592|Experimental|Phase 1 high-dose group|
32824878|NCT04869592|Placebo Comparator|Phase 1 placebo group|
32824879|NCT04869592|Experimental|Phase 2 low-dose group A|
32824880|NCT04869592|Experimental|Phase 2 low-dose group B|
32824881|NCT04869592|Experimental|Phase 2 low-dose group C|
33102008|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
32824882|NCT04869592|Experimental|Phase 2 low-dose group D|
32824883|NCT04869592|Experimental|Phase 2 high-dose group A|
32824884|NCT04869592|Experimental|Phase 2 high-dose group B|
32824885|NCT04869592|Experimental|Phase 2 high-dose group C|
32824886|NCT04869592|Experimental|Phase 2 high-dose group D|
33317915|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
32824887|NCT04869592|Placebo Comparator|Phase 2 placebo group A|
32824888|NCT04869592|Placebo Comparator|Phase 2 placebo group B|
32824889|NCT04869592|Placebo Comparator|Phase 2 placebo group C|
33102009|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
33102010|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
32824890|NCT04869592|Placebo Comparator|Phase 2 placebo group D|
32824891|NCT04495686|Experimental|Caregiver PWD-ADRD TCCI|Participants in the Caregiver PWD-ADRD telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
32824892|NCT04495686|No Intervention|Caregiver for PWD-ADRD (BMT)|Participants in the Caregiver PWD-ADRD best medical treatment (BMT) group will not receive care coordination.
32824893|NCT04495686|Experimental|Caregiver for PWD-TBI TCCI|Participants in the Caregiver PWD-TBI telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
32824894|NCT04495686|No Intervention|Caregiver for PWD-TBI (BMT)|Participants in the Caregiver PWD-TBI best medical treatment (BMT) group will not receive care coordination.
32824895|NCT05709652|Experimental|Experimental|Patients subjected to aortic CTA with a gantry revolution time of 0.23 sec
32824896|NCT05709652|Active Comparator|Control|Patients subjected to aortic CTA with a gantry revolution time of 0.28 sec
32824897|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
32824898|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
32824899|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
32824900|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
32824901|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
33102011|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
33102012|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
33102013|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
33102014|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
33102015|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
33102016|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
33102017|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
32824902|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
32824903|NCT04495842|Experimental|Intervention|Participants receive an active essential oil blend to inhale for 15 minutes. The blend contains plant based oils sourced from flowers and citrus plants.
32824904|NCT04495842|Placebo Comparator|Control|Participants receive an inert comparison to inhale for 15 minutes.
32824905|NCT05709496|Experimental|De-escalated radiotherapy to the prostate|De-escalated radiotherapy to the prostate with an intra-prostatic boost to the dominant .
32824906|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
32824907|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
32824908|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
32824909|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
32824910|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
32824911|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
32824912|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
32824913|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
32824914|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
32824915|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
32824916|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
32824917|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
32824918|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
32824919|NCT05709418|Experimental|Mathematics intervention|Low-performing children get targeted support with a scripted intervention
32824920|NCT05709418|No Intervention|Control group|Business as usual
32824921|NCT05709340|Experimental|study group|
32824922|NCT05709340|Active Comparator|control group|
32824923|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
32824924|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
32824925|NCT03328078|Experimental|Emavusertib (CA-4948) dose escalation|Part A1: Dose-level cohorts with up to approximately 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib .
32824926|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg daily (QD) of oral ibrutinib. The starting dose of emavusertib to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 20 patients ata potential dose level will be required to establish optimal combination dosing.
32824927|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose expansion|"In the expansion phase, the emavusertib recommended Phase 2 dose (RP2D) in combination with ibrutinib will be administered in Non-Hodgkin Lymphoma (NHL) disease-specific cohorts. Approximately 131 NHL patients will be enrolled in 4 NHL disease specific cohorts:~Cohort 1 - Marginal zone lymphoma (MZL)~Cohort 2 - ABC diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or NOS-type~Cohort 3 - Primary central nervous system lymphoma (PCNSL)~Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include:~Mantle Cell Lymphoma (MCL), MZL~Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL)~Patients with NHL and known myddosome mutations~Patients may be candidates for maintaining ibrutinib while emavusertib will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable."
32824928|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
32824929|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
32824930|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
32824931|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
32824932|NCT04783246|Experimental|Group A- Intervention/Non-Intervention|Participants in this arm will initially be randomized to the intervention period and will receive the interventions for 11 weeks followed by no interventions for 11 weeks.
32824933|NCT04783246|Active Comparator|Group B- Non-Intervention/Intervention|Participants in this arm will initially be randomized to the non-intervention period for 11 weeks followed by the intervention period for 11 weeks.
32824934|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
32824935|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
33317916|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
33317917|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
32824936|NCT04724746|Experimental|Written Exposure and Cognitive Behavioral Therapy|Participants receive 5 to 6, 60 minute, sessions of written exposure therapy for posttraumatic stress disorder combined with cognitive behavioral therapy for substance use disorder.
32824937|NCT02494830|Experimental|ketamine 5 mg intravenous|
32824938|NCT02494830|Experimental|ketamine 10 mg oral|
32824939|NCT02494830|Experimental|ketamine 20 mg oral|
32824940|NCT02494830|Experimental|ketamine 40 mg oral|
32824941|NCT02494830|Experimental|ketamine 80 mg oral|
32824942|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
32824943|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
32824944|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
32824945|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
32824946|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
32824947|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
32824948|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
32824949|NCT05484180|Experimental|experimental group|As a nursing initiative to the experimental group in the research; Training and consultancy supported guided imagery application based on the health promotion model was applied.
32824950|NCT05484180|No Intervention|control group|No attempt will be made on individuals in the control group during the research process. After the research process is over; After the training booklet, Mp3 player loaded with directed imagery recording and exercise materials are delivered, guided imagery application based on the Health Promotion Model will be supported by training and counseling.
32824951|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
32824952|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
32824953|NCT05475132|Experimental|Exergaming|App based exercise games for dexterity will be used
32824954|NCT05475132|Active Comparator|Conventional Dexterity Exercises|Dexterity exercises used conventionally will be done in this.
32824955|NCT04351048|Experimental|SW|stepwise excavation
32824956|NCT04351048|Experimental|OneS|one step excavation
32824957|NCT03336840|Experimental|Metformin|
32824958|NCT03336840|Experimental|Probiotics|
32824959|NCT03336840|Experimental|Metformin and Probiotics|
32824961|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
32824962|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
32824963|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
32824964|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
32824965|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
32824966|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
32824967|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
32824968|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
32824969|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
32824970|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.~MF Brief introduction:~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
32824971|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
32824972|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
32824973|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
32824974|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
32824975|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
33317918|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
33317919|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
33317920|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
33317921|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
32824976|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
32824977|NCT05706532||Healthy|30 healthy subjects; age >18; sinus rhythm; absence of autonomic diseases or dysfunctions.
32824978|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
32824979|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
32824980|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).~Patients in the MTD study should be about 10, according to Fleming."
32824981|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
33317922|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
33317923|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
33317924|NCT03680872|Experimental|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
32824982|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
32824983|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.~Week 28 = Controlled Human Malaria Infection (CHMI)"
32824984|NCT05705752|Experimental|Balance|Balance training group.
32824985|NCT05705752|Active Comparator|Pilates|Pilates group.
32824986|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
32824987|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
32824988|NCT05674318|Experimental|Alpha-lactalbumin|
32824989|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
32824990|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
32824991|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
32824992|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
32824993|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
32824994|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
32824995|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
32824996|NCT01483612|Experimental|Lifestyle counseling|
33317925|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
33317926|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
33317927|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
33317928|NCT00823654||Unaffected High Risk Women with BRCA mutations|
33317929|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
33317930|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
32955928|NCT05765825|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with serplulimab and thoracic radiation therapy (30Gay/10f）. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
32955929|NCT05765812|Experimental|Phase 1: Arm A - Debio 0123 + Temozolomide|Participants will receive Debio 0123, escalating doses along with temozolomide (TMZ) in each 28-day cycle for up to 2 years.
32955930|NCT05765812|Experimental|Phase 1: Arm B - Debio 0123 + Temozolomide + Radiotherapy|Participants will receive Debio 0123, escalating doses along with TMZ and concomitant administration of radiotherapy (RT) for up to 6 weeks.
32955931|NCT05765812|Experimental|Phase 2: Debio 0123 RP2D + Temozolomide|Participants will receive Debio 0123 RP2D along with TMZ in each 28-day cycle for up to 2 years.
32955932|NCT05765799||Patient who receives a consultation before an interventional procedure|Any patient who receives a consultation before an interventional procedure will be included. Questionary will be administrated.
32955933|NCT05765773|Experimental|The study group consisted of 200 volunteers|The study group is planned to screen a maximum of 250 volunteers inclusive, of which it is planned to include 200 men and women aged 60 years and older who meet the criteria for inclusion in the study and do not have non-inclusion criteria.
32955934|NCT05765773|No Intervention|Control group|Retrospective immunogenicity data obtained in the framework of clinical study № VKI-I/II-08/20 on healthy volunteers aged 18-60 years.
32955935|NCT05765747|Experimental|Yunnan Baiyao|The Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
32955936|NCT05765747|Active Comparator|celecoxib|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
32955937|NCT05765734|Experimental|TAS3351 Part A (Dose Escalation)|Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.
32955938|NCT05765734|Experimental|TAS3351 Part B (Dose Expansion)|TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.
32955939|NCT05765734|Experimental|TAS3351 Part C (Phase 2)|To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.
32955940|NCT05765721|Experimental|intervention group|Patients in this group will receive a 8-week family-based frailty self-management program including: (1) one 20-30 minute individual consultation (teaching how to join the family-based frailty self-management program by using poster); (2) provided self-management booklet; (3) provided family-based frailty self-management program video and individual consultation; (4) telephone follow-up once per week for 12 weeks
32955941|NCT05765721|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
32955942|NCT05765708|Experimental|Motor imagery group|Motor imagery group
32955943|NCT05765708|Experimental|Action Observation Group|Action Observation Group
32955944|NCT05765708|Experimental|Action Observation + Motor imagery Group|
32955945|NCT05765708|No Intervention|Control|
32955946|NCT05765695|Experimental|Treated group|
32955947|NCT05765682|Active Comparator|Mepivacaine Spinal|Mepivacaine (60 mg: 3ml of 2%) or will be injected into the intrathecal space.
32955948|NCT05765682|Active Comparator|Bupivacaine Spinal|Isobaric bupivacaine (10mg: 2ml or 0.5%) will be injected into the intrathecal space.
32955949|NCT05765669|Experimental|Operative|Percutaneous transiliac-transsacral screw fixation
32955950|NCT05765669|Experimental|Non-operative|Pain management and physical therapy advanced with weight bearing as tolerated.
32955951|NCT05765656|Experimental|GP - pharmacist collaboration and pharmacist motivational interviewing|Once randomized, the patient will have three motivational interviews with their pharmacist. Each time, a report will be sent to the GP.
32955952|NCT05765656|No Intervention|Usual Care|The patient is handled by his GP and the pharmacist as usual (medical encounter plus medication dispensation)
32955953|NCT05765643|Experimental|Nurse parental support in symptom management using a mobile health App over 3 months|
32955954|NCT05765643|No Intervention|Wait-listed control|Parents in this group can join the usual community social or health care services as usual.
32955955|NCT05765630|Active Comparator|Healthy patients|
32955956|NCT05765630|Experimental|CKD patients not receiving antiplatelet agents|
32955957|NCT05765630|Experimental|CKD patients receiving antiplatelet agents|
32955958|NCT05765630|Experimental|Patients with constitutional thrombopathy with RAP1B activation defect|
32955959|NCT05765630|Experimental|Patients with ACS in the previous month treated with antiplatelet agents|
32955960|NCT05765617|Placebo Comparator|Control|Placebo 2x1 per day
32955961|NCT05765617|Experimental|Calcitriol|the treatment group received calcitriol 2x400 iu per day for 5 day
32955962|NCT05765604|Experimental|test group|low dose and high dose, only one dose at day 0
32955963|NCT05765604|Active Comparator|control group|one dose at day 0
32955964|NCT05765591|Experimental|Balneotherapy group|"The patients allocated to the Balneotherapy group were subject to 3 weekly sessions of Balneotherapy together with an structured program of aquatic exercises on alternate days in groups of 8 during 4 weeks. The weekly planning was structured as following:~st day: Pool, shower, inhalation and aquatic exercises~nd day: Pool, shower, inhalation.~rd day: Pool, shower, inhalation and aquatic exercises"
32955965|NCT05765591|No Intervention|Control group|Patients from the control group were instructed to not participate in any BT-related activity during the duration of the study and to continue with usual care and activities
32824997|NCT01483612|No Intervention|control|
32824998|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
32824999|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
32825000|NCT02497560|Placebo Comparator|Placebo|vegetable oil
32825001|NCT04558840|Active Comparator|Enhanced Recovery After Surgery (ERAS) Arm|"ERAS Arm will undergo multimodal regiment:~Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery.~During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above).~Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain."
32825002|NCT04558840|Active Comparator|Current Practice Arm|The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
32825003|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
32825004|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
32825005|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
33102018|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
33102019|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
32825006|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
32825007|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
32825008|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
32825009|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
32825010|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
32825011|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
32825012|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
32825013|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
32825014|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
32825015|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
32825016|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
32825017|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
32825018|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
32825019|NCT04500106||Participants With Nurse Support, Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, using video devices.
32825020|NCT04500106||Participants With Nurse Support, Not Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, not using video devices.
32825021|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
32825022|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
32825023|NCT04477330|Experimental|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
33102020|NCT02922452|Experimental|BMS-986141 and Dilitazem|
32825024|NCT04477330|Sham Comparator|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
32825025|NCT04461418|Active Comparator|Dexamethasone|Dose starting at 4 mg daily (for patients randomized to the Dexamethasone arm).
32825026|NCT04461418|Active Comparator|Prednisone|Dose starting at 25 mg/day (a calculation of equipotent steroid equivalencies will be used).
32825027|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
32825028|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
32825029|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
32825030|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
33102021|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
33102022|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
33102023|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
32825031|NCT05667610|Experimental|Intervention group (immune-supportive diet)|"Immune-supportive diet (for 4 months) on top of peanut and/or nut free diet~Feasibility of adherence to the Immune-supportive diet (intervention group only) and dietary compliance by Likert scale after 2,5 and 4 months of dietary intervention (2x)"
32825032|NCT05667610|Active Comparator|Control group|- Peanut and/or nut free diet only
32825033|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
32825034|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
32825035|NCT05654428|Experimental|Experimental Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~Mckenzie Extension~Prone press-ups~Head life in prone~Prone on elbow~Prone on hands~Prone on pillow"
32825036|NCT05654428|Active Comparator|Control Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~William Flexion~Single knee to chest~Double knee to chest~Straight Leg Raise~Bridging~Pelvic tilt"
32825037|NCT05641792|Experimental|CGM pre-, intra- and postoperatively|Patients will have a Dexcom G6 system placed on admission on outer part of the arm, glycaemia will be monitored for 10 consecutive days
32825038|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
32825039|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
32825040|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
32825041|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
32825042|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
32825043|NCT05233020|Experimental|Robotic|Fifteen patients undergo rVHR operation.
32825044|NCT05233020|Experimental|hybrid|Fifteen patients undergo hybrid operation.
32825045|NCT03335826|Experimental|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
32825046|NCT03335826|Active Comparator|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
32825047|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
32825048|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
32825049|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
32825050|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
32825051|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
32825052|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
32825053|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
32825054|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
32825055|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
32825056|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
32825057|NCT05622760|Experimental|Audiovisual information|Group of participants to whom the information is given through an audiovisual medium.
32825058|NCT05622760|Placebo Comparator|Written information|Group of participants to whom the information is given through the writing that is available on the website of the health organization.
32825059|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
32825060|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
32825061|NCT01711372|Placebo Comparator|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
32825062|NCT01711372|Active Comparator|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
32825063|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
32825064|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
32825065|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
32825066|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
32825067|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
32825068|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
32825069|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
32825070|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
32825071|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
33102024|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
33102025|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source~1 once daily during 2 months"
33102026|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source~1 once daily during 2 months"
33102027|NCT02922491|Placebo Comparator|Group control|"400 mg of starch~1 once daily during 2 months"
33102028|NCT02922491|No Intervention|No intervention|Without intervention
33102029|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
33102030|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
33102031|NCT04687722|Experimental|High Intensity Aerobic Training Group.|The experimental group will receive High Intensity Aerobic Training at 80-90% of Heart Rate Maximum calculated using karvonen rule.
33102032|NCT04687722|Active Comparator|Control Group|The control group will receive routine low Intensity aerobic Training at 40-60% of Heart Rate Maximum calculated using karvonen rule.
33102033|NCT03457454||Primary Care Provider/Staff Participants Interviews|"Up to two primary care providers and at least one staff person at each of the 16 clinics, with approximately 5 interviewees per clinic. Eligible providers and staff include physicians, nurse practitioners, nurses, case managers, medical assistants, administrative staff, or other employees of the clinic involved in the cancer screening and follow-up process.~If the participant verbally consents, the research team member will conduct an interview with the provider to learn about the current processes used to support and monitor colorectal cancer screening (CRC) from screening initiation through follow-up; assess capacity and interest in implementing Evidence Based Practices for supporting and monitoring CRC screening, including any ideas interviewees have or find appealing; and engage the organizations as partners to build interest, capacity, and infrastructure for future intervention trial and other future studies."
33102034|NCT03457454||Patient Participants Interviews|"10 patients across 5 clinics will be recruited for interviews, which will address the patient experience with screening and follow-up.~If the participant verbally consents, the research team member will conduct an interview with the patient participant to gain a deeper understanding of the CRC screening process from the patient's perspective; the gaps, challenges, or road blocks/speed bumps to completing CRC screening steps; and what organizations can do better or differently to help people complete the CRC screening process."
33102035|NCT03457454||Patient Participants Anonymous Survey|-Patient participants will be recruited to take an anonymous mailed survey, which will address patient level barriers to screening and follow-up focusing on out of pocket costs.
33102036|NCT03457454||Colonoscopy Provider/Staff Participants Interviews|"Colonoscopy providers and a staff or mid-level provider in each office will be recruited for interviews.~If the participant consents, the research team member will conduct an interview to learn about current processes used to support and monitor colorectal cancer screening from the perspective of gastroenterology/colonoscopy sites and to learn about how gastroenterology/colonoscopy sites communicate and coordinate care with other healthcare organizations and patients to support and monitor colorectal cancer screening."
33102037|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
33102038|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
33102039|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
33102040|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
32825072|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
32825073|NCT02496546|Experimental|LEO 32731 cream|Topical application
32825074|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
32825075|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
32825076|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
32825077|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
32825078|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
32825079|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
32825080|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
32825081|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
32825082|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
32825083|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
32825084|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
32825085|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
32825086|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
32825087|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
32825088|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
32825089|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
32825090|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
32825091|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
32825092|NCT02494284|Experimental|Short term dual therapy|
32825093|NCT02494284|Active Comparator|Long term dual therapy|
32825094|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
32825095|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
32825096|NCT03342066||A|Cariogram
32825097|NCT03342066||B|CAMBRA
32825098|NCT04226872|Experimental|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
32825099|NCT04226872|No Intervention|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
32825100|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
32825101|NCT05611840|Experimental|Robotic group|One-stage robotic common bile duct exploration and cholecystectomy
32825102|NCT05611840|Active Comparator|Endo-laparoscopic group|Two stage therapeutic endoscopic retrograde cholangiopancreatography (ERCP) with interval laparoscopic cholecystectomy
32825103|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
32825104|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
32825105|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
32825106|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
32825107|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
32825108|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
32825109|NCT04187326|Experimental|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
32825110|NCT04187326|Experimental|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
32825111|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
32825112|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
32825113|NCT04494828|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/ kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
32825114|NCT04494828|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
32825115|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
32825116|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
32825117|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
32825118|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
32825119|NCT04494906|Experimental|Interactive stepping exercise group|Participants will execute interactive stepping exercise 2 times per week for 8 weeks (16 sessions).
32825120|NCT04494906|Active Comparator|Square stepping exercise group|Participants will execute square stepping exercise 2 times per week for 8 weeks (16 sessions).
32825121|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
32825122|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
32825123|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
32825124|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
32825125|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
32825126|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
32825127|NCT01714804|Experimental|Prospective|Accell Evo3
32825128|NCT05582434|Experimental|One gel treatment|Every participant will be instructed to apply a topical retinoid every day.
32825129|NCT05582434|Experimental|Two gel treatment|One-third of the participants will be instructed to apply adapalene and the clindamycin phosphate/benzoyl peroxide gel every day.
32825130|NCT05582434|Experimental|Three gel treatment|One-third of the participants will be instructed to apply adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.
32825131|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
32825132|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
32825133|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
32825134|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
32825135|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
32825136|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
32825137|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
32825138|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
32825139|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
32825140|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
32825141|NCT04167358|Experimental|Participants receiving linerixibat|Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER [Group 1]) and Phase 3 study (212620 GLISTEN [Group 2]), will receive linerixibat.
32825142|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
32825143|NCT03340194||Systemic sclerosis patients|
32825144|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
32825145|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
32825146|NCT04102150|Experimental|DS-3201b|
32825147|NCT05465460|Active Comparator|Banana blossom|Participants received banana blossom 225 mg tablet orally four time per day for 14 days.
32825148|NCT05465460|Placebo Comparator|Placebo|Participants received placebo tablet orally four time per day for 14 days.
32825149|NCT04072744||Participants|General Study Participants
32825150|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
32825151|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
32825152|NCT04046224|Experimental|Sequential dose escalation|"ST-920 is administered as a single infusion:~Cohort 1: 0.5e13 vg/kg~Cohort 2: 1.0e13 vg/kg~Cohort 3: 3.0e13 vg/kg~Cohort 4: 5.0e13 vg/kg"
32825153|NCT04046224|Experimental|Expansion Cohorts|"Anti Alpha-Gal A Antibody Positive Cohort~Anti Alpha-Gal A Antibody Negative Cohort~Female Cohort~Renal Cohort~Cardiac Cohort"
32825154|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
32825155|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
32825156|NCT03339960|Active Comparator|Robotic camera controlled|
32825157|NCT03339960|Active Comparator|Human camera controlled|
32825158|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
32825159|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
32825160|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
32825161|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
32825162|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
32825163|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
32825164|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
32825165|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
32825166|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:~E-Content Clinics- Content Clinics are offered online using digital video technology.~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
32825167|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
32825168|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
32825169|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
32825170|NCT02494128|Active Comparator|Intervention group|Education in group leadership
32825171|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
32825172|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
32825173|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
32825174|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
32825175|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
32825176|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
32825177|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
32825178|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
32825179|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
32825180|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
32825181|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
32825182|NCT03330990|Other|Entrectinib / Midazolam|
32825183|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
32825184|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
32825185|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
32825186|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
32825187|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
32825188|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
32825189|NCT01785875|Experimental|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
32825190|NCT03334968||Patient group|Acute ischemic stroke patients
32825191|NCT03334968||Control group|Those served as control group
32825192|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
32825193|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
32825194|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
32825195|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
32825196|NCT04576715|Experimental|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
32825197|NCT04576715|Active Comparator|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
32825198|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
32825199|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
32825200|NCT04576559|Experimental|Modified dental visual aids|
32825201|NCT04576559|Active Comparator|Regular dental visual aids|
32825202|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
32825203|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
32825204|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
32825205|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
32825206|NCT03338946||CIED subjects|CIED interrogation
32825207|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
33102041|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
32955966|NCT05765578||Moderna-Only Vaccine/Booster Series (MMMM Group)|Individuals who previously received Moderna COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Moderna mRNA1273.222).
32825208|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
32825209|NCT04494204|Experimental|Intervention|2 tablets Immunofree 500 mg tablets thrice a day for 10 days and 1 capsule Reginmune 750 mg twice a day for 10 days
32825210|NCT04494204|Active Comparator|Comparator Agent|As per standard National Clinical Management Protocol for COVID-19 by Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services, (EMR Division), Version 3, 13.06.20
32825211|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
32825212|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
32825213|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
32825214|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
32825215|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
32825216|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
32825217|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
32825218|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
32825219|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
32825220|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
32825221|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825222|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825223|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825224|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825225|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825226|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825227|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
33102042|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
32825228|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825229|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825230|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825231|NCT03330132|Experimental|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
32825232|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
32825233|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
32825234|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
32825235|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
32825236|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
32825237|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
32825238|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
32825239|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
32825240|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
32825241|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
32825242|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
32825243|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
32825244|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
32825245|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
32825246|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
32825247|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
32825248|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
32825249|NCT03329742|Experimental|Low protein diet arm|10% protein content
32825250|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
32825251|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
32825252|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
32825253|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
32825254|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
32825255|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
32825256|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
32825257|NCT03329586|Experimental|Training|
32825258|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed~at baseline: on admission to inpatient treatment~at follow-up: 6 months after admission on outpatient basis"
32825259|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
32825260|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
32825261|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
32825262|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
32825263|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
32825264|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
32825265|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
32825266|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
32825267|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
32825268|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
32825269|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
32825270|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
32825271|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
32825272|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
32825273|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
32825274|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
32825275|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
32825276|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
32825277|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
32825278|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
32825279|NCT03875638|Experimental|Early Alzheimer's Disease Group Low Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of low-dose levetiracetam (125 mg twice daily)
32825280|NCT03875638|Experimental|Early Alzheimer's Disease Group High Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of high-dose levetiracetam (500mg twice daily).
32825281|NCT03875638|Placebo Comparator|Early Alzheimer's Disease Group Placebo|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of placebo twice daily.
32825282|NCT03875638|No Intervention|Healthy Control Group|A group of demographically similar subjects without Alzheimer's Disease will undergo baseline testing only, without any intervention
32825283|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
32825284|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
32825285|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Carboplatin will be administered intravenously 3 times per cycle"
32825286|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Cyclophosphamide will be administered once per cycle"
32825287|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
32825288|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
32825289|NCT05560360|Experimental|healthy subjects|
32825290|NCT05464602|Experimental|Intervention group Lavender|Each patient in this group received inhalation aromatherapy of lavender oil.
32825291|NCT05464602|Experimental|Intervention group Geranium|Each patient in this group received inhalation aromatherapy of geranium oil.
32825292|NCT05464602|No Intervention|Control group|Each patient in this group did not receive any additional treatment.
32825293|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
32825294|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
32825295|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
32825296|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
32825297|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
32825298|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
32825299|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
32825300|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
32825301|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
32825302|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
32825303|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF~SVF will be cultured to abstain MSC~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
32825304|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
32825305|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
32825306|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
32825307|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
32825308|NCT03337932|Active Comparator|MEM-7 days doxycycline|
32825309|NCT03337932|Active Comparator|MEM-14 days doxycycline|
32825310|NCT03337932|Placebo Comparator|Controls|
32825311|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
32825312|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
32825313|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
32825314|NCT03333564|Other|Control group|No intervention was given
32825315|NCT05464446||Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 5 and 18 who were diagnosed with DMD by a specialist physician as a result of gene analysis and/or muscle biopsy and their families were included in the study.
32825316|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
32825317|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
32825318|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.~Intervention is related to the administration of contrast agents:~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
32825319|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
32825320|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
32825321|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
32825322|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
32825323|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
32825324|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
32825325|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
32825326|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
32825327|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
32825328|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
32825329|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
32825330|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
32825331|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
32825332|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
32825333|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
32825334|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
32825335|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
32825336|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
32825337|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery~Ocusweep system compared to neuropsychological testing"
32825338|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
32825339|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
32825340|NCT03337386|Experimental|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
32825341|NCT03337386|Experimental|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
32825342|NCT03337386|Active Comparator|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
32825343|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
32825344|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
32825345|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
32825346|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
32825347|NCT03328260|Experimental|Treatment|
32825348|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
32825349|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
32825350|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
32825351|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
32825352|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
32825353|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
32825354|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
32825355|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
32825356|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
32825357|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
32825358|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
32825359|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
32825360|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|500 mg vitamin C /day
32825361|NCT04494282|Active Comparator|Same day|The ERP will be performed the same day of the endoscopic drainage of PP
32825362|NCT04494282|Active Comparator|Other day|The ERP will be performed 6 weeks after the endoscopic drainage of PP.
32825363|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
32825364|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
32825365|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
32825366|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
32825367|NCT03327870||1|Sjogren's Syndrome
32825368|NCT03327870||2|Sicca
32825369|NCT03327870||3|Incomplete Sjogren's Syndrome
32825370|NCT03327870||4|Healthy Volunteers
32825371|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
32825372|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
32825373|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
32825374|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
32825375|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
32825376|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
32825377|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
32825378|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
32825379|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
32825380|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
32825381|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
32825382|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
32825383|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
32825384|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
32825385|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
32825386|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
32825387|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
32825388|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
32825389|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
32825390|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
32825391|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
32825392|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
32825393|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
32825394|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
32825395|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
32825396|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
32825397|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
32825398|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
32825399|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
32825400|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
32825401|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
32825402|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825403|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825404|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825405|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825406|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825407|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
32825408|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
32825409|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
32825410|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
32825411|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
32825412|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
32825413|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
32825414|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
32825415|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
32825416|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
32825417|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~There were no tension on the tape and no muscle stretching during the application."
32825418|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
32825419|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
32825420|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
32825421|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
32825422|NCT05542576|Experimental|AMDX2011P 25mg|25mg (1ml) single bolus injection intravenous for diagnostic review
32825423|NCT05542576|Experimental|AMDX2011P 50mg|AMDX2011P 50mg (2ml) single bolus injection intravenous for diagnostic review
32825424|NCT05542576|Experimental|AMDX2011P 100mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
32825425|NCT05542576|Experimental|AMDX2011P 200mg|AMDX2011P 200mg (6-8ml) single bolus injection intravenous for diagnostic review
32825426|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
32825427|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
32825428|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
32825429|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
32825430|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
32825431|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
32825432|NCT03679624|Experimental|Cohort A - Ibrutinib naive|Cohort A will consist of subjects who are ibrutinib naïve and appropriate for ibrutinib based treatment. Treatment naïve subjects will be eligible to enroll in this cohort. All subjects in this cohort will receive ibrutinib plus daratumumab
32825433|NCT03679624|Experimental|Cohort B - Ibrutinib response plateau|Cohort B will consist of subjects who have had at least 6 months of exposure to single agent ibrutinib and who have demonstrated an IgM response plateau defined by two IgM measurements, at least 8 weeks apart that have changed <15% from the previous mark. All subjects in this cohort will receive ibrutinib plus daratumumab
32825434|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
32825435|NCT05530720||Online survey with 3.000 participants using mobile website technology|
32825436|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
32825437|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
32825438|NCT05464368|Experimental|Cohort 1: (A+; CDR = .5, 1; AD)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan #1. If a 3rdPET scanoccurs,this third scanwill always be [18F]GTP1.
32825439|NCT05464368|Experimental|Cohort 2: (A-; CDR=0; OC)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan#1.If a 3rdPET scan occurs, this third scan will always be [18F]GTP1.
32825440|NCT05464368|Experimental|Cohort 3: (A+; CDR = 0, .5, 1; AD)|Unblinded and randomized to receive 18F-RO948or 18F-MK6240 or [18F]GTP1for PET Scan #1. PET scan #2 will be 18F-RO948or 18F-MK6240 or [18F]GTP1NOT received in PET scan #1. PET scan # 3 will be 18F-RO948or 18F-MK6240 or [18F]GTP1NOT received in PET scan #1 or #2. Efforts will be made to include about 1/3 CDR = 0; 1/3 CDR = .5; 1/3 CDR = 1 in Cohort 3. Efforts will also be made to completethe study with about equal numbers of subjects whose PET scan #1 start with each of the three tracers.
32825441|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
32825442|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
32825443|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
32825444|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
32825445|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
32825446|NCT02490618|Experimental|Test|Probiotic tablet
32825447|NCT02490618|Placebo Comparator|Control|Control tablet
32825448|NCT05464290|Experimental|Nanofat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels.
32825449|NCT03331848|Placebo Comparator|PLACEBO|
32825450|NCT03331848|Experimental|PXT002331 - 20mg|
32825451|NCT01728844|Active Comparator|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
32825452|NCT01728844|Experimental|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
32825453|NCT01728844|Experimental|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
32825454|NCT01728844|Experimental|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
32825455|NCT04494126|Experimental|Tranexamic acid|Experimental: TXA Group One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
32825456|NCT04494126|Placebo Comparator|Placebo|Placebo Comparator: Control Group Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
32825457|NCT05517694|Experimental|pelvic floor exercises, behavioral therapy and respiratory exercises group|Interventions of this group include pelvic floor exercises and behavioral therapy plus respiratory exercises for 8 weeks.
32825458|NCT05517694|Active Comparator|pelvic floor exercises and behavioral therapy group|Interventions of this group include pelvic floor exercises and behavioral therapy for 8 weeks.
32825459|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
32825460|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
32825461|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
32825462|NCT05503966|Experimental|Positive ABM|The ABM intervention will be initiated two weeks after antidepressant treatment started (baseline) and continues with two daily sessions for two weeks.
32825463|NCT05503966|Active Comparator|No ABM|This group will in addition to TAU complete the schedule of intermediate assessments as in the ABM group, but no ABM , thus controlling for the aspects of the ABM group that are additional to TAU (increased engagement in cognitive activity and repeated assessment over time), but not including the training component itself (SSRI Active comparison group).
32825464|NCT05503966|No Intervention|TAU|Patients allocated to this group will be assessed at baseline and at the primary end-point as well after 12 weeks and 6 months follow-up. They will not complete any instruments during the intervention period to prevent the effect of some cognitive activity and provide a more ecologically valid version of TAU as it happens in primary care.
32825465|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
32825466|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
32825467|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
32825468|NCT03323970||Physicians|
32825469|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
32825470|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
32825471|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
32825472|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
32825473|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
32825474|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
32825475|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
32825476|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
32825477|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
32825478|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
32825479|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
32825480|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
32825481|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
32825482|NCT05469412|Experimental|Interventional group|Standard management combined with distraction by using technology (Tablets/iPads).
32825483|NCT05469412|Active Comparator|Control group|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
32825484|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
32825485|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
32825486|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
32825487|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
32825488|NCT04851496||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32825489|NCT04851496||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32825490|NCT04851496||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32825491|NCT04851496||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32825492|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
32825493|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
32825494|NCT04838782|Experimental|Repeat Surgical Resection|Standard surgical operative management according to local practices.
32825495|NCT04838782|Active Comparator|Management Without Re-operation|Non-surgical management with standard care according to local practices.
32825496|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
32825497|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
32825498|NCT05317156|Experimental|Prone position-Cold vapor group|Cold vapor will be applied to the prone position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
32900971|NCT05255172|Experimental|Supervised exercise|The exercise intervention will include 2 supervised sessions of ergometer cycling with a warm up period of 10 minutes and 20 minutes of cycling at the aerobic intensity below the anaerobic threshold as determined from baseline results. Patients in the exercise arm will have 1 unsupervised exercise session where the participants walk or bicycle for 30 minutes at an intensity experienced as somewhat hard (Borg 13) according to the Borg Rating of Perceived Exertion Scale.
32900972|NCT05255172|No Intervention|Standard of Care|The control group will receive advise to continue to live as usual. After 4 and 8 weeks, participants in the control group will be contacted by telephone for inquiry of general wellbeing. No other interventions will be performed in the control group.
33317931|NCT05669222|Experimental|FAST Guided Strategy (μQFR+RWS)|"μQFR is measured in all non-infarct related arteries containing any non-culprit lesion with visually-assessed DS% ≥50% and ≤90% with RVD ≥2.5 mm.~μQFR ≤0.80: PCI~RWS ≥13%: PCI~μQFR >0.80 and RWS <13%: Deferral~DS% >90%: PCI without the need of μQFR or RWS~For all patients undergoing PCI, post-PCI μQFR measurement is recommended; if μQFR <0.90, if the reason is obvious post-dilation with a non-compliant balloon or bail-out stenting should be considered; if the reason is not obvious intravascular imaging should be considered."
32900974|NCT05294328|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|Aceclidine/Brimonidine combination ophthalmic solution
32900975|NCT05294328|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|Aceclidine ophthalmic solution
32900976|NCT05294328|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary Vehicle ophthalmic solution
32900977|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~smectite, dose 3 g, once daily orally until diarrhea stopped"
32900978|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
32900979|NCT05254626|Experimental|Diabetic Group 1|40 diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
32900980|NCT05254626|Active Comparator|Diabetic Group 2|40 diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
32900981|NCT05254626|Experimental|Non-diabetic Group 1|40 non-diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks.
32900982|NCT05254626|Active Comparator|Non-diabetic Group 2|40 non-diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
32900983|NCT05254236|Experimental|Medium-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using medium-dose COVID-19 Vaccine (Vero Cell), Inactivated
32900984|NCT05254236|Experimental|High-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using high-dose COVID-19 Vaccine (Vero Cell), Inactivated
32900985|NCT05293002|Experimental|Restorer Iliac Stent System|RESTORER Iliac Stent system for the treatment of Aorto-iliac lesions (TASC A, B, C and D) according to IFU
32900986|NCT05202912|Other|Cohort A(Food effect)|
32825499|NCT05317156|Experimental|Supine position-Cold vapor group|Cold vapor will be applied to the supine position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
32825500|NCT05317156|No Intervention|Prone position-Control group|Patients in the prone position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
32825501|NCT05317156|No Intervention|Supine position-Control Group|Patients in the supine position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
32825502|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
32825503|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
32825504|NCT05446714|Active Comparator|conventional hyrax|CH 4 BANDS for expansion of maxilla and observation improvement of the air way
32825505|NCT05446714|Active Comparator|Hybrid hyrax|HH 2 BANDS for expansion of maxilla and observation improvement of the air way
32825506|NCT05446714|Active Comparator|Maxillary skeletal expander|MSE 2 BANDS AND 4 for expansion of maxilla and observation improvement of the air way
32825507|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
32825508|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
32825509|NCT05316922|Experimental|TSH suppression during irradiation|"From 14 days beforehand and throughout their RT, patients in the experimental arm will receive L-thyroxine in the morning, starting with 1-2 μg/kg, and adjusting the dose every 3 days to ensure TSH < 0.3 μIU/mL before RT beginning. The 0.3 μIU/mL threshold is just below normal range not causing hyperthyroidism, and is defined as mild TSH suppression. Based on hormone status, L-thyroxine doses will be gradually increased to patients' individual minimum TSH-suppressive dose before starting RT, maintained throughout the treatment, then rapidly tapered off and stopped. During radiation treatment course will be checked twice a week for serum FT3, FT4, TSH assays in order to maintain TSH < 0.3 μIU/mL, possibly without exceeding normal levels of FT3 and FT4. Once a week patients will also have a full visit and any other blood examination according to protocol in use and Institutional practice."
32825510|NCT05316922|No Intervention|Any TSH suppression during irradiation|Patient in the standard arm will perform radiotherapy treatment without any TSH suppression. At the end of radiation they will do serum FT3, FT4, TSH assay and then, after one year from RT, thyroid ultrasound + serum FT3, FT4, TSH assay.
32825511|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
32825512|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
32825513|NCT05316844||Office Employees Group|Office Employees with neck pain
32825514|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
32825515|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
32825516|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
32825517|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
32825518|NCT04836520|Experimental|SHR6390+anatrozole|Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
32825519|NCT03331458|Experimental|subjects with prostate cancer|
32825520|NCT04826692|Experimental|Metformin|Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
32900987|NCT05202912|Other|Cohort B(Single dose)|
32825521|NCT04826692|Placebo Comparator|Placebo|Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
32825522|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
32825523|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
32825524|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
32825525|NCT04825990|Experimental|Single Arm Treatment|Patients will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week dosing cycle (Q3W) and olaparib 300 mg capsules twice a day (BID) every day starting from Day 1 of Cycle 1. Treatment with protocol therapy will continue until objective disease progression, any prohibitive toxicity or until a maximum of 35 treatment cycles (up to 2 years).
32825526|NCT03326466||Patients with SAP|
32825527|NCT03326466||Healthy Controls|
32825528|NCT04816474|Experimental|Education and Phone Counseling Service|Patients in this group will be trained online for 6 weeks. After the online training is over, a telephone consultation service will be provided once a week for 6 weeks.
32825529|NCT04816474|No Intervention|Control|No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
32825530|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
32825531|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
32825532|NCT04809298|Other|Free-hand lumbar punction|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the free-hand method.
32825533|NCT04809298|Active Comparator|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
33405224|NCT04053530|Experimental|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
33405225|NCT04053530|Experimental|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
33405226|NCT04053530|Active Comparator|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
32825534|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
32825535|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
32825536|NCT01738672|Experimental|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
32825537|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
32825538|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
32825539|NCT04790578|Experimental|ZoeInsights Application Arm|Participants will receive free access to the ZI app for the 12-week intervention. After completing initial set-up, participants will be asked to record physical activity and symptoms regularly via scheduled in-app routines. Further use of ZI (eg. Custom daily routines, additional graphing, medication tracking, accessing linked health resources) during the intervention will be possible ad libitum. After the initial 12-weeks of the EXCEL+ZI intervention, participants have continued free access to the ZI app for up to 1 year.
32825540|NCT04790578|Active Comparator|Waitlist control|During the 12-week intervention the participants will only take part in an online delivered EXCEL exercise class and will not have access to the ZI app. After completion of the 24-week test, the participants will be granted access to the ZI app.
32825541|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
32825542|NCT05316766|Experimental|Intervention|Will receive intervention through the multi-user touch surface
32825543|NCT05316766|Active Comparator|Treatment as usual|This will receive conventional therapy
32825544|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
33405227|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
33405228|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
32825545|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
32825546|NCT05316454|Experimental|Experimental|Patients with hypertension benefit from self-efficacy support in terms of medication adherence and self-efficacy.
32825547|NCT05316454|No Intervention|Control|No change.
32825548|NCT01808651|Experimental|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
32825549|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease~Clinical intervention:~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
32825550|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry~Clinical intervention: Inhaled corticosteroids (ICS)"
32825551|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma~Clinical Intervention: LABA + LAMA + ICS"
32825552|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma~Clinical Intervention: LABA + ICS inhaled therapy"
32825553|NCT02488590||OTHER|"patients with another diagnosis or healthy persons~clinical Intervention: undefined - according to diagnosis"
32825554|NCT01738750|Experimental|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
32825555|NCT01738750|No Intervention|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
32825556|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
32825557|NCT05316376|Experimental|dd-nabTC|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5, day 1, every 4 weeks)
32825558|NCT05316376|Active Comparator|CONTROL|paclitaxel (175 mg/m2, day 1, every 4 weeks) combined with carboplatin (AUC=6, day1, every 4 weeks)
32825559|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
32825560|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
32825561|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
32825562|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
32825563|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
32825564|NCT01743976|Experimental|Donepezil|donepezil 5 mg every day
32825565|NCT01743976|Placebo Comparator|Placebo|Placebo (sugar pill) every day
32825566|NCT05316064|Experimental|probiotic 9 log CFU/day|Intervention consists of daily oral administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
32825567|NCT05316064|Placebo Comparator|placebo|placebo contains primarily carrier without probiotic and it is identical in taste and appearance and appear as light-yellow powder. It is also taken by the participants for 12 weeks.
32825568|NCT05315986|Experimental|Group 1: Sleep intervention (ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
32825569|NCT05315986|Experimental|Group 2: Sleep intervention (ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
32825570|NCT05315986|Experimental|Group 3: No sleep intervention (Control ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
32825571|NCT05315986|Placebo Comparator|Group 4: No sleep intervention (Control ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
32825572|NCT05464212|Active Comparator|USG Guided Greater Occipital Nerve Block (GONB)|
32825573|NCT05464212|Active Comparator|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency (GONB+PRF)|
32825574|NCT05315908|Active Comparator|Automated call|Patients receive up to two automated phone calls in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
32825575|NCT05315908|Active Comparator|Text messaging|Patients receive up to two text messages in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
32825576|NCT05315830|Experimental|HER2 Vaccine alone|0.6 μg HER2 Vaccine
32825577|NCT05315830|Experimental|HER2 Vaccine plus Standard of Care Chemotherapy|0.6 μg HER2 Vaccine plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy
32825578|NCT05464056|Experimental|BUILT Study|One group receives the intervention.
32825579|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
32825580|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
32825581|NCT05315440|Active Comparator|control group|"The treatment of control group will be organized according to the classic protocol currently in use in our Institute which consists of:~30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation."
32825582|NCT05315440|Experimental|experimental group|30 minutes of passive and active assisted mobilization guided by the therapist associated with instrument assisted soft tissue mobilization, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
32825583|NCT04442568|Active Comparator|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
32825584|NCT04442568|No Intervention|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
32825585|NCT04716322|Other|Adapted Physical Activity|A 16-week health-adapted physical activity program and 5-year follow-up
32825586|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
32825587|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF"
32825588|NCT05463822|Experimental|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
32825589|NCT04639960|Experimental|Risperidone|
32825590|NCT04639960|Placebo Comparator|Placebo|
32825591|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
32825592|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
32825593|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
32825594|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
32825595|NCT04597996|Experimental|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied twice, the first one to be performed 4 weeks after Web-based education is completed and the second one 3 months after Web-based education is completed.
32825596|NCT04597996|No Intervention|No Intervention Group|The control group will not have any intervention during the study.
32825597|NCT04579120||African American|African American participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
32825598|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
32825599|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
32825600|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
32825601|NCT04566016|Experimental|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
32825602|NCT04566016|Active Comparator|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
32825603|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
32825604|NCT03320538|Experimental|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
32825605|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
32825606|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
32825607|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
32825608|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
32825609|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
32825610|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
32825611|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
32825612|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
32825613|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
32825614|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
32825615|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
32825616|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
32825617|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
32825618|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
32825619|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
32825620|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
32825621|NCT03325764|Other|sleeve gastrectomy|Assessment before and after sleeve gastrectomy
32825622|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
32825623|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
32825624|NCT01746784|Experimental|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
32825625|NCT01746784|Placebo Comparator|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
32825626|NCT04513678|Experimental|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
32825627|NCT04513678|No Intervention|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
32825628|NCT04507360|Experimental|Engagement Strategy - 1|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
32825629|NCT04507360|Experimental|Engagement Strategy - 2|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
32825630|NCT00706134|Placebo Comparator|Placebo|
32825631|NCT00706134|Experimental|Aliskiren 75 mg|
32825632|NCT00706134|Experimental|Aliskiren 150 mg|
32825633|NCT00706134|Experimental|Aliskiren 300 mg|
32825634|NCT04474834||PRS|Providing polygenic risk score (PRS)
32825635|NCT04471714|Experimental|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
32825636|NCT04471714|Experimental|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
32825637|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
32825638|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
32825639|NCT05405790||Patients receiving TEVAR|
32825640|NCT05315284|Other|Patients with fresh non-comminuted fracture mid-shaft clavicle|
32825641|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
32825642|NCT05315206|Experimental|Citicoline Treated Group, TC Group|In a group of patients with open angle glaucoma (OAG), Citicoline in oral solution (10 ml / day) will be administered for 12 months (Citicoline Treated Group, TC Group)
32825643|NCT05315206|Placebo Comparator|Placebo Treated Group, TP Group|in another group of patients with open angle glaucoma (OAG) will be administered Placebo (Containing all excipients of Citicoline in oral solution) (10 ml / day) for 12 months (Placebo Treated Group, TP Group)
32825644|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
32825645|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
32825646|NCT03325686|Experimental|vitamin D supplement|D
32825647|NCT03325686|Placebo Comparator|control|P
32825648|NCT05315128|Active Comparator|Intralesional methotrexate|Group A 30 patients received intralesional injection of MTX with an insulin syringe into the tumor at a dose ranging between 12.5 mg to 25 mg according to the tumor size every week until complete improvement or for a maximum of 8 sessions.
32825649|NCT05315128|Active Comparator|Intramuscular methotrexate|Group B 30 patients received systemic MTX (SC, or IM) was injected at a dose of 25 mg every week until clearance or for a maximum of 8 sessions.
32825650|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
32825651|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
32825652|NCT05315050|Experimental|Educational session and Informational Pamphlet|
32825653|NCT05315050|Active Comparator|Informational Pamphlet|
32825654|NCT05314504|Experimental|Test group|Treatment administration to subjects
33405229|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
32825655|NCT05314504|No Intervention|Control group|After primary endpoint evaluation, eligible subjects will receive treatment at Week 12
32825656|NCT03322410|Experimental|Patients|
32825657|NCT05300308||transperitoneal pelvic lymph node dissection for treatment of urogenital cancer|patients planned for transperitoneal pelvic lymph node dissection for treatment of urogenital cancer (including prostate or bladder cancer)
32825658|NCT03325530||Focus Group|
32825659|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
32825660|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
32825661|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
32825662|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
33102043|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
33317932|NCT05669222|Sham Comparator|Standard Treatment Strategy|"PCI should be performed of all non-culprit lesions with visual DS% ≥70% in all non-infarct related arteries with RVD ≥2.5 mm;~For a non-culprit lesion with visually DS% 50-70%, PCI can be performed if FFR ≤0.80 or iFR ≤0.89."
33317933|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
33317934|NCT02473874||Skin Spect dermoscope|Skin mole
32825663|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
32825664|NCT01808573|Experimental|neratinib plus capecitabine|neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
32825665|NCT01808573|Active Comparator|lapatinib plus capecitabine|lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
32825666|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
32825667|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
32825668|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
32825669|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
32825670|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
32825671|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
32825672|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
32825673|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
32825674|NCT01746940|Placebo Comparator|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
32825675|NCT01746940|Active Comparator|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
32825676|NCT01746940|Active Comparator|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
32825677|NCT03325218||Questionnaire Set A|
32825678|NCT03325218||Questionnaire Set B|
32825679|NCT01747330|Experimental|Creon micro, minimicrospheres|
32825680|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
32825681|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
32900024|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
32825682|NCT04493580|Experimental|iDBT Treatments|15 weekly DBT sessions. During each session, participants will be sent 30-40 PowerPoint slides including general information on particular topic, overview of skills, and homework sheets to be completed and returned to therapists. Therapists involved will be a psychiatry resident, a psychologist, and a registered nurse who will also facilitate the in-person groups. The content and format of the online program will directly corresponded with that of the in-person group. Participants will be asked to send their homework sheets back to therapists by a specific day each week. The following day, the therapist will email feedback regarding the homework submitted and send next week's PowerPoint slides, information sheets, and homework. In order to be eligible to receive the materials, participants are required to send in homework prior to deadline. If homework was not returned, reminder email will be sent. If more than two sessions are missed, participants are excluded from the program.
32825683|NCT04493580|Active Comparator|In-Person DBT Treatments|Weekly skills-building groups titled Managing Powerful Emotions (MPE) includes Mindfulness, Distress Tolerance, Emotion Regulation, and Interpersonal Effectiveness. Personality Disorders Service offers more advanced therapy groups for individuals who have successfully completed MPE and wish to continue seeking treatment modalities. Chrysalis Day Treatment Program (CDTP) is for an individual who has progress through two prior phases. In phase one, individuals will participate in a DBT-informed skill-building group (MPE). Once completed, the individual will progress to phase two which includes attending a psychotherapy group, incorporating DBT skills-building. Finally, in phase three, individuals who wish to participate in a more advanced and complex psychological treatment program, apply to participate in CDTP. The CDTP is an intensive day treatment program integrating DBT skills-building, psychodynamic psychotherapy, and a range of other group therapy modalities.
32825684|NCT04769128|Active Comparator|Group (A) (control group)(traditional physical therapy programme)|Group (A) (control group): Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training. 3 sessions/ week for 12 weeks.
32825685|NCT04769128|Experimental|Group (B) (experimental or manipulative group)|"Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training in addition to T3-T4 thoracic manipulation (Maitland screw technique grade V) 3 sessions/ week for 12 weeks."
32825686|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
32825687|NCT05253274|Experimental|Virtual Reality application group|VR application will be applied to the experimental group during the emergency surgical intervention under local anesthesia.
32825688|NCT05253274|No Intervention|Control|The patients in the control group routinely receives standard care in the emergency service. No application will be made to the control group.
32825689|NCT04442958|Experimental|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
32825690|NCT04442958|No Intervention|Non-Plasma Therapy Group|Standart critical care treatment group
32825691|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
32825692|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
32825693|NCT04443114|Other|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
32825694|NCT04443114|Other|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
32825695|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
32825696|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
32825697|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
32825698|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
32825699|NCT03319758|Experimental|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
32825700|NCT05220748|Experimental|RM-1995 Photoimmunotherapy (Phase 1a Monotherapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
32825701|NCT05220748|Active Comparator|RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
32825702|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
32825703|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
32825704|NCT04400578|Experimental|TRICIN|"If a patient is eligible~local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application~Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application~Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
32825705|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
32825706|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
32825707|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
32825708|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
32825709|NCT01808339|Experimental|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
32825710|NCT01808339|Experimental|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
32825711|NCT01808339|Placebo Comparator|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
32825712|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
32825713|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
32825714|NCT01749904|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
32825715|NCT01749904|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
32825716|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
32825717|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
32825718|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
32825719|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
32825720|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
32825721|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
32825722|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
32825723|NCT04585139|Other|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
32825724|NCT04585139|Active Comparator|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
32825725|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
32825726|NCT04311268|Experimental|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
32825727|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
32825728|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
32825729|NCT05190874||Device: Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler Interference Screw System
32825730|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
32825731|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
32825732|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
32825733|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
32825734|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
32825735|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
32825736|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
32825737|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
32825738|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
32825739|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
32900025|NCT03917966|Experimental|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
32900026|NCT03917966|Experimental|SHR-1210+Apatinib|SHR-1210+Apatinib
32900027|NCT00242684||Group 1|older patients admitted to a TCU unit
33317935|NCT02473874||Spatially modulated quantitative|Skin mole
32825740|NCT01751230|Experimental|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
32825741|NCT01751230|No Intervention|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
32825742|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
32825743|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
32825744|NCT05182606|Experimental|Implementation bundle|"Participating clinics will experience integration of the Implementation Bundle into their practices."
32825745|NCT05164432|Experimental|High risk of preterm birth|Women at high risk of preterm birth
32825746|NCT05164432|Active Comparator|Women with low risk pregnancies|Women with uncomplicated pregnancies anticipated to deliver at term
32825747|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
32825748|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
32825749|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
32825750|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
32825751|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
32825752|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
32825753|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
32825754|NCT05463588|Experimental|Collection of pre-test data from the experimental and control groups|Asking vas, ODI, sf-36 quality of life scale questions
32825755|NCT05463588|Experimental|Calculation of the pre-test fall risk index|Calculation of patients' fall risk indices
32825756|NCT05463588|Experimental|giving back health education to the experimental and control groups|Back health training was given to both groups, and the experimental group was given training on using virtual glasses.
32825757|NCT05463588|Experimental|collection of post-test data for the experimental and control group|Asking vas, ODI, sf-36 quality of life scale questions
32825758|NCT05463588|Experimental|Calculation of the post-test fall risk index|Calculation of patients' fall risk indices
32825759|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
32825760|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
32825761|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
32825762|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
32825763|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
32825764|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
32825765|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
32825766|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
32825767|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
32825768|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
32825769|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
32825770|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
32825771|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
32825772|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
32825773|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
32825774|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
32825775|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
32825776|NCT02487654|Active Comparator|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
32825777|NCT02487654|Experimental|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
32825778|NCT03315936|Experimental|Single rising dose part|
32825779|NCT03315936|Experimental|Relative bioavailability (rel BA) part|
32825780|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
32825781|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
32825782|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
32825783|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
32825784|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
32825785|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
32825786|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
32825787|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
32825788|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
32825789|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
32825790|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
32825791|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
32825792|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
32825793|NCT03319056|Active Comparator|Real purification|Air purifier turned on
32825794|NCT03319056|Sham Comparator|Sham purification|Air purifier turned off
32825795|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
32825796|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
32825797|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
32825798|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
32825799|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
32825800|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
32825801|NCT02490384|No Intervention|Expectant management|No cerclage
32825802|NCT02490072|Experimental|Dexmedetomidine group|
32825803|NCT02490072|Placebo Comparator|normal saline|
32825804|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
32825805|NCT02483910|Experimental|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
32825806|NCT02483910|Active Comparator|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
32825807|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
32825808|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
32825809|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
32825810|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
32825811|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
32825812|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
32825813|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
32825814|NCT02483598|Experimental|Buspirone|Buspirone alone
32825815|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
32825816|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
32825817|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
32825818|NCT03321318|Experimental|A group|AK-R215, test drug
32825819|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
32825820|NCT01784861|Experimental|Phase I Dose Level 0: X-82 + Everolimus|"X-82 100 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
32825821|NCT01784861|Experimental|Phase I Dose Level 1: X-82 + Everolimus|"X-82 150 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
32825822|NCT01784861|Experimental|Phase I Dose Level 2: X-82 + Everolimus|"X-82 200 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
32825823|NCT01784861|Experimental|Phase II: X-82 + Everolimus|"X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~28 days =1 cycle"
32825824|NCT01784861|Experimental|Phase I Dose Level 3: X-82 + Everolimus|"X-82 300 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
32825825|NCT01784861|Experimental|Phase I Dose Level 4: X-82 + Everolimus|"Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST~X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose~28 days =1 cycle"
32825826|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
32825827|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
32825828|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
32825829|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
32825830|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
32825831|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
32825832|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
32825833|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
32825834|NCT01751308|Experimental|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
32825835|NCT01751308|Experimental|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
32825836|NCT01751308|Experimental|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
32825837|NCT01751308|Experimental|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
32825838|NCT01751308|Experimental|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
32825839|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
32825840|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
32825841|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:~- Video informed consent information, followed immediately by outcomes questionnaire"
32825842|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
33405230|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
32825843|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
32825844|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
32825845|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
32825846|NCT01751386|Experimental|Baclofen|Baclofen 10 mg t.i.d.
32825847|NCT01751386|Placebo Comparator|Placebo|Placebo t.i.d.
32825848|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
32825849|NCT05373264|Active Comparator|Hydrochlorothiazide|Oral hydrochlorothiazide 25mg, once daily, for a total of 156 weeks
32825850|NCT05373264|Placebo Comparator|Placebo|Matching oral placebo, once daily, for a total of 156 weeks. The placebo is inert.
32825851|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
32825852|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
32825853|NCT01752400|Experimental|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
32825854|NCT03321240||The SEEG group|Group with the SEEG analysis
32825855|NCT03321240||The direct surgery group|Group with a direct surgery
32825856|NCT01752712|Experimental|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
32825857|NCT01752712|Placebo Comparator|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
32825858|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
32825859|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
32825860|NCT05127928|Experimental|Supplementation|Vitamin C and Vitamin E before exercise
32825861|NCT05127928|Placebo Comparator|Placebo|Placebo before exercise
32825862|NCT01754350|Experimental|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
32825863|NCT01754350|Active Comparator|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
32825864|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
32825865|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
32825866|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
32825867|NCT05114668|Experimental|Stage 1|- Stage 1 (Dose Escalation Cohorts): Stage 1 is a multiple ascending dose escalation of EVT801 in patients with advanced solid tumours to evaluate the safety and tolerability of EVT801 and to determine MTD / RP2D for further investigation.
32825868|NCT05114668|Experimental|Stage 2|- Stage 2 (Biomarker Expansion cohorts): A biomarker expansion cohort, in which all subjects will receive EVT801 at the MTD / RP2D, will be recruited to explore pharmacodynamic outcomes and further elucidate tolerability, activity, and pharmacokinetics.
32825869|NCT05113186|Experimental|Neoadjuvant and adjuvant therapy with lenvatinib|"Neoadjuvant therapy with lenvatinib to complete a 3-week course, stopping 1 week before the planned date of PA procedure  LENVABLA  protocol, version 1.3 du 25/05/2021 12/55~- Adjuvant therapy with lenvatinib for 3 months starting after the PA evaluation (± 14 days) The daily dose of lenvatinib will be 12 mg (≥60 kg) or 8 mg (<60 kg). Lenvatinib will be taken within 2 hours after a light meal, preferably in the morning."
32825870|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
32825871|NCT02727192|No Intervention|Control group|No sleep apnea treatment
32825872|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
32825873|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
32825874|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
32825875|NCT05093140|Experimental|camrelizumab+R-CHOP|Induction therapy: camrelizumab in combination with rituximab Immunochemotherapy: rituximab, cyclophosphamide, hydroxyldaunorubicin, vincristine, prednisone Maintenance therapy: camrelizumab in patients achieved CR after immunotherapy
32825876|NCT03315312|Active Comparator|Fissure sealant|
32825877|NCT03315312|Experimental|Fluoride varnish|
32825878|NCT05080972|Experimental|in-the-kNOW mobile app.|Participants will be assigned to the in-the-kNOW mobile app for four (4) months.
32825879|NCT05080972|Active Comparator|Control condition.|Participants will be randomized to receive a one-time virtual women's health counseling session with a healthcare provider.
32900028|NCT00243152|Active Comparator|Lamotrigine to Placebo Crossover|The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
32825880|NCT05076214|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer.~The group training session will begin with a 3-5 minutes check-in round followed by a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied"
32825881|NCT05076214|Active Comparator|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together.
32825882|NCT05021848|Experimental|Experimental group|The experimental group (N=14) received a 90-minute partnered multicomponent exercises intervention once weekly for 12 weeks
32825883|NCT05021848|No Intervention|control group|The control group (N=14) carried out the usual activities without intervention. (After 12-wk, multicomponent exercises intervention will be given)
32825884|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
32825885|NCT04955236|Experimental|Partial scalp block|Bilateral block of the greater lesser and third occipital nerves using bupivacaine 0.25% with epinephrine 1:200,000
32825886|NCT04955236|Active Comparator|Fentanyl group|Fentanyl infusion will be administered till time of dural closure
32825887|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
32825888|NCT04943770||WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|"Patients will be randomised 4:4 to a specific stimulating rates order (A, B, C, D) for approx. 3-6 weeks per rate (12-24 weeks in total). Each period is followed by a wash-out phase.~At each frequency systematic assessment of the sweet-spot(s) will be performed. Various pulse width and amplitude values may be used to optimize therapy (up to 1KHz). These programmes will be saved in the subject's remote control based on the pre-generated rate randomization sequence."
32825889|NCT05463510||Pediatric melanocytic nevus|50 patients and 301 pediatric nevi were evaluated
32825890|NCT04086862|Active Comparator|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
32825891|NCT04086862|Experimental|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
32825892|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
32825893|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
32825894|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
32825895|NCT04071652|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
32825896|NCT04044274|Experimental|IOPstim|
32825897|NCT04021030|Experimental|Cognitive Behavioral Therapy (CBT)|
32825898|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
32825899|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
32825900|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
32825901|NCT03957304|Experimental|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
32825902|NCT03957304|Active Comparator|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
32825903|NCT03957304|Active Comparator|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
32825904|NCT03957304|Active Comparator|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
32825905|NCT02483286|Experimental|ICG|Integrated Care Group
32825906|NCT02483286|Experimental|MTG|Muscle Training Group
32825907|NCT02483286|Experimental|XBG|X-box Group
32825908|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
32825909|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
32825910|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
32825911|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
32825912|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
33102044|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
33405231|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
32825913|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
32825914|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
32825915|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
32825916|NCT02486562||People diagnosed with Multiple Sclerosis|
32825917|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825918|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825919|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825920|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825921|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825922|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
32825923|NCT05404776|Experimental|Without tension (tension free)|The study group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be left free of tension and will hang freely.
32825924|NCT05404776|Active Comparator|Tension|The control group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be pulled to create tension and will then be taped to the patient's inner thigh.
32825925|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
32825926|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
32825927|NCT05460780|Experimental|MATTISSE TEC|Patient included receive MATTISSE TEC
32825928|NCT05459766|Experimental|AO+MI|Video-clips observation representing motor contents, followed by motor imagery (12 minutes a day per 3 days).
32825929|NCT05459766|Active Comparator|CTRL|Usual care, consisting of preoperative education.
32825930|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
32825931|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
32825932|NCT03315156||Patients|patients with AOM
32825933|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
32825934|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
32825935|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
32825936|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
32825937|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
32825938|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
32825939|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
32825940|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
32825941|NCT02255110|Experimental|TH-302 and doxorubicin|
33405232|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
33405233|NCT05285462|Active Comparator|Usual Care PT|Patients will attend normal course of PT without influence from study team.
32825942|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
32825943|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
32825944|NCT03896152|Experimental|Arm 1|approximately 2 year Treatment with low LNP023 dose
32825945|NCT03896152|Experimental|Arm 2|approximately 2 year Treatment with higher LNP023 dose
32825946|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
32825947|NCT03877510|Experimental|Open Label IPX203|Subjects will receive IPX203 140 mg, IPX203 210 mg, IPX203 280 mg, or IPX203 350 mg for approximately 9 months. The dose and dosing frequency will be determined by the investigator.
32825948|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
32825949|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
32825950|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
32825951|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
32825952|NCT04895644|Experimental|No Hard Collar|Patient randomised to not wearing a Hard Collar for 12 weeks
32825953|NCT04895644|No Intervention|Standard Care Arm - Hard Collar|Patient randomised to wearing a Hard Collar for 12 weeks - standard care
32825954|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
32825955|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
32825956|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
32825957|NCT04892602||Rheumatiod arthritis patients|
32825958|NCT04892602||Psoaritic arthritis|
32825959|NCT04892602||Control group|
32825960|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
32825961|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
32825962|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
32825963|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
32825964|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
32825965|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
32825966|NCT01807624|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
32825967|NCT02482506|Other|SG-WLP|Self-guided weight loss program
33405234|NCT05285462|Experimental|Usual Care PT + VR Pain Education|Patients will attend normal course of PT without influence of duration or frequency of care. Patients will also receive up to 12 session of pain education delivered via VR headset
32825968|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
32825969|NCT03317808|Active Comparator|Heavy slow resistance exercise|
32825970|NCT03317808|Placebo Comparator|Traditional supervised exercise|
32825971|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
32825972|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
32825973|NCT02486640||Betaferon|
32825974|NCT01808326|Experimental|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
32825975|NCT05714358|Experimental|INTERVENTION GROUP|Face to face education programme and mobile app were used.
32825976|NCT05714358|No Intervention|CONTROL GROUPS|Only face to face education was used.
32955967|NCT05765578||Pfizer-Only Vaccine/Booster Series (PPPP Group)|Individuals who previously received Pfizer COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Pfizer-BNT 162b2 bivalent booster).
33405235|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
32825977|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
32825978|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
32825979|NCT01808560|Experimental|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
32825980|NCT01808560|No Intervention|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
32825981|NCT01808560|Experimental|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
32825982|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.~Interventions are:~Hyperventilation~6% CO2 breathing~Infusion of sodium nitroprusside"
32825983|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
32825984|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
32825985|NCT02486172|Other|Peer supporter|Peer support program
32825986|NCT01809106|Active Comparator|Morphine|
32825987|NCT01809106|Experimental|Oxycodone|
32825988|NCT01809106|Experimental|Buprenorphine|
32825989|NCT01809106|Experimental|Fentanyl|
32825990|NCT02479932|Active Comparator|Extraperitoneal cesarean|
32825991|NCT02479932|Active Comparator|Transperitoneal cesarean|
32825992|NCT03828136|Experimental|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
32825993|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
32825994|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
32825995|NCT03804580|Experimental|osimertinib|All patients recieve osimertinib
32825996|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
32825997|NCT02482584|Other|Control group|Control group
32825998|NCT03317574|Experimental|MEDITOXIN|
32825999|NCT03317574|Active Comparator|BOTOX|
32826000|NCT01765972|Other|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
32826001|NCT01765972|Other|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
32826002|NCT01765972|Other|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
32826003|NCT01765972|Other|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
32826004|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
32826005|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
32826006|NCT02486250||ReVeRe 1|A subset of 250 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
32826007|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
32826008|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
32826009|NCT01810666|Experimental|Recombinant Factor VIII|
33405236|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
32826010|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
32826011|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
32826012|NCT01766440|Experimental|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
32826013|NCT03317340||Patient Undergoing Urodynamics|
32826014|NCT05714046|Experimental|Yoga Group|In addition to routine tennis training yoga exercise training was applied to the yoga group 2 days a week for 8 weeks with the telerehabilitation method.
32826015|NCT05714046|Experimental|Control Group|Routine Tennis training and information training was given to Control group.
32826016|NCT01811212|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32826017|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
32826018|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
32826019|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
32826020|NCT01767064|Experimental|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
32826021|NCT01767064|No Intervention|Control|Usual care with no posted letters.
32826022|NCT03317184|Experimental|Periumbilical incisions|
32826023|NCT03317184|Experimental|Pfannenstiel incision|
32826024|NCT04350814|Experimental|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
32826025|NCT04350814|Active Comparator|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
32826026|NCT02482038|Experimental|geko device|
32826027|NCT01811680|Experimental|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
32826028|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
32826029|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
32826031|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
32826032|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
32826033|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
32826034|NCT03552562|Other|30 patients with mild diabetic retinopathy|
32826035|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
32826036|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
32826037|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
32826038|NCT01767688|Experimental|Moderate Hepatic Impairment Group|
32826039|NCT01767688|Experimental|Healthy Matched Control Group|
32826040|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
32826041|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
32826042|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
32826043|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
32826044|NCT04492176|Experimental|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%，ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.
32826045|NCT04492176|No Intervention|before treatment|the patient did not receive laser treatment
32826046|NCT04769752||No beta-blocker|Patient do no treat with beta-blocker before the surgery
32826047|NCT04769752||Beta blocker|Patient treat with beta-blocker in accordance to international guidelines
32826048|NCT04769752||Beta blocker2|Patient treat with beta-blocker without respect of international guidelines
32826049|NCT05713968||patients with EAT-10 higher than 3 or frailty questionnaire higher than 2|patients may have high risk of aspiration
32826050|NCT05713968||patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients may have low risk of aspiration
32826051|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
32826052|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
32826053|NCT01768000|Experimental|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
32826054|NCT01768000|No Intervention|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
32826055|NCT04492878|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|
32826056|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
32826057|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
32826058|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
32826059|NCT05713812|Active Comparator|Active Comparator|"IFC + Hot pack for 20 minutes~MDT (prone positioning) for 10 minutes.~Lumbar SNAGs + lumbar rotation mobilization.~Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~Sham Kinesiotape will be applied"
32826060|NCT05713812|Experimental|Experimental Group|"IFC + Hot pack for 20 minutes~MDT (Prone positioning) for 10 minutes.~Lumbar SNAGs + lumbar rotation mobilization.~Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~Kinesiotape will be applied"
32826061|NCT05454072|Experimental|Sinonasal Microbiota Transfer|The transfer site for patients will be prepared by endoscopically removing any visible crusting, mucin, and purulent discharge from the sinuses and via manual high-volume (>60 ml), high-pressure saline wash on day 0. The donor mucus sample will be homogenized using sterile, disposable rotor-stator homogenizer tips for 30 seconds and 5 ml of donor mucus will be instilled into the affected sinus cavity(ies) using a masked syringe under endoscopic visualization, with the recipient's head in a dependent position. Patients will remain in this position for 15 minutes to facilitate transfer.
32826062|NCT05454072|Sham Comparator|Sham Sinonasal Microbiota Transfer|Sterile saline will replace the SNMT donor mucus in the masked syringe and will be delivered in an identical manner to the SNMT intervention.
32826063|NCT04492644||elderly inpatients|Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.
32826064|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
32826065|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
32826066|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
32826067|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
32826068|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
32826069|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
32826070|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
32826071|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
32826072|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
32826073|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
32826074|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
32826075|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
32826076|NCT02479308|Placebo Comparator|Placebo|
32826077|NCT02485782||Hemodialysis patients|"midweek dialysis session~patients on maintenance hemodialysis at least 3 months~stable dry weight~single-pool Kt/V >1.4~no clinical cardiovascular disease during the 6 months preceding entry"
32826078|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
33405237|NCT05648279|No Intervention|Routine hemodynamic management (control)|In patients assigned to routine hemodynamic management, hemodynamic management will performed as per anesthesiologist preference. Cardiac index monitoring will be will measured using the Baxter Starling Fluid Management System (Baxter, Deerfield, IL, USA). The attending anesthesiologist will be blinded to cardiac index measurements. Cardiac index monitoring can be unblinded upon request. Mean arterial blood pressure will be maintained above 65 mmHg.
32826079|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
32826080|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
32826081|NCT05461560|Sham Comparator|Control: Sucrose solution|Participants will consume 50g of sucrose dissolved in 500 ml of tap water
32826082|NCT05461560|Experimental|Experimental: Seaweed extract in sucrose solution|Participants will consume 50g of sucrose and 1g of seaweed extract dissolved in 500 ml of tap water
32826083|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
32826084|NCT03314220|No Intervention|standard care|
32826086|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
32826087|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
32826088|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
32826089|NCT05713578|Experimental|apantamide+docetaxel+ADT|The dosage is adjusted according to the adverse reaction (according to the instructions).Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator;The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles. It is up to the researcher to decide whether to use prednisone or prednisolone.
32826090|NCT05713578|Active Comparator|apantamide+ADT treatment|Patients were treated with apantamide and ADT after enrollment. The patient received each drug treatment according to the instructions. The dosage is adjusted according to the adverse reaction (according to the instructions)Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT used in each research center are determined by the investigator.
32826091|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
32826092|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
32826093|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
32826094|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
32826095|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
32826096|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
32826097|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
32826098|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
32826099|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
32826100|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
32826101|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
32826102|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
32826103|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
32826104|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
32826105|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
32826106|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
32826107|NCT05715138|Experimental|GPi-DBS|The DBS electrodes are implanted into posteroventral GPi bilaterally.
32826108|NCT05715138|Experimental|STN-DBS|The DBS electrodes are implanted into dorsolateral STN bilaterally.
32826109|NCT05715060|Active Comparator|stainless steel wire closure|conventional closure of median sternotomy by stainless steel wire
32826110|NCT05715060|Active Comparator|PDS sternal closure|closure of median sternotomy by PDS
32826111|NCT02481180|Experimental|T0001|
32826112|NCT02481180|Active Comparator|Enbrel|
32826113|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
32826114|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
32826115|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
32826116|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
32826117|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
32826118|NCT02478528|Experimental|Experimental|
32826119|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
32826120|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
32826121|NCT02478606|No Intervention|Control Group|Without intervention
32826122|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
32826123|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
32826124|NCT01769170|Placebo Comparator|Placebo|Matching placebo administered orally twice weekly
32826125|NCT01769170|Active Comparator|Brincidofovir|100 mg brincidofovir administered orally twice weekly
32826126|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
32826127|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
32826128|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
32826129|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
32826130|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
32826131|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
32826132|NCT05714904|Experimental|Dose escalation|"2 cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS101e at Day 0. Cohort 2: Subretinal administration of a single high dose ZVS101e at Day 0."
32826133|NCT04350970|Active Comparator|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
32826134|NCT04350970|Active Comparator|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
32826135|NCT04350970|Active Comparator|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
32826136|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
32826137|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
32826138|NCT01815502|Experimental|Dobutamine + Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
32826139|NCT01815502|Placebo Comparator|Dobutamine + placebo|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
32826140|NCT05713422||Operative procedure; standard treatment|Vaginal level I and/or level II repair will be performed as usual (eg anterior and/or posterior colporrhaphy, sacrospinous fixation etc.) without perineoplasty as decided by surgeon and patient. This procedure is considered as the control group.
32826141|NCT05713422||Operative procedure; standard treatment including level III repair|Vaginal level I and/or level II repair will be performed as usual, but now including perineoplasty (level III repair) as decided by surgeon and patient. The decision of a perineoplasty to vaginal level I and/or level II repair is based on a shared decision made by surgeon together with the patient. The considerations upon which this decision has been established in a consensus meeting of Dutch urogynecologists and will be collected by a questionnaire, This group is considered as the 'intervention' group.
32826142|NCT05714826|Experimental|Intervention Arm|Preop intervention Arm Referral to Perioperative Optimization of Senior Health (POSH) Program Remote patient monitoring device orientation, initial intake, and education UTSW ERAS protocol perioperatively Inpatient geriatrics co-management Monitored recovery Post-operative monitoring with Acticare for 90 days Post-op specialist continuity of care
32826143|NCT05714826|Active Comparator|Control Arm|Enhanced Recovery After Surgery Usual referral and recovery care as needed Standard follow-up protocol
32826144|NCT01769248|Active Comparator|Fine needle aspiration|fine needle aspiration
32826145|NCT01769248|Active Comparator|Fine needle biopsy|Fine needle biopsy
32826146|NCT03316560|Experimental|Group 1: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
32955968|NCT05765565|Experimental|Octaray (intervention)|Octaray created 3D map quality
32955969|NCT05765565|Active Comparator|Pentaray (control)|Pentaray created 3D map quality
32826147|NCT03316560|Experimental|Group 2: Phase 1/2 Dose Escalation and Low Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug. This will be the low dose group for the phase 2 expansion."
32826148|NCT03316560|Experimental|Group 3 and Group 4 Phase 1/2 Dose Escalation|Group 3 male subjects at least 18 y/o and Group 4 male subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
32826149|NCT03316560|Experimental|Group 5 Phase 1/2 Dose Escalation and High Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug. This will be the high dose group for the phase 2 expansion."
32826150|NCT03316560|Experimental|Group 6 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
32826151|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
32955970|NCT05765552|Active Comparator|Control Group|Participants in control group will receive an exercise program consisted of upper and lower range of motion exercises.The exercises will be started as 8-10 repetitions and 1 set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 8 weeks, 2 days a week, each session will last for 30 minutes.
33102045|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
32826152|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
32826153|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
32826154|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
32826155|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
32826156|NCT05714748|Experimental|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval.
32826157|NCT02258152|Placebo Comparator|Placebo|
32826158|NCT02258152|Experimental|SYN120|
32826159|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
32826160|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
32826161|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
32826162|NCT03301012|Experimental|Smartphone Addiction Recovery Coach (SARC) - Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
32826163|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
32826164|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
32826165|NCT01817374|Other|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:~prior to initiation of treatment (baseline);~at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);~at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);~at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
32826166|NCT05713266||Severe COVID-19 survivors|Adult COVID-19 survivors who had 'severe COVID-19' during the acute phase and have at least one of the following pre-existing conditions: Hypertension, Asthma, COPD, Heart Failure, Chronic kidney disease and/or Diabetes. 'Severe COVID-19' is defined as requiring hospital or intensive level care for treatment of the infection and its complications.
32826167|NCT04492332|Sham Comparator|normal controls with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
32826168|NCT04492332|Sham Comparator|normal controls without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
32826169|NCT04492332|Active Comparator|BTSS patients with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
32826170|NCT04492332|Active Comparator|BTSS patients without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
32826171|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
33405238|NCT05648279|Experimental|Personalized hemodynamic management (intervention)|"In patients assigned to personalized hemodynamic management, intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index measured the day before surgery using a predefined treatment algorithm.~Preoperative baseline cardiac index will be determined at least one day before surgery with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2).~Mean arterial blood pressure will be maintained above 65 mmHg. The study intervention will start at the beginning of surgery and will end at the end of surgery."
32826172|NCT02485470|No Intervention|Usual Care|
33405239|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
32826173|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
32826174|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
32826175|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
32826176|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
32826177|NCT01770652|Experimental|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
32826178|NCT01770652|Experimental|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
32826179|NCT01770652|Experimental|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
32826180|NCT01770652|Experimental|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
32826181|NCT05714514||Imlifidase administered in the ConfIdeS study|
32826182|NCT05714514||Best available treatment administered in the ConfIdeS study|
32826183|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
32826184|NCT01820416|Experimental|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
32826185|NCT01820416|Placebo Comparator|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
32826186|NCT01820416|No Intervention|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
32826187|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
32826188|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
32826189|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
32826190|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
32826191|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
32826192|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
32826193|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
32826194|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
32826195|NCT02480556|Experimental|Group A|manual seperation of the placenta
33405240|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
32826196|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
32826197|NCT01771666|Experimental|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
32826198|NCT05713188|Experimental|Treatment|All volunteers will receive the same treatment
33102046|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
32826199|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
32826200|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
32826201|NCT01821352|Active Comparator|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
32826202|NCT01821352|Placebo Comparator|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
32826203|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
32826204|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
32826205|NCT05713032|Active Comparator|standard voltage group|The Standard voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage 45 Volt for Duration of 480sec done in 2 cycles.
32826206|NCT05713032|Active Comparator|high voltage group|The High voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage will be gradually increased to reach the highest voltage for each patient (55-75 Volt) for Duration of 480sec done in 2 cycles.
32826207|NCT01772758|Experimental|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
32826208|NCT01772758|Experimental|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
32826209|NCT01772758|Experimental|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
32826210|NCT01772758|No Intervention|Healthy Controls|baseline measurements were done with no intervention
32826211|NCT05712954|No Intervention|control group|The study will start with the women in the control group. The women in the control group, who were selected in accordance with the sample selection criteria and agreed to be a participant, will be given data collection tools for the pre-test on the day of the procedure and no intervention will be made other than the counseling given at the hospital. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
32826212|NCT05712954|Experimental|music group|The women in the 1st group will be pre-tested with data collection tools before the HSG, then after they are taken to the table, headphones will be put on and music will be played. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics. After the women in this group are completed, the 2nd group will be started.
32826213|NCT05712954|Experimental|video group|2. The women in the group will be pre-tested with data collection tools before the HSG, and after they are taken to the table, a video with natural landscape pictures prepared by the researcher will be opened on the iPad. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
32826214|NCT05714436||Work Package 1a|Longitudinal interviews with patients and family carers to generate thematic framework for co-design workshops
32826215|NCT05714436||Work Package 1b|On-line focus groups with healthcare professionals to generate thematic framework for co-design workshops
32826216|NCT05714436||Work Package 2|Co-design workshops to generate decisions about priority areas for intervention development
32826217|NCT01775410|Experimental|Wolverine System|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
32826218|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
32826219|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
32826220|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
32826221|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
32826222|NCT02480322||BMI-matched control group|
32826223|NCT02480322||Normal-weight control group|
32826224|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
32826225|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
32826226|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
32826227|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
32826228|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
32826229|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
32826230|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
32826231|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
32826232|NCT05712876|Experimental|Single ascending dose (SAD) CK-0045 Dose level 1 to 7|At each dose level 6 participants will receive a single dose of CK-0045 either by s.c. or i.v. administration
32826233|NCT05712876|Placebo Comparator|SAD placebo|At each dose level 2 participants will receive a single dose of matching placebo either by s.c. or i.v. administration
32826234|NCT05712876|Experimental|Multiple ascending dose (MAD) CK-0045 Dose level 1 to 4|At each dose level 6 participants will receive a loading dose on Day 1 followed by a dose on Day 8 and Day 15 of CK-0045 either by s.c. or i.v. administration
32826235|NCT05712876|Placebo Comparator|MAD placebo|At each dose level 2 participants will receive matching placebo on Day 1, Day 8 and Day 15 either by s.c. or i.v. administration
32826236|NCT05709600|Active Comparator|Fasting mimicking diet|Human fasting mimicking diet (Prolon®) for five days prior to living kidney donation in donor: Day 1 of Prolon® supplies ~4600 kJ, day 2-5 provide ~3000kJ.
32826237|NCT05709600|Active Comparator|Ketogenic diet|Isocaloric, ketogenic diet 7 days prior to living kidney donation in the kidney donor with below 5% of energy from carbohydrate (<20g/day), approximately 15% from protein (<100g/day) and 80% from fat (>125g/day) without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
32826238|NCT05709600|Active Comparator|Dietary restriction of sulfur containing amino acids|Isocaloric, dietary restriction of sulfur containing amino acids in the donor without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
32826239|NCT05709600|Active Comparator|Control-Group|Healthy, low-fat, moderate protein and high carbohydrate diet in the donor as described in the current nutritional recommendations of the American Diabetes Association achieved by the Fortimel® diet (Nutricia Milupa GmbH, Erlangen, Germany)
32826240|NCT01824082|Experimental|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
32826241|NCT01824082|Placebo Comparator|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
32826242|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
32826243|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
32826244|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
32826245|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
32826246|NCT05521542|Experimental|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo a planned percutaneous coronary intervention with SirPlux™.
32826247|NCT04999098|Active Comparator|treatment group 1: Echinaforce Forte (EFF) Tablets (chewed)|"1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets."
32826248|NCT04999098|Active Comparator|treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed)|"2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 & 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets."
32826249|NCT04999098|Active Comparator|treatment group 3: Echinaforce Tincture (EFT, gargling)|"3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture."
32826250|NCT01824160|Other|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
32826251|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
32826252|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
32826253|NCT04977726|Experimental|STRIVE - Simulation Training for Resilience in Various Environments|
32826254|NCT04977726|Sham Comparator|Control|
32826255|NCT01775800|Experimental|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
32826256|NCT01775800|No Intervention|Usual care|Patients will receive the usual hemodialysis care with no modifications
32826257|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
32826258|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
32826259|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
32826260|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
32826261|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
32826262|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
32826263|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
33405241|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
32826264|NCT01825408|Active Comparator|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
32826265|NCT01825408|Active Comparator|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
32826266|NCT01825408|Active Comparator|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
32826267|NCT01825408|Active Comparator|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
32826268|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
32826269|NCT01776268|Experimental|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
32826270|NCT01776268|No Intervention|No oral priming|No oral priming
32826271|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
32826272|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
32826273|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
32826274|NCT04945824|Experimental|Novel Intracanalicular Insertion Device|
32826275|NCT02476656||GPNC|CenteringPregnancy group prenatal care
32826276|NCT02476656||IPNC|Individual prenatal care
32826277|NCT01777126|Active Comparator|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
32826278|NCT01777126|Experimental|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
32826279|NCT04937634|Experimental|Melphalan|
32826280|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
32826281|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
32826282|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
32826283|NCT05686044|Experimental|7.5mg Buntanetap|Buntanetap 7.5mg oral capsule with daily administration for a period of 12 weeks
32826284|NCT05686044|Experimental|15mg Buntanetap|Buntanetap 15mg oral capsule with daily administration for a period of 12 weeks
32826285|NCT05686044|Experimental|30mg Buntanetap|Buntanetap 30mg oral capsule with daily administration for a period of 12 weeks
32826286|NCT05686044|Placebo Comparator|Placebo|Placebo oral capsule with daily administration for a period of 12 weeks
32826287|NCT04931628|Active Comparator|salvianolic acid group|salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
32826288|NCT04931628|Placebo Comparator|0.9% NaCl|0.9%NaCl 250ml, injection, 14 days
32826289|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
32826290|NCT04913610|Experimental|Part 1: Arm A|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
32826291|NCT04913610|Experimental|Part 1: Arm B|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by ABBV-4083 for 7 days.
32826292|NCT04913610|Experimental|Part 1: Arm C|Participants will receive ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
32826293|NCT04913610|Experimental|Part 1: Arm D|Participants will receive ABBV-4083 + albendazole for 3 days followed by ABBV-4083 + placebo for albendazole for 4 days followed by placebo for ABBV-4083 for 7 days.
32826294|NCT04913610|Experimental|Part 1: Arm E|Participants will receive placebo for ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
32826295|NCT04913610|Experimental|Part 2: Arm K|Participants will receive active regimen from Part 1 followed by ivermectin at Month 6.
32826296|NCT04913610|Experimental|Part 2: Arm L|Participants will receive active regimen from Part 1 followed by placebo for ivermectin at Month 6.
32826297|NCT04913610|Experimental|Part 2: Arm M|Participants will receive active regimen from Part 1 followed by placebo for ivermectin or matching placebo at Month 6.
32826298|NCT04913610|Experimental|Part 2: Arm N|"Scenario 1: Participants will receive placebo for ABBV-4083 + placebo for albendazole followed by ivermectin at Month 6.~Scenario 2: Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for appropriate duration followed by ivermectin or matching placebo at Month 6."
32826299|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
32826300|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
32826301|NCT04905888|Experimental|Hyperbaric oxygen therapy|Treatment with hyperbaric oxygen
33405242|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
32826302|NCT04905888|No Intervention|Control|Control, no treatment.
32826303|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
32826304|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
32826305|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
32826306|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
32826307|NCT02476188|Experimental|Patients control|Samples of blood at H0
32826308|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
32826309|NCT01778296|Experimental|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
32826310|NCT04887870|Experimental|Phase 2/3: Open label extension of parent study|The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
32826311|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
32826312|NCT05670288||Spinal Cord Injury|Patients who have had an acute spinal cord injury in the past 72 hours
32826313|NCT05665452|Active Comparator|Group (1)|patients will receive stretch and strength exercises
32826314|NCT05665452|Experimental|Group (2)|patients will receive stretch, strength, patellar mobilization, retinacula release and deep friction message
32826315|NCT01827358|Experimental|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
32826316|NCT01827358|No Intervention|Group 2|No treatment
32826317|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
32826318|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
32826319|NCT05652738|Active Comparator|Group I: (passive cooling group)|
32826320|NCT05652738|Placebo Comparator|Group II: (Blanket roll III cooling group)|
32826321|NCT04868604|Experimental|67Cu-SAR-bisPSMA|"In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).~In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation."
32826322|NCT01780324|No Intervention|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
32826323|NCT01780324|Experimental|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
32826324|NCT02989792|Other|Unique study arm|
32826325|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
33102047|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
33102048|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
33405243|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
33405244|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
32826326|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
32826327|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
32826328|NCT01780870|No Intervention|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
32826329|NCT01780870|Active Comparator|Weight loss group|Full Meal replacement Protocol
32826330|NCT02477982||control group|BMI ≤ 25 kgm-2
32826331|NCT02477982||obese group|BMI ≥ 30 kgm-2
32826332|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment~Treatment days 7 and 8:~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day~NASOGASTRIC TUBE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)~Treatment day 6 and 7:~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7~Treatment day 7:~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
32826333|NCT02472600|No Intervention|No intervention|Control arm without any intervention
32826334|NCT04858776|Experimental|Treatment|
32826335|NCT04858776|Sham Comparator|Control|
32826336|NCT01781806|Active Comparator|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.~High Risk Cohort Criteria (one or more of the following has to be met):~No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.~STD diagnosis during the last 12 months.~Previous PEP use during the last 12 months (* see exclusion criteria)~Has at least one HIV infected sexual partner for ≥4 weeks."
32826337|NCT01781806|Active Comparator|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
32826338|NCT05315076|Experimental|Thoracic Manipulation Posterior anterior and conventional therapy|Thoracic Manipulation Posterior anterior and conventional therapy
32826339|NCT05315076|Experimental|Muscle Energy Technique (PIR) and conventional treatment|Muscle Energy Technique (PIR) and conventional treatment
32826340|NCT04844892|Experimental|PROTECT Diaphragm Pacing Therapy|
32826341|NCT01985230|Experimental|ReActiv8 Implant|
32826342|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
32826343|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
32826344|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
32826345|NCT01784848|Experimental|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
32826346|NCT01784848|Active Comparator|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
32826347|NCT05417568|Experimental|Healthy Participants|"Healthy participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
32826348|NCT05417568|Experimental|Calcium Oxalate Kidney Stone|"Calcium oxalate kidney stone participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
32826349|NCT01753648|Experimental|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
32826350|NCT01753648|Experimental|healthy controls|30 healthy age- and sex-matched controls
32826351|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~20 minutes duration, middle frequency (30 Hz) of electrical stimulation~conventional treatments permitted"
32826352|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~conventional treatments permitted"
32826353|NCT01746238|Experimental|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
33405245|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
32826354|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).~Maintenance treatment (D4 to D14)~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14~CSA IVC or PO at a target rate of 150-200 ng / ml"
32826355|NCT01782898|Active Comparator|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
32826356|NCT01782898|Placebo Comparator|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
32826357|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
32826358|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
32826359|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
32826360|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
32826361|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
32826362|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
32826363|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
32826364|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
32826365|NCT04825236|Experimental|Decision Aid Users|Patients with CF who are given access to the MyVoice:CF decision aid
32826366|NCT04825236|Experimental|CF Healthcare Providers|Members of the adult CF care team who interact with patients who have used the decision aid
32826367|NCT04802148|No Intervention|control (natural healing)|Extraction socket is naturally healed
32826368|NCT04802148|Experimental|Test 1 (membrane guided regeneration)|Extraction socket is filled with graft (FDBA) and covered with collagen membrane
32826369|NCT04802148|Active Comparator|Test 2 (collagen plug)|Extraction socket is filled with a collagen plug
32826370|NCT01783054|Experimental|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
32826371|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
32826372|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
32826373|NCT05405088|Other|Open-label cohort, with short follow-up|This is a collection of data from postoperative questionnaires and simple, non-invasive clinical observations. The oral surgery acts in question are performed in daily practice without any change in patient management. The intraoperative data collected come from routine care. Postoperative data (pain and analgesic intake) are collected by self-questionnaires and no visit on purpose is required.
32826374|NCT05402202|Experimental|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
32826375|NCT05402202|Active Comparator|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment
32826376|NCT05397600|Experimental|T4032|
32826377|NCT05397600|Active Comparator|Lumigan|
32826378|NCT05388084|Active Comparator|Male peer led intervention|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
32826379|NCT05388084|Active Comparator|Standard of care and delayed intervention|Standard of care standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
32826380|NCT04784520|Experimental|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
32826381|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
32826382|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
32826383|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
32826384|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
32826385|NCT02471976|No Intervention|Group A|the centres applies their usual practices
32826386|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
32826387|NCT01832506|Experimental|MSC2156119J|
32826388|NCT05618028|Experimental|ABBV-525 Dose Escalation|Participants will receive escalating doses of ABBV-525 until doses for optimization are determined, as part of an approximately 64 month study period.
32826389|NCT05618028|Experimental|ABBV-525 Dose Optimization|Participants will receive one of two doses of ABBV-525 until the recommended phase 2 dose (RP2D) is determined, as part of an approximately 64 month study period.
32826390|NCT05618028|Experimental|ABBV-525 Dose Expansion|Participants will receive the RP2D dose of ABBV-525, as part of an approximately 64 month study period.
32826391|NCT05607420|Experimental|Dose finding part|"UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified.~Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part"
32826392|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
32826393|NCT02477748|Placebo Comparator|Placebo|Inert tablets
32826394|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
32826395|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
32826396|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
33317936|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
33317937|NCT03841526|Experimental|Glucagon RTU, 50% insulin pump reduction|
32826397|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
32826398|NCT01783522|Experimental|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
32826399|NCT01783522|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
32826400|NCT04734366|Experimental|"Uterine closure with Baseball suture technique"|"Participants will undergo Baseball suture closure of the hysterotomy site at the time of cesarean section."
32826401|NCT04734366|Active Comparator|Single Layer Continuous Locked|Participants will undergo Single Layer Continuous Locked suture closure of the hysterotomy site at the time of cesarean section.
32826402|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
32826403|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
32826404|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
32826405|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
32826406|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
32826407|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
32826408|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
32826409|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
32826410|NCT04674306|Experimental|Treatment α-lactalbumin and zymosan|"Participants diagnosed with triple negative breast cancer (TNBC) will be treated with successively higher doses of α-lactalbumin and zymosan in a traditional 3 + 3 phase I trial design. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants will be enrolled sequentially into 1 of 5 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan DL2: 100 mcg a-lactalbumin + 10 mcg Zymosan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL4: 500 mcg a-lactalbumin + 30 mcg Zymosan DL5: 500 mcg a-lactalbumin + 60 mcg Zymosan"
32826411|NCT04674306|Experimental|Preventitive a-lactalbumin and zymosan|"Participants with a genetic risk for developing TNBC who plan to undergo prophylactic mastectomy will be treated with α-lactalbumin and zymosan at doses based on the TNBC cohort. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants enrolled in the prevention cohort we will be enrolled at the dose level being used in the TNBC cohort if no DLTs above Grade 1 have been observed. If the TNBC cohort proceeds to the next dose level before another prevention cohort patient is enrolled, the next prevention patient will be enrolled on the next dose level along with the TNBC cohort.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan DL2: 100 mcg a-lactalbumin + 10 mcg Zymosan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL4: 500 mcg a-lactalbumin + 30 mcg Zymosan DL5: 500 mcg a-lactalbumin + 60 mcg Zymosan"
32826412|NCT01783912|Experimental|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
33317938|NCT03841526|Placebo Comparator|Placebo, 50% insulin pump reduction|
33317939|NCT03841526|Experimental|Glucagon RTU, no basal rate reduction|
33317940|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
33317941|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
32826413|NCT01783912|Active Comparator|Attention Control Group|"This arm of the project will address the following question:~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
32826414|NCT01783912|No Intervention|Motivated Smokers Comparison Group|"This arm of the project will address the following question:~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
32826415|NCT02475330|Experimental|Dietary Supplement: Flaxseed|
32826416|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
32826417|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
32826418|NCT05583708|Experimental|Experimental: Pembrolizumab + Lutetium Lu177|"All patients will receive pembrolizumab once every 6 weeks + Lutetium Lu177 dotatate once every 2 months~Pembrolizumab Cycle=6 weeks (for up to 2 years) Lutetium Lu177 dotatate Cycle=2 months (4 doses total)"
32826419|NCT01783990||Active|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
32826420|NCT01783990||Passive|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.
32826421|NCT05576454|Experimental|BAT2606 Injection|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
32826422|NCT05576454|Active Comparator|Mepolizumab Injection (EU-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
32826423|NCT05576454|Active Comparator|Mepolizumab Injection (US-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
32826424|NCT01733056|Placebo Comparator|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
32826425|NCT01733056|Experimental|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
32826426|NCT01733056|Experimental|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
32826427|NCT05574816|Active Comparator|Patient without breast lump|No breast lump identified during mammography (ACR 1 et 2 Birads classification)
32826428|NCT05574816|Experimental|Patient with breast lump|Suspicious breast lump identified during mammography (ACR 4b, c ou ACR 5 Birads classification)
32826429|NCT04672824|Experimental|ChAdOx1 RVF group 1|Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly
32826430|NCT04672824|Active Comparator|Control group|Placebo (Normal Saline), 0.5ml delivered intramuscularly
32826431|NCT04672824|Experimental|ChAdOx1 RVF group 2|Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly
32826432|NCT04672824|Experimental|ChAdOx1 RVF group 3|Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly
32826433|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
32826434|NCT01833988|Active Comparator|Usual Care|Usual Care
32826435|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
32826436|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
32826437|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
32826438|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
32826439|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
32826440|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
32826441|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
32826442|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
32826443|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
32826444|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
32826445|NCT05363436|No Intervention|Control|Normal Standard Practices of Prescribing
33405246|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
32826446|NCT05363436|Experimental|Intervention|Providers prescribed a base of 15 narcotic pills
32826447|NCT04641078|Experimental|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
32826448|NCT04641078|Other|Arm B|SBRT only
32826449|NCT05349630|Placebo Comparator|Healthy individuals - pre-iron|"Five healthy participants will be enrolled. Baseline echocardiography and exercise data prior to oral iron supplementation will be obtained as part of the parent study to this study (NCT05272514)."
32826450|NCT05349630|Active Comparator|Healthy individuals - post-iron|The same five healthy participants will complete echocardiography and exercise testing after taking 30 days of oral iron supplementation.
32826451|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
32826452|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
32826453|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
32826454|NCT04575870||Treatment Group 4: 28 min waiting period|Participants undergo their planned tracheobronchoscopy + 28 minute waiting period prior to modified functional endoscopic swallowing exam
32826455|NCT04575870||Treatment Group 5: 13 min waiting period|Participants undergo their planned tracheobronchoscopy + 13 minute waiting period prior to modified functional endoscopic swallowing exam
32826456|NCT03582774|Active Comparator|Arm I (standard of care)|Participants receive standard of care SRT.
32826457|NCT03582774|Experimental|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
32826458|NCT02474940|Experimental|Intervention #1|NF-HYP
32826459|NCT02474940|Experimental|Intervention #2|MM-HYP
32826460|NCT02474940|Experimental|Intervention #3|HYP-ONLY
32826461|NCT01784614|Experimental|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
32826462|NCT01784614|Experimental|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
32826463|NCT01784614|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
32826464|NCT01784614|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
32826465|NCT01784614|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
32826466|NCT05314686||Technical validity of data transmitted remotely.|The first twenty participants will participate in the step of the study aimed at assessing the technical validity of data transmitted remotely from devices connected to the telerehabilitation system.
32826467|NCT05314686||Clinical feasibility.|The last twenty participants will perform their pulmonary rehabilitation program at home using the telerehabilitation system over an eight-week period.
32826468|NCT01733212|Experimental|Ginger|2 gm powder of ginger filled in a capsule
32826469|NCT01733212|Placebo Comparator|Placebo|2 gm of placebo pill (A capsule)
32826470|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
32826471|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
32826472|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
32826473|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
32826474|NCT05335668|Experimental|Patients with central poststroke pain|Patients with central poststroke pain
32826475|NCT05335668|Experimental|Patients without central poststroke pain|Patients without central poststroke pain
32826476|NCT05335668|Active Comparator|healthy controls|healthy volunteers
32826477|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
32826478|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
32826479|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
32826480|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
32826481|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
32826482|NCT01784926|Other|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
32826483|NCT01784926|Other|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
32826484|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
32826485|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
32826486|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
32826487|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
32826488|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
32826489|NCT04491786|Experimental|GAPA|Participants will treated with preoperative 600 mg of gabapentin plus nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
32826490|NCT04491786|No Intervention|Non-GAPA|Participants will treated with nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
32826491|NCT04540302|Experimental|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
32826492|NCT04540302|Other|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
32826493|NCT04540302|Experimental|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
32826494|NCT04540302|Experimental|AVF/AVG Central study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
32826495|NCT04540302|Other|AVF/AVG Central control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
32826496|NCT04749784|Experimental|High dose IP|Two tablets IP daily for 12 weeks
32826497|NCT04749784|Experimental|Low dose IP|One tablet IP + one tablet placebo daily for 12 weeks
32826498|NCT04749784|Placebo Comparator|Placebo|Two tablets placebo daily for 12 weeks
32826499|NCT01786252|Experimental|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
32826500|NCT01786252|Placebo Comparator|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
32826501|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
32826502|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
33102049|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
33102050|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
33102051|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
33102052|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
32826503|NCT04749316|Experimental|AcuTENS|Patients treated with TENS over Acupuncture points for faecal incontinence
32826504|NCT04749316|Sham Comparator|Sham|Sham treatment arm with no electrical stimulations over acupuncture points
32826505|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
32826506|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
32826507|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
32826508|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
32826509|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
32826510|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
33102053|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
33102054|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
33102055|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
33102056|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
33102057|NCT05467566|Experimental|Stimulation + exercise group|30-minute exercise program (based on Pilates method) combined with active transcranial direct current stimulation.
32826511|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
32826512|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 1|Single inhalational administration of 4D-710 Dose Level 1
33102058|NCT05467566|Sham Comparator|Sham stimulation + exercise group|This arm will perform the same procedures of experimental group but the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
33102059|NCT02921945|Experimental|SCT800|
32826513|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 2|Single inhalational administration of 4D-710 Dose Level 2
32826514|NCT05248230|Experimental|4D-710 Dose Expansion Cohort|Single inhalational administration of 4D-710 at the selected dose
32826515|NCT01786876|Experimental|Radiolabeled SPD557|
32826516|NCT05242146|Experimental|GB5121|GB5121 orally twice per day (BID)
32826517|NCT05230914|Experimental|NCCT|NCCT and CTA will be used to screen patients for endovascular treatment
32826518|NCT05230914|Active Comparator|CTP|NCCT, CTA, and CTP will be used to screen patients for endovascular treatment
32826519|NCT05230290|Experimental|KD6001 Injection|Participants will be administered KD6001 at an applicable dose as monotherapy
32826520|NCT01786954|Experimental|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
32826521|NCT01786954|Experimental|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
32826522|NCT05217810||Atectura inhalation capsule (150/80ug)|Indacaterol acetate/Mometasone furoate; 150/80ug
32826523|NCT05217810||Atectura inhalation capsule (150/160ug)|Indacaterol acetate/Mometasone furoate; 150/160ug
32826524|NCT05217810||Atectura inhalation capsule (150/320ug)|Indacaterol acetate/Mometasone furoate; 150/320ug
33102060|NCT05467527|Experimental|PACT Group|A combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks
33102061|NCT05467527|Placebo Comparator|Control Group|A combination of 6 online modules and 4 group-based video conferencing sessions of daily parenting challenges in caring for a child with SHCN plus positive parenting advice via a mobile app across 12 weeks
33102062|NCT04689230|Active Comparator|upper eyelid blepharoplasty|"traditional upper eyelid blepharoplasty : upper eyelid entire length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with subcuticular 6/0 vicryl suture"
33102063|NCT04689230|Experimental|small incision technique|"medial upper eyelid 4 mm length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with interrupted 6/0 vicryl sutures"
33102064|NCT04689269|Active Comparator|McGrath-King Vision|The participants will attempt double-lumen tube intubation using the McGrath (X-blade) laryngoscope then they will use the King Vision (channelled blade size 3) in the same order.
33102065|NCT04689269|Active Comparator|King Vision-McGrath|The participants will attempt double-lumen tube intubation using the King Vision (channelled blade size 3) then they will use the McGrath (X-blade) laryngoscope in the same order.
33102066|NCT05467488|No Intervention|Non irradiated implants (group A)|
33102067|NCT05467488|Active Comparator|UVA irradiated group (group B)|
33102068|NCT05467488|Active Comparator|UVC irradiated group (group C)|
33102069|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
33102070|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
33102071|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
33102072|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
33102073|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
32826525|NCT04517838||Basic science (biospecimen collection)|Patients undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence for patients with stage I-III, or progressive disease for patients with stage IV. Patients with stage IV HER2 positive breast cancer with no disease progression >= 2 years on the same line of therapy, undergo blood sample collection at baseline anytime during their treatment with anti-HER2 therapies, 8 and 16 weeks after the first blood draw, and at the time of invasive disease recurrence. Patients also undergo tumor tissue collection for the evaluation of gene expression and DNA variants.
32826526|NCT01837654|Experimental|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
32826527|NCT01837654|Experimental|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
32826528|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
32826529|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
32826530|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
32826531|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
32826532|NCT01838980|Experimental|Colonoscopy|
32826533|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
32826534|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
32826535|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
32826536|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
32826537|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
32826538|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
32826539|NCT01789138|Experimental|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
32826540|NCT01789138|No Intervention|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
32826541|NCT01841632|Experimental|MultiStem|"Dose escalation~Cohort 1~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 2~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 3~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 4~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
32826542|NCT01807949|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
32826543|NCT01807949|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
32826544|NCT01807949|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
32826545|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
32826546|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
32826547|NCT01806779|Experimental|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
32826548|NCT01806779|Experimental|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
32826549|NCT01789840|Experimental|Prostate artery embolization (PAE)|Prostate artery embolization using Embosphere Microspheres
32826550|NCT01789840|Active Comparator|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
32826551|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
32826552|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
32826553|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
32826554|NCT01792024|Experimental|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
32826555|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
32826556|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
32826557|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
32826558|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
32826559|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
32826560|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
32826561|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
32826562|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
32826563|NCT04350736|Experimental|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
32826564|NCT04350736|Experimental|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
32826565|NCT04350736|Experimental|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
32826566|NCT04350736|Experimental|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
32826567|NCT01607957|Experimental|TAS-102|
32826568|NCT01607957|Placebo Comparator|Placebo|
32826569|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
32826570|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
32826571|NCT01795534|Experimental|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
32826572|NCT01795534|Placebo Comparator|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
32826573|NCT01806623|Experimental|Fluconazole|
32826574|NCT01806545|Active Comparator|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
32826575|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
32826576|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
32826577|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
32826578|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
32826579|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
32826580|NCT01847560||Dabigatran|
32826581|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
32826582|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
32826583|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
32826584|NCT05329090|Experimental|experimental group|Experimental therapeutic strategy based on the use of rituximab in combination with glucocorticoids
32826585|NCT05329090|Placebo Comparator|control group|Control therapeutic strategy based on glucocorticoids plus placebo
32826586|NCT05328778|Experimental|Normal Weight group|n=16, 18.5kg/m² ≤ BMI ≤ 24.9kg/m²
32826587|NCT05328778|Experimental|Obese group|n=16, 25≤BMI≤39.9kg/m²
32826588|NCT05328778|Experimental|Morbidly Obese group|n=16, BMI≥40kg/m²
32826589|NCT01796236|Active Comparator|Minimally invasive surgery and BA400|This arm involves no soft tissue reduction around the BA400 implant.
32826590|NCT01796236|Active Comparator|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
32826591|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).~Aged 19 or more~Treated with R-CHOP therapy"
32826592|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
32826593|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
32826594|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
32826595|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
32826596|NCT05211570|Experimental|AB8939|AB8939 administered as a single agent
32826597|NCT05211570|Experimental|AB8939 plus azacitidine|AB8939 administered in combination with azacitidine
32826598|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
32826599|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
32826600|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
32826601|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
32826602|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
32826603|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
33102074|NCT05467449||Hematologically normal|Based on immunophenotyping
33102075|NCT05467449||Hematologically abnormal|Based on immunophenotyping
32826604|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
32826605|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
32826606|NCT04362228|Experimental|Whole-body exercise|
32826607|NCT05328544|Experimental|ACL Reconstruction with the use of autogenous spongiform bone grafts|Stabilization of the tibial insertion with a bioabsorbable screw (Arthrex) with simultaneous application to the tibial canal of autogenous cancellous bone grafts taken during the drilling of this canal.
32826608|NCT05328544|Active Comparator|ACL Reconstruction without the use of autogenous spongiform bone grafts|Stabilization of the tibial attachment with a bioabsorbable screw (Arthrex) without simultaneous application of autogenous cancellous bone grafts to the tibial canal.
32826609|NCT05328310|Active Comparator|Telmisartan|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, telmisartan is given as the primary antihypertensive agent.
32826610|NCT05328310|Experimental|Nebivolol|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, nebivolol is given as the primary antihypertensive agent.
32826611|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
32826612|NCT01797328|Active Comparator|cold provocation|cold arm
32826613|NCT01797328|Active Comparator|to avoid feeling cold|warm arm
32826614|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
32826615|NCT05328232|Experimental|Olive oil|
32826616|NCT05328232|No Intervention|Routine care|
32826617|NCT01797484|Active Comparator|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
32826618|NCT01797484|No Intervention|No additional medication|No additional medication - control group
32826619|NCT01798186|Experimental|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
32826620|NCT01798186|Experimental|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
32826621|NCT01798186|Experimental|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
32826622|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
32826623|NCT01852084|Experimental|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
32826624|NCT01852084|Experimental|enVista control lens|Spherical control lens
32826625|NCT01798264|Experimental|10 mcg./day|ITCA 650 (exenatide in DUROS)
32826626|NCT01798264|Experimental|20 mcg/day|ITCA 650 (exenatide in DUROS)
32826627|NCT01798264|Experimental|40 mcg/day|ITCA 650 (exenatide in DUROS)
32826628|NCT01798264|Experimental|80 mcg/day|ITCA 650 (exenatide in DUROS)
32826629|NCT01798966|Experimental|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
32826630|NCT05326984|No Intervention|Control group|This subjets will receive conventional chemotherapy alone. The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21.
32826631|NCT05326984|Experimental|Interventional group|"This group will receive conventional chemotherapy plus metformin 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.~The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21."
32826632|NCT01799278|Experimental|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
32826633|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
32826634|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
32955971|NCT05765552|Experimental|Dual-Task Training Group|Participants in the dual-task training group will receive exercises involving both motor and cognitive functions.Dual-task training sessions will begin with 10 minutes of stretching and proceed with 20 minutes of motor-cognitive dual-task exercises (counting backwards from 30 on double stance, naming the months and singing when standing on soft surfaces, finding words that starts with a given letter etc.) and sessions will end with 10 minutes of cooling.Exercises will be applied for 8 weeks 2 days a week each session will last for 30 minutes.
32955972|NCT05765539|Experimental|Pregnant women benefitting ultrasound examination|This is the unique arm of the study. This arm is made of eligible pregnant women, with a pregnancy of at least 37 weeks.
33405247|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
32955973|NCT05765526|Experimental|The scalp of discomfort or itching and one treatment|Participants with discomfort or itching scalp who will receive one treatment with the device and complete the questionnaire.
32955974|NCT05765500|Experimental|Arm A: Relugolix|"55 participants will be randomized in a 1:1 fashion to Relugolix and stratified by intent to treat with radiation and will complete study procedures as outlined:~Surveys at baseline and at months 3, 6, 9, and 12.~Medication diary entries.~Cycles 1 - 6:~--Days 1 - 28 of 28 day cycle: Predetermined dose of Relugolix. Participant will self-administer at home.~Follow up visits every 3 months for 12 months."
32955975|NCT05765500|Active Comparator|Arm B: Leuprolide|"55 participants will be randomized in a 1:1 fashion to Leuprolide and stratified by intent to treat with radiation and will complete study procedures as outlined:~Surveys at baseline and at months 3, 6, 9, and 12.~Cycle 1 and Cycle 4:~--Day 1 of 28 day cycle: Predetermined dose of Leuprolide. Injection will be administered in clinic.~Follow up visits every 3 months for 12 months."
32955976|NCT05765487|Active Comparator|Sildenafil Cream, 3.6%|Contains both Sildenafil and L-arginine
32955977|NCT05765487|Placebo Comparator|Placebo Cream|Contains L-arginine, no Sildenafil
32955978|NCT05765487|Other|Vehicle Cream|Contains no L-arginine, no Sildenafil
32955979|NCT05765474|Experimental|Training with Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the experimental group will include the practice variable of interest.
32955980|NCT05765474|Other|Training without Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the control group will not include the practice variable of interest.
32955981|NCT05765448|Active Comparator|Soy-based control meal|Bowl of soup noodles prepared with 10g soy protein isolate soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
32955982|NCT05765448|Experimental|Laver/nori macroalgae (Porphyra umbilicus) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
32955983|NCT05765448|Experimental|Laver/nori macroalgae (Porphyra umbilicus) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
32955984|NCT05765448|Experimental|Microalgae (Chlorella vulgaris) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
32955985|NCT05765448|Experimental|Microalgae (Chlorella vulgaris) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
32955986|NCT05765435|Other|Control|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program. There will be no stimulation.
32955987|NCT05765435|Experimental|NMES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise sessions.
32955988|NCT05765435|Experimental|NMES and FES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise and walking sessions.
32955989|NCT05765422|Other|sedentary|Participant does not meet WHO's recommendations with the physical activity
32955990|NCT05765422|Other|OMS recommandations|Participant does not meet WHO's recommendations (2.5-5 hours per week of moderate physical activity OR 1.25-2.5 hours per week of vigorous physical activity);
32955991|NCT05765422|Other|More than the OMS recommandations|Participant is practicing physical activity more than the WHO recommendations
32955992|NCT05765409|Experimental|TIMCA|The intervention will combine elements of motivational interviewing, cognitive and behavioral therapy and an attachment-based intervention. Sessions with both the adolescent and his parents are planned.
33405248|NCT03650660||Patients with liver cirrhosis|
33405249|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
33405250|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
32826635|NCT01800838|Experimental|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
32826636|NCT01782131|Experimental|Posaconazole (POS)|Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
32826637|NCT01782131|Active Comparator|Voriconazole|Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
32826638|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
32826639|NCT05313880||Digital tool Survey|Sequential patients from the 4 heart failure clinics at our institution will be offered to take part in the study.
32826640|NCT01802554|Experimental|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
32826641|NCT01802554|Active Comparator|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
32826642|NCT01781975|Experimental|Imatinib Mesylate|400 mg imatinib given once daily basis.
32826643|NCT01781975|Placebo Comparator|Placebo|Placebo given once daily basis.
32826644|NCT01855360|Experimental|TUDCA and Doxycycline|INTERVENTION: Patients meeting study criteria were prescribed TUDCA taken orally, 250 mg three times daily. and doxycycline taken orally, 100 mg twice daily.
32826645|NCT01802710|Experimental|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
32826646|NCT01802710|Active Comparator|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
32826647|NCT04351126|Other|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
32826648|NCT04351126|Experimental|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
32826649|NCT04351126|Experimental|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
32826650|NCT01804673|Experimental|Fentanyl-ITS|
32826651|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
32826652|NCT01774097|Experimental|ALD-301|Participants will receive ALD-301 via intramuscular injection
32826653|NCT01774097|Placebo Comparator|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
32826654|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
32826655|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
32826656|NCT05302336|Active Comparator|Liposomal doxorubicin + Cyclophosphamide|Liposomal doxorubicin + cyclophosphamide A 35mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
32826657|NCT05302336|Active Comparator|Docetaxel + Cyclophosphamide|Docetaxel + Cyclophosphamide T 75mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
32826658|NCT05300542|Experimental|Skin UVB irradiated 1.25MED|
32826659|NCT05300542|Experimental|Skin UVB irradiated 1.6MED|
32826660|NCT05300542|No Intervention|Untreated Skin|
32826661|NCT01804036|Active Comparator|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
32826662|NCT01804036|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
32826663|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
32826664|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
32826665|NCT01857232|Other|Control|OND + DEX + FOS followed by oral DEX
32826666|NCT01857232|Placebo Comparator|Placebo|OND + APD403 followed by oral PLACEBO
32826667|NCT01857232|Experimental|Low dose APD403|OND + APD403 followed by oral APD403 low dose
32826668|NCT01857232|Experimental|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
32826669|NCT01857232|Experimental|High dose APD403|OND + APD403 followed by oral APD403 high dose
32826670|NCT01804114|Active Comparator|Local anesthetic continuous infusion|Pain management following hernia repair
32826671|NCT01804114|Placebo Comparator|Placebo continuous infusion|Placebo pain management following hernia repair
32826672|NCT05275036||Cancer Arm|Participants with new diagnosis of lymphoid malignancies, from whom blood samples will be collected.
32826673|NCT05275036||Benign Arm|Participants with new diagnosis of benign lymphoid diseases, from whom blood samples will be collected.
32826674|NCT01766128|Active Comparator|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
32826675|NCT01766128|Placebo Comparator|Placebo|The patients in this arm are treated with placebo
32826676|NCT02859558|Experimental|Arm 1: Fiebig I/II|Participants enrolled during Fiebig stages I or II (non-reactive HIV-1 antibody).
32826677|NCT02859558|Experimental|Arm 2: Fiebig III/IV|Participants enrolled during Fiebig stages III or IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2).
32826678|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stage V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band).
32826679|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
32826680|NCT02830542|Placebo Comparator|Placebo|Placebo
32826681|NCT05185440|Active Comparator|GIFTSS Training Only|Training for college health center clinicians and staff in implementation of GIFTSS Training
32826682|NCT05185440|Experimental|GIFTSS Training and Learning Collaborative|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative to support implementation
32826683|NCT05185440|Experimental|GIFTSS Training and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with provider scripts to support implementation
32826684|NCT05185440|Experimental|GIFTSS Training, Learning Collaborative, and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative as well as provider scripts to support implementation
32826685|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
32826686|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
32826687|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
32826688|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
32826689|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
32826692|NCT05229250||Healthy subjects|Subjects without FLIA
32826693|NCT05229250||Patient subjects|Subjects with FLIA
32826694|NCT01075672|Experimental|Cognitive Behavioral Therapy|
32826695|NCT01075672|Experimental|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
32826696|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
32826697|NCT05166382|Experimental|Group 1: SomaSignal Informed Medical Management (CVDT2D test, informed)|Blood draw for cardiovascular CVDT2D test at baseline and 6 months (+/- 30 days). SomaSignal Test results will be sent to the providers and then shared with study participants. Participants' medical record will be reviewed, and they may be contacted within 30 days after baseline and 6-month visits to review changes in treatment strategy (nothing, add/remove medication, etc.) made at visit.
32826698|NCT05166382|Placebo Comparator|Group 2: Standard of Care (CVDT2D test, uninformed)|Similar to group 1 but SomaSignal CV test results will not be provided to participants until after the intervention period.
32826699|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
32826700|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
32955993|NCT05765409|Active Comparator|Treatment as Usual|"The comparator, an active control, will be Treatment As Usual (TAU) group, i.e., the therapy usually practiced in the services. Given the multiplicity of investigating centers and the different treatments offered according to the patient's problems, it seems difficult to choose a single reference treatment for the control arm. Each investigating center undertakes to adopt the treatment that seems most effective and appropriate for each patient"
32826701|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
32955994|NCT05765396||COVID-19 positive patients|Participants screened with known COVID-19 positive test results obtained within 48hrs of recruitment.
32955995|NCT05765396||COVID-19 negative patients|Participants screened with known COVID-19 negative test results obtained within 48hrs of recruitment.
32826702|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
32826703|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
32826704|NCT04491708|Experimental|Apparatus Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
32826705|NCT04491708|Experimental|Mat Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
32826706|NCT05058430|Experimental|Human Factors|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.~Primary performance endpoints:~The user can select the device properly.~The user can use the device as instructed in the IFU."
32826707|NCT05042518|Experimental|Intervention group|The participant in the intervention group will practice breathing control and self-talk with objectives for relaxation. The duration of training is 4-5 minutes in each session, 4 sessions per week for 1 month.
32826708|NCT05042518|Placebo Comparator|Control group|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month).
32826709|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
32826710|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
32826711|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
32826712|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
32826713|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
32826714|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
32826715|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
32826716|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
32826717|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
32826718|NCT01861054|Experimental|Treated patients - Total|Patients eligible will be treated with Reparixin as add-in monotherapy
32826719|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
32826720|NCT04241718|Other|Single-arm|No comparator, placebo, or randomization
32826721|NCT05323032|Experimental|Normal subjects|Normal subjects at banha university that are seeking regular ophthalmic check-up.
32826722|NCT05305794|Experimental|Semaglutide|
32826723|NCT05305794|Active Comparator|Control|
32826724|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
32826725|NCT01861756|No Intervention|Standard care|
32826726|NCT05301582||Group|A total of 70 consecutive adult patients, aged 18-65 years scheduled for elective laparoscopic surgery under general anesthesia will be included in the study.
32826727|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
32826728|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
32900029|NCT00243152|Active Comparator|Placebo to Lamotrigine Crossover|The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
32900030|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
32900031|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
32826729|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
32826730|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
32826731|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
33405251|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
32826732|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
32826733|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
32826734|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
32826735|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
32826736|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
32826737|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
32826738|NCT01862614|Experimental|Buffered Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc buffered 4% articaine.
32826739|NCT01862614|Active Comparator|Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc 4% articaine (unbuffered).
32826740|NCT05166876|Experimental|Brequinar monotherapy|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
32826741|NCT05166876|Placebo Comparator|Placebo|Placebo matching brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
32826742|NCT05166876|Experimental|Brequinar-Dipyridamole Combination|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met. All subjects assigned to this arm will also receive dipyridamole 75 mg tablets TID.
32826743|NCT00558688|Experimental|1|Light Therapy
32826744|NCT00558688|Experimental|2|Light Therapy
32826745|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
32826746|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
32826747|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
32826748|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
32826749|NCT01375608|Other|decitabine|active treatment
32826750|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
32826751|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
32826752|NCT05008900|Experimental|Surveillance|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will go on surveillance. Routine PSA will be conducted and a repeat PSMA PET/CT imaging will be conducted when the PSA rises to greater than 0.5 to less than 1.0 ng/mL.
32826753|NCT05008900|No Intervention|Salvage radiotherapy|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA of greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will receive salvage radiotherapy to the prostate bed. This radiotherapy may or may not include the pelvic lymph nodes.
32826754|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
32826755|NCT02473770||Disaster responders|Conducting emergency disaster relief.
32826756|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
32826757|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
32826758|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
32826759|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
32826760|NCT05748340|Other|Control group|21normal infant aged 3-6 months
32826761|NCT05748340|Other|Group a|21 patient of unilateral cleft lip had mishra technique repair
32826762|NCT05748340|Other|Group b|21 patient of unilateral cleft lip had modified Millard technique repair
32826763|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
32826764|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
32826765|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
32826766|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
32826767|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
32826768|NCT05232552|Experimental|anlotinib|3 cycles of anlotinib (12mg, d1-14)was given concurrently with docetaxel plus cisplatin chemotherapy as induction , then 2 additional cycles of anlotinib concurrent with definitive chemoradiation (IMRT with conccurent cisplatin)
32826769|NCT05748262||Primary infections during March-May 2022|Hospitalized COVID-19 patients infected with BA·2 during 1 March to 23 May 2022 from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital.
32826770|NCT05748262||Primary infections during December 2022-January 2023|Primary infections with BA.5-sublineages during 1 December 2022 to 14 January 2023, matched 1:1 by age and sex with reinfections during the same period.
32826771|NCT04807894|Experimental|Vaginal Testosterone Cream Arm|Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
32826772|NCT04807894|Placebo Comparator|Vaginal Placebo Cream Arm|Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
32826773|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
32826774|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
32826775|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
32826776|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
32826777|NCT01515462|Experimental|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
32826778|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
32826779|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
32826780|NCT00916656|Experimental|Prospective Arm|
32826781|NCT00916656|Other|Historical Control|
32826782|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
32826783|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
32826784|NCT05127642||Postpartum hemorrhage patients|
32826785|NCT05127642||Controls (non postpartum hemorrhage patients)|
32826786|NCT05351892|Experimental|Treatment A-B|Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
32826787|NCT05351892|Experimental|Treatment B-A|Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
32826788|NCT00555646|Experimental|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
32826789|NCT05121948|Experimental|Phase 1a Cohort 1 - 10 mg|10 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826790|NCT05121948|Experimental|Phase 1a Cohort 2 - 20 mg|20 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826791|NCT05121948|Experimental|Phase 1a Cohort 3 - 40 mg|40 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826792|NCT05121948|Experimental|Phase 1a Cohort 4 - 75 mg|75 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826793|NCT05121948|Experimental|Phase 1a Cohort 5 - 125 mg|125 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826794|NCT05121948|Experimental|Phase 1a Cohort 6 - 150 mg|150 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826795|NCT05121948|Experimental|Phase 1b Cohort 7 - Dose 1 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
32826796|NCT05121948|Experimental|Phase 1b Cohort 8 - Dose 2 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
33317942|NCT00306995|Experimental|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
32826797|NCT01873846|Experimental|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
32826798|NCT00711282|Experimental|A|
32826799|NCT00711282|Experimental|B|
32826800|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
32826801|NCT05748028||Parkinson Disease|Patients affected by Parkinson's disease admitted for rehabilitation in Maugeri Clinical Scientific Institutes
32826802|NCT05748028||Multiple System Atrophy|Patients affected by Multiple System Atrophy admitted for rehabilitation in Maugeri Clinical Scientific Institutes
32826803|NCT05585320|Experimental|IMM-1-104|Dose Escalation and Dose Expansion
32826804|NCT04064346|Experimental|Lixivaptan|Lixivaptan capsules, 100-200 mg twice a day (BID)
32826805|NCT04064346|Placebo Comparator|Placebo|Matching placebo capsules BID
32826806|NCT05747950|Other|Vibration group|"Vibration is defined as a mechanical stimulus characterized by oscillating movements.~has been defined.The first method is a hand held as a local vibration application that can be applied directly to the widest part of the muscle with the object.is named. The second method, called whole body vibration, is a vibration source applied on the platform. Participants immediately after the sessions in addition to conventional physiotherapy.~Upper extremity flexor on the hemiplegic side in supine position, 8 weeks, 3 sessions per week with a CE certified vibration device with a frequency of 50-110 Hz and an amplitude of 1-4 mm. Local vibration will be applied for 15 minutes each."
32826807|NCT05747950|Other|Modified Constraint-Induced Movement Therapy group|Modified Constraint-İnduced Movement Therapy is a rehabilitation technique that promotes 'repetitive' use of the affected upper extremity in people with upper extremity neurological motor deficits. Constraint-İnduced Movement Therapy upper extremity after stroke it is a rehabilitation approach used to increase functional use. post stroke Approximately 20-25% of surviving patients can meet the motor criteria of mCIMT. Participants In addition to conventional treatment, they can use their intact extremities at home with a shoulder stabilization orthosis.Restraint, grasping on the hemiplegic side, using spoons and forks, combing hair daily life activities, 8 weeks, 3 days a week, and approximately 3 hours Modified Constraint-İnduced Movement Therapy m(CIMT) will be applied.
32826808|NCT05747950|Other|Control group|Control group in the training group, will be given a program that includes joint range of motion exercises, strengthening exercises, mobility and transfer activities, and various activities in order to increase participation in daily life activities as a routine conventional treatment in 60-minute sessions, 3 days a week, for 8 weeks.
32826809|NCT05747872|Experimental|İntervention Grup|Buerger Allen exercises programme will be applied to the type 2 diabetes mellitus patients with foot ulcer. Patients in the intervention group performed daily Buerger Allen exercises for 12 weeks. Patients in the study intervention group were taught Buerger Allen exercises and were asked to exercise twice daily for 12 weeks. Individuals will be given an exercise diary, including the pictures of the exercises, to better manage this process. Reminder phone calls were made once a week to support the exercise program and increase motivation.
32826810|NCT05747872|No Intervention|Control Grup|The control group received standard wound care but no exercises.
32826811|NCT05579470|Other|NIATx Model|Receiving NIATx Coaching
32826812|NCT04053816|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
32826813|NCT04053816|Active Comparator|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
32826814|NCT04051242|Experimental|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval [#K162193] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
32826815|NCT05575648|Other|Duchenne Muscular Dystrophy|Children who have been diagnosed with Duchenne Muscular Dystrophy.
32826816|NCT05575648|Active Comparator|Healthy Subjects|Children who have a normal motor and cognitive development.
32826817|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
32826818|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
33317943|NCT00306995|Experimental|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
33405252|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
32826821|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32826822|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32826823|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32826824|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
32826825|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
32826826|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
32826827|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
32826828|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
32826829|NCT05747716|Experimental|SBRT, Fruquintinib, Cadonilimab|
32826830|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32826831|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32826832|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32826833|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32826834|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
32826835|NCT05542264|Active Comparator|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
32826836|NCT05542264|Experimental|SEP-363856|
32826837|NCT05747482|Other|Omentectomy|Omentectomy during cancer gastric surgery
32826838|NCT05747482|Other|Omental preservation|Preserval omentation during cancer gastric surgery
32826839|NCT05535244|Experimental|Cohort A1: Prior BCMA antibody-drug conjugate (ADC) or chimeric antigen receptor T (CAR-T)|Participants in Cohort A1 will be treated at the double step-up split dosing regimen.
32826840|NCT05535244|Experimental|Cohort A2: Prior BCMA Bispecific|Participants enrolled into exploratory Cohort A2 will receive the same dosing regimen as Cohort A1.
32826841|NCT05535244|Experimental|Cohort B1: Prior BCMA ADC or CAR-T|Participants enrolled in expansion Cohort B1, will be given cevostamab at the recommended Phase 2 dose (RP2D).
32826842|NCT05535244|Experimental|Cohort B2: Prior BCMA Bispecific|Expansion Cohort B2 will be opened, after the intiial results from Cohort A2, at the same dose as per Cohort B1.
32826843|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
32826844|NCT00704340|Active Comparator|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
32826845|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
32826846|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
32826847|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
32826848|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
32826849|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
32826850|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
32826851|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
32826852|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
32826853|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
32826854|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
32826855|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
32826856|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
32826857|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
32826858|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
32826859|NCT05747326|Experimental|Study group|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
32826860|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
32826861|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
32826862|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
32826863|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
32826864|NCT02473224|Experimental|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10^7 GEC oral dose on Day 1, n=11
33317944|NCT00306995|Experimental|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
32826866|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
32826867|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
32826868|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
32826869|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
32826870|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
32826871|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
32826872|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
32826874|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
32826875|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
32826876|NCT02473068|Active Comparator|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
32826877|NCT02473068|Experimental|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
32826878|NCT05496868|Experimental|Reparixin + Standard of care|Reparixin tablets 1200 mg TID (2 tablets x 600 mg TID) as add-on to the standard of care (SoC).
32826879|NCT05496868|Placebo Comparator|Placebo + Standard of care|Placebo tablets with the same schedule of reparixin, as add-on to the standard of care (SoC)
32826880|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
32826881|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
32826882|NCT05747170|Experimental|Group 1|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: natural odor (mint) for 5 minutes, neutral odor (water) for 5 minutes, chemical odor (gasoline) for 5 minutes."
32826883|NCT05747170|Experimental|Group 2|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: chemical odor (gasoline) for 5 minutes, neutral odor (water) for 5 minutes, natural odor (mint) for 5 minutes."
32826884|NCT03888612|Experimental|ARV-110|"Part A: Oral tablet(s), once or twice daily in 28 day cycles~Part B: Oral tablet(s), once or twice daily in 28 day cycles"
32826889|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
32826890|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
32826891|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
32826892|NCT05747092|Active Comparator|Control group: free gingival graft for gingival recession|
32826893|NCT05747092|Experimental|Test group: connective tissue graft for gingival recession|
32826894|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
32826895|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
32826896|NCT05747014||Novapak Subjects|Subjects that are enrolled in the Novapak Study.
32826897|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
32826898|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
33405253|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
33405254|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
32826901|NCT05746936||Obese patients underwent laparoscopic gastric bypass|
32826902|NCT05746936||obese patients underwent robotic gastric bypass|
33317945|NCT00306995|Experimental|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
33317946|NCT00306995|Experimental|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
33405255|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
33405256|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
32826903|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
32826904|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
32826905|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
32826906|NCT05454124|Experimental|Training visual sensitivity|A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
32826907|NCT05454124|Experimental|Combination training|In combination training, investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpassing benefits of the individual training alone. The visual sensitivity task will alternate across blocks with the spatial integration task, using the timing of targets and location switches from spatial attention training.
32826908|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
32826909|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
32826910|NCT04491630|Active Comparator|Self-Hypnosis (SH)|
32826911|NCT04491630|Active Comparator|Mindfulness meditation (MM)|
32826912|NCT04491630|Active Comparator|Christian prayer (CP)|
32826913|NCT04491630|No Intervention|Control condition (CN)|Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.
32826914|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
32826915|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
32826916|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
32826917|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
32826918|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
32826919|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
32826920|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
32826921|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
32826922|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
32826923|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
32826924|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
33317947|NCT00306995|Experimental|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
32826925|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
32826926|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
32826927|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
32900032|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
32955996|NCT05765357|Experimental|Trastuzumab for injection|4mg/kg, Single dose for intravenous infusion
32826928|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
32826929|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
32826930|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
32826931|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
32826932|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
32826933|NCT02472678|Other|Standard care|The control group will receive standard care.
32826934|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
32826935|NCT03686124|Experimental|Dose Escalation|Dose escalation of IMA203
32826936|NCT03686124|Experimental|Extension Cohort A|IMA203 at RP2D
32826937|NCT03686124|Experimental|Extension Cohort B|IMA203 at RP2D + nivolumab
32826938|NCT03686124|Experimental|Extension Cohort C|IMA203CD8 at provisional RP2D
32826939|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
32826940|NCT03311100||Lung cancer|
32826941|NCT03311100||Central Nervous System Cancers|
32826942|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
32826943|NCT03311100||Skin cancers|
32826944|NCT03311100||Sarcomas|
32826945|NCT03311100||Urothelial cancer|
32826946|NCT03311100||Hepatocarcinoma|
32826947|NCT05422534|Placebo Comparator|Observational + placebo|Participants will receive placebo with standard of care or regular activity for 12 weeks.
32826948|NCT05422534|Active Comparator|Observational+ CoQ10|Participants will receive CoQ10 1800 mg/day with standard of care or regular activity for 12 weeks.
32826949|NCT05422534|Placebo Comparator|HB HIIT +placebo|Participants will receive placebo and home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks. The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
32826950|NCT05422534|Active Comparator|HB HIIT + CoQ10|Participants will received CoQ10 1800/day with home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
32826951|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
32826952|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
32826953|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
32826954|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
32826955|NCT05421598|Experimental|Amlitelimab dose level 1|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 1 every 4 weeks (Q4W) until Week 20 (inclusive) and every 12 weeks (Q12W) starting from Week 24 and thereafter.
32826956|NCT05421598|Experimental|Amlitelimab dose level 2|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 2 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
32826957|NCT05421598|Experimental|Amlitelimab dose level 3|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 3 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
32826958|NCT05421598|Placebo Comparator|Placebo|Initial loading dose of amlitelimab matching placebo on Day 1, followed by one injection of amlitelimab matching placebo Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
32826959|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
32826960|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
32826961|NCT05416372|No Intervention|Control communities|Communities randomized to the control arm will receive a strengthening of the capacity to manage blood pressure at their local health center. Healthcare workers at the local health center will receive standard supplies, reference materials, and training in blood pressure measurement and management on-site. In the event of any stock-outs due to higher demand for antihypertensives during the trial implementation, the trial will temporarily provide these medications to primary health facilities until the Ministry of Health supply chain is restored. Of note, control communities will receive Religious Engagement in Health Intervention after the trial is complete.
33405257|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
32900034|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
32900035|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
32900036|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
33405258|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
33405259|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
33317948|NCT00306995|Experimental|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
33317949|NCT00121108|Placebo Comparator|Placebo|Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
32826962|NCT05416372|Experimental|Religious Engagement in Health Intervention communities|Communities randomized to the intervention arm will receive a strengthening of the capacity to manage blood pressure at their local health center plus Religious Engagement in Health Intervention for blood pressure (BP), which includes three evidence-based components; 1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, 2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and 3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
32826963|NCT03313284|Experimental|Study Group|
32826964|NCT05746468|Experimental|Intervention group|The intervention group will receive a combination of (1) a time-based system-triggered EMI, which will collect participants' sources and status of depression, anxiety and depression in daily life and provide instructions (audios and videos) on mindfulness practice, and (2) a longitudinal survey in parents of children with ASD. The participants will first complete a baseline questionnaire, and then participate in EMI via a smartphone application (App) for 8 consecutive weeks and receive the exercise prompts daily. The EMI will include questions of the self-reported feelings of depression, anxiety and depression. After the 8-week EMI, the participants will be invited to complete a post-experimental survey with similar questions in the baseline questionnaire. Two months after completing the EMI, participants will be contacted to complete a telephone follow-up survey with similar questions in the baseline questionnaire.
32826965|NCT05746468|Active Comparator|Control group|The control group will receive the longitudinal survey exactly the same as the intervention group and 8-week mindfulness-based short-messages sent by the research team on a daily basis. The messages will contain instructions of mindfulness-based practice which will be the same as the intervention group.
32826966|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
32826967|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
32826968|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
32826969|NCT05409976|Experimental|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
32826970|NCT03313206|Experimental|Patients with Resectable head and neck mucosal melanomas|
32826971|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
32826972|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
32826973|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
32826974|NCT03666780||Subject|"All patients who signed informed consent and are implanted with a LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post implant:~At discharge (+/- 1 day)~1-3 months (+/- 1 week)~6 months (+/- 2 weeks)~12 months (+/- 1 month)~2 years (+/- 3 month)~3 years(+/- 3 month) Patients who have undergone a LAmbre explant should remain in the study and adhere to the above mentioned follow-up time point until completion of 3 years follow-up period.~After the patient has completed the 3 years follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care."
32826975|NCT05736094|Other|Dual-frequency ultrasound|Dual-frequency ultrasound for detection of prostate cancer
32826976|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
32826977|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
32826978|NCT03304938|Active Comparator|Lavender oil|
32826979|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
32826980|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
32826981|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
32826982|NCT03310554|Other|ordinary plastic biliary stents group|
32826983|NCT03310476|Experimental|Baked, consumed chilled potatoes|
32826984|NCT03310476|Experimental|Boiled, consumed hot potatoes|
32826985|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
32826986|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
32826987|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
32826990|NCT03312972|Experimental|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
32826991|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
32826992|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
32900037|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
32826993|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
32826994|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
32826995|NCT00559936|Experimental|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
32826996|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
32826997|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
32826998|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
32826999|NCT04768738|Experimental|Above Threshold Group|In the above threshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
32827000|NCT04768738|Experimental|Subthreshold Group|In the subthreshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
32827001|NCT04768738|Sham Comparator|Control Group|In the control group, bicycle exercise was performed under the same load with the current-free headset produced for sham applications for 5 minutes. Participants were shown that the device was working, but no current was given.
32827002|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
32827003|NCT03312816|Active Comparator|low dosage|low added POP
32827004|NCT03312816|Active Comparator|Medium dose|medium added POP
32827005|NCT03312816|Active Comparator|Hige dose|high added POP
32827006|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
32827007|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
32827008|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
32827009|NCT05353192|Experimental|Recombinant human growth hormone|Recombinant human growth hormone Injection (15IU/5mg/3ml/bottle)；0.05 mg/kg/d by subcutaneous injection for 52 weeks
32827010|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
32827011|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
32827012|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
32827013|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
32827014|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
32827015|NCT05341492|Experimental|Treatment|Patients will receive 2*10e6/kgCAR-T cells.
32827016|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
32827017|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
32827018|NCT05336188|Experimental|Smartphone|Participants randomized into the Smartphone app arm would use the smartphone app OptiMAT in conjunction with treatment as usual (TAU). Participants would use OptiMAT to complete daily self-assessments of opiate misuse, opiate craving, opiate withdrawal, and mood. The app will personalized feedback for maintaining abstinence goals. The app would also use geographic ecological momentary assessment (GEMA) to intervene via push notification when participants enter areas previously identified as high-risk for opiate use.
32827019|NCT05336188|No Intervention|Monitoring Only|Participants randomized into the Monitoring Only arm would undergo treatment as usual (TAU) but without the smartphone app.
32827020|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
32827021|NCT03312582|Placebo Comparator|Manual debridement and placebo|
32827022|NCT05704582|Experimental|Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
32827023|NCT05704582|Active Comparator|Addiction supportive intervention|The Addiction supportive intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use.
32827024|NCT03304470|Experimental|ATx201 2% CREAM|
32827025|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
32827026|NCT04350580|Experimental|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started before the 96th hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
32827027|NCT04350580|Placebo Comparator|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
33405260|NCT05285384|Experimental|SpikoGen COVID-19 Vaccine|
33405261|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
32827028|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
32827029|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
32827030|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
32827031|NCT02469324|Experimental|Compassionate Mind Training|
32827032|NCT05290402||an application-based digital navigator|"JEEVA is a new digital health navigator app. This app can be used on a mobile phone or tablet. JEEVA has all of the surgical teaching information from the traditional paper packet and also has additional resources like brief videos, checklists, and reference photos."
32827033|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
32827034|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
32827035|NCT05699122|Active Comparator|The Control Group - Persistent erythema with intact epidermis|The Control Group - Persistent erythema with intact epidermis
32827036|NCT05699122|Experimental|The Experimental Group - Persistent erythema with intact epidermis|The Experimental Group - Persistent erythema with intact epidermis
32827037|NCT05699122|Active Comparator|The Control Group - Erythema with signs of epidermis loss|The Control Group - Erythema with signs of epidermis loss
32827038|NCT05699122|Experimental|The Experimental Group - Erythema with signs of epidermis loss|The Experimental Group - Erythema with signs of epidermis loss
32827039|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
32827040|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
32827041|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
32827042|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
32827043|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
32827044|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
32827045|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
32827046|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
32827047|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
32827048|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
32827049|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
32827050|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
32827051|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
32827052|NCT03304158|Experimental|FCHV visit-diabetes|
32827053|NCT03304158|No Intervention|FCHV no visit-diabetes|
32827054|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
32827055|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
32900038|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
32827056|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
32827057|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
32827058|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
32827059|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
32827060|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
32827061|NCT05168826||Transcatheter Aortic Valve Implantation (TAVI)|
32827062|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
32827063|NCT04442100|Experimental|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
32827064|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
32827065|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
32827066|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
32827067|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
32827068|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
32827069|NCT03311802||1|
32827070|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
32827071|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
32827072|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
32827073|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
32827074|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
32827075|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
32827076|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
32827077|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
32827078|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
32827079|NCT05207202|Active Comparator|EIT-PEEP strategy|Patients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial
32827080|NCT05207202|Active Comparator|ARDSNet-PEEP strategy|PEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 88% and 95%, and PaO2 between 55mmHg and 80mmHg.
32827081|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
32827082|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
32827083|NCT05080686|Experimental|ThoraxBelt (Inpatients)|Received ThoraxBelt after the surgery in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Inpatients).
32827084|NCT05080686|No Intervention|Standard Care (Inpatients)|Standard Care with IV PCA and on-request oral painkiller.
32827085|NCT05080686|Experimental|ThoraxBelt (Outpatients)|Received ThoraxBelt at the emergency room in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Outpatients).
32827086|NCT05080686|No Intervention|Standard Care (Outpatients)|Standard Care and on-request oral painkiller.
32827087|NCT05047926|No Intervention|Primary Cytoreductive Surgery|Women diagnosed with or having a high suspicion for ovarian cancer and undergoing primary surgical intervention for debulking of tumor.
32827088|NCT05047926|Experimental|Neoadjuvant Chemotherapy prior to Cytoreductive Surgery|Women diagnosed with or having a high suspicion for ovarian cancer and recommended to have Neoadjuvant Chemotherapy (NACT) prior to undergoing an interval debulking surgical intervention.
32900039|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
32827089|NCT05683288|Experimental|IASTM|"EYYDM will be applied to the upper trapezius and sternocleideomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute. The instruments will be applied to the soft tissue at 30º-60º angles with multidirectional strokes (stroking) movements."
32827090|NCT05683288|Experimental|Myofascial Release|Basic movements will be used in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions within the scope of myofascial release application. The application will take 3 minutes for each region.
32827091|NCT05683288|Experimental|Control|It will include 250W infrared application on the cervical region from 50cm away for 15 minutes and TENS application for 20 minutes at 80Hz frequency with 150ms current transit time.
32827092|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
32827093|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
32827094|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
32827095|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
32827096|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
32827097|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
32827098|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
32827099|NCT03308994||Oral first line disease modifying treatments|
32827100|NCT03308994||Injectable first line disease modifying treatments|
32827101|NCT05248126|Active Comparator|Comparator arm|All patients randomized to this arm will participate in a standard patient education program.
32827102|NCT05248126|Experimental|Experimental arm|All patients randomised to this arm have the opportunity to participate in a patient education programme via a chatbot.
32827103|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
32827104|NCT05232916|Placebo Comparator|0.9% Normal Saline|0.9% normal saline in HLA-A*02 positive and HER2/neu positive subjects 0.9% normal saline intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal doses over 3 years)
32827105|NCT05232916|Experimental|GLSI-100|GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects GLSI-100 intradermally (GP2 and GM-CSF syringes), every month for first 6 months then every 6 months for next 2.5 years (11 intradermal doses over 3 years)
32827106|NCT05232916|Experimental|GLSI-100, Open-label|Open-label arm: GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects GLSI-100 intradermally (GP2 and GM-CSF syringes), every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
32827107|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
32827108|NCT05225584|Experimental|Phase 1a Dose Escalation Lymphomas|KT-333 dosed IV weekly in 28 day cycles
32827109|NCT05225584|Experimental|Phase 1a Dose Escalation Solid Tumors|KT-333 dosed IV weekly in 28 day cycles
32827110|NCT05225584|Experimental|Phase 1b Dose Expansion PTCL|KT-333 dosed IV weekly in 28 day cycles
32827111|NCT05225584|Experimental|Phase 1b Dose Expansion CTCL|KT-333 dosed IV weekly in 28 day cycles
32827112|NCT05225584|Experimental|Phase 1b Dose Expansion LGL-L|KT-333 dosed IV weekly in 28 day cycles
32827113|NCT05225584|Experimental|Phase 1b Dose Expansion Solid Tumor|KT-333 dosed IV weekly in 28 day cycles
32827114|NCT05225584|Experimental|Phase 1a Dose Escalation LGL-L|KT-333 dosed IV weekly in 28 day cycles
32827115|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
32827116|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
33102076|NCT04689984|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and astaxanthin 6 mg tablet once daily (experimental group).
32827117|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
33102077|NCT04689984|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
33102078|NCT02921711||LVIS®|
33102079|NCT05467254|Experimental|CLL1+CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
33102080|NCT03981341|Experimental|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
32827118|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
32827119|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
33102081|NCT03981341|Experimental|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
33102082|NCT04620057|Experimental|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
33102083|NCT04620057|Placebo Comparator|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
33102084|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
33102085|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
33102086|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
33102087|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
33102088|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
33102089|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
33102090|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
33102091|NCT04615143|Experimental|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w*2 cycles) and as adjuvant treatment after surgery for 1 year
33102092|NCT04615143|Experimental|Tislelizumab Combined Lenvatinib|Patients enrolled will receive Tislelizumab combined Lenvatinibas neoadjuvant treatment before surgery (Tislelizumab: 200mg q3w*2 cycles+Lenvatinib 8/12mg qd*4weeks) and as adjuvant treatment after surgery for 1 year
33102093|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
33317950|NCT00121108|Active Comparator|Motavizumab|Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
32827120|NCT05224336|Experimental|Psilocybin|Participants will receive 25mg oral psilocybin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
32827121|NCT05224336|Placebo Comparator|Niacin|Participants will receive 100mg oral niacin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
32827122|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
32827123|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
32827124|NCT05202106|No Intervention|Control|Families in the control group will not receive any interventions and will simply complete baseline and endline surveys.
33102094|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
33317951|NCT03978845|Experimental|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
33317952|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
33317953|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
32827125|NCT05202106|Experimental|Home visits|Families in the home visiting arm will receive visits by trained child development agents every two weeks between enrollment and 2 years of age.
32827126|NCT05202106|Experimental|Afini|Families in the Afini arm will be introduced to the Afini app on Messenger and encouraged to use this platform throughout the study.
32827127|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
32827128|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
32827129|NCT04491474|Active Comparator|Group 1|bilateral great occipital nerve blockade and bilateral isotonic injection into the supraorbital region.
32827130|NCT04491474|Active Comparator|Group 2|bilateral supraorbital nerve blockade and bilateral isotonic injection into the great occipital nerve region
32827131|NCT04491474|Active Comparator|Group 3|bilateral great occipital nerve blockade and bilateral supraorbital nerve blockade
32827132|NCT04491474|Sham Comparator|Group 4|saline injection to bilateral great occipital nerve and supraorbital nerve region
32827133|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
32827134|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
32827135|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
32827136|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
32827137|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
32827138|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
32827139|NCT05182372|Experimental|Enhanced dCBT-I|This group will complete d-CBTI and be assigned a coach that will help with completion of the treatment and will be available to call personally to discuss questions and issues.
32827140|NCT05182372|No Intervention|Control dCBT-I|Participants in this group will complete dCBT-I individually without assistance from a healthcare provider
32827141|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
32827142|NCT05176288|Experimental|Axitinib, Avelumab and Palbociclib|"During each 28 day (+/- 3 days) study cycle, all participants will receive:~Axitinib: 2x Daily until it is determined participant must stop the drug~Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined participant must stop the drug.~Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is determined participant must stop the study drug"
32827143|NCT05168956||Sexual offender|Patients followed up in the sexual offender's department of University Hospital of Saint Etienne will be included.
32827144|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32827145|NCT05110612|Experimental|Extended Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 8 sessions.
32827146|NCT05110612|Experimental|Brief Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 2 sessions.
32827147|NCT05110612|Sham Comparator|Control|Participants will receive sham Episodic Recent Thinking intervention.
32827148|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
33317954|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
33317955|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
33317956|NCT03850366|Experimental|Bortezomib|
32827151|NCT05728008||subject treated with ustekinumab (anti-IL12-23)|subjects treated with ustekinumab (anti-IL12-23) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy
32827152|NCT05728008||subject treated withtofacitinib (pan JAK inhibitor)|subjects treated with tofacitinib (pan JAK inhibitor) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy.
32955997|NCT05765357|Active Comparator|Herceptin|4mg/kg, Single dose for intravenous infusion
32827153|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
32827154|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
32827155|NCT04490382|Experimental|Patients undergoing Neuromodulation|Patients, who have had a lower limb amputation and undergoing neuromodulation as part of standard of care.
32827156|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.~be given by ."
32827157|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
32827158|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
32827159|NCT03308292|No Intervention|Control Group|
33317957|NCT01566812|Experimental|Breast feeding optimization|
33317958|NCT01566812|Active Comparator|Usual/routine care|
32827160|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
32827161|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
32827162|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
32827163|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
32827164|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
32827165|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
32827166|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
32827167|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
33317959|NCT05181592|Experimental|Luspatercept (single arm)|open-label, single-arm
33317960|NCT04673708|Other|Hashim Talib Hashim|It is a video with +18 different contents to know the effect of much video than the others.
32827168|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
32827169|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
32827170|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
32827171|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
32827172|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
32827173|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
32827174|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
32827175|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
32827176|NCT05727930|Experimental|High-intensity, task-specific (i.e., walking) interventions|30 1-hr sessions of walking training targeting higher cardiovascular intensities over approximately 2 months
32827177|NCT05727930|Active Comparator|High-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting higher cardiovascular intensities over approximately 2 months
32827178|NCT05727930|Active Comparator|Low-intensity, task-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
32827179|NCT05727930|Active Comparator|Low-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
32827180|NCT05727852||Experimental: patients with chronic respiratory diseases|"Included patients, aged ≥ 18 years, with chronic respiratory diseases: COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis and other interstitial lung diseases.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of electrocardiogram (ECG), phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
32827181|NCT05727852||Active Comparator: Control|"Included subjects, aged ≥ 18 years.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
32827182|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
32827183|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
33317961|NCT04673708|Experimental|Mustafa Ahmed Ramadhan|Is is an assessment of the vital signs among the participants and the change with the showing of videos.
33317962|NCT05181514|Placebo Comparator|Normal Saline|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of normal saline
32827184|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
32827185|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
32827186|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
32827187|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
32827188|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
32827189|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
32827190|NCT04490460|Placebo Comparator|First 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
32827191|NCT04490460|Active Comparator|Second 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
32827192|NCT03302598|Other|patients with enterocutaneous fistula|
32827193|NCT04998682|Experimental|Targeted Axillary Dissection (TAD)|During standard of care (SoC) surgery to remove breast cancer, study participants will undergo a sampling of lymph nodes in the axilla first and then complete removal of axillary lymph nodes under the arm.
32827194|NCT04883112|No Intervention|No Intervention: ankle dorsiflexion|ankle dorsiflexion pre measurement with bipedestation position, will be performed
32827195|NCT04883112|Experimental|Experimental: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
32827196|NCT04883112|Placebo Comparator|Placebo: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
32827197|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
32827198|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
32827199|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
32827200|NCT04951570||Hematoma Expansion (HE) group|
32827201|NCT04951570||non-HE group|
32827202|NCT04490772||Patients with Covid-19|COVID-19 patients presented with gastrointestinal manifestations
32827203|NCT04929808|Active Comparator|Control group|Will receive the standard institutional skin care for acute radiodermatitis
32827204|NCT04929808|Experimental|Experimental group|Will receive the novel, self-prepared skin care product
32827205|NCT05120310|Experimental|Intervention|"Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge).~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for Sleep Program (using Healthie platform)."
32827206|NCT05120310|Other|Waitlist Control|"Participants will be instructed to not participate in any mindfulness meditation activities for eight weeks. The research team will send the participant study instructions. At the end of eight weeks participants will be given access to the Calm app and will be able to schedule one live 20-minute coaching session with a Calm Coach.~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for sleep Program. The Calm Coaching for sleep program is administered by Calm for six weeks."
32827207|NCT05117346|Experimental|To Establish the Safety and Efficacy of CARDIX-101 in Chronic Bradycardia Patients|"Treatment Regimen: A total of 20±4 chronic bradycardia subjects with a heart rate (H.R.) average of less than 60 bpm will be enrolled in the study (6±3/cohort). A clinical study period of 14±2-days is planned for each enrollment of patients.~Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment."
32827208|NCT05116410|Experimental|HS-20094 (Single dose)|Escalating doses of HS-20094 administered subcutaneously (SC) once in healthy participants.
32827209|NCT05116410|Experimental|HS-20094 (Multiple doses)|Escalating doses of HS-20094 administered SC once weekly for four weeks in healthy participants.
32827210|NCT05116410|Placebo Comparator|Placebo (Single dose)|Placebo administered SC once in healthy participants.
32827211|NCT05116410|Placebo Comparator|Placebo (Multiple doses)|Placebo administered SC once weekly for four weeks in healthy participants.
32827212|NCT05727696|Active Comparator|radial shortening|
32827213|NCT05727696|Active Comparator|capitate shortening|
32827214|NCT05727618|Experimental|pituitrin group|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
32827215|NCT05727618|Placebo Comparator|normal saline group|Intravenous infusion of normal saline at the same dose and speed
32827216|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
32827217|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
32827218|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
32827219|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
32827220|NCT03307668|Experimental|CaReS-1S|
32827221|NCT03307668|Active Comparator|Microfracture|
32827222|NCT05727384|Experimental|Clazakizumab|Participants received Clazakizumab 5 mg as a subcutaneous injection every 4 weeks for 24 weeks
32827223|NCT05727384|Placebo Comparator|Placebo|Participants received Clazakizumab placebo as a 5 mg subcutaneous injection every 4 weeks for 24 weeks
32827224|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
32827225|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
32827226|NCT04927312|Experimental|PF-06947386 + Metronidazole|Multiple intravenous infusion of ceftazidime-avibactam followed by intravenous infusion of metronidazole, repeated every 8 hours for 5-14 days.
32827227|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
32827228|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
32827229|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
32827230|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
32827231|NCT05624788||Specialist Referral: Neurology|
32827232|NCT05624788||Specialist Referral: Ophthalmology|
32827233|NCT05624788||Specialist Referral: Oncology|
32827234|NCT03302208|Active Comparator|pregabalin group|
32827235|NCT03302208|Placebo Comparator|placebo group|
32827236|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
32827237|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
32827238|NCT05727306||People with Alopecia Areata|Children and adults aged 12+ with new onset Alopecia Areata registered with a contributing GP practice during the study period.
32827239|NCT05727306||People without Alopecia Areata|Children and adults aged 12+ without Alopecia Areata registered with a contributing practice during the study period.
32827240|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
32827241|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
32827242|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
32827243|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
32827244|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
32827245|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
32827246|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
32827247|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
32827248|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
32827249|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
32827250|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
32827251|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
32827252|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
32827253|NCT04874038|Experimental|Intervention|Intraoperative intravenous lidocaine/placebo infusion
32827254|NCT04874038|Placebo Comparator|Control|Intraoperative intravenous lidocaine/placebo infusion
32827255|NCT05727150|Experimental|Patient operated by Supraclavicular Artery flap for Reconstruction|Supraclavicular artery flap will be used for reconstruction
32827256|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
33102095|NCT05467137|Experimental|Standard of care + MSOT|Standard of care + MSOT
32827257|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
32827258|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
32827259|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
32827260|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
32827261|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
32827262|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
32827263|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
32827264|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
32827265|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
32827266|NCT02468388|Experimental|maltitol|
32827267|NCT02468388|Active Comparator|xylitol|
32827268|NCT02468388|Placebo Comparator|gum base|
32827269|NCT02468388|No Intervention|no gum|
32827270|NCT03306732|Active Comparator|Thiamine group|
32827271|NCT03306732|Placebo Comparator|Placebo group|
32827272|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
32827273|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32827274|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32827275|NCT03260322|Experimental|ASP8374|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 (monotherapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 8 dose strengths).
32827276|NCT03260322|Experimental|ASP8374 and pembrolizumab|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 and pembrolizumab (combination therapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 5 dose strengths of ASP8374 and one fixed dose strength of pembrolizumab).
32827277|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
32827278|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
32827279|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
32827280|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
32827281|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
32827282|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
32827283|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
32827284|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
32827285|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
32827286|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
32827287|NCT05726916|Experimental|Experimental group|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
32827288|NCT05726916|Active Comparator|Control group|Blood pressure control with renin angiotensin system blockers
32827289|NCT05726838||Inclisiran|Patients prescribed inclisiran on top of standard of care lipid-lowering therapy
33102096|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
32827290|NCT05726760||Study group - Parturients having spinal anaesthesia|ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited. The investigators intend to recruit 60 parturients. The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. A patient information leaflet will be provided for the parturients.
32827291|NCT05726760||Control group - Parturients not having spinal anaesthesia|6 parturients will be recruited as a control group. ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited.
32827292|NCT03301818|Experimental|Patients undergoing USI repair|
33102097|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
33102098|NCT04689035|Experimental|Cohort 1|AVLX-144_dose1
33102099|NCT04689035|Experimental|Cohort 2|AVLX-144_dose2
33102100|NCT04689035|Experimental|Cohort 3|AVLX-144_dose3
33102101|NCT04689035|Experimental|Cohort 4|AVLX-144_dose4
33102102|NCT04689035|Experimental|Cohort 5|AVLX-144_dose5
33102103|NCT04689035|Experimental|Cohort 6|AVLX-144_elderly
32827293|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
32827294|NCT04491162|Active Comparator|Conventional gait therapy|Conventional gait therapy.
32827295|NCT04491162|Experimental|BWST training|Conventional gait therapy + Body weight support treadmill training
32827296|NCT04491318||Experimental group|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
32827297|NCT05726682|Experimental|High risk AML and MDS|Participants with high risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic HSCT will receive 3 doses of SAR445419. A myeloablative conditioning (MAC) and a reduced intensity conditioning (RIC) cohort will be included.
32827298|NCT05726604|No Intervention|3D CT Scan|Assesment of an usual cardiac dosimetry based on 3D CT scan. Only this dosimetry will be used to treat the patients. Because of the crossover model, patients are included in both arms.
32827299|NCT05726604|Experimental|4D CT scan with respiratory gating|Assesment of an experimental cardiac dosimetry based on 4D CT scan. Not used to treat the patients. Because of the crossover model, patients are included in both arms.
32827300|NCT05726526|Experimental|Intervention Group|Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months, and the System Usability Scale (SUS) at 12 months.
32827301|NCT05726526|No Intervention|Control Group|Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months.
32827302|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
32827303|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
32827304|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
32827305|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
32827306|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
32827307|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
32827308|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
32827309|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
32827310|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
32827311|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
33317963|NCT05181514|Experimental|20% Intralipid|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of Intralipid 20%.
32827312|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
32827313|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
32827314|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
32827315|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
32827316|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
33405262|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
33405263|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
32827317|NCT02468232|Experimental|LCZ696|Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
32827318|NCT02468232|Active Comparator|Enalapril|In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
32827319|NCT04793464|Experimental|Promotores|The Promotores de Salud intervention involves specified outreach and psychoeducation on SARS-CoV-2 health related behaviors.
32827320|NCT04793464|Active Comparator|Control|Services as usual includes outreach as usual strategies and pamphlets on site at events.
32827321|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
32827322|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
32827323|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
32827324|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
32827325|NCT05726448|Experimental|Telehealth solution|Telehealth solution offered
32827326|NCT05726448|No Intervention|Usual care|Control
32827327|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
33317964|NCT04662398|Active Comparator|Case (Testes shocker device)|The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males.
32827328|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
32827329|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
32827330|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
32827331|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
32827332|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
32827333|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
32827334|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
32827335|NCT04754152|Experimental|TBS Group|On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
32827336|NCT04754152|Placebo Comparator|Drug Group|Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.
32827337|NCT03141346|Active Comparator|Control|A control health education program to promote general health and safety
32827338|NCT03141346|Experimental|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
32827339|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
32827340|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
32827341|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
32827342|NCT03023332|No Intervention|Control|No intervention or treatment
32827343|NCT03023332|Active Comparator|Usual care|Bipolar education
33102105|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
32827344|NCT04712110|Experimental|TAK-019|TAK-019 0.5 mL, intramuscular injection in the upper arm
32827345|NCT04712110|Placebo Comparator|Placebo|TAK-019 Matching Placebo, intramuscular injection in the upper arm
32827346|NCT04630834|Active Comparator|Intervention group|Intervention Group: ibuprofen 10 mg/kg (maximum 600mg) plus acetaminophen 15mg/kg (maximum 650mg)
32827347|NCT04630834|Placebo Comparator|Placebo Group|Placebo Group: Ibuprofen 10mg/kg (maximum 600 mg) plus placebo 15mg/kg (maximum 650mg)
33102106|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
33102107|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
33317965|NCT04662398|Sham Comparator|Control (non testes shocker device)|These groups will not given the shocks, shame device will be used instead and then compare the two results.
33317966|NCT05253976||Patients who received the NexGen TM Augmentation Patella|
33317967|NCT05669846|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy (Treatment Phase 1) and by a sigmoidoscopy (Treatment Phase 2). FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.~Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle."
33405264|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
32827348|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)~Regimen B (cycles 5-8):~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)~There is a one week break between the end of cycle 4 and the beginning of cycle 5.~Regimen C:~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
32827349|NCT04737304|Experimental|Dose Regimen Low Dose|Low Dose Strength
32827350|NCT04737304|Experimental|Dose Regimen High Dose|High Dose Strength
32827351|NCT04737304|Placebo Comparator|Placebo|Placebo
32827352|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
32827353|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
32827354|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
32827355|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
32827356|NCT05722704|Experimental|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
32827357|NCT05722704|Active Comparator|Occlusal reduction|Normal room temperature saline irrigation protocol with occlusal reduction
32827358|NCT05722704|No Intervention|Control|Normal room temperature saline irrigation protocol without occlusal reduction
32827359|NCT04735432|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
32827360|NCT04735432|Experimental|efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
32827361|NCT02994160|Experimental|Fast electrodes|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
32827362|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
32827363|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
32827364|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
32827365|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
32827366|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
32827367|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
32827368|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
32827369|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
32827370|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
32900040|NCT00248534|Experimental|IV Rituximab|"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide [TMZ] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression"
33317968|NCT03841786|Placebo Comparator|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
33317969|NCT03841786|Experimental|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
32827371|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
32955998|NCT05765344|Experimental|Bulevirtide (BLV), Moderate Hepatic Impairment|"Participants with moderate hepatic impairment will receive BLV 2 mg injection once daily for 6 days starting on Day 1.~Following completion and evaluation of pharmacokinetics (PK) and safety data, additional participant groups and BLV doses may be initiated."
33317970|NCT04644614|Active Comparator|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
32955999|NCT05765344|Experimental|BLV, Severe Hepatic Impairment|"Participants with severe hepatic impairment will receive BLV 2 mg injection once daily for 6 days starting on Day 1.~Following completion and evaluation of PK and safety data, additional participant groups and BLV doses may be initiated."
32956000|NCT05765344|Experimental|BLV, Normal Hepatic Function (Matched Control Participants)|Participants with normal hepatic function will receive BLV 2 mg once daily for 6 days.
32956001|NCT05765331|Experimental|Chatbot-aid intervention|Chatbot-aid intervention group
33405265|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
32956002|NCT05765331|No Intervention|Control group|Written routine nursing health education guidance intervention.
32956003|NCT05765292|Active Comparator|probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.
32956004|NCT05765292|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
32956005|NCT05765279|Experimental|Treatment Group 1|
32956006|NCT05765279|Experimental|Treatment Group 2|
32956007|NCT05765279|Placebo Comparator|Control Group 3|
32956008|NCT05765279|Placebo Comparator|Control Group 4|
32956009|NCT05765266|Experimental|ACP Max™|Single 6 ml intra-articular (IA) injection of the output of ACP Max™
32956010|NCT05765266|Active Comparator|40 mg of methylprednisolone acetate|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
32956011|NCT05765240|Experimental|Group 1|Hyaluronic acid gel will be applied to the extraction site of the patients in group 1 immediately after the extraction.
32956012|NCT05765240|Experimental|Group 2|"Alveolar socket in group 2, will ve irradiated with an energy dose of J/cm2, 20mW/670 nm potency and 4 for 7 minutes immediately after extraction.~It will be irradiated with an energy dose of J/cm2."
32956013|NCT05765240|No Intervention|Control Group|
32956014|NCT05765201||High IOP|Eyes in this arm will maintain an IOP of 65mmHg throughout the cataract surgery.
32956015|NCT05765201||Low IOP|Eyes in this arm will maintain an IOP of 28mmHg throughout the cataract surgery.
32956016|NCT05765188||< 25 years|42 patients younger than 25 years at the time of loop electrosurgical excision procedure
32956017|NCT05765188||> 25 years|73 patients 25 years or older at the time of loop electrosurgical excision procedure
32956018|NCT05765175|Active Comparator|Repeat catheter ablation (CA)|
32956019|NCT05765175|Experimental|Varian Cardiac Radioablation (CRA)|
32956020|NCT05765162||All patients form age 18 and above|All patients form age 18 and above
32956021|NCT05765149||Sleep Cohort|This is an observational study. We plan to recruit 1000 pregnant women during 10-13 weeks gestational age to build a sleep cohort. Their sleep changes during pregnancy will be recorded for identifying similar groups.
32956022|NCT05765136||Close collaboration group|Preterm infants born in hospitals where the Close Collaboration with Parents training program has been successfully implemented
32956023|NCT05765136||Single-family room group|Preterm infants born in hospitals that have implemented an architectural change to single-family room design
32956024|NCT05765136||Control group|Preterm infants born in hospitals that have not gone through any of the two aforementioned interventions (single-family room architecture or Close Collaboration with Parents training program)
32956025|NCT05765123|Experimental|Gastric Emptying assessment|Assessment of gastric emptying made following glucose consumption
32956026|NCT05765110|Experimental|Parkinson's disease patients with DBS|All Parkinson's disease patients with bilateral deep brain stimulation (DBS) in the subthalamic nucleus
32956027|NCT05765110|Experimental|Parkinson's disease patients without DBS|All Parkinson's disease patients without bilateral deep brain stimulation (DBS) in the subthalamic nucleus
32956028|NCT05765110|No Intervention|Healthy Controls|All healthy volunteers
32956029|NCT05765097|Experimental|Artificial pancreas group|Using artificial pancreas system (composed of a CGM, a pump and AndroidAPS software) to treat adult patients with diabetes
33405266|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
32956031|NCT05765071|Active Comparator|Treatment|Botulinum toxin (Botox) injection
32956032|NCT05765071|Placebo Comparator|Control|Normal saline injection
32956033|NCT05765045|Experimental|Nursing triage group|Using a triage protocol for medical imaging conducted by a triage nurse in the emergency department
33405267|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
32827372|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
32827373|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
32827374|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
32827375|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
32827376|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
32827377|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
32827378|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
32827379|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
32827380|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
32827381|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
32827382|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
33405268|NCT05284994|Other|TQ-B3525 Tablets + Osimertinib Mesylate Tablets.|TQ-B3525 tablets combined with osimertinib mesylate tablets, 30 days as a treatment cycle.
32827383|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
32827384|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
32827385|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
32827386|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
32827387|NCT04622176||Patients with rectal cancer|Patients with rectal cancer will be included and asked to participate in the study where a MMUS will be used after resection to test diagnostic accuracy.
32827388|NCT03300960|Experimental|Provera|
32827389|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
32827390|NCT04583254|Experimental|Arm 1 EBRT+High-dose (HDR) Brachytherapy Experimental|
32827391|NCT04583254|Active Comparator|Arm 2 EBRT+High-dose (HDR) Brachytherapy Standard of Care|
32827392|NCT02993146|Experimental|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
32827393|NCT05722158|Placebo Comparator|Placebo|This group will be provided with a placebo solution for comparative purposes.
32827394|NCT05722158|Experimental|Collagen-based product CP1|This group will be provided with a the collagen-based product CP1, which will be compared to the placebo group.
32827395|NCT05722158|Experimental|Collagen-based product CP2|This group will be provided with a the collagen-based product CP2, which will be compared to the placebo group.
32827396|NCT05722158|Experimental|Collagen-based product CP3|This group will be provided with a the collagen-based product CP3, which will be compared to the placebo group.
32827397|NCT05722158|Experimental|Collagen-based product CP4|This group will be provided with a the collagen-based product CP4, which will be compared to the placebo group.
32827398|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
32827399|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
32827400|NCT05721690|Experimental|UED-A|Tracheal Intubation with UED-A videolaryngoscope
32827401|NCT05721690|Active Comparator|GLIDESCOPE|Tracheal Intubation with Glidescope Titanium videolaryngoscope
32827402|NCT04768582|Experimental|Efient group|ACS patients who received oral Prasugrel after coronary angiography been done
32827403|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
32827404|NCT02485444|Active Comparator|Oxytocin|
32827405|NCT02485444|No Intervention|Observation|
32827406|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
32827407|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
32827408|NCT04556188||Cases|RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
32827409|NCT04556188||RHD controls|RHD patients not offered Cardiac surgery
32827410|NCT04556188||Anticoagulation controls|Norwegian patients on anticoagulant therapy due to mechanical valve implants
32827411|NCT04547374||Cohort 1 - GaH Intervention|Cohort 1 - GaH intervention group
32956034|NCT05765045|No Intervention|Regular care group|Regular triage in the emergency department
32827412|NCT04547374||Cohort 2 - Standard-of-care control group|"Cohort 2 - Standard-of-care control group~*Importantly, these individuals are eligible for referral to GaH at the discretion of their physicians.*"
32827413|NCT04490538||Critically ill patients|Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.
32827414|NCT04490304|Other|posterior soft tissue repair durability|
33102108|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
32827415|NCT04443010|Experimental|Phase 1 part: Dose Finding|Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
32827416|NCT04443010|Experimental|Phase 2 part: Signal Seeking|32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
32827417|NCT04443010|Active Comparator|Phase 2b part: Activity Evaluation_control arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide)."
32827418|NCT04443010|Experimental|Phase IIb part: Activity Evaluation_treatment arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF."
32827419|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
33317971|NCT04644614|Sham Comparator|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
33317972|NCT05181202||Hypersensitivity reaction group|The patients get hypersensitivity after Pegylated liposomal doxorubicin injection.
33317973|NCT05181202||None hypersensitivity reaction group|The patients do not get hypersensitivity after Pegylated liposomal doxorubicin injection.
33102109|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
33102110|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
33102111|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
33102112|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
33102113|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
33102114|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
33102115|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
33102116|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
33102117|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
33102118|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
33102119|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
33317974|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
33317975|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
33317976|NCT05116514|Experimental|Case manager group|
33317977|NCT05116514|No Intervention|Control|
32827420|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
33102120|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
33317978|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
32827421|NCT04428346|Active Comparator|Contigency Management (Intervention)|
32827422|NCT04428346|No Intervention|Standard of Care (Control)|
32827423|NCT04490694|Experimental|TACE Combined with Lenvatinib|
32827424|NCT04601584|Experimental|GNR-084, dose level 1|Anti-CD19/CD3 antibody
32827425|NCT04601584|Experimental|GNR-084, dose level 2|Anti-CD19/CD3 antibody
32827426|NCT04601584|Experimental|GNR-084, dose level 3|Anti-CD19/CD3 antibody
32827427|NCT04601584|Experimental|GNR-084, dose level 4|Anti-CD19/CD3 antibody
32827428|NCT04601584|Experimental|GNR-084, dose level 5|Anti-CD19/CD3 antibody
32827429|NCT04601584|Experimental|GNR-084, dose level 6|Anti-CD19/CD3 antibody
32827430|NCT05711394|Experimental|Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose A to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
32827431|NCT05711394|Experimental|Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose B to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
32827432|NCT05711394|Experimental|Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of high dose atogepant once a day for 12 weeks.
32827433|NCT05711394|Experimental|Double-Blind Treatment Period: Placebo (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
32827434|NCT05711394|Experimental|Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of low dose atogepant once a day for 12 weeks.
32827435|NCT05711394|Experimental|Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of high dose atogepant once a day for 12 weeks.
32827436|NCT05711394|Experimental|Double-Blind Treatment Period: Placebo (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
32827437|NCT05711394|Experimental|Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of low dose atogepant once a day for 12 weeks.
32827438|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
32827439|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
32827440|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
32827441|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
32827442|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
32827443|NCT02359474|Experimental|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
32827444|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
32827445|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
32827446|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
32827447|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
32827448|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
32956035|NCT05765032|Experimental|SHR-A1921|A1：SHR-A1921+Adebrelimab A2：SHR-A1921+Carboplatin A3：SHR-A1921+Cisplatin A4：SHR-A1921+Bevacizumab A5：SHR-A1921+Adebrelimab+Carboplatin A6：SHR-A1921+Adebrelimab+Cisplatin B1：SHR-A1921+Adebrelimab B2：SHR-A1921+Adebrelimab+Carboplatin/Cisplatin
32827449|NCT05707962|Experimental|intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
32827450|NCT05707962|No Intervention|non intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
32827451|NCT02218840||Behavioral|Evaluation of cigar smoking topography
32827452|NCT05704296|Experimental|Y-composite grafting|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
32827453|NCT05704296|Active Comparator|Aortocoronary grafting|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
32827454|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
32827455|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
32827456|NCT05698680|Experimental|Prednisolone 30mg (Day 0-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 150 mg for prednisolone."
32827457|NCT05698680|Active Comparator|Colchicine 1.5 mg (Day 0), 1.0 mg (Day 1-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 5.5mg for colchicine."
32827458|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
32827459|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
32827460|NCT04350346|Active Comparator|The patient group who taken Motilitone|
32827461|NCT04350346|Active Comparator|The patient group who taken Gasmotin|
32956036|NCT05764993|Experimental|Group #1|SCIgR with Cuvitru 125 mg/kg/week + standard of care management
32956037|NCT05764993|Placebo Comparator|Group #2|Standard of care management = 20 patients
33317979|NCT03840928||Ankylosing Spondylitis|
33317980|NCT03840928||Fibromyalgia|
33317981|NCT03840928||Gout|
32827462|NCT04074226|Experimental|Ultrasound-guided ESP block with liposomal bupivacaine|For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
32827463|NCT04074226|Active Comparator|Ultrasound-guided QL block with liposomal bupivacaine|"For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site."
32827464|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
32827465|NCT04537312|Experimental|Supportive care (RNSM, surveys)|RNMS Surveys
32827466|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
32827467|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
32827468|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
32827469|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
32827470|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
32827471|NCT04060108||MDMA Within Subject Cross-over|Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
32827472|NCT05697822|Experimental|Mobile Phone and Cloud-based Electronic Contact and Recording System|In this arm pregnant women will be given a smart mobile-phone with an application installed which will have their detailed health-related information. They will be able to use this application to input their daily symptoms. This will also contain results of examinations or investigations that they have undergone in a clinic. All this information will be stored in a cloud and the healthcare worker at the local health post will also be able to access this information in their mobile phone and keep track of the pregnant women under their care. In the event of a concerning symptom, the health worker will be flagged. The health coordinators in the rural municipality will also be able to keep track of the pregnant women in their area through a cloud-based database.
32827473|NCT05697822|No Intervention|Usual Standard of Care Arm|Pregnant women will visit the health posts or hospitals for antenatal checks routinely as advised. Their records will be kept in paper-based forms and registers. They will not be tracked regularly by their healthcare provider by electronic means. Their daily symptoms will not be recorded anywhere. They will still be able to contact their healthcare providers or visit the health centers if necessary. They will not have a personal electronic health record. No one will keep active track of the pregnant women through electronic means.
32827474|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
32827475|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
32827476|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
32900041|NCT00248612|Experimental|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
32900042|NCT00248612|Active Comparator|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
33317982|NCT03840928||Crohn's-related Arthritis|
33317983|NCT03840928||Juvenile Idiopathic Arthritis|
33317984|NCT03840928||Lupus|
33317985|NCT03840928||Myositis|
32827477|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
32827478|NCT04058470|Experimental|TR follow by R-CHOP|"TR follow by R-CHOP:~TR: Toripalimab,Rituximab, R-CHOP: Rituximab, Cyclophosphamide,Doxorubicin,Vincristine,Prednisone"
32827479|NCT05696808|Experimental|Indian hepatoprotective diet (IHPD)|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
32827480|NCT05696808|Active Comparator|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
32827481|NCT04465708|Other|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the HOPS provider and student. The HOPS intervention will be delivered by either a member of the school team (HOPS-ST), referred to as a school provider, or a member of the research team (HOPS-RT), referred to as a research provider. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
32827482|NCT04465708|No Intervention|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
32827483|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
32827484|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
32827485|NCT04449874|Experimental|Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
32827486|NCT04449874|Experimental|Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.
32827487|NCT04449874|Experimental|Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)|Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.
32827488|NCT04449874|Experimental|Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)|Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.
32827489|NCT04449874|Experimental|Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.
32827490|NCT04449874|Experimental|Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II."
32827491|NCT04449874|Experimental|Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II."
32827492|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
32827493|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
32827494|NCT05680818|Experimental|Encaleret|Participants will undergo encaleret dosing titration as needed in order to achieve the optimal encaleret dose to reach acceptable calcium levels.
32827495|NCT05680818|Other|Standard of Care (SoC)|Participants randomized to SoC treatment will continue calcium supplements and active Vitamin D (calcitriol or alfacalcidol)
32827496|NCT05456256|Experimental|LP-300 in Combination with Pemetrexed and Carboplatin|"LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
32827497|NCT05456256|Active Comparator|Pemetrexed and Carboplatin (Standard of Care)|"Pemetrexed and Carboplatin Only (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
32827498|NCT04805502|Experimental|Aerobic Exercise (AE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions."
32900043|NCT00248612|Active Comparator|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
33317986|NCT03840928||Osteoarthritis|
33317987|NCT03840928||Osteoporosis|
33317988|NCT03840928||Psoriasis|
33317989|NCT03840928||Psoriatic Arthritis|
32827499|NCT04805502|Experimental|Resistance Exercise (RE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets with rest period of 30-60 seconds between sets as needed.[100] Seated isokinetic exercise using Cybex machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on Cybex machines. Core exercises will be performed at the end of the session (i.e. seated side bends)."
32827500|NCT04805502|Experimental|Combination Exercise (AERE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AERE group will switch between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeated repeat with different exercises.[106-108] The investigators will also calculate the metabolic minutes per week (METmin/wk) of all participants in order to account for potential differences in energy expenditure based on activity, though the dose of 150 min/wk at moderate intensity is held constant between exercise groups."
32827501|NCT04805502|No Intervention|Control (no exercise)|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
32827502|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
32827503|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
32827504|NCT05660616|Experimental|Gemcitabine + supportive care|Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care.
32827505|NCT05660616|Other|supportive care|best supportive care alone.
32827506|NCT05447520|Experimental|Montelukast Group|Patients will receive conventional DMARDs plus montelukast 10 mg tablet once daily for 16 weeks.
32827507|NCT05447520|Placebo Comparator|Control Group|Patients will receive conventional DMARDs plus placebo tablet daily for 16 weeks
32827508|NCT05438550|Active Comparator|14-day bismuth-containing quadruple therapy (BQT)|14-day bismuth-containing quadruple therapy (BQT) Nexium (Esomeprazole, Astrazeneca Pharmaceutical Co., LTD.) 20mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
32827509|NCT05438550|Experimental|14-day Tegoprazan high-dose dual therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
32827510|NCT05432856|Experimental|Time-Restricted Eating and Sedentary Time Reduction|Group 1 (Experimental intervention): Participants assigned to this group will receive standard chemotherapy treatment plus a dietary program, and sedentary time reduction strategies, program and a Fitbit monitor. If you are randomized into this group, you will be asked to follow TRE, will receive nutritional education and individualized recommendations on improving diet quality and healthy eating practices, and given to strategies to work towards reducing sedentary time. These components will be gradually introduced over the 24-week program.
32827511|NCT05432856|No Intervention|Nutrition and Exercise Guidelines|"Group 2 (Non-experimental intervention): Participants randomized to this group will receive standard chemotherapy treatment plus a single, group-based nutrition during cancer class, as well as a copy of Canada's Food Guide, physical activity guidelines, and a Fitbit monitor. You will be asked to only make dietary changes if they are recommended within the class or by your doctor, and to maintain your usual timing and number of meals consumed per day. Throughout the 24-week period, you will receive seven brief phone calls from a study staff member to ask about your symptoms and provide support. After the end of the study, participants in this group will be offered a one-one-one counselling session with a registered dietitian."
32827512|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
32827513|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
32827514|NCT05429892|Experimental|TRTsocialmot1 arm|"Smokers will receive real-time video-based motivational counseling and home-based food delivery.~Participants will receive educational material."
32827515|NCT05429892|Active Comparator|TRTmot3 arm|"Smokers will receive real-time video-based motivational counseling only.~Participants will receive educational material."
32827516|NCT05429892|Active Comparator|TRTsocial2 arm|"Smokers will receive home-based food delivery only.~Participants will receive educational material."
32827517|NCT05426070|Experimental|Strength training-based exercise|The strength training-based exercise intervention will be delivered via group-based Zoom sessions, motivational text messages, and a website. Participants will take part in two group-based Zoom exercise sessions (40-minute exercise sessions and 20 minutes of motivational counseling) and two individual exercise sessions per week for six months. Exercise sessions will include a combination of various aerobic and muscle strengthening exercises designed to keep heart rate in the 60-85% range of maximum heart rate. Motivational counseling will be focused on increasing motivation to exercise and habit formation. Strength training-based participants will also receive access to a mobile phone-friendly study website and will receive text messages. Both the website and text messages will contain motivational content to complete the exercise sessions.
33317990|NCT03840928||Rheumatoid Arthritis|
33317991|NCT03840928||Scleroderma|
33317992|NCT03833882|Experimental|MAF1217/Cationorm|
33317993|NCT03833882|Experimental|Cationorm/MAF1217|
32827518|NCT05426070|No Intervention|No contact, wait-list control|Participants in the no contact, wait-list control intervention will participate in assessments at baseline and six months. Following the six month assessment, participants will have the option of receiving the strength training-based intervention as described above.
32827519|NCT05411484|Experimental|Pilot Arm|Self-controlled 10 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel
32827520|NCT05403684|No Intervention|Usual-volume breastfeeding (UV Group)|Infants will receive cup-feeding (to standardize the volume at each feeding) per standard of care guidelines (SOC: 140-180 mL/kg/day) with volumes adjusted for weight and infant age.
32827521|NCT05403684|Experimental|High-volume breastfeeding (HV Group)|Along with SOC volume provided via cup-feeding, the mother will continue to express and feed the baby hind-milk reaching 240 mL/kg/day with volumes adjusted for weight and infant age (200-240 ml/kg/day).
32827522|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
32827523|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
32827524|NCT05639946|Experimental|Experimental group|Participants with severe neuropathic pain will receive brivaracetam treatment
32827525|NCT05639946|Placebo Comparator|Control group|Participants with severe neuropathic pain will receive placebo drug
32827526|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
32827527|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
32827528|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
32827529|NCT03299790|No Intervention|Healthy controls|
32827530|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
32827531|NCT05617326|Experimental|screening by a GP|Each patient in this group will have a screening for AAA performed by a trained general practitioner
32827532|NCT05617326|Other|screening by a radiologist (conventional)|Each patient in this group will have AAA screening performed by a radiologist
32827533|NCT05609994|Experimental|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
32827534|NCT05391906|Experimental|Intravoxel Incoherent Motion(IVIM) MRI|Intravoxel incoherent motion (IVIM) is based on diffusion-weighted imaging (DWI)
32827535|NCT05388396||PIMS-TS patients|Pediatric patients with PIMS-TS admitted to the PICU in selected time period
32827536|NCT05382858|Experimental|PSA-STN|Participants randomized in this arm will receive bilateral PSA stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral STN stimulation for another two months.
32827537|NCT05382858|Experimental|STN-PSA|Participants randomized in this arm will receive bilateral STN stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral PSA stimulation for another two months.
32827538|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
32827539|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
32827540|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
32827541|NCT05352204||micronecrosis(+) group|
32827542|NCT05352204||micronecrosis(-) group|
32827543|NCT05335434|Experimental|INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT|"The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first~-THOR LX2.3 with LED Lollipop"
32827544|NCT05327556|Active Comparator|0.5 mcg/kg Dose|Providers use 0.1 mL/kg of 5 mcg/mL epinephrine for target dose 0.5 mcg/kg
32827545|NCT05327556|Active Comparator|1.0 mcg/kg Dose|Providers use 0.1 mL/kg of 10 mcg/mL epinephrine for target dose of 1.0 mcg/kg
33405269|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
33405270|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
33102121|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
33102122|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
33102123|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
33102124|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
33102125|NCT05466981|Experimental|Current smokers with an HCV infection|Persons who currently smoke cigarettes and are also HCV RNA+
33102126|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
33102127|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
33102128|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
33102129|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
33102130|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
33102131|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
33102132|NCT02921243||Stool Sample Collection|
33102133|NCT02921243||Prebiotic|
33405271|NCT04053296||The first pregnancy with PAH group|
33102135|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
33102136|NCT01283581|Experimental|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
33102137|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
33102138|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
33102139|NCT05466903|No Intervention|Control arm|patients were given a liquid diet 6 hours after the operation
33102140|NCT05466903|Experimental|Experimental arm|patients were given a liquid diet 2 hours after the operation
33102141|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
33102142|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
33102143|NCT01283542|Experimental|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
33102144|NCT05466864|Experimental|TMU Hospital|Potential participants with suspected OSA will be identified from the schedule of the TMU sleep labs. Those subjects who satisfy the study conclusion and exclusion criteria will be approached and invited to participate in the study.
33102145|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
33317994|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
33405272|NCT04053296||The second pregnancy with PAH group|
33405273|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
33405274|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
33405275|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
33405276|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
33102146|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
33102147|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
33102148|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
33102149|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
33102150|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
33102151|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
33405277|NCT03648242|Experimental|Interruptive Clinical Decision Support|
32827546|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.~Patients with Normal Renal function:~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Patients with Acute Kidney injury:~Pediatric and surgery units: 2 months-6 years (10)~PICU: 2 months-6 years (10)~Haematology-oncology unit: 2 months-6 years (10)"
32827547|NCT05597124|Experimental|Cardio-Dance Fitness|This is the experimental group. Participants will meet three times a week for dance classes for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
32827548|NCT05597124|Active Comparator|Strength, Flexibility & Balance|This is the active control group. Participants will meet three times a week for strength, flexibility, and balance exercises for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
32827549|NCT05587062|Experimental|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
32827550|NCT05587062|Active Comparator|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
32827551|NCT05581602|Experimental|Hemiparetic post-stroke subjects|Stroke patients with motor sequelae in the upper limb.
32827552|NCT05581602|Other|Healthy subjects|Subjects without stroke.
32827553|NCT05578092|Experimental|Phase 1/1B Monotherapy|Dose Escalation/Evaluation
32827554|NCT05578092|Experimental|Phase 1/1B Combination Therapy|Dose Escalation/Evaluation
32827555|NCT05578092|Experimental|Phase 2|MRTX0902 and adagrasib combination RP2D administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12C mutation to include the following: NSCLC, CRC, Other Solid Tumors
32827556|NCT05575128|Experimental|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
32827557|NCT05575128|Other|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
32827558|NCT05322876|Experimental|Healthy Hearts Family Program|Participants will be enrolled in the standard Healthy Hearts Family Program 6-month family-based cardiovascular disease prevention program.
32827559|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
32827560|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
32827561|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
32827562|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
32827563|NCT04795830|Active Comparator|Control group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of GC Corporation's EQUIA Forte High Translucency glass ionomer restorative (GC EQUIA Forte HT Fil Capsule) will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
32827564|NCT04795830|Active Comparator|Control group with Restoration|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
32827565|NCT04795830|Experimental|Study group with Restoration|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
32827566|NCT04795830|Experimental|Study group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
32827567|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
32827568|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
32827569|NCT05545956|Active Comparator|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
32827570|NCT05545956|Experimental|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
32827571|NCT04489992||Standard radiology studies with AI|"The experiment is conducted on three types of studies:~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) with artificial intelligence results;~Chest X-ray for lung pathology detection (hereinafter referred to as XR) with artificial intelligence results;~Mammography for breast cancer detection (hereinafter referred to as MG) with artificial intelligence results;"
32827572|NCT04489992||Standard radiology studies without AI|"The experiment is conducted on three types of studies:~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) without artificial intelligence results;~Chest X-ray for lung pathology detection (hereinafter referred to as XR) without artificial intelligence results;~Mammography for breast cancer detection (hereinafter referred to as MG) without artificial intelligence results;"
32827573|NCT05529732|Experimental|Application Group|Oral and written consent will be obtained from the patients by face-to-face interview technique at least one day before the surgery. Then, face-to-face interview technique and data collection tools (Personal Information Form and Trait Anxiety Scale) will be applied. It is estimated that the process of obtaining consent and filling out the form will take approximately 5 minutes. The mobile application will be installed on the mobile devices of the patients and the user name and password will be defined by the researcher so that they can log into the mobile application. In the application, a patient warning notification will be sent on the 3rd, 7th and 10th days to remind the patients to fill in the State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form, which are included in the questionnaires menu and will be active when the day comes.
32827574|NCT05529732|No Intervention|Control Group|Written consent will be obtained from the patients through a face-to-face interview at least one day before the surgery and the data collection form (Personal Information Form and Trait Anxiety Scale) will be filled. During this period, standard care and follow-up protocols will be applied to the patients by the clinic. Patients in the control group will be called by phone on the 3rd, 7th and 10th days of discharge. State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form will be applied by the researcher. The process is estimated to take 15 minutes.
32827575|NCT05516004|Experimental|PXL 330|Participants will receive riboflavin 0.25% solution (Peschke TE), one drop every minute for 25 minutes to the eye, followed by UVA light 9mW/cm2 continuous mode for 10 minutes
32827576|NCT05496348||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label
32827577|NCT05257512|Experimental|Phase I/II Study of SY-3505|SY-3505 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose. In phase II, SY-3505 will be given at RP2D in advanced ALK-positive NSCLC patients.
32827578|NCT04489680|Experimental|Surgical Trainees undergoing Cleft Palate Training|26 UK specialty trainees performed a vomerine mucosal flap and intra-velar veloplasty in a one-hour workshop. Pre- and post-simulation questionnaires assessing cleft knowledge and surgical confidence were compared for statistical significance.
32827579|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
32827580|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
32827581|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
32827582|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
32827583|NCT04779216|Experimental|Active Romosozumab 210mg Injection|Romosozumab 210mg injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
32827584|NCT04779216|Placebo Comparator|Placebo|Placebo injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
32827585|NCT05216328|Active Comparator|Macrogol/electrolytes|"Macrogol/electrolytes is started at a dose of 1 sachet once a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of macrogol/electrolytes may be increased to 2 sachets a day during the study period.~The effect of laxatives will be judged after 14 days."
32827586|NCT05216328|Active Comparator|Magnesium hydroxide|Magnesium hydroxide is started at a dose of 724 mg three times a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of magnesium hydroxide may be increased to 1448 mg three times a day during the study period. The effect of laxatives will be judged after 14 days.
32827587|NCT04756908|Experimental|Opira AIOL|
32827588|NCT04756908|Active Comparator|Monofocal AIOL|
32827589|NCT04756908|Active Comparator|Multifocal AIOL|
32827590|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
32827591|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
32827592|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
32827593|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
32827594|NCT04489524|Experimental|individualized counselor-led MI sessions and NRT|The intervention (4 individualized counselor-led MI sessions and nicotine replacement therapy [NRT]) consisted of four 60-min in-person sessions of AMI counseling and a packet of self-help smoking cessation materials. Participants were provided NRT packs and counseled on their use.
33102152|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
33102153|NCT01283386|Experimental|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
33102154|NCT01283386|Active Comparator|LR Therapy|Rituximab and chlorambucile
32827595|NCT04489524|Active Comparator|general health education, self-help materials, and NRT|Participants in this condition were provided with four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco. Strategies for quitting smoking were also provided to participants in this group as well as a supply of NRT and counseling on its use.
32827596|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
32827597|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
32827598|NCT04749264||Mindfulness Meditation Retreat|6 to 7-days mindfulness meditation retreat
32827599|NCT04749264||No intervention, Matched control|Adults participants will be recruited from social media and local community of meditation practitioners, and will be matched to the retreat group by gender, age and level of experience in meditation.
32827600|NCT02466360||chronic lower back pain|
32827601|NCT04745130|Experimental|Intervention arm 1|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
32827602|NCT04745130|Experimental|Intervention arm 2|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
32827603|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
32827604|NCT05184972||Non-reported patients treated for in-hospital cardiac arrest|
32827605|NCT05184972||Reported patients treated for in-hospital cardiac arrest|
32827606|NCT04490226|Experimental|fasting, active|36 hours fasting, PAL 1.6
32827607|NCT04490226|Experimental|ketogenic diet, active|24 hours of ketogenic diet (liquid meals), PAL 1.6
32827608|NCT04490226|Experimental|exogeneous ketone bodies, active|24 hours of ketone body supplements (Beta-Hydroxybutyrate as Ca-Mg-salt) additional to a normal diet (liquid meals), PAL 1.6
32827609|NCT04490226|Experimental|fasting, inactive|36 hours fasting, PAL 1.3
32827610|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
32827611|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
32827612|NCT05165394|Placebo Comparator|Placebo|Participant follows Placebo schedule (57 days)
32827613|NCT05165394|Experimental|Antidepressant|Participant follows NBI-1065846 schedule (57 days)
32827614|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
32827615|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
32827616|NCT04489602||Intervention|Each patient complete ObsQoR-10F questionnaire 3 times (before delivery, on Day 1, on Day 2)
32827617|NCT03585270|Experimental|Clazosentan|Participants will receive clazosentan for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
32827618|NCT03585270|Placebo Comparator|Placebo|Participants will receive clazosentan matching-placebo for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
32827619|NCT03501576||Inactivated Influenza Vaccine|Patients will be vaccinated with an FDA approved seasonal inactivated influenza vaccine
32827620|NCT03501576||Qualifying subjects to receive a SARS-CoV2 vaccine.|Patients receive a SARS-CoV2 vaccine.
32827621|NCT03501576||Clinical Group Receiving SARS-CoV2 Booster Vaccines|Patients receive a SARS-CoV2 vaccine.
32827622|NCT05152758|No Intervention|Usual Care|Patients will receive the usual care.
32827623|NCT05152758|Experimental|Physical Activity Prescription (PARx)|Patients will be prescribed technology-based physical activity programming.
32827624|NCT05142462||EUROSCUP Fixe|120 patients who received EUROSCUP Fixe
32827625|NCT05140200|Experimental|Cohort 1: Participants receiving GSK3511294 at Dose level 1|
32827626|NCT05140200|Experimental|Cohort 2: Participants receiving GSK3511294 at Dose level 2|
32827627|NCT05133102||Control|Patients who have undergone an endoscopy within the last three years and have never been diagnosed with Barrett's esophagus.
32827628|NCT05133102||Barrett's Esophagus|Patients who have undergone an endoscopy within the last three years and have histologically confirmed Barrett's esophagus. BE segment must be M>1cm, and has not be treated with endoscopic eradication therapy (focal mucosal resection without subsequent eradication therapy is allowed).
32827629|NCT05124210|Experimental|Cohort A: Participants receiving sotrovimab via Intravenous administration|
32827630|NCT05124210|Experimental|Cohort B: Participants receiving sotrovimab via Intramuscular administration|
32827631|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
32827632|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
33102155|NCT05466786||Experimental ARM|All patients received standard care for postoperative management.
33102156|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate~nd period: Tenofovir Disoproxil"
33317995|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
32827635|NCT03286686|Experimental|Experience 1|
32827636|NCT03286686|Experimental|Experience 2|
32827637|NCT03286686|Experimental|Experience 3|
32827638|NCT03286686|Experimental|Experience 4|
32827639|NCT03286686|Experimental|Experience 5|
32827640|NCT03286686|Experimental|Experience 6|
32827641|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
32827642|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
32827643|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
32827644|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
32827645|NCT04662372||Patients|Patients
32827646|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
32827647|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
32827648|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
32827649|NCT04656600|Experimental|Cerezyme® / Imiglucerase|Cerezyme® (imiglucerase for injection) is administered by intravenous infusion, 60 U/kg once every 2 weeks.
32827650|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
32827651|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
32827652|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
32827653|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
32827654|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
32827655|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
32827656|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
32827657|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
32827658|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
32827659|NCT04645212||1|Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
32827660|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
32827661|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
32827662|NCT05093244|Experimental|SeQuent Please ReX|Drug coated balloon (DCB) catheter.
32827663|NCT05093244|Active Comparator|Plain old balloon angioplasty (POBA)|
32827665|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
32827666|NCT04489446|Experimental|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
32827667|NCT04489446|Placebo Comparator|Control|Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
32827668|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
32827669|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
32827670|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
32827671|NCT02717832|Experimental|Insulin Sensitivity|
32827672|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
32827673|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
32827674|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
32827675|NCT04550676|Experimental|High intensity interval training|
32827676|NCT04550676|Active Comparator|Continuous moderate intensity exercise|
32827677|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
32827678|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
32827679|NCT04626882|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
32827680|NCT04626882|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
32827681|NCT02988960|Experimental|Escalating Arm 1: ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
32827682|NCT02988960|Experimental|Escalating Arm 2: ABBV-927|Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
32827683|NCT02988960|Experimental|Escalating Arm 3: ABBV-927+ABBV-181|Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
32827684|NCT02988960|Experimental|Escalating Arm 4: ABBV-927+ABBV-181|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
32827685|NCT02988960|Experimental|Escalating Arm 5 (Japan): ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
32827686|NCT02988960|Experimental|Escalating Arm 6 (Japan): ABBV-927+ABBV-181|Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
32827687|NCT02988960|Experimental|Expansion Arm A: ABBV-927|Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
32827688|NCT02988960|Experimental|Expansion Arm B: ABBV-927+ABBV-181|Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
32827689|NCT02988960|Experimental|Expansion Arm C: ABBV-927+ABBV-181|Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
32827690|NCT05040750||moderate to severe COVID 19 patients|moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed
32827691|NCT04497168|Experimental|Citalopram|20mg daily
32827692|NCT04497168|Placebo Comparator|Placebo|matching placebo pills
32827693|NCT04608474|Experimental|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
32827694|NCT04608474|Experimental|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
32827695|NCT02927262|Experimental|Gilteritinib|Participants received gilteritinib 120 mg (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-specified discontinuation criterion was met.
32827696|NCT02927262|Placebo Comparator|Placebo|Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-specified discontinuation criterion was met.
32827697|NCT04705350|Experimental|Zampilimab Cohorts|Participants will be randomized to receive predefined single doses of zampilimab.
32827698|NCT04705350|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
32827699|NCT04993638||EUROSCUP MOBILE cementless|107 who received cementless version of EUROSCUP MOBILE
32827700|NCT04993638||EUROSCUP MOBILE cemented|40 who received cemented version of EUROSCUP MOBILE
32827701|NCT04467606|Experimental|Experimental|The experimental group will receive a discharge planning which use the strategy of motivational interviewing.
32827702|NCT04467606|No Intervention|Control|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
32827703|NCT04459338|Placebo Comparator|Saline|Saline infused during the hyperglycemic clamp with escalating doses of glucagon
32827704|NCT04459338|Active Comparator|Exendin-9,39|Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon
32827705|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
32827706|NCT04956198||Patients with newly diagnosed as well as relapsed/refractory sarcomas.|The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas
32827707|NCT04947384||Patients with moderate mitral valve disease, undergoing interventions|Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.
32827708|NCT04947384||Patients undergoing mitral valve interventions without pulmonary hypertension|Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.
33102157|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil~nd period: Tenofovir Disoproxil fumarate"
32827709|NCT04947384||Patients with precapillary pulmonary hypertension scheduled for right heart catheterization|Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.
32827710|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
32827711|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
32827712|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
32827713|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
32827714|NCT04938960||Biological Heart Valve|Participants receiving a biological heart valve
32827715|NCT04938960||Mechanical Heart Valve|Participants receiving a mechanical heart valve
32827716|NCT04936230|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32827717|NCT04936230|Experimental|Arm B (atezolizumab, SBRT)|Patients receive atezolizumab as in Arm A. Patients also undergo SBRT for 3 fractions over 2 weeks in the absence of disease progression or unacceptable toxicity.
32827718|NCT02331498|Other|A Pazopanib|Open label study with one group
32827719|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
32827720|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
32827721|NCT01781429|Experimental|BVD-523|
32827722|NCT01773473|Experimental|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
32827723|NCT01773473|Experimental|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
32827724|NCT01772693|Experimental|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
32827725|NCT01772693|Sham Comparator|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
32827726|NCT01779869|Experimental|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
32827727|NCT01772537|No Intervention|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
32827728|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
32827729|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
32827730|NCT04573517|Experimental|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
32827731|NCT04573517|Active Comparator|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
32827732|NCT04572581|Experimental|Exclusively Human Milk Diet|This group will receive human milk only. If the mother is not producing enough breast milk, this group will receive donor milk supplementation.
32827733|NCT04572581|No Intervention|Formula-based Diet|If the mother is not producing enough breast milk, this group will receive formula supplementation (the standard of care).
32827734|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI >5)
32827735|NCT01772147|Experimental|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
32827736|NCT01772147|Active Comparator|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
32827737|NCT01771913|Sham Comparator|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
32827738|NCT01771913|Active Comparator|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
32827739|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
32827740|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
32827741|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
32827742|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
32827743|NCT04570319|Experimental|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
32827744|NCT04570319|Placebo Comparator|Placebo|a capsule containing placebo comparator
32827745|NCT01770743|Experimental|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
32827746|NCT01770743|Experimental|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
33102158|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
32827747|NCT01770743|Experimental|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
33102159|NCT01283152|Other|Lactulose|Per standard of care
33102160|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
32827748|NCT01770743|Experimental|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
32827749|NCT01770743|Active Comparator|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
32827750|NCT01777997|Experimental|FTC/RPV/TDF|
32827752|NCT01770509|Active Comparator|Standard of care|Standard of care: Dressings +Compression garments
32827753|NCT01770509|Experimental|Application of NMBM|Daily application of NMBM
32827754|NCT01770353|Experimental|Pilot Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
32827755|NCT01770353|Experimental|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
33102161|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
32827756|NCT01777763|Experimental|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
32827757|NCT01777763|Experimental|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
32827758|NCT01769339|Experimental|Miconazole plus Hydrocortisone|
32827759|NCT01769105|Active Comparator|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
32827760|NCT01769105|Active Comparator|Lipiflow|Patients receive a singe Lipiflow-treatment
32827761|NCT01777139|Experimental|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
32827762|NCT01768637|Experimental|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
33102162|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
33102163|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
33102164|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
33102165|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
32827763|NCT01768637|Active Comparator|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
32827764|NCT01886872|Active Comparator|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
32827765|NCT01886872|Experimental|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32827766|NCT01886872|Experimental|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32827767|NCT01768559|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
32827768|NCT01768559|Active Comparator|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
32827769|NCT01768559|Active Comparator|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
32827770|NCT01812694|Active Comparator|Enhanced Standard Care|Standard prenatal care plus education
32827771|NCT01812694|Experimental|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
33102166|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
33102167|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
33102168|NCT02932371|Experimental|Cardiac Surgery|
32827772|NCT00983619|Experimental|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827773|NCT00983619|Experimental|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827774|NCT00983619|Experimental|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827775|NCT00983619|Experimental|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827776|NCT00983619|Experimental|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827777|NCT00983619|Experimental|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827778|NCT00983619|Experimental|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827779|NCT00983619|Experimental|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827780|NCT00983619|Experimental|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
32827781|NCT00983619|Experimental|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
32827782|NCT00983619|Experimental|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
32827783|NCT00983619|Experimental|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
32827784|NCT00653068|Experimental|Arm I (chemotherapy, autologous PBSC, 3D-CRT)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks."
32827785|NCT00653068|Experimental|Arm II (chemotherapy, 3D-CRT, autologous PBSC)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
32827786|NCT03028311|Other|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
32827787|NCT01767857|Experimental|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
32827788|NCT01767857|Placebo Comparator|Placebo|Placebo administered IV every two weeks, plus best supportive care
32827789|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
32827790|NCT04553835|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
32827791|NCT04553835|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
32827792|NCT04553835|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
32827793|NCT04553835|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
32827794|NCT05608785|Experimental|HER2 protein positive 3+ or FISH amplification or HER protein 2+ but FISH amplification|"Initial treatment (4-6 cycles): IBI315 injection, oxaliplatin, capecitabine~IBI315: 1200 mg per cycle d1 dosing, intravenous drip, 3 weeks as one treatment cycle.~Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: IBI315 monotherapy maintenance~- IBI315: 1200 mg IV drip per cycle d1 for 3 weeks."
32827795|NCT05608785|Experimental|Positive for Claudin 18.2 protein|"Initial treatment (4-6 cycles): PD-L1 monoclonal antibody, TST001 injection, oxaliplatin, capecitabine~TST001: 3mg, 4.5mg and 6mg dose levels for hill climbing trial, dose per cycle d1, IV drip, 3 weeks for one treatment cycle. 3-6 patients were enrolled in each dose level (3 patients were enrolled if no DLT was present, if present extended to 6 patients)~TQB2450 injection: 1200 mg per cycle d1 dosing, IV drip, 3 weeks as a treatment cycle.~Oxaliplatin: 130 mg/m2 per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: TQB2450 injection + TST001~TST001: maintenance at the dose level used (3mg/4.5mg/6mg), dosed d1 per cycle, IV drip, 3 weeks as a treatment cycle.~TQB2450 injection: 1200mg, dosed d1 per cycle, intravenous drip, 3 weeks as a treatment cycle."
32827796|NCT05608785|Experimental|Her2 protein, Claudin18.2 protein were negative|"Initial treatment (4-6 cycles): TQB2450 injection, Anrotinib, Oxaliplatin, Capecitabine~TQB2450 injection: 1200mg per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~Anrotinib: 1 capsule (10 mg) once daily, dosed every cycle d1-d14, stopping for 2 consecutive weeks, 3 weeks as a treatment cycle~Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3-week treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks as a treatment cycle.~Patients with CR/PR/SD enter maintenance therapy: PD-L1 inhibitor, anlotinib~PD-L1 monoclonal antibody (TQB2450): 1200 mg d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~Anlotinib: 1 capsule (10mg) once daily, d1-d14 per cycle, stopping for 2 weeks, 3 weeks as a treatment cycle."
32827797|NCT04394013|Experimental|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
32827798|NCT04394013|Active Comparator|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
32827799|NCT04550169||Intensive Care Coordination|Intensive Care Coordination along with Standard of Care
32827800|NCT04550169||Control|Standard of Care alone
32827801|NCT04552509|Other|Observation|Observational study of patient efficacy and side effects
32827802|NCT05608551|Experimental|AA TF-CBT|Participants receive a 10-week animal-assisted trauma-focused group therapy.
33405278|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
32827803|NCT05608551|Active Comparator|TF-CBT|Participants receive a 10-week standard trauma-focused group therapy.
32827804|NCT04349644|Experimental|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
32827805|NCT04349644|No Intervention|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
32827806|NCT04556097|Experimental|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
32827807|NCT04556097|Active Comparator|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
32827808|NCT03828760|Experimental|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
32827809|NCT03828760|No Intervention|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
32900044|NCT00248612|Placebo Comparator|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
33102169|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
32827810|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
32827811|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
32827812|NCT01775501|Experimental|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
32827813|NCT03786640||Single Arm|Patients implanted with an SJM Tendril STS 2088 or Isoflex 1944/1948 lead, together with an Assurity MRI or Endurity MRI pacemaker, and who will undergo a 3T MRI scan are eligible to participate in this study.
32827814|NCT04124835|Experimental|Intervention Group|In the intervention group, the use of the Swiss Ball will be performed through active exercises of pelvic anteversion and retroversion, lateralization and circumduction according to the obstetric evaluation.
32827815|NCT04124835|Other|Control Group|The control group will receive the usual routine care of the service.
32827816|NCT03726658|Experimental|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
32827817|NCT03726658|Experimental|AGN-241751 10mg|AGN-241751, oral administration, once per day
32827818|NCT03726658|Experimental|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
32827819|NCT03726658|Placebo Comparator|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
32827820|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
32827821|NCT03721042|Experimental|exhaled air|exhaled air analysis of patients
32827822|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
32827823|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
32827824|NCT04553445|Experimental|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
32827825|NCT04553445|Experimental|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
32827826|NCT04347525|Experimental|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
32827827|NCT04347525|No Intervention|Control|This group will receive treatment as usual
32827828|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
32827829|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
32827830|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
32827831|NCT04346667|Active Comparator|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
32827832|NCT04346667|Experimental|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
32827833|NCT04346667|Active Comparator|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
32827834|NCT04346667|Placebo Comparator|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
32827835|NCT03471364|Experimental|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
32827836|NCT03471364|Placebo Comparator|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
32827837|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
32827838|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
32827839|NCT04129983|Experimental|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight * 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
32827840|NCT04129983|Experimental|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight * 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
32827841|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
32827842|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
32827843|NCT05608239|Experimental|Sculptra® Aesthetic|
32827844|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
32827845|NCT05608161||Patients with unilateral sudden deafness with complete recovery of peripheral hearing|The patients who recovered from sudden deafness underwent speech recognition rate tests under different masking conditions and different signal-to-noise ratio conditions within 2 weeks after complete recovery of peripheral hearing and were followed up 3 times at 1, 6, and 12 months after recovery. The test content is the same as the first time.
33102170|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
32827846|NCT05608161||Healthy control group|Age-, gender-, and educational-matched healthy controls were enrolled as healthy control group to test speech recognition rates under different masking conditions and different signal-to-noise ratio conditions.
32827847|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
32827848|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
32827849|NCT04553289|Experimental|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
32827850|NCT04553289|Active Comparator|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
32827851|NCT03024489|Experimental|Palbociclib-Cetuximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
32827852|NCT03059121||HIV-infected ART-naïve|HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen
32827853|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
32827854|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
32827855|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
32827856|NCT04129593|Experimental|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
32827857|NCT04129593|Experimental|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
32827858|NCT04552665||Adults|Patients who have cardiac arrhythmia
32827859|NCT04768894|Active Comparator|14-28 days|In group 1,the time interval between initial and re-TUR was 14-28 days,
32827860|NCT04768894|Active Comparator|29-42 days|In group 2, the time interval between initial and re-TUR was 29-42 days
32827861|NCT04768894|Active Comparator|43-56 days|In group 3, the time interval between initial and re-TUR was 43-56 days
32827862|NCT01775189|Placebo Comparator|Treatment A|
32827863|NCT01775189|Experimental|Treatment B|
32827864|NCT01775189|Placebo Comparator|Treatment C|
32827865|NCT01775189|Active Comparator|Treatment D|
32827866|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
33102171|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
33102172|NCT00532350|Experimental|1|QAT370
32827867|NCT04768816|Placebo Comparator|Placebo Comparator|Placebo 0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
32827868|NCT04768816|Experimental|Experimental|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells#1*10^7/kg). The infusion speed is 1ml/min.
32827869|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion.~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
32827870|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
32827871|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
32827872|NCT04129203|Experimental|Trial arm|Mechanical thrombectomy using Versi Retriever
32827873|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
32827874|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
32827875|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
32827876|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
32827877|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
32827878|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
33102173|NCT00532350|Placebo Comparator|2|Placebo
33102174|NCT00532350|Active Comparator|3|Tiotropium
33102175|NCT02920775||Pain|
32827879|NCT04551963|Experimental|Zanubrutinib + Moderate CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg twice daily (BID) + fluconazole (days 4 - 10), zanubrutinib 320 mg once daily (QD) (days 13 - 19), zanubrutinib 80 mg BID + diltiazem (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
32827880|NCT04551963|Experimental|Zanubrutinib + Strong CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg QD + voriconazole (days 4 - 10), zanubrutinib 320 mg QD (days 13 - 19), zanubrutinib 80 mg QD + clarithromycin (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
32827881|NCT04128813|Active Comparator|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
32827882|NCT04128813|Active Comparator|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
32827883|NCT04128813|No Intervention|Control group|No intervention.
32827884|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
32827885|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
32827886|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
32827887|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
32827888|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
32827889|NCT03832816|Placebo Comparator|Placebo|Distilled Water
33102176|NCT02920775||PCP|
32827890|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
32827891|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
32827892|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
32827893|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
32827894|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
32827895|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
32827896|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
32827897|NCT04129047|Experimental|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
32827898|NCT04129047|Active Comparator|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
32827899|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
32827900|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
32827901|NCT04231084|Active Comparator|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
33102177|NCT02920775||Dentist|
33102178|NCT02920775||Surgery|
33102179|NCT02920775||Emergency Medicine|
33102180|NCT02920775||Oncology|
33102181|NCT02920775||Hospice and Palliative Medicine|
33405279|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
32827902|NCT04231084|Experimental|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
32827903|NCT04551105|Active Comparator|First session: manual review first and then review with CADx|"Reader Group X interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
32827904|NCT04551105|Active Comparator|First session: review with CADx first and then manual review|"Reader Group Y interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
32827905|NCT04551105|Active Comparator|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Reader Group X interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
32827906|NCT04551105|Active Comparator|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Rader Group Y interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
32827907|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
32827908|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
32827909|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
32827910|NCT04124211|Experimental|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
33102182|NCT02920775||Anesthesiology|
33102183|NCT02920775||Neurology|
33102184|NCT02920775||Nurse Practitioners|
33102185|NCT02920775||Pediatrics|
33102186|NCT02920775||Physical Medicine & Rehabilitation|
33102187|NCT02920775||Physician Assistant|
33102188|NCT02920775||Rheumatology|
33102189|NCT02920775||All Other Specialties|
33102190|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
32827911|NCT03314974|Experimental|TBI Regimen|
32827912|NCT03314974|Experimental|Non-TBI Regimen|
32827913|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
32827914|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
32827915|NCT04127799|Experimental|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
32827916|NCT04127799|Active Comparator|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
32827917|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
32827918|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
32827919|NCT04127877|Experimental|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
32827920|NCT04127877|No Intervention|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
32827921|NCT04768660|Other|normal|people will not use chewing gums after whipple operation
32827922|NCT04128033|Experimental|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
32827923|NCT04128033|Placebo Comparator|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
32827924|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
32827925|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
32827926|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
32827927|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
32827928|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
32827929|NCT04123821|Experimental|Group A|
32827930|NCT04123821|No Intervention|Group B|
32827931|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
32827932|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
32827933|NCT04123899|Experimental|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
32827934|NCT04123899|Experimental|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
32827935|NCT04124055|Experimental|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
32827936|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
32827937|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
32827938|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
32827939|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
32827940|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
32827941|NCT04123587|Experimental|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
32827942|NCT01890226|No Intervention|Control|
32827943|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
32827944|NCT04127721|Experimental|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
32827945|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
32827946|NCT04123743|Experimental|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
33317996|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
33405280|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
33405281|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
32827947|NCT04123743|Placebo Comparator|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
32827948|NCT04123119|Experimental|Rotarix Arm|
32827949|NCT04393077|No Intervention|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
32827950|NCT04393077|Experimental|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
32827951|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
32827952|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
32827953|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
32827954|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
32827955|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
32827956|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
32827957|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
32827958|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
32827959|NCT04127409|Placebo Comparator|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
32827960|NCT04127409|Experimental|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
32827961|NCT04127409|Experimental|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
32827962|NCT04127409|Experimental|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
32827963|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
32827964|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
32827965|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
32900045|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
32900046|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
33102191|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
33102192|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
33317997|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
33317998|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
33317999|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
33102193|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
33102194|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
33102195|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
32827966|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
33102196|NCT00532389|Experimental|Panobinostat (LBH589)|
32827967|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
32827968|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
32827969|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
32827970|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
32827971|NCT04122963|Active Comparator|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
32827972|NCT04122963|Active Comparator|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
32827973|NCT03945448|Experimental|Single dose liposomal Amphotericin and fluconazole|"Experimental:~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
32827974|NCT03945448|Active Comparator|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
33102197|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
33102198|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
33102199|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
33102200|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
33102201|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
32827975|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
32827976|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
32827977|NCT04122651|Experimental|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
32827978|NCT04122651|Active Comparator|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
32827979|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
32827980|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
32827981|NCT03926338|Experimental|PD-1 inhibitor plus COX inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab) plus COX inhibitor (Celecoxib)
32827982|NCT03926338|Experimental|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
32827983|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
32827984|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
32827985|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
32827986|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
32827987|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
32827988|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.~Babies in the control group who took care practices in accordance with normal hospital procedures."
32827989|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
32827990|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
32827991|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
32827992|NCT04122807|Active Comparator|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
32827993|NCT04122807|Experimental|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
32827994|NCT03875716|Experimental|Low Risk|"Observation without adjuvant therapy~Pathologic T0-2, N0-1~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck~-≤2 positive lymph nodes confined to level II and/or level III~No extranodal extension~Clear margins"
32827995|NCT03875716|Experimental|Intermediate Risk|"Reduced-dose radiation (46Gy)~Pathologic T0-2N0-2 and any one of the following features:~->2 positive lymph nodes~<15 lymph nodes retrieved on neck dissection for each side of the neck~Positive lymph nodes in level IB, IV, or V~-≤1mm extranodal extension~Positive lymph node(s) contralateral to the primary tumor~Close margins"
32827996|NCT03875716|Experimental|High Risk|"Postoperative radiation (60Gy) without chemotherapy~Pathologic T0-4N0-2 and any one of the following features:~->1mm extranodal extension~Microscopic positive margins"
32827997|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
32827998|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
32827999|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
32828000|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
32828001|NCT04122027|Active Comparator|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
32828002|NCT04122027|Active Comparator|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
32828003|NCT02506192|Experimental|Modified-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
32828004|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
32828005|NCT04122105|Experimental|intervention|sildenafil administration perioperative to renal transplant
32828006|NCT04122105|Active Comparator|control|renal transplant recipients
32828007|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
33405282|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
32828008|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
32828009|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
32828010|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
32828011|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
32828012|NCT02270632|Placebo Comparator|Arm 1|Placebo
32828013|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
32828014|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
32828015|NCT04127019|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
32828016|NCT04127019|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
32828017|NCT04127019|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
32828018|NCT02244034||760 patients who underwent open cardiac and/or thoracic aortic surgery using CPB|
32828019|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
32828020|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
32828021|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
32828022|NCT04127097|Experimental|cartoon group|
32828023|NCT04127097|No Intervention|control group|
32828024|NCT04121481|Placebo Comparator|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
32828025|NCT04121481|Active Comparator|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
33405283|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
32828026|NCT04121715|Active Comparator|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
32828027|NCT04121715|Experimental|standard medication+fastigial nucleus stimulation|"fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.~standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
32828028|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
32828029|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
32828030|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
32828031|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
32828032|NCT03295227|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32828033|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
32828034|NCT04121247|Experimental|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
32828035|NCT04121247|Experimental|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
32900047|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
32828036|NCT03853798|Experimental|Cohort 1|"Participants who received placebo in Study AG348-C-006 will enroll in Cohort 1.~Part 1 (Dose Optimization Period, 12 weeks): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day and then to 50 mg twice a day depending on their response to AG-348 and tolerability.~Part 2 (Fixed Dose Period, 12 weeks): Last dose received in Part 1, twice a day.~After completion of Part 2, participants who, in the opinion of the Investigator, have demonstrated clinical benefit from AG-348 treatment will continue AG-348 treatment in the Continued Treatment Period."
32828037|NCT03853798|Experimental|Cohort 2|"Participants who received AG-348 in Study AG348-C-006 will enroll in Cohort 2.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-006."
32828038|NCT03853798|Experimental|Cohort 3|"Participants who received AG-348 in Study AG348-C-007 will enroll in Cohort 3.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-007."
32828039|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
32828040|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
32828041|NCT04121091|Experimental|Pramipexole|
32828042|NCT04127253|Experimental|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
32828043|NCT04127253|Placebo Comparator|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
32828044|NCT04127253|Sham Comparator|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
32828045|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
32828046|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
32828047|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
32828048|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
32828049|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
32828050|NCT04392843|Other|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
32828051|NCT04392843|Active Comparator|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
32828052|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
32828053|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
32828054|NCT04121013|Active Comparator|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
32828055|NCT04121013|No Intervention|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
32828056|NCT04126707|Experimental|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
32828057|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
32828058|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
32828059|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
32828060|NCT04120623|Experimental|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
32828061|NCT04120623|Active Comparator|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
32828062|NCT01767467|Experimental|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
32828063|NCT01767467|Placebo Comparator|Placebo Group|Subjects will receive the placebo vaccine.
32828064|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
32828065|NCT02988232|Placebo Comparator|Placebo|admission to placebo
33405284|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
32828066|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
32738751|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
32738752|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
32738753|NCT03073317|No Intervention|CONTROL|Usual clinic control
32738754|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
32738755|NCT04485403|Experimental|Ibuprofen|Depending on body weight, patients will be divided into two groups. Women with a body weight <70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
32738756|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
32738757|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
32738758|NCT03073239||ALS epidemiological characterization|epidemiological characterization
32738759|NCT03073239||Genetic findings in ALS patients|genética characterization
32738760|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
32738761|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
32738762|NCT02490137|Experimental|Game Players|Participants that will play video game
32738763|NCT02490137|No Intervention|Control|No video game experience
32738764|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
32738765|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
32738766|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
32738767|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
32738768|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
32738769|NCT03205345|Placebo Comparator|Placebo|Matching placebo
32738770|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
32738771|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
32738772|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
32738773|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
32738774|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
32738775|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
32738776|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
32738777|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
32828067|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
32828068|NCT03025984|Active Comparator|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
32828069|NCT03025984|No Intervention|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
32828070|NCT04758897|Experimental|Single Arm|"5.0*10^7 on D1~1.0*10^8 on D1~2.0*10^8 on D1~2.0*10^8 on D1 and D2~2.0*10^8 on Days 1 to 3~2.0*10^8 on Days 1 to 4~2.0*10^8 on Days 1 to 5"
32828071|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
32828072|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
32828075|NCT01932112|Other|adenosine arm|single arm study
32828076|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
32828077|NCT04120311|Experimental|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone~Other Names:~• Sustained Release Transscleral Dexamethasone"
32828078|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
32828079|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
32828080|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
32828081|NCT04120389|Experimental|BCL group|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
32828082|NCT04120389|Active Comparator|control group|
32828083|NCT04120077|Placebo Comparator|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
32828084|NCT04120077|Experimental|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
32828085|NCT04120077|Experimental|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
32828086|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
32828087|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
32828088|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
32828089|NCT04126239||healthy volunteer|
32828090|NCT04122339|Experimental|MAX-10181|tablet
32828091|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
32828092|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
33405285|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
32828093|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
32828094|NCT04127331|Active Comparator|Routine|Patients who are scheduled for routine outpatient surgery.
32828095|NCT04127331|Active Comparator|Urgent|Patients who are scheduled for urgent surgery.
32828096|NCT04127331|Active Comparator|Emergent|Patients who are scheduled for emergency surgery.
32828097|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
32828098|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
32828099|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
32828100|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
32828101|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
32828102|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
32828103|NCT01933984|Experimental|Individualized dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
32828104|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
32828105|NCT04120155|Other|Dissecting the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary dessection during the upper lobe thoractomy.
32828106|NCT04120155|Other|Preserving the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary preservation during the upper lobe thoractomy.
32828107|NCT04126083|Experimental|Lofexidine|Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.
32828108|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
32828109|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
32828110|NCT04393545|Active Comparator|HV night splint (SP) group|
32828111|NCT04393545|Active Comparator|exercise (EX) group|
32828112|NCT04393545|Active Comparator|high-voltage galvanic stimulation (EL) group|
32828113|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
32828114|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
32828115|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
32828116|NCT01935622|Placebo Comparator|Placebo|Placebo
32828117|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
32828118|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
32828119|NCT03008187|Experimental|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.~Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.~Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
32828120|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
32828121|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
32828122|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
32828123|NCT01936324|Experimental|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
32828124|NCT01936324|Experimental|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
32828125|NCT04274673|Other|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
33405286|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
33405287|NCT04021472|Experimental|Text message|Participants receive text messages about healthy eating or physical activity.
32828126|NCT04274673|Other|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
32828127|NCT04274673|Other|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
32828128|NCT02979561|Experimental|group of dabigatran|
32828129|NCT02979561|Active Comparator|group of warfarin|
32828130|NCT04100733|Active Comparator|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
32828131|NCT04100733|Experimental|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
32828132|NCT01766921|Experimental|aH5N1c - High dose|
32828133|NCT01766921|Experimental|aH5N1c - Low dose|
32828134|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
32828135|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
32828136|NCT04759053|Active Comparator|FNB|
32828137|NCT04759053|Active Comparator|Core biopsy|
32828138|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
32828139|NCT04393467|Experimental|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
32828140|NCT04393467|Sham Comparator|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
32828141|NCT01774799|Experimental|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
32828142|NCT01774799|Active Comparator|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
32828143|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
32828144|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).~Treatment duration = minimum 6 weeks/Max 13 weeks"
32828145|NCT03825783|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
32828146|NCT04569539|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane
32828147|NCT03824223|Other|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
32828148|NCT03824223|Other|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
32828149|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
32828150|NCT03828903|Experimental|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
32828151|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
32828152|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
32828153|NCT03828825|Experimental|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
32828154|NCT04569461|Experimental|Single Arm|Subjects with unfavorable localized prostate cancer will be enrolled.This is a single arm, phase II study of pembrolizumab (Keytruda), SBRT, and Short-term Androgen Deprivation Therapy (STADT), known together as trimodality therapy, followed by radical prostatectomy 8 weeks after SBRT.
32828155|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
32828156|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
32828157|NCT04125615|Experimental|Protected Non-Clinical Time|Protected non-clinical time
32828158|NCT04125615|No Intervention|Control Period|No protected non-clinical time
32828159|NCT03829371|Experimental|ARM A (enrollment closed)|"Velcade (V):~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.~Melphalan (M):~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
32828160|NCT03829371|Experimental|ARM B (enrollment closed)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
32828161|NCT03829371|Experimental|ARM A2|"Velcade (V):~- 1.3 mg/m2 subcutaneously twice weekly on weeks 1, 2, 4, and 5 of cycle 1 (days 1,4,8,11,22,25,29,32) and once weekly on weeks 1, 2, 4, and 5 of cycles 2 through 9 (days 1,8,22,29).~Melphalan (M):~- 9 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Daratumumab:~-16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) with oral or intravenous dexamethasone (to manage infusion reactions) at a dose of 20 mg once weekly in cycle 1 (days 1,8,15,22,29,36), every 3 weeks in cycles 2 through 9 (days 1,22), and every 4 weeks thereafter until disease progression or unacceptable toxic effects. Dexamethasone at a dose of 20 mg was substituted for prednisone on day 1 of each cycle."
32828162|NCT03829371|Experimental|ARM B2|"Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Daratumumab:~-intravenous at a dose of 16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter; preinfusion medications were administered approximately 1 hour before each daratumumab dose."
32828163|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
32828164|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
32828165|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
32828166|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
32828167|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
32828168|NCT04125303|Experimental|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
32828169|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
32828170|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
32828171|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
32828172|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
32828173|NCT04125849|Active Comparator|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
32828174|NCT04125849|Active Comparator|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
32828175|NCT01765751|Active Comparator|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
32828176|NCT01765751|Active Comparator|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
32828177|NCT01765751|Sham Comparator|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
32828178|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
32828179|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
32828180|NCT01938664|Experimental|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
32828181|NCT01938664|Placebo Comparator|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
32828182|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
32828183|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
32828184|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
32828185|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
32828186|NCT04562987|Active Comparator|Core|All participants will receive the Core component, which includes access to weekly telecoaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Telecoaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
32828187|NCT04562987|Experimental|Move|Telecoaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
32900048|NCT00249470|Experimental|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
32828188|NCT04562987|Experimental|Exercise|Telecoaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
32828189|NCT04562987|Experimental|Combo (Move+Exercise)|Includes telecoaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
32828190|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
32828191|NCT01736657|Experimental|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
32828192|NCT04124679|Experimental|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
32828193|NCT04124679|No Intervention|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
32828194|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
32828195|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
32828196|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
32828197|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
32828198|NCT01736579|Experimental|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
32828199|NCT01736579|Experimental|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
32828200|NCT02974335||Primary Care Providers (PCPs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
32828201|NCT02974335||Medical Assistants (MAs) + Registered Nurses (RNs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
32828202|NCT02974335||Patients|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
32828203|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
32828204|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
32828205|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 1: Daratumumab.~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 2: Daratumumab.~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
32828206|NCT01940146|Placebo Comparator|SPARC Placebo|
32828207|NCT01940146|Experimental|SPARC1310 I|
32828208|NCT01940146|Experimental|SPARC1310 II|
32828209|NCT01940146|Experimental|SPARC1310 III|
32828210|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
32828211|NCT04124913|Experimental|Dydrogesterone|
32828212|NCT04124913|Active Comparator|Vaginal progesterone|
32828213|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
32828214|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
32828215|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
32828216|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
32900049|NCT00249470|Other|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
32828217|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
32828218|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
32828219|NCT03902301|Active Comparator|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
32828220|NCT03902301|Experimental|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
32828221|NCT01764659||All enrolled patients|Contrast-enhanced 4D computed tomography
32828222|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
32828223|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
32828224|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
32828225|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
32828226|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
32828227|NCT01736189||Participants treated with adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks
32828228|NCT01903564||normal|pregnant women with uncomplicated pregnancies
32828229|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
32828230|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
32828231|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
32828232|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
32828233|NCT04169711|Experimental|ARO-HIF2|
32828234|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
32828235|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
32828236|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
32828237|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
32828238|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
32828239|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
32828240|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
32828241|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
32828242|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.~Intervention : rTMS"
32828243|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
32828244|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
32828245|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
32828246|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
33102202|NCT05466708|Experimental|Esketamine combined with dexmedetomidine|Esticketamine was administered at 1mg/kg, IVP, then intravenously pumped at 0.25-1.5mg/ kg (kg×h) in combination with dexmedetomidine 1.0μg/kg for 20 min, followed by continuous intravenously pumped at 0.2-0.7mg/ kg (kg×h), maintaining a RASS score of -2-0.
33102203|NCT05466708|Active Comparator|Dexmedetomidine|Dexmedetomidine was administered at 1.0μg/kg for 20 min, followed by continuous intravenous pumping at 0.2-0.7mg/ kg×h to maintain a RASS score of -2-0
33102204|NCT02920541|Experimental|S 055746|
33102205|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
33318000|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
32828247|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
32828248|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
32828249|NCT04274205|Active Comparator|Influence on brief supportive psychotherapy|Intervention group
32828250|NCT04274205|Active Comparator|Influence of brief supportive psychotherapy|Control group
32828251|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
32828252|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
32828253|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
32828254|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
32828255|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
32828256|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
32828257|NCT03822429||women < 35 years old|
32828258|NCT03822429||women between 36 and 38 years old|
32828259|NCT03822429||women between 39 and 40 years|
32828260|NCT03822429||women > 41 years old|
32828261|NCT01735175|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
32828262|NCT01735175|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
32828263|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
32828264|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
32828265|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
32828266|NCT01942720|Other|Capsule endoscopy|
32828267|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
32828268|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
32828269|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
32828270|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
32828271|NCT01762943|Experimental|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
32828272|NCT01762943|Experimental|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
32900050|NCT05266820|Experimental|TAS-102+Thalidomide|Thalidomide 100mg PO BID+TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
32900051|NCT05266820|Active Comparator|TAS-102|TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
32900052|NCT05266742|Experimental|END|Use of web based education
32828273|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:~Upper deltoid with the side-load ID adapter~Upper deltoid with the AD ID adapter~Suprascapular (behind the shoulder) with the side-load ID adapter~Suprascapular with the AD ID adapter~Forearm with the side-load ID adapter~Forearm with the AD ID adapter"
32828274|NCT03827733||AD patients|Participants who are diagnosed with AD.
32828275|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
32828276|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
32828277|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
32828278|NCT03331354|Experimental|Compass|a distant learning vocational program
32828279|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
32828280|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
32828281|NCT04392063|Other|Cerebral palsy|Not included
32828282|NCT01903798|Active Comparator|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
32828283|NCT01903798|Experimental|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
32828284|NCT01903798|Active Comparator|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
32828285|NCT01903798|Experimental|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
32828286|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
32828287|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
32828288|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
32828289|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
32828290|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
32828291|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
32828292|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
32828293|NCT04273815|Experimental|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
32828294|NCT04273815|Experimental|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32828295|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
32828296|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
32828297|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
32828298|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
32828299|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
32828300|NCT01734785|Active Comparator|Linagliptin|5 mg once daily
32828301|NCT01734785|Experimental|Empaglifozin + Linagliptin low dose|1 tablet once daily
32828302|NCT01734785|Experimental|Empagliflozin + Linagliptin high dose|1 tablet once daily
32828303|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
32828304|NCT03821805|No Intervention|Control group|Rest for 30 min
32828305|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
32828306|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
32828307|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
32828308|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
32828309|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
32900053|NCT05266742|No Intervention|END free|patient witout of web based education
33102206|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
33102207|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
32828310|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
32828311|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
32828312|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
32828313|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
32828314|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
32828315|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
32828316|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed~Supine MRI will be performed~Participant will receive mammography and ultrasound~Breast Radiologist will take a brief survey.~Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care~Standard of care will be performed"
32828317|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
32828318|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
32828319|NCT03820869|Active Comparator|Control|Children with ASD
32828320|NCT03820869|Experimental|Intervention|Children with ASD
32828321|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
32828322|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
32828323|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
32828324|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
32828325|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
32828326|NCT02670525|Experimental|Relapsed/Refractory leukemia|"Cohort 1: Relapsed/refractory leukemia~Acute lymphoblastic leukemia, first or greater relapse~Acute myeloid leukemia, first or greater relapse~Leukemia refractory to induction chemotherapy~Other recurrent leukemia~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy~After the screening procedures confirms patient eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
32828327|NCT02670525|Experimental|New diagnosis|"Cohort 2: New diagnosis~Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))~New diagnosis infant MLL-rearranged ALL or low hypodiploid (<40 chromosomes) ALL~Rare leukemia- e.g., JMML, leukemia of ambiguous lineage~Secondary leukemia~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant~After the screening procedures confirms eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
32828328|NCT04392297||Patients with CMV infection|
32828329|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
32828330|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
32828331|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
32828332|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
33102208|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
33102209|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
33102210|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
33102211|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
33405288|NCT05203848|Experimental|Dance program intervention|The community dance program (CDP) will be developed to promote older adults' physical and mental well-being through dancing. The contents of the program are developed based on the literature review (Rossberg-Gempton & Poole, 2008). The CDP will be delivered over a period of 8 weeks.
33405289|NCT05203848|Placebo Comparator|Control group|There will be no dance intervention among control group participants.
32828333|NCT02954055|Experimental|Arm B|"Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
32828334|NCT03820635||Calcified|those with evidence of vascular calcification
32828335|NCT03820635||Non-calcified|those with no evidence of vascular calcification
32828336|NCT03313180|Experimental|All patients|
32828337|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828338|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828339|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828340|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828341|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828342|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828343|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828344|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828345|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828346|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828347|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828348|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828349|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828350|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828351|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828352|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828353|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
32828354|NCT02670213||NovoThirteen®|
32828355|NCT03275506|Experimental|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.~In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
32828356|NCT03275506|Active Comparator|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~- In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
32828357|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
32828358|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
32828359|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
32828360|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
32828361|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
32828362|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
32828363|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
32828364|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
32828365|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
32828366|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
32828367|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
32828368|NCT05735860|Experimental|Virtual Reality Exposure Therapy (VRET)|
32828369|NCT05735860|Active Comparator|Progressive Muscle Relaxation (PMR)|
32828370|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
32828371|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
32828372|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
32828373|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
32828374|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
32828375|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
32828376|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
32828377|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
32828378|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
32828379|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
32828380|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
32828381|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
33102212|NCT01282216|Active Comparator|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
33405290|NCT05759208|Experimental|Placebo|OK-101 Placebo Ophthalmic Solution (vehicle): 1 drop BID in each eye (N = ~80)
33102213|NCT01282216|Active Comparator|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
32828382|NCT05735704||Patients with Hematological Malignancies - Discovery stage|"The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, HGL, FL, and MZL transformed to large cell lymphoma), FL, MZL, de novo AML, secondary AML, MDS, For patients, it is expected, after signing the informed consents, that the serial samplings will be performed during the disease follow-up according to the standard clinical practice and/or recommended schedule and disease assessment plan.~Bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure."
32828383|NCT05735704||Patients with Hematological Malignancies - Second stage|"In the second stage, at least 250 patients with MM and 250 patients with NHL and at least 100 patients with each of the remaining blood cancer conditions mentioned above will be tested. It is expected that the majority of these patients will be tested also during the disease follow-up.~For patients, it is expected, after signing the informed consents, that the serial samplings will be performed during the disease follow-up according to the standard clinical practice and/or recommended schedule and disease assessment plan"
32828384|NCT05735704||Patients with Hematological Malignancies - Third stage|The last stage consists in the screening of a larger group of subjects with high risk of blood cancer. This stage will include three populations: up to 1000 follow-up patients from each blood cancer: AML, lymphoma and MM.
32828385|NCT05735704||Elderly patients (>65 years old) at risk of developing MM -Third stage|"up to 600 elderly patients (>65 years old) at risk of developing MM In order to allow a maximum follow-up period for at-risk subjects as part of the study, and to meet the recruitment goals, the screening, and enrollment can begin in the first stage of the trial.~Follow-up patients, at-risk individuals for MM, and at-risk first-degree relatives will donate blood periodically according to the follow up plan."
32828386|NCT05735704||first-degree relatives of patients - Third stage|"Up to 400 first-degree relatives of patients (and in particular siblings). In order to allow a maximum follow-up period for at-risk subjects as part of the study, and to meet the recruitment goals, the screening, and enrollment can begin in the first stage of the trial.~Follow-up patients, at-risk individuals for MM, and at-risk first-degree relatives will donate blood periodically according to the follow up plan."
32828387|NCT05735704||Healthy subjects - Discovery stage|"Healthy subjects that serve as controls are expected to donate blood a single time. Following this donation, their participation will end.~At Tel-Aviv Sourasky Medical Center (TASMC) up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery."
32828388|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test~15 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
32828389|NCT03823677|No Intervention|control group 30|"30 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
32828390|NCT03823677|No Intervention|control group 60|"60 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
32828391|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
32828392|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
32828393|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
32828394|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
32828395|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
32828396|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
32828397|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
32828398|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
32828399|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
32828400|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
32828401|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
32828402|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
32828403|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
32828404|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
32828405|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
32828406|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
32828407|NCT02916771|Experimental|Ixazomib|"Cycles 1-9~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~Cycle 10-24~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Supportive measures consistent with optimal patient care may be given throughout the study"
32828408|NCT05735626|Experimental|Piperine 150μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA (NeuroConn, Germany) with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (150μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
33102214|NCT01282216|Active Comparator|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
32828409|NCT05735626|Experimental|Piperine 1mM+ tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (1 mM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
32828410|NCT05735626|Experimental|Capsaicin 10μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of capsaicin (10 μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or capsaicin + tDCS randomly in the first or second day depending on the randomization."
32828411|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
32828412|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
32828413|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
32828414|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
32828415|NCT04768192||Pediatric patients with acquired brain injury|Subjects with a acquired brain injury occurred in the last 10 months prior the beginning of the treatment
32828416|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
32828417|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
32828418|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
32828419|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
32828420|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
32828421|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
32828422|NCT04758585|Active Comparator|Study Group|
32828423|NCT04758585|No Intervention|Control Group|
32828424|NCT02987140|Experimental|PD+FoG|PD patients with FoG
32828425|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
33405291|NCT05759208|Experimental|Low Dose OK-101|0.05% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = ~80)
32828426|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
32828427|NCT04273659|Experimental|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
32828428|NCT04273659|Experimental|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
32828429|NCT05735470|Experimental|Antibacterial bone traction needle|The bone traction needle with an antibacterial coating.
32828430|NCT05735470|No Intervention|bone traction needle|The bone traction needle without an antibacterial coating.
32828431|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
32828432|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
32828433|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
32828434|NCT01760447|Experimental|Sitagliptin/Metformin|Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
33405292|NCT05759208|Experimental|High-Dose OK-101|0.1% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = ~80)
33405293|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
32828435|NCT01760447|Placebo Comparator|Metformin|Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
32828436|NCT01760447|Experimental|Sitagliptin/Metformin XR|Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
33102215|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
32828437|NCT01760447|Placebo Comparator|Metformin XR|Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
32828438|NCT01952470|Experimental|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
32828439|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
32828440|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
32828441|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
32828442|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
32828443|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
32828444|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
32828445|NCT03825315|Experimental|DAXI for Injection: LOW Dose|LOW Dose Group
32828446|NCT03825315|Experimental|DAXI for Injection: HIGH Dose|HIGH Dose Group
32828447|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
32828448|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
32828449|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
32828450|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
32828451|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
32828452|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
32828453|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
33102216|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
33102217|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
33102218|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
33102219|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
33102220|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
32828454|NCT05735392|Other|Trastuzumab emtansine as per SmPC for liquid biopsy and tissue collection|"Patients will receive trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 21 days, as perSummary of Product Characteristics (SmPC).~Peripheral blood samples will be taken by venipuncture prior to initiation of study therapy (T0), and at designated time-points after the first (T1) the second (T2), the third(T3)and after the sixth(T6), the ninth(T9), until the 12thcycle of T-DM1(see Fig.1) on-treatment and finally at progression."
32828455|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
32828456|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
32828457|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
33102221|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
32828458|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
33102222|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
32828459|NCT05735314|Experimental|Step 1 (3 clinics) - 6 months control followed by 24 months of intervention|
32828460|NCT05735314|Experimental|Step 2 (4 clinics) - 12 months control followed by 18 months of intervention|
32828461|NCT05735314|Experimental|Step 3 (4 clinics) - 18 months control followed by 12 months of intervention|
32828462|NCT05735314|Experimental|Step 4 (4 clinics) - 24 months control followed by 6 months of intervention|
32828463|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
32828464|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
32828465|NCT05735236|No Intervention|Control|Participants undergo standard post-operative physical therapy as prescribed by their surgeon.
32828466|NCT05735236|Active Comparator|BFR Cuff|Patients undergo standard post-operative physical therapy as prescribed by their surgeon with the addition of a Blood Flow Restriction (BFR) cuff that is used during their exercises.
32828467|NCT03825549|No Intervention|Control|No intervention
32828468|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
32828469|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
32828470|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
32828471|NCT01450215|Experimental|Revlimid|
32828472|NCT01450215|No Intervention|Revlimid and dexamethasone|
32828473|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
32828474|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
32828475|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
32828476|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
32828477|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
32828478|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
32828479|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
32828480|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
32828481|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
32828482|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
32828483|NCT04391829|Experimental|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
32828484|NCT01954264|Other|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
32828485|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
32828486|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
32828487|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
32828488|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
32828489|NCT01450527||Patient fulfilling the criteria of ARDS|
32828490|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
32828491|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
32828492|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
32828493|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
32828494|NCT01917214||Non-Interventional Study|
32828495|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
32828496|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
32828497|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
32828498|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32828499|NCT04758429||Development or Training Cohort|will provide the data to be used for algorithm development and training.
32828500|NCT04758429||Test or Validation Cohort|will provide data to be used for algorithm validation.
32828501|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
32828502|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
32828503|NCT01450839|Experimental|E2020 5 mg tablet and tape|
32828504|NCT01450839|Placebo Comparator|2|
32828505|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
32828506|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
32828507|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
32828508|NCT01450917||Group C|Non brachial plexus injured patients
32828509|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
32828510|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
32828511|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
32828512|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
32828513|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:~pilocarpine - 0.5%~brimonidine - 0.2%~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
32828514|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
32828515|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
32828516|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
32828517|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
32828518|NCT04273971|Experimental|Plyometric exercise|
33405294|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
33405295|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
33405296|NCT04334304|Active Comparator|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
32828522|NCT04758663|Experimental|Declarative memory|Napping v. wake effect on declarative memory in habitual and non-habitual nappers.
32828523|NCT04758663|Experimental|Overnight Physiology|Napping v. wake effect on overnight physiology in habitual and non-habitual nappers.
33405297|NCT04334304|Experimental|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
32828524|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
32828525|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
32828526|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
32828527|NCT01451151|Experimental|Treated|
32828528|NCT01732835|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
32828529|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
32828530|NCT05734924|Active Comparator|study group|The patient in this group will received low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT for 30 minutes /session, treatment will be conducted for 3times/week for five weeks combined with cervical stabilization exercise protocol
32828531|NCT05734924|Sham Comparator|control group|The patient in this group will sham magnetic therapy in addition to, cervical stabilization exercise protocol; treatment will conduct for 3 times/ week for five weeks.
32828532|NCT03824613||Endometrial cancer patients|
32828533|NCT03824613||Control group|Patients without cancer
32828534|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
32828535|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
32900111|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
32828536|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
32828537|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
32828538|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:~Coloplast Test product 1 and thereafter Coloplast Test product 2~Coloplast Test product 2 and thereafter Coloplast Test product 1"
32828539|NCT01451619|Experimental|Laropiprant|
32828540|NCT01451619|Placebo Comparator|Placebo|
32828541|NCT03054519|Active Comparator|Metformin|Metformin daily
32828542|NCT03054519|Placebo Comparator|Placebo|Placebo daily for six months.
32828543|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
32828544|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
32828545|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
32828546|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
32828547|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
32828548|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
32828549|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
32828550|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
32828551|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
32828552|NCT01957930|Experimental|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
32828553|NCT01957930|Active Comparator|Standard treatment|Mixed Insulin (2-3 times a day)
32828554|NCT01957930|No Intervention|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
32828555|NCT01759511|Experimental|Simtuzumab|Participants will receive simtuzumab.
32828556|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
32828557|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
32828558|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
32828559|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
32828560|NCT04414007|Experimental|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
32828561|NCT04414007|Active Comparator|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
33318001|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
33318002|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
33318003|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
32828562|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
32828563|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
32828564|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
32828565|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
32828566|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
32828567|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
32828568|NCT05734846|Active Comparator|Silicone Hydrogel Multifocal Control Lenses|Participant will wear Control Lenses for one week, then crossover to Experimental Lenses for one week.
32828569|NCT05734846|Experimental|Silicone Hydrogel Multifocal Test Lenses|Participant will wear Test Lenses for one week, then crossover to Control Lenses for one week.
32828570|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
32828571|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
32828572|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
32828573|NCT05734768||Preterm newborns and their parents|Thirty premature children born between 32 and 36+6 weeks of gestation, and their parents.
32828574|NCT05734768||term newborns and their parents|Thirty children, born at more than 37 weeks (≥37+0), and their parents
32828575|NCT01452399|Experimental|Shave Margins|
32828576|NCT01452399|Active Comparator|No shave margins|
32828577|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
32828578|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
32828579|NCT01758731|Experimental|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
32828580|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
32828581|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
32828582|NCT04168775|Other|Home PIFR monitoring|Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting
32828583|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
32828584|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
32828585|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
32828586|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
32828587|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
32828588|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
32828589|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
32828590|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
32828591|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
32828592|NCT01452711|Experimental|TAK-438 20 mg QD|
32828593|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
32828594|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
32828595|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
32828596|NCT01757405|Experimental|≤ 3 doses of 90 µg/kg rFVIIa BI|
32828597|NCT01757405|Experimental|One dose of 270 µg/kg rFVIIa BI|
32828598|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
32900112|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
32828599|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
32828600|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
32828601|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
32828602|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
32828603|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
32828604|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
32828605|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
32828606|NCT04273503|Experimental|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
32828607|NCT02947581|Experimental|Interventions|Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
33102223|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
32828608|NCT02947581|Active Comparator|Comparison regime|Albendazole and praziquantel placebo. Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
32828609|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
32828610|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
32828611|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
32828612|NCT05608083|Experimental|HEARTS NOW|Participants in the HEARTS NOW group participants will participate in a weekly six-session online HEARTS class via Zoom about relationships.
32828613|NCT05608083|Active Comparator|HEARTS LATER|Participants in the HEARTS LATER group will participate in a six-week online support group via Zoom about relationships. Participants in this arm will have the option of taking the HEARTS class after the study has ended.
32828614|NCT05606757|Experimental|Cohort 1, BOTOX Dose A|Participants will receive BOTOX Dose A
32828615|NCT05606757|Experimental|Cohort 1, BOTOX Dose B|Participants will receive BOTOX Dose B.
32828616|NCT05606757|Placebo Comparator|Cohort 1, Placebo|Participants will receive placebo for BOTOX.
32828617|NCT05606757|Experimental|Cohort 2, BOTOX Dose A|Participants will receive BOTOX Dose A
32828618|NCT05606757|Experimental|Cohort 2, BOTOX Dose B|Participants will receive BOTOX Dose B
32828619|NCT05606757|Experimental|Cohort 2, BOTOX Dose C|Participants will receive BOTOX Dose C
32828620|NCT05606757|Placebo Comparator|Cohort 2, Placebo|Participants will receive placebo for BOTOX
32828621|NCT05606757|Experimental|Cohort 3, BOTOX Dose A|Participants will receive BOTOX Dose A
32828622|NCT05606757|Experimental|Cohort 3, BOTOX Dose B|Participants will receive BOTOX Dose B.
32828623|NCT05606757|Experimental|Cohort 3, BOTOX Dose C|Participants will receive BOTOX Dose C.
32828624|NCT05606757|Experimental|Cohort 3, Placebo|Participants will receive placebo for BOTOX.
32828625|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
32828626|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
32828627|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
32828628|NCT03823599|Active Comparator|control group|Alcohol brief intervention
33102224|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
33102225|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
32828629|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
32828630|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
32828631|NCT05606679||Patients undergoing ART with oocyte donation|Healthy patients with no history of RIF and RM which have undergone or are undergoing ART with oocyte donation and SET.
32828632|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
32828633|NCT04273893|Experimental|SBRT Additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
32828634|NCT04273893|Active Comparator|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
32828635|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
32828636|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
32828637|NCT05608473|Experimental|Exercise Group|A 10-minute video consisted of 14 exercises was uploaded to the computers of the participants in the exercise group. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
32828638|NCT05608473|No Intervention|Control Group|The control group was given one session of training on postural correction.
32828639|NCT04391751|Experimental|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
32828640|NCT04391751|Active Comparator|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
32828641|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
32828642|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
32828643|NCT05606367|Experimental|Non-slip Balloon Catheter|Subjects in experimental arm will be treated with the Non-slip Balloon Catheter manufactured by Shanghai Microport Rhythm Co. Ltd.
32828644|NCT05606367|Active Comparator|NSE Coronary Dilatation Catheter|Subjects in control arm will be treated with Lacrosse® NSE manufactured by Goodman Medical Co. Ltd.
32828645|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
32828646|NCT04391361|Experimental|trial group|
32828647|NCT04391361|Placebo Comparator|control group|
32828648|NCT05604807|Experimental|Dementia course with VR|Dementia course with virtual reality consists of dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
32828649|NCT05604807|Active Comparator|Dementia course with no VR|Dementia course with no virtual reality consists of intergenerational learning, world café teaching method and community practice with no dementia virtual reality activity.
32828650|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
32828651|NCT05603325||Patient participants|Current inpatients within the acute mental health ward in which the study is taking place.
32828652|NCT05603325||Staff participants|Staff working within the acute mental health ward in which the study is taking place including nursing, mental, occupational therapy, estate and management team members
32828653|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
32828654|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
32828655|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
32828656|NCT04272957|Experimental|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
32828657|NCT04273191|Experimental|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
32828658|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
32828659|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
32828660|NCT04391985|Active Comparator|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
32828661|NCT04391985|Active Comparator|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
32828662|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828663|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828664|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828665|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828666|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
32828667|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828668|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828669|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
32828670|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
32828671|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
32828672|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
32828673|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
32828674|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
32828675|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
32828676|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
32828677|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
32828678|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
32828679|NCT01455597|Experimental|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream 3 times a week for up to 40 weeks.
32828680|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
32828681|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
32828682|NCT01454349|Experimental|PRX302|
32828683|NCT01454349|Placebo Comparator|Inactive substance|
32828684|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
32828685|NCT01454427||healthy volunteers|
32828686|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
32828687|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
32828688|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
32828689|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
32828690|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
33318004|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
32828691|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
32828692|NCT04847193|Experimental|Placebo|Participants receive a study drink supplemented with a placebo over a time period of 5 days.
32828693|NCT04847193|Experimental|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
32828694|NCT04847193|Experimental|Iso-alpha acids|Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
32828695|NCT04847193|Experimental|Xanthohumol/Iso-alpha acids|Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
32828696|NCT04844931|Experimental|RIC + PostC in addition to standard treatment|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.
32828697|NCT04844931|Active Comparator|Standard treatment|
32828698|NCT04848519|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for propranolol hydrochloride and every 3 or 6 weeks for pembrolizumab for up to 2 years in the absence of disease progression or unacceptable toxicity.
32828699|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
33318005|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
32828700|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
32828701|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
32828702|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
32828703|NCT04273035|Active Comparator|Midazolam Group|"Midazolam(Buccolam 5mg/ml)~0.5mg/kg oral, max 12mg~one time~given 30 min prior to going to holding"
32828704|NCT04273035|Active Comparator|IPAD group|"No premedication~IPAD when arriving at the holding~any games, movies, clips, puzzles"
32828705|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
32828706|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
32828707|NCT01454817|Other|Patients with ICDs|
32828708|NCT01454817|Other|Caregivers of Patients with ICDs|
32828709|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
32828710|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
32828711|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
32828712|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
32828713|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
32828714|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
32828715|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
32828716|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
32828717|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 1 to 60 months
32828718|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 1 to 60 months
33102226|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
33102227|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
32828719|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose A|Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
32828720|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose B|Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
32828721|NCT03859869|Experimental|Non-Resected Participants Receiving Pancrelipase Dose B|Non-resected participants are administered with Pancrelipase dose B.
33102228|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
33102229|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
33102230|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32828722|NCT04848285|Active Comparator|Standard care group|Standard of care (SC) mobility protocol performed by the Stroke Unit nursing and physiotherapy staff. The SC consists of one or two sessions per days of out-of-bed sitting and standing, adapted to patient´s tolerability, and one session of physiotherapy per day. Mobilization will be schedule to start from 24 hours from symptoms onset according to the local Stroke Unit protocol.
32828723|NCT04848285|Experimental|Intensive mobilization group|The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
32828724|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
32828725|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
32828726|NCT04841967|Experimental|TELL Tool Group|Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.
32828727|NCT04841967|Active Comparator|eBook Attention-Control|Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
33102231|NCT00623857|Active Comparator|1|Zinc
33102232|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
33102233|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
33102234|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
33102235|NCT05466435|Experimental|Heavy Slow Resistance group|Heavy slow resistance exercise will be given along with traditional physical therapy program
33102236|NCT05466435|Placebo Comparator|Control group|Traditional physical therapy program will be given to the control group
33102237|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
33318006|NCT05153668|Experimental|Adjuvant Everolimus After Surgical Dilation|Individuals will take low dose everolimus for 6 weeks after dilation.
33318007|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
33318008|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
32828728|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
32828729|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
32828730|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
32828731|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
32828732|NCT01455207|Other|alcoholic patients|
32828733|NCT01455207|Other|korsakoff patients|
32828734|NCT01455207|Other|healthy controls|
33102238|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
33102239|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
33102240|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
33102241|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
33102242|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
33318009|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks~Symptomatic treatment dose: Three times a day for six weeks"
33318010|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
33405298|NCT04334304|Experimental|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
32828735|NCT02866149|Other|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.~Timing of blood sampling:~inclusion~after #8 weeks on therapy~at progression or 6 months from inclusion for patient without progressive disease~if toxicity grade 3 or 4, or grade 2 until 1 month."
32828736|NCT02866149|Other|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).~Timing of blood sampling:~inclusion~after 1 cycle of therapy (weeks 3-4)~up to 2 other samples, timepoints decided by the investigator"
32828737|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
32828738|NCT02866149|Other|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
32828739|NCT02866149|Other|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
32828740|NCT02866149|Other|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib~Timing of blood sampling:~Inclusion day (2 samples)~after #2 weeks of therapy~after #4 weeks of therapy~at progression."
32828741|NCT02866149|Other|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
32828742|NCT02866149|Other|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
32828743|NCT02866149|Other|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.~Blood sampling at 4 timepoints."
32828744|NCT02866149|Other|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.~Timing of blood sampling:~Inclusion~after #4 weeks of therapy~at the first tumoral evaluation (month 3 or 4)~at progression."
32828745|NCT02866149|Other|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
32828746|NCT02866149|Other|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.~Timing of blood sampling:~Inclusion~after #3-5 weeks of therapy~at the first tumoral evaluation (month 2 or 3)~at progression."
32828747|NCT02866149|Other|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).~Timing of blood sampling:~J1C1~J2C1~J1C2~J1C5 (first tumoral evaluation)."
32828748|NCT02866149|Other|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.~One tumour sampling.~Timing of blood sampling:~before treatment~at W8 of treatment (after radiological examination)~at W12 of treatment~at progression or 18 months after the beginning of treatment"
32828749|NCT02866149|Other|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.~Timing of blood sampling:~At inclusion~After biopsy post inclusion (or in 15 days after)~after 1 or 2 months of treatment~at progression or 18 months after inclusion"
32828750|NCT02866149|Other|Cohort 16 - Mum immunothérapie|"This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.~Timing of blood sampling :~at inclusion~at cycle 2 or 3 of treatment~at the first tumoral evaluation (C5D1)~at progression"
32828751|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
32828752|NCT04846959||Pregnant Women Exposed to Risankizumab|Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis and exposed to risankizumab at any time during pregnancy.
32828753|NCT04846959||Pregnant Women Not Exposed to Risankizumab|Pregnant women of any age in the US who are diagnosed with plaque psoriasis and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.
32828754|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
32828755|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
32828756|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
32828757|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
32828758|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
32828759|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
32828760|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
32828761|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
32900113|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
32828762|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
32828763|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
32828764|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
32828765|NCT04840641|No Intervention|Baseline|The investigators measure the baseline of flucloxacillin and cocktaildrugs.
32828766|NCT04840641|Experimental|Flucloxacillin treatment|The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
32828767|NCT01455909|Experimental|ITCA 650 60 mcg/day|
32828768|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
32828769|NCT04844619|Experimental|KDR2-2 group|The patients with NVG will receive 4.0 mg/ml or 16.0mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
32828770|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
32828771|NCT01757171|Experimental|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
32828772|NCT01757171|Experimental|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
32828773|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, standard dose|Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
32828774|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, high dose|Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
32828775|NCT04847349|Placebo Comparator|Placebo for live microbial (probiotic) consortium|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.
32828776|NCT01456065|Other|Vaccine weekly administration|
32828777|NCT01456065|Other|Vaccine biweekly administration|
32828778|NCT04842123|Other|Atrial fibrillation (AF)|Patients with a known history of AF who are in AF at the time of study screening.
32828779|NCT04842123|Other|Normal Sinus Rhythm (SR)|Patients with no known diagnosis of AF or other arrhythmia
32828780|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
32828781|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
32828782|NCT04843137||Individuals with cervical spinal cord injury|Cohort of individuals who have experiences a chronic spinal cord injury at the cervical level (specifically C5-C7).
32828783|NCT04847583|Experimental|Telacebec (Q203) with COVID-19 standard of care (SoC)|
32828784|NCT04847583|Active Comparator|COVID-19 Standard of care (SoC)|
32828785|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
32828786|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32828787|NCT04847817||Index cases|Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
32828788|NCT04847817||Households cases|Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
33102243|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
32828789|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
32828790|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
32828791|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
32828792|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
32828793|NCT02931513||PBC patients|Patients with primary biliary cholangitis
32828794|NCT04847505|Experimental|Neuroendocrine cancer patients|"All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician.~Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed."
33102244|NCT01280812|Active Comparator|Pedometer|Non-intervention group
32828795|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
32828796|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
32828797|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 1|
32828798|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 2|
32828799|NCT04846491|Active Comparator|Nucleot(s)ide-treated patients-Control Group|
32828800|NCT04846491|Other|Treatment Naive Group|
32828801|NCT01756079|Experimental|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
32828802|NCT04848675|Experimental|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
32828803|NCT04848675|Active Comparator|Brisk walking|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
32828804|NCT05587179|Experimental|Lateral side-lying recovery position with extended arm|The lateral side-lying recovery position with extended arm is directly based on the revised 2021 ERC guidelines recommending to extend the dependent arm and placing it next to the creased upper lying arm, which supports the head.
32828805|NCT05587179|Active Comparator|Lateral side-lying recovery position with bent arms|In the lateral side-lying recovery position with bent arms, the elbow of the dependent arm will now be bent with palm up and the far knee still flexed.
32828806|NCT04272645|Experimental|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
32828807|NCT04272645|Experimental|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
32828808|NCT04272645|Experimental|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
32828809|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
33102245|NCT02932020|Experimental|Group A|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
33102246|NCT02932020|Other|Group B|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
33102247|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
33102248|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
33102249|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
33102250|NCT05466396||Smokers with Pre-COPD|Smoking history ≥ 10 pack-years 0.7≤ FEV1/FVC<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
33102251|NCT05466396||Smokers with Mild-COPD|Smoking history ≥ 10 pack-years FEV1/FVC<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
32828810|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
32828811|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
32828812|NCT04846569|Experimental|Transition Theory-based Intervention|Participants in the intervention arm will receive the Transition Theory-based intervention consisting of 4 sessions with a community health worker (2 during pregnancy, 2 postpartum) to support their transition from pregnancy to postpartum.
32828813|NCT04846569|Active Comparator|Enhanced Standard of Care Control|Participants in the control arm will receive the standard of care plus one session with a community health worker.
32828814|NCT04390815|Experimental|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.~The patients in this arm will receive conventional therapy."
32828815|NCT04390815|Placebo Comparator|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
32828816|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
32828817|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
32828818|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
32828819|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
32828820|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
32828821|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
32828822|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
32828823|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
32828824|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
32828825|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
32828826|NCT04843683|Experimental|Stereotactic ablative radiotherapy (SBRT) Arm|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
32828827|NCT04843683|No Intervention|Observational Arm|Potential participants who are eligible to be included in the study, but who choose not to have the SBRT procedure, can still receive standard medical treatment alone and be followed up with study visits and questionnaires.
32828828|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
32828829|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
32828830|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
32828831|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
32828832|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
32828833|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
32828834|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
32828835|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
32828836|NCT01890525||PROMISE study patients|
32828837|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
32828838|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
32828839|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
32828840|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
32828841|NCT01890603|Experimental|Care Coordination Arm|
32828842|NCT01890603|Active Comparator|Quality Measure Improvement|
32828843|NCT04845321|Experimental|VNRX-9945|Oral dosing
32828844|NCT04845321|Placebo Comparator|Placebo|Oral dosing
32828845|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
32828846|NCT01457001|Experimental|25-OH-D vitamin|
32828847|NCT01457001|No Intervention|control|
33102252|NCT05466396||Non-Smokers with Pre-COPD|Smoking history < 10 pack-years or never-smokers 0.7≤ FEV1/FVC<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
33102253|NCT05466396||Non-Smokers with Mild-COPD|Smoking history < 10 pack-years or never-smokers FEV1/FVC<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
32828848|NCT02846883|Active Comparator|Intravenous infusion of 1 million allogenic MSC's/Kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
32828849|NCT02846883|Active Comparator|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
32828850|NCT02846883|Placebo Comparator|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
32828851|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
32828852|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
32828853|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
32828854|NCT02845947|Experimental|Music Therapy|Music Therapy to be provided for pediatric patients undergoing extubation readiness trial
32828855|NCT02845947|No Intervention|Control|Patients undergoing standard extubation readiness trial
32828856|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
32828857|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
32828858|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
32828859|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
32828860|NCT05026827|Experimental|Iyengar Yoga|Participants will engage in 10 weekly IY classes
32828861|NCT05026827|Active Comparator|Socialization Control|Participants will engage in 10 weekly socialization control group sessions
32828862|NCT05026827|No Intervention|Healthy Comparison Group|A group of participants will also be followed for 10 weeks
32828863|NCT05026749|Placebo Comparator|Control Group|
32828864|NCT05026749|Active Comparator|AZM 20mg/kg Treatment Group|
32828865|NCT05022459||Emicizumab Prophylaxis|This group will include patients on standard of care Emicizumab prophylaxis for Hemophilia A
32828866|NCT05022459||FVIII Prophylaxis|This group will include patients on standard of care FVIII prophylaxis for Hemophilia A
32828867|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
32828868|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
32828869|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
32828870|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
32828871|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
32828872|NCT01457547|Experimental|DTPa 1 Group|
32828873|NCT01457547|Active Comparator|DTPa 2 Group|
32828874|NCT01457625||liver fat contents|
32828875|NCT01457859|Active Comparator|Conventional sutures|
32828876|NCT01457859|Experimental|Antiseptic sutures|
32828877|NCT01890993||Liraglutide|
32828878|NCT01890993||DPP-4|
32828879|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
32828880|NCT05020353|Experimental|Investigational Device|Observed self-test of oral fluid with the OraQuick HIV Self-Test
32828881|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
32828882|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
32828883|NCT05023629|Other|Patients with a significant coronary artery lesion|Balloon inflation for 90s
32828884|NCT05026671|Active Comparator|Group DL|The control group consists of intubating the trachea with an endotracheal tube alone (without stylet).
32828885|NCT05026671|Experimental|Group DLS|The Experimental group consists of intubating the trachea with an endotracheal tube + stylet.
32828886|NCT05026671|Experimental|Group VL|The Experimental consists of intubating the trachea with an endotracheal tube + Video-laryngoscope
32828887|NCT05026671|Experimental|Group VLS|The Experimental consists of intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
32828888|NCT05021913|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 23
32828889|NCT05021913|Active Comparator|Comparator product|Juvéderm Volift™ with lidocaine (Allergan, Inc)
32828890|NCT05028699|Experimental|Snack|32 g of a common bean baked snack per day for 28 days.
32828891|NCT05028699|No Intervention|Control|
32828892|NCT05026047|Experimental|patients consulting in an infectious disease department|no comparator
32828893|NCT04346355|Experimental|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
32828894|NCT04346355|Other|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
32828895|NCT05025423|Experimental|venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma|Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.
32828896|NCT04272255|Active Comparator|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
32828897|NCT04272255|Placebo Comparator|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
32828898|NCT04272255|Experimental|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
32828899|NCT04271787||strongly dissatisfied|
32828900|NCT04271787||dissatisfied|
32828901|NCT04271787||neutral|
32828902|NCT04271787||satisfied|
32828903|NCT04271787||strongly satisfied|
32828904|NCT04271787||don't know|
32828905|NCT01458015|Active Comparator|oxycodone|
32828906|NCT01458015|Active Comparator|tapentadol|
32828907|NCT05023707|Experimental|CAR-T infusion|FLT3 positive relapsed or refractory acute myeloid leukemia
32828908|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
32828909|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
32828910|NCT05022927|Experimental|Dose escalation part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
32828911|NCT05022927|Experimental|Expansion part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent To evaluate the anti-tumor effect.
32828912|NCT05022927|Experimental|Concomitant use part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab and to determine the MTD.
32828913|NCT05022927|Experimental|Biomarker part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to evaluate the biomarkers.
32828914|NCT05026125|Active Comparator|Group control|3 μg/kg (Ideal Body Weight) of Remifentanil
32828915|NCT05026125|Experimental|Group Active|3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil
32828916|NCT02843763|Other|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).~Intervention : blood sample"
32828917|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.~Intervention : blood sample"
32828918|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
32828919|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
32828920|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
32828921|NCT02843763|Other|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.~Intervention : blood sample"
32828922|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
32828923|NCT01891071|No Intervention|Standard care|Standard care
32828924|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
32828925|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
32828926|NCT02890641||Children undergoing epilepsy surgery at the Rothschild Foundation, Paris.|Sequencing of paired blood-brain DNA samples
32828927|NCT04273113|Experimental|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
32828928|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
32828929|NCT01458483|Experimental|Baroreceptor Stimulation|
32828930|NCT04390425|No Intervention|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
32828931|NCT04390425|Experimental|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
32828932|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
32828933|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
32828934|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
32828935|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
32828936|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
32828937|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
32828938|NCT01891539||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
32828939|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
32828940|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
32828941|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
32828942|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
32828943|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
32828944|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
32828945|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
32828946|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
32828947|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
32828948|NCT04272567|Sham Comparator|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
32828949|NCT04272567|Experimental|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
32828950|NCT04272567|Experimental|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
32828951|NCT04272567|Experimental|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
32828952|NCT04272567|Experimental|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
32828953|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
32828954|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
32828955|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
32828956|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
32828957|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.~The research MRI sequences will also be tested during the add-on research MRI scan."
32828958|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
32828959|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
32828960|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
32828961|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
32828962|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
32828963|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
32828964|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
32828965|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
32828966|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
32828967|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
32828968|NCT02356653|Experimental|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
32828969|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
32828970|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
32828971|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
32828972|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
32828973|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
32828974|NCT04390269||susceptible (non infected|This group either exposed and not infected .
32828975|NCT04390269||control group|normal control subject
32828976|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
32828977|NCT04390035|No Intervention|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
32828978|NCT04390035|Experimental|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
32828979|NCT05022693|Experimental|BIO89-100 30 mg, Open Lable, Single Dose|
32828980|NCT05029089|Experimental|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
32828981|NCT05029089|Active Comparator|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
32900114|NCT01392859|Experimental|Initial Treatment: Levocetirizine(LCT)|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
32828982|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
32828983|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
32828984|NCT02498613|Experimental|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
32828985|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
32828986|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
32828987|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
32828988|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
32828989|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
32828990|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
32828991|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
32828992|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
32828993|NCT05020743||Patients with ALSP|
32828994|NCT05020743||Asymptomatic carriers of the CSF1R gene mutation|
32828995|NCT04391127|Experimental|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
32828996|NCT04391127|Experimental|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.
32828997|NCT05024253|Experimental|patient is receiving Tranexemic acid (TXA )|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare TXA injection at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion at a dose of 5mg/kg/hour will be given until wound closure."
32828998|NCT05024253|Placebo Comparator|standard treatment (saline)|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare 50 ml of 0.9% saline or TXA at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion of saline will be given until wound closure."
32828999|NCT04390893|Experimental|ultrasound positioning group|
32829000|NCT04390893|Active Comparator|leak test positioning group|
32829001|NCT05026593|Active Comparator|Sintilimab+EP|During each 21-day cycle, participants receive Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
32829002|NCT05026593|Experimental|IBI110+Sintilimab+EP|During each 21-day cycle, participants receive IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
32829003|NCT01459731||Age 18-29|
32829004|NCT01459731||Age 30-39|
32829005|NCT01459731||Age 40-49|
32829006|NCT01459731||Age 50-59|
32829007|NCT01459731||Age 60-69|
32829008|NCT01459731||Age 70+|
33102254|NCT05466396||Healthy Controls|Healthy volunteers without smoking history FEV1/FVC ≥ 0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
32829009|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
32829010|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
32829011|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
32829012|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
32829013|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
32829014|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
32829015|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
32829016|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
32829017|NCT01459887|Experimental|combination group|
32829018|NCT01459887|Experimental|sequential group|
32829019|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
32829020|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
32829021|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
32829022|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
32829023|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
32829024|NCT01890135|Placebo Comparator|placebo|matched placebo
32829025|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
32829026|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
32829027|NCT05587023|Experimental|Test group|the test group was injected with 0.5% ropivacaine 6ml.
32829028|NCT05587023|Placebo Comparator|Control group|The control group was injected with 6ml normal saline
32829029|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
32829030|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
32829031|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
32829032|NCT02682147|Experimental|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
32829033|NCT02682147|Experimental|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
32829034|NCT02682147|Experimental|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
32829035|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
32829036|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
32829037|NCT02678091|Experimental|Patients|Patients with an orbital mass
32829038|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
32829039|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
32829040|NCT01892943||Patients with LHON|
32829041|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
32829042|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
32829043|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
32829044|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
32829045|NCT02675829|Experimental|Cohort 1: Lung cancers, HER2 mutant|
32829046|NCT02675829|Experimental|Cohort 2: Lung cancers, HER2 amplified|
32829047|NCT02675829|Experimental|Cohort 3: Colorectal cancers|
32829048|NCT02675829|Experimental|Cohort 4: Endometrial cancers|
32829049|NCT02675829|Experimental|Cohort 5: Salivary gland cancers|
32829050|NCT02675829|Experimental|Cohort 6: Other solid cancers|
32829051|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
32829052|NCT01755767|Experimental|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
32829053|NCT01755767|Experimental|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
32829054|NCT01755767|Placebo Comparator|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
32829055|NCT01755767|Placebo Comparator|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
32829056|NCT01893021||Postpartum Malawian women|
32829057|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
32829058|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
32829059|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
32829060|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
32829061|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
32829062|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
32829063|NCT05586633|Active Comparator|deep paravertebral- periforaminal ozone injection|
32829064|NCT05586633|Active Comparator|transforaminal steroid injeciton|
32829065|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
32829066|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
32829067|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
32829068|NCT02327403|Experimental|Proteinuric Kidney Transplant Recipients|Belatacept conversion
32829069|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
32829070|NCT01893177|Experimental|Elderly subjects aged over 60 years|
32829071|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
32829072|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
32829073|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
32829074|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
32829075|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
32829076|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
32829077|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
32829078|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
32829079|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
32829080|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
32829081|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
32829082|NCT02655393|Experimental|Mitopure 250 mg single dose|single dose of Mitopure soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829083|NCT02655393|Experimental|Mitopure 500 mg single dose|single dose of Mitopure soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829084|NCT02655393|Experimental|Mitopure 1000 mg single dose|single dose of Mitopure soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829085|NCT02655393|Experimental|Mitopure 2000 mg single dose|single dose of Mitopure soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829086|NCT02655393|Experimental|Mitopure 500 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829087|NCT02655393|Experimental|Mitopure 1000 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
32829088|NCT02655393|Experimental|Mitopure 250 mg multiple dose|Repeated 28 day dosing of Mitopure soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)
32829089|NCT02655393|Experimental|Mitopure 500 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)
32829090|NCT02655393|Experimental|Mitopure 1000 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)
32829091|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
32829092|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
32829093|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
32829094|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
32829095|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
32829096|NCT05740150|Experimental|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|
32829097|NCT05740150|Active Comparator|Heparin lock (heparin 100 IU/mL)|
32829098|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
32829099|NCT02359383|No Intervention|Control grup|Conventional medical treatment
32829100|NCT05734612|Experimental|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
32829101|NCT05734612|Placebo Comparator|Placebo|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
32829102|NCT01893255||Cohort|
32829103|NCT02349867|Experimental|Treatment (chemotherapy, chemoradiation)|Participants receive gemcitabine IV infusion over 30 minutes (200 mg/m2 weekly) x 6, concurrent administration of oral sorafenib and oral vorinostat (both per dose-escalation schema), and concurrent RT( 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy) administered at 1.8-Gy fractions to a total dose of 50.4 Gy over 5 ½ weeks (28 daily fractions).
32829104|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
32829105|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
32829106|NCT01730339|Active Comparator|Group 1|
32829107|NCT01730339|Active Comparator|Group 2|
32829108|NCT02309151|Experimental|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
32829109|NCT02309151|No Intervention|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
32829110|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
32829111|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
32829112|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
32829113|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
32829114|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
32829115|NCT05734534|Experimental|BFR-ST and BFR-HIT|Participants will be allocated to a BFR intervention including resistance training and high-intensity intervals performed on a bicycle ergometer, both performed with BFR.
32829116|NCT05734534|Active Comparator|HL-ST and HIT|Participants will be allocated to heavy load resistance training and high-intensity intervals performed on a bicycle ergometer, both performed without BFR
32829117|NCT05734534|Experimental|BFR-P|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR.
32829118|NCT05734534|Experimental|BFR-NMES|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR with neuromuscular electrical stimulation (BFR-NMES) twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR-NMES.
32829119|NCT05734534|Active Comparator|Control group|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will allocated to usual care, consisting of daily physiotherapy sessions.
32829120|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
32829121|NCT05740072|Experimental|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
32829122|NCT05740072|Active Comparator|No drying before wrapping|Immediately after birth, the infant will be wrapped in a plastic bag without drying
32829123|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
33102255|NCT05466279|Experimental|Remazolam general anesthesia group (R group)|
32829124|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
32829125|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
32829126|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
32829127|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
32829128|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
32829129|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
32829130|NCT02615691|Experimental|Previously untreated patients (PUPs)|"Part A (Main Study): Participants age <3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age <3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs.~Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery >=30-60% FVIII levels for dental or other invasive surgery.~Part B (Immune tolerance induction [ITI]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months."
32829131|NCT01754753|Active Comparator|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
32829132|NCT01754753|No Intervention|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
32829133|NCT04758273|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
32829134|NCT04758273|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
32829135|NCT04758273|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
32829136|NCT04758273|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32829137|NCT04758273|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32829138|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
32829139|NCT04758273|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32829140|NCT04758273|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32829141|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
32829142|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
32829143|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
32829144|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
32829145|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
32829146|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
32900115|NCT01392859|Experimental|Initial Treatment: Placebo|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
32900116|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
32900117|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
32829147|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
33318011|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
33405299|NCT04334304|Experimental|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
32829148|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
32829149|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
32829150|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
32829151|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
32829152|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
32829153|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
32829154|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
32829155|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
32829156|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
32829157|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
32829158|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
32829159|NCT05739916|Experimental|Sequence A(Before→ After)|
32829160|NCT05739916|Experimental|Sequence B(After→ Before)|
32829161|NCT02791581|Experimental|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
32829162|NCT02791581|Experimental|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
32829163|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
32829164|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
32829165|NCT05586867||Hemodialysis patient|
32829166|NCT02786277|No Intervention|Usual Care|No alert will be fired
32829167|NCT02786277|Experimental|Alert|An alert informing the provider of acute kidney injury will be fired.
32829168|NCT05734300|Experimental|CELS|The Combined Endoscopic Laparoscopic Surgery (CELS) is a hybrid procedure that enables large local excisions of the colon without segmental resection while under general anaesthesia. In our study, CELS refers only to endoscopic assisted laparoscopic resection.
33405300|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
32829169|NCT05734300|Active Comparator|Standard Surgery|Standard surgical resection of colonic cancer following standard oncologic principles while under general anaesthesia.
32829170|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
32829171|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
32829172|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
32829173|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
32829174|NCT02600949|Experimental|Cohort A (personalized vaccine, imiquimod)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients then receive imiquimod cream topically in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
32829175|NCT02600949|Experimental|Cohort B (personalized vaccine, imiquimod, pembrolizumab)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
32829176|NCT02600949|Experimental|Cohort C and D (vaccine, imiquimod, pembrolizumab, APX005M)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Beginning about 1 hour after each vaccine, patients also receive sotigalimab IV over 60 minutes on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and weeks 6,12, and 24, then every 3 months, and at week 39.
32829177|NCT02596191|Experimental|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
32829178|NCT02596191|Experimental|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
32829179|NCT02596191|Experimental|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
32829180|NCT02596191|Other|control group|Healthy volunteers
32829181|NCT01728623|Experimental|E7080|
32829182|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
32829183|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
32829184|NCT05586399|Experimental|Exercise intervention|Participants performing a rehabilitation program for 5 times a week in a total of 4 weeks in one of two rehabilitation centers in Trondheim, Norway. The aim is to perform a total of 20 maximal strength training interventions supervised by one or more health professionals. Maximal strength training will be performed with 4 repetitions and 4 series at 90-95% of one repetition maximum.
32829185|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
33405301|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
32829187|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
32829188|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
32829189|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
32829190|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
32829191|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
32829192|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
32829193|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
32829194|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
32829195|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
32829196|NCT04757727||EDB|Adult women (> 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP
32829197|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
32829198|NCT04757181|Experimental|IBD patients|IBD patients will be used as their own control. Participants will start the study in a baseline phase (4 weeks) and intervention phase (8 weeks)
32829199|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
32829200|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
32829201|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
32829202|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
32829203|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
32829204|NCT02777385|Experimental|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
32829205|NCT02777385|Experimental|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
32829206|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days
32829207|NCT02304783|Placebo Comparator|Placebo|Placebo: one pill per day for five days
32829208|NCT02304783|Active Comparator|paracetamol|paracetamol: 1000mg per day for five days
32829209|NCT02554773|Experimental|Fitusiran|Patients will be administered subcutaneous (SC) fitusiran once monthly or every 2 months according to the dose selection rules defined in protocol.
32829210|NCT02553447|Experimental|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
32829211|NCT02553447|Experimental|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
32829212|NCT02553447|No Intervention|Arm III (control)|Patients receive no intervention.
32829213|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
32829214|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
32829215|NCT02300883||no treatment|no treatment
32829216|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
32829217|NCT01928290|Experimental|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
32829218|NCT01928290|Experimental|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.~Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
32829219|NCT04272177|Experimental|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
32829220|NCT04272177|No Intervention|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
32829221|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
32829222|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
32829223|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
32829224|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
32829225|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
32829226|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
32829227|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
32829228|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
32829229|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
32829230|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
32829231|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
32900118|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
32829232|NCT02532621|Experimental|Venous InterGraft Connector|Venous InterGraft Connector will be implanted and used with a sutured arterial anastomosis to create a AV shunt for dialysis access. In standard use, both the arterial and venous anastomoses are sutured. The Venous InterGraft Connector is intended to replace suturing of the venous anastomosis.
32829233|NCT02772081|Experimental|Curosurf LISA|"Single dose of poractant alfa 200 mg/kg via brief insertion of a thin catheter (CHF 6440) into the trachea in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
32829234|NCT02772081|Active Comparator|Curosurf Endotracheal Tube|"Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
33318012|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
32829236|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
32829237|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
32829238|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
32829239|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
33102256|NCT05466279|Active Comparator|Propofol + midazolam general anesthesia control group (group P)|
33102257|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
32829240|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
33318013|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
33318014|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
32829241|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
33102258|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
32829242|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
32829243|NCT02766543|Experimental|MRI-guided Transurethral Ultrasound Ablation Device|Magnetic resonance imaging-guided transurethral ultrasound ablation of whole-gland prostate tissue.
32900119|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
32900120|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
33102259|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
33102260|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
33102261|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
33102262|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
33102263|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
33318015|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
33318016|NCT05669768|Experimental|pamiparib+tamoxifen|
33318017|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
33318018|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
33318019|NCT05282654|No Intervention|Usual Care (Arm 1)|During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.
33318020|NCT05282654|No Intervention|Usual Care (Arm 2)|During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
33318021|NCT05282654|Experimental|Intervention (Arm 3)|During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.
32829244|NCT02766465|Experimental|Donor Arm|"Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens:~A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft"
32829245|NCT02766465|Active Comparator|No-Donor Arm|No-donor arm patients will continue with standard of care per their SCD physician.
32829246|NCT02515383||Part 1 (MDASI questionnaire, interview)|Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
32829247|NCT02515383||Part 2 (MDASI questionnaires, interview)|Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
32829248|NCT02514837||Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
32829249|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
32829250|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
32829251|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
33318022|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~INSPIRIS RESILIA;~EDWARDS INTUITY;~Carpentier-Edwards PERIMOUNT Magna-Ease."
33318023|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~SAPIEN 3;~SAPIEN XT."
32829252|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
32829253|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
32829254|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
32829255|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or~Have an infected total hip replacement (any surface bearing)~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Have had a prior revision of your total hip~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
32829256|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:~Have a total hip replacement with a ceramic component~Have a metal-on-polyethylene total hip replacement.~Have your original or revised total hip replacement.~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Have cemented components.~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
32829257|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
32829258|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
32829259|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
32829260|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
32829261|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
32829262|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
32829263|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
32829264|NCT05733286|Active Comparator|Suvorexant Arm|
32829265|NCT05733286|Placebo Comparator|Placebo Arm|
32829266|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment"
32829267|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
32829268|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
32829269|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
32829270|NCT02753283|Experimental|Denosumab, then Zoledronic Acid|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
32829271|NCT02753283|Placebo Comparator|Placebo Group, then Zoledronic Acid|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
32829272|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
32829273|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
32829274|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
32829275|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
32829276|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
32829277|NCT01928524|Experimental|DOS2W Dose level 1A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
32829278|NCT01928524|Experimental|DOS2W Dose level 2A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
32829279|NCT01928524|Experimental|DOS2W Dose level 3A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
32829280|NCT01928524|Experimental|DOS2W Dose level 4A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
32829281|NCT01928524|Experimental|DOS3W Dose level 1B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
32829282|NCT01928524|Experimental|DOS3W Dose level 2B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
32829283|NCT01928524|Experimental|DOS3W Dose level 3B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
32829284|NCT05739760|Experimental|"Families assigned the Cuddle and Calm booklet"|A poem about emotional expression in times of upset
32829285|NCT05739760|Experimental|"Families assigned the Health and Safety booklet"|A poem about health and safety with tips on topics such as first aid and injury prevention
32829286|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
32829287|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
32829288|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
32829289|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.~This is a single arm phase II clinical trial."
32829290|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
32829291|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
32829292|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.~Ciprofloxacin 500mg by mouth twice a day for three days."
32829293|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration~Oral Placebo, one cap twice a day for three days."
32829294|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
32829295|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
32829296|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
33318024|NCT00306527|Active Comparator|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
32829297|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
32829298|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
32829299|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
32829300|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
32829301|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
32829302|NCT01753193|Experimental|Anifrolumab|Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
32829303|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
32829304|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
32829305|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
32829306|NCT02242773|Experimental|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
32829307|NCT02477163|Experimental|single group|Patients of chronic renal failure
32829308|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
32829309|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
32829310|NCT02470377|Experimental|Target 1: Occipital Cortex|After determination of the motor threshold, the TMS coil will be positioned over the midline occipital cortex using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
32829311|NCT02470377|Experimental|Target 2: Cerebellar Vermis|After determination of the motor threshold, the TMS coil will be positioned over the midline cerebellar vermis using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
32829312|NCT02470377|Active Comparator|Target 3: Cerebellar Hemisphere|After determination of the motor threshold, the TMS coil will be positioned over the lateral cerebellar hemisphere using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
32829313|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
32829314|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
32829315|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
32829316|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
32829317|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
32829318|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
32829319|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
32829320|NCT05739682|Experimental|Antimicrobial Corticosteroid mixture|"Each canal will receive 5 minutes of final irrigation with the antimicrobial-corticosteroid solution of a freshly prepared mixture of:~1 ml of Levofloxacin (Tavanic, Sanofi Aventis, Egypt).~1 ml of Fluconazole (Sunny fungal, Sunny pharmaceuticals, Egypt).~1 ml of Dexamethasone sodium phosphate (Dexamethasone, Amriya, Egypt)."
32829321|NCT05739682|Active Comparator|Cryotherapy|Each canal will receive final irrigation with 20ml of cold saline (2.5°c) for 5 minutes.
32829322|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
32829323|NCT05739604||Survivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was survival.
32829324|NCT05739604||Nonsurvivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was fatal.
32829325|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
32829326|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
32829327|NCT05739526|Experimental|Participants|"All participants will be asked to complete the following:~participate in 12 individual mental health counseling sessions~participate in 3 group counseling sessions~receive information on community resources related to their social and mental health needs/challenges"
32829328|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
32829329|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
33318025|NCT00306527|Active Comparator|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
32829330|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
32829331|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
32829332|NCT02219373|Experimental|Gabapentin|
32829333|NCT02219373|Experimental|Oxcarbazepine|
32829334|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
32829335|NCT02727387|Experimental|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
32829336|NCT05511844|Experimental|Part 1 Dose Escalation|All participants receive ORM-5029 in escalating dose cohorts in Part 1 Dose Escalation and at the Expansion Dose Level (EDL) in Part 2 Dose Expansion.
32829337|NCT05511844|Experimental|Part 2 Dose Expansion|All participants receive ORM-5029 at dose levels with pharmacodynamic activity or efficacy signals (Expansion Cohort A) or at the Expansion Dose Level (EDL) (Expansion Cohorts B and C).
32829338|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
32829339|NCT05583357|Experimental|Cohort 1|
32829340|NCT05583357|Experimental|Cohort 2|
32829341|NCT05583357|Active Comparator|Cohort 3|
32829342|NCT05583357|Active Comparator|Cohort 4|
32829343|NCT05726968|Active Comparator|● Group P1 (N 15)|Patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
32829344|NCT05726968|Active Comparator|● Group P2 (N 15)|Patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).
32829345|NCT05726968|Active Comparator|● Group P3 (N 15)|patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)
32829346|NCT04757025|Experimental|Electrical Impedance Tomography|patient monitored by Electrical Impedance Tomography
32829347|NCT04757025|Active Comparator|Peripheral arterial Saturation|patient monitored by Peripheral arterial Saturation alone
32829348|NCT05503264|Experimental|NMDAR autoimmune encephalitis (AIE) cohort|Adults and adolescents with definite or probable NMDAR encephalitis
32829349|NCT05503264|Experimental|LGI1 AIE cohort|Adults with LGI1 encephalitis
32829350|NCT05503264|Placebo Comparator|NMDAR autoimmune encephalitis (AIE) Placebo cohort|Adults and adolescents with definite or probable NMDAR encephalitis
32829351|NCT05503264|Placebo Comparator|LGI1 AIE Placebo cohort|Adults with LGI1 encephalitis
32829352|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.~Collection of clinical information and biochemical laboratory results."
32829353|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
32829354|NCT02987062||Warfarin|Patients with AF treated with warfarin.
32829355|NCT02987062||Apixaban|Patients with AF treated with apixaban.
32829356|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
32829357|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
32829358|NCT05583045|Experimental|Olive Leaf Tea (OLT)|Daily intake, for 12 weeks, of olive leaf tea + lifestyle behavior change program.
32829359|NCT05583045|Placebo Comparator|Placebo tea (CON)|Daily intake, for 12 weeks, of placebo tea + lifestyle behavior change program
32829360|NCT05739448|No Intervention|control|
32829361|NCT05739448|Experimental|fortification (FOR)|
32829362|NCT05739448|Experimental|fortification + physical activity (FAP)|
32829363|NCT01753115|Experimental|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
32829364|NCT01753115|Experimental|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
32829365|NCT01753115|Experimental|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
32829366|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
32829367|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
32829368|NCT05739370|Experimental|Ger-iPST|Prospective participants will be contacted by telephone to confirm eligibility, explain the study protocol, and obtain informed consent. An in-person or videoconference assessment will be used to administer baseline PHQ-9 to confirm enrolment criteria and will be asked questionnaire to gather demographic information. Participants will then be provided with an email link to access the Online Psycho Therapy Tool (OPTT). PHQ-9 will be collected again at the mid-point (4 weeks) and after completing the program through OPTT. Caregivers will be invited to assist the participant if required in completing Ger-iPST modules, and weekly telephone support calls by a research assistant will be provided to assist with any difficulty navigating technical aspects of the Ger-iPST platform.
32829369|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
32829370|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
32829371|NCT05739214|Experimental|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
32829372|NCT05739214|Experimental|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
32829373|NCT05739214|Active Comparator|traditional wound care|"Traditional wound care inform of~Wound care treatment~Debridement to remove necrotic tissue~Irrigation of the wound by normal saline~Change dressing daily to protect wound from infection~Foot care~Wash feet daily, dry carefully especially between toe~Avoid extreme temperatures~Inspection daily of foot blisters~Foot wear~Avoid walking bare foot~Properly fitted shoes~Avoid wearing open-toed shoes"
32829374|NCT05719714|Experimental|Intervention group|Thirty individuals will be randomized to dapagliflozin 10mg to be taken daily for six months.
32829375|NCT05719714|No Intervention|Standard of Care group|Thirty individuals will be randomized to standard of care treatment.
32829376|NCT05484076|Experimental|breastfeeding counseling|Pregnant women will be given breastfeeding counseling, which will take place in a total of five sessions at specified intervals.
32829377|NCT05484076|No Intervention|control group|No training will be given to the control group. They will be asked to fill in the questionnaires included in our study at specified intervals.
32829378|NCT05713006|Experimental|Alectinib escalation dose|Alecensa 150 mg Roche
33318026|NCT00306527|Active Comparator|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
33318027|NCT00306527|Active Comparator|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
32829381|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
32829382|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
32829383|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
32829384|NCT05586789|Experimental|Ranquilon|Study drug Ranquilon, tablets, 1 mg, 2 tablets 3 times a day (daily dose - 6 mg/day), daily, for 28 days
32829385|NCT05586789|Placebo Comparator|Placebo|Placebo, tablets, 2 tablets 3 times a day, daily, for 28 days
32829387|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
32829388|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
32829389|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
32829390|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
32829391|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
32829392|NCT05581485|No Intervention|Intubated general anesthesia LMS|The patients received a LMS with intubated general anesthesia.
32829393|NCT05581485|Experimental|Non-intubated LMS with spontaneous breathing|The patients received a non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
32829394|NCT05581485|Experimental|Non-intubated LMS with dexmedetomidine|The patient received a non-intubated LMS optiflow (HFNO) device and was administered dexmedetomidine.
32829395|NCT05738980|Experimental|anti-Tim3-blocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
32829396|NCT05738980|Experimental|Unblocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
32829397|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
32829398|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
32829399|NCT04748614||Before SARS-Cov2|Before SARS-Cov2
32829400|NCT04748614||After SARS-Cov2|After SARS-Cov2
32829401|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
32829402|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
32829403|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
32829404|NCT05703412|Experimental|Transition-FOCUS mHealth Intervention|"All participants will download the tFOCUS app to their mobile phone. tFOCUS uses EMA to assess variables identified as being salient to treatment engagement and illness self-management. The application delivers algorithm-driven micro interventions to address reported problem(s). Data is transmitted to a clinician dashboard, which can be used for remote monitoring."
32829405|NCT05703412|Active Comparator|Check-In|Control participants will receive the currently recommended best practices of post-discharge care, including follow-up appointments, instructions, referrals and a follow-up check in.
32829406|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
32829407|NCT05738902||Women affected by gynecological cancer.|Women affected by confirmed gynecological cancer treated with open access surgery and managed according to ERAS guidelines.
32829408|NCT01894035||Group 1|
32829409|NCT05457400|Active Comparator|ENSO 16|The participants receive 30g ENSO 16 dissolved in 200 mL water and blood will be collected at defined time points (0 - 15 - 30 - 45 - 60 - 90 - 120 - 180 minutes; ±3 min at each time point).
32829410|NCT05457400|Active Comparator|Glucose Powder|The participants receive Glucose in the same dosage and blood is also taken at the same time points.
32829411|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
32829412|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
33405302|NCT04996368|Active Comparator|low dose (10mg/kg)|The dose of tranexamic acid varies widely ranging from 10mg/kg to 100mg/kg. We are comparing 10mg/kg to conventional 30mg/kg dose. The result of this study will help us to review our current practice.
32829413|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
32829414|NCT01727141|Placebo Comparator|Placebo|b.i.d
32829415|NCT05696392|Experimental|Treatment Group: Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily (BID) as a thin film.
32829416|NCT02438085||ACS patients|prospective collection of data and follow-up
32829417|NCT05442112|Experimental|Wellness Smartphrase|This arm will receive a secure message after the conclusion of their standard clinic visit providing a set script containing information on a number of wellness-related topics in MS (sleep, diet, exercise).
32829418|NCT05442112|No Intervention|No Intervention|This arm will not receive a secure message after their appointment, and will instead receive their standard care with their provider.
32829419|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
32829420|NCT05693740|Active Comparator|group 1|Patients in this group will undergo pulsed light accelerated crosslinking (pl-ACXL)
32829421|NCT05693740|Active Comparator|group 2|Patients in this group will undergo continuous-light accelerated crosslinking (cl-ACXL)
32829424|NCT05738668||Anti-NMDAR encephalitis|Patients with well-characterized anti-NMDAR encephalitis.
32829425|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
32829426|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
32829427|NCT05439694|Experimental|Gelatin Sponges soaked with TXA|21 patients will have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) each sponge will be soaked with one ampoule and applied between the anterior rectus sheath and the rectus abdominis muscle, one sponge on each muscle.
32829428|NCT05439694|Experimental|Gelatin Sponges|2 Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2)
32829429|NCT05439694|No Intervention|NO SPONGE|21 patients will have no sponge inserted 10 ml of saline
32829430|NCT04558619|Other|Kōmmour Prenatal|
32829431|NCT02170155||Patients with CSM|
32829432|NCT02170155||Patients with spinal injury (SCI)|
32829433|NCT02170155||Healthy controls|
32829434|NCT05738590||inflammatory muscle disease|
32829435|NCT05738590||degenerative muscle disease|
32829436|NCT02165787||patients|
32829437|NCT02165787||healthy control subjects|
32829438|NCT05434078|Experimental|Orthofeet Shoes|Participants will be given Orthofeet shoes to wear for 6 weeks
32829439|NCT05434078|No Intervention|No Orthofeet shoes|This group will not be wearing Orthofeet shoes for 6 weeks
32829440|NCT02714439|Experimental|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
32829441|NCT05683678||Cohort 1|"Participants who started selumetinib and discontinued selumetinib before enrollment (the discontinued cohort)."
32829442|NCT05683678||Cohort 2|"Participants who started selumetinib before enrollment and are continuing to receive selumetinib at the time of enrollment (the continuing cohort)."
32829443|NCT05683678||Cohort 3|"Participants who intend to initiate selumetinib within approximately 3 months after enrollment (the initiating cohort)."
32829444|NCT02713269|Experimental|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
32829445|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
32829446|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
32829447|NCT05738512|Active Comparator|Medial Flap Coblation Turbinoplasty|
32829448|NCT05738512|Active Comparator|Submucous Resection|
32829449|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
32829450|NCT05430178|Experimental|NAFLD|Participants in the pediatric NAFLD clinic
32829451|NCT05430178|Experimental|Ob control|Participants with obesity, without NAFLD
32829452|NCT05430178|Experimental|NW control|Participants in the normal range for body weight, without NAFLD
32829453|NCT05430178|Experimental|Liver control|Participants undergoing liver biopsy or liver surgery, without NAFLD
32829454|NCT05424484|Experimental|Hernia prevention cohort|single arm study, no control arm
32829455|NCT04350034|Experimental|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
32829456|NCT04350034|Placebo Comparator|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
32829457|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
32829458|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
32829459|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
32829460|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
32829461|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
32829462|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
32829463|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
32829464|NCT05738356|Active Comparator|Three-step adhesive|The orthodontic appliances were bonded to the patients teeth using conventional 3 step adhesive (3M™ Transbond™ XT, 3M Unitek, United States)
32829465|NCT05738356|Experimental|Self-etch primer adhesive|The orthodontic appliances were bonded to the patients teeth using self-etch primer (3M™ Transbond™ Plus, 3M Unitek, United States).
32829466|NCT05738356|Experimental|One-step adhesive system|The orthodontic appliances were bonded to the patients teeth using one-step adhesive system (GC Ortho Connect™, GC Orthodontics, Germany)
32829467|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
32829468|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
32829469|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
32829470|NCT02986906|Active Comparator|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
32829471|NCT05658562|Experimental|MT-2111 dosing regimen|
32829472|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
32829473|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
32829474|NCT05414968|Experimental|Pilot Feasibility Arm|Each participant will receive the same 45-minute intervention on 10 days spread over no more than 14 days total. At the end of each session, pain will be assessed on scales such as the Defense and Veterans Pain Rating Scale (DVPRS) to establish the safety and feasibility of the proposed intervention.
32829475|NCT05654350||Patients with neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect and neglect anosognosia.
33318028|NCT00306527|Active Comparator|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
32829476|NCT05654350||Patients without neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect but no neglect anosognosia.
32829477|NCT02162667|Experimental|CT-P6|
32829478|NCT02162667|Active Comparator|Trastuzumab|
32829479|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
32829480|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
32829481|NCT05651854|Experimental|Bhramari pranayama breathing|Bhrāmarī Prāṇāyāma breathing involves inhalation through both nostrils and producing humming sound of a bee while exhaling (Nivethitha et al., 2016).
32829482|NCT05651854|Experimental|Sheetali pranayama breathing|Sheetali pranayama involve inhalation through extension of the tongue outside the mouth and roll the sides of the tongue up so that it would form a tube. At the end of inhalation, the tongue is drawn in, mouth is closed and exhale through the nose (Thanalakshmi et al., 2014).
33318029|NCT00306527|Active Comparator|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
32829484|NCT05646862|Experimental|Inavolisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
32829485|NCT05646862|Active Comparator|Alpelisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
32829486|NCT05403190|Experimental|Study arm|Patients with prostate cancer
32829487|NCT05402020||Tio/Olo cohort|COPD patients included in the NHI database between 2014 and 2019 and who received Tiotropium/olodaterol (Tio/Olo).
32829488|NCT05402020||ICS/LABA cohort|COPD patients included in the NHI database between 2014 and 2019 and who received inhaled corticosteroids/ Long-acting ß2-agonists (ICS/LABA).
32829489|NCT05736640|Active Comparator|Denosumab|
32829490|NCT05736640|Placebo Comparator|Placebo|
32829491|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
32829492|NCT05393284|Experimental|OPL-0401 Dose 1|Participants are randomized to OPL-0401 Dose 1 twice daily for 24 weeks
32829493|NCT05393284|Placebo Comparator|Placebo|Participants are randomized to matching Placebo twice daily for 24 weeks
32829494|NCT01751867|Experimental|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
32829495|NCT01751867|Experimental|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
32829496|NCT05637658|No Intervention|control group|No application will be made to the participants in the control group.
32829497|NCT05637658|Experimental|Exercise group|Participants will perform aerobic exercise 3 times a week at an intensity of 60-80% of age-adjusted maximal heart reserve on the treadmill and bicycle ergometer for 4 weeks.
32829498|NCT05636800|Experimental|Microwave Treatment (Swift System)|3-4 Watts applied locally for up to a 3 second burst to each AK lesion, repeated 3 times per lesion. Burst is defined as a single delivery of microwave energy. There will be approximately 20 seconds between each repeat dose.
32829499|NCT05636800|No Intervention|No Treatment|No Treatment administered
32829500|NCT02418195|Active Comparator|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40 milliliters (mL) over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
32829501|NCT02418195|Active Comparator|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
32829502|NCT02418195|Active Comparator|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
32829503|NCT02418195|No Intervention|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
32829504|NCT05633914|Experimental|Tucidinostat and nab-paclitaxel|
32829505|NCT05386030|Experimental|saypha® VOLUME Lidocaine|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
32829506|NCT05386030|Active Comparator|Juvéderm® Voluma™ XC|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
32829507|NCT04756947||Pelvic injury|Paediatric patients (age ≤ 18 years) with a single pelvic bone fracture or pelvic ring injury, excluding pathological fractures.
32829508|NCT04756947||Pelvic and acetabular injury|Paediatric patients (age ≤ 18 years) with a combined pelvic and acetabular injury or an isolated acetabular fracture, excluding pathological fractures.
32829509|NCT05383612|Experimental|Group I:3% diquafosol|70 people, 70 eyes.
32829510|NCT05383612|Other|Group II:3% diquafosol and warm compresses and lid massage|70 people, 70 eyes.
33318030|NCT00306527|Active Comparator|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
32829512|NCT05382364|Experimental|Tucatinib Treatment|Chinese participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma, or colorectal cancer receive tucatinib 300 mg by mouth twice daily during 21-day cycles. Treatment continues until there is evidence of unacceptable toxicity or documented progression.
32829513|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
32829514|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
32829515|NCT05630014|Experimental|Family Caregivers of PLWD at High Risk for Delirium|Participants will complete the Aliviado DSD Caregiving Mastery Program. This involves a caregiver education/training period from Week 0 to Week 2, and an implementation period from Week 3 to Week 6.
32829516|NCT05381896|Active Comparator|Control Group|Patients in this group will receive conventional scoliosis exercise program for 1 hour, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
32829517|NCT05381896|Experimental|Training Group|In addition to the conventional scoliosis exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
32829518|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
32829519|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
32829520|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
33318031|NCT00306527|Active Comparator|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
33318032|NCT05669378|Experimental|Intervention group|The experimental group will receive the Appetite to Play + intervention which is a capacity-building intervention that support childcare providers in implementing the best practices for active play. It includes a 3 e-learning online modules and then the are supported with weekly . bi-weekly emails.
33318033|NCT05669378|Other|Standard of care waitlist control|The standard of care waitlist control group will receive the intervention at 3-months post-randomization. The standard of care group has access to the Appetite to Play materials which are available to everyone. The site includes resources that childcare providers can use.
32829524|NCT02156739|Experimental|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
32829525|NCT02152683|Experimental|long protocol|Renova
32829526|NCT02152683|Experimental|short protocol|Renova
32829527|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
32829528|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
32829529|NCT05736250||TEST group|smoker patients
32829530|NCT01751165|Experimental|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
32829531|NCT01751165|Experimental|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
32829532|NCT01751165|Experimental|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
32829533|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
32829534|NCT05351866|Experimental|SparkRx|5-week CBT-based mobile intervention for adolescents with depressive symptoms
32829535|NCT05351866|Active Comparator|Educational Control|5-week mobile control with education about depression
32829536|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
32829537|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
32829538|NCT05736172|Experimental|Pain group education|In this group, the education session will be provided in a face-to-face group setting.
32829539|NCT05736172|Active Comparator|Pain material education|In this group the same education session will be provided in written form by means of a leaflet.
32829540|NCT01751087|Other|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
32829541|NCT01751087|Active Comparator|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
32829542|NCT01751087|Active Comparator|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
32829543|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32829544|NCT05605678||All Eligible Participants|All Participants diagnosed with severe HemA with or without inhibitors, moderately severe to severe HemB, or HemB with inhibitors will be enrolled and continue to receive their usual hemophilia treatment regimen under SOC therapy. Bleeding episodes and treatment data will be collected during the prospective follow up period in a diary. No intervention will be administered as part of this study.
32829545|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
32829546|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
32829547|NCT04745793||Thyroids|The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
32829548|NCT04745793||Parathyroids|The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland
32829549|NCT05348356|Experimental|Nirogacestat Open-Label|All participants will receive open-label nirogacestat
32829550|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
32829551|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
32829552|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
32829553|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
32829554|NCT05335486|Experimental|RELEARN - Intervention|"Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~In addition, intervention group participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
32829555|NCT05335486|Active Comparator|Standard care control|Standard Care control. Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
32829556|NCT02141919|Experimental|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
32829557|NCT05736016|Active Comparator|Active Therapy|Active comparator will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program. The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the time of the treatment and follow-up period the treatment arm will be provided with individually made corrective medial wedge insoles to be used during all therapeutic and other everyday activities.
32829558|NCT05736016|Sham Comparator|Sham Therapy|Sham comparator arm will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program . The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the treatment and follow-up the control arm will be provided with individually made sham insoles to be used during all therapeutic and other everyday activities.
32829559|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|"Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.~Possible Re-treatment of the included patients with GA101: 1000 mg i.v. and ABT-199: 20 - 400 mg p.o."
33102264|NCT05466162|Experimental|Soft tissue mobilization + joint and nerve Mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
32829560|NCT05335096|Experimental|Intervention group|
32829561|NCT05335096|Active Comparator|TAU group|
32829562|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
32829563|NCT03838978|Experimental|Calypso Knee System|Calypso Knee System
32829564|NCT05319730|Active Comparator|Paclitaxel or irinotecan|Participants receive paclitaxel 80-100 mg/m^2 intravenously (IV) on days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m^2 IV on day 1 of every 14-day cycle until PD or discontinuation.
32829565|NCT05319730|Experimental|Pembrolizumab + MK-4830 + paclitaxel or irinotecan|Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m^2 IV on days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan 180 mg/m^2 180 mg/m^2 on day 1 every 14-day cycle until PD or discontinuation.
32829566|NCT05319730|Experimental|Pembrolizumab + MK-4830 + lenvatinib|Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every day until PD or discontinuation.
32829567|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
32829568|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
32829569|NCT01750697|Experimental|Rituximab|
32829570|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
32829571|NCT01750229|Sham Comparator|Sham|Frequency Setting - Sham
32829572|NCT01750229|Experimental|1200 Hz|Frequency Setting - 1200 Hz
32829573|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
32829574|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
32829575|NCT05586711|Active Comparator|Vaginal estradiol 10 μg|
32829576|NCT05586711|Active Comparator|Vaginal DHEA 6,5 mg|
32829577|NCT05317858|Experimental|Pembrolizumab with Exablate BBBD|Using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy.
32829578|NCT05317858|Active Comparator|Control Arm (Pembrolizumab only)|subjects will undergo planned pembrolizumab monotherapy.
32829579|NCT02124057||Healthy female control|Age-matched healthy control women
32829580|NCT02124057||Healthy male control|Age-matched healthy control men
32829581|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
32829582|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
32829583|NCT02124057||SMBA|SBMA carrier women
33318034|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
32829584|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
32829585|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
32829586|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
32829587|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
32829588|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
32829589|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
32829590|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
32829591|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
32829592|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
32829593|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
32829594|NCT05304364|Experimental|DLP-160 alpha-10|One time single Naltrexone Implant for a duration of 123 days
32829600|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
32829601|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
32829602|NCT05562388|Experimental|MAD therapy|MAD Therapy
32829603|NCT05022004|Experimental|BRIN-20-01|
32829604|NCT05022004|Active Comparator|Azopt®|
32829605|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
32829606|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
32829607|NCT05303194|Other|Patient Priorities Care (PPC) Adaptation|5 Hispanic patients with multiple chronic conditions (MCC) and no dementia. In order to adapt PPC for Hispanics with MCC, five Hispanics with MCC will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
32829608|NCT05303194|Other|PPC Feasibility Testing|20 Hispanic patients with multiple chronic conditions (MCC), including dementia. In order to adapt PPC for Hispanics with MCC and dementia, twenty Hispanics with MCC and dementia will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
32829609|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
32829610|NCT05257798|Experimental|PF-06823859|Participants will receive 900 mg of PF-06823859 via intravaneous (IV).
32829611|NCT05257798|Placebo Comparator|Placebo|Participants will receive placebo via IV.
32829612|NCT02109471||corneal opacities|
32829613|NCT04976530|Sham Comparator|Control|Standard of care with Sham set-up
32829614|NCT04976530|Experimental|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
32829615|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
32829616|NCT01984671|No Intervention|Standard Care Control|
32829617|NCT05529784||Severe, uncontrolled CRSwNP patients in therapy with Dupilumab|
32829618|NCT05524246|Experimental|Pravastatin Prophylactic Treatment|
32829619|NCT05256706|Experimental|SomaSignal Informed Medical Management SSCVD|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will be sent to the providers and participants approximately 2-4 weeks after testing.
32829620|NCT05256706|Active Comparator|Standard of Care (Uninformed Arm)|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will not be provided to the provider or participant until the 6-month visit.
32829623|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.~Provision of informed consent."
32829624|NCT01976091|Experimental|Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)|Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
32829625|NCT01976091|Experimental|Cohort 1B Low Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
32829626|NCT01976091|Experimental|Cohort 2 High Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
32829627|NCT04415866|Experimental|Effects of PASAT on Sensory Testing|After baseline evaluation of light and pain sensitivity FM subjects and controls will undergo the PASAT task. This task consists of responding to a rapid presentation of numbers by ear phones. Subjects are asked to add each 2 consecutive numbers and provide a response each time the sum is equal to 13. This test will last several minutes and delivered at increasing speed.
32829628|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
32829629|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
32829630|NCT04349488|Active Comparator|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32829631|NCT04349488|Placebo Comparator|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
32829632|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
32829633|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
32829634|NCT04406818|Active Comparator|Healthy Control|
32829635|NCT04406818|Active Comparator|Sickle Cell Anemia|
32829636|NCT02683473||Infants|Infants aged 1-3 months
32829637|NCT04406740||All Participants|Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia in the MHealth East Bank operating rooms in which the administration of a nondepolarizing neuromuscular blocking drug (rocuronium or cisatracurium) is anticipated.
32829638|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
32829639|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
32829640|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
32829641|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
32829642|NCT04404712|Experimental|[11C]MK-3168 PET Scan|
32829643|NCT04349800|Experimental|Single Ascending Dose - 5 mg|
32829644|NCT04349800|Experimental|Single Ascending Dose - 10 mg|
32829645|NCT04349800|Experimental|Single Ascending Dose - 20 mg|
32829646|NCT04349800|Experimental|Single Ascending Dose - 40 mg|
32829647|NCT04349800|Experimental|Single Ascending Dose - 80 mg|
32829648|NCT04349800|Experimental|Single Ascending Dose - 160 mg|
32829649|NCT04349800|Experimental|Single Ascending Dose - 300 mg|
32829650|NCT04349800|Experimental|Single Ascending Dose - 600 mg|
32829651|NCT04349800|Experimental|Formulation Screen|
32829652|NCT04349800|Experimental|Food Effect|
32829653|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
32829654|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
32829655|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection
32829656|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
32829657|NCT05238688|Experimental|Thoracic Epidural Analgesia (TEA) group|Patients in this group will receive Thoracic Epidural analgesia.
32829658|NCT05238688|Experimental|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Patients in this group will receive Thoracic Epidural analgesia in addition to high thoracic ultrasound-guided erector spinae plane block (ESPB).
32829659|NCT01962753|Experimental|18FAV45|
33102265|NCT05466162|Active Comparator|joint and nerve mobilizations|"Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
32829664|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
32829665|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
32829666|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
32829667|NCT05238142|Experimental|MiniMed 780G System|Adult participants with insulin-requiring type 2 diabetes age 18-80 using the MiniMed 780G system for a combined run-in period and study period will be approximately 135 days long. At the conclusion of the 90-day study period, subjects will be given the opportunity to transition to a period of continued access.
32829668|NCT01521741||Breast Cancer|
32829669|NCT04919590|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
32829670|NCT04919590|Other|Assessment only control|After an initial enrollment message, participants will be contacted monthly to assess e-cigarette use. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
32829671|NCT04919590|Other|Waitlist control|After an initial enrollment message, participants will receive no contact from study staff except for 1-month and 7-month follow-up assessments. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
32829672|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
32829673|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
32829674|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
32829675|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
32829676|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
32829677|NCT04915144|Active Comparator|Standard PRRT|For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
32829678|NCT04915144|Experimental|Personalized PRRT|For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
32829679|NCT05229952|Experimental|Constant infusion of 13C2-oxalate|Subjects who have passed screening, will consume a low-oxalate, normal calcium controlled diet for 5 days total. On Days 3 and 4, subjects will collect two 24-hour urines. On Day 5, they will receive a carbon 13 oxalate infusion which will occur at a constant rate for 6 hours, in the fasted state, following a priming dose. Hourly urine and twice hourly blood samples will be collected during the 6 hours. Meals will be resumed at the end of the infusion and timed urine collections will take place at home until the next day. A DXA scan will be performed to assess body composition at another date.
32829680|NCT04378270|Experimental|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
33405303|NCT04996368|Active Comparator|high dose or conventional group (30mg/kg)|dose 30mg/kg regularly use in our center as a prophylaxis for prevention of bleeding before open heart surgery
32829683|NCT05199688|Experimental|Cohort 1: Participants with body weight ≥10kg to <20kg|Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients
32829684|NCT05199688|Experimental|Cohort 2 Participants with body weight ≥20kg to <40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
32829685|NCT05199688|Experimental|Cohort 3 Participants with body weight ≥40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
32829686|NCT04309474|Experimental|Elezanumab|Participants will receive elezanumab dose A
32829687|NCT04309474|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
32829688|NCT04871464|Experimental|Probiotics|Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
32829689|NCT04871464|Placebo Comparator|Placebo|Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
32829690|NCT04871464|No Intervention|Healthy control|Healthy subjects without constipation matched for age and sex to PD subjects
32900121|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
33318035|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
33318036|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
32829691|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
32829692|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
32829693|NCT05197504||intervention|atezolizumab + bevacizumab
32829694|NCT02293096|Experimental|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.~metoprolol succinate~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
32829695|NCT04866082||ESICM and ESAIC members|questionnaire - Members of European Society of Intensive Care and European Society of Anaesthesiology and Intensive Care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
32829696|NCT05192200|Experimental|Anti-Beta Interferon drug (PF-06823859)|IV infusion
33318037|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
33318038|NCT03980951|Active Comparator|combined spinal epidural group|Bupivacaine 2.5 mg
33318039|NCT03980951|Active Comparator|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
33318040|NCT03980951|Active Comparator|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
33318041|NCT03980795|Experimental|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
33318042|NCT03980795|No Intervention|Control|Usual care
32829703|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
32829704|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
32829705|NCT01723163|Experimental|Intervention|Abstinence Reinforcement Therapy (ART)
32829706|NCT01723163|Other|Control|Telephone Counseling
32829707|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
32829708|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
32829709|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
32829710|NCT04223752|Experimental|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to <18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
32829711|NCT04223752|Experimental|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to <12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
32829712|NCT04223752|Experimental|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to <7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
32956038|NCT05764967|Experimental|Low Dye Taping|One Arm will be given Low Dye taping. The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive will be used for all of the taping procedures. Prior to application of the tape, any hair in the region will be shaved and the foot and leg will be washed with soap and warm water to remove any dirt or oils that might decrease the adhesion of the tape. The Transverse Tibial Rotation (TTR) measurements will be repeated following application of tape.
33318043|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
33318044|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
33318045|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
32829713|NCT04223752|Experimental|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to <2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
32829714|NCT04223752|Experimental|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to <3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
32829715|NCT05169814|Placebo Comparator|Acute Wounds - Control|This arm will include patients with acute wounds and will receive standard of care: irrigation with normal saline.
33102266|NCT03741530|Experimental|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
32829716|NCT05169814|Experimental|Acute Wounds - Experimental|This arm will include patients with acute wounds and will receive experimental treatment: irrigation with micro/nanobubbles (MNB's) in normal saline.
32829717|NCT05169814|Placebo Comparator|Chronic Wounds - Control|This arm will include patients with chronic wounds and will receive standard of care: negative pressure wound therapy with instillation (NPWTi) using normal saline.
32829718|NCT05169814|Experimental|Chronic Wounds - Experimental|This arm will include patients with chronic wounds and will receive experimental treatment: negative pressure wound therapy with instillation (NPWTi) using micro/nanobubbles (MNB's) in normal saline.
32829719|NCT04191460|Experimental|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
33102267|NCT03741530|Placebo Comparator|Control group|Giving standard management for ICH
33102268|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
33318046|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
33318047|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
32829720|NCT04191460|Experimental|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
32829721|NCT04191460|Experimental|WP-II selected dose|n=14: expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
32829722|NCT04187404|Experimental|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma.~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma."
32829723|NCT04187404|Experimental|randomized extension of Cohort 2A (3 arms): C2A-I|Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
32829724|NCT04187404|Experimental|randomized extension of Cohort 2A (3 arms): C2A-II|11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.
32829725|NCT04187404|Active Comparator|randomized extension of Cohort 2A (3 arms): C2A-III|11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.
32829726|NCT04165486|Experimental|Part 1: ION464|ION464 will be administered at multiple-ascending doses by IT injection at regular intervals over 12 weeks.
32829727|NCT04165486|Placebo Comparator|Part 1: Placebo|ION464-matching placebo will be administered by IT injection at regular intervals over 12 weeks.
32829728|NCT04165486|Experimental|Part 2: ION464|ION464 will be administered at the same doses as Part 1 by IT injection, at regular intervals, for 72 weeks.
32829729|NCT04165486|Placebo Comparator|Part 2: Placebo|ION464-matching placebo will be administered by IT injection, at regular intervals, for 72 weeks.
32829730|NCT04155580|Experimental|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
32829731|NCT04155580|Experimental|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
32829732|NCT04155580|Experimental|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
32829733|NCT01721759|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
32829734|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
32829735|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
32829736|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
32829739|NCT04796896|Experimental|mRNA-1273|"Part 1: Participants will receive 2 IM injections of mRNA-1273 at doses pre-specified for this study, on Days 1 and 29. Participants will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After protocol amendment (PA) 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1 on Days 1 and 29. Participants (6 to <12 year) will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 3: Participants will receive 2 IM injections of mRNA-1273 on Days 1 and 29 as primary series then 1 IM injection as Dose 3, on Day 149 ≥3 months and ≤5 months after receipt of Dose 2 of primary series. All 3 injections will be administered at lower dose than that of Part 1."
32829740|NCT04796896|Placebo Comparator|Placebo|Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to <12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.
32829741|NCT04776850|Experimental|Treatment (PTIS, HCT)|See Detailed Description.
32829742|NCT04766086|Experimental|GBS6 and Tdap|Multivalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
32829743|NCT04766086|Experimental|GBS6 and Placebo|Multivalent group B streptococcus vaccine and Placebo
32829744|NCT04766086|Experimental|Placebo and Tdap|Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
32829745|NCT05137054|Experimental|Cohort 1: REGN5458 or Linvoseltamab + Daratumumab|REGN5458 + Daratumumab
32829746|NCT05137054|Experimental|Cohort 2: REGN5458 or Linvolseltamab + Carfilzomib|REGN5458 + Carfilzomib
32829747|NCT05137054|Experimental|Cohort 3: REGN5458 or Linvoseltamab + Lenalidomide|REGN5458 + Lenalidomide
32829748|NCT05137054|Experimental|Cohort 4: REGN5458 or Linvoseltamab + Bortezomib|REGN5458 + Bortezomib
32829749|NCT05137054|Experimental|Cohort 5: REGN5458 or Linvoseltamab + Pomalidomide|REGN5458 + Pomalidomide
32829750|NCT05137054|Experimental|Cohort 6: REGN5458 or Linvoseltamab + Isatuximab|REGN5458 + Isatuximab
32829751|NCT05137054|Experimental|Cohort 9: REGN5458 or Linvoseltamab + Nirogacestat|REGN5458 + Nirogacestat
32829752|NCT04756726|Experimental|Phase 1: Arm A - CFT7455|Participants with r/r NHL or r/r MM will be treated with oral CFT7455 as a single agent administered according to different dosing schedules
32829753|NCT04756726|Experimental|Phase 1: Arm B1 - CFT7455|Participants with r/r MM will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
32829754|NCT04756726|Experimental|Phase 1: Arm B2 - CFT7455 in combination with dexamethasone|Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort
32829755|NCT04756726|Experimental|Phase 1: Arm C - CFT7455|Participants with r/r NHL will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules in each cohort until determination of MTD/RP2D
32829756|NCT04756726|Experimental|Phase 2: Arm 1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455
32829757|NCT04756726|Experimental|Phase 2: Arm 2 - CFT7455 in combination with dexamethasone|Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone
32829758|NCT04756726|Experimental|Phase 2: Arm 3 - CFT7455|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
32829759|NCT04756726|Experimental|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455
32829760|NCT04132648|Experimental|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
32829761|NCT04132648|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
32829762|NCT04116658|Experimental|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
32829763|NCT04116658|Experimental|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
32829764|NCT04116658|Experimental|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab (US only)
32829765|NCT04721002||Participants With Multiple Myeloma|Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
32829766|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
32829767|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
32829768|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
32829769|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
32829770|NCT05117554|Experimental|SAD-AB521 Dose 1|"Participants will receive Dose 1 of AB521 orally with water under fasting conditions."
32829771|NCT05117554|Experimental|SAD-AB521 Dose 2|"Participants will receive Dose 2 of AB521 orally with water under fasting conditions."
32829772|NCT05117554|Experimental|SAD-AB521 Dose 3|"Participants will receive Dose 3 of AB521 orally with water under fasting conditions."
32829773|NCT05117554|Experimental|SAD-AB521 Dose 4|"Participants will receive Dose 4 of AB521 orally with water under fasting conditions."
32829774|NCT05117554|Placebo Comparator|SAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
32829775|NCT05117554|Experimental|MAD-AB521 Dose 1|"Participants will receive Dose 1 of AB521 orally with water under fasting conditions."
32829776|NCT05117554|Experimental|MAD-AB521 Dose 2|"Participants will receive Dose 2 of AB521 orally with water under fasting conditions."
32829777|NCT05117554|Placebo Comparator|MAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
32829778|NCT05117554|Experimental|DDI-AB521 Dose + Midazolam|Participants will receive highest safe dose level of AB521 from MAD and midazolam orally with water under fasting conditions
32829779|NCT04093570|Experimental|Main Extension Study: ASTX727|The recommended starting dose is the fixed-dose combination (FDC) tablet, containing 100 mg cedazuridine and 35 mg decitabine, once daily, Days 1 through 5 in 28-day cycles. Participants should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
32900122|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
33318048|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
33102269|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
33318049|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
33318050|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
32829780|NCT04093570|Experimental|Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4|"Participants will receive ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants will fast for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants will receive a high-calorie/high-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose.~Participants will continue treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they will continue to receive ASTX727 unless there is occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
32829781|NCT04093570|Experimental|Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4|"Participants will receive ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants will fast for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants will receive low-calorie/low-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose.~Participants will continue treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they will continue to receive ASTX727 unless there is occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
32829782|NCT04034056||Obinutuzumab|
32829783|NCT04708054|Experimental|Treatment (venetoclax, busulfan, fludarabine, cladribine)|Patients receive venetoclax PO QD on days -22 to -3, busulfan IV over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.
32829784|NCT05112640|Active Comparator|Suture wound closure|Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.
32829785|NCT05112640|Experimental|Absorbable staple wound closure|Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.
32829786|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
32829787|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
32829788|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
32829789|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
32829790|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Surgeon will perform the periarticular injections:~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~Intravenous sedation with midazolam and propofol."
32829791|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Adductor canal block technique:~Supine position, after IV sedation~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~Local anesthetic will be delivered periarterial between 12 and 6 o'clock~Intravenous sedation with midazolam and propofol.~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
32829792|NCT05072704|Active Comparator|Control group|Sufentanil IV injection
32829793|NCT05072704|Experimental|OFA group|Dexmedetomidine IV infusion
32829794|NCT04000360|Experimental|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
32829795|NCT04000360|No Intervention|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
32829796|NCT03969004|Experimental|Cemiplimab|
32829797|NCT03969004|Placebo Comparator|Placebo|
32829798|NCT03951454|Experimental|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
32829799|NCT03951454|Other|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
32829800|NCT03924934||Possible CA-HRE|Patients with suspected CA-HRE, discharged home after a previous hospitalization or outpatient visit during which CA-HRE was isolated from a clinical culture (approximately 210 patients)
32829801|NCT03924934||HA-HRE|Hospitalized patients with healthcare-associated HRE, who are not discharged home (HA-HRE) (210 selected control patients)
32829802|NCT03924934||HA-HRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-HRE was isolated from a clinical culture (100)
32829803|NCT03924934||Community contacts|Contacts of patients with HRE (approximately 1,500)
32829804|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
32829805|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
33102270|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
32829806|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
33318051|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
32829808|NCT04678336|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
32829809|NCT04655404|Experimental|Feasibility Cohort|Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
32829810|NCT04655404|Experimental|Surgical Cohort|Larotrectinib administered PO, BID @100 mg/m2 3-5 days prior to definitive surgery, followed by Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
32829811|NCT04648774|Active Comparator|Active serratus anterior plane (SAP) block with Ropivacaine 0.2%|
32829812|NCT04648774|Placebo Comparator|Placebo serratus anterior plane (SAP) block with normal saline|
32829813|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
32829814|NCT05065840|Experimental|4 Pillars Program|Patients at study clinics who consent to have their HPV vaccination history verified with the Georgia Registry of Immunization Transactions and Services (GRITS).
32829815|NCT05065840|No Intervention|Adjacent time-period Control Group|The background HPV update rate among PLWH will be obtained by using the electronic medical record (EMR) and GRITS to identify HPV vaccination uptake 18 months prior to the intervention. These data are collected retrospectively and no study participants are prospectively assigned to this study arm.
32829816|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
32829817|NCT04349878|Placebo Comparator|Control|scaling and root planing alone
32829818|NCT04349878|Active Comparator|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
32829819|NCT04629508|Experimental|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
32829820|NCT04629508|Experimental|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
32829821|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
32829822|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
32829823|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|
32829824|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|
32829825|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|
32829826|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|
32829827|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
32829828|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
32829829|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
32829830|NCT04607122|Experimental|Landiolol group|Landiolol infusion (2µg/kg/min) administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
32829831|NCT04607122|Placebo Comparator|Placebo group|Saline solution infusion administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
32829832|NCT03099382|Experimental|camrelizumab|
32829833|NCT03099382|Active Comparator|Investigator's Choice of Standard Therapy|Docetaxel or Irinotecan
32829834|NCT04593472|Experimental|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
32829835|NCT04593472|Placebo Comparator|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
32829836|NCT04590664|Experimental|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32829837|NCT03818776|Experimental|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
32829838|NCT03818776|Experimental|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
33102271|NCT02920268|No Intervention|Controls|No intervention
33102272|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
33102273|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
33318052|NCT03980639||abatacept|patients with abatacept prescription
33318053|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
32829839|NCT03813238|Experimental|Deutetrabenazine|administered as oral tablets at a starting dose of 6 mg once daily
32829840|NCT03813238|Placebo Comparator|Placebo|Matching placebo
32829841|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
32829842|NCT03057964|No Intervention|Control|
32829843|NCT03755206|Other|Intervention|Interrupted time series design
32829844|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
32829845|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
32829846|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
32829847|NCT04570384|Active Comparator|IV L-Citrulline (Turnobi) Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
32829848|NCT04570384|Placebo Comparator|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
32829849|NCT04556890|Experimental|Active rTMS/Active iTBS DFPLC/Sham Pain M1|
32829850|NCT04556890|Experimental|Sham rTMS/ Active iTBS Pain|
32829851|NCT04556890|Experimental|Active rTMS/Active iTBS|
32829852|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
32829853|NCT04541212||Cohort A|Prospective
32829854|NCT04541212||Cohort B|Retrospective/Prospective
32829855|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
32829856|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
32829857|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
32829858|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
32829859|NCT04511962||Fast track group|Participants randomised to the fast track group will receive the pulmonary rehabilitation intervention 14 ± 7 days after randomisation.
32829860|NCT04511962||Wait list group|Participants randomised to the wait-list group will receive the pulmonary rehabilitation intervention 56 ± 7 days after randomisation.
32829861|NCT04507828|Experimental|Combined DIBH-Expiration Planning Technique|Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan. In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used. If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique. If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol. Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day. Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
32829862|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
32829863|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
32829864|NCT04494412|Experimental|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
32829865|NCT04494256|Experimental|Part 1: Cohort A|Participants with ALS will receive BIIB105 Dose 1, intrathecally (IT), as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
32829866|NCT04494256|Experimental|Part 1: Cohort B|Participants with ALS will receive BIIB105 Dose 2, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
32829867|NCT04494256|Experimental|Part 1: Cohort C1|Participants with ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
32829868|NCT04494256|Experimental|Part 1: Cohort D1|Participants with ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
32829869|NCT04494256|Experimental|Part 1: Cohort C2|Participants with polyQ-ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
32829870|NCT04494256|Experimental|Part 1: Cohort D2|Participants with polyQ-ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
32829871|NCT04494256|Placebo Comparator|Part 1: Cohorts A-D2: Placebo|Participants with ALS and polyQ-ALS for Cohorts A, B, C1 and C2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days, and participants with ALS and polyQ-ALS for Cohorts D1 and D2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
32829872|NCT04494256|Experimental|Part 2: Cohorts A-C2: Open-Label|Participants who complete Cohorts A, B, C1, and C2 will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by twenty-five maintenance doses on twenty-five later days.
32829873|NCT04494256|Experimental|Part 2: Cohorts D1, D2: Open-Label|Participants who complete Cohorts D1 and D2 will have a blinded Loading Dose Period, during which those who received placebo in Part 1 will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, while those who received BIIB105 in Part 1 will receive 2 loading doses of BIIB105 Dose 4, IT, on Days 1 and one later day, and placebo on Day 15. After the blinded Loading Dose Period, participants will receive BIIB105 Dose 4 as twenty-five maintenance doses on twenty-five later days.
32829874|NCT03664726|Experimental|Episodic Future Thinking (EFT) & Neutral Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal
32829875|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT) & Neutral Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal (e.g. department job transfer).
32829876|NCT03664726|Experimental|Episodic Future Thinking (EFT) & Scarcity Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
32829877|NCT03664726|Experimental|Episodic Recent Thinking (ERT) & Scarcity Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
32829878|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
32829879|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
32829880|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
32829881|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
32829882|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
32829883|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
32829884|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
32829885|NCT02563522|Active Comparator|Active|Engensis (VM202) + standard of care
32829886|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
32829887|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
33102274|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
33318054|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:~Serum total PSA concentration is over 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
33318055|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:~Serum total PSA concentration is under 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
33405304|NCT04312386|Experimental|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
32829888|NCT02180724|Experimental|Previously Treated|Subjects previously treated with Waldenström Macroglobulinemia N=92
32829889|NCT02180724|Experimental|Treatment Naïve|Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14
32829890|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
32829891|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
32829892|NCT04383210|Experimental|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
32829893|NCT04383210|Experimental|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
32829894|NCT04383210|Experimental|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
32829895|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
32829896|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
32829897|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
32829898|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
32829899|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
32829900|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
32829901|NCT04355832|Placebo Comparator|Placebo 1|The participants will be randomized to placebo infusion.
32829902|NCT04355832|Placebo Comparator|Placebo 2|The participants will be randomized to placebo infusion.
32829903|NCT04355832|Experimental|GLP-1|The participants will be randomized to Glucagon-like peptide-1 infusion.
32829904|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
32829905|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
32829906|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
32829907|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
32829908|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
32829909|NCT04895982|Experimental|BNT162b2|Intramuscular Injection
32829910|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
32829911|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
32829912|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
32900123|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
32900124|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
33102275|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
33102276|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
32829913|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
32829914|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
32829915|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
32829916|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
32829917|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
32829918|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
32829919|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
32829920|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
32829921|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
32829922|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
32829923|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
32829924|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
32829925|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
32829926|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
32829927|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
32829928|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
32829929|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
32829930|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
32829931|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
32829932|NCT03510988|Experimental|Women with newly diagnosed breast cancer|Women with newly diagnosed breast cancer recruited for hybrid dedicated breast PET/MRI for extent of disease staging prior to management in lieu of breast MRI alone. IV FDG and Gadolinium was injected once prior to the study as per protocol and weight. In each second consecutively recruited patient FDG dosage was decreased by 20% up to 40% of weight-based dosage to ascertain feasibility of imaging at lower FDG dosages. IV Gadolinium was injected once with weight dependent dosages as per clinical standard of care.
32829933|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.~Patients will be given access to the website to learn about the arm precaution program."
32900125|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
32900126|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
32900127|NCT01482091|Placebo Comparator|Intranasal Saline|
32829934|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
32829935|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
32829936|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
32829937|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
32829938|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
32829939|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
32829940|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
32829941|NCT04273932|Experimental|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
32829942|NCT04273932|Experimental|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
32829943|NCT04273932|Experimental|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
32829944|NCT04273932|No Intervention|No lithium treatment|Control arm
32829945|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
32829946|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
32829947|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
32829948|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
32829949|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
32829950|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
33405305|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
32829953|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
32829954|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
32829955|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
32829956|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
32829957|NCT04258722|Experimental|Trainee + Teleneonatologist|Trainee, teleneonatologist, nurse, and respiratory therapist will perform resuscitation
32829958|NCT04258722|Active Comparator|Trainee|Trainee, nurse, and respiratory therapist will perform resuscitation.
32829959|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
32829960|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
32829961|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
32829962|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
32829963|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
32829964|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
32829965|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
32829966|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
32829967|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
32829968|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
32829969|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
32829970|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|oral
32829971|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|oral
32829972|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
32829973|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
32829974|NCT01921335|Active Comparator|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
33318056|NCT03978221|Experimental|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
33318057|NCT03978143|Other|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
33318058|NCT03978143|Other|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
32829975|NCT01921335|Active Comparator|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
32829976|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
32829977|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
32829978|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
32829979|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
32829980|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
33102277|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
33318059|NCT03978143|Other|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
33318060|NCT03978143|Other|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
32829981|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
32829982|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
32829983|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
32829984|NCT01908777|Experimental|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
32829985|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
32829986|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
32829987|NCT01905813|Experimental|INCB040093|
33102278|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
33318061|NCT03978143|Other|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
33318062|NCT03978143|Other|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
33318063|NCT00294671|Active Comparator|Diflunisal|Diflunisal 250 mg po bid
33318064|NCT00294671|Placebo Comparator|Placebo|Placebo 1 po bid
33318065|NCT01064453||Group 1|
32829988|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
32829989|NCT05566587|Other|Western to Mediteranean to Western Diet|Weeks 2 and 3 = WD Weeks 4 and 5 = MD Weeks 6 and 7 = WD
32829990|NCT05566587|Other|Mediteranean to Western to Mediteranean Diet|Weeks 2 and 3 = MD Weeks 4 and 5 = WD Weeks 6 and 7 = MD
32829991|NCT02316886|Experimental|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) +Optimal Medical Treatment
32829992|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
32829993|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
32829994|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
32829995|NCT05544201|Experimental|40 Hz HD-tACS|The stimulation parameters of HD-tACS include: 20 minutes at 40 Hz, 2 milliamps.
32829996|NCT05544201|Active Comparator|HD-tDCS|The stimulation parameters of HD-tDCS include: 20 minutes at 2 milliamps, 20 seconds fade-in and 20 seconds fade-out.
32829997|NCT05544201|Sham Comparator|Sham HD-tCS|In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes. This procedure mimics the transient skin sensation of tingling induced by active HD-tACS and HD-tDCS without producing any sustainable effects.
32829998|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.~Intervention: HPV screening for women Intervention: HPV screening for men"
32829999|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
32830000|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
32830001|NCT01900977|Other|Standard of Care|"Includes:~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
32830002|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
32830003|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
32830004|NCT01893567|Experimental|Clobex spray|
32830005|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
32830006|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
32830007|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
32830008|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
32830009|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
32830010|NCT01485861|Experimental|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|"Participants will receive Ipataseritib 400 mg once daily in the AM for Cycle 1 day 1-18. On Day 19, Ipataseritib 400 mg will be switched to PM dosing for the remainder of the Cycle 1.~Prednisone 5 mg starts in the PM of Cycle 1 day 8 and taken BID thereafter for the remainder of the study treatment Abiraterone 1000mg once a day starts on Cycle1 day 12 in the AM and should be taken at the same time as Ipataseritib. Starting from cycle 1 day 19, Ipataseritib and Abiraterone are dosed in PM at should be taken together at the same time each day until cycle 2 day 1. Starting from Cycle 2 Day 1, Participants may choose to take Ipatasertib and Abiraterone in either the AM or PM; however, they should be taken together at approximately the same time each day.~Participants will receive the study treatment until disease progression or intolerable toxicity."
32830011|NCT04847466|Experimental|1/Arm 1|1-week lead in for PD-L1 CAR NK cell monotherapy followed by combination therapy of Pembrolizumab plus N-803
32830012|NCT04249596|Experimental|Open Treatment|All subjects will be treated for 8 weeks of treatment with Tianeptine (Tianeurax 12.5 mg) 3 times a day (9am, 1pm, 5pm).
32830013|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
32830014|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
32830015|NCT04248816|Experimental|Usual Care|Standard of care
32830016|NCT04248816|Experimental|Opt-out|Facilitated outreach and opt-out framing
32830017|NCT04248816|Experimental|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
32830018|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
32900128|NCT01482091|Experimental|Intranasal Fentnayl|
32900129|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
32830019|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
33318066|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
33318067|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
32830020|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
32830021|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
32830022|NCT04240080|No Intervention|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
32830023|NCT04240080|Experimental|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
32830024|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
32830025|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
32830026|NCT04756089|Experimental|Breast stimulation|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
32830027|NCT04756089|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
32830028|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
32830029|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
32830030|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
32830031|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
32830032|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
32830033|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
32830034|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
32830035|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
32830036|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
32830037|NCT04201782||Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
32830038|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
32830039|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
32830040|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
32830041|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
32830042|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
32830043|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
32830044|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
32830045|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
32830046|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
32830047|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
32830048|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
32900130|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
33318068|NCT03980327|Experimental|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
32830049|NCT04197258|Experimental|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
32830050|NCT04197258|No Intervention|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
32830051|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
32830052|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
32830053|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
32830054|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
32830055|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
32830056|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
33102279|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
33102280|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
33102281|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
33102282|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
33102283|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
33102284|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
33102285|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
33102286|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
33102287|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
33102288|NCT05466045|Experimental|experimental group|Experimental group received olive oil application
32830057|NCT01991548|Other|Diabetic participants with study devices|
32830058|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
32830059|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
33102289|NCT05466045|Placebo Comparator|control group|Control group received normal saline application
33102290|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
33102291|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
32830060|NCT00581373|Experimental|1|water 16 oz
32830061|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
33102292|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
33102293|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
33102294|NCT02920151|No Intervention|CONTROL GROUP|usual routine
33318069|NCT03980327|Placebo Comparator|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
33318070|NCT03980249|Experimental|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
32830062|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
32830063|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
32830064|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
32830065|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
33318071|NCT01495598|Experimental|Phase 1 Pomalidomide 5mg Daily|Up to six subjects will initially be treated with for 21 days of a 28 day cycle
33318072|NCT01495598|Experimental|Phase 2 Pomalidomide 5mg Daily|15 human immunodeficiency virus (HIV) positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mg daily for 21 days of a 28 day cycle
33405306|NCT05745480||Pre-Intervention Period: Usual Care with Ad-Hoc Addiction Consults|UW Hospital launched an Addiction Medicine inpatient consult service in 1991 to address the high prevalence of substance use disorders in hospitalized adults. Currently, a single screening item queries 'marijuana or other recreational drug use,' but no formal screening process was in place specifically targeting opioid misuse. For patients at risk of an opioid use disorder, the practice was ad-hoc consultations at the discretion of the primary provider.
33405307|NCT05745480||Post-Intervention Period: Artificial intelligence-driven clinical decision support|The technical architecture that enabled the real-time, NLP CDS tool incorporated industry-leading and emerging technological capabilities. The NLP CDS infrastructure exports the notes from the EHR, organizes them and feeds them into an NLP pipeline, inputed the processed text features into the opioid screener deep learning model, and delivered the resultant scores back to the bedside electronic health record as a best practice alert.
32830066|NCT01991860|Experimental|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
32830067|NCT01991860|Placebo Comparator|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
32830068|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
32830069|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
32830070|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
32830071|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
32830072|NCT02463552|Placebo Comparator|Placebo|
32830073|NCT02463552|Experimental|Naproxen|
33405308|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
32830074|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
32830075|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
32830076|NCT01871571|Experimental|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
33405309|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
33405310|NCT03451721|Experimental|ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
33405311|NCT00603954|Active Comparator|TBI + fludarabine|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
32830077|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
32830078|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
33405312|NCT00603954|Active Comparator|TLI + ATG|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
33405313|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
33405314|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
33405315|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
33405316|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
33405317|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
32830079|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
32830080|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
32830081|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
32830082|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
32830083|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
32830084|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
32830085|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
32830086|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
32830087|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
32830088|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
32830089|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
32830090|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
33405318|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
33405319|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
32830091|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
32830092|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
32830093|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
32830094|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
32830095|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
32830096|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
32830097|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
32830098|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
32830099|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
32830100|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
32830101|NCT01853163|Other|GBCA|Patients who have received GBCAs in the past
32830102|NCT03298620|Experimental|Intervention|Electric toothbrush
32830103|NCT03298620|Active Comparator|Control|New standard manual toothbrush
33405320|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
33405321|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
33405322|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
32830104|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
32830105|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
32830106|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
32830107|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
32830108|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
32830109|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
32830110|NCT03348670|Experimental|Assess for Licorice Dietary Supplement Oral activity|"Licorice Dietary Supplement Oral~Dietary Supplement Oral"
32830111|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
32830112|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
32830113|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
32830114|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
32830115|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
32830116|NCT03296514|Other|Intervention|These people will receive the MBSR
32830117|NCT03328468|Experimental|Breathing Exercise|
32830118|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
32830119|NCT03298464|Experimental|NGM313|
32830120|NCT03298464|Active Comparator|Pioglitazone|
32830121|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium"
32830122|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
32830123|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
32830124|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
32830125|NCT04491084|Experimental|FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140), and SBRT|"Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease. Subjects on Arm 1 with extensive disease will initially receive SBRT to a single site of disease but may receive additional cycles of FLT3 ligand, anti-CD40 antibody, and SBRT at later time points."
32830126|NCT04491084|Active Comparator|Standard care|Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease.Subjects on Arm 2 with extensive disease are expected to receive some form of standard systemic therapy (e.g., docetaxel). Subjects on Arm 2 with limited disease may also receive standard systemic therapy following completion of SBRT to all sites of evident disease, at the discretion of the treating physicians.
32830127|NCT01852071|Experimental|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
32830128|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
32830129|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
32830130|NCT04084548|Experimental|Lidocaine and placebo|Lidocaine and placebo
32830131|NCT04084548|Experimental|Ketamine and placebo|Ketamine and placebo
32830132|NCT04084548|Experimental|Lidocaine and ketamine|Lidocaine and ketamine
32830133|NCT04084548|Placebo Comparator|Placebo and placebo|Placebo and placebo
32830134|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
32830135|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
32830136|NCT03296358|No Intervention|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
33318073|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
33318074|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
33318075|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~comparing patients with versus those without pouchitis~no intervention"
33318076|NCT05668130|Experimental|Sacrospinous Ligament Fixation Arm|Women randomized to this arm will undergo sacrospinous ligament fixation for apical suspension procedure during pelvic organ prolapse surgery.
33318077|NCT05668130|Experimental|Uterosacral Liganemt Suspension Arm|Women randomized to this arm will undergo uterosacral ligament suspension for apical suspension procedure during pelvic organ prolapse surgery.
33318078|NCT01204970||COPD|COPD Gold class 1-4
33318079|NCT01204970||Transplant|Lung transplant recipients
33318080|NCT01204970||Control|Patients with normal spirometric data
33318081|NCT01297166|Experimental|LEO 27989 ointment|
33318082|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
33318083|NCT04561544|Experimental|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
33318084|NCT04561544|Other|Intervention in Spring 2021|Control in Fall 2020
32830137|NCT03296358|Experimental|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
32830138|NCT03296358|Experimental|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
32830139|NCT04756323|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
32830140|NCT04756323|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
32830141|NCT04756323|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
32830142|NCT04756323|Experimental|medium dosage on day 0, 28(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
32830143|NCT04756323|Experimental|high dosage on day 0, 28(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
33318085|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
32830144|NCT04756323|Placebo Comparator|placebo on day 0, 28(18~59years)|Two doses of placebo on the schedule of day 0,28
32830145|NCT04756323|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32830146|NCT04756323|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32830147|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
33405323|NCT04285242||Participants with Cancer|Assessments and observations for up to 40 days with one overnight hospital stay.
32830148|NCT04756323|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32830149|NCT04756323|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
32830150|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
32830151|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
32830152|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
32830153|NCT04756713|Active Comparator|Chemotherapy|Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
32830154|NCT04756713|Experimental|Uterine evacuation|Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
32830155|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
32830156|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
32830157|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
32830158|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
32830159|NCT04489056||Study group|This group will consist of 50 pregnant women, who experienced pPROM between 22+5 and 28+0 gestational weeks, either presenting at the primary study site, or being referred from other hospitals, and delivered at preterm by cesarean section.
33318086|NCT05667818|Experimental|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
33318087|NCT05667818|Active Comparator|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
33318088|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
33318089|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
33318090|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
33318091|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
33318092|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
33318093|NCT01205282|Placebo Comparator|Placebo|
32830160|NCT04489056||Control group|This group will consist of 50 pregnant women, who are scheduled for elective cesarean section at the outpatient department of the primary study site, between a 32+0 and 37+0 gestational weeks, and delivered at term by cesarean section.
32830161|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
32830162|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
32830163|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
32830164|NCT03296202||HIV patients|4500 patients infected with HIV-1
32830165|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
32830166|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
32830167|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
32830168|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
32830169|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
32830170|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
32830171|NCT03296046||PPBL patients|
32830172|NCT00453531|Experimental|Healthy Volunteers|
32830173|NCT03295968|No Intervention|Water and Rest|
32830174|NCT03295968|Experimental|Water and High Intensity Exercise|
32830175|NCT03295968|Experimental|Ibuprofen and Rest|
32830176|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
32830177|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
32830178|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
32830179|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
33102295|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
33318094|NCT03902912|Experimental|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
33318095|NCT05666414|Experimental|computer guided sandwich interpositional bone grafting|patient specific cutting guide were fabricated to perform the osteotomies ( and another patient specific guide was then fabricated to start the fixation of the cut bony segment a full digital intervention for sandwich interpositional grafting in patients with vertically atrophied mandible (bilateral split mouth study)
32830180|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
32830181|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
32830182|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
32830183|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
32830184|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
32830185|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
32830186|NCT01892592|No Intervention|Usual Care|No Interventions
32830187|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
32830188|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
32830189|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
32830190|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
32830191|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
32830192|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
32830193|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
32830194|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
32830195|NCT01895907||Special Olympic athletes|
32830196|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
32830197|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
32830198|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
32830199|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
32830200|NCT04489836|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
32830201|NCT04489836|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
32830202|NCT04755621|Experimental|Core stability Group|
32830203|NCT04755621|Active Comparator|Control Group|
33405324|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
32830204|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
32830205|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
32830206|NCT04755543|Experimental|I-A|LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
32830207|NCT04755543|Experimental|I-B|If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
32830208|NCT04755543|Experimental|I-C|If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
32830209|NCT04755543|Experimental|I-D|Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
32830210|NCT04755543|Experimental|I-E|Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg：If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
32830211|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
32830212|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
32830213|NCT00437151|Active Comparator|1|More frequent than normal office visits
32830214|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
32830215|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
32830216|NCT00437151|Active Comparator|4|No intervention or reminders
32830217|NCT05392023|Experimental|Group A|Scapular Stabilization exercise program
32830218|NCT05392023|Other|Group B|Relaxation Exercises of cervico- scapular region
32830219|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
32830220|NCT05347251|Experimental|Group A|Cervicothoracic mobility program
32830221|NCT05347251|Other|Group B|Conventional Treatment
32830222|NCT05343741||Helpseeking Ecuadorian adult and adolescent clients|The participants will be adolescent (11-17 years) and adult (>18 years) clients presenting with common non-severe mental health problems who seek mental health services at the Centro de Psicología Aplicada. The CPA is an outpatient psychological service where students of the last semesters of the Clinical Psychology degree develop and practice their psychological care skills as co-therapists of professional clinical psychologists.
32830223|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
33405325|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
32830224|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
32830225|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
32830226|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
32830227|NCT00436527|Other|1|
32830228|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
33405326|NCT04271748|Experimental|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
33405327|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
32830229|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
32830230|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
32830231|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
32830232|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
32830233|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
32830234|NCT05333601|Experimental|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
32830235|NCT01722916|Experimental|Dose of Hyaluronidase|
32830236|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
32830237|NCT04034238|Experimental|1. Dose escalation|LMB-100 at escalating doses plus tofacitinib
33405328|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=11).Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
32830238|NCT04034238|Experimental|2. Dose expansion|LMB-100 at optimal dose plus tofacitinib
32830239|NCT05329623|Experimental|Normal hepatic function|Matched healthy participants with normal hepatic function
32830240|NCT05329623|Experimental|Mild hepatic impairment|Mild hepatic impaired participants with Child-Pugh A (score of 5 to 6)
32830241|NCT05329623|Experimental|Moderate hepatic impairment|Moderate hepatic impairment with Child Pugh B (score from 7 to 9)
32830242|NCT05329623|Experimental|Severe hepatic impairment|Severe hepatic impairment with Child Pugh C (score from 10 to 15)
32830243|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
32830244|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
32830245|NCT04489290|Experimental|D005 Vaginal Mousse|
32830246|NCT04489290|Placebo Comparator|Placebo|
32830247|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
32830248|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
32830249|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
32830250|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
32830251|NCT00291525|Experimental|AVR Low Risk without warfarin|AVR Low Risk without warfarin
32830252|NCT00291525|Active Comparator|AVR low risk with standard warfarin|AVR low risk with standard warfarin
33318096|NCT05666414|Active Comparator|conventional sandwich osteotomy interpositional bone grafting|conventional interpositional bone grafting was done for patients with vertically atrophied mandibles (bilateral split mouth study)
32830253|NCT00291525|Experimental|AVR High risk with lower warfarin|AVR High risk with lower warfarin
32830254|NCT00291525|Active Comparator|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
32830255|NCT00291525|Experimental|MVR with lower warfarin|MVR with lower warfarin
32830256|NCT00291525|Active Comparator|MVR with standard warfarin|MVR with standard warfarin
32830257|NCT04479618|Active Comparator|Usual practice (negative control)|After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
32830699|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
33318097|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
33318098|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
33318099|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
33318100|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
33318101|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
33318102|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
33405329|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
33405330|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
32830258|NCT04479618|Experimental|improvised dressings (experimental)|After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
32830259|NCT04479618|Active Comparator|advanced dressings (positive control)|"After initial cleansing/debriding, the advanced dressing group (3) will have a cut piece of a 4x24 standard (pink) polymeric membrane dressing roll large enough to extend at least 0.5 cm beyond all open and closed (inflamed or damaged) wound edges applied as per the Instructions for Use (the periwound is blotted dry, but the wound bed remains moist from the final saline rinse). One wrap of stretch gauze will hold the polymeric membrane dressing in place. The approximate open wound edges will be marked on the dressing backing. As per the manufacturer's instructions for use, patients will change the dressings when saturation reaches any of the wound edges, as indicated by a change in color on the backing of the dressing, visible through the stretch gauze. Routine rinsing will not be performed; the wounds will be rinsed at dressing changes only if visible loose debris is present."
32830260|NCT04030650||healthy volunteers|
32830261|NCT04030650||patients|patients with lower limb amputations
32830262|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
32830263|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
32830264|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
32830265|NCT03297918|No Intervention|Control group|no intervention
32830266|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
32830267|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
32830268|NCT04011384|No Intervention|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
32830269|NCT04011384|Experimental|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
32830270|NCT01787487|Experimental|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
32830271|NCT01787487|Experimental|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
32830272|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
32830273|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
32830274|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
32830275|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
32830276|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
32830277|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
32830278|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
32830279|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
32830280|NCT00280761||1|Single Arm Trial
32830281|NCT02061748||dabigatran|
32830282|NCT02061748||warfarin|
32830283|NCT03999996|Experimental|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV 0.5 mL, injection, subcutaneously, once at Month 15 for participants from parent trials DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
32830284|NCT03999996|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
32830285|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
32830286|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
32830287|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
32830288|NCT01436968|Experimental|ProstAtak®|Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT
32830289|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
33405331|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
32830290|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
32830291|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
32830292|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
32830293|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
33405332|NCT02435433|Experimental|Ramucirumab + Best Supportive Care (BSC)|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
33405333|NCT02435433|Placebo Comparator|Placebo + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
32830294|NCT04441866|Active Comparator|Automated algorithms|Automated 3D techniques in measuring fetal biometry and reconstructing standard anatomical planes
32830295|NCT04441866|Placebo Comparator|Standard technique|Standard 2D assessment
32830296|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
32830297|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
32830298|NCT02062294||Cohort|
33405334|NCT02435433|Experimental|Open Label Ramucirumab + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
32830299|NCT04441632|Other|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
32830300|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
32830301|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
32830302|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
33405335|NCT02435433|Experimental|Ramucirumab MEE Cohort + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
33405336|NCT02435433|Placebo Comparator|Placebo MEE Cohort + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
32830303|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
32830304|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
32830305|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
32830306|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
32830307|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
32830308|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
32830309|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
32830310|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
32830311|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
32830312|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
32830313|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
33405337|NCT01372371|Active Comparator|Vancomycin|
32830700|NCT00160173|Experimental|EstroGel® Gel 0.9 grams 0.03%|0.9 g of EstroGel® 0.03% applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
32830701|NCT00160173|Experimental|EstroGel® Gel 1.25 grams 0.03%|1.25 g of EstroGel® 0.03% applied to one arm and 0.9 g of placebo gel applied on the other arm once daily for 12 weeks.
33405338|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
32830314|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
32830315|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
32830316|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
32830317|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
33102296|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
33102297|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
33102298|NCT05466006|Active Comparator|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at peri-implant small buccal dehiscence with subepithelial connective tissue graft harvested from the patient's palate
32830318|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
33405339|NCT01372371|Active Comparator|Intravenous Antibiotic|
33102299|NCT05466006|Experimental|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at peri-implant small buccal dehiscence with xenogenic volume stable collagen matrix
33102300|NCT02920190|Experimental|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
33102301|NCT05465850|Active Comparator|Filtek Z350XT|
33102302|NCT05465850|Experimental|Essentia universal shade, GC composite|
33102303|NCT05465850|Experimental|Omnichroma composite|
33102304|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
33405340|NCT05167383|Active Comparator|Intervention VR group|. In the VRH group the patients received a 30-minute session of virtual reality hypnosis when in active labor and had access to standard care.
33405341|NCT05167383|Placebo Comparator|Standard treatment|Patients in the control group received only standard care.
32830319|NCT02002936|Experimental|SyB C-1101|
32830320|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
32830321|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
32830322|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
32830323|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
32830324|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
32830325|NCT05229978||Patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
32830326|NCT05229978||Informal carers of patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
32830327|NCT05229978||Dementia experts/specialists|Given their expertise on dementia from a professional point of view, a focus group is conducted with dementia specialists in order to elicit their views and ideas on health data engagement interface like Dynamic Consent.
32830328|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
32830329|NCT00003270|Experimental|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
32830702|NCT00160173|Placebo Comparator|Placebo Gel|0.9 g of placebo gel applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
32830703|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
33102305|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
33102306|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
33318103|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
33318104|NCT04533308|Experimental|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
33318105|NCT04533308|No Intervention|Control|Patients in the control group will not receive any psychological interventions.
33318106|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
32830330|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
32830331|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
32830332|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.~Training session:~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
32830333|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
32830334|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
32830335|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
32830336|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
32830337|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
32830338|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
32830339|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
32830340|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
32830704|NCT03285282|No Intervention|Control|
32830705|NCT03285204||ALS patients|
32830706|NCT03285204||Friedreich Ataxia patients|
33318107|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
33318108|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
33318109|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
33318110|NCT01205516|Experimental|Methadone|
33318111|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
33318112|NCT01297634|Other|Botulinum Toxin Type-A 1U|
33318113|NCT01297634|Other|Botulinum Toxin Type-A 2U|
33318114|NCT01297634|Other|Botulinum Toxin Type-A 3U|
33318115|NCT01201070|No Intervention|control group|
33318116|NCT01201070|No Intervention|no treatment|
33318117|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
33318118|NCT03850964|Active Comparator|(Moderate Cohort) Pazopanib - 150 mg|150 mg pazopanib oral capsules (six 25 mg placebo capsules daily).
33318119|NCT03850964|Placebo Comparator|(Moderate Cohort) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
33318120|NCT03850964|Active Comparator|(Severe Cohort) Pazopanib - 150 mg|Pazopanib 150 mg oral daily dosing (six 25 mg Pazopanib capsules).
33318121|NCT03850964|Placebo Comparator|Severe Cohort) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
32831172|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
32831173|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
32831174|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
32831175|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
32831176|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
32831177|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
32831178|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
32831179|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
32831180|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
33032945|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
33032946|NCT01957501||Major Depressive Disorder Participants|
33032947|NCT01957501||Bipolar Disorder Participants:|
33032948|NCT01957501||Healthy Control Participants|
33032949|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
33032950|NCT01957527||Ticagrelor discontinuation|
33032951|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
33032952|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
33032953|NCT01957566|Experimental|APS|
33032954|NCT01957592||Subjects with diabetes mellitus (type 2)|
33032955|NCT01957605||prone position|Patient scheduled for surgery in the prone position
33032956|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
33032957|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
33032958|NCT01957631|Active Comparator|Corticosteroid injection|Corticosteroid injection
33032959|NCT01957631|Experimental|Platelet rich plasma injection|Platelet rich plasma injection
33032960|NCT01957670|Experimental|Treatment with Lacrima medical device|
33032961|NCT01957683|Experimental|Single Arm|
33032962|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
33032963|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
33032964|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR~Docetaxel IV once weekly at a starting dose of 20 mg/m2.~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
33032965|NCT01957774|Experimental|THR-18|
33032966|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
33032967|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
33032968|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
33032969|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
32831181|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
32831182|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
32831183|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
32831184|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
32831185|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
32831186|NCT02020018|Experimental|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
32831187|NCT02020018|Active Comparator|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
32831188|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
32831189|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
32831190|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
32831191|NCT02020252||Touchscreen Participants|New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.
32831192|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
32831193|NCT03265548|Experimental|Intervention|Video laryngoscopy
32831194|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
32831195|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
32831196|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
32831197|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
32831198|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
32831199|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
32831200|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
32831201|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
32831202|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
32831203|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
32831204|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
32831205|NCT04782843||Cohort|"he retrospective cohort studied includes all the patients included in a previous study carried out in our center, the objective of which was to study the diagnostic performance of the HEP score in surgical intensive care.~The cohort studied is made up of all patients admitted for surgical resuscitation between October 2011 and October 2013 and validating the following criteria:~Inclusion criteria: any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (UFH or LMWH), and suspected of TIH by a clinician in the department according to the criteria of the SFAR 2002.~Non-inclusion criteria: minor patients, pregnant women and adults incapable."
32831206|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
32831207|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
32831208|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
32831209|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
32831210|NCT04782765|Experimental|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
32831211|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
32831212|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
32831213|NCT04389801|Experimental|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
32831214|NCT04389801|Placebo Comparator|control group|Will receive glucose 5% over 4 hrs infusion
32831215|NCT04782141|Experimental|Positioning the trunk and upper limb to improve the coordination the hand.|The study investigated the effects of the trunk and upper limb positioning on improving wrist and hand coordination.
32831216|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
32831217|NCT01606995||Group 1|
32831218|NCT04054557|Active Comparator|Arm I (Standard of Care office Visits)|Participants receive standard of care office visits approximately every 3 months (± 2 weeks) for one year.
32831219|NCT04054557|Experimental|Arm II (Standard of Care Office Visits, survey, telehealth)|Patients receive standard of care as in Arm I and 4 automated electronic surveys every 3 weeks (+/- 1 weeks) for a total of 18 electronic surveys over one year. Patients who report severe or very severe side effects, or stopping or are thinking about stopping their ET will have a follow up encounter with a research coordinator.
32831220|NCT04054557|Experimental|Arm III (Smart Pill Bottle, messaging)|Patients receive a wireless smart pill bottle that performs daily time-specific reminders to open the pill bottle and take the medication. Additional messages are triggered by the pill bottle when non-adherence is indicated (lack of bottle opening or no change in remaining pills), as well as when medication is skipped.
32831221|NCT04782453|Experimental|ToQuit|Participants from the ToQuit intervention arm will receive the messages on their mobile phones for 8 weeks. The messages will be sent for 3-4 days a week.
32831222|NCT04782453|Other|Control|Participants from the control group will be sent the details of other functional tobacco helplines in India.
32831223|NCT03548220|Placebo Comparator|Placebo|Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.
32831224|NCT03548220|Experimental|AG-348, 5 mg|Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
32831225|NCT03548220|Experimental|AG-348, 20 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
32831226|NCT03548220|Experimental|AG-348, 50 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
32831227|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
32831228|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
32831229|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~No significant medical history~Take no medications (other than birth control pills)~Fever free~No history of head trauma or recent injury/infection~No history of neurological or psychiatric disorders or alcohol or drug dependency."
32831230|NCT04050969|Active Comparator|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
32866652|NCT04816344||Group MK (n=35)|Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg ketofol (10% ketamine + 10% propofol) iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg iv ketofol was given as additional dosage.
32831231|NCT04050969|Experimental|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
32831232|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
32831233|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
33318692|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
33318693|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:~'Usual care'~PEP mask therapy"
32831234|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
32831235|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
32831236|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
32831237|NCT04781985|Experimental|suprapubic cystolithotomy|Extraction of the vesical stone via open exploration of the bladder.
32831238|NCT04730739|Experimental|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The patient must have been treated with either Knee Spanning or Damage Control FastFrame External Fixation System.
32831239|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
32831240|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
33318694|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
33318695|NCT03952572|Experimental|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
33318696|NCT03952572|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
32831241|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
32831242|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
32831243|NCT04754997|No Intervention|Control group|This group will not take any exercise intervention.
32831244|NCT04754997|Active Comparator|Traditional exercise training group|This group will get traditional therapy that is include range of motion exercises and resistance exercise training.
32831245|NCT04754997|Experimental|Specific exercise training group|This group will get a specific programme that combinated with closed kinetic chain exercises and core exercises training
32831246|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
32831247|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
32831248|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
32831249|NCT01145235||Females previously treated with Macrolane in their breasts.|
32831250|NCT03265236||Group1|Patients with early rheamatoid arthritis
32831251|NCT03265236||Group 2|patients with late rheamatoid arthritis
32831252|NCT03265236||Group 3|Healthy control
32831253|NCT04701411|Experimental|Darvadstrocel|Darvadstrocel (Cx601), 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
32831254|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
32831255|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
32831256|NCT01571895|Experimental|DF2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
32831257|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
32831258|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
32831259|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
32831260|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
32831261|NCT04778241|Experimental|Micro-Osteoperforation group|All the participants bonded by the care provider with 0.022 inch MBT prescription appliance (Ortho TechanologyTM,USA). Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
32831262|NCT04778241|No Intervention|Control group|All the participants in this group bonded by the principal investigator with 0.022-inch slot MBT prescription appliance (Ortho TechanologyTM,USA). No micro-osteoperforation was used in this group.
32831263|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
32831264|NCT04754919|Active Comparator|Transition intervention group|Intervention group -will be working with the specialist diabetes transition nurse. The nurse will follow a specific protocol involving visits, clinic support, community support and appointment rearranging. She will also maintain communication with the Hospital based adult and paediatric diabetes teams and the participants General Practitioner and relevant community health care professionals.
32831265|NCT04754919|Placebo Comparator|Post Transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
32831266|NCT04754841|Experimental|SURVIVAL AND FUNCTIONALITY INVITRO IN CRYOPRESERVED PLATELETS|Platelet concentrates will be administered 3 alternatives of cryopreservative solution: 5% dimethylsulfoxide (solution 1), 5% dimethylsulfoxide plus 160 mg of 5% dextrose (solution 2) and 5% dimethylsulfoxide plus 2% albumine (solution 3 ). They will then be frozen at -80 ° C and their survival and functionality will be subsequently evaluated in vitro.
32831267|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
32831268|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
33102539|NCT05467241|Experimental|Self-induced therapeutic tremor (SITT) combined with mindfulness|"This arm will consist of self-induced therapeutic tremor (SITT) training combined with mindfulness training that is performed during a 60 minute session, 2 times per week, for 4 weeks.~Self-induced therapeutic tremor (SITT) combined with mindfulness: SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. During SITT muscles will gently shake, and release built up stress. This shaking of muscles lets the participant's body physically let go of tension and stress. Mindfulness is the ability to be fully present in a moment so that the participant can focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them. Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed."
33102540|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
33102541|NCT05467202|Experimental|Treatment group|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
33102542|NCT05338788||Patient Group|"Thirty-two 32 patients with cervical disk herniation related chronic neck pain participated in this cross-sectional controlled study. Patients who aged 18-64 years, had neck pain for at least 12 weeks, no tumor, trauma, fracture pathology in the spinal region and no history of spine surgery were included.~The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control. The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI) was assessed."
33102543|NCT05338788||Control Group|"Twenty-three 23 age and sex-matched asymptomatic controls participated in this cross-sectional controlled study.~The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control.The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI)was assessed."
33318697|NCT00299975|Experimental|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
33318698|NCT00299975|Experimental|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
33318699|NCT00299975|Experimental|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
33318700|NCT03951090|Experimental|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
32831269|NCT04001595||Participants with FKRP gene mutation|
32831270|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
32866653|NCT04816344||Group DP (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage.
33318701|NCT03951090|Active Comparator|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
33318702|NCT03954522|Experimental|Expérimental|psychologist interview and psychometrics scales
33318703|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
33318704|NCT00004980|Experimental|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
33318705|NCT00004980|Placebo Comparator|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
32831271|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
32831272|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
32831273|NCT04781829|No Intervention|Control|Critically ill patients with pneumonia will be treated with an antibiotic strategy at the discretion of the treating clinician
32831274|NCT04781829|Experimental|Interventional|Critically ill patients with pneumonia will be treated with an antibiotic strategy based on results from the BioFire Pneumonia Panel
32831275|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
32831276|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
33318706|NCT03954756|Experimental|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
32831277|NCT04778319|Active Comparator|tubal occlusion|occlusion of tubes
32831278|NCT04778319|Sham Comparator|non occlusion of tube|non occlusion of tubes
32831279|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
32831280|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
32831281|NCT01110681|Experimental|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
32831282|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
32831283|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
32831284|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
32831285|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
32831286|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
32831287|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
32831288|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
32831289|NCT04778007||Globus pharyngeus patients|The first group consists of 80 globus pharyngeus patients who have at least a year of globus sensation complaints. The participants will given the Turkish Version of the Laryngopharyngeal Measure of Perceived Sensation Questionnaire (T-LUMP), consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale. After the two weeks, 80 participants will given the T-LUMP and Visual analog scale for sampling.
32831290|NCT04778007||Healty subjects|The second group consists of 80 healty participants will given the T-LUMP consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale
32831291|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:~Week 0: 160 mg SC~Week 2: 80 mg SC~Followed by 40 mg SC every 2 weeks' maintenance therapy"
32831292|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
32831293|NCT04781751|No Intervention|dexamethasone|dexamethasone with local anesthetics injected for carpal tunnel relief
32831294|NCT04781751|Active Comparator|Insulin group|insulin with local anesthetics and dexamehtasone injected for carpal tunnel relief
32831295|NCT04781205|Experimental|Intervention|Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
32831296|NCT04781205|No Intervention|Usual care|No intervention at all
33318707|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
32831297|NCT05387928|Experimental|Dose Escalation|KL340399 weekly on Days 1, 8 and 15 on repeated 21-day cycles in escalating doses.
32831298|NCT04777695||CICU Inpatients|This is a prospective observational study of all children admitted to the pediatric CICU during a one month period of time for patients aged 0 to less than or equal to 22 years of age, as per the World Health Organization definition of a pediatric patient.
33318708|NCT03983525|Experimental|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
33318709|NCT03983525|Active Comparator|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
32831299|NCT04488276||Pregnant women|Non smoking pregnant and post-partum women
32831300|NCT04488276||Smoking fathers|Expectant or new fathers who smoke
32831301|NCT04643379|Experimental|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:~Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.~Pembrolizumab 200 mg intravenous (IV) Day 1.~Carboplatin AUC 5 IV on Day 1 for up to six cycles."
32831302|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
32831303|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
33318710|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
33318711|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
33318712|NCT00326885|Experimental|Catumaxomab|
33326865|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
32831304|NCT04781439|No Intervention|non-switching|control group
32831305|NCT04781439|Experimental|IV-to-PO conversion within 48-72 hours|early switching
32831306|NCT04781439|Experimental|IV-to-PO conversion after 72 hours|late switching
32831307|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
32831308|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
32831309|NCT04777773|Other|control group|classical physical therapy+ classical physical therapy
32831310|NCT04777773|Other|study group|classical physical therapy+ dual-task training
33032970|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
33032971|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
33032972|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
33032973|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
33032974|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
33032975|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
33032976|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
33032977|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
33032978|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
33032979|NCT01957904|Other|ArterX Surgical Sealant|
33032980|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
33032981|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
32831311|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
32831312|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
32831313|NCT04777383|Experimental|Vascular effects of iontophoresed vasoactive substances|"Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.~Vasoactive substances:~Miochol-E (Acetylcholine),10 mg/ml, Bausch & Lomb~Methacholine chloride, 100 mg/ml, APL~Norepinephrine, 1 mg/ml, Pfizer~Phenylephrine, 10 mg/ml, Unimedic~Atropine, 10 mg/ml, Bausch & Lomb~Neostigmine, 2.5 mg/ml, Unimedic Pharma~Sterile water, 100 ml, Braun"
32831314|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
32831315|NCT04780971|Other|Post-PCI intra-coronary physiological and OCT measurements|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
32831316|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)~Leptomeningeal metastasis cohort (LM cohort)"
32831317|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
32831318|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
32831319|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
32831320|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
32831321|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
32831322|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
32831323|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
32831324|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
32831325|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
32831326|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
32831327|NCT04780659|Experimental|Vaccination with Comirnaty according to standard of care treatment|All study participants will receive Comirnaty according to current approval.
32831328|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
32831329|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
32831330|NCT03252288|No Intervention|No intervention|No intervention
32831331|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
32831332|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
32831333|NCT04780815|Experimental|myBluTM Formulation 1|
32831334|NCT04780815|Experimental|myBluTM Formulation 2|
32831335|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
33326866|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
32831336|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
33318713|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
32831337|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
32831338|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
32831339|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
32831340|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
32831341|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
32831342|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
32831343|NCT04777227|Active Comparator|Debridement|A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr
32831344|NCT04777227|Sham Comparator|Debridement with needle insertion|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
32831345|NCT04777227|Placebo Comparator|Debridement with physiological water injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
32831346|NCT04777227|Experimental|Debridement with lidocaine injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
32831347|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
32831348|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
32831349|NCT04780737||Prophylactic cholecystectomy|Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy
32831350|NCT04780737||On-demand cholecystectomy|Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease
32831351|NCT04776915||Study Group|Infertile patients due to polycystic ovarian syndrome
32831352|NCT04776915||Control Group|Infertile patients due to unexplained infertility
32831353|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
32831354|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
32831355|NCT04467255|Active Comparator|group a|aerobic training
32831356|NCT04467255|Active Comparator|group b|endurance training
32831357|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
32831358|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
33032982|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
32831359|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
32831360|NCT04780347|Experimental|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel combined with capecitabine
32831361|NCT04780347|Active Comparator|Capecitabine|Capecitabine
32831362|NCT04780503||Intubation Group/ Non-Intubation Group|Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied
32831363|NCT04780503||Dying patients / Surviving patients|Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure
32831364|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
32831365|NCT01013415|Experimental|ARM 1|Arm I (N=5) received antiretroviral therapy (ART) plus low dose IL-2 (1.2 million units/m2) subcutaneously daily for 56 days
32831366|NCT01013415|Experimental|ARM 2|Arm 2 (N=5) received ART plus a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
32831367|NCT01013415|Experimental|ARM 3|Arm 3 (n=5) received ART plus IL-2 (1.2 million units/m2) and a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
32831368|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
32831369|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
32831370|NCT04776603||Group 1|group 1 includes patients who axial length(AL)<26mm
32831371|NCT04776603||Group 2|group 2 includes patients who axial length（AL）≥26mm
32831372|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
32831373|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
32831374|NCT04780191|Experimental|Active MyoRegulator® treatment|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
32831375|NCT04780191|Sham Comparator|Sham MyoRegulator® treatment|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
32831376|NCT03252132|Active Comparator|12-week resistance training|
32831377|NCT03252132|No Intervention|No training|
32831378|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
32831379|NCT04776291|Experimental|Recruitment and image processing|
32831380|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
32831381|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
32831382|NCT03937167|No Intervention|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
32831383|NCT03937167|Experimental|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
32831384|NCT03937167|No Intervention|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
32831385|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
32831386|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
32831387|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
32831388|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
32831389|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
32831390|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
32831391|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
32831392|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
32831393|NCT04779723|Active Comparator|LRYGB Procedure|LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.
32831394|NCT04779723|Active Comparator|LSG Procedure|35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.
32831395|NCT05387850||Elderly patients over the age of 65|Elderly patients over the age of 65 undergoing elective non-cardiac surgery
32831396|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
32831397|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
32831398|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
32831399|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
32831400|NCT04776135|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally.
32831401|NCT04776135|Experimental|MT-1186 via a nasogastric tube|Subjects receive the edaravone oral suspension via a nasogastric tube
32831402|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
32831403|NCT04775823|Experimental|Hybrid composite nano-ceramic|
32831404|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
32831405|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
32831406|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
32831407|NCT04779801|Experimental|ABFT|Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.
32831408|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
32831409|NCT04779255|Experimental|Tumescent anesthesia|Patient who will receive tumescent anesthesia as analgesic treatment
32831410|NCT04779255|Active Comparator|Painkillers and cold water|Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment
32831411|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
33102544|NCT05325840|Experimental|music therapy|"Experimental Group: Pre-test will be applied to pregnant women before the intervention. Since ST will be applied later, Nki will be applied to pregnant women, and their props will then be right lateral or lateral. NST registration form will be filled.~After the pregnancy is given, the type of music (Classical Turkish Music, Turkish Classical Music, Lullaby) is asked according to the preferences of the pregnant women and their music is given for 20 minutes. The NST process will be implemented from start to finish. In the application, music from pregnant women will be played on MP3 players. After the NST procedure is applied, the pregnant women will have a son."
33102545|NCT05325840|No Intervention|standard of care|"Control group: First of all, Personal Information Form, State Anxiety Scale and blood pressure measurement will be made to the pregnant women in the control group. In order to perform the NST procedure, the pregnant women will be given the left side or right side position to fix the probes. NST registration form will be filled.~20 minutes after positioning the pregnant women. During the routine NST procedure will be applied and no intervention will be made. After the NST procedure is completed, the State Anxiety Scale and blood pressure measurement will be repeated as the last test of the pregnant women."
33318714|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
33318715|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
33318716|NCT03979703|Experimental|Intervention group|Intervention will be a 12 week yoga class
33318717|NCT03979703|No Intervention|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
32831412|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
32831413|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
32831414|NCT04775901|Other|CT-guided lung biopsy|Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.
32831415|NCT04775901|Experimental|Template-guided lung biopsy|Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.
32831416|NCT04775979|Experimental|Diphenylcyclopropenone (DPCP)|Applying DPCP topically
32831417|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
32831418|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
32831419|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
32831420|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
32831421|NCT03259932|Other|usual management|
32831422|NCT03259932|Experimental|physical training|
32831423|NCT04779567|Experimental|Acetaminophen|Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day
32831424|NCT04779567|Placebo Comparator|Placebo|100 ml saline 0.9% iv 4 times a day
32831425|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
32831426|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
32831427|NCT03291210|Experimental|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
32831428|NCT03291210|Active Comparator|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
32831429|NCT04756245|Experimental|Virtual Reality|Participants engage in intervention procedures using virtual reality software.
32831430|NCT04756245|Active Comparator|Video Conference|Participants engage in intervention procedures using video conference software.
32831431|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
32831432|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
32831433|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
32831434|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
32831435|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
32831436|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
32831437|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
32831438|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
32831439|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
33318718|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
33318719|NCT03983447|Experimental|School-based intervention to promote Physical Activity (PA)|"This intervention included :~Physical (Environmental) adaptation of playground~Time adaptation of lunch breaks~Curriculum-based program of children~Workshops and newsletters for parents~Meetings for teachers"
32831440|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
32831441|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
32831442|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
32831443|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
32831444|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
32831445|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
32831446|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
32831447|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
32831448|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
32831449|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
32831450|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
32831451|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
32831452|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
32831453|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
33032983|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
33032984|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
33032985|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
33032986|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
33032987|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
33032988|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
33032989|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
33318720|NCT03983447|No Intervention|Control|Nothing has changed in the school.
33318721|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
32831454|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
32831455|NCT04754685|Active Comparator|Mild knee osteoarthritis|30 patients had mild knee osteoarthritis
32831456|NCT04754685|Active Comparator|Moderate knee osteoarthritis|30 patients had moderate knee osteoarthritis
32831457|NCT04754685|Active Comparator|Severe knee osteoarthritis|30 patients had severe knee osteoarthritis
32831458|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
32831459|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
32831460|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
32831461|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
32831462|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
32831463|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
32831464|NCT04775589|Experimental|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
32831465|NCT03251742|Active Comparator|Fontan patient population|
32831466|NCT03251742|Sham Comparator|Healthy volunteers|
32831467|NCT04775277||cases|pregnant female with idiopathic pulmonary fibrosis
33102546|NCT05466968|Experimental|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
32831468|NCT04775277||control group|pregnant female with bronchial asthma
33102547|NCT05466968|Placebo Comparator|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
33102548|NCT04562805|Experimental|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
33102549|NCT04562805|Active Comparator|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
32831469|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
32831470|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
32831471|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
32831472|NCT04775511|Experimental|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
32866654|NCT04816344||Group DK (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg ketofol iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg ketofol iv was given as an additional dosage.
33102550|NCT05466812|Experimental|Sr-89 treated group|Sr-89 treatment
33102551|NCT05466773|Experimental|CN group|Giving nutrition education for nurse, but not for patients
33102552|NCT05466773|Experimental|CP group|Giving nutrition education for patients, but not for nurses
33102553|NCT05466773|Experimental|CNP group|Giving nutrition education for both patients and nurses
33102554|NCT05466773|No Intervention|NC group|No nutrition education for patients and nurses
33102555|NCT00533793|Active Comparator|SoC|Standard of Care
33318722|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
33318723|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
33318724|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
33318725|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
33318726|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
33102556|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
33102557|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
33102558|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
33102559|NCT05466695|Experimental|tadalfil group|Patients will use daily tadalafil 5 mg for 2 months
33102560|NCT05466695|Experimental|sildenafil group|Patients will use daily sildenafil 25 mg for 2 months
33102561|NCT04686747||Esophageal Cancer|
33102562|NCT04686747||Gastric Cancer|
33102563|NCT04686747||Pancreatic Cancer|
33102564|NCT04686747||Colorectal Cancer|
33102565|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
33102566|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
32831473|NCT04775511|Experimental|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
32831474|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
32831475|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
33102567|NCT05466617|Experimental|PuzzleWalk|"PuzzleWalk incorporates behavior change techniques (BCTs), a theory-based method of promoting healthy behavior change by leveraging psychological determinants. The example techniques included in PuzzleWalk are a comprehensive, visualized user guide, self-monitoring of target performance, contingent rewards, and goal setting.~It is a spot the difference puzzle game comprising 660 major city images around the world. This format was chosen because it is easy to understand the purpose of the game, and it can quickly capture the user's interests without a complex comprehension process. Moreover, this visual image-based game facilitates visual interaction, which is a unique strength of individuals with ASD. The most unique design element of PuzzleWalk is the conversion algorithm between steps and game-solving time. Specifically, the user's accumulated steps are directly converted to game-solving time to motivate PA participation."
33102568|NCT05466617|Experimental|Google Fit|Google Fit (Google LLC) is a PA-tracking platform developed by Google for Android and Apple iOS. The app uses a sensor built into a smartphone device to automatically track PA, including steps and active minutes. It also allows users to journal and record a variety of forms of PA (eg, cycling, weightlifting, and yoga) by manually setting the activity tracking mode. Google Fit uses a heart point-based reward system as a gamification strategy to provide users with individualized exercise tips incorporated with PA recommendations outlined by the American Heart Association. The number of heart points received based on active minutes is the app's primary gamification strategy.
33102569|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
33102570|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
32831476|NCT03246360|Experimental|continuous administration of cloxacillin|
32831477|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
33318727|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
33318728|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
33102571|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
33102572|NCT04484610|Experimental|Appropriate Opioid Quantities|Pharmacists in the intervention regions are invited to complete an eLearning program to promote the practice change intervention of assessing and dispensing appropriate quantities of opioids prescribed for acute pain.
33102573|NCT04484610|No Intervention|Usual Practice|Pharmacists in the comparison regions are not targeted for the practice change intervention (they are not invited nor provided access to the eLearning program).
33318729|NCT01065467|Experimental|Treatment|LBH589
33318730|NCT01065545|Experimental|Clofarabine|
33102574|NCT04687670|Experimental|Intervention group(pET)|Personalized embryo transfer of a single vitrified blastocyst in a HRT cycle according to the ERA test results.
33102575|NCT04687670|Active Comparator|Control group(FET)|Frozen embryo transfer of a single vitrified blastocyst in a HRT cycle according to the clinical standard practice.
33318731|NCT01065623|Experimental|Arm 1|
33318732|NCT03979469|Experimental|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
33102576|NCT05321316|Experimental|68Ga-N188|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.
33326867|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
32831478|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
32831479|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
32831480|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
32831481|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
32831482|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
32831483|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
32831484|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~Sham Paracervical Block done with capped spinal needle~osmotic dilators placed in the usual fashion~postprocedural assessment"
32831485|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~18 ml 1% buffered lidocaine Paracervical Block~osmotic dilators placed in the usual fashion~postprocedural assessment"
32831486|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
32831487|NCT03251976|Experimental|Intervention|video decision aid
32831488|NCT03251976|Active Comparator|Usual care|
32831489|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
32831490|NCT03251664||Anemic|Hemoglobin <11 g/l
32831491|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
32831492|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
32831493|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
32831494|NCT04488198|No Intervention|Control group|20 CIBD patients do not receive acupuncture or placebo-acupuncture.
32831495|NCT04488198|Active Comparator|Acupuncture group|20 CIBD patients receive 8 sessions of acupuncture therapy with 0,3 x 30mm needles (asia-med special number 16).
32831496|NCT04488198|Placebo Comparator|Placebo group|20 CIBD patients receive 8 sessions of sham acupuncture with placebo-needles 0,3 x 30mm (Streitberger).
32831497|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831498|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831499|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831500|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831501|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831502|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831503|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831504|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
32831505|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
32831506|NCT04488120|Experimental|Occlutech septal occluder ( Figulla Flex II)|Occlutech septal occluder (Figulla Flex II)
32831507|NCT04488120|Active Comparator|Amplatzer Septal Occluder (ASO)|St. Jude AGA septal occluder (Amplatzer ASO)
32831508|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
32831509|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
32831510|NCT04488042|Experimental|Stapler-less|after the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
32831511|NCT04488042|Active Comparator|Conventional Stapler|no reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
32831512|NCT00898365||Ancillary-correlative (renal tumor classification, biology)|Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
32831513|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
32831514|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
32831515|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
32831516|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
32831517|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
32831518|NCT04487808|Active Comparator|Average American Diet|Diet representative of average American intake in terms of diet quality measured by the Healthy Eating Index-2015.
32831519|NCT04487808|Active Comparator|Average American Diet + Pecans|Diet that approximates average American intake in terms of diet quality measured by the Healthy Eating Index-2015, but includes 2 oz./day of pecans.
32831520|NCT04487808|Active Comparator|Healthy Diet + Pecans|High diet quality, measured by Healthy Index-2015 score >95, and includes 2 oz./day of pecans.
32831521|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
32831522|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
32831523|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
32831524|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
32831525|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
32831526|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
32831527|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
32831528|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
32831529|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
32831530|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
32831531|NCT00897507||Ancillary-Correlative (genotype assessment)|Tumor tissue samples undergo genotype assessment on the Pyrosequencing platform. Contingency tables and X^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. Cox proportional hazards evaluate the risk of relapse given genotype and other confounders. Genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.
32831532|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
33102577|NCT05466266|Experimental|ICE group|ICE group without TEE detection before procedure
33102578|NCT05466266|Active Comparator|TEE group|TEE group with non-ICE usage at the entire procedure
33318733|NCT03979469|Active Comparator|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
33318734|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
33102579|NCT05307354|Experimental|Nerve Mobilization Group|Tibial nerve mobilization in addition to foot-ankle joint range of motion exercises
33102580|NCT05307354|Active Comparator|Control group|Only joint range of motion exercises
33102581|NCT05466227|Experimental|Implementing Modified Valsalva|Implementing Modified Valsalva
33318735|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
33102582|NCT04472793||Full-Time CCHMC Employees|
33102583|NCT05466149|Experimental|Furmonertinib 240mg QD|Treating patients of locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy.
33102584|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
33102585|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
33102586|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
33102587|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
33102588|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
33102589|NCT01276639|Experimental|Active Treatment 10 mg BID|
33102590|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
33102591|NCT01276639|Placebo Comparator|Placebo Treatment|
33102592|NCT05465915|Active Comparator|Blue|"Session - Titration with 0.30ms pulse width~Session - Titration with 0.15ms pulse width~Session and further - continue with 0.15ms pulse width"
33102593|NCT05465915|Active Comparator|Red|"Session - Titration with 0.15ms pulse width~Session - Titration with 0.3ms pulse width~Session and further - continue with 0.3ms pulse width"
32831533|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
32831534|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
32831535|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
32831536|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
33102594|NCT05465837||Non covid Tracheostomy Patients|Adult patients (>18 years) who underwent tracheostomy without having the covid-19 infection
32831537|NCT00888771||1|
32831538|NCT00888771||2|
32831539|NCT00888771||3|
32831540|NCT00888771||4|
32831541|NCT04487730|Experimental|"Engage & Connect Psychotherapy"|"Engage & Connect, a modified adapted version of Engage. Its principal intervention is social reward exposure - facilitating engagement in rewarding and meaningful social activities with significant others. In Engage-S therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding social activities of their choice."
32831542|NCT04487730|Active Comparator|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
32831543|NCT03845361|Experimental|C. hand|Radial artery cannulation
32831544|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
32831545|NCT04775121|Experimental|Experimental|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
32831546|NCT03251040|Other|Fibrin sealant|Single arm pilot study
32831547|NCT04754763|Experimental|Propolis|Propolis was applied by disposable micro brush on particular sensitive teeth and left undisturbed for 60 seconds to let it dry. Followup was done at 7th, 15th and 30th day
32831548|NCT04754763|Active Comparator|Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE)|Application of Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE) on sensitive surfaces was applied single coated for 20 seconds, gently applied air for 5 seconds and cured for 10 seconds (as per manufacturer's instructions). Followup was done at 7th, 15th and 30th day
33102595|NCT05465837||Covid-19 Tracheostomy Patients|Adult patients (>18 years) who underwent tracheostomy had the covid-19 infection
33102596|NCT04452357|Experimental|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
33318736|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
33102597|NCT04449198|Experimental|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
33102598|NCT04449198|No Intervention|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
33102599|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
33102600|NCT04448145||COVID-19 Positive|Participants who have been diagnosed with COVID-19 or experienced symptoms of COVID-19.
33102601|NCT04448145||COVID-19 Negative|Participants who have never tested positive for COVID-19.
33102602|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
32831549|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
32831550|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
32831551|NCT04774653||MIH Group in short stature from 6-8 years old|Molar Incisor Hypomineralization in stunted children aged from 6-8 years
32831552|NCT04774653||HSPM Group in short stature from 5-8 years old|Hypomineralization of Second Primary Molars in stunted children aged from 5-8 years
32831553|NCT04774653||Both MIH &HSPM Group in stunted (from 5-8) years old|When both primary molars and permanent teeth( First permanent molars & permanent incisors) are hypo-mineralized in children with short stature with age range from 5-8 years old
32831554|NCT04774887|Experimental|HPV vaccination|Children receiving HPV vaccine will be studies for seroconversion to HPV types, and aflatoxin levels in blood will be measured and compared to seroconversion.
32831555|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
32831556|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
33318737|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
32831558|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
32831559|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
32831560|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
32831561|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
33102603|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
33102604|NCT05465720|Active Comparator|motor|
33102605|NCT05465720|Experimental|sensory|
33102606|NCT05465720|Experimental|cognitive|
33102607|NCT05463458|Placebo Comparator|control|included 51 patients who will receive Standard of nutrition Care (2.0 g/kg body weight/day(A I) Calories should be in range of 25-30 Kcal/kg body weight/day.
33102608|NCT05463458|Experimental|case|included 51 patients who will receive adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) and anti-oxidants.
32831562|NCT04754451|No Intervention|Group P(placebo)|Attach two placebo patches for 12 hours, above and below the incision site.
32831563|NCT04754451|Experimental|Group L(lidocaine patch)|Attach two lidocaine patches for 12 hours, above and below the incision site.
32831564|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
32831565|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
33318738|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
33318739|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
32831568|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
32831569|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
32831570|NCT04778943||oblique lateral interbody fusion (OLIF)|Patients with lumbar spinal stenosis undergoing oblique lateral interbody fusion (OLIF)
32831571|NCT04778943||minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)|Patients with lumbar spinal stenosis undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
32831572|NCT04774341||CDSS (MedicBK) Analysis|
32831573|NCT04774341||Core Laboratory Analysis|
32831574|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
32831575|NCT04774263||General population|general population
32831576|NCT04774263||emergency caregivers|emergency caregivers
32831577|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
32831578|NCT04774029|Experimental|BVN Block|Patients will receive temporary basivertebral nerve block using lidocaine during the vertebral augmentation procedure for osteoporotic compression fracture.
32831579|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
32831580|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
32831581|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
32831582|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
32831583|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
32831584|NCT03244956|Experimental|patients with RAS mutation|
32831585|NCT03244956|Experimental|patients with BRAFV600E mutation|
32831586|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
32831587|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
32831588|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
32831589|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
32831590|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
32831591|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
32831592|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
32831593|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
32831594|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
32866655|NCT00073333|Active Comparator|1|Social skills training and exposure
33318740|NCT01060943|Experimental|TheraFill|atelocollagen filler
33318741|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
33318742|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
32831595|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
32831596|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
33102609|NCT05459792|Experimental|ultrasound guided median nerve block|A linear transducer will be placed on the ventral aspect of the mid-forearm, where the median nerve is visible in the fascial plane between the flexor digitorum superficialis and flexor digitorum profundus after raising a skin wheal using local anesthetic, the needle will be introduced in-plane view from lateral to medial and aimed at the fascial plane adjacent to the median nerve.
33102610|NCT05459792|Experimental|ultrasound guided radial nerve block|A linear transducer will be placed on the forearm: at the elbow (the radial nerve between the brachioradialis and the biceps muscle). the preferred approach is to start proximally above the elbow and identify the radial nerve as a triangular hyperechoic structure coming off the distal humerus. then following this distally to the antecubital fossa, where the nerve will branch into its superficial and deep branches. the needle will be introduced in-plane view from lateral to medial aimed at the fascial plane adjacent to the radial nerve.
33102611|NCT05459792|Placebo Comparator|local infiltration|Intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle.
33102612|NCT04686825|Experimental|T1|DA-8010 2.5 mg (Fasting)
33102613|NCT04686825|Experimental|T2|DA-8010 2.5 mg (Fed)
33102614|NCT04686825|Experimental|T3|DA-8010 5 mg (Fasting)
33102615|NCT04686825|Experimental|T4|DA-8010 5 mg (Fed)
33102616|NCT05456750|Experimental|treatment group|The treatment group receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days each week, for 2 weeks (total 10 times in one course)
33102617|NCT05456750|Sham Comparator|control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
33102618|NCT05455892||Elder patients hospitalized for COVID-19 in geriatric short stay units.|All patients over 70 years of age, with a positive Polymerase Chain Reaction or a high presumption of COVID-19, hospitalized in short geriatric units in University Hospital of Lyon, who agree with retrospective collection of their clinical datas.
33102619|NCT05454800|Experimental|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions. In addition to corrective exercises specific to scoliosis, physical activity counseling will also be given.
33102620|NCT05454800|Experimental|Scoliosis Specific Corrective Exercises|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions.
32831597|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
33102621|NCT04686552|Experimental|cinnamon|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.
33102622|NCT04686552|No Intervention|control|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon
33102623|NCT05453630|Experimental|Patient Navigation Intervention|Patients randomized to this arm will receive language-concordant patient navigation from a trained navigator, over the phone and via text and email, to assist patients to complete colonoscopy to screen for colorectal cancer.
32831598|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
33102624|NCT05453630|Other|Usual Care Control|Participants randomized to this arm will receive an educational brochure about the importance of colonoscopy to screen for colorectal cancer.
33102625|NCT00533988|No Intervention|5592|Standard triple lumen catheter
32831599|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
32831600|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
32831601|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
32866656|NCT00073333|Active Comparator|2|Exposure treatment
32866657|NCT00073333|Placebo Comparator|3|Placebo
32866658|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
32866659|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
33102626|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
33102627|NCT05285748|Experimental|Self-Paced Intensity Physical Activity|
33102628|NCT05285748|Active Comparator|Prescribed Moderate Intensity Physical Activity|
33102629|NCT05424887|Experimental|100 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 100 mg AK3280 b.i.d. for 24weeks
32831602|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)~Prizes of low monetary value will be given to participants based on competition performance"
32831603|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
32831604|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
32831605|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
32831606|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
32831607|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831608|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831609|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831610|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831611|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831612|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
32831613|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
32831614|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
32831615|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
32831616|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
32831617|NCT02354482||Diverse, high-risk patient populations|
32831618|NCT03250572||control group|
32831619|NCT03250572||NAFLD patients without hepatic fibrosis|
32831620|NCT03250572||NAFLD patients with hepatic fibrosis|
32831621|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
32831622|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
32831623|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
32831624|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
32831625|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
32831626|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
32831627|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
32831628|NCT01970176|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
32831629|NCT01970176|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
32831630|NCT03254160|Experimental|DNS-3379 (0.5mg)|
32831631|NCT03254160|Experimental|DNS-3379 (2.5mg)|
32831632|NCT03254160|Placebo Comparator|Placebo|
32831633|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
32831634|NCT03250728|Other|CDG with stroke-like history|
32831635|NCT03250728|Other|CDG without stroke-like history|
32831636|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
32831637|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
32831638|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
32831639|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 16 weeks. Fifteen minutes of working memory practice, recalling the correct sequence of digits, each presented for 500 msec, from 5 digits up to 10 digits will be completed for 15 minutes following PATH training.
32831640|NCT03655782|Sham Comparator|Orientation Discrimination training|The sham treatment will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
32831641|NCT03655782|Experimental|N-Back Working Memory Task|Participants are required to compare each item on a computer screen to the item that they saw n-items back in the sequence. The participant plays a simple game where they control the movement of an astronaut that needs to collect correct gems, avoid incorrect gems, and also obstacles, to succeed at the game. If the participants performs well then they can be advanced to the 2-back, 3-back, 4-back, etc where they make similar matches but to earlier items in the sequence. This gamified task consists of a color n-back with 6 colors (a new color every 3 seconds, requiring subjects respond to targets by tapping the screen and navigating the astronaut to the targets, and avoiding the distractors) with 30% targets, and where the n-level will change every 2 minutes depending on performance (increase if performance is >85% and decrease if <75%). Sessions consist of 10 ~2 minute blocks, each with n-level as determined by the adaptive procedure and with user paced breaks between blocks.
32831642|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
32831643|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
33102630|NCT05424887|Experimental|200 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 200 mg AK3280 b.i.d. for 24weeks
33102631|NCT05424887|Placebo Comparator|placebo|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
33102632|NCT05424887|Experimental|Extension Study Cohort|The extension study includes a 24-week medication observation period and a 4-week safety follow-up period. Subjects who meet the requirements will enter the extension study after 24 weeks of treatment in the main study. Subjects entering the extension study will continue to orally take AK3280 200 mg for 24 weeks.
32831644|NCT02024386|No Intervention|Control arm|No drug
32831645|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
32831646|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
32831647|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
32831648|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
32831649|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
32831650|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
32831651|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
33102633|NCT05284500||Pediatric cardiac surgery patients|Patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution.
33102634|NCT05423639|Experimental|Control group 1|Testing Palodent sectional matrix system only when placing Class II resin composite restorations is to increase proximal contact tightness.
33102635|NCT05423639|Active Comparator|Intervention group 2|A pre-contoured instrument called Optra contact (Ivoclar, Vivadent) will be used with group 2. For testing palodent matrix systems with Optracontact when placing Class II resin composite restorations is to increase proximal contact tightness with adjacent teeth when compared with group 1.
32831652|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
32866660|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
33102636|NCT05281185|Active Comparator|Severe haemophilia A patients with weight-based prophylaxis|Severe haemophilia A patients with low-dose standard half-life concentrates weight-based prophylaxis
33102637|NCT05281185|Experimental|Severe haemophilia A patients with low dose extended half-life PK-guided prophylaxis|Severe haemophilia A patients with low-dose extended half-life concentrates PK-guided prophylaxis
33102638|NCT00532532|Experimental|1|AV650 low dose
33102639|NCT00532532|Experimental|2|AV650 high dose
33102640|NCT00532532|Experimental|3|Placebo
33102641|NCT04393935|Experimental|Pharmacy delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
33102642|NCT05405036||Students|60 second-year students studying at the Department of Physiotherapy and Rehabilitation at University are planned to attend.
33318743|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
32831653|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
32831654|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
32831655|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
32831656|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
32831657|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
32831658|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
32831659|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
32831660|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
32831661|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
32831662|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
32831663|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
32831664|NCT00838383|Placebo Comparator|Placebo|
32831665|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
32831666|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
32831667|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
32831668|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
32831669|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
32831670|NCT03254082|Experimental|Sumac|Sumac sorghum flour
32831671|NCT03254082|Experimental|Wheat|Wheat flour
32831672|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
32831673|NCT03254082|Active Comparator|Sucrose|Table sugar
32831674|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
32831675|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
32831676|NCT04779099|Experimental|4-session intervention|
32831677|NCT04779099|Active Comparator|Treatment as usual|
32831678|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
32831679|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
32831680|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
32831681|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
32831682|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
32831683|NCT04778865|Experimental|Vitamin D-correction|Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.
32831684|NCT04778865|Active Comparator|Vitamin D-RDA|Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.
32831685|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
32831686|NCT03242850|Experimental|Intervention group|
32831687|NCT04778709|Experimental|Bone Graft A|Bone Graft A: Mixture of 25% small-particle cortical, 25% large particle cortical, 25% small particle cancellous, 25% large particle cancellous allograft
32831688|NCT04778709|Active Comparator|Bone Graft B|Bone Graft B: 100% large particle cancellous allograft
32831689|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
32831690|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
32831691|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32831692|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32831693|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32831694|NCT04773951|Experimental|Dose escalation and extension group|"JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;~JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;~JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;~JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined."
32831695|NCT03253536||entire cohort|none (observational study)
32866661|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
32866662|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
32866663|NCT04816656|Experimental|Experimental arm|All patients were presented the digital PROMs platform during their chemotherapy
32866664|NCT05617560|Experimental|Telemedical care|
32831696|NCT04773795|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
32831697|NCT04773717|Experimental|Ascorbic acid|"Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours."
32831698|NCT04773717|Placebo Comparator|Placebo|Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
32831699|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
32831700|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
32831701|NCT04444167|Experimental|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
32831702|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
32831703|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
32831704|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
32831705|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
32831706|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
32831707|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
32831708|NCT04400253|Experimental|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
32831709|NCT04400253|No Intervention|Control group|The group group will receive print materials about physical activity.
32831710|NCT04342143||Stroke|Patients who have a diagnosis of stroke by a stroke consultant from UK National Health Service Trust within 3 months to 5 years of study start date.
32831711|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
32831712|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
32831713|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
32831714|NCT04773561|Experimental|multifetal pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
32831715|NCT04773561|Active Comparator|singleton pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
32831716|NCT04773561|Active Comparator|age-stratified healthy non-pregnant women|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed.
32831717|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
33102643|NCT04390308||Intervention|The cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
32831718|NCT05605743|Experimental|Exercised group|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
32831719|NCT05605743|No Intervention|control group|this will be a thirty-patient wait-list group that will no receive any shape of training
32831720|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
32831721|NCT02000895||Preterm infants|>24 weeks <37 weeks gestational age
32831722|NCT02000895||Term infants|>37 weeks' gestational age
32831723|NCT02000895||Follow-up at 6 Years|Children enrolled from the birth cohort(s) to be followed at 6 to 10 years of age.
33102644|NCT04390308||Control|No intervention
33102645|NCT05384795||General anesthesia|
32831724|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~Dexa 4mg po bid on D0-2"
32866665|NCT04816266||Myopic patients|
33102646|NCT05384795||Spinal anesthesia|
33102647|NCT05384795||Peripheral nerve block|
33318744|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
32831725|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
32831726|NCT04773327|Experimental|PEG-rhG-CSF prevention|Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,
32831727|NCT04773327|No Intervention|non-prevention|Only close monitoring after chemotherapy
32831728|NCT01748825|Experimental|ARM 1 AZD1775 200 mg Once Daily|
32831729|NCT01748825|Experimental|ARM 2 AZD1775 225 mg Once Daily|
32831730|NCT01748825|Experimental|ARM 3 AZD1775 225 mg Twice Daily|
32831731|NCT01748825|Experimental|ARM 4 AZD1775 225 mg Twice Daily (week 1-only dosing)|
32831732|NCT01748825|Experimental|ARM 5 AZD1775 250 mg Once Daily|
32831733|NCT01748825|Experimental|ARM 6 AZD1775 300 mg Once Daily|
32831734|NCT01748825|Experimental|ARM 7 AZD1775 300 mg Twice Daily|
32831735|NCT01748825|Experimental|ARM 8 AZD1775 400 mg Once Daily|
32831736|NCT01748825|Experimental|ARM 9 Expansion Cohort 1: AZD1775 225 mg Twice Daily|
33102648|NCT05381480|Active Comparator|In-home Preventive Health Visits by Advanced Practice Nurse|APRNs will perform in-home multidimensional health assessment with quarterly follow up visits to provide individualized patient education, negotiation of recommendations to maintain/improve health and wellness. All participants continue to receive care from their primary care provider and other community-based providers, although use might be modified. Throughout the intervention, participants are encouraged to take a primary role in the management of their own health. APRNs coach and guide the participant in navigating existing service providers as well as accessing and establishing new services. Having the program in-home promotes an atmosphere of shared decision-making, while allowing the nurse to observe the physical and social environment. Key to this model is identification of individual profiles of health strengths and health risks; recommendations and negotiation over priority health behavior change; and quarterly follow up.
33102649|NCT05381480|Active Comparator|On-site Evidence-based Physical Activity, Health and Wellness Classes|Curriculum. There will be three categories of classes offered at sites randomized into this intervention. A physical activity class will be offered three times weekly, and will include elements of Tai Chi, fall prevention, and arthritis exercises. Class content/activity will be modified for all levels of ability. A class focused on mental health and functioning will be offered weekly, and include activities targeting depression prevention, memory enhancement, and engagement (e.g., life review, agile mind). There will also be offered a weekly multi-topic class with a repeating cycle of topics and instructors including medication management, computer literacy and electronic health records, etc.. Tenants will be engaged in choosing topics that reflect the group consensus on importance. Altogether, at each location there will be five scheduled class opportunities each week for tenants to choose among.
33102650|NCT05376683|No Intervention|Control|
33102651|NCT05376683|Active Comparator|Telemonitoring group|
33102652|NCT05376683|Active Comparator|AI. + Telemonitoring group|
32831737|NCT01748825|Experimental|ARM 10 Expansion Cohort 2: AZD1775 300 mg Once Daily|
32831738|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
32831739|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
32831740|NCT05605587|Experimental|Leflunomide 20mg|
32831741|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
32831742|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
32831743|NCT02028208|Experimental|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
32831744|NCT02028208|Experimental|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
32831745|NCT02028208|Experimental|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
32831746|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
32831747|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
32831748|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
32831749|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
32831750|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
32831751|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
32831752|NCT00789399|Placebo Comparator|Placebo|
32866666|NCT04816266||Hypermetropic patients|
32866667|NCT04816266||Emmetropic people|
32831753|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
32831754|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
32831755|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
33102653|NCT04330482|Other|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
33102654|NCT04330482|Experimental|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
33102655|NCT05354297|Experimental|Cecelia Health|Access to live Cecelia health coach on the telephone for 1 year plus access to Cecelia health coach by text messaging (via the OneTouch Reveal mobile diabetes app). Subjects will be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) diabetes app.
33102656|NCT05354297|Experimental|Fitbit|Fitbit Inspire 2 wearable plus 1 year subscription to premium Fitbit application. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
33102657|NCT05354297|Experimental|Noom|Noom behavioural weight loss program subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
33102658|NCT05354297|Experimental|Welldoc|Multi-condition support program from Welldoc subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter.
33102659|NCT05276544|Experimental|phone counseling|dietary intervention via phone counseling
33102660|NCT05276544|Experimental|video counseling|dietary intervention via video counseling
33102661|NCT05276544|Experimental|Traditional follow up|dietary intervention via traditional follow up
33102662|NCT05346614|Experimental|Active lifestyle intervention|Individuals in the active intervention group will undergo diabetyping (diabetes type 2 phenotyping: glucose, and C-peptide responses to a glucose challenge). Based on the diabetype, individuals will receive recommendations to follow either a calorie-restricted (500kcal deficit minimum) low carbohydrate or a modified Mediterranean diet for a period of 18 weeks (total intervention is 24 weeks). Secondly, individuals will follow a personalized exercise program. Guidance and coaching (individual and small group) will be given via mobile app and digital platform. Individuals will receive real-time feedback based on their diet, exercise, and glucose levels (via continuous glucose monitoring for 4 weeks). Medications will be slowly withdrawn over the intervention period, with a focus on the first phase of the intervention.
33102663|NCT05346614|No Intervention|Usual care group|Individuals in the usual care group will receive standard diabetes care.
33102664|NCT04322565|Experimental|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
33102665|NCT04322565|No Intervention|Standard of care|Standard of care for COVID-19 pneumonia
33102666|NCT04687826||Pancreaticoduodenectomy in 2015|Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
33102667|NCT04687826||Pancreaticoduodenectomy in 2017|Patients who underwent pancreaticoduodenectomy in 2017 got liberal intraoperative fluid therapy and most of the patients spent the first postoperative night in a regular ward.
33102668|NCT05267691||sun-protected|All patients with basal cell carcinoma in a sun protected body site
33102669|NCT05267691||sun-exposed|All patients with basal cell carcinoma in a sun exposed body site
33102670|NCT05342285||normal FMD|SLE femals patientd with normal flow mediated whose ages from 18 to 45yrs
33102671|NCT05342285||abnormal FMD|SLE femals with abnormal flow mediated dikation ages between 18 to 45yrs old
33102672|NCT05342285||Normal female|normal femals whise ages from 18 to 45yrs old
33102673|NCT05259189|Experimental|NBL-012 Injection|Two subjects will be enrolled in the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of NBL-012 Injection for subsequent dose cohorts
33102674|NCT05259189|Placebo Comparator|Placebo|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo.
33102675|NCT05335889||Type 2 Diabetes group|Participants with Type 2 Diabetes will wear eButton and Continuous Glucose Monitoring (CGM) for 2 weeks and complete food diaries to record carb grams.
33318745|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
33318746|NCT00297479|Experimental|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
33102676|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
33102677|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
33318747|NCT00297479|Active Comparator|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
33318748|NCT00297479|Active Comparator|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
33318749|NCT01069367|Experimental|Arm:1|
33318750|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
33318751|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
33102678|NCT05333354|Experimental|Experimental(simulation education group)|The experimental group (simulation teaching group), the content of simulation teaching is based on the simulation model, and includes five important elements: Instructor, student, educational practice, simulation situation design and characteristics, and result that design covering the four stages of learning, concrete experience, reflective observation, abstract conceptualization and action experience, and design lesson plans, which include delirium assessment and delirium risk factor detection. Delirium prevention and management (PADIS guidelines). The main objectives of the teaching plan design of the experimental group are: to be able to confirm delirium by assessment of the Delirium Assessment Scale; to confirm the risk factors by the history taking; to propose treatment and measures according to the assessment results. Secondary goals: Be able to perform handovers.
33102679|NCT05333354|No Intervention|Control(traditional group)|Nurses in the control group did not receive simulated situational teaching, but received classroom teaching 3 times (once every other week) (delirium assessment, risk factor assessment; PADIS treatment), each session of about 2 hours. In order to avoid inconsistent teaching content, the control group and the experimental group are not to be together in classroom.
33102680|NCT05227638|Active Comparator|Schroth group|The Schroth group performed Schroth exercises
32831756|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
32831757|NCT02455674||Age under 6 years|"All children 1 to 6 years~Used formula for weight calculation:~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
32831758|NCT02455674||Age over 6 years|"All children 6 to 12 years~Used formula for weight calculation:~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
32831759|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
32831760|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
32831761|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
32831762|NCT04773093|Active Comparator|Continous Intravenous Lidocaine Infusion|Patient will recieve Continous Intravenous Lidocaine Infusion
32831763|NCT04773093|Placebo Comparator|Placebo|Patient will recieve placebo (NaCl 0.9% infusion)
32831764|NCT01720043|Experimental|All participants|All participants enrolled
32831765|NCT05605353||Colorectal|Patients with rectal or colon cancer
32831766|NCT05605353||Gynaecological|Patients with uterine, ovarian or cervical cancers
32831767|NCT05605353||Urological|Patients with bladder or prostate cancers
32831768|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
33102681|NCT05227638|Active Comparator|PNF group|"PNF group (PG) performed chop and lift exercises"
33102682|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
33102683|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
33318752|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
33318753|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
33318754|NCT00688870|Experimental|1|13vPnC
33318755|NCT00688870|Active Comparator|2|7vPnC
33318756|NCT00297167|Experimental|EUR-1008 (APT-1008) First, Then Placebo|
33318757|NCT00297167|Experimental|Placebo First, Then EUR-1008 (APT-1008)|
32831769|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
32831770|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
32831771|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
33318758|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
32831772|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
32831773|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
32831774|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
32831775|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
32831776|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
32831777|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
32831778|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
33102684|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
32831779|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
32831780|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
32831781|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
32831782|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
32831783|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
32831784|NCT01747811|Experimental|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
32831785|NCT01747811|Placebo Comparator|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
32831786|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
32831787|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
32831788|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
32831789|NCT03242226|Experimental|two spectacles|
32831790|NCT03242226|Active Comparator|single vision spectacles|
32831791|NCT03195699|Experimental|Dose escalation study|Participants will receive up to 4 dose levels of TTI-101 to determine RP2D
32831792|NCT03195699|Experimental|Dose expansion study|Enrollment in the dose expansion may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101
32831793|NCT03195699|Experimental|Food effect study|Participants will be treated with TTI-101 at the RP2D under fed and fasted conditions to assess the bioavailability of TTI-101 and to determine the best conditions for taking the study drug
32831794|NCT03195699|Experimental|Dose expansion, cross-over study|Participants will be administered different formulations of TTI-101 to compare bioavailability.
32831795|NCT03249246||Infection only|The patients have only infection
32831796|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
32831797|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
32831798|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
32831799|NCT03135327|Experimental|Interventional Phase - Ocufolin Group|Participants in this group will receive the Ocufolin medical food for 6 months.
32831800|NCT03135327|No Intervention|Observational Phase Group|Participants in this group will be studied and followed up for 1-2 years.
32831801|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
32831802|NCT05605197|Experimental|U87 CAR-T cells|The Patients are enrolled into 2 dose level cohorts in sequence
32831803|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
32831804|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
32831805|NCT04772781|Experimental|S (+) - Ibuprofen|
32831806|NCT04772781|Active Comparator|Ibuflex® - ibuprofen|
32831807|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
32831808|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
32831809|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
32831810|NCT05605041|No Intervention|Did Not Use Headspace|Those that did not use headspace during the time the study is conducted
32831811|NCT05605041|Experimental|Did Use Headspace|Those that were randomized into the group and used Headspace at least once during the study period
33032990|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
33032991|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
33032992|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
33032993|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
33032994|NCT01958047|Experimental|ASP3652|One single dose
33032995|NCT01958099|Other|Injury Prevention Specialist|
33032996|NCT01958099|Experimental|Kiosk Intervention|
33318759|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
33318760|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
33318761|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
33318762|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
32831812|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
33318763|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
33318764|NCT03215758|Active Comparator|QAW039|QAW039 once daily
33318765|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
33318766|NCT00290771|Experimental|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
33318767|NCT00290771|Experimental|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
33318768|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
33318769|NCT00274625|Experimental|1|Surgisis Gold Graft
33318770|NCT00274625|Active Comparator|2|Control
32902453|NCT05560100||Policy Experts|"An individual who has a degree in bioethics with at least ONE of the following criteria:~>= 5 years of experience in obtaining informed consent or an advanced graduate degree in bioethics~Has served on ethics related committee in a healthcare institution or healthcare society/professional association~Is or has been a member of a state licensing board"
32902454|NCT05560100||Legal Experts|"An individual who is an attorney and who has had training in health law as evidenced by at least ONE of the following criteria:~Evidence of training based on ONE of the follow:~Concentration/Certification in Health Law~L.L.M in health or medical law~SJD in health law~Experience in litigating medical malpractice cases involving failure to obtain informed consent~Published scholarship on informed consent in an academic journal (>= 1)"
32902455|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
32902456|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
32902457|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
33318771|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
33318772|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
33318773|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
33318774|NCT01325597|No Intervention|Control group|No intervention.
33318775|NCT00290693|Experimental|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
33318776|NCT03214666|Experimental|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
32902458|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
32902459|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
32902758|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
32902759|NCT01578577|Experimental|Nurse Educator + EHMI|
33326868|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
32831813|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
32831814|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
32831815|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
32831816|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
32831817|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
32831818|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
32831819|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
33102685|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
33318777|NCT03214666|Experimental|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
33318778|NCT03564496|Active Comparator|Healthy Controls|20 Healthy Controls
33318779|NCT03564496|Experimental|MS Patients|40 individuals diagnosed with MS recruited from the MS Center/ Neurology Department at NYULMC
33102687|NCT00534144|Active Comparator|Iron Sucrose|
33102688|NCT00534144|Active Comparator|Ferric Gluconate|
33318780|NCT00274469|Experimental|1|Fulvestrant
33318781|NCT00274469|Active Comparator|2|Anastrozole
33318782|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
33318783|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
33318784|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
33318785|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
33318786|NCT01556776|Placebo Comparator|Placebo|placebo
33102690|NCT00534183|Experimental|1|Olanzapine
33102691|NCT00534183|Active Comparator|2|Risperidone
33102692|NCT00534183|Active Comparator|3|haloperidol
33102693|NCT05303714|Active Comparator|Arm A (FOLFOX)|Patients randomized in the Arm A will undergo to 6 courses of systemic chemotherapy according to FOLFOX regimen, after these six courses of chemotherapy, radiologic restaging (CT scan) as well as a second staging laparoscopy will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, after a multidisciplinary discussion, patient will undergo to either further 6 courses of chemotherapy or to cytoreductive surgery plus HIPEC.
33318787|NCT05425810|Experimental|Transtibial patient|All the recruited participants will be included in this arm and will go through the socket manufacturing, fitting, and testing procedure.
33318788|NCT05416996||Shared Medical Appointments|
33318789|NCT05416996||Usual Care Appointments|
33318790|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
33318791|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
33318792|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
33318793|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
33318794|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
33318795|NCT05353036||Adolescents|Patients 12-21 years undergoing anesthetic care
33318796|NCT05294614|Other|A B B B B B B B B C C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A B B B B B B B B C C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
33326869|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
33326870|NCT01283256||Experimental|
32831820|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
32831821|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
32831822|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
32831823|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
32831824|NCT01718483|Placebo Comparator|Placebo|
32831825|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
32831826|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
32831827|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
32831828|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
32831829|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
32831830|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
32831831|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
32831832|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment of ALTE05N1, patients receive a mailed packet introducing the LTFC. Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
32831833|NCT04487574|Experimental|XC221|"XC221 100 mg orally.~1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period."
32831834|NCT04487574|Placebo Comparator|Placebo|"Placebo orally.~1 tablet of Placebo 2 times a day during 14 days of treatment period"
32831835|NCT04487418|Experimental|Surgery group with electro cautery|Surgery will be performed with electro cautery.
32831836|NCT04487418|Experimental|High level diode laser surgery|High power diode laser surgery will be performed.
32831837|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
32831838|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
32831839|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
32831840|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32831841|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
32831842|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
32831843|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32831844|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
32831845|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
32831846|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
32831847|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
32831848|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
32831849|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
32831850|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
32831851|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
32831852|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
32831853|NCT03241602|Active Comparator|Group of pulmonary recruitment|
32831854|NCT03241602|No Intervention|group receive passive exsufflation through port|
33326871|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
32831856|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
32831857|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
32831858|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
32831859|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
32831860|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
32831861|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
33102694|NCT05303714|Experimental|Arm B (FOLFOX and PIPAC)|Patients randomized in the ARM B will undergo to 6 courses of systemic chemotherapy (FOLFOX regimen) plus PIPAC every two cycles of chemo (Fig.1). At least seven days should last between each PIPAC and the next chemotherapy course, and at least 14 days should last between the chemotherapy course and the next PIPAC. After six courses of chemotherapy and 3 PIPACs procedure, a radiologic restaging (CT scan) as well as a laparoscopic reassessment will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, patient will be treated with cytoreductive surgery plus HIPEC.
33102695|NCT04269408|Experimental|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
33318797|NCT05294614|Other|A A B B B B B B B B C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A B B B B B B B B C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
33102696|NCT04269408|Other|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
33102697|NCT05298605|Experimental|Faith in Action!|"A train-the-trainer approach will be used to educate lay health navigators to present the culturally adapted Faith in Action! curriculum and to provide breast cancer screening navigation to Korean American women within faith-based settings"
33102698|NCT05298605|Active Comparator|Control|A presentation of lifestyle recommendations (e.g., physical activity, nutrition) will be provided to control groups.
33102699|NCT00534222||Quetiapine|
33102700|NCT00534222||Olanzapine|
33102701|NCT00534222||Risperidone|
33102702|NCT05296928|Experimental|umbilical incision|Placing the laparoscopic trocar by cutting the umbilicus directly at the entrance to the abdomen
33102703|NCT05296928|Active Comparator|subumbilical incision|Placing a laparoscopic trocar by making a sub-umbilicus incision at the entrance to the abdomen
33102704|NCT05226195|Experimental|Group 1: Sterile Kinesio tape application|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
33102705|NCT05226195|No Intervention|Group 2: Control group|The standard post-surgical protocol applied in our clinic will be applied to Group 2. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
33318798|NCT05294614|Other|A A A B B B B B B B B C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A A B B B B B B B B C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
33318799|NCT05225818|Experimental|Experimental: PLAN - Home|Trained NPs will deliver the PLAN-Home to the enrolled participants, which consists of home-based dementia evaluation, education, and care planning for older adults with probable dementia.
33318800|NCT05225818|No Intervention|No intervention: Control Group|The control group will receive a copy of the publicly available educational material on 10 warning signs and symptoms of Alzheimer's disease and action steps prepared by Alzheimer's Association.
33318801|NCT05180422|Experimental|Dose Expansion|AMG 510/MVASI
33318802|NCT02599558|Experimental|Cytosponge-directed food reintroduction|Subjects will follow the six-food elimination diet per clinical protocol. The cytosponge will be used to monitor the diet at certain timepoints during food reintroduction
33318803|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
32831862|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
32831863|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
32831864|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
32831865|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
32831866|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
32902760|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
33102706|NCT05284838|Experimental|Error Management Training (Difficult)|Participants receive the learning strategy Error Management Training and encounter difficult questions.
33102707|NCT05284838|Experimental|Error Management Training (Easy)|Participants receive the learning strategy Error Management Training and encounter easy questions.
33318804|NCT01314976|Experimental|Metronidazole|Active treatment.
33318805|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
33318806|NCT02379520|Experimental|Group A|HPV Specific T Cells
33318807|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
33318808|NCT04651504|Experimental|Primary Care Clinics|"Southern Illinois Healthcare System will contact the site management and ask for participation in the study~Eligible providers and staff will be identified by clinic management. The research coordinator will work with the clinic to schedule a virtual site visit(s). The study team will interview providers and staff at the beginning and/or end of each active intervention period to assess knowledge and attitudes about CRC screening and follow-up processes, the Consolidated Framework for Implementation Research (CFIR) constructs such as role clarity within the clinical team, and satisfaction with the intervention and implementation. Post-implementation surveys will also ask about work-arounds and adaptations of the intervention tools and perceived efficacy."
33318809|NCT04575142|Experimental|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
33102708|NCT05284838|Active Comparator|Error Avoidance Training|Participants receive the learning strategy Error Avoidance Training.
33102709|NCT05223387|Experimental|Study Group|Anthogyr Axiom TL REG and corresponding Multi-Unit abutments
33102710|NCT05223387|Active Comparator|Control Group|Anthogyr Axiom BL REG and corresponding Multi-Unit abutment
33102711|NCT00532727|Experimental|Arm A|Carboplatin
33102712|NCT00532727|Active Comparator|Arm B|Docetaxel
33102713|NCT04261218|Experimental|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), under fasting conditions, and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
33102714|NCT04261218|Experimental|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 100 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
33318810|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
33318811|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
33318812|NCT04521634||Acute Stroke + Diabetes|People who have experienced and acute stroke and also have diabetes
33102715|NCT05274620|Other|IntelliCare|8 weeks of IntelliCare
33102716|NCT05262998|Active Comparator|CONTROL|Plate fixation
33102717|NCT05262998|Experimental|INTERVENTION|Intramedullary Screw
33102718|NCT05214378|Experimental|Treatment Arm|The investigators will test an alternative pattern of sacral root stimulation in individuals who are already implanted with the device. Study participants will act as their own controls.
32831867|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
32831868|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
32831869|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
32831870|NCT03248778|Experimental|disclosure-support counseling|
32831871|NCT03248778|No Intervention|Treatment as Usual|
32831872|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
32831873|NCT00725049|Active Comparator|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
32831874|NCT00725049|No Intervention|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
32831875|NCT00715143|Other|All subjects will be receive the Novation Ceramic on Ceramic Articulating Hip System|All subjects will receive the Novation Ceramic on Ceramic Articulating Hip System.
32831876|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
32831877|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
33102719|NCT04260243|Sham Comparator|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
33102720|NCT04260243|Experimental|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
33318813|NCT04521634||Acute stroke|People without diabetes who have experienced and acute stroke
32831878|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
32902761|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
33102721|NCT05258903|Experimental|Ulnar artery|Ulnar artery cannulation under USG-guidance
33102722|NCT05258903|Active Comparator|Radial artery|Radial artery cannulation under USG-guidance
33102723|NCT04687410|Active Comparator|FNA|
33102724|NCT04687410|Experimental|FNB|
33102725|NCT00532766|Experimental|2|Jusline Humulin
32831879|NCT04772625||PFA|The cohort consists of all patients operated with patellofemoral arthroplasty for isolated patellofemoral osteoarthritis in Denmark from Jan 1 2008 to Dec 31 2015. The number of patients is expected to be around 500. A patellofemoral arthroplasty is defined as an arthroplasty consisting of a metal trochlear component and a polyethylene patella component. The definition of isolated patellofemoral osteoarthritis in the study is pragmatic and given by the operating surgeon.
32831880|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
32831881|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
32831882|NCT04296045|Active Comparator|Glucose|Glucose
32831883|NCT04296045|Experimental|MCE|
32831884|NCT04296045|Experimental|MCE + Glucose|
32831885|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
32831886|NCT00693459|Other|Circular anal dilator|Circular anal dilator group-An anoscope has been developed that outlines the precise path for hemorrhoid excision. This instrument allows a modified Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation.
32831887|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
32831888|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
32831889|NCT00687765|Experimental|1|
32831890|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
32831891|NCT03248544|Other|control|Control patients will not be received any intervention
32831892|NCT05596695|Experimental|Intervention Group|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anesthesia.
32831893|NCT05596695|No Intervention|Standard of Care Group|Intraoperative blood pressure management will be performed according to local clinical standard of care.
32831894|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
32831895|NCT03238950|Other|Synthetic|Training conducted on synthetic model
32831896|NCT03239028||Danish National Birth Cohort|
33318814|NCT04504942|Experimental|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
33102726|NCT04687449|Active Comparator|Active Comparator: Curcumin therapy added to standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
33102727|NCT04687449|Active Comparator|Active Comparator: Placebo with Standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
33102728|NCT05258786|Experimental|Intervention group|Transabdominal ultrasound will be applied to optimize the training program of contracting pelvic floor muscles, aiming to decrease postpartum urinary and fecal incontinence. Transperineal ultrasound will be used for pre-labor-coached maternal pushing aiming to improve pushing during the second stage of labor, reduce operative deliveries, the incidence of perineal tears, and urinary and fecal incontinence.
33102729|NCT05258786|No Intervention|Control group|A pelvic floor physiotherapist will provide the participants with a verbal explanation of how to contract pelvic floor muscles. without ultrasound.
33102730|NCT05258786|No Intervention|Standard care|Questionnaires only at four timeline points - before delivery at recruitment (T0), a week later (T2), immediately postpartum (T3), and two months postpartum (T4)
33102731|NCT04221009|Experimental|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
32831897|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
32831898|NCT04486794|Experimental|Treatment at baseline|
32831899|NCT04486794|Active Comparator|Treatment at Month 1|
32831900|NCT00217737|Active Comparator|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
32902762|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
32831901|NCT00217737|Experimental|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
32831902|NCT00217737|No Intervention|Arm C (observation)|Patients undergo observation.
32831903|NCT03248622||Anti-HBc positive|Anti-HBc positive
32831904|NCT03248622||HCV positive Cohort|HCV positive Cohort
32831905|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
32831906|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
32831907|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
32831908|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
32831909|NCT03238716|Active Comparator|NM Re-ed and Exercise|
32831910|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
32831911|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
32831912|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
32831913|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
32831914|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
32831915|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
32831916|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
32831917|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
32831918|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
32831919|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
32831920|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
32831921|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
32831922|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
32831923|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
32831924|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
32831925|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
32831926|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
32831927|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
32831928|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|
32831929|NCT04486482|Other|Self Supportive Care (SSC) Alone|
32831930|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
32831931|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
32831932|NCT04486092|Experimental|Valproic Acid|
32831933|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~Treat upon emergence of acquire resistance~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~Progressive disease on recent scans~Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
32831934|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
32831935|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
32831936|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
32831937|NCT00643617|Other|Heterogeneous dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery
32831938|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
32831939|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
32831940|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
32831941|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
32831942|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
32831943|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
32831944|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
32831945|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
32831946|NCT05588115||Concussion|Patients presenting to the ED who are diagnosed with concussion according to the ICD-10 criteria and absent of comorbidities.
32831947|NCT05588115||MSK|Patients presenting to the ED who are diagnosed with a muscle or skeletal injury (MSK; soft tissue damage or inflammation, fractured bone, etc.) and absent of comorbidities.
32831948|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
32831949|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
32831950|NCT00632307||1|COPD
32831951|NCT00632307||2|lung cancer
32831952|NCT00632307||3|airway infection
32831953|NCT00632307||4|interstitial lung disease
32831954|NCT00632307||5|sleep apnea
32831955|NCT00632307||6|pulmonary disorders with pleural infusions
32831956|NCT00632307||7|sarcoidosis
32831957|NCT00632307||8|healthy persons
32831958|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
32831959|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
32831960|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
32831961|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
32831962|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
32831963|NCT03240198||COPD|
32831964|NCT03240198||Controls|
32831965|NCT04771845||EEG-grid-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation
32831966|NCT04771845||MRI-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation
32831967|NCT04771845||NACC controls|National Alzheimer's Coordinating Center matched controls
32831968|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
32831969|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
32831970|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
32831971|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
32831972|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
32831973|NCT04771533|Experimental|Passive stabilization of the trunk and the upper extremity|The intervention (passive stabilization of the trunk and the upper arm) was tested in post-stroke patients (study group) and in patients with back pain, but without neurological deficits (control group)
32831974|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
32831975|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
32831976|NCT04771143|Experimental|AFQ056|Experimental study drug
32831977|NCT04771143|Placebo Comparator|Placebo|Matching placebo
32831978|NCT04487184|Active Comparator|Facilitation|From origin to insertion
32831979|NCT04487184|Experimental|Relaxation|From insertion to origin
32831980|NCT04487184|Placebo Comparator|Cross|Cross the muscle fiber
32831981|NCT04487184|Sham Comparator|Control|No tape
32831982|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
32831983|NCT03400371||Controls|People without a lifetime history of seizures.
32831984|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
32831985|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
32831986|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
32831987|NCT04771377|Experimental|standard protein supplementation (SPS)|0.8g protein/ IBW/ day
32831988|NCT04771377|Experimental|High protein supplementation (HPS)|1.2g protein/ IBW/ day
32831989|NCT04771377|Experimental|HPS + PA|1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks
32831990|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
32831991|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
32831992|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
32831993|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
32831994|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
32831995|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
32831996|NCT05450835|Experimental|Arm A|In OGT group,After the enterotomy was made, the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube. Then, the anaesthesiologist continued to pull back the nasogastric tube for 10 cm to ensure that the stapler would not clamp the nasogastric tube. After that, the surgeon began to fire the stapler to perform side-to-side esophagojejunostomy.
32831997|NCT05450835|Active Comparator|Arm B|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al. After firing the stapler, two openings were converted into a single entry hole to create an end-to-side oesophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
32831998|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
32831999|NCT00057681|Experimental|1|Participants will receive treatment with lithium for 8 to 16 weeks
32832000|NCT00057681|Experimental|2|Participants will receive treatment with valproate for 8 to 16 weeks
32832001|NCT00057681|Experimental|3|Participants will receive treatment with risperidone for 8 to 16 weeks
32832002|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
32832003|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
33102732|NCT05258279|Experimental|Pemetrexed+Carboplatin+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
33102733|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
32832004|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
32832005|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
32832006|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
32832007|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
33318815|NCT04466800|Experimental|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
33102734|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
33102735|NCT05257967|Experimental|Experimental arm|ddPCR and BC Cancer NGS panel completed on cerebral spinal fluid and blood circulating tumor DNA
33102736|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
33102737|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
33102738|NCT05235815|Experimental|Sonoanatomy and retro SCTL compartment block|"During phase 1, ten healthy human volunteers will be involved. A bilateral ultrasound scan will be performed in the paravertebral region to describe the sonoanatomy of the retro SCTL compartment.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block."
33318816|NCT04466800|No Intervention|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
32832008|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.~There is a secondary metric as to patient reported pain on a 1-10scale."
32832009|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
32832010|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
33102739|NCT05230979|Experimental|Normal weight|People with normal weight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
32832011|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
32832012|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
33102740|NCT05230979|Experimental|Overweight|People with overweight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
33102741|NCT05230979|Experimental|Glycemic index|Determination of glycemic index under the ISO 26642:2010.
33102742|NCT00532818|Placebo Comparator|1|
33102743|NCT00532818|Experimental|2|
33102744|NCT04687397||Disorders of consciousness|Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State
33102745|NCT05209035|Active Comparator|Trazodone|
33102746|NCT05209035|Placebo Comparator|Placebo|
32832013|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
32832014|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
32832015|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
32832016|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
32832017|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
32832018|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
32832019|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
32832020|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
32832021|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
33102747|NCT04687202||Patients developing CA|Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019
33102748|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
33102749|NCT04686708||Pre-pandemic period|Patients managed in the pre-pandemic period
33102750|NCT04686708||Pandemic period|Patients managed in the pandemic period
33102751|NCT00534300|Experimental|A|
33102752|NCT00534300|Placebo Comparator|B|
33102753|NCT05202405|Experimental|Sequence A|Period 1 : Reference Drug(AD-221A and AD-221B) Period 2 : Test Drug(AD-221)
33318817|NCT01882816|Experimental|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
33318818|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
33326872|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
32832022|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
32832023|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
32832024|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
32832025|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
32832026|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
33102754|NCT05202405|Experimental|Sequence B|Period 1 : Test Drug(AD-221) Period 2 : Reference Drug(AD-221A and AD-221B)
33102755|NCT05211440|Placebo Comparator|Placebo (Maltodextrin)|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days.
33102756|NCT05211440|Experimental|BC-006|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days.
33102757|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
33102758|NCT05201300|Experimental|Remimazolam 6|Remimazolam starts at 6 mg/kg/hr until loss of consciousness
33102759|NCT05201300|Experimental|Remimazolam 12|Remimazolam starts at 12 mg/kg/hr until loss of consciousness
33102760|NCT05201300|Active Comparator|Propofol|Propofol starts at a target controlled infusion 4 µg/ml until loss of consciousness.
33102761|NCT05200377||Cerebral small vessel disease group|Patients with clinically and radiologically evidenced cerebral small vessel disease. Patients are grouped by severity of cerebral small vessel disease assessed by comprehensive MRI findings.
33102763|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
33102764|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
33102765|NCT05190458|Other|Non-invasive mechanical ventilation (group A)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
33102766|NCT05190458|Other|High Velocity Nasal Insufflation (group B)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
33102767|NCT04169334|No Intervention|Control group|Group receiving care as usual
32832027|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
32832028|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
32832029|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
32832030|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
32832031|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
32832032|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
32832033|NCT03234660|Placebo Comparator|control|placebo infusion
32832034|NCT04485780|Placebo Comparator|Botulinum toxin injection during surgery|Patients in this group underwent Botulinum toxin injection during surgery
32832035|NCT04485780|Experimental|Botulinum toxin injection one week before surgery|Patients in this group underwent Botulinum toxin injection at the outpatient clinic one week before surgery
32832036|NCT00059475|Experimental|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
32832037|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
32832038|NCT00059475|Experimental|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
32832039|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
32832040|NCT00059475|Experimental|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
33326873|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
32832041|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
32832042|NCT00059475|Experimental|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
32832043|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
32832044|NCT03234504||Normal healthy volunteers|
32832045|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
32832046|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
32832047|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
32832048|NCT00060333|Experimental|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
32832049|NCT03234270|Experimental|F35 pilots|
32832050|NCT03234270|Active Comparator|F15 pilots|
32832051|NCT03234192|Active Comparator|Therapeutic ultra sound|
32832052|NCT03234192|Active Comparator|Astym Treatment Technique|
32832053|NCT03234192|Active Comparator|Graston Treatment Technique|
32832054|NCT04770987||hyperlaxity|30 individuals with systemic hyperlaxity as defined by a score of 5 or greater on the Beighton Hypermobility Scale
32832055|NCT04770987||control|30 healthy, age and gender matched individuals without hyperlaxity
32832056|NCT04486872|Experimental|anti-CD19 and anti-CD20 dual specific CAR-T Cells|
32832057|NCT04770597|Experimental|Intervention|CO2 values on sensor visible to staff
32832058|NCT04770597|Sham Comparator|Sham control|CO2 values on sensor not visible to staff
32832059|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
32832060|NCT05386797|Experimental|Geniculate Artery Embolization arm|
32832061|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
32832062|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
32832063|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
32832064|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
32832065|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
32832066|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
32832067|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
32832068|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
32832069|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
32832070|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
33318819|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
33318820|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
33318821|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
32832074|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
32832075|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
32832076|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
32832077|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
32832078|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
32832079|NCT03236766|Other|No intervention|
32832080|NCT04485936|Experimental|Epitomee Device|the participants receive the device which is non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of early satiation and prolonged satiety
32832081|NCT03246984|Experimental|VasQ device implantation|
33318822|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
33318823|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
33318824|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
33318825|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
33318826|NCT03648892|Other|Main|Healthy volunteers, within three BMI strata, under controlled overnight fasting conditions following a period of dietary stabilization
33318827|NCT00272987|Experimental|Cohort 1|Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
33318828|NCT00272987|Experimental|Cohort 2|Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
33318829|NCT00272987|Experimental|Cohort 3|Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO
33405363|NCT05008887|Experimental|Fractional CO2 laser and topical methotrexate solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of methotrexate solution (2.5% concentration vial 50mg/2ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
32832082|NCT00061893|Experimental|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
32832083|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
32832084|NCT02452788|No Intervention|Usual Care|Usual Care
32832085|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
32832086|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
32832087|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
32832088|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
32832089|NCT05383833|Experimental|Creatine Monohydrate Arm|This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks).
32832090|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
32832091|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
32832092|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
32832093|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
32832094|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
32832095|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
32832096|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
32832097|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
32832098|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
32832099|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
32832100|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
32832101|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
32832102|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
32832103|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
32832104|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
32832105|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
32832106|NCT01974700|Active Comparator|Levetiracetam|
32832107|NCT01974700|No Intervention|No anti-epileptic treatment|
32832108|NCT04753281|Other|Lifestyle counselling|Participants will receive an assessment appointment and up to 8 follow up sessions with a Health Psychologist to help them set goals and monitor changes of their own self management behaviour.
32832109|NCT04753281|No Intervention|Treatment as usual|Treatment as usual
32832110|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
32832111|NCT04753203|Experimental|A single arm study with Alpelisib plus Capecitabine|A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer
32832112|NCT03236610|Experimental|tenofovir|
32832113|NCT03236610|Active Comparator|tenofovir plus entecavir|
32832114|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
32902763|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
33318830|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
33318831|NCT01070927|Experimental|cohort 1|
32832115|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
32832116|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
32832117|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
32832118|NCT05606601|Experimental|Intervention arm|Participants randomized into the intervention arm will be given immediate access to a fully functional version of the Minder app that includes baseline, interim and follow-up surveys and access to all app components and e-coaching.
32832119|NCT05606601|No Intervention|Control arm|Participants randomized into the control arm will be given access to a restricted version of the app that only includes access to a generic study introduction video and baseline and follow up survey assessments delivered via the app.
33318832|NCT01070927|Experimental|cohort 2|
33318833|NCT03976271|Active Comparator|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
33318834|NCT03976271|Active Comparator|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
32832120|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
32832121|NCT03233490|Experimental|CPR training intervention|CPR training without web course
32832122|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
32832123|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
32832124|NCT05287893|Experimental|IBSM challenge and pyronaridine PK/PD population profile|"Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes.~Day 8 participants will be dosed with pyronaridine when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL.~Different doses of pyronaridine will be administered across and within cohorts in order to effectively characterise the PK/PD relationship.~The highest dose of pyronaridine administered will be no more than 720 mg; the lowest dose administered will be no less than 180 mg.~Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and pyronaridine concentration.~Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 47±2, or earlier."
32832125|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
32832126|NCT02357758|No Intervention|Healthy Population|Healthy population
32832127|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
32832128|NCT01552434|Experimental|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32832129|NCT01552434|Experimental|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32832130|NCT01552434|Experimental|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32832131|NCT05606445||1|Healthy young (18-30 years old) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
32832132|NCT05606445||2|Healthy middle aged (40-55y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
32832133|NCT05606445||3|Healthy old (>65y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
33318835|NCT03976271|Active Comparator|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
33318836|NCT03976271|Active Comparator|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
33318837|NCT03976271|Active Comparator|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
33318838|NCT03976271|Active Comparator|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
33318839|NCT01069835||1|Non-small cell lung cancer patients
33318840|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
33318841|NCT01069913|Active Comparator|BG00012 API|BG00012 API
33318842|NCT01730950|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
33318843|NCT01730950|Experimental|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
33102768|NCT04169334|Experimental|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
33102769|NCT05180903|Experimental|Bulk Fill resin composite restorations reinforced by ultra high molecular weight polyethylene.|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany) reinforced by ultra high molecular weight polyethylene. (Ribbond THM, Ribbond Inc, Seattle, WA, USA)
32738818|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
32738819|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
33102770|NCT05180903|Active Comparator|Bulk Fill resin composite restorations|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany)
33102771|NCT05191251||Full-term pregnant women with HEMSTOP|"Full-term pregnant women who have given birth vaginally or by cesarean section. Patients for whom a HEMSTOP questionnaire could be carried out in prepartum, during the pre-delivery anesthesia consultation.~Patients who received follow-up during pregnancy as recommended. Age over 18"
33102772|NCT04686513||Obese young adult|
33102773|NCT04686513||Non Obese young adult|
33102774|NCT05152004|Experimental|High dose dual therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days
33102775|NCT05152004|Active Comparator|Hybrid therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days
33102776|NCT05132153|Active Comparator|(Group A) will receive milrinone|Patients will receive milrinone 50 microgram/kg in 5ml volume, over 5 min by nebulization
33102777|NCT05132153|Placebo Comparator|(Group B) will receive normal saline|Patients will receive 5 ml saline by nebulization over 5 min
33102778|NCT00534378|No Intervention|1|
33102779|NCT05131997|Experimental|AD-221|AD-221, Placebo of AD-221A, AD-221B and AD-221C
33102780|NCT05131997|Experimental|AD-221A|AD-221A, Placebo of AD-221, AD-221B and AD-221C
33102781|NCT05131997|Active Comparator|AD-221B|AD-221B, Placebo of AD-221, AD-221A and AD-221C
33102782|NCT05131997|Active Comparator|AD-221C|AD-221C, Placebo of AD-221, AD-221A and AD-221B
33102783|NCT05186961||caregivers|Person who provided primary care for children younger than 18 years with swallowing disorders.
33102784|NCT05115890|Experimental|Exercise training|Patients with HFpEF will participate in the 8 weeks of supervised, two-legged, knee extensor exercise training for 3 days per week. Each exercise session will involve a 5-min warm-up and a 5-min cool-down, and exercise intensity will range between 40%-90% of maximal work rate. Maximal work rate will be re-assessed every two weeks.
33102785|NCT00534456|Experimental|Active|
33102786|NCT00534456|Placebo Comparator|Placebo|
33102787|NCT05104229|Active Comparator|Standard of Care|standard VTE chemoprophylaxis
33102788|NCT05104229|Experimental|Aspirin|Aspirin VTE chemoprophylaxis
33102789|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
33102790|NCT05163990|Experimental|TEAS group|10 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.
33102791|NCT05163990|No Intervention|Control group|Electrodes are connected at bilateral Neiguan points and Zusanli points 10 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group.
33102792|NCT05077631|Experimental|ACD856|
33102793|NCT05077631|Placebo Comparator|Placebo|
32738820|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
32738821|NCT05004363|Active Comparator|Lokelma|Lokelma therapy
32738822|NCT05004363|Placebo Comparator|Control|Placebo
32738823|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
32738824|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
32738825|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
32738826|NCT02489747|Experimental|WBE group|wheat bran extract
32738827|NCT02489747|Placebo Comparator|Placebo group|placebo
32738828|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
32738829|NCT03224845|Experimental|Cognitive behavioural skills training|
32738830|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
32738831|NCT02486393||type of surgery|patients undergoing parotid surgery
32738832|NCT05003973|Experimental|home-based anti-resistance exercise|
32738833|NCT05003973|Experimental|usually care|
32738834|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
32738835|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
32738836|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
32738837|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
32832134|NCT05606445||4|People with mild cognitive impairment (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
33102794|NCT04153032|Experimental|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
32832135|NCT05606445||5|People with mild dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
32832136|NCT05606445||6|People with moderate dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
32832137|NCT05606445||7|People with severe dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
32832138|NCT05606289|Experimental|CIT officers|Police officers randomized to the experimental group will receive a 40-hour CIT training curriculum.
32832139|NCT05606289|No Intervention|Non-CIT officers|Police officers randomized to the no-intervention group will not receive the 40-hour CIT training curriculum.
32832140|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
32832141|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
32832142|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
32832143|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
32832144|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
32832145|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
32832146|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
32832147|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
32832148|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
32832149|NCT04752969||Hypothyroidia|20 subjects diagnosed with hypothyroidism
32832150|NCT04752969||Hyperthyroidia|20 subjects diagnosed with hyperthyroidism
32832151|NCT04752969||Healthy|20 age-matched healthy control subjects
32832152|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
32832153|NCT02359006|Active Comparator|minocycline|200mg minocycline
32832154|NCT02359006|Placebo Comparator|Placebo|Sugar pill
32832155|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
32832156|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
32832157|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
32832158|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
32832159|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
32832160|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
32832161|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
32832162|NCT04486014|Experimental|Erector spinae plane block (ESP)|Patients would receive erector spinae plane block
32832163|NCT04486014|Experimental|Serratus anterior plane block (SAP)|Patients would receive serratus anterior plane block
32832164|NCT04485702|Active Comparator|MELT-100|3mg midazolam and 25mg ketamine sublingual tablet
32832165|NCT04485702|Active Comparator|IV midazolam|2mg Intravenous midazolam
32832166|NCT04485702|Active Comparator|IV ketamine|6mg Intravenous ketamine
32832167|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
32832168|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
32832169|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
32832170|NCT00068367|Experimental|Arm I (OSI-774)|"Drug: erlotinib hydrochloride~Other Names:~OSI-774 150 mg per day, daily until disease progression"
33102795|NCT04153032|Experimental|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
32832171|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
32832172|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
32832173|NCT01975090|Experimental|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
32832174|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
32832175|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
32832176|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
32832177|NCT02880891|Experimental|splinted|splinted crown
32832178|NCT02880891|No Intervention|non-splinted|single crown
32832179|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
32832180|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
32832181|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
32832182|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
32832183|NCT05255133|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
32832184|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
32832185|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
32832186|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
32832187|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
32832188|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
32832189|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
32832190|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
32832191|NCT03233178||Liraglutide|Patients initiation liraglutide
32832192|NCT03233178||Sitagliptin|Patients initiating sitagliptin
32832193|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
32832194|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
32832195|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
32832196|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
32832197|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
33032997|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-I is the intervention arm with combination of two drugs such as low dose propofol and Isoflurane MAC awake.
32832198|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
32832199|NCT03233100|Experimental|FMT group|
32832200|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
32832201|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
32832202|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
32832203|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
32832204|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
32832205|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
32832206|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
32832207|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
32832208|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
32832209|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
32832210|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
32832211|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
32832212|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
32832213|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
32832214|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32832215|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32832216|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
32832217|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
33032998|NCT01958138|Active Comparator|alone isoflurane|The group-II is the control arm of study by using the only Isoflurane 1.2 MAC
33032999|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
33033000|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
32832218|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
32832219|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
32832220|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
32832221|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
32832222|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
32832223|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
32832224|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
32832225|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
32832226|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
32832227|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
32832228|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
32832229|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
32832230|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
32832231|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
32832232|NCT03228810||Men >18 years old with metastatic prostate cancer|
32832233|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
33102796|NCT04153032|Experimental|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
33102797|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
33102798|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
33102799|NCT04138524|Experimental|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
33102800|NCT05065502|Active Comparator|Academic Detailing (AD) Only|One-on-one educational outreach to employees and providers.
33102801|NCT05065502|Experimental|AD + LEAP Combined|This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
33102802|NCT05121792|Experimental|Therapist online training in Prolonged Grief Disorder Therapy|Participants will be given access to an online 10-module interactive tutorial about Prolonged Grief Disorder Therapy.
33102803|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
33102804|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
33102805|NCT05062070|Active Comparator|5 Percent TolaSure Topical Gel|5% (w/w) TolaSure Gel
33102806|NCT05062070|Placebo Comparator|Topical Vehicle Gel|TolaSure Vehicle Gel
33102807|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
33102808|NCT00534573|Active Comparator|Amisulpride|Comparison
33102809|NCT04686890|Active Comparator|postoperative opiod (morphine) consumption|patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
32832234|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
32832235|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
32832236|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
32832237|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
32832238|NCT01747499|Experimental|Cohort 1|"Conditioning treatment~Transplant on Day 0~15 mg/m^2 azacitidine Days 7-11~15 mg/m^2 azacitidine Days 35-39~15 mg/m^2 azacitidine Days 63-67~15 mg/m^2 azacitidine Days 91-95"
32832239|NCT01747499|Experimental|Cohort 2|"Conditioning treatment~Transplant on Day 0~30 mg/m^2 azacitidine Days 7-11~30 mg/m^2 azacitidine Days 35-39~30 mg/m^2 azacitidine Days 63-67~30 mg/m^2 azacitidine Days 91-95"
32832240|NCT01747499|Experimental|Cohort 3|"Conditioning treatment~Transplant on Day 0~37.5 mg/m^2 azacitidine Days 7-11~37.5 mg/m^2 azacitidine Days 35-39~37.5 mg/m^2 azacitidine Days 63-67~37.5 mg/m^2 azacitidine Days 91-95"
32832241|NCT01747499|Experimental|Cohort 4|"Conditioning treatment~Transplant on Day 0~45 mg/m^2 azacitidine Days 7-11~45 mg/m^2 azacitidine Days 35-39~45 mg/m^2 azacitidine Days 63-67~45 mg/m^2 azacitidine Days 91-95"
32832242|NCT01747499|Experimental|Phase II Cohort|"Conditioning treatment~Transplant on Day 0~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 7-11~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 35-39~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 63-67~Dose determined in Phase I - 45 mg/m^2 attitudinize Days 91-95"
32832243|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
32832244|NCT00071721|Experimental|1|
32832245|NCT00071721|Placebo Comparator|2|
32832246|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
32832247|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
32832248|NCT05606133|Experimental|Circulating HPV DNA|
32832249|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
32832250|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
33102810|NCT04686890|Active Comparator|peroperative continuous opioid (remifentanil) consumption|continuous remifentanil infusion was given during the whole procedure
32832251|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
32832252|NCT05606055|Experimental|SDT|-75 patients of immediate treatment, will be those patients without immuno-virological data that accept to start the treatment the same day of the first consultation with the hospital specialist (arm 1 or SDT).
32832253|NCT05606055|Active Comparator|Conventional|- 75 patients of conventional treatment, will be those who in their first consultation with the hospital specialist already have previous immuno-virological data or reject the start of immediate treatment (arm 2 or conventional).
32832254|NCT03232710|Experimental|pilot study group|
33102811|NCT04686890|Active Comparator|postoperative numerated rating scale|at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
33102812|NCT00533000|Experimental|A|Smoking cessation
33102813|NCT00533000|No Intervention|B|
33102814|NCT04136340|Active Comparator|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
33102815|NCT04136340|Experimental|Home Telemedicine follow-up|
33102816|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
33102817|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
33102818|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
32832255|NCT03232710|Experimental|group 1 (under fasting condition)|
32832256|NCT03232710|Experimental|group 2 (under fasting condition)|
32832257|NCT03232710|Experimental|group 3 (under fed condition)|
32832258|NCT03232710|Experimental|group 4 (under fed condition)|
32832259|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:~Reiferon Retard® 160 µg /week subcutaneous injection.~Ribavirin in a dose of 13 mg/kg/day orally"
32832260|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
32902764|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
33102819|NCT05103306||Triple OADs failure|Inadequatelly controlled type 2 diabetes patients despite triple combination therapy with metformin, glimepiride, and DPP-4 inhibitor
33102820|NCT05047952|Experimental|Vortioxetine|"Participants aged 18-64 years: start at 10 mg vortioxetine once daily for the first 2 weeks, then dosed up to 20 mg vortioxetine once daily for weeks 2-8.~Participants aged 65+ years: start at 5 mg vortioxetine once daily for the first 2 weeks, then dosed up to 10 mg vortioxetine once daily for weeks 2-8."
33102821|NCT05047952|Placebo Comparator|Placebo|Placebo capsule taken once daily for weeks 0-8.
32832261|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:~Bon-One ® 0.5 µg daily orally~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
32832262|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
32832263|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
32832264|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
32832265|NCT05605977|No Intervention|Control group|regular early intervention
32832266|NCT05605977|Experimental|Traditional visual-motor training program|traditional visual-motor training program plus regular early intervention
32832267|NCT05605977|Experimental|Computerized visual-motor training program|computerized visual-motor training program plus regular early intervention
32832268|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
32832269|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
32832270|NCT04753125|Active Comparator|compliance treatment|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance for 3, 6. 9 and 12 months
32832271|NCT04753125|Active Comparator|compliance for blood test|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance, follow-up via a game in a smartphone app through an interactive game with stimuli to pass the phase as the treatment was completed and blood tests were performed in 3,6,9 and 12 months.
33102822|NCT05042999|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
33102823|NCT05042999|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
33102824|NCT05016791|Active Comparator|Active|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider. In addition, participants in this arm shall be loaned an Apple Watch device and undergo an education session to familiarise themselves with the study recording schedule and how to perform recordings.
33102825|NCT05016791|No Intervention|Control|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider.
33102826|NCT05102097|Experimental|Experimental Group|Treadmill walk: i- warm up ( 5 minutes ) II- Main exercise (30 minutes) III- cool down (5 minutes) IV- Standard of care (10minutes)
33102827|NCT05102097|Active Comparator|Control group|Standard of care (10 minutes)
33102828|NCT05007002|Experimental|Robot-based therapy|Chronic stroke patients receiving robot-based therapy
33102829|NCT04988399|Experimental|Reiki Recipients|The Practitioner enters a gassho (two hands coming together at the heart) meditative state with the Distance Symbol. Reiji-ho - moving the joined hands until the thumbs touch the space between the brows. Going into a relaxed state by using a breathing technique. Say the person's name three times. Proceed with byosen (method using the sensitivity in the hands to treat those areas in need of Reiki) scanning technique. Chiryo (standard session visualizing all hand positions) for 5 minutes each: Jawbone-Back of the head-Throat-Lungs-Area of participant's concern-Stomach-Intestines-Kidneys-Spinal cord. At the end of the session, visualize towards the participant's feet to help integrate the healing. Visualize brushing the Biomagnetic field around the participant's body from head to feet. Inform the participant that the session has been completed. Include time to rest quietly for a few minutes. Encourage participant to sip water (if they prefer) and ask them about their experience.
33102830|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
33102831|NCT05097885|Experimental|Sub Acute (12 week) Whole Body Training|
32832272|NCT04753125|Placebo Comparator|demographic socio-economic and sexuality questionnaire|Questionnaire applied to all patients with positive VDRL
32832273|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
32902765|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
32902766|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
32902767|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
33417160|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
32832274|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
32832275|NCT05118009|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
32832276|NCT05118009|No Intervention|Control|Patients randomized to control will continue routine practice.
32832277|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
32832278|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
32832279|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
32832280|NCT00158223|Placebo Comparator|placebo|Participants will receive encapsulated placebo made to match active drug
32832281|NCT00158223|Experimental|pimozide|Participants will receive pimozide flexible dosing
32832282|NCT03228576||TREVISE|
32832283|NCT00158379|Experimental|Paclitaxel|
32832284|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
32832285|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
32832286|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
32832287|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
32832288|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
32832289|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
32832290|NCT03232320|Experimental|MEDITOXIN|
32832291|NCT03232320|Placebo Comparator|Placebo|
32832292|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
32832293|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
32832294|NCT00158925|Experimental|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
32832295|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
32832296|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
32832297|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
32832298|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
32832299|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
32832300|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
32832301|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
32832302|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
32832303|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
32866668|NCT05617482|Active Comparator|Ultrasound guided ilioinguinal, iliohypogastric TAP block|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
32832304|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
32832305|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
32832306|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
32832307|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
32832308|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
32832309|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
32832310|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
32832311|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
32832312|NCT00163293|Placebo Comparator|Placebo|
33102832|NCT04980443|Experimental|FIT positive individuals|FIT-positive individuals of whom we will collect blood samples and who will undergo a colonoscopy after blood sampling.
33102833|NCT04971980|Experimental|hUC-MSC infusion (BC-U001)|Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001
33102834|NCT04965779|Experimental|Intervention group (Abdominal binder)|The abdominal binder is applied after the women come to the clinic (postpartum 1st hour) following cesarean delivery and removed after the postpartum 48th hour. Postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided together with the application of the abdominal binder.
33102835|NCT04965779|Active Comparator|Control group (No abdominal binder)|Only postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided with no abdominal binder or similar application.
33102836|NCT04960241|Active Comparator|Homebased telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
33102837|NCT04960241|Active Comparator|Homebased rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
33102838|NCT04960241|Active Comparator|No physical rehabilitation|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
33102839|NCT05080959|Experimental|CPL-01|CPL-01 200mg, 400mg, 600mg
33102840|NCT05080959|Experimental|Naropin|150mg
33102841|NCT05080959|Experimental|Placebo|30mL normal saline (0.9%)
33102842|NCT00533078|Other|1|
33102843|NCT05064267||CKD stage 3|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 3 from a non-inflammatory etiology.
33102844|NCT05064267||CKD stage 4|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 4 from a non-inflammatory etiology.
32832313|NCT00163293|Active Comparator|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
32832314|NCT00163293|Active Comparator|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
32832315|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
32832316|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
32832317|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
32832318|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
32832319|NCT02033200|Experimental|Active|Stendra 200 mg
32832320|NCT02033200|Placebo Comparator|Placebo|placebo
32832321|NCT00076245|Experimental|1 Light therapy|
32832322|NCT00076245|Experimental|2 Cognitive behavioral therapy|
32832323|NCT00076245|Experimental|3 Light therapy plus cognitive behavioral therapy|
32832324|NCT00076245|No Intervention|4 Control|
32832325|NCT02140554|Experimental|Group A|"Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting"
33102845|NCT05064267||CKD stage 5|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 5 from a non-inflammatory etiology.
33102846|NCT01274338|Experimental|Arm A (HIP)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
33102847|NCT01274338|Experimental|Arm B (HDI)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
33102848|NCT01274338|Experimental|Arm C (LIP)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
33318844|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
33318845|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
33318846|NCT00271505|Experimental|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
32738838|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
33326874|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
32738839|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
32738840|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
32738841|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
32738842|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
32738843|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
32738844|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
32738845|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
32738846|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
32738847|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
32738848|NCT05463497|Other|Group 1(N=10)|"Treatment A for Period 1 Treatment C for Period 2 Treatment B for Period 3~*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
32738849|NCT05463497|Other|Group 2(N=10)|"Treatment B for Period 1 Treatment A for Period 2 Treatment C for Period 3~*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
32738850|NCT05463497|Other|Group 3(N=10)|"Treatment A for Period I Treatment E Treatment D~*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
32738851|NCT05463497|Other|Group 4(N=10)|"Treatment D for Period 1 Treatment A for Period 2 Treatment E for Period 3~*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
32738852|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
32738853|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
32738854|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
32738855|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
32738856|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
32738857|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
32738858|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
32738859|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
32738860|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
32738861|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
32738862|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
32738863|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
32746759|NCT04756635|Experimental|Experimental Group|Measures taken before and after the defined IF periods. Two groups of participants will be included in this project: 1) resistance trained group (tested for neuromuscular function, anaerobic capacity and body composition); 2) endurance trained group (tested for aerobic and anaerobic capacity and body composition). Experimental condition: pre- and post-4 weeks of IF. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48- hour interval) to ensure full recovery.
32832326|NCT02140554|Experimental|Group B|"Group B1:~Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting~Group B2:~Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting"
32832327|NCT02140554|Experimental|Group C|Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by plerixafor mobilization and apheresis transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
32832328|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
32832329|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
32832330|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
32832331|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
32832332|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~fosfomycin 3 g orally 2 hours before prostate biopsy, or~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
32832333|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
32832334|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
32832335|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
32832336|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
32832337|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
32832338|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
32832339|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
33102849|NCT01274338|Experimental|Arm D (HIP; Pediatric)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
32832340|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
32832341|NCT00078897|Active Comparator|Selenium|Participants receive oral selenium 200 mcg once daily.
32832342|NCT00078897|Placebo Comparator|Placebo|Participants receive oral placebo once daily.
32832343|NCT01746017|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
32832344|NCT01746017|Experimental|LY2922470 (Part A)|Single ascending dose of LY2922470 [starting at 1 milligram (mg)] administered orally to healthy participants in up to 3 of 4 study periods in Part A
32832345|NCT01746017|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
32832346|NCT01746017|Experimental|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
32832347|NCT05234502|Experimental|Group-1 (Ketogenic diet)|Group-1 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with an anthracycline. And simultaneously with standard neoadjuvant therapy containing taxane (12 weeks), KD will be planned for Group-1
33102850|NCT01274338|Experimental|Arm E (HDI; Pediatric)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
33326875|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
33326876|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
32832348|NCT05234502|Other|Group-2 (Adequate and balanced healthy diet)|Group-2 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with anthracycline and taxane (12 weeks).
32832349|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
32832350|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
32866669|NCT05617482|Active Comparator|Ultrasound guided transversus abdominis plane block|The transducer will be placed at between the lower rib margin and the iliac crest, the 23-gauge Quincke spinal needle needle passed through the external oblique and internal oblique muscle till reaching the transversus abdominis sheet. 20 ml of 0.25% bupivacaine will be injected
32902768|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
33102851|NCT01274338|Experimental|Arm F (LIP; Pediatric)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
33102852|NCT04942730|Experimental|FluBuBe|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
33102853|NCT04068402|Experimental|Treatment|
32832351|NCT04556045|Experimental|Radiation Therapy + Exercise Therapy|The exercise therapy group will receive the exercise intervention in addition to their standard of care radiation treatment. At their baseline visit, they will meet with the exercise physiologist, each participant will be provided a personalized exercise prescription to follow at home and will be asked to record what they do in between daily radiation treatment visits on the exercise tracking log provided to them. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the treatment and exercise prescription. The exercise physiologist will meet with the participant at every radiation treatment visit for a brief 15-30 minute exercise counseling check-in. After the participant's five radiation treatments, the exercise physiologist will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
32832352|NCT04556045|No Intervention|Radiation Therapy|The observational group will continue with their usual standard of care of radiation therapy. The study team will provide patients with an educational pamphlet at the end of their baseline visit. Additionally, the participant's medical record will be reviewed for serious adverse events during their time on study. Baseline and final measurements will be obtained.
32832353|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
33102854|NCT04917302|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
33102855|NCT04917302|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
33102856|NCT04049760|Experimental|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
33102857|NCT04909190|No Intervention|1xIFU|Subjects in this arm are randomized to have a saline flush volume according to the IFU of the used device.
33102858|NCT04909190|Experimental|4xIFU|Subjects in this arm are randomized to have a saline flush volume of 4x of what is stated in the IFU of the used device.
33102859|NCT04034901|Experimental|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
33102860|NCT05062590|Experimental|Group Intervention|Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
33102861|NCT05062590|No Intervention|Group control|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations
33102862|NCT04903964|Experimental|oral nutrition only group that received nutrition education|This group consists of children who are fed orally according to their chronological age. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the hospitalized child after the operation will be determined and the measurements will be checked.
33102863|NCT04903964|Experimental|group that received nutrition education and fed with nutritional support|This group consists of children who receive nutritional support provided by oral food supplements, oral food supplements, enteral tube feeding and / or parenteral nutrition. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the child hospitalized after the operation will be determined and the measurements will be checked.
33318847|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
32832354|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
32832355|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
33326877|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
33326878|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
32832356|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
32832357|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
32832358|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
32832359|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
32832360|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
32832361|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
32832362|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
32832363|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
32832364|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
32832365|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
32832366|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
32832367|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
32832368|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
32832369|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
32832370|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
32832371|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
32832372|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
32832373|NCT03227718||athletic background|ex-gymnasts
32832374|NCT03227718||control|age-matched non-gymnastics background
32832375|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
32832376|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
32832377|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
32832378|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
32832379|NCT00080535|Experimental|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
32832380|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
32832381|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
32832382|NCT01897545|Active Comparator|PV isolation|
32832383|NCT01897545|Active Comparator|PV isolation+renal denervation|
32832384|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
32832385|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
32832386|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
32832387|NCT05061381|Experimental|A Lust for Life Schools Programme Group|A Lust for Life programme will be delivered to primary school pupils by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
32832388|NCT05061381|No Intervention|Waiting list control group|Participants will be placed on a sixteen-week waiting list for the programme.
32902769|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
32902770|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
33326879|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
32832389|NCT01745393|Experimental|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
32832390|NCT01745393|Active Comparator|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
32832391|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
32832392|NCT00081861|Experimental|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
32832393|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
32832394|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
33102864|NCT04903964|No Intervention|control group|While collecting research data on the specified dates; Comparison group (KG) will be selected as many as the number of volunteers who want to participate in the research. No nutritional attempt will be made to the child included in this group. The parameters used in the evaluation of growth (height, head and chest circumference measurement) and the Ankara Development Screening Inventory (AGTE) will be applied to children aged 0-3 who are followed up due to congenital heart disease.
32832395|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
32832396|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
32832397|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
32832398|NCT03230760|Experimental|treatment|
32832399|NCT03230682||major depressive disorder|
32832400|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
32832401|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
32832402|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
32832403|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
32832404|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
32832405|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
32832406|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
32832407|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
33102865|NCT00534690|Other|1|
33102866|NCT00534690|Other|2|
33102867|NCT04901936|Experimental|Pegcetacoplan|
32832408|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
32832409|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
32832410|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
33102868|NCT04033497|Experimental|TRAMs I|"Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)~Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
33102869|NCT01272193|Experimental|IDegAsp OD|
33102870|NCT01272193|Active Comparator|IGlar OD|
33102871|NCT04899206||ARBs only|Hypertensive patients under pharmacological treatment with ARBs
33102872|NCT04899206||ACEIs only|Hypertensive patients under pharmacological treatment with ACEIs
32832411|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
32832412|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
32832413|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
32832414|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
32832415|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
32832416|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
32832417|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
32832418|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
32832419|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
33102873|NCT04899206||ARBs + ACEIs|Hypertensive patients under pharmacological treatment with ARBs and ACEIs
33102874|NCT04899206||Other Antihypertensive Drugs|Hypertensive patients under pharmacological treatment with non-angiotensin agents (diuretics, calcium channel blockers and/or β-blockers alone or combined among them)
33102875|NCT04899206||Angiotensin Agents and Other Antihypertensive Drugs|Hypertensive patients under combined pharmacological treatment with Angiotensin Agents (ACEIs and/or ARBs) and Other Antihypertensives (non-angiotensin agents)
33326880|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
32832420|NCT01744691|Experimental|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
32832421|NCT04484766||Patient after pre-eclampsia|Patients with pre-eclampsia who were treated at the University Hospital of Jena between 1999-2009.
32832422|NCT04484766||Patients after PETN treatment|Patients of the PETN pilot study, with PETN and patients who received PETN as an individual therapy trial
32832423|NCT01982968|No Intervention|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
32832424|NCT01982968|Active Comparator|Surgery|Subjects will receive laparoscopic fundoplication surgery
32832425|NCT04485390||First responder group|Cardiac arrest victims in remote areas resuscitated by the first responders before the arrival of the EMS.
32832426|NCT04485390||EMS groups|Cardiac arrest victims in remote areas resuscitated by the EMS.
32832427|NCT04555577|Experimental|Stage I (nedisertib, radiation therapy, temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive nedisertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
32832428|NCT04555577|Experimental|Stage II (nedisertib, radiation, temozolomide, surgery)|"CONCURRENT: Patients receive nedisertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.~ADJUVANT: Patients receive temozolomide as in Stage I."
32832429|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
32832430|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
32832431|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
32832432|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
32832433|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
32832434|NCT01716533|Other|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
32832435|NCT01716533|Other|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
32832436|NCT01716533|Other|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
32832437|NCT01716533|Other|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
32832438|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
32832439|NCT04348786|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
32832440|NCT04348786|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
32832441|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
32832442|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
32832443|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
32832444|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
32832445|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
32832446|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
32832447|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
32832448|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
32832449|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
32832450|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
32832451|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
32832452|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
32902771|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
32832453|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
32832454|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
32832455|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
32832456|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
32832457|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
33102876|NCT04019613|Experimental|Subjects undergoing clinical invasive hemodynamic stress test|Subjects scheduled for standard-of-care, clinically indicated, invasive hemodynamic stress test will undergo lung ultrasound and assessment of extravascular lung water by pulmonary thermodilution technique.
32832458|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
32832459|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
32832460|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
32832461|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
32832462|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
32832463|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
32832464|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
32832465|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
33102877|NCT04687163|Experimental|OXA 130|Patients received sorafenib or lenvatinib Plus HAIC of 130 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
33102878|NCT04687163|Active Comparator|OXA 85|Patients received sorafenib or lenvatinib Plus HAIC of 85 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
33102879|NCT04017117|Experimental|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
33102880|NCT04017117|Active Comparator|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
33102881|NCT04686812|Experimental|Worksite health promotion program|Participants had a baseline health risk assessment (HRA) after which they were invited to participate in a workplace health promotion program. The intervention lasted six months and included the following components: nutrition counseling, physical activity, and stress management. HRAs were performed 6 and 12 months after intervention onset.
33102882|NCT04686812|No Intervention|Control|Participants only had a baseline and follow-up health risk assessments at 6 and 12 months.
33102883|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
33102884|NCT01270828|Placebo Comparator|Placebo|
33102885|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
33102886|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
33102887|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
33102888|NCT03987165|Experimental|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
33102889|NCT03987165|No Intervention|Control|
32832466|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
32832467|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
32832468|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
32832469|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
32832470|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
32832471|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
32832472|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
32832473|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
32832474|NCT02040298|Active Comparator|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months
32832475|NCT02040298|Active Comparator|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
32832476|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
32832477|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
32832478|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
32832479|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
32832480|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
32832481|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
32832482|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
32832483|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
32832484|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
32832485|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
32832486|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
32832487|NCT04485468||Parkinson's disease patients|Parkinson's disease patients and over 18 years old
32832488|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
32832489|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
32832490|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
32832491|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
32832492|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
32832493|NCT00081939|Experimental|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects > 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
32832494|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
32832495|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
32832496|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
32832497|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
32832498|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
32832499|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
32832500|NCT05027217||Standard ICU Arm (Main study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
32832501|NCT05027217||COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
32832502|NCT05027217||Non-COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from medical, surgical, trauma and neurological/neurosurgical patients who are not admitted for COVID-19.
32832503|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
32832504|NCT05004675|Experimental|lerodalcibep|300 mg SC dosed monthly
32832505|NCT05004675|Active Comparator|inclisiran|284 mg SC dosed Day 1 and Day 90
32832506|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
32832507|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
32832508|NCT03221088|No Intervention|Negative control group|Untreated Control Group
32832509|NCT05003037|Experimental|Wild-type Genotype|
32832510|NCT05003037|Experimental|EGFR mutation|
32832511|NCT04485000|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1) in addition to receiving standard postnatal care.
32832512|NCT04485000|Other|Waitlist Cpntrol|The waitlist control group will receive standard postnatal care for 12 weeks and will participate in the online 1-day CBT-based workshop at T2 (12 weeks post baseline).
32832513|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
32832514|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
32832515|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
32832516|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~patients with osteoarthritis of the hip or knee and rehabilitated in the institute~patients with primary and secondary tumors of the skeleton~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
32832517|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
32832518|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
32832519|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
32832520|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
33318848|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
32832521|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
32832522|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
32832523|NCT01985932|Other|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
32832524|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
32832525|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
32832526|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
32832527|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
32832528|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
32832529|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
32832530|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
32832531|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days."
32832532|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
32832533|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
32832534|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
32832535|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
32832536|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
32832537|NCT04821921||Patients with diabetes mellitus|Approximately 750 patients with diabetes mellitus from 3 GP practices specialized on diabetes treatment
32832538|NCT00082329|Experimental|G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Participants received subcutaneous injection of G-CSF (10 mcg/kg/day) for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
32832539|NCT03220620||GDT Group|receives goal-directed therapy
32832540|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
32832541|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
32832542|NCT02451462|No Intervention|placebo arm|placebo
32832543|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
32832544|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
32832545|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
32832546|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
32832547|NCT00082641|Experimental|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
32832548|NCT00082641|Experimental|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
32832549|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
33318849|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
33318850|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
32832550|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
32832551|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
32832552|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
32832553|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
32832554|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
32832555|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
32832556|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
32832557|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
32832558|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
32832559|NCT03207360|Experimental|Pain Coping Skills|
32832560|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
32832561|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
32832562|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
32832563|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
32832564|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
32832565|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
32832566|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
32832567|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
32832568|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
32832569|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
32832570|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
32832571|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~The placebo does not contain any psychoactive substance."
32832572|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
32832573|NCT00167661|Experimental|Campath 1-H|Campath 1-H
32832574|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
32832575|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
32832576|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
32832577|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
32832578|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
32832579|NCT03206580|Experimental|Concentric training|Concentric training
32832580|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
32832581|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
32832582|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
32832583|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
32832584|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
32832585|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
32832586|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
32832587|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
32832588|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
32832589|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
32832590|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
32832591|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
32832592|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
32832593|NCT00170157|Experimental|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy <= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy <= 21 days prior to enrollment) of AA therapy.
32832594|NCT00170157|Active Comparator|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
32832595|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
32832596|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
32832597|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
32832598|NCT02043574|Other|Stretching (Control)|Six months of stretching
32832599|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
32832600|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
32832601|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
32832602|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
32832603|NCT00170625|Experimental|Hycamtin|
32832604|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
32832605|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
32832606|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
32832607|NCT02150889|No Intervention|Lean Trained|Metabolic control
32832608|NCT02150889|Experimental|Obese or Overweight|Running Program Yoga Program
32832609|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
32832610|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
32832611|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
32832612|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
32832613|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
32902772|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
32902773|NCT05215886||Surgery|Patients scheduled for or have already completed Weight Loss Surgery at UC Davis Medical Center
32902774|NCT00582998|Active Comparator|Standard Wound Dressing|Standard post-operative wound dressing
32832614|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
32832615|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
32832616|NCT02043808||Dabigatran|
32832617|NCT02043808||Warfarin|
32832618|NCT04748991|Experimental|Intravenous Vernakalant|Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.
32832619|NCT04748991|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.
33318851|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
32832620|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
32832621|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
32832622|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
32832623|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
32832624|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
32832625|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
32832626|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
33102890|NCT04893551|Experimental|Tilvestamab|Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.
33102891|NCT03982407|Experimental|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
33102892|NCT03980262|Experimental|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
33102893|NCT03980262|Active Comparator|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
33102894|NCT04687124|Active Comparator|Fish oil|dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
33102895|NCT04687124|Placebo Comparator|standard care|The departmental usual procedure with the possibility of requiring of a dietician when needed
33102896|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
33102897|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
33102898|NCT03878589|Active Comparator|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
33102899|NCT03878589|Active Comparator|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
33102900|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
33102901|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
33102902|NCT05060562||Post COVID 19 symptoms Positive|The presence of persistent COVID-related symptoms after being cured.
33318852|NCT03546322||Registry|Head and neck cancer patients monitored on registry
32832627|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
32832628|NCT03206268||healthy eyes|
32832629|NCT03206268||uveitis eyes|
32832630|NCT03217656||Mother-child birth cohort|
32832631|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
32832632|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
32832633|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
32832634|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
32832635|NCT03206112||Healthy Volunteers|Healthy Volunteers
32832636|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
32832637|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
32832638|NCT00176865|Active Comparator|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
32832639|NCT00176865|Active Comparator|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
32832640|NCT00176865|Active Comparator|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
32832641|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
32832642|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
32832643|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
32832644|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
32832645|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
32832646|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
32832647|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
32832648|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
32832649|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
32832650|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
32832651|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
32832652|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
32832653|NCT00177255|Experimental|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
32832654|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
32832655|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
32832656|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
32832657|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
32832658|NCT00178191|Experimental|200 units Botox|200 units Botulinum-A toxin
33102903|NCT05060562||Post COVID 19 symptoms Negative|No persistent COVID-related symptoms after cured
33102904|NCT04685954|Experimental|Bulk-Fill|Filtek™ Bulk Fill Posterior, 3M ESPE, St. Paul MN, USA (FB)
32832659|NCT00178191|Experimental|300 units Botox|300 units Botulinum-A toxin
32832660|NCT00178191|Placebo Comparator|Placebo|Placebo
32832661|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
32832662|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
32832663|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
33102905|NCT04685954|Experimental|Incremental|Filtek Ultimate Universal, 3M ESPE, St. Paul MN, USA (FU)
32832664|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
32832665|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
32832666|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
32832667|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
32832668|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
32832669|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
32832670|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
32832671|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
32832672|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
32832673|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
32832674|NCT00178503|Placebo Comparator|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
33102906|NCT05059470|Experimental|Pembrolizumab|The infusions are given every 6 weeks
33102907|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
33318853|NCT01571986||NIV|All patients with acute respiratory failure treated with non-invasive ventilation who give informed consent about treatment of their clinical data
33318854|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
32832675|NCT00178503|Active Comparator|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
32832676|NCT00178503|Active Comparator|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
32832677|NCT00178503|Active Comparator|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
32832678|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
32832679|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
32832680|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
32832681|NCT03205332|No Intervention|Control|Assessment only.
32832682|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
32832683|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
32832684|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
32832685|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt~, 3 days/week, for 4 weeks (12 sessions)"
32832686|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
32832687|NCT00085293|Experimental|Treatment|Starting dose 6 mg/m^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
32902775|NCT00582998|Active Comparator|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
33102908|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
32832688|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
32832689|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
32832690|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
32832691|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
32832692|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
32832693|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
32832694|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
32832695|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
32832696|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
32832697|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
33318855|NCT04500574|Experimental|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
32832698|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
32832699|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
32832700|NCT03205020||women with preterm labor|
32832701|NCT03205020||women delivered at full term|
32832702|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
33318856|NCT04500574|Placebo Comparator|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
33318857|NCT03635944||Group A|Infants born in Lyon (France)
33318858|NCT03635944||Group B|Infants born in Stockholm (Sweden)
33318859|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
33318860|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
33318861|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
33318862|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
33318863|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
33318864|NCT03132454|Experimental|Arm I (palbociclib, sorafenib)|Patients receive palbociclib PO QD on days 1-28. Patients also receive sorafenib PO QD on days 1-28 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33318865|NCT03132454|Experimental|Arm II (palbociclib, decitabine)|Patients receive palbociclib as in Arm I. Beginning cycle 2, patients receive palbociclib PO QC on days 1-7 and decitabine IV QD over 1 hour on days 8-17 of cycle 2 and days 8-12 of cycles 3-8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33318866|NCT03132454|Experimental|Arm III (palbociclib, dexamethasone)|Patients receive palbociclib as in Arm I. Patients also receive dexamethasone PO QD or IV over 15-30 minutes on days 1-4 and 15-18 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33318867|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
33318868|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
32832703|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
32902776|NCT05208476|Experimental|Participants|All subjects will be observed for one menstrual cycle then given Osteopathic manipulative treatment during the second menstrual cycle. During the third menstrual cycle, participants will continue to be observed.
32902777|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
32902778|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
32832704|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
32832705|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
32832706|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
32832707|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
32832708|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
32832709|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
32832710|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
32832711|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
32832712|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
32832713|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
32832714|NCT00085839|Experimental|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
32832715|NCT00085839|Active Comparator|Standard Chemotherapy|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
32832716|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
32832717|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
32832718|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
32832719|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
32832720|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
32832721|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
32832722|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
32832723|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
32832724|NCT03204630|Placebo Comparator|Control|Standard infant formula
32832725|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
32832726|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
32832727|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
32832728|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
32902779|NCT05204186||Group A|Patient with (Group A) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
32832729|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
32832730|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
32832731|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
32832732|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
32832733|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
32832734|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
32832735|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
32832736|NCT02380612|Experimental|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
32832737|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
32832738|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
32832739|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
32832740|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
32832741|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
32832742|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
32832743|NCT02403622|Experimental|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
32832744|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
32832745|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
32832746|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
32832747|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
32866670|NCT05617482|Active Comparator|Ultrasound guidedQuadratus lumborum block|The transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
33318869|NCT04891198|Experimental|Subjects with TMB-H/TMB-L|Subjects receive KN035 400 mg Subcutaneously on Day 1 and day 15 of cycle 1 and on day 1 of every subsequent 4-week cycle (Q4W)
33318870|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
32902780|NCT05204186||Group B|Patient without (Group B) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
33102909|NCT04687176|Experimental|Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)|"Induction: Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and Ascorbic acid 1g daily for 42 days Consolidation: ral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles.~Maintenance: Oral Arsenic trioxide 10mg daily, ATRA (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total)."
32832748|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
33102910|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
33102911|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
32902781|NCT04266392|Experimental|1|
32902782|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
33102912|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
33102913|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
33102914|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
33102915|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
33318871|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
33318872|NCT00289991|Active Comparator|Itraconazole|
33318873|NCT00289991|Experimental|Voriconazole|
32902783|NCT05121350|Experimental|Arotinib hydrochloride capsule + Epirubicin|Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle
32902784|NCT05121350|Active Comparator|Placebo + Epirubicin|Placebo combined with epirubicin, 21 days as a treatment cycle
32902785|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
32902786|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
32902787|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
32902788|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
32902789|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
32902790|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
32902791|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
32902792|NCT00583700|No Intervention|1|Control for study - watchful waiting.
32902793|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
32902794|NCT05540743|Other|JIA associated uveitis|patients diagnosed with Juvenile idiopathic arthritis and uveitis taking immunosuppression including biologics 9of any type according to their rheumatologist recommendations) for control of their autoimmune uveitis.
32902795|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
32902796|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
32902797|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
32902798|NCT05094986|Experimental|Intervention group: IMA Intervention|"General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes.~Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies)."
32902799|NCT05094986|Active Comparator|Control group|Healthcare professionals from the control group prescribed medication and provided information as usual.
32902800|NCT04257188||minimally invasive vitrectomy under subtenon anaesthesia|
32902801|NCT04257188||minimally invasive vitrectomy under general anaesthesia|
32832749|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
32832750|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
32832751|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
32832752|NCT00180297|Experimental|Mid septal site location|RV lead is placed at mid septum.
32832753|NCT00180297|Active Comparator|Apical site location|RV lead is placed in apical position
32832754|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
32832755|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
32832756|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
32832757|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
32832758|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
32832759|NCT04733937|Active Comparator|a2 Group|The infant group consuming a2 Platinum® stage 1 infant formula
32832760|NCT04733937|Active Comparator|Control Group|The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula
32832761|NCT04733937|No Intervention|breast feeding|
32832762|NCT02051452|Experimental|Methylphenidate|Methylphenidate
32832763|NCT02051452|Placebo Comparator|placebo|Saline
32832764|NCT00180687|Sham Comparator|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
32832765|NCT00180687|Placebo Comparator|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
32832766|NCT00180687|Experimental|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
33318874|NCT00289913|Experimental|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
32832767|NCT00180687|Active Comparator|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
32832768|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
32832769|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
32832770|NCT00181623|Experimental|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
32832771|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
32832772|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
33102916|NCT01269346|Experimental|1|
32832773|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
32832774|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
32832775|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
32832776|NCT04708132|Active Comparator|screw retained restorations|
32832777|NCT04708132|Other|implant-retained ball overdentures|
32832778|NCT00087633|Experimental|1|
32832779|NCT00087633|No Intervention|2|
32832780|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
32832781|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
32832782|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
32832783|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
32832784|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
33033001|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
33033002|NCT01958229||CHB patients without cirrhosis|
33033003|NCT01958242|No Intervention|Preoperative blood harvesting|
33033004|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
33033005|NCT01958307|Experimental|Intervention|Lifestyle intervention
33033006|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
32746760|NCT04756635|Other|Control Group|Participants of each group serving as their own controls. Control condition: pre- and post4 weeks of normal diet. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48-hour interval) to ensure full recovery.
32746761|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
32746762|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
32746763|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
32746764|NCT05612295|Experimental|MBPP group|The Mindfulness-based Peak Performance (MBPP) program consists of eight 60-min training sessions, once weekly for 8 weeks, which aim to enhance human performance.
32746765|NCT05612295|Active Comparator|Self-talk group|The self-talk intervention serving as the active control group will be included in the current trial. In line with the MBPP intervention, the self-talk intervention is also designed to enhance athletic performance, and will consist of eight 60-min meaningful sessions, once per week for eight weeks.
32746766|NCT05612295|No Intervention|Waiting-list control|The participants in waiting-list control group are advised to maintain their everyday lifestyles and regular training. Once the participants in WC finish the experiment, they will be invited to participate in one of the 8-week interventions (i.e., MBPP or ST) based upon their preference.
32746767|NCT05612217||patients with CVD|20 patients per 1 center: patients with CVD C1 class 4 patients with CVD C2 class; 2 patients with CVD with classes other than C1-C2 (C4-C6); 8 patients with either C0s CVD or with skin pathologic conditions of lower extremities other than CVD;
32746768|NCT05033067|No Intervention|Usual Care|
32746769|NCT05033067|Experimental|Intervention (P3-BC) Usual Care|intervention + usual care group. In addition to receiving usual care, patients will have access to the aid and related materials before consultation with the physician about cystectomy and urinary diversion.
32746770|NCT05614557|No Intervention|Control|
32746771|NCT05614557|Experimental|Formulation 1|
32746772|NCT05614557|Experimental|Formulation 2|
32746773|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
32746774|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
32746775|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
32746776|NCT04747197|Experimental|EYP-1901 440 ug|EYP-1901 440 ug, single dose
32746777|NCT04747197|Experimental|EYP-1901 2060 ug|EYP-1901 2060 ug, single dose
32746778|NCT04747197|Experimental|EYP-1901 3090 ug|EYP-1901 3090 ug, single dose
32746779|NCT04744389|Experimental|Hypothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
32746780|NCT04744389|Experimental|Normothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
32746781|NCT04699695||Biologic Treatment|Subjects prescribed a biologic agent per standard of care
32746782|NCT04699695||Other Treatments|Subjects prescribed other treatment modalities exclusive of biologic therapy per standard of care
32746783|NCT05614479|Other|Intervention group|Use of the MAHA mobile application
32746784|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
32746785|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
32746786|NCT04695171||Prior Primary Large Hiatal Hernia with LINX Placement MSA|Patients who were previously implanted with the LINX device during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
32746787|NCT04695171||Prior Primary Large Hiatal Hernia with Fundoplication|Patients who previously underwent lower esophageal sphincter reconstruction by fundoplication during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at about 3 and 5 years to determine recurrence of hiatal hernia.
32746788|NCT04186546||Cases|Zephyr Valve Procedure
32746789|NCT04644315|Experimental|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
32746790|NCT05205759|Experimental|Bamlanivimab Etesevimab|Bamlanivimab 700 mg + Etesevimab 1400 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
32746791|NCT05205759|Experimental|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
33102917|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
33102918|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
32832785|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
32832786|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
32832787|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
32832788|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
32832789|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
32832790|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
32832791|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
32832792|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
32832793|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
32832794|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
32832795|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
32832796|NCT00182793|Experimental|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
32832797|NCT00182793|Experimental|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
32832798|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
32832799|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
32832800|NCT01954875||healthy controls|healthy subjects as controls
32832801|NCT00183339|Placebo Comparator|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
32832802|NCT00183339|Experimental|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
32832803|NCT01743989|Experimental|Nilotinib 24-month treatment|Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
32832804|NCT01743989|Experimental|Nilotinib 36-month treatment|Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
32832805|NCT01743989|Experimental|Not randomized|Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
32832806|NCT00183729|Experimental|Memantine (1)|Memantine for 12 weeks
32832807|NCT00183729|Placebo Comparator|Placebo (2)|Placebo for 12 weeks
32832808|NCT00185679|Experimental|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
32832809|NCT00186069|Active Comparator|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
32832810|NCT00186069|Placebo Comparator|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
32832811|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
32832812|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
32832813|NCT01898325|Other|Naïve GD patients|"Naïve GD patients~Intervention: device - Fibroscan"
32832814|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
32832815|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
32832816|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
32832817|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
32832818|NCT04555187||Covid19-positive|Covid19 test positive. age >= 18 y.
32832819|NCT04555187||Covid19-negative|Covid19 test negative. age >=18y
33102919|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
33102920|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
33102921|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
33102922|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
32746792|NCT05205759|Active Comparator|Casirivimab Imdevimab|Casirivimab 600 mg + Imdevimab 600 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
32746793|NCT05205291||Parkinson's disease patients|18 patients with Parkinson's disease who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
32746794|NCT05205291||Healthy controls|6 healthy controls who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
32746795|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
32746796|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
32746797|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
32746798|NCT05558163|Other|PPI through traditional penoscrotal approach|cases of erectyl dysfunction who underwent PPI throug penoscrotal approach
32746799|NCT05558163|Other|PPI through novel transverse scrotal approach|cases of erectyl dysfunction who underwent PPI throug novel transverse scrotal approach
32746800|NCT04984473|Sham Comparator|Sham arm|Perform inspiratory muscle training at 2% maximal inspiratory pressure for 12 weeks.
32746801|NCT04984473|Active Comparator|Non-sham arm|Perform inspiratory muscle training at 40% maximal inspiratory pressure for 12 weeks.
32746802|NCT04582695|Active Comparator|Written Exposure Therapy|
32746803|NCT04582695|Experimental|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
32746804|NCT04971447|Experimental|Group: transgender men|
32746805|NCT04971447|No Intervention|Groupe: control cis-gender women|
32746806|NCT04971447|Experimental|Group: transgender women|
32746807|NCT04971447|No Intervention|Groupe: control cis-gender men|
32746808|NCT04394715|Experimental|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
32746809|NCT04394715|No Intervention|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
32746810|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
32746811|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
32746812|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
32746813|NCT05557929||Hemodialysis patients|The present study will comparatively evaluate a series of parameters (measured with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis) in end-stage kidney disease patients undergoing hemodialysis between the end of the long and the end of the short interdialytic interval. The primary aim of the study is the evaluation of cardiorespiratory fitness - cardiovascular reserve assessed with cardiopulmonary exercise testing at these time points.
32746814|NCT05557929||Controls without CKD|Controls without CKD will be evaluated with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis at one time point (baseline visit)
32746815|NCT05557773|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
32746816|NCT05557773|Experimental|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
32746817|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
32746818|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
32746819|NCT05557383|Experimental|use peanut ball|Registered nurses were educated by the investigators on the study protocol, and standard care was given to both the intervention and control groups.The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
32746820|NCT05557383|No Intervention|usual care|usual nursing care.
32746821|NCT04819191|Experimental|SHARING Choices|"Components of SHARING Choices include:~A letter from the clinic introducing an initiative to prepare persons and families for Advance Care Planning (ACP); Access to a facilitator trained to lead ACP discussions; Patient-family agenda-setting to align perspectives about the role of family and stimulate discussion about ACP; Facilitated registration to the patient portal (for patient and family) as desired; Education & resources about Alzheimer's Disease and Related Dementias (ADRD) for clinic staff."
32746822|NCT04819191|No Intervention|Usual care|Usual care
32746823|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
32746824|NCT04306341|Experimental|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
32746825|NCT04306341|No Intervention|Control|Dialectical Behavior Therapy (treatment as usual)
32746826|NCT05610969|Active Comparator|Music group|self-selected music
32746827|NCT05610969|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
32746828|NCT05557149|Sham Comparator|Neutral VR|Ten minutes virtual reality exposure to neutral stimuli (e.g. neutral picture frames)
32746829|NCT05557149|Experimental|Cocaine VR|Ten minutes virtual reality exposure to cocaine use-related stimuli (i.e. peers using cocaine, cocaine paraphernalia, cocaine use preparing, cocaine use, etc.)
32746830|NCT05557149|Other|Relaxation|Ten minutes respiratory relaxation (eyes closed and sitted on a chair)
32746831|NCT04417738|Active Comparator|Active|Patients will receive the active treatment.
32832820|NCT01742897|Experimental|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
32832821|NCT04554485|Experimental|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
32832822|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
33102923|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
32832823|NCT04564703|Experimental|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
32832824|NCT04564703|Experimental|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
32832825|NCT04564703|Experimental|cohort 3|Iberdomide will be given orally at 0.75 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
32832826|NCT01741259|Experimental|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
32832827|NCT01741259|Experimental|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
32832828|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
32832829|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
32832830|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
32832831|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
32832832|NCT02387554|Active Comparator|HGP0904|amlodipine
32832833|NCT02387554|Active Comparator|HGP0608|losartan
32832834|NCT02387554|Active Comparator|HGP1405|chlorthalidone
32832835|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
32832836|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
32832837|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
32832838|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
32832839|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
32832840|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
32832841|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
32832842|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
32832843|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
32832844|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
32832845|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
32832846|NCT01740791|Experimental|Velpatasvir 5 mg (GT 1a)|Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.
32832847|NCT01740791|Experimental|Velpatasvir 25 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
32832848|NCT01740791|Experimental|Velpatasvir 50 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
32832849|NCT01740791|Experimental|Velpatasvir 100 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.
32832850|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
32832851|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1b)|Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
32832852|NCT01740791|Experimental|Velpatasvir 150 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
32832853|NCT01740791|Experimental|Velpatasvir 25 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
32832854|NCT01740791|Experimental|Velpatasvir 50 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
32832855|NCT01740791|Experimental|Velpatasvir 150 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
33102924|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
32832856|NCT01740791|Experimental|Velpatasvir 150 mg (GT 4)|Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
32832857|NCT01740791|Experimental|Velpatasvir up to 400 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.
32832858|NCT01740401|Experimental|Cyclophosphamide, Ipilimumab|"Treatment:~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
32832859|NCT01740323|Placebo Comparator|Placebo|Placebo
32832860|NCT01740323|Experimental|Curcumin|500 mg BID
32832861|NCT00090051|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
32832862|NCT00090051|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
32902802|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
33033007|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
33033008|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
33033009|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
33033010|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
33033011|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
33033012|NCT01958359|No Intervention|Control|Untreated control group
33033013|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
33102925|NCT05051085|Experimental|"Internet-delivered treatment: SpilleFri."|"All participants receive the internet-delivered therapist-assisted 8-modules treatment program SpilleFri."
32746832|NCT04417738|Sham Comparator|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
32746833|NCT04275297|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
32746834|NCT04275297|Placebo Comparator|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
32746835|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
32746836|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
32746837|NCT05556759|Placebo Comparator|control group|patients will be operated on under general anesthesia
32746838|NCT05556759|Active Comparator|IPS group|patients will receive an ultrasound-guided anterior iliopsoas muscle space (IPS) block
32746839|NCT05556759|Active Comparator|Supra-iliac QL group|patients will receive an ultrasound-guided supra-iliac anterior quadratus lumborum (QL) block
32746840|NCT02173054|Placebo Comparator|Adapalene gel|"Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face"
32746841|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning~Wash face by prepared facial foam and dry their face~Apply placebo cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply placebo cream all over the face"
32746842|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning~Wash face by prepared facial foam and dry their face~Apply Eucerin cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply Eucerin cream all over the face"
32746843|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extraction|Patient with osteoporosis - antiresorptive treatment > 4 years who have had previous tooth extraction without development of MRONJ
32746844|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous resection|Patient with osteoporosis - antiresorptive treatment > 4 years who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
32746845|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection|Patient with osteoporosis - antiresorptive treatment > 4 years with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
32746846|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extraction|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
32746847|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
32746848|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
32746849|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous tooth extraction|Cancer patient treated with high dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
32746850|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous resection|Cancer patient treated with high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
32746851|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Simultaneously with resection|Cancer patients (breast, prostate or multiple myeloma) treated with high dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
32746852|NCT04741828|Experimental|Vi-DT Typhoid Conjugate Vaccine|Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.
32832863|NCT01740089|Experimental|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
32832864|NCT01740089|Experimental|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
32832865|NCT01740089|Active Comparator|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
32832866|NCT04390347|Experimental|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
32832867|NCT04390347|Placebo Comparator|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
32832868|NCT01739933|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
32832869|NCT01739933|Active Comparator|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
32832870|NCT00094497|Active Comparator|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
32832871|NCT00094497|Active Comparator|Sz-M|streptozotocin and mitotane
32832872|NCT01738919|Active Comparator|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
32832873|NCT01738919|Active Comparator|Non-subluxated - operation|Operative treatment with extension block technique
32832874|NCT00094887|Experimental|Inhaled Nitric Oxide|Participants receive Inhaled nitric oxide (INO)
32832875|NCT00094887|Placebo Comparator|Placebo|Participants receive Nitrogen gas
32832876|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
32832877|NCT04564391|Active Comparator|Whey protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of whey protein (=60 g / day)
32832878|NCT04564391|Active Comparator|Casein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of casein (=60 g / day)
32832879|NCT04564391|Active Comparator|pea protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of pea protein (=60 g / day)
32832880|NCT04564391|Placebo Comparator|placebo arm|Three weeks, twice daily supplementation with 30 g of placebo (=60 g / day)
32832881|NCT04552301|Experimental|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
32832882|NCT04552301|Active Comparator|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
32832883|NCT00097695|Experimental|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
32832884|NCT00097695|Placebo Comparator|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
32832885|NCT00097695|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
32832886|NCT00097695|Experimental|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
32832887|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
32832888|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
32832889|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
32832890|NCT00099021|Experimental|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
32832891|NCT00195039|Experimental|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
32832892|NCT04645719|Placebo Comparator|Lactate ringer group|Patients will receive only general anesthesia
32832893|NCT04645719|Active Comparator|Real weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the actual body weight
32832894|NCT04645719|Active Comparator|Corrected ideal weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the corrected ideal weight
32832895|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
33102926|NCT01268683|Experimental|Glyburide for Injection|This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours
32832896|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
32832897|NCT00198081|Experimental|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
32832898|NCT00198081|Experimental|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
32832899|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
32832900|NCT00100659|Active Comparator|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
32832901|NCT00100659|Placebo Comparator|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
32832902|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
32832903|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
32832904|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
32832905|NCT00101361|Active Comparator|1|oxandrolone
32832906|NCT00101361|Placebo Comparator|2|placebo
32832907|NCT01726179|Experimental|Resin infiltration|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Control. Teeth in this arm are treated by the resin infiltration technique using Icon (DMG, Germany) according to manufactures´ instructions. In addition patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
32832908|NCT01726179|Other|Control|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Resin infiltration. Teeth randomized into this arm do not recieve any special treatment except general oral nonivasiv treatment (flossing and brushing). Patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
32832909|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
32832910|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
32832911|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
32832912|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
32832913|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
32832914|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
32832915|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
32832916|NCT02410798|Experimental|TransLoc electrode|Electrode placement
32832917|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
32832918|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
32832919|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
32832920|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
32832921|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
32832922|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
32832923|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
32832924|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
32832925|NCT00200343|Experimental|Ursodeoxycholic acid 150mg / day|
32832926|NCT00200343|Experimental|Ursodeoxycholic acid 600mg / day|
32832927|NCT00200343|Experimental|Ursodeoxycholic acid 900mg / day|
32832928|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
32832929|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
32832930|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
32832931|NCT03203928|No Intervention|Control|No treatment provided.
32832932|NCT00201123|Placebo Comparator|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
32832933|NCT00201123|Experimental|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
32832934|NCT00201123|Experimental|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
32832935|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
32832936|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
32832937|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
32832938|NCT03225768|Experimental|Guided Training|
32832939|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
32832940|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
32832941|NCT01175655|Experimental|MSC|
32832942|NCT04633395|Experimental|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
32832943|NCT04633395|Active Comparator|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
32832944|NCT00201825|Experimental|Docetaxel and Capecitabine|
32832945|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
32832946|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
32832947|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
32832948|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
33102927|NCT05037201|No Intervention|Usual care|The control arm will receive usual health system messaging about the importance and deadlines for receiving COVID-19 vaccination.
33102928|NCT05037201|Experimental|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
32832949|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
32832950|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
32832951|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
32832952|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
32832953|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
32832954|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
32832955|NCT04563377|Experimental|ChAdOx1.HTI and MVA.HTI vaccination|"1x dose of ChAdOx1.HTI at 5 x 10^10 vp~1x dose of MVA.HTI at 2 x 10^8 pfu"
32832956|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
32832957|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
32832958|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
32832959|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
32832960|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
32832961|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
32832962|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
32832963|NCT00202449|Experimental|1|Prazosin
32832964|NCT00202449|Active Comparator|2|Paroxetine
32832965|NCT00202449|Placebo Comparator|3|Placebo
32832966|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
32832967|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
32832968|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
32832969|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
32832970|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
32832971|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
32832972|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
32832973|NCT05545072|Experimental|Dupilumab|150 mg/mL in a pre-filled syringe to deliver 300 mg in 2 mL given subcutaneous every 2 weeks during the treatment period
32832974|NCT05545072|Placebo Comparator|Placebo|Pre-filled syringe to deliver 2 mL given subcutaneous every 2 weeks during the treatment period
32832975|NCT00203229|Placebo Comparator|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
32832976|NCT00203229|Active Comparator|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
32832977|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
32832978|NCT05543044|Experimental|TAY receiving peer mentor intervention|Transition age youth with EDs (n=35) will receive a peer mentor delivered transition intervention
33102929|NCT02021474|Experimental|AGX-201|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
33318875|NCT00289913|Experimental|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
32832979|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
32832980|NCT03224988||Normal Adults|
32832981|NCT03224988||MCI Adults|
32832982|NCT00203931|Active Comparator|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
32832983|NCT00203931|Experimental|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
32832984|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
32832985|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
32832986|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
32832987|NCT02412982|No Intervention|Serum anti-Xa < 0.1 IU/mL|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
32832988|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
32832989|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
33405364|NCT05008887|Active Comparator|Fractional CO2 laser and topical 5-fluorouracil solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of 5-fluorouracil solution 5% concentration vial 250mg/5ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
32956155|NCT05730829|Active Comparator|Standard neuromuscular exercise and OA education|Participants in this group will receive an 8-week in-person group exercise program held twice weekly, in which they will receive exercise instructions (60 minutes) and standard osteoarthritis (OA) education (15 to 20 minutes/week for the first 4 weeks). A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component (i.e., the specific movements) of this group will be similar to those of the other group without the added techniques of breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness. The standard OA education videos will cover the following topics: common OA symptoms, risk factors associated with knee OA, and the effects of exercise and self-management tips. The exercise and education components will be delivered by a physiotherapist in the research team.
32956156|NCT05729373|Experimental|SEP-363856|dosed once daily tablet
32956157|NCT05729373|Placebo Comparator|Placebo|dosed once daily tablet
32746878|NCT04745559|Experimental|Treatment|Pneumococcal conjugate vaccine (PCV13) .5 ml will be administered intramuscularly three times: 7 days (range 4 to 21 days) before apheresis collection and on day +30 (range +21 to +37) and day +90 (range +75 to +115) after CAR T cell infusion.
32746879|NCT03971175|Active Comparator|Forceps group|
32746880|NCT03971175|Experimental|Cryobiopsy group|
32746881|NCT03961113||assessment by questionnaire|
32746882|NCT04744155|Experimental|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
32746883|NCT04744155|Active Comparator|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
32746884|NCT04512885||Patients with type 1 diabetes|
32746885|NCT04512885||Health professionals|
32746886|NCT04480749|Other|Routine Testing|Among men in the control group, they will receive a list of local clinics that can provide free syphilis testing.
32746887|NCT04480749|Experimental|Self-Testing|In the intervention arm we will provide a treponemal rapid syphilis test kit to all individuals in the intervention arm of the pilot, delivered through MSM community facilitators. This is similar to existing rapid treponemal test kits that are available at many clinical facilities. Kits will be accompanied by simplified pictorial instructions on finger prick blood sample collection.
32746888|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
32746889|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
32746890|NCT05700747|Experimental|Health Through Activity (HTA) Intervention|"Participants will undergo study procedures as outlined:~Complete a baseline survey regarding activity level and quality of life.~Attend 6 weekly study visits at the MGH Institute of Health Professions IMPACT Practice Center.~Attend final study visit and complete the Satisfaction survey and an individual, semi-structured interview with site staff to supply feedback about the program.~After six weeks, complete the Satisfaction survey again."
32746892|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
32746893|NCT02149108|Placebo Comparator|Placebo + BSC|
32746894|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
32746895|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
32746896|NCT05700669|Experimental|Dose Escalation|Three dose levels of AsiDNA delivered intravenously weekly in combination with Olaparib
32746897|NCT05700669|Experimental|Dose Expansion: Recurrent Epithelial Ovarian Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
32746898|NCT05700669|Experimental|Dose Expansion: Metastatic Castration-resistant Prostate Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
32746899|NCT05700669|Experimental|Dose Expansion: Recurrent Breast Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
32746900|NCT04440891|Experimental|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
32746901|NCT04440891|Experimental|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
32746902|NCT04440891|Sham Comparator|TMS-Sham with X-Torp task|TMS sham control with VR 1
32746903|NCT04440891|Sham Comparator|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
32746904|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
32746905|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
32746906|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
32746907|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
32832990|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
32832991|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
32832992|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
32832993|NCT02390908|Experimental|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
32832994|NCT02390908|Active Comparator|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
32832995|NCT02390908|Experimental|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
32832996|NCT02390908|Experimental|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
32832997|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
32832998|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
32832999|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
32833000|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
32833001|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
32833002|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
32833003|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
32833004|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
32833005|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
32833006|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
32833007|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
32833008|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
32833009|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
32833010|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
32833011|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
32833012|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
32833013|NCT00354874|Experimental|GW642444 50mcg|
32833014|NCT00354874|Experimental|GW642444 100mcg|
32833015|NCT00354874|Experimental|GW642444 200mcg|
32833016|NCT00354874|Active Comparator|salmeterol 50mcg|
32833017|NCT00354874|Placebo Comparator|placebo|
32833018|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
32833019|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
32833020|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
32833021|NCT05508646|Experimental|Intervention arm|Twelve participants will be randomized for the intervention. The music therapy intervention takes place once a week for 6 weeks via telemedicine, with the first session reserved for music therapy intake/assessment. There are 5 additional visits, once per week. The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
32833022|NCT05508646|Other|Control arm|Twelve participants will be randomized to receive a personalized music CD that they keep and can listen to as they wish.
32833023|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
32833024|NCT01711619|Active Comparator|OMM|optimized medical management
32833025|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
32833026|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
32833027|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
32833028|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
32833029|NCT05508412|Experimental|Intervention with HRV monitor|
32833030|NCT05508412|Experimental|Intervention without HRV monitor|
32833031|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
32833032|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
32833033|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
33102930|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
33405365|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
33405366|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
32833034|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
32833035|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
32833036|NCT04485078||Axial spondyloarthritis patients|QST with clinical scales
32833037|NCT04485078||Healthy controls|QST
32833038|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
32833039|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
32833040|NCT05507242|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
32833041|NCT05507242|Placebo Comparator|Placebo|Placebo subcutaneous injection
32833042|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
32833043|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
32833044|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
32833045|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
32833046|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
32833047|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
32833048|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
32833049|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
32833050|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
32833051|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
32833052|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
32833053|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
32833054|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
32833055|NCT04943848|Experimental|"Lead In: rHSC-DIPGVax Monotherapy"|rHSC-DIPGVax for 8 total doses
32833056|NCT04943848|Experimental|Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B."
32833057|NCT04943848|Experimental|Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C."
32833058|NCT04943848|Experimental|Part C: Dose Expansion|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity."
32833059|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
32833060|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
32833061|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
32833062|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
32866671|NCT04816422|Experimental|Proprioceptive neuromuscular facilitation|Bilateral upper extremity pattern for trunk by Chopping, Lifting 2. Bilateral lower extremity pattern for trunk. 3. Trunk lateral flexion. 4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
33102931|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
32833063|NCT04938232|Experimental|Disease Progression after previous therapy|"Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are also eligible to proceed to combination therapy with nivolumab and ipilimumab, if they are clinically stable.~Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles~Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles~Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles"
32833064|NCT03209076|Experimental|Robotic|Robotic low anterior resection
32833065|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
32833066|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
32833067|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
32833068|NCT05719246|Experimental|IBS Patients Doing Yoga|"All patients will fall under the arm of IBS Patients Doing Yoga and will follow the yoga videos that are assigned to them during the study. The participants are their own controls and their symptom changes will be recorded pre- and post-video watching and participation."
32833069|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
32833070|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
32833071|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
32833072|NCT03209310||Control Group|Children with typical development were included in this study
32833073|NCT05719168|Experimental|Patients with medical refractory GERD|"Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.~Participants undergo a hydrogen and emthane breath test on a seperate day."
32833074|NCT05719168|Active Comparator|Healthy controls without gastrointestinal symptoms|Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.
32833075|NCT04907500|Experimental|Multifocal IOL|Implantation of a multifocal intraocular lens
32833076|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
32833077|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
33102932|NCT05010291|Experimental|Standard of Care (SOC) messaging|Participants randomized into this arm will receive standard voice call reminders + the Standard of Care (SOC) text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include the SOC text
33102933|NCT05010291|Experimental|Loss aversion messaging|Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
32833078|NCT05719090|Active Comparator|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
32833079|NCT05719090|Active Comparator|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
32833080|NCT05719090|Active Comparator|No blood flow restriction|This group serves as the control group for this study
32833081|NCT04485312|Active Comparator|caries preventive protocol|preventive protocol for special needs ( tooth brushing , topical fluoride and mouth wash)
32833082|NCT04485312|Other|chlorhexidine varnish added to the caries preventive protocol|chlorhexidine varnish preventive caries protocol for special needs
32833083|NCT05483920|Experimental|One-time educational video|A one-time educational video on best practices for good sleep hygiene
32833084|NCT05483920|Experimental|One-time educational video plus automated text messaging|A one-time educational video on best practices for sleep hygiene plus daily automated text messages to reinforce habit.
32833085|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
32833086|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
32833087|NCT05477134|Experimental|The study cohort consisting of children with type 2 diabetes and healthy controls|"In Study Day 1, participants will be given a primed dose of stable isotopes followed by continuous intravenous infusions for 5 hours. The investigators will use the following isotopes: U-13C6-Arg, 5,5-2H2-Cit, 15N2-Orn, 2H5-Phe, Na13CO3, and 13C5-Orn.~On Study Day 2, participants will drink a 75-gram glucose solution prior to an oral glucose tolerance test.~On Study Day 3, participants will drink a 75-gram glucose solution and will be injected 5-gram arginine into their veins."
32833088|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
32833089|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
32833090|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
32833091|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
32833092|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
32833093|NCT05718934|Active Comparator|"Group N for Standard reversal"|Standard reversal of 50 µg.kg-1 neostigmine (up to a maximum dose of 5mg) and 7 µg.kg-1 glycopyrrolate at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
32833094|NCT05718934|Experimental|"Group S for Sugammadex"|Sugammadex 0.5 mg.kg-1 IV will be performed at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
32833095|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
32833096|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
32833097|NCT05476276|Experimental|EN21-01 ISA|The EN21-01 Intervention Specific Analysis is detailed in the protocol (NCT#)
32833098|NCT05476276|Placebo Comparator|Placebo Comparator|Each ISA will detail the use of the Placebo Comparator.
32833099|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
32833100|NCT03202290|Other|Controls|healthy controls
32833101|NCT02452242|Experimental|ABX464|
32833102|NCT02452242|Placebo Comparator|Placebo|
32833103|NCT05462080||Movement Disorders Patients|
32833104|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
32833105|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
32833106|NCT04869514|Active Comparator|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
32833107|NCT04869514|Active Comparator|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
32833108|NCT04869514|Sham Comparator|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
32833109|NCT04869514|No Intervention|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
32833110|NCT03208764|Experimental|Nitric Oxide treatment|
32833111|NCT05718856|Active Comparator|efficacy of TPO-RAs|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24."
32833112|NCT05718856|Experimental|efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as patients in TPO-RAs monotherapy group. The dose of TPO-RAs was adjusted according to the subject platelet count. Two kinds of anti-CD 20 monoclonal antibody could be used in this study. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Subjects weighing less than 30kg will be given rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps. Participants in the eltrombopag monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of rituximab 375mg/m2. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.
32833113|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
32833114|NCT05718778|Experimental|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
32833115|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
32833116|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
32833117|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
32833118|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
32833119|NCT00355498||1|Controls
32833120|NCT00355498||2|Mild Cognitive Impairment
32833121|NCT00355498||3|Alzheimer's disease
32833122|NCT00355498||4|FTD
32833123|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
32833124|NCT05718466|Experimental|Fractionated Radiosurgery and Bevacizumab|FRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
32833125|NCT05718466|Active Comparator|Bev with Chemo|Bev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression
32833126|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
32833127|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
32833128|NCT05452720|Experimental|Experimental Arm|This is a single-arm study. All participants in this study will undergo implantation with MASA Valve.
32833129|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
32833130|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
32833131|NCT03202056|No Intervention|Control|Control group. No intervention.
32833132|NCT05445466|Active Comparator|Active HD-tDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the OFC for 5 days (10 total sessions).
32833133|NCT05445466|Sham Comparator|Active Control (alpha, 10 Hz)|10 passive sham control; Two, twenty-minute sessions of passive sham control to the OFC for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
32833134|NCT05445466|Experimental|Personalized Beta-Gamma tACS|10 tACS; Two, twenty-minute sessions of tACS to the OFC for 5 days (10 total sessions).
32833135|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
32833136|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
32833137|NCT05426356|Active Comparator|Non-Surgical Treatment|Non-surgical management (NSM) of sacral insufficiency or fragility fractures (SFIF)
32833138|NCT05426356|Experimental|Surgical Treatment|Surgical fixation of sacral insufficiency or fragility fractures (SFIF) with concomitant fusion of the sacroiliac (SI) joint
32833139|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
32833140|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
32833141|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
32833142|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
32833143|NCT04835506|Experimental|proactive infliximab optimization|proactive infliximab optimization using a pharmacokinetic dashboard
33405367|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
33405368|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
33405369|NCT04944771|Experimental|Treatment ABC|Participants will be randomized to receive oral doses of Treatment A, Treatment B and Treatment C.
32833144|NCT04835506|Experimental|standard of care infliximab dosing|standard of care infliximab dosing
33405370|NCT04944771|Experimental|Treatment ACB|Participants will be randomized to receive oral doses of Treatment A, Treatment C and Treatment B.
32833145|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
32833146|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
32833147|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
32833148|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
32833149|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
32833150|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
32833151|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
32833152|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
33033014|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
33033015|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
32956158|NCT05720741|Experimental|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although not yet formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
32956159|NCT05720741|Placebo Comparator|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
32956160|NCT05715931|Experimental|Toripalimab plus Trastuzumab with FLOT(5-FU+leucovorin+docetaxel+oxaliplatin)|
32956161|NCT05714774|Experimental|Patients with localized prostate cancer|Patients with localized prostate cancer for which focal treatment, hemi-ablation or total ablation of the prostate is indicated will be treated by HIFU applied by FocalOne device.
32956162|NCT05714007|Experimental|Treatment group|"Iron to be administered as intravenous ferric derisomaltose:~Where Hb (hemoglobin) ≥100 g/L, dosage according to body weight is as follows:~Body weight <50 kg: 500mg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 1500 mg.~Where Hb <100 g/L, dosage according to body weight is as follows:~Body weight <50 kg: 500mg; Body weight 50 to <70 kg: 1500mg; Body weight ≥70 kg: 2000 mg."
32956163|NCT05714007|Active Comparator|Control group|"Iron to be administered as oral ferrous succinate:~1 tablet (100 mg) tid (three times daily), starting on the first postoperative day and continuing for 4 weeks."
32956164|NCT05711862|Experimental|1 week Placebo then 1 week SUVO|After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
33405371|NCT04944771|Experimental|Treatment BAC|Participants will be randomized to receive oral doses of Treatment B, Treatment A and Treatment C.
33405372|NCT04944771|Experimental|Treatment BCA|Participants will be randomized to receive oral doses of Treatment B, Treatment C and Treatment A.
33405373|NCT04944771|Experimental|Treatment CAB|Participants will be randomized to receive oral doses of Treatment C, Treatment A and Treatment B.
33405374|NCT04944771|Experimental|Treatment CBA|Participants will be randomized to receive oral doses of Treatment C, Treatment B and Treatment A.
32956165|NCT05711862|Experimental|1 week SUVO then 1 week Placebo|After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo
32956166|NCT05711719|Experimental|Vericiguat|Initial 2.5 mg/day for two weeks, then 5 mg/day for two weeks, and then 10 mg/day for two weeks. Systolic blood pressure will be measured before and following each titration The participant will receive the final titration dose for a total of six weeks.. The drug is administered as an oral tablet once daily.
32956167|NCT05711719|Placebo Comparator|Placebo|A placebo tablet will be administered orally once daily.
32956168|NCT05708989|Active Comparator|Caudal Block|Patients will receive a caudal block prior to surgery.
32956169|NCT05708989|Experimental|Pudendal Block|Patients will receive a pudendal block prior to surgery.
32956170|NCT05708183||Intervention|Districts that have substituted MMS for IFA as part of routine antenatal care
32956171|NCT05708183||Comparison|Districts that continue to deliver IFA as part of routine antenatal care
32956172|NCT05705258||Aflibercept treatment|The patients will be included in this study by investigators who are prescribing Aflibercept (AFL) routinely in their clinical practice. The enrollment of each patient in this study is able to accept at latest in 6 months from initiation of treatment.
32956173|NCT05699317|Experimental|Intervention|
32956174|NCT05698992||Experimental group|Patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden, and who are planned to undergo curative surgery treatment at Skåne University Hospital. n=100 (anticipated)
32956175|NCT05698992||Historical control group|The historical control group consists of patients, living in Southern Sweden, who underwent esophageal or gastric cancer surgery between 2013 - 2021 at Skåne University Hospital. n=100 (anticipated)
32956176|NCT05698914|Experimental|Telehealth mindfulness-based intervention (MBI)|Eight, weekly telehealth mindfulness sessions delivered one-on-one with mindfulness instructor
32956177|NCT05698914|Active Comparator|Telehealth Education (EDU)|Eight, weekly post-surgical educational sessions delivered one-on-one with physical therapist
32956178|NCT05695378|Experimental|Main Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 0 to Week 36.
32956179|NCT05695378|Placebo Comparator|Main Study: Placebo|Subjects will receive visually identical placebo pills of KM-819 orally.
32956180|NCT05695378|Experimental|Ancillary Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 40 to Week 76.
32956181|NCT05687110|Experimental|Treatment (novobiocin sodium)|Patients receive novobiocin sodium PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, on day 15 of cycle 1, and at time of progression. Patients undergo medical imaging scans at baseline and every 8 weeks.
32956182|NCT05686200|Experimental|Experimental group|Participants performed wrist-forearm exercise training within 2 weeks after the operation, that is, from 24 hours to 2 weeks after the operation, twice a day in the morning and evening, 3 groups each time, and each single item was repeated 5 times in each group (maintain for 5 seconds). Exercise for 40 minutes a day, use the mobile phone to install the forearm isometric exercise software program within the 3rd to 8th week, use the Bluetooth device to connect the hand-held gripper to perform the forearm isometric exercise, 2 times a day, morning and evening, and train 3 groups each time, 20 times each time , hand grip strength for 3 seconds each time, increase by 1 second per week, and rest for 90 seconds between groups.
33033016|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
33033017|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
33405375|NCT04944771|Experimental|Treatment DEF|Participants will be randomized to receive oral doses of Treatment D, Treatment E and Treatment F.
33405376|NCT04944771|Experimental|Treatment DFE|Participants will be randomized to receive oral doses of Treatment D, Treatment F and Treatment E.
32833153|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
32833154|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
32833155|NCT05424640|No Intervention|Baseline|Collection of baseline data 1 week before intervention
32833156|NCT05424640|Experimental|Dietary fiber 1|"15 g/day oat fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
33102934|NCT05010291|Experimental|Social norms messaging|Participants randomized into this arm will receive standard voice call reminders + social norms text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include social norms framing.
33102935|NCT05010291|Experimental|Altruism messaging|Participants randomized into this arm will receive standard voice call reminders + altruism text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include altruism framing.
32833157|NCT05424640|No Intervention|Wash-out 1|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833158|NCT05424640|Experimental|Dietary fiber 2|"15 g/day dietary fiber mix I 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833159|NCT05424640|No Intervention|Wash-out 2|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833160|NCT05424640|Experimental|Dietary fiber 3|"15 g/day dietary fiber 3 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833161|NCT05424640|No Intervention|Wash-out 3|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833162|NCT05424640|Experimental|Dietary fiber 4|"15 g/day rye fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833163|NCT05424640|No Intervention|Wash-out 4|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
32833164|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
32833165|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
32833166|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
32833167|NCT05718388|Other|Control group (A)|They received a physiotherapy program
32833168|NCT05718388|Experimental|study Group (B)|They received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second
32833169|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
32833170|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
32833171|NCT04812964|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
32833172|NCT04812964|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
33102936|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
33102937|NCT04686071|Experimental|PNF method|
32833173|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
33102938|NCT04686071|Other|standard rehabilitation|
33102939|NCT05000385||Healthy|healthy complete dentition
33102940|NCT05000385||Dental caries|complete dentition with bilateral dental caries (ICDAS 4,5 or 6)
33102941|NCT05000385||Occlusal contacts|occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries
33102942|NCT05000385||Dentures|patients with dentures, no caries and/or missing occlusal contacts on remaining teeth
32833174|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
32833175|NCT05718310|Active Comparator|Nitroglycerin|Nitroglycerin diluted in 250 ml of sodium chloride 0.9% will be administered once via an infusion pump intravenously, at a dose of 0.5 μg/kg/min in 20 minutes.
32833176|NCT05718310|Placebo Comparator|Saline|250 ml of sodium chloride 0.9% will be administered intravenously in 20 minutes via an infusion pump.
32833177|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
32833178|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
32833179|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
32833180|NCT05718232|Experimental|SBRT+TACE+Lenvatinib|Patients in SBRT+TACE+Lenvatinib group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib. SBRT will begin within 3 weeks after the first TACE.
32833181|NCT05718232|Active Comparator|Lenvatinib|Patients in Lenvatinib group will take oral lenvatinib alone.
32833182|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
32833183|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
32833184|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
32833185|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
32833186|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
32833187|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
32833188|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
32833189|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
32833190|NCT05372380|Experimental|Sequence F/AE/F+AE|A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(F, AE, F+AE) assigned to on sequence group in Period 1, Period 2, and Period 3.
32833191|NCT03201276||Drug group|patients taking glucosamine
32833192|NCT05718076||group 1|Eyes are categorized by fundus META-PM as grade 0
32833193|NCT05718076||group 2|Eyes are categorized by fundus META-PM as grade 1
32833194|NCT05718076||group 3|Eyes are categorized by fundus META-PM as grade 2
32833195|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
32833196|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
32833197|NCT05370118|Experimental|Telerehabilitation physical activity behavioral (TPAB) intervention|Individuals in the TPAB intervention will participate in a weekly session for 12 weeks with their primary caregiver and the research interventionist (RH). Established behavior-change techniques will be used in the TPAB intervention, based largely on the combination of the Social Cognitive Theory, Control Theory, and Operant Conditioning,43 including behavioral techniques, and patient-centered communication (e.g., motivational interviewing).44 The behavior-change techniques are designed to target and improve daily steps. Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
32833198|NCT05370118|No Intervention|Control Group|Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
32833199|NCT03201510||Observational|Observational study
33102943|NCT01268293|Experimental|1|
33102944|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
32833200|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
32833201|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
32833202|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
32833203|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
33318876|NCT00289913|Experimental|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
33318877|NCT00289913|Experimental|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
33318878|NCT00289913|Experimental|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered."
33318879|NCT01325675|Experimental|Interval training|Interval training
32833204|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
32833205|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
32833206|NCT05717998||Ancillary-correlative (CMR, PET/CT, biospecimen collection)|Within 2 weeks of starting RT, patients undergo CMR, cardiac PET/CT and blood sample collection at baseline, then between fractions 12-17 of RT and at 6 months after completion of RT.
32833207|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
32833208|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
32833209|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
32833210|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
32833211|NCT03119298||Control group|Healthy subjects matched for age and sex
32833212|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
32833213|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
32833214|NCT05717842||People with ESLD and eGFR between >=25 and <=40ml/min|"> 18 years old~Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis)~Candidates with two native kidneys.~Willing to participate and sign informed consent"
33318880|NCT01325675|No Intervention|Control|Live as usual
32833215|NCT04789096|Experimental|PD-L1 positive|"Participants will receive:~Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
32833216|NCT04789096|Experimental|PD-L1 negative|"Participants will receive:~Tucatinib (oral) at a dose of 300 mg BD on day 1-21~Capecitabine (oral) at a dose of 1000 mg/m^2 BD on day 1-14 of each 21-day cycle~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
32833217|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
32833218|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
32833219|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
33033018|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
33033019|NCT01958398|No Intervention|Control|Untreated control group
33033020|NCT01958411||18FDG-PET/CT|
33033021|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
33318881|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
33318882|NCT00270413|Experimental|1|sutent
33318883|NCT00270413|No Intervention|2|
33318884|NCT01325831|Experimental|transcranial magnetic stimluation|
33318885|NCT01325831|Sham Comparator|rTMS_sham|
33318886|NCT00289289|Active Comparator|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
33318887|NCT00289289|Active Comparator|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
33318888|NCT00289289|No Intervention|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
33318889|NCT00270257|Experimental|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
33033022|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
33033023|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
33033024|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
33318890|NCT00270257|Experimental|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
33318891|NCT00269633|Placebo Comparator|Red Light Box 657 nm|Red Light Box 657 nm
33405377|NCT04944771|Experimental|Treatment EDF|Participants will be randomized to receive oral doses of Treatment E, Treatment D and Treatment F.
33405378|NCT04944771|Experimental|Treatment EFD|Participants will be randomized to receive oral doses of Treatment E, Treatment F and Treatment D.
32833220|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
32833221|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
32833222|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
32833223|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
32833224|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
32833225|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
32833226|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
32833227|NCT05334940||Atopic disorders|Patients with at least 2 atopic disorders who are eligible for systemic therapy with biologics
32833228|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
32833229|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
32833230|NCT05333458|Experimental|Arm I (atezolizumab, selienexor)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Patients also receive selinexor PO QW on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, CT, MRI, and collection of blood samples throughout the study.
32833231|NCT05333458|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I. Patients also undergo biopsy, CT, MRI, and collection of blood samples throughout the study.
32833232|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
32833233|NCT02448186|No Intervention|Waitlist|3-month waitlist control
32833234|NCT05296096|Active Comparator|Standard protein and exercise|All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.
32833235|NCT05296096|Experimental|High protein plus exercise|"High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team.~Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily."
32833236|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
32833237|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
32833238|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
32833239|NCT05278468||case group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University who had positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
32833240|NCT05278468||control group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University with negative positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
32833241|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
32833242|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
32833243|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
32833244|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
32833245|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
33102945|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
33102946|NCT01268098|Experimental|25 µg dose|25 µg
33102947|NCT01268098|Experimental|50 µg dose|50 µg
33102948|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
33102949|NCT01674803|Active Comparator|Orsiro|
33102950|NCT01674803|Active Comparator|Synergy|
33102951|NCT01674803|Active Comparator|Resolute Integrity|
33102952|NCT04959825|Active Comparator|melatonin group|Melatonin group (group M )will receive melatonin as a premedication 1 hour before surgery in a dose of 5 mg
33102953|NCT04959825|Placebo Comparator|control group|15 patients will be enrolled for open nephrectomy will receive sugar-coated tablets. Control group(group C)
33318892|NCT00269633|Active Comparator|Blue Light Box 467 nm|Blue Light Box 467 nm
33318893|NCT00269477|Experimental|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
33405379|NCT04944771|Experimental|Treatment FDE|Participants will be randomized to receive oral doses of Treatment F, Treatment D and Treatment E.
33405380|NCT04944771|Experimental|Treatment FED|Participants will be randomized to receive oral doses of Treatment F, Treatment E and Treatment D.
32833246|NCT04730518|Experimental|Yoga-based Group Therapy|"The yoga-based group therapy (YBGT) involves a four-week intervention with weekly group therapy sessions in addition to TAU. The fifty-minute session takes place with a group size of max. 10 participants and was held once a week by a psychologist who is experienced in yoga-based therapy.~A yoga session starts with breathing exercises (pranayama), followed by various exercises in standing, sitting and lying down (asanas), which are accompanied by mindful instructions from the psychologist. Every yoga session ends with a final relaxation (shavasana), which can take the form of a body scan, for example."
32907315|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
32907316|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
32907317|NCT04955574|Experimental|Probiotic + Antibiotic Placebo|
32907318|NCT04955574|Experimental|Probiotic + Antibiotic|
32907319|NCT04955574|Placebo Comparator|Probiotic Placebo + Antibiotic Placebo|
32907320|NCT04751279||Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)|Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score <2) and recent diagnosis (<5 years)
32907321|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (<5 years)
32907322|NCT04751279||Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis without signs of activity (Benamore score <2), persistent form (>5 years)
32907323|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (>5 years)
32907324|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
32907325|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
32907326|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
32907327|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant~Patient Enrollment and Baseline Data Collection~First Intervention Visit:~Comprehensive assessment of sexual dysfunction~Normalization & Education~Therapeutic interventions~Referral to Sexual Health Clinic if applicable~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
32907328|NCT04716335|Experimental|Harmine + DMT|
32907329|NCT04716335|Experimental|Harmine + Placebo(DMT)|
32907330|NCT04716335|Placebo Comparator|Placebo(Harmin & Placebo)|
32833247|NCT04730518|Active Comparator|Treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
32833248|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
32833249|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
32833250|NCT04708756|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
32833251|NCT04708756|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
32833252|NCT04708756|No Intervention|Control Group|Patients will not receive the Collabree application and will continue to receive standard care.
32833253|NCT04705168||Participants displaying nevi|"Participants displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter. These patients have atypical mole syndrome, which is a high-risk nevus phenotype and the target patient population in this study."
32833254|NCT04484844|Experimental|Shield Force Plus Varnish|Shield force plus (SFP), Self-reinforcing (SR) monomer technology supplied in the form of one component self-etching light-cured dental adhesive, which is characterized by an SR monomer component that penetrates the tooth substrate. Multi-point interactions with apatite calcium and three-dimensional cross-linking occur reactions.it forms a thin even, hard coating on the tooth surface that gives the tooth substrate a superior binding power.
32833255|NCT04484844|Active Comparator|Sodium Fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
32833256|NCT04700098|Experimental|Internet-based behavioral treatment for insomnia + HBPR|Internet version of cognitive-behavioral treatment for insomnia plus home-based pulmonary rehabilitation
33405381|NCT05197569|No Intervention|Control group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
32833257|NCT04700098|Experimental|HBPR only|Home-based pulmonary rehabilitation only
32833258|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
33102954|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
33102955|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
33102956|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
33102957|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
33102958|NCT04959201|Experimental|NMDAE plus Antioxidant agent (AO)|An NMDA enhancer plus a drug with antioxidant property
33102959|NCT04959201|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
33102960|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
33102961|NCT05471453|Sham Comparator|DHEA group|75 mg DHEA supplementation per day for 3 months before IVF
33102962|NCT05471453|Experimental|DHEA+CoQ10+Tocotrienol group|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
33102963|NCT05471453|No Intervention|Control group|No supplementation before IVF
32833259|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
32833260|NCT04673656|Placebo Comparator|Test Group 1|Group 1 will receive 84 days of placebo BID
32833261|NCT04673656|Active Comparator|Test Group 2|Group 2 will receive 84 days of 0.5 g of BKR-017 BID
32833262|NCT04673656|Active Comparator|Test Group 3|Group 3 will receive 84 days of 1.0 g of BKR-017 BID
33102964|NCT04949607|Experimental|Chronic Traumatic Brain Injury|Subjects aged 18-70 years with chronic traumatic brain injury receiving Inulin treatment.
33102965|NCT04949607|Experimental|Healthy Controls|Healthy subjects aged 18-70 years receiving Inulin treatment.
33102966|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
33102967|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
33102968|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
33102969|NCT05471180|Placebo Comparator|Control group|Control group (n=39) - 3M Cavilon ® protective spray film + simulation of the use of laser (placebo) - after cleaning the skin, the pain scale will be applied and after application of FBM in the same points of the group that will undergo irradiation. To mimic the action of the laser, the BIP noise will be recorded and its activation will be done by the nursing employee who provides the care, after simulating the use of the laser, the use of the 3M Cavilon ® protective spray film will be applied. The application of the laser will be immediate in 8 points of the perineum region in the areas that present lesions, these applications will occur 1 x a day every 24 hours for three consecutive days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. A photographic record of the lesion will be made on days 0 and 3 of treatment and after 2 days after treatment to monitor the recovery of the IAD
32833263|NCT04673656|Active Comparator|Test Group 4|Group 4 will receive 84 days of 1.5 g of BKR-017 BID
32833264|NCT04485156|Active Comparator|Arm 1 (Conventional treatment group)|"Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment~- 6 months in total"
32833265|NCT04485156|Experimental|Arm 2 (High-dose rifampicin group)|"High-dose rifampicin, isoniazid, and pyrazinamide~Rifampicin: 30mg/kg~Isoniazid: 300mg/day~Pyrazinamide: 1000mg/day (<50kg), 1500mg/day (50-70kg), 2000mg /day (>70kg), till culture conversion Duration of the treatment~Till 12 weeks after culture conversion on liquid media"
32833266|NCT04666012|Experimental|Group 1: low dose|Subject will receive single dose of AdCLD-CoV19(2.5x10^10VP) as intramuscular injection.
32833267|NCT04666012|Experimental|Group 2: middle dose|Subject will receive single dose of AdCLD-CoV19(5.0x10^10VP) as intramuscular injection.
32833268|NCT04666012|Experimental|Group 3: high dose|Subject will receive single dose of AdCLD-CoV19(1.0x10^11VP) as intramuscular injection.
32833269|NCT04666012|Experimental|Group 4: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
32833270|NCT04666012|Experimental|Group 5: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
32833271|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
32833272|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
32833273|NCT04637620|Experimental|NMDAE|An NMDA enhancer
32833274|NCT04637620|Active Comparator|SSRI|Sertraline (selective serotonin reuptake inhibitor)
32833275|NCT04637620|Placebo Comparator|Placebo|Placebo
32833276|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
32833277|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
32833278|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
32833279|NCT05271604|Experimental|BA3021|BA3021 alone in PD-1/L1 failure patients
32833280|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
32833281|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
32833282|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
32833283|NCT04614766|Experimental|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
32833284|NCT04614766|Active Comparator|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
32833285|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
33318894|NCT00269477|Experimental|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
32833286|NCT00355186|No Intervention|Control|
32833287|NCT00355186|Experimental|Early|
32833288|NCT00355186|Experimental|Late|
32833289|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
32833290|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
32833291|NCT04614532|Other|patients with alzheimer's disease|
32833292|NCT04614532|Other|control subject|Matching by age (± 5 years), gender, and grade level
32833293|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
32833294|NCT05717764|Experimental|Experimental group|Patients will receive mitoxantrone hydrochloride liposome injection combined with capecitabine therapy
32833295|NCT05717764|Active Comparator|Control group|Patients will receive capecitabine monotherapy.
32833296|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
32833297|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
32833298|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
32833299|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
32833300|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
32833301|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
32833302|NCT05717608|Active Comparator|high fructose in caucasian dutch type 2 diabetes subjects|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
32833303|NCT05717608|Placebo Comparator|low fructose in caucasian dutch type 2 diabetes subjects|low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
32833304|NCT05717608|Active Comparator|high fructose in surinamese asian type 2 diabetes|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
32833305|NCT05717608|Placebo Comparator|low fructose in surinamese asian type 2 diabetes|low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
32833306|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
32833307|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
32833308|NCT04562740|Experimental|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
32833309|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
32833310|NCT04560088|Experimental|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
32833311|NCT04560088|Active Comparator|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
32833312|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
32833313|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
32833314|NCT05717530|Active Comparator|wound site local anesthesic infiltration|at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site
32833315|NCT05717530|Active Comparator|Erector spinae plane block|: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction
32833316|NCT05717530|No Intervention|No additional procedures were applied to the patients|No additional procedures were applied to the patients
32833317|NCT04535362|Active Comparator|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
32833318|NCT04535362|Active Comparator|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
32833319|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
32833320|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
32833321|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
32833322|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
32833324|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
32833325|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
32833326|NCT05234944|Experimental|Intervention|A CDCES trained by the research team will deliver the intervention via HIPAA compliant telehealth/videoconferencing platform. There will be 2 sessions within approximately 6 months. Prior to each session, participants will complete an assessment of T1D-specific health-related quality of life, which will generate a summary report for each person that lists aspects of quality of life that are going well and aspects that are potential areas for improvement. The CDCES will review the reports with the participants, focusing on building on areas of strength and teaching brief behavioral strategies or resources to address aspects of quality of life that could be improved. Strategies may include stress management, problem-solving techniques, goal-setting, strategies to seek social support, or other brief behavioral skills. The CDCES will also offer information about relevant resources and will provide referrals for mental health support as needed.
32833327|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
32833328|NCT05716516|Other|Treatment Arm|Treatment Phase: Patients will be treated with 17b-estradiol until disease progression. At this point, the patient will end protocol therapy
33102970|NCT05471180|Experimental|Experimental group|Experimental group (n= 39) 3M Cavilon ® protective spray film + FBM - skin cleaning and pain scale application will be performed and after laser application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. The photographic record of the lesion will be performed on days 0 and 3, 5 and 7 days of treatment. To monitor the participants and observe the recovery and obtainment of skin healing. It will be used the Globaid tool that will be applied in both groups.
33102971|NCT00535808|Experimental|1|Administration of nitroprusside
33102972|NCT00535808|Experimental|2|Administration of nitroglycerine
33102973|NCT00535808|Experimental|3|Administration of sevoflurane
33102974|NCT04920903|Experimental|COR588|
33102975|NCT04920903|Placebo Comparator|Placebo|
33102976|NCT05471063|Experimental|ABCD treatment|In this single-arm research, patients were treated with ABCD 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) combined with flucytosine 100 mg/kg/d for induction therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks. Then, patients were treated with Fluconazole (400-600 mg/d) ± flucytosine (100 mg/kg/d) for consolidation therapy for at least 6 weeks.
33102977|NCT04920396|Experimental|IRPL|Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45
33102978|NCT04920396|Active Comparator|Warm compress|Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes
33102979|NCT05471024|Active Comparator|Digitized Mounted Articulator Scan|"Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
33102980|NCT05471024|Experimental|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
33102981|NCT05471024|Experimental|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
33102982|NCT04912206|Experimental|Intervention|Point-of-Care Ultrasound on top of diagnosis work-up
33102983|NCT04912206|No Intervention|Control|Usual diagnosis work-up without Point-of-Care Ultrasound
33102984|NCT05470946|Other|Enteroscopy|Double balloon enteroscopy
33102985|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 1 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
33102986|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
33102987|NCT04910100|Experimental|Timolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
32833329|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
32833330|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
32833331|NCT05225116|Experimental|Sintilimab+Lenvatinib+Radiotherapy|
32833332|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
32833333|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
32833334|NCT04503772|Experimental|Experimental arm (all patients)|"Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).~According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS."
32833335|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
32833336|NCT03200496|Experimental|TALION®|
32833337|NCT03200496|Experimental|DA-5206(Fasting)|
32833338|NCT03200496|Experimental|DA-5206(Fed)|
32833339|NCT04492618|Experimental|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
32833340|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
32833341|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
32833342|NCT03838042|Experimental|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
32833343|NCT04485234||All patients|All lesions undergo assessment with coronary pressure sensor and either Doppler velocity or coronary thermodilution
32833344|NCT04477564||Unprovoked proximal deep vein thrombosis|
32833345|NCT04477564||Provoked distal deep vein thrombosis|
32833346|NCT04477564||age-matched control group with no history of vein thrombosis|
32833347|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
32833348|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
32833349|NCT05204836|Experimental|Zoledronic Acid Injection|Participants will receive 1 dose of 5 mg/100 mL intravenous zoledronic acid
32833350|NCT05204836|Placebo Comparator|Placebo|Participants will receive 1 dose 100 ml Saline.
32833351|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
32833352|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
32833353|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
32833354|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
32833355|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
32833356|NCT05711836||patients|
32833357|NCT05711836||controls|
32833358|NCT05201404|Experimental|Namodenoson (CF102)|Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events
32833359|NCT05201404|Placebo Comparator|Placebo|Matching placebo orally BID, until disease progression or unacceptable adverse events
32833360|NCT05194540|Experimental|Tralokinumab subcutaneous dosing with Device A|An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.
32833361|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
32833362|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
32833363|NCT04449328|Experimental|Patient with first stroke causing hemiplegic|"Patient with first stroke causing hemiplegic will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
32833364|NCT04449328|Sham Comparator|healthy subjects|"Healthy subjects will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
32833365|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
32907331|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
33102988|NCT04910100|Active Comparator|Timolol Ophthalmic Solution 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
32833366|NCT04438564|Other|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
32833367|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
32833368|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
32833369|NCT05708482|Experimental|Sling-Swing Group|"While the pregnant woman has 6 cm cervical dilatation examination, the flexible fabric will pass under the arms of the pregnant woman to form a hanger shape. The pregnant woman will be asked to hold the fabric on her feet in a squat and the hanging technique will be applied for 10 minutes. Then, a swing shape will be created in such a way that the flexible fabric will wrap around the chest area of the pregnant woman. The pregnant woman will be asked to hold the fabric in a squat above the knee and the rocking technique will be applied for 10 minutes. Subsequently, uterine contractions, fetal heart rate, fetal head level, position and presence of molding will be evaluated.~Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), this applicant will be experienced by them as the same procedure, hourly.~A Birth Satisfaction Form will be filled at the 2nd hour after delivery.."
32833370|NCT05708482|No Intervention|Standard Care Group|"While the pregnant woman has 6 cm cervical dilatation examination, uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated.~Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated every hour.~A Birth Satisfaction Form will be filled at the 2nd hour after delivery. At the end of the study, delivery times and satisfaction of pregnant women will be analyzed."
32833371|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
32833372|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
32833373|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
32833374|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
32833375|NCT05704504|Experimental|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with ecological momentary assessment (EMA)and personalized telephone support.
32833376|NCT05704504|Active Comparator|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention.
32833377|NCT05704504|No Intervention|No intervention control group (CON)|Participants in the CON group will not be given any intervention during the study period but will be advised to remain their typical lifestyle throughout the trial period.
32833378|NCT02447562|Active Comparator|G_AH|Usual care group
32833379|NCT02447562|Other|G_SP|Phone-based care
32833380|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
32833381|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
32833382|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
32833383|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
32833384|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
32833385|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
32833386|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
32833387|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
32833388|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
32833389|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
32833390|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
32833391|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
33102989|NCT04686149||Neo CCRT+Neo CTx +/- cystectomy|Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
32833392|NCT05681260|Experimental|Standard risk Arm A|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, Capizzi escalating methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
32833393|NCT05681260|Experimental|Standard risk Arm B|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, high dose methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
32833394|NCT05681260|Experimental|High Risk T-LBL|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who fail to achieve at least a PR at the end of Induction (EOI). Induction I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), deIayed intensification, and maintenance therapy. Triple intrathecal injections.
32833395|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
32833396|NCT03834220|Experimental|Debio 1347|Participants will receive Debio 1347 once daily from Day 1 to Day 28 in 28-Day cycles.
32833397|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
32833398|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
32833399|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
32833400|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
32833401|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
32833402|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
32833403|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
32833404|NCT05156632|Experimental|Medium-dose group|4800 participants including 3400 participants aged 18-59 years ,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of medium-dose COVID-19 Vaccine 5-8 months after their second dose.
32833405|NCT05156632|Experimental|High-dose group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of high-dose COVID-19 Vaccine 5-8 months after their second dose.
32833406|NCT05156632|Placebo Comparator|Placebo group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of placebo 5-8 months after their second dose.
32833407|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
32833408|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
32833409|NCT05679622|Experimental|FMT group|In the refractory ulcerative colitis group, our study is aims to repeated and multiple FMTs plus PEN in the treatment of refractory pediatric UC; As a first-line treatment group for UC, repeated and multiple FMTs plus PEN as a first-line treatment for active UC in children.
32833410|NCT05132374|Experimental|Treatment Group|Those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation
32833411|NCT05132374|No Intervention|Waitlist-control group|Those who receive no intervention until the end of the evaluation period)
32833412|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
32833413|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
32833414|NCT02447016|Active Comparator|atripla|Tab Atripla QD
32833415|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
32833416|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
32833417|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
32833418|NCT05676346||LUTS|Patients with lower urinary tract symptoms with CACV > 3 and/or IPSS > 7.
32833419|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
32956183|NCT05686200|Other|Control group|The control group began to use soft rubber balls for isometric contraction exercise from the 2nd day to the 8th week after operation. 2 times a day in the morning and evening, 3 groups of training each time, each group holds the ball for 5 minutes, and rests for 90 seconds between groups. Each grip training must be completed 20 times within 1 minute (keep 3 seconds each time in the first week) , increase by 2 seconds every week, and keep each grasping time for 10 seconds from the 5th to the 8th week.
32956184|NCT05686070|Experimental|Asundexian|Participants will receive asundexian.
32956185|NCT05686070|Placebo Comparator|Placebo|Participants will receive placebo.
32956186|NCT05684796|Active Comparator|Anticoagulation (AC)|Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.
32956187|NCT05684796|Active Comparator|Indigo|Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.
32956188|NCT05683600|Experimental|LYB001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
32956189|NCT05683600|Active Comparator|Placebo Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive placebo at day 0 as a booster vaccination
32956190|NCT05683184||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
32956191|NCT05683184||Opioid Use Disorder|Patients diagnosed with opioid use disorder
32956192|NCT05681468|Experimental|KETO-Can|KETO diet supplemented with Canola oil (high in MUFA and omega-3 FA).
32956193|NCT05681468|Experimental|KETO-Sat|KETO diet supplemented with butter, coconut and palm oil (high in SFA).
32956194|NCT05681468|Active Comparator|Low fat diet (LFD)|Low fat diet supplemented with whole grains and other low-fat foods.
33318895|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
32956195|NCT05669794||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
32956196|NCT05668741|Experimental|VX-522|Participants will receive a single dose of different dose levels of VX-522.
32956197|NCT05664425|Experimental|Mechanical treatment arm + oral hygiene reinforcement|Subjects receive oral hygiene reinforcement, and additionally submucosal instrumentation with ultrasonics with a plastic tip.
32956198|NCT05664425|No Intervention|Oral hygiene reinforcement alone|Subjects receive oral hygiene reinforcement, but do not receive submucosal instrumentation.
32956199|NCT05661578|Experimental|Tiragolumab and Atezolizumab IV FDC|Participants will receive tiragolumab and atezolizumab as an intravenous fixed dose combination (IV FDC) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
32956200|NCT05656664|Placebo Comparator|Placebo|Placebo daily 12 weeks
32956201|NCT05656664|Experimental|Folic Acid|Folic acid 800 ug/day 12 weeks
32956202|NCT05655546|Other|Intervention Arm|Participants in this group will complete the baseline study activities, as described above. Additionally, participants will be instructed to create a Cue Health account and download the Cue Health App. Using the app and the 10 Cue Health COVID-19 molecular tests that are provided (or Cue Health Flu+COVID molecular tests if available and FDA authorized), the participant will perform tests after exposure or if symptoms arise. Participants can also use the test for close contacts who are exposed to COVID-19 and/or have symptoms. If COVID-19 infection occurs, participants will have access to telemedicine to discuss further with a healthcare professional. When clinically indicated, medication for the treatment of COVID-19 (and/or Influenza in case of Cue Health Flu+COVID test availability) will be prescribed and delivered to the participants' delivery address. Participants can also seek care through other healthcare providers or not seek care, at their discretion.
32956203|NCT05655546|No Intervention|Control Arm|Participants in the control group will complete the baseline study activities, as described above. If symptoms arise or COVID-19 infection occurs, participants will test and seek care as they normally would.
32956204|NCT05653232|Experimental|Prophylaxis (P2W)|Prophylaxis is one dose of sofosbuvir/velpatasvir (SOF/VEL) pre-HCV D+/R- kidney transplant (KT), continued for 2 weeks.
32956205|NCT05653232|Experimental|Transmit and Treat (T&T)|T&T is study-supplied SOF/VEL for 12 weeks starting on post-HCV D+/R- kidney transplant day participant's insurance approves standard of care DAAs, or post-KT day 14, whichever comes first.
33318896|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
33318897|NCT00269399|Experimental|Rifaximin Treatment Arm|rifaximin 400mg taken 3 times a day
33318898|NCT00269399|Active Comparator|Vancomycin Comparator Arm|vancomycin 125mg taken 4 times a day
32956209|NCT05648838|Experimental|Pivot Balloon|mornitoring with transcatheter Tricuspid Regurgitation reduction system
32956210|NCT05645744||Prior MB-102 CAR-T cell investigational product.|Patients previously treated with MB-102 CAR-T cell investigational product.
32956211|NCT05645744||Prior MB-106 CAR-T cell investigational product.|Patients previously treated with MB-106 CAR-T cell investigational product.
32956212|NCT05645627|Placebo Comparator|Group 1|Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 48
32956213|NCT05645627|Experimental|Group 2|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 2 IBI112 through week 48
32956214|NCT05645627|Experimental|Group 3|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 3 IBI112 through week 48
32956215|NCT05644041|Experimental|Gemcitabine induction|Patients will receive Gemcitabine once weekly for 6 weeks.
33033025|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
33318899|NCT00289133|Active Comparator|GVF|Gamma Vacuum Foil polyethylene tibial insert
33318900|NCT00289133|Active Comparator|P.F.C.|Cross-linked polyethylene tibial insert
32833420|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
32833421|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
32833422|NCT05674630|Experimental|Magic Touch drug eluting balloon based strategy - 6/12 months invasive follow up|Patients randomized to DEB-based strategy will receive treatment with DEB (Magic Touch, Concept Medical®) throughout the entire lesion length, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
33102990|NCT01268059|Active Comparator|Carboplatin/Paclitaxel|Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min], and paclitaxel 200 milligram per square meter [mg/m^2]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
33102991|NCT01268059|Experimental|Carboplatin/Paclitaxel + MEDI-575|Carboplatin/paclitaxel regimen (carboplatin AUC = 6 mg/mL*min, and paclitaxel 200 mg/m^2) followed by MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575. Subjects were enrolled from North America/European Union (EU) and Japan regions.
33318901|NCT00288587|Active Comparator|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
32833423|NCT05674630|Active Comparator|Drug eluting stent based strategy - 6/12 months invasive follow up|Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
32833424|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
32833425|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
32833426|NCT05669014|Experimental|Daxdilimab|Daxdilimab will be administered by subcutaneous (SC) injection over a total of 44 weeks.
32833427|NCT05669014|Placebo Comparator|Placebo|Matching placebo will be administered by SC injection over a total of 24 weeks, then will be administered active drug by SC injection up to Week 44
32833428|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
32833429|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
32833430|NCT04304482|Experimental|ANAVEX2-73 Active|ANAVEX2-73 liquid oral solution
32833431|NCT04304482|Placebo Comparator|ANAVEX2-73 Placebo|Placebo liquid oral solution
32833432|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
32833433|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
32833434|NCT04745260|Experimental|Intranasal Midazolam and Intranasal Fentanyl|Study participants assigned to the combination (experimental) group will receive a weight-based dose of intranasal Fentanyl (50mcg/mL concentration at 2mcg/kg up to 100mcg) followed by intranasal Midazolam (5mg/mL concentration at 0.2mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
32833435|NCT04745260|Active Comparator|Intranasal Midazolam|Study participants assigned to the control (active comparator) group will receive only intranasal Midazolam (5mg/mL concentration at 0.3mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
32907360|NCT04373018|Experimental|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
32907361|NCT04366154||Patients|
32907362|NCT04366154||Caregivers|
33102992|NCT00535886|Active Comparator|Elaidic Acid|
33102993|NCT00535886|Experimental|Vaccenic Acid|
33102994|NCT00535886|Placebo Comparator|Oleic Acid|
33102995|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
33102996|NCT01267825|Active Comparator|Standard medical care|
33318902|NCT00288587|Active Comparator|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
33102997|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
32833436|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
32833437|NCT05123872|Experimental|prefrontal tDCS at home|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
32833438|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
32833439|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
32833440|NCT05650372|Experimental|High intensity resistive exercise group|Participants of this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition.
32833441|NCT05650372|Active Comparator|Low intensity resistive exercise group|Participants in this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition.
32833442|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.~Olaparib- Oral, on determined days per cycle~Temozolomide- Oral, on determined days per cycle"
32833443|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
32833444|NCT03199248||the participant accepted aspiration for DMC only|
32833445|NCT04745338|Placebo Comparator|low caloric diet|low caloric diet (1200cal/day)
32833446|NCT04745338|Active Comparator|cryolipolysis|cryolipolysis 3 sessions one session every 6 weeks by 3max cool shaping device
32833447|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
32833448|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
32833449|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
32833450|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
32833451|NCT04291768|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
32833452|NCT04291768|Active Comparator|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
32833453|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
32833454|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
32833455|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
32833456|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
32833457|NCT04271332|Experimental|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
32833458|NCT04271332|Placebo Comparator|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
32833459|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
32833460|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
32833461|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
32833462|NCT04229056|Experimental|Specific computer-based cognitive rehabilitation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.
32833463|NCT04229056|Active Comparator|General computer-based cognitive stimulation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.
32833464|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
33318903|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
32833465|NCT03118128|No Intervention|No metformin|
32833466|NCT05100472|Experimental|Hormone Therapy and Radiation|Patients enrolled in this study will receive ADT for 6 months which will consist of bicalutamide 50 mg PO daily starting approximately 1-2 weeks before leuprolide 22.5mg injected every 3 months. The HDR prostate brachytherapy procedure will be performed approximately 3 months after starting ADT to allow for potential radiosensitization and cytoreduction. Approximately 4 weeks after the HDR boost, patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
32833467|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
32833468|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
32833469|NCT03198936|Experimental|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
32833470|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
32833471|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
32833472|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
32833473|NCT05642650|Experimental|Novel wearable device strategy group|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps.
32833474|NCT05642650|No Intervention|Control group|Patients receive a standard of care for heart failure without a wearable device.
32833475|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
32833476|NCT05087914|Experimental|Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)|"The study drug, Carbidopa-Levodopa, is an FDA-approved medicine traditionally used for the treatment of Parkinson's disease. The study drug will be used for an un-approved or un-labeled use: potentially managing pain in post-surgical patients. Carbidopa/Levodopa is an artificially made version of a naturally occurring hormone that helps regulate brain activity (Levodopa), combined with an artificially made version of a naturally occurring molecule that inhibits the breakdown of Levodopa (Carbidopa).~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
32833477|NCT05087914|Placebo Comparator|Placebo + Naproxen (250mg)|"Placebo:Participants will receive 1 the capsules on a three-times a day schedule for 5 days. A placebo looks like the study drug but is an inactive substance that has no medication. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
32833478|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
32833479|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
32833480|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
32833481|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
32833482|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
32833483|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
32833484|NCT03194724||High Vitamin A exposure|There was no intervention
32833485|NCT03194724||Low vitamin A exposure|No intervention
32833486|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
32833487|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
32833488|NCT04179526|Experimental|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
32833489|NCT04179526|No Intervention|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
32833490|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
32833491|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
32907363|NCT04934748|Active Comparator|Tight Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
32833492|NCT05637970|Active Comparator|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
32833493|NCT05637970|Experimental|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
32833494|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
32833495|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
32833496|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
32833497|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
32833498|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
32833499|NCT05637190|Experimental|Expressive Arts Therapy group|The Expressive Arts Therapy group will receive the Expressive Arts intervention via face-to-face workshops for 2 consecutive weeks (2 hours per session). there are a total of 3 batches (around 15 participants per batch) for the intervention.
32833500|NCT05637190|No Intervention|Waitlist control group|The Waitlist control group will not receive any intervention during the study, but they will receive self-help art therapy materials after the whole study procedure.
32833501|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
32833502|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
32833503|NCT04152148|Experimental|500mg BAT4306F|3 weeks of a cycle
32833504|NCT04152148|Experimental|750mg BAT4306F|3 weeks of a cycle
32833505|NCT04152148|Experimental|900mg BAT4306F|3 weeks of a cycle
32833506|NCT04152148|Experimental|1000mg BAT4306F|3 weeks of a cycle
32833507|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
32833508|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
32833509|NCT05631886|Experimental|TP53-EphA-2-CAR-DC plus anti-PD-1 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and TP53-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, TP53-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks. Anti-PD-1 antibody is administered 2 days after the first dose of TP53-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 4 weeks afterwards, until:~Unacceptable toxicity occurred or disease progression; or~Reactive T cells are undetected repeatedly after the last vaccine dose; or~Vaccine exhaustion."
32833510|NCT02446002|Experimental|Lofexidine + Naltrexone|
32833511|NCT04125316||Asthma|Asthma patients
32833512|NCT02445924||Control group 1|ten non smoker volunteers
32833513|NCT02445924||Control group 2|ten smoker volunteers
32833514|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
32833515|NCT05072626|Active Comparator|high MCT formula with breast milk (or infant formula)|high MCT formula with breast milk（or infant formula）: Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
32833516|NCT05072626|Experimental|MCT powder with breast milk (or infant formula)|Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
32833517|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
32833518|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
32833519|NCT05627830|Experimental|Ultrasound Guided Prolotherapy forTreatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space guided by ultrasound probe the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
32833520|NCT05627830|Active Comparator|Non-Guided Ultrasound ( Blind) Prolotherapy for Treatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space by anatomical land mark (blindly), and we also call it ( conventional prolotherapy ) the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
32833521|NCT04118764|Experimental|Focused ultrasound treatment|Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).
32833522|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
32833523|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
32833524|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
32833525|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
32833526|NCT04345198|Experimental|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
32833527|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
32833528|NCT03198390||Healthy subjects|
32833529|NCT05618080||LGMD Type R1/LGMD2A/CAPN3|No intervention will be administered.
32833530|NCT03192618|Experimental|treatment group|
32833531|NCT03192618|No Intervention|control group|
32833532|NCT01706159|Experimental|rFXIII|
32833533|NCT01706159|Active Comparator|Placebo|
32833534|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
32833535|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
32833536|NCT04113226|Active Comparator|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
32833537|NCT04113226|Experimental|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
32833539|NCT04552223|Experimental|Nivolumab Plus Relatlimab Group|Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.
32833541|NCT02444286||standard care group|optimal standard of care therapy
32833542|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
32833543|NCT04552145|Active Comparator|surgery|Decompression surgery
32833544|NCT04552145|Active Comparator|physiotherapy|Physical therapy program
32833545|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
32833546|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
32833547|NCT05044000|Experimental|Heavy blanket|Patients will start with heavy blanket during 15 days
32833548|NCT05044000|Placebo Comparator|Non-heavy blanket|Patients will start with non-heavy blanket during 15 days
32833549|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
32833550|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
32833551|NCT05039476|Active Comparator|Retinol face cream|Retinol face cream on one half of the participant's face
32833552|NCT05039476|Placebo Comparator|Placebo face cream|Placebo face cream on one half of the participant's face
32833553|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
32833554|NCT05031598|Experimental|Long-term fasting|The participants will undergo 6-12 fasting days according to the Buchinger Wilhelmi fasting program
32833555|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
32833556|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
32833557|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
32833558|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
32833559|NCT04100200|Active Comparator|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
32833560|NCT04100200|Active Comparator|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
32833561|NCT04100200|Active Comparator|Combination|Mixed berry composite + FOS served as a frozen drink
32833562|NCT04100200|Placebo Comparator|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
32833563|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
32833564|NCT00356356|Experimental|All subjects|257 subjects
32833565|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
32833566|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
32907364|NCT04934748|Active Comparator|Tight Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
32956216|NCT05643755|Experimental|Intervention|Intervention group: educational material provided on the day of surgery containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
32956217|NCT05643755|No Intervention|Control|Control group: standard clinical care
32956218|NCT05643573|Experimental|Asundexian|Participants will receive asundexian and apixaban matching placebo.
32956219|NCT05643573|Active Comparator|Apixaban|Participants will receive apixaban and asundexian matching placebo.
32956220|NCT05642208|Experimental|Experimental Group|"Injections will be spaced as :~Every 3 weeks between M0 and M4,~Every 4 weeks between M4 and M8 (if ADCT<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used),~Then every 5 weeks until the end of the clinical trial (M12) (if ADCT<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used).~In case of ADCT≥7 or IGA > 2 or disease assessed as uncontrolled by the investigator, the injection interval treatment will be step up to the previous interval.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~The dosage is usually :~300 mg per injection for adults and adolescents (12-17 years) weighing more than 60 kg~200 mg per injection for adolescents (12-17 years) weighing less than 60 kg."
32956221|NCT05642208|No Intervention|Control group|"in this group the interval between injections is maintained every 2 weeks (14 days) throughout the clinical trial.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~Treatment will be prescribed in the control group according to the marketing authorization dosage (see paragraph 5.1). The dosage is usually :~300 mg every 14 days for adults and adolescents (12-17 years) weighing more than 60 kg~200 mg every 14 days for adolescents (12-17 years) weighing less than 60 kg."
32956222|NCT05640180||External control arm (ECA)|ECA built from patients from Optum® Electronic Health Records (EHR) real world data (RWD) that closely match Sodium/glucose cotransporter-2 inhibitors (SGLT2i) subgroups from the randomized clinical trials (RCTs).
32956223|NCT05640180||Internal control arm (ICA)|ICA built from participants from two RCTs called FIDELIO-DKD and FIGARO-DKD pooled for the FIDELITY analyses. FIDELIO-DKD/FIGARO-DKD placebo controls treated with SGLT2is at baseline.
32956224|NCT05640089|Experimental|Emotion network up-regulation + standard care|NF protocol targeting emotion networks (NFE) (plus standard care)
32956225|NCT05640089|No Intervention|Standard care|Continuation of treatment as usual.
32956226|NCT05638672|Experimental|Treatment group|Huashi Baidu Granule+Monapiravir simulant
32956227|NCT05638672|Active Comparator|Control group|Monapiravir+Huashi Baidu Granule Simulator
32956228|NCT05637840|Experimental|Sleep limited|Participants will be asked to limit their sleep
32956229|NCT05637840|Experimental|No sleep limitation|Participants will be asked to get their normal amount of sleep.
32956230|NCT05635669|Experimental|Sacral acupoints group (Sacral group)|Participants will receive sacral acupoints combination treatment at bilaterally Huiyang(BL35) and Zhongliao(BL33) with prone position during the whole treatment course.
32956231|NCT05635669|Experimental|Abdominal acupoints group (Abdominal group)|Participants will receive abdominal acupoints combination treatment at unilateral Zhongji(RN3), Guanyuan(RN4) and bilaterally Dahe(KI12) with dorsal position during the whole treatment course.
32956232|NCT05635669|Experimental|Alternating acupoints group (Alternating group)|Participants will receive treatment of sacral acupoints combination and abdominal acupoints combination alternately. (For example, A for the first time, B for the second time, A for the third time, and so on. )
32956233|NCT05634811|Experimental|VLA15|Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).
32956234|NCT05634811|Placebo Comparator|Normal Saline (Placebo)|Participants will receive 0.9% sodium chloride solution for injection
32956235|NCT05634746|Experimental|APT-1011|APT-1011 3 mg HS
32956236|NCT05634746|Placebo Comparator|Placebo|Placebo HS
32956237|NCT05633680||Breast cancer group|Breast cancer is finally determined through breast puncture biopsy or excisional tissue biopsy and sent for pathological diagnosis
32956238|NCT05633680||Non-breast cancer group|By breast puncture biopsy or excisional tissue biopsy and sent to pathology for final determination of benign tumor. and healthy women
32956239|NCT05628623|Active Comparator|Arm A: Cytarabine|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)"
32956240|NCT05628623|Experimental|Arm B: Cytarabine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8"
32956241|NCT05628623|Experimental|Arm C: Daunorubicin + Cytarabine Liposome+ Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3 with Venetoclax 400 mg orally once daily on Days 1-14"
32956242|NCT05628623|Experimental|Arm D: Azacitidine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference) with Venetoclax 400 mg orally once daily on Days 1-28"
32956246|NCT05616013|Placebo Comparator|Bimagrumab placebo|Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40
32956247|NCT05616013|Other|Bimagrumab placebo + 1.0 mg semaglutide|Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
32833567|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
32833568|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
32833569|NCT03194412|No Intervention|Control group|Without intervention
32833570|NCT04032730|No Intervention|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
32833571|NCT04032730|Experimental|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
32833572|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
32833573|NCT05573074|Experimental|tPBM Group|Visit 1: t-PBM at irradiance dose of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive active t-PBM of 291.7 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
32833574|NCT05573074|Active Comparator|Sham Group|Visit 1: t-PBM at irradiance does of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive Sham of 0 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
32833575|NCT03194100||Diabetes Mellitus|
32833576|NCT03194100||Prediabetes|
32833577|NCT03194100||Normal glucose tolerance|
32833578|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
32833579|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
32833580|NCT04031560|Experimental|Experimental|Integrative treatment
32833581|NCT04031560|No Intervention|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
32833582|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
32833583|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
32833584|NCT02443974|No Intervention|Control group|Keep medication usual
32833585|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
32833586|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
32833587|NCT04016974|Experimental|Oral semaglutide|
32833588|NCT04016974|Placebo Comparator|Placebo|
32833589|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
32833590|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
32833591|NCT05180760|Active Comparator|Smartphone app arm|Use the dedicated smartphone app for NAFLD patients
32833592|NCT05180760|Other|Standard of care|Standard of care
32833593|NCT05169060|Experimental|Fish oil capsules|Subjects will be randomized for the treatment of fish oil capsules. Subjects will take daily supplements of two or four fish oil capsules per day, 2 and 4 g respectively. Treatment will continue for 16 weeks. Fish oil capsules are enriched in omega-3 polyunsaturated fatty acids.
32833594|NCT05169060|Experimental|Fish oil and Salsalate|Salsalate is a non-steroid anti-inflammatory drug. Subjects taking 2 or 4g of fish oil capsules will be randomized to take in addition 1.5 or 3.0 g of salsalate per day. The combined treatment of fish oil and salsalate will continue for 8 weeks.
32833595|NCT05003986|Experimental|Population 1: FSGS and/or MCD|Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns
32833596|NCT05003986|Experimental|Population 2: IgAN, IgAV, or AS|Subjects with biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or subjects with Alport syndrome (AS)
32833597|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
32833598|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
32833599|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
32833600|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
32833601|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
32833602|NCT04974736|Experimental|iEHR + Navigator|
32833603|NCT04974736|No Intervention|Usual Care Control|Usual care delivery in pediatric primary care offices.
32907365|NCT04934748|Active Comparator|Routine Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial
33318904|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
33318905|NCT00288509|Experimental|Dysport|250-1000 units
33318906|NCT03976193|Placebo Comparator|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
32833604|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
32833605|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
32833606|NCT04971070||Hypoglycemic disturbance group|
32833607|NCT04971070||Hypoglycemia was not a disorder of consciousness group|
32833608|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
32833609|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
32833610|NCT05556850|Experimental|Rehabilitation using STABL platform|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to virtual rehabilitation using the STABL platform
32833611|NCT05556850|No Intervention|Rehabilitation using standard physical therapy|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to standard physical therapy.
32833612|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
32833613|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
32833614|NCT05553418|Experimental|"In-Clinic wear first"|Participant will wear the devices first during 27 hr in-clinic wear first followed by injection, then a short-term wear period in-clinic followed by injection, and finally at home for 27 hrs followed by injection.
32833615|NCT05553418|Experimental|"Home wear first"|Participant will wear the devices at home first with return to clinic for injection, followed by a short-term wear period in-clinic for injection, and finally during a 27hr in-clinic stay for injection
32833616|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
32833617|NCT03936478|Experimental|8.2 Gy Radiation Therapy|Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
32833618|NCT05233878||Cohort group|Patients over 18 with a confirmed diagnosis of one or multiple cervical paragangliomas
32833619|NCT05552092|Experimental|Experimental|The patients with ASA class 1-2 (20-65 years old) who are undergoing elective surgery with supine or lithotomy position, without position change, scheduled to last more than 90 min.
32833620|NCT05549908|Experimental|Experimental 4 doses|Inoculate experimental vaccine according to 2-1-1 immunization procedure
32833621|NCT05549908|Experimental|Experimental 5 doses|Inoculate experimental vaccine according to 1-1-1-1-1 immunization procedure
32833622|NCT05549908|Active Comparator|SPEEDA® 4 doses|Inoculate SPEEDA® according to 2-1-1 immunization procedure
32833623|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
32833624|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
32833635|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
32833636|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
32833637|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
32833638|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
32833639|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
32833640|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
32833641|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
33102998|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
33102999|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
33103000|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
33103001|NCT04895475||Lactating Mothers|Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
32833642|NCT05723224|Experimental|Endoscopic ultrasound-guided gallbladder treatment|Endoscoipc gallbladder drainage under EUS guide using lumen apposing metal stents (LAMS) followed when needed by endoscopic lithotripsy.
32833643|NCT03197220|Experimental|fish|
32833644|NCT03197220|Experimental|walnut|
32833645|NCT03197220|Experimental|fish-walnut|
32833646|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
33103002|NCT05470829|Experimental|Part 1 75mg ZM-H1505R or placebo|"75 mg was selected for PK bridging.Twelve healthy subjects were enrolled,of which 8 subjects received ZM-H1505R and 4 subjects received placebo.~Subjects were administrated in the morning under fasting conditions on Day 1 and afterwards Day 4 - Day 14 once daily,i.e. after 3-day washout period and followed by 11-day consecutive administration.Safety and tolerability evaluation was performed on Day 3,Day 6,Day 10 and Day 17 after the initial administration.~Two sentinel subjects (one male and one female) were enrolled to reveived ZM-H1505R.When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects,and study drug concentration of sentinel subjects after the initial administration had been analysed so that PK sampling timepoints for the remaining subjects was determined, the remaining 10 subjects were enrolled to receive ZM-H1505R or placebo at a 3:2 ratio in a randomized manner."
33326881|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
32833647|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
32833648|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
32833649|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
32833650|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
32833651|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
32833652|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
32833653|NCT03197688||Notapplicable|Not applicable as non-interventional study
32833654|NCT03903484|Experimental|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
32833655|NCT03901534|Other|Moderate to Severe OSA - treated|Moderate-to-severe OSA Treated with and adherent to Auto-CPAP
32833656|NCT03901534|Experimental|Moderate to Severe OSA - withdrawal|Moderate-to-severe OSA Withdrawal of Auto-CPAP
33326882|NCT01283412|Active Comparator|Arm P|Placebo infusion
33326883|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
32833657|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
32833658|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
32833659|NCT05723146|Experimental|Spatial cognition assessment|A single session of spatial cognition assessment (baseline) will be proposed to participants. This assessment will be based on paper-and-pencil tasks and immersive virtual reality tasks (with an HTC Vive Pro Head-Mounted-Display). The assessment will last around 1 hour.
32833660|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32833661|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
32833662|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
32833663|NCT05715658|Experimental|Evaluating the pharmacokinetics of dabigatran etexilate in elderly healthy subjects|Adult healthy subjects and elderly healthy subjects only took one 110mg dabigatran etexilate capsule orally, and elderly patients with atrial fibrillation took dabigatran etexilate according to routine medical care.
32833664|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
32833665|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
32833666|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)~Increase morning bright light exposure via bright light goggles (30 m after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
32833667|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
32833669|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
32833670|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
32833671|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
32833672|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
32833673|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
32833674|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
32833675|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
32833676|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
32833677|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
32833678|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
32833679|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
32833680|NCT04745182|Experimental|MASTERY|For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last ~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
32833681|NCT00357604|Active Comparator|A1|
32833682|NCT00357604|Experimental|A2|
32833683|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
32833684|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
32833685|NCT05723068||Patients with chronic hepatitis D|
32833686|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
32833687|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
32833688|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
32833689|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
32833690|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
33405382|NCT05197569|Experimental|Thyme oil group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
33405383|NCT01374945|No Intervention|SOC preparation and colonoscopy|
33405384|NCT01374945|Experimental|Miniprep and Clearpath|
33405385|NCT05197413|Experimental|Arrae Bloat supplement|"The Bloat capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms."
33405386|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
33405387|NCT05197101|Experimental|nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation|
33405388|NCT05039775|Experimental|Study group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal and will use EROS-CTD Clitoral Therapy Device in addition to psychosexual support sessions and will be closely followed for three months.
33405389|NCT05039775|Other|Control group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal will receive psychosexual support sessions and will be closely followed after 3 months.
33405390|NCT05197023|Experimental|SHR-1819 injection|
33405391|NCT05197023|Placebo Comparator|placebo|
33405392|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
33405393|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
33405394|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
33405395|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
33405396|NCT05196711|Experimental|MAX-40070|MAX-40070 is a liniment with two dose specification: 0.5%, 2% (Weight/Volume). In SAD phase, MAX-40070 will be applied once in each cohort, and there will be 6 cohorts. For the first 2 cohorts, 0.5% MAX-40070 will be used. For the rest 4 cohorts, 2% MAX-40070 will be used. In MAD phase, MAX-40070 2% will be applied once daily for consecutive 14 days in each cohort.
33405397|NCT05196711|Placebo Comparator|Placebo|Placebo is a liniment with two dose specification: 0.5%, 2% (Weight/Volume) to match with active drug in 2:1 manner ( 6 active: 2 placebo in each cohort).
33405398|NCT04878003|Experimental|Arm 1|KRT-232 administered orally as 240 mg once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles
33405399|NCT04878003|Experimental|Arm 2|TL-895 administered orally as 150 mg twice daily continuously in 28-day cycles
33405400|NCT04865289|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
33405401|NCT04865289|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
33405402|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
33405403|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
32833691|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
32833692|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
32833693|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
32833694|NCT05715502|Experimental|Experimental|Experimental: All recruited participants will be treated with salvage partial (focal) prostate brachytherapy for the lesion of recurrent prostate cancer with appropriate margin.
32833695|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
32833696|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
32833697|NCT05715424|Experimental|Cluster A|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster A. The intervention was administered at month 6 and monitored for two years.
32833698|NCT05715424|Experimental|Cluster B|The study population (school-based) was divided into four clusters. Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster B. The intervention was administered at month 12 and monitored for one and a half years.
32833699|NCT05715424|Experimental|Cluster C|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention. and one cluster was randomly selected as Cluster C. The intervention was administered at month 18 and monitored for a continuous period of one year.
32833700|NCT05715424|Experimental|Cluster D|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster D. The intervention was implemented at month 18 and an evaluation of the effect of the intervention was performed.
33405404|NCT05196555|Experimental|microscopic surgical repair of cleft palate with intravelar veloplasty (IVVP)|
33405405|NCT04885881|Active Comparator|Ozone therapy group|Patients with myofascial pain syndrome receiving ozone injection
33405406|NCT04885881|Active Comparator|Lidocaine injection group|Patients with myofascial pain syndrome receiving lidocaine injection
33405407|NCT01375179|Experimental|KRP203|"Experimental~Edit~Experimental"
33405408|NCT01375179|Placebo Comparator|Placebo|Placebo
33405409|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
33405410|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
33405411|NCT04820205|Experimental|intranasal dexmedetomdine and kemtaine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
33405412|NCT04820205|Active Comparator|oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
33405413|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
32833701|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
32833702|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
32833703|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
32833704|NCT03718546||Sibling pediatric donors|Donors who are donating to a sibling
32833705|NCT03718546||Sibling recipients and caregivers|Recipients who are receiving a transplant from a sibling
32833706|NCT03718546||Non-donor sibling|From the donor-recipient families
32833707|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
32833708|NCT03718546||Healthy comparison|A matched sample
32833709|NCT03718546||Parents|Parent/caregiver of study participating donor.
32833710|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;~GP Supervision;~Audio-visual and written materials/guidelines for GP's;~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;~Booklets for patients once consent gained."
32833711|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
32833712|NCT02443116|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 - Placebo
32833713|NCT02443116|Experimental|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
32833714|NCT02443116|Experimental|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
32833715|NCT02443116|Experimental|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
32833716|NCT02443116|Placebo Comparator|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
32833717|NCT02443116|Experimental|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
32833718|NCT02443116|Experimental|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
32833719|NCT02443116|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 - Placebo
32833720|NCT02443116|Experimental|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
32833721|NCT05715190|No Intervention|Control|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment.
32833722|NCT05715190|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient clinic as prescribed by the physician). Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
32833723|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
32833724|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
32833725|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
32833726|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
32833727|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
32833728|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
32833729|NCT05722834|Experimental|SOAR intervention|The SOAR intervention will be a remote intervention that will follow a self-regulation process in which the participant first selects a specific problem to address and researches how asthma is preventing resolution of the problem, and finally identifies and develops a plan to achieve the objective.
32833730|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
32833731|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
32833732|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
32833733|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
32833734|NCT00356746||1|elective CABG only patients
32833735|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
32833736|NCT00356824||1|HIV-infected children in Uganda
32833737|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
32833738|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
32833739|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
32833740|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
32833741|NCT05722756||group A|treated with Vojta therapy
33103003|NCT05470829|Experimental|Cohort 1 of Part 2 50mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 50 mg dose group (cohort 1). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
33103004|NCT05470829|Experimental|Cohort 2 of Part 2 100mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 100 mg dose group (cohort 2). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
33103005|NCT05470829|Experimental|Cohort 3 of Part 2 200mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 200 mg dose group (cohort 3). Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
33103006|NCT00593281|No Intervention|1|IV Morphine
33103007|NCT00593281|Experimental|2|SC Morphine with Hylenex
33103008|NCT00593281|Active Comparator|3|SC Morphine with Saline
33103009|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
33103010|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
33103011|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
33103012|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
33103013|NCT04327102|Experimental|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
33103014|NCT04327102|No Intervention|No intervention:The control group|No intervention except conventional care were performed for the control group
33103015|NCT04686981||mesenteric artery thromboembolism patients without intestinal necrosis|After laparoscopic exploration, If there is no intestinal necrosis, minimally invasive intravascular thrombus aspiration treatment will be performed,
33103016|NCT04686981||mesenteric artery thromboembolism patients with intestinal necrosis|After laparoscopic exploration, If intestinal necrosis occurs, open surgery, mesenteric artery embolectomy and necrotic bowel resection, intestine fistula will be performed.
33103017|NCT00536003|Experimental|1|
33103018|NCT00536003|Placebo Comparator|2|
33103019|NCT00593437||1|diagnosed with normal bone density by Norland Excel
33103020|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
33103021|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
33103022|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
33103023|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
33103024|NCT00593515|Experimental|1|Family CBT
33103025|NCT00593515|Active Comparator|2|Child-focused CBT
33103026|NCT00533091|Active Comparator|1|MEDI-545
33103027|NCT00533091|Other|2|Placebo
33103028|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
32833742|NCT05722756||group B|treated with Vojta therapy combined with craniosacral therapy
32833743|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
32833744|NCT03716934|Experimental|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
32833745|NCT03716934|Active Comparator|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
32833746|NCT05722600|Experimental|Hardaliye Group|Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
32833747|NCT05722600|Placebo Comparator|Placebo Group|Placebo Group consumed 250 ml/day of placebo drink for 28 days.
32833748|NCT03196674|Active Comparator|manipulated feedback|
32833749|NCT03196674|Active Comparator|non-manipulated feedback|
32833750|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
33405414|NCT05195931||Preload and Afterload|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in preload (head-up tilt and saline infusion), and afterload (nitroprusside and phenylephrine infusion).
32833751|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
32833752|NCT04483830|Placebo Comparator|group A|patient with the early stages of COVID-19 to received an oral dose of placebo twice a day for 21 days
32833753|NCT04483830|Active Comparator|group B|patient in the early stages of COVID-19 to received an oral dose of 500LRU of sulodexide twice a day for 21 days.
32833754|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
32833755|NCT05182242|Experimental|Patients|Pregnant women with sonographic signs
32833756|NCT05182242|Other|Health professionals|biologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
32833757|NCT05712382|Active Comparator|Coping with emotions, Parent handbook, Problem-solving risky situations, and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833758|NCT05712382|Active Comparator|Coping with negative emotions, Parent handbook , and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
32833759|NCT05712382|Active Comparator|Coping with negative emotions, Parent handbook , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833760|NCT05712382|Active Comparator|Coping with negative emotions and Parent handbook|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use.
32833761|NCT05712382|Active Comparator|Coping with negative emotions, Problem-solving for risky situations , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833762|NCT05712382|Active Comparator|Coping with negative emotions and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
32833763|NCT05712382|Active Comparator|Coping with negative emotions and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833764|NCT05712382|Active Comparator|Coping with negative emotions|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions.
32907366|NCT04934748|Active Comparator|Routine Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
32956248|NCT05616013|Other|Bimagrumab placebo + 2.4 mg semaglutide|Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule
32833765|NCT05712382|Active Comparator|Parent handbook , Problem-solving for risky situations , and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833766|NCT05712382|Active Comparator|Parent handbook and Problem-solving for risky situations|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833767|NCT05712382|Active Comparator|Parent handbook and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833768|NCT05712382|Active Comparator|Parent handbook|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use.
32833769|NCT05712382|Active Comparator|Problem-solving for risky situations and Recovering from slips|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833770|NCT05712382|Active Comparator|Problem-solving for risky situations|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
32833771|NCT05712382|Active Comparator|Recovering from slips|To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
32833772|NCT05712382|No Intervention|Assessment only control condition|Participants in this condition will complete assessments but will not receive any additional intervention content.
32833773|NCT04484064|No Intervention|Standard care|"Patients in the standard care arm will use an electronic adherence monitor (MEMS®) without any feedback (electronic data will be blinded to patients, clinicians and investigators until the analysis)"
32833774|NCT04484064|Experimental|Adherence program|"Patients in the adherence program will use the MEMS® and the pharmacist will provide an electronic feedback on medication adherence since the last visit. The identified determinants of medication adherence will be discussed with the patient."
32833775|NCT05722522|Experimental|Secukinumab|"Name and Strength: 2 X Secukinumab 150 mg / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
32833776|NCT05722522|Placebo Comparator|Placebo|"Name and Strength: 2 X Placebo / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
32833777|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
32833778|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
32833779|NCT05712304|No Intervention|conventional examination|For patients in the CE group, the colonoscope was withdrawn directly from the splenic flexure to the rectum, and polyps that were found were removed
32833780|NCT05712304|Experimental|second examination|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
32833781|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
32833782|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
32833783|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
32833784|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
32833785|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
32833786|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
32833787|NCT05722366|Active Comparator|Active Video Game İntervention|"The active video games intervention will be carried out with a virtual reality system (XBOX360, Microsoft, USA) consisting of a console and a sensor.~Active video games consist of Bowling, River Rush, Rally Ball and Reflex Ridge games.~Participants will exercise for a total of 25 minutes with light-paced games for warm-up for the first 5 minutes, then brisk games with different body movements until the 15 minutes are complete, and light-paced games for 5 minutes to cool down.~Participants will complete active video games in the same order."
32956249|NCT05616013|Experimental|10 mg/kg bimagrumab|Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40
33103029|NCT01606384|Placebo Comparator|Placebo|Twice daily
33405415|NCT05195931||Contractility|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in contractility with adjustments in heart rate (by adjusting pacemaker), dobutamine infusion, and during exercise.
32833788|NCT05722366|Active Comparator|Aerobic Exercise Intervention|The exercise intervention will consist of a continuous moderate intensity walking session on the treadmill. After the first 5 minutes of warm-up,a at 55-70% of the peak heart rate reserve(HRR)with a 15-minute walking session, and 5 minutes of cooling down total of 25 minutes of exercise will be performed.
32833789|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
32833790|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
32833791|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
32833792|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
32833793|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
32833794|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
32833795|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
32833796|NCT05165550|Experimental|Cohort 1|Elsulfavirine 20 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
32833797|NCT05165550|Experimental|Cohort 2|Elsulfavirine 40 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
32833798|NCT05165550|Experimental|Cohort 3|Elsulfavirine 80 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
32833799|NCT04166669|Experimental|Cohort 1|Drugs: APX001, itraconazole
32833800|NCT04166669|Experimental|Cohort 2|Drugs: APX001, rifampin
32833801|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
32833802|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
32833803|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
32833804|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
32833805|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
32833806|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
32833807|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
32833808|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
32833809|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
32833810|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
32833811|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
32833812|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
32833813|NCT02441868|Experimental|Intervention|all participants will receive the training
32833814|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
32833815|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
32833816|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
32833817|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
32833818|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
33405416|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
32956250|NCT05616013|Other|10 mg/kg bimagrumab + 1.0 mg semaglutide|Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
32956251|NCT05616013|Other|10 mg/kg bimagrumab + 2.4 mg semaglutide|Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule
32956252|NCT05616013|Experimental|30 mg/kg bimagrumab|Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40
32956253|NCT05616013|Other|30 mg/kg bimagrumab + 1.0 mg semaglutide|Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28, and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
32956254|NCT05616013|Other|30 mg/kg bimagrumab + 2.4 mg semaglutide|Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide per the dose escalation schedule
32956255|NCT05611905||11C-para-aminobenzoic acid PET/CT|
33405417|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
32956257|NCT05609643||Rinvoq|Participants will receive Rinvoq as prescribed by their physician according to local label.
32956258|NCT05604690|Experimental|Treatment Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Avacc 10 via intranasal application.~Cohort 1 will receive a low dose of Avacc 10~Cohort 2 will receive a high dose of Avacc 10.~Dosage Form: Liquid Unit Dose: Investigational product (IP) in Phosphate Buffered Saline Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
32956259|NCT05604690|Active Comparator|OMV Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Outer Membrane Vesicles (OMV) comparator via intranasal application.~Dosage Form: Liquid Unit Dose: OMV comparator in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
32956260|NCT05604690|Placebo Comparator|Placebo Are: Cohort 1 and 2|Subjects will receive 2 doses of placebo via intranasal application. Dosage Form: Liquid Unit Dose: Placebo in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Clear, colorless in glass vial
32956261|NCT05603910|Experimental|Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation Therapy (EBRT) Group|"Participants in this group will receive a combination treatment of Lenvatinib, Pembrolizumab, and Hypofx Pelvic EBRT over a period of approximately 10 to 12 weeks.~Lenvatinib - administered in a 3 plus 3 escalation/de-escalation design. Participants will receive 1 of 4 of the following dose levels:~Dose level 1- 4 mg Dose level 2- 8 mg Dose level 3 (Starting dose) - 12 mg Dose level 4- 16 mg~Pembrolizumab- 200 mg IV will be administered on Day 1, 22 and 43~HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks."
32956262|NCT05603312|Experimental|AAV-GAD Dose 1 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 1 into the STN
32956263|NCT05603312|Experimental|AAV-GAD Dose 2 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 2 into the STN
32956264|NCT05603312|Sham Comparator|Sham treatment group|Eligible participants will undergo a sham surgical procedure
32956265|NCT05602376|Experimental|U=U testing messaging scripts|Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men
32956266|NCT05602376|Experimental|U=U adherence messaging scripts|Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care
32956267|NCT05602376|No Intervention|Standard of Care (SoC) messaging|"Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation~Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program"
32956268|NCT05600270|Active Comparator|Angled wire|Angled guidewire intervention arm
32956269|NCT05600270|Active Comparator|Straight wire|Straight guidewire intervention arm
32956270|NCT05599594|Experimental|Neroli oil|Neroli oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
32956271|NCT05599594|Experimental|Lemongrass oil|Lemongrass oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
32956272|NCT05594823|Active Comparator|Fixed - dose diuretic|Pre-determined, fixed daily dose of diuretic (furosemide)
32956273|NCT05594823|Experimental|Flexible diuretic regimen|Variable daily dose of diuretic (furosemide) determined based on a pre-specified weight-based scale.
32956274|NCT05592483||Prospective Cohort|Patients with HER2+ unresectable and/or mBC who are planned to receive T-DXd for 2L or earlier metastatic treatment.
32956275|NCT05590741|Experimental|Treatment|All participants will receive a 12-session version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session.
32956276|NCT05589272|Experimental|Cognitive training + active-tDCS|Cognitive training + active-tDCS 4 times per week (20 minutes per session, each (~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
32956277|NCT05589272|Sham Comparator|Cognitive training + sham-tDCS|Cognitive training + sham-tDCS 4 times per week (20 minutes per session, each ~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
32956278|NCT05587491|Other|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid argonplasma.
33033026|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
32833819|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
33103030|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
33405418|NCT05195619|Experimental|Cohort 1|metastatic NSCLC of any histology without any actionable oncogenic driver treated by SOC. Maintenance treatment with pemetrexed and/or maintenance/continuation of pembrolizumab, nivolumab or atezolizumab is allowed.
32833820|NCT03196128|Active Comparator|Digital|
32833821|NCT03196128|Active Comparator|Non Digital|
32833822|NCT04484298|Experimental|reference group|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
32833823|NCT04484298|Experimental|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.
32833824|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
32833825|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
32833826|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
32833827|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
32833828|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
32833829|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
32833830|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
32833831|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
32833832|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
32833833|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
32833834|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
32833835|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1000 mg, 1200 mg) in combination with daily 250 mg oral dose of gefitinib
32833836|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
32833837|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
32833838|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
32833839|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
32833840|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
32833841|NCT04483986|Active Comparator|Study group|This arm is going to include the patients who are performed rectus reapproximation.
32833842|NCT04483986|No Intervention|Control group|This arm is going to include the patients who are not performed rectus reapproximation.
32833843|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
32833844|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
32833845|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
32833846|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
32833847|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
32833848|NCT02441478|Experimental|Patients|
32833849|NCT02441478|Active Comparator|Controls|
32833850|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
32833851|NCT05722288|Experimental|Arm I (time-restricted eating)|Patients undergo time-restricted eating Monday through Friday only of each week on study during standard RT or chemoRT. Patients also undergo collection of blood throughout the trial.
32833852|NCT05722288|Active Comparator|Arm II (nutritional counseling)|Patients receive nutritional counseling on study. Patients also undergo collection of blood throughout the trial.
32833853|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
32833854|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
32833855|NCT05710198|Experimental|citicoline eye drops 2%|Citicoline eye drops 2%. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication.
32833856|NCT05710198|Placebo Comparator|Placebo eye drops|Placebo eye drops. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication
32833857|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
32833858|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
32833859|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
32833860|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
32833861|NCT05709028|Experimental|Intervention arm|"A single dose of oral fosfomycin trometamol (Monurol), dosed as:~≥ 1 to <12 years of age: 2 grams (of fosfomycin base) as a single dose~Children ≥ 12 years and <18 years of age: 3 grams (of fosfomycin base) as a single dose For children who have persistent fevers at 48 hours, the dose of oral fosfomycin may be repeated every 48 hours, to a maximum of 3 doses.~For a subset of 30 children aged 1-12 years (inclusive) at the primary recruitment sites (RCH, SCH and CHW) two blood samples will be taken after the first oral fosfomycin dose to determine plasma fosfomycin concentrations. The timing of these samples after the oral fosfomycin dose are as follows, with participants being randomly allocated to one of the two sampling groups:~Sample 1 Sample 2 Group 1 (n=15) 20 minutes to 180 minutes post dose 4-12 hours post dose Group 2 (n=15) 120 to 240 minutes post dose 12 to 18 hours post dose"
32833862|NCT05709028|Active Comparator|Standard of Care Arm|Management as per physician preference based on institutional prescribing practices and local antibiograms. For participants administered an oral antibiotic in the Standard of Care arm, a tolerability questionnaire will be administered at the time of the first dose.
32833863|NCT05722132|Active Comparator|One cycle-no monetary incentive|
32833864|NCT05722132|Active Comparator|One cycle-fixed amount of incentive|
32833865|NCT05722132|Active Comparator|One cycle-raffle as incentive|
32833866|NCT05722132|Active Comparator|4 cycles- no monetary incentive|
33103031|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
32833867|NCT05722132|Active Comparator|4 cycles- fixed amount of incentive|
33103032|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
32833868|NCT05722132|Active Comparator|4 cycles- raffle as incentive|
32833869|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
32833870|NCT05722054||Incidence of tropical infectious diseases|All study participants will be followed up for 12 months through active and passive detection visits. Active detection takes place every month for all pathogens except for P. falciparum which is detected every two weeks.
33103033|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
32833871|NCT05722054||Healthy and equilibrate diet|One-fourth of the study participants will be randomly assigned to receive an equilibrate diet for 21 days comprising breakfast, lunch and educational recommendations for an equilibrate diet
32833872|NCT05722054||In vitro|30 to 50 participants selected from the study population. The in vitro study procedures are performed at the screening visit and every two months+/- 1, and when an active case of tropical infection occurs
32833873|NCT05722054||Adaptive in vitro|100 to 150 selected participants. The adaptive in vitro study procedures are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
32833874|NCT05722054||Ex vivo|All study participants. The ex vivo are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
32833875|NCT01787682|Experimental|Boost High Protein|Boost high protein with added spirulina
32833876|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
32833877|NCT01687920|Experimental|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
32833878|NCT01687920|Experimental|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
32833879|NCT01687920|Experimental|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
32833880|NCT01687920|Experimental|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
32833881|NCT01687920|Experimental|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
32833882|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
32833883|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
32833884|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
33405419|NCT05195619|Experimental|Cohort 2|metastatic NSCLC with actionable oncogenic driver such as EGFR mutation, ROS-1 or ALK rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity.
33405420|NCT01375335|Experimental|Dobutamine|
33405421|NCT05195307|Experimental|Music Group|Application Group Pregnant women in the application group were regularly listened to music for 20 minutes a day for 10 days. In addition, the pregnant women in the application group were trained by the researcher on preparing for normal delivery.
33405422|NCT05195307|No Intervention|Control Group|In the study, pregnant women in the control group were trained by the researcher on preparing for normal delivery.
32956279|NCT05586022||Patients with lower extremity arterial occlusion undergoing endovascular revascularization|We will enroll the patients with lower extremity arterial occlusive disease admitted to the Department of Vascular Surgery of The First Affiliated Hospital of Xi 'an Jiaotong University. These patients undergo successful endovascular revascularization of the diseased vessel.
32956280|NCT05582915||Adult patients with severe Bell's palsy|Adult patients recently diagnosed with severe Bell's palsy and referred to the ENT Department by A&E or by general practitionner.
32956281|NCT05581797|Experimental|Psilocybin-assisted psychotherapy|Interpersonal Therapy integrated with psilocybin
32956282|NCT05581498|Experimental|GLAUCOMA|"we will recruit patients with a diagnosis of primary Glaucoma for the experimental group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
32956283|NCT05581498|Active Comparator|CONTROL|"we will recruit normally sighted older adults for the control group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
32956284|NCT05581030|Experimental|Hyper-CVAD + Calaspargase pegol Treatment|Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.
32956285|NCT05580770|Experimental|Phase 1 Dose Escalation Cohorts Ranging in Dose|Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
32956286|NCT05580770|Experimental|Phase 2 Dose Expansion A|Participants with cutaneous melanoma harboring NRAS mutations
32956287|NCT05580770|Experimental|Phase 2 Dose Expansion B|Participants with NSCLC harboring KRAS mutations
32956288|NCT05580770|Experimental|Phase 2 Dose Expansion C|Participants with NSCLC or cutaneous melanoma harboring BRAF Class II or Class III mutation or BRAF Fusion mutation
32956289|NCT05579977|Experimental|PF-07081532 20 mg T2DM|PF-07081532 20 mg daily in T2DM
32956290|NCT05579977|Experimental|PF-07081532 40 mg T2DM|PF-07081532 40 mg daily in T2DM
32956291|NCT05579977|Experimental|PF-07081532 80 mg T2DM|PF-07081532 80 mg daily in T2DM
32956292|NCT05579977|Experimental|PF-07081532 160 mg T2DM|PF-07081532 160 mg daily in T2DM
32956293|NCT05579977|Experimental|PF-07081532 260 mg T2DM|PF-07081532 260 mg daily in T2DM
32956294|NCT05579977|Placebo Comparator|Placebo T2DM|Placebo daily in T2DM
32956295|NCT05579977|Experimental|PF-07081532 80 mg Obesity|PF-07081532 80 mg daily in Obesity
32956296|NCT05579977|Experimental|PF-07081532 140 mg Obesity|PF-07081532 140 mg daily in Obesity
32956297|NCT05579977|Experimental|PF-07081532 200 mg Obesity (Option 1)|PF-07081532 200 mg daily in Obesity
32956298|NCT05579977|Experimental|PF-07081532 200 mg Obesity (Option 2)|PF-07081532 200 mg daily in Obesity
32956299|NCT05579977|Experimental|PF-07081532 260 mg Obesity|PF-07081532 260 mg daily in Obesity
32956300|NCT05579977|Active Comparator|Rybelsus 14 mg T2DM|Semaglutide 14 mg daily in T2DM
32956301|NCT05579977|Placebo Comparator|Placebo Obesity|Placebo in Obesity
32956302|NCT05577741|Experimental|Interventional Group|"Patients complete a measurement session at inclusion visit (Day 1). These measures include an assessment of explicit and implicit craving, a measure of mindfulness skills and a measure of the perceived richness (in stimuli) of daily environment. After inclusion visit, patients randomized in the interventional group will have 6 sessions of enriched environment (from Day 2 to Day 9).~The enriched environment includes:~the multisensory virtual reality pod offers sessions of 20 minutes of mindfulness in immersive situations. Some immersive situations are relaxing and others trigger cues in order to improve craving management;~the cognitive bike offers training sessions of 20 minutes. The patient pedals while using a touch pad with cognitive training games. This simultaneously stimulate motor skills and cognition by means of bicycle-game coupling.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
32956303|NCT05577741|Active Comparator|Control Group|"Patients complete a similar measurement session to the intervention arm, that include psychological tasks and questionnaires at inclusion visit (Day 1). After inclusion visit, patients randomized in the control group wil received the standard of care.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
32956304|NCT05576012|Experimental|SOL-116 single ascending dose starting from 0.075 mg/kg (SC administration)|
32956305|NCT05576012|Placebo Comparator|Placebo single dose (SC administration)|
32956306|NCT05574010|Experimental|Cohort 1 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 1
32956307|NCT05574010|Experimental|Cohort 2 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 2
32956308|NCT05574010|Experimental|Cohort 3 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 3
32956309|NCT05574010|Placebo Comparator|Group 1 in Part B|All eligible Part B participants will receive 3 intravenous (IV) infusions of placebo
32956310|NCT05574010|Experimental|Group 2 in Part B|All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 4
32956311|NCT05574010|Experimental|Group 3 in Part B|All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 5
32956312|NCT05574010|Experimental|Group 4 in Part B|All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 6
32956313|NCT05573503|Experimental|Intervention|Participants complete baseline assessments and are then assigned the intervention.
33103034|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
32833885|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
33103035|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
33405423|NCT05194527||Patients with Acute Mesenteric Ischemia|Patients that are diagnosed with Acute mesenteric Ischemia
33405424|NCT05194527||Patient with another underlying disease/condition|Patients that are diagnosed not with acute mesenteric ischemia, but with a other underlying disease/condition
32833886|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
32833887|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
32833888|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
32833889|NCT01336530|Experimental|Tepilta®|
32833890|NCT01336530|Active Comparator|Oxetacaine|
32833891|NCT01336530|Active Comparator|Antacids|
32833892|NCT01336530|Placebo Comparator|Placebo|
32833893|NCT05721898||Fracture Cases|Fragility Fracture Cases: Post-menopausal females between 50-80 years who have experienced a fragility fracture of the arms (including wrist fractures) or legs (including hip, pelvis, or ankle fractures) after the age of 50 years. Fractures of the spine, digits, toes or face will not be considered. A fragility fracture is operationally define based on self-report of an arm or leg fracture caused by falls from a height <6 inches. A fragility fracture will not count if it is associated with 1) running, bicycling or other similar fast-moving activity such as sports subjects, 2) being struck by a falling or otherwise quickly moving heavy object, or 3) a motor vehicle accident. Insufficiency/stress fractures will not be included. Body mass index between 18.5 and 35 kg/m2.
32833894|NCT05721898||Non-Fracture Controls|Controls: Post-menopausal females between 50-80 years who have not experienced a fracture at any site after the age of 40 years (does not include fractures of the digits, toes or face). Does not self-report losing more than 1.5 inches in stature (height) in the previous 15 years. Body mass index between 18.5 and 35 kg/m2.
32833895|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
32833896|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
32833897|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
32833898|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
32833899|NCT00777348|Experimental|1|DSCG + Reproterol
32833900|NCT00777348|Active Comparator|2|DSCG
32833901|NCT00777348|Active Comparator|3|Reproterol
32833902|NCT00777348|Placebo Comparator|4|Placebo
32833903|NCT05703490||Cognitive Impaired Group|older adults (age 50 years and older) with either clinical diagnosis of cognitive impairment or determined to have cognitive impairment based on Montreal Cognitive Assessment (MoCA) Test, score of 26 or lower
32833904|NCT05703490||Cognitive Intact Group|Older adults age matched with Cognitive Impaired Group with MoCA score of greater than 26
32833905|NCT04484454|Experimental|Omega 3 Oil Supplementation|Following all necessary screening, patients will be provided with the ProdromeNeuro Omega-3 oil supplement and instructed to consume the equivalent of 1 cc of the oil supplement per day for the first month, followed by 2 cc of the supplement/day for the second month, and finally ending with 4 cc/day of the supplement for the third month. Neurocognitive assessment and serology testing will take place at baseline, end of month 1, end of month 2, end of month 3, and one month post intervention-termination.
32833906|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
32833907|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
32956314|NCT05569252|Experimental|DS-1211b low dose|Participants who will be randomized to receive a DS-1211 tablet once daily for 12 weeks.
32956315|NCT05569252|Experimental|DS-1211b middle dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
32956316|NCT05569252|Experimental|DS-1211b high dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
32956317|NCT05569252|Placebo Comparator|Placebo|Participants who will be randomized to receive a placebo tablet once daily for 12 weeks.
32956318|NCT05565196|Experimental|Birth companion intervention arm|Women who deliver in facilities in the experimental arm will be exposed to a facility-based intervention designed to improve companionship in labor, childbirth, and postpartum periods.
32833908|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
32833909|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
32833910|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
32833911|NCT02440152|Experimental|Deep brain stimulation|
32833912|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
32833913|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
32833914|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
32833915|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
32833916|NCT04483596||M|will receive 5 mg melatonin orally at 9 p.m. the night before surgery and another 5 mg melatonin with 15 ml of plain water 30 min before operation and 5 mg melatonin at 9 p.m. in the day of operation and for the first three postoperative days
32833917|NCT04483596||C|received a placebo in the form of one tablet of 500 mg paracetamol that packaged the same way as melatonin at the same times
32833918|NCT05721586|Experimental|CURODONTTM REPAIR: + Fluoride varnish (DURAFLOR)|
32833919|NCT05721586|Active Comparator|Fluoride Varnish (DURAFLOR) only|
32833920|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
32833921|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
32833922|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
32833923|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
33103036|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
33405425|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
33405426|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
33103037|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
33103038|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
33103039|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
33103040|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
33103041|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
33405427|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
33405428|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
33405429|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
32833924|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
32833925|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
32833926|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
32833927|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
32833928|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
33103042|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
33103043|NCT05470595|Experimental|Atezolizumab/Platinum/Etoposide|Atezolizumab/Platinum/Etoposide Platinum will be cisplatin or carboplatin at the investigators discretion.
33103044|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
33103045|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
33103046|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
33103047|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
33103048|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
33405430|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
32833929|NCT03295396|Experimental|Arm A|ONC201 in relapsed H3 K27M glioma
32833930|NCT03295396|Experimental|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:~Primary malignant lesion located in the pons or spinal cord.~Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).~Prior bevacizumab treatment of >4 doses of >7.5 mg/Kg~Tumors with known 1p/19q co-deletion."
32833931|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).~Dinner: ad libitum buffet meal"
32833932|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
32833933|NCT02978482|Experimental|durvalumab|durvalumab alone
32833934|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
32833935|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
32833936|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
32833937|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
32833938|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
32833939|NCT04344808|Experimental|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
32833940|NCT04344808|Active Comparator|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
32833941|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
32833942|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
32833943|NCT05695846|Other|Patients with supra-esophageal gastroesophageal reflux disease|GERD patients with complaints of regurgitation and supra-esophageal symptoms
32833944|NCT05721508|Experimental|Individual practice at home|Participants will undergo a training program combining physical and cognitive activities in individual practice at home.
32833945|NCT05721508|Experimental|Group practice in a traditional group environment (gymnasium)|Participants will undergo a training program combining physical and cognitive activities in group practice in a traditional group environment (gymnasium).
32833946|NCT05721508|Experimental|Group practice in an enriched environment fostering social relations|Participants will undergo a training program combining physical and cognitive activities in group practice in an enriched environment fostering social relations.
32833947|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
32833948|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
32833949|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
32833950|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
32866672|NCT04816422|Active Comparator|Conventional treatment|"Procedure Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
32866673|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
32866674|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
33103049|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
33326884|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
33326885|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
33405431|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
32833951|NCT05721352|Experimental|Single Arm Study|"All participants will receive access to the phone application with a virtual reality headset and heart rate variability Bluetooth ear sensor.~Participants will be instructed to download a free phone app Elite Heart Rate Variability, login using study provided de-identified research email address, pair the Bluetooth ear sensor and record a five-minute resting heart rate variability reading at baseline and each time point of the study prior to beginning intervention.~Participants will be asked to use the intervention phone application for 7-10 minute sessions twice daily 5 days a week for 8 weeks.~For the first 8 weeks, participants will receive brief, daily texts encouraging participation in the smart phone application.~During weeks 9 through 12, will receive relaxation reminders daily via text to determine if use is sustained past the intervention phase"
32833952|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
32833953|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
32833954|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
32833955|NCT00357682|Experimental|Arm A|20mg Esomeprazole
32833956|NCT00357682|Experimental|Arm B|80mg Esomeprazole
32833957|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
32833958|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
32833959|NCT05721274|Experimental|Intervention|"The study will adopt a pretest/post-test quasi-experimental design. The approach of the proposed project is to implement a participatory community engagement and demand creation strategy with trust-building community mobilization and a conditional community-based incentive scheme to reduce the refusals to vaccination and improve polio immunization coverage in intervention UCs. Clusters will be formed on a population of 1500-2000 in each intervention UC. Committees would be formed with approximately 5-7 prominent members of the community.~Intervention Non-cash, incentives would be given and decided with consensus by UC committees and aim to improve infrastructure linked to health including water and sanitation and toilets in the community."
32833960|NCT05721274|No Intervention|Control arm|This would be the standard of care
32833961|NCT05721040||Covid-19 Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
32833962|NCT05721040||Control Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
32833963|NCT00105027|Active Comparator|CRVO Observation|
32833964|NCT00105027|Active Comparator|CRVO 1 mg dose triamcinolone acetonide|
32833965|NCT00105027|Active Comparator|CRVO 4 mg dose triamcinolone acetonide|
32833966|NCT00105027|Active Comparator|BRVO standard care|
32833967|NCT00105027|Active Comparator|BRVO 1 mg dose triamcinolone acetonide|
32833968|NCT00105027|Active Comparator|BRVO 4 mg dose triamcinolone acetonide|
32833969|NCT05720962|Experimental|experimental group|The experimental group will be provided with routine midwife support and uninterrupted accompanying support.
32833970|NCT05720962|No Intervention|control group|Only routine midwife support will be provided to the control group.
32833971|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
32833972|NCT00106119|Active Comparator|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
32833973|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
32833974|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
32833975|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
32833976|NCT03132532|Experimental|Arm A (platinum doublet chemotherapy, lower dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.
32866675|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
32833977|NCT03132532|Experimental|Arm C (platinum doublet chemotherapy, higher dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.
32833978|NCT04629105|Active Comparator|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
32833979|NCT04629105|Placebo Comparator|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
32833980|NCT04629105|Active Comparator|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
32833981|NCT04629105|Placebo Comparator|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
32833982|NCT00006411|Active Comparator|1|cornea assigned from donor age group <66.0 years
32833983|NCT00006411|Active Comparator|2|cornea assigned from donor age group >= 66.0 years
32833984|NCT05720806|Experimental|Weight bearing as tolerated (WBAT) immediately following surgery.|Subjects will be able to self-select weight bearing based on pain and confidence in surgical hip.
32833985|NCT05720806|Active Comparator|Flat foot weight bearing (FFWB) for 2 weeks after surgery.|Subjects will be limited to FFWB, approx 20lbs through the surgical hip.
32833986|NCT04374747|Experimental|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
32833987|NCT04374747|No Intervention|Information|Control condition of information on healthy eating during breastfeeding
33103050|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
33103051|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
33103052|NCT01606618||Spina bifida aperta|
33103053|NCT01606618||Acquired traumatic spinal cord injury|
33103054|NCT01606696|Experimental|HIIT|Higher intensity interval training.
33103055|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
33103056|NCT05470439|Experimental|MI-CARE Intervention|Pharmacist-community health worker team providing coordinated care tailored to high-risk patients with hypertension. MI-CARE intervention participants will meet with the pharmacist-CHW team for medication optimization and tailored case management. Pill counts will be completed to assess adherence and BP will be measured at each visit to guide antihypertensive medication optimization and provide feedback to participants about their adherence and BP control. Intervention visits will be followed by a booster one month later.
33103057|NCT05470439|No Intervention|Waitlist Control|Participants enrolled in this arm will receive usual medical care
33103058|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
33103059|NCT00593671|Active Comparator|PGS group|
33103060|NCT00593671|No Intervention|control group|
33103061|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
33103062|NCT02892721|Other|Training with feedback|See intervention description
33103063|NCT05470205|Experimental|Reproducibility - Cohort 1|"Patients scheduled for hepatic venous pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE procedures using different ultrasound contrast agents (Definity and Sonazoid in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.~Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min."
33326886|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
32833988|NCT00030147|Experimental|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
32833989|NCT00030147|Experimental|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
32833990|NCT00030147|Active Comparator|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
32833991|NCT00030147|Placebo Comparator|Placebo|Placebo skin patch and placebo tablets for eight weeks.
32833992|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
32833993|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
32833994|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
32833995|NCT02709486|Experimental|Low dose|Investigational product
32833996|NCT02709486|Experimental|High dose|Investigational product
32833997|NCT02709486|Placebo Comparator|Placebo|Investigational product
32833998|NCT03110770|Experimental|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
33103064|NCT05470205|Experimental|HCC monitoring - Cohort 2|"Patients identified as having CSPH will be monitored every 6 ± 2 months to check for HCC by SHAPE with Sonazoid for the duration of this project ( for 18-24 months on average).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
33103065|NCT05470205|Experimental|New β-blockers - Cohort 3|Patients newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
32833999|NCT03110770|Experimental|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
32834000|NCT03110770|Experimental|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
32834001|NCT03110770|Experimental|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
32834002|NCT03110770|Placebo Comparator|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
32834003|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
32834004|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
32834005|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
32834006|NCT03085810|Experimental|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
32834007|NCT03085810|Active Comparator|Substudy Group 1|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
32834008|NCT03085810|Experimental|Substudy Group 2|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
32834009|NCT02440074|Experimental|MSV autologous transplantation|
32834010|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
32834011|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
32834012|NCT05191758|No Intervention|no supplements|no supplements will be taken
33103066|NCT05470205|Experimental|Ccreening for varices - Cohort 4|"Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices according to the Baveno VI or the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index and FIB-4 will undergo a SHAPE examination.~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
33103067|NCT00593710|Experimental|1|Losartan
33103068|NCT00593710|Active Comparator|2|Atenolol
33103069|NCT04885686|Experimental|Endomethasone N RCS|Endomethasone N RCS is used in combination with gutta percha points for the permanent obturation of root canals.
32834013|NCT05191758|Experimental|3 grams of supplements|subjects will take 3 grams of supplements once per day
32834014|NCT05191758|Experimental|6 grams of supplements|subjects will take 3 grams of supplements twice per day
33103070|NCT04885686|Active Comparator|Endomethasone SP RCS|Endomethasone SP RCS is used in combination with gutta percha points for the permanent obturation of root canals.
33103071|NCT00593749|Active Comparator|HCS|Intervention group
33103072|NCT00593749|Placebo Comparator|Control|Control
33103073|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
33103074|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
32834015|NCT05191758|Experimental|9 grams of supplements|subjects will take 3 grams of supplements three times per day
32898506|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
32834016|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
32834017|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
32834018|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence and voiding in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
32834019|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
32834020|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
33103075|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
33103076|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
33103077|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
32834021|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
32834022|NCT05673070|Experimental|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
32834023|NCT05673070|Active Comparator|Control MVI|For the prenatal arm, this group will receive a control multivitamin-mineral supplement pill and a 200 mg docosahexaenoic acid (DHA) pill that are commercially available.
32834024|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
32834025|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
33103078|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
33103079|NCT04883970|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 124I-18B10(10L) PET/CT scans
33103080|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
33103081|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
33326887|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
32834026|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
32834027|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
32834028|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
32834029|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
32834030|NCT05720650||Case subjects diagnosed with gestational hypertension or preeclampsia|This is a restrospective observational study and there is no intervention.
32834031|NCT05720650||Control subjects diagnosed without any hypertensive disorders|This is a restrospective observational study and there is no intervention.
32834032|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
32834033|NCT03188562|Experimental|TEMLA|"PET/CT~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
32834034|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
32834035|NCT05720416|Experimental|muscle strength training and protein supplementation|
32834036|NCT05720416|Placebo Comparator|usual care|
32834037|NCT05720416|Experimental|muscle strength training|
33326888|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
33326889|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
33326890|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
33326891|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
33326892|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
32834040|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
32834041|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
32834042|NCT02434224|No Intervention|control|standard care
32834043|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
33103082|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
33103083|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
33103084|NCT04882449|Experimental|Bodyport Scale|All subjects will be given the Bodyport scale to use
33103085|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
33103086|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
33103087|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
33103088|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
33103089|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
33103090|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
33103091|NCT04874376|Experimental|IOL retrospective data collection|Experimental arm: Premium Monofocal intraocular lens.
33103092|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
33103093|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
33103094|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
33103095|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
33103096|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
33103097|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
33103098|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
33103099|NCT02892799|Active Comparator|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
32834044|NCT00358306||a|those with previous history of Acute kidney injury
32834045|NCT05720338|Active Comparator|Standard of care|Intraperitoneal drain will be placed near the pancreatic resection margin, which is the routine standard of care.
32834046|NCT05720338|No Intervention|Omitting Standard of Care|No intraperitoneal drain will be placed in the participants, which omits the routine standard of care.
32834047|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
32834048|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
32834049|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
32834050|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
32834051|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
32834052|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
32834053|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
32834054|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
32834055|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
32834056|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
32834057|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
32834058|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
32834059|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
33103100|NCT02892799|Experimental|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
32834060|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
32834061|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
32834062|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
33103101|NCT05470166|Experimental|infusion of intraoperative lidocaine to patients undergoing whipple surgery|lidocaine 1.5mg/kg infused as bolus, then 2mg/kg/hr through the operation
33103102|NCT05470166|Experimental|saline infusion of same volume of lidocaine|same amount of normal saline infused as bolus and infusion
33103103|NCT00594451||I|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
33103104|NCT00594451||II|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
33103105|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
33103106|NCT00594529|Other|1|
33103107|NCT05470127|Experimental|SUREcore biopsy needle|The SUREcore needle will be used to collect up to 10 tissue samples
33103108|NCT05470127|Active Comparator|Standard of Care biopsy needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples
33103109|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
33103110|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
33103111|NCT05470049|Experimental|Treatment group A: SHR8554 Injection and SHR0410 Injection|
33103112|NCT05470049|Experimental|Treatment group B: SHR8554 Injection and SHR0410 Injection|
33103113|NCT05470049|Placebo Comparator|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection|
33103114|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
33103115|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
33103116|NCT01260142|Experimental|Arm 1|
32834063|NCT04345042|No Intervention|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
32834064|NCT04345042|Experimental|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
32834065|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
32834066|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
32834067|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
32834068|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
32834069|NCT05720260|Active Comparator|goserelin/ fulvestrant|Control arm
32834070|NCT05720260|Experimental|goserelin/ fulvestrant/ capivasertib|Control arm plus AKT inhibitor
32834071|NCT05720260|Experimental|goserelin/ fulvestrant/ capivasertib/ durvalumab|Control arm plus AKT inhibitor and immunotherapy
32834072|NCT05720260|Experimental|goserelin/ fulvestrant/ durvalumab|Control arm plus immunotherapy
32834073|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
32834074|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
32834075|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
32834076|NCT05652790|Experimental|Enhanced Rehabilitation Programme (ERP)|"60-120 MINUTES OF ENHANCED REHABILITATION~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
32834077|NCT05652790|Other|Standard Care|Standard care received at usual NHS facility
32907367|NCT04594733|Active Comparator|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Participants will be randomized to 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout
33103117|NCT01260142|Experimental|Arm 2|
33103118|NCT01260142|Experimental|Arm 3|
32834078|NCT05720182|Experimental|Healthy Volunteers|"Healthy subjects are not subjected to any type of treatment besides non-invasive lower leg muscle compressibility measurements in rest and after exercise.~All 35 healthy subjects will undergo four times four measurements in rest (m. tibialis anterior of both legs, using two different internal landmarks). These four times four measurements in rest will each be done by three observers.~To measure the effect of exercise, compressibility will be measured immediately, one minute, and five minutes after a standard treadmill exercise at just one leg. The treadmill exercise and the corresponding measurements will be performed twice to address for measurements of both legs."
32834079|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
32834080|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
32834081|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
32834082|NCT02978170|Experimental|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
32834083|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
32834084|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
32834085|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
32834086|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
32834087|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
32834088|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
32834089|NCT05720026|Experimental|Treatment group|SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
32834090|NCT05720026|Active Comparator|Control group|Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
32834091|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
32834092|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
32834093|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
32834094|NCT05642884|Experimental|Teleprehab|The participants selected for the teleprehab arm will undergo a supervised 8-week multi-modal exercise program in a telehealth format (using doxy.me, a free telehealth platform) delivered by licensed physical or occupational therapists who have undergone cancer specific rehabilitation training within Select Medical's ReVital® cancer rehabilitation program. Participants will attend teleprehab sessions 2 times per week for a total of 16 sessions.
32834095|NCT05642884|Other|Attention Control|The participants randomized to the attention control arm will not undergo an exercise regimen, but will be contacted by the study staff on the phone once a week..
32834096|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
32834097|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
32834098|NCT04483674|Experimental|Biktarvy|Patients will receive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks
32834099|NCT05719870|Experimental|Intervention group|Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival >7 days.
32834100|NCT05719870|No Intervention|Control group|"Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival >7 days.~The control group will be discharged following standard care procedures, and will receive only appropriate corrections and clarifications in case mistakes in the comprehension of the medical recommendations."
32834101|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
32834102|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
32834103|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
32834104|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
32834105|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
32834106|NCT05638750|Experimental|Intervention|Participants will participate in the rehabilitation intervention.
32834107|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
33103119|NCT01259869|Experimental|PX-866|
32834108|NCT02434458||Control|Healthy control subjects
32834109|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
32834110|NCT05719792||Those who had lumbar radicular pain|Patients with lumbar radicular pain identified by inclusion and exclusion criteria
32834111|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
32834112|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
32834113|NCT03187704|Active Comparator|filtration|Air filtration in homes
32834114|NCT03187704|Sham Comparator|no filtration|Sham air filtration
32834115|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation~1 placebo tablet at two different timepoints before surgery"
32834116|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery~1 placebo tablet at two different timepoints before surgery"
32834117|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery~no stimulation"
32834118|NCT03190902|Experimental|specific computer training (ST) - POMS|
32834119|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
32834120|NCT03190902|Experimental|specific computer training (ST) - ADHD|
32834121|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
32834122|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
32834123|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
32834124|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
32834125|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
32834126|NCT05629702|Experimental|Standard Temozolomide with Sativex|"Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~Sativex up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
32834127|NCT05629702|Placebo Comparator|Standard Temozolomide with Sativex-matched placebo|"Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~Sativex-matched placebo up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
32834128|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
32834129|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
32834130|NCT05719636|Active Comparator|Conventional treatment|
32834131|NCT05719636|Experimental|Progressive resistance exercise|
32834132|NCT03190746||No SNP|Subjects have two copies of the wild type gene
32834133|NCT03190746||SNP present|Subjects have one or two copies of the SNP
32834134|NCT05628532|Experimental|Use of the DBLG1 system|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection or open-loop pump), the patient will start a 42-day treatment period with the DBLG1 system followed by an optional 42-day extension period.
32834135|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
32834136|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
32834137|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
32834138|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
32834139|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
32834140|NCT05719480||Liver Cancer patients|Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (Version 2019) of the Chinese Medical Association
32834141|NCT05719480||Liver Cirrhosis patients|Patients who meet the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Liver Cirrhosis (2019) issued by the Hepatology Branch of the Chinese Medical Association
32834142|NCT05719480||Fatty Liver patients|Patients whose liver imaging findings meet the imaging diagnostic criteria for diffuse fatty liver disease or whose liver biopsy histology changes meet the pathological diagnostic criteria for fatty liver disease
33405432|NCT04585893|Experimental|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.~High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
33405433|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
32834143|NCT05719480||Hepatitis patients|Patients who meet the diagnostic criteria for hepatitis B (ws 299-2008) and are diagnosed as hepatitis B;
32834144|NCT05719480||healthy people|Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism
32834145|NCT04483752|Other|Patients hospitalised for SARS CoV-2 infection.|
32834146|NCT05625802|Experimental|Erector Spinae Plane Block (ESPB)|
32834147|NCT05625802|No Intervention|External control|
32834148|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
32834149|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
32834150|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
32834151|NCT05623306|Experimental|SEEG Guided DBS ON-OFF (Stimulation-Sham)|Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period.
32834152|NCT05623306|Sham Comparator|SEEG Guided DBS OFF-ON (Sham-Stimulation)|Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.
32834153|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
32834154|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
32834155|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
32834156|NCT05621746||Participants with Haemophilia A|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
32834157|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
32834158|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
32834159|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
32834160|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
32834161|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
32834162|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.~The starting dose will be 2 mg per day, and will be adapted every week for one month.~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
32834163|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
32834164|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
32834165|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
32834166|NCT05718544|Experimental|Combined supplement|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
32834167|NCT05718544|Placebo Comparator|Placebo|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
32834168|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
32834169|NCT05616598|Active Comparator|Pateint group|Men with HCV
32834170|NCT05616598|No Intervention|Control group|Men without HCV
32834171|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
32834172|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
33405434|NCT05194371||Definitive (chemo)radiotherapy|
32956319|NCT05565196|No Intervention|Standard of care arm|Women who deliver in facilities in the experimental arm will be exposed to the standard of care for labor, delivery, and the postpartum period.
32956320|NCT05562947|Experimental|Implant arm|Participants will have the implant (pre-filled intraoperatively with ranibizumab 100 mg/mL) surgically inserted on Day 1. After Day 1, patients in the implant arm will attend monthly study visits, and receive implant refill-exchanges with ranibizumab 100 mg/mL at Week 24 and Week 48. At the Week 48 study visit, patients will move to the long term extension phase of the study and continue receiving refill-exchanges Q24W until the end of study. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter
32956321|NCT05562947|Experimental|Intravitreal arm|Participants will receive intravitreal ranibizumab 0.5 mg injections starting on Day 1. Patients will receive intravitreal ranibizumab 0.5 mg Q4W until Week 44. At the Week 48 study visit, patients will receive the PDS implant (pre-filled intraoperatively with ranibizumab 100 mg/mL), move to the long-term extension phase of the study and receive Q24W refill exchanges until the end of study. If patients are unable to attend the Week 48 visit due to extenuating circumstances, they should return no later than the next scheduled visit (Week 52), when they will receive the PDS implant. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter.
32956322|NCT05556226|Experimental|ABBV-154 Dose A|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.
32956323|NCT05556226|Experimental|ABBV-154 Dose B|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.
32956324|NCT05555706|Experimental|B013+ Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
32956325|NCT05552612||Long COVID|Patients with Long COVID
32956326|NCT05552612||Without Long COVID|Patients who do not have Long COVID
32956327|NCT05549765|Experimental|Pharmacopucture on suboccipital muscles|"The Pharmacopucture group will recieve 3 sessions of Pharmacopucture on suboccipital muscles; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.~The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine."
32956328|NCT05549765|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture(except on suboccipital parts), chuna, pharmacoacupuncture and Korean herbal medicine
32956329|NCT05544240|Experimental|Treatment Arm|Treatment Arm
32956330|NCT05544227|Experimental|SV-102 Treatment Arm|SV-102 Treatment Arm
32956331|NCT05542758|Experimental|Total Body HIIT Program|This Total Body HIIT program (circuit and bike training) will involve 3 sessions per week (35-40 min on nonconsecutive days) progressed across the 12 weeks. All session will be lead by undergraduate exercise science students or doctor of physical therapy students and supervised by a physical therapist.
32956332|NCT05541315|Experimental|JNJ-88260237|Participants will be randomized into 6 cohorts to receive single oral dose of JNJ-88260237 on Day 1. The doses in each cohort (Cohorts 2 to 4 and 6) will be escalated based on the safety and pharmacokinetics (PK) data of the previous cohort. For Cohort 5, participants will receive a single-dose of JNJ-82260237 in fasted conditions and a single dose of JNJ-82260237 in fed conditions with dosing sequence determined by randomization.
32956333|NCT05541315|Placebo Comparator|Placebo|Participants in Cohorts 1 to 4 and 6 will receive single oral dose of matching placebo on Day 1.
32956334|NCT05540860|Experimental|Cohort 1|Drug: EDG-5506 Drug: Placebo
32956335|NCT05540860|Experimental|Cohort 2|Drug: EDG-5506 Drug: Placebo
32956336|NCT05540860|Experimental|Cohort 3|Drug: EDG-5506 Drug: Placebo
32956337|NCT05534815|No Intervention|Usual Care Control group|Participants in the Usual Care Control group will receive methadone or buprenorphine treatment, counseling, and employment services.
32956338|NCT05534815|Experimental|Initiation Only group|Participants assigned to the Initiation Only group will be able to earn abstinence-contingent stipends for working with the employment specialist for up to 20 hours per week and performance stipends for engaging in job-seeking behaviors. When employed, those participants will be able to earn abstinence-contingent wage supplements for up to 40 hours worked (verified by pay stubs) in a community job. Participants can earn from both Therapeutic Workplace Work Hours and from wage supplements for working in a community job, however, participants will only be able to earn stipends and wage supplements for a maximum total of 40 hours.
32956339|NCT05534815|Experimental|Initiation and Maintenance group|"The Initiation and Maintenance group procedures will receive the same intervention as the Initiation Only participants for 24 weeks (during the Initiation period). Then, Initiation and Maintenance participants will receive a low-magnitude incentive intervention for 52 weeks (the Maintenance period, weeks 25-76) to maintain drug abstinence and employment. The low-magnitude incentive intervention will be identical to the final weeks of the high magnitude incentive intervention, with two important exceptions.~During the low-magnitude intervention, participants will receive money per hour for maintaining drug abstinence and work (stipends for working with the employment specialist and wage supplements for providing pay stubs).~During weeks 25-76, if a participant in the Initiation and Maintenance group provides a drug-positive urine sample or misses a required mandatory sample, the participant will not receive any incentive."
32956340|NCT05532696|Experimental|ABT-101|"Part 1- dose-escalation: ABT101 in patient with advanced cancer disease~Part 2- dose expansion: ABT101 in patients with NSCLC with confirmed HER2 mutations"
32956341|NCT05528302|Experimental|Tech-CBT intervention|Participants allocated to the Tech-CBT intervention group will attend six telehealth videoconferencing sessions - 1 session per week over 6 weeks. Each session will last between 60 to 90 minutes and will be facilitated by a trained therapist. During each session, the participant will learn and practice different psychotherapy techniques. The participant will be encouraged to practice these skills between sessions with the technology provided, either on their own or with the help of their support person.
33326893|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
33326894|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
33326895|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
33326896|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
33326897|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
32834173|NCT05717296|Experimental|with multimedia support|
32834174|NCT05717296|Sham Comparator|without multimedia support|
32834175|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
32834176|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
32834177|NCT03187392|Active Comparator|lidocaine injection|
32834178|NCT03187392|Experimental|lidocaine-prilocaine cream|
32834179|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
32834180|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
32834181|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
32834182|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
32834183|NCT05717218|Experimental|Interventional|All patients included
32834184|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
32834185|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
32834186|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
32834187|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
32834188|NCT05608798|Other|Examination with the ODI-Tech medical device|"Diffuse reflectance spectroscopy (DRS) operating within the visible wavelength region will be used for the microvascular oxygen saturation and haematocrit measurements.~Computer-assisted microscopy (CAM) will be used for recording frames of skin microcirculation."
32834189|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
32834190|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
32834191|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
32834192|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
32834193|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
32834194|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
32834195|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
32834196|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
32834197|NCT05605600||Patients with Low Anterior Resection Syndrome|Patients with lived-experience of anterior resection surgery, who may or may not have subsequently developed bowel dysfunction symptoms, will be invited to take part in a focus group. They will discuss a new questionnaire and the phrasing of the questions, ensuring clarity and reducing the potential variability in interpretation of each question.
32834198|NCT00214539|Experimental|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
32834199|NCT00214539|Active Comparator|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
32834200|NCT05717062|Experimental|Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC|Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
32907368|NCT04594733|Active Comparator|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|Participants will be randomized to 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout
32907369|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
32907370|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
32907371|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
32907372|NCT04366232|Experimental|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra 300 mg IV~Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
33405435|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
33405436|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
32834201|NCT05717062|Active Comparator|Placebo Intravenous (IV) + Placebo Oral + SOC|Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
32834202|NCT05603494|Experimental|home spirometry group|
32834203|NCT00955552|Active Comparator|Cosamin DS®|"glucosamine hydrochloride 500 mg and chondroitin sulfate 400 mg (Cosamin DS®, Nutramax Laboratories).~The medication was supplied as capsules, with the daily dose of 3 capsules."
32834204|NCT00955552|Experimental|Glucosamine/ chondroitin sulphate|Glucosamine hydrochloride 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal The medication was supplied as capsules, with the daily dose of 3 capsules.
32834205|NCT05716984|Active Comparator|recombinant human brain natriuretic peptide|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
32834206|NCT05716984|Placebo Comparator|placebo|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
32834207|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
32834208|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
32834209|NCT00608764||AA COPD Participants|African-American participants with COPD
32834210|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
32834211|NCT05601154|Active Comparator|Crest Cavity Protection|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
32834212|NCT05601154|Active Comparator|Crest Cavity Protection followed by Act Mint Fluoride Rinse|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
32834213|NCT05601154|Active Comparator|Colgate PreviDent 5000+|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
32834214|NCT05601154|Experimental|Colgate PreviDent 5000+ followed by Act Mint Fluoride Rinse|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
32834215|NCT05716906|Experimental|Melatonin|5mg melatonin gummy 30 min before bedtime for 2 consecutive nights
32834216|NCT00216099|Experimental|Investigational Treatment|"Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle~Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.~Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
32834217|NCT04344652|Experimental|Photoscreening|Photoscreening of patients 0 to 10 years of age
32834218|NCT05716828|Experimental|Balint group|Participants in the Balint group completed Balint training for a period of three months.
32834219|NCT05716828|No Intervention|non-Balint group|
32834220|NCT04565925|Experimental|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
32834221|NCT04565925|Experimental|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
32834222|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
32834223|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
32834224|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
32834225|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
32834226|NCT00017914||Healthy Volunteer|Healthy subject who has not received anti-inflammatory medications and should not has undergone surgery or any major trauma within the 8 weeks prior to enrollment.
32834227|NCT00017914||Myositis Patient|Patient should have documented evidence that he/she meets criteria for an idiopathic inflammatory myopathy (IIM)
32834228|NCT00017914||Non-Myositis Patient|Patients with other myopathies/autoimmune diseases/complications similar to myositis patients. Close relatives of IIM patients (affected or unaffected siblings, children, parents, grandparents)
32834229|NCT00039195|Experimental|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
32834230|NCT05591170|Experimental|Study Group|"Participants received single, high, oral dose of vitamin D3 (120,000 IU), serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) at baseline, 3 days and 7 days after bolus dose were measured.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
32834231|NCT05591170|No Intervention|Control Group|"Serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) were measured at baseline, 3 days and 7 days after.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
32907373|NCT04366232|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
32907374|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
32834232|NCT05587348|Experimental|1. Best Practice Advisory|Four practices receive a suite of tools intended to increase the rate of referral to DSMES classes for patients with type 2 diabetes. In these four practices, the assigned DCE specialist will have access to a list of eligible patients who have upcoming appointments with their primary care providers. The DCE specialist will message the providers about the eligible patients via the EHR. They will also place a pended order for referral to DSMES class for the eligible patients. The health care provider will be able to either approve or deny the order for the referral Additionally, when an eligible patient presents for an appointment in one of the four intervention clinics, a best practice advisory (BPA) will fire within the EHR and encourage the provider to place a referral for DSMES classes.
32834233|NCT05587348|Placebo Comparator|2. Silent Best Practice Advisory|Two practices will not receive the suite of tools, but the lists and BPA will be created and sent to the research team.
32834234|NCT05587348|Experimental|3. Peer Support|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will be assigned a peer supporter who will work with the participant and encourage attendance to the DSMES classes in addition to the usual support offered by the clinic.
33326898|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
32834235|NCT05587348|Placebo Comparator|4. Usual Care|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will receive the usual support offered by the clinic.
32834236|NCT00218439|Experimental|1|Active medication for 4 weeks followed by placebo for 4 weeks
32834237|NCT00218439|Experimental|2|Placebo for 4 weeks followed by active for 4 weeks
32834238|NCT04344730|Placebo Comparator|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
32834239|NCT04344730|Experimental|Standard oxygen 2|Standard oxygen and Dexamethasone
32834240|NCT04344730|Experimental|CPAP 1|CPAP and placebo of Dexamethasone
32834241|NCT04344730|Experimental|CPAP 2|CPAP and Dexamethasone
32834242|NCT04344730|Experimental|HFNO 1|HFNO and placebo of Dexamethasone
32834243|NCT04344730|Experimental|HFNO 2|HFNO and Dexamethasone
32834244|NCT04344730|Placebo Comparator|mechanically ventilated 1|placebo
32834245|NCT04344730|Experimental|mechanically ventilated 2|Dexamethasone
32834246|NCT05716672||240mg group|Maintenance of the 240mg dose for 12 weeks after the first administration of Lazertinib
32834247|NCT05716672||160mg group|Reduction of the 160mg dose for 12 weeks after the first administration of Lazertinib
32834248|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.~Other: Switch to smoking only little cigars"
32834249|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.~Other: Switch to smoking only little cigars"
32834250|NCT04752579|Experimental|Pilates exercise program|Participants allocated to this group will receive a 10-week Pilates exercise program with each session having a duration of 45'.
32834251|NCT04752579|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home-based general exercise sheet
32834252|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
32834253|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
32834254|NCT00108303||Diagnostic|A diagnostic was performed
32834255|NCT05723458|Active Comparator|Cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa|
32834256|NCT05723458|Placebo Comparator|Placebo cream containing vaseline|
32834257|NCT05716594|Experimental|Enteral-extended Anti-reflux Stents Group|Patients are going to implant enteral-extended anti-reflux stents
32834258|NCT05716594|Active Comparator|Traditional Stents Group|Patients are going to implant traditional stents
32834259|NCT05723302|Experimental|Maximal Inspiratory Pressure|MIP Maximal Inspiratory Pressure
32834260|NCT05723302|Experimental|Maximal Expiratory Pressure|MEP Maximal Expiratory Pressure
32834261|NCT04344418|Active Comparator|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
32834262|NCT04344418|Experimental|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
32834263|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
32834264|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
32834265|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
32834266|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
32834267|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
32834268|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
32834269|NCT02959060|Experimental|BMS-986177 and Rifampin|
33326899|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
33405437|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
33405438|NCT01376661||Active Surveillance/ Prostate Cancer|
32834270|NCT00109005|Experimental|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
32834271|NCT00109005|Experimental|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
32834272|NCT05716360||Group 1|Aneuryms treated with Flow-Diverting Stents and had a diameter above 8 mm
32834273|NCT05716360||Group 2|Aneuryms treated with Flow-Diverting Stents and had a diameter below 8 mm
32834274|NCT05716360||Group 3|Aneurysms treated with metalic bare stents
32834275|NCT05370508|Experimental|Cohort 1|Dose level 1 of SONALA-001 (ALA) and Dose level 1 of Exablate device
32834276|NCT05370508|Experimental|Cohort 2|Does level 2 of SONALA-001 (ALA) Dose level 2 of Exablate device
32834277|NCT05370508|Experimental|Cohort 3|Dose level 3 of SONALA-001 (ALA) and Dose level 3 of Exablate device
32834278|NCT05370508|Experimental|Cohort 4|Dose level 4 of SONALA-001 (ALA) and Dose level 4 of Exablate device
32834279|NCT05370508|Experimental|Cohort 5|Dose level 5 of SONALA-001 (ALA) and Dose level 5 of Exablate device
32834280|NCT05370508|Experimental|Cohort 6|Dose level 6 of SONALA-001 (ALA) and Dose level 6 of Exablate device
32834281|NCT05370508|Experimental|Cohort 7|2 treatments of SONALA-001 (ALA) and Exablate device
32834282|NCT05370508|Experimental|Cohort 8|3 treatments of SONALA-001 (ALA) and Exablate device at the Recommended Phase 2 Dose (RP2D)
32834283|NCT05370508|Experimental|Cohort 9|Expansion to approximately 30 patients at the Recommended Phase 2 Dose (RP2D) and the Recommended Phase 2 Schedule (RP2S) of SONALA-001 (ALA) and Exablate device
32834284|NCT05365828||Gestational parents|The study is composed of a sample of LGBTQIA+ and cisgender, heterosexual parents who are receiving antenatal care at the participating hospitals.
32834285|NCT00359008||1|Intermediate AMD
32834286|NCT00359008||2|New untreated CNV subject
32834287|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
32834288|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
32834289|NCT05565118|Experimental|Standard Surgical Treatment + Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology. During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
32834290|NCT05716204|Experimental|High force lateral distraction group|High force lateral distraction of the hip in maximun adjusted position.
32834291|NCT05716204|Sham Comparator|Placebo distraction group|Placebo lateral distraction of the affected hip in maximun adjusted position.
32834292|NCT05360680|Experimental|CUE-102 (1mg/kg) Dose Escalation|CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
32834293|NCT05360680|Experimental|CUE-102 (2 mg/kg) Dose Escalation|CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
32834294|NCT05360680|Experimental|CUE-102 (4 mg/kg) Dose Escalation|CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
32834295|NCT05360680|Experimental|CUE-102 (8 mg/kg) Dose Escalation|CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
32834296|NCT05360680|Experimental|CUE-102 Dose Expansion at Determined RP2D|Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years
32834297|NCT05360446|Placebo Comparator|Placebo|Subcutaneous injection
32834298|NCT05360446|Experimental|Inclisiran sodium|Subcutaneous injection
32834299|NCT05716126|Experimental|[14]Iruplinalkib(WX-0593) 120 mg(orla solution)|Volunteer will receive a single oral dose of 120 mg [14C]Iruplinalkib (WX-0593) administered by mouth, as a solution.
32834300|NCT05357950|Active Comparator|PrimeC|2 tablets of PrimeC administered twice daily (4 tablets a day), at a daily dose of 1496 mg
32834301|NCT05357950|Placebo Comparator|Placebo|2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
32834302|NCT05561452|Experimental|Single PRP Injection + Exercise|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
32902880|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
32902881|NCT05247086|No Intervention|Convention closure|Conventional closure of the surgical wound after mesh removal surgery.
32902882|NCT05247086|Experimental|Negative pressure therapy|Negative pressure therapy of the surgical wound after mesh removal surgery.
32902883|NCT05247008|Other|Thyme honey interventional arm in geriatric patients having end-stage renal disease.|Thyme honey used as mouth rinse in treatment of xerostomia in geriatric patients with end-stage renal disease.
32956342|NCT05528302|No Intervention|Control|Participants allocated to the Control group will receive usual care (i.e., no treatment for anxiety) and a mid-point check-in phone call/video call/email (depending on their preference) from the study team approximately 3 weeks after completing the initial questionnaires. This mid-point check-in is to identify whether there have been any changes to their usual care.
32956343|NCT05527184|Experimental|IMGN151 Open Label|IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability.
32956344|NCT05526157||Patients with CKD+T2D in Study period I|In the pre-finerenone approval period (Study period I), 4 new-user cohorts to be identified, based on the first use of any drug in these classes: SGLT2i, GLP-1 RA, sMRA, or nsMRA.
32956345|NCT05526157||Patients with CKD+T2D in Study period II|In the post-finerenone approval period (Study period II), 5 new-user cohorts to be created based on the use of any drug in these classes: SGLT2i, GLP-1 RA, sMRA, finerenone, and other nsMRA).
32956346|NCT05521191|Experimental|RGLS8429|"The study will consist of three sequential cohorts of 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~Cohort 1: first dose level of RGLS8429 or placebo~Cohort 2: second dose level of RGLS8429 or placebo~Cohort 3: third dose level of RGLS8429 or placebo"
32956347|NCT05521191|Experimental|Placebo|"The study will consist of three sequential cohorts of 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~Cohort 1: first dose level of RGLS8429 or placebo~Cohort 2: second dose level of RGLS8429 or placebo~Cohort 3: third dose level of RGLS8429 or placebo"
32956348|NCT05520073|Experimental|Lactobacillus and Vitamin C|Lactobacillus and Vitamin C supplements daily self-administration for 14 days
32956349|NCT05520073|Placebo Comparator|Vitamin C|Vitamin C supplements daily self-administration for 14 days
32956350|NCT05515692|Experimental|Treatment (electron beam radiotherapy)|Patients undergo radiotherapy simulation on day -14 using either a clinical setup or CT simulation at the discretion of the treating radiation oncologist. Patients then undergo electron beam radiotherapy on day 0. Patients also undergo skin biopsies at baseline, day 28, and day 168 after radiotherapy, and high frequency ultrasound (HFUS) scans on days 28, 56, 84, 112, 140, and 168 after radiotherapy.
32956351|NCT05512260|Other|Women aged 23 -74 and men aged 60 - 74 invited to population based cancer screening|Women aged 23 -74 targeted for breast cancer, cervical and bowel screening and men aged 60-74 targeted for bowel screening will be invited to the project. Efforts will be made to recruit participants who normally do not participate in research and screening, such as those with various disabilities, participants who live outside society and foreign born.
32956352|NCT05510544|Experimental|Experimental arm: plerixafor, G-CSF|plerixafor in combination with granulocyte colony stimulating factor (G-CSF) for CD34+ HSC mobilization in poorly mobilized lymphoma patients
32956353|NCT05510492|Experimental|EXPERIMENTAL GROUP|EXPERIMENTAL GROUP CONSISTS OF 47 NURSES.
32956354|NCT05510492|Experimental|CONTROL GROUP|CONTROL GROUP CONSISTS OF 48 NURSES.
32956355|NCT05509699|Experimental|Surufatinib in combination with anti-PD-1/L1 therapy|Surufatinib 250 mg orally once plus anti-PD-1/L1, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
32956356|NCT05509699|Experimental|Anti-PD-1/L1 monotherapy|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy
32956357|NCT05508022|Experimental|Breathing Exercise|Breathing exercises will be applied to the participants in the experimental group.
32956358|NCT05506618|Other|Group A: Sample Collection|2x Nasopharyngeal Swab Sample Collection
32956359|NCT05506618|Other|Group B: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection
32956360|NCT05506618|Other|Group C: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection for sample pooling
32956361|NCT05506618|Other|Group D: Sample Collection|2x Nasal Swab Sample Collection
32956362|NCT05505903||Vaginal delivery|Newborn Infants born by vaginal delivery.
32956363|NCT05505903||Regular Cesarean section|Newborn infants born by regular Cesarean section
32956364|NCT05505903||Friendly Cesarean section|Newborn infants born by friendly Cesarean section
32956365|NCT05501899|Experimental|Treatment Arm (single arm)|
32956366|NCT05500326|Experimental|Intervention|All participants will received one dose of oral 3mg Ivermectin tablet
32956367|NCT05498493|Experimental|Cognitive Rehabilitation|Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks.
32746908|NCT04421859|Experimental|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
32746909|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
32746910|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
32956368|NCT05498493|Active Comparator|Brain Health Education Program|The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles).
32956369|NCT05495126|Active Comparator|Standard Limbic Access|In this arm, participants will refer through the standard pathway of Limbic Access. During this process patients provide the minimal required information (e.g. demographic information) as well as some basic information about their experienced mental health symptoms (e.g. PHQ-9 & GAD-7). This information is attached to the referral provided to the clinician before the clinical assessment.
32956370|NCT05495126|Experimental|Limbic Access with AI|In this arm, provide all information as in the standard Limbic Access pathway. Based on this information a machine-learning model is used to predict the most likely presenting problem, based on which up to two additional anxiety specific measures are administered in order to collect more tailored information about the patients' experienced mental health symptoms. All the information is attached to the referral provided to the clinician before the clinical assessment.
32746911|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
33405439|NCT05193747||Paediatric patients scheduled for general anesthesia|Paediatric patients (between 1 year -19 years) undergoing elective general anaesthesia with presumed duration over 1 hour will be eligible for inclusion
33405440|NCT05193513|Experimental|group (1)|tow perpendicular miniscrews supported hybrid expanders
33405441|NCT05193513|Experimental|group (2)|tow angulated miniscrews supported hybrid expanders
33405442|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
32907375|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
32746912|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
32746913|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
32746914|NCT05549973|Experimental|Anlotinib Hydrochloride Capsule|Anlotinib Hydrochloride Capsule, 21 days as a treatment cycle.
32746915|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
32907376|NCT05557877|Experimental|Prevention (low-dose aspirin)|"Patients undergo standard of care breast biopsy for assessment of abnormalities seen on imaging, as well as collection of blood during screening. If cancer is found, patient is taken off study and treatment options are discussed with treating physician.~Patients without a cancer finding on biopsy then receive low-dose aspirin PO daily and undergo collection of blood on study. Patients may undergo ultrasound guided breast biopsy as clinically indicated."
32907377|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
32907378|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
32907379|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
32907380|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
32907381|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
32907382|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
32907383|NCT04347512|Experimental|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
32907384|NCT04347512|Active Comparator|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
32907385|NCT04347512|Experimental|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
32907386|NCT05525273|Experimental|Dabrafenib and trametinib|Dabrafenib 75 mg twice daily and trametinib 2 mg once daily
32907387|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
32907388|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
32907389|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
32907390|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
32907391|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
32907392|NCT04365842|Experimental|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
32907393|NCT04365842|Active Comparator|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
32907394|NCT04372316|Active Comparator|methylcobalamin injection|
32907395|NCT04372316|Active Comparator|methylcobalamin tablet|
32907396|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
32907397|NCT02241356|Active Comparator|single vision glasses|single vision glasses
32907398|NCT02241356|Experimental|bifocals|bifocal glasses
32907399|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
33405443|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
33405444|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
33405445|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
33405446|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
32834303|NCT05561452|Experimental|Multiple PRP Injection+ Exercise|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
32834304|NCT05561452|Sham Comparator|Saline Injection + Exercise|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
33405447|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
33405448|NCT01376739||Group 1|
32834305|NCT05561374|Experimental|Low-dose OKN-007, two times a day (BID)|Dose Escalation Cohort 1
33405449|NCT05190783|Experimental|formocresol pulpotomy|gold standard arm which pulpotomy will be done with formocresol
33405450|NCT05190783|Active Comparator|formocresol partial pulpotomy|partial pulpotomy will be done with formocresol
33405451|NCT05190783|Active Comparator|MTA pulpotomy|in this group complete pulpotomy will be done with MTA
32834306|NCT05561374|Experimental|Low-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 2
33405452|NCT05190783|Active Comparator|MTA partial pulpotomy|in this study group partial pulpotomy will be done with MTA
33405453|NCT05190783|Active Comparator|pulpotomy with Theracal LC|in this study group complete pulpotomy will be done with Theracal LC
33405454|NCT05190783|Active Comparator|partial pulpotomy with Theracal LC|in this study group partial pulpotomy technique will be done with Theracal LC
33405455|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
32834307|NCT05561374|Experimental|Mid-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 3
32834308|NCT05561374|Experimental|High-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 4
32834309|NCT05353348|Experimental|Iron treatment intervention arm|
32834310|NCT05353348|Placebo Comparator|Placebo control arm|
32834311|NCT05716048|Experimental|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo 12 weeks of supervised aerobic cycling exercise training. During the last 8 weeks of cycling exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
32834312|NCT05716048|Active Comparator|KF-mSMT Plus Stretching Exercise Training|Participants will undergo 12 weeks of supervised stretching and toning exercise training. During the last 8 weeks of stretching exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
32834313|NCT05352724|Experimental|Hydration drink A|Water with electrolytes and glucose 625 ml 3 times a week for 4 weeks, during exercise
32834314|NCT05352724|Active Comparator|Hydration drink B|Water with electrolytes and calorie-free sweetener 625 ml 3 times a week for 4 weeks, during exercise
32834315|NCT05352724|Placebo Comparator|Hydration drink C|Water with flavoring and coloring 625 ml 3 times a week for 4 weeks, during exercise
32898507|NCT02197273|Experimental|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
32898508|NCT01288027|Experimental|Alglucosidase Alfa|
33405456|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
33405457|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
33405458|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
33405459|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
33405460|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
33405461|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
33405462|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
33405463|NCT05177835|Experimental|ABX464 -25mg|All subjects will receive ABX464 given at 25 mg QD.
33405464|NCT01376817|Experimental|Omega 3|
33405465|NCT01376817|Active Comparator|MCT / LCT|
33405466|NCT01375803|Experimental|1|3g/day
32956371|NCT05490771|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment and CT or MRI at baseline, every 2 cycles for the first 26 cycles, and then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
32746916|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
32746917|NCT03321747|Experimental|Phase 1/Dose Level 1|11 Gy will be given in 5 fractions for a total dose of 55 Gy
32746918|NCT03321747|Experimental|Phase 1/Dose Level 2|12 Gy will be given in 5 fractions for a total dose of 60 Gy
32956372|NCT05489588|Experimental|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
32956373|NCT05488119|Experimental|Pilot Intervention|The design for this phase is a prospective pilot study. The intervention modules (co-developed with the stakeholder advisory board in Phase 1 of this aim) will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment.
32956374|NCT05486481|Experimental|Phase 1a: Dose Escalation Level 1 (venetoclax)|All patients receive 200 mg venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32956375|NCT05486481|Experimental|Phase 1a: Dose Escalation Level 2 (venetoclax)|All patients receive 400 mg venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32956376|NCT05486481|Experimental|Phase 1a: Dose Escalation Level 3 (venetoclax, dexamethasone)|All patients receive the maximum tolerated dose or the recommended phase 2 dose of venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle and, dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32956377|NCT05486481|Experimental|Phase 1a: Dose Escalation Level 4 (venetoclax, dexamethasone, daratumumab)|All patients receive the maximum tolerated dose or the recommended phase 2 dose of venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle, dexamethasone PO on days 1, 8, 15, and 22 of each cycle, and daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32956378|NCT05486481|Experimental|Phase 1b: Dose Expansion (venetoclax, dexamethasone, daratumumab)|Phase 1b dose-expansion cohort will open if dose level 4 is the MTD/RP2D. All patients receive the maximum tolerated dose or the recommended phase 2 dose of venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle, dexamethasone PO on days 1, 8, 15, and 22 of each cycle with daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
32956379|NCT05486481|Experimental|Phase 2: Arm A (venetoclax, dexamethasone, daratumumab)|Patients receive venetoclax PO QD on days 1-28 of each cycle, dexamethasone PO on days 1, 8, 15, and 22 of each cycle, and daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity
32956380|NCT05486481|Experimental|Phase 2: Arm B (dexamethasone, daratumumab)|Patients receive dexamethasone PO on days 1, 8, 15, and 22 of each cycle, and daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33326900|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
33326901|NCT01283568||1 - Gamaline+Hipericin - fertile women|
32956383|NCT05471830||Patient survey|Survey-eligible patients with Commercial or Medicare Advantage health insurance who are current/past users of sMRA therapies and diagnosed with chronic kidney disease (CKD), type 2 diabetes (T2D) or heart failure (HF).
32956384|NCT05465954|Experimental|Treatment (efineptakin alfa, pembrolizumab)|"BEFORE SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1. Patients then undergo surgery 1 week later.~AFTER SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1 of each cycle. Cycles repeat every 42 days for 2 years in the absence of disease progression or unacceptable toxicity."
32956385|NCT05444803|Other|Femoral nerve block group|Thirty minutes before the placement of spinal block, patients will be receive a femoral nerve block with Bupivacaine.
32956386|NCT05444803|Other|Peri-capsular nerve group block group|Thirty minutes before the placement of spinal block, patients will be receive a peri-capsular nerve group block with Bupivacaine.
32956387|NCT05444465|Experimental|Isolated Bioinductive Repair|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
32956388|NCT05444465|Active Comparator|Completion and Repair|Surgical treatment of partial-thickness rotator cuff tears using the standard surgical technique 'Completion and Repair'.
32956389|NCT05443438|No Intervention|3D-3D|All items presented in 3D form
32956390|NCT05443438|Experimental|3D-2D|Initial items in 3D, generalization in 2D
32956391|NCT05443438|Experimental|2D-3D|Initial items in 2D, generalization in 3D
32956392|NCT05443438|Experimental|2D-2D|Initial items in 2D, generalization in 2D
32956393|NCT05443399|No Intervention|3D-3D|All items presented in 3D form.
32956394|NCT05443399|Experimental|3D-2D|Initial exposure to items in 3D, generalization in 2D
32956395|NCT05443399|Experimental|2D-3D|Initial exposure to items in 2D, generalization in 3D
32956396|NCT05443399|Experimental|2D-2D|Initial exposure to items in 2D, generalization in 2D
32956397|NCT05442775|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm take 1 reldesemtiv 300 mg oral tablet twice a day for a 600 mg total daily dose (TDD)
33326902|NCT01283568||2- Gamaline+Hipericin - climateric women|
33103120|NCT05469932|Active Comparator|Treatment|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 4. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
33103121|NCT05469932|Placebo Comparator|Placebo|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 0. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
33103122|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
33103123|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
32898509|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
32898510|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
32898511|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
32898512|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
32898513|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
32898514|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
32898515|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
32898516|NCT01289431|Experimental|Mapracorat|
32898517|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
32898518|NCT01289665|Experimental|Lubricating Gel|
32898519|NCT01289665|Active Comparator|Water|
32898520|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
32898521|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
32898522|NCT01290445||Exposed|Infants exposed in utero to varenicline
32898523|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
32898524|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
32898525|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
32898526|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
32898527|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
32898528|NCT00101660|Experimental|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
32898529|NCT01267279|Placebo Comparator|Placebo|
32898530|NCT01267279|Experimental|Zoledronic Acid|
32898531|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
32898532|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
32898533|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
32898534|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
32898535|NCT04351789|Experimental|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
32898536|NCT04351789|No Intervention|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
32898537|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~disease progression~intolerable toxicity~complete response - 2 full additional cycles~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
32898538|NCT01270555|Experimental|Bupropion|
32898539|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
32898540|NCT01340053|Placebo Comparator|Placebo|Capsule that is identical in size and color to other treatments
32898541|NCT01340053|Experimental|Low Dose|10 mg capsule of tenapanor
32898542|NCT01340053|Experimental|Mid Dose|30 mg capsule of tenapanor
32898543|NCT01340053|Experimental|High Dose|100 mg capsule of tenapanor
32956398|NCT05442567|Experimental|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956399|NCT05442567|Experimental|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956400|NCT05442567|Experimental|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing >15 to <30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956401|NCT05442567|Experimental|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing >15 to <30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956402|NCT05442567|Experimental|Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956403|NCT05442567|Experimental|Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study until participant withdrawal, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first.
32956404|NCT05442567|Other|Observational Cohort: Early Terminated Participants From Parent Studies|Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.
32956405|NCT05441215|Experimental|nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given by mouth two times a day as a tablet
32956406|NCT05434754|Experimental|eHealth Tool|The Intervention is a text messaging algorithm that will operate like a chatbot, querying adolescents with T1D about their confidence with different aspects of T1D self-management as they are preparing to transition to adult diabetes care. The intervention has 4 components of messaging: personalized Educational Content, Standard Educational Curriculum, Provide participant compensation for filling out the questionnaires, Question & Answer feature.
32956407|NCT05434754|No Intervention|Control|Participants randomized to the control arm will also be offered the same incentives to complete questionnaires (outcome measures) but will not receive any other components of the intervention - no personalized/customized support or diabetes resource messages and no reminders. Control arm participants will continue with their usual T1D transition care.
32956408|NCT05433415|Experimental|Black Girls Move (BGM) Treatment Condition|BGM is guided by the Anti-Racist Public Health Critical Race Praxis with adaptive mechanisms to support Black adolescent females as they navigate a racist society. The BGM treatment condition will include mothers as active participants in all components of the weekly, 12-session intervention to test the impact of actively leveraging the daughter/mother relationship . Participants in our prior research endorsed the importance of daughters and mothers actively engaging in group meetings together on weekends. Participants set PA and diet goals and self-monitor goal attainment. Dyads participate in structured activities designed to facilitate communication, problem solving, role assignment, and relationship quality. Dyads use a variety of videos, role play, discussion, and activities to achieve session outcomes. The sessions are led by trained facilitators who follow a standardized facilitator manual.
32956409|NCT05433415|Active Comparator|Daughters-Only Comparison Condition (DOCC)|The DOCC runs parallel to the BGM intervention and includes daughters-only group meetings. The DOCC incorporates all components of BGM except Family Systems Theory strategies. Daughters in DOCC will receive PA and diet behavior content based on Anti-Racist Public Health Critical Race Praxis and Social Cognitive Theory with daughter-only group activities. DOCC facilitators will lead group meetings and discussions. All DOCC daughters will self-monitor their progress towards PA goals using Fitbit® and progress towards diet goals using Start Simple with My Plate®.
32956410|NCT05431777||Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma who were treated with avelumab as first-line maintenance therapy
32956411|NCT05426200|Experimental|Health Coaching|Patient will work with a health coach to improve self-management skills, and receive usual pre-transplant education.
32956412|NCT05426200|No Intervention|Control|Patients will receive usual pre-transplant education.
32956413|NCT05410366||Emergency department (ED) patients|Adult emergency department patients presenting with a chief complaint of 1) low back pain, 2) headache, or 3) minor head injury.
32956414|NCT05407376|Active Comparator|Intervention- High Dose|Participation will last approximately 6 months. Participants enrolled in the high-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study.
32956415|NCT05407376|Active Comparator|Intervention-Low Dose|Participation will last approximately 6 months. Participants enrolled in the low-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study. The amount of produce provided in this arm will be lower per month per household size than the high dose arm.
32956416|NCT05407376|No Intervention|Usual Care|Participation will last approximately 6 months. Participants enrolled in the Usual Care arm will complete 3 questionnaires and collection of the HbA1c at the end of study.
33103124|NCT02116335|Experimental|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
33103125|NCT02116335|Placebo Comparator|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
32898544|NCT00004660|Experimental|Radiotherapy|
32898545|NCT00004660|Sham Comparator|Sham treatment|
32898546|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
32898547|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
32898548|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
32898549|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
32898550|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
32898551|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
32898552|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
32898553|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
32898554|NCT01341067||Basal insulin, approved oral medications|
32898555|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
32898556|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
32898557|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
32898558|NCT00005446||Postmenopausal women with coronary heart disease|
32898559|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
32898560|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
32898561|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
32898562|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
32898563|NCT01273207|Experimental|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
32898564|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
32898565|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
32898566|NCT01342549|Active Comparator|Arm 1|sodium valproate
32898567|NCT01342549|Active Comparator|Arm 2|naltrexone
32898568|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
32898569|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
32898570|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
32898571|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
32898572|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
32898573|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
32898574|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
32898575|NCT01345513||Solid Tumor Cancer|
32898576|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
33103126|NCT05469776|Experimental|bicruciate-retaining total knee arthroplasty|The prosthesis is minimally constrained and allows the preservation of both cruciate ligaments. All implants are cemented.
33103127|NCT05469776|Active Comparator|posterior-stabilized total knee arthroplasty|The prosthesis requires the excision of both cruciate ligaments
33103128|NCT05469659|Experimental|Tofogliflozin|
32834316|NCT05715970|Experimental|General population|25,000 subjects, divided between Sicily and Malta. Approximately 10,000 students aged between 12 and 18 will be enrolled in Malta and approximately 15,000 adults (>18 years) will be enrolled in Sicily. These numbers are dictated by the need to obtain heterogeneous samples comparable with the subjects diagnosed in the previous ITAMA project (20,000). In Sicily, screening will be carried out in the GPs (Italian takers) clinics. In Malta the recruitment will be performed in the schools (Maltese takers). Furthermore, in Malta, a further extension of the results provides for the execution of the PoCT+questionnaire in the asymptomatic first-degree relatives of the pediatric subjects with an ascertained diagnosis of CD identified in the previous project.
32834317|NCT04745494|Active Comparator|OT administration|All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.
32834318|NCT04745494|Placebo Comparator|Placebo administration|All participants will receive a single dose of a placebo delivered via a nasal spray.
32834319|NCT05552950|Experimental|experimental group|Individuals using the BioBlock® antiviral nasal spray immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
32834320|NCT05552950|Placebo Comparator|control group|Placebo is used by individuals immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
32834321|NCT05551936|Experimental|Investigational Group|"Phase 1:~90 mg/m^2 of bendamustine by IV on Day 1 and 2 of a 28 day cycle (up to 3 Cycles)~375 mg/m^2 of rituximab by IV on Day 1 of a 28 day cycle (up to 3 Cycles)~Participants enrolled in this phase will be given one of 3 different dose levels of tazemetostat along with the drugs above (for up to 3 Cycles). 3 patients will be assigned to the lowest dose level and if the dose is tolerated, 3 more patients will be enrolled one dose level higher. Up to 18 participants being enrolled.~Dose Level 1: 400 mg of tazemetostat orally twice daily~Dose Level 2: 600 mg of tazemetostat orally twice daily~Dose Level 3: 800 mg of tazemetostat orally twice daily~Phase 2:~6 patients from Phase 1 who were treated at the recommended Phase 2 dose will be added to 21 additional patients.~375 mg/m^2 of rituximab through IV on Day 1 of a 28 day cycle (Cycles 1-6)~Tazemetostat orally twice daily of a 28 day cycle (Cycles 1-6)"
32834322|NCT05715814|Experimental|Empagliflozin|
32834323|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
32834324|NCT05547100|Experimental|5mg OLZAPINE /10mg SAMIDORPHAN|Open label, single dose 5mg OLZ/10 mg SAM
32834325|NCT05335876|Experimental|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec|Patients who received OAV101 IT or OAV101 IV in AveXis/ Novartis or Novartis Gene Therapies Phase I to IIIb clinical trials
32834326|NCT00109473|Experimental|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
32834327|NCT00109473|Active Comparator|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
32834328|NCT04344106|Experimental|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
32834329|NCT05326282|Experimental|Multi-parametric and micro ultrasound|Transrectal ultrasound imaging in men with suspected or known low grade prostate cancer using both standard and micro-ultrasound technology
32834330|NCT05136976|Placebo Comparator|Placebo|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
32834331|NCT05136976|Active Comparator|Rituximab|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
32834332|NCT00040443|Experimental|CX516|CX516 - 900 mg
32834333|NCT00040443|Placebo Comparator|Placebo|Placebo
32834334|NCT05321992|No Intervention|Usual Care Community|Participants in this arm will not be given the eCHEC program
32834335|NCT05321992|Active Comparator|eCHEC Community|Participants in this arm will be given the eCHEC program as their intervention
32834336|NCT05136430|Experimental|Self-Regulation strategies + large changes (SR)|This arm will receive the Self-Regulation strategies + large changes (SR) intervention followed by smoking cessation treatment
32834337|NCT05136430|Active Comparator|Healthy Lifestyle Education (LE)|This arm will receive the healthy Lifestyle Education (LE) intervention followed by smoking cessation treatment
32834338|NCT00044655|Active Comparator|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
32898577|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
32898578|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
32898579|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
32898580|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
32898581|NCT01295515|Experimental|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
32834339|NCT00044655|Active Comparator|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
32834340|NCT05130892|Experimental|Colchicine group|1 tablet (0.5mg) / time, once a day
32834341|NCT05130892|Experimental|Tranilast group|1 capsule (0.1g) / time, 3 times a day;
32834342|NCT05130892|Experimental|Oridonin group|2 tablets (0.5g) / time, 3 times a day
32834343|NCT05130892|No Intervention|Non-intervention group|
32834344|NCT05442424|Experimental|Produce Vouchers|Half of parent-child dyads will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market.
32834345|NCT05442424|Active Comparator|Wait-List Control|Half of parent-child dyads will be placed on a 6 month wait list and will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market, after completing the 6 month waiting period and follow up data collection.
33405467|NCT01375803|Experimental|2|6g/day
32834347|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
32834348|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
32834349|NCT05130346|Experimental|Mindfulness Based Stress Reduction (MBSR)|
32834350|NCT05130346|No Intervention|Standard of Care (SOC)|
33405468|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
32834353|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
32834354|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
32834355|NCT05533060||TBI group|patients with traumatic brain injury (TBI) treated surgically
32834356|NCT05533060||RN group|relatively normal (RN) participants including patients with other brain diseases, for example, gliomas, meningiomas, and schwannomas, treated surgically
32834357|NCT05532904|Other|Intervention|"This 6-week program of care will include:~group education sessions including a psycho-education component (1 session / week)~a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
32834358|NCT05532904|No Intervention|Control|Usual care (waiting list)
32834359|NCT05312242|Active Comparator|IFA + Standard of Care|Iron and Folic Acid (IFA) tablets dispensed 30 tablets at a time + standard of care [Represents standard of care comparison]
32834360|NCT05312242|Experimental|MMS 30 + novel counseling|MMS dispensed 30 tablets at a time (MMS 30) with novel counseling
32834361|NCT05312242|Experimental|MMS 180 + novel counseling|MMS dispensed 180 tablets at a time (MMS 30) with novel counseling
32834362|NCT00223665|Experimental|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
32834363|NCT05311540|Experimental|Zinc intervention|9 mg/day Zinc suspension via og tube along with the routinely used standard multivitamin product containing 3 mg daily dose of Zn, started on day 7 until discharge from hospital
32834364|NCT05311540|No Intervention|Control|These infants received only standard commercial multivitamin product containing 3 mg daily dose of Zn
32834365|NCT05122390|Experimental|Contraction Coper|The digital application Contraction Coper is provided from pregnancy week 25. The application contains two different modules. One is an informational module about the method (about 60 minutes), the other is a contraction module to be used in early labour (in total 6 hours).
32834366|NCT05122390|Active Comparator|Contraction Coper Plus|The digital application Contraction Coper with additionally support from a midwife in two different occasions during pregnancy.
32834367|NCT05122390|No Intervention|Control|Conventional antenatal care.
32834368|NCT00223821|Active Comparator|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
32834369|NCT00223821|Experimental|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
32834370|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
32834371|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
32834372|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
32834373|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
32834374|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
32834375|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
32834376|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
32834377|NCT00224289|Other|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
32834378|NCT05117476|Experimental|Module A Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619
32834379|NCT05117476|Experimental|Module A Cohort Expansion|Patients with select solid tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module A Escalation arm
33103129|NCT05469659|Active Comparator|Metformin|
33103130|NCT04686006||Graves disease|
33103131|NCT05469620|No Intervention|Control|Receive usual care.
33103132|NCT05469620|Experimental|Education|Receive nutrition education.
33103133|NCT05469620|Experimental|Meal|Receive meal kit.
33103134|NCT05469620|Experimental|Education and Meal|Receive both nutrition education and meal kit.
33103135|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
33103136|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
32746919|NCT03321747|Experimental|Phase 1/Dose Level 3|13 Gy will be given in 5 fractions for a total dose of 65 Gy
32746920|NCT03321747|Experimental|Phase 1/Dose Level 4|14 Gy will be given in 5 fractions for a total dose of 70 Gy
33326903|NCT01283568||3- Gamaline- control - fertile women|
32746921|NCT03321747|Experimental|Phase 2|The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
33326904|NCT01283568||4 - Gamaline control - climateric women|
33326905|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
32746922|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
32746923|NCT03285789|Experimental|Dyslexics with normal visual attention span|
32746924|NCT03285789|Active Comparator|controls|
32746925|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
32746926|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
32746927|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
32746928|NCT05549817|Experimental|Synchronous Telerehabilitation Group|The exercise program was applied to groups that include three participants of the synchronous group 3 days per week by video conference method on an online platform (Zoom) with the supervision of a physiotherapist. The time of the group session was organized according to the availability of participants in that group and the physiotherapist using shared calendar availability (Doodle). The physiotherapist sent a reminder to participants one hour prior to each session including the video conference meeting link. Each exercise session lasted approximately 40 minutes. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist demonstrated the exercises as needed, supervised the group by giving real-time feedback, and progressed the exercise program according to the needs of each group.
32746929|NCT05549817|Active Comparator|Asynchronous Telerehabilitation Group|The exercise program was prescribed and followed up 3 days per week via the mobile application (FizyoTr). A notification was sent to participants' phones via mobile application prior to each session and attendance to the exercise program was recorded. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist progressed the exercise program according to the assessment at 4 weeks and the needs of each participant.
32746930|NCT04741282|Experimental|pulmonary telerehabilitation plus progressive muscle relaxation training|This group will perform six week pulmonary rehabilitation program and progressive muscle relaxation exercise at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
32746931|NCT04741282|Active Comparator|pulmonary telerehabilitation|This group will perform six week pulmonary rehabilitation program at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
32746932|NCT05549583|Experimental|Reference group|Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature
32746933|NCT05549583|Experimental|Test group|Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature
32746934|NCT05554809|Experimental|Dynamic stretching|
32746935|NCT05554809|Experimental|Static stretching|
32746936|NCT05554809|Active Comparator|Controll|
32746937|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
32746938|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
32746939|NCT05549505|Experimental|ARV-471 monotherapy|ARV-471 taken once daily until surgical resection
32746940|NCT05549505|Active Comparator|Anastrozole monotherapy|Anastrozole 1mg taken once daily until surgical resection
32746941|NCT05554731|Experimental|New balloon catheter for Endotracheal hemostasis + Traditional Therapy|"Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~Balloon closure after informed consent (it can be blocked in emergency);~CTA (can be performed as an emergency prior to balloon blockage);~Artery interventional therapy (if necessary);~Surgery (if needed)."
32746942|NCT05554731|Active Comparator|Traditional Therapy|"Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~CTA (can be performed as an emergency prior to balloon blockage);~Artery interventional therapy (if necessary);~Surgery (if needed)."
32746943|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
32956417|NCT05406817|Experimental|SNDX-5613|"Participants will be administered a single dose of SNDX-5613 (containing ~100 microcuries [14C]-SNDX-5613) in the AME part of the study.~Each dose administered after the first dose in the AME part of the study will be nonradiolabeled SNDX-5613. SNDX-5613 may continue to be administered following completion of the AME part of the study. Doses will be administered in continuous 28-day cycles until either PD or unacceptable toxicity."
32956418|NCT05405166|Experimental|Isatuximab Subcutaneous (SC)|Isatuximab dose will be administered SC weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days in duration. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days).
32956419|NCT05405166|Active Comparator|Isatuximab Intravenous (IV)|Isatuximab dose will be administered via IV infusion weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days).
32956420|NCT05403853|Experimental|Monitoring of Diabetes Mellitus|Venous blood draw of up to 24ml and up to 4 fingersticks
32746944|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
32956421|NCT05398263|Experimental|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.
33326906|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
32956422|NCT05398263|Placebo Comparator|Placebo|Placebo subcutaneous injection, in an accessorised pre-filled syringe.
32956424|NCT05386277|Other|LeMaitre TufTex Single Lumen Embolectomy Catheter|The LeMaitre® Single Lumen Embolectomy Catheter is a catheter that consists of a natural latex rubber balloon secured with ligatures to a single lumen radiopaque shaft. When the balloon the emboli and/or thrombi can be removed by withdrawing the catheter tip through the arteriotomy.
32956425|NCT05384405|Active Comparator|active stimulation|Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
32956426|NCT05384405|Sham Comparator|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
32956427|NCT05378386||TPVR|Transcatheter Pulmonary Valve Replacement
32956428|NCT05372614|Experimental|Treatment (neratinib, trastuzumab deruxtecan)|Patients receive neratinib PO QD on days 1-21 (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD study) of each cycle and trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32956429|NCT05368246|Experimental|Interventional arm|Electrical stimulation to the dorsal genital nerve.
32956430|NCT05361668|Experimental|40 mg Paltusotine|
32956431|NCT05361668|Experimental|80 mg Paltusotine|
32956432|NCT05355818|Experimental|Delgocitinib cream|Delgocitinib cream 20 mg/g twice daily
32956433|NCT05355818|Placebo Comparator|Cream vehicle|Cream vehicle twice daily
32956434|NCT05348876|Experimental|Darolutamide (BAY1841788)|Participants with high-risk nmCRPC will receive darolutamide.
32956435|NCT05348577|Experimental|capivasertib + docetaxel|Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.
32956436|NCT05348577|Placebo Comparator|placebo + docetaxel|Participants receive placebo in combination with docetaxel and steroids on a background of ADT.
32956437|NCT05338125|Experimental|Intervention arm|Patients undergoing the extra intra-operative electrophysiological measurement
32956438|NCT05335772|Experimental|VR-AOT|Experimental group, observing actions in virtual reality
32956439|NCT05335772|Other|VR-LO|Control group, observing a matched dose of videos depicting landscapes in virtual reality
32956440|NCT05327647|Experimental|Bicalutamide|Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days
32956441|NCT05327647|Active Comparator|Control Arm|Induction intravesical Bacille Calmette-Guérin treatment
32956442|NCT05324033||muscle invasive cancer bladder|
32956443|NCT05324033||non-muscle invasive cancer bladder|
32956444|NCT05321342|Experimental|Intervention group|This group will receive Professional Development and Coaching (CCU)
32956445|NCT05321342|No Intervention|Control group|Business as usual
32956446|NCT05320380|Experimental|Cohort 1 (IMGN632)|Patients receive IMGN632 IV on days 1 and 22. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32956447|NCT05320380|Experimental|Cohort 2 (IMGN632, CPX-351, ITT, fludarabine, cytarabine)|"CYCLE 1: Patients receive IMGN632 IV on days 1 and 22 and CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients with CNS1 also receive ITT consisting of methotrexate IT, hydrocortisone or prednisolone IT, and cytarabine IT on day 0 of cycle 1 (NOTE: Patients who received IT cytarabine or ITT at time of diagnostic LP do not need to repeat ITT on day 0 if given within 7 days of starting protocol therapy). Patients with CNS2 receive ITT QW until the CSF is clear for a maximum of 6 ITT treatments in the absence of disease progression or unacceptable toxicity.~CYCLE 2: Patients receive ITT on day 0, IMGN632 IV on days 1 and 22, fludarabine IV over 30 minutes QD on days 1-5, and cytarabine IV over 1-3 hours QD on days 1-5 in the absence of disease progression or unacceptable toxicity."
32956448|NCT05320380|Active Comparator|Cohort 3, Arm A (CPX-351, fludarabine, cytarabine)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2 and cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2 in the absence of disease progression or unacceptable toxicity.
33326907|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
33326908|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
32746945|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
33326909|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
33326910|NCT01587066|Active Comparator|Quetiapine fumarate|
33326911|NCT01587066|Active Comparator|Divalproex sodium|
33326912|NCT03873948||Control|Healthy patients
33326913|NCT03873948||Periodontitis|Patients with periodontal disease
32746946|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
32746947|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
32746948|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
32746949|NCT05554653|Active Comparator|Leucine enriched essential amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
32746950|NCT05554653|Placebo Comparator|Carbohdyrate Placebo|Iso-caloric placebo (4g maltodextrin to replace LEAA). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
32746951|NCT05554575|Experimental|BT-007 CD7 CAR-T cells in R/R T-LBL|Subjects will receive BT-007 CD7 CAR-T cells infusion on Day 0 : 100% of total dose.
32746952|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
32746953|NCT02153229|Experimental|patients who undergo RP alone|
32746954|NCT05549349||Cholecystectomy during hospitalization|In this group, patients will have their cholecystectomy during the initial hospitalization. We will look at the mode of feeding between the biliary crisis and the cholecystectomy.
32746955|NCT05549349||Delayed cholecystectomy|In this group, patients will have their cholecystectomy deferred from their initial hospitalization for various reasons. They will be seen again 3 months after leaving hospital. They will or will not have been cholecystectomized during this interval. Their mode of feeding as well as biliary events will be studied.
32746956|NCT01318317|Experimental|Treatment (cellular adoptive immunotherapy following PBSCT)|Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with G-CSF and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplant. Patients receive standard myeloablative conditioning followed by autologous PBSCT. Patients then undergo infusion of ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR on day 2 or 3 after transplant.
32746957|NCT05549271||Obese patients who underwent a Laparoscopic One Anastomosis Gastric Bypass (OAGB) 5 years ago|Patients (BMI > or = 35kg/m2 +/- co-morbidities) who have been operated on using the Gastric bypass procedure built with an Omega loop of 200 cm and a unique gastro-jejunal anastomosis
32746958|NCT05549271||Obese patients who underwent a Laparoscopic Roux-en-Y Gastric ByPass (RYGBP) 5 years ago|Patients (BMI > or = 35kg/m2 +/- co-morbidities) who have been operated on using the Roux-en-Y gastric bypass which consists in a small gastric pouch (30cc), a 150cm alimentary limb and a 50cm biliary limb. Mesenteric defects were closed.
32746959|NCT05549193|Experimental|Mild and Moderate-Severe Urinary Incontinence Group|10 sets of pelvic floor muscle training and 2 sets of abdominal muscle strengthening training were given every day for 6 weeks. All analyzes were conducted at the beginning and end of the 6-week training. The same training program was applied to both groups ( Group 1 (mild urinary incontinence) and Group 2 (moderate-severe urinary incontinence), and the effects were compared according to the severity of incontinence.
32746960|NCT05700201|Experimental|Intervention|Healthy lifestyle intervention
32746961|NCT05700201|Experimental|Control|Standard care (psychotherapy)
32746962|NCT05700903|Active Comparator|Prostate Cancer|Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer
32746963|NCT05700903|Active Comparator|Healthy + ADT|Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks
32746964|NCT05700903|Placebo Comparator|Healthy + Placebo|Healthy men undergoing placebo for 9 weeks.
32746965|NCT04426227|Experimental|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
32746966|NCT04426227|Active Comparator|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
32746967|NCT05554185|Experimental|group A|aspirin 100mg and probiotics 1 bag
32746968|NCT05554185|Placebo Comparator|group B|aspirin 100mg and placebo1 bag
32746969|NCT05554029|Experimental|Study group|Patients with rheumatic diseases
32746970|NCT05548959|Experimental|Microshunt patients|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous microshunt implantation.
32746971|NCT05548959|Experimental|Ab interno trabeculectomy patientes|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous ab interno trabeculectomy.
32746972|NCT05558631||Residents of the municipality of Leiria aged 18 years or more.|
32746973|NCT05553951|Experimental|Interventions group|will receive systematic and structured nursing supervison about their adherence
32746974|NCT05553951|Placebo Comparator|Control group|Will receive usual care
32746975|NCT05558475|Experimental|Digital CBTi with Coaching|coaching integrated with Digital CBTi to increase engagement/adherence
32746976|NCT05558475|No Intervention|Digital CBTi without Coaching (+ initial contact)|The control will be an enhanced treatment as usual condition where participants will receive: 1) provider referral to Digital CBTi; 2) initial enrollment contact and 3) NO virtual coaching contacts. If subjects have a question or need technical support, they will be instructed to contact study staff for assistance.
32746977|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
32746978|NCT04325841|Experimental|Autologous Murine Anti-CD19 CAR-T treatment|
32746979|NCT05558397|Active Comparator|Control Group (Oral Morphine)|The control group will be composed of 15 patients who will receive oral drug treatment according to the Clinical Protocol and Therapeutic Guidelines for Chronic Pain of the Brazilian Ministry of Health. The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients. The treatment will be carried out orally in a home environment.
32746980|NCT05558397|Experimental|Interventional Group (Epidural morphine)|The intervention group will be composed of 15 patients who will undergo a surgical procedure for subcutaneous implantation of a catheter (Celsite ST304-19BBraun) that allows epidural administration of morphine and ropivacaine drugs. The treatment plan for such patients includes Patient Controlled Analgesia (PCA). Patients in this group will receive, via catheter, an anesthetic solution containing 2.0 mL of morphine (1.0 mg/mL), 3.0 mL of ropivacaine (7.5 mg/mL) and 5.0 mL of distilled water. For 24 hours after this application, if the patient continues to have pain, they may use a rescue dose of oral morphine of 10 mg.
32746981|NCT05558319|Active Comparator|Control arm (A)|"INDUCTION: Isatuximab + VRD, 4 cycles. Isatuximab (IV) 10 mg/Kg, 1st cycle D: 1,8,15, 22. Cycles 2-4: D 1,15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: Isatuximab + VRD, 2 cycles. Isatuximab (IV) 10 mg/Kg. D 1-15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~CONTINUOUS TREATMENT: Lenalidomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
32746982|NCT05558319|Experimental|EXPERIMENTAL ARM (B): Extended VRD and Early Rescue Intervention|"INDUCTION: Includes two experimental lines:~VRD extended to 18 cycles: Induction (VRDx6): Bortezomib (SC) 1.3 mg/m2, D: 1, 4, 8, and 11 (Q4W). Lenalidomide 25 mg (PO), D: 1-21 (Q4W). Dexamethasone 40 mg (PO) D 1 to 4 and 9 to 12 (Q4W). Isatuximab (IV) 10 mg/kg, D: 1, 8, 15, and 22 (Q4W) and D: 1-15 in subsequent cycles.~Early detection of treatment failure and Early Rescue Intervention (ERI): Isatuximab-Iberdomide-Dexamethasone in continuous treatment. Isatuximab (IV) 10mg/kg Cycle 1: Days 1, 8, 15, and 22 (Q4W). Cycles 2 onwards: Days 1 and 15 (Q4W). Isatuximab will be infused monthly after 1 year treatment (Day 1 Q4W) including ASCT. Iberdomide (PO) 1,6 mg. D: 1-21 (Q4W). Dexamethasone (PO) 40 mg. D: 1, 8, 15, and 22 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2. CONSOLIDATION (VRDx2)- Extended VRD: VDx10, followed by lenalidomide plus dexamethasone maintenance.~CONTINUOUS TREATMENT: Lenalidomide 15 mg, D: 1-21, and dexamethasone 20 mg, D: 1-4 (Q4W)."
32746983|NCT05558319|Experimental|EXPLORATORY ARM (C)|"INDUCTION: Iberdomide plus Isatuximab, bortezomib and dexamethasone (four cycles). Isatuximab (IV) 10 mg/kg D 1, 8, 15, and 22 in the first Q4W; and days 1-15 in subsequent cycles. Iberdomide (PO) at 1.6 mg on days 1-21 of every 4-week cycle. Bortezomib (SC) at 1.3 mg/m2 on days 1, 4, 8, and 11 of every 4-week cycle. Dexamethasone 40 mg (PO) D 1-4, 9-12 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: two cycles (Q4W) of Isatuximab, Iberdomide, Bortezomib and Dexamethasone, as in induction, starting approximately 2 months after hospital discharge or 3 months after transplantation. Isatuximab will be infused monthly since the start of continuous therapy (after the second cycle of consolidation).~CONTINUOUS TREATMENT: Iberdomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
32746984|NCT05700825|Active Comparator|In-person|
32746985|NCT05700825|Experimental|Telehealth|
32746986|NCT05700513|Active Comparator|Intervention arm|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
32746987|NCT05700513|Placebo Comparator|Control arm|Placebo capsules containing maltodextrin
32746988|NCT05543343|Experimental|Ntaphylococcus albicans tablets|Participants received High-dose Staphylococcus albicans tablets (0.3 mg/tablet, 8 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days) or Normal-doseStaphylococcus albicans tablets (0.3 mg/tablet, 4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days)+ placebo (4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
32746989|NCT05543343|Placebo Comparator|Placebo|Participants received placebo (8 tablets each time, 3 times a day, Shandong Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
32746990|NCT05548647|Active Comparator|Behavioral Treatment + Placebo|Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo
32746991|NCT05548647|Active Comparator|Behavioral Treatment + Medication|Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide
32746992|NCT05699031|Experimental|APP-GROUP|Patients allocated in the app-group will use the app to rehabilitate.
32746993|NCT05699031|Active Comparator|PHYSIO-GROUP|Patients allocated in the physio-group will rehabilitate according to the usual care protocol
32746994|NCT05553717|Active Comparator|group 1|33 patients who will receive aspirin 150mg + carvedilol 12.5mg twice daily plus other traditional therapy of ischemia for three months.
32834380|NCT05117476|Experimental|Module B Combination Therapy Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 in combination with pembrolizumab
32834381|NCT05117476|Experimental|Module B Combination Therapy Cohort Expansion|Patients with select tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab
32834382|NCT01897623|Other|ultrasound of aorta|
32834383|NCT00045435|Experimental|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
32834384|NCT05529706|Experimental|Brain Health Program|A multimodal educational and interactive diet, exercise and computerized cognitive exercise public health program.
32834385|NCT05529238|Other|supervised group during study|monthly physiotherapist appointment for half of the cohort including pelvic floor examination by physiotherapist including digital palpation and perineometry.
32834386|NCT05529238|No Intervention|unsupervised group during study|No intervention. Participants to practice kegel exercises at home.
32834387|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
32834388|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
32834389|NCT05113342|Experimental|Arm 1: Dose Level 1|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
32834390|NCT05113342|Experimental|Arm 2: Dose Level 2|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
32834391|NCT05113342|Experimental|Arm 3: Dose Level 3|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
32834392|NCT05113342|Experimental|Arm 4: Dose Expansion|In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.
32834393|NCT00047619|Experimental|Pulsatile lavage group|pulsatile lavage therapy
32834394|NCT00047619|Sham Comparator|Sham lavage group|sham pulsatile lavage
32834395|NCT05304442|Experimental|Intravenous Ferric Derisomaltose|One single dose of ferric derisomaltose, 1000 mg Intravenous over at least 20 minutes.
32834396|NCT05304442|Active Comparator|Oral Iron|ferrous sulfate 65 mg once daily for 42 days.
32834397|NCT05102188||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
32834398|NCT05292820||Transwomen vaginoplasty|Transgender women who underwent vaginoplasty
32834399|NCT00111657|Experimental|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study."
32834400|NCT05292586|Experimental|CHF 1535 pMDI|CHF 1535 pMDI 800/24µg TDD
32834401|NCT05292586|Active Comparator|CHF 718 pMDI|CHF 718 pMDI 800µg TDD
32834402|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
32834403|NCT00703326|Experimental|ramucirumab (IMC-1121B) + docetaxel|
32834404|NCT00703326|Placebo Comparator|placebo + docetaxel|
32834405|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
32834406|NCT05521360|Experimental|Experimental|Participants randomized to the experimental group will complete baseline assessments, the 6 week AMT treatment online and then complete the follow up assessment (8 weeks total)
32834407|NCT05521360|No Intervention|Control|Participants randomized to the control group will be matched to the experimental group on demographic and outcome measures. Control participants will take the baseline assessments, will wait 7 weeks and take the follow-up assessment (8 weeks total). Control group participants are able to enrol in the AMT intervention at the end of their wait-list control period.
32834408|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
32834409|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
32834410|NCT05513950|Experimental|Test Treatment|A single intravenous (IV) dose of CHF10067
32834411|NCT05513950|Placebo Comparator|Reference treatment|A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)
32834412|NCT05513560|Experimental|IBUDILAST|Participants will receive 20 mg dose (2 pills) twice per day taken by mouth.
32834413|NCT05513560|Experimental|PENTOXIFYLLINE|Participants will receive a 400mg dose (1 pill) 3 times per day taken by mouth.
33326914|NCT03873948||Cardiovascular|Patients with cardiovascular disease
32956449|NCT05320380|Experimental|Cohort 3, Arm B (CPX-351, fludarabine, cytarabine, IMGN632)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 and IMGN632 IV on days 1 and 22 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2, cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2, and IMGN632 IV on days 1 and 22 of cycle 2 in the absence of disease progression or unacceptable toxicity.
32956450|NCT05319925||Study 1|"Initial examination of the developed questionnaire in the first 100 participants to identify problematic questions and to optimise the instrument.~To evaluate test-retest reliability, collected data of the first 100 patients will be used as baseline value and re-assessed in Study 2."
32956451|NCT05319925||Study 2|"Second examination in 300 additional participants and re-assessment in participants from Study 1 (n=400) to validate modified questionnaire in its final form.~To evaluate test-retest reliability, data of Study 1 is compared against Study 2 of the same participant sample (n=100)."
32956452|NCT05315570|Experimental|Intervention arm|Study participants will be followed up as per clinical practice and will receive the investigational electronic platform, including an Android-based app. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
32956453|NCT05315570|No Intervention|Control arm|No specific mobile apps will be provided to study participants, who will be followed as per clinical practice. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
32956454|NCT05315310|Experimental|REAL Training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
32956455|NCT05307679|Experimental|Basmisanil|Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of the trial on Day 365.
32956456|NCT05307679|Placebo Comparator|Placebo|Participants will receive oral placebo BID on the first day of treatment, then TID until the end of the trial on Day 365.
32956457|NCT05303532|Experimental|Durvalumab|Participants will receive durvalumab.
32956458|NCT05303467|Experimental|Treatment|The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
32956459|NCT05302375|Experimental|iPath*D|An online platform that connects patients screening positive for clinically significant depression in cancer settings to a range of online and inperson evidence-based treatments, facilitated by an interactive DA.
32956460|NCT05300464|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
32956461|NCT05297565|Experimental|Part 1 Arm A: Subcutaneous Nivolumab|
32956462|NCT05297565|Active Comparator|Part 1 Arm B: Intravenous Nivolumab|
32956463|NCT05297565|Experimental|Part 2: Subcutaneous Nivolumab|
32956464|NCT05296798|Other|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|
32956465|NCT05296798|Active Comparator|Arm A, Maintenance Therapy: Phesgo|
32956466|NCT05296798|Experimental|Arm B, Maintenance Therapy: Giredestrant plus Phesgo|
33318907|NCT03976193|Active Comparator|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
33318908|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:~NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)~RightEye's eye-tracking battery~Highmark Interactive's EQ application~Cambridge Brain Science's neuropsychological tests"
32956469|NCT05294718|Active Comparator|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
32956470|NCT05294718|Active Comparator|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
32956471|NCT05288595|Experimental|Pediatric patients with malignant or non-malignant hematologic condition|The infusion of the final TCRαβ/CD19 depleted product will be given through the recipient's central venous catheter and will be administered fresh, without cryopreservation whenever possible. If the product must be cryopreserved and then thawed, this will be done according to institutional standards.
33318909|NCT03741803|Active Comparator|Delayed cord clamping|
33318910|NCT03741803|Active Comparator|Early cord clamping|
33318911|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
33318912|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
33318913|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
33318914|NCT00266825|Experimental|DHA capsules|DHA capsules
33318915|NCT00266825|Placebo Comparator|Placebo capsules|Placebo capsule
33318916|NCT03976037|Active Comparator|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
33103137|NCT01808820|Experimental|Safety Pilot: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of leukapheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Enrollment of participants in the Pilot group will be staggered until the second participant has no treatment limiting toxicities. For the first five subjects to be enrolled in the pilot, the administration of DC to each subject will be delayed until the prior subject has received the second administration of DC. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
32834414|NCT05513560|Placebo Comparator|PLACEBO|Participants will receive 2 placebo pills twice per day taken by mouth OR 1 placebo pill 3 times a day taken by mouth.
33103138|NCT01808820|Experimental|Expansion Cohort: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis within after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of pheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
33103139|NCT05469386|Placebo Comparator|Placebo|Placebo capsule administered in the morning
33103140|NCT05469386|Experimental|Methylphenidate ER (.3 mg/kg dose)|Methylphenidate ER (.3 mg/kg dose)administered in the morning
33103141|NCT05469386|Active Comparator|General Classroom|General classroom procedures
33103142|NCT05469386|Experimental|Positive Behavior Support Classroom|Positive Behavior Support Classroom procedures
33103143|NCT05469386|Experimental|Academic accommodations|Academic accommodations are used during seat work and quiz
33103144|NCT05469347|Experimental|Alirocumab|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive alirocumab.
33103145|NCT05469347|Placebo Comparator|Placebo|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive a placebo to match alirocumab.
33103146|NCT01468896|Experimental|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
33103147|NCT05469230||Typically developed children group|Typically developed children will be from both genders. the age range will be (8-16) years old and will be recruited from public governmental schools
33103148|NCT05469230||Beta thalassemia group|children diagnosed with beta thalassemia major and intermedia will be recruited from Abo-El-Rish Pediatric Hospital. the age will be (8-16) years and will be from both genders
33405469|NCT04560075|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
32834415|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
32834416|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
32834417|NCT04752423||PATIENT group|Adult patients shedule for general anesthesia
32834418|NCT04752423||NURSE group|Nurse anesthesist in charge of the corresponding patient
32834419|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
32834420|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
32834421|NCT05101720|Experimental|Ultrasound Guided Axillary Access|Direct visualization of axillary vein with ultrasound will be obtained and used as a guidance for venous puncture.
32834422|NCT05101720|Active Comparator|Fluoroscopic Guided Axillary Access|Standard technique: using the intersection of the lateral borders of the second and third rib as a radiological landmarks.
32834423|NCT00047697|Experimental|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
32834424|NCT00047697|Placebo Comparator|Placebo|Placebo
32834425|NCT05094154|Active Comparator|anti-pseudomonal cephalosporin|Participants in the anti-pseudomonal cephalosporin arm will receive at least one dose of an anti-pseudomonal cephalosporin.
32834426|NCT05094154|Active Comparator|anti-pseudomonal penicillin|Participants in the anti-pseudomonal penicillin arm will receive at least one dose of an anti-pseudomonal penicillin.
32834427|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
32834428|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
32834429|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
32834430|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
32834431|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
32834432|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
33318917|NCT03976037|Active Comparator|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
33318918|NCT00265889|Experimental|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
33318919|NCT00265889|Experimental|Good Risk|First recurrence patients
33326915|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
32956472|NCT05275543|Experimental|Physical and Occupational Therapy with Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions with Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
32956473|NCT05275543|No Intervention|Physical and Occupational Therapy without Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions without Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
32956474|NCT05275543|Experimental|Parents/Guardians of Hospitalized Children who use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with Paro Robot"
32956475|NCT05275543|No Intervention|Parents/Guardians of Hospitalized Children who do not use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with out Paro Robot"
32834435|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
32834436|NCT00112125|Experimental|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
32834437|NCT00112125|No Intervention|Optimal medical treatment|Treatment with optimal medical therapy only.
32834438|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
32834439|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)~The regimen will be administered as a dose dense schedule."
32834440|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
32834441|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
32834442|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
32834443|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
32834444|NCT04528719|Experimental|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
32834445|NCT04528719|Experimental|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
32834446|NCT04528719|Experimental|Cohort 3: Dose B in Younger Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
32834447|NCT04528719|Experimental|Cohort 4: Dose C in Younger Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
32834448|NCT04528719|Experimental|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
32834449|NCT04528719|Experimental|Cohort 6: Dose G in Children|Three total injections, 1 injection of either Dose G of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
32834450|NCT04528719|Experimental|Cohort 7: Dose A in Older Adults|Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
32834451|NCT04528719|Experimental|Cohort 8: Dose B in Older Adults|Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
32956476|NCT05269953|Experimental|Active stimulation|
32956477|NCT05269953|Sham Comparator|Sham stimulation|
32956478|NCT05269953|No Intervention|Waitlist (no stimulation)|Treatment as usual
32956479|NCT05268939|Experimental|Nasal Swab|Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
32956480|NCT05268939|Experimental|Nasopharyngeal Swab|Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
32956481|NCT05265845|Experimental|Intervention|Interactive text messages that include goal setting, tailored feedback, and skills training.
32956482|NCT05265845|Active Comparator|Control|Text4Baby
32956483|NCT05263908||PAXLOVID PACK|Subjects administered PAXLOVID PACK
32956484|NCT05259527|Experimental|Vitamin D Replacement|Participants will receive prescribed oral vitamin D2 to achieve a serum vitamin D level between 30 ng/mL to 50 ng/mL.
32956485|NCT05259527|Active Comparator|Standard of Care|Participants will receive standard-of-care advice to take over the counter vitamin D.
32956488|NCT05256641|Experimental|Group I (acalabrutinib)|Beginning day 90, patients receive acalabrutinib PO QD and then PO BID once no longer on prophylactic antifungal (CYP34A inhibitors) until day 365 in the absence of disease progression or unacceptable toxicity.
32834452|NCT04528719|Experimental|Cohort 9: Dose C in Older Adults|Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
32834453|NCT04528719|Experimental|Cohort 10: Dose E in Older Adults|Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
32834454|NCT04528719|Experimental|Cohort 11: Dose F in Older Adults|Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
32834455|NCT04528719|Experimental|Cohort 12: Dose E in Women of Child-Bearing Potential|Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.
32834456|NCT04528719|Experimental|Cohort 13: Dose F in Women of Child-Bearing Potential|Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.
32834457|NCT04528719|Experimental|Cohort 14: Dose A in Women of Child-Bearing Potential|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
32834458|NCT04528719|Experimental|Cohort 15: Dose B in Japanese Older Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
32834459|NCT05085886|Experimental|DepCare Intervention|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers in the intervention arm will receive education and decisional support for optimizing mental health treatment and access to quality improvement/implementation meetings. Eligible patients will receive a tool that facilitates enhanced screening, diagnosis recognition, treatment selection support, psychoeducation, and activation.
32834460|NCT05085886|Active Comparator|Enhanced Usual Care|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers and patients in the active comparator arm will have access to this clinic-level strategy (i.e., the same clinic level intervention as in the DepCare group), but will not receive any provider or patient-level interventions.
32834461|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
32834462|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
32834463|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
32834464|NCT05500222|Active Comparator|Resmetirom|80 mg daily
32834465|NCT05500222|Placebo Comparator|Placebo|matching placebo daily
32834466|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
32834467|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
32834468|NCT05083468|Experimental|SR750 tablet|Ascending single and multiple doses of SR750 tablets orally
32834469|NCT05083468|Placebo Comparator|matching placebo|Ascending single and multiple doses of matching placebo orally
32834470|NCT00112593|Experimental|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
32834471|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
32834472|NCT05280106|Experimental|Pre-dilution online hemodiafiltration|The study was conducted for a 28-week period in two phases: For the first 12 weeks, all of the patients were subjected to CD with pre-dilution oL-HDF.After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. The second phase will run after finishing the first phase with the same protocol but with post-dilution online HDF.There will be 2 weeks washout period before starting this phase
32834473|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
32834474|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
32834475|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
32834476|NCT00112671|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32834477|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
32834478|NCT05279092|Active Comparator|Bupivacaine-Liposomal Bupivacaine (B-LB)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an Interspace between the popliteal artery and capsule of the posterior knee (iPACK) block.
32834479|NCT05279092|Experimental|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
32834480|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy~J44 : end of the radiochemotherapy~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
32834481|NCT05273632|Active Comparator|Oxytocin|Pre- Operative Oxytocin is given intravenously 5-10 minutes slowly before skin incision
32834482|NCT05273632|Active Comparator|Tranexamic acid and Etamsylate|Tranexamic acid and Etamsylate are slowly given intravenously 10 minutes before start of Cesarean Delivery
32834483|NCT05273632|Placebo Comparator|Saline|Normal saline (about 200 ml) is given intravenously 10 minutes before start of Cesarean Section
32834484|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
32834485|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
32834486|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
32834487|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
32834488|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
33103149|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
33103150|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
33103151|NCT05469152|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
32834489|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
32834490|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
32834491|NCT05075746||enVista Toric 0.9D intra ocular lens|
33103152|NCT01410825|Experimental|Gene transfer|Open label single arm study
33103153|NCT05469113|Experimental|Repaglinide - Period 1|Single dose of repaglinide administered orally.
33103154|NCT05469113|Experimental|Selpercatinib and repaglinide - Period 2|"Multiple doses of selpercatinib along with single dose of repaglinide administered orally.~There will be a 24-hour washout period between Period 1 and 2."
33103155|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
33103156|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
32834492|NCT05075746||enVista non-Toric (spherical) intra ocular lens|
32834493|NCT05269966|Experimental|Brolucizumab|"Brolucizumab, formerly known as ESBA1008, is a humanized single-chain Fv (scFv) antibody fragment.~Its Intravitreal injections.~Brolucizumab 6 mg will be administered by IVT injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients will receive loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) will be performed based on BCVA and OCT to assess whether the patient will require q8w or q12w dosing."
32834494|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
32834495|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
32834496|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
32834497|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
32834498|NCT05494996||Questionnaires assessed partners|"≥18 years old;~Participants who are married or in a romantic relationship;~Be able to read and communicate in Chinese."
32834499|NCT05075278|Active Comparator|Attending physician for direct 1:1 supervision|Participants will be assigned to an attending physician for direct 1:1 supervision. The participants will fill out a survey at the end of the day for 16 consecutive days.
32834500|NCT05075278|Experimental|Senior resident for direct 1:1 supervision|Participants will be assigned to an senior resident as a direct supervisor with oversight from an attending physician (in accordance with CMS/ACGME staffing criteria). The participants will fill out a survey at the end of the day for 16 consecutive days.
32834501|NCT02429466|Experimental|Guadecitabine (SGI-110)|
32834502|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
32834503|NCT03184896||Hip Fracture|
32834504|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
32834505|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
33326916|NCT01587144|Placebo Comparator|Placebo|Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
32834507|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
32834508|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
32834509|NCT04343950|Experimental|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
32834510|NCT04343950|Active Comparator|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
32834511|NCT04343950|Experimental|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
32834512|NCT04343950|Active Comparator|Usual Care 2: No intervention|No reminders will be sent.
32834513|NCT04343950|Experimental|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
32834514|NCT04343950|Active Comparator|Usual Care 3: Invitation letter|Letter invitations will be sent.
32834515|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
32834516|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
32834517|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
32834518|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
32834519|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
32834520|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
32834521|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
32746995|NCT05553717|No Intervention|group 2 control|33 patients who will receive aspirin 150mg + Captopril 12.5mg twice daily plus other traditional therapy of ischemia for three months.
32746996|NCT05543031|Experimental|Study group|"There are 9 (35,8%) female and 14 (64,2%) male preschool cochlear implant users in the study group.~Children ranging in age from 5 to 7 who also have 5-6 years old language skills."
32746997|NCT05543031|Experimental|Control group|"There are 9 (35.8%) female and 14 (64,2%) male preschool children with normal hearing in the control group.~Children ranging in age from 5 to 6 who also have age-appropriate language skills."
32746998|NCT05700435|Experimental|Randomization|At two study sites, we will randomly assign participants to the VTC/in-person group or CBT group using a ratio of 2:1 to assign participants to the VTC/in-person or CBT training modalities. We anticipate 84 participants (42 per site) will be assigned to the CBT modality and 168 (84 per site) will be assigned to the VTC/in-person modality.
32746999|NCT05700435|Active Comparator|Self-selection|At two study sites, participants will be able to self-select which SMART training modality they will complete (VTC/in-person or CBT).We aim to recruit 250 participants in the self-selection arm.
32747000|NCT05553483|Experimental|pranayama and acupoint stimulation by laser|"for 6 weeks,This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) will be (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama)"
32747001|NCT05553483|Active Comparator|acupoint stimulation by laser|for six weeks, This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints. The stimulated bilateral points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
32747002|NCT05542953|Experimental|Alzheimer's Disease|AD subjects will undergo PET imaging using [18F]APN-1607.
32747003|NCT05542953|Experimental|Mild Cognitive Impairment Due to Alzheimer's Disease|MCI subjects will undergo PET imaging using [18F]APN-1607.
32747004|NCT05542953|Experimental|Healthy Volunteers|Healthy control subjects will undergo PET imaging using [18F]APN-1607.
32747005|NCT05553327|No Intervention|Control|
32747006|NCT05553327|Experimental|Multimodal prehabilitation|
32747007|NCT05542875|Experimental|Group A (Thrust Manipulation)|Participants will be randomly allocated to Group A which will recieve Thrust manipulation treatment in addition to standard treatment protocol. Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants for 4 sessions on alternate days
32747008|NCT05542875|Experimental|Group B (Non-Thrust Manipulation)|Participants will be randomly allocated to group B which, in addition to standard treatment protocol, will recieve Maitland grade III or IV manipulation from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Participants will recieve 4 sessions on alternate days
32747009|NCT05700123||Video|
32747010|NCT05700123||Music|
32747011|NCT05700123||Vocal-Local|
32747012|NCT05542797|Experimental|Micronised progesterone|Micronized progesterone will be given to 70 pregnant women with threated miscarriage.
32747013|NCT05542797|Experimental|Dydrogesterone|Dydrogesterone will be given to 70 pregnant women with threated miscarriage.
32747014|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
32747015|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
32747016|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
32747017|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
32747018|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
32747019|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
32747020|NCT04320849||Patients with Biotronik Leads|"Patients with these models: LSiello S, Solia S~Description: Active Fixation Leads"
32747021|NCT04320849||Patients with Boston Scientific Leads|"Patients with these models: 4452, 4453, 4456, 4457~Description: FINELINE II/FINELINE II Sterox Passive Fixation (polyurethane)~Boston Scientific 4463, 4464, 4465, 4469, 4470, 4471 FINELINE II/FINELINE II Sterox EZ Positive Fixation (polyurethane)"
32747022|NCT04320849||Patients with Abbott Leads|"Patients with these models: LDA 210Q~Description: Optisure Single Coil Defibrillation Lead"
32747023|NCT04320849||Patients with Medtronic Leads|"Patients with these model: 6935M~Description:Quattro Secure Single Coil Defibrillation Lead"
32747024|NCT05553093|Experimental|Tirzepatide|Tirzepatide 5、10、15mg
32747025|NCT05553093|Active Comparator|Insulin Glargine|Insulin Glargine 6 international unit (IU)
32747026|NCT05553015||PH Patients receiving treprostinil sodium treatment|Patients with pulmonary hypertension receiving treprostinil sodium treatment
32747027|NCT05542719||frequency of dyslipidemias|To describe the frequency of dyslipidemias in high-risk and very high-risk patients with atherosclerotic cardiovascular disease and analyze the impact of using an application to achieve dyslipidemia treatment goals at one-year follow-up.
32956489|NCT05256641|Experimental|Group II (acalabrutinib)|Beginning day 60, patients receive acalabrutinib PO QD and then PO BID from day 74 if there are no dose reductions until day 365 in the absence of disease progression or unacceptable toxicity.
33103158|NCT05469074|Active Comparator|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
32747028|NCT04757740|Active Comparator|Platelet rich fibrin Group|Platelet rich fibrin. Group P
32956490|NCT05256641|Experimental|Group III (acalabrutinib)|Beginning anytime between days 28-104, patients receive acalabrutinib PO BID until day 365 in the absence of disease progression or unacceptable toxicity.
32956491|NCT05251363|Other|Solia S LBB lead|
32747029|NCT04757740|Active Comparator|Methylprednisolone acetate|Group S
32747030|NCT05552937|Experimental|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
32956492|NCT05249543|Experimental|Unified protocol|Transdiagnostic cognitive-behavioral therapy focusing on emotional processes central to the development and maintenance of anxiety disorders, particularly neuroticism.
32747031|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
32747032|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
32747033|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
32747034|NCT04739722|Experimental|ColonoSight Test|All participants will be evaluated with the Colonosight Test system and a colonoscopy.
32747035|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
32747036|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
32747037|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
32747038|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
32747039|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
32747040|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
32747041|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
32747042|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
32747043|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
32747044|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
32747045|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
32747046|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
32747047|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
32747048|NCT05134792|No Intervention|No intravenous immunoglobulin (IVIG)|The control group are burn patients with inclusion criteria that did not receive IVIG.
32747049|NCT05134792|Experimental|Intravenous immunoglobulin (IVIG) group|Pediatric burn patients between 1and 5 years with 10% or greater burn area of TBSA within 24 hours of onset of burn will receive intravenous immunoglobulin.
32747050|NCT04738318|Experimental|Treatment Arm (Glucocorticoid)|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.
32747051|NCT04738318|Placebo Comparator|Control Arm (Placebo)|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
32747052|NCT05177692|Active Comparator|Intervention group - Vguard|Intervention group will be fitted with a Vguard system Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
32747053|NCT05177692|No Intervention|Control group - regular intra-ventricular drainage|Control group will be fitted with a standard system for drainage of ventricular fluid Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
32747054|NCT04737850|Experimental|PartA, open-label|Hetrombopag plus standard of care
32747055|NCT04737850|Experimental|PartB, double-blind treatment group|Hetrombopag plus standard of care
32747056|NCT04737850|Placebo Comparator|Placebo Comparator|Placebo plus standard of care Part B, double-blind treatment group
32747057|NCT04751656|Experimental|Steady Intervention|Participants asked to engage in Steady Intervention for 12 months
32747058|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
32747059|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
32747060|NCT04751422||Observational (data collection)|Patients' medical data is collected retrospectively.
32747061|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
33405470|NCT04560075|Active Comparator|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
33405471|NCT04812171||smoker participants|"Current cigarette smokers older than 18 years, without previously reported systemic disease, not taking medications influencing imunological system or bone metabolism.~Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment."
32834522|NCT05246098||Adults|Adult survivors of severe acute respiratory syndrome (SARS) SARS-CoV-2 disease admitted to participating ICUs. Adults are defined as adults as greater than or equal to, 18 years old. We will include adults with a confirmed diagnosis of COVID-19.
33405472|NCT04812171||non-smoker participants|Healthy non-smokers paired with smoker group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
32834523|NCT05246098||Pediatrics|Pediatric survivors of severe SARS-CoV-2 disease admitted to participating pediatric intensive care units (PICUs). The investigators define children as less than 18 years old. We will include pediatric patients with COVID-19 and those with multi-system inflammatory syndrome in children (MIS-C).
32834524|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
32834525|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
32834526|NCT05064358|Experimental|Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1|
32834527|NCT05064358|Experimental|Cohort 2: Participants receiving belantamab mafodotin at DL 2|
32834528|NCT05064358|Experimental|Cohort 3: Participants receiving belantamab mafodotin at DL 3|
32834529|NCT05064358|Experimental|Cohort 4: Participants receiving belantamab mafodotin at DL 4|
32834530|NCT05064358|Experimental|Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification|
32834531|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
32834532|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
32834533|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
32834534|NCT03189654||Control group|Oxygen Administration via nasal tube
32834535|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
32834536|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
32834537|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
32834538|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
32834539|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
32834540|NCT05057728|Experimental|Intervention group (SEP+)|SEP+ is designed as a multi-focused (child, teacher, parent) school-based intervention, which can be employed as either a universal (i.e. targeting all children) or an indicated prevention program (i.e. targeting specifically children at risk for behavior problems). The SEP+ intervention comprises three types of intervention: 1) the classroom-based intervention in the form of a curriculum of 43 activities (2-3 activities/week) delivered over 4-months aimed at developing social-emotional skills; 2) a 6-sessions (2-2.5h/session) teacher training focused on increasing the use of positive discipline strategies and developing coaching skills for supporting children's social-emotional learning; and 3) a 6 sessions parent training (1.5.-2h/session) aiming to teach ways to manage parenting stress, to increase parent-child quality time, support children's emotion regulation and problem-solving, as well as increase positive discipline strategies.
32834541|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
32834542|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
32834543|NCT02433600|Active Comparator|Cow's milk-based infant formula|
32834544|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
32834545|NCT05243056|Experimental|Arm I (Y-AMBIENT)|Patients receive three themed education sessions over 1 hour each, written materials, and videos at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss how they are doing and discuss any concerns that they are still managing at months 2, 3, and 4.
32834546|NCT05243056|Active Comparator|Arm II (enhanced usual care)|Patients receive usual care at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss their chemotherapy regimen at months 2, 3, and 4.
32834547|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
32898582|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
32834548|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
32834549|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
32834550|NCT05242822|Experimental|Part A - dose escalation|Dose escalation of KIN-3248 in patients with solid tumors
32834551|NCT05242822|Experimental|Part B - dose expansion|Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A
32834552|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
32834553|NCT05235334|Experimental|Device user|Participant will engage in treatment with the MySOLIUS device, twice per week for 16 weeks
32834554|NCT05232994|Experimental|combination metformin and esomeprazole|Combination 2 g of oral extended release metformin, in divided doses and Esomeprazole 20mg daily until delivery.
32834555|NCT05232994|No Intervention|expectant management|
32834556|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:~Post-operative nausea and vomiting~Chemotherapy-induced nausea and vomiting"
32834557|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:~Hyperemesis gravidarum~Post-operative nausea and vomiting"
32834558|NCT05231044|Experimental|KX01 Ointment 1%|KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp
32834559|NCT05231044|Placebo Comparator|Placebo|Vehicle Ointment is applied topically once daily for 5 consecutive days on face or scalp
32834560|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
32834561|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
32834562|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
32834563|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
32834564|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
32834565|NCT05466214|Experimental|CBC Treatment Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will use the CBC model to do so.
32834566|NCT05466214|No Intervention|Control Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will engage in business as usual.
32834567|NCT05464186|Experimental|Whole milk|3 cups a day of whole milk for 1 year
32834568|NCT05464186|Experimental|Nonfat milk|3 cups a day of nonfat milk for 1 year
32834569|NCT05459584|Experimental|Experimental: Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
32834570|NCT05459584|No Intervention|No Intervention: Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
32834571|NCT05451004|Experimental|Lympathic Mapping with SPECT-CT guided Radiotherapy|
32834572|NCT05451004|Active Comparator|Bilateral Neck Radiotherapy|
32834573|NCT05222308|Other|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
32834574|NCT05050942|Experimental|CAM2029|
32834575|NCT05050942|Active Comparator|Octreotide LAR or lanreotide ATG|
32834576|NCT05049460|Active Comparator|Active intervention|Four sessions of theta burst stimulation, amounting to 7200 pulses at 120% resting motor threshold. Targeting will be done using neuronavigation and processed resting state brain scan.
32834577|NCT05049460|Placebo Comparator|Sham TMS|Four sessions of sham TMS. Targeting will be done using neuronavigation and processed resting state brain scan.
32834578|NCT05445544||Pregnant women and Follow-up of pregnant women's newborns|The pregnant woman is pregnant until she gives birth. The fecal ,serum,saliva,urine,vaginal secretions,umbilical cord blood,placenta and amniotic fluids who are were caesarean delivered will be collected
32834579|NCT05039554|Active Comparator|acceptance and commitment therapy (ACT) alone|Participants randomized to this cohort will receive only acceptance and commitment therapy.
32834580|NCT05039554|Active Comparator|Valera smartphone application (app) alone|Participants randomized to this cohort will receive the Valera app and will receive a smartphone with network connectivity if necessary.
32747062|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
32747063|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
32834581|NCT05039554|Experimental|ACT + Valera app|Participants randomized to this cohort will receive both ACT and the Valera app (and a smartphone with network connectivity if necessary).
32834582|NCT05039554|Placebo Comparator|treatment as usual (TAU)|Participants randomized to this cohort will not receive any experimental treatments.
32834583|NCT05218018|Other|Intervention|Only one arm of study
32834584|NCT05030428|Experimental|Inclisiran sodium|Subcutaneous injection
32834585|NCT05030428|Placebo Comparator|Placebo|Subcutaneous injection
32834586|NCT05429476|Experimental|Alteplase with standard therapy|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
32834587|NCT05429476|No Intervention|Standard therapy|Standard therapy
32834588|NCT05428384||mono arm|Each subject will have at baseline and at 3 month follow-up CardioMEMS readings paired with cardiac MRI scans and measurements completed for each subject will be under nominally the same conditions.
32834589|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
32834590|NCT05194462|Active Comparator|Pelvic Floor Physical Therapy (PFPT)|6 sessions of PFPT over a 12 week period with planned home exercises as per physical therapist's recommendation.
32834591|NCT05194462|Active Comparator|Biofeedback device|Pericoach® by Analytica is a vaginal device with recommendation for daily use during the 12 week period.
32834592|NCT05194462|Other|Comparator|Women who decline randomization but agree to participate in the comparator arm will be asked to complete the questionnaires at baseline, 3-months and 1-year. They will have no in-person follow up or intervention and will receive the usual postpartum care as determined by their obstetrician.
32834593|NCT05410132|Experimental|Internet-based mindfulness-based training group (iMBT)|"Participants in the iMBT group will be expected to complete an Internet-based mindfulness-based training delivered over a 6-week period via an internet e-learning mental health platform. They will be assessed at four different time points:~(1) before intervention (T0), (2) 2,4 weeks since the commencement of group (T1,2), (3) 6 weeks after (i.e., when the intervention ends) (T3), (4) at 3-month follow-up(T4)."
32834594|NCT05410132|No Intervention|Treatment-as-usual control group (TAU)|The TAU group will be advised to seek assistance from their usual healthcare provider when needed. They will be offered access to the Internet-based mindfulness-based course content after the study has ended.
32834595|NCT05001022|Experimental|ALG-020572|Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days
32834596|NCT05001022|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days
32834597|NCT04745416||Leukemia and COVID-19|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test
32834598|NCT04745416||Leukemia|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19
32834599|NCT04999696|Experimental|Laparoscopic radical hysterectomy|
32834600|NCT04999696|Active Comparator|Laparotomic radical hysterectomy|
32834601|NCT04995406||Active TB ATB|Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity
32834602|NCT04995406||Latent Tuberculosis Infections LTBI|Participants with presumed latent TB infection
32834603|NCT04995406||Healthy controls HC|Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study
32834604|NCT04995406||Non-tuberculous symptomatic participants|This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.
32834605|NCT05401084|Active Comparator|Carbohydrate|Counseling, education, and implementation of low carbohydrate diet.
32834606|NCT05401084|Active Comparator|Low gluten|Counseling, education, and implementation of low gluten diet.
32834607|NCT05401084|No Intervention|Standard|No change/intervention in diet. Continuation of standard diet.
32834608|NCT05169970|Experimental|Patients with low-intermediate risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions).
32834609|NCT05169970|Experimental|Patients with high risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions) with a boost of up to 45Gy to the dominant intraprostatic lesion as identified on pretreatment MRI plus hypofractionated pelvic EBRT (25Gy in 5 fractions).
32834610|NCT05168800|Experimental|Dialogue-Based Webinar|
32834611|NCT05168800|Experimental|Social Media Website|
32834612|NCT05168800|Active Comparator|Enhanced Usual Practice|
32834613|NCT04343794|Experimental|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
32834614|NCT04343794|No Intervention|Control|Usual standard care
32834615|NCT04993066|Experimental|Treatment Arm|All study subjects are to receive treatment with GentleMax Pro Plus device. Subjects will be scheduled to receive as little as one (1) and up to eight (8) treatments with the GentleMax Pro Plus™ Laser System. Up to 2 follow-ups will occur.
32834616|NCT04986358|Other|Patient cohorte|Cohort of patients who will benefit from surgical management of their Hallux Valgus with post-operative follow-up at 2 years
32956493|NCT05249543|Active Comparator|Diagnosis-specific cognitive-behavioral therapy|Cognitive-behavioral therapy specifically designed for a particular anxiety disorder as specified in evidence-based treatment protocols, which are commonly based on a specific theory or model of the development and maintenance of an anxiety disorder.
33318920|NCT02795182|Other|Zanubrutinib abd Tislelizumab|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tislelizumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
32956495|NCT05243342|Experimental|Dose escalation|Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD)
32956496|NCT05243342|Experimental|Dose expansion|Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D)
32956497|NCT05239741|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
32956498|NCT05239741|Active Comparator|Standard of Care Chemotherapy|Participants receive 1 of 6 possible standard chemotherapy regimens at the discretion of the investigator: (1) mFOLFOX6; (2) mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 14-day cycle (Q2W); (3) mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly Q2W; (4) FOLFIRI; (5) FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 Q2W; OR (6) FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly Q2W. Participants with documented disease progression following chemotherapy can receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
32956499|NCT05233033|Experimental|Phase 1a Dose Escalation|
32956500|NCT05233033|Experimental|Phase 1b Dose Expansion MYD88MT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 mutant DLBCL.
32956501|NCT05233033|Experimental|Phase 1b Dose Expansion MYD88WT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 wild type DLBCL.
32956502|NCT05228652||Affected Individuals|Virilised 46XX CAH individuals aged 16 years or above
32956503|NCT05228652||Parents of affected individuals|Parents of virilised 46XX CAH individuals aged 2 years and over.
32956504|NCT05226130|Active Comparator|Active cervical transcutaneous vagus nerve stimulation|Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
32956505|NCT05226130|Placebo Comparator|Sham cervical transcutaneous vagus nerve stimulation|Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
32956506|NCT05225103|Experimental|SAFETY-A Implementation Sites|New Brief Trauma-Informed Intervention (based on SAFETY-A) in addition to Enhanced Usual Care in Juvenile Detention Sites
32956507|NCT05225103|Experimental|Comparison Implementation Sites|Enhanced Usual Care in Juvenile Detention Facility
32956508|NCT05219916|Experimental|Adult patients infected by HIV, controlled under treatment.|Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.
32956509|NCT05219318|Experimental|Treatment pause|Treatment pause for 12 months
32956510|NCT05219318|Active Comparator|Treatment continuation|Treatment continuation regimens with PD-1/PD-L1 ICI + VEGFR-TKI until disease progression or unacceptable toxicity
32956511|NCT05215639||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
32956512|NCT05214534||Experimental|Retrospective analysis of the correlation between SuPAR measurement and patient outcome after hospitalization
32956513|NCT05207670|Experimental|Cohort A|Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.
32956514|NCT05207670|Experimental|Cohort B|Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
32956515|NCT05207670|Experimental|Cohort C|Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
32956516|NCT05207670|Experimental|Cohort D|Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
32956517|NCT05207670|Experimental|Cohort E|Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
32956518|NCT05204732|Experimental|Experimental group|"Speech training: 4 times 1 hour of intonation training for 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 2 postmeasurements)"
32956519|NCT05204732|Sham Comparator|Control group|"Speech training: : 4 times 1 hour sham therapy (info sessions + active intervention non-verbal communication) during 4 weeks + 4 times 1 hour intonation training during 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 3 postmeasurements)"
32956520|NCT05201456||Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite pressure monitoring single use flexible scope, real-time pressure monitoring technology, which will provide surgeons with intraluminal pressure data in the kidneys and ureter.
32956521|NCT05201456||Non-Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite Non-pressure monitoring single use flexible scope.
32956522|NCT05199584|Experimental|200 mg ENV-101|ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles
33318921|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
33318922|NCT01333774||Group 1|
33318923|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
32834617|NCT00360256||Control|
32834618|NCT00360256||Case group|
33103159|NCT05469074|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
33103160|NCT00594724|Experimental|1|
33103161|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
33103162|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
32834619|NCT05159908|Placebo Comparator|Placebo schedule|Participant follows Placebo schedule (13 weeks)
32834620|NCT05159908|Experimental|Dose schedule A|Participant follows Dose schedule A (13 weeks)
32834621|NCT05159908|Experimental|Dose schedule B|Participant follows Dose schedule B (13 weeks)
32834622|NCT05159908|Experimental|Dose schedule C|Participant follows Dose schedule C (13 weeks)
32834623|NCT05388214|Experimental|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
32834624|NCT04982224|Experimental|REGN5093-M114|
32834625|NCT00358852||Patients with Schizophrenia|
32834626|NCT05383456||Study Participants|Waist and hip circumferences, CT Scan and FibroScan and Quality of Life questionnaire, vital signs, urine and blood testing in Adults with HIV on continuous Anti-Retroviral Therapy treatment.
32834627|NCT05383378|Experimental|si-544|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
32834628|NCT05383378|Placebo Comparator|Placebo|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
33103163|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
33103164|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
33103165|NCT00622921|Other|1|Couples-based behavioral psychotherapy
33103166|NCT05469035|Experimental|Experimental|Nurses in the experimental group participated in mobile-based video learning.
32834629|NCT05155852||Post-delivery preeclampsia patients|Women admitted to the high-risk unit(s) with elevated blood pressure and neurological symptoms, such as headache, after delivery.
32834630|NCT05008276||Youth with obesity and elevated HbA1c|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
32834631|NCT05008276||Healthy normal-weight controls|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
32834632|NCT04971772||"DCB (Legflow .035) group"|"treatment with Drug Coated Balloon angioplasty with the Legflow .035 Paclitaxel Balloon Dilatation catheter."
32834633|NCT04971772||POBA group|treatment with standard POBA (uncoated) angioplasty (type and brand at the physician's discretion)
32834634|NCT04877080|Experimental|Fast Dual CAR-T treatment|CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
32834635|NCT05448118|Experimental|Virtual POC Toxicology Testing|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
32834636|NCT05382286|Experimental|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab|"Participants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles~Pembrolizumab will be administered for a maximum of 35 cycles."
32834637|NCT05382286|Active Comparator|Pembrolizumab + Treatment of Physician's Choice (TPC)|"Participants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens:~Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of 28-day cycles~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of 28-day cycles~Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles"
32834638|NCT05381662|Experimental|Cohort 1|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia without Chemotherapy pretreatment
32834639|NCT05381662|Experimental|Cohort 2|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia with Chemotherapy pretreatment
32834640|NCT05380180|Experimental|OneClick Social Engagement Intervention Group|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8.
32834641|NCT05380180|Other|OneClick Social Engagement Waitlist Control Group|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension.
32834642|NCT04502446|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
32834643|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
32834644|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
33103167|NCT05469035|Active Comparator|Control|Nurses in the experimental group participated in face-to-face learning.
33103168|NCT02892526||Vital wounds|from abdominoplasty of alive persons
33103169|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
33103170|NCT00594763||TS|Women with Turner syndrome
33103171|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
33103172|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
32834645|NCT04492306|Active Comparator|3M single bond, etch and rinse adhesive|"O.I. will clean the labial surface of tooth with polishing paste and brush Roughening of the surface may be needed by diamond point The tooth will be isolated by rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 10 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist.~Apply 2 to 3 consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 40 s. Light curing of all resin materials was performed using a LED device (Bluephase 20i, Ivoclare Vivadent, Schaan, Liechtenstein) delivering 1100 mW/cm2."
32834646|NCT04492306|Experimental|DMSO pre-treatment before 3M single bond application|The same steps of the comparator group with additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 1% DMSO/H2O solutions on etched-dentin followed by blot drying until paper filters no longer absorbed liquids from the bonding surface by capillarity then apply adhesive.
32834647|NCT04486924|Experimental|Globe Mapping and Ablation System|
32834648|NCT04482400|Experimental|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
32834649|NCT04482400|Active Comparator|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
32834650|NCT04479514|Experimental|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
32834651|NCT04472338||Screening (biospecimen collection)|Participants undergo collection of blood and urine samples every 12 months, and when any biopsy occurs for up to 10 years, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.
32834652|NCT04469920|Experimental|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
32834653|NCT04469920|Experimental|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
32834654|NCT04469920|Experimental|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
32834655|NCT04469920|Experimental|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
32834656|NCT04469920|Experimental|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
32834657|NCT04469920|Experimental|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
32834658|NCT04469920|Experimental|Group 7- normal hepatic function|Subjects with normal hepatic function
32834659|NCT04469842|Experimental|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
32834660|NCT04469842|Active Comparator|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
32834661|NCT04868500|Experimental|Massachusetts General Hospital (MGH) Participants|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
32834662|NCT04868500|Experimental|Massachusetts General Hospital (MGH) Clinical Site Staff|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
32834663|NCT04864834|Experimental|SOK583A1 (40 mg/mL)|Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
32834664|NCT04864834|Active Comparator|Eylea EU (40 mg/mL)|"IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.~EU: European"
32834665|NCT04855240|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
32834666|NCT04855240|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
32834667|NCT04855240|Placebo Comparator|Placebo|Placebo
32834668|NCT04941898||TAK-660 15-50 international units per kilograms (IU/kg)|Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
32834671|NCT04842760||No platelet disorders or no HIT|Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.
32834672|NCT04842760||HIT patients with anti-PF4/H antibodies|patients with anti-PF4/H antibodies but for whom HIT was ruled out.
32834673|NCT04842760||platelet dysfunction or HIT|Patients with platelet dysfunction or suffering from HIT
32834674|NCT04468360|Experimental|IV Allopregnanolone (Allo) for Extinction Retention (Expt. 1)|Arm 1 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after completion of extinction training.
32956523|NCT05199584|Experimental|300 mg ENV-101|ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles
32834675|NCT04468360|Placebo Comparator|IV Placebo for Extinction Retention (Expt. 1)|Arm 2 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after completion of extinction training.
32834676|NCT04468360|Experimental|IV Allo for Reconsolidation Blockade (Expt. 2)|Arm 1 of Expt. 2 will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
32834677|NCT04468360|Placebo Comparator|IV Placebo for Reconsolidation Blockade (Expt. 2)|Arm 2 of Expt. 2 will include will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
32834678|NCT04454086|Experimental|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
32834679|NCT04932694|Experimental|Study group|Core stabilization exercises will be conducted for 8 weeks, 3 sessions per day at home, and exercises will be supervised remotly.
32834680|NCT04932694|No Intervention|Control group|No exercise will be given to the participants in the control group
32834681|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
33103173|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
33405473|NCT04812171||diabetic participants|Participants reporting diabetes melitus type II, having gycated hemoglobin test, not taking medications influencing imunological system or bone metabolism, non-smokers Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
33405474|NCT04812171||non-diabetic participants|Healthy non-smokers paired with diabetic group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
32834682|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
32834683|NCT04442464|Experimental|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
32834684|NCT04442464|No Intervention|Control Eye|Non-lens wearing eye
32834685|NCT04833010|Active Comparator|No cloth face mask|Cross-over randomization. Participants randomized to this arm will not wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
32834686|NCT04833010|Experimental|Cloth face mask|Cross-over randomization. Participants randomized to this arm will wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
32834687|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
32834688|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
32834689|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
32834690|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
32834691|NCT04907110|Experimental|Exercise + NR|Participants will be asked to take two pills of NR (250mg/pill) twice daily (a total of 4 pills/day; 1000mg/day), for 40 days. During days 17-38 of the NR intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of NR supplementation.
32834692|NCT04907110|Placebo Comparator|Exercise + Placebo|Participants will be asked to take two pills of placebo, twice daily (a total of 4 pills/day), for 40 days. During days 17-38 of the intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of the placebo supplementation.
32834693|NCT04807738|Active Comparator|"Neuroproprioceptive facilitation and inhibition"|"ARM 1 - Neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT), with former positive probative evidence on MS and are recommended for MS intervention."
32834694|NCT04807738|Experimental|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"ARM 2. Experimental group, neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) through virtual reality and software inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). We believe that the VR environment might lead to better results due to greater motivation effect, novelty effect, entertainment effect, as well as activating the reward system. We believe the VR might enhance the activation of mirror neurons, it might also activate proprioception. The present physiotherapist is to ensure proper execution of the tasks. The correlation of the two arms of the study should indicate, whether virtual reality and the software used are as effective, or more effective in sustaining the hand motor function and axial stability, than traditionally led therapy."
32834695|NCT04803058|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
32834696|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
32956524|NCT05198843|Experimental|Treatment (icosapent ethyl, dasatinib)|Patients receive icosapent ethyl PO BID and dasatinib PO QD in each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32956525|NCT05196035|Experimental|Finerenone (Kerendia, BAY94-8862)|Participants will receive finerenone treatment.
33318924|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
33318925|NCT01333930|Experimental|Test product (Active O2)|
33318926|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
33318927|NCT01334008|Other|Blood sampling|
33318928|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
33318929|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
33318930|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
33318931|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
33318932|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
33318933|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
33318934|NCT01334398||Initial Treatment Group|
33318935|NCT01334398||Deferred Treatment Group|
33318936|NCT03209362|Experimental|SI-613|
33318937|NCT03209362|Placebo Comparator|Placebo|
33318938|NCT05151406|Active Comparator|medical students|5th year undergraduate medical students
33318939|NCT05151406|Active Comparator|nursing students|4th year undergraduate nursing students
33318940|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
33318941|NCT02932462|Placebo Comparator|Placebo|Vehicle
33318942|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
33318943|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
33318944|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
33318945|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
33318946|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
33318947|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
33318948|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with or without
33318949|NCT03205150|Experimental|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
33318950|NCT03205150|Experimental|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
33318951|NCT03205150|Experimental|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
33318952|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
32956526|NCT05196035|Placebo Comparator|Placebo|Participants will receive placebo to finerenone.
32956527|NCT05192382|Experimental|Paltusotine|
33318953|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
33318954|NCT04936984|Experimental|Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
33318955|NCT04936984|Experimental|Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
33318956|NCT04936984|Experimental|Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
33318957|NCT04936984|Experimental|Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
32834697|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
32834698|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
32834699|NCT04394416|Experimental|Imatinib|Imatinib oral 400 mg daily for 14 days.
32834700|NCT04394416|Active Comparator|Placebo|Placebo oral for 14 days
32834701|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
32834702|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
32834703|NCT04887298|Experimental|Liposomal Annamycin (L-Annamycin)|
32834704|NCT04796506|Active Comparator|Exercise Group|PD participants randomized to progressive resistance training PRT) will have 12 weeks of supervised PRT 3 times per week. After the 1st 12 weeks, responders to PRT (increase in slow wave sleep) will continue PRT for an additional 12 weeks, non-responders to PRT will transition to endurance training (ET).
32834705|NCT04796506|Placebo Comparator|Delayed Exercise Group|PD participants randomized to the delayed exercise control group will not exercise for the 1st 12 weeks of the study. After the 1st 12 weeks, participants in the delayed exercise group will transition to PRT for the 2nd 12 weeks.
32834706|NCT04794634|Experimental|Alzheimer Disease|
32834707|NCT04794634|Experimental|Lewy body disease|
32834708|NCT04794634|Active Comparator|healthy patient|
32834709|NCT04792528|Experimental|One training period|One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
32834710|NCT04792528|Experimental|Two training periods|Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
32834711|NCT04792528|Active Comparator|Active control|The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
32834712|NCT04782232||Patients with failing/absence of the right heart|Patients with acute or chronic, conservatively uncontrollable heart failure of varying pathogenesis, graded as stage III or IV according to NYHA, with an anticipated need for short-term to long-term right ventricular or biventricular support.
33326917|NCT01587144|Active Comparator|Lucanthone|Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
33326918|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
32834715|NCT04388332||Retrospective|20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
32834716|NCT04388332||Prospective|20 patients who are receiving Tritanium C as standard of care.
32834717|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
32834718|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
32834719|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
32834720|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
32834721|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
32834722|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
32834723|NCT04360174|Experimental|OTX-TIC-Cohort 1|15 µg (formulation1) implant
32834724|NCT04360174|Experimental|OTX-TIC-Cohort 2|26 µg (formulation1) implant
32834725|NCT04360174|Experimental|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
32834726|NCT04360174|Experimental|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
32834727|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
32834728|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
32834729|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
32834730|NCT04360018|Active Comparator|arm one|participants receive alcohol beverage
32834731|NCT04360018|Placebo Comparator|arm two|Placebo
32834732|NCT04358224|Other|open-label|open-label
32834733|NCT04357132|Other|VR-Biofeedback|
32834734|NCT04357132|Other|VR-Distraction|
32834735|NCT04357054|Active Comparator|Normal uterus|Darwish test
32834736|NCT04357054|Active Comparator|Myomatous uterus|Darwish test
32834737|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
32834738|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
32956528|NCT05192382|Placebo Comparator|Placebo|
33318958|NCT04901416|Experimental|Experimental Arm|"Lymphodepleting (LD) chemotherapy will be administered daily for 3 days to all subjects prior to DVX201. Lymphodepleting chemotherapy will consist of the following:~Cyclophosphamide 300 mg/m2 IV over 30 to 60 minutes daily x 3 (day -5 to day - 3)~Fludarabine 30 mg/m2 IV over 30 minutes daily x 3 (day -5 to day -3)~Patients will receive DVX201 at one of 3 prespecified doses infused on day 0 and 7 (± 1 day) for 1 cycle."
32834739|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
32834740|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
32834741|NCT00112827|Experimental|Arm I|See Detailed Description
32834742|NCT04317040|Experimental|Efprezimod alfa|Participants receive single dose of 480 mg efprezimod alfa, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
32834743|NCT04317040|Placebo Comparator|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
32834744|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
32834745|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
33318959|NCT04886050|Active Comparator|LC350189 Formulation A (Tablet)|Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.
32834746|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
32834747|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
32834748|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
32834749|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
32834750|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
32834751|NCT04752345|Active Comparator|Control group|Pharmacoinvasive strategy, fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early invasive strategy (in case of successful fibrinolysis)
32834752|NCT04752345|Experimental|Experimental group|Reduced-dose fibrinolysis combined with immediate invasive therapy
32834753|NCT04314076|Active Comparator|Gait Training (GT) with Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS
32834754|NCT04314076|Other|Gait training (GT) without Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS
32834755|NCT04752111|Experimental|Group E (esmolol infusion)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
32834756|NCT04752111|Placebo Comparator|Group T (TAP block)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
32834757|NCT04343170|Placebo Comparator|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
32834758|NCT04343170|Experimental|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
32834759|NCT04313140|Experimental|Patient's Glioma grade|magnetic resonance spectroscopy
32834760|NCT04748770||patients with BMI≥30 kg/m2|
32834761|NCT04748770||patients with 25≤BMI≤30 kg/m2|
32834762|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
32834763|NCT00226239|Experimental|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m^2, on day 1, docetaxel 75 mg/m^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m^2 on day 1 and 250 mg/m^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m^2 and cetuximab 250 mg/m^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
32898583|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
32898584|NCT01277341|Experimental|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
32898585|NCT01277341|Experimental|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
32898586|NCT01277341|Experimental|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
32898587|NCT01277341|Placebo Comparator|Placebo|Placebo nasal spray
32898588|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
33318960|NCT04886050|Active Comparator|LC350189 Formulation B (Capsule)|Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.
33318961|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
32834771|NCT04033822|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the trial will not receive accelerated cholecystectomy surgery to correct cholecystitis. No services will be taken away but patients will continue with care as originally provided by the healthcare system.
32834772|NCT04033822|Experimental|FAST Intervention|Patients diagnosed with cholecystitis and randomized to the FAST intervention arm of the study will undergo surgery as soon as possible with a goal of surgery within 6 hours of diagnosis.
32834773|NCT04729972|Experimental|NT-501 CNTF Implant|Participants from the NTMT-01/02 Extenstion study or participants from the NTMT-03 study which received an implant Studies with a CNFT implant in one eye will receive an implant in the fellow eye
32834774|NCT00227019|Experimental|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
32834775|NCT04728412|Experimental|patients undergoing bronchoscopy under sedation with or at risk of respiratory failure|
32834776|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:~MycoF/lytic blood culture system~Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis~Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis~Histoplasma antigen in urine (HAg) LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
32834777|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:~CrAg LFA for cryptococcosis~HAg LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
32834778|NCT00113217|Experimental|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
32834779|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
32834780|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
32834781|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
32834782|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
32834783|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
32834784|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
32834785|NCT04718116|Active Comparator|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
32834786|NCT04718116|Active Comparator|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
32834787|NCT04718116|Active Comparator|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
32834788|NCT04429503|Active Comparator|aflibercept Q8|Administered every 8 weeks after a loading phase
32834789|NCT04429503|Experimental|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
32834790|NCT04429503|Experimental|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
32834791|NCT04717414|Experimental|Experimental Arm: Luspatercept (ACE-536)|Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)
32834792|NCT04717414|Placebo Comparator|Control Arm: Placebo|Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
32834793|NCT00115869|No Intervention|No-intervention control|
32834794|NCT00115869|Experimental|Social influences school-based smoking prevention curriculum|
32834795|NCT04250025|Experimental|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
32834796|NCT04250025|No Intervention|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
32834797|NCT04276792|Experimental|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
32834798|NCT04276792|Active Comparator|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
32834799|NCT00053703|Active Comparator|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
32834800|NCT00053703|Active Comparator|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
32834801|NCT00053703|Active Comparator|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
32834802|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
32834803|NCT04269772|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
32834804|NCT04269772|Other|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
32834805|NCT00231309|Other|single arm|
32834806|NCT04267120|Experimental|Lenvatinib + Pembrolizumab|"Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.~Subjects may be treated with pembrolizumab for a maximum of 35 cycles or approximately 2 years, but treatment with lenvatinib can continue beyond 2 years if the subject does not meet other treatment discontinuation criteria."
32834807|NCT00116337|Experimental|Expiratory Muscle Stimulator|Procedure/Surgery: spinal cord stimulation to restore cough
32834808|NCT04265872|Experimental|Bortezomib followed by pembro/cis|There is only one arm.
32834809|NCT04271709|Active Comparator|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
32834810|NCT04271709|Placebo Comparator|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
32834811|NCT04252846||Perampanel|Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
32834812|NCT00232479|Experimental|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
32834813|NCT04713202|Experimental|Telotristat Ethyl + PRRT|"Telotristat ethyl, 250 mg, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
32834814|NCT04713202|Placebo Comparator|Placebo + PRRT|"Placebo, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
32834815|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
32834816|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
32834817|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
32834818|NCT04710628|Experimental|PEMBROLIZUMAB + LENVATINIB|"Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted).~Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed"
32834819|NCT00233103|Experimental|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
32834820|NCT00233103|Placebo Comparator|Placebo|Placebo for 10 weeks.
32834821|NCT04000750|Experimental|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
32834822|NCT04000750|Active Comparator|Control|Participants will consume all calories within a ~12 hour window each day (4 separate meals + needed snacks).
32834823|NCT04704076|Experimental|Early, Small-Volume Supplementation (ESVS)|Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age
32834824|NCT04704076|Active Comparator|Exclusive Breastfeeding|Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications
32834825|NCT00117585|Other|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
32834826|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
32834827|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
32834828|NCT04685356|Experimental|IBAIP Group|Children benefiting from assessment and intervention providing by a healthcare professional (physiotherapist or psychomotor therapist) trained and certified for IBAIP. This care will take place upon discharge from the hospital at the rate of one session per month for 6 months. The sessions will take place in the presence of at least one of the parents and at home. These children will also benefit from standard follow-up (medical follow-up, paramedical or specialized medical support depending on the development and needs).
33318962|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
32834829|NCT04685356|Active Comparator|Control group|Children benefiting from standard care upon discharge from hospital with 1 medical consultation per month and, medical sepcialist and / or paramedical(physiotherapy, speech therapy, psychomotricity, etc.). consultations if indicated by the physician providing follow-up
32834830|NCT04246216|Experimental|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
32834831|NCT04246216|Active Comparator|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
32834832|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
32834833|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
32834834|NCT00118131|Experimental|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
32834835|NCT03997630|Experimental|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
32834836|NCT03997630|Active Comparator|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
32834837|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
32834838|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
32834839|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
32834840|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
32834841|NCT02436486|Placebo Comparator|Placebo|
32834842|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
32834843|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
32834844|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
32834845|NCT04342858|Other|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
32834846|NCT04342858|Active Comparator|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
32834847|NCT04342858|Experimental|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
32834848|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
32834849|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
32834850|NCT04243096|Experimental|Exercise-based Physical Therapy|12 week in-person exercise-based physical therapy
32834851|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
32834852|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
32834853|NCT04236544|Experimental|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access via a data-protected study platform (www.erecover.de) to PExMS and DECIMS-Wiki for a two-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
32834854|NCT04236544|Active Comparator|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a two-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
33103174|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
32834855|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
32834856|NCT04676854|Experimental|PRIMA Bionic Vision System|
32834857|NCT00255177|Placebo Comparator|Placebo|
33103175|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
33103176|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
33103177|NCT05471466|Active Comparator|Diathermy- Electrosurgical Unit Cutting Settings|One half of the neck incision in each participant was made using diathermy (electrosurgical unit cutting settings at 15 watts Blend One mode).
33103178|NCT05471466|Active Comparator|Scalpel- Surgical Blade|One half of the neck incision in each participant was made using a scalpel (size 10 surgical blade).
33318963|NCT04885036|Active Comparator|Treatment As Usual|This group will receive treatment as usual within the family unit
33405475|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
32834858|NCT00255177|Active Comparator|150 mg daily|
32834859|NCT00255177|Active Comparator|300mg daily|
32834860|NCT00255177|Active Comparator|300mg twice daily|
32834861|NCT04670224|Experimental|QLB technique|
32834862|NCT04670224|Active Comparator|Intravenous anesthesia without QLB|
32834863|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
32834864|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
32834865|NCT04223986|Other|Ultrasound and Troponin T|5 images transferred to cardiologist
32834866|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
32834867|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
32834868|NCT00361036|Experimental|1|BeadBlock treatment arm
32834869|NCT00361036|Active Comparator|2|Embospheres control arm
32834870|NCT03955432|Experimental|LINQ ICM|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.
32834871|NCT03952624||Control|FNS <= 3
32834872|NCT03952624||Fatigued|FNS >= 4
32834873|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
32834874|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
32834875|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
32834876|NCT04665856|Experimental|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
32834877|NCT04665856|Placebo Comparator|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
32834878|NCT04342936|Experimental|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
32834879|NCT04342936|Active Comparator|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
32834880|NCT04201288|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered in person at session 1 and by telephone at session 2.
32834881|NCT04201288|Placebo Comparator|Enhanced-Treatment-as-Usual (ETAU)|In addition to receiving treatment-as-usual at the clinic, ETAU participants will receive a 2-session program of HIV education.
32902884|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
33103179|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
33103180|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
33103181|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
33103182|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
33405476|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
33405477|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
32834882|NCT05442580|Experimental|Cohort A Dose Level 1: Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834883|NCT05442580|Experimental|Cohort A Dose Level -1 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level -1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834884|NCT05442580|Experimental|Cohort A Dose Level 2 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 2: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834885|NCT05442580|Experimental|Cohort A Dose Level 3 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 3: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834886|NCT05442580|Experimental|Cohort B Dose Level 1: Multiple Myeloma (MM)|Cohort B Dose Level 1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834887|NCT05442580|Experimental|Cohort B Dose Level -1: Multiple Myeloma (MM)|Cohort B Dose Level -1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834888|NCT05442580|Experimental|Cohort B Dose Level 2: Multiple Myeloma (MM)|Cohort B Dose Level 2 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834889|NCT05442580|Experimental|Cohort B Dose Level 3: Multiple Myeloma (MM)|Cohort B Dose Level 3 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
32834890|NCT03933826||Patients who have selected radical cystectomy|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected radical cystectomy as their second-line treatment
32834891|NCT03933826||Patients who have selected medical management|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected medical management as their second-line treatment
32834892|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
32834893|NCT03931174|Active Comparator|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
32834894|NCT03931174|Experimental|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
32834895|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
32834896|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
32834897|NCT03915496|Experimental|PF-04965842 200 mg|
32834898|NCT03915496|Experimental|PF-04965842 100 mg|
32834899|NCT03915496|Placebo Comparator|Placebo|
32902885|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
32902886|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
32907400|NCT04479761|Experimental|Virtual Reality|Participants will be wearing a virtual reality headset and observing 2 types of scenes: abstract (a display of stars) or contextual (a subway station).
32834900|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
32834901|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
32834902|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
32834903|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
32834904|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
32834905|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:~LunaRich X Capsules (12 capsules per day)~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
32834906|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
32834907|NCT02976766|Experimental|Gypenosides|
32834908|NCT02976766|Placebo Comparator|Placebo|
32834909|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
32834910|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
32834911|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
32834912|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
32834913|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
33103183|NCT05582590|Experimental|Cohort 1|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Day 1 of each cycle
33103184|NCT05582590|Experimental|Cohort 2|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Days 1 and 8 of each cycle
33405478|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
32834914|NCT04648930||Xolair|S.C. Injection
32834915|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
33103185|NCT05582590|Experimental|Cohort 3|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Days 1, 8, and 15 of each cycle
32834916|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
32834917|NCT04639336||Patients with Pompe disease|
32834918|NCT04638712|Other|Group 1 without trastuzumab|
32834919|NCT04638712|Other|Group 2 with trastuzumab|
32834920|NCT04178122|Experimental|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
32834921|NCT04178122|Experimental|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
32834922|NCT04177264|Experimental|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression [OA DC] and splenic lymphatic pump technique [SpLPT]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
32907401|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
32907402|NCT04365764||Not exposer to the treatment (control group)|
32907403|NCT04365686|Active Comparator|Group K|Ketofol group
33103186|NCT05582590|Experimental|Cohort 4|4 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Day 1, and 2 x 10^8 NEXI-003 T cells administered by intravenous infusion on Days 8 and 15 of each cycle
32834923|NCT04177264|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
33103187|NCT05582590|Experimental|Dose Expansion Stage|Dose Expansion Stage to further define the safety and clinical activity, and to confirm the recommended Phase 2 dose of the NEXI- 003 T cell product at the dose established from the Dose Escalation Stage.
33405479|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
33405482|NCT05760885|Experimental|Sensory Augmentation|Participants will receive sensory augmentation in the form of non-invasive vibration, while balance training is performed as described below.
32834924|NCT04177264|No Intervention|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
32834925|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
32834926|NCT01372410|Experimental|GSK573719|inhaled medication
32834927|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
32834928|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
33405483|NCT05760885|Active Comparator|Control|Participants will receive balance training, without any sensory augmentation.
32834929|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
32834930|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
32834931|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
32834932|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
32834933|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
32834934|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
32834935|NCT02428686|Experimental|epoetin beta|
32834936|NCT04342624|Experimental|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
32834937|NCT04342624|Placebo Comparator|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
32834938|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
32834939|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
32834940|NCT04624672|Placebo Comparator|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
32834941|NCT04624672|Active Comparator|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
32834942|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
32834943|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
32834944|NCT02975596|Other|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
32834945|NCT02975596|Other|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
32834946|NCT02975596|Other|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
32834947|NCT02975596|No Intervention|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
32834948|NCT02975596|No Intervention|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
32834949|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
32834950|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
32834951|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
32834952|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
32907404|NCT04365686|Active Comparator|Group P|propofol group
32956529|NCT05187533|Other|Mild dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
33103188|NCT05468879|Experimental|Glimepiride 3 mg Tablet|Participants received Glimepiride 3 mg Tablet with 240 mL of 20% glucose solution
33103189|NCT05468879|Active Comparator|Amaryl® 3 mg tablet|Participants received Amaryl® 3 mg tablet (Glimepiride 3 mg) with 240 mL of 20% glucose solution
33103190|NCT05577559|Active Comparator|Superficial cervical group|patients will receive bilateral ultrasound guided superficial cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
33103191|NCT05577559|Active Comparator|Erector spinae group|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
32834953|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
32834954|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
32834955|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
32834956|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
32834957|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
33103192|NCT05569915|Experimental|Trauma Expressive Writing|In the trauma condition, we ask participants to write about a traumatic experience, prompting them to write their very deepest thoughts and feelings about the most traumatic experience of their entire life or an extremely important stressful, upsetting, or emotional issue that has affected them.
33103193|NCT05569915|Experimental|Stigma Expressive Writing|In the stigma condition, we ask participants to write about an experience of stigma, prompting them to write about their very deepest thoughts and feelings about the most difficult or painful experience of stigma or bias (e.g., prejudice, bullying, rejection, discrimination) based on one or more of their identities (e.g., race/ethnicity, gender identity, sexual identity, religion) that they have faced.
33103194|NCT05569915|Placebo Comparator|Control|In the control condition, we ask participants to write about their day, prompting them to write about what they did yesterday from the time they got up until the time they went to bed.
33103195|NCT04320433|Experimental|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
33103196|NCT05471388|Active Comparator|case|
33103197|NCT05471388|Active Comparator|control|
33103198|NCT05558449|Active Comparator|VR|"Patients in the VR group (19 patients) will receive VR alone without hypnosedation. The VR headset will be used on these patients without an external voice or device allowing hypnosis. The VR module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
33103199|NCT05558449|Experimental|VRH|"The patients in the VRH group (19 patients) will benefit from a hypnosedation session with a VRH headset during the local anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
33103200|NCT05558449|Active Comparator|C|Patients in group C (control group, 19 patients) will receive only midazolam-based pharmacological sedation. This will be administered with intermittent boluses of 1 mg until patient comfort and sedation on the Richmond analgo-sedation scale (RASS) of -3 (response to verbal stimulus) is achieved.
33103201|NCT04326907|Experimental|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
33103202|NCT04326907|No Intervention|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
33103203|NCT05468801|Experimental|Individualized Homeopathic Remedy plus Standard Pharmacologic Treatment|Each subject receives an individually selected homeopathic remedy (individualized homeopathic remedy) as an add on to the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
33103204|NCT05468801|Placebo Comparator|Placebo plus Standard Pharmacologic Treatment|Subjects receive an indistinguishable placebo plus the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
33318964|NCT04885036|Experimental|EFST intervention|This group will receive an EFST stand alone treatment consisting of a two days EFST course and 6 individual parental guidance sessions
33318965|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
33318966|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
32834958|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
32834959|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
32834960|NCT04614610|Active Comparator|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
33318967|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
33318968|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
33318969|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
33318970|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
32834961|NCT04614610|Placebo Comparator|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
32834962|NCT04152772|Active Comparator|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
32834963|NCT04152772|Active Comparator|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
32834964|NCT04152772|Sham Comparator|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
32834965|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
32834966|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
32834967|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
32834968|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
32834969|NCT04343014|Experimental|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
33405484|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
33405485|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
32834970|NCT04343014|Active Comparator|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
32834971|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
32834972|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
32834973|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
32834974|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
32834975|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
32834976|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
32834977|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with possible endocrine conditions
32834978|NCT03184350|Other|Adjuvant pelvic proton radiation|
32834979|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
32834980|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
32834981|NCT04131166|Other|Metabolically healthy lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
32834982|NCT04131166|Experimental|Metabolically healthy obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
32834983|NCT04131166|Experimental|Metabolically healthy obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
32834984|NCT04131166|Experimental|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
32834985|NCT04131166|Experimental|Metabolically unhealthy obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
32834986|NCT04131166|Experimental|Metabolically unhealthy obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
32834987|NCT04131166|Experimental|Metabolically unhealthy obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
32834988|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
32834989|NCT04606576|Placebo Comparator|Placebo|Fish Oil
32834990|NCT04606576|Experimental|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
32834991|NCT04606576|Experimental|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
32834992|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
32834993|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
32956530|NCT05187533|Other|Moderate dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
32956531|NCT05187533|Other|Severe dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
32956532|NCT05187377|Experimental|Growth Hormone then Saline|12 weeks in each treatment phase (rhGH then placebo) and a four week wash-out period between phases.
32956533|NCT05187377|Placebo Comparator|Placebo (saline) then Growth Hormone|12 weeks in each treatment phase (placebo then rhGH) and a four week wash-out period between phases.
32956534|NCT05186818|Experimental|CK-3773274 up to 20 mg|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 24 weeks
32834994|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
32834995|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
32834996|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
32834997|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
32834998|NCT04121182|Experimental|Nursing home with On-line training|"25 randomized residents will be included by nursing home Half of the institutions (randomized too) will benefit from an on-line training on the prevention and management of resident lung diseases"
32834999|NCT04121182|Active Comparator|Nursing home with usual practice|This group of Institutions continue their usual practice (routine care) and will not benefit from training during the study period.
32835000|NCT04119544|Active Comparator|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
32835001|NCT04119544|Experimental|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
32835002|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
32835003|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
32835004|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
32835005|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
32835006|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
32835007|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
32835008|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
32835009|NCT04596202|Experimental|Supine Position|It is the supine position. The body parts of the patient stand as if the patient is standing upright. The head, neck and shoulders should be supported with a pillow placed under the head. Arms are aside and body muscles are relaxed. The upper arms should lie on both sides of the body, should slightly be moved away from the body and should be supported by a pillow.
32835010|NCT04596202|Experimental|Prone Position|It is the position where the patient lies face down with his/her head turned to the side. Arms are stretched to both sides of the head. The prone position (prone lying) is a relaxing and resting position.
32835011|NCT04596202|Experimental|Lateral position|Lateral position is the left or right lateral lying position. The lateral position is given to the patient to provide proper anatomical lying and to reduce lateral flexion of the back and the strain of the large back muscles. This position prevents pressure on the bones in the back.
32956535|NCT05186818|Placebo Comparator|Placebo to match CK-3773274|Patients will receive placebo for up to 24 weeks
32956536|NCT05177588|Experimental|Metformin|Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
32956537|NCT05177588|No Intervention|Standard of Care|Patients in the control arm will continue the SOC medications
32956538|NCT05174078|Experimental|Medically-Tailored Meals (MTM)|Medically-tailored meals delivered to participants' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
32956539|NCT05174078|Experimental|Produce Box and Recipes|Weekly produce box delivered to participants' homes and access to recipes via the internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
32956540|NCT05174078|No Intervention|Standard of Care|Matched controls from the same base population as participants in the intervention arms. Controls will identified from the electronic medical record (EMR).
32956541|NCT05171660|Experimental|Sintilimab + XELOX + Bevacizumab|Sintilimab + XELOX + Bevacizumab
32956542|NCT05171660|Active Comparator|XELOX + Bevacizumab|XELOX + Bevacizumab
32956543|NCT05171075|Experimental|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
32956544|NCT05171075|Active Comparator|Dalteparin|Dalteparin administered subcutaneously daily
32956545|NCT05171049|Experimental|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
32956546|NCT05171049|Active Comparator|Apixaban|Apixaban administered orally twice a day
32956547|NCT05169515|Experimental|Arm 1|Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 or SC mosunetuzumab + CC-99282.
32956548|NCT05169515|Experimental|Arm 2|Participants will receive intravenous (IV) glofitamab + CC-220 or IV glofitamab + CC-99282.
32835012|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
32835013|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
32835014|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
32835015|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
32835016|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
32835017|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
32835018|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
32835019|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
32835020|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
32835021|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
32835022|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
32835023|NCT04594798|Experimental|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
32835024|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
32835025|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
33103205|NCT04326985|Experimental|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
33103206|NCT04326985|Active Comparator|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
33103207|NCT05547178||Eurythmy Therapy (performed as part of the ENTAiER main study)|
33103208|NCT05547178||Tai Chi (performed as part of the ENTAiER main study)|
33103209|NCT05547178||Standard Care|
33103210|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
33318971|NCT04727086|Experimental|Medication (BP1.3656)|Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
33318972|NCT04727086|Placebo Comparator|Placebo pills|Participants will receive matching placebo pills for 14 days.
33318973|NCT03201562|Experimental|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
33318974|NCT03201562|Active Comparator|Aceclidine|Aceclidine single dose
33318975|NCT03201562|Sham Comparator|Vehicle|Vehicle single dose
33318976|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
33318977|NCT03321916|Sham Comparator|Sham|
33318978|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
32907405|NCT04468841|Experimental|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
33103211|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
33103212|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:~Hypertension~Obesity and/or type 2 diabetes~Cardiovascular disease~Chronic obstructive lung disease"
33103213|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
33103214|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
33103215|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
33103216|NCT00595543|Active Comparator|1|
33103217|NCT00595543|Active Comparator|2|
33103218|NCT00595543|Active Comparator|3|
33318979|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
33318980|NCT04693390|Experimental|Acupuncture|The acupuncture will be applied at points LI4, ST36, HT7, in association with auriculotherapy point Master Cerebral, immediately after induction of anesthesia for 20 minutes
33318981|NCT04693390|No Intervention|Standard care group|The patients will follow the standard procedure
33318982|NCT03290950|Experimental|Cohort 1|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
33326919|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
33405486|NCT04690023|Active Comparator|PENG block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block. Patients in PENG group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
32835026|NCT04592770|Experimental|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
32835027|NCT04592770|Placebo Comparator|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
32835028|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
32835029|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
32835030|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
32835031|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
32835032|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
32835033|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
32835034|NCT03184584|Experimental|PBI-4050|
32835035|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
32835036|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
33326920|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
33326921|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
32835039|NCT03184506|Sham Comparator|control group|
32835040|NCT03184506|Active Comparator|pre-warming group|
32835041|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
32835042|NCT04118998|Experimental|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
32835043|NCT04118998|Active Comparator|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
32835044|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
32835045|NCT04108156|Experimental|PDS Arm|Participants randomized to the PDS arm will receive intravitreal ranibizumab injection every 4 weeks (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 24-weeks (Q24W) thereafter
32835046|NCT04108156|Active Comparator|Intravitreal Arm|Participants randomized to the intravitreal arm will receive intravitreal ranibizumab injection every 4 weeks until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
33326922|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
33326923|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
32835049|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
32835050|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
32835051|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
32835052|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
32835053|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
32835054|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
32835055|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
32835056|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
32835057|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
32835058|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
32835059|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
32835062|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
32835063|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
32835064|NCT02435160|Experimental|Ulcerative Colitis|
32835065|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
32835066|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
32835067|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
32835068|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
32835069|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
32835070|NCT04570852|Experimental|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
32835071|NCT03186144|Experimental|No arm : descriptive study|
32835072|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
32835073|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
32835074|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
32835075|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
32835076|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
32835077|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
33326924|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
33326925|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
33326926|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
32835078|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
32835079|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
32835080|NCT00361894|Experimental|Arm 1|
32835081|NCT00361894|Active Comparator|Arm 2|
32835082|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
32835083|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
32835084|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
32835085|NCT04556578|Experimental|High-flow ECCO2R|Extracorporeal support using high flow circulation
32835086|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
32835087|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
32835088|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
32835089|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
33103219|NCT05519098||Inclusion group|"Patients referred for colonoscopy:~≥18 years old~Consenting to participate~Exclusion criteria:~Endoscopists~Employment or family member employed at Augere Medical AS~Patients:~Severe comorbidity, NYHA III-IV~Pregnancy~Hospitalized patients~Active inflammatory bowel disease~Poor bowel preparation defined as Boston Bowel Preparation Score as ≤1 in any segment~Absence or unable to provide consent~Cecum not reached"
33103220|NCT04207801|Experimental|Arm-1|400 mg AUR101 twice daily
33103221|NCT04207801|Experimental|Arm-2|600 mg AUR101 twice daily
32835090|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
32835091|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
32835092|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
32835093|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
32835094|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
32835095|NCT04550494|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and 4 hours after talazoparib dose on day 1 of cycle 2, and an optional biopsy either at the restaging follow up or at the time of disease progression.
32835096|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
32835097|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
32835098|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
32835099|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
32835100|NCT03184116|No Intervention|Control|No additional intervention
32835101|NCT04072432|Experimental|Cohort 1|120 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
32835102|NCT04072432|Experimental|Cohort 2|240 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
32835103|NCT04072432|Experimental|Cohort 3|360 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
32835104|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
32835105|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
32835106|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
32835107|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
32835108|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
32835109|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
32835110|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
32835111|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
32835112|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
32835113|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
32835114|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
32835115|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
32907446|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
33103222|NCT04207801|Placebo Comparator|Arm-3|Matching Placebo twice daily
33103223|NCT00595660|Active Comparator|1|Needle 21 for FNA
33103224|NCT00595660|Active Comparator|2|22 needle for FNA
33103225|NCT00595660|Active Comparator|3|23 needle for FNA
32835116|NCT04343326|Active Comparator|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
33103226|NCT00595660|Active Comparator|4|24 needle for FNA
32835117|NCT04343326|Active Comparator|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
33103227|NCT05504746|Experimental|SHEN26 capsule (SAD and FE part)|SHEN26 capsule 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
32835118|NCT04343326|Active Comparator|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
32835119|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
32835120|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
32835121|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
32835122|NCT04536376|Experimental|Resilience Program|a 4 week program focused on improving resilience
32835123|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
32835124|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
32835125|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
32835126|NCT00362206|Experimental|1|
32835127|NCT00362206|Experimental|2|
32835128|NCT00362206|Active Comparator|3|
32835129|NCT03185442|Experimental|PRF-fMRI|
32835130|NCT03748186|Experimental|STRO-002 treatment|"Dose Escalation: STRO-002 at increasing dose levels~Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg"
32835131|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
32835132|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
32835133|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
32835134|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
32835135|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
32835136|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
32835137|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
32835138|NCT03682042|No Intervention|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
32835139|NCT02974972||Pith Moromo 2 Cohort|
32835140|NCT03669718|Experimental|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
32835141|NCT03669718|Placebo Comparator|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
32835142|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
32835143|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
32835144|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
32835145|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
32835146|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
32835147|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
32902887|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
32907447|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
33103228|NCT05504746|Experimental|SHEN26 capsule (MAD part)|SHEN26 capsule 200mg, 400mg, and 600mg dose groups
33103229|NCT05504746|Placebo Comparator|SHEN26 placebo (SAD and FE part)|SHEN26 placebo 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
33103230|NCT05504746|Placebo Comparator|SHEN26 placebo (MAD part)|SHEN26 placebo 200mg, 400mg, and 600mg dose groups
32835148|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
32835149|NCT00362752|Placebo Comparator|Placebo|
32835150|NCT00362752|Experimental|Norfloxacin 400 mg bid|
32835151|NCT00118209|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy~Cyclophosphamide 750 mg/m^2 IV on Day 1~Doxorubicin 50 mg/m^2 IV on Day 1~Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1~Prednisone 40 mg/m^2/day PO on Days 1-5~filgrastim or pegfilgrastim as defined in the protocol~Required ancillary medications is administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
32835152|NCT00118209|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment:~Cycle 1 Doses:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy~Doxorubicin 10 mg/m^2/day CIVI on Days 1-4~Etoposide 50 mg/m^2/day CIVI on Days 1-4~Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)~Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)~Prednisone 60 mg/m^2 PO BID on Days 1-5~Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.~Required ancillary medications are administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
32835153|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.~Will receive social/behavioral support~Will receive research staff contact time to encourage them to increase their physical activity level~The participants will be given the option of a third supervised session each week"
32835154|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
32835155|NCT03657394|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
32835156|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
32835157|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
32835158|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
32835159|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
32835160|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
32835161|NCT04342156|Experimental|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
32835162|NCT04342156|Other|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
32835163|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835164|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835165|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835166|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835167|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835168|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835169|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32907448|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
32907449|NCT02241902||No pyuria|
32907450|NCT02241902||Persistent pyuria|
32956549|NCT05164133|Experimental|All Participants|Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
32956550|NCT05156034|Experimental|SRK-001- Dose 1|Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
32956551|NCT05156034|Experimental|SRK-001- Dose 2|Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
32835170|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835171|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835172|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835173|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835174|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835175|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835176|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835177|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835178|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835179|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32956552|NCT05156034|Experimental|SRK-001- Dose 3|Participants will receive IV SRK-001 Q2W for 4 doses.
32956553|NCT05156034|Placebo Comparator|Placebo|Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
32956554|NCT05155709|Experimental|Arm 1: Unfit adult participants with AML who responded sub-optimally to standard of care|Unfit adult participants with AML who responded sub-optimally to at least 2 and not more than 4 cycles ( 1 cycle=28 days) of first-line venetoclax plus azacitidine therapy
32956555|NCT05155709|Experimental|Arm 2: Newly diagnosed unfit adult participants with high-risk AML|Unfit adult participants with newly diagnosed AML and with adverse genetic risk stratification (according to ELN 2022)(Except TP53 mutation positive participants).
32956556|NCT05155345|Experimental|Non-fractionated/Dose-finding|Participants will receive a single dose of mosunetuzumab.
32835180|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32956557|NCT05155345|Experimental|Fractionated/Dose-escalation|Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
32956558|NCT05155085|Experimental|Lirentelimab (AK002) SC 300 mg|Subjects in this arm will receive 7 doses of 300 mg of lirentelimab (AK002) administered subcutaneously every 2 weeks.
32956559|NCT05155085|Other|Placebo|Placebo
32956560|NCT05153239|Experimental|Lurbinectedin|Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
32956561|NCT05153239|Experimental|Lurbinectedin plus Irinotecan|"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):~Irinotecan (Day 1 and Day 8)~Lurbinectedin (Day 1)"
32956562|NCT05153239|Active Comparator|Control arm|"Best Investigator's choice prior to randomization between:~Irinotecan on Day 1 q3wk~Topotecan on Days 1-5 q3wk"
32956563|NCT05147662|Experimental|Main study (Part A) and the extension study (Part B)|Part A will last for 6 months. After completing Part A participants will continue in the extension study for another 18 months.
32956564|NCT05144724|Experimental|Volume Targeted Ventilation|Positive pressure ventilation will be provided using a set tidal volume
32956565|NCT05144724|Active Comparator|Pressure guided Ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
32956566|NCT05143307|Experimental|Long Term Follow Up|Participants who received EBT-101 in a parent study will undergo long term follow up
32956567|NCT05142241|Experimental|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD on days 1-28 and temozolomide PO QD on days 2-6 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans at baseline, every 2 cycles for one year, every 3 cycles for patients on study for more than one year, and every 4 cycles for patients on study more than 3 years.
32835181|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835182|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835183|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835184|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835185|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
33103231|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
32835186|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
32835187|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
32835188|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
32835189|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
33326927|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
32835190|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
32835191|NCT04483284|Experimental|TACE combined with Camrelizumab|Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.
32835192|NCT00235833|Experimental|Adalimumab 40 mg eow|
32835193|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
32835194|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
32835195|NCT03648268|Active Comparator|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
32835196|NCT03648268|Sham Comparator|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
32835197|NCT03648268|Active Comparator|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
32835198|NCT03648268|Sham Comparator|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
33103232|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
33103233|NCT04326868|Active Comparator|Albendazole|ABZ (400mg)
33103234|NCT04326868|Experimental|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
33103235|NCT04326868|Experimental|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
33326928|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
33326929|NCT01167816|Experimental|azacitabine|
33326930|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
32835199|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
32835200|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
32835201|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
32835202|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
32835203|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
32835204|NCT03185598||non-MACE|no MACE occurred
32835205|NCT03185598||MACE|MACE occurred
32835206|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
32835207|NCT00255801|Experimental|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
32835208|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
32835209|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
32835210|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
32835211|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
32835212|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
32835213|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
32835214|NCT02425332|Experimental|Lokomat assessment|
32835215|NCT01898949|Experimental|Cold Exposure|
32835216|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
32835217|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
32835218|NCT04751955|Experimental|Olinvacimab plus Capecitabine|A single arm study with Olinvacimab plus Capecitabine
32835219|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
33318983|NCT03290950|Experimental|Cohort 2|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
33318984|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
33318985|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
33318986|NCT04520932|Experimental|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
32835220|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
32835221|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
33318987|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 16th March 2020.
33318988|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
33318989|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
32835222|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
32835223|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
32835224|NCT00239733|Experimental|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
32835225|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
32956568|NCT05140941|Experimental|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, one tablet taken once daily for 84 days
32956569|NCT05139836||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
32956570|NCT05139368|Experimental|Treatment (hypo-fractionated radiotherapy)|Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.
32956571|NCT05133258||Chronic Suppurative Otitis Media group|Enrolled subjects with persistent otorrhea due to CSOM and prescribed with standard of care (prescription for antibiotic drops from a pharmacy of their choice with specific written instructions for self-administration).
32956572|NCT05131477|Experimental|KY1005 Dose Level 1|Every 4 weeks
32956573|NCT05131477|Experimental|KY1005 Dose Level 2|Every 4 weeks
32956574|NCT05131477|Experimental|KY1005 Dose Level 3|Every 4 weeks
32956575|NCT05131477|Experimental|KY1005 Dose Level 4|Every 4 weeks
32956576|NCT05131477|Placebo Comparator|Placebo|Every 4 weeks
32956577|NCT05119140|Experimental|Mesalamine and Hydroxychloroquine|All participants will be on Mesalamine and Hydroxychloroquine
32835226|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
32835227|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
32835228|NCT01682681||Topiramate|
32835229|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
33103236|NCT05502016|Experimental|Intervention|Family model diabetes self-management education and support
33103237|NCT05502016|Active Comparator|Wait-list Control|Family model diabetes self-management education and support
32835230|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
32835231|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
32835232|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
33103238|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
33103239|NCT05458024|Active Comparator|Ergocalciferol (Vitamin D2)|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules. These will be given in a single dose prior to discharge from the Emergency Department.
33103240|NCT05458024|Placebo Comparator|Ergocalciferol placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU Ergocalciferol capsules administered in the active treatment arm.
33103241|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
33103242|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
33103243|NCT05470998|No Intervention|control group|this group will include 25 patients who will receive their standard therapy for 3 months
33318990|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
33318991|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
33318992|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
33318993|NCT04040920|Experimental|Ozone therapy|Ozone application before pits and fissure sealants
33318994|NCT04040920|Active Comparator|Pits and fissure sealants|
32835233|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
32835234|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
32835235|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
32835236|NCT00240981|Experimental|Treatment|
32835237|NCT00240981|Placebo Comparator|Placebo|
32835238|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
32835239|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
32835240|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
32835241|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
32835242|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
32835243|NCT04483128|Sham Comparator|Sham IFC therapy: Control group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~NO intensity (0 mA)~Session duration: 25 minutes"
32835244|NCT04483128|Experimental|IFC therapy: Experimental group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~Intensity will depend on subjet's tolerance but without generating visible muscle twitches.~Session duration: 25 minutes"
33103244|NCT05470998|Active Comparator|L-Arginine group|this group will include 25 patients who will receive L-Arginine 0.1-0.2 g/kg/day and their standard therapy for 3 months
33103245|NCT00595816|Experimental|1|Active treatment: physical training and counselling
33103246|NCT00595855|Active Comparator|TE|trabeculectomy
33103247|NCT00595855|Experimental|DS|deep sclerectomy
33103248|NCT00595894||1|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
33103249|NCT00595894||2|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
33103250|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
33103251|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
33318995|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
33326931|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
32835245|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
32835246|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
33103252|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
33103253|NCT05468684||Neck Pain-Associated Disorders|neck pain without an acceleration-deceleration mechanism
33103254|NCT05468684||Whiplash-Associated Disorders|neck pain resulting from a traumatic acceleration-deceleration mechanism and classified as WAD Grade I-III on the modified Quebec Task Force Scale
33103255|NCT02888899|Experimental|Standard treatment|
33318996|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
33318997|NCT03268954|Experimental|Azacitidine 75 mg/m^2|Azacitidine 75 milligram per square meter (mg/m^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
33318998|NCT03268954|Experimental|Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
33103256|NCT02888899|Experimental|PTNS in addition to standard treatment|
33103257|NCT00596089||1|Men and women 60 years and older
33103258|NCT00596089||2|Men and women 20-30 years of age
33318999|NCT03912532|Experimental|NGM282 Dose 1|Administered by subcutaneous injection
33319000|NCT03912532|Experimental|NGM282 Dose 2|Administered by subcutaneous injection
33103259|NCT05470959|Other|ACTIVA bioactive|bioactive ionic resin composite
33103260|NCT05470959|Other|Riva LC|Resin-modifed glass ionomer
33103261|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
33319001|NCT03912532|Experimental|NGM282 Dose 3|Administered by subcutaneous injection
33319002|NCT03912532|Placebo Comparator|Placebo|Administered by subcutaneous injection
33103262|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
33103263|NCT05468645|Experimental|[14C]Hemay005|
33103264|NCT04320394|Other|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
33319003|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
32835247|NCT04134923||[11C] Pittsburgh Compound-B (PIB)|Using [11C] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
33103265|NCT02892487|Experimental|Early active swallowing therapy|
33103266|NCT02892487|No Intervention|Usual care|
33103267|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
33103268|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
33103269|NCT05468567||Military person with acoustic trauma (experimental group)|Active or reserve military member, diagnosed with acoustic trauma for at least one month. Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup.
33103270|NCT05468567||Normal hearing volunteers (control group)|Person without known hearing loss.
33103271|NCT00596206|Experimental|1|100 mg of leflunomide
33103272|NCT00596206|Active Comparator|2|20 mg of leflunomide
33103273|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
33103274|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
33103275|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
33103276|NCT05438914|Experimental|Reverse Shoulder Arthroplasty with subscapularis repair|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
33103277|NCT05438914|No Intervention|Reverse Shoulder Arthroplasty without subscapularis repair|The subscapularis will not be repaired.
33103278|NCT05468528|Experimental|linear ablation group|The linear ablation is performed on the basis of Ω-type linear ablation. Further stepwise ablation of the left atrial anterior wall increases the blockage of the LA roof and the MVA isthmus. Ablation in CS or ethanol ablation of vein of Marshall. Also, epicardial ablation on the roof or rigid between LAA-LPVs may be applied if necessary.
33103279|NCT05468528|Other|PVI group|pulmonary vein isolation ablation alone
33103280|NCT05427448|Experimental|Prospective multisite clinical trial with consecutive recruitment.|Patients consulting in memory clinics from Montpellier, Nîmes, or Perpignan. CSF AD biomarkers performed for diagnostic purpose in clinical routine practice
33103281|NCT00624130|Experimental|Arm 1|
33103282|NCT00624130|Active Comparator|Arm 2|
33103283|NCT05468450|Active Comparator|Ultrasound-guided-foam sclerotherapy (UGFS)|Injection of Polidocanol foam into SSV
33103284|NCT05468450|Active Comparator|Endovenous Laser Ablation (EVLA)|Ablation of SSV using laser energy
33103285|NCT04686123|Experimental|Group A|Group A performed active Stretching of Pectoralis Minor (PMi) muscle along with the strengthening of Lower Trapezius muscle under the supervision of a physiotherapist
33103286|NCT04686123|Active Comparator|Group B|Group B performed active Stretching of the Pectoralis Minor (PMi) muscle only under the supervision of a physiotherapist.
33319004|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
33319005|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
33319006|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
32835248|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
32835249|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
32835250|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32835251|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
32835252|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
32835253|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
32835254|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
32835255|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
32835256|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
32835257|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
32835258|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
32835259|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
32835260|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
32835261|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
32835262|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM + Tech Detailing|
32835263|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM|
32835264|NCT04549259|Experimental|Social Support + Stigma Reduction + Technology Detailing|
32835265|NCT04549259|Experimental|Social Support + Stigma Reduction|
32835266|NCT04549259|Experimental|Social Support + SBCM + Technology Detailing|
32835267|NCT04549259|Experimental|Social Support + SBCM|
32835268|NCT04549259|Experimental|Social Support + Technology Detailing|
32835269|NCT04549259|Experimental|Social Support|
32835270|NCT04549259|Experimental|Stigma Reduction + SBCM + Technology Detailing|
32835271|NCT04549259|Experimental|Stigma Reduction + SBCM|
32835272|NCT04549259|Experimental|Stigma Reduction + Technology Detailing|
32835273|NCT04549259|Experimental|Stigma Reduction|
32835274|NCT04549259|Experimental|SBCM + Technology Detailing|
32835275|NCT04549259|Experimental|SBCM|
32835276|NCT04549259|Experimental|Technology Detailing|
32835277|NCT04549259|No Intervention|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
32835278|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
32835279|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
32835280|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
32835281|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
32835282|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
32835283|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
32835284|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
33319007|NCT03187756|Experimental|Cyclophosphamide|
33326932|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
33103287|NCT05409664|Experimental|webMFT|Survivors randomized to webMFT will receive the evidence-based intervention for moderate-to-vigorous physical activity (MVPA) promotion that consists of MVPA counseling matched to patients' motivational readiness, and self-monitoring of MVPA (via Fitbit Inspire 2). The goal for the 3-month program will be to gradually increase the amount of moderate-intensity aerobic exercise that is performed, to the current national recommendations of at least 150 minutes of MPVA per week. Our goal is to promote aerobic exercise that is safe and enjoyable, such as walking.
33103288|NCT05409664|Active Comparator|MVPA tracking|These survivors will be asked to self-monitor moderate-to-vigorous physical activity (MVPA) participation by wearing the Fitbit Inspire 2 each day over 12 weeks. This group will not receive the MVPA counseling from the coaches.
33103289|NCT04320355|Experimental|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
33103290|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
33103291|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
33103292|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
33319008|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
33103293|NCT05388721||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
33319009|NCT02926924|Active Comparator|Wound Vac|Wound vac
33103294|NCT05388721||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
33103295|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
33103296|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
32835285|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
33103297|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
33103298|NCT00536549|Experimental|A|Guardina RT monitoring
33103299|NCT00536549|Active Comparator|B|
33103300|NCT04208074|Experimental|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
33103301|NCT05387668|Experimental|Part A: Japanese cohort|Three ascending dose levels of either BGB-23339 or placebo.
33103302|NCT05387668|Experimental|Part B: Caucasian cohort|One dose level of either BGB-23339 or placebo based on data collected in Part A.
33103303|NCT05468372|Active Comparator|Amphotericin B arm (standard of care)|Intravenous liposomal amphotericin B [5 mg/kg per day] for at least 4 weeks followed by maintenance therapy. Maintenance therapy (after four weeks of treatment initiation) will be continued for at least 12 weeks or longer as decided by the treating physician. The maintenance therapy will be posaconazole. However, if therapeutic drug monitoring is not possible or the participants opt to use isavuconazole or amphotericin, the same will be permitted and noted
33319010|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
32835286|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
32835287|NCT05143632|No Intervention|Intermittent NIBP monitoring|Oscillometric intermittent (3 mins) noninvasive blood pressure monitoring
32835288|NCT05143632|Experimental|ClearSight|Continuous non invasive hemodynamic monitoring
32835289|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: inhaler sensor"
32835290|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.~Interventions: inhaler sensor and mobile application for asthma adherence"
32835291|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
33103304|NCT05468372|Experimental|Posaconazole arm|Combination of liposomal amphotericin B (5 mg/kg per day) and posaconazole for first 7 days followed by oral posaconazole only (for induction as well as maintenance therapy). The first four weeks of therapy will be called induction therapy
33103305|NCT04207957|Other|IV|2 h IV infusion (Groups A/B)
33103306|NCT04207957|Other|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
33103307|NCT04207957|Other|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
33103308|NCT04207957|Other|oral (intact tablet)|30 mg tablets (Group C)
33103309|NCT04207957|Other|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
33319011|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
33405487|NCT04690023|Active Comparator|SFICB block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block. Patients in SFICB group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
32835292|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
32835293|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
32835294|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
32835295|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
32835296|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
32835297|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
32835298|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
32835299|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
32835300|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
32835301|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
32835302|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
32835303|NCT03183258|Experimental|Sentinel Skin Flap|
32835304|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
32835305|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
32835306|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
32835307|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
32835308|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
32835309|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
32835310|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
32835311|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
32835312|NCT03117270|Experimental|oral filgotinib tablets|
32835313|NCT03117270|Placebo Comparator|placebo tablets|
32835314|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
33319012|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
33319013|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
32835315|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
32835316|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
33103310|NCT05383339||Patients|Patients with autoimmune diseases, vasculitis and autoinflammatory diseases
33103311|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
33103312|NCT00535977|Experimental|2|Dietary intervention of frozen peas
33103313|NCT05342077|Experimental|Virtual Reality-Reward Training (VR-RT)|7 sessions of positive VR immersion and positive memory specificity training exercises designed to savor rewarding features of immersion followed by memory specificity training exercises to savor rewarding features of autobiographical memory.
33103314|NCT05342077|Active Comparator|Virtual Reality-Memory Training (VR-MT)|7 sessions of neutral VR immersion and neutral memory specificity training exercises, designed to train memory of objective non-emotional stimuli followed by memory exercises to neutral autobiographical memories.
33103315|NCT05468333|Experimental|Main arm|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time.
33103316|NCT00596518|Experimental|PF-00734200|
33103317|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
33103318|NCT04326556|Experimental|Prospective cohort for etiological and prognostic purposes|
33103319|NCT04326634|Experimental|Controlled exercises Group|
33103320|NCT04326634|Experimental|Non controlled exercises Group|
33103321|NCT00596596|Active Comparator|1|0,5 mg prucalopride
33103322|NCT00596596|Active Comparator|2|1 mg prucalopride
33103323|NCT00596596|Active Comparator|3|2 mg prucalopride
33103324|NCT00596596|Placebo Comparator|5|Placebo arm
33103325|NCT00596596|Active Comparator|4|4 mg prucalopride
33103326|NCT05468294|Experimental|Ph I: F16IL2 + Nivolumab|"Patients will receive a fixed dose of Nivolumab and the following increasing dose levels of F16IL2: 15, 30, 50 and 70 Mio IU.~Once the RD is established, 17 patients will receive a fixed dose of Nivolumab and F16IL2 at the RD, established during the Phase I part of the study."
33103327|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
32835317|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
32835318|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
32835319|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
33103328|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
33103329|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
32835320|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
32835321|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.~Feedback of this screening will be given to the team responsible for patient treatment."
32835322|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
32835323|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
32835324|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
32835325|NCT02175004|Experimental|Previous Placebo-Inotersen 300 mg|Participants received subcutaneous (SC) doses of 300 milligrams (mg) inotersen once weekly for up to 260 weeks. Participants who received inotersen-matching placebo in the previous study- ISIS 420915-CS2 (NCT01737398) were included in this group.
32835326|NCT02175004|Experimental|Previous Inotersen-Inotersen 300 mg|Participants received SC doses of 300 mg inotersen once weekly for up to 260 weeks. Participants who received inotersen in the previous study- ISIS 420915-CS2 were included in this group.
32835327|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
32835328|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
32835329|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
32835330|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
32835331|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
32835332|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
32835333|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
32835334|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
32835335|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
32835336|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
32835337|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
32835338|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
32835339|NCT02425722|Experimental|ASP0456 0.0625mg|oral
32835340|NCT02425722|Experimental|ASP0456 0.125mg|oral
32835341|NCT02425722|Experimental|ASP0456 0.25mg|oral
32835342|NCT02425722|Experimental|ASP0456 0.5mg|oral
32835343|NCT02425722|Placebo Comparator|Placebo group|oral
32835344|NCT03609580|Experimental|1 week Pre-operative Tamsulosin administration|
32835345|NCT03609580|Experimental|3 days Pre-operative Tamsulosin administration|
32835346|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
32835347|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
32835348|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
32835349|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
32835350|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
32835351|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
32835352|NCT02430636|No Intervention|Control|The patients without treatment
32835353|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
32835354|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
32835355|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
32835356|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
32835357|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
32835358|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
32835359|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
32835360|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
32835361|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
32835362|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
32835363|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
32835364|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
32835365|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
32835366|NCT02424240||IGF-I/ IGFBP-3 ratio group|
32835367|NCT02424240||IGF-1 and IGFBP-3|
32835368|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
32835369|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
32835370|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
32835371|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
32835372|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
32835373|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
32835374|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
32835375|NCT01703117|Experimental|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
32835376|NCT01703117|Placebo Comparator|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
32835377|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
32835378|NCT01593917||Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study|Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.
32835379|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
33103330|NCT00536588|Experimental|SCH 721015 with SCH 209702|
33103331|NCT00596791|Other|1 arm|Open-lable study with one arm.
32835380|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
33103332|NCT05312866|Active Comparator|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
33103333|NCT05312866|Active Comparator|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
33103334|NCT05470803|Experimental|Cohort A: 03 doses Pfizer/Wyeth|Group 1: AstraZeneca/Fiocruz Group 2: Pfizer/Wyeth Group 3: Clover SCB-2019
33103335|NCT05470803|Experimental|Cohort B: 03 doses AstraZeneca/Fiocruz|Group 4: AstraZeneca/Fiocruz Group 5: Pfizer/Wyeth Group 6: Clover SCB-2019
33103336|NCT05470803|Experimental|Cohort C: 03 doses Sinovac/Butantan or 02 doses and 01 dose AstraZeneca/Fiocruz|Group 7: AstraZeneca/Fiocruz Group 8: Pfizer/Wyeth Group 9: Clover SCB-2019
32835381|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835382|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835383|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835384|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835385|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835386|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
32835387|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
32835388|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
33103337|NCT05470803|Experimental|Cohort D: 02 doses AstraZeneca/Fiocruz and 01 dose Alum/CpG adjuvanted 9 or 30 µg Clover SCB-2019|Group 10: Clover SCB-2019
33103338|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
33103339|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
33103340|NCT05468255|Experimental|Metabolic|Metabolic: Participants will have their blood glucose levels measured via continuous glucose monitoring for 3 days while participating in their normal exercise routines (EX). Participants will also have their blood glucose levels measured for 3 days while not exercising (NOEX), following immediately by 3 days of a return to normal activity(REX). Participants will be randomized to participate in the EX or NOEX/REX phases first. The EX and NOEX/REX phases will be separated by at least 1 week
33103341|NCT05468255|Experimental|Vascular|Vascular: Participants will have their blood vessel health measured while performing their normal exercise routines (EX) and while undergoing 1, 3, 5 days of no exercise (NOEX) followed immediately by 1 and 3 days of return to exercise (REX).
32835389|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
32835390|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
32835391|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
33103342|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
33103343|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
32835392|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
32835393|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
32835394|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
32835395|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
32835396|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
32835397|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
32835398|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
32835399|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
32835400|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
32835401|NCT03106896||healthy control (CON group)|healthy population
32835402|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
32835403|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
32835404|NCT01592747|Placebo Comparator|Placebo|Dosing will be once daily for up to 12 weeks.
32835405|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
32835406|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
32835407|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
32835408|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
32835409|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
33103344|NCT04326790|Experimental|Intervention|Colchicine, on top of standard treatment
33103345|NCT04326790|Active Comparator|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
33103346|NCT05468177|Experimental|neoadjuvant chemotherapy|Cetuximab+ mFOLFOX+ Anti-PD-1+Surgery
33103347|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
33103348|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
33103349|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
33103350|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
33103351|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
33103352|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
33103353|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
33103354|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
33103355|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
33103356|NCT00536627|No Intervention|2|
33103357|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
33103358|NCT00597103||2|Incident patients new to more frequent dialysis
32835410|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
32835411|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
32835412|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
32835413|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
33103359|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
33103360|NCT00597142|Experimental|1|
33103361|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
33103362|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
33103363|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
33103364|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
33103365|NCT04326595|Active Comparator|surgical termination|
32835414|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
33103366|NCT04326595|Active Comparator|medical termination|
33103367|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
33103368|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
33103369|NCT00597220|Experimental|1|Omega 3
33103370|NCT00597220|Placebo Comparator|2|
33103371|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
33103372|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
33103373|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
33103374|NCT00597259|Experimental|A|
32835415|NCT04768439|Experimental|200 IU/d vitamin D|Patients will receive low-dose vitamin D (200 IU/d)
32835416|NCT04768439|Experimental|1600 IU/d vitamin D|Patients will receive high-dose vitamin D (1600 IU/d)
32835417|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
32835418|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
32835419|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
32835420|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
32835421|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
32835422|NCT04767815|Experimental|Sequence 1|"Period 1: A (Fasting)~Period 2: B (30 minutes after a High-fat meal)~Period 3: C (2 hours after a High-fat meal)"
32835423|NCT04767815|Experimental|Sequence 2|"Period 1: B (30 minutes after a High-fat meal)~Period 2: C (2 hours after a High-fat meal)~Period 3: A (Fasting)"
32835424|NCT04767815|Experimental|Sequence 3|"Period 1: C (2 hours after a High-fat meal)~Period 2: A (Fasting)~Period 3: B (30 minutes after a High-fat meal)"
32835425|NCT04767815|Experimental|Sequence 4|"Period 1: A (Fasting)~Period 2: C (2 hours after a High-fat meal)~Period 3: B (30 minutes after a High-fat meal)"
32835426|NCT04767815|Experimental|Sequence 5|"Period 1: C (2 hours after a High-fat meal)~Period 2: B (30 minutes after a High-fat meal)~Period 3: A (Fasting)"
32835427|NCT04767815|Experimental|Sequence 6|"Period 1: B (30 minutes after a High-fat meal)~Period 2: A (Fasting)~Period 3: C (2 hours after a High-fat meal)"
32835428|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
32835429|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
32835430|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
33103375|NCT00597259|Active Comparator|B|Entecavir Alone
33103376|NCT05468060|Experimental|PA1010 5mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA1010 tablets or 5mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
33103377|NCT05468060|Experimental|PA1010 10mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 10mg of PA1010 tablets or 10mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
33103378|NCT05468060|Experimental|PA1010 20mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 20mg of PA1010 tablets or 20mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
33103379|NCT05468060|Experimental|PA1010 30mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30mg of PA1010 tablets or 30mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
32956584|NCT05112965|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
32956585|NCT05109234|Experimental|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
32956586|NCT05107960||Azilsartan|Azilsartan tablets or granules formulation, orally once daily. For children aged 6 years or older, the usual initial oral dosage of azilsartan is 2.5 mg and 5 mg once daily for those weighing <50 kg and >=50 kg, respectively.
32956590|NCT05099328|Experimental|Recast Therapy Provided By Clinician|Children will be exposed to recasts at a rate of 1/minute. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 recasts). 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed Speech Language Pathologist (SLP).
32956591|NCT05099328|Experimental|Illustrated Syntax Stories Provided by Clinician|Children will be listen to books that are specially scripted to promote the use of a particular syntax target. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 exposures), with 2 books read at each visit. 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed SLP.
32956592|NCT05099328|Experimental|Recast Therapy Provided by a Caregiver|Caregivers will receive two training sessions on how to provide recast therapy and demonstrate their skill at providing recast therapy with support from the clinician. Caregivers will then provide recast therapy at a rate of 1 recast per minute to their children for a minimum of 16 hrs (960 exposures) scheduled at their own convenience.
32956593|NCT05099328|Experimental|Illustrated Syntax Stories Provided by a Caregiver|Caregivers will receive two training sessions on how to provide read illustrated syntax stories to their children and demonstrate their skill at reading these stories with support from the clinician. Caregivers will then read these stories to their children for a minimum of 32 book readings (960 exposures)
32956595|NCT05091424|Experimental|R/R CLL|Participants will receive weekly step-up dosing of mosunetuzumab until the target dose is reached, after which mosunetuzumab will be administered once every 21 days for up to 17 cycles (cycle = 21 days) or until objective disease progression or unacceptable toxicity, whichever occurs first.
32956596|NCT05091346|Experimental|Phase 1b and 2: E7386 + Pembrolizumab|Participants will receive E7386 twice daily (BID) along with pembrolizumab 200 mg intravenous (IV) infusion once every 3 weeks (Q3W) in 21-day treatment cycle until RP2D is determined in Phase 1b. The recommended dose for Phase 2 part of the study will be based on Phase 1b result. Participants will continue to receive study treatment in Phase 2 part until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study.
32956597|NCT05091346|Experimental|Phase 2: E7386 + Pembrolizumab + Lenvatinib|Participants will be randomized to receive E7386 Dose 1 (Cohort 1) or Dose 2 (Cohort 2) tablet, BID, orally in combination with pembrolizumab 200 mg Q3W IV infusion plus lenvatinib 8 mg capsule, orally, once daily (QD) continuously in 21-days treatment cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study. The dose of treatment depends on tolerability data of both Cohorts.
32956598|NCT05078229|Experimental|FOCUS|Focusing On mindfulness for Caregivers Under Stress (FOCUS)will consist of six one-on-one, 45-60 minute sessions delivered either in-person (sessions 1-3) or via video conference (sessions 4-6). The first few sessions will primarily focus on how to direct attention to the breath or some object of attention (e.g., parts of the body). As the program progresses, participants are asked to apply these skills to thoughts and emotions. Throughout the treatment, caregivers are reminded to utilize existing coping skills, as well as how to integrate the new skills learned throughout this program for managing stress. Formal mindfulness meditations are conducted within each session, lasting from 7-20 minutes; participants will be asked to practice mindfulness exercises daily.
32956599|NCT05078229|Active Comparator|Healthy Living|Healthy Living (HL) will consist of six, 45-60 minute sessions delivered one-on-one; sessions 1-3 in-person on HCT unit and sessions 4-6 via video conference. HL will be based on the American Cancer Society's (ACS) Caregiver Resource Guide.
32956600|NCT05078229|No Intervention|Standard of Care - Enhanced Care|Participants in Enhanced Care will receive treatment consistent with what is offered to all caregivers of allogeneic HCT patients. This entails the option of attending weekly support groups and meeting with social workers as needed. At the baseline session, participants randomized to Enhanced Care will be provided with a modified version of the ACS Caregiver Resource Guide.
32956602|NCT05059873|Experimental|Systemic corticosteroid group|Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.
32956603|NCT05059873|Placebo Comparator|Control group|Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.
32956604|NCT05056727|Experimental|Sodium Zirconium Cyclosilicate (SZC)|SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
32956605|NCT05056727|Placebo Comparator|Placebo|Placebo + Lisinopril/Valsartan
32956606|NCT05055024|Experimental|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
33033027|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
33033028|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
33033029|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
32835431|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
33103380|NCT05468060|Experimental|PA1010 45mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 45mg of PA1010 tablets or 45mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
33103381|NCT05468060|Experimental|PA1010 60mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 60mg of PA1010 tablets or 60mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
33103382|NCT05468060|Experimental|PA1010 10mg before and after meals|Ten subjects will be administered 10mg PA1010 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA1010 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
33103383|NCT05468060|Experimental|PA1010 10mg after and before meals|Ten subjects will be administered 10mg PA1010 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA1010 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
33103384|NCT02892253|Experimental|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
33103385|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
33103386|NCT05470764|Experimental|PERINDOPRES® TRIO (Test)|A single oral dose of the test product PERINDOPRES® TRIO 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets.
33103387|NCT05470764|Active Comparator|TRIPLIXAM® 10 mg /2.5 mg/10 mg|A single oral dose of the reference product TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets.
33103388|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
33103389|NCT00597298|Sham Comparator|2|
33103390|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
33103391|NCT05271019|No Intervention|Control group: Conventional Rehabilitation Program|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
33103392|NCT05271019|Experimental|Experimental group: Conventional Rehabilitation Program + Inspiratory Muscle Training (IMT)|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
33103393|NCT05470725|Experimental|Control (normal renal function or mild renal impairment)|Estimated glomerular filtration rate (eGFR) ≥60 mL/min
33103394|NCT05470725|Experimental|Moderate to severe renal impairment|eGFR 15 to 59 mL/min
33103395|NCT05470725|Experimental|Kidney failure|"eGFR <15 mL/min, including:~Subjects not on dialysis; and~Subjects on dialysis, with study drug administration on a non-dialysis day"
33103396|NCT00597337|Experimental|1|Receiving FearNot
33103397|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
33103398|NCT00597415|Placebo Comparator|A 1|A 1=placebo
33103399|NCT00597415|Active Comparator|A 2|A 2=celecoxib
33103400|NCT00597454|Experimental|1|
32835432|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
33103401|NCT04686110|Other|Patients Amyotrophic Lateral Sclerosis|
33103402|NCT04686110|Other|Control subjects|
33103403|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
33103404|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
33103405|NCT05470686|Other|HEART SURGERY PATIENTS with cardio pulmonary bypass|
33103406|NCT00597610|Experimental|1|
33103407|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
33103408|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
33103409|NCT04686032|Experimental|Advanced Rehab Group|The experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and TENS during the first 3 post-operative days following abdominal hysterectomy
33103410|NCT04686032|Active Comparator|Early ambulation Group|Participants of this group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy
33103411|NCT00597688|Active Comparator|1|Chlorhexidine gel
33103412|NCT00597688|Placebo Comparator|2|Placebo gel
33103413|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
33103414|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
32835433|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
32835434|NCT02416440||screening for diabetes prevalence|blood samples
32835435|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
32835436|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
32835437|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
32835438|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
32835439|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
32835440|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
32835441|NCT03181698||first group|patients with more than one episodes of mania
32835442|NCT03181698||second group|sex-matched and age- matched healthy controls
32835443|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
32835444|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
32835445|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
32835446|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
32835447|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
32835448|NCT02423928|Experimental|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
32835449|NCT02051608|Placebo Comparator|Part 1 (Double Blind treatment): Placebo|Participants received matching placebo by subcutaneous (SC) injection every 4 weeks (Q4W) up to 100 weeks during Part 1 of the study.
32835450|NCT02051608|Experimental|Part 1 (Double Blind treatment): Gantenerumab|Participants received 105 mg Gantenerumab by SC injection Q4W for 24 weeks and if eligible 225 mg SC injection Q4W from weeks 28-100 during Part 1 of the study.
32835451|NCT02051608|Placebo Comparator|Part 2 (Open-Label Extension [OLE] treatment): Placebo switched to Gantenerumab Up to 1200 mg|Participants who had received Placebo in Part 1, received Gantenerumab at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
32835452|NCT02051608|Experimental|Part 2 (OLE treatment): Gantenerumab up to 1200 mg|Participants who had received Gantenerumab in Part 1, received treatment at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
32835453|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
32835454|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
32835455|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
32835456|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
32835457|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
32835458|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
33103415|NCT05467982|Experimental|Integrated Illness Management and Recovery (I-IMR) PLUS COVID-19 ENHANCEMENT:|In addition to the primary intervention (Integrated Illness Management and Recovery), participants received 3 additional COVID-19 related educational/skills training sessions provided individually, remotely by I-IMR Specialists.
33103416|NCT05467982|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP) ONLY:|No additional COVID-19 intervention was provided to this group. These participants only received the primary disease management intervention (CDSMP)
32835459|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
32835460|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
32835461|NCT02415972||All study participants|Patients with Stroke
32835462|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
32835463|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
32835464|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
32835465|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
32835466|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
32835467|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
32835468|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
32835469|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
32835470|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
32835471|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
32835472|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
32835473|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
32835474|NCT04767659|Experimental|Women candidate for clinical trial|Twenty adult women with a recent diagnosis of breast cancer, candidate for NAC, besides assessing the response to neoadjuvant chemotherapy using standard imaging evaluation, will undergo optical imaging at six selected time points from prior to commencement of NAC/baseline to the completion of NAC treatment (prior to surgery).
32835475|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
32835476|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
32835477|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
32835478|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
32835479|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
32835480|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
32835481|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
32835482|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
32835483|NCT01981720|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
32835484|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
32835485|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
32835486|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
32835487|NCT01900132|Experimental|1/All Subjects|Healthy Volunteers and patients
32835488|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
32835489|NCT02420886|No Intervention|Traditional Single step culture media|
32835490|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
33103417|NCT05470530|Active Comparator|IT group|Participants were received normal saline 2 mL intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL (10mg) plus 0.5 mL (2mg) dexamethasone diluted in 0.5 ml of 0.9% saline, overall 3 ml volume intrathecally. The dose of 2mg of dexamethasone was demonstrated by Amer (2018) to be the least effective intrathecal dose.
33103418|NCT05470530|Active Comparator|IV group|Participants were received dexamethasone 2 mL (8mg) intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL plus 1 mL of 0.9% saline
33103419|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
32835491|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
32835492|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
32835493|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
32835494|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
32835495|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
32835496|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835497|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835498|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835499|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835500|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835501|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
32835502|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
32835503|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
32835504|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
32835505|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
32835506|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
32835507|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
32835508|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
32835509|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
32835510|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
32835511|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
32835512|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
32835513|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
33103420|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
33103421|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
33103422|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
32835514|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
32835515|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
33103423|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
33103424|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
33103425|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
33103426|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
33103427|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
33103428|NCT05467865|Experimental|Experimental, nutrition education program|
32835516|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.~The number of this group will be double than the control group to get more information about safety and efficacy."
32835517|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
32835518|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
32835519|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
32835520|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
32835521|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
32835522|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
32835523|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
32835524|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
32835525|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
32835526|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
32835527|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
32835528|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
32835529|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
32835530|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
32835531|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
32835532|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
32835533|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
32835534|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
32835535|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
33103429|NCT05467865|No Intervention|control group|
33103430|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
33103431|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
33103432|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
33103433|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
33103434|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
33103435|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
33103436|NCT04130347||Pancreatic resection|
33103437|NCT04130347||Liver resection|
33103438|NCT04130347||HIPEC surgery|
33103439|NCT04130347||Gynecological debulking surgery|
33103440|NCT00536666|Other|1|Iron oligosaccharide
33103441|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
33103442|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
32835536|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
32835537|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
32835538|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
32835539|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
32835540|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
32835541|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
32835542|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
32835543|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
32835544|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
32835545|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
32835546|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
32835547|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
33103443|NCT05467826|Experimental|Arm 1|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
33103444|NCT05467826|Experimental|Arm 2|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
33103445|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
33103446|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
33103447|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
33103448|NCT05467787|Experimental|Message-based psychotherapy (MBP)|
33103449|NCT05467787|Experimental|Video-chat psychotherapy (VCP)|
33103450|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
33103451|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
33103452|NCT00598234|Placebo Comparator|2|Placebo
33103453|NCT05467397|Experimental|Patients will undergo [11C]acetate PET/CT|Patients will undergo a single [11c]acetate PET scan OR Patients will undergo an [11c]acetate PET scan, initiate treatment with rapamycin or rapalogs and receive a second [11c]acetate PET scan 3 or 4 months after starting the treatment.
33103454|NCT04326205|Experimental|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
33103455|NCT04326205|Active Comparator|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
33103456|NCT04326205|Active Comparator|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
33103457|NCT04326205|Placebo Comparator|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
33103458|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
33103459|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
33103460|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
33103461|NCT05470452|Experimental|Physician AI-assisted diagnosis group|
33103462|NCT05470452|Sham Comparator|Physician Independent Diagnostic Group|
33103463|NCT00598546||1|
33103464|NCT05466656|Experimental|Quasi-experimental uncontrolled, before-and-after.|The intervention will consist of the use of a continuous quality improvement cycle model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.
33103465|NCT00598624|Experimental|A|
32835548|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
32835549|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
32835550|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
32835551|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
32835552|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
32835553|NCT04482504||healthy pregnant women|"200 healthy pregnant women in 36.-38. Week of pregnancy. The investigators involve every healthy pregnant woman in 36.-38. week of pregnancy.~Exclusion criteria:~Unwilling to participate~Minors (under 18 years old)~e) Unfamiliar with slovak language f) Multiple pregnancy g) Musculoskeletal and neurological abnormalities"
32835554|NCT04482504||non-pregnant women|"30 non-pregnant healthy control women The investigators involve every healthy non-pregnant woman.~Exclusion criteria:~Unwilling to participate~Minors (under 18 years old)~e) Unfamiliar with slovak language f) Pregnancy g) Musculoskeletal and neurological abnormalities"
33103466|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
33103467|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
33103468|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
33103469|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
33103470|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
33103471|NCT05466344|Active Comparator|Herbst Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
33103472|NCT05466344|Active Comparator|TFBC Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
33103473|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
33103474|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
32835555|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
33103475|NCT00598741|Experimental|1|
33103476|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
33103477|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33103478|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
33103479|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
33103480|NCT05466305|Placebo Comparator|Maxillary complete denture reinforced by chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by chrome cobalt alloy
33103481|NCT05466305|Experimental|Maxillary complete denture reinforced by gold plated chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by gold plated chrome cobalt alloy
33103482|NCT00622999||All|All patients
33103483|NCT04207684|Experimental|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
33103484|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
33103485|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
33103486|NCT05604950||S group|underwent surgical treatment.
33103487|NCT05604950||NS group|underwent non-surgical treatment with RT and/or chemoradiotherapy.
33103488|NCT04321564||Nullipar pregnant women|
33103489|NCT04321564||multipar pregnant women|
33103490|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
32835556|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
32835557|NCT04410497|Experimental|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
33103491|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
33103492|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
33103493|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
32835558|NCT04410497|Active Comparator|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
32835559|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
32835560|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
32835561|NCT03116880||Image registration|
32835562|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
32835563|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
32835564|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
32835565|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
32835566|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
32835567|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
32835568|NCT04348877|Other|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
32835569|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
32835570|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
32835571|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
32835572|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
32835573|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
32835574|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
32835575|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
32835576|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
32835577|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
32835578|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
32835579|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
32835580|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
32835581|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
32835582|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
32835583|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
32835584|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
32835585|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
32835586|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
32835587|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
32835588|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
32835589|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
32907451|NCT03983993|Experimental|Treatment (niraparib, panitumumab)|Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33103494|NCT05603858||Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
33103495|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
33319014|NCT03183778|Experimental|Patiromer + Research Diet|"During the first phase (week 2), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (less than or equal to 1 serving/day), and eliminates high-potassium fruits and vegetables.~During the second phase (weeks 3 and 4), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources."
33319015|NCT03182686|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
33319016|NCT03182686|Placebo Comparator|Placebo 4 mL dose|4 mL injection of Placebo
33319017|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
33103496|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
33103497|NCT05511181|Experimental|BioWave|BioWaveGO is a FDA 510(k) cleared high frequency neurostimulator. Patients that are first randomized to the BioWave arm will receive a 30 minute treatment in the clinic with a BioWaveGO device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the BioWaveGO device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the TENS treatment (as described in the TENS arm).
33319018|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
33319019|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
33319020|NCT04522102|Experimental|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
33319021|NCT04522102|No Intervention|Comparator|Avoid antiplatelet therapy.
33103498|NCT05511181|Active Comparator|TENS|Patients that are first randomized to the TENS arm will receive a 30 minute treatment in the clinic with an Intensity 5000 TENS device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the TENS device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the BioWaveGO treatment (as described in the BioWave arm).
33103499|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
33103500|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
33103501|NCT05603819||Bipolar disorder|Patients with depression suffering from bipolar disorder.
33103502|NCT05603819||Major depressive disorder|Patients with depression suffering from major depressive disorder.
33103503|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
33103504|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
33103505|NCT00536211|Experimental|1|Exercise
33103506|NCT00536211|Active Comparator|2|Metformin
33103507|NCT02914873|Active Comparator|Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
33103508|NCT02914873|Experimental|Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
33103509|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
33103510|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
33103511|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
33103512|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
33103513|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 1|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
33103514|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 2|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
33103515|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 3|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
33103516|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 4|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
33103517|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 5|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
33103518|NCT05262400|Experimental|Part 2A|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and Endocrine Therapy)
33103519|NCT05262400|Experimental|Part 2B|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior endocrine therapy and up to 1 prior line of chemotherapy for advanced or metastatic disease and no prior treatment with any CDK4/6 inhibitor for advanced disease)
33103520|NCT05262400|Experimental|Part 2C|PF-07220060 + PF-07104091 + Letrozole (ER+/HER2- Breast Cancer with no prior treatment with any CDK4/6 inhibitor for advanced disease)
33103521|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
32835590|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
32835591|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
32835592|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
33103522|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
32835593|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
32835594|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
33103523|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
33103524|NCT05243641|Experimental|Part 1b (dose escalation)|This portion of the study will enroll a maximum of 27 patients in the dose-finding trial including the possibility of adding up to 6 additional ER+ patients in a safety assessment of aromatic inhibitor treatment
33103525|NCT05243641|Experimental|Part 2 (dose expansion)|This portion of the study will enroll a maximum of 29 patients
33103526|NCT00536289|Active Comparator|1|Sharp needles
33103527|NCT00536289|Experimental|2|Blunt tipped needles
33103528|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
33103529|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
33103530|NCT05601791|Active Comparator|Discoradicular contact+ESI TF|Patients with discorradicular contact who underwent ESI TF
33103531|NCT05601791|Active Comparator|Discoradicular contact+PLDD|Patients with discorradicular contact who underwent PLDD
33103532|NCT05601791|Active Comparator|Without discoradicular contact+ESI TF|Patients without discorradicular contact who underwent ESI TF
33103533|NCT05601791|Active Comparator|Without discoradicular contact+PLDD|Patients without discorradicular contact who underwent PLDD
33103534|NCT05470062|Experimental|experimental group|wear the insoles for at least 4-h every day for 1-month
33103535|NCT05470062|No Intervention|control group|not wear insoles for at least 4-h every day for 1-month
33103536|NCT02465164|Other|Cook catheter|Control
33103537|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
33103538|NCT04685642|No Intervention|non-drug|
33103539|NCT04685642|Active Comparator|Aspirin|
33103540|NCT04685642|Active Comparator|Statin|
33103541|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
33103542|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
33103543|NCT04685564|Experimental|RBD1016 experiment group|Subjects in experiment groups will receive a single subcutaneous injection of RBD1016.
33103544|NCT04685564|Placebo Comparator|placebo gruop|Subjects in placebo groups will receive a single subcutaneous injection of placebo.
33103545|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
33103546|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
33103547|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
33103548|NCT05595785|Experimental|Physical-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The physical-based yoga practice was Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis. The yoga class sessions included the physical postures of yoga with an emphasis on alignment, holding postures, and breathing normally.~Each yoga class session sequentially included the following physical postures of yoga: (1) standing in stillness; (2) pranayama deep breathing and warm up; (3) standing series- balance postures, wide leg postures; (4) transition from the standing postures to the floor postures with tree pose; (5) floor series - wind removing, sit up movements, cobra posture, kneeling postures; (6) cool down-stretching, spine twist, Kapalbhati breathing, and Savasana."
32835595|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
32835596|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
32835597|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
32835598|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
32835599|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
32835600|NCT02423304||test|"50 periodontitis patients~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
32835601|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
32835602|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
32835603|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
32835604|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
32835605|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
32835606|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
32835607|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
32835608|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
32835609|NCT04410419|No Intervention|Standard Care|Standard care for patients with diabetes pre-operatively .
32835610|NCT04410419|Experimental|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
32835611|NCT01587989|Active Comparator|A Methotrexate|
32835612|NCT01587989|Experimental|B Methotrexate Placebo|
32835613|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
32835614|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
32835615|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
32835616|NCT04124393|Active Comparator|Water Exchange (WE) Colonoscopy|In the WE group, the air pump will be turned off before starting the procedure. During the insertion phase, the colon will be irrigated with warm water (32C-35C). WE entails the infusion of water to open the lumen and simultaneous suction if the endoscope has two channels, and sequentially if the endoscope has only one channel. When the cecum is reached and after most of the water is suctioned to collapse the cecal lumen, CO2 will be opened. The colonoscope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The colonoscope will then be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
32835617|NCT04124393|Active Comparator|CO2 Insufflation Colonoscopy|In the CO2 group, colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the colonoscope will be withdrawn from the cecum to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then, the colonoscope will be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
32835618|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
32835619|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
32835620|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
32835621|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
32835622|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
32835623|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
32835624|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
32835625|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
32835626|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
32835627|NCT01697501|Experimental|Chronic hepatitis B patients|
33319022|NCT05240092|Experimental|Haptonomy Group|A home visit was made to the experimental group, and haptonomy was applied for at least 30 minutes, once a week, for 7 weeks (with the researcher for 3 weeks, with the husband by providing the training brochure and video that will help the practice for the next 4 weeks).
33319023|NCT05240092|No Intervention|Standard of care Group|The control group did not receive any treatment.
33319024|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
33319025|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
33319026|NCT05239702|Experimental|Crohn Disease|
33319027|NCT05239702|Experimental|Ulcerative Colitis|
33319028|NCT05239702|Experimental|Dermatomyositis|
33319029|NCT05239702|Experimental|Still Disease|
33319030|NCT05239702|Experimental|Autoimmune Diseases|
33319031|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
33319032|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
33319033|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
33319034|NCT03175198||Patients with nonvalvular atrial fibrillation (NVAF)|Patients with nonvalvular atrial fibrillation (NVAF) taking daily oral dose of Prazaxa® Capsules (Dabigatran etexilate). Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg [as 2 capsules of 75 mg] twice a day (b.i.d)) or 220 mg (110 mg [as 1 capsule of 110 mg] b.i.d) for a treatment duration of 52 weeks.
33319035|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
33319036|NCT03175120|Experimental|Insulin degludec/liraglutide|
33319037|NCT03175120|Active Comparator|Insulin degludec|
32835628|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
32835629|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
32835630|NCT01781728|Active Comparator|RT naive|
33319038|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
32835631|NCT01781728|Active Comparator|Previous RT|
33103549|NCT05595785|Experimental|Mindfulness-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The mindfulness-based yoga practice included all elements of the physical-based yoga class sessions with the addition of mindfulness cues.~The mindfulness cues included body scan, mindful movement, and yoga nidra. Beyond verbal physical cues on how to control breathing and perform precise body movements during the yoga postures, verbal mindfulness cues asked participants to focus on the sensations of their breathing and body awareness non judgmentally, e.g. Feel your breathe move in through your nose and fill your lungs from bottom to top. Feel your breath exit the nose and empty lungs from top to bottom. Keep your attention on your breath and your body."
33103550|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
33103551|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
33103552|NCT05312346||responsiveness to erythropoietin stimulating agent|we evolute responsiveness of patients on hemodialysis for erythropoietin stimulating agents or not and factors effecting this response
33103553|NCT05568563|Experimental|Ethyl chloride|
33319039|NCT04942210|Experimental|vYF|1 injection of vYF at Day 1
33319040|NCT04942210|Active Comparator|YF-VAX|1 injection of YF-VAX at Day 1
33319041|NCT05213182|Experimental|Intervention|The intervention arm (n=104 adolescent mothers) participated in the 12 in-person peer support group sessions and completed sociodemographic, base-, mid-, and end-line surveys.
33319042|NCT05213182|No Intervention|Control|The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys.
33319043|NCT05206162|Active Comparator|continuous theta burst stimulation|cTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s.
33319044|NCT05206162|Active Comparator|intermittent theta burst stimulation|iTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in an intermittent train of 190s for iTBS, with repeated cycles of 2s stimulation and 8s pause.
33319045|NCT05206162|Sham Comparator|sham stimulation|Sham stimulation over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s using a plastic spacer (25mm thickness) between coil and scalp, preventing effective cortical stimulation.
33319046|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
33319047|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
33319048|NCT05118724|Experimental|Atezolizumab 840mg|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses)
33319049|NCT05118724|Experimental|Atezolizumab 840mg plus IMM-101|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses) One initial dose of IMM-101 intradermally at 1.0 mg 14 ±2 days before start of atezolizumab treatment, followed by 12 treatment cycles Q4W: IMM-101 intradermally at a dose of 0.5 mg (q2w) for 1 cycle (2 doses), followed by 0.5 mg intradermally for 11 cycles (11 doses)
33319050|NCT05097586|Experimental|active tDCS|2mA of direct current delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
33319051|NCT05097586|Sham Comparator|control|Sham stimulation where the current is turned off after 30 seconds in a slow ramp down, delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
33319052|NCT05068570|Experimental|EXPERMINTAL GROUP|start with cycle at a pace of 15-25 cycles per minute without resistance and end with cycle 45cycles per minute
33319053|NCT05068570|No Intervention|CONTROL GROUP|selected respiratory exercise program
33319054|NCT03036748|Experimental|TX control|Kidney transplant recipients with urinary albumin/creatinin-ratio < 30mg/g
33319055|NCT03036748|Experimental|TX Proteinuria|Kidney transplant recipients with urinary albumin/creatinin-ratio > 300mg/g
33319056|NCT04933786|Experimental|Digital Health Nudging|During 12-week intervention period participants receive daily text messages via WhatsApp on their smartphone to encourage them to be physically active in their daily lives.
33319057|NCT04933786|No Intervention|Control|During 12-week control period participants receive no text messages.
32835632|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
32835633|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
33103554|NCT05568563|Experimental|Honey|
33319058|NCT04935736|Experimental|CORTISOMOL SP|Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.
33319059|NCT04935736|Active Comparator|SEALITE REGULAR|The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.
33319060|NCT03167242|Experimental|Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
32835634|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
32835635|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
32835636|NCT01703806||Conventional Treatment|Patients in the conventional treatment group will be treated according to the 2006 ACC/AHA guidelines and they will be referred for surgery if they experience any symptoms, and referred for surgery if exertional dyspnea, LV ejection fraction <0.60, LV end-systolic dimension >40 mm, Doppler estimated pulmonary artery pressure > 50 mmHg, or atrial fibrillation develops.
32835637|NCT01703806||Early Surgery|Patients in the early surgery group should undergo mitral valve surgery within 6 months of enrollment.
32835638|NCT03528226|Experimental|Exercise Training|
32835639|NCT03528226|Other|Control|
32835640|NCT00362830|Experimental|1|
33103555|NCT05568563|No Intervention|Control|
32835641|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
33103556|NCT05470023|Active Comparator|Brushing with LivFresh Dental Gel|Subjects will brush twice daily for the study duration with LivFresh Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33103557|NCT05470023|Active Comparator|Brushing with LivFree Dental Gel|Subjects will brush twice daily for the study duration with LivFree Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33103558|NCT05470023|Active Comparator|Brushing with AIM Dental Gel|Subjects will brush twice daily for the study duration with AIM Dental Gels with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33319061|NCT03167242|Experimental|Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 800 mg and LUM-SDF 960 mg
33319062|NCT03167242|Experimental|Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
33319063|NCT03167242|Experimental|Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 days|Participants received KAF156 200 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
33319064|NCT03167242|Experimental|Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
33319065|NCT03167242|Experimental|Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
33319066|NCT03167242|Active Comparator|Part A - Cohort 7: Coartem|Participants received Coartem twice daily via oral administration for 3 days
32835642|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
32835643|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating doses of Lenalidomide
32835644|NCT01352962|Experimental|Arm 2|Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
33319067|NCT03167242|Experimental|PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 200 mg and LUM-SDF 960 mg
33319068|NCT03167242|Experimental|Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
33319069|NCT03167242|Experimental|Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
33319070|NCT03167242|Experimental|Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
33103559|NCT05470023|Active Comparator|Brushing with Crest Prohealth Dental Gel|Subjects will brush twice daily for the study duration with Crest Prohealth Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33319071|NCT03167242|Active Comparator|Part B - Cohort 4: Coartem|Participants received Coartem twice daily via oral administration for 3 days
33319072|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
33319073|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
33319074|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
33103560|NCT05470023|Active Comparator|Brushing with Parodontax Dental Gel|Subjects will brush twice daily for the study duration with Parodontax Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33103561|NCT05470023|Active Comparator|Brushing with Colgate Total Dental Gel|Subjects will brush twice daily for the study duration with Colgate Total Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33103562|NCT05470023|Active Comparator|Rinsing with Lumineux or Listerine Mouthwashes|Subjects will be asked to rinse twice daily with 1 capful for 1 minute with Lumineux or Listerine Mouthwashes directly after brushing their teeth, while continuing with their usual oral hygiene protocol. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
33103563|NCT05561933|Placebo Comparator|Choice Group|Participants assigned to the Choice group will receive a list of digital (i.e., links to TED talks) and hard-copy (i.e., books) resources that focus on the science of well-being and may support well-being. It is up to participants whether and to what extent they choose to engage with these resources. A study library with 10 copies of each recommended book will be accessible to participants should they wish to read any of the suggested books. After follow-up testing, Choice group participants will be provided free access to the HMP training.
33103564|NCT05561933|Experimental|Healthy Minds Program (HMP) Group|"Participants in the experimental arm will be assigned to the Healthy Minds Program Foundations training (HMP) which consists of 30-days of didactic and experiential content in a scientifically-derived model of well-being.~A second random assignment will occur among intervention participants in which participants will receive the standard Foundations training or the Foundations training plus once per day push notifications (i.e., a micro-interventions) that provide a very brief opportunity to practice with the HMP content of that day. HMP participants will not be made aware of this second assignment."
33103565|NCT00536861|Experimental|1|
33103566|NCT05469984|Active Comparator|women with term prolonged>18h rupture of membrane|women with term prolonged >18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery
33319075|NCT04780828||GROUP I|Group I will include cases classified as normal weight (healthy) with a body mass index of 18.5-24.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined for this group will be made. Since this group was not considered as obese, it was determined as the control group.
33319076|NCT04780828||GROUP II|Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
33319077|NCT04780828||GROUP III|Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
33319078|NCT04780828||GROUP IV|Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
33103567|NCT05469984|Active Comparator|women with preterm labor|women with term prolonged >18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery plus IV gentamicin 5 mg/kg every 24 hours
33103568|NCT00536900|Experimental|1|Advisor-Teller Money Manager
33103569|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
33103570|NCT05312190|Experimental|Zhenqi Buxue Oral Liquid|Zhenqi Buxue Oral Liquid, 10 ml each time, 2 times a day for 3 menstrual cycles, orally
33319079|NCT04780828||GROUP V|Group V will include cases classified as class III (morbid) obese, with a body mass index of 40 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
33319080|NCT05441410|Experimental|PfSPZ-CVac/Pyramax|200.000 PfSPZ of PfSPZ Challenge NF54 will be administered by DVI along with one weight-adjusted oral dose of Pyramax each on day 1, day 6, and day 29
33103571|NCT05312190|Experimental|Zhenqi Buxue Oral Liquid and Progesterone Capsules|Zhenqi Buxue Oral Liquid was taken orally, 10 ml at a time, twice a day for 3 menstrual cycles + orally from the second half of menstrual cycle, Progesterone Capsules 200mg, once a day for 10 days for 3 menstrual cycles
33103572|NCT05312190|Active Comparator|Progesterone Capsules|Progesterone Capsules 200mg, qd*10 days*3 menstrual cycles, orally
33103573|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
33103574|NCT05469906||interventional group|kidney graft preserved with M101
33103575|NCT05469906||control group|kidney graft preserved in standard condition (without M101)
33103576|NCT05469828|Experimental|treatment|The effects of Crizanlizumab will be assessed in 20 nontransfused SCD subjects. After comprehensive baseline assessment one month prior the time of study initiation, patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses). Safety laboratories will be drawn at each infusion visit. There will be a follow up phone call the day after receiving the medication. Comprehensive blood and vascular testing will be repeated at Week 11 and Week 23 of treatment.
33103577|NCT05469828|Active Comparator|control|A total of 10 SCD subjects will be recruited from the hematology clinic at CHLA, generating a similar distribution of SS and Sß0 hemoglobin. They will be studied twice, once at the beginning of the study, time 0, and once at the end of study, after 6 months. They will undergo the same cerebral, peripheral and cardiopulmonary testing procedures as the patients undergoing therapy. They will also have monthly phone calls to determine clinical outcomes such as crisis frequency, medication use, hospitalizations and other pertinent clinical findings that may arise.
33103578|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
33103579|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
33103580|NCT00537212|Sham Comparator|3|Subjects will receive phototherapy alone, without dietary counselling.
33103581|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
33103582|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
33103583|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
33103584|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
33103585|NCT05541926|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
33103586|NCT05541926|No Intervention|Standard of Care|Standard of care practice in counties prior to the implementation of e-Connect
33319081|NCT05441410|Experimental|MVA ME-TRAP/ChAd63 ME-TRAP|MVA ME-TRAP 1.5 x 10^8 pfu will be administered intramuscularly on day 1 for priming. ChAd63 ME-TRAP 5 x 10^10 vp will subsequently administered by DVI on day 29.
33319082|NCT05441410|Placebo Comparator|Saline/placebo pill|"As placebo comparator to PfSPZ-CVac/Pyramax, saline will be administered intravenously along with an oral placebo pill on day 1, day 6, and day 29.~As placebo comparator to MVA ME-TRAP/ChAd63 ME-TRAP, saline will be administered intramuscularly on day 1 and intravenously on day 29. No placebo pill will be used to compare to the arm MVA ME-TRAP/ChAd63 ME-TRAP."
33319083|NCT05438056|Experimental|providing training to mothers of premature babies with a mobile application|providing training with mobile application to mothers discharged home with their premature babies +standard education prior to discharge
33319084|NCT05438056|No Intervention|standard education prior to discharge control group; standard education prior to discharge|standard education prior to discharge
33319085|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
33319086|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
33319087|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
33103587|NCT05469750|Experimental|Dalpiciclib+ letrozole +capecitabine|"Dalpiciclib 150 mg was given orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~letrozole 2.5mg po qd capecitabine 1000mg/m2 po bid"
32835645|NCT03465592|Experimental|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
32835646|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
33103590|NCT05311761|Experimental|CogMe Personal Assistant (PA)|The CogMe PA is a dedicated application built by CogMe with the purpose of assessing the cognitive functions of patients and providing them with a short and stimulating interaction. The application runs on a standard tablet. The CogMe PA is designed to be easily understandable and usable also for older adults with little or no experience in mobile applications. The questions in the Q&A session are based on validated cognitive tests shown to be associated with delirium and are built to assess the subjective wellbeing and cognitive function of the patients. The repeated use of the application will allow to detect any changes or anomalies during the hospitalization period.
33103591|NCT05530109||Patients with idiopathic generalised epilepsy|
33103592|NCT05530109||healthy controls|age- and sex-matched healthy controls
33103593|NCT05469594||Termination of pregnancy between 12-14 weeks of gestation|
33103594|NCT05469594||Termination of pregnancy between 14-16 weeks of gestation|
33103595|NCT05525078|Experimental|Switch Group|Participants in the Switch group will receive a 5-week supply of e-cigarettes.
33103596|NCT05525078|Active Comparator|Meds Group|Participants in the Meds Group will receive a 5-week supply of combination nicotine replacement therapy (transdermal nicotine patch and short-acting nicotine lozenge).
33103597|NCT05469516|Experimental|Ultherapy and Radiesse|"Delivered to the lower face areas as drawn using a single transducer with a focal depth of 1.5mm (following a previously published paper (Lowe, 2021) but with extension of the lower treatment area to the two-ruler width (Ulthera marking ruler) as treatment zones. Application will be delivered through a cross-hatching technique.~Immediately following MFU-V or up to a week after, diluted CaHA will be administered following the Global Consensus Guidelines published in 2018 by de Almeida et al as follows 1) 1 syringe or 1.5ml of CaHA diluted 1:1 with saline for a total of 3ml of solution or 1.5 diluted CaHA per side will be injected in the subdermal plane with a cannula using a retrograde fanning technique."
33103598|NCT05514587||Suicidal act|Patients who has committed a suicidal act
33103599|NCT05514587||Suicidal thoughts without acting on them|Patients with suicidal thoughts without acting on them
33103600|NCT05514587||No suicidal ideation or acting out|Patients without suicidal ideation or acting out of patients in crisis admitted to the Crisis Center
33103601|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
33103602|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
33319088|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
32835647|NCT02975050||Side location|u-Cor device will be applied on side location
32835648|NCT02975050||Front location|u-Cor device will be applied on front location
32835649|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
32835650|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
32835651|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
32835652|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
33103603|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
33103604|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
32956607|NCT05053971|Experimental|Treatment (entinostat, ZEN003694)|"PHASE I RUN-IN PERIOD: Patients receive ZEN003694 PO QD during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE II RUN-IN PERIOD: Patients receive ZEN003694 PO QD or entinostat PO QW during days -14 to 1 based on the order to which they are enrolled to the study (e.g. every other patient starts by taking ZEN003694 alone for 14 days). Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE I & II COMBINATION TREATMENT: Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14."
32956608|NCT05051644|Experimental|Steps 2 Change (S2C)|Participants randomized to S2C will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks in the outpatient OAT clinic. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting after Session 1. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain and benefits of activity. Session 2 and 3 will emphasize benefits of low impact physical activity and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
32956609|NCT05051644|Active Comparator|Control|Participants randomized to control will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks focused on problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
32956610|NCT05050227|Experimental|cCBT Enhanced Collaborative Care|Participants in the intervention arm will receive computerized cognitive behavioral therapy (cCBT) supported by a depression care manager in addition to the usual care provided.
32956611|NCT05050227|Active Comparator|Usual Care|Participants in the usual care arm will receive the usual care provided as described below.
32956612|NCT05049096|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
33319089|NCT05432050||Remimazolam anesthesia|General anesthesia will be induced and maintained by remimazolam and the depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
32956613|NCT05049096|Sham Comparator|sham-control group|In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
32956614|NCT05047978|Active Comparator|A routine cow's milk-based infant formula|A routine cow's milk-based infant formula
32956615|NCT05047978|Experimental|A partially hydrolyzed cow's milk protein (PHP) infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
32956616|NCT05047250|Experimental|Atezolizumab|Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
32956617|NCT05047250|Active Comparator|Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)|Participants will receive platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease).
32956618|NCT05045664|Active Comparator|Standard|Standard dose (24 Gy) involved site radiotherapy plus Rituximab
32956619|NCT05045664|Experimental|Experimental|ow-dose (4 Gy) involved site radiotherapy in combination with Obinutuzumab
32956620|NCT05037552|Active Comparator|BIPOLAR FORCEPS|The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.
32956621|NCT05037552|Experimental|FLOSEAL|"FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.~During this study, it will be used in 1st intention."
32956622|NCT05032040|Experimental|vudalimab|
32956623|NCT05028634|Experimental|Cohort 1 - Ozanimod|"Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
32956624|NCT05028634|Experimental|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|"Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
32956625|NCT05028634|Experimental|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
32956626|NCT05028634|Experimental|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
32956627|NCT05028075|No Intervention|Usual Care|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months, 6 months, and 9 months.
33319090|NCT04874194|Experimental|Treatment (omacetaxine, venetoclax)|Patients receive omacetaxine SC BID on days 2-3 or 2-4, and venetoclax PO on days 1-7, 1-10 or 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
33319091|NCT01330186||Anal cancer|
33319092|NCT01330264||Dyad|
33319093|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
33319094|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
32835653|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
32835654|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
32835655|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
32835656|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
32835657|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
32835658|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
32835659|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
32835660|NCT00568672|Placebo Comparator|2|Placebo
32835661|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
32835662|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
32835663|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
32835664|NCT04744246|Active Comparator|Without Load|5 kilometer walk with no load carried
32835665|NCT04744246|Experimental|With Load|5 kilometer walk with load
32835666|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
32835667|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
32835668|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
32835669|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
32835670|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
32835671|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
32835672|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
32835673|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:~Diet 1 (20% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
32835674|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:~Diet 2 (40% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
32835675|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
32835676|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
32835677|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
32835678|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
32835679|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
32835680|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
32835681|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
32835682|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
32835683|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
32835684|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
32835685|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
32835686|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32835687|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32835688|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
32835689|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
32835690|NCT04743700|Experimental|Piezocision on Experimental Side A|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome to accelerate maxillary canine retraction
32835691|NCT04743700|Experimental|Micro-osteoperforations on Experimental side B|Three MOPs with the help of mini-implant screw driver,mesial and distal to canine(in a vertical line) with the help of minisrew implant driver to accelrate maxillary canine retraction
32835692|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
32835693|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
32835694|NCT04744168|Experimental|Acupuncture|In the experimental arm, pregnant women at term will benefit one or two acupuncture sessions with five points : 4GI, 6RP, 34VB,36E,3F. The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both.
32835695|NCT04744168|Placebo Comparator|Placebo acupuncture|"In the placebo arm, pregnant women will benefit one or two acupuncture sessions with one point which is located outside the acupuncture meridian.~The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both."
32835696|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
32835697|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
32835698|NCT01696877|Active Comparator|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
32835699|NCT01696877|Experimental|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
32835700|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
32835701|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
32835702|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
33103605|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
32956628|NCT05028075|Experimental|Intervention|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months and 9 months. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
32956629|NCT05026177|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
32956630|NCT05026177|Experimental|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
32956631|NCT05026177|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
32956632|NCT05021354|Experimental|Dry needling+eccentric exercises|It is established a plan of treatment base on the evidence for dry needling, eccentric exercise in the patient with lateral epicondylalgia. This is done in two sessions, one session every 10 days and with a duration of about 45 minutes.
32956633|NCT05021354|Active Comparator|Control group|Control group of patients with epicondylalgia.
32956634|NCT05019261|Experimental|Intervention|Multi-component Family Support Intervention
32956635|NCT05019261|No Intervention|Control|Usual ICU care
32956636|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 1] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose 1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
32956637|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc2 [dose 1] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc2 [dose 1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
32956638|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 1] + MK-5180) + SOC Chemotherapy|Participants in Japan receive MK-3475A (pembrolizumab Conc1 [dose 1] + MK-5180) SC on Day 1 of Cycle 1, with background SOC chemotherapy, and then receive 400 mg pembrolizumab IV on Day 1 of Cycles 2 to 18, with background SOC chemotherapy. A cycle is 42 days.
32956639|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 2] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose 2] + MK-5180) SC on Day 1 of Cycles 1 to 35 without background standard of care (SOC) chemotherapy. A cycle is 21 days.
32956640|NCT05015855|Placebo Comparator|OBGYN-PrEP|OBGYN-PrEP has 4 parts: (1) prioritize PrEP; (2) train providers in PrEP and intervention; (3) identify PrEP-appropriate women through a risk screen; and (4) monitor progress and fidelity to protocol.
32956641|NCT05015855|Experimental|NP-PC PrEP|NP-PC PrEP incorporates the standard of care and practices in OBGYN-PrEP but enhances access to additional skilled providers, as the PrEP provider burden is shifted to a Nurse Practitioner (NP) who will use a sexpositive approach to deliver PrEP services via telemedicine
32956642|NCT05012631|Experimental|Losartan|Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.
32956643|NCT05009069|Experimental|Atezolizumab + Tiragolumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab plus tiragolumab (Day 1 of each 21-day cycle for 3 cycles)."
32956644|NCT05009069|Other|Atezolizumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab (Day 1 of each 21-day cycle for 3 cycles)."
32956645|NCT05002543||MANTRA Aortic Sub-study|"Subjects diagnosed with aortic valve disease who are considered suitable to undergo aortic valve replacement with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Tissue Valve:~Perceval® PLUS SUTURELESS AORTIC HEART VALVE~Perceval® S SUTURELESS AORTIC HEART VALVE~Mechanical Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~Bicarbon Fitline Aortic (LFA)~Bicarbon Slimline Aortic (LSA)~Bicarbon Overline Aortic (LOV)~Carbomedics Prosthetic Heart Valve Models:~Standard Aortic Valve~Reduced Aortic Valve~Supra-Annular Aortic Valve (Top Hat)~Orbis™ Aortic Valve~Ascending Aorta Prostheses~CARBOMEDICS-CARBO-SEAL™~CARBOMEDICS CARBO-SEAL™ VALSALVA"
33033030|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
33103606|NCT05311410|Active Comparator|Control group|
33103607|NCT05311410|Active Comparator|Study group|
33319095|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
32747064|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
32747065|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
32747066|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
32747067|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
32747068|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
32747069|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
32956646|NCT05002543||MANTRA Mitral/Tricuspid Sub-study|"Subjects diagnosed with mitral and/or tricuspid valve disease who are considered suitable to undergo mitral valve repair/replacement and/or tricuspid valve repair with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Annuloplasty Rings:~SOVERING™ ANNULOPLASTY DEVICE models~annuloplasty ring, mitral model~annuloplasty band, mitral and tricuspid models~Carbomedics Annuloplasty Ring models:~CARBOMEDICS ANNULOFLO®~CARBOMEDICS ANNULOFLEX®~Memo Annuloplasty Ring o MEMO 3D™ SEMIRIGID ANNULOPLASTY RING~Mitral Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~o Bicarbon Fitline Mitral (LFM)~Carbomedics Prosthetic Heart Valve Models:~Standard Mitral Valve~Orbis™ Mitral Valve~OptiForm® Mitral Valve"
32747070|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
32956647|NCT05002543||MANTRA Memo 4D Sub-study|Subjects diagnosed with mitral valve disease who are considered suitable to undergo mitral valve repair with a CORCYM Memo 4D annuloplasty ring can be included in this study.
32956648|NCT05000645|No Intervention|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
32956649|NCT05000645|Experimental|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
32956650|NCT05000645|Experimental|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
32956651|NCT04990479|Experimental|Cohort 1a|Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.
32956652|NCT04990479|Experimental|Cohort 2a|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.
32956653|NCT04990479|Experimental|Cohort 2b|Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).
32956654|NCT04989218|Experimental|Novel combination of chemotherapy and immunotherapy|"This study has one arm. All enrolled patients will receive a combination of a platinum based chemotherapy regimen (gemcitabine and cisplatin) and a combination of two immune check point inhibitors, anti- CTLA4 (Tremelimumab) and anti PDL-1 (durvalumab).~Gemcitabine will be administered (gemzar) intravenously, 1000mg/m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles. Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.~Tremelimumab will be administered intravenously, 300mg flat dose, on Day 1 of cycle 1 only. Durvalumab will be administered intravenously 1500mg on Day 1 of a 21 day cycle for 4 cycles."
32956655|NCT04985227|Experimental|Home weight monitoring|Weighing scales will be provided to the parents to weigh their infant and enter the weight daily during the weekdays into the patient portal.
32956656|NCT04985227|No Intervention|Control|The parents will visit their Primary Care office in the usual manner as recommended by their Pediatrician.
32956657|NCT04983862|Experimental|Illuminare-1|
32956658|NCT04980612|Experimental|Group 1|4 cohorts of 10 participants to MBPR (First 3 groups single-arm, final group of 10 randomly assigned to MBPR)
32956659|NCT04980612|Active Comparator|Group 2|The last 20 participants will be randomly assigned to MBSR or MBPR, which will results in a control group with ~10 participants undergoing MBSR
32956660|NCT04965753|Experimental|FHD-609|Up to approximately 104 patients will be enrolled in dose escalation and expansion.
32956661|NCT04964544|Other|Open Label, Single Arm Technology-Assisted Cholesterol Trial|Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health
32956662|NCT04954196|Experimental|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
32956663|NCT04954196|Placebo Comparator|Placebo arm|Single dose per os placebo (microcrystalline cellulose) administration per day
32956664|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Day 1 until Week 24|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Day 1 until Week 24.
32956665|NCT04944784|Placebo Comparator|Placebo twice daily, from Day 1 until Week 24|Patients in this arm take 2 placebo oral tablets twice a day from Day 1 until Week 24.
32956666|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48 for patients who were not down titrated during the 24 weeks of blinded dosing.
32956667|NCT04944784|Experimental|150 mg reldesemtiv twice daily for a 300 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48 for patients who were down titrated for any reason during the 24 weeks of blinded dosing.
32956668|NCT04944290|Experimental|Perrigo active|
32956669|NCT04944290|Active Comparator|Reference active|
32956670|NCT04937166|Experimental|DSP107 in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
32956671|NCT04936464|Experimental|Intervention Group|30-minute treatments, twice weekly x12 weeks
32956672|NCT04936464|Sham Comparator|Sham Group|30-minute treatments, twice weekly x12 weeks
32956673|NCT04931654|Experimental|Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistance|AZD7789 monotherapy
32956674|NCT04931654|Experimental|Dose Expansion Part B1: NSCLC IO acquired resistance|AZD7789 Monotherapy
32956675|NCT04931654|Experimental|Dose Expansion Part B2: NSCLC IO naive|AZD7789 Monotherapy
32956676|NCT04931017|Experimental|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity.
32747071|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
32956677|NCT04931017|Active Comparator|Cohort B (metformin ER with waiting period))|Participants receive no intervention for 26 weeks, then cross-over to Cohort A.
33033031|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
32747072|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
32835703|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
32835704|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
32835705|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
32835706|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
32835707|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
32835708|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
32835709|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
32835710|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
32835711|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
32835712|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
32835713|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
32835714|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
32835715|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
32835716|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
32835717|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system~Treatment will be administered on an inpatient basis"
32835718|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
32835719|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
32835720|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
32835721|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
32747073|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
32747074|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
33103608|NCT05490290|Active Comparator|Active|In the active intervention the CDSS is implemented with decision support. Physicians are made aware of the referral guidelines and appropriate exams are suggested. Their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate and feedback is provided. Physicians are able to change their request in response to the feedback.
32835722|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
32835723|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
32835724|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
32835725|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
32835726|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
32835727|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
32835728|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
32835729|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
32835730|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
32835731|NCT02419482|No Intervention|control|Physical activity recommended
32835732|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
32835733|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
32835734|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
32835735|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
32835736|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
32835737|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
32835738|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
32835739|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
32835740|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
32835741|NCT02413632|Other|First period|"creation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
32835742|NCT02413632|Other|Second period|"validation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
32835743|NCT02421094|Active Comparator|GR-MD-02|Active
32835744|NCT02421094|Placebo Comparator|Placebo|Placebo
32835745|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
32835746|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
32835747|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
32835748|NCT02462122|Experimental|IDP-118 Lotion|Lotion
32835749|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
32835750|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
32835751|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
32835752|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
32835753|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
32835754|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
32835755|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
32835756|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
32835757|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
32835758|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
32835759|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
32835760|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
32835761|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
33326933|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
32835762|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
32835763|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
32835764|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
32835765|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
32835766|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
32835767|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
32835768|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
32835769|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)~Personalized vaccine (Day 1)~Booster dose of personalized vaccine (Day 43)~Booster dose of personalized vaccine (Day 85)"
32835770|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
32835771|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
32835772|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
32835773|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
32835774|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
32835775|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
32835776|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
32835777|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
32835778|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
33103609|NCT05490290|No Intervention|Control|The control condition will consist of computerized order entry with structured data entry of the clinical indication and tracking of the imaging exams requested. The CDSS is implemented but without decision support and physicians are blinded to these referral guidelines. Without their knowledge their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate. They receive no feedback to their requests.
32835779|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
32835780|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
32835781|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
32835782|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
33103610|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
33103611|NCT05478707|Placebo Comparator|Placebo|Saline subcutaneous injection, volume matched to dulaglutide, i.e. 0.5 mL weekly for 14 weeks
33103612|NCT05478707|Active Comparator|Dulaglutide|Dulaglutide (0.75 mg/0.5 mL weekly for 2 weeks, then 1.5 mg/0.5 mL weekly for 12 weeks) subcutaneous injection
33326934|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
33326935|NCT01167972||1|
32835783|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
32835784|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
32835785|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
32835786|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
32835787|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
32835788|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
32835789|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CHTP 1.1 M)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of mCC)."
32835790|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
32835791|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
32835792|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
32835793|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
32835794|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
32835795|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
32835796|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
32835797|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
32835798|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
32835799|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
32835800|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
32835801|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
32835802|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
32835803|NCT02418936||WS|WS diagositic kit
32835804|NCT02418936||LVAS|LVAS diagositic kit
32835805|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
32835806|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
32835807|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
32835808|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
33103613|NCT05478707|Active Comparator|Exercise training|Supervised high intensity interval training on a stationary bicycle will be conducted 3 days per week for 14 weeks. Participants will warm up at low intensity for 3 min then repeat 1-min bouts of 100% peak power output followed by 1-min recovery at 50 W. Training will start with 6 intervals per session, increasing by 2 intervals every 2 weeks. Sessions will end with a 10-min cool-down.
33103614|NCT05469399|Experimental|GBVRLPCA|Students in the experimental group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lectures, and a game practice for a week. One week later, students will be given a knowledge test, an objectively structured clinical exam for skill evaluation, and an evaluation form for game practice.
33103615|NCT05469399|Active Comparator|Control Group|The students in the control group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lessons, and no application will be made for a week. After one week, students will be given a knowledge test and an objective structured clinical exam for skill assessment.
33103616|NCT05303844|Experimental|H101 + Tislelizumab|(Dose escalation and cohort expansion) H101 administered by Intraperitoneal injection in combination with Tislelizumab administered intravenously (IV).
33319096|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
33319097|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|"The study will involve 3 visits:~Outpatient screening visit~Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)~Outpatient follow-up visit"
33319098|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
32835809|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
32835810|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
32835811|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
32835812|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
32835813|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
32835814|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
32835815|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
32835816|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
32835817|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
32835818|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
32835819|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
32835820|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
32835821|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
32835822|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:~A reminder letter indicating need for screening~A FIT kit with completion instructions~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~A pre-paid return mailer for FIT Kit"
32835823|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:~A reminder letter indicating need for screening~Instructions for obtaining a FIT kit~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
32835824|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
32835825|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
32835826|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
33319099|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
32835827|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once
32835828|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once
32835829|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once
32835830|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
32835831|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
32835832|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
32835833|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
32835834|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
32835835|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
32835836|NCT02421900||group 1|Atrial fibrillation patients
32835837|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
32835838|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
32835839|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
32835840|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
32835841|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
32835842|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
32835843|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
32835844|NCT02412774|Experimental|Water|Water after the main meal+ Diet
32835845|NCT02435524|Experimental|A&T Intervention Communes|
32835846|NCT02435524|No Intervention|Control Communes|
32835847|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
32835848|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
32835849|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
32835850|NCT02439814|Experimental|Pregnenolone|
32835851|NCT02439814|Placebo Comparator|Placebo|
32835852|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
32835853|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
32835854|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
32835855|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
32835856|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
32835857|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
33033032|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
33033033|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
33103617|NCT05454137|Experimental|participate in shared medical appointment|The POTS shared medical appointment will occur once monthly for four months. Each visit will last 1.5 hours. The group will meet in our clinic group space and lifestyle management therapies will be taught by a physician and another provider ie occupational therapist, dietician etc
33103618|NCT05454137|No Intervention|Do not participate in shared medical appointment|participants will only have one-on-one traditional visit with the physician
33103619|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
33103620|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
33103621|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
33103622|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
33103623|NCT05451641|Experimental|Wide-rigid cuff|The wide-rigid cuff will be randomly assigned to one of the subject's arms.
33103624|NCT05451641|Experimental|Narrow-elastic band|The narrow-elastic band will be randomly assigned to another arm of the subject.
33103625|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
33103626|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
33103627|NCT05469165|Experimental|Cyproheptadine 4 Mg Oral Tablet|Participants will receive cyproheptadine 4mg tablet orally three times a day for three months, with a daily increase of 4mg/dose if the previous dose was well tolerated, up to 0.5 mg/kg/day.
33103628|NCT05469165|Placebo Comparator|Placebo|Participants will receive a matched placebo orally three times a day for 3 months. Daily titration similar to the treatment arm.
33103629|NCT05433740|Experimental|Group I: Adjustable ligament|In the adjustable ligament method, binding tape with a button at one end and button holes along the band was wrapped around the outer end of the bite-block section of the device. The ends of the tape were then passed over the outer end of the bite block between two tubes and adjusted at or above the ear level (except neck veins), and fixed by inserting the button through the appropriate hole.
33103630|NCT05433740|No Intervention|Group II: Adhesive tape|The laryngeal mask was fixed using the standard method using adhesive tape.
33103631|NCT05294133|No Intervention|control group|no intervention
33103632|NCT05294133|Experimental|physical activity|
33103633|NCT05469048||Critically ill patients sepsis suspected|Patients suspected of sepsis and admitted to ICU
33103634|NCT05422235|Other|Control Group|Subjects in this group will be asked to continue their routine medical treatment for 24 weeks.
33103635|NCT05422235|Experimental|Aerobic Exercise|In order to determine the exercise capacity of subjects, submaximal exercise test will be performed.Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
33103636|NCT05422235|Experimental|Aerobic Exercise+ Foot-Related Exercises|In addition to walking training specific to the subject in the 2nd group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Participants will be followed for 24 weeks.
33103637|NCT05468814|Experimental|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
33103638|NCT05468814|Active Comparator|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
33103639|NCT05399342||LAAOS III Extended Follow-Up Cohort|Patients randomized into the LAAOS III trial who have consented to longer term observational follow-up. There is no intervention in this study.
33103640|NCT05398289|Experimental|4-week duration of antibiotic therapy|
33103641|NCT05398289|Active Comparator|standard 6-week duration of antibiotic therapy|
33103642|NCT05391581|Placebo Comparator|SAL-WAT|Saline infusion, saline injection, water ingestion
32747075|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
32747076|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
33103643|NCT05391581|Active Comparator|SAL-GLU|Saline infusion, saline injection, glucose ingestion
33103644|NCT05391581|Active Comparator|SAL-GIP|Saline infusion, GIP injection, water ingestion
33103645|NCT05391581|Active Comparator|SAL-GLP-2|Saline infusion, GLP-2 injection, water ingestion
33103646|NCT05391581|Experimental|GIA-WAT|GIPR antagonist infusion, saline injection, water ingestion
33103647|NCT05391581|Experimental|GIA-GLU|GIPR antagonist infusion, saline injection, glucose ingestion
33103648|NCT05391581|Experimental|GLA-WAT|GLP-2R antagonist infusion, saline injection, water ingestion
33103649|NCT05391581|Experimental|GLA-GLU|GLP-2R antagonist infusion, saline injection, glucose ingestion
33326936|NCT01283802||IOCUS|
32747077|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
32747078|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
32747079|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
32747080|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
32747081|NCT05548257||All patients were reviewed|
32747082|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
33103650|NCT05391503|Active Comparator|Active treatment|Active light therapy
33103651|NCT05391503|Placebo Comparator|Control treatment|Placebo light therapy
33103652|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33103653|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33103654|NCT00536367||Patients seen for ADHF at OSUMC|
33103655|NCT05386901|Experimental|Conventional positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set the PEEP value to 5 cmH2O until the end of the operation.
33319100|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
32747083|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
33103656|NCT05386901|Experimental|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set initial PEEP to 0cmH2O,and the PEEP is increased by 2 cmH2O every 2 minutes.Observing the PEEP value corresponding to the maximum lung dynamic compliance during the process that lung dynamic compliance=Vt/(Pplat-PEEP).After the incremental PEEP process is completed, setting the PEEP value for ventilation until the end of the operation.
33103657|NCT05386082||Study participants|Study participants
32747084|NCT05542641|Experimental|real rTMS|verum rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
32747085|NCT05542641|Sham Comparator|sham rTMS|sham rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
32747086|NCT05698953|Experimental|Reiki Group|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
32747087|NCT05698953|Placebo Comparator|Placebo Group|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days Placebo Reiki group is applied to the sham Reiki by an independent nurse during the same application period.
33103658|NCT05468775|Experimental|intervention group|
33103659|NCT05468775|No Intervention|control group|
33319101|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
33319102|NCT01330810|Active Comparator|Meriva|2g Meriva powder
33319103|NCT01330888||Group 1|ARNG Chaplains
33319104|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
33319105|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
32747088|NCT05698953|No Intervention|Control Group|No intervention is made in the control group. Standard care was used
32747089|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
32747090|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
32747091|NCT05548101|No Intervention|Conventional Insemination|Oocytes will be fertilized via conventional insemination: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Insemination will occur 4-6 hours post-retrieval. Sperm will be collected as a fresh specimen and washed with Irvine Scientific Continuous Single Culture-NX. Sperm concentration and motility will be assessed before and after washing according to WHO 6th edition criteria. Sperm will be prepared to achieve a concentration of 200,000 sperm per 100 microliter drop. 6 drops of prepared sperm will be added to each dish.
32747092|NCT05548101|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|Oocytes will be fertilized via ICSI: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Oocytes will be immediately exposed to hyaluronidase to strip the cumulus and coronal cells. Embryologists will assess the maturation status under inverted microscopy. ICSI will be performed on all mature metaphase II oocytes 4 hours after retrieval. Injected oocytes will then be placed in a fresh culture dish and returned to the incubator.
32747093|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
32747094|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
32747095|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
32747096|NCT05552781|Experimental|20 mg QD, oral|H002 20mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32747097|NCT05552781|Experimental|40 mg QD, oral|H002 40mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32747098|NCT05552781|Experimental|80 mg QD, oral|H002 80mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32747099|NCT05552781|Experimental|150 mg QD, ora|H002 150mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32835858|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
32835859|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
32835860|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
32835861|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
32835862|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
32835863|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
33103660|NCT05385458|Experimental|ACT Intervention|Participants will attend 6-8 individual psychotherapy sessions via telephone, text or videoconference. Sessions will last approximately 1 hour and occur every 3-4 weeks. Participants will be enrolled in the Intervention Group for 18-36 weeks. All sessions will be audio recorded. Participants will also be able to attend all available usual care services such as: support groups, First Link, education classes at the Alzheimer Society. Any services utilized will be documented by Alzheimer Society staff.
33103661|NCT05385458|Active Comparator|Usual Care|Participants will be enrolled as an Alzheimer Society client. Participants will receive 1 First Link 'check-in' telephone call from a staff member at the time of enrolment. Participants will receive a 2nd 'check-in' First Link telephone call from a staff member 3-4 months following enrolment. Participants will be enrolled in the Usual Care Group 12-16 weeks. Participants will also be able to attend all available usual care services such as: support groups, etc. Any services utilized will be documented by Alzheimer Society staff.
33103662|NCT05384717|Experimental|Fidget group|Participants in the experimental fidget group select a fidget from 4 options: fidget spinner, stress ball, pop-it, or fidget cube
33103663|NCT05384717|Placebo Comparator|Control group|No fidget choice provided
33103664|NCT05468658|Experimental|Experimental Group (A): Feng Shui Birth Unit|"The cabinets will be painted using salmon and pastel green.~It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~Live nature videos and sounds will be projected onto the wall.~Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~Natural plants will be placed.~Lighting will be used.~Bed linen will be designed according to the Feng Shui.~Wooden bell will be used.~Turtle, elephant and Wu Lou objects will be placed.~The Bagua mirror will be placed.~Crystals will be placed.~Natural stones will be placed.~The fountain will be placed in the east compass direction of the unit.~Straw bamboo separator will be used."
33405488|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
32835864|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
32835865|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
33103665|NCT05468658|No Intervention|Control Group (B): Routine Birth Unit|The delivery unit of the institution consists of a small corridor, a labor room, a delivery room and a baby room. In the small corridor, there is a desk, document cabinets, vaccine cabinet and medicine cabinet for the midwife to work. The institution's routine delivery unit is equipped with standard medical devices and supplies. However, there are medical devices that are not used in the unit. White bed linens designed with the standard hospital logo are used in the unit. However, the curtains are plain cream, the walls are light blue, and the ceilings are white.
32835866|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
32835867|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
32835868|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
32835869|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
32835870|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
32835871|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
32835872|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
32835873|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
32835874|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
32835875|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
33319106|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
33319107|NCT01331122|Placebo Comparator|placebo|placebo
33319108|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
32835876|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
32835877|NCT02523196|Other|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
32835878|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
32835879|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
33319109|NCT01331278|Active Comparator|Custom Cutting Blocks|
32835880|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
32835881|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
32835882|NCT05067114||Observational Cohort|Screening, detection, and referral for atrial fibrillation
32835883|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
32835884|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
32835885|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
32835886|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
32835887|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
32835888|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
32835889|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
32835890|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
32835891|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
32835892|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
32835893|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
32835894|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
32835895|NCT05064150||NET patient observational cohort|Patients diagnosed with lung or gastrointestinal neuroendocrine tumors
33319110|NCT01331278|Active Comparator|Computer Assisted Surgery|
33319111|NCT01331356|Experimental|Injection of botulinum toxin type A|
33319112|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
33319113|NCT01315288|Other|Video presentation|
33319114|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
33319115|NCT01331746|Placebo Comparator|Placebo|
33319116|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
33326937|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
32835896|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
32835897|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
32835898|NCT05052996|Experimental|ISL+LEN|"Participants will receive the following for at least 48 weeks:~Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~Day 2: LEN only oral 600 mg (2 x 300 mg)~Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg (2 x 1 mg)"
32835899|NCT05052996|Experimental|B/F/TAF|"Participants will receive the following for at least 48 weeks:~bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily~After 48 weeks, participants will switch from B/F/TAF to ISL+LEN~Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~Day 2: LEN only oral 600 mg (2 x 300 mg)~Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg~Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study."
33319117|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
33319118|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
33319119|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
33319120|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
33319121|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
33319122|NCT01332058|Experimental|Motivational Interviewing (MI)|
33319123|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
33319124|NCT04245748|Active Comparator|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
33319125|NCT04245748|Active Comparator|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
33319126|NCT04245436|Active Comparator|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
33319127|NCT04245436|Active Comparator|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
33319128|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
33319129|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
33319130|NCT01332214|Experimental|AZD2820|
33319131|NCT01332214|Placebo Comparator|Placebo|
33319132|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
33319133|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
33319134|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
33319135|NCT01332448||Orlistat 120|Orlistat 120mg tid
33319136|NCT01332448||Orlistat 60|Orlistat 60 mg tid
33319137|NCT01332448||Placebo|No active drug
33319138|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
33319139|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
33319140|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
33319141|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
33319142|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
33319143|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
33319144|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
32835900|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
32835901|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
32835902|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
32835903|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
33319145|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
33319146|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
33319147|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.~CKD: nondiabetic nephropathy~duration hemodialysis 3-48 months~Hb-11-13 g/dl~well controlled hypertension ( < 140/90 mmHg)~without ACEi, ARB, allopurinol treatment~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
33319148|NCT04484428|Experimental|Treatment Arm A|K-285
33319149|NCT04484428|Active Comparator|Treatment Arm B|Menthol
33319150|NCT01332604|Experimental|A|
33319151|NCT01332604|Experimental|B|
33319152|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
33319153|NCT01332682|Other|Nutrition Counseling|
32835904|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
33319154|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
33319155|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
33319156|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
33319157|NCT01332838|Experimental|Sigvaris special compression stocking|
33319158|NCT01332838|Active Comparator|Standard Compression|
33319159|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
33319160|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
33319161|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
33319162|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
33319163|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
33319164|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
33319165|NCT01333150|Experimental|Propranolol|
33319166|NCT01333150|Experimental|Placebo|
33319167|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
33319168|NCT01333306|Experimental|tDCS and cognitive training|
33319169|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
32835905|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
32835906|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
33319170|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
33319171|NCT02972008||patients with constitutional von Willebrand factor (vWF) deficiency|
33319172|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
33319173|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
33319174|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
33319175|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
33319176|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
33319177|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
33319178|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
33319179|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
33319180|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
33319181|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
33319182|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
33319183|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
33319184|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
33319185|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
33319186|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
33319187|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
33319188|NCT02818582|Active Comparator|GS-5734 100mg given intravenously daily for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
33319189|NCT02818582|Placebo Comparator|Normal saline intravenously for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days
33319190|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32835907|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
32835908|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
32835909|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
32835910|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
32835911|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
32835912|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
32835913|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
32835914|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
32835915|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
32835916|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
32835917|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
32835918|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
32835919|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
32835920|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
32835921|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
32835922|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
32835923|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
32835924|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
32835925|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
32835926|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
32835927|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
32835928|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
32835929|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
32835930|NCT02417220|Active Comparator|Weight Watchers Online 2015|
32835931|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
32835932|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
32835933|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
32835934|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
32835935|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
32835936|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
32835937|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
33103666|NCT04319926|Experimental|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
32835938|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
32835939|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
33319191|NCT01333618|Experimental|curving introducer|
32835940|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
32835941|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
32835942|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
33319192|NCT01333618|Placebo Comparator|straight introducer|
33319193|NCT05186506|Experimental|Ensatinib|225 mg administered once daily orally for two years.
33319194|NCT05186506|Active Comparator|Platinum-Based Chemotherapy|Patients in the chemotherapy group were allowed to cross into the Ensatinib treatment group after the disease progressed.
32835943|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
32835944|NCT02530528|Experimental|2% CHG 1 min|single administration, 1 min application time
32835945|NCT02530528|Experimental|2% CHG 2 min|single administration, 2 min application time
32835946|NCT02530528|Experimental|2% CHG 3 min|single administration, 3 min application time
32835947|NCT02530528|Active Comparator|Comparator 2% CHG|Single administration, Marketed CHG
32835948|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
32835949|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
32835950|NCT02411058|Experimental|Uninformed|Condition 1
32835951|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
32835952|NCT02530996|Experimental|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
32835953|NCT02530996|Experimental|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
32835954|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
32835955|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
32835956|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
32835957|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
32835958|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
32835959|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
32835960|NCT03174678|Other|Control|Apple juice
32835961|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
32835962|NCT02409498|Placebo Comparator|no pudendal block|Saline
32835963|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
32835964|NCT02409420|No Intervention|Control|Usual care
32835965|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
32835966|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
32835967|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
32835968|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
32835969|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
32835970|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
32835971|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
32835972|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
32835973|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
32835974|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
32835975|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
32835976|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
33319195|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
32835977|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
32835978|NCT03177174|Active Comparator|Docetaxel|
32835979|NCT03177174|Active Comparator|Cisplatin|
32835980|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
32835981|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
32835982|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
32835983|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
32835984|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
32835985|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
32835986|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
32835987|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
32835988|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
32835989|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
32835990|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
32835991|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
32835992|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
32835993|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
32835994|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
32835995|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
32835996|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
32835997|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
32835998|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
32835999|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
32836000|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
32836001|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
32836002|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
32836003|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
32836004|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
32836005|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
32836006|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
32836007|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
32836008|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
32836009|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
32836010|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
32836011|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
32836012|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
32836013|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
32836014|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
32836015|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
32836016|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
32836017|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
32836018|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
32836019|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
32836020|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
33319196|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
32836021|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
32836022|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
33319197|NCT01337518|Experimental|EZN-4176|
33319198|NCT05186194|Experimental|Experimental (Treatment) Group|Oral vitamin D1000IU, 1/day, calcium 1200mg, 1/day, for 8 weeks.
33319199|NCT05186194|Placebo Comparator|Control Group|Oral placebo, for 8 weeks.
33319200|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
33319201|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
33319202|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
33319203|NCT04446676|Active Comparator|Stem stabilization|Group of patients with stem endoprosthesis stabilization
33319204|NCT04446676|Active Comparator|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
33319205|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
33319206|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
33319207|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
33319208|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
33319209|NCT05186038||Population of children and adolescents between 2 and 18 years old|Population of children and adolescents between 2 and 18 years old who are diagnosed with celiac disease or are suspected to suffer the disease.
33319210|NCT04442152|Experimental|Intervention|See intervention description
33319211|NCT04442152|No Intervention|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
33319212|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
33319213|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
33319214|NCT01338532|Active Comparator|Supervised exercise + patient education|
33319215|NCT01338532|Active Comparator|Patient education|
33319216|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
33319217|NCT02882152|Active Comparator|Morphine|intrathecal morphine
33319218|NCT05185804|Experimental|Group DD217|Study drug Dimolegin - DD217, 60 mg orally, 1 time per day
33319219|NCT05185804|Active Comparator|Group Clexane|Reference drug Clexane, 40 mg subcutaneously, 1 time per day
33319220|NCT01338688||Td ,Td and TIG|
33319221|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
33319222|NCT05185648|Experimental|post-training scores|evaluating qualities of trauma care after standard trauma traning
33319223|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
33319224|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
33319225|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
33319226|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
32836023|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
32836024|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
32836025|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
32836026|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
32836027|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
32836028|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
32836029|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
32836030|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
32836031|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
32836032|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
32836033|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
32836034|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
32836035|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
32836036|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
32836037|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
32836038|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
32836039|NCT00363922|Experimental|1|Rehabilitation in institution
32836040|NCT00363922|Active Comparator|2|Rehabilitation at home
32836041|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
32836042|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
32836043|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
32836044|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
32836045|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
32836046|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
32836047|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
32836048|NCT02538016|Other|Tolvaptan|
32836049|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
32836050|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
32836051|NCT04341142|Experimental|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
32836052|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
32836053|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
32836054|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
32836055|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
32836056|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
32836057|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
32836058|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
32836059|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
32836060|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
33103667|NCT04319926|Experimental|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
33103668|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
32836061|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
32836062|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
32836063|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
32836064|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
32836065|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
33405489|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
33405490|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
33405491|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
33405492|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
32836066|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
32836067|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
32836068|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
32836069|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
32836070|NCT04482348|Active Comparator|the mind is a great story teller-positively framed|explanations for more pain than expected
32836071|NCT04482348|Active Comparator|the mind is a great story teller-negatively framed|explanations for more pain than expected
32836072|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-positive frame|explanations for more pain than expected
32836073|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-negative frame|explanations for more pain than expected
32836074|NCT04482348|Active Comparator|"mixed emotion and cognition (mind and body work together)"|explanations for more pain than expected
32836075|NCT04482348|Active Comparator|"physically based explanations over-excited state"|explanations for more pain than expected
32836076|NCT04482348|Active Comparator|"physically based explanations overstimulated"|explanations for more pain than expected
32836077|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
32836078|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
32836079|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
32836080|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
32836081|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
33103669|NCT05384132|Experimental|Scaling and Root Planing (SRP) + Livfresh Dental Gel (LDG)|SRP at Baseline with use of LDG (test dentifrice) for twice daily brushing between study visits.
33103670|NCT05384132|Active Comparator|Scaling and Root Planing (SRP) + standard fluoride dentifrice|SRP at Baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits.
33103671|NCT05226871|Other|Arm 1|Cetuximab
33103672|NCT05226871|Experimental|Arm 2|Palbociclib plus Cetuximab
33103673|NCT05226871|Other|Arm 3|Palbociclib plus Fulvestrant
33103674|NCT05226871|Other|Arm 4|Palbociclib plus Letrozole
32836082|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
32836083|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
32836084|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
32836085|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
32836086|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
32836087|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
33319227|NCT05185414|Other|RNA sequencing in genetically solved lissencephaly cases|RNA expression patterns in lissencephalies. RNA sequencing will be applied to the genetically solved lissencephaly cases. The acquired information on RNA expression patterns will be implemented in unsolved lissencephaly cases.
33103675|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
33103676|NCT05216016|No Intervention|Control Group|Individuals will receive a handout with additional job related services; e.g. Job Accommodation Network.
33319228|NCT05185414|Other|RNA sequencing in genetically unsolved lissencephaly cases|Obtain a genetic diagnosis in unsolved lissencephaly cases by implementation of RNA expression patterns obtained in arm 1.
32836088|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
32836089|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
32836090|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
32836091|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
32836092|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
32836093|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
32836094|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
32836095|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
32836096|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
32836097|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
32836098|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
32836099|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
32836100|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
32836101|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
32836102|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
32836103|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
32836104|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
32836105|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
32836106|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
32836107|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
33319229|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
33319230|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
33319231|NCT01339156|Experimental|P3914|
33319232|NCT01339156|Placebo Comparator|Placebo|
33319233|NCT01339234|Experimental|Body-weight supported treadmill training|
33319234|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
33319235|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
33319236|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
33319237|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
33319238|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
33319239|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
32836108|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
32836109|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
32739260|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
32836110|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
32836111|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
32836112|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
32836113|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
32836114|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
32739261|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
32739262|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
32739263|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
32739264|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
32739265|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
32739266|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane|Control arm
32739267|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane + Hemoadsorption using HA380|Intervention arm
32739268|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
32739269|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
32739270|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
32739271|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
32739272|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
32739273|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
32739274|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
32739275|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
32739276|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
32739277|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
32739278|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
32739279|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
32739280|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
32739281|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
32739282|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
32956678|NCT04929223|Experimental|Inavolisib + Cetuximab|"Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days).~Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each."
33405493|NCT05759949|Experimental|RLY-5836 Single Agent Arm|RLY-5836 single agent arm for participants with unresectable or metastatic solid tumors
32739283|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
32739284|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
32739285|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
32739286|NCT04991259|Experimental|Preemptive CRRT|In patients randomized to early CRRT, CRRT would be initiated within 12 hours of randomization.
32739287|NCT04991259|Active Comparator|Standard Medical Treatment|"In patients randomized to SMT group, CRRT would be initiated as per the existing standard protocol.~in patients with worsening hyperammonemia despite two sessions of plasma-exchange~patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)."
32739288|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
32739289|NCT04997343|Experimental|MS patients|All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
32739290|NCT04997343|Other|Healthy controls|Healthy subjects will undergo only the neurophysiological evaluation at baseline.
32739291|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
32739292|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
32739293|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
32739294|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
32739295|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
32739296|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
32739297|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
32739298|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
32739299|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
32739300|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
32739301|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
32739302|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
32739303|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
32739304|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
32739305|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
32739306|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
32739307|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
32739308|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
32739309|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
32739310|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
32739311|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
32739312|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
32739313|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
32739314|NCT03071679|Experimental|Omiganan|
32739315|NCT03071679|Experimental|Imiquimod|
32739316|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
32956679|NCT04929223|Experimental|Inavolisib + Bevacizumab|Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days).
32956680|NCT04929223|Experimental|Atezolizumab + Tiragolumab + Bevacizumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with Tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and Bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days)
32956681|NCT04929223|Experimental|Atezolizumab + Tiragolumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days)
32956682|NCT04929223|Experimental|Atezolizumab + SY-5609|Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, or 5 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days) Open in the United States only.
32956683|NCT04929223|Experimental|GDC-6036 + Cetuximab + FOLFOX|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFOX on Days 1 and 15 with GDC-6036 PO QD on Days 1-28. (Cycle length=28 days)
32956684|NCT04929223|Experimental|GDC-6036 + Cetuximab|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 with GDC-6036 PO QD on Days 1-28. (Cycle length=28 days)
32956685|NCT04925544|Experimental|VK-2019_arm|1800 mg VK 2019 once daily, cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
32956686|NCT04924608|Experimental|Arm A|Selumetinib
32956687|NCT04924608|Placebo Comparator|Arm B|Placebo
32739317|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
32956688|NCT04922840|Experimental|High-intensity exercise (HIIT)|"Usual care; CVD risk assessment, lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication.~The 12-week intervention is carried out as individual or group sessions with maximal 4 patients, supervised by physiotherapists in primary health care. The HIIT group complete two weekly HIIT sessions and a third weekly session with exercise at moderate intensity. Exercise is tailored to each individual to provide the same relative exercise stress and to ensure progression. Target exercise intensity is tracked by a heart rate monitor.~Individual exercise session are recorded in a training diary. Succeeding the intervention, a questionnaire will be distributed to patients in the HIIT group. Semi-structured interviews will target physiotherapists supervising HIIT and 5-7 patients in the HIIT group."
33319240|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
32739318|NCT03071679|Placebo Comparator|Placebo|Vehicle
32739319|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
32739320|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
32739321|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
32739322|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
32739323|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
32739324|NCT05001321||Training Group|Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
32739325|NCT05001321||Internal Validation Group|Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
32739326|NCT05001321||External Validation Group|Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
32739327|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
32739328|NCT03201679||Patients without preoperative sepsis|
32739329|NCT04996953||165 patients with insomnia|
32739330|NCT02478749|Experimental|Infant|patients aged younger than 1year
32739331|NCT02478749|Experimental|Child|patients aged 1year to 5years
32739332|NCT02478749|Experimental|Adult|adult patients
32739333|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
32739334|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
32739335|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
32747100|NCT05552781|Experimental|250 mg QD, oral|H002 250mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32836115|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
32836116|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
32836117|NCT04481100|Experimental|Experimental Group|Itraconazole capsule 100mg twice daily for 6 weeks concurrent with chemoradation.
32836118|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
32836119|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
32836120|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
32836121|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
32836122|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
33319241|NCT01339624|Active Comparator|NASAL FENTANYL,|
33319242|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
33319243|NCT05184946|Experimental|Anti-PD1 combined with SOX|Camrelizumab will be administered one day before SOX regimen.
33319244|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
32836123|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
32836124|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
32836125|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
32836126|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
32836127|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
32836128|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
32836129|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
32836130|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
32836131|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
32836132|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
32836133|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
32836134|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
32836135|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
32836136|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
32836137|NCT02401620||single-group studies|Patients with RA diagnosed
32836138|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
32836139|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
32836140|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
32836141|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
32836142|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
32836143|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
32836144|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
32836145|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
32836146|NCT02407782|Experimental|Ivermectin|
32836147|NCT02407782|Experimental|Permethrin|
32739336|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
32956689|NCT04922840|No Intervention|Usual care|Control group participants receive the same treatment as usual care; CVD risk assessment including lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication. Control group participants are invited to a physiotherapist-led theoretical and practical HIIT session following study completion.
32956690|NCT04921488|Experimental|Patients with indication for colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
32956691|NCT04920032|Experimental|TASIRI|"Patients randomized to the experimental arm (TASIRI) will be treated with TAS-102 25mg/m2 p.o. on days 1-5 and irinotecan 180mg/m2 i.v. on day 1 every 14 days. If ANC <1500/uL on day 1 of a cycle, then G-CSF will be added on day 6 for three days."
32956692|NCT04913064|Experimental|Prevention (white button mushroom)|Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
32956693|NCT04908176|Experimental|Participants with metastatic, unresectable GIST, non-CNS solid tumors, or CNS tumors|Participants will receive 5 mg of midazolam orally on Day 1 and Day 17. Participants will receive avapritinib 300 mg daily, orally on starting on Day 3. Participants with CNS tumors will receive avapritinib 300 mg daily orally, until Day 56.
32956694|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
32956695|NCT04906525|Experimental|Resistance training|Participants will undergo 6 weeks of supervised resistance training
32956696|NCT04903288|Experimental|Eladocagene Exuparvovec|Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
32956697|NCT04901624|Experimental|Personal Risk + Loss Protection|Personal Risk + Loss Protection
32956698|NCT04901624|Experimental|Personal Risk + Lottery Incentive|Personal Risk + Lottery Incentive
32956699|NCT04901624|Experimental|Family Risk + Loss Protection|Family Risk + Loss Protection
32956700|NCT04901624|Experimental|Family Risk + Lottery Incentive|Family Risk + Lottery Incentive
32956701|NCT04898023|Experimental|zinc-green tea extract-ascorbic acid|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
32956702|NCT04898023|Placebo Comparator|Placebo|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
32956703|NCT04893109|Experimental|Arm A. T-DM1 followed by Trastuzumab SC|Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles
32956704|NCT04893109|Experimental|Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone|Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.
32956705|NCT04889521||HIV and painful neuropathy|Persons living with HIV who also have painful distal sensory polyneuropathy in the feet.
32956706|NCT04889521||HIV without painful neuropathy|Persons living with HIV who do NOT have painful distal sensory polyneuropathy in the feet.
32956707|NCT04888923||Healthy Controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina.
32956708|NCT04883645|Experimental|Experimental: Topical Aldara|"All patients receive the same treatment (there is no placebo arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."
32956709|NCT04883450||Risk of pancreatic cancer|Subjects with an increased predicted 18-month risk of pancreatic cancer
32956710|NCT04882540|Experimental|brivaracetam|This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
32956711|NCT04878354|Placebo Comparator|Placebo|Gelatine (fish source), mannitol and sodium hydroxide
32956712|NCT04878354|Experimental|Intervention/treatment|Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
32956713|NCT04871100|Experimental|UP-A|Cognitive behavior therapy using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules.
32956714|NCT04871100|Active Comparator|Problem Solving therapy|Skills based approach for managing negative moods and stress.
32956715|NCT04868123|Experimental|Mindfulness Meditation|6 weeks of daily mindfulness meditation (guided by audio recordings) performed at home
32956716|NCT04868123|Experimental|Transcutaneous nerve stimulation (TENS)|6 weeks of daily TENS treatment performed at home
32956717|NCT04868123|No Intervention|Usual Care|Usual care (no additional treatment)
32956718|NCT04864392|Experimental|LNA043 Dosing Regimen A|LNA043 injection to the knee with dosing regimen A
32956719|NCT04864392|Experimental|LNA043 Dosing Regimen B|LNA04 injection to the knee with dosing regimen B
32956720|NCT04864392|Experimental|LNA043 Dosing Regimen C|LNA043 injection to the knee with dosing regimen C
32956721|NCT04864392|Experimental|LNA043 Dosing Regimen D|LNA043 injection to the knee with dosing regimen D
32956722|NCT04864392|Placebo Comparator|Placebo|Injection to the knee
32956723|NCT04859829||Patients with autoimmune dysmotility receiving IVIG infusions|
32956724|NCT04859829||Patients with autoimmune dysmotility without IVIG infusions|
33103677|NCT05216016|Experimental|Intervention Group|Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.
32836148|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
32836149|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.~Patients with acute upper G.I hemorrhage.~Informed consent."
32836150|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
32836151|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
32836152|NCT04896450|Experimental|Test group|Test subjects receive GTR and early initiation of OTM.
32836153|NCT04896450|Active Comparator|Control group|Control subjects receive only GTR.
32836154|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
32836155|NCT02405052||Patients|Emergency department patients with unexplained chest pain
32836156|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
32836157|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
32836158|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
33319245|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
33319246|NCT01339780|Experimental|Breast Cancer|
33319247|NCT01339780|Experimental|Prostate Cancer|
32836159|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
32836160|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
32836161|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
32836162|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
32836163|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
32836164|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
32836165|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
32836166|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
33319248|NCT05184634|Active Comparator|Working group|The data of the control group will be compared with the data of the study group.
32836167|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
32836168|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836169|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836170|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836171|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32956725|NCT04851158|Experimental|ShotBlocker|ShotBlocker will be used on 35 patients. For the patient group that is applied ShotBlocker, after cleansing the skin, the protruding surface of the device is placed facing the skin surface. The injection is applied with the appropriate technique, then ShotBlocker is removed and a light pressure is applied to the area with a cotton pad for 15-20 seconds.
33103678|NCT05382416|Experimental|Peer Toolkit Training|Participants assigned to this arm will attend online or in-person trainings on the SHARE! Peer Toolkit, which requires 60 hours of time to be completed over 10 weeks.
32836172|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836173|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836174|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
33319249|NCT05184634|Active Comparator|Control Group|The data of the study group will be compared with the data of the control group.
33319250|NCT01340092|Active Comparator|Family Navigator|Family navigation
33319251|NCT01340092|No Intervention|Standard Care|standard care
33319252|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
33319253|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
33405494|NCT05759949|Experimental|RLY-5836 + Fulvestrant Arm|RLY-5836 + fulvestrant combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
32836175|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836176|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
33319254|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
33319255|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
33319256|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
32836177|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
32836178|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
32836179|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
32836180|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
32836181|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
32836182|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
32836183|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
32836184|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
32836185|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
32836186|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
32836187|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
32836188|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
32836189|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
32836190|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
32836191|NCT04480866|Other|First-void urine collection|Women self-collect three first-void urine samples (random order) at home.
32836192|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
32836193|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
32836194|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
33319257|NCT05184322|Experimental|Cohort 1|Cohort 1 will enroll 10 healthy participants, doses ranging from 2mg to 7mg.
32836195|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
32836196|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
32836197|NCT04743544||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
32836198|NCT04481802|Experimental|RadiaAce gel|RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
32836199|NCT04481802|Active Comparator|Biafine|one of the standard skin care in radiation oncology, this treatment was chosen as the comparator.
32836200|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
32836201|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
32836202|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
32836203|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
32836204|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
32836205|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
32836206|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
33103679|NCT05382416|No Intervention|Wait-list Control|The wait-list control will continue practice as usual and not receive peer toolkit training until after the follow-up data collection.
33319258|NCT05184322|Experimental|Cohort 2|Cohort 2 will enroll 10 healthy participants, doses ranging from 2mg to 15mg.
32836207|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
32836208|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
32836209|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
32836210|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
33103680|NCT05194579|Other|PF-06881894 by on-body injector (OBI)|PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection
33103681|NCT05194579|Other|PF-06881894 by prefilled syringe (PFS)|PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection
33103682|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
33103683|NCT05212155|Other|Participating families|Parent/child dyads enrolled in the open-label program
33103684|NCT05378594|Experimental|House dust mite nasal allergen challenge|House dust mite allergic patients to undergo nasal allergen challenge with house dust mite extract
33103685|NCT05378594|Experimental|Silver birch pollen nasal allergen challenge|Silver birch pollen allergic patients to undergo nasal allergen challenge with silver birch pollen extract
33103686|NCT01366612|Active Comparator|Group 1|FLUDARABINE AND BUSULFAN
33103687|NCT01366612|Experimental|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
33103688|NCT05468580|Active Comparator|endoscopic Coeliac Artery Release (eCAR)|Patients randomized in the Intervention Group.
33103689|NCT05468580|Sham Comparator|Sham Operation|Patients randomized in the Sham group.
33103690|NCT05366114||New patients at the GoodHope EDS clinic at Toronto General Hospital|All patients seen in the EDS clinic are eligible for inclusion, regardless of their presenting diagnosis or the results of their assessments.
33103691|NCT04206943|Experimental|A Low Dose|4 x 10^6 Car-T cell/ kg
33103692|NCT04206943|Experimental|B High Dose|6 x 10^6 Car-T cell/ kg
33103693|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
33103694|NCT05200962|Experimental|Active tDCS group|The experimental arm receives real (or active) electrical stimulation for 20 minutes
33103695|NCT05200962|Sham Comparator|sham tDCS group|The sham arm receives sham (or no real) intervention in which stimulation lasts for 30 seconds and ends afterward.
33103696|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~Cytoxan 1200mg/m2~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~Irinotecan 50 mg/m2/day x 5 days~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
33103697|NCT05352659|Experimental|Face-to-face and online LGBTQ training+|The Study Intervention arm receives the organization-level LGBTQ climate assessment and technical assistance, the provider-level face-to-face LGBTQ training along with links to publicly available on-line training.
33103698|NCT05352659|Other|On-line resources|The Comparison Intervention arm receives only links to publicly available on-line resources.
33103699|NCT01158664|Experimental|0.6 mm tread pitch implant|
33103700|NCT01158664|Experimental|0.1 mm tread pitch implant|
33103701|NCT05180773|Active Comparator|Bromocriptine Treatment Arm|100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.
33103702|NCT05180773|Placebo Comparator|Placebo Arm|100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.
32836211|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
32836212|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
32836213|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
32836214|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
32836215|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
32836216|NCT04340986||patients with Hepatocellular carcinoma|
32836217|NCT04340986||patients with Cholangiocarcinoma|
32836218|NCT04743622|Experimental|Monoprost (preservative-free latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
32836219|NCT04743622|Active Comparator|Xalatan (preserved latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
33103703|NCT05180773|Other|Breastfeeding Observational Cohort|Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.
33103704|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
33103705|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
32836220|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
33103706|NCT05193240|Experimental|preliminary swallowing test|compared as nasofibroscopy and ultrasound examination of vocal cords
33103707|NCT05350514||T1D|Young adults with youth-onset type 1 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
33103708|NCT05350514||T2D|Young adults with youth-onset type 2 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
33103709|NCT05350514||NDM|Age-similar group of young adults without diabetes (n=5)
33103710|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
33103711|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
32836221|NCT02400918|No Intervention|Control|Waitlist control
32836222|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
32836223|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
32836224|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
32836225|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
32836226|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
32836227|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
32836228|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
32836229|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
32836230|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
32836231|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
32836232|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
32836233|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
32836234|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
33103712|NCT01135459|Experimental|CEP-33457|Participants will receive CEP-33457 200 mcg SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
33103713|NCT01135459|Placebo Comparator|Placebo|Participants will receive placebo matching to CEP-33457 SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
33103714|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
33103715|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
33405495|NCT05759949|Experimental|RLY-5836 + Palbociclib + Fulvestrant Arm|RLY-5836 + palbociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
33103718|NCT05178667|Experimental|High dose|4 capsules with 1.6g of active product per day: 2 at breakfast and 2 at dinner
33103719|NCT05178667|Active Comparator|Low dose|4 capsules with 0.8g of active product per day: 2 at breakfast and 2 at dinner
32956726|NCT04851158|Experimental|Local Vibration|Local Vibration will be used on 35 patients. For the patient group that was subject to local vibration, local vibration was applied to the region with a vibrator for five minutes prior to injection, following a previous study on this subject. After that, 70% alcohol was used to cleanse the skin. The injection was applied with the appropriate technique, then a light pressure was applied to the area with a cotton pad for 15-20 seconds.
32956727|NCT04851158|No Intervention|Control|For the control group (n=35), IM injection into the ventrogluteal region without using any tools is performed with the appropriate technique.
33319259|NCT05184322|Experimental|Cohort 3|Cohort 3 will enroll 10 healthy participants, doses ranging from 7mg to 30mg.
33319260|NCT05184322|Experimental|Cohort 4|Cohort 4 will enroll 10 otherwise 'healthy' participants with obesity, doses ranging from 7mg to 30mg.
32739337|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
32739338|NCT04990713|Placebo Comparator|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with saline placebo. Local anesthetic administered will be ropivacaine 0.2%.
32739339|NCT04990713|Experimental|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with local anesthetic. Local anesthetic administered will be ropivacaine 0.2%.
32739340|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
32739341|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
32739342|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
32739343|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
32739344|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
32739345|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
32739346|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
32739347|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
32739348|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
32739349|NCT04990791|Other|Aspirin 20mg|Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD
32739350|NCT04990791|Other|Asprin 75mg|Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD
32739351|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
32739352|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
32739353|NCT05713487|Experimental|preventive treatment group|
32739354|NCT05713487|No Intervention|control group|
32739355|NCT04990557|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
32739356|NCT04990557|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.~A total of 2 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
33103720|NCT05178667|Placebo Comparator|Maltodextrin|4 placebo capsules (maltodextrin) per day: 2 at breakfast and 2 at dinner
32956728|NCT04848506|Experimental|CK-3773274 up to 20 mg|Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
32956729|NCT04821856|Experimental|Cannabidiol 100mg/ml|"The starting dose of cannabidiol (CBD) will be 5 mg/kg/day and will be administered orally twice daily in doses of 2.5 mg/kg (up titration phase from day 1 to 7). After one week, the dose of CBD will be increased to 10 mg/kg/day in two daily doses of 5mg/kg (8-week maintenance phase from day 8 to 63). On completion of the maintenance phase the dose of CBD will be decreased to 5mg/kg/day for one week (day 64 to 70), after which the CBD administration will cease.~A ceiling dose of 1000mg/day will be administered to all participants weighing 100kg or greater. These participants will receive a dose of 500mg/day during up- and down-titration.~Doses will be rounded to the nearest 10mg (0.1mL)."
32956730|NCT04821856|Placebo Comparator|Placebo|"The control group will receive placebo medium-chain triglyceride (MCT) oil which is indistinguishable from the active medication in appearance, smell and taste.~Dose will be matched for volume to the cannabidiol arm, and administered twice daily for 10 weeks (including up- and down-titration)."
32956731|NCT04808076|Active Comparator|iNPH patients|Shunt operation
32956732|NCT04808076|No Intervention|Healthy Individuals|Healthy individuals without any neurological disease.
32956733|NCT04801680||Mpact 3d metal|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. The
32956734|NCT04801654||Ion released group|First 30 patients will be assessed for metalic ion released by blood sample. the patients will be monitored until 10 years follow-up for long term performance of the device
32956735|NCT04801654||Other group|The remaining 125 patients will be not assessed for metalic ion released; they will be monitored until 10 years follow-up for long term performance of the device
32956736|NCT04798768|Experimental|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
32956737|NCT04788095|Experimental|Device feasibility (app-based mindfulness program)|Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
32956738|NCT04788043|Experimental|Magrolimab (Hu5F9 G4) and pembrolizumab|All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).
32956739|NCT04784260||Group A (normozoospermic): >15 mill/ml and >32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing, library preparation and bioinformatic analysis.
32956740|NCT04784260||Group B (normozoospérmic): <15 mill/ml and <32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing,library preparation and bioinformatic analysis.
32956741|NCT04778267|Active Comparator|TPVB (thoracic paravertebral block)|TPVB will be performed in the sitting position A high frequency linear ultrasound probe will be applied in the parasagittal plane approximately 2-3 cm lateral to the midline till identification of the 3rd thoracic vertebra (T3) in the same side of surgery. Then the transducer will be moved progressively more medially until transverse processes are identified.The image acquired will have the transverse process located superiorly and an image of lower rib located inferiorly on the screen.The needle tip is to be observed to enter through the superior costotransverse ligament and loss of resistance sensation will be experienced. After confirming the anterior displacement of pleura with 2-3 mL of local anesthetic (LA), 30 ml of 0.25% bupivacaine and 4 mg dexamethasone will be administered for the block.
32956742|NCT04778267|Experimental|ES-PI (erector spinae-pectointercostal block)|"ESPB In the second group (ES-PI) Using a high frequency linear ultrasound probe, it will be located in a longitudinal orientation at the level of T3 spinous process and then will be placed 3 cm laterally from the midline to the side involved in the surgery. .a 22-gauge block needle will be inserted in-plane at an angle of 30-40°. 20 mL of 0.25% bupivacaine hydrochloride and 3 mg dexamethasone will be injected in the plane deeper to the erector spinae muscle.~PIPB While the patient is in the supine position, a high frequency linear probe will be placed parallel to the long axis of the sternum at a distance 2-3 cm from the attachment of the second rib and sternum to identify the Pectoralis major muscle, external intercostal muscles and the second rib in the superficial plane. by separation of fascial layers of between the external intercostal and the pectoralis muscles, a total of 10 ml of 0.25% bupivacaine and 1 mg dexamethasone will be injected."
32956743|NCT04763356|No Intervention|Usual Care (UC)|The UC group (control) models the current standard of care model. The NTSS-6 will be completed daily by participants using the SCH system. The results will not be reported to their oncology team. Participants will be counseled at study entry to contact their treating care team to manage CIPN symptoms. They will also receive a reminder to do so at the end of each reporting session. UC participants will attend all regular visits with these providers and can receive any type of treatment for their CIPN symptoms. There are no limitations on the therapies that can be prescribed, or the means by which the clinical team communicates with the participant. Treating physicians will be provided with links to the current ASCP and NCCN guidelines but will not be provided with the algorithm as this group is meant to reflect current standard medical practice.
32956744|NCT04763356|Experimental|SCH with NP follow-up (SCH-NP)|Participants will report daily symptom as above. The SCH system will notify the study NP for any of the following symptoms measured by the NTSS6: aching, allodynia, burning, lancinating, numbness, and prickling that are concerning. Participants will receive a NP call back either the same day or the next day, depending on the time they reported their symptoms. The NP will follow a standardized script to elicit details about the CIPN symptoms and recommend and prescribe CIPN treatment per the treatment algorithm.
32956745|NCT04761627|Active Comparator|Continued-use Group (Ustekinumab)|Participants will receive subcutaneous injection of ustekinumab up to Week 52.
32836235|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
32836236|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
32836237|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
32836238|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
32836239|NCT02406768||HIV negative unexposed|HIV negative controls
32836240|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
32836241|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
32836242|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
32836243|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
32836244|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
32836245|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
32836246|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
32836247|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
33319261|NCT05184322|Experimental|T2026 tablet|Tablet containing no ecnoglutide but T2026 2 participants receiving T2026 tablet will be enrolled in each cohort.
32836248|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
33103721|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
33103722|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
33103723|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
33319262|NCT05184322|Placebo Comparator|Placebo tablet|placebo containing no ecnoglutide or T2026 2 participants receiving placebo tablet will be enrolled in each cohort.
33319263|NCT01340404|Experimental|Stem Cell Transplantation|
33319264|NCT01340404|Active Comparator|Transfusion program|
33319265|NCT05184010|Experimental|arthroscopic release with ulnar nerve mini open release|
33319266|NCT05184010|Placebo Comparator|arthroscopic release alone without ulnar nerve mini open release|
33319267|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
33103724|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
33103725|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
33103726|NCT05133726|Experimental|Text Message cluster|This arm will receive only daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together)
33103727|NCT05133726|Experimental|Text message with or without peer support|All individuals in this cluster will receive daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together) with some selected members also receiving peer support for six months
33103728|NCT05133726|No Intervention|Control group|This group will only receive usual care plus weekly text message over 6 weeks (six information text messages all together) with provides information about community services
33103729|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
33319268|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
33319269|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
33319270|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
33103730|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
33103731|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
33103732|NCT00537719|Placebo Comparator|placebo|placebo injection
32836249|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
32836250|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
32836251|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
32836252|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
32836253|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
33319271|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
33319272|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
33319273|NCT00286091|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
32836254|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
33103733|NCT05468385|Experimental|Tragus stimulation|Vagus nerve stimulation via tragus
33319274|NCT00286091|Experimental|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
33319275|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
32836255|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
32836256|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
32836257|NCT03172650||study group|non alcoholic fatty liver disease patients
32836258|NCT03172650||Control group|fatty liver patients
32836259|NCT03172572||Indication for surgery|Solid neoplasms
32836260|NCT02404506|Experimental|Arm: Eribulin mesilate|
32836261|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
32836262|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
32836263|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
32836264|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
32836265|NCT04481646||1|Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.
32836266|NCT04481646||2|Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.
32836267|NCT04481646||3|Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.
32836268|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
32836269|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
32836270|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
32836271|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
32836272|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
32836273|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
32836274|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
33103734|NCT05468385|Sham Comparator|Sham stimulation|Sham stimulation via earlobe
33103735|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
33103736|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
33103737|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
33319276|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
33319277|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
33319278|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
33319279|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
33319280|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
33319281|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
33319282|NCT00285857|Experimental|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
33319283|NCT05183386|No Intervention|Control Group|The dental socket heals spontaneously
33319284|NCT05183386|Experimental|Experimental group|Distinct bone graft regeneration strategies (PRGF, Autologous bone and DFDBA)
32956746|NCT04761627|Experimental|Switching Group (Ustekinumab - ABP 654)|Participants will initially receive injection of ustekinumab up to Week 16. Thereafter, starting from Week 28, participants will switch between ABP 654 and ustekinumab every 12 weeks up to Week 52.
32956747|NCT04760691|Active Comparator|Pre-Exposure Prophylaxis (PrEP) only|Truvada one tablet by mouth daily
33319285|NCT03975101|Experimental|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
33319286|NCT03975101|Experimental|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
32956748|NCT04760691|Experimental|PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist|Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once
32956749|NCT04760691|Experimental|PrEP plus Low Dose Estrogen|Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks
32956750|NCT04760691|Experimental|PrEP plus High Dose Estrogen|Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks
32956751|NCT04760691|Experimental|High Dose Estrogen|Estradiol 6 mg by mouth daily x 2 weeks
32956752|NCT04746794|Experimental|Point of Care|In the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
32956753|NCT04746794|Experimental|Direct Patient Engagement|"In the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers."
32956754|NCT04746794|No Intervention|Stakeholder Interviews and Surveys|Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and multiple follow-ups. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The midpoint and final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
32956755|NCT04740801|Other|PVI procedure|Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
32956756|NCT04740671|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
32956757|NCT04740671|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
32956758|NCT04736355|Experimental|DAOIB|oral, for 24 weeks
32956759|NCT04736355|Placebo Comparator|Placebo|oral, for 24 weeks
32956760|NCT04736199|Experimental|Darolutamide+ADT|Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
32956761|NCT04736199|Placebo Comparator|Placebo+ADT|Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
32956762|NCT04736173|Active Comparator|Arm A - Study Part 1 (Platinum-based Chemotherapy)|Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion.
32956763|NCT04736173|Experimental|Arm B - Study Part 1 (Zimberelimab Monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
32956764|NCT04736173|Active Comparator|Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive zimberelimab in combination with AB154 by IV infusion.
32956765|NCT04736173|Experimental|Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.
32956766|NCT04736173|Experimental|Arm E - Study Part 2 (Pembrolizumab)|Participants will receive pembrolizumab by IV infusion.
32956767|NCT04735471|Experimental|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-001 (Part 1a).
32956768|NCT04735471|Experimental|ADI-001 Dose Extension|ADI-001 is administered via infusion at MAD/MTD to evaluate the safety of multiple doses (Part 1b).
32956769|NCT04735471|Experimental|ADI-001 Dose Expansion|Dose Expansion ADI-001 is administered via infusion at the MTD/MAD to confirm recommended phase 2 dose (Part 2).
33033034|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
33033035|NCT01958632||N|nerve suture
33033036|NCT01958632||NT|nerve transplantation
33405496|NCT05759949|Experimental|RLY-5836 + Ribociclib + Fulvestrant Arm|RLY-5836 + ribociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
33405497|NCT05759949|Experimental|RLY-5836 + Abemaciclib + Fulvestrant Arm|RLY-5836 + abemaciclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
32836275|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
33405498|NCT02954237||AMPLATZER™ Cardiac Plug|Subjects who were implanted with AMPLATZER™ Cardiac Plug will be included in this arm.
33405499|NCT04269213|Experimental|Treatment (CPX-351)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients who do not achieve remission receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 5-8 weeks after the start of the last induction, patients who achieve CR receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 45 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
32836276|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
32836277|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
33405500|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
32836278|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
32836279|NCT04482192|Active Comparator|Thoracic paravertebral block group|Continuous thoracic paravertebral block with 1% lidocaine infusion for 3 postoperative days through a paravertebral catheter inserted intraoperatively by the surgeon.
32836280|NCT04482192|Active Comparator|Systemic analgesia group|patients in this group will receive paracetamol and ketorolac by intravenous infusion every 6 hours for 3 postoperative days
32836281|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
33405501|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
32836282|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
32836283|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
32836284|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
32836285|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
32836286|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
32836287|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
32836288|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
32836289|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
32836290|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
32836291|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
32836292|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
32836293|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
32836294|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
32836295|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
32836296|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
32836297|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
32836298|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
32836299|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
33033037|NCT01958632||VM|vein-in-muscle conduit
32836300|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
32836301|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
33319287|NCT03975101|Experimental|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
33319288|NCT03975101|No Intervention|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
33319289|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
33319290|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
33319291|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
33319292|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
33319293|NCT05183074|Experimental|MR-linac group|Pts received ultra-hypofractionated RT for primary w/o adjacent oligo-metastatic diseases on 1.5-Tesla MR-Linac
33319294|NCT05182996|Other|smoking education|smoking education
33319295|NCT05182918||Patients in OMT and other SUD treatment|Patients in opioid maintenance treatment and other substance use disorder treatment
33319296|NCT00284141|Experimental|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
33319297|NCT05182684|Experimental|Single arm|Electrocardiograms were measured by VP-100 for more than 6 hours and transmitted to a central server.
33319298|NCT05182138|Placebo Comparator|Unfortified potato plus placebo|Volunteers given potato with no fortified zinc and a placebo
33319299|NCT05182138|Active Comparator|Zinc Biofortified potato plus placebo|Volunteers given potato biofortified with zinc and a placebo
33319300|NCT05182138|Active Comparator|Unfortified potato plus zinc supplement|Volunteers given potato with no fortified zinc and a zinc supplement
33319301|NCT03975257|Experimental|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
33319302|NCT03975257|Experimental|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
33319303|NCT03975257|No Intervention|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
33319304|NCT04901494||SSRI for at least one year prior to the diagnosis of MCI|subjects with an initial diagnosis of MCI who were treated with an SSRI for at least one year prior to the diagnosis of MCI
33319305|NCT04901494||SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI|SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI
33319306|NCT04901494||Subjects without SSRI use|Subjects without SSRI use
33319307|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
33319308|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
33319309|NCT03975725|Experimental|witcard|
33319310|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
33319311|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
33319312|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
33319313|NCT01315990|Experimental|FOLFIRI + Cetuximab|
33319314|NCT00265343|Experimental|1|asenapine
33319315|NCT00265343|Active Comparator|2|olanzapine
33319316|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
33319317|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
33319318|NCT03975881|Experimental|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
33319319|NCT05163574|Experimental|High dose|20 patients
33319320|NCT05163574|Active Comparator|Low dose|20 patients
33319321|NCT05162950||SW CAH|Patients with 21-hydroxylase deficiency, salt wasting form.
33319322|NCT05162950||SV CAH|Patients with 21-hydroxylase deficiency, simple virilising form.
33319323|NCT05162950||NC CAH|Patients with 21-hydroxylase deficiency, non-classic form.
33319324|NCT05162950||Carrier CAH|Healthy individuals, heterozygous carriers a mutation in the CYP21A2 gene. Recruited among parents of patients with CAH.
33319325|NCT05162950||Control|Healthy sex and age matched controls
33319326|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
33319327|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
33319328|NCT00283595|Active Comparator|1|Treatment with rHGH
33319329|NCT00283595|Placebo Comparator|2|Treatment with Placebo
33319330|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
32836302|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
33033038|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
33033039|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
32836303|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
32836304|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
32836305|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
32836306|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
32836307|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
32836308|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
32836309|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
32836310|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
32836311|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
32836312|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
32836313|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
32836314|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
32836315|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
32836316|NCT02406534||Normal Pulmonary Function|
32836317|NCT02406534||Reduced Pulmonary Function|
32836318|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
32836319|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
32836320|NCT02406456|Experimental|Neurofeedback|
32836321|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
32836322|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
32836323|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
32836324|NCT04440696|Experimental|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
32836325|NCT04440696|Experimental|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
32836326|NCT04440696|Experimental|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
32836327|NCT04440696|Experimental|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
33033040|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
33103738|NCT04685603|Experimental|Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
33103739|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
33103740|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
33103741|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
33103742|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
33103743|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
33103744|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
33103745|NCT04685837|Experimental|Tele-rehabilitation group|The participants randomly assigned to the tele-rehabilitation group will use a computer application to know and execute the exercise protocol. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the application works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
33103746|NCT04685837|Experimental|Face to face group|Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
33319331|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
33319332|NCT01342042|Active Comparator|Metformin|
33319333|NCT01342042|Active Comparator|exenatide-4|
33319334|NCT00265109|Other|open label|Open-label trial; all participants received levetiracetam
33319335|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
33319336|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
33319337|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
32747101|NCT05552781|Experimental|350 mg QD, oral|H002 350mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
32747102|NCT05548023|Experimental|Treatment|
32747103|NCT05548023|Placebo Comparator|Placebo|
32747104|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
32747105|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
32747106|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
32747107|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
32747108|NCT05542329|No Intervention|Control|Standard of care
32747109|NCT05542329|Experimental|Tele-Medecine|The experimental group will be given a case of connected devices dedicated to telemedicine allowing them to closely monitor their state of health during the 3 months following discharge from hospital
32747110|NCT05547945|Other|health promotion program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
32747111|NCT05547945|No Intervention|Control group|The control received as usual care.
32747112|NCT05698797|Experimental|Experimental group 1|In this group participants received hip abductor and external rotator strengthening exercises in addition to conventional physical therapy.
32747113|NCT05698797|Active Comparator|Experimental group 2|In this group participants received proprioceptive training and conventional physical therapy.
32747114|NCT05698797|Active Comparator|Control group|In this group participants received conventional physical therapy alone.
32747115|NCT05552625|Active Comparator|TADIOS + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
32747116|NCT05552625|Placebo Comparator|Placebo + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
32747117|NCT05552547|Active Comparator|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row.
32836328|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
32836329|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
33103747|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
33103748|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
33103749|NCT05468346|Experimental|[14C]-HEC585|[14C]-HEC585,solid powder，200 mg/100 µCi,single dose，oral
33103750|NCT00537758|Experimental|1|Cognitive Behavior Therapy
33103751|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
33103752|NCT00537758|Experimental|3|CBT + BWL
32747118|NCT05552547|Experimental|24-Hour Blood Pressure Machine|Participants will be asked to wear this machine for 24 hours.
32747119|NCT05552391|Placebo Comparator|bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
32747120|NCT05552391|Active Comparator|bupivacaine - ketamine|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
32747121|NCT05552391|Active Comparator|bupivacaine - Dexametomedine|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
32747122|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
32747123|NCT05552313|Experimental|kinesio taping with thoracic manipulation and conventional treatment|experimental group will be given kinesio taping with thoracic manipulation and conventional treatment
32747124|NCT05552313|Sham Comparator|sham kinesio taping with thoracic manipulation and conventional treatment|control group will be given sham kinesio taping with thoracic manipulation and conventional treatment
32747125|NCT04740814|Experimental|Certolizumab pegol|Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
32747126|NCT05551923||Acute cerebral hemorrhage|intestinal flora disturbance To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
32747127|NCT05551923||The group without stroke|The group without stroke
32747128|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
32747129|NCT05551845||Subject use both KD-595 Arm Automatic Electronic BPM and mercury sphygmomanometers|
32747130|NCT05551767|Experimental|Experimental arm|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation. Effect of induction therapy will be assesed by PET/CT and by endoscopic evaluation with biopsy of suspected residual tumor. Managemant of any residual tumor will be performed according with local rules and standards.
32747131|NCT05551689|Active Comparator|ADHD monitoring as usual|ADHD patient monitoring as usual based on psychostimulant prescription and follow up
32747132|NCT05551689|Experimental|FOCUS ADHD|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool
32747133|NCT05551689|Experimental|FOCUS ADHD and the elegibility for discount concession on treatment purchase|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool. In this arm patients are also eligible for a discount of at least 25% of the drug cost (after the first month of treatment) if they register and maintain at least 80% of their treatment adherence on the FOCUS ADHD app. The discount is granted after week 4 until the end of the follow up period.
32747134|NCT05547789||Study group|
32747135|NCT05547789||Control group|
32747136|NCT05698719||STEMI patients undergoing physiological assessment of a non-culprit lesion|vFFR, FFR, RFR, dPR, CFR and IMR
32747137|NCT05698641||HFNC|Patients treated with HFNC
32747138|NCT05698641||NIV|Patients treated with NIV
32747139|NCT05700357|Active Comparator|Thoracic Paravertebral Block 20 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
32747140|NCT05700357|Active Comparator|Thoracic Paravertebral Block 25 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 25 ml of 0.25% bupivacaine will be injected into this area.
32747141|NCT05700357|Active Comparator|Thoracic Paravertebral Block 30 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
32747142|NCT05542251|Experimental|Parent Educational Program|Caregivers of children with gross motor delays who are randomized to receive an educational intervention delivered through social media.
32747143|NCT05542251|No Intervention|Control Group|Caregivers of children with gross motor delays who are randomized to the waitlist control group who will receive an educational intervention delivered through social media after a 9 week waiting period.
32836330|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
32836331|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
32836332|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
32836333|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
32836334|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
32836335|NCT02400372|Experimental|research group|Medihoney Dressing
32836336|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
32836337|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
32836338|NCT03170310|Experimental|Apatinib|
32836339|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
32836340|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
32836341|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
32836342|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
32836343|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
32836344|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
32836345|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
32836346|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
32836347|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
33319338|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
32836348|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
33319339|NCT01342120||Quetiapine|Quetipine users
33319340|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
33319341|NCT01342120||Risperidone|Risperidone users
33319342|NCT01342120||Olanzapine|Olanzapine users
32836349|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
32836350|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
32836351|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
32836352|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
32836353|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
32836354|NCT02581384|Experimental|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
32836355|NCT02581384|Experimental|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
32836356|NCT02581384|Experimental|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
32836357|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
32836358|NCT02581384|Experimental|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
33033041|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
33319343|NCT04887688|Experimental|Group A: Wound treated using exciflex|Intervention treated wounds in Group A participants will be covered using the exciflex bandage which will be activated to deliver ES using a 10% duty cycle, i.e. ES will be active for 1 minute out of every 10 minutes. ES will be delivered for up to 10 weeks or until the wound is healed for 3 days. The exciflex bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. The exciflex power/control module will then be transferred to a new sterile flexible substrate and the exciflex bandage reapplied to the wound.
32836359|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
32836360|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
32836361|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
32836362|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
32836363|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
33326938|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
32836364|NCT05249452||Adult transplant-eligible SCD patients with a MSD|Sickle cell disease patients aged 16 years and older with an available matched sibling donor.
32836365|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
32836366|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
32836367|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
32836368|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
32836369|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
32836370|NCT05249296|Experimental|Group 1: intervention/control group|"Phase 1: Two weeks of green space intervention~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
32836371|NCT05249296|Experimental|Group 2: control/intervention group|"Phase 1: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of green space intervention~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
32836372|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
32836373|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
32836374|NCT05249218|Active Comparator|Group starting intervention with vegetable protein|Phase A followed by Phases B, C, D, E.
32836375|NCT05249218|Active Comparator|Group starting intervention with animal protein|Phase A followed by Phases D, E, B, C.
32836376|NCT02399904|Experimental|1|
32836377|NCT04481022|Other|group will receive proximal control exercises|
32836378|NCT05248048|Experimental|NKG2D CAR-NK|CAR-T infusion
32836379|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
32836380|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
33033042|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
33033043|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
33033044|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
33033045|NCT01958736|Experimental|Experimental|Ballistic Strength Training
33033046|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
32836381|NCT04003480|Experimental|FRAME|Vein graft to be treated with FRAME
32836382|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
32836383|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
32836384|NCT03970252|Experimental|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
33319344|NCT04887688|No Intervention|Group B: Wound treated using standard of care|Control treated wounds in Group B participants will be covered with a standard of care hydrogel dressing such as Restore (Hollister Inc) together with Tegaderm . The SoC dressing will be used for up to 10 weeks or until the wound is healed for 3 days. The SoC bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. A fresh sterile SoC bandage will then be reapplied to the wound.
33319345|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
33319346|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
33033383|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
32747171|NCT05550753|Placebo Comparator|Control|Will NOT be offered the BT coaching intervention during of 4-months (February 1st 2023- May 31st 2023). Will be offered the coaching intervention after the study completion (from September 1st 2023 - December 31st 2023).
33319347|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
33319348|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
33319349|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
33319350|NCT04882696|No Intervention|usual care with bare feet|patients will be treated barefoot during their stay
32747172|NCT05550675||Double incontinence|
32747173|NCT05550675||faecal incontinence|
32747174|NCT05550675||controls|
32747178|NCT05541549|Placebo Comparator|Placebo|
32747179|NCT05541549|Experimental|CE-VST01-JC|
32747180|NCT05550441|Placebo Comparator|Placebo group|
32747181|NCT05550441|Experimental|Dapagliflozin group|
32747182|NCT05550363|Experimental|DEXYCU|DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
32747183|NCT05550363|Placebo Comparator|Placebo|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
32747184|NCT05550285|Experimental|Orbital Volume After Using Guided Calvarial Graft in Floor Recontsruction|
32747185|NCT05550285|Experimental|Orbital Volume After Using 3D Printed Titanium mesh in Floor Recontsruction|
32747186|NCT05550207|Experimental|AXS-07 (meloxicam-rizatriptan)|Up to 8 weeks
32747187|NCT04321941|Experimental|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
32747188|NCT04321941|Active Comparator|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
32747189|NCT05546931|Experimental|Intervention|A smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
32747190|NCT05546931|Active Comparator|Enhanced usual care|WebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
32747191|NCT05540925||Low-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score ≤ 90.
32747192|NCT05540925||High-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score > 90.
32747193|NCT05699733|Experimental|Mechanical traction force 30% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 30% of the body weight as a traction force
32747194|NCT05699733|Experimental|Mechanical traction force 20% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 20% of the body weight as a traction force
32747195|NCT05699733|Experimental|Mechanical traction force 10% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 10 % of the body weight as a traction force
32747196|NCT05546853|Experimental|Experimental|NP137+ mFOLFIRINOX
32747197|NCT05535699|Experimental|scapular muscle strengthening exercises|Group A (n=22): will receive a program of scapular muscle strengthening exercises for 18 sessions (3 sessions per week for six weeks)
32747198|NCT05535699|Experimental|PNF exercise|Group B (n=22): will receive a scapular PNF exercise program for the same frequency as in group A
32747199|NCT05535699|No Intervention|control|Group C (n=22): will be a control group who will not receive any treatment during the study period.
32747200|NCT05540769|Experimental|case group|
32747201|NCT05540535||Bilateral Symmetrical Hearing Loss|"Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate, moderately-severe, severe, or profound sensorineural HL in the past three month and on.~Moderate hearing will be defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear, moderately-severe hearing will be defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear, severe HL will be defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear and profound HL will be defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear. Asymmetry of HL will be defined as a difference in PTA that is greater than dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears."
32836385|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm~Week 3: Betaine anhydrous 1000 mg BID"
32836386|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
32836387|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
32836388|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
32836389|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
32836390|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
32836391|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
32836392|NCT03858712|Other|Passive Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~ePRO Home: -- ePRO oral between visits at home.~Passive care team alert -- EHR inBasket notification"
32836393|NCT03858712|Other|Active Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~ePRO Home: -- ePRO oral between visits at home.~Active care team alert -- practice nurse monitoring of ePRO home responses score = 3 indicating a moderate-severe toxicity (grade 3 or higher"
32836394|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
32836395|NCT02396706|Placebo Comparator|Placebo|Placebo
32836396|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
32836397|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
32836398|NCT04480398||Ayurveda|Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
32836399|NCT04480398||Control|Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
32836400|NCT04708522|Experimental|Breath Control|Participants in the breath control study arm will be given a breathing exercise that is to be completed in a comfortable upright seated posture. This intervention exercise will be completed daily for a period of 8 weeks.
32836401|NCT04708522|Experimental|Guided Mindfulness|Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
32836402|NCT04708522|Sham Comparator|Control|Participants in the control group will receive a sham intervention. The sham intervention will involve minimal instructed meditation exercise. This intervention exercise will be completed daily for a period of 8 weeks.
32836403|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
32836404|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
32836405|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by the 1st Coaching visit. They receive wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, workbook & 10 phone-based coaching calls focused on sitting less/standing more. There is a 3 month measurement visit. Program ends at 6 months when they wear an activPAL & have a measurement visit. Coach provides feedback on activPAL sitting time after all activPAL wears (Bsln, 3, 6 & 12 month). They may opt to wear activPAL at 6 weeks & get feedback. They are re-randomized at 6 months; half to be assigned to intervention boosters (5 more phone sessions/a 9-month optional activPAL) before the 12 month final activPAL & final measurement visit. Those not randomized to boosters will have no contact until the 12 month visit. UPDATE: As of 3/31/2022, (final year 5), i-STAND ppts will no longer be re-randomized at 6 months. We will no longer follow to the 12-month timepoint & will end all activities after 6-months.
32836406|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by the 1st phone-based Coaching visit. No prompting devices/desks are offered; coaching focuses on topics related to healthy living, but with no focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants receive a workbook. All content is from KaiserPermanente WA and is available to all members. Participants select topics & review them with their health coach. At 3 months, participants have a measurement visit. The program ends at 6 months where participants will wear an activPAL and have a measurement visit. After that, there is no contact with the study team until 12 months when they will again wear an activPAL & have a final measurement visit. UPDATE: As of 3/31/2022, our final year (year 5) of the study, participants randomized to the control arm will no longer be followed to the 12-month timepoint and will end all activities after the 6-month timepoint.
32836407|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
32836408|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
33033384|NCT01962389|Experimental|Winsor Laser Catheter|
33319351|NCT04882696|Experimental|specific care with anti-slip socks|Patients in this group will wear non-slip socks
32836409|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
32836410|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
32836411|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
33319352|NCT04806022|Experimental|Mental Fatigue Task first|"First appointment :~Pre-fatigue assessment~mental fatigue task~post-fatigue assessment~7 resting days~second appointment~Pre-fatigue assessment~Muscle fatigue task~post-fatigue assessment"
32836412|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
32836413|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
32836414|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
32836415|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
32836416|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
32836417|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
32836418|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
32836419|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
32836420|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
32836421|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
32836422|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
32836423|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
32836424|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
32836425|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
32836426|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
32836427|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
32836428|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
32836429|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
32836430|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
32836431|NCT03429244|Experimental|Low and intermediate risk prostate cancer|
32836432|NCT03400150|Experimental|ProSpace group|Marking + ProSpace implantation + IMRT
32836433|NCT03400150|Sham Comparator|Control group|Marking + IMRT
32836434|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
32836435|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
32836436|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
32836437|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
32836438|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
32836439|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
32836440|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
32836441|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
32836442|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
32836443|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
32836444|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
32836445|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
32836446|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
33319353|NCT04806022|Experimental|Muscle fatigue task first|"First appointment :~Pre-fatigue assessment~Muscle fatigue task~post-fatigue assessment~7 resting days~second appointment~Pre-fatigue assessment~mental fatigue task~post-fatigue assessment"
32836447|NCT01763320|Experimental|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
32836448|NCT01763320|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
32836449|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
32836450|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
32836451|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
32836452|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
32836453|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
32836454|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
32836455|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
32836456|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
32836457|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
32836458|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
32836459|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
32836460|NCT03168204|Experimental|Risk of being frail experimental group|
32836461|NCT03168204|No Intervention|Risk of being frail control group|
32836462|NCT03168204|No Intervention|No/low risk of being frail|
32836463|NCT03168204|No Intervention|Risk of being frail care avoiders|
32836464|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
32836465|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
32836466|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
32836467|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
32836468|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
32836469|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
33033385|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
33103753|NCT05123040|Experimental|Ruxolitinib;hCG (Pregnyl®) ;Corticosteroids|"Ruxolitinib 10 mg by mouth twice daily (with dose adjustments as indicated) through day 56, followed by taper~hCG (Pregnyl®) 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses (total 17 doses through day 56)~Corticosteroids (Prednisone, or IV methylprednisolone equivalent)~Dose level 1 (starting dose) = 1 mg/kg~Dose level 2 = 0.5 mg/kg~Dose level 3 = 0.25 mg/kg~Dose level 4 = 0.1 mg/kg~Dose level 5 = 0 mg/kg"
33103754|NCT04685096||Asian skin|Twice-daily application for 55 Days
33103755|NCT04685096||African-American skin|Twice-daily application for 55 Days
33103756|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
32836470|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
33103757|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
33103758|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
33103759|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
33103760|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
33103761|NCT05110014|Other|Primary Care Office Visits|"The limited use dataset will contain the following data elements for each completed patient visit:~Date of clinic visit (where each date is indicated by a number relative to the clinic's Launch Date)~Clinic (designated by a unique study clinic identifier)~Type of visit completed (for example, new patient visit, return patient visit, annual exam)~Patient age~Patient gender~Patient race/ethnicity~Patient primary insurance~Nursing staff who roomed the patient (designated by a unique study identifier)~Whether patient used mPATH-CheckIn program (Y/N)~Whether nursing staff used mPATH Nursing Module to transmit mPATH data to electronic health record (Y/N)~Whether patient has a diagnosis of depression in the problem list in the EHR (Y/N)~Whether patient has an antidepressant medication listed in the active medication list ( (Y/N)~Results of depression screening items~Results of fall risk screening items~Results of safety at home screening items"
32836471|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
32836472|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
33405502|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
32836473|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
32836474|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
32836475|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
32836476|NCT04742218|Experimental|Fasted-Fed|Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)
32836477|NCT04742218|Experimental|Fed-Fasted|Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)
32836478|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
32836479|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
32836480|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
32836481|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
32836482|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
32836483|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
32836484|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
33405503|NCT05744466||Cohort 1|Participants that have initiated deucravacitinib
32836485|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
32836486|NCT04933422|Experimental|CM93 pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), pre-treatment with CM93 prior to surgical resection of recurrent glioblastoma
32836487|NCT04933422|No Intervention|No pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), no pre-treatment prior to surgical resection of recurrent glioblastoma
32836488|NCT04927416|Experimental|Differentiated thyroid cancer (DTC)|Patients with DTC but not HTC
32836489|NCT04927416|Experimental|Hurthle cell thyroid cancer (HTC)|Molecularly and histologically unique subtype of DTC - Hurthle cell thyroid cancer (HTC),
32836490|NCT04927416|Experimental|Medullary thyroid cancer (MTC)|Patients with metastatic thyroid cancer of neuroendocrine origin - medullary thyroid cancer (MTC)
32836491|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
32836492|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
32836493|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
32836494|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
32836495|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
32836496|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
32836497|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
32836498|NCT04340674|Experimental|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
32836499|NCT04340674|No Intervention|Control group|Group that maintain the same medical treatment and not receive additional intervention.
32836500|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
32836501|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
32836502|NCT03167736|Experimental|Electric dry needling, manipulation|
32836503|NCT03167736|Active Comparator|conventional physical therapy|
32836504|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
32836505|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
32836506|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
32836507|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
32836508|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
32836509|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
32836510|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
32836511|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
32836512|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
32836513|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
32836514|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
32836515|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
32836516|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
32836517|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
32836518|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
33405504|NCT05744466||Cohort 2|Participants that have initiated apremilast
33405505|NCT05208372||Laparotomy group|Patients who undergo radical laparotomy for gastric cancer.
33103762|NCT05468268|Experimental|20 Hz rTMS|"rTMS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode.~Stimulation parameters will be rTMS delivery of 1600 pulses divided into blocks: 20 Hz for 2 seconds (40 pulses) followed by 28 seconds of pause, with a stimulation intensity equal to 100% of the motor threshold value at rest."
32836519|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
32836520|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
32836521|NCT02398968|No Intervention|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
32836522|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
32836523|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
32836524|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
32836525|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
32836526|NCT02398812|No Intervention|Usual care|Usual care (reference group).
32836527|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
32836528|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
32836529|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
32836530|NCT02395380|Experimental|C-reactive protein dosage|
32836531|NCT02402478||Stable coronary artery disease|Patients with chest pain
32836532|NCT02402400|Active Comparator|Oral Ticagrelor|
32836533|NCT02402400|Experimental|Sub Lingual Ticagrelor|
32836535|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
32836536|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
32836537|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
32836538|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
32836539|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
32836540|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
32836541|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
32836542|NCT02394990|Active Comparator|Control|Participants receive only ABI
32836543|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
32836544|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
32836545|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
32836546|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
32836547|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
32836548|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
32836549|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
32836550|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
32836551|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
32836552|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
33103763|NCT05468268|Sham Comparator|Sham rTMS|"Sham rTMS will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation. This 30 mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
33103764|NCT05338658|Experimental|Peptide Alarm Therapy + Pembrolizumab|"Participants receive pembrolizumab 200 mg every 3 weeks (Dose Finding Component) or a disease appropriate PD1/PD-L1 inhibitor (Dose Expansion Component) for 2 treatment courses per standard of care.~The first dose of PAT is given on Day 1 and on Day 3 (36 to 48 hours after the 1st PAT dose)~A second course of the PD1/PD-L1 inhibitor is given per standard of care on Day 22 (Cycle 2 Day 1)."
33103765|NCT02277171|Experimental|Nitric oxide impregnated catheter|
33103766|NCT00537875|Active Comparator|1|
33103767|NCT00537875|Placebo Comparator|2|
33103768|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
33103769|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
33103770|NCT05105061|Experimental|Ketamine (1) then Placebo (2)|Participants will receive an intramuscular injection of racemic ketamine, followed the next day by an intramuscular injection of saline (placebo)
33103771|NCT05105061|Placebo Comparator|Placebo (1) then Ketamine (2)|Participants will receive an intramuscular injection of saline (placebo), followed the next day by an intramuscular injection of racemic ketamine
33103772|NCT04870463|Active Comparator|Gold Standard Group|Patients treated with multi-braces fixed appliances and a conventional sequence of aligning and levelling arches (Ni-Ti arches with the same force in all sections)
33103773|NCT04870463|Experimental|Intervention Group|Patients treated with multi-braces fixed appliances and a different sequence of aligning and levelling arches (some arches provide individual forces for each group of teeth (incisors, premolars and molars))
33103774|NCT05095740|Active Comparator|repetitive transcranial magnetic stimulation (rTMS)|5 consecutive days of rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
33103775|NCT05095740|Sham Comparator|Sham rTMS|5 consecutive days of sham rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
33103776|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
33103777|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
33103778|NCT05093712||Phase I (survey)|Patients complete surveys over 10 minutes on their background, health literacy level, barriers to cancer care, and knowledge of cervical cancer and its treatment.
33103779|NCT05093712||Phase II (survey, educational video)|Patients watch educational video on cervical cancer. Patients also complete surveys over 5-10 minutes at baseline and after watching educational video.
33103780|NCT04864262|Experimental|Photovoice|
33103781|NCT05091255|Experimental|Patients|
32836553|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
32836554|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
33405506|NCT05208372||Laparoscopy group|Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
32836555|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
32836556|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
32836557|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
32836558|NCT05731882|Experimental|Catheter ablation+E-SeaLATM|
33103782|NCT04853264|Experimental|Experimental: intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
33103783|NCT04853264|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse.
33319354|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
32836559|NCT05443204|Experimental|Standard Formula (Fortimel)|Fats 35% total caloric volume (VCT) Carbohydrates: 49% del VCT Proteins: 16% del VCT Density: 1.5 kcal/ ml
32836560|NCT05443204|Experimental|Specific formula for diabetes (Nutrision Advanced)|Fats: 46% del VCT (60% monounsaturated fatty acids) Carbohydrates: 31% del VCT Proteins: 21% del VFiber: 2% VCT (80% soluble y 20% insoluble) Density: 1.5kcal/ml
32836561|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
32836562|NCT04340518|Experimental|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
32836563|NCT05731414|Experimental|Individual CBTp + Group Sham CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion."
32836564|NCT05731414|Experimental|Group CR + Individual Befriending (Sham CBTp)|"Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials.~Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth."
32836565|NCT05731414|Experimental|Individual CBTp + Group CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials."
32836566|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
32836567|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
32836568|NCT04741672|Experimental|Intervention group|Providing guidance and calling after discharge routine procedure.
32836569|NCT04741672|Experimental|Control group|Discharge routine procedure.
32836570|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
32836571|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
32836572|NCT05731336||NR group (Non-retreatment/rechallenge group)|participants who receive immunotherapy or targeted drugs or other chemotherapy beyond treated with oxaliplatin and irinotecan
32836573|NCT05731336||RT group (Retreatment group)|participants retreated oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed after 3 months of oxaliplatin or irinotecan discontinuation.
32836574|NCT05731336||RC group (Rechallenge group)|participants rechallenging oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed within 3 months of oxaliplatin or irinotecan discontinuation.
32836575|NCT04481178||patients with nevus of Ota|patients with nevus of Ota who had been treated with laser at Siriraj hospital
32836576|NCT04340908|Experimental|Treatment|Dapagliflozin 10 mg tablet
32836577|NCT04340908|Placebo Comparator|Control|matching placebo tablet
32836578|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
32836579|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
32836580|NCT05731024|Experimental|Close-loop synchronization controller|One-hour period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during SPONT mode.
32836581|NCT05731024|Active Comparator|Conventional|One-hour period where the synchronization of pressure support of patient effort during SPONT mode will be manually set.
32836582|NCT05745870|Experimental|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
32836583|NCT05745870|Placebo Comparator|Placebo Supplementation|Participants will consume 10g/d maltodextrin for 42 consecutive days
32836584|NCT05730868|Experimental|group 1 myofascial release|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
32836585|NCT05730868|Experimental|group 2 muscle energy technique|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
32836586|NCT05730868|Experimental|group 3 MFR & MET|combination of two soft tissue release techniques to release tension from muscles which relieves pain and increase range of motion
32836587|NCT05730868|Experimental|group 4 conventional therapy|combination of traditional techniques to relieve pain and spasm
33103784|NCT05075811|Experimental|Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)|Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
33103785|NCT05075811|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s).
33103786|NCT04806191|Experimental|Intervention|Patients will be assessed by GPs who have attended an outreach workshop and trained at using an evidence based strategy for shoulder examination and treatment. GPs will have access to a decision support tool and patients is offered a tailored information package for self management.
33103787|NCT04806191|Active Comparator|Treatment as usual (TAU)|The participants enrolled in the control period will receive treatment as offered in general practice.
33319355|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
33319356|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
33319357|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
33103788|NCT05067426|Experimental|HIIT-HV|"HIIT-HV - high intensity interval training high volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period. Each training session is followed by 30 minutes of low-intensity training (total of 300 minutes of additional low-intensity training during this period)."
32836588|NCT04480320|Experimental|Pericapsular nerve group block|
32836589|NCT04480320|Placebo Comparator|Saline placebo group|
32836590|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
32836591|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
32836592|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
32836593|NCT05730790|Experimental|Cognitive-motor dual task training (DTT)|Participants attended 14 sessions (40 minutes each) of dual task cognitive-motor training, 2 times per week for 7 weeks. Each cognitive-motor training session comprised of performing a dual task activity - gameplay using a virtual reality (VR) system while walking on a treadmill, of progressive difficulty pitched to the participant's performance.
32836594|NCT05730790|Active Comparator|Cognitive single task training (CSTT)|Participants attended 14 sessions (32 minutes each) of single task cognitive training, 2 times per week for 7 weeks. Each cognitive training session comprised of game play using a virtual reality (VR) system, of progressive difficulty pitched to the participant's performance
32836595|NCT05730790|Active Comparator|Motor single task training (MSTT)|Participants attended 14 sessions (40 minutes each) of single task motor training over a period of 7 weeks. Each motor training session comprised of walking on a treadmill, of progressive difficulty pitched to the participant's performance
32836596|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
32836597|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
32836598|NCT05730634|Experimental|Intervention arm|Atorvastatin 40mg once daily.
32836599|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
32836600|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
32836601|NCT05726890|Experimental|bedtime checking|"The intervention is based on the principles of graduated extinction, defined as an effective and recommended therapy in the treatment of bedtime problems and night-wakings by the AASM. The basic guidelines for this intervention are: (1) When the infant shows tired signs, he/she should be put to bed awake; (2) parents should minimize their involvement after putting the infant to bed; (3) if the child protests/cries, the parent should check the infant's crib every few minutes (e.g., 5 minutes), briefly comfort the infant without taking him/her out of the crib, and help the infant resume a sleeping position/find sleep aids (e.g., pacifier); (4) disengage and leave the crib until the next visit, (5) In order to increase consistency, the same parent should implement the intervention.~In the bedtime checking arm, parents will be instructed to implement the changes only at bedtime and will be asked to continue soothing their infant at night, as they normally do"
32836602|NCT05726890|Active Comparator|standard checking|"Same as for bedtime checking at bedtime, but in the standard checking arm, parents apply the intervention guidelines also when the infant wakes up during the night."
32836603|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
32836604|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
32836605|NCT05705830|Experimental|Pulse Magnetotherapy+medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received pulse magnetic therapy and conventional antianxiety drugs
32836606|NCT05705830|Sham Comparator|medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received sham magnetic therapy and conventional antianxiety drugs
32836607|NCT05705830|Other|Healthy control|100 healthy controls who met the inclusion criteria received sham magnetic therapy
32836608|NCT05745792||Patients with Hu Abs|Patients harboring Hu Abs and a neurological syndrome
32836611|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
32836612|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
32836613|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
32836614|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
33319358|NCT05155774|Active Comparator|Control group, controlled every 6th week|"This group was controlled every 6th week, in accordance with what is deemed to be golden standard for treatment with a Twin Block orthodontic appliance."
33319359|NCT05155774|Experimental|Test group, controlled every 4th week|This group was controlled every 4th week, testing if a more frequent control interval would increase compliance with a Twin block orthodontic appliance.
32956770|NCT04718181|Experimental|Part 1|"Cohort A+B: participants will receive, in a five-period crossover way, a single oral dose of risdiplam oral solution 5 mg in fasted state and thereafter risdiplam/F21 or F22 dispersible tablet 5 mg as tablet in fasted and fed states; tablet dispersed in water in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations.~Cohort C+D: participants will receive, in a two-period fixed sequence design, a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state and omeprazole 40 mg once daily for 7 days + a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state, on the 7th day of omeprazole. There will be a 14-day wash-out between the two treatment periods.~Cohort E: participants will receive, in a two-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations."
32956771|NCT04718181|Experimental|Part 2 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as tablet dispersed in water in both fed and fasted states."
32956772|NCT04718181|Experimental|Part 3 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as tablet dispersed in water in both fed and fasted states."
32956773|NCT04713735|Placebo Comparator|Control: Placebo|Control: Placebo
32956774|NCT04713735|Experimental|Investigational: 600 mg bovine lactoferrin supplement|Investigational: 600 mg bovine lactoferrin supplement
32956775|NCT04712812||Proband with AP-4 Associated HSP|Male or female patients of all ages with (1) onset of hereditary spastic paraplegia symptoms before the age of 18 years and/or (2) the presence of variants in HSP related genes and/or a relative of a person with such a diagnosis.
32956776|NCT04712643|Experimental|Arm A: atezolizumab + bevacizumab + TACE|Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.
32956777|NCT04712643|Active Comparator|Arm B: TACE alone|Participants will receive on-demand transarterial chemoembolization.
32956778|NCT04704648|Other|Surgical Excision|Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). Standard of care topical antibiotics are given for infection prevention following surgery. No drugs or device treatments are administered for treatment of OSSN in this protocol.
32956779|NCT04698681||Biomarker Screening|Patients with stage IV nonsquamous NSCLC not previously treated with systemic therapy for metastatic disease and who meet all of study inclusion criteria and none of the exclusion criteria.
32956780|NCT04696497|Other|Muscular Assessment|All the patients will received the muscular assessments
32956781|NCT04682639|Experimental|Etrasimod Dose 1|
32956782|NCT04682639|Experimental|Etrasimod Dose 2|
32956783|NCT04682639|Placebo Comparator|Placebo and Etrasimod|Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
32956784|NCT04682366|Experimental|Tamsulosin|Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
32956785|NCT04682366|Placebo Comparator|Placebo|Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.
32956786|NCT04666610|Experimental|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
32956787|NCT04666610|Experimental|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
32956788|NCT04666610|Experimental|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
32956789|NCT04666610|Experimental|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
32956790|NCT04666610|Experimental|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
32956791|NCT04666610|Experimental|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
33319360|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
33319361|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
33319362|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
32836615|NCT05681494|Active Comparator|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
33103789|NCT05067426|Experimental|HIIT-LV|"HIIT- LV - high intensity interval training low volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period."
33103790|NCT05067426|No Intervention|Control group|Participants continue with their regular training program.
33405507|NCT05208294|Experimental|High expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects).
32836616|NCT05681494|Experimental|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
32836617|NCT05745714|Experimental|Ruxolitinib + venetoclax + dexamethasone + cyclophosphamide + cytarabine|"Each cycle has 28 days~Cycle 1: All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles:~All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, will receive a lower dose of venetoclax compared to dose level 1.~Patients in dose level 2, will receive a higher dose of venetoclax compared to dose level 1.~All patients receive age adapted intrathecal chemotherapy."
32836618|NCT04840030|No Intervention|Standard health advice (SHA-control)|"The participant will receive verbal information of risk factors and information, reassessment, and written materials regarding approved recommendations on active and healthy aging on topics such as diet, physical activity, cognitive training as well as risk factor control following the state of the art and published guidelines by the Department of Health of the Basque Government/ Basque Country Public Health System (Osakidetza) and the WHO (Guidelines for risk reduction of cognitive decline and Dementia and the Guidance on person-centered assessment and pathways in primary care - ICOPE). Participants in this group will receive the best standard health care from their primary care and specialist health teams according to already established routines as well as usual social services assessments and care as needed."
32836619|NCT04840030|Experimental|Multidomain intervention (MM-Int)|Participants in this group will receive the same verbal and written recommendations as to the ones in the SHA-Control group but then they will perform a 2 year structured program with periodic individual and group visits regarding 1) Risk factor control (vascular factors, polypharmacy); 2) Cognitive training, 3) Physical activity, 4) Dietary changing program and 5) emotional counseling and social engagement.
32836620|NCT02974270|Experimental|Leuprolide acetate|
32836621|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
32836622|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
32836623|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
32836624|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
32836625|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
32836626|NCT04770922||Pediatric ALL patients on 6-mercaptopurine|Pediatric ALL patients treated with 6-mercaptopurine who did not experience neutropenia.
32836627|NCT04770922||Pediatric ALL patients on 6-mercaptopurine with neutropenia|Pediatric ALL patients treated with 6-mercaptopurine who experienced neutropenia.
32836628|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
32836629|NCT04669600|Experimental|BIVV0020|All eligible participants will receive BIVV020 for at least 52 weeks.
32836630|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
32836631|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or~Upon a significant relapse of paraprotein, defined as:~Duplication of M-component in two consecutive readings taken ≤2 months apart; or~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
32836632|NCT04631926|Other|Hip Muscle Exercises|Hip Muscle Exercises
32836633|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
32836634|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
32836635|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
32836636|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
33103791|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
33103792|NCT00551681|Active Comparator|2|transvenous left ventricular lead
33103793|NCT00551720|Experimental|Standard Care|
32836637|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
32836638|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
32836639|NCT04480788|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
32836640|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s)
32836641|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%)
32836642|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%)
32836643|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
32836644|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
32836645|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
32836646|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
32836647|NCT04544098|Experimental|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
32836648|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
32836649|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
32836650|NCT04485052|Experimental|IBI188+azacitidine|1L unfit AML receive IBI188 every week by intravenous(IV) and azacitidine daily in Day 1-7 of each four weeks(Q4W) by subcutaneous(IH)
32836651|NCT04485052|Experimental|IBI188+decitabine|R/R AML receive IBI188 every week by intravenous(IV) and decitabine daily in Day 1-10 of each four weeks(Q4W) by subcutaneous(IH)
32836652|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
32836653|NCT04394962|No Intervention|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
32836654|NCT04394962|Experimental|Study group|Exposure to virtual reality environment exposure
32836655|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
32836656|NCT04741048|Experimental|CI624 Slim 20 Electrode|
32836657|NCT04388254|Experimental|Simufilam 100 mg oral tablets throughout|Simufilam 100 mg oral tablets administered twice daily (BID) for the full 24 months (including the randomized period Month 12 to Month 18)
32836658|NCT04388254|Placebo Comparator|Simufilam 100 mg oral tablets / Placebo / Simufilam 100 mg oral tablets|This placebo arm is only for Month 12 to Month 18. Day 1 to Month 12, as well as Month 18 to Month 24 are open-label treatment periods of simufilam 100 mg b.i.d. for all subjects.
32836659|NCT04740970|Experimental|JNJ-64304500|Participants will receive JNJ-64304500 dose 1 subcutaneous (SC) injection at Week 0 and then dose 2 SC injection every 2 weeks from Week 2 through Week 22.
32836660|NCT04740970|Placebo Comparator|Placebo|Participants will receive matching placebo SC injection at Week 0 and then every 2 weeks from Week 2 through Week 22.
32836661|NCT04309084|Experimental|Phase I|Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
32836662|NCT04340128|Active Comparator|1|Intra-lesional injection of Glucantime once a week
32836663|NCT04340128|Experimental|2|Intra-lesional injection twice a week, 0.1/cm2
32836664|NCT04740502|Other|Concordant preoperative studies|Patients with concordant neck ultrasound and MIBI scan
32836665|NCT04740502|Other|Unclear preoperative studies|Patients with discordant or negative neck ultrasound and MIBI scan
32836666|NCT04258852|Experimental|Low Strength, High Strength|
32836667|NCT04258852|Experimental|High Strength, Low Strength|
32836668|NCT04145674|Experimental|25 mg d-methadone|The experimental drug is a tablet formulation of d-methadone HCl in dose strength of 25 mg.
32836669|NCT04145674|Placebo Comparator|Placebo|The placebo is an exact match to the active tablets in size, color and marking without the active ingredient d-methadone HCl.
32836670|NCT00366964|No Intervention|Device|
32836671|NCT02698176|Experimental|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
32836672|NCT02698176|Experimental|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
32836673|NCT02698176|Experimental|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
33103794|NCT00551720|Experimental|Motivational Enhancement|
33103795|NCT04686201|Experimental|intervention group|
32836674|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
32836675|NCT02393976|Other|CONTROL|STANDARD NUTRITION
32836676|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
32836677|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
32836678|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
32836679|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
32836680|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
32836681|NCT05745636|Experimental|Broccoli, mustard, vitamin C|770 mg Broccoli Seed Extract (BSE) with 290 mg mustard seed powder (MSP) and 200 mg vitamin C
32836682|NCT05745636|Placebo Comparator|Placebo|inactive excipients including microcrystalline cellulose, rice hull, maltodextrin, ascorbyl palmitate and silicon dioxide
32836683|NCT04861038|Experimental|aerSleep II|Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
32836684|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
32836685|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
32836686|NCT04024462|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
32836687|NCT04024462|Experimental|Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.
32836688|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
32836689|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
32836690|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
32836691|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
32836692|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
32836693|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
32836694|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
32836695|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
32836696|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
32836697|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
32836698|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
32836699|NCT03733054||Men|Men with lower limb amputation
32836700|NCT03733054||Women|Women with lower limb amputation
32836701|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
32836702|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
32836703|NCT03711760|Experimental|intervention|telepsychology treatment
32836704|NCT03711760|No Intervention|usual care|standard of care
32836705|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
32836706|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
32836707|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
32836708|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
32836709|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
32836710|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
32836711|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
32836712|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
32836713|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
32836714|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
32836715|NCT04480632|Experimental|ABO compatible convalescent plasma|A 500 ml dose of convalescent plasma (from a single donor or two 250 ml units from one or two donations) collected by apheresis will be administered. In case of plasma storage, plasma unit will be thawed following parameters of blood bank. Administration will take place slowly and over the course of four hours. When two 250 ml units are administered, second unit must be administered after the first unit in a period not exceeding 12 hours.
32836716|NCT04480632|No Intervention|Usual care|Usual medical care for critically ill patients at ICU
32836717|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
32836718|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
32836719|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
32836720|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
32836721|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
32836722|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
32836723|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
32836724|NCT04340440|Active Comparator|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
32836725|NCT04340440|Active Comparator|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
32836726|NCT00367042|No Intervention|1|
32836727|NCT00367198|Active Comparator|1|30 ml per serving
32836728|NCT00367198|Active Comparator|2|60 ml per serving
32836729|NCT00367198|No Intervention|3|chronic hemodialysis patients
32836730|NCT00367198|No Intervention|4|healthy subjects
32836731|NCT04340050|Experimental|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
32836732|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
32836733|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
32836734|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
32836735|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
32836736|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
32836737|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
32836738|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
32836739|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
32836740|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
32836741|NCT05745324|Experimental|Smoker vs Nonsmokers|SRP would be performed for Smokers (ENDS and conventional cigarette) and Nonsmokers and their inflammatory biomarkers would be assessed.
32836742|NCT05745324|Experimental|ENDS users and Nonsmokers|SRP would be performed for ENDS users and Nonsmokers and their inflammatory biomarkers would be assessed.
32836743|NCT05745324|Experimental|Smokers with periodontitis and Nonsmokers|SRP would be performed for Smokers with periodontitis and health nonsmokers and their inflammatory biomarkers would be assessed.
32836744|NCT05745324|Experimental|Smokers with periodontitis and Nonsmokers with periodontitis|SRP would be performed for Smokers and Nonsmokers with periodontitis and their inflammatory biomarkers would be assessed.
32836745|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
32836746|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
32836747|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
32836748|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
32836749|NCT03081052|Active Comparator|Lung transplant with iNO|
32836750|NCT03081052|Active Comparator|Lung transplant with iEPO|
32836751|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
32836752|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
32836753|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
32836754|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
32836755|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
32836756|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
32836757|NCT02392962|Experimental|Experimental I|This group performed static stretching
32836758|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
32836759|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
32836760|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
32836761|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
32836762|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
32836763|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
32836764|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
32836765|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
32836766|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
32836767|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
32836768|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
32836769|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
33103796|NCT04686201|No Intervention|control group|
33103797|NCT05056584|Experimental|Healthy control subjects|Healthy control subjects, matched for age, sex and BMI
33103798|NCT05056584|Experimental|Patients with End-stage Renal Disease|Patients with hemodialysis-treated ESRD.
33103799|NCT05056584|Experimental|Patients with liver cirrhosis|Patients with Child-Pugh A or B Cirrhosis
33103800|NCT05467995|Experimental|AK111 75mg|AK111 75mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
33103801|NCT05467995|Experimental|AK111 150mg|AK111 150mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
33103802|NCT05467995|Experimental|AK111 300mg|AK111 300mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
32836770|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
32836771|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel~The drug will be administered at a pre-determine dosage"
32836772|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
32836773|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
32836774|NCT02834884||RP-1828 IMMUcan|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
32836775|NCT02834884||RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.~Tumor type: CNS"
33103803|NCT05467995|Placebo Comparator|Placebo|Placebo will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
33103804|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
33103805|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
32836776|NCT02834884||RP-1843 Arcagen (CLOSED for recruitment since November 2022)|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.~Tumor types: all 10 EURACAN domains"
32836777|NCT02834884||RP-1920 BioRadon|"The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon).~Tumor type: Thorax"
32836778|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
32836779|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
32836780|NCT00367276|Experimental|Arm 1|
32836781|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
32836782|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
32836783|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
32836784|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
32836785|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
32836786|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
32836787|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
32836788|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
32836789|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
32836790|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
32836791|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
32836792|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
32836793|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
32836794|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
32836795|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
32836796|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
32836797|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
32836798|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
32836799|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
32836800|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
32836801|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
32836802|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
32836803|NCT01984762|Active Comparator|SG|sleeve gastrectomy
32836806|NCT01587352|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32836807|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
32836808|NCT00975520|Other|Observation|Observation
32836809|NCT00703222|Experimental|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
32836810|NCT00703222|Experimental|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
33319363|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
33319364|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
33319365|NCT05150782|Experimental|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).
33319366|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
32836816|NCT04465240|Experimental|Virtual reality simulation of neighborhood disadvantage|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood representative of disadvantage they were assigned to. Then they will watch a video again during a recovery period.
32836817|NCT04465240|Active Comparator|Virtual reality simulation of neighborhood affluence|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood, representative of affluence they were assigned to. Then they will watch a video again during a recovery period.
32836818|NCT04449250|Active Comparator|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
32836819|NCT04449250|Active Comparator|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat test meal).
32836820|NCT04437862|Experimental|Q Revascularization System|
32836821|NCT04344028|Experimental|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
32836822|NCT04344028|Active Comparator|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
32836823|NCT04344028|Placebo Comparator|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
32836824|NCT04344028|Sham Comparator|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
32836825|NCT04337710|Experimental|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
32836826|NCT04337710|Active Comparator|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
32836827|NCT04317430|Active Comparator|Treatment group|Niclosamide tablets 1 gram once daily
32836828|NCT04317430|Placebo Comparator|Control group|Lactose tablets
32836829|NCT04277884|Experimental|Firibastat|Capsules
32836830|NCT04277884|Placebo Comparator|Placebo|Matching capsules
32836831|NCT04129840|Active Comparator|Intervention 1: dual combination|dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
32836832|NCT04129840|Active Comparator|Intervention 2: triple combination|triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
32836833|NCT04129840|Placebo Comparator|Standard of care|start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
32836834|NCT04085848|Experimental|Groupe intervention|Usual care and music therapy
32836835|NCT04085848|No Intervention|Groupe contrôle|Usual care
32836836|NCT04023058|No Intervention|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
32836837|NCT04023058|Experimental|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
32836838|NCT04023058|No Intervention|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
32836839|NCT04023058|Experimental|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
32836840|NCT04023058|Other|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
32836841|NCT04023058|Other|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
32836842|NCT03921814|Experimental|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
32836843|NCT03836950|Experimental|active rTMS|For active rTMS, a butterfly coil and MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) will be used. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
32836844|NCT03836950|Sham Comparator|sham rTMS|For sham rTMS, the procedure will be carried out at the left DLPFC but a sham coil will be used. The MagVenture coil has an active side and a placebo side allowing a double-blind study to be conducted. The sham system looks, sounds and feels like active rTMS.
32836845|NCT03821272|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan, then three injections (one every 3 months) of PepCan for a total of 7 injections.
32836846|NCT03821272|Placebo Comparator|Placebo|Four injections (one every 3 weeks) of placebo, then three injections (one every 3 months) of placebo for a total of 7 injections.
32836847|NCT03680794|Experimental|Patients with ophthalmic surgery|
32836848|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
32836849|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
32836850|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
32836851|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
32836852|NCT03189706|Experimental|Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS)|Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
32836853|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
32836854|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
32836855|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
32836856|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
32836857|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
32836858|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
32836859|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
32836860|NCT02535286|Experimental|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
32836861|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
32836862|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
32836863|NCT01834924|Active Comparator|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
32836864|NCT01834924|No Intervention|Control|Standard provider medication counseling
32836865|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
32836866|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
32836867|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
32836868|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
32836869|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
32836870|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
32836871|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
32836872|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
32836873|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
32836874|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
32836875|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
32836876|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
32836877|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
32836878|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
32836879|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
32836880|NCT02649556|Active Comparator|CC|Ad libitum use of CC
32836881|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
33319367|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
33319368|NCT04683796|Experimental|100% APRP|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
33103806|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
33319369|NCT04683796|Active Comparator|100% AS|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
33319370|NCT05251246|No Intervention|Without recovery management program|
33319371|NCT05251246|Experimental|Trained in the recovery management program|Half of the included volunteered participants are randomized in the intervention group
33319372|NCT03760120|Active Comparator|PEP standard|
33319373|NCT03760120|Sham Comparator|PEP sham|
33319374|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
33319375|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
33319376|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
33319377|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
33319378|NCT04399252|Experimental|LGG Arm|Participants in this arm will be given LGG for 28 days.
33319379|NCT04399252|Placebo Comparator|Placebo|Participants in this arm will be given a placebo for 28 days.
33319380|NCT05250934|Experimental|Robotic group|In the robotic group, each patient undergoes 20 upper limb robotic telerehabilitation sessions, each session lasting 1 hour. The frequency is 5 sessions/week. Each session is performed at the patient's home, with direct supervision of a caregiver and remote supervision of a physical therapist, using three webcams able to show (a) the frontal and (b) the sagittal plane of the patient, as well as (c) the monitor of the robot.
33319381|NCT04391686||COVID intensive care unit|
33319382|NCT04391686||intensive care unit|
33319383|NCT04391686||obesity|
33319384|NCT05117320|Experimental|AI support|
33319385|NCT05117320|No Intervention|Non-AI support|
33319386|NCT00283439|Experimental|Single Arm: AMG 531 Dose-Escalating Cohort Study|
33319387|NCT05114824|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy
33319388|NCT05114824|No Intervention|Control Group|Control group
33319389|NCT03233230|Placebo Comparator|Placebo|
33319390|NCT03233230|Experimental|M2951 25 mg QD|
33319391|NCT03233230|Experimental|M2951 75 mg QD|
33319392|NCT03233230|Experimental|M2951 50 mg BID|
33319393|NCT00283049|Experimental|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
33319394|NCT00283049|Experimental|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
33319395|NCT00283049|Experimental|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
33319396|NCT04645108|Experimental|Coached|
33319397|NCT04645108|Active Comparator|No Coach|
33319398|NCT00264875|Experimental|1|
33319399|NCT05089864|Other|Early stent placement|Stent placement 5-7 weeks post-STAR procedure
33319400|NCT05089864|Other|Later stent placement|Stent placement 12-14 weeks post-STAR procedure
33319401|NCT04897672||case|case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency
33319402|NCT04897672||control|control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography
33319403|NCT05069662||Patients treated with oral anticancer drugs|Patients treated with oral anticancer drugs followed in the Oncoral program
33319404|NCT05250700||Adults (40-70yrs)|
33319405|NCT05064202|Experimental|Impella CP|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the experimental arm will be treated with an Impella CP (+/- standard of care)
33319406|NCT05064202|Other|Standard of care|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the control arm will be treated with inotropes (standard of care)
33319407|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
33319408|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
33319409|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
33319410|NCT03635398|Active Comparator|oral administration of midazolam|
33319411|NCT04832074|Experimental|Dry Needling|"Dry needling will be performed with 'solid filiform needles'. The procedure is as follows: The participant will lie in the prone position. The overlying skin will be cleaned with antiseptic spray. The taut band and MTrP, will be localized manually.~After measuring the Pain Pressure Thresholds in this location and the control (located 3 cm lateral to the MTrP), the needle within its plastic guide tube will be placed over the MTrP. After a tapping movement to insert the needle, the needle will be moved to the muscle around the bundle and moved forward and backward to the tissue to elicit a small muscle twitch. After eliciting LTR, needling will be stopped. If no twitch were elicited, needling will stopped after two or three stellate movements"
32836882|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
32836883|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
32836884|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
32836885|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
32836886|NCT03924323|Experimental|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
32836887|NCT03924323|Placebo Comparator|Placebo|Matching oral administration of placebo once daily
32836888|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
32836889|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
32836890|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
32836891|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
32836892|NCT02692716|Experimental|Oral semaglutide|
32836893|NCT02692716|Placebo Comparator|Placebo|
32836894|NCT05745012|Sham Comparator|group A: control group|
32836895|NCT05745012|Experimental|group B: ARMS procedure|
32836896|NCT01580969|Experimental|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
32836897|NCT01580969|Experimental|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
32836898|NCT01580969|Experimental|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
32836899|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
33405508|NCT05208294|Experimental|High expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule.
32836900|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
32836901|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
32836902|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
32836903|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
32836904|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
32836905|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
32836906|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
32836907|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
32836908|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
32836909|NCT04547777|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
32836910|NCT05666778|Other|Intervention Arm|After completing 12 months observation of usual practices of menstrual hygiene management, all participants will be provided reusable menstrual cups that can be worn during sex. The menstrual cup training is comprised of a 2 hour group session that covers basic information on reproductive health, menstrual health, and menstrual hygiene, cup use (insertion/removal), storage, cleaning. In the first three months after intervention delivery, there are monthly phone calls to assess usage and for trouble shooting. There are 12 months of observation in the menstrual cup arm, with Bacterial vaginosis (BV) and vaginal microbiome (VMB) assessment at the beginning of the 12-month period, at 6 months, and at 12 months. Sexually transmitted infection (STI) is measured at the beginning of the 12- month intervention period, and then at 12 months.
32836911|NCT02393040|Experimental|PRP/Saline|"PRP/Saline~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
32836912|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
32836913|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
32836914|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
32836915|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
32836916|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
33319412|NCT04832074|Sham Comparator|Sham Dry Needling|"The same approach will be used with the exception of piercing the skin. The guide tube will press against the tissue and the sham needle will be allowed to drop against the skin. The handle will be tapped briskly but not breaking the skin. The sham needle will stay within the guide tube and will be pressed against the skin twice so as to mimic the quick in and out technique."
32836917|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
32836918|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
32836919|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~Participate in a fitness program which includes:~8 group meetings of 90 minutes weekly~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
32836920|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
32836921|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
32836922|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
32836923|NCT05744856|No Intervention|Standard GDM care|"After being diagnosed with GDM, standard care includes counseling on nutrition and physical activity. All patients are referred to an endocrinologist at the General Hospital, yet this is not covered by insurance unless the patients have received a referral letter from a health station. The endocrinologist will perform blood glucose measurements (venous blood sample) once every four weeks at the General Hospital until gestational week 36, after which it will be monitored once a week until delivery. The cut-off for c-section is 3800g (no matter the mother's GDM status).~Treatment recommended by the endocrinologist may include home-monitoring of blood glucose and insulin treatment in the most severe cases. The home-monitoring requires that the women are able to buy the glucometer and test strips themselves."
32836924|NCT05744856|Experimental|Self-care with informal support|"Standard care + Self-care/informal support intervention~The detailed content of the self-care/informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
32836925|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
32836926|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
32836927|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
32836928|NCT02692482|Active Comparator|standard care|
32836929|NCT05659602|Experimental|HH-120 group|HH-120 Nasal Spray
32836930|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
32836931|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
32836932|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
32836933|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
32836934|NCT05630820|Experimental|Bepirovirsen|
32836935|NCT05630820|Placebo Comparator|Placebo|
32836936|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
32836937|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
32836938|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
32836939|NCT04495439|Other|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
32836940|NCT04495439|Other|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
33405509|NCT05208294|Experimental|Low expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg).
32836941|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
32836942|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
32836943|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
32836944|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
32836945|NCT02392260|Experimental|Vasculight prototype zero level|
32836946|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
32836947|NCT05744778|Experimental|Physical therapy and rehabilitation|The patient group who underwent physical therapy and rehabilitation.
32836948|NCT05744778|Experimental|Dry needling|The patient group who underwent dry needling for trigger points in the upper trapezius muscle along with physical therapy and rehabilitation.
32836949|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
32836950|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
32836951|NCT03166644|Experimental|Intervention Group|Patients with standard practice
32836952|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
32836953|NCT01692119|No Intervention|usual care|usual care
32836954|NCT05744700|Active Comparator|Inulinase|Total 2,000 INU inulinase per day for 28 days
32836955|NCT05744700|Placebo Comparator|Placebo|Maltodextrin for 28 days
32836956|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
32836957|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
32836958|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
32836959|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
32836960|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
32836961|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
32836962|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
32836963|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
32836964|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
32836965|NCT05624580|Experimental|Single Dose 1: NNC0582-0001 10 milligram (mg)|Participants will receive a single dose of NNC0582-0001 10 mg or matching placebo injection subcutaneously.
32836966|NCT05624580|Experimental|Single Dose 2: NNC0582-0001 30 mg|Participants will receive a single dose of NNC0582-0001 30 mg or matching placebo injection subcutaneously.
32836967|NCT05624580|Experimental|Single Dose 3: NNC0582-0001 90 mg|Participants will receive a single dose of NNC0582-0001 90 mg or matching placebo injection subcutaneously.
32836968|NCT05624580|Experimental|Single Dose 4: NNC0582-0001 250 mg|Participants will receive a single dose of NNC0582-0001 250 mg or matching placebo injection subcutaneously.
32836969|NCT05624580|Experimental|Single Dose 5: NNC0582-0001 600 mg|Participants will receive a single dose of NNC0582-0001 600 mg or matching placebo injection subcutaneously.
32836970|NCT05624580|Experimental|Single Dose 6: NNC0582-0001 1000 mg|Participants will receive a single dose of NNC0582-0001 1000 mg or matching placebo injection subcutaneously.
32836971|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
32836972|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
33319413|NCT04812652|Experimental|Intervention group: Digitally distributed yoga|"Type of yoga: Physical yoga sequences that through scientific evaluation have proven to be effective and relevant for the target group. There will be 3 different programs during the 12-week-intervention Dose: twice weekly for 12 weeks; one yoga class live broadcasted and digitally distributed to the patient's computer or mobile device, and one class pre-recorded video for self-training.~Sequences: The yoga class will be 60 minutes including 10 minutes of final relaxation. Thereafter, a 5 minutes reflection will be offered.~Home Training: Instructions for yoga home practice will be standardized. The three yoga programs will be distributed in video-links for the participants to view at a time-point that suits them during the week. The recommendation will be to yoga at home once a week in addition to the digital yoga class in real time.~Participants are expected to use their own computer or mobile device."
33319414|NCT04812652|No Intervention|Control group: Regulare care|Receive regular care, including written standardized information about the importance of physical activity by their contact nurse or physiotherapist, when discharged from the hospital accordingly to the routines at the clinic.
32836973|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
32836974|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
32836975|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
32836976|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
32836977|NCT01577381|Experimental|PF-04382923|
32836978|NCT01577381|Placebo Comparator|Placebo|
32836979|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
32836980|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
32836981|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
32836982|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
33319415|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
33319416|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
33319417|NCT04837378|Experimental|Abdominal Massage Group|Abdominal massage process stage; After the preliminary test data were obtained, the hands were warmed and creamed with vaseline, abdominal massage was applied to the patient in the supine position for 15 minutes. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
33319418|NCT04837378|Experimental|In-bed Exercise Group|In-bed exercise process phase; After the pre-test data were obtained, the patient was applied passive in-bed exercises for approximately 15 minutes in all extremities in the supine position. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
33319419|NCT04837378|No Intervention|Control Group|Control group stage; Gastrointestinal complications and comfort parameters were recorded in this group at the same time as the experimental groups without any intervention.
33319420|NCT05250232|Experimental|onlays conservative|conservative onlays preparation with partial cusp coverage only defective cusps
33319421|NCT05250232|Active Comparator|onlays conventional|onlays preparation design conventional as all cusps covered with shoulder finish line preparation
33319422|NCT05226442|Experimental|Argatroban|Continuous infusion of 0,3μg/kg/min to target an aPTT of 50-70sec and/or Hemoclot of 0,60 - 0,80 µg/mL
33319423|NCT05226442|Active Comparator|Unfractionated Heparin|Continuous infusion of Unfractionated Heparin to target an aPTT of 50-60 seconds and/or Anti-Xa level between 0.20 and 0.30 IU/ml and/or thrombin time >20sec.
33319424|NCT04800874|Experimental|Cohort 1|Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
33319425|NCT04800874|Experimental|Cohort 2|Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
33319426|NCT04800874|Experimental|Cohort 3|Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
33319427|NCT01316458|Experimental|imatinib mesylate|
33319428|NCT04391452|Experimental|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
33319429|NCT04391452|Placebo Comparator|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
32836983|NCT01691105|No Intervention|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
32836984|NCT01691105|Experimental|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
32836985|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
33405510|NCT05208294|Experimental|Low expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule.
32836986|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
32836987|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
32836988|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
32836989|NCT04339192|Experimental|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
32836990|NCT04339192|No Intervention|Medical group|receiving medical treatment only
32836991|NCT04782258|Experimental|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
32836992|NCT04782258|Experimental|Tolvaptan Tablets|Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. Treatment duration is 18 months.
32836993|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
32836994|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
32836995|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
32836996|NCT00118365|Placebo Comparator|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
32836997|NCT00118365|Experimental|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
32836998|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
32836999|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
32837000|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
32837001|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
32837002|NCT05744622|Experimental|chemically cured conventional glass ionomer restorative (Ketac Universal Aplicap)|For restoration of M1 group, capsule activation will be performed through loading of the KetacTM Universal AplicapTM GIC capsule into its activator keeping the applicator nozzle closed, using the ball of my hand to depress the activator lever firmly as far as it will go and hold it down for 2 to 4 seconds. Then the capsule will be mixed in a high frequency mixing device for 8 seconds. The mixed capsule will be immediately removed from the mixer and loaded into the AplicapTM Applier then application nozzle will be opened to extrude the mixture directly into the preparation as a single bulk within 1:40 minute. The preliminary contour will be done using a ball burnisher.
32837003|NCT05744622|Experimental|Ketac Universal Aplicap enhanced with light-emitting diode radiant heat|Restoration of M2 group will be performed following the same steps which will be carried out for M1 group but the achieved restorations will be enhanced by light-emitting diode radiant heat for 60 seconds
32837004|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
32837005|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
32837006|NCT03165240|Experimental|BI 690517 Dose 1|
32837007|NCT03165240|Experimental|BI 690517 Dose 2|
32837008|NCT03165240|Experimental|BI 690517 Dose 3|
32837009|NCT03165240|Experimental|Eplerenone|
32837010|NCT03165240|Placebo Comparator|Placebo|
32837011|NCT04123535|Experimental|Undifferentiated Pleomorphic Sarcoma (UPS)|All enrolled participants will be scheduled to receive pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor or approximately 2 weeks after a pre-procedure biopsy of the metastatic tumor target depending on diagnosis at enrollment. For patients enrolled with metastatic disease, pre and post-MRgFUS biopsy samples will be obtained.
32902888|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
33405511|NCT05213988|Experimental|Low-Carbohydrate/High-Protein Diet|
33405512|NCT05213988|Experimental|Fibrate|
32837012|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
32837013|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
32837014|NCT05746494|Experimental|Active anodal tDCS first, then Sham tDCS|Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); sham stimulation (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing.
32837015|NCT05746494|Sham Comparator|Sham tDCS first, then Active anodal tDCS|Sham tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing Intervention.
32837016|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
32837017|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
32837018|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
32837019|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
32837020|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
32837021|NCT05746416||s-TDAPT group|Ticagrelor 180mg + Aspirin 100mg within 6 months after index PCI
32837022|NCT05746416||l-TDAPT group|Ticagrelor 120mg + Aspirin 100mg within 6 months after index PCI
32837023|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
32837024|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
32837025|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
32837026|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
32837027|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
32837028|NCT01587079|Experimental|PT001|PT001 MDI
32837029|NCT01587079|Experimental|PT005|PT005 MDI
32837030|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
32837031|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
32837032|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
32837033|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
32837034|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
32837035|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
32837036|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
32837037|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
32837038|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
32837039|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
32837040|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
32837041|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
32837042|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
32837043|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
32837044|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
32837045|NCT04739644|Experimental|Experimental: WRISTBOT Group|"The patients in the WRISTBOT Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation by WRISTBOT device"
32837046|NCT04739644|Active Comparator|Control group|The patients in the Control Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation performed by physiotherapist.
32837047|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32837048|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32837049|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32837050|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
32837051|NCT04739488|Experimental|Breathing exercise and inhaler training|This group were given pursed lip breathing exercise and inhaler training.
32837052|NCT04739488|Experimental|inhaler training|This group were given only inhaler training
32837053|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
32837054|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
32837055|NCT04739566|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib 150 mg orally (PO) twice daily, trametinib 2mg PO once daily for 3 months
32837056|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
33319430|NCT01316536|Experimental|With Music|This randomized group will receive music
32837057|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
32837058|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
32837059|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
32837060|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
32837061|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
32837062|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
33319431|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
32837063|NCT05746338|Experimental|Ring-type wearable device|The ring-type wearable device achieved continuous monitoring of blood oxygen saturation during sleep and established a OSAS screening algorithm based on oxygen saturation, which might become a complement to polysomnography.
32837064|NCT05746338|Active Comparator|Polysomnography|Overnight polysomnography (PSG) monitor was used as the gold standard to: 1) examine the accuracy of blood oxygen monitoring assessed via a ring-type wearable device in comparison to traditional finger clip pulse oximeter; 2) assess the agreement between the ring-type wearable device and PSG monitor on OSAS screening.
32837065|NCT02660788|Active Comparator|Control Arm|Mail
32837066|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
32837067|NCT03166410|Experimental|Cell Treatment|
32837068|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
32837069|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
32837070|NCT00118755|Experimental|1|
32837071|NCT00118755|Active Comparator|2|
32837072|NCT03165006||Screened women with breast cancer|
32837073|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
32837074|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
32837075|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
32837076|NCT01541371|Experimental|Paliperidone ER|
32837077|NCT00121173|Experimental|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.~Genetic (recombinant DNA vaccine)"
32837078|NCT00121173|Experimental|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
32837079|NCT00121173|Experimental|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
32837080|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
32837081|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
32837082|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
32837083|NCT00121251|Experimental|Sorafenib + Gemcitabine + Capecitabine|Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
32837084|NCT04546139||fast group|
33405513|NCT05213988|Experimental|Intermittent Fasting|
33405514|NCT05213988|No Intervention|Control|
32837085|NCT04546139||slow group|
32837086|NCT02664220|Experimental|Povidone-iodine irrigation|
32837087|NCT02664220|Active Comparator|No irrigation|
32837088|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
32837089|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
32837090|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
32837091|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
32837092|NCT04339348|Experimental|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
32837093|NCT04339348|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
32837094|NCT04339348|Placebo Comparator|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
32837095|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
32837096|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
32837097|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
32837098|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
32837099|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
32837100|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
32837101|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
32837102|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
32837103|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
32837104|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
32837105|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
32837106|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
32837107|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
32837108|NCT01687595|Experimental|HerpV 240 μg + QS-21 50 μg|Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1. At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
32837109|NCT01687595|Placebo Comparator|Placebo|Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
32837110|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
32837111|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
32837112|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32747202|NCT05540535||Control participants with normal hearing.|Normal hearing will be defined as a PTA below 25dB (0.5-4 kHz) bilaterally. Subjects above 65 years of age, with symmetric ARHL in the high frequencies (>3K), with unaided PTA < 40 dB (0.5-4KHz) will be included in the control group as well.
32747203|NCT05535543||Baseline slope of phase iii|Severe ARDS patients who are intubated and mechanically ventilated and will undergo prone positioning
32747204|NCT05698095|Experimental|Cohort 1 - 0.5 mg single-dose|A single 0.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32747205|NCT05698095|Experimental|Cohort 2 - 2.5 mg single-dose|A single 2.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32747206|NCT05698095|Experimental|Cohort 3 - 4.5 mg single-dose|A single 4.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32747207|NCT05698095|Experimental|Cohort 4 - 7 mg single-dose|A single 7 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32837113|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32837114|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
32837115|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
32837116|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
32837117|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
32837118|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
32837119|NCT04739410|Experimental|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
32837120|NCT04739410|Placebo Comparator|SOC standard of care|These participants were given standard of care without Ivermectin standard of care only symptomatic treatment
32837121|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
32837122|NCT03165864|Placebo Comparator|Placebo|Saline .9%
32837123|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
32837124|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
32837125|NCT04545749|Experimental|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
32837126|NCT04545749|Experimental|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
32837127|NCT04545749|Experimental|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
32837128|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
32837129|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
32837130|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
32837131|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
32837132|NCT05746182||Participants with Pancreatic Neuroendocrine Neoplasms|
32837133|NCT04739332|Experimental|NBO intervention for at-risk mothers|NBO intervention for at- risk mothers. 3 NBO sessions added to the routine follow-up delivered once per week during the first month postpartum. The intervention is delivered by a nurse certified in the NBO system.
32837134|NCT04739332|No Intervention|Treatment as usual|Participants receive 3 routine follow-up by the local health visitor/midwife during the first month
32837135|NCT04339114|Sham Comparator|Control meal|Pancake
32837136|NCT04339114|Active Comparator|Control meal + Cinnamon|Pancake seasoned with cinnamon
32837137|NCT04339114|Active Comparator|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
32837138|NCT04339114|Active Comparator|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
32837139|NCT04707898|Experimental|Group Single Bond Universal|Single Bond Universal adhesive system with selective-etch approach following the manufacturer's instruction
32837140|NCT04707898|Experimental|Group G-Premio Bond|G-Premio Bond Adhesive System with selective-etch approach following the manufacturer's instruction
32837141|NCT04707820|Experimental|Patient group|- Patient with an acute SARS-CoV-2 infection, confirmed by PCR or typical CT images, requiring hospitalization in a COVID unit at Rouen University Hospital.
32837142|NCT04707820|No Intervention|control group|- Rouen University Hospital staff free of any symptomatology compatible with an SARS-CoV-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since February 1, 2020
32837143|NCT04707742|Experimental|Povidone-iodine 2% (Betadine© bucal 100 mg/ml)|"Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).~The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water)."
32837144|NCT04707742|Experimental|Hydrogen peroxide 1% (Oximen® 3%)|Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
33103807|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
33103808|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
32837145|NCT04707742|Experimental|Clorhexidine 0,12% (Clorhexidine Dental PHB©)|"Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2).~Rinses were ready to use in their commercial formulas."
32837146|NCT04707742|Experimental|Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)|"Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).~Rinses were ready to use in their commercial formulas."
32837147|NCT04707742|Placebo Comparator|Control (Distilled Water)|Distilled water.
32837148|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
32837149|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
32837150|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
32837151|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
32837152|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
32837153|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
32837154|NCT00368056|Experimental|1|eszopiclone 3 mg
32837155|NCT00368056|Placebo Comparator|2|Placebo tablet
32837156|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
32837157|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
32837158|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
32837159|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
32837160|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
32837161|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
32837162|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
32837163|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
32837164|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
32837165|NCT04544735|Experimental|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will will integrate two key components: pelvic health PT interventions (i.e., vaginal dilators, Pelvic Floor Muscle Training) and coping skills training for managing symptoms and improving treatment adherence. The intervention aims to improve women's sexual function after pelvic radiation
32837166|NCT04475315|Experimental|Papillary Muscle Sling Group|Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
32837167|NCT04475315|Active Comparator|Controls Group|Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
32837168|NCT05746104|Experimental|SWIG Arm|This is the only arm for the study and will be experimental. All patients will receive the appropriate dosage of the study drug, which will then be used for visualization of the tumor intraoperatively.
32837169|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
32837170|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
32837171|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
32837172|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
32837173|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
32837174|NCT05580432|Experimental|Immediate behavioral intervention|Participants will receive the intervention immediately
32837175|NCT05580432|Active Comparator|Delayed behavioral intervention|Participant will receive the intervention after a 12 month delay
32837176|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
32837177|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
32837178|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
32837179|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
32837180|NCT03114930|Other|Standard output|
32837181|NCT03114930|Other|Non standard output|
32837182|NCT05432674|Experimental|Digital Fall Prevention|Subjects will participate in Digital Fall Prevention intervention for 12 weeks
32837183|NCT05563896||China|We plan to enroll 200 healthy adults in this study at five different international sites (China, Iran, Kenya, Senegal, UAE). Forty subjects will be enrolled at each site. Previous studies showed energy requirements varied with sex and age of the participants. Therefore, in each site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
32837184|NCT05563896||Sénégal|Forty subjects will be enrolled at Senegal site.In Senegal site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
32837185|NCT05563896||Kenya|Forty subjects will be enrolled at Kenya site.In Kenya site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
32837186|NCT05563896||United Arab Emirates|Forty subjects will be enrolled at UAE site.In UAE site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
32837187|NCT05563896||Iran|Forty subjects will be enrolled at Iran site.In Iran site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
32837188|NCT05744388|Active Comparator|Stylet shape modification group|"Endotracheal tube diameter size 7.5 mm and disposable rigid blade size 3 for the female patients and ETT diameter size 8.00 mm and disposable rigid blade size 4 for the male patients will be prepared. The under surface of the blade will be lubricated by soluble jelly, taking care not to touch the camera source of light.~The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis. Once the tip of the tube introduced inside the glottis, the stylet will be removed and the tube will be advanced more inside the trachea. The equality of air entry will be assessed by the stethoscope and the tube will by fixed by adhesive tape after inflating the cuff."
32837189|NCT05744388|No Intervention|Standard shape of the stylet group|The second group will be a control group, they will be handled by the standard shape of the stylet and the blade without lubrication.
32837190|NCT05425498|Experimental|Physical Activity Program Group|In the physical activity group, In the physical activity group, a 12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model. Assessments will perform just before starting to study, at the end of 12 weeks (just after the physical activity program), and the end of 24 weeks.
33405515|NCT05207904|Experimental|tislelizumab plus chemotherapy|
32837191|NCT05425498|No Intervention|Control group|In the control group, information about physical activity will be given without applying the physical activity program. Control group's assessments will be performed when they are included in the study, at the end of 12 weeks and 24 weeks.
32837192|NCT05746026|Experimental|STUDY GROUP|• The study subjects who fulfilled the inclusion criteria were interviewed individually in the garden of the clubs in order to collect the necessary data (tool I, II, III, and IV). Then, the researcher interviewed the clients in group composed of 8 older adults to implement the Psycho-educational Program . Each session taken about 30-45 minutes.
32837193|NCT05746026|Active Comparator|Control group|Control group exposed to the usual routine care
32837194|NCT05425108|Active Comparator|CP1 device|
32837195|NCT05425108|No Intervention|Control|
32837196|NCT05417854|Experimental|Ultrasound Group|
32837197|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
32837198|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
32837199|NCT05409430|Experimental|Patients with Acute Ischemic Stroke (AIS)|Patients with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.
32837200|NCT04738630|Experimental|Experimental: HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
32837201|NCT05352958||Patients with Amyotrophic Lateral Sclerosis|"ALS~certain or probable according to the revised Escorial criteria~no indication for non-invasive ventilation"
32837202|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
32837203|NCT05339542|Experimental|Platelet rich plasma group|"platelet rich plasma (PRP) will be produced through whole blood centrifuge using a specific methodology in a strict aseptic setting. Then, blood will be collected and mixed with anticoagulant and Citrate-phosphate-dextrose adenine in a 10 volume blood to 1 volume anticoagulant ratio. The blood will be centrifuged for 10 minutes at 1000 rpm. Afterward, the plasma will be transferred to a new glass tube and centrifuged for 15 minutes at 3000 rpm. At the bottom of the tube, platelets will form a pellet. Finally, pure platelet-rich plasma will be obtained at a concentration of up to four times higher than baseline. Prior to the injection, calcium gluconate will be combined with PRP (at a ratio of 0.3 ml ca gluconate/ml PRP).~The injection will be done once."
32837204|NCT05339542|Active Comparator|Methylprednisolone group|"2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound guidance to the plantar fascia.This group serves as active comparative group.~The injection will be done once."
32837205|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
32837206|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
32837207|NCT04338568|Active Comparator|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
32837208|NCT04338568|Active Comparator|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
32837209|NCT05744310|Active Comparator|ALS patients that choose life prolonging treatment with LTMV and their families|
32837210|NCT05744310|Active Comparator|ALS patients that decline life prolonging treatment with LTMV and their families|
32837211|NCT05335252|Experimental|Dronabinol|Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
32837212|NCT05335252|Placebo Comparator|Placebo|Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
32837214|NCT05319808|Experimental|Group A|Telehealth using NeckCare equipment
32837215|NCT05319808|Active Comparator|Group B|Exercises without telehealth intervention
32837216|NCT05319808|No Intervention|Group C|No intervention provided by the researchers
32837217|NCT05317312|Experimental|MR-107A-02 1.25 mg twice in a 24 hour period|Oral tablet, one day of dosing
32837218|NCT05317312|Experimental|MR-107A-02 5 mg twice in a 24 hour period|Oral tablet, one day of dosing
32837219|NCT05317312|Experimental|MR-107A-02 15 mg twice in a 24 hour period|Oral tablet, one day of dosing
32837220|NCT05317312|Placebo Comparator|Placebo twice in a 24 hour period|Oral tablet, one day of dosing
32837221|NCT05308108||Children with Obstructive Sleepapnea|
32837222|NCT05297812||Moderate to Advanced Emphysema|Patients with moderate or advanced Emphysema as measured by baseline inspiratory PERC-15 below the study median
32837223|NCT05297812||Minimal Emphysema|Patients with minimal emphysema as measured by baseline inspiratory PERC-15 above the study median
32837224|NCT05291806|Placebo Comparator|Reference|
32837225|NCT05291806|Active Comparator|Whole cereal kernels Dose A|
32837226|NCT05291806|Active Comparator|Whole cereal kernels Dose B|
32837227|NCT05291806|Active Comparator|Cut cereal kernels Dose A|
32837228|NCT05273788|Active Comparator|1Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 1Hz with the magnetic coil.
32837229|NCT05273788|Active Comparator|10Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 10Hz with the magnetic coil.
32837230|NCT05273788|Sham Comparator|Sham Arm|Sham intervention with 2400 total sham stimulations with the magnetic coil.
32902889|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
32837231|NCT05257018|Experimental|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~Rituximab 375 mg / m^2，D1~Cyclophosphamide 750 mg / m^2，D2~Doxorubicin Hydrochloride Liposome Injection 35mg / m^2，D2~Vincristine 1.4mg/m^2 (dose capped at 2 mg)，D2~Prednisone 50 mg， bid D2-6~Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24h after chemotherapy）"
32837232|NCT05248984||Ketorolac 30 mg|Participants will receive single dose of intravenous (IV) Ketorolac 30mg
32837233|NCT05248984||Ketorolac 60 mg|Participants will receive single dose of intravenous (IV) Ketorolac 60mg
32837234|NCT05237128|Experimental|Very low-carbohydrate diet|
32837235|NCT05237128|Experimental|Moderate-carbohydrate plate-method diet|
32837236|NCT05227534|Experimental|Participants 40 years of age or older with cancer risk|The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
32837237|NCT05227222|Experimental|PEP-device|Positive expiratory pressure device: continuous treatment with PEP-device breathing air for 20 minutes followed by 10 minutes rest and assessment. Inspiration through nose/mouth, expiration through device.
32837238|NCT05227222|No Intervention|spontaneous recovery|Control group: Resting and breathing air for 20 + 10 minutes.
32837239|NCT05218798|Active Comparator|Continous Treadmill Running Test|One of the four testing conditions the subject will be allocated to is a Continous Treadmill Running Test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
32837240|NCT05218798|Active Comparator|Continous 2-mile run test|One of the four testing conditions the subject will be allocated to is a Continous 2-mile run test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
32837241|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - first trial|"Aerobic capacity will be measured using the field-based 30-15IFT test. This intermittent, incremental test consists of 30-second shuttle runs interspersed with 15-second active recovery periods. Running speed will be set at 8 km/h for the first 30-second run and increased by 0.5 km/h in each 30-second phase thereafter. The speed of the last successfully completed stage will be recorded as the test result, i.e. the maximum running speed (V) during IFT. Vo2max will be estimated by the following equation:~Vo2max IFT (ml/min/kg) = 28.3 - 2.15G - 0.741A - 0.0357BM + 0.058A X VIFT + 1.03VIFT where G stands for subjects gender, A for age and BM for body mass, respectively."
32837242|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - second trial|The procedures will be the same as previously described
32837243|NCT05218252|Other|Hand soft tissue defects|Patients with mild to moderate hand soft tissue defects with exposed bone, tendons or cartilage resulting from trauma, tumor ablation or postburn deformities.
32837244|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
32747208|NCT05698095|Experimental|Cohort 5 - 10 mg single-dose|A single 10 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32747209|NCT05698095|Experimental|Cohort 6 - 16 mg single-dose|A single 5-MeO-DMT 16 mg or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
32747210|NCT05698095|Experimental|Cohort 7 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 4.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
32837245|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
32837246|NCT01683071|Experimental|(Part 1) EXPAREL 67 mg|5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
32837247|NCT01683071|Experimental|(Part 1) EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
32837248|NCT01683071|Experimental|(Part 1) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
32837249|NCT01683071|Placebo Comparator|(Part 1) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
32837250|NCT01683071|Experimental|(Part 2) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
32837251|NCT01683071|Placebo Comparator|(Part 2) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
32837252|NCT04707508|Experimental|Valsartan and metformin|
32837253|NCT04707508|Active Comparator|Metformin only|
32837254|NCT05189080|Experimental|Open Trial|Patients within the Wake Forest Baptist Health system who no-showed for scheduled well child visits at Pediatrics-Downtown Health Plaza, Family Medicine-Piedmont Plaza, Pediatrics-Winston East, Family Medicine-Peace Haven, and Pediatrics-Clemmons.
32837255|NCT05164822||Necrotizing Vasculitis|"Patient with an initial diagnosis or a relapse of :~- Systemic Vasculitic Neuropathy (SVN): Primary Necrotizing Vasculitis answering the Chapel Hill Consensus Conference criteria associated with a symptomatic Vasculitic Peripheral Neuropathy~Or~- Non Systemic Vasculitic Neuropathy (NSVN): pure symptomatic peripheral neurological impairment without systemic visceral impairment"
32837256|NCT05145400|Experimental|Single Arm|All subjects will receive the same treatment on the study, consisting of isatuximab, lenalidomide, and dexamethasone with 28 days cycles.
32837257|NCT05140642|Active Comparator|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
33319432|NCT05198128|Experimental|Calcium intravenous infusion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
32837258|NCT05140642|Experimental|Artificial Intelligence Annotation|In preliminary work, a novel AI algorithm developed to assess LVEF was shown to be more precise than human interpretation in 10,030 echocardiograms done at Stanford University (Ouyang et al. Nature, 2020). With randomization, a proportion of the preliminary interpretations will be done by AI technology and the study team will assess how different this preliminary interpretation is from the final interpretation.
32837259|NCT05099068|Experimental|IMMUNOTHERAPY COHORTS|This cohort include following cancers treated with immunotherapy : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); MSI-High, any tumor types and HPV-related cancers,any tumor types
32837260|NCT05099068|Experimental|TARGETED THERAPIES COHORTS|This cohort include following cancers treated with targeted therapies : Metastatic GIST; BRAF-mutated tumors (CRC (BRAF V600E), lung (V600 only) and thyroid (all BRAF mutation with known sensitivity to Dabrafenib) cancer); All solid tumor types with RET fusion / mutation and Chronic Lymphocytic Leukemia (CLL) in the relapsed setting.
32837261|NCT05099068|Experimental|CHEMOTHERAPY COHORTS|This cohort include following cancers treated with chemotherapies : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); Metastatic Triple negative breast cancer (TNBC); Glioblastoma; Advanced high grade epithelial ovarian cancer
32837262|NCT01567865|Active Comparator|Reference Lot|Lot of Vaccine produced in existing facility
32837263|NCT01567865|Experimental|New Lot #1|First lot of vaccine produced in new facility
32837264|NCT01567865|Experimental|New Lot #2|Second lot of vaccine produced in new facility
32837265|NCT01567865|Experimental|New Lot #3|Third lot of vaccine produced in new facility
32837266|NCT05049226|Experimental|Two doses of SV at interval 60 to less than 90 days|Participants who have received two doses of SV at interval 60 to less than 90 days
32837267|NCT05049226|Experimental|Two doses of SV at interval 90 to less than 120 days|Participants who have received two doses of SV at interval 90 to less than 120 days
32837268|NCT05049226|Experimental|Two doses of SV at interval 120 to 180 days|Participants who have received two doses of SV at interval 120 to 180 days
32837269|NCT05044936|Experimental|Training|Visit 1: sign consent form, pregnancy tests for females, resting blood pressure, height/weight, body composition, and VO2max test. Visit 2: 1-repetition maximum (RM) test and protocol familiarization. Visit 3: perform a muscle-damaging exercise protocol. Pre-exercise soreness and blood samples will be collected. After, they will perform the pre-exercise testing to assess baselines levels of power and sprint times. Upon completion, they will undergo the muscle-damaging exercise protocol. Post-exercise blood samples and soreness will be collected. The participant will then be given either placebo or CBD cream to rub into their quadriceps. Visit 4 & 5: collect blood samples and soreness scale measurements. Participants will then be given the same treatment (placebo or CBD cream) as they had on visit 3. Visit 6 will be similar to visit 3, except the participant will be given the opposite treatment (placebo or CBD cream). Visits 7 & 8 will be similar to visits 4 & 5, respectively.
32837270|NCT05006872|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
32837271|NCT05006872|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
32837272|NCT05005546|Experimental|Experimental: Yoga|
32837273|NCT05005546|Experimental|Experimental: Laughter Yoga|
32837274|NCT05005546|No Intervention|Control|
32837275|NCT05005000|Experimental|MFAT|
32837276|NCT05005000|Active Comparator|Steroid (Control)|
32837277|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
32837278|NCT05002114|Placebo Comparator|Placebo Group|Does not get active topical CBD. Instead, gets an identical placebo-containing topical agent.
32837279|NCT05002114|Experimental|Active Group|Does get active topic CBD.
32837280|NCT04973566|Experimental|Part 1: Etanercept and Nipocalimab|Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
32837281|NCT04973566|Experimental|Part 2 (Cohort 1): Nipocalimab|Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.
32837282|NCT04973566|Experimental|Part 2 (Cohort 2): Nipocalimab and Hydroxychloroquine (HCQ)|Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.
32837283|NCT03900533|Experimental|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
32837284|NCT03900533|Active Comparator|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
32837285|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
32837286|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
32837287|NCT04738786|Active Comparator|Wide surgical safety margin|1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
32837288|NCT04738786|Active Comparator|Narrow surgical safety margin|1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
33319433|NCT05198128|Placebo Comparator|saline|0.9 % saline intravenous infusion
32837289|NCT04950010|Experimental|High-Intensity Interval Training (HIIT)|Breast cancer survivors randomized to HIIT will participate in a high-intensity interval training program for 8 weeks.
32837290|NCT04950010|Active Comparator|Moderate-Intensity Exercise (MOD)|Breast cancer survivors randomized to MOD will participate in a moderate-intensity aerobic exercise program for 8 weeks.
32837291|NCT04950010|No Intervention|Usual Care (UC)|Individuals randomized to UC will be instructed to continue standard cancer care and engage in habitual lifestyle behaviors.
32837292|NCT04749004|Experimental|Intervention Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~Setting-up of a commitment contract on the individual's goal of monthly steps taken~Provision of financial incentives upon achievement of one's goal of steps taken~Provision of nudges (reminders)"
32837293|NCT04749004|No Intervention|Control Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~To keep incentives constant the control group will also receive the flat payment of €10 to disentangle the effects between the contract and financial incentives."
32837294|NCT04748146|Other|Intervention and Control group|Each patient will receive electrical and sham stimulation, meaning that each patient will act as their own control.
32837295|NCT04635826|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
32837296|NCT04635826|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
32837297|NCT04635826|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
32837298|NCT04635826|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
32837299|NCT04597840|Experimental|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
32837300|NCT04597840|Other|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
32837301|NCT04567810|Experimental|Part A: 2 mg preparation|Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.
32837302|NCT04567810|Experimental|Part A: 4 mg preparation|Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.
32837303|NCT04567810|Experimental|Part A: 8 mg preparation|Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.
32837304|NCT04567810|Placebo Comparator|Part A: placebo preparation|Participants receive placebo matching anti-SARS-CoV-2 IgY.
32837305|NCT04567810|Experimental|Part B: 6 mg total daily dose|Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
32837306|NCT04567810|Experimental|Part B: 12 mg total daily dose|Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
32837307|NCT04567810|Experimental|Part B: 24 mg total daily dose|Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
32837308|NCT04567810|Placebo Comparator|Part B: 0 mg total daily dose|Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.
32837309|NCT04556344|Experimental|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
32837310|NCT04556344|Sham Comparator|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
32837311|NCT04338802|Placebo Comparator|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
32837312|NCT04338802|Experimental|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
32837313|NCT04455022||Any infant who will have a blood culture collected.|During the study period educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
32902890|NCT04492436|Experimental|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
33319434|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
33319435|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
33319436|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
33319437|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
33319438|NCT01485874|Experimental|Doxil + BIBF 1120|
33319439|NCT05000710|Experimental|study arm|"Study treatments include:~Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21)."
33319440|NCT05159128|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts|Healthy Japanese participants will receive JNJ-75105186 or matching placebo orally in Cohorts 1-3.
33319441|NCT05159128|Experimental|Part 2: Single Dose (SD) Cohort|Healthy Chinese participants will receive JNJ-75105186 or matching placebo orally in Cohort 4.
33319442|NCT04786756|Active Comparator|Lateral Approach of Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
33319443|NCT04786756|Active Comparator|Medial Approach of Costoclavicular Block|US-guided medial approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
33319444|NCT05073250|Experimental|Experimental arm|Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
33319445|NCT05056324|Experimental|Intervention group|
32747211|NCT05698095|Experimental|Cohort 8 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 7 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
32747212|NCT05698095|Experimental|Cohort 9 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (4.5 mg followed by 11.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
32747213|NCT05546619|Experimental|Treating with a Design Protocol|
32747214|NCT05540379|Active Comparator|Group A: Ob/Gyn physicians|It is about 51 participants whom had performed less than 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
32747215|NCT05540379|Active Comparator|Group B: Ob/Gyn physicians|It is about 51 participants whom had performed at least 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
32747216|NCT05535465|Experimental|Intervention arm|Heath system strengthening with additional trained mobile health care worker to help community health workers
32747217|NCT05535465|No Intervention|Standard of care|National strategy to control malaria
32747218|NCT05540301|Experimental|Modified Sleeper Stretch Group|Modified sleeper stretch was performed for four weeks.
32747219|NCT05540301|Active Comparator|Modified Cross-Body Adduction Stretch Group|Modified cross-body adduction stretch was performed for four weeks.
32747220|NCT05535387|Experimental|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans.
32747221|NCT05540145||Experimental: SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody|SOX: Oxaliplatin+S-1
32747224|NCT05592561|Experimental|Caffeine group|Subjects will receive 200 mg of caffeine powder which was obtained from a 200 mg capsule (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada). Researchers will break open the capsule and mix with water and 5/8 tsp of crystal light immediately before subjects ingest the randomly assigned treatment.
32747225|NCT05592561|Placebo Comparator|Placebo|flavored water (sweetened with crystal light powder, 0.5 tsp) will be provided to subjects without any caffeine powder added.
32747226|NCT05592561|Experimental|Theanine group|200mg pure theanine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) + 8 oz water+ 0.55 tsp crystal light will be ingested.
32747227|NCT05592561|Experimental|Tyrosine group|2000 mg pure tyrosine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) +8 oz water + 0.5 tsp crystal light will be ingested.
32747228|NCT05698017|Active Comparator|Low dose hOMSC300|Single IT administration of low dose hOMSC300
32747229|NCT05698017|Active Comparator|High dose hOMSC300|Single IT administration of high dose hOMSC300
32747230|NCT05698017|Other|Sham Procedure|Lumbar puncture only
32747231|NCT05697939||Adolescent Idiopathic Scoliosis|"Inclusion criteria~Ages 10 and 18 years old~Referred for evaluation of or diagnosed with adolescent idiopathic scoliosis~Exclusion criteria~Scoliosis caused by another condition (e.g., secondary scoliosis)~Parents/guardians unable to consent~English is not the primary language (to avoid miscommunication)"
32747232|NCT05546541||subjects normal weight undergo to PRP treatment|subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment.
32747233|NCT05546541||subjects overweight undergo to PRP treatment|subjects with BMI values that exceed the normal weight range (BMI>25) undergo to PRP treatment.
32747234|NCT05546541||subjects with normal weight undergo to microfragmented adipose tissue treatment|subjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment.
32747235|NCT05546541||subjects overweight undergo to microfragmented adipose tissue treatment|subjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI>25).
32747236|NCT05546463|Experimental|Intervention group|"During the suture procedure, the children in the intervention group played digital games.~Children began playing digital games about one minute before the local anesthesia procedure, continued to play digital games throughout the suturing procedure."
32747237|NCT05546463|Experimental|Control group|During the suture procedure, the children in the control group did not play digital games.
32747238|NCT05699655|Experimental|Tislelizumab combined with apatinib and oxaliplatin plus S1|
32747239|NCT05699655|Active Comparator|oxaliplatin plus S1|
32747240|NCT05546385|Active Comparator|Active device|
32747241|NCT05546385|Placebo Comparator|Sham device|
32747242|NCT05539833|Experimental|TCR-T cells|
32747243|NCT05699577||metastatic breast cancer|
32747244|NCT05699577||non metastatic breast cancer|
32747245|NCT05699499|Experimental|KeryFlex|Patients 18 years and older presenting with retronychia and/or lichens planus of the toenails and/or fingernails to the Weill Cornell Medicine, Department of Dermatology, specialized nail clinic.
32747246|NCT05699421||CITEMB project participants|This is a single cohort, observational prospective multicenter study. The participating centers of the Barcelona Northern Metropolitan Area are primary attention centers - ASSIR Muntanya, ASSIR Esquerra, ASSIR Santa Coloma de Gramenet, ASSIR Badalona-Sant Adrià and hospitals - Vall d'Hebron University Hospital in Barcelona, BCNatal, Hospital Clínic /Hospital Sant Joan de Déu University of Barcelona and Trias i Pujol University Hospital.
32747247|NCT05592327|Experimental|Citric acid abutment|"Antimicrobial-coated abutments (citric acid) will be allocated to the test group.~Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N"
32837314|NCT04453150|Experimental|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
32837315|NCT04453150|Experimental|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
32837316|NCT04453150|Experimental|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
32837317|NCT04453150|Experimental|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
32837318|NCT04453150|Experimental|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
32837319|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
32837320|NCT04414306|Experimental|Experimental Arm 1|Attendees at in-person events (e.g. health fairs) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online or telephone survey follow-up.
32837321|NCT04414306|Experimental|Experimental Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up.
32837322|NCT04414306|Experimental|Experimental Arm 3|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
32837323|NCT04414306|Experimental|Experimental Arm 4|Patients identified by one or more healthcare systems to be due or overdue for colorectal cancer screening will be informed by their healthcare provider or healthcare system (e.g. via the healthcare system's patient portal) that they are due for screening and will be informed how to schedule an colorectal cancer screening related appointment (e.g. discussion with primary care provider about colorectal cancer screening options) along with the option to receive education about colorectal cancer screening. Patients who are interested in receiving education may view the education with or without participating in the research study. Patients who elect to be study participants will participate in consenting, eligibility screening, pre-test, post-test, and possible three- and six-month using a parallel structure to study arms two and three.
32837324|NCT04387474|Experimental|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
32837325|NCT04387474|Other|Control group|traditional rehabilitation training.
32837326|NCT04359394||PP patients|patients with active PP
32837327|NCT04358458|Experimental|Monotherapy Arm|
32837328|NCT04358458|Experimental|Combination Arm|
32837329|NCT04357990|Experimental|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
32837330|NCT04357990|Placebo Comparator|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
32837331|NCT01567085|Experimental|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
32837332|NCT04344184|Active Comparator|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
33103809|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
33319446|NCT05056324|Active Comparator|Control group|
33405516|NCT05715606|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
32837333|NCT04344184|Placebo Comparator|Standard of care|Dextrose 5% Water
32837334|NCT04337944|Experimental|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
32837335|NCT04290754|Experimental|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
32837336|NCT04290754|Active Comparator|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
32837337|NCT01566773|Experimental|PT001 MDI (Dose 1)|
32837338|NCT01566773|Experimental|PT001 MDI (Dose 2)|
32837339|NCT01566773|Experimental|PT001 MDI (Dose 3)|
32837340|NCT01566773|Experimental|PT001 MDI (Dose 4)|
32837341|NCT01566773|Experimental|PT001 MDI (Dose 5)|
32837342|NCT01566773|Experimental|PT001 MDI (Dose 6)|
33103810|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
33319447|NCT04372498|Experimental|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4) and other patients with V282 mutations with demonstrated in-vitro sensitivity to senicapoc. These mutations lead to hyperactivation of the channel and red cell dehydration. Up to 6 patients are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
33319448|NCT00546754|Experimental|1|Drug Arm
32837343|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
33319449|NCT00546754|Active Comparator|2|active comparator
33319450|NCT04768426|Experimental|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day cycles
32837344|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
32837345|NCT04276714|Experimental|Adjustable socket|First week of the study is with adjustable socket
32837346|NCT04276714|Experimental|Classical socket|First week of the study is with classical socket
32837347|NCT04134442|Experimental|Bupivacaine Liposome|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
32837348|NCT04134442|Active Comparator|Standard therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
32837349|NCT04116437|Experimental|Zanubrutinib|"Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib~Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib"
32837350|NCT04127578|Experimental|Low dose|
32837351|NCT04127578|Experimental|High dose|
32837352|NCT04103476|Experimental|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
32837353|NCT04103476|Placebo Comparator|Placebo|Oral matching placebo
32837354|NCT01566149|Active Comparator|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
32837355|NCT01566149|Active Comparator|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
32837356|NCT04068064|Experimental|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
32837357|NCT04068064|Placebo Comparator|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
32837358|NCT04114877|Experimental|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
32837359|NCT04114877|Active Comparator|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
33103811|NCT04981236|Active Comparator|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
33319451|NCT04473508|Experimental|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
33319452|NCT04473508|Placebo Comparator|Control|Local administration of Placebo ( Saline Solution)
33319453|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
33319454|NCT00282347|Experimental|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
33319455|NCT00282347|Placebo Comparator|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
33319456|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
33319457|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
33319458|NCT00405964|Experimental|5-mg Desloratadine tablet|
33319459|NCT00405964|Placebo Comparator|Placebo tablet|
33319460|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
33319461|NCT00264797|Active Comparator|Methylphenidate|
33319462|NCT00264797|Placebo Comparator|Methylphenidate (Placebo)|
33319463|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
33319464|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
33319465|NCT00282113|Active Comparator|ProBioPlus|
33319466|NCT00282113|Active Comparator|Culturelle|
33319467|NCT00282113|Placebo Comparator|Placebo|
33319468|NCT01343680|Active Comparator|10U/l heparin|
33319469|NCT01343680|Experimental|normal saline|
33319470|NCT04502836|Experimental|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
32837360|NCT04341922|Experimental|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
32837361|NCT04341922|No Intervention|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
32837362|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
32837363|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
33319471|NCT04502836|No Intervention|control group|Participants in this group will not receive any psychological intervention prior to the test.
32837364|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
32837365|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
32837366|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
32837367|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
32837368|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
32837369|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
32837370|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
32837371|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
32837372|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
32837373|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
32837374|NCT02975128|Experimental|Patients|
32837375|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
32837376|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
32837377|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
32837378|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
32837379|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
32837380|NCT05743062|Experimental|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds.
32837381|NCT05743062|Other|Control|Participants will serve as their own controls. Participants will not be given any VR intervention at first but they are requested to fill out the survey to collect the baseline data.
32837382|NCT05742204||Lung cancer group|Patients age over 18, with confirmed diagnosis of lung cancer.
32837383|NCT05742204||Control group|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
32837384|NCT05742048||traumatic patient suspect to have long bone fracture between 18 - 65 years old|
32837385|NCT05740956|Experimental|HS-10502|HS-10502 Tablets，PO，QD
32837386|NCT05740644|Experimental|Blood Loss and Saline Infusion|
32837387|NCT05739552|Experimental|Telerehabilitation|
32837388|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
32837389|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
32837390|NCT05553912|Experimental|QBSafe intervention|
32837391|NCT05553912|No Intervention|usual care|
32902891|NCT04492436|Experimental|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
33103812|NCT04981236|Experimental|Periarticular block|Participants receiving periarticular block
33103813|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
33319472|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
33319473|NCT01343758|No Intervention|Normal Saline Bolus|
33319474|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
33319475|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
32837392|NCT03361306|Experimental|KRd-Elotuzumab|"Induction (4 28-day cycles):~Carfilzomib (IV) @ 20 mg/m^2, Day 1 of Cycle 1; @ 56 mg/m^2, Day 8,15 of Cycle 1; @ 56 mg/m^2, Day 1,8,15 of Cycles 2-4~Lenalidomide (Oral) @ 25 mg, once daily at bedtime on Days 1-21 of each cycle (Cycles 1-4)~Dexamethasone @ 28 mg orally OR 8 mg IV, once weekly on Day 1,8,15,22 of Cycles 1-2; @28 mg orally OR 8 mg IV on Day 1 of Cycles 3-4~Elotuzumab (IV) @ 10 mg/kg, once weekly on Day 1,8,15,22 of Cycles 1-2; @ 20 mg/kg on Day 1 of Cycles 3-4~Maintenance (28-day cycles):~Elotuzumab (IV) @ 20 mg/kg, Day 1 of each cycle (Cycles 1-n)~Lenalidomide (Oral) @ 15 mg (or last tolerated dose if <15 mg), once daily at bedtime on Days 1-21 of each cycle (Cycles 1-n)"
32837393|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
32837394|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
32837395|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
32837396|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
32837397|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
32837398|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
32837399|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
33405517|NCT04150692|Experimental|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
32837402|NCT05735496|Experimental|TQB2102 injection|intravenous infuse TQB2102 injection every three weeks, 21 days as a treatment cycle. (1.5mg/kg, 3mg/kg, 4.5mg/kg, 6mg/kg, 7.5mg/kg, 9mg/kg)
32837403|NCT04771169|Experimental|Vestibular Training Group|This Group will receive vestibular Adaptation and Balance exercises
32837404|NCT04771169|Active Comparator|Virtual Reality Group|This Group will receive virtual reality training by using exergaming.
32837405|NCT04410029|Experimental|Intervention|Standard counseling + Healthwise Decision Aid
32837406|NCT04410029|Active Comparator|Control|Standard counseling + a control informational handout.
32837407|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
32837408|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
32837409|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
32837410|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
32837411|NCT03316300|Experimental|NT-501|
32837412|NCT03316300|Sham Comparator|Sham|
32837413|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
32837414|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
32837415|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
32837416|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
32837417|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
32837418|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
32837419|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
32837420|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
33103814|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
32837421|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
32837422|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
32837423|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
32837424|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
32837425|NCT04113317|Experimental|Treatment Group|Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen
32837426|NCT04113317|No Intervention|Control Group|Liver cirrhosis standard treatment only
32837427|NCT04341844|Experimental|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
32837428|NCT04341844|Placebo Comparator|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
32837429|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
32837430|NCT03264664|Experimental|E7386 BID|E7386 will be administered as a single agent orally, initially twice daily (BID) continuously in 28 days treatment cycle. The dose will be escalated in cohorts of participants subject to safety data and the absence of DLTs. Based on the emerging data after completion of Dose Escalation Part, identifying MTD or RP2D, or after a decision is made to evaluate more than one potential RP2D level, a Dose Expansion Part will be initiated. Participants will continue to receive study treatment in extension phase until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study program.
32837431|NCT04111991|Active Comparator|Usual Care|Usual care in the NCH Complex Concussion Clinic
32837432|NCT04111991|Experimental|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
32837433|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
32837434|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
32837435|NCT04111133|Experimental|Carvedilol + Ivabradine|
32837436|NCT04111133|Active Comparator|Carvedilol|
32837437|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
32837438|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
32837439|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
32837440|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
32837441|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
32837442|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
32837443|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
32837444|NCT03228394|Experimental|Ganaxolone|Intravenous
33319476|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
33319477|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
33319478|NCT00281957|Experimental|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
33319479|NCT00281957|Experimental|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
32837445|NCT03228394|Placebo Comparator|Placebo|Intravenous
32837446|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
32837447|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
33319480|NCT01071161|Experimental|Azithromycin|
33319481|NCT01071161|Placebo Comparator|Placebo|
33319482|NCT03975335|Experimental|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
33319483|NCT03975335|Placebo Comparator|Control group|Control group received session on carrier guidance.
33319484|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
32837450|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
32837451|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
32837452|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
32837453|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
32837454|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
32837455|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
32837456|NCT04744948|Placebo Comparator|low caloric diet|low caloric diet 1200cal/day
32837457|NCT04744948|Experimental|treadmill|treadmill aerobic exercise training
32837458|NCT04341688|Experimental|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
32837459|NCT04341688|Experimental|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
32837460|NCT04341688|Active Comparator|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
32837461|NCT04341688|Active Comparator|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
32837462|NCT04341688|Placebo Comparator|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
32837463|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
32837464|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
32837465|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
32837466|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
32837467|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
32837468|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
32837469|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
32837470|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
32837472|NCT03027310||Healthy Volunteers|adult healthy volunteers
32837473|NCT03027310||tremor patients|adult patients with tremor
32837474|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
32837475|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
32837476|NCT04744792||Patients|All the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
32837477|NCT04744792||Spouses|Spouses of the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
32837478|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
32837479|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
32837480|NCT01559129|Placebo Comparator|Placebo|
32837481|NCT01559129|Experimental|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
33103815|NCT00552149|Active Comparator|1|GEMOX
33103816|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
32956792|NCT04666610|Experimental|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
32837482|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
32837483|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
32837484|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
32837485|NCT05730270|Experimental|Stress reduction program 1|Participants will complete stress reduction lessons for two weeks
32837486|NCT05730270|Experimental|Stress reduction program 2|Participants will complete stress reduction lessons for two weeks
32837487|NCT05730270|No Intervention|Waitlist|Participants will have an opportunity to complete one of the two programs of stress reduction lessons after data collection is completed
32837488|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
32837489|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
32837490|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
32837491|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
32837492|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
32837493|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
32837494|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
32837495|NCT05534022|Experimental|Test myopia control lenses (BSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
32837496|NCT03162198||Cirrhosis with HCC|
32837497|NCT03162198||Cirrhosis without HCC|
32837498|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
32837499|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
32837500|NCT05727774|Experimental|Hot water condition|Participants do the water biking training for two weeks, 1 hour a day, in hot water temperature (35°C)
32837501|NCT05727774|Sham Comparator|Neutral water condition|Participants do the water biking training for two weeks, 1 hour a day, in neutral water temperature (25°C)
32837502|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
32837503|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
32837504|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
32837505|NCT05530590|Experimental|Training to Serve (TTS) in person training|Participants are provided access to the pretest one week before the training. On the day of training, when the trainers arrive, participants have a final opportunity to complete the baseline survey before the intervention. Tablets will be available to complete pre- and post- surveys. The training for management takes 3-4 hours, and for staff, one hour. For consistency and feasibility, both trainings are conducted by the same trainers at the same visit. Immediately after the intervention, participants complete the post-intervention seminar evaluation assessing knowledge and attitudes/comfort in serving SGM clients.
32956793|NCT04666610|Experimental|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
32837506|NCT05530590|Experimental|Training to Serve online training (eTTS)|Participants are provided a unique identifier to access the online website. The opening page welcomes them to the study, then directs them to the chunked consent materials and baseline survey. As soon as they have completed this, they receive access to the intervention, which for management is expected to take 1-2 hours and for staff, 30-45 minutes (i.e., the online equivalent of 3-4 and 1 hour, respectively). After completion of the required modules, participants receive access to the optional modules as well as the posttest survey to evaluate the training. Once the post-test is complete, they are thanked for their involvement and informed they will receive an e-mail to access a follow-up survey in six months' time.
32837507|NCT05530590|No Intervention|Waitlist control|Participants complete the baseline survey, then they receive a note thanking them for completing all activities and informing them the intervention will be available in 6 months' time.
32837508|NCT05505942|Experimental|Lifestyle Physical Activity (LPA)|The LPA arm will receive 7 LPA sessions with a trained interventionist to assist in adding LPA to the participant's routine.
32837509|NCT05505942|Active Comparator|Fitbit Only|The Fitbit only arm will receive only brief check in phone calls and only related to assisting with any Fitbit functioning issues.
32837510|NCT05489718|Experimental|treated with different doses of single intravitreal inmection of IBI324|
32837511|NCT05489718|Experimental|treated with different doses of multiple intravitreal inmection of IBI324|
32837512|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
32837513|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
32837514|NCT05329506||Supportive care patient population|Attitudes and Believes About Vaccinations, questionnaires
32837515|NCT05323734|Experimental|Ganaxalone (GNX)|oral suspension, 3 times a day (TID)
32837516|NCT05323734|Placebo Comparator|Placebo matching GNX|oral suspension, TID
32837517|NCT03115008|Experimental|Video-based terminal feedback|
32837518|NCT03115008|No Intervention|Conventional concurrent feedback|
32837519|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
33319485|NCT03974633|Placebo Comparator|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
32837520|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
32837521|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
32837522|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
32837523|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
32837524|NCT03165630|No Intervention|Group 1|Education or Control group.
33319486|NCT03974633|Experimental|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
32837525|NCT03165630|Experimental|Group 2|Transportation incentives
32837526|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
32837527|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
32837528|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
32837529|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
32837530|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
32837531|NCT05703360|Experimental|Waitlist Group|Those randomly assigned to the waitlist group will complete initial inclusion tests and baseline tests at Visit 1. They will receive no intervention during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. Next they will perform the VR audiovisual stimulation during Period 2 (week 7-12) and then repeat baseline tests post-intervention at Visit 3.
32837532|NCT05703360|Experimental|VR Intervention First|Those randomly assigned to the intervention-first group will complete initial inclusion tests and baseline tests at Visit 1. They will perform the VR audiovisual stimulation during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. They will receive no intervention during Period 2 (week 7-12) and then repeat baseline tests at Visit 3.
32837533|NCT04775550|Experimental|Daratumumab, Bortezomib,Lenalidomide,Dexamethasone|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Cycle Length is 28 days.~The names of the study drugs involved in this study are:~Daratumumab~Bortezomib~Lenalidomide~Dexamethasone"
32837534|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
32837535|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
32837536|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
33405518|NCT04150692|Active Comparator|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, [Dara-SC])
32902892|NCT04492436|Placebo Comparator|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
32837537|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
33319487|NCT03974633|Experimental|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
33319488|NCT03974633|Experimental|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
33319489|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
33319490|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
33319491|NCT00281099|Active Comparator|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
33319492|NCT00281099|Active Comparator|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
33405519|NCT05715450|Other|Falciformopexy for Treatment Perforated Peptic Ulcer|Use falciform ligament flap for repair perforated peptic ulcer
33405520|NCT05207514|Experimental|Nanoxel M|AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
32837538|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
32837539|NCT02926066|Experimental|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
32837540|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
32837541|NCT02900482||case group|Patients with a history of congenital hip dislocation
32837542|NCT02900482||control group|Patients with no history of congenital hip dislocation
32837543|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
32837544|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
32837545|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
32837546|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
32837547|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
32837548|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
32837549|NCT02741128|Experimental|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
32837550|NCT02741128|Placebo Comparator|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
32837551|NCT02735746||High fidelity functional lung imaging|High fidelity functional lung imaging (HFFLI) is an improved method of measuring pulmonary function by analyzing 3-Dimensional (3D) motion. Using this technique, we are able to detect and localize pathological changes in the lung with sub-segmental resolution. The approach uses a unique cross-correlation analysis and non-linear optimization to reconstruct lung tissue motion from a small number of standard projections. All participants will undergo standard 4D Computed Tomography (CT), standard Cone Beam CT, research Low-dose Cinefluorography, and additional research Pulmonary Function Tests.
32837552|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
32837553|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
32837554|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
32837555|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
32837556|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
32837557|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
32837558|NCT04104451|Experimental|Dose 1|
32837559|NCT04104451|Experimental|Dose 2|
32837560|NCT04104451|Experimental|Dose 3|
32837561|NCT01541215|Experimental|Lira + Met|
32837562|NCT01541215|Placebo Comparator|Placebo + Met|
32837563|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
32837564|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
32837565|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
32837566|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
32837567|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
32837568|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
32837569|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
32837570|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
32837571|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
32837572|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
32837573|NCT04103281||Sepsis Patients|
32837574|NCT04103281||Control Patients|
32837575|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
32837576|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
32837577|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
32837578|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
32837579|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
32837580|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
32837581|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
32837582|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
32837583|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
32837584|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
32837585|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
32837586|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
32837587|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
32837588|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
32837589|NCT04109807|Experimental|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours.
32837590|NCT04109807|Experimental|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours. For the second exposure session, the same participant will be exposed to FA for 6 hours.
32837591|NCT04756271|Experimental|Health-care workers|Healthy health-care workers at Zagazig University Hospital who opt by their free well to administer 2 doses of SARS-Cov-2 inactivated vaccine at 0 and 21 days. Blood samples will be withdrawn from them to investigate the immune response to the given vaccine
33319493|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
32837592|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
32837593|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
32837594|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
32837595|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
32837596|NCT01556165|Experimental|rasagiline|
32837597|NCT01556165|Placebo Comparator|placebo|
32837598|NCT01537549|Experimental|Juvenon|
33405521|NCT05207514|Active Comparator|Taxotere|AC(Doxorubicin, Cyclophosphamide) followed by Taxotere
32837599|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
33405522|NCT05213676|Active Comparator|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
33405523|NCT05213676|Active Comparator|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
33326939|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
32837600|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
32837601|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
32837602|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
32837603|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
32837604|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
32837605|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
32837606|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
32837607|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
32837608|NCT01582789|Active Comparator|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
32837609|NCT01582789|Active Comparator|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
32837610|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
33326940|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
33326941|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
33326942|NCT01168050|Experimental|Nilotinib|
33326943|NCT01170312|Active Comparator|Autologous conditioned plasma|
33326944|NCT01170312|Placebo Comparator|Normal saline|
33326945|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
33326946|NCT03870594||diabetic|patients suffer from diabetes mellitus
33326947|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
33326948|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
33326949|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
32837611|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
32837612|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
32837613|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
32837614|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
32837615|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
32837616|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
32837617|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
32837618|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
32837619|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
32837620|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
32837621|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
32837622|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
32837623|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
32837624|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
32837625|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
32837626|NCT04114669|Experimental|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
32837627|NCT04114669|Placebo Comparator|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
32837628|NCT01536535|Experimental|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) < 45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
32837629|NCT01536535|Experimental|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
32837630|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
32837631|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
32837632|NCT04767763||Patients with Acute Kidney Injury|Patients with acute kidney injury and indications for initiation of continuous renal replacement therapy (CRRT) were included to this study irrespective of their gender, race and age.
32837633|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
32837634|NCT01563913|Placebo Comparator|Arm 2|Placebo
32837635|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
32837636|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
32837637|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
32837638|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
32837639|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
32837640|NCT04114357|Experimental|Intervention Group|This arm will consume the supplement daily for 4 weeks.
32837641|NCT04114357|No Intervention|Control Group|This arm will not receive the supplement for 4 weeks.
32837642|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
32837643|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
32837644|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
32837645|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
32837646|NCT04410211|Active Comparator|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.~Full vital signs monitoring are done for every participant"
32837647|NCT04410211|Active Comparator|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
32837648|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
32837649|NCT01553591|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
32837650|NCT01553591|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
32837651|NCT01553591|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
32837652|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
32837653|NCT01581931|Experimental|Linagliptin and metformin|single tablets
32837654|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
32837655|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
32837656|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
32837657|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
32837658|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
32837659|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
32837660|NCT01553279|Experimental|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
32837661|NCT01553279|Experimental|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
32837662|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
32837663|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
32837664|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
32837665|NCT01535443|Experimental|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
32837666|NCT03028259||lab results|monitoring of
32837667|NCT04108403|Experimental|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
32837668|NCT04108403|Active Comparator|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
32837669|NCT04108403|Active Comparator|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
32837670|NCT04108403|Active Comparator|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
32837671|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
32837672|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
32837673|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
32837674|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
32837675|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
32837676|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
32837677|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
32837678|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
32837679|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
32837680|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
32837681|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
32837682|NCT04739189|Experimental|Obese adolescent|
32837683|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
32837684|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
32837685|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
32837686|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
32837687|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
32837688|NCT01548287|Placebo Comparator|Placebo|Placebo daily
32837689|NCT04410185|Experimental|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
32837690|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
32837691|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
32837692|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
32837693|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
32837694|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
32837695|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
32837696|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
32837697|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
32837698|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
32837699|NCT01544309|Experimental|Atorvastatin administration group|
32837700|NCT01544309|Experimental|Rosuvastatin administration group|
32837701|NCT01544153|Other|WEB only|Control group receiving no additional intervention
32837702|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
32837703|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
32837704|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
32837705|NCT01543685|Experimental|Indomethacin 40 mg TID|
32837706|NCT01543685|Experimental|Indomethacin 40 mg BID|
32837707|NCT01543685|Experimental|Indomethacin 20 mg TID|
32837708|NCT01543685|Active Comparator|Celecoxib 200 mg|
32837709|NCT01543685|Placebo Comparator|Placebo|
32837710|NCT04104659||MK 6240|
32837711|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
32837712|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
32837713|NCT04767737|Experimental|Topical lavender oil group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
32837714|NCT04767737|Placebo Comparator|Placebo group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
32837715|NCT04767737|No Intervention|Control groups|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
32837716|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32837717|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
32837718|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
32837719|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
32837720|NCT03028181||1|Control group non-exposed to tobacco smoking
32837721|NCT03028181||2|Control group exposed to tobacco smoking
32837722|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
32837723|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
32837724|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
32837725|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
32837726|NCT01539317|Active Comparator|Topical liquid lidocaine|
32837727|NCT01539317|Placebo Comparator|Topical Saline|
32837728|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
32837729|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
32837730|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
32837731|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
32837732|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
32837733|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
32837734|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
32837735|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
32837736|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
32837737|NCT01537133|No Intervention|Healthy Control|
32837738|NCT01537133|No Intervention|Atopic Non-asthmatics|
32837739|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
32837740|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
32837741|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
32837742|NCT01535729||Cohort|
33405524|NCT05213520|Experimental|Alternate Day Intermittent Energy Restriction|Participants assigned to this diet will be asked to alternate between full calorie (no restriction) eating days with eating 40% of their daily caloric requirement on the other day. For example, if their requirement is 2000 calories they would eat 800 calories one day and as much as you want on the other day and repeat every two days. There will be occasional exceptions allowed with maximum of two 40% days in a row (followed by two full days) based on personal schedule with prior approval. They will follow this for 4 weeks.
33405525|NCT05213520|Active Comparator|Reduced Calorie Diet|Participants assigned to this diet will be asked to restrict calorie intake by 500-1000 calories below their daily energy requirement every day. They will follow this for 4 weeks.
33405526|NCT04250337|Experimental|Lebrikizumab + Topical Corticosteroid|"500 mg Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of 250 mg Lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14.~Topical corticosteroid (TCS) will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response."
33405527|NCT04250337|Placebo Comparator|Placebo + Topical Corticosteroid|"Two placebo subcutaneous (SC) injections as a loading dose at Baseline and Week 2 followed by a single injection of placebo every Q2W from Week 4 until Week 14.~TCS will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response"
32837743|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
32837744|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
32837745|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
32837746|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
32837747|NCT02655016|Experimental|Participants receiving Niraparib|
32837748|NCT02655016|Placebo Comparator|Participants receiving Placebo|
32837749|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
32837750|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
32837751|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
32837752|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
32837753|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
32837754|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
32837755|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
32837756|NCT02652676|Experimental|Reversible Pulmonary Artery Banding Procedure|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
32837757|NCT02617966||Affected|Participants with retinal disease
32837758|NCT02617966||Unaffected|Healthy volunteers
32837759|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
32837760|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
32837761|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
32902893|NCT00609128|Experimental|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
33405528|NCT05207436|Experimental|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (B-CBCT) weekly. Prior to each session, the Veteran participant will self-administer intranasal oxytocin. The estimated length of treatment participation is 8 to 15 weeks. All procedures take place in the Veterans home via home-based clinical video teleconferencing (CVT).
32837762|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
32837763|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
32837764|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
32837765|NCT04341610|Active Comparator|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
32837766|NCT04341610|Placebo Comparator|Placebo|Saline
32837767|NCT04767425|Experimental|Experimental|
32837768|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32837769|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32837770|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
32837771|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837772|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837773|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
33326950|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
32837774|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837775|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837776|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837777|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837778|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837779|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
32837780|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
32837781|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
32837782|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
32837784|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
32837785|NCT05274750|Experimental|Participants receiving depemokimab (GSK3511294)|
32837786|NCT05274750|Placebo Comparator|Participants receiving placebo|
32837787|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
32837788|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
32837789|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
32837790|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
32837791|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
32837792|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
32837793|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
32837794|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
32837795|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
32837796|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
32837797|NCT02689284|Experimental|Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
32837798|NCT02689284|Experimental|Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
32837799|NCT05671770||Cohort 1|Patients with chronic kidney disease
32837800|NCT05671770||Cohort 2|Patients with hypertrophic cardiomyopathy
32837801|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
32837802|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
32837803|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
32837804|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
32837805|NCT05252364|Experimental|Part 1 - Dose Escalation, 25mg/d (Cohort 1)|Oral tablet(s), once daily in 28-day cycles
32837806|NCT05252364|Experimental|Part 1 - Dose Escalation, 50mg/d (Cohort 2)|Oral tablet(s), once daily in 28-day cycles
32837807|NCT05252364|Experimental|Part 1 - Dose Escalation 100mg/d (Cohort 3)|Oral tablet(s), once daily in 28-day cycles
32837808|NCT05252364|Experimental|Part 1 - Dose Escalation 200mg/d (Cohort 4)|Oral tablet(s), once daily in 28-day cycles
32837809|NCT05252364|Experimental|Part 1 - Dose Escalation 300mg/d (Cohort 5)|Oral tablet(s), once daily in 28-day cycles
32837810|NCT05252364|Experimental|Part 1 - Dose Escalation 400mg/d (Cohort 6)|Oral tablet(s), once daily in 28-day cycles
32837811|NCT05252364|Experimental|Part 1 - Dose Escalation 500mg/d (Cohort 7)|Oral tablet(s), once daily in 28-day cycles
32837812|NCT05252364|Experimental|Part 1 - Dose Escalation 600mg/d (Cohort 8)|Oral tablet(s), once daily in 28-day cycles
32837813|NCT05252364|Experimental|Part 1 - Dose Escalation 700mg/d (Cohort 9)|Oral tablet(s), once daily in 28-day cycles
32837814|NCT05252364|Experimental|Part 1 - Dose Escalation 800mg/d (Cohort 10)|Oral tablet(s), once daily in 28-day cycles
32837815|NCT05252364|Experimental|Part 2 - Dose Expansion|Oral tablet(s), once daily in 28-day cycles
32837816|NCT04440150|Other|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
32837817|NCT04440150|Other|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
32837818|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
32837819|NCT03164070||Control group|Control group of healthy persons
32837820|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
32837821|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
32837822|NCT03161340|Experimental|Treatment group|Rapamycin group
32837823|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
32837824|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
32837825|NCT05424822|Experimental|Part A: Dose Escalation|Participants will receive JNJ-80948543 by subcutaneous (SC) administration to determine the putative recommended Phase 2 dose (RP2D) and dosing schedule(s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.
32837826|NCT05424822|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-80948543 by SC administration.
32837827|NCT04714320|Experimental|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.
33319494|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
33319495|NCT01070459|Experimental|Follow-up first aerobic exercise group|
33319496|NCT01070459|Placebo Comparator|Follow-up control group|
32837828|NCT04714320|Placebo Comparator|Placebo|IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.
32837829|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
32837830|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
32837831|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
32837832|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
32837833|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
32837834|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
32837835|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
32837836|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
32837837|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
32837838|NCT05676216|Active Comparator|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping
32837839|NCT05676216|Experimental|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping
32837840|NCT05676216|Experimental|Diphenhydramine with Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push
32837841|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
32837842|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
32837843|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
32837844|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
32837845|NCT04700202||Retrospective Cohort|Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
32837846|NCT04693650|Experimental|Treatment group- UHF(+RF) stimulation|Patients implanted with leads and be administered with UHF stimulation
32837847|NCT04693650|No Intervention|Control group|Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)
32837848|NCT04676724|Experimental|GSK3228836 for 24 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 24 weeks, followed by up to 24 weeks of PegIFN.
32837849|NCT04676724|Experimental|GSK3228836 for 12 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 12 weeks, followed by up to 24 weeks of PegIFN.
32837850|NCT03160950|Experimental|LuxaCrown|
32837851|NCT05212272|Experimental|PET-MRI In High-Grade Glioma Patients Undergoing Chemoradiation|PET scan and MRI scan of the brain, blood draw, and 1-hour of memory testing.
32837852|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
32837853|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
32837854|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share On|
32837855|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share Off|
32837856|NCT05180448|Experimental|Coach Share On + Group Share Off + Friend/Family Share On|
32837857|NCT05180448|Experimental|Coach Share On + Group Share Off + Group Share Off|
32837858|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share On|
32837859|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share Off|
32837860|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share On|
32837861|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share Off|
32837862|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
32837863|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
32837864|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
32837865|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
32837866|NCT05675982|Experimental|Minimal residual disease assessment|
32837867|NCT05675904||Yes Textbook Outcome|Patients undergoing scheduled colon cancer surgery with a R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
32837868|NCT05675904||No Textbook outcome|Patients undergoing scheduled colon cancer surgery without any of the following items: R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
33319497|NCT01070459|Experimental|Follow-up second aerobic exercise group|
33319498|NCT00262925|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
32837871|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
32837872|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
32837873|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
32837874|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
32837875|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
32837876|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
32837877|NCT05130528|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
32837878|NCT05130528|Experimental|Sensorimotor Intervention|Infants randomly assigned to this arm will participate in the sensorimotor intervention starting in the hospital and lasting for 6 months. This intervention includes 10 visits with a physical or occupational therapist and parent working together to advance an intervention program and 6 months of parent daily intervention. In addition, this arm will continue with any intervention in the community recommended by their health care team.
32837879|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
32837880|NCT04601064|Experimental|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
32837881|NCT04601064|No Intervention|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
32837882|NCT05421858|Experimental|Fosmanogepix (PF-07842805) IV/oral|"Fosmanogepix will be administered as an Intravenous (IV) infusion given directly into a vein in the arm. There is an option to switch from the IV infusion to the oral form of fosmanogepix which is taken by mouth.~Matching placebos for caspofungin and fluconazole will also be administered (a placebo does not have any medicine in it but looks just like the caspofungin and fluconazole)."
32902894|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
33405529|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
33405530|NCT04011540|No Intervention|Usual Care|Usual care
33319499|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
33319500|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
32837883|NCT05421858|Active Comparator|Caspofungin IV/ Fluconazole oral|"Caspofungin will be administered as an intravenous (IV) infusion given directly into a vein in the arm. There is an option to switch from the IV infusion to oral fluconazole which is taken by mouth.~Matching placebos for fosmanogepix will also be administered (a placebo does not have any medicine in it but looks just like the medicine fosmanogepix being studied)."
32837884|NCT04574232|Other|athletic subjects|athletic subjects who may need intra-articular knee infiltration
32837885|NCT05101902||Overall Study|Participants will undergo antibody and genetic screen, initial pre-screening, eligibility monitoring and eligibility confirmation for potential transition to the treatment trial center once a treatment assignment in the study CAH-301 becomes available. Participation in Study CAH-300 is permitted to continue until treatment assignment is available in the treatment trial or unless, during eligibility monitoring or eligibility
32837886|NCT05087550||Liver Transplantation patients|
32837887|NCT05083338||Observational (questionnaire, pain assessment, biospecimen)|Patients complete questionnaires over 15 minutes and undergo pain assessments prior to surgery and at 3, 6 and 12 months after surgery. Patients also undergo blood sample collection before surgery and optionally at 3, 6 and 12 months after surgery.
32837888|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
32837889|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
32837890|NCT05071716|Experimental|Rifaximin SSD-40mg IR|
32837891|NCT05071716|Placebo Comparator|Placebo|
32837892|NCT05064618|Experimental|Phase I study; 3+3 Design|"Phase I study; single-center, open-label, uncontrolled, dose-finding study~MIKE-1 (AM80, Tamibarotene) After the DLT assessment period, if there is no evidence of disease progression or unacceptable toxicity to the patient according to RECIST v1.1, the investigational drug in each dose group will continue to be administered orally twice daily after breakfast and dinner for up to 24 weeks.The dose of the study drug will not be reduced or increased in the same subject.~6 mg dose group (level 1).~8 mg dose group (level 2).~4 mg group (level 0). To be considered when two or more cases of DLT occur at level 1.~GEM/nab-PTX (Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) will be administered intravenously."
32837893|NCT05064618|Experimental|Phase II study; Single-centre, open-label, single arm, uncontrolled study.|The dose of MIKE-1 will be fixed at the clinically recommended dose determined in Phase I. MIKE-1 will be administered orally twice daily after breakfast and dinner, and treatment will be continued until the occurrence of intolerable toxicity or disease progression, up to a maximum of six courses, to confirm efficacy and safety (tolerability).
32837894|NCT05063916|Experimental|AK104|cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).
32837895|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
32837896|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
32837897|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
32837898|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
32837899|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
32837900|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
32837901|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
32837902|NCT04557384|Experimental|Ramucirumab|Participants received starting dose of 700 milligram (mg) ramucirumab loading dose (LD) subcutaneously (SC) followed, a week later, by 350 mg ramucirumab maintenance dose (MD) administered SC once a week.
32837903|NCT04548648|Other|Open-label, single-arm|A multicenter open-label, single-arm, phase 2 study designed to investigate the antitumor effects of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL), and relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Subjects will receive acalabrutinib at the dose of 100 mg every 12 hours. Prophylactic administration of broad spectrum triazole antifungal agent isavuconazole will be performed while subjects receive acalabrutinib.
32837904|NCT04546542||pSS patients under Hydroxychloroquine (HCQ) 2016-AAO dose|Patients under Hydroxychloroquine (HCQ) 2016-American Academy of ophtalmology (AAO) dose will have HCQ blood levels, disease activity and adherence evaltuated at study entry and before 3 and 6-months.
32902895|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
33319501|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
33405531|NCT04687059|Experimental|PQ Grass Standard Dosing Regimen|Cumulative dose 27600 SU
32837905|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
32837906|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
32837907|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
32837908|NCT04443348|Experimental|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
32837909|NCT04443348|Experimental|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
32837910|NCT04443348|Experimental|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
32837911|NCT05063448|Experimental|DadSpace Intervention|Participants will take part in a 12-hour educational discussion-based mentoring program intervention over 8 weeks. The intervention will be facilitated by a trained father facilitator and will include education and support on topics relevant to perinatal fathers. Topics include father identity, stress management, infant development, co-parenting, masculinity and caregiving, healthy communication, and work-life balance. Participants will additionally have access to a brief educational podcast series on related topics. Participants will also be invited to monthly follow-up daddy/baby drop-in groups.
32837912|NCT05056818||Observational (medical records)|Patients' medical records and past imaging examinations are reviewed.
32837913|NCT05054400|Other|F18 Fluciclovine|"radioactive imaging agent help researchers better see how the disease is responding to laser interstitial thermal therapy (LITT)"
32837914|NCT05039736|Experimental|cabozantinib|cabozantinib by mouth every day for 6 weeks
32837915|NCT05039736|Experimental|nivolumab|nivolumab by vein every 4 weeks for up to 2 years
32837916|NCT05038254|Active Comparator|Arm I (standard of care)|Patients receive standard of care consisting of oncology care provided via telemedicine.
32837917|NCT05038254|Experimental|Arm II (standard of care, remote monitoring)|Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
32837918|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
32837919|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
32837920|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
32837921|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
32837922|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
32837923|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
32837924|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
32837925|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
32837926|NCT05373654|Experimental|Patients that have at least one year of follow-up since the procedure.|
32837927|NCT05231850|Experimental|Tislelizumab|Tislelizumab
32837928|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
32837929|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
33405532|NCT04687059|Experimental|PQ Grass Alternative Dosing Regimen|Cumulative dose 27600 SU
33405533|NCT04687059|Placebo Comparator|Placebo Option 1|Suspension for injection
33405534|NCT04687059|Placebo Comparator|Placebo option 2|Solution for injection
32837930|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
33319502|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
33319503|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
33319504|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
33405535|NCT04682145||Haemophilia A patients|All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.
32956794|NCT04665570||Treatment|The decision to prescribe Acarbose/Metformin fixed dose combination (FDC) will be solely at the discretion of the Investigator and in accordance with his/her experience. Patients can only be enrolled in the study if the decision to treat with Acarbose/Metformin fixed dose combination has been made by the treating physician in advance and independent of study inclusion.
32956795|NCT04661384|Experimental|Treatment (IL13Ralpha2-CAR T cells)|Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
32956796|NCT04661033|Experimental|Isatuximab Part A/Cohort 1|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
32956797|NCT04661033|Experimental|Isatuximab Part A/Cohort 2|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
32956798|NCT04661033|Experimental|Isatuximab Part A/Cohort 3 (optional)|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
32956799|NCT04661033|Experimental|Isatuximab Part B|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
32956800|NCT04656301|Experimental|Psilocybin|A single dose of Psilocybin 25mg p.o.
32956801|NCT04656184|Experimental|KINERET|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature <38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
32956802|NCT04656184|Active Comparator|Intravenous Immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
32956803|NCT04651153|Experimental|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
32956804|NCT04651153|Placebo Comparator|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
32956805|NCT04649905||Surgical Treatment|Patient's in this cohort will undergo surgical treatment for OCD of the knee.
32956806|NCT04649905||Nonoperative Treatment|Patient's in this cohort will undergo nonoperative treatment for OCD of the knee.
32956807|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
32956808|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
32956809|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
32956810|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
32956811|NCT04644068|Experimental|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
32956812|NCT04644068|Experimental|Module 4: AZD5305 + Trastuzumab Deruxtecan|AZD5305 + T- Dxd
32956813|NCT04644068|Experimental|Module 5 AZD5305 + Datopotamab Deruxtecan|AZD5305 + Dato-DXd
32956814|NCT04642898|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
32956815|NCT04642898|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
32956816|NCT04642898|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
32956817|NCT04642898|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
32956818|NCT04642898|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
32956819|NCT04642898|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
32956820|NCT04631016|Experimental|MEDI3506|Approximately 72 participants will be randomized to receive MEDI3506
32956821|NCT04631016|Placebo Comparator|Placebo|Approximately 72 participants will be randomized to receive placebo
32956822|NCT04616560|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 35 cycles in the absence of disease progression or unacceptable toxicity.
32956823|NCT04598711|Experimental|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
33033386|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
33405536|NCT05760807|Experimental|Intranasal oxytocin|Participants will receive oxytocin by intranasal spray under clinician supervision (1 insufflation equating to an active dose of 24 IU) twice daily (i.e., 48 IU per day), delivered over 7 days of a residential inpatient withdrawal admission.
33405537|NCT05760729||Inflammatory bowel disease patients|It is mandatory to have a certain diagnosis of IBD before the inclusion.
33319505|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
33319506|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
33319507|NCT00262847|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
33319508|NCT00262847|Experimental|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
33319509|NCT00262847|Experimental|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
33319510|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
33319511|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
33319512|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
33319513|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
33319514|NCT05329532|Experimental|Patients with TNBC, advanced/unresectable SCCHN, high grade serous ovarian carcinoma, or RCC|
33319515|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; monotherapy)|
33319516|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; combination)|
33319517|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
33319518|NCT01303562|Active Comparator|Test muffin made with whole oats|
33319519|NCT01303562|Active Comparator|Test muffin made with whole barley|
33319520|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
33319521|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
33319522|NCT04270760|Active Comparator|Arm 1 Olpasiran Dose 1|
33319523|NCT04270760|Active Comparator|Arm 2 Olpasiran Dose 2|
33319524|NCT04270760|Active Comparator|Arm 3 Olpasiran Dose 3|
33319525|NCT04270760|Active Comparator|Arm 4 Olpasiran Dose 4|
33319526|NCT04270760|Placebo Comparator|Arm 5 Placebo Dose 5|
33319527|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
33319528|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
33319529|NCT03817268|Experimental|Capecitabine monotherapy group|
33319530|NCT03817268|No Intervention|Control group|
33319531|NCT00280397|Experimental|1|
33319532|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
33319533|NCT03817112|Active Comparator|Propofol|Propofol infusion
33319534|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
33319535|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
33319536|NCT05302934||Pheno4U|The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies.
33319537|NCT00262301|Experimental|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
33319538|NCT00262301|Placebo Comparator|Saline|Saline solution
33319539|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
33319540|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
33319541|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
33319542|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
33319543|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
33319544|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
33319545|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
33319546|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
33319547|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
33319548|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
33326951|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
33319549|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
33319550|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
33319551|NCT00279305|Experimental|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
33319552|NCT00279305|Placebo Comparator|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
33319553|NCT04224272|Experimental|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
33319554|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
33319555|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
33326952|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
32837941|NCT05007678|No Intervention|Standard of Care|The usual care will be offered as per current advice on management of hospitalised patients.
32837942|NCT05007678|Active Comparator|leflunomide|Patients admitted to the hospital COVID-19 positive and within 2 weeks of symptoms' onset will be treated with loading dose of 100 mg leflunomide for 3 days, followed by 20 mg once daily. Participants with ALT/AST levels 2 times above upper limits of normal reference range will receive 10mg instead of 20mg.
32837943|NCT03114384|Experimental|Healthy volunteers|
32837944|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
32837945|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
32837946|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
32837947|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
32837948|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
32837949|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
32837950|NCT04177290|Experimental|sintilimab (M1b) 200mg|
32837951|NCT04177290|Active Comparator|sintilimab (approved) 200mg|
32837952|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
32837953|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
32837954|NCT03160482||Papillary carcinoma, classical variant|
32837955|NCT03160482||Follicular carcinoma|
32837956|NCT03160482||Colloid nodule|
32837957|NCT03160482||Hyperplastic nodule|
32837958|NCT03160482||Adenomatoid nodule|
32837959|NCT03160482||Follicular adenoma|
32837960|NCT03160482||Papillary carcinoma, follicular variant|
32837961|NCT03160482||Medullary carcinoma|
32837962|NCT03160482||Lymphocytic thyroiditis|
32837963|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
32837964|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
33326953|NCT01170468|Placebo Comparator|Placebo|Placebo daily
32902896|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
33326954|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
33326955|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
32837965|NCT05676996|Experimental|attachment-based support group|"In addition to the routine follow-ups and trainings that the pregnant women in the intervention group can receive from the hospital, they will be included in the Attachment Based Support Program. Within the scope of the 1st stage of this support; A mobile application. There are 12 videos on connecting in the mobile application. These videos were shot by the researcher in a professional studio. 22nd-26th of pregnancy. The participants included in the study during the weeks of participation installed this mobile application on their phones during participation. It was requested to complete watching the videos by 36 weeks. In the second phase of Attachment-Based Support, breastfeeding and skin-to-skin contact support are provided to mothers on postpartum day 0."
32837966|NCT05676996|No Intervention|routine follow-up control group|The control group pregnants were left to the routine follow-up of the hospitals during their pregnancy and postpartum period. In this follow-up; When pregnant women apply to the outpatient clinic services of the hospital, appointments are made for their monthly routine follow-up. Information and practices that support mother-infant attachment in attachment-based support modules are not included in these trainings.
33405538|NCT05760729||Healthy controls|Patients who have never had the diagnosis of inflammatory bowel disease
32837967|NCT05676918|Experimental|Positive Intervention|Ten weekly sessions. Session duration: 90 minutes.
32837968|NCT05676918|Active Comparator|Cognitive Behavior Therapy|Ten weekly sessions. Session duration: 90 minutes.
32837969|NCT04756518||COVID 19 group|The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.
32837970|NCT04756518||CONTROL group|A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.
32837971|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
32837972|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
32837973|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
32837974|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
32837975|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
32837976|NCT05676840|Other|conventional niti arch wire group|all participants in this group will be placed conventional 014 niti lower archwire.
32837977|NCT05676840|Other|super elastic niti archwire group|all participants will be given super elastic 014 lower NiTi archwire.
32837978|NCT05676840|Other|thermal niti archwire group|all participants will be given thermal lower 014 niti archwire.
32837979|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
32837980|NCT03320070|Experimental|Acthar Gel in DBT Then Acthar Gel in OLE|Participants received Acthar Gel as a 1 milliliter (mL) injection under the skin, twice weekly, for 24 weeks in the double-blind treatment (DBT) phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional open-label extension (OLE) phase.
32837981|NCT03320070|Experimental|Placebo in DBT Then Acthar Gel in OLE|Participants received Acthar Gel matching placebo as a 1 mL injection under the skin, twice weekly, for 24 weeks in the DBT phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional OLE phase.
32837982|NCT05675358|Experimental|virtual reality|In the study, Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used, and the Epic Roller Coasters train game, an application that would attract the attention of children, was determined by the researchers. The virtual reality application was started 2 minutes before the procedure and continued until the procedure was completed.
32837983|NCT05675358|No Intervention|control|The child in the control group did not receive any additional intervention.
32837984|NCT02667912|Experimental|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
32837985|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
32837986|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
32837987|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
32837988|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
32837989|NCT04977336|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
32837990|NCT04977336|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
32837991|NCT04977336|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
32837992|NCT04915872||Participant|Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy
32837993|NCT05675124|Experimental|Needlescopic laparoscopic adrenalectomy|Needlescopic laparoscopic surgery refers to the use of instruments with a diameter of less than or equal to 3 mm for laparoscopic surgery.
32837994|NCT05675124|Active Comparator|conventional laparoscopic adrenalectomy|a 12 mm camera port ,and two additional (left anterior axillary line and left midclavicular line; for left tumors) or three additional(right anterior axillary line, right midclavicular line, and subxiphoid; for right tumors) 5 mm working ports along the ipsilateral subcostal were created regionally.
33319556|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
32837995|NCT05674968|Experimental|Managing Challenging Behaviors in ADHD|This is a 7-session behavioral parent training delivered to children ages 3-7 referred to the study after an initial ADHD diagnosis or when challenging behaviors are identified by their medical provider.
32837996|NCT05674968|No Intervention|Wait List|Families assigned to the wait list will complete measures at baseline, 14 weeks, and 24 weeks. After 24 weeks they will be offered the experimental treatment.
32837997|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
32837998|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
32837999|NCT05674890|Experimental|Single arm|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized.
32838000|NCT04888338||Observational (data collection)|Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.
32838001|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
32838002|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
32838003|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
32838004|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
32838005|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
32838006|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
32838007|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
32838008|NCT04832412|Experimental|BrainPhyt Low dose|2 capsules of 275mg BrainPhyt for 24 weeks
32838009|NCT04832412|Placebo Comparator|Placebo|2 capsules of 275mg Maltodextrin
32838010|NCT04083378|Active Comparator|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
32838011|NCT04083378|Experimental|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
32838012|NCT04036188|Experimental|Triamcinolone Cream + Vitamin D3|This arm will continue to take Vitamin D3 at Week 16 to Week 28.
32838013|NCT04036188|Placebo Comparator|Triamcinolone Cream + Placebo|Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
32838014|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
32902897|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
33319557|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
33319558|NCT01325909|Active Comparator|Exercise|
33319559|NCT01325909|No Intervention|No Exercise|
33319560|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
33319561|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
33319562|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
33319563|NCT05030402|Experimental|Maitland group|31 patients receives tens, SW, Maitland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
32838015|NCT04797780|Experimental|Tamibarotene + Azacitidine|"Tamibarotene: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
32956824|NCT04598711|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
33405539|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
32838016|NCT04797780|Placebo Comparator|Tamibarotene Matched Placebo + Azacitidine|"Placebo: Tamibarotene-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
32838017|NCT04794816||Observational (questionnaire administration)|Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.
32838018|NCT05676450|Other|cell-free DNA (cfDNA) samples|"cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.~Blood will be drawn 3 times (by vein)"
32838019|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
32838020|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
32838021|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
32838022|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
32838023|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
32838024|NCT04761120||Group 1: Primary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 1 will enroll 200 subjects undergoing surgical repair of primary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In primary mitral regurgitation, backflow through the closed valve is caused by disease intrinsic to the mitral valve tissue itself.
32838025|NCT04761120||Group 2: Secondary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 2 will enroll 200 subjects undergoing surgical repair of secondary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In secondary mitral regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
32838026|NCT04761120||Group 3: Primary tricuspid disease repair surgery with a full Tailor Ring implant|Group 3 will enroll up to 50 subjects undergoing surgical repair of primary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
32838027|NCT04761120||Group 4: Secondary tricuspid disease repair surgery with a full Tailor Ring implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In secondary tricuspid regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
32838028|NCT04761120||Group 5: Primary tricuspid disease repair surgery with a partial Tailor Ring or Tailor Band implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes posterior annuloplasty with either a partial Abbott SJM Tailor Ring with cut zone removed or an Abbott SJM Tailor Band. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
32838029|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
32838030|NCT04439838|Experimental|Treatment group|
32838031|NCT04439838|Placebo Comparator|Placebo group|
32838032|NCT02694822|Experimental|AGEN1884|anti-CTLA-4 antibody
32838033|NCT04479774|Experimental|Experimental Group (Group A)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
32838034|NCT04479774|Other|Control group: (Group B)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
32956825|NCT04597047|Other|All Patients:|Capillary and Venous Blood Collections
33405540|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
32838035|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
32838036|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
32838037|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
32838038|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
32838039|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
32838040|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
32838041|NCT02388360|Other|topical prostaglandin analogs|
32838042|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
32838043|NCT03921216||Diabetic nephropathy, on hemodialysis|
32838044|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
32838045|NCT03921216||Chronic kidney disease, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
32838046|NCT03921216||Diabetic nephropathy, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
32838047|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
32838048|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
33405541|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
32838049|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
32838050|NCT03896568|Experimental|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
32838051|NCT03896568|Experimental|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
32838052|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
32838053|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
32838054|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
32838055|NCT02168868||Control Group of Children|2-12 years old age & sex-matched controls - typically developing (TD) children
32838056|NCT02168868||Children-Autism Spectrum Disorder|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00)
32838057|NCT02168868||Children-Autism Spectrum Disorder+SCT|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00) due to undergo stem cell transplantation therapy
32838058|NCT02168868||High-risk infants|Infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD
32838059|NCT02168868||Mothers of high-risk infants|Mothers of recruited infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD
32838060|NCT02135874|Experimental|Treatment (combination chemotherapy)|See Detailed Description.
32838061|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
32838062|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.~Intervention: Implantable spinal cord stimulation."
32838063|NCT02131584|Experimental|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
32838064|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
32838065|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
32838066|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
32838067|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
32838068|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
32838069|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
32838070|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
32838071|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
32838072|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
32838073|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
32838074|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
32838075|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
32838076|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
32838077|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
32838078|NCT02985671|Experimental|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium & Placebo of Voltaren~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
32838079|NCT02985671|Active Comparator|Voltaren® + Experimental Drug Placebo|"Voltaren & Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
32838080|NCT04767269|Experimental|cuminum cyminum mouthwash|cuminum cyminum mouthwash in chronic gingivitis patients
32838081|NCT04767269|Active Comparator|herbal mouthwash|herbal mouthwash in chronic gingivitis patients
32838082|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
32838083|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
32838084|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
32838085|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
32838086|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32838087|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32838088|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32838089|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32838090|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
32838091|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
32838092|NCT04101851|Experimental|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0/ypTis) at the final pathology of lumpectomy.
32838093|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
32838094|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
32838095|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
32838096|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
32838097|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
32838098|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
32838099|NCT01527383|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
32838100|NCT01527383|Placebo Comparator|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
32838101|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
32838102|NCT01526057|Experimental|A - PF-05280586|
32838103|NCT01526057|Active Comparator|B - Rituximab EU|
32838104|NCT01526057|Active Comparator|C- Rituximab-US|
32838105|NCT00121719|Experimental|1|
32838106|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
32838107|NCT01525901|Placebo Comparator|Normal saline|Injection
32838108|NCT00123123|Placebo Comparator|Placebo (Vehicle Control)|Delivered Twice a day
32838109|NCT00123123|Experimental|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
32838110|NCT00123123|Experimental|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
32838111|NCT04748393||Study cohort|Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.
32838112|NCT00262509|Experimental|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
32838113|NCT00262509|No Intervention|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
32838114|NCT00242385|Experimental|ARALAST Fr. IV-1|60 mg/kg
32838115|NCT00242385|Active Comparator|ARALAST|60mg/kg
32838116|NCT00242619|Experimental|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
32838117|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
32838118|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
32838119|NCT00264381|Active Comparator|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
32838120|NCT00243243|Experimental|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
32838121|NCT00243243|Placebo Comparator|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
32838122|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
32838123|NCT00265473|Experimental|Allogeneic Islets of Langerhans|Islet infusion
32838124|NCT00246441|Experimental|Paroxetine|Active medication containing the drug Paroxetine
32838125|NCT00246441|Placebo Comparator|Placebo|A Placebo medication that appears just like the active medication but does not contain placebo
32838126|NCT00246519|Experimental|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
32838127|NCT00246519|Experimental|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP < 120/70, then add atenolol 50 mg if BP < 120/70, then atenolol 100 mg if BP < 120/70.
32838128|NCT00247377|Active Comparator|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
32838129|NCT00247377|Active Comparator|LAP-BAND|Subject undergoes LAP-BAND procedure
32838130|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
32838131|NCT00125619|Active Comparator|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
32838132|NCT00125619|Experimental|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
32838133|NCT00248547|Active Comparator|Aprepitant|
32838134|NCT00248547|Placebo Comparator|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
32838135|NCT01525589|Experimental|PM01183|
32838136|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
32838137|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
32838138|NCT01524887|Placebo Comparator|Placebo control|
32838139|NCT00266799|Experimental|Pegylated liposomal doxorubicin|
32838140|NCT00266799|Active Comparator|Capecitabine|
32838141|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
32838142|NCT00248781|Experimental|Arm 1|exercise
32838143|NCT00248781|Other|Arm 2|health education
32838144|NCT04101539|Active Comparator|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation [PVI]).
32838145|NCT04101539|Experimental|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
32838146|NCT04101071|Experimental|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
32838147|NCT04101071|Active Comparator|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
32838148|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
32838149|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
32838150|NCT00250497|Experimental|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
32838151|NCT00250497|No Intervention|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
32838152|NCT00125931|Experimental|Pentazocine/Talwin|Talwin NX
32838153|NCT00267111|Experimental|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
32838154|NCT00267111|Placebo Comparator|Placebo Group|
32902898|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
32902899|NCT00669578|Experimental|CC-4047|
33319564|NCT05030402|Active Comparator|Control group|32 receives tens, SW, conventional physiotherapy and exercises as treatment. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
32838155|NCT04183179|Experimental|Program|"The 14-week healthy eating program activities including four components:~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
32838156|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
32838157|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
32838158|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
32838159|NCT00128193|Experimental|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
32838160|NCT00128193|Experimental|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
32838161|NCT00128193|Experimental|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
32838162|NCT00128193|Experimental|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
32838163|NCT00128193|Experimental|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
32838164|NCT00128193|Experimental|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
32838165|NCT05240781|Active Comparator|Zotarolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS) patients undergoing elective PCI.
32838166|NCT05240781|Experimental|Sirolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
32838167|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
32838168|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
32838169|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
32838170|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
32838171|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
32838172|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
32838173|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
32838174|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
32838175|NCT00130923|Experimental|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
32838176|NCT00130923|Active Comparator|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
32838177|NCT04100213|Experimental|TSST|
32838178|NCT04117581|Active Comparator|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
32838179|NCT04117581|Placebo Comparator|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
32838180|NCT02103153|Experimental|Picosure Laser System|
32838181|NCT01899573|Experimental|Treatment|
32838182|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
32838183|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
32838184|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
33319565|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
33405542|NCT03998319|Experimental|Tenecteplase (1/3 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
32838185|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
32838186|NCT00272337|Active Comparator|1|81 mg Aspirin
32838187|NCT00272337|Active Comparator|2|162 mg Aspirin
32838188|NCT00272337|Active Comparator|3|325 mg Aspirin
32838189|NCT00272337|Active Comparator|4|650 mg Aspirin
32838190|NCT00272337|Active Comparator|5|1300 mg Aspirin
32838191|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
32838192|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
32902900|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
32956826|NCT04587518|Experimental|Immediate Treatment|Participants in this group will receive the intervention immediately.
32838193|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
32838194|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
32838195|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
32838196|NCT04410055|Active Comparator|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
32838197|NCT04410055|Active Comparator|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
32838198|NCT04410055|Active Comparator|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
32838199|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
32838200|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of Docosahexaenoic acid (DHA) and L-alanyl-glutamine (8g/d).
32838201|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
32838202|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
33319566|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
33405543|NCT03998319|Placebo Comparator|Sterile Water for injection (WFI)|Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.
33319567|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
32838203|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
32838204|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
32838205|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
32838206|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
32838207|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
32838208|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
32838209|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
32838210|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
32838211|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
32838212|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
32838213|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
33319568|NCT00278993|Active Comparator|1|With stratification
32838214|NCT01578187|Experimental|Hair2Go device|
32838215|NCT01561963|Experimental|Apremilast and Rifampin|"Participants received the following 3 treatment regimens:~A single oral dose of 30 mg apremilast on Day 1 (Period 1);~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2);~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3)."
32838216|NCT04852003|Experimental|SHR0410 Injection|
32838217|NCT04852003|Placebo Comparator|Placebo for SHR0410 Injection|
32838218|NCT04852003|Active Comparator|Morphine|
33319569|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
32838219|NCT01576783|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
32838220|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
32838221|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
32838222|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
32956827|NCT04587518|Experimental|Waitlist/Delayed Treatment|Participants in this group will receive the intervention after an 18-week wait.
32956828|NCT04578756|Experimental|Cariprazine Dose 1|Participants with Schizophrenia 13 to 17 years will receive cariprazine.
32838223|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
32838224|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
32838225|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
32838226|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
32838227|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
32838228|NCT01534273|Experimental|35 mg LY2886721|QD oral dosing for 14 consecutive days
32838229|NCT01534273|Experimental|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
32838230|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
32838231|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
32838232|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
32838233|NCT04479384|Experimental|Intervention group|Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
32838234|NCT04479384|No Intervention|Control group|Supine position 10 minutes on the bench.
32838235|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
32838236|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
33405544|NCT03998319|Experimental|Tenecteplase (1/6 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/6 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
32838237|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
32838238|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
32838239|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
32838240|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
32838241|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
32838242|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
32838243|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
32838244|NCT04743102|Experimental|Biopsy cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.
32838245|NCT04743102|Active Comparator|Conventional cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.
32838246|NCT04439604||patient undergoing surgery under general anaesthesia|
33319570|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
33319571|NCT03974867|Experimental|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
33319572|NCT03974867|Experimental|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
32838247|NCT04479930|Experimental|HappyAir Group|The HappyAir app comprises two main parts: an educational program providing patients useful information and advice about their illness and data collection related to physical activity and disease.
32838248|NCT04479930|No Intervention|Control group|The control group only underwent the scheduled check-ups
32838249|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
32838250|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
32838251|NCT02387736|Experimental|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
32838252|NCT02387736|Active Comparator|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
32838253|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
32838254|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
32838255|NCT01664910|Experimental|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
32838256|NCT05581290|Experimental|Multi-Modal Sensor Patch Measurements|Subjects referred to Mayo Clinic in Arizona Cardiology Clinic who have an underlying cardiac structural condition will have a 15-minute data collection via the prototype device, AI-Flex, and standard of care electrocardiogram (ECG), temperature, and photoplethysmogram (PPG) measurements.
32838257|NCT05298540|Experimental|Home-based computerised cognitive training|Participants will be asked to complete 40 sessions (20 minutes / day, 5 days / week) of cognitive training over the 8-week intervention period (this will be assessed using automated data reports of user activity generated in collaboration with BrainHQ). Training will commence one week postoperatively to avoid the effects of sedatives, postoperative pain, sleep deprivation, and patient fatigue, and to improve adherence
32838258|NCT00133575|Experimental|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838259|NCT00133575|Experimental|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838260|NCT00133575|Experimental|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838261|NCT00133575|Experimental|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838262|NCT00133575|Experimental|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838263|NCT00133575|Experimental|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
32838264|NCT00133809|Experimental|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
32956829|NCT04578756|Experimental|Cariprazine Dose 2|Participants with Bipolar I Disorder, 10 to 12 years (weighing <=40 kg) will receive cariprazine.
33319573|NCT03816410|Experimental|LAA amputation group|
33319574|NCT03816410|No Intervention|No LAA amputation group|
33319575|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
33319576|NCT03799406|Placebo Comparator|Placebo group|placebo
33319577|NCT05270876|Experimental|Investigational|Recipients of cochlear implant or suitable for implantation
33319578|NCT05270876|Active Comparator|Standard of Care|Recipients of cochlear implant or suitable for implantation
33319579|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
33319580|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
33319581|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
33405545|NCT03983733|Experimental|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
32838265|NCT00134043|Experimental|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
32838266|NCT05177367|Experimental|Sequential Variety, Small Portion|3 courses each consisting of a different food served in a small portion.
32838267|NCT05177367|Experimental|Sequential Variety, Large Portion|3 courses each consisting of a different food served in a large portion.
32838268|NCT05177367|Experimental|Simultaneous Variety, Small Portion|3 courses each consisting of 3 foods served in small portions.
32838269|NCT05177367|Experimental|Simultaneous Variety, Large Portion|3 courses each consisting of 3 foods served in large portions.
32838270|NCT05177367|Experimental|Single Food, Small Portion|3 courses each consisting of the same food served in a small portion.
32838271|NCT05177367|Experimental|Single Food, Large Portion|3 courses each consisting of the same food served in a large portion.
32838272|NCT05176977|Experimental|Peer Specialist - Whole Health Coaching (PS-WHC)|Participants will meet with a Peer Specialist for 18 sessions over 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist, and 2) a structured Whole Health Coaching curriculum.
32838273|NCT05176977|No Intervention|Enhanced Usual Care (EUC)|Usual PACT care plus Hot Spotter Analytics (consists of access to field-based dashboard that allows PACTS to identify homeless Veterans on their panels who were super-utilizers, and the hot spotter manual).
32838274|NCT04389255||Healthy people|65 people will be included.
32838275|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
32838276|NCT04751721|Experimental|CoronoVac Vaccine Group|
32838277|NCT03715998|Experimental|Group 1: firibastat 100 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
32838278|NCT03715998|Experimental|Group 2: firibastat 500 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
32838279|NCT03715998|Active Comparator|Group 3: ramipril 5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
32838280|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
32838281|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
32838282|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
32838283|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
32838284|NCT05569746|Experimental|INM004|2 doses of 4 mg/kg separated by 24 h
32838285|NCT04751643|Experimental|TPE + usual treatments in intensive care unit according to the current state of knowledge.|"TPE + usual treatments in intensive care unit according to the current state of knowledge : 3 TPE sessions i.e. one per day during 3 consecutive days on day 1-3 (day 0 = inclusion Visit date)) + usual treatments in intensive care unit.~Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)"
32838286|NCT04751643|Active Comparator|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
32838287|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
32838288|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
32838289|NCT04717323|Experimental|Patients|Gait with and without pelvic assistance
32838290|NCT04717323|Experimental|Controls|Gait with no pelvic assistance
32838291|NCT03657108|Experimental|group 1 of 60 Gy dose|The first 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
32838292|NCT03657108|Experimental|group 2 of 60 Gy dose|The second 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
32838293|NCT03657108|Experimental|group 1 of 75 Gy dose|The third 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
32838294|NCT03657108|Experimental|group 2 of 75 Gy dose|The fourth 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
32838295|NCT01629498|Experimental|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
32838296|NCT01629498|Experimental|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
32838297|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
32838298|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
32838299|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
32838300|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
32838301|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
32838302|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
32838303|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
32838304|NCT00278655|Experimental|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
32838305|NCT03113604||Patients with untreated CHC not sorafenib|
32838306|NCT03113604||Patients with non-sorafenib CHC|
32838307|NCT03113604||Patients with CHCs responding to sorafenib|
32838308|NCT04388943||1|
32838309|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~Platelet count: (>350 x 109/L) (+1 point)~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~Leukocyte count (> 11 x 109/L)(+1 point).~body mass index (≥ 35 Kg/m2) (+1 point)."
32838310|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
32838311|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
32838312|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
32838313|NCT04641507|Active Comparator|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
32838314|NCT04641507|Active Comparator|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
32838315|NCT01591356|Experimental|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32838316|NCT04518969|No Intervention|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
32838317|NCT04518969|Experimental|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
32838318|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
32838319|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
32838320|NCT04489173|Experimental|Treatment|Treatment with TAS102
32838321|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
32838322|NCT00138645|Experimental|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
32838323|NCT00138645|Active Comparator|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
32838324|NCT00512070|Experimental|IIA (0.3mg day melatonin)|0.3mg day melatonin
32956830|NCT04578756|Experimental|Cariprazine Dose 3|Participants with Bipolar I Disorder, 10 to 12 years (weighing >40 kg) will receive cariprazine.
33405546|NCT05759793|Experimental|CAR-GPRC5D cells|"The tolerability and safety of CARGPRC5D cells will be assessed according to the 3+3 doseescalation design.There will be three dose levels, 0.5×10^6, 1.0×10^6, 2.0x10^6cells/kg. For each level, 3-6 subjects will be enrolled."
32838325|NCT00512070|Experimental|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
33405547|NCT03953079|Experimental|GB-102 1 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 1 mg in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
32838326|NCT00140205|Experimental|Fed state or fasting state|"1-day fed studies with administration of r-metHuLeptin at three different doses (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg). All subjects participated in 3 studies in the fed condition (Part A) and 3 separate 72-hour fasting studies.~Intervention administered was-r-metreleptin in 3 different doses"
32838327|NCT05668026|Experimental|Immediate start|Study participants will receive venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
32838328|NCT05668026|Active Comparator|14-days lead-in|Study participants will receive placebo for 28 days, and then start venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
32838329|NCT05661552|Experimental|Evolocumab treatment group|The experimental group will receive Rosuvastatin 5 mg, Ezetimibe 10 mg, and evolocumab by subcutaneous injection. Evolocuumab will be administered at a dose of 140 mg once during the study period.
32838330|NCT05661552|Active Comparator|Group not receiving evolocumab|The control group receives Rosuvastatin 5 mg and Ezetimibe 10 mg.
32838331|NCT00279591|Active Comparator|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
32838332|NCT00279591|Placebo Comparator|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
32838333|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
32838334|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
32838335|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
32838336|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
32838337|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
32838338|NCT00141765|Experimental|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
32838339|NCT04051203|Experimental|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
32838340|NCT04051203|Active Comparator|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
32838341|NCT04051203|Placebo Comparator|Normal Saline|Placebo injection, with no known treatment effects.
32838342|NCT02668692|Experimental|LEO 80185 gel|
32838343|NCT02668692|Active Comparator|Dovobet ® ointment|
32838344|NCT01899807|Other|Single Arm|
32838345|NCT00281463|Experimental|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
32838346|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
32838347|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
32838348|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
32838351|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
32838352|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
32838353|NCT03105882|Experimental|Neuro-Spinal Scaffold|
32838354|NCT00144963|Experimental|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
32838355|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
32838356|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
32838357|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
32838358|NCT03490656|Experimental|Healthy volunteer population|
32838359|NCT03490656|Experimental|Patient population|
32838360|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
32838361|NCT02985593|Experimental|KHK4083|IV/SC administration
32838362|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
32838363|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
32956831|NCT04578756|Experimental|Cariprazine Dose 4|Participants with Bipolar I Disorder, 13 to 17 years will receive cariprazine.
33405548|NCT03953079|Experimental|GB-102 2 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 2 mg in the study eye at Baseline, intravitreal (IVT) GB-102 1 mg at Month 6 and sham at Months 2, 4, 8 and 10.
33405549|NCT03953079|Active Comparator|Aflibercept 2 mg|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
32838364|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
33405550|NCT04572399|Experimental|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
32838365|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
32838366|NCT05549154|Experimental|High-dose vitamin D group|Vitamin D2 softgels 50,000 U/week
32838367|NCT05549154|Experimental|Low-dose vitamin D group|low-dose vitamin D group
32838368|NCT05549154|Placebo Comparator|Control group|Placebo
32838369|NCT05231538|Experimental|Neurodevelopmental Therapy|The treatment group received neurodevelopment treatment lasting for 3 months (3sessions per week). Additionally, for this study, the NDT programme included passive stretching of the lower limb muscles (e.g. hamstrings, gastrocsoleus), followed by techniques of reducing spasticity and facilitating more normal patterns of movement while working on motor functions. In each session, exercises included patients sustaining themselves on their forearms and hands, sitting, crawling, semi-kneeling, and in standing positions supported by the Physical therapist until tone reduction achieved. Balance and corrective reactions were developed by using a CP ball and tilt board.
32838370|NCT05231538|Active Comparator|Routine Physical Therapy|The control group underwent the exercises (stretching, passive range of motion, and active range of motion).
32838371|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
32838372|NCT02391792||patients|patients with septic shock
32838373|NCT02391792||control|patients without septic shock
32838374|NCT02391792||healthy volunteers|
32838375|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
32838376|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
32838377|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
32838378|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
32838379|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
32838380|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
32838381|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
32838382|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
32838383|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
32838384|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
32838385|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
32838386|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
32838387|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
32838388|NCT04099121|Other|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
32838389|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
32838390|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
32838391|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
32838392|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
32838393|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
32838394|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
32838395|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
32838396|NCT02386878|No Intervention|No Intervention|No intervention
32838397|NCT04098107|Experimental|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
32838398|NCT04788888|Experimental|Navitor Transcatheter Aortic Valve, FlexNav Delivery System|Navitor valve implantation, FlexNav Delivery system (small and large) and and Navitor Loading System (small and large)
32838399|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
32838400|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
32838401|NCT02383212|Experimental|Monotherapy Cohort|Cemiplimab will be administered alone
32838402|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy~Doses of cemiplimab will be administered in combination with Cyclophosphamide~Doses of cemiplimab will be administered in combination with Docetaxel"
32838403|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
32838404|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
32838405|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
32838406|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
32838407|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
32838408|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
32838409|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
32838410|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
32838411|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
32838412|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
32838413|NCT01532869|Placebo Comparator|Placebo|
32838414|NCT01532869|Experimental|Tocilizumab|
32838415|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
32838416|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
32838417|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
32838418|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
33319582|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
32838419|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
32838420|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
32838421|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
32956832|NCT04578756|Experimental|Cariprazine Dose 5|Participants with Autism Spectrum Disorder, 10 to 12 years (weighing <=40 kg) will receive cariprazine.
32838422|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
32838423|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
32838424|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
32838425|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
32838426|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
32838427|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
32838428|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
32838429|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
33405551|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
33405552|NCT03885999|Experimental|Fecobionics studies|
33405553|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
33405554|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
32838430|NCT01529749|Active Comparator|EFV/FTC/TDF|
32838431|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
32838432|NCT01529749|Experimental|FTC/TDF + MK-0518|
32838433|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
32838434|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
32838435|NCT01529515|Placebo Comparator|Placebo|
32838436|NCT04101721|Experimental|Aflibercept Group|Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
32838437|NCT04101721|Experimental|Laser Group|Patients will undergo laser treatment in each eligible eye at baseline.
32838438|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
32838439|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
32838440|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
32838441|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
32838442|NCT02666664|Placebo Comparator|Placebo|Placebo control
32838443|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
32838444|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
32838445|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
32838446|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
32838447|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
32838448|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
32838449|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
32838450|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
32838451|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
32838452|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
32838453|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
32838454|NCT04775706|Experimental|HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active|
32838455|NCT04775706|Placebo Comparator|Matching Placebo|
32956833|NCT04578756|Experimental|Cariprazine Dose 6|Participants with Autism Spectrum Disorder, 10 to 12 years (weighing >40 kg) will receive cariprazine.
32956834|NCT04578756|Experimental|Cariprazine Dose 7|Participants with Autism Spectrum Disorder, 13 to 17 years will receive cariprazine.
32838456|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
32838457|NCT04774536|Experimental|CRISPR_SCD001 Drug Product|CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
32838458|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
32838459|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
32838460|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
32838461|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
32838462|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
32838463|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
32838464|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
32838465|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
32838466|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
32838467|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
32838468|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
32838469|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
32838470|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
32838471|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
33103817|NCT05467878||Group I|Patients undergoing regional anesthesia were studied. It can be in the form of combined spinal epidural or epidural anesthesia.
32838472|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
33319583|NCT00277355|Experimental|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
32838473|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
32838474|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
32838475|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
32838476|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
32838477|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
32838478|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
32838479|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
32838480|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
32838481|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
32838482|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
32838483|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
32956835|NCT04578756|Experimental|Cariprazine Dose 8|Participants with Autism Spectrum Disorder, 5 to 9 years will receive cariprazine.
32956836|NCT04574076||N8-GP|Patients with haemophilia A
32956837|NCT04573504|Experimental|Antibiotic Group|The antibiotic regimen chosen is based on the Royal College of Obstetricians and Gynecologists' recommendations (Augmentin and Flagyl or Clindamycin and Flagyl if they are allergic to Penicillin). The dosage for the antibiotics are the following: Flagyl 500mg po BID (twice a day) X 5 days, Clindamycin 400 mg po TID (three times a day) X 5 days, Augmentin 875mg po BID X 5 days.
32956838|NCT04573504|Placebo Comparator|Placebo Group|Women randomized not to receive antibiotics will be given placebo tablets postpartum, so they will all have an identical experience to the women in the experimental (antibiotic) group.
33033387|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
33405555|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
32838484|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
32838485|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
32838486|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
32838487|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
32838488|NCT01576705|Experimental|Thyroxin + folinic acid|
32838489|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
32838490|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
32838491|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
32838492|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
32838493|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
32838494|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
32838495|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
32838496|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
32838497|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
32838498|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
32838499|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
32838500|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
32838501|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838502|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838503|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838504|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838505|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838506|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
32838507|NCT00145041|Experimental|VSLI|Single armed study; all subjects received VSLI
32838508|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
32838509|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
32838510|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
32838511|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
32838512|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
32838513|NCT05165238|Experimental|Coaching program|Participants will complete a 4-week coaching program in an on-line group setting. The purpose of the program will be to help participants change dietary behaviors via a small changes approach.
32838514|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
32838515|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
32838516|NCT04123561|Experimental|TLC599|TLC599 (1mL) IA injection
32838517|NCT04123561|Active Comparator|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
32838518|NCT04123561|Placebo Comparator|Normal Saline|Normal saline (1mL) IA injection
32838519|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
32838520|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
32838521|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
32838522|NCT04479228|Experimental|NAGI bi-flanged metal stent (BFMS)|The WON will be punctured using a standard 19-gauge FNA needle and the aspirate was sent for biochemical and microbial analysis. A 0.025-inch (Visiglide; Olympus Corporation, Tokyo, Japan) or 0.035-inch stiff guidewire (Jag Wire; Boston Scientific) passed through the needle into the cyst cavity to form at least 1 to 2 loops under fluoroscopic guidance. A 6F cystotome (Endo-flex GmbH Dusseldorf, Germany) will be passed over the guidewire for creating a fistula. Subsequently, a 6-mm balloon dilator (Hurricane; Boston Scientific Corporation or Titan balloon, Wilson Cook) will be used to further dilate the fistula tract. After this, the stent delivery catheter is advanced over the guidewire across the PFC wall and the BFMS (Nagi; Taewoong Medical, Gyeonggi-do, South Korea) deployed using sonographic, fluoroscopic and endoscopic visualization.
32838523|NCT04479228|Experimental|Plastic stents|Double-pigtail plastic stents will be used. A minimum of one 10Fr pigtail plastic stent will be placed. After initial EUS-guided access, the ostomy will be dilated first, using a cystotome, and secondly with a balloon dilation. The plastic stent will be inserted and delivered following the routine technique of each interventional endoscopist. The number of the plastic stents and the size of the balloon used to dilate the ostomy will depend on the WON size and content.
32838524|NCT05133648||Hip Surgery without COVID-19 infection|January to December 2021
32838525|NCT05133648||Hip Surgery with COVID-19 infection|January to December 2021
32838526|NCT05133648||Hip Surgery pre-pandemic|January 2017 to December 2019
32838527|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
32838528|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
32838529|NCT01575769|Experimental|1|
32838530|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
32838531|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
32838532|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
32838533|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
32838534|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
32838535|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
32838536|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
32838537|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
32838538|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
32838539|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
32838540|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
32838541|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
32838542|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
32838543|NCT04096625|Experimental|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
32838544|NCT04096625|Sham Comparator|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
32838545|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
32838546|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
32838547|NCT00145587|Other|1|
32838548|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
33103818|NCT05467878||Group 2|Patients in whom general anesthesia and iv analgesic methods are preferred are in this group.
33103819|NCT05467878||Group 3|Patients who prefer peripheral block under general anesthesia and ultrasound are in this group.
33405556|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
33405557|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
32838549|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
33405558|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
32838550|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.~The walking program was the same as the one for the control group."
33405559|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
33405560|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
33405561|NCT05760651||Multiple Sclerosis Patients|Patients diagnosed with multiple sclerosis.
33405562|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
32838551|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
32838552|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
32838553|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
32838554|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
32838555|NCT02381964|Placebo Comparator|Placebo|Matched placebo
32838556|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
32838557|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
32838558|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
32838559|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
32838560|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
32838561|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
32838562|NCT04694807|Experimental|Group-based Cognitive Behavioural Therapy|A group delivered treatment format of CBTgrief (12 sessions).
32838563|NCT04694807|Active Comparator|Individually delivered Cognitive Behavioural Therapy|An individual delivered treatment format of CBTgrief (12 sessions).
32838564|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
32838565|NCT05505240|Experimental|Cold temperature|18°C
32838566|NCT05505240|Experimental|Room temperature|22°C
32838567|NCT05505240|Experimental|Thermoneutral temperature|28°C
32838568|NCT05505240|Experimental|Hot temperature|38°C
32838569|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
32838570|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
32838571|NCT04251351|Experimental|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
32838572|NCT04251351|Sham Comparator|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
32838573|NCT04748471|Experimental|18-45 years old|18 - 45 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
32838574|NCT04748471|Experimental|65-74 years old|65 - 74 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
32838575|NCT04748471|Experimental|At least 75 years old|At least 75 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
32838576|NCT05469282|Experimental|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT) and the ordinary person
32838577|NCT00147069||Controls|Non-smoking control subjects without lung disease
32838578|NCT00147069||Asthmatics|Non-smokers patients with asthma
32838579|NCT00147069||Non-COPD smokers|Current smokers without airways obstruction, FEV1 >80% predicted
32838580|NCT00147069||COPD smokers|Patients with COPD and cigarette smokers
32838581|NCT02382042|Active Comparator|Intensive Referral Intervention|
32838582|NCT02382042|No Intervention|Standard Care|
32838583|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
32838584|NCT00284739|Experimental|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
33405563|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
32739357|NCT04990557|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 4 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
32739358|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
32739359|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
32739360|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
32838585|NCT00284739|Placebo Comparator|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
32739361|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
32739362|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
32739363|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
32739364|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
32739365|NCT03074721|Other|PCI with PCI Suite Software|
32739366|NCT03074721|Other|conventional PCI|
32739367|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
32739368|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
32739369|NCT03314831||No inflammation|Patients without systemic inflammation.
32739370|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
32739371|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
32739372|NCT03071367|Experimental|Clinical Simulation|
32739373|NCT03071367|No Intervention|Classical Learning|
32739374|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
32739375|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
32739376|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
32739377|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
32739378|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
32739379|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
32739380|NCT05713409||Adult patients with an established diagnosis of CD going through ileocecal resection|
32739381|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
32739382|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
32739383|NCT03199105|Experimental|preoperative education and tetracaine|
32739384|NCT03199105|Experimental|tetracaine|
32739385|NCT05713331|Experimental|CLS-R|Web-based remote training for school mental health providers
32739386|NCT05713331|Active Comparator|CLS|In-person training for school mental health providers
32739387|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
32739388|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
32739389|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
32838586|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
32838587|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
32838588|NCT05030298|Experimental|Cohort A (stereotactic biopsy, radiosurgery, surgery)|Patients undergo MRI-guided stereotactic biopsy. Patients then undergo radiosurgery over 1 fraction. Within 14 days, patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
32838589|NCT05030298|Active Comparator|Cohort B (surgery, radiation therapy, chemotherapy)|Patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
32838590|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
32838591|NCT00149643|Active Comparator|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
32838592|NCT00149643|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
32838593|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
32838594|NCT04410289|Experimental|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
32838595|NCT04410289|Active Comparator|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
32838596|NCT02381730|Experimental|Aflibercept|
32838597|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
32838598|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
32838599|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
32838600|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
32838601|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
32838602|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
32838603|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
32838604|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
32838605|NCT00149799|Experimental|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
32838606|NCT00149799|Placebo Comparator|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
32838607|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
32838608|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
32838609|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
33319584|NCT00277355|Placebo Comparator|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
32838610|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
32838611|NCT04204863||SE patients|
32838612|NCT02385630|Experimental|Esophagectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
32838613|NCT02385630|Experimental|Gastrectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
32838614|NCT04157673|Experimental|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
32838615|NCT04157673|Experimental|Episodic Future Thinking introduced at 8 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 6-week period following a 8-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
32838616|NCT04157673|Experimental|Episodic Future Thinking introduced at 10 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 4-week period following a 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
32838617|NCT01790763|Active Comparator|Keramatrix|Keramatrix
32838618|NCT01790763|Active Comparator|Mepilex|Mepilex
32838619|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
32838620|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
32838621|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
32838622|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
32838623|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
32838624|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
32838625|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
32838626|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
32838627|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
32838628|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
32838629|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:~Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
32838630|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
32838631|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
32838632|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
32838633|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
33405564|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
33405565|NCT05759481|Experimental|Propofol|Low-dose propofol infusion at 25 mcg/kg/min
32838634|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
32838635|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
32838636|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
32838637|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
32838638|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
32838639|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
32838640|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
32838641|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
32838642|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~There will be a washout period of 10 days between TPI and TPII"
32838643|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
32838644|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
32838645|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
32838646|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
32838647|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
32838648|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
32838649|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
32838650|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
32838651|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
32838652|NCT04101565|Experimental|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
32838653|NCT04101565|No Intervention|Usual care|Usual care that is consistent with typical maternity care in involving expectant fathers.
32838654|NCT00324753|Experimental|Intervention|Communication sheet
32838655|NCT00324753|Other|Control|Standard of care brochures
32838656|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
32838657|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
32838658|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
32838659|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
32838660|NCT04439682|Experimental|Study group|Aerobic exercise will be performed for a single session
32838661|NCT04439682|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
32838662|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
32838663|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
32838664|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
32838665|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
32838666|NCT00289107|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
33405566|NCT05759481|Placebo Comparator|Placebo|Same volume of 0.9% normal saline as the study group
32838667|NCT00289107|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
33405567|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
33405568|NCT03427827|No Intervention|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
32838668|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
32838669|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
32838670|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
32838671|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
32838672|NCT00326781|Active Comparator|Nicotine Nasal Spray|
32838673|NCT00326781|Active Comparator|Transdermal Nicotine patch|
32838674|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
32838675|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
32838676|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
32838677|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
32838678|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
32838679|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
32838680|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
32838681|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
32838682|NCT05445414|Experimental|Intervention group|"Participants randomized to the intervention group will be asked to use the SteWARdS Antibiotic Defense app-an evidence-based serious game app developed by the study team-for a minimum of five days. They will also need to complete three sets of questionnaires - one set at baseline, one set after completing the quest in the app, and another set 6-10 weeks after they complete the quest in the app."
32838683|NCT05445414|No Intervention|Control group|Participants randomized to the intervention group would be asked to complete two sets of questionnaires - one set at baseline and another set 6-10 weeks later.
32838684|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
32838685|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
32838686|NCT04958304||Moderna COVID-19 Vaccine in Pregnant Women|The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).
32838687|NCT04710342|Experimental|CTO proximal cap crossing|To demonstrate that CapBuster breaks the proximal cap of CTO's
32838688|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
32838689|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
32838690|NCT05440344|Experimental|Imlunestrant (Mild Hepatic Impairment)|Imlunestrant administered orally.
32838691|NCT05440344|Experimental|Imlunestrant (Moderate Hepatic Impairment)|Imlunestrant administered orally.
32838692|NCT05440344|Experimental|Imlunestrant (Severe Hepatic Impairment)|Imlunestrant administered orally.
32838693|NCT05440344|Experimental|Imlunestrant (Normal Hepatic Function)|Imlunestrant administered orally.
32838694|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
32838695|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
32838696|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
32838697|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
33405569|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
32838698|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
32838699|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
32838700|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
32838701|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
32838702|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
33405570|NCT03633513||Caregivers|Environmentally matched healthy control subjects
33405571|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
33405572|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
33405573|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
33405574|NCT03357939|Experimental|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
33405575|NCT03357939|Active Comparator|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
33405576|NCT05759403||Patients with parkinson's disease|Genetic analysis, clinical data , cortical excitbility
33405577|NCT05759403||patients with Parkinson dementia complex|Genetic analysis, clinical data , cortical excitbility
33405578|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
33405579|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
32838703|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash~."
32838704|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
32838705|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
32838706|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
32838707|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
32838708|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
32838709|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
32838710|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
32838711|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
32838712|NCT00289341|Placebo Comparator|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
32838713|NCT00289341|Experimental|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
32838714|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
32838715|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
32838716|NCT05233332|Experimental|phase IIa: HL-085 in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085
32838717|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
32838718|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With RAS or other BRAF-Mutated or MEK1/2-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
32838719|NCT05233332|Experimental|phase IIb: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
32838720|NCT04010175|Active Comparator|Control group|
33405580|NCT05760495||Single arm|ART-experienced PLWH
33405581|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
33405582|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
32838721|NCT04010175|Experimental|Experimental group 1|Moderate frequency cognitive distance training
32838722|NCT04010175|Experimental|Experimental group 2|High frequency cognitive distance training
32838723|NCT04932096|Experimental|Melatonin|(melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)
32838724|NCT04932096|Placebo Comparator|Placebo|Placebo
32838725|NCT00289653|Experimental|single open-label treatment arm|Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period.
32838726|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
32838727|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
32838728|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
32838729|NCT00290199|Experimental|Transcervical Foley Catheter|
32838730|NCT00290199|No Intervention|No Foley|
32838731|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
32838732|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
32838733|NCT00291135|Experimental|1|Oral Letrozole 2.5 mg daily for six months
32838734|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
32838735|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
32838736|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
32838737|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
32838738|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
32838739|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
32838740|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
32838741|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
32838742|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
32838743|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
32838744|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
32838745|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
32838746|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
32838747|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
32838748|NCT02384694|Experimental|Intervention|Zumba dance intervention
32838749|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
32838750|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
32838751|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
32838752|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
32838753|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
32838754|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
32838755|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
32838756|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
32838757|NCT02018835|Other|patients of an aortic bicuspidie|
32838758|NCT02018835|Other|patients of a syndrome of Marfan|
32838759|NCT02018835|Other|Healthy volunteers|
32838760|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
32838761|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
32838762|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
32838763|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~3 seated-standing passages without help~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
32838764|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
32838765|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
32838766|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
32838767|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
32838768|NCT00330915|Experimental|A|
32838769|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
32838770|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
33327308|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
32838771|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
32838772|NCT03026933|Experimental|Treatment|KI1107
32838773|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
32838774|NCT02389140|Experimental|Trigger point treatment|Trigger point release
32838775|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
32838776|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients~Glasgow score < or = 9 or~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
32838777|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:~Intubated and mechanically ventilated~Undergoing urgent non severe surgery"
32838778|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
32838779|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
32838780|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
32838781|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
32838782|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
32838783|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
32838784|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
32838785|NCT04861584|Experimental|Toripalimab+Gemcitabine/Cisplantin（GC）|Subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. . Toripalimab is given every 21 days for 4 doses starting C1D1. Subjects will then have consolidative surgery to remove their primary tumor within 6 weeks after their last dose of neoadjuvant therapy.
32838786|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
32838787|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
32838788|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
32838789|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
32838790|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
32838791|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
32838792|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
32838793|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
32838794|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
32838795|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~No previous nausea and vomiting 24 hours prior to radiotherapy"
32838796|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
32838797|NCT05231226|Experimental|Immediately CR group|Immediately open non-IRA after successful emergency PCI of IRA in STEMI patients with MVD
32838798|NCT05231226|Active Comparator|Staged (within 45 days) CR group|Strategy of opening non-IRA by stages after emergency PCI of IRA in STEMI patients with MVD
32838799|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
32838800|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
32838801|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
32838802|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
32838803|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
32838804|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
32838805|NCT01500317|Placebo Comparator|Placebo|Placebo tid
32838806|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
32838807|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
32838808|NCT02383914||Subscapularis rupture|
32838809|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
32838810|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
32838811|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
32838812|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
32838813|NCT02388672|No Intervention|Control|No treatment control group
32838814|NCT02379468|Experimental|Pedyphar|Ointment
32838815|NCT02379468|Active Comparator|Panthenol|Ointment
32838816|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
32838817|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
32838818|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
32838819|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
32838820|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
32838821|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
32838822|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
32838823|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
32838824|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
32838825|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
32838826|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
32838827|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
32838828|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
32838829|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
32838830|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
32838831|NCT04675398|Active Comparator|Open-loop deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation.
32838832|NCT04675398|Active Comparator|Randomized deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation at random time points.
32838833|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb movement|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of contralateral limb movement.
32838834|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb rest|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of no movement for contralateral limb.
32838835|NCT00333177|Experimental|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
32838836|NCT00333177|Active Comparator|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
32838837|NCT00333177|Experimental|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
32838838|NCT00333177|Active Comparator|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
32838839|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
32838840|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
32838841|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
32838842|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
32838843|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
32838844|NCT04653402|Experimental|Study arm 1|Placing a closed suction drain after hydrocelectomy for primary vaginal hydrocele
32838845|NCT04653402|Active Comparator|Study arm 2|Not placing a drain after hydrocelectomy in primary vaginal hydrocele
32838846|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
32838847|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
32838848|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
32838849|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
32838850|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
32838851|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
32838852|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
32838853|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
32838854|NCT00335283|Active Comparator|Lansoprazole|
32838855|NCT00335283|Placebo Comparator|Sugar Pill|
32838856|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
32838857|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
32838858|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
32838859|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
32838860|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
32838861|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
32838862|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
32838863|NCT03656718|Experimental|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
32838864|NCT03656718|Experimental|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
32838865|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
32838866|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
32838867|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
32838868|NCT02371824||MRI Sequence|
32838869|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
32838870|NCT01890837|Placebo Comparator|Placebo|Placebo TID
32838871|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
32838872|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
32838873|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
32838874|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
32838875|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
32838876|NCT02378688|Experimental|MT-1303|
32838877|NCT02378688|Placebo Comparator|Placebo|
32838878|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
32838879|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
32838880|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
32838881|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
32838882|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
32838883|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
32838884|NCT00295503|Experimental|1|cisplatin, pemetrexed, and bevacizumab
32838885|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
32838886|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
32838887|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):~nTregs~Prednisolone~MMF~Tacrolimus"
32838888|NCT03105648||thyroid cancer|
32838889|NCT03105648||benign thyroid nodules|
32838890|NCT00335517|Experimental|10mg Depodur|
32838891|NCT00335517|Experimental|15mg DepoDur|
32838892|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
32838893|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
32838894|NCT00298155|Active Comparator|Group 1|Goserelin + dutasteride
32838895|NCT00298155|Active Comparator|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
32838896|NCT00298155|Active Comparator|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
32838897|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
32838898|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
32838899|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
32838900|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
32838901|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
32838902|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
32838903|NCT01880541|Experimental|hypnosedation|hypnosedation
32838904|NCT01880541|Other|general anesthesia|general anesthesia
32838905|NCT00298233|Active Comparator|Standard Dose oseltamivir adult cohort|All participants >= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
32838906|NCT00298233|Active Comparator|Double Dose oseltamivir Adult cohort|All participants >= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
32838907|NCT00298233|Active Comparator|Standard Dose Oseltamivir child cohort|All participants <15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
32838908|NCT00298233|Active Comparator|Double Dose Oseltamivir child cohort|All Participants <15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
32838909|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
32838910|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
32838911|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
32838912|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
32838913|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
32838914|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
32838915|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
32838916|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
32838917|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
32838918|NCT00298389||Non smokers|Non smokers included no history of respiratory or allergic disease, normal baseline spirometry
32838919|NCT00298389||Smokers|Smoking history of at least 10 pack years
32838920|NCT00298389||COPD|Patients with stable COPD
32838921|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
32838922|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
32838923|NCT01498679|Placebo Comparator|Placebo|placebo comparator
32838924|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
32838925|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
32838926|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
32838927|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
32838928|NCT02101437|Placebo Comparator|control|normal subjects.
32838929|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
32838930|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
32838931|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
32838932|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
32838933|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
32838934|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
32838935|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
33405583|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
32838936|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
32838937|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
32838938|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
32838939|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
32838940|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
32838941|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
32838942|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
32838943|NCT02371044||Rivaroxaban|N=20
32838944|NCT02371044||Apixaban|N=20
32838945|NCT02371044||Dabigatran|N=20
32838946|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
32838947|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
32838948|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
32838949|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
32838950|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
32838951|NCT01559389|Experimental|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
33327309|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
33327310|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
32838952|NCT01559389|No Intervention|Male Partners|This arm comprises healthy male partners
32838953|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
32838954|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
32838955|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
32838956|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
32838957|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
32838958|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
32838959|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
32838960|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
32838961|NCT00305565|Other|Low Dose|
32838962|NCT00305565|Other|Medium Dose|
32838963|NCT00305565|Other|High Dose|
32838964|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
32838965|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
32838966|NCT04540692|Active Comparator|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
32838967|NCT04540692|Experimental|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
32838968|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
32838969|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
32838970|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
32838971|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
32838972|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
32838973|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
32838974|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
32838975|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
32838976|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
32838977|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
32838978|NCT04489212|Experimental|Treatment (follow-up, observation)|Patients who have recurrence or progression during treatment or observation have medical charts are reviewed every 6 months for 5 years. Patients who complete adjuvant treatment are followed for observation 3 days after radiation therapy, 1 month after radiation therapy, every 3 months after radiation therapy for 2 years, every 6 months for 1 year, and then annually for 2 years.
32838979|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
32838980|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
32838981|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
32838982|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
33327311|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
33405584|NCT03567057|Experimental|ADS-5102, 274 mg|274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks
32838983|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
32838984|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
32838985|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
32838986|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
32838987|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
32838988|NCT04419168|Experimental|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
32838989|NCT04419168|Experimental|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
32838990|NCT04419168|No Intervention|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and we will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
32838991|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
32838992|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
32838993|NCT04406766|Experimental|Connected nutrition pump system|
32838994|NCT02376660|Experimental|Oats|70 grams oats
32838995|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
32838996|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
32838997|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
32838998|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
32838999|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
32839000|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
32839001|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
32839002|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
32839003|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
32839004|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
32839005|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
32839006|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
32839007|NCT04086030|Sham Comparator|Sham Postoperative Rehabilitation|Patients in this group will complete the standardized postoperative rehabilitation program with sham BFR, which is pressure of 20 mmHG. Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set. The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
32839008|NCT04086030|Experimental|BFR Postoperative Rehabilitation|Assigned intervention of BFR where exercises are performed with BFR at 80% limb occlusion pressure (LOP). Patients in this group will undergo blood flow restriction (BFR) training during their postoperative rehabilitation program (use an inflatable cuff that prevents blood flow from flowing out of the leg while patients perform physical therapy exercises). Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set.16 The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
32839009|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
32839010|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
32839011|NCT00302055|Active Comparator|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
32839012|NCT00302055|Experimental|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
33405585|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
32839013|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
32839014|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
32839015|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
32839016|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
32839017|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
32839018|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839019|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839020|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839021|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839022|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839023|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
32839024|NCT04409821|Experimental|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
32839025|NCT01558297|Experimental|Motivational Interviewing|
32839026|NCT01558297|Active Comparator|Nutritional Counseling|
32839027|NCT01558297|Active Comparator|Treatment as usual|
32839028|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
32839029|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
32839030|NCT00308061|Experimental|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
32839031|NCT00308061|Active Comparator|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
32839032|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
32839033|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
32839034|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
32839035|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
32839036|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
32839037|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
32839038|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
32839039|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
32839040|NCT00302133|Experimental|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
32839041|NCT00302133|Placebo Comparator|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
32839042|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
33405586|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
33405587|NCT05760417||Patients wiht Hyperthyroidism|Patients diagnosed with hyperthyroidism.
33405588|NCT04388787|Experimental|stochastic resonance (SR) vibration|SR applied sub threshold at 90% of participant's detection threshold
33405589|NCT04388787|Sham Comparator|Sham treatment|SR devices worn but not turned on (0% of participant's detection threshold).
33405590|NCT04388787|Experimental|Unblinded treatment|SR is applied above participant's detection threshold at a participant selected intensity.
33405591|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Paclitaxel- CB-839 (Pac-CB) combination~Participants must self-identify as African ancestry (includes African American).~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
33405592|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~Participants must self-identify as African ancestry (includes African American).~No prior systemic therapy for advanced or metastatic disease.~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
33405593|NCT03057600|Experimental|Cohort 3 - Non-African ancestry, 3rd line+|"Intervention = Pac-CB combination~Participants do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 1."
33405594|NCT03057600|Experimental|Cohort 4 - Non-African ancestry, 1st line|"Intervention = Pac-CB combination~Participants do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 2."
33405595|NCT04382937|Experimental|P1101 + Ribavirin|P1101 400 µg SC Q2W
32839043|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
32839044|NCT00304161|Active Comparator|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
32839045|NCT00304161|Placebo Comparator|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
32839046|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
32839047|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
32839048|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
32839049|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
33405596|NCT04382937|Active Comparator|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
33405597|NCT04355169|Experimental|Naldemedine 1.25 mg|Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
33405598|NCT04355169|Experimental|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
33405599|NCT04355169|Experimental|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
33405600|NCT04355169|Placebo Comparator|Placebo|Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
33405601|NCT05206890||fluzoparib treatment|patients with Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
33405602|NCT05212974||Nurses|Adult (≥ 20 and ≤80 years) male and female participants with verification of registered nurse license.
33405603|NCT05212974||General publics|Adult (≥ 20 and ≤80 years) male and female participants with reading abilities above the intermediate level.
32839050|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
32839051|NCT04398420|Active Comparator|TVERP|
32839052|NCT04398420|Active Comparator|TURis|
32839053|NCT04398420|Active Comparator|HoLEP|
32839054|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
32839055|NCT04044456|Experimental|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
32839056|NCT04044456|Placebo Comparator|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
32839057|NCT04039230|Experimental|Sacituzumab Govitecan+Talazoparib|"Sacituzumab Govitecan is administered on days 1 and 8 of a 21 day cycle.~Talazoparib is administered daily"
32839058|NCT01524913|Experimental|Hyaluronic acid|
32839059|NCT01524913|Active Comparator|Corticosteroid|
32839060|NCT01524913|Placebo Comparator|Saline|
32839061|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
32839062|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
32839063|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
32839064|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
32839065|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
32839066|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
32839067|NCT03881137|Experimental|Intervention|Geriatric assessment with management
32839068|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
32839069|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
32839070|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
32839071|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
32839072|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
32839073|NCT02375958|Experimental|Triple Negative Breast Cancer|
32839074|NCT02375958|Experimental|Head and Neck Cancer|
32839075|NCT02375958|Experimental|Esophageal Cancer|
32839076|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
32839077|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
32839078|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
32839079|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
32839080|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
32839081|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
32839082|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
32839083|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
32839084|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
32839085|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
32839086|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
32839087|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
32839088|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
32839089|NCT02365194|Other|Standard Counseling|initial clinic counseling
32839090|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
32839091|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
32839092|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
32839093|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
32839094|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
32839095|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
32839096|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
32839097|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
32839098|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
32839099|NCT05653908|Experimental|Daily monitoring|
32839100|NCT04645602|Experimental|Lenvatinib + Pembrolizumab|"Participants will take:~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.~Participants will be followed up to one (1) year after study treatment."
32839101|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
32839102|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
32839103|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
32839104|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
32839105|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
32839106|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
32839107|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
32839108|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
32839109|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
32839110|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
32839111|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
32839112|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
32839113|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
32839114|NCT02368938||Several communities in the north of Shanghai|
32839115|NCT02368704||control|"control subjects with :~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
32839116|NCT02368704||case|"Diabetic patients with :~Having type 2 diabetes for at least 6 months~HbA1c ≤ 8%~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
32839117|NCT01524289|Experimental|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
32839118|NCT01524289|Placebo Comparator|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
32839119|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
32839120|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
32839121|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32839122|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32839123|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
32839124|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
32839125|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
32839126|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
32839127|NCT05653830||Patients with chronic hepatitis B|Patients who meet the diagnostic criteria for chronic hepatitis B for long-term follow-up
32839128|NCT05653830||Patients with chronic hepatitis C|Patients who meet the diagnostic criteria for chronic hepatitis C for long-term follow-up
32839129|NCT05653830||Patients with chronic hepatitis D|Patients who meet the diagnostic criteria for chronic hepatitis D for long-term follow-up
32839130|NCT05653830||Patients with autoimmune liver disease（PBC\AIH\PSC）|Patients who meet the diagnostic criteria for autoimmune liver disease（PBC\AIH\PSC） for long-term follow-up
33405604|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
32839131|NCT05653830||Patients with NAFLD|Patients who meet the diagnostic criteria for NAFLD for long-term follow-up
32839132|NCT05653830||Patients with ALD|Patients who meet the diagnostic criteria for ALD for long-term follow-up
32839133|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
32839134|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
32839135|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
32839136|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
32839137|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
32839138|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):~Review of home medication and medication reconciliation based on Primary Care data~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment~Development of the pharmacological history and registration in the medical record~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team~Pharmacotherapy monitoring~Treatment validation and medication reconciliation at discharge~During the hospitalization (if admission from the ED):~Treatment review and medication reconciliation~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team~Pharmacotherapy monitoring~Validation and medication reconciliation at discharge~Patient education at discharge"
32839139|NCT02368548|Other|Standard Care|"Stages:~Pharmaceutical care program in the episode at the Emergency Department:~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.~During the hospitalization (if admission from the ED):~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness."
32839140|NCT04101331|Experimental|Cohort A|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%
32839141|NCT04101331|Experimental|Cohort B|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%
32839142|NCT04101331|Experimental|Cohort C|TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%
32839143|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
32839144|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
32839145|NCT04561206|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
32839146|NCT04110301|Experimental|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
32839147|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
32839150|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
32839151|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
32839152|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
32839153|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
32839154|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
32839155|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
32839156|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
32839157|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index <30 kg/m2
32839158|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index >=30 kg/m2
32839159|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index >=30 kg/m2
32839160|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
32839161|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
32839162|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
32839163|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
32839164|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
32839165|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
32839166|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
32839167|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
32839168|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
32839169|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
32839170|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
32839171|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
32839172|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
32839173|NCT03105492||Pregnant women|Women who are pregnant
32839174|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
32839175|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
32839176|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
32839177|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
32839178|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
32839179|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
32839180|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
32839181|NCT04439058|Active Comparator|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
32839182|NCT04439058|Other|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
32839183|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
32839184|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
32839185|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
32839186|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
32839187|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
32839188|NCT02367612|Placebo Comparator|Placebo|Placebo
32839189|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
32839190|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
32839191|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
32839192|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
32839193|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
32839194|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.~Follow by email or mail is identical to the control group."
32839195|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
32839196|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
32839197|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
32839198|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
32839199|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
32839200|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
32839201|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
32839202|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
32839203|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
32839204|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
32839205|NCT01557517|Experimental|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
32839206|NCT01557517|Placebo Comparator|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
32839207|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
32839208|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
32839209|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
32839210|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
32839211|NCT03483246|Experimental|Group B - fecal microbiota transplantation|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation
32839212|NCT03483246|Placebo Comparator|Group A- Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation
32839213|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
32839214|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
32839215|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
32839216|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
32839217|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
32839218|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
32839219|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
32839220|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
32839221|NCT04092803|No Intervention|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
32839222|NCT04092803|Experimental|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
32839223|NCT03372564|Experimental|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
32839224|NCT03372564|No Intervention|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
32839225|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
32839226|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
32839227|NCT04091633|Active Comparator|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
32839228|NCT04091633|Experimental|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
32839229|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
32839230|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
32839231|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
32839232|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
32839233|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
32839234|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
32839235|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
32839236|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
32839237|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
32839238|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
32839239|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
32839240|NCT02367378||MIS|Those who received minimally invasive surgical procedures
32839241|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
32839242|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
32839243|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
32839244|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
32839245|NCT01496183|Placebo Comparator|Placebo|
32839246|NCT01496183|Experimental|Olanzapine|
32839247|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32839248|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
32839249|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
32839250|NCT02362776||breast cancer patients|
32839251|NCT02362776||lung cancer patients|
32839252|NCT02362776||control subjects|
32839253|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
32839254|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
32839255|NCT04505280|Experimental|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
32839256|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
32839257|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
32839258|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
32839259|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
32839260|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
32839261|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32839262|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32839263|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32839264|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32839265|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32902901|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
32739390|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
32739391|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
32739392|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
32739393|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
32739394|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
32739395|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
32739396|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
32739397|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
32739398|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
32739399|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
32739400|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
32739401|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
32739402|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
32739403|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
32739404|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
32739405|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
32739406|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
32739407|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
32739408|NCT02482415|No Intervention|Control|
32739409|NCT03209947|Experimental|Ulnar nerve ultrasound|
32739410|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
32739411|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
32739412|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
32739413|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
32739414|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
32739415|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
32739416|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
32839266|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
32839267|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839268|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839269|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839270|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839271|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839272|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839273|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839274|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839275|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
32839276|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
32839277|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
32839278|NCT01829724||Healthy volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
32839279|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
32839280|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
32839281|NCT04573140|Experimental|Phase I adult (Stratum 1)|A maximum of 28 adult patients will be enrolled in dose-escalation study using the BOIN design with an initial embedded accelerated titration design (ATD).
32839282|NCT02366676|Experimental|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)
32839283|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
32839284|NCT03003780|No Intervention|Usual Care|
32839285|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
32739417|NCT02478047|Experimental|Matching points ST36+CV12|
32739418|NCT02478047|Experimental|Matching points PC6+CV12|
32739419|NCT02478047|Experimental|Matching points CV3+CV12|
32739420|NCT04996485|Experimental|Experimental group №1 (Secukinumab )|Secukinumab - subcutaneous injections into the shoulder according to the schedule of 0,1,2,3 weeks, then injections 1 time in 3 months up to 52 weeks of therapy.
32739421|NCT04996485|Experimental|Experimental group №2 (Ustekinumab)|Ustekinumab - subcutaneous injections in the shoulder on schedule 0; 1 month, then every 2 months up to 52 weeks of therapy.
32739422|NCT04996485|Experimental|Experimental group №3 (Dupilumab)|"Dupilumab - subcutaneous injections in the shoulder:~for patients weighing from 15 to <30 kg: initial dose - 600 mg (2 injections of 300 mg), then 300 mg every 4 weeks; for patients weighing from 30 to <60 kg: initial dose - 400 mg (2 injections of 200 mg), then 200 mg every 2 weeks; for patients weighing 60 kg or more: the initial dose is 600 mg (2 injections of 300 mg), then 300 mg every 2 weeks."
32839286|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
32839287|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
32839288|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;~Oral alkalinization~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.~Dietary recommendations~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
33103820|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
33103821|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
32839289|NCT01494467|Experimental|CD5024|CD5024 1% Cream
32839290|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
32839291|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
32839292|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
32839293|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
32839294|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
32839295|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
32839296|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
32839297|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
32839298|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
32839299|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
32839300|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
32839301|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
32839302|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
32839303|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
32839304|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
32839305|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
32839306|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
32839307|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
32839308|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
32839309|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
32839310|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
32839311|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
32839312|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
32839313|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
32839314|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
32839315|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
32839316|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
32839317|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
32956839|NCT04560972|Experimental|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
32956840|NCT04557046|Other|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
32956841|NCT04557046|Other|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
32956842|NCT04557046|Other|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
32956843|NCT04557046|Other|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
32956844|NCT04557046|Other|Group E: Sample Collection|Nasal swab
32956845|NCT04545385|Experimental|TEV-48574|Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
32956846|NCT04545385|Placebo Comparator|Placebo|Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.
32956847|NCT04542421|Experimental|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
32956848|NCT04532814|Other|Lean|Control
32956849|NCT04532814|Experimental|Obese|
32956850|NCT04524390|Experimental|Maralixibat|"Maralixibat chloride oral solution administered twice daily, up to 600* microgram per kilogram, for 26 weeks and in the OLE for all patients.~*equivalent to 570 mcg/kg/day maralixibat free base"
32956851|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
32956852|NCT04521335|Experimental|Treatment: all patients|disulfiram and copper gluconate in combination
32956853|NCT04515615|Experimental|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
32956854|NCT04515004|Experimental|Intervention|All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
32956855|NCT04514107|Active Comparator|Control|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD). n=1740
32956856|NCT04514107|Experimental|Intervention|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD) and Wolbachia-infected Aedes aegypti (wMel) mosquitoes. n=1740
32956857|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
32956858|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
32956859|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
32956860|NCT04505410|Experimental|Tofacitinib plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
32956861|NCT04505410|Active Comparator|Tofacitinib only group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.
32956862|NCT04505410|Experimental|Infliximab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with infliximab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
32956863|NCT04505410|Active Comparator|Infliximab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with infliximab
32956864|NCT04505410|Experimental|Ustekinumab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with ustekinumab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
32956865|NCT04505410|Active Comparator|Ustekinumab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with ustekinumab
32956866|NCT04504669|Experimental|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
32956867|NCT04504669|Experimental|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
32956868|NCT04502563|Experimental|Active arm|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
32956869|NCT04502563|Sham Comparator|Control|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
32956870|NCT04502030|Experimental|Panzyga|
32956871|NCT04502030|Placebo Comparator|Placebo|
33327312|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
33327313|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
33327314|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
33405605|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
33405606|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
32839318|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
33405607|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
33405608|NCT05760339|Experimental|Time-restricted feeding|Subjects will follow a daily time-restricted feeding regimen consisting of an 8h ad libitum eating period and a 16h water fasting period during the last two weeks before surgery, followed by routine preoperative fasting before surgery.
33405609|NCT05760339|Active Comparator|Carbohydrate loading|Subjects will follow their usual diet in the pre-surgical weeks and will receive a maltodextrin beverage on the evening before surgery, as well as two hours before induction of anaesthesia
33405610|NCT05760339|No Intervention|Control group|Subjects will continue their usual diet and proceed with standard preoperative fasting (i.e., eat up until 6 hours and take clear liquids up until 2 hours before induction of anaesthesia).
33405611|NCT05212896|Experimental|Dose Escalation: Phase Ia|Participants will receive escalating doses of BC006 at assigned dose (0.08, 0.3, 1.0, 3.0, 10, 20 mg/kg) via intravenous (IV) infusion every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
33405612|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 1|Participants with GCTTS will receive BC006 at recommended dose for expansion (RDE) IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 24 weeks of treatment, whichever occurs first.
33405613|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 2~4|Participants with other solid tumors will receive BC006 at RDE IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
33405614|NCT03310905|Experimental|Isolated Abdominal Wall Transplant|
33405615|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
33405616|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
33405617|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
33405618|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
33405619|NCT05212662|Experimental|TTI-0102|Cysteamine-pantetheine disulfide (TTI-0102) is supplied in a vial as a powder to be dissolved in water and administered orally.
33405620|NCT05212662|Placebo Comparator|Placebo|Placebo is supplied in a vial as a powder to be dissolved in water and administered orally.
33405621|NCT04308603|Experimental|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
33405622|NCT05212506||vaccinated and unvaccinated|
33405623|NCT03012789|Other|Post Surgery|
33405624|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide
33405625|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
33405626|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
33405627|NCT05759169|Experimental|Intervention|In line with the literature and expert opinions, each dialysis application has been applied to individuals for 30 minutes for the first 30 minutes of 4 weeks, with a 40-43°C hot water-filled foot wash tub, placing both feet of the individual (Afrasiabifar et al., 2022; Kim et al., 2021 Shafeik et al., 2018). The researcher implemented the voluntary consent Form, Patient Demonstration Form, foot Bath Application Monitoring Chart, fatigue VAS Scale Form, dialysis Symptom Index and Hemodialysis Comfort Scale in person. At the end of the fourth week, the researcher refilled the foot Bath Application Monitoring Chart, the fatigue VAS Scale Form, the dialysis Symptom Index, and the Hemodialysis Comfort Scale. A total of 12 sessions have been performed in the foot bath, including during each dialysis treatment for 4 weeks.
32839319|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
32839320|NCT02362932|Experimental|Intervention|Sanitation
32839321|NCT02362932|No Intervention|Control|No sanitation
32839322|NCT03922542|Active Comparator|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
32839323|NCT03922542|Active Comparator|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
32839324|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
32839325|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
32839326|NCT01493687|Experimental|CD5024|CD5024 1% Cream
32839327|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
32839328|NCT02362308||Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
32839329|NCT02362308||Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
32839330|NCT02373618|Experimental|Experimental: DN and Conventional PT|
32839331|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
33327315|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
32839332|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
32839333|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
32839334|NCT00350337|Experimental|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
32839335|NCT00350337|Experimental|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
32839336|NCT00350337|Experimental|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
32839337|NCT00350337|Placebo Comparator|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
32839338|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
32839339|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
32839340|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
32839341|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
32839342|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
32839343|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
32839344|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
32839345|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
32839346|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
32839347|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
32839348|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
32839349|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
32839350|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
32839351|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
32839352|NCT02361996||Coronary Stenting|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extant of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
32839353|NCT02361996||Aortic Valve Replacement|"inclusion criteria:~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
32839354|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
32902902|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
32902903|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
32902904|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
32902905|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
32839355|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
32839356|NCT03898362|Active Comparator|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
32839357|NCT03898362|Active Comparator|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
33327316|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
32739423|NCT04996485|Active Comparator|Control group (Symptomatic therapy)|symptomatic therapy with emollients + systemic retinoids
32839358|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
32839359|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
32839360|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
32839361|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
32839362|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
32739424|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
32739425|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
32739426|NCT05713175|Active Comparator|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
32839363|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
32839364|NCT01493531|Placebo Comparator|Placebo + allopurinol|
32839365|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
32839366|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
32839367|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
32839368|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
32839369|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
32839370|NCT03870750|Experimental|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
32839371|NCT03870750|Experimental|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
32839372|NCT03870750|Experimental|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
32839373|NCT03870750|Active Comparator|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
32839374|NCT00304707|Experimental|2|participants in this arm receive bupropion
32839375|NCT00304707|Placebo Comparator|1|placebo
32839376|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
32839377|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
32839378|NCT04409483|Active Comparator|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
32839379|NCT04409483|Experimental|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
32839380|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
32839381|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
32839382|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
32739427|NCT05713175|Active Comparator|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
33327317|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
33327318|NCT01174134|Experimental|Milk-based beverage with DHA|
32839383|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
32839384|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
32839385|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
32839386|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
32839387|NCT03113136|Active Comparator|Low wattage E cigarette device|
32839388|NCT03113136|Active Comparator|High wattage E cigarette device|
32839389|NCT03113136|Active Comparator|Usual brand cigarette|
32839390|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
32839391|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
32839392|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
32839393|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
32839394|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
32839395|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
32839396|NCT03113058|Experimental|study group|
32839397|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
32839398|NCT00313209|Placebo Comparator|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
32839399|NCT02437110|Experimental|ALS|20 participants with ALS and a level of HERV-K >1000 copies/ml
32839400|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
32839401|NCT02372994|No Intervention|Control Group|Participants receive usual care.
32839402|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
32839403|NCT02373150|Experimental|Group A1|Dose 1 or placebo
32839404|NCT02373150|Experimental|Group A2|Dose 2 or placebo
32839405|NCT02373150|Experimental|Group A3|Dose 3 or placebo
32839406|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
32839407|NCT02361684|Experimental|Blended CBT treatment|
32839408|NCT02361684|Active Comparator|Treatment as usual|
32839409|NCT04271397|Other|Active tuberculosis|
32839410|NCT04271397|Other|Latent tuberculosis infection|
32839411|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
32839412|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
32839413|NCT05267847|Experimental|Cryotherapy during inferior alveolar nerve block|
32839414|NCT05267847|Active Comparator|Inferior alveolar nerve block|
32839415|NCT05267457||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
32839416|NCT05267457||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
32839417|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
32839418|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
32839419|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
32839420|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
32839421|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
32839422|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
33103822|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
33103823|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
33103824|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
32739428|NCT05713175|Active Comparator|Fixtoe device|Fixtoe device, simulating the metatarsophalangeal joint stabilization tape technique . Worn for one month, prior to definitive treatment.
32739429|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
32739430|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
32739431|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
32739432|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
32739433|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
32739434|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
32739435|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
32739436|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
32739437|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
32739438|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
32739439|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
32739440|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
32739441|NCT05713097||ATD withdrawal|"ATD treatment was decided to be stopped at the discretion of the attending physician. Then, patients were followed after ATD withdrawal to determine who would have relapse of GD.~Finally, patients were divided into 2 groups: Relapse and No relapse"
32739442|NCT05713097||No ATD withdrawal|Patients treated with ATD still the end of the study
32739443|NCT04921917|No Intervention|Control|Standard of care: neoadjuvant radiation therapy (NRT).
32739444|NCT04921917|Experimental|Neoadjuvant Exercise Regimen|Subjects will receive conventional NRT in conjunction with a prescribed exercise regimen during the usual 10-week duration of NRT treatment prior to tumor resection.
32739445|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
32739446|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
32739447|NCT05713019|Placebo Comparator|Effect of saline|Saline will be inhaled from a nebuliser
32739448|NCT05713019|Active Comparator|Effect of ATP|ATP solution will be inhaled from a nebuliser
32739449|NCT04990089||VIVO|Patients in which VIVO is used.
32739450|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
32739451|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
32739452|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
32739453|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
32739454|NCT04990245||patients with ulcerative colitis|patients with ulcerative colitis and planned endoscopy as part of routine care
32739455|NCT05712941|Experimental|Letrozole 2.5mg by mouth once a day (QD) + Lerociclib 150mg by mouth twice a day (BID)|
32739456|NCT05712941|Placebo Comparator|Letrozole 2.5mg by mouth once a day (QD) + Placebo|
32739457|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
32739458|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
32739459|NCT04990011|Experimental|BioXclude amnion chorion membrane|
32739460|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
32839423|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
32839424|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
32839425|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
32839426|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
32839427|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
32839428|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
32839429|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
32839430|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
32839431|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
32839432|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
32839433|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
32839434|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
32839435|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
32839436|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
32839437|NCT05267301|Experimental|AlmgaPL|New consumers of iwi self-elected to start taking 2 capsules a day with 1000 mg of AlmegaPL, containing 250 mg of eicosapentaenoic acid (EPA), 150 mg polar lipids and 15 mg chlorophyll.
32839438|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
32839439|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
32839440|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
32839441|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
32839442|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
32839443|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
32839444|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
32839445|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
32839446|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
32839447|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
32839448|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
32839449|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
32839450|NCT03917407|Active Comparator|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
32839451|NCT03917407|Active Comparator|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
33103825|NCT00552227|Experimental|1|
33103826|NCT00552227|Placebo Comparator|2|
32839452|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
32839453|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
32839454|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
32839455|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
32839456|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
32839457|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
32839458|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
32839459|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
32839460|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
32839461|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
32839462|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
32839463|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
32839464|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
32839465|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
32839466|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
32839467|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
32839468|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
32839469|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
32839470|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
32839471|NCT05267145|Experimental|the blood storage bag contains blood preservation solution III|a blood storage bag containing blood preservation solution III preserves the washed RBC
32839472|NCT05267145|No Intervention|empty blood bag to store washed RBC|an empty blood storage bag preserves the washed RBC
32839473|NCT02358954|Experimental|Vestibular Pain interactions|
32839474|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
32839475|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
32839476|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
32839477|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
32839478|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
32839479|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
32839480|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
32839481|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
32839482|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
32839483|NCT02358642|Placebo Comparator|Placebo|Placebo
32839484|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
32839485|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
32839486|NCT01791933||CAM treatment|
32839487|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
33405628|NCT05759169|No Intervention|Control|Patients in the control group have been informed about the voluntary Form, Patient Demonstration Form, fatigue VAS Scale Form, dialysis Symptom Index, and Hemodialysis Comfort Scale performed by the researcher in person. At this stage, no attempt was made to the control group at the end of the fourth week; during the last hemodialysis session, the researcher, with the fatigue VAS Scale Form, the dialysis Symptom Index and the Hemodialysis Comfort Scale face-to-face, treated the patients.
33405629|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
33405630|NCT03849768|Experimental|HS-10296|110mg PO once daily
33405631|NCT03849768|Active Comparator|Gefitinib|250mg PO once daily
33405632|NCT05759091|Experimental|cognitive defusion interventional group|patients with schizophrenia who suffer from persistent delusions participated in cognitive defusion techniques on individual base through sex sessions twice weekly with homework assignments between sessions and skills demonstration by simulation and psychodrama.
33405633|NCT05759091|No Intervention|control group|patients with schizophrenia who suffer from persistent delusions participated in usual routine care in the hospital.
33405634|NCT05760261|Experimental|GSK3882347 and MDZ|Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.
33405635|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
33405636|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
33405637|NCT03065400|Experimental|Pembolizumab|
33405638|NCT05200065|Experimental|Thulium Laser Enucleation|Patients in this arm will undergo thulium laser enucleation of the prostate.
33405639|NCT05200065|Experimental|Bipolar Enucleation|Patients in this arm will undergo bipolar enucleation of the prostate.
33405640|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
33405641|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
33405642|NCT05734989||Hispanic/Latinx patients at risk for CKD|Adult patients in the Hispanic/Latinx Durham community screened for CKD
33405643|NCT05734989||PCPs caring for Hispanic Latinx patients screened for CKD in the Durham Community|Primary Care Providers (PCPs) caring for Hispanic Latinx patients who agree to use the study guidelines and interventions for screening and monitoring their patients for CKD.
32839488|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
32839489|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
32839490|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
32839491|NCT01522651|Experimental|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
32839492|NCT01522651|Experimental|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
32839493|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
32839494|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
32839495|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
32839496|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
32839497|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
32839498|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
32839499|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
32839500|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
32839501|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
32839502|NCT05267067|Active Comparator|manual respirtory exercises|Using manual traditional respiratory exercises.
32839503|NCT05267067|Active Comparator|Respiratory exercises with respiratory pressure meter|Using pressure respiratory meter in exercises.
32839504|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
32839505|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
32839506|NCT04389021|Experimental|VR|The intervention group will receive VR support upon the standard of care during the procedure.
32839507|NCT04389021|No Intervention|Control|The control group will have standard care without the VR support.
32902906|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
32902907|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
33319585|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
33319586|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
33319587|NCT03974399|Other|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
33319588|NCT05593094|Experimental|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
33319589|NCT05593094|Experimental|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
33319590|NCT05593094|Experimental|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
33319591|NCT05593094|Experimental|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
33319592|NCT05593094|Experimental|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
33319593|NCT05593094|Experimental|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
33319594|NCT05593094|Experimental|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
33319595|NCT05593094|Experimental|1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1b Arm1:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
32839508|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
33319596|NCT05593094|Experimental|1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1b Arm2:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
33319597|NCT05593094|Experimental|1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta|"Phase 1b Arm3:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
33327319|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
32839509|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
32839510|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
32839511|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
32839512|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
32839513|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
32839514|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
32839515|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
32839516|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
32839517|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
32839518|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
32839519|NCT05266833|No Intervention|Control|Students in the control class received regular class instruction during the 5 weeks. This instruction did not deviate from regular instruction that was provided to all classes, including the intervention classes. During the intervention period, control group students completed the assessments once per week. The control class is considered a treatment-as-usual active control.
32839520|NCT05266833|Experimental|Self-Paced Breathing|The self-paced slow diaphragmatic breathing intervention provided guidance for participants to breathe at a slower pace than normal with brief, organic pauses after each inhale and exhale, and with exhales longer than inhales. Participants were guided to breathe at their own pace while following these principles of longer exhales and brief pauses after each inhale/exhale. They were invited to slow their pace when ready, both during each 5-minute session and over the course of the 5 weeks.
32902908|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
32902909|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
32902910|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
32902911|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
32839521|NCT05266833|Experimental|Guide-Paced Breathing|The guide-paced slow diaphragmatic breathing intervention comprised slow breathing with all exhales twice as long as the inhales; e.g., a 3-second inhale was followed by a 6-second exhale. Participants were instructed to breathe in sync with the guided pace. The breathing pace slowed over the 5 weeks: for weeks 1-2, the breath pattern comprised a 3-second inhale followed by a 6-second exhale; for weeks 3-4, the timing was 4 and 8, respectively; and was 5 and 10 for the last week.
33103827|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
33103828|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
33405644|NCT05212350|Active Comparator|Pancreatic anastomosis|"Pancreatic anastomosis (PA) will be carried out according to the techniques adopted by the participating Centre, either pancreaticojejunostomy (PJ) (i.e. dunking PJ, Cattel-Warren duct-to-mucosa PJ, Blumgart PJ) or pancreatico-gastrostomy (PG) will be considered eligible. Any mitigation strategy (i.e. ETS, use of glues/biological matrices to protect the anastomosis, surgical feeding jejunostomy, prophylactic hydrocortisone/somatostatin administration) can be used according to the Center practice. The other two anastomosis, hepaticojejunostomy and duodenojejunostomy (in case of Longmire-Traverso pancreatoduodenectomy) or gastrojejunostomy (in case of Kausch-Whipple pancreatoduodenectomy), will be carried out as usual according to each Institution's operative standards.~At least one surgical drain will be placed in the retroperitoneum in all patients."
32839524|NCT01792167|Experimental|Second Step|Second Step Curriculum
32839525|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
32839526|NCT03027739|Experimental|Arm 1|CART-19 cells treated
32839527|NCT03842163||Patients with LVH of unknown etiology|
32839528|NCT04417218|Experimental|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
32839529|NCT04417218|Experimental|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
32839530|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
32839531|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
32839532|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
32839533|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
32839534|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
32839535|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
32839536|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
32839537|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
32839538|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
32839539|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
32839540|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
32839541|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
32839542|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
32839543|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
32839544|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
32839545|NCT03827811||PandrTB cohort|endTB and endTB-Q study participants on experimental regimen
33103829|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
33103830|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
32839546|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
32839547|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
32839548|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
32902912|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
32902913|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
32902914|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
32902915|NCT04242602|Other|Study Subjects|
32902916|NCT04220684|Experimental|Conditioning Regimen|Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2g/ m2/day (days -6 to day -2)
32902917|NCT04220684|Experimental|Induction|Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks. Days may vary and KDS-1001 can be given from days 0 to 21
32902918|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
32902919|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
32902920|NCT01799798|Experimental|Denosumab subcutaneously|
32902921|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
32902922|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
32902923|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
32902924|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
32902925|NCT00672854|Active Comparator|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
32902926|NCT00672854|Experimental|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
32902927|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
32902928|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
32902929|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
32902930|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
32902931|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
32902932|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
32902933|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
32902934|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
32902935|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
33327320|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
32839549|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
32839550|NCT04438980|Experimental|Methylprednisolone Arm|Standard of care plus Methylprednisolone
32839551|NCT04438980|Placebo Comparator|Placebo Arm|Standard of care plus placebo
32839552|NCT05266755|Placebo Comparator|Patiens who will receive stanrdar care after hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge the standar following we are doing now in our hospital
32839553|NCT05266755|Active Comparator|Patiens who will receive FLS following after the hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge a FLS following, multidisciplinary, with a web and mobile app aplication
32839554|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
32839555|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
32839556|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
32839557|NCT03827499|No Intervention|Controls|No intervention
32839558|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
32839559|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
32839560|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
32839561|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
32839562|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
32839563|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
32839564|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
32839565|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
32839566|NCT03818607|Other|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
32839567|NCT03818607|Other|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
32839568|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
32839569|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
32839570|NCT04099927|Experimental|SHR0410|Experimental: SHR0410 dose escalation.
32839571|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
32839572|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
32839573|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
32839574|NCT01792479|Experimental|Arm B: BIND-014 weekly|
32839575|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
32839576|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
32839577|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
32839578|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
32839579|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
32839580|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
32839581|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
32839582|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
32839583|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
32839584|NCT01790217||Cohort|
33319598|NCT05593094|Experimental|1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1c Arm1:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
32839585|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
32839586|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
32839587|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
32839588|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
32839589|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
32839590|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
32839591|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
32839592|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
32839593|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
32839594|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
32839595|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
32839596|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
32839597|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
32839598|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
32839599|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
32839600|NCT01552915|Placebo Comparator|Placebo|
32839601|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
32839602|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
32839603|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
32839604|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
32839605|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
32839606|NCT02360514|Experimental|hantaan virus vaccine|
32839607|NCT03027505|Experimental|MUAC<125mm|no medical complication
32839608|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
32839609|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
32839610|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
32839611|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
32839612|NCT03911557|Experimental|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
32839613|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
32839614|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
32839615|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
32839616|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
32839617|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
32839618|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
32839619|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
32839620|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
32839621|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
32902936|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
32739461|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
33319599|NCT05593094|Experimental|1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1c Arm2:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
33319600|NCT05593094|Experimental|1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO|"Phase 1c Arm3:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
32739462|NCT04989933|Active Comparator|ESP 20 ml|Ultrasound-Guided erector spinae plane block with 20 ml of 0.25% bupivacaine
32739463|NCT04989933|Active Comparator|ESP 30 ml|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine
32739464|NCT05712863|Experimental|BreatheSmart Intervention|"104 subjects will be provided with the BreatheSmart Platform, which consists of:~HeroTracker asthma sensor that counts asthma dosage and monitors real-time medication adherence~Mobile Spirometer that offers remote clinical-grade lung function monitoring~BreatheSmart mobile application that provides patients with real-time alerts and allows patients to complete quality of life surveys"
32739465|NCT04989855|Experimental|Fruquintinib plus Tislelizumab|Fruquintinib 5mg QD d1-d14, Q3W; Tislelizumab 200mg IV Q3W d1
33319601|NCT00262223|Active Comparator|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
32956876|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
33319602|NCT00262223|Placebo Comparator|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
33319603|NCT05575700|Experimental|Ibuprofen|Participants received ibuprofen 400 mg tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
32739466|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
32739467|NCT04987125|Experimental|Dyspnea Neuroscience education|
32739468|NCT04987125|Active Comparator|Usual care|
32739469|NCT04492163|Experimental|Experimental: TTFields|Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
32739470|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
32739471|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
32739472|NCT04915287|Experimental|Avatrombopag|Oral administration of Avatrombopag Maleate Tablets to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whose mean baseline platelet count is less than 50 × 10^9/L. RhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc., are prohibited during the trial.
32739473|NCT04915287|Experimental|Conventional treatment|Conventional treatment (platelet transfusion if needed or rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.) to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whoes mean baseline platelet count is less than 50 × 10^9/L.
32739474|NCT05709353|Experimental|MDMA-assisted prolonged exposure therapy|Administration of 80 -160 mg MDMA (80 mg is the minimum dose for the session, the first session has a supplement dose of 40mg offered 60 to 90 minutes following initial 80 mg dose (80-120mg), and the second session has the option of an additional 40mg offered 60 to 90 minutes following initial 80 - 160mg dose). Each session will last approximately 6 to 7 hours. These three 'dosing' sessions will be interspersed between 14 weeks prolonged exposure therapy sessions (COPE). In total there are 12 sessions of COPE therapy across the 14 weeks.
32739475|NCT05709353|Placebo Comparator|Placebo with prolonged exposure therapy|Administration of an inactive placebo during 'dosing' sessions. Each session will last approximately 6 to 7 hours. These three 'dosing' sessions will be interspersed between 14 weeks prolonged exposure therapy sessions (COPE). In total there are 12 sessions of COPE therapy across the 14 weeks
32739476|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.~Procedure: Carotid Artery Stenting"
32739477|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
32739478|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
32739479|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
32739480|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
32739481|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
32739482|NCT04484467|Experimental|Food supplement Standart Zdorovya GASTRO|"In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days."
32956877|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
33319604|NCT05575700|Placebo Comparator|Placebo|Participants received identical placebo tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
32956878|NCT04477304|Experimental|Behavioral Intervention Arm|Clinicians in clinics randomized to the intervention group will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three categories: Opioid naïve, At-risk for long-term use, or Long-term opioid recipient. These EHR-based nudges include elements of accountable justification, defaults and precommitments. Clinicians will also receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
32956879|NCT04477304|No Intervention|Control|Clinicians in clinics randomized to the control group will receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
32956880|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
32956881|NCT04454645|Experimental|Modified ABC|12-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
32956882|NCT04454645|Active Comparator|Modified DEF|12-session home visiting intervention designed to increase parental playful interactions that stimulate infant cognitive and motor development
32956883|NCT04452747|Active Comparator|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
32956884|NCT04452747|Active Comparator|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
32956885|NCT04448249|Experimental|Interventional group|The interventional group keeps a traditional follow up (day hospitalization then consultation with a MD within two to twelve months) but also meets an APN between the day hospitalization and the MD consultation, within one to six months
32956886|NCT04448249|No Intervention|Control group|The control group of patients keeps a traditional follow-up: day hospitalization then consultation with a MD within two to twelve months
32956887|NCT04439136|Experimental|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32956888|NCT04438161|Active Comparator|Low Risk|"Low risk natural history study (n=250*)~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
32956889|NCT04438161|Experimental|High Risk|"High risk families in prospective longitudinal study of newborns (n=150*).~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.~Participants in this arm will be randomized to:~PERCCS (see attached figure and table for details)~Care as Usual"
32956890|NCT04418661|Experimental|SAR442720 + Pembrolizumab|"Part 1:~SAR442720 (also known as RMC-4630) will be administered orally twice a week (BIW) followed by pembrolizumab which is given intravenously (IV) once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination."
32956891|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score > 50%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
32956892|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score 1-49%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
32956893|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Escalation|Part 3A; SAR442720 and adagrasib will be administered orally on a continuous basis.
32956894|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Expansion|"Part 3B:~Once SAR442720 dose is confirmed in Part 3A SAR442720 and adagrasib will be administered orally on a continuous basis."
32956895|NCT04418661|Experimental|SAR442720 + Pembrolizumab continuous|"Part 4:~SAR442720 will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
32956896|NCT04418440|No Intervention|Control|Routine NHS care following traumatic brain injury
32956897|NCT04418440|Experimental|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
32956898|NCT04408066|Experimental|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
32956899|NCT04408066|Experimental|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
32956900|NCT04406584|Placebo Comparator|Saline|Injection of 1cc saline into olfactory cleft x4
32956901|NCT04406584|Experimental|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
33033047|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
33319605|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
32739483|NCT04484467|Placebo Comparator|Placebo|In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days.
32739484|NCT05709197|Experimental|Braun anastomosis|Open pancreatoduodenectomy with Braun enteroenterostomy
32739485|NCT05709197|Other|Standard Child reconstruction|Open pancreatoduodenectomy only
32739486|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
32739487|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
32739488|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
32739489|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
32739490|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
32739491|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
32739492|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
32739493|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
32739494|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
32739495|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
32739496|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
32739497|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
32739498|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
32739499|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
32739500|NCT02669225|Experimental|Rested Wakefulness|RW PET/MR Scanning Sessions
32739501|NCT02669225|Experimental|Sleep Deprivation|SD PET/MR Scanning Sessions
32739502|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
32739503|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
32739504|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
32739505|NCT05356481|Experimental|Experimental Group A|will recieve (low frequency segmental muscle vibration of 41 Hz over flexors muscles of upper limb Pectoralis minor, Biceps brachii, Flexor carpi muscle + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion.The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
32739506|NCT05356481|Experimental|Experimental Group B|group receive (low frequency segmental muscle vibration of 41 Hz over extensors muscles of upper limb Triceps brachii, Extensor carpi radialis longus & brevis + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
32739507|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
32739508|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
32739509|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
32739510|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
32839622|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
32839623|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
32839624|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
32839625|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
32839626|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
32839627|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
32839628|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
32839629|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
32839630|NCT05266599|Active Comparator|MTA Fillapex group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. MTA Fillapex sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
32839631|NCT05266599|Active Comparator|AH Plus group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. AH Plus sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
32839632|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
32839633|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
32839634|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
32839635|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
32839636|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
32839637|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
32839638|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
32839639|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
32839640|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
32839641|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
32839642|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
32839643|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
32839644|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
32839645|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
32839646|NCT05266443|Placebo Comparator|Irritable bowel syndrome with normal mood receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be supplemented with placebo drinks.
32839647|NCT05266443|Active Comparator|Irritable bowel syndrome with normal mood receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be given lactobacillus-containing cultured milk drinks.
32839648|NCT05266443|Placebo Comparator|Irritable bowel syndrome with subthreshold depression receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be supplemented with placebo drinks.
32839649|NCT05266443|Experimental|Irritable bowel syndrome with subthreshold depression receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be given lactobacillus-containing cultured milk drinks.
32839650|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
32839651|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
32839652|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
32839653|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
32839654|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
32839655|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
32839656|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
32839657|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
32839658|NCT04337970|Experimental|Phase Ib, Dose Level 1|3-6 participants
32839659|NCT04337970|Experimental|Phase Ib, Dose Level 2|3-6 participants
32839660|NCT04337970|Experimental|Phase Ib, Dose Level 3|3-6 participants
32839661|NCT04337970|Experimental|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
32839662|NCT05265897|No Intervention|Usual Care|Brief form letter with lung cancer screening results
32839663|NCT05265897|Experimental|CAQ|"Usual care, plus Commonly Asked Questions after Lung Cancer Screening informational document (CAQ)"
32839664|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
32839665|NCT04751253|Active Comparator|1500 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 1500 J plus exercises.
32839666|NCT04751253|Active Comparator|3000 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 3000 J plus exercises.
32839667|NCT04751253|Sham Comparator|exercises + sham LASER|consist of 17 patients, they will apply exercises plus sham LASER.
32839668|NCT04751097|Experimental|Digital Platform|
32839669|NCT04751097|No Intervention|Routine Care|
32839670|NCT04320030|Experimental|[18F]-DPA-714|pretherapeutic [18F]-DPA-714 PET/CT scan
32839671|NCT04751175|Experimental|Ketamina bolus plus Dexamethasone bolus plus infusion ketamine|Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)
32839672|NCT04751175|Experimental|Ketamine bolus plus ketamine infusion|Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.
32839673|NCT04751175|Active Comparator|Dexametasone arm|Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA
32839674|NCT04751175|Placebo Comparator|Saline bolus|Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA
32902937|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
32747248|NCT05592327|Placebo Comparator|Control non coated abutment|Non- coated abutments (citric acid) will be allocated to the control group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N
33033388|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
33033389|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
32747249|NCT05539755|Experimental|Non-surgical therapy of peri-implantitis|Subjects over 18 years old were consecutively included in the study if they present at least one implant in function for more than 1 year diagnosed with peri-implantitis following the case definition of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (Berglundh et al., 2018).
32747250|NCT05592171|Other|Occlusafe assisted MWA+ DEB-TACE|
32747251|NCT05592171|Other|Occlusafe assisted MWA|
32747252|NCT05592171|Other|MWA+ DEB-TACE|
32747253|NCT05539677||Melanoma|
32747254|NCT05539677||Soft tissue sarcoma|
32747255|NCT05539677||Kidney cancer|
32747256|NCT05539677||Primary brain tumors|
32747257|NCT05539677||Malignant neoplasms|
32747258|NCT05539677||Prostate cancer|
32747259|NCT05539677||Colorectal cancer|
32747260|NCT05546307|Experimental|one relaxation session before the examination|
32747261|NCT05546307|Active Comparator|No relaxation session before the examination|
32747262|NCT05539521|Experimental|Remimazolam Besylate|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
32747263|NCT05539521|Active Comparator|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 3.0 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
32747264|NCT05546229||Controls|Subjects not taking medications for opioid use disorder
32747265|NCT05546229||Methadone|Subjects taking methadone for opioid use disorder
32747266|NCT05546229||Buprenorphine|Subjects taking buprenorphine for opioid use disorder
32747267|NCT05592015|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients who achieve a response (CR or PR) may receive an additional 12 months of ruxolitinib, for a maximum of 24 months.
32747268|NCT05591937|Active Comparator|Symptom Severity Decision-Making|Using current symptom severity level to guide triaging and adapting level of care.
32747269|NCT05591937|Experimental|Data-Driven Decision-Making|Using data-driven algorithm that considers social determinants of mental health, early life adversity/stress, predisposing, enabling and need influences upon health services use, and comprehensive mental health status to guide triaging and adapting level of care.
32747270|NCT05591781|Experimental|Vest Airway Clearance System|Thirty patients (Group A) received high frequency chest wall oscillation with vest system in addition to their prescribed medication, 3 times per week for three successive weeks and the total duration of each session was 15-30 minutes
32747271|NCT05591781|Active Comparator|Lung flute (OPEP)|Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day
32747272|NCT05538975|Experimental|Group A|home based plan of aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
32747273|NCT05538975|Placebo Comparator|Group B|Supervised aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
32747274|NCT05697549|Experimental|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of CBT. And it is focused on the treatment of speech-language related problems. CBLT helped the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. The main aim of CBLT is to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and AAC.
32747277|NCT05545995||TIME LAPSE|Women who proceed to embryo transfer after time lapse assisted embryo selection.
32747278|NCT05545995||NI-PGT-A|Women who proceed to embryo transfer after non-invasive PGT-A assisted embryo selection.
32747279|NCT05545917|Experimental|APP care|The experimental arm will receive advanced practice physiotherapy care.
32747280|NCT05545917|Active Comparator|Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician.
32747281|NCT04426149|Experimental|interventional|supplement: trehalose
32747282|NCT05538741|Experimental|Bolus|Remimazolam bolus injection for 20 seconds
32747283|NCT05538741|Active Comparator|Continuous|Remimazolam continuous infusion
32747284|NCT05591469|Experimental|Noncontact Respiration monitoring group|
32747285|NCT05591469|Experimental|Contact Respiration monitoring group|
32747286|NCT05591391|Experimental|Mallya|Patients use Mallya cap to record the time and dosage of insulin injection
32747287|NCT05591391|Active Comparator|Standard care|Patients receive standard care.
32747288|NCT05538507|Active Comparator|Group I severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and smart soup
32747289|NCT05538507|Sham Comparator|Group II severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and placebo
32747290|NCT05538507|Active Comparator|Group III Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and smart soup
32747291|NCT05538507|Sham Comparator|Group IV Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and placebo
32839675|NCT04293042|Experimental|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
32839676|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
32839677|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
33405645|NCT05212350|Experimental|Total pancreatectomy|Total pancreatectomy will be carried out according to each Institution's operative standards. Preservation of the spleen will be considered whenever possible according to Kimura technique. Either ligation or preservation of gastric vessels (right/left gastric artery/vein) will be allowed according to clinical necessity but will be recorded and correlated with postoperative outcomes. The reconstruction phase will be carried out according to each Institution's operative standards. One or more surgical drains can be left in place according to surgeon's preference.
33405646|NCT04165863|Experimental|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
33405647|NCT04165863|Active Comparator|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
33405648|NCT05211492|Other|Chronic pain|
33405649|NCT05211492|Other|Acute pain|
33405650|NCT05211492|Other|Control group|
33405651|NCT05199675|Experimental|Digital Peer Support Training Program|The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments. The pre-post with control evaluation design will be utilized to evaluate program outcomes. Fidelity will be the primary outcome assessed to demonstrate the effectiveness of the digital peer support training program. It will be measured by the extent to which adolescents' responses to real-cases of peer disclosure indicate Mattering, selfhood, compassion and mindfulness. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes. Cost-effectiveness analysis will inform the development of a scalability and sustainability plan.
33405652|NCT05199675|Active Comparator|Waitlist control for Digital Peer Support Training Program|Students in the wait-list control arm will receive the training program after the conclusion of the trial with the intervention arm. The pre-post with control evaluation design will be utilized to evaluate program outcomes. The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments.The same set of primary and secondary outcomes assessed in the experimenter arm will be included. Specifically, fidelity will be the primary outcome assessed. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes.
33405653|NCT03824808|Active Comparator|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
33405654|NCT03824808|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
33405655|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
32839678|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
32839679|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
32839680|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
32839681|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
32839682|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
32839683|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
32839684|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
32839685|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
32839686|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
32839687|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
32839688|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
32839689|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
32839690|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
32839691|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
32902938|NCT04062032|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
33319606|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
33319607|NCT03975569|Experimental|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
32839692|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
33319608|NCT05569070|Experimental|Guided Young United Parents! (YUP!) Website Intervention|The Guided YUP! website intervention is the confirmatory contrast, which will involve two months of directed use of the YUP! website.
33319609|NCT05569070|Sham Comparator|Nutrition Website|The nutrition website is the control counterfactual condition.
33319610|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
33319611|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
32839693|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
32839694|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
32839695|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
32839696|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
32839697|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
32839698|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
32839699|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
32839700|NCT01792791||Single Arm|
32839701|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
32839702|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
32839703|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
32839704|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
32839705|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
32839706|NCT02359422|No Intervention|Wait-list control|
32839707|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
32839708|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
32839709|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
32839710|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
32839711|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
32839712|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
32839713|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
32839714|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
32839715|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
32839716|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
32839717|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
33319612|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
32839718|NCT02356926||Control|Usual care and routine management
32839719|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
33319613|NCT03798548|Experimental|Brief Bedside CBT|
33319614|NCT03798548|No Intervention|Treatment As Usual|
33319615|NCT05216432|Experimental|RLY-2608 for patients with unresectable or metastatic solid tumors|Multiple doses of RLY-2608 for oral administration.
32839720|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
32902939|NCT04062032|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
33319616|NCT05216432|Experimental|RLY-2608 + fulvestrant combination for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant as determined during Part 1 Dose Escalation.
33319617|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
33319618|NCT03798392|Active Comparator|SP group|
33319619|NCT03798392|Active Comparator|Baska group|
33319620|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
33319621|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
33319622|NCT03813758||finger after digital nerve cut|
33319623|NCT03813758||healthy finger|
33319624|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
32902940|NCT03981380||MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
33319625|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
33319626|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
33319627|NCT01301534||Control group|4. Control group (i.e. usual care)
33319628|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
33319629|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
33319630|NCT03798236|Experimental|PBF-1650 40mg|
33319631|NCT03798236|Experimental|PBF-1650 80mg|
33319632|NCT03798236|Experimental|PBF-1650 120mg|
33319633|NCT03798236|Experimental|PBF-1650 240mg|
33319634|NCT03798236|Placebo Comparator|Placebo|
33319635|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
33319636|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
33319637|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
33319638|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
33319639|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
33319640|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
33319641|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
33319642|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
33319643|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
33319644|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
33319645|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
33319646|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
33319647|NCT04109924|Experimental|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33319648|NCT04093076|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
33319649|NCT04093076|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
32902941|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
33319650|NCT04093076|Placebo Comparator|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
33319651|NCT04093076|Placebo Comparator|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
33319652|NCT04070768|Experimental|Gemtuzumab Ozogamicin(GO) + Venetoclax|Gemtuzumab Ozogamicin(GO) + Venetoclax
33319653|NCT01560494|Experimental|STAC curriculum|
33319654|NCT01560494|No Intervention|Conventional Curriculum|
33319655|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
32839721|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
32839722|NCT02356536|Experimental|Experimental|
32839723|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
32839724|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
33319656|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
32839725|NCT01570387|Experimental|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
32839726|NCT01570387|Experimental|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
32839727|NCT01570387|Experimental|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
32839728|NCT01570387|Experimental|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
32839729|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
32839730|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
32839731|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
32839732|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
32839733|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
33405656|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
32839734|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
32839735|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
32839736|NCT01570309|Placebo Comparator|Sugar pill|
32839737|NCT03147300|Active Comparator|Östergötland region - Control group|
32839738|NCT03147300|Experimental|Östergötland region - Intervention group|
32839739|NCT03908125|Other|Continuous Glucose Monitoring Device|
32839740|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
32839741|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
32839742|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
32839743|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
32839744|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
32839745|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
32839746|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
32839747|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
33033390|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
32839748|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
32839749|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
32839750|NCT02356146||All KT recipient|
32839751|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
32839752|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
32839753|NCT02039154|Experimental|Aerobic and strength training group|
32839754|NCT02039154|Active Comparator|Balance and flexibility group|
32839755|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
32839756|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
32839757|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
32839758|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
32839759|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
32839760|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
32839761|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
32839762|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
32839763|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
33103831|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
33103832|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
33103833|NCT04793477|Experimental|K files (Dentsply Caulk, Milfors, DE, USA)|Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
32839764|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
33103834|NCT04793477|Experimental|VDW.ROTATE (VDW, Munich, Germany).|Instrumentation with VDW.ROTATE files shall be performed with a glide path to WL using VDW.ROTATETM 15.04 until reaching working length (1.3cNm and 300-400 rpm), the next instrument in the sequence is VDW.ROTATETM 20.05 until reaching working length (2.1cNm and 300-400rpm). and finally instrument with VDW.ROTATETM 25.04 (2.3cNm and 300-400rpm)
33103835|NCT04793477|Experimental|Reciproc® blue (RCP, VDW, Munich, Germany)|Instrumentation with Reciproc blue files shall be performed with only one file and move it in a pecking motion (the amplitude will not exceed 3mm). All the instruments shall be cleaned after 3 pecks.
33103836|NCT04974801|Other|Provox Life HMEs followed by Usual Care HMEs|Use of Provox Life devices during a period of six weeks followed by use of Usual Care devices during a period of six weeks.
32839765|NCT04824703|Active Comparator|Conservative oxygen therapy|"Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88%~If spo2 >94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94%~If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 %~If spo2 < 88 % return to previous spo2 that achieve target spo2.~if an arterial blood gas demonstrate that the PaO2 is < 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg )~During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment.~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
33103837|NCT04974801|Other|Usual Care HMEs followed by Provox Life HMEs|Use of Usual Care devices during a period of six weeks followed by use of Provox Life devices during a period of six weeks.
33319657|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
33319658|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
33319659|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
33319660|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).~No mechanical support device allowed."
32839766|NCT04824703|Placebo Comparator|Liberal oxygen therapy|"Spo2 target > 95%~No specific measures will be taken to avoid high fio2 or high po2~Use of upper alarm limit for spo2 will be prohibited~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
32839767|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
32839768|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
33319661|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
33319662|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
33319663|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
32839769|NCT02347956|Experimental|Reduced port group|
32839770|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
32839771|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
32839772|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
32839773|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
32839774|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
32839775|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
32839776|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
32839777|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
32839778|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
32839779|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
32839780|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
32839781|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
32839782|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
32839783|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
32839784|NCT03150030||Healthy controls|Healthy control subjects
32839785|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
32839786|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
32839787|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
32839788|NCT03146988|Active Comparator|Neulasta®|
32839789|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
32839790|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
32839791|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
32839792|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
32839793|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
32839794|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
32902942|NCT03722966|Experimental|Varenicline/Counseling + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
32902943|NCT03722966|Experimental|Varenicline/Counseling|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
33103838|NCT04788680|Experimental|Experimental: Beverage 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
33319664|NCT04954820|Experimental|Experimental arm|2 additional infusions of Lutathera® according to the marketing authorization schema
33319665|NCT04954820|No Intervention|Control arm|No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.
33319666|NCT03812978|No Intervention|Control|Standard treatment
33319667|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
33319668|NCT01303952|Experimental|Eculizumab|
32839795|NCT04250922|Placebo Comparator|Arm A: SoC + placebo for LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
33103839|NCT04788680|Experimental|Experimental: Beverage 2|Participants receive a beverage with a defined amount of non-nutritive sweetener.
32839796|NCT04250922|Experimental|Arm B: SoC + 12 g/day of LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive LAM561 every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm B will receive LAM561 during the Maintenance Phase. Patients will continue to be administered with LAM561 after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
32839797|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
32839798|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
32839799|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
32839800|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
32839801|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
32839802|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
32839803|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
32839804|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
32839805|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
32839806|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
32839807|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
32839808|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
32839809|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
32839810|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
32839811|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
32839812|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
33103840|NCT04788680|Experimental|Experimental: Beverage 3|Participants receive a beverage with a defined amount of monosaccharide.
33103841|NCT04788680|Experimental|Experimental: Beverage 4|Participants receive a beverage with a defined amount of disaccharide.
32839813|NCT03146520||Polyps|subjects with adenoma or polyps
32839814|NCT03146520||Other cancers|subjects with other cancers
32839815|NCT03146520||Healthy|subjects with no evidence of CRC
32839816|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
32839817|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
32839818|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
32839819|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
32839820|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
32839821|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
32839822|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
32839823|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
32839824|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
32956902|NCT04399772|Experimental|Cognitive Functional Therapy+ pathway|Treatment is performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Patients receive max 10 consultations over 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions to reinforce the physiotherapist work.The ethical committee made blinding conditional on a possibility of usual care after CFT+ if: the patient does not feel ready to stop treatment AND analgesic treatment is inappropriate OR the social situation is problematic OR significant psychological distress.
32956903|NCT04399772|Active Comparator|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
32956904|NCT04394546|Experimental|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
32839825|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
32839826|NCT04478448|Experimental|T test|Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir
32839827|NCT04478448|Active Comparator|B reference|Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir
32839828|NCT04478526|Experimental|e-CBT|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
32898589|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
33103842|NCT04967430|Experimental|Treatment|To receive a dose of peginterferon lambda 180mcg SC at baseline (Day 0).
33103843|NCT04967430|Placebo Comparator|Placebo|"Patients in this arm will receive a single SC dose of 0.9% sodium chloride (normal saline) solution at baseline (Day 0).~A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse."
33103844|NCT04783103|Active Comparator|Active adTMS|Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
33103845|NCT04783103|Sham Comparator|Sham adTMS|Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
33103846|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33103847|NCT05467839|Experimental|vitillgo patients|
33103848|NCT04781504|Experimental|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
33103849|NCT04781504|Experimental|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
33103850|NCT05142436|Experimental|Cohort 1: Non-combusted cigarette variant 42001402 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
33405657|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
32839829|NCT04478526|Experimental|Pharmacotherapy|Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
32839830|NCT04478526|Experimental|e-CBT + Pharmacotherapy|Participants will commence both treatments described above simultaneously.
33405658|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
33405659|NCT05109156||This is an observational study|This is an observational study
33405660|NCT05736120||Phase I|Online bulletin boards (OBB)
33405661|NCT05736120||Phase II|Virtual focus groups (real-time)
33405662|NCT05059314|Experimental|Interventional group|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
33405663|NCT05059314|No Intervention|Control group|Routine activity
33405664|NCT05734716|Experimental|EPO Arm|participants administered subcutaneous erythropoietin injection (50 IU/kg 3x/week for 3 weeks) prior to ascent to altitutude. participants additionally administered sham intravenous treatment twice, with dosages occurring three weeks apart and final shame dose occurring 48 hours prior to ascent to altitude.
32839831|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
32839832|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
32839833|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
32839834|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
32839835|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
32839836|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
32839837|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
32839838|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
32839839|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
32839840|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
32839841|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
32839842|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
32898590|NCT04769635|Experimental|CPAP ttt|
32898591|NCT04351477|Experimental|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
33103851|NCT05142436|Experimental|Cohort 2: Non-combusted cigarette variant 42001399 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
32839843|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
32839844|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
32839845|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
32839846|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
32839847|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
32839848|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
32839849|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
32839850|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
32839851|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
32839852|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
32839853|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
32839854|NCT01569841|Experimental|IDeg|
32839855|NCT01569841|Active Comparator|IGlar|
32839856|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
32839857|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
32839858|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
32839859|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
32839860|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
32839861|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
32839862|NCT01569763|Experimental|Aurora Endometrial Ablation|
32839863|NCT02354430|Active Comparator|Water-exercise|
32839864|NCT02354430|No Intervention|Control group|
32839865|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
32839866|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
32839867|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
32839868|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
32839869|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
32839870|NCT02354196||CCTA|Subjects who underwent a CCTA
32839871|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
32839872|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
32839873|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
32839874|NCT05653596|Experimental|Experimental: VR restorative intervention|Individuals who are assigned to the experimental group will receive a 4-week VR-based cognitive intervention.
32839875|NCT05653596|No Intervention|Control: Usual care|Individuals who are assigned to the control group will receive the usual care and then receive the same intervention as they wish.
32839876|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
32839877|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
32839878|NCT02268474|Experimental|532nm KTP Laser vs 595nm Pulse Dye Laser|"This is a single-center prospective, randomized, controlled split-face study in 20 subjects diagnosed with Erythematotelangiectatic Rosacea and/or Papulopustular Rosacea.~This two arm, split-face study will consist of:~Treatment arm involving treatments with 532nm KTP laser~Active control arm involving treatments with 595nm Pulse Dye Laser (PDL)~Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization."
32839879|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
32839880|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
32839881|NCT03658629|Experimental|Dose A|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; in-clinic mix with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
32839882|NCT03658629|Experimental|Dose B|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
32839883|NCT03658629|Experimental|Dose C|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 75 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
32839884|NCT03658629|Experimental|Dose D|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and 90 µg HA per B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
32839885|NCT03658629|Experimental|Dose E|Alternating deltoid injections of Quad-NIV (60 µg HA per A and B strain without adjuvant) on Day 0 and Licensed 2018-2019 Influenza vaccine on Day 28.
32839886|NCT03658629|Experimental|Dose F|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine on Day 0 and Placebo on Day 28.
32839887|NCT03658629|Experimental|Dose G|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine on Day 0 and Placebo on Day 28.
32839888|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
32839889|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
32839890|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
32839891|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
32839892|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
32839893|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
32839894|NCT02346786|Experimental|Mineral Water|mineral water
32839895|NCT02346786|Active Comparator|Tap Water|usual water intake
32839896|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
32839897|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
32839898|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
32839899|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
32839900|NCT05265819|Active Comparator|Group A|Group A: Control group No intervention was provided for 12 weeks except thyroid hormone replacement therapy
32839901|NCT05265819|Experimental|Group B|Group B: Exergaming exercise The volunteers carried out 36 exergaming sessions
32839902|NCT05265819|Experimental|Group C|Group C: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
32839903|NCT05265819|Experimental|Group D|Group D: Exergaming exercises and Mediterranean diet Exergaming exercises are used in addition to Mediterranean diet
32839904|NCT02346942||Patients who have no history of bDMARD therapy use|
32839905|NCT02346942||Patients who have a prior history of bDMARD therapy use|
32839906|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
32839907|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
32839908|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
32839909|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
32839910|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
32839911|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
32839912|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
32839913|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
32839914|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
32839915|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)~The treatments will be administrated in accord with the guideline for other types of cancer.~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
32839916|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)~The treatments will be administrated in accord with the guideline for other types of cancer."
32898592|NCT04351477|No Intervention|Control|No use of mechanical massage chair for 3 weeks
32839917|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
32839918|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
32839919|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
32839920|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
32839921|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
32839922|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
32839923|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
32839924|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
32839925|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
32839926|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
32839927|NCT05242341|Experimental|app use teaching|"Intervention includes teach the subjects one-on-one to use the My Health Bank for 30 minutes (such as download, register, test, find information, etc.), and provide pre-recorded 1-minute instructional videos for viewing when needed at home. The intervention group also accepts to follow the use of My Health Bank app at home every two weeks for a period of two months. Both groups will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety (prohibited medicines and concomitant medications)."
32839928|NCT05242341|No Intervention|B|will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety
32839929|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
32839930|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
32839931|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
32839932|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
32839933|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
32839934|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
32839935|NCT02346396|Experimental|Patients with neuropathic chronic pain|
32839936|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
32839937|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
32839938|NCT04121442|Experimental|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
32839939|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
32839940|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
32839941|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
32839942|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
32839943|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
32839944|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
32839945|NCT02349828|No Intervention|No treatment|standard of care
32839946|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
32839947|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
32898593|NCT00101816|Experimental|1|
32898594|NCT00102518|Experimental|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
32956905|NCT04394546|Active Comparator|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
32956906|NCT04375982|Other|Blood collection|Venepuncture and fingerstick to obtain venous blood and capillary blood respectively
32956907|NCT04370301|Experimental|Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3."
32956908|NCT04350866||Pre-Implementation (0-, 6-, 12-, or 18-months)|Following training in BBTI, all sites (except site 1) will enter the pre-implementation phase for 6-, 12-, or 18-months. During this phase, sites will not receive any access to or support for the implementation strategies. They will deliver and implement BBTI as they see fit. Qualitative interviews will be conducted at the end of this phase.
32956909|NCT04350866||Implementation (12-months)|After the pre-implementation phase, all sites will enter a 12-month implementation phase (except site 1, which will begin implementation following BBTI training). During this phase, sites will receive access to and support for the bundle of implementation strategies, both from the hub site and their local champion/internal facilitator. During this phase, PCMHI clinicians trained in BBTI will receive feedback as necessary regarding their BBTI skills from their local champion/internal facilitator. During this phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
32956910|NCT04350866||Post-Implementation (6-months)|Following the 12-month implementation phase, each site will have access to and support for the implementation strategies removed and similar to the pre-implementation phase, will deliver and implement BBTI as they see fit. During this 6-month phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
32956911|NCT04340115||Participants treated with RINVOQ|Participants treated with upadacitinib in accordance with approved local label. Decision to treat with upadacitinib was made prior to offering participation in this study.
32956912|NCT04329325|Experimental|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
32956913|NCT04320888|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
32956914|NCT04293341|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
32956915|NCT04293341|Active Comparator|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
32956916|NCT04291703|Experimental|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 24 hours after completion of the previous dose. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
32956917|NCT04291703|Placebo Comparator|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 24 hours after completion of the previous dose. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
32956918|NCT04288921|Experimental|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
33405665|NCT05734716|Experimental|Iron Arm|participants administered intravenous iron sucrose (200mg) twice, dosages occurring three weeks apart with final dosing occurring 48 hours prior to ascent to altitude. Participants additionally administered sham subcutaneous injection (sterile saline) 3x/week for 3 weeks.
32956919|NCT04288921|Experimental|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
32956920|NCT04280692|Experimental|Group 1: PfSPZ 6,400|"Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites.~Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
32956921|NCT04280692|Experimental|Group 1: PfSPZ 12,800|"Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites~Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
32956922|NCT04280692|Experimental|Group 3: PfSPZ 25,600|"Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites~Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
32956923|NCT04278560|Experimental|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
33033391|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
33405666|NCT05734716|Placebo Comparator|Placebo|participants administered sham injections (sterile saline) 3x/week for 3 weeks as well as sham intravenous infusion (sterile saline) twice with dosages occurring three weeks apart and final dosing occurring 48 hours prior to ascent to altitude.
33405667|NCT05044884|Experimental|Otago exercise group|"The Otago exercise group will practice the Otago exercise protocol which includes strength and balance exercises along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
33405668|NCT05044884|Active Comparator|Circuit training group|"The Circuit training group will practice balance exercises including Stance exercise, Functional strength exercise, Transition exercise and Gait training along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
33405669|NCT05211258|Experimental|a novel portable upper gastrointestinal endoscopy system|
33405670|NCT05733390|Experimental|JZP541|Participants who will be randomized to receive JZP541.
33405671|NCT05733390|Placebo Comparator|Placebo|Participants who will be randomized to receive placebo.
33405672|NCT05733000|Experimental|COHORT 1 (Devimistat, 5-FU, HCQ)|Patients with colorectal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
33405673|NCT05733000|Experimental|COHORT 2 (Devimistat, 5-FU, HCQ)|Patients with pancreatic cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
33405674|NCT05733000|Experimental|COHORT 3 (Devimistat, 5-FU, HCQ, Gemcitabine)|Patients with gastroesophageal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients with urothelial, ovarian, or non-small cell lung cancer receive devimistat IV, gemcitabine IV, plus HCQ PO on study. Patients with biliary tumors receive devimistat IV and gemcitabine IV or HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
33405675|NCT05210946|Experimental|Pemigatinib in Advanced Non-Small Cell Lung Cancer Patients with FGFR Gene Alterations|"This study is a prospective single-arm clinical study. Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to"
33405676|NCT05210868|Experimental|CM355|"Dose Escalation Phase CM355~Dose Expansion Phase CM355"
33405677|NCT04879368|Experimental|RegoNivo|"Participants in the RegoNivo arm will;~self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and;~receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion.~After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days."
33405678|NCT04879368|Active Comparator|Standard of Care|"Participants in the control arm will receive investigator choice chemotherapy with any of the following agents~taxane (paclitaxel or docetaxel)~irinotecan or~oral trifluridine/tipiracil (TAS102)~All treatment groups will receive Best Supportive Care (BSC)."
33405679|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
33405680|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
33405681|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
33405682|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
32956924|NCT04278560|Active Comparator|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
32956925|NCT04263194|Experimental|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
32956926|NCT04263194|Experimental|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
32956927|NCT04263194|Placebo Comparator|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
32956928|NCT04250155|Experimental|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
32956929|NCT04250155|Experimental|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
32956930|NCT04250155|Experimental|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
32956931|NCT04250155|Experimental|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
32956932|NCT04248569|Experimental|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
32956933|NCT04247126|Experimental|Group 1: Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
32956934|NCT04247126|Experimental|Group 2: SY-5609 + Fulvestrant|Participants with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
32956935|NCT04247126|Experimental|Group 3: SY-5609 + Gemcitabine|Participants with PDAC will receive SY-5609 in combination with gemcitabine in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine at the recommended combination dose.
32956936|NCT04247126|Experimental|Group 4: SY-5609 + Gemcitabine + Nab-paclitaxel|Participants with PDAC will receive SY-5609 in combination with gemcitabine plus nab-paclitaxel in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine plus nab-paclitaxel at the recommended combination dose.
32956937|NCT04245228|No Intervention|Usual Care Group|Routine caregiver transplant education
32956938|NCT04245228|Experimental|Wellness Coaching Intervention|Caregivers will be assigned a wellness coach
32956939|NCT04241250|Experimental|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
32956940|NCT04241250|Experimental|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
32956941|NCT04240093|Experimental|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
32956942|NCT04240093|Active Comparator|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
32956943|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
32956944|NCT04220619|No Intervention|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
32956945|NCT04220619|Experimental|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
32956948|NCT04200352|Experimental|TEV-50717|The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).
32956949|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
32956950|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
32956951|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal), nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.
32956952|NCT04198766|Active Comparator|Part 4 Pembrolizumab Expansion Arm, Randomized|Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks
32956953|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab in NSCLC, Randomized|Subjects with non-small cell lung cancer will be treated with alternating every 6 weeks dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV
32956954|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab in NSCLC; Randomized|Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles
32956955|NCT04198766|Experimental|Part 2 INBRX-106 Escalation in NSCLC|Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
32956956|NCT04198766|Experimental|Part 2 INBRX-106 Escalation in Various Solid Tumor Types|Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
32956957|NCT04198766|Experimental|Part 4 INBRX-106 Expansion with Pembrolizumab in Uveal Melanoma|Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
32956958|NCT04198766|Experimental|Part 4 INBRX-106 Expansion with Pembrolizumab in MSI-high, TMB-high or MMR-deficient tumors|Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
32956959|NCT04198701|Experimental|Pilot|
32956960|NCT04198701|Experimental|Pivotal - Roll-In|
32956961|NCT04198701|Experimental|Pivotal - Paroxysmal AF|
32956962|NCT04198701|Experimental|Pivotal - Persistent AF|
32956963|NCT04191889|Experimental|TRIPLET|
32956964|NCT04181996|Placebo Comparator|Placebo|Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.
32956965|NCT04181996|Experimental|Colchicine|Colchicine: 0.6 mg colchicine capsule to be taken once a day.
32956966|NCT04179162|Experimental|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
32956967|NCT04168489|Active Comparator|active rTMS|
32956968|NCT04168489|Sham Comparator|sham rTMS|
32956970|NCT04163432|Experimental|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
32956971|NCT04163432|Experimental|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
32956972|NCT04161885|Experimental|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care|Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
32956973|NCT04161885|Experimental|Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
32956974|NCT04161885|Experimental|Part 2: Arm B - Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
32956975|NCT04152954|Active Comparator|Traditional cannula|Cervical Medial Branch Radiofrequency Neurotomy using a conventional cannula, the patient lying prone with a posterior approach.
32956976|NCT04152954|Experimental|Multi-tined cannula|Cervical Medial Branch Radiofrequency Neurotomy using a Multi-Tined cannula, the patient lying in lateral decubitus with a lateral approach
32956977|NCT04151706|Experimental|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.
32956978|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
32956979|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
32956980|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
32956981|NCT04147819|Experimental|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
32956982|NCT04147819|Experimental|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
32956983|NCT04147819|Experimental|HER2 low expressing breast cancer|Dose expansion of BAY2701439
32956984|NCT04147819|Experimental|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
33033392|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
32956985|NCT04147468|Active Comparator|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
32956986|NCT04147468|Experimental|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
32956987|NCT04143126|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
32956988|NCT04143126|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 2 hours per week; Location: Pittsburgh, PA only"
32956989|NCT04136184|Experimental|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks.
32956990|NCT04136184|Active Comparator|Inotersen|Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to Eplontersen administered subcutaneously once every 4 weeks until the end of study.
33327321|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
33405683|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
32956993|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
32956994|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
32956995|NCT04119453|Experimental|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.
32956996|NCT04114734|Experimental|Park Rx|Participants will be given a park prescription as part of their treatment plan
32956997|NCT04114734|No Intervention|No Park Rx|Usual care only
32956998|NCT04109482|Experimental|Relapsed or Refractory BPDCN|Treatment with MB-102.
32956999|NCT04109313|Experimental|LOU064|Participants will be asked to take selected dose of LOU064 twice daily for 52 weeks
32957000|NCT04099251|Experimental|Nivolumab|
32957001|NCT04099251|Placebo Comparator|Placebo|
32957002|NCT04097821|Experimental|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
32957003|NCT04097821|Experimental|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
32957004|NCT04097821|Experimental|Part 1 Arm 3: Ruxolitinib + Sabatolimab|Safety run-in of Sabatolimab added to existing stable dose of ruxolitinib
32957005|NCT04097821|Experimental|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
32957006|NCT04097821|Experimental|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
32957007|NCT04097821|Experimental|Part 2 Arm 3: Ruxolitinib + Sabatolimab|Sabatolimab added to existing stable dose of ruxolitinib
32957008|NCT04097821|Active Comparator|Part 2 Arm 6: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
32957009|NCT04097821|Experimental|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
32957010|NCT04097821|Experimental|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
33405684|NCT05758935|Experimental|Mobile application|A six weeks, rule-based chatbot intervention
32957011|NCT04097821|Active Comparator|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
32957012|NCT04097821|Experimental|Part 1 Arm 4: Ruxolitinib + Rineterkib|Dose escalation of Rineterkib added to existing stable dose of ruxolitinib
32957013|NCT04097821|Experimental|Part 1 Arm 5: Ruxolitinib + NIS793|Safety run-in of NIS793 added to existing stable dose of ruxolitinib
32957014|NCT04097821|Experimental|Part 2 Arm 4: Ruxolitinib + Rineterkib|Rineterkib added to existing stable dose of ruxolitinib
32957015|NCT04097821|Experimental|Part 2 Arm 5: Ruxolitinib + NIS793|NIS793 added to existing stable dose of ruxolitinib
32957016|NCT04097353|Experimental|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
32957017|NCT04097353|Sham Comparator|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
32957018|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
33327322|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
33405685|NCT04097301|Experimental|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.~PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).~Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3"
32839948|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
32839949|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
32839950|NCT04478916||Geriatric evaluation Group|Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)
32839951|NCT04478916||Control Group|
32839952|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
32839953|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
32839954|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
32839955|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
32839956|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
32839957|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
32839958|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
32839959|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
32839960|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
32839961|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
32839962|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
32839963|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
32839964|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
32839965|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
33327323|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
33327324|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
33327325|NCT03859440|Experimental|DSiHy (test lens)|
33327326|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
33327327|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
33327328|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
33327329|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
33327330|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
33327331|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
33327332|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
33327333|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
33327334|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
33327335|NCT01285440||Diagnostic Imaging|
32839966|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
32839967|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
32839968|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
32839969|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
32839970|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
32839971|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
32839972|NCT04089930||Vaccine|Those SLE patients who had been given herpes zoster vaccine in our original RCT
32839973|NCT04089930||Placebo|Those SLE patients who had been given placebo vaccination in our original RCT
32839974|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
32839975|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
32839976|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
32839977|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
32839978|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
32839979|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
32839980|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
32839981|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
32839982|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
32839983|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
32839984|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
32839985|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
32839986|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
32839987|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
32839988|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
32839989|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
32839990|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
32839991|NCT05255718|Placebo Comparator|Control|The placebo supplement will have no polyphenol content and will consist of 100 mL of the following mixture: black cherry Koolaid, blue and red food coloring, sucrose and sorbitol. This placebo will match the sugar content of the chokeberry juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
32839992|NCT05255718|Experimental|Aronia|100 mL of Aronia juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
32839993|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
32839994|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
32839995|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
32839996|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
32839997|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
32839998|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
32839999|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
32840000|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
32840001|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
32840002|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
32840003|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
32840004|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
32840005|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
32840006|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
32840007|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
32840008|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
32840009|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
33327336|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
33405686|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
32840010|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
32840011|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
32840012|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
32840013|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
32840014|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
32840015|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
32840016|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
32840017|NCT02345616|Experimental|Nitric oxyde|
32840018|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
32840019|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
32840020|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
32840021|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
32840022|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
32840023|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
32840024|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
32840025|NCT05013411||Healthcare workers|Healthcare workers with patient care experience and are willing to share their experience of current practices of obtaining patient observations.
32840026|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
32840027|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
32840028|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
32840029|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
32840030|NCT04976283|Active Comparator|Pioglitazone|The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
32840031|NCT04976283|Active Comparator|Empagliflozin|The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
32840032|NCT04976283|Active Comparator|Pioglitazone + Empagliflozin|The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
32840033|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840034|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840035|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840036|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840037|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840038|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840039|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
32840040|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
32840041|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
32957019|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
32957020|NCT04092270|Experimental|Treatment (peposertib, PLD)|Patients receive peposertib PO BID on days 1-21, days 1-28, or or days 1-7 (depending on dose level) and pegylated liposomal doxorubicin hydrochloride IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32957021|NCT04083235|Experimental|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
32957022|NCT04083235|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
32957023|NCT04069026|Experimental|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
32957024|NCT04069026|Experimental|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC
32957025|NCT04068610|Active Comparator|Control Arm (FOLFOX + Bevacuzimab)|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)
32957026|NCT04068610|Experimental|Exp. Arm (FOLFOX + Bevacuzimab + Durvalumab + Oleclumab)|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W"
33327337|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
33405687|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
32957030|NCT04065438|Experimental|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
32957031|NCT04054401|Experimental|DRG Neurostimulation with Spinal Fusion|
32957034|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
32957035|NCT04026113|Experimental|Linaclotide 72 μg|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
32957036|NCT04026113|Experimental|Placebo|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
32957037|NCT04026113|Experimental|Linaclotide 145 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
32957038|NCT04026113|Experimental|Linaclotide 290 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
32957039|NCT04025554|Experimental|1/Active treatment|Patients with MS will be assigned to the same intervention
32957040|NCT04015180|Experimental|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
32957041|NCT04015180|Active Comparator|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
32957042|NCT04006119|Experimental|Ad-RTS-hIL-12 + veledimex in combination with cemiplimab-rwlc|Intratumoral Ad-RTS-hIL-12 and oral veledimex (activator ligand, 20mg) given in combination with cemiplimab-rwlc via infusion.
32957043|NCT04004793|Experimental|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
32957044|NCT04004793|Placebo Comparator|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
32957045|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
32957046|NCT04002011|Active Comparator|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.~Dosage adapted to INR = [2.0-3.0], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR > or = 2.0.~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
33103852|NCT05142436|Experimental|Cohort 3: Non-combusted cigarette variant 42001401 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
33103853|NCT05142436|Experimental|Cohort 4: Non-combusted cigarette variant 40007386 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
33103854|NCT05142436|Experimental|Cohort 5: Non-combusted cigarette variant 42001402 and product use mode A|Subjects randomized to use of a non-combusted cigarette variant and product use mode A
32840042|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
32840043|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
32840044|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
32840045|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
32840046|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
32840047|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
32840048|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
32840049|NCT02345304|Experimental|Treatment 2|single dose of digoxin
32840050|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
32840051|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
32840052|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
32840053|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
32840054|NCT02108457||Proton subjects|
32840055|NCT02108457||IMRT subjects|
32840056|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
32840057|NCT03148626|Placebo Comparator|Control|Usual education.
32840058|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
32840059|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
32840060|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
32840061|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
32840062|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
32840063|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
32840064|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
32840065|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
32840066|NCT04108273|Experimental|OST Intervention|
32840067|NCT04108273|Other|Waitlist|
32840068|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
32840069|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
32840070|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
32840071|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
32840072|NCT02108691|Placebo Comparator|Placebo|
32840073|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
32840074|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
32840075|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
32840076|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
32840077|NCT01549951|Experimental|Orteronel+Prednisone|
32840078|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
33327338|NCT01288716|Placebo Comparator|Placebo|
33327339|NCT01288716|Active Comparator|Arbaclofen|
33405688|NCT05199363|Active Comparator|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
33405689|NCT05199363|Active Comparator|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
33405690|NCT05199363|Active Comparator|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers."
33405691|NCT05199363|No Intervention|Control|Study participant will obtain standard information about magnetic resonance imaging before examination.
33405692|NCT05760105||Ankylosing Spondylitis Patients|Patients diagnosed with ankylosing spondylitis.
33405693|NCT05199129|Experimental|HCP1904-3|
33405694|NCT05199129|Active Comparator|RLD2001-1|
33405695|NCT02811783|Active Comparator|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
33405696|NCT02811783|Placebo Comparator|Placebo Lotion|Placebo Lotion
33405697|NCT02746029||Children with cardiac murmur|
33405698|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
32840079|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
32840080|NCT04937751||Invasive fusariosis|
32840081|NCT04937751||Fusarium keratitis|
32840082|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
32840083|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
32840084|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
32840085|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
32840086|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
32840087|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
32840088|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
32840089|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
32840090|NCT01517893|Placebo Comparator|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
32840091|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32840092|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32840093|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32840094|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32898597|NCT02090894|Experimental|UV Light|
33405699|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
33405700|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
32840095|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32840096|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
32840097|NCT02344992|Experimental|Biochaperone Insulin Lispro|
32840098|NCT02344992|Active Comparator|Humalog®|
32840099|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
32840100|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
32840101|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
32840102|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840103|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
32840104|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840105|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
32840106|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840107|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
32840108|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
32840109|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
32840110|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
32840111|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
32840112|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
32840113|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
32840114|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840115|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
32840116|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840117|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
32840118|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
32840119|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
32840120|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
32840121|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
32840122|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
32840123|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
32840124|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
32840125|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
32840126|NCT02342184|Experimental|GB-0998|
32840127|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
32840128|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
32840129|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
32840130|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
32840131|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
32840132|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.~Excellent pregnancy success rates."
32840133|NCT02039232|Experimental|CarboFix Pedicle Screw System|
32840134|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
32840135|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
33405701|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by combined docetaxel + prostvac
33405702|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
32840136|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
32840137|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
32840138|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
32840139|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
32840140|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
32840141|NCT02348814||normal weight|BMI 20-25
32840142|NCT02348814||overweight|BMI 25-30
32840143|NCT02348814||obese|BMI 30-35
32840144|NCT02348814||morbidly obese|BMI > 35
32840145|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
32840146|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
32840147|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
32840148|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
32840149|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
32840150|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
32840151|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
32840152|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
32840153|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
32840154|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
32840155|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
32840156|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
32840157|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~Has not received any treatment for OSA~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
32840158|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
32840159|NCT05255094|Experimental|AK102 regimen 1|
32840160|NCT05255094|Experimental|AK102 regimen 2|
32840161|NCT05255094|Placebo Comparator|Placebo 1|
32840162|NCT05255094|Placebo Comparator|Placebo 2|
32840163|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
32840164|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
32840165|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
32840166|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
32840167|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
32840168|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
32840169|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
32840170|NCT02341794|Experimental|Rosuvastatin|
32840171|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
32840172|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
32840173|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).~Intervention: podcast + mobile diet app"
32840174|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).~Intervention: podcast + theory-based mobile diet app"
32840175|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
32840176|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
32840177|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
32840178|NCT00360555|Placebo Comparator|placebo|placebo comparator
32957047|NCT04002011|Active Comparator|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
32957048|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
32957049|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
32957050|NCT03988595|Experimental|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
32957051|NCT03988595|Experimental|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
32957052|NCT03988595|Experimental|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
32957053|NCT03988595|Experimental|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
32957054|NCT03988595|Experimental|aerobic training 375 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
32957055|NCT03985527|Experimental|Transvenous nerve stimulation|
32957056|NCT03983850|No Intervention|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
32957057|NCT03983850|Experimental|Phase I Dose De-escalation|PTCy at de-escalating doses (25 mg/kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess for safety and determine Phase II dose (up to 12 evaluable patients)
32957058|NCT03983850|Experimental|Phase I duration de-escalation of MMF|MMF at de-escalating duration (days +5 to +18 only, no MMF))
32957059|NCT03983850|Experimental|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in a small pilot (up to 5 evaluable patients) for comparative data
32957060|NCT03983850|Experimental|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) to assess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
32957061|NCT03983850|Experimental|Phase II efficacy of reduced duration MMF|MMF at duration identified from de-escalation evaluation.
32957062|NCT03969563|Experimental|MBSR|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
32957063|NCT03969563|Active Comparator|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
32957064|NCT03969446|Experimental|Cohort I Arm I (pembrolizumab, decitabine)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
33103855|NCT05142436|No Intervention|Cohort 6: Usual Brand Cigarettes|Subjects randomized to continue to smoke usual brand cigarettes
33103856|NCT05142436|No Intervention|Cohort 7: Assisted Smoking Cessation|Subjects assigned to assisted smoking cessation
32738864|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the object (doll or cube) to the patient.~The nurse leaves the patient alone with the object.~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the object."
32747292|NCT05538507|Active Comparator|Group V MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given smart soup
32840179|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
33103857|NCT05142436|No Intervention|Cohort 8: Never-Smokers|Never-smokers
32840180|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
32840181|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
32840182|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
32840183|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
32840184|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
32840185|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
32840186|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
32840187|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
32840188|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
32840189|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
32840190|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
32840191|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
32840192|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
32840193|NCT04078698|Experimental|Treatment with the IgG immunoadsorbers GLOBAFFIN® or LIGASORB®|Treatment with the IgG immunoadsorbers GLOBAFFIN® or LIGASORB® in clinical routine according to their intended use.
32840194|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
32840195|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
32840196|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
32840197|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
32840198|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
32840199|NCT04477980||Culture positive empyema|Patients with empyema confirmed by a positive pleural fluid culture, irrespective of its gross fluid appearance
32840200|NCT04477980||Culture negative empyema|Patients with empyema confirmed by a gross pus appearance AND a negative pleural fluid culture
32840201|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840202|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840203|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840204|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840205|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840206|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
32840207|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
32840208|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
32840209|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840210|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840211|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840212|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840213|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840214|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
32840215|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
33327340|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
32957065|NCT03969446|Experimental|Cohort I Arm II (pembrolizumab, decitabine, venetoclax)|Patients with pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10 or 1-5. Patients who achieve a CR receive decitabine on days 1-5. Patients also receive venetoclax PO QD on days 1-14. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
32957066|NCT03969446|Experimental|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
32957067|NCT03968991|Active Comparator|Healthy volunteer group|male or female healthy volunteers
32957068|NCT03968991|Experimental|Subjects with acquired visual impairment|visual acquired disability
32957069|NCT03968991|Experimental|Subjects with congenital visual impairment|Visual congenital disability
32957070|NCT03968107||Women with a pregnancy of at least 31 weeks|All pregnant women with a pregnancy of at least 31 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures, will be proposed inclusion in the study.
32957071|NCT03950336|Other|"Prebiotics + Low n-6 PUFA Diet"|A combination of beta-fructans (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
32957072|NCT03950336|Other|"Placebo + Control Diet."|A combination of maltodextrin (5g/day) and a control diet following the guidelines of Canada's Food Guide.
32957073|NCT03944772|Experimental|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
33405703|NCT05198973|Experimental|Bumblebee Breath group|Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face. this group will be 28 patients to receive half an hour daily for ( 1 month)
33405704|NCT05198973|No Intervention|control group|this group (28 patients) will receive no training
33405705|NCT05720715|Active Comparator|group A|receive cyclosporine eye drops together with prednisolone eye drops.
33405706|NCT05720715|Placebo Comparator|group B|receive topical prednisolone with placebo eye drops (tear replacement).
33405707|NCT05410353|Experimental|Active Intervention Group|Look AHEAD Intervention program adapted for delivery via Health IT modified for cultural and social norms applicable to under-served population groups
33405708|NCT05410353|Active Comparator|Comparison Group|Look AHEAD DSE (Diabetes Support and Education) Comparison Group intervention adapted to be delivered via the EHR patient portal with telephonic support
33405709|NCT05198661|Other|Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient|patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis
33405710|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
33405711|NCT02310867|Experimental|Hand transplant with Belatacept|
33405712|NCT05406453|No Intervention|Madagascar standard of care|"Description :~Passive case finding,~Smear microscopy testing, and~household contact tracing"
33405713|NCT05406453|No Intervention|Best practices|"Description :~Active case finding,~Smear microscopy~Xpert MTB/RIF Ultra testing (= rapid test by Genexpert for tuberculosis (TB) and rifampin resistance (RIF-R)) and~household contact tracing"
33405714|NCT05406453|Experimental|Novel intervention|"Description :~Active case finding,~Smear microscopy~Xpert MTB/RIF Ultra testing and~household contact tracing"
33405715|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
33405716|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
33405717|NCT05758857|Experimental|Guidelines-based physical activity|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
33405718|NCT05758857|Experimental|Guidelines-based physical activity and healthy eating|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
33405719|NCT05758857|Placebo Comparator|Stretching exercise|Whole-body stretching
33405720|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
33405721|NCT05296083|Experimental|G3P-01 50mg Dose Treatment Period 1|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period one dose will be 50mg of IP.
33405722|NCT05296083|Experimental|G3P-01 500mg Dose Treatment Period 2|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period two dose will be 500mg of IP.
33405723|NCT05296083|Experimental|G3P-01 1000mg Dose Treatment Period 3|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period three dose will be 1000mg of IP.
33405724|NCT05296083|Experimental|G3P-01 2000mg Dose Treatment Period 4|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period four dose will be 2000mg of IP.
33405725|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
33405726|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
32957074|NCT03944772|Experimental|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
33319669|NCT04952714||Dynamic Cohort|"Initially, participants who meet the inclusion criteria will be recruited to assemble a cohort of patients with sepsis and those who develop sepsis-induced acute kidney injury will be observed.~Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device (Baxter), at a dose of 25 mL / Kg of PrismaSate dialysis solution (Baxter) and the removal filter oXiris® cytokines (Baxter) vs. the standard filter, for patients who require it, in the presence of a confirmed diagnosis of acute renal failure.~Hemodynamic and ventilatory parameters will be monitored every 24 hours, and inflammatory parameters every 48 hours. A follow-up will be done at 28 days to establish mortality."
33319670|NCT03970616|Experimental|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
32840216|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
32840217|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
32840218|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
32840219|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
32840220|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
32840221|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
32840222|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
32840223|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
32840224|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
32840225|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
32840226|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
32840227|NCT02039310||≥ 65 years / opts for radical cystectomy|
32840228|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
32840229|NCT03111966||Spanish cohort with HCV treated with DAA|
32840230|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
32840231|NCT02341170|No Intervention|Observation|Observation
32840232|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
32840233|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
32840234|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
32840235|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
32840236|NCT05254860|Experimental|Interrupted suture|
32840237|NCT05254860|Experimental|Continous suture|
32840238|NCT05254704||Group - assessment of reproductibility of TEX-Q-F|"This groupe will fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation (without further information) This group will be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
32840239|NCT05254704||Group - assessment of the responsiveness of the questionnaire after information|"This group will also fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation and AFTER a phone interview (about 15 minutes) with an experienced practitioner to provide appropriate information concerning the anesthesia and the postoperative rehabilitation process.~This group will also be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
32840240|NCT05254470||Pre-Low Intensity Continuous Ultrasound Treatment|Routine care for pain alleviation, range of motion and ability to return to work with traditional therapies from rehabilitation.
32840241|NCT05254470||Post-Low Intensity Continuous Ultrasound Treatment|Routine care of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies.
32840242|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
32840243|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
32840244|NCT02343978|Experimental|KWA-0711 High dose|
32840245|NCT02343978|Experimental|KWA-0711 Low dose|
32840246|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
32840247|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
32840248|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
32840249|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
32840250|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
32957075|NCT03944772|Experimental|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
33319671|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
33319672|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
33319673|NCT05534126|Active Comparator|Stellate Ganglion Block|
32840251|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
32840252|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;~Health lifestyles educational strategies;~Instruct and promote school physical education;~The monitoring and instruction of obesity related behaviors (focus group)"
32840253|NCT02343588|No Intervention|Receive no intervention|Usual practice
32840254|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
32840255|NCT04823676|Active Comparator|Probiotic composition|A capsule containing a mix of probiotic strains (1.5 x 10^9 CFU/capsule ) administered once daily for 4 months
32840256|NCT04823676|Placebo Comparator|Placebo|A capsule containing placebo administered once daily for 4 months
32840257|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
32840258|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
32840259|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
32840260|NCT02332356|No Intervention|observation step up|
32840261|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
32840262|NCT02332356|No Intervention|observation step down|
32840263|NCT05254080|Experimental|Active taVNS then Sham taVNS|Participants will receive active then sham (placebo) ear stimulation.
32840264|NCT05254080|Experimental|Sham taVNS then Active taVNS|Participants will receive sham (placebo) then active ear stimulation.
32840265|NCT04766268|Experimental|PAE group|Patients with BPH with moderate lower urinary tract symptoms fulfilling the inclusion criteria and exclusion criteria will be enrolled in the trial to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
32840266|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
32840267|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
32840268|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
32840269|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
32840270|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
32840271|NCT02337114|Other|Comparison group|Treatment as Usual
32840272|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
32840273|NCT02340858|No Intervention|Control|The patients without treatment
32840274|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
32840275|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
32840276|NCT02332044|Experimental|Erdosteine 300mg|
32840277|NCT02332044|Experimental|Bepotastine besilate 10mg|
32840278|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
32840279|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
32840280|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
32840281|NCT02336880|No Intervention|Control group|Care as usual
32840282|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
32840283|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
32840284|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
32840285|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
32840286|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis~Patients treated with curative intent (stage I-IVb)"
32840287|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour~Patients treated with curative intent (stage I-IVb)"
32957076|NCT03944772|Experimental|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
33319674|NCT05534126|Placebo Comparator|Placebo|
33319675|NCT01301690||Neck masses|Neck mass received US and US-FNA
32840288|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
33327341|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
32840289|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
32840290|NCT05253924||Preterm children (PT)|gestational age at birth <37
32840291|NCT05253924||Full-term children (FT)|gestational age at birth ≥ 37 weeks
32840292|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
32840293|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
32840294|NCT05253768|Experimental|intervention|Patients who receive a fecal microbiota transplantation via a nasointestinal tube.
32840295|NCT05253768|Placebo Comparator|placebo|Patients who receive a placebo FMT via a nasointestinal tube.
32840296|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
32840297|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
32840298|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
32840299|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
32840300|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
32840301|NCT05253612|Other|ISPOCD test battery|The participants will be randomized to start with ISPOCD test battery followed by Mindmore digitalized cognitive test battery with 2 weeks passing between the cognitive testing for both groups
32840302|NCT05253612|Other|Mindmore digitalized cognitive test battery|Strating with Mindmore digitalized cognitive test battery followed by ISPOCD test battery, with 2 weeks passing between the cognitive testing for both groups
32840303|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
32840304|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
32840305|NCT02340624|No Intervention|Control group|No intervention(control group)
32840306|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
32840307|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
32840308|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
32840309|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
32840310|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
32840311|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
32840312|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
32840313|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
32840314|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
32840315|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
32840316|NCT04630938|Active Comparator|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
32840317|NCT04630938|Active Comparator|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
32840318|NCT04630938|Placebo Comparator|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
32840319|NCT04604262|Experimental|Treatment Group|Waterpik® in addition to the manual toothbrush
32840320|NCT04604262|No Intervention|Control|Manual toothbrush
32840321|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
32840322|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
32840323|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
32840324|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
32840325|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
33103858|NCT04960176|Active Comparator|Acupuncture Group|Acupuncture will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
32957077|NCT03944772|No Intervention|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
32957078|NCT03944772|Experimental|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
32957079|NCT03944772|Experimental|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
32957080|NCT03944772|Experimental|Module 7: Etoposide + Durvalumab + Carboplatin or Cisplatin|The patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.
32957081|NCT03944772|Experimental|Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.|The patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).
32957082|NCT03944772|Experimental|Module 9: Osimertinib + Selumetinib|The patients in this group will receive osimertinib taken in combination with selumetinib
32957083|NCT03944772|Experimental|Module 10: Osimertinib + datopotamab deruxtecan|The patients in this group will receive osimertinib taken in combination with datopotamab deruxtecan.
32957084|NCT03934437|Experimental|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for patient supporters, to help facilitate communication.
32957085|NCT03934437|Active Comparator|LTC|Existing linkage to care and retention (LTCR) services which are standard-of-care
32957086|NCT03904264|Experimental|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
32747293|NCT05538507|Sham Comparator|Group VI MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given placebo
32957087|NCT03904264|No Intervention|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
32957088|NCT03903692|Experimental|Marine polysaccharide dressing|
32957089|NCT03903692|Active Comparator|Carboxymethylcellulose dressing|
32957090|NCT03890731|Other|Adult patients|Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
32957091|NCT03886610||Healthy controls|Individuals without spinal cord injury
32957092|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
32957093|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
32957094|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Patients receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
32957095|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
33319676|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
33319677|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
33319678|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
33319679|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
33319680|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
33319681|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
33319682|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
32957101|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
32957102|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32957103|NCT03831711|Experimental|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
32957104|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
32957105|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
32957106|NCT03809624|Experimental|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
32747294|NCT05538429|Experimental|ESPB&SAPB|erector spinal plane block combined with serratus anterior plane block
32957107|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
32957108|NCT03809624|Experimental|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
32957109|NCT03809624|Experimental|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
32957110|NCT03809624|Experimental|Expansion Cohort Nasopharyngeal or Oropharyngeal Carcinoma|Patients with head and neck squamous cell carcinoma (NPC or OPC) will be treated with single-agent INBRX-105 at either the MTD or RP2D.
32957111|NCT03809624|Experimental|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
33405727|NCT05757219|Experimental|Pre-Modulation Treatment|Participants will receive itacitinib 200 mg PO QD beginning at time of apheresis approximately 4-6 weeks prior to CAR-T-cell therapy and will continue until Day 30 (30 Days Post-CAR-T-cell therapy)
33405728|NCT02966834|Placebo Comparator|Placebo|Participants will receive matching placebo
33405729|NCT02966834|Experimental|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
33405730|NCT02966834|Experimental|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
33405731|NCT02966834|Experimental|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
33405732|NCT02966834|Experimental|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
33405733|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
33405734|NCT05755815|Active Comparator|Group A (RLB block)|Ultrasound-guided RLB block will be performed under strict aseptic precautions with patient turned to the lateral position.
33405735|NCT05755815|Active Comparator|Group B (Peritoneal block)|Peritoneal block will be performed under strict aseptic precautions before giving an incision for the ports, and at the end of surgery and before the removal of trocars
33405736|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
32840326|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
32840327|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
32840328|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
32840329|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
32840330|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
32840331|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
32840332|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
32840333|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
32840334|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
32840335|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
32840336|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch"
32840337|NCT04594746|Experimental|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
32840338|NCT04594746|Placebo Comparator|Placebo|Oral placebo
32840339|NCT02790138|Placebo Comparator|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
32840340|NCT02790138|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
32840341|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
32840342|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
32840343|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
32840344|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
32840345|NCT04492800|Other|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
33405737|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
33405738|NCT05198271|Experimental|Management of risk factors|"-6 month program for reduction /correction of risk factors in patient with active RA :~Smoking cessation~weightloss~Increased physical activity~Periodontal treatment~Decreased anxiety"
33405739|NCT04052984|Experimental|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
33405740|NCT04052984|No Intervention|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
32898598|NCT00103376|Experimental|Part A: Velcade|Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
32898599|NCT00103376|Experimental|Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist|Patient will start Part B after completing Part A or may be enrolled to part B only.
33405741|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
33405742|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
32840346|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
32840347|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
32840348|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
32840349|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:~(CR FB, CR RP, PS FB, PS RP)."
32840350|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
33327342|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
32840351|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
32840352|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
32840353|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
32840354|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
33405743|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
32840356|NCT00397839|Placebo Comparator|Placebo|
32840357|NCT00397839|Experimental|Ibandronate|
32840358|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
32840359|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
32840360|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
32840361|NCT03104946||Bronchopulmonary Dysplasia|
32840362|NCT03104946||Retinopathy|
32840363|NCT03104946||Severe Retinopathy|
32840364|NCT03104946||Neonatal Necrotizing Enterocolitis|
32840365|NCT03104946||Brain injury|
32840366|NCT03104946||sepsis|
32840367|NCT03104946||Patent Ductus Arteriosus|
32840368|NCT03104946||Respiratory Distress Syndrome|
32840369|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
32840370|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
32840371|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
32840372|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
32840373|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
32840374|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
32840375|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
32840376|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
32840377|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
32840378|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
32840379|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
32840380|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
32840381|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
32840382|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
32840383|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
32840384|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
32747295|NCT05538429|Active Comparator|TPVB|thoracic paravertebral block
32747296|NCT05591235|Active Comparator|Metformin|
32747297|NCT05591235|Active Comparator|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|
32747298|NCT05591235|Active Comparator|Dapagliflozin|
32747299|NCT04425837|Active Comparator|Standard care alone|
32747300|NCT04425837|Experimental|SARS-CoV-2 convalescent plasma treatment plus standard care|
32747305|NCT05589519|Experimental|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition for the rehabilitation of the partial edentulous.
32747306|NCT05538351||Fluid assessment|All patients enrolled in this study will have a clinical assessment to identify hydration status, patient reported signs and symptoms of hydration and Bioimpedance using the Body composition Monitor (BCM).
32747307|NCT05545527||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
32747308|NCT05545527||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
32747309|NCT05545527||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
32747310|NCT05538195|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x10^6 cells/kg
32747311|NCT05538195|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
32747312|NCT05537961|Experimental|Mindfulness|Weekly mindfulness instruction embedded in classroom setting
32747313|NCT05537961|No Intervention|No Intervention|Classroom setting completed as usual
32747314|NCT05523063||Breast cancer patients followed at CAMI|The trial population concerns all adult patients with breast cancer followed at the Croix-Rousse hospital, who have been under care for less than 3 months or who are going to be treated at the CAMI.
32747315|NCT05537805|Experimental|proximal tubal occlusion|Infertile patients that were referred to our unit for uni or bilateral proximal tubal occlusion demonstrated by HyFoSy or hysterosalpingography.
32747316|NCT05537649|Active Comparator|Oatmeal porridge|Cold-stored oatmeal porridge (38 g oats) and stored for 24 h at 4 degrees Celsius
32747317|NCT05537649|Active Comparator|Oatmeal porridge treated with amylomaltase|Cold-stored oatmeal porridge (38 g oats) treated with 30 enzyme units/g oats of amylomaltase and stored for 24 h at 4 degrees Celsius
32747318|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
32747319|NCT05417217|Active Comparator|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
32747320|NCT05417217|Experimental|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
32747321|NCT05389839|Experimental|Wechat program guidance group|Wechat program guidance group using insulin dose calculator
32747322|NCT05389839|Active Comparator|clinical experience treatment group|clinical experience treatment group using physician experience
32747323|NCT05389449|Experimental|Danicopan|Participants will receive their last dose of danicopan from the parent study the night prior to Day 1 of this LTE study and will continue daily treatment with danicopan together with their background C5i therapy.
32747324|NCT05361993|Experimental|Biofeedback therapy|three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training (using the Infiniti3000A biofeedback system Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
32747325|NCT05361993|Active Comparator|Drug therapy|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
32747326|NCT05355207|Experimental|TRL1068|all subjects will receive a single intravenous dose of 15 mg/kg of TRL1068 on Day 1
32747327|NCT05315193|Experimental|Structured In-patient and Home plan|Structured In-patient and Home plan
32747328|NCT05315193|Placebo Comparator|Conventional therapy|Conventional protocol as per guidelines
32747329|NCT05302167|Experimental|Feasibility/ acceptability|
32747330|NCT05545215||Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
32747331|NCT04425681|Experimental|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
33319683|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
32840385|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
32840386|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
32840387|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
32840388|NCT04681443|Active Comparator|Successful treatment|Patients with successfully treated pilonidal sinus disease
32840389|NCT04681443|Active Comparator|Treatment failure|Pilonidal sinus disease patients with treatment failure
32840390|NCT02339298|Active Comparator|Music group|music application
32840391|NCT02339298|Sham Comparator|Control group|only headphones
32840392|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
32840393|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
32840394|NCT04615299|Active Comparator|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
32840395|NCT04615299|Sham Comparator|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
32840396|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
32840397|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
32840398|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
32840399|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
32840400|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
32840401|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
32840402|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
32840403|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
32840404|NCT00363675|Experimental|All study participants|Children with hand burns
32840405|NCT02330952|Experimental|Prednisone|
32840406|NCT02330952|Placebo Comparator|Placebo|
32840407|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
32840408|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
32840409|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
32840410|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
32840411|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
32840412|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
32840413|NCT02040792|Placebo Comparator|Placebo|Placebo
32840414|NCT02040792|Experimental|44 mcg|TD-4208
32840415|NCT02040792|Experimental|88 mcg|TD-4208
32840416|NCT02040792|Experimental|175 mcg|TD-4208
32840417|NCT02040792|Experimental|350 mcg|TD-4208
32840418|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
32840419|NCT02338830|No Intervention|No treatment group|Women received no treatment
32840420|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
33405744|NCT03648866||Patients|interview patients who have participated in compassion rounds
32840421|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
32840422|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
32840423|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
32840424|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
32840425|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
32840426|NCT04271241|No Intervention|Control (Ctrl)|Ctrl group di not undergo any training
32840427|NCT04271241|Experimental|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
32840428|NCT04271241|Experimental|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
32840429|NCT04271241|Experimental|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
32840430|NCT02338674|Experimental|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
32840431|NCT02338674|Active Comparator|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
32840432|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
32840433|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
32840434|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
32840435|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
32840436|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
32840437|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
32840438|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
32840439|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
32840440|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
32840441|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
32840442|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
32840443|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
32840446|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
32840447|NCT04458207|Experimental|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
32840448|NCT04458207|Active Comparator|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
32840449|NCT04270929|Experimental|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
32840450|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
32840451|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
32840452|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
32840453|NCT01793961|Other|"Healthy volunteers"|no smokers
32840454|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
32840455|NCT04417179|Experimental|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
32840456|NCT04417179|Experimental|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
32840457|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
32840458|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
32840459|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
32840460|NCT04410627|No Intervention|Standard of Care|
32840461|NCT04410627|Experimental|Standard of Care + HoPE|
32840462|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
33319684|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
33319685|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
32840463|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
32840464|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
33319686|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
33319687|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
33319688|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
32840465|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
32840466|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
32840467|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
32840468|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
32840469|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
32840470|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
32840471|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
32840472|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
32840473|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
32898600|NCT00042224|Experimental|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
32840474|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
32840475|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
32840476|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
32840477|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
32840478|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
32840479|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
32840480|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
32840481|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
32840482|NCT02335398|Experimental|methadone|single group
32840483|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
32840484|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
32840485|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
32840486|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
32840487|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
32840488|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
32840489|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
32840490|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
32840491|NCT02330484|No Intervention|Group with no incentives|
32840492|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
32840493|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
32840494|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
32840495|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
32840496|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
32957112|NCT03809624|Experimental|Combination Expansion Cohort Non-small Cell Lung Cancer|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
32957113|NCT03809624|Experimental|Combination Expansion Cohort Melanoma|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
33327343|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
32840497|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.~Clinical and angiographic exclusion criteria as stated in the study protocol."
32840498|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:~Symptoms of ischaemia~Development of pathologic Q waves in the electrocardiogram (ECG)~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.~Identification of an intracoronary thrombus by angiography.~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
32840499|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
32840500|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
32840501|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
32840502|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
32840503|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
32840504|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
32840505|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
32840506|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
32840507|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
33103859|NCT04960176|Sham Comparator|Non-Invasive Sham Acupuncture Group|Non-invasive sham acupuncture using a blunted needle will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
32840508|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
32840509|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
32840510|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
32840511|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
32840512|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
32840513|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
32840514|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
32840515|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
32840516|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
32840517|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
32840518|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
32840519|NCT02337582|Active Comparator|Intervention|
32840520|NCT02337582|Other|Control|
32840521|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
32840522|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
32840523|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
32898601|NCT00042224|Active Comparator|2 Clozapine|Clozapine for 8 weeks
33319689|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
32957114|NCT03809624|Experimental|Combination Expansion Cohort Cohort PD-L1 Positive Basket|CPI-relapsed/refractory patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
32957115|NCT03809624|Experimental|Combination Expansion Cohort CPI Naive Non-small Cell Lung Cancer|CPI naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
32739511|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
32957116|NCT03809624|Experimental|Combination Expansion Cohort CPI Naive HNSCC|CPI naive patients (PD-L1 IHC >50%) will be treated with INBRX-105 in combination with Pembrolizumab.
32957117|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
32957118|NCT03808662|Active Comparator|Arm 2:Standard of Care|
33319690|NCT05624294|Experimental|2mg CS0159|One tablet daily for seven days.
33319691|NCT05624294|Experimental|4mg CS0159|Two tablet daily for seven days.
32957119|NCT03789591|Active Comparator|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
32957120|NCT03789591|Experimental|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
32957121|NCT03783026|Experimental|Apremilast|Participants will receive apremilast 30 mg twice a day for 48 weeks.
32957122|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
32957123|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
32957124|NCT03768063|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawl of study consent, unacceptable toxicity, pregnancy, patient non-compliance, or study termination by the Sponsor, whichever occurs first.
32957125|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
32957126|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
32957127|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
32957128|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
32957129|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
32957130|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
32957131|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
32957132|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
33319692|NCT05624294|Experimental|6mg CS0159|Three tablet daily for seven days.
33319693|NCT05644730|Experimental|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
33319694|NCT03797768|Experimental|Intervention|
33319695|NCT03797768|No Intervention|Control|
33319696|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
33319697|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
33319698|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
33319699|NCT05528978||Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
33319700|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
33405745|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
32840524|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
32840525|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
32840526|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
32840527|NCT04271319|Experimental|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
32840528|NCT04271319|Sham Comparator|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
32840529|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
32840530|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
32840531|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
32840532|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
32840533|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
32840534|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
32840535|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
32840536|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
32840537|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
32840538|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
32840539|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
32840540|NCT02334774|Experimental|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
32840541|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
32840542|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
32840543|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
32840544|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
32840545|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
32840546|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
32840547|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
32840548|NCT02334540|Other|purses or a calorie/protein matched smoothie|
32840549|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
32840550|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
32840551|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
32840552|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
32840553|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
32840554|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
32840555|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
32840556|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
32840557|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
33103860|NCT04768010|Experimental|Misoprostol|Participants will receive 100-200 micrograms of oral misoprostol twice daily.
32840558|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
32840559|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
32840560|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
32840561|NCT03144882|Placebo Comparator|placebo|control group
32840562|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
32840563|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
32840564|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
32840565|NCT04210245|Experimental|Daily 0.3 mg dose|Administered by subcutaneous injection
32840566|NCT04210245|Experimental|Daily 1 mg dose|Administered by subcutaneous injection
32840567|NCT04210245|Experimental|Daily 3 mg dose|Administered by subcutaneous injection
32840568|NCT04210245|Placebo Comparator|Placebo|Administered by subcutaneous injection
32840569|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.~Intervention: PET CT 18 FDG"
32840570|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
32840571|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
32840572|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
32840573|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
32840574|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
32840575|NCT04138173|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
32840576|NCT04138173|No Intervention|Usual care group|Usual care
32840577|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
32840578|NCT02034396|Other|Blood draw|One blood draw at enrollment
32840579|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
32840580|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
32840581|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
32840582|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
32840583|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
32840584|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
32840585|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
32840586|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
32840587|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
32840588|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
32840589|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
32840590|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
32840591|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
32840592|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
32840593|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
32840594|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
32957133|NCT03695380|Experimental|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
32957134|NCT03695380|Experimental|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
32957135|NCT03695380|Experimental|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
32957136|NCT03695380|Experimental|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
32957137|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
33405746|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
33405747|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
32957138|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
32957139|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
32957140|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
32957141|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
32957142|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
32957143|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks."
32957144|NCT03635112|Placebo Comparator|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
32957145|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
32957146|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
32957147|NCT03620409||Healthy subjects|Healthy controls
32957148|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
32957149|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
32957150|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
32957151|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
32957152|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
33103861|NCT05466513|Experimental|Experimental Group|Facial tactile stimulation was applied for 2 minutes.
32840595|NCT02329236||children with constitutional growth delay|
32840596|NCT02329236||children with Familial short stature|
32840597|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
32840598|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
32840599|NCT02328768|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 8-24 hours every day until the patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
32840600|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
32840601|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
32840602|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
32840603|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
32840604|NCT04477590|No Intervention|NO EXERCISE TRAINING|25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
32840605|NCT04477590|Experimental|EXERCISE TRAINING FED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
32840606|NCT04477590|Experimental|EXERCISE TRAINING FASTED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
32840607|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
32840608|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
32840609|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
32840610|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
32840611|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
32840612|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
32840613|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
32840614|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
32840615|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
32840616|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
32840617|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
32840618|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
32840619|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
32840620|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
32840621|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
32840622|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
32840623|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
32840624|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
32840625|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
32840626|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
32840627|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.~The conditioning regimen will include:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
32840628|NCT02039934|Experimental|high intensity interval training|
32840629|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
32840630|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
32840631|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
32840632|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
32840633|NCT03111654|Other|Patients with pericardial closure of the auricle|
32840634|NCT03111654|Other|Patients without closure of the auricle|
32840635|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
32840636|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
32840637|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
32840638|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
32840639|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
32840640|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
32840641|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
32840642|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
32840643|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
32840644|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
32840645|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
32840646|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
32840647|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
32840648|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
32840649|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
32840650|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
32840651|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
32840652|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
32840653|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
32840654|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
32840655|NCT03842358|Experimental|Phase I - Training Set|"20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data~A hand-held hybrid probe will be used for the scans"
32840656|NCT03842358|Experimental|Phase 2: Prospective Trial|"US-DOT (US/NIR) Imaging Exam~Breast biopsy or FNA performed (standard of care)~A hand-held hybrid probe will be used for the scans"
32840657|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
32840658|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
32840659|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
32840660|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
32840661|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
32840662|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
32840663|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
32840664|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
32840665|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
32840666|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
32840667|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
32840668|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
32840669|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
32840670|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
32840671|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
32840672|NCT05076942|Experimental|Chemoradiation|Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29
32840673|NCT03145116|Experimental|509|
32840674|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
32840675|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
32840676|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
32840677|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
32840678|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
32840679|NCT03804996|Experimental|TG-1101|"Arm Description: TG-1801 and ublituximab will be administered once every 4 weeks (28-day cycle) for up to 6 cycles followed by TG-1801 monotherapy.~To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy."
32840680|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.~All participants will receive a FLT PET/MR scan."
32840681|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
32840682|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
32840683|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
32840684|NCT03144024|Experimental|band|
32840685|NCT03144024|Active Comparator|Rigid ring|
32840686|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
32840687|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
32840688|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
32840689|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
32840690|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
32840691|NCT02333448||patients with suspected invasive candidiasis|
32840692|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
33405748|NCT04009382|Experimental|Baduanjin|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
33319701|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
33405749|NCT04009382|Active Comparator|Cognitive Fitness Program|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
32957157|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
32957158|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
32957159|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
32957160|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
32957161|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
32957162|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
32957163|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
32957164|NCT03558945|Experimental|Personalized neoantigen vaccine|Patients will receive radical resection surgery and at least one circle of post-operative chemotherapy. After chemotherapy, personalized neoantigen vaccines will be administered subcutaneously.
32957165|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
32957166|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
32957167|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
32957168|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
32957169|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
32957170|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
32957171|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
32957172|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
33319702|NCT03880292|Other|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
33319703|NCT01302236|Experimental|Eplerenone|
33319704|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
33319705|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
33319706|NCT03797534|No Intervention|Standard anticoagulant group|
33319707|NCT03797534|Experimental|Bayesian model group|
33319708|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
33319709|NCT03797300|Experimental|Primary|
33319710|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
33319711|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
33319712|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
33319713|NCT05651438||E-Athletes|E-Athletes who are over the age of 18, have participated in professional matches for at least one year, and have an E-sports license were evaluated.
33319714|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
33319715|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
33319716|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
33319717|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
33319718|NCT03812744|Experimental|WCCE|
33319719|NCT03812744|Placebo Comparator|Placebo|
33319720|NCT05651282|Experimental|Progesterone Challenge Test|10-day course of medroxyprogesterone acetate (Provera) 10 mg per os (po) daily.
33319721|NCT05501522|Experimental|Primary series of mRNA-1273 manufactured by ModernaTX, Inc.|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
33319722|NCT05501522|Placebo Comparator|Primary series of mRNA-1273 manufactured by ModernaTX, Inc. (Placebo)|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
33319723|NCT05501522|Experimental|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
33319724|NCT05501522|Placebo Comparator|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca (Placebo)|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
33319725|NCT05501522|Experimental|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
33405750|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
33405751|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
33405752|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
33405753|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
33405754|NCT03647930|No Intervention|Control|No MPH
32840693|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
32840694|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
32840695|NCT05076474|Experimental|TR1R2|T(Orlistat 60-mg) R1(Alli 60-mg) R2（Alli 60-mg×2）
32840696|NCT05076474|Experimental|R2TR1|R2（Alli 60-mg×2） T(Orlistat 60-mg) R1(Alli 60-mg)
32840697|NCT05076474|Experimental|R1R2T|R1(Alli 60-mg) R2（Alli 60-mg×2） T(Orlistat 60-mg)
32840698|NCT05076318|Experimental|Alanine-infusion|Alanine infusion taking place over a 3 hour period while monitorering metabolic changes in blood samples before and after dialysis
32840699|NCT05076240||Adults with ventilator associated pneumonia in COVID-19 ARDS|Patient hospitalized in intensive care unit for acute respiratory distress related to a Sars-Cov2 infection having contracted ventilator associated pneumonia. The diagnosis was made by culture but also with a FilmArray® multiplex PCR analysis.
32840700|NCT05076162||Group 1|Serum 25(OH)D levels <12 ng/ml
32840701|NCT05076162||Group 2|Serum 25(OH)D levels ≥12 ng/ml
32840702|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
32840703|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
32840704|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
32840705|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
32840706|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
32840707|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
32840708|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
32840709|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
32840710|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
32840711|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
32840712|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
32840713|NCT02035566|No Intervention|Usual Care|
32840714|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
32840715|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
32840716|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
32840717|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
32840718|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
32840719|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
32840720|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
32840721|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
32840722|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
32840723|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
33405755|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
32840724|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
32840725|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
32840726|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
32840727|NCT03143868|Experimental|Aerobic Exercise|
32840728|NCT03143868|Experimental|Resistance Exercise|
32840729|NCT03143868|Placebo Comparator|No Exercise|
32840730|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
32840731|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
32840732|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
32840733|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
32840734|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
32840735|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
32840736|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
32840737|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
32840738|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
32840739|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
32840740|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
32840741|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
32840742|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
32840743|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
32840744|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
32840745|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
32840746|NCT04869930||Autism Spectrum Disorder (ASD)|Early childhood (pre-diagnosis) OR existing diagnosis of moderate/severe ASD
32840747|NCT04869930||Fragile X Syndrome (FXS)|Existing diagnosis of Fragile X Syndrome
32840748|NCT04869930||Healthy Controls|No diagnosed chronic conditions
32840749|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
32840750|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
32840751|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
32840752|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
32840753|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
32840754|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
32840755|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
32840756|NCT05081778||Obese patient following a medical course|
32840757|NCT05081778||Obese patient following a surgical course|
32840758|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
32840759|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
32840760|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
32840761|NCT05077878||normal|Patients with non-orthodontic treatment and have no root resorption
32840762|NCT05077878||mild to moderate|Patients with orthodontic treatment and have mild to moderate root resorption
32840763|NCT05077878||severe|Child patients with non-orthodontic treatment and have severe root resorption
33405756|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
33405757|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
33405758|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
33405759|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
33405760|NCT05284916||patients admitted at Sohag University Hospital diagnosed with liver diseases|The study will be conducted in two stages. The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance
33405761|NCT05702541|Other|LID# 2223194 MF, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
33405762|NCT05702541|Other|AOHG MF, then LID# 223194 MF|Lotrafilcon B multifocal contact lenses worn first, followed by lehfilcon A multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
33405763|NCT05701527|Experimental|Part A-Cohort 1|Patients will be administered Dose 1 of EBC-129 as a monotherapy.
33405764|NCT05701527|Experimental|Part A-Cohort 2|Patients will be administered Dose 2 of EBC-129 as a monotherapy.
33405765|NCT05701527|Experimental|Part A-Cohort 3|Patients will be administered Dose 3 of EBC-129 as a monotherapy.
33405766|NCT05701527|Experimental|Part A-Cohort 4|Patients will be administered Dose 4 of EBC-129 as a monotherapy.
33405767|NCT05701527|Experimental|Part A-Cohort 5|Patients will be administered Dose 5 of EBC-129 as a monotherapy.
33405768|NCT05701527|Experimental|Part B|Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.
32840764|NCT05077644|Other|Participants who use Stella App|Participant experience in using the mobile application and EPDS results
32840765|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
32840766|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
32840767|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
32840768|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
32840769|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
32840770|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
32840771|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
32840772|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
32840773|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
32840774|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
32840775|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
32840776|NCT05081310|Experimental|SVC arm|Patients who will receive SVC isolation by the means of cryoballoon after the PVI procedure
32840777|NCT05081310|Active Comparator|PVI arm|Patients who will receive convectional cryoballoon PVI procedure
32840778|NCT05081076|Active Comparator|Glazed surface|One side of the zirconia crown will receive glazed surface treatment according to standard laboratory procedure and manufacturer's recommendations (Ceramill Stain & Glaze Kit).
32840779|NCT05081076|Experimental|Polished surface|The contralateral side of the zirconia crown will receive polished surface treatment (polishing rubbers kit in the sequence indicated by the manufacturer - EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
32840780|NCT03838692|Experimental|Ponatinib Arm|Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
32840781|NCT03774186|Active Comparator|Sensor-augmented pump therapy (SAPT)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor but there will be no automated insulin adjustments made by the system.
32840782|NCT03774186|Experimental|Hybrid closed-loop therapy (HCL)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor with automated insulin adjustments made by the system, but continued meal boluses from the women.
32840783|NCT03505944|Experimental|Treatment|Venetoclax+lenalidomide+rituximab
32840784|NCT05077098|Experimental|ADXS-504|Subjects with Biochemically Recurrent Prostate Cancer will receive ADXS-504 with dose escalation schema
33319726|NCT05501522|Placebo Comparator|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/J&J (Placebo)|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive Placebo.
33327344|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
33327345|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
32840785|NCT05071950|Other|14 days continuous glucose monitoring|The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
32840786|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
32840787|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
32840788|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
32840789|NCT01549873|Active Comparator|Inhaled anesthesia|
32840790|NCT01489111|Experimental|Surgery|
32840791|NCT04106401|Experimental|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
32840792|NCT04106401|Active Comparator|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
32840793|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
32840794|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
32840795|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
32840796|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
32840797|NCT04106245|Experimental|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
32840798|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
32840799|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
32840800|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
32840801|NCT03027115|No Intervention|Control|no treatment
32840802|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
32840803|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
32840804|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
32840805|NCT04749823|Experimental|Blended treatment program|The blended treatment program will consist of a combination of specific active exercises of the neck and general aerobic exercises. This contains a program of 12 weeks, including 9 supervised online sessions supplemented with 1 to 3 individual home exercises sessions without supervision per week, with a total of 3 sessions/week.
32840806|NCT04749823|Active Comparator|Specific strength exercise program|This group will receive an exercise program with specific strength exercises of the neck muscles. Within a 12-week period, patients will receive 9 online treatment sessions under supervision and 1 to 3 additional home exercise sessions without supervision, with a total of 3 sessions/week..
32840807|NCT04749823|Active Comparator|General aerobic exercise program|This control group will perform general aerobic exercises. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
32840808|NCT01515865|Experimental|Midodrine HCl|
32840809|NCT01515865|Placebo Comparator|Placebo|
32840810|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
32840811|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
32840812|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
32840813|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
32840814|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
32840815|NCT04072107|Experimental|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
32840816|NCT04072107|Experimental|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
32840817|NCT04013061||Standard consultation|
32840818|NCT04013061||Pharmacist-anesthesiologist consultation|
32840819|NCT05288049|Experimental|Intervention aiming to enhance cognitive reserve (CR)|The psychological intervention to enhance cognitive reserve (CR) will be conducted in a group format (6-8 individuals). Each session will last approximately 60 minutes. The full psychological intervention will have 12 sessions (1 per week) and will last three months. Moreover, to remind the participants of the contents of the intervention, a follow-up session will be held every two months between the last session of the psychological intervention and the 12-month assessment. Most of the tasks of the psychological intervention will use pen and paper with audiovisual support. However, some sessions will use mobile apps and virtual reality. Virtual reality will be implemented for each patient in the sessions focusing on mindfulness training. The contents of the sessions are adapted to the different ages of the attendees. Groups with adolescents and those with young adults will be run separately.
33319727|NCT05501522|Active Comparator|Primary series of BNT162b2 manufactured by Pfizer/BioNTech|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
32840820|NCT05288049|Active Comparator|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention. After the 12-month assessment, subjects in the support group will be offered the intervention although this will be out of the scope of this study.
32840821|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
32840822|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
32840823|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
32840824|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
32840825|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
32840826|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
32840827|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
32840828|NCT00411411|Experimental|Januvia|Active treatment
32840829|NCT05287815||1|experimental(30 people) groups health education will be given by making a home visit
32840830|NCT05287815||2|control(30 people) no intervention
32840831|NCT05287659|Experimental|VLCKD group|patients followed a structured VLCKD protocol (800Kcal/die)
32840832|NCT05287659|Active Comparator|VLCKD and Physical Training group|patients followed a structured VLCKD protocol (800Kcal/die) combined with interval training (IT), two times a week
32840833|NCT05287659|Active Comparator|LCD and Leucine supplementation group|patients followed a LCD regimen (1000 kcal/day) with supplementation of 18 g whey proteins which 4.1 g of leucine
32840834|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
32840835|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
32840836|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
32840837|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
32840838|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
32840839|NCT01795599|Experimental|mifepristone/misoprostol|
32840840|NCT01795599|Active Comparator|misoprostol|
32840841|NCT01795599|Active Comparator|mifepristone|
32840842|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
32840843|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
32840844|NCT01515319|Experimental|2mg Y242 (Part A)|Y242 single dose, subcutaneous
32840845|NCT01515319|Experimental|7.5mg Y242 (Part A)|Y242 single dose, subcutaneous
32840846|NCT01515319|Experimental|15mg Y242 (Part A)|Y242 single dose, subcutaneous
32840847|NCT01515319|Experimental|30mg Y242 (Part A)|Y242 single dose, subcutaneous
32840848|NCT01515319|Experimental|60mg Y242 (Part A)|Y242 single dose, subcutaneous
32840849|NCT01515319|Experimental|90mg Y242 (Part A)|Y242 single dose, subcutaneous
32840850|NCT01515319|Placebo Comparator|Placebo - Part A|0.9% saline
32840851|NCT01515319|Experimental|60mg Y242 (Part B1)|Y242 single subcutaneous dose, administered once a week for 5 weeks
32840852|NCT01515319|Experimental|90mg Y242 (Part B2-B4)|Y242 single subcutaneous dose, administered once a week for 5 weeks
32840853|NCT01515319|Placebo Comparator|Placebo - Part B|0.9% saline
32840854|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
32840855|NCT04409431|Experimental|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
32840856|NCT04409431|No Intervention|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
33327346|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
32840857|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
32840858|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
33405769|NCT05701527|Experimental|Part C|Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.
32840859|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
32840860|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
32840861|NCT01492361|Experimental|AMR101|AMR101 (icosapent ethyl) + statin therapy, daily
32840862|NCT01492361|Placebo Comparator|Placebo|Placebo + statin therapy, daily
32840863|NCT05287503|Experimental|Ambroxol|"Ambroxol hydrochloride 200 mg tablets Dose: 1.2 g daily~Escalation scheme:~Day 1 - 5 200 mg 200 mg once a day Day 6 - 10 400 mg 200 mg twice a day Day 11 - 15 600 mg 200 mg three times a day Day 16 - 20 800 mg 400 mg twice a day Day 21 - 25 1000 mg 400 mg + 200 mg + 400 mg a day Day 26 - 365 1200 mg 400 mg three times a day"
32840864|NCT05287503|Placebo Comparator|Placebo|Excipients
32840865|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
32840866|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
32840867|NCT05287191|Experimental|Experimental arm|Intravenous magnesium sulphate as first line followed by digoxin IV loading as second line and then amiodarone IV as third line treatments for fast AF
32840868|NCT05287191|Active Comparator|Standard of care arm|Intravenous amiodarone as compactor group intervention
32840869|NCT03586635||Patients with Multiple Sclerosis|
32840870|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
32840871|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
32840872|NCT03361215||Atopic dermatitis|Patients with dermatologist-diagnosed atopic dermatitis, psoriasis or autoimmune skin disease.
32840873|NCT03361215||Controls|Healthy volunteers with no history of atopic, autoimmune or chronic inflammatory disease.
32840874|NCT03491631|Experimental|2 drugs combination group|
32840875|NCT03491631|Experimental|3 drugs combination group|
32840876|NCT04271007|Active Comparator|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
32840877|NCT04271007|Active Comparator|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
32840878|NCT01794585|Experimental|Virtual Reality Based Exercise|
32840879|NCT01794585|Active Comparator|Standard Exercise|
32840880|NCT05287035|Active Comparator|Steroid injection|Dexamethasone will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
32840881|NCT05287035|Placebo Comparator|Saline solution|Saline will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
32840882|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
32840883|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
32840884|NCT03464175|Active Comparator|Use of a heat and moisture exchanger (HME) filter|
32840885|NCT03464175|Active Comparator|Use of a dry ventilator circuit specific for aerosol therapy|
32840886|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
32840887|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
32840888|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32840889|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
32840890|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
32840891|NCT05286723|Experimental|Multicomponent Training|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training Strength training Balance and coordination training Return to calm"
32840892|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
32840893|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
32840894|NCT05286645|Active Comparator|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
32840895|NCT05286645|Placebo Comparator|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
32840896|NCT04271631|No Intervention|Control|Received conventional education group
32840897|NCT04271631|Experimental|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
32840898|NCT04271631|Experimental|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
32840899|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
32840900|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
32840901|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
32840902|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
32840903|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
32840904|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
32840905|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
32840906|NCT05286489|Experimental|group A|Qigong exercise program twice weekly for 8 weeks postmastectomy in addition to traditional medical and physical therapy treatment.
32840907|NCT05286489|Other|group B|traditional medical and physical therapy treatment only .
33319728|NCT05501522|Placebo Comparator|Primary series of BNT162b2 manufactured by Pfizer/BioNTech (Placebo)|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
33319729|NCT05501522|Experimental|Primary series of BBIBP-CorV manufactured by Sinopharm|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
32840908|NCT00420459|Experimental|Aripiprazole|
32840909|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
32840910|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
32840911|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
32840912|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
32840913|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
32840914|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
32840915|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
32840916|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
32840917|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
32840918|NCT04750551|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
32840919|NCT04750551|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
32840920|NCT04750317|Experimental|Patients with reduced oxygen saturation ≤93% treated with tofacitinib|Patients with oxygen saturation ≤93% on admission treated with tofacitinib and standard of care treatment
32840921|NCT04750317|No Intervention|Patients with reduced oxygen saturation treated with SoC|Patients with oxygen saturation ≤93% on admission treated with standard of care only
32840922|NCT04750317|Experimental|Patients with preserved oxygen saturation >93% on admission treated with tofacitinib|Patients with oxygen saturation >93% on admission treated with tofacitinib and standard of care
32840923|NCT04750317|No Intervention|Patients with preserved oxygen saturation >93% on admission treated with SoC|Patients with oxygen saturation >93% on admission treated with standard of care only
32840924|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
32840925|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
32840926|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
32840927|NCT01491737|Experimental|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
32902944|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
33103862|NCT05466513|No Intervention|Control Group|No intervention was applied.
33319730|NCT05501522|Placebo Comparator|Primary series of BBIBP-CorV manufactured by Sinopharm (Placebo)|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo
32957173|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
32957174|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
33319731|NCT05501522|Active Comparator|Primary series of CoronaVac|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
32957175|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
32957176|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
32957177|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
32957178|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
32957179|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
32957180|NCT03534726||Patients|Patients with cardiomyopathy
33319732|NCT05501522|Placebo Comparator|Primary series of CoronaVac (Placebo)|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose Placebo
32957181|NCT03534726||Normal subjects|No prior history of heart disease.
32957182|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
32957183|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
32957184|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
32957185|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
32957186|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
32957187|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
32957188|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
33319735|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
33319736|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
33319737|NCT05143190|Experimental|PTR-01|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg once monthly for a total of 5 doses.
33319738|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
33319739|NCT01302314|Experimental|cognitive rehabilitation|
33319740|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
33319741|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
33319742|NCT05108948||Spinal deformity operated patients|
33319743|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
33319744|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
32957189|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
33319745|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
32957190|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
32957191|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
32957192|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
32957193|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
32957194|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
32957195|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
32957196|NCT03500354|Experimental|Nutrient|Nutrient drink
32957197|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), and at Week 8 (600 mg/3 mL)."
32957198|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), and at Week 8 (900 mg/3 mL)."
32957199|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry) and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg (3 mL) IM injection AND RPV LA administered as a 900 mg (3 mL) IM injection, every eight weeks through Week 96."
32957200|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
32957201|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
32957202|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
32957203|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
32957204|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
32957205|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
32957206|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
32957207|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
32957208|NCT03483337||head and neck cancer or thyroid cancers (differentiated and undifferentiated)|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies at two months (60 days) and four months (120 days) after completion of all treatments, including systemic therapy if (+/- 2 weeks or 14 days). Imaging on or immediately after systemic therapy treatment (+/- 2 weeks or 14 days) to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed. Patients who will be receiving radiation therapy treatment will also have recommended weekly imaging during their course of treatment.
32957209|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
32957210|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
32957211|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
32957212|NCT03455582|Active Comparator|Control|40 Healthy controls
32957213|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.~Proposition of reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
32957214|NCT03453268|Other|2: Control|Usual treatment
32957215|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
33319746|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
32957216|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
32957217|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
33103863|NCT04943757|Experimental|PTBCy graft-versus-host disease prophylaxis|Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration
33103864|NCT00552461|Experimental|1|
33319747|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
33319748|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
32957218|NCT03444701|Experimental|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
32957219|NCT03444701|Experimental|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. Once the MTD will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 3-week or in a 2-week regimen based on the evaluations in Part 1.
32957220|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
32957221|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
32957222|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. PET/CT occurs if a) an MRI can't be performed concurrently; or b) the participant already had an MRI of the abdomen/pelvis or pelvis only.
32957223|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
32957224|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
32957225|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
32957226|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
32957227|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
32957228|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
32957229|NCT03380962|Experimental|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
32957230|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
32957231|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
32957232|NCT03282916|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
32957233|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
32957234|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
32957235|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
32957236|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
32957237|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
32957238|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
33103865|NCT04935528|Other|vaccined salaried staff (group 1)|"vaccined salaried staff group (Distinction between~Employees vaccinated with two doses of vaccine (2 Pfizer doses or 2 Astra doses or 1 Pfizer dose + 1 Astra dose) and never infected with SARS-CoV-2~And mmployees vaccinated with one dose of Pfizer or Astra vaccine and previously infected with SARS-CoV-2"
33405770|NCT05198037|Experimental|Active transcranial direct current stimulation (tDCS)|Weak direct currents with 2 mA are delivered 20 minutes per session (including 30s ramp-up and 30s ramp-down) during tailored upper extremity task practice. Total sessions are 20 over 10 days.
32840928|NCT01491737|Active Comparator|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
32840929|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
33405771|NCT05198037|Sham Comparator|Sham tDCS|The device is automatically shut down after 2-minute stimulation. Treatment sessions and frequency are the same as the Experimental arm.
32840930|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
32840931|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
32840932|NCT04088305|Experimental|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
32840933|NCT04088305|No Intervention|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
32840934|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
32840935|NCT04088227|Active Comparator|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
32840936|NCT04088227|Experimental|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
32840937|NCT04750629||SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing|Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
32840938|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
32840939|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
32840940|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
32840941|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
32840942|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
32840943|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
32840944|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
32840945|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
32840946|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
32840947|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
32840948|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
32840949|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
32840950|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
32840951|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
32840952|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
32840953|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
32840954|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
32840955|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
32840956|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
33319749|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
33319750|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
33319751|NCT02748668||ECMO|No intervention. Blood specimen collection.
33319752|NCT02748668||Control|No intervention. Blood specimen collection.
33319753|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
32840957|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
32840958|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
32840959|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
32840960|NCT05286021||Supine group|Children undergoing surgery in the supine position using the Ambu Auragain
32840961|NCT05286021||Prone group|Children undergoing surgery in the prone position using the Ambu Auragain
32840962|NCT01793493|Experimental|Cognitive stimulation|
32840963|NCT01793493|Active Comparator|Sanitary education|
32840964|NCT05285865|Active Comparator|Conventional Treatment|Thrice a day ,Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
32840965|NCT05285865|Experimental|Scapular Mobilization|Thrice a day Scapular mobilization (SM) along with Conventional treatment
32840966|NCT05285787|Experimental|EPN-701, 10mg orally daily over 14 days|Single arm
32840967|NCT01491035|Experimental|Cohort CC1, 6 children|
32840968|NCT01491035|Experimental|Cohort CC2, 6 children|
32840969|NCT01491035|Experimental|Cohort CC3, 6 children|
32840970|NCT01491035|Experimental|Cohort CC4, 6 children|
32840971|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
32840972|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
32840973|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
32840974|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
32840975|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
32840976|NCT04748315|Experimental|SEMT(1:1)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:1.
32840977|NCT04748315|Experimental|SEMPT(1:3)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:3.
32840978|NCT04748315|No Intervention|Control|Participants in this arm will receive no intervention
32840979|NCT04409327|Experimental|10 mg daily RTB101|TORC1 inhibitor
32840980|NCT04409327|Placebo Comparator|Placebo|Placebo
32840981|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
32840982|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
32840983|NCT04088981|Active Comparator|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
32840984|NCT04088981|Active Comparator|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
32840985|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
32840986|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
32840987|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
32840988|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
32840989|NCT01485887|Experimental|Venlafaxine ER|
32840990|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
32840991|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
32840992|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
32840993|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
32840994|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
33103866|NCT04935528|Other|non vaccined salaried staff (group 2 - witnesses)|non vaccined salaried staff group wtih positive SARS-CoV-2
33319754|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
33319755|NCT03796364|Active Comparator|control group|standard SRILI treatment
33319756|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
32840995|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
32840996|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
33405772|NCT05253495|Experimental|Cohort 1a|"Mature B-cell Non-hodgkin Lymphoma [MB NHL], GROUP B will receive reduction therapy with dexamethasone, vincristine and cyclophosphamide (DOC), then undergo disease assessment. If tumor reduction ≥ 20%, will get induction 1 and 2 with polatuzumab vedotin, cyclophosphamide, vincristine, methotrexate, rituximab, doxorubicin (Pv-COM3RA25D) 1 and 2, then Consolidation 1 with rituximab, cytarabine, methotrexate (R-CYM) . Patients will undergo disease assessment post Consolidation 1. If no residual disease, they proceed to receive Consolidation 2 with Pv-R-CYM (R-CYM 2).~Cohort Ia patients with < 20% tumor reduction post DOC will be assigned to Cohort Ib starting at Induction 1. Cohort Ia patients with residual disease post Consolidation 1 will be assigned to Cohort Ib starting at Consolidation 1 polatuzumab vedotin, rituximab, high dose cytarabine, cytarabine, high dose methotrexate, etoposide (Pv-R-CYVE 1)."
32840997|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
32840998|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
32840999|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
32841000|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
32841001|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
32841002|NCT04656925|Experimental|Contingency management A-B-A|All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods.
32841003|NCT04767451||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
32841004|NCT04767451||Control group|The study population will consist of 50 women with POI as a study group and 50 patients with normal healthy women as a control group. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
32841005|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
32841006|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
32841007|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
32841008|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
32841009|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
32841010|NCT01513759|Experimental|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
32841011|NCT01484561|Active Comparator|Sequence 1|
32841012|NCT01484561|Placebo Comparator|Sequence 2|
32841013|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
32841014|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
32841015|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
32841016|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
32841017|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
32841018|NCT01483625|Experimental|tiotropium 18mcg|active
32841019|NCT01483625|Placebo Comparator|Placebo|placebo
32841020|NCT01485991|Experimental|TMC435/PR|
32841021|NCT01485991|Active Comparator|TVR/PR|
32841022|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
32841023|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
32841024|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
32841025|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
32841026|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
32841027|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
32841028|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
32841029|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
32841030|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
32841031|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
32841032|NCT05258331|Experimental|Single Arm|CT303
32841033|NCT05244681|Other|People with chronic non-specific neck pain|Group of people with chronic non-specific neck pain who agreed to participate in a semi-structured interview about their experience using an immersive virtual reality serious game at home
32841034|NCT05241795|Active Comparator|Group A: Knee exercises then Ankle exercises|Patients will receive a rehabilitation protocol starting with knee training followed by ankle training.
32841035|NCT05241795|Experimental|Group B: Ankle exercises then Knee exercises|Patients will receive a rehabilitation protocol starting with ankle training followed by knee training.
32841036|NCT01482221|Experimental|1|
32841037|NCT01482221|Experimental|2|
32841038|NCT01482221|Placebo Comparator|3|
32841039|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
32841040|NCT04649879|Experimental|Convalescent plasma treatment|"Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions.~If steroid therapy has not already been initiated, betamethasone 3 mg daily will be given concomitantly with steroid therapy or longer if clinically indicated but for a maximum of 10 days."
32841041|NCT04649879|Active Comparator|Control|Standard of care for COVID-19 patients.
32841042|NCT04087109|Experimental|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
32841043|NCT04087109|No Intervention|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
32841044|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
32841045|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
32841046|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
32841047|NCT04086875|Experimental|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
32841048|NCT04086875|Experimental|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
32841049|NCT04086875|Active Comparator|Phase II Group II (usual care)|Participants receive usual care.
32841050|NCT04408781|Experimental|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
32841051|NCT04408781|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
32841052|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
32841053|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
32841054|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
32841055|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
32841056|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
32841057|NCT01512745|Experimental|apatinib|
32841058|NCT01512745|Placebo Comparator|placebo|
32841059|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
32841060|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
33405773|NCT05253495|Experimental|Cohort 1b|MB NHL, GROUP C will receive reduction therapy with DOC. Patients with < 20% tumor reduction will be off protocol. Patients with ≥ 20% tumor reduction get Induction 1 and 2 with cyclophosphamide, doxorubicin, dexamethasone, high dose methotrexate, polatuzumab vedotin, and triple intrathecal chemotherapy (M8A30D CPR) 1 and 2, then Consolidation 1 with Pv-R-CYVE 1. If no residual disease, they get Consolidation 2 (Pv-R-CYVE 2), followed by Maintenance (M) 1 with M8A30D CP, M 2 with Pv-cytarabine/etoposide, M 3 with cyclophosphamide, doxorubicin, dexamethasone and polatuzumab vedotin (A30D CP), and M 4 with Pv-cytarabine/etoposide. Cohort Ib patients with CNS disease will receive additional intrathecal chemotherapy and high dose methotrexate during Consolidation.
32841061|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
32841062|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
32841063|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
32841064|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
32841065|NCT01478087|Other|Mysorba(single-arm)|
32841066|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
32841067|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
32841068|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
32841069|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
32841070|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
32841071|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
32841072|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
32841073|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
32841074|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
32841075|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
32841076|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
32841077|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
32841078|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
32841079|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
32841080|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
32841081|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
32841082|NCT01511419|Experimental|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.~Route of administration: Intranasal aerosol.~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
32841083|NCT01511419|Placebo Comparator|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.~Dose: 0.5 ml; 0.25 ml/nare~Route of administration: Intranasal aerosol~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
32841084|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
32841085|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
32841086|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
32841087|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
32841088|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
32841089|NCT04388631||Exposed group|Male patient discharged with COVID-19
32841090|NCT04388631||Control group|Healthy male volunteers without COVID-19
32957239|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
32957240|NCT03194646|Experimental|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
32957241|NCT03194646|Experimental|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
32957242|NCT03194646|Experimental|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
32957243|NCT03194646|Other|B(Standard of care)|Standard of care as determined by the investigators, this could be watch & wait or non-hormonal medical treatment
32957244|NCT03192020|Experimental|Percutaneous needle fasciotomy (PNF)|PNF is a treatment in which the Dupuytren's contracture cord causing the contracture is not excised, but only divided with a hypodermic needle.
32957245|NCT03192020|Experimental|Collagenase clostridium histolyticum (CCH)|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times. One injection is performed normally at least to three different places in the cord.
32957246|NCT03192020|Active Comparator|Limited fasciectomy (LF)|In LF, the thickened part of the palmar fascia causing the contracture is excised through skin incision.
32957247|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
32957248|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
32957249|NCT03125928|Experimental|Investigational Arm|
32957250|NCT03114319|Experimental|TNO155|TNO155 for oral administration
32957251|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
32957252|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
32957253|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
32957254|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
32957255|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
32957256|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
32957257|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
32957258|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
32957259|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
32957260|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
32957261|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
32957262|NCT02983045|Experimental|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels to determine the RP2D Part 1 of RP2D in patients with advanced or metastatic melanoma, RCC, NSCLC, urothelial carcinoma, or TNBC.
32957263|NCT02983045|Experimental|Dose Expansion: Combination of NKTR-214 + nivolumab|NKTR-214+nivolumab in patients with advanced or metastatic solid tumor malignancies to assess the efficacy of the RP2D.
32957264|NCT02983045|Experimental|Experimental: Combination of NKTR-214 + nivolumab + ipilimumab|To assess the safety and tolerability of NKTR 214 + nivolumab + ipilimumab triplet therapy and establish RP2D dosing schedules for Part 4 in patients with advanced or metastatic melanoma, RCC, NSCLC, or UCC in a first-line setting (1L).
32957265|NCT02983045|Experimental|Experimental: Dose Expansion of Part 3|To further assess the RP2D triplet combination dosing schedules from Part 3 in 1L NSCLC and 1L RCC patients.
33103867|NCT04935528|Other|vaccined patients (group 3)|vaccined patient group
33327347|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
32841091|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
32841092|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
32841093|NCT04388397|Experimental|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
32841094|NCT04388397|Active Comparator|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
32841095|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
32841096|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
32841097|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
32841098|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
32841099|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
32841100|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
32841101|NCT00442689|Placebo Comparator|3|Placebo
32841102|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
32841103|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
32841104|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
33405774|NCT05253495|Experimental|Cohort 2a|Classical Hodgkin lymphoma, INTERMEDIATE RISK will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 2 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1 and 2). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will continue therapy with 4 cycles of Bv-NVD-R (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
32841107|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
32841108|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
32841109|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
32841110|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
32841111|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
32841112|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
32841113|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
32841114|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
32841115|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
32841116|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
32841117|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
32841118|NCT04388709|Experimental|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
32841119|NCT04388709|No Intervention|Best supportive care|Best supportive care
32841120|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
32841121|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
32841122|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
32841123|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
32841124|NCT01475825|Experimental|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
32841125|NCT01475825|Placebo Comparator|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
32841126|NCT01475825|Experimental|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
32841127|NCT01475825|Placebo Comparator|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
32841128|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
33327348|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
32841129|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
32841130|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
32841131|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
32841132|NCT04085315|Experimental|Dose Escalation (Closed to Enrollment)|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
33319757|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
33319758|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
33319759|NCT05093504|Sham Comparator|Control|Standard of care with Sham set-up
33319760|NCT05093504|Experimental|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
33319761|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
33319762|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
33319763|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
33319764|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
32841133|NCT04085315|Experimental|Dose Expansion: Cohort A|Stage IV EGFR-mutant NSCLC currently receiving and progressing on osimertinib who have received no more than one additional line of systemic cancer therapy other than osimertinib (e.g., chemotherapy +/- immunotherapy, amivantamab +/- Lazertinib) for metastatic disease. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
32841134|NCT04085315|Experimental|Dose Expansion: Cohort B|Stage IV EGFR-mutant NSCLC patients who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
32841135|NCT01484431|Experimental|Tadalafil|"Light Weight <25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.~Middle Weight: 25 kg to <40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
32841136|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
32841137|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
32841138|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
32841139|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
32841140|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
32841141|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
32841142|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
32841143|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
32841144|NCT01473953|Placebo Comparator|Placebo|
32841145|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI <3 at baseline and stable remission for the last 3 months
32841146|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
32841147|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
32841148|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
32841149|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
32841150|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
32841151|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
32841152|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
32841153|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
32957266|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
32957267|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
33319765|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
32957268|NCT02944136|Active Comparator|Enhanced Usual Care|Referred to a therapist and/or psychiatrist in their home town depending on the type of treatment they prefer (e.g., behavioral and/or medication)
32841154|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
32841155|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
32841156|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
32841157|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
32841158|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
32841159|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
32841160|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
32841161|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
32841162|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
32841163|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
32841164|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
32841165|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
32841166|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
32841167|NCT01472939|Placebo Comparator|Placebo + PPI|
32841168|NCT04082897|Experimental|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :~cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)~Cycle 2-8: 1000 mg iv on day 1~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:~Cycles 1: day 2~Cycle 2-18: day 1~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
32841169|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
32841170|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
32841171|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
32841172|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
32841173|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
32841174|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
32957269|NCT02944136|Experimental|stepped collaborative care|At least biweekly contact from a care coordinator by phone and face-to- face visits occurring approximately every 2 months during the patients outpatient visits or treatment, and 24/7 access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
33319766|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
33103868|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
32841175|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
32841176|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
32841177|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
32841178|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
32841179|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
32841180|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
32841181|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
32841182|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
32841183|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
32841184|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
32841185|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
32841186|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
32841187|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
32841188|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
32841189|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
32841190|NCT01483183|Placebo Comparator|Placebo Part 2|
32841191|NCT01483027|Experimental|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
32841192|NCT01483027|No Intervention|Control group|Standard of care second-line chemotherapy with no added therapy
32841193|NCT04087291|Active Comparator|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
32841194|NCT04087291|Active Comparator|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
32841195|NCT04087291|Active Comparator|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
32841196|NCT04087291|No Intervention|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
32841197|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
32841198|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
32841199|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
32841200|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
32841201|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
32841202|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
33103869|NCT05465265|Active Comparator|Intervention and control group|To establish the effect of navigation on PrEP uptake, adherence and retention among PWID.
33103870|NCT05465265|Placebo Comparator|Control group|To establish the effect of providing PrEP information through pamphlets on PrEP uptake, adherence and retention among PWID.
32957270|NCT02933892|Active Comparator|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
32957271|NCT02933892|Active Comparator|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
32957272|NCT02923440|Experimental|Congenital heart defects|
32957273|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
32957274|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery. Patients undergo blood and urine sample collection throughout the study.
32957275|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
32957276|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
32957277|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
32957278|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
32957279|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptin, S-100B, GFAP, NFL and UCHL-1 proteins
32957280|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
32957281|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
32957282|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
32957284|NCT02678689|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
32957285|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
32957286|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
32957287|NCT02659956||Individuals without known CNS disease|Family members of patient participants
32957288|NCT02659956||Patient controls|a target population of 50 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
32957289|NCT02659956||Patients with multiple sclerosis|Up to 150 adults (age >= 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
32957290|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
32957291|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
32957292|NCT02564263|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
32957293|NCT02564263|Active Comparator|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
32957294|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
32957295|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
32957296|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
33103871|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
33103872|NCT00552539|No Intervention|2|no intervention
33103873|NCT00552539|Experimental|3|educational video and post test survey
33103874|NCT00552539|No Intervention|4|post test survey
32957297|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
32957298|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
32957299|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
32957300|NCT02522247|No Intervention|Controls|Only waiting 6 months
32957301|NCT02496208|Experimental|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 22 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography or magnetic resonance imaging and collection of blood samples throughout the trial.
32957302|NCT02496208|Experimental|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|See detailed description.
32957303|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
32957304|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
32957305|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
32957306|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
32957307|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
32957308|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
32957309|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
32957310|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
32957311|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
32957312|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
32957313|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
32957314|NCT02359565|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 cycles in the absence of disease progression or unacceptable toxicity.
32957315|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
32957316|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
32957317|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
32957318|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
33033393|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
32957319|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
32957320|NCT02257853|No Intervention|Control Group|No intervention group
32957321|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
32957322|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
32957323|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
32957324|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
32957325|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
32957326|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
32957327|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
32957328|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
33319767|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
32957329|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
32957330|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
32957331|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
32957332|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
32957333|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Intestinal Type Adenocarcinoma with functional p53.~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by radiotherapy"
32957334|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy"
32957335|NCT02019706|Experimental|Imaging|All subjects will be imaged
32957336|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
32957337|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
32957338|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
32957339|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
33319768|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
33319769|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
32957340|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
32957341|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
32957342|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
32957343|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
32957344|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
32957345|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
32957346|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
32957347|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
32957348|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
32957349|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
32957350|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
32957351|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
32957352|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
32957353|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
32957354|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
33405775|NCT05253495|Experimental|Cohort 2b|COHORT IIb (Classical Hodgkin lymphoma, HIGH RISK) Cohort IIb patients will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment will be performed with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-NAVD-R 1 and 2), followed by 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
33405776|NCT01840293||Primary Breast Cancer|
32957355|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
32957356|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
32957357|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
32957358|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
32957359|NCT01285817|Experimental|traetment|
32957360|NCT01285479||fingolimod|prescribed fingolimod 0.5 mg/day, including generic versions of fingolimod
32957361|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
32957362|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
32957363|NCT01164241||1|Eczema
32957364|NCT01164241||2|unaffected relatives
33405777|NCT01840293||Recurrent/Metastatic Breast Cancer|
32957365|NCT01164241||3|healthy volunteers
32957366|NCT01164241||4|other allergic phenotypes
33405778|NCT05225025|Experimental|ROSE Intervention|
32957367|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
32957368|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
32957369|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
32957370|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
32957371|NCT01105975|Placebo Comparator|Placebo|
32957372|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
32957373|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
32957374|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
32957375|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
32957376|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
32957377|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
32957378|NCT01063517|Experimental|1|Olaparib + paclitaxel
32957379|NCT01063517|Active Comparator|2|paclitaxel + placebo
32957380|NCT00831623|Experimental|Proton radiation therapy|Single arm
32957381|NCT00819637|Experimental|Arformoterol 3 doses|
32957382|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
32957383|NCT00819637|Active Comparator|Levalbuterol 3 doses|
33405779|NCT05225025|Active Comparator|Standard of Care|
32957385|NCT00651456|Active Comparator|1|Standard Chemotherapy
32841203|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
32841204|NCT04409587|No Intervention|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
32841205|NCT04409587|Active Comparator|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
32841206|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
33405780|NCT05131113|No Intervention|Control group|The control group will receive the usual care
32841207|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
32841208|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
32841209|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
32841210|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
32841211|NCT01463527|Experimental|Open Capnography|
32841212|NCT01463527|Placebo Comparator|Capnography Blind|
32841213|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
32841214|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
32841215|NCT01509079|Experimental|Vitamin D3 4000 IU|
32841216|NCT01509079|Active Comparator|Vitamin D3 600 IU|
32841217|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
32841218|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
32841219|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
32841220|NCT04080115|Experimental|Attention Training Technique (ATT)|
32841221|NCT04080115|Active Comparator|Sham intervention control condition|
32841222|NCT04650217|Active Comparator|L-DOPA + Exercise|N=20 subjects assigned to L-DOPA + Exercise will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive exercise training 4 times a week (exercise)
32841223|NCT04650217|Active Comparator|LDOPA + Control|N=20 subjects assigned to L-DOPA + Control will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive a stretching and toning regime (Control).
32841224|NCT04650217|Placebo Comparator|Placebo + Exercise|N=20 subjects assigned to Placebo + Exercise will receive placebo three times daily and also will receive exercise training 4 times a week (exercise).
32841225|NCT04650217|Placebo Comparator|Placebo + Control|N=20 subjects assigned to Placebo + Control will receive placebo three times daily and also will receive a stretching and toning regime (Control).
32841226|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
32841227|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
32841228|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
32841229|NCT01462435|Experimental|Diclofenac Test (lower dose)|
32841230|NCT01462435|Experimental|Diclofenac Test (upper dose)|
32841231|NCT01462435|Active Comparator|Celecoxib|
32841232|NCT01462435|Placebo Comparator|Placebo|
32841233|NCT01472081|Experimental|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
32841234|NCT01472081|Experimental|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
32902945|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.
32841235|NCT01472081|Experimental|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
33319770|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
33319771|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
32841236|NCT01472081|Experimental|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
32841237|NCT01472081|Experimental|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
33319772|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
33319773|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
33319774|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
33319775|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
33319776|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
33319777|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
33319778|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
32841238|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
32841239|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
32841240|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
32841241|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
32841242|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
32841243|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
32841244|NCT01470599|Experimental|5mg BID|
32841245|NCT01470599|Experimental|10mg BID|
32841246|NCT04409171||PD|pancreaticoduodenectomy
32841247|NCT04409171||DP|distal pancreatectomy
32841248|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
32841249|NCT04623593|Active Comparator|ACDF|Anterior cervical discectomy and fusion.
32841250|NCT04623593|Experimental|ACDA|Anterior cervical discectomy with arthroplasty.
32841251|NCT04618523|Experimental|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
32841252|NCT04618523|Experimental|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
32841253|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
32841254|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
32841255|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
32841256|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
32841257|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
32841258|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
32841259|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
32841260|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
32841261|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
32841262|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
33319779|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
33319780|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
32841263|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
32841264|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
32841265|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
32841266|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
32841267|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
32841268|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
32841269|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
32841270|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
32841271|NCT01506271|Experimental|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
32841272|NCT01506271|Experimental|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
32841273|NCT01506271|Placebo Comparator|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
32841274|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
32841275|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
32841276|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
32841277|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
32841278|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
32841279|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
32841280|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
32841281|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
32841282|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
32841283|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
32841284|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
32841285|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
32841286|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
32841287|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
32841288|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
32841289|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
32902946|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
32902947|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
32902948|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
32902949|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
33327349|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
33327350|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
32841290|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
32841291|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)~Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer~Diagnostic Test: Study group (group A)"
32841292|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
32841293|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
32841294|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
32841295|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
32841296|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
32841297|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
32841298|NCT01460719|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
32841299|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
32841300|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
32841301|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
32841302|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
32841303|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
32841304|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
32841305|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
32841306|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
32841307|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
32841308|NCT03331731|Experimental|Single arm|Single Arm
32841309|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
32841310|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
32841311|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
32841312|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
32841313|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
32841314|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
32841315|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.1 mg/kg Q2W)|Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841316|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32957386|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
33327351|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
32841317|NCT01693562|Experimental|Escalation Cohort (MEDI4736 1 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841318|NCT01693562|Experimental|Escalation Cohort (MEDI4736 3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841319|NCT01693562|Experimental|Escalation Cohort (MEDI4736 10 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841320|NCT01693562|Experimental|Escalation Cohort (MEDI4736 15 mg/kg Q3W)|Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841321|NCT01693562|Experimental|Exploration Durvalumab 20 mg/kg (Q4W)|Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841322|NCT01693562|Experimental|Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841323|NCT01693562|Experimental|Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W)|Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841324|NCT01693562|Experimental|Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841325|NCT01693562|Experimental|Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)|Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841326|NCT01693562|Experimental|Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841327|NCT01693562|Experimental|Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841328|NCT01693562|Experimental|Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841329|NCT01693562|Experimental|Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841330|NCT01693562|Experimental|Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
33327352|NCT00585832|Experimental|DASH-4-Teens Intervention|DASH-4-Teens Intervention is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
33327353|NCT00585832|Other|Routine Care|Routine Care is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
33327354|NCT03092752||Patients with T2DM|
33327355|NCT03395236|Experimental|Treatment|StellarexTM 0.014 OTW Drug-coated Angioplasty Balloon (Stellarex Balloon)
33327356|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
33327357|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
33327358|NCT03750240|Experimental|Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
33103875|NCT04917783|Other|Standard of Care|Caregivers in the standard of care-arm will receive immediate verbal feedback by a psychologist on their neurocognitive testing results, recommendations, and guidance for implementing recommendations (e.g., sending a 504 Plan request to the school). This report will contain information regarding background, test results, a summary and impressions, and bullet-pointed recommendations.
33405781|NCT05131113|Experimental|Interventionist group|The interventional group will add an individualized physical exercise program to the usual care.
32841331|NCT01693562|Experimental|Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841332|NCT01693562|Experimental|Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841333|NCT01693562|Experimental|Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841334|NCT01693562|Experimental|Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)|Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841335|NCT01693562|Experimental|Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841336|NCT01693562|Experimental|Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)|Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841337|NCT01693562|Experimental|Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
32841338|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
32841339|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
32841340|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
32841341|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
32841342|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
32841343|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
32841344|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
32841345|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
32841346|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
32841347|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
32841348|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
33405782|NCT05054751|Experimental|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side.The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
32841349|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
32841350|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
32841351|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
32841352|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
32841353|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
32841354|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
32841355|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
32841356|NCT02073461|Placebo Comparator|Vehicle|Vehicle
32841357|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
32841358|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
32841359|NCT01590758|Placebo Comparator|Topical placebo control|
32841360|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
32841361|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
32841362|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
32841363|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
32841364|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
32841365|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
32841366|NCT01692938||No Retinal Disease|
32841367|NCT01692938||Retinal Disease|
32841368|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
32841369|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
32841370|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
32841371|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
32841372|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
32902950|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
32841373|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
32841374|NCT00535587|Experimental|1|
33405783|NCT05054751|Placebo Comparator|Placebo+Fulvestrant|"Placebo: The dose of placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
33405784|NCT04791735|Experimental|Laparoscopic approach for liver resection of HCC|
32957387|NCT00639639|Experimental|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
33405785|NCT04791735|Experimental|laparotomy|
33405786|NCT05573295||Children with CLP|
33405787|NCT05573295||Healthy controls with gender-age match|
33405788|NCT05007249|Other|Overweight or obese minors with intellectual disability|
33405789|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
33405790|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
33405791|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
33417161|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
32841375|NCT00535587|Experimental|2|
32841376|NCT00535587|Experimental|3|
32841377|NCT00535587|Experimental|4|
32841378|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
32841379|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
32841380|NCT01475461|Placebo Comparator|Placebo|
32841381|NCT01475461|Experimental|PF-04937319 - Dose 1|
32841382|NCT01475461|Experimental|PF-04937319 - Dose 2|
32841383|NCT01475461|Experimental|PF-04937319 - Dose 3|
32841384|NCT01475461|Experimental|PF-04937319 - Dose 4|
32841385|NCT01475461|Active Comparator|Sitagliptin|
32841386|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
32841387|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
32841388|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
32841389|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
32957388|NCT00639639|Experimental|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
32841390|NCT01565642|No Intervention|Control|Attention control information on dementia care
32841391|NCT01475071|Experimental|Metvix and daylight|
32841392|NCT01475071|Active Comparator|Metvix and lamp|
32841393|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
32841394|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
32841395|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
32841396|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
32841397|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32841398|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
32841399|NCT01565564|Active Comparator|The usual care arm|
32841400|NCT01565564|Active Comparator|The shared care arm|
32841401|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
32841402|NCT04546958|Active Comparator|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
32841403|NCT04546958|Experimental|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
32841404|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
32841405|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
32841406|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
32841407|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
32841408|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
32841409|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
32841410|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
32841411|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
32841412|NCT01502293|Experimental|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
32841413|NCT01502293|Experimental|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
32841414|NCT01502293|Experimental|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
32841415|NCT01474681|Experimental|HSC835|HSC835 infusion
32841416|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
32841417|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
32841418|NCT01588184|Experimental|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32841419|NCT01588184|Experimental|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32841420|NCT01588184|Experimental|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32841421|NCT01588184|Experimental|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32841422|NCT01588184|Experimental|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32957389|NCT00639639|Experimental|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
32957390|NCT00639639|Experimental|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
32957391|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
32957392|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
32957393|NCT00079417|Experimental|Treatment (chemotherapy, surgery)|Patients receive chemoreduction comprising carboplatin IV over 60 minutes followed by vincristine IV over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local laser therapy, cryotherapy, and/or radioactive plaque comprising iodine I 125 or ruthenium Ru 106.
33319781|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
33319782|NCT05078918|Experimental|Comprehensive care program|Intervention group receiving newly developed comprehensive care program pre- and post-operatively.
33319783|NCT05078918|Active Comparator|Usual care|Control group receiving usual care
33319784|NCT01304576|Experimental|patient with right parietal lesions|
32957398|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
32957399|NCT04387968||agents with no contact with the public|administrative workers
32957400|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
32957401|NCT04387578|Experimental|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
32957402|NCT04387578|Experimental|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
32957403|NCT04387578|Experimental|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
33319785|NCT01304576|Active Comparator|patient with left parietal lesions|
32957404|NCT04387500|Experimental|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
32957405|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
32957406|NCT04386876|Experimental|Orvical-Kaletra-Orvical-Kaletra|In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. All periods were performed under fasting state.
32957407|NCT04386876|Experimental|Kaletra-Orvical-Kaletra-Orvical|In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.
32957408|NCT04387032|Experimental|Experimental group|Experimental group (students with hypomobile SIJs)
32957409|NCT04387032|Sham Comparator|Control group|control group (students without hypomobile SIJs)
32957410|NCT04386486|Experimental|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
32957411|NCT04386486|Sham Comparator|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
32957412|NCT04386642|Experimental|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
32957413|NCT04386642|Placebo Comparator|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
32957414|NCT04386408|Experimental|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
32957415|NCT04386408|Placebo Comparator|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
32957416|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
32957417|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
32957418|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
33033394|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
32957419|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
32957420|NCT04385784|Experimental|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
32957421|NCT04385784|Experimental|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
32957422|NCT04385784|Active Comparator|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
32957423|NCT04385550|Experimental|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
32957424|NCT04385550|Active Comparator|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
32957425|NCT04385316||Gastric Cancer|
32957426|NCT04385316||Colorectal Cancer|
32957427|NCT04385316||Bladder Cancer|
32957428|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
32957429|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
32957430|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
32957431|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
32957432|NCT04384536|Experimental|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
32957433|NCT04384536|No Intervention|Control group|Control group used thumb spica splint and had rest
32957434|NCT04384380|Experimental|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
32957435|NCT04384380|No Intervention|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
32957436|NCT04384458|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
32957437|NCT04384458|Active Comparator|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
32957438|NCT04383990|Active Comparator|Early Glargine|To take insulin Glargine at 6-7 pm
32957439|NCT04383990|Active Comparator|Late Glargine|To take insulin Glargine at 10-12 pm
32957440|NCT04384224|Placebo Comparator|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
32957441|NCT04384224|Experimental|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
32957442|NCT04384224|Experimental|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
32957443|NCT04384224|Sham Comparator|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
32957444|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
32957445|NCT04383678||COVID-19 positive patients|
33417162|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
33417163|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
33417164|NCT04913441|Experimental|Routine physical therapy|"Patients in this group will get every session of 30 min 3 times per week on alternative days for 12 weeks~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~ROM exercises repeats 5 times for 10 minutes"
32957446|NCT04383600|No Intervention|Conventional side|Canine retraction was commenced without micro-osteoperforations.
32957447|NCT04383600|Experimental|Mops side|Canine retraction was commenced with micro-osteoperforations.
32957448|NCT04383366||Patients with keratoconus|
32957449|NCT04383054|Experimental|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
33033395|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
33319786|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
33319787|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
33319788|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
32841423|NCT01588184|Experimental|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
32841424|NCT01588106||Test group|patients using CONTOUR Next USB
32841425|NCT01588106||Control group|patients using standard CONTOUR
32841426|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
32841427|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
32841428|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
32841429|NCT04857164|Experimental|Pembrolizumab combined with Chemotherapy|"Chemotherapy regimen* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)~*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)"
32841430|NCT01691378|Experimental|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
32841431|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
32841432|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
32841433|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
32841434|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
32841435|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
33319789|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
33319790|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
33319791|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
33319792|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;~Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
33319793|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
32841436|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
32841437|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
32841438|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
32841439|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
32841440|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
32841441|NCT00535743|Placebo Comparator|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
32841442|NCT00535743|Experimental|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
33417165|NCT04913441|Experimental|Manual physical therapy with routine physical therapy|"Patients in group B will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Mulligan technique (NAGS and SNAGS) will repeats 5 times for 10 minutes"
32957450|NCT04383054|Active Comparator|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
32957451|NCT04382742|Experimental|Exercise|
32957452|NCT04382274|Experimental|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
32957453|NCT04382274|Experimental|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
32957454|NCT04382040|Experimental|ArtemiC|Active study treatment + Standard care
32957455|NCT04382040|Placebo Comparator|PLACEBO|Placebo + Standard care
32957456|NCT04381884|Experimental|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
32957457|NCT04381884|No Intervention|CONTROL|Patients in this group will receive standard care.
32957458|NCT04381962|Experimental|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
32957459|NCT04381962|No Intervention|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
32957460|NCT04382430|Experimental|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted & 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
32957461|NCT04382430|Active Comparator|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
32957462|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
32957463|NCT04381338|Experimental|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program~Intubated patient GCS >8: passive mobilization; postural positioning GCS< 8: passive and active-assist mobilization; postural positioning~Extubated patient~If strength < 3 MRC: passive and/or active-assist; functional retraining~If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation~Intubated patient GCS >8: postural positioning GCS< 8: postural positioning, cautious inspiratory muscle training~Extubated patient~If strength < 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training~If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.~Frequency of sessions: 3×15 min/day"
32957464|NCT04381338|No Intervention|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
32957465|NCT04381026|Placebo Comparator|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
32841443|NCT00535743|Experimental|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841444|NCT00535743|Experimental|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32957466|NCT04381026|Experimental|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
32841445|NCT00535743|Experimental|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841446|NCT00535743|Experimental|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841447|NCT00535743|Placebo Comparator|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841448|NCT00535743|Experimental|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
33319794|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
33319795|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
32841449|NCT00535743|Experimental|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841450|NCT00535743|Experimental|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841451|NCT00535743|Experimental|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841452|NCT00535743|Experimental|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
32841453|NCT00535743|Placebo Comparator|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841454|NCT00535743|Experimental|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841455|NCT00535743|Experimental|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841456|NCT00535743|Experimental|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841457|NCT00535743|Experimental|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841458|NCT00535743|Experimental|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841459|NCT00535743|Placebo Comparator|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841460|NCT00535743|Experimental|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841461|NCT00535743|Experimental|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841462|NCT00535743|Experimental|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841463|NCT00535743|Experimental|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841464|NCT00535743|Experimental|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
32841465|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
32841466|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
32841467|NCT01564784|Experimental|Arm A|
32841468|NCT01564784|Active Comparator|Arm B|
32841469|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
32841470|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
32841471|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
32841472|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
32841473|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
32841474|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
32841475|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
32841476|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
32841477|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
32841478|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
32957467|NCT04381104|Active Comparator|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
32957468|NCT04381104|Placebo Comparator|Placebo|The control arm will receive 2 capsules of placebo.
32957469|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
32957470|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
32957471|NCT04380402|Experimental|Treatment|40 mg
32957472|NCT04380402|No Intervention|Control|Standard care
32957473|NCT04380324|Experimental|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
32957474|NCT04380324|Placebo Comparator|Placebo|Healthy participants in each cohort will receive the placebo comparator.
32957475|NCT04380246||Clinicians|"Clinicians who care for pediatric patients >50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.~This cohort will complete a qualitative interview about pain and distress in infants and young children."
32957476|NCT04380012|Experimental|Single drug group|Pyrotinib: 400 mg, po, qd, 21d for a treatment cycle
32957477|NCT04380012|Experimental|Dual-targeted drug group|Pyrotinib: 400 mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8 mg/kg, then 6 mg/kg, iv, q3w, 21d for one treatment cycle
32957478|NCT04380168|Active Comparator|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
32957479|NCT04380168|Active Comparator|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
32957480|NCT04380168|Active Comparator|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
32957481|NCT04379934|Other|Heart failure|Ejection fraction < 45%
32957482|NCT04379934|Other|Non-heart failure|Ejection fraction > 45%
32957483|NCT04379856|Experimental|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
32957484|NCT04379856|Experimental|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
32957485|NCT04379856|Experimental|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
32957486|NCT04379778|Experimental|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
32957487|NCT04379778|No Intervention|Standard care|Habitual lifestyle including standard care.
32957488|NCT04379388|Experimental|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
32957489|NCT04379388|No Intervention|Usual care control|Participants will receive referral to a quit smoking hotline
32957490|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
32957491|NCT04378998|Experimental|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
32957492|NCT04378998|No Intervention|Usual care|
32957493|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
32957494|NCT04378608|Other|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
32957495|NCT04378452||COM-COVID cohort|Individuals of >16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020]
32957496|NCT04378218|Experimental|HIIT Intervention|
32957497|NCT04378062|Active Comparator|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
32957498|NCT04378062|Experimental|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
32957499|NCT04378062|Experimental|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
32957500|NCT04377906|Experimental|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
32957501|NCT04377906|Experimental|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
32957502|NCT04377906|Experimental|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
32957503|NCT04377906|No Intervention|control|regular diet
32957504|NCT04377828|Experimental|Laser intervention|1 to 2 sessions of pigment laser1
32957505|NCT04377750|Experimental|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
32957506|NCT04377750|Placebo Comparator|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
32957507|NCT04377516|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
32957508|NCT04377516|Active Comparator|Exercise group|pelvic floor muscle training
33417166|NCT04913441|Experimental|Stretching physical therapy with routine physical therapy|"Patients in this group will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Stretching exercises repeats 5 times for 10 minutes"
32957509|NCT04377516|Placebo Comparator|Control group|pelvic girdle education
32957510|NCT04377516|Other|Health group|pelvic girdle education
32957511|NCT04377282|Experimental|Buckwheat|Cooked buckwheat
32841479|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
33405792|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
33405793|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
33405794|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
33417167|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
32841480|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
32841481|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
32841482|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
32841483|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
32841484|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
32841485|NCT04467489||CA (non-CASH)|Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
32841486|NCT04467489||CA (CASH)|Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
32841487|NCT04467489||Young with seizure|Young (<30 years old) healthy control cohorts with seizures in the prior year
32841488|NCT04467489||Young without seizure|Young (<30 years old) healthy control cohorts without seizures in the prior year
32841489|NCT04467489||Older with HMA|Older (>50 years old) with hemorrhagic microangiopathy (HMA)
32841490|NCT04467489||Older without HMA|Older (>50 years old) without hemorrhagic microangiopathy (HMA)
32841491|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
32841492|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
32841493|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
32841494|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
32841495|NCT04424199||LBD patients R-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
32841496|NCT04424199||LBD patients L-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
32841497|NCT04424199||RBD patients R-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
32902951|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
32957512|NCT04377282|Experimental|Couscous|Cooked couscous
32841498|NCT04424199||RBD patients L-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
32841499|NCT04424199||HC R-PA|"A group of 10 healthy controls (HC) will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
32841500|NCT04424199||HC L-PA|"A group of 10 healthy controls (HC) will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
32841501|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
32841502|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
33417168|NCT04905173|Experimental|Hypertrophic Cardiomyopathy|Subjects with a documented diagnosis of hypertrophic cardiomyopathy (HCM) will have an echocardiogram at rest followed by an echocardiogram with Valsalva maneuver as part of regular care. If these tests show no severe obstruction, subjects will continue with both squat-to-stand and amyl nitrite.
32841503|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
32841504|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
32841505|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
32841506|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
32841507|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
32841508|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
32841509|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
32841510|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
32841511|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
32841512|NCT04345341|Active Comparator|Laparoscopic assisted TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
32841513|NCT04345341|No Intervention|no TAP block|no TAP block would be done
32841514|NCT01465763|Experimental|tofacitinib 10 mg BID|
32841515|NCT01465763|Placebo Comparator|Placebo|
32841516|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
32841517|NCT04322097|Other|Lingual Muscle Stimulation Patients|DISE
32841518|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
32841519|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
32841520|NCT04220463|Experimental|Hypnosis group|For the hypnosis group, hypnotic support is set up by an IDE previously trained and dedicated during the implementation of the NIV. The dedicated IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated IDE.
32957513|NCT04377282|Experimental|Water|Potable water
32957514|NCT04376970|Active Comparator|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
32957515|NCT04376970|Active Comparator|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
32957516|NCT04377048|Experimental|Nivolumab/GS|"Part-1: GS Induction~Patients will receive GS for 1 cycle.~S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle~BSA < 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day~Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle~After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.~Part-2: Nivolumab Add-On~Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle~S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~The treatment will be continued until disease progression, intolerance to study treatment or death."
32957517|NCT04376892||Group 1|Exercise capacity under 149 meter
32957518|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
32957519|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
32957520|NCT04376892||Group 4|Exercise capacity above 340
32957521|NCT04376814|Experimental|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
32957522|NCT04376814|Active Comparator|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
32957523|NCT04376034|Other|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
32957524|NCT04376034|Active Comparator|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
32957525|NCT04376034|Active Comparator|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
32957526|NCT04376190|No Intervention|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
32957527|NCT04376190|Experimental|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
32957528|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
32957529|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
32957530|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
32957531|NCT04375488|Experimental|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
32957532|NCT04375488|Experimental|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
32957533|NCT04375488|No Intervention|Control Group|150 min per week walking suggestions were given.
32957534|NCT04375098|Experimental|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
32957535|NCT04375098|Experimental|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for >7 days after enrolment
32957536|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
32957537|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
32957538|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
32957539|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
32957540|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
32957541|NCT04374942|Experimental|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
32957542|NCT04374942|Placebo Comparator|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
32957543|NCT04374786|Experimental|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
32957544|NCT04374864|Experimental|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
32957545|NCT04374396|Sham Comparator|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
32957546|NCT04374396|Experimental|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
32841521|NCT04220463|Placebo Comparator|Control group|In the control group, in order to preserve the knowledge of the evaluator, the IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
32841522|NCT04081727|Experimental|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
32841523|NCT04081727|Other|Reference Group - V-Loc Barbed Suture|Will not be comparative against the test article, but will be performed for reference and safety.
32841524|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
32841525|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
32841526|NCT01796769|Experimental|Conventional|
32841527|NCT01796769|Active Comparator|Telemedicine|
32841528|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
33417169|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
33417170|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
32841529|NCT04081337|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
32841530|NCT04081337|Placebo Comparator|Placebo|Placebo administered SC.
32841531|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
32841532|NCT04081103|Experimental|Nexagon® (lufepirsen) High Dose Concentration|
32841533|NCT04081103|Experimental|Nexagon® (lufepirsen) Low Dose Concentration|
32841534|NCT04081103|Placebo Comparator|Vehicle|
32841535|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
32841536|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
32841537|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
32841538|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
32841539|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
32841540|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
32841541|NCT04163835|Experimental|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
32841542|NCT04163835|Experimental|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
32841543|NCT04163835|Experimental|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
32841544|NCT04163835|Placebo Comparator|Placebo Group|The intervention is a placebo.
32841545|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
32902952|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
33103876|NCT04917783|Experimental|Health Literacy|"Participants randomized to the experimental health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations of their neurocognitive testing results along with the full written report. The domains listed as either satisfactory or needing help listed on the passport card will directly correspond to those listed on the full report."
33103877|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
32957547|NCT04374318|Active Comparator|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
32957548|NCT04374318|Active Comparator|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
32957549|NCT04374552|Experimental|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
32957550|NCT04374552|Placebo Comparator|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
32957551|NCT04374162|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
32957552|NCT04374162|Experimental|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
32957553|NCT04373850|Experimental|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
32957554|NCT04373850|No Intervention|Control group|Will receive only the standard discharge planning.
32957555|NCT04374006|Experimental|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
32957556|NCT04374006|Experimental|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
32957557|NCT04374006|Active Comparator|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
32957558|NCT04374006|Placebo Comparator|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
32957559|NCT04374006|Sham Comparator|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
32957560|NCT04373772|Experimental|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
32957561|NCT04373772|No Intervention|control group|Routine care for the control group
32957562|NCT04373538|Experimental|Memory Support Intervention|
32957563|NCT04373304|Experimental|low FODMAP diet|
32957564|NCT04373070|Experimental|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
32957565|NCT04373070|Other|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
32957566|NCT04372836|No Intervention|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
32957567|NCT04372836|Experimental|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
32957568|NCT04372290|Experimental|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
32957569|NCT04372290|Experimental|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
33417171|NCT01357187|Other|Control|
33417172|NCT01357187|Experimental|Treatment|
32957570|NCT04372290|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
32957571|NCT04372290|Experimental|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
32957572|NCT04372290|Experimental|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
33103878|NCT04908852||Cohort 1|This is a prospective, longitudinal, observational exploratory study. Ten subjects will be enrolled and will complete baseline and week 4 blood draws and symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
33103879|NCT04756388|Active Comparator|Executive Training|The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
33417173|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
33417174|NCT01349543|Experimental|Viral Challenge|
32957573|NCT04372290|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
32957574|NCT04372290|Experimental|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
33405795|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
33405796|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
33405797|NCT05200533|Experimental|Task-sharing and shifting|In the task-sharing and shifting group, family physicians shifted acute low back pain consultations to physiotherapists. Patients with acute low back pain are seen by the physiotherapist instead of family physician. Physiotherapist diagnose acute low back pain, identify red and yellow flags, prescribe sick leave and medications and can refer the patient to additional physical therapy treatment.
33405798|NCT05200533|Active Comparator|Usual care|In the usual care group, patients with acute low back pain are seen by their family physician.
33405799|NCT05560815||The Swedish surgical population|All adult patients (≥18 years) undergoing any surgical procedure registered in SPOR during 1 January 2015 - 31 December 2020.
32841546|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
32841547|NCT04750161||Psoriasis Vulgaris|
32841548|NCT04750161||Atopic Dermatitis|
32841549|NCT04750161||Ichthyosis Vulgaris|
32841550|NCT04750161||Healthy Controls|
32841551|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
32841552|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
32841553|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
32841554|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
32841555|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
32841556|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
32841557|NCT04750083|Experimental|phase II|Thirty-sixty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
32841558|NCT04750083|Experimental|phase III-experimental|Three hundred and twenty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
32841559|NCT04750083|Experimental|phase III-control|Three hundred and twenty participants will receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
32841560|NCT04409912|Experimental|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
32841561|NCT04409912|Placebo Comparator|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
32841562|NCT02124603||single group|Patients undergone cataract surgery
32841563|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
32841564|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
32841565|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
32841566|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
32841567|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
32841568|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
32841569|NCT02945787|Experimental|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
33405800|NCT05200299|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 12 cycles as adjuvant chemotherapy. They can change the regimen to mFOLFOX6 or CapeOx after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mFOLFOXIRI. Total 24 weeks.
32841570|NCT02945787|Active Comparator|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
32841571|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
32841572|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
32841573|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
32841574|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
32841575|NCT02892591|Placebo Comparator|Placebo|No active study drug
32841576|NCT00469911|Experimental|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
32841577|NCT00469911|Experimental|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
32841578|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
32841579|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
32841580|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
32841581|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
32841582|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
32841583|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
32841584|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
32841585|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
32841586|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
32841587|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
32841588|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
32841589|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
32841590|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
32841591|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
32841592|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
32841593|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
32841594|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
32902953|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
33319796|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~Day 8-12 (during CRT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
33319797|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
33319798|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
32841595|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
32841596|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
33319799|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
33319800|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
33319801|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
33319802|NCT03794960|Experimental|TOL-3021|
33319803|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
33319804|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
33319805|NCT00980954|Experimental|Arm I: Cisplatin/Radiation Therapy|Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
33319806|NCT00980954|Experimental|Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel|Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33319807|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
32841597|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
33319808|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
33319809|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
32841598|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
32841599|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
32841600|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
32841601|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
32841602|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
32841603|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
32841604|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
32841605|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
32841606|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
32841607|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
32957575|NCT04372290|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
33319810|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
33319811|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
33319812|NCT05625386|Other|Real Stimulation|The continuous theta burst stimulation (iTBS) protocol lasted 10 min and consisted of 1800 pulses. In the iTBS session, this 10min protocol was repeated for ten times (18000 pulses in total) separated by 50 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first iTBS session and after the last iTBS session.
33319813|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
33319814|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
33319815|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
33319816|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
33319817|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
33319818|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
33319819|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
32957576|NCT04372290|Experimental|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
33319820|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
33319821|NCT05625230|Experimental|Behavior activation-PLUS T-RAC|Behavioral: Behavior activation/BA plus T-RAC Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity. After activity planning, the participants will follow an XboxKinect exergame for 10 minutes, an actfulness exercise and will imagine one planned activity using dynamic imagery. From session 2 restructuring action memories are added.
33319822|NCT05625230|Active Comparator|Arm 2 Behavioral activation|"Behavioral: Behavior activation/BA Participants in the behavioral activation arm will undergo a BA procedure. A therapist will administer an 8 sessions behavioral activation intervention based on the manual used in the COBRA trial.~Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity."
33319823|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
33319824|NCT03794648|Experimental|Intervention Group|
32957577|NCT04372290|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
32957578|NCT04372212|Active Comparator|Inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
32841608|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
33405801|NCT05200299|Active Comparator|mFOLFOX6 or CapeOx adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 12 cycles as adjuvant chemotherapy or CapeOx once every three weeks for 8 cycles as adjuvant chemotherapy. Total 24 weeks.
32841609|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
32841610|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
32841611|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
32841612|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
32841613|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
32841614|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
32841615|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
32841616|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
32841617|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
32841618|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
32841619|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
32841620|NCT04080167|Other|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
32841621|NCT04080167|Other|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
32841622|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
32841623|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
32841624|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
32841625|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
32841626|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
32841627|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
32841628|NCT01461551|Experimental|Sevoflurane|
32841629|NCT01461551|Experimental|Propofol|
32841630|NCT01461551|Experimental|Combine of sevoflurane and propofol|
32841631|NCT04077359|Experimental|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
32841632|NCT04077359|Active Comparator|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
32841633|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
32841634|NCT04599257|Experimental|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
32841635|NCT01460381|Experimental|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
32841636|NCT01460381|Experimental|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.~Period 2 (Days 8-15): EM participants did not participate in this period."
32841637|NCT02985359||Comparison district|Existing routine community health services by government
32841638|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
32841639|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
33417175|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
32841640|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
33417176|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
33417177|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
33417178|NCT01353209|Experimental|Letrozole|
33417179|NCT01353209|Placebo Comparator|Placebo|
33417180|NCT04700137|Active Comparator|Caring Contacts + Introductory Phone Call (CC+)|"Healthcare provider and staff participants who are randomized to both caring text messages and an introductory phone call.~Adult and adolescent participants who are randomized to both caring text messages and an introductory phone call."
33417181|NCT04700137|Active Comparator|Caring Contacts (without phone call) (CC)|"Healthcare provider and staff participants who are randomized to only caring text messages.~Adult and adolescent patient participants who are randomized to only caring text messages."
32841641|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
32841642|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
32841643|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
32841644|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
32841645|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
32841646|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
32841647|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
32841648|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
32841649|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
32841650|NCT01796847||PTEN, hyperglycemia|
32841651|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
32841652|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
32841653|NCT03431259|Experimental|Enrollment group|
32841654|NCT03431259|No Intervention|Information group|
32841655|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
32841656|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
32841657|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
32841658|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
32841659|NCT00475215|Experimental|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
32841660|NCT00475215|Experimental|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
32841661|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
32841662|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
33417182|NCT03637491|Experimental|Avelumab and binimetinib|Open label
33417183|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
33319825|NCT03794648|No Intervention|Control Group|
33417184|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
32739512|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
32739513|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
32841663|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
33417185|NCT01353287||TAVI live case or video-taped transmission|
33417186|NCT01353287||TAVI without transmission|
33417187|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
33417188|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
33417189|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
32739514|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
32739515|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
32739516|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
32739517|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
32739518|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
32739519|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
32739520|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
32739521|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
32739522|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
32739523|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
32739524|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
32739525|NCT05715203||Syndromic TAA|Subjets with clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
32739526|NCT05715203||Non-syndromic TAA|Subjets without clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
32739527|NCT05702567|Experimental|RF + PFMT|The participants recieve 18 sessions of radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one.
32739528|NCT05702567|Placebo Comparator|PFMT|The participants recieve 18 sessions of no radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one. The RF device is started, but in this case, the program does not work or apply radiofrequency to the patients.
32739529|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
32739530|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
32739531|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
32739532|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
32739533|NCT05679323||Early discharge|Patients who will be discharged 24 hours after cesarean section
32739534|NCT05679323||Traditional discharge|Patients who will be discharged 48 hours after cesarean section
32739535|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
32739536|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
32739537|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
32739538|NCT03208777||control group|taking blood samples from apparently healthy people
32739539|NCT03208777||benign colorectal|taking blood samples from patients
32739540|NCT03208777||malignant colorectal|taking blood samples from patients
32739541|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
32739542|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
32739543|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
32739547|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
32739548|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
32739549|NCT05667233|Active Comparator|Train to failure|Training regime will be highly uncomfortable since it will be both physically and psychologically challenging to push to momentary muscular fatigue (MMF; i.e., failure).
32739550|NCT05667233|Active Comparator|Train to non-failure|Training regime will be moderately uncomfortable as participants will be training at a close proximity to failure (4-0 repetitions in reserve; i.e., non-failure).
32739551|NCT03195439|Experimental|patients in ICU|
32739552|NCT02481089||training group|
33405802|NCT05746611|Experimental|Cohort 1|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.~Purified protein derivative (TB-PPD) :~Dosage form: Injection. Main components and contents: Purified protein derivative of tuberculin 50IU/ml. 0.1ml (5U) of the product was inhaled and injected into the palmar skin of the forearm by the Mondu's method."
33103880|NCT04756388|Experimental|Strategy Development only|In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
33405803|NCT05746611|Experimental|Cohort 2|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
33405804|NCT05741307|Experimental|Patients 2|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application 6 weeks after inclusion : from T1 to T2."
33405805|NCT05741307|Experimental|Patients 1|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application at inclusion : from T0 (inclusion) to T1."
33405806|NCT03940989|Experimental|3-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, 5 days/week for three weeks.
33405807|NCT03940989|Experimental|15-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, one day/week for 15 weeks.
33405808|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
33417190|NCT04550455|Experimental|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
32841664|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
32841665|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
32841666|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
32841667|NCT04085263|Sham Comparator|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
32841668|NCT04085263|Experimental|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
32841669|NCT01500187|Active Comparator|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
32841670|NCT01500187|Experimental|3M Vanish Varnish|5% sodium fluoride varnish
32841671|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
32841672|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
32841673|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
32841674|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
32841675|NCT04085185|Experimental|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
32841676|NCT04085185|Experimental|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
32841677|NCT04085185|Experimental|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
32841678|NCT04085185|Experimental|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
32841679|NCT00479037|Active Comparator|PTH(1-84)|
33417191|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
32841680|NCT00479037|Active Comparator|Strontium Ranelate|
32841681|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
32841682|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
32841683|NCT00479115|Experimental|AMD3100|
32841684|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
32841685|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
32841686|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
32841687|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
32841688|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
32841689|NCT04082767|Active Comparator|Dexmedetomidine|
32841690|NCT04082767|Active Comparator|Midazolam|
32841691|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
32841692|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
32841693|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
32841694|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
32841695|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
32841696|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
32841697|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
32841698|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
32841699|NCT01456897|Experimental|OPC-34712|
32841700|NCT04082689|Active Comparator|Assisted Infant Toilet Training-Group A|"Parents to Children randomized to group A will be instructed in how infant toilet training is performed by the investigators. They receive a book in Swedish concerning infant toilet training and a brief summary of the book made by the investigators. The parents are encouraged to begin infant toilet training as early as possible, 0-2 months of age~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
32841701|NCT04082689|Active Comparator|Assisted Infant Toilet Training- Group B|"Parents to Children randomized to group B will be instructed in how infant toilet training is performed by the co-workers doing the ultrasound measure of rectal diameter at 9 months. They receive a book in Swedish concerning infant toilet training and a brief summary of it made by the investigators. They start infant toilet training at the age of 10-11 months.~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
32841702|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
32841703|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
32841704|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
32841705|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
32841706|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
32841707|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
32841708|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
32841709|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
32841710|NCT04748263||Fronto-Temporal Dementia (FTD)|10 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
32841711|NCT04748263||Alzheimer's Dementia (AD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
32841712|NCT04748263||Parkinson's Disease (PD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
32841713|NCT04748263||Healthy volunteers|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
33417192|NCT04250753||Patients with lumbar spinal stenosis|
33417193|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
33417194|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
32841714|NCT04082533|Active Comparator|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
32841715|NCT04082533|Placebo Comparator|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
32841716|NCT04082533|Active Comparator|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
32841717|NCT04082533|Placebo Comparator|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
32841718|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
32841719|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
32841720|NCT00556491|Active Comparator|minocycline|
32841721|NCT00556491|Placebo Comparator|placebo|
32841722|NCT05622669||Myeloma|Individuals experiencing fatigue related to myeloma or its treatment
32841723|NCT05622669||Long COVID|Individuals experiencing fatigue related to Long COVID
32841724|NCT05622669||Heart failure|Individuals experiencing fatigue related to heart failure or its treatment
32841725|NCT05622669||Controls|Individuals who are not experiencing problematic fatigue and who do not have myeloma, long COVID, or heart failure
32841726|NCT05622591|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001
32841727|NCT05622513||cases|obesity / overweight children
32841728|NCT05622513||controls|normal weight children
32841729|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
32841730|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
32841731|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
32841732|NCT05622357|Experimental|Short course RT followed by full course of chemotherapy then surgery|Short course radiation therapy ( 25 Gy/ 5 fractions/ 1 week) , followed by 6 cycles of chemotherapy CAPOX, followed 4-6 weeks by surgery.
32841733|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
32841734|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
32841735|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
32841736|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
32841737|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
32841738|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
32841739|NCT05622279|Experimental|percutaneous tenotomy + PRP|There will be a single arm receiving the treatment being evaluated
32841740|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
32841741|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
32841742|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
32841743|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
32841744|NCT01455415|Experimental|1: Pregabalin|
32841745|NCT01455415|Placebo Comparator|2: Placebo|
32841746|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
32841747|NCT01471171|Experimental|Placebo|3-week treatment periods
32841748|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
32841749|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
32841750|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
32841751|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
32841752|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
32841753|NCT01497067|Experimental|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
32841754|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
32841755|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
32841756|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
32841757|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
32841758|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
32841759|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
32841760|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
32841761|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
32841762|NCT01470469|Active Comparator|SPD503|
32841763|NCT01470469|Placebo Comparator|Placebo|
32841764|NCT04644367|Experimental|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
32841765|NCT04644367|Active Comparator|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity on their own for three times per week. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
32841766|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
32841767|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
32841768|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
32841769|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
32841770|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
32841771|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
32841772|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
32841773|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
32841774|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
32841775|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
32841776|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
32841777|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
32841778|NCT01586624|Experimental|Dose Escalation Phase Cohort 1 (Steady state dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841779|NCT01586624|Experimental|Dose Escalation Phase Cohort 2 (Steady state dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841780|NCT01586624|Experimental|Dose Escalation Phase Cohort 3 (Steady state dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
33417195|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
32841781|NCT01586624|Experimental|Dose Escalation Phase Cohort 4 (Steady state dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841782|NCT01586624|Experimental|Dose Escalation Phase Cohort 5a (Steady state dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841783|NCT01586624|Experimental|Dose Escalation Phase Cohort 5b (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841784|NCT01586624|Experimental|Dose Escalation Phase Cohort 6 (Steady state dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
32841785|NCT01586624|Experimental|Expansion Phase (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Expansion cohort at the recommended phase 2 dose of vandetanib and selumetinib defined in the escalation phase.
32841786|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
32841787|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
32841788|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
32841789|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
32841790|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
32841791|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
32841792|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring < 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
32841793|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring > 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
32841794|NCT01458587|Experimental|ALA|
32841795|NCT01458587|Placebo Comparator|Vehicle|
32841796|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
32841797|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
32841798|NCT01458275|Placebo Comparator|Placebo|
32841799|NCT01458119|Experimental|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
32841800|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
32841801|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
32841802|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
32841803|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
32841804|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
32841805|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
32841806|NCT01585766|Experimental|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
32841807|NCT01585766|Experimental|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
32841808|NCT01585766|Experimental|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
32957579|NCT04372212|Active Comparator|Inversion and Ligation|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
32957580|NCT04372134|Active Comparator|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
32957581|NCT04372134|Sham Comparator|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
32957582|NCT04371978|Experimental|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
32957583|NCT04371978|No Intervention|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
32957584|NCT04371822|Active Comparator|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
32957585|NCT04371822|Active Comparator|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
32957586|NCT04371822|Active Comparator|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
32957587|NCT04371822|Active Comparator|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
32957588|NCT04371822|Placebo Comparator|placebo|No intervention
32957589|NCT04371510|Other|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
32957590|NCT04370886|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
32957591|NCT04370886|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
32957592|NCT04370886|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
32957593|NCT04370886|Placebo Comparator|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
32957594|NCT04370964|Other|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
32957595|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
32957596|NCT04370808||Critical patients|Critical patients (admission to ICU)
32957597|NCT04370496|Experimental|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
33405809|NCT03875781|Active Comparator|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
33405810|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
33405811|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
33405812|NCT05181423||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
33405813|NCT05181423||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
33405814|NCT04934319|Experimental|Balance training|A single training group
32957598|NCT04370262|Active Comparator|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
32957599|NCT04370262|Placebo Comparator|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
32957600|NCT04370340|No Intervention|control|
32957601|NCT04370340|Active Comparator|intervention|
32957602|NCT04369872|Experimental|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
32957603|NCT04369716|Active Comparator|Whole fruit 1|Oranges
32957604|NCT04369716|Active Comparator|Whole fruit 2|Apples
32957605|NCT04369716|Experimental|Juice 1 + pomace|Orange Juice + orange pomace
33417196|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
33417197|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
32957606|NCT04369716|Experimental|Juice 2 + pomace|Apple Juice + apple pomace
32957607|NCT04369716|Active Comparator|Juice 1 alone|Orange Juice
33417198|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
32957608|NCT04369716|Active Comparator|Juice 2 alone|Apple Juice
32841809|NCT01585766|Experimental|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
32841810|NCT01585766|Experimental|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
32841811|NCT01585766|Placebo Comparator|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
32841812|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
32841813|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
32841814|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
32841815|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
32841816|NCT01457339|Placebo Comparator|Placebo|
32841817|NCT01456949|Other|Single Arm|Cryoablation
32841818|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
32841819|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
32841820|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
32841821|NCT04077047|Other|Intervention pilot|
32841822|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
32841823|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
32841824|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
32841825|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
32841826|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
32841827|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
32841828|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
32841829|NCT04530773|Experimental|GROUP1|
32841830|NCT04530773|Experimental|GROUP2|
32841831|NCT04530773|Experimental|GROUP3|
32841832|NCT04530773|Experimental|GROUP4|
32841833|NCT04530773|Experimental|GROUP5|
32841834|NCT01585298|Experimental|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
32841835|NCT04124198|Experimental|Transoral robotic surgery (TORS)|
32841836|NCT04124198|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
32841837|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
32957609|NCT04369404|No Intervention|Usual care|In the usual care group, the providers do not have access to the decision aids.
32957610|NCT04369404|Experimental|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
32957611|NCT04369248||Control group|30 healthy women with BMI < 30 between 18 and 35 years old
32841838|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
32841839|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
32841840|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
32841841|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
32841842|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
32841843|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
32841844|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
32841845|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
32841846|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
32841847|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
32841848|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
32841849|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
32841850|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
32841851|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
32841852|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
32841853|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
32841854|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
32841855|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
32841856|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
32841857|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
32841858|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
32841859|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
32841860|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
32841861|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
32841862|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
32841863|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
32841864|NCT01496287|Experimental|Tube placement group|
32841865|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
32841866|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
32841867|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
32841868|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
32841869|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
32841870|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
32841871|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
33033396|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
33405815|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
32841872|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
32841873|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
32841874|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
32841875|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
32841876|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
32841877|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
32841878|NCT04767932|Experimental|control group|the control group will receive regular exercise training at same time.
32841879|NCT04113200|Experimental|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
32841880|NCT04113200|Other|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
32841881|NCT04112810|Experimental|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
32841882|NCT01584440|Placebo Comparator|Placebo|Participants will receive placebo during Stage 1 and Stage 2 of the study.
32841883|NCT01584440|Experimental|AVP-923|Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
32841884|NCT01584440|Experimental|Placebo then AVP-923|Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.
32841885|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
32841886|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
32841887|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32841888|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32841889|NCT01468597||One group|Emergency surgery
32841890|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
32841891|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
32841892|NCT04112342|Other|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin.
32841893|NCT04112342|Other|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin
32841894|NCT04112342|Other|Cohort 3|Patients who will receive palliative radiation (+/-concurrent systemic therapy) for any tumor involving the skin.
32841895|NCT04112342|Other|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin.
32841896|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
32841897|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
32841898|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
32841899|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
32841900|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
32841901|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
32841902|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
32841903|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
32841904|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
32841905|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
32841906|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
32841907|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
32841908|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
32841909|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
32841910|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
32841911|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
32841912|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
32841913|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
32841914|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
32841915|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
32841916|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
32841917|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
32841918|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
32841919|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
32841920|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
32841921|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
32841922|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
32841923|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
32841924|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
32841925|NCT01560416|Active Comparator|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
32841926|NCT01560416|Active Comparator|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
32841927|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
32841928|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
32841929|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
32841930|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
32841931|NCT01685138|Experimental|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
32841932|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
32841933|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
32841934|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
32841935|NCT03887936|Experimental|Testosterone arm|Testosterone gel 1.62%
32841936|NCT03887936|Placebo Comparator|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
32841937|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
32841938|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
32841939|NCT04410458|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
32957612|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score >8 and/ or hyperandrogenemia defining the testosterone level > 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level > 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume >10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI < 30 between age of 18 and 35.
32957613|NCT04369248||Obese PCOS|Obese group are the women with BMI > 30 between age of 18 and 35.
32957614|NCT04369092|Other|without swallowing problem|patients without swallowing problem
32957615|NCT04369092|Other|mild swallowing problem|patients with mild swallowing problem
32957616|NCT04369092|Other|severe swallowing problem|patients with severe swallowing problem
32957617|NCT04369170|Other|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
32957618|NCT04369170|Experimental|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
32957619|NCT04368624||Participants with PKU|"Patients with classical PKU phenotype (serum phenylalanine concentration > 10 mg/dL on a normal diet at diagnosis) # ~25~Patients with hyperphenylalaninemia (serum phenylalanine concentration < 10 mg/dL on a normal diet at diagnosis) # ~15~Patients with PKU on therapy with Kuvan # ~10"
32957620|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
32957621|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
32957622|NCT04368546||Healthy controls|Age-matched subjects without known disease.
32957623|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
32957625|NCT04368000|Experimental|Prone Positioning|
32957626|NCT04368000|Active Comparator|Usual care|
32957627|NCT04367766|Active Comparator|Immediate Implant Placement|prosthetically driven immediate implant placement (WinSix, Biosafin) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
32957628|NCT04367766|Active Comparator|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm
32957629|NCT04367766|Active Comparator|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm .
32957630|NCT04367532|Experimental|Foam rolling|Foam rolling of cuff muscles.
32957631|NCT04367532|Experimental|Tissue flossing|Tissue flossing of cuff muscles.
32957632|NCT04367532|No Intervention|Control group|Without any intervention.
32957633|NCT04367376|Experimental|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
32957634|NCT04367376|Experimental|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
32957635|NCT04367454|Experimental|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
32957636|NCT04367454|No Intervention|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
32957637|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
32957638|NCT04366986||Pregnant Women|Women who are currently pregnant
32957639|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
32957640|NCT04366674|Active Comparator|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
32957641|NCT04366674|Active Comparator|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
32957642|NCT04366674|Experimental|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
32957643|NCT04366596|Experimental|DEB group|angioplasty with paclitaxel eluting balloon
32957644|NCT04366596|Placebo Comparator|POB group|Angioplasty with plain old balloon
32957645|NCT04366284|Active Comparator|NOCTEM only (NOCTEM)|No external or internal facilitation
32957646|NCT04366284|Active Comparator|External Facilitation (NOCTEM+EF)|External facilitation only
32957647|NCT04366284|Active Comparator|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
32957648|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
32957649|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
32957650|NCT04366128|Experimental|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
32957651|NCT04365972|Experimental|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
32957652|NCT04366050|Experimental|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days~Intervention: Ramipril"
32957653|NCT04366050|Placebo Comparator|Placebo|Placebo in the form of a capsule, taken orally for 14 days
32957654|NCT04365894|No Intervention|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
32957655|NCT04365894|Experimental|Intervention|The intervention group with learning activities based on the transformative learning theory.
32957656|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957657|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957658|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957659|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957660|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957661|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957662|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
32957663|NCT04365738|Experimental|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
32957664|NCT04365738|Placebo Comparator|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
32957665|NCT04365582|Experimental|Azithromycin|Azithromycin
32957666|NCT04365582|Experimental|Hydroxychlororquine|Hydroxychlororquine
32957667|NCT04365582|Experimental|Lopinavir/Ritonavir|Lopinavir/Ritonavir
32957668|NCT04365582|No Intervention|standards of care|SoC
32957669|NCT04365270|Experimental|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.~will be placed in the prepared cavity over the last layer of caries"
32957670|NCT04365270|Experimental|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
32957671|NCT04365270|Active Comparator|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
32957672|NCT04365270|Placebo Comparator|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
32957673|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score <-2.5 as determined by dual energy X ray absorbitometry
32957674|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
32957675|NCT04365504||Normal|Post menopausal females with T score >-1 as determined by dual energy X ray absorbitometry
32957676|NCT04365192||I-gel|
32957677|NCT04365192||Self-pressurized air-Q|
32957678|NCT04365426|Experimental|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
32957679|NCT04365426|Experimental|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
32957680|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.~Eligible consenting patients will sign informed consent."
32957681|NCT04365036|Experimental|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
32957682|NCT04365036|Active Comparator|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
32957683|NCT04364490|Experimental|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
32957684|NCT04364490|Experimental|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
33405816|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
33405817|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
33405818|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
33405819|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
33405820|NCT05543733|Experimental|Home exercise program|
33405821|NCT05732532|Active Comparator|Anesthetic without steroid group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and normal saline.
33405822|NCT05732532|Experimental|Anesthetic with dexamethasone group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and dexamethasone.
33405823|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 15 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, for 16 to 18 days
33405824|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation + supplementation coenzyme Q10|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 22 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, 22 patients who will be on spa rehabilitation and at the same time on supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg, for 16 to 18 days
33405825|NCT05178225|Placebo Comparator|healthy control|15 healthy control volunteers (no Covid-19 or other pathologies)
33405826|NCT05210244|Experimental|BJ supplementation|
33405827|NCT05210244|Placebo Comparator|PLA supplementation|
33405828|NCT05731908|Experimental|BI 690517 mild hepatic impairment (Child-Pugh A)|
33405829|NCT05731908|Experimental|BI 690517 normal hepatic function|control group
33405830|NCT05731908|Experimental|BI 690517 moderate hepatic impairment (Child-Pugh B)|
33405831|NCT05543187|Experimental|TAK-625, Primary cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose [MTD]), orally, BID up to study completion.
33405832|NCT05543187|Experimental|TAK-625, Supplemental cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose [MTD]), orally, BID up to study completion.
33405833|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
33405834|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
32957685|NCT04364490|Active Comparator|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
32957686|NCT04364334||Knee registry patients|
32957687|NCT04363944|Experimental|mRehab|Use of mRehab in a home program
32957688|NCT04364022|Active Comparator|Lopinavir/Ritonavir|
32957689|NCT04364022|No Intervention|Active surveillance|
32957690|NCT04363710|Experimental|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
32957691|NCT04363710|No Intervention|Control Group|Participants in this arm were kept on their standard medical treatment
32957692|NCT04363866|Experimental|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
32957693|NCT04363866|Placebo Comparator|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
32957694|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
32957695|NCT04363554|Other|Urine dilution test|Urine dilution test
32957696|NCT04363554|Other|Urine concentration test|Urine concentration test
32957697|NCT04363476|Experimental|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
32957698|NCT04363476|Other|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
32957699|NCT04363242|Experimental|Part A|Dose escalation of SYN125. Each dose level (low, medium, high) will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
32957700|NCT04363242|Experimental|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
32957701|NCT04363086|Experimental|TAU|
32957702|NCT04363086|Experimental|iFD|
32957703|NCT04363086|Experimental|iFD + weekly phone calls|
32957704|NCT04363398|Experimental|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
32957705|NCT04363398|Active Comparator|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
32957706|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
32957707|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
32957708|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
32957709|NCT04362384|Experimental|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
32957710|NCT04362384|Active Comparator|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
32957711|NCT04361916|Experimental|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
32957712|NCT04361760|Experimental|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
32957713|NCT04361760|Experimental|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
32957714|NCT04361526|No Intervention|Control|standard intensive care alone
32957715|NCT04361526|Experimental|Cytokine Adsorption|cytokine adsorption plus standard intensive care
32957716|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
32957717|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
32957718|NCT04361448|Other|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
32957719|NCT04361292|Active Comparator|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
32957720|NCT04361292|Active Comparator|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
32957721|NCT04361214|Experimental|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
32957722|NCT04361370|Experimental|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
32957723|NCT04361136|Experimental|Delgocitinib cream 1 mg/g|Single topical occlusive administration
32957724|NCT04361136|Experimental|Delgocitinib cream 3 mg/g|Single topical occlusive administration
32957725|NCT04361136|Experimental|Delgocitinib cream 8 mg/g|Single topical occlusive administration
32957726|NCT04361136|Experimental|Delgocitinib cream 20 mg/g|Single topical occlusive administration
32957727|NCT04361136|Placebo Comparator|Delgocitinib cream vehicle|Single topical occlusive administration
32957728|NCT04361058|Experimental|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
32957729|NCT04361058|Experimental|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
32957730|NCT04360746|Active Comparator|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
32957731|NCT04360746|Other|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
32957732|NCT04360902|No Intervention|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
32957733|NCT04360902|Experimental|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
33405835|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
33405836|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
32957734|NCT04360668|Experimental|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
32957735|NCT04360668|Active Comparator|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
32957736|NCT04360668|Active Comparator|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
32957737|NCT04360512|Experimental|One session|One session of talus posteriorization
32957738|NCT04360512|Experimental|Two sessions|Two sessions of talus posteriorization
32957739|NCT04360512|Experimental|Three sessions|Three sessions of talus posteriorization
32957740|NCT04360512|Experimental|Four sessions|Four sessions of talus posteriorization
32957741|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
32957742|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
32957743|NCT04359966|Active Comparator|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
32957744|NCT04359966|Experimental|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
32957745|NCT04359966|Active Comparator|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
33405837|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
33405838|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
32957746|NCT04359966|Experimental|Second line therapy for H pylori infection second arm|"Tripple second line therapy~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
32957747|NCT04360122|Active Comparator|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
32957748|NCT04360122|Active Comparator|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
32957749|NCT04360122|Active Comparator|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
32957750|NCT04360122|No Intervention|Non-interventional group|No-intervention
32957751|NCT04360356|Experimental|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
32957752|NCT04360356|Active Comparator|Standard care|Oxygen via ventilators
32957753|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
32957754|NCT04359810|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
32957755|NCT04359810|Active Comparator|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019
32957756|NCT04359264|Experimental|Cash transfer|
32957757|NCT04359264|No Intervention|Control|
32957758|NCT04359342|Experimental|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
32957759|NCT04359342|Placebo Comparator|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
32957760|NCT04359342|Experimental|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
32957761|NCT04359342|Placebo Comparator|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
32957762|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
32957763|NCT04358796|Experimental|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
32957764|NCT04358796|Sham Comparator|Control environment|Cognitive testing in 1ATA, air in breathing-masks
32957765|NCT04358718|Active Comparator|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
32957766|NCT04358718|Experimental|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
32957767|NCT04358562|Experimental|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
32957768|NCT04358562|Experimental|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
32957769|NCT04358250|Experimental|direct superior approach|Direct superior approach 25 patients
32957770|NCT04358250|Active Comparator|posterolateral approach|posterolateral approach 25 patients
32957771|NCT04358094|Experimental|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
32957772|NCT04358094|Other|Standard script|Patient who received standard script during peripherical veinous access set up
32957773|NCT04358484|Experimental|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
32957774|NCT04358484|No Intervention|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
32957775|NCT04358172|Experimental|Mobile app|Participants in this group is educated using the mobile application
32957776|NCT04358172|No Intervention|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
32957777|NCT04357860|Experimental|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
32957778|NCT04357860|Experimental|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
32957779|NCT04357860|Active Comparator|Control|Subjects treated with the best available treatment up to 14 days.
32957780|NCT04358016|Experimental|terlipression|terlipression 1mg；once every 6 hours；5days
32957781|NCT04358016|Active Comparator|Control|Somatostatin，3mg， once every 12 hours; 5 days
32957782|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
32957783|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
32957784|NCT04357704|Experimental|bilateral cochlear implant recipients|
32957785|NCT04357704|Active Comparator|normal hearing listners|
32957786|NCT04357470|Active Comparator|USF Group|DRF with ulnar styloid fracture
32957787|NCT04357470|Active Comparator|NON-USF Group|DRF without ulnar styloid fracture
32957788|NCT04357392|Experimental|Glucocorticoid intervention group|prednisone
32957789|NCT04357392|Placebo Comparator|Placebo control group|placebo
32957790|NCT04357002|Experimental|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
32957791|NCT04357002|Active Comparator|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
32957792|NCT04357002|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
32957793|NCT04357080||Case|Patients with urethral stricture recurrence
32957794|NCT04357080||Control|Patients with normal, patent urethra
32957795|NCT04356924|Experimental|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
32957796|NCT04356924|Active Comparator|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
32957797|NCT04356924|No Intervention|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers.
32957798|NCT04356846|Experimental|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
32957799|NCT04356846|Experimental|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
32957800|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
32957801|NCT04356222|Experimental|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
32957802|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
32957803|NCT04356300|Experimental|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
32957804|NCT04356300|No Intervention|The control arm|Patients in the control arm will not be given exosome of MSC.
32957805|NCT04356456|Experimental|Lumenato Supplement|Lumenato oleoresin
32957806|NCT04356456|Placebo Comparator|Placebo|paraffin oil
32957807|NCT04355988|Active Comparator|Well controlled diabetics|Nonsurgical root canal treatment
32957808|NCT04355988|Active Comparator|Poorly controlled diabetics|Nonsurgical root canal treatment
32957809|NCT04355988|Active Comparator|Healthy control group|Nonsurgical root canal treatment
32957810|NCT04356066|Other|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.~Physical examination including thorough clinical examination.~Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
32957811|NCT04355754|Experimental|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
32957812|NCT04355910|Experimental|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
32957813|NCT04355910|Active Comparator|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
32957814|NCT04355910|No Intervention|Control|No advice to restrict energy
33405839|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
33405840|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
33405841|NCT04624620|Experimental|Pilot|Participants will participate in a 16 week, culinary intensive study that will consist of 2 hour virtual classes taught by a chef, a dietitian, and a health coach that focus on diet, culinary competency, daily physical activity, mindfulness and support for behavior change.
33405842|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
33405843|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
33405844|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
33405845|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
33405846|NCT05210166|Active Comparator|Active tSCS and Lokomat|"20 sessions, 5 sessions per week of active transcutaneous spinal cord stimulation (tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes tSCS will be applied at the beginning of each session."
32957815|NCT04355676|Experimental|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
32957816|NCT04355676|Experimental|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
33405847|NCT05210166|Placebo Comparator|Sham tSCS and Lokomat|"20 sessions, 5 sessions per week of sham transcutaneous spinal cord stimulation (sham-tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes sham-tSCS will be applied at the beginning of each session."
33405848|NCT05542407|Experimental|Obese|Subjects with BMI > 30 kg/m2
33405849|NCT05542407|Experimental|Non-Obese|Subjects with BMI ≤ 29.9 kg/m2
33405850|NCT05284682||Dilated cardiomyopathy|Patients with heart failure on the basis of dilated cardiomyopathy.
32957817|NCT04355598|Experimental|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
32957818|NCT04355598|Active Comparator|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
32957819|NCT04355598|Placebo Comparator|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
32957820|NCT04355286|Experimental|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
32957821|NCT04355520|Experimental|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
32957822|NCT04355442||contained patients|contained patients
32957823|NCT04355442||Comparative patients|Comparative patients
32957824|NCT04355208|Experimental|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
32957825|NCT04355208|Active Comparator|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
32957826|NCT04355052|Active Comparator|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
32957827|NCT04355052|Experimental|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
32957828|NCT04355052|No Intervention|C - NI|No Intervention
32957829|NCT04354974|Active Comparator|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper and pencil exercises and manipulable tools~Objective: Learning problem-solving strategies for use in daily life~Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
32957830|NCT04354974|Active Comparator|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper tools and verbal exchange with the patient~Objective: Improvement of the patient's quality of life~Themes: Mood, social skills, autonomy, motivation, sleep"
32957831|NCT04354896|Experimental|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
32957832|NCT04354896|Placebo Comparator|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
32957833|NCT04354662|Experimental|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
32957834|NCT04354350||Ramipril|Reference group
32957835|NCT04354350||Telmisartan|Exposure group
32957836|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
32957837|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
32957838|NCT04354194|Experimental|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
32957839|NCT04354194|Experimental|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
32957840|NCT04354116|Experimental|MARPE|Maxillary expander anchored in mini-implants (MARPE)
32957841|NCT04354116|Active Comparator|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
32957842|NCT04353882||patients with tumor recurrence|
32957843|NCT04353882||patients with-out tumor recurrence|
33103881|NCT04756388|Experimental|Computerized Cognitive Training only|In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
33405851|NCT05284682||Control group without heart failure|Control group from the ablation laboratory without heart failure
33405852|NCT05210010|Other|Algorithm|All participating cardiologists.
32957844|NCT04353336|Experimental|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
32957845|NCT04353336|No Intervention|No intervention|standard of care treatment alone.
32957846|NCT04353726|Experimental|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
32957847|NCT04353180|Active Comparator|13 cis retinoic acid doses orally plus the standard therapy|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
33405853|NCT03792867|Experimental|Radical Resection and HIPEC|
33405854|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
33405855|NCT05755152|Experimental|Cranberry PLP|Chew the treatment chewing gum made with PLP for 30 minutes
32957848|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid plus the standard therapy|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
32957849|NCT04353180|Active Comparator|13 cis retinoic acid doses orally|Infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
32957850|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
32957851|NCT04353180|Sham Comparator|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
32957852|NCT04352868|Active Comparator|Toric soft contact lens|Toric soft contact lens
32957853|NCT04352868|Experimental|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
32957854|NCT04352946|Experimental|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
32957855|NCT04352946|Placebo Comparator|Placebo|Placebo will be administered as 400mg orally once for 60 days.
32957856|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
32957857|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
32957858|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
32957859|NCT04352322|Experimental|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
32957860|NCT04352322|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
32957861|NCT04352400|Active Comparator|Nafamostat|Nafamostat mesylate on top of best standard of care.
32957862|NCT04352400|Placebo Comparator|Placebo|Placebo on top of best standard of care.
32957863|NCT04352478||Elder|elderly (≥60 years old).
32957864|NCT04352478||Young|young (<60 years old)
32957865|NCT04351932|Active Comparator|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
32957866|NCT04351932|Active Comparator|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
32957867|NCT04351932|Active Comparator|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
32957868|NCT04352088||Allergic rhinitis patients|
32957869|NCT04352088||Allergic rhinitis and asthma patients|
32957870|NCT04352088||Healthy individuals|
32957871|NCT04351542|Experimental|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
32957872|NCT04351542|Active Comparator|Usual Care Group|Participants followed the usual care.
32957873|NCT04351464|Active Comparator|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
32957874|NCT04351464|Experimental|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
32957875|NCT04351308|Experimental|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);~I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);~apatinib = 500 mg QD;"
32957876|NCT04351308|Experimental|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);~camralizumab = 200mg ivgtt. Q2W;"
32957877|NCT04351308|Active Comparator|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);"
32957878|NCT04351152|Experimental|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
32957879|NCT04351152|Placebo Comparator|Placebo Arm|Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
33103882|NCT04741997|Active Comparator|Surveillance|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will receive adjuvant treatment for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
33405856|NCT05755152|Experimental|Cranberry Extract Control|Chew the control chewing gum made with Cranberry Extract for 30 minutes
33405857|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
32957880|NCT04351074|Active Comparator|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
32957881|NCT04351074|Active Comparator|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
33405858|NCT05754450|Experimental|AVTX-803|AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day
32957882|NCT04350918|Experimental|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
32957883|NCT04350918|Experimental|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
32957884|NCT04350762|Experimental|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
32957885|NCT04350762|No Intervention|Control|No dietary supplements. Participants will continue current intake.
32957886|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
32957887|NCT04350528||Chlorpromazine|
32957888|NCT04350528||Pentobarbital|
32957889|NCT04350684|Experimental|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
32957890|NCT04350684|Active Comparator|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
32957891|NCT04350450|Experimental|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
32957892|NCT04350450|No Intervention|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
32957893|NCT04350216|Experimental|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
32957894|NCT04349592|Experimental|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
32957895|NCT04349592|Active Comparator|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
32957896|NCT04349592|Placebo Comparator|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
32957897|NCT04349748|Experimental|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
32957898|NCT04349748|Experimental|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
32957899|NCT04349748|Experimental|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
32957900|NCT04349748|Experimental|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
32957901|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
32957902|NCT04348812|Experimental|tDCS Active|Transcranial direct current stimulation with ABMT
32957903|NCT04348812|Sham Comparator|tDCS sham|Transcranial direct current sham stimulation with ABMT
32957904|NCT04348890|Experimental|Treatment Arm|
33405859|NCT05338749|Experimental|Cognitive Training|Participants in this condition will received game-based cognitive training.
33033048|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)~Supernatant removed and collected into syringe~Injected onto surface of fat graft~Rest added to piece of gelfoam~Place gelfoam + PRP on the TM perforation"
33405860|NCT05174871|Active Comparator|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months
32957905|NCT04347330|Experimental|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP <120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP <120 mmHg or no more titration planned. If the home SBP is not <120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
32957906|NCT04347330|Active Comparator|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP <135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is <125 mmHg.
32957907|NCT04347642|Active Comparator|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
32957908|NCT04347642|Experimental|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
32957909|NCT04347252|Experimental|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
32957910|NCT04347252|Experimental|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
32957911|NCT04347252|Experimental|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
32957912|NCT04346940|Experimental|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
32957913|NCT04346940|Active Comparator|Control Group|Group to be given an exercise brochure
32957914|NCT04347096|Experimental|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
33405861|NCT05174871|Experimental|Time-Restricted Feeding|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.
33405862|NCT05193474|No Intervention|Refuse to integrate palliative care into usual care.|Usual ESRD care team
33405863|NCT05193474|Experimental|Agree to integrate palliative care into usual care.|Usual ESRD care + combined palliative care team
33405864|NCT04793841||General population|sexually experienced adults (aged 18 or above) of the randomly selected household
33405865|NCT04793841||men who have sex with men|men who have sex with men aged 18 or above and normally living in Hong Kong
33405866|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
33405867|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
33405868|NCT05139849|Active Comparator|Intervention|"Adrenaline, vasopressin and steroids arm (intervention)~At randomization~1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR.~1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR~In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the hydrocortisone dos will be reduced daily to 67 ml (200 mg) and 33 ml (100 mg) and then discontinued). Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml (300mg hydrocortisone/ d) for maximum 3 days to prevent retardation of infarct healing."
33417199|NCT01370161|Experimental|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
33417200|NCT01370161|Active Comparator|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
32841940|NCT04410458|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
32841941|NCT04410458|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
32841942|NCT04410458|Placebo Comparator|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
32841943|NCT01684202|Experimental|OPC-41061|
32841944|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
32841945|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
32841946|NCT01559090|Experimental|1|MEDI-546 100 mg IV
32841947|NCT01559090|Experimental|2|MEDI-546 300 mg IV
32841948|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
32841949|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
32841950|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
32841951|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
32841952|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
32841953|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
32841954|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
32841955|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
32841956|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
32841957|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
32841958|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
32841959|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
32841960|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
32841961|NCT04408261|Experimental|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
32841962|NCT04408261|Placebo Comparator|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
32841963|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
32841964|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
32841965|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
32841966|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32841967|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32902998|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
32902999|NCT03000985|No Intervention|Control|Treatment as usual
33319826|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
32903000|NCT00618332|Active Comparator|1|2 weeks of treatment
32903001|NCT00618332|Placebo Comparator|2|2 weeks of treatment
32903002|NCT03001141||Single group - observational|
32903003|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
32903004|NCT03000907|No Intervention|Control|Clinical practise
32903005|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
32903006|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
32903007|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
32903008|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
32903009|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
32903010|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
32903011|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
32903012|NCT03700190||Control|Healthy child
32903013|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
32903014|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
32903015|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
32903016|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
32903017|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
32903018|NCT00619970|Active Comparator|Healthy Control|Healthy controls
32903019|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
32903020|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
32903021|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
32903022|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
32903023|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
32903024|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
32903025|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
32903026|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
32903027|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
32903028|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
32903029|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
32903030|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
32903031|NCT03006991||poor efficacy|patients can not reach effective outcome.
32903032|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
32903033|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
32903034|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
32903035|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
32903036|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
32903037|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
32903038|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
32903039|NCT00620126|Active Comparator|Control|Best Available Care
32903040|NCT03376646|Experimental|Cohort A: Dissolve™|
32841968|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32841969|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32841970|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32841971|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
32841972|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
32841973|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
32841974|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
32841975|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
32841976|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
32841977|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
32841978|NCT01576484|Placebo Comparator|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
32841979|NCT01576484|Experimental|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
32841980|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
32841981|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
32841982|NCT01467427|Experimental|NNC-0156-000-0009|
32841983|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
32841984|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
32841985|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
32841986|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
32841987|NCT01576406|Experimental|A1: normal hepatic function|
32841988|NCT01576406|Experimental|A2: normal hepatic function|
32841989|NCT01576406|Experimental|B: mild hepatic impairment|
32841990|NCT01576406|Experimental|C: moderate hepatic impairment|
32841991|NCT01576406|Experimental|D: severe hepatic impairment|
33319827|NCT05027594|Experimental|Dose Escalation Part|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
33319828|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 single agent|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
32841992|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32841993|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32841994|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
32841995|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
33319829|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 in combination with dexamethasone|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
32841996|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
32841997|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
32841998|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
32841999|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
32842000|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
32842001|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
32842002|NCT04105010|Experimental|AZD4205 Group A|Group A: Open label AZD4205 at dose A, once daily (Phase 1)
32842003|NCT04105010|Experimental|AZD4205 Group B|Group B: Open label AZD4205 at dose B, once daily (Phase 1)
32842004|NCT04105010|Experimental|AZD4205 Group C|Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
32842005|NCT04105010|Experimental|AZD4205 Group D|Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
32842006|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
32842007|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
32842008|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
32842009|NCT01576016|Experimental|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
32842010|NCT01576016|Experimental|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
33319830|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
32842012|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
32842013|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
32903041|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
32903042|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
33319831|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
33319832|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
33319833|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
33319834|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
33319835|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
33319836|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
33319837|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
33319838|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
33319839|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
33319840|NCT03794492|Experimental|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
33319841|NCT01304810||NicVAX|NicVAX vaccine
33319842|NCT01304810||Placebo vaccine|Placebo vaccine
33103883|NCT04741997|Experimental|Encorafenib and Binimetinib after Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
33103884|NCT04741997|Experimental|Encorafenib and Binimetinib after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
33103885|NCT04741997|Experimental|Nivolumab after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will receive nivolumab for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
32739553|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
32739554|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
32739555|NCT05667155|Experimental|CB dualCAR-NK19/70|All subjects were intravenously administrated with CB dualCAR-NK19/70
32739556|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
32739557|NCT02449759|No Intervention|Control Group|This group will receive no intervention
32739558|NCT05666609|Active Comparator|Group 4weeks|Duration of placed seton 4 weeks
32739559|NCT05666609|Active Comparator|Group 12weeks|Duration of placed seton 12 weeks
32739560|NCT03198013|Experimental|Module A|Single Ascending Dose
32739561|NCT03198013|Experimental|Module B|Multiple Ascending Dose
32739562|NCT05651399|Active Comparator|Remimazolam|A maintenance dose of remimazolam is administered for sedation
32739563|NCT05651399|Active Comparator|Propofol|A maintenance dose of propofol is administered for sedation
32739564|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
32739565|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
32739566|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
32739567|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
32739568|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
32739569|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
32739570|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
32739571|NCT05715047|Experimental|CBT for Fatigue Program|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~Baseline questionnaires.~10 intervention sessions.~Questionnaires and surveys 3 and 5 months after enrollment."
32739572|NCT05715047|Active Comparator|Usual Care|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~Baseline questionnaires.~Receive material from the Blood and Marrow Transplant Information Network describing common medical causes of fatigue after HCT and recommendations for management.~Questionnaires and surveys 3 and 5 months after enrollment."
32739573|NCT03119311|Experimental|VOG group|Video-oculography
32739574|NCT03119311|Active Comparator|APCT group|alternative prism cover test
32739575|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
32739576|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
32739577|NCT02447341||In patients|
32739578|NCT02447341||Out patients|
32739579|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
32739580|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
32739581|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
32739582|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
32739583|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
32739584|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
32957915|NCT04347096|Other|Control Intervention|The control intervention group will only receive educational tools (usual care).
33405869|NCT05139849|Placebo Comparator|Control|"Adrenaline alone arm (control)~At randomization 1 ml sodium chloride 9 mg/ml (placebo) will be administered as soon as possible after adrenaline during the first five cycle of drug administration during CPR 1 ml sodium chloride 9 mg/ml (placebo) will be administered only during the first cycle of drug administration during CPR~b In the ICU sodium chloride 9 mg/ml (placebo) At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the dos will be reduced daily to 67 ml and 33 ml and then discontinued. Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml for 3 days."
33405870|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
33405871|NCT05515341||Medical Device Therapy/Procedure for Chronic Pain|
33405872|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
33405873|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
33405874|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 1, Dose 1|Participants will be administered with KP104 as a weekly maintenance dose for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the Internal Data Review Committee (IDRC) to determine Dosing Regimen 2
32842014|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
32842015|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone [GCTB], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
32842016|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
32842017|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
32842018|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
32842019|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
32842020|NCT04410536|Other|Symptomatic drugs - bridge theray - mindfu|"abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;~oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);~mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
32842021|NCT04410614|Experimental|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
32842022|NCT04103450|Experimental|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
32842023|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
32842024|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
32842025|NCT04109144|Experimental|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
32842026|NCT04109144|Active Comparator|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
32842027|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
32842028|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
32842029|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
32842030|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
32842031|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
32842032|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
32957916|NCT04346862|Experimental|Acetyl-L-carnitine hydrochloride|
32957917|NCT04346862|Placebo Comparator|Placebo|
32842033|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
33405875|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 2, Dose 2|Participants will be administered with KP104 dose regimen 2 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the IDRC to determine Dosing Regimen 3.
32842034|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
32842035|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
32842036|NCT04075903|Experimental|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
32842037|NCT04075903|No Intervention|Control|Usual Care
32842038|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
32842039|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
32842040|NCT01556438|Experimental|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
32842041|NCT01556438|Experimental|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
32842042|NCT01556438|Experimental|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
32842043|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
32842044|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
32842045|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
32842046|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
32842047|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
32842048|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
32842049|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
32842050|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
32842051|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
32842052|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
32842053|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
32842054|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
32842055|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
32842056|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
32842057|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
32842058|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
32842059|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
32842060|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
32842061|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
32842062|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
32842063|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
32842064|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
32842065|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
32842066|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
32842067|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
32842068|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
32842069|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
32842070|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
32842071|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
32842072|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
32842073|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
32842074|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
32842075|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
32842076|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
32842077|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
32842078|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
32842079|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
32842080|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
32842081|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
32842082|NCT01491841|Experimental|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
32842083|NCT01491841|Experimental|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
32842084|NCT01491841|Experimental|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
32842085|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
32842086|NCT04081441|Experimental|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
32842087|NCT04081441|Experimental|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
32842088|NCT04081441|Experimental|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
32842089|NCT04081441|Other|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
32842090|NCT04408573|No Intervention|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
32842091|NCT04408573|Experimental|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
32842092|NCT04408573|Experimental|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
32842093|NCT04408573|Experimental|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
32842094|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
32842095|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
32842096|NCT04408495|Experimental|Intervention group_MRA|Recruitment maneuvers and high PEEP
32842097|NCT04408495|Active Comparator|Control group|No recruitment maneuvers and low PEEP
32842098|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
32842099|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
32842100|NCT01572740|Experimental|Lira+Insulin|
32842101|NCT01572740|Placebo Comparator|Placebo+Insulin|
32842102|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
32842103|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
32842104|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
32842105|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
32842106|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
32842107|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
32842108|NCT05622123|Experimental|Patients with type 1 diabetes who have completed the ENCAPSULATE-DM1 or FMT preserve-DM1 trial|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4 to quantify beta cell mass
32842109|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
32842110|NCT01553084|Experimental|Effectiveness of Combination NRT|
32842111|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
32842112|NCT01536860|Placebo Comparator|Control Test Drink|control drink
32842113|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
32842114|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
32842115|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
32842116|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
32842117|NCT01552928|Active Comparator|Moxifloxacin|
32842118|NCT01552928|Placebo Comparator|Placebo|
32842119|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
32842120|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
32842121|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
32842122|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
32842123|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
32842124|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
32842125|NCT04108676|Experimental|single arm|Drug: Fluzoparib Drug: Omeprazole
32842126|NCT04121546|Experimental|Intervention Arm|Patients will receive the telecare intervention.
32842127|NCT04121546|No Intervention|Usual Care Arm|Patients will receive usual care.
32842128|NCT01552772|Experimental|Aripiprazole IM Depot|
32842129|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
32842130|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
33033049|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
32842131|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
32842132|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
32842133|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
32842134|NCT03028376||Moderate TBI patients|GCS 9-13
32842135|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
32842136|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
32842137|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
32842138|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
32842139|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
32842140|NCT04767295|Experimental|Camrelizumab, Albumin Paclitaxel, Carboplatin|"ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.~Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment."
32842141|NCT00488865|Other|Intravascular Filter Device|
32842142|NCT05560659|No Intervention|Stereotactic ablative body radiotherapy (SABR) alone|1-3 fractions of SABR to all sites of disease
32842143|NCT05560659|Experimental|SABR plus 2 cycles of 177Lu-PSMA|cycles of 177Lu-PSMA with 1-3 fractions of SABR to all sites of disease between cycle 1 and 2
32842144|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
32842145|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
32842146|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
32842147|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
32842148|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
32842149|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
32842150|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
32842151|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
32842152|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
32842153|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
32842154|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
32842155|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
32842156|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
32842157|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
32842158|NCT00490269|Active Comparator|Dronabinol|
32842159|NCT00490269|Placebo Comparator|Placebo|
32842160|NCT05621655|Experimental|Mid dose in toddlers (7-71 months old, 3 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
32842161|NCT05621655|Experimental|Mid dose in toddlers (7-71 months old, 2 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
32842162|NCT05621655|Experimental|High dose in toddlers (7-71 months old, 3 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
32842163|NCT05621655|Experimental|High dose in toddlers (7-71 months old, 2 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
32842164|NCT05621655|Placebo Comparator|Placebo in toddlers (7-71 months old, 3 doses)|Placebo in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
32842165|NCT05621655|Placebo Comparator|Placebo in toddlers (7-71 months old, 2 doses)|Placebo in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
32842166|NCT05621655|Experimental|Mid dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
32842167|NCT05621655|Experimental|Mid dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
32842168|NCT05621655|Experimental|High dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
32842169|NCT05621655|Experimental|High dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
32842170|NCT05621655|Placebo Comparator|Placebo in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
32842171|NCT05621655|Placebo Comparator|Placebo in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
32842172|NCT05621499|Experimental|experimental group1|HAIC
32842173|NCT05621499|Experimental|experimental group 2|Lenvatinib+Sintilimab
32842174|NCT05621421||Patients with long coronary artery lesions|Consecutive patients with functionally significant (FFR ≤ 0.8) long lesion requiring a stent length of ≥ 30mm to undergo FFR and IVUS guided PCI.
32842175|NCT05621343||Latent TB on treatment|"Treatment according to existing Swedish guidelines with:~Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months OR Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6 months"
32842176|NCT05621343||Latent TB not on treatment|Latent TB without indication for treatment OR patient who do not want to receive treatment
32842177|NCT05621343||Active TB with treatment|Treatment according to existing Swedish guidelines. Duration and choice of antibiotic therapy depending on the condition.
32842178|NCT05621343||Healthy control|Healthy
32842179|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
32903043|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
33405876|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 3, Dose 3|Participants will be administered with KP104 dose regimen 3 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by IDRC to determine the Optimal biologic dose (OBD) for Part 2.
32842180|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
32842181|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
32842182|NCT05560503||significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S2-S4 as significant liver fibrosis.
32842183|NCT05560503||non-significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S0-S1 was defined as non-significant liver fibrosis.
32842184|NCT05617911|Experimental|Blood flow restriction and standard of care therapy|The experimental BFR therapy will be incorporated into the standard therapy sessions and will not elongate the treatment session, quantity of sessions or incur any additional cost. As the participant progresses over time in therapy sessions, the discretion of the PT will determine when they have graduated beyond receiving any benefit from BFRT as demonstrated by quad strength.
32842185|NCT05617911|Placebo Comparator|Sham and standard of care therapy|The sham comparator control group will also follow the Exercise Protocol in their physical therapy sessions with a non inflated blood flow restriction cuff attached in the same position as the experimental group. Similar to the intervention group, as participant's progress in therapy, the Physical Therapist will use their clinical decision making to advance the person through resistance and repetition increases.
32842186|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
32842187|NCT01446913|Active Comparator|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
32842188|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
32842189|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
32842190|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
32842191|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
32842192|NCT01420549|Experimental|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
32842193|NCT01420549|Active Comparator|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
32842194|NCT00491829|Experimental|flibanserin|50 mg qhs
32842195|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
32842196|NCT00491829|Placebo Comparator|placebo|placebo qhs
32842197|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
32842198|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
32842199|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
32842200|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
32842201|NCT05560347|Experimental|Experimental Group|Hot water will be applied to the participants in the experimental group at the 2nd and 6th hours postoperatively. During the hot water application, the feet of the individual will be immersed in the hot water application device and kept in the device for 20 minutes. At the end of the 20th minute, the feet of the individual will be removed from the device and dried with a towel for 10 minutes and the application will be completed. The data will be obtained by using the Introductory Information Form, Visual Analog Scale (VAS), Postpartum Comfort Scale and Post Cesarean Patient Evaluation Form.
32842202|NCT05560347|No Intervention|Control Group|Routine care will be given to the control group
32842203|NCT05611125|Experimental|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, and 6 months.
32842204|NCT05611125|No Intervention|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, and 6 months.
32842205|NCT01440517|Experimental|Tc99m-Maraciclatide|
32842206|NCT05560269|Experimental|verbal and physical constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval → 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
32842207|NCT05560269|Active Comparator|verbal constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval → 15 repetitions of kettlebell swings using verbal cues to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
32903044|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
33405877|NCT05504187|Experimental|Part 2: OBD Cohort, Dose 4|Participants will be administered with KP104 OBD for 24 Weeks.
33405878|NCT05191368||Normal group|Healthy people who received two doses of COVID-19 vaccine
32842208|NCT05560269|Experimental|physical constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
32842209|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
32842210|NCT05560035|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
32842211|NCT05560035|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
32842212|NCT05559645|Experimental|Cohort 1: EGFR sensitizing mutations, T790M neg|
32842213|NCT05559645|Experimental|Cohort 2: EGFR sensitizing mutations|
32842214|NCT05559645|Experimental|Cohort 3: EGFR uncommon mutations|
32842215|NCT05559645|Experimental|Cohort 4: EGFR Exon20ins|
32842216|NCT05459259||Patients participants|Adults who have undergone elective knee arthroplasty with post-operative arthrofibrosis/stiffness who have undergone MUA in the previous 24 months or are currently listed for a MUA.
32842217|NCT05459259||Healthcare Professionals|Physiotherapists/Occupational Therapist/ Nurses and Orthopedic surgeons with clinical experience in the management of patients with arthrofibrosis following knee joint arthroplasty
32842218|NCT05418387|Experimental|Group A|Patients randomized to receive the Social Support Network intervention
32842219|NCT05418387|Active Comparator|Patient Navigation|Patients randomized to receive Usual Care (patient navigation)
32842220|NCT01440049||Eplerenone|
32842221|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
32842222|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
32842223|NCT05559567|Other|Orthokeratology|Orthokeratology is fitting of a contact lens for overnight wear to flatten the cornea and correct myopia temporarily during the day. This procedure has also been shown to slow down the axial length growth in children.
32842224|NCT00497289|Experimental|1|Lipidem 20 %
32842225|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
32842226|NCT05559489|Experimental|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth or via naso-enteric access for moderate sized burn injuries (15-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
32842227|NCT05559489|Active Comparator|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (15-40% TBSA).
32842228|NCT05559333|Active Comparator|zirconomer|zirconia reinforced glass ionomer cement
32842229|NCT05559333|Active Comparator|Equia Fil|High viscosity glass ionomer cement
32842230|NCT05559333|Active Comparator|glass carbomer|glass ionomer cement containing nano sized- carbonized particles.
32842231|NCT05559333|Active Comparator|Tetric-evo ceram bulk fill|Bulk fill composite resin
32842232|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
32842233|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
32842234|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
32842235|NCT05559177|Experimental|Treatment of recurrent or metastatic bladder cancer|Lack of conventional effective treatment, failure or recurrence of treatment with conventional methods (surgery, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, etc.), or refusal of conventional treatment
32842236|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
32842237|NCT05555901|Experimental|Fruquintinib+ chemotherapy|Patients will receive fruquintinib+ FOLFIRI once every four weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine as maintenance treatment.
32842238|NCT05555901|Active Comparator|Bevacizumab+ chemotherapy|Patients will receive bevacizumab+ FOLFIRI once every two weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive bevacizumab + capecitabine as maintenance treatment.
32842239|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
32842240|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
32842241|NCT01439971|Experimental|1|
33319843|NCT05625074||CHUP Angiology and Vascular Surgery Service|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
32957918|NCT04347174|Experimental|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days~+ Standard therapy of COVID-19"
32957919|NCT04347174|Placebo Comparator|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of Placebo intra-dermal for 3 consecutive days
33319844|NCT05625074||CHUSJ Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
33319845|NCT05625074||CHUC Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
33319846|NCT03792230|Experimental|Video|This group received educatıon via video material
33319847|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
33319848|NCT03792230|No Intervention|Control|This group received standart clinical education
33319849|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
33319850|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
33319851|NCT05624996|Active Comparator|Arm I (image guided RT, chemotherapy, immunotherapy)|Patients undergo conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
33319852|NCT05624996|Experimental|Arm II (SBRT, image guided RT, chemotherapy, immunotherapy)|Patients undergo SBRT and conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
33319853|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
33319854|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
33319855|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
33319856|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
33319857|NCT00262067|Experimental|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
33319858|NCT00262067|Placebo Comparator|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
33319859|NCT05624762|Active Comparator|LIFU group|receive LIFU therapy
33319860|NCT05624762|Sham Comparator|Control group|receive sham LIFU therapy
33319861|NCT01304888|Experimental|Food basket w/o nutrition education|
33319862|NCT01304888|Experimental|Food basket + nutrition education|
33319863|NCT01304888|Experimental|Control|
33319864|NCT01304888|Experimental|Cash + health and nutrition education|
33319865|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
33319866|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
33319867|NCT03974165|Experimental|Cereal-legume product 1|Treatment with cereal-legume product-1
33319868|NCT03974165|Experimental|Cereal-legume product 2|Treatment with cereal-legume product-2
33319869|NCT03974165|Experimental|Cereal product|Treatment with cereal product
33319870|NCT03974165|Active Comparator|Reference food|Treatment with reference food
33319871|NCT00275561|Experimental|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
33405879|NCT05191368||RA Patients injected with 2 doses of vaccine|RA Patients who received two doses of COVID-19 vaccine
33405880|NCT05191368||Unvaccinated RA patients|RA Patients who received zero doses of COVID-19 vaccine
33405881|NCT05329545|Experimental|XMT-1536 (upifitamab rilsodotin)|XMT-1536 (upifitamab rilsodotin)
33033050|NCT01958775|Placebo Comparator|Placebo|placebo
33319872|NCT00275561|Placebo Comparator|Placebo|Placebo inhaler swallowed bid for 6 weeks
33319873|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
33319874|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
32842242|NCT01439971|Experimental|2|
33319875|NCT04925570|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
33319876|NCT04925570|Other|Digitally-delivered Psychoeducation|"Psychoeducation delivers weekly fact sheets that include information on:~Alcohol-specific topics;~Drug-specific topics;~General addiction topics;~Statistics relating to alcohol and substance use."
33319877|NCT01070849|Active Comparator|a) educational booklet|
33319878|NCT01070849|Active Comparator|b) IRENA|
33319879|NCT01070849|Experimental|c) RÜCKGEWINN|
33319880|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.~."
33319881|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
33319882|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
33319883|NCT05569148|Experimental|Faricimab PFS Configuration|
32842243|NCT01439971|Experimental|3|
32842244|NCT01439971|Experimental|4|
32842245|NCT01439971|Experimental|5|
32842246|NCT05555277||Anorexia Nervosa|Individuals aged 18 years and younger with anorexia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
32842247|NCT05555277||Bulimia Nervosa|Individuals aged 18 years and younger with bulimia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
32842248|NCT01797939||Erosive reflux disease (ERD)|
32842249|NCT01797939||Non-erovise reflux disease (NERD)|
32842250|NCT01797939||Functional heartburn (FH)|
32842251|NCT05554497|Experimental|Mindfulness training|8 week virtual mindfulness-based stress reduction curriculum. Weekly 2.5 hour sessions over zoom.
32842254|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
32842255|NCT04914117|Experimental|RC118 for injection|"Part A (Dose Escalation): RC118 will be administered through IV infusion at the various dose levels, including 0.25, 0.5, 1.0, 1.5, 2, 2.5, and 3 mg/kg, 1-12 subjects for each dose level.~Part B (Dose Confirmation): RC118 will be administered at up to two dose levels, which is equal or lower than MTD/MAD, through IV infusion. Each dose level contains 3-6 subjects."
32842257|NCT04843527|Active Comparator|FreeStyle Libre|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
32842258|NCT04843527|Active Comparator|FreeStyle Libre plus food logging|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
32842259|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
32842260|NCT04808583|Active Comparator|Group (A)|conventional TLH with uterine artery ligation after the cornual pedicles
32842261|NCT04808583|Experimental|Group (B)|TLH with uterine artery ligation at its origin at the beginning of the operation
32842262|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
32842263|NCT05440929||Clinicans|Participants will include: physicians, nurse practitioners, physician assistants, and nurse navigators. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
32842264|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
32842265|NCT05418777|Experimental|TMP-SMX|Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
32842266|NCT05418777|Placebo Comparator|Placebo|Suspension with placebo by mouth every 12 hours for 10 days
32842267|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
32842268|NCT04899063|Other|ELIOS Procedure|ELIOS Procedure
32842269|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
32842270|NCT05409183|Experimental|CRD-740|"Part A: Participants in Part A randomly assigned to this arm will take CRD-740 twice daily at two ascending dose levels over 12 weeks.~Part B: Participants in Part B randomly assigned to this arm will take CRD-740 twice daily at a single dose level over 12 weeks."
32842271|NCT05409183|Placebo Comparator|Placebo|"Part A: Participants in Part A randomly assigned to this arm will take placebo twice daily at two ascending dose levels over 12 weeks.~Part B: Participants in Part B randomly assigned to this arm will take placebo twice daily at a single dose level over 12 weeks."
33319884|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
33319885|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
32842272|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
32842273|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
32842274|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
32842275|NCT05395689|Experimental|Active substance|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae solution administered by the subcutaneous route for 12 months using a rush schedule
32842276|NCT05395689|Placebo Comparator|Placebo|Saline solution administered by the subcutaneous route for 12 months using a rush schedule
33405882|NCT05329545|Placebo Comparator|Placebo|Saline placebo will be administered with same schedule and stopping rules as for the assigned interventions in the Experimental Arm.
32842278|NCT04742751|Experimental|Treatment|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With Metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
32842279|NCT05390775|Experimental|Written Exposure Therapy|
32842280|NCT05390775|Placebo Comparator|Non-emotional Writing|
32842281|NCT05376657|Placebo Comparator|Placebo drink|
32842282|NCT05376657|Experimental|Cherry collagen drink|
32842283|NCT05365503|Experimental|Shamiri Intervention|The Shamiri intervention group will recieve a brief character strength intervention that will be delivered over the span of 4 weeks. There will be four sessions each lasting one hour each.
32842284|NCT04479813|Experimental|No conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
32842285|NCT04479813|Experimental|No conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
32842286|NCT04479813|Experimental|Remote pre-conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
32842287|NCT04479813|Experimental|Remote pre-conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
32842288|NCT04474899|Experimental|Phase 1|Moxonidine 0.4mg/daily
32842289|NCT04474899|Experimental|Phase 2|Amlodipine 5mg
32842290|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
32842291|NCT04411251|Experimental|Outdoor|Nature-centered therapy in a near-natural area
32842292|NCT04411251|Active Comparator|Indoor|Conventional therapy in rooms mainly in a hospital building
32842293|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
32842294|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
32842298|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
32842299|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
32842300|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
32842301|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
32842302|NCT05244447|Experimental|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10
32842303|NCT05209659||Low Back Pain|Pragmatic Mobilization The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment)
32842304|NCT04234815|Experimental|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
32842305|NCT04234815|Active Comparator|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
32842306|NCT00511095|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
32842307|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
32842308|NCT05178771|Experimental|test site|The test site will receive ScRp in addition to PRF
32842309|NCT05178771|No Intervention|control sites|The control site will be treated by ScRp only
32842310|NCT05108805|Experimental|YESCARTA in the Outpatient Setting|Participants will receive YESCARTA therapy in the outpatient setting
32842311|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
32842312|NCT04111185|Experimental|Receive Blood Volume Analysis Guided Treatment|The health care team will be provided with BVA results and may use the information to make decisions regarding the participant's treatment.
32842313|NCT04111185|No Intervention|Receive Standard of Care Treatment|The health care team will not be provided with the BVA results. The participant will receive the same treatment they would have received if they weren't in the study.
32842314|NCT04053387|Experimental|Tapinarof (DMVT-505) Cream Group|"Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study.~Subjects entering with a PGA ≥ 1 received treatment with tapinarof cream, 1% until they achieve a PGA = 0, at which time treatment was discontinued and subjects were monitored for durability of response (remittive response). If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~This treatment and re treatment pattern of use was continued until the end of the study"
32842315|NCT04050423||Breast Characterization|
32842316|NCT04045743|Experimental|Bermekimab (MABp1)|
32842317|NCT04045743|Experimental|Placebo|
32842318|NCT04037397|Active Comparator|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
32842319|NCT04037397|Active Comparator|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
32842320|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
32842321|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
32842322|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
32842323|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
32842324|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
32842325|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32842326|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
32842327|NCT05070819|Experimental|Cardiac surgery patients|"After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.~After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained~At the end of Teboul' test when lower limbs are lifted~30 minutes of CPB~End of CPB~End of volume transition from CPB circuit to patient~Before Teboul' test at the end of surgery~End of Teboul' test when lower limbs are lifted"
32842328|NCT03922581|Experimental|Mindfulness-Based Cognitive Therapy|Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
32842329|NCT03922581|No Intervention|Wait-list Control Group|Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment. Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
32842330|NCT03912909|Active Comparator|Phase 1|Empagliflozin 10mg daily or placebo
32842331|NCT03912909|Placebo Comparator|Phase2|Empagliflozin 10mg daily or placebo
32842332|NCT03903471|Experimental|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
32842333|NCT03903471|Active Comparator|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
32842334|NCT05014893|No Intervention|Control|Control group, without specific treatments
33405883|NCT05704530|Other|1. primary resection then follow-up|Scenario 1: primary resection then follow-up - Study-specific liquid biopsies will be collected in 98 patients, at the time of routine labs. Samples will be acquired before resection, at 6-8 weeks, 6 and 12 months after resection.
33405884|NCT05704530|Other|2. chemoradiation followed by resection and follow-up|Scenario 2: chemoradiation followed by resection and follow-up - Study-specific liquid biopsies will be collected in 50 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks, 6 and 12 months after surgery. A subgroup of patients will undertake adjuvant immunotherapy and will constitute Group 3. Timing of sampling will be adjusted accordingly as per study flowcharts.
33405885|NCT05704530|Other|3. chemoradiation followed by resection followed by adjuvant immunotherapy|chemoradiation followed by resection followed by adjuvant immunotherapy - Study-specific liquid biopsies will be collected in 100 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks after surgery and during adjuvant immunotherapy every 3 months including a sample at the end of treatment.
33405886|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
32842335|NCT05014893|Experimental|Cognitive training|This group receives treatments to improve cognitive function.
33405887|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
33405888|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
33405889|NCT05327361|Active Comparator|Control Group|Participant will receive sunscreen in the morning and at the beginning of the afternoon for 3 months.
33405890|NCT05327361|Experimental|Liftactiv B3|Participants will undergo a wash out phase of two weeks where they regularly apply a moisturizer (Hydreane Legere) in the morning and a sunscreen in the morning and at the beginning of the afternoon. On the 3rd week, participants will apply Liftactiv B3 serum daily in the morning before sunscreen and in the evening (two applications daily) on half face for 3 months.
33405891|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
33405892|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
33405893|NCT05312229|Experimental|Replicating Effective Programs (REP)|A stakeholder-informed training and technical assistance implementation strategy
33405894|NCT05312229|Active Comparator|REP + External Facilitation (Enhanced REP)|REP plus site specific weekly facilitation to support CTI implementation.
32842336|NCT04992975||Alzheimer's disease|"Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.~Repeat neuroimaging and neurocognitive tests after one year."
32842337|NCT04992975||Control group|"Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.~Repeat neuroimaging, neurocognitive tests after one year."
32842338|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
32842339|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
32842340|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
32842341|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
32842342|NCT04988061|Experimental|Counselling arm|Educating and Counselling are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
33405895|NCT05312229|No Intervention|Control Group|No CTI implementation
33405896|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
33405897|NCT05307393|No Intervention|A|
33405898|NCT05307393|Experimental|B|Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement.
33405899|NCT05307393|Experimental|C|Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
33405900|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
33405901|NCT05077449|Experimental|XZP-3287+Fulvestrant|
33405902|NCT05077449|Placebo Comparator|Placebo + Fulvestrant|
33405903|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
33405904|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
33405905|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
33405906|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
33405907|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) High Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-High formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
32842343|NCT04988061|No Intervention|standard arm|The information about hearing screening results and an appointment date are provided as a routine by either nurses or nurse assistances who perform the screening test.
32842344|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
32842345|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
32903045|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
32957920|NCT04346784|Experimental|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
32957921|NCT04346784|Experimental|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
32957922|NCT04346784|Experimental|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
32957923|NCT04346784|Placebo Comparator|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
32957924|NCT04346550|Active Comparator|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
32957925|NCT04346550|No Intervention|Without Drain Group|No drain was placed
32957926|NCT04345848|Experimental|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
32957927|NCT04345848|Active Comparator|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
32957928|NCT04345770|Sham Comparator|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
32957929|NCT04345770|Experimental|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
32957930|NCT04345692|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
32957931|NCT04345692|No Intervention|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
32957932|NCT04345380|Active Comparator|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
32957933|NCT04345380|Active Comparator|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
32957934|NCT04345380|Active Comparator|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
32957935|NCT04345458|Experimental|group I|twice weekly 25 mg prefilled liquid etanercept
32957936|NCT04345458|Experimental|group II|once weekly 50 mg prefilled liquid etanercept
32957937|NCT04345458|Active Comparator|group III|25 mg twice weekly lyophilized etanercept powder
32957938|NCT04345614|Experimental|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
32957939|NCT04345614|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
32957940|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
32957941|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
32957942|NCT04344990|Active Comparator|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
32957943|NCT04344990|Active Comparator|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
32957944|NCT04344990|Active Comparator|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
32957945|NCT04344834||Health care workers|Egyptian health care workers
32957946|NCT04344834||General population|Any Egyptian personnel
32957947|NCT04344834||Recovered fromCOVID-19|Patients recovered from COVID-19
32957948|NCT04344756|Experimental|Active Coagulation|
32957949|NCT04344756|No Intervention|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance < 30mL/min.
32957950|NCT04344288|Experimental|Prednisone group|Prednisone during 10 days after randomization
32957951|NCT04344288|Other|Control group|
32842346|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
32842347|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
32842348|NCT03621735|Other|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
32842349|NCT03621735|Other|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
32842350|NCT04947735|Experimental|CYPRESS Extension Test Arm|Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
32842351|NCT04947735|Placebo Comparator|CYPRESS Extension Control Arm|Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
32842352|NCT04926285|Experimental|Cohort 1|Omacetaxine 0.625 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
32842353|NCT04926285|Experimental|Cohort 2|Omacetaxine 1.25 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
32842354|NCT04926285|Experimental|Cohort 3|Omacetaxine 2.0 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
32842355|NCT04926285|Experimental|Cohort 4|Omacetaxine 2.5 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
32842356|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1~Single I.V. dose of tasimelteon 2 mg on Day 6"
32842357|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1~Single oral dose of tasimelteon 20 mg on Day 6"
32842358|NCT03419481|Experimental|pembrolizumab|
32842359|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
32842360|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
32842361|NCT03385005|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
32842362|NCT03385005|Active Comparator|Spinal Cord Injury Participants|This arm consists of spinal cord injury participants receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
32842363|NCT02132169|Experimental|AC-170 0.24%|
32842364|NCT02132169|Placebo Comparator|AC-170 0%|
32842365|NCT04065321||Control group|250 patients will be assigned into control group.
32842366|NCT04065321||Trial group|250 patients will be assigned into trial group.
32842367|NCT03224949||Healthy controls|
32842368|NCT03224949||Alcoholic hepatitis|
32842369|NCT03224949||Alcoholic steatosis|
32842370|NCT03224949||Alcoholic cirrhosis without HCC|
32842371|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
32842372|NCT03224949||Alcoholic cirrhosis with HCC|
32842373|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
32842374|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
32842375|NCT03174405|Experimental|AVELUMAB|
32842376|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
32842377|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
32842378|NCT03121677|Experimental|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 & every 4 wks during Cycles 7-12 & vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12~After 2 cycles, restaging will be performed, & patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD may initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).~After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 & 12 & 2 additional doses 8 wks apart."
32842379|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
32842380|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
32842381|NCT02913729|Experimental|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
32842382|NCT02913729|Active Comparator|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
32842383|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
32842384|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
32957952|NCT04344522|Experimental|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
32957953|NCT04344522|Experimental|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
32957954|NCT04344210|Experimental|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
32957955|NCT04344210|No Intervention|Usual Care|Participants will receive the usual care
32957956|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
32957957|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
32957958|NCT04343508|Experimental|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
32957959|NCT04343196|Experimental|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
32957960|NCT04343196|Active Comparator|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
32957961|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
32957962|NCT04342728|Active Comparator|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
32957963|NCT04342728|Active Comparator|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
32957964|NCT04342728|Active Comparator|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
32957965|NCT04342728|Other|Standard of Care|Standard of care medications only as prescribed by patient's physician.
32957966|NCT04342650|Active Comparator|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
32957967|NCT04342650|Placebo Comparator|Placebo|Placebo tables of equal characteristics and duration of treatment.
32957968|NCT04342416|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
32957969|NCT04342104||NIV|Patients on Bilevel NIV
32957970|NCT04342104||CPAP|Patients on CPAP
32957971|NCT04341870|Experimental|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
32957972|NCT04341870|Active Comparator|Sarilumab|Sarilumab only
32957973|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age > 18
32957974|NCT04341402|Experimental|Experimental|miconazole 3% & diclofenac sodium 1% & urea 40% in topical gel daily for 6 months.
32957975|NCT04341636|Experimental|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
32957976|NCT04341636|Active Comparator|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
32957977|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
32957978|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
32957979|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
32957980|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
32957981|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
32957982|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen~After ADT performed, serum testosterone level should reach castrated level, i.e. < 50 ng/dL after 6 weeks of treatment~Able to consent for the participate in the study"
33319886|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
33319887|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
33319888|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
33319889|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
32842385|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
32842386|NCT00525057|Experimental|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
32842387|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
32842388|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
32842389|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
32842390|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
32842391|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
32842392|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
32842393|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
32842394|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
32842395|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
32842396|NCT00564447|Experimental|Azithromycin-2 hours post dose|
32842397|NCT00564447|Experimental|Azithromycin-12 hours post dose|
32842398|NCT00564447|Experimental|Azithromycin-24 hours post dose|
32842399|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
32842400|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
32842401|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
32842402|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
32842403|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
32842404|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
32842405|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
32842406|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
32842407|NCT00525837|Other|varenicline|open label varenicline
32842408|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
32842409|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
32842410|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
32842411|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
32842412|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
32842413|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
32842414|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
32842415|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
32842416|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
32842417|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
32842418|NCT03644277|Experimental|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
32842419|NCT03644277|Active Comparator|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
32842420|NCT03644277|Placebo Comparator|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
32842421|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
32842422|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
32842423|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).
32842424|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).
32842425|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
32842426|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
32842427|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).
32842428|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
33405908|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) Med Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Medium formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
32842429|NCT05363241|No Intervention|Conservative group (CG)|The patients will receive standard pharmacological treatment (oral analgesics, intra-articular injection with corticosteroids) and physiotherapy for 6 months, where the end of the study occurs. After this period, the patient is guaranteed to undergo the cooled radiofrequency procedure, with medical indication.
32903046|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
32903047|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
33405909|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) Low Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Low formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
33405910|NCT05496231|Active Comparator|Gardasil 9 (Gar9) Group|Healthy females aged 16 to 26 years receive 3 doses of the marketed HPV vaccine on Day 1, Month 2, and Month 6.
32739585|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
32739586|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
32739587|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739588|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739589|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739590|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739591|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739592|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
32739593|NCT05714891|Experimental|Neoadjuvant therapy (JDQ443) followed by surgery.|"If *MPR/cPR* - standard of care adjuvant treatment may be followed by experimental adjuvant therapy (JDQ443)~*Major Pathological Response (MPR)/ Complete Pathological Response (cPR)"
32739594|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
32739595|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
32739596|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
32739597|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
32739598|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
32739599|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
32739600|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
32739601|NCT05714813|Experimental|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training 3 times a week for 24 consecutive weeks for a total of 72 training sessions.
32739602|NCT05714813|Other|Control Group|Participants in this arm will receive two lectures on fitness, diet, or cognition each month for 24 weeks for a total of 12 lectures.
32739603|NCT05714735||Whole-brain venography|Cerevbral venography
32739604|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
32739605|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
32842430|NCT05363241|Experimental|Radiofrequency cooled group with classical targets (CRF-CT)|The patients will undergo the CRF procedure using the classical therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve). So that patients do not know in which group of the study they are included, the probe will be placed in the aforementioned genicular nerves and also in the recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve, but will not receive radiofrequency in the recurrent fibular nerve nor in the infra-patellar branch of the saphenous nerve, receiving radiofrequency only in the genicular nerves. Oral analgesics will be prescribed for the patient to use if necessary.
32842431|NCT05363241|Experimental|Radiofrequency cooled group with revised targets (CRF-RT)|The patients will undergo the CRF procedure using the revised therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve, recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve). So that patients do not know in which group of the study they are included, the probe will be placed in all the aforementioned nerves and will receive radiofrequency in all of them. Oral analgesics will be prescribed for the patient to use if necessary.
32842432|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
32842433|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
32842434|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
32842435|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
33405911|NCT05074485|Experimental|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
33405912|NCT05074485|Experimental|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
33405913|NCT05305287|Experimental|NAFL TZD|T2D with non-alcoholic fatty liver (NAFL), treated with pioglitazone
33405914|NCT05305287|Placebo Comparator|NAFL Placebo|T2D with non-alcoholic fatty liver (NAFL), treated with placebo
33405915|NCT05305287|Experimental|NASH TZD|T2D with non-alcoholic steatohepatitis (NASH), treated with pioglitazone
33405916|NCT05305287|Placebo Comparator|NASH Placebo|T2D with non-alcoholic steatohepatitis (NASH), treated with placebo
33405917|NCT03259425|Experimental|Nivolumab and HF10, all participants|
33405918|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
32842436|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
32842437|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
32842438|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
32842439|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
32842440|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
32842441|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
32842442|NCT05246631|Active Comparator|Dexamethasone|5 mg intravenous dexamethasone
32842443|NCT05246631|Active Comparator|Haloperidol|1 mg intravenous haloperidol
32842444|NCT05246553|Experimental|Modified cochlear implant recipients|"Patients suffering from severe to profound hearing loss and severe bilateral vestibulopathy implanted with a modified cochlear implant providing 1 to 3 extracochlear electrodes implanted in proximity to the ampullary branches of the vestibular nerve (vestibular electrodes).~All experiments will be carried out while the vestibular electrodes are inactive, and while electrical stimulation is delivered to one or several vestibular electrodes, with and without concurrent cochlear stimulation."
32842445|NCT05246553|Active Comparator|Cochlear Implant Patients (CI)|Unilateral or bilateral cochlear implant recipients with normal vestibular function documented within the clinical follow up of their cochlear implant, and without previous history of vestibular symptoms or complaints.
32842446|NCT05246553|Active Comparator|Bilateral vestibulopathy Patients (BV)|Patients with documented diagnosis of bilateral vestibulopathy, according to the guidelines of the Barany society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
32842447|NCT05246553|Active Comparator|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
32842448|NCT05246553|No Intervention|Healthy Subjects (HS)|Normal auditory functiona and without previous auditory or vestibular symptoms or complaints. Normal vestibular function documented with the video-head impulse test.
32842449|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
32842450|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
32842451|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
32842452|NCT05363085||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
33405919|NCT03259269||Delamanid and companion WHO Group 5 drugs|
32842453|NCT05246475|Experimental|PET-MRI|Simultaneous 18F-EF5 PET and DW-MRI
32842454|NCT01446965|Experimental|Wearable defibrillator|subjects in the Device Group will receive a LifeVest® wearable cardioverter-defibrillator (manufacturer: ZOLL Medical Corporation) plus guideline-directed medical therapy for post-myocardial infarction patients
33103886|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
33103887|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
33103888|NCT04900077|Experimental|treatment group|treated by Carriere® Motion™ Appliance
33103889|NCT04900077|No Intervention|control group|no treatment
33103890|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
33319890|NCT05669144|Experimental|exosome therapy|"a) Intracoronary and intra-myocardial injection of exosomes (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes"
33319891|NCT05669144|Experimental|mitochondria therapy|"b) Intracoronary and intra-myocardial injection of mitochondria (5 patients)~1 mL of exosomes containing 10 million mitochondria"
33319892|NCT05669144|Experimental|co-transplantation of mitochondria and exosome therapy|"c) co-transplantation Intracoronary and intra-myocardial injection of exosomes and mitochondria (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes~1 mL of exosomes containing 10 million mitochondria"
33319893|NCT05669144|Placebo Comparator|placebo|1 mL of placebo solution
32842455|NCT01446965|No Intervention|Conventional treatment|subjects in the Control Group will only receive guideline-directed medical therapy for post-myocardial infarction patients
32842456|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
32842457|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
32842458|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
32842459|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
32842460|NCT05362851|Experimental|YYC301-1, YYC301-2, YYC301-3 & Celecoxib placebo|"YYC301-1 is a capsule. It is composed of Celecoxib 200mg and Tramadol 37.5mg complex.~YYC301-2 is a capsule. It is composed of Celecoxib 200mg and Tramadol 75mg complex.~YYC301-3 is a capsule. It is composed of Celecoxib 200mg and Tramadol 150mg complex."
32842461|NCT05362851|Active Comparator|YYC301-1 placebo, YYC301-2 placebo, YYC301-3 placebo & Celecoxib|"Concomitant Drugs with Celecoxib 200mg and YYC301-1 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-2 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-3 placebo one capsule."
32842462|NCT04408235|Active Comparator|Low-Dose LMWH|Enoxaparin 4000 IU daily
32842463|NCT04408235|Experimental|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
32842464|NCT05362617|Experimental|FOLFIRI|"Irinotecan 180 mg/m2 I.V 30-90 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46~48 hours,）~Repeat Every 14 days"
32842465|NCT05362617|Active Comparator|mFOLFOX6|"Oxaplatin 85 mg/m2 I.V 120 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46~48 hours,）~Repeat Every 14 days"
32842466|NCT04121312|Experimental|Facilitation Intervention|"A brief, web-based facilitation guide (called Weight Loss Your Way Kickoff Materials) that encourages initial and sustained engagement in online tracking and social network tools for weight loss.The intervention also includes 8 emails sent over 12 weeks to further motivate use of the online tools and weight loss."
32842467|NCT03517137|Experimental|Treatment|
32842468|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
32842469|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
32842470|NCT05246397|Experimental|Cardiac surgery patients|Patients undergoing cardiac surgery
32842471|NCT05362539|Experimental|Hematuria patients|Voided urine was collected from consecutive patients presented with hematuria at our institute for urine cytology and DNA hypermethylation assay of the assigned genes using methylation-specific Polymerase Chain Reaction (PCR). Further assessment by office cystoscopy and imaging with subsequent inpatient cystoscopic biopsy for positive findings, was done. The diagnostic characteristics of DNA hypermethylation and urine cytology were assessed based on its capability to predict UBC noninvasively
32842472|NCT05246319||Patients with small intestine neuroendocrine tumors|Evaluation of preoperative abdominal imaging in patients who underwent an a resection for neuroendocrine tumors
32842473|NCT01446419|Experimental|Intracept Treatment|
32842474|NCT01446419|Sham Comparator|Sham Treatment|
32842475|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
33103891|NCT04666298|Experimental|300 mg inclisiran sodium|Subcutaneous injection
33103892|NCT04666298|Experimental|200 mg inclisiran sodium|Subcutaneous injection
33103893|NCT04666298|Experimental|100 mg inclisiran sodium|Subcutaneous injection
33103894|NCT04666298|Placebo Comparator|Placebo|Subcutaneous injection
32842476|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
32842477|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
32842478|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
32842479|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
32842480|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
32842481|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
32842482|NCT05361681|Experimental|interventional arm|Participants were charging full electric cars, using high power charging systems
32842483|NCT05361291|Active Comparator|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine
32842484|NCT05361291|Experimental|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine with 2mg dexamethasone|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone
32842485|NCT05361291|Experimental|Inferior Alveolar nerve block with plain 2% lidocaine mixed with 2mg dexamethasone|An Inferior Alveolar nerve block was given with plain 2% lidocaine mixed with 2mg dexamethasone
32842486|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
32842487|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
32842488|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
32842489|NCT05355285|Experimental|Baseline Euglycemia|"Subjects with T1DM (Groups 1 and 2): 1) receive a low dose insulin infusion to reduce their plasma glucose to euglycemia; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min to maintain euglycemia during a Baseline MRI scanning period.~Subjects without diabetes (Groups 3 and 4) are scanned during a Baseline MRI scanning period (no intervention is needed to maintain euglycemia in these subjects)."
32842490|NCT05355285|Experimental|Hyperglycemic Clamp|"Subjects with T1DM (Groups 1 and 2): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min.~Subjects without diabetes (Groups 3 and 4): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L."
32842491|NCT05355285|Experimental|Hyperinsulinemic Euglycemic Clamp|Subjects without diabetes or depression (Group 3) have a second study visit at least 15 days after the Hyperglycemic Clamp visit. They receive a variable insulin infusion to match individual insulin levels to the levels attained during the Hyperglycemic Clamp and they receive a variable glucose infusion to maintain euglycemia.
32842492|NCT05245929|Active Comparator|Skeletally anchored Distal Jet appliance|
32842493|NCT05245929|Active Comparator|Skeletally anchored Hyrax screw distalizer|
32842494|NCT03218475|Experimental|MR Guided Focused Ultrasound|
32842495|NCT05354973||CAR T Cell Treatment|
32842496|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
32842497|NCT05353725||COVID-19 ARDS|Patients with COVID-19 ARDS on veno-venous ECMO (vvECMO)
32842498|NCT05353725||Influenza ARDS|Patients with Influenza ARDS on vvECMO
32842499|NCT05353725||ARDS of Other Ethiologies|Patients with ARDS of Other Ethiologies on vvECMO
32842500|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
32842501|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
32842502|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
32842505|NCT05344287||Typical American Diet|African American individuals who self-report adhering to a typical American diet prior to enrolling in the study.
32842506|NCT05344287||Plant-Based Diet|African American individuals who self-report adhering to a plant-based diet prior to enrolling in the study.
32842507|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2~Auto-SCT will take place on Day 0 as per institutional guidelines~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
32842508|NCT05324085|Experimental|Exercise intervention group|Participants will undergo supervised treadmill exercise three times each week for eight weeks, in addition to treatment as usual (TAU).
32842509|NCT05324085|Other|Control group|Participants will undergo TAU. The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
32957983|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Able to consent for the participate in the study"
32957984|NCT04340544|Experimental|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
32957985|NCT04340544|Placebo Comparator|Placebo|Equivalent number of placebo capsules
33405920|NCT04923555|Experimental|Group/Cohort1|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit
32842510|NCT05219877|Experimental|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
32842511|NCT05219877|Active Comparator|Post-urodynamic Levofloxacin|Levofloxacin 500 mg will be given for 3 days, once daily, post-urodynamic examination
32842512|NCT01445171|Other|Study Valve|Subjects act as own control
32842513|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
32842514|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
32842515|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
32842516|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
32842517|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
32842518|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
32842519|NCT05263791|Experimental|Airmod|The experimental device are installed in the same patient as the reference device to compare the non-inferiority of the respiratory rate measurement.
32842520|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
32842521|NCT05214339|Experimental|TRIPLET|"Combination Product: Hepatic Arterial Infusion combined with Bevacizumab and Sintilimab Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.~Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times. 2. Intravenous infusion of Bevacizumab 7.5mg/kg every 3 weeks on the 4th day. 3. On the 25nd day of treatment, namely the second session of HAIC, intravenous infusion of Sintilimab 200mg every 3 weeks. 4. The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
32842522|NCT03830463|Experimental|CTP-692|
32842523|NCT03830463|Placebo Comparator|Placebo|
32842524|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
32842525|NCT02738229|Placebo Comparator|control|placebo pill
32842526|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
32842527|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
32842528|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
32842529|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
32842530|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
32842531|NCT02471391|Experimental|Ibrutinib + ABT-199|
32842532|NCT05152641|Experimental|BGE-117 4mg|BGE-117 4mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
32842533|NCT05152641|Experimental|BGE-117 8mg|BGE-117 8mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
32842534|NCT05152641|Experimental|BGE-117 16mg|BGE-117 16mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
32842535|NCT05152641|Placebo Comparator|Placebo|Matching Placebo Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
32842536|NCT01444391|Experimental|Tympanostomy Tube Placement|
32842537|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
32842538|NCT05065671|Experimental|Tolcapone|Tolcapone 100 mg by mouth once
32842539|NCT05065671|Experimental|Duloxetine|Duloxetine 20 mg by mouth once
32842542|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
32842543|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
32842544|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
32842545|NCT04865367||DEG n1: euploid medium|culture media derived from euploid embryos
32842546|NCT04865367||DEG n2: aneuploid medium|culture media derived from aneuploid embryos
33319894|NCT00274937|Experimental|Stratum I (radiotherapy, chemoprotective agent)|Patients undergo radiotherapy 5 days a week for 8 weeks. Patients also receive amifostine subcutaneously on the same days they undergo radiotherapy.
33319895|NCT00274937|Experimental|Stratum II (chemotherapy, chemoprotective agent, radiotherapy)|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.
32842547|NCT04865367||DEG n3: medium arrested embryos|culture media derived from arrested embryos
33319896|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
33319897|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
33319898|NCT04914728|Experimental|mini-invasive lumbar arthrodesis|"The patient will be admitted to the hospital on the morning of the surgery, operated on the same morning by either the posterior or anterior mini-invasive approach.~The choice of the approach depends on the specificity of the pathology leading to the arthrodesis procedure and the surgeon's experience. It is the surgeon who decides this in agreement with the patient. The patient will be discharged in the evening after agreement of the anaesthetist and the surgeon."
33319899|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
33319900|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
33319901|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
33319902|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
33319903|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
33319904|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
33319905|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
33319906|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
33319907|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
33319908|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
33319909|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
33319910|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
33319911|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
33319912|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
33319913|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
33319914|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
33319915|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
33319916|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
33319917|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
33319918|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
33319919|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
33319920|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
33319921|NCT04798898|Experimental|Intervention (+RFA) arm|Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
33319922|NCT04798898|No Intervention|Control (-RFA) arm|Liver resection
33319923|NCT05624528|Experimental|Tolcapone|100mg of tolcapone twice daily for two weeks, then 200mg tolcapone twice daily for the remaining six weeks.
33319924|NCT05624528|Placebo Comparator|Placebo|100mg of placebo twice daily for two weeks, then 200mg of placebo twice daily for the remaining six weeks.
33319925|NCT00251693|Experimental|Dexlansoprazole MR 60 mg QD|
33319926|NCT00251693|Experimental|Dexlansoprazole MR 90 mg QD|
33319927|NCT00251693|Active Comparator|Lansoprazole 30 mg QD|
32842548|NCT04865367||DEG n4: control culture medium|pure culture media without contact to embryos
32842549|NCT02121639|Experimental|AZD5363|AZD5363
32842550|NCT02121639|Placebo Comparator|Placebo|Placebo
32842551|NCT04847427|Experimental|Core exercises training|Participants will perform 4 core exercises
32842552|NCT04847427|Experimental|Structural exercises training|Participants will perform 4 structural (Olympic lifting) exercises
32842553|NCT04847427|Experimental|Accentuated eccentric exercises training|Participants will perform 4 exercises with eccentric loading
32842554|NCT04847427|Experimental|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
32842555|NCT04798833|Experimental|Integrated Newborn Care Kit|"The integrated newborn care kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, three misoprostol tablets (200ug each), 4% chlorhexidine solution, sunflower oil emollient, temperature monitoring strip or sticker, a fleece blanket, a reusable, non-electric, heating device, and a pictorial instruction guide. Lady Health Workers will be equipped with a hand-held electronic scale to identify low birth weight newborns.~Participants in this arm will receive the same local standard of care as the no intervention arm."
32842556|NCT04798833|No Intervention|Control (Local Standard of Care)|"In the control arm, LHWs will deliver the local standard of care, which entails both anti-natal and post-natal LHW home visits. As part of standard practice, LHWs visit pregnant women in their homes during the 3rd trimester, at which time these health workers:~Provide instructions regarding proper nutrition during pregnancy~Encourage that delivery take place in a facility~Discuss the fundamentals of safe water, sanitation, and hygiene behavior~Encourage exclusive breastfeeding~These community health workers will identify early danger signs in newborns such as infections and teach caregivers to identify the same symptoms, so that early interventions can be made. If danger signs are identified, the LHW will refer newborns to the appropriate level of health care."
32842557|NCT01585545||patients with NSCLC|
32842558|NCT04763499|Experimental|Freeze dried strawberry powder|"39g of freeze dried strawberry powder, which represents three daily servings of strawberries.~The powder will be mixed in one cup of water."
32842559|NCT04763499|Placebo Comparator|control powder|39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.
32842560|NCT01542177||Pancreatic cancer|
32842561|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
32842562|NCT04460703|Sham Comparator|Control|Control message about birdfeeding
32842563|NCT04460703|Active Comparator|Baseline message|These participants will be assigned a message about the benefits of vaccination. All other treatment arms include this baseline language.
32842564|NCT04460703|Experimental|Personal freedom|Experimental message arm.
32842565|NCT04460703|Experimental|Economic freedom|Experimental message arm.
32842566|NCT04460703|Experimental|Social benefit, self-interest|Experimental message arm.
32842567|NCT04460703|Experimental|Social benefit, community interest|Experimental message arm.
32842568|NCT04460703|Experimental|Economic benefit|Experimental message arm.
32842569|NCT04460703|Experimental|Social pressure- guilt|Experimental message arm.
32842570|NCT04460703|Experimental|Social pressure- embarrassment|Experimental message arm.
32842571|NCT04460703|Experimental|Social pressure- anger|Experimental message arm.
32842572|NCT04460703|Experimental|Trust in science|Experimental message arm.
32842573|NCT04460703|Experimental|Not bravery arm|Experimental message arm.
32842574|NCT04428801|Experimental|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
32842575|NCT04428801|Placebo Comparator|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
32842576|NCT04404075||Group 1 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
32842577|NCT04404075||Group 2 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
32842578|NCT04404075||Group 3 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
32842579|NCT04404075||Group 4 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
32842580|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
33319928|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33319929|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
33319930|NCT03793712|Experimental|Lu AF11167 low dose|
33319931|NCT03793712|Experimental|Lu AF11167 high dose|
33319932|NCT03793712|Placebo Comparator|Placebo|
33319933|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
33319934|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
33319935|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
33405921|NCT04923555|Experimental|Group/Cohort2|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit
32842581|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
32842582|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
32842583|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
32842584|NCT01551212|Experimental|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: < 5 ng/mL)
32842585|NCT01551212|Active Comparator|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
32842586|NCT04381611||Primary Glaucoma|
32842587|NCT04381611||Glaucoma Surgery|
32842588|NCT04381611||Glaucoma Laser|
32842589|NCT04381611||Glaucoma Surgery Combined|
32842590|NCT04381611||Glaucoma treatment|
32842591|NCT04381611||Glaucoma imaging|
32842592|NCT04381611||Glaucoma co-morbidity|
32842593|NCT04381611||Glaucoma untreated|
32842594|NCT04381611||Glaucoma Suspect|
32842595|NCT04381611||Secondary Glaucoma|
32842596|NCT00573261|Experimental|Pregabalin|Pregabalin medication
32842597|NCT00573261|Placebo Comparator|Placebo|Placebo
32842598|NCT04315233|Experimental|Treatment: all patients|Ribociclib and belinostat will be given at escalating doses and on multiple administration schedules throughout the dose escalation component of the study. The MTD identified in the dose escalation component will be used to define the dose and administration schedule used in the dose expansion.
32842599|NCT04268199|Other|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
32842600|NCT04256889|Experimental|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
32842601|NCT04251975|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
32842602|NCT04251975|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
32842603|NCT04514211||Propofol|General anesthesia using propofol infusion
32842604|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
32842605|NCT00574197|Other|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
32842606|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
32842607|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
32842608|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
32842609|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
32842612|NCT00574587|Experimental|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
32842613|NCT04120220|Experimental|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
32842614|NCT04120220|Experimental|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
32842615|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
32842616|NCT00575367|Active Comparator|AzaSite|
32842617|NCT00575367|Active Comparator|Vigamox|
32903048|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
32903049|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
33319936|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
33405922|NCT04923555|Placebo Comparator|Group/Cohort3|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit
33405923|NCT05491317|Experimental|Radiotherapy + GEN1042|
33405924|NCT05491317|Experimental|Radiotherapy + GEN1042 + pembrolizumab|
33405925|NCT03101241|Experimental|CX-8998|
33103895|NCT04887558|Active Comparator|NCI QuitGuide and NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT.
33319937|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
32842618|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~B: Maintenance Therapy -~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
32842619|NCT04417569||stimulated cycles|Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection
32842620|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
32842621|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
32842622|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
32842623|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
32842624|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
32842625|NCT00606489|Placebo Comparator|1|
32842626|NCT00606489|Experimental|2|
32842627|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
32842628|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
32842629|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
32842630|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
32842631|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
32842632|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
32842633|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
32842634|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
32842635|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
32842636|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
32842637|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
32842638|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
32842639|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
32842640|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
32842641|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
32842642|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
32842643|NCT04363437|Active Comparator|Colchine|
32842644|NCT04363437|Active Comparator|Usual Care|
32842645|NCT03910166|Experimental|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
32842646|NCT03910166|Active Comparator|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
32842647|NCT02138097||Glitazones|
32842648|NCT02138097||Linagliptin|
32842649|NCT02138097||Meglitinides|
32842650|NCT02138097||Metformin|
32842651|NCT02138097||Non-insulin injectables|
32842652|NCT02138097||Saxagliptin|
32842653|NCT02138097||Sitagliptin|
32842654|NCT02138097||Sulfonylurea|
32842655|NCT01570244|Experimental|Reference|multiple doses of Microgynon
32842656|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
32903050|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
33319938|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
33405926|NCT03101241|Placebo Comparator|Placebo|
33319939|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
33319940|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
33319941|NCT03974477|Experimental|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
33319942|NCT03974477|No Intervention|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
33319943|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
33319944|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
33319945|NCT01305512|Experimental|SPARC1028|
33319946|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
33319947|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
32842657|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
32842658|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
32842659|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
32842660|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
32842661|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
32842662|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
32842663|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
32842664|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
32842665|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
32842666|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
32842667|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
32842668|NCT01549886|Experimental|MGD + Rituximab + Y-90-Zevalin|"Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
32842669|NCT01549886|Active Comparator|Rituximab + Y-90-Zevalin|Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
32842670|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
32842671|NCT04767230|Active Comparator|A heart-healthy diet + Flaxseed + Olive oil|A heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner) for 3 months
32842672|NCT04767230|Placebo Comparator|A heart-healthy diet|Recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars for 3 months
32903051|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
33405927|NCT05007093|Experimental|Anlotinib hydrochloride|
33405928|NCT05483283|Other|Arm 1|Empowerment and Navigation
33405929|NCT05483283|Other|Arm 2|Standard of Care (SOC)
32842673|NCT04119362||Patients with pancreatic adenocarcinoma|Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
32842674|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
32842675|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
32842676|NCT04233567|Experimental|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32842677|NCT04107506|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
32842678|NCT04107506|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
32842679|NCT00581061|Experimental|Vesicare Treatment|
32842680|NCT04107272|Experimental|Experimental group|Real rTMS
32842681|NCT04107272|Sham Comparator|Control group|Sham rTMS
32842682|NCT01443845|Experimental|1|Roflumilast
32842683|NCT01443845|Placebo Comparator|2|Placebo
32842684|NCT04754204||Patients indicated for Mobile Cardiac Telemetry Monitoring|Patients indicated for Mobile Cardiac Telemetry Monitoring while meeting inclusion/exclusion criteria and enrolled in sequential manner.
32842685|NCT01549652|Experimental|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
32842686|NCT01549652|Experimental|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
32842687|NCT04118504|Experimental|Intervention group|Lifestyle intervention on through mobile application
32842688|NCT04118504|No Intervention|Control group|Usual care
32842689|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
32842690|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
32842691|NCT04070027|Active Comparator|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
32842692|NCT04070027|Active Comparator|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
32842693|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
32842694|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
32842695|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
33405930|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32842696|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
32842697|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
32842698|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
32842699|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
32842700|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
32842701|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
32842702|NCT04752098|Other|premature infants and full term infants|"The study visits will be at ≥3 time points at ages: within the first 28 days after birth, 2 months, 3 months, and, if still hospitalized, at 4 months and at 6 months.~The ultrasound machine to the nursery or neonatal intensive care unit at a scheduled time.~The appropriate ultrasound probe will be placed on the infant's tibia and a miniature hydrophone near the probe. A series of ultrasound measurements will be obtained and the ultrasound data will be saved for offline processing.~The Investigators will repeat the measurement in 3 locations of the infant's tibia.~Each ultrasound measurement takes a few seconds. The complete ultrasound study will take about 15 minutes at each visit.~All procedures will be conducted in the nursery or neonatal intensive care unit to ensure infant safety.~The ultrasound measurement for full-term infants can be done in ultrasound lab."
32842703|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
32842704|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
32842705|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
32842706|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
32842707|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
32842708|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
32842709|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
32842710|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
32842711|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
32842712|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
32842713|NCT02740179|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
32842714|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
32842715|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
32842716|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
32842717|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
32842719|NCT04066725|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
32842720|NCT04066725|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
32842721|NCT04066725|Placebo Comparator|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
32842722|NCT04047693|Experimental|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
32842723|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
32842724|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
32842725|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
32842726|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
32842727|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
32842728|NCT00612573|Placebo Comparator|Placebo|
32842729|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
32842730|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
32842731|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
32842732|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
32842733|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
32842734|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
32842735|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
32842736|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
32842737|NCT01547780|Experimental|Baseline brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to baseline brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
32842738|NCT01547780|Experimental|Repeat brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to repeat brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
32842739|NCT01547780|Experimental|Single brain PET in Chronic TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Chronic (5 months - 5 years post-injury) traumatic brain injury (TBI) patients.
32842740|NCT01547780|Experimental|Single brain PET in healthy subjects|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Healthy Subjects.
32842741|NCT00583011|Experimental|Local Anesthesia|Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.
32842742|NCT00583011|Placebo Comparator|Placebo-Normal saline|Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.
32842743|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
32842744|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
32842745|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
32842746|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
32842747|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
32842748|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
32842749|NCT01532648|Experimental|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
32842750|NCT01532648|Placebo Comparator|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
32842751|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
32842752|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
32842753|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
32842754|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
32842755|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
32842756|NCT01532570|Experimental|TA-650|
32842757|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
32842758|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
32842759|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
32842760|NCT03930849|Experimental|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
32842761|NCT03930849|No Intervention|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
32842762|NCT03930849|Experimental|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
32842763|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
32842764|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
32842765|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
32842766|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
32842767|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
32903052|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
32957986|NCT04340622|Active Comparator|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
32957987|NCT04340622|Placebo Comparator|Small reduction in opioid cravings and use|Sham condition.
32957988|NCT04340934|Experimental|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
32957989|NCT04340778|Experimental|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
32957990|NCT04340778|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
32957991|NCT04340778|Placebo Comparator|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
32957992|NCT04340466||Suspected or proven COVID-19 critically ill patients|
32957993|NCT04340466||Control|
32957994|NCT04340388|Active Comparator|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
32957995|NCT04340388|Active Comparator|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
33405931|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
33405932|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
33405933|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
33405934|NCT04309266|Experimental|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
33405935|NCT04226742|Experimental|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
33405936|NCT04226742|Active Comparator|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
33405937|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
33405938|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
33405939|NCT04031040|Experimental|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
33405940|NCT05588453|Experimental|Treatment (UD TGFbetai NK cells, temozolomide)|Patients receive UD TGFbetai NK cells IV over 30 minutes on day 1 and temozolomide PO daily on days 1-5. Treatment with UD TGFbetai NK cells repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Cycles of temozolomide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33405941|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
33405942|NCT01311401||Kama village (Kfar Kama )|Circassian community
33405943|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
33405944|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
32957996|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
32957997|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
32957998|NCT04340232|Experimental|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
33405945|NCT03775200|Experimental|Low dose|Low dose Psilocybin
33405946|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
33405947|NCT03775200|Experimental|High dose|High dose Psilocybin
33405948|NCT05588063|Experimental|Intervention Group|The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3 on the dial indicator. The remaining settings will be stored in the device and will not need to be set for each treatment. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.
33405949|NCT05588063|Sham Comparator|Sham Group|The sham device will be disabled internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3. This inactive sham method was chosen because previous studies have shown that stimulation with placement of the ear clip on other parts of the ear such as the earlobe, although not innervated by the vagus nerve, results in some vagus nerve activity. Inactive sham methodology has been used in previous studies.
32842768|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
33405950|NCT05188326|Experimental|Azacitidine|Vidaza consists of 50 mg/ m2 s.c or i.v for 7 days (5 + weekend off + 2) every 28 days and increase after 1st cycle, if well tolerated, to 75 mg/m2 s.c or i.v. for 7 days (5 + weekend off + 2) every 28 days for further 5 cycles followed by cycles every 56 days for 4 years and six months
33405951|NCT05188326|Placebo Comparator|Best supportive care|No drug administration
33405952|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
33405953|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
33405954|NCT05186454|Active Comparator|Morphine|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 200 µg of morphine intrathecally.
32842769|NCT03820479||Apfel score 1|Female
32842770|NCT03820479||Apfel score 2|Female, non smoker
32842771|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
32842772|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
32842773|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
32842774|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
32842775|NCT03571191|Experimental|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
32842776|NCT03475251|Experimental|CS1003|
32842777|NCT03475251|Experimental|CS1003 + regorafenib|
32842778|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
32842779|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
32842780|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
32842781|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
32842782|NCT00620061|Experimental|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
32842783|NCT04122443|Active Comparator|Acetaminophen|Acetaminophen alone
32842784|NCT04122443|Active Comparator|Oxycodone/ acetaminophen|Oxycodone + acetaminophen
32842785|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
32842786|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
32842787|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
32842788|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
32842789|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
32842790|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
32842791|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
32842792|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
32842793|NCT03373695|Experimental|Dissolve™|
32842794|NCT03373695|Active Comparator|SeQuent®Please|
32842795|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
32842796|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
32842797|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
32842798|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
32842799|NCT05247411|Experimental|Educational intervention|a Skype-videoconference, which included a 30 min educational intervention, was held with each subject.
32842800|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
32842801|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
32842802|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
32842803|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
32842804|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.~Interventions:~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
32842805|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.~Interventions:~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
32842806|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
32842807|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
32842808|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
32842809|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
32842810|NCT03026309||healthy|healthy volunteers.
32842811|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
32842812|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
32842813|NCT05247177|Experimental|Multimodal general anesthesia|General anesthesia maintained by co-administration of sevoflurane, dexmedetomidine and ketamine by using a predefined EEG density spectrum array pattern
32842814|NCT05247177|Active Comparator|Conventional general anesthesia|General anesthesia maintained by administration of sevoflurane alone to keep a bispectral index between 40-60
32842815|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
32842816|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
32842817|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
32842818|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
32842819|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
32842820|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
32842821|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
32842822|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
32842823|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
32842824|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
32842825|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
32842826|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
32842827|NCT05247099||children with systemic diseases|Systemic diseases such as Nephritic syndrome, and other systemic diseases that can affect the eyes.
32842828|NCT05247099||healthy children|"The exclusion criteria for the subjects were eye diseases or other systemic diseases that can affect the quality or volume of tears or the secretion of tears. These included~eyelid diseases: eyelid entropion, eyelid ectropion, ptosis, and palpebral dyskinesia;~conjunctival diseases: pterygium and conjunctivitis;~history of ocular surface chemical injury;~history of eye surgery within 6 months or history of retinal laser photocoagulation;~systemic diseases: Sjogren syndrome, Parkinson's disease, rheumatoid arthritis, Grave's disease, systemic lupus erythematosus, and others."
32842829|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
32842830|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
32842831|NCT05247021|Experimental|erector spinae block group (E)|patients will receive bilateral ultrasound guided erector spinae block before the lumbar spine surgery starts.(20ml of bupivacaine 0.25%) after receiving general anesthesia
32842832|NCT05247021|No Intervention|control group (C)|patients will receive standard general anesthesia for lumbar spine surgery according to hospital protocol.
32903053|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
32842833|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
33319948|NCT00250835|Experimental|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day [1700 mg/m2/day] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
32842834|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
32842835|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
32842836|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
32842837|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
32842838|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
32842839|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.~HSCT (performed ideally within 1 month from the end of consolidation).~Post HSCT therapy (MRD monitoring)"
32842840|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
32842841|NCT00669279|Experimental|Carvedilol CR|
32842842|NCT00669279|Experimental|Atenolol|
32842843|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
32842844|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
32842845|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
32842846|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
32842847|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
32842848|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
32842849|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
32842850|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
32842851|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
32842852|NCT04409522|Experimental|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
32842853|NCT04409522|Active Comparator|Control Group|Participants in this group will receive the usual treatment of COVID-19
32842854|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
32842855|NCT04105946|Active Comparator|OFA Group|patients undergoing FESS under opiod free anesthesia
32842856|NCT04105946|Active Comparator|TIVA Group|patients undergoing FESS under total intravenous anesthesia
32842857|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
32842858|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
32842859|NCT04098146||Mandibular Reconstruction|Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care
32842860|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
32842861|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
32842862|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
33319949|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
33319950|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
33319951|NCT05624372||Investigator|Child and Adolescent Psychiatrists, Speech Therapists
33319952|NCT05624372||Participant|Kids aged 4-18 diagnosed with ADHD
33319953|NCT05624216|Experimental|BTL-084 Treatment|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
32842863|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32842864|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
32842865|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
32842866|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
32842867|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
32842868|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
32842869|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
32842870|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
32842871|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
32842872|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
32842873|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
32842874|NCT01530464|Active Comparator|Aminophylline|
32842875|NCT01530464|Active Comparator|Ambrisentan|
32842876|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
32842877|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
32842878|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
32842879|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
32842880|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
32842881|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
32842882|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
32842883|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
32842884|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
32842885|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
32842886|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
32842887|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
32842888|NCT00635739|Active Comparator|A, 1|
32842889|NCT00635739|Placebo Comparator|A, 2|
32842890|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
32842891|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
32842892|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
32842893|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
32842894|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
32842895|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
32842896|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
32842897|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
32842898|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
32842899|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
32842900|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
33319954|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
33319955|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
33319956|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
32842901|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
32842902|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
32842903|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
32842904|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
32842905|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
32842906|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
32842907|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
32842908|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
32842909|NCT04836455|Experimental|The Real Cost vaping prevention ads - Health effects theme|
32842910|NCT04836455|Experimental|The Real Cost vaping prevention ads - Addiction theme|
32842911|NCT04836455|Other|Neutral vaping ads|
32842912|NCT00674583|Experimental|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
32842913|NCT00674583|Active Comparator|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
32842914|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
32842915|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
32842916|NCT01420081|Experimental|B|PI3K Basal, IV Compound
32842917|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
32842918|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
32842919|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
32842920|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
32842921|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
32842922|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
32842923|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
32842924|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
32842925|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
32842926|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
32842927|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
32842928|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
32842929|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
32842930|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
32842931|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
32842932|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
32842933|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
32842934|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
32842935|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
32842936|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
32842937|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
32842938|NCT03027986|No Intervention|Standard physiotherapy|
32842939|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
32842940|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
32842941|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
32903054|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
33319957|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
32842942|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
32842943|NCT03027830|Experimental|iFR pressure-wire|
32842944|NCT03027830|Active Comparator|Conventional|
32842945|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
32842946|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
32842947|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
32842948|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
32842949|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
32842950|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
32842951|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
32842952|NCT01439009|Experimental|Tolvaptan|15 mg
32842953|NCT01439009|Placebo Comparator|Placebo|Placebo
32842954|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
32842955|NCT00675987|Placebo Comparator|Placebo|Placebo 1 tab po QD
32842956|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
32842957|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
32842958|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
32842959|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
32842960|NCT01571453|Active Comparator|Venlafaxine extended release|
32842961|NCT04121195|Other|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
32842962|NCT04120961|Experimental|prolonged continuous use of bivalirudine|A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
32842963|NCT04120961|Other|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
32842964|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
32842965|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
32842966|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
32842967|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
32842968|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
32842969|NCT01419769|Experimental|AXIOS Stent and Delivery System|
32842970|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
32903055|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
32903056|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
32842971|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
32842972|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
32842973|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
32842974|NCT01570751|Experimental|IDeg followed by IGlar|
33405955|NCT05186454|Active Comparator|Multimodal|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam intrathecally
32842975|NCT01570751|Experimental|IGlar followed by IDeg|
32842976|NCT01419535|Experimental|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
32842977|NCT01419535|Experimental|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
32842978|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
32842979|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
32842980|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
32842981|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
32842982|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
32842983|NCT01418365|Experimental|Metronidazole + MMX placebo|
32842984|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
32842985|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
32842986|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
32842987|NCT00676065||1|Women who take oral contraceptives containing drospirenone
32842988|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
32842989|NCT00676065||3|Women who take oral contraceptives containing other progestogens
32842990|NCT00678015|Experimental|1|
32842991|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
32842992|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
32842993|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
32842994|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
32842995|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
32842996|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
32842997|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
32842998|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
32842999|NCT04064879|Experimental|Deployment of AD-SVF|Administration of autologous adipose derived SVF
32843000|NCT00641745|Experimental|1|Lurasidone
32843001|NCT00641745|Active Comparator|2|Risperidone
32843002|NCT01799421||Non-haematologic cancer|
32843003|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
32843004|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
32843005|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
32843006|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
32843007|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
32843008|NCT01439347|Experimental|Vincristine Sulfate Injection (VSI)|VSI dosed at 1.4 mg/m^2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes.
32843009|NCT01439347|Experimental|Marqibo|Marqibo dosed at 2.25 mg/m^2 (without any dose cap) as an IV infusion over 60 minutes.
32843010|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
32843011|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
33405956|NCT05177640|Experimental|99mTC-duramycin|single dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-CT scanning at different time points
33417201|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
32843012|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
32843013|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
32843014|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
32843015|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
32843016|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
32843017|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
32843018|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
32843019|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
32843020|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
32843021|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
32843022|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
32843023|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
32843024|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
32843025|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
32843026|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
32843027|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
32843028|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
32843029|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
32843030|NCT00681291|Active Comparator|2|Strattice
32843031|NCT00648375|Experimental|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
32843032|NCT00648375|Placebo Comparator|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
32843033|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
32843034|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
32843035|NCT00651573|Active Comparator|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
32843036|NCT00651573|Active Comparator|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
32843037|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
32843038|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
32843039|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
32843040|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
32843041|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
32843042|NCT00654069|Placebo Comparator|Placebo|Tablet
32843043|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
32843044|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
32843045|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
32843046|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
32843047|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
32843048|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
32843049|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
32843050|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
32843051|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
32843052|NCT04407949|Other|event detection|
32843053|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
32843054|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
32843055|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
32843056|NCT01418209|Active Comparator|Venlafaxine XR|
33417202|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
33417203|NCT01370239|Experimental|Hu3S193|Single arm
33417204|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
32843057|NCT01418209|Placebo Comparator|Placebo|
32843058|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
32843059|NCT00655473|Placebo Comparator|Placebo|
32843060|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
32843061|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
32843062|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
32843063|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
32843064|NCT00655707|Experimental|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
32843065|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
32843066|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
32843067|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
32843068|NCT01438411|Other|Cholic Acid|Active drug
32843069|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
32843070|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
32843071|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
32843072|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
32843073|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
32843074|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
32843075|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
32843076|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
32843077|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
32843078|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
32843079|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
32843080|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
32843081|NCT04747717|Experimental|Mitomycin C and cisplatin regimen|mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
32843082|NCT04747717|Active Comparator|Paclitaxel and carboplatin regimen|paclitaxel at 175 mg/m2 and carboplatin AUC5-6
32843083|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
32843084|NCT01416805|Active Comparator|Treatment as Usual|
32843085|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
32843086|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
32843087|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843088|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843089|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843090|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843091|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843092|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
32843093|NCT04064489|No Intervention|neutral|No specific instructions for prescribing prophylaxis or not
32843094|NCT04064489|Active Comparator|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score > or = 7 : treatment (low molecular weight heparin or fondaparinux); score < 7 : no treatment)
32843095|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
32843096|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
32843097|NCT04512053|Experimental|TAS-303|
32843098|NCT04512053|Placebo Comparator|Placebo|
32843099|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
32843100|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
32843101|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
32843102|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
32843103|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
32843104|NCT01437397|Placebo Comparator|5|Placebo
32843105|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
32843106|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
32843107|NCT04072393|Experimental|Home-based cardiac rehabilitation|"The intervention consists of a prescribed course of home-based cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 12 weeks.~Each customized exercise session includes three phases:~a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level~a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity~a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase~The patient will complete a brief questionnaire on the teleHeart application after completing each exercise session on how well they tolerated the exercise. The patient's CR team will receive daily updates from the patient's teleHeart application. Based on feedback from the application, the CR team may modify the patient's exercise program going forward."
32843108|NCT04066309|Experimental|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
32843109|NCT04066309|Experimental|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
32843110|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
32843111|NCT04071691||Active LVV|Patients with active LVV
32843112|NCT04071691||Stable LVV|Patients with inactive LVV
32843113|NCT04070833|Active Comparator|Vitamin D + fish oil|
32843114|NCT04070833|Active Comparator|Vitamin D + fish oil placebo|
32843115|NCT04070833|Active Comparator|Vitamin D placebo + fish oil|
32843116|NCT04070833|Placebo Comparator|Vitamin D placebo + fish oil placebo|
32843117|NCT04070521|Experimental|Observational EEG Monitoring|
32843118|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
32843119|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
32843120|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
32843121|NCT04066075|Experimental|Telerehabilitation with low vision provider|
32843122|NCT04066075|Experimental|Telerehabilitation w/ low vision provider plus tele-extender|
32843123|NCT04066075|Active Comparator|Usual Care (active control)|
32843124|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
32843125|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
32843126|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
32843127|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
32843128|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
32843129|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
32843130|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
32843131|NCT04064333|Experimental|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
32843132|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
32843133|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
32843134|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
32843135|NCT04069273|Experimental|Arm A (Ramucirumab and Paclitaxel)|"All patients receive pembrolizumab monotherapy (generally once every 3 weeks). Then this is followed by ramucirumab + paclitaxel (study drug[s] are generally given once per week). As study treatment moves forward, a patient-tailored disease-specific algorithm is applied in which pembrolizumab is re-introduced and integrated with ramucirumab + paclitaxel if clinical benefit is anticipated.~NOTE: All registered patients receive pembrolizumab, then patients are randomized to Arm A (ramucirumab + paclitaxel with patient-tailored disease-specific potential re-introduction of pembrolizumab with ramucirumab + paclitaxel) or Arm B (concurrent pembrolizumab with ramucirumab + paclitaxel)"
32843136|NCT04069273|Experimental|Arm B (Pembolizumab, Ramucirumab and Paclitaxel)|All patients receive pembrolizumab monotherapy (generally once every 3 weeks), which is followed by pembrolizumab + ramucirumab + paclitaxel (study drug[s] are generally given once per week).
32843137|NCT01436149|Experimental|Antidepressant + SPD489|
32843138|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
32843139|NCT04063267|Experimental|E cigarettes|
32843140|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
32843141|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
32843142|NCT04049851|Experimental|Moxidectin|
32843143|NCT04049851|Active Comparator|Ivermectin|
32843144|NCT04049383|Experimental|1 x 10^5 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
32843145|NCT04049383|Experimental|2.5 x10^5 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
32843146|NCT04049383|Experimental|7.5 x10^5 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
32843147|NCT04049383|Experimental|2.5 x10^6 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
32843148|NCT04049383|Experimental|Dose Expansion Phase|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort. Subjects will receive one of four dose levels. The dose expansion arm will be updated with the appropriate dose in the future based on the escalation results.
32843149|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
32843150|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
32843151|NCT01527500|Sham Comparator|Sham|Sham injection
32843152|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
32843153|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
32843154|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
32843155|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
32843156|NCT01441063|Experimental|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
32843157|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
32843158|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
32843159|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
32843160|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
32843161|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
32843162|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
32843163|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
32843164|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
32843165|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
32843166|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
32843167|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
32843168|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
32843169|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
32843170|NCT04061239|Experimental|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.~The treatment includes up to 2 cycles of induction as follows:~1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5~1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients < 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
32843171|NCT04061239|Other|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:~conventional 7+3 cytarabine/daunorubicin chemotherapy regimen~treatment with s.c. Azacitidine"
32843172|NCT04060849|Experimental|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
32843173|NCT04060849|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
32843174|NCT04048057|Experimental|Modarete Intensity Continous Training|
32843175|NCT04048057|Experimental|High Intensity Interval Training I|
32843176|NCT04048057|Experimental|High Intensity Interval Training II|
32843177|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
32843178|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
32843179|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
32843180|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
32843181|NCT01414075|Experimental|Arm A + E (Participants on HD): Roxadustat Only, No Iron|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
32843182|NCT01414075|Experimental|Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
32843183|NCT01414075|Experimental|Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection [for example, Ferrlecit®] or equivalent) once a week for 12 weeks.
32843184|NCT01414075|Experimental|Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
32843185|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
32843186|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
32843187|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
32843188|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
32843189|NCT04766905|Experimental|Issa1|Dr.A.Sayed Issa and his team
32843190|NCT04408079|Experimental|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
32843191|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
32843192|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
32843193|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
32843194|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
32843195|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
32843196|NCT01392547|Experimental|rFVIIa|
32843197|NCT01392547|Experimental|vatreptocog alfa|
32843198|NCT01435655|Experimental|open|tafamidis
32843199|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
32843200|NCT01434667|Experimental|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
32843201|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
32843202|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
32843203|NCT01418339|Experimental|Aripiprazole|Aripiprazole was administered orally once a week (QW) for 8 weeks in a double-blind manner. Participants randomized to aripiprazole received aripiprazole tablets at a starting dose of 52.5 milligrams (mg) QW on Day 0. At Week 1, according to the investigator's discretion based on efficacy and tolerability, the dose of aripiprazole could remain at 52.5 mg QW or could be increased to 77.5 mg QW. The dose could be increased to 110 mg QW as early as Week 2. For the remainder of the study (up to Week 8), the dose was to be adjusted up and down among these three dose levels, as determined by the investigator.
32843204|NCT01418339|Placebo Comparator|Placebo|Participants randomized to placebo received aripiprazole-matching placebo, tablet, orally, QW for 8 weeks in a double-blind manner.
32843205|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
32843206|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
33103896|NCT04887558|Experimental|Smart-T Mental Health and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT.
33405957|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
32843207|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
32843208|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
32843209|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
32843210|NCT01392469|Experimental|Imatinib + Bosentan + Sildenafil|Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
32843211|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
32843212|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
32843213|NCT04039087|Active Comparator|Sildenafil|active sildenafil 40 mg p.o. three times per day
32843214|NCT04039087|Placebo Comparator|Placebo Arm|placebo three times per day
32843215|NCT04061369|Experimental|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
32843216|NCT04061369|Experimental|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
32843217|NCT04061369|Experimental|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
32843218|NCT04061369|Experimental|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
32843219|NCT03025789|Experimental|Open label arm|children and adults to receive fexinidazole either as inpatients or outpatients.
32843220|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
32843221|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
32843222|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
32843223|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
32843224|NCT04505969||SCD patients and healthcare professionals|
32843225|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting or in the resuscitation unit .
32843226|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting or in the resuscitation unit.
32843227|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
33103897|NCT04887558|Experimental|Smart-T Mental Health+ and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT.
33405958|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
33405959|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
32843228|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
32843229|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
32843230|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
32843231|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
32843232|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
32843233|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
32843234|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
32843235|NCT04059965|Experimental|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
32843236|NCT04059965|Active Comparator|Control Arm|This cohort of patients will receive usual care
32843237|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
32843238|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
32843239|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
32843240|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
32843241|NCT01415531|Placebo Comparator|2|Dose-matched placebo
32843242|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
32843243|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
32843244|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
32843245|NCT01433263|Experimental|30mg/kg BYM338|
32843246|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
32843247|NCT01432951|Experimental|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
32843248|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
32843249|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
32843250|NCT04407793||Non-diverticulosis|Patients without diverticulosis
32843251|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
32843252|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
32843253|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
33417205|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
32843254|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
32843255|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
32843256|NCT04407871|Experimental|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
32843257|NCT04407871|Placebo Comparator|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
32843258|NCT04407871|Placebo Comparator|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
32843259|NCT04407871|Placebo Comparator|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
32843260|NCT01432171|Experimental|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
32843261|NCT01432171|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
32843262|NCT04036123|Experimental|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
32843263|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
32843264|NCT04034719|Experimental|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.~They will have a portage scarf to help them to keep their child skin-to-skin"
32843265|NCT04034719|Active Comparator|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.~They wont have a portage scarf."
32843266|NCT04496713|No Intervention|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
32843267|NCT04496713|Experimental|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
32843268|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
32843269|NCT04490941|Experimental|Intervention group|
32843270|NCT04490941|Other|Control group|
32843271|NCT04767581|Active Comparator|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
32843272|NCT04767581|Placebo Comparator|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
32843273|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
32843274|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
32903057|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
32843275|NCT04049591|Active Comparator|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
32843276|NCT04049591|Active Comparator|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
32843277|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
32843278|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
32843279|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
32843280|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
32843281|NCT01433159|Experimental|HP011-101|
32843282|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
32843283|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
32843284|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
32843285|NCT01413503|Experimental|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
32843286|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
32843287|NCT02036970|Experimental|Part 1 Dose-Ranging Bardoxolone methyl 2.5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 2.5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
32843288|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
32843289|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 10 mg/Part 2: Open-Label|Participants received bardoxolone methyl 10 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
32843290|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 20 mg/Part 2: Open-Label|Participants received bardoxolone methyl 20 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
32843291|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone methyl 2.5 mg|Participants received bardoxolone methyl 2.5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
32843292|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone methyl 5 mg|Participants received bardoxolone methyl 5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
32843293|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants received bardoxolone methyl 10 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
32843294|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone methyl 20 mg|Participants received bardoxolone methyl 20 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
32843295|NCT02036970|Experimental|Part 1: Dose Titration: Bardoxolone methyl 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 started with bardoxolone methyl 5 mg once-daily from Day 1 and escalated to bardoxolone methyl 10 mg once-daily starting at Week 4 thru Week 16. Participants who continued to Part 2 continued to receive the same bardoxolone methyl dose once-daily in Part 2 (Week 16 and onwards)
32843296|NCT02036970|Placebo Comparator|Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 received Placebo once-daily from Day 1 thru Week 16. Participants who continued to Part 2 initially received bardoxolone methyl 5 mg once-daily from Week 16 thru Week 20 and bardoxolone methyl 10 mg from week 20 onwards
32843297|NCT05031000|Experimental|Subject POCT glucometer measurement|Blood glucose measurement POCT glucometer
32843298|NCT05021562||Niraparib 200-300 milligrams (mg)|Arm description: Niraparib 200 mg, capsules, orally, once daily. For adult participants weighing 77 kilograms (kg) or more and with platelet count 150,000/mcrL or higher before the first dose of this drug, niraparib 300 mg, capsules, orally, once daily.
32843299|NCT05080920|Experimental|Rosmalip®|Participants receive Rosmalip® (diterpene phenols 11,25 mg) 1 capsule orally once daily for 16 weeks
32843300|NCT05080920|Placebo Comparator|Placebo|Participants receive Placebo 1 capsule matching Rosmalip® orally once daily for 16 weeks
32843301|NCT05069376|Experimental|The intraureteral placement of distal end of ureteral stent|Patients randomized to this group received 5-16/5-18 D-J stent with intraureteral placement of the distal end
32903058|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
32843302|NCT05069376|Active Comparator|The conventional placement of the distal end of ureteral stent|Patients randomized to this group received 5-22/5-24 D-J stent with bladder placement of the distal end
32843303|NCT05006820||No intervention|
32843304|NCT04984512|Experimental|Mitizodone Phosphate tablet 10mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
32843305|NCT04984512|Experimental|Mitizodone Phosphate tablet 20mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
32843306|NCT04984512|Experimental|Mitizodone Phosphate tablet 40mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
32843307|NCT04984512|Active Comparator|Placebo|Placebo,tablet,orally,once daily for 10 weeks.
32843308|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
32843309|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
32843310|NCT04973826|Experimental|ATM-AVI treatment arm|Chinese healthy volunteers
32843311|NCT05387616|Experimental|Copanlisib + Obinutuzumab|
32843312|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
32843313|NCT05387460||Training cohort|The cohort of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology is a training cohort Intervention/treatment
32843314|NCT05387460||validation cohort|The cohort of Women's Hospital, School of Medicine, Zhejiang University is a validation cohort
32843315|NCT05387382||Patients pending bariatric surgery|A continuous cohort of patients pending bariatric surgery
32843316|NCT03091764||NMIBC Patient High Risk|"Any of the following:~T1 tumours~CIS (carcinoma in situ)~Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented)~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
32843317|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
32843318|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, <3cm, no CIS~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
32843319|NCT05064774|Active Comparator|control group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy after the surgery once a week for 12 weeks. They were encouraged to do exercises 3 to 5 times every day.
32843320|NCT05064774|Experimental|myofascial release group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy the same as the control group once a week for 12 weeks. In addition to physiotherapy they took myofascial release sessions twice a week for 4 weeks between 4 and 7 weeks.
32843321|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
32843322|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
32843323|NCT01432457|Placebo Comparator|Placebo|
32843324|NCT05062278|Experimental|Intravenous Vinblastine|Single dose intravenous vinblastine (6mg/m2) in bolous.
32843325|NCT05062278|Active Comparator|Oral Hydroxiurea|Patient will recieve oral hydroxiurea at a dose of 50mg/kg/day until response or administration of induction chemotherapy
32843326|NCT05026788||Intra-COVID lockdown|Any patients treated for orthopaedic trauma within the mandatory lockdown due to the pandemic.
32843327|NCT05026788||Pre/post-COVID lockdown|Any patients treated for orthopaedic trauma either before or after the imposition of lockdown induced by the pandemic.
32843328|NCT02823990|Experimental|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32843329|NCT04873908|Other|conventional rehabilitation|
32843330|NCT04873908|Experimental|Modified constraint-induced therapy|
32843331|NCT04873908|Experimental|Proprioceptive Training|
32843332|NCT04858620|No Intervention|No treatment|
32843333|NCT04858620|Experimental|Treatment|
32843334|NCT04858620|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
32843335|NCT04854486|Experimental|Treatment Group|Xylitol + GSE
32843336|NCT04854486|Placebo Comparator|Control placebo|Saline
32843337|NCT04835688|Experimental|Ventilation tube insertion|Ventilation tube insertion into the tympanic membrane.
32843338|NCT04835688|Sham Comparator|Sham-treatment|Sham-treatment. Manipulation of the tympanic membrane to simulate ventilation tube insertion without performing a ventilation tube insertion.
32843339|NCT04957602||Metastatic non-small cell lung cancer patients|Metastatic non-small cell lung cancer patients who have not initiated their treatment yet (osermertinib or chemotherapy (associated or not with immunotherapy)
32843340|NCT02427126|Experimental|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
32843341|NCT02427126|Active Comparator|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
32843342|NCT04917120|Experimental|VRH (virtual reality hypnosis)|
32843343|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
32843344|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
32843345|NCT04831554|Experimental|single chest tube group|
32843346|NCT04831554|No Intervention|multiple chest tubes group|
32843347|NCT04807920|Experimental|Intravesical OnabotulinumtoxinA|The treatment group will receive 100 units of BOTOX® reconstituted in 10mL of injectable preservative-free normal saline at the time of cystoscopy. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted OnabotulinumtoxinA at each injection site, approximately 1cm apart along the posterior bladder wall, for a total of 20 injection sites (4 rows of 5 injection sites). This will be the only treatment.
32843348|NCT04807920|Placebo Comparator|Placebo|Subjects randomized to the placebo group will undergo the same procedure but will only receive 10mL of injectable preservative-free normal saline. This will be the only treatment.
32843349|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
32843350|NCT00658515|Placebo Comparator|Placebo|
32843351|NCT04797312|Experimental|Opioid free anesthesia (OFA) protocol|
32843352|NCT04797312|Sham Comparator|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|
32843353|NCT05080374|Experimental|HVLA + exercise Group|Spinal manipulation (HVLA) + trunk exercise program
32843354|NCT05080374|Experimental|HVLA + kinesiotaping group|Spinal manipulation (HVLA) + Kinesiotaping (lumbar)
32843355|NCT05080374|Experimental|HVLA + Respiratory exercise group|Spinal manipulation (HVLA) + respiratory exercise program
32843356|NCT04470882|Experimental|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
32843357|NCT04470882|Active Comparator|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
32843358|NCT04470882|Experimental|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
32843359|NCT05080140||Simvastatin|
32843360|NCT05080140||Ezetimibe|
32843361|NCT05080140||Omega -3 fatty acids-|
32843362|NCT05080140||Simvastatin+ Ezetimibe|
32843363|NCT05080140||Simvastain + ezetimibe + omega|
32843364|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
32843365|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
32843366|NCT04426110||"Period 1 Control"|No Music. Wound stitches procedure conducted according to clinical practice.
32843367|NCT04426110||"Period 2 Music"|Music by headphones. Wound stitches procedure conducted according to clinical practice
32843368|NCT04413318|Experimental|electronic device followed by pneumatic device|Children receive continuous control of tracheal cuff pressure with the electronic device (VBM©) for 6-hours followed by continuous control of tracheal cuff pressure with the pneumatic device (Nosten©) for 6-hours.
32843369|NCT04413318|Experimental|pneumatic device followed by electronic device|Children receive the reverse sequence (continuous control using the pneumatic device (Nosten©) for 6-hours followed by the electronic device (VBM©) for 6-hours
32843370|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
32843371|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
32843372|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
32843373|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
32843374|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
32843375|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
33405960|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
33405961|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
32843376|NCT03142386|Active Comparator|Control Group|Physiotherapy
32843377|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
32843378|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
32843379|NCT04280640||Metastatic Cancer Pts Receiving Molecularly Targeted Therapy|Metastatic cancer patients (with liver and/or lung metastasis) who will receive molecularly targeted therapy based on genomic testing data
32843380|NCT04280640||GI Cancer Pts|Gastrointestinal cancer patients (with liver and/or lung metastasis) who will receive 3rd line treatments or enrolled on a targeted therapy treatment trial
32843381|NCT04280640||Bladder Cancer Pts|Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment
32843382|NCT04053517||Observational (questionnaire administration)|Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed.
32843383|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
32843384|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
32843385|NCT04032925|Experimental|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
32843386|NCT04133688|Experimental|Mobile application (ASC)|mobile app / devise
32843387|NCT04133688|Active Comparator|Paper diary|paper diary
32843388|NCT04645290|Experimental|"Intervention group: Educational Intervention KARER"|General objective of the intervention: Implement self-care strategies and care actions aimed at people facing chronic diseases with disabilities, applying knowledge, ability and attitudes that allow them to act in a timely manner, reducing the risk of complications, improving well-being and the quality of life of the person cared for and of himself. Through face-to-face, virtual interdisciplinary educational actions (B-learning) and with simulation support.
32843389|NCT04645290|No Intervention|Usual Care|The people assigned to this group will receive their own responses from the institution providing care services to which they belong. These instructions consist of: information on the disease process and treatment received from the medical group, information on assistance by the nursing group and finally, the administrative procedures carried out by social work.
32843390|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients >=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
32843391|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
32843392|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
32843393|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
32843394|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
32843395|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
32843396|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
32843397|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
32843398|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
32843399|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
32843400|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
32843401|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
32843402|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
32843403|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
32843404|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
32843405|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
32843406|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
32843407|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
32843408|NCT05079438|Experimental|CRT with Dendrobium huoshanense Suppository|"Dendrobium huoshanense Suppository: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
32843409|NCT05079438|No Intervention|CRT with Placebo|"Placebo: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
32843410|NCT04053127|Experimental|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
32843411|NCT04053127|Sham Comparator|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
32843412|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
32843413|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
32843414|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
32843415|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
32843416|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
32843417|NCT05079048|Active Comparator|conventional retentive element|The conventional group received implant-supported mandibular overdentures retained by metal housings and nylon retentive elements,
32843418|NCT05079048|Experimental|PEEK retentive element|PEEK group received implant-supported mandibular overdentures retained by PEEK housings ,
32843419|NCT04477278|Experimental|Audio-Guided Mindfulness Intervention|Brief, 8-minute, audio-guided mindfulness intervention delivered prior to osteopathic manipulation.
32843420|NCT04477278|Active Comparator|History of Osteopathy|Brief, 8-minute, audio-guided history of osteopathy delivered prior to osteopathic manipulation.
32843421|NCT03140748|Other|Patients with fungal peritonitis|
32843422|NCT03140748|Other|Patients with peritonitis without yeast|
32843423|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
32843424|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
32843425|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
32843426|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
32843427|NCT01389973|Placebo Comparator|Double-blind: placebo|
32843428|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
32843429|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 2, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
32843430|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
32843431|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
32843432|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
32843433|NCT03502278|No Intervention|Waitlist|Waitlist
32843434|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
32843435|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
32843436|NCT04529460||Previously COVID-19 positive|Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
32843437|NCT04529460||Previously COVID19 negative|No previous symptoms of COVID-19
32843438|NCT04032067|Active Comparator|Control Group|"GV1001-Placebo ID injection administered every 2 weeks through Week 24~+ Proscar PO administered once a day through Week 24"
32843439|NCT04032067|Experimental|Study Group 1|"GV1001 0.56 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
32843440|NCT04032067|Experimental|Study Group 2|"GV1001 1.12 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
32843441|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
32843442|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
32843443|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
32843444|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
32843445|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
32843446|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
32843447|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
32843448|NCT02924220||Case patients|"Patients with culture-proven listeriosis. Case patients are classified in 3 groups :~Septicemic infections: isolation of Lm in blood cultures.~CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.~MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
33405962|NCT05176080|Experimental|Treatment group|Famitinib Plus SHR6390 and Endocrine therapy
33405963|NCT05162898|Experimental|GROUP 1|
33405964|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
33405965|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
32843449|NCT02924220||Control patients|"Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.~Septicemic controls: febrile patient with same co-morbidities as septicemic cases.~CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.~MF controls: febrile pregnant patient without obvious focal infection.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
32843450|NCT05078658|Experimental|Low-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
32843451|NCT05078658|Active Comparator|Recommended carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with 50% (+/- 5%) of the recommended energy from carbohydrates.
32843452|NCT04051957|Experimental|Isosorbide Mononitrate|
32843453|NCT04051957|Placebo Comparator|Placebo|
32843454|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
32843455|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
32843456|NCT05078424|Experimental|CBT Treatment group|This group receives CBT interventions that aim to improve mental well-being, depressive and anxiety symptoms in young people.
32843457|NCT05078424|No Intervention|Wait-list Control group|This group does not receive CBT intervention but will receive appropriate intervention after the CBT treatment group and follow-up phases complete.
32843458|NCT02859168|Experimental|Myofascial Induction session|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
32843459|NCT02859168|Placebo Comparator|Placebo session|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
32843460|NCT02784600||Partial or full-thickness rotator cuff tear|Rotation Medical bioinductive implant
32843461|NCT02458560|Experimental|single-arm|
32843462|NCT05387304||COVID-19 infections|SARS-Cov-2 RNA postive
32843463|NCT05387226|Experimental|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously
32843464|NCT04206150|Active Comparator|Group 1(femoral triangle apex)|the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal)
32843465|NCT04206150|Active Comparator|Group 2(femur length/15*2 cm above)|the adductor canal catheter is inserted femur length/15*2 cm above the location where the nerve block performed in group 1
32843466|NCT04206150|Active Comparator|Group 3(femur length/15 cm below)|the adductor canal catheter is inserted femur length/15cm below the location where the nerve block performed in group 1.
32843467|NCT05084274|Active Comparator|Lifestyle intervention group|12-week lifestyle modification programme through face-to-face lifestyle counseling and physiotherapy combined with a follow-up programme using video consultations and online training sessions
32843468|NCT05084274|No Intervention|Standard-of-care group|No intervention
32843469|NCT05387070|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
32843470|NCT05387070|Placebo Comparator|placebo|Placebo for TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
32843471|NCT05084196|Experimental|Melatonin Arm|Melatonin 5 mg capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
32843472|NCT05084196|Placebo Comparator|Placebo Arm|Placebo capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
32843473|NCT00591123|Experimental|FOLFOX, plus 5-FU and Erlotinib|single arm
32843474|NCT05311878|Experimental|EEG based perceptual training|Subjects complete a perceptual learning task in which EEG-based visual feedback is provided
32843475|NCT05311878|Active Comparator|Behavior based perceptual training|Subjects complete a perceptual learning task in which ground truth visual feedback is provided
32843476|NCT05311098|Experimental|Vestibule Group|Cryoablation
32843477|NCT01429441|Experimental|Ocriplasmin|
32843478|NCT01429441|Sham Comparator|Sham injection|
32843479|NCT04149990|Active Comparator|Entresto|Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks
33405966|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
33405967|NCT05113290|Experimental|H101+Sorafenib|H101 combined with Sorafenib
32843480|NCT04149990|Placebo Comparator|Placebo|Matching placebo B.I.D. for 26 weeks
32843481|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
32843482|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
32843483|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
32843484|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
32843485|NCT04120038|Experimental|SMART & Peer Support|
32843486|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
32843487|NCT01429285|Active Comparator|Usual care|Usual care
32843488|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
32843489|NCT05084040|No Intervention|A|Porth-a-Cath maintenance with 60-day interval
32843490|NCT05084040|Experimental|B|Porth-a-Cath maintenance with 90-day interval
32843491|NCT05277714|Experimental|NF|
32843492|NCT05277714|Sham Comparator|Sham|
32843493|NCT00594009|Experimental|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
32843494|NCT05083962|Active Comparator|Healthy Lifestyle Program Intervention Arm|
32843495|NCT05083962|No Intervention|Waitlist Control Group|
32843496|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
32843497|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
32843498|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
32843499|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
32843500|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
32843501|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
32843502|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
32843503|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~video based education"
32843504|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~direct education"
32843505|NCT04090476|Experimental|BIG for Life Exercise Group|This arm includes the entire cohort enrolled who will participate in the three times a week one hour community exercise group for a total of 8 weeks
32843506|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
32843507|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
32843508|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
32843509|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
32843510|NCT05083650|Experimental|Amniotic membrane without internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy using an amniotic membrane to plug the macular hole using air as tamponade.
32843511|NCT05083650|Active Comparator|Amniotic membrane with internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy + internal limiting membrane peeling using an amniotic membrane to plug the macular hole using air as tamponade.
32843512|NCT04063566|Other|Total cohort|The study will consist of one group, one arm, all receiving the same screening procedures.
32843513|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
32843514|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
32843515|NCT05174052|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme.
32903059|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
33405968|NCT05113290|Active Comparator|Sorafenib|Patients take Sorafenib only
32843516|NCT05174052|Active Comparator|Intervention Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme
32843517|NCT05083494||Melanoma|
32843518|NCT05083494||clear cell renal cancer|
32843519|NCT05083494||Urothelial Carcinoma of the bladder|
32843520|NCT05083494||squamous cell carcinomas of the head and neck|
32843521|NCT05083494||non-small cell lung cancer|
32843522|NCT00682617|Experimental|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
32843523|NCT00682617|Experimental|3 Month Exercise Program|3 month exercise program
32843524|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
32843525|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
32843526|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
32843527|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
33405969|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
32843528|NCT03968562|Active Comparator|2% Doxycycline Cream in Generic Aquaphor|2% Doxycycline Cream in Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Placebo Comparator
32843529|NCT03968562|Placebo Comparator|Generic Aquaphor|Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Active Comparator.
33405970|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
33405971|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
33405972|NCT03461952|Experimental|Nivolumab|240mg Q2W
33405973|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
33405974|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
33405975|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
33405976|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
33405977|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
33405978|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
33405979|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
33405980|NCT05101824|Other|Single arm|All recruited patients are treated with SABR.
33405981|NCT05062746|Experimental|MRT group|One session Matrix-Rhythm Therapy
33405982|NCT05062746|Other|Control group|One session routine, conventional physiotherapy and rehabilitation
32843530|NCT03425292|Active Comparator|1 SOC (closed to enrollment)|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
32843531|NCT03425292|Experimental|2 Nivo|Nivolumab
32843532|NCT03425292|Experimental|3 Nivo-Ipi (closed to enrollment)|Nivolumab plus Ipilimumab
32843533|NCT03425292|Experimental|4 Nivo-Ipi-CCNU-TMZ|Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide
32843534|NCT03425292|Experimental|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus 5-day Temozolomide
32843535|NCT03425292|Experimental|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus 5-day Temozolomide
32843536|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
32843537|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
32843538|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
32843539|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
32903060|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
33405983|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
33417206|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
32843540|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
32843541|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
32843542|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
32843543|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
32843544|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
32843545|NCT01428661|Experimental|tasimelteon|
32843546|NCT01428661|Placebo Comparator|placebo|
32843547|NCT05168670|Experimental|Study arm|Protection of eyes with tinted soft scleral eye shields followed by IPL administration directly on eyelids
32843548|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
32843549|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
32843550|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
32843551|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
32843552|NCT05083104||age and sex matched healthy control individuals.|controls divided into groups ,each group match in age and sex with cases
32843553|NCT05083104||mild and severe cases of COVID 19 patients|Covid 19 cases diagnosed by PCR , mild cases have symptoms as fever, dry cough, and diarrhea and severe cases admitted in ICU
32843554|NCT05163600|Experimental|COPD|Diagnosed COPD according to GOLD-guidelines
32843555|NCT05163600|Experimental|Healthy|Age ≥ 18 years Clinically healthy
32843556|NCT01790373|Experimental|Suubi+Adherence|"Suubi+Adherence intervention arm provides:~Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
32957999|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
32958000|NCT04339686||Suspicion of COVID 19|
32958001|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
32958002|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
32843557|NCT01790373|Active Comparator|Bolstered Standard of Care|"Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
32843558|NCT05144802|Experimental|group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : FreeStyle Libre 2 will be applied on right arm and Dexcom G6 will be applied on left arm.
32843559|NCT05144802|Active Comparator|group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : Dexcom G6 will be applied on right arm and FreeStyle Libre 2 will be applied on left arm.
32843560|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
32843561|NCT05125848|Experimental|Hemodialysis Single Group Assignment|All enrolled subjects will be connected to the CM-1500 for monitoring during their hemodialysis session
32843562|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
32843563|NCT05110950|Active Comparator|No suction EBUS-TBNA|In this technique the stylet is slowly removed without any kind of device in order to avoid active suction.
32843564|NCT05110950|Active Comparator|Passive suction through dedicated EBUS-TBNA syringe|After rapid stylet removal, suction is applied through a vacuteiner syringe, without active aspiration.
32843565|NCT05110950|Active Comparator|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|After rapid stylet removal, suction is applied through Cameco syringe pistol, that can apply active suction manually.
32843566|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
32843567|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
32843568|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
32843569|NCT03866148|Active Comparator|ILR|Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
32843570|NCT03866148|No Intervention|No ILR|Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).
32843571|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
32843572|NCT03864276|Experimental|inhalation anesthesia (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
32843573|NCT03864276|Experimental|Total intravenous anesthesia (propofol) group|Anesthesia is induced and maintained with propofol and sufentanil
32843574|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
32843575|NCT05082792|Other|doppler US for native AVF in upper limb|creation of native arteriovenous fistula in upper limb in chronic kidney disease patients on hemodialysis
32843576|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
32843577|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
32843578|NCT01427803|Experimental|Arm 1|
32843579|NCT05102214|Experimental|Phase 1a dose-escalation stage|Phase 1a uses the Bayesian optimal interval (BOIN) design, to investigate the safety and determine the MTD of HLX301. Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 15 mg/kg are planned for dose finding. Intra-patient dose escalation is not permitted. Enrollment will continue until a maximum of 30 patients are enrolled.
32843580|NCT05102214|Experimental|Phase 1b dose-expansion stage|Patients with NSCLC will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX301. Phase 1b dose expansion will include 20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
32843581|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort A|20 per-protocol treated patients with non-small cell lung cancer (NSCLC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
32843582|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort B|20 per-protocol treated patients with gastric/esophagogastric junction adenocarcinoma (GC/EGJ), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
32958003|NCT04338906|Experimental|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
32843583|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort C|20 per-protocol treated patients with head and neck squamous cell carcinoma (HNSCC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
33103898|NCT04663724|Experimental|Experimental Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
33103899|NCT04663724|Active Comparator|Comparator Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
33103900|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
33103901|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
33103902|NCT04863339|Experimental|Tranexamic Acid|Participants in the Tranexamic Acid arm will receive a dose of Tranexamic Acid.
33103903|NCT04863339|Placebo Comparator|Placebo|Patients in the placebo arm will receive a saline placebo.
33103904|NCT04684277|Experimental|antidepressant treatment|recieve antidepressant treatment
33405984|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
33103905|NCT04684277|Experimental|antidepressant treatment combined with Internet-based interventions|recieve antidepressant treatment combined with Internet-based interventions
33103906|NCT05604183|Experimental|Subjects|"On all subjects included in the study (see inclusion / exclusion criteria and informed consent) both procedures will be performed.~The result of these procedures (retinal scan, result from cognitive test and blood sample) will be used to build diagnostic classification models."
32843584|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort D|20 per-protocol treated patients with urothelial carcinoma (UC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
32843585|NCT04973202||Inpatients for alcohol detoxifications|French patients who were hospitalized for alcohol detoxification from 2011 to 2020
33103907|NCT05603871||ligamentoplasty of ligamentum teres|"The patients will be examined for:~Length of both lower limbs in relation to each other.~Length of both lower limbs according to patient age.~Presence of hump related to the outer surface of the hip~Presence of pain, abnormal gait, Trendlenburg test.~An addition to the steps of the open reduction, the following were done:~Identification of ligamentum teres~Ligamentoplasty of ligamentum teres"
32843586|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
32843587|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
32843588|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
32843589|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
32843590|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
32843591|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
32843592|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
32843593|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
32843594|NCT01408459|Active Comparator|Tomato product|Motivational telephone counseling weekly
32843595|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
32843596|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
32843597|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
32843598|NCT04476966|Experimental|T test|Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron
32843599|NCT04476966|Active Comparator|B reference (first dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (first dose)
32843600|NCT04476966|Active Comparator|B reference (second dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (second dose)
33103908|NCT04651985||Injured Achilles tendon participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
32843601|NCT00661557|Experimental|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
33103909|NCT04651985||Healthy Achilles tendon (contralateral) of participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
33103910|NCT04647968|Other|Primary closure of tracheo-cutaneous fistula|This group will undergo a protocoled primary closure of their tracheotomy.
32843602|NCT00661557|Active Comparator|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
32843603|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
32843604|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
32843605|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
32843606|NCT04994886|Experimental|Targeted Epidural Spinal Stimulation|"Participants will undergo a surgery for Targeted Epidural Spinal Stimulation (TESS). The neurostimulation system will be used to manage blood pressure instability.~Patients will then proceed to one month of an intensive device configuration protocol to configure the TESS settings of their investigational device to regain hemodynamic stability. After the intensive device configuration phase, daily supervised at-home hemodynamic TESS will be tested for 5 sessions per week for two weeks. Thereafter, and up to 10 months post-implant, patients will have a minimum of 5 TESS supported at-home sessions per week and one laboratory visit per month during a long-term at-home hemodynamic TESS phase. Finally, patients will have to undergo additional testing during a configuration of additional TESS programs phase. During this phase TESS configurations for hemodynamic stability, respiratory function, trunk stability and spasticity will be tested."
32843607|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
32843608|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
32843609|NCT03821610|Active Comparator|Fludarabine / Melphalan / Alemtuzumab|Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells
32843610|NCT03821610|Experimental|Cyclophosphamide / TBI (8Gy)|Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow
32843611|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
32843612|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
32843613|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
32843614|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
32843615|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
33405985|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
32843616|NCT03768414|Experimental|Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32843617|NCT03768414|Experimental|Arm II (cisplatin, gemcitabine hydrochloride)|Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32843618|NCT04044001|Experimental|Stage 1 - Cohort 1 (BTZ 250)|Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
32843619|NCT04044001|Experimental|Stage 1 - Cohort 2 (BTZ 500)|Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
32843620|NCT04044001|Experimental|Stage 1 - Cohort 3 (BTZ 750)|Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
32843621|NCT04044001|Experimental|Stage 1 - Cohort 4 (BTZ 1000)|Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
32843622|NCT04044001|Experimental|Stage 1 - Cohort 5 (BTZ 1250)|Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
32843623|NCT04044001|Experimental|Stage 1 - Cohort 6 (BTZ 1500)|Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
32843624|NCT04044001|Experimental|Stage 1 - Cohort 7 (BTZ 1750)|Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
32843625|NCT04044001|Experimental|Stage 1 - Cohort 8 (BTZ 2000)|Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
32843626|NCT04044001|Experimental|Stage 2 - Arm 1 (BTZ high)|Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
32903061|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
33405986|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
32958004|NCT04338906|Active Comparator|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
32958005|NCT04338282|Experimental|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
32958006|NCT04338438|Experimental|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
32958007|NCT04338126|Experimental|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
32958008|NCT04338126|Placebo Comparator|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
32958009|NCT04337736|Active Comparator|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
32958010|NCT04337736|Active Comparator|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
32958011|NCT04337658|Experimental|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
32958012|NCT04337658|Active Comparator|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
32958013|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
32958014|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
32958015|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
32958016|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
32958017|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
32958018|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
32958019|NCT04337268|Active Comparator|human glucagon-like peptide-1|"Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1"
32958020|NCT04337268|Placebo Comparator|Placebo|"Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
32958021|NCT04336566|Active Comparator|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
32958022|NCT04336566|Placebo Comparator|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
32958023|NCT04336254|Experimental|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
32958024|NCT04336254|Placebo Comparator|Control group|Routine treatment + Intravenous saline injection (Placebo)
32958025|NCT04336488|Experimental|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
32958026|NCT04336488|Active Comparator|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
32958027|NCT04336176|Active Comparator|PulseFlow DF boot|PulseFlow DF boot
32958028|NCT04336176|Active Comparator|Usual Care|Measurements will be taken from patients wearing usual standard of care
32958029|NCT04336176|Sham Comparator|Sham|Sham shoe (closest to barefoot or baseline pressures)
32958030|NCT04335864|Active Comparator|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
32958031|NCT04335864|Active Comparator|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
32958032|NCT04335786|Experimental|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
32958033|NCT04335786|Placebo Comparator|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
32958034|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
32958035|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
32958036|NCT04335708|Experimental|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
32958037|NCT04335708|Placebo Comparator|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
32958038|NCT04335474||Surgical drainage|Cases that have surgical management
32958039|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
32958040|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
32958041|NCT04335318|Experimental|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
32958042|NCT04335318|No Intervention|Standard Colonoscopy group|Standard clinical procedure
32958043|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
32958044|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
32958045|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
32958046|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
32958047|NCT04335006|Experimental|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
32958048|NCT04335006|Experimental|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
32958049|NCT04335006|Active Comparator|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
32958050|NCT04334694|Other|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
32958051|NCT04334928|Experimental|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Strength: 200 mg/245 mg tablets~Dose: one tablet once a day (both at dinner)"
32958052|NCT04334928|Experimental|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg~Strength: 200 mg tablets~Dose: one tablet once a day (both at dinner)"
32958053|NCT04334928|Experimental|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg~Strength FTC/TDF:200 mg/245 mg tablets~Strength HC: 200 mg tablets~Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
32958054|NCT04334928|Placebo Comparator|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Placebo tablets with similar appearance to study drugs.~Dose: one tablet once a day (both at dinner)"
32958055|NCT04334850|Experimental|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
33405987|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
33405988|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
33405989|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
33405990|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
33405991|NCT05630339|Experimental|Intervention group|Will receive 1.2 g of magnesium chloride (equivalent to 360 mg of magnesium elemental) + 4000 IU of vitamin D once a day, for four months.
33405992|NCT05630339|Placebo Comparator|Control group.|Will receive inert placebo for four months.
33405993|NCT04968366|Experimental|DC vaccine group|Subjects will receive five to eight doses of the DC vaccine through i.d. injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
33405994|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
33405995|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
33405996|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
33405997|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
33405998|NCT05723874|Experimental|Period 1 (Reference treatment (R)): BI 425809|
33405999|NCT05723874|Experimental|Period 2 (Test treatment (T)): bosentan + BI 425809|
33406000|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
33406001|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
33406002|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
33406003|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
33406004|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
33406005|NCT03446885|Experimental|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
32958056|NCT04334850|Other|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
32843627|NCT04044001|Experimental|Stage 2 - Arm 2 (BTZ medium)|Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
32843628|NCT04044001|Experimental|Stage 2 - Arm 3 (BTZ low)|Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
32843629|NCT04044001|Active Comparator|Stage 2 - Arm 4 (control)|"Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.~The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:~participants weighing 38 - 54 kg: 3 tablets~participants weighing 55 - 70 kg: 4 tablets~participants weighing >70 kg: 5 tablets"
32843630|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
32843631|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
32843632|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
32843633|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
32843634|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
32843635|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
32843636|NCT00663039|Experimental|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
32843637|NCT00663039|Experimental|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
32843638|NCT04387539|Active Comparator|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
32843639|NCT04387539|Active Comparator|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
32843640|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
32843641|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
32843642|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
32843643|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
32843644|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
32843645|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
32843646|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
32843647|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
32843648|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
32843649|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
32843650|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
32843651|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
32843652|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
32843653|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
32958057|NCT04334616|Active Comparator|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
32958058|NCT04334616|Active Comparator|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
32958059|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
32958060|NCT04334382|Experimental|Hydroxychloroquine|
32958061|NCT04334382|Active Comparator|Azithromycin|
32843654|NCT03706482|Experimental|Postnatal|"15 participants.~Administration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
32843655|NCT03706482|Experimental|Prenatal|"15 participants.~Administration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
32843656|NCT03706482|No Intervention|Prospective control (untreated)|"1-30 participants.~Subjects eligible for the trial but not willing/able to participate in any of the experimental arms."
33103911|NCT04647968|Other|Secondary closure of tracheo-cutaneous fistula|This group will undergo a protocoled secondary closure of their tracheotomy.
32843657|NCT03706482|No Intervention|Historic control|"30-150 participants.~Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
32843658|NCT04387383|Experimental|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
32843659|NCT04387383|Placebo Comparator|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
32843660|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
32843661|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
32843662|NCT03705156|Experimental|ZL-2306|The starting dose is 300 mg or 200 mg based on patient's body weight.
32843663|NCT03705156|Placebo Comparator|Placebo|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
32843664|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
32843665|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
32843666|NCT04056689|Experimental|DNL151 Low Dose|
32843667|NCT04056689|Experimental|DNL151 Mid Dose|
32843668|NCT04056689|Experimental|DNL151 High Dose|
32843669|NCT04056689|Placebo Comparator|Placebo|
32843670|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
32843671|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
32843672|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
32843673|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
32843674|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
32843675|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
32843676|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
32843677|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
32843678|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
32843679|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
32843680|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
32843681|NCT03554226|Experimental|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
32843682|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
32843683|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
32843684|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
32843685|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
32843686|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
32843687|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
32843688|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
32843689|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
32843690|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
32843691|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
32843692|NCT01411319|Experimental|LEAD Radiation Therapy|Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
32843693|NCT03538860|Other|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
33103912|NCT04634513|Experimental|Cohort 1: Shigella Vaccine at 10^8 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
32843694|NCT03538860|Other|Method B first then Method A|Asynchronous telepsychiatry - that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
32843695|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
32843696|NCT03537222||MyPOS|
32843697|NCT04055909|Experimental|nangibotide 1|
32843698|NCT04055909|Experimental|nangibotide 2|
32843699|NCT04055909|Placebo Comparator|Placebo|
32843700|NCT04952220||native septic arthritis of the knee|"Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:~thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)"
32843701|NCT04922268|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
32843702|NCT04922268|Experimental|External focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
32843703|NCT04054895|Experimental|Physiological pacing|"Pacing the his-purkinje system.~Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria [Europace. 2019 Oct 9. doi: 10.1093/europace/euz275]."
32843704|NCT04054895|Active Comparator|Biventricular resynchronization therapy|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
32843705|NCT04880928|Experimental|injection solution|Mydrane, Tropicamid 0,02%, Phenylephrine 0,31%, Lidocain 1%, injection solution
32843706|NCT04880928|Active Comparator|Standard eye Drops|Phenylephrine 10% and Tropicamid 0,5% eye drops
32843707|NCT03496038|Experimental|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
32843708|NCT03496038|Active Comparator|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
32843709|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
32843710|NCT01543490|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
32843711|NCT01543490|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
32843712|NCT03473574|Experimental|Arm A|Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
32843713|NCT03473574|Experimental|Arm B|Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
32843714|NCT03473574|Other|Arm C|Gemcitabine in combination with Cisplatin
32843715|NCT03473574|Experimental|Arm D|Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
32843716|NCT03473574|Experimental|Arm E|Durvalumab in combination with Gemcitabine and Cisplatin
32843717|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
32843718|NCT04869228|Experimental|GT0918 in the treatment arm|GT0918 tablets : oral, 1 time / day, 2 tablets / time, after meals
32843719|NCT04869228|Placebo Comparator|Placebo in the placebo arm|placebo : oral, 1 time / day, 2 tablets / time, after meals
32843720|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
32843721|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
32843722|NCT04758780|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
32843723|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
32843724|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
32843725|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
32843726|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
32843727|NCT04877652||ADHF patients|Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.
32843728|NCT04855188|Experimental|YVOIRE Y-Solution 540|
32843729|NCT04855188|Active Comparator|YVOIRE volume plus|
32843730|NCT05393856|Experimental|fed state in PART B|
32843731|NCT05393856|Experimental|fasted state in PART B|
33103913|NCT04634513|Experimental|Cohort 2: Shigella Vaccine at 10^9 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
32843732|NCT04768062|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.
32843733|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
32843734|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
32843735|NCT04759326|Active Comparator|Hippotherapy treated group|The hippotherapy protocol will comprise three cycles. The first one consists of one session per day for 2 weeks allowing (i) to evaluate the patient and his neuro-functional skills, and (ii) to determine and carry out the treatment taking into account the silent barriers that may exist (PSTD, fatigue, pain, fear...) and strongly interfere with functional outcome (developing ways to overcome them). After a 9-week 'wash out' period (during which the patient consolidates the new patterns, translates them into daily activities and identifies new needs) where the patient continues his or her outpatient neurorehabilitation care, a further intermediate 1-week daily capacity building hippotherapy cycle follows. Then, after a second 9-week 'wash out' period (where the patient once again consolidates the new patterns, translates them into daily activities and identifies new needs), a final 1-week daily capacity building hippotherapy cycle will be carried out. Protocol will last 22 weeks.
32843736|NCT04759326|Placebo Comparator|Conventional neurorehabilitation treated group|Patients in the control group will receive standard outpatient rehabilitation treatment consisting of a program of physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support per week corresponding to the four weeks in which the treated group will be in hippotherapy. For the remaining 18 weeks, the treatment options for each patient, regardless of the group, will also include physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support.
32843737|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
32843738|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
32843739|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
32843740|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
32843741|NCT05393778|Experimental|Measured Technique|Patients in this group will have pre-operative planning done using the measured technique.
32843742|NCT05393778|Experimental|Navigated Technique|Patients in this group will have pre-operative planning done using the navigated technique.
32843743|NCT04751994|Experimental|Iron supplement/ ferrous sulphate syrup|administration of daily iron drops, 7.5mg/day iron as ferrous sulphate
32843744|NCT04751994|Placebo Comparator|supplement with placebo|administration of daily placebo drops
32843745|NCT00687453|Experimental|1|Insulin glargine at bedtime
32843746|NCT00687453|Active Comparator|2|NPH twice-daily
32843747|NCT05393700|Experimental|AOT-sleep|They will be asked to watch video-clips representing motor contents before sleeping.
32843748|NCT05393700|Active Comparator|AOT-control|They will be asked to watch video-clips representing motor contents at least 12 hours before sleeping.
32843749|NCT05393700|Sham Comparator|Control|They will be asked to watch video-clips representing landscapes before sleeping.
32843750|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
32843751|NCT04738422|Experimental|Alkaline glycine Inhalation|Subjects inhale alkaline glycine
32843752|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
32843753|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
32843754|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
32843755|NCT02618148|Experimental|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
32843756|NCT02618148|Experimental|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
32903062|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
33103914|NCT04634513|Experimental|Cohort 3: Shigella Vaccine at 10^10 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
32843757|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
32843758|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
32843759|NCT05393622|Experimental|Intervention, Placement of Device & Stimulation|Placement of neurostimulation device & stimulation of prefrontal cortex target
32843760|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
32843761|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
32843762|NCT04692714|Experimental|Experimental knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented without additional cement using the MAKO robot
32843763|NCT04692714|Active Comparator|Conventional knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented with additional cement using the MAKO robot
32843764|NCT04683588|Experimental|intervention arm|"Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes~Before Surgery: Nursing coaching, 30-45 minutes~Surgery Day: Nursing coaching, 30-45 minutes~Postoperative 1st Day: Nursing coaching, 30-45 minutes~Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes~Day of discharge: Nursing coaching, 30-45 minutes.~15 days after discharge: Nursing coaching, 60 minutes~45 days after the operation: Nursing coaching, 60 minutes.~90 days after surgery: Nursing coaching, 60 minutes."
32843765|NCT04683588|No Intervention|Control arm|Patients in the control group will receive routine postoperative nursing care.
32843766|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
32843767|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
32843768|NCT04680936|Active Comparator|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
33103915|NCT04634513|Experimental|Cohort 4: Shigella Vaccine or Placebo|2:2:1 randomization to receive either two doses of vaccine, 1 dose of vaccine and one dose of placebo, or two doses of placebo at Days 1 and 29 (Cohort n=30)
32843769|NCT04680936|Active Comparator|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
32843770|NCT04680936|Active Comparator|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
32843771|NCT05393544|Experimental|Intervention|The intervention utilizes an existing care coordination smartphone app to allow participants to engage with a recovery coach during and after an inpatient admission to an inpatient withdrawal management facility (i.e. detox).
32843772|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
32843773|NCT01404325|Experimental|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
32843774|NCT01404325|Experimental|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
32843775|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
32843776|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
32843777|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
32843778|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
32843779|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
32843780|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
32843781|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
32843782|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
32843783|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
32843784|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
32843785|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
32843786|NCT04655586|Experimental|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
32843787|NCT04655586|Experimental|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
32843788|NCT04655586|Active Comparator|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
32843789|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
32843790|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
32843791|NCT05082246|Other|Pre- and Post- Intervention|Data will be gathered in participants with pre-intervention and post-intervention comparison.
32843792|NCT04629690|No Intervention|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
32843793|NCT04629690|Experimental|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
32843794|NCT05393154||Study Participant|Non-destructive imaging of biopsies using the Aquyre system
32843795|NCT05392998||Vivity patients|"The study will include patients >40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) < 20/20 and with postoperative refractive astigmatism > 0.50D will be also excluded .~Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination."
32843796|NCT04583124|Experimental|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
32843797|NCT04583124|Active Comparator|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
32843798|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
32843799|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
32843800|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
32843801|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
32843802|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
32843803|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
32843804|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
32843805|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
32843806|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
32843807|NCT05392686|Experimental|Experimental: PD1 + PARP|"For the Induction Phase, participants receive 4 cycles:~PD1 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant to maintenance therapy.~For the Maintenance Phase, participants receive PD1 IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral PARP 100 mg twice daily. Until centrally verified progressive disease, physician decision or intolerable toxicity."
32843808|NCT05082168||Respiratory tract infection|Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support
32843809|NCT05082168||Sepsis|Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support
32843810|NCT05082168||Cardiac surgery|Patients admitted to ICU for mechanical ventilatory support following cardiac surgery
32843811|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
32843812|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
32843813|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
32843814|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
32843815|NCT04508634|Active Comparator|Metformin Group|Metformin Group
32903063|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
32903064|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
32958062|NCT04333758|Experimental|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
32958063|NCT04333992|Active Comparator|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
32958064|NCT04333992|Active Comparator|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
32958065|NCT04333836|Experimental|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
32958066|NCT04333836|Active Comparator|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
32958067|NCT04332978|Experimental|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
32958068|NCT04332978|Active Comparator|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
32958069|NCT04332900|No Intervention|Control condition|In this condition there will not be any application of therapeutic approach.
32958070|NCT04332900|Experimental|Intervention proximal condition|The proximal therapeutic approach will be the SERF strap (S.E.R.F. strap; DonJoy Orthopedics, Inc., vista, CA).
32958071|NCT04332900|Experimental|Intervention distal condition|The distal therapeutic approach will be a pair of foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each (Propulsão Produtos Biomecânicos, Minas Gerais, Brazil).
32958072|NCT04333212|Other|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
32958073|NCT04332666|Placebo Comparator|Placebo|Standard of care treatment
32958074|NCT04332666|Experimental|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
33103916|NCT04630184|Experimental|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
33406006|NCT03446885|Experimental|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
33406007|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
33406008|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
33406009|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
33406010|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
33406011|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
33406012|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
33406013|NCT05209698||Ethnic groups- Jews and Arabs|Data will be extracted from electronic medical records for all people with PD residing in a specific HMO district according to a record-based survey (e.g., individuals whose medical records include a diagnosis of PD). Currently, there are 2500 patients with PD in that district. In the second part of the study, a sub-sample of 100 Jewish and 100 Arab Patients with Parkinson's disease will be asked to answer standardized questionnaires.
33406014|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
33406015|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~TC (docetaxel + cyclophosphamide)~AC (doxorubicin + cyclophosphamide)~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
33406016|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
33417207|NCT05191069|Experimental|Moringa Oleifera Mouthwash|15ml of Moringa Oleifera mouthwash will be given to be used twice daily for 6 months.
33417208|NCT05191069|Placebo Comparator|Placebo Mouthwash|The mouthwash will have all other ingredients other than Moringa Oleifera extract. Participants will be advised to use 15ml of Placebo mouthwash twice daily for 6 months.
32843816|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
32843817|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
32843818|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
32843819|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
32843820|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
32843821|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
32843822|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
32843823|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
32843824|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
32843825|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
32843826|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
32843827|NCT05081856|Experimental|intervention group|The group mobilized for at least 20 minutes 6 times a day with a modular medical equipment carrying vehicle
32843828|NCT05081856|No Intervention|control group|The group mobilized for at least 20 minutes 6 times a day with a routin practice
32843829|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
32843830|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
32843831|NCT00690339|Experimental|1|Augmentation
32843832|NCT00690339|Experimental|2|Reconstruction
32843833|NCT00690339|Experimental|3|Revision-augmentation
32843834|NCT00690339|Experimental|4|Revision-reconstruction
32843835|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
32843836|NCT04368936||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 1-14 years
32843837|NCT04368936||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
32843838|NCT04368936||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
32843839|NCT04368936||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
32843840|NCT04368936||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed Epilepsia
32843841|NCT04368936||EFS: group of individuals with Epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
32843842|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
32843843|NCT00690495|Active Comparator|2|Propofol 1%
32843844|NCT04273386|Experimental|Evaluation|Cases will be evaluated for oral health and data will be recorded.
32843845|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
32843846|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
32843847|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
32843848|NCT04366440|Other|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
32843849|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
32843850|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
32843851|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
32843852|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
32843853|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
32958075|NCT04332822|Active Comparator|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
32958076|NCT04332822|Experimental|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6~Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
32843854|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
32843855|NCT04351230|Active Comparator|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32843856|NCT04351230|Experimental|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32843857|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
32843858|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
32843859|NCT04200534|Experimental|Group I (centralized care strategy)|Participants receive counseling over the phone to help them quit smoking and learn about lung cancer screening over 15-20 minutes for 6-8 sessions over 8 weeks. Participants may also receive nicotine patches.
32843860|NCT04200534|Active Comparator|Group II (usual care)|Participants receive counseling on lung cancer screening and smoking cessation from primary care providers at health care visit.
32843861|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
32843862|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
32843863|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
32843864|NCT04186650|Experimental|Autologous genetically modified tissue-engineered skin graft|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
32843865|NCT04175184|Experimental|Experimental group|"Exercise programme: 2-3 sets of 10-15 repetitions of shoulder girdle and glenohumeral strengthening exercises performed in different positions in addition to three stretching exercises.~Mobilisation with movement (MWM): the participant and physiotherapist will decide one movement more functionally relevant to the patient. Afterwards, attempts of MWM will be applied to different joints in order to identify one particular MWM that improves significantly the movement previously selected. Then, one set of six to ten repetitions will be applied. This process of pragmatically using MWM will be conducted in every session, but from the second session onwards, two to three sets of ten repetitions will be applied, with an interval of sixty seconds between sets. In case of failure to identify an MWM that improves the movement significantly, the patient decides which one seemed to be best and one set of six repetitions will be applied to the onset of discomfort."
32958077|NCT04332510|Experimental|Infant milk 1|
32958078|NCT04332510|Experimental|Infant milk 2|
32958079|NCT04332510|Experimental|Infant milk 3|
32958080|NCT04332510|Experimental|Infant milk 4|
32958081|NCT04332276|Experimental|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
32958082|NCT04332276|Active Comparator|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
32958083|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
32958084|NCT04332042|Experimental|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
33103917|NCT04630184|Placebo Comparator|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
32843866|NCT04175184|Sham Comparator|Placebo group|"The exercise programme is exactly the same as the experimental group.~Sham MWM: the participant and physiotherapist will decide together one movement that is more functionally relevant to the patient. Afterwards, a sham MWM (Delgado-Gil et al 2015) will be applied and the movement previously selected will be repeated six times in the first consultation. The participant will be informed that he/she should move to the onset of symptoms, if they occur.This process will be conducted in every session, but from the second session onwards, two to three sets of 10 repetitions will be applied, with an interval of sixty seconds between sets. In case the sham MWM failed to improve the movement significantly, one set of six repetitions will be applied only."
32843867|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
32843868|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
32843869|NCT04092192|Active Comparator|Forceps|Subjects randomized to this cohort will have their IVC filter removed using a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed.
32843870|NCT04092192|Active Comparator|Snare|Subjects randomized to this cohort will have their IVC filter removed using an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.
32843871|NCT05392218|Experimental|motivational interviewing|
32843872|NCT05392218|Sham Comparator|attention group|
32843873|NCT04028388|Active Comparator|Docetaxel IV|This study arm will receive docetaxel at 75 mg/m2 given i.v. as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily.
32843874|NCT04028388|Experimental|ModraDoc006/r|This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in the evening (7-12 hours after the morning dose), on Day 1, 8 and 15 of a 21-day cycle, plus 5 mg oral prednisone twice daily.
32843875|NCT04216056|Experimental|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
32843876|NCT04216056|No Intervention|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
32843877|NCT04205760|No Intervention|Control group|Standard Care as per local guidelines
32843878|NCT04205760|Experimental|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
32843879|NCT04194840|Experimental|Transplant Wellness Clinic|"Physical therapy consult~Intake vitals~CARG online survey, mental status exam~Medication review~Nutrition survey~Social work: available on prn basis (as-needed)~Exit survey~Recommendations made and given to the participant and sent to the referring MD. Participant receives post clinic phone call before transplant. Referring MD receives questionnaires. Data collected depending on if participant moved forward with transplant"
32843880|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
32843881|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
32843882|NCT05392140|Experimental|intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
32843883|NCT05392140|Active Comparator|non-intervention group|standard care practice will continue
32843884|NCT05392062|Other|Respiratory insufficiency|Subject with respiratory insufficiency
32843886|NCT01796301|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
32843887|NCT01796301|Active Comparator|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
32843888|NCT03361410|Experimental|Grape Powder|
32843889|NCT03361410|Placebo Comparator|Placebo Powder|
32843890|NCT04118790||Minor Stroke patients|"Clinical Assessment~MRI scan session"
32843891|NCT04118790||TIA patients|"Clinical Assessment~MRI scan session"
32843892|NCT04118790||Healthy Controls|MRI scan session
32843893|NCT04103346|Active Comparator|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
32843894|NCT04103346|Sham Comparator|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
32843895|NCT04095936|Experimental|AMG531|
32843896|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
32843897|NCT04092582|Experimental|MTPS9579A|
32843898|NCT04092582|Placebo Comparator|Placebo|
32843899|NCT01204905|Experimental|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
33103918|NCT04630184|No Intervention|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
33103919|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
32843900|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
33417209|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
32843901|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
32843902|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
32843903|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
32843904|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
32843905|NCT01388335|Experimental|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
32843906|NCT03402282|Experimental|embolization|upper rectal artery embolization
32843907|NCT03402282|Active Comparator|surgical treatment|surgical repair through the classic technique (Milligan and Morgan technique)
32843908|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
32843909|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
32843910|NCT03359460|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32843911|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
32843912|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
32843913|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
32843914|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
32843915|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.~The regimen of administration of the chemotherapy is as following:~Carboplatin AUC 6 - IV - Day (D) 1~Paclitaxel 80mg / m² - IV - D1, D8, D15~one cycle every 3 weeks"
32843916|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.~The regimen of administration of the chemotherapy is as following:~Cisplatin 80mg / m² - IV or IP - D1~Epirubicin 60mg / m² - IV - D3~one Cycle every 3 weeks."
32843917|NCT03356652|Experimental|Tailor-made CRT delivery|Patient undergoes acute noninvasive electrical dyssynchrony study with various CRT configurations. CRT device is then implanted with optimal configuration.
32843918|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
32843919|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
32843920|NCT04027075|Experimental|Intervention|This group will be asked to use the Rewire app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
32843921|NCT04027075|No Intervention|Services as usual|This group will receive services as usual from the Department of Youth Services.
32843922|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
32843923|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
32843924|NCT05391594|Experimental|Single Subject Design|The investigators will use a longitudinal design with baseline, immediate and post-intervention data collections. The intervention will include customized posture support in seated, standing or walking devices that will be used in the child's educational setting or home (for early intervention) to facilitate specific educational activities.
32843925|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
32843926|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
33103920|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
33103921|NCT00552773|Experimental|Cyclamen Europaeum|
33417210|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
32843927|NCT03147378|Experimental|arm A Fasting-Fed condition|ModraDoc006/r will be administered in fasting condition week 1 and in fed condition week 2
32843928|NCT03147378|Experimental|arm B Fed-Fasting condition|ModraDoc006/r will be administered in fed condition week 1 and in fasting condition week 2
32843929|NCT04466137|Experimental|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
32843930|NCT04466137|Experimental|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
32843931|NCT04466137|Active Comparator|Positive Control Group|rhG-CSF/PEG-rhG-CSF
32843932|NCT00713661|Experimental|TachoSil®|
32843933|NCT00159744|Active Comparator|Arm 1|Asenapine
32843934|NCT00159744|Active Comparator|Arm 2|Olanzapine
32843935|NCT00159744|Placebo Comparator|Arm 3|Placebo
32843936|NCT04041973|Experimental|ACT arm|Artemether-lumefantrine (AL) x 3 days followed by 1 day per week
32843937|NCT04041973|Active Comparator|Multivitamin arm|Multivitamin x 3 days followed by 1 day per week
32843938|NCT03125304|Experimental|treatment group|Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.
32843939|NCT03125304|Placebo Comparator|control group|Control group will receive acupuncture at non-acupoints.
32843940|NCT00713817|Experimental|Sativex|
32843941|NCT00713817|Placebo Comparator|Placebo|
32843942|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
32843943|NCT03948516||Participants tested for Sickle cell disease|
32843944|NCT05391516||All Participants|Participants; 18-80 years old, who volunteered to participate in the study, patients with shoulder problems.
32843945|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
32843946|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
32843947|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
32843948|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
32843949|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
32843950|NCT02914470|Experimental|carbo, cyclo, atezolizumab|The starting dose is carboplatin AUC 5mg/ml*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously
32843951|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
32843952|NCT05383950|Experimental|smartphone application based 12-week pulmonary or cardiac rehabilitation|
32843953|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
32843954|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
32843955|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
32843956|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
32843957|NCT02409654|Active Comparator|Individualized stroke prevention|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
32843958|NCT02409654|Placebo Comparator|Routine Care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
32843959|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
32843960|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
32843961|NCT05088330|Experimental|D-VRD|treatment with D-VRD in NDMM
32843962|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
32843963|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
32843964|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
32843965|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
32843966|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
32843967|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
32843968|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
32843969|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
32843970|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
32843971|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
32843972|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
32843973|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
32843974|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
32843975|NCT03138408|Experimental|SC-004|
32843976|NCT03138408|Experimental|SC-004 and ABBV-181|
32843977|NCT03139890|Experimental|High-fat milkshake|
32843978|NCT03139890|Experimental|High-carbohydrate milkshake|
32843979|NCT03139890|Experimental|High-protein milkshake|
32843980|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
32843981|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
32843982|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
32843983|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
32843984|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
32843985|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
32843986|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
32843987|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
32843988|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
32843989|NCT05230446|Other|Percutaneous Coronary Intervention|Interventional comparitor, compared to an optimal performance goal of 7% MACCE resulted from past CABG results
32843990|NCT05088174|Experimental|D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine|
32843991|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
32843992|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
32843993|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
32843994|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
32843995|NCT03041688|Experimental|Treatment (decitabine, navtemadlin)|"Patients receive decitabine IV over 1 hour on days 1-10 and navtemadlin PO QD on days 4-10. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5 and navtemadlin PO QD on days 4-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32843996|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
32843997|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
32843998|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
32843999|NCT03455634|No Intervention|Control|no intervention
32844000|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
32844001|NCT03469050|Experimental|Rifaximin delayed released 800 mg b.i.d.|(i.e. 2 x 400 mg tablet twice a day; total daily dose: 1600 mg) for 10 consecutive days a month, for 12 months
32844002|NCT03469050|Experimental|Rifaximin delayed released 400 mg b.i.d|(i.e. 1x400 mg tablet plus 1 placebo tablet twice a day; total daily dose: 800 mg) for 10 consecutive days a month, for 12 months
32844003|NCT03469050|Placebo Comparator|Placebo b.i.d.|(i.e. 2 x placebo tablets twice a day) for 10 consecutive days a month, for 12 months.
32958085|NCT04332120|Active Comparator|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
32958086|NCT04332120|Active Comparator|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
32958087|NCT04332120|Active Comparator|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
32958088|NCT04331808|Experimental|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
32958089|NCT04331808|No Intervention|Standard of care|
33033051|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
33406017|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
33406018|NCT04957524|Active Comparator|Set Amplitude|This arm is to test a specific amplitude. Participants will be instructed to set the amplitude to 20 mA, frequency to 20 Hz, and pulse duration to 5 mS. The parameters will stay the same for the entire session. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
33406019|NCT04957524|Experimental|Customizable Amplitude|In this arm, the participant will set the frequency to 12 Hz and pulse duration to 1 millisecond. The participant will be instructed to increase the amplitude gradually and set it at the maximal tolerable amplitude. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
33406020|NCT03718013|Experimental|accelerated dTMS|
33406021|NCT03718013|Active Comparator|standard dTMS|
33406022|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
33406023|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
33406024|NCT05567159|Experimental|Donanemab|Donanemab administered intravenously (IV).
33406025|NCT04945746|Experimental|Software VX1 + Stability|Utilization of the software VX1 + Stability
33406026|NCT05209542|Active Comparator|Hysterosalpingo-Foam Ultrasonography|3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
33406027|NCT05209542|Active Comparator|laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
33406028|NCT05702034|Experimental|Milvexian|Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT [single antiplatelet therapy] or DAPT [dual antiplatelet therapy]) will receive milvexian orally twice daily.
33406029|NCT05702034|Placebo Comparator|Placebo|Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.
33406030|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
33406031|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
33406032|NCT05564273|No Intervention|Placebo|Participants who have metabolic issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
33406033|NCT05564273|Active Comparator|Viome's Precision Nutrition Program|Participants who have metabolic issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
33406034|NCT05564273|Active Comparator|Viome's condition-based supplements|Participants who have metabolic issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
33406035|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
33406036|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
33406037|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
33406038|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
33417211|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
33417212|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
32958090|NCT04331418|No Intervention|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
32958091|NCT04331418|Experimental|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
32958092|NCT04331418|Experimental|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
32958093|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
32958094|NCT04331184|Experimental|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
32958095|NCT04330872|Active Comparator|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).~The study's total duration is 3 days."
32958096|NCT04330872|Placebo Comparator|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)~The study's total duration is 3 days."
32958097|NCT04331028|Experimental|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
32958098|NCT04331028|No Intervention|Control|After dental extraction, no treatment will be applied
32958099|NCT04330794|Experimental|NMFACT|record the caries index using the NMFACT chart
32958100|NCT04330794|Active Comparator|DMF index|record the caries index using the DMF chart
32958101|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
32958102|NCT04330404|Experimental|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
32958103|NCT04330404|Active Comparator|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
32958104|NCT04330326|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
32958105|NCT04330326|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
32958106|NCT04329858|Active Comparator|conventional glass ionomer|
32958107|NCT04329858|Experimental|zinc modified glass ionomer|
32958108|NCT04329858|Experimental|silver modified glass ionomer|
32958109|NCT04329468|Experimental|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
32958110|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
32958111|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
32958112|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
32958113|NCT01620996|Active Comparator|2|Sydney Family Practice
32958114|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
32958115|NCT01138020|Experimental|Arm 1|Cognitive intervention
32958116|NCT01138020|Active Comparator|Arm 2|Educational intervention
32958117|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
32958118|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
32958119|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
32958120|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
32958121|NCT00567684|Experimental|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
32958122|NCT05620680|Experimental|Treatment group|CD7 CAR-T treatment group
32958123|NCT05620602||Remedial treatment within 3 months|
32958124|NCT05620602||Remedial treatment within 3 to 6 months|
32958125|NCT05620602||Remedial treatment within 6 to 12 months|
32958126|NCT05620602||Remedial treatment after 12 months|
32958127|NCT05620446|Active Comparator|endoscopic managment of sigmoid volvulus|patients are subjected to untwist the volvulus first by endoscopy then one or two days later are subjected to sigmoid colon fixation by endoscopy using 2-shot anchor device
32958128|NCT05620446|No Intervention|surgical management of sigmoid volvulus|patients aresubjected for surgical colostomy ( hartman's procedure ) , then later on after 6 weeks , they are subjected for surgical sigmoid fixation or excision either by open or laparoscopic approach
32958129|NCT05620290|Experimental|Treatment Arm|Malignant Melanoma patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy
32958130|NCT05620212||RC Group|Recovery College partakers in any way (see description of intervention).
32958131|NCT05620212||Control Group|Participants with similar mental health profile as RC group, but do not participate in an RC. These participants are sampled from the Panel Psychisch Gezien (PPG), monitored by the Trimbos-institute.
32958132|NCT05620056||drug exposure|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
32958133|NCT05619978||3L+ Cohort|Patients who initiated third-line treatment (3L) therapy. Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
32958134|NCT05619978||T315I cohort|Patients with chronic myeloid leukemia with T315I mutation
32844004|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
32844005|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
32844006|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
33103922|NCT00552773|Placebo Comparator|Placebo|
33103923|NCT04608539|Experimental|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
32844007|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
32844008|NCT01794663|Experimental|OPN-305|
32844009|NCT01794663|Placebo Comparator|Matching placebo|
32844010|NCT05087706||Locally advanced patients with molecular-guided therapy|Locally advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
32844011|NCT05087706||Advanced patients with molecular-guided therapy|Advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
32844012|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
32844013|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
32844014|NCT03393936|Experimental|CCT301-59|The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
32844015|NCT03393936|Experimental|CCT301-38|The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
32844016|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
32844017|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
32844018|NCT05087316|Active Comparator|Standard treatment|
32844019|NCT05087316|Experimental|Oral Appliance|
32844020|NCT05087160||semester pre pandemia in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2019, pre pandemia
32844021|NCT05087160||semester pre pandemia in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2019, pre pandemia
32844022|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
32844023|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
32844024|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
32844025|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
32844026|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
32844027|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
32844028|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
32844029|NCT05087004|Experimental|Teen Council Pogram|Teens assigned to the intervention group received a 1-year long Teen Council Program.
32844030|NCT05087004|No Intervention|Control Group|Teens assigned to the control group did not receive any intervention.
32844031|NCT05086926|Experimental|Exercises and CSI|A corticosteroid injection in the lateral hip prior to performing an 8-week home exercise program
32844032|NCT03138174||Diabetes|One group consisting of diabetic subjects
32844033|NCT00697203|Experimental|Dalcetrapib 300mg|
32844034|NCT00697203|Experimental|Dalcetrapib 600mg|
32844035|NCT00697203|Experimental|Dalcetrapib 900mg|
32844036|NCT00697203|Placebo Comparator|Placebo|
32844037|NCT03325842||Cerebral palsy|ASKp will be submitted to children of 5 to 15 years with hemiplegia or diplegia due to Cerebral Palsy, with normal or slightly impaired cognitive level.
32844038|NCT03325842||Healthy individuals|ASKp will be submitted to children of 5 to 15 years with typical development
32844039|NCT05086848|Experimental|Treatment group:|Irinotecan liposome plus 5-fluorouracil, Leucovorin
32844040|NCT03295500||Experimental Group One|In this group ,the participants receive the dose fraction of 49Gy/7f (BED 83.3Gy) by cyberknife.
32844041|NCT03295500||Experimental Group Two|In this group ,the participants receive the dose fraction of 54Gy/6f(BED 102.6Gy) by cyberknife.
32844042|NCT03295500||Control Group|In this group ,the participants receive the dose fraction of 55Gy/5f(115.5Gy) by cyberknife.
32844043|NCT00830895|Experimental|RAD001|RAD001 10mg/day
32903094|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
32903095|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
32903096|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
33103924|NCT04608539|Active Comparator|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
32844044|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
32844045|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
32844046|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
32844047|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
32844048|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
32844049|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
32844050|NCT05086614|Experimental|Thymosin|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
32844051|NCT05086614|No Intervention|Observe|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
32844052|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
32844053|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
32844054|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
32844055|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
32844056|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
32844057|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
32844058|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
32844059|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
32844060|NCT05086536||early stage decompensation cohort|Patients occurred first decompensated events and initiating nucleoside analogs (NUCs) based treatment within 3 months were retrospectively included.
32844061|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
32844062|NCT02990325|Experimental|ABX464 50mg|ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days
32844063|NCT01793025|Experimental|ATAC Therapy|
32844064|NCT05086458|No Intervention|No intervention|the patients in this arm will not receive probiotics.
32844065|NCT05086458|Experimental|Dietary Supplement|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks.
32844066|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
32844067|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
32844068|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
32844069|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
32844070|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
32844071|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
32844072|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
32844073|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
32844074|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
32844075|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
32844076|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
32844077|NCT01115283|Experimental|Perceptual learning|Patients will be asked to practice a range of visual discrimination tasks for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
32844078|NCT01115283|Experimental|Occlusion therapy|The fellow sound will be covered with a standard eye patch for a period of time (1-2 hrs/day, 4-5 days/wk for ~1-3 months). The idea is to push the brain to use the weaker amblyopic eye.
32844079|NCT01115283|Experimental|Video game|Patients will be asked to play videogames for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
32844080|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
32844081|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
32844082|NCT03113994|Active Comparator|Rosuvastatin|
32844083|NCT03113994|Placebo Comparator|Placebo|
32844084|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
32844085|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
32844086|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
32844087|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
32844088|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
32844089|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
32844090|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
32844091|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
32844092|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
32844093|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
32844094|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
32844095|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
32844096|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
32844097|NCT05085912|Experimental|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
32844098|NCT05085912|Active Comparator|Group B|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation
32844099|NCT05085912|Active Comparator|Group C|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
32844100|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
32844101|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
32844102|NCT05085444|Experimental|Treatment of Scleroderma|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
32844103|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
32844104|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
32844105|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
32844106|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
32844107|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
32844108|NCT02964546||Blood sample|
32844109|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
32844110|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
32844111|NCT05084898|Active Comparator|Intervention|Far-UVC light as an additional method of disinfection
32844112|NCT05084898|Placebo Comparator|Placebo|"Inactive fluorescent light (no additional disinfection)"
32844113|NCT05084820|Experimental|Action observation treatment|Action observation treatment
33103925|NCT04603352|Experimental|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
33103926|NCT04603352|No Intervention|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
33103927|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
33103928|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
32844114|NCT05084820|Active Comparator|conventional treatment|conventional treatment
33103929|NCT04831164||Case|Patients with MRI confirmed rotator cuff tears
33103930|NCT04831164||Control|Patients without rotator cuff tears
32844115|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
32844116|NCT05082324|Experimental|adapted physical activity|
32844117|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
32844118|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
33103931|NCT04592120|Experimental|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
33103932|NCT04592120|No Intervention|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
33417213|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
32844119|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
32844120|NCT05079672|Active Comparator|Group Dexmedetomidine|The patient will receive Dexmedetomidine, at the rate of 0,3μg/ kg/h, in continuous intravenous infusion from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
32844121|NCT05079672|Placebo Comparator|Group 0,9% Saline|The patient will receive a 0,9% saline, in continuous intravenous infusion, from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
32844122|NCT03138018|Active Comparator|Standard instruction|
32844123|NCT03138018|Experimental|Reduced threat instruction|
32844124|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
32844125|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
32844126|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
32844127|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
32844128|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
32844129|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
32844130|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
32844131|NCT04766827|Experimental|albumin-bound paclitaxel combined with cisplatin (AP regimen)|Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
32844132|NCT04766827|Active Comparator|docetaxel combined with cisplatin (TP regimen)|docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
32844133|NCT02960568|Experimental|Primaquine|Poor and Intermediate Metabolizers will receive 30 mg oral primaquine (PQ) and have peripheral blood draws over a 24-hour period to measure PQ pharmacokinetics
32844134|NCT02960568|No Intervention|No primaquine|Extensive and Ultra Metabolizers will not be eligible for the pharmacokinetic portion of the study and participation will be complete after receiving genotype information
32844135|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
32844136|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
32844137|NCT02948790|Experimental|Neuristim|Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).
32844138|NCT02948790|Active Comparator|Digisonic SP EVO cochlear implant|Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).
32844139|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
32844140|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
32844141|NCT02864004|Experimental|APO group|An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours
32844142|NCT02864004|Active Comparator|Control group|Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.
32844143|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
32844144|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
32844145|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
32844146|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
32844147|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
32844148|NCT02721654|Experimental|Plasma-Lyte 148®|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
32844149|NCT02721654|Active Comparator|0.9% sodium chloride|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
32844150|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
32844151|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
32844153|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
32844154|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
32844155|NCT05068206|Experimental|AK105+Anlotinib+CapeOx|"Treatment period (6 cycles):~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Oxaliplatin for injection: intravenous infusion on Day 1; Capecitabine tablet:oral administration, twice daily (BID) .~Maintenance period:~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Capecitabine tablet:oral administration, twice daily (BID) . Every 3 weeks is as one cycle.Oxaliplatin is administered for 6 cycles, and AK105 can be administered continuously for 1 year but at most for 2 years. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
32844156|NCT05068206|Experimental|Anlotinib+CapeOx|"Treatment period (6 cycles) Anlotinib hydrochloride capsule: QD orally; Oxaliplatin for injection: D1 intravenous infusion on Day 1; Capecitabine tablet: BID oral administration.~Maintenance period:~Anlotinib hydrochloride capsule: QD orally; Capecitabine tablet: BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
32844157|NCT05068206|Active Comparator|Bevacizumab+CapeOx|"Treatment period (6 cycles):~Bevacizumab D1 intravenous infusion; Oxaliplatin D1 intravenous infusion; Capecitabine BID oral administration.~Maintenance period:~Bevacizumab D1 intravenous infusion; Capecitabine BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
32903097|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
32903098|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
32903099|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
33417214|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
33417215|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
32844158|NCT05063370|Active Comparator|Levosimendan group|Patients will be admitted to ICU preoperatively and Levosimendan infusion will be started after insertion of an arterial line 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
32844159|NCT05063370|Other|Standard group|Patients will not receive Levosimendan perioperatively and will be managed with standard care according to our institutional protocol
32844160|NCT02590380|Active Comparator|treatment group (MESA)|Patients randomized to the treatment group will receive surgery with the MESA Rail Deformity System.
32844161|NCT02590380|Active Comparator|control group (USS II)|Patients randomized to the control group will receive surgery with the DePuy Synthes USS II System.
32844162|NCT02553954|Experimental|Collection of healthy skin tissue|Collection of healthy skin tissue
32844163|NCT05377866||Study population|Patients undergoing percutaneus coronary intervention for chronic total occlusion. The procedures will all be done using mixed reality to enable remote proctoring. The study is a feasibility trial.
33417216|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
32844165|NCT05090124|Experimental|anti-TNF treatment|"Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. The actual Adalimumab product selected at site will be dictated by what is used in standard care.~The single-use, pre-filled syringe will be removed from storage at 2-8oC at least 30 minutes prior to administration to allow the contents to come to room temperature. The pre-filled syringe will be visually inspected for discolouration and particulates as per the product Summary of Product Characteristics.To facilitate maintenance of the blind, the pre-filled syringe (PFS) presentation will be used. The pen presentation will not be used."
32844166|NCT05090124|Placebo Comparator|Placebo|Sodium chloride 0.9% for injection will be used as a placebo to adalimumab. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. Prior to administration, the prepared placebo syringe will be visually inspected for discolouration and particulate matter prior to administration.
32844167|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
32844168|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
32844169|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
32844170|NCT05377710|Experimental|Glycobone|Patients will be implanted at T0 with Glycobone
32844171|NCT05020392|Experimental|Effective of CAR-T-CD19 cells with concurrent BTK inhibitor|After enrollment, all subjects will receive oral BTK inhibitor immediately and BTK inhibitor treatment will continue for up to 90 days (or longer for who are benefiting from BTK inhibitor) after CAR-T-CD19 infusion. Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive lymphodepletion with low dose fludarabine and cyclophosphamide on day -5 to -3, followed by one infusion of CAR-T-CD19 cells (2*10^6 to 4*10^6 cells/kg) on day 0.
32844172|NCT05020392|Active Comparator|Effective of CAR-T-CD19 cells monotherapy|Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive lymphodepletion with low dose fludarabine and cyclophosphamide on day -5 to -3, followed by one infusion of CAR-T-CD19 cells (2*10^6 to 4*10^6 cells/kg) on day 0.
32844173|NCT04988802|Active Comparator|Patients taking food supplement with levothyroxine|Patients will start taking food supplement with levothyroxine in the evening, and the other tablet of the food supplement in the evening for 8 weeks.
32844174|NCT04988802|Placebo Comparator|Patients taking placebo with levothyroxine|Patients will start taking placebo with levothyroxine in the evening, and the other tablet of the placebo in the evening for 8 weeks.
32844175|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
32844176|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
32844177|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
32844178|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
32844179|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
32844180|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
32844181|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
33417217|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
33417218|NCT05683587|Experimental|experimental group|intervention
32844182|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
32844183|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
32844184|NCT04980534|Experimental|Viusid Plus Asbrip Adjuvant|25 Patients who received standard therapy Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days AND Viusid (sachets with powder for dilution, oral administration) 1 sachet bid and Asbrip (liquid form, oral administration) 10 ml bid for the total duration of hospitalization. Time Frame: 21 days.
32844185|NCT04980534|Experimental|Viusid Plus Asbrip Monotherapy|25 Patients who did not receive standard antiviral therapy with the inclusion of food supplements Viusid (4.5 gr every 12 hours, oral administration) and Asbrip (10 mL every 12 hours, oral administration). Time Frame: 21 days.
32844186|NCT04980534|Active Comparator|Control|30 patients who received standard therapy (Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days), without the inclusion of food supplements Viusid and Asbrip.
32844187|NCT04962204|Active Comparator|Virtual visitation group|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
32844188|NCT04962204|No Intervention|Control group|Phone interview between physicians-caregivers once a day
32844189|NCT05089968||Patient from the first wave of COVID-19|57 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 1st wave from January 24, 2020 to July 10, 2020
32844190|NCT05089968||Patient from the Second wave of COVID-19|211 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 2nd wave from July 11, 2020 to January 8, 2021
32844191|NCT04951050|Experimental|Drug eluting stent|
32844192|NCT05089890|Other|Sorbact® Compress|Patients already assigned to start treatment with Sorbact® Compress as it is judged by the investigator to be the most suitable for their wounds
32844193|NCT05089890|Other|Sorbact® Gel Dressing|Patients already assigned to start treatment with Sorbact® Gel Dressing as it is judged by the investigator to be the most suitable for their wounds
32844194|NCT05089890|Other|Sorbact® Ribbon Gauze|Patients already assigned to start treatment with Sorbact® Ribbon Gauze as it is judged by the investigator to be the most suitable for their wounds
32844195|NCT04931238|Experimental|JS016 treatment group|Standard therapy + JS016 injection Standard therapy including vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
32844196|NCT04931238|No Intervention|Control group|Standard therapy Standard therapy includes vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
32844197|NCT04543500|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
32844198|NCT04543500|Active Comparator|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
32844199|NCT05089578||Individuals with Covid-19|Interviews were conducted with individuals who had Covid-19, and their experiences with the integrative methods they used were determined.
32844200|NCT04927182|Experimental|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|
32844201|NCT04927182|Experimental|Moderate Exercise Training (Age Group 2; 31 to 45 years)|
32844202|NCT04927182|Experimental|Moderate Exercise Training (Age Group 3; Above 45 years)|
32844203|NCT05089500|Experimental|Endoscopic injection sclerotherapy|
32844204|NCT05089500|Experimental|Endoscopic Band Ligation|
32844205|NCT05089422|Experimental|Children with exotropia|squint surgery
32844206|NCT04476888|Experimental|Treatment arm/CP recipient|"Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.~These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
32844207|NCT04476888|Other|Control arm|"Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.~These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
32844208|NCT05089344|Experimental|mild stimulation protocol + growth hormone adjuvant|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~. For those in the GH group, 8 IU recombinant human GH will be administered starting from Day 14 of the previous cycle Till administration of HCG for ovulation triggering"
32844209|NCT05089344|Active Comparator|Mild stimuation protocol|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~."
32844210|NCT01420627|Experimental|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
32844211|NCT04413630|Experimental|Study group|family workshop
32844212|NCT05089266|Experimental|CAR T cells|
32844213|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
32844214|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
32844215|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
32844216|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
32844217|NCT05088954|Active Comparator|Patients diagnosed with metabolic syndrome|
32844218|NCT05088954|Active Comparator|Patients without a diagnosis with metabolic syndrome|
32844219|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
33417219|NCT01349777|Experimental|Pregrel®|clopidogrel
33417220|NCT01349777|Active Comparator|Plavix®|clopidogrel
33417221|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
33417222|NCT04240925|Experimental|Standard NIMV protocol with sigh breaths|
32844220|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
32844221|NCT04787094|Experimental|Yoga Group|The sessions will begin with breathing exercises in standing, sitting, supine and prone positions, and these exercises will be applied for about 10 minutes. After the breathing exercises, the sudden relaxation technique, which will take 2-3 minutes, firstly contracting the whole body from the feet to the head and then completely relaxing it.
32844222|NCT04787094|Experimental|Spinal Stabilization Exercise Group|"Spinal stabilization exercises will be applied to the individuals in this group for 8 weeks / 2 days a week, approximately 50-60 minutes a day under the supervision of a physiotherapist.~Spinal stabilization exercises will be progressed in 3 phases by gradually increasing the difficulty."
32844223|NCT04771962|Experimental|DESFLURANE|desflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia
32844224|NCT04771962|Active Comparator|SEVOFLURANE|the controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia.
32844225|NCT04726098|Active Comparator|Low dose group|Dexamethasone 6mg/day for 10 days
32844226|NCT04726098|Active Comparator|High dose group|Dexamethasone 20mg/day for 5 days + Dexamethasone 10mg/day for 5 days (Total 10 days)
32844227|NCT05088798|Experimental|18F-Fluoro Dopa Imaging|single arm
32844228|NCT04712838|Experimental|group A|
32844229|NCT04712838|Experimental|group B|
32844230|NCT04712838|Experimental|group C|
32844231|NCT04712838|Experimental|group D|
32844232|NCT04712838|Experimental|group E|
32844233|NCT04712838|Experimental|group F|
32844234|NCT01385371|Experimental|SCH 697243|
32844235|NCT01385371|Placebo Comparator|Placebo|
32844236|NCT04697160||Patients who received systemic therapies for R/R DLBCL|
32844237|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
32844238|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
32844239|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
32844240|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
32844241|NCT04041115|Active Comparator|Control|personalized nutritional therapy + aerobic exercise
32844242|NCT04041115|Active Comparator|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
32844243|NCT05088720|Experimental|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
32844244|NCT05088720|Active Comparator|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
32844245|NCT05365945|Experimental|The study group|
32844246|NCT05365945|Active Comparator|The control group|
32844247|NCT05377632|Active Comparator|Hybrid-Group|Laparoscopic and Robotic-assisted combined (partial) nephrectomy via the hybrid (trans-peritoneal and retroperitoneal) access route
32844248|NCT05377632|Active Comparator|Retroperitoneal-Group|Robotic-assisted laparoscopic (partial) nephrectomy via the retroperitoneal access route
32844249|NCT05088642|Experimental|Mild hepatic impairment (Child-Pugh Class A)|
32844250|NCT05088642|Experimental|Moderate hepatic impairment (Child-Pugh Class B)|
32844251|NCT05088642|Experimental|Normal hepatic function|
32844252|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
32844253|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
32844254|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
32844255|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
32844256|NCT05084118|Active Comparator|Landiolol group|Randomized patients receiving low dose landiolol after cardiac surgery
32844257|NCT05084118|Placebo Comparator|Placebo group|Randomized patients receiving 0,9% saline solution after cardiac surgery
32844258|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
32844259|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
32844260|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
32844261|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
32844262|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
32844263|NCT05075070|Experimental|Experimental Group|A total 400 HIV-infected subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days.
32844264|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
32958135|NCT05619900||Mucopolysaccharidosis I|Prenatally or postnatally diagnosed individuals
33417223|NCT04240925|Active Comparator|Standard NIMV protocol without sigh breaths|
33417224|NCT04700007|Experimental|Study group|
33417225|NCT01349855|Experimental|Cohort 1|Dose Level 1
33417226|NCT01349855|Experimental|Cohort 2|Dose Level 2
32844265|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
32844266|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.~This is the original BPS exercise (already validated in other studies)."
32844267|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
32844268|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
32844269|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
32844270|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
32844271|NCT05365321|Experimental|WP1122|Experimental drug with Concentration 100mg/mL - administered q12h PO for 10 days
32844272|NCT05365321|Placebo Comparator|placebo|Placebo Administered q12h PO for 10 days
32844273|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
32844274|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
32844275|NCT04507308|Experimental|Transdiagnostic Sleep and Circadian Intervention|All participants will undergo baseline assessment and then complete a brief, single-session sleep-focused intervention based on psychoeduation and handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth).
32844276|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
32844277|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
32844278|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
32844279|NCT04505670|Experimental|Donepezil and Topical Zinc Oxide|donepezil 5mg daily and topical zinc oxide 20% three times daily
32844280|NCT04505670|Placebo Comparator|Placebo and Topical Zinc Oxide|Placebo daily and topical zinc oxide 20% three times daily
32844281|NCT04429464|Experimental|Non-randomized|All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.
32844282|NCT01382251||Patient|Patients undergoing ambulatory surgery
32844283|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
32844284|NCT04404192|Experimental|PH94B|Intranasal spray 3.2 micrograms four times a day for 28 days
32844285|NCT04404192|Experimental|Placebo|Intranasal spray four times a day for 28 days
32844286|NCT05033184|Experimental|Brief Action Planning Exercise|
32844287|NCT05033184|Active Comparator|Goal Setting Exercise|
32844288|NCT04335084|Experimental|Medical Workers|Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
32844289|NCT04335084|Placebo Comparator|Placebo|Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection
32844290|NCT02992743|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
33417227|NCT04655079|Experimental|Real tDCS group|Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
32844292|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
32844293|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
32844294|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
32844295|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
32844296|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
32844297|NCT02995785|Other|Experimental:simulation-based training|Experimental
32844298|NCT02995785|Other|Active comparatorr: traditional training|Traditional
32844299|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
32844300|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
32844301|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
32844302|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
32844303|NCT02992041|Placebo Comparator|Placebo|
32844304|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
32844305|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
32844306|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
32844307|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
32844308|NCT02991027|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
32844309|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
32844310|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
32844311|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
32844312|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
32844313|NCT02849652|Other|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
32844314|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
32844315|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
32844316|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32844317|NCT04832178|Placebo Comparator|Placebo|
32844318|NCT04832178|Experimental|SUMOR|
32844319|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
32844320|NCT02990949|No Intervention|Control group|
32844321|NCT04234854||Carotid Artery Stenting|Consecutive patients older than 18 yrs with symptomatic carotid artery stenosis qualified for endovascular revascularization.
32844322|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
32844323|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
32844324|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
32844325|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
32844326|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
32844327|NCT04231032|Active Comparator|Active ventricular pacing|Asynchronous dual chamber pacing (DOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
32844328|NCT04231032|Placebo Comparator|Back-up ventricular pacing|Asynchronous atrial pacing with intrinsic ventricular activation (AOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
32844329|NCT01270035|Experimental|ADA 80 mg eow + MTX|
32844330|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
32844331|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
32844332|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
32844333|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
32844334|NCT04792788|Active Comparator|NAVA/PSV/NAVA|6 patients
32844335|NCT04792788|Active Comparator|PSV/NAVA/PSV|6 patients
32844336|NCT05738148|Active Comparator|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed[2,3]. Chest compressions and epinephrine will be continued until ROSC."
32844337|NCT05738148|Experimental|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC [2,3] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
32844338|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
32844339|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
32844340|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
32844341|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
32844342|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
32844343|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
32844344|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844345|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
32844346|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844347|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
32844348|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844349|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
32844350|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844351|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
32844352|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844353|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
32844354|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
32844355|NCT04061226||Central obesity group|Normal weight central obesity patients (by BMI and WHR).
32844356|NCT04061226||Without central obesity group|Normal weight patients without central obesity (by BMI and WHR).
32844357|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
32844358|NCT04541706|Experimental|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
32844359|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
32844360|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
32844361|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
32844362|NCT05738070||Patients with acute ischemic stroke|All the patients with stroke admitted to the hospital from July 2021 to July 2022 were included in this study. Patients with the following criteria were included in the study: (1) anterior circulation stroke established by diffusion-weighted imaging (DWI), (2) MRI performed within 72 hours of stroke onset, (3) Patient with occlusion of the vessel on MRA (Magnetic Resonance Angiography). (4) MRI performed before or during intravenous thrombolysis (IVT) or mechanical thrombectomy (MT). Infarcts with hemor¬rhagic transformation cases were not included in the study due to suboptimal SVS quantification
32844363|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
32844364|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
32844365|NCT05737914|Active Comparator|Endoscopic thoracic T3 sympathectomy|
32844366|NCT05737914|Active Comparator|ThoracicT3 radiofrequency ablation|
32844367|NCT00714753|Experimental|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
32844368|NCT04449042||COVID19 positive|a recently performed test which is positive for coronavirus infection
32844369|NCT04449042||COVID19 negative|a recently performed test which is negative for coronavirus infection
32844370|NCT04449042||COVID19 presumed positive|patients who do not have testing or who have negative testing but whose symptoms, history, physical exam, laboratory and imaging findings are consistent with infection with COVID19 and are treated as positive
32844371|NCT04449042||COVID19 presumed negative|patients who do not have testing, but based on symptoms, history, physical exam, laboratory and imaging findings are deemed to be low risk for COVID19 infection and are treated as negative
32844372|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
32844373|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
32844374|NCT03222648|Experimental|Structured Responsive Exercise Training|8 week twice weekly supervised structured responsive static-cycle based exercise training. Training protocol used the same as Loughney et al. 2016
32844375|NCT03222648|Active Comparator|Standard of Care Arm|Completion of outcome measures only
32844376|NCT00707343|Experimental|All patients|All participants enrolled.
32844377|NCT03852810||Receiving surgical intervention via XEN Gel Stent (XEN)|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
32844378|NCT03852810||Receiving surgical intervention via trabeculectomy|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
32844379|NCT04409652|Placebo Comparator|Control group|The endotracheal extubation is performed in head on bed without pillow.
32844380|NCT04409652|Active Comparator|Head elevation group|The endotracheal extubation is performed in head elevation on pillow (slight flextion of neck on chest) .
32844381|NCT04373616|Experimental|ACI-24|
32844382|NCT04373616|Placebo Comparator|Placebo|
32844383|NCT04341090|Experimental|Arm 1|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal
32844384|NCT04341090|Experimental|Arm 2|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal
32844385|NCT04341090|Experimental|Arm 3|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted
32844386|NCT04341090|Experimental|Arm 4|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal
32844387|NCT04341090|Experimental|Arm 5|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal
32844388|NCT04341090|Experimental|Arm 6|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted
32844389|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
32844390|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
32844391|NCT04273854|Experimental|Intervention|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice.
32844392|NCT04273854|No Intervention|Control|The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures.
32844393|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
32844394|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
32844395|NCT05737602|Experimental|3RP-VHL|"An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.~Complete pre- and post-intervention surveys."
32844396|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
32844397|NCT04097964|Experimental|FaCES Intervention|Primary care providers will deliver anticipatory guidance for adolescents reporting no drug, alcohol or marijuana use in past year, an abbreviated brief intervention for adolescents who report using these substances one or twice in the past year, and a full brief intervention for adolescents who report using these substances monthly or weekly in the past year.
32844398|NCT04097964|Active Comparator|Treatment as usual|Usual care will be delivered by primary care providers during the clinic visit
32844399|NCT04092504|No Intervention|Control group|Standard care at the unit
32844400|NCT04092504|Experimental|Gero-Erat|New care pathway that is built on the concept of ERAS and CGA
32844401|NCT04089150|Active Comparator|Arm A|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~Option 2: gemcitabine + nab-paclitaxel (3 cycles)~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
32844402|NCT04089150|Experimental|Arm B|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~Option 2: gemcitabine + nab-paclitaxel (3 cycles)~Stereotactic Radiotherapy (SBRT) to commence within 3 weeks of completing initial chemotherapy: 40 Gray (Gy) in 5 fractions over 2 weeks~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
32958136|NCT05619900||Mucopolysaccharidosis II|Prenatally or postnatally diagnosed individuals
32958137|NCT05619900||Mucopolysaccharidosis IV A|Prenatally or postnatally diagnosed individuals
32958138|NCT05619900||Mucopolysaccharidosis VI|Prenatally or postnatally diagnosed individuals
32958139|NCT05619900||Mucopolysaccharidosis VII|Prenatally or postnatally diagnosed individuals
32958140|NCT05619900||Infantile-Onset Pompe Disease|Prenatally or postnatally diagnosed individuals
32958141|NCT05619900||Neuronopathic Gaucher|Prenatally or postnatally diagnosed individuals
32958142|NCT05619900||Wolman Disease|Prenatally or postnatally diagnosed individuals
32958143|NCT05619822|Other|TAU + waiting list|Treatment as usual
32958144|NCT05619822|Experimental|TAU + A comprehensive third-generation intervention|he protocol will bedeveloped following the three stages of recovery from trauma (Herman, 2015): first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced. The therapy will be administered in 11 90-minute individual sessions per week, combining strategically ACT, Mindfulness, EMDR as well as Positive Psychology interventions.
32958145|NCT05619666|Other|Severity of COVID-19 infection|Based on the severity of Covid-19 infection patients were divided into 2 groups: First group (MMG) mild to moderate group and second group (SSG) stable severe group.
32958146|NCT05616702|Experimental|Pressure Biofeedback Therapy + Progressive Muscle Relaxation Technique + Thermotherapy.|"This study ARM will receive following therapies~Pressure Biofeedback Therapy~Progressive Muscles Relaxation Technique~Thermotherapy"
32958147|NCT05616702|Active Comparator|Progressive Muscle Relaxation Technique + Thermotherapy|"This study ARM will receive following therapies~Progressive Muscles Relaxation Technique~Thermotherapy"
32958148|NCT05614752||Treatment group|treated with Fexuclue Tablet 40mg
32958149|NCT05605470|Experimental|Arm 1 (1 dose of ChulaCov19 BNA159 vaccine)|Participants will be randomized to receive ChulaCov19 BNA159 vaccine (50 mcg) given by IM (n=100)
32958150|NCT05605470|Active Comparator|Arm 2 (one dose of active comparator vaccine)|Participants will be randomized to receive Comirnaty® (Pfizer/BNT) vaccine (30 mcg) given by IM (n=50)
32958151|NCT05578638|Experimental|aloe Vera group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
32958152|NCT05578638|Experimental|rosemary group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
32958153|NCT05578638|Experimental|aloe Vera rosemary compound|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
32958154|NCT05578638|No Intervention|control group|
32958155|NCT05508594|Experimental|CT001|
32958156|NCT05508594|Placebo Comparator|Placebo|
32958157|NCT05508594|Active Comparator|Sufentanil 27 mcg|
32958158|NCT05508594|Active Comparator|Ketamine 27 mg|
32958159|NCT05508594|Active Comparator|Sufentanil 13 mcg|
32958160|NCT05508594|Active Comparator|Ketamine 13 mg|
32958161|NCT05508594|Active Comparator|Sufentanil 40 mcg|
32958162|NCT05508594|Active Comparator|Ketamine 40 mg|
33406039|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
33406040|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
33406041|NCT05208996|Experimental|siCoV/KK46|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use
33406042|NCT02675946|Experimental|Arm 1: CGX1321 Single Agent dose escalation and dose expansion|"Arm 1: Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle."
33406043|NCT02675946|Experimental|Arm 2: CGX1321 in combination with pembrolizumab dose escalation, dose expansion and Roll-over,|"Arm 2: Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).~Arm 2: Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
33406044|NCT02675946|Experimental|Arm 3: CGX1321 in combination with encorafenib + cetuximab, dose escalation and dose expansion|Arm 3: Phase 1b: Ascending doses of CGX1321, once daily, orally for 3 weeks (21 days) followed by a one-week (7 day) washout period in combination with enocrafenib administered orally once daily and cetuximab administered IV once weekly
33417228|NCT04655079|Sham Comparator|Sham group|Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks
33417229|NCT01318655|Experimental|NKTR-118|
33417230|NCT01318655|Placebo Comparator|Placebo|
33417231|NCT04654533|Experimental|COSC|"Eight weekly manualized sessions of Circle of Security Classroom (COSC), delivered in groups, two hours per session, 5-10 childcare providers per group.~COSC is facilitated by a psychologist who is a registered COSP facilitator and who has completed the an additional COSC online training."
32958163|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 13 mg|
32958164|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 27 mg|
32958165|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 40 mg|
32958166|NCT05508594|Active Comparator|Sufentanil 27 mcg/Ketamine 13 mg|
32844403|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
32844404|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
32844405|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
32844406|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
32844407|NCT01678560|Active Comparator|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
32844408|NCT01678560|Active Comparator|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
32844409|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
32844410|NCT03980574|Experimental|Crossover Group|The crossover group will be further randomly assigned (1:1) with 20 patients in each group. The two crossover arms of the study will follow the patients for 8 weeks. At the end of week 8, all crossover patients will have a 1 week wash out period. Thereafter, patients will be crossed-over to the opposing arm of the study for an additional 1+8 weeks (R Drink 8 oz 3-5x/day versus a placebo drink 8 oz 3-5x/day).
32844411|NCT03980574|Experimental|Non-crossover Group|The non-crossover group of the study will follow 20 patients for the entire 17 weeks and participants in this arm will not be crossed over, will not have a washout period, and will consume R Drink for the total duration of the study. If patients in this arm wish to continue on the R Drink, for 6 additional months they may do so. At the end of the optional 6 months these patients will have a repeat research transthoracic echocardiogram. Data collection will occur at baseline, week 8, and week 17. An additional 6 month data collection time point will occur for patients in the third arm opting to continue R Drink.
32844412|NCT05365165||sevoflurane|Standard anesthesia management will be applied in the induction and maintenance of anesthesia. In the induction of anesthesia 1mg/kg lidocaine , 1.5-2mg/kg propofol , 1 mcg /kg fentanyl citrate, 0.6 mg/kg rocuronium bromide will be administered. Sevoflurane for maintenance of anesthesia and propofol and fentanyl if needed bolus will be applied. BIS monitoring will be performed to control the depth of anesthesia.
32844413|NCT03925350|Experimental|Niraparib|Patients receive niraparib PO daily
32844414|NCT03617562|Experimental|Superior Capsular Reconstruction|Patients will be treated with the new technique of superior capsular reconstruction with dermal allograft.
32844415|NCT03617562|Active Comparator|Partial Repair|Patients will have a partial repair with residual defect as an established standard procedure.
32844416|NCT04890912|Active Comparator|Conventional Fractionation Pelvic Radiation|Patients randomized to the conventional fractionation arm will be treated with intensity-modulated or volumetric arc therapy technique as per standard protocol.
32844417|NCT04890912|Experimental|Stereotactic Hypofractionated Radiation|Patients randomized to hypofractionation will be treated the stereotactic hypofractionated technique.
32844418|NCT04014205|Experimental|Part 1 Dose Escalation|Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL
32844419|NCT04014205|Experimental|Part 2 Dose Expansion|"Arm 1: Patients with r/r MCL~Arm 2: Patients with other types of B-cell malignancies, including:~CLL/SLL with/without prior treatment~r/r FL~r/r MZL"
32844420|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
32844421|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
32844422|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
32844423|NCT04875780|Experimental|Digital diabetes prevention app intervention|Participants will receive web-based diabetes prevention curriculum, virtual social group support and digital tracking via the smartphone app.
32844424|NCT04875780|Active Comparator|Digital weight loss tracking app intervention|Participants will receive the same intervention as the digital diabetes prevention curriculum app group except the web-based diabetes prevention curriculum.
32844425|NCT04875780|Other|Wait-list control (usual care)|Participants will receive usual care in the form of an annual review and blood test, together with general lifestyle advice.
32844426|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
32844427|NCT04874766|Experimental|Surgical face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a surgical mask
32844428|NCT04874766|Sham Comparator|Sham face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a sham mask
32844429|NCT04814628|Experimental|healthy volunteer subject|"A single healthy volunteer subject will participate in the study as a model of a pregnant woman in the third trimester of pregnancy, with a functional respiratory capacity reduced by 20% thanks to elastic restraints performed under the control of functional respiratory explorations.~8 obstetric anesthesiologists will participate in the 4 scenarios;"
32844430|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
32903100|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
32903101|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
32903102|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
32958167|NCT05508594|Active Comparator|Sufentanil 27 mcg/Ketamine 40 mg|
32958168|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 13 mg|
32958169|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 27 mg|
32958170|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 40 mg|
32958171|NCT05462262|Experimental|intensive lipid-lowering group|Goal for LDL-C <1.8 mmol/L or ≥50% reduction from baseline.
32958172|NCT05462262|Active Comparator|moderate-intensity lipid-lowering group|Goal for LDL-C <2.6 mmol/L or 30%-50% reduction from baseline.
32958173|NCT05443074|Active Comparator|Face to face intervention group|This group will be composed of participants who will receive face to face physiotherapy instruction session.
32958174|NCT05443074|Experimental|Remote intervention group|This group will be composed of participants who will receive real time remote physiotherapy instruction session.
32958175|NCT05443074|Active Comparator|Control group|This group will be composed of participants who will not receive any type of physiotherapy instruction session during the period of the study.
32958176|NCT05428020|Experimental|Indwelling foley catheter|Short-term indwelling foley catheter
32958177|NCT05428020|Placebo Comparator|No Foley catheter|No foley catheter
32958178|NCT05417100|Experimental|Methadone bolus|Patients will be administered methadone 0.2 mg/kg IV.
32958179|NCT05417100|Placebo Comparator|Saline placebo|Patients will be administered 0.2 mg/kg IV of saline placebo.
32958180|NCT05391438|Other|Meal-timing|All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period.
32958181|NCT05345106||Premenopausal women with obesity|
32958182|NCT05345106||Postmenopausal women with obesity|
32958183|NCT05345106||Men with obesity|
32958184|NCT05345106||Premenopausal women without obesity|
32958185|NCT05345106||Postmenopausal women without obesity|
32958186|NCT05345106||Men without obesity|
32958187|NCT05285826|Experimental|V503|Participants will receive a single 0.5 mL intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
32958188|NCT05285826|Placebo Comparator|Placebo|Participants will receive a single 0.5 mL IM injection of placebo at Day 1, Month 2, and Month 6.
32958189|NCT05281536|Experimental|Postural Changes from 45° to 10° in supine decubitus|Postural changes from 45° to 10° in supine decubitus Three times of 60 minutes each step before (45°, baseline) - during (10°, intervention) - after (45°, control)
32958190|NCT05278884|Experimental|ACLS and then VAST teaching intervention|For each hospital, the intervention will be to pair a 2-day technical resuscitation skills training adapted from the ACLS/AHA and a 3-day VAST course for a multidisciplinary team of 20 participants (i.e., nurses, doctors, non-physician anesthesia providers). Participants' resuscitation skills will be tested at 4 time points: immediately before the ACLS course, immediately after the ACLS course, immediately after the VAST Course, and at 4 months post training.
32958191|NCT05136690|Experimental|Panel A: Healthy Control Participants|In Part 1, HC participants receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), HC participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
32958192|NCT05136690|Experimental|Panel B: Participants with Mild-to-Moderate SZ|In Part 1, participants with mild-to-moderate SZ receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), SZ participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
32958193|NCT05135754|Other|Test product - new supporting ostomy product and support service|The arm includes the newly developed ostomy support product togethter with a support service
32958194|NCT05106426|Experimental|HC2 intervention Group|Participants in this group will receive the Healthy Caregivers-Healthy Children (HC2) intervention for 24 months
32958195|NCT05106426|Active Comparator|Jump Start Control Group|Participants in this group will receive the Jump Start intervention for 24 months
32958196|NCT05106426|No Intervention|Parents/Caregivers of Participants receiving HC2 intervention|Parents/caregivers of participants receiving the HC2 program will not be receiving any intervention.
32958197|NCT05106426|No Intervention|No Intervention: Parents/Caregivers of participants receiving Jump Start Intervention|Parents/caregivers of participants receiving the Jump Start program will not be receiving any intervention.
32958198|NCT05064462||All the patients included in the study|50 patients, at least 18 years old, first heart transplant
32958199|NCT05035680|Active Comparator|Arm i - Seasonal influenza vaccine|Single 0.5 mL intramuscular (IM) injection of an unadjuvanted seasonal influenza vaccine
32958200|NCT05035680|Experimental|Arm ii - SWE and unadjuvanted seasonal influenza vaccine|Single 0.8 mL IM injection of SWE mixed with unadjuvanted seasonal influenza vaccine
32958201|NCT05035680|Active Comparator|Arm iii - MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
32958202|NCT04985058||Patients with breast cancer randomised in arm A of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm A of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician.
32958203|NCT04985058||Patients with breast cancer randomised in arm B of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm B of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician; additionally they will receive personalised support (as a few word text) for each side-effect reported.
33033052|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
33033053|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
33033054|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
32844431|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
32844432|NCT04716504||Minimally invasive surgery for a benign or malignant pulmonary lesion.|"The patients will be divided in three categories depending on the Body Mass Index:~Category 1: 18,5 kg/m2 < BMI < 24,9 kg/m2 -Category 2: 25 kg/m2 < BMI < 29,9 kg/m2 /~Category 3: 30,0 kg/m2 < BMI < 34,9 kg/m2"
32844433|NCT04683510|No Intervention|Control Group|This group will receive no intervention before receiving the AMPLIFI Recruitment Call
32844434|NCT04683510|Other|Navigation|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a phone call from a Research Specialist who will discuss the importance of research participation for cancer survivors to increase research awareness and aid in recruitment. The information will focus on the importance of research and will be delivered from the perspective of either a researcher or a cancer survivor.
32844435|NCT04683510|Other|Brochure|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a brochure which will focus on the importance of research participation for cancer survivors in order to increase research awareness and aid in recruitment.
32844436|NCT04557696|No Intervention|Control Group|Standard oncology curriculum for medical trainees in oncology programs.
32844437|NCT04557696|Experimental|Reflective Group|Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs.
32844438|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
32844439|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
32844440|NCT04550754||Patients hospitalized for tramadol withdrawal|Patients hospitalized for tramadol withdrawal in Montpellier University Hospital and Nîmes University Hospital from 01/01/2015 to 31/12/2019
32844441|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
32844442|NCT02999919|Active Comparator|BMI < 30|BMI <30
32844443|NCT05737524|Experimental|Telerehabilitation (VAST 2)|
32844444|NCT02994615||hypertrophic cardiomyopathy|
32844445|NCT02994615||Control|
32844446|NCT04526652|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine 1mcg/kg
32844447|NCT04526652|Placebo Comparator|Placebo|Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)
32844448|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
32844449|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
32844450|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
32844451|NCT04505826|Experimental|OP-1250 Dose Escalation|This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer and to determine the RP2D
32844452|NCT04505826|Experimental|OP-1250 Expansion|This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 monotherapy at the RP2D and to estimate preliminary data of anti-tumor efficacy
32844453|NCT04500210|Placebo Comparator|Placebo|one capsule daily
32844454|NCT04500210|Active Comparator|Turmeric extract|one capsule daily
32844455|NCT04493190|Experimental|Scapular control training group|Participants in these group will be taught how to correctly movement arm overhead. And they will undergo series of movement tasks with mirror and also receive scapular-focused exercises. The difficulty of the movements protocol will increase weekly.
32844456|NCT04493190|Experimental|General exercise group|Participants in this group will receive a general strengthening exercise, focusing on the shoulder muscles. And the load will progressively increase weekly.
32844457|NCT04493190|No Intervention|Healthy subject group|No intervention.
32844458|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
32844459|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
32844460|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
32844461|NCT04039633|Experimental|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
32844462|NCT04039633|Sham Comparator|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
32844463|NCT00159432|Experimental|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
32844464|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:~Being 85 years older and over (Yes/No)~Male (Yes/No)~Home services (Yes/No)~Taking 5 different medication daily (Yes/No)~Use of walking aid (Yes/No)~Disoriented (Yes/No)"
32844465|NCT05737368|Experimental|Patients will receive the treatment of fractionated radiotherapy and Cadonilimab|fractionated radiotherapy (500cGy *5F, 600cGy*5F, 350cGy*10F, according to the tumor volume); within 14 days after receiving radiotherapy, Cardunizumab (10mg/kg, Q3W, d1)
32844466|NCT02969850|Experimental|Vitamin D Supplementation|Participant will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
32844467|NCT02969850|Placebo Comparator|Placebo|Participant will receive a placebo. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
32844468|NCT05737212|Experimental|Group 1|"Radiation dose: 9 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 9 Gy-Eq"
32844469|NCT05737212|Experimental|Group 2|"Radiation dose: 11 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 11 Gy-Eq"
32844470|NCT05737212|Experimental|Group 3|"Radiation dose: 13 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 13Gy-Eq"
32844471|NCT02339766|Sham Comparator|Group 1|Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
32844472|NCT02339766|Active Comparator|Group 2|Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
32844473|NCT02339766|Active Comparator|Group 3|Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
32844474|NCT05092464|Experimental|Single arm open label study|12 week-treatment of 5% natural lactic acid-enriched cream (BID)
32844475|NCT04287660|Experimental|BiRd combined with BCMA CAR T-cells infusion|
32844476|NCT04280016|Experimental|Exercise Added to Off-loading|Participants in this arm will participate in exercise at the healthcare facility one time a week (away from where wound care is provided) and be instructed in a home exercise program that they will be encouraged to perform at least three days per week with no more than two days between sessions. Wound care will continue at the facility as is standard, utilizing off-loading.
32844477|NCT04069104||ABCD training with standard feedback|Asymmetry, Border, Color, Diameter (ABCD) training message intervention with standard dermatological feedback
32844478|NCT04069104||ABCD training with motivational feedback|ABCD training message intervention with dermatological feedback and a motivational message
32844479|NCT04069104||ABCD training with no feedback|ABCD message intervention with no feedback
32844480|NCT04069104||UDS method training with standard feedback|Ugly Duckling Sign (UDS) method message intervention with dermatological feedback.
32844481|NCT04069104||UDS method training with motivational feedback|UDS message intervention with dermatological feedback and a motivational message.
32844482|NCT04069104||UDS training with no feedback|UDS message intervention with no feedback.
32844483|NCT04069104||ABCD-F training with standard feedback|ABCD-F intervention with dermatological feedback.
32844484|NCT04069104||ABCD-F training with motivational feedback|ABCD-F intervention with dermatological feedback and a motivational message.
32844485|NCT04069104||ABCD-F training with no feedback|ABCD-F intervention with no feedback.
32844486|NCT04069104||No message intervention with standard feedback|No message intervention, but with dermatological feedback.
32844487|NCT04069104||No message intervention with motivational feedback|No message intervention, but with dermatological feedback and a motivational message.
32844488|NCT04069104||No message intervention with no feedback|No message intervention and no feedback. True control.
32844489|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
32844490|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
32844491|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
32844492|NCT05092308||Parents and their children with Behavioral insomnia|Parents and their children aged 6-36 months with sleep problems will be invited to participate into the study from Sleep Outpatient Clinic
32844493|NCT05092308||Parents and their children without sleep problem|Parents and their children aged 6-36 months without sleep problems will be invited to participate into the study followed up in Well Child Clinic
32844494|NCT05737056||Children diagnosed with rheumatoid purpura at the pediatric emergency department|Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.
32844495|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
32844496|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
32844497|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
32844498|NCT04540224||Control|Healthy volunteers
32844499|NCT04011163|Experimental|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
32844500|NCT05091996|Experimental|Post-isometric muscle relaxation group|The post-isometric relaxation techniques were administered to the mandibular adductors and muscles responsible for lateral movements of the mandible.
32844501|NCT05091996|Experimental|Myofascial release group|The myofascial release procedure was performed successively in the area of the anterior parts of the temporal muscles, the superficial parts of the masseter muscles and the sternocleidomastoid muscles.
32844502|NCT05091840||patients requiring intubation at birth and subsequent surfactant administration|
32844503|NCT05091840||patients who receive surfactant by LISA|
32844504|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
32844505|NCT00704847|Placebo Comparator|2|SMC021 Placebo
32844506|NCT01380769|Experimental|CRLX101|
32844507|NCT01380769|Other|Best supportive care|
32844508|NCT05091762|No Intervention|Blank control group|
32844509|NCT05091762|Experimental|Exercise group|
32844510|NCT05091762|No Intervention|Hyperlipidemia group|
32844511|NCT05091762|No Intervention|Hyperlipidemia and medication group|
32844512|NCT05091762|Experimental|Hyperlipidemia and exercise group|
32844513|NCT05091762|Experimental|Hyperlipidemia and medication and exercise group|
32844514|NCT05091762|No Intervention|Routine treatment group|
32844515|NCT05091762|Experimental|Routine treatment and exercise group|
32844516|NCT03393468|Experimental|Sequence A: Dapivirine gel|Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device.
32844517|NCT03393468|Experimental|Sequence B: Dapivirine gel|Participants will receive up to 10 g of dapivirine gel administered rectally via a coital simulation device, followed by a 2- to 4-week washout period. Participants will then receive a second dose of 2.5 g of dapivirine gel administered rectally via an applicator.
32844518|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
32844519|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
32844520|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
32844521|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
32844522|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
32844523|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
32844524|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
32844525|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
32844526|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
32844527|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
32844528|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
32844529|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
32844530|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
32844531|NCT03030534|Experimental|Experimental Group|Educational Package and software package
32844532|NCT03030534|Active Comparator|Control group|Health promotion tips
32844533|NCT04270539|Experimental|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
32844534|NCT04270539|No Intervention|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
32844535|NCT02600208|Experimental|Single Experimental Arm|Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device
32844536|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
32844537|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
32844538|NCT02570100|Experimental|Biological collection|Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.
32844539|NCT01395823|Other|ergocalciferol supplementation|
32844540|NCT01395823|Placebo Comparator|placebo|
32903103|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
32844541|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
32844542|NCT00158184|Active Comparator|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
32844543|NCT00158184|Active Comparator|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
32844544|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
32844545|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
32844546|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
32844547|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
32844548|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
32844549|NCT02356302|Experimental|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
32844550|NCT02356302|Experimental|MK-2048 IVR|The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
32844551|NCT02356302|Experimental|MK-2048A IVR|The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
32844552|NCT02356302|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
32844553|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
32844554|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
32844555|NCT04270461|Experimental|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
32844556|NCT05091216|Experimental|Traditional Chinese Medicine Mouthwash Group|The subjects use traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
32844557|NCT05091216|Active Comparator|Dilute 50 times of Traditional Chinese Medicine Mouthwash Group|The subjects use dilute 50 times traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
32844558|NCT02999451|Experimental|snare group|snare-assisted POEM
32844559|NCT02999451|Active Comparator|conventional group|knife-assisted POEM
32844560|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
32844561|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
32844562|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
32844563|NCT05091138|Active Comparator|Mg and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 150mg of Mg.
32844564|NCT05091138|Active Comparator|Buprenorphine and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 300 mcg of buprenorphine.
32844565|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
32844566|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
32844567|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
32844568|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
32844569|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
32844570|NCT05094882||RUL|patients who recieved the resection of right upper lobe (RUL)
32844571|NCT05094882||RML|patients who recieved the resection of right middle lobe ()
32844572|NCT05094882||RLL|patients who recieved the resection of right lower lobe (RML)
32844573|NCT05094882||LUL|patients who recieved the resection of left upper lobe (LUL)
32844574|NCT05094882||LLL|patients who recieved the resection of left lower lobe (LLL)
32844575|NCT05094726|Experimental|Group A|the participant will received photobiomodulation session.
32844576|NCT05094726|Placebo Comparator|Group B|the participant will received placebo photobiomodulation session.
32844577|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
32844578|NCT05094648||group A|Covidpatient Who pass on high flow nasal therapy
32844579|NCT05094648||group B|Covidpatient who failed on high flow nasal therapy and need NIV
32844580|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
32844581|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
32844582|NCT05735184|Experimental|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
32844583|NCT05735184|Experimental|Dose Escalation: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
32844584|NCT05735184|Experimental|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
32844585|NCT05735184|Experimental|Dose Escalation: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
32844586|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
32844587|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
32844588|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax in R/R NPM1-m (A-3)|Ziftomenib/Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
32844589|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L NPM1-m (A-4)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed NPM1-m AML patients
32844590|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
32844591|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy
32844592|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L KMT2A-r (B-3)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed KMT2A-r AML patients
32844593|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
32844594|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
32844595|NCT05094492|Experimental|Self assembling peptide P11-4 with fluoride|P11-4 forms a 3D matrix within subsurface of incipient carious lesions , allowing formation of new hydroxyapatite crystal facilitating guided regeneration of enamel lesions. Combination with fluoride will have a synergistic effect on remineralization potential
32844596|NCT05094492|Active Comparator|Fluoride varnish|Gold standard agent for remineralization of incipient carious lesions.
32844597|NCT01380691|Experimental|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms [g/kg] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
32844598|NCT01380691|Experimental|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
32844599|NCT01380691|Experimental|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
32844600|NCT01380691|Experimental|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
32844601|NCT01270893|Experimental|Nilotinib and Surgical Resection|
32844602|NCT01270893|Experimental|Nilotinib and Potential Resection|
32844603|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
32844604|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
32844605|NCT02835222|Experimental|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
32844606|NCT02835222|Active Comparator|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
32844607|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
32844608|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
32844609|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
32844610|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
32844611|NCT05377398|Experimental|1) Intervention group|"Participants in this arm will be offered~a digital individual-level intervention (Bit Habit) &~group-based or individual-level healthy lifestyle and green power intervention~a mini-intervention for substance use if their level of substance use is above certain risk level."
32844612|NCT05377398|No Intervention|2) Control group|"The control group is assumed to continue with current health information and national recommendations for healthy lifestyle and use of services as usual."
32844613|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
32844614|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
32844615|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
32844616|NCT02993289|No Intervention|Control group 1: Episodic migraine|
32844617|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
32844618|NCT02840448||Case|Subjects with WS/SVAS/WS gene region variation
32844619|NCT02840448||Controls|Healthy volunteers
32844620|NCT04386447|Experimental|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
32844621|NCT04386447|Experimental|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
32844622|NCT04386447|Other|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~Prophylaxis for deep vein thrombosis~Steroids are not routinely recommended but may be considered in selected patients."
32844623|NCT05377008|Experimental|Intervention|Parents in the intervention arm will receive one single-session intervention one month after completion of baseline measures. They will also complete a feasibility exit interview one month after completion of their data collection period (i.e., at 7 months).
32844624|NCT05377008|No Intervention|Control|Families in the control arm will complete measures at the exact same timepoints as those in the intervention arm but will not receive the single session intervention and will not complete the feasibility exit interview. They will receive the same information as the intervention arm via an education manual at the completion of their data collection period.
32844625|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
32844626|NCT02993055|Experimental|Ulimorelin|Active
32844627|NCT02993055|Placebo Comparator|Placebo|Placebo
32844628|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
32844629|NCT02114814|Experimental|Intervention group|Diabetes self-management and family support
32844630|NCT02114814|Active Comparator|Attention control group|General health information
32844631|NCT01380535|Experimental|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
32844632|NCT01380535|Active Comparator|Standard of Care|Participants receive standard of care only
32844633|NCT00725361|Experimental|Active|Ambrisentan
32844634|NCT05721612|Experimental|Study group|
32844635|NCT05721612|Active Comparator|Control gorup|
32844636|NCT04385979|Active Comparator|Curcumin|%2 Curcumin gel
32844637|NCT04385979|Active Comparator|Nanocurcumin|%1 NanoCurcumin gel
33319958|NCT04869644|Experimental|Intervention: Behavioral Change Techniques to encourage Habit Formation|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
32844638|NCT05094024|Active Comparator|Central kitchen-prepared MDCF-2 arm|Children randomized to this arm will receive 25gm of kitchen-prepared version of MDCF-2 twice daily.
32844639|NCT05094024|Experimental|Ready-to-use supplementary food (RUSF) arm|Children randomized to this arm will receive 25g RUSF twice daily.
32844640|NCT05094024|Experimental|Freshly reconstituted MDCF-2 ingredients|Children randomized to this arm will receive individually packaged MDCF-2 ingredients, combined into 21.72g servings provided twice daily.
32844641|NCT05094024|Experimental|MDCF-2 shelf-stable foil pouch prototype with green banana powder|Children randomized to this arm will receive 21.77gm of shelf-stable foil pouch prototype with green banana powder twice daily.
32844642|NCT05094024|Experimental|MDCF-2 shelf-stable foil pouch prototype with sweet potato|Children randomized to this arm will receive 23.34gm of MDCF prototype with sweet potato twice daily.
33319959|NCT04785326|Experimental|DMB-3115|Patients randomized to receive DMB-3115 at the beginning of the study will continue to receive the same treatment
33319960|NCT04785326|Active Comparator|Stelara|Patients randomized to receive Stelara at the beginning of the study will be re-randomized at Week 28 in a 1:1 ratio to either continue on Stelara or will be transitioned to receive DMB-3115
33319961|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
32844646|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
32844647|NCT02816424|No Intervention|Control|
32844648|NCT01275885|Active Comparator|Vitamin D3 10µg|
32844649|NCT01275885|Active Comparator|Vitamin D3 30µg|
32844650|NCT01275885|Active Comparator|Vitamin D3 40µg|
32844651|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
32844652|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
32844653|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
32844654|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
32844655|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
32844656|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
32844657|NCT05090670|Experimental|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
32844658|NCT05090670|Active Comparator|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
32844659|NCT01275963||Control|Healthy individuals without structural heart disease
33319962|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
33319963|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
33319964|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
33319965|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
32844660|NCT01275963||CAD|Patients with coronary artery disease
32844661|NCT01275963||DCM|Participants with dilated cardiomyopathy
32844662|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
32844663|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
32844664|NCT01275963||RCM|Patients with restrictive cardiomyopathy
32844665|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
32844666|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
32844667|NCT05376618||stable COPD|
32844668|NCT05376618||Healthy|
32844669|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
32844670|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
32844671|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
32844672|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
32844673|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
32844674|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
32844675|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
33033055|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
33319966|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
32844676|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
32844677|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
32844678|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
32844679|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
32844680|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
32844681|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
32844682|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
32844683|NCT05718570||Participants with Adult Growth Hormone Deficiency (AGHD)|Participants will be treated with commercially available Sogroya according to routine clinical practice at the discretion of the treating physician. The decision to treat a participant with Sogroya has been made prior to and independently from the decision to include the participant in this study.
32844684|NCT01271439|Experimental|cetuximab|
32844685|NCT05706948|Experimental|High Intensity Interval Training (With Face Mask)|
32844686|NCT05706948|Experimental|High Intensity Interval Training (Without Face Mask)|
32844687|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
32844688|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
32844689|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
32844690|NCT05090592||myopic children|Myopic children use overnight orthokeratology or 0.01% atropine eye drop per night for myopia control
32844691|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
32844692|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
32844693|NCT05082636||case|54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital,
32844694|NCT05082636||control|besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).
32844695|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
32844696|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
32844697|NCT05093478|Experimental|Treatment|
32844698|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
32844699|NCT05376072|Experimental|Experimental data|
32844700|NCT05695170|Active Comparator|Individual intervention condition|"PreventT2 individual lifestyle intervention curriculum (2021 revised National DPP curriculum, freely available from the CDC)"
32844701|NCT05695170|Experimental|Couple-based intervention condition|"PreventT2 Together (couple-based adaptation of PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the National DPP)"
32844702|NCT05367193|Experimental|pars plana vitrectomy performed using NGENUITY® 3D Visualization System (Alcon, TX, USA)|NGENUITY® 3D Visualization System (Alcon, TX, USA)
32844703|NCT05367193|Active Comparator|standard binocular microscope pars plana vitrectomy|standard binocular microscope pars plana vitrectomy
32844704|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
32844705|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
32844706|NCT05369299|Experimental|Two-piece zirconia implants|Immediate dental implant placement will be performed by using the new two-piece zirconia implant Straumann® Pure Ceramic Two Piece Implant
32844707|NCT05369299|Active Comparator|Two-piece titanium implants|Immediate dental implant placement will be performed by using the conventional two-piece titanium implant Neoss® ProActive Tapered Implant
32844710|NCT05364385|Experimental|S/B group- infants|Infants randomized to the study group (S/B group) will receive surfactant and Budesonide - 0.5 mg -1mL
32844711|NCT05364385|Placebo Comparator|S/P group- control / placebo comparator|Infants randomized to the control group (S/P group) will receive surfactant and placebo (Normal Saline -1mL)
32844712|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
32844713|NCT05368597||Native vessel PCI|Native vessel PCI, which choose native coronary artery as the target vessel
33319967|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
32844714|NCT05368597||Bypass graft PCI|Bypass graft PCI, which choose the graft vessel as the target vessel
32844715|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
32844716|NCT01276275||Exposure Group 1|First time users of ticagrelor
32844717|NCT01276275||Exposure Group 2|First time users of clopidogrel
32844718|NCT01276275||Exposure Group 3|First time users of prasugrel
32844719|NCT05365711||Pregnant women|Microbiological samples are collected from the pregnant women in the mid-pregnancy and during the delivery. Patient records of these women and newborns are investigated for any infections or complications during and after the delivery.
32844720|NCT05365711||Partners|Partners of the pregnant women will be studied to understand the household transmission of studied bacteria and possible risk factors for carriage.
32844721|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
32844722|NCT05363059||BS group|The group of bariatric surgery therapy in metabolic syndrome patients.
32844723|NCT05363059||MT group|The group of medical therapy in metabolic syndrome patients
32844724|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
32844725|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
32844726|NCT03420222|Experimental|AVP-786|Participants were to receive AVP-786-28 (deudextromethorphan hydrobromide [d6-DM] 28 milligrams [mg]/quinidine sulfate [Q] 4.9 mg) once daily (OD) for the first 7 days, followed by AVP-786-28 twice daily (BID) for the next 7 days. Beginning on Day 15, participants were to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) BID for 10 weeks.
32844727|NCT03420222|Placebo Comparator|Placebo|Participants were to receive placebo BID for 12 weeks.
32844728|NCT04766593|Experimental|Oncological functional reeducation program|"It will consist of the following actions:~Prescription of multimodal physical exercise: This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).~Retraining in activities of daily living: Gradation and simplification of activities and training in energy saving techniques (EAT).~Finally, an exhaustive daily record of the activity carried out by the patient will be carried out, from which it will be modified, adapting it to the clinical situation of the patient."
32844729|NCT04766593|Active Comparator|Prescription of multimodal physical exercise|This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The guideline will be to maintain a multimodal exercise to perform exercises of different characteristics, including aerobic exercises, balance exercises and low-load strength exercises for muscle groups, both in the upper quadrant and the lower quadrant. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
32844730|NCT04386291|Active Comparator|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
32844731|NCT04386291|Experimental|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
32844732|NCT04386291|Experimental|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
32844733|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
32844734|NCT05032014|Experimental|probiotics group|"The oral probiotic (Lactobacillus rhamnosus Probio-M9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
32844735|NCT05032014|Placebo Comparator|placebo group|Immunotherapy with placebo alone
32844736|NCT05032014|No Intervention|healthy control group|healthy control group
32844737|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
32844738|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
32844739|NCT04039243|Experimental|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
32844740|NCT04039243|Active Comparator|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
32844741|NCT04039243|No Intervention|Monitoring|
32844742|NCT05030376|Experimental|patients with ileostomy without type 2 diabetes|intraileal glucose or saline infusion via ileostomy
32844743|NCT05030376|Experimental|patients with ileostomy with type 2 diabetes|intraileal glucose or saline infusion via ileostomy
32903104|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
32903105|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
33319968|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
33319969|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
33319970|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
33033056|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
33033057|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
33033058|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
32844744|NCT04039165|Experimental|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, and complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program. During times when in-person visits cannot happen (e.g., COVID-19), we will do virtual group sessions instead of meeting at the clinics, conducted via videoconference platform (i.e., Zoom), the group walks will not happen, and all exercise will be done individually to comply with social distancing measures.
32844745|NCT04039165|No Intervention|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
32844746|NCT04000399|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
32844747|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
32844748|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
32844749|NCT05366179|Experimental|Single Arm|"CAR.B7-H3 T cells:~Subjects with refractory or recurrent glioblastoma multiforme, have cells collected following their initial surgical resection to manufacture CAR.B7-H3 T cells, preferably before initiation of adjuvant chemoradiation."
32844750|NCT05375916|Experimental|Sustained-release opioid|3mg of sustained-release hydromorphone three times a day
32844751|NCT05375916|Active Comparator|Short-acting opioid|1-4 mg of short-acting hydromorphone 2-4 times a day as needed
32844752|NCT04361851|Experimental|Single Arm|Pembrolizumab and Daratumumab
32844753|NCT04352179|Experimental|Virtual Education Simulation|All participants will have access to the virtual education simulations.
32844754|NCT05095506|Experimental|eHeatlh Intervention Arm|The intervention platform is an interactive, web-based self-management program comprised of computer-adaptive tests (CATs) to assess depression, anxiety, and resilience and multimedia-assisted components. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs, receive score reports, and watch a system-assigned self-management strategy video (which is selected by the system based on the participant's current level of depression/anxiety symptoms).
32844755|NCT05095506|Active Comparator|Active Control Arm|The active control condition is a static web-based program which also includes computer-adaptive tests (CATs) to assess depression, anxiety, and resilience, but does not provide score reports and plays a predetermined educational video (related to health promotion after SCI) each week. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs and watch the educational video.
32844756|NCT04407715|Placebo Comparator|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
32903106|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
32903107|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
32903108|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
32903109|NCT00682838|No Intervention|Usual care (UC)|Control Group
32903110|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
32903111|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
32903112|NCT00626210|Experimental|Modafinil|
32903113|NCT01653080|Experimental|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
32903114|NCT00626366|Experimental|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
32903115|NCT00626366|Experimental|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
32903116|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
32844757|NCT04407715|Active Comparator|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
32844758|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
33417232|NCT04654533|No Intervention|Control|"Usual care control condition, i.e., standard practice in the participating childcare centers.~Teams of childcare providers are allocated to either COSC or waitlist in clusters, and baseline and follow-up measures are collected parallel in both groups. Childcare providers allocated to the waitlist will receive COSC after the follow-up data have been collected."
32844759|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
32844760|NCT00727857|Active Comparator|Metformin 850 mg BID|
32844761|NCT05361421|Experimental|Intensive targeting group|Intensive lipid loweroing therapy with LDL-cholesterol goal of <55mg/dL
32844762|NCT05361421|Active Comparator|Conventional therapy group|Initiate and maintain moderate intensity statin therapy
32844763|NCT05095194|Experimental|High myopia patients who had cataract surgery with IOL and capsular tension ring implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
32844764|NCT05095194|Experimental|High myopia patients who had cataract surgery with IOL implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
32844765|NCT00217165|Placebo Comparator|placebo|cellulose
33033059|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
33417233|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
33417234|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
32844766|NCT00217165|Active Comparator|active drug|taurine
32844767|NCT04537728|Experimental|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
32844768|NCT05092152|Active Comparator|Propofol|
32844769|NCT05092152|Experimental|Esketamina|
32844770|NCT05081700||Patients with relapsing MS|Patients with relapsing remitting MS who are intending to receive ocrelizumab.
32844771|NCT05019066|Active Comparator|Herbal Combination Group|"Tablets of the herbal formulation will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/healthy-hair-tablets-10)~Each 500 mg tablet contains a proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa~Dose: subjects in this group will take 2 herbal formulation tablets twice per day for a total of 4 tablets per day"
32844772|NCT05019066|Placebo Comparator|Placebo Group|"Supplement appearing similar to the herbal combination formulation.~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 2 placebo tablets twice per day for a total of 4 tablets per day"
32844773|NCT05001360|Experimental|XBI-302 + Nivolumab|FMT capsules XBI-302 will be administered orally every two weeks for 12 weeks and then every four weeks for 12 weeks. Nivolumab will be intravenously infused every two weeks for 24 weeks.
32844774|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
32844775|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
32844776|NCT04986150|Experimental|Milk Protein|4 daily 20-gram doses of milk protein (dairy yoghurt) consumed for 4 consecutive days after the exercise bout
32844777|NCT04986150|Placebo Comparator|Placebo|4 daily doses of low-protein placebo product (oat-based yoghurt) consumed for 4 consecutive days after the exercise bout
32844778|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
32844779|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
32844780|NCT05022810|Experimental|Test Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period.
32844781|NCT05022810|Active Comparator|Reference Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period
32844782|NCT01525550|Experimental|sunitinib|
32844783|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
32844784|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
32844785|NCT05016570|Experimental|Picture narrative lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format which uses text in combination with sequences of pictures to communicate a coherent message. The designs follow conventions from comics/graphic narratives and key stakeholders were involved during the design process.
32844786|NCT05016570|Active Comparator|Text with pictures lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text with non-narrative pictures for decoration. The pictures have been extracted from the picture narratives being used Arm 1.
32844787|NCT05016570|Active Comparator|Text-only lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text and no pictures.
32844788|NCT04730232|Experimental|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
32844789|NCT04276779|Experimental|Alcohol and Negative Mood|
32844790|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
32844791|NCT04276779|Active Comparator|Alcohol and Positive Mood|
32844792|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
32844793|NCT04701918|Experimental|Pembrolizumab + Cryoablation|Participants will be given 200 mg pembrolizumab intravenously once every 3 weeks. This will continue for up to 2 years as per standard of care. Participants will receive cryoablation between the 1st and 2nd doses of pembrolizumab. Cryoablation consists of using a CT scan to guide one or more thin needles to the tumor through your skin, where extreme cold is applied.
32844794|NCT04279197|Experimental|FZHY Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~Fuzheng Huayu tablets"
32844795|NCT04279197|Placebo Comparator|Placebo Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~placebo"
32844796|NCT04699032|Experimental|Severe Renal Impairment|eGFR (mL/min/1.73 m2): <30 not on hemodialysis
32844797|NCT04699032|Experimental|Normal Healthy Match|eGFR (mL/min/1.73 m2): ≥90
32844798|NCT04699032|Experimental|Moderate Renal Impairment|eGFR (mL/min/1.73 m2): ≥30 to 60
32844799|NCT04699032|Experimental|Mild Renal Impairment|eGFR (mL/min/1.73 m2): ≥60 to 90
32844800|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
32844801|NCT04540848|Experimental|Exparel plus supraclavicular block|
32844802|NCT04540848|Active Comparator|Bupivacaine HCL plus supraclavicular block|
32844803|NCT04540848|Active Comparator|supraclavicular block only|
32844804|NCT01271751|Experimental|GFT505 80mg|
32844805|NCT01271751|Placebo Comparator|Matching placebo|
32844806|NCT00211237|Experimental|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
32844807|NCT00211237|Active Comparator|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
32844808|NCT04793100|Experimental|Follow-up for 1 year|
32844809|NCT04437030|Active Comparator|Patient|Patient with Head and neck cancer
32844810|NCT04437030|Other|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
32844811|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
32844812|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
32844813|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
32844814|NCT04774146||triple air fluid exchange|those undergoing triple air fluid exchange
32844815|NCT04774146||irrigation|those undergoing vitreous chamber irrigation with comparable volume of BSS
32844816|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
32844817|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
32844818|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
32844819|NCT04760028|Other|sevoflurane|Adjust sevoflurane concentration as required
32844820|NCT05003310|Experimental|Active Stimulation; Period 1|Active stimulation for 12 weeks in addition to stable dose of csDMARD therapy.
32844821|NCT05003310|Sham Comparator|Sham Stimulation; Period 1|Sham stimulation for 12 weeks in addition to stable dose of csDMARD therapy.
32844822|NCT05003310|Experimental|Open label active stimulation, Period 2|Open label active stimulation for 12 additional weeks in addition to stable dose of csDMARD therapy.
32844823|NCT05003310|Other|Open label RA Drug, Period 2|Open label drug treatment with baricitinib for 12 weeks in addition to stable dose of csDMARD therapy.
32844824|NCT05003310|Experimental|RA drug combined with active stimulation, Period 3|Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks. Participants will also receive a stable dose of csDMARD therapy.
32844825|NCT05003310|Experimental|Active stimulation combined with RA drug, Period 3|Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks. Participants will also receive a stable dose of csDMARD therapy.
32844826|NCT05003310|Other|Long-term Follow-up, Period 4|Standard of care treatments with or without stimulation
32844827|NCT05366101|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
32844828|NCT05366101|Active Comparator|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
32844829|NCT05366101|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
32844830|NCT04993560||Homologous booster|Two doses of BBIBP-CorV, followed by BBIBP-CorV
32844831|NCT04993560||Heterologous booster|Two doses of BBIBP-CorV, followed by BNT162b2
32844832|NCT05365555||Fascia Iliaca Compartment Block (FICB)|Participants with a radiologically verified hip fracture receiving a FICB using a blind technique guided by anatomical landmarks.
32844833|NCT05365555||Femoral Nerve Block (FNB)|Participants with a radiologically verified hip fracture receiving a FNB using ultrasound guidance for direct nerve visualisation.
32844834|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
32844835|NCT01525238|Experimental|Dapagliflozin 5 mg|
32844836|NCT01525238|Experimental|Dapagliflozin 10 mg|
33319971|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
32844837|NCT05374356|Active Comparator|High spinal anesthesia|"Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).~Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
32844838|NCT05374356|No Intervention|Control group|"Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
32844839|NCT00717405|Experimental|1|
32844840|NCT05369143|Experimental|Chiropractic care Group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor with at least five years of clinical experience.The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints. Chiropractors use these biomechanical characteristics as clinical indicators of spinal dysfunction and vertebral subluxation.
32844841|NCT05369143|Placebo Comparator|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The control intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust. No spinal adjustment will be performed during any control intervention. This control intervention is not intended to act as a sham treatment session
32844842|NCT04022239|Experimental|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
32844843|NCT04022239|Experimental|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
32844844|NCT01276743||T1DM|Children and adolescents with T1DM
32844845|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
32844846|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
32844847|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
32844848|NCT05630599||ILD|ILD, or lung fibrosis, is one of a spectrum of fibrotic diseases, associated with ageing, obesity, diabetes and pollution, that are responsible for ~45% of premature deaths in Western Europe. Of >90,000 patients in the United Kingdom with ILD, ~30,000 have idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, the most severe form. idiopathic pulmonary fibrosis is a disease of unknown aetiology that is more frequent in males presenting mainly in the sixth and seventh decades of life. There is no cure and median survival, just 3-5 years following diagnosis is worse than for many cancers.
32844849|NCT05630599||COPD|COPD is a common, long term condition of the lungs that is usually caused by cigarette smoking. In addition to daily symptoms and limitations in activities, patients are prone to developing chest infections called 'exacerbations'. Exacerbations are a significant problem: unpleasant for patients, and sometimes severe enough to cause hospital admission (and therefore National Health Service pressures) and death.
32844850|NCT05630599||COVID-19|Recovery from COVID19 has many unknowns, especially in the long term. Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia, progressing to lung injury and acute respiratory distress syndrome (ARDS) and, in the longer term, pulmonary fibrosis. Notably, the consequences of COVID-19 include effects on other organs including: heart, kidneys, and brain.
32844851|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
32844852|NCT01271985|Active Comparator|Minimal care|Minimal care.
32844853|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
32844854|NCT03832699|Experimental|Oral progesterone|
32844855|NCT03832699|Active Comparator|Vaginal progesterone|
32844856|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
32844857|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
32844858|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
32844859|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
32844860|NCT03997903|Experimental|Imatinib Intervention|
32844861|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
32844862|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
33406045|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
32844863|NCT03997513|Experimental|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
32844864|NCT03997513|No Intervention|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
32844865|NCT05369767|Experimental|SAD, SHR-2004|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 injection
32844866|NCT05369767|Placebo Comparator|SAD, SHR-2004 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 placebo injection
33406046|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
33406047|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
32844867|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
33406048|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
32844868|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
32844869|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
32844870|NCT05360017|Experimental|Robot in lower limb motor function training of stroke patients with hemiplegia|"Test equipment: litestepper single lower limb rehabilitation training robot~Device type: Class II medical device"
32844871|NCT01277133||Cohort|
32844872|NCT05366803|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults. Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times.
32844873|NCT05366803|No Intervention|Usual Activity Control|Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times. Participants carry about their normal activities during this period.
32844874|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
33406049|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
33406050|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
32844875|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
33406051|NCT04052594|Experimental|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
33406052|NCT04052594|Placebo Comparator|Placebo - IV|Placebo administered IV to participants with dyslipidemia
33406053|NCT04052594|Experimental|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
33406054|NCT04052594|Placebo Comparator|Placebo - SC|Placebo administered SC to participants with dyslipidemia
33406055|NCT04816812|Other|Exercise|In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.
33406056|NCT04816812|Other|Comparison|Comparison
32844876|NCT05630287|Experimental|[14C] Selpercatinib - Part 1|[14C] Selpercatinib administered as an oral solution
32844877|NCT05630287|Experimental|Selpercatinib and [14C] Selpercatinib - Part 2|Single oral dose of Selpercatinib followed 2 hours later by single dose of [14C] Selpercatinib administered as an intravenous (IV) push.
32844878|NCT01525082|Experimental|Bevacizumab + Capecitabine + Temozolomide|Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
32844879|NCT04386915|Experimental|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
32844880|NCT04386915|Placebo Comparator|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
33319972|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
32844881|NCT04386915|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
32844882|NCT04386915|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
32844883|NCT04386915|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
32844884|NCT04386915|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
32844885|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
32844886|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
32844887|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
32844888|NCT04386681|Experimental|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
32844889|NCT04386681|No Intervention|Treatment as usual- Control group|Not receiving the RCBI intervention
32844890|NCT04386525|Experimental|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
32844891|NCT04386525|No Intervention|Controle|for comparison with interventional arm
32844892|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
32844893|NCT04018651|Experimental|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
32844894|NCT05632705|Experimental|Intervention arm|In this arm, prior to closing the sheath and skin, unused drapes, gloves and instruments will be used to close the sheath and the skin.
32844895|NCT05632705|No Intervention|Control arm|In this arm sheath and skin closure will be according to the standard protocol
32844896|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
32844897|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
32844898|NCT03996499|Experimental|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
32844899|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
32844900|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
32844901|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
33319973|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
33319974|NCT04663568|Other|Levonorgestrel-releasing intrauterine system|
33319975|NCT04772612|Experimental|Sitravatinib in healthy subjects|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.
33319976|NCT04772612|Experimental|Sitravatinib in subjects with mild hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment
33319977|NCT04772612|Experimental|Sitravatinib in subjects with moderate hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment
32844902|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
32844903|NCT01277367|Experimental|E|These members will receive a direct payment.
32844904|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
32844905|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
32844906|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
32844907|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
32844908|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
32844909|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
32844910|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
32844911|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
32844912|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
32844913|NCT04088864|Experimental|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
32844914|NCT04088864|Experimental|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
32844915|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
32844916|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
32844917|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
32844918|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
32844919|NCT02991261|Experimental|SPARC001 type I|Treatment type I
32844920|NCT02991261|Experimental|SPARC001 type II|Treatment type II
32844921|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
32844922|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
32844923|NCT03994861|Active Comparator|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
32844924|NCT03994861|Sham Comparator|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
32844925|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
32844926|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
32844927|NCT04018495|Experimental|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
32844928|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
32844929|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
32844930|NCT01277679|Other|Heart Failure|Heart Failure cohort
32844931|NCT04018105|Experimental|taking metformin 30 or 60 minutes before the OGTT|
32844932|NCT04018105|Placebo Comparator|No metformin before OGTT|
32844933|NCT02991417|Experimental|CDVAX|
32844934|NCT05366647|Active Comparator|Canaloplasty|Canaloplasty ab externo
32844935|NCT05366647|Active Comparator|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
32844936|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
32844937|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
32844938|NCT05632549|Placebo Comparator|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
32844939|NCT05632549|Experimental|L-carnitine|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
32844940|NCT05632549|Experimental|Biotin|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
32844941|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
32844944|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
32844945|NCT05632315|Experimental|ESCRE/CRE BL-BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
32844946|NCT05632315|No Intervention|ESCRE/CRE BL-BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
32844947|NCT05632315|Experimental|ESCRE/CRE carbapenem +/- BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI
32844948|NCT05632315|No Intervention|ESCRE/CRE carbapenem +/- BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
32844949|NCT05632315|Experimental|ESCRE/CRE Fluoroquinolone|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone
32844950|NCT05632315|No Intervention|ESCRE/CRE Fluoroquinolone standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone standard of care (SOC)
32844951|NCT05632315|Experimental|MRSA lipo/glycopeptide|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide
32844952|NCT05632315|No Intervention|MRSA lipo/glycopeptide standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide standard of care (SOC)
32844953|NCT05632315|Experimental|MRSA oxazolidinone|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone
32844954|NCT05632315|No Intervention|MRSA oxazolidinone standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone standard of care (SOC)
32844955|NCT05632315|Experimental|PsA BL-BLI|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
32844956|NCT05632315|No Intervention|PsA BL-BLI standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
32844957|NCT05632315|Experimental|PsA carbapenem +/- BLI|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: carbapenem +/- BLI
32844958|NCT05632315|No Intervention|PsA carbapenem +/- BLI standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
32844959|NCT05632315|Experimental|PsA Fluoroquinolone|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: Fluoroquinolone
32844960|NCT05632315|No Intervention|PsA Fluoroquinolone standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (PsA) Antibiotic Class: Fluoroquinolone standard of care (SOC)
32844961|NCT05632315|Experimental|VRE lipopeptide|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide
32844962|NCT05632315|No Intervention|VRE lipopeptide standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide standard of care (SOC)
32844963|NCT05632315|Experimental|VRE oxazolidinone|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone
32844964|NCT05632315|No Intervention|VRE oxazolidinone standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone standard of care (SOC)
32844965|NCT03994471|Experimental|XyloCore peritoneal dialysis solution|Patients will receive 2 to 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
32844966|NCT03994471|Active Comparator|Glucose peritoneal dialysis solution|Patients randomized to glucose solution will continue the 2 to 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
32844967|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
32844968|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
32844969|NCT03993613|Experimental|human apotransferrin|Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.
32844970|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
32844971|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
32844972|NCT01277835|Experimental|Lidocaine Infusion|
32844973|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
32844974|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
32844975|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
32844976|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
32844977|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
32844978|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
32844979|NCT05632159|Placebo Comparator|conventional anaesthesia group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
32844980|NCT05632159|Active Comparator|Mg sulphate group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
32844981|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
33033060|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
32844982|NCT04017013|Active Comparator|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:~Surgery of the upper abdomen: T7-T8.~Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
32844983|NCT04017013|Experimental|Lidocaine Infussion|Intravenous lidocaine
32844984|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
32844985|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
32844986|NCT05631847|Sham Comparator|Direct endovascular treatment group|Direct endovascular treatment (EVT) without intravenous thrombolysis (IVT)
32844987|NCT05631847|Active Comparator|Bridging treatment group|Intravenous thrombolysis (IVT) followed by endovascular treatment (EVT)
32844988|NCT04385901|No Intervention|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
33406057|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
32844989|NCT04385901|Experimental|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
32844990|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
32844991|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
32844992|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
32844993|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
32844994|NCT00729807|Experimental|Pentamidine|
32844995|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
32844996|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
32844997|NCT04385511|Experimental|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
32844998|NCT04385511|No Intervention|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
32844999|NCT03992131|Experimental|Arm A: Oral rucaparib and oral lucitanib|"Phase 1b (Dose escalation): Up to 55 patients with advanced or metastatic solid tumors.~Phase 2 (Dose expansion): Up to 80 patients with High Grade Ovarian Cancer."
32845000|NCT03992131|Experimental|Arm B: Oral rucaparib and IV sacituzumab govitecan|"Phase 1b (Dose escalation): Up to 55 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, platinum resistant Ovarian Cancer, or a tumor with a BRCA1, BRCA2, PALB2, RAD51C, or RAD5/1D mutation~Phase 2 (Dose expansion): Up to 139 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, or platinum resistant Ovarian Cancer"
32845001|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
32845002|NCT05366023|No Intervention|No contact|0 hours of activities during intervention period of study
32845003|NCT05366023|Experimental|TDD1|10 hours of top-down driven cognitive training games
32845004|NCT05366023|Experimental|TDD2|10 hours of top-down driven cognitive training games
32845005|NCT05366023|Experimental|TDD1 + TDD2|20 hours of top-down driven cognitive training games
32845006|NCT05366023|Experimental|BUD1|10 hours of bottom-up driven cognitive training games
32845007|NCT05366023|Experimental|BUD2|10 hours of bottom-up driven cognitive training games
32845008|NCT05366023|Experimental|BUD1 + BUD2|20 hours of bottom-up driven cognitive training games
32845009|NCT05366023|Experimental|BUD2 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845010|NCT05366023|Experimental|BUD1 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845011|NCT05366023|Experimental|BUD2 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845012|NCT05366023|Experimental|BUD2 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
32845013|NCT05366023|Experimental|BUD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845014|NCT05366023|Experimental|BUD1 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
32845015|NCT05366023|Experimental|BUD1 + BUD2 + TDD2|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845016|NCT05366023|Experimental|BUD1 + BUD2 + TDD1|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
32845017|NCT05366023|Experimental|BUD1 + BUD2 + TDD1 + TDD2|20 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
32845018|NCT05366023|Active Comparator|CSA10|10 hours of cognitive stimulating activities
32845019|NCT05366023|Active Comparator|CSA20|20 hours of cognitive stimulating activities
32845020|NCT05366023|Active Comparator|CSA30|30 hours of cognitive stimulating activities
32845021|NCT05366023|Active Comparator|CSA40|40 hours of cognitive stimulating activities
32845022|NCT01278147|No Intervention|controle|patient without fatigue education program
32845023|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
32845024|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
32845025|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
32845026|NCT04248127|Experimental|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
32845027|NCT04248127|Placebo Comparator|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
32845028|NCT05631691|Experimental|Experimental Group|school students
32845029|NCT05631691|No Intervention|Comparison Group|school students
32845030|NCT03990805|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
32845031|NCT03990805|Placebo Comparator|saline|saline
32845032|NCT03990493|Experimental|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
32845033|NCT04226599|Experimental|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
32845034|NCT04226599|Active Comparator|PTA Group|This group treated with plain balloon catheter.Armada 35
32845035|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
32845036|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
32845037|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
32845038|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
32845039|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
32845040|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
32845041|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
32845042|NCT05631301|Experimental|Move&Connect-Youth|"Sessions run weekly at the Bloorview Research Institute by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Weekly sessions will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, fatigue management, advocacy skills, and goal setting.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
32903117|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
32845043|NCT05631301|Experimental|Move&Connect-Youth-Virtual|"Sessions run weekly via Zoom videoconferencing by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Weekly sessions taking place over Zoom will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, mood coping skills, fatigue management, advocacy skills, and goal setting.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
32845044|NCT05631301|Other|Move&Connect-Youth Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
32845045|NCT05631301|Experimental|Move&Connect-Caregiver|"The treatment sessions run once a week at the Bloorview Research Institute and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress & daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
32845046|NCT05631301|Experimental|Move&Connect-Caregiver-Virtual|"The treatment sessions run once a week using Zoom videoconferencing and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress & daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
32845047|NCT05631301|Other|Move&Connect-Caregiver Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
32845048|NCT00582231||1|Participants that are starting penile injections therapy.
32845049|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
32845050|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
32845051|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
32845052|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
32845053|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
32845054|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
32845055|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
32845056|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
32845057|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
32845058|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
32845059|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
33319978|NCT04772612|Experimental|Sitravatinib in subjects with severe hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment
32845060|NCT04489667|Other|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
33319979|NCT03810326|Experimental|Intervention|
32845061|NCT04407091|Experimental|[14C]AZD4831 Oral Solution|One 10 mg dose of [14C]AZD4831 Oral Solution
32845062|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
32845063|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
32845064|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
32845065|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
32845066|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
32845067|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
32845068|NCT05631145|Experimental|Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA)|MT combined with XKSA for 2 weeks.
32845069|NCT05631145|Placebo Comparator|Morita therapy (MT)|MT alone for 2 weeks
32845070|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
32845071|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
32845072|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
32845073|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
32845074|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
32845075|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
32845076|NCT04007029|Experimental|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
32845077|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
32845078|NCT05631067|Experimental|BP monitoring arm|Participants will be adults >18 years of age admitted for delivery with a diagnosis of HDP (i.e., chronic hypertension, gestational hypertension, preeclampsia, eclampsia, the HELLP syndrome, or chronic hypertension with superimposed preeclampsia) per the American College of Obstetricians and Gynecologists Criteria.
32845079|NCT05631067|Active Comparator|Control arm|Control participants will be adults >18 years of age with an uncomplicated pregnancy and delivery, and without a diagnosis of HDP.
32845080|NCT03989713|Experimental|MRD-triggered arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.~(Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)~Safety follow-up and observational follow-up"
32903118|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
33319980|NCT05669066|No Intervention|Control|This group will undergo a standardized conventional intra-operative and postoperative analgesia regimen. Anesthetic type and postoperative analgesia will be standardized.
33319981|NCT05669066|Experimental|Mindful meditation|Start the MM program 2 weeks preoperatively and continue for 30 days post operatively. Study subjects will meet with the meditation instructor for 30 minutes once, 2 weeks prior to surgery, and daily during hospital admission following total joint replacement (TJR). Throughout the intervention period, subjects will be asked to practice daily 15 minutes twice a day, and record their daily meditation experience. Upon discharge from hospital, subjects will receive telephone follow up sessions with the research assistant weekly until 30 days have elapsed. Subjects will be required to show compliance by recording their daily meditation experience in the Daily Meditation Diary (Post-op). At the end of the meditation intervention period, subjects will be asked to provide their feedback in the Patient Satisfaction Survey. Will undergo a standardized, conventional intra-operative postoperative analgesia regimen in addition to the meditation intervention. Anesthetic type will be standardized
33326956|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
32845081|NCT03989713|Experimental|Prophylactic Arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)~Safety follow-up and observational follow-up"
32845082|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
32845083|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
32845084|NCT03989401|Experimental|Multimedia video education|The experimental group conducted multimedia video education while admission.
32845085|NCT03989401|No Intervention|None multimedia video education|The control group conducted usual nursing of oral face-to-face education on admission.
32845086|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
32845087|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
32845088|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
32845089|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
32845090|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
32845091|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
32845092|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
32845093|NCT03988855|Experimental|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
32845094|NCT03988855|Experimental|Part 2|30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
32845095|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
32845096|NCT03988543|No Intervention|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
32845097|NCT03988543|Experimental|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
32845098|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
32845099|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
32845100|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
32845101|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
32845102|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
32845103|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
32845104|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
32845105|NCT03988309|Active Comparator|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
32845106|NCT03988309|No Intervention|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
32845107|NCT04277559|Active Comparator|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
33406058|NCT04795362||patients with Delayed cerebral ischemia|50 adult patients hospitalized in neurological intensive care unit for subarachnoid hemorrhage, in whom the onset of delayed cerebral ischemia is suspected will be included.
32845108|NCT04277559|Active Comparator|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
32845109|NCT04277559|Placebo Comparator|No music|the patients will not listen.
32845110|NCT03987841|Experimental|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. Single-arm study, a group of participants meeting eligibility requirements will be invited to participate.
32845111|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
32845112|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
32845113|NCT00750165|Experimental|Titration Night|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
32845114|NCT05634031|Experimental|Patients with INOCA|Patients to undergo coronary angiogram and/or coronary CT angiogram for suspected ischemic symptoms of angina and dyspnea but do not have obstructive epicardial coronary artery disease.
32845115|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
32845116|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
32845117|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
32845118|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
32845119|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~Placebo, 1 capsule before the session~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
32845120|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
32845121|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
32845122|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
32845123|NCT04407403|Experimental|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
32845124|NCT04407403|Experimental|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
32845125|NCT04407403|No Intervention|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
32845126|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
32845127|NCT03594643||control|patient not smoking nor using electronic cigarette
32845128|NCT03024541||LASA study|
32845129|NCT03024541||InterRAI consortium|
32845130|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
32845131|NCT01430585|Experimental|A|
32845132|NCT01430585|Experimental|B|
32845133|NCT01430585|Active Comparator|C|
32845134|NCT04005859|Active Comparator|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
32845135|NCT04005859|Experimental|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
32845136|NCT04052945|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
32845137|NCT04052945|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
32845138|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
32845139|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
32903119|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
32845140|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
32845141|NCT04004611|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants >40 kilograms (kg)
32845142|NCT04004611|Experimental|Mirikizumab Dose 2|Mirikizumab administered IV and SC. Participants ≤40 kg
32845143|NCT04004611|Experimental|Mirikizumab Dose 3|Mirikizumab administered IV and SC. Participants ≤40 kg
32845144|NCT05633719||Pediatric solid cancer|
32845145|NCT03986593|Other|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
32845146|NCT03986047|Experimental|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
32845147|NCT03986047|Experimental|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
32845148|NCT03986047|Sham Comparator|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
32845149|NCT03985501||newborn screening for sickle cell disease|Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
32845150|NCT03984643|Experimental|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
32845151|NCT03594097|Experimental|Treatment cookies|
32845152|NCT03594097|Active Comparator|Control cookies|
32845153|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
32845154|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
32845155|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
32845156|NCT01408901|Placebo Comparator|D: placebo + attention control group|
32845157|NCT04182763|Experimental|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
32845158|NCT04182763|Experimental|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
32845159|NCT04182763|Experimental|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
32845160|NCT04182763|Placebo Comparator|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2 (medium dose)
32845161|NCT04182763|Experimental|Open-label arm|Up to 24 months of CoA-Z at dose 2
32845162|NCT05633485|Experimental|Experimental|An animation-supported training based on the health promotion model for COVID-19 disease and prevention measures was given to the participants.
32845163|NCT05633485|No Intervention|Control|No intervention was applied to the participants in the control group.
32845164|NCT05633251|Experimental|School 1|
32845165|NCT05633251|Experimental|School 2|
32845166|NCT05633251|Experimental|School 3|
32845167|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :~who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)~OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
32845168|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
32845169|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
32845170|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
32845171|NCT04044521|Experimental|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
32845172|NCT04044521|Experimental|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18."
32845173|NCT04044521|Experimental|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 6, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
32845174|NCT04044521|Experimental|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.~At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
32845175|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
32845176|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
32845177|NCT04748159|Experimental|Infants in prone position|The purpose of this intervention study is to evaluate short-term effects (within one hour) of prone positioning on vital signs in infants under 12 months of age with acute RSV bronchiolitis.
32903120|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
32845178|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
32845179|NCT04044131|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
32845180|NCT04044131|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
32845181|NCT04748081||Surgery cohort|Patients who underwent hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4) between 2000 and 2012 were identified as the surgery cohort.
32845182|NCT04748081||Control cohort|Patients without any record of hepatectomy between 2000 and 2012 were defined as the control cohort.
32845183|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
32845184|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
32845185|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
32845186|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
32845187|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
32845188|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
32845189|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
32845190|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen~Those compatible with life are managed by full investigation and given standard care for each case"
32845191|NCT02985385||Normal Fetal Ultrasounds|Given normal care
32845192|NCT03976375|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
32845193|NCT03976375|Active Comparator|Docetaxel|Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
32845194|NCT03976375|Experimental|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
32845195|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
32845196|NCT01408277|Active Comparator|Control|Standard Care
32845197|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
32845198|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
32845199|NCT03598855|No Intervention|Control|
32845200|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
32845201|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
32845202|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
32845203|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
32845204|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
32845205|NCT05633017||Pulmonary Rehab Patients|Patients who attend respiratory therapy at John Muir Pulmonary Rehab facility
32845206|NCT05633017||Control|Healthy adults, 18+
32845207|NCT03984175|Experimental|Patients with ARDS at three Intermountain tertiary hospitals|
32845208|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
32845209|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
32845210|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
32845211|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
32845212|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
32845213|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
32845214|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
32845215|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
33406059|NCT04052750|No Intervention|The control group|Patients in this group only received medications without daily text message reminder
33406060|NCT04052750|Experimental|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
33406061|NCT04379154|Experimental|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
33406062|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
33406063|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
33406064|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
33406065|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
33406066|NCT04373226|Experimental|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
33406067|NCT04373226|Active Comparator|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
33406068|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
33406069|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
32845216|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
32845217|NCT05632861|Experimental|Experimental group|HuHuangLianzonggan capsule, 4 pills, take orally after meals, 2 times a day
32845218|NCT05632861|Placebo Comparator|Placebo group|HuHuangLianzonggan capsule placebo, 4 pills, take orally after meals, 2 times a day
32845219|NCT05632783|Experimental|chondroitin sulfate 800 mg tablets|oral chondroitin sulfate 800 mg tablet
32845220|NCT05632783|Placebo Comparator|placebo|oral placebo tablets matching the IP tablets
32845221|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
32845222|NCT05630443|No Intervention|ERAS|Ordinary ERAS treatment postoperatively without any prone position or voicetraining
32845223|NCT05630443|Active Comparator|+prone position|Ordinary ERAS treatment adding the prone position and voicetraining in short intervals
32845224|NCT00219349|Experimental|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
32845225|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
32845226|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
32845227|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
33406070|NCT04708158|Experimental|Active|Inhaled Novaferon, given 20 ug BID, daily for 7 days
33406071|NCT04708158|Placebo Comparator|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
33406072|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
32845228|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
32845229|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
32845230|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
32845231|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
32845232|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
32845233|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
32845234|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
32845235|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
32845236|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
32845237|NCT00218257|Active Comparator|Progesterone|200mg progesterone twice daily
32845238|NCT00218257|Placebo Comparator|Placebo|Placebo twice daily
32845239|NCT01523366|Experimental|Ticagrelor|
32845240|NCT01523366|Active Comparator|Clopidogrel|
32845241|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
32845242|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
32845243|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
32845244|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
32845245|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
32845246|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
32845247|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
32845248|NCT03976219|Experimental|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
32845249|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
32845250|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
32845251|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
32845252|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
32845253|NCT04003051|Experimental|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
32845254|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
32845255|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
32845256|NCT00217087|Other|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
32845257|NCT00217087|Other|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
32845258|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
32845259|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
32845260|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
32845261|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
32845262|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
32845263|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
32845264|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
32845265|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
32845266|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
32845267|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
32845268|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
32845269|NCT01406717|Experimental|SPIL1033|
32845270|NCT01406717|Placebo Comparator|Placebo|
32845271|NCT01406015|Active Comparator|Spironolactone|
32845272|NCT01406015|Placebo Comparator|Placebo|
32845273|NCT00215683|Experimental|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
32845274|NCT00215683|Experimental|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
32845275|NCT00215683|Experimental|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
32845276|NCT00215137|Experimental|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
32845277|NCT00215137|Placebo Comparator|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
32845278|NCT00215137|Active Comparator|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
32845279|NCT04406779||Patients with breast cancer|Patients with breast cancer
32845280|NCT04406779||Control|Healthy patients without breast cancer
32845281|NCT00214201|No Intervention|1|Standard of Care CNI immunosuppression
32845282|NCT00214201|Experimental|2|Calcineurin inhibitor withdrawal
32845283|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
32845284|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
32845285|NCT04407325|Experimental|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
32845286|NCT03984097|Experimental|Treatment Phase: TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
32845287|NCT03984097|Experimental|Treatment Phase: TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are >75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
32845288|NCT03984097|Experimental|Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)|TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.
32845289|NCT03976063|Active Comparator|Nifedipine|
32845290|NCT03976063|Placebo Comparator|Placebo|
32845291|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
32845292|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
32845293|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
32845294|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
32845295|NCT04001413|No Intervention|Arm A: Observational|No intervention, observational arm.
32845296|NCT04001413|Experimental|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
32845297|NCT04001413|Experimental|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
32845298|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
32845299|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
32845300|NCT01486784|Experimental|Phase 1 DL1|26mg/m2/dose IV once per week x 3 weeks of 4 week cycle
32845301|NCT01486784|Experimental|Phase 1 DL-1|17mg/m2 IV/dose once per week x 3 weeks of 4 week cycle
32845302|NCT01486784|Experimental|Phase 1 DL-1a|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
32845303|NCT01486784|Experimental|Phase 1 DL-1b|17mg/m2/dose IV three times per week x 3 weeks of 4 week cycle
32845304|NCT01486784|Experimental|Phase 1 DL-1c|22mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
32845305|NCT01486784|Experimental|Phase 1 DL-1d|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
32845306|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
32845307|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
32845308|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
32845309|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
32845310|NCT01521884||RA Patients treated with SC anti-TNF|
32845311|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
32845312|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
32845313|NCT03597451||Control|Healthy individuals of similar age and sex to patients
32845314|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
32845315|NCT03027596|No Intervention|Control group|no intervention
32845316|NCT04198909|Experimental|Cohort 1|
32903121|NCT01596751|Experimental|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
32845317|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
32845318|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
32845319|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
32845320|NCT04198441|Active Comparator|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
32845321|NCT04198441|Active Comparator|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
32845322|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
32845323|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
32845324|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
32845325|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
32845326|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
32845327|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
32845328|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
32845329|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
32845330|NCT04673058|Experimental|Spinal Manipulation Group|After the patients were evaluated in terms of somatic dysfunction, the appropriate techniques of Cervical Upglide Thrust, Cervical Downglide Thrust, Cervical Traction Thrust, Cervical Rotation Thrust, Cervico-Thoracic Distraction Manipulation, Cervico-Thoracic Lateral Glide (Spinous Push) Manipulation, Supine Screw Thoracic Thrust, Prone Thoracic Thrust, and Lumbar Spine Rotation Manipulation will be applied to patients.
32903122|NCT01596751|Experimental|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
32903123|NCT01596751|Experimental|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
32903124|NCT01596751|Experimental|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.~Lead-in phase treatment:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.~Treatment given in each 21 day cycle:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
32903125|NCT03000751|Active Comparator|Track A|Simple Audit Report In-Person Meeting Multi-Component Intervention
32903126|NCT03000751|Active Comparator|Track B|In-Person Meeting Simple Audit Report Multi-Component Intervention
32903127|NCT03000751|Other|Track C|Simple Audit Report Multi-Component Intervention
32903128|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
32903129|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
32903130|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
32903131|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
32903132|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
32903133|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
32845331|NCT04673058|Sham Comparator|Sham Manipulation Group|A treatment will be applied which is very similar to active treatment but aimed to have minimal therapeutic effect. For this, the practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position. In this way, the movement will be imitated without reaching the elastic zone and a stronger similarity will be provided compared to sham treatments such as light touch or massage.
32845332|NCT04673058|No Intervention|No Intervention Group|These patients will receive only their pharmacological treatments.
32845333|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
32845334|NCT03597373||not reintubation|Favourable respiratory function
32845335|NCT05374278|Experimental|Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers|Establish [18F]RP-115 safety in the clinic with male and female PET imaging.
32845336|NCT05374278|Experimental|Cohort 2 - [18F]RP-115 in patients with Alzheimer disease|Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls
32845337|NCT05374278|Experimental|Cohort 2 - [18F]RP-115 in age-matched controls|Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls
32845338|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
32845339|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
32845340|NCT04619472|Experimental|Radiofrequency Ablation (RFA)|The subjects will first undergo interventional bronchoscopy to reach the target lesion through the bronchial pathway. Then the lung lesions will be treated with radiofrequency ablation using the pulmonary radiofrequency ablation system and the disposable pulmonary radiofrequency ablation catheter.
32845341|NCT04198519|Active Comparator|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
32845342|NCT04198519|Active Comparator|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
32845343|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
32845344|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
32845345|NCT05097612|Experimental|Healthy participant|This is a repeated measures design. All participants receive both the intervention and the placebo comparator.
32845346|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
32845347|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
32845348|NCT04850898|Placebo Comparator|Normal Saline Placebo Control|Placebo control dosed 1 time via intravenous infusion
32845349|NCT04850898|Experimental|SAB-176 - 25mg/kg|Investigational Medicinal Product dosed 1 time at 25 mg/kg on day 1 via intravenous infusion
32845350|NCT04198285|Experimental|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
32845351|NCT04198285|No Intervention|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
32845352|NCT04510584|Experimental|Atezolizumab and Bevacizumab|"A cycle will be every 3 weeks.~Atezolizumab will be given intravenously (by vein) at a dose of 1200 mg once every cycle. Bevacizumab will be given intravenously at a dose of 15 mg/kg once every cycle. Up to 17 cycles of study treatment may be given.~Participants may be able to receive the study treatment for more than 17 cycles if the participants and the study doctor thinks that they are benefiting."
32845353|NCT04198129|Experimental|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
32845354|NCT04198129|Active Comparator|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
32845355|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
32845356|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
32845357|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
32845358|NCT04438434|Experimental|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
32845359|NCT04438434|Active Comparator|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
32845360|NCT04438434|Placebo Comparator|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
32845361|NCT04198051|Experimental|treatment group|
32845362|NCT03596983|Experimental|Short Sleep Patients|
32845363|NCT04462146|Experimental|Internet-based intervention|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
32845364|NCT04462146|Active Comparator|Face-to-face treatment by videoconference|Face-to-face Intervention by videoconference applied by a therapist: Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
32845365|NCT03755401|Experimental|TFPP|TFPP is a manualized 16-24 session psychodynamic psychotherapy targeted on trauma symptoms of PTSD
32845366|NCT03755401|Active Comparator|TAU|TAU in this study is treatment for PTSD as currently delivered at the VA
32845367|NCT04289298|Experimental|Engage-A|Participants receive 9 individual in-person or remote therapy sessions. Each session will last approximately 60 minutes. During the sessions, the therapist will encourage the participant to engage in physical and social activities that are pleasurable or rewarding.
32845368|NCT04289298|Experimental|Clinician|Clinicians will be trained in Engage-A and supervised while utilizing the therapy.
32845369|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
32845370|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
32845371|NCT04064814|Active Comparator|Flunarizine|flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
32845372|NCT04064814|Experimental|Alpha Lipoic Acid|Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks
32845373|NCT03969043|Experimental|Young volunteers|"Volunteers between 18 ans 45 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
32845374|NCT03969043|Experimental|Older Volunteers|"Volunteers between 60 ans 85 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
32845375|NCT04039932|Experimental|Intervention|
32845376|NCT04039932|No Intervention|Standard of Care|
32845377|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
32958204|NCT04902066|Experimental|Cognitive Behavioural Virtual Reality Therapy (CBT-VR)|The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.
32958205|NCT04902066|Active Comparator|Traditional Cognitive Behavioural Therapy|The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.
32958206|NCT04831320|Experimental|nab-Paclitaxel + Nivolumab|"nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.~Nivolumab 480 mg IV Day 1 of each 28-day cycle."
32958207|NCT04614558|Experimental|Isatuximab for MGRS|Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.
32958208|NCT04597086|Experimental|Group I (BWLT, best practice)|Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
32958209|NCT04597086|Active Comparator|Group II (standard of care)|Patients receive standard of care during hospital stay.
32958210|NCT04578678||Apathy Group|Patients diagnosed with apathy
32958211|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
32958212|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
32958213|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
32958214|NCT04506762|No Intervention|Control|Standard of care for peri operative analgesia
32958215|NCT04506762|Experimental|Intervention|Bilateral ESP catheters for peri operative regional analgesia
32958216|NCT04505358|Experimental|30 mg PU AD 3:2 ratio|will be administered orally, as 30 mg active dose strength tablets qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
32958217|NCT04505358|Placebo Comparator|30 mg Placebo 3:2 ratio|will be administered orally, as 30 mg placebo tablets (placebo has no active ingredients) qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
32958218|NCT04133142|No Intervention|Medical treatment|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
32958219|NCT04133142|Experimental|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
32958220|NCT04133142|Experimental|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery.
32958221|NCT04133142|Experimental|Late block single|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
33033397|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
33406073|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
33406074|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
33406075|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
32845378|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
33406076|NCT04360980|Active Comparator|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
33406077|NCT04360980|No Intervention|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
32845379|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
32845380|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
33406078|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
32845381|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
32845382|NCT04033614|Experimental|Patients with Laparostoma|"Patients needing a laparostoma will be treated with the fasciotens abdomen device. The distance between the fasciae will be measured frequently using a ruler.~12 months after the treatment an ultrasound measurement will be performed to assess hernia formation"
32845383|NCT04197817|Active Comparator|JS002|JS002, Subcutaneous or intravenous injection
32845384|NCT04197817|Placebo Comparator|Placebo,|Placebo,Subcutaneous or intravenous injection
32845385|NCT05375682|Experimental|Integrated care program|ICP intervention consists of several core intervention components.
32845386|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
32845387|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
32845388|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
32845389|NCT04615338||Homicidal group|The group of patients presented with homicidal open neck injuries
32845390|NCT04615338||Suicidal group|The group of patients presented with suicidal open neck injuries
32845391|NCT04615338||Accidental group|The group of patients presented with accidental open neck injuries
32845392|NCT04197661|Active Comparator|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
32845393|NCT04197661|Active Comparator|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
32845394|NCT04197661|Active Comparator|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
32845395|NCT04197661|Active Comparator|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
32845396|NCT04065984|Experimental|Neuro-Muscular electrical stimulation treatment arm|Active muscle stimulation with a view that this will lead to muscle preservation through muscle fibre recruitment
32845397|NCT04065984|Sham Comparator|Neuro-Muscular electrical stimulation Placebo arm|Stimulator set at a sub therapeutic threshold so as to not recruit muscle fibres
32845398|NCT04197895|Experimental|test group|Socket preservation with APRF
32845399|NCT04197895|Active Comparator|control group|natural healing
32845400|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
32845401|NCT03785574|Active Comparator|A:chemotherapy immediately|Treated with chemotherapy immediately. First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
32845402|NCT03785574|Experimental|B:follow up|"B1: follow up until hCG level met FIGO diagnostic criteria of GTN, then chemotherapy.~B2: follow up until hCG level declined to normal spontaneously."
32845403|NCT04197427|Experimental|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
32845404|NCT04197427|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
32845405|NCT04585854|Other|Control|Control population who will undergo two cardiovascular magnetic resonance exams: one at rest and one after drinking caffeine.
32845406|NCT04562220|Experimental|Vibration Group|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
32845407|NCT04562220|Active Comparator|Control Group|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions.
32845408|NCT04471038|Experimental|Cohort 1|1 mg/mL SAB-176 in normal (0.9%) Saline; concentration 1 mg/mL (0.1%)
32845409|NCT04471038|Experimental|Cohort 2|10 mg/kgSAB-176 in normal (0.9%) Saline; concentration 4 mg/mL (0.4%)
32845410|NCT04471038|Experimental|Cohort 3|25 mg/kgSAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
32845411|NCT04471038|Experimental|Cohort 4|50 mg/kg SAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
32845412|NCT04471038|Placebo Comparator|Cohort 5|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
32845413|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
32845414|NCT03481842|Experimental|Vaginal Suppositories|"Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA~The composition of the suppository:~Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose~Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose~Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose"
32845415|NCT04197739|Experimental|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
32845416|NCT04197739|Active Comparator|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
32845417|NCT04197505|Experimental|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
32845418|NCT04197349|Experimental|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
32845419|NCT04197349|Experimental|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
32845420|NCT04197349|Experimental|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
32845421|NCT05371626|Other|Suture-less entropion technique|suture-less technique for cicatricial entropion
32845422|NCT03982225|Experimental|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32845423|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32845424|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32845425|NCT03982225|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32845426|NCT04429854|Experimental|Convalescent Plasma|"4 units of convalescent plasma:~2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~2 units of plasma should be administered between 24h and 36h after the first infusion"
32845427|NCT04429854|Other|Standard of Care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
32845428|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
32845429|NCT03422094|Experimental|Cohort A: NeoVax+Nivolumab (start at time of progression)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression"
32845430|NCT03422094|Experimental|Cohort B: NeoVax+Nivolumab (start with Cycle 2)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)"
32845431|NCT03422094|Experimental|Cohort C: NeoVax + Nivolumab (start with Cycle 1)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)"
32845432|NCT03422094|Experimental|Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle"
32845433|NCT03422094|Experimental|Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 …)~Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1"
32845434|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
32845435|NCT05351424|Experimental|Audiovisual Intervention- Radiation Therapy Education|Audiovisual video will be provided to the subjects as educational material.
32845436|NCT05351424|Active Comparator|Written Brochure- Radiation Therapy Education|Written brochures will be provided to the subjects as educational material.
32845437|NCT05351424|Experimental|Audiovisual Intervention- Cancer Clinical Trials|Audiovisual video will be provided to the subjects as educational material.
32845438|NCT05351424|Active Comparator|Written Brochure- Cancer Clinical Trials|Written brochures will be provided to the subjects as educational material.
32845439|NCT03973489|Experimental|Wild Type (WT) MUD Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
32845440|NCT03973489|Experimental|Common Variant (CV) MUD Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
32845441|NCT03973489|Experimental|Wild Type (WT) Healthy Control Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
32845442|NCT03973489|Experimental|Common Variant (CV) Healthy Control Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
32845443|NCT03225378||Acute circulatory failure|Mechanically ventilated patients displaying acute circulatory failure in whom the physician decides to perform a fluid challenge (fluid loading of 500 mL of crystalloid solution) and a passive leg raising test to predict fluid responsiveness.
32845444|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
32845445|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
32845446|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
32845447|NCT04356534|Active Comparator|Control group|local standard of care which include antivirals and supportive care
32845448|NCT04356534|Experimental|Intervention group|convalescent patient plasma 400ml given as 200ml over 2 hours in 2 consecutive days, plus routine local standard of care
32845449|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
32845450|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
32845451|NCT05338866||Cohort 1. Cohort 2|"A total of 6 courses of oxaliplatin plus capecitabine chemotherapy and 2 courses of capecitabine single drug chemotherapy were performed. Concurrent chemoradiotherapy starts at the second cycle.~Cohort 1: For patients with low rectal cancer who refused surgery before the initial diagnosis and treatment, the first stage of radiotherapy used conventional linear accelerated radiotherapy, with doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. Subsequently, the second stage of radiotherapy boost was continued with MR linear accelerator, and the dose was GTV 16~20Gy/8~10f for 2 weeks.~Cohort 2: For locally advanced low rectal cancer patients who did not achieve clinical complete remission 6-8 weeks after neoadjuvant radiochemotherapy and refused surgery, radiotherapy was given in the first stage at the doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. In the second stage, MR linear accelerator was used for radiotherapy boosting, and the dose was GTV 30Gy/15f for 3 weeks."
32845452|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
32845453|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
32845454|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
32845455|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
32845456|NCT03591211|Experimental|Qigong Training|
32845457|NCT03591211|Active Comparator|Cognitive Training|
32845458|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
32845459|NCT03596359|Active Comparator|Control group|The control group received routine treatment
32845460|NCT02696382|Active Comparator|Usual Care (UC)|"Participants in the Usual Care (UC) group will receive standard, low-intensity physical therapy following discharge from acute hospitalization."
32845461|NCT02696382|Experimental|Progressive High Intensity Therapy|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization."
32845462|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
32845463|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
32845464|NCT02471118|Experimental|1st 50 subjects to Enter the Study|"At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study.~At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications."
32845465|NCT02471118|Experimental|2nd group of 50 subjects|At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.
32845466|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
32845467|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
32845468|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
32845469|NCT04197115|No Intervention|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
32845470|NCT04197115|Active Comparator|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
32845471|NCT02579850|Experimental|CHF 5993 + Ultibro matched placebo|"Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire"
32845472|NCT02579850|Active Comparator|Ultibro + CHF 5993 matched placebo|"Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire"
33406079|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
32845473|NCT04196881|Experimental|Training|group will receive training about ADHD
32845474|NCT04196881|No Intervention|Control|group will not receive training about ADHD
33406080|NCT03647072|Active Comparator|CHOP|CHOP only
33406081|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
33406082|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
33406083|NCT05284136|Experimental|Crohn's disease exclusion diet (CDED)|16-week course of Crohn's disease exclusion diet (CDED) and Partial Enteral Nutrition.
32845475|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
32845476|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
32845477|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
32845478|NCT04126200|Experimental|Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)|
32845479|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)|
32845480|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
32845481|NCT04126200|Experimental|Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)|
32845482|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)|
32845483|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)|
32845484|NCT04126200|Active Comparator|Belantamab mafodotin monotherapy cohort expansion|
32845485|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
32845486|NCT04126200|Experimental|Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)|
32845487|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)|
32845488|NCT04126200|Experimental|Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)|
32845489|NCT04126200|Experimental|Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)|
32845490|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)|
32845491|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)|
32845492|NCT04196725|Experimental|Physical therapy treatment|
32845493|NCT04196725|Experimental|Lifestyle treatment|
32845494|NCT04196725|No Intervention|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
32845495|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
32845496|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
32845497|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
32845498|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
32845499|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
32845500|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
32845501|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
32845502|NCT02467452|Experimental|BDP/FF/GB|Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
33033398|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
33406084|NCT05284136|Active Comparator|Steroids|oral prednisolone at an initial dose of 40 to 60 mg/day.
33406085|NCT03875690|Experimental|Experimental group|
33406086|NCT03875690|Placebo Comparator|Control group|
32738865|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the cube to the patient.~The nurse leaves the patient alone with the cube.~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the cube."
32738866|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
32738867|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
32738868|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
32738869|NCT02489513|Other|Single group assignment|[14C]-AG-120
32738870|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
32738871|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
32738872|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
32738873|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
32738874|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
32738875|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
32738876|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
32738877|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
32738878|NCT03321227|Experimental|Snack skipping|No snack provided
32738879|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
32738880|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
32738881|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
32738882|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
32738883|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
32738884|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
32738885|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
32738886|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
32738887|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
32738888|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
32738889|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
32738890|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
32738891|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
32738892|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
32738893|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
32738894|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
32738895|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
32738896|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
32738897|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
32738898|NCT03204253|Active Comparator|rFSH alone|control group
32738899|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
32738900|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
32738901|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
32845503|NCT02467452|Active Comparator|FlF/VI + Tiotropium|FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
32845504|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
33406087|NCT03646916|Active Comparator|Dexamethasone|
33406088|NCT03646916|No Intervention|Non-treatment|
33406089|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Participants will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
32845505|NCT05375526|Experimental|Primary staging laparotomy for suspicion of early stage EOC|In case of a primary staging laparotomy the diagnosis of malignancy is based on a frozen section of the resected adnexa, followed by the sentinel node technique during the same procedure.
32845506|NCT05375526|Experimental|Secondary staging laparotomy for EOC|On the other hand, in some cases early stage EOC is only diagnosed after the primary surgery, when the surgeon resects the ovary with the suspicion of benign disease. If the adnexa are already removed before the diagnosis of malignancy, a secondary staging laparotomy is required and, in this case, a single step approach for SLN is not feasible.
32845507|NCT03981055|Experimental|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
32845508|NCT03981055|Sham Comparator|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
32845509|NCT05375448|Experimental|Intervention|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
32845510|NCT03945565|Active Comparator|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
32845511|NCT03945565|Active Comparator|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
32845512|NCT05102682|Experimental|Balance rehabilitation exercise|Balance rehabilitation exercise program using exoskeleton device
32845513|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
32845514|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
32845515|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
32845516|NCT05102604|Active Comparator|Avocado|one avocado per day
32845517|NCT05102604|Placebo Comparator|Habitual Diet|maintain habitual diet
32845518|NCT03980665|Experimental|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
32845519|NCT03980665|No Intervention|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
32845520|NCT05102526|Experimental|"Young Millie prevention program, active teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and physical self-esteem. Teachers will also participate by delivering planned activities to their students in addition to each week's theme, in parallel with an externally delivered program. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
32845521|NCT05102526|Active Comparator|"Young Mili prevention program, passive teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and body image. Teachers will not participate in the program, they will be present in class only during the program on transfer abroad. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
32845522|NCT03971461|Experimental|Lutathera|
32845523|NCT04438122|Active Comparator|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
32845524|NCT04438122|Active Comparator|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
32845525|NCT04438122|No Intervention|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
32845526|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
32845527|NCT03883542||serous BOT|simple serous BOT ovarian tissue
32845528|NCT03883542||serous BOT with non-invasive implants|BOT ovarian tissue presenting with non-invasive implants
32845529|NCT03883542||sBOT with micropapillary grow pattern|BOT ovarian tissue presenting with micropapillary grow pattern
32845530|NCT03883542||serous BOT with invasive implants|sBOT ovarian tissue presenting with invasive implants at the time of diagnosis
32845531|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
32845532|NCT05102448|Experimental|Tofacitinib|Partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
32845533|NCT05102448|Active Comparator|Methotrexate|Participates would be given tablets of methotrexate (2.5mg per tablet) 15mg each week, the treatment duration will last 12 months during the whole follow-up period.
32845534|NCT03855696|Experimental|MG1113|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection."
32845535|NCT03855696|Placebo Comparator|Placebo of MG1113|"Placebo of MG1113~Each vial contains 1mL of study drug"
32845536|NCT04196179|Experimental|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral"
32845537|NCT04196179|Experimental|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
32845538|NCT03818880|Experimental|Treatment|Subjects wearing novel spectacle lenses will be assessed
32845539|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
32845540|NCT05098158|Experimental|Single arm pain treatment|Arm includes usual pain care plus the chosen two telehealth interventions x 6 weeks
32845541|NCT04195711||blinq screened|Patients screened by new birefringent screener
32845542|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
32845543|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
33406090|NCT03446573|Active Comparator|TAF based regimen (TBR)|Participants will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible participants will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
32845544|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
32845545|NCT04195867|Experimental|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
32845546|NCT05102058||Conventional group (GC)|Not receive perioperative additional medication.
32845547|NCT05102058||Magnesium-dexmedetomidine therapy group (GMD)|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.
32845548|NCT04195165|Experimental|SIT|Subject will be asked to take <3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
32845549|NCT04195165|Experimental|SIT+EX|Subject will be asked to take <3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
32845550|NCT04195165|Experimental|ACTIVE+EX|Subject will be asked to take >10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
32845551|NCT05097690||Case|Case (Fatal Suicide)
32845552|NCT05097690||Control|Control (Non-Fatal Suicidal Behavior)
32845553|NCT03956797|Experimental|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
32845554|NCT03956797|Experimental|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
32845555|NCT04534296|Experimental|Early Mobilization Group (EM group)|Early mobilization will be performed in this arm. Critically ill children will be assessed for appropriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the children's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
32845556|NCT04534296|Active Comparator|Routine Care Group (RC group)|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
32845557|NCT05327166|No Intervention|Usual Care|Participants assigned to this arm will receive usual care.
32845558|NCT05327166|Experimental|ED-LINC Intervention|Patients assigned to the ED-LINC intervention will receive 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
32845559|NCT05101512|Experimental|Patient with critical ischemia of the lower limb|Patient eligible and scheduled for bypass in venous allograft stored at + 4 ° C with distal anastomosis below the knee
32845560|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
32845561|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
32845562|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
32845563|NCT04192123|Experimental|Experimental|"All patients will receive an occlusive patch per test treatment as follows:~Treatment 1: HM242-Solution~Treatment 2: HM242-Gel~Treatment 3: HM242-Solution and HM242-Gel~Treatment 4: Irritant control (sodium lauryl sulfate (SLS))~Treatment 5: Negative control"
32845564|NCT04195243|Experimental|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
32845565|NCT04195243|Experimental|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
32845566|NCT04195243|Placebo Comparator|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
32845567|NCT04195321|Active Comparator|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
32845568|NCT04195321|Active Comparator|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
32845569|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
33406091|NCT04305756|Experimental|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
33406092|NCT04305756|Active Comparator|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.~For BMI <40: 40mg injected subcutaneously every 24 hours~For BMI > or = to 40: 40mg injected subcutaneously every 12 hours"
32845570|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
32845571|NCT04194931|Experimental|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
33406093|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
33406094|NCT02898662|Placebo Comparator|Placebo|Matching placebo
33406095|NCT04437810|Experimental|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
33406096|NCT04437810|Placebo Comparator|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
33406097|NCT04368156|No Intervention|Control|
32845572|NCT04023643|Experimental|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
32845573|NCT04023643|Active Comparator|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
32845574|NCT03965845|Experimental|Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg|
32845575|NCT03965845|Experimental|Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg|
32845576|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg|
32845577|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg|
32845578|NCT03965845|Experimental|Part 2: Expansion|The recommended phase 2 dose (RP2D) determined from Part 1 will be the treatment for all cohorts in expansion Part 2.
32845579|NCT03594955|Experimental|SAR440234|SAR440234 was administered as intravenous infusion once weekly for 6 weeks per Cycle. Per plan, participants were to receive first 2 to 3 doses as Lead-in doses followed by a fixed dose until the end of treatment or unless the dose needs to be decreased for safety reasons. Due to early study termination, all participants received only 1 treatment cycle at a dose of 1 nanogram per kilogram (ng/kg) once weekly.
32845580|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
32845581|NCT04194697|Experimental|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
32845582|NCT04194697|Other|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
32845583|NCT04766359|Experimental|Albumin-Bound paclitaxel combined with radiotherapy|"Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
32845584|NCT04766359|Experimental|Cisplatin combined with radiotherapy|"Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
32845585|NCT04027621|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
32845586|NCT04027621|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
32845587|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
32845588|NCT03954145|Active Comparator|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
32845589|NCT03954145|Experimental|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
32845590|NCT04194463|Experimental|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
32845591|NCT04190953|Experimental|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
32845592|NCT04190953|Experimental|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
32845593|NCT04190953|No Intervention|Control|Patients will wait 1,5 years before the start of treatment
32845594|NCT04193605|Active Comparator|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
32845595|NCT04193605|No Intervention|Standard of Care|The control condition will continue receiving usual care or standard of care.
32845596|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
32845597|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
32845598|NCT04020601|Active Comparator|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
32845599|NCT04020601|Sham Comparator|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
32845600|NCT04198597|Experimental|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
32845601|NCT04198597|Experimental|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
32845602|NCT04198597|Experimental|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
32845603|NCT04198597|Experimental|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
32845604|NCT04029805|Experimental|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
32845605|NCT04029805|Placebo Comparator|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
32845606|NCT04193995|Experimental|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
32845607|NCT04193761|Active Comparator|Control|
32845608|NCT04193761|Active Comparator|Chronic hepatitis|
32845609|NCT04193761|Active Comparator|Cirrhosis|
32845610|NCT04193761|Active Comparator|Hepatocellular carcinoma|
32845611|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
32845612|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
32845613|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
32845614|NCT04196959|Experimental|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
32845615|NCT04194073|Experimental|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
32845616|NCT03369444|Experimental|FLT180a, 6x10e^11 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 6x10e^11 vg/kg
32845617|NCT03369444|Experimental|FLT180a, 2 x 10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 2 x 10e^12 vg/kg
32845618|NCT03369444|Experimental|FLT180a, 1x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1 x 10e^12 vg/kg
32845619|NCT03369444|Experimental|FLT180a, 1.3x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1.3 x 10e^12 vg/kg
32845620|NCT04029727|Experimental|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
32845621|NCT04029727|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
32845622|NCT04193683|Sham Comparator|Sham-Ultrasound|Intervention will include one session sham-ultrasound application to both lower extremities of participant. The total time will be 15 minutes.
32845623|NCT04193683|Experimental|Myofascial Release Technique+Sham-Ultrasound|In addition to one session sham-ultrasound, the intervention will include one session myofascial release technique to both lower extremities of participant. The total time will be 30 minutes.
32958222|NCT04133142|Experimental|late block repeated|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery."
32958223|NCT03956082|Other|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
32958224|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
32958225|NCT03789864||single-arm, non-randomized Biodynamic imaging (BDI)|Single-arm, non-randomized, Biodynamic phenotypic profiling of cancer (specifically, mycosis fungoides) therapy, gemcitabine . Standard of Care treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.
32958227|NCT03552978|Experimental|Tech-facilitated IC intervention|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will then receive 8 counseling sessions (video or telephone). The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min. Participants will be asked to use the Stay Quit Coach (SQC) app between sessions, and the iCO® Smokerlyzer®
32958228|NCT03552978|Active Comparator|VA Quitline|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will also receive weekly proactive telephone sessions through the VA Quitline, a standard of care, proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor.
32958229|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
32958230|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
32958231|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
32958232|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
32958233|NCT03063450|Experimental|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
32958234|NCT03063450|Placebo Comparator|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
33033399|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
33033400|NCT01962584||SAM|patients with suspected acute myocarditis
33033401|NCT01962584||HC|Healthy controls
33406098|NCT04368156|Experimental|Gammacore treatment|
33406099|NCT05283980|Experimental|Bupivacaine Group|Receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block
32845624|NCT04029571|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
32845625|NCT04029571|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
32845626|NCT04029571|No Intervention|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
32845627|NCT01677624|Experimental|E7040|
32845628|NCT03964051|Experimental|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
32845629|NCT03318666|Active Comparator|Enhanced Usual Care (EUC)|Both arms will receive this intervention
32845630|NCT03318666|Experimental|Supporting Our Valued Adolescents (SOVA)|This arm will receive the SOVA intervention in addition to Enhanced Usual Care
32845631|NCT03913039||transperineal protocol|"Transperineal biopsy approach with avoidance of rectal flora~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~Multi-antibiotic prophylaxis~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
32845632|NCT03913039||Traditional biopsy|"Transrectal approach~Standard 12-core template~Surgeon-specific antibiotic prophylaxis~Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
32845633|NCT05097378|Experimental|EncoBini Arm|Oral encorafenib 450mg once daily and oral binimetinib 45mg twice daily for 8 weeks pre-operative and for up to 44 weeks post-operative.
33406100|NCT05283980|Placebo Comparator|Control group|Receive up to 25 ml of normal 0.9% sodium chloride for the Pecs block
33406101|NCT04354272||Questionnaire|
33406102|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
32845634|NCT05097378|Active Comparator|Standard Arm|Immediate surgery followed by Investigator's choice of standard adjuvant therapy to commence within 12 weeks of surgery and to continue for up to 52 weeks.
32845635|NCT04193293|Experimental|Duvelisib BID + Pembrolizumab q3w|"Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)~Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles."
32845636|NCT05097300|Experimental|Manual therapy and vagus nerve stimulation group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle). Vagus nerve stimulation will be performed through a diaphragmatic breathing exercise, during 5 minutes, adding neural tension of median nerve.
32845637|NCT05097300|Active Comparator|Manual therapy group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle).
32845638|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
32845639|NCT05085600|Active Comparator|Exercise Group|20-minute session, composed of 2 blocks of 10 repetitions, holding each exercise for 10 seconds, a 40-second rest between each repetition and 2 minutes between blocks.
32845640|NCT05085600|Experimental|Exercise + Manual Therapy Group|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
32845641|NCT04199845|Experimental|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10^10 CFU of Lactobacillus plantarum PS128.
32845642|NCT04199845|Placebo Comparator|placebo|Placebo containing starch will be given twice daily for 8 weeks.
32845643|NCT05084664|Experimental|group A|premodulated current
32845644|NCT05084664|Experimental|group B|diadynamic current
32845645|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC>200 pg/ml，plasma renin concentration(PRC)<2.5μIU/ml，with hypokalemia
32845646|NCT04193137||non Primary Aldosteronism|ARR<10 pg/μIU or ARR>10 pg/μIU and PAC post FST<60pg/ml
32845647|NCT05060484|Active Comparator|Healthy Women Aged 18 to 26 Years|1200 healthy women aged18 to 26 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil®9 : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
33033402|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
32845648|NCT05060484|Active Comparator|Healthy Women Aged 27 to 45 Years|600 healthy women aged 27 to 45 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil® : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
32845649|NCT04193059|Active Comparator|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+ cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle)
32845650|NCT04193059|Experimental|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
32845651|NCT04193059|Active Comparator|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
32845652|NCT04193059|Experimental|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
32845653|NCT05289882|Experimental|PASS Program Condition|Participants in this condition will take part in weekly physical activity, augmented with built-in opportunities to socially connect, and be directed to veteran-specific support services and resources.
32845654|NCT05289882|No Intervention|Waitlist Control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 6-month assessment period (following randomization). They will be asked to complete the same measures (and will be remunerated in the same way as those in the PASS program condition, based on the completion of study measures). At the end of the 6-month trial, participants in this condition will have the opportunity to participate in the PASS program.
32845655|NCT04199611|Experimental|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
32845656|NCT04199611|Active Comparator|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
32845657|NCT04199611|Active Comparator|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
32845658|NCT04199611|No Intervention|Self-help Group|This group do not receive any interventions and do self-help care.
32845659|NCT03962647|Experimental|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
32845660|NCT03962647|Active Comparator|Letrozole Control|
32845661|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
32845662|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
32845663|NCT00624234|No Intervention|Typically Developing Readers|Control group
32845664|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
32845665|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
32845666|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
32845667|NCT04028791|Experimental|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
32845668|NCT04438200||Adolescents|Individuals aged 10-19 years
32845669|NCT04438200||Young Adults|Individuals aged 20-39 years
32845670|NCT04438200||Elderly Adults|Individuals aged 40+ years
32845671|NCT04199923|Experimental|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
32845672|NCT04199923|Experimental|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
32845673|NCT04199923|Experimental|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
32845674|NCT05286996|Experimental|Iovera|Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
32845675|NCT05286996|Placebo Comparator|Placebo|Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
32845676|NCT04029103|Active Comparator|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
32845677|NCT04029103|Experimental|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
32845678|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
32845679|NCT04028635|Experimental|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
32845680|NCT04028635|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
32845681|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
32845682|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
32845683|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
32845684|NCT03131466|Experimental|PRF Group|This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
32845685|NCT03131466|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment with steroid and local anesthesia.
32845686|NCT03078972||Advanced Heart Failure|40 patients with advanced heart failure scheduled to undergo Left Ventricular Assist Device (LVAD) insertion will be recruited for testing. Test subjects will complete testing prior to, and following LVAD implantation.
32845687|NCT03078972||Healthy controls|10 age-matched healthy individuals will be recruited to establish normal/reference values.
32845688|NCT03078972||Mild Heart Failure|A second control group comprised of 10 age-matched individuals will be recruited to establish normal/reference values for individuals with mild, medically managed heart failure.
32845689|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|The treatment group will receive monitoring and prophylaxis of delirium. The study arm designed to prevent delirium incorporates reorientation (watches, calendar, family photos, use of hearing aids, glasses and dentures, cognitive stimulation (newspaper, magazines, radio, television), early mobilisation, early enteral nutrition, early removal of drains or catheters, normalizing sleep-awake-rhythm.
32845690|NCT03060174|No Intervention|Standard|The standard group will receive standard monitoring and standard treatment. The indication, choice and dosage of the medication used to treat delirium will be at the discretion of the ward doctor and will not be influenced by this study. The chosen medication as well as its dosage will be documented.
32845691|NCT04192513|Active Comparator|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
32845692|NCT04192513|Active Comparator|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
32845693|NCT04192513|Active Comparator|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
32845694|NCT05091684|Experimental|Fibrinogen|Patients with refractory thrombocytopenia, following intensive chemotherapy, and presenting grade ≥ 2 hemorrhagic symptoms, will receive adjuvant fibrinogen administration and platelet transfusions.
32845695|NCT04192279||lactate group|Lactate early guide resuscitation
32845696|NCT04192279||control group|early guide resuscitation without lactate
32845697|NCT05066880|Experimental|Yoga|Participants allocated to the yoga group will receive the yoga-based intervention through an internet-based video conference remotely in real-time. Each class will accommodate a maximum of 5 subjects. A qualified physiotherapist who was a certificated yoga instructor will teach in these classrooms. The 8-week exercise intervention consists of three times per week sessions of yoga.
32845698|NCT05066880|Experimental|Aerobic exercise|Participants of the aerobic exercise group will be requested to perform unsupervised aerobic training in the home environment (e.g., at home, park, backyard, or in the local gym). The 8-week exercise intervention consists of three times per week sessions of aerobic exercise. Training will consist of a 10-min warm-up period, aerobic activity, and 5-min cool-down period.
32845699|NCT05066880|No Intervention|Wait-list|Participants in the wait-list group will be advised to continue their habitual physical activity next to usual medical care. A yoga or aerobic exercise program of 8 weeks will be offered after the ending of the study period.
32845700|NCT04199377|Experimental|hip or knee replacement|total hip or knee replacement
32845701|NCT04819542|Experimental|drain + compression bandage|
32845702|NCT04819542|Active Comparator|drain without compression bandage|
32845703|NCT04199455|Experimental|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
32845704|NCT04199455|Placebo Comparator|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
32845705|NCT04191343|Experimental|The control group|
32738902|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
32845706|NCT04949100|Experimental|Microcurrent|
32845707|NCT04949100|Placebo Comparator|Placebo|
32845708|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
32845709|NCT04199143|Experimental|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
32845710|NCT04199143|Experimental|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
32845711|NCT04616274||Venetoclax|Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
32845712|NCT04613622||Venetoclax|Adult patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from August 2020 to December 2025.
32845713|NCT04022629|Active Comparator|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
32845714|NCT04022629|Active Comparator|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
32845715|NCT04604340|Active Comparator|transfemoral access|control
32845716|NCT04604340|Active Comparator|transradial access|case
32845717|NCT04027933|Active Comparator|Experimental|Education Based on Standard Patient Simulation was given to this group
32845718|NCT04027933|No Intervention|Control|Control group
32845719|NCT04515186|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate, 20 mg/kg/day for 20 days parenterally
32845720|NCT04515186|Active Comparator|Miltefosine monotherapy|Miltefosine monotherapy 2.5 mg/kg/day for 28 days orally
32845721|NCT04515186|Experimental|Thermotherapy + miltefosine|"Thermotherapy (one session, 50⁰C for 30 applications*) + miltefosine 2.5 mg/kg/day for 21 days orally."
32845722|NCT04021303|Experimental|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
32845723|NCT04021303|Active Comparator|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
32845724|NCT04021225|Active Comparator|Ectoin® Allergy Eye Drops 2%|"20 Patients:~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
32845725|NCT04021225|Active Comparator|Ectoin® Eye Spray Colloidal|"20 Patients:~-Ectoin® Eye Spray Colloidal (bitop AG)"
32845726|NCT04021225|Active Comparator|Tears Again® Eye Spray|"20 Patients:~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
32845727|NCT05097066||Elective neurosurgery|Any elective neurosurgical procedure.
32845728|NCT05097066||Non-elective neurosurgery|Any non-elective neurosurgical procedure.
32845729|NCT04021147|Experimental|Action Observation|
32845730|NCT04021147|Experimental|Motor Imagery|
32845731|NCT04021147|Experimental|Visual mirror feedback|
32845732|NCT04021147|Active Comparator|Orofacial exercise|
32845733|NCT05096910|Active Comparator|Monofilament Suture Group|Monofilament sutures will be used for uterine closure.
32845734|NCT05096910|Active Comparator|Polyfilament Suture Group|Polyfilament sutures will be used for uterine closure.
32845735|NCT04027387|Experimental|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
32845736|NCT04027387|Experimental|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
32845737|NCT04027387|Experimental|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
32845738|NCT05096676|Experimental|Adolescents diagnosed with Autism spectrum disorder|Participants in the ASD group received oxytocin and placebo in a randomized, double-blind placebo-controlled manner.
32845739|NCT05096676|No Intervention|Typically developing adolescents|Control participants were recruited using online ads. This group did not receive oxytocin or placebo due to ethical constraints in Israel.
32845740|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
32845741|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
32845742|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
32845743|NCT04497324|Experimental|Experimental group|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
32845744|NCT04497324|No Intervention|Control group|Standard of care
32845745|NCT03948763|Experimental|V941 Monotherapy|V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
32845746|NCT03948763|Experimental|V941 + Pembrolizumab|V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
32845747|NCT04896840|Experimental|Treatment group|Telerehabilitation and motor learning principles will be applied.
32845748|NCT04896840|Experimental|Control Group|Motor learning principles will be applied in the clinic.
32898776|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
33033403|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
32738903|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
32738904|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
32738905|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
32738906|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
32738907|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
32738908|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
32738909|NCT03321071|Experimental|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
32738910|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
32738911|NCT03321071|No Intervention|Passive control|Children in this condition will not attend a summer program.
32738912|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
32738913|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
32738914|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
32738915|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
32738916|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
32738917|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
32738918|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
32738919|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
32738920|NCT02485769|Placebo Comparator|Placebo|Placebo arm
32738921|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
32738922|NCT03223519|Placebo Comparator|Placebo|
32738923|NCT03223519|Active Comparator|Ibuprofen|
32738924|NCT03223519|Active Comparator|Magnesium|
32738925|NCT03223519|Active Comparator|Vitamin C|
32738926|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
32738927|NCT03320915|No Intervention|Usual care|Usual care
32738928|NCT03220165|Experimental|Treatment|MGL-3196
32738929|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
32738930|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
32738931|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
32738932|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
32738933|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32738934|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
32738935|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
33406103|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
33406104|NCT04315038||All patients|Spinal anesthesia
32845749|NCT05096520|Active Comparator|radiofrequency group|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
32845750|NCT05096520|Active Comparator|control group|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
33406105|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
32845751|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
32845752|NCT05269446||STEMI patients|STEMI: patients diagnosed with ST-segment elevation myocardial infarction
32845753|NCT05269446||SA patients|SA: patients diagnosed with stable angina
32845754|NCT05269446||Healthy subjects|Patients with suspected coronary artery disease, but coronary angiography (CAG) indicates no obvious coronary stenosis
32845755|NCT03948529|Experimental|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
32845756|NCT04856592|Experimental|VICI Stent|
32845757|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
32845758|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
32845759|NCT05096130|No Intervention|Control Group - No intervention|The control group will not participate in any intervention for the duration of the study. In addition, the participants will be instructed to follow their usual daily schedule for 6 months. Changes in health, medication, or habits will be discussed by the investigators' team and reassess the continuation or the termination of the investigated participant.
32845760|NCT05096130|Experimental|Lifestyle Medicine Strategies Groupo|The LSM (LifeStyle Medicine) group, will receive a 6-month lifestyle change intervention targeting the correction of diet, improving physical activity and exercise levels, reducing stress levels, and improving sleep hygiene by LSM registered professionals.
32845761|NCT04020757|Other|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
32845762|NCT05095974||A (main group)|29 Consecutive patients with a singleton pregnancy complicated by severe PE will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
32845763|NCT05095974||B (control group)|29 Consecutive healthy patients with a singleton pregnancy (control group) will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
32845764|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
32845765|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
32845766|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
32845767|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
32845768|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
32898777|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
32845769|NCT04437966|Experimental|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
32845770|NCT04437966|No Intervention|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
32845771|NCT04190407|Other|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
32845772|NCT04605432|Experimental|PEG-FFI prep|"On the day before colonoscopy, an experienced researcher would go to the ward to have a face-to-face conversation with the patient to know if patients have the risk factors for bowel preparation failure.~The bowel preparation regimens for patients with risk factors would be optimized. In addition to drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min, the patient also drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at 20:00- 21:00 hours on the day before the colonoscopy. Patients without risk factors drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.~Patients would received a booklet to explain the details of diet restriction, preparation method and the pictures of bowel preparation of results.The researcher would give a detailed oral explanation of the booklet."
32845773|NCT04605432|Active Comparator|PEG-nonFFI prep|Patients in the PEG-nonFFI group would only receive routine patient education on bowel preparation of colonoscopy, which was completed by ward nurse. all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
33319982|NCT05064410|Experimental|Educational Intervention and Referral for Fecal Immunochemical Test (FIT) Kit or Colonoscopy|The Community Health Educator (CHE) will provide online, phone or in-person colorectal cancer (CRC) early detection, prevention, and screening education to increase knowledge of CRC and the importance of screening. These sessions will be conducted in small in-person sessions, virtually within a group, virtually via a self-paced/self-directed online learning module, or one-on-one via phone. Additionally, the CHE will provide information regarding FIT kit and colonoscopy screening and the screening process for attendees. The CHE and research assistant will be prepared to provide access to screening resources and services through participants' existing coverage. Those participants who do not have a primary care provider will be provided information on obtaining FIT kits through the mechanisms of the Federally Qualified Health Center (FQHC) and/or a colonoscopy through the cancer center on a case by case basis.
33326957|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
33326958|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
32845774|NCT04190173|Experimental|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
32845775|NCT04190173|Placebo Comparator|Placebo|Placebo tablet to mimic Prucalopride made by starch
32845776|NCT04190095|Experimental|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
32845777|NCT04305600||Aim 1|Aim 1 participants will be recruited from participants in the first BRAIN study at VUMC.
32845778|NCT04305600||Aim 2|Aim 2 participants will be recruited from the ICU populations at both VUMC and RUMC.
32845779|NCT04020679|No Intervention|Control arm|Participants will not receive GOCI materials
32845780|NCT04020679|Experimental|Intervention|Participants will receive GOCI materials and clinicians will receive training.
32845781|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
32845782|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
32845783|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
32845784|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
32845785|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
32845786|NCT05230836|Experimental|30 kilohertz|Alternating current stimulation at 30 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
32845787|NCT05230836|Experimental|40 kilohertz|Alternating current stimulation at 40 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
32845788|NCT05230836|Experimental|50 kilohertz|Alternating current stimulation at 50 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
32845789|NCT05230836|Sham Comparator|Sham stimulation|Sham stimulation via transcutaneous, 15 minutes each intervention, following the same procedures as 30, 40 and 50kHz HFAC groups.
32845790|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
32845791|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
32845792|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
32845793|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
33033404|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
32845794|NCT05104164|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
32845795|NCT05104086|Active Comparator|evaluate the value of ultrasound elastography in dignosis of endometriomas|evaluation of endometrioma by ultrasound elastography and will be repeated after 4 weeks
32845796|NCT05104086|Active Comparator|evaluate the value of ultrasound elastography in ovarian hemorrhagic cysts|revaluation of ovarian hemorrhagic cyst by ultrasound elastography and noticing the change of values
32845797|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
32845798|NCT05104008|Active Comparator|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
33319983|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
33103933|NCT04816617|Experimental|Aerobic Exercise|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
33103934|NCT04816617|Placebo Comparator|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
33103935|NCT04543682|Experimental|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
33103936|NCT04543682|Experimental|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
33103937|NCT04543682|Other|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes).
33103938|NCT05603676|Experimental|Hypertensive IHHC|Hypertensive participants who performed IHHC
33326959|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
32845799|NCT05104008|Active Comparator|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors & abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
32845800|NCT04020211||HF10|SCS stimulation with HF10 therapy
32845801|NCT04577820|Experimental|garetosmab|
32845802|NCT04198831|Experimental|acupuncture group|Receiving acupuncture and moxibustion treatment
32845803|NCT04198831|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
32845804|NCT04097600|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
32845805|NCT04097600|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
32845806|NCT04097600|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
32845807|NCT04097600|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
32845808|NCT04097600|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
32845809|NCT04097600|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
32845810|NCT04020367|Other|patients with biopsy|
32845811|NCT04161534|Active Comparator|Arm Sling Group|
32845812|NCT04161534|Experimental|KT Tape Group|
32845813|NCT04096820|Experimental|Open Label|Uromune will be taken by the participant for 90 days.
32845814|NCT04766203|No Intervention|Global screening of high-performance athletes for REDS|This arm collects data with an online survey to assess prevalence and signs and symptoms of REDS in elite female and male elite and recreational athletes and para-athletes over the age of 15 years across the world.
32845815|NCT04766203|No Intervention|Basic screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline blood sample and potentially (where abnormalities are present) a follow-up 6 months later.
32845816|NCT04766203|No Intervention|Advanced screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline test for bone density (DXA scans), resting metabolic rate and exercise testing. Potentially (where abnormalities are present) a follow-up 6 months later.
32845817|NCT04766203|Experimental|Treatment of Canadian athletes with REDS: a holistic intervention arm|In this arm, varsity level to elite Canadian athletes and para-athletes with REDS will participate in a nutritional intervention aiming to improve energy availability and thus, REDS status.
32845818|NCT04409756|Other|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
32845819|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
32845820|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
32845821|NCT04532970|Placebo Comparator|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
32845822|NCT04532970|Experimental|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
32845823|NCT04100408||Ancillary-Correlative (biospecimen collection)|LCH patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal brushing will be sequenced, genotyped, and analyzed.
32845824|NCT01272765|Placebo Comparator|Control Group|
32845825|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
32845826|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
32845827|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
32845828|NCT05103852|Experimental|Patients with right cardiac catheterization|
32845829|NCT04198363|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
32845830|NCT04198363|Active Comparator|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
32845831|NCT05268042|Experimental|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
33033405|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
33033406|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
33033407|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
33326960|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
32738936|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
32738937|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
32738938|NCT03320759|No Intervention|No rehabilitation|
32738939|NCT03320759|Experimental|Rehabilitation|
32738940|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
33103939|NCT05603676|Placebo Comparator|Hypertensive placebo|Hypertensive participants who performed placebo intervention
32738941|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
32738942|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
32738943|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
32738944|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
32738945|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
32738946|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
32738947|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
32738948|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
32738949|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
32738950|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
32738951|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
33326961|NCT01168206|Placebo Comparator|Placebo|
32738952|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
32738953|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
32738954|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
32738955|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
32738956|NCT02485613||bortezominb and dexamethasone group|
32738957|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
32738958|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
32738959|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
32738960|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
32845832|NCT05268042|Active Comparator|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
32845833|NCT04190563|Experimental|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
32845834|NCT04190563|Placebo Comparator|Pain Education|Brief behavioral education on pain.
32845835|NCT05228496|Experimental|Tislelizumab combined with Sitravatinib|
32845836|NCT04020133|Active Comparator|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
32845837|NCT04020133|Active Comparator|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
32845838|NCT04565574|Experimental|Part A: E7090 35 mg (Fasted + Fed + Fed)|Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
32845839|NCT04565574|Experimental|Part A: E7090 35 mg (Fed + Fasted + Fed)|Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
32845840|NCT04565574|Experimental|Part B: E7090 35 mg + Rabeprazole 20 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.
32845841|NCT04565574|Experimental|Part C: E7090 35 mg + Rifampin 600 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.
32845842|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
32845843|NCT01521494|Experimental|PA21 750 mg/day|
32845844|NCT01521494|Experimental|PA21 1500 mg/day|
32845845|NCT01521494|Experimental|PA21 2250 mg/day|
32845846|NCT01521494|Experimental|PA21 3000 mg/day|
32845847|NCT01521494|Placebo Comparator|Placebo|
32845848|NCT04166058|Active Comparator|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
32845849|NCT04166058|Active Comparator|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
32845850|NCT04166058|Active Comparator|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
32845851|NCT04195633|Experimental|Arm A (high dose treosulfan)|Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is > 1,000/uL for 3 consecutive days.
32845852|NCT04195633|Experimental|Arm B (low dose treosulfan)|Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.
32845853|NCT04026919|Experimental|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
32845854|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
32845855|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
32845856|NCT05103774||Group A: children exposed to any type of radiation or contrast|Group A: children exposed to any type of radiation or contrast
32845857|NCT05103774||Group B : children not exposed to an type of radiation or contrast|Group B : children not exposed to an type of radiation or contrast
32845858|NCT04026841|Experimental|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
32845859|NCT04128774||GBM-dexa|Participants with clinical diagnosis of GBM, that require dexamethasone due to neurological deficits. Dose is based on the clinical judgement of the treating physician but should be given at least two weeks. Dexamethasone is given once a day.
32845860|NCT04128774||GBM-control|Participants with clinical diagnosis of GBM not requiring dexamethasone treatment.
33103940|NCT05603676|Active Comparator|Healthy IHHC|Healthy participants who performed IHHC
33326962|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
33326963|NCT01168362||High risk group|positive cardiovascular risk group
33326964|NCT01168362||Low risk group|negative cardiovascular risk group
33326965|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
33326966|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
32958235|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
32958236|NCT02748018|Experimental|Hybrid Closed Loop Arm|The HCL Arm will use the MiniMed System (i.e., using Auto Mode) for 6 months during the study period.
32958237|NCT02748018|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump). Each cohort (CSII, MDI, or SAP) will be used as the control arm to be compared to the experimental arm (HCL).
32958238|NCT02186418|Experimental|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
32958239|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
32958240|NCT02173080||ADPKD group without PLD|will receive PLD-Q
32958241|NCT02173080||Healthy controls|receive PLD-Q
32958242|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
32958243|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
32958244|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
32958245|NCT01354002||Protocol Participants|All participants enrolled on protocols
32958246|NCT01326000|Experimental|KRAS WT A|
32958247|NCT01326000|Active Comparator|KRAS WT B|
32958248|NCT01326000|Experimental|KRAS mutant A|
32958249|NCT01326000|Active Comparator|KRAS mutant B|
32958250|NCT00807456|Experimental|Subjects treated with ASTRA TECH Implant System, OsseoSpeed™ Profile implant|
32958251|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
32958252|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
32958253|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
32958254|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
32958255|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
32958256|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
32958257|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
32958258|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
32958259|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
32958260|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
32958261|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
32958262|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
32958263|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
32958264|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
32958265|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
32958266|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
32958267|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
32958268|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
32958269|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
32958270|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
32958271|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
32958272|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
32958273|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
32958274|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
32958275|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
32958276|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
32958277|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
32958278|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
32958279|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
32958280|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
32958281|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
32958282|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
32958283|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
33103941|NCT05603676|Sham Comparator|Healthy Placebo|Healthy participants who performed placebo intervention
32845861|NCT04027855|Other|collection of PBMC from healthy donors|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
32845862|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
32845863|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
32845864|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
32845865|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
32845866|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
32845867|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
33319984|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
33319985|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
32958284|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
32958285|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
33319986|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
33319987|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
33319988|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
33319989|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
33319990|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
33319991|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
33319992|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
33319993|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
33319994|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
33319995|NCT01305668||Emphysema phenotype|
33319996|NCT01305668||No-Emphysema phenotype|
33319997|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
33319998|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
33319999|NCT03716024|Experimental|PTK 0796|
33320000|NCT03716024|Active Comparator|Linezolid|
33320001|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
33320002|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
32845870|NCT05252208|Experimental|Stretching|Stretching
33103942|NCT04526639|Experimental|Virtual Reality games for training executive functions|Virtual Reality games for training three core executive functions
32845871|NCT05252208|Experimental|Walking|Walking
32845872|NCT04194775|Experimental|Nofazinlimab (CS1003)|
32845873|NCT04194775|Placebo Comparator|Nofazinlimab (CS1003) placebo|
32845874|NCT05103462|Experimental|Telehealth Physical Therapy|Weekly sessions of education, advice and exercise instruction provided by a licensed physical therapist using real-time, interactive video conferencing platform.
32845875|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
32845876|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
32845877|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
32845878|NCT04026763|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
32845879|NCT04026685|Active Comparator|Phenylephrine infusion only|Phenylephrine infusion only
32845880|NCT04026685|Active Comparator|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
32845881|NCT04024033|Active Comparator|capsule|patinets receiveing pine cone extract tablets
32845882|NCT04024033|Placebo Comparator|placebo capsule|patinets receiving placebo
32845883|NCT04026061|Experimental|FMA group|Receiving the FMA training and tool
32845884|NCT04026061|Placebo Comparator|control group|Receiving a simple tablet training and some websites
32845885|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
32845886|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
32845887|NCT03952351|Experimental|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
32845888|NCT03952351|No Intervention|Standard care|
32845889|NCT04766281|Active Comparator|MLC901 (NeuroAiD II)|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
32845890|NCT04766281|Placebo Comparator|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
32845891|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
32845892|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
32845893|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
32845894|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
32845895|NCT04190485|Experimental|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
32845896|NCT04190485|Experimental|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
32845897|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
32845898|NCT01278693|Other|L-carnitine|it is kind of supplement
32845899|NCT04193527|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ (123I) ioflupane. Single photon emission computed tomography (SPECT) imaging will be performed between 3 to 6 hours post-injection and will last approximately 20 minutes to 1 hour.
32845900|NCT03957577||All participants|Participants with COPD or Asthma-COPD overlap syndrome (ACOS)
32845901|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
32845902|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
32845903|NCT04147273|Other|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
32845904|NCT04022161|Placebo Comparator|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
32845905|NCT04022161|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
32845906|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
32903134|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
32958286|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
32958287|NCT03033888|No Intervention|Control Group|
32958288|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
32958289|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
32958290|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
32958291|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
32958292|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
32958293|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
32958294|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
32958295|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
32958296|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
32958297|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
32958298|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
32958299|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
32958300|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
32958301|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
32958302|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
32958303|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
32958304|NCT03032796|Experimental|BBT|Body-Brain Trainer
32958305|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
32958306|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
32958307|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
32958308|NCT03032562||1|Patients with neuromuscular disease
32958309|NCT03032562||2|Patients with chronic obstructive pulmonary disease
32958310|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
32958311|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
32958312|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
32958313|NCT03032484|Experimental|Bevacizumab|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
32958314|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
32958315|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
33320003|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
33320004|NCT00250679|Active Comparator|Formoterol 12 ųg 2x/day|
33320005|NCT00250679|Experimental|Arformoterol 15 ųg 2x/day|
33320006|NCT00250679|Experimental|Arformoterol 25 ųg 2x/day|
33320007|NCT05620706|Experimental|Treatment group|GCP3 CAR-T cells
33320008|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
33320009|NCT03791294|No Intervention|Control|No treatment
33320010|NCT01567358|Experimental|NI-071|
33103943|NCT04526639|Placebo Comparator|Control VR Game on Playground|A relaxing virtual reality game for control group to play in VR playground without training their executive functions
32845907|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
33320011|NCT01567358|Active Comparator|Remicade|
32845908|NCT01676220|Experimental|HOE901-U300|
32845909|NCT01676220|Active Comparator|Lantus|
32845910|NCT04027231||Ahlback I|
32845911|NCT04027231||Ahlback II|
32845912|NCT04027231||Ahlback III|
32845913|NCT04027231||1 year following TKA|
32845914|NCT04027231||TKA revision|
32845915|NCT03933631|Experimental|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
32845916|NCT03933631|Active Comparator|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
32845917|NCT01276587|Experimental|Single arm|
32845918|NCT04026997|Experimental|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
32845919|NCT04026997|Placebo Comparator|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
32845920|NCT04026997|Experimental|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
32845921|NCT04026997|Placebo Comparator|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
32845922|NCT04026997|Experimental|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
32845923|NCT04026997|Active Comparator|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
32845924|NCT01275105|Other|Vehicle|
32845925|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
32845926|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
32845927|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
32845928|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
32845929|NCT01273389|Placebo Comparator|Placebo|
32845930|NCT03951337|Experimental|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
32845931|NCT04026139|Experimental|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
32845932|NCT04026139|Active Comparator|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
32845933|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
32845934|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
32845935|NCT04026373|Experimental|modified Prolonged Exposure|
32845936|NCT04026373|Active Comparator|Treatment as usual|
32845937|NCT05102838||Hepatitis B cohort|"Patients with HBsAg and/or HBV DNA positive;~Patients without cirrhosis."
32845938|NCT05102838||Hepatitis C cohort|"Patients with anti-HCV and/or HCV RNA positive;~Patients without cirrhosis."
32845939|NCT05102838||Cirrhosis cohort|"Patients diagnosised with cirrhosis;~Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
32845940|NCT05102838||Liver cancer cohort|"Patients diagnosised with liver cancer;~Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
32845941|NCT04029649|Experimental|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
32845942|NCT04029649|Placebo Comparator|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
32845943|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
32845944|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
32845945|NCT05093556|Experimental|iCHART - Interactive CBT for Headache And Relaxation Training|10 week interactive-voice response technology (IVR) based cognitive behavioral therapy for headache
32845946|NCT03950635|Experimental|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
32845947|NCT03950635|Experimental|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
32845948|NCT03608436|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
32845949|NCT03608436|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
32845950|NCT03947281|Experimental|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
32845951|NCT03947281|Experimental|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
32845952|NCT03486678|Experimental|SHR1210+GEMOX|This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
32845953|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
32845954|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
32845955|NCT04154046|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
32845956|NCT04154046|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
32845957|NCT04025671|Experimental|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
32845958|NCT04025671|Active Comparator|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
32845959|NCT04025671|Active Comparator|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
32845960|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
32845961|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
32845962|NCT03412188|Experimental|group 1 Eltrombopag arm|"Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period."
32845963|NCT03412188|Active Comparator|group 2 conventional Treatment|"Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).~patients will continue on the conventional line of treatment"
32845964|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
32845965|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
32845966|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
32845967|NCT03383016||Men at high-rik of prostate cancer|Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
32845968|NCT03930823|Other|Interview|One to one interviews with older people from Turkish origin in Belgium
32845969|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
32845970|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
32845971|NCT04022395|Experimental|stress cardiac MRI|"To optimize the scan protocol and the sequence parameters~To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients~To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
32845972|NCT05019846|Experimental|SRT+ADT|Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect
32845973|NCT05019846|No Intervention|SRT alone|Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).
32845974|NCT01278849|Experimental|ASA404 + standard therpy|
32845975|NCT04146805|Experimental|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
32845976|NCT04146805|Placebo Comparator|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
32845977|NCT04007094|Experimental|Study Arm|Participants will be entered into the single armed study in which one side of the fusion will be coated with milled local autograft bone and the opposite fusion side will be supplemented with an equal volume of Depuy Synthes ViviGen.
32845978|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
32845979|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
33320012|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
32845980|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
32845981|NCT04020289|Experimental|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
32845982|NCT04020289|Other|treatment as usual (TAU)|Patients received treatment as usual
32958316|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
32845983|NCT04949412||non-severe COVID19|Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types or A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura.
32845984|NCT04949412||Severe Covid19|Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥30 times/minute; ii) hypoxia: oxygen saturation (resting state) ≤93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
32845985|NCT04385355|Other|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
32845986|NCT04385355|Experimental|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
32845987|NCT04023175|Active Comparator|In office|Patients will undergo our standard in office preoperative counseling.
32845988|NCT04023175|Experimental|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
32845989|NCT04914858|Experimental|Education group|Education
32845990|NCT04914858|No Intervention|Control group|No Intervention
32845991|NCT04022473|Experimental|Bafiertam|oral capsules administered twice daily
32845992|NCT04022473|Active Comparator|Tecfidera|oral capsules administered twice daily
32845993|NCT05375058||pandemic group (2020)|includes patients who presented to the hospital during the period of acute restrictions and shutdowns extending from the 17th of March to the 6th of June 2020
32845994|NCT05375058||pre-pandemic group (2019)|which represents the same period in the previous year
32845995|NCT03972696|Active Comparator|BA3S|Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
32845996|NCT03972696|Experimental|BA2|RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
32845997|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
32845998|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
32845999|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
32846000|NCT03845946||Hereditary angioedema type I/II|Hereditary angioedema with C1Inh deficiency
32846001|NCT03845946||Acquired angioedema|Angioedema with acquired C1Inh deficiency
32846002|NCT03845946||Drug induced angioedema|Angioedema associated with ACEi used
32846003|NCT03845946||Mast cell induced angioedema|Spontaneous mast cell induced isolated angioedema
32846004|NCT03845946||Hereditary angioedema with nC1Inh|Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations
32846005|NCT01485614|Experimental|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
32846006|NCT01485614|Placebo Comparator|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
32846007|NCT01485614|Active Comparator|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
32846008|NCT01485614|Placebo Comparator|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
32846009|NCT00722553|Other|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
32846010|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
32846011|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
32846012|NCT04853082|Active Comparator|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company
32846013|NCT04853082|Placebo Comparator|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules
32846014|NCT03928015|Experimental|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
32846015|NCT03928015|Active Comparator|Systemic analgesics|Systemic analgesics only
32846016|NCT03831906|No Intervention|Control|"All children admitted in the hospital and presenting with WHO-defined severe pneumonia will be immediately managed as part of routine care per the WHO Standard of Care (SOC), including broad spectrum antibiotics, oxygen therapy if required, additional supportive care and specific therapies for comorbidities such as HIV infection.~For research purposes, children will benefit from HIV testing, malaria testing, and complete blood count (CBC) if not systematically performed as routine care in the country/hospital, as well as from a digitalized chest X-ray (CXR). Additionally, samples will be collected for future biomarkers studies (biobank)."
32846017|NCT03831906|Experimental|Interventional|Children will benefit from the WHO SOC and additional strategies for research purposes (HIV and malaria testing, CBC, CXR, and biobank) as described in the control arm, plus the study intervention.
33320013|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
32846020|NCT04792164|Experimental|The experimental group will receive US guided nerve block|The experimental group will receive US guided nerve block by lidocaine before open inguinal hernia repair.
32846021|NCT04792164|Other|The control group will receive usual infiltration|The control group will receive usual infiltration by lidocaine before open inguinal hernia repair.
32846022|NCT04386213|Experimental|Paclitaxel Drug-coated Balloon|
32846023|NCT04386213|Active Comparator|SeQuent® Please Paclitaxel Drug-coated Balloon|
32846024|NCT04025437|Experimental|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
32846025|NCT04025437|Active Comparator|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
32846026|NCT03229512|Experimental|Intervention|Topical 1% Sildenafil Cream
32846027|NCT01279083|Experimental|Concentration 1|
32846028|NCT01279083|Experimental|Concentration 2|
32846029|NCT01279083|Experimental|Concentration 3|
32846030|NCT01279083|Experimental|Concentration 4|
32846031|NCT01279083|Placebo Comparator|Vehicle Solution|
32846032|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
32846033|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
32846034|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
32846035|NCT04716114|Experimental|SKLB1028|Subjects will receive 150 mg orally twice daily (BID) in continuous 28-day cycles
32846036|NCT04716114|Active Comparator|Salvage Chemotherapy|"Chemotherapy will be given in 28-day cycles. Subjects on low-dose cytarabine (LoDAC) will receive 10 to 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injections for 7 to 14 days.~Subjects on azacitidine will receive 75 mg/m^2 daily by SC or IV, for 5 to 7 days.~Subjects on homoharringtonine (HHT), cytarabine and aclarubicin (HAA) will receive 2 mg/m^2 of HHT by IV, for 7 days (day 1 to 7) (or HHT 2 mg/m^2, twice daily, day 1 to 3); 100~200 mg/m^2 of cytarabine by IV for 7 days (day 1~7) and 20 mg/d of aclarubicin by IV for 7 days (day 1 to 7).~Subjects on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1000~2000 mg/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 g/m^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until ANC>0.5 x 10^9 / L."
32846037|NCT00752973|Experimental|Treatment arm|MALG treatment
32846038|NCT04025593|Active Comparator|RCHOP|
32846039|NCT04025593|Experimental|RCHOPX|
32846040|NCT05168124|Active Comparator|Acceptance Commitment Therapy for chronic fatigue|ACT for chronic fatigue involves psychoeducation on the clinical picture of CFS/ME and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for generalized anxiety disorders is adapted to the needs of patients with CFS, i.e., the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms (fatigue, powerlessness, unrestful sleep, among others). In addition, value goals and scopes of action are defined, in which the individual stress limits of each participant are identified and taken into account. In addition, it is recommended that the participants move within their respective energy limits under the regular evaluation of activity and rest phases using a diary, as well as regularly apply study-specific interventions between the appointments of group therapy.
32846041|NCT05168124|Active Comparator|Micro breaks in everyday life for chronic fatigue|Micro breaks in everyday life (MBEL) includes restructuring the patients' daily routine in terms of how they organize their breaks. A therapy manual is developed for this purpose, which is divided into three phases. In the first phase, patients learn to allow or integrate regular MB of one to five minutes in their daily routine. Appropriate examples are used to show when and where MB can be incorporated and this is practiced at home over the first few weeks until a routine has been established. Patients are encouraged to keep a break diary. In the second phase, the MBs are filled in with content. MB can be designed differently, e.g., with physical activity of moderate or high intensity, with short breathing or relaxation exercises, with nutrition or even with doing nothing. In the third phase, an individual optimization of the design of breaks in everyday life follows and an expansion towards meaningful mental time-out, a combination of relaxation break and mental activation.
32846042|NCT05168124|No Intervention|Waiting Group|
32846043|NCT04099940|Experimental|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
32846044|NCT04099940|Active Comparator|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
32846045|NCT05374980|Experimental|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
32958317|NCT03031704||Endoscopic mucosectomy|
33406106|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
33406107|NCT04844567|Experimental|COVVR_A|Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
33406108|NCT04844567|Experimental|COVVR_B|Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
33406109|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
33406110|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
33406111|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
33406112|NCT03913130|Experimental|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
33406113|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
33406114|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.~The school staff focus group will include school personnel from the targeted schools."
33406115|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
33406116|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
33406117|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
33406118|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
33406119|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
33406120|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
33406121|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
33406122|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
33406123|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
32738961|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
32738962|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
32846046|NCT05374980|Placebo Comparator|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
32846047|NCT05374980|No Intervention|Healthy volunteer|Patients with Helicobacter pylori negative (ΔUBT<2%) need blood test and collect stool samples at first, and collect stool samples again after 2 months.
32846048|NCT02709967|Active Comparator|Material support|Writing materials
32846049|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
32846050|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
32846051|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
32846052|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
32846053|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
32846054|NCT02976714|Other|CF patients|CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care.
32846055|NCT04146415|Experimental|Cardiac amyloidosis patients|
32846056|NCT00736125|Active Comparator|1|
32846057|NCT00736125|Active Comparator|2|
32846058|NCT02957292|Experimental|Levonorgestrel IUD|13,5 mg Levonorgestrel intrauterine device
32846059|NCT02957292|Active Comparator|Copper IUD|Copper (380mm2) intrauterine device
32846060|NCT04146181|Experimental|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
32846061|NCT02595060|Experimental|150 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
32846062|NCT02595060|Experimental|450 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
32846063|NCT02595060|Placebo Comparator|inhaled placebo|once daily inhaled placebo for 3 days
32846064|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
32846065|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
32846066|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
32846067|NCT00753363|Experimental|Arm 2|6 months of weight loss
32846068|NCT04437420||T-ALL|
32846069|NCT04437420||B-ALL|
32846070|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
32846071|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
32846072|NCT01273779|Placebo Comparator|Placebo|
32846073|NCT01273779|Experimental|Talactoferrin alfa|
32846074|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
32846075|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
32846076|NCT03925675|Experimental|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
32846077|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
32846078|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
32846079|NCT03023124|Experimental|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
32846080|NCT03023124|Experimental|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
32846081|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
32846082|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
32846083|NCT01279005||20-50 YEARS OLD MSM|
32846084|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
32846085|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
32846086|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
32846087|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
32846088|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
32846089|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
32958318|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and CXR as standard of care - received point-of-care ultrasound exam as part of the study
32846090|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
32846091|NCT05100576|Experimental|Active group|This group gets the telemedicine system, with the devices, and gets life-style guide by telephone consultation/ visits, during 3 months
32846092|NCT05100576|No Intervention|Comparator group|This group gets the normal, evidence based therapy, without extra visits.
32846093|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
32846094|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
32846095|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
32846096|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
32846097|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
32958319|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
32958320|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
32958321|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
32958322|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
32958323|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
32958324|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
32958325|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
32958326|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
32958327|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
32958328|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
32958329|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
32958330|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
32958331|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
32958332|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
32958333|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
32958334|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
32958335|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
32958336|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
32958337|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
32738963|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
32738964|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32958338|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
32958339|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
32958340|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
32958341|NCT03030144|No Intervention|Control group|Routine nursing care
32958342|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
32958343|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
32958344|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
32958345|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
32958346|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
32958347|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
32958348|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
32958349|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
32958350|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
32958351|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
33406124|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
32846098|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
32846099|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
32846100|NCT05100498|Experimental|Web-based oncofertility support tool|"User-centered design practices were used to develop an oncofertility support website for women with breast cancer before treatment. The steps of the Ottawa Decision Support Framework were used throughout the development process. A multidisciplinary steering group was assembled, and the input was provided. Guidelines from the International Patient Decision Aid Standards were applied to test the quality of the oncofertility support website.~Three steps included:~Identify the supportive needs of a patient;~Guide the development of support interventions;~Evaluate the quality of web-based oncofertility support."
32846101|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
32846102|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
32846103|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
32846104|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
32846105|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
32846106|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
32846107|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
32846108|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
32846109|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
32846110|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
32846111|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
32846112|NCT04146259||group A|Control
32846113|NCT04146259||Group B|Post-surgical hypoparathyroidism
32846114|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
32846115|NCT04145869|Experimental|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
32846116|NCT04145869|Active Comparator|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
32846117|NCT05100186|Experimental|Dexamethasone Ophthalmic Insert|Day of surgery, in OR placement versus Day 1 Post-Op, In-office (HOPD)
32846118|NCT04323462|Experimental|Intensive Glucose Control|"Intensive Glucose control Insulin ≥3 times per day; Goals: prePBG 80-130 & post PBG <180 (60% of all readings); HbA1c <8% at 3 months SMBG at least 14 readings/week (3-5 FBG, rest PPBG) and/or CGMS readings Reexamined weekly for 1 month; then fortnightly for 3 months and then monthly till 6 months~Intensive subgroup will receive a standard glucometer with strips as one-week supply or CGMS for glycemic monitoring. They will receive a diabetic monitoring log/chart for home use. The chart and glucometer will have to be shown at each week of follow up. Number of hypoglycemic events in past week will be checked for each patient. This sub group will receive instructions to use 3 times bolus (regular/analogue) and single time basal insulin (glargine). Treatment goals will be conveyed at first contact and reinforced at each visit. Insulin dose modulation will be done telephonically. Patients will be reviewed weekly for 1 month and then fortnightly."
32846119|NCT04323462|Active Comparator|Conventional Glucose control|Fixed dosage of oral anti-diabetic drugs/insulin per week as patient is receiving prior; Insulin <3 times per day SMBG <3 times per day
32846120|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
32846121|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
32846122|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
32846123|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
32846124|NCT04149223|No Intervention|Control|Current practice at baseline, routine cirrhosis care.
32846125|NCT04149223|Experimental|Intervention|Use of a standardized cirrhosis order set.
32846126|NCT04149223|Active Comparator|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
32846127|NCT04318392||Patients with suspected sarcoidosis|Patients presenting with suspected sarcoidosis.
32846128|NCT04318392||Healthy controls|Healthy controls matched for age and gender. Recruitment of spouses and partners will also take place where possible.
32846129|NCT04698434|Active Comparator|0.5mg/kg esketamine group|0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
32846130|NCT04698434|Active Comparator|.75mg/kg esketamine group|0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
32846131|NCT04698434|Active Comparator|1.0mg/kg esketamine group|1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
32846132|NCT04146025|Experimental|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
32846133|NCT04146025|No Intervention|Control Group|Education only
32846134|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
32846135|NCT01273935||Non-Responder|According to the result of platelet function test
32846136|NCT04385745|Experimental|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
32846137|NCT04385745|Experimental|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
32846138|NCT04142749|Active Comparator|Oltipraz|Oltipraz 30mg
33406125|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
33406126|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
33406127|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
33406128|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
33406129|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
33406130|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
33406131|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
33406132|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
32846139|NCT04142749|Placebo Comparator|Placebo|Placebo 30mg
32846140|NCT01508702|Experimental|lesinurad 400 mg|
32846141|NCT01508702|Placebo Comparator|placebo|
32846142|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
32846143|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
32846144|NCT04263948|Experimental|Picado Arm|All the patients undergo multidimensional tele monitoring for 7 weeks using an upgraded version of the Picado internet platform
32846145|NCT04143217|Experimental|Open-Label Treatment|SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
32846146|NCT05100108|No Intervention|Control group|They will be on a waiting list. They will be assessed before and after the 8 week program but will not take part in it.
32846147|NCT05100108|Experimental|Experimental group|Participants in this group will take part in the 8 sessions of dog-assisted therapy. They will be assessed before and after the 8 week program.
32846148|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
32846149|NCT05099796|Active Comparator|Transforaminal epidural steroid injection (TESI) group|"This procedure was applied only once.~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 40 mg (1mL) of triamcinolone acetonide, 2 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected."
32846150|NCT05099796|Active Comparator|Caudal epidural steroid injection (CESI) group|"This procedure was applied only once~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized which showed bilateral L5-S3 distribution without vascular flow. A mixture of 40 mg (1mL) of triamcinolone acetonide, 7 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected. A total of 10 cc mixture was used for CESI."
32846151|NCT02337270|Experimental|Group 1 Aerosol|Receive 10^6 Ad5Ag85A by aerosol at day 0
32846152|NCT02337270|Experimental|Group 2 Aerosol|Receive 2x10^6 Ad5Ag85A by aerosol at day 0
32846153|NCT02337270|Experimental|Group 3 Intramuscular|Receive 10^8 Ad5Ag85A by intramuscular injection at day 0
32846154|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
32846155|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
32846156|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
32846157|NCT01484834|Placebo Comparator|Control Company|No intervention
32846158|NCT04024813|Placebo Comparator|Placebo (N=25)|Placebo for the remainder of the study
32846159|NCT04024813|Experimental|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
32846160|NCT04024813|Experimental|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
32846161|NCT04024813|Experimental|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
32846162|NCT05374902|Experimental|Procedural informational animation group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
32846163|NCT05374902|Experimental|Buzzy group|Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
32903135|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
33406133|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
33406134|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
32958352|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
32958353|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
32958354|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
32958355|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
32958356|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
32958357|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
32958358|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
32958359|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
32958360|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
32958361|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
32958362|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
32958363|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
32958364|NCT03023514|Active Comparator|P|vaginal Progesterone
32958365|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
32958366|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
32958367|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
32958368|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
32958369|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
32958370|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
32958371|NCT03020784|Placebo Comparator|Placebo|IV placebo
32958372|NCT03020784|Experimental|PF-06818883|Experimental drug
32958373|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
32958374|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
32958375|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
32958376|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
32958377|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).~Each administration of IMP was separated by a washout period of at least 7 days."
33406135|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
33406136|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
33406137|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
32846164|NCT05374902|Experimental|Multiple interventions group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit. Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
33103944|NCT04802616|Experimental|Polyvalent mechanical bacterial lysate|Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
33103945|NCT04802616|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.
32846165|NCT05374902|No Intervention|Control group|Children in this group received standard care. A local anesthetic is not used, and the parents are with their children during the procedure in the standard care of the blood collection unit
32846166|NCT04145791|No Intervention|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
32846167|NCT04145791|Experimental|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
32846168|NCT01484132|Experimental|Composite|
32846169|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
32846170|NCT04150770|Experimental|Patients with Childhood Uveitis|5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks
32846171|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution~Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
32846172|NCT03717961|Placebo Comparator|Placebo group|"Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
32846173|NCT04026438|Experimental|Intervention Arm - potassium phosphate injection|
32846174|NCT04026438|No Intervention|Control Arm|
32846175|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
32846176|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
32846177|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
32846178|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
32846179|NCT05104320|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
32846180|NCT05104320|Active Comparator|sternotomy CABG|Patients undergoing thoracotomy OPCABG.
32846181|NCT04024111|Experimental|KONTAKT(c)|A social skills group training
32846182|NCT04024111|Active Comparator|Art group|A social Art group
32846183|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
32846184|NCT04145557|Placebo Comparator|skaling root planing|
32846185|NCT04145557|Active Comparator|skaling root planing and diode laser|
32846186|NCT05099406|Active Comparator|Transcranial direct current stimulation (tDCS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Current intensity of 2mA is applied during 20 minutes at the left M1, with anodal electrode placed in C3 and cathodal in FP2, following the International 10-20 EEG System. Ramp-up and ramp-down comprises 15 seconds at the beginning and end of the stimulation period.
32846187|NCT05099406|Active Comparator|Transcranial alternant current stimulation (tACS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Two electrodes will be placed at F3 and F4 and connected together for 10-Hz tACS (or the frequency which shows best sensitivity or specificity), and one electrode at Pz will be the return electrode. This setting is used to stimulate the somatosensory cortical region. Stimulation will last for 20 minutes, with a ramp-up and ramp-down of 15 seconds at the beginning and end of the session.
32846188|NCT05099406|Placebo Comparator|Sham stimulation|The electrode montage will be either the tDCS (for half of the participants) or the tACS montage (for the other half), and we will just apply the current at the ramps terms, but no current in the interval between the ramps which practically comprises the whole session. As for the two other group, fifteen sham stimulation sessions will be daily scheduled in a non-interrupted period of two weeks.
32846189|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
32903136|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
32903137|NCT05566639|Experimental|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
33320014|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
33406138|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
32958378|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).~Each administration of IMP was separated by a washout period of at least 7 days."
32958379|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
32958380|NCT03019536|Experimental|LY3303560 IV|Multiple doses of LY3303560 administered intravenously (IV) for up to 48 weeks, followed by a 16 week follow-up period
32958381|NCT03019536|Experimental|Placebo IV|Multiple doses of placebo administered IV for up to 48 weeks, followed by a 16 week follow-up period
32958382|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
32958383|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
32958384|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
32958385|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
32958386|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
32958387|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
32958388|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
32958389|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
32958390|NCT03019146|No Intervention|Control|No intervention
32958391|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
32958392|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
32958393|NCT03018990|Active Comparator|Healthy control|
32958394|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
32958395|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
32958396|NCT03018678||Patients with HOFH|No intervention
32958397|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
32958398|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
32958399|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
32958400|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
32958401|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
32958402|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
32958403|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
32958404|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
32958405|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
33406139|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
33406140|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
32846190|NCT03924973|Experimental|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
32846191|NCT03924973|Other|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
32846192|NCT01520324|Experimental|Patients with UC undergoing colonoscopy|
32846193|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
32846194|NCT01279473|Experimental|Nilotinib|
32846195|NCT05111730|Experimental|The shockwave Group|Group (A) study group received medical care and standard chemotherapy and shock wave, three times / week for three successful months.
32846196|NCT05111730|No Intervention|the traditional treatment group|group (B) control group received medical care and standard chemotherapy only.
32846197|NCT04145713|Experimental|Probiotic group|
32846198|NCT04145713|Placebo Comparator|Placebo group|
32846199|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
32846200|NCT05108220||R-101|CBD oil, 30 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
32846201|NCT05108220||R-102|CBD oil, 20 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
32846202|NCT05108220||R-103|CBD oil, 30 mg CBD per serving, <0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
32846203|NCT05108220||R-104|CBD oil, 20 mg CBD per serving, <0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
32846204|NCT05108220||R-105|CBD capsule, 15 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
32846205|NCT05108220||R-106|CBD capsule, 25 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
32846206|NCT05108220||R-107|CBD capsule, 15 mg CBD per serving, <0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
32846207|NCT05108220||R-108|CBD capsule, 25 mg CBD per serving, <0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
32846208|NCT05108220||Control|Waitlist control; no product
32846209|NCT04145479|Experimental|low-resistance|women will perform low-resistance physical activity
32846210|NCT04145479|Experimental|aerobic|women will perform aerobic physical activity
32846211|NCT05107986||Patients diagnosed with complicated groin hernia|
32846212|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
32846213|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
32846214|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
32846215|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
32846216|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
32846217|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
32846218|NCT04530630|Experimental|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
32846219|NCT03945799|Experimental|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
32846220|NCT04024345|Experimental|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
32846221|NCT05112900|No Intervention|Usual Care|Participants will only receive public service announcement-type messaging on COVID-19 testing every 3 weeks such as recommendation to obtain COVID-19 testing if exposed or experience symptoms and information on testing options through the school or district.
32903138|NCT05566639|Active Comparator|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
32903139|NCT05566405|Active Comparator|General Anaesthesia|Patients undergoing open retropubic radical prostatectomy under general anaesthesia
32903140|NCT05566405|Active Comparator|Combined (Epidural and Spinal) Anaesthesia|Patients undergoing open retropubic radical prostatectomy under combined (epidural and spinal) anaesthesia
32958406|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
32738965|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32958407|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
32738966|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
32738967|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
32738968|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
32738969|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
32738970|NCT02450461||Asthma|20 patients with asthma
32738971|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
32738972|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
32738973|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
32738974|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
32738975|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
32738976|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
32738977|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
32738978|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
32738979|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
32738980|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
32738981|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
32846222|NCT05112900|Experimental|Text Messaging (TM)|This arm consists of a text message (TM) prompt asking if a participant has COVID-19 symptoms or if a participant has been exposed to a person who has tested positive for COVID-19. If a participant responds yes, they will receive a TM prompt for immediate testing and to re-test. Participants will be provided with information on testing options. After 24 hours, the participant will receive another TM that asks if they tested and what their results are. After 3 days, participants will be prompted to re-test.
32846223|NCT05112900|Experimental|Text Messaging + Health Navigator (TM + HN)|This arm consists of continued text messages (TM) about COVID-19 testing options with the addition of a brief telephone call from a health navigator (HN). These calls will be conducted using Motivation and Problem Solving (MAPS). MAPS is an empirically validated proactive coaching approach used to address barriers and motivate participants to utilize testing options if they are experiencing COVID-19 symptoms or have been exposed to someone that has tested positive for COVID-19.
33406141|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
33406142|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
33406143|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
33406144|NCT05628779|Experimental|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)
33406145|NCT05628779|No Intervention|Standard Of Care (SOC)|Patients will continue the SOC with heart failure medication following the European Society of Cardiology guideline 2021 recommendations (e.g. diuretics)
33406146|NCT05284526|Experimental|parkinsonian patients with and without dopaminergic drug treatment|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without dopaminergic drug treatment during the preparation and execution of movements
33406147|NCT05284526|Experimental|parkinsonian patients with and without High-frequency stimulation of the subthalamic nucleus|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without High-frequency stimulation (HFS) of the subthalamic nucleus (STN) during the preparation and execution of movements
33406148|NCT05284526|Active Comparator|control subjects|Electroencephalogram (EEG) of control subjects during the preparation and execution of movements
33406149|NCT04186494|Active Comparator|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
33406150|NCT04186494|Experimental|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
33406151|NCT04186494|Experimental|Combination CPAP/Liraglutide|Combination of both interventions
33406152|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
33406153|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
33406154|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
33406155|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
33406156|NCT04052360|Experimental|Cenerimod / ACT-334441|
33406157|NCT04052360|Placebo Comparator|Matching Placebo|
33406158|NCT05693142|Experimental|RGX-202 Dose 1|A single IV infusion of RGX-202 at a dose of 1×10^14 GC/kg body weight
33406159|NCT05693142|Experimental|RGX-202 Dose 2|A single IV infusion of RGX-202 at a dose of 2x10^14 GC/kg body weight
33406160|NCT01311167|Experimental|Dexamethasone|
33406161|NCT01311167|Placebo Comparator|Placebo|
33406162|NCT05691192|Experimental|Cognitive Leisure Activities|"Participants in the intervention group will engage in cognitive leisure activities for 12 weeks and will be instructed to track their daily activity level in minutes through a daily online questionnaire. To maintain motivation and improve adherence to the study protocol, participants will also receive regular follow-up phone calls from a member of the research team every 2 weeks.~After the initial 12 weeks, the groups will be crossed over and the study will continue for another 12 weeks."
33406163|NCT05691192|No Intervention|Passive control|Participants in the passive control group will not receive information regarding the intervention and cognitive leisure activities. They will instead be instructed to carry on as usual and to expect active participation in the study in 12 weeks from the time of enrolment.
33406164|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
33406165|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
33406166|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
33406167|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
32846224|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
32846225|NCT04436874|Experimental|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
32846226|NCT04436874|Experimental|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
32846227|NCT04436874|Experimental|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
32846228|NCT04436874|Experimental|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
32846229|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
32958408|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
32958409|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
32846230|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
32846231|NCT01507298||Capsule endoscopy|
32846232|NCT01507298||24 hour oesophageal pH study|
32846233|NCT04144153|Experimental|Opioid Free Anesthesia Group|
32846234|NCT04144153|Active Comparator|Opioid Anesthesia Group|
32846235|NCT05073354||Pre-implementation|Patients experiencing shock without trauma prior to any SWOT model training or devices
32846236|NCT05073354||Partial-implementation|Patients experiencing shock without trauma after training and device deployment has been started but not fully implemented
32846237|NCT05073354||Full-implementation|Patients experiencing shock without trauma once all training is in place and devices are deployed
32846238|NCT04023721|Experimental|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
32846239|NCT04023721|Experimental|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
32846240|NCT04023721|Experimental|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
32846241|NCT05067816|Active Comparator|Distance Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a distance scale-up format where each site implementation team will receive technical assistance individually. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
32846242|NCT05067816|Experimental|Quality Improvement Collaborative Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a quality improvement collaborative scale-up format where implementation teams will work collaboratively during training and implementation. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
32846243|NCT04023877|Experimental|E2027|Participants will receive approximately 130 microcurie (μCi) of [14C]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
32846244|NCT04023955||Intervention|Twitter messages delivered over 1 month period
32846245|NCT02412540|No Intervention|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
32846246|NCT02412540|Experimental|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
32846247|NCT04145245|Experimental|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
32846248|NCT04145245|Placebo Comparator|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
32846249|NCT04145323|Experimental|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
32846250|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
32846251|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
32846252|NCT05106972|Experimental|UC-MSC infusion|UC-MSC infusion by intravenus, 1*10^8 cells/dose, 2 doses (apart from 24weeks)
32846253|NCT04146337|Experimental|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
32846254|NCT04146337|No Intervention|Control|Routine follow-up
32846255|NCT04094948|Experimental|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
32846256|NCT04094948|Placebo Comparator|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
32846257|NCT04023565|Experimental|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
32846258|NCT05106504||Parkinson's disease patients|Parkinson's disease patients receiving medical cannabis for pain related to the disease
32846259|NCT04149847|Experimental|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
32846260|NCT04149847|Experimental|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
32846261|NCT05111496||Patient requiring intervention (complex coronary dilation or coronary recanalization)|Patient requiring intervention with a predicted risk of exceeding the radiological threshold (Air Kerma> 3Gy): complex coronary dilation, coronary recanalization
32846262|NCT04144855|Experimental|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
32846263|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
32846264|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
32846265|NCT04144777|Experimental|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
32846266|NCT04144777|No Intervention|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
32846267|NCT04164654|Experimental|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
32846268|NCT04164654|Other|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
32846269|NCT04149769|Other|Interventional|Walking in an exoskeleton within the home and community.
32846270|NCT01519778|Experimental|TR-701 FA|
32846271|NCT05039814||AKI|patients suffered postoperative acute kidney injury
32846272|NCT05039814||Non-AKI|patients did not suffer postoperative acute kidney injury
32846273|NCT04144933|Experimental|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
32846274|NCT04144933|Active Comparator|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
32846275|NCT05106660|Experimental|Ambulatory Care Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy as ambulatory care procedure with same-day discharge
32846276|NCT05106660|Active Comparator|Next Day Discharge Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy with next day discharge
32846277|NCT04023097|Experimental|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
32846278|NCT04023097|Active Comparator|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
32846279|NCT05111340|Experimental|Adult patients undergoing sedation with or without associated local anesthesia|
32846280|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
32846281|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
32846282|NCT05066022|Experimental|Experimental: CT0590 CAR T cells|Dose-escalated CAR T cells infusion
32846283|NCT03948919|Active Comparator|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).
32846284|NCT03948919|Placebo Comparator|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
32846285|NCT05020080|Experimental|ECR MEP conditioning - Stroke|MEP operant conditioning of ECR in stroke survivors
32846286|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
32846287|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
32846288|NCT05111106||Non-Pathology Eyes|Cataract Surgery with implantation of Symfony IOL in eyes without pre-existing pathology..
32846289|NCT05111106||Glaucoma Eyes|Cataract Surgery with implantation of Symfony IOL with pre-existing glaucoma.
32846290|NCT05111106||Retinopathy Eyes|Cataract Surgery with implantation of Symfony IOL in eyes with pre-existing retinal pathology..
32846291|NCT04022941|Experimental|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
32846292|NCT04022941|Placebo Comparator|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
32846293|NCT05087862|Active Comparator|Pericapsular nerve group block|Twenty milliliters of bupivacaine 0.5% (100 milligrams) with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle. Additionally, ketorolac 30 mg will be administered intravenously.
32846294|NCT05087862|Experimental|Periarticular local anesthetic infiltration|Sixty milliliters of 0.25% bupivacaine (150 milligrams), 5ug/mL epinephrine, and ketorolac 30 mg will be deposited at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
32846295|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
32846296|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
32846297|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
32903141|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
32846298|NCT05111028|Active Comparator|Period 1|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
32846299|NCT05111028|Experimental|Period 2|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
32846300|NCT04022707|Experimental|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
32846301|NCT04022707|Experimental|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
32846302|NCT05110716|Experimental|Gains, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in an ascending order of bundle size.
32846303|NCT05110716|Experimental|Gains, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in a descending order of bundle size.
32846304|NCT05110716|Experimental|Losses, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
32846305|NCT05110716|Experimental|Losses, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
32846306|NCT04144699||Wheezing 3~11months|Patient has wheezing, age 3 to 11 months
32846307|NCT04144699||Wheezing 12~23months|Patient has wheezing, age 12 to 23 months
32846308|NCT04144699||Wheezing 24~35months|Patient has wheezing, age 24 to 35 months
32846309|NCT04144699||Wheezing 36~107months|Patient has wheezing, age 36 to 107 months
32846310|NCT04144699||No wheezing 3~11months|Patient do not have wheezing, age 3 to 11 months
32846311|NCT04144699||No wheezing 12~23months|Patient do not have wheezing, age 12 to 23 months
32846312|NCT04144699||No wheezing 24~35months|Patient do not have wheezing, age 24 to 35 months
32846313|NCT04144699||No wheezing 36~107months|Patient do not have wheezing, age 36 to 107 months
32846314|NCT05106114|Experimental|Intensive gait training rehabilitation protocole|"Functional gait training~Strengthening interventions~High intensity interval training"
32846315|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
32846316|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
32846317|NCT04144075|Experimental|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
32846318|NCT04144075|Active Comparator|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
32846319|NCT04144075|Placebo Comparator|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
32846320|NCT04977024|Experimental|Arm I (COH04S1)|Patients receive one dose of COH04S1 IM in the upper arm on days 0 and 28.
32846321|NCT04977024|Experimental|Arm II (EUA SARS-CoV-2 vaccine)|Patients receive one dose of EUA SARS-CoV-2 vaccine IM in the upper arm on days 0 and 28.
32846322|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
32846323|NCT05110560|No Intervention|control group|step counts will be followed
32846324|NCT05110560|Experimental|intervention group|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
32846325|NCT04143685|Active Comparator|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
32846326|NCT04143685|Active Comparator|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
32846327|NCT05082090||Implanted with Orthofix Spinal products|Study will include 2000+ subjects implanted with Orthofix Spine devices including spine fixation systems and motion preservation systems (i.e. M6-C artificial cervical disc and M6-L artificial lumbar disc)
32846328|NCT04148599|Active Comparator|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
32846329|NCT04148599|Active Comparator|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
32846330|NCT04148599|Placebo Comparator|placebo|saline infusion will be administered preoperatively and continued intraoperatively
32846331|NCT04143763|Active Comparator|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
32846332|NCT04143763|No Intervention|Control group|receive general health information through a mobile message.
32846333|NCT05110482|Active Comparator|syntocinon group|"in this group :5 mL syringe containing a bolus of 1 IU of oxytocin and infusion syringe which will be prepared with a 50 mL syringe containing 0.4 IU/mL of oxytocin and infusion rate of 7.5 IU/h will be administrated to the patient after delivery of the fetus shoulder, Additional bolus syringes will be prepared for use as rescue boluses if needed  which will be 5 ml syringe containing 3 IU of oxytocin"
32903142|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
32903143|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
32846334|NCT05110482|Active Comparator|carbetocin group|"in this group :5 mL syringe containing a bolus of 100 mcg of carbetocin and infusion syringe  which will be prepared with a 50 mL syringe containing normal saline will be administrated for the patient after delivery of the fetus shoulder. Additional bolus syringes will be prepared for use as rescue boluses if needed which will be 5 ml syringe containing 100 mcg of carbetocin"
32846335|NCT04143841|Active Comparator|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
32846336|NCT04143841|Sham Comparator|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
32846337|NCT04930458|Experimental|Nanosilver fluoride group|Nanosilver fluoride will be applied on carious lesion
32846338|NCT04930458|Active Comparator|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate group|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate will be applied on carios lesion
32846339|NCT04930458|Active Comparator|Sodium fluoride varnish group|Sodium fluoride varnish will be applied on carios lesion
32846340|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
32846341|NCT03021733||Non-operative|Patients whom elected non-operative treatment
32846342|NCT03021733||Operative|Patients whom elected operative treatment
32846343|NCT04917588|Experimental|Saypha® FILLER HQ|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma HQ Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
32846344|NCT04917588|Active Comparator|Saypha® FILLER C1|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma C1 Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
32846345|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
32846346|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
32846347|NCT05105958|Experimental|Tideglusib|Patients receive 1000 mg Tideglusib once daily per os
32846348|NCT05105958|Placebo Comparator|Placebo|Patients receive placebo matching Tideglusib 100 mg once daily per os
32846349|NCT03769285|Experimental|Nicotinamide|
32846350|NCT03769285|Placebo Comparator|Placebo|
32846351|NCT05101356|Experimental|Treatment (sargramostim, LabVax 3(22)-23)|Patients receive sargramostim SC and LabVax 3(22)-23 ID on weeks 1, 2, 4, 8, and 12 in the absence of disease progression or unacceptable toxicity.
32846352|NCT04022317|Experimental|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
32846353|NCT04022317|Active Comparator|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
32846354|NCT05005416|Experimental|GOALS Intervention|The experimental arm is an 8-week cognitive-behavioral based physical therapy (PT) intervention for chronic spine pain. The manualized intervention utilizes a hybrid tele-rehabilitation delivery model. GOALS comprises an initial in-person evaluation (60 min) by a research physical therapist, followed by 6 remote treatment sessions (30-45 min each) conducted by the same physical therapist once a week by telephone. A second in-person evaluation is conducted at the midpoint of the GOALS intervention to assess progress and advance the participant's home exercise program.
32846355|NCT05005416|Active Comparator|Usual Care Physical Therapy|The control arm is Usual Care physical therapy (PT) at a local Federally Qualified Health Center (FQHC), which offers PT services at 4 outpatient clinics across San Diego county. Participants in the Usual Care group attend an initial PT evaluation at a FQHC Physical Rehabilitation Clinic. The frequency and type of PT intervention are then determined by the treating physical therapist in accordance with standard clinical practice at the FQHC.
32846356|NCT04022005|Experimental|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
32846357|NCT03943537|Experimental|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
32846358|NCT05105724|Experimental|PRP|ovarian injections of PRP were administered to the patients
32846359|NCT05105724|No Intervention|No ovarian puncture or injection|no ovarian puncture or injection was used in the patients
32846360|NCT04021849|Experimental|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
32846361|NCT04021849|Sham Comparator|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
32846362|NCT05099250|Placebo Comparator|Control group: Bupivacaine Group (B group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side
32846363|NCT05099250|Active Comparator|Magnesium Group (M group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.
32846364|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
32903144|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
32846365|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
33103946|NCT05599581|Experimental|Tu'Washindi intervention plus usual HIV prevention services|Participants in the intervention wards will receive the Tu'Washindi intervention plus access to evidence-based HIV prevention services offered throughout the county. These include PrEP delivery through ministry of health, which is accessible to all AGYW.
32846366|NCT04764006|Experimental|Surufatinib plus Sintilimab|Drug: Surufatinib plus Sintilimab Surufatinib will be given orally. Sintilimab will be given intravenously
32846367|NCT04143451|Active Comparator|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
32846368|NCT04143451|Active Comparator|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
32846369|NCT04143451|Active Comparator|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
33320015|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
33320016|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
33320017|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
33320020|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.~Interventions: cystoscopy"
33320021|NCT05358860|Experimental|Acne Scars|
33320022|NCT04589624|Active Comparator|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
33320023|NCT04589624|Experimental|Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)|Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
33320024|NCT04550156|No Intervention|Control Arm|Patients are treated according to current local standards
33320025|NCT04550156|Experimental|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
33320026|NCT01306448|Experimental|vibrating capsule|
33320027|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
33320028|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
33320029|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
33320030|NCT03790748|Experimental|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
33320031|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
33320032|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
33320033|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
33320034|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
33320035|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
33320036|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
33320037|NCT05566652|Experimental|NPS|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Neural Pressure Support Ventilation.
33320038|NCT05566652|Sham Comparator|PSV|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Pressure Support Ventilation.
33320039|NCT01306526||Moderate to Severe OSA|
33320040|NCT05693870|Experimental|Group I (B&L)|13 Band and loop (B&L) appliance were included in group one
32958410|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
32958411|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
32958412|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
32958413|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
32958414|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
32958415|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
32958416|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
32958417|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
32958418|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
32958419|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
32958420|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
32958421|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
32958422|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
32958423|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
32958424|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
32958425|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
32958426|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
32958427|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
32958428|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
33033408|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
33033409|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
32846370|NCT05105646||Patients|"• All patients undergoing primary total knee arthroplasty for osteoarthritis of the knee reported in the Dutch Arthroplasty Register.~and~• Patients who filled out the EQ-5D-3L anxiety/depression score."
32846371|NCT04143529|Experimental|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
32846372|NCT04143529|Placebo Comparator|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
32846373|NCT05080062|Experimental|Painrehabilitation + Demand and ability protocol|Will receive pain-rehabilitation and the intervention ( an interview called Requirements and functional Schedule, with the patients employer and an occupational therapist)
32846374|NCT05080062|Active Comparator|Painrehabilitation|Will receive pain-rehabilitation
32846375|NCT05105412|Experimental|Lenalidomide and Gemcitabine|Lenalidomide and Gemcitabine
32846376|NCT04766047|Active Comparator|DEXMEDETOMIDINE AND AKI|The patients of the group undergoing EVAR under general anesthesia will receive dexmedetomidine intraoperatively.
32846377|NCT04766047|No Intervention|CONTROL AND AKI|The patients of the group undergoing EVAR under general anesthesia will not receive dexmedetomidine intraoperatively.
32846378|NCT04662294|Experimental|T-ALL|
32846379|NCT04662294|Experimental|T-NHL|
32846380|NCT04662294|Experimental|AML|
32846381|NCT04021927|Experimental|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
32846382|NCT04629300|Experimental|Supportive Care Mobile Application|"Complete study questionnaires at two time points:~upon enrollment at baseline prior to randomization~approximately 12 weeks after the baseline assessment time point.~Participants will be provided with a study-issued tablet computer to access mobile app and receive a comprehensive tutorial and detailed instructions on how to use the app.~Participants will have approximately 10 weeks to complete the intervention modules at self initiated pace. The app will provide prompts as reminders to complete the modules.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
32846383|NCT04629300|Active Comparator|Usual Care|"Complete study questionnaires at two time points:~upon enrollment at baseline prior to randomization~approximately 12 weeks after the baseline assessment time point.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
32846384|NCT04021615|Experimental|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
32846385|NCT04021615|Active Comparator|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
32846386|NCT05061498|Other|Additional Pacing maneuvers|In all study participants additional pacing maneuvers (cycle lenght and output) are performed
32846387|NCT04021459|Other|women with endometrial cancer|
32846388|NCT03940261|Experimental|High Intensity Interval Training|
32846389|NCT03940261|Active Comparator|Continuous Moderate Intensity Training|
32846390|NCT04633668|Experimental|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
32846391|NCT04633668|Active Comparator|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
32846392|NCT04596228|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device
32846393|NCT04747951|Experimental|total neoadjuvant therapy|Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.
32846394|NCT04747951|Active Comparator|standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
32846395|NCT05105022|Experimental|propofol|Propofol at a dose of 2mg/kg will be administered I.V. .
32846396|NCT05105022|Active Comparator|Sevoflurane|Sevoflurane (4%) will be used for inhalational induction.
32846397|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
32846398|NCT04148677||No treatment|Patients will not receive a treatment
32846399|NCT04515888||target population|The target population of the study consists of breast cancer female patients over 50 years old followed for an invasive carcinoma expressing hormone receptors, non metastatic, undergoing adjuvant hormone therapy.
32846400|NCT04515888||control population|The control group will be composed of patients followed for an in situ carcinoma treated by surgery +/- radiotherapy, without hormone therapy.
32846401|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
32846402|NCT04149613||Controls|cancer free
32846403|NCT04148053||Active TB|"Subjects met the following:~Either Pulmonary or Extra-pulmonary tuberculosis patients~TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
32846404|NCT04148053||Latent TB|"Subjects met the following:~TB Contact in history.~Chest X-ray suggestive of non-TB.~without any symptoms suggestive of TB.~TST and/or IGRA positive."
32846405|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
32846406|NCT02656680|Experimental|FB+Friends|FB+Friends is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8.
32846407|NCT02656680|Active Comparator|FB Only|FB Only Facebook-delivered weight loss intervention including only study participants.
32846408|NCT04148209|Experimental|Treatment|Participants receiving PF-07081532
32846409|NCT04148209|Placebo Comparator|Placebo|Participants receiving Placebo
32846410|NCT04147897|Active Comparator|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
32846411|NCT04147897|Active Comparator|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
32846412|NCT04458792|Experimental|Experimental: Biological collection|"For all the patients include in the study :~Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)~MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~radiotherapy toxicity : Blood samples collected before the radiotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
32846413|NCT04765891|Experimental|Positional Release Therapy|Participants were randomly assigned the positional release therapy treatment group. The participants underwent the treatment.
32846414|NCT04765891|Experimental|Therapeutic Massage|Participants were randomly assigned the therapeutic massage treatment group. The participants underwent the treatment.
32846415|NCT05104944|Experimental|Arm A (Intervention - Standard Care and Serial MRIs)|Immobilisation discontinued on the basis of MRI defined disease resolution at 3, 6, 9 or 12 months. In the intervention arm participants will receive additional MRIs at 3, 6, 9 and 12 months. Patients randomised to serial MRI will not undergo further MRI once remission has been diagnosed i.e. if remission is diagnosed at 6 months the MRI at 9 and 12 months will not occur.
32846416|NCT05104944|No Intervention|Arm B (Control - Standard Care and one additional MRI)|Immobilisation discontinued on the basis of clinical remission determined by skin temperature measurement and MRI. In the standard care arm participants will receive one additional MRI when the temperature measurements, X-ray and/or signs and symptoms indicate to the clinical team that the foot is in remission. A temperature difference of ≤ 2ºC which is maintained or improves on two separate consecutive occasions for a period of ≥4weeks will be the indicator to arrange the second MRI, to confirm the diagnosis of remission. If participants in either arm of the trial have not reached remission at the end of the 12 month active phase of the study they will exit the study. Ongoing standard care will be provided by their clinical team.
32846417|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
32846418|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
32846419|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
32846420|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
32846421|NCT05104788|Experimental|Icotinib with platinum-based chemotherapy|Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
32846422|NCT04405843|Experimental|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
32846423|NCT04405843|Placebo Comparator|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
32846424|NCT04316364|Experimental|Treatment group A|Neoadjuvant setting: Drug: SHR-1316 and carboplatin and Paclitaxel (Albumin Bound) 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
32846425|NCT04316364|Experimental|Treatment group B|Neoadjuvant setting: Drug: SHR-1316 and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
32846426|NCT04316364|Placebo Comparator|Treatment group C|Neoadjuvant setting: Drug: Placebo and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: Placebo up to 16 cycles
32846427|NCT04142671|Experimental|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
32846428|NCT03916003|Experimental|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
32846429|NCT03916003|No Intervention|standard care|As per national guidelines for P. falciparum treatment
32846430|NCT04142827|Experimental|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
32846431|NCT04142827|No Intervention|Therapy with usual care|The patients will be under usual care for observational
32846432|NCT04231500||patients with GVHD after allo-HSCT|Exploration of the skin-microbiota in patients with GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure and additional skin biopsies from affected and healthy skin sites in case of GVHD
32846433|NCT04231500||patients without GVHD after allo-HSCT|Exploration of the skin-microbiota in patients without GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure
32846434|NCT04147741|Experimental|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
32846435|NCT04147741|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
32846436|NCT04972500|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
32846437|NCT04972500|No Intervention|Control|No intervention
32846438|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
32846439|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
32846440|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
32846441|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
32846442|NCT04918212|Experimental|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
32846443|NCT04977804|Active Comparator|Eccentric only training|This is the experimental control; where this group will be used as the standard active comparison condition.
32846444|NCT04977804|Experimental|Eccentric plus blood-flow restriction|This is the experimental condition involving the eccentric resistance training with blood flow restriction.
32846445|NCT05580913|Experimental|Subjective auto-regulation training|Participants complete their resistance-training sets to termination based on rating of perceived exertion
32846446|NCT05580913|Experimental|Objective auto-regulation training|Participants complete their resistance-training sets to termination based on reaching a critical slow velocity
32846447|NCT05580913|Active Comparator|Traditional standardized training|Participants complete their resistance-training sets by lifting a prescribed percentage of their estimated one-repetition maximum (as determined from baseline four-repetition maximum strength testing)
32846448|NCT04781478|Active Comparator|Biorepair Gel (Q1-Q3) and Chlorhexidine 1% gel (Q2-Q4)|The patients receive Biorepair Gel application in quadrants Q1 and Q3, whereas they receive chlorhexidine 1% gel in quadrants Q2 and Q4.
32846449|NCT04781478|Active Comparator|Chlorhexidine 1% gel (Q1-Q3) and Biorepair Gel (Q2-Q4)|The patients receive chlorhexidine 1% gel in quadrants Q1 and Q3, whereas they receive Biorepair Gel application in quadrants Q2 and Q4.
32846450|NCT03937843|Experimental|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:~Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:~Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
32846451|NCT04436562|Experimental|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of [14C]-poziotinib
32846452|NCT05104398||Baseline therapy|Group 1 (n=29) continued to receive standard treatment.
32846453|NCT05104398||Basic therapy + Efferon CT|group 2 (n=13) received HP procedure once, for 3-4 hrs, using Efferon CT adsorbers containing mesoporous SDC beads uptaking 6-60 kD molecules followed by continuous veno-venous hemodiafiltration. Group 2 included more severe patients requiring HP support.
32846454|NCT04141969|Active Comparator|RLP|ReaLife+
32846455|NCT04141969|Placebo Comparator|Inert|Inert brown powder to look similar to RLP
32846456|NCT04141969|No Intervention|Control|Not given RLP or the placebo
32846457|NCT03935113|Experimental|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
32846458|NCT04018872|Experimental|Itraconazole|Itraconazole capsule 300mg twice daily for 6-8 weeks following chemoradation.
32846459|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
32846460|NCT03978078|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
32846461|NCT04147429|No Intervention|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
32846462|NCT04147429|Experimental|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
32846463|NCT03962868|Experimental|Endoscopic submucosal dissection (ESD)|
32846464|NCT03962868|Active Comparator|Endoscopic Mucosal Resection (WF-piece meal EMR)|
32846465|NCT04147507|Experimental|Music Therapy|
32846466|NCT04147507|Other|Control|Life style Modification.
32846467|NCT03915691|Active Comparator|Isthmus targeted approach using Ripple Mapping|Intervention: Isthmus targeted approach using Ripple Mapping catheter ablation of atrial tachycardia.
32846468|NCT03915691|Active Comparator|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
33320041|NCT05693870|Experimental|Group II (Ssb&l)|13 Single-sided Band and loop (SsB&L) appliance were included in group two
33320042|NCT05693870|Experimental|Group III (DBW)|13 Direct Bonded Wire (DBW) appliance were included in group three
32903145|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
33033410|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
33320043|NCT05693870|Experimental|Group IV(T&L)|13 Tube and Loop (T&L) appliance were included in group four
33320044|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
33320045|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
33320046|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
33320047|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
33320048|NCT05078840||Patients with DLBCL limited stages and without risk factors|Patients with DLBCL in limited stages and without risk factors that will receive standard chemoimmunotherapy and their treatment will be adapted according to PET response after 3 cycles.
32846472|NCT03896737|Experimental|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
32846473|NCT03896737|Active Comparator|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.~TREATMENT SCHEMA INDUCTION~ARM VTd:~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.~Repeat for four 4-week induction cycles."
32846474|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
32846475|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
32846476|NCT04140877|Other|Visu OD, Control OS|Contralateral eye study
32846477|NCT04140877|Other|Control OD, Visu OS|Contralateral eye study
32846478|NCT05581459|Experimental|63 Hz vibration group|Vibration of 63 Hz frequency was applied.
32846479|NCT05581459|Active Comparator|42 Hz vibration group|Vibration of 42 Hz frequency was applied.
32846480|NCT05581459|Sham Comparator|Sham vibration group|No actual vibration was applied.
32846481|NCT04651374|Experimental|Geko Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
32846482|NCT04651374|No Intervention|No Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
32846483|NCT03896035|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
32846484|NCT03896035|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
32846485|NCT04868136|Experimental|Warm-up, then no warm-up|Participants' visit 2 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session. Participants' visit 3 consisted of the 30 minute exercise session without a warm-up.
32846486|NCT04868136|Experimental|No warm-up, then warm-up|Participants' visit 2 consisted of the 30 minute exercise session without a warm-up. Participants' visit 3 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session.
32846487|NCT04141189|Experimental|weekly|weekly fetal surveillance
32846488|NCT04141189|Active Comparator|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
32846489|NCT05078268|Experimental|Combined group|Participants in combined group will receive both HRV biofeedback training and self-help CBT-I concurrently.
32846490|NCT05078268|Active Comparator|Self-help CBT-I only group|Participants in self-help CBT-I only group will receive self-help CBT-I only.
33320049|NCT00261833|Experimental|Zemaira®|
33320050|NCT00261833|Placebo Comparator|Placebo|
32846493|NCT05076786|Experimental|Chidamide + Etoposide + Cisplatin/Carboplatin|Experimental arm will be treated by chidamide combined with etoposide and cisplatin/carboplatin regimen for 4-6 cycles.
32846494|NCT04141033|Other|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
32846495|NCT04141033|Other|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
32846496|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
32846497|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
32903146|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
33320051|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
33320052|NCT05610644|Active Comparator|TRF of RDA|A time-restricted model of consumption of the RDA of protein/day.
33320053|NCT05610644|Active Comparator|TRAD of RDA|A typical American dietary ingestion pattern of the RDA of protein/day.
33406168|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
32846498|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
32846499|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
32846500|NCT03476317|No Intervention|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
32846501|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
32846502|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
32846503|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
32846504|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
32846505|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
32846506|NCT04548882|Experimental|Calypso Knee System|Calypso Knee System
32846507|NCT04140643|Experimental|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
32846508|NCT04140643|Active Comparator|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
32846509|NCT05068752|Experimental|Vemurafenib in Combination with Sorafenib|
32846510|NCT05581147||Klinefelter syndrome|Males affected by 47,XXY non-mosaic Klinefelter syndrome. Subgroups according to pubertal stage: pre-pubertal, pubertal and adults. Subgroups according to gonadal status: eugonadal, hypogonadal and receiving testosterone replacement therapy (TRT).
32846511|NCT05581147||Healthy controls|Euthyroid, age- and pubertal stage-matched males Subgroups according to pubertal stage: pre-pubertal, pubertal and adults.
32846512|NCT05581147||Chronic lymphocytic thyroiditis|Adult males affected by chronic lymphocytic thyroiditis
32846513|NCT05049330||Derivation Cohort|The derivation cohort collected data to derive the clinical decision rule.
32846514|NCT05049330||Validation Cohort|The validation cohort collected data to validate the clinical decision rule
32846515|NCT05581069|Experimental|STEPS|All participants receive the STEPS intervention
32846516|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
32846517|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
32846518|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
32846519|NCT03345186|Experimental|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
32846520|NCT03345186|No Intervention|Standard of care|Standard of care for gout patients
32846521|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
32846522|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
32846523|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
32846524|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
32846525|NCT05043792|Active Comparator|Dose 1 (Low dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
32846526|NCT05043792|Active Comparator|Dose 2 (Middle dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
32846527|NCT05043792|Active Comparator|Dose 3 (High dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
32846528|NCT05043792|Placebo Comparator|Placebo|TT-00920 Placebo, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
33033411|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
33033412|NCT01962662|Other|control group|U/E exercise
33406169|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
32846529|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
32846530|NCT04528758|Experimental|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
32846531|NCT04528758|Active Comparator|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
32846532|NCT04140409|Experimental|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
32846533|NCT04452474|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
32846534|NCT04452474|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
32846535|NCT05580991|Experimental|CAN1012|CAN1012 intratumoral injection given alone
32846536|NCT04527510||Conventional-reading|
32846537|NCT04527510||Second-reading|
32846538|NCT04527510||Concurrent-reading|
32846539|NCT04527510||Tow-view-reading|
32846540|NCT04527510||Handheld US-screening|
32846541|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
32846542|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
32846543|NCT05580835|Experimental|PET MRI - PSMA|Patients with an imaging diagnosis of HCC and submitted to PET MRI - PSMA
32846544|NCT04527432|Other|All participants|Survey at 6 and 12 months time with optional antibody tests
32846545|NCT03913273|Experimental|Intervention group|Intervention: AMI transtibial amputation
32846546|NCT03913273|Active Comparator|Control group|Intervention: Standard transtibial amputation
32846547|NCT04436718|Experimental|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
32846548|NCT04436718|No Intervention|Usual care|Patients are assessed daily by primary care providers per usual care.
32846549|NCT04879290|Active Comparator|Control Group FiO2=1|FiO2 = 1 (100%) 10mn before emergence of general anesthesia
32846550|NCT04879290|Experimental|Intervention Group FiO2 0.5|Fi02 = 0.5 (50%) 10mn before emergence of general anesthesia
32846551|NCT04836390|Experimental|Treatment Arm|All subjects will receive NK infusions.
32846552|NCT03912805|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
32846553|NCT03912805|Experimental|ET-01 1610U|botulinum toxin, Type A, topical liniment, administered once at baseline
32846554|NCT04809168||AS patients|AS patients diagnosed according to the modified New York criteria
32846555|NCT04809168||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint lasting more than three months
32846556|NCT03909685|Experimental|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
32846557|NCT03909685|No Intervention|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
32846559|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
32846560|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
32846561|NCT04642950|Experimental|NPC-26|Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
32846562|NCT04642950|Placebo Comparator|NP-26 Placebo|Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
32846563|NCT04795284||Patients with symptomatic lumbar spinal stenosis|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
32846564|NCT04795284||Healthy elderly|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
32846565|NCT05110170|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
32846566|NCT05110170|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
32846567|NCT05110092|Experimental|The exercise group|The exercise group received usual care and breathing-based leg resistance exercise program for 12 weeks.
33033413|NCT01962701||OCT-group|OCT prior to C-section
32846568|NCT05110092|No Intervention|The control groups|The control group received usual care
32846569|NCT05109936|Experimental|Experimental arm|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), urate-lowering treatment, for a period of 2 x 6 weeks.
32846570|NCT05109936|No Intervention|Standard care arm|Prescription deferred to 6 weeks (42 days +/- 3 days) of ADENURIC 80 mg / day (febuxostat): hypouricemic treatment, for a period of 6 weeks.
32846571|NCT04791384|Experimental|Abemaciclib/Elacestrant|Abemaciclib and Elacestrant combination
32846572|NCT04472208|Experimental|Ambulatory Monitoring Solution|The evaluable device is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
32846573|NCT04522440|Experimental|Inpatients in hospice Ward|Inpatients in hospice Ward with pain control problems
32846574|NCT04427982|Experimental|Experimental Group|All participants will attend a 2-month weekly light-to-moderate intensity dance workshop followed by a brief diabetes education and discussion session.
32846575|NCT04374240|Experimental|AdNRGM followed on day 2 by CB1954|The proposed dose levels for AdNRGM are 10^10, 3x10^10, 10^11, 3x10^11, 10^12 vp while the prodrug CB1954 will be given at a standard dose of 24 mg/m^2
32846576|NCT05109468||Anal cancer patients|Non-metastatic squamous anus cancer with the presence of an HPV infection authenticated on the biopsy
32846577|NCT05109390|Experimental|Part 1: Danicopan plus Cyclosporine|"Participants (N=14) received danicopan and cyclosporine in a fixed sequence over 2 periods:~Treatment A (Period 1): 300 milligrams (mg) cyclosporine administered on Day 1.~Treatment B (Period 2): 200 mg danicopan administered 3 times daily (TID) on Days 1-7 with 300 mg cyclosporine coadministered on Day 5.~There was a washout period of 3 days between the dose of cyclosporine in Period 1 and the first dose of danicopan in Period 2."
32846578|NCT05109390|Experimental|Part 2: Danicopan plus Tacrolimus|"Participants (N=28) received danicopan and tacrolimus in a fixed sequence over 2 periods:~Treatment C (Period 1): 2 mg tacrolimus administered on Day 1.~Treatment D (Period 2): 200 mg danicopan administered TID on Days 1-10 with 2 mg tacrolimus coadministered on Day 5.~There was a washout period of 7 days between the dose of tacrolimus in Period 1 and the first dose of danicopan in Period 2."
32846579|NCT05109390|Experimental|Part 3: Danicopan plus Antacids and Omeprazole|"Participants (N=30) received danicopan, calcium carbonate, aluminum/magnesium hydroxide/simethicone, and omeprazole in fixed sequences over 2 periods:~Treatment E1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment E2 (Period 1): 200 mg danicopan coadministered with 1 gram calcium carbonate on Day 5.~Treatment F1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment F2 (Period 1): 200 mg danicopan coadministered with 200 mg aluminum hydroxide/200 magnesium hydroxide/25 mg simethicone on Day 5.~Note: Participants were randomized in a 1:1 ratio to receive either Treatment E2 or F2 coadministered with danicopan on Day 5.~Treatment G1 (Period 2): 40 mg omeprazole administered once daily (QD) on Days 1-4.~Treatment G2 (Period 2): 40 mg omeprazole administered QD with 200 mg danicopan administered orally TID on Days 5-8.~There was a washout period of 2 days between the last dose of danicopan in Period 1 and the first dose of omeprazole in Period 2."
32846580|NCT04783974||Patients assuming SSRI|Patients treated with dental implants and assuming selective serotonin reuptake inhibitors
32846581|NCT04783974||Patients assuming PPI|Patients treated with dental implants and assuming proton pump blockers
32846582|NCT04783974||Patients assuming Anti-inflammatory drugs|Patients treated with dental implants and assuming anti-inflammatory drugs
32846583|NCT04783974||Patients assuming Anti-hypertensive drugs|Patients treated with dental implants and assuming anti-hypertensive drugs
32846584|NCT04783974||Control group - Patients not assuming the studied drugs|Patients treated with dental implants and not assuming any of the following drugs: selective serotonin reuptake inhibitors, proton pump blockers, anti-inflammatory drugs, anti-hypertensive drugs
32846585|NCT04030182||Level of vitamin D|Level in blood sample of vitamin D for each patient
32846586|NCT05109312|Experimental|Treatment Group 1 Cohort 1|HTX-011 + multimodal analgesic (MMA) regimen
32846587|NCT05109312|Active Comparator|Treatment Group 2 Cohort 1|Bupivacaine HCl + MMA
32846588|NCT05109312|Experimental|Treatment Group 1 Cohort 2|HTX-011 + MMA
32846589|NCT05109312|Active Comparator|Treatment Group 2 Cohort 2|Bupivacaine HCl + MMA
32846590|NCT05109078|Experimental|[14C]- Rongliflozin|Patients will receive single dose of [14C]- Rongliflozin (Suspension, 50mg/100μCi)
32846591|NCT05109000|Experimental|Normal Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of normal saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
32846592|NCT05109000|Experimental|Bacteriostatic Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of bacteriostatic saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
32846593|NCT05108766|Experimental|Tildrakizumab|Subjects will receive 100 mg subcutaneous (SC) Tildrakizumab at Week 0 and Week 4, 100 mg subcutaneous placebo at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
32846594|NCT05108766|Placebo Comparator|Placebo|Subjects will receive 100 mg subcutaneous placebo at Week 0 and Week 4, and 100 mg subcutaneous Tildrakizumab at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
32846595|NCT05108610|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
32846596|NCT05108610|Experimental|Shi-style manipulations|Shi-style manipulations is a cervical manipulation for cervical spondylosis.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
32846597|NCT05108532||Patients after revisional bariatric surgery.|This cohort will include patients, who underwent revisional bariatric surgery.
33033414|NCT01962701||None-OCT-group|No OCT prior to C-section
33320054|NCT05610644|Experimental|TRF of 2RDA|A time-restricted model of consumption of twice the RDA of protein/day.
33406170|NCT04233840|Experimental|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
33406171|NCT04233840|Active Comparator|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
33406172|NCT04233840|Active Comparator|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
33406173|NCT04233840|Experimental|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
33406174|NCT03787758|Experimental|SAGE-718|
32846598|NCT05104710||AIM 1|"Hypothesis: IMC-βγ can help to differentiate between ALS and mimic diseases at initial presentation.~Patients who present to a neuromuscular clinic with symptoms that might be from ALS but for whom a diagnosis is not yet known, will be studied. Measurements of intermuscular coherence will be made using surface electrodes. A standard neurological examination and questionnaire about ALS symptoms will be completed. No interventions will be made. A patient's final diagnosis will be determined using standard-of-care testing. Six months after initial IMC measurement, a determination will be made whether the IMC predicted the diagnosis of ALS."
32846599|NCT05104710||AIM 2|"Hypothesis: Characterization of demographic-specific distributions will improve the specificity of IMC-βγ for ALS.~To optimize cutoff values for abnormal IMC, IMC-βγ will be measured in neurotypical controls across a range of age, race, ethnicity, and sexes."
32846600|NCT05104710||AIM 3|"Hypothesis: IMC-βγ will decrease with disease progression.~Because IMC-βγ measures functional input from motor neurons in the brain, it should decrease as these neurons are lost. IMC will be measured sequentially about every 3 months in patients with ALS, and will be compared to measures of clinical progression."
32846601|NCT03876990|Experimental|Multiplex PCR + Current strategy|Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
32846602|NCT03876990|Active Comparator|Current strategy alone|Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
32846603|NCT03799380|Active Comparator|Control - Standard of Care|Standard of care nutritional support
32846604|NCT03799380|Experimental|Experimental - Gatorade|Standard of care nutritional support with the addition of daily Gatorade G2
32846605|NCT04941924|Experimental|Intervention|Biliary stenting plus radio-frequency ablation of the bile duct
32846606|NCT04941924|Active Comparator|Control|Biliary stenting alone
32846607|NCT03952494|Experimental|Intervention group|Intervention group will have the PGx test results available via Epic, three days after the biospecimen is received.
32846608|NCT03952494|Experimental|Control group|"The control group will be considered in TAU(treatment as usual) group but will have the PGx test results available after 24 weeks.~Note: Patient in both the groups will be followed for 24 weeks and will take questionnaires every other week."
32846609|NCT05098314||EHPAD with personalized interventions|EHPAD with personalized interventions.
32846610|NCT05098314||EHPAD without personalized interventions|EHPAD without personalized interventions
32846611|NCT03680196|Experimental|cerebral palsy patients|cerebral palsy patients who have GMFCS level3,4,5 and 2 years old and under 10 years old apply an A injection of medication Botulinum A injection
32846612|NCT04814472|Experimental|Oral Solution vs. Tablet Formulation|"There will be 3 treatments, each single dose administered based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 750 mg BLD-0409 oral solution formulation (solution) under fasting conditions.~Treatment B: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fasting conditions.~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fed conditions."
32846613|NCT04814472|Experimental|Tablet Formulation Dose Proportionality|"There will be 4 treatments, each single dose administered under fed conditions (standard meal) based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 250 mg BLD-0409 tablet formulation (1 x 250 mg tablet).~Treatment B: 500 mg BLD-0409 tablet formulation (2 x 250 mg tablet).~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablet).~Treatment D: 1000 mg BLD-0409 tablet formulation (4 x 250 mg tablet)."
32846614|NCT03661632|Experimental|Dose Escalation|"Part 1: BMS-986310 + Nivolumab Combination Dose Escalation~Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy.~Sub-Study B: A cohort of PD[L]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab"
32846615|NCT03661632|Experimental|Cohort Expansion|"Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1.~BMS-986310 + Nivolumab combination will be administered in specific patient populations."
32846616|NCT03514602|Experimental|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
32846617|NCT03514602|Active Comparator|Control|The control group will receive smoking cessation education only.
32846618|NCT04748250|Experimental|Acupuncture Group|This group will receive acupuncture therapy for 30 minutes, three times per week for six months using the internationally recognized standard acupuncture needle which is 3 cm long with diameter o.3 mm, pushing it with twisting movement to the required depth until the De Qi sensation will be obtained.
32846619|NCT04748250|Experimental|Soy Group|This group will receive soy products for six months which including: Soy milk: 100 millilitre of soy milk every day, every bottle of original soy milk contains 300 millilitre or Soy beans: 100 gram of cooked soy beans per day.
32846620|NCT04748250|Experimental|Acupuncture and Soy Group|Every patient in this group will receive acupuncture therapy sessions in abdominal acu-points as in group (A) for 30 minutes, three times per week for six months in addition to administration of soy products in the form of soy milk or soy beans daily in breakfast for three months as in group (B).
32846621|NCT04726878|Placebo Comparator|Controlled|Standard care without regional block. General anesthesia. After the end of the surgery, the patient-controlled analgesia with oxycodone.
32846622|NCT04726878|Experimental|ESP block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.375% ropivacaine will be performed. Then, the patient will be treated as in the controlled group.
32846623|NCT04726878|Sham Comparator|Sham block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.9% saline will be performed. Then, the patient will be treated as in the controlled group.
32846624|NCT04525638|Experimental|177Lu-DOTATATE + Nivolumab|Patients will receive 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
32846625|NCT04164342|Experimental|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
32846626|NCT03512262|Experimental|Abaloparatide (BA058)|Abaloparatide is an active synthetic peptide of parathyroid hormone
32846627|NCT03512262|Placebo Comparator|Placebo|Placebo with no peptide of parathyroid hormone
32846628|NCT04701216|Experimental|Experimental: SHR8735 cohort 1|The subjects will receive a multiple dose of SHR8735 (low dose).
32846629|NCT04701216|Experimental|Experimental: SHR8735 cohort 2|The subjects will receive a single dose of SHR8735 (medium dose).
32846630|NCT04701216|Experimental|Experimental: SHR8735 cohort 3|The subjects will receive a single dose of SHR8735 (high dose).
32846631|NCT03456882|Active Comparator|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
33406175|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
33406176|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
32846632|NCT03456882|Placebo Comparator|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
32846633|NCT04663230||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
32846634|NCT04663230||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
32846635|NCT04663230||Control|Patients with invasive exclusion of pulmonary hypertension (mean pulmonary arterial pressure below 25 mmHg) undergoing diagnostic CMRI due to the evaluation of dyspnoea.
32846636|NCT04706364||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder
32846637|NCT04706364||Healthy Control|Typically developing individuals without a history of autism
32846638|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
32846639|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
32846640|NCT04701060|Experimental|Camrelizumab combined with apatinib|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
32846641|NCT05116098|Active Comparator|100 pulmonary positive patients on tb protocol adding to supplement zinc 50 mg 400 mg once daily|
32846642|NCT05116098|Placebo Comparator|control group 100 patients only on tuberculosis national protocol|
32846643|NCT05080764|Experimental|1h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
32846644|NCT05080764|Experimental|3h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
32846645|NCT05080764|Placebo Comparator|1h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
32846646|NCT05080764|Placebo Comparator|3h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
32846647|NCT04464408|Experimental|Favipiravir|Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
32846648|NCT04464408|Placebo Comparator|Placebo|9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
32958429|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
32958430|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
32958431|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
32958432|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
32958433|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
32958434|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
32958435|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
32958436|NCT03016260||Infliximab (Remicade®)|
32958437|NCT03016260||Adalimumab (Humira®)|
32958438|NCT03016260||Etanercept (Enbrel®)|
32958439|NCT03016260||Golimumab (Simponi®)|
32958440|NCT03016260||Certolizumab Pegol (Cimzia®)|
32958441|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
32958442|NCT03016260||Etanercept biosimilar (Benepali®)|
32958443|NCT03016260||Infliximab biosimilar (Flixabi®)|
32958444|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
32958445|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
32958446|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
32958447|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
32958448|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
32958449|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
32958450|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
32958451|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
32958452|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
32958453|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
32958454|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
32958455|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
32958456|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
32958457|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
32958458|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
32958459|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
32958460|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
32958461|NCT03015246|Placebo Comparator|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
32958462|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
32958463|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
32958464|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
33033415|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
32846649|NCT04601376|Experimental|Mobile monitoring group|
32846650|NCT04589598|Experimental|FNS|those who are treated with femoral neck system (FNS)
32846651|NCT04589598|Active Comparator|MCS|those who are treated with multiple cannulated screw (MCS)
32846652|NCT04587570|Experimental|Group 1: Infiltration of PRP|The proband gets Platelet Rich Plasma injected in the thumb saddle joint.
32846653|NCT04587570|Experimental|Group 2: Infiltration of Fat|The proband gets fat injected in the thumb saddle joint.
32846654|NCT04587570|Experimental|Group 3: Infiltration of PRP and Fat|The proband gets a mixture of Platelet Rich Plasma (PRP) and Fat injected in the thumb saddle joint.
32846655|NCT04587570|Placebo Comparator|Group 4: Infiltration of NaCl|The proband gets NaCl injected in the thumb saddle joint.
32846656|NCT04585620|Active Comparator|BTX-A|"Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).~At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes."
32846657|NCT04585620|Placebo Comparator|Placebo|At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.
32846658|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
32846659|NCT05115708|Active Comparator|Kahook dual blade ab-interno Trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
32846660|NCT05115708|Active Comparator|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group.
32846661|NCT04468932|Experimental|Active TMS first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
32846662|NCT04468932|Experimental|Sham treatment first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week sham TMS period. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week TMS intervention prior to their final assessment.
32846663|NCT04339218|Experimental|Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin|Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
32846664|NCT04339218|Active Comparator|Arm pembrolizumab-pemetrexed-carboplatin|Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
32846665|NCT04253808|Experimental|Arm A|The experimental arm (N=6) were provided a CRHF diet with enough calories to maintain body weight for appoximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks. The CRHF diet was composed of 45% fats (mostly) unsaturated fats, 25% proteins, and 30% carbohydrates.
32846666|NCT04253808|Active Comparator|Arm B|"Arm B (N=7) were provided a regular composition diet prescribed with enough calories to maintain body weight for approximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks.~The regular composition diet was composed of ~50-52% carbohydrates, ~30% fats, and 18-20% proteins,"
32846667|NCT04253808|No Intervention|Control group|The control group (N=26) followed applicable eligibility criteria but did not receive any intervention.
32846668|NCT05115318||Adult Tourette syndrome patients|Patients will be assessed before (baseline), 4 (visit 2) and 12 weeks (visit 3) after use of Medical cannabis via inhaled dried buds or sublingual oil extract. The percentage of THC and CBD were pre-set to 10% and 2%, respectively. All patients received the same general instructions for treatment titration, which was to start with 1 drop or puff a day and increase by 1 drop or puff as needed. There was no fixed schedule for the incremental increases, thus each patient freely raised the dose as well as number of daily consumptions until clinical benefit was achieved or SE emerged over a follow-up period of 12 weeks.
32846669|NCT05115162|Experimental|elerehablitation home exercise group|"Telerehabilitation home exercise group received indoor walking and general exercise program for 6 weeks.~Indoor walking was performed 3 days a week, for 30 minutes. General exercise program was consisted of flexibility, strengthening the shoulder and trunk muscles, bridge exercises, lying on the back, cycling and squatting exercises. All of the general exercises were repeated 3 days a week, 2 sets and each set with 10 repetitions.~Two synchronized exercise education sessions were performed with the exercise group. In the first of these sessions, the content of the exercise program was explained. In the second, it was checked whether the exercises were done correctly. After synchronous education sessions, an asynchronous home exercise program, consisting walking and general exercise program continued for 6 weeks."
32846670|NCT05115162|No Intervention|Control Group|This group did not participate in any exercise program for 6 weeks.
32846671|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
32846672|NCT04474860||Malignant Hyperthermia|Samples from Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia and samples from their blood relations will receive genetic testing.
32846673|NCT03895801|Experimental|Group A Experimental + active comparator|IFX-1 + reduced dose GC
32958465|NCT03015246|Experimental|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
32958466|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
32846674|NCT03895801|Active Comparator|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
32846675|NCT03895801|Placebo Comparator|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
32846676|NCT04469478|Experimental|Virtual Reality for imaging review|Each participant (patient and caregiver(s)) will undergo standard 2D imaging review on a computer screen, followed by 3D imaging review in virtual reality during their radiation oncology consultation
32846677|NCT05114928||Progression Group (P-group)|Eyes that showed progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 7 eyes).
32846678|NCT05114928||No Progression Group (NP-group)|Eyes that showed no progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 11 eyes).
32846679|NCT05114772|Active Comparator|Recurrent Atrial fibrillation|patients developed Recurrent Atrial fibrillation catheter ablation
32846680|NCT05114772|Active Comparator|NO Recurrent Atrial fibrillation|patients didn't develop Recurrent Atrial fibrillation catheter ablation
32846681|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
32846682|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
32846683|NCT05069766|Experimental|BioXmark™|
32846684|NCT05580679|Experimental|Abdominal massage group|Abdominal massage using for evaluation of constipation.
32846685|NCT05580679|No Intervention|Standart care group|No intervention palliative care patient
32846686|NCT04521582|Experimental|Active Group|Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within ~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in ~2 weeks. If blood pressure is controlled (<140/90 mmHg) after ~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in ~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.
32846687|NCT04521582|Active Comparator|Comparison Group|"Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility (the usual care) which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment."
32846688|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
32846689|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
32846690|NCT01482884|Placebo Comparator|2|placebo sc injection
32846691|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
32846692|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
32846693|NCT05065554|Experimental|ACALABRUTINIB + RITUXIMAB/BIOSIMILAR|"Acalabrutinib and rituximab (or biosimilar) with be contained in the treatment regimen.~Acalabrutinib will be administered twice daily, with 28 consecutive days defined as a treatment cycle. Acalabrutinib will be administered for 48 cycles or until disease progression or unacceptable toxicity.~Rituximab will be administered on Days 1, 8, 15, and 22 of Cycles 1 and 4. Participants will have study visits every cycle for cycles 1-6, then every 3 cycles, with the next visit at Cycle 9, then C12, C15, etc.~Participants will continue acalabrutinib until disease progression or intolerable adverse effect develops. They will be followed for up to 2 years after completion of 48 cycles of treatment or until death"
32846694|NCT04140253|Active Comparator|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
32846695|NCT04140253|Experimental|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
32846696|NCT05114304||Pulmonary Langerhans cell histiocytosis (PLCH)|Adults with pulmonary Langerhans cell histiocytosis
32846697|NCT01518374|Experimental|Florbetapir-PET Scans|
32846698|NCT04140097||COPD patients with acute exacerbation|
32846699|NCT04140097||COPD patients without acute exacerbation|
32846700|NCT04359654|Experimental|Dornase alfa treatment|Best available care and nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure
32846701|NCT04359654|No Intervention|Best available care|Best available standard of care
32846702|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
32846703|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
32846704|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
32846705|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
32846706|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
32846707|NCT04272762|Active Comparator|Ablation|pulmonary vein isolation
32846708|NCT04272762|Placebo Comparator|Placebo|placebo procedure
32846709|NCT03859466|Experimental|Intervention Arm|In the intervention arm, 300 shockwave impulses per coronary supply territory, at an energy flux density of 0.38mJ/mm2 and a frequency 3Hz, are applied in direct contact with the ischaemic myocardium of the left ventricle. The intervention is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
32846710|NCT03859466|No Intervention|Sham Control Arm|In the sham control arm, the same manipulations are performed with an inactive shockwave applicator in direct contact with the ischaemic myocardium of the left ventricle as in the intervention arm. The sham treatment is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
32846711|NCT04436172|No Intervention|pre intervention|Before intervention
32846712|NCT04436172|Experimental|post intervention|Received soinal anesthesia
32846713|NCT03446989|Experimental|Case management|Those who did not agree to participate in the NLCM were enrolled into the control group and received the standard care: visits to their RA physicians on a regular basis with health education administered by a ward nurse during each visit. The education sessions lasted for approximately 15 minutes and consisted of consultation about disease symptoms, related treatments, and disease management.
32846714|NCT04740060|Experimental|Augmented Feedback without Virtual Reality(VR)|
32846715|NCT04740060|Experimental|Augmented Feedback with Non-Game based VR|
32846716|NCT04740060|Experimental|Augmented Feedback with Game based VR|
32846717|NCT05580289|No Intervention|control group|Routine care of the patient will be done and the level of pain will be determined with McGill pain scale questionnaire short form
32903147|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
32903148|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
33320055|NCT05610644|Experimental|TRAD of 2RDA|A typical American dietary ingestion pattern of twice the RDA of protein/day.
33320056|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
33320057|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
33320058|NCT03973463|Sham Comparator|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
33320059|NCT03973463|Experimental|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
33320060|NCT03973463|Experimental|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
33320061|NCT01308320|Placebo Comparator|saline|control group
33320062|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
33320063|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
33320064|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
33320065|NCT01072253||eye amputated|lost an eye
33320066|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
33320067|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
33320068|NCT05693714||1|One group who have adenovirus infection
33320069|NCT05695196|Experimental|direct NMT|swab parent nares then insert swab directly into neonate nares
33320070|NCT05695196|Experimental|indirect NMT|swab parent nares, inoculate swab into saline, instill liquid into neonate nares
33320071|NCT05695196|Placebo Comparator|placebo|instill sterile saline into neonate nares
33320072|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
33320073|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
33320074|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
33320075|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
32846718|NCT05580289|Experimental|detrimental group|Warm half shower + dry hot application will be applied to the experimental group in the early postoperative period.mplementation Phase: After mobilizing the patients in the experimental group, who have regained their muscle strength and can be mobilized, their legs will be washed with 40-45oC warm tap water for 5 minutes (down from the hip level) until their legs are up to the femur acetabulum level, and then the patient will be taken to the bed for 20 minutes. Dry hot application will be done over the bladder. Palpation and bladder examination will be performed every hour to understand bladder filling in patients who will be expected to urinate within 6-8 hours after surgery.
32846719|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
32846720|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
32846721|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
32846722|NCT04720326|Experimental|Envarsus®|Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
32846723|NCT04720326|Active Comparator|Advagraf®|Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
32846724|NCT04080986|No Intervention|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32846725|NCT04080986|Active Comparator|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32846726|NCT04080986|Active Comparator|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
32846727|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
32846728|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
32846729|NCT05580211|Other|Investigational Stimulation Pattern 1-Randomized|
32846730|NCT05580211|Other|Investigational Stimulation Pattern 2-Randomized|
32846731|NCT05580211|Other|Investigational Stimulation Pattern-Open Label|
32846732|NCT05580133||Peroneus Longus Tendon autograft|All-Inside Single-Bundle for ACL Reconstruction with Full Thickness of the Peroneus Longus Tendon
32846733|NCT05580133||six-strand-hamstring autograft|All-Inside Single-Bundle for ACL Reconstruction with six-strand-hamstring autograft
32846734|NCT04697784|Experimental|Subjects who receive the TREO Abdominal Stent-Graft System|Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.
32846737|NCT03895489|Experimental|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
32846738|NCT03895489|Active Comparator|Stryker|Stryker Triathlon Total Knee prosthesis
32846739|NCT03895489|Active Comparator|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
32846740|NCT04688502|Experimental|high intensity interval training wearing a face mask|high intensity interval training wearing a face mask
32846741|NCT04688502|Active Comparator|high intensity interval training wearing no face mask|high intensity interval training wearing no face mask
32846742|NCT04688502|Experimental|continuous exercise training wearing a face mask|continuous exercise training wearing a face mask
32846743|NCT04688502|Active Comparator|continuous exercise training wearing no face mask|continuous exercise training wearing no face mask
32846744|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
32846745|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
32846746|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
32846747|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
32846748|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
32846749|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
32846750|NCT04188756|Other|Exercise|Group under exercise training for 15 weeks with High intenstiy interval training under medical control
32846751|NCT04188756|No Intervention|Control|Group with standard care according to current guidelines
32846752|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~smooth and soft stool like sausage or snake~Voluntary participate in this study"
32846753|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
32846754|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
32958467|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
32846755|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
32846756|NCT04688190||Transcatheter Mitral Valve Implantation (TMVI)|Patients with successful TMVI screening, who underwent Transcatheter Mitral Valve Implantation subsequently. All devices may be included.
32846757|NCT04688190||Interventional mitral valve edge-to-edge repair (E2E)|Patients with TMVI screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair.
32846758|NCT04688190||Mitral valve surgery (Surgery)|Patients with TMVI screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement).
32846759|NCT04688190||Medical therapy (OMT)|Patients with TMVI screening failure, who subsequently underwent conservative or optimal medical therapy (OMT).
32846760|NCT05589649|Experimental|Erector spinae plane block|Ultrasound-guided erector spinae plane block
32846761|NCT05589649|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
32846762|NCT04405921|Experimental|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
32846763|NCT04405921|Active Comparator|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
32846764|NCT05113836||Any patient hospitalised in intensive care for a COVID-19 infection.|Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study.
32846765|NCT05583565|Experimental|study group|receiving sensory integration approach
32846766|NCT05583565|Active Comparator|control group|receiving conventional physical therapy
32846767|NCT04516902|Experimental|100 μg LSD + MDMA placebo|100 μg LSD + MDMA placebo
32846768|NCT04516902|Experimental|LSD placebo +100 mg MDMA|LSD placebo +100 mg MDMA
32846769|NCT04516902|Experimental|100 μg LSD + 100 mg MDMA|100 μg LSD + 100 mg MDMA
32846770|NCT04516902|Placebo Comparator|LSD placebo+ MDMA placebo|LSD placebo+ MDMA placebo
33406177|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
33406178|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
33406179|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
32846774|NCT04516434|Experimental|Intraurethral Electrical Stimulation|"This procedure is specific to the urethral stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the urethra and positioned with the electrode contact 10-14 mm from the bladder neck to stimulate the proximal urethra. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be 2-20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to the proximal urethra at strong desire to void during cystometry. The participant will then be given permission to void at maximum cystometric capacity with continuous intraurethral stimulation."
32846775|NCT04516434|Experimental|Intravesical Electrical Stimulation|This procedure is specific to the bladder stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the bladder through the urethra and the electrode contacts will be positioned to be floating within the bladder. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be set at 20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to bladder sensory nerves for up to 60 minutes prior to the start of urodynamic studies.
32846776|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
32846777|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
32846778|NCT05113602|Experimental|Simultaneous acquisition of EEG signals|
32846779|NCT05113134|Experimental|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder
32846780|NCT04406077|Experimental|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
33406180|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
33406181|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
33406182|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
33406183|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
33406184|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
33406185|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
33406186|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
33406187|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
33406188|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
33406189|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
33406190|NCT02896400|No Intervention|Control|Control arm, no intervention
33406191|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
33406192|NCT04691154|Experimental|L606|
33406193|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
32846781|NCT03919266|Other|Control|usual antibiotic treatment
32846782|NCT03919266|Experimental|Intervention|targeted antibiotic treatment according to the results of PCR multiplex
32846783|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Zinc.|Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma
32846784|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Vitamin D|Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals
32846785|NCT04765267|Other|Topical Corticosteroid|Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm
32846786|NCT04405531|Experimental|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
32846787|NCT04405531|Experimental|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
32846788|NCT02487420|Other|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
32846789|NCT02487420|Other|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
32846790|NCT05583409|Experimental|Osimertinib plus SBRT|SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment
32846791|NCT05583409|Active Comparator|Osimertinib|Osimertinib 80mg, po, Qd
32846792|NCT03916302||Complicated outcome|"The patients meet at least one of the following criteria:~systolic blood pressure < 90 mmHg for at least 15 minutes~need for catecholamine administration because of persistant arterial hypotension or shock~need for mechanical ventilation~need for cardiopulmonary resuscitation~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
32846793|NCT03916302||Non-complicated outcome|"The patients meet none of the following criteria:~systolic blood pressure < 90 mmHg for at least 15 minutes~need for catecholamine administration because of persistant arterial hypotension or shock~need for mechanical ventilation~need for cardiopulmonary resuscitation~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
32846794|NCT04405453|Active Comparator|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
32846795|NCT04405453|Active Comparator|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
32846796|NCT05112588|Experimental|Individual and digital support Intervention (IDSI)|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit according to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
32846797|NCT05112588|No Intervention|Care as usual|One arm including in women with gestational diabetes who will be subject to care as usual at the Health care unit.
32846798|NCT05112588|No Intervention|Control|One arm with women with normal glucose tolerance as control. Will be examined carefully at the same time-point as women in the intervention.
32846799|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
32846800|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
32846801|NCT03890484|Experimental|New Peers|Participants will drink with two new peers (i.e. strangers), who they did not know prior to the study and their Peer Type.
32846802|NCT03890484|Experimental|Close Friends|Participants will recruit and drink with two of their close friends and their Peer Type
32846803|NCT03893539|Other|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
32846804|NCT05112510||event group|The patients with nasopharyngeal carcinoma developed distant metastasis or recurrence after standard treatment.
32846805|NCT05112510||non-event group|The patients with nasopharyngeal carcinoma did not develop distant metastasis or recurrence after standard treatment.
32958468|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
33320076|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
33320077|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
32958469|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
32958470|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
32958471|NCT03014856||OB-NMR|overweight and obese children and adolescents
32958472|NCT03014856||NMR-C|normal-weight children and adolescents
32958473|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
32958474|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
32958475|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
32958476|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
32958477|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
32958478|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
32958479|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
32958480|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
33320078|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
33320079|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
33320080|NCT01306838|Active Comparator|Control Group|Routine care
32958481|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
32958482|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
32958483|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
32958484|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
32958485|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
32958486|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
32958487|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
32958488|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
33320081|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
33320082|NCT03788018|Experimental|Effect of IV saline on PONV|
33320083|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
33320084|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
33320085|NCT05585060|Experimental|PEEP titration for mechanical ventilated AECOPD patients|Pre- and post-self-controlled trials for invasive mechanical ventilated AECOPD patients during PEEP titration.
32903149|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
32903150|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
32903151|NCT05144737|Other|Immediate Intervention Group|Participants in the immediate intervention group will immediately begin 6 months of the adapted DPP lifestyle intervention with a Lifestyle Coach and remote monitoring of blood pressure and body composition. This will be followed by a 6-month observation period where the intervention (Lifestyle Coach) will be withdrawn. In this period, participants will be evaluated for the maintenance of lifestyle changes.
32903152|NCT05144737|Other|Delayed Intervention Group|Participants in the delayed intervention group will receive remote monitoring of blood pressure and body composition for the 1st 6 months (without the Lifestyle Coach) and then will receive the adapted DPP lifestyle intervention with a Lifestyle Coach after 6 months.
32903153|NCT05134363|Active Comparator|Dexmedetomidine 0.5 mic/kg bolus|selective alpha 2 adrenergic receptor agonist
32903154|NCT05134363|Active Comparator|dexmedetomidine 0.75 mic/kg bllus|selective alpha 2 adrenergic receptor agonist
32903155|NCT05134363|Placebo Comparator|Placebo group|receving equal volume of normal saline
32903156|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
32903157|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
32903158|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
32903159|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
32903160|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
32903161|NCT05069155|No Intervention|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
32903162|NCT05069155|Experimental|Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period.~At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design."
32903163|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
32903164|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
32903165|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
32903166|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
32903167|NCT03006445|Experimental|FYU-981|
32903168|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
32903169|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
32903170|NCT05011123|Experimental|Group 1|1 injection of vYF vaccine at Day 1
32903171|NCT05011123|Active Comparator|Group 2|1 injection of Stamaril vaccine at Day 1
32903172|NCT05007847|Active Comparator|Active|Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
32903173|NCT05007847|No Intervention|Control|Participants in the control arm will be advised to continue with the standard of care and advised to contact their direct clinical team or primary care physician should they experience any symptoms of concern (palpitations, dizziness, collapse). They will be contacted by the study team at 6 and 12 months for clinical assessment (symptoms, hospitalisation data, further stroke events, mortality).
32903174|NCT05237479|Placebo Comparator|Control Group|DAA THA under spinal anesthesia ( standard of care at Montefiore)
32903175|NCT05237479|Active Comparator|Intervention Group|DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
32903176|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
32846806|NCT05112354|Experimental|the main group|"Management plan~If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator"
32846807|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
32846808|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
32846809|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
32846810|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
32846811|NCT05109624|No Intervention|group(A) control group|pronation cycles each last for 16 hours every 24 hours
32846812|NCT05109624|Active Comparator|group(B)|pronation cycles each last for 24 hours followed by 6 hours supine position
32846813|NCT05105334|Experimental|Nonablative fractional laser alone|
32846814|NCT05105334|Experimental|Nonablative fractional laser alternating with microneedling with radiofrequency|
33320086|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
33320087|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
32846817|NCT05112120||Single centre single arm observational cohort|Olumiant (4mg) will be administered in line with standard of care guidance. This is the standard dose in line with license for use in active moderate to severe RA. A dose adjustment from 4mg to 2mg is permitted during the study depending on side-effects
32846818|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
32846819|NCT03587155||Control|Embryo or infant without ASNS mutation.
32846820|NCT03639324|Experimental|Dose Combination 1-1|idelalisib + venetoclax
32846821|NCT03639324|Experimental|Dose Combination 1-2|idelalisib + venetoclax
33320088|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
33320089|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
33320090|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
32846822|NCT03639324|Experimental|Dose Combination 1-3|idelalisib + venetoclax
32846823|NCT03639324|Experimental|Dose Combination 1-4|idelalisib + venetoclax
32846824|NCT03639324|Experimental|Sub-Trial Dose Combination 2-1|idelalisib + venetoclax
32846825|NCT03639324|Experimental|Sub-Trial Dose Combination 2-2|idelalisib + venetoclax
32846826|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
32846827|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
32846828|NCT05702749|Active Comparator|Intervention: PREHAB and Surgery|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo microsurgical resection of VS.
32846829|NCT05702749|Placebo Comparator|Control: Surgery (No PREHAB)|Subjects will undergo microsurgical resection of VS.
32846830|NCT05702749|Active Comparator|Intervention: PREHAB and SRS|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo stereotactic radiosurgery.
32846831|NCT05702749|Placebo Comparator|Control: SRS (No PREHAB)|Subjects will undergo stereotactic radiosurgery.
32846832|NCT03625986|Experimental|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 58 mg/ml nicotine for the duration of 6 weeks.
32846833|NCT03625986|Placebo Comparator|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
32846834|NCT05583253|Active Comparator|Vitrectomy group with previous refractive surgery|Cases with primary retinal detachment that are prepared for pars-plana vitrectomy with previous history of refractive surgery.
32846835|NCT05583253|Active Comparator|Vitrectomy group with no previous intraocular surgery|Subjects with primary retinal detachment that are prepared for pars-plana vitrectomy with no previous history of intraocular surgery.
32846836|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
32958489|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
32958490|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
32958491|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
32958492|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
32958493|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
32958494|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
32958495|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
32958496|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
32958497|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
32958498|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
32958499|NCT03013764|Placebo Comparator|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
32958500|NCT03013764|Experimental|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
32958501|NCT03013530||Patients with chronic disease|
32958502|NCT03013296|Placebo Comparator|Placebo|Saline
32958503|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
32958504|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
32958505|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
32958506|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
32958507|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
32958508|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
32958509|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
32958510|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
32958511|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
32958512|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
32958513|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
32958514|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
32958515|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
32958516|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
32958517|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
32958518|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
32958519|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
32958520|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
33033416|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
32846837|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
32846838|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
32846839|NCT05583175|Experimental|Venetoclax plus RIC|Administration with oral Venetoclax plus RIC regimen for allo-HSCT in the elderly patients with myeloid malignancies.
32846840|NCT05099562|Experimental|Acupuncture group|This is a one-arm study. Breast cancer patients with peripheral neuropathy were measured using the FACT/ GOG-Ntx and EORTC QLQ-CIPN20 scales. Our clinical study included breast cancer patients diagnosed with peripheral neurotoxicity caused by taxanes-based drugs who would receive acupuncture treatment. Neurotoxicity was identified based on NCI-CTCAE 5.0 for daily or almost daily numbness in the hands and feet, tingling, and other symptoms of peripheral neuropathy over the past two to three weeks. Blood samples were collected from patients to detect SNP associated with neurotoxicity.
32846841|NCT05583097|No Intervention|Selective cytology according to EU-TIRADS|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed according to EU-TIRADS criteria.
32846842|NCT05583097|Active Comparator|Non-selective cytology|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed on all nodules >1 cm. Cytology will also be performed on EU-TIRADS 5-nodules measuring between 0.5 and 1 cm.
32846843|NCT03542994|Other|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
32846844|NCT03542994|Other|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
32846845|NCT03542994|Other|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
32846846|NCT03542994|Other|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
32846847|NCT03542994|Other|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
32846848|NCT03542994|Other|Cohort 6|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 660 mg, capsule, once daily, 29 days"
32846849|NCT03542994|Other|Cohort 7|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
32846850|NCT03542994|Other|Cohort 8|up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days
32846851|NCT03542994|Other|Cohort 9|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
32846852|NCT03891901|Experimental|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
32846853|NCT03891901|Experimental|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
32846854|NCT03891901|Experimental|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
32846855|NCT03891901|Experimental|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
32846856|NCT03891901|Experimental|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
32846857|NCT03891901|Experimental|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
32846858|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
32846859|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
32846860|NCT05098392|No Intervention|Treatment as usual/Sibling interaction|Children with autism will spend time with their typically developing siblings for 20-30 mins at least three times a week
32846861|NCT05098392|Experimental|Sibling-mediated intervention|Children with autism will receive explicit instruction from their typically developing siblings
32846862|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
32846863|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
32903177|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
32903178|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
32903179|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
32903180|NCT02980939|Placebo Comparator|Euhydration - no thirst|
32958521|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
32958522|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
32958523|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
33406194|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
33406195|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
33406196|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
33406197|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
33406198|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
33406199|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
33406200|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
33406201|NCT05283902||Effectiveness group|There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study.
33406202|NCT05283902||Elderly group - Immunogenicity|240 participants from the Effectiveness group, with quotas distributed by sex (50% male and 50% female) and age group, will be invited to participate in biological sample collection for the immunogenicity study.
33406203|NCT05283902||Immunosupressed group|240 biorepository samples from a cohort of immunosuppressed patients with autoimmune diseases who received the fourth dose, in a study conducted by the same team of researchers.
33406204|NCT05284448|Experimental|Pentoxifylline Group|25 patients will receive pentoxifylline (Trental SR®) 400 mg three times daily with their standard therapy for 6 months.
33406205|NCT05284448|No Intervention|Control Group|25 patients will receive their standard therapy only
33406206|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
33406207|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
33406208|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
33406209|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
33406210|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
33406211|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
33406212|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
33406213|NCT03032250|Experimental|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
33406214|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
32846864|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
32846865|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
32846866|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
32846867|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
33406215|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
32846868|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
32846869|NCT04081896||In Clinic Rehabilitation|Participants who are undergoing supervised exercise based rehabilitation in the SpineZone clinic
32846870|NCT04081896||Online Rehabilitation|Participants who will be undergoing online-based coaching and exercise as prescribed via telephone, online chat, or web-based interactions with SpineZone rehabilitation staff (physical therapists and physicians)
32846871|NCT05582863|Experimental|Intervention group.|"The experimental group attended a VR exercise routine twice a week for 12 weeks.~Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state."
33320091|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
32958524|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
33320092|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
32846872|NCT05582863|No Intervention|Control group.|Participants in the control group received no intervention and had normal daily activites.
32846873|NCT05582785|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
32846874|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
32846875|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
32846876|NCT03452826|Experimental|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
32846877|NCT03452826|No Intervention|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
32846878|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
32846879|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
32846880|NCT03437616|Experimental|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
32846881|NCT03437616|No Intervention|Control group|Control group does not receive Tulppa rehabilitation during the study.
32846882|NCT05702515||Adult male patients scheduled to receive a PICC insertion|Adult male patients scheduled to receive a PICC insertion using the Vascular Positioning System G4 tip navigation system
32846883|NCT05040126|Active Comparator|Arm 1 - 26 weeks of BDQ +Pa + LZD (600mg)|"26 wks. of BDQ +Pa + LZD (600mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in Arm1.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
32846884|NCT05040126|Experimental|Arm 2 - 9 weeks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg)|"9 wks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 2 and ½ tablet of 600 mg once daily in CP of Arm 2 .~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
32903181|NCT02980939|Experimental|Dehydration - no Thirst|
32903182|NCT04987723|Other|AF + HFrEF cohort|"Left Ventricular Ejection Fraction (LVEF) < 50% by echocardiogram during routine screening or within 12 months prior to enrolment day. The echo must have been performed >3 weeks after optimisation of HF and rate control therapies, otherwise repeat imaging will be performed after this has been achieved~With~NYHA functional status II-III at the enrolment visit."
32958525|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
32958526|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
32958527|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
32958528|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
32958529|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
32958530|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
32958531|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
32958532|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
32958533|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
32958534|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
32958535|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
32958536|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
32958537|NCT03011502|Experimental|Experimental arm|
32958538|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
32958539|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
32958540|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
32958541|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
32958542|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
32958543|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
32958544|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
32958545|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
32958546|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
33320093|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
33320094|NCT05693636||Total Wrist Fusion|Patients with end-stage wrist arthritis treated with total wrist fusion.
32846885|NCT05040126|Experimental|Arm 3 -13 weeks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg)|"13 wks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 3 and ½ tablet of 600 mg once daily in CP of Arm 3.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
32846886|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
32846887|NCT03407040||1/Cancer Patients|Patients with a cancer diagnosis enrolled on protocol 03-C-0277
32846888|NCT05702437||MetS Group|it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.
32846889|NCT05702437||Control Group|it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.
32846890|NCT03221244|Experimental|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
32846891|NCT03221244|Active Comparator|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
32846892|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
32846893|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
32846894|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
32846895|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
32846896|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
32846897|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
32846898|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
32846899|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
32846900|NCT03100578|Experimental|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
32846901|NCT03100578|Active Comparator|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
32846902|NCT05582473|No Intervention|Wait-List Control Group|Randomized subjects will wait for a 3 month period before being assigned to the LST-LC education. This group of subjects will act as the control group.
32846903|NCT05582473|Other|Learning Skills Together-Latino Caregivers (LST-LC)|The study team convened a team of health care professionals, including nursing, occupational therapy, speech-language pathology, gerontology, nutrition, and dental hygiene, to develop a community-based education program for family caregivers.
32846904|NCT03069300|Experimental|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
32846905|NCT03069300|No Intervention|prednisolone|40mg prednisolone for 28 days
32846906|NCT05582317|Active Comparator|Biodentine|20 primary molars were treated by Biodentine
32846907|NCT05582317|Active Comparator|Simvastatin|20 primary molars were treated by Biodentine
32846908|NCT05582317|Active Comparator|combination of Biodentine and Simvastatin|20 primary molars were treated by Biodentine
32846909|NCT03977064|Experimental|Intensive treatment group|The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.
32846910|NCT03977064|No Intervention|Standard treatment group|Patients will be taken care of by general physician without lifestyle program.
32903183|NCT04987723|Other|AF + symptoms cohort|"Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrolment day~With~modified European Heart Rhythm Association symptom classification 2b-4."
32903184|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
32903185|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
32958547|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
32846911|NCT03891355|Experimental|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)~K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;~K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)~R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but < 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
32846912|NCT03954132||Subject with Chronic Obstructive pulmonary disease|
32846913|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
33320095|NCT05693636||Total Wrist Arthroplasty|Patients with end-stage wrist arthritis treated with total wrist arthroplasty of the fourth generation
32846914|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
32846915|NCT03898284||Impulse Oscillometry|Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.
32846916|NCT05702359|Experimental|Glucose as reference food|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3 and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32846917|NCT05702359|Experimental|Control juice|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3 and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32846918|NCT05702359|Experimental|Juice containing vitamin D3|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple, and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3, and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180 min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32846919|NCT05702359|Experimental|Juice containing ω3 fatty acids|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3 and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32846920|NCT05702359|Experimental|Juice containing probiotics|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3 and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32958548|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
32958549|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
32958550|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
33033417|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
33320096|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
32846921|NCT05702359|Experimental|Juice containing probiotics, vitamin D3 and ω3 fatty acids|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), and juice containing vitamin D3, juice containing ω3 fatty acids, juice containing probiotics and juice containing probiotics, vitamin D3 and ω3 fatty acids, each tested once, in different visits along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180min and salivary insulin 0, 15, 30, 45, 60, 90, 120 and 180min after food consumption. The first glucose and salivary insulin sample were taken exactly 15min after the first bite of food or drink.
32846922|NCT05028738|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
32846923|NCT05028738|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
32846924|NCT03886272|Experimental|BI 730357 (Test)|
33320097|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
33320098|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
33320099|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
32846925|NCT03886272|Experimental|BI 730357 (Reference)|
32846926|NCT05581927|Experimental|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure.
32846927|NCT05581927|Active Comparator|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia.
32846928|NCT02936388|Experimental|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
32846929|NCT02936388|Active Comparator|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
32846930|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
32846931|NCT04515342||Participants|This is a cross-sectional study involving approximately 150 patients. They undergo a physical examination, fill out a questionnaire, have blood samples drawn, undergo a Dual Energy X-ray Absorptiometry (DXA) scan and different physical procedures to assess muscle strength and muscle function.
32846932|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
32846933|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
32846934|NCT04591626|Experimental|Dulaglutide|Dulaglutide administered subcutaneously (SC) in combination with insulin glargine given SC.
32846935|NCT04591626|Placebo Comparator|Placebo|Placebo administered SC in combination with insulin glargine given SC.
32846936|NCT05702281|Other|ReLARC 3|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 3 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
32846937|NCT05702281|Other|ReLARC 10|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 10 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
32846938|NCT05702203|No Intervention|Standard Care|Infants allocated to the control group will receive standard care during admission. Standard care includes involvement of a multi-professional team consisting of medical and nursing team, psychologists/psychiatrists, social workers, breastfeeding counsellor, speech therapist, nutritional counsellor and physiotherapists
32846939|NCT05702203|Experimental|Creative Music Therapy|A certified, well-trained and experienced music therapist will formulate an individualized, culturally adapted treatment plan based on an initial infant-parent assessment, which includes assessment of parental needs, musical heritage, culture, context, and parental integration in the therapeutic process. During hospitalization 3 times per week 20 minutes of creative music therapy sessions will be performed, a minimum of 10 therapy session. After discharge, every other two weeks a music therapy session will be performed at home until the age of six months.
32846940|NCT04518306|Experimental|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
32846941|NCT04518306|Active Comparator|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
32846942|NCT04518306|Placebo Comparator|Placebo|Placebo
32846943|NCT03580135|Experimental|Propolis powder|"resin (50%),~vegetable Balsam, wax~essential aromatic oils (30%)~salivary secretions (10%)~pollen(5%)~other substances (5%) including amino acids~,ethanol vitamin A, B complex, and E, minerals, steroids~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
32846944|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
32846945|NCT03379272|Active Comparator|GOLD STANDARD|RECORDING WITH EEG GOLD STANDARD
32846946|NCT03379272|Experimental|NEURONAUTE|RECORDING WITH THE NEURONAUTE
32846947|NCT01890252|Experimental|Hyper CL|Hyper osmotic contact lens
32846948|NCT01890252|Experimental|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
32846949|NCT01890252|Active Comparator|saline solution|hypertonic solution
32846950|NCT03901573|Experimental|Checkpoint Inhibitor-Naive cSCC, MCC Pts|Anti-PD-1/PD-L1 naïve patients with cSCC and MCC
32846951|NCT03901573|Experimental|Checkpoint Inhibitor-Relapsed/Refractory cSCC MCC Melanoma Pts|Anti-PD-1/PD-L1 relapsed/refractory patients with cSCC, MCC and melanoma
32846952|NCT04765579||4in1|4in1 block will be applied in the operation room
32846953|NCT04765579||medical|medical analgesics will be applied in the service
33320100|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~database (Health Systems Evidence) access;~monthly e-mail alerts; and~full-text article availability."
32846954|NCT04369482|Active Comparator|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
32846955|NCT04369482|Active Comparator|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
32846956|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
32846957|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
32846958|NCT05585515|No Intervention|Control|16/8 hours wake/sleep regime for 3 consecutive days at home and for consecutive 2 days in sleep laboratory
32846959|NCT05585515|Experimental|Sleep restriction|18/6 hours wake/sleep regime for 3 consecutive days at home and one day in sleep laboratory, followed by recovery night of 8 hours sleep
32846960|NCT05585515|Experimental|Sleep deprivation|16/8 hours wake/sleep regime for 3 consecutive days at home, one night of sleep deprivation (24/0 hours) in sleep laboratory, followed by recovery night of 8 hours sleep
32846961|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
32846962|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
32846963|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
32846964|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
32846965|NCT05583019||Healthy Control|Those who do not have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Clear (0) or Almost Clear (1) on the Investigator's Static Global Assessment (ISGA) at intake.
32846966|NCT05583019||Mild Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Mild (2) on the Investigator's Static Global Assessment (ISGA) at intake.
32846967|NCT05583019||Moderate Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Moderate (3) on the Investigator's Static Global Assessment (ISGA) at intake.
32846968|NCT05583019||Severe Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Severe (4) on the Investigator's Static Global Assessment (ISGA) at intake.
32846969|NCT05701969|Experimental|Melatonin group|These subjects will receive melatonin
32846970|NCT05701969|Placebo Comparator|Placebo group|These subjects will receive placebo
32846971|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
32846972|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Patients receive dexamethasone PO BID for 7 days. Patients also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
32846973|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Patients receive placebo PO BID for 7 days. Patients also complete resistance training and moderate intensity walking as in Arm I.
32846974|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
32846975|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
32846976|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
32846977|NCT03583333|Experimental|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL/500 mg Cilastatin, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
32846978|NCT03583333|Active Comparator|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
32846979|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
32846980|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
32846981|NCT01602510|Placebo Comparator|Placebo|Placebo
32846982|NCT03899467|Experimental|Arm 1: biological dose group|"400mg/day of proxalutamide~Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
33033418|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
32846983|NCT03899467|Experimental|Arm 2: MTD dose group|"500mg/day of proxalutamide~Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
32846984|NCT04952142|Experimental|minimal water exchange|We suctioned the lumen and infused water by constant pressure on the air-water valve button of the endoscope at the rectum to open the lumen.
32846985|NCT04952142|No Intervention|traditional water exchange colonoscopy|The water exchange colonoscopy reached the cecum through continuous infusion and suction of water in the whole colon via an additional flushing pump.
33320101|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
33320102|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
32958551|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
33033419|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
33320103|NCT05694884|Placebo Comparator|Placebo|Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14
33320104|NCT05694884|Experimental|ASLAN004|Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose
33320105|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
32846986|NCT03887533|Experimental|VTS-270 at 500 mg/kg|Participant received dose of 500 mg/kg of intravenous VTS-270 administered over 2 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
32846987|NCT03887533|Experimental|VTS-270 at 1000 mg/kg|Participant received 1000 mg/kg of intravenous VTS-270 over 4 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
32846988|NCT04511754|Experimental|Experiential Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the experiential training condition, the trainees will receive information about the skills with examples and will have opportunity to practice using short video clips of actors portraying clients. The trainees will be asked to respond to the short clips using the skills they learned. A trainer (a graduate student in clinical psychology) will pause and process the trainees' reactions after they respond to each practice video clip and will provide feedback to the trainees about their performance on the practice.
32846989|NCT04511754|Active Comparator|Standard Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
32846990|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
32846991|NCT04945512|Experimental|Study group; Epidural catheter and PCA|Epidural catheter will be placed in the preoperative period. After induction, 10 ml of 0.25% bupivacaine will be administered through the epidural catheter and bupivacaine PCA will be started.
32846992|NCT04945512|No Intervention|Control group; No block, IC PCA|Postoperative pain control will be achieved with intravenous morphine PCA.
32846993|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
32846994|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
32846995|NCT04934982|Experimental|1|the group of LRH
32846996|NCT04934982|Active Comparator|2|the group of ARH
32846997|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
32846998|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
32846999|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
32847000|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
32847001|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
32847002|NCT04306458|Experimental|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
32847003|NCT04306458|Active Comparator|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
32847004|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32847005|NCT04501926||Controls|Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
33406216|NCT03444155|Active Comparator|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
33406217|NCT03444155|Active Comparator|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
33406218|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
33406219|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
33406220|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
33406221|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
32903186|NCT04906369||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
32903187|NCT05164471|Experimental|FLT180a|A single dose of FLT180a will be administered. Dose will be determined by enrollment cohort. The first 3 patients will receive 7.7 x 10e11 vg/kg. The dose in subsequent cohorts will be determined by the DMC based on review of data from the prior cohort(s).
32903188|NCT05160961|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
32903189|NCT05160961|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
32903190|NCT05673031||68Ga-HA-DOTATATE|68Ga-HA-DOTATATE Intravenous injection of 100-250 MBq 68Ga-HA-DOTATATE
32903191|NCT05672875||Healthy and Symptomatic Subjects|Blood sample testing on the Anthrax LF Dx System
32903192|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
32903193|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
32903194|NCT05672797|No Intervention|Control|Participants in the control group will not receive additional adherence reminders or financial incentives during the 9-month study.
32903195|NCT05672797|Experimental|Wellth|Participants will be eligible to receive $30 at the end of three consecutive 30-day periods ($90 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 4-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 4-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
32903196|NCT05672797|Experimental|Wellth + Habit Training|Participants will also be eligible for $30 at the end of three consecutive 30-day periods ($90 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Similar to T1, participants will lose $2 (from their $30 total) for every day they miss a check-in with the Wellth app within a 4-hour window around the time of day of their choosing at the start of each 30-day period. Participants will not have to pay money, i.e. they lose $2 per missed check-in from the $30 of incentives until their incentives equal $0. Thus, participants will be ineligible for any financial incentives if they miss more than 15 days in a 30-day period, where this group's check-in includes one photo of pill-taking and one photo of their contextual cue.
32903197|NCT02248051|Experimental|CXA-10|
32903198|NCT05672641|Experimental|Inertial training group|13 young men, physical education students. Inertial training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using Cyklotren device (Inerion, Poland).
32903199|NCT05672641|Experimental|Body building training group|13 young men, physical education students. Body building training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using traditional free weights.
32903200|NCT05672563|Experimental|women with previous CSP|experimental: women with previous cesarean scar pregnancy that are invited to our unit for sonographic evaluation.
32903376|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
32847006|NCT04501926||Cases|Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
32847007|NCT04161378||RHB-SG 01|Patients with early mobilization (< 2 days after the onset of symptoms)
32847008|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
32847009|NCT05701813|Experimental|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
32847010|NCT05701813|Placebo Comparator|PLACEBO|Cellulose 4.3 grams once a day for 90 days.
32847011|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
32847012|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
32847013|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
32847014|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
32847015|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
32847016|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
32847017|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
32847018|NCT05118984|Active Comparator|Azithromycin group|Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).
32847019|NCT05118984|Placebo Comparator|Placebo group|placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule every 12hrs for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.
32847020|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
32847021|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
32847022|NCT01927770||WES/WGS|Eligible adults (or parents of eligible children) consenting to enroll in an NIH study thatincludes WES/WGS.
32847023|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
32847024|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
32847025|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
32847026|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
32847027|NCT03580057|Experimental|BPI and D|Both interventions.
32847028|NCT03580057|No Intervention|Control|
32847029|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
32847030|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
32847031|NCT04514328|Experimental|one group|patients with mild or moderate Alzheimer disease
32847032|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
32847033|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
32847034|NCT02802852|Experimental|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
32903286|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
32903287|NCT00199238|Placebo Comparator|Placebo|Once daily/ 28 days
32903288|NCT00199238|Experimental|rupatadine 5mg|Once daily/ 28 days
32847035|NCT04405609|Experimental|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
32847036|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847037|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847038|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847039|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847040|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847041|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks~followed by a 4 weeks break (after last dose of 2nd cycle)~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
32847042|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
32847043|NCT00886548||Ultrasound performed|Single arm study.
32847044|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
32847045|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
32847046|NCT00409266|Other|Functional flexion axis of the knee|The functional flexion axis of the knee can be established by computer-assisted intra-operative data, through range of motion techniques, not specific landmarks such as epicondyles.
32847047|NCT04405375|Experimental|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
32847048|NCT05118672|Experimental|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Group 1: paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg FDC (experimental drug).
32847049|NCT05118672|Placebo Comparator|Placebo group|Group 2: Placebo
32847050|NCT05703217|Active Comparator|classical physical therapy and rehabilitation program|In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
32847051|NCT05703217|Active Comparator|virtual reality assisted walking and balance exercise program|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds.
32847052|NCT05118438|Experimental|Nursing intervention|The recruited participants were clients of a self-sufficiency support center for sexually exploited women located in South Korea, recruited through snowball sampling after obtaining permission from the director of the support center.
32847053|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~sweet orange (Citrus sinensis L. Persoon)~fine lavender (Lavandula angustifolia P. Miller)~little seed from the mandarin tree (Citrus reticulata blanco)"
32847054|NCT03583801|Placebo Comparator|without aromatherapy|
32847055|NCT05106348||Wheelchair Rugby Group|wheelchair rugby players, elite athletes, national team athletes
32847056|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
32847057|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
32847058|NCT05073588|Active Comparator|Indo Mediterranean diet|Indian version of Mediterranean diet will be given to NAFLD children
32847059|NCT05073588|Active Comparator|Calorie restricted Diet|Diet restricted in calories will be given to NAFLD children
32847060|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
32847061|NCT02776488|Experimental|ELI Arm|Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
32847062|NCT02776488|Placebo Comparator|Placebo|Placebo infusion of normal saline in Part 2 RCT
32847063|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
32847064|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
32847065|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
32738982|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
32847066|NCT02750826|Other|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
32847067|NCT02750826|Other|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
32847068|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
32847069|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
32847070|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
32847071|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
32847072|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
32847073|NCT05701579||Patients with ACL Degeneratio Mucosa|Patients with ACL Degeneratio Mucosa
32847074|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
32847075|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
32847076|NCT04765501||Patients group|Individuals with headache
32847077|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
32847078|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
32847079|NCT05701501|Experimental|Vitamin B5 group|Based on the standard IBD treatment, Vitamin B5 (5mg/tablet) is given orally three times a day, four tablets each time, for 12 weeks.
32847080|NCT05701501|Placebo Comparator|Control group|Based on the standard IBD treatment, the same type of placebo tablets are given orally three times a day, four tablets each time, for 12 weeks.
32847081|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
32847082|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
32847083|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
32847084|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
32847085|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
32847086|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
32847087|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
32847088|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
32738983|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
32738984|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
32847089|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
33406222|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
32847090|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
33406223|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
33406224|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
32847091|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
32847092|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
32847093|NCT03583489|Placebo Comparator|Placebo|
32847094|NCT03583489|Experimental|APD421|
32847095|NCT03583489|Experimental|APD421 + ondansetron|
32847096|NCT03159871|Experimental|Stratafix suture|
32847097|NCT03159871|Active Comparator|Vicryl suture|
32847098|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
32847099|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
32847100|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
32847101|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
32847102|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
32847103|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
32847104|NCT02594124|Experimental|Group 1|Participants transitioned from ISIS 396443-CS3B (NCT02193074)
32847105|NCT02594124|Experimental|Group 2|Participants transitioned from ISIS 396443-CS4 (NCT02292537)
32847106|NCT02594124|Experimental|Group 3|Participants transitioned from ISIS 396443-CS12 (NCT02052791)
32847107|NCT02594124|Experimental|Group 4|Participants transitioned from ISIS 396443-CS3A (NCT01839656)
32847108|NCT02594124|Experimental|Group 5|Participants transitioned from 232SM202 (NCT02462759)
32847109|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
32847110|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
32847111|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
32847112|NCT04965168|Active Comparator|controls|phacoemulsification and IOL implantation
32847113|NCT04965168|Active Comparator|diabetic without pseudoexfoliation|phacoemulsification and IOL implantation
32847114|NCT04965168|Active Comparator|non-diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
32847115|NCT04965168|Active Comparator|diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
32847116|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
32847117|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
32847118|NCT03158467||Phase 1|
32847119|NCT03158467||Phase 2|
32847120|NCT04937478||Hemodialysis patients|Patients who undergo hemodialysis in hospital every two to three days.
32847121|NCT05117580|Experimental|Active group|The active group get telemedicine devices, and lifestyle interventions.
32847122|NCT05117580|No Intervention|Comparator Group|The comparator group get the evidence based treatment.
32847123|NCT03583177||healthy volunteers|
32847124|NCT03583177||cancer patients|
32847125|NCT03583177||undergoing chronic hemodialysis patients|
32847126|NCT04886544|Experimental|Test group|Hyaluronic acid dermal filler at Week 0
32847127|NCT04886544|No Intervention|Control group|Remain untreated until Week 26
32847128|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
32847129|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
32847130|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
32847131|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
32847132|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
32847133|NCT04818372|Experimental|Dose escalation|"Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.~Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg)."
32847134|NCT04818372|Experimental|Dose expansion _Cohort 1|This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
32903289|NCT00199238|Experimental|rupatadine 10 mg|Once daily/ 28 days
32847135|NCT04818372|Experimental|Dose expansion _Cohort 2|This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
32847136|NCT05701189|Experimental|Efgartigimod Alfa-Fcab|20mg/kg of Intravenous efgartigimod on days 1 and 5, with normal saline administered as placebo on days 2-4
32847137|NCT05701189|Active Comparator|Intravenous Immunoglobulin (IVIg)|0.4g/kg of IVIg daily for 5 days
32847138|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
32847139|NCT01462578|Experimental|Azacytidine|Azacytidine injection: 75 mg/m²/d, subcutaneous
32847140|NCT04601844|Experimental|Cohort 1|Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
32847141|NCT04601844|Experimental|Cohort 2|Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
32847142|NCT04601844|Experimental|Cohort 3|Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1
32847143|NCT03059173|Experimental|Myo-Inositol + Levomefolic acid|The experimental group will receive the dietary supplement: 4 g of MYO + 0.736 mg of 5-MTHF, glucosamine salts per day per os (in 2 bags per day) in addition to the standard therapy (Clomiphene Citrate).
32847144|NCT03059173|Placebo Comparator|Placebo|The control group will receive the standard therapy ( Clomiphene Citrate) and a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
32847145|NCT05117268|Experimental|Silver Diamine Fluoride|In the experimental group, 44 children will be provided with SDF application, after gross debris removal to allow better contact of SDF. The entire dentition will be treated with sodium chloride fluoride varnish to prevent caries.
32847146|NCT05117268|Placebo Comparator|Glass Ionomer Restoration|In placebo control group n= 44 participants will be enrolled. High viscosity glass ionomer restoration will be placed after complete caries excavation using high-speed handpiece and air/water coolant. Patient will be dispensed with clear postoperative instructions.
32847147|NCT05117268|Active Comparator|Hall Technique|In active comparator group, n= 44 study participants will be enrolled. Pre-formed metal crowns will be selected according to the tooth size and filled with low viscosity glass ionomer cement and seated using digital/ finger pressure.
32847148|NCT05122338|Placebo Comparator|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
32847149|NCT05122338|Active Comparator|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
32847150|NCT05122338|Active Comparator|Compound lidocaine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
32847151|NCT05122338|Active Comparator|Compound lidocaine and esketamine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine and 0.4mg/kg esketamine are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
32847152|NCT05701111|Experimental|Mindfulness Curriculum|Participants will undergo a mindfulness curriculum in the classroom for 6-8 weeks and complete surveys before the start and after completion.
32847153|NCT05701111|Experimental|Teachers|Participants will be trained in the mindfulness curriculum and implement it in the classroom for 6-8 weeks. They will complete surveys before training and after implementation.
32847154|NCT05701111|Experimental|Counselors|Participants will be trained in Cue-Centered Therapy and implement the treatment with student clients for 15-18 weeks. They will complete surveys before training and after 3 months after the start of implementation.
32847155|NCT05701111|Experimental|CCT|Participants that report PTSD symptomatology during the mindfulness curriculum surveys will be eligible to participate in Cue-Centered Therapy treatment for 15-18 weeks. They will complete surveys before and after treatment.
32847156|NCT05701111|Other|iSWAB-DNA|Students that give prior consent to participating in DNA buccal swabs and the mindfulness curriculum are randomly selected to give buccal swabs prior to and after the mindfulness curriculum intervention. A subset of those students that qualify for CCT will give another buccal swab after CCT completion. DNA will be sent to Dr. Urban's lab for analysis of genetic resilience markers.
32847157|NCT05116644||Included patients|Included patients: 165
32847158|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
32847159|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
32847160|NCT04386174|Other|Group A|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
32847161|NCT04386174|Other|Group B|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
32847162|NCT04014894|Experimental|ET019003-T Cells|The trial will enroll 9 patients with leukemia and 9 patients with lymphoma. Each disease has 3 dose-levels.
32847163|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
32847164|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
32847165|NCT05121870|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|standard of care (SOC) plus UC-MSCs
32847166|NCT05121870|Placebo Comparator|Placebo|SOC plus placebo.
32847167|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
32847168|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
32903290|NCT00199238|Experimental|rupatadine 20 mg|Once daily/ 28 days
33406225|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
33406226|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
32903291|NCT05671315|Experimental|Combined treatment group|Peginterferon alfa-2b Injection combined Nucleos (t) ide Analogue therapy
32903292|NCT05671315|Active Comparator|Monotherapy group|Nucleos (t) ide Analogue monotherapy
32903293|NCT05671081|Active Comparator|General anethesia +Dexmedetomidine plus Bupivacaine for Erector spinae plane block|
32903294|NCT05671081|Active Comparator|General anethesia +Magnesium sulfate plus Bupivacaine for Erector spinae plane block|
32903295|NCT05671081|Active Comparator|general anesthesia+conventional postoperative narcotic analgesia|
32903296|NCT05670067|Active Comparator|immediate implant with bone graft (autogenous)|with immediate implant placement autogenous grafting using maxillary tuberosity will be done
32903297|NCT05670067|Active Comparator|immediate implant with bonegraft (xenograft)|with immediate implant placement grafting with xenograft will be done
32903298|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
32903299|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
32903300|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
32903301|NCT05666323|No Intervention|Control Group|The control group will not receive any intervention.
32903302|NCT05666323|Experimental|Phase 1: TM1|Patients in the TM1 condition will be randomized to receive either an autonomy supportive message, or a directive motivational message.
32903303|NCT05666323|Experimental|Phase 1: TM+|Patients in the TM+ condition will be randomized to receive 5 text messages in scheduled succession. These messages will be either an autonomy supportive message, or a directive motivational message.
32903304|NCT05666323|Experimental|Phase 2: TM1 and PN|Patients in the TM1 and PN condition will be randomized to receive either an autonomy supportive message, or a directive motivational message. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
32903305|NCT05666323|Experimental|Phase 2: TM1 continued|"Patients in the TM1 continued arm have the continued option to reply to the first text message in Phase 1: TM1. They do not receive any additional intervention."
32903306|NCT05666323|Experimental|Phase 2: TM+ and PN|Patients in the TM+ and PN condition will be randomized to receive 3 additional either autonomy supportive messages, or directive motivational messages. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
32903307|NCT05666323|Experimental|Phase 2: TM+ continued|Patients in TM+ continued will receive 3 additional either autonomy supportive messages, or directive motivational messages.
32903308|NCT05665933|Experimental|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|PSYCHOEDUCATION PROGRAM Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
32903309|NCT05665933|No Intervention|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION ON EXAM ANXIETY IN ADOLESCENTS|Similar training will be provided after the study is completed. Number of People: 30
32903310|NCT01799096|Experimental|Sucrose|Receives sucrose
32903311|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
32903312|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
32903313|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
32903314|NCT05516017|Experimental|Vestibular Electrical Stimulation and exercises with pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick ear and a cathode electrode is placed on the healthy ear.The skin to be treated will be cleaned and dried The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks. Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the experimental group will also wear pinhole glasses while applying VES."
32903315|NCT05516017|Active Comparator|VES and exercises without pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick side and the cathode will be placed on the healthy ear. The skin to be treated will be cleaned and dried. The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks.Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the active comparator will not wear pinhole glasses while VES is applied."
32903316|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
32903317|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
33320106|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
33320107|NCT03787784|Experimental|AI visible group|
32958552|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
32958553|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
32738985|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
32958554|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
32958555|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
32958556|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
32958557|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
32958558|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
32958559|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
32958560|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
32958561|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
32958562|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
32958563|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription~, every bag weighs 4.87g, take it one bag each time, two times a day."
32958564|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
32958565|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
32958566|NCT03009786||Elderly institutionalized subjects or outpatients|
32958567|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
32958568|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
32958569|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
32958570|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
32958571|NCT03009084|No Intervention|Control group|Usual care.
32958572|NCT03008694|Experimental|1|PET/CT
32958573|NCT03008928|No Intervention|Control|No intervention
32958574|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
32958575|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
32958576|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
32958577|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
32958578|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
32958579|NCT03008772||Stent Types|the stent types for angina classification at follow up
32958580|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
32958581|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
32958582|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
32958583|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
32958584|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
33320108|NCT03787784|No Intervention|AI invisible group|
33320109|NCT05694806||patients with symptomatic Mediastinal mass syndrome|patients with symptomatic Mediastinal mass syndrome at diagnosis or at relapse of a patient with haematological malignancy admitted to the Intensive Care unit
33320110|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
32847169|NCT03918486||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
33103947|NCT05599581|No Intervention|Standard of care HIV (Usual) prevention services only|Participants in the non-intervention (control) wards will have access to evidence-based standard of care HIV prevention services offered throughout the county. These include PrEP delivery through Ministry of Health facilities, which is accessible to all AGYW.
33103948|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
33103949|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
33103950|NCT04772274|Experimental|SB17|SB17 (proposed ustekinumab biosimilar)
33320111|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
33320112|NCT03790358|Placebo Comparator|Placebo|Placebo
33320113|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
33320114|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
33320115|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
33320116|NCT03790514|Experimental|Heat Wrap Group|
33320117|NCT03790514|Placebo Comparator|Control Group|
33320118|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
32738986|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
32738987|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
32738988|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
32738989|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
32738990|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
32738991|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
32738992|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
32738993|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
32738994|NCT04992663|Experimental|Intervention group (VR-group)|"The participants randomised into this group are offered the BirthVR intervention during Labour.~The VR group receives a VR information moment during labour and the possibility to exercise with the VR glasses and they receive VR during labour from the moment they are in active labour and use VR as much as they prefer. After labour, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated and participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5).~As soon as VR does not serve as adequate pain relief during labour and a women requests additional pain medication this will be offered according to local protocol."
33103951|NCT04772274|Active Comparator|EU Stelara|EU sourced Stelara (ustekinumab)
33103952|NCT04772274|Active Comparator|US Stelara|US sourced Stelara (ustekinumab)
33320119|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
33406227|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
32738995|NCT04992663|No Intervention|Care as usual group|Patients randomised to the care as usual group will be offered pain medication during labour according to the local protocol, and on maternal request only. Postpartum participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5)
32738996|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm, all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
33406228|NCT04114110||Admitted inpatients|no intervention
33406229|NCT04114110||Staff with RTLS badges|no intervention
33406230|NCT03931902|Experimental|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
33406231|NCT03931902|Active Comparator|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
32847170|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
32847171|NCT03874494|Experimental|Brexpiprazole|2-4 mg/day, once daily for 6 weeks, oral administration
32847172|NCT03874494|Active Comparator|Aripiprazole|10-20 mg/day, once daily for 6 weeks, oral administration
32847173|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
32847174|NCT05113992|Experimental|Intervention group massaged with frankincense and myrrh oil|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm. Individuals who did not develop any reaction after thirty minutes and who met other inclusion criteria were included in the study. At the beginning of the study, the patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using 4% massage oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
32847175|NCT05113992|Sham Comparator|. Placebo group massaged with jojoba oil,|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm. Individuals who did not develop any reaction after 30 minutes and who met other inclusion criteria were included in the study. At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using jojoba fixed oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
32847176|NCT05113992|No Intervention|Control group|At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. No intervention was applied to individuals in the control group. In order to ensure standardization between the groups, after 15 minutes of verbal communication, they were taken to the EPS process. After the procedure, VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
32847177|NCT05696119|Experimental|I-PROTECT|I-PROTECT includes physical and psychological injury prevention information and training (i.e., the intervention) and tailored support to implement it specifically developed for Swedish community youth handball.
32847178|NCT05696119|Active Comparator|Control group|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
32847179|NCT04436328|Experimental|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
32847180|NCT04436328|Active Comparator|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
32847181|NCT05692921|Experimental|Remote Home Monitoring (RHM)|Remote Home Monitoring Platform (RHM): will be utilized to help tailor education and support for the patient after they have been discharged from the hospital. The platform will provide access to and delivery of health related education and information for continued self-care within the community. The platform will be used to evaluate post discharge symptoms and for health care providers to access the need for continued direct patient care and education through virtual processes.
32847182|NCT05692921|Active Comparator|Rapid Response Nursing (RRN)|"Rapid Response Nursing Team (RRN): The RRN will help clients/patients to:~Understand their current health conditions, treatments, how to manage symptoms and when/who to ask for help; Specifically; they will~Help clients to understand their hospital discharge plan;~Support patients during their recovery at home;~Reinforce and contribute to in-hospital education about heath health and recovering safely at home;~Review medications to help clients understand the purpose, side effects and how to take prescribed medications correctly, including assisting clients with getting prescriptions filled;~Connect with their Home Clinic, ensuring everyone has the necessary information for follow-up care;~Connect clients with a Home Clinic if they do not have one; and~Access appropriate home supports to help clients remain at home safely for as long as possible."
32847183|NCT05692921|No Intervention|Registry|"Registry Arm:~Patients who fit the criteria for study inclusion and choose not to participate in the main study will be provided with an opportunity to consent to the registry arm of the study. The registry arm of the study is an opportunity to establish a standard of care group free from research bias. Patients who enroll in the registry will only need to complete a short questionnaire before they are discharged home which will take approximately 5 minutes. Additionally, research staff will also complete a medical chart review to identify specific medical information related to their demographics, cardiac procedure, hospital stay, recovery, and to identify any re-admissions to hospital that may have occurred after the patient has been discharged home."
32847184|NCT04223466|Experimental|Subxiphoid group|Subxiphoid procedure for thymectomy.
32847185|NCT04223466|Active Comparator|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
32847186|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
33033420|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
33406232|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
33406233|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
33406234|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
33406235|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
33406236|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
33406237|NCT03658304|Experimental|Mitomycin C|
33406238|NCT04538040|Experimental|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
32847187|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
32847188|NCT05044806|Experimental|Ultrasound-guided-RIC group|Patients in the ultrasound-guided-RIC group will receive percutaneous coronary intervention (PCI), usual pharmacotherapy and pre-, per-, and post-operative ultrasound-guided remote ischemic conditioning (RIC). The pressure applied during cuff inflation is total occlusion pressure (TOP) determined with ultrasound measurement.
32847189|NCT05044806|Experimental|Traditional RIC group|Patients in the traditional RIC group will receive PCI, usual pharmacotherapy and pre-, per-, and post-operative traditional RIC. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
32847190|NCT05044806|Other|Control group|Patients in the control group will receive PCI and usual pharmacotherapy.
32847191|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
32847192|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
33406239|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
32847193|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
32847194|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
32847195|NCT05024292||Anterior circulation cerebral infarction|
32847196|NCT05024292||Posterior circulation cerebral infarction|
32847197|NCT02616432|Experimental|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
32847198|NCT02616432|No Intervention|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
32847199|NCT05690035|Experimental|patients with mCRC|Tislelizumab 200mg ivdrip every 3 weeks; Fruquintinib 5mg qd day 1-14, every 3 weeks
32847200|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
32847201|NCT05688241|Experimental|Group A: patients who undergo allogeneic HCT|Patients with EBV driven lymphomas (e.g., natural killer (NK)/T-cell lymphoma), with EBV complications (e.g. haemophagocytic lymphohistiocytosis (HLH), CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT.
32847202|NCT05688241|Experimental|Group B: patients after HCT or SOT|EBV-driven PTLD that develop after a HCT or solid organ transplantation (SOT) and show decreased response to rituximab.
32847203|NCT05121012||Group 1|Patients with MSA-P
32847204|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
32847205|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
32847206|NCT03156127|Experimental|BR-UPS 5 mg tablet|
32847207|NCT03156127|Active Comparator|Inisia 5 mg tablet|
32847208|NCT05002530|Experimental|Aerosolized 13 cis retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32847209|NCT05002530|Experimental|Aerosolized All trans retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized all trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
32847210|NCT05002530|Placebo Comparator|Standard therapy|Standard therapy
32847211|NCT05700487|No Intervention|Control Group|Patients in this group continued their routine medicaltreatmentprogram without any treatment
32847212|NCT05700487|Experimental|Intervention Group|Pelvic floor exercises (PTE) training in the preoperative period, regular PTE was performed three times a day for 6 months in the postoperative period, and the continuity of the exercises was checked by telephone
32847213|NCT04975464||Control|eGFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0. Non-CKD population.
32847214|NCT04975464||Mild CKD|eGFR 45 - <60
32847215|NCT04975464||CKD|eGFR < 45
33103953|NCT04398797|Experimental|Intervention|Use of notification algorithm and nurse follow-up
33406240|NCT03950024|Experimental|with arthrogenic Muscle Inhibition|
33406241|NCT03950024|Active Comparator|without arthrogenic Muscle Inhibition|
32847216|NCT04975464||Dialysis/Transplant|active dialysis for dialysis participants or kidney transplant for transplant participants
32847217|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
32847218|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
33320120|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
32847219|NCT05113914|Experimental|Healthy, physically fit men|All participants underwent a single CPET test with pre- and post-exercise blood measurements.
32847220|NCT04937322||Interventional Endoscopy procedures|All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations for pancreatico-biliary disorders since June 2011 and extending forward through June 2023.
33320121|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
32847222|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
32847223|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
32847224|NCT04235244|Experimental|left lower abdominal region|5 minutes before and after application to the right upper abdominal region. local cold application
32847225|NCT04235244|Experimental|right upper abdominal region|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
32847226|NCT04235244|Experimental|left upper abdominal region|Coolant spray will be applied to the upper left abdominal region for 15 sec.
32847227|NCT04235244|No Intervention|right lower abdominal region|SC injection will be applied to the left lower abdominal region without any cold application.
32847228|NCT05659693|Experimental|Experimental Group|Digital literacy education specific to menopause will be given to this group.
32847229|NCT05659693|No Intervention|Control Group|no intervention will be applied to this group.
32847230|NCT03156205|Experimental|Interactive Music Therapy|
32847231|NCT03156205|Other|passive music listening|
32847232|NCT03156205|Other|passive earphone-use|
32847233|NCT04885608|Experimental|PReGe|Group that will perform the intervention with therapeutic exercise.
32847234|NCT04510194|Experimental|Treatment Arm - Metformin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin alone.
32847235|NCT04510194|Placebo Comparator|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
32847236|NCT04510194|Experimental|Treatment Arm - Ivermectin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the ivermectin alone.
32847237|NCT04510194|Experimental|Treatment Arm - Fluvoxamine Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the fluvoxamine alone.
32847238|NCT04510194|Experimental|Treatment Arm - Metformin and Fluvoxamine Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and fluvoxamine.
32847239|NCT04510194|Experimental|Treatment Arm - Metformin and Ivermectin Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and ivermectin.
32847240|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
32847241|NCT04827420|Experimental|MiQuit Care|Intervention arm: Advise to quit + automatic linkage to quitline + patient navigation
32847242|NCT04827420|Active Comparator|Enhanced Standard of Care|Active Comparator: Advise to quit + written self-help materials
32847243|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
32847244|NCT03157765|No Intervention|Routine care|These patient receive routine care
32847245|NCT04513548|Experimental|Ligelizumab|test drug
32847246|NCT04513548|Placebo Comparator|Placebo|placebo
32847247|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
32847248|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
32847249|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
32847250|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
32847251|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
32847252|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
32847253|NCT00307242|Active Comparator|Direct switch to Adefovir Dipivoxil from Lamivudine|
32847254|NCT00307242|Active Comparator|Overlapping Lamivudine and Adefovir Dipivoxil for 3 months followed by ADV monotherapy|
32847255|NCT05120778|Experimental|conventional medical treatment|Volunteers will maintain habitual medical treatment.
32847256|NCT05120778|Experimental|exercise training + conventional medical treatment|Volunteers will maintain habitual medical treatment and will participate in a 16-week exercise training based on high-intensity interval training (stationary bikes), and strength training (weight-bearing exercises).
32847257|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
32847258|NCT05120700|Experimental|Stromal vascular fraction|Treatment of cartilage injury with a tissue engineering construct.The patients will be adults diagnosed with a single, 3 to 6 cm2 full-thickness cartilage lesion, symptomatic and with no improvement with non-operative treatment.
33103954|NCT04398797|No Intervention|Control|Standard regime (usual care)
32847261|NCT04512768|Active Comparator|Standard ICBT|Participants in the Standard ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia.
32847262|NCT04512768|Experimental|Sleep-Enhanced ICBT|Participants in the Sleep-Enhanced ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. In addition, participants in the Sleep-Enhanced ICBT condition will also receive a newly developed lesson designed to target insomnia.
32847263|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
33103955|NCT00536796||Patients at very high risk|
33103956|NCT00536796||Patients at high risk|
33103957|NCT00536796||Patients at medium risk|
33103958|NCT00536796||Patients at low risk|
33103959|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
33103960|NCT04388852|Experimental|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33103961|NCT04370327|Active Comparator|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
33406242|NCT03964506|Experimental|Cohort 1- AML or MDS|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
32847264|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
32847265|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
33103962|NCT04370327|Active Comparator|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
33103963|NCT04370327|Active Comparator|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
33103964|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
32847266|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
32847267|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
32847268|NCT05652907|Experimental|FSD201|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally from Day 0 to Day 56.
32847269|NCT05652907|Placebo Comparator|Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets twice daily (BID) orally from Day 0 to Day 56.
32847270|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
32847271|NCT02653170|Experimental|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
33103965|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
32958585|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32958586|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).~Rest Phase: Rest for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.~Maintenance Phase: No maintenance treatment until disease progression confirmed."
32958587|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
32958588|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
32958589|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
32958590|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
32958591|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32958592|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32958593|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
32958594|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
32958595|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
32958596|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
32958597|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
32958598|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
32958599|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
32958600|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
32958601|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
32958602|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
32958603|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
32958604|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
32958605|NCT03007680|No Intervention|No core muscle activation|
32958606|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
32958607|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
32958608|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
32958609|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
32958610|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
32958611|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
32958612|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
32958613|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
32958614|NCT03007056||Period 1|year 2011 nCPAP
32958615|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
32958616|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
32958617|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
32958618|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
32958619|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
32958620|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
32847272|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
32847273|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
32847274|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
32847275|NCT05120622|Experimental|Tremelimumab|Patients who will receive local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab
32847276|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
32847277|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
32847278|NCT05087784|Experimental|Intervention:|Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app.
32847279|NCT05087784|No Intervention|Control arm:|Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material.
32847280|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
32847281|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
32847282|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
32847283|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
32847284|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
32847285|NCT04223154|Experimental|Real TBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
32847286|NCT04223154|Sham Comparator|Sham TBS to the dlPFC|One session of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
32847287|NCT05230056|Experimental|PG|
32847288|NCT05230056|Active Comparator|CTRL|
32847289|NCT05119842|Experimental|Treatment|Treatment with the VOIS Implant
32847290|NCT05698771|Experimental|NR|A total of 6 individuals comprising 3 males and 3 females will receive NR 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NMN-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
32847291|NCT05698771|Experimental|NMN|A total of 6 individuals comprising 3 males and 3 females will receive NMN 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NR-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
32847292|NCT05698147|Experimental|X-MTX-Ritu|"Escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.and the phase 2 expansion at the recommended dose level based on phase 1b trial. And，~Methotrexate 3.5 g/m2, d1 and Rituximab 375 mg/m2, d0, 28-days cycle.The total 6 cycles, 28 days per cycle."
32847293|NCT04207320|Experimental|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
32847294|NCT04207320|Experimental|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
32847295|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
32847296|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
32847297|NCT04205604|Experimental|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
32847298|NCT04182750|Experimental|Intervention group|Pharmacist consultation in early pregnancy (gestation week <12)
32847299|NCT04182750|No Intervention|Control group|Standard care.
32847300|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
32847301|NCT03156829|Experimental|Splint alone|
32847302|NCT03156829|Experimental|Cortico-steroid alone|
32847303|NCT03156829|Experimental|Splint and cortico-steroid combined|
32847304|NCT04325334|Experimental|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
32847305|NCT04319328||Cefazolin|n = 20
32847306|NCT04319328||Ceftazidime|n = 20
32847307|NCT04319328||Ciprofloxacin|n = 20
32847308|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
32847309|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
33406243|NCT03964506|Experimental|Cohort 2- CMML, aCML, CML, CNL, MDS/MPN|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
32847310|NCT05229510|Experimental|50 mg/mL Virazole (10 ml total volume)|50 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
32847311|NCT05229510|Experimental|50 mg/mL Virazole (20 ml total volume)|50 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
32847312|NCT05229510|Experimental|100 mg/mL Virazole (10 ml total volume)|100 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
32847313|NCT05229510|Experimental|100 mg/mL Virazole (20 ml total volume)|100 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
32847314|NCT05229510|Placebo Comparator|Placebo|Placebo aerosolized and administered until solution depleted
32847315|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
32847316|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
32847317|NCT05229276|Experimental|Sternum Guard|The treatment of interest was Sternum GuardTM application during sternotomy.
32847318|NCT05229276|Active Comparator|Bone wax|The 'bone wax' arm was the control group of active comparator as the widely-used materials during sternotomy.
32847319|NCT03155659||CHNS|
32847320|NCT03155659||NHANES|
32847321|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
32847322|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
32847323|NCT04425174||QL|QL = 30 patients representing the case group receiving QL block.
32847324|NCT04425174||EP|EP = 30 patients representing the control group receiving epidural anesthesia.
32847325|NCT05119452|Other|Assisted monitoring|In the Assisted monitoring arm, C-reactive protein and musculoskeletal ultrasound information will be made available to the clinical assessors who, at each time-point will use this information, along with information from the clinical examination, to identify patients experiencing recurrence of inflammation which will then be counted as subclinical flare according to predefined criteria.
32847326|NCT05119452|Other|Clinical monitoring|In the Clinical monitoring arm, the results of C-reactive protein and musculoskeletal ultrasound information will be recorded but will not be made available to the clinical assessor who at each time-point will make the decision on whether the patient is experiencing or has experienced a clinical flare according to predefined criteria based on information from the clinical examination.
32847327|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
32847328|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
32847329|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
32847330|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
32847331|NCT05229042|Active Comparator|Active arm|Subjects received ricolinostat
32847332|NCT05229042|Placebo Comparator|Placebo arm|Subjects received placebo
32847333|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
32847334|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
32847335|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
32847336|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
32847337|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
32847338|NCT05108142|Experimental|Control meal|Participants were asked to visit the lab and consume the control meal (hot, freshly cooked pasta)
32847339|NCT05108142|Experimental|Resistant starch meal|Participants were asked to visit the lab and consume the resistant starch meal (re-heated pasta)
32847340|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
32847341|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
33033421|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
33033422|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
33033423|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
33033424|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
33033425|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
32958621|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
32958622|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
32958623|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
32958624|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
32958625|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
32958626|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
32958627|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
32958628|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
32958629|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
32958630|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
32958631|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
32958632|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
32958633|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
32958634|NCT03006120||Group 1|Conservative management
33406244|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
32958635|NCT03006120||Group 2|Angiografic stenting
32958636|NCT03006120||Group 3|Surgery
32958637|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral~Dexamethasone 2x6 mg iv for 2 days~Zinc 50 mg/day~Beta-carotene 25,000 IU~Vitamin D3 50,000 IU/weekly"
32958638|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg~Dexamethasone 2x6 mg iv for 2 days"
32958639|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
32958640|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
32958641|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
32958642|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
32958643|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
32958644|NCT03005652|Experimental|Mindfulness intervention|consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
33103966|NCT04362527|Experimental|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
32847342|NCT05228964|Experimental|Open-label focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min once a day, five days a week for 3 weeks.
32847343|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
32847344|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
32847345|NCT05102994||VRL patients group|Presenting clinical features suggestive for VRL with positive finding in laboratory exam
32847346|NCT05102994||uveitis group|Even if characterized as clinical features of presumed VRL, no positive laboratory investigations for lymphoma and well response to IMT
32847347|NCT05703061|No Intervention|Normal Sleep Condition Group|This group will not partake in the intervention, they will sleep the normal amount that they do on a regular basis. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
32847348|NCT05703061|Experimental|10-hour Time in Bed Group|This group will partake in the intervention of increasing time in bed to 10 hours per night. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
32847349|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32847350|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
32847351|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
32847352|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
32847353|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
32847354|NCT04405687||Severe head and face deformity|
32847355|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
32847356|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
32847357|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
32847358|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
32847359|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
32847360|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
32847361|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
32847362|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
32847363|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
32847364|NCT05228418|Experimental|Participant|All participants who meet inclusion criteria will be offered oral naltrexone in the ED, a bridge prescription for oral naltrexone, and be referred to outpatient MAT clinic where participants will be offered monthly IM naltrexone injections.
32847365|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
32847366|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
32847367|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
32847368|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
32847369|NCT01670851||Strattice|eLAPE
32847370|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
32847371|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
32847372|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
32847373|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
32847374|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
32847375|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
32847376|NCT05633563|Active Comparator|Active Drug|Study participants receiving Trimetazidine
32847377|NCT05633563|Placebo Comparator|Placebo|Study participants receiving placebo (calcium)
32847378|NCT03925272|Experimental|Patients with Suppurated Hidradenitis|"Human biological samples :~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
33406245|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
33406246|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
32903318|NCT05644249|Experimental|Experimental treatment|Each patient will be scheduled for 3 courses of combined treatment: in total 3 PIPAC with cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 and 6 cycles of FOLFOX systemic chemotherapy.
33406247|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
32903320|NCT00686582|Experimental|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
32903321|NCT00686582|Experimental|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
32903322|NCT00686582|Other|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
32903323|NCT02223637||Exposure group|"Pregnant women who were exposed to~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
32903324|NCT00631358|Experimental|Maxidex|Maxidex
32903325|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
32903326|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
32903327|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
32903328|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
32903329|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
32903330|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
32903331|NCT04143061|Experimental|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
32903332|NCT04143061|Active Comparator|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
32903333|NCT04143061|Experimental|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
32903334|NCT04143061|Active Comparator|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
32903335|NCT04143061|Experimental|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
32903336|NCT04143061|Active Comparator|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
33406248|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
32903337|NCT04143061|Experimental|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
32903338|NCT04143061|Active Comparator|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
32903339|NCT04143061|Experimental|Group 9|MenACYW conjugate vaccine and age-recommended routine pediatric vaccine(s), toddlers aged 12 to 23 months in India
32903340|NCT04143061|Active Comparator|Group 10|Age-recommended routine pediatric vaccine(s) (RPV) only, toddlers aged 12 to 23 months in India
32903341|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
32903342|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
32903343|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
32903344|NCT04028011||PSG and novel wearable device|75 patients will wear polysomnography at the same time as the Novel wearable device
32903345|NCT04028011||PG and novel wearable device|75 patients will wear polygraphy at the same time as the novel wearable device
32903346|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
32903347|NCT05626231|Experimental|Gender-Affirming Psychotherapy (GAP)|"The single-arm intervention study will test an online asynchronous gender-affirming training intervention called GAP Training."
32903348|NCT00689078|Active Comparator|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
32903349|NCT00689078|Active Comparator|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
32903350|NCT00689078|Active Comparator|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
32903351|NCT00689078|Placebo Comparator|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
32903352|NCT05590819|Experimental|bilateral rTMS|5 hertz(Hz), 1000 pulses, 90% resting motor threshold(RMT) stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
32903353|NCT05590819|Experimental|unilateral rTMS|5 hertz(Hz), 1000 pulses, 90% RMT stimulation on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
32903354|NCT05590819|Placebo Comparator|control group of rTMS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
32903355|NCT05590819|Experimental|bilateral iTBS|600 pulses iTBS stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
32958645|NCT03005652|Active Comparator|Health education intervention|"follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration.~The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention."
32958646|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
32958647|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
32958648|NCT03005028||Control|
32958649|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
32958650|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
32958651|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
32958652|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
32958653|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
32958654|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
32958655|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958656|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958657|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958658|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958659|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958660|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958661|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958662|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958663|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
33103967|NCT04362527|Placebo Comparator|Placebo|The patients randomized to this arm will have Saline solution
33103968|NCT04769466|Experimental|Staff|Staff will be trained in the platform, and complete life story interviews with residents at their facilities. Upon completion of training, staff will complete surveys regarding it's effectiveness and utility, and following the completion of the interview, the resident's life story books, summary materials, and staff tools will be delivered four weeks later. Life story materials are meant to assist staff in providing more personalized care and a mechanism for residents to feel more deeply understood.
33320122|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
33320123|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
32847379|NCT03925272|Experimental|Patients with Alzheimer disease|"Human biological samples :~stool, blood (20 ml), nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
32847380|NCT03925272|Experimental|Patients with familial adenomatous polyposis|"Human biological samples :~whole blood (30 to 100 mL), optional stool collection~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
32847381|NCT03925272|Experimental|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears~Bio-clinical data :~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
32847382|NCT03925272|Experimental|Healthy cases|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
32847383|NCT03925272|Experimental|Healthy cases relatives|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
32847384|NCT03925272|Experimental|Subjects vaccinated against COVID-19|"Human biological samples :~whole blood and derived products: serum, DNA, PBMCs, saliva, nasopharyngeal swab~Bio-clinical data :~ethno-geographical origin, family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases, specific history of otorhinolaryngology and broncho-pulmonary and treatments, specific COVID-19 history, risk factor for a severe form of COVID-19, symptoms of COVID-19 or positive test for SarsCov-2 positive"
32847385|NCT05632627|Active Comparator|Full Spectrum Cannabidiol|Full Spectrum Cannabidiol (<0.3% THC) Oral softgel capsule, 210mg/day
32847386|NCT05632627|Active Comparator|Broad Spectrum Cannabidiol|Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day
32847387|NCT05632627|Placebo Comparator|Hemp Seed Oil|Placebo Oral softgel capsule, 210mg/day
32847388|NCT04746937|Placebo Comparator|Control Group|They will receive standard therapy plus placebo
32847389|NCT04746937|Active Comparator|Nitazoxanide Group|They will receive standard therapy plus nitazoxanide
32847390|NCT04588350|Experimental|i-SEP autotransfusion system|Use of i-SEP autotransfusion system during the surgery
32847391|NCT05220319|Placebo Comparator|Placebo|"100 ml of NaCl 0,9%, not containing corticosteroids, given at induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 100 ml of NaCl 0,9% will be administered at the beginning of CPB."
32847392|NCT05220319|Active Comparator|Methylprednisolone|"250 mg of methylprednisolone made up with 100 ml NaCl 0,9%, given at the induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 250 mg methylprednisolone will be administered at the beginning of CPB."
32847393|NCT05615077|Experimental|Combined exercise-education intervention group|Combined exercise-education intervention by fall risk state for 12 months during intervention period.
32847394|NCT05615077|No Intervention|Control group|No intervention for 12 months during intervention period.
32847395|NCT04555902|Active Comparator|Standard Mailer and Small Gift|A postcard encourages mammograms and includes a small gift.
32847396|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and Small Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; a small gift is included.
32847397|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and No Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; the small gift is not included.
32847398|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
32847399|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
32847400|NCT05227872||Decompensated HF|
32847401|NCT05227872||Compensated HF|
32847402|NCT04543591|Experimental|Ravulizumab|"In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC).~In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC)."
32847403|NCT04543591|Placebo Comparator|Placebo|In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
32847404|NCT04499352|Experimental|treatment arm A|
32847405|NCT04499352|Experimental|treatment arm B|
32903356|NCT05590819|Experimental|unilateral iTBS|600 pulses iTBS on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
32847406|NCT04131270|Experimental|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
32847407|NCT04131270|Active Comparator|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
32847408|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
32847409|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
32847410|NCT04497870|Active Comparator|540 mg|Peppermint oil at a dose of 180 mg thrice daily orally
32847411|NCT04497870|Experimental|900 mg|Peppermint oil at a dose of 180 mg five times daily orally
32847412|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
33320124|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
32847413|NCT03154879||Comatose cardiac arrest survivors|
32847414|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
32847415|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
32847416|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
32847417|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
32847418|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
32847419|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
32847420|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
32847421|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
32847422|NCT04498429|Experimental|Integrated Manual and Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Integrated/Manual Cueing intervention.
32847423|NCT04498429|Experimental|Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Verbal Cueing intervention
32847424|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
32847425|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
32847426|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
32847427|NCT04080908|Experimental|Ferumoxytol injection treatment|
32847431|NCT04409678|Experimental|activity|
32847432|NCT04409678|No Intervention|bed rest|
32847433|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
32847434|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
32847435|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
32847436|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
32847437|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
32847438|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
32847439|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
32958664|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958665|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958666|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
32958667|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
32958668|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
32958669|NCT03004092|Experimental|Total cohort|
32958670|NCT03004404|Experimental|BI 730357|
32958671|NCT03004404|Placebo Comparator|Placebo|
32958672|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
32958673|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
32958674|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
32958675|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
32958676|NCT03003702|Experimental|ETH|Overnight monitoring
32958677|NCT03003702|Other|CTH|Morning monitoring
32958678|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
32958679|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
32958680|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
32958681|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
32958682|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
32958683|NCT03003234|Other|Duodenal fluid aspiration|
32958684|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
32958685|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
32958686|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
32958687|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
32958688|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
32958689|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
32958690|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
32958691|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
32958692|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
32958693|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
32958694|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
32958695|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
32958696|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
32738997|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm , all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
32847440|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
32847441|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
32847442|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
32847443|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
32847444|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
32847445|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
32847446|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
32847447|NCT01676467||Healthy smoking|Healthy smoking control subjects
32847448|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
32847449|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
32847450|NCT02707939||Controls|Patients with no developmental diagnoses
32847451|NCT04310748|Active Comparator|Total Intravenous Anesthesia(TIVA)|Anesthesia is maintaining with TIVA (Group 1)
32847452|NCT04310748|Active Comparator|Inhalation Anesthesia|Anesthesia is maintaining with inhalation anesthesia (Group 2)
32847453|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
32847454|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
32847455|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
32847456|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
32847457|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
32847458|NCT01631292|Placebo Comparator|600 IU D3|
32847459|NCT01631292|Active Comparator|2000 IU D3|
32847460|NCT01631292|Active Comparator|4000 IU D3|
32847461|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
32847462|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
32847463|NCT01189422|Experimental|Segment 1: 3 Arms|
32847464|NCT01189422|Experimental|Segment 2: 4 Arms|
32847465|NCT04302636|Experimental|The hypoglycemic index diet group|"Patients in the experimental group ate two portions of food each day.This diet will last for 12 weeks.~Food provided by the canteen: one egg for breakfast;Lunch and dinner are 50g of rice with all the dishes.~Dietary nutrition and supplementary food: according to the weight and height of the patient, the daily energy required was calculated, which was divided into six levels: 1400kcal, 1600kcal, 1800kcal, 2000kcal, 2200kcal and 2400kcal.The six corresponding nutritional auxiliary food powders are: 20g-30g-40g-50g-60g-70 g.The suspension was prepared in the proportion of 160ml warm water poured into 55 grams and given to the patient."
32847466|NCT04302636|No Intervention|General diet group|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
32847467|NCT05222256|Experimental|Group (L) levosimendan group|Patients in this group will receive levosimendan (0.1 μg/kg/min) during re-warming of the patients.
32847468|NCT05222256|Active Comparator|Group (A) Adrenaline group|Patients in this group will receive Adrenaline (0.05 μg /kg/min) during re-warming of the patients.
32847469|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
32847470|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
32847471|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
32847472|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
32847473|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
32847474|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
32847475|NCT04372381|Active Comparator|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
32847476|NCT04372381|Active Comparator|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
32847477|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
32847478|NCT01672021|Other|PET/MRI|PET/MRI
32847479|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
32847480|NCT03154489|Other|Acenocoumarol|
32847481|NCT03154489|Other|control group|
32847482|NCT05607979|Active Comparator|TRIAL INTERVENTION|Trial intervention is wound treatment with Lavior Diabetic Wound Gel.
32903357|NCT05590819|Placebo Comparator|control group of iTBS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
32903358|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
32903359|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
33320125|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
33320126|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
33320127|NCT05693402||Group 1 consisting of treated patients using OFA|Group 1 consisted of 56 (Mean age was 54±14 years)
32847483|NCT05607979|Active Comparator|CONTROL THERAPY|Control therapy is defined as Smith & Nephew Solosite Gel Hydrogel Wound Dressing, according to actual guidelines or local clinical standards. Standard therapy is defined as the currently accepted and widely used treatment for the respective wound type, based on the results of past research. Therapy options for standard wound care are treatments that experts agree to be appropriate, accepted, and widely used.
32847484|NCT05201040|Experimental|Mannitol-combined Hyaluronic acid|2.0mL/syringe for one treatment
32847485|NCT05201040|Placebo Comparator|Normal saline|2.0mL for one treatment
32847487|NCT04248036|Other|Circle Of Security Parenting, COS-P|Pilot study, assessing eligibility, outcome measures and compliance to Group intervention
32847488|NCT04371055|Experimental|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:~Continuous Rhythm Monitoring using an implantable cardiac Monitor~Intervention group with low risk for AF:~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
32847489|NCT04371055|Other|Standard of Care|Standard of care rhythm monitoring
32847490|NCT04228848|Active Comparator|Healthy adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
32847491|NCT04228848|Experimental|ACL adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
32847492|NCT04228848|Active Comparator|Healthy adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
32847493|NCT04228848|Experimental|ACL adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer
32847494|NCT04052724|Experimental|Intervention group LINGI|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
32847495|NCT04052724|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
32847496|NCT04336033|Experimental|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
32847497|NCT04336033|Placebo Comparator|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
32847498|NCT00698022|Experimental|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
32847499|NCT00698022|Placebo Comparator|Risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
32847500|NCT00698022|Placebo Comparator|Risperidone-matched placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
32847501|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
32847502|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
32847503|NCT04335799|Experimental|Weight Loss Plus Stress Management|Diabetes Prevention Program Intensive Lifestyle Intervention augmented with stress management training
32847504|NCT04335799|Active Comparator|Weight Loss Only|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
32847505|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
32847506|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
32847507|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
32847508|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
32847509|NCT01672333|Experimental|Pathological Response|
32847510|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
32847511|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
32847512|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
32847513|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
32847514|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
32847515|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
32847516|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
32847517|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
32847518|NCT00617994|Experimental|Group A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
32847519|NCT00617994|Experimental|Group B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
32958697|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
32958698|NCT03002376|Experimental|REGN2810|REGN2810 treatment
32958699|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
32958700|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
32958701|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
32958702|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
32958703|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
32958704|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
32958705|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
32958706|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
32958707|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
32958708|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
32958709|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
32958710|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
32958711|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
32958712|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
32958713|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
32958714|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
32958715|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
32958716|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
33320128|NCT05693402||Group 2 consisting of treated patients using NOFA|Group 2 consisted of 60 patients (Mean age was 51±12 years)
32903360|NCT05568979||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
32903361|NCT05568979||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
32903362|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
32903363|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
32903364|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
32903365|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
32903366|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
32903367|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
32903368|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
32903369|NCT03977233|Experimental|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
32903370|NCT03951649|Experimental|Occipital Nerve block|"Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.~Site of injection will be cleaned with an alcohol swab.~5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.~After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
32903371|NCT03951649|Active Comparator|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
32903372|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
32903373|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
32903374|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
32903375|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
32903377|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
33406249|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
32847520|NCT00617994|Experimental|Group C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
32847521|NCT05067595|Experimental|Arm I (upper FMT)|Patients receive upper FMT capsules PO over 2 days.
32847522|NCT05067595|Experimental|Arm II (Lower FMT)|Patients undergo lower FMT via colonoscopy on day 0.
32847523|NCT05067595|Experimental|Arm III (upper FMT, fiber supplementation)|Patients receive upper FMT capsules PO over 2 days. Patients receive fiber supplementation PO while on study.
32847524|NCT05067595|Experimental|Arm IV (Lower FMT, fiber supplementation)|Patients undergo lower FMT via colonoscopy on day 0. Patients receive fiber supplementation PO while on study.
32847525|NCT04405219|Sham Comparator|smokers (S)|
32847526|NCT04405219|Active Comparator|non smokers (NS)|
32847527|NCT05046366||Lung cancer group|Participants with lung cancer/pulmonary nodules
32847528|NCT05046366||Pulmonary tuberculosis group|Participants with pulmonary tuberculosis
32847529|NCT05046366||COIVD-19 group|Participants with COIVD-19
32847530|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
32847531|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
32847532|NCT05561179|Experimental|GERD + HA injections|This group is comprised by patients with GERD, assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to HA injections at the lower esophageal level.
32847533|NCT05561179|Placebo Comparator|GERD without HA injections|This group is comprised by patients with GERD assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to sodium chloride at the lower esophageal level.
32847534|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
32847535|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
32847536|NCT05456425|Placebo Comparator|Vehicle|Emulsion eye drop without drug
32847537|NCT05456425|Experimental|0.1% CBT-001|0.1% CBT-001 emulsion eye drop
32847538|NCT05456425|Experimental|0.2% CBT-001|0.2% CBT-001 emulsion eye drop
32847539|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
32847540|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
32847541|NCT03754309|Placebo Comparator|Placebo|Matched placebo
32847542|NCT05409937|Experimental|Improved Hot Weather Combat Uniform|Wearing the Improved Hot Weather Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
32847543|NCT05409937|Experimental|Army Combat Uniform|Wearing the Army Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
32847544|NCT05409937|Experimental|Army Combat Uniform + Silk Weights|Wearing the Army Combat Uniform + a base layer of silk weights; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
32847545|NCT05409937|Experimental|Army Combat Uniform- XR|Wearing the Army Combat Uniform; Asked to perform 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, followed by 60 min of standing with minimal movement
32847546|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
32847547|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
32847548|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
32847549|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
32847550|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
32847551|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
32847552|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
32847553|NCT03719521|Active Comparator|Control Arm|Routine existing services
33406250|NCT03956784|Experimental|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
32847554|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
32847555|NCT03706417|Experimental|Telemedicine|Babies that received telemedicine consult intervention.
32847556|NCT03706417|No Intervention|Historical control|Historical controls who have not received a telemedicine consult.
32847557|NCT01676545||Chronic Periodontitis|
32847558|NCT01676545||Control|
32847559|NCT03661255|Experimental|PC CARES Intervention|Experimental: PC CARES Intervention Participants will attend 1-7 sessions of the PC CARES curriculum, either virtually or in-person. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
32847560|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
32847561|NCT05401045|Experimental|observation group|"Exercise plan: Each session of the self-designed METexercises were divided into 8 components. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening.Metabolic equivalent intensity: The intensity of exercise was expressed as metabolic equivalents (METs).~Exercise training: Members of the fatigue management team in the ward taught the patients to perform MET exercises using videos.The fatigue management team members confirmed that the patient could perform the exercise independently and correctly."
32847562|NCT05401045|No Intervention|control group|Participants received routine exercise health education that included information pertaining to CRF (causes of CRF, clinical manifestations, related factors, the necessity and importance of fatigue prevention, and measures to improve CRF, etc.) and exercise (3-5 times per week, regardless of the type of exercise). The patients were also informed about the precautions for exercise.
32847563|NCT04933903|Experimental|Protocol Therapy|Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1, 15, 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).
32847564|NCT03641677|Experimental|EVLP|
32847565|NCT03641677|Active Comparator|Control|
32847567|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
32847568|NCT03600103|No Intervention|Control|Participants will receive standard of care.
32847569|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
32847570|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
32847571|NCT03589339|Experimental|NBTXR3 activated by SABR followed by anti-PD-1 monotherapy|Intratumoral injection of NBTXR3 followed by SABR followed by monotherapy with nivolumab or pembrolizumab
32847572|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
32847573|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
32847574|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
32847575|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
32847576|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
32847577|NCT04880239|Active Comparator|Sacralcolpopexy with posterior colpoperineorrhaphy|
32847578|NCT04880239|No Intervention|Sacralcolpopexy without posterior colpoperineorrhaphy|
32847579|NCT01673269|Experimental|ERCP with direct examination of the CBD|
32847580|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
32847581|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
32847582|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
32847583|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
32847584|NCT03427099|Active Comparator|Control group|usual care
32847585|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
33103969|NCT04769466|Experimental|Residents|Residents will be screened for their cognitive status and compete interviews with a researcher prior to participation in the life story interview. Residents will then be interviewed again at T3 about four weeks after the life story books, summaries, and staff materials have been delivered.
32847586|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
32847587|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
32847588|NCT04508244|Active Comparator|TBI with positive troponin|Patients will receive IV propranolol for 6 days
32847589|NCT04508244|Placebo Comparator|TBI with negative troponin (a)|Patients will receive IV placebol for 6 days
32847590|NCT04508244|Experimental|TBI with negative troponin (b)|Patients will receive IV propranolol for 6 days
32847591|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
32847592|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
32847593|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
32847594|NCT04995510||Chronic Obstructive Pulmonary Disease Group|Individuals diagnosed with chronic obstructive pulmonary disease by ''Bolu Abant Izzet Baysal University'' Faculty of Medicine, Department of Chest Diseases and referred to the Physiotherapy and Rehabilitation Department of Bolu Abant Izzet Baysal University Health Sciences Faculty
32847595|NCT04995510||Healthy Group|Volunteer healthy individuals with similar demographic characteristics and without any diagnosed disease will be recruited
32847596|NCT04764877|No Intervention|Standard Care|Standard teaching and physical exam for any patient that would be seen at our Hilltop Primary Care center asthma clinic. This included baseline PFTs. FOR THIS STUDY a second set of PFTs were obtained at the end of the visit
32847597|NCT04764877|Experimental|OMT arm|As above BUT with the addition of standardized OMT focusing on lung functionality. OMT provided by either our OMM attending at that time (Dr Wolf) or residents trained by her for this study (Drs. Regan, Jones, Pe and Bryant)
32847598|NCT04764955|Placebo Comparator|Group A (Placebo)|Prenatal Period 0 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
32847599|NCT04764955|Experimental|Group B (4200:0 IU/week)|Prenatal Period 4200 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
32847600|NCT04764955|Experimental|16800:0 IU/week|Prenatal Period 16800 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
32847601|NCT04764955|Experimental|28000:0 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
32847602|NCT04764955|Experimental|28000:28000 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 28000 IU/week (delivery-6 months postpartum)
32847603|NCT04511208|Experimental|Cooling vest, then without cooling vest, then without cooling vest, then cooling vest (ABBA)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed one surgery without the cooling vest. Then on another day, they performed another surgery without the cooling vest. Then they finally performed one surgery with the cooling vest.
32847604|NCT04511208|Experimental|Without cooling vest, then cooling vest, then cooling vest, then without cooling vest (BAAB)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed one surgery with the cooling vest. Then on another day, they performed another surgery with the cooling vest. Then they finally performed one surgery without the cooling vest.
32847605|NCT04511208|Experimental|Cooling vest, then cooling vest, then without cooling vest, then without cooling vest (AABB)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed another surgery with the cooling vest. Then on another day, they performed one surgery without the cooling vest. Then they finally performed another surgery without the cooling vest.
32847606|NCT04511208|Experimental|Without cooling vest, then without cooling vest, then cooling vest, then cooling vest (BBAA)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed another surgery without the cooling vest. Then on another day, they performed one surgery with the cooling vest. Then they finally performed another surgery with the cooling vest.
32847607|NCT04834297|Experimental|SVS mattress|Infants randomized to the experimental arm will have the SVS mattress placed in their crib within 24 hours of birth and will continue till discharge home after the completion of monitoring phase of NOWS or till determination is made to initiate pharmacotherapy for NOWS.
32847608|NCT04834297|No Intervention|Standard mattress|Infants randomized to the no intervention arm will continue to be cared for using the standard hospital crib mattress throughout their birth hospitalization.
32847609|NCT01673581||Low risk prostate cancer|
32847610|NCT04510740||Hepatocellular Carcinoma (HCC)|Patients with Hepatocellular Carcinoma (HCC)
32847611|NCT04510740||Cholangiocarcinoma (CCC)|Patients with Cholangiocarcinoma (CCC)
32847612|NCT03126331|Experimental|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
32903378|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
32903379|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
32903380|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
33103970|NCT04360538||COVID19 positive|ICU patients coronavirus positive
33103971|NCT04360538||non-COVID19|ICU patients without coronavirus
32903381|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
32903382|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
32903383|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
32903384|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
32903385|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
32903386|NCT00593372|No Intervention|II|Drug Therapy Only
32903387|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
32903388|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
32903389|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
32903390|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
32903391|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
32903392|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later).~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU.~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
32903393|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
32903394|NCT05556733|Experimental|Faecal Microbiota Transplantation|Subjects will receive Faecal Microbiota Transplantation
32903395|NCT05556733|No Intervention|Control|The control subjects will not receive FMT
32903396|NCT03875287|Experimental|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
32903397|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
32903398|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
33103972|NCT05579145|Experimental|5-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 5 seconds.
33103973|NCT05579145|Experimental|10-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 10 seconds.
32903399|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
32903400|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
32903401|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
32903402|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
32903403|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
32903404|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
33103974|NCT04359914||NCoV-A-COVID|"adult patients of every age~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
32847613|NCT03126331|Experimental|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
33406251|NCT03956784|Other|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
33406252|NCT03403751|Experimental|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
33406253|NCT03403751|Placebo Comparator|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
33406254|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32847614|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
32847615|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
33406255|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32847616|NCT01770067|Experimental|Infected CIED and Infection-Prone Patients Prior to CIED Implantation|Administration of high-dose antibiotics (CITA)
32847617|NCT01770067|Active Comparator|Infected CIED extraction|Extraction of infected CIED
32847618|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
32847619|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
32847620|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
32847621|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
32847622|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
32847623|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
32847624|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
32847625|NCT04404673||Open rectal resection|
32847626|NCT04404673||Laparoscopic rectal resection|
32847627|NCT04404673||Robotic rectal resection|
32847628|NCT04404673||Trans-anal TME (Ta-TME)|
32847629|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
32847630|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
32847631|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
32847632|NCT01673971||Natural History|
32847633|NCT01673971||Treatment|
32847634|NCT02855593||Physicians|Physicians who perform acupuncture
32847635|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
32847636|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
32847637|NCT02081365|No Intervention|High Anxiety Wailist Control|
32847638|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
32847639|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
32847640|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
32847641|NCT01674127|Placebo Comparator|placebo|
32847643|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
32847644|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
32847645|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
32847646|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
32958717|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
32958718|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
32958719|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
32958720|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
32958721|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patients referred to stress imaging with suspected ischemia."
32958722|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
32958723|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
32958724|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
32958725|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
32958726|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
32958727|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
32958728|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
32958729|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
32958730|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
32958731|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
32958732|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
32958733|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
32958734|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
32958735|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
32958736|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
32958737|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
32958738|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
32958739|NCT03000192||Breast cancer|Women aged <50 years
32958740|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
32958741|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
32958742|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
32958743|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
32958744|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
32958745|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
32958746|NCT02999412|Other|Usual care (Control)|
32958747|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
32958748|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
32958749|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
32958750|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
32958751|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
32958752|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
32958753|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
33406256|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
32958754|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
32958755|NCT02991066||Control|healthy volunteers.
33406257|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
33406258|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
33406259|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
32958756|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
32958757|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
32958758|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
32958759|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
32958760|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
33406260|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
32958761|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
32958762|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
32958763|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
32958764|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
32958765|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
32958766|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
32958767|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
32958768|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
32958769|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
32958770|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
32958771|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
32958772|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
32958773|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
32958774|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
32958775|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
32958776|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
32958777|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
32958778|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
32958779|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
32958780|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32958781|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
32958782|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
32958783|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
32958784|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
32958785|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
32847647|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
32847648|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
32847649|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
32847650|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
32847651|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
32847652|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
32847653|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
32847654|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
32847655|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
32847656|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
32847657|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
32847658|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
32847659|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
32847660|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
32847661|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
32847662|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
32847663|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
32847664|NCT05316337|Experimental|Atrial fibrillation|
32847665|NCT05316337|Experimental|Normal Sinus Rhythm|
32847666|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
32847667|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
32847668|NCT04404517|Active Comparator|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
32847669|NCT04404517|Active Comparator|80mg2w|Adalimumab at an administration of 80 mg every two weeks
32847670|NCT04688905||Dyspnea explained by heart failure with preserved ejection fraction|All patients fulfilling invasive criteria for heart failure with preserved ejection fraction
32847671|NCT04688905||Dyspnea not explained by heart failure with preserved ejection fraction|All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction
32847672|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
32847673|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
32847674|NCT03159793|Active Comparator|Group A|Live Modelling
32847675|NCT03159793|Active Comparator|Group B|Filmed Modelling
32847676|NCT03159793|No Intervention|Group C|No Modelling
32847677|NCT05301283|Experimental|Treatment|"Participants will receive pretreatment diagnostic MRIs to generate MRI habitats (images of tumor regions/subregions in different sequences). These images will identify radioresistant cells within the tumor to allow for more precise and higher doses of radiation to the resistant cells.~Participants will then be treated with neoadjuvant external beam radiation by using the intensity modulated radiation (IMRT) technique, with dose painting (simultaneous integrated boost/SIB) to 70 Gray Units (Gy), 60 Gy, and 50 Gy in 25 fractions for habitats 1, 2, and 3, respectively."
32847678|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
32903405|NCT04387682|Other|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
33103975|NCT04359914||NCoV-A-CONTROL|"adult patients of every age~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
33103976|NCT04359914||NCoV-P-COVID|"pediatric patients~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
33103977|NCT04359914||NCoV-P-CONTROL|"pediatric patient~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
33103978|NCT04758975|Experimental|Venetoclax + Rituximab +/- Ibrutinib|"VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12: 400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2~At the end of Cycle 12 the MRD status is checked:~3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity"
33103979|NCT04755114|Experimental|Turkish Music Group|After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations, the music group will be played to the music desired by the patient for 30 minutes. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
33103980|NCT04755114|Experimental|Comedy Film Group|fter the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations,the Comedy film group will watch a comedy movie video. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
33326967|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32847679|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
32847680|NCT05281627||Emergency Laparotomy Patients|All adult patients (18+) who have undergone Emergency Laparotomy surgery, are recovering well (no illness which is expected to limit life to <6m post op) and have sufficient English-language and cognitive skills to complete the study questionnaires.
32847681|NCT05281627||Family Caregivers|Adult (18+) family members, close friend or caregivers of the individual who has received EmLap treatment have sufficient English-language and cognitive skills to complete the study questionnaires.
32847682|NCT01670071|Experimental|Paliperidone extended-release|
32847683|NCT01670071|Active Comparator|Risperidone immediate-release|
32847684|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
32847685|NCT01670227|Other|Control Condition|No intervention
32847686|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
32847687|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
32847688|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
32847689|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
32847690|NCT01674829|Experimental|Biological: MA09-hRPE Cellular therapy|"Biological: MA09-hRPE Cellular therapy~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
32847691|NCT01568671|Experimental|Healthy older lean white men|White men aged 55-75 years with BMI between 18.5 and 25.0 kg/m2
32847692|NCT01568671|Experimental|Healthy young lean black men|Black men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
32847693|NCT01568671|Experimental|Healthy young lean white men|White men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
32847694|NCT01568671|Experimental|Healthy young lean white women|White women aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
32847695|NCT01568671|Experimental|Healthy young white men with obesity|White men aged 18-35 years with BMI between 30.0 and 40.0 kg/m2
32847696|NCT01674907||Cohort|
32847697|NCT04747093|Experimental|ITNK group|
32847698|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
32847699|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
32847700|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
32847701|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
32847702|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
32847703|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
32847704|NCT04763785||Patients with keratoconus corneas|Corneal tomography on patients with keratoconus diagnosis
32847705|NCT04763785||participants with healthy corneas|Corneal tomography on healthy participants
32847706|NCT04763785||retrospective part|fully anonymised Picture data of existing 4500 patients
32847707|NCT03861091|Experimental|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
32847708|NCT03861091|Placebo Comparator|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
32847709|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
32847710|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
32847711|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
32847712|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
32847713|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
32847714|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
32847715|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
32847716|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
32847717|NCT01426217|No Intervention|Control|Control arm using standard of care operating room procedures and equipment
32847718|NCT01426217|Experimental|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
32847719|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
32847720|NCT04042415|No Intervention|Free diet controls|Patients on free diet
32847721|NCT04042415|Experimental|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
32847722|NCT04042415|Experimental|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
32847723|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
32847724|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
32847725|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
32847726|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
32847727|NCT03852901|Experimental|Single Arm|Single group
32847728|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
32847729|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
32847730|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
32847731|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
32847732|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
32847733|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
32847734|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
32847735|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
32847736|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
32847737|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
32847738|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
32847739|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
32847740|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
32847741|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
32847742|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
32847743|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
33406261|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
33406262|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
32847744|NCT04404361|Experimental|Pacritinib and SOC|Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
32847745|NCT04404361|Placebo Comparator|Placebo and SOC|4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
32847746|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
32847747|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
32847748|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following:~Power: 40 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 3~D-pulse mode."
32847749|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following:~Power: 0.5 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 1,~Smart-pulse mode."
33406263|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
33406264|NCT01180374|Experimental|Active Cannabidiol and Placebo|
33406265|NCT01180374|Placebo Comparator|Placebo and Placebo|
33406266|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
33406267|NCT03418571|Placebo Comparator|Placebo|
33406268|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
33406269|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
33406270|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
33406271|NCT05545943|Experimental|2-days of calorie restriction with whole body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) with two 10-min whole body cooling practices on separate days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
33406272|NCT05545943|Experimental|6-days of calorie restriction|"Healthy young subjects participated in 6-day CR (0 kcal with water provided ad libitum).~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
32847750|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
32847751|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
32847752|NCT04764409||Group 1|This group includes patients who underwent chemoembolization of hepatic arteria
32847753|NCT04764409||Group 2|This group includes patients who underwent chemoinfusion of hepatic arteria
32847754|NCT04764565|Experimental|Nuun Instant|2 servings of Nuun instant in 1 liter water
32847755|NCT04764565|Placebo Comparator|Control|1 liter of water
32847756|NCT04764565|Experimental|Nuun Electrolyte|2.1 servings of Nuun Electrolyte in 1 liter water
32847757|NCT04404751|Active Comparator|Arm 1|
32847758|NCT04404751|Active Comparator|Arm 2|
32847759|NCT04404751|Sham Comparator|Arm 3|
32847760|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
32847761|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
32847762|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in SMI|Participants will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of task persistence focused cessation counseling delivered via telehealth.
32847763|NCT04404829|Experimental|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
32847764|NCT01676155||Patient with active tuberculosis|
32847765|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
32847766|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
32847767|NCT04747639|Active Comparator|verum 500|500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
32903406|NCT04387682|No Intervention|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
33406273|NCT05545943|No Intervention|2-days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 2 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
32958786|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
32958787|NCT02988024|Experimental|LY03005|LY03005 80 mg
32958788|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
32958789|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
32958790|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
32958791|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
32958792|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
32958793|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
32958794|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
32958795|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:~7 full days for most infections~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
32958796|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
32958797|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
32958798|NCT02987712|No Intervention|Survey 1|Common practice
32958799|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
32958800|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
32958801|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
32958802|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
32958803|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
32958804|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
33033426|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
32958805|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
32958806|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
32958807|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
32958808|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
32958809|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
32958810|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
32958811|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
32958812|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
32958813|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
32958814|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
32958815|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
32958816|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
32958817|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
32958818|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
32958819|NCT02986464|Active Comparator|Standard pharmacological treatment|
32958820|NCT02986464|Experimental|Virtual Reality distraction|
32958821|NCT02986230|Experimental|PCP-focused group|The PCP-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
32958822|NCT02986230|Experimental|SDMT-focused group|The SDMT-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The SDMT-focused arm also provides shared decision making tools to patient and provider at the time of the visit.
33326968|NCT01170780|Placebo Comparator|Placebo|Saline
33326969|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
32958823|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
32958824|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
32958825|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
33326970|NCT01274208||Gaucher Disease with Hepatitis C|
33326971|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
32958826|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
32958827|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
32958828|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
33326972|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
32958829|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
32958830|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
32958831|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
32958832|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
32958833|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
32958834|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
32958835|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
32958836|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
32958837|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
32958838|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
32958839|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
32958840|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
32958841|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
32958842|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
32958843|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
32958844|NCT02981862|Experimental|CaptHPV method|
32958845|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
32958846|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
32958847|NCT02981394||BMAC Group|Intervention Group
32958848|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
32958849|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
32958850|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
32958851|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
32958852|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
32958853|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
32958854|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
32958855|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
32958856|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
32958857|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
32958858|NCT02980770||Normal Blood Gases|Normal Blood Gases
32958859|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:~4D MR sequence in cine mode 4D velocity mapping sequence"
32958860|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
32958861|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
33326973|NCT01165944|Active Comparator|Insulin injection with pramlintide|
33326974|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
33326975|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
33406274|NCT05545943|No Intervention|6 days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
32958862|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
32958863|NCT02980302|Other|Patient|
32958864|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
32958865|NCT02980302|Other|Two control patients|
32958866|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
32958867|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
32958868|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
32958869|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
32958870|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
32958871|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
32958872|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
32958873|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
32958874|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
32958875|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
32958876|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
32958877|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
32958878|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
32958879|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
32958880|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
32958881|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
32958882|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
32958883|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
32958884|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
32958885|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
32958886|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
32958887|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
32958888|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
32958889|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
32958890|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
32958891|NCT02978898||PB peripheral blood|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
32958892|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
32958893|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
32958894|NCT02978586||[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
32958895|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
32958896|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
32958897|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
32958898|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
32958899|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
32958900|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
32958901|NCT02978196|Experimental|Injection of 99m-Tc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
32958902|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
32958903|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
32958904|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
32958905|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
32958906|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
32958907|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
32958908|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
32958909|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
32958910|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
32958911|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
32958912|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
32958913|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
32958914|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
32958915|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
32958916|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
32958917|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
32958918|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
32958919|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
32958920|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
32958921|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
32958922|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
32958923|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
32958924|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
32958925|NCT02976558|Experimental|Treatment Group|"Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
32958926|NCT02976558|No Intervention|Control Group|control group. No interventions
32958927|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
32958928|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
32958929|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
32958930|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
32958931|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
32958932|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
32958933|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
32958934|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
32958935|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
32958936|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
32958937|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
32958938|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
32958939|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
32958940|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
32958941|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
32958942|NCT02975778|Experimental|Aged, 65 and over|
32958943|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
32958944|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
32958945|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
32958946|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
32958947|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
32958948|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
32958949|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
32958950|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
32958951|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
32958952|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
32958953|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
32958954|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
32958955|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
32958956|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
32958957|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
32958958|NCT02974998|Active Comparator|Standard HTC|Participants received the standard HTC available in South Africa for this population.
32958959|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
32958960|NCT02975232|No Intervention|Control|no intervention
32958961|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.~Previous treatments will be continued."
32958962|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
32958963|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
33326976|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
33326977|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
33326978|NCT01281930|Experimental|Wick placement into abscess cavity|
33326979|NCT01281930|Active Comparator|Full packing of abscess cavity|
33326980|NCT01282008||Focus Groups|Focus Groups about smoking messages
33326981|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
32738998|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
32738999|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
32739000|NCT03203395|Experimental|Heart patients|Screening and counselling
32739001|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
32739002|NCT03203317|Experimental|Exercise|10 min of maximal exercise
32739003|NCT03316313||Date of birth|Those people born within the years 1945-1965
32739004|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
32739005|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
32739006|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
32739007|NCT03201289||Cardiac surgery|
32739008|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
32739009|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
32739010|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
32739011|NCT04992351||WALANT group|WALANT was used exclusively as anesthesia method for the operation
32739012|NCT04992351||control|tourniquet with regional or general anesthesia was used for the operation
32739013|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
32739014|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
32739015|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
32739016|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
32739017|NCT04992585|Experimental|PTBD with primary metal stent implantation|PTBD with primary metal stent implantation is performed in the same session as a one step-procedure
32739018|NCT04992585|Active Comparator|PTBD with secondary metal stent implantation|PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter
32739019|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Minced spinach (10 mg lutein) given every second day for a 15 days period."
32739020|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
32739021|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
32739022|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
32739023|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
32739024|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
32739025|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
32739026|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
32739027|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
32739028|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
32739029|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
32739030|NCT04999293||The Elderly Undergoing Percutaneous Coronary Intervention|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
32739031|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
32847768|NCT04747639|Placebo Comparator|control 500|500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
32847769|NCT04747639|Active Comparator|verum 250|250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
33406275|NCT05545943|Experimental|2-days of calorie restriction without whole-body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) without whole body cooling.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
32739032|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
32739033|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
32739034|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
32739035|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
32739036|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
32847770|NCT04747639|Placebo Comparator|control 250|250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
32847771|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
32739037|NCT05003739|Experimental|Logica Mirror|Since the trial is not comparative, the only arm implies the use of the investigational device (Logica Mirror femoral stem)
32739038|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
32739039|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
32739040|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
32739041|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
32739042|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
32739043|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
32739044|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
32739045|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
32739046|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
32739047|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
32739048|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
32739049|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
32739050|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
32739051|NCT04998903||Stem cell transplant with Graft versus host disease|Patients who following hematopoietic stem cell transplant suffered from graft versus host disease and presented with pulmonary infiltrates.
32739052|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
32739053|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
32739054|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
32739055|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
32847772|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
32847773|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
32847774|NCT03841357|Experimental|Abatacept and Usual Care (Part I)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
32847775|NCT03841357|Active Comparator|Active Comparator: Usual Care (Part I)|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
32847776|NCT03841357|Experimental|Abatacept and Usual Care (Part II)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
32847777|NCT04115748|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
32847778|NCT04115748|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
32847779|NCT04115748|Active Comparator|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
32847780|NCT04115748|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
32847781|NCT04115748|Experimental|Filgotinib 200 mg (Long Term Extension [LTE])|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 34 weeks.
32847782|NCT04115748|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 34 weeks.
32847783|NCT03838159|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment (200 mg/m3 Paclitaxel+ AUC5 Carboplatin+ 360 mg Nivolumab) will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) .~Adjuvant treatment:Nivolumab: 480 mg Q4W (+/- 3 days) for 6 months (6 cycles). Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months."
32847784|NCT03838159|Active Comparator|Control: Neo-Adjuvant Chemotherapy|"Neoadjuvant treatment (200mg/m3 Paclitaxel+ AUC5 Carboplatin). It will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)"
32847785|NCT04747015|Active Comparator|Cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus
32847786|NCT04747015|Active Comparator|Active management|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
32847787|NCT03755713|Experimental|ASP0892 Low Dose (Cohort A)|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
32847788|NCT03755713|Experimental|ASP0892 High Dose (Cohort B)|After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).
32903407|NCT04387682|No Intervention|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
32903408|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
32903409|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
32903410|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
32903411|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
32903412|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
32903413|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
32903414|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
32903415|NCT00595556|Experimental|A|Zonisamide
32903416|NCT00595556|Placebo Comparator|B|placebo
32903417|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
32903418|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
33320129|NCT05694728|Experimental|The Group of Investigational Vaccine|"For Mid-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#60μg#40μg#20μg#20μg#20μg#20μg and 20μg respectively, totaling 270μg of antigens.~For High-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#80μg#60μg#30μg#30μg#30μg#30μg and 30μg respectively, totaling 360μg of antigens."
33320130|NCT05694728|Active Comparator|The Group of Active Control Vaccine|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens.
33320131|NCT05694650||Focus|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
32847789|NCT03755713|Placebo Comparator|Placebo|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
32847790|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
33320132|NCT05694650||Interview|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
33320133|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
33320134|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
32847791|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
32847792|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks (a delay of +/- 2 weeks to initiate the locoregional treatment is authorized after the day 1 of cycle 1 of palbociclib plus letrozole). After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
32847793|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
32847794|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
32847795|NCT04747171|Active Comparator|magnesium intrathecal|
32847796|NCT04747171|Active Comparator|dexamethasone intrathecal|
32847797|NCT04747171|Active Comparator|dexmedetomidine intrathecal|
32847798|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
32847799|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
32847800|NCT03835117|Experimental|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
32847801|NCT03835117|Placebo Comparator|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
32847802|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
32847803|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
32847804|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
32847805|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
32903419|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
33320135|NCT05694572||Pacemaker system|Patients implanted with ENO or ALIZEA family pacing systems
33320136|NCT05694572||ICD system|Patients implanted with ULYS family ICD systems
33320137|NCT05694572||CRT-D system|Patients implanted with GALI family CRT-D systems
33320138|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
33320139|NCT01306136|Experimental|Prolonged Exposure|
33320140|NCT01306136|Active Comparator|Usual care|
33320141|NCT05533814|Experimental|Perampanel|Participants will be administered oral perampanel at a starting dose of 2 milligram (mg) per day. Doses of perampanel will then be up titrated in increments of 2 mg every 2 weeks up to maximum of 8 mg per day at the discretion of the investigator, and the dose may be administered up to maximum tolerated dose (MTD) according to the clinical response and tolerance of individual participants.
33320142|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
33326982|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
32847806|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
32847807|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
32847808|NCT04972188|Experimental|ZYIL1|Capsule administration. Six subjects will be recruited in each cohort. safety data up to day 14 will be evaluated. Single dose will be administered in ascending manner starting from 12.5 mg.
32847809|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
32847810|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
32847811|NCT04508088||Crohn Disease|"This group will be 46 adolescents, ages 13-20, who have been recently (within 3 months) diagnosed with Crohn Disease.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
32847812|NCT04508088||Control|"Controls will be matched for age, Tanner staging, and BMI percentile.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
32847813|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
32847814|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
32847815|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
32847816|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
32847817|NCT03745729|Experimental|Treatment group|
33320143|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
32847818|NCT03745729|Placebo Comparator|Control group|
32847819|NCT04904952|Active Comparator|Experimental|This arm includes 30 OCD patients receiving SSRIs
32847820|NCT04904952|Placebo Comparator|Control|This arm includes 30 OCD patients receiving SSRIs
32847821|NCT04242498|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
32847822|NCT04242498|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
32847823|NCT04242498|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
32847824|NCT04242498|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
32847825|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
32847826|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
32847827|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
32847828|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
32847829|NCT05130138|Experimental|Pharmaceutical conciliation|Patients with Chronic Myeloid Leukemia taking TKI with a molecular response < 4,5 Log will participate to pharmaceutical conciliation.
33103981|NCT04755114|No Intervention|Control group|"After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min).~Pain level and vital signs will be evaluated and saliva sample will be taken for the final test (30th minute) and follow-up (60th minute) simultaneously with the administration group without any intervention."
33320144|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
33320145|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
33326983|NCT01170936|Experimental|Canakinumab|
32847830|NCT04763863||Ostomates|Ostomates with leakage issues and stoma created at least 3 months ago
32847831|NCT04240704|Experimental|JBH492 single agent|Patients with R/R CLL or NHL
32903420|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
33326984|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
32847832|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
32847833|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
32847834|NCT04756596||Study group|70 patients with normal vision (NVG) 30 patients with low vision (LVG) These patients will be tested on the DDVIT
32847835|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
32847836|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
32847837|NCT05048784|Experimental|Treatment Sequence ABC|"Participants will be administered sotorasib dose A orally in the following order:~Treatment A - as 3 tablets (test 1)~Treatment B - as 8 tablets (reference)~Treatment C - as 3 tablets (test 2)"
33320146|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
32958964|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
32958965|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
32847838|NCT05048784|Experimental|Treatment Sequence BAC|"Participants will be administered sotorasib dose A orally in the following order:~Treatment B - as 8 tablets (reference)~Treatment A - as 3 tablets (test 1)~Treatment C - as 3 tablets (test 2)"
32847839|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
32847840|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
32847841|NCT04706520|Experimental|Group 1: Vinegar|Participants will consume 400 mL/day vinegar beverage providing 1,500 mg/day acetic acid [200 mL vinegar beverage, twice per day (prior to breakfast and dinner)] for 12 weeks.
32847842|NCT04706520|Experimental|Group 2: Vinegar/Placebo Combination|Participants will consume 200 mL/day vinegar beverage and 200 mL/day placebo beverage providing 1,200 mg/day lactate [200 mL placebo beverage 1x/day] and 750 mg/day acetic acid [200 mL vinegar beverage 1x/day] (prior to breakfast and dinner) for 12 weeks.
32847843|NCT04706520|Placebo Comparator|Group 3: Placebo|Participants will consume 400 mL/day placebo beverage containing 1,250 mg/day lactate [200 mL placebo beverage, and 200 mL placebo beverage (prior to breakfast and dinner) for 12 weeks.
32847844|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
32847845|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
32847846|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
32847847|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
32847848|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
32847849|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
32847850|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
32847851|NCT04005846|Other|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
32847852|NCT04005846|Other|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
32847853|NCT03629652|Experimental|Head down position|head-down position treatment combined with conventional rehabilitation.
32847854|NCT03629652|Sham Comparator|Conventional Rehabilitation|Conventional rehabilitation treatment
32847855|NCT03742141|Experimental|Intraoperative Video Laryngoscopy|Participants undergoing neck procedures
32847856|NCT03441750|Experimental|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
32847857|NCT03441750|Other|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
32847858|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
32847859|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
32903421|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
32847860|NCT03423264|Experimental|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
32847861|NCT03423264|No Intervention|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
32847862|NCT03660553|Active Comparator|Multiple Subcutaneous Injection (MSI)|MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.
32847863|NCT03660553|Experimental|Basal Insulin (BI)|BI group will receive only one injection of insulin glargine in the morning.
32847864|NCT04527744|Experimental|the Yonsei point group|Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point.
32847865|NCT04527744|Active Comparator|the levator labii superioris alaeque nasi muscle group|For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
32847866|NCT03657667|Other|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
32847867|NCT04976010||CKD G3-5|Patients with CKD and an estimated eGFR < 60ml/min not yet on dialysis
32847868|NCT04976010||End stage kidney disease (ESKD) CKD G5 Hemodialysis|Patients on hemodialysis for at least 3 months
32847869|NCT04976010||Normal kidney function|Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR > 90ml/min
32847870|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
32847871|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
32847872|NCT04503954|Experimental|Self-management group|Self-management group Chronic disease self-management program is conduct training skills, person how to live together with personal chronic disease to make life quality better.
32847873|NCT04503954|Placebo Comparator|Control group|Control group will continue general psychiatric intervention.
32847874|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
32847875|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
32847876|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
32847877|NCT04464720|Other|Intervention after One Week|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional week.
32847878|NCT03823885|Experimental|E-cig|One time exposure to e-cig
32847879|NCT03823885|Experimental|sham|One time exposure to empty e-cig
32847880|NCT03198468|Experimental|Vapor Ablation|
32847881|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
32847882|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
32847883|NCT03179748||turoctocog alfa|Patients with haemophilia A
32847884|NCT04881318|Experimental|Waist-High Compression Tights and Medications|Participants will wear the waist-high compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of waist-high compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
32847885|NCT04881318|Experimental|Waist-High Compression Tights and No Medications|Participants will wear the waist-high compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of waist-high compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
32847886|NCT04881318|Experimental|Abdominal Compression Garments and Medications|Participants will wear the abdominal compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of abdominal compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
32847887|NCT04881318|Experimental|Abdominal Compression Garments and No Medications|Participants will wear the abdominal compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of abdominal compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
32847888|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire~kV x-ray images~Conebeam CT"
32847889|NCT04868292|Experimental|SPR206|Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.
32958966|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
32958967|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
32958968|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
32847890|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
32847891|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
32847892|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Erector Spinae block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
32847893|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Paravertebral block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
32847894|NCT03653611||Clinician Participants|Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
32847895|NCT03653611||Patient Participants|200 patients, who are enrolled in Aim 1 (approximately 40 from each PBRN) will be invited to take a CAPTURE opinion survey
32847896|NCT04351386||Atrial Fibrillation (AF)|Patients diagnosed with AF during reference ECG
32847897|NCT04351386||Normal Sinus Rhythm (NSR)|Patients with NSR during reference ECG
32847898|NCT04351386||Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
32847899|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
32847900|NCT04824534||Healthy subjects|
32847901|NCT04824534||Healthy subjects matching baseline characteristics with patients|
32847902|NCT04824534||Patients with sarociliac joint dysfunction|
32847903|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
32847904|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
32847905|NCT04803552|Experimental|Contactless sleep apnea screening vs respiratory polygraphy|
32847906|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
32847907|NCT04232124|Experimental|Hypertension Management Model|Aim 1. Execute a smaller version of the LA Barbershop BP Study through the new Nashville network as the test case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a research protocol and evaluating a HTN intervention; and C) creating a local registry of potential subjects as platform for enrolling black men in future research studies.
32847908|NCT03819283|Other|Hepatic evaluation|
32847909|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
32847910|NCT03651895|Placebo Comparator|Placebo Group|Placebo
32847911|NCT04760184||COVID19 positives after autologous stem cell transplantation|All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 who has tested positive for SARS-CoV-2 from start of conditioning until the end of the study period 31st March 2021.
32847912|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
32847913|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
32847914|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
32847915|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
32847916|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
32847917|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
32847918|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
32847919|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
32847920|NCT04183530||SCOPD|Participants with stable COPD diagnosed according to GOLD criteria and hasn't encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
32847921|NCT04183530||AECOPD|Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
32847922|NCT04183530||Smoking healthy controls|Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
32847923|NCT04183530||Non smoking healthy controls|Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
32958969|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
32739056|NCT04992039|No Intervention|Control Arm|Participants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
32739057|NCT04992039|Experimental|Intervention Arm|Participants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
32739058|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
32739059|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
32739060|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
32739061|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
32739062|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
32739063|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
32739064|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
32739065|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
32739066|NCT04991727||PEEP|The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway.Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed.Pulmonary ultrasound was performed. The PEEPgroup was given the first RM (pulmonary retraction) with pressure maintained at 40cmH2O for 30s, followed by a 7cmH2O PEEP to maintain mechanical ventilation, and the RMS was repeated every 30 minutes until the end of surgery
32739067|NCT04991727||ZEEP|"The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway. Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed~On pulmonary ultrasound, patients in the ZEEP group maintained normal mechanical ventilation throughout the operation without PEEP or RMS"
32739068|NCT02484365||single arm study|No treatment or intervention will given to the patients
32739069|NCT03119467|Experimental|Single arm|RP4010 to be administered
32739070|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
32739071|NCT04999137|Experimental|Intravenous vitamin C 1.5g + intravenous vitamin B1|intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
32739072|NCT04999137|Experimental|Intravenous Vitamin C 3g + intravenous vitamin B1|Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
32739073|NCT04999137|No Intervention|Usual Care|Usual care
32739074|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
32739075|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
32739076|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
32739077|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
32739078|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
32739079|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
32739080|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
32739081|NCT05353361|Experimental|SHR-A1811combined Pyrotinib|
32739082|NCT05353361|Experimental|SHR-A1811Combined Pertuzumab|
32739083|NCT05353361|Experimental|SHR-A1811Combined SHR-1316|
32739084|NCT05353361|Experimental|SHR-A1811Combined Albumin-bound Paclitaxel|
32739085|NCT03200743||Hpertension|
32958970|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
32958971|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
32958972|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
32958973|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
32958974|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
32958975|NCT02974374|Experimental|PF-06835919|
32958976|NCT02974374|Placebo Comparator|Placebo|
32958977|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
32958978|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
32958979|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
32958980|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
32958981|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
33320147|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
33320148|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
33320149|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
33320150|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
32958986|NCT02973672|Experimental|SGM-101|
32958987|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
32958988|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
32958989|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
32739086|NCT03200743||Health|
32958990|NCT02973360|Placebo Comparator|Placebo|Soybean oil
32958991|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
32958992|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
32958993|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
32958994|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
32958995|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
32958996|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
32958997|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
32958998|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
32958999|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
32959000|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
32959001|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
32959002|NCT02959398|Active Comparator|standard mammography|standard mammography
32959003|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
32739087|NCT03072615||1|receiving TE before and 30 min after TIPS
32739088|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
32739089|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
32959004|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
32959005|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.~Hypertension group will measure TOI and BP."
32959006|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
33033427|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
33320151|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
33320152|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
33320153|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
33320154|NCT03713684|Placebo Comparator|Placebo|Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).
32959007|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
32959008|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
32959009|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
32959010|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
32739090|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
32959011|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
32959012|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
32959013|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
32959014|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
32959015|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
32959016|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
32959017|NCT04769622||patients affected by untreated Periodontitis|patients coming to the Unit of Periodontics at the University of Siena will be screened for the inclusion in the study. All patients eligible for the inclusion in the study will undergo non-surgical periodontal treatment and will be administered a questionnaire about lifestyles (adherence to mediterranean diet, sleep quality, physical activity, perceived stress). Patients will be then reevaluated at 3 months after the completion on non-surgical periodontal therapy.
32959018|NCT04769778|Experimental|Valsartan|Treatment with valsartan
32959019|NCT04769778|No Intervention|no treatment|no treatment received
32959020|NCT04769076|Experimental|Paclitaxel(Album-bound)|Subjects will receive neoadjuvant therapy with paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab) as well as radical concurrent radiotherapy and chemotherapy.
32959021|NCT04769232|Active Comparator|Standard Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by standard imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (estimation of the number of eosinophilic neutrophils according to the following categories 1: 0, 2: 1-6, 3. 7-14, 4. 15-50, 5. :50-100, 6. > 100, together with an estimation of an absolute number of eosinophilic neutrophils) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently for all other 10 biopsies using this imaging modality by endoscopist.
32959022|NCT04769232|Experimental|High Magnification Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by high magnification imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (see above) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently all other 10 biopsies using this imaging modality by endoscopist.
32959023|NCT04768998||Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, POP).
32959024|NCT04768998||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, SUEP).
32959025|NCT04768998||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (POP, SUEP).
32959026|NCT04768842|Experimental|LY3209590 Lyophilized Formulation|LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.
32959027|NCT04768842|Experimental|LY3209590 Solution Formulation|LY3209590 as solution formulation administered SC in one of the two study periods.
32959028|NCT04768764|Active Comparator|Group 1 Middle Adductor Canal Block|"Ultrasound Guided Middle Adductor Canal Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for middle adductor canal block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
32959029|NCT04768764|Active Comparator|Group 2 Femoral Nerve Block.|"Ultrasound Guided Femoral Nerve Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
32959030|NCT04768530|Active Comparator|Scaling and Root Planing (SRP)|
32959031|NCT04768530|Experimental|Scaling and Root Planing with Nitazoxanide hydrogel|
32959032|NCT04768140|Experimental|Bobath group|A conventional physiotherapy program was applied to this group. Additionally, Bobath treatment approach was applied for 10 repetitions during a 30-min session in the experimental group, in addition to the conventional physiotherapy program.
32959033|NCT04768140|Active Comparator|Conventional physiotherapy group|Only conventional physiotherapy program was applied to this group.
32739091|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
32959034|NCT04749654|Experimental|Fixed space maintainers|band-and-loop type fixed space maintainers were applied
32959035|NCT04749654|Experimental|Removable space maintainers|All removable space maintainers were produced of an acrylic base and retention elements that were a vestibule arch, (Adam's and C clasps).
32959036|NCT04749498|Active Comparator|White Bread|White bread with a standard test breakfast
32959037|NCT04749498|Active Comparator|Whole Wheat Bread|Whole wheat bread with a standard test breakfast
32959038|NCT04749498|Experimental|Barley Bread|Barley bread with a standard test breakfast
32959039|NCT04749498|Experimental|Oat Bread|Oat bread with a standard test breakfast
32959040|NCT04749342|Experimental|Complete Decongestive Therapy|Complete decongestive therapy (CDT) is also known as complex decongestive therapy. It involves a two-stage treatment protocol. The first stage consists of skin care, manual lymph drainage, exercises and compression with multi-layered bandages. The second stage aims to optimize and conserve the volume reduction obtained in stage one. This is achieved by using a low-stretch elastic garment in combination with skin care and exercises
32959041|NCT04749342|Experimental|Compression Bandaging|External compression is the mainstay of management for all stages of lymphedema. The efficacy of compression therapy alone, or combined with MLD, has been supported by randomized clinical trials
32959042|NCT04749420||Patients group|Individuals with cervical radiculopathy
32959043|NCT04748562|Active Comparator|400 mg progesterone group|Taking 400 mg vaginal progesterone
32959044|NCT04748562|Active Comparator|200 mg progesterone group|Taking 200 mg vaginal progesterone
32959045|NCT04745286|Experimental|S-ketamine group|
32959046|NCT04745286|Placebo Comparator|saline group|
32959047|NCT04745364|Experimental|Session One|Session One participants undergo the 4-week course from 2/21/2021 to 3/15/2021
32959048|NCT04745364|Experimental|Session Two|Session Two participants undergo the 4-week course from 3/22/2021 to 4/12/2021
32959049|NCT04745442|Experimental|Best available treatment + Antithrombin|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
32959050|NCT04745442|Active Comparator|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
32959051|NCT04744740||PTSD+Suicidal Ideation|US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
32959052|NCT04744740||PTSD-Suicidal Ideation|US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
32959053|NCT04744818|Active Comparator|Immediate iron treatment|Iron and multivitamin syrup
32959054|NCT04744818|Placebo Comparator|Delayed iron treatment|Multivitamin syrup
32959055|NCT04745052||Patients with acute ischemic stroke|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
32959056|NCT04744896|Experimental|cryolipolysis|3max cool shaping device is administered 3 times for each patient, one session every 6 weeks, each session is 40 minutes.
32959057|NCT04744896|Experimental|treadmill|aerobic training in form of high intensity interval training, three times per week for 3 weeks by treadmill(jkexer focus 8020A) each session is for 20 minutes.
32959058|NCT04744896|Active Comparator|treadmill+cryolipolysis|aerobic training 3 times per week and cryolipolysis once every 6 weeks
32959059|NCT04744506|Experimental|TAD ARM|
32959060|NCT04744584||Patients with medication reconciliation|Patient with medication reconciliation during 1st hospitalization
32959061|NCT04744584||Patients without medication reconciliation|Patient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
32959062|NCT04744038|Experimental|Investigational Device|Participants will then be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device. Participants will use their own mask with the investigational device for the duration of this study.
32959063|NCT04743882||A|
32959064|NCT04743882||B|
32959065|NCT04743882||C|
32959066|NCT04743726||Endoscopy|Chinese volunteers who are scheduling for gastro-colonoscopy
32959067|NCT04743648|Experimental|Intervention Group|After determining the experimental and control groups, pre-tests were performed.The program was applied to students in the experimental group.The program was implemented for six weeks based on the theme of innovative thinking.The program developed a training program based on the Tyler Taba model. This model, which is often used in developing educational programs, includes all the necessary steps to teach and accept a new concept. In the ITDP training program, an interactive educational content has been created in which knowledge will be transformed into behavior.In the training, subjects were taught in units, workshops were held, seminars were given. Post-tests were applied at the end of the training.
32959068|NCT04743648|No Intervention|Control Group I|Pre-test and post-tests were applied to the non-intervention group
32959069|NCT04743648|No Intervention|Control Group II|Pre-test and post-tests were applied to the non-intervention group
33033428|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
33406276|NCT05545943|Active Comparator|2-days of usual diet with whole-body cooling|"Healthy young subjects participated two 10-min whole body cooling practices on separate days and were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
33406277|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
33406278|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
33406279|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
33406280|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
33406281|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
33406282|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
32847924|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
33406283|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
33406284|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
33406285|NCT05543369|Experimental|Cohort 1 : Healthy Japanese Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
33406286|NCT05543369|Experimental|Cohort 2: Healthy Non-Asian Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
33406287|NCT05536115||Study population|Study patients are patients with post-extraction dry socket.
33406288|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
33406289|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
33406290|NCT04464954|Experimental|Auricular semi-permanent (ASP gold) needles|
33406291|NCT04464954|Experimental|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
33406292|NCT04464954|Experimental|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
33406293|NCT05685186||PCD Cohort|"The PCD cohort will include individuals who have a genetically confirmed diagnosis of PCD with 2 identified pathogenetic variants within 1 of 4 genetic/ultrastructural variants:~DNAI1 ODA defect~Other ODA defect~IDA-MTD defect, CCDC39 or CCDC40~Radial Spoke defect"
33406294|NCT05685186||Healthy Volunteer Cohort|The healthy volunteer cohort will include health individuals.
33406295|NCT03628248|Experimental|embolization|
33406296|NCT03628248|Other|No embolization|
33406297|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
32847925|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
32847926|NCT00003469|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32847927|NCT04748640|Experimental|Treatment group|Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
32847928|NCT03811873|Other|Intervention|Single-Arm trial
33406298|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
33406299|NCT03442985|Placebo Comparator|Placebo regimen|
33406300|NCT05522075|Experimental|Exercise Group|Binge drinkers who have been assigned to exercise group will receive baseline assessment, 8-week exercise training plus alcohol abstinence intervention, and post-intervention assessment.
33406301|NCT05522075|Active Comparator|Non-exercise Group|Binge drinkers who have been assigned to non-exercise group will receive baseline assessment, 8-week alcohol abstinence intervention, and post-intervention assessment.
33406302|NCT05522075|No Intervention|Alcohol abstainer/moderate drinker group|Alcohol abstainer/moderate drinker will complete baseline assessment only and will not receive any intervention.
32847929|NCT04670484|Other|Healthy subjects wearing masks|Subjects wearing masks to prevent coronavirus infection spread in COVID19 pandemic
32847930|NCT03732781|Experimental|Radspherin|
33033429|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
33406303|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
32847931|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
32847932|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
32847933|NCT02268552|Experimental|branaplam|branaplam Treatment
32847934|NCT03644485|Experimental|Standard Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 1 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
32847935|NCT03644485|Experimental|Delayed Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 3 - 5 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
32847936|NCT04657926|Experimental|APPA|"APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) & 2-hydroxy-4-methoxyacetophenone (2H4MA) administered to 75 participants as 2 x 400mg capsules b.d. for 28 days~."
32847937|NCT04657926|Placebo Comparator|Placebo|2 capsules b.d. for 28 days
32847938|NCT04070898|No Intervention|control group|Bladder catheter removal 24 hours after surgery
32847939|NCT04070898|Experimental|experimental group|Removal of the bladder catheter after the surgical intervention
32847940|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
32847941|NCT04000620||cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning.
32847942|NCT04000620||no cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning.
32847943|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
32847944|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
32847945|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
32847946|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
32847947|NCT03638791||Healthy controls|Matched Controls without treatment
32847948|NCT03638791||OCD|Exposure and response inhibition
32847949|NCT03805789|Experimental|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
32847950|NCT03805789|Experimental|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
32847951|NCT03805789|Experimental|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
32847952|NCT03805789|Experimental|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
32847953|NCT03805789|Placebo Comparator|Placebo|Albumin solution administered intravenously
32847954|NCT03805399|Experimental|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
32847955|NCT03805399|Experimental|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2;If B2 was closed, enter into B4;
32847956|NCT03805399|Experimental|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
32847957|NCT03805399|Experimental|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
32847958|NCT03805399|Experimental|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
32847959|NCT03805399|Experimental|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
32847960|NCT03805399|Experimental|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
32847961|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
32847962|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
32847963|NCT03725059|Experimental|Pembrolizumab+Chemotherapy (KX/KA[E]C)|In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
32898778|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
32959070|NCT04743414|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.
32959071|NCT04743336||Normal weight (<25 kg/m2)|
32959072|NCT04743336||overweight (25-29.9 kg/m2)|
32959073|NCT04743336||obese (≥30 kg/m2)|
32959074|NCT04743180||LUMINOR© drug eluting balloon|
32959075|NCT04743258|Experimental|EXTRACTION|treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
32959076|NCT04743258|Experimental|DISTALIZATION|treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
32959077|NCT04742790|Experimental|Patients|The study will recruit volunteers (1) suffering from disabling post-operative pain for more than two weeks following surgery (thoracotomy, sternotomy and breast cancer surgery), (2) currently being treated for their post-operative pain with an opioid analgesic - along with possible other treatments - and (3) for which the treating physician is about to introduce an additional non-opioid drug for the treatment of their pain (e.g. an antiepileptic or an anti-depressant).
32959078|NCT04742478||Eligible subjects who underwent RA prior to PCI (with informed consent taken to join the study)|Informed consent to be obtained either prior to PCI with rotational atherectomy planned or within 48 hours after rotational atherectomy. There will be data collection of history/demographics, laboratory results, symptoms, any serious adverse events recording for this cohort as well as a telephone follow up at 12months post rotational atherectomy.
32959079|NCT04742478||Eligible subjects who underwent RA prior to PCI (without informed consent taken to join the study)|Subjects that were demised or refused to give consent will fall under this cohort. The data collection of this cohort will be done through screening of in-hospital data via available local PCI database/registry.
32959080|NCT04742244|Placebo Comparator|Placebo|0 mg LVE/capsule, 2capsule/day, 14days
32959081|NCT04742244|Experimental|Lemon Verbena extract|200 mg LVE/capsule, 2capsule/day, 14days
32959082|NCT04741854|Experimental|Investigational Device|Participants will be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device.
32959083|NCT04741152||Revealed insulinoma|Cases when the tumor was revealed by the preoperative diagnostics and confirmed after the tumor elimination
32959084|NCT04741152||Hidden Insulioma|Group when the insulinoma haven't been revealed preoperative and intraoperatively and the blind resection was performed.
32959085|NCT04740840|Experimental|Levamlodipine group|Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
32959086|NCT04740840|Sham Comparator|Amlodipine group|To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
32959087|NCT04740762|Experimental|Intervention group|The study group were provided with individual counseling program and followed in this study, in addition to the usual care provided by healthcare professionals.
32959088|NCT04740762|No Intervention|Control group|The control group continued to receive the routine care
32959089|NCT04740450|Experimental|study side|receive KT technique described by Gozluklu et al in 2020
32959090|NCT04740450|Placebo Comparator|Control side|tapped with wound tape following the same technique
32959091|NCT04740216|Experimental|exercise therapy plus jaw device|exercise therapy plus jaw device
32959092|NCT04740216|Placebo Comparator|exercise therapy|exercise therapy
32959093|NCT04740138|Experimental|DBT Skills + Parent Training|
32959094|NCT04739826||flumatinib|flumatinib 600mg QD, fasting administration
32959095|NCT04739826||nilotinib|nilotinib 300mg BID, fasting administration
32959096|NCT04739904||Preterm born|Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
32959097|NCT04739904||Full-term control|Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
32959098|NCT04739748||Respiratory ICU patient|patient in RICU that developed ventilator-associated pneumonia
32959099|NCT04739436|Other|Bilateral hearing aid fitting group|
32959100|NCT04739436|Active Comparator|Unilateral hearing aid fitting group|
32959101|NCT04739202|Experimental|Patients with tumors positive for EBV or microsatellite instable tumors (group 1)|Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).
32959102|NCT04739202|Experimental|Patients with genomically stable tumors (group 2)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
32959103|NCT04739202|Experimental|Patients with tumors with chromosomal instability (group 3)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
32959104|NCT04739514|Active Comparator|Mild dysphagia|
32959105|NCT04739514|Active Comparator|Moderate dysphagia|
32739092|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
32959106|NCT04739514|Active Comparator|Severe dysphagia|
32959107|NCT04739124||Diabetic patients|Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre
32959108|NCT04739124||Caregivers|Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis
33320155|NCT03713684|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.
33326985|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
32959112|NCT04739046|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy
32959113|NCT04738656||Mediterranean-style diet plan|"Mediterranean-style diet plan (6 months): 22% proteins, 53% carbohydrates, and 25% of lipids.~52 participants."
32959114|NCT04738656||Open protein diet plan|"Open protein presents (6 months) 40% of proteins, 29% carbohydrate and 31% of lipids.~26 participants."
32959115|NCT04738500|Active Comparator|PENG Block|PENG Block combinate with PCA
32959116|NCT04738500|Sham Comparator|CONTROL|PCA
32959117|NCT04738188|Experimental|Drug-eluting bead transarterial chemoembolization(DEB-TACE)|
33320156|NCT03713684|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.
33320157|NCT03713684|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.
33320158|NCT05694494|Experimental|iLiFE|receiving Lifestyle-integrated Functional Exercise training and home safety assessment
33320159|NCT05694494|Placebo Comparator|attention control|upper limb exercise training
33320160|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
33320161|NCT05694416|Experimental|Etoposide Plus Cisplatin group|Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5
32847964|NCT03725059|Placebo Comparator|Placebo+Chemotherapy (PX/PA[E]C)|In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
33320162|NCT05694416|No Intervention|Temozolomide group|Temozolomide 150-200mg/m2 d1-5
32847965|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
32847966|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
33326986|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
33326987|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
33326988|NCT01171014|Placebo Comparator|Placebo|Placebo
32847967|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
32847968|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
32847969|NCT03825822|Experimental|ImPaC Resource Intervention (INT)|The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
32847970|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their unit or institutional standard pain practices and any strategies that they would normally use to improve them (e.g. new staff orientation).
32847971|NCT03724903|Experimental|Ductal lavage|Ductal lavage and breast massage for two weeks.
32847972|NCT03724903|Active Comparator|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
32847973|NCT03722017|No Intervention|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, [OTC medications] and active in-hospital medications. Pre-hospital [and OTC] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
32847974|NCT03722017|Experimental|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
32847976|NCT04348279|Active Comparator|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
32847977|NCT04348279|Experimental|propylene mesh|in the test group, the donor sites received propylene mesh.
32847978|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
32847979|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
32847980|NCT03713515|Experimental|Practice Faciliation|Will be supported by a practice facilitator
32847981|NCT03713515|No Intervention|Usual Care|Using a stepped wedge design, all practice sites begin as part of the Usual Care (UC) control condition and will receive standard hypertension management that is part of the current clinic procedure. No practice facilitation will occur at this time.
32898779|NCT00154466|Experimental|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
32898780|NCT00154466|No Intervention|postinfarction patients|those in the nontraining group continued their usual lifestyle
32898781|NCT00154466|Placebo Comparator|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
32898782|NCT00117806|Experimental|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
33103982|NCT04748952||Adult with horizontal bone defect|"30 implants will be placed in osteotomy sites prepared by osseodensification for patients with horizontal bone deficiency based on radiographic findings (CBCT).~Alveolar ridge width will be measured intraoperatively before and after osteotomy site preparation to assess the amount of ridge expansion. Implant stability will be measured immediately after implant installation and 16 weeks later."
33103983|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
33103984|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
33103985|NCT04327544|Experimental|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
33103986|NCT04327544|No Intervention|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
33103987|NCT05569122|Experimental|Aim 1: Primary Mitochondrial Disease Patients|"The participant has the interventions/study visits occur in a random order:~CPET pGz administration through pGz Bed pGz administration through Gentle Jogger"
33406304|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
33406305|NCT01311635|Experimental|Treatment A|
33103988|NCT05569122|Experimental|Aim 1: Healthy Controls|"The participant has the interventions/study visits occur in a random order:~pGz administration through Gentle Jogger CPET pGz administration through pGz Bed"
33103989|NCT05569122|Experimental|Aim 2: PICU Patients|All participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
33103990|NCT05567367|Experimental|RT234 0.2 mg, Single Ascending Dose (SAD)|Part 1, SAD Cohort 1A
33103991|NCT05567367|Experimental|RT234 0.6 mg followed by oral vardenafil 20mg on day 3, SAD|Part 1, SAD Cohort 2A1
33103992|NCT05567367|Experimental|Oral vardenafil 20mg followed by RT234 0.6 mg on day 3, SAD|Part 1, SAD Cohort 2A2
33103993|NCT05567367|Experimental|RT234 1.2 mg, SAD|Part 1, SAD Cohort 3A
33103994|NCT05567367|Experimental|RT234 2.4 mg, SAD|Part 1, SAD Cohort 4A
33103995|NCT05567367|Experimental|RT234 2.4 mg, Multiple Ascending Dose (MAD)|Part 2, MAD Cohort 1B
33103996|NCT05562024|Experimental|T cell injection targeting TAA06 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 2.0 × 10^6, 4.0 × 10^6 and 8.0 × 10^6 CAR-T/kg groups in order of sequence.
33103997|NCT04291001|Active Comparator|ENG Implant alone|Women will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
33406306|NCT01311635|Experimental|Treatment B|
33406307|NCT01311635|Experimental|Treatment C|
33406308|NCT01311635|Experimental|Treatment D|
32847982|NCT04403503|Active Comparator|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
32847983|NCT04403503|Active Comparator|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
32847984|NCT00249795|Experimental|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
32847985|NCT00249795|Placebo Comparator|Placebo|Matching placebo up to final follow-up visit
32847986|NCT04404127|Placebo Comparator|No induction Arm|
32847987|NCT04404127|Active Comparator|Induction with basiliximab|
32847988|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
33406309|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
33406310|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
33406311|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
32847989|NCT04763629|Experimental|Interval Training (IT)|Patients randomized to this group will perform 45 minutes of exercise on treadmill, alternating intervals of ten minutes at 50-60% of VO2 peak and two intervals five miutes at 85-90% of VO2 peak
32847990|NCT04763629|Experimental|Compbined Training (CT)|Patients randomized to this group will perform 45 minutes of exercise in which they will perform aerobic continuous training on tradmill (20 minutes) and resistance training (25 minutes)
32847991|NCT04763473|Placebo Comparator|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
32847992|NCT04763473|Experimental|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
32847993|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
33406312|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
33406313|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
33406314|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
33406315|NCT01311245|No Intervention|Control group|Assessment only
33406316|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
33406317|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
32847994|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
32847995|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
32847996|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
32847997|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
32847998|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
32847999|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
32848000|NCT04271943|Active Comparator|COMPUTER BASED EXERCISES|
32848001|NCT04271943|Active Comparator|AEROBIC EXERCISES|
32848002|NCT04580004|Experimental|Medication Optimization Group|Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.
32848003|NCT04580004|No Intervention|Control Group|Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.
32848004|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
32848005|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
32848006|NCT03738696|Experimental|Liposomal bupivacaine Interscalene Block|"Interscalene block:~10cc (133mg) liposomal bupivacaine;PLUS~10cc 0.25% bupivacaine"
32848007|NCT03738696|Active Comparator|Ropivacaine Interscalene Catheter|"20cc 0.25% bupivacaine interscalene block; PLUS~Ropivacaine 0.25% interscalene catheter (6ml/hr for 48hrs)"
32848008|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
32848009|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
32848010|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
32848011|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
32848012|NCT04436094|Experimental|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
32848013|NCT04436094|Active Comparator|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
32848014|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
32848015|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
32848016|NCT04209504||Continuous Perineural Catheter|Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
32848017|NCT04209504||10 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
32848018|NCT04209504||20 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
32848019|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
32848020|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
32848021|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
32848022|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
32848023|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
32848024|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
32848025|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
32848026|NCT03704610|Experimental|INFLIXIMAB|Infliximab 5 mg/kg D1-D15, then infliximab every 4 weeks W6-W10-W14
32848027|NCT03704610|Other|Placebo|placebo injection D1-D15 then infliximab 5 mg/kg W6-W8-W12-W16-W20
32848028|NCT03716167|Experimental|Laser Treatment|Summus Laser treatment with infrared light
32848029|NCT03716167|Sham Comparator|Sham treatment|Sham Summus Laser treatment with no infrared light
32848030|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
32848031|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
32848032|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
32848033|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
32848034|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
32848035|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
32848036|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
32848037|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
32848038|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
32848039|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
32848040|NCT03797989|Experimental|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
32848041|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
32848042|NCT03797989|Experimental|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
32848043|NCT03797989|Experimental|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
32848044|NCT03797989|Experimental|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
32848045|NCT03797989|Experimental|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
32848046|NCT03797989|Experimental|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
32848047|NCT03797989|Experimental|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
32848048|NCT03797989|Experimental|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
32848049|NCT00247611|Other|Control|Participants will receive the control condition
32848050|NCT00247611|Experimental|Intervention|Participants will receive the LifeWindows Intervention sessions
32848051|NCT04532190|Experimental|Active rTMS|Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
32848052|NCT04532190|Sham Comparator|Sham rTMS|For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
32848053|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
32848054|NCT04202874|Experimental|Bupivacaine|Administration of 20ml of bupivacaine 0.25% on each side, for a total of 40ml.
32848055|NCT04202874|Placebo Comparator|Saline|Administration on 20ml of normal saline on each side, for a total of 40ml.
32959118|NCT04738188|Active Comparator|conventional transarterial chemoembolization(cTACE)|
32959119|NCT04737798|Experimental|oil pulling with coconut oil|patients used oil pulling therapy with coconut oil for 4 days
32959120|NCT04737798|Active Comparator|oil pulling with sesame oil|patients used oil pulling therapy with sesame oil for 4 days
32959121|NCT04737486|Experimental|Single Ascending Dose Cohort 1-4|Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.
33406318|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
32959122|NCT04737486|Placebo Comparator|Single Ascending Dose Cohort 1-4, Placebo|Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.
32959123|NCT04737486|Experimental|Multiple Ascending Dose Cohort 1-2|Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.
32959124|NCT04737486|Placebo Comparator|Multiple Ascending Dose Cohort 1-2, Placebo|Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.
32959125|NCT04737564|Experimental|ABC10 + SEEK|Participants assigned to this arm will receive the standard Attachment and Biobehavioral Catch-up intervention (ABC 10) as well as SEEK (Safe Environment for Every Kid).
32959126|NCT04737564|Experimental|ABC3 + SEEK|Participants assigned to this arm will receive an abbreviated version of the Attachment and Biobehavioral Catch-up intervention (ABC 3) as well as SEEK (Safe Environment for Every Kid).
32959127|NCT04737564|Active Comparator|SEEK Only|Participants assigned to this arm will receive SEEK (Safe Environment for Every Kid) only.
32959128|NCT04737408|Active Comparator|"Usual care"|"Usual care prevention: atorvastatin 40 mg per day for 18 months"
32959129|NCT04737408|Experimental|"Intensive care"|"Intensive care prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months"
32959130|NCT04737174|Experimental|ES-481|Administered as 25 mg oral gelatin capsules
32959131|NCT04736784|Experimental|Beetroot juice|115 ml of beetroot juice per day for seven days
32959132|NCT04736784|Experimental|Leafy green vegetable juice|250 ml of green leafy vegetable juice per day for seven days
32959133|NCT04736238|Experimental|Trial group|The patients who receive arthroscopic surgery.
32959134|NCT04736238|Other|Control group|The patients who receive BrostrÖm surgery.
32959135|NCT04735848|Experimental|6mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
32959136|NCT04735848|Experimental|30mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
32959137|NCT04735848|Experimental|60mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
32959138|NCT04735848|No Intervention|Baseline|Baseline measurement
32959139|NCT04735302||Sarcoidosis, Nonsarcoidosis|
32959140|NCT04735302||Malign, benign|
32959141|NCT04734912|Other|Gastroscopy in transnasal technique|All patients with indication for gastroscopy in transnasal techqiue are included.
32959142|NCT04735146|Experimental|Experimental Group|The Experimental Group will be involved in 1 weekly session of adapted physical activity lasting 1 hour for 6 weeks within the normal cycle of accompanying birth meetings provided by the University Hospital of Bologna.
32959143|NCT04735146|No Intervention|Control Group|The control group is expected to participate in 6 birth accompaniment meetings held online, 1 hour of which will be dedicated to the topic of exercise and physical activity recommendations in pregnancy.
32959144|NCT04734522|Experimental|The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
32959145|NCT04734522|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
32959146|NCT04734756|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
32959147|NCT04734834|Placebo Comparator|Placebo|"Placebo will be provided orally to the Placebo Group. Placebo will be blinded and labeled either as A or B."
32959148|NCT04734834|Active Comparator|"Prodovite® VMP35"|"Prodovite® VMP35 will be provided orally to the Treatment Group. Prodovite® VMP35 will be blinded and labeled either as A or B."
32959149|NCT04734600|Experimental|aerobic training program|group a:twenty patients who will receive aerobic training program combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
32959150|NCT04734600|Active Comparator|myofascial release technique|group B: twenty patients who will receive myofascial release technique combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
32959151|NCT05314842|Active Comparator|control group|the group that have caries in primary molars and treat them with formocresol
32959152|NCT05314842|Experimental|experimental group|the group that have caries in primary molars and treat them with premixed bioceramic MTA
32959153|NCT05314530|Experimental|Intervention group|Will receive a rehabilitation intervention
32959154|NCT05314530|Active Comparator|Controll|Will receive conventional rehabilitation
32959155|NCT05314140||Coronary artery calcium score evaluation|Patients with diabetes and having a CT scan for evaluation of their coronary artery calcium score will be consecutively include. The indication of the scanner is at the choice of the clinician (usually cardiologist and/or diabetologist), in compliance with the recommendations
32959156|NCT05313984||Patients planned for the 2-staged tined-lead procedure.|"Patients with the following indications:~Overactive bladder without urgency urinary incontinence.~Overactive bladder with urgency urinary incontinence.~Non-obstructive urinary retention.~Dysfunctional voiding or Fowler Syndrome.~Fecal incontinence."
33406319|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
33406320|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
33406321|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
33406322|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
32848056|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
32848057|NCT04452162|Other|Salivary Gland Tumor|
32848058|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
32848059|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
32848060|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
32848061|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
32848062|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
32848063|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
32848064|NCT04412694|Experimental|supplementation group|Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
32848065|NCT04412694|Placebo Comparator|placebo group|Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
32848066|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
32848067|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
32848068|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
32848069|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
32848070|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
32848071|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
32848072|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
32848073|NCT00246753|Other|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
32848074|NCT03972072|Experimental|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
32848075|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
32848076|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
32848077|NCT03761160|Experimental|Mobile Health App|"The developed mobile health app will include the following facets:~Physical activities~Dietary regimen.~The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.~Users will be asked to record the type of physical activity they engaged in during the week, and for how long.~The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is"
32848078|NCT03761160|Active Comparator|Usual Care|Usual care per hospital guideline
32848079|NCT03600480|Experimental|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
32898783|NCT00117806|Placebo Comparator|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
32959157|NCT05313906|Experimental|exprimental group|RC48 plus AK105 and cisplatin
33406323|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
33406324|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
33406325|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
33406326|NCT05218512||WB-EMS|Young recreationally active males without any disease.
33406327|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
33406328|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
33406329|NCT05218278||Patients with favorable neurlogical outcome|CPC 1/2
33406330|NCT05218278||Patients with non-favorable neurological outcome|CPC3-5
33406331|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
33406332|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
33406333|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
33406334|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
33406335|NCT05658029|Experimental|Open label treatment group|
33406336|NCT05520281|Experimental|Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor) from diagnosis to terminal stages
33406337|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
33406338|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
33406339|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
33406340|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
32959158|NCT05313828||group 1'|patients with viral ulcers will receive antiviral medication with antibiotics
32959159|NCT05313828||group 2|patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
32959160|NCT05313828||group 3|patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
32959161|NCT05313828||group 4|patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
32959162|NCT05313750|Experimental|sitafloxacin group|Oral sitafloxacin (0.1g one time daily) for 10 days
33406341|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
33406342|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
33406343|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
33406344|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
33406345|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
33406346|NCT05218122||LKD syndrome|liver and kidney deficiency syndrome
33406347|NCT05218122||PBS syndrome|phlegm and blood stasis syndrome
33406348|NCT05218122||NC group|Normal Control group
33406349|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
33406350|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days"
33406351|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
33406352|NCT03695406|Experimental|Mind-Body Group Intervention|
32959163|NCT05313750|Active Comparator|levofloxacin group|Oral levofloxacin (0.4g one time daily) for 10 days
33103998|NCT04291001|Active Comparator|ENG Implant plus oral UPA|Women will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
33103999|NCT00536952|Experimental|Arm 1|Pulmozyme
32959164|NCT05313672||IPF patients with UIP pattern requiring NIV|
32959165|NCT05313672||ARDS patients requiring NIV|
32959166|NCT05313126|Experimental|sterile male Aedes albopictus-exposed|Sterile male Aedes albopictus are released in the area.
32959167|NCT05313126|No Intervention|control|Sterile male Aedes albopictus are not released in the area.
32959168|NCT05295420|Experimental|platelet-rich plasma|to assess the role of platelet-rich plasma in the treatment of SUI as a non-invasive method
32959169|NCT05294016|Other|Patient group|
32959170|NCT05294016|Other|Control group|
32959171|NCT05290350||OSA Cohort|Patients With post COVID-19 condition and OSA
32959172|NCT05290350||Control Cohort|Patients With post COVID-19 condition without OSA
32959173|NCT05275530|No Intervention|Standard of Care|"No Intervention-Standard Care~UCLA Health has a mailed FIT outreach program. This group will receive standard FIT mailer protocol. They will receive a tailored MyChart message indicating the importance of CRC screening and not be presented with a choice for screening modalities."
32959174|NCT05275530|Experimental|FIT Choice|This group will receive a tailored message via MyChart with information about CRC screening and using the FIT kit for noninvasive screening. They will then have to actively choose if they want CRC screening with a FIT kit vs no screening. If they opt for screening, the investigators will mail them a FIT kit.
32959175|NCT05275530|Experimental|Colonoscopy Choice|This group will receive a tailored message via MyChart with information about CRC screening and colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a colonoscopy vs no screening. If they opt for screening, the investigators will direct them to our patient navigators to get scheduled for a colonoscopy.
32959176|NCT05275530|Experimental|Dual Choice|This group will receive a tailored message via MyChart with information about CRC screening and using either the FIT kit or colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a FIT kit, a colonoscopy, or no screening. If they opt for screening, the investigators will either mail them a FIT kit or direct them to our patient navigators to schedule a colonoscopy, depending on their choice.
32959177|NCT05248464||Rheumatic diseases patients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
32959178|NCT05213910|Experimental|Patients using the product|
32959179|NCT05201196|Active Comparator|Conventional physical therapy|Conventional physical therapy Muscle strengthening and Muscle Stretching, TENS.
32959180|NCT05201196|Experimental|Task Oriented Training|Experimental group was given Task Oriented protocol including different task specific functional activities
32959181|NCT05158530|Experimental|Interventional Group|Pulmonary exercises + Aerobic training, 40%-60% intensity 3 days/ week for 4 weeks
32959182|NCT05158530|Placebo Comparator|Control group|Pulmonary exercises, 3 sessions per week and 3-5 repetitions in a session for 4 weeks.
32959183|NCT05139342|Active Comparator|PD patients|patients diagnosed with PD will be allocated to this arm
32959184|NCT05139342|Active Comparator|MSA patients|patients diagnosed with MSAwill be allocated to this arm
32959185|NCT05139342|Active Comparator|4RT patients|patients diagnosed with 4RT will be allocated to this arm
32959186|NCT05138952|Experimental|Mindfulness Meditation|30-day program of mindfulness meditation comprising weekly group meditation tuition and support sessions and daily app-based mediation practice.
32959187|NCT04734288|Experimental|Immune response|This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.
32959189|NCT04662684|Experimental|Rivaroxaban|Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge
32959190|NCT04662684|No Intervention|No intervention|control
32959191|NCT04661202|Experimental|Exercise training group|"Aerobic exercise~Resistance exercise (including pelvic floor muscle training with biofeedback)~Stretching exercise~Home exercise"
32959192|NCT04661202|No Intervention|Control group|"．Usual care~After baseline assessment, the participants will receive health and lifestyle advices related to bowel symptoms, which include maintaining moderate physical activity, healthy diet, and ideal defecation posture, and establishing a personal bowel schedule and other behavioral changes that promote regular bowel movements.~Upon request, the participants will be provided with the same intervention program as the exercise training group after 8 weeks participation."
32959193|NCT04634682|Experimental|MYODM|MYODM, three times a day, orally
32959194|NCT04634682|No Intervention|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
32959195|NCT04614480|Other|Metastatic breast cancers|
32959196|NCT04614480|Other|Metastatic prostate cancers|
32959197|NCT04614480|Other|Metastatic lung cancers|
32959198|NCT04614480|Other|Metastatic colorectal cancers|
32959199|NCT04614480|Other|metastatic otorhinolaryngeal cancer|
32959200|NCT04614480|Other|metastatic ovarian cancer|
32959201|NCT04614480|Other|Pancreatic cancers|
32959202|NCT04614480|Other|Others metastatic cancers|
32959203|NCT04531410|Experimental|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
32959204|NCT04531410|Active Comparator|Oleic|Oleic acid 13 g and 600 algal DHA
32959205|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
32959206|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
32959207|NCT04442256|Other|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
32959208|NCT04175106|Experimental|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
32959209|NCT04175106|Experimental|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
32848080|NCT03600480|Active Comparator|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
33104000|NCT00536952|Placebo Comparator|Arm 2|Placebo
33104001|NCT04684004||TTC patients with hyperglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
33104002|NCT04684004||TTC patients with normoglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
33104003|NCT04681170|Other|Age 5-10 years|Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
33104004|NCT04681170|Other|Age11-15years|Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
33104005|NCT04681170|Other|16 to ≤17 years|Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
33104006|NCT04286438|Experimental|Bentracimab (PB2452) Infusion - Open Label Active Drug|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. Patients with uncontrolled major or life-threatening bleeding.~Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients in need of urgent surgery or invasive procedure."
33104007|NCT04675632||The intervention group|the tibial run off would be treated through endovascular therapy
33104008|NCT04675632||the non-intervention group|the tibial run off would not be treated through endovascular therapy
33104009|NCT04675476|Experimental|Multilevel Intervention|
33104010|NCT04675476|No Intervention|Nonequivalent Control Group|
33104011|NCT04282616|Experimental|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
33326989|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
32848081|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
32848082|NCT00246129|Active Comparator|Campath-Tacrolimus|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
32848083|NCT00246129|Experimental|Daclizumab-Tacrolimus-Mycophenolate|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
32848084|NCT04131972|Experimental|Single arm 1|Each patient will be planned to perform 7 study visits and at the second visit excision / lumpectomy and REGENERA implant will be performed during the same surgical intervention.
32848085|NCT03789253||AS cohort with progression|AS cohort with tumor progression
32848086|NCT03789253||AS cohort without progression|AS cohort without tumor progression
32848087|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
32848088|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
32848089|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
32848090|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
32848091|NCT04345575|Experimental|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
32848092|NCT04345575|Active Comparator|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
32848093|NCT02848716|Active Comparator|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
32848094|NCT02848716|Experimental|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
32848095|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
32898784|NCT01363999|Experimental|A|RO5317116/F01 bilayer tablet
32959210|NCT04175106|Experimental|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
32959211|NCT04175106|Placebo Comparator|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
32959212|NCT04123470|Experimental|Treatment|Delolimogene mupadenorepvec plus atezolizumab
32959213|NCT04044144|Experimental|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
32959214|NCT04014660|Active Comparator|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
32959215|NCT04014660|Placebo Comparator|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
32959216|NCT04713930|Experimental|JNJ-61393215|Participants will receive one of 3 single oral doses of JNJ-61393215 on Day 1, escalated sequentially based on the safety review in Cohorts 1, 2, and 3 up to Day 5.
32959217|NCT04713930|Active Comparator|Placebo|Participants will receive a single oral dose of placebo on Day 1 in Cohorts 1, 2, and 3 up to Day 5.
32959218|NCT04714008||Active gamblers in 2019/2020|Three panels of 40 000 gamblers active in 2019 and 2020, either in France or Sweden
32959219|NCT04714008||Newly registered gamblers in 2019 or 2020 (France and Sweden)|Six panels of 10 000 gamblers who newly registered either during the period of March-May 2019 or of March-May 2020, either in France or Sweden
33406353|NCT05217966|Experimental|Preoperative radiotherapy for early breast cancer|Radiation: Single Pre-Operative Radiation Therapy
32959220|NCT04713696|Experimental|Functional training|Participants received functional training
32959221|NCT04713696|Active Comparator|Routine training|Participants received routine training
32959222|NCT04713306||Participants in the Swedish Neuro Register|Participants are patients with parkinsonian symptoms
32959223|NCT04713384|Experimental|Treatment|Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
32959224|NCT04712916|Experimental|Intervention group|Individualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
32959225|NCT04712916|No Intervention|Control group|Participant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.
32959226|NCT04712760||Transient congenital hypothyroidism|- children with congenital hypothyroidism who are no longer treated with Levothyroxine at an age of 3 years and 6 months
32959227|NCT04712760||Permanent congenital hypothyroidism|- children with congenital hypothyroidism who are still treated with Levothyroxine at an age of 3 years and 6 months
32959228|NCT04708002|Other|First EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
32959229|NCT04708002|Other|Early intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
32959230|NCT04708002|Other|Late intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
32959231|NCT04708002|Other|Last EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
32959232|NCT04708080||Group E|patients who underwent thoracic epidural catheter for postoperative analgesia
32959233|NCT04708080||Group I|Patients who cannot be applied thoracic epidural catheter for postoperative analgesia
32959234|NCT04707924|Experimental|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
32959235|NCT04707924|No Intervention|Control area|No treatment performed on control areas.
32959236|NCT04707456|No Intervention|MFM staff-level operator|
32959237|NCT04707456|Other|MFM fellowship trainee-level operator|
32959238|NCT04707378|Active Comparator|active left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC.
32959239|NCT04707378|Sham Comparator|sham left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of sham stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (sham) over the left DLPFC.
32959240|NCT04706910|Experimental|18F-DOPA injection|All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
32959241|NCT04706832|Other|ThorS-MagNT Treatment|Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
32959242|NCT04706286|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B"
32959243|NCT04706286|Experimental|Group 2|"Period 1: Treatment B~Period 2: Treatment A"
32959244|NCT04706052||Superficial Parotidectomy Patient|All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy
32959245|NCT05140122||Primary caregivers of individuals with Dravet Syndrome|
33033430|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
33406354|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
33406355|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
33406356|NCT03421392||Idiopathic thrombocytopenic purpura|
33406357|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
33406358|NCT03421392||without thrombocytopenia|
32848096|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
32848097|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
32848098|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
32848099|NCT02738034|Experimental|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
32848100|NCT02738034|Active Comparator|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
32848101|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
32848102|NCT01279629||Tazarotene 0.1%|
33406359|NCT05217732|Experimental|Single dose of ZX-7101A treatment A|Administrated as a single oral dose in healthy subjects
33406360|NCT05217732|Experimental|Single dose of ZX-7101A treatment B|Administrated as a single oral dose in healthy subjects
32848103|NCT01279629||Calcipotriol 0.005%|
32848104|NCT04762849|Experimental|laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR)|Laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. A ring with shape memory put on the gastric pouch
32848105|NCT04762849|Active Comparator|laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery|Laparoscopic one anastomosis gastric bypass (MGB/OAGB) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
32848106|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
32848107|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
32848108|NCT04502394|Experimental|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
32848109|NCT04502394|Experimental|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
32848110|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
32848111|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
32848112|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
32848113|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
32848114|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
32848115|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
32848116|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
32848117|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
32848118|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
32848119|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
32848120|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
32848121|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
32848122|NCT01274403|Active Comparator|Melphalan and Prednisone|
32848123|NCT03182868|Experimental|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
32848124|NCT03182868|Experimental|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
32848125|NCT03182868|Experimental|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
32848126|NCT03182868|Experimental|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
32898785|NCT01363999|Experimental|B|RO5317116/F03 bilayer tablet
32898786|NCT01363999|Experimental|C|RO5317116/F04 active-coated tablet
32848127|NCT03182868|Experimental|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
32848128|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
33406361|NCT05217732|Experimental|Single dose of ZX-7101A treatment C|Administrated as a single oral dose in healthy subjects
32848129|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
32848130|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
32848131|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
32848132|NCT00754377||Comparison group|Received a different curriculum.
32848133|NCT03780517|Experimental|BOS172738|In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
32848134|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
32848135|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
32848136|NCT03779269|Experimental|color meditation|only color meditation
32848137|NCT03779269|Experimental|Sound meditation|Only sound mediation
32848138|NCT03779269|Experimental|Color and sound combined meditation|Combined group
32848139|NCT03779269|No Intervention|Control group|Only control group
32848140|NCT02985918|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
32848141|NCT02985918|Active Comparator|Conventional-intensity NPPV|The patients will receive conventional-intensity noninvasive positive pressure ventilation.
32848142|NCT00245583|Experimental|Topiramate|25mg to 300mg daily dose
32848143|NCT00245583|Placebo Comparator|Placebo|placebo equivalent tablets
32848144|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
32848145|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
32848146|NCT04129320|Experimental|Experimental Arm 1|Enoblituzumab plus MGA012
32848147|NCT04129320|Experimental|Experimental Arm 2|Enoblituzumab plus MGD013
32848148|NCT04053426||"Population before"|Patient included before implementation of care algorithm.
32848149|NCT04053426||"Population after"|Patients included after the implementation of care algorithm and training of health professionnals
32848150|NCT04012242||NAFLD patients who are scheduled for liver biopsy|
32848151|NCT04762303|Experimental|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
32848152|NCT04762303|No Intervention|No MedReviewRx|During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.
32848153|NCT02764476|Experimental|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
32848154|NCT02764476|Active Comparator|Control|Eight 30 minute sessions of virtual reality therapy.
32848155|NCT04348903|Experimental|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
32848156|NCT04348903|Experimental|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
32848157|NCT00893178||CHF with elevated PAP|CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
32898787|NCT01363999|Experimental|D|RO4607381/F49 tablet
33406362|NCT05217732|Experimental|Single dose of ZX-7101A treatment D|Administrated as a single oral dose in healthy subjects
33406363|NCT05217732|Experimental|Single dose of ZX-7101A treatment E|Administrated as a single oral dose in healthy subjects
33406364|NCT05217732|Experimental|ZX-7101A food effect|Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.
32848158|NCT00893178||CHF patient without elevated PAP|CHF patients (LVEF > 35%) with normal mean pulmonary pressure
32848159|NCT00893178||Normal EF with elevated PAP|Patients with normal LVEF < 60% with elevated mean pulmonary pressure
32848160|NCT04506528||Patients with COVID-19|Analyses of the cohort data will include (1) all patients, or (2) hospitalized patients meeting specific inclusion criteria.
32848161|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
32848162|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
32848163|NCT00754845|Experimental|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
32848164|NCT00754845|Placebo Comparator|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
32848165|NCT03772717|Experimental|VitalStim400|"The stimulation devices used in this study are VitalStim 400, electrical neuromuscular stimulators, which have been used in multiple previous clinical studies for modulation of pain and have received FDA approval. The (2) electrodes for the device will be placed on the subjects left cervical (neck) region. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.~Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters."
32848166|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
32848167|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
32848168|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
32848169|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
32848170|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
32848171|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
32848172|NCT03699319|Experimental|Standard Dose Cohort: CPI-613 + mFOLFIRINOX|"Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.~Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m^2 given at a rate of 4 ml/min (dose level (DL) 2). Participants receiving a dose of 1000mg/m^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If <33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m^2 and 1000 mg/m^2.~Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort~Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower."
32848173|NCT04505436|Experimental|HM15211|
32848174|NCT04505436|Placebo Comparator|Placebo|
32848175|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
32848176|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
32848177|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
32848178|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
32848179|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
32848180|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
32848181|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
32848182|NCT03969186|Experimental|Daily telehealth follow-up|The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
32848183|NCT03969186|No Intervention|Standard of care follow-up|Standard of care
32848184|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
32848185|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
32848186|NCT02117076|Active Comparator|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
32898788|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
32848187|NCT02117076|Active Comparator|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
32848188|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
32848189|NCT01573650||group 1|Group 1a (standard): Epineural Suture Group 1b (experimental): Epineural suture and Fibrin Wrap
32848190|NCT01573650||group 2|Group 2a (standard): Epineural suture and autologous nerve transplantation from lateral antebrachial cutaneous nerve (LACN) Group 2b (experimental): Epineural suture and Fibrin Conduit
32848191|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
32848192|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
33326990|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
33326991|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
32848193|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
32848194|NCT03763578|Experimental|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
32848195|NCT03763578|Active Comparator|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
32848196|NCT03763578|No Intervention|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
32848197|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
32848198|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
32848199|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
32848200|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
32848201|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
32848202|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
32848203|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
32848204|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
32848205|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
32848206|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
32848207|NCT00816582|Experimental|PET/CT Guided FES Therapy|All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.
32848208|NCT03771391|Experimental|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
32848209|NCT03771391|Experimental|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
32848210|NCT03771391|Experimental|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
32848211|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
32848212|NCT05128188||Patients on haemodialysis|5 patients on haemodialysis will be recruited. The study involves a single dialysis session and two MRI scans (one prior and one following dialysis) and collection of clinical data.
32848213|NCT03771313|Other|PK/PD|Open-label prospective study with participants receiving treating physician-approved intravenous ceftaroline, dosed according to current recommendations. Blood samples collected at baseline, 1 hour, 1.5 hours, 3 hours, and 6 hours after infusion.
32848214|NCT01274871||lung cancer surgery|
32848215|NCT03704688|Experimental|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
32848216|NCT03704688|Experimental|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
32848217|NCT03704688|Experimental|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
32848218|NCT03704688|Experimental|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
32848219|NCT03704688|Experimental|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
33326992|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
33326993|NCT01171092|Experimental|bortezomib and G-CSF|
32848220|NCT03704688|Experimental|Phase II|Maximum tolerated dose as established in Phase I portion
32848221|NCT03600649|Experimental|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
32848222|NCT03600649|Experimental|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
32848223|NCT03600649|Experimental|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
32848224|NCT05127798||Adult from 18 to 70 years old AML in first line|Patients >/= 18 years old with recent diagnosis of AML who receive treatment with intensive chemotherapy according to our local guidelines.
32848225|NCT00244881|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
32848226|NCT03701958|Other|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
32848227|NCT04763395||non-severe COVID19|"Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.~A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura."
32848228|NCT04763395||Severe Covid19|Severe COVID19 was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR >-30 times/minute; ii) hypoxia: oxygen saturation (resting state) <-93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) <- 300 mmHg (millimeters of Mercury), or iv) the occurrence of respiratory or another organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
32848229|NCT03446508|Experimental|Active frontal|Active HD-tDCS
32848230|NCT03446508|Experimental|Active parietal|Active HD-tDCS
32848231|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
32848232|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
32848233|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
32848234|NCT00530517|Experimental|1|
32848235|NCT05404698|Experimental|Aerobic intradialytic exercise|10 patients will perform Aerobic exercise with the cycle ergometer prototype (EXALT) during hemodialysis
32848236|NCT05404698|Experimental|Standard care|10 patients will receive hemodialysis treatment (usual care)
32848237|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
32848238|NCT03686605||Cancer pain patients|
32848239|NCT05404620|Experimental|Schroth exercises|"Mobilization in the spine between ribs will be performed to increase the mobility of joints. To strengthen the muscles such as erector spinae, iliopsoas, and the quadratus lumborum, muscle activation will be done. Then the four exercises of the Schroth method which are the 50 x Swiss ball exercise, Prone exercise, Sail exercise, and the Muscle-cylinder exercise will be performed. This will be followed by hot pack and static stretching of muscles."
32848240|NCT05404620|Experimental|PNF technique|This technique involves the specific program and pattern of PNF that are deep breathing, pelvic posterior tilting, DI flexion & Extension of UL and D2 flexion, and extension of LL. + Hot pack + static stretching of the involved muscles.
32848241|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
32848242|NCT05404464||Infertile couples|Infertile couples who came to the hospital for ART treatment
32848243|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
32848244|NCT04435938|Experimental|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
32848245|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
32848246|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
32848247|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
32848248|NCT03765853|Other|Stretching Postural®|
32848249|NCT03765853|No Intervention|Control|
32848250|NCT04366362|Active Comparator|Convetional reconstruction group|Patients will undergo ACL reconstruction based on conventional ACL surgery
32848251|NCT04366362|Experimental|Individualised reconstruction group|Patients will undergo ACL reconstruction based on their special anatomical and functional characteristics and with the use of a navigation system
32848252|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
32848253|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
32848254|NCT05123976|Experimental|Treatment A|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)
32848255|NCT05123976|Active Comparator|Treatment B|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
33406365|NCT05217576|Other|Comparison|"Comparison study:~The participants (at least 300) will be tested once with each of the 3 devices. First, a measurement with the NBM-200 will be performed according to the user manual. The best finger to use, in order of preference: 1) right thumb 2) left thumb 3) right index 4) left index.~The POC capillary test will follow the NBM-200 test, and the venous test will be performed last. A venous blood sample will be obtained from all participants in the comparison study, even if a subject is designated to donate and is deferred from donation because of low hemoglobin."
32848256|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
32848257|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
32848258|NCT05127096||Cohort A|Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).
32848259|NCT05127096||Cohort B|Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.
32848260|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
32848261|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
32848262|NCT05126940||nurses|ED nurses trained to perform LUS and blinded to the final diagnosis
32848263|NCT05126940||emergency physician|"certified emergency physician who had accomplished a full mentoring program for Ultra-Sound Life Support."
32848264|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
32848265|NCT04246164|Active Comparator|HD-tDCS combined with CT|HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
32848266|NCT04246164|Sham Comparator|sham HD-tDCS combined with CT|sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
32848267|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
32848268|NCT00005803|Experimental|Treatment (tandem transplantation)|See Detailed Description
32848269|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
32848270|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
32848271|NCT05123898|Other|1 group|The patients underwent implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the upper jaw.
32848272|NCT05123898|Experimental|2 group|"The patients underwent implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibromatrix"
32848273|NCT03760315||Sepsis|All enrolled patients
32848274|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
32848275|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
32848276|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
32848277|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
32848278|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
32848279|NCT03680131|Active Comparator|EB01 Cream Placebo|EB01 Cream containing 0% EB01 w/w applied BID
32848280|NCT03680131|Experimental|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
32848281|NCT03680131|Experimental|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
32848282|NCT03680131|Experimental|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
32848283|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
32848284|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
32848285|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
33326994|NCT03753204|Experimental|Weinberger protocol|During the Weinberger protocol, salt loading will be achieved by the combination of a high-salt diet (isocaloric, 160 mEq Na and 70 mEq K), and an infusion of 2L of saline (300 mEq Na+). Patients will have free access to water but their food will be limited to that provided by the protocol. Salt depletion will be accomplished by administering an isocaloric diet containing 10 mEq Na and 70 mEq K and continued unlimited water intake. At 8 am, 12 noon and 4 pm, subjects will be given 40 mg of furosemide or lasix orally.
33326995|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
32848286|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
32848287|NCT03593629|No Intervention|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
32848288|NCT03593629|Experimental|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
32848289|NCT03593629|Experimental|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
32848290|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
32848291|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
32848292|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
32848293|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
32848294|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
32848295|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
32848296|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
32848297|NCT01279941|No Intervention|Testing Only|
32848298|NCT01279941|Experimental|Testing & Intervention|
32848299|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
32848300|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
32848301|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
32848302|NCT04185012|Experimental|Benralizumab|Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
32848303|NCT04185012|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
32848304|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
32848305|NCT01276899||Neoadjuvant setting|
32848306|NCT01276899||Metastatic setting|
32898789|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
32959246|NCT05139966|Placebo Comparator|G0 - placebo|All placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED.
32959247|NCT05139966|Experimental|G1: 100% - sodium fluoride (100% free NaF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED.
32959248|NCT05139966|Experimental|G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED.
32959249|NCT05139966|Experimental|G3: 100% nano fluoride (225 ppm)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED.
32959250|NCT05138562|Placebo Comparator|Placebo|4 Placebo capsules
32959251|NCT05138562|Active Comparator|TU2670 High Dose|320mg, QD
32959252|NCT05138562|Active Comparator|TU2670 Medium Dose|240 mg, QD
32959253|NCT05138562|Active Comparator|TU2670 Low Dose|120 mg, QD
32959254|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
32959255|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
32959256|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
32959257|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
32959258|NCT00577512|Experimental|HD DTPACE|DTPACE
32959259|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
32959260|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
32959261|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
32959262|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
32959263|NCT00578214|Placebo Comparator|Placebo|
32959264|NCT00578214|Experimental|Prospective Midazolam|
32959265|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
32959266|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
32959267|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
32959268|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
32959269|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
32959270|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
32959271|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
32959272|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
32959273|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
32959274|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
32959275|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
32959276|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
32959277|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
32959278|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
32959279|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
32959280|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
32959281|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
32959282|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
32959283|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
32959284|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
32959285|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
33406366|NCT05217576|Other|Precision A & B|"Precision study:~At least 12 subjects will be tested 6 consecutive times with the NBM-200, on either the right or left thumb, and then 6 times with the capillary device (with a separate finger-prick for each test).~At least 3 males and 3 females at 2 study sites (total of 12), preferably with hemoglobin levels close to the cutoff levels of 12.5 g/dL for females and 13 g/dL for males. Each subject will be tested on each of their right and left thumbs and indices (4 fingers) using at least two operators and two NBM-200 instruments on each finger.~A laboratory test with venous blood is not required for participants in the precision study."
33406367|NCT03440411|Active Comparator|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
33406368|NCT03440411|Experimental|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
32959286|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
32959287|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
32959288|NCT00585780|Active Comparator|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
32959289|NCT00585780|Placebo Comparator|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
32959290|NCT00585780|Active Comparator|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
32959291|NCT00585780|Placebo Comparator|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
32959292|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
32959293|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
32959294|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
32959295|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
32959296|NCT05247216|Experimental|Hemay007 800 mg QD group|Drug: 800mg QD of Hemay007; daily oral administrtion for 12 weeks
32959297|NCT05247216|Experimental|Hemay007 1200 mg QD group|Drug: 1200mg QD of Hemay007; daily oral administrtion for 12 weeks
32959298|NCT05247216|Experimental|Hemay007 600 mg QD group|Drug: 600mg QD of Hemay007; daily oral administrtion for 12 weeks
32959299|NCT05247216|Placebo Comparator|placebo group|Drug: placebo of Hemay007; daily oral administrtion for 12 weeks
32959300|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
32959301|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
32959302|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
32959303|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
32959304|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
33033431|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
32739606|NCT05714657|Experimental|Radiotherapy|"The volume treated to the regional lymphatics will be according to the characteristics of the primary site and involved lymph nodes. The dose of radiotherapy delivered will be 30 Gy, over the course of 10 treatments (5 daily treatments/week).~Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol.1 In patients requiring treatment of the primary site, reduced dose (30 Gy) will be delivered."
32959305|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
32959306|NCT02041416||Group 1|REDCap and paper pencil
32959307|NCT02041416||Group 2|REDCap twice
32959308|NCT02041416||Group 3|Support Screen and paper pencil
32959309|NCT02041416||Group 4|Support Screen twice
32959310|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
32959311|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
32959312|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
32959313|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
32959314|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
32959315|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
32959316|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
32959317|NCT00166530|Active Comparator|1|Arm 1: Active comparator
32959318|NCT00166530|Experimental|2|Arm 2: Drug
32959319|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
32959320|NCT00589056|Experimental|Single arm|Nelfinavir
32959321|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
32959322|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
32959323|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
32959324|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
32959325|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
32959326|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
32959327|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
32959328|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
32959329|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
32959330|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
32959331|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
32959332|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
32959333|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
32959334|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
32959335|NCT00595530|Experimental|Ketamine|This group will receive ketamine
32959336|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
32959337|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
32959338|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
32959339|NCT00597246|Experimental|1|
32959340|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
32959341|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
33033432|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
32848307|NCT05126706|Experimental|Digital lifestyle management group|In the experimental group (digital lifestyle management group), 54 patients are randomly assigned to the digital lifestyle management group. The patients use this application for the first 4 months with Noom applications with 1:1 personalized coaching intervention, and then, use this app by self-help program without coaching intervention. In order to monitor the psychological state of the patients, all the patients are given daily assessment online questionnaires and additional questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
32848308|NCT05126706|No Intervention|Non-digital lifestyle management group|In the control group (Non-digital lifestyle management group), 26 patients are randomly assigned to the control group (Non-digital lifestyle management group). The patients follow conventional postoperative care protocol after total thyroidectomy for thyroid cancer without using Noom application. All patients are given questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
33326996|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
33326997|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
33326998|NCT03868176||Active comparator: standard of care|
32848309|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
32848310|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~CHC staff leadership key informant interviews (up to 5 at each site)~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
32848311|NCT01275183|Experimental|Raltegravir and cisplatin|
32848312|NCT05126628|Active Comparator|Active Comparator: Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
32848313|NCT05126628|Placebo Comparator|Placebo Comparator: Placebo + Usual Care|Placebo + usual care as determined by care provider
32848314|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 30, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
32848315|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
32848316|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
32848317|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
32848318|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted in year one. In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children < 5 years of age presenting to the ED departments.
32848319|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
32848320|NCT05126394|Experimental|Group A ( SAPB) group|this group of patients receives serratus anterior plane block, just after induction of anesthesia.
32848321|NCT05126394|No Intervention|Group B: control group|this group of patients does not receive any blockade, they receive conventional IV analgesics.
32848322|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
32848323|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
32848324|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
32848325|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
32848326|NCT04762615||Patients with renal pathology treated with immunosuppressive drugs|Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs
32848327|NCT04762615||Patients with renal pathology without treatment|Control group
32848328|NCT04762615||Patients after renal transplantation taking immunosuppressive drugs|Female in reproductive age after renal transplantation taking immunosuppressive drugs
32848329|NCT05126004|No Intervention|Control group|receive supportive care
32848330|NCT05126004|Experimental|AZA+NAC group|AZA 50mg Subcutaneous daily d1-d5 + NAC 600mg oral bid d1-28， 28 days for one cycle
32848331|NCT03672643|Other|single arm|Crizotinib
32848332|NCT05125926|Experimental|low-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848333|NCT05125926|Placebo Comparator|Placebo comparator Ⅰ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
33326999|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
33327000|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
32848334|NCT05125926|Experimental|high-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848335|NCT05125926|Placebo Comparator|Placebo comparator Ⅱ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
33327001|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
32848336|NCT05125926|Experimental|low-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848337|NCT05125926|Placebo Comparator|Placebo comparator Ⅲ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848338|NCT05125926|Experimental|high-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848339|NCT05125926|Placebo Comparator|Placebo comparator Ⅳ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
32848340|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
32848341|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
32848342|NCT05125770||new crown vaccination|Collect all the couples who gave birth in Ditan Hospital or one of the mothers and newborns who were injected with the new crown vaccine during the peri-pregnancy period as the observation group
32848343|NCT05125770||non new crown vaccination|Collect the pregnant women and newborns who were not vaccinated with the new crown vaccine during the peri-pregnancy of the couples who gave birth in our hospital during the same period as the control group
32848344|NCT05123430|Experimental|MitraClip operated patients suffering from serious mitral insufficiency|
32848345|NCT00350701|Experimental|androgel 5g|androgel 5g
32848346|NCT00350701|Experimental|androgel 10g|androgel 10g
32848347|NCT00350701|Placebo Comparator|placebo|placebo
32848348|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
32848349|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
32848350|NCT05123352||Standard intensive chemotherapy|Patients with acute myeloid leukemia in this cohort will receive standard induction chemotherapy that combines seven days of cytarabine and three days of anthracycline (7+3 regimen).
32848351|NCT05123352||Bcl-2 inhibitor-based targeted therapy|Patients with acute myeloid leukemia in this cohort will receive Bcl-2 inhibitor-based targeted therapy, such as combination of bcl-2 inhibitor plus decitabine/azacitidine with or without sorafenib.
32848352|NCT01275417||adult|100 volunteers age ranged 18-80 years old
32848353|NCT01275417||children|60 children under 10 years old.
32848354|NCT03585205||cognitive load with/ without stress induction|"Participants will engage in demanding cognitive load computerized tasks (such as N-back and Stroop tasks). They will engage in these tasks once in a non-stressful (neutral condition), and once in a stressful condition.~Psychological stress will be induced by the following methods:~Limiting time for task completion~Providing negative feedback on participants' performance in relation to others~Presentation of sudden, loud sounds during task"
32848355|NCT05122806|Other|Bioexalk cohort|All patients included in Explore ALK GFPC 03-2019 study who agree to participate in Bioexalk.
32848356|NCT01677325|Experimental|Chinese herb|Chinese herb
32848357|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
32848358|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
32848359|NCT04277247|Experimental|Botulinum Toxin Type A Treatment|Injections
32848360|NCT04277247|Placebo Comparator|Placebo|Injections
32848361|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
32848362|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
32848363|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
32848364|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
32848365|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
32848366|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
32848367|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
32848368|NCT04276077|Experimental|High-frequency electrical muscle stimulation|
32848369|NCT04276077|Experimental|Low-frequency electrical muscle stimulation|
32848370|NCT04276077|No Intervention|Control|
32848371|NCT04177524|Experimental|Arm 1|Participants alternate between using the Manual Mode of the app for 2 weeks and Auto-Detect Mode of the app for 2 weeks, for a total of 4 periods (8 weeks).
32848372|NCT04177524|Experimental|Arm 2|Participants use the Auto-Detect Mode of the app for 4 weeks, followed by the Manual Mode for 4 weeks.
32848373|NCT04177524|Experimental|Arm 3|Participants use the Background Mode of the app for 4 weeks, followed by the Auto-Detect Mode of the app for 4 weeks.
32848374|NCT00006151|Experimental|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD&C) plus behavioral therapy.
32848375|NCT00006151|Placebo Comparator|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD&C) plus behavioral therapy.
32848376|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
32848377|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
32848378|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
32848379|NCT05125692|Other|women with symptomatic post cesarean Istmocele|vaginal surgical repair of post cesarean symptomatic isthmocele using conventional low cost surgical techniques
32848380|NCT04761757|Active Comparator|Control Arm|
32848381|NCT04761757|Active Comparator|Intervention Arm|
32848382|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
32848383|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
32848384|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
32848385|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
32848386|NCT03666559|Experimental|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
33327002|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
33327003|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
32959342|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
32959343|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
32959344|NCT00601146|Experimental|Low-dose Chest CT screening|Annual low-dose Chest CT screening
32959345|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
32848387|NCT04500912|Active Comparator|Supraflex Cruz stent|Randomization to Supraflex Cruz stent
32848388|NCT04500912|Active Comparator|Ultimaster Tansei stent|Randomization to Ultimaster Tansei stent
32848389|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
32848390|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
32848391|NCT05111184|Other|Internvention group|
32848392|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
32848393|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
32848394|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg granulocyte colony-stimulating factor [G-CSF]).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
32848395|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
32848396|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
32959346|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
32959347|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
32959348|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
32959349|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
33327004|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
33327005|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
33327006|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
33327007|NCT03870282|Experimental|9h 15m Goal|
32848397|NCT04187898|Experimental|Expansion Phase: Eflapegrastim @ 30 mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycles 1-4: Administered on the same day as TC chemotherapy, 30 minutes following the end of TC administration.~Each cycle is 21 days."
32848398|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32848399|NCT03663205|Experimental|Tislelizumab combined with Platinum and Pemetrexed|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Cisplatin 75 mg/m2 administered as an intravenous (IV) infusion over 2 hours Q3W (every 3 weeks) for 4 to 6 cycles or Carboplatin AUC 5 administered as an IV infusion over 15 minutes Q3W for 4 to 6 cycles. Pemetrexed 500 mg/m2 administered as an IV infusion over 10 minutes Q3W.
32848400|NCT03663205|Active Comparator|Cisplatin or Carboplatin and Pemetrexed|
32848401|NCT05403216||OLP(-)|Oral lichen planus (OLP) with negative thyroid antibody group
32848402|NCT05403216||OLP(+)|OLP with positive thyroid antibody group
32848403|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
32848404|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
32848405|NCT00245271|Experimental|1|OMS103 Irrigation Solution
32848406|NCT00245271|Placebo Comparator|2|Balanced Salt Solution (BSS)
32848407|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
32848408|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
32848409|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
32848410|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
32848411|NCT00243867|Experimental|Arm A|(Taxoprexin® + carboplatin)
32848412|NCT00243867|Active Comparator|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
32848413|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
32848414|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
32848415|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
32848416|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
32848417|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
32848418|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
32848419|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
32848420|NCT04403269|Experimental|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
32848421|NCT04402957|Placebo Comparator|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
32848422|NCT04402957|Experimental|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
32848423|NCT00245037|Experimental|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
32848424|NCT04402879|Experimental|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
32848425|NCT04402879|No Intervention|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
32848426|NCT03532399||Pediatric Cardiac Catheterization|
32848427|NCT03532399||Pediatric Cardiac Surgery|
32848428|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
32848429|NCT00241839|Active Comparator|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
32848430|NCT00241839|Placebo Comparator|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
32848431|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
33327008|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
33327009|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
33327010|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
32848432|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
32848433|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
32848434|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
32848435|NCT05347381|Experimental|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
32848436|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
32848437|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
33327011|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
32848438|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
32848439|NCT05347615||EDOF|Eye after EDOF lens Implantation
32848440|NCT05347615||Monofocal|Eye after Monofocal lens Implantation
32848441|NCT03528109|Experimental|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
32848442|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
32848443|NCT03528109|Experimental|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week). Patient-centered telehealth was closed when the recruitment goal was met in May 2021.
32848444|NCT01276353|Experimental|1|
32848445|NCT01276353|Active Comparator|2|
32848446|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
32848447|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
32848448|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
32848449|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
32848450|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
32848451|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.~Aspirin will be administered 100 mg daily."
32848452|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
32848453|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
32848454|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
32848455|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
32848456|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
32848457|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
32848458|NCT01675609|Placebo Comparator|Placebo|
32848459|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
32848460|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
32848461|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
32848462|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
32848463|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
32848464|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
32848465|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
32848466|NCT04403659|Experimental|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
32848467|NCT04403659|No Intervention|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
33327012|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
33327013|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
33327014|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
32848468|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
32848469|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
32848470|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
32848471|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
32848472|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
32848473|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
32848474|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
32848475|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
32848476|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
32848477|NCT05125536|Experimental|Experimental group|"Before the application, the Descriptive Characteristics Data Form and Assessment Scale of Adaptation Difficulty in Elderly were administered to the experimental group by the investigator through face-to-face interviews. A cd containing songs in Nihavent theme (instrumental), computer and sound system were used during the application. The patients in the experimental group were informed about the music session in advance. The sessions lasted 12 weeks in total and there were two sessions per week (Monday and Wednesday), and each session took approximately 50 minutes to complete. One week after the last music session (end of 12th week), the Assessment Scale of Adaptation Difficulty in the Elderly was re-administeredto the experimental group ."
32848478|NCT05125536|No Intervention|Control group|No intervention was performed for the patients in the control group.
32848479|NCT05125458||Subjects with dermatological diseases|500 Subjects attending the Dermatology outpatient clinic of the Vanvitelli University hospital with a diagnosis of psoriasis or hidradenitis suppurativa or atopic dermatitis of any grade of severity.
32848480|NCT05125458||Subjects with HIV or HBV|500 Subjects attending the Infectious diseases outpatient clinic of the Vanvitelli University hospital and with HIV or HBV infection.
32848481|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
32848482|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
32848483|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
32848484|NCT03800121||Localized sarcoma with neoadjuvant chemotherapy|"In total, several blood tests specific to the EXOSARC study will be necessary:~A first blood test of 7 mL during the initial assessment (inclusion)~Then four blood samples of 32mL distributed over 6 months"
32848485|NCT03800121||Metastatic or locally advanced sarcoma|"In total, several blood tests specific to the EXOSARC study will be necessary :~A first blood of 7 mL during the initial assessment (inclusion)~Then three blood samples of 32 mL distribuated over 3 months"
32848486|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
32848487|NCT05125380|Active Comparator|1- Triage arm for HPV pos women|HPV positive women
32848488|NCT05125380|Experimental|2- Triage arm for HPV pos women|HPV positive women
32848489|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
32848490|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
32848491|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
32848492|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
32848493|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
33327015|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
32848494|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
32848495|NCT02403193|Experimental|PBF-509_80 mg|
33327016|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
32848496|NCT02403193|Experimental|PBF-509_160 mg|
32848497|NCT02403193|Experimental|PBF-509_320 mg|
32848498|NCT02403193|Experimental|PBF-509_640 mg|
32848499|NCT02403193|Experimental|PBF509_160 mg +PDR001|
32848500|NCT02403193|Experimental|PBF509_320 mg+PDR001|
32848501|NCT02403193|Experimental|PBF509_640 mg +PDR001|
32848502|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
32848503|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
32848504|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
32848505|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
32848506|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
32848507|NCT03573349|Other|Ketamine|Open-label, non-randomized
32848508|NCT05387148|Experimental|Cannabidiol (CBD)|For a total of three days, so that both study participants and staff are blind to treatment condition
32848509|NCT05387148|Placebo Comparator|Placebo|For a total of three days, so that both study participants and staff are blind to treatment condition
32848510|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
32848511|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
32848512|NCT03569917|Experimental|patient under Ceftriaxone treatment|
32848513|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
32848514|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
32848515|NCT03458221|Experimental|A - ER active tumors|In case of an aberrantly active Estrogen Receptor (ER) pathway, patients will be treated with Letrozole 2.5mg daily orally until progression of disease.
32848516|NCT03458221|Experimental|B - AR active tumors|In case of an aberrantly active androgen receptor (AR) pathway, patients will be treated with Bicalutamide 150mg daily orally until progression of disease.
32848517|NCT03458221|Experimental|C - PI3K active tumors|In case of an aberrantly active phosphoinositide 3-kinase (PI3K) pathway, patients will be treated with Everolimus 10mg daily orally until progression of disease.
32848518|NCT03458221|Experimental|D - HH and/or PI3K active tumors|In case of an aberrantly active Hedgehog (HH) or PI3K pathway, patients will be treated with Itraconazole 300mg twice daily orally until progression of disease.
32848519|NCT05076084||Patients aged 0 to 18 years followed for Vernal keratoconjunctivitis|Treated (or having been treated) with tacrolimus 0.1% ophthalmic solution previously treated with ciclosporin 2% ophthalmic solution with treatment failure.
32848520|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
32848521|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
32848522|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
32848523|NCT05072340|Experimental|RISE (Blended learning)|"Students will undergo a training that comprises of six sessions: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS and virtual face-to-face platform, Zoom. Each session will take approximately one to two hours per week. One session is made available each week to encourage completion before moving onto the next session. Students will be provided with materials in the form of interactive videos. Virtual face-to-face sessions, online forum, quizzes and homework will be additionally available to students."
32848524|NCT05072340|Active Comparator|RISE (Asynchronous learning)|"Students will also undergo a six-session training comprising of: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS. One session is made available each week to encourage completion before moving onto the next session. Participants will be reminded via emails and short message service (SMS) to complete the intervention. Students will be provided with materials in the form of interactive videos in LumiNUS."
32848525|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
32848526|NCT05071404||Cases|Patients treated with infliximab sc.
32848527|NCT01677637||All measurements|Total measured population
32848528|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
32959350|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
32959351|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
32959352|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
32959353|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
32959354|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
32959355|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
32959356|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
33033433|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
33406369|NCT03440411|Experimental|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
33406370|NCT03440411|Active Comparator|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
32739607|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
32739608|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
32739609|NCT05714579|Experimental|severe aortic stenosis with complete right bundle branch block|patients with aortic stenosis undergoing a Transcatheter Aortic Valve Implantation procedure
32739610|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
32739611|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
32739612|NCT05456555|Experimental|Flapless with Enamel Matrix Derivatives (EMD)|Closed non-surgical treatment of periodontal intrabony defects with the combined use of Enamel Matrix Derivatives (EMD).
32739613|NCT05456555|Active Comparator|Flapless alone|Closed non-surgical treatment of periodontal intrabony defects without any adjunct.
32739614|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
32739615|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
32739616|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
32739617|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
32739618|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
32739619|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
32739620|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
32739621|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
32739622|NCT05633771||Hyrimoz|Patients prescribed with Hyrimoz
32739623|NCT03208465|Experimental|Patients with Empagliflozin|
32739624|NCT03208465|Active Comparator|Patients with Sitagliptin|
32739625|NCT02480699|Experimental|Hemodialysed patients|
32739626|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
32739627|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
32739628|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
32739629|NCT05714423|Active Comparator|Mini-PCNL Group|In this group kidney stones will be treated with Mini-PCNL Surgery
32739630|NCT05714423|Active Comparator|RIRS Group|In this group kidney stones will be treated with Retrograde Intrarenal Surgery.
32739631|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
32739632|NCT05408819||Coplanar Template group|Paticipant will undergo coplanar template assisted CT-guided abdominal tumor biopsy or fiducial markers implantation and the prospective accuracy and safety data will record.
32739633|NCT05406791|Experimental|Sensor-enabled digital mental health intervention (DMHI)|"Patients randomized to sensor-enabled DMHI condition will use Ksana Health's Vira mobile therapy platform with support from a study coach"
32739634|NCT05406791|Experimental|Experimental: Control Treatment (CT)|Participants randomized to the CT condition will use a Mood Education App designed by researchers at the University of Virginia to deliver psychoeducational content to help people self-manage symptoms of depression, anxiety, and stress.
32739635|NCT05621447|Experimental|TAS-303, [14C]TAS-303|
32739636|NCT02446873|No Intervention|Control|Control group
33327017|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
32739637|NCT02446873|Experimental|Treatment|Egg supplementation
32959357|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
32959358|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
32959359|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
32959360|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
32959361|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
32959362|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
32959363|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
32959364|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
32959365|NCT00626808||1|Children less than 24 months of age
32959366|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
32959367|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
32959368|NCT00626808||4|Children 24-59 months of age with immunosuppression
32959369|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
32959370|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
32959371|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
32959372|NCT00627978|No Intervention|Control|
32959373|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
32959374|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
32959375|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
32959376|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
32959377|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
32959378|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
32959379|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
32959380|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
32959381|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
32959382|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
32959383|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
32959384|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
32959385|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
32959386|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
32959387|NCT00638274|Active Comparator|Air|Air 3 ml used to identify epidural space
32959388|NCT00638274|Active Comparator|Saline|Saline 3 ml used to identify epidural space
32959389|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
32959390|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
32959391|NCT00641862|Placebo Comparator|Placebo|Placebo
32959392|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
32959393|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
32959394|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
32959395|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
32959396|NCT00645450|Experimental|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
32959397|NCT00645450|Placebo Comparator|Placebo|Weekly doses of placebo following recollection of traumatic memory
32959398|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
32959399|NCT00647400|Experimental|Adalimumab 40 mg every other week|
32959400|NCT00647400|Experimental|Adalimumab 80 mg every other week|
32959401|NCT00648648|Experimental|MK-1775 325 mg Single Dose|Participants received MK-1775 325 mg, orally, on Day 1.
32959402|NCT00648648|Experimental|MK-1775 650 mg Single Dose|Participants received MK-1775 650 mg, orally, on Day 1.
32959403|NCT00648648|Experimental|MK-1775 1300 mg Single Dose|Participants received MK-1775 1300 mg, orally, on Day 1.
33033434|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
33327018|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
33327019|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
32848529|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
33104012|NCT04282616|Experimental|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
33104013|NCT04282616|Experimental|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
33327020|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
33327021|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
33327022|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
33327023|NCT03870282|Experimental|Personal Goal|
33327024|NCT03870282|Experimental|"Personal Goal | Texts B"|
32848530|NCT05057832||Cases|Patients treated with Ustekinumab.
32848531|NCT05124756|Experimental|Bioelectric stimulation|Bioelectric stimulation on quadriceps muscle and kidneys: 45 minutes, 3 times/week, 8 weeks, 24 sessions.
32848532|NCT05124756|No Intervention|Control|No intervention.
32848533|NCT00758667|No Intervention|Standard treatment|Standard treatment
32848534|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
32848535|NCT04412772|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
32848536|NCT04412772|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
32848537|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
32848538|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
32848539|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
32848540|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
32848541|NCT05124600|Experimental|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
32848542|NCT05124600|No Intervention|Waiting list|Participants will be on the waiting list.
32848543|NCT05041920|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design.
32848544|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
32848545|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
32848546|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
32848547|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
32848548|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
32848549|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
32848550|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will then receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
32848551|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/No Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
32898790|NCT00257894|Experimental|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
32898791|NCT00257894|Placebo Comparator|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
33320163|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
32959404|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 100 mg single dose, orally, on Day 2 of each cycle.
32959405|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 200 mg single dose, orally, on Day 2 of each cycle.
33327025|NCT03870282|Experimental|"Personal Goal | Texts A"|
33327026|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
32959406|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
33327027|NCT03870282|Experimental|"Personal Goal | Incentive B"|
32959407|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
32959408|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
33327028|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
32848552|NCT03984786|Experimental|ICBT alcohol misuse: No Assessment Interview/Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
32848553|NCT03984786|Experimental|ICBT for alcohol misuse: No Assessment Interview/No Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
32848554|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2019, and treated in the Medical Oncology Departments of participating sites.
32848555|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
32848556|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
32848557|NCT05033262|No Intervention|Control|
32848558|NCT05033262|Experimental|Intervention|
32848559|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
32848560|NCT05032716|Active Comparator|Balance exersices group|received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance
32848561|NCT05032716|Active Comparator|Balance exersices and treadmill group|received the same traditional physical therapy program as the same applied in group of balance exercise (30 min), in addition to treadmill training (30 min)
32848562|NCT03807453||Psoriasis Vulgaris patients-Lesion|
32848563|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
32848564|NCT03807453||Seborrheic Dermatitis-Lesion|
32848565|NCT03807453||Seborrheic Dermatitis-Lesion free|
32848566|NCT03807453||Control Group|
32848567|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
32959409|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
32959410|NCT00648648|Experimental|MK-1775 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg single dose orally, on Day 2 of each cycle.
33033435|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
33327029|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
32848568|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
32848569|NCT05005338|Experimental|Cohort A|
32848570|NCT04413084|Experimental|Gaze stability exercises|Group I will receive Gaze stability exercises.
32848571|NCT04413084|Experimental|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
32848572|NCT04412850|Experimental|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
32848573|NCT04412850|Placebo Comparator|placebo group|Normal Saline in equal volume as the control group.
32848574|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
32848575|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
32848576|NCT05124522|Experimental|MSPA eClass|
32848577|NCT05124522|No Intervention|Waiting list|
32848578|NCT05124444|Experimental|Cases (tolerant patients)|
32848579|NCT05124444|Experimental|Controls|
32848580|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.~The ongoing antiepileptic medication will be continued unchanged"
32848581|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
32848582|NCT03969264|Active Comparator|Carb Snacks|Will follow study diet based on the Dietary Guidelines and consume study carbohydrate snacks between meals.
32848583|NCT03969264|Experimental|Tree Nut Snacks|Will follow study diet based on the Dietary Guidelines and consume study tree nut snacks between meals.
32848584|NCT03957330|Experimental|Community Mental Health Clinic|In this arm, clients will be assigned to therapists working in a community mental health clinic in Saskatchewan where the focus of the setting is primarily on face-to-face treatment and ICBT makes up a small component of the workload in the clinic.
32848585|NCT03957330|Experimental|Once a week therapist contact|In once a week treatment, therapists will email their clients once a week on a pre-determined day.
32848586|NCT03957330|Experimental|Reflection Questionnaire|"In the reflection questionnaire, patients will be asked to complete the following questions five times during the treatment period (beginning lesson 2-5 and then at the point they complete post-questionnaires):~How much of the lesson were you able to review?~How much effort were you able to put into the lesson?~How difficult was the lesson?~Please share any difficulties you had with the lesson.~How understandable was the lesson?~How helpful did you find the lesson?~Please describe an example of what you learned.~To what extent have you continued to use strategies from previous lessons~If applicable, please provide an example of what you are working on from previous lessons~Please indicate which Additional Resources you reviewed this week.~If applicable, please share any skills you are working on from the Additional Resources."
32848587|NCT03957330|Experimental|Specialized Internet Therapy Clinic|In this arm, clients will be assigned to therapists working in a specialized internet therapy clinic where the therapists only deliver ICBT.
32848588|NCT03957330|Experimental|Twice a week therapist contact|In twice a week treatment, therapists will email their clients twice a week on pre-determined days.
32848589|NCT03957330|Experimental|No Reflection Questionnaire|In this arm, no reflection questions will be asked of clients receiving ICBT.
32848590|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
32848591|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
32848592|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
32848593|NCT05124366|Experimental|Study group|Nanovitamin E, nanovitamin C and propolis extract gel
32848594|NCT05124366|Placebo Comparator|Placebo|Gel without nanovitamin E, nanovitamin C and propolis extract
32848595|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
32848596|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
32848597|NCT03916848|Experimental|Combined Micro-Macro SEEG Electrodes|Implanting SEEG electrodes with combined micro-macro electrodes capable of recording clinical data and experimental micro electrode single unit data
32848598|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
32848599|NCT05118594|Experimental|Pre-treatment recommendations|Therapists receive automatized feedback at the beginning of the treatments with recommendations regarding the most appropriate interventions to use with their patients based on a machine learning algorithm developed on a previous study.
32848600|NCT05008536|Experimental|Anti-BCMA CAR-NK Cells|After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated
32848601|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
32848602|NCT03846492|Experimental|Active tDCS|The direct current will be delivered at 2 mA intensity via rubber electrodes in saline- soaked sponges for 30 min per day for 2 weeks, 5 days/week. Inhibitory stimulation will be delivered to the frontal lobes.
32848603|NCT03846492|Sham Comparator|sham tDCS|Sham tDCS will use the same parameters except that the device will automatically turn off after a certain duration.
32848604|NCT05373420||All individuals tested for COVID-19 in Belgium|All individuals of 18 years old and over tested for COVID-19 at least once in Belgium until the 31st of August 2021
32848605|NCT04345419|Experimental|Remdesivir|Remdesivir with standard of care treatment standard of care treatment
32848606|NCT04345419|Placebo Comparator|Standard of care|Standard of care treatment alone.
32848607|NCT04841070|Experimental|Persistent pulmonary hypertension of the newborn.|Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.
32848608|NCT04270695||blood flow restriction|An inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
32848609|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
32848610|NCT04830774|Other|COVID-19 patients with new-onset AF|Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.
32848611|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
32848612|NCT00759525|Placebo Comparator|2|Placebo
32848613|NCT03616470|Experimental|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
32848614|NCT03616470|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
32848615|NCT03606876|Experimental|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
32848616|NCT03606876|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
32848617|NCT03606876|Active Comparator|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
32848618|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
32848619|NCT03599934|Experimental|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
32848620|NCT03599934|No Intervention|Control group|The control group will continue their usual daily routine.
32848621|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
32848622|NCT04759014||Group 1|21 patients using non-articulated dynamic foot (non-articulating ankle, NAA)
32848623|NCT04759014||Group 2|21 patients using dynamic foot with hydraulic ankle (articulating hydraulic ankle, AHA)
32848624|NCT03510390|Experimental|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
32848625|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
32848626|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
32848627|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
32848628|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
32848629|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
32848630|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
32848631|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
32848632|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
32848633|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
32848634|NCT04553562|Experimental|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
32848635|NCT04553562|Sham Comparator|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
32848636|NCT04553562|No Intervention|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
32848637|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
32848638|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
32848639|NCT03291990|Experimental|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
32848640|NCT00087919||Maywood|The were 743 subjects were sampled from Maywood, Il. There was no intervention.
33406371|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
32848641|NCT00087919||Nigeria|There were 1188 Nigerian sampled from Igbo-Ora and Ibadan, Nigeria. There was no intervention.
32848642|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
32848643|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
32848644|NCT05346757|Other|miRFec test|The miRFec test corresponds to the combination of fecal hemoglobin concentration and fecal miRNA expression
32848645|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
32848646|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
32848647|NCT05170698|Experimental|coalition excision and arthroereisis|Talocalcaneal bar excision is done and then arthroereisis implant is applied in subtalar joint to correct rigid pes planovalgus in adolescent
32848648|NCT05170698|Experimental|coalition excision and corrective osteotomies|Talocalcaneal bar excision is done and then according to degree of deformity either medial displacement calcaneal osteotomy or evans or cotton osteotomy is done or combined together to correct rigid pes planovalgus in adolescents
32848649|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
32848650|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
32848651|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
32848652|NCT03566797||SC-CIP|Patients developing SC-CIP
32848653|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
32848654|NCT05403918|Active Comparator|conventional physiotherapy|15 patients will receive conventional physiotherapy including a hot pack, TENS, therapeutic ultrasound, shoulder anteroposterior, posteroanterior, and inferior glides followed by active and active-assisted range of motion exercises, isometric exercises, Codman's pendulum exercises, wand, pulley, and finger ladder exercises.
32848655|NCT05403918|Experimental|scapular stabilization exercises along with conventional physiotherapy|15 participants will receive conventional treatment along with scapular stabilization exercises program consisting of strengthening exercises (Middle Trapezius, Lower Trapezius, Serratus Anterior, and Rhomboid Muscles) and stretching exercises (Pectoralis Minor, Levator Scapulae, Upper Trapezius, Teres Major). Appropriate exercises will be given to patients according to the type of Scapular Dyskinesia.
32848656|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
32848657|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
33327030|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
33327031|NCT03870282|Experimental|"Personal Goal | Incentive A"|
33327032|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
33327033|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
33327034|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
33327035|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
33327036|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
33327037|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
33327038|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
33327039|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
33327040|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
33327041|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
33327042|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
33327043|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
33327044|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
33327045|NCT01171248||type 1 diabetes|
33327046|NCT01171248||non-diabetics|
33327047|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
33327048|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
33327049|NCT01277016|No Intervention|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
33327050|NCT01277016|Experimental|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
33327051|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
32848658|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
33406372|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
32739638|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
32739639|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
32739640|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
32739641|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
32739642|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
32739643|NCT04484779|Experimental|IIM System|The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).
32739644|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.~Patients are admitted to the hospital ward for 14 days."
32739645|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
32739646|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
32739647|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
32739648|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
32848659|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
32848660|NCT04901988|No Intervention|Arm A|In Arm A, patients and clinicians will remain blinded to the ctDNA result and will be managed as per standard of care with regular clinical review and imaging, and treated if they develop evidence of disease recurrence.
32739649|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
32739650|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
32739651|NCT05485961|Experimental|CSL300 (low dose)(Phase 2b)|Intravenous (IV) administration
32739652|NCT05485961|Experimental|CSL300 (medium dose)(Phase 2b)|IV administration
32739653|NCT05485961|Experimental|CSL300 (high dose)(Phase 2b)|IV administration
32739654|NCT05485961|Placebo Comparator|Placebo (Phase 2b)|IV administration
32739655|NCT05485961|Experimental|CSL300 (Phase 3)|IV administration
32739656|NCT05485961|Placebo Comparator|Placebo (Phase 3)|IV administration
32739657|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
32739658|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
32739659|NCT05483231|Experimental|Family integrated care intervention group|Provide Family integrated care for very low birth weight infants in the NICU.
32739660|NCT05483231|Other|Routine nursing care group|Perform routine nursing care for very low birth weight infants in the NICU.
32739661|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:~15 patients with non-small cell lung cancer (NSCLC)~10 patients with hepatocellular cancer:~10 patients with colorectal cancer~10 patients with breast cancer~10 patients with prostate cancer~10 patients with glioblastoma"
32739662|NCT02446561|Active Comparator|MRXXX|Active comparator
32739663|NCT02446561|Experimental|MR1XXX|MR1XXX
32739664|NCT02446561|Experimental|MR2XXX|MR2XXX
32739665|NCT02446561|Experimental|MR3XXX|MR3XXX
32739666|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
32739667|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
32739668|NCT04484389|Experimental|Study Group|Individual exercises will be applied to individuals with Chronic disease.
32739669|NCT04484389|Active Comparator|Control Group|Group to be given an exercise brochure
32739670|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
32739671|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
32848661|NCT04901988|Experimental|Arm B|Patients randomised to Arm B will not be blinded to the positive ctDNA result and will be treated with the intervention.
32848662|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
32848663|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
32848664|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
32848665|NCT04427280||Arm A|Suspected acute COVID-19 infection
32848666|NCT04427280||Arm B|Asymptomatic patients with no clinical suspicion of COVID-19
32848667|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
32848668|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
32848669|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
32848670|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
32848671|NCT03200340|Placebo Comparator|Placebo|Matching placebo
32848672|NCT03200340|Experimental|EC-18 500 mg|1 capsule of EC-18
32848673|NCT03200340|Experimental|EC-18 1000 mg|2 capsules of EC-18 500 mg
32848674|NCT03200340|Experimental|EC-18 2000 mg|4 capsules of EC-18 500 mg
32848675|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
32848676|NCT03498625|Other|Clinical remission CD|
32848677|NCT04762147|Experimental|Paracetamol group-P|Paracetamol 15mg/Kg was dministered 30 minutes before the start of surgery
32848678|NCT04762147|Active Comparator|Fentanyl group-F|Fentanyl 2mcg/kg was administered at the time induction of anaesthesia
32848679|NCT05403840||MVRR: Patients due to undergo surgical MV repair/replacement|
32848680|NCT05403840||TMVI: Patients due to undergo transcatheter MV intervention|
32848681|NCT04273737|Experimental|Amantadine|Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)
32848682|NCT02963064|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
32848683|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
32848684|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
32848685|NCT04183062|Experimental|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
32848686|NCT04325880|Placebo Comparator|Placebo arm|Patients in this arm will receive a placebo formula
32848687|NCT04325880|Active Comparator|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
32848688|NCT04325880|Active Comparator|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
32848689|NCT04325880|Active Comparator|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
32848690|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
32848691|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
32848692|NCT02943954|Other|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
32848693|NCT02943954|Other|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
32848694|NCT04385043|Experimental|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
32848695|NCT04385043|Active Comparator|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
32848696|NCT04862442|Experimental|Group 1=Video-conference based Qigong exercises|After initial result evaluation, participants of Group A will perform Qigong exercises for 40 to 45 minutes per session for 3 days a week for 6 weeks via the online video conference method.
32848697|NCT04862442|Experimental|Group 2=A-synchronized video Qigong exercises|"Group B will perform the same routine via a-synchronized video sections for 6 weeks.~Basic Qigong exercises will be performed by volunteers for 6 weeks and progression will be logged."
32848698|NCT04846608||Nursing home residents with behavioural problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for disorientation, agitation, dementia or behavioural problems during the study period
32848699|NCT04846608||Nursing home residents with other problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for other reasons
32848700|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 26 mothers with no diagnosis of preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
32848701|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 26 mothers with diagnosis of mild or severe preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
32848702|NCT04846218|Active Comparator|Group 1|They will receive a single dose of 0.2 mg triptorelin (Decapeptyl® Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections
32848703|NCT04846218|Active Comparator|Group 2|They will receive a single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest®).
33406373|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
32848704|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
32848705|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
32848706|NCT04152486|Experimental|Intervention arm|The vaccine Ad26.ZEBOV (5x10^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
32848707|NCT02512692|Experimental|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
32848708|NCT03933072|Experimental|patients with complete spinal cord injury|the planned interventions have been described in the section below
32848709|NCT04807998||Group EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score of 12 or greater was defined as EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
32848710|NCT04807998||Group non-EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score less than 12 was defined as non-EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
32848711|NCT04499664||Blood donors|Healhy young male bloddonors, aged 30-45
32848712|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
32848713|NCT01594398|Experimental|entinostat C1D1 fed|Entinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
32848714|NCT01594398|Experimental|entinostat C1D1 fasted|Entinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
32848715|NCT04700514|No Intervention|Control group|"Children diagnosed with retinoblastoma and received exam under anesthesia (EUA) before the age of 30 months, and is not yet 4 years old~Children who are undergoing exams and treatment such as EUA, chemoport insertion, or intra-arterial chemotherapy under general anesthesia~Sevoflurane is used only for anesthesia"
32848716|NCT04700514|Experimental|Dexmedetomidine group|"Children who are diagnosed with retinoblastoma and are scheduled for the first EUA before their age of 30 months.~No history of anesthesia"
32848717|NCT04682106|Experimental|LY3493269|Multiple doses of LY3493269 administered orally.
32848718|NCT04682106|Placebo Comparator|Placebo|Placebo administered orally.
32848719|NCT05403606|Experimental|Experimental Group (GASPARD®)|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
32848720|NCT05403606|No Intervention|Control group:|Spinal cord injured patient with traditional follow-up with therapeutic education at discharge from initial care
32848721|NCT05403528|No Intervention|3D-3D|All items presented in 3D form
32848722|NCT05403528|Experimental|3D-2D|Initial items in 3D, retention and generalization in 2D
32848723|NCT05403528|Experimental|2D-3D|Initial items in 2D, retention and generalization in 3D
32848724|NCT05403528|Experimental|2D-2D|All items in 2D
32848725|NCT05129904||Double plasma molecular absorption system treatment|Patients treat with DPMAS alone or in combination with plasma exchange
32848726|NCT05129904||Standard medical therapy|Patients with standard medical therapy except for DPMAS treatment or other artificial liver support system
32848727|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
32848728|NCT04572828|Active Comparator|Group 1: Waiting 1 Minute After Paracervical Block|
32848729|NCT04572828|Active Comparator|Group 2: Waiting 3 Minute After Paracervical Block|
32848730|NCT04572828|Placebo Comparator|Group 3: Control Group|
32848731|NCT04572828|Active Comparator|Group 4: Waiting 60 Minute After Taking Oral NSAIDs|
32848733|NCT05316597|Experimental|Terpenes On|"Forest bathing intervention with no filtration of terpenes from inhaled air (terpenes on)"
32848734|NCT05316597|Active Comparator|Terpenes Off|"Forest bathing intervention with filtration of terpenes from inhaled air (terpenes off)"
32848735|NCT05318391||Group/Cohort|Retrospective Cohort： Participants who diagnosed with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients and treated with BTK inhibitor or lenalidomide and its biosimilars.
32848736|NCT05134350|Experimental|Arm A (LOXO-305 - Fasted)|LOXO-305 administered orally while fasting
32848737|NCT05134350|Experimental|Arm B (LOXO-305 - Fed)|LOXO-305 administered orally with standard meal
32848738|NCT05134350|Experimental|Arm C (Omeprazole + LOXO-305 Fasted)|Omeprazole + LOXO-305 administered orally while fasting
32848739|NCT05129826|Experimental|older adult|Subjects who has aged ≥ 60 years old.
32848740|NCT05134194|Experimental|Arm A|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
32848741|NCT05134194|Experimental|Arm B|Capecitabine or eribulin or gemcitabine or vinorelbine
32848742|NCT05129514|Experimental|Manual Lymphatic Drainage (MLD)|
32848743|NCT00761007|Experimental|Ibodutant 10 mg|
32848744|NCT00761007|Experimental|Ibodutant 30 mg|
32848745|NCT00761007|Experimental|Ibodutant 60 mg|
32848746|NCT00761007|Placebo Comparator|Placebo|
32848747|NCT04435704|Experimental|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
32848748|NCT00761085|Active Comparator|Methadone-Children|Methadone comparison to standard of care for pain management
32848749|NCT00761085|Active Comparator|Morphine-Children|Morphine standard of Care pain management
32848750|NCT00761085|Active Comparator|Methadone-Adults|Methadone comparison to standard of care for pain management
32848751|NCT00761085|Active Comparator|Morphine-Adults|Morphine standard of Care pain management
32848752|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
32848753|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
32848754|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
32848755|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
32848756|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
32848757|NCT05129436||Establishment of method|healthy volunteers who are asked to donate peripheral blood for the establishment of the method
32848758|NCT05129436||Influenza vaccination|Subjects receiving the influenza vaccine Vaxigrip Tetra 2020/2021 by Sanofi Pasteur Europe.
32848759|NCT05315505|Experimental|Maintenance|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The maintenance arm will receive home visits for supervised physical exercise and progressively alternated with phone calls to motivation and feedback"
32848760|NCT05315505|Active Comparator|control|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The control group will have access to the usual follow."
32848761|NCT04397562|Experimental|LVL group|Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
32848762|NCT04397562|Placebo Comparator|Placebo group|Single subcutaneous administration of placebo in combination with standard therapy
32848763|NCT05744271|Experimental|FES+VFBT|Functional electrical stimulation combined with visual feedback balance training
32848764|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
32848765|NCT01362270|Experimental|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
32848766|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
32848767|NCT04902612|Experimental|HM242-Solution|
32848768|NCT04902612|Active Comparator|Saline|
32848769|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
32848770|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
32848771|NCT04413006|Experimental|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
32848772|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
32848773|NCT04940676|Active Comparator|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
32848774|NCT04940676|Placebo Comparator|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding of 5 minutes after breakfast and dinner for 7 days
32848775|NCT00089479|Experimental|1|
32848776|NCT00089479|Active Comparator|2|
32848777|NCT05057052|Experimental|Cryoablation in combination with Sintilimab plus regorafenib|
32848781|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
32898792|NCT00258128|Experimental|Treatment|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
32848782|NCT05055726|Experimental|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|"Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis.~The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC.~In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day.~In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds."
32848783|NCT04916106|Experimental|One parameter TEA group for 4 weeks|Choose two acupoints,give 25Hz electrical stimulation for 4 weeks.
32848784|NCT04916106|Experimental|Another parameter TEA group for 4 weeks|Choose two acupoints,give 100 Hz electrical stimulation for 4weeks.
32848785|NCT04916106|Experimental|Sham-TEA group for 2 weeks, and the random TEA for the next 2 weeks.|Choose two non-acupoints，give 25Hz and 100Hz electroacupuncture stimulation respectively for the first 2 weeks. Then give supplement TEA treatment as described above for the next 2 weeks.
33406374|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
32848786|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
32848787|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
32848788|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
32848789|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
32848790|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
32848791|NCT05744115|Experimental|Ga-68-PSMA-11 PET/CT|Administration of Ga-68-PSMA-11 and acquisition of PET/CT
32848792|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
33406375|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
32848793|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
32848794|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
32848795|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
32848796|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
32848799|NCT04496232|No Intervention|Normal SDF|Using routine semen processing method
32848800|NCT04496232|Active Comparator|Physiological ICSI (PICSI)|Sperm selection using PICSI dishes for selecting sperm with lower DNA fragmentation index for ICSI
32848801|NCT04496232|Active Comparator|Second ejaculate|Using the second ejaculate as a way of reducing SDF in the semen sample used for ICSI
32848802|NCT05744037|Experimental|CAR-T Cell Infusion|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
32848803|NCT04409132|Experimental|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
32848804|NCT04409132|Experimental|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
32848805|NCT04409132|Experimental|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
32848806|NCT04409132|Experimental|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
33320164|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
33406376|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
33320165|NCT05492942|No Intervention|Clinician prompting and Decision Support, Best Practice Advisory (BPA)|Access to an existing BPA for risky alcohol use and alcohol use disorder.
33406377|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
33320166|NCT05492942|Experimental|BPA plus Population Health Management (BPA+PHM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM).
33320167|NCT05492942|Experimental|BPA plus Clinical Care Management (BPA+CCM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a clinician care manager (CCM).
33406378|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
33406379|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
33406380|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
32848807|NCT05132946|Active Comparator|Group (B): will receive erector spinae plane block.|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
32848808|NCT05132946|No Intervention|• Group (C): will not receive any block.|
32848811|NCT05132868|Experimental|pre-educated with educational video|"Participants will receive a message to view educational videos prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The video will be shared with patients via MyHealth in the education tab in advance of the genetic counseling session"
32848812|NCT05132868|Experimental|pre-educated with pamphlet|Participants will receive a message to view a pamphlet prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The pamphlet will be sent to patients who cannot access the video via regular mail in advance of the genetic counseling session
32848813|NCT05132868|Other|educated during the session|Participants will receive traditional genetic counseling. . After the genetic counseling session, they will fill out a validated survey called the Multi-dimensional Measure of Informed Choice (MMIC) that assesses attitudes, knowledge, and uptake of genetic testing
32848814|NCT05743959||Patients with stage I-III biliary tract cancers|Patients with stage I-III biliary tract cancers eligible for curative surgical resection
32848815|NCT05132712|Experimental|Use of ACE inhibitor|losartan potassium will be administered 25 mg daily
32848816|NCT05132712|Placebo Comparator|placebo group|matched for age and gender
32848817|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
32848818|NCT04886700|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
32848819|NCT04789434|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose：200mg frequency：1 time for 2 months duration：2 years
32848820|NCT04789434|No Intervention|No intervention|No intervention
32848821|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
32848822|NCT04736082|Experimental|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.
32848823|NCT04736082|Active Comparator|Control Group: Infant Formula with intact protein|Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.
32848824|NCT04736082|No Intervention|Breast Fed Group|Exclusively breast milk
33320168|NCT05492942|Experimental|BPA plus Population Health Management plus Clinical Care Management (BPA+PHM+CCM)|Access to the existing Epic BPA risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM) and clinician care manager (CCM)
33320169|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
33320170|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
33320171|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
33320172|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
33320173|NCT03789344|Experimental|Acupuncture treatment|
33320174|NCT03789344|Active Comparator|Psychotherapy|
33320175|NCT03789344|Placebo Comparator|blank control|
33320176|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
33320177|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
33320178|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
33320179|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
33320180|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
32959411|NCT00648648|Experimental|MK-1775 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus MK-1775 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
32959412|NCT00648648|Experimental|MK-1775 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
32959413|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
32959414|NCT00648648|Experimental|MK-1775 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
32959415|NCT00648648|Experimental|MK-1775 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
32959416|NCT00648648|Experimental|MK-1775 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
32959417|NCT00648648|Experimental|MK-1775 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
32959418|NCT00648648|Experimental|MK-1775 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
32959419|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959420|NCT00648648|Experimental|MK-1775 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959421|NCT00648648|Experimental|MK-1775 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959422|NCT00648648|Experimental|MK-1775 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959423|NCT00648648|Experimental|MK-1775 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959424|NCT00648648|Experimental|MK-1775 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959425|NCT00648648|Experimental|MK-1775 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959426|NCT00648648|Experimental|MK-1775 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959427|NCT00648648|Experimental|MK-1775 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959428|NCT00648648|Experimental|MK-1775 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
32959429|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
32959430|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
32959431|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
32959432|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
32959433|NCT00654654|Experimental|Active|
32959434|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
32959435|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
32959436|NCT00659802|Placebo Comparator|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
32959437|NCT00659802|Experimental|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
32959438|NCT00659802|Experimental|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
32959439|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
32959440|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
32959441|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
32959442|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
32959443|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
33406381|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
32959444|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
32959445|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
32959446|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
32959447|NCT00662298|Experimental|Severe Asthma|
32959448|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
32959449|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
32959450|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
32959451|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
32959452|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
32959453|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
32959454|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
32959455|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
32848825|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
32848826|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
32848827|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
32848828|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
32848829|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
32848830|NCT04702464|Experimental|Treatment Administration|"Day 1: Single dose of 100 mg fedratinib~Days 10 to 23, inclusive: Single dose of 400 mg fluconazole on Day 10 and once daily (QD) doses of 200 mg fluconazole on Days 11 to 23, inclusive~Day 18: Single dose of 100 mg fedratinib coadministered with the 200-mg fluconazole dose."
32959456|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
32848831|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
32848832|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
32848833|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
32848834|NCT04776174|Experimental|standard and telerobotic ultrasound|Included patients will have both ultrasound examination: standard ultraosound (abdominal, cardiac or pulmonary depending on the prescription and telerobotic ultrasound
32848835|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
32848836|NCT01503164|Sham Comparator|Lifestyle counseling|
32848837|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
32848838|NCT04719858|Experimental|Intervention|Intervention group that will install the #LIFEGOALS app.
32848839|NCT04719858|No Intervention|Control|Control group that will not receive any intervention.
32848840|NCT03805269|Experimental|TAP block|USG guided TAP block
32848841|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
32848842|NCT00088465|Experimental|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
32848843|NCT05094180|Other|Face-to-face consultation|
32848844|NCT05094180|Active Comparator|Teleconsultation|
32848845|NCT05094180|Active Comparator|Video consultation|
32848846|NCT04086446|Active Comparator|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
32848847|NCT04086446|Sham Comparator|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
32848848|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
32848849|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
32848850|NCT04653636||Adhesive capsulitis|Patients presenting to the physical medicine and rehabilitation department [tertiary care] of Cochin Hospital with a clinically diagnosis of severe adhesive capsulitis for whom first-line medical treatment is not effective.
32848851|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
32848852|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
32848853|NCT04616898|Active Comparator|Diode Laser Treatment Only|Group 1: Patient 1- Laser Only This patient will present 20+, 14, 7, and 1 days prior to his/her scheduled abdominoplasty. Between 20 and 30 days prior, the patient will receive the first laser treatment on the 20+ day site 1. 14 days prior, the patient will receive laser treatment on the 14 day site 2. 7 days prior, the patient will receive laser treatment on the 7 day site 3. 1 day prior to the scheduled abdominoplasty, the patient will receive laser treatment on the 24 hour site 4.
32848854|NCT04616898|Active Comparator|Diode Laser and RadioFrequency Treatment|This patient will present 14 days and 7 days prior to his/her scheduled abdominoplasty. 14 days prior, the patient will be treated at site 1 with the laser and radiofrequency and site 3 with the laser only. 7 days prior, the patient will be treated at site 2 with the laser and radiofrequency and site 4 with the laser only.
32848855|NCT04616898|Active Comparator|Multiple Diode Treatments|These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
32848856|NCT04086368|Active Comparator|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
32848857|NCT04086368|Experimental|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
32848858|NCT00784641|Experimental|Novel Bausch & Lomb Contact Lens|Novel Bausch & Lomb daily disposable contact lenses
32848859|NCT00784641|Active Comparator|SofLens|Bausch & Lomb SofLens daily disposable contact lenses
32848860|NCT00784641|Active Comparator|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
32959457|NCT00671502|Placebo Comparator|Placebo|tablet
32848861|NCT04560738|Experimental|Administration of [14C]-CC-92480|[14C]-CC-92480 will be administered as an oral solution. A single oral dose of [14C]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
32848862|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
32848863|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
32848864|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
32848865|NCT03088189||Placebo|Mothers are receiving placebo
32848866|NCT04550208||Healthy basketball or volleyball players|Basketball and volleyball players Landing biomechanics of different landing tasks is investigated in a population of volleyball and basketball players
32848867|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
32848868|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
32848869|NCT04405674|Experimental|Tislelizumab plus chemotherapy|Tislelizumab plus Carboplatin/Nab-paclitaxel as induction treatment and followed by Tislelizumab plus pemetrexed as maintenance treatment.
32848870|NCT04405674|Experimental|Tislelizumab plus chemotherapy plus Bevacizumab|Tislelizumab plus Nab-paclitaxel and Bevacizumab as induction treatment and followed by Tislelizumab plus Bevacizumab as maintenance treatment.
32848871|NCT05743881|Experimental|Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
32848872|NCT05743881|Experimental|Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
32848873|NCT05743881|Placebo Comparator|Part A: Placebo (Age Group: 8 to <24 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
32848874|NCT05743881|Experimental|Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
32848875|NCT05743881|Experimental|Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
32848876|NCT05743881|Experimental|Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
32848877|NCT05743881|Experimental|Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
32848878|NCT05743881|Placebo Comparator|Part B: Placebo (Age Group: 5 to <8 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
32848879|NCT00088153|Experimental|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
32848880|NCT00088153|Placebo Comparator|Placebo|Placebo patches or pills
32848881|NCT04478682|Experimental|WhatsApp Messaging Application|Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
32848882|NCT04478682|No Intervention|Standard breastfeeding support|She will receive standard breastfeeding support after delivery. Breastfeeding will not receive continuous breastfeeding support for the first 6 months after discharge.
32848883|NCT04470960|Experimental|participating community centers|Training course for the community center health coordinators Professional guidance for the CC health coordinators
32848884|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
32848885|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
32848886|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
32848887|NCT04405518|Active Comparator|Control group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 8mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
32848888|NCT04405518|Experimental|intervention group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 11mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
32848889|NCT05743803||Before|This group will undergo their preoperative fasting period as standard care.
32848890|NCT05743803||After|This group will undergo their preoperative fasting period after the sensitization campaign about preoperative fasting rules.
32848891|NCT05743725|Active Comparator|A: Dexmedetomidine|Brain tumor excision under general anesthesia. This group will receive dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery.
32848892|NCT05743725|Active Comparator|B: Magnesium sulphate|Brain tumor excision under general anesthesia. This group will receive a 2 gm magnesium infusion for 30 minutes.
32848893|NCT04494048||Endoscopic Bariatric Therapies (EBT).|patients undergoing Endoscopic Bariatric Therapies
32848894|NCT05547321|Experimental|Monotherapy (OMTX705)|OMTX705 is administered as single agent.
32848895|NCT05547321|Experimental|Combination (OMTX705 + pembrolizumab)|OMTX705 is administered in combination with pembrolizumab.
32848896|NCT04912518|Active Comparator|Dexmedetomidine (DEX) group|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
32848897|NCT04912518|Placebo Comparator|Placebo (Saline) group|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.
32848898|NCT05541939|Experimental|Treatment Arm A|Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin
32848899|NCT05541939|Experimental|Treatment Arm B|Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)
32848900|NCT00087685|Experimental|RAD001|RAD001 10 mg by mouth Daily
32848901|NCT04094558|Active Comparator|IBS-D|Participant diagnosed with Irritable Bowel Syndrome, diarrhea predominant, confirmed by study doctors using Rome IV criteria.
32848902|NCT04094558|Active Comparator|IBS-C|Participant diagnosed with Irritable Bowel Syndrome, constipation predominant, confirmed by study doctors using Rome IV criteria.
32848903|NCT04094558|Active Comparator|Healthy Control|Participant with no ongoing medical conditions affecting GI health.
32848906|NCT05153460||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
32848907|NCT05064696|Active Comparator|Group 1 (Control group)|Surgical wound will be covered with the standard non-stick gauze dressing.
32848908|NCT05064696|Experimental|Group 2 (Treatment group)|Surgical wound will be covered with the PICO dressing.
32848909|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
32848910|NCT05011812|Experimental|Part 1, Treatment A|Dose level 1 of PBI-0451
32848911|NCT05011812|Experimental|Part 1, Treatment B|Dose level 2 of PBI-0451
32848912|NCT05011812|Experimental|Part 1, Treatment C|Dose level 3 of PBI-0451
32848913|NCT05011812|Experimental|Part 1, Treatment D|Dose level 4 of PBI-0451
32848914|NCT05011812|Experimental|Part 2, Treatment E|PBI-0451 =/< Dose level 1
32848915|NCT05011812|Experimental|Part 2, Treatment F|PBI-0451 =/< Dose level 2
32848916|NCT05011812|Experimental|Part 2, Treatment G|PBI-0451 =/< Dose level 3
32848917|NCT05011812|Experimental|Part 2, Treatment H|PBI-0451 =/< Dose level 4
32848918|NCT05011812|Experimental|Part 3, Treatment J|PBI-0451 + ritonavir (a CYP450 3A inhibitor)
32848919|NCT05011812|Experimental|Part 3, Treatment K|PBI-0451 + ritonavir
32848920|NCT05011812|Experimental|Part 3, Treatment L|"PBI-0451 dose TBD~+ midazolam (a sensitive CYP450 3A substrate)"
32848921|NCT05011812|Experimental|Part 1, Treatment M|Dose level 2 of PBI-0451 with food
32848922|NCT05011812|Experimental|Part 2, Treatment I|PBI-0451 =/< Dose level 5
32848923|NCT05011812|Experimental|Part 1, Treatment N|Dose Level 5 of PBI-0451
32848924|NCT05535231|Experimental|Turmeric test product|Turmeric
32848925|NCT05535231|Active Comparator|Turmeric comparator|Turmeric
32848926|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
32848927|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
32848928|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
32848929|NCT05532735|Experimental|2 mg ANXV - active|ANXV (human recombinant Annexin A5), infusion, 2 mg daily during five days.
32848930|NCT05532735|Placebo Comparator|2 mg ANXV - placebo|Saline, infusion, daily during five days.
32848931|NCT05532735|Experimental|4 mg ANXV - active|ANXV (human recombinant Annexin A5), infusion, 4 mg daily during five days.
32848932|NCT05532735|Placebo Comparator|4 mg ANXV - placebo|Saline, infusion, daily during five days.
32848933|NCT05532735|Experimental|1 mg ANXV - active|ANXV (human recombinant Annexin A5), infusion, 1 mg daily during five days.
32848934|NCT05532735|Placebo Comparator|1 mg ANXV - placebo|Saline, infusion, daily during five days.
32848935|NCT04662450|Experimental|Affective pain stimuli group|affective/neutral word pairs
32848936|NCT04662450|Experimental|Sensory pain stimuli group|sensory/neutral word pairs
32848937|NCT04662450|Placebo Comparator|Control group|affective/neutral and sensory/neutral word pairs
32848938|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
32848939|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
32959458|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
32959459|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
33320181|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
33320182|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
33320183|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
33320184|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
33320185|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
32848942|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
32848943|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
32848944|NCT05743257||Experimental group|Volunteers living in a deprived neighborhood with urban transformations in Paris (France)
32848945|NCT05743257||Control group|Volunteers living in a deprived neighborhood without urban transformations in Paris (France).
32848946|NCT05743179|Experimental|Zoledronate|Zoledronate intravenous infusion (5mg) once and usual care will be provided to the patient and mark the start of 12-month follow-up period
32848947|NCT05743179|No Intervention|Control|Only usual care will be provided to the patient with 12-month follow-up period.
32848948|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
32848949|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
32848950|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
32848951|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
33320186|NCT04751084|Active Comparator|treatment group|20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer
32848953|NCT04383405|Experimental|Sequential Preparotory Approach|
32848954|NCT04383405|Active Comparator|Conventional|
32848955|NCT01479530|Placebo Comparator|Placebo|
32848956|NCT01479530|Experimental|Azilect®|
32848957|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
32848958|NCT04383561|Active Comparator|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
32848959|NCT04383561|Placebo Comparator|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
32848960|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
32848961|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
32848962|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
32848963|NCT00087529|Experimental|1|
32848964|NCT00087529|Placebo Comparator|2|
32848965|NCT00794313|Experimental|Amantadine|
32848966|NCT00794313|Experimental|Amantadine plus Topiramate|
32848967|NCT00794313|Placebo Comparator|Sugar Pill|
32848968|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
32848969|NCT05743101|Experimental|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
32848970|NCT05743101|Placebo Comparator|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
32848971|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
32848972|NCT00087139|Experimental|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32848973|NCT04085510|Experimental|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
32848974|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
32848975|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
32848976|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
32848977|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
32848978|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
32848979|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
32848980|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
32848981|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
32848982|NCT00786825|No Intervention|2|Healthy control subjects
32848983|NCT03492229|Experimental|tDCS+AMT|TDCS in combination with movement training before treadmill training
32848984|NCT03492229|Active Comparator|tDCS|tDCS only before treadmill training
32848985|NCT03492229|Active Comparator|AMT|Movement training only before treadmill training
32848986|NCT03492229|Sham Comparator|Control|No priming before treadmill training
33320187|NCT04751084|Placebo Comparator|control group|2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer
32848987|NCT05743023|Experimental|Consciousness-based Ayurvedic lifestyle Intervention|In the intervention group, each participant will receive a structured education and be asked to follow a 12-week personalized diet and daily routine protocol based on the assessment of their current Ayurvedic mind-body state. Participants will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week.
32848988|NCT05743023|Active Comparator|Waitlist control|Participants in the waitlist control group will not receive any intervention. They will continue usual care and will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week. Participants n this group receive their personalized protocol at the end of 12 weeks after completing all the data collection.
32848989|NCT04348513|Experimental|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
32848990|NCT04348513|Placebo Comparator|Placebo|Composition identical apart from the active substance. Same dosage.
32848991|NCT04402255|Experimental|behcet group|this group includes 16 patients with behçet
32848992|NCT04402255|Experimental|fmf group|this group includes 16 patients with fmf
32848993|NCT04402255|Active Comparator|healty control|this group includes 16 healthy control
33104014|NCT04282616|No Intervention|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
32848994|NCT00768261|No Intervention|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
32848995|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
32848996|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
32848997|NCT00768261|No Intervention|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
32848998|NCT05346991|Experimental|Intervention arm|Implementation of the Tobacco-Free Teachers, Tobacco Free Society program in government schools in Bihar, India
32848999|NCT05346991|No Intervention|Control arm|Delayed intervention - control arm schools receive the program after all data collection is complete
32849000|NCT05742945|Experimental|ILR|Breast cancer patients receiving axillary lymph node dissection and immediate lymphatic reconstruction
32849001|NCT05742945|No Intervention|non-ILR|Breast cancer patients receiving only axillary lymph node dissection
32849002|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
32849003|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
32849004|NCT04279275||Survey|Knowledge survey
32849005|NCT05742867||Cohort 1|High-risk Muscle-Invasive Bladder Cancer (MIBC) participants following radical cystectomy
32849006|NCT03804723|Experimental|GC withdrawal|
32849007|NCT03804723|Placebo Comparator|non GC withdrawal|
32849008|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
32849009|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
32849010|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
32849011|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
32849012|NCT03837015|Active Comparator|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
32849013|NCT03837015|Active Comparator|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
32849014|NCT03837015|Active Comparator|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
33104015|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
33104016|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
32849015|NCT03837015|Active Comparator|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
32849016|NCT03830853||Successful CTO PCI achieved|Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.
32849017|NCT05742789|Other|Propofol|Anesthesia
32959460|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
32849018|NCT05742789|Other|Isofluran|Anesthesia
32849019|NCT05742789|Other|Sevofluran|Anesthesia
32849020|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
32849021|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
32849022|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
32849023|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
32849024|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
32849025|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
32849026|NCT00086281|Experimental|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
32849027|NCT00086281|Active Comparator|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
32849028|NCT00086281|Experimental|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
32849029|NCT00086281|Placebo Comparator|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
32849030|NCT00086047|Experimental|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
32849031|NCT00086047|Active Comparator|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
32849032|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
32849033|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
32849034|NCT00085423|Experimental|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
32849035|NCT04079192|Experimental|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
32849036|NCT04079192|Active Comparator|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
32849037|NCT05742555|Experimental|Experimental Group|
32849038|NCT05742555|No Intervention|Control Group|
32849039|NCT01677793||Child and adolescent population|
32849040|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
32849041|NCT05447403|Experimental|Chewing gum combined with WeChat enhanced instructions group|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
32849042|NCT05447403|No Intervention|Control group|Patients in the control group are guided by regular instructions.
32849043|NCT03418753||single|subjects with abnormal intracranial pressure
32849044|NCT05424081|Experimental|EMBER|Self-help tool to increase weight management engagement
32849045|NCT05424081|Active Comparator|Control|List of treatments
32849046|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
32849047|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
32849048|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
32849049|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
32849050|NCT03447379|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
32849051|NCT03447379|Active Comparator|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
32849052|NCT03837093|Experimental|dose A|ILT-101
32849053|NCT03837093|Experimental|dose B|ILT-101
32849054|NCT03837093|Experimental|dose C|ILT-101
32849055|NCT03837093|Experimental|dose D|ILT-101
32849056|NCT03837093|Experimental|dose E|ILT-101
32849057|NCT03837093|Experimental|Placebo|
32849058|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
32849059|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
32849060|NCT05397093|Experimental|Phase 1a: Dose Escalation|Various doses will be tested in participants with EOC, NSCLC and RCC.
32849061|NCT05397093|Experimental|Phase 1b: Expansion|"Cohort 1: Participants with epithelial ovarian cancer (EOC)~Cohort 2: Participants with non-small cell lung cancer (NSCLC)~Cohort 3: Participants with renal cell carcinoma (RCC)"
32849062|NCT05389293|Experimental|Participants with newly diagnosed Follicular Lymphoma|Participants with newly diagnosed FL in need of systemic therapy
32849063|NCT00084487|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33406382|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
32849064|NCT05384223|Experimental|RRFT (Risk Reduction through Family Therapy)|
32849065|NCT05384223|Active Comparator|TAU:Encompass|
32849066|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- ctDNA-POSITIVE: FOLFIRI Protocol~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drugs~5-Fluorouracil~Irinotecan~Leucovorin"
32849067|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~-- Active surveillance.~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician. ."
32849068|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician"
32849069|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab~-ctDNA-Positive, MSI-H: Nivolumab Protocol~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).~infusions will consist of the drug Nivolumab"
32849070|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drug Cetuximab"
32898793|NCT00258128|Placebo Comparator|Placebo|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
32959461|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
33406383|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
33406384|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
33406385|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
33406386|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
33406387|NCT05657639|Experimental|CAV regimen|
33406388|NCT05657639|Active Comparator|MEC regimen|
33406389|NCT05656625||group distal nerve block(DNB)|Radial, median and ulnar nerve blocks were used alone or in combinations as a method of anesthesia for patients who had undergone hand and wrist surgery.
32849071|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
32849072|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
32849073|NCT05740449|Experimental|sub-study A - Epigenetic approach|"Decitabine / Venetoclax and Navitoclax.~Each cycle lasts 28 days.~Cycle 1: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally, with a ramp-up dose on day 1 and navitoclax once a day, Day 3 - 28 orally depending on the weight of the patient (dose level 1).~Cycle 2: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally and navitoclax once a day, Day 1 - 28 orally depending on the weight of the patient (dose level 1).~Patients in dose level 2: will receive decitabine 20 mg/m2 intravenous once a day on 5 consecutive days (Day 1 - 5).~Patients in dose level -1: will receive venetoclax 200 mg adult equivalent dose, once a day, Day 1 - Day 28 orally.~All patients receive age adapted intrathecal chemnotherapy."
33104017|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
33104018|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
32849074|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
32849075|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
32849076|NCT05358249|Experimental|JDQ443+trametinib|JDQ443 in combination with trametinib
32849077|NCT05358249|Experimental|JDQ443+ribociclib|JDQ443 in combination with ribociclib
32849078|NCT05358249|Experimental|JDQ443+cetuximab|JDQ443 in combination with cetuximab
32849079|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
32849080|NCT03087799|No Intervention|Wait List Control|
32849081|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
32849082|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
32849083|NCT05738889||Group 1: Patients with fixed lingual retainers applied with Bis-GMA containing composite|In the maxilla and mandible, the lingual surfaces of the anterior six teeth, including the canines, were roughened and bonded by applying 37.5% phosphoric acid for 30 seconds. Then, the retainer wire was adhered to the lingual surfaces of the teeth between the canine-canines in the maxilla and mandible, where a fixed lingual retainer will be applied, with a flowable composite adhesive containing Bis-GMA, with 10 seconds of illumination for 60 seconds for each tooth.
32849084|NCT05738889||Group 2: Patients with fixed lingual retainers applied with Bis-GMA-free composite|The lingual surfaces of the anterior six teeth, including the canines, in the maxilla and mandible were roughened by the application of 37.5% phosphoric acid for 30 seconds. Since the applied composite system is one-stage, no additional bond application was done. Fixed lingual retainer wire was applied with a Bis-GMA-free flowable composite adhesive with 60 seconds exposure for 10 seconds for each tooth.
32849085|NCT05738889||Group 3: Patients with vacuum-formed retainers|Impressions were taken with alginate impression material from the maxilla and mandible of the volunteers whose treatment was completed, and a model was obtained with a hard cast. On the models obtained, vacuum formed retainers were prepared with a vacuum forming machine. The use and care instructions of vacuum formed retainers were explained to the patient orally. vacuum formed retainers were used by the patient for 22 hours.
32849086|NCT05738889||Group 4: Patients with hawley retainers|Impressions were taken with alginate impression material from the volunteers in the Hawley retainers group and a model was obtained with hard plaster. Wire elements were made on the model obtained and the appliance was prepared from transparent acrylic material. After the leveling and polishing processes were completed, the hawley retainers was attached to the mouth. It is stated that the appliance is used for 22 hours in 1 day. The use and care instructions of the Hawley retainers are explained to the patient.
32849087|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
33104019|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
33320188|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
33320189|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
32849088|NCT05349669|No Intervention|Conventional CPB|Elective cardiopulmonary bypass (CPB) procedures with an expected time >120 minutes for each extracorporeal procedure.
32849089|NCT05349669|Experimental|CPB with Jafron|Elective cardiopulmonary bypass (CPB) procedures with Jafron use with an expected time >120 minutes for each extracorporealprocedure.
32849090|NCT03483883|Experimental|Single Arm|
32849091|NCT05737875||Distal pancreatectomy|Patients who have undergone a distal pancreatectomy, retrospective analysis of post pancreatectomy fistula risk factors
32849092|NCT03482167|Placebo Comparator|Placebo|placebo
32849093|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
32849094|NCT04384185|Experimental|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
32849095|NCT04384185|Experimental|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
32849096|NCT03443323|Experimental|OST-S Intervention group|
32849097|NCT03443323|No Intervention|Treatment as usual control group|
32849098|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
32849099|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
32849100|NCT05737797|Experimental|Endometrial cancer patients|Endometrial cancer patients Cervical cytology during surgical intervention.
32849101|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
32849102|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
32849103|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
32849104|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
32849105|NCT03439423||Patients who underwent EVAR|
33406390|NCT05656625||group brachial plexus block(BPB)|Brachial plexus blocks (infraclavicular, axillary etc.) was applied to patients who were going to undergo hand and wrist surgery.
32849108|NCT03439267|Active Comparator|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
32849109|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
32849110|NCT05737017|Experimental|The ClearCoajet group|During the endoscopic resection procedures, the ClearCoajet will be used for injection and initial hemostasis for intraprocedural bleeding.
32849111|NCT05737017|Active Comparator|The control group|During the endoscopic resection procedures, the conventional injector will be used for injection.
32849112|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
32849113|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
32849114|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
32849115|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
32849116|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
32849117|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
32849118|NCT05317065|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
32849119|NCT05317065|No Intervention|Control|Control
32849120|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
32849121|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
32849122|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
32849123|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
32849124|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
32849125|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
32849126|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
32849127|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
32849128|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
32849129|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
32849130|NCT00789867|Experimental|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
32849131|NCT00789867|Experimental|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
32959462|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
32959463|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
33406391|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
33406392|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
33406393|NCT03639077|Experimental|Allograft bone alone|
33406394|NCT03639077|Experimental|Allograft and xenograft mixture|
33406395|NCT03417245|Experimental|Factor On-demand|Participants received on-demand factor concentrates (as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion for the treatment of breakthrough bleeding episodes from Day 1 up to a total of 9 months.
33406396|NCT03417245|Experimental|Fitusiran 80 mg Prophylaxis|Participants received open-label fitusiran 80 milligram (mg) administered subcutaneously (SC) as prophylaxis once monthly from Day 1 up to a total of 9 months. Participants received on-demand factor concentrates (per investigator's discretion and within bleeding dosing guidelines) for the treatment of breakthrough bleeding episodes.
33406397|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
33406398|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
32849132|NCT00789867|Experimental|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
32849133|NCT04384653|Experimental|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
32849134|NCT04384653|Experimental|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
32849135|NCT02648724|Experimental|Part 1: 6 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.
32849136|NCT02648724|Experimental|Part 1: 12 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 12 mg/kg. A substitute or an additional dose level could potentially be evaluated.
32849137|NCT02648724|Experimental|Part 1: 18 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 18 mg/kg. A substitute or an additional dose level could potentially be evaluated.
32849138|NCT02648724|Experimental|Part 1: 24 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 24 mg/kg. A substitute or an additional dose level could potentially be evaluated.
32849139|NCT02648724|Experimental|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.
32849140|NCT02648724|Experimental|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification were to receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
32849141|NCT02648724|Experimental|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
32849142|NCT05308953|Experimental|NVG-291 SAD|Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.
32849143|NCT05308953|Experimental|NVG-291 MAD|Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.
32849144|NCT05308953|Experimental|NVG-291 MAD - Males and Premenopausal Females|Participants will receive 1 dose daily for for 14 consecutive days. The dose maximum daily dose in Part 3 will not exceed the maximum daily dose tolerated in either Part 1 or 2.
32849145|NCT05291637||Medical management cohort|Patients who have undergone medical management stroke treatment from 1/01/2003 to 01/01/2022; this could include intravenous thrombolysis.
32849146|NCT05291637||EVT management cohort|Patients who have undergone EVT stroke treatment from 01/01/2015 to 01/01/2022
32849147|NCT04199130|Experimental|Intervention Group 1|This arm will receive BrainHQ for the first four weeks of the study, and Goal Management Training for the second four weeks.
32849148|NCT04199130|Experimental|Intervention Group 2|This arm will receive Goal Management Training for the first four weeks of the study, and BrainHQ for the second four weeks.
32849149|NCT04199130|No Intervention|Treatment-as-usual|
32849150|NCT04487028||Thoracic Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
32849151|NCT04113720|Experimental|Group A|children will receive levobupivacaine 0.25% by peritonsillar infiltration after intubation 3- 5 min before the start of surgery.
32849152|NCT04113720|Active Comparator|Group B|children will receive levobupivacaine 0.25% plus dexmedetomidine 1µg/kg diluted in 4 ml saline 0.9% and given by peritonsillar infiltration (2 ml per tonsil), after intubation 3- 5 min before the start of surgery.
32849153|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
32849154|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
32898794|NCT01364623|Experimental|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
33406399|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
32849155|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
32849156|NCT04449744|Active Comparator|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
33104020|NCT04656951|Experimental|Daratumumab added to VCd in induction, Vd in maintenance and Rd at relapse|"Daratumumab at standard dose of 1800 mg will be administered subcutaneously at weekly intervals in cycles 1-2 and every 2 weeks in cycles 3-6 and every 4 weeks in cycles 7-8 together with VCD using bortezomib weekly s.c. for 8 cycles of 28 days each, cyclophosphamide i.v. at 500 mg/m2 on d1 of every cycle and dexamethasone p.o. at 20 mg per week.~Maintenance will be daratumumab subcutaneously every 4 weeks with bortezomib s.c. and dexamethasone 20 mg every 2 weeks until progression or intolerance.~At relapse/progression treatment will be daratumumab 1800 mg subcutaneously weekly during cycle 1-2, every 2 weeks in cycle 3-6 and every 4 weeks thereafter together with lenalidomide 25 mg p.o. day 1-21 and dexamethasone 20-40 mg weekly."
33104021|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
33104022|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
33104023|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
33104024|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
33104025|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
33104026|NCT04268147||FA Controls|Healthy, age-matched controls
33104027|NCT04268147||SCA Controls|Healthy, age-matched controls
33406400|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
32849157|NCT04449744|Experimental|MySafeRx Group B-(coaching + dispenser based on clinical need)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a manual lockbox, and a standardized protocol for supervising self-administration of medication via videoconferencing. Participants will be assessed bi-weekly by their clinical team for substance abuse, coaching and medication adherence, compliance with urine drug screen policies, safety/ risk or mental health concerns, and diversion. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study.
32849158|NCT04374084|Experimental|Moxibustion plus Cupping|"Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas:~A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6)."
32849159|NCT04374084|No Intervention|Basic therapy|Basic therapy: rehabilitation direction and basic breathing exercise.
32849160|NCT04142424|Experimental|Cohort 1 healthy subjects: AZD2693 Dose 1|Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849161|NCT04142424|Experimental|Cohort 2 healthy subjects: AZD2693 Dose 2|Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849162|NCT04142424|Experimental|Cohort 3 healthy subjects: AZD2693 Dose 3|Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849163|NCT04142424|Experimental|Cohort 4 healthy subjects: AZD2693 Dose 4|Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849164|NCT04142424|Experimental|Cohort 5 healthy subjects: AZD2693 Dose 5|Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849165|NCT04142424|Experimental|Cohort 6 healthy subjects: AZD2693 Dose 6|Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1.
33104028|NCT00537186|Other|1|Iron oligosaccharide
33104029|NCT04255160|Experimental|Estradiol|Transdermal estradiol (0.1mg/day patch)
33104030|NCT04255160|Placebo Comparator|Placebo|Placebo
33104031|NCT04251260|Experimental|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
33104032|NCT04251260|No Intervention|Control group|No intervention
33104033|NCT04244786|Active Comparator|active anodal tDCS to ventrolateral prefrontal cortex (VLPFC)|1.5 milliamp (mA) anodal tDCS over right ventrolateral prefrontal cortex; 20-minutes, 6-sessions
33104034|NCT04244786|Sham Comparator|sham anodal tDCS to VLPFC|Identical electrode montage, sham tDCS over 6 sessions.
33104035|NCT04642014|Experimental|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
33104036|NCT04234334|Experimental|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
33104037|NCT04234334|Experimental|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
32849166|NCT04142424|Experimental|Cohort 7 healthy Japanese subjects: AZD2693 Dose 7|Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849167|NCT04142424|Experimental|Cohort 8 healthy Japanese subjects: AZD2693 Dose 8|Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1.
32849168|NCT04142424|Experimental|Cohort 9 healthy Chinese subjects: AZD2693 Dose 9|Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1.
33406401|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
32849169|NCT03930342|Experimental|Native CHOICES Intervention|Native-CHOICES will comprise usual care plus 2 MI sessions delivered over 4 weeks; a contraception counseling session at a local clinic; and 3 months of electronic messaging to boost the effects of MI and counseling by increasing perceptions of social connection and social support for behavior change. Contraception counseling will be completed within 2 weeks after the second MI session, so the maximum duration of MI and counseling for each participant will be 6 weeks. Electronic messaging will include positive motivational content consistent with alcohol and contraception use goals set in the MI sessions.
32849170|NCT03930342|No Intervention|Wait-list Control Group|The control condition will comprise usual care for the 6-month study period, with a wait-list design that offers women the Native- CHOICES program after they have completed the 6-month data collection.
32849171|NCT04493892|Experimental|Educational Intervention|All participants receive educational information on the potential health risk of endocrine disruptor chemicals in hair care products, specifically phthalates. Provide information on how to reduce exposure.
32849172|NCT03926910|Experimental|VESAP|patient receiving stimulation test to detect hypovolemia
32849173|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
32849174|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
32849175|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
32849176|NCT04215120|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
32849177|NCT04215120|Experimental|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
32849178|NCT00081289|Experimental|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m^2/day 5 days/week during RT, and irinotecan 50 mg/m^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
32849179|NCT00081289|Experimental|Neoadjuvant chemoradiation with oxaliplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m^2/day 5 days/week during RT, and oxaliplatin 50 mg/m^2 IV for 2 hours days 1, 8, 15, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
32849180|NCT03917160|Experimental|EMS treatment|Subjects will undergo treatment with EMS and measurements
32849181|NCT03917160|No Intervention|Control|Subjects will undergo measurements only
32849182|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
32849183|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
32849184|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
32849185|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
32849186|NCT03815916|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
32849187|NCT03815916|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
32849188|NCT03815916|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
32849189|NCT03815916|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
32849190|NCT03859128|Active Comparator|Group A|TORIPALIMAB 240mg ,Q3W, up to 16 Weeks
32849191|NCT03859128|Placebo Comparator|Group B|Placebo 240mg Q3W, up to 16 Weeks
32959464|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
32849192|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
32849193|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
32849194|NCT03873870|Experimental|68Ga -DOTATATE PET scan|
32849195|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
32849196|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
32849197|NCT05202522|No Intervention|Control Group|During the study. participants in the control group will not receive the virtual GERAS DANCE intervention. However, they will receive the virtual GERAS DANCE intervention following study completion for equal opportunity to participate in the program.
32849198|NCT05202522|Experimental|Virtual GERAS DANCE Group|Virtual GERAS DANCE will be delivered for 1-hr twice weekly for 6 weeks.
32849199|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
32849200|NCT03479827||Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
32849201|NCT03389022|Active Comparator|Treatment1|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
32849202|NCT03389022|Active Comparator|Treatment2|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
32849203|NCT03389022|Active Comparator|Treatment3|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
32849204|NCT03389022|Placebo Comparator|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
32849205|NCT03389022|Active Comparator|Treatment4|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
32849206|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
32849207|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
32849208|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
32849209|NCT03715686|Experimental|Wire localization|Intervention: procedure: wire localization
32849210|NCT03694938|Experimental|Magnetic resonance imaging|Annual MRI during 3 years
32849211|NCT00080899|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
32849212|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
32849213|NCT03518736|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
32849214|NCT03518736|Experimental|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
32849215|NCT03518736|Experimental|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
32849216|NCT03714516|Experimental|Online psychological intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
32849217|NCT04987398||Intubation for respiratory reasons|All patients who were intubated for respiratory reasons (i.e. acute respiratory distress syndrome, pneumonias, pleural effusions for example)
32849218|NCT04987398||Intubation for neurological reasons|All patients who were intubated for neurological reasons (i.e. stroke, intracranial bleeding, cervical fracture with tetraparesia for example)
32849219|NCT04987398||Intubation for other reasons|All patients who were intubated for other reasons than respiratory or neurological (i.e. intubation before surgery, cardiac arrest, hemodynamic instability and polytraumatism without respiratory distress or neurological pathology necessitating intubation)
32849220|NCT03320226|Other|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
32849221|NCT03259698|Experimental|ARM 1 = TEXT MESSAGING SUPPORT|"PEP will be delivered by ID physician and participants will receive weekly text message check-ins and optional automated text appointment reminders via the WelTel system."
32849222|NCT03259698|Experimental|ARM 2 = NO TEXT MESSAGING SUPPORT|"PEP will be delivered according to the standard of care by an infectious diseases physician. Participants will not receive text message reminders or check-in."
32849223|NCT03259698|Experimental|ARM 3 = NURSE-LED nPEP|PEP will be delivered by a sexual health clinic nurse operating under a medical directive.
32849224|NCT03259698|Active Comparator|ARM 4 = ID PHYSICIAN-LED nPEP,|PEP will be delivered according to the standard of care by an infectious diseases physician.
32849225|NCT02576184|Experimental|Biologic Mesh|Biologic mesh placed in retromuscular position
32849226|NCT02576184|Experimental|Synthetic Mesh|Synthetic mesh placed in retromuscular position
32849227|NCT02576184|No Intervention|No Mesh|No mesh
32849228|NCT00089635|Experimental|Panitumumab|Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.
32849229|NCT03445728|Experimental|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
32849230|NCT03445728|Placebo Comparator|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
32849231|NCT02795520|Experimental|OTS167IV|
32849232|NCT03435835|Experimental|Sham, then heat therapy|Participants were fitted with liquid-circulating trousers. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States). At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the heat therapy (HT) treatment. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC.
32849233|NCT03435835|Experimental|Heat therapy, then sham|Participants were fitted with liquid-circulating trousers. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC. At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the sham treatment. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States).
32849234|NCT03159000|Experimental|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
32849235|NCT03159000|Placebo Comparator|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
32849236|NCT00086671|Experimental|ABT-874 200 mg weekly|
32849237|NCT00086671|Placebo Comparator|Placebo|
32849238|NCT00086671|Experimental|ABT 874 QOW|
32849239|NCT02464878|Other|Main study treatment|
32849240|NCT02010606|Experimental|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
32849241|NCT02010606|Experimental|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
32849242|NCT00084253|Active Comparator|1|
32849243|NCT00084253|Active Comparator|2|
32849244|NCT03054792|Experimental|FAZA - BOLD- DW- MRS|"18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg [0.14 mCi/kg]) Route/method of administration: intravenous injection.~Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, MR Spectroscopy [MRS]"
32849245|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
32849246|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
32849247|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
32849248|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
32849249|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
32849250|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
32849251|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
32849252|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
32849253|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
32849254|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
32849255|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
32849256|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
32849257|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
32849258|NCT01678339||1|
32849259|NCT02951364||LDV/SOF|Adult Korean participants and pediatric Korean participants aged 12 to <18 years with genotype 1, 2, 4, 5, and 6 chronic HCV infection who are initiating commercial Harvoni regimen
32849260|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
32849261|NCT01500200|Experimental|ALKS 5461|
32959465|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
32849262|NCT01500200|Placebo Comparator|Placebo|
32959466|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
32849263|NCT00083941|Experimental|TroVax and IL-2|TroVax: Intramuscular into the deltoid muscle of the upper arm, 10x dose (6.83 x 108 pfu/ml). IL 2: High dose IL 2, 600,000 IU/kg intravenously every 8 hours up to a maximum of 15 injections.
32849264|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
32849265|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
32849266|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
32849267|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
32849268|NCT04969848||eMSGait|Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.
32849269|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
32849270|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
32849271|NCT01512810|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
32849272|NCT01512810|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
32849273|NCT05131932|Experimental|Inlet patch|Patients found to have an inlet patch on upper endoscopy
32849274|NCT05131932|No Intervention|Controls|Patients without an inlet patch on upper endoscopy
32849275|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
32849276|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
32849277|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
32849278|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
32849279|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
32849280|NCT01678651|Active Comparator|Human FSH|Human FSH
32849281|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
32849282|NCT04684446|Experimental|Arm 1|AZD1222 on Day 1 followed by rAd26-S on Day 29
32849283|NCT04684446|Experimental|Arm 2|rAd26-S on Day 1 followed by AZD1222 on Day 29
32849284|NCT03084523|Experimental|1|80 patients with intracranial atherosclerosis
32849285|NCT04094090|Experimental|Pulsed, accelerated|4 mW, 10-15 sec on, 10-15sec off, 45 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
32849286|NCT04094090|Experimental|Pusled, accelerated|8 mW, 10-15 sec on, 10-15 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
32849287|NCT04670796|Experimental|HLX02|patient receive one dose of HLX02
32849288|NCT04670796|Active Comparator|EU-sourced Trastuzumab (Herceptin®)|patient receive one dose of EU-sourced Trastuzumab (Herceptin®)
32849289|NCT04670796|Active Comparator|US-licensed Trastuzumab (Herceptin®)|patient receive one dose of US-licensed Trastuzumab (Herceptin®)
32849290|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
32849291|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
32849292|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
32849293|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
32849294|NCT04626570|Experimental|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
32849295|NCT04626570|No Intervention|Management as usual|management of obesity with nutritional and dietary treatment as usual
32849296|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
32849297|NCT04493736||Case|Any person receiving services from a mental health provider who is able to either consent or for whom parental consent is able to be obtained.
32849298|NCT05130918|Experimental|Phenolmicin P3 and Bosexil|Group in which patients were administered Phenolmicin P3 and Bosexil suppositories twice a day for 5 days, then once a day for other 10 days after thulium laser enucleation of prostate was performed.
32849299|NCT05130918|No Intervention|Controls|Group in which patients were not administered Phenolmicin P3 and Bosexil suppositories after thulium laser enucleation of prostate was performed.
32898795|NCT01364623|Experimental|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
32849300|NCT04402021|Experimental|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
32849301|NCT04402021|Other|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
32849302|NCT02525796|Placebo Comparator|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
32849303|NCT02525796|Active Comparator|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
32849304|NCT02525796|Experimental|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
32849305|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
32849306|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
32849307|NCT01019616|Experimental|Chemotherapy|
32849308|NCT01019616|No Intervention|Control|
32849309|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
32849310|NCT00735384||Patients with critical illness myopathy|Patients with,e.g., sepsis, with secondary myopathy
32849311|NCT00735384||Patients with Primary Myopathies|Patients with primary myopathy, e.g., Duchenne Muscular Dystrophy, Myotonia
32849312|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
32849313|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
32849314|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
32849315|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
32849316|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
32849317|NCT04492020|Experimental|Treatment Sequence A|Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
32849318|NCT04492020|Experimental|Treatment Sequence B|Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
32849319|NCT04275973|Other|Healthy controls|The Control participants are for methods development and do not constitute a formal study group
32849320|NCT04275973|Experimental|Prosthesis user with transtibial or transfemoral amputation|Experiments will use standard commercially available prostheses for participants with lower-limb amputation. Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
32849321|NCT04275973|Experimental|Orthoses user with drop-foot|"This arm will consists of participants with drop-foot. A subset of the drop-foot population will be persons with Multiple Sclerosis and currently drop-foot.~For participants in this arm, standard commercially-available orthoses or standard-of-care custom orthoses will be used, as well as standard commercially-available electrical stimulation neuro-orthoses."
32849322|NCT04761445|Experimental|Straumann Standard Plus (SP)|Patients receiving Straumann SP implants of 4.1 mm in diameter and length of 10 mm.
32849323|NCT04761445|Experimental|JDental care Octa (JD Octa)|Patients receiving JD Octa implants of 4.3 mm in diameter and 10 mm in length.
32849324|NCT05136768|Experimental|Single arm|Sintilimab combined with platinum-based chemotherapy and SBRT
32849325|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
32849326|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
32849327|NCT05136612|Experimental|control grup|conventional physiotherapy
32849328|NCT05136612|Experimental|intervention group|Armeo spring robotic rehabilitation
32849329|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
32849330|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
32849331|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
32849332|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
32849333|NCT05136534|Experimental|group A|subarachnoid anesthesia wit hyperbaric prilocaine
32849334|NCT05136534|Active Comparator|group B|local anesthesia + mild sedation
32849335|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
32849336|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
32849337|NCT05136378|No Intervention|Control Arm|Wait and Watch.
32849338|NCT05136378|Experimental|Low Dose Selenious Yeast|Receive 200μg Selenious Yeast per day.
32849339|NCT05136378|Experimental|High Dose Selenious Yeast|Receive 400μg Selenious Yeast per day.
32849340|NCT04271449|Experimental|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
32849341|NCT04271449|Experimental|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
32849342|NCT04271449|Sham Comparator|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
32849343|NCT05135832|Experimental|Patient-reported outcomes arm (experimental arm)|"This arm will be assigned to intervention by weekly electronic reporting of symptoms and side effects in an app. A specifically developed alert-algorithm will in real-time guide the patient to adjust supportive care or contact the hospital.~The reported symptoms are sent to the hospital to a healthcare professional - depending on the severity of the reported symptoms the healthcare professional can schedule a visit at the clinic.~The patient will also receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) including the Physical Function domain in the app each month.~Patient satisfaction regarding the patient-reported outcomes will be measured with the validated Patient-Reported Experience Measurement questionnaire at termination of participation."
32849344|NCT05135832|No Intervention|Standard of care|"This arm will continue standard procedure regarding side effect registration and handling.~The patients will receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QOL-C30) at baseline, after 1, 3, and 6 months of participation in the study."
32849345|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
32849346|NCT05135598|Experimental|Health behavior change intervention|Participants will receive a pedometer, workbook, partner, and 15 weekly phone group meetings.
32849347|NCT05135520|Active Comparator|Transabdominal specimen extraction|The outcomes of transabdominal specimen extraction in a classic way in patients who underwent multiport laparoscopic surgery for resection of kidney
32849348|NCT05135520|Experimental|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of kidney
32849349|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
32849350|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
32849351|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
32849352|NCT04270045||Single|Non-invasive forced airway oscillometry. Normative data will be established form term neonates without pulmonary disease
32849353|NCT05138016|Experimental|Exercise testing with soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill with soft exosuit assistance.
32849354|NCT05138016|Active Comparator|Exercise testing without soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill.
32849355|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
32849356|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
32849357|NCT05135442|Experimental|bortezomib group|On the basis of standard single membrane plasma exchange (2L/d) and hormone therapy (1mg/kg prednisone or equivalent methylprednisolone), bortezomib was given intravenous injection of 1.3mg/m2 d1, 4, 8, 11 (total 4 doses).
32849358|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
32849359|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
32849360|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
32849361|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
32849362|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
32849363|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
32849364|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
32849365|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849366|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
32849367|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
32849368|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
32849369|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
33406402|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
33406403|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~Hydrocortisone 50mg every 6 hours x 4-days"
33406404|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
33406405|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
33406406|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
33406407|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
33406408|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
33406409|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
33406410|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
33406411|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
33406412|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
33406413|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
33406414|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
33406415|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
33406416|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
33406417|NCT05677932|Experimental|Bright light therapy|10,000lux bright light
33406418|NCT05677932|Experimental|Placebo group|50 lux dim red light
32959467|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
32959468|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
33406419|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
33406420|NCT03395405|Experimental|Nitazoxanide (500 mg)|"A single 500 mg tablet of nitazoxanide administered orally twice daily with food for 56 consecutive doses over 28 days.~Nitazoxanide: a synthetic antiprotozoal agent, chemically designated as 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide. Nitazoxanide will be supplied as 500 mg round, yellow, film-coated tablets."
33406421|NCT03395405|Placebo Comparator|Placebo|"A single matching placebo tablet administered orally twice daily with food for 56 consecutive doses over 28 days.~Placebo: a round, yellow, film-coated tablet with the same inactive ingredients as the nitazoxanide tablet. The placebo tablet will be formulated for the same appearance as nitazoxanide."
33406422|NCT05492825|Experimental|Yoga|Participants in the yoga group will receive a manualized intervention of 12 weekly, group-based, 60-minute yoga classes, and guided home practice.
33406423|NCT05492825|Experimental|Physical Therapy|Participants in the PT group will receive a manualized intervention of 12 weekly, individual, 60-minute PT sessions, with home practice, based on the Saper protocol.
33406424|NCT05492825|Other|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians.
33406425|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
33406426|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
33406427|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
32959469|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
33104039|NCT00552890|Experimental|ATK|modified Atkins diet
33406428|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
33406429|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
32959470|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
33104040|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
32849370|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
32959471|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
33406430|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
33406431|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
33406432|NCT05467553|Experimental|TAF and P1101 combination therapy with UDCA|Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
32849371|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849372|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
32849373|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849374|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849375|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849376|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
32849377|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849378|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849379|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
32849380|NCT05130684|Experimental|Neo-CRT|"Nivolumab 240 mg, 30-min IVF, Q2W on days -14, 1, 15, and 29;~Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8, 15, 22, and 29;~Cisplatin 30 mg/m2,1h-IVF,on days 1, 8,15, 22, and 29;~RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
32849381|NCT04402411|Active Comparator|Control Group|Patients will receive general anesthesia with intravenous opioid
32849382|NCT04402411|Experimental|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
32849383|NCT04402411|Experimental|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
32849384|NCT05135364|Experimental|Camrelizumab+HAIC+TKI*|*For patients who have not received molecular targeted therapy in the past, lenvatinib is recommended; For patients who have received sorafenib or lenvatinib in the past, regorafenib is recommended.
32849385|NCT03089515|Active Comparator|Healthy Controls|
32849386|NCT03089515|Experimental|Survivors|
32849387|NCT05265507|Experimental|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
32849388|NCT05265507|Active Comparator|Ondansetron|Ondansetron (4mg) was intravenously given at the ending of the surgery.
32849389|NCT05130372|Active Comparator|Static Stretching Group|The static stretching method was actively applied while standing.The person was positioned facing the wall, supporting the wall with both hands, with the dominant foot behind. The point where a feeling of tension in the plantar flexor muscles was created and held in this position for 30 seconds. Afterward, a 15-second rest break was given. After completing 3 repetitions (3x30sec) in total, measurements were started.
32849390|NCT05130372|Active Comparator|PNF Stretching Method Group|The person was positioned supine, and the ankle joint was dorsiflexed by the physiotherapist to the point where the tension was felt. Then, while the person was trying to push the foot towards the plantarflexion direction for 10 seconds, the movement was prevented by the physiotherapist and isometric contraction was achieved at 20% of the maximum voluntary contraction. After 10 seconds, the person was asked to relax slowly and passive stretching was applied to the plantar flexors for 20 seconds. The contract-relax technique was applied for 30 seconds and completed with 3 repetitions (3x30sec) with 15-second rest intervals.
32849391|NCT05130372|Active Comparator|Myofascial Relaxation Method Group|A comfortable position was achieved by placing a rolled towel on the front of the ankle. The roller was massaged along with the plantar flexors for 30 seconds. The movement of the cylinder from bottom to top and from top to bottom was done for a second. Three repetitions were completed (3x30sec) with a 15-second rest break. For the pressure of the roller to be stable during the application, the numbered pain scale was shown to the participants, and attention was paid to ensure that the perceived severity was 7/10 according to the numbered pain scale. Participants with dry skin in the application area were asked to moisturize with cream beforehand to avoid complications.
32849392|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
32849393|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
32849394|NCT05135286|Experimental|BRIMOCHOL™ PF|A single drop in each eye at a visit.
32849395|NCT05135286|Active Comparator|Carbachol PF|A single drop in each eye at a visit.
32849396|NCT05135286|Placebo Comparator|Vehicle|A single drop in each eye at a visit.
32849397|NCT05260203|Experimental|App RITA|The interventional study group will use the Device Rita, an application that allow the oncological and onco-hematological patients to receive and communicate information about the quality of life and about the treatment related adverse events, providing a support in the therapy management. The access to the app functionalities is granted when the physician habilitates the personal profile. The app can be also used from people designated from the patient as caregiver, who can view the data inserted by the patient and, if enabled, they can insert the data for the patient.
32959472|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
32849398|NCT05260203|No Intervention|Retrospective Historical|This clinical trial has no control intervention; on the other hand, the clinical outcomes of this treatment will be compared with the retrospective clinical data obtained from a historical group of comparison. The historic control used in this clinical trial is specifically selected to reflect the endpoints. According to a feasibility phase of this study, the information on the date of start and end of treatments is routinely collected in the medical records of patients, and for this reason, these data are potentially already available for the historical control group.
33406433|NCT05467553|Active Comparator|TAF and P1101 combination therapy without UDCA|TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
33406434|NCT03387059|Experimental|Forielle Endometrial Washing|
32849399|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
32849400|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
32849403|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
32849404|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
32849405|NCT05134896|Experimental|normal healthy group|Spatial light modulator
32849406|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
32849407|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
32849408|NCT05137470||Newly HD patients|Newly admitted patients with uremia who started hemodialysis treatment
32849409|NCT05137470||MHD patients|Maintenance hemodialysis patients
32849410|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
32849411|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
32849412|NCT05710575|Experimental|probiotic group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
32849413|NCT05710575|Experimental|placebo group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
32849414|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
32849415|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
32849416|NCT05136924|Experimental|OC-01|(varenicline 1.2mg/ml) nasal spray
32849417|NCT05136924|Placebo Comparator|Placebo|(vehicle) nasal spray
32849418|NCT05255679|Experimental|Early FES|Receives standard care plus FES cycling in Phase 1 (starting 14 to 21 days after injury and for 3 months) and Phase 2 (from month 3 to month 6 after enrollment).
32849419|NCT05255679|Experimental|Delayed FES|Receives standard care only in Phase 1 (considered Control group in Phase 1), and standard care plus FES cycling in Phase 2 (from month 3 to month 6 after enrollment).
32849420|NCT05255679|No Intervention|Control|Receives standard care only
32849421|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
32849422|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
32849423|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
32849424|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
32849425|NCT05134818|Experimental|group OT +|In this group (OT +), the resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
32849426|NCT05134818|No Intervention|group OT-|In this group (OT-), the resident will not use the observer tool and will observe other residents to insert a CVC on the simulator without any physical support.
32849427|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
32849428|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
33406435|NCT03387059|No Intervention|No Endometrial Washing|
32849429|NCT05134506|Experimental|Dance for PD® classes|Dance for PD® was developed by the Brooklyn Parkinson Group (BPG) in collaboration with the Mark Morris Dance Group (MMDG) in 2001. It was designed to introduce people with PD to techniques used by dancers to control movement and it integrates different dance genres while participants dance individually and in groups rather than partnered.
32849430|NCT05115240|Experimental|Audio-guided mindfulness-based intervention (body scan)|
32849431|NCT05115240|Experimental|Enhanced Audio-guided mindfulness-based intervention (body scan)|Participants undergo the same audio-guided body scan intervention. However, in this arm the instruction focuses on the positive effects of mindfulness-based interventions and body scan aiming to optimize participants' interventions outcome expectations of the intervention. The idea of this arm is to assess whether the effects of the mindfulness-based intervention can be augmented by boosting participants positive expectations prior to the intervention.
33406436|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
33406437|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
32849432|NCT05115240|Active Comparator|Audio-Book|Participants in this group listen to an audio-book for the same duration as the participants in the two experimental groups.
32849433|NCT05066646|Experimental|CT103A in relapsed and refractory multiple myeloma patients|CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
32849434|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
32849435|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
32849436|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
32849437|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
32849438|NCT05123508|Experimental|Treatment Arm|2940nm laser and BBL treatment
32849439|NCT05123508|Experimental|Control Arm|One side of the treatment area will act as a control. No treatment on the control side.
32849440|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
32849441|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
32849442|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
32849443|NCT05301660|Experimental|Experimental group|People with schizophrenic disorders: receiving nicotine transdermal patches.
32849444|NCT05301660|Placebo Comparator|Control group|People with schizophrenic disorders: receive placebo treatment.
32849445|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
32849446|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
32849447|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
32849448|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
32849449|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
32849450|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
32849451|NCT05621031|Experimental|PDExperimental|This group will receive usual care (physical therapy) and whole body vibration sessions.
32849452|NCT05621031|Active Comparator|PDControl|This group will receive usual care (physical therapy) and placebo whole body vibration session.
32849453|NCT05105490||Chronic Discogenic Low Back Pain|"Patient is skeletally mature and between 21 and 60 years of age.~Patient has Degenerative Disc Disease (DDD) at one or more levels~between L1 and S1 but must have a single level identified as the pain generator.~Patient has adequate disc height (6mm) at the level to be treated~Patient is not responsive to conservative, non-surgical treatment for back pain."
32849454|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
32849455|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
32849456|NCT03084835|Active Comparator|UC|Usual Care
32849457|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
32849458|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
33406438|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
33406439|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
33406440|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
33406441|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
32849459|NCT04767035|Active Comparator|MELT-100 3/25|MELT-100 3mg midazolam / 25 mg ketamine
32849460|NCT04767035|Active Comparator|MELT-100 2 x 3/25|MELT-100 2 doses of 3mg midazolam / 25mg ketamine
32849461|NCT04767035|Active Comparator|ketamine IV 18mg|
32849462|NCT04767035|Active Comparator|Midazolam IV 3.5mg|
32849463|NCT05125614||Developement set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at Seoul St.Mary's Hospital
32849464|NCT05125614||Validation set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at St.Vincent''s Hospital
32849465|NCT04402177|Experimental|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
32849466|NCT04402177|Active Comparator|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
32849467|NCT05229705|Experimental|Resistance exercise|Exercises will be completed in Kevin Shoemaker's (Co-I) exercise lab in the Health Sciences Building. Participants will use the programmable weight machines along with free weights to target the primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. We will record the number of sets completed and the load lifted for each exercise for each participant at every class.
32849468|NCT05229705|No Intervention|Control (balance and tone exercise)|Exercises will be completed in the Health Science Exercise lab. These will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation (Liu-Ambrose et al., 2010; Liu-Ambrose et al., 2012; Nagamatsu et al., 2012; Nagamatsu et al., 2013).
32849469|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
32849470|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
32849471|NCT05227599|Other|Daily Diary Method Cohort|"Participants will be asked to complete a self-report questionnaire that has been validated to assess daily affect. There are 5 items assessing positive affect (joyful, cheerful, happy, lively, proud) and 5 items assessing negative affect (miserable, mad, afraid, scared sad). The respondent is asked to rate these 10 different feelings on a 5-point Likert scale from 1, not much or not at all to 5, a lot."
32849472|NCT05073900|Experimental|Rhomboid intercostal block|Ultrasound guided rhomboid intercostal block
32849473|NCT05073900|Active Comparator|Erector spinae plane block|Ultrasound guided erector spinae plane block
32849474|NCT05222529|Experimental|Glycopyrronium 25μg|Glycopyrronium 25μg for two weeks
32849475|NCT05222529|Experimental|Glycopyrronium 12.5μg|Glycopyrronium 12.5μg for two weeks
32849476|NCT05222529|Placebo Comparator|Placebo|Placebo for two weeks
32849477|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
32849478|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
32898796|NCT01364623|Experimental|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
32849479|NCT05293314||Patients with bronchiectasis|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of haemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualisation of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
32849480|NCT05293314||Healthy control group|Control group is healthy participants.
32849481|NCT03803163|Experimental|TransCon Treprostinil|
32849482|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
32849483|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
32849484|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
32849485|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
32849486|NCT05071170||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
32849487|NCT05287308|Experimental|AC followed by albumin-bound paclitaxel|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by albumin-bound paclitaxel for 4 cycles.
32849488|NCT05287308|Active Comparator|AC followed by taxanes|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by paclitaxel or docetaxel for 4 cycles.
32849489|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
32849490|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
32849491|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
32849492|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
32849493|NCT04491396|Other|GYYB|This is a single-arm pre-post design.
32849494|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
32849495|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
32849496|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
32849497|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
32849498|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
32849499|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
32849500|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
32849501|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
32849502|NCT05346211|Experimental|Curcumin Single|"The Single dose group will consume 1 placebo sachet and one curcumin sachet per day.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
32849503|NCT05346211|Experimental|Curcumin Double|"The double dose group will consume two sachets per day of curcumin.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
32849504|NCT05346211|No Intervention|Placebo|"Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Participants will consume two sachets per day.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
32849505|NCT05694897|Active Comparator|Erector spinae block using a combination of bupivacaine and magnesium sulfate|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 3.75ml magnesium sulfate for treatment of postoperative pain
32849506|NCT05694897|Active Comparator|Erector spinae block using a combination of bupivacaine and dexmedetomidine|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 1ug/kg dexmedetomidine for treatment of postoperative pain
32849507|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
32849508|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
32849509|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
32849510|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
32849511|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
32849512|NCT04576494|Experimental|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
32849513|NCT05212233||Patients with MM and/or CLL|This is a non-interventional study. All enrolled patients will complete a telephone interview. A subset of patients will complete the optional follow-up interview. The clinical practice sites through which patients are being recruited and enrolled on to the study will each complete the Site Survey. Physicians at these sites who treat patients with MM or CLL will be invited to complete the Physician Survey.
32849514|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
32849515|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
32849516|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
32849517|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
32849518|NCT05306106|Other|Glucose|The control product, said to be the reference product, is an oral solution of 50 g of glucose.
32849519|NCT05306106|Other|a truffle match|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849520|NCT05306106|Other|a hazelnut chocolate cookie|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849521|NCT05306106|Other|a Paris Brest style eclair|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849522|NCT05306106|Other|a hazelnut chocolate finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849523|NCT05306106|Other|a lemon finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849524|NCT05306106|Other|a elderflower madeleine|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
32849525|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
32849526|NCT03831789|Experimental|Bilateral cerebellar rTMS|
32849527|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
32849528|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
32849529|NCT05205993|Experimental|Intrauterine infusion of antibiotics|Thirty women will receive only intrauterine infusion of antibiotics for 30 days.
32849530|NCT05205993|Experimental|Combination of intrauterine infusion and oral administration of antibiotics|Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.
32849531|NCT05205993|Active Comparator|Oral administration of antibiotics|Thirty women will receive only oral administration of antibiotics for 30 days.
32849532|NCT04585776|Experimental|LY900014 + Insulin Degludec|LY900014 (100 units/milliliter (U/mL)) is a prandial insulin administered subcutaneously (SC) 0-2 minutes before meals. Insulin degludec (100 U/mL) is a basal insulin administered once daily SC. Participants received individually adjusted insulin doses during the 35-day titration period. The target glucose values were: fasting glucose 80-110 milligrams per deciliter (mg/dL), overnight glucose excursion (the difference between bedtime and prebreakfast glucose levels) < or = +/- 30 mg/dL, postprandial glucose peak <140 mg/dL or <20% increase from premeal level. Following the titration period, there was an 11-day maintenance period during which the doses were kept unchanged unless for safety reasons.
32849533|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
32849534|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
32849535|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
32849536|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
32849537|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
33320190|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
32849538|NCT04401631||Interventions|"A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.~A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.~A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.~A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
33320191|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
32849543|NCT05305716|Experimental|online pilates group|Online pilates training was done for a total of 8 weeks, 2 days a week for 1 hour. Microsoft Teams program was used to perform the exercises online. The investigators divided the individuals in the online pilates exercise group into seven smaller groups of 3 or 4 to verify whether they correctly did the exercises. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises and 15 minutes of cooling and stretching exercises was arranged for the online pilates group and the exercises were performed as 10 repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during pregnancy was used in the online training.
32849544|NCT05305716|Active Comparator|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
32849545|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
32849546|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
32849547|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
32849548|NCT05282862|Active Comparator|Freehand|Conventional bone augmentation using a particulate graft material (DBBM) and a collagen barrier membrane.
32849549|NCT05282862|Experimental|Guided|Bone augmentation performed using the materials as in the Freehand group, but using a surgical guide to help define the shape of the guide.
32849550|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
32849551|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
32849552|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
32849553|NCT04383249||Pathology result|Pathology result of the hernia sac
32849554|NCT05305326||Control|Singleton pregnancies undergoing elective pre-labour CS at gestational age (37+0 to 40+0) that are healthy
32849555|NCT05305326||Gestational diabetes|Singleton pregnancies complicated with gestational diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
32849556|NCT05305326||Type 1 diabetes with pregnancy|Singleton pregnancies complicated with Type 1 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
32849557|NCT05305326||Type 2 diabetes with pregnancy|Singleton pregnancies complicated with Type 2 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
32849558|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
32959473|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
33104044|NCT04225520|Active Comparator|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
33104045|NCT04225520|Experimental|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
33320192|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
32849559|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
32849560|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.~Derivation Cohort of Prognostic Prediction Model:~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
32849561|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.~Validation Cohort of Prognostic Prediction Model:~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
32849562|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
32849563|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
32849564|NCT04564014|Experimental|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
32849565|NCT04564014|Active Comparator|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
32849566|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
32849567|NCT03802617|Experimental|MR13A9 low dose|
32849568|NCT03802617|Experimental|MR13A9 medium dose|
32849569|NCT03802617|Experimental|MR13A9 high dose|
32849570|NCT03802617|Placebo Comparator|Placebo|
32849571|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
32849572|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
32849573|NCT05275140|Experimental|Experimental group 1 (adapted taekwondo)|The general structure of the adapted taekwondo will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the adapted taekwondo (will consist of non-contact activities, distributed in 10-min of basic postures and specific movements with the upper limbs and 20-min of lower limb movements performed individually and in pairs with and without the implementation of taekwondo. In addition, choreographies or forms (sequence of arm and leg movements that simulate an imaginary combat) specific to this modality were adapted to the characteristics of older women for 10-min; and will be developed to finish with the cool down for 10-min through dynamic and static flexibility exercises.
32849574|NCT05275140|Active Comparator|Experimental group 2 (multi-component training)|The general structure of the multi-component training will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the multi-component training (distributed work in a circuit, which includes resistance training focused on the large muscles of the upper limbs and lower limbs combined with exercises aimed at cardiorespiratory fitness, agility and postural control, using elastic bands, poles, 2-kg medicine balls and chairs). The training volume will start (the first 4-weeks) with 3 sets of 10 repetitions per muscular exercise with a 2-min rest period between sets, performing slow movements of two seconds in concentric contraction and four seconds in eccentric contraction. Between weeks 5 to 8, the volume will increase to 4 sets of 10 repetitions per muscular exercise with 2-min of rest between sets.
32849575|NCT05275140|Active Comparator|Experimental group 3 (walking program)|The walking program will be distributed in three weekly sessions of 45- to 60-min every other day, for 16-weeks (48 sessions). The general structure of the protocol will include a 5-min warm-up consisting of joint mobility and flexibility exercises. Next, the main part will be developed for 30- to 45-min (increased by 5-min every 4-weeks) consisting of walking on flat ground, touring the jogging circuit that the University has on campus, and ending with 5-min cool down through dynamic and static flexibility exercises.
33406442|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
33406443|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
33406444|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
32959474|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
33406445|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
32849576|NCT05275140|No Intervention|Control group|The control group, the individuals will participate in the assessments (initial and final) and will be asked to maintain their usual activities. An undergraduate student (support personnel) will contact the participants by telephone (once a week) to consult them about their health status and monitor their activities. At the end of the intervention period, the control group will be invited to participate in a physical activity program that will be developed at the University based on the results of this project.
32849577|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
33406446|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
33406447|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
33406448|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
33406449|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
33406450|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
33406451|NCT03714191||Improved outcomes|
32849578|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
33406452|NCT03714191||Regulatory reminder|
32849579|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
32849580|NCT05659797|Experimental|FES BPET-DBT|FES-BPET/DBT imaging session
33406453|NCT03714191||Billing and documentation|
32849581|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
32849582|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
32739672|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
32739673|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
32849583|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
32849584|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
32849585|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
32849586|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
32849587|NCT04570878|Experimental|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
32849588|NCT04570878|Active Comparator|Control|No regional block is provided at the end of surgery.
32849589|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
32849590|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
33406454|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
33406455|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
33406456|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
32739674|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
32739675|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
32959475|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
32739676|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
32739677|NCT03196453|Placebo Comparator|Placebo|Placebo
32739678|NCT05587595||children with complicated sickle cell disease hospitalised in pediatric intensive care unit (PICU)|
32739679|NCT05587595||children with complicated sickle cell disease hospitalised but not in intensive care unit|
32739680|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
32739681|NCT02476253|No Intervention|Control|No intervention
32739682|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
32739683|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
32739684|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
32739685|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
32739686|NCT04996407|Active Comparator|survival thermal blanket|Patient will be using survival thermal blanket as substitute for perforated blanket with forced air warmer during anesthesia
32739687|NCT04996407|Active Comparator|draping fabric|Patient will be using draping fabrics as substitute for perforated blanket with forced air warmer during anesthesia
32739688|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
32739689|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
32739690|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
32739691|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
32739692|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
32739693|NCT04456569|Experimental|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
32739694|NCT04456569|No Intervention|Standard of Care|Participants in this arm will receive standard of care only.
32739695|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
32739696|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
32739697|NCT04989777|No Intervention|Control group|Patients with AMI and shock stage B were received Standardized treatment
32739698|NCT04989777|Experimental|IABP group|Patients with AMI and shock stage B were received Standardized treatment and IABP treatment
32739699|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
32739700|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
32739701|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
32739702|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
33406457|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
32849591|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
32849592|NCT05273502|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the project, and participants will be assessed at baseline and end-of-study.
32849593|NCT05273502|No Intervention|Control group|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
32849594|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
32849595|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
32849596|NCT01499576|Experimental|Acetic acid spraying|
32849597|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
32849598|NCT04546074|Experimental|Treatment|
32849599|NCT00802113|Experimental|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
33406458|NCT02726880|Active Comparator|Referral for care|
33406459|NCT02726880|Experimental|Behavioral therapy|
33406460|NCT05677074|Experimental|Tolerance test of fish oil, cod oil, and krill oil|All participants will have their tolerance of three different dietary supplements tested (fish oil, cod oil, and krill oil) using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
33406461|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
32849600|NCT00802113|Experimental|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
32849601|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
32849602|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
32849603|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
32849604|NCT04545606|Experimental|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
32959476|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
32959477|NCT00676572||Severe asthma|
32959478|NCT00676572||Non-severe asthma|
32959479|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
32959480|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
32959481|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
32959482|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
33406462|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
33104046|NCT04617912|Experimental|PennPET Explorer|"All subjects will be scanned in the CT scanner and then the scanner bed will be moved into position in the PennPET Explorer for initiation of the PET scan. For all PET scans a radioactive imaging drug is used.~The radiotracer injection may be performed according to one of the following scenarios:~As part of a clinical standard-of-care (SOC) PET/CT or PET/MRI scan (using an FDA-approved radiotracer; the PennPET Explorer cannot yet accommodate a study that requires a commercially available 510(k)-approved instrument for clinical results, subjects in this group will be scanned on both a commercial instrument (PET/CT or PET.MRI) and the PennPET Explorer),~As part of another research study (using either an FDA-approved radiotracer or an investigational radiotracer),~As a research injection designed specifically to utilize the PennPET Explorer (using an FDA-approved radiotracer)."
32849605|NCT04545606|Experimental|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
32849606|NCT04545606|Experimental|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
32849607|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
32849608|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
32849609|NCT04535778|Experimental|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. Participants will also have access to the standard charity resources.
33320193|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
33320194|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
33320195|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
32849610|NCT04535778|Active Comparator|Standard charity resources|Participants will be directed to the standard resources provided by the charities involved in the study.
32849611|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
32849612|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
32849613|NCT04401475|Experimental|Stage 1|Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
33320196|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
33320197|NCT04703348|Other|Healthy patients|Healthy patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
32849614|NCT04401475|Experimental|Stage 2|Stage 2 (Phase III Study - Canada) For a 1:1 ratio of patients treated with EB05 vs. Placebo, 80% power, and a two-sided alpha of 0.05 (equivalent to one sided test with an alpha of 0.025) to detect an Odds Ratio of 1.50, a total of 884 evaluable patients will be required for Stage 2 (Phase III study). Allowing for 20% attrition, a total of 1,105 patients will be enrolled in this Stage.
32849615|NCT01476644|Other|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
33320198|NCT04703348|Other|Complex regional pain syndrome patients|Complex regional pain syndrome patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
32849616|NCT04533360||Community Cohort 1|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
32849617|NCT04533360||Community Cohort 2|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
32849618|NCT04533360||Healthcare Provider Cohort 1|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
32849619|NCT04533360||Healthcare Provider Cohort 2|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
33320199|NCT04703348|Other|Musculoskelettal disorders patients|Musculoskelettal disorders patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
32849621|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
32849622|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
32849623|NCT05304858||TME Analysis|Participants who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) will volunteer for a biopsy of a site in the body that contains prostate cancer, such as a bone, a lymph node or an organ such as the liver OR are planned to undergo standard of care surgical procedures such as orthopedic surgery or neurosurgery based on a subjects clinical needs.
32849624|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
32849625|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
32849626|NCT03425539|Experimental|Lucerastat|
32849627|NCT03425539|Placebo Comparator|Placebo|
33104047|NCT04200755|Experimental|Dupilumab|30 patients; Dupilumab s.c. injection; 2 ready-to-use syringes (600 mg) initial (V1), 1 ready-to-use syringe (300 mg) every 14 days (V2- V13) Dupilumab s.c. injection in healthy skin, 24 weeks
33320200|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
32849628|NCT04490616|Experimental|RR-GR|MCI patients with social cognition deficits will receive 4 weeks of rTMS stimulation
32849629|NCT04490616|Other|SR-GR|MCI patients with social cognition deficits will receive 2 weeks of placebo treatment, followed by 2 weeks of real rTMS stimulation
33320201|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
32849630|NCT05304624|Active Comparator|Group 1: ErCr:YSGG laser|"Waterlase iPlus,Biolase-USA Er,Cr:YSGG laser (2780nm) was set at frequency 50Hz, power of 2.5W and 1562.5 W/cm2. MZ6 (400µm fiber tip) was used in contact mode for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
32849631|NCT05304624|Experimental|Group 2: Diode laser|"Ilase, Biolase-USA Diode laser (940nm) was set at power of 1.2W and 750 W/cm2. 400µm fiber tip was used in contact mode and continuous-wave for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
32849632|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
32849633|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32849634|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
32849635|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
32849636|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
32849637|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~Brief talk by health professionals.~Role-plays"
32849638|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
32849639|NCT05231772|Experimental|Probiotics|Patients in the Test arm will receive Saccharomyces boulardii (Saccharomyces), (Enterol), Biocodex Ltd, France, registration number LP-000622 from 21.09.2011 at a dose of 250 mg 2 times a day for 3 months.
32849640|NCT05231772|Placebo Comparator|Placebo|Patients in the Placebo arm will receive the placebo at a dose of 250 mg 2 times a day for 3 months.
32849641|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
32849642|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
32849643|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
33104048|NCT04200755|Placebo Comparator|Placebo|15 patients; placebo s.c. injection; 2 ready-to-use syringes initial (V1), 1 ready-to-use syringe every 14 days (V2-V13) placebo s.c. injection in healthy skin, 24 weeks
32849644|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
32849645|NCT01498952|Experimental|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
32849646|NCT01498952|Experimental|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
32849647|NCT01498952|Experimental|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
32849648|NCT01498952|Experimental|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
32849649|NCT01498952|Active Comparator|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
32849650|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
32849651|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
32849652|NCT04511988|Experimental|Experimental|blood sample (20 ml) and biopsy
32849653|NCT05304312|Experimental|Women with Kegel Exercises book|"We gave the patient the Kegel Exercises guidebook for them to study, follow, and keep track of their exercise.~The Kegel Exercises regiment was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day needed to be done every day for 12 weeks."
32849654|NCT05304312|No Intervention|Women without Kegel Exercises book|We did not give the Kegel Exercises guidebook for the patients We taught the same Kegel Exercises regiment that was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day and needed to be done every day for 12 weeks
32849655|NCT05130567|Experimental|Single-dose Experimental Group|LP-128 capsule will be adminstrated one time at doses up to 240mg
32849656|NCT05130567|Placebo Comparator|Single-dose Control Group|Placebo capsule will be adminstrated one time at doses up to 240mg
32849657|NCT05130567|Experimental|Multi-dose Experimental Group|LP-128 capsule will be adminstrated once daily, for up to 14 days
32849658|NCT05130567|Placebo Comparator|Multi-dose Control Group|Placebo capsule will be adminstrated once daily, for up to 14 days
32849659|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
32849660|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
32849661|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
33104049|NCT04185974|Experimental|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
32849662|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
33104050|NCT04185974|Active Comparator|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
33104051|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
33104052|NCT04173533|Placebo Comparator|Control Group|Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle
33104053|NCT04173533|Experimental|Experimental Group|Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle
32849663|NCT05636319|Experimental|Test group 1: ABO1020|Intramuscularly inject 15 μg of ABO1020 into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
32849664|NCT05636319|Placebo Comparator|Test group 2: Placebo|Intramuscularly inject 0 μg of placebo into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
32849665|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
32849666|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
32849667|NCT04608266|Experimental|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
32849668|NCT04608266|Placebo Comparator|Placebo|Placebo tablets, oral administration
32849669|NCT05304156||Standard of Care in patients with AML|"Standard of Care including a first course containing one of the following backbones without addition of third agent before day 8 of induction (approved drugs such as midostaurine or investigational agents administered beyond day 8 are allowed) :~7+3 induction 3+7 with daunorubicin (or idarubicin) and cytarabine~CPX-351 induction"
32849670|NCT05685433|Experimental|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
32849671|NCT05228106||Patients eligible for [68Ga]-PSMA-617-PET|All cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with a [68Ga]-PSMA-617 dose calculated depending on the characteristics of the PET tomograph and patient weight (maximum 370 MBq). 60-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.
33104054|NCT05544591|Experimental|611 Q2W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q2w from Week 2 to Week 14 (7 cycles).
32849672|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
32849673|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
32849674|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
32849675|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
32849676|NCT04489134|Experimental|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
32849677|NCT04489134|Experimental|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
32849678|NCT04489134|Experimental|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
32849679|NCT04489134|Experimental|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro (Envarsus®)
32849680|NCT05685355||Gingivitis samples|"Inclusion criteria:~Adult subjects attending PPDH can give informed consent.~Subjects who are diagnosed to have gingivitis only and have 24 or more teeth.~Subjects who are otherwise medically healthy.~Subjects who can attend multiple dental visits.~Exclusion criteria~Subjects who are in acute dental infection or in pain.~Subjects who have oral mucosal diseases that preclude retraction of soft tissues for photos.~Subjects who are in the fixed appliance for orthodontic treatment.~Subjects who are pregnant, or medically unfit for periodontal charting or require antibiotic coverage (e.g. risk of infective endocarditis)"
32849681|NCT00774267||1|
32849682|NCT00774267||2|
32849683|NCT00774267||3|
32849684|NCT00774267||4|
32849685|NCT05213130|Experimental|Information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., as well as a clear reminder to inform donors that their blood has saved patient's life.
32849686|NCT05213130|No Intervention|Non-information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., but there will be no reminder to inform donors that their blood has saved patient's life.
32849687|NCT04400851|Experimental|Sintilimab in advanced childhood cancer patients|
32849688|NCT05191056|Placebo Comparator|Placebo drink|
32849689|NCT05191056|Experimental|MelaGene drink|
32849690|NCT01461044||Cohort|
32849691|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
32849692|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
32849693|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
32849694|NCT04464876|Experimental|Treatment|SATURN TA TMVR Device implanted
32849695|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
32849696|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
32849697|NCT04041869|Experimental|MapTrek|
32849698|NCT04460352|Active Comparator|Control arm (A)|"Neoadjuvant chemoradiotherapy followed by esophagectomy.~Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.~Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy.~Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,"
32898797|NCT01364623|Experimental|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
32959483|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
33104055|NCT05544591|Experimental|611 Q4W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q4w on week 4, 8, 12 and two injections of placebo on week 2, 6, 10, 14.
32849699|NCT04460352|Experimental|Experimental arm (B)|"Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer.~Radiotherapy: Two alternative schemes:~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.~Chemotherapy: Three alternative regimens:~1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy.~2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5.~2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5."
32849700|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
32849701|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
32849702|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
32849703|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
32849704|NCT01421303||AS patients who are working and treated with Enbrel|
32849705|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
32849706|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
32849707|NCT05303922|Experimental|DECT and MRI|Patients will be scanned with both DECT and MRI.
32849708|NCT05101239||A: Acute mTBI|Consists of up to 80 patients with acute mTBI. All acute mTBI subjects will be scanned per the HHI study design at 3 to 5 timepoints relative to their time of injury ( Visit 1 within 72 hours; Visit 2, 7 +/- 4 days; Visit 3, 30 +/- 7 days; Visit 4, 90 +/- 14 days; Visit 5, 180 +/- 30 days from injury). Even though for practicality Visits 1 and 5 are optional, every effort will be made to image as close to the time of acute injury as possible and to complete imaging for all time points.
32849709|NCT05101239||B: Control|Consists of 40 age-matched participants described above who will undergo imaging twice on the MAGNUS 3.0T MRI scanner at two distinct time points. The 2 MRI imaging sessions will be at least 2 weeks apart. One of the 2 visits will include a clinical MRI scan using the same MRI acquisition protocols used for Group A. Because age-matched Controls are not expected to exhibit structural and functional changes during the study period, it was not deemed necessary for the interval between scan-visit time points to be identical for all participants in Group B.
32849710|NCT05101239||C: Chronic mTBI|Consists of 40 age-matched participants with chronic mTBI (≥6 months and <5 years from mTBI injury to enrollment). Participants in this group will have 1 set of procedures at the Baseline Visit. This cohort will be used to understand functional and structural changes in chronic mTBI patients to identify indications of progression of patients from the acute to chronic phase
32849711|NCT04348201|Active Comparator|foot reflexology|foot reflexology session which takes about 20 minutes.
32849712|NCT04348201|Active Comparator|dietary modification|diet must be rich in vitamins.
32849713|NCT05085561|Active Comparator|REC-994 200 mg|REC-994 200 mg po once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
32849714|NCT05085561|Active Comparator|REC-994 400 mg|REC-994 400 mg po QD (2 200 mg REC-994 tablets)
32849715|NCT05085561|Placebo Comparator|Placebo|Matching Placebo po QD (2 matching placebo tablets)
32849716|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
32849717|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
32849718|NCT05303766|Experimental|RFT group|The treatment of the patients in the radio frequency thermo-coagulation of the genicular nerves was conducted under the guidance of C-arm X-ray machine . The C-arm machine showed that the radiofrequency cannula needle was advanced percutaneously towards the periosteal areas connecting the shaft of the femur to bilateral epicondyles and the shaft of the tibia to the medial epicondyle while the lateral image showed that the depth of the needle insertion was about 50% of the diameter of the femur or tibia. The radiofrequency electrodes were connected and tested. These induced abnormal pain around the knee joint at 50 Hz and 0.1-0.3 V, but did not induce contraction of the muscles of the knee joint at 2 Hz and > 2.0 V. The location of the needle tip was confirmed by the C-arm, and 0.5 mL of 1% lidocaine was used for local anesthesia. The temperature of RFT was increased gradually to 70°C for 180 seconds.
32959484|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
32959485|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
32959486|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
32959487|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
32959488|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
32959489|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
32959490|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
32959491|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
32959492|NCT00680706|Experimental|Thiamine|Receives thiamine
32849719|NCT05303766|Experimental|IAPRF group|The puncture site was selected in the middle of the medial or lateral edge of the patella. After local anesthesia was administered with 0.5% lidocaine, the radiofrequency cannula needle was inserted slowly between the patella and femoral condyles. The needle was gradually inserted into the joint cavity, and then a small volume of saline was administered using a syringe. If any resistance was encountered, which indicated that the needle tip was located in a ligament or tendon, the surgeon readjusted the needle tip until the injection proceeded without any significant resistance. After entering the joint cavity, the C-arm x-ray is used confirm that the cannula needle was located in the middle of the joint space. Subsequently, sensory stimulation using 50 Hz/2 Hz was performed at > 2 V, to prevent inducing pain or muscle contraction. Then, an automatic PRF mode ≤ 45 V (≤ 42°C, 2 Hz, pulse width of 20 ms) was administered for 300 seconds.
32849720|NCT05303766|Experimental|IAS group|The puncture procedure was similar to that for the IAPRF group. After the cannula needle was inserted to the articular cavity, 1 mL compound betamethasone (2 mg betamethasone sodium phosphate and 5 mg betamethasone dipropionate) was injected. Then, the needle was withdrawn, and the puncture site was dressed aseptically.
32849721|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
32849722|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
33104056|NCT05544591|Placebo Comparator|placebo|Four subcutaneous injections of placebo as a loading dose on week 0 Day 1, followed by two injections q2w from Week 2 to Week 14 (7 cycles).
32849723|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
32849724|NCT05080725|Experimental|Generalized sarcopenia group|Older adults will be recruited from local community centers, physician offices, and retirement communities via flyers. Participants will complete 16 sessions of standard of care swallowing exercises 2 times per week for 8 weeks. All sessions will be conducted via Webex. During each session, a series of standard of care swallow exercises will be performed following a demonstration from a trained speech-language pathologist.
32849725|NCT05303688|Experimental|Drug: Dexketoprofen Tremetamol|50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, Istanbul, Turkey) were administrated 30 minutes before incision in the treatment group (deksketoprofen trometamol n= 15)
32849726|NCT05303688|Placebo Comparator|Drug: Steril Salin (control)|iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15)
32849727|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
32849728|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
32849729|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
32849730|NCT04383717|Active Comparator|Proposed treatment group|Levamisole and isoprinosine
32849731|NCT04383717|Active Comparator|Control group|hydroxychloroquine and azithromycin
32849732|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
32849733|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
32849734|NCT05055258|Experimental|300 mg KVD824|300 mg KVD824 twice a day for 12 weeks
32849735|NCT05055258|Experimental|600 mg KVD824|Two 300 mg KVD824 tablets twice a day for 12 weeks
32849736|NCT05055258|Experimental|900 mg KVD824|Three 300 mg KVD824 tablets twice a day for 12 weeks
32849737|NCT05055258|Placebo Comparator|Placebo to KVD824|One, two or three placebo tablets to be taken twice a day for 12 weeks
32849738|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
32849739|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
32849740|NCT05685277|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg/25 mg dose of the test product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32849741|NCT05685277|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 10 mg/25 mg dose of the test product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32849742|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
32849743|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
32849744|NCT05303454|Experimental|Cartoons|Reduce Pain and Fear Levels of Children
32849745|NCT05303454|Experimental|Musical-moving Toys|Reduce Pain and Fear Levels of Children
32849746|NCT05303454|No Intervention|CONTROL|NOT Reduce Pain and Fear Levels of Children
33104057|NCT04158440|Experimental|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg)|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
33104058|NCT04158440|Active Comparator|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Placebo
33104059|NCT01534065|Experimental|Barricaid|CE Marked Device
33104060|NCT04150874|Experimental|Lumason Microbubbles|Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered
33104061|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
32849747|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
32849748|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
32849749|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
32849750|NCT05189496|Experimental|hyperbaric oxygen therapy group|30-40 times hyperbaric oxygen therapy
32849751|NCT05189496|No Intervention|control group|No hyperbaric oxygen therapy
32849752|NCT04386798|Other|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
32849753|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
32849754|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
32849755|NCT04279015|Active Comparator|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
32849756|NCT04279015|Active Comparator|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
32849757|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
32849758|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
32849759|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
32849760|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
32849761|NCT04386330|Experimental|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
32849764|NCT04279717||Subjects with von Willbrand Disease Acquired|
32849765|NCT04279717||Subjects with von Willbrand Disease Congenital|
32849766|NCT05046171|Experimental|Arm 1: Pharmacist-led deprescribing intervention|Pharmacists will complete a comprehensive medication assessment with the participant via telemedicine and discuss tailored recommendations for discontinuations of potentially inappropriate medications. The pharmacist will document the evaluation and recommendations and communicate to the participant and care team members. The pharmacist will telephone each participant at least one time after the initial intervention to assess adherence to instructions and recommendations, and to assess any symptoms potentially related to medication discontinuation.
32849767|NCT05046171|Active Comparator|Arm 2: Patient education brochure|Participants will receive a brochure discussing medication appropriateness and deprescribing in general terms
32849768|NCT05689021|Experimental|Treatment (CJNJ-67652000 and prednisone)|Patients receive CJNJ-67652000 PO and prednisone PO on study. Patients also undergo blood specimen collection, CT or MRI, and bone scan throughout the trial.
32849769|NCT04371120||Brain Injury Survivors|Traumatic or acquired brain injury survivors, patients of RHI
32849770|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
32849771|NCT04891107|Experimental|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Will walk for 30 minutes at a time, 5 times a week, for 4 weeks using the wearable sensor system at home or in the community.
32849772|NCT04362696|Experimental|active stimulation|
32849773|NCT04362696|Sham Comparator|sham stimulation|
32849774|NCT04362306|Experimental|Planned Intervention|Patients will be scheduled for CT (computed tomography ) simulation for radiation treatment planning. Prior to simulation, patients will be asked to complete anxiety and patient satisfaction questionnaires. Following completion of the questionnaires, each patient will receive the first intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic. The patient will then be asked to complete a second set of anxiety and patient satisfaction questionnaires and will then undergo the planned simulation.
32849775|NCT04362306|Active Comparator|No Planned Intervention|After patients are enrolled into this study, they will be scheduled for CT simulation for radiation treatment planning. Prior to simulation, patients will receive anxiety and patient satisfaction questionnaires to complete
32959493|NCT00680706|Placebo Comparator|Control|
32959494|NCT00680862||Group 1|VA employees
33406463|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
32959495|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
32959496|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
32959497|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
32959498|NCT00683046|Experimental|Drug Intervention|
32959499|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
32959500|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
32959501|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
32959502|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
32959503|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
32959504|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
32959505|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
32959506|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
32959507|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
32959508|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
32959509|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
32959510|NCT00690924|Experimental|Calcitriol|
32959511|NCT00691002|Experimental|LEO 80190|Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
32959512|NCT00691002|Placebo Comparator|LEO 80190 vehicle|Ointment Vehicle
32959513|NCT00691002|Active Comparator|Calcipotriol|Calcipotriol 25 mcg/g in the ointment vehicle
32959514|NCT00691002|Active Comparator|Hydrocortisone|Hydrocortisone 10 mg/g in the ointment vehicle
32959515|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
32959516|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
32959517|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
32959518|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
32959519|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
32959520|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
32959521|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
32959522|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
32959523|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
32959524|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
32959525|NCT00702468|Experimental|Sativex|Sativex
32959526|NCT00702468|Placebo Comparator|Placebo|Placebo
32959527|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
32959528|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
32959529|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
32959530|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
32959531|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
33406464|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
33406465|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
33406466|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
32959532|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
32959533|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
32959534|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
32959535|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
32959536|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
32959537|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
32959538|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
32959539|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
32959540|NCT00706836|Placebo Comparator|Placebo|Placebo
32959541|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
32959542|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
32959543|NCT00708942|No Intervention|3|
32959544|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
32959545|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
32959546|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
32959547|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
32959548|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
32959549|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
32959550|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
32959551|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
32959552|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32959553|NCT00712296|Experimental|ASHMI 4|ASHMI 4 capsules twice a day
32959554|NCT00712296|Experimental|ASHMI 12|ASHMI 12 capsules twice a day
32959555|NCT00712296|Placebo Comparator|Placebo|Placebo 6 capsules twice a day
32959556|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
32959557|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
32959558|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
32959559|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
32959560|NCT00714792||2|women with no urge symptoms
32959561|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
32959562|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
32739703|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
33320202|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
32959563|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
32959564|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
32959565|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
32959566|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
32959567|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
32959568|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
32959569|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
32959570|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
32959571|NCT00716586|Experimental|Trusopt (2% dorzolamide)|Intent to treat population. All participants assigned to Trusopt (2% dorzolamide)
32959572|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
32959573|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
32959574|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
32959575|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
32959576|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
32959577|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
32959578|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
32959579|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
32959580|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
32959581|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
32959582|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
32959583|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
32959584|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
32959585|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
32959586|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
32959587|NCT00719160|Placebo Comparator|Esomeprazole|
32959588|NCT00719160|Active Comparator|Placebo|
32959589|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
32959590|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
32959591|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
32959592|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
33320203|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
32849776|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
32849777|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
32849778|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
32849779|NCT05303142||Individuals with a history of EHI|Service personnel who have a history of EHI.
32849780|NCT05303142||Control participants without a history of EHI|"Matched control participants with no history of EHI. They will be matched to the experimental group for parameters that are known to influence thermoregulatory responses to exercise heat-stress.~Relative aerobic fitness (V̇O2max; ml∙kg-1∙min-1)~Body mass (kg)~Body surface area (m2)~Age~Sex"
32849781|NCT05688787|Active Comparator|Perineural injection arm|"30 patients will be received 4 sessions of perineural injection~1 week a part with optional additional sessions per the physician recommadation and the patient preference .injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest &amp; T10 cross over iliac crest at a distance 8-10cm"
32849782|NCT05688787|No Intervention|Standard treatment|will be received standard of care treatment of fibromyalgia
32849783|NCT04861935|Placebo Comparator|ultrasound evaluation of sacral region in normal pediatric patients|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
32849784|NCT04861935|Active Comparator|ultrasound evaluation of sacral region in patients with sacral dimple|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
32849785|NCT01498484|Experimental|HCT EBV+ PTLD R/R Rituximab|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849786|NCT01498484|Experimental|SOT EBV+ PTLD R/R Rituximab|Patients with EBV+PTLD solid organ transplant (SOT) who were R/R to rituximab or R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After 3 week observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849787|NCT01498484|Experimental|EBV+ AID-LPD|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity
32849788|NCT01498484|Experimental|EBV+ PID-LPD|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849789|NCT01498484|Experimental|EBV+ Viremia|Patients with EBV+ viremia will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849790|NCT01498484|Experimental|EBV+ Leiomyosarcoma|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849791|NCT01498484|Experimental|EBV+ Lymphoma|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849792|NCT01498484|Experimental|EBV+ NPC|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849793|NCT01498484|Experimental|EBV+ Other Solid Tumor|Patients with EBV+ other solid tumors will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
32849794|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
32849795|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
32849796|NCT05688631||Diabetic participants (case group)|Participants diagnosed with type 2 diabetes mellitus
32849797|NCT05688631||Healthy participants (control group)|Participants not diagnosed with type 2 diabetes mellitus or any other chronic diseases
32898798|NCT00258206|Experimental|rituximab + cyclophosphamide|Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12
32898799|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
32898800|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
32898801|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
32849798|NCT04860453|Experimental|Affected participants with 5 or more discordant cancers - WES|"Affected individuals with a family history of 5 or more discordant cancers in unilateral descent with a 3-generation pedigree will receive SOC CLIA/CAP multicancer panel (DNA collected via blood draw or punch biopsy) to examine monogenic variant diagnostic yield. Eligible participants (families with no mutations and at least 2 affected and 1 non-affected family members) may move forward with WES.~Any identified monogenic variants of interest will be sent to an industry partner with CLIA/CAP certification for validation. A 6-month follow-up visit will take place during which variants will be discussed and participants who underwent gHFI variant counting (those who were not considered a gene candidate) will have results explained. Appropriate genetic counselling, recurrence risk, and additional clinical referrals will be made as necessary"
32849799|NCT04860453|Active Comparator|SOC genetic counseling (routine clinical care)|"Affected individuals (cancer) with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing will receive SOC CLIA/CAP multicancer panel in order to examine monogenic variant diagnostic yield (retrospective data)~This arm would also include prospective participants from the 5 or more discordant cancers group who DID have a variant identified and therefore did not move on to WES."
33320204|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
33320205|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
33320206|NCT05690048|Experimental|Vancomycin + A/B + FMT|"Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
33320207|NCT05690048|Placebo Comparator|Placebo Vancomycin + A/B + Placebo FMT|"Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~Placebo Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
33320208|NCT05462522|Experimental|MAD Stage|Participants will be randomized in a ratio of 4:1 to receive RO7303509 or placebo, as subcutaneous (SC) injection, every 4 weeks, (Q4W) up to 12 weeks.
33320209|NCT05462522|Experimental|OSE Stage|Participants will receive RO7303509 as SC injection at the same dose as that administered during the MAD stage, Q4W for up to 52 weeks.
33320210|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
32849800|NCT05683327|Active Comparator|Hyaluronic Acid 150 mg|Take 150 mg/day of hyaluronic acid.
32849801|NCT05683327|Active Comparator|Hyaluronic Acid 80 mg|Take 80 mg/day of hyaluronic acid.
32849802|NCT05683327|Placebo Comparator|Placebo|Take 0 mg/day of hyaluronic acid.
33320211|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
33320212|NCT01308866|No Intervention|Control|Usual care
33320213|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
32849803|NCT05138874|Experimental|Trending Feedback + Private Commitment|Clinicians receive both Trending Feedback + Private Commitment interventions.
32849804|NCT05138874|Experimental|Trending Feedback + Public Commitment|Clinicians receive both Trending Feedback + Public Commitment interventions.
32849805|NCT05138874|Experimental|Trending Feedback + Commitment Control|Clinicians receive Trending Feedback intervention + Commitment Control.
32849806|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Private Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Private Commitment interventions.
32849807|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Public Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Public Commitment interventions.
32849808|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Commitment Control|Clinicians receive Benchmark Peer Comparison Feedback intervention + Commitment Control.
32849809|NCT05138874|Experimental|Public Commitment + Feedback Control|Clinicians receive Public Commitment intervention + Feedback Control.
32849810|NCT05138874|Experimental|Private Commitment + Feedback Control|Clinicians receive Private Commitment intervention + Feedback Control.
32849811|NCT05138874|No Intervention|Commitment Control + Feedback Control|Clinicians receive no intervention.
32898802|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
32898803|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
33320214|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
33320215|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
33320216|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
33320217|NCT05694026|Experimental|IPL+|Participants in the IPL+ group used DQS 1 drop 6 times/per day for four weeks along with 2 sessions of IPL, 2 weeks apart.
33320218|NCT05694026|Experimental|IPL|IPL treatment sessions were administered once at 2- weeks interval to all participants for 4 weeks.
33320219|NCT05694026|Experimental|DQS|DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks.
33320220|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
33320221|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
32959593|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
32959594|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
32959595|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
32959596|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
32959597|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
33320222|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
32959598|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
32959599|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
32959600|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
32959601|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
32959602|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
32959603|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
32959604|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
32959605|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
32959606|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
32959607|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
32959608|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
32959609|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
32959610|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
32959611|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
32959612|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
32959613|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
32959614|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
32959615|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
32959616|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
32959617|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
32959618|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
32959619|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
32959620|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
32959621|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
32959622|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
32959623|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
32739704|NCT04986813|Active Comparator|Group Tranexamic Acid|50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.
32739705|NCT04986813|Placebo Comparator|Control group|50 patients were kept as a control group and were not given TXA.
32959624|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
32959625|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
32959626|NCT00733278|Experimental|Copper IUD|Copper IUD
32959627|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
32959628|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
32959629|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
32959630|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
32959631|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
32959632|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
32959633|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
32959634|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
32959635|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
32959636|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
32959637|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
32959638|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
32959639|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
32959640|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
32959641|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
32959642|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
32959643|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
32959644|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
32959645|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
32959646|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
32959647|NCT00740376|Experimental|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
32959648|NCT00740376|Active Comparator|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
32959649|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
32959650|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
32959651|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
32959652|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
32959653|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
32959654|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
32959655|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
32959656|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
32959657|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
32959658|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
32959659|NCT00742872|Experimental|1|Mosapride
32959660|NCT00742872|Placebo Comparator|2|Placebo
32959661|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
32959662|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
32959663|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
32959664|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
32959665|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
32959666|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
32959667|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
32959668|NCT00748410|Experimental|7 Days Repeat Dose|
32959669|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
32959670|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
32959671|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
32959672|NCT00749268|Active Comparator|A|
32959673|NCT00749268|Active Comparator|B|
32959674|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
32959675|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
32959676|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
32959677|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
32959678|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
32959679|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
32959680|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
32959681|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
32959682|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
32959683|NCT00753636|Experimental|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
32959684|NCT00753948|Experimental|Chronic Tetraplegia|Individuals with chronic tetraplegia
32959685|NCT00753948|Active Comparator|Mild Asthma|Individuals with diagnosed mild asthma
32959686|NCT00753948|Placebo Comparator|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
32959687|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
32959688|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
32959689|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
32959690|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
32959691|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
32959692|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
32959693|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
32959694|NCT00756600|Active Comparator|1|Regional Anesthesia
32959695|NCT00756600|Active Comparator|2|General Anesthesia
32959696|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
32959697|NCT00756678|Active Comparator|2|Polyethylene glycol 400
32959698|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
32959699|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
32959700|NCT00758784|Experimental|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
32959701|NCT00758862|Experimental|1|
32959702|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
32959703|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
32959704|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
32959705|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
32959706|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
32959707|NCT00759408|Experimental|1|BQ-123
32959708|NCT00759642|Experimental|Lapatinib|lapatinib
32959709|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
32959710|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
32959711|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
32959712|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
32959713|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
32959714|NCT00761202|Active Comparator|1|Optive Eyedrops
32959715|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
32959716|NCT00761592|Active Comparator|1|
32959717|NCT00761592|Active Comparator|2|
32959718|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
32959719|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
32959720|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
32959721|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
32849812|NCT05302830|Experimental|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
32849813|NCT05302830|Placebo Comparator|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
32849814|NCT04348266|Experimental|RFA|The assigned location will be treated with RFA at all lesion.
32849815|NCT04348266|No Intervention|Control|No treatment will not be performed at this location. However, if endoscopist detects any suspicious lesion during the scheduled endoscopy, the biopsy will be done and standard treatment will be performed accordingly.
32849816|NCT04849221||Patients|Head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke)
32849817|NCT04849221||healthy subjects|No otologic or neurological history
32849818|NCT04348032|Active Comparator|PLD|PLD 40 mg/m2 D1 ivgtt q4w
32849819|NCT04348032|Experimental|PLD + Apatinib|PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
32849820|NCT05682235|Experimental|Therapeutic Exercise AND Pain Neurophysiology Education|"Therapeutic exercise:~Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, prevent risk factors for solid and optimize overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and diminish the threatening meaning of pain."
32849821|NCT05682235|Sham Comparator|Sham Comparator|Talks about healthy habits
32849822|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
32849823|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Forward Skin Stretch|Adaptation to Altered Auditory Feedback + Forward Skin Stretch
32849824|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Backward Skin Stretch|Adaptation to Altered Auditory Feedback + Backward Skin Stretch
32849825|NCT04818021|Experimental|Speech Repetition Control|Speech Repetition Control
32849826|NCT03083275|Experimental|Resistance Training|
32849827|NCT03083275|No Intervention|Control|
32849828|NCT04343352|Experimental|In application group; Mobile Epilepsy Training Program Impleme|"Mobile epilepsy training program will be introduced to the parents in the application group and pre-tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale).~The participants will only use the mobile epilepsy training program application.~Parents in the application group will be monitored for 3 months using the mobile epilepsy training program. The researcher will follow the participants' use of the mobile application with the interface of the mobile epilepsy training program.~During the monitoring phase, the Epilepsy Information Questions screen will be given once every 15 days, and the training module will be reopened automatically on missing or incorrect answers and the parent's information on this subject will be renewed.~- At the end of the 3rd month, posttests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale) will be applied face-to-face."
32849829|NCT04343352|No Intervention|In the control group|"- The purpose of the project will be shared with the parents in the control group, and the pre-tests Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied.~There is no structured training program in the outpatient functioning. Routine practice of the hospital; is the education and information provided by the physician to the family during the outpatient clinic.~At the end of the 3rd month, the final tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied face to face.~After the work is completed, the mobile application will be installed on the phones of the control group, the application will be taught and applied."
32849830|NCT05007873|Experimental|Treatment (dasatinib, decitabine and cedazuridine)|"Patients receive dasatinib PO QD on days 1-28. Beginning cycle 4, patients also receive decitabine and cedazuridine PO QD on days 1-3. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 12 years in the absence of disease progression or unacceptable toxicity."
32849831|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
32849832|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
32849833|NCT01474772|Experimental|Pregabain|
32849834|NCT01474772|Placebo Comparator|Placebo|
32849835|NCT04341012||Normal|No known medical conditions
32849836|NCT04341012||Liver Cirrhosis|Clinically diagnosed with cirrhosis
32849837|NCT04341012||COVID-19 tested|Persons with known test results for COVID-19 RNA
32849838|NCT04341012||Other|Persons with other medical diagnosis, no known liver disease, negative for COVID-19
32849839|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
32849840|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
32849841|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
32959722|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
33320223|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
33320224|NCT05443802|Experimental|Experimental|Reduced dose of rapid-acting insulin of 0.05 IU/kg/h from randomization until resolution of DKA
32849842|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
32849843|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
32849844|NCT05688553|Experimental|Flexi-bar group|
32849845|NCT05688553|Active Comparator|balance and strength group|
32849846|NCT05302518|Experimental|Cognitive behavioral therapy with exposure in virtual reality|This arm of the study will receive cognitive behavioral therapy with exposure in virtual reality. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
32849847|NCT05302518|Active Comparator|Cognitive behavioral therapy with exposure in vivo|This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
32849848|NCT03801681||myocarditis|patients with clinically suspected myocarditis
32849849|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
32849850|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
32849851|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
32849852|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
32849853|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
32849854|NCT04984551|Experimental|Arm I: ECHO Participants (ECHO clinics, workshop, education)|Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants also receive 5 core lectures through an internet-based professional education curriculum.
32849855|NCT04984551|Experimental|Arm II: Patients (questionnaire, medical chart review)|Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15 minute interview in person or phone about the care they received by their physician at baseline, end of month 4 and month 12.
32849856|NCT04984551|Experimental|Arm III: Caregivers (questionnaire)|Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15-minute interview in person or by phone their family member received by their physician.
32849857|NCT05137392|Experimental|Test group|The test group will receive the novel regimen of oral hygiene instruction, including use of a commercially available intelligent toothbrush connected to the Chinese consumer version of an application and receiving targeted oral health message as well as use of interdental toothbrush
32849858|NCT05137392|Other|Control group|The test group will receive the standard regimen of oral hygiene instruction, including use of a commercially available manual toothbrush and receiving a brochure for oral hygiene instruction as well as use of interdental toothbrush
32849859|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
32849860|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
32849861|NCT05129124|Experimental|T01: +6.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849862|NCT05129124|Experimental|T02: +6.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849863|NCT05129124|Experimental|T03: -3.00-2.75 x180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849864|NCT05129124|Experimental|T04: -3.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849865|NCT05129124|Experimental|T05: -9.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
33320225|NCT05443802|Other|Control|Rapid-acting insulin dose of 0.10 IU/kg/h in accordance with usual recommendations until resolution of DKA
32849866|NCT05129124|Experimental|T06: -9.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849867|NCT05129124|Experimental|T07: -12.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849868|NCT05129124|Experimental|T08: -12.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
32849869|NCT05129124|Active Comparator|C01: +6.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
32849870|NCT05129124|Active Comparator|C02: +6.00-2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
32849871|NCT05129124|Active Comparator|C03: -3.00-2.75 x180|Commercially available Ultra for Astigmatism Contact Lenses
32849872|NCT05129124|Active Comparator|C04: -3.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
32849873|NCT05129124|Active Comparator|C05: -9.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
33320226|NCT01311284|Active Comparator|Macintosh|
33320227|NCT01311284|Active Comparator|Mcgrath|
33320228|NCT01311284|Active Comparator|Airtraq Nasotracheal|
33320229|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
33320230|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
33320231|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
33320232|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
33320233|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
33320234|NCT03784664|Active Comparator|Arterial blood gas|
33320235|NCT03784664|Experimental|Veinous blood gas|
33320236|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
33320237|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
33320238|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
33320239|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
33320240|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
33320241|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
33320242|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
33320243|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
33320244|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
33320245|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
33320246|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
33320247|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
33320248|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
33320249|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
33320250|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
33320251|NCT01561352|Experimental|Factor VII|
33320252|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
33320253|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
33320254|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
33320255|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
33320256|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
33406467|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
32849874|NCT05129124|Active Comparator|C06: -9.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
32849875|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
32959723|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
32849876|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
32849877|NCT05302362|Sham Comparator|Sham tDCS Group|Sham transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, 0mA stimulation for 19 min 30 sec.
32849878|NCT05302362|Active Comparator|Conventional tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, continuous 1.5mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
32849879|NCT05302362|Experimental|Tailored tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 2.0mA, continuous 2.0mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
32849880|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
32849881|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
32849882|NCT05679271|Experimental|venous stenting|"Venous stenting associated to antiaggregation protocol:~Venous stenting: venous approach can be performed via femoral, brachial or jugular puncture. Autoexpansible stent should delivered at the level of the fistulous sinus. If distal access catheter is wide enough, stent can be delivered directly through it. After partial deployment of the stent, Labbe vein's flow may be restricted. If necessary, several stents can be used in the same procedure to cover the whole length of fistulous sinus area. After stent deployment, ballon angioplasty is compulsory and must be performed using a ballon of equivalent size to the stent. The procedure ends after stent deployment and angiographic arterial post-op controls.~Antiaggregation protocol: aspirin (160mg for 3 months) + clopidogrel (75mg/d 5 days before stenting and 75mg/d for 1 month after stenting) OR ticagrelor (180mg 2h before stenting and 90mg twice a day for 1 month) in case of clopidogrel platelet resistance."
32849883|NCT05679271|Active Comparator|no treatment|standard care (no treatment)
32849884|NCT04326504||Patients starting DTG-based regimens|ART-naïve patients, starting cART regimens based on DTG
32849885|NCT04326504||Switch cohort|Patients on stable ART regimens switching to DTG (any reason)
32849886|NCT04326504||Therapy failure|ART-experienced patients switching to DTG-containing regimens due to virological failure
32849887|NCT04326504||Non-DTG group|Patients who started a non-DTG containing regimen
32849888|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Gemcitabine (Arm A)|"Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (500 mg/m^2 to 1000 mg/m^2) of gemcitabine on Day 1 of each cycle (where each cycle is 21 days).~Not currently enrolling."
32849889|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Lenalidomide (Arm B)|"Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (15 mg to 25 mg) of lenalidomide once daily on a 2 weeks on and 1 week off schedule, starting on Day 1 of each cycle (where each cycle is 21 days).~Not currently enrolling."
32849890|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day 1 of each cycle (where each cycle is 21 days). Participants will also receive polatuzumab vedotin at a dose of 1.8 mg/kg on Day 1 of each cycle (where each cycle is 21 days).
32849891|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Umbralisib (Arm D)|"Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (600 mg to 800 mg) of umbralisib once daily, starting on Day 1 of each cycle (where each cycle is 21 days).~Not currently enrolling."
32849892|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Gemcitabine (Arm A)|"Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with gemcitabine at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.~Not currently enrolling."
32849893|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Lenalidomide (Arm B)|"Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with lenalidomide at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.~Not currently enrolling."
32849894|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|"Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with polatuzumab vedotin at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.~Not currently enrolling."
32898804|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
32898805|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
32959724|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
33320257|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
33320258|NCT05535296|Experimental|Intervention group|Standard health examination and related feedback. Functional examination. Risk profile and related advice.
32849895|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Umbralisib (Arm D)|"Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with umbralisib at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.~Not currently enrolling."
32849896|NCT05672329|Experimental|Group 1: Low-flow apnoeic oxygenation|Group 1) 0.2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
32849897|NCT05672329|Experimental|Group 2: High-flow apnoeic oxygenation|Group 2) 2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
32849898|NCT05672329|Active Comparator|Group 3: Control group apnoeic oxygenation|Group 3) 4 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
32849899|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
32849900|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
32849901|NCT04401787|Active Comparator|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
32849902|NCT04401787|Active Comparator|open anterior resection|Open anterior resection for 56 patients
32849903|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
32849904|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
32849905|NCT04923633||Phase I Instrument-Assisted Soft Tissue Manipulation (IASTM) Stroke Pattern Analysis|Fifteen (n=15) experienced clinicians, each with 8 or more years experiences in instrument-assisted soft tissue manipulation (IASTM), will participate in an observational studying analyzing their application of basic stroke patterns (linear, curved) to a consistent research assistant/model. IASTM is a type of massage that uses rigid devices. A Quantifiable Soft Tissue Manipulation (QSTM) device system will be used for determining objective metrics of stroke parameters (e.g. stroke force, rate, angle) and results will be compared between participants to determine characteristic stroke profile patterns for use in training and research.
32849906|NCT04923633||Phase II Consistency of IASTM Force Application|"The reproducibility of applying a targeted STM stroke force will be determined within and between therapists, both with and without visual monitoring of the QSTM metrics and graphic display. Two novice and two experienced therapists will be trained using QSTM. A novice is defined as a clinician with <1 year and an experienced with >8 years of practice. Fifty (n=50) healthy, non-obese subjects will be enrolled that meet the inclusion/exclusion criteria. First, the clinicians will apply a self-perceived moderate force for 15sec (non-therapeutic dose), within subject tolerance, without using QSTM feedback. Then, the clinician will apply a targeted force of 10N with visual monitoring of QSTM feedback. This process will be repeated 5-7 days later to determine repeatability. After testing, subjects will participate in simple back and/or leg stretches and an ice pack applied."
32849907|NCT04923633||Phase III Reliability of Dynamic Pressure Pain Threshold Assessment|"The reliability of dynamic pressure pain threshold (DPPT) assessment over a specified area will be determined. Two novice and two experienced clinicians will be trained using QSTM. Subjects (n=50) will be recruited that meet the inclusion/exclusion criteria of healthy, non-obese, younger (≥18 but ≤30yo) and older individuals (≥50 but ≤75yo) (males and females). The clinicians will apply force to standardized areas of the back and thigh regions for 1 min, using the Quantifiable Soft Tissue Manipulation (QSTM) device system. The force applied will be applied up to but below the threshold of when a subject says to stop when they feel the pressure change into any sort of irritating discomfort/pain. Secondary clinical outcomes will be assessed before and after testing since testing could have effects on the soft tissue, pain, and physical performance measures. After testing, the subject will be instructed in simple back and/or leg stretches and an ice pack applied."
32849908|NCT05668039|Experimental|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP/ECPT) is a non-invasive technique used to improve cardiac and cerebral perfusion. It aims to achieve 'diastolic augmentation' by increasing arterial blood pressure and retrograde aortic blood flow during diastole. This technique is currently used to treat refractory angina and heart failure, and was demonstrated to be well tolerated without limiting side effect. Practially, blood pressure cuffs are put along the lower limbs and are inflated to 300 mmHg pressure intermittently during one hour session. 15 sessions will be performed over 15 weeks.
32849909|NCT05668039|Sham Comparator|Sham procedure|The procedure will be identical to the experimental procedure, excluding the pressure that will reach only 80 mmHg.
32849910|NCT04301310|Experimental|Treatment Group|
32849911|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
32849912|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
32849913|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
32849914|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
32849915|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
32849916|NCT04291404|No Intervention|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
32849917|NCT04291404|Experimental|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
32849918|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
32959725|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
32959726|NCT00765648|Active Comparator|1|nicardipine intravenous
32959727|NCT00765648|Active Comparator|2|Labetalol
32959728|NCT00766116|Experimental|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza 2 days then GO at 3 mg/m^2"
33406468|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
33406469|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
32959729|NCT00766116|Experimental|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin~75mg/m^2 5-Aza for 4 days then GO at 6 mg/m^2"
32959730|NCT00766116|Experimental|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
32959731|NCT00766116|Experimental|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
32959732|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
32959733|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
32959734|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
32959735|NCT00769314|Placebo Comparator|2|
32959736|NCT00769392|Other|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
32959737|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
32959738|NCT00770874|Active Comparator|2|Cisplatin (arm B)
32849919|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
32959739|NCT00771264|Active Comparator|Urgent PC|
32959740|NCT00771264|No Intervention|Sham / Placebo|
32959741|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
32959742|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
32959743|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
32959744|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
32959745|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
32959746|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
32849920|NCT05665387|Experimental|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID
32849921|NCT05665387|Experimental|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID
32849922|NCT05665387|Placebo Comparator|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution BID
32849923|NCT05302206|Experimental|patients with ileostomy without type 2 diabetes|colonic glucose or saline infusion via ileostomy
32959747|NCT00773604|Other|Treatment|Deep Brain Stimulation
32959748|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
32959749|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
32959750|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
32849924|NCT05302206|Experimental|patients with ileostomy with type 2 diabetes|colonic glucose or saline infusion via ileostomy
32959751|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
32959752|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
32959753|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
32959754|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
32959755|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
32959756|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
32959757|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
32959758|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
32959759|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
32959760|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
32959761|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
33406470|NCT03275389|Active Comparator|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
33104062|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
33406471|NCT03414983|Experimental|Arm A|Nivo + SOC
33104063|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
33104064|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
33104065|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
33104066|NCT05539794|Experimental|Intervention|The intervention group will follow a physical exercise and lifestyle counselling program.
33104067|NCT05539794|No Intervention|Control|Standard care
33104068|NCT05527470|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
33104069|NCT05527470|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
33104070|NCT01258348|Experimental|LY573636 +sunitinib|
33104071|NCT00537225|Experimental|A-Exercise group|Home based exercise
33104072|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
33104073|NCT05141266|Experimental|Brief Intervention Medication Therapy Management (BI-MTM)|Brief Intervention Medication Therapy Management (BI-MTM) is the overarching model made up of 4 evidence-based components: Medication Therapy Management (MTM); Screening, Brief Intervention, and Referral to Treatment (SBIRT); naloxone dispensing, and Patient Navigation (PN). Each component is sequentially delivered within the model and addresses a critical aspect of opioid medication misuse and risk. The pharmacy-based portion of BI-MTM (MTM+SBIRT+naloxone) will be delivered by a PharmD level pharmacist, and PN will be delivered by a bachelor's level interventionist.
33104074|NCT05141266|Other|Standard of Care|Standard of Care is the treatment as usual condition, which follows federal and Utah state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Specifically, SMC in Utah requires pharmacists to: (1) offer counseling, (2) document counseling has been offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution.The duration of SMC in the current study is a single 5-10 minute session delivered by a University of Utah pharmacist other than the study pharmacist that possesses a similar level of education and professional licensing.
33104075|NCT05513352|No Intervention|Experiment 1 - Normal hearing - AAT|Each participant assigned to the normal hearing group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
33104076|NCT05513352|No Intervention|Experiment 1 - Hearing impaired - AAT|Each participant assigned to the normal hearing impaired group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
33104077|NCT05513352|No Intervention|Experiment 2 - normal hearing _ SAT|Each participant assigned to the normal hearing group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
33104078|NCT05513352|No Intervention|Experiment 2 - hearing impaired - SAT|Each participant assigned to the hearing impaired group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
33104079|NCT05513352|No Intervention|Experiment 2 - tinnitus - SAT|Each participant assigned to the tinnitus group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
33104080|NCT05513352|Experimental|Experiment 3 - normal hearing (tACS) - AAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
33104081|NCT05513352|Sham Comparator|Experiment 3 - normal hearing (sham) - AAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
33104082|NCT05513352|Experimental|Experiment 3 - hearing impaired (tACS) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
33104083|NCT05513352|Sham Comparator|Experiment 3 - hearing impaired (sham) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
33104084|NCT05513352|Experimental|Experiment 3 - tinnitus (tACS) - AAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
33406472|NCT03414983|Active Comparator|Arm B|SOC
33406473|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
33406474|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
33406475|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
32959762|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
32959763|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
32959764|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
32959765|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
32959766|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
32959767|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
32959768|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
32959769|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
32959770|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
32959771|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
32959772|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
32959773|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
32959774|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
32959775|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
32959776|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
32959777|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
32959778|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
32959779|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
32959780|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
32959781|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
32959782|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
32959783|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
32959784|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
32959785|NCT00795288|Placebo Comparator|Placebo|Placebo
32959786|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
32959787|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
32959788|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
32959789|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
32959790|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
32959791|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
32959792|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
32959793|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
32959794|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
32959795|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
32959796|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
32959797|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
32959798|NCT00799578|Experimental|Cystagon-EC|
32959799|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine gluconate (CHG) 2% w/v CHG/isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied @ same time
32959800|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially
32959801|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate (CHG) 4% w/v in an aqueous base
32959802|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile deionized water - 3 swabsticks applied at the same time.
32959803|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied sequentially.
32959804|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
32959805|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
32959806|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
32959807|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
33320259|NCT05535296|No Intervention|Control group|Standard health examination and related feedback. Functional examination.
33320260|NCT05127590|Experimental|RBN-2397 in combination with pembrolizumab|RBN-2397 orally in combination with the fixed approved dose of IV pembrolizumab
33320261|NCT00261443|Placebo Comparator|A1|/Active Comparator
32849925|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
32849926|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
32849927|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
32849928|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
32849929|NCT05301738|Experimental|Plyometric exercise group|Participants in this group received the plyometric training program
32849930|NCT05301738|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
32849931|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
32849932|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
32849933|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
32849934|NCT04325958|Placebo Comparator|Placebo cannabis|Participants will drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC)
32849935|NCT04325958|Experimental|Active cannabis|Participants will drive the simulator before and after smoking an active cannabis cigarette (12.5% THC)
32849936|NCT05688319|Experimental|experimental group|The participants in the experimental group were divided into five groups of eight participants each according to the number of days they visited the center. The training was conducted face to face in the meeting room of the special education and rehabilitation center. Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks . The duration of each training session was 60-90 minutes. The weekly training sessions for all the experimental groups were completed on the same day.
33320262|NCT00261443|Experimental|A2|
33320263|NCT05111132|Experimental|7.5 ml/kg|Group 1, receiving a fluid challenge of 7,5 ml/kg in 5 minutes
33320264|NCT05111132|Experimental|12.5 ml/kg|Group 2, 12.5 ml/kg of fluid challenge in 5 minutes
32849937|NCT05688319|No Intervention|control group|The control group did not receive any training, and there was no interaction between the experimental group and the control group during the training period.
32849938|NCT04486404||Group 1|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra and Ec.
32849939|NCT04486404||Group 2|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra, Ch and Ec.
32849940|NCT04401397|Experimental|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
32849941|NCT04401397|Active Comparator|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
32849942|NCT05095818|No Intervention|Standard of Care with EMR Enhancements|Participants in this arm will receive Standard of Care with EMR Enhancements.
32849943|NCT05095818|Experimental|Standard of Care with EMR Enhancements and PrEP-RN|Participants in this arm will receive Standard of Care with EMR Enhancements and PrEP-RN.
32849944|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
32849945|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
32849946|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
33320265|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
32959808|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
32959809|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
32959810|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
32959811|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
32959812|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
32959813|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
32959814|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
32959815|NCT00803400|Active Comparator|Alprazolam|Patients assigned to the pharmacological plan
32959816|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|Patients assigned to mix plan
32959817|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
32959818|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
32959819|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
32959820|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
32959821|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
32959822|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
32959823|NCT00805038|Placebo Comparator|Control|Usual care
32959824|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
32959825|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
32959826|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
32959827|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
32959828|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
32959829|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
32959830|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32959831|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
32959832|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
32959833|NCT00810498|Experimental|Trilogy|Trilogy Device
32959834|NCT00810498|Active Comparator|Standard of Care|Participants prescribed ventilator
32959835|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
32959836|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
32959837|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
32959838|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
32849947|NCT04310826|Experimental|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
32849948|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
32849949|NCT04283604|Experimental|ADHD with MPH|ADHD participants, taking MPH before the second session
32849950|NCT04283604|No Intervention|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
32849951|NCT04283604|No Intervention|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
32849952|NCT04761367|Other|INTERVENTION GROUP|The IG will participate in a 6-month exercise program based on the PAIR exercise protocol and will receive educational sessions and material on the importance of maintaining an active life style after THR or TKR
32849953|NCT04761367|No Intervention|CONTROL GROUP|The CG will receive only educational sessions and material on the importance of maintaining an active life style after THR or TKR
32849954|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
32849955|NCT05656729|Placebo Comparator|Placebo|Placebo 8-week daily administration
32849956|NCT05656729|Active Comparator|Multistrain probiotic|Dietary Supplement: Multistrain Probiotic 12-week daily administration
32849957|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
32849958|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
32849959|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
32849960|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
32849961|NCT05082714|Experimental|tocilizumab|tocilizumab plus usual care
32849962|NCT05082714|Experimental|baricitinib|baricitinib plus usual care
32849963|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
32849964|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
32849965|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
32849966|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
32849967|NCT04272840|No Intervention|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
32849968|NCT04272840|Experimental|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
32849969|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
32849970|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
32959839|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
32959840|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
32959841|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
32959842|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
32959843|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
32959844|NCT00812838|Placebo Comparator|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
32959845|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
32959846|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32959847|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
32959848|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
33033436|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
33406476|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
33406477|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
33406478|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
33406479|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
32849971|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
32849972|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
32849973|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
32849974|NCT05073042|Experimental|Morning exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
32849975|NCT05073042|Experimental|Evening exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
32849976|NCT05073042|Active Comparator|Time of choice exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
32849977|NCT05073042|No Intervention|No exercise period|"During the two-week washout (i.e., break) periods between the exercise interventions, participants will not have an exercise goal. Participants will continue to receive weekly emails and wear a physical activity sensor daily."
32849978|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
32849979|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
32849980|NCT04239456|Experimental|Group A|Receive intervention 2 weeks after group assignment.
32849981|NCT04239456|Other|Group B|Wait List - Receive intervention 3 months after initial testing.
32849982|NCT00810459|Experimental|Trilogy ventilator|Trilogy ventilator
32849983|NCT00810459|Active Comparator|Standard of Care|Participants currently prescribed ventilator
32849984|NCT04229940|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
32849985|NCT04229940|Active Comparator|No bridging|The hernia defect is left without closure prior to application of the mesh.
32849986|NCT05645107|Experimental|XEMBIFY + Standard Medical Treatment (SMT)|"Participants will receive a loading dose of 150 milligrams per kilograms per day (mg/kg/day) (Week 1, Days 1 to 5) subcutaneously (SC) for 5 consecutive daily doses followed by weekly infusions of 150 mg/kg starting Week 2 (Day 8) through Week 53 (end of Treatment Phase).~The SMT will include the antileukemic treatments and the other supportive treatments that the participants will need during their participation."
32849987|NCT05645107|Placebo Comparator|Placebo + SMT|"Participants will receive sterile 0.9 percent Sodium Chloride Injection, United States Pharmacopeia (USP) or equivalent starting at Week 1 (Days 1 to 5) SC for 5 consecutive daily doses followed by weekly infusions starting at Week 2 (Day 8) through Week 53.~The SMT will include the antileukemic treatments and the other supportive treatments that the participants will need during their participation."
32849988|NCT04227756|Experimental|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
32849989|NCT04227756|Active Comparator|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
32849990|NCT04227756|Active Comparator|Mescaline-300/500|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
32849991|NCT04227756|Placebo Comparator|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
32849992|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
32849993|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
32849994|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
32849995|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
33033437|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
33406480|NCT05198622|Experimental|Intercostobrachial Nerve Preservation Arm|Intercostobrachial nerve preserving axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
32849996|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
32849997|NCT05345977|Experimental|Unified Protocol|The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
32849998|NCT05044962|Experimental|Aim 1a (PK study group 1)|Initiating injectable cabotegravir/rilpivirine (LA ART) and DMPA
32849999|NCT05044962|Experimental|Aim 1a (PK study group 2)|Initiating injectable cabotegravir/rilpivirine (LA ART) and and etonogestrel implant
32850000|NCT05044962|Experimental|Aim 1a (PK study group 3)|Initiating injectable cabotegravir/rilpivirine (LA ART) and levonorgestrel implant.
32850001|NCT05044962|Active Comparator|Aim 1a (PK study group 4)|Receiving injectable cabotegravir/ rilpivirine (LA ART) and not using any hormonal contraceptive method (e.g. copper IUD)
32850002|NCT05044962|Active Comparator|Aim 1a (PK study group 5)|AGYW without HIV and not exposed to antiretrovirals (e.g., for PrEP) initiating DMPA
32850003|NCT05044962|Experimental|Aim 2a (Hybrid trial intervention group)|AGYW with viral suppression on their current ART regimen to switch to cabotegravir/ rilpivirine.
32850004|NCT05044962|Active Comparator|Aim 2a (Hybrid trial comparator group)|AGYW with viral suppression to continue their oral ART regimen.
32850005|NCT05639335|Other|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
32850006|NCT05639335|Experimental|Character|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
32850007|NCT04198506|Experimental|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
32850008|NCT04198506|Active Comparator|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
32850009|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
32850010|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
32850011|NCT05634967||Disease-matched cohort (Comparison Group 1)|comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group).
32850012|NCT05634967||Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)|healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study.
32850013|NCT05634967||Kesimpta-exposed cohort|women and infants who are exposed to Kesimpta during pregnancy to treat MS.
32850014|NCT04073628|Active Comparator|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
32850015|NCT04073628|Placebo Comparator|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
32850016|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
33033438|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
33033439|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
33033440|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
33033441|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
32850017|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
33104085|NCT05513352|Sham Comparator|Experiment 3 - tinnitus (sham) - AAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
32850018|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
32850019|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
32850020|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
32850021|NCT05043714|Experimental|Intravenous|Patients will receive a first study treatment cycle consisting of one IV infusion of NG-641 on Days 1, 3 and 5 and one IV infusion of nivolumab on Day 15. Patients will then receive nivolumab monotherapy given once every four weeks (on Day 15 of each 28-day cycle), until progression, unacceptable toxicity, withdrawal of consent, completion of 8 cycles of treatment, or the study ends, whichever occurs first.
32850022|NCT04908501||Intervention group|Services of the non-transversal clinical departments of the Bordeaux University Hospital willing to participate to the programme.
32850023|NCT04908501||Control group|Services of the non-transversal clinical departments of the Bordeaux University Hospital not willing to participate to the programme.
32850024|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
32850025|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
32850026|NCT04721691|Active Comparator|IP|Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Epidiolex at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
32850027|NCT04721691|Placebo Comparator|Placebo|Placebo is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe. The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Placebo at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
32850028|NCT04207788|Experimental|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
32850029|NCT04207788|Active Comparator|Usual care|The elderly with hip fracture in the control group will receive usual care.
32850030|NCT04760821|No Intervention|Usual Care|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2. Usual Care means the clinical protocol approved by the enrolling center.
32850031|NCT04760821|Experimental|Trimetazidine|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2 plus trimetazidine.Usual Care means the clinical protocol approved by the enrolling center.
32850032|NCT04382079|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
33104086|NCT05513352|Experimental|Experiment 4 - normal hearing (tACS) - SAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33104087|NCT05513352|Sham Comparator|Experiment 4 - normal hearing (sham) - SAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33320266|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
33406481|NCT05198622|Active Comparator|Intercostobracial Nerve Sacrifice Arm|Intercostobrachial nerve sacrificing axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
32959849|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
33406482|NCT04661137|Experimental|Carfilzomib-containing Regimen|"Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 80 mg on days 1, 8 and 15."
33406483|NCT04661137|Experimental|Pomalidomide-containing Regimen|"Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 60 mg on days 1, 8 and 15."
32959850|NCT00821184|Active Comparator|Vesicare|Vesicare alone
32959851|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
32959852|NCT05237154|Experimental|Intermittent fasting (IF)|Alternate-day intermittent fasting. Consumption of 25% of daily energy requirements on scheduled fasting days involving energy restriction for 2 non-consecutive days of the week and ad libitum feeding on the other 5 days of the week. Period: 8 weeks.
32959853|NCT05237154|Experimental|Exercise: High-Intensity Interval Training (HIIT)|High intensity circuit training. Progressive training protocol 3x/week, for 8 weeks, with at least 1 day of rest between sessions and duration of 25 minutes each session - 4 minutes of initial warm-up, 18 minutes of the main part and 3 minutes of relaxation. First and second week: 30 second run and recovery time. Third and fourth week: 35-second runtime and 25-second recovery time. Fifth and Sixth Week: 40-second runtime and 20-second recovery time. Seventh and eighth weeks: 45-second runtime and 15-second recovery time.
32959854|NCT05236842|Active Comparator|Sulthiame 100 mg|Sulthiame film-coated tablets 100 mg once daily 15 weeks
32959855|NCT05236842|Active Comparator|Sulthiame 200 mg|Sulthiame film-coated tablets 200 mg once daily 15 weeks
32959856|NCT05236842|Active Comparator|Sulthiame 300 mg|Sulthiame film-coated tablets 300 mg once daily 15 weeks
32959857|NCT05236842|Placebo Comparator|Placebo|Placebo film-coated tablets once daily 15 weeks
32959858|NCT05236686|Experimental|Hepato-celiac lymphadenectomy|This single-arm, single-center, phase II trial is to evaluate the safety and effectiveness of hepato-celiac lymphadenectomy in the treatment of ovarian cancer with hepato-celiac lymph nodes metastases, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
32959859|NCT05235906|Experimental|Surufatinib + Sintilimab|
32959860|NCT05235594|Experimental|Experimental: Smart shirt|The research intervention is, for all twenty patients, to wear a smart t-shirt connected to a smart phone throughout the day (preferably 8 hours pr day) for 2 weeks.
32959861|NCT05235438|Experimental|IMM27M|IMM27M 0.1, 0.3, 1.0, 2.0, 3.0 mg/kg
32959862|NCT05215860|Active Comparator|Habit cessation counselling with management for OPMD|n=100; Habit cessation counselling with general and medical management for OPMD
32959863|NCT05215860|Experimental|Habit cessation counselling, management for OPMD and intraoral photographs|n=100; Habit cessation counselling with standard management for OPMD and visual exposure to personal intraoral photographs of oral lesions at baseline and review
32959864|NCT05209620|Experimental|Orelabrutinib Combined with Pemetrexed|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration, Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
32959865|NCT05206812|Experimental|durvalumab|The operable non-small cell lung carcinoma patients (resectable stage IIA~IIIB)
32959866|NCT05174988|Experimental|Angle stitch|"If the allocation corresponds to Angle stitch, surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) apexes. Knot tying technique (intra-corporeal vs extracorporeal) will be up to surgeon preference. After this is completed, barbed suture will be used to re-approximate the remainder of the vaginal cuff from right to left, backtracking once at the end for reinforcement."
32959867|NCT05174988|No Intervention|control|"If the subject's group corresponds to Control group, the surgeon will re-approximate the cuff in a standard fashion, using a running-barbed suture (2-0 V-LOC 90 with tapered needle), starting at the right apex, moving towards the left, and then back-tracking once to further reinforce the closure."
32959868|NCT05172648|Active Comparator|control group|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength
32959869|NCT05172648|Other|contrast group|Moisten the mouth with sterile distilled water with an oral cotton swab.
32959870|NCT05131152|Experimental|cyclosporine group|"Mild DE patients: topical usage of 0.05% cyclosporine Eye Drops BID + 0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks.~Moderate DE patients: topical usage of 0.05% cyclosporine Eye Drops BID +0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks, and 0.02% Fluoromethalone Eye Drops BID for 4 weeks."
32959871|NCT05131152|Experimental|control group|Mild DE patients: 0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks Moderate DE patients: 0.02% Fluoromethalone Eye Drops BID for 4 weeks +0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks.
32959872|NCT05110872|Experimental|Menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 menthol cigarettes per day will be recruited.
32959873|NCT05110872|Experimental|Non-menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 non-menthol cigarettes per day will be recruited.
32850033|NCT04382079|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
32850034|NCT04382079|No Intervention|control|Routine care to encourage oral care three times a day.
32850035|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
32850036|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
32850037|NCT04017819|Active Comparator|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
32850038|NCT04017819|Experimental|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
32850039|NCT04017819|Experimental|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)
32850040|NCT05019222|Experimental|Arm 1) Sevoflurane group|Sevoflurane based inhalation anesthesia
32850041|NCT05019222|Active Comparator|Arm 2) Remimazolam group|Remimazolam based total intravenous anesthesia
32850042|NCT03081559|Experimental|Intervention|Healthy Divas intervention
32850043|NCT03081559|No Intervention|Control|Treatment as usual
32850044|NCT05017740|Active Comparator|ICSI|
32850045|NCT05017740|Active Comparator|PICSI|
32850046|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
32850047|NCT05688007||Cases|pregnant women with established preterm labor - gestational age: (28-36 weeks), having: Regular uterine contractions are at least 3 in 10 min each lasting 40 seconds. Progressive cervical dilatation (at least 4 cm).
32850048|NCT05688007||Controls|pregnant women not in labor - gestational age: (28- 36 weeks)
32850049|NCT04999956|Experimental|dynamic navigation|
32850050|NCT04999956|Sham Comparator|freehand|
32850051|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
32850052|NCT01459718|Experimental|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
32850053|NCT04154826|Experimental|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
32850054|NCT04154826|Experimental|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
32850055|NCT03081481|Experimental|PRX302|intraprostatic administration
32850056|NCT04918407|Experimental|Empagliflozin|Adding 25mg Empagliflozin on Insulin
32850057|NCT04918407|Active Comparator|Insulin alone|Just contriling the blood glucose with Insulin
32850058|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
32850059|NCT01488240|Active Comparator|Distal|part of scar distal to heart
32850060|NCT04916769|Experimental|Bosutinib capsule contents mixed with applesauce|Bosutinib capsule contents mixed with applesauce to healthy participants
32850061|NCT04916769|Experimental|Bosutinib capsule contents mixed with yogurt|Bosutinib capsule contents mixed with yogurt to healthy participants
32850062|NCT04916769|Active Comparator|Bosutinib intact capsules|Bosutinib intact capsules to healthy participants
32850063|NCT04989660|Experimental|Treatment Group|6% aqueous phenol, 1.5 mL per target site
32850064|NCT04989660|Placebo Comparator|Placebo Group|Isotonic saline, 1.5 mL per target site
32850065|NCT05623189|Experimental|HTD1801|HTD1801,1250 mg, BID
32850066|NCT05623189|Placebo Comparator|placebo|placebo, BID
32850067|NCT04008069|Experimental|Study drug|sarilumab 200 mg subcutaneously every two weeks
32850068|NCT04008069|Placebo Comparator|placebo|placebo subcutaneously every two weeks
32850069|NCT04022772|Experimental|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. After 3 months, patients continue to be contacted by the health coach at least once monthly for an additional 3 months.
32850070|NCT04022772|Active Comparator|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
32850071|NCT05621863|Experimental|Aim 1 Group 1|"Order of Treatments:~Meal Challenge 1, Meal Challenge 2, Meal Challenge 3"
32850072|NCT05621863|Experimental|Aim 1 Group 2|"Order of Treatments:~Meal Challenge 1, Meal Challenge 3, Meal Challenge 2"
32850073|NCT05621863|Experimental|Aim 1 Group 3|"Order of Treatments:~Meal Challenge 2, Meal Challenge 3, Meal Challenge 1"
32850074|NCT05621863|Experimental|Aim 1 Group 4|"Order of Treatments:~Meal Challenge 2, Meal Challenge 1, Meal Challenge 3"
33406484|NCT04661137|Experimental|Exploratory/Daratumumab-containing Regimen|"Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).~Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 100 mg on days 1, 8, 15 and 22."
33104088|NCT05513352|Experimental|Experiment 4 - hearing impaired (tACS) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33104089|NCT05513352|Sham Comparator|Experiment 4 - hearing impaired (sham) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33104090|NCT05513352|Experimental|Experiment 4 - tinnitus (tACS) - SAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33104091|NCT05513352|Sham Comparator|Experiment 4 - tinnitus (sham) - SAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
33104092|NCT05513352|Experimental|Experiment 5 - normal hearing (NF right) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the right relative to the left parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
33320267|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
33320268|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
33320269|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
33320270|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
33320271|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
33320272|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
33320273|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
33320274|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
33320275|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
33320276|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33320277|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33320278|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33320279|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33320280|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
32850075|NCT05621863|Experimental|Aim 1 Group 5|"Order of Treatments:~Meal Challenge 3, Meal Challenge 1, Meal Challenge 2"
33406485|NCT05186766|Experimental|Intervention Group|Video-Assisted Operating Room Introduce Program (VIASP-OR)
33320281|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33406486|NCT05186766|No Intervention|Control Group|Standart Nursing Care
33320282|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
32850076|NCT05621863|Experimental|Aim 1 Group 6|"Order of Treatments:~Meal Challenge 3, Meal Challenge 2, Meal Challenge 1"
32850077|NCT05621863|Experimental|Aim 2 Typical American Diet|
32850078|NCT05621863|Experimental|Aim 2 Typical American Diet Plus Test Foods|
32850079|NCT05621863|Experimental|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|
32850080|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
32850081|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
32850082|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
32850083|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
33320283|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
33320284|NCT01560962|Other|PI vs no intervention|In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.
32850084|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
32850085|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
32850086|NCT05687851|Experimental|treatment arm|Participants receive candonilimab at a dose of 10 mg/kg, Q3W (Day 1 of each 21 day treatment cycle) via IV infusion, until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraws informed consent, or candonilimab treatment over 2 years. During the q3w dosing period of candonilimab, participants receive radiotherapy including external beam radiotherapy (EBRT) and followed by brachytherapy.
32850087|NCT04663347|Experimental|Arm 1 - Epcoritamab + R-CHOP|In subjects with previously untreated DLBCL
32850088|NCT04663347|Experimental|Arm 2 - Epcoritamab + R2|In subjects with R/R FL
33104093|NCT05513352|Active Comparator|Experiment 5 - normal hearing (NF left) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the left relative to the right parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
33104094|NCT05136898|Experimental|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102. Treatment Visit 1 will occur at the investigative site and instillation will be performed by a qualified physician. Treatment Visits 2 to 6 will occur at the patient's home and instillation will be performed by a properly trained and qualified home health professional.
32850089|NCT04663347|Experimental|Arm 3 - Epcoritamab + BR|In subjects with previously untreated FL
32850090|NCT04663347|Experimental|Arm 4 - Epcoritamab + R-DHAX/C|In subjects with R/R DLBCL Eligible for ASCT
32850091|NCT04663347|Experimental|Arm 5 - Epcoritamab + GemOx|In subjects with R/R DLBCL Ineligible ASCT
32850092|NCT04663347|Experimental|Arm 6 - Epcoritamab + R2|In subjects with previously untreated FL
32850093|NCT04663347|Experimental|Arm 7 - Epcoritamab maintenance|In subjects with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L
32850094|NCT04663347|Experimental|Arm 8 - Epcoritamab + R mini-CHOP|In subjects with previously untreated DLBCL who are ineligible to receive full-dose anthracycline
32850095|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
32850096|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
32850097|NCT05687773|Experimental|Leap Motion Controller on Flat display - Non-Immersive Group|
32850098|NCT05687773|Experimental|Leap Motion Controller on Head-Mounted Display - Immersive Group|
32850099|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
32850100|NCT04384731|Experimental|Surfactant arm|patient receiving the surfactant
32850101|NCT04384731|No Intervention|Control arm|patient not receiving the surfactant
32850102|NCT04483362|Experimental|Physical Activity|Behavioural change techniques to promote physical activity
32850103|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
32850104|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents~without take nutrition meal replacement & exercise prescription"
33320285|NCT01560962|Other|PI vs hygiene|In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.
33320286|NCT01560962|Other|PI vs azasite|In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.
33320287|NCT01560962|Other|PI vs tobradex|In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.
33320288|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
32850105|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
32850106|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - only face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
32850107|NCT04972890|Placebo Comparator|Control group|with 2cc saline/NaCl 0,9% solution once at baseline
33320289|NCT05401058|Experimental|Experimental group|Droperidol 1.25mg/0.5ml
33320290|NCT05401058|Placebo Comparator|Placebo group|Normal saline 0.5ml
32850108|NCT04972890|Experimental|Stem Cell Group|with umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline
33320291|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
33320292|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
33320293|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
32850111|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 1 and test drug 2|
32850112|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 3 and test drug 4|
32850113|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 5 and test drug 6|
33320294|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
33320295|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
33320296|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
33320297|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
33320298|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
33406487|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
32850114|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 7|
32850115|NCT05042466|Experimental|Plant Medicine On Boarding|The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
32850116|NCT05042466|Experimental|Participant|0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
32850117|NCT05042466|Experimental|Psychiatrist|Psychiatrist QC scaling back SSRI's replacing with psilocybin.
32850118|NCT05042466|Experimental|On-Boarding Plant Medicine Specialist|The On-Boarding Provider will control dosage of the plant medicine via Telehealth.
32850119|NCT04791891||Low Back Pain (LBP)|"Adult women and men with self-reported LBP.~Inclusion Criteria for potential LBP participants~At least 18 years old;~Internet access;~Fluent in English or French;~Self-reported LBP.~Exclusion Criteria: No exclusion criteria will be adopted in this study.~No exclusion criteria will be adopted in this study"
32850120|NCT05052684|Experimental|Leaflex™ Performer|
32850121|NCT05615467|Experimental|LY3556050 + Metformin + Iohexol|LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).
32850122|NCT04547595|No Intervention|CONTROL|Standard care
32850123|NCT04547595|Active Comparator|Hypnosis|Standard care + intervention
32850124|NCT05613517||Healthy individual|Healthy individual without eye disorder.
32850125|NCT04756869||Health Care Workers at Risk for COVID-19|Health care workers at risk for COVID-19 will be monitored using wearing sensors and smartphone technology.
32850126|NCT04640961|Experimental|Cingal|
32850127|NCT05687617|Experimental|Gastric cancer with ICG|Patient to receive IV ICG during diagnostic laparoscopy.
32850128|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
32850129|NCT04541043|Experimental|active treatment|Nefecon 16 mg once daily by mouth for 9 months
32850130|NCT05608681|Experimental|EP-104IAR 4 mg|4 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850131|NCT05608681|Experimental|EP-104IAR 8 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850132|NCT05608681|Experimental|EP-104IAR 12 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850133|NCT05608681|Experimental|EP-104IAR 16 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850134|NCT05608681|Experimental|EP-104IAR 10 mg|4 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850135|NCT05608681|Experimental|EP-104IAR 20 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850136|NCT05608681|Experimental|EP-104IAR 30 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850137|NCT05608681|Experimental|EP-104IAR 40 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
32850138|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
32850139|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
32850140|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
32850141|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
33320299|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
33320300|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
33320301|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
33320302|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
33320303|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
32850142|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
33104095|NCT04596540|Experimental|SEL-212A|IV infusion of SEL-212A every 28 days for a total of up to 12 infusions
33406488|NCT05160714|Experimental|Adaptive SBRT Boost|Dose-escalated SBRT boost to an ADC-based high risk subvolume in HNC
33406489|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
33406490|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
32850143|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
32850144|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
32850145|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
32850146|NCT04537377|Experimental|VTX-801|
32850147|NCT04527315||COVID-19 ICU Patients|
32850148|NCT04527315||Control|
32850149|NCT05687539|Experimental|Mastiha water|Patients will receive 10ml of Mastiha water before every meal for one month
32850150|NCT05687539|Experimental|Mastiha capsules|Patients will receive 2 Mastiha capsules (2x350mg) before every meal for one month
32850151|NCT05687539|No Intervention|Control-Mastiha free|Patients will follow a Mastiha free one month period
32850152|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
32850153|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
32850154|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
32850155|NCT05470543|Experimental|Nurse-led Supportive Care Group|
32850156|NCT05470543|No Intervention|Control Group|The control group received only usual care. They did not receive any intervention during the study period.
32850157|NCT05687461||People at high risk for VTE|Patients who are admitted to the hospital for acute medical illness or surgery operations.
32850158|NCT05687461||People diagnosed with VTE|Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.
32850159|NCT05602597|Experimental|Part A - Itraconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 200mg Itraconazole by mouth twice daily beginning on Day 3 through Day 10. On Day 7 200 mg Itraconazole and 10 mg HMPL-689 will be simultaneously administered."
32850160|NCT05602597|Experimental|Part B - Fluconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 400mg Fluconazole by mouth daily on Day 3, then 200 mg Fluconazole by mouth daily Day 4 through Day 10. On Day 7 200 mg Fluconazole and 10 mg HMPL-689 will be simultaneously administered."
32850161|NCT05602597|Experimental|Part C - Rimfampin|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 600mg Rifampin by mouth daily beginning on Day 3 through Day 11. On Day 10 600mg Rifampin will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
32850162|NCT05602597|Experimental|Part D - Rabeprazole|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 40mg Rabeprazole by mouth daily beginning on Day 3 through Day 9. On Day 9 40mb Rabeprazole will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
32850163|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
32850164|NCT04608201|Experimental|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
32850165|NCT04608201|Placebo Comparator|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
32850166|NCT04955652|Active Comparator|Standard of Care|A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
32850167|NCT04955652|Experimental|Silent Best Practice Alert|A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
32850168|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
32850169|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
32850170|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
32850171|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
32850172|NCT04520217|Experimental|4% Imipramine Cream on UVB-Treated Areas|"2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.~2g of base cream will be applied to the UVB-treated areas on volar forearm and back.~No cream will be applied to a UVB-treated area on the back"
32850173|NCT04951986|Experimental|High dose Rifampicin plus Levofloxacin|Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days
33406491|NCT05142774|Experimental|tapinarof cream|Tapinarof 1%, cream
33406492|NCT03274687|Active Comparator|Conventional radiation therapy|Conventional post-prostatectomy radiation therapy (COPORT) over 7 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
33406493|NCT03274687|Experimental|Hypofractionated radiation therapy|Hypofractionated post-prostatectomy radiation therapy (HYPORT) over 5 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
33406494|NCT03909750|Experimental|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
32850174|NCT04951986|Experimental|Prednisone|Prednisone 1.5 mg/kg for 14 days
33406495|NCT03909750|Experimental|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
32850175|NCT04951986|Active Comparator|Standard TB treatment|High dose rifampicin/levofloxacin comparator
32850176|NCT04951986|Placebo Comparator|Placebo|Prednisone comparator
32850177|NCT04278859|Experimental|0.3mg/kg repeat dose every 21 days up to 2 years|
32850178|NCT04278859|Experimental|1 mg/kg repeat dose every 21 days up to 2 years;|
32850179|NCT04278859|Experimental|3 mg/kg repeat dose every 21 days up to 2 years;|
32850180|NCT04278859|Experimental|10 mg/kg repeat dose every 21 days up to 2 years;|
32850181|NCT04484337|Experimental|Part 1:Cohort 1: CAB 400 mg/mL IM gluteal|
32850182|NCT04484337|Active Comparator|Part 1:Cohort 1: CAB 200 mg/mL IM gluteal|
32850183|NCT04484337|Experimental|Part 1:Cohort 2: CAB 400 mg/mL SC abdominal|
32850184|NCT04484337|Active Comparator|Part 1:Cohort 2: CAB 200 mg/mL SC abdominal|
32850185|NCT04484337|Experimental|Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)|
32850186|NCT04484337|Active Comparator|Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)|
32850187|NCT04484337|Experimental|Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)|
32850188|NCT04484337|Active Comparator|Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)|
32850189|NCT04484337|Experimental|Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)|
32850190|NCT04484337|Active Comparator|Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)|
32850191|NCT04484337|Experimental|Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)|
32850192|NCT04484337|Active Comparator|Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)|
32850193|NCT04484337|Experimental|Part 1: Cohort 4b: CAB 400 mg/mL (SC)|
32850194|NCT04484337|Experimental|Part 1: Cohort 4h: CAB 400 mg/mL (SC)|
32850195|NCT04484337|Active Comparator|Part 1: Cohort 4h: CAB 200 mg/mL (SC)|
32850196|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
32850197|NCT04944420|Experimental|Intervention|"Intervention group will have access to Health enSuite Caregivers, an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote well-being and provides tools to help caregivers implement these strategies in their everyday lives.~Health enSuite Caregivers is designed to offer advice to caregivers of persons with dementia based on an assessment of their specific needs. Topics are divided into five main content areas, which are recommended based on an assessment of the caregivers current challenges and sources of stress."
32850198|NCT04944420|No Intervention|Waitlist Control|Participants in the control group will be wait-listed and receive only treatment as usual from their healthcare providers during the study. After their participation is the study has ended, participants in the control group will be given access to the full Health enSuite Caregivers program.
32850199|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
32850200|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
32850201|NCT03809247||Pancreatic cancer|such as Pancreatic ductal adenocarcinoma, Pancreatic acinar adenocarcinoma, and so on.
32850202|NCT03809247||Other pancreatic diseases|such as chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN); Solid pseudopapillary tumors (SPT); Serous cystic neoplasm (SCN); Pancreatic neuroendocrine neoplasm (P-NN); Mucinous cystic neoplasm (MCN) and so on.
32850203|NCT04278703|Active Comparator|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
32850204|NCT04278703|Active Comparator|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
32850205|NCT04278703|Active Comparator|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
32850206|NCT04907058|Experimental|Treatment with CO2|Patients were treated with an effective lowest concentration of CO2 delivered by the novel CO2 supply system.
32850207|NCT04449003||Adolescents with Tourette Syndrome|Adolescents (aged 13-17 years) with Tourette Syndrome
32850208|NCT04449003||Adolescents without any neurologic or psychiatric diagnoses|Adolescents (aged 13-17 years) without any history of tics
32850209|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
32850210|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
32850211|NCT04402281||suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
32850212|NCT04402281||suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
32959874|NCT04982718|Experimental|Oral fluid-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST.
32959875|NCT04982718|Experimental|Blood-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the next 250 participants will receive a blood-based fingerstick HCV ST.
32959876|NCT04982718|No Intervention|Control standard of care|In the control group, participants will receive information about standard of care HCV antibody testing available at local testing sites in their community and information about additional supporting materials, such as access to live chat and a call center for questions about testing.
32959877|NCT04956276|Experimental|Cohort 1: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
32959878|NCT04956276|Experimental|Cohort 2: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
32959879|NCT04956276|Experimental|Cohort 3: ALXN1830|If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
32959880|NCT04946994|Experimental|High intensity interval training|
32959881|NCT04946994|Active Comparator|Continuous moderate intensity exercise|
32959882|NCT04905342|Experimental|NVP-1805|NVP-1805 (80/10/20.8mg)
32959883|NCT04905342|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
32959884|NCT04900116|Active Comparator|Group 1|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
32959885|NCT04900116|Active Comparator|Group 2|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
32959886|NCT04900116|Active Comparator|Group 3|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
32959887|NCT04900116|Placebo Comparator|Group 4|In this group, US guided PENG block will be performed with 20 ml saline solution (%0.9 NaCl) using a 22 gauge 10 mm block needle.
32959888|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
32959889|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
32959890|NCT04699890||without heart failure|Patient without heart failure
32959891|NCT04694976||Sickle cell disease children from Lyon, France|Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.
32959892|NCT04690530||patients admitted in medical intensive care unit who require mechanical ventilation and sedation|The main goals of the study are to characterize cerebral hemodynamics and oxygenation as well as to study the effects of therapeutics on it in critically-ill patients. For this purpose, we plan to include all consecutive patients admitted in our medical intensive care unit who require mechanical ventilation and sedation and in whom the attending physician decides to perform one of the studied therapeutics (fluids, vasopressors or inotropes administration, blood transfusion, prone positioning, passive leg raising test, end-expiratory occlusion test) within the first 72h of ventilation onset. Cerebral hemodynamics (cerebral blood flow and cerebral autoregulation) as well as cerebral oxygenation will be non-invasively studied before and after therapeutics.
32959893|NCT04640298|Experimental|Cingal|
32959894|NCT04603248|Experimental|Single Arm|
32959895|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
32959896|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
33406496|NCT03909750|Experimental|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
32959897|NCT04340700|Experimental|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
32959898|NCT04340700|Placebo Comparator|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
32959899|NCT04213248|Experimental|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
32959900|NCT04070040|Experimental|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
32959901|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
32959902|NCT03936270|Experimental|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
33104096|NCT04596540|Experimental|SEL-212B|IV infusion of SEL-212B every 28 days for a total of up to 12 infusions
33406497|NCT04651218|No Intervention|control|sedentary control group watches TV between being assessed for outcome measures
32850213|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
32850214|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
33406498|NCT04651218|Experimental|exercise|exercise treatment performs exercise between being assessed for outcome measures
32850215|NCT05687383|Experimental|Safe breastfeeding pillow|Safe breastfeeding pillow increase the comfort and safety of postpartum women during breastfeeding, thereby prolonging breastfeeding and ensuring optimal nutrition for the baby
32850216|NCT05687383|Placebo Comparator|Breastfeeding pillow|Providing a comfortable, supportive and safe environment for healthier and breastfeeding for women and babies
32850217|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
32850218|NCT04401891|No Intervention|Routine Pre-Operative Education in MD office prior to surgery|
32850219|NCT04401891|Experimental|Formal Pre-operative education/therapy prior to surgery|
32850220|NCT03319537|Experimental|Pevonedistat|
32850221|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
32850222|NCT04382703|Experimental|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
32850223|NCT04382703|Active Comparator|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
32850224|NCT01459016|Experimental|Imaging Biomarkers|
32850225|NCT04208217|Experimental|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
32850226|NCT04208217|Experimental|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
32850227|NCT04087278|Active Comparator|Metabotype A|Taking treatment
32850228|NCT04087278|Active Comparator|Metabotype B|Taking treatment
32850229|NCT04087278|Active Comparator|Metabotype 0|Taking treatment
32850230|NCT04087278|Placebo Comparator|Placebo|Taking matching placebo
32850231|NCT04382859|Active Comparator|TAP block with liposomal bupivacaine|Active comparator
32850232|NCT04382859|Other|TAP block with 0.25% bupivacaine|Standard comparator
32850233|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed~Transfer to ICU after surgery"
32898806|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
32898807|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
32898808|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
32898809|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
32898810|NCT03015935||Optical|visual-assisted entry
32898811|NCT03015935||Veress|Veress entry
32898812|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
32898813|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
32898814|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
32898815|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
32898816|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
32898817|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
32898818|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
32898819|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
32898820|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
32898821|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
32898822|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
32898823|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
32898824|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
32903422|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
33104097|NCT04596540|Placebo Comparator|Placebo|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
32903423|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
32903424|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
32903425|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
32903426|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
32903427|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
32903428|NCT00597818|Placebo Comparator|Placebo|Participants receive matching placebo capsules for 20 months
32903429|NCT00597818|Experimental|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
32903430|NCT00597818|Experimental|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
32903431|NCT00597818|Experimental|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
32903432|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
32903433|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
32903434|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
32903435|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
32903436|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
32903437|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
32903438|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
32903439|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
32903440|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
32903441|NCT00691808|Experimental|High Dose|
32903442|NCT00691808|Experimental|Low Dose|
32903443|NCT00691808|Placebo Comparator|Placebo|
32903444|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
32903445|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
32903446|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
32903447|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
32903448|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
32903449|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
32903450|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
32903451|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
32903452|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
32903453|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
32903454|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
32903455|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
32903456|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
32903457|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33406499|NCT05114382|Other|A prospective, multi-center, open-label, single arm study|Patients undergoing assessment and ablation of cardiac arrhythmiast. who are scheduled for an electrophysiology (EP) procedure and meet all inclusion criteria will be enrolled in the study and undergo the EP procedure. Intracardiac signals will be passively recorded using the CathVision Cube® System in parallel with the commercial (CE marked) EP recording system for post procedure evaluation. The investigational device will not be used for direct clinical care decisions or therapy. The EP procedure will be guided by the study site Standards Of Care.
33406500|NCT02542956|Active Comparator|Exparel|Injection of Exparel
33406501|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
33406502|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
33406503|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
33406504|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
33406505|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
33406506|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
33406507|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
33406508|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
33406509|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
33406510|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
33406511|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
33406512|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
32850234|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:~Open peripheral vein fluid infusion~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed~Transfer to ICU after surgery"
32850235|NCT02800434|Experimental|hand allograft|
32850236|NCT04382547|Experimental|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
32850237|NCT04382547|Active Comparator|control|Patients with Covid-19 associated pneumonia receiving standard treatment
32850238|NCT05687305|Active Comparator|Intervention Group|On the 1st and 2nd postoperative days, patients in the intervention group will listen to white noise with a bluetooth headset for 30 minutes before going to sleep, and they will be kept under observation during this time.Patients in the control group will be monitored according to their routine clinical procedures. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. Patients in the control group will also be followed up at the same times and with the same forms.
32850239|NCT05687305|No Intervention|No Intervention Group|Patients in the control group will not receive any intervention other than their routine. Data collection forms will be applied to the participants in the control group at the same time as the intervention group.
32850240|NCT04084860|Experimental|CI-581a + MET/MBRP|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
32850241|NCT04084860|Experimental|CI-581a + Medication Management|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment ( no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
32850242|NCT04084860|Active Comparator|CI-581b + MET/MBRP|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
32850243|NCT04084860|Active Comparator|CI-581b + Medication Management|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
32850244|NCT05687227|Experimental|EXPERIMENT GROUP|The trainings were held in groups of 4-6 people. The trainings, which were held in three sessions, were held on the days and times that were convenient for the participants. Since the participants were required to attend all sessions, additional session/sessions were held in case of not being able to attend the trainings. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Until the end of the research, the participants were told that they could reach the researcher at any time and ask questions. Finally, at the 6th month, a post-test form was applied to the participants.
32903458|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
32850245|NCT05687227|No Intervention|CONTROL GROUP|No training or counseling was given to the control group. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Finally, at the 6th month, a post-test form was applied to the participants.
32850246|NCT04134663|Experimental|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
32850247|NCT04134663|Active Comparator|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
32850248|NCT04134663|Placebo Comparator|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
32850249|NCT05431998|Experimental|The use of demineralized autogenous tooth graft in the jumping gap of the immediate implant|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high-speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill (Gold Bone Mill, MCT Bio, Korea). Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid (Chemajet Chemicals, Egypt) for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the bone defect around the immediately placed implant.
32850250|NCT05431998|Active Comparator|The use of autogenous bone graft in the jumping gap of the immediate implant|A horizontal vestibular incision will be placed below the mucogingival junction and a mucoperiosteal flap will be reflected then autogenous bone particles will be collected from the participants using Automatic Bone Collector Bur (ACM Bur) by NeoBiotch, from the mandibular retro-molar region, speed 300rpm, torque 30Ncm, with irrigation.
32850251|NCT05588323|Experimental|Cohort 1: ≥ 12 to < 18 Years|Participants will receive 0.05 milligrams (mg) to 0.2 mg naldemedine based on their body weight once daily for 7 days.
33104098|NCT01258075|Experimental|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
33104099|NCT01258075|Experimental|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
33104100|NCT01257568|Other|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
33320304|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
33104101|NCT04687878|Experimental|Insulin|Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks
33104102|NCT04687878|Placebo Comparator|Placebo|Normal saline, twice a day, intranasally, every day for 12 weeks
32850252|NCT05588323|Experimental|Cohort 2: ≥ 6 to < 12 Years|Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days.
32850253|NCT05588323|Experimental|Cohort 3: ≥ 2 to < 6 Years|"Participants will be enrolled in this cohort after the safety and PK data has been evaluated for cohorts 1 and 2.~Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days."
32850254|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
32850255|NCT05433493|Experimental|Intervention group|"Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving individual CS or to the control group receiving treatment as usual (participating in the activities previously established in their individual intervention plan).~Participants in the intervention group will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same protocol in every participant site."
32850256|NCT05433493|No Intervention|Control group|Participants in the control group will receive treatment/activities as usual, participating in the activities previously established in their individual intervention plan.
32850257|NCT04372875|Experimental|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
32850258|NCT04372875|No Intervention|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
32850259|NCT05431764|Experimental|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients were treated with gemcitabine, cisplatin and camrelizumab for 6 cycles, followed by whole-target radiotherapy (IMRT for locoregional lesion and SBRT for oligometastatic lesions) and camrelizumab maintenance therapy.
32850260|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
32850261|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
32850262|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
32850263|NCT05431530||Ovarian cancer|Tumor involving rectosigmoid colon
32850264|NCT05569759|Experimental|zetomibzomib + standard-of-care (glucocorticoids)|Initial 30 mg dose of zetomipzomib, followed by weekly 60 mg doses of zetomipzomib, for the remaining 23 weeks of the treatment period.
32850265|NCT05569759|Placebo Comparator|placebo + standard-of-care (glucocorticoids)|Initial 30 mg dose of placebo (sterile water for injection), followed by weekly 60 mg doses of placebo, for the remaining 23 weeks of the treatment period.
32850266|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
32850267|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
32850268|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
32959903|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
32959904|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
32959905|NCT03781986|Experimental|APG-115 monotherapy|APG-115 will be administered in an open label fashion until progression, intolerance, or patient preference.
32959906|NCT03781986|Experimental|APG-115 + Carboplatin [terminated]|APG-115 and Carboplatin will be administered in an open label fashion until progression, intolerance, or patient preference. [Phase 1 was terminated early and this arm was discontinued. An MTD was not established during Phase 1.]
32959907|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
32959908|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
32959909|NCT03419676|No Intervention|Control|No reinforcement.
32959910|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
32959911|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
32959912|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
32959913|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
32959914|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
32959915|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
32959916|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
32959917|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
32959918|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
32959919|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
32959920|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
32959921|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
32959922|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
32959923|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
32959924|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
32959925|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
32959926|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
32959927|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
32959928|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
32959929|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
32959930|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
32850269|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
32850270|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
33104103|NCT05118802||Observational (interview, survey)|"Part I: Patients and clinicians attend semi-structured interviews over 20-30 minutes or cognitive interviews over 60 minutes in support of survey refinement.~Part II: Patients complete survey over 15 minutes."
33104104|NCT05116774|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor~In Part 2, all subjects receive BCX9930 monotherapy"
32850271|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
32850272|NCT03382561|Active Comparator|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32850273|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
32850274|NCT04383015|Other|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
32850275|NCT04383015|Other|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
32850276|NCT04383015|Other|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
32850277|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
32850278|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
32850279|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
32850280|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
32850281|NCT04292847|Experimental|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
32850282|NCT00845481|Experimental|all patients apply all products|
32850283|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
32850284|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
32850285|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
32850286|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
32850287|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
32850288|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
32850289|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
32850290|NCT01458392|Experimental|Dalantercept|dalantercept
32850291|NCT01421069|Experimental|1|
32850292|NCT04276233|Experimental|Participants with severe eosinophilic asthma|Participants with severe eosinophilic asthma will receive Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses). Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
32850293|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
32850294|NCT04681430|Experimental|convalescent plasma (CP)|Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1
32850295|NCT04681430|Other|Standard of Care|Standard of care allowed
32850296|NCT04681430|Experimental|Camostat Mesilate|Tablets 600 mg per day in 3 doses over 7 days
32850297|NCT04681430|Placebo Comparator|Placebo camostat|Placebo Tablets in 3 doses over 7 days (blinded)
32850298|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
32850299|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
32850300|NCT03309475|Experimental|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
32903459|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
32903460|NCT02994901||Group 1|Geriatric patient with Sarcopenia
32850301|NCT03309475|Active Comparator|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
32850302|NCT04091984||Prospera Arm|There is no intervention in this study. Adult patients who have received a kidney allograft from a genetically different donor in the past 2 years including within 60 days and who have been selected by their healthcare provider to receive Prospera dd-cfDNA testing according to their regular interval testing schedule as part of their clinical care will have medical records pertaining to their kidney rejection status collected at each study visit.
32850303|NCT04091984||Control Arm|The control arm will consist of retrospective data review of cases where a renal allograft from a genetically different donor was performed. Data pertaining to to their kidney rejection status from a minimum of 3 time points per year post allograft (up to 5 years) or until renal allograft failure will be collected.
32850304|NCT05345665|Other|Echography|For the neuronal blockade of the patient, anesthesiologists used an echography.
32850305|NCT05345665|Other|Neurostimulation|For the neuronal blockade of the patient, anesthesiologists used neurostimulation.
32850306|NCT05345665|Other|Active mobilization|For the neuronal blockade of the patient, anesthesiologists used active mobilization.
32850307|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
32850308|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
32850309|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
32850310|NCT05398237|Experimental|TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light|We have one arm, which consists of participants with a broad range of sun damage on the forearm. Based on the standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36), we will include mild (N=12), moderate (N=12), and severely (N=12) sun damaged skin.
32850311|NCT05686993|Experimental|Cinnarizine and nifedipine|Cinnarizine 30 mg oral TDS for 2 weeks, 2 weeks of washout, then Nifedipine 60 mg oral daily for 2 weeks
32850312|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
32850313|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
32850314|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
32850315|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
32850316|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
32850317|NCT03379051|Experimental|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
32850318|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
32850319|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
32850320|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
32850321|NCT05556967|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation (200 mg per capsule) 4-200 mg capsules given by mouth once on the only study visit day.
32850322|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
32850323|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
32850324|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
32850325|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
32850326|NCT00815685|Experimental|Eicosapentaenoic Acid|
32850327|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
32850328|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
32850329|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
32850330|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
32850331|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
32850332|NCT05552209||Orthosis group 1|Use of Elbow Mid 500 device during sport practice
32850333|NCT05552209||Control group 1|Control group of the Elbow Mid 500 group - no medical device used during sport practice
32850334|NCT05552209||Orthosis group 2|Use of Elbow Strap device during sport practice
32850335|NCT05552209||Control group 2|Control group of the Elbow Strap group - no medical device used during sport practice
32903461|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
32903462|NCT02994901||Group 3|healthy control group
32850336|NCT04239027|Experimental|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
32850337|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
33320305|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
32850338|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
32850339|NCT05540041|Experimental|Bubble breathing play therapy|Children in intervention group 2 will be given a bubble breathing play therapy intervention. With this intervention, it is aimed to teach the child and parent to breathe correctly and deeply, to relax them, to reduce their anxiety and fears, to relax, to direct their attention to something other than pain. In the intervention pediatric surgery service, investigative coaching will be applied 30 minutes before premedication. The procedure time is planned to be at least 5-10 minutes. The intervention will be implemented with a ready-made foam bubble toy. The toy will be provided by the researcher and given to the children as a gift.
32850340|NCT05540041|Experimental|Tell-show-do play therapy|Tell-show-do play therapy initiative will be applied to children included in intervention group 1. The initiative will be applied to children without disturbing the parent-child relationship. The intervention will be applied for 10-15 minutes. The tell-show-do play therapy initiative will be implemented using the directed play therapy method and therapeutic play tools. Amigurumi dolls, medical toys (surgical shirt, movable toy bed) and real medical materials such as stethoscope, patient armband, bone, mask, degree will be used as therapeutic play tools.
32850341|NCT05540041|Other|No intervention|The participants in the control group will be given routine nursing care.
32850342|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
32850343|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
32850344|NCT05686915||Revision Total Hip Arthroplasty|Patients who received a revision total hip surgery utilizing a ceramic femoral head with a titanium sleeve
32850345|NCT00815997|Sham Comparator|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
32850346|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
32850347|NCT05384119|Experimental|Phase 1b: Dose Escalation|Participants will receive up to 3 dose levels of TTI-101 added to palbociclib and AI to determine the RP2D.
32850348|NCT05384119|Experimental|Phase 2: Dose Expansion|Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 added to palbociclib and AI.
32850349|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
32850350|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
32850351|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
32850352|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
32850353|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
32850354|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
32850355|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
32850356|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
32850357|NCT05686837||People infected with NTM isolates identified in a cluster|All people with CF infected with NTM respiratory isolated identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
32959931|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
33320306|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
33406513|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
33406514|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
33406515|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
33406516|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
32850358|NCT05686837||People infected with NTM isolates not identified in a cluster|All people with CF infected with NTM respiratory isolated not identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
32850359|NCT02979522|Experimental|Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
32850360|NCT02979522|Experimental|Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
32850361|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
33417235|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
32850362|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
32850363|NCT05533801|Experimental|Treatment A: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 milligram (mg) in the lower abdomen using a vial and syringe on Day 1.
32850364|NCT05533801|Experimental|Treatment B: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 mg in the lower abdomen using AI on Day 1.
32850365|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
32850366|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
32850367|NCT05367505|Experimental|iFuse-3D|Titanium fusion implant in combination with trans-iliac screws
32850368|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
32850369|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
32850370|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
32850371|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
32850372|NCT04401007|Experimental|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
32850373|NCT04401007|Experimental|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
32850374|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
32850375|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
32850376|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
32850377|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
32850378|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
32850379|NCT03375619||Participants who received CAR-20/19-T cells.|Participants who received CAR-20/19-T cells in study NCT03019055.
33104105|NCT05116774|Active Comparator|Continued C5 inhibitor therapy|In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor
32850380|NCT00964002|Experimental|Efavirenz|"Patients will receive efavirenz 600 mg daily as oral tablets at bedtime and in fast condition (1-2 hours far from dinner) until objective biological, radiological or clinical disease progression or study discontinuation (withdrawal of consent or when the patient meets one criterion for treatment discontinuation).~Individual dose escalation will be possible: if biological progression occurs at month 3, dose could be increased to 1200 mg/day in asymptomatic and non radiological progression patients (by step of 200 mg every 15 days)."
32850381|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
32850382|NCT05526313|Experimental|1.2mg/m2|
32850383|NCT05526313|Experimental|2.4mg/m2|
32850384|NCT05526313|Experimental|4.0mg/m2|
32850385|NCT05526313|Experimental|6.0mg/m2|
32850386|NCT05526313|Experimental|8.4mg/m2|
32850387|NCT05526313|Experimental|11.2mg/m2|
32850388|NCT05526313|Experimental|15mg/m2|
32850389|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:~regular operating theater~ultra-Clean operating theaters"
32850390|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
32850391|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
33104106|NCT04687839|Experimental|Healthy adult subjects|"It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.~The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).~Twice daily application on the treated area."
32850392|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
32850393|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
32850394|NCT05364931|Experimental|Cotadutide 300μg|
32850395|NCT05364931|Placebo Comparator|Placebo 300μg|
32850396|NCT05364931|Experimental|Cotadutide 600μg|
32850397|NCT05364931|Placebo Comparator|Placebo 600μg|
32850398|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
32850399|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
32850400|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
32850401|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
32850402|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
32850403|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
32850404|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
32850405|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
32850406|NCT02577120||Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
32850407|NCT02577120||High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
32850408|NCT02577120||High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
32850409|NCT02577120||High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
32850410|NCT02577120||High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
32850411|NCT01399697|Experimental|A|
32850412|NCT01399697|Active Comparator|B|
32850413|NCT00853671|Experimental|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
32850414|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
32850415|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:~Multiple co-morbidities~Patients choice~Mild disease /symptoms~Awaiting Surgery"
32850416|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
32850417|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
32850418|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
33104107|NCT05014087|Experimental|Arm A: Digoxin|In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.
33104108|NCT05014087|No Intervention|Arm B: No Digoxin|In the no digoxin arm, no study drug or placebo will be administered.
33104109|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
33104110|NCT01256788|Placebo Comparator|Saline injection|
32850419|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
32850420|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
32850421|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
32850422|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
33104111|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
33104112|NCT04687566|Experimental|dextromethorphan|Dextromethorphan, 60 mg per day, once daily, for 12 weeks
33104113|NCT04687566|Experimental|memantine|Memantine, 5 mg per day, once daily, for 12 weeks
33104114|NCT04687566|Experimental|dextromethorphan and memantine|Dextromethorphan (60mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks
33104115|NCT04687566|Placebo Comparator|placebo|placebo, once daily, for 12 weeks
33104116|NCT04683809|Experimental|Exercise group|Patients in this group will attend telerehabilitation sessions.
33320307|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
32850423|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
32850424|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
32850425|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
32850426|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
32850427|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
32850428|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
32850429|NCT03336931||High-risk childhood cancers|Expected survival < 30%
32850430|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
32850431|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
33104117|NCT04683809|No Intervention|Control group|Patients in this arm will be subject to routine follow up.
33104118|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
33104119|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
33104120|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
33104121|NCT05507892|Experimental|Treatment|Participants who will receive 100 mg of canagliflozin daily for six (6) months in addition to standard of care.
33104122|NCT05590000|Experimental|Gemini rechargeable Spinal Cord Stimulation (SCS) System|Patients will be implanted with the Gemini rechargeable SCS System
33104123|NCT04128371|Experimental|1|Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7.
33104124|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
33104125|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
33104126|NCT04684043||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
33104127|NCT04683926|Experimental|Desmetramadol 10 mg, fasted|While fasting a single oral dose of 10 mg desmetramadol under.
33104128|NCT04683926|Experimental|Desmetramadol 20 mg, fasted|While fasting a single oral dose of 20 mg desmetramadol.
32850432|NCT05523427|No Intervention|Standard treatment of IBS|"Mebeverine 135 mg Sulpiride 25 mg Simethicone 200 mg~They were administered in a single capsule, three time daily before meals."
33104129|NCT04683926|Experimental|Desmetramadol 30 mg , fasted|While fasting a single oral dose of 30 mg desmetramadol.
32850433|NCT05523427|Experimental|Probiotics + Standard treatment of IBS|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
32850434|NCT05334433|Experimental|Local anesthesia injection with the comfort in jet (Needless system)|A needle-less injection approach will be used to administer the local anesthetic solution
32850435|NCT05334433|Active Comparator|Local anesthesia injection with needle injection (conventional technique).|A conventional aspirating syringe fitted with 27-gauge long needles will be used to administer the local anesthetic solution.
32850436|NCT04760197||patient under cancer immunotherapy with inflammatory ophthalmological manifestations|patient(>18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations
32850437|NCT04347967|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
32850438|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
32850439|NCT03334045||Controls|Healthy controls
32850440|NCT01496612|Experimental|Study Phase|
32850441|NCT01496612|Placebo Comparator|Alternate Study Phase|
32850442|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
32850443|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
32850444|NCT00790218|Experimental|CF102 1mg|An open-label trial in 28-day cycles.
32850445|NCT00790218|Experimental|CF102 5mg|An open-label trial in 28-day cycles.
32850446|NCT00790218|Experimental|CF102 25mg|An open-label trial in 28-day cycles.
32850447|NCT05349019||Part A/Sub Cohort A1|15 healthy participants 18-35 years of age
32850448|NCT05349019||Part A/Sub Cohort A2|15 healthy participants 65-80 years of age
32850449|NCT05349019||Part A/Sub Cohort A3|Control group age and sex matched to the PD participants in Part B of the study
32850450|NCT05349019||Part B|60 participants with a confirmed diagnosis of Parkinson's disease and a heterozygous G2019S mutation in the LRRK2 gene
32850451|NCT03300427|Experimental|sacubitril/valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. Two strengths of sacubitril/valsartan will be available for use after randomization, 49 mg sacubitril/51 mg valsartan and 97 mg sacubitril/103 mg valsartan. After randomization, subjects in this arm will receive sacubitril/valsartan 100 mg orally twice daily (BID). The dose will be then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration is not possible). Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate the 100 mg BID dose at the minimum. In total, participants will be on sacubitril/valsartan for a minimum of 8 weeks and a maximum of 10 weeks.
32850452|NCT03300427|Active Comparator|valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. In this arm, Valsartan 80 mg and 160 mg will be used as comparative drug, taken orally BID at home. Depending on the screening/run-in dose the subjects in this arm will get either valsartan 80 mg BID or valsartan 160 mg BID. During the treatment period the dose of valsartan will be up-titrated to the highest tolerated dose (160 mg BID) or maintained at 80 mg BID if up-titration is not possible. Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate at least 80 mg BID dose of valsartan. The treatment phase will be a minimum of 8 weeks, and a maximum of 10 weeks.
32850453|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
32850454|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
32850455|NCT05499013|Experimental|Phase 1 open-label SLN124|SLN124 for subcutaneous (s.c.) injection
32850456|NCT05499013|Experimental|Phase 2 Blinded SLN124|SLN124 for subcutaneous (s.c.) injection
32850457|NCT05499013|Placebo Comparator|Phase 2 Blinded Placebo|Sodium chloride for s.c. injection
32850458|NCT05431452|No Intervention|Group 1 (Control Group)|"There is no non-pharmacological method applied during routine heel blood collection in the clinic where the research will be conducted. No intervention will be applied to this group within the scope of the research. In order to minimize the risk of aspiration during the procedure, the head of the bed in the incubator will be elevated at a 45-degree angle. The 1st minute before the procedure, the 1st minute and the 2nd minute during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
32850459|NCT05431452|Experimental|Group 2 (Breast milk)|"2 minutes before the procedure, the bedside of the baby will be raised at an angle of 45 degrees and 2 ml of breast milk will be given by the research clinic nurse with the help of a sterile injector, provided that each baby will be their own breast milk. Heel blood collection will be performed 2 minutes after breast milk is given. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
32850460|NCT05431452|Experimental|Group 3 (Supine Fetal Position)|"This method is a lower form of the method of taking the baby into the nest and is defined as the process of keeping the baby's upper and lower extremities flexed by hand, and taking the body into a closed position close to the midline. While applying this method, the baby can be placed in a lateral, supine or prone position (Neto et al., 2020).~In our research, according to the literature, the baby will be placed in the fetal position 3 minutes before the procedure, and the baby will be kept in the fetal position for 3 minutes after the procedure. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
32959932|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
32959933|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
32959934|NCT00822588|Experimental|1|
32959935|NCT00822588|No Intervention|2|
32959936|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
32959937|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
32959938|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
32959939|NCT00824460|Experimental|1.25 g PA21|
32959940|NCT00824460|Experimental|5.0 g PA21|
32959941|NCT00824460|Experimental|7.5 g PA21|
32959942|NCT00824460|Experimental|10.0 g PA21|
32959943|NCT00824460|Experimental|12.5 g PA21|
32959944|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
32959945|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
32959946|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
32959947|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
32959948|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
32959949|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
32959950|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
32959951|NCT00830076|Experimental|Sitagliptin + placebo metformin|
32959952|NCT00830076|Experimental|Metformin + placebo sitagliptin|
32959953|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
32959954|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
32959955|NCT00830232|Active Comparator|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
32959956|NCT00830232|Active Comparator|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
32959957|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
32959958|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
32959959|NCT00831480|Experimental|1|All subjects will take everolimus
32959960|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
32959961|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
32959962|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
32959963|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
32959964|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
32959965|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
32959966|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
32959967|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
32850461|NCT05431452|Experimental|Group 4 (Kangaroo maternal care)|"10 minutes before the procedure, the mother will be placed on the mother's chest at an angle of 60 degrees, with only the diaper left under the baby in the baby adjustment room, in a way that it will contact the mother's chest directly from skin to skin. In order not to lower the newborn's body temperature, a thin blanket will be covered on his back and the mother will be asked to gently soothe the baby's movements by wrapping her hands around the newborn's back. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
32850462|NCT05431452|Experimental|Group 5 (Supine Fetal position + Breast milk)|"The head of the baby's bed is elevated to a 45-degree angle and before the procedure, 2 ml of breast milk will be given with the help of a sterile injector by the research clinical nurse, on the condition that each baby has its own breast milk, and then the baby will be placed in the fetal position (Shah et al., 2012; Shukla et al. , 2018). After the baby is held in the fetal position for 3 minutes, heel blood sampling will be performed. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form. In line with the literature recommendations, the baby will be supported in the fetal position for 3 minutes after the procedure (Axelin et al. 2006; Cignacco et al. 2010; Obeidat et al. 2009; Çağlayan and Balci, 2014)."
32850463|NCT05431452|Experimental|Group 6 (Kangaroo care + Breast milk)|"The head of the baby's bed will be raised at an angle of 45 degrees and before the procedure, 2 ml of breast milk will be given by the research clinical nurse with the help of a sterile injector, provided that each baby is breast milk, and then the mother will be in direct skin-to-skin contact with the mother's breast, with only the diaper under the baby in the baby adaptation room. It will be placed on the mother's chest at an angle of 60 degrees. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
32850464|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
32850465|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
32850466|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
32850467|NCT04849260|Experimental|Pexa-Vec combined with ZKAB001|"The combined treatment group is divided into two dose groups. The principle of 3+3 is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort."
32850468|NCT04849260|Active Comparator|ZKAB001 monotherapy|ZKAB001 monotherapy.
32850469|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
32850470|NCT05431218|No Intervention|normal vitamin D levels|Patients with normal vitamin D levels (30-100ng/ml) No interference is implied. Observation only
32850471|NCT05431218|Active Comparator|Mild vitamin D deficiency|Patients with mild vitamin D deficiency (20-29 ng/ml)They will receive 4000 IU of cholecalciferol per day for 3 months
32850472|NCT05431218|Active Comparator|Moderate vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 5000-6000 IU daily for 3 months
32850473|NCT05431218|Active Comparator|Severe vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 7000-8000 IU daily for 3 months
32850474|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
32850475|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
32850476|NCT05431062|Active Comparator|Thoracic paravertebral block|USG guided TPVB will be performed with 0.5 mL/kg %0.25 Buvicaine in the paravertebral space.
32850477|NCT05431062|Active Comparator|Erector spinae plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between erector spine muscle and transverse process
32850478|NCT05431062|Active Comparator|Serratus anterior plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between serratus anterior muscle and external intercostal muscles
32850479|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
32850480|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
32850481|NCT05430984|Active Comparator|Laparoscopic TAPP inguinal hernia repair with mesh fixation|the mesh will be fixed to the abdominal wall using suture, spiral tacks.
32850482|NCT05430984|Active Comparator|Laparoscopic TAPP inguinal hernia repair without mesh fixation|the mesh will be left as it is and the operation will be concluded
32850483|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
32850484|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
32850485|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
32850486|NCT03696121|Experimental|Intervention|Desmopressin injection
32850487|NCT03696121|Placebo Comparator|Control|Normal Saline
32850488|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
32850489|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
32850490|NCT03298945|Active Comparator|Golytely|4-L split-dose Golytely bowel prep
32850491|NCT03298945|Experimental|Miralax-Gatorade prep|2-L split-dose Miralax-Gatorade bowel prep
32850492|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
32850493|NCT03371407||Parkinsonian patient under dopaminergic medication|
32850494|NCT03371407||Parkinsonian patient without dopaminergic medication|
32850495|NCT03371407||Control participants|
32850496|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
32850497|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
32850498|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
32850499|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
32850500|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
32850501|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
32850502|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
32850503|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
32850504|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
32850505|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
32850506|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
32850507|NCT04400773|Experimental|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
32850508|NCT04400773|Experimental|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
32850509|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32850510|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
32850511|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
32850512|NCT04279405|Experimental|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
32850513|NCT05237115|Experimental|Clostridium butyricum group|given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
32850514|NCT05237115|Experimental|Bacillus clotting group|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
32850515|NCT05237115|Active Comparator|bismuth quadruple therapy|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
32850516|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
32850517|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
32850518|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
32850519|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
32850522|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
32850523|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
32850524|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
32850525|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
32850526|NCT05236959|Experimental|Mindfulness-Based Cognitive Therapy|A group-based treatment combining intensive training in mindfulness mediation and elements of cognitive therapy (see further above).
32850527|NCT05236959|Other|Treatment as Usual|Participants in this group continue with their usual care and follow the regimes suggested by their GP or mental health professionals (see further above).
32850528|NCT05487547|Experimental|Study arm|Subjects will receive 4 treatments at 2-weeks intervals. Each treatment will consist of IPL administered on the malar region, followed by RF administered around the eye, followed by Meibomian gland expression (MGX). Follow-up will be conducted at 4 weeks after the 4th treatment session.
32850529|NCT04040621|Experimental|Ceftazidime-avibactam|This arm includes 4 cohorts
32850530|NCT05486533|Experimental|Experimental|The experimental group will be given acupressure.
32850531|NCT05486533|No Intervention|Control|It will only take routine treatment and care.
32850532|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
32850533|NCT05686447||Multiple myeloma|Multiple myeloma (MM) is a hematologic malignant tumor characterized by abnormally cloned plasma cells in bone marrow, whose growth can lead to destructive bone injury, acute kidney injury, anemia, and hypercalcemia.
32850534|NCT05686447||Healthy control|Individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex.
32850535|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
32850538|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
32850539|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
32850540|NCT03326713|Other|Usual Care (UC)|Control
32850541|NCT00857493|Experimental|Group 1|
32850542|NCT00857493|Experimental|Group 2|
32850543|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
32850544|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
32850545|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
32850546|NCT04399915||Healthy Subjects|
32850547|NCT05236569|Experimental|Tranexamic acid|The intervention was 1 ml of 10 mg/ml of tranexamic acid solution which was given intradermally.
32850548|NCT05236569|Placebo Comparator|Placebo|The placebo was 1 ml of 0.9% normal saline which was given intradermally.
32850549|NCT05090371|Experimental|Ofatumumab|20 mg
32850550|NCT05090371|Active Comparator|DMT continued therapy|Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.
32850551|NCT00857727|Experimental|Drug|Dexmedetomidine
32850552|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
32850553|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
32850554|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
32850555|NCT05087173|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
32850556|NCT05073367||Participants with H. Pylori|Participants having evidence of H. pylori infection or having a positive result of H. pylori diagnostic testing recorded at inpatient or outpatient visits using pre-existing electronic medical record data in China will be observed retrospectively for 54 months.
32850557|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
32850558|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
32850559|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
32850560|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
32850561|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
32850562|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
32850563|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
32850564|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
32850565|NCT05035537|Experimental|Group 1 (PGDT)|Group 1(PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol
32850566|NCT05035537|No Intervention|Group 2 (control)|Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring
32850567|NCT05236335|Experimental|Ketone ester|
32850568|NCT05236335|Placebo Comparator|Placebo|
32850569|NCT05033041|Active Comparator|Group 1 Study Drug Metoclopramide|Intravenous administration of 10 mg metoclopramide
32850570|NCT05033041|Placebo Comparator|Group 2 Study Drug Placebo|Intravenous administration of sterile normal saline
32850571|NCT05236101|Experimental|CD:H Scale|Pictures drawn using the CD:H Scale were evaluated.
32850572|NCT05029063|Experimental|Experimental|Rivaroxaban 10mg OD
32850573|NCT05029063|Placebo Comparator|Control|Identical Placebo 10mg OD
32850574|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
32850575|NCT05686291|Experimental|Treatment group|Participants in the treatment condition start the online volunteer training immediately after randomization and completed the online module within 2-week. Then they are invited to attend the face-to-face training within 1-week. They will complete the post-intervention assessment right after they finish the face-to-face training, and be invited to participate in an interview.
33104130|NCT04683926|Experimental|Desmetramadol 30 mg , fed|After feeding a single oral dose of 30 mg desmetramadol.
33104131|NCT04684082||Single Group Assignment|Patients will receive colonic irrigation as bowel preparation prior to colonoscopy.
33104132|NCT04683887|Experimental|Tape application|
33104133|NCT04683887|No Intervention|No tape application|
33104134|NCT05506956|Experimental|Flotetuzumab Following Allogeneic Transplant|All participants will receive one cycle (28 days) of flotetuzumab. After one cycle, all participants will undergo a bone marrow biopsy to assess response and based on the response, may receive additional cycles up to a total cycle of six cycles.
33104135|NCT05506722|Active Comparator|Testes shocker|This device is working and giving the electrical shocks regularly.
32850576|NCT05686291|No Intervention|Wait-list control group|Participants in the waitlist control group will wait for 4 weeks without the training and then complete the post-intervention assessment. The waitlist control participants will start training (equivalent to that of the treatment group) immediately after completing the post-intervention assessment.
33104136|NCT05506722|Placebo Comparator|Fake Testes shocker|This device is not giving electricity but it is working with a red light, so the participants cannot suspect it.
33104137|NCT05504616|Experimental|Intervention Group|"Participants randomized to the intervention group will receive an initial electronic communication (i.e. email) that includes:~Link to physical activity education. This will be an educational module based on Phase 1 results and evidence-based literature regarding the benefits of physical activity in the general population and specific to axSpA.~One week after receiving the physical activity educational module, participants will receive access to the ADAS application and an .ics file for each 3-week cycle of electronic calendar reminders to engage in physical activity."
33320308|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
32850577|NCT05686057||single vessel diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
32850578|NCT05686057||2 vessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
32850579|NCT05686057||multivessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
32850580|NCT05686057||non-ischemic control patients|sST2 level will be withdrawn at the baseline
32850581|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
32850582|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
32850583|NCT05685979||Patients undergoing robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|Patients with ASA( American Society of Anesthesiologists) physical status 1-3 who underwent robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.
32850584|NCT05685901|Experimental|High polyphenolic olive oil|Participants were required to take 2 mL of early harvest olive oil (normal early harvest olive oil) twice a day for three months and went through a clinical questionnaire at days 15, 30, 60 and 90. Participants were sent an envelope closed with instructions and informed consent. The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity. This study was approved by the independent ethic committee of the Hospital Nuestra Señora del Prado in Talavera de la Reina, belonging to the National Health System in Spain, and conducted in accordance with Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all patients. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
32850585|NCT05685901|No Intervention|No intervention|Participants were required to complete a questionnaire at days 15, 30, 60 and 90 of the study. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
32850586|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
32850587|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
32850588|NCT05023291|Other|test group|All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.
32850589|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
32850590|NCT03288727|Experimental|Negative IF result|
32850591|NCT03288727|Experimental|Positive IF result|
32850592|NCT05018377|Active Comparator|Raj'z catheter|
32850593|NCT05018377|Active Comparator|NAVI catheter|
32850594|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
32850595|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
32850596|NCT03287947|Experimental|A|Nintedanib
32850597|NCT05235867||dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~>4 cc/kg/day of urine output (a.k.a. fluid dumpers; n=5)"
32850598|NCT05235867||non-dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~<2 cc/kg/d of urine output (a.k.a. non-dumpers; n=5)"
32850599|NCT03282955|Experimental|Lipidem|i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)
33406517|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
33406518|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
33406519|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
33406520|NCT02744677|Experimental|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
32739706|NCT04996329|Experimental|comprehensive smoking cessation intervention group|Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
32739707|NCT04996329|Active Comparator|brief smoking cessation intervention group|brief smoking cessation intervention only
32739708|NCT04995783||Ulcerative Colitis|
32739709|NCT04995783||Crohn's Disease|
32739710|NCT04995783||Rheumatoid Arthritis|
32739711|NCT04995783||Psoriasis|
32739712|NCT04995783||Control|
32739713|NCT03069729||Control group|non-diabetic; no intervention
32739714|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
32739715|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
32739716|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
32739717|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
32739718|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
32739719|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
32739720|NCT03109223|Active Comparator|Commercially availabel infant formula|
32739721|NCT03109223|Experimental|Test formula with 2-FL|
32739722|NCT03109223|Active Comparator|Breast Fed|
32739723|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
32739724|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
32739725|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
32739726|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
32739727|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
32739728|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
32739729|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
32739730|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
32739731|NCT05010317|Experimental|Group receiving the mindfulness and acceptance intervention|This group will under go six sessions of the mindfulness and acceptance based therapy. These sessions will be delivered in six weeks, utilizing 2 hours every week. This will be in addition to the standard of care (clinic based counselling).
32739732|NCT05010317|Active Comparator|Control group|This group will continue receiving the usual clinic based care (counselling) only.
32739733|NCT04433559|Active Comparator|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
32739734|NCT04433559|Placebo Comparator|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
32739735|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
32739736|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
32739737|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
32739738|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
32739739|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~Insertion of FFRD with application over the lower archwire"
32739740|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
32739741|NCT04989153||non-atrophic gastritis|No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)
32739742|NCT04989153||mild-moderate atrophic gastritis|The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)
32739743|NCT04989153||severe atrophic gastritis|The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)
32739744|NCT04989153||gastric cancer|gastric cancer
32739745|NCT04963751|Active Comparator|pre-operative counseling with their caregiver|Patients will be asked to attend a standard-of-care pre-operative teaching session with their parent.
32739746|NCT04963751|Placebo Comparator|caregiver-only counseling.|Parents-only will attend a standard-of-care pre-operative teaching session.
32739747|NCT04911959|Active Comparator|control group|patients receive transcatheter arterial chemoembolization (TACE) only.
32739748|NCT04911959|Experimental|Intervention group|patients receive transcatheter arterial chemoembolization (TACE) and lenvatinib 8mg per day.
32739749|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
32739750|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
32739751|NCT04988919|Experimental|4D dietary supplement|Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
32739752|NCT04988919|Placebo Comparator|placebo|flavored water (raspberry lemonade Crystal Light®)
32739753|NCT05382533|Experimental|Hypertriglyceridemia intervention (group A)|"Carbohydrates: ≤ 50 en% (sucrose + glucose + fructose ≤ 10 en%, where sucrose ≤ 5 en% and fructose ≤ 20 g/d)~Fat: 30-35 En%~Protein: 20 En%~marine n3 PUFA (EPA/DHA): ≥ 4000 mg/d (10 g fish oil)"
32739754|NCT05382533|No Intervention|Hypertriglyceridemia control (group B)|no menu plans, no study foods
32739755|NCT05382533|Experimental|Prediabetes intervention (group C)|"Carbohydrates: 40 ± 2 En%~Sucrose + glucose + fructose ≤ 10 En%~Free sugars < 5% of daily energy~Fat: 40 ± 2%~Protein: 20 ± 2 En%~n3 PUFA: ≥ 500 mg/d"
32739756|NCT05382533|No Intervention|Prediabetes control (group D)|no menu plans, no study foods
32739757|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
32739758|NCT02475473|No Intervention|Control|Control
32739759|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
32739760|NCT02475551|Experimental|Treatment|IdeS as a single infusion
32739761|NCT04995705|Experimental|Experimental Group Based ACT|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. This consisted of 2.5 hour sessions over 5 consecutive weeks.
32739762|NCT04995705|Active Comparator|Waitlist Control Group -|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. Participants within the waitlist control arm of the study had to wait six weeks before they were offered the same intervention as the intervention arm. They received treatment as usual.
32739763|NCT04891133|Experimental|Active arm|4mg Baricitinib up to 14 days + SoC
32739764|NCT04891133|Placebo Comparator|Comparator|Matching placebo up to 14 days + SoC
32739765|NCT04891809|Experimental|IRd followed by IR|Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
32739766|NCT04891809|Other|Rd followed by R|Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
32739767|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
32739768|NCT05376059|No Intervention|Control Condition|Participants in this group will not receive any oureach at all
32739769|NCT05376059|Experimental|How incentive receive|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues, including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
32739770|NCT05376059|Experimental|How incentive holdout|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is eligible for an incentive but not randomly assigned to it.
32739771|NCT05376059|Experimental|How incentive ineligible|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is not eligible for an incentive.
32739772|NCT05376059|Experimental|How and why incentive receive|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives), including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
32739773|NCT05376059|Experimental|How and why incentive holdout|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is eligible for an incentive but not randomly assigned to it.
32739774|NCT05376059|Experimental|How and why incentive ineligible|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is not eligible for an incentive.
32739775|NCT04985877|Experimental|Sarcopenia group|Yakult light 300 supplementation with sarcopenia patient
32739776|NCT04985877|No Intervention|Non sarcopenia group|no intervention to sarcopenia patient
32959968|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
32959969|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
32959970|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
32959971|NCT00837252|Experimental|Finasteride|
32959972|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32959973|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
32959974|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
32959975|NCT00843180|Experimental|massage|
32959976|NCT00843180|No Intervention|control|usual care only as control arm
32959977|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
32959978|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
32739777|NCT04985877|No Intervention|Control group|no intervention to non-sarcopenia people
32739778|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
32739779|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
32739780|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
32739781|NCT02472587||Pap test|Women attending our institute in order to do Pap test
32739782|NCT05368259|Experimental|AGBS + Moderate Intensity Lifestyle Therapy Group|Patients randomized to treatment will receive the AGBS device
32739783|NCT05368259|No Intervention|Moderate Intensity Lifestyle Therapy (CONTROL) Group|Patients randomized to the control arm will receive moderate-intensity lifestyle therapy.
32739784|NCT04433481|Experimental|DABIGATRAN|150mg BD for 12 months
32739785|NCT04433481|Placebo Comparator|Placebo|Placebo
32739786|NCT04860635|Experimental|F14 (sustained release celecoxib)|Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
32739787|NCT04986111|Experimental|Linear skin closure with wound drain|Reduce fluid collection and dead space by inserting drain into the subcutaneous layer using the wound closure method previously used in the experimental center. The linear suture has a relatively quick time to stitch out.
32739788|NCT04986111|Active Comparator|Purse-string skin closure with negative pressure wound therapy|Close the wound with a purse-string suture which is better in terms of surgical site infection but known to take a long time for wound healing, and use negative pressure wound therapy to help granulation of tissues and help healing.
32739789|NCT02472431|Experimental|ADRC injection|
32739790|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
32739791|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
32739792|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
32739793|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
32739794|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
32739795|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
32739796|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
32739797|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
32739798|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
32739799|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
32739800|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
32739801|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
32739802|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
32739803|NCT04988607|Experimental|osimertinib plus bevacizumab|Osimertinib 80 mg (QD) in combination with Bevacizumab (15 mg/kg) (Q3W)
32739804|NCT04988607|Active Comparator|osimertinib|All patients randomized into this will only receive Osimertinib 80mg (QD)
32739805|NCT05366699|Experimental|Group A|Group A will under axillary lymphadenectomy alone
32739806|NCT05366699|Active Comparator|Group B|Group B will undergo axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) using reverse mapping using the SPY System.
32739807|NCT04995471|Experimental|In presence RRT - prototype software|10 biweekly in presence sessions of 45 minutes supervised by a trainer
32739808|NCT04995471|Experimental|In presence RRT - online platform|10 biweekly in presence sessions of 45 minutes supervised by a trainer
32739809|NCT04995471|Experimental|Tele-RRT - prototype software|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
32739810|NCT04995471|Experimental|Tele-RRT - online platform|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
32739811|NCT04995471|No Intervention|No intervention|5 weeks no intervention period
32959979|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32850600|NCT03282955|Active Comparator|Lipofundin MCT|i.v. lipid emulsion
32850601|NCT05685667|Experimental|Laser-induced microjet injector (Mirajet)|The left/right assignment was sealed in a nontransparent envelop.
32850602|NCT05685667|Active Comparator|Needle injection (control)|The left/right assignment was sealed in a nontransparent envelop.
32850603|NCT05007535||HD-IVUS-guided primary PCI|Prospective, single arm, observational
32850604|NCT04999657|Active Comparator|Active|Device: Non-invasive low-frequency tibial nerve stimulator
32850605|NCT04999657|Sham Comparator|Sham|Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)
32850606|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
32850607|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
32850608|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
32850609|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
32850610|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
32850611|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
32850612|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
32850613|NCT05235789|Experimental|Intervention group|The social workers in each center of primary care held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
32850614|NCT05235789|Active Comparator|Control group|The control group (GC) in each center of primary care will take the usual medical care for depression, according with up-dated national and international guidelines.
32850615|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
32850616|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
32850617|NCT05235555||Patients with symptomatic severe AS undergoing TAVI.|
32850618|NCT00860379|Placebo Comparator|Placebo|Placebo
32850619|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
32850620|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
32850621|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
32850622|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
32850623|NCT04999111|Experimental|Cohort 1: Group 1: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single intramuscular (IM) injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
32850624|NCT04999111|Experimental|Cohort 1: Group 2: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
32850625|NCT04999111|Experimental|Cohort 1: Group 3: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
32850626|NCT04999111|Experimental|Cohort 2: Group 4: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
32850627|NCT04999111|Experimental|Cohort 2: Group 5: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
32850628|NCT04999111|Experimental|Cohort 2: Group 6: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
32850629|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
32850630|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
32850631|NCT05235477|Experimental|Tube technique.|"The excavator is used to do the same on the palatal aspect. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect. To harvest the graft, the incision is made parallel to and 2 mm away from the gingival margin. A thin flap containing the keratinized tissue is separated, then the second incision is made parallel to the gingival margin, but perpendicular to the alveolar bone. With a sharp periosteal elevator, the graft is raised with the periosteum and released at its anterior and posterior ends, and then from its base ."
32850632|NCT05235477|Active Comparator|Hyaluronic acid.|The product used in this trial is Restylane Lidocaine (Restylane-Lidocaine cross-linked Hyaluronic Acid Filler, Galderma S.A, Sweden). Restylane was the first FDA-approved HA filler in 2003. Restylane is a non-animal stabilised cross-linked HA filler with an HA concentration of 20 mg/ml. It is a minimally invasive non-surgical injection of hyaluronic acid that observed to overcome the major limiting factor in most surgical techniques regarding the limited blood supply and the small working space. Supported by a recent study conducted by Jinng etal. 2019, who reported significant increase in the height of the gingival papilla and reduction of the area of the black triangle between baseline and 3 or 6 months in a group with thick gingival biotype after injection with hyaluronic acid, that was adding possible maximum effect with minimal postoperative hazards.
33320309|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
32850633|NCT04997785|Experimental|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
32850634|NCT04997785|Active Comparator|Intravenous Morphine|Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.
32850635|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
32850636|NCT00860847|No Intervention|Placebo|placebo pills will be given
32850637|NCT05685589|Experimental|Mindfulness-based Intervention|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
32850638|NCT05685589|No Intervention|Delayed Treatment Control|Participants will be instructed to engage in treatment as usual during their 8-week wait period. After their wait period, participants will be enrolled in the mindfulness-based intervention.
32850639|NCT05235243|Experimental|The Full Intervention (FI) group|The full intervention (FI) group received a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules, and self-monitoring modules.
32850640|NCT05235243|Active Comparator|The partial intervention (PI) group|The partial intervention (PI) group received an intervention identical to the FI group (a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules) with the exclusion of the self-monitoring modules.
32850641|NCT05235243|No Intervention|Waiting List (WL) group|Waiting List (WL) group did not undergo any intervention during the study period. However, WL participants were told that the program will commence in three months. During their waiting time participants were instructed to reduce their daydreaming activity to the best of their ability. Since all participants were recruited for this study from an online support forum (that is not part of this research design), the investigators labeled WL as the Internet Support as Usual (ISAU) group.
32850642|NCT04347733|Experimental|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
32850643|NCT04347733|Experimental|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
32850644|NCT04347733|Active Comparator|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
32850645|NCT05326165|Experimental|Compression therapy|"Participants will receive a ready to wear compression sleeve and glove with embedded sensor.~Compression sleeve will be set to 20-30mm Hg pressure with instructions to wear for 12 hours a day for four consecutive weeks.~Participants will also receive a journal to record usage and standard of care post-operative lymphedema monitoring and education and asked to fill out questionnaires."
32850646|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
32850647|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
32850648|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
32850649|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
32850650|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
32850651|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
32850652|NCT05317507|Experimental|Randomization order 1|Participants receive placebo at visit 1, 50 mg CBD at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850653|NCT05317507|Experimental|Randomization order 2|Participants receive placebo at visit 1, 100 mg CBD at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850654|NCT05317507|Experimental|Randomization order 3|Participants receive 50 mg CBD at visit 1, placebo at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850655|NCT05317507|Experimental|Randomization order 4|Participants receive 50 mg CBD at visit 1, 100 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850656|NCT05317507|Experimental|Randomization order 5|Participants receive 100 mg CBD at visit 1, 50 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850657|NCT05317507|Experimental|Randomization order 6|Participants receive 100 mg CBD at visit 1, placebo at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
32850658|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
32850659|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
32850660|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
32850661|NCT03243019|Experimental|SIROLIMUS|
32850662|NCT04382625|Experimental|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
33406521|NCT02744677|Experimental|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
33320310|NCT05382260|Experimental|Disorders of consciousness(DOC)|The participants in this arm are disorders of consciousness, containing of vegetative state(VS) and minimally conscious state(MCS).
33320311|NCT05382260|Other|Health control|They are health people with normal hearing, acting as a control for DOC group.
32850663|NCT04382625|No Intervention|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
32850664|NCT04631809|Active Comparator|invasive Coronary Angiography alone|
32850665|NCT04631809|Experimental|CT-Coronary Angiography + invasive Coronary Angiography|
33320312|NCT01343914||Cohort|
33320313|NCT05346068|Experimental|Study Device|
32850668|NCT01673646|Experimental|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
32850669|NCT01673646|Experimental|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
32850670|NCT01673646|Experimental|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
32850671|NCT04974541|Experimental|Cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga
32850672|NCT04974541|Active Comparator|Cardiac rehabilitation with standard psychosocial care|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial education component
32850673|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD1222|Previously vaccinated with AZD1222, dosing on day 1
32850674|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD2816|Previously vaccinated with AZD1222, dosing on day 1
32850675|NCT04973449|Other|mRNA booster: one dose of AZD1222|Previously vaccinated with an mRNA vaccine, dosing on day 1
32850676|NCT04973449|Other|mRNA booster: one dose of AZD2816|Previously vaccinated with an mRNA vaccine, dosing on day 1
32850677|NCT04973449|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
32850678|NCT04973449|Other|2 doses of AZD2816, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
32850679|NCT04973449|Other|2 doses of AZD2816, 12 weeks apart|Previously unvaccinated. First dose day 1, second dose day 85
32850680|NCT04973449|Other|one dose of AZD1222 + one dose AZD2816, 4 weeks apart|Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29
32850681|NCT04969471|Experimental|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
32850682|NCT04969471|Experimental|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
32850683|NCT04042584|Experimental|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
32850684|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
32850685|NCT04278391|Experimental|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
32850686|NCT04278391|Experimental|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
32850687|NCT05296837|Experimental|40mg of oral doxycycline|Arm A will receive submicrobial dose doxycycline (40mg) administered as 20mg twice a day for 8 weeks
32850688|NCT05296837|Active Comparator|100mg of oral doxycycline|Arm B will receive 200mg of oral doxycycline administered as 100mg twice a day for 8 weeks
32850689|NCT05296837|Placebo Comparator|Placebo|Arm C will receive a placebo twice a day for 8 weeks
32850690|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
32850691|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
32850692|NCT03240523|Experimental|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
32850693|NCT03240523|Experimental|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
32850694|NCT03240523|Experimental|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes~With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B."
32850695|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
32850696|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
32850697|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
32850698|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
32850699|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
32850700|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
33320314|NCT05346068|Active Comparator|Control Device|
33320315|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
32850701|NCT04829448|Experimental|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
32850702|NCT04829448|No Intervention|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
32850703|NCT05430672|Other|Subjects with aortic dissection|Subjects receive endovascular treatment.
32850704|NCT04399525|Experimental|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
32850705|NCT04399525|Experimental|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
32850706|NCT04399525|Experimental|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
32850707|NCT04399525|Experimental|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
33406522|NCT05035368|Experimental|Ladarixin - placebo|"In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks)."
32850708|NCT04822662|Experimental|Experimental Group: Epilepsy education program|The training prepared for epilepsy will be held in 3 main modules and 5 sessions with two weeks intervals. Each session will last 25 minutes. Trainings will be given to adolescents and their parents online.
32850709|NCT04822662|No Intervention|Control Group|The control group will receive standard epilepsy treatment without any training intervention. The group did not receive any other intervention.
32850710|NCT04278937|Active Comparator|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
32850711|NCT04278937|No Intervention|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
32850712|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
32850713|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
32850714|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
32850715|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
32850716|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
32850717|NCT05272735|Experimental|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
32850718|NCT04278469|Active Comparator|Patients with chemotherapy|
32850719|NCT04278469|No Intervention|Patients without chemotherapy|
32850720|NCT05264389||Poly-Tape Device|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
32850721|NCT05430516||Families|Patients with confirmed SARS-Cov-2 infection and their household members of all ages can be enrolled in the study, if at least one household member is a child age under 18.
32850722|NCT04278547|Experimental|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
32850723|NCT04278547|No Intervention|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
32850724|NCT05430438|Experimental|Group A|Patients will undergo dialysis (4 sessions) with low dialysate sodium (137 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with standard dialysis sodium (140 mEq/L).
32850725|NCT05430438|Experimental|Group B|Patients will undergo dialysis (4 sessions) with standard dialysate sodium (140 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with low dialysis sodium (137 mEq/L).
32850726|NCT05261269|Experimental|Dose Escalation (DAN-222)|The starting dose of DAN-222 will be administered IV every week (QW) to subjects in the first cohort.
32850727|NCT05261269|Experimental|Dose Escalation (DAN-222 + niraparib)|The starting dose of DAN-222 will be administered IV every week (QW), in combination with daily oral niraparib.
32850728|NCT05261269|Experimental|Dose Expansion (DAN-222)|Single agent DAN-222 in HRD-positive or HRD-negative tumors.
32850729|NCT05261269|Experimental|Dose Expansion (DAN-222 + niraparib, HRD-positive)|Combination DAN-222 with niraparib in HRD-positive tumors.
32850730|NCT05261269|Experimental|Dose Expansion (DAN-222 + niraparib, HRD-negative)|Combination DAN-222 with niraparib HRD-negative tumors.
32850731|NCT05428956|Active Comparator|Single breath technique|The technique of single maximal inhalation will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale slowly and maximally and hold the breath for at least 5 seconds. After the breath holding maneuver the patient will be asked to exhale. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval. The duration of the breath hold will be measured by a stop watch.
32959980|NCT00848172|Active Comparator|Octanoic Acid|
32959981|NCT00848172|Placebo Comparator|Placebo|
32959982|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
33406523|NCT05035368|Experimental|Placebo - Ladarixin|"In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks)."
32850732|NCT05428956|Experimental|Tidal breath technique|The technique of 5 tidal breaths will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale 5 tidal breaths after administrating salbutamol in the spacer. After each breath patient will be asked to breathe out in the spacer. The spacer has a one way-valve and does not allow the exhaled air to enter in to the chamber, thus preventing rebreathing and dilution of the inhaled medicine. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval
32850733|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
32850734|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
32850735|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
32850736|NCT05425836|Active Comparator|Oxygen supplementation in the conventional arm|will be delivered by nasal cannula. At 5 minutes prior to sedation the flow rate would be kept a 5 L/minute.; The flow will be increased to 6-8 L/minute to maintain SPO2 ≥92% during the procedure, up to a maximum of 15 L/minute, depending on the patient tolerance.
32850737|NCT05425836|Experimental|Oxygen supplementation in HFNC arm|HFNC (OptiFlowTM; Fisher & Paykel, Auckland, New Zealand) will be started 5 minutes before the sedation at a flow rate of 30 Litres/minute and at a fraction of inspired oxygen (FiO2) of 0.30, which will be titrated by increments of 10 liters/minute depending on oxygen demand to keep SPO2 ≥92% during the procedure. The flow rate will be maintained between 30- and 70-liters minute, depending on the patient tolerance.
32850738|NCT05210673|Experimental|group A|non ERAS pathway
32850739|NCT05210673|Active Comparator|group B|ERAS pathway
32850740|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
32850741|NCT03238807|No Intervention|Control Group|Control Group
33320316|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
33320317|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
33320318|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
33320319|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
32850746|NCT05142345|Experimental|CONTINUUM Intervention Post-Hospital Discharge|Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
32850747|NCT05142345|Active Comparator|Usual Care Post-Hospital Discharge|Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences. Participants will complete questionnaires about their cancer and care.
32850748|NCT05246371|Experimental|propofol and dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine
32850749|NCT05246371|Experimental|desflurane|Patients will receive maintenance of general anesthesia by desflurane.
32850750|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
32850751|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
32850752|NCT03967704|Experimental|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.~- Arm 1 (intervention): two additional consultations with the rheumatology"
32850753|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
32850754|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
32850755|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
32850756|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
32850757|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
32850758|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
32850759|NCT04900519|Experimental|STI-6643|STI-6643 will be provided in a single use 10-mL high borosilicate type 1 glass vial at a concentration of 500mg/10 mL (50 mg/mL) administered intravenously weekly for 4 weeks, then biweekly for Cycles 2 and up.
32850760|NCT03942744|No Intervention|high-flux hemodialysis|high-flux hemodialysis cut-off membrane above 50
32850761|NCT03942744|Active Comparator|on-line hemodiafiltration|postdilutional on-line hemodiafiltration with a convective transport above 21 liters
32850762|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose) in seronegative subjects|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
32850763|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose) in seronegative subjects|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
32850764|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)in seronegative subjects|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
33320320|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
33320321|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
32850765|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose)|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
32850766|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose)|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
32850767|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
32850768|NCT04891471|Experimental|SRS/SBRT arm|Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.
32850769|NCT04891471|Active Comparator|WBI arm|Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.
33320322|NCT05330702|Experimental|Tuberosity Connective Tissue Graft (CTG)|Subjects in this arm will have a tuberosity connective tissue graft at the time of immediate implant placement.
32850770|NCT00863343||All|Anyone presenting with influenza-like-illness
33320323|NCT05330702|Experimental|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft|Subjects in this arm will have Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft at the time of immediate implant placement.
33320324|NCT05330702|No Intervention|No Soft Tissue Augmentation|Subjects in this arm will have no soft tissue augmentation at the time of immediate implant placement.
33320325|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
33320326|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
33320327|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
33320328|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
33320329|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
32850771|NCT03941652||Women with gestational diabetes without a prior GDM|The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
32850772|NCT03941652||Women with gestational diabetes with or without a prior GDM|The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 12) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview.
32850773|NCT03941652||General pregnant women|The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
32850774|NCT03941652||Health care professionals|Nurses/midwifes (n=up to 15) will be interviewed for collecting user requirements for the professional eMOM GDM application in semi-structured interviews. Also the usability of the user interface prototypes will be evaluated using cognitive walkthrough.
32850775|NCT04489758|Experimental|Constrictive Bronchiolitis|Veterans with surgical lung biopsy-proven constrictive bronchiolitis
33320330|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
33320331|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
33320332|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
33320333|NCT01344148|Experimental|Anti- TB therapy HAART|
33320334|NCT05011292|Active Comparator|Control Group|The control group includes parents that will view an educational video about a topic other than infant SCB consumption.
33320335|NCT05011292|Experimental|Intervention Group|The intervention group will include those parents who participate in the study after the control data has been collected and two SCB reduction-related videos have been introduced (one for showing at the 4-month visit and one for the 12-month visit).
33320336|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
33320337|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
33320338|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
33320339|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
33320340|NCT01335100||controls|age and gender matched sibilings
33320341|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
33320342|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
33320343|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
33320344|NCT04942964|Experimental|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
33320345|NCT04942964|Experimental|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
32850776|NCT04489758|Active Comparator|Controls|Control patients with minimal smoking history and no chronic lung disease or respiratory symptoms
32850777|NCT05238805|Other|Observational heart and kidney metabolism|Participants will have a PET scan with 11C-Acetate followed by a TEP Scan with 11C-Acetoacetate all in the same day.
32850778|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
32850779|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
33406524|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
33406525|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
32850780|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
32850781|NCT05252689|Active Comparator|monolithic zirconia single posterior crowns with deep chamfer finish line|monolithic zirconia single posterior crowns with deep chamfer finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
32850782|NCT05252689|Experimental|monolithic zirconia single posterior crowns with vertical finish line|monolithic zirconia single posterior crowns with vertical finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
32850783|NCT04878289|Experimental|TOTAL Intervention|TOTAL video and participate in three one-on-one, 30-minute motivational sessions via VVC at 1-week, 6-months, and 12-months
32850784|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of VS-6766 (RO5126766) and Defactinib (VS-6063) were evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation followed a 3+3 design with a maximum of four patient cohorts.~This arm is now complete."
32850785|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).~This arm is now complete."
32850786|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).~This arm is now complete."
32850787|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with LGSOC (20 patients).
32850788|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with CRC (10 patients).~This arm is now complete."
32850789|NCT03875820|Experimental|Dose Expansion KRAS G12V mutant NSCLC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS G12V mutant NSCLC (10 patients).
32850790|NCT03875820|Experimental|Dose Expansion RAS/RAF mutant endometrioid cancer cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) (10 patients).
32850791|NCT03875820|Experimental|Dose Expansion pancreatic cancer|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with pancreatic cancer (10 patients).
32850792|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
32850793|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
32850794|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850795|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850796|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850797|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850798|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850799|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
32850800|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
32850801|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
32850802|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
32850803|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
32850804|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
32850805|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least 10 years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
32850806|NCT05373186|Experimental|BC Combo THDB0207|Single administration of BC Combo THDB0207
32850807|NCT05373186|Active Comparator|Humalog® Mix25|Single administration of Humalog® Mix25
32850808|NCT05373186|Active Comparator|Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus®
32850809|NCT05353764|Experimental|SNB group|patients in the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine.
32850810|NCT05353764|No Intervention|control group|patients in control group will receive general anesthesia without nerve block.
32850811|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
32850812|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
32850813|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
32850814|NCT04488666|Experimental|npSIMS|Group will receive the Aatru Medical npSIMS device
32850815|NCT04399759|Experimental|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
32850816|NCT04399759|Active Comparator|Control group|Home health education
33320346|NCT04942964|Experimental|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
32850819|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
32850820|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
32850821|NCT04278001|Other|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
32850822|NCT05222269|Experimental|68Ga-PTF|150 (+/-50) Megabecquerel (MBq) 68Ga-PTF will be injected intravenously at three timepoints during the course of the standard of care treatment.
32850823|NCT05306262|Active Comparator|hypnotic trance|Hypnosis session of comfort for 20 minutes
32850824|NCT05306262|Experimental|hypnotic trance + catalepsy|Catalepsy + Hypnosis session of comfort for 20 minutes
32850825|NCT04863157|Experimental|Survivor-SHIP|Parents/guardians will take part in 3 education sessions over a one month period. During the sessions, they will learn more about common sleep problems following cancer treatment and ways to understand their child's unique patterns. They will then be educated about behavioral changes they can make to improve their child's sleep.
32850826|NCT04802538|Experimental|Study Group|All patients will begin the study by using their normal ostomy pouching equipment for 28 days. This will be followed by a transition to using the OstoRing® for 28-47 days.
32850827|NCT05239884|Experimental|Product usage order EFDGCHBA|Subjects will use each of the 8 products (EFDGCHBA) during an evaluation period, followed by a 4 hour Test Session
32850828|NCT05239884|Experimental|Product usage order HAGBFCED|Subjects will use each of the 8 products (HAGBFCED) during an evaluation period, followed by a 4 hour Test Session
32850829|NCT05239884|Experimental|Product usage order CDBEAFHG|Subjects will use each of the 8 products (CDBEAFHG) during an evaluation period, followed by a 4 hour Test Session
32850830|NCT05239884|Experimental|Product usage order DECFBGAH|Subjects will use each of the 8 products (DECFBGAH) during an evaluation period, followed by a 4 hour Test Session
32850831|NCT05239884|Experimental|Product usage order FGEHDACB|Subjects will use each of the 8 products (FGEHDACB) during an evaluation period, followed by a 4 hour Test Session
32850832|NCT05239884|Experimental|Product usage order BCADHEGF|Subjects will use each of the 8 products (BCADHEGF) during an evaluation period, followed by a 4 hour Test Session
32850833|NCT05239884|Experimental|Product usage order ABHCGDFE|Subjects will use each of the 8 products (ABHCGDFE) during an evaluation period, followed by a 4 hour Test Session
32850834|NCT05239884|Experimental|Product usage order GHFAEBDC|Subjects will use each of the 8 products (GHFAEBDC) during an evaluation period, followed by a 4 hour Test Session
32850835|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
32850836|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
32850837|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
32850838|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
32850839|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
32850840|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
32850841|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
32850842|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
32850843|NCT05216341|Experimental|Stage 1: Arm 1 (OLP-1002, 1 μg)|"Participants will receive once single dose of 1 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850844|NCT05216341|Experimental|Stage 1: Arm 2 (OLP-1002, 3 μg)|"Participants will receive once single dose of 3 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
33406526|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
32850845|NCT05216341|Experimental|Stage 1: Arm 3 (OLP-1002, 10 μg)|"Participants will receive once single dose of 10 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850846|NCT05216341|Experimental|Stage 1: Arm 4 (OLP-1002, 25 μg)|"Participants will receive once single dose of 25 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850847|NCT05216341|Experimental|Stage 1: Arm 5 (OLP-1002, 50 μg)|"Participants will receive once single dose of 50 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850848|NCT05216341|Experimental|Stage 1: Arm 6 (OLP-1002, 80 μg)|"Participants will receive once single dose of 80 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850849|NCT05216341|Experimental|Stage 2: Arm 1 (OLP-1002, 1μg)|"Participants will be randomised to receive single dose of 1μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850850|NCT05216341|Experimental|Stage 2: Arm 2 (OLP-1002, 2μg)|"Participants will be randomised to receive single dose of 2μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
32850851|NCT05216341|Placebo Comparator|Stage 2: Arm 3 (Placebo)|"Participants will be randomised to receive single dose of Placebo on Day 1~Mode of Administration: subcutaneously injection"
32850852|NCT05114967||Patients undergoing surgery|Patients undergoing surgery during the 4th wave of the pandemic for 1 month duration in the University Hospital of Larissa
32850853|NCT03837756|Placebo Comparator|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
32850854|NCT03837756|Active Comparator|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
32850855|NCT03837756|Active Comparator|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
32850856|NCT03837756|Active Comparator|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
32850857|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
32850858|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
32850859|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
32850860|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
32850861|NCT05205967||Patients who received the Galleri® test|
32850862|NCT05205967||Patients who were eligible to receive the Galleri® test but did not|External contemporaneous control cohort
32850863|NCT01397201|Experimental|BI 54903 - low dose|Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoralkane (HFA) metered dose inhaler (MDI)
32850864|NCT01397201|Experimental|BI 54903 - medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
32850865|NCT01397201|Experimental|BI 54903 - high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
32850866|NCT01397201|Active Comparator|Fluticasone propionate|Fluticasone HFA MDI containing ICS plus placebo matching Respimat inhaler
32850867|NCT01397201|Placebo Comparator|Placebo|Placebo matching Respimat inhaler plus placebo matching HFA MDI
32850868|NCT04845919|Experimental|5-ALA mediated sonodynamic therapy|
32850869|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
32850870|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
32850871|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
32850872|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
32850873|NCT05205733|No Intervention|In-Clinic Semen Analysis Testing|Men needing semen analysis for infertility work-up.
32850874|NCT05205733|Experimental|No in-clinic semen analysis testing|Men needing semen analysis for infertility work-up.
32850875|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
32850876|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
32850877|NCT04839367|Experimental|Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.
32850878|NCT04839367|Experimental|Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.
32850879|NCT04839367|Experimental|Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.
32850880|NCT00834483|Experimental|1|Knotless suture for wound closure
32850881|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
32850882|NCT04596865||Pancreatic ductal adenocarcinoma|Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015
32850883|NCT04596865||Ampullary cancer|Patients who underwent pancreaticoduodenectomy for ampullary cancer between 01/06/2010 and 31/05/2015
32850884|NCT04596865||Distal extrahepatic cholangiocarcinoma|Patients who underwent pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma between 01/06/2010 and 31/05/2015
32850885|NCT04982289|Experimental|ALXN1830 Dosing Arm 1|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
32850886|NCT04982289|Experimental|ALXN1830 Dosing Arm 2|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
32850887|NCT04982289|Experimental|ALXN1830 Dosing Arm 3|Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.
33327052|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
33327053|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
32850890|NCT05200039||Study group|Older men who were treated for localized or locally advanced prostate cancer with curative intent at the age of 70 years or more
32850891|NCT05200039||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019, matched on age and education
32850892|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
32850893|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
32850894|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
32850895|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
32850896|NCT04830553|Experimental|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
32850897|NCT04830553|No Intervention|Waiting list.|Each couple will go through an initial waiting period before the treatment phase. Duration of the waiting period: five weeks.
32850898|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
32850899|NCT05196685||Group Vertigo|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test scores of 1 and above will be sent to ENT
32850900|NCT05196685||Group control|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test score below 1
32850901|NCT05171101|Experimental|MAVEN|
32850902|NCT05171101|No Intervention|Control|Participants enrolled in the control group will receive no mentoring activities but will complete all study measures and assessments.
32850903|NCT04820647|Experimental|Kessler Foundation STRength IDentification and Expression (KF-STRIDE)|
32850904|NCT04820647|No Intervention|Services as Usual|
32850905|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
32850906|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
32850907|NCT04817995|Experimental|Intervention group|The intervention group will get a 6-week internet-based stress recovery intervention.
32850908|NCT04817995|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
32850909|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
32850910|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
32850911|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
32850912|NCT04054947|Experimental|Suicide Prevention Program|
32850913|NCT04054947|No Intervention|Usual Care|
32850914|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
32850915|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
32850916|NCT05155579|Experimental|Groups 1a, 2a and 3a|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
32850917|NCT05155579|Experimental|Group 1b, 2b and 3b|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
32850918|NCT05155579|Experimental|Group 4a|150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
32850919|NCT05155579|Active Comparator|Group 4b|150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
32850920|NCT05155579|Experimental|Group 4c|Group 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
32850921|NCT05155579|Experimental|Group 5a|30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent and OPV vaccines at 6, 10 and 14 weeks of age.
32850922|NCT05155579|Active Comparator|Group 5b|30 children who will receive 3 doses of pentavalent and OPV vaccines at 6, 10 and 14 weeks of age.
32850923|NCT05155579|Experimental|Group 6a|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
33104138|NCT05504616|No Intervention|Control Group|Participants randomized to the control group will receive usual care, which includes standard rheumatology care and access to educational materials on the importance of exercise and physical activity available through the TWH Spondylitis Program and through the public domain. They will receive a link to the physical activity educational module at baseline. They also have access to the program physiotherapist for a single one-hour individualized exercise consultation as requested by either the patient or the treating rheumatologist.
33104139|NCT04108364|Experimental|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
33320347|NCT04231942|Experimental|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
33104140|NCT04108364|No Intervention|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
33104141|NCT05502276|Active Comparator|Endoscopic Submucosal Dissection (ESD)|The Endoscopic Submucosal Dissection (ESD) procedures will be performed with the devices commonly used at the Services of Endoscopy of the Centers participating in the study. There are several models of knives on the market, produced by different companies, all considered equally effective by international guidelines.
33104142|NCT05502276|Experimental|Endoscopic Full-Thickness Resection (EFTR)|"The FTRD® (Full Thickness Resection Device; Ovesco Endoscopy, Tübingen, Germany) is the only over-the-scope device designed to undergo Endoscopic Full-Thickness Resection (EFTR) using a clip-and-cut technique. It consists of a 14 mm modified over-the-scope-clip (OTSC) mounted on the outside of a 23 mm cap, which has a preloaded 13 mm monofilament loop at the end. This device received the CE mark for the lower digestive tract in September 2014 and its efficacy and safety have been evaluated in preclinical studies and clinical trials."
33104143|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
33406527|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
32850924|NCT05155579|Experimental|Group 6b|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
33104144|NCT05491083|Experimental|Phase 1b Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 on day 1 of each 3-weekly cycle
33104145|NCT05491083|Experimental|Phase 2 Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 each 3-weekly cycle
33104146|NCT04106999|Placebo Comparator|Placebo|Normal Saline will be infused as per the protocol
33104147|NCT04106999|Experimental|Intervention group|Dexmedetomidine will be infused as per the protocol
33104148|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
32850925|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32850926|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32850927|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32850928|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
33104149|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
33406528|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
32739812|NCT02475317|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
32739813|NCT02475317|Experimental|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
32739814|NCT02475317|Experimental|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
32739815|NCT02475317|Experimental|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
32739816|NCT02475317|Experimental|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
32739817|NCT02475317|Experimental|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
32850929|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
32850930|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
32850931|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
32850932|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
33327054|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
33327055|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
33327056|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
32850933|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
33327057|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
32850934|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
32850935|NCT04399681|Other|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
32739818|NCT02475317|Experimental|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
32739819|NCT02475317|Experimental|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
32739820|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
32850936|NCT05144815|Experimental|Exercise protocol + IPC group|Patients in this group (n=17) will undergo an endurance training protocol. Prior to this training (8-12 minutes before) they will undergo ischaemic preconditioning.
32850937|NCT05144815|Sham Comparator|Exercise protocol + Sham IPC group|Patients in this group (n=17) will undergo the same training as the previous group and with the same frequency and duration, but the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.
32850938|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
32850939|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
32850940|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
32850941|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
32850942|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
32850943|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
32850944|NCT04797013|Active Comparator|rhTNK-tPA (0.25mg/kg)|rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
32850945|NCT04797013|Active Comparator|rt-PA (0.9mg/kg)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.
32850946|NCT02302833|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32850947|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
32850948|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
32850949|NCT00838695|Experimental|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
32850950|NCT00838695|Experimental|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
32850951|NCT04775173|Experimental|Low dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 5-10 ng/ml by adjusting sirolimus dose, for 1 year.
32850952|NCT04775173|Active Comparator|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
32850953|NCT05120947|Experimental|42 Gray (Gy) Radiation|42 gy of radiation therapy will be administered in 10 fractions.
32850954|NCT05120947|Experimental|39 Gray (Gy) Radiation|39 gy of radiation therapy will be administered in 8 fractions.
32850955|NCT05120947|Experimental|32.5 Gray (Gy) Radiation|32.5 gy of radiation therapy will be administered in 5 fractions.
32850956|NCT00839241|Experimental|Autologous Blood Transfusion|
32850957|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
32850958|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
32850962|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
32850963|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
32850964|NCT04760431|Active Comparator|Group A|Trastuzumab, Taxanes and Pertuzumab
32850965|NCT04760431|Experimental|Group B|Trastuzumab, Taxanes and TKIs
32850966|NCT04560283|Experimental|Experimental group receiving HYALOGYN®|
32850967|NCT04560283|Placebo Comparator|Control group undergoing expectant management|
32850968|NCT04751071|Active Comparator|Roflumilast|Roflumilast 500 µg tablet plus standard therapy
32850969|NCT04751071|Placebo Comparator|Placebo|placebo tablet plus standard therapy
33327058|NCT02526186|No Intervention|Standard of Care|Standard of Care only
32850970|NCT04750213||Participants Receiving Humira (Adalimumab)|Participants receiving Adalimumab for Pyoderma Gangrenosum (PG).
32850971|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
32850972|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
32850973|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
32850974|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
32850975|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
32850976|NCT04746313||Patients with systemic sclerosis|The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization
32850977|NCT04746313||Healthy subjects|Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex
32850978|NCT04742803|Other|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Straberi Epistamp needling treatment
32850979|NCT04742803|Other|No Treatment|Non-Randomized patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production.
32850980|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
32850981|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
32850982|NCT04277767||mild cognitive impairment (MCI)|observational
32850983|NCT04277767||Patients with mild to moderate AD|observational
32850984|NCT04277767||Normal controls|observational
32850985|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
32850986|NCT00868959|Experimental|lurasidone|
32850987|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
32850988|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
32850989|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
32850990|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
32850991|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
32850992|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
32850993|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
32850994|NCT04053283|Experimental|Intravenous|In the IV cohort, patients will receive a single cycle of study treatment, with three single doses of NG-641 on Days 1, 3 and 5 by IV infusion.
32850995|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
32850996|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
32850997|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
32850998|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
32959983|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
32959984|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
32959985|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
32959986|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
32959987|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
32850999|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
32851000|NCT03838887||control group|"Pregnant women:~Age between 18-35 years~Parity: primigravidas and multiparas.~Have no history of preeclampsia or eclampsia.~Have no history of chronic hypertension.~Not diabetic.~Not have antiphospholipid syndrome.~Not have autoimmune disease such as SLE"
32851001|NCT03838887||High risk group|"Pregnant women with:~History of preeclampsia -Eclapmsia~Chronic hypertension~Diabetic~Antiphospholipid syndrome.~Autoimmune syndrome such as SLE."
32851002|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
32851003|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
33406529|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
32851004|NCT04021537|Experimental|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
33406530|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
33406531|NCT02236806|Placebo Comparator|Arm 4|Placebo
33406532|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
33406533|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
33406534|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
33406535|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
33406536|NCT03054870|Other|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
32851005|NCT04021537|Active Comparator|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
32851006|NCT04277923|Experimental|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
32851007|NCT04277923|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
32851008|NCT05233722|Placebo Comparator|Post-exercise insulin sensitivity following placebo administration|Young healthy males will ingest placebo (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
32851009|NCT05233722|Experimental|Post-exercise insulin sensitivity following Rapamycin administration|Young healthy males will ingest Rapamycin (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
32851010|NCT00869349|Experimental|IFS Intervention Group|
32851011|NCT00869349|Active Comparator|Education Group|
32851012|NCT04482816|Experimental|Physiological pacing|"Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle.~If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms).~Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria."
32851013|NCT04482816|Active Comparator|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
32851014|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
32851015|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
32851016|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
32851017|NCT04783662||Robust|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal to 0
32851018|NCT04783662||Pre Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is 1 or 2
32851019|NCT04783662||Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal or greater than 3
32851020|NCT04004065|Experimental|Part A: SRP-5051|Participants received escalating dose levels of SRP-5051, every 4 weeks, via intravenous (IV) infusion for up to 75 weeks during Part A. Once the doses have been selected for Part B, all participants who have completed Part A will transition to Part B.
32851021|NCT04004065|Experimental|Part B: SRP-5051|Participants will receive SRP-5051 at the doses selected based on data from Part A every 4 weeks, via IV infusion, for up to 2 years. This includes the participants who rollover from Part A, as well as the additional participants who will be enrolled at the beginning of Part B.
32851022|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
32851023|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
32851024|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
32851025|NCT00870363|No Intervention|4|HIV-negative
32851026|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
32851027|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
32851028|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
32851029|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
32851030|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
32851031|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
32851032|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
32851033|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
32851034|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
32851035|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
32851036|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
32851037|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
32851038|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
32851039|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
32851040|NCT05179746|Active Comparator|With electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
32851041|NCT05179746|Placebo Comparator|Without electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
32851042|NCT04933188||control|Lean health controls with a BMI<25kg/m2
32851043|NCT04933188||overweight|patients with a BMI of 25-30kg/m2
32851044|NCT04933188||obesity|patients with a BMI of over 30kg/m2
32851045|NCT04738890|Experimental|MBCT-PCCFA plus TAU|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing, plus treatment as usual.
32851046|NCT04738890|Other|TAU control|Treatment as usual control group
32851047|NCT01396187|Experimental|Treatment|
32851048|NCT01396187|Placebo Comparator|Placebo|
32851049|NCT03257761|Experimental|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32851050|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
32851051|NCT04174170|Experimental|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32851052|NCT04174170|Experimental|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32851053|NCT04174170|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
32851054|NCT04704193|Experimental|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
32851055|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
33104150|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
33104151|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
33104152|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
32851056|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
32851057|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
32851058|NCT00871845|No Intervention|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) <25
32851059|NCT00871845|Other|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
32851060|NCT04738110||KCH patients|75 high grade glioma patients from KCH
32851061|NCT04738110||NHNN patients|75 high grade glioma patients from NHNN
32851062|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
32851063|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
32851066|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
32851067|NCT04731168|No Intervention|Control|
32851068|NCT04731168|Experimental|MAD|Patients will have a mandibular advancement device during the first postoperative night
32851069|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
32851070|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
32851071|NCT04696159|Experimental|Endoscopic Per-Oral Pyloromyotomy (POP)|The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
32851072|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
32851073|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
32851074|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
32851075|NCT04816890|Experimental|M1 Pram P037|Multi daily administration of M1 Pram P037 by subcutaneous injection
32851076|NCT04816890|Active Comparator|Insulin lispro|Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
32851077|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
32851078|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
32851079|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
33104153|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
33104154|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
32851080|NCT01392677|Placebo Comparator|matching placebo tablet|
32851081|NCT04102410|Experimental|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
32851082|NCT04102410|Sham Comparator|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
32851083|NCT05180227|Placebo Comparator|Without Stimulation|Participant will complete an orthostatic challenge without transcutaneous stimulation.
32851084|NCT05180227|Active Comparator|With Stimulation|Participant will complete an orthostatic challenge with transcutaneous stimulation.
32851085|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
32851086|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
32851087|NCT03927001|Other|Intervention|NeVa Stent Retrievers
32851088|NCT03104088||SPG4 patients|
32851089|NCT03104088||Healthy controls|
32851090|NCT00841971|Experimental|anidulafungin|anti-fungal agent
32851091|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
32851092|NCT04776954|Active Comparator|Forced Air Warming System|Participants in this arm will receive warming using a forced air warming system.
32851093|NCT04776954|Active Comparator|Resistive Blanket Warming System|Participants in this arm will receive warming using a resistive blanket warming system.
32851094|NCT03650725||Mandatory Split bowel preparation|Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.
32851095|NCT03650725||Optional Split bowel preparation|Patients will be advised on split-dose bowel preparation (as per option 1), but will also receive instructions on day before bowel preparation. The instructions will indicate that split-dose bowel preparation is the optimal preparation for cleansing the bowel and for visualizing polyps, but they may choose day before bowel preparation if the split dose preparation is too difficult for them.
32851096|NCT04724460|Active Comparator|Long DOAC|Administration of Rivaroxaban for 18 months
32851097|NCT04724460|Active Comparator|Short DOAC|Administration of Rivaroxaban for 6 months
32851098|NCT04399135|Active Comparator|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
32851099|NCT04399135|Active Comparator|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
32851100|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
32851101|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
32851102|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
32851103|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
32851104|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
32851105|NCT03907969|Experimental|Core Module: AZD7648 Monotherapy|AZD7648 will be administered orally on an empty stomach
32851106|NCT03907969|Experimental|Combination Module 1: AZD7648 + PLD|AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)
32851107|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
32851108|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
32851109|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
32851110|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
32851111|NCT04399213|Experimental|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
32851112|NCT04399213|Experimental|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
32851113|NCT04399213|Experimental|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
32851114|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
32851115|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
32851116|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
32959988|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
32959989|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
32959990|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
32959991|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
32959992|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
32959993|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
32959994|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
32959995|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
32959996|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
32959997|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
32959998|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
32959999|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
32960000|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
32960001|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
32960002|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
32960003|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
32960004|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
32960005|NCT00868374|Experimental|1|Quetiapine XR
32960006|NCT00868374|Placebo Comparator|2|
32960007|NCT00868452|Experimental|Lurasidone|
32960008|NCT00868452|Placebo Comparator|Placebo|
32960009|NCT00869622|Active Comparator|Risedronate|Active drug
32960010|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
32960011|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls. Scan will be done with regadenoson contrast.
32960012|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
32960013|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
32960014|NCT00875550|Active Comparator|Dexmedetomidine High dose|
32960015|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
32960016|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
32960017|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
32960018|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
32960019|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
32960020|NCT00879060|Experimental|Spironolactone|Experimental group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to experimental group will be initiated on 25mg of spironolactone. If at week 4, serum potassium is <5.5 mmol/L and serum creatinine-baseline creatinine is <0.5 mg/dl, the study drug will be increased to the target dose of 50mg once daily.
32960021|NCT00879060|Placebo Comparator|Placebo Control|Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
32960022|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
32960023|NCT00880464|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
32960024|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
32960025|NCT00884052|Experimental|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
32960026|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
32960027|NCT00884754|Active Comparator|90º curvature, malleable stylet|
32960028|NCT00885768||A|patients with renal artery stenosis
32960029|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
32960030|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
32960031|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
32960032|NCT00886626|Experimental|Exenatide|Exenatide
32960033|NCT00886626|No Intervention|Control|Control - no intervention
32960034|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
32960035|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
32960036|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
32851117|NCT03995004|Experimental|Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Normal Saline (1mL) on induction and continued q12h for 4 more doses."
32851118|NCT03995004|Active Comparator|Dexamethasone|"Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
32851119|NCT03995004|Experimental|Dexa_Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
32851120|NCT03253549|Experimental|SMArTVIEW|
32851121|NCT03253549|No Intervention|Standard Care|
33327059|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
32851122|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
33327060|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
32851123|NCT03685305|Experimental|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
32851124|NCT03685305|Active Comparator|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
32851125|NCT03103776|Other|Patients who have Graves disease|
32851126|NCT03103776|Other|Patients having a goiter|
32851127|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
32851128|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
32851129|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
32851130|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
32851131|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
32851132|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
32851133|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
32851134|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
32851135|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
32851136|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
32851137|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
32851138|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
32851139|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
32851140|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
32851141|NCT04685928|Experimental|MRI arm|MRI prostate with contrast, followed by MRI-guided biopsy under local anaesthesia only if MRI show suspicious lesion. Men with non-suspicious MRI will not receive a biopsy.
32851142|NCT04685928|Active Comparator|TP-arm Systematic biopsy|24-core Systematic transperineal prostate biopsy under local anaesthesia
32851143|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
32851144|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
32851145|NCT04669938||Patients hospitalized for COVID-19|
32851146|NCT03845023|Placebo Comparator|2-Night at Home|An initial 2-night, at-home blinded baseline period in which all subjects received placebo
32851147|NCT03845023|Experimental|3-Night Run In|AD036 Dose 1 (Low Dose: 25/5) or Placebo
32851148|NCT03845023|Experimental|7-Night|A 7-night treatment period in which subjects received the treatment to which they were randomized, i.e., 1 of the 3 different fixed-dose combinations of drugs, or placebo
32851149|NCT03845023|No Intervention|End of Study|End of Study Visit
32851150|NCT02192619||observational|
32851151|NCT03957876|Experimental|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
32851152|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
32851153|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
33327061|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
32851154|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
32851155|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
32851156|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
32851157|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
32851158|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
32851159|NCT04512924|Active Comparator|Group 1|
32851160|NCT04512924|Experimental|Group 2|
32851161|NCT03249103|Experimental|All subjects|Up to 24 subjects will receive placebo, NYX-2925 20 mg QD, and NYX-2925 200 mg QD for sequential 2 week treatment periods, then go into Follow-up for 1 week.
32851162|NCT03216213|No Intervention|Control|Vignette contains no extra information
32851163|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
32851164|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
32851165|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
32851166|NCT04701762|Experimental|videolaryngoscopy|Initial intubation performed using GlideScope videolaryngoscope.
32851167|NCT04701762|Active Comparator|conventional direct laryngoscopy|Initial intubation performed using direct laryngoscopy.
32851168|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
32851169|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
32851170|NCT03841669|Experimental|Aerobic Exercise Group|This is the experimental group. Supervised exercise will be held 2 times a week for 60 minutes and 1 time a week for 30 minutes at home.
32851171|NCT03841669|Active Comparator|Physical Activity & Health Information Group|This is the control group. Participants will engage in daily life monitoring every 6 weeks.
32851172|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
32851173|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
32851174|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
32851175|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
32851176|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
32851177|NCT00873873||Persistent obstruction|(pattern of asthma progression)
32851178|NCT00873873||Late obstruction|(pattern of asthma progression)
32851179|NCT00873873||Late normal|(pattern of asthma progression)
32851180|NCT00873873||Persistent normal|(pattern of asthma progression)
32851181|NCT04398589|Experimental|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
32851182|NCT04398589|Placebo Comparator|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
32851183|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32851184|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
32851185|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
32851186|NCT04657315|Other|The investigational drug into the Intratumoral administration|The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
32960037|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
32960038|NCT00887562|Placebo Comparator|placebo|Placebo
32851187|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
32851188|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
32851189|NCT04654039||Treatment of Infertility|Non intervention
32851190|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
32851191|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
32851192|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
32851193|NCT03862014|Active Comparator|SDF+ARR|SDF+ARR will be applied on molars with MIH
32851194|NCT04695132|Experimental|Illness Management and Recovery treatment programme (intervention group)|These patients receive the Illness Management and Recovery treatment. Treatment takes place during 2 Group sessions and 1 individual session per week.
32851195|NCT04695132|No Intervention|Treatment as usual (control group)|These patients receive treatment as usual consisting of the standard treatment given at the respective inpatient forensic mental health facility where they are admitted.
32851196|NCT00875277|Experimental|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
32851197|NCT00875277|Placebo Comparator|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
32851198|NCT00875277|Experimental|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
32851199|NCT00875277|Experimental|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
32851200|NCT00875277|Experimental|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
32851201|NCT00875277|Active Comparator|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
32851202|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:~1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)~45 minute, physical activity led by facilitator (one-two times per week);~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and~weigh-in during weight management group and individual visits (once each week)."
32851203|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~partnering with participant on BWLI homework;~meeting with participant and BWLI facilitator individually;~attending all other health care appointments; and~partnering on tasks that arise out of those appointments."
32851204|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
32851205|NCT04634539|Experimental|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
32851206|NCT03245983|Experimental|Patient willing to participate|
32851207|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
32851208|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
32851209|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
32851210|NCT01323309||enhanced usual care (EUC)|
32851211|NCT03750786|Experimental|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
32851212|NCT03750786|Active Comparator|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
32851213|NCT04466527|Experimental|Treatment|Subjects in this arm will undergo laser treatment on their active acne vulgaris lesions. Subjects will serve as their own control.
32851214|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
32851215|NCT03215745|No Intervention|Control group|Usual care
32851216|NCT04457245|Active Comparator|Arm I (dRT)|150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
32851217|NCT04457245|Experimental|Arm II (18F-DCFPyL, PET/CT, dRT)|162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
32851218|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
32851219|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
32851220|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
32851221|NCT04691700|Active Comparator|Goreisan|Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment
32851222|NCT04691700|Active Comparator|No Goreisan|Standard treatment without Goreisan (TJ-17)
32851223|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
32851224|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
32851225|NCT03202303|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
32851226|NCT03202303|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
32851227|NCT04685070|Experimental|HS-10296 (Almonertinib)|
32851228|NCT03828799|Experimental|Folfirinox-R|Folfirinox + regorafenib
32851229|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
32851230|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
32851231|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
32851232|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
32851233|NCT04450771|Experimental|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe & consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge & changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
32851234|NCT04450771|Active Comparator|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 5 parent-only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSC intervention is psychoeducation about health & social impacts of restrictive eating and supporting parent & child exploration of motivation to change eating patterns & choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
32851235|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^3)|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
32851236|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
32851237|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^4)|Participants will receive a single dose of rZIKV/D4Δ30-713 or placebo at study entry (Day 0).
32851238|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
32851239|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
32851240|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
32851241|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
32851242|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
32851243|NCT03736668|Experimental|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
32851244|NCT04444453|Experimental|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
32851245|NCT04444453|No Intervention|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
32851246|NCT03324672|Active Comparator|TRIGGER|
32851247|NCT03324672|Experimental|TRIGGER+CURETAPE|
32960039|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
32960040|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
32960041|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
32960042|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
32960043|NCT00889824|Experimental|prosthesis group|balance prosthesis
32960044|NCT00890682|Experimental|Sky0402|Injection of Study Drug
32960045|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
32851248|NCT04276753|Experimental|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.~Test product will be applied topically on full face twice a day for 8 weeks."
32851249|NCT04276753|Placebo Comparator|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
32960046|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
32960047|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days"
32960048|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days~Carboplatin AUC=5 IV every 21 days"
32960049|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
32960050|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
32960051|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
32960052|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
32851250|NCT03299088|Experimental|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32851251|NCT03299088|Experimental|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
32851252|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
32851253|NCT04665336|Experimental|Intervention Group Lifestyle counseling|"Obese individuals with evening chronotype will be trained on sleep hygiene in order to create behavioral changes in line with circadian rhythms and an intervention program called Circadian Timing Program which was created by the researcher in line with the relevant literature will be implemented for 12 weeks. This program includes sleep hygiene recommendations and regulation of daylight exposure, sleep, meal, caffeine intake and exercise times. To determine participants' sleep times they will be asked to keep a sleep diary and sleep records will be taken with the smart bracelet. Participants will be given a password to access the research website. The website of the study will be used for the training, control, motivation and communication of the Participants."
32851254|NCT04665336|No Intervention|Control group|Participants will be asked to follow their normal daily lifestyle, maintain normal sleep and eating habits and no further instructions or suggestions will be provided during the study.
32851255|NCT03670134|Experimental|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
32851256|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
32851257|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
32851258|NCT03657342|Experimental|L-CsA treatment plus SoC|Liposomal Cyclosporine A 5 mg twice daily for 48 weeks + Standard of Care Therapy
32851259|NCT03657342|Active Comparator|Control treatment|In this arm only the standard of care is administered. Standard of care is a maintenance regimen of immunosuppressive agents.
32851260|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
32851261|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
32851262|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
32851263|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
32960053|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
32960054|NCT00895830|Placebo Comparator|1|
32960055|NCT00895830|Experimental|2|0.3mg dose level
32960056|NCT00895830|Experimental|3|1mg dose level
32960057|NCT00895830|Experimental|4|2mg dose level
32960058|NCT00895830|Experimental|5|3mg dose level
32960059|NCT00896064|Experimental|Formulation 1|
32851264|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
32851267|NCT03630822|Experimental|beneficiary of the advance directive program|
32851268|NCT03630822|Active Comparator|beneficiary of standard Support|
32851269|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
32851270|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
32851271|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
32851272|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
32851273|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
32851274|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
32851275|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
32851276|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
32851277|NCT04488354|Experimental|CLBR001 treated patients|Patients who have been administered with CLBR001
32851278|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
32851279|NCT05148858||Cases|Patients affected by COVID-19 infection
32851280|NCT05148858||Control|Normal subjects not affected by COVID-19 infection
32851281|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
32851282|NCT04479852|Experimental|SP-624|Daily oral capsule, 20 mg/day
32851283|NCT04479852|Placebo Comparator|Placebo|Daily oral capsule
33406537|NCT03414047|Experimental|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
33406538|NCT03414047|Experimental|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received <3 lines of prior therapy.
32851290|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
32851291|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
32851292|NCT04479696|Experimental|Arm I (NIRS)|Patients receive standard of care verbal and written education materials. Patients also receive a customized video which includes a description of each of their tumor, functional areas of the brain affected, and possible symptoms from the tumor and radiation treatment based on the neuro-imaging features. Patients and their caregivers watch the video together or separately over 1.5-3 minutes before the end of the first week of radiation treatment. Within 2 weeks after watching the NIRS video, patients complete an optional survey over 5-10 minutes.
32851293|NCT04479696|Active Comparator|Arm II (standard of care)|Patients receive standard of care verbal and written education materials.
32851294|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
32851295|NCT02912988|No Intervention|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
32851296|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
32851297|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
32851298|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
32851299|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
32851300|NCT04882644|Experimental|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 3 months and a health education content for 12 months.
32960060|NCT00896064|Experimental|Formulation 2|
32960061|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
32960062|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
32960063|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
33406539|NCT03414047|Experimental|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
32960064|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
32960065|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
32960066|NCT00900666|Placebo Comparator|Saline injection|
32960067|NCT00900666|Experimental|Botulinum toxin injection|
32960068|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
32960069|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
32960070|NCT00902226|Experimental|Escitalopram|
32960071|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
32960072|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
32960073|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
32960074|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
32960075|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
32960076|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
32960077|NCT00905268|Placebo Comparator|D: Placebo|placebo
32960078|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
32960079|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
32960080|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
32960081|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
32960082|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
32960083|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
32960084|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
32960085|NCT00911586|Experimental|Testosterone Undecanoate|Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.
32960086|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
32960087|NCT00911742|Active Comparator|2 Zytram (R)|
32960088|NCT00911898|Experimental|MM-111|
32960089|NCT00912990|Placebo Comparator|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
32960090|NCT00912990|Active Comparator|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
32960091|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
32960092|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
32960093|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
32960094|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
32960095|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
32960096|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
32960097|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
32960098|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
32960099|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
32960100|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
32960101|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
32960102|NCT00915954|Active Comparator|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
32851301|NCT04882644|No Intervention|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
33406540|NCT03414047|Experimental|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
32851302|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
32851303|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
32851304|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
32851305|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
32851306|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
32851307|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
32851308|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
32851309|NCT03573414|Experimental|Healthy men and women|"Intervention:~2*breakfast containing 40 g of raspberry powder, 30 g milled flax seeds and 250 mL of soy Milk."
32851310|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
32851311|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
32851312|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
32851313|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
32851314|NCT04381845|Other|psychiatric patient|patients who are hospitalized in psychiatric department
32851315|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
32851316|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
32851317|NCT04562610|Active Comparator|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:~Acetaminophen 1,000 mg by mouth prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2 grams by mouth prior to operation~Gabapentin 600mg by mouth prior to operation"
32851318|NCT04562610|Active Comparator|Group B: Intravenous agents|"Group B patients will receive:~Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2grams intravenous at start of operation~Gabapentin 600 mg by mouth prior to operation"
32851319|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
32851320|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
32851321|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
32851322|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO
32851323|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO
32851324|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO
32851325|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO
32851326|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO
32851327|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
32851328|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
32960103|NCT00915954|Active Comparator|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
32960104|NCT00915954|Active Comparator|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
32960105|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
32960106|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
32960107|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
32960108|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
32960109|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
32960110|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
32960111|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
32960112|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
32960113|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
32960114|NCT00924612|Experimental|Fasting (Treatment A)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
32960115|NCT00924612|Experimental|Very low fat diet (Treatment B)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with very low fat (6-10% fat).
32960116|NCT00924612|Experimental|Low fat diet (Treatment C)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with low fat (20% fat).
32960117|NCT00924612|Experimental|Normal diet (Treatment D)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with normal fat (30% fat).
32960118|NCT00924612|Experimental|High fat diet (Treatment E)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with high fat (50% fat).
32960119|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
32960120|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
32960121|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
32960122|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
32960123|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
32960124|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
32960125|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
32960126|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
32960127|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
32960128|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
32960129|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
32960130|NCT00928200|Experimental|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
33327062|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
33104155|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
33104156|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON|During the 2nd year after adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo. If this dose is proven safe, in the third year, 10 more patients will receive 0.1 mg/kg IV DON, 14 patients will receive 1.0 mg/kg IV DON, and 5 will receive placebo. Should promising risk-benefit ratio profile be shown in year 2 and 3, the study will continue with increased doses of 5.0 mg/kg IV DON, and 10.0 mg/kg IV DON, and 7 placebo patients.
33104157|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON|During the 2nd year after adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo. If this dose is proven safe, in the third year, 10 more patients will receive 0.1 mg/kg IV DON, 14 patients will receive 1.0 mg/kg IV DON, and 5 will receive placebo. Should promising risk-benefit ratio profile be shown in year 2 and 3, the study will continue with increased doses of 5.0 mg/kg IV DON, and 10.0 mg/kg IV DON, and 7 placebo patients.
33104158|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 5.0 mg/kg IV DON|During the 2nd year after adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo. If this dose is proven safe, in the third year, 10 more patients will receive 0.1 mg/kg IV DON, 14 patients will receive 1.0 mg/kg IV DON, and 5 will receive placebo. Should promising risk-benefit ratio profile be shown in year 2 and 3, the study will continue with increased doses of 5.0 mg/kg IV DON, and 10.0 mg/kg IV DON, and 7 placebo patients.
33104159|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 10.0 mg/kg IV DON|During the 2nd year after adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo. If this dose is proven safe, in the third year, 10 more patients will receive 0.1 mg/kg IV DON, 14 patients will receive 1.0 mg/kg IV DON, and 5 will receive placebo. Should promising risk-benefit ratio profile be shown in year 2 and 3, the study will continue with increased doses of 5.0 mg/kg IV DON, and 10.0 mg/kg IV DON, and 7 placebo patients.
33104160|NCT05478720|Placebo Comparator|Dose escalation in Malawian children with cerebral malaria - placebo|During the 2nd year after adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo. If this dose is proven safe, in the third year, 10 more patients will receive 0.1 mg/kg IV DON, 14 patients will receive 1.0 mg/kg IV DON, and 5 will receive placebo. Should promising risk-benefit ratio profile be shown in year 2 and 3, the study will continue with increased doses of 5.0 mg/kg IV DON, and 10.0 mg/kg IV DON, and 7 placebo patients.
32739821|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
32739822|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
32739823|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
32739824|NCT04844489|Other|Blood samples|
32739825|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
32739826|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
32739827|NCT04995393|Active Comparator|Glove|A heated glove containing water.
32739828|NCT04995393|Active Comparator|Blanket|A heated blanket.
32739829|NCT04995393|Active Comparator|Gel pack|A heated gel pack.
32739830|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
32739831|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
32739832|NCT04988139|Active Comparator|Intervention group|traditional rehabilitation programs with additional individualized educational training
32739833|NCT04988139|No Intervention|Control group|traditional rehabilitation programs without additional individualized educational training
32739834|NCT05322473|Experimental|sonelokimab dose 1|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
32739835|NCT05322473|Experimental|sonelokimab dose 2|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
32739836|NCT05322473|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be re-randomized to receive a sonelokimab dosage regimen during Part B.
32739837|NCT05322473|Active Comparator|adalimumab|Subjects randomized to this arm will receive adalimumab during the Double-Blind Treatment Period and will be reallocated to receive sonelokimab dosage regimen during Part B.
32739838|NCT04995159|Experimental|Poststent SAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy
32739839|NCT04995159|Active Comparator|Poststent DAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy
32851329|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
32851330|NCT05318547|Experimental|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
32851331|NCT05318547|Experimental|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
32851332|NCT04380909|Experimental|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
32851333|NCT04380909|Other|Waiting control group|Access to internet-based intervention after 3 weeks.
32851334|NCT00896181|Experimental|Chemoradiation for Nasopharyngeal Carcinoma|"INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity."
32851335|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
32851336|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
32851337|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
32851338|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
32851339|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
32851340|NCT05311137||Closed-loop Group|Groups of Patients Adhering to Closed-Loop Therapy.
32851341|NCT05311137||No Closed-loop Group|Patients who have not undergone closed-loop treatment or patients who have not undergone standard surgery and medication.
32851342|NCT05311137||Exchange Group|Groups of patients with delayed compliance with closed-loop therapy for atrial fibrillation.
32851343|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
32851344|NCT03837795|Experimental|Neurofeedback therapy group|
32851345|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
32851346|NCT03830697|Placebo Comparator|Sham intervention|
32851347|NCT04381065|Experimental|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
32851348|NCT04381065|Placebo Comparator|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
32851349|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
32851350|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
32851351|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
32851352|NCT03460977|Experimental|Dose Escalation (Part 1A)|Participants with SCLC, CRPC and FL will receive PF-06821497 at escalating dose levels
32851353|NCT03460977|Experimental|Dose Escalation (Part 1B)|Participants with FL will receive PF-06821497 at escalating dose levels
32851354|NCT03460977|Experimental|Dose Escalation (Part 1C)|Participants with CRPC will receive PF-06821497 at escalating dose levels.
32851355|NCT03460977|Experimental|Dose Escalation (Part 2A)|Participants with CRPC and SCLC will receive PF-06821497 at escalating dose levels in combination with SOC.
32851356|NCT03460977|Experimental|Dose Expansion (Part 2B)|Participants with CRPC will receive PF-06821497 in combination with SOC or SOC alone.
32851357|NCT03460977|Experimental|Japan Cohort|Participants with CRPC will receive PF-06821497 at one or two doses
32851358|NCT03460977|Experimental|China cohort|Participants will receive PF-06821497 at one or two doses
32851359|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
32851360|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
32851361|NCT04561986|Active Comparator|Arm A: Standard of care (SOC) + tocilizumab (TCZ)|SOC, as below + TCZ (162 mg every week, subcuataneous administration)
32851362|NCT04561986|No Intervention|Arm B: SOC|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration
32851363|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
32851364|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
32851365|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
32851366|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
32851367|NCT04546698||Healthy people|
32851368|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
32851369|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
32851370|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
32851371|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
32851372|NCT05315349|Experimental|Patient requiring cardiac surgery for myocardial revascularization|
32851373|NCT04382157|Experimental|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
32851374|NCT04382157|Placebo Comparator|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
32851375|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
32851376|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
32851377|NCT00880425||Participants with continuous headache|
32851378|NCT00880425||Participnts with non-continuous headache|
32851379|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
32851380|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
32851381|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
32851382|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
32851383|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
32851384|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
32851385|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
32851386|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
32851387|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
32851388|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
32851389|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
32851390|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
32851391|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
32851392|NCT00858078||Previously referred|Previously-enrolled subjects from NCI Protocol 01-C-0009
32851393|NCT00858078||Self-referred|Self-referred women at increased familial risk of breast and ovarian cancer were recruited through an hereditary breast/ovarian cancer advocacy group
32851394|NCT04424862|Experimental|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
32851395|NCT04424862|Active Comparator|Control|Ponticelli Regimen
32851396|NCT05310513||ICU group|patients admitted to ICU with PRES.
32851397|NCT05310513||Non-ICU group|patients not admitted to ICU with PRES.
33104161|NCT05003089|Experimental|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
33104162|NCT05003089|Experimental|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
32851398|NCT04368780|No Intervention|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
32851399|NCT04368780|Experimental|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
32851400|NCT04333602|Experimental|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
32851401|NCT04333602|No Intervention|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
32851402|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
32851403|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
32851404|NCT05073666||pulmonary embolism|Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
32851405|NCT05073276|Active Comparator|Non-weightbearing for the first six weeks after surgery|Not weightbearing after surgery
32851406|NCT05073276|Experimental|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
32851407|NCT00882687|Experimental|0.1% Lifitegrast|
32851408|NCT00882687|Experimental|1.0% Lifitegrast|
32851409|NCT00882687|Experimental|5.0% Lifitegrast|
32851410|NCT00882687|Placebo Comparator|Placebo|
32851411|NCT05073198|Experimental|Experiment|Giving educational brochures about testicular cancer and Testicular Self-Examination to the students in the experimental group
32851412|NCT05073198|No Intervention|Control|No intervention
32851413|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
32851414|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
32851415|NCT05310123|Experimental|AC-11|6 months of treatment with AC-11
32851416|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
32851417|NCT02294461|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer. Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
32851418|NCT02294461|Experimental|Placebo|Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
32851419|NCT02294461|Experimental|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
32851420|NCT04313166|Experimental|Cu(II)ATSM|copper-containing synthetic small molecule
32851421|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
32851422|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
32851423|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
32851424|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
32851425|NCT04197726|Experimental|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
32851426|NCT04197726|Active Comparator|Control white bread|Reference white bread (wild-type)
33406541|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
33406542|NCT01411332|Active Comparator|Arm I: SIMRT|'Participants in this group will receive the Standard Fractionated Intensity Modulated Radiotherapy (SIMRT) consisting 40 fractions over 8 weeks.
33406543|NCT01411332|Active Comparator|Arm II: HTIMRT|Participants in this group will receive the Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT) consisting of 38 fractions over 7.5 weeks.
33406544|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
32960131|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
33033061|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
33406545|NCT03709901|Placebo Comparator|Placebo|Injection of saline
33406546|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
33406547|NCT05448677|Experimental|Experimental|Ezurpimtrostat+Atezolizumab-Bevacizumab
33406548|NCT05448677|Active Comparator|Control|Atezolizumab-Bevacizumab
33406549|NCT04858932||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
33406550|NCT04858932||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
33406551|NCT04858932||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
33406552|NCT05216718|Experimental|Conventional flap|BABA robotic-thyroidectomy that using conventional flap
33406553|NCT05216718|Active Comparator|Mini-flap|BABA robotic-thyroidectomy that using Mini-flap
33406554|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
33406555|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
33406556|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
33406557|NCT05216640|Active Comparator|High Flow Nasal Cannula|Standard operating procedures represented by high flow nasal cannula oxygen therapy
33406558|NCT05216640|Active Comparator|High Velocity Nasal Insufflation|Standard operating procedures represented by high velocity nasal insufflation therapy
33406559|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
33406560|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
33406561|NCT00472680|Experimental|1|High Dietary Protein
33406562|NCT00472680|Active Comparator|2|Normal Dietary Protein
33406563|NCT05674266|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
33406564|NCT05674266|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
33406565|NCT05670912|Experimental|active group|Take 2 tablets each time (study drug), 3 times a day, a total of 0.9g per day. Take it with warm water half an hour before meals.
33406566|NCT05670912|Placebo Comparator|control group|Take 2 tablets of the control drug (placebo) each time, 3 times a day, 0.9g a day. Take it with warm water half an hour before meals.
33406567|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
33406568|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
33406569|NCT05216406|Experimental|5-HTP|The dietary supplement (100 mg of 5-hydroxytryptophan; CLEANMOOD™) was provided by NURA™ (Irvine, California USA). Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
33406570|NCT05216406|Placebo Comparator|Control|The placebo consisted of maltodextrin. Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
33406571|NCT04811898|Experimental|Experimental single arm|Single group with 5 dose escalation for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg)
33406572|NCT05223270|Experimental|intervention group-1|Hydrocolloid wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
33406573|NCT05223270|Experimental|intervention group-2|Hydrocelluler wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
32960132|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
32960133|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
32960134|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
32960135|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
32960136|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
32960137|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
32960138|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
33327063|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
33327064|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
32960139|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
32960140|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
32960141|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
32960142|NCT00935064|Placebo Comparator|Placebo|
32960143|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
32960144|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
32960145|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
32960146|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
32960147|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
32960148|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
33406574|NCT05223270|No Intervention|control group|Patients in this group were treated without placing an additional dressing under the NIMV mask.
32960149|NCT00939900|Experimental|aclasta|aclasta group
32960150|NCT00939900|No Intervention|control|control group
32960151|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
32960152|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
32960153|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
32960154|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
32960155|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
32960156|NCT00940446|Active Comparator|Control|Metal staple wound closure
32960157|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
32960158|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
32960159|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
33033062|NCT01958892||TURP|
33033063|NCT01958892||TUERP|
32960160|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
32960161|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
32960162|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
32960163|NCT00943800|Experimental|High Risk Patients eligible for radiation|
32960164|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
32960165|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
32960166|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
32960167|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
32960168|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
32960169|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
32960170|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
32960171|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
32960172|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
32960173|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
32960174|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
32960175|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
32960176|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
32960177|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
32960178|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
32960179|NCT00947310|Experimental|A|Standard ICD Programming
32960180|NCT00947310|Experimental|B|High rate cutoff
32960181|NCT00947310|Experimental|C|Long ICD duration delay
32960182|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
32960183|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
32960184|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
32960185|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
32960186|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
33033064|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
32851427|NCT01394939|Experimental|Single Agent_ Cohort 1|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF) Cohort 1: JX-594 3 x 10^8 plaque forming unit (pfu), Days 1, 8,15, 22, and 29"
32851428|NCT01394939|Experimental|Single Agent_Cohort 2|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: RAC VAC GM-CSF Cohort 2: JX-594 1 x 10^9 pfu, Days 1, 8,15, 22, and 29"
32851429|NCT01394939|Experimental|Combination_Cohort 3|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF Irinotecan: 180 mg/m2 IV every 2 weeks. JX-594 3 x 10^8 pfu Day 1,8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
32851430|NCT01394939|Experimental|Combination_Cohort 4|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF JX-594 1 x 10^9 pfu Day1, 8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
32851431|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
32851432|NCT05036304|Active Comparator|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
32851433|NCT05036304|Experimental|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
32851434|NCT05620953||SARI case|
32851435|NCT04193514|Experimental|Acceptance and Commitment Therapy|
32851436|NCT04193514|No Intervention|Treatment as Usual|
32851437|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
32851438|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
32851439|NCT05072418||Children with dyslexia|
32851440|NCT05072418||Non-dyslexic children|
32851441|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
32851442|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
32851443|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
32851444|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
32851445|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
32851446|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
32851447|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
32851448|NCT04133532|Experimental|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
32851449|NCT04133532|Experimental|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
32851450|NCT03806257|No Intervention|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
32851451|NCT03806257|Experimental|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
32851452|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
33033065|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
33104163|NCT05003089|Active Comparator|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
32851453|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
32851454|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
32851455|NCT01391663|Experimental|Alogliptin 25 mg QD|
32851456|NCT01391663|Experimental|Alogliptin 50 mg QD|
32851457|NCT03176173|Experimental|Immunotherapy plus Image-guided Radiation Therapy|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while continuing their prior treatment with the treating physician's choice of regular medical care immunotherapy.
32851458|NCT03176173|Active Comparator|Immunotherapy Alone (Regular Medical Care)|Patients who decline to undergo radiation therapy will continue their prior treatment with the treating physician's choice of regular medical care immunotherapy.
32851459|NCT04057872|Active Comparator|TPE in Septic Shock|The patients in this arm will receive TPE
32851460|NCT04057872|No Intervention|Reference Population|The patients will receive the standard of care for septic shock treatment
32851461|NCT02220985|Experimental|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
32903463|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
32903464|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
32903465|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
32903466|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
32903467|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
32903468|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
32903469|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
32903470|NCT05484661|Experimental|Exercise + BCAA|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. BCAA will include ~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
32903471|NCT05484661|Placebo Comparator|Exercise + Placebo|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. Placebo will include ~7-10 g of maltodextrin (100 mg/kg) daily for eight weeks.
32903472|NCT05424133|Experimental|Active cycle of breathing technique|Group A will receive Active cycle of breathing technique with routine chest physiotherapy.
32903473|NCT05424133|Active Comparator|High frequency chest wall oscillation|Group B will receive High frequency chest wall oscillations with routine chest physiotherapy
32903474|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
32903475|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
32903476|NCT05411653|Experimental|Virtual reality training with motor imagery|Xbox Kinect VR with MI training Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session
32903477|NCT05411653|Active Comparator|Conventional physical therapy|a range of motion exercises, muscle strengthening, functional training, balance training, and gait training. T
32903478|NCT00692276|Experimental|1|Interspinous Process Spacer Device
32903479|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
32903480|NCT02248987||Clozapine|stable patients treated with clozapine
32903481|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
32903482|NCT02248987||Healthy volunteer|healthy controls
32903483|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
32903484|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
32903485|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
32903486|NCT03363919|Active Comparator|1 Hz left prefrontal rTMS|36 sessions of 1 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 continuous pulses.
32903487|NCT03363919|Active Comparator|10 Hz left prefrontal rTMS|36 sessions of 10 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 pulses with 4 seconds on and 36 seconds off.
32903488|NCT05392309|Experimental|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
32903489|NCT05392309|Active Comparator|conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
32851462|NCT02220985|Experimental|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
32851463|NCT02220985|Experimental|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
33406575|NCT05669898|Active Comparator|Single-injection ACB combined with IV-PCA morphine|Allocation of which participant is to receive single-injection adductor canal block combined with intravenous morphine patient-controlled analgesia (IV-morphine PCA) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle. Finally, the IV-morphine PCA will be connected to the intravenous catheter of the patient for postoperative pain management.
33406576|NCT05669898|Active Comparator|Continuous adductor canal infusion combined with intravenous NSAID|Allocation of which participant is to receive continuous adductor canal infusion in combination with intermittent intravenous non-steroidal anti-inflammatory drug (NSAID) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, a peripheral nerve catheter will be implanted into adductor canal by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following the peripheral nerve catheter is implanted, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through the catheter. Intravenous tenoxicam 20 mg for a total amount of 3 doses at 24-hour interval after surgery will be added in the postoperative pain management.
33406577|NCT05223114||HIV+COPD+|40 male and female adults > 35 years with COPD and HIV
33406578|NCT05223114||HIV+COPD-|40 male and female adults > 35 years with HIV but no COPD
33406579|NCT05223114||HIV-COPD+|40 male and female adults > 35 years with COPD not HIV
33406580|NCT05223114||HIV-COPD-|40 male and female adults > 35 years with no COPD and no HIV
33406581|NCT05222958|Experimental|Experimental:|The intervention consists of using a smoking cessation app. Patients assigned to the intervention group will be given the access code to the Gestobb App and advice on how to use it.
33406582|NCT05222958|No Intervention|No intervention|Patients in the control group will continue their follow-up visits at ASSIR and will be offered smoking cessation treatment following standard practice protocols.
33406583|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
33406584|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
33406585|NCT04618614|Experimental|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
33406586|NCT04618614|Active Comparator|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
32851464|NCT02220985|Experimental|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
32851465|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
32851467|NCT04038047||Core|Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).
32851468|NCT05072106|Active Comparator|Single agent lurbinectedin cycle|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
32903490|NCT00692978|Experimental|Asthma|Asthma patients
32903491|NCT00692978|Active Comparator|Healthy volunters|Healthy participants
33406587|NCT04618614|Sham Comparator|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
32739840|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
32903492|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
32903493|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
32903494|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
32903495|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
32903496|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
32903497|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
32903498|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
32903499|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
32903500|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
32903501|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
32903502|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
32903503|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
32903504|NCT03004573|Experimental|Deep brain stimulation|
32903505|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
32903506|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
32903507|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
32903508|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
32903509|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
32903510|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
32903511|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
32903512|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
32903513|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32903514|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32903515|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
32903516|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
32903517|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
32903518|NCT00603044|No Intervention|No treatment|
32903519|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
32903520|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
32903521|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
32903522|NCT00646646|Active Comparator|propofol|active drug
32903523|NCT00646646|Active Comparator|dexmedetomidine|sedative
33406588|NCT05222646|Active Comparator|Metoclopramide group|They will be receiving10mg of Metoclopramide intramuscularly
33406589|NCT05222646|Active Comparator|Hyoscine bromide group|They will be receiving 20 mg of Hyoscine bromide
32851469|NCT05072106|Active Comparator|Bosentan co-administration cycle|"Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).~Lurbinectedin: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1 in first three patients. Dose for remaining five patients will depend on PK and safety outcomes in first three patients."
32851470|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
32851471|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
32851472|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
32851473|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
32851474|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
32851475|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
32851476|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
32851477|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
32851478|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
32851479|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
32851480|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
32851481|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
32851482|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
32851483|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
32851484|NCT05315895||general population|general population in a specific area and specifc time range.
32851485|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
32851486|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
32851487|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
32851488|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
32851489|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
32851490|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
32851491|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
32851492|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
32851493|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
32851494|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
32851495|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
32851496|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
32851497|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
32903524|NCT00646646|Active Comparator|midazolam|Sedative
32903525|NCT00646646|Placebo Comparator|placebo|placebo control
32960187|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
33406590|NCT04538352|Experimental|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
33406591|NCT04538352|Experimental|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
32960188|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
32960189|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
32960190|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
32960191|NCT00955266|Placebo Comparator|Placebo|Normal saline
32960192|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
32960193|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
32960194|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
32960195|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
32960196|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
32960197|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
32960198|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
32960199|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
32960200|NCT00959166|Other|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
32960201|NCT00959166|Other|HIV mono|HIV-infected individuals without hepatitis C co-infection
32960202|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
32960203|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
32960204|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
32960205|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
32960206|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
32960207|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
32960208|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
32960209|NCT00964548|Experimental|Dantrolene (low dose)|
32960210|NCT00964548|Experimental|Dantrolene (high dose)|
32960211|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
32960212|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
32960213|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
32960214|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
32960215|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
33104164|NCT05003089|Placebo Comparator|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
32851498|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
32851499|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
32851500|NCT03358875|Experimental|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
32851501|NCT03358875|Experimental|Docetaxel|75 mg/m2 IV Q3W
32851502|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
32851503|NCT05071482|Experimental|flumatinib arm|600 mg QD oral administration, fasting (2 hours before administration and 1 hour after administration).
33406592|NCT05222568||BCVmin=0|This study was a prospective observational study, and the patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
32851504|NCT05071482|Active Comparator|imatinib arm|600 mg QD oral administration, with a meal
32851505|NCT04477746||Standard Laparoscopy group (LS)|7 surgeons performing surgical procedures using the standard laparoscopic approach
32851506|NCT04477746||Robot- assisted laparoscopic group (RALS)|6 surgeons performing surgical procedures using the robot-assisted laparoscopic approach
32851507|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
32851508|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
32851509|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
32851510|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
32851511|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
32851512|NCT03328455|Experimental|Inhibitory control training|"In the inhibitory control training condition, participants will be trained with tasks that involve both response withholding and rule switching. For example, participants will sort polygons based on features (e.g., shape or color) and will be asked to either provide or withhold sorting responses when presented with different cues. Rule-switching is introduced when participants must inhibit the rule used in the previous trial set and change the focus of their attention to a new sorting and/or inhibitory rule. Task difficulty will progressively increase over the course of training based on participants' abilities."
32851513|NCT03328455|Sham Comparator|knowledge-based training|The knowledge-based training condition serves as the control, in which participants will be presented with questions from different categories such as vocabulary, science, or geography and asked to select the correct answer from 4 alternatives within a certain time limit. Task difficulty will progressively increase over the course of training based on participants' abilities.
32851514|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
32851515|NCT04442269|Experimental|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
32851516|NCT04442269|Experimental|Placebo|Matching dupilumab without active substance
32851517|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
32851518|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
32851519|NCT05315115|Experimental|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
32851520|NCT05315115|Sham Comparator|Control group|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
32851521|NCT05313321||Primary total hip arthroplasty receiving the Insignia Stem|Patients undergoing primary total hip arthroplasty that will likely receive the Insignia Stem and associated Stryker Acetabular Component.
32851522|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
32851523|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
32851524|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
32960216|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
32739841|NCT03109067|Experimental|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
32739842|NCT04491773||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months
32739843|NCT04491773||Control Group|Healthy controls without previous surgery of radical prostatectomy.
32739844|NCT02472197|Experimental|morcellation|
32739845|NCT02472197|Active Comparator|standard resection|
32739846|NCT04988451|Experimental|ASL Services - Adult ASL Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
32739847|NCT04988451|Experimental|ASL Services - Child Language Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
32739848|NCT04783571|Experimental|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
32739849|NCT04783571|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
32739850|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
32739851|NCT04743245|Experimental|PCI with SSO2 therapy|
32739852|NCT04743245|Active Comparator|anterior AMI patients treated with PCI and stenting within 6 hours|
32739853|NCT04994847||APOE Unimpaired Observational Trial|300 participants who are cognitively unimpaired; Yearly procedures: blood draw Every Two Year Procedures: cognitive and clinical assessments, CSF collection, MRI, and Tau and Amyloid PET scans
32739854|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
32739855|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
32739856|NCT04994925|Active Comparator|Control ready meal|Control supermarket brand ready meal with high energy density
32739857|NCT04994925|Experimental|Test ready meal with low energy density|Slimming world test ready meal with low energy density
32739858|NCT02474849|Active Comparator|Conventional cigarette|
32739859|NCT02474849|Experimental|First-generation e-cigarette|
32739860|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
32739861|NCT02474849|Experimental|Closed modular system e-cigarette A|
32739862|NCT02474849|Experimental|Closed modular system e-cigarette B|
32739863|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
32739864|NCT03068403|Other|Radiochemotherapy|
32739865|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
32739866|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
32739867|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
32739868|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
32739869|NCT05290181|Experimental|Pilates exercise and whatsapp text message group|A support program including pilates exercises and sending text messages will be applied to the students in the intervention group for 8 weeks. Online pilates exercises will be done 2 days a week and individual short messages will be sent to their smartphones via the Whatsapp application 3 days a week. Participants will be provided with Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises. The exercises will be done online in the presence of a research physiotherapist with The Australian Physiotherapy & Pilates InstituteMatwork Level 1 (APPI) certificate.
32739870|NCT05290181|No Intervention|Control group|No intervention will be made in the control group.
32739871|NCT03068325|Experimental|TF-EAT|
32739872|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
32739873|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
32739874|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
32739875|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
32739876|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
32739877|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
32739878|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32739879|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32739880|NCT04984863|Experimental|magnetically controlled capsule endoscopy|magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices
32739881|NCT04985175|Experimental|QPL group|receive 2-pages ESRD QPL leaflets, circle the questions they want to ask before consultation. encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
32739882|NCT04985175|No Intervention|Usual care group|without receiving provision of QPL encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
32739883|NCT05264597||ACLR group|Patients after ACLR with a standardized followup in the Sport Medicine department
32739884|NCT05264597||Control group|Age and sexe-matches volunteers
32739885|NCT04985019|Experimental|I (Prepectoral)|VR treatment group Participants received the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for panic disorder.
32739886|NCT04985019|No Intervention|II (Subpectoral)|Waiting list Participants in a waiting list.
32739887|NCT05249621|Experimental|MZE001|MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
32739888|NCT05249621|Placebo Comparator|Placebo|Excipients containing no active ingredients.
32851525|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
32851526|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
32851527|NCT04380675|Active Comparator|Music during ESWL|Patients listen to music during ESWL
32851528|NCT04380675|No Intervention|ESWL without music|Patients don't listen to music during ESWL
32851529|NCT04440007|Experimental|Abivertinib with Standard of Care|STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care
32851530|NCT04440007|Active Comparator|Standard of Care|Standard of care treatments for COVID-19 as determined appropriate by the Investigator
32851531|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
32851532|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
32851533|NCT05312541|Placebo Comparator|Opioid Based Anesthesia|Pre induction of general anesthesia with placebo 1 h before surgery. induction of general anesthesia with fentanyl1ug/kg/ iv then infusion of 1 ug/kg/h
32851534|NCT05312541|Active Comparator|opioid free anesthesia|Pre induction of general anesthesia with gabapentin 300 mg tab 1 h before surgery. induction of general anesthesia with ketamine 0.5 mg/kg iv, Lidocaine 1 mg/kg iv then continuous infusion with 2 mg/kg/hr, dexamethasone 0.1 mg/kg.iv, magnesium sulfate 20 mg/kg.iv
32851535|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
32851536|NCT04398823|Active Comparator|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
32851537|NCT04398823|Placebo Comparator|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
32851538|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
32851539|NCT05071638|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion. Cell dose for all patients was targeted at 5×107 cells per kilogram.
32851540|NCT05071638|No Intervention|control group|The control group received standardized treatment without special treatment.
32851541|NCT04410913|Experimental|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
32851542|NCT04410913|Active Comparator|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
32851543|NCT03101670|Experimental|filgotinib|
32851544|NCT03101670|Placebo Comparator|placebo|
32851545|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
32851546|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
32851547|NCT05312463|Experimental|Tongjiang granule group|Experiment group: oral administration of Tongjiang granule with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
32851548|NCT05312463|Placebo Comparator|Tongjiang granule simulant group|Control group:oral administration of Tongjiang granule simulant with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
32851549|NCT05070936|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backwards both open and closed eyes, and walking on tandem both open and closed eyes. Exercise program was applied for 8 weeks. Patients were observed in the hospital every two weeks. The exercises given in the session were given as home exercises, 3 times a day, for 10 repetitions.
32851550|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
32851551|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
32851552|NCT02013336|Experimental|MM-398 + cyclophosphamide|MM-398+cyclophosphamide
32851553|NCT04397653|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
32851554|NCT04397653|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
32851555|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
32851556|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
32851557|NCT04397965|Experimental|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
32851558|NCT04435236|Active Comparator|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
33406593|NCT05222568||BCVmin>0|The patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
32851559|NCT04435236|Sham Comparator|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
32851560|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
32851561|NCT04397497|Experimental|Mavrilimumab|Single dose of IV Mavrilimumab
32851562|NCT04397497|Placebo Comparator|Placebo|Single dose of matching IV placebo
32851563|NCT04412538|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
32851564|NCT04412538|Experimental|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
32851565|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
32851566|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
32851567|NCT04412538|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
32851568|NCT04412538|Experimental|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
32851569|NCT04412538|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
32851570|NCT04412538|Placebo Comparator|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
32851571|NCT05312073|Other|Patients with ichtyosis|
32851572|NCT05312073|Other|Patients without ichtyosis|
32851573|NCT04397341|Experimental|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
32851574|NCT01391507|Placebo Comparator|Placebo|
32851575|NCT01391507|Experimental|20 mg COR-1|
32851576|NCT01391507|Experimental|80 mg COR-1|
32851577|NCT01391507|Experimental|160 mg COR-1|
32851578|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
32851579|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
32851580|NCT04398511|Experimental|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
32851581|NCT04398511|Placebo Comparator|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
32851582|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
32851583|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
32851584|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
32851585|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
32851586|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
32851587|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
32851588|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
32851589|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
32851590|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
32851591|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
32851592|NCT05071092|Experimental|Intervention group|The intervention will consist of personalized guidance from a dietician focussing on improving adherence to the Dutch dietary guidelines.
32851593|NCT05071092|No Intervention|Usual care group|The usual care group will not receive any special guidance regarding healthy nutrition, but will have access to their care team as usual.
32851594|NCT05311995|Active Comparator|Group 1|trocar entry areas:Periumblical, left lower quadrant, suprapubic
32851595|NCT05311995|Active Comparator|Group 2|trocar entry areas: Periumblical, left lower quadrant, right lower quadrant
32851596|NCT05311995|Active Comparator|group 3|trocar entry areas: Periumblical, right lower quadrant, suprapubic
32851597|NCT05311995|Active Comparator|Group 4|trocar entry areas: Periumblical, left lower quadrant, left upper quadrant
32851598|NCT02008357|Experimental|Solanezumab|"Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
32851599|NCT02008357|Placebo Comparator|Placebo|"Placebo IV every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
33406594|NCT05222490|Experimental|Diabetic with Ulcers|Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment
33406595|NCT05222490|Experimental|Diabetic without Ulcers|Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment
33104165|NCT04985968|Experimental|Cobitolimod 250 mg|"Dose of 250 mg cobitolimod~2 treatments during induction study and subsequently every third week"
33104166|NCT04985968|Experimental|Cobitolimod 500 mg|"Dose of 500 mg cobitolimod~2 treatments during induction study and subsequently every third week"
32851600|NCT05365919|Experimental|Intervention|The intervention group will be offered to participate in the Family Talk Intervention
32851601|NCT05365919|No Intervention|Standard support|The control group will receive standard support
32851602|NCT03940326|Experimental|Levetiracetam|
32851603|NCT03940326|Active Comparator|Valproate|
32851604|NCT05311293||Patients with simple diarrhea-predominant irritable bowel syndrome|
32851605|NCT05311293||Patients with irritable bowel syndrome accompanied by anxiety and depression|
32851606|NCT05311293||Healthy Volunteers|
32851607|NCT05365763||Medical oncologists|5 medical oncologists; trained in the serious illness conversation guide
32851608|NCT05365763||specialty palliative care|6 specialty palliative care physicians; trained in serious illness conversation guide
32851609|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
32851610|NCT04036409|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
32851611|NCT04036409|Active Comparator|Standard Control of Systolic Blood Pressure|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg
32851612|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
32851613|NCT04347889|Experimental|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
32851614|NCT04347889|Active Comparator|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
32851615|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
32851616|NCT04759963||Group A|follow up for 6 women who gave birth through a cesarean delivery with Midline approach epidural anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
32851617|NCT04759963||Group B|follow up for 13 women who gave birth through a cesarean delivery with Midline approach spinal anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
32851618|NCT04759963||Group C|follow up for 7 women who gave birth through a cesarean delivery with general anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
32851619|NCT04759963||Group D|follow up for 12 women who are the control group (who did not experience any pregnancy or anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
32851620|NCT01473524|Experimental|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
32851621|NCT01473524|Experimental|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
32851622|NCT01473524|Placebo Comparator|DB Placebo|Matching placebo for 12 months during the DB phase.
32851623|NCT01473524|Experimental|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
32851624|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
32851625|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
32851626|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
32851627|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
32851628|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
32851629|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
32851630|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
32851631|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
32851632|NCT01390649|Experimental|IgPro10|
32851633|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.~Dose Expansion Phase~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
32903526|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
32903527|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
32960217|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
33104167|NCT04985968|Placebo Comparator|Placebo|"Dose of Placebo~2 treatments during induction study and subsequently every third week"
33406596|NCT05222490|Active Comparator|Control|Generally Healthy Non-diabetic Subjects
32739889|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
32739890|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
32960218|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
33406597|NCT05222334|Experimental|Intrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for intrafascial interscalene brachial plexus block group
33406598|NCT05222334|Experimental|Extrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for extrafascial interscalene brachial plexus block group
33406599|NCT04465266|Experimental|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
33406600|NCT04465266|Experimental|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
33406601|NCT04465266|Experimental|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
32739891|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
32739892|NCT05217563|No Intervention|Standard Care|Standard Care Control Group (Group 1). Parents in the standard care control group will receive a pamphlet containing evidence-based information on needle pain management. Parents in the standard care control group will not receive any information regarding pain memory reframing, nor will they be encouraged to talk about their children's pain vaccine injection experience. Parents in the standard care control group will receive text/email reminders to use needle pain management strategies before each second vaccination appointment.
32739893|NCT05217563|Active Comparator|Intervention Group (Pamphlet and video only)|Intervention Group (Group 2; Pamphlet and video Only). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management and a pamphlet summarizing memory reframing principles. The pamphlet will have a link to a video summarizing the memory reframing strategies.
32739894|NCT05217563|Active Comparator|Intervention Group (Pamphlet, video, and verbal Instructions).|Intervention Group (Group 3; Handout and Verbal Instructions). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management, a pamphlet summarizing memory reframing principles (with a video link), and verbal instructions on how to use the intervention principles with their children. The instructions will be provided via telephone or video conferencing and will last approximately 10 to 15 minutes. Trained graduate students or post-doctoral fellows will deliver the instructions. Similar to previous interventions, to boost mastery of the material, the researcher will provide suggestions for specific questions and remarks to make while reminiscing. The instructions will be audio-recorded to allow fidelity coding.
32739895|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
32739896|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~Patient has to be aged ≥ 18~Patient has to be able to complete questionnaire in French~Patient must benefit from health insurance~Patient must sign an informed consent form~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
32739897|NCT04984707|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.
32739898|NCT04984707|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.
32739899|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
32739900|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
32739901|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
32739902|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
32739903|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
32739904|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
32739905|NCT04985097|Active Comparator|Experimental group|Half an hour of active visual training per day for a period of 20 consecutive days with the Optictrain software
32739906|NCT04985097|Sham Comparator|Control group|Half an hour of using a videogame without specific stimuli to improve visual performance (Fun Kid Racing 3.53 for Android) per day for a period of 20 consecutive days
32739907|NCT05338853|Experimental|Gongs Mmobilization|to deal adhesive capsulitis
32739908|NCT05338853|Experimental|scapular mobilization|to deal adhesive capsulitis
32739909|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
32739910|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
32739911|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
32739915|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
32739916|NCT00705575|Active Comparator|Aliskiren (300 mg)|
32739917|NCT04994379|Experimental|1 mA tDCS|Participants receive the stimulation with an intensity of 1 mA.
32739918|NCT04994379|Experimental|1.5 mA tDCS|Participants receive the stimulation with an intensity of 1.5 mA.
32739919|NCT04994379|Sham Comparator|Sham tDCS|Participants receive the sham stimulation (zero electric current after a short initial increase).
32739920|NCT04993989||Pharmacy based survey|Patients received a questionnaire, which was filled out and returned to the Contract Research Organization (CRO) or, alternatively to the pharmacy.
32739921|NCT05208437|Experimental|Complete oral feeding intervention group|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale. Feeding of premature infants using different interventions based on the results of the Feeding Preparation Scale.
32739922|NCT05208437|Active Comparator|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding. Routine nursing care is identical to the control group.
32739923|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
32739924|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
32739925|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
32739926|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
32739927|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
32739928|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
32739929|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
32739930|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
32739931|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
32739932|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
32739933|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
32739934|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
32739935|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
32739936|NCT04585763|Experimental|Single Arm|
32739937|NCT05199935|Experimental|Intervention|Are shown the intervention video after filling out baseline questionnaire
32739938|NCT05199935|Other|Control|Are shown a control at Time 0, baseline and the intervention video after main outcome data is collected at Time 1
32739939|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
32739940|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
32739941|NCT02636283|Active Comparator|Entresto|oral route
32739942|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
32739943|NCT05317949|Experimental|Integrated neuromuscular training program group|Integrated neuromuscular training program group will perform exercise in three major domains
32739944|NCT05317949|Active Comparator|General fitness exercises program group|General fitness exercises program group will perform general fitness exercises
32739945|NCT03668223|Experimental|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
32739946|NCT03668223|No Intervention|Usual Care|Standard psychosocial care
32739947|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
32739948|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
32739949|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
32739950|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
32739951|NCT04450953|Active Comparator|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period without eplerenone, until the end of the study.
32739952|NCT04450953|Active Comparator|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
32739953|NCT04983849|Active Comparator|hydrogel metronidazole 25%|metronidazole hydrogel in adjunct to non surgical periodontal therapy
32739954|NCT04983849|Active Comparator|scaling and root planing|the only use of scaling and root planing
32739955|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
32739956|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
32739957|NCT04983537|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
32739958|NCT04983537|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
32739959|NCT04983537|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
32739960|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
32739961|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
32739962|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
32739963|NCT04491851|Experimental|LM3 group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
32739964|NCT04491851|Experimental|NODAGA group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
32739965|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
32739966|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
32739967|NCT03558711|Experimental|study group|
32739968|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).~Maintenance~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
32739969|NCT04983381|Experimental|Education Group|Participants were grouped as; those who were given information about vaginal examination in the training group (n=40) and those who were not given information about vaginal examination in the control group (n=40).
32739970|NCT04983381|No Intervention|Control Group|Women were not given information about vaginal examination in the control group
32739971|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
32903528|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
32739972|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
32739973|NCT05315063|Experimental|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
32739974|NCT05315063|Experimental|Muscle Energy Technique (PIR)|muscle energy technique
32739975|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
32739976|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
32739977|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
32739978|NCT04521413|Experimental|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
32739979|NCT04521413|Experimental|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
32739980|NCT04521413|Experimental|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
32739981|NCT04521413|Experimental|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
32739982|NCT04521413|Experimental|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
32739983|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
32739984|NCT04511741||invasive mechanical ventilation|
32739985|NCT04511741||non invasive mechanical ventilation|
32739986|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
33406602|NCT04434300|Other|Dapto SC-IV|"First stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg"
32851634|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
32851635|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
32851636|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
32851637|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
32851638|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
32851639|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
32851640|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
32851641|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
32851642|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
32851643|NCT04383691|Experimental|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
32851644|NCT04383691|Placebo Comparator|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
32851645|NCT05070468|Active Comparator|Group A|Prescribing Vaginally Dexamethasone tablets to the Group A
32851646|NCT05070468|Placebo Comparator|Group B|Prescribing Vaginally placebo tablets to the Group B
32851647|NCT01390181|Experimental|Losartan|
32851648|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
32851649|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
32851650|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
32851651|NCT05311059|Experimental|Ovarian drilling|
32851652|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
32851653|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
32851654|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
32851655|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
32851656|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
32851657|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
32851658|NCT05365061|Experimental|Periosteal electrical dry needling followed by no maintenance treatments|Periosteal electrical dry needling followed by no maintenance treatments
32851659|NCT05365061|Active Comparator|Periosteal electrical dry needling followed by maintenance treatments every other month|Periosteal electrical dry needling followed by maintenance treatments every other month
32851660|NCT05365061|Active Comparator|Periosteal electrical dry needling followed by monthly maintenance treatments|Periosteal electrical dry needling followed by monthly maintenance treatments
32851661|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
32903529|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
32960219|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
32851662|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
32851663|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
32851664|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
33104168|NCT01349322|Active Comparator|Arm I|Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks in the absence of disease progression or unacceptable toxicity.
32851665|NCT03672487|Active Comparator|60/300mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.~Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days."
32851666|NCT03672487|Experimental|30/150mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.~Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening."
32851667|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
32851668|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
32851669|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
32851670|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
32851671|NCT04014335|Experimental|IONIS-FB-LRx|
32851672|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
32851673|NCT05070234||short stature children born small for gestational age|This group was defined as a group of children whose birth weight and/or birth length equal or less than -2 SD for sex and gestational age, and who had failed to catch up in growth, remaining short after 2 years old.
32851674|NCT04760119|Active Comparator|Vein bypass surgery first strategy|
32851675|NCT04760119|Active Comparator|Endovascular treatment first (drug coated balloon angioplasty) strategy|
32851676|NCT05360615|Experimental|Empagliflozin|
32851677|NCT05360615|Placebo Comparator|Placebo|
32851678|NCT03722550|Active Comparator|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
32851679|NCT03722550|Experimental|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
32851680|NCT03722550|Experimental|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
32851681|NCT03722550|Active Comparator|Breastfed Group|Non-randomized Breastfed reference group
32851682|NCT04381377|Experimental|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
32851683|NCT04381377|Placebo Comparator|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
32851684|NCT04033289|Experimental|experimental group|
32851685|NCT04033289|No Intervention|control group|
32851686|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
32851687|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
32851688|NCT05070000||US|Ultrasound
32851689|NCT05070000||CT|Computed tomography
32851690|NCT05070000||US after CT|Ultrasound after Computed tomography
32851691|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
32960220|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
32960221|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
32960222|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
32960223|NCT00973752|Experimental|Experimental|All patients treated on same arm
32851692|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
32851693|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
32960224|NCT00974142|Experimental|Cyclosporine|
32960225|NCT00974142|Placebo Comparator|Placebo|
32960226|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
32851694|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
32851695|NCT04346381|Experimental|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
32851696|NCT04375891|Other|Radiotherapy|Radiotherapy alone
32851697|NCT04375891|Other|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
32851698|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
32851699|NCT05310825|Experimental|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850 W for 50 seconds in a microwave oven which will be brought by the researcher. After heating, the temperature of the cleaning towels will be measured with an infrared thermometer. The reason for heating the wipes is to bring them to the same temperature as the bath water and thus to prevent any factors arising from a temperature difference.
32960227|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
32960228|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
32851700|NCT05310825|Other|Traditional Body Wiping Bath|Before bathing, two basins will be filled with a suitable amount (2/3 of the basin) of water at a suitable temperature (43°C). Water temperature will be measured by the researcher with a water thermometer. This thermometer will be used to bring the bath water to the correct temperature. Neutral soap will be added to the water of one basin, while the water of the other basin will be used for rinsing. The neutral soap to be used will not dry the skin or cause chafing or irritation, and it will be noon-allergenic. At the same time, soap with these characteristics is one which is routinely used for patient hygiene in the intensive care unit where the study will be conducted. The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water.
32851701|NCT04032119|Experimental|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
32851702|NCT04032119|Active Comparator|Non-epinephrine|No epinephrine would be added into the solution
32851703|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851704|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32960229|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
32851705|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851706|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851707|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851708|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851709|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32960230|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
32960231|NCT00977184|Experimental|Real rTMS|
32960232|NCT00977184|Sham Comparator|Sham rTMS|
32960233|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
32851710|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
32851711|NCT04011137|No Intervention|Control|No exercise - 30-min of rest
32851712|NCT04011137|Experimental|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
32851713|NCT04011137|Experimental|Moderate-intensity continous training|25 min at 45% peak power output
32851714|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
32851715|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
32851716|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
32851717|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
32851718|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
32851719|NCT04375033|Experimental|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48."
32851720|NCT04375033|Experimental|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
32851721|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
32851722|NCT01496066|Experimental|LAL|LAL implanted
32851723|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
32851724|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:~4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM."
32851725|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:~2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.~1 placebo capsule twice a day, AM and PM."
32851726|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM
32851727|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
32851728|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
32851729|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
32851730|NCT04084262||All Study Participants|Phantom® Intramedullary Nail combined with a supinating reduction technique
32851731|NCT03831763|Active Comparator|ColdZyme|
32851732|NCT03831763|No Intervention|Optional care only|
32851733|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
32851734|NCT05310591|Experimental|Patients with MRD negative disease status: Time to Event Continual Reassessment Method (TITE-CRM)|
32851735|NCT05310591|Experimental|For relapsed patients|
32851736|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
32851737|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
32851738|NCT04010435|Active Comparator|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
32960234|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
32960235|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
32960236|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
32960237|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
32960238|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
32960239|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
32960240|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
32960241|NCT00983346|Experimental|All patients|All participants enrolled.
32851739|NCT04010435|Active Comparator|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
32851740|NCT04010435|No Intervention|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
32851741|NCT05314569|Placebo Comparator|Control group(C)|anesthesia will be maintained using Isoflurane 1.2MAC keeping the bispectral index( BIS) between 40-60%.
33320348|NCT04231942|Experimental|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
33406603|NCT04434300|Other|Dapto IV-SC|"First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)"
33406604|NCT05214690|Experimental|Sequence A|cross-over
32851742|NCT05314569|Active Comparator|Ketamine-dexmedetomidine group( KD)|After induction of anesthesia , dexmedetomidine will be given(1 ug /kg ) over 10 min, then ketamine(2 m/kg) . maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing Dexmedetomidine( 0.5 μg/.kg /.h r)) ketamine,( 1 m/kg/hr),
32851743|NCT05314569|Active Comparator|. Fentanyl- midazolam group (FM)|After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).
32851744|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
32851745|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
32851746|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
32851747|NCT03559465|Sham Comparator|healthy subject|
32851748|NCT04031417|Other|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
32851749|NCT04031417|Other|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
32851750|NCT04031417|Other|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
32851751|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
32851752|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
32851753|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
32851754|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
32851755|NCT04030169|Experimental|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
32851756|NCT05318313||Telerehabilitation only|Participants choose to have all of their physical therapy provided virtually throughout the length of the study
32851757|NCT05318313||In-person only|Participants choose to have all of their physical therapy provided in-person throughout the length of the study
32851758|NCT05318313||Hybrid 1|The TR PT evaluation and follow-up visits in the initial 6 weeks will be performed via Zoom software and subsequent follow-up visits will switch to in person after 6 weeks
32851759|NCT05318313||Hybrid 2|The PT evaluation and follow-up visits in the initial 6 weeks will be performed in person and will switch to TR via Zoom software after 6 weeks
32851760|NCT05367635|Experimental|Phase 1a：Dose escalation|Eleven dose levels are tentatively planned for Phase 1a and administered every 3 weeks.
32851761|NCT05367635|Experimental|Phase 1b: Dose expansion|The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.
32851762|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
32851763|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
32851764|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
32851765|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
32851766|NCT03211143|Experimental|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
32851767|NCT03211143|Experimental|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
32851768|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
32851769|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
32851770|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
32851771|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
32851772|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
32851773|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
32851774|NCT05363189||No venons augmentation|Retrospective group of patients who have not received venous augmentation during their operation.
32851775|NCT05363189||Venous augmentation|Retrospective group of patients who have received venous augmentation during their operation.
32851776|NCT05363189||ERAS protocol|Retrospective group operated according to the traditional ERAS (enhanced recovery after surgery) protocol
32851777|NCT05363189||Sahlgrenska recovery protocol|Prospective group operated according to the Sahlgrenska recovery protocol.
32851778|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~Stem cell infusion - day 0~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
32851779|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
32851780|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
32851781|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
32851782|NCT04028843|No Intervention|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
32851783|NCT04028843|Experimental|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
32851784|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
32851785|NCT05365217|Experimental|Arm A - Nonacog beta pegol (On-demand/Prophylaxis)|Participants on on-demand treatment for 28 weeks, thereafter prophylactic treatment
32851786|NCT05365217|Experimental|Arm B - Nonacog beta pegol (Prophylaxis)|Participants on prophylactic treatment only
32851787|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
32851788|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
32851789|NCT05367245|Experimental|Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
32851790|NCT05367245|Placebo Comparator|Placebo for Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
32851791|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined or cannot access. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
32851792|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined or cannot access. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
32851793|NCT04028531||Sample Collection|"Blood tests required for assessment~Specimens and data will also be collected from outside sites~Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
32851794|NCT05365529|Placebo Comparator|Standard of Care|The participants in this arm will receive the standard health and nutritional wellness guidelines and will be required to log food entries through the use of a smartphone app.
32851795|NCT05365529|Experimental|Time-Restricted Eating|The participants in this arm will limit the number of hours they eat in day to a 8-10-hour window and will also receive the standard health and nutritional wellness guidelines. They will also be required to log food entries through the use of a smartphone app.
32851796|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
32851797|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
32851798|NCT04380285|Active Comparator|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
32851799|NCT04380285|Active Comparator|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
32960242|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
32960243|NCT00986544|Sham Comparator|Absence of drain|
32851800|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
32851801|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
32851802|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
32851803|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
32851804|NCT03210597|Experimental|hydro-power|Resistance water exercise
32851805|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
32851806|NCT03217305|Other|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
32851807|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
32851808|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
32851809|NCT04381689|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
32851810|NCT04381689|Active Comparator|GSK PFS|Fluarix Tetra Pre-filled Syringe
32851811|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
32851812|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
32851813|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
32851814|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
32851815|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
32851816|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
32851817|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
32851818|NCT00512317|Experimental|ganaxolone|active experimental drug
32851819|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
32851820|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
32851821|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
32851822|NCT04337827|Experimental|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
32851823|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
32851824|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
32851825|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
32851826|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
32851827|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
32851828|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
32851829|NCT05361317|Other|Hallux valgus correction|Hallux valgus correction for all patients : intervention during intraoperative visit, with Nexis® PECA Bunion Implantable Osteosynthesis Medical Device
32851830|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
32851831|NCT04468529|Experimental|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
32851832|NCT04468529|Placebo Comparator|Placebo group|placebo + standard basic therapeutic medication
32851833|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
33406605|NCT05214690|Experimental|Sequence B|cross-over
32851834|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
32851835|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
32851836|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
32851837|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
32851838|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
32851839|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
32851840|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
32851841|NCT05630573|Experimental|TNM001 Injection dose 1 or placebo|low dose administered
32851842|NCT05630573|Experimental|TNM001 Injection dose 2 or placebo|medium dose administered
32851843|NCT05630573|Experimental|TNM001 Injection dose 3 or placebo|high dose administered
32851844|NCT02643420|Experimental|Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)|Participants received SPI-2012 13.2 milligram (mg)/0.6 milliliter (mL) (3.6 mg Granulocyte Colony-Stimulating Factor [G-CSF]) fixed-dose subcutaneous (SC) injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy was administered on Day 1 of each cycle and included Docetaxel 75 mg/m^2 intravenous (IV) infusion and Cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care.
32851845|NCT02643420|Experimental|Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|Participants received pegfilgrastim 6 mg SC injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy on Day 1 of each cycle included Docetaxel 75 mg/m^2 IV infusion and Cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care.
32851846|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
32851847|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
32851848|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
32851849|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
32851850|NCT04408937|Experimental|tropifexor AM 200 micrograms and Placebo (PM)|Tropifexor 200 μg (AM) and Placebo (PM) once daily each
32851851|NCT04408937|Experimental|tropifexor PM 200 micrograms and Placebo (AM)|Tropifexor 200 μg (PM) and Placebo (AM) once daily each
32851852|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
32851853|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
32851854|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
32851855|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
32851856|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
32851857|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
32851858|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
32851859|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
32851860|NCT04398277|Active Comparator|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
32851861|NCT04398277|Active Comparator|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
32747332|NCT05545059|Experimental|sacubitril/valsartan group|The experimental group will be sacubitril/valsartan group. Patients assigned to this group will receive sacubitril/valsartan 200mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
32851862|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
32851863|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
32851864|NCT04479540|Experimental|Hospitalized SARS Cov-2|Hospitalized patients diagnosed with SARS Cov-2 infection
32851865|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
32851866|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
32851867|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
32851868|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
32851869|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
32851870|NCT04435314|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
32851871|NCT04435314|Placebo Comparator|Placebo|Subjects will receive placebo TID.
32851872|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
32851873|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
32851874|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
32851875|NCT01456052|Experimental|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
32851876|NCT01456052|Experimental|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
32851877|NCT01456052|Placebo Comparator|Placebo|Matching placebo administered orally.
32851878|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
32851879|NCT01387607|Experimental|Pregabalin|
32851880|NCT01387607|Placebo Comparator|Placebo|Matched placebo
32851881|NCT05069454|Active Comparator|Exposure group|Healthcare workers vaccinated by any of the available COVID19 vaccine;
32851882|NCT05069454|Active Comparator|Control group|Have not received any doses of any form of COVID-19 vaccine
32851883|NCT04408274|Experimental|Computerized Tests|
32851884|NCT04408274|Placebo Comparator|Placebo Control|
32851885|NCT05069688|Experimental|Dolutegravir PK during standard and high-dose rifampicin|This is a single arm study: all patients are started on HIV/TB cotreatment considered standard of care and then for two weeks (study weeks 20-21) high-dose rifampicin is given during which safety and pharmacokinetics are examined.
32960244|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
32960245|NCT00986856|Experimental|Fucidin® cream|
32960246|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
32960247|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
32960248|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
32960249|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
32960250|NCT00987948|Experimental|Maraviroc|
32960251|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
32960252|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
32960253|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
32960254|NCT00990288|No Intervention|Control|No intervention.
32960255|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
32739987|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
32960256|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
32960257|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
32960258|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
32960259|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
32960260|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
32960261|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
32960262|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
32960263|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
32960264|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
32960265|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
32960266|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
32960267|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
32960268|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
32960269|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
32960270|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
32960271|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
32960272|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
32960273|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
32960274|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
32960275|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32960276|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
32960277|NCT00999102|Experimental|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
32960278|NCT00999102|Experimental|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
32960279|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
32960280|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
32960281|NCT01000818|Experimental|Period 1|MK0518
32960282|NCT01000818|Experimental|Period 2|famotidine + MK0518
32960283|NCT01000818|Experimental|Period 3|omeprazole + MK0518
32960284|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
32960285|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
32960286|NCT01001442|Experimental|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
33320349|NCT04231942|No Intervention|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
32851886|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
32851887|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
32851888|NCT05069064|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
32851889|NCT05069064|Other|non-music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
32851890|NCT04479306|Experimental|Arm A (osimertinib, alisertib)|Patients receive osimertinib PO QD on days 1-28 and alisertib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm B.
32851891|NCT04479306|Experimental|Arm B (osimertinib, sapanisertib)|Patients receive osimertinib PO QD on days 1-28 and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm A.
32851892|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
32851893|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
32851894|NCT04025489|Experimental|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
33406606|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
32851895|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
32851896|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
32851897|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
32851898|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
32851899|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
32851900|NCT03451045|Experimental|Lenabasum 20 mg BID|
32851901|NCT03451045|Experimental|Lenabasum 5 mg BID|
32851902|NCT03451045|Placebo Comparator|Placebo BID|
32851903|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
32851904|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
32851905|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
32851906|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
32851907|NCT01831011|Experimental|mildronate|infusion of mildronate
32851908|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
32851909|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
32851910|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
32851911|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
32851912|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
32851913|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
32851914|NCT04277065|Experimental|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
32851915|NCT04277065|Active Comparator|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
32851916|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
32851917|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
32851918|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
32851919|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
32851920|NCT03430843|Experimental|Tislelizumab|Tislelzumab on Day 1, given every 21 days
32739988|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
32739989|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
32851921|NCT03430843|Active Comparator|Investigator chosen chemotherapy|"Paclitaxel will be administered on Day 1, given every 21 days or on a weekly schedule.~OR docetaxel will be administered on Day 1, given 21 days. OR irinotecan will be administered on Days 1, 8, given 21 days."
32851922|NCT05630495|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns of South-East Asian ethnicity and skin type.
32851923|NCT01831167|Experimental|dynamic light|dynamic light
32851924|NCT01831167|No Intervention|reference|normal light
32851925|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
32851926|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
32851927|NCT05630417|Experimental|Geriatric Massage Group|The fragility of the elderly, the sensitivity of skin, muscle and bone tissue necessitate modification of massage techniques according to the individual characteristics of the elderly. Geriatric massage is a form of massage applied according to the characteristics of the elderly individual and can be applied to all body parts according to the needs of the elderly. However, since diabetic neuropathy, which is a long-term complication that is common in individuals with Type 2 diabetes and can affect all body parts, shows more symptoms in the feet, foot massage as a geriatric massage may be effective in reducing diabetes symptoms and improving blood parameters. Because of its more systemic effects, back massage was preferred.
32851928|NCT05630417|No Intervention|Control Group|No attempt will be made by the researcher on the elderly with Type 2 diabetes in the control group. The elderly in this group will benefit from the standard care practices offered by the institution.
32851929|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
32851930|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
32851931|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
32851932|NCT03219567|Experimental|Normals|Normal subjects will be imaged with the OCT system to ensure the imaging range of the system.
32851933|NCT03219567|Experimental|Patients with a history of cataract surgery or high myopia|Subjects will be imaged with both the OCT system and MRI. Reconstructions of the eye from each modality will then be compared.
32851934|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
32851935|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
32851936|NCT01386125|Experimental|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
32851937|NCT01386125|Placebo Comparator|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
32851938|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
32851939|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
32851940|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
32851941|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
32851942|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
32851943|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
32851944|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
32851945|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
32851946|NCT05630261|Experimental|Self-help CBT-I|Participants assigned to the CBT-I group will receive the self-help CBT-I intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
32851947|NCT05630261|Active Comparator|Self-help CBT-D|Participants assigned to the CBT-D group will receive the self-help CBT-D intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
32851948|NCT05068986|Other|single arm intervention|
32851949|NCT05094258|Active Comparator|mobile insert|Unicondylar knee arthroplasty with mobile insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
32851950|NCT05094258|Active Comparator|fixed insert|Unicondylar knee arthroplasty with fixed insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
32851951|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
32851952|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
32903530|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
32851953|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
32851954|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
32851955|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
32851956|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
32960287|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
32851957|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
32851958|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
32851959|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
32851960|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
32851961|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
32851962|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
32851963|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
32851964|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
32851965|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
32851966|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
32851967|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
32851968|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
32851969|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
32851970|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
32851971|NCT05060874||single group|gripwise or jamar will be randomly assessed first
32851972|NCT05036928||HIV infection group|
32851973|NCT03218319|Experimental|All patients|
32851974|NCT01384877|Experimental|Lidocaine|Lidocaine
32851975|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
32851976|NCT00114517|Active Comparator|17B-estradiol|Oral 17B-estradiol 1 mg daily
32851977|NCT00114517|Placebo Comparator|Placebo|Matching oral 17B-estradiol placebo daily
32851978|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
32851979|NCT05021328|Experimental|Anlotinib combined with SBRT|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Toripalimab 240mg iv drip D1 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
32851980|NCT05021328|Experimental|Anlotinib combined with SBRT and Toripalimab|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
32851981|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
32851982|NCT05632679|Experimental|personalized music intervention|
32851983|NCT05632679|Active Comparator|selected audio book|
32851984|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
32851985|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
32851986|NCT04746391|Experimental|Solacea_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851987|NCT04746391|Experimental|Solacea_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851988|NCT04746391|Experimental|Solacea_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851989|NCT04746391|Experimental|FX800_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851990|NCT04746391|Experimental|FX800_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851991|NCT04746391|Experimental|FX800_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
32851992|NCT04766567|Experimental|Serosal myomectomy|Patients with singleton pregnancy, who had serosal myomectomy during cesarean section
32851993|NCT04766567|Experimental|Endometrial myomectomy|Patients with singleton pregnancy, who had endometrial myomectomy during cesarean section
32851994|NCT04766567|Placebo Comparator|Control group|Patients with singleton pregnancy, who did not have myomectomy during cesarean section
32851995|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
32851996|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
32851997|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
32851998|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
32851999|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
32852000|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
32852001|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
32852002|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
32852003|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
32852004|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
32852005|NCT00033631|Active Comparator|70.2 Gy|70.2 Gy 3D-CRT/IMRT
32852006|NCT00033631|Experimental|79.2 Gy|79.2 Gy 3D-CRT/IMRT
32852007|NCT03218007|Experimental|acute coronary syndrome|
32852008|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
32852009|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
32852010|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
32852011|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
32852012|NCT03217929|Active Comparator|Active-taVNS|
32852013|NCT03217929|Sham Comparator|Sham-taVNS|
32852014|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
32852015|NCT01831869|No Intervention|blank|no intervention
32852016|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
32852017|NCT01839357|Experimental|Rivaroxaban|
32852018|NCT04746157|Experimental|Intervention group|Patients will have a directly contact with the lead nurse by telephone during the study. The referent nurse will provide support and will promote engagement of patient to adequate secondary prevention measures. In addition, she will provide education based on stroke risk and identified vascular risk factors by Stroke Riskometer.
32852019|NCT04746157|No Intervention|Usual care|Usual care
32852020|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
32852021|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
32852022|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
32852023|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
32852024|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
32852025|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
32852026|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
32852027|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
32852028|NCT01455428|Experimental|Lyrica (pregabalin)|
32852029|NCT01455428|Placebo Comparator|Placebo|
33320350|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
32960288|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
32739990|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
32960289|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
32960290|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
32739991|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
32739992|NCT04448873|Active Comparator|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
32739993|NCT04448873|Experimental|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:~10% monthly reduction of the previous dose at most.~At least 5 half-lives between each reduction (2 weeks).~Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.~At least 6 months for the duration of guided discontinuation.~Regular assessments and evaluations should be done.~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
32739994|NCT04430855|Experimental|Upadacitinib 30 mg|Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).
32739995|NCT04430855|Experimental|Placebo followed by Upadacitinib 15 mg|Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).
32739996|NCT05148299|Experimental|Pegcetacoplan|
32739997|NCT04378907|Active Comparator|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
32739998|NCT04378907|Experimental|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
32739999|NCT04378907|Experimental|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
32740000|NCT04378907|Experimental|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
32740001|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
32740002|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
32740003|NCT05134727|Experimental|Part 1 (single ascending doses [SAD])|Healthy participants will be randomized to a single dose of AZD5055 or placebo.
32740004|NCT05134727|Experimental|Part 2 (multiple ascending doses [MAD])|Healthy participants will be randomized to repeated dosing with AZD5055 or placebo
32740005|NCT05130983|Experimental|15ml of ExoFlo at Day 0, 2, 4, Week 2, Week 6, and every 8 weeks after that to week 46|Arm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).
32740006|NCT05130983|Experimental|15ml of ExoFlo at Day 0, 2, 4, Week 2, Week 6, and every 4 weeks after that to week 46|Arm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15).
32740007|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
32740008|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
32740009|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
32740010|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
32740011|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
32740012|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
32740013|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
32740014|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
32740015|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
32740016|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
32740017|NCT04359017|Experimental|Lidocaine Hematoma Block|
32852030|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
32852031|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
32852032|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
32852033|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
32852034|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
32852035|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
32852036|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
32852037|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
32852038|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
32852039|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
32852040|NCT05632289|Experimental|osteopathic treatment|
32852041|NCT05632289|Sham Comparator|sham of osteopathic treatment|
32852042|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
32852043|NCT04023773|Experimental|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
32852044|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
32852045|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
32852046|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
32852047|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
32852048|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
32852049|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
32852050|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
32852051|NCT05631743|Experimental|VR-CBT|A trained psychotherapist provides CBT-VR for up to 10 sessions over 10 weeks.
32852052|NCT05631743|Active Comparator|Self-management|Participants use a commercial VR application at home for guided self-management at their own pace over 10 weeks.
32852053|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
32852054|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
32852055|NCT01832337|Experimental|precondition|
32852056|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
32852057|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
32852058|NCT05631665|Experimental|postmenopausal women|women with postmenopausal sexual function problems will be the study arm
32852059|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Activity and Lifestyle Questionnaires~Fat Mass Measurement"
32852060|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Cardiac Catheterization~Activity, Lifestyle and Medication Compliance Questionnaires~Fat Mass Measurement~Retinal Photography (Optional)~I123 MIBG scan (Optional)"
32852061|NCT05631587|Experimental|Intervention condition (WExercise)|Participants will receive a written information sheet (i.e., PA guide, safety precautions, and goal) same as the control group. In addition, participants in the WExercise group will be provided with 10 weekly technology-based classes delivered in a mobile application aimed at promoting PA. Participants will be given individualised access to the app. The classes aim at developing reflective, regulatory, and reflexive processes of cancer survivors to engage in PA based on the M-PAC framework. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
32852062|NCT05631587|Active Comparator|Control condition (Self-directed exercise)|Participants will receive a one-page written information sheet regarding the PA guidelines for cancer survivors and exercise safety precautions extracted from the website of the Centre for Health Protection of the HKSAR Government. Although mixed aerobic and resistance exercise are recommended, participants will be provided with a simple goal of increasing their aerobic exercise levels to 150 minutes of moderate aerobic activity or 75 minutes of vigorous aerobic exercise per week because resistance exercise requires instructions from trained personnel.
32852063|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
32852064|NCT05631431|Placebo Comparator|Placebo|
32852065|NCT05631431|Active Comparator|Treatment|
32852066|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
32852067|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
32852068|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
32852069|NCT03089281|Other|SmartDelay™ algorithm|Subjects programmed with AV Delay and pacing chamber determined by SmartDelay
32852070|NCT03089281|Other|Fixed AV Delay with BiV pacing|Subjects programmed with a Fixed AV Delay of 120ms with BiV pacing
32852071|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
32852072|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
32852073|NCT04023071|Experimental|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
32852074|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
32852075|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule|FT516 on an extended-dosing schedule in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
32852076|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning|Bendamustine conditioning followed by FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
32852077|NCT01839825|Experimental|QuietCare|QuieCare system installed
32852078|NCT01839825|No Intervention|control|no system installed
32852079|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
32852080|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
32852081|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
32852082|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
32852083|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
32852084|NCT03570385|Experimental|Patient with Optic Neuritis|
32852085|NCT04009109|Experimental|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
32852086|NCT04009109|Experimental|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
32852087|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
32852088|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
32852089|NCT01454726|Other|control group|receiving the Western medical treatment alone.
32852090|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
32852091|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
32852092|NCT03084367||iFR post angiographically successful PCI|
32852093|NCT04007393|Other|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
32852094|NCT04007393|Other|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
32852095|NCT04076696|Experimental|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
32852096|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
32852097|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
32852098|NCT05364203|No Intervention|no intervention|Injections were done as usual without mask.
32852099|NCT05364203|Active Comparator|Comparator|Injections are made as in standard practice. The virtual reality headset is added to the patient. In this case, there is no image or sound. The mask is off.
33320351|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
33320352|NCT01335256|Experimental|Arm 1|
33320353|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
33320354|NCT01309256||R-robot group|retrospective robot group
32852100|NCT05364203|Experimental|Intervention|Injections are made as in standard practice. We add the virtual reality mask with the image and the sound.
33320355|NCT01309256||P-robot group|prospective robot group
32852101|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
32852102|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
32852103|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
32852104|NCT05368805|Experimental|Part A|On Day 1, a single oral dose of dabigatran etexilate 150 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of fruquintinib 5 mg at approximately 1 hour prior to administration of a single oral dose of dabigatran etexilate 150 mg under fasted conditions and serial PK samples will be collected
32852105|NCT05368805|Experimental|Part B|On Day 1, a single oral dose of rosuvastatin 10 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of rosuvastatin 10 mg with fruquintinib 5 mg under fasted conditions and serial PK samples will be collected
32852106|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
32852107|NCT01454570|Experimental|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
32852108|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
32852109|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
32852110|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32852111|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
32852112|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
32852113|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
32852114|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
32852115|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
32852116|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
32852117|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
32852118|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
32852119|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
32852120|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
33406607|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
33406608|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
33406609|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
33406610|NCT05222100||Women without breast implants|Women without breast implants participating in the mammography screening program.
33406611|NCT05222100||Women with breast implants|Women with breast implants participating in the mammography screening program.
33406612|NCT05194644|Experimental|Routine physical therapy + Sensorimotor stimulation|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min In Sensory Stimulation Gustatory, Tactile, Olfactory, Visual, Auditory Stimulation will be applied alternatively Time duration will be 4 min In motor stimulation first warm up session for 5-10 min, strengthening exercise, PNF techniques for upper and lower limb, abdominal curls and then different Balance exercises for 6 min 5 times a week
33406613|NCT05194644|Placebo Comparator|Routine physical therapy|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min
33406614|NCT04397796|Experimental|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
32852121|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
32852122|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
32852123|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
32852124|NCT01725711|Experimental|Implant System|
32852125|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
32852126|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
32852127|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
32852128|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
32852129|NCT05360381|Experimental|Phase 1a dose-escalation stage|"Phase 1a uses the 3+3 design, to investigate the safety and determine the MTD of HLX35. Seven dose levels of 0.015 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg are planned for dose finding. Enrollment will continue until a maximum of 42 patients are enrolled"
32852130|NCT05360381|Experimental|Phase 1b dose-expansion stage|Patients with sqNSCLC (EGFR H score≥200) will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX35. Phase 1b dose expansion will include 15-20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
32852131|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
32852132|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
32852133|NCT05630729|Other|My Kidney Guru Intervention|Youth Participants with CKD will complete the 9 My Kidney Guru modules over the 6-month intervention period, at a rate of approximately one module every 2-3 weeks. Parent participants will complete the parent module within the first t2 weeks of the intervention period, and to review the remaining youth modules by the end of the trial period. Participants will complete outcomes measures within 1 month prior to beginning the intervention. Software usage data will be gathered regarding fidelity and dosage of the My Kidney Guru intervention. Within 1 month of completing the intervention period, participants will complete the same set of outcomes assessments, along with an evaluation survey of the intervention. Once post-intervention data collection has been completed and the intervention period has ended, participants will participate in a 45 minute follow up Web-Ex focus group to provide feedback on their experiences with My Kidney Guru and collect additional suggestions for improvement.
32852134|NCT03271333||patients with systemic sclerosis|
32852135|NCT05068830|Experimental|Exercised plasma (ExPlas)|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
32852136|NCT05068830|Active Comparator|Octaplasma|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
32852137|NCT05068830|Placebo Comparator|Saline|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
32852138|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
32852139|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
32852140|NCT05630651|Experimental|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
32852141|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
32852142|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
32852143|NCT05068050|Experimental|Experimental group|This arm will be provided by horse-assisted therapy interventions.
32852144|NCT05068050|Active Comparator|Control group|This arm will be provided by the physical exercise interventions.
32852145|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
32960291|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
32960292|NCT01004718|Experimental|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
32960293|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
32960294|NCT01005810|Active Comparator|N-Acetylcysteine|
32960295|NCT01005810|Placebo Comparator|Placebo|
32960296|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
32960297|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
32960298|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
32960299|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
32960300|NCT01007526|Experimental|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
32960301|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
32960302|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
32960303|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
32960304|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
32960305|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
32960306|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
32960307|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
32960308|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
32960309|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
32960310|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
32960311|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
32960312|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
32960313|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
32960314|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
32960315|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
32960316|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
32960317|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
32960318|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
32960319|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
32960320|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
32960321|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
32960322|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
32960323|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
33320356|NCT01309256||P-laparoscopic group|prospective laparoscopic group
32852146|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
32852147|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
32852148|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
32852149|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
32852150|NCT05068362|Other|Implant|Use of Medpor implant in auricle reconstruction in microtia
32852151|NCT04005989|Placebo Comparator|PLACEBO GROUP|injection of saline solution
32852152|NCT04005989|Active Comparator|Low dose group|hASC injection (1x10e6 / kg body weight)
32852153|NCT04005989|Active Comparator|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
32852154|NCT04005989|Active Comparator|High dose group|injection of hASC (4x10e6 / kg body weight)
32852155|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
32852156|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
32852157|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
32852158|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
32852159|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
32852160|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
32852161|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
32852162|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
32852163|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
32852164|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
32852165|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
32852166|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
32852167|NCT05633303|Experimental|Patients with underlying LVZs (≥30% of LVZs in the LA body)|"Study 1- Developing a methodology and technique for sequential CV assessment. Twenty patients.~Study 2- Assess the mechanistic importance of RDCV slowing sites in AF. Twenty patients.~Study 3- Assess the impact autonomic modulation has on CV dynamics and RDCV slowing sites. Twenty patients.~Study 4- GP site ablation and substrate modification guided by RDCV slowing sites whereby substrate ablation is limited to substrate with these electrical properties and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~. Study 5- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
32852168|NCT05633303|Experimental|Patients without underlying LVZs (<30% of LVZs in the LA body)|"Study 1- Mechanistic importance of GP site ablation. Twenty patients.~Study 2- GP site ablation in addition to PV isolation and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~Study 3- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
32852169|NCT01725945|No Intervention|Usual Care|Usual Care
32852170|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
32960324|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
32960325|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
32960326|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
32960327|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
32960328|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
32960329|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
32960330|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
32960331|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
32960332|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
32960333|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
32852171|NCT04287829|Experimental|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.~Treatment continues until disease progression by modified RECIST 1.1 for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
32852172|NCT05368649|Experimental|Healthy Volunteers|Short-wave diathermy
32852173|NCT05368649|No Intervention|Shoulder Pain|Volunteers with unilateral shoulder pain
32852174|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
32852175|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
32852176|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
32852177|NCT03083821|Experimental|Arm A|
33406615|NCT04397796|Placebo Comparator|Placebo|Subjects in the control arm will be treated with placebo
32852178|NCT05367869|Experimental|Intraoperative Spraying Methylene Blue In Thyroidectomy|
32852179|NCT05067738|Other|Discharge|Phase 1-Patients will continue to be admitted after their surgery as is the current practice. Phase 2-Patients will have their chest tube removed once they meet chest tube removal criteria and will be discharged home once they meet discharge criteria.
32852180|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
32852181|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
32852182|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
32852183|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
32852184|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
32852185|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
32852186|NCT05361161|Experimental|Transarterial Chemoembolization With Lipiodol for Initial Unresectable Gastric Cancer|
32852187|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
32852188|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
32852189|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
32852190|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
32852191|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
32852192|NCT03082027||ultrasonography|diagnostic tool
32852193|NCT03082027||operative release|
32852194|NCT05366777|Experimental|Maxigesic group|At the end of induction, the Maxigesic group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 min, every 6 hours, a total of 4 times.
32852195|NCT05366777|Placebo Comparator|Control group|At the end of induction, the control group will receive intravenous normal saline with the same volume and same time points as the intervention group receives.
32852196|NCT05067660|Active Comparator|Cohort A - Standard-of-care template-based salvage radiotherapy|Study participants in cohort A undergo template-based salvage radiotherapy according to current standard-of-care protocol. Dose fractionations include dose of 70/2 Gy in the prostatic bed, 50/2 Gy in the pelvic lymph node area and 45/1,8 Gy in the para-aortic lymph node. To the PSMA PET-CT positive lymph nodes, a boost dose will be considered depending on the anatomic site and will be delivered with a simultaneous integrated boost technique (SIB). The typical boost dose to PSMA PET-CT positive lymph nodes is 57,5/2,3 Gy, respecting normal tissue constraints. The dose to PSMA PET-CT positive areas in the prostatic bed is 74-78/2 Gy.
32852197|NCT05067660|Experimental|Cohort B - PSMA PET CT-targeted stereotactic ablative radiotherapy|Study participants in cohort B undergo stereotactic ablative radiotherapy, targeted only to PSMA PET-CT-positive areas judged to be suspicious of prostate cancer metastasis by nuclear medicine physician. Dose fractionations in the experimental arm vary from 24/8 Gy to 30/10 Gy in PSMA PET-CT positive lymph nodes in pelvic or para-aortic areas. PSMA PET-CT positive areas in the prostatic bed receive a dose of 35/7 Gy.
33104169|NCT01349322|Experimental|Arm II|Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
32852198|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
32852199|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
32852200|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
32852201|NCT03139045|Active Comparator|Venous puncture without VVV|
32852202|NCT04021043|Experimental|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
32852203|NCT04021043|Experimental|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
32852204|NCT04021043|Experimental|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
32852205|NCT04859088|Experimental|Partial Enteral Nutrition|Patients allocated to Partial Enteral Nutrition study arm will be asked to replace 50% of their daily energy requirements with a proprietary formula (Modulen IBD, Nestle) for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
32852206|NCT04859088|No Intervention|Unrestricted diet|Patients allocated to unrestricted diet study arm will be asked to follow their normal diet for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
32852207|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
32852208|NCT03080545|Experimental|Open Label Enstilar|open label
32852209|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
32852210|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
32852211|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
32852212|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
32852213|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
32852214|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
32852215|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
32852216|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
32852217|NCT04283617|Experimental|Diabetic with short duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
32852218|NCT04283617|Experimental|Diabetic with long duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
32852219|NCT05632913|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed
32852220|NCT04480164|Experimental|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
32852221|NCT04480164|Experimental|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
32852222|NCT04480164|Experimental|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
32852223|NCT04480164|Placebo Comparator|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
32852224|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
32852225|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
33104170|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
33104171|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
33104172|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
32852226|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
32852227|NCT05632835|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries.
32852228|NCT05632835|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
32852229|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
32852230|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
32852231|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
32852232|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
32852233|NCT05247619|Experimental|Intervention|Tislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin
33320357|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
33104173|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
33104174|NCT04066127|Experimental|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
33104175|NCT04066127|Other|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
33104176|NCT04982965|Experimental|Active THC|Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI.
33104177|NCT04982965|Placebo Comparator|Placebo THC|Participants will be administered 400mg of vaporized cannabis (<.1%) before pain testing and fMRI.
32852234|NCT04020965|No Intervention|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
33104178|NCT04976101|Experimental|Sinusoidal Galvanic Vestibular Stimulation|"Treatment:~1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz."
33104179|NCT04976101|Placebo Comparator|Placebo|"Treatment:~1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz."
33104180|NCT04206826|Experimental|PREDELFI Film|
33320358|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
32852235|NCT04020965|Experimental|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
32852236|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
33104181|NCT04206826|Placebo Comparator|CONTROL Film|
33104182|NCT04060355|Experimental|Savvy Participants|Using an on-line survey method, each caregiver will be asked to complete the post-program fidelity monitoring survey that seeks responses to the program (feel more knowledgeable, more competent, better equipped, etc.) and asks them to assess the interventionist's performance and verify that certain key elements of the program were covered.
33320359|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
33320360|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
33320361|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
33320362|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
33320363|NCT01072487|No Intervention|Standard|Standard monitoring.
33320364|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
33320365|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
33320366|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
33406616|NCT04315896|Active Comparator|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
33406617|NCT04315896|Placebo Comparator|placebo|identical placebo, one tablet every 12 hours for 10 days
32960334|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
32960335|NCT05395962|Active Comparator|BLM|
32960336|NCT05395962|Experimental|BLM+CBP|
32960337|NCT05395728|Experimental|Group 1|Deflate the cuff at the beginning of the mechanical ventilation weaning protocol
32960338|NCT05395728|Active Comparator|Group 2|Deflate the cuff after complete weaning from mechanical ventilation
32960339|NCT05395572|Experimental|Tape|Kinesio tape will be applied to the neck to help facilitate underactive muscles and ROM will be assessed
33320367|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
32960340|NCT05395572|No Intervention|Control|ROM will be assessed before tape application to determine any changes
32960341|NCT05395416|Experimental|HEC74647PA+HEC110114 100 mg/200 mg|Phase II: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg or200 mg once daily and HEC110114 tablets 600 mg once daily
32960342|NCT05395416|Experimental|HEC74647PA+HEC110114|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg /200 mg once daily and HEC110114 tablets 600 mg once daily
32960343|NCT05395416|Placebo Comparator|Placebo|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Placebo Capsules once daily and HEC110114 Placebo tablets once daily
32960344|NCT05394480|Experimental|clinical treatment|"4 dentist treated 36 patient in clinical group~- For treatment in a clinic, children with positive or definitely positive (Frankl 3 and 4) behaviour according to the Frankl Scale (Behavior Evaluation Scale) 28, with the data observed in the first session, were included in the clinical treatment group. According to the clinical examination of these patients, 36 healthy children aged 5-6 years who did not require pulpal treatment and whose caries level was 1-4 according to the ICDAS (International Caries Detection And Assessment System) 29 scoring were selected. The limits of the treatment were determined as compomer filling applied to 2 primary molars after local anaesthesia, and the duration of the treatment was limited to 30 to 60 minutes."
32960345|NCT05394480|Experimental|deep sedation|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or absolutely negative behaviour (Frankl 1 and 2) according to the Frankl Scale, were reserved for treatment under deep sedation. In order to provide standardization among patients suitable for sedation, 36 children (n=9) whose dmft (decayed, missing, filled teeth index) were less than their age, and the duration of the procedure would be limited to between 30 and 40 minutes, were included in the study."
32960346|NCT05394480|Experimental|general anaesthesia|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or definitely negative behaviour according to the Frankl Scale (Frankl 1 and 2), were reserved for treatment under general anaesthesia. In order to provide standardization among patients suitable for general anaesthesia, 36 healthy children (n=9) whose dmft was equal to, or higher than their age were allocated. In addition, patients whose treatment time would be limited to 30 to 60 minutes were included."
32960347|NCT05394246|Experimental|FluoAB intraoperative fluorescence imaging|The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.
32960348|NCT05394168|Experimental|HLX53|
32960349|NCT05394090|Experimental|saliva-stimulated group|In approximately 50 randomly selected patients (group 1), from the second day of admission until the end of hospitalization, a 15-minute manual stimulation of the submandibular and sublingual bib was performed internally and externally. In addition, oral hygiene was performed in patients, taking into account the tongue and cheeks.
32960350|NCT05394090|No Intervention|the group in which the saliva was not stimulated|There was no saliva in the group of 50 patients
32960351|NCT05391048|Experimental|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
32960352|NCT05391048|Experimental|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
32960353|NCT05387538|Experimental|One-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in one layer suturing the pancreatic duct to the mucosa of jejunum.
32960354|NCT05387538|Experimental|Two-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in two layer. The first layer will be suturing the pancreatic capsule to the seromuscular layer of jejunum and the 2nd layer will be suturing the pancreatic duct to the mucosa of jejunum.
32960355|NCT05386602||Prior trial patients|In stage III, patients who have been on an experimental cancer medicine trial for less than 6 weeks will complete a draft PREM-ECM (less than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (less than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
32960356|NCT05386602||On trial patients|In stage III, patients who have been on an experimental cancer medicine trial for more than 6 weeks will complete a draft PREM-ECM (more than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (more than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
32960357|NCT05386602||Carers of patients|In stage III, carers of patients recruited on an experimental cancer medicine trial will be asked to complete a draft PREM-ECM-carers, the Adult Carer Quality of Life Questionnaire (AC-QOL), the EQ5D-5L, and the Hospital Anxiety and Depression Scale (HADS) at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 carers will be asked to repeat the draft of the PREM-ECM-carers approximately one week later at time point 2 (T2). In Stage IV, the PREM-ECM-carer will be administered alone.
32960358|NCT05344950|Experimental|AURA|In addition to usual care, participants assigned to this arm will have access to our Audio + Radio (AURA) system.
32960359|NCT05344950|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
32960360|NCT05017584|Experimental|Hyperbaric bupivacaine 10.5mg|
32960361|NCT05017584|Experimental|Hyperbaric bupivacaine 12mg|
32960362|NCT05017584|Experimental|Hyperbaric bupivacaine 13.5mg|
32960363|NCT05017584|Experimental|Hyperbaric bupivacaine 15mg|
32960364|NCT05010096|Experimental|Arm I (elimusertib, copanlisib)|Patients receive Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 4 and 18. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
32960365|NCT05010096|Experimental|Arm II (elimusertib, copanlisib)|Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
32960366|NCT04999332|Experimental|Perioperative chemotherapy with LOTS|"LOTS as one cycle:~Leucovorin (30 mg) twice daily per oral, day 1 to 7; Oxaliplatin (85 mg per square meter) intravenously, day 1; Docetaxel (40 mg per square meter) intravenously, day 1; S-1 (35 mg per square meter) twice daily per oral, day 1 to 7~Pre-operative part:~Four cycles of LOTS every two weeks~Operative part:~Curative gastrectomy or gastroesophagectomy plus D2 lymphadenectomy~Post-operative part:~Four cycles of LOTS every two weeks"
32960367|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~1A: Persons with asymptomatic infection, ages 18 through 55, inclusive~1B: Persons with asymptomatic infection, age > 55~1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55~1D: Persons with symptomatic infection (ie, COVID-19), age > 55"
32960368|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~2A: Persons 18 through 55 years of age~2B: Persons > 55 years of age"
32960369|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
32960372|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
32960373|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
32960374|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
32960375|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
32960376|NCT04147416|Experimental|HSK3486|HSK3486 for Sedation
32960377|NCT04147416|Active Comparator|Propofol|Propofol for Sedation
32960378|NCT04129866|Experimental|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
32960379|NCT04129866|Placebo Comparator|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
32960380|NCT04098432|Experimental|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
32960381|NCT03984318|Experimental|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
32960382|NCT03927066|Experimental|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
32960383|NCT03899532|Experimental|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
32960384|NCT03899532|Placebo Comparator|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
32960385|NCT03786042|Active Comparator|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
32960386|NCT03786042|Sham Comparator|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
33033066|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
33033067|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
33033068|NCT01958970|Experimental|PINTA 745|
33406618|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
33406619|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
33406620|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
33406621|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
33406622|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
33406623|NCT05221788|Experimental|GDHT(goal-directed hemodynamic therapy)|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If stroke volume (SV) increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but MAP <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate (HR) more than 20% above baseline), plasma was administered until urine output and/or heart rate returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
32740018|NCT04315961|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
32740019|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
32740020|NCT05083481|Experimental|ASP1570 Monotherapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle.
32740021|NCT05083481|Experimental|ASP1570 Monotherapy Tumor Specific Dose Expansion - Response-triggered Tumor (Part 2)|Participants will receive ASP1570 in a 21-day cycle in tumor-specific cohort if dose escalation cohort had partial response (PR) or complete response (CR) in same tumor type at a dose that has been cleared and deemed tolerable.
32740022|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Melanoma (Part 2)|Participants who have melanoma will receive recommended Phase 2 dose (RP2D) of ASP1570 in a 21-day cycle.
32740023|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Non-Small Cell Lung Carcinoma (NSCLC) (Part 2)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle.
32740024|NCT05083481|Experimental|ASP1570 + Pembrolizumab Combination therapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle. Pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
32740025|NCT05083481|Experimental|ASP1570 + Pembrolizumab Combination therapy Dose Expansion - NSCLC (Part 2)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle. Pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
32740026|NCT05081531|Other|Adaptive Radiotherapy in Head and Neck cancer patients|"Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.~At week 3 from RT start, patients will repeat contrast simulation CT with, and MRI and FDG-PET scan for treatment replanning. Patient will start with the new plan in week 4."
32740027|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
32740028|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
32740029|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
32740030|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
33033069|NCT01958970|Placebo Comparator|Placebo|
33406624|NCT05221788|No Intervention|control|Continuous infusion of compounded sodium lactate 5-7 ml/kg/h was allowed to receive colloidal solution, norepinephrine and dobutamine at the discretion of the anesthesiologist.
32740031|NCT04220021|Experimental|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
32740032|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
32740033|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
32740034|NCT05065541|Experimental|Part 1|
32740035|NCT05065541|Experimental|Part 2|
32740036|NCT05065541|Experimental|Part 3|
32740037|NCT01375673|Experimental|Exercise|Exercise: Walking Strength Training Bicycling
32740038|NCT01375673|No Intervention|Usual Care|Usual Care
32740039|NCT05064761|Experimental|Treatment group|PLLA new dilution for treatment to improve appearance of cellulite.
32740040|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
32960387|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
32960388|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
32960389|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
32740041|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
32960390|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
32960391|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
32960392|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
32960393|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
32960394|NCT03125148|Active Comparator|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
32960395|NCT03125148|Experimental|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
32960396|NCT03029364||Male and Female Adults|Completion of Study Protocol
32960397|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
32960398|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
32960399|NCT02406222|Experimental|Pomalidomide Dexamethasone Cyclophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22~Cyclophosphamide 500mg orally on days 1, 8 and 15"
32960400|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
32960401|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
32960402|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
32740042|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
32740043|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
32740044|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
32740045|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
32740046|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
32740047|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
32740048|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
32740049|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
32740050|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
32740051|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
32740052|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
32740053|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
32740054|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
32740055|NCT03994601|Experimental|Arm A BMS-986288|
32740056|NCT03994601|Experimental|Arm B BMS-986288 in combination with Nivolumab|
33406625|NCT05194098|Experimental|Major Depression Disorder Group: iTBS-EEG|Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: intermittent theta stimulation (iTBS): the investigators will stimulate a dorsomedial prefrontal cortex target at the scalp location (0x 60y 60z). Standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes, per session; total session length, including setup is 10-15 min.
32960403|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
32960404|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
32960405|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
32960406|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
32960407|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
32960408|NCT01024686|Experimental|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
32960409|NCT01024686|No Intervention|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
32960410|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
32960411|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~Patients also demonstrate a weight regain of 15% of excess body weight loss."
32960412|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
32960413|NCT01027806|Active Comparator|Montelukast|
32960414|NCT01027806|Placebo Comparator|Placebo|
32960415|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
32960416|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
32960417|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
32960418|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
32960419|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
32960420|NCT01032330|Active Comparator|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
32960421|NCT01032954|Active Comparator|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
32960422|NCT01032954|Active Comparator|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
32960423|NCT01032954|Active Comparator|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
32960424|NCT01033422|Experimental|CF101 1mg|CF101 1mg orally q12 hours
32960425|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
32960426|NCT01033422|Experimental|CF101 2mg|CF101 2mg orally q12 hours
32960427|NCT05593848|Experimental|Experimental Group (Intratissue Percutaneous Electrolysis Group)|"The treatment to be performed in the Intratissue percutaneus electrolysis Group will consist of:~Palpation and localization of the myofascial trigger points in the infraspinatus muscle of the affected shoulder.~Application of the ultrasound-guided intratissue percutaneus electroysis technique (1 or 2 approaches) on the myofascial trigger points with the greatest clinical manifestations for the subject. The needle will remain at intramuscular level without movement and a galvanic current discharge will be applied in the area, through the needle, whose intensity will oscillate between 0.5 and 3 milliAmperes (mA).~Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
32960428|NCT05593848|Active Comparator|Active Control Group (Dry Needling Group)|"The treatment to be performed in the Dry Needling Group will consist of:~palpation and localization of myofascial trigger points in the infraspinatus muscle of the affected shoulder.~Application of the ultrasound-guided dry needling technique (1 or 2 approaches) on the myofascial trigger points with major clinical manifestations for the subject. The physiotherapist will move the needle into the muscle using Hong's rapid entry and exit technique.~Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
32960429|NCT05593536|Experimental|Group 1 (biological nurturing)|In biological feeding, the mother takes a semi-sitting position and the baby lies face down on the mother's breast and belly, with every part of her body in contact with the mother.
32960430|NCT05593536|Experimental|Group 2 (classic breastfeeding)|In classical breastfeeding, the mother holds her baby in her arms and breastfeeds while she is in a sitting position.
32960431|NCT05593536|No Intervention|Group 3 (control)|The mother will breastfeed her baby as she wishes.
32960432|NCT05593458|Experimental|Arterial infusion group|"3 cycles of neoadjuvant chemotherapy: Oxaliplatin arterial infusion+S-1~surgery and 5 cycles of adjuvant chemotherapy using SOX regimen"
32960433|NCT05593458|Active Comparator|SOX group|"3 cycles of neoadjuvant chemotherapy: SOX regimen~surgery and 5 cycles of adjuvant chemotherapy using SOX regimen"
32852237|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
32852238|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
32852239|NCT05249803||Patients with COVID-19 pneumonia|These patients were admitted in ICU for management of Covid-19 pneumonia usual care was offered to all patients
32852240|NCT04020419|Experimental|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
32852241|NCT04020419|Placebo Comparator|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
32852242|NCT01726647||No product is tested|No intervention
32852243|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
32852244|NCT05247307|Experimental|Intervention|"Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
33104183|NCT04060355|Experimental|Interventionists|Three recorded semi-structured video interviews will be conducted with each interventionist. One will occur immediately after training; this will focus on their sense of the completeness and adequacy of the training program, including the training methods, videos, and materials, and their perceived readiness to lead the program. Another interview will be done immediately after the conduct of each of the two Savvy programs they lead, asking them to report on their own performance as interventionists, including any adaptation processes in which they might have engaged, and to reflect on ways the training might be improved to strengthen their skills, including for adaptation. In total: 18 interviews.
33104184|NCT04060355|Experimental|Organizational Leaders|Recorded semi-structured video interviews with sponsoring organizations' key contact persons will be conducted immediately after the interventionist training and then after each of two Savvy offerings. The conversation will focus on identifying ways to strengthen and improve the training, certification, and fidelity monitoring system. Information about time and resource costs of the program, caregiver demand, and caregiver recruitment and feedback (3 interviews per organization) will be also collected.
32852245|NCT05247307|Active Comparator|Control|"Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
32852246|NCT04018937|Experimental|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
32852247|NCT00805584|Experimental|Arm 1|
32852248|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
32852249|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
32852250|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
32852251|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
32852252|NCT05067192||Parkinson's Disease|Patients with Parkinson's Disease. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
32852253|NCT05067192||Dementia with Lewy Bodies|Patients with Dementia with Lewy Bodies. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
32852254|NCT05067192||Multiple System Atrophy|Patients with Multiple System Atrophy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
32852255|NCT05067192||Corticobasal Syndrome|Patients with Corticobasal Syndrome. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
32852256|NCT05067192||Progressive Supranuclear Palsy|Patients with Progressive Supranuclear Palsy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
32852257|NCT05067192||Healthy controls|Healthy contols. Contols will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
32852258|NCT04017767|Experimental|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
32852259|NCT04017767|Active Comparator|Without OSA|Individuals without OSA defined as having AHI less than 5.
32852260|NCT05244655||Patients without painscores available during hospital stay|
32852261|NCT05244655||Patients with painscores available during hospital stay|
32852262|NCT05066958|Experimental|boost anti-viral immunity after T-cell depleted HSCT|
32960434|NCT05593380|Experimental|Bioelectrical impedance analysis(BIA) monitoring|Care based upon intracranial pressure and cerebral edema.
32960435|NCT05593380|Active Comparator|ICP monitoring|Care based upon intracranial pressure.
32960436|NCT05593380|Other|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
32960437|NCT05593224|Experimental|Intracranial Stent (Tonbridge)|Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd. ).
32960438|NCT05593068||Dialysed patients with suspicion of hepatic iron|Patients on dialysis at Claude Galien Private Hospital who had one or more MRI scans to monitor possible hepatic iron overload between May 2012 and March 2018.
32960439|NCT05592912|Experimental|Low dose HydroLenz treatment|
32960440|NCT05592912|Experimental|High dose HydroLenz treatment|
32960441|NCT05592912|Placebo Comparator|Control, i.e., no HydroLenz treatment|
32960442|NCT05592834|Experimental|Positive deviance (PD)|This group will receive only the positive deviance intervention and not the PFT
32960443|NCT05592834|Experimental|Parent facilitator training (PFT)|This group will receive only the parent facilitator training intervention and not the PD
32960444|NCT05592834|Experimental|Parent facilitator and positive deviance(PFT/PD)|This group will receive both the PD and PFT interventions
32960445|NCT05592834|Active Comparator|Control|This group will receive neither the PD nor the PFT interventions but care as usual.
32960446|NCT05592678|Active Comparator|Predicted Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance.
32960447|NCT05592678|Active Comparator|Predicted Non-Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance.
32960448|NCT05592288|Experimental|Intervention group|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. PREDIABE-TR mobile app usage (six months).
32960449|NCT05592288|No Intervention|Control grup|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. Routine practice (Brochures of the Public Health Directorate, Mobile apps of the Ministry of Health, etc.)
32960450|NCT05590884|Experimental|Age Group 1: patients aged 3 to 23 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
32960451|NCT05590884|Experimental|Age Group 2: patients aged 28 days to less than 3 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
32960452|NCT05590884|Experimental|Age Group 3: patients aged from birth to 27 days (term newborns)|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
32960453|NCT05525988|Experimental|Hemi-Hamate Graft for Proximal Pole Scaphoid Reconstruction|[All participants enrolled in this study for proximal pole scaphoid reconstruction using the Hemi-Hamate autograft]
32960454|NCT05524116|Active Comparator|Group TX (Telehealth Exercise)|Participants in this group will receive a supervised and group-based exercise program once a week for 8 weeks via telehealth.
32960455|NCT05524116|Experimental|Group TMX (Telehealth Exercise and Mindfulness)|Participants in this group will receive a supervised, group-based integrated mindfulness and exercise program once a week for 8 weeks via telehealth.
32960456|NCT05517564|Experimental|A (GM-60106)|Drug: GM-60106 Dosage: Part A: 2.5, 5, 10, 20, 40, 60, or 100 mg, Part B: 5, 10, 20 mg, Part C: 10, 20 mg Dosage Form: Bovine-gelatin capsules Route of Administration: Oral
32960457|NCT05517564|Experimental|B (Placebo)|Dosage Form: Bovine-gelatin capsules Route of Administration: Oral Matching placebo has an identical formulation to the GM-60106 drug product, prepared without the active pharmaceutical ingredient
32960458|NCT05489328|Experimental|Candidate-1|Participants to receive a single injection of Candidate-1.
32960459|NCT05489328|Experimental|Candidate-2|Participants to receive a single injection of Candidate-2.
32960460|NCT05489328|Experimental|Candidate-3|Participants to receive a single injection of Candidate-3.
32960461|NCT05489328|Experimental|Candidate-4|Participants to receive a single injection of Candidate-4.
32960462|NCT05489328|Experimental|Candidate-5|Participants to receive a single injection of Candidate-5.
32960463|NCT05489328|Experimental|Candidate-6|Participants to receive a single injection of Candidate-6.
32960464|NCT05489328|Active Comparator|Candidate Control|Participants to receive a single injection of Candidate Control.
32960465|NCT05489328|Other|13-valent pneumococcal conjugate vaccine (13vPnC)|Participants to receive a single injection of 13vPnC.
32960466|NCT05489328|Other|15-valent pneumococcal conjugate vaccine (PCV15)|Participants to receive a single injection of PCV15.
32960467|NCT05479344|Experimental|Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The current intervention involves the identification of character strengths (the first week, 90 minutes of intervention), the perception of the meaning of life (the second week, 90 minutes of intervention), the learning of strategies to develop hope (the third week, 90 minutes of intervention), and the understanding of emotion regulation strategies (the fourth week, 90 minutes of intervention).
32960468|NCT05479344|Other|Waiting list group|The waiting list group will receive the same intervention at the end of the 6-month follow-up test.
32960469|NCT05467098|Experimental|Individuals with and without Shoulder Pain|"Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation~Individuals without shoulder pain will receive dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula"
32960470|NCT05461404|Experimental|Emollient arm|Infants will receive gentle, hygienic whole-body massage by trained nurses (not parents or other family members) with 3g of SSO per kg of body weight - a dose sufficient to saturate the skin - three times daily for the first 14 days and twice daily thereafter during the duration of their stay in the hospital until death, discharge or through day 28 after birth.
32960471|NCT05461404|No Intervention|Control arm|Infants in the control group will receive the standard of care for infants in the neonatal care unit, which does not include use of topical emollients or massage (i.e., family members will not be allowed to apply skin care products to their infants), or other particular measures to prevent skin breakdown or to modulate skin barrier function.
32852263|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
32852264|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
32852265|NCT00218543|Experimental|Atomoxetine|Atomoxetine
32852266|NCT04477668|Experimental|Helmet group|Patients will be allocated to helmet non-invasive ventilation
32852267|NCT04477668|No Intervention|Control group|Patients will be allocated to standard of care
32852268|NCT00795522|Experimental|Arm 1|Desloratadine
32852269|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
33104185|NCT04207021|Experimental|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
32852270|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
32852271|NCT05366309|Active Comparator|Standard Care (Control) Group|Participants randomised to this group will receive usual care in terms of their education.
32852272|NCT05366309|Experimental|Tailored Education Group|Participants randomised to this group will receive tailored education, which is additional to standard care.
32852273|NCT05243251|Active Comparator|Olanzapine|82 patients will receive olanzapine 5 mg daily at night for 4 weeks
32852274|NCT05243251|Placebo Comparator|Placebo|82 patients will receive placebo for 4 weeks
32852275|NCT04434612|Experimental|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
32852276|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
32852277|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
32852278|NCT01720641|No Intervention|Control|Standardized partner notification counseling
32852279|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
32852280|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
32852281|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
32852282|NCT05008770||Older adults without sarcopenia|Healthy volunteers aged 65+ years who do not fulfill diagnostic criteria for sarcopenia, according to the revised European Working Group on Sarcopenia in Older People (EWGSOP2)
32852283|NCT02997475||Women with Bulimia Nervosa|
32852284|NCT02997475||Women Healthy Controls|
32852285|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
32852286|NCT05245123||Families of rare diseased children|Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
32852287|NCT05245123||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
32852288|NCT04376424|Experimental|Ultra Sound Guided Therapy Group|Hand carried ultrasound will be used in this group to measure IVCd, collapsibility along with internal jugular vein collapsibility. The results of the ultrasound will be unblinded to the treating team.
32852289|NCT04376424|No Intervention|Conventional Therapy Group|Conventional therapy will occur the use of hand carried ultrasound. The results will be blinded to the treating team. The managing team will analyze the data at the end of the study.
32852290|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
32852291|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
32852292|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
32852293|NCT05244265|Experimental|Mindfulness-based stress reduction (MBSR)|The 9 session MBSR program following the manual (Kabat-Zinn, 1982).
32852294|NCT05244265|Active Comparator|Treatment as usual (TAU)|Participants take part in their treatment as usual in outpatient habilitation and other services.
32852295|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
32852296|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
32852297|NCT00216671|Experimental|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
33406626|NCT05194098|Sham Comparator|Major Depression Disorder Group: SHAM-EEG|"Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: sham stimulation (SHAM): Sham stimulation will entail the same procedures for the active stimulation day, but with the sham side of the DB-80 A/P placed exactly on the same anatomical target in the same position and duration, but without any active stimulation.~*Note, iTBS and SHAM stimulation sessions will occur on separate days scheduled one week apart (counterbalanced, across subjects). The two stimulation visits follow identical procedures (with the sole difference being active vs. sham rTMS stimulation), with each followed directly by post-stimulation EEG assessment with SLOT and MID tasks."
32852298|NCT00216671|Active Comparator|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
32852299|NCT05245669|Experimental|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
32852300|NCT05245669|Active Comparator|EU Sourced Prolia|EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.
32852301|NCT05245669|Active Comparator|US Sourced Prolia|US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.
32852302|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
32852303|NCT00783354|Active Comparator|Continuous Treatment|
32852304|NCT00783354|Experimental|PRN regimen|
32852305|NCT05240365|Experimental|SDF modified Hall technique|"When Hall technique is used an accurate size of PMC is placed without local anesthesia, caries removal, or tooth preparation.~SDF is applied directly to carious lesions to arrest caries, the technique is noninvasive and relatively painless that could be a good option for treating dental caries in children"
32852306|NCT05240365|Active Comparator|Conventional pulpotomy and stainless steel crown|Amputation of the coronal pulp and treatment of the remaining vital radicular portion with a long term clinically successful medicament. Then using an accurate size of stainless steel crown.
32852307|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
32852308|NCT05245344||Patients with RRMS (untreated)|"Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria;~EDSS score ≤ 5.5;~Age between 18 and 55 years (exclusive);~no disease modifying therapies for at least 3 months or treatment naïve;~no corticosteroid administration in the previous month;~disease duration <10 years;~Ability to provide written informed consent."
32852309|NCT05245344||Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)|"Main inclusion criteria of NMOSD patients (Wingerchuk et al., 2015):~Positive test for Aquaporin 4 IgG;~Age between 18 and 55 years (exclusive);~no immunosuppressive therapies for at least 3 months or treatment naïve.~no corticosteroid administration in the previous month~disease duration <10 years~Ability to provide written informed consent"
32852310|NCT05245344||Healthy subjects (HD)|"Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.~Ability to provide written informed consent."
32852311|NCT04206553|Experimental|dupilumab|
32852312|NCT04206553|Experimental|Matching placebo|
32852313|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
32852314|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
32852315|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~Vorinostat: 400mg PO on 1-4 and 15-18"
32852316|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
32852317|NCT00750750|Active Comparator|1|MFNS once daily
32852318|NCT00750750|Experimental|2|MFNS twice daily
32852319|NCT00750750|Active Comparator|3|Amoxicillin
32852320|NCT00750750|Placebo Comparator|4|Placebo
32852321|NCT04379661|Experimental|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
32852322|NCT04379661|No Intervention|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
32852323|NCT04397887|Experimental|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
32852324|NCT05245110|Experimental|experimental group|received a tele-exercise training program
32852325|NCT05245110|No Intervention|control group|usual care only
32852326|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Nutramigen®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
32903531|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
33417236|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
33417237|NCT03368079|Experimental|Negative Pressure Suction Device|
32852327|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Althera®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
32852328|NCT05066802|Experimental|modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42~46h continuous infusion, every other week for 6 cycles (12 weeks).
32852329|NCT04379739|Experimental|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
32852330|NCT04379739|Experimental|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
32852331|NCT05066568|Other|Sequence of interventions starting with tDCS as the first intervention|"Week 1 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 4 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes.~Week 5 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes"
32852332|NCT05066568|Other|Sequence of interventions starting with Hypnosis as the first intervention|"Week 1 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 4 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes~Week 5 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes."
32852333|NCT04379427|Experimental|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
32852334|NCT04379427|Experimental|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
32852335|NCT04379427|Other|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
32852336|NCT05248633|Active Comparator|Radiotherapy|
32852337|NCT05248633|Experimental|Chemotherapy combined with radiotherapy|
32852338|NCT00216203|Experimental|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
32852339|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
32852340|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
32852341|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
32852342|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
32852343|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
32852344|NCT05246917|Experimental|Handsewn ileocolic anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
32852345|NCT05246917|No Intervention|Side to side stapled anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
32852346|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
32852347|NCT00653796|Active Comparator|Atorvastatin|
32852348|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
33417238|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
32852349|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
32852350|NCT05244109|Experimental|NSAIDs|Patients responding to any class of NSAIDs and unlikely to initiate biotherapy
32852351|NCT05244109|Experimental|Anti-TNF antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-TNF treatment arm
32852352|NCT05244109|Experimental|Anti-IL17 antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-IL-17 treatment arm
32852353|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
32852354|NCT00651144|Active Comparator|Ezetimibe|
32852355|NCT00651144|Active Comparator|Rosuvastatin|
32852356|NCT00651144|Placebo Comparator|Placebo|
32852357|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
32852358|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
32852359|NCT04276285|Active Comparator|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
32852360|NCT04276285|Active Comparator|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
32852361|NCT04276285|No Intervention|No TAP|No TAP block will be performed
32852362|NCT04276519|Experimental|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
32852363|NCT04276519|Active Comparator|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
32852364|NCT05066256|Experimental|Fluid responsive test|Measure cardiac output, inferior vena cava (IVC) diameter variation and LV diastolic function (E/e') baseline Fluid challenge Measure cardiac output, IVC diameter variation and LV diastolic function (E/e') after fluid challenge
32852365|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
32852366|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
32852367|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
32852368|NCT03100812|Experimental|Group A|
32852369|NCT03100812|Experimental|Group B|
32852370|NCT04378413|Experimental|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
32852371|NCT04378413|Experimental|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
32852372|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
32852373|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
32852374|NCT05066334|Experimental|Active Arm|"Two procedures:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control"
32852375|NCT05066334|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection and without placebo injection."
32852376|NCT03218683|Experimental|Monotherapy AZD5991|Dose escalation - multiple dose levels
32852377|NCT03218683|Experimental|Monotherapy AZD5991 expansion|Dose expansion
32852378|NCT03218683|Experimental|AZD5991 + venetoclax|Dose escalation - multiple dose levels
32852379|NCT05066412|Experimental|Arm 1|Prophylactic CD45RA-depleted DLI
32852380|NCT05242627|No Intervention|DGSOM Class of 2023|
32852381|NCT05242627|Experimental|DGSOM Class of 2024|
32852382|NCT05066178|Experimental|CAS Treatment for MV ASD|Participants will receive CAS treatment, modified for minimally verbal children with autism
32852383|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
32852384|NCT03182491||Anaphylaxis|
32852385|NCT03182491||Febrile transfusion reactions|
32852386|NCT03182491||Mild allergic reactions|
32852387|NCT03182491||Healthy controls|
32852388|NCT05065788||2020 Lockdown period|Patients who access to Ophthalmological emergency service during lockdown period in 2020
32852389|NCT05065788||2019|Patients who access to Ophthalmological emergency service in 2019 definite periods
32852390|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
32852391|NCT05244720|Experimental|Intervention|"Baseline questionnaire filled out at recruitment. Invited to an examination of the liver, by fibroscan and blood samples, shortly after recruitment.~Follow-up by phone after 6 months."
32852392|NCT05244720|Other|Control|Baseline questionnaire filled out at recruitment. Follow-up by phone after 6 months. Invited to an optional examination of the liver, by fibroscan and blood samples, after 6 months.
32852393|NCT01727583|Active Comparator|Lipid 1|Meal intake
32852394|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
32852395|NCT01727583|Active Comparator|Lipid 2|Meal intake
32852396|NCT01727583|Active Comparator|Lipid 3|Meal intake
32852397|NCT01727583|Active Comparator|Lipid 4|meal intake
32960472|NCT05412498|Experimental|Training|Participants in this arm will perform five battle rope training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
32960473|NCT05412498|No Intervention|Control|Participants in this arm will receive no intervention.
32960474|NCT05408520|Experimental|Amputation with TMR|Amputation will follow standard procedure, but with the addition of the TMR procedure, which involves rerouting severed or injured nerves to new muscle targets using microsurgical techniques to provide the nerve endings with a new muscle to innervate.
32960475|NCT05408520|No Intervention|Amputation without TMR (SOC)|A traditional amputation follows the normal standard of care, with transection of peripheral nerves.
32960476|NCT05402826|Placebo Comparator|Placebo|Patients will receive placebo pills.
32960477|NCT05402826|Active Comparator|Zinc+vitamin E supplements|Patients will receive zinc tablets plus alpha-tocopherol.
32960478|NCT05397678|Experimental|BCG-Denmark|Infants randomized to receive BCG-Denmark at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-AJ vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
32960479|NCT05397678|Active Comparator|BCG-Bulgaria|Infants randomized to receive BCG-Bulgaria at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-Bulgaria vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
32960480|NCT05385042|Other|Non-anaemic pregnant women|50 pregnant women who have normal haematocrit (not anaemic) at 12 weeks.
32960481|NCT05385042|Other|Anaemic pregnant women|100 pregnant women who have haematocrit below 33% (equates to Hb 11g/dL) in first trimester (<14 weeks gestation) and below 30% (equates to Hb 10g/dL).
32960482|NCT05376930|Experimental|DWP16001|DWP16001 Tablets
32960483|NCT05306028|Experimental|Metformin or insulin treatment|
32960484|NCT05302596|Experimental|Semaglutide|Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks.
32960485|NCT05302596|No Intervention|standard of care only|Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise)
32960486|NCT05246202|Experimental|Anxiety-alcohol personalized feedback intervention (AA-PFI 2.0)|Participants complete the brief (~20-30 minute) AA-PFI 2.0 at baseline.
32960487|NCT05246202|Active Comparator|Control personalized feedback intervention (C-PFI)|Participants complete the brief (~20-30 minute) C-PFI at baseline.
32960488|NCT05244798|Experimental|Group of sintilimab combined with neoadjuvant chemotherapy|sintilimab (D1 administration) was given in combination with chemotherapy (TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
32960489|NCT05244798|Experimental|Group of sintilimab combined with neoadjuvant chemoradiotherapy|sintilimab (D1) was administered in combination with concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin-paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
32960490|NCT05244798|Other|Group of neoadjuvant chemoradiotherapy|The control group received neoadjuvant chemoradiotherapy and the regimen was as follows:Chemotherapy regimen: TP regimen: albumin paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
32960491|NCT05193708|Active Comparator|Digital Indirect bonding|An indirect bonding tray will be fabricated from a 3D printed model
32960492|NCT05193708|Experimental|Windowed Bonding technique|3D printed guide with windows for positioning the bracket
32960493|NCT05179668|Experimental|Intervention arm|Hemodialysis patients receiving dapagliflozin 10 mg once daily
32960494|NCT05179668|Placebo Comparator|Placebo|Hemodialysis patients receiving placebo oral tablet once daily
32960495|NCT05163912|Experimental|Intervention|Virtual home intervention
32960496|NCT05141214|Active Comparator|Dietary Consult with Virtual Reality (intervention)|Those in the VR group will receive the same educational dietary review by the registered dietician, and additionally participate in a VR experience through an application called Chaos Café. In Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
32960497|NCT05141214|No Intervention|Dietary Consult without Virtual Reality (SOC)|Those in the SOC group will have the typical appointment, which includes a review of healthy diet choices with a registered dietitian and follow up according to clinic's SOC.
32960498|NCT05116020||Chiropractic patient participants|Usual chiropractic care
32960499|NCT05088564|Experimental|I (Hand-sewn group)|Doudenojejunal anastomosis by hand-swen method
32960500|NCT05088564|Active Comparator|II (Stapling group)|Doudenojejunal anastomosis by hemi-double-stapling method
33033070|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
32852398|NCT05244642|Experimental|Group A (Penpulimab)|Participants receive Penpulimab 200mg intravenously (IV) on Day 1, Q2W for 24 months.
32852399|NCT05244642|Active Comparator|Group B (Chemotherapy)|Participants receive investigator's choice of chemotherapy Q2W or Q3W for up to 4 or 6 cycles.
32852400|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
32852401|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
32852402|NCT04158037|Experimental|mHealth App|Participants will receive the gambling disorder mHealth app.
32852403|NCT04158037|No Intervention|Wait List Control|Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
32852404|NCT05244564|Experimental|3MDR delivered via Augmented Reality Head Mounted Display|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
32852405|NCT05244564|Active Comparator|3MDR delivered in the Computer Assisted Rehabilitation Environment (CAREN)|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
32852406|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
32852407|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
32852408|NCT04396951|No Intervention|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.~Measure during 6 hours with indirect calorimetry"
32852409|NCT04396951|Active Comparator|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
32852410|NCT04396951|Active Comparator|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
32852411|NCT04378647|Active Comparator|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]
32852412|NCT04378647|Experimental|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]
32852413|NCT05244330||Partial vaccination|One dose of vaccine received at least 7 days prior to study enrollment
32852414|NCT05244330||Full vaccination|Two doses of COVID-19 vaccine received at least 7 days prior to study enrollment
32852415|NCT05244330||Unvaccinated|No dose of COVID-19 vaccine for at least 7 days prior to study enrollment
32852416|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
32852417|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
32852418|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
32852419|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
32852420|NCT04378335|Experimental|one arm|oral disorder
32852421|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
32852422|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
32852423|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
32852424|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
32852425|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
32852426|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
32852427|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
32852428|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
32852429|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
32852430|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
32852431|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
32852432|NCT04380129|Experimental|Μusic therapy-conversation sessions|
32852433|NCT04380129|Active Comparator|Discussion sessions|
32852434|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
32852435|NCT04784221|Experimental|Radiation by protontherapy associated to nanoparticles injection|
32852436|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
32852437|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
32852438|NCT05249725|Experimental|Irsogladine Maleate|
32852439|NCT05249725|Placebo Comparator|Hydrotalcite|
33417239|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
33417240|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
32852440|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
32852441|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
33417241|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
33417242|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
33417243|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
33417244|NCT01733147|Placebo Comparator|Placebo|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive a placebo which looks exactly like the study drug, but contains no active ingredient, to be taken orally for six months.
32852442|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
32852443|NCT05241535|Experimental|Sequence 1 (starting with MT-7117 or Placebo)|"Treatment A or B (a single oral dose of MT-7117 or Placebo), Treatment C (a single oral dose of moxifloxacin), then Treatment A or B (a single oral dose of placebo or MT-7117)."
32852444|NCT05241535|Experimental|Sequence 2 (starting with MT-7117 or Placebo)|Treatment A or B (a single oral dose of placebo or MT-7117), Treatment A or B (a single oral dose of MT-7117 or Placebo), then Treatment C (a single oral dose of moxifloxacin).
32852445|NCT05241535|Experimental|Sequence 3 (starting sequence with Moxifloxacin)|Treatment C (A single oral dose of moxifloxacin), Treatment A or B (a single oral dose of placebo or MT-7117), then Treatment A or B (a single oral dose of MT-7117 or Placebo).
32852446|NCT01721811|Experimental|Healthy|Healthy study participanats
32852447|NCT01721811|Experimental|Diabetes|Patients with diabetes
32852448|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
32852449|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
32852450|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
32852451|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
32852452|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
32852453|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
32852454|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
32852455|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
32852456|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
32852457|NCT05240833|Experimental|VExUS-Guided Arm|VExUS results will be available for the treating physician. Patients will be treated according to current clinical practice. The use of diuretic and diuretic dosage will depend on treating physician's criteria.
32852458|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
32852459|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
32852460|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
32852461|NCT04116151|Experimental|Intervention group|Local administration of the Alantel (R) cream on the affected skin
32852462|NCT04116151|Placebo Comparator|Control group|Local administration of the Placebo cream on the affected skin
32852463|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
32852464|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
32852465|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
32852466|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
32852467|NCT00144924|Experimental|laparoscopic pyloromyotomy|
32852468|NCT00144924|Active Comparator|open pyloromyotomy|
32852469|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
32852470|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
33320368|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
32852471|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
32852472|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
32852473|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
32852474|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
32852475|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
32852476|NCT05243706|No Intervention|Control group|30 patients will receive Vincristine 1.5 mg/m2 (maximum: 2 mg) or Vinblastine 6 mg/m2 according to treatment protocol.
32852477|NCT05243706|Experimental|Loratadine group|30 patients will receive One tablet 10 mg orally once daily starting with vincristine or vinblastine administration for three cycles
32852478|NCT05243706|Experimental|diosmin 450mg / hesperidin 50 mg group|30 patients will receive 50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet orally twice daily starting with vincristine or vinblastine administration for three cycles
32852479|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
32852480|NCT04115293|Placebo Comparator|Placebo|
32852481|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
32852482|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
32852483|NCT05064930|Active Comparator|Bifidobacterium lactis|Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule
32852484|NCT05064930|Active Comparator|Bacillus coagulans|Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule
32852485|NCT05064930|Placebo Comparator|Maltodextrin|Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.
32852486|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
32852487|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
32852488|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
32852489|NCT05243316|Active Comparator|Patients with clamping of the chest tube|Patients with 6hour clamping prior to removal
32852490|NCT05243316|Sham Comparator|Patients without clamping of the chest tube|Patients will have chest tube removed immediately
33320369|NCT03776006||TPLA|
32852492|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
32852493|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
32852494|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
32852495|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
32852496|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
32852497|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
32852498|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
32852499|NCT01722357|Experimental|Pedometer + Exercise Counseling|
32852500|NCT01722357|Experimental|Pedometer|
32852501|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
32852502|NCT05243238|Active Comparator|Hesperidin group|
32852503|NCT05243238|Active Comparator|Diosmin|
32852504|NCT05243238|Active Comparator|Hesperidin and diosmin|
32852505|NCT05243238|No Intervention|control group|
32852506|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
32852507|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
32898825|NCT04780061|Experimental|Treatment|"Specific Product: Vitamin D3 50,000 IU~Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period~Specific Product: Vitamin K2/D~Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).~Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.~Specific Product: Vitamin C/Zinc~Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day."
33320370|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
33320371|NCT01320020|Experimental|catumaxomab|
32852508|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:~Parent-targeted BSweet2Babies video~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
32852509|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
32852510|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
32852511|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
32852512|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
32852513|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
32852514|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
32852515|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
32852516|NCT04104529|Experimental|Biological collection|"Biological collection~For all the patients include in the study :~samples of blood samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database~Ancillary study :~For metastatic thyroïd cancer and neuroendocrine tumor :~anapath blocks of the initial diagnosis will be archived dosimetric data will be collected for the cycle 1 blood sample additionnal will be realized at the cycle 1"
32852517|NCT05034198|No Intervention|Stakeholder Input|Behavioral health staff (BHS) will be asked to complete two semi-structured qualitative interviews and a set of surveys. The first interview will be about perceived barriers and facilitators on utilizing a remote training platform. The second interview will cover perceived feasibility and acceptability of the proposed training, consultation, and the implementation of evidence-based practices. The surveys will ask about the perceived acceptability, appropriateness, and feasibility of the remote training platform.
32852518|NCT05034198|No Intervention|Asynchronous Training Development|Mental health trainers with expertise in the treatment of externalizing and internalizing behavior disorders will video-record the training modules and produce them using lecture capture technology (i.e., showing speaker and Power Point slides on a split screen). Each training module will be approximately 45 minutes long.
32852519|NCT05034198|Experimental|Initial Mini-Tiral|BHS will be given a procedures manual with instructions on how to access the video-recorded training modules on-demand. All participants will take part in this mini-trial. Immediately after BHS watch the videos, they will be asked to complete three brief surveys regarding the appropriateness, feasibility and acceptability of each training module and provide comments about each.
32852520|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
32852521|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
32852522|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
32852523|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
32852524|NCT05240521|Other|ARM A: GA-AT0119 / Placebo|Cross-over Study
32852525|NCT05240521|Other|ARM B: Placebo / GA-AT0119|Cross-over Study
32852526|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
33320372|NCT00260429|Experimental|AA4500 0.58 mg|
33320373|NCT00260429|Placebo Comparator|placebo|
33320374|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
33320375|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
33320376|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
33320377|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
33320378|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
33320379|NCT05312762|Experimental|MaxioCel|Microfiber wound dressing
33320380|NCT05312762|Active Comparator|AquaCel Extra|Hydrofiber dressing
33320381|NCT00379288|Experimental|MF/F 200/10 mcg BID|
33320382|NCT00379288|Experimental|MF/F 400/10 mcg BID|
33320383|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
33320384|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
33320385|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
33320386|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
33320387|NCT00243503|Experimental|A|
33320388|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
33320389|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
33320390|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
33417245|NCT01733147|Active Comparator|Omega-3 polyunsaturated fatty acids|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive Omega-3 free fatty acids supplements to be taken orally for six months.
33320391|NCT04725136|Experimental|High-dose repeat administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 3 repeated subcutaneous injection at 4 week intervals
33417246|NCT02961881|Experimental|blinatumomab|
32852527|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
32852528|NCT05000502|Experimental|Home-based aerobic exercise training|home-based aerobic exercise condition will receive a fitness bracelet (with heart rate measurement capability) and weekly exercise counseling from an exercise trainer (i.e., exercise physiologist) by videoconference. The weekly counseling will be guided by the fitness bracelet data (both participant and exercise trainer will share the same log in information). The aerobic exercise progression will gradually increase duration and intensity of aerobic exercise with the goal of improving cardiorespiratory fitness.
32852529|NCT05000502|Active Comparator|Home-based standard attention flexibility/toning control|Home-based standard attention flexibility/toning control will receive light resistance bands, stretching/toning log book, and weekly videoconference counseling from an exercise trainer.
32852530|NCT05246293|Experimental|Tofacitinib Arm|Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.
32852531|NCT04378257|Experimental|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.~Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~Acknowledging emotions and normalizing current stress~Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~Behavioral Activation Acceptance and Commitment Therapy (ACT)~Grounding, Breathing, Acceptance of emotions, and de-fusion"
32852532|NCT04378257|Active Comparator|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
32852533|NCT05000190|Experimental|250 mg citicoline|Opaque capsule
32852534|NCT05000190|Placebo Comparator|0 mg citicoline|Opaque capsule matched in appearance to the active capsule
32852535|NCT05240053|Active Comparator|group (1)|Group 1: included 25 patients who were subjected to enhance recovery program after laparoscopic colorectal surgery .
32852536|NCT05240053|No Intervention|group (2)|Group 2: included 25 patients who were subjected to traditional way
32852537|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
32852538|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
32852539|NCT05248477|No Intervention|usual practice|
32852540|NCT05248477|Experimental|Premex protocol|a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children
32852541|NCT04984200||AB|
32852542|NCT04099381|Experimental|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
32852543|NCT04099381|Experimental|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
32852544|NCT04099381|Other|Group 3 Control|Patients with standard therapy as a control group.
32852545|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
32852546|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
32852547|NCT04435002|Experimental|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
32852548|NCT04435002|No Intervention|Control Group|
33320392|NCT04725136|Experimental|High-dose single administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
32898826|NCT04780061|Placebo Comparator|Control|"Specific Product: Vitamin D3 50,000 IU~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg~Specific Product: Vitamin K2/D~Placebo Equivalent: Medium chain triglyceride oil~Specific Product: Vitamin C/Zinc~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg"
32898827|NCT04644731||Pediatric patients who require fluid removal|Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care
33406627|NCT05194098|No Intervention|Baseline Evaluation (Major Depressive Disorder and Healthy Control Groups)|"HC and MDD participants will have visits for clinical assessment and a baseline EEG session to complete reward processing tasks (SLOT AND MID). The SLOT task is a 288-trial EEG task developed in our laboratory. Design features mimic structural characteristics common to real-word slot machines, including sound effects and visualizations, and the display consists of 3 sequentially populated slot reels. Participants initiate each trial via button press, after which timing of the slot reels is automated, such that reward outcome is independent of task performance.~The MID task is a 130-trial EEG task designed to model anticipatory and consummatory sub-stages of reward processing in the context of participants being rewarded based on their response times to a cued target detection task."
33406628|NCT05178654|Experimental|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
32960501|NCT05048628|Active Comparator|İce Pieces İmpregnated Group|Impregnation of pieces of ice was delivered to us; one ice cube is planned after wearing and movements automatically by the throat purchase to exit use and sound program, and move with one ice cube after movement. It can be used after extubation. It is in sound class with Visual Analogue Scale (VAS) for the use of customers before and after the application. Extubation is in the last 0. hours, no small application is made, only in sound class with VAS. Evaluated by Stout's Hoarseness Scale
32960502|NCT05048628|Active Comparator|Green Tea Gargle Solution Group|To the patients included in the gargle group with green tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of green tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0. th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.0
32960503|NCT05048628|Active Comparator|Arnica Montana Tea Gargle Solution Group|To the patients included in the gargle group with arnica montana tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of arnica montana tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.
33406629|NCT04108962|Experimental|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
33406630|NCT04015362|Experimental|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
33406631|NCT04015362|Sham Comparator|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
33406632|NCT05221710|No Intervention|Acupuncture Group|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling)"
33406633|NCT05221710|Experimental|Electroacupuncture Group|On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation
33406634|NCT05221710|No Intervention|Neuromuscular Electrical Stimulation Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points
33406635|NCT04002102|Experimental|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
33406636|NCT04002102|Other|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
33406637|NCT04002102|Active Comparator|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
33406638|NCT05657106|Experimental|Syringe Service Program Plus a Harm Reduction Kiosk Intervention|The intervention to be implemented in the intervention county involves enhancing its existing SSP model with a KyOSK. The intervention county SSP operates identically to the comparison county. As in the comparison county, a card reader will be installed in the intervention county SSP at the beginning of the study to provide objective data on visits and supply access. The KyOSK will resemble a vending machine. The KyOSK will include harm reduction, wound care, hygiene, and other supplies; offer overdose education and other content; a sharps container with a device to obtain data on syringe disposal; and an innovative call-back feature for care navigation by recovery coaches. While the KyOSK is operating, the intervention county will operate its traditional SSP 40 hours/week.
33406639|NCT05657106|No Intervention|Syringe Service Program|The comparison county SSP operates in the local health department and provides syringes, cookers/cottons, naloxone, wound care kits, condoms and lubricant, snacks, drinks, and sharps containers. A peer support specialist is present for consultation with clients upon request during SSP hours. The SSP will expand it hours from 3 hours/week to 40 hours/week at the same time the intervention county receives its KyOSK, to be comparable. SSP clients who enroll in the study will receive a swipe card linked to their SSP client identification. Card readers will be installed in the SSP for clients to swipe upon entry. Staff will provide clients with the same menu of supplies as those in the KyOSK and the same supply/time interval limits will be imposed. SSP clients will receive a resource guide.
32960504|NCT05048628|No Intervention|Control Group|Patients in the control group; sore throat and hoarseness scores at 0 hour immediately after extubation,to collect at 4, 6 and 8 hours after extubation, sore throat (Visual Analogue Scale) VAS; Stout s Voice if hoarseness It is evaluated with the Slightness Scale.
32960505|NCT05007990||Active|Participants include individuals who are caregivers of an individual with a chronic medical condition, OR individuals who support caregivers of an individual with a chronic medical condition.
32960506|NCT05007990||Bereaved|Participants include individuals who were caregivers of an individual with a chronic medical condition who has died, OR individuals who support the caregiver.
32960507|NCT04959396|Experimental|Treatment|IUB SEAD procedure
33320393|NCT04725136|Experimental|Low-dose repeat administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 3 repeated subcutaneous injection at 4 week intervals
33320394|NCT04725136|Experimental|Low-dose single administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
33320395|NCT04725136|Placebo Comparator|Placebo|Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals
32852552|NCT05064852||Surufatinib|Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
32852553|NCT05240287|Active Comparator|Study group -adults with pes planus|"Individuals between the ages of 20-45~Individuals with bilateral pes planus according to the Navicular Drop Test and Foot Posture Index"
32852554|NCT05240287|Other|Control group -adults without pes planus (normal foot)|"Individuals between the ages of 20-45~Individuals without pes planus according to the Navicular Drop Test and Foot Posture Index"
32852555|NCT04434690|Experimental|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
32852556|NCT04434690|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
32852557|NCT00912873|Active Comparator|0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
32852558|NCT00912873|Experimental|0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
32852559|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
32852560|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
32852561|NCT05059782|Active Comparator|Group A (drug treatment group)|Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
32852562|NCT05059782|Experimental|Group B (radiotherapy group)|IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
32852563|NCT05059782|Experimental|Group C (radiotherapy + drug group)|Drug therapy is the same as group A; IFRT is the same as group B.
32852564|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
32852565|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
32852566|NCT05242081|Experimental|S-ketamine|
32852567|NCT05242081|Active Comparator|Sufentanil|
32852568|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
32852569|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
32852570|NCT05244733|Experimental|Social Engage (S-ENGAGE)|S-ENGAGE is a skills-based psychotherapy that focuses on helping patients engage in meaningful rewarding social activities. Subjects will receive 10 one-hour individual sessions of S-ENGAGE over 10 weeks.
32852571|NCT05244733|Placebo Comparator|The Healthy Lifestyles Education Program|The healthy lifestyles education program consists of a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources. Study staff meet with participants once, individually, for 1 hour to review each section and answer questions participants might have.
32852572|NCT04080661|Experimental|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
32852573|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
32852574|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
32852575|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
33320396|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
33320397|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
33320398|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
33320399|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
33320400|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
33104186|NCT04207021|Placebo Comparator|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
33104187|NCT03457272|Experimental|New risk assessment|New risk assesment
33104188|NCT03457272|No Intervention|Standard|Standard risk assessment
33104189|NCT04970953||Patients with intermediate risk for HFpEF at rest|Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.
33104190|NCT05467683|Other|Open Exposure-Based Therapy (EBT)|All participants will receive a well-established psychological treatment.
33104191|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
33104192|NCT01255423|Placebo Comparator|Placebo|
33104193|NCT01255306||NO IOP|Patients without raised IOP
33104194|NCT01255306||RAISED IOP|Patients with raised IOP
33104195|NCT04006964||Identification Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
33104196|NCT04006964||Validation Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
33104197|NCT05463042|Experimental|Intermittent Hypoxia|Participants will receive intermittent hypoxia and perform balance and gait assessments before and after the intermittent hypoxia session.
33104198|NCT05463042|Sham Comparator|Normoxia (sham)|Participants will receive normoxia and perform balance and gait assessments before and after the normoxia session.
33104199|NCT01254721|Experimental|1|Seroquel XR tablet
33104200|NCT01254721|Active Comparator|2|Seroquel XR + lithium
33104201|NCT04005053|Experimental|Low-Dose NAC|3600 NAC mg/day
33104202|NCT04005053|Experimental|High-Dose NAC|5400 NAC mg/day
33104203|NCT04005053|Placebo Comparator|Placebo|Placebo
33406640|NCT04989582|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
32852576|NCT05059548||Male Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
32852577|NCT05059548||Female Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
32852578|NCT04409210|Experimental|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
32852579|NCT04409210|Other|Control Group|The control group just receive routine treatment and routine management.
32852580|NCT03098316||POAG|Primary open angle glaucoma patients
32852581|NCT03098316||NTG|Normal/Low tension glaucoma patients
32852582|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
32852583|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
32852584|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
32852585|NCT05059392|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly sessions, each 90 minutes, up to 14 participants/group. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
32852586|NCT03149029|Experimental|BRAFV600 mutant|"Pembrolizumab administered intravenously every three weeks~Dabrafenib taken every twelve hours orally~Trametinib taken every twelve hours orally"
32852587|NCT03149029|Experimental|BRAFV600 wild type|"Pembrolizumab administered intravenously every three weeks~Trametinib taken every twelve hours orally"
32852588|NCT05064228|Experimental|m-ReACT app condition|Participants will download the m-ReACT app on their mobile phones and will be asked to engage with the app for a period of 12 weeks.
32852589|NCT05064228|Active Comparator|Brief Advice|Participants will be given a one time brief informational session on the importance of engaging in substance-free activity while in AUD treatment.
32852590|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
32852591|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
32852592|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
32852593|NCT04078555|Experimental|ENERGI-F703 GEL|topical application on target venous leg ulcer, twice daily
32852594|NCT04078555|Placebo Comparator|ENERGI-F703 GEL matched vehicle|topical application on target venous leg ulcer, twice daily
32852595|NCT05064072|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
33104204|NCT04519671|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
33104205|NCT04519671|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)
33406641|NCT04989582|No Intervention|No intervention|Nurses randomly assigned by applying a random selection method
32960508|NCT04923126|Experimental|Phase I: Recurrent and/or progressive low-grade glioma without prior exposure to MEK inhibitors|Participants will receive mirdametinib at one of the dose levels twice daily days 1-28. For the first cycle of treatment, participants will take mirdametinib tablets dissolved in water. After the first cycle of treatment, participants may receive the medicine the same way (dissolved in water) or may receive capsules. Treatment repeats every 28 days for up to 26 cycles of treatment (24 months) in the absence of disease progression or unacceptable toxicity.
33320401|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
32960509|NCT04923126|Experimental|Phase 2, Cohort 1: Newly diagnosed and/or previously untreated (except surgery)|Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
32960510|NCT04923126|Experimental|Phase 2, Cohort 2: Recurrent and/or Progressive without prior exposure to MEK inhibitors|Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
32960511|NCT04923126|Experimental|Phase 2, Cohort 3a:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants with previous exposure to mirdametinib may receive a starting dose lower than the RP2D, depending on the dose they tolerated during their previous exposure. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
32960512|NCT04923126|Experimental|Phase 2, Cohort 3b:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
32960513|NCT04910724|Experimental|20% Energy Deficit|Energy Deficit equal to 20% total daily energy requirements.
32960514|NCT04910724|Experimental|40% Energy Deficit|Energy Deficit equal to 40% total daily energy requirements.
32960515|NCT04910724|Experimental|60% Energy Deficit|Energy Deficit equal to 60% total daily energy requirements.
32960516|NCT04896762||Extrapulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with extrapulmonary system affection
32960517|NCT04896762||pulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with pulmonary disease
32960518|NCT04799418|Experimental|Experimental Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
33320402|NCT00239837|Experimental|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
32960519|NCT04780932|Placebo Comparator|Control Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Placebo 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
32960520|NCT04780932|Experimental|Experimental Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Macitentan 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
32960521|NCT04780776|Experimental|UVB treatment arm|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 16-week study where they will be exposed to their individualized titration evaluation.
32960522|NCT04780776|Sham Comparator|Sham comparator arm|The sham comparator group will undergo the procedures as the treatment group with the exception that the Solius Photobiological System will only be turned on to emit visible radiation.
32960523|NCT04627038|Experimental|LY3556050|LY3556050 given orally
32960524|NCT04627038|Placebo Comparator|Placebo|Placebo given orally
32960525|NCT04507074|Experimental|Patients With Obesity|40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.
32960526|NCT04507074|Active Comparator|Normal-Weight Patients|20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.
32960527|NCT04480008|Experimental|Resilient Living Program|All participants will be in the Resilient Living Program arm. Study participation involves participating in a 12-week stress management and resilience training program. This will involve four virtual sessions (video or phone) and answering questions about their health, well-being, and quality of life. There will also be online modules to watch and an accompanying journal (with prompts) to keep.
32960528|NCT04460430|Experimental|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
32960529|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
32960530|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
32960531|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
33033071|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
33320403|NCT00239837|No Intervention|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
33320404|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
32852596|NCT05064072|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube
32852597|NCT05064072|Active Comparator|Silk plaster|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube
32852598|NCT04075435|Other|All subjects|This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.
32852599|NCT05063838|Experimental|Pharmacogenomic group|The perioperative (anesthetic and postoperative pain management) plan for each patient will be determined preoperatively by the treating anesthesia team. Thereafter, the pharmacogenomic results of the patient will be released and a personalised anesthetic plan formulated based on international pharmacogenomic guidelines. The treating anesthesia team will then modify the perioperative care plan based on the patients' pharmacogenomic results and the international pharmacogenomic guidelines.
32852600|NCT05063838|No Intervention|Control group|Perioperative care will be managed according to current 'standard care' practice at Peter MacCallum Cancer Centre.
32852601|NCT04276129|Experimental|post-surgical CHX mouth-rinses (treatment group - CHX)|periodontal surgery + post-surgical CHX mouth-rinses + buccal attached gingival (G) biopsies 24 hr after surgical procedure
32852602|NCT04276129|Other|NO post-surgical mouth-rinses treatment (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
32852603|NCT05063760|Experimental|TGCT patients - exercise|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
32852604|NCT05063760|No Intervention|TGCT patients - nonexercising controls|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
32852605|NCT05247853||Group 1|HPV-vaccinated women living with HIV
32852606|NCT05247853||Group 2|HPV-unvaccinated women living with HIV
32852607|NCT05247853||Group 3|HIV[-] women who are HPV-vaccinated
32852608|NCT05063682|Experimental|Treatment|Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells.
32852609|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
32852610|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
32852611|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
32852612|NCT05063526||Group B|"40 patients who are mechanically ventilated due to pulmonary disease at respiratory ICU had their diagnosis as follows: 21 (53%) had COPD, 8 (20%) had asthma, 5 (13%) had bronchiectasis, 5 (13%) had pneumonia and~1 (3%) had viral influenza H1N1. Out of group B patients, 11 patients (13.75%) had failed weaning, of which 6 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 3 patients were re-intubated and 2 patients died."
32852613|NCT05063526||Group A|40 patients on mechanical ventilation due to non-pulmonary disease at respiratory ICU had their diagnosis as follows: 24 (60%) had congestive heart failure, 4 (10%) had diabetes mellitus, 4 (10%) had sepsis other than pneumonia, 2 (5%) had epilepsy, 2 (5%) had embolic hemiplegia, and 4 (10%) had chronic renal failure. Out of group A patient, 9 patients (11.25%) had failed weaning of which 4 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 2 patients were reintubated and 3 patients died.
32852614|NCT05063526||control group.|40 patients Chronic obstructive pulmonary disease (COPD) from Outpatient Clinic
32852615|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)~1 arm for all patients"
32852616|NCT05063058|Experimental|Molecular guided therapy|
32852617|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
32852618|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
32852619|NCT05063292|No Intervention|Control group|Patients covered with a 41 centigrade degrees double layered cotton cloth
32852620|NCT05063292|Experimental|Prewarmed group|Patients receive active prewarming with an air forced blanket ( full body blanket) 30 minutes prior to the operation
32852621|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
32852622|NCT02390011||MRI|Day 1
32852623|NCT05063214||Ultrasound assessment|Muscle ultrasound evaluation
32852624|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
32852625|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
32852626|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
32852627|NCT01929421|Experimental|Gemcitabine/ s-1|
32852628|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
32852629|NCT04474002|Active Comparator|4L Klean Prep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl and aspartame 0.0494g
32852630|NCT04474002|Experimental|1L Klean prep® and 2 sachets Picoprep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl, aspartame 0.0494g, sodium picosulfate 0.01g, magnesium oxide 3.5g, citric acid 12.0g
33033072|NCT01958996|Experimental|idarubicin|
32852631|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.~For CapeOx regimen:~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.~For mFolfox6 regimen:~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
32852632|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
32852633|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
32852634|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
32852635|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
32852636|NCT03744936|Experimental|DA4Afib|Developing a tool to use during the encounter
32852637|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
32852638|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
32852639|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
32852640|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
32852641|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
32852642|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
32852643|NCT01929655|Experimental|Radium-223 dichloride|
32852644|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
32852645|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
32852646|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
32852647|NCT01834677||Healthy Human|
32852648|NCT01834677||Depressed Human|
33104206|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
32852649|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
32852650|NCT01834677||Human Diagnosed with Parkinson's Disease|
32852651|NCT01922557||NICOM|
32852652|NCT04506931|Experimental|Short Message Service (SMS) survey|Participants will receive an SMS survey
32852653|NCT04506931|Experimental|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
32852654|NCT04506931|Experimental|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
32852655|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
32852656|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
32852657|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
32852658|NCT02398825|Experimental|Ponatinib|
32852659|NCT02640612|Experimental|BI 695501|
32852660|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
32852661|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
32898828|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
32898829|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
32898830|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
32898831|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
33104207|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
33104208|NCT04896385|Experimental|Ruxolitinib cream|Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
32852662|NCT04379193|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
33406642|NCT05221632|Experimental|accelerated continue theta-burst stimulation|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first rTMS session and after the last rTMS session.
32852663|NCT04379193|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
32852664|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
32852665|NCT04379349|Experimental|Active SMS|Weekly interactive SMS text messaging check-ins.
32852666|NCT04379349|Sham Comparator|Sham SMS|Weekly minimally interactive SMS text messages.
32852667|NCT05062512||Participants living with and without neurodegenerative diseases|No intervention
32852668|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
33406643|NCT05221632|Active Comparator|1-HZ repetition transcranial magnetic stimulation Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 80% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
33406644|NCT04928040|Experimental|Fluid challenge|Fluid challenge effects on optic nerve sheath diameter
32852669|NCT04379271|Experimental|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
32852670|NCT04379271|Placebo Comparator|Placebo|twice-daily (BID) oral placebo (+ SoC)
32852675|NCT05058534||Very preterm infants born between November 30, 2018 and November 30, 2019|Infants born between November 30, 2018 - November 30, 2019, before implementation of the new multiperfusion neonatal system
32852676|NCT05058534||Very preterm infants born between December 1st, 2019 and December 31st, 2022|Infants born between January 1rst, 2019 - December 31st, 2022, after implementation of the new multiperfusion neonatal system
32852677|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
32852678|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
32852679|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
32852680|NCT03659604|Experimental|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
32852681|NCT03659604|Active Comparator|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
32852682|NCT03659604|Other|Passive control|School classes will not receive any intervention, thus no game.
32852683|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
32852684|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
32852685|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
32852686|NCT05058066|Active Comparator|Control implant loaded at 6 weeks post-surgery|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
32852687|NCT05058066|Experimental|Test implant loaded at 6 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
32852688|NCT05058066|Experimental|Test implant loaded at 3 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
32852689|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
32852690|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
32852691|NCT01723215|No Intervention|Control|Control: will not receive any intervention
32852692|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
32852693|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
32852694|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
32852695|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
32852696|NCT05061732|Experimental|RBCL|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
32852697|NCT05061732|Experimental|RBLM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
32852698|NCT05061732|Experimental|RBCM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
32852699|NCT05061732|Experimental|RA|Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
32852700|NCT05061732|Experimental|RAB|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
32852701|NCT05061732|Experimental|RAM|Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
32852702|NCT05061732|Experimental|RBAM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
32852703|NCT05061732|Experimental|RBAM4|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
32852704|NCT05061732|Experimental|RBDM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
32852705|NCT05061732|Active Comparator|RBTM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
32852706|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
32852707|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
32852708|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
32852709|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
32852710|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
32852711|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
32852712|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
32852713|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
32852714|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
32852715|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
32852716|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
32852717|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
32852718|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
32852719|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
32852720|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
32852721|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
32852722|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
32852723|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
32852724|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
32852725|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
32852726|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
32852727|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
32852728|NCT00639769|Experimental|Therapeutic Intervention|
32852729|NCT05061342||Cancer Patients|Those with cancer.
32852730|NCT05061342||Normal (non cancer) controls|Those without cancer.
32852731|NCT01723293|No Intervention|Control|Sedentary pregnant women
32852732|NCT01723293|Experimental|Exercise group|
32852733|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
32852734|NCT01729065|No Intervention|Home Program|Participants perform home program only.
32898832|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
32852735|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
32852736|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
32852737|NCT05061264|Experimental|Active infection group|A cohort of 38 patients carrying an active infection (mesh sinus, exposed mesh or enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with PVDF mesh.
32852738|NCT05061264|Active Comparator|Clean control group|A cohort of 38 patients with ventral hernias, and submitted to clean ventral hernia repair with PVDF mesh.
32852739|NCT01723371|Experimental|Carvedilol|
32852740|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
32852741|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
32852742|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
32852743|NCT05057598|Experimental|Intervention group on diet and lifestyles|The arm consists to provide survivors with evidence-based recommendations and to promote improved nutrition and physical activity through videos and lectures available on the website (theoretical lectures on preventive strategies, and practical videos on cooking techniques and specific physical exercises).
32852744|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
32852745|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
32852746|NCT05057286|Experimental|Subjects with gummy smile|The study procedure consisted of recruitment, pre&post-operative photography, gingivoplasty, BTX-A injection, recall visits, and data collecting.
32852747|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
32852748|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
32852749|NCT05060796|Experimental|EGFR CAR-T|Group: 3 dose levels
32852750|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
32852751|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
32852752|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
32852753|NCT01922947|Sham Comparator|Health Counseling|
32852754|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
32852755|NCT03100266|Placebo Comparator|placebo|Inactive capsules
32852756|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
32852757|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
32852758|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
32852759|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
32852760|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
32852761|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
32852762|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
32852763|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
32852764|NCT05060952||PJI|Patients with septic arthroplasty failure
32852765|NCT05060952||Aseptic|Patients with aseptic causes of arthroplasty failure
32852766|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
32852767|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
32852768|NCT05057208||Vaccinated|COVID Vaccinated
32852769|NCT05057208||Non-vaccinated|COVID Non-vaccinated
32852770|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
33406645|NCT04916730|Placebo Comparator|Standard of Care (SOC)|Participants will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
33406646|NCT04916730|Experimental|TRE + SOC|Participants in this arm will receive standard of care nutritional behavioral counseling and will implement a daily, self-selected, 10-hour window within which they must consume all calories. They will also be required to log their caloric intake through the use of a smartphone app
33320405|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
33320406|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
33320407|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
33320408|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
33320409|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
33320410|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
33406647|NCT04907292||Planned Cesarean delivery|Patients who have an elective Cesarean delivery at Mount Sinai Hospital
32852771|NCT00639223|Active Comparator|Pravastatin|
32852772|NCT00639223|Experimental|Red yeast Rice|
32852773|NCT04434534|Experimental|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
32852774|NCT04434534|Active Comparator|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
32852775|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
32852776|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
32852777|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
32852778|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
32852779|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
32852780|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
32852781|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
32852782|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
32852783|NCT05056662||Group 1|Patients with negative invasive functional evaluation
32852784|NCT05056662||Group 2|Patients with positive invasive functional evaluation undergoing PCI
32852785|NCT05056662||Group 3|Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
32852786|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
33320411|NCT01320098|Experimental|Home-Based Parenting Program|
33320412|NCT01320098|Experimental|Clinic-Based Parenting Program|
33320413|NCT01320098|Other|Wait-List Control Group|
33320414|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
33320415|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
33320416|NCT01335490|No Intervention|Control|
33320417|NCT05668988|Experimental|DZD9008|
33320418|NCT05668988|Active Comparator|Platinum-based Chemotherapy|
33320419|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
33320420|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
33320421|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
33320422|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
33320423|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
33320424|NCT01335646|Active Comparator|Surgery|
33320425|NCT01335646|Active Comparator|Non-operative|
33320426|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
33320427|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
33320428|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
33320429|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
33320430|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
33406648|NCT04907292||Unplanned Cesarean delivery|Patients who have an unplanned Cesarean delivery at Mount Sinai Hospital
32852787|NCT05056740||MS|Patients with a definite MS diagnosis according to the 2017 McDonald criteria
32852788|NCT05056740||Red-flag MS|Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS
32852789|NCT05056740||Other CNS autoimmune diseases|Patients with a definite diagnostic of CNS autoimmune disease that is not MS
32852790|NCT05056740||Controls|Patients with a definite diagnostic of non-inflammatory CNS disorder
32852791|NCT05056896|Experimental|Low Dose Aspirin|Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.
32852792|NCT05056896|Experimental|Placebo|Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.
32852793|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
32852794|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
32852795|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
32852796|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
32852797|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
32852798|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
32852799|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
32852800|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
32852801|NCT05056194|Experimental|Valiloxybate|XW10172 Modified Release (MR) Granules for Oral Suspension
32852802|NCT05056194|Placebo Comparator|Placebo|Placebo Granules for Oral Suspension
32852803|NCT01923025|Experimental|RO5545965|
32852804|NCT01835613|Other|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
32852805|NCT05056038|Active Comparator|Lateral Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
32852806|NCT05056038|Active Comparator|Posterior Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
32852807|NCT04661761|Experimental|stimulated salivary flow rate|stimulated salivary flow rate determined in a crossover design: first using Paraffin Pellets from Aurosan GmbH; thereafter using Chewing wax from the Saliva-Check Buffer from GC Europe
32852808|NCT04379037|Experimental|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
32852809|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
32852810|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
32852811|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
32852812|NCT05060406|Experimental|LY06006 60mg|"injection~Interventions:~Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
32852813|NCT05060406|Placebo Comparator|Placebo|"injection~Interventions:~Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
32852814|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
32852815|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
32852816|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
32852817|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
32852818|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
32852819|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
32852820|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
32852821|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
32852822|NCT05055804|Experimental|ELG Device Comparison to Whole Blood Testing|Participant will place thumb in the ELG device for scan. Scan generally takes between 1-2 minutes. ELG then displays a readout of both a glucose and A1C reading on the screen of the ELG device.
33406649|NCT05221476||polytraumatized patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
33406650|NCT05643534|Experimental|Tenpanor 50 mg BID|Patients will be randomized to receive 50 mg tenapanor twice daily
33406651|NCT05643534|Experimental|Tenpanor 25 mg BID|Patients will be randomized to receive 25 mg tenapanor twice daily
32960532|NCT04410042|Experimental|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
32960533|NCT04410042|Placebo Comparator|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
32960534|NCT04316910||Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
32960535|NCT04316910||Non-Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
32960536|NCT04308330|Experimental|Vorinostat|"The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT.~Cycle 1~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~Temozolomide: 125 mg/m2/day PO Days 1-5.~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~Cycles 2-12~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~Temozolomide: 125 mg/m2/day PO Days 1-5.~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~Vorinostat: Dose per escalation schema daily Days 1-5.~Vorinostat will not be administered during Cycle 1."
32960537|NCT04241796|Experimental|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:~Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.~Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
32960538|NCT04191876|Experimental|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
32960539|NCT04150458|Experimental|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
32960540|NCT04104594|Experimental|patients with chronic rhinosinusitis with nasal polyps|
32960541|NCT04104594|Other|Patients with an indication for septoplasty = control group|
32960542|NCT03952416|No Intervention|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
32960543|NCT03952416|Experimental|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
32960544|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
32960545|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
32960546|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
32960547|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
32960548|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
32960549|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
33104209|NCT04896385|Placebo Comparator|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
33406652|NCT05643534|Placebo Comparator|Placebo Comparator|Patients will be randomized to receive matching placebo twice daily
33406653|NCT04865796|Experimental|Group 1|Patients will use products based on lactoferrin.
32852823|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
32852824|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
32852825|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
32852826|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
32852827|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
32852828|NCT01724073|No Intervention|no test food|control group receiving no test food
32852829|NCT05055882||children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
32852830|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
32852831|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
32852832|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
32852833|NCT04378803|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
32852834|NCT04378803|Experimental|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
32852835|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
32852836|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
32852837|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
32852838|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
32852839|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
32852840|NCT05046678||Control|Periodontally healthy, non-smoking
32852841|NCT05046678||Smokers with periodontally healthy|Periodontally healthy, smoking
32852842|NCT05046678||Non-smokers with gingivitis|Gingivitis, non-smoking
32852843|NCT05046678||Smokers with gingivitis|Gingivitis, smoking
32852844|NCT05046678||Non-smokers with periodontitis|Periodontitis, non-smoking
32852845|NCT05046678||Smokers with periodontitis|Periodontitis, smoking
32852846|NCT00637273|Experimental|1|
32852847|NCT00637273|Active Comparator|2|
32852848|NCT00637273|Active Comparator|3|
32852849|NCT04378725|No Intervention|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
32852850|NCT04378725|Experimental|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
32852851|NCT01724151||Healthy adults|Healthy adults, over 45 years old
32852852|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
32852853|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
32852854|NCT05036382||Experimental Group|A group that receives an incentive message one month after the start of the experiment
32852855|NCT05036382||Control Group|A group that does not receive an incentive message (for equity, incentive messages will be sent in the last month of the experiment)
32852856|NCT01835847|Experimental|A single-arm study|
32852857|NCT05046210|Experimental|LHA group (EG)|"Behavioral: LHA intervention~Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day, whereas the participants in the EG also received 4 lessons from a LHA over 4 weeks."
32852858|NCT05046210|Placebo Comparator|Leaflet group (CG)|"Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.~The participants in the CG received oral exercise intervention and leaflets only."
32852859|NCT01835925||Tissue specmien|
33406654|NCT04865796|Experimental|Probiotics|Patients will use products based on probiotics for home oral care.
33406655|NCT04865796|Active Comparator|Standard therapy|Patients will use standard toothpastes for home oral care.
32960550|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
32960551|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
32960552|NCT03680508|Experimental|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32960553|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
32960554|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
32960555|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
32960556|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
33406656|NCT05221242|Experimental|Patients with PLV|All patients will receive ceramic partial laminate veneers as treatment. As this is a split mouth design, one side of the mouth will receive partial laminate veneers bonded with a conventional light-curing resin cement and the other side of the mouth with a pre-heated resin composite.
33406657|NCT04811118|Experimental|Albumin-bound docetaxel|Subjects will receive albumin-bound docetaxel via intravenous infusion (IV) once every three weeks (a cycle), at the dose of 75mg/m2
32960557|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
32960558|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
32960559|NCT03406338|Active Comparator|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
32960560|NCT03406338|Experimental|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
33406658|NCT04811118|Experimental|Taxotere|Subjects will receive Taxotere via intravenous infusion once every three weeks (a cycle), at the dose of 75mg/m2.
32960562|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
32960563|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
32960564|NCT03129126|Experimental|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
32960565|NCT03129126|Experimental|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
32960566|NCT03129126|Experimental|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
32960567|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
32960568|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
32960569|NCT03015402|Experimental|Sodium Nitrite|
32960570|NCT03015402|Placebo Comparator|Placebo|
33104210|NCT04003805|Experimental|Switching from Smoking Cigarettes to SREC|
33406659|NCT04795674|Experimental|ADHD EWM|Participants will receive EWM training sessions.
33406660|NCT04795674|Placebo Comparator|ADHD Placebo|Participants will receive placebo training sessions.
33406661|NCT05642442|Placebo Comparator|Placebo|Participants who will receive a matching placebo during the Dose Titration, Optimization Period, and Maintenance Period.
33406662|NCT05642442|Experimental|Sulvecaltamide|Participants who will receive an optimal dose of suvecaltamide during the Dose Titration, Optimization Period, and Maintenance Period.
33406663|NCT04979988||Japanese patients with ALK+ NSCLC who received lorlatinib|lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy
33406664|NCT05221164|Experimental|Intervention with 162 mg aspirin|Aspirin 162 mg daily for prevention of preeclampsia in pregnant patients at Family Medicine Clinic
33406665|NCT04647084|Experimental|Intradermal Lidocaine 2%|
33406666|NCT04647084|Experimental|Buzzy|
33406667|NCT05221008|Experimental|group A|Experimental: SHR6508 Placebo Comparator: normal saline
33406668|NCT05221008|Experimental|group B|Experimental: SHR6508 Placebo Comparator: normal saline
33406669|NCT05221008|Experimental|group C|Experimental: SHR6508 Placebo Comparator: normal saline
33406670|NCT05221008|Experimental|group D|Experimental: SHR6508 Placebo Comparator: normal saline
33406671|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
32960571|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
32960572|NCT01531374|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
33406672|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
32960573|NCT01531374|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
32960574|NCT01531374|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
32960575|NCT01240902|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
32960576|NCT01240902|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
32960577|NCT01240902|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
32960578|NCT01240902|Active Comparator|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
32960579|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
32960580|NCT01037790|Experimental|Arm 1 - Metastatic breast cancer|"Metastatic breast cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
32960581|NCT01037790|Experimental|Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation|"Metastatic colorectal cancer that harbors the Kras or BRAF mutation~PD-0332991 Given orally, 125 mg QD on a 21-day"
32960582|NCT01037790|Experimental|Arm 3 - Advanced or metastatic esophageal and/or gastric cancer|"Advanced or metastatic esophageal and/or gastric cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
32960583|NCT01037790|Experimental|Arm 4 - Cisplatin-refractory, unresectable germ cell tumors|"Cisplatin-refractory, unresectable germ cell tumors~PD-0332991 Given orally, 125 mg QD on a 21-day"
32960584|NCT01037790|Experimental|Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations|"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.~PD-0332991 Given orally, 125 mg QD on a 21-day"
32960585|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
32960586|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
32960587|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
32960588|NCT01040052|Experimental|Study Group|
32960589|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
32960590|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
32960591|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
32960592|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
32960593|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
32960594|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
32960595|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
32960596|NCT01044030|Experimental|Xylitol syrup|
32960597|NCT01044030|Placebo Comparator|Placebo|
32960598|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
32960599|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
32960600|NCT01044264|Placebo Comparator|Placebo|
32960601|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
33033442|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
33104211|NCT04003805|Experimental|Switching from Smoking Cigarettes to Nicotine Mini-Lozenge|
33104212|NCT04003805|No Intervention|Usual Brand Cigarettes|
33406673|NCT04620798|Experimental|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
33406674|NCT04620798|No Intervention|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
32852862|NCT01726569|Experimental|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session and follow up counseling after operation 1 week and 6 weeks
32852863|NCT01726569|Other|traditional counseling|Subjects will be participate or not participate in pre-operative counseling and/or post-operative counseling with a rural hospital's doctor/nurse.
32852864|NCT05045742||Training|A subset of patients that are used to train the machine learning algorithm.
32852865|NCT05045742||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
32852866|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
32852867|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
32852868|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
32852869|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
32852870|NCT05055414|Experimental|UI030|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
32852871|NCT05055414|Placebo Comparator|Placebo|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
32852872|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32852873|NCT01836081|Experimental|fluid responsiveness|
32852874|NCT05055492|No Intervention|Control period|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
32852875|NCT05055492|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
32852876|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
32852877|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
32852878|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
32852879|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
32852880|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
32852881|NCT01720563|Placebo Comparator|Control|Placebo
32852882|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
32852883|NCT05036694|Other|Ambulatory HIV positive patients|Ambulatory HIV positive patients with signs and symptoms of TB, and Ambulatory HIV positive patients with advanced disease and CD4 less than 200 cell.
32852884|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
32852885|NCT05036460|Active Comparator|Ultrasonography + direct visualization|To detect using ultrasonography assisted direct visualization.
32852886|NCT05036460|Experimental|Direct visualization|To detect using direct visualization.
32852887|NCT05055180||HFpEF with pulmonary hypertension|Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines
32852888|NCT05055180||HFpEF without pulmonary hypertension|Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines
32852889|NCT05055180||Patients without HFpEF|Patients without invasive evidence of HFpEF
32852890|NCT04377789|No Intervention|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
32852891|NCT04377789|Active Comparator|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
32852892|NCT04377789|Active Comparator|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
32852893|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
32852894|NCT01728753|Placebo Comparator|Placebo|Placebo
32852895|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
32852896|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
32852897|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
32852898|NCT05055102||Patient with WOVEX bifurcated prosthesis|"Patients who have undergone open abdominal aortic surgery between January 1st, 2013 and December 31, 2017 in Burgundy Dijon Hospital.~Patients who have been treated with a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses)"
32852899|NCT03130777|Experimental|TPVR - Main Cohort|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
32852900|NCT03130777|Experimental|TPVR - PDS Registry|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
33104213|NCT05575258|Active Comparator|Sequence 1: Agro (Green) - Conventional (Yellow)|"First, the agro-ecological sourced diet will be consumed.~Secondly, the conventional sourced diet will be consumed."
33406675|NCT05639556||Cohort 1|Forced expiratory volume in 1 second (FEV1) <60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation). If no stable spirometry data are available in the 12 months prior to enrollment, from the prior 24 months will be used.
32852901|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
32852902|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
32852903|NCT05045508|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|
32852904|NCT05045508|Placebo Comparator|Placebo (vehicle) nasal spray|
32852905|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
32852906|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
32852907|NCT05035914|Experimental|Experimental: anlotinib+mXELIRI|"Dose-escalation phase:~A: anlotinib 8 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~B: anlotinib 10 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~C: anlotinib 12 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~Dose-expansion phase:~anlotinib RP2D, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;"
32852908|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
32852909|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
32852910|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
32852911|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
32852912|NCT04379895|Active Comparator|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
32852913|NCT04379895|Active Comparator|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
32852914|NCT05054634||Experimental Group (EG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
32852915|NCT05054634||Control Group (CG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
32852916|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
32852917|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
32852918|NCT05045274|Active Comparator|dapagliflozin|(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month
32852919|NCT05045274|Placebo Comparator|conventional therapy|"Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
32852920|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
32852921|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
32852922|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
32852923|NCT05045352|Active Comparator|Echogenic needle|venous access performed under ultrasound guidance with echogenic needles
32852924|NCT05045352|No Intervention|Non-Echogenic needles|venous access performed under ultrasound guidance with non-echogenic needles
32852925|NCT00915759|Active Comparator|ProKera|
32852926|NCT00915759|Placebo Comparator|Bandage contact lens|
32852927|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
32852928|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
32852929|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
32852930|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
32852931|NCT05045118|Experimental|Intervention arm|Single-arm prospective, multiple assessment intervention study. Participants will receive a digital structured patient education material
32852932|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
32852933|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
32852934|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
32852935|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
32852936|NCT01724775||CME surgery for colon cancer|
32852937|NCT01724775||non-CME surgery for colon cancer|
32852938|NCT01836315||Obese|Defined by a BMI >35 kg/M2
32852939|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
32852940|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
32852941|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
32852942|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
33104214|NCT05575258|Active Comparator|Sequence 2: Conventional (Yellow) - Agro (Green)|"First, the conventional sourced diet will be consumed.~Secondly, the agro-ecological sourced diet will be consumed."
32852943|NCT05044728|Experimental|Neoadjuvant Chemotherapy Immunotherapy stage|Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
32852944|NCT05054478|Experimental|Experimental Arm|"4 days of dexamethasone. According to local practice, one dose of doxorubicine (30 mg/m2 IV) or cyclophosphamide (750 mg/m2 IV) may also be added~Induction Treatment (4 months): Subject will receive 4 x 28 days cycles of Dara-VRD induction:~Daratumumab sc 1800 mg on D1 D8 D15 D22 for cycle1 & 2 and D1 D15 for cycle 3 & 4 Bortezomib sc 1.3 mg/m2 on D1 D4 D8 D11 for each cycle Lenalidomide po 25 mg on D1 to D21 for each cycle Dexamethasone po 20 mg on D1 D2 D8 D9 D15 D16 D22 D23 for each cycle~High dose melphalan 200mg/m2 as conditioning therapy and first ASCT~First consolidation : 2 cycles of Dara-VRd~Daratumumab 1800 mg s.c D1 D15~Bortezomib 1.3 mg/m2 s.c D1 D8 D15 D22~Lenalidomide 25 mg p.o from D1 to D21~Dexa 20 mg p.o D1 D8 D15 D22~High dose melphalan 200mg/m2 as conditioning therapy and second ASCT Second consolidation : 6 cycles of Dara-VRd (every 2 months for 2 years) Then maintenance: Lenalidomide every 28 days (25 mg from D1 to D21) for 1 year"
32852945|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
32852946|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
33104215|NCT05454852||Participants|Adult patients within 6 months of ART initiation or re-initiation
33104216|NCT04862533|Experimental|Beta-alanine + PFMT|Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
33104217|NCT04862533|Experimental|Placebo + PFMT|Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
33104218|NCT05570656|Active Comparator|AS patients|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
33104219|NCT05570656|Active Comparator|healthy volunteers|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
33104220|NCT04853095|Experimental|Intervention group (PerFix)|Peritoneal fixation technique
32852947|NCT04314648|Active Comparator|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
32852948|NCT04314648|No Intervention|Usual Care|Usual care for people with alcohol or opioid use disorder.
33104221|NCT04853095|Active Comparator|Control group (no PerFix)|Standard of care (i.e. no fixation)
33104222|NCT04001777|Experimental|APG-1252 plus Osimertinib (AZD9291)|APG-1252 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase; Dose of osimertinib will be fixed at 80mg QD based on approved label.
33104223|NCT04842604|Experimental|Participants from B1371019 and B1371012|"Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.~The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.~Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study."
33320431|NCT05513534|Experimental|Standard Hatha Yoga|A yoga program adapted for those with PD will be used in the current study. It will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. The program will be based on principles of Hatha yoga which incorporate longer holds and deep breathing. Each session will include a warm-up, three yoga flows, a balance training section, and a cooldown phase. The first four weeks will emphasize proper alignment, breathing, and technique. Additionally, the classes will be led by a certified yoga instructor and include multiple on-site assistants to ensure a safe training environment. Participants will also be provided with assistive devices (i.e. chairs, yoga blocks, and blankets) if they are required.
32852949|NCT01724853|Other|Surgery|Preferred surgery
32852950|NCT01724853|Other|Conservative|Conservative treatment
32852951|NCT04472364|Experimental|HemoPill|All participants will receive the blood detection capsule HemoPill Acute ®.
32852952|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
32852953|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
32852954|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
32852955|NCT05035446|Experimental|single-incision plus one-port laparoscopic surgery(SILS + 1)|It requires an auxiliary small incision and one more port to perform laparoscopic gastrectomy
32852956|NCT05035446|Other|conventional laparoscopic surgery(CLS)|It requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy
32852957|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
32852958|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
32852959|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
32852960|NCT05044494||study group|non-prompt surgery after acute type a aortic dissection occurred
32852961|NCT05044494||control group|prompt surgery after acute type a aortic dissection occurred
32852962|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
32852963|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
32852964|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
32852965|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
32852966|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
32852967|NCT05035758|No Intervention|Control Goups|The control group (A) receives standard exercise therapy that is part of the rehabilitation at the center and no additional intervention
32852968|NCT05035758|Experimental|Transcendental Meditation|The intervention group (B) receives transcendental meditation sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
32852969|NCT05035758|Experimental|Yoga|The intervention group (C) receives yoga sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
32852970|NCT05044260|Experimental|Direct Sinus elevation using SLA Kit|
32852971|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
32852972|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
32852973|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
32852974|NCT04151082|Experimental|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
32852980|NCT01493414|Experimental|INC424|5 - 25 mg twice a day (BID)
32852981|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
32852982|NCT01923493|Experimental|tuina|tuina treatment
32903532|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
32852983|NCT05035524|Active Comparator|Sodium Bicarbonate|Adjuvant SB treatment Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group
32852984|NCT05035524|Placebo Comparator|Placebo|Placebo
32852985|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
32852986|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
32852987|NCT05054322|No Intervention|Standard Care|Participants will be monitored via video call twice a day without any specific drugs.
32852988|NCT05054322|Experimental|Fluticasone propionate with spacer|Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care
32852989|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
32852990|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
32852991|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
32852992|NCT04409366|Active Comparator|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
32852993|NCT04409366|Experimental|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
32852994|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
32852995|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
32852996|NCT03097380|Experimental|AZD2115|
32852997|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
32852998|NCT03097380|Experimental|[11C]AZ13754366|
32852999|NCT04275505|Active Comparator|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
32853000|NCT04275505|Placebo Comparator|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
32853001|NCT04396327|Active Comparator|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
32853002|NCT04396327|Experimental|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
32853003|NCT03097458|Experimental|Counselling|short-term counselling for families
32853004|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
32853005|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
32853006|NCT03104257||Healthy Controls|Subjects with no current cannabis use
32853007|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
32853008|NCT03097224|No Intervention|Control group|Usual care
32853009|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
32853010|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
32853011|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
33104224|NCT05540314||Subjects that have undergone robotic bariatric surgery|Subjects that have undergone robotic bariatric surgery between January 2018 and December 2019
33406676|NCT05639556||Cohort 2|FEV1 ≥60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation).
32853012|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
32853013|NCT05043948||Coronary Artery Disease_collateral flow grade 2|
32853014|NCT05043948||Coronary Artery Disease_collateral flow grade 0|
32853015|NCT05043948||Peripheral Artery Disease_collateral flow grade 2|
32853016|NCT05043948||Peripheral Artery Disease_collateral flow grade 0|
32853017|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
32853018|NCT05053542||With or without enema before operation|Patients who had received pre-operative bowel preparation(PBP) were identified using electronic medical records. Patients prescribed an enema solution (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before surgery were allocated to the PBP group. Patients who received no PBP were allocated to none PBP group.
32853019|NCT04759729|Experimental|PRO+D group|Participants will receive probiotic as well as vitamin D supplementation.
32853020|NCT04759729|Experimental|PL+D group|Participants will receive placebo instead of probiotics and vitamin D supplementation.
32853021|NCT05053698||Initial gas tamponade|Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
32853022|NCT05053698||Initial silicone oil tamponade|Primary vitrectomy and fluid-air exchange with silicone oil tamponade
32853023|NCT05053698||Relapse treated with gas tamponade|Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
32853024|NCT05053698||Relapse treated with silicone oil tamponade|Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
32853025|NCT05052840|Experimental|Muscle endurance training (MET)|
32853026|NCT05052840|Active Comparator|Conventional Treatment|
32853027|NCT04396561|Experimental|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
32853028|NCT04396561|Experimental|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
32853029|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
32853030|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
32853031|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
32853032|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
32853033|NCT05053074|Experimental|NHF - NHF/CO2|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.
32853034|NCT05053074|Experimental|NHF/CO2 - NHF|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.
32853035|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
32853036|NCT00985231|Active Comparator|SofLens59 contact lens|
32853037|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
32853038|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
32853039|NCT05053386|Experimental|Idarubicin|10mg idarubicin is dissolved in 5ml water for injection, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
32853040|NCT05053386|Active Comparator|Epirubicin|50mg epirubicin is dissolved in 5ml 5% glucose solution, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
32853041|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
32853042|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
32853043|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
32853044|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
32853045|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
32853046|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
32853047|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
32853048|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
32853049|NCT05034666|Active Comparator|Before education|"Before alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is before applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
32853050|NCT05034666|Active Comparator|After education|"After alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is after applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
32853051|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
32853052|NCT05052450||Dementia with Alzheimer|Patients previously diagnosed with Alzheimer disease would be included
32853053|NCT05052450||Dementia with Lewy Body Dementia|Patients previously diagnosed with Lewy Body Dementia would be included
32853054|NCT05052450||Dementia with Fronto-Temporal Dementia|Patients previously diagnosed with Fronto-Temporal Dementia would be included
32853055|NCT05052450||Dementia with Vascular Disease|Patients previously diagnosed with Dementia with Vascular Disease would be included
32853056|NCT05052450||Dementia with Parkinson Disease|Patients previously diagnosed with Dementia with Parkinson Disease would be included
32853057|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
33104225|NCT04820179|Experimental|Cabozantinib 40mg + Atezolizumab 1200mg|Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.
33104226|NCT04785469|Experimental|Eccentric training group|
33104227|NCT04785469|Active Comparator|Control group|
33406677|NCT05220774||anesthetist-administered sedation (AAS)|Patients undergoing ERCP and receiving AAS
32853058|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
32853059|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
33406678|NCT05220774||endoscopist-directed conscious sedation (EDCS)|Patients undergoing ERCP and receiving EDCS
32853060|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
32853061|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
32853062|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
32853063|NCT01725555|Experimental|Fasted treatment|
32853064|NCT01725555|Experimental|Fed treatment|
32853065|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
32853066|NCT03409887|Experimental|Base Group|Base of GIC
32853067|NCT03409887|Active Comparator|Control Group|Direct composite restoration
32853068|NCT04377633|Sham Comparator|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
32853069|NCT04377633|Experimental|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
32853070|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
32853071|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
32853072|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
32853073|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
32853074|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
32853075|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
32853076|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
32853077|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
32853078|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
32853079|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
32853080|NCT01360866|Experimental|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
32853081|NCT01360866|Experimental|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
32853082|NCT01360866|Experimental|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
32853083|NCT01360866|Experimental|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
32853084|NCT01360866|Experimental|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
32853085|NCT01360866|Experimental|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
32853086|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
32853087|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
32853088|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
32853089|NCT00985153|Experimental|1|ProQuad Lot 1
32853090|NCT00985153|Experimental|2|ProQuad Lot 2
32853091|NCT00985153|Experimental|3|ProQuad Lot 3
32853092|NCT00985153|Active Comparator|4|M-M-R II + Varivax
32853093|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
32853094|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
32853095|NCT05034276|Experimental|MORE-VR|Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
32853096|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
32853097|NCT05051826|Experimental|1.Drag Umbrella 2. Hand Resistance 3.Resistance Suit|"In the water, a small umbrella is attached to the athlete to increase resistance.~In the water, increase resistance by increasing the area of the hand.~In the water, use swim shorts that increase resistance"
32853098|NCT05051826|Experimental|1 Resistance 2 Bands Swiss Ball 3 Medicine Ball 4 Pulley Pull|"On land, use a stretch rope to increase resistance.~On land, inflatable bouncy balls are used to increase strength.~On land, solid balls are used to increase strength.~On land, pulleys are used to increase resistance."
32853099|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
32853100|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
32853101|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
32853102|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
33406679|NCT04940208||post COVID-19 ICU survivors|Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
32853103|NCT05034588||Intensiv care patients after acute kidney injury|Patients with condition after intensive care stay and acute kidney injury and subsequent convalescence (without preexisting underlying cardiac disease or other disease with potential cardiac involvement).
32853104|NCT05034588||Intensiv care patients without kidney injury|Patients with condition after intensive care stay and subsequent convalescence (without kidney injury and preexisting underlying cardiac disease or other disease with potential cardiac involvement).
32853105|NCT05034120|Experimental|MB:Single arm|10 subjects will be enrolled in this arm. The subjects will take a single dose XZP-3621 tablet after a low-fat meal and perform excretion collection consistently.
32853106|NCT05034120|Experimental|FE:Arm A|Cycle1 Day1: fasting; Cycle2 Day10: High-fat meal; Cycle3 Day19: Low-fat meal
32853107|NCT05034120|Experimental|FE:Arm B|Cycle1 Day1: High-fat meal; Cycle2 Day10: Low-fat meal; Cycle3 Day19: fasting
32853108|NCT05034120|Experimental|FE:Arm C|Cycle1 Day1: Low-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: High-fat meal
32853109|NCT05034120|Experimental|FE:Arm D|Cycle1 Day1: fasting; Cycle2 Day10: Low-fat meal; Cycle3 Day19: High-fat meal
32853110|NCT05034120|Experimental|FE:Arm E|Cycle1 Day1: High-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: Low-fat meal
32853111|NCT05034120|Experimental|FE:Arm F|Cycle1 Day1: Low-fat meal; Cycle2 Day10: High-fat meal; Cycle3 Day19:fasting
32853112|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
32853113|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
32853114|NCT05051748|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
32853115|NCT05051748|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA).
32853116|NCT05051748|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
32853117|NCT05051748|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
32853118|NCT05051748|Active Comparator|In-office bleaching + Remineralization|n-office bleaching was applied followed by MI-Paste Plus®
32853119|NCT05051748|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
32853120|NCT05051748|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by in-office bleaching and lastly MI-Paste Plus®
32853121|NCT05051748|No Intervention|Control|no treatment (control).
32853122|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
32853123|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
32853124|NCT05051670|Experimental|SP group|patients group underwent gastrectomy using da vinci SP
32853125|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
32853126|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
32853127|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
32853128|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
32853129|NCT01837017|No Intervention|Control|Wait-list control.
32853130|NCT04395235|Experimental|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
32853131|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
32853132|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
32853133|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
32853134|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
32853135|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
32853136|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
32903533|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
32853137|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
32853138|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
32853139|NCT05043558|Experimental|beprostaglandin sodium|
32853140|NCT05043558|No Intervention|control group|
32853141|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
32853142|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
32853143|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
32853144|NCT05043480|Experimental|PEMF arm|In this single-arm study, all participants will be assigned to the intervention arm.
32853145|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
32853146|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
32853147|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
32853148|NCT05051280|Experimental|CBCT guidance group|Left atrial appendage occlusion under cone-beam computed tomography fusion image guidance
32853149|NCT05051358||Subjects undergoing Therapeutic Endoscopic Ultrasound|"Procedures that will be captured include:~EUS- ERCP, Endoscopic Hepatology - EUS, EUS-Coils placement, EUS Glue injection, EUS-Fiducial placement, EUS-Neurolysis, EUS-Stent placement, EUS-alcohol injection, EUS-guided Ablation, EUS-guided anastomosis, EUS Guided ERCP for gallbladder, pancreatic duct or biliary duct drainage, EUS guided - Hemostasis, EUS guided- Therapy for cancer or premalignant lesion (Injection, neurolysis, fiducial, aspiration, RFA ), EUS - Fluid Collection, abscess or cavity drainage, EUS - Guided Ductal Drainage, EUS - Guided Anastomosis"
32853150|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
32853151|NCT05050968|Experimental|Adapted Physical Activity Group|Patients will follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.
32853152|NCT05050968|No Intervention|Control group|Patients will receive standard hospital management
32853153|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
32853154|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
32853155|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
32853156|NCT05033496||Newborn infants|Newborn infants born in our medical center
32853157|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
32853158|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
32853159|NCT05051046|Experimental|Hypnosis|
32853160|NCT05051046|No Intervention|General anesthesia|Common practice
32853161|NCT05050656|Active Comparator|Group D (duloxetine group)|Two hours before surgery, participants received oral duloxetine 60 mg tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
32853162|NCT05050656|Placebo Comparator|Group C (control group)|Two hours before surgery, participants received oral placebo tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
32853163|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
32853164|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
32853165|NCT05050890||Breast cancer|Breast cancer patients who are currently receiving neoadjuvant therapy
32853166|NCT05050812|Experimental|Grounded|All participants will sleep on a grounding mat for at least six hours per 24-hour period.
32853167|NCT03069859|Experimental|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
32853168|NCT03069859|Placebo Comparator|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
32853169|NCT05050734|Experimental|CBIT-E|For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
32903534|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
32903535|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
32903536|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
32903537|NCT00650078|Placebo Comparator|Placebo|
32903538|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
33406680|NCT05220696||Critically ill patients with shock|Critically ill patients with shock
32853170|NCT05050734|No Intervention|Waitlist Control (WLC)|These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
32853171|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
32853172|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
32853173|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
32853174|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
32853175|NCT04470024|Experimental|Arm 1|Vax + delayed anti-PD-1
32853176|NCT04470024|Experimental|Arm 2|Vax + anti-GITR + delayed anti-PD-1
32853177|NCT05042622|Experimental|Cytokine adsorber patients on ECMO|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
32853178|NCT05042622|Experimental|Cytokine adsorber patients with sepsis|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
32853179|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients on ECMO|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
32853180|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients with sepsis|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
32853181|NCT05042622|No Intervention|Control (subgroups)1|No filter will be installed into the ECMO in this study group (15 patients)
32853182|NCT05042622|No Intervention|Control (subgroups) 2|No filter will be installed into the patient with sepsis (15 patients)
32853183|NCT05042856|Experimental|PanOptix|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
32853184|NCT05042388|Experimental|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Group intervention comprised of didactics and trainings in cognitive behavioral therapy relapse prevention skills and mindfulness meditation.
32853185|NCT05042388|Active Comparator|Treatment-As-Usual (TAU)|Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
32853186|NCT05033730|No Intervention|Standard care: Control (Group A)|Patients who are scheduled for elective surgical upper airway surgery will be given General Anesthesia by an anesthesiologist who is the principal investigator and the surgical procedures will be done by the same ENT surgeon. IV Induction of Anesthesia with Propofol Target controlled infusion (TCI), Remifentanil Target controlled infusion (TCI) and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed endotracheal tube after direct laryngoscopy. After intubation by a Suitable size Endotracheal tube, they will be mechanically ventilated using Volume Controlled Ventilation (VCV) with 40% Oxygen and minute ventilation adjusted to keep ETCO2 of 40 mmHg or less, and a PEEP of 5 cmH2O.
32853187|NCT05033730|Experimental|Intervention Group: (Group B)|General Anesthesia will be induced with IV Induction of Anesthesia by an anesthesiologist with Propofol (Target controlled infusion), Remifentanil (Target controlled infusion), and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed Tritube after direct laryngoscopy. They will be mechanically ventilated using Flow Controlled Ventilation (FCV) with 40% Oxygen, Flow rate:13L/Min., Peak Airway Pressure (15 cmH2O), and a PEEP of (5 cmH2O) to keep ETCO2 of 40 mmHg or less. The anesthesia will be maintained with Intravenous Infusion of Propofol, Remifentanil (TCI) to keep BIS 40-60.
32853188|NCT05050422|Placebo Comparator|Control|
32853189|NCT05050422|Active Comparator|Study|
32853190|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa simplex|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
32853191|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of junctional epidermolysis bullosa|"Female patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
32853192|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa dystrophic|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
32853193|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of Kindler syndrome|Female patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
32903539|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
32903540|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
32903541|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
32903542|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
33104228|NCT03989102|Experimental|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
32853194|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa simplex|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
32853195|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of junctional epidermolysis bullosa|"Male patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
32853196|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa dystrophic|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
33104229|NCT03989102|Experimental|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
33104230|NCT03989102|Placebo Comparator|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
32853197|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of Kindler epidermolysis bullosa|Male patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
32853198|NCT04471818|Experimental|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
32853199|NCT04471818|Placebo Comparator|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
32853200|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
32853201|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
32853202|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
32853203|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
32853204|NCT05033418|Experimental|IPRP + CBT-I|Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)
32853205|NCT05033418|Active Comparator|IPRP-UC|Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)
32853206|NCT05050188|Experimental|cohort 1: H008 20mg|H008 20mg tablets, orally, once, daily, for 7 days
32853207|NCT05050188|Experimental|cohort 1: H008 placebo 20mg|H008 placebo 20mg tablets, orally, once, daily, for 7 days
32853208|NCT05050188|Experimental|cohort 1: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
32853209|NCT05050188|Experimental|cohort 2: H008 40mg|H008 40mg tablets, orally, once, daily, for 7 days
32853210|NCT05050188|Experimental|cohort 2: H008 placebo 40mg|H008 placebo 40mg tablets, orally, once, daily, for 7 days
32853211|NCT05050188|Experimental|cohort 2: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
32853212|NCT04434378|Placebo Comparator|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
32853213|NCT04434378|Experimental|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
32853214|NCT00981799|Experimental|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
32853215|NCT00981799|Experimental|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
32853216|NCT00981799|Experimental|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
32853217|NCT00981799|Experimental|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
32853218|NCT04979598||Acute unilateral vestibular deafferentiation|Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
32853219|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
32853220|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
32853221|NCT05033106|Active Comparator|Eyes with IVI bevacizumab|0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye
32853222|NCT05033106|Active Comparator|Eyes with IVI ranibizumab|A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant
32853223|NCT03095040|Experimental|CM082 combined with everolimus|
32853224|NCT03095040|Experimental|CM082|
32853225|NCT03095040|Active Comparator|Everolimus|
32898833|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
33104231|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
33104232|NCT04491825||Mycosis fungoides (MF)|
33104233|NCT04491825||Eczema (Atopic Dermatitis)|
33104234|NCT04491825||Chronic Plaque-Psoriasis|
33104235|NCT04491825||Healthy Control Skin|
33104236|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
33104237|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
33104238|NCT03980093|Experimental|Education plus Values|
33104239|NCT03980093|Active Comparator|Education|
33104240|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
33104241|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
33104242|NCT03945734|Experimental|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
33104243|NCT04473768||NTS bloodstream infection|growth of NTS in blood culture
33104244|NCT04473768||NTS/Pf malaria co-infection|concurrence of current Pf malaria infection and NTS bloodstream infection
33104245|NCT04473768||Other pathogen bloodstream infections|growth of a pathogen other than NTS in blood culture
32853226|NCT05049642|Experimental|Group 1|Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion. Afterwards one drop of C-NAC will be instilled into the study eye of group 1. 1 hour after treatment VAS and the symptom questionnaire will be performed repeatedly in both groups. Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days. Patients assigned to group 1 will receive Lacrimera® for home treatment over the following 5 days. 1 drop of Lacrimera® is supposed to be installed into the eye 20 minutes prior to installation of the respective antibiotic eye drops or ointments.
32853227|NCT05049642|No Intervention|Group 2|Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days.
33104246|NCT04473768||Severe Pf malaria mono-infection|defined according to WHO-criteria
33104247|NCT04473768||Other causes of febrile illness requiring hospital admission|"Current Pf malaria infection: see above~Recent Pf malaria infection: see above~Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests~If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined"
33104248|NCT03939065|Experimental|Insulin Pump and CGM|
33104249|NCT03939065|Other|Standard of Care and CGM|
33104250|NCT05425290|Experimental|Intervention Arm|
33104251|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
33104252|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
33104253|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
33104254|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
33104255|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
33104256|NCT03911414|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
33406681|NCT05685966||Infertile couples from the research center who visited for fertility disorders|Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.
32853228|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
32853229|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
32853230|NCT05042154|No Intervention|Standard of Care Cohort for COPD|Standard care patients will receive routine clinical management as per their treating physicians based on the GOLD Criteria.
32853231|NCT05042154|Active Comparator|WatchPAT Cohort|Consented patients will undergo group randomization to either standard AECOPD care or to the WatchPAT One cohort (WPC). The WPC will undergo a single night of in-hospital sleep apnea testing from 2200 to 0600 using the WatchPAT One, a portable and disposable home sleep apnea testing device (Itamar Medical, Israel [WPAT]).
32853232|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
32853233|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
32853234|NCT05049486|No Intervention|MRI sequences and (DTI)|The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
33417247|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
32853235|NCT05049486|Active Comparator|CT scan|Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed.
32853236|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
32853237|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
32853238|NCT05049408||Group OSCC|Patients with Oral Squamous Cell Carcinoma (OSCC)
32853239|NCT05049408||Group OPMD|Patients with oral potentially malignant disorders (OPMD)
32853240|NCT05049408||Group HC|Healthy Control
32853241|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
32853242|NCT01924039|Other|treatment as usual|
32853243|NCT05032404|Experimental|BNT103|All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.
32853244|NCT03099499|Experimental|ONC201 treatment Arm|
32853245|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
32853246|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
32853247|NCT05049564|Experimental|keyhole group|patient harbored aneurysm who was treated by microsurgical clipping via keyhole approach.
32853248|NCT05049564|Experimental|conventional group|patient harbored aneurysm who was treated by microsurgical clipping via conventional craniotomy.
32853249|NCT05049564|Experimental|endovascular group|patient harbored aneurysm who was treated by endovascular coiling via femoral approach.
32853250|NCT03486067|Experimental|Administration of CC-93269|
32853251|NCT05049018|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was for one hour and 15 minutes rest in between. The first part included: muscle strengthening and facilitation exercises, stretching exercises, and postural reactions exercises. The second part included: functional exercise for facilitation of arm-reaching and arm-hand skills, manipulative tasks (grasping and release activities), and daily living activities for the affected upper limb.~The traditional treatment program was applied for both groups by therapists, experienced in stroke rehabilitation. It was carried out three sessions per week for twelve successive weeks."
32853252|NCT05049018|Experimental|Experimental Group|"Participants in the experimental group received two hours treatment program that included three parts, the first and the second parts (similar to that were applied for participants in the control group). These two parts were applied for one hour followed by 15 minutes rest, then the third part was applied for one hour. The third part of the program was a one-hour virtual reality intervention program by using (ArmeoSpring) virtual reality equipment to simulate a range of upper limb tasks that facilitate arm activities, manipulative skills, and daily living tasks through using different interactive games and soft-wares.~The traditional treatment part of the program was applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program was applied by other experienced physiotherapists, who were well trained in using the (ArmeoSpring) System. All three parts of the program were carried out three sessions per week for twelve successive weeks."
32853253|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
32853254|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
32853255|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
32853256|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
32853257|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
32853258|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
32853259|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
32853260|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
32853261|NCT03481075|Experimental|Rigid and Elastic registration softwares|
32853262|NCT03095898|Experimental|True Acupuncture|
32853263|NCT03095898|Sham Comparator|Sham Acupuncture|
32853264|NCT03095898|No Intervention|Control Group|
32853265|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32853266|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
32853267|NCT05032482|Other|Investigational Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
32853268|NCT05032482|Other|Investigational Treatment 2|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
32853269|NCT05032248|Experimental|tacrolimus|group I (Colchicine and topically applied Tacrolimus),
32853270|NCT05032248|Placebo Comparator|placebo|group II (Colchicine and topically applied Placebo),
32853271|NCT03408795|Other|JORS-LDG Group|Participants in JORS-LDG Group score the performance of procedure after LDG.
33104257|NCT03911414|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
33104258|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
33104259|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
33104260|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
33104261|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
33104262|NCT04772053|Experimental|Participants undergoing tumor biopsy|
33104263|NCT03861143|Experimental|BT-11 low-dose (500 mg)|Oral
33104264|NCT03861143|Experimental|BT-11 high-dose (1,000 mg)|Oral
33104265|NCT03861143|Placebo Comparator|Placebo|Oral
33104266|NCT04428060|Experimental|PERSEUS CPR|Patients will be resuscitated according to the PERSEUS protocol
33104267|NCT04428060|Active Comparator|CONTROL|Patients will be resuscitated according to current Advanced Life Support guidelines
33104268|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
33104269|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
33104270|NCT04684160|Active Comparator|Fixed-bearing group|
33104271|NCT04684160|Experimental|Mobile-bearing group|
33104272|NCT04390698|Experimental|nerve block+opioid-free general anesthesia|Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia
33104273|NCT04390698|Sham Comparator|sham bock+opioid general anesthesia|Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia
32853272|NCT05032170||Locator Group|The participant has a mandibular overdenture supported by two implants with locator attachments. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
32853273|NCT05032170||Bar Group|The participant has a mandibular overdenture supported by two implants with a dolder bar attachment. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
32853274|NCT00633217|Active Comparator|arm 1|
32853275|NCT00633217|Experimental|arm 2|
32853276|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
32853277|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
32853278|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
32853279|NCT00215657|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
32853280|NCT00215657|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
32853281|NCT00215657|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
32853282|NCT00215657|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
32853283|NCT00215657|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
32853284|NCT00215657|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
32853285|NCT00215657|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
32853286|NCT00215657|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
32853287|NCT00633061|Experimental|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
32853288|NCT00633061|No Intervention|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
32853289|NCT05041764||PCR positive|samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed
32853290|NCT05041764||PCR negative|samples that are p negative for the detection of SARS-CoV2. T
32853291|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
32853292|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
32853293|NCT05041686|Experimental|CADISS® System|
33104274|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of > 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
33104275|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of > 5 but < 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
33104276|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of <6) acute stroke, either ischemic or hemorrhagic. (n= 25)
33104277|NCT01254331|Experimental|Single arm|
33104278|NCT03795701|Placebo Comparator|Placebo|Subjects in placebo group will receive placebo plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will also be asked to maintain physical activity.
32853294|NCT00632827|Experimental|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
32853295|NCT05041608||Subjects undergoing Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
32853296|NCT00214019|Placebo Comparator|Placebo Diskus|Placebo comparator
32853297|NCT00214019|Experimental|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
32853298|NCT00214019|Experimental|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
32853299|NCT00214019|Experimental|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
32853300|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
32853301|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
32853302|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
32853303|NCT05047848|Experimental|chidamide + fulvestrant|
32853304|NCT00210119|Experimental|Imatinib mesylate|Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.
32853305|NCT05048004||periprocedural oral anticoagulation|Oral anticoagulation will be continued without a periprocedural pause
32853306|NCT05048004||no periprocedural oral anticoagulation|Pause of oral anticoagulation on the day of the intervention
32853307|NCT03998033|Experimental|ET140202 T cells|ET140202 Receptor (+) T Cells
32853308|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
32853309|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
32853310|NCT05031858|Experimental|Vojta Therapy|Reflex turn first phase: Patient positioned supine with legs flexed 30º-45º. The pectoral area is stimulated for five minutes on each side x 2 consecutive times. Total 20 minutes per session.
32853311|NCT05031858|Active Comparator|Control Group|.Inspiratory techniques, mucociliary clearance techniques (expiratory). Use of inspiratory and expiratory incentives. Employment of mechanical assistants
32853312|NCT03997487|Experimental|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
32853313|NCT05047614|Experimental|Study 1|Twelve patients in study group 1 receiving lumbar repositioning feedback training
32853314|NCT05047614|Experimental|Study 2|Twelve patients in study group 2 receiving transverses abdominis training
32853315|NCT05047614|Experimental|Study 3|Twelve patients in study group 3 receiving both lumbar repositioning feedback training and tranversus abdominis training
32853316|NCT05047614|Experimental|Control|Twelve patients in control group receiving conventional lumbar propriception physical therapy program .
32853317|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
32853318|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
32853319|NCT05047458|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
32853320|NCT05047458|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
32853321|NCT05047458|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
32853322|NCT05041452||Noncirrhotic portal hypertension (NCPH)|Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).
32853323|NCT05041452||Cirrhotic portal hypertension|Patients with cirrhosis and portal hypertension.
33417248|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
32746552|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~Pre-transplant full blood count serial measures every / 3 months for 2 years.~Pre transplant serum Iron study and annually for 2 years.~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~Post-transplant serum FGF-23 (as independent risk factor) at 6months.~Different immunosuppressive protocols.~Pre-transplant panel reactive antibody,donor-specific antibody"
32746553|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose escalation)|"DSF (dose level (DL) 1=125mg, DL 2=250mg, DL 3=375 mg, DL 4=500mg). DSF starts at DL 2 and escalated using the Time-to-Event Continual Reassessment Method~3 day lead-in of oral DSF once daily (QD) prior to surgery (optional)~2 mg Cu gluconate 3 times daily (TID) on days when DSF is given (optional pre-surgery)~Surgery performed per routine clinical care.~After surgery, evaluation to confirm the final pathological diagnosis as GBM (if not the patient will not continue with the 2nd part of the study).~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles."
32746554|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose expansion)|"Surgery performed per routine clinical care.~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles.~If a patient develops recurrent tumor during follow-up and plans to undergo another resection, he/she may opt for an optional preoperative DSF study prior to salvage surgery."
32746555|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
32746556|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
32746557|NCT04789707||KERATOCONUS group|"All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
32746558|NCT04789707||CONTROL group|"workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
32746559|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
32746560|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
32746561|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
32746562|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
32746563|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
32746564|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
32746565|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
32746566|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
32746567|NCT05472051||Young girls housekeepers|Malian young girls migrating from rural areas towards Bamako to seek for a job as housekeepers. Include young girls aged at least 12 years.
32746568|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
32746569|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
32746570|NCT04789239|Experimental|SZC + MRA treated heart failure patients|"Optimal dose of SZC, which is an approved drug for hyperkalemia in Sweden.~The subject is treat with 5 mg daily however it can be reduced to once every second day, or inreased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with a mineralcorticoid receptor antagonist (spironolacton or eplerenon), 25 mg or 50 mg depending on what dose they could tolerate."
32746571|NCT04789239|Placebo Comparator|Placebo + MRA treated heart failure patients|The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
32746572|NCT04789317||Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.|The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
32746573|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
32746574|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
32746575|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
32746576|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
32746577|NCT02203305|Experimental|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
32746578|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
32746579|NCT01705119|Experimental|Mechanically Ventilated|
32746580|NCT04789473||Control Normal Glycemic Pregnancy|Cohort of control adults who are currently pregnant or have been pregnant within the last year, but were not diagnosed with gestational diabetes.
32746581|NCT04789473||Gestational Diabetic Cohort|Cohort of adults who are currently pregnant or have been pregnant within the last year, but were diagnosed with gestational diabetes.
32746582|NCT01626118|Experimental|Indomethacin 40 mg TID|
32746583|NCT01626118|Experimental|Indomethacin 40 mg BID|
32746584|NCT01626118|Placebo Comparator|Placebo|
32746585|NCT01626118|Experimental|Indomethacin 20 mg TID|
32746586|NCT05471583||Main group|There is only one group in the study. It is observational.
32746587|NCT04789005|Active Comparator|Phenylephrine group|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
32746588|NCT04789005|Experimental|Norepinephrine group|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
32746589|NCT04788849||Women referred to colposcopy|Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.
32746590|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
32746591|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
32746592|NCT05469243||psychedelics|50 non active military participants not under the care of Dr. Gupta will be recruited through word of mouth and advertising to self-identify as having used psychedelic medicine for non recreational purposes (Appendix B recruitment letter). In addition to demographic information, they will be asked to complete the PGIC and anxiety, mood, pain and disability subscales, PEG, HADS and DI, provide information on their past medical history, nature/indications for use, and adverse events. This data will be collected once per participant and they will be able to speak with a research associate if further clarification if necessary at anytime.
32746593|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
32746594|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
32746595|NCT05468229|Active Comparator|dorzagliatin|Dorzagliatin 50 mg single dose
32746596|NCT05468229|Placebo Comparator|placebo|matching placebo
32746597|NCT05475327|Other|Conventional Physical Therapy|Heat therapy and education regarding back care management.
32746598|NCT05475327|Experimental|Relaxation exercises|Progressive relaxation exercises along with Deep Breathing exercises.
32960602|NCT01044966|Experimental|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
32960603|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
32960604|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
32960605|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
32960606|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
32960607|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
32960608|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
32960609|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
32960610|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
32960611|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
32960612|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
32960613|NCT01051518|Experimental|CoreValve|
32960614|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
32960615|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
32960616|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
32960617|NCT01053078|Experimental|Naltrexone|
32960618|NCT01053078|Placebo Comparator|Placebo|
32960619|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
32960620|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
32960621|NCT01053312|Experimental|1 flutemetamol|
32960622|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
32960623|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
32960624|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
32960625|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
32960626|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
32960627|NCT01058070|Experimental|Implantable Device|Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
32960628|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
32960629|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
32960630|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
32960631|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
32960632|NCT01064076|Experimental|S-ICD System|This is a single arm study
32960633|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
32960634|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
32960635|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
32960636|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
32960637|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
32960638|NCT01066026|Experimental|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
32960639|NCT01066026|Active Comparator|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
32960640|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
32960641|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
32960642|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
32960643|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
32960644|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
32960645|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
32960646|NCT01076244|Other|Minimally invasive lumbar decompression|
32960647|NCT01082952||Asthmatic patients|
32960648|NCT01082952||Non asthmatic patients|
32960649|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
32960650|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
32960651|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
32960652|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
32960653|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
32960654|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
32960655|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
32960656|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
32960657|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
32960658|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
32960659|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
32960660|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
32960661|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
32960662|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
32960663|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
32960664|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
32960665|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
32960666|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
32960667|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
32960668|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
32960669|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 500 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin"
32960670|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin~Co-administration of 50 mg sitagliptin and 500mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet"
32960671|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500mg metformin"
32960672|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500 mg metformin~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet"
32960673|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
32960674|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
32960675|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
33417249|NCT03334539|Placebo Comparator|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
32960676|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
33417250|NCT04308707||Surgical specialties|
33417251|NCT04308707||Anesthesiology|
33417252|NCT01350089|Placebo Comparator|Placebo|
33406682|NCT05220618|Experimental|Memory Training Group|This group will receive an online two-week intervention to train the specificity of autobiographical memories. During the two-week intervention and the following two weeks, participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day. EMA is an Experience Sampling Method assessment system that allows data to be collected from participants in their natural environment at various points in time (McDevitt-Murphy et al., 2018). For this study, we designed an EMA to monitor essential project variables throughout the intervention (2 weeks; from Day 0 to Day 15) and then as a follow-up (2 weeks after; from Day 16 to Day 30).
32853324|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
32853325|NCT05041296||Chronic group|Chronic epilepsy with recurrent seizures
32853326|NCT05041296||Acute group|Epilepsy and short-term history of seizures
32853327|NCT05041296||Control group|Healthy participants
32853328|NCT03993353|Experimental|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
32853329|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
32853330|NCT05031312|Active Comparator|inferior oblique anterior nasal transposition|Group A for inferior oblique anterior nasal transposition 2mmx2mm posterior and nasal to inferior rectus insertion to control vertical deviation especially large angle vertical deviation and V pattern with more potent postoperative effect in unilateral and bilateral cases
32853331|NCT05031312|Active Comparator|inferior oblique myectomy|Group B for inferior oblique myectomy to control vertical deviation but not of large angle which lead to residual inferior oblique overaction
32853332|NCT03993041|Experimental|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
32853333|NCT03993041|Active Comparator|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
32853334|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
32853335|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
32853336|NCT05040906|Experimental|H02+ Chemotherapy|Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
32853337|NCT05040906|Active Comparator|Rituxan+Chemotherapy|Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
32853338|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
32853339|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
32853340|NCT05040828|Experimental|Early interventional treatment group|The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
32853341|NCT05040828|Active Comparator|Post-onset treatment group|The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
32853342|NCT05040828|Active Comparator|Control group|The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
32853343|NCT04250363|Experimental|M5717|Participants will receive single ascending oral dose of M5717 powder in capsule after DVI of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
32853344|NCT04250363|Placebo Comparator|Placebo|Participants will receive placebo matched to M5717 after DIV of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
32853345|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)~4 times group activities (2 hr / each times)~LINE group interaction~Reminder and feedback form researcher"
32853346|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)~Health promotion manual"
32853347|NCT05047380||coccycodinia group|A total of 54 patients diagnosed with coccycodinia
32853348|NCT03595475||Psychiatric RBD cases|"Presence of REM sleep without atonia;~At least one of the followings is present: i). Dream enactment behaviors, SRIs, potentially injurious or disruptive behaviors by history; ii). Abnormal REM sleep behaviors documented during v-PSG monitoring;~Absence of electroencephalogram (EEG) epileptiform activity during REM sleep unless RBD can be clearly distinguished from any concurrent REM sleep related seizure disorder;~The sleep disturbance is not better explained by other sleep disorder (e.g., obstructive sleep apnea, medical or neurological disorder, mental disorder, medication use, or substance use disorder)"
32853349|NCT03595475||Psychiatric control|"Age- and sex- matched with pRBD proband;~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG; 5) Free of neurodegenerative diseases"
33417253|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
33417254|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
33104279|NCT03795701|Experimental|Liraglutide 3.0|Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will be asked to maintain physical activity. The dose of Saxenda® will be increased weekly in the first 4 weeks (.6; 1.2; 1.8; 2.4 mg) and maintained on 3 mg for 12 weeks.
32853350|NCT03595475||Healthy control|"Age- and sex- matched with pRBD proband;~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on RBDQ-HK and v-PSG;~Free of neurodegenerative diseases"
32853351|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
32853352|NCT00983437|Experimental|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
32853353|NCT05046756|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
32853354|NCT05046756|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
32853355|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
32853356|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
32853357|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
32853358|NCT05031390|Experimental|Physiotherapist-led training|Physiotherapy-led training of patients with FAIS
32853359|NCT05031234|Active Comparator|Group with morphine|conventional general anaesthesia with morphine
32853360|NCT05031234|Experimental|Group without opiates|general anaesthesia without opiates
32853361|NCT03989219||lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
32853362|NCT05026242|Experimental|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
32853363|NCT05026242|Active Comparator|Control|Participants will be provided with isocaloric snacks
32853364|NCT00988741|Experimental|ARQ 197|
32853365|NCT00988741|Placebo Comparator|placebo|
32853366|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
32853367|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
32853368|NCT03989063|Experimental|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
32853369|NCT03989063|Active Comparator|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
32853370|NCT03989063|Experimental|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
32853371|NCT03989063|Active Comparator|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
32853372|NCT05031156|Active Comparator|non-splinting of OT Bridge system|Leaving the dental implants abutments solitary followed by denture pick up
32853373|NCT05031156|Experimental|splinting of OT Bridge|Splinting of implants abutments using titanium wire then followed by denture pick up
32853374|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
32853375|NCT05040594|Experimental|Treatment A (right) B (left)|Subjects will receive PavéDerm J-Fill Soft Dermal Filler and Restylane® Lyft Lidocaine. One product will be randomized, per NLF.
32853376|NCT05040594|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane® Lyft Lidocaine and PavéDerm J-Fill Soft Dermal Filler. One product will be randomized, per NLF.
32853377|NCT05025930|Experimental|endoscopic surgical instrument control system (SP1000: single- port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (SP1000)
32853378|NCT05025930|Active Comparator|Comparator: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (IS3000)
32898834|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
32898835|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
32898836|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
32853379|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
32853380|NCT05025696|Experimental|Intervention|Blacksoap(R) applied whole body twice daily
33104280|NCT04673578|Experimental|Celecoxib|Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight > 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.
33104281|NCT04673578|Placebo Comparator|Placebo (microcrystalline cellulose)|Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.
32853381|NCT05025696|Placebo Comparator|Control|Johnson and Johnsons Baby Soap applied whole body twice daily
32853382|NCT03984461|Active Comparator|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
32853383|NCT03984461|Active Comparator|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
32853384|NCT03984461|Active Comparator|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
32853385|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
32853386|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
32853387|NCT03599219|Other|control|donors with an hemorrhagic score <2.
32853388|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
32853389|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
32853390|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
32853391|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
32853392|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
32853393|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
32853394|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
32853395|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
32853396|NCT05040516||Group 1|"The planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (TAS), 24-hour Holter electrocardiography, polysomnography and echocardiography.~A 10 ml of venous blood sample will be collected by venopuncture. Laboratory tests will be performed using commercially available standardized tests."
32853397|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
32853398|NCT01042977|Placebo Comparator|2|matching placebo tablet
32853399|NCT05040438|Experimental|Autologous NK cell infusion combined with HAIC|HAIC of 5-FU (500 mg/m2, Q4W) and cisplatin (15 mg/m2, Q4W) will be administered for up to 4 cycles to patients with locally advanced HCC. Subjects who achieved sustained SD or better based on the mRECIST criteria after 2nd cycle of HAIC will be enrolled to receive 1x10^9 cells VAX-NK/HCC infusion.
32853400|NCT03598751|Experimental|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
32853401|NCT03598751|Placebo Comparator|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
32853402|NCT05030532|Experimental|EVERYbody Project: Expert facilitator version|"This gender inclusive, dissonance-based body image program was created from focus group feedback. Based on the Body Project, the program retains key dissonance activities while expanding the inclusivity focus (e.g., expanding the gender focus, exploring diversity within appearance ideals, critically discussing the impact of limited diversity representation in cultural appearance norms).~Around 10% of content from the previous trial was modified to form the current intervention. Changes focused on enhancing diversity-focused content. College students with body image content interest completed two days (16 hours) of training on the program manual, group management, and conducting inclusive conversations. Post training, students self-assessed their facilitation readiness and were evaluated by two trainers on facilitation expertise. Peer leaders with sufficient expertise were invited to facilitate EVERYbody Project groups."
32853403|NCT05030532|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists, and (2) The Mask You Live In. Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
32853404|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
32853405|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age <18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
32898837|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
32853406|NCT05030142|Experimental|Mechanical thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
32853407|NCT05030142|Active Comparator|Active Comparator|Best medical treatment alone (usual care)
32853408|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
32853409|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
32853410|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
32853411|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
32853412|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
32853413|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
32853414|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
32853415|NCT04766489|Experimental|Complete Deongestive Therapy|Patients will be given complete decongestive therapy for 5 days a week and for a mean of 20 sessions. Each session will be of approximately 2 hours and 15 minutes in duration, although short stretch bandaging will be left on for 23 hours a day.
32853416|NCT05039658|Experimental|Single agent treatment arm with IBI110|IBI110 administered at RP2D
32853417|NCT05039658|Experimental|Combination treatment arm with IBI10 and sintilimab|IBI110 and sintilimab administered at RP2D
32853418|NCT01837485|Experimental|Lactol|
32853419|NCT01837485|Placebo Comparator|Placebo|
32853420|NCT04177823|Experimental|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
32853421|NCT05039580|Experimental|PD-1 monoclonal antibody group|PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.
32853422|NCT05025306|No Intervention|control group|only atraumatic extractions were done, honey was not applied
32853423|NCT05025306|Experimental|experimental group|ziziphus honey was applied into the sockets after tooth extractions in experimental group
32853424|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
32853425|NCT05025228||Paracetamol IV|Patients with femur fracture that received an initial analgesic treatment with paracetamol intravenously (IV).
32853426|NCT05025228||Paracetamol OR|Patients with femur fracture that received an initial analgesic treatment with paracetamol orally (OR).
32853427|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
32853428|NCT05025072|Experimental|Test IMP|Hydroxycarbamide dispersible tablets (20 x 50 mg)
32853429|NCT05025072|Active Comparator|Reference IMP|Hydroxycarbamide film-coated tablet (1000 mg)
32853430|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
32853431|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
32853432|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
32853433|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
32853434|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
32853435|NCT05030064|Experimental|Intestinal flora capsule(FMT)|The group includes 27patients.They will receive 16 capsules of intestinal bacteria each time, once a week, 4 times in a row.Each capsule contains 200mg of fecal bacteria.
32853436|NCT05030064|Placebo Comparator|Placebo group|The group includes 27patients.They will receive 16 Placebo capsules each time, once a week, 4 times in a row.
32853437|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
32853438|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
32853439|NCT05024682|Experimental|conventional pulsed radiofrequency|
32853440|NCT05024682|Experimental|pulse dosed pulsed radiofrequency|
32853441|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
32853442|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
32853443|NCT05024604||study group|women receiving mini pills as a method of contraception with symptoms not diagnosed with us
32853444|NCT05024604||Control group|women attending to office hysteroscopy unit and not taking hormonal therapy
32898838|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
33104282|NCT03760523|Experimental|Minnelide Dose Escalation|A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
33104283|NCT05414058|Experimental|Apo-Methylphenidate ER arm|Apo-Methylphenidate ER, 36 mg, oral, once a day, every morning, 4 weeks duration. Methylphenidate ER will be started at 18 mg to test tolerability and will be titrated at day 7 to a dose of 36 mg.
33104284|NCT05414058|No Intervention|Treatment as usual arm|Participants in the treatment as usual arm will continue with their current treatment as decided by their treatment team.
33104285|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
33104286|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
33104287|NCT04381923|Active Comparator|Helmet Continuous Positive Airway Pressure (CPAP)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC, helmet CPAP will be applied unless a specific contraindication is present.
33104288|NCT04381923|Active Comparator|High Flow Nasal Oxygen (HFNO)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC , HFNO (≥ 40 LPM) will be applied unless a specific contraindication is present
33104289|NCT00537342|Experimental|A|Biological Vaccine
32853445|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
32853446|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
32853447|NCT05039502|Experimental|Retreatment system using in rotational motion|Previous root canal filling materials were removed with D1-D2-D3 retreatment files with using an endodontic motor in rotational motion
32853448|NCT05039502|Experimental|Retreatment system using in reciprocal motion|Previous root canal filling materials were removed with Reciproc 25 file with using an endodontic motor in reciprocal motion
32853449|NCT05039502|Experimental|Retreatment system using in additional rotational motion|Previous root canal filling materials were removed with XP-endo finisher r file with using an endodontic motor in rotational motion
32853450|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
32853451|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
32853452|NCT05039034||Low-risk Group|Low-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
32853453|NCT05039034||Mediate-risk Group|Mediate-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
32853454|NCT05039034||High-risk Group|High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
32853455|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
32853456|NCT05024838||Spinal anesthesia|The investigators retrospectively collected the electronic medical record of patients receiving spinal anesthesia from July 1, 2018, to Dec 31, 2018. Patients less than 18 years old were excluded from this study.
32898839|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
33104290|NCT00537342|Placebo Comparator|B|
33104291|NCT03724019|Experimental|Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
33104292|NCT03724019|No Intervention|Group S|
33104293|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
33104294|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
33104295|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
33104296|NCT04338516|Active Comparator|Bio-Oss® Collagen,|subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)
33104297|NCT04338516|Experimental|Ossix™ Bone|subjects treated with Ossix™ Bone (Datum Dental Ltd)
33104298|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Escalation|Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
33104299|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Expansion|Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
33104300|NCT05399511||Practising GPs|GPs working in primary care setting.
33104301|NCT00537420|Placebo Comparator|1|Nasal Placebo
33104302|NCT00537420|Placebo Comparator|2|Capsule Placebo
33104303|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
33104304|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
32960677|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
32960678|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
32960679|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
32960680|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
32960681|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
32960682|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
32960683|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
33406683|NCT05220618|No Intervention|Control Group|This group will receive no intervention to train the specificity of autobiographical memories. During four weeks (from Day 0 to Day 30), participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day.
33406684|NCT05684328|Experimental|WLI Then NBI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by white light imaging(WLI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with narrow band imaging(NBI). Stop watch will be utilized to remind endoscopists.
33406685|NCT05684328|Active Comparator|NBI Then WLI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by narrow band imaging(NBI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with white light imaging(WLI). Stop watch will be utilized to remind endoscopists.
33417255|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
32960684|NCT01096680|Experimental|SPD489 20 mg|
32960685|NCT01096680|Experimental|SPD489 50 mg|
33417256|NCT01357421|Experimental|TT301|Investigational drug TT301
33417257|NCT01357421|Placebo Comparator|Placebo|Normal saline
32960686|NCT01096680|Experimental|SPD489 70 mg|
32960687|NCT01096680|Active Comparator|Armodafinil|
32960688|NCT01096680|Placebo Comparator|Placebo|
32960689|NCT01096992|Experimental|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
32960690|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
32960691|NCT01096992|Experimental|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
32960692|NCT01096992|Experimental|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
32960693|NCT01096992|Experimental|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
32960694|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
32960695|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
32960696|NCT01098006|Other|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
32960697|NCT01098006|Other|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
32960698|NCT01098006|Other|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
32960699|NCT01098006|Other|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
32960700|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
32960701|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
32960702|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
32960703|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
32960704|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
32960705|NCT01101750|Other|Liver and Kidney Transplant Patient Arm|Standard of Care Intervention: Participants on this arm receive Gardasil vaccine and have a history of liver or kidney transplant.
32960706|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
32960707|NCT01102218|Active Comparator|erythropoietin alone|
32960708|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
32960709|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
32960710|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
32960711|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
32960712|NCT01104090|Experimental|C-MAC direct laryngoscopy, then C-MAC indirect laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and then using C-MAC with indirect laryngoscopy.
32960713|NCT01104090|Experimental|C-MAC indirect laryngoscopy, then C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with indirect laryngoscopy first and then using C_MAC with direct laryngoscopy.
32960714|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
32960715|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
33104305|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
33104306|NCT00537420|Active Comparator|6|Sibutramine 10 mg
32960716|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
32960717|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
32960718|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
32960719|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
32960720|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
32960721|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
32960722|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
32960723|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
32960724|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
32960725|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
32960726|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
32960727|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
32960728|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
32960729|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
32960730|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
32960731|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
32960732|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
32960733|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
32960734|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
32960735|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
32960736|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
32960737|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
32960738|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
32960739|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
32960740|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
32960741|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
33417258|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
33104307|NCT03645122|Experimental|Physiology|Different neural elements will be stimulated and evoked potentials will be recorded via electromyography. Metrics used to quantify evoked potentials will be used to infer changes in physiological functioning of the nervous system.
33104308|NCT03645122|Experimental|Behavior|A visuomotor task will be performed and force signals will be recorded. Metrics used to quantify force signals will be used to infer changes in control processes governing movement.
33104309|NCT04295889|Active Comparator|Group A|"Group A will receive an invitation for home based albuminuria screening using a more conventional urine collection device (known as Peespot Test)."
33104310|NCT04295889|Active Comparator|Group B|"Group B will receive an invitation for home based albuminuria screening using an app (internet application) and an ACR dipstick test (known as ACR| EU Test)."
32853457|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
32853458|NCT05029908||TMD disorders|"75 patients with temporomandibular disorder (TMD) who will apply to the outpatient clinic of Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included in our study. Ethics Committee approval was obtained from Bakırköy Sadi Konuk Training and Research Hospital before starting the study and a voluntary consent form will be signed by the patients before the evaluation.~In this cross-sectional study; 75 participants aged 18-65 years who has temporomandibular joint (TMJ) complaints for more than 3 months and has the cognitive ability to understand test instructions will be included. Patients with a history of previous TMJ operation, muscle, neurological or rheumatic disease that may affect TMJ, and a history of facial/cervical trauma or neoplasia will excluded from the study."
33104311|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
33104312|NCT04268706|Experimental|CD30 positive r/r classical Hodgkin Lymphoma|"Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.~Patients will be treated with autologous CD30.CAR-T cells."
32853459|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
33104313|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
32853460|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
32853461|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
32853462|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
32853463|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
32853464|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
32853465|NCT05029440|Experimental|Electromagnetic and Exercise Group|Pulsed Electromagnetic Field (PEMF) PEMF was administered to the whole body using a 1.8×0.6m mat Exercise Program Exercise program to facilitate bone health
32853466|NCT05029440|Active Comparator|Laser and Exercise Group|Pulsed High Intensity Laser Therapy (HILT) HILT was administered to lumbar region and femoral head using Exercise Program Exercise program to facilitate bone health
32853467|NCT05029440|Active Comparator|Exercise Group|Exercise Program Exercise program to facilitate bone health
33104314|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
33406686|NCT04900506|Active Comparator|cemented hemiarthroplasty , posterior SPAIRE approach|Posterior SPAIRE approach: lateral decubitus position, preservation of the piriformis tendon and obturator internus, detatchment of obturator externus , capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair, repair of obturator externus.
32853468|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
32853469|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
32853470|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
32853471|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
32853472|NCT05024448|Active Comparator|Prednisone|Prednisone, 60mg/d, for 10 days
32853473|NCT05024448|Placebo Comparator|Placebo|
32853474|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
32853475|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
32853476|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
32853477|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
32853478|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
32853479|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
33104315|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
33104316|NCT03511196|Experimental|Adaptive ADT+ Standard of Care|Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve >75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
33104317|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
33104318|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
33406687|NCT04900506|Active Comparator|cemented hemiarthroplasty, anterior approach|Anterior approach: supine position, both legs washed and draped, intermuscular plane between m. tensor fascia lata and m. sartorius, capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair
33406688|NCT05220228|Experimental|Prucalopride|Prucalopride - 1mg for 2 days, and then increased to 2mg for a further 5-8 days. Testing will occur on day 7 ideally, but may take place up to and including day 10.
32853480|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
32853481|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
32853482|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
32853483|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
32853484|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
32853485|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
32853486|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
32853487|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
32853488|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
32853489|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
32853490|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
32853491|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
32853492|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
32853493|NCT01041495|Experimental|cyclobenzaprine ER|
32853494|NCT01041495|Placebo Comparator|placebo|
32853495|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
32853496|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
32853497|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
32853498|NCT03759431|Experimental|Vocal-cord Radiotherapy|
32853499|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
32853500|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
32853501|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
32853502|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
32853503|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
32853504|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
32853505|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
32853506|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
32853507|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
33104319|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
33406689|NCT05220228|Placebo Comparator|Placebo|Placebo (sucrose / lactose) for 7-10 days
32960742|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
33406690|NCT05635734|Experimental|Experimental arm|"Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
33406691|NCT05220150|Experimental|Alzheimer's patients|Patient diagnosed with early onset Alzheimer's disease.
32960743|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
33406692|NCT05220150|Active Comparator|Control|Healthy volunteers that do not have Alzheimer's disease.
33406693|NCT05220072|Experimental|Carbon-14 BIA 28-6156|Healthy volunteers receive a single dose of Carbon-14 BIA 28-6156
32960744|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
32960745|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
32960746|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
33406694|NCT05672862||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
32960747|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
32960748|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
32960749|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
33406695|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
33406696|NCT05219526|Experimental|Subject BGMS measurement|Blood glucose measurement using BGMS
32960750|NCT01119222|Active Comparator|Gabapentin 1200mg|
32960751|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
32960752|NCT01119222|Active Comparator|Morphine 10 mg|
32960753|NCT01119222|Placebo Comparator|Placebo formulations|
33417259|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
32960754|NCT01119456|Experimental|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
32960755|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
32960756|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
32960757|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960758|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960759|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
33104320|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
33104321|NCT04218279|Experimental|Sleep Health Education|At baseline, the experimental group will have immediate access to 10 brief education modules focused on diverse elements of sleep health and fatigue.
33104322|NCT04218279|Active Comparator|Wait List Control|At 3 months after baseline, the wait-list control group will be provided access to the 10 education modules focused on diverse elements of sleep health and fatigue..
33104323|NCT03471845|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
33104324|NCT04183374|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
33104325|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
32853508|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
32853509|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
32853510|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
32853511|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
32853512|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
32853513|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
32853514|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
32853515|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
32853516|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
32853517|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
32853518|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
32853519|NCT03595319|Experimental|Elder patients|Older than 65
32853520|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
32853521|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
32853522|NCT03595007||Phase 1|
32853523|NCT03595007||Phase 2|
32853524|NCT03595007||Phase 3|
32853525|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
32853526|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
32853527|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
32853528|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
32853529|NCT04407065|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
32853530|NCT04407065|Active Comparator|HCG|HCG is used to trigger ovulation
32853531|NCT01044381|Experimental|Luliconazole Solution, 10%|
32853532|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
32853533|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
32853534|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
32853535|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
33104326|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
33104327|NCT03466151|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
33104328|NCT03466151|Active Comparator|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
33406697|NCT04765644|Active Comparator|Celecoxib|"Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
32853536|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
32853537|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
32853538|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
32853539|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
32853540|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
32853541|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
32853542|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
32853543|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
32853544|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
32853545|NCT01040637|Experimental|TD-1211 OIC dose level 3|Ascending doses
32853546|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
32853547|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
32853548|NCT01040637|Placebo Comparator|Placebo|Ascending doses
32853549|NCT04020887|No Intervention|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
32853550|NCT04020887|Experimental|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
32853551|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
32853552|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
32853553|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
32853554|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
32853555|NCT03594149|No Intervention|control|No levofloxacin will be given.
32853556|NCT03830073||Group I:|Seventy patients with pancreatitis
32853557|NCT03830073||Group II:|Thirty healthy controls
32853558|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
32853559|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
32853560|NCT04379583||Subjects|Female subjects providing DNA saliva sample
32853561|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
32853562|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
32853563|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
32853564|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
32853565|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
32853566|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
32853567|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
32853568|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
33104329|NCT04178538|Experimental|25 years and older- ACL recon with DBM, Internal brace|Patients in this arm will be 25 years of age and over and receive ACL reconstruction augmented with demineralized bone matrix, bone marrow, and internal brace
33104330|NCT04178538|Active Comparator|25 years and older- Standard ACL reconstruction|Patients in this arm will be 25 years of age and over will receive an allograft All-Inside ACL reconstruction
32853569|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
32853570|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
32853571|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
32853572|NCT05620875||Group with DO2i <280 ml/min/m2 during cardiopulmonary bypass|
32853573|NCT05620875||Group with DO2i >280 ml/min/m2 during cardiopulmonary bypass|
32853574|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
32853575|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
32853576|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
32853577|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
32853578|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
32853579|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
32853580|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
32853581|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
32853582|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
32853583|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
32853584|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
32853585|NCT01837875|No Intervention|Control|Mailed informational literature
32853586|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
32853587|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
32853588|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
32853589|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
32853590|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
32853591|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
32853592|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
32853593|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
32853594|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
32853595|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
32853596|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
32853597|NCT01838109|No Intervention|Control group|no intervention total 87 patients
32853598|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
32853599|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
32853600|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.~Time to completion is recorded."
32853601|NCT04406909|Experimental|Training|Access to training at membership training facility
32853602|NCT04406909|No Intervention|No training|No access to training at membership training facility
32853603|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
32853604|NCT03592511|Experimental|Intervention|WGPF-burger group
32853605|NCT03592511|Placebo Comparator|Control|Control-burger group
32853606|NCT03407001|Experimental|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
32853607|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
32853608|NCT03406923|No Intervention|Usual care|Receive usual care only.
32853609|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
32853610|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
32853611|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
32853612|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
32853613|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
32853614|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
32853615|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
32853616|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
32853617|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
32853618|NCT03591653|Experimental|LXI-15028 50mg group|
32853619|NCT03591653|Placebo Comparator|Placebo group|
32853620|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
32853621|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
32853622|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
32853623|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
32853624|NCT03591497|Experimental|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
32853625|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
32853626|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
32853627|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
32853628|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
32853629|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
32853630|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
32853631|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
32853632|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
32853633|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
32853634|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
32853635|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
32853636|NCT04377399|Active Comparator|high dose|vitamin D (40,000 IU weekly) for 24 weeks
32853637|NCT04377399|Active Comparator|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
32853638|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
32853639|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
32853640|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
32853641|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
32853642|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
32853643|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
32853644|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
32853645|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
32853646|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
32853647|NCT01673178|Placebo Comparator|Placebo Arm|
32853648|NCT01673178|Experimental|25 mg|
32853649|NCT01673178|Experimental|50 mg|
32853650|NCT01673178|Experimental|100 mg|
32853651|NCT01673178|Experimental|150 mg|
32853652|NCT03406221|Experimental|Intervention arm|
32853653|NCT03406221|Active Comparator|Control Arm|
32853654|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
32853655|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
32853656|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
32853657|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
32853658|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
32853659|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
32853660|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.~Patients will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SGRQ-I;~HRQoL - SF36;~Anxiety and depression;~Symptoms - mMRC~Symptoms - UCSD/SOBQ;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
32853661|NCT03400839||Control Group|"Age-matched peers without lung diseases.~Participants will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SF36;~Anxiety and depression;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
32853662|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
32853663|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
32853664|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
32853665|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
32853666|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
32853667|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
32853668|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
32853669|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
32853670|NCT05024526|Experimental|edaravone dexborneol group|
32853671|NCT05024526|Active Comparator|edaravone group|
32853672|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
32853673|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
32853674|NCT03405987||ECV < median|
32853675|NCT03405987||ECV ≥ median|
32853676|NCT05024370||Multiparas, planned cesarean section|Multiparas having a planned cesarean section at the departement of Obstetrics and Gynecology in Herning Hospital. Uncomplicated pregnancy that makes early discharge possible.
32853677|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
32853678|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
32853679|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
32853680|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
32853681|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
32853682|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
32853683|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
32853684|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
32853685|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
32853686|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
32853687|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
32853688|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
32853689|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
32853690|NCT05037240|Active Comparator|Intervention Group|
32853691|NCT05037240|Placebo Comparator|Placebo|
32853692|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853693|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853694|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853695|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853696|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853697|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
32853698|NCT05037006|Experimental|Group I-30|Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
32853699|NCT05037006|Experimental|Group I-50|Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
32853700|NCT05037006|Experimental|Group I-70|Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
32853701|NCT05037006|Experimental|Group V-30|Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
32853702|NCT05037006|Experimental|Group V-50|Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
32853703|NCT05037006|Experimental|Group V-70|Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
32853704|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
32853705|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
32853706|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
32853707|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
32853708|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
32853709|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
32853710|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
32853711|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
32853712|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
32853713|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
32853714|NCT05028192||Rectal cancer after neoadjuvant treatment|Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
32853715|NCT05028192||Control group|Patients who will undergo programmed abdominal surgery through any approach type for no neoplastic or inflammatory disease.
32853716|NCT04377243|Experimental|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
32853717|NCT04377243|Placebo Comparator|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
32853718|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
32853719|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
32853720|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
32853721|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
32853722|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
32853723|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
32853724|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
32853725|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
32853726|NCT05028036|Experimental|Personalized lifestyle intervention|The intervention consists of a personalized lifestyle treatment program to address specific lifestyle issues.
32853727|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
32853728|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
32853729|NCT05018364||cases|measure serum erythropoietin level
32853730|NCT05018364||controls|measure serum erythropoietin level
32853731|NCT04375371|Active Comparator|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
32853732|NCT04375371|No Intervention|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
32853733|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
32853734|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
32853735|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
32853736|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
32853737|NCT03593213|Experimental|Cariprazine 4.5 mg/day (Open-label Treatment Period)|Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
32853738|NCT03593213|Placebo Comparator|Placebo (Double-blind Treatment Period)|Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
32960760|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960761|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32746599|NCT04788381||Participants with CRC or lung cancer was performed unexpected operation|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
32746600|NCT05475249|Placebo Comparator|white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) without immersion in fluorescent liquid
32960762|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960763|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960764|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960765|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960766|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960767|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960768|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960769|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960770|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960771|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960772|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960773|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960774|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32746601|NCT05475249|Experimental|fluorescence white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) with immersion in fluorescent liquid
32746602|NCT05466591|Experimental|Pre-hospital rule-out strategy|Patients undergo a point-of-care troponin T measurement. If troponin is low, an acute coronary syndrome is considered ruled-out and the care for the patient is transferred to the general practitioner. If troponin is elevated, the patient is immediately transported to the emergency department.
32746603|NCT05466591|No Intervention|Emergency department rule-out strategy|According to standard care, the patients are immediately transported to the emergency department.
32853739|NCT03593213|Experimental|Cariprazine 3.0 mg/day (Double-blind Treatment Period)|Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
32853740|NCT03593213|Experimental|Cariprazine 4.5 mg/day (Double-blind Treatment Period)|Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
32853741|NCT05023824|Experimental|alpha-blocker withdrawal|receives 5-ARI monotherapy
32853742|NCT05023824|Experimental|5-ARI withdrawal|receives alpha-blocker monotherapy
32853743|NCT05023824|Active Comparator|combination therapy|receives alpha-blocker and 5-ARI
32853744|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
32853745|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
32853746|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
32853747|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
32853748|NCT05023902|Active Comparator|Pilates|The Pilates Mat exercise group followed an eight-week exercise program. The exercise protocol of this study was designed by the researchers (Table I). According to previous reports, 6 to 8 weeks of Pilates training has positive effects on physical and psychological health (Akbas, Unver, 2021; Bavli & Koybasi, 2016; Pourvaghar, Bahram, Sharif & Sayyah, 2014; Rogers & Gibson, 2009). As the program advanced, 20-cm diameter mini soft balls, Pilates rings, 65 cm diameter soft gymnastic balls, and rubber bands were used in this order as materials in Pilates exercises. After an initial warm-up exercises at a slow pace for 10 minutes, Pilates exercises with and without equipment were performed for 40 minutes. The exercises ended with a 10- minute recovery and stretching exercises for relaxation of all muscle groups
32853749|NCT05023902|Experimental|NIA Dance|NIA includes nine basic movement forms, 13 principles, and 52 basic moves. The nine movement forms were derived from martial arts, dance arts, and the healing arts of the Alexander Technique, Feldenkrais Method, and Yoga (Rosas & Rosas, 2004). The 13 principles specify areas related to fitness, personal growth, and lifestyle. Centered on the joy of movement, they focus on, for example, being sensitive to personal rhythms, making the correct movement choices, and experiencing positive changes in daily life. The moves of NIA are used to engage all body areas, improve fitness, and facilitate self-healing.
32853750|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
32853751|NCT05023746||Clinically diagnosed as non-small cell lung cancer samples|
32853752|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
32853753|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
32853754|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
32853755|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
32853756|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
32853757|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
32853758|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
32853759|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
32853760|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
32853761|NCT04191317|Experimental|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
32853762|NCT04191317|Active Comparator|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
32853763|NCT05023590|Active Comparator|cryo ablation|cryo ablation of left atrium during mitral valve open chest intervention
32853764|NCT05023590|Active Comparator|radio frequency ablation|radio frequency ablation of left atrium during mitral valve open chest intervention
32853765|NCT04198337|Experimental|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
32853766|NCT05028114|Experimental|Part 1 (Formulation Optimisation)|Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.
32853767|NCT05028114|Experimental|Part 2 (Placebo Assessment)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods."
32853768|NCT05028114|Experimental|Part 3 (Titration Tolerability)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants will be randomised to either study drug or the matching placebo."
32853769|NCT04199819|Other|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
32853770|NCT05023668||Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy|Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy
32853771|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
32853772|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
32853773|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
32853774|NCT04199351|Experimental|Part A|AMG 171 or placebo, 2 SAD cohorts
32853775|NCT04199351|Experimental|Part B|AMG 171 or placebo, 1 MAD cohort
32853776|NCT04199351|Experimental|Part C|AMG 171 or placebo, 3 titration cohorts
32853777|NCT04193033|Experimental|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
32853778|NCT04193033|No Intervention|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
32853779|NCT04193033|No Intervention|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
32853780|NCT04953390|Experimental|Experimental|All study participants wearing study devices and evaluating three different microphone settings in simulated noise environments in lab, and using study devices during home trial period.
32853781|NCT04198883|Experimental|Protheracytes|Single arm study : Stem cells injection called Protheracytes
32853782|NCT04950114|Experimental|200 mg Dose Cohort|Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
32853783|NCT04192331|Experimental|2/3dose strategy|HER2 negative advanced breast cancer patient
32853784|NCT04192331|Active Comparator|3/4dose strategy|HER2 negative advanced breast cancer patient
32853785|NCT04766255|Active Comparator|Control Group|Implant placement and prosthetic rehabilitation of the missing tooth
32853786|NCT04766255|Experimental|SCTG group|Implant placement, soft tissue augumentation of Connective Tissue Graft (from the palate) (SCTG) at the implant site and prosthetic rehabilitation of the missing tooth.
32853787|NCT04766255|Experimental|CM group|Implant placement, soft tissue augumentation of porcine collagen matrix (CM) at the implant site and prosthetic rehabilitation of the missing tooth.
32853788|NCT04766255|Experimental|PADM group|Implant placement, soft tissue augumentation of Porcine acellular dermal matrix (PADM) at the implant site and prosthetic rehabilitation of the missing tooth.
32853789|NCT04948944|Experimental|active transcranial direct current stimulation|The investigators use Soterix mini-CT Stimulator to deliver 30 minutes 2mAmp tDCS to the bilateral DLPFC (optimized lateral electrode placement montage), with the the anode on the left hemisphere and the cathode on the right hemisphere. The electrodes are rubber and are placed in an MRI compatible holder and affixed with conductive paste. The investigators will use a bespoke headstrap to place the electrodes, which are held in place by the conductive paste.
32853790|NCT04948944|Sham Comparator|sham transcranial direct current stimulation|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
32853791|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
32853792|NCT04195217|Active Comparator|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
33320432|NCT05513534|Experimental|Power Resisatnce Training|: A high-velocity resistance (power) will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. Each training session will begin with a brief warm-up. Each session will consist of three sets of 10 repetitions each with 1.5 to 2- to minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds. Exercise order will be randomized during each session and upper and lower body exercises will be alternated whenever possible.
33320433|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
33320434|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
33320435|NCT01344694||patient with liver fat|30 patients with liver fat
33320436|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
33320437|NCT01344694||control|30 control subjects
32853793|NCT04195217|No Intervention|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
32853794|NCT04133064|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
32853795|NCT04376931|Experimental|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
32853796|NCT04193345|Active Comparator|Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
32853797|NCT04193345|Active Comparator|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
32853798|NCT03969953|Experimental|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
32853799|NCT03969953|Placebo Comparator|Placebo|Matched placebo, twice daily.
32853800|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
32853801|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
32853802|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
32853803|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
32853804|NCT04374981|Experimental|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
32853805|NCT04374981|Experimental|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
32853806|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
32853807|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
32853808|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
32853809|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
32853810|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
32853811|NCT04375059|Active Comparator|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
33320438|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
33320439|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
33320440|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
33320441|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
33320442|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
33320443|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
33320444|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
32853812|NCT04375059|No Intervention|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
32853813|NCT05017896||Normal Perfusion|
32853814|NCT05017896||Low Perfusion|
32853815|NCT04199975|Other|Orthoses|Only one single arm in this study
32853816|NCT03403803||Control Group|
32853817|NCT03403803||Optune Only|
32853818|NCT03403803||Optune and TMZ|
32853819|NCT04199585|Experimental|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
32853820|NCT04199585|Experimental|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition"
32853821|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
32853822|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
32853823|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
32853824|NCT04375215|Active Comparator|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
32853825|NCT04375215|Active Comparator|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
32853826|NCT04199507||Autism|Assessment of physical activity level and physical fitness
32853827|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
32853828|NCT04108884|Experimental|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
32853829|NCT04108884|Other|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
32853830|NCT04199039|Experimental|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
32853831|NCT04199039|No Intervention|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
32853832|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
32853833|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
32853834|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
32853835|NCT04199429|Experimental|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
32853836|NCT04199429|Active Comparator|Control|Standard nursing time dedicated daily to patients and parents.
32853837|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
32853838|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
32853839|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
32853840|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
32853841|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
32853842|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
32853843|NCT04100148|Experimental|SyncAV Arm|Treatment Arm
32853844|NCT04100148|Active Comparator|Fixed AV Delay Arm|Control Arm
32853845|NCT04198493|Experimental|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.~This group will also be instructed in sleep hygiene and dietary counseling~Intervention:~Device: CPAP Other: Conservative treatment for OSA"
32853846|NCT04198493|Active Comparator|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
32853847|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
32853848|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
32853849|NCT04198259|Active Comparator|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
32853850|NCT04198259|Experimental|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
32853851|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
32853852|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
32853853|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
32853854|NCT04197947|Experimental|PD patient who have FoG|
32853855|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
32853856|NCT03404583|No Intervention|Usual Care|Evidence-based care
32853857|NCT03968315|Experimental|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
32853858|NCT04375293|Experimental|AERD|Patients suffering from AERD
32853859|NCT04375293|Sham Comparator|Healthy|Healthy Controls
32853860|NCT04375293|Active Comparator|CRSwNP|Patients suffering from CRS with nasal polyps
32853861|NCT04375293|Active Comparator|CRSsNP|Patients suffering from CRS without nasal polyps
32853862|NCT05023356||Contact vital signs monitoring|Routine monitors with cables
32853863|NCT05023356||Non-contact vital signs monitoring|Camera
32853864|NCT04197323|Experimental|Alprostadil liposomes for injection|
32853865|NCT04197323|Active Comparator|KAISHI for injection|
32853866|NCT04374825|Experimental|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
32853867|NCT04374825|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
32853868|NCT04374825|No Intervention|Usual care|Patients' usual health care as received over the duration of the pilot trial
32853869|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
32853870|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
32853871|NCT04197245|Experimental|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
32853872|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
32853873|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
32853874|NCT04196855|Experimental|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
32853875|NCT04196855|No Intervention|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
32853876|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
32853877|NCT05022888|Active Comparator|myofascial pain syndrome|Patients diagnosed with myofascial pain syndrome Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
32853878|NCT05022888|Active Comparator|Healthy volunteers|Healthy volunteers Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
32853879|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
32853880|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
32853881|NCT04196621|Active Comparator|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
32853882|NCT04196621|Active Comparator|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
32853883|NCT04196309|Experimental|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
32853884|NCT04196309|No Intervention|Control group|No intervention
32853885|NCT03090126||Alveolar hypoventilation|
32853886|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
32853887|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
33104331|NCT04178538|Experimental|24 years and younger- ACL recon with DBM, Internal brace|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft augmented with demineralized bone matrix, bone marrow, and internal brace
32853888|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
33104332|NCT04178538|Active Comparator|24 years and younger- Standard ACL reconstruction|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft standard all inside technique
33104333|NCT03283826|Experimental|ATA188|Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.
33104334|NCT03283826|Placebo Comparator|Placebo|Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
33104335|NCT04105335|Experimental|Cohort 1 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
33104336|NCT04105335|Experimental|Cohort 2 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
32853889|NCT04196465|Experimental|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
32853890|NCT05027412|Experimental|En Bloc TURBT with Collins Loop|"If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.~After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected."
33104337|NCT04105335|Experimental|Cohort 3 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
33406698|NCT04765644|Placebo Comparator|Placebo|"Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
33406699|NCT05216874|Experimental|Occlusal stabilization splint|Skeletal class III laterognathia surgery patients who has occlusal stabilization splint thearapy for at least 2 mounths before surgery
33104338|NCT04105335|Experimental|Expansion Cohort MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA RP2D administered once every 3 weeks on Day 1 of every 3 week cycle. Pembrolizumab 200mg administered once 3 weeks on Day 8 of every 3 week cycle.
32853891|NCT05027412|Active Comparator|Conventional TURBT|The TURB will be carried out with bipolar current according to the traditional technique.
32853892|NCT04196231|Active Comparator|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
32853893|NCT04196231|Active Comparator|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
32853894|NCT04196231|Active Comparator|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
32853895|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
32853896|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
32853897|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
32853898|NCT04195997|Experimental|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
32853899|NCT04195997|Active Comparator|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
32853900|NCT05023200||Population|Adults (age ≥18 years) identified by their treating clinician as having lower limb cellulitis that requires intravenous or oral antibiotic treatment either from the hospital or another service based outside of the hospital, which will conduct ongoing follow-up regardless of location.
32853901|NCT05027334|Experimental|Interventional arm|Participants will be asked to use a designed mobile app to monitor their blood sugar levels
32898840|NCT04621175|Active Comparator|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
33104339|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
33104340|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
33104341|NCT04092777|Experimental|Strong Minds Program|This is a 10-session, culturally-adapted intervention, that includes cognitive behavioral therapy techniques combined with mindfulness exercises, led by a Community Health Worker.
33104342|NCT04092777|Other|Enhanced Usual Care|Enhanced usual care includes check in calls by a Care Manager 4 times over the course of 6 months and educational materials about depression and anxiety.
33104343|NCT04075383|Other|immediate dental implant|The implant is installed immediately after tooth extraction.
33104344|NCT04075383|Other|immediate-delayed dental implant|The implant is installed 8 weeks after tooth extraction.
33104345|NCT04683770||HR + / HER2 - advanced breast cancer|
33320445|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
33320446|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
33320447|NCT04228354|Experimental|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
33320448|NCT04228354|Experimental|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
32853902|NCT04195841|Experimental|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
32853903|NCT04195841|Experimental|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
33320449|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
32853904|NCT05023122|Experimental|vitamin D3 + calcium|vitamin D3 (cholecalciferol) 800 IU QD and calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
33320450|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
33320451|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
33320452|NCT01344928|Experimental|HIT training|
33320453|NCT01344928|Active Comparator|Aerobic exercise training|
33320454|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
32853905|NCT05023122|Active Comparator|calcium only|only calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
32853906|NCT05022966||Older people|
32853907|NCT04195373|Experimental|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
32853908|NCT04195373|Experimental|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
33104346|NCT00537498|Experimental|1|Interventional group
33104347|NCT03104699|Experimental|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
33104348|NCT01254019|Experimental|GSK2402968|6mg/kg
33104349|NCT01254019|Experimental|Placebo|dose-matched
33104350|NCT04687644|Experimental|Online Education|The education program developed within the scope of the research consists of five modules. In order to use the question and answer method in education, to make the education interactive and to receive feedback, 4 separate training groups of 7 people will be formed. The training will take place on the online platform, not face to face. Midwives will be contacted by phone and / or e-mail and the researcher will give a brief information about the research after introducing himself. A social media group will be created for each training group in order to communicate, announce trainings and inform changes.
33104351|NCT04687644|Active Comparator|Control|Midwives who attend the online forms of study will complete the survey. In the survey there are demographic and their view about woman centred care question forms. There are also Patient Centred Care Competency Scale and Minnesota Job Satisfaction Questionnaire. They will complete the survey.
33104352|NCT03055871|No Intervention|Standard education control group|The control group package will consist of Canada's PA guidelines recommending 180 min per week for young children, transitioning to 60 minutes of activity a day for children at five and a breakdown of ways for the parent to help their child achieve this PA (unstructured, endurance, strength, activities) commensurate with this guide. The guide also contains arguments and information about the benefits of PA.
33104353|NCT03055871|Other|Physical activity planning intervention|The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercise for children where they list physical activities that they have found fun in the past, as well as activities that they would find enjoyable to do as a family.
33320455|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
33104354|NCT03055871|Other|Habit formation intervention|The habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines, or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
32853909|NCT04195373|Experimental|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
32853910|NCT05022576|Experimental|PSMA PET/CT guided biopsy arm|Ga-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
32853911|NCT04195295|Experimental|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
33320456|NCT04082416|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
32853912|NCT04195295|Experimental|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
32853913|NCT04195295|Active Comparator|open flap debridement|open flap debridement procedure only.
32853914|NCT05022732|Placebo Comparator|Control formula|Excipients and gum arabic in tablet
32853915|NCT05022732|Active Comparator|Experimental formula|Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)
32853916|NCT04194983|Experimental|Fish oils and dairy fats|
32853917|NCT04194983|Placebo Comparator|Fish oils and plant fats|
32853918|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
32853919|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
32853920|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
32853921|NCT04194827|Experimental|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
32853922|NCT04194827|Active Comparator|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
32853923|NCT05022420||Salivary gland biospy,|100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
32853924|NCT05022420||muscular biopsy,|muscular biospy use for the diagnosis of muscular auto-immune disease.
32853925|NCT05022420||neuro muscular biospy|neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
32853926|NCT05022420||temporal arteries biospy|temporal arteries biospy uses for the diagnosis of giant cell arteritis
32853927|NCT04194749|Experimental|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health & Science University website.
32853928|NCT04194749|Active Comparator|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
32853929|NCT04406753|Experimental|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
32853930|NCT04406753|Active Comparator|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
32853931|NCT05017350|Experimental|Radiofrequency ablation group|hemostasis using radiofrequency ablation for track bleeding
32853932|NCT04194905|Experimental|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
32853933|NCT04194905|Active Comparator|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
32853934|NCT05017428|Experimental|Low Dose|The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.
32853935|NCT05017428|Experimental|Medium Dose|The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.
33104355|NCT05360082||Healthy controls|
33104356|NCT05360082||Premanifest HD mutation carriers|"HTT CAG repeat length ≥ 40~UHDRS Diagnostic confidence level < 4"
33104357|NCT05360082||Manifest HD mutation carriers|"HTT CAG repeat length ≥ 40~UHDRS Diagnostic confidence level = 4~Shoulson-Fahn stage 1-2"
33320457|NCT04082416|Placebo Comparator|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
33320458|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
33320459|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
32853936|NCT05017428|Experimental|High Dose|The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.
32853937|NCT05017428|Placebo Comparator|Placebo|In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.
32853938|NCT00013611|No Intervention|Antiretroviral therapy alone|
32853939|NCT00013611|Experimental|Proleukin plus antiretroviral therapy|
32853940|NCT04194515||YH1 group|
32853941|NCT04194515||Metformin group|
32853942|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
32853943|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
32853944|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
32853945|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
32853946|NCT04194281|Experimental|Action Observation Therapy [AOT]|
32853947|NCT04374591|Other|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
32853948|NCT04374591|Placebo Comparator|Control|placebo
33406700|NCT05216874|No Intervention|Control|Skeletal class III laterognathia surgery patients did not have occlusal stabilization splint thearapy
33406701|NCT04720872|Experimental|Experimental group|"Manual therapy: 4 sessions, 1 session per week (20 minutes approximately).~Physical therapist-directed vestibular rehabilitation: 4 weeks, 1 session per week with the physical therapist (30 minutes approximately), after manual therapy.~Home based vestibular rehabilitation: 4 weeks (2 sessions per day)."
32853951|NCT04193813||POAF|
32853952|NCT04193813||Non POAF|
32853953|NCT05017116|Experimental|Part A，single dose group|Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.
32853954|NCT05017116|Experimental|Part B, multiple dose group|Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.
32853955|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
32853956|NCT03088878|Experimental|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
32853957|NCT03088878|Experimental|Part 2|Cirmtuzumab plus ibrutinib
32853958|NCT03088878|Experimental|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
32853959|NCT03088878|Active Comparator|Part 3 - Arm B|Ibrutinib only
32853960|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
32853961|NCT04406675|Other|Patients Amyotrophic Lateral Sclerosis|
32853962|NCT04406675|Other|Control subjects|
32853963|NCT05022030|Experimental|Arm A|mCapOX (capecitabine+oxaliplatin) plus cetuximab
32853964|NCT05022030|Active Comparator|Arm B|mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab
32853965|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
32853966|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
32853967|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
32853968|NCT04192643|Experimental|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
32853969|NCT04192643|Placebo Comparator|NO TRANEXAMİC ACİD|100 ml salin solution
32853970|NCT05022108|Experimental|Antihistamine test|The forearm was sensitized at four points (A, B, C and D). Point A: positive control sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine was applied and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol were applied. Point D was sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point occurred 15 minutes after the procedure.
32853971|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3~Pembrolizumab 200mg IV administration 2 days after local ablation~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
32853972|NCT05021952|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
33320460|NCT04667416|No Intervention|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
33320461|NCT04667416|Experimental|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
32853973|NCT05021952|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
32853974|NCT00010257|Experimental|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
32853975|NCT04192565|Experimental|Robotic Endoluminal Resection|Robotic resection of mucosal lesions of the colon and rectum
32853976|NCT05021874|Active Comparator|Physiotherapeutic procedures: magnetotherapy|Magnetotherapy is a pulsating, non-homogeneous magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) will be applied using an elliptical applicator with a beam width of approx. 5 cm. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
32853977|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-led therapy|Magneto-led therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and LED diodes with the wavelength of 860 nm were applied using an elliptic magnetic-light (IR) applicator with a diameter of 5 [cm] containing 47 infrared diodes. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
32853978|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-laser therapy|Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and a low-energy laser with infrared wavelength of 808 [nm] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
32853979|NCT05021874|Active Comparator|Physiotherapeutic procedures: manual therapy of soft tissues|Manual therapy of soft tissues will include: post-isometric relaxation of the masseter, cellular and tissue mobilization with Kibler fold, masseter trigger point therapy. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
32853980|NCT04192721|Experimental|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
32853981|NCT04192721|No Intervention|Control group|No counseling was given to the control group during the study.
32853982|NCT05022186|Experimental|Group receiving Cannabidiol|These patients will receive cannabidiol 5% without other medication for cognition and depression
32853983|NCT05022186|Experimental|Group receiving Homotaurine|These patients will receive Vivimind (homotaurine) without other medication for memory and depression
32853984|NCT05022186|No Intervention|Control group|These patients will not receive treatment
32853985|NCT04191941|Experimental|Novel CAR-T|Novel CAR-T cells will be administered intravenously
32853986|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
32853987|NCT05016648||PEARS patients|Patients who underwent the personalized external aortic root support procedure at the AMC. Cerebral monitoring measurements (NIRS, EEG, TCD and blood pressure) are used for the study.
32853988|NCT04192097|No Intervention|Traditional teaching|No specific curriculum about professionalism
32853989|NCT04192097|Experimental|Professionalism curriculum|Traditionnal teaching + professionalism curriculum
32853990|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
32853991|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
32853992|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
32853993|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
32853994|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
32853995|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
32853996|NCT04191473|Experimental|group P|
32853997|NCT04191473|Other|group C|
32853998|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
32853999|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
32854000|NCT04191629|Experimental|50K to 200K cells|
32854001|NCT04191629|Experimental|50K to 200K cells with endothelial brushing|
32854002|NCT04191629|Experimental|500K cells|
32854003|NCT04191629|Experimental|500K cells with endothelial brushing|
32854004|NCT05016492|Experimental|Digital game group|The digital game group received the standard 4-week course of rehabilitation but with an additional 30-min interactive digital game training session per week.
32854005|NCT05016492|Active Comparator|Standard rehab group|The standard rehab group received the standard 4-week course of rehabilitation delivered in one 30-min session per week.
32854006|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
32854007|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
32854008|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
33320462|NCT01309490|Experimental|Ribavirin, nucleoside analog|
33320463|NCT04883840|Placebo Comparator|Placebo|
33320464|NCT04883840|Experimental|Rosuvastatin 10 mg|
33406702|NCT04720872|No Intervention|Control group|Home based vestibular rehabilitation: 4 weeks (2 sessions per day). The participants attended the center once a week to check correct execution of the exercises.
32854009|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
32854010|NCT05016414|No Intervention|Control|4 days of strict bed rest
32854011|NCT05016414|Experimental|Lower body negative pressure|4 days of strict bed rest with nightly lower body negative pressure at -20mmHg
32854012|NCT04191551||Gastric intestinal metaplasia|Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.
32854013|NCT04191551||Controls|Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)
32854014|NCT04377477|Experimental|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
32854015|NCT05016102|Other|Control condition|30 min to watching exercise-related video
32854016|NCT05016102|Other|Aerobic exercise condition|20 minutes of moderate-intensity exercise on treadmill
32854017|NCT05016102|Other|Resistance exercise condition|One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise.
32854018|NCT04190927|Experimental|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
32854019|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:~Tretinoin gel~Adapalene Benzoyl peroxide"
32854020|NCT05016336|Experimental|strategy-based cognitive training + social interaction|The experimental group received twelve 60 minutes sessions of strategy-based cognitive training. (i.e., training in mnemonic memory strategies). We chose to train multiple strategies instead of a single one in effort to reach larger training gains. each session began with engaging conversations between the researcher and participants. After each practice trial, participants were encouraged to share their ideas/stories/associations or visual images (mnemonic uses) in turn. All other participants were allowed to give feedback relating to what can be learned from each mnemonic use or give their own ideas on how they think it can be improved.
32854021|NCT05016336|Active Comparator|social interaction|The social interaction control group received the same number of group meetings but without the strategy training. Meetings content consisted of providing tools for making social connections, providing tools for interpersonal communication and raising the participant's sense of personal well-being through group contact.
32854022|NCT03962465|Experimental|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
32854023|NCT03962465|Experimental|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
32854024|NCT05021406|Experimental|Carvedilol+ NUCs therapy|Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
32854025|NCT05021406|No Intervention|NUCs therapy|Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
32854026|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:~Pedometers use;~Weekly contact (telephone or face-to-face);~Contact based on a self-determination theory.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
32854027|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
32854028|NCT04766177|Experimental|bumetanide group|Bumetanide a dose of 0.5 mg twice per day
32854029|NCT04766177|Placebo Comparator|Placebo|Placebo twice daily
32854030|NCT05021796||Nurses|"Including criteria: (1) registered nurses, (2) nurses undergoing a training for asthma telecounseling, (3) age 21 or more.~Excluding criteria: (1) nurses with previous training for asthma counseling, (2) nurses who do not take care of patients with asthma, (3) Pregnant women"
32854031|NCT04191083|Experimental|Motor Imagery|
32854032|NCT04191083|Experimental|Double Time Motor Imagery|
32854033|NCT04191083|Experimental|Action observation|
32854034|NCT04191083|Placebo Comparator|Placebo group|
32854035|NCT05021718|Experimental|Intervention group (IG)|A total of 35 patients in IG received different back and hip strengthening exercises five times a week for six weeks. They were also instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
32898841|NCT04621175|Active Comparator|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
32854036|NCT05021718|Active Comparator|Control group (CG)|The remaining 35 patients were allocated to CG. The patients in CG were treated with Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks, followed by hot moist compression for the next three weeks. Moreover, they were instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
32854037|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
32854038|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
32854039|NCT04466280|Active Comparator|Control Group|Participants in this group use personal protective equipment in the face of patients with COVID-19
32854040|NCT04466280|Experimental|Intervention Group 1|In this group, participants will receive 200 mg of hydroxychloroquine tablets daily in addition to personal protective equipment.
32854041|NCT04466280|Experimental|Intervention Group 2|In this group, participants, while observing and using complete personal protective equipment, will apply a thin layer of Dentol gel to the vestibular area of the mouth daily, every 6 to 8 hours.
32854042|NCT04190771|Experimental|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
32854043|NCT04190771|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
32854044|NCT05016180|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
32854045|NCT05016180|Experimental|Ropivacaine|Before the induction of anesthesia, Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
32854046|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
32854047|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
32854048|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
32854049|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
32854050|NCT04190459||LSG|laparoscopic sleeve gastrectomy
32854051|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
32854052|NCT05021016|Experimental|"Group 1: Vaccine"|150 volunteers who will be vaccinated with the EpiVacCorona vaccine with two doses spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
32854053|NCT04190069|No Intervention|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
32854054|NCT04190069|Experimental|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
32854055|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
32854056|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
32854057|NCT03093948|Experimental|Remote Ischemic post-conditioning|
32854058|NCT03093948|No Intervention|standard of care|
32854059|NCT05015868|Experimental|IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)|"Step1: standard of care.~acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data~complete neuropsychological assessment~genetic tests through Next generation sequencing epilepsies panel, or exome~Step 2: experimental~- combined Electroencephalogram-Functional brain magnetic resonance imaging registration.~Step 3: experimental~In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~execution of High Density-Electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone(PI, Italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
32854060|NCT04190303||Baseline (pre-intervention)|Current routine care
32854061|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
32854062|NCT05009472|Experimental|Cleft Lip and Palate Patient|Cleft patient with transverse maxillary constriction and anteroposterior deficiency
32854065|NCT05015946|Experimental|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
32854066|NCT04193423|Experimental|A-Group: craniocervical and cervicothoracic extension training|
32854067|NCT04193423|Experimental|B-Group: craniocervical flexion training|
32854068|NCT04193423|Active Comparator|C-Group: control group|No intervention will be performed due to the fact that they will be still on the waiting list.
32854069|NCT05015790|Experimental|use of virtual reality Bliss Solution|in the experimental arm the patient will receive the usual practice associated with a virtual reality session (20 minutes renewable) in a world chosen with the patient beforehand
32854070|NCT05015790|No Intervention|current practice, without Bliss Solution|patient will receive the usual practice, local anesthesia
32854071|NCT05015322|Active Comparator|subacromial injection|ultrasound (US)-guided subacromial injection
32854072|NCT05015322|Active Comparator|acromioclavicular joint and subacromial injection|ultrasound (US)-guided acromioclavicular joint and subacromial injection
33320465|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
32854073|NCT05015322|Active Comparator|suprascapular nerve block|ultrasound (US)-guided suprascapular nerve block
32854074|NCT04195139|Experimental|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
32854075|NCT04195139|Active Comparator|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
32854076|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
32854077|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
32854078|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
32854079|NCT05021250|Experimental|Lipiodol marking|HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.
32854080|NCT00919503|Experimental|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
32854081|NCT00919503|Experimental|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
32854082|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
32854083|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
32854084|NCT03957941|Experimental|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
32854085|NCT03957941|Active Comparator|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
32854086|NCT05020704|Experimental|empagliflozin|empagliflozin 10mg once daily
32854087|NCT05020704|Placebo Comparator|Placebo|matched placebo
32854088|NCT05020548|Active Comparator|pressure 10|mask ventilation with peak inspiratory pressure of 10 cmH2O
32854089|NCT05020548|Active Comparator|pressure 15|mask ventilation with peak inspiratory pressure of 15 cmH2O
32854090|NCT05020548|Active Comparator|pressure 20|mask ventilation with peak inspiratory pressure of 20 cmH2O
32854091|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
32854092|NCT02979665||Control|DME consults not requiring anti-VEGF
32854093|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
32854094|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
32854095|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
32854096|NCT04374435|Experimental|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
32854097|NCT04374435|Experimental|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
32854098|NCT04374435|Experimental|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
32854099|NCT04193501|Experimental|Experimental arms|Melatonin dose: 3mg/OD
32854100|NCT04193501|Placebo Comparator|Control arms|Placebo
32854101|NCT04433910|Experimental|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
32854102|NCT04433910|No Intervention|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
32854103|NCT04374279|Active Comparator|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
32854104|NCT04374279|No Intervention|Standard of care only|Randomized participants receive standard of care only.
32854105|NCT03957551|Experimental|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
32854106|NCT03086694||group surgery|using medications to maintain low stable blood pressure
32854107|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
33320466|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
32854108|NCT05009550|Active Comparator|Erector spinae plane block group (ESP)|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group. Then standard sedation method is applied to all patients.
32854109|NCT05009550|Other|Control Group|This Group was received no intervention.Standard sedation method is applied to all patients.
32854110|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
32854111|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
32854112|NCT04193267|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
32854113|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
33320467|NCT01320332|Experimental|ASP3291 low dose|
33320468|NCT01320332|Experimental|ASP3291 high dose|
32854114|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
33320469|NCT01320332|Placebo Comparator|Placebo|
32854115|NCT04021199|Active Comparator|T1D Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
32854116|NCT04021199|Experimental|MODY Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
32854117|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
32854118|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
32854119|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
32854120|NCT04024787|Experimental|Immediate intervention|
32854121|NCT04024787|No Intervention|Waitlist|
32854122|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
32854123|NCT03403335|No Intervention|Control Group|
32854124|NCT05014308|Experimental|piezocision group|piezocision surgical procedure was done according to Dibart's et al,
32854125|NCT05014308|Experimental|fiberotomy group|the fiberotomy procedure followed Edward's et al
32854126|NCT05014308|No Intervention|control group|no intervention
32854127|NCT04024475||A: Opportunistic screening & benign prostate syndrome (BPS)|Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
32854128|NCT04024475||B: Localized/locally advanced PCa with curative intent|B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
32854129|NCT04024475||C: Biochemical relapse|Patients with PSA progression after RP with or without systemic therapy
32854130|NCT04024475||D: Metastatic PCa but hormone sensitive|Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
32854131|NCT04024475||E: Metastatic castration resistant prostate cancer (mCRPC)|Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
32898842|NCT04621175|Active Comparator|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
32898843|NCT04621175|Active Comparator|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
32898844|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
32854132|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
32854133|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
32854134|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
32854135|NCT05014386|Active Comparator|Ahmed Glaucoma Valve Implantation|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
32854136|NCT05014386|Active Comparator|Ologen augmentation group|In addition to what is planned for the other Arm;, a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure.
32854137|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
32854138|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
32854139|NCT00211757|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.
32854140|NCT00211757|Experimental|Divalproex Sodium|Subjects will receive the study drug, divalproex sodium.
32854141|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
32854142|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
32854143|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
32854144|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
32854145|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, >=60 min/day of moderate/vigorous physical activity.
32854146|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, <60 min/day of moderate/vigorous physical activity.
32854147|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, >=60 min/day of moderate/vigorous physical activity.
32854148|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, <60 min/day of moderate/vigorous physical activity.
32854149|NCT04960644|Experimental|MTX and corticosteroid|perimental: MTX and corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response MTX (5-6mg/m^2/day,Maximum dose 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
32854150|NCT04960644|Active Comparator|corticosteroid|perimental: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response
32854151|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
32854152|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
32854153|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
32854154|NCT04373967|Experimental|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
32854155|NCT04373967|Active Comparator|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
32854156|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
32854157|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
32854158|NCT04026191|Other|Orthovisc-T|
32854159|NCT04026425|Experimental|ME/CFS|Adults with ME/CFS
32854160|NCT04026425|Active Comparator|Healthy controls|Healthy, low-active adults
32898845|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
33320470|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
32854161|NCT04373499|Experimental|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:~answer questions about how to use the inhaler as part of a pre-video assessment.~watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.~answer questions on the tablet to assess how well they understand how to use the inhaler.~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
32854162|NCT04373499|Active Comparator|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
32854163|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
32854164|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
32854165|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
32854166|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
32854167|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
32854168|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
32854169|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
32854170|NCT03955757|Experimental|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
32854171|NCT03955757|Active Comparator|Control|Control communities will behave as usual
32854172|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
32854173|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
32854174|NCT04028609|Experimental|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
32854175|NCT04028609|Active Comparator|Services as Usual|Subjects receive medical services as usual.
32854176|NCT05019768|Active Comparator|sCXL|Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes
32854177|NCT05019768|Experimental|aCFXL|"Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.~Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes"
32854178|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
32854179|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
32854180|NCT04020575|Experimental|Dose Escalation|"Dose escalation or de-escalation is tested in cohorts of 3 patients each using standard 3+3 dose-finding."
32854181|NCT04020575|Experimental|Luminal|Dose Expansion - 15 patients will be enrolled with luminal (hormone receptor positive, HER2 negative) metastatic breast cancer.
32854182|NCT04020575|Experimental|HER2+|Dose Expansion - 15 patients will be enrolled with HER2+ metastatic breast cancer.
32854183|NCT04020575|Experimental|Triple Negative|Dose Expansion - 15 patients will be enrolled with triple negative metastatic breast cancer.
32854184|NCT05008614|Experimental|Erector spinae plane block group (ESP group)|"Patients receiving continuous unilateral ESP block.~Interventions:~Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)"
32854185|NCT05008614|Active Comparator|Thoracic epidural analgesia group (TEA group)|"Patients receiving thoracic epidural analgesia.~Interventions:~Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)"
32854186|NCT04022057|Active Comparator|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
32854187|NCT04022057|Sham Comparator|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
32854188|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
32854189|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
32854190|NCT04029701|Experimental|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
33406703|NCT05649774|Active Comparator|Myofascial Release (MFR)|The therapist will place its hands on the T12-L1 levels as well as on the sacrum. A cross handed hold will be performed along the fascia. Then for the gluteus Medius and maximus muscle, the therapist will stand facing the participant's leg and closed to the superior border of participant's pelvis. The therapist will place the palm of the hand on the anterior surface, allowing the fingers to rest on the outer fibers of the gluteal muscles stabilizing the pelvis of the participants. Allow the participant to flex its knee while applying adequate amount of stretch on the hip joint in an open pack position. Hold, wait for the release and stretch again. for tensor fascia Latae, The therapist will place several slightly adducted fingers of its one hand on the superior fibers proximal to the insertion on the anterior superior iliac crest and the thumb as well as the other fingers of the other hand on the distal muscle fibers. Hold, wait for the release and stretch again.
32854191|NCT04029701|Placebo Comparator|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
32854192|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
32854193|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
32854194|NCT04029935|Experimental|Physical Fatigue Condition|
32854195|NCT04029935|Placebo Comparator|Control Condition|
32854196|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
32854197|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
32854198|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
32854199|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
32854200|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
32854201|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
32854202|NCT04021277|Experimental|ACT with chemotherapy in metastatic solid tumours|Part 1: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with solid tumours
32854203|NCT04021277|Experimental|ACT with chemotherapy in metastatic CRC|Part 2: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
32854204|NCT04021277|Experimental|ACT with chemotherapy in metastatic PDAC|Part 2: PS101 administered together with standard of care chemotherapy (Gemcitabine and nab-paclitaxel) and US insonation over the targeted liver metastasis in patients with metastatic Pancreatic Duct Adenocarcinoma (PDAC)
32854205|NCT04376463|Experimental|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
32854206|NCT04376463|Experimental|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
32854207|NCT04376463|Experimental|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
32854208|NCT04376463|Experimental|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
32854209|NCT04029779|Experimental|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
32854210|NCT04029779|No Intervention|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
32854211|NCT04373187|Experimental|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
32854212|NCT04373187|Experimental|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
32854213|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
32854214|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
32854215|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
32854216|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
32854217|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
33104358|NCT04605055|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
33104359|NCT04605055|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
33104360|NCT04683458||Paclitaxel-coated devices|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).
33104361|NCT04683458||Controlls|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).
32854218|NCT00921843|Experimental|Methadone 0.1mg/kg|Methadone 0.1mg/kg
32854219|NCT00921843|Experimental|Methadone 0.2mg/kg|Methadone 0.2mg/kg
32854220|NCT00921843|Experimental|Methadone 0.3mg/kg|Methadone 0.3mg/kg
33104362|NCT04319497|Other|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
33104363|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
32854221|NCT00921843|Placebo Comparator|Control|No methadone
32854222|NCT04020653|Placebo Comparator|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
32854223|NCT04020653|Experimental|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
32854224|NCT04020653|Experimental|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
32854225|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
32854226|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
32854227|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
32854228|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
32854229|NCT05013918||Hospitalized people in Nursing Home|
32854230|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
32854231|NCT05008458||children with febrile seizures|
33104364|NCT00537537|Active Comparator|1|Telbivudine
33104365|NCT00537537|Active Comparator|2|Telbivudine
33104366|NCT00537537|Active Comparator|3|Telbivudine
33104367|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
32854232|NCT05008458||febrile children without seizures|
32854233|NCT05008458||healthy control children|
32854234|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
32854235|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
32854236|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
32854237|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
32854238|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
32854239|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
32854240|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
32854241|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
32854242|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
32854243|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
32854244|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
32854245|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
32854246|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
32854247|NCT04372641|Experimental|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32854248|NCT05008302|Experimental|To improve the coordination of the wrist and hand after stroke in three age groups.|The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
32854249|NCT05019690|Experimental|Apatinib Combined With Albumin-Bound Paclitaxel|Participants will receive apatinib combined with albumin-bound paclitaxel until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32854250|NCT04029467|Active Comparator|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
32854251|NCT04029467|Experimental|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
32854252|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
32854253|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
32854254|NCT05019300||COVID-19 patients discharged from critical care units|Adults over 18 years of age who have been hospitalized after COVID-19 diagnosis in the critical care units of Red Salud UC Christus who have been cognitively evaluated with Montreal Cognitive Assessment (MoCA) days prior to their discharge. All patients with a previous history of confirmed neurocognitive or psychotic disorders, prior to hospital admission, were excluded.
32854255|NCT04028999|Experimental|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
32854256|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
32854257|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
32854258|NCT05019456|Experimental|Vaccine|Participants who elect to receive the vaccine
32854259|NCT03402399|Other|Primary Myelofibrosis|Blood test
32854260|NCT03402399|Other|Secondary Myelofibrosis|Blood test
32854261|NCT05019378|Experimental|autologous SVF treatment|Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint
32854262|NCT05019378|No Intervention|Placebo group|No treatment
32854263|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
32854264|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
32854265|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
32854266|NCT05013606|Experimental|Active Treatment: Hydrogen water|Hydrogen pills mixed in a water glass that is ingested up to five time a day for 30 days.
32854267|NCT05013606|Placebo Comparator|Placebo: Inactive pill|Inactive pills mixed in a water glass that is ingested up to five time a day for 30 days.
32854268|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
32854269|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
32854270|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
32854271|NCT04020497|Experimental|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
32854272|NCT04020497|Active Comparator|SAU (Support as usual)|SAU alone which was chosen as a control condition.
32854273|NCT05013684|Active Comparator|Older adults with BPPV|
32854274|NCT05013684|No Intervention|Older adults without BPPV|
32854275|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
32854276|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
32854277|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
32854278|NCT05013762|Active Comparator|Speed-biased complex motor skill training|"Participants will perform 400 complex movements per day over 4 days over a one-week period. The task requires participants to navigate their hand through a track projected on the surface of a table with a width of 5cm. Participants receive adaptive score based on their movement time. ."
32854279|NCT05013762|Other|Accuracy-biased complex motor skill training|The accuracy-biased group receives a dose equivalent intervention with a emphasize on accuracy. The width of the track projected on the table is narrower (less than 2cm) and the adaptive score received are based on their accuracy to say within the boundary of the track.
32854280|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
32854281|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
32854282|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
32854283|NCT04020263|Experimental|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
32854284|NCT04020263|Placebo Comparator|Placebo|Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.
32854285|NCT00924885|Experimental|Thin Follicle Aspiration Needle|Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
32739093|NCT05714267|Experimental|Active noise cancelling|Patients corresponding to the number 1 blocks in the randomization table according to the order of surgery were included in the active noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the active noise control headset (Sony WH1000xm4) was placed on the patient's head. The active noise control feature of the headset was turned on and it was not removed until the dressing of the patient was closed at the end of the operation. In this group, the vital signs of the patients were followed up during the surgery. At the end of each surgery, the researcher disinfected the earplugs with an antiseptic solution containing 2% chlorhexidine. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
32854286|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|"Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg."
32854287|NCT05013060|Active Comparator|The mixture of probiotics and microcapsulated sodium butyrate|One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
32854288|NCT05013060|Placebo Comparator|Placebo|Maltodextrin
32854289|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
32854290|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
32854291|NCT05008068|Experimental|PRF alone|
32854292|NCT05008068|Active Comparator|PRF in addition to Simvastatin|
32854293|NCT04027985|Experimental|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
32854294|NCT04027985|Sham Comparator|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
32854295|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
32854296|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
32854297|NCT04020809|Experimental|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
32854298|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
32854299|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
32854300|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
32854301|NCT04027751|Experimental|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
32854302|NCT04027751|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
32854303|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
32854304|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
32854305|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
32854306|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
32854307|NCT04027907||T2DM|
32854308|NCT04027907||healthy controls|
32854309|NCT05018988|Experimental|Oral vitamin D3 spray|10µg/day for 12 weeks (BetterYou ltd.)
32854310|NCT05018988|Placebo Comparator|Placebo Comparator|Xylitol (BetterYou ltd.)
32854311|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
32854312|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
32854313|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
32854314|NCT03401775|No Intervention|Group2|No intervention will be administered
32854315|NCT04406285|Active Comparator|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
32854316|NCT04406285|Experimental|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
32854317|NCT04406285|Active Comparator|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
33104368|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
33104369|NCT04566445|Experimental|GT005 Medium Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
33104370|NCT04566445|Experimental|GT005 High Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
32854318|NCT04406285|Experimental|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
33104371|NCT04566445|No Intervention|Untreated control|Approximately 83 subjects are planned, with subjects randomised to untreated control.
32854319|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
32854320|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
33104372|NCT04319770|Active Comparator|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
33104373|NCT04319770|Experimental|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
32854321|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
32854322|NCT04377165|Active Comparator|Newsfeed|This will provide you with reliable accurate information on the pandemic.
32854323|NCT04377165|Experimental|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
32854324|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
33104374|NCT04551469|Experimental|Treatment Arm|30 minutes of listening to music
32854325|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
33406704|NCT05649774|Active Comparator|Kinesio Taping (KT)|"Lumbar star correction technique was applied. 4 tape I strips will be cut. The paper from the center will be torn. The targeted area will be stretched as tolerated at the lumbar region. The therapist will apply 25% to 35% tension to the strip within the therapeutic zone over the target tissue. End the strip with no tension and activate the adhesive. For the second strip change the posture in order to change the stretch on the tissue, apply the second strip with 25% to 35% tension in the center of the tape and end with no tension. Activate the adhesive. Now flex the trunk and rotate on one side. Apply the third tape strip with 25% to 35% tension in the center of the tape. Apply the fourth tape strip with flexion and rotation on the opposite side again with 25% to 35% tension on the strip.~The tape will be changed 3 times per week."
33104375|NCT04551469|No Intervention|Standard of Care|actual sounds of the intensive care unit environment
33406705|NCT05649774|Experimental|Myofascial Release with Taping (MFKT)|Same Protocol of MFR followed by KT
32854326|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
32854327|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
32854328|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
32854329|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
32854330|NCT04376697|Experimental|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
32854331|NCT04028765|Active Comparator|Oral Misoprostol|Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
32854332|NCT04028765|Active Comparator|Oxytocin|IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
32854333|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
32854334|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
32854335|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
32854336|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
32854337|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
32854338|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
32854339|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
32854340|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
33104376|NCT04073472|Experimental|mesenchymal stem cells (MSCs)|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed.
33104377|NCT04548349|Experimental|Altreno Group|
33104378|NCT04548349|Experimental|BPO Group|
33104379|NCT04548349|No Intervention|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
33104380|NCT04072809||All participants|All participants in the study will experience the same procedures.
32854341|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
32854342|NCT04026971|Experimental|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
32854343|NCT04026971|Other|Classical Nutrition Education|Classic nutrition training and diet list is provided.
32854344|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
32854345|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
32854346|NCT04022135|Active Comparator|Folic acid|0.6 mg/day
32854347|NCT04022135|Experimental|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
32854348|NCT05007912||Orvil Group|Group that used the Orvil (circular stapler) for esophagojejunostomy
32854349|NCT05007912||Linear Group|Group that used the linear stapler for esophagojejunostomy
32854350|NCT04372719|Experimental|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
32854351|NCT04957914|Active Comparator|Insulin Glargine (Period 1)|Insulin glargine administered subcutaneously (SC).
32854352|NCT04957914|Experimental|LY3209590 (Period 2)|LY3209590 administered SC.
32854353|NCT04027127|Active Comparator|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
32854354|NCT04027127|Active Comparator|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
32854355|NCT04957758|Active Comparator|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
32854356|NCT04957758|Placebo Comparator|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray
32854357|NCT04027283|Active Comparator|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
32854358|NCT04027283|Active Comparator|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
32854359|NCT04027283|Active Comparator|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
32854360|NCT04027283|Active Comparator|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
32854361|NCT04027283|Placebo Comparator|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
32854362|NCT04027283|Placebo Comparator|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
32854363|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
32854364|NCT02241915|Sham Comparator|Control|No microbial sealant
32854365|NCT04954794|Experimental|TACE in combination with Sintilimab plus a bevacizumab biosimilar|
32854366|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
32854367|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
32854368|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
32854369|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
32854370|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
32854371|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
32854372|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
32854373|NCT02241993||Type 1 diabetic|
32854374|NCT04027673|Experimental|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
32854375|NCT04027673|No Intervention|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
32854376|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
32854377|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
33104381|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
32854378|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
32854379|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
32854380|NCT05012514|No Intervention|Control- Without intervention|The participants have the right side of the abdomen as a control without inversion
32854381|NCT05012514|Active Comparator|LLLT- With intervention|The participants received the LED PBMT treatment with associated red and infrared wavelengths sequentially on the left side of the abdomen
32854382|NCT04027205|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
32854383|NCT04027205|Active Comparator|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
32854384|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
32854385|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
32854386|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854387|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854388|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854389|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854390|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854391|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854392|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
32854393|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
32854394|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
32854395|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
32854396|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
32854397|NCT04026503|Experimental|Live Long Walk Strong|8 week rehabilitation program
32854398|NCT04026503|Active Comparator|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
32854399|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
32854400|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
32854401|NCT03953261|Experimental|Curcumin|
32854402|NCT03953261|Placebo Comparator|Placebo|
32854403|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
32854404|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
32854405|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
32854406|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE~LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),~HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)~HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
32854407|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
32854408|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
32854409|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
32854410|NCT03022565|Experimental|Vorinostat|"Vorinostat:~400 mg orally, once daily for 15 days."
33320471|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
32854411|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
32854412|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
32854413|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
32854414|NCT04026269|Experimental|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
32854415|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
32854416|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
32854417|NCT05001204|Experimental|68Ga-NOTA-RM26 PET/CT|Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.
32854418|NCT03022409|Experimental|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
32854419|NCT03022409|Experimental|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
32854420|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
32854421|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
32854422|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
32854423|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
32854424|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
32854425|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
32854426|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
32854427|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
32854428|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
32854429|NCT02242227|Placebo Comparator|Placebo|
32854430|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
32854431|NCT04366947|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
32854432|NCT04366947|Experimental|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
32854433|NCT05011968|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce (soil, water, harvesting time)
32854434|NCT05011968|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Iodine crop lettuce.
32854435|NCT03950609|Experimental|Treatment (lenvatinib, everolimus)|Patients receive lenvatinib PO daily and everolimus PO daily on days 1-28. Treatments repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32854436|NCT04366557|Experimental|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
32854437|NCT04366557|Other|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
33406706|NCT05649774|Sham Comparator|Placebo Treatment|The control group received a sham myofascial release for 40 minutes per treatment session, three times a week for three weeks. The sham myofascial release was applied by gently placing the hands over the same areas treated in the MFR group,without sliding, just enough to maintain contact for the desired time.
33406707|NCT05649696|Experimental|r-SAK group|intravenous injection of single bolus 5 mg r-SAK in 3min
33406708|NCT05649696|Placebo Comparator|normal saline group|intravenous injection of 10ml saline in 3min, r-SAK and saline are the same in appearance
33406709|NCT05214846|Experimental|Education and Counseling|"After obtaining written informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. Women were counseled for 6 weeks.~Anxiety-depression levels (post-test) were applied by phone call 6 weeks later.This education consisted of the definition and the purpose of pregnancy and pregnancy problems and nutrition during pregnancy, sexuality during pregnancy, number of fetal movements, preparation of the delivery bag, breast care, etc."
32854438|NCT05000892|Experimental|Sintilimab + Carboplatin + Nab-paclitaxel|"Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
32854439|NCT04025957|Experimental|SHR-1501 dose escalation|SHR-1501 given subcutaneously
32854440|NCT04025957|Experimental|SHR-1501 dose expansion|SHR-1501 given subcutaneously
32854441|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
32854442|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
32854443|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
32854444|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
32854445|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
32854446|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
32854447|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
32854448|NCT04372407|Experimental|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
32854449|NCT05007600|Experimental|trial group|Participants in the experimental group received an 8-week intensive (Monday to Friday) online interactive course.
32854450|NCT05007600|No Intervention|Control group|Participants in the control group consumed 8 weeks of unidirectional online video and audio programs (such as from YouTube).
32854451|NCT04372485|Other|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
32854452|NCT04372485|No Intervention|Usual care|Adolescents in this arm will receive usual care.
32854453|NCT05000814||cDLT|patients using conventional double lumen tube
32854454|NCT05000814||VDLT|patients using Vivasight DLT
32854455|NCT02242383||Essential hypertension|
32854456|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
32854457|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
32854458|NCT04366479|Experimental|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
32854459|NCT05000112||Patients with mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is seen on surface of the vaginal mucosa, the patient is diagnosed with mesh exposure.
32854460|NCT05000112||Patients without mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is not seen on surface of the vaginal mucosa, bimanual examination will be performed to confirm no foreign body can be feeled on surface of the vaginal mucosa. Then the patient belong to this group.
32854461|NCT04025723|Active Comparator|Young|men aged between 18 to 30 years old
32854462|NCT04025723|Active Comparator|Middle-aged|men aged between 35 to 50 years old
32854463|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
32854464|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
32854465|NCT04366089|Active Comparator|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
32854466|NCT04366089|Experimental|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
32854467|NCT05011500|Experimental|Starting with closed mask|Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.
32854468|NCT05011500|Experimental|Starting with open mask|Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.
33320472|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
32854469|NCT05011500|Experimental|Starting with no mask|Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.
32854470|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
32854471|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
32854472|NCT05011110|Experimental|GraduSOX (left leg) & Sigvaris (right leg)|Half of participants will wear a GraduSOX compression stocking on their left leg whilst wearing a Sigvaris compression stocking on their right leg.
32854473|NCT05011110|Experimental|GraduSOX (right leg) & Sigvaris (left leg)|Half of participants will wear a GraduSOX compression stocking on their right leg whilst wearing a Sigvaris compression stocking on their left leg.
32854474|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
32854475|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
32854476|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
32854477|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
32854478|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
32854479|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
32854480|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
32854481|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
32854482|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
32854483|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
32854484|NCT03079830|Sham Comparator|Saline continous|Piritramid
32854485|NCT04371939|Experimental|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
32854486|NCT04371939|Experimental|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
32854487|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
32854488|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
32854489|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
32854490|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
32854491|NCT02242539|Experimental|Height measurement poster|
32854492|NCT02242539|Experimental|Community-based monitoring|
32854493|NCT02242539|No Intervention|Control|
32854494|NCT05011344|Experimental|Exposed hospital staff|"Hospital health care or non-health care staff willing to participate in the study:~Healthcare personnel (physician, nurse, caregiver) who have worked for a minimum of 2 weeks since March 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of COVID-19 infection, in the participating centers: intensive care units, emergency rooms, radiology, COVID-19 units;~Staff (physician, technician) who have worked for a minimum of 2 weeks since March 1, 2020 in the AP-HM laboratories handling samples from patients confirmed or suspected of having COVID-19 infection."
33320473|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
33320474|NCT03780530|Active Comparator|subcuticular suturing|
33320475|NCT03780530|Active Comparator|surgical glue|
33320476|NCT03780530|Active Comparator|adhesive steri-strip tape|
32960775|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960776|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960777|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960778|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960779|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960780|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
33320477|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
32960781|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960782|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960783|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960784|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960785|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960786|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960787|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
32960788|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
32960789|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
32960790|NCT01121172||lean|
32960791|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
32960792|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
32960793|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
32960794|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
33320478|NCT04879160||1/ Cohort 1A|Clinician raters familiar with NF1
33320479|NCT04879160||2/ Cohort 1B|Clinician raters without specific NF1 familiarity
33320480|NCT04879160||3/ Cohort 2A|Non-clinician raters familiar with NF1
33320481|NCT04879160||4/ Cohort 2B|Non-clinician raters without specific NF1 familiarity
33320482|NCT04879160||5/ Cohort 3|Subjects with NF1
33320483|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
33320484|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
33320485|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
32854495|NCT05011344|Other|'Non-exposed' hospital workers|Hospital health care worker (physician, nurse, caregiver) willing to participate in the study who has not worked since March 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having COVID-19 infection.
32854496|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
32854497|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
32854498|NCT04999800|Experimental|Pembrolizumab combined with Anlotinib|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated
32854499|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.~Cyproterone acetate taken for at least 6 months."
32854500|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
32854501|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.~Never exposed to cyproterone acetate."
32854502|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
32854503|NCT04366011|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
32854504|NCT04366011|Experimental|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
32854505|NCT02242851||Hypertensive patients|
32854506|NCT04999878|Experimental|treatment group|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
32854507|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
32854508|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
32854509|NCT04459104|Experimental|chronic low back patients|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
32854510|NCT04459104|Experimental|breast cancer survivors having chronic pain|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
32854511|NCT04459104|Active Comparator|healthy pain-free controls|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
32854512|NCT04365621|Other|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
32854513|NCT04458090|Experimental|Intervention|Receive hospice patient decision aid
32854514|NCT04458090|No Intervention|Control|Does not receive hospice decision aid
32854515|NCT04365543|Experimental|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
32854516|NCT04365543|Experimental|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
32854517|NCT04457856|Experimental|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
32854518|NCT04457856|Placebo Comparator|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
32854519|NCT04371705|Experimental|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
32854520|NCT04371705|Placebo Comparator|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
32854521|NCT02243085||photoselective vaporization|
32903543|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
32960795|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
32960796|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
32960797|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
32960798|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
32960799|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
32960800|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
32960801|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
32960802|NCT01123512|Experimental|Kiva VCF Treatment System|
32960803|NCT01123512|Active Comparator|Balloon Kyphoplasty|
33406710|NCT05214846|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.The control group was called by phone at the end of 6 weeks and told that they would be retested and 6 weeks later, they were called by phone and their anxiety and depression levels (posttest) were applied. directed to continue
33406711|NCT05201898|Placebo Comparator|usual medical management|with regular doctor visits every 3 months
33406712|NCT05201898|Experimental|usual medical management+individual dietary consultation|with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
32960804|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
32960805|NCT05307120|Experimental|Intervention|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on Android smartphones that enables continuous monitoring of nutrition (via food diary), physical activity (via activity tracker Fitbit and self-reported activities) and blood glucose values (via Freestyle libre 2 sensors). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
32960806|NCT05307042||2012-cohort|
32960807|NCT05306730|Experimental|FOCUS group|"Group of patients with chest pain undergoing FOCUS ( Focused Cardiac Ultrasound ).~Patients with odd registration number."
32960808|NCT05306730|Active Comparator|Non-FOCUS group|Patients with even registration number.
32960809|NCT05306184||ECT group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving ECT as treatment
32960810|NCT05306184||TCA group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving medication (TCA) as treatment
32960811|NCT05304546|Experimental|Single Arm MK3475, encorafenib and binimetinib|Intravenous pembrolizumab 400 mg Q6W + oral encorafenib 450 mg QD + oral binimetinib 45mg BID, for the first 4 weeks of the study. Starting week 5, monotherapy pembrolizumab 400 mg Q6W.
32960812|NCT05291442|No Intervention|control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
32960813|NCT05291442|Experimental|Intervention group|"To integrate Family System Care and Theme Care Action Module to improve resilience, family function, self-efficacy, and quality of life for stroke patients and their caregivers.~First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
32960814|NCT05289960|Other|patients eligible for weaning by spontaneous breathing trial|
32960815|NCT05289960|Other|non invasive ventilation after weaning|
32960816|NCT05288478|Active Comparator|Group A|First 6 weeks they will use the mouthrinse 5 times a day, following 4 week washout period.
32960817|NCT05288478|Active Comparator|Group A, second period|"After the washout period, the next 6 weeks the will use the mouthrinse twice a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
32960818|NCT05288478|Active Comparator|Group B|First 6 weeks they will use the mouthrinse twice a day, following 4 week washout period
32960819|NCT05288478|Active Comparator|Group B, second period|"After the washout period, the next 6 weeks they will use the mouthrinse 5 times a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
32960820|NCT05202210||patients with Noonan syndrome|extra sample of blood and urine will be collected and stored for research utilisation
32960821|NCT05152446|Experimental|Infusion management scheme|To implement infusion management scheme, then observe the continuous changes.
32960822|NCT05115942|Experimental|Hydronidone group|Patients were given three capsules of hydronidone three times a day for 52 weeks.
32960823|NCT05115942|Placebo Comparator|The placebo group|Patients were given three capsules of placebo three times a day for 52 weeks.
32960824|NCT04974138|Active Comparator|CC with amlodipine 5mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besylate tablets (5mg/d)
32960825|NCT04974138|Experimental|CC with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
32960826|NCT04974138|Active Comparator|CT with amlodipine 5mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besylate tablets (5mg/d)
32960827|NCT04974138|Experimental|CT with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
32960828|NCT04973982|Active Comparator|ENVARSUS|ENVARSUS used as per licence
33320486|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
33320487|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
32854522|NCT05011032|Other|Control Group|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
32854523|NCT05011032|Experimental|Non-diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
32746647|NCT05474235||ALS or Suspected ALS Patient|Subjects with clinical diagnosis of possible, laboratory-supported probable, probable or definite, ALS or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features or a blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features.
32854524|NCT05011032|Experimental|Diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
32854525|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
32854526|NCT05006898|Experimental|PBO Investigational drug|Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
32854527|NCT05006898|Active Comparator|Pilocarpine|Pilocarpine was instilled in the other oye.
32854528|NCT05006898|Active Comparator|Brimonidine|Brimonidine was instilled in the other eye.
32854529|NCT04463628||Questionnaire and/or interview|An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).
32854530|NCT02243241|Experimental|HYD|
32746648|NCT05474235||Blood Relative of ALS Patient|Subjects with family history (first, second or third degree blood relative) of ALS or other motor neuron disease.
32746649|NCT05474235||Healthy Control|Subjects with no personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease
32854531|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
32854532|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
32854533|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
32854534|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
32854535|NCT04365309|No Intervention|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
32854536|NCT04365309|Experimental|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
32854537|NCT04365231|Experimental|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
32854538|NCT04365231|Active Comparator|conventional management of patients|Regular management of patients
32854539|NCT05007210|Experimental|Prenatal massage therapy group|Prenatal massage therapy for prenatal attachment, physiological and psychological distress, maternal and fetal well-being.
32854540|NCT05007210|No Intervention|Control group|Pregnant women in the control group were interviewed twice (once a week for 30th and 34th week) by the same massaging midwife. No additional attempt was made except for filling out the forms and evaluating the biophysical profile by the obstetrician in these interviews. The massaging midwife's phone number was given to the pregnant women in both groups if they want to reach anytime. A phone number was set for the study, and this phone number was used by the massaging midwife. This service has been provided for pregnant women to reach her whenever they want.
32854541|NCT02243319|Experimental|Group 1|"A → B → C~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
32854542|NCT02243319|Experimental|Group 2|C → A → B
32854543|NCT02243319|Experimental|Group 3|B → C → A
32854544|NCT02243319|Experimental|Group 4|C → B → A
32746650|NCT05187273|Experimental|intervention|
32854545|NCT02243319|Experimental|Group 5|B → A → C
32854546|NCT02243319|Experimental|Group 6|A → C → B
32960829|NCT04973982|Active Comparator|ADOPORT|ADOPTION used as per licence
32746651|NCT05187273|No Intervention|control|
32854547|NCT05007054||Percutaneous coronary intervention|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months.
32746652|NCT05135325|Experimental|No-blood-type message|This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
32746653|NCT05135325|Experimental|Blood-type message|This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
32746654|NCT05135325|No Intervention|Shortage control|This group will not receive a message.
32746655|NCT05135325|No Intervention|No-shortage control|This group will not receive a message.
32746656|NCT04426305|Experimental|Intervention arm|psychosocial support
32746657|NCT04426305|Active Comparator|control arm|care as usual
32746658|NCT05474157||Study group|15 patients Patients followed in the Intensive Care Unit due to COVID-19 infection
32746659|NCT05474157||Control group|15 patients Patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period
32746660|NCT05474079|Experimental|Statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% heart rate reserve (HRR) three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
32746661|NCT05474079|No Intervention|Statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their general practitioner (GP).
32746662|NCT05474079|Experimental|Non-statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
32746663|NCT05474079|No Intervention|Non-statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their GP.
32746664|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
32746665|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
32746666|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
32746667|NCT05474001|Active Comparator|Fentanyl group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 20 μg (0.5 mL) fentanyl IT.~1 mL IV normal saline immediately after the placement of the spinal."
32746668|NCT05474001|Active Comparator|Granisetron group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 0.5 mL normal saline IT.~1 mg (1 mL) IV granisetron after spinal placement."
32746669|NCT05474001|Placebo Comparator|Control group|"10 mg hyperbaric Bupivacaine ( 2ml ) IT and normal saline 0.5 ml~1 ml normal saline IV after spinal placement."
32746670|NCT05316753|Experimental|Schiller Defigard HD- 7 - DGHD7|Device: Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard HD- 7 - DGHD7, Schiller Medical, France) with adult pads (0-21-0003 Schiller) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 200J, 200J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 min post-shock), otherwise after the 3rd shock Other Name: DGHD7
32746671|NCT05316753|Active Comparator|LIFEPAK 15, Physio-Control - LP15|"Device: Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 360J, 360J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock.~Other Name: LP15"
32746672|NCT05313945|Experimental|Passive indwelling urinary catheter removal|The passive indwelling urinary catheter removal takes place due to gravity.
32746673|NCT05313945|Active Comparator|Manual indwelling urinary catheter removal|The manual indwelling urinary catheter removal takes place by manual traction by a nurse.
32746674|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
32746675|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
32854548|NCT05007054||Coronary artery bypass grafting|The left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. Te procedure was performed by surgeons experienced in onpump or of-pump surgery at the operator's discretion.
32854549|NCT05007054||Medical therapy|Patients with neither PCI nor CABG treatment were allocated to the MT alone group. For medical therapy, antiplatelet medication, statins, renin-angiotensin system blockade, β-blockers, and nitrate were used.
32854550|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
32854551|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
32854552|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
32854553|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
32854554|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
32854555|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
32854556|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
32854557|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
32854558|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
32854559|NCT04364919|Experimental|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
32854560|NCT04364919|No Intervention|control group|The control group received routine prenatal care only.
32854561|NCT04364685|Active Comparator|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
32854562|NCT04364685|Experimental|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
32854563|NCT04371237|Experimental|Intermittent pneumatic compression|IPC sleeve device on leg
32854564|NCT04371237|Experimental|Heat therapy|Custom water-circulating garment on leg
32854565|NCT02243787|Experimental|COVA322|single i.v. infusion
32854566|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
32854567|NCT05010330||healthy control|healthy people
32854568|NCT05010330||lung cancer|patients diagnosed with lung cancer
32854569|NCT05010252|Experimental|Cycled Light|It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies over 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
32854570|NCT05010252|No Intervention|Dim light|no intervention
32854571|NCT04371159|Experimental|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
32854572|NCT05009940|Experimental|Gradusox then Sigvaris compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Gradusox compression stockings applied to both legs.~After a washout period, the second intervention received are Sigvaris compression stockings applied to both legs."
32854573|NCT05009940|Experimental|Sigvaris then Gradusox compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Sigvaris compression stockings applied to both legs.~After a washout period, the second intervention received are Gradusox compression stockings applied to both legs."
32854574|NCT00922701|Experimental|Peritoneal Dialysis Solution|
32854575|NCT05006664|Experimental|Brentuximab Vedotin (Adcetris) in Combination with CHEP|Single arm, open label, Brentuximab Vedotin (Adcetris) in Combination with CHEP
32854576|NCT04346901|Other|Single Intervention|Before-and-After type of research
32854577|NCT04993872|Experimental|BIC/FTC/TAF|Development phase 4: Biktarvy®
32854578|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
32854579|NCT04994028|Active Comparator|Conventional treatment|Conventional treatment that include behavioral and life style modification and dyspnea prevention education
32854580|NCT04994028|Experimental|conventional treatment with volume Spirometry and deep breathing|Conventional treatment along with volume Spirometry and deep breathing exercise
32854581|NCT04364607|Active Comparator|Neostigmine group|After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine
32854582|NCT04364607|Placebo Comparator|Placebo group|After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo
32854583|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
32854584|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
32854585|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
32854586|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
32854587|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
32854588|NCT04370769||Women with Kidney Disease|Women with kidney disease
32854589|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
32960830|NCT04944654|Experimental|Assigned intervention|Biktarvy OD for 96 weeks
32960831|NCT04733664|Experimental|Cohort 1|Patients will receive one dose of visible fluorescent injectate (VFI)™ and one dose of iohexol approximately 4 hours prior to undergoing dialysis followed by a second dose of VFI and iohexol approximately 1 hour after completing dialysis.
32960832|NCT04503720|Experimental|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
32960833|NCT04503720|Active Comparator|PCA|"PCA (Morphine) and CLoWI (normal saline)~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:~Concentration: 1mg/ml~Bolus (Loading): 1mg~Lockout Interval: 5 minutes~Maximum hourly dose of 10mg"
32960834|NCT04487964|Active Comparator|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
32960835|NCT04487964|Active Comparator|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
32960836|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
32960837|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
32960838|NCT04461600|Experimental|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
32960839|NCT04342182|Experimental|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
32960840|NCT04342182|No Intervention|Standard of care|standard of care (supportive care, oxygen, antibiotics)
32960841|NCT04187352|Experimental|CS1001+ Fluorouracil+Cisplatin|
32960842|NCT04187352|Active Comparator|Placebo+ Fluorouracil+Cisplatin|
32960843|NCT04142892|Experimental|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
32960844|NCT04125498|Active Comparator|OMT|Osteopathic manual treatment
32960845|NCT04125498|Active Comparator|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
32960846|NCT04125498|Sham Comparator|Placebo|Similar to OMT without pressure.
32960847|NCT04125498|Active Comparator|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
32960848|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
32960849|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
32960850|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
32960851|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
32960852|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
32960853|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
32960854|NCT03792360|Experimental|Single Arm|
32960855|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
33033443|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
33406713|NCT05201898|Experimental|usual medical management+individual dietary consultation+ daily tea drinking|with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
33406714|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
33406715|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
32960856|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
32960857|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|
32960858|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
32960859|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
32960860|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
32960861|NCT03336372|Experimental|Picato topical gel|
32960862|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
32960863|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
32960864|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
32960865|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
32960866|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
32960867|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.~For each dose patient will receive 6 injections at 3 interval weeks."
32960868|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
32960869|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
32960870|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
32960871|NCT02323464||Control subjects|Controls from the population without colorectal cancer
32960872|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
32960873|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
32960874|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
32960875|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
32960876|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
32960877|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
32960878|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
32960879|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
32960880|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
32960881|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
32960882|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
32960883|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
32960884|NCT01128426||1|
32960885|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
32960886|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
32960887|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
32960888|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
32960889|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
32960890|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
32960891|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
32854590|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
32854591|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.~Until 11,March, 2015, 59 cases are collected."
32854592|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
32854593|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
32854594|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
32854595|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
32854596|NCT05006742|Active Comparator|CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
32854597|NCT05006742|Active Comparator|FB-CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
32854598|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
32854599|NCT05006586||RVF|All patients having undergone repair for rectovaginal fistula
32854600|NCT04999722|Active Comparator|APP group|Participants with diabetes who had access to a mobile APP
32854601|NCT04999722|Placebo Comparator|Control Group|Diabetes participants who accepted the traditional management model
32854602|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
32854603|NCT04364139|Experimental|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
32854604|NCT04364139|Experimental|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
32854605|NCT04364139|Experimental|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
32854606|NCT04364139|Experimental|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
32854607|NCT04364139|Experimental|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
32854608|NCT04364139|Experimental|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
32854609|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
32854610|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
32854611|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|
32854612|NCT04370925|Active Comparator|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
32854613|NCT04370925|Experimental|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
32854614|NCT02244255|Experimental|FLOMAX®|
32854615|NCT02244255|Active Comparator|HYTRIN®|
32854616|NCT04363983|Active Comparator|Located/resected colorectal cancer|
32854617|NCT04363983|Active Comparator|Advanced colorectal cancer|
32854618|NCT04363983|Active Comparator|Located/resected pancreatic cancer|
32854619|NCT04363983|Active Comparator|Advanced pancreatic cancer|
32854620|NCT04363983|Active Comparator|Located/resected biliary tract cancer|
32854621|NCT04363983|Active Comparator|Advanced biliary tract cancer|
32854622|NCT04363983|Active Comparator|Located/resected gastroesophageal cancer|
32854623|NCT04363983|Active Comparator|Advanced gastroesophageal cancer|
32854624|NCT04363983|Active Comparator|Located/resected neuroendocrine cancer|
32854625|NCT04363983|Active Comparator|Advanced neuroendocrine cancer|
32854626|NCT04363827|Experimental|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
32854627|NCT04363827|No Intervention|Group 1: Observation|observation only
32854628|NCT04363827|Experimental|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
32854629|NCT04363827|No Intervention|Group 2: Observation|Observation only
32854630|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
32854631|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
32854632|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
32854633|NCT02244333||Patients with symptomatic BPS|
32854634|NCT04364061|Experimental|Women with overweight or obesity|
32854635|NCT04363749|Experimental|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
32854636|NCT04363749|Active Comparator|15 healthy controls|dyspnea rating to various dyspneic stimulus
32854637|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
32854638|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
32854639|NCT04363593|Other|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
32854640|NCT04363593|Other|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
32854641|NCT04363593|Other|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
32854642|NCT04370223|Experimental|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
32854643|NCT04370223|No Intervention|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
32854644|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
32854645|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
32854646|NCT04376307|Experimental|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
32854647|NCT04370457|Experimental|Experimental arm|Administration of the MyPal ePRO system
32854648|NCT04370457|No Intervention|Standard care arm|No further intervention besides standard palliative care approach if needed
32854649|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
32854650|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
32854651|NCT04993794|Active Comparator|XueBiJing|XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min
32854652|NCT04993794|Placebo Comparator|Normal saline|0.9% saline every 12 h (q12h) for 60 min
32854653|NCT04363515|No Intervention|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
32854654|NCT04363515|Experimental|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
32854655|NCT05006508|Experimental|Usage of tool|Participants get access to the tool and use it regularly
32854656|NCT05006508|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.
32854657|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
32854658|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
32854659|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
32854660|NCT04999410|Experimental|Long-HITT|Long work bout durations (4 minutes) on cycle ergometers or home trainers
32854661|NCT04999410|Active Comparator|Medium HIIT-L|Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity
32854662|NCT04999410|Active Comparator|Medium HIIT-H|Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs
32854663|NCT04999410|Active Comparator|Short HIIT|Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs
32854664|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
32854665|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
32854666|NCT04993092|Experimental|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
32854667|NCT04993092|Active Comparator|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
32854668|NCT04376073|Experimental|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh <77 kg) po QD day1~21, Anlotinib 12mg po QD day1~14.~Starting dose of anlotinib changed to 10mg from 2020-11-13."
32960892|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
32854669|NCT05006274||Group 1-Traditional soft tissue balance|Patients in group 1 will receive traditional, manual soft-tissue balancing during surgery. For the purpose of the study, the balance will be quantitatively assessed at the end of the case, by means of surgeon-blinded VERASENSE measurements before and after cementation.
32854670|NCT05006274||Group 2-Soft tissue balance using VERASENSE|For the patients in Group 2, intra-operative sensor feedback will be used in creating a quantitatively balanced knee (VERASENSE, OrthoSensor Inc.). Thereby, a quantitatively balanced knee is characterized by a mediolateral load differential below 15lbs at 10-45-90 degrees of flexion.
32854671|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.~For each patient a lung ultrasound examination will be performed."
32854672|NCT04999176|Experimental|Rivaroxaban|Oral Rivaroxaban (10 mg once daily) for 30 days post-operative
32854673|NCT04999176|Active Comparator|Enoxaparin|Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative
32854674|NCT04363203|Active Comparator|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
32854675|NCT04363203|Active Comparator|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
32854676|NCT04363203|Placebo Comparator|Placebo|The pills packs for the 3 arms are identical.
32854677|NCT04363359|Experimental|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
32854678|NCT04363359|Experimental|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
33406716|NCT05638698|Experimental|TG01/QS-21 (Vaccine arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, [priming/booster phase]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
32854679|NCT04363359|Active Comparator|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
32854680|NCT04363359|Active Comparator|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
32854681|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
32854682|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
32854683|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
32854684|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
32854685|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
32854686|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
32854687|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
32854688|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
32854689|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
32854690|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
32854691|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
32854692|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
32854693|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
32854694|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
32854695|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
32854696|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
32903544|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
32960893|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
33320488|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
32960894|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
32960895|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
32960896|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
32960897|NCT01134198|Placebo Comparator|placebo|Placebo
32960898|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
32960899|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
32960900|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
32960901|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
32960902|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
32960903|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
32960904|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
32960905|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
32960906|NCT01137006|Experimental|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
32960907|NCT01137006|Experimental|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
32960908|NCT01137396|Experimental|Modafinil|
32960909|NCT01137396|Placebo Comparator|Placebo|
32960910|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
32960911|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
32960912|NCT01139190|Experimental|PL3100|
32960913|NCT01139190|Active Comparator|Naproxen|
32960914|NCT01139814|Experimental|Catheter Robot|device
32960915|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
32960916|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
32960917|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
32960918|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
32960919|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
32960920|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
32960921|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
32960922|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
32960923|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
32960924|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
32960925|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
32960926|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
32960927|NCT01143792|Experimental|CRA + HIV prevention|
32960928|NCT01143792|Active Comparator|Case Management + HIV prevention|
32960929|NCT01143792|Active Comparator|MET + HIV prevention|
32960930|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
32960931|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
32960932|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
32960933|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
32960934|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
32854697|NCT04457310|Experimental|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
32854698|NCT04457310|Experimental|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
32854699|NCT04457310|Experimental|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
32854700|NCT04457310|Experimental|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
32854701|NCT04457310|Placebo Comparator|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
32854702|NCT04369521|Experimental|Intervention|low free sugar diet with nutrition and exercise recommendation
32854703|NCT04369521|No Intervention|control|regular diet with nutrition and exercise recommendation
32854704|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
32854705|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
32854706|NCT04457232|Experimental|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
32854707|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
32854708|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
32854709|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
32854710|NCT04998630|Experimental|A (4Hz)|ESWT frequency 4Hz washout period: 1 week
32854711|NCT04998630|Experimental|B (8Hz)|ESWT frequency 8Hz washout period: 1 week
32854712|NCT04998552|Experimental|SBRT (Cyberknife)|5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
32854713|NCT04998552|Active Comparator|IMRT|1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).
32854714|NCT04376151|Experimental|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
32854715|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
32854716|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
32854717|NCT04998474|Experimental|FRAME-001 personalized vaccine|"Prospective, single arm, multi center, open-label, phase II clinical trial.~Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs."
32854718|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
32854719|NCT05005884|Active Comparator|oral phenolics intake|Prescription of oral phenolics 250 mg two times daily
32854720|NCT05005884|Placebo Comparator|placebo caplet intake|Prescription of oral phenolics 250 mg two times daily
32854721|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
32903545|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
32854722|NCT04375995|Other|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
32854723|NCT04375995|Other|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
32854724|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
32854725|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
32854726|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
32854727|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
32854728|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
32854729|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
32854730|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
32854731|NCT04370535|Placebo Comparator|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
32854732|NCT04370535|Active Comparator|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
32854733|NCT04370535|Placebo Comparator|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
32854734|NCT04370535|Active Comparator|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
32854735|NCT04993014|Active Comparator|Cohort 1, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline
32854736|NCT04993014|Experimental|Cohort 1, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline
32854737|NCT04993014|Active Comparator|Cohort 2, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline
32854738|NCT04993014|Experimental|Cohort 2, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline
32854739|NCT05005494|Active Comparator|Magnesium sulfate IV|10 patients scheduled for thyroidectomy
32854740|NCT05005494|Placebo Comparator|Placebo|10 patients scheduled for thyroidectomy
32854741|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
32854742|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
32854743|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
32854744|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
32854745|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
32854746|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
32854747|NCT04375839|Experimental|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
32854748|NCT04375839|Active Comparator|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
32854749|NCT04025567|Experimental|1/Arm 1|Oral vancomycin
32854750|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
32854751|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
32854752|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
32854753|NCT04025177|Experimental|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
32854754|NCT04358055|Experimental|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
32854755|NCT04992702|Experimental|Animated Video|The information in the ACL animated video (https://vimeo.com/281721823) was displayed as a story of a typical athlete who sustained an injury and how this could be prevented through evidence-based prevention strategies.
32854756|NCT04992702|Active Comparator|Web-based Article|The active control group received commonly accessed information from a WebMD web-based article on ACL injury prevention.
32854757|NCT04992702|Placebo Comparator|Placebo control|The placebo control group intervention received an educational video from the CDC about concussions that is comparable in duration to that of the ACL video (https://youtu.be/fSRWF44wgn8).
32903546|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
32903547|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
33406717|NCT05638698|Experimental|TG01/QS-21 + Balstilimab (Vaccine + PD-1 arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. Balstilimab is given intra-venously as infusion and begins week 3, then given every 2 weeks for up to 51 weeks. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, [priming/booster phase]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) given once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
32854758|NCT04347057|Experimental|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
32854759|NCT04347057|Experimental|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
32854760|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
32854761|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
32854762|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
32854763|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
32854764|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
32854765|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
32854766|NCT04362033|Experimental|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
32854767|NCT04362033|Experimental|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
32854768|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
32854769|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
32854770|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
32854771|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
32854772|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
32854773|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
32854774|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
32854775|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
32854776|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
32903548|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
32960935|NCT01144338|Experimental|Exenatide Once Weekly|
32960936|NCT01144338|Placebo Comparator|Placebo|
32960937|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
32960938|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
32960939|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
32960940|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
32960941|NCT01146834|Experimental|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
32960942|NCT01146834|Experimental|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
32960943|NCT01146834|Experimental|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
32960944|NCT01146834|Experimental|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
32960945|NCT01146834|Experimental|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
32960946|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
32960947|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
32960948|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
32960949|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
32960950|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
32960951|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
33406718|NCT05637138|Other|Healthy volunteer|"The totality of the measurements will be carried out on a single visit following the obtaining of the consent (obtained the same day or during a preceding visit).~The total duration of this single visit, including the time of information, the collection of consent and all the measurements is estimated at 2 hours per subject.~Before the installation of the different measuring devices, a preliminary interview and a clinical examination will be carried out in order to verify in particular the absence of skin lesions.~The measurement of subcutaneous microcirculation (no unit) and tcpO2 (kPa) will be carried out simultaneously with the measurement of CO2 diffusion (main criterion), during a single session of measurements at 5 different temperatures (non-thermostated, then thermostated at 35, 38, 41 and 44°C)"
33406719|NCT05707338|Active Comparator|laparoscopic group|
32960952|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
32960953|NCT01149876|Experimental|Nu Skin Product|
32960954|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
32960955|NCT01149876|Active Comparator|Tretinoin cream 0.05|
32960956|NCT01149876|Placebo Comparator|over the counter moisturizer|
33406720|NCT05707338|Active Comparator|open group|
33406721|NCT05707260|Active Comparator|CKD SMS intervention|CKD SMS (Chronic Kidney Disease Self-Management Support) intervention (6,27), guided by the Social Cognitive Theory, through the manipulation of self-efficacy, is educational for the adult with CKD in early stages where a primer will be used which contains a primer that explains the functions of the kidneys, the first signs and symptoms of CKD and the strategies to control or delay the progression of CKD, such as the benefits of maintaining a healthy lifestyle and adherence to treatment. Also, a diary for participants to record side effects of medications, monitor their clinical data, treatment plan and questions for medical appointments.
33406722|NCT05707260|No Intervention|Conventional intervention|The conventional intervention corresponds to the protocol established in the program of the renal unit for the management of people with CKD in early stages.
32960957|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
32960958|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
32960959|NCT01151046|Placebo Comparator|Placebo + exemestane|
32960960|NCT01151436|Experimental|hyaluronic acid|
32960961|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
33406723|NCT05197374|Experimental|Group 1|Cases who received estradiol pretreatment then underwent ICSI.
32854777|NCT04149587||Brodalumab 210 mg Q2W|Participants will receive brodalumab 210 milligrams (mg) administered as 1 subcutaneous injection at Day 1 and at Weeks 1 and 2 followed by 210 mg every 2 weeks (Q2W) thereafter until Week 26.
32854778|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
32854779|NCT04992468|Experimental|GnRH-a+rhCG|Ovulation triggering with GnRH-a+rhCG
32854780|NCT04992468|Active Comparator|GnRH-a|Ovulation triggering with GnRH-a
32854781|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 250mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
32854782|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 300mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
32854783|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 200mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
32854784|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 150mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
32854785|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
32854786|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
32854787|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
32854788|NCT04025099|Experimental|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)~One ~60-minute Intuitive Eating class per week (total = 10 classes);~Two ~60-minute yoga classes per week (total = 20 classes);~Repeat one of the ~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
32854789|NCT04025099|Active Comparator|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space)~One ~60-minute Healthy Eating class per week (total = 10 classes);~Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
32854790|NCT04025099|No Intervention|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:~a. Assessments (held in STAR tower)~•Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
32854791|NCT04140929|Experimental|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
32854792|NCT04140929|No Intervention|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
32854793|NCT04149977|Experimental|blood flow restriction therapy (pressure cuff)|The cuff will be placed around the upper thigh of the injured leg and set at a pressure that will prevent approximately 80% arterial blood flow. The machine will determine what pressure is required to reach that 80%, when placed on the leg and turned on.
32854794|NCT04149977|Placebo Comparator|blood flow restriction therapy (placebo)|Patients with a placebo pressure will have a pressure setting, 50% lower than the effective setting as stated in the experimental arm
32854795|NCT04912596|Placebo Comparator|Placebo group|Two different Reference Placebo inhalers and two different Test Placebo inhalers
32854796|NCT04912596|Active Comparator|Reference 1 group|One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers
32854797|NCT04912596|Active Comparator|Reference 2 group|Two different Reference inhalers and two different Test Placebo inhalers
32854798|NCT04912596|Experimental|Test group|One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers
32854799|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
32854800|NCT04141631|Experimental|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~Hb < 13g/dL the day before surgery~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
32903549|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
32960962|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
33406724|NCT05197374|No Intervention|group 2|Cases who underwent ICSI directly without receiving any pretreatment
33406725|NCT05707182|Experimental|Prostate Cancer|18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
33406726|NCT05707104|Experimental|Pilates exercises|performing Pilates exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
33406727|NCT05707104|Experimental|plyometric exercises|performing plyometric exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
33406728|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
33406729|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
33406730|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
33406731|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
33406732|NCT05191290|Active Comparator|heparin anticoagulation|standard heparin anticoagulation during plasmapheresis
32854801|NCT04141631|No Intervention|Control Group|"Only postoperative anemia will be managed:~RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~Iron sucrose administration if Hb > 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
32854802|NCT04909008|Experimental|Exercise Training|Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
32854803|NCT04909008|No Intervention|Control Groups|Two sets of exercise testing while continuing with standard medical care in between.
33406733|NCT05191290|Experimental|citrate anticoagulation|sodium citrate anticoagulation during plasmapheresis
32854804|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
32854805|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
32854806|NCT04997928||Group 1 (n=20; with mild symptoms)|"Group 1 (n=20; with mild symptoms)~Covid positive patients with mild symptoms who required to be hospitalized,~Symptomatic (fever, cough, weakness, joint pain, etc.) new patients who apply to the Covid clinic for the first time,~Patients with stable vital signs and/or SpO2 ≥92% in room air, no radiological signs of lung involvement or mild pneumonia,~Patients who have not been started on steroid therapy and who have not yet received anticoagulant therapy."
32854807|NCT04997928||Group 2 (n=20; with moderate symptoms)|"Group 2 (n=20; with moderate symptoms)~Patients who are positive for Covid 19 and admitted to the covid clinic for the first time;~Radiologically moderate pneumonia findings and/or SpO2=88-92% in room air,~Patients who have not been started antiviral, steroid, and anticoagulant treatment."
32854808|NCT04997928||Group 3 (n=20; with severe symptoms)|"Group 3 (n=20; with severe symptoms)~Patients who are currently hospitalized in the Covid clinic,~Patients with radiological findings of severe pneumonia or ARDS and/or high FiO2 requirement due to respiratory failure.~Patients of this group may have received antiviral, anticoagulant, and/or steroid and/or biologic agent treatment."
32854809|NCT04997928||Group 4 (n=20; Control group)|"Group 4 (n=20; Control group)~The control group will be composed of healthy adult individuals applying to adult allergy outpatient clinics on a voluntary basis.~Patients who have not been previously diagnosed with Covid-19 and have not vaccinated against Covid-19,~The control patients will be matched with the study groups according to age, gender, and BMI."
32854810|NCT04357743|Experimental|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
32854811|NCT04357743|Active Comparator|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
32960963|NCT01153620|Placebo Comparator|Ringer's Solution|
32960964|NCT01153620|Active Comparator|Lavasept 0.04%|
32960965|NCT01154322|Experimental|Pediatric mask|
32960966|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
32960967|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
32960968|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
32960969|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
32960970|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
32960971|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
32960972|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
32960973|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
32960974|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
32960975|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
32960976|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
33406734|NCT05627544||First 6 year group|Patients who underwent hip replacement between 2010 and 2016 by the same experienced surgeon in our hospital
33406735|NCT05627544||Second 6 year group|Patients who underwent hip replacement between 2017 and 2022 by the same experienced surgeon in our hospital
32854812|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
32854813|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
32854814|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
32854815|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
32854816|NCT04024241||high dose of cytarabine|high dose of cytarabine
32854817|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
32854818|NCT03074916||DIP arthroplasty|
32854819|NCT03074916||DIP arthrodesis|
32854820|NCT04024163|Experimental|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
32854821|NCT04996992||Parkinson's disease|The cohort includes patients with Parkinson's disease who underwent MRgFUS pallidothalamic tractotomy (PTT).
32854822|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
32854823|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
32854824|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
32854825|NCT04996836|Experimental|BC diagnosis and Omics|"Participants will be offered:~Liquid biopsy of ctDNA and targeted NGS (BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMARCA4, CDK12);~Whole-genome RRBS"
32854826|NCT04996836|No Intervention|BC diagnosis and standard of the care|Participants will not be offered targeted NGS or whole-genome RRBS but will receive their usual clinical care
32854827|NCT04996524|Experimental|epidural analgesia group|
32854828|NCT04996524|No Intervention|systemic analgesia group|
32854829|NCT04023851||Adolescent patient|"Participant between the ages of 15-18~Participants who are taking antiepileptic drug for seizure control"
32854830|NCT04023851||Parents with epilepsy children|"Participants who have child with epilepsy (ages of 1-15)~Participants' child who are taking antiepileptic drug for seizure control"
32854831|NCT04996914|Experimental|TACE+SBRT.|If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .
32854832|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
32854833|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
32854834|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
32854835|NCT03074760||Contaminated acequias|
32854836|NCT03074760||Non-contaminated acequias|
32854837|NCT04145375|Experimental|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
32854838|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
32854839|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
32854840|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
32854841|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
32854842|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
32854843|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
32854844|NCT04996290|Active Comparator|PENG + LFCN block|"The participants in this group received a combined regional technique just before surgery:~Pericapsular nerve group (PENG) block~Lateral femoral cutaneus nerve (LFCN) block"
32854845|NCT04996290|No Intervention|No regional anesthesia|Control group
32854846|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.~No interventions are planned."
32854847|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.~No interventions are planned."
32854848|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.~no interventions are planned."
32854849|NCT04023617|Experimental|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
32854850|NCT04023617|Active Comparator|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
32854851|NCT04023149|Experimental|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
32854852|NCT04023149|Placebo Comparator|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
32854853|NCT04023305|Experimental|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
32854854|NCT04023305|Experimental|Focal ARDS|ARDS patient with focal lung imaging phenotype
32854855|NCT04149431|Active Comparator|Derinat|nasal drops
32854856|NCT04149431|Placebo Comparator|Placebo|nasal drops
32854857|NCT04149275|Experimental|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
32854858|NCT04148963|Experimental|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
32854859|NCT04148963|Placebo Comparator|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
32854860|NCT04022837|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
32854861|NCT04022837|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
32854862|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
32854863|NCT04022759|Active Comparator|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
32854864|NCT04022759|Experimental|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
32854865|NCT03022331||Observational|
32854866|NCT04022915|Experimental|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
32854867|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
32854868|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
32854869|NCT04022993|Active Comparator|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
32854870|NCT04022993|Experimental|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
32854871|NCT04148885|Experimental|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
32854872|NCT04022525||leflunomide responsive vs non-responsive|
32854873|NCT03944057|Experimental|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
32854874|NCT04022291|Experimental|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
32854875|NCT04022291|Active Comparator|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
32854876|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
32854877|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
32854878|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
32898846|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
33406736|NCT05707026|Experimental|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied to densified Centre of Coordination (CC) points located on the myofascial sequences for 5 to 8 minutes at each CC point
33406737|NCT05707026|Experimental|stretching techniques|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets
32854879|NCT04022369|Experimental|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
32854880|NCT04022369|No Intervention|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
32854881|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
32854882|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
32854883|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
32854884|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
32854885|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
32854886|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
32854887|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
32854888|NCT03941873|Experimental|Sitravatinib monotherapy|Two dose levels of sitravatinib as monotherapy, 80 mg once daily and 120 mg once daily, will be evaluated in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer. A modified 3+3 design will be used in the dose escalation to confirm recommended Phase 2 dose (RP2D)
32854889|NCT03941873|Experimental|Sitravatinib plus Tislelizumab|The combination dose escalation of sitravatinib (80 mg once daily and 120 mg once daily; modified 3+3 design) with tislelizumab (200 mg every 3 weeks, in both cohorts) will be evaluated in unresectable locally advanced or metastatic HCC or G/GEJ cancer participants . If the combination dose of 80 mg sitravatinib and 200 mg tislelizumab has been declared tolerable, the dose of sitravatinib will be escalated to 120 mg and tislelizumab will remain fixed at 200 mg. Approximately 12 to 24 evaluable participants will be treated. The dose of tislelizumab during dose escalation for the combination will be kept fixed at 200 mg
32854890|NCT03941873|Experimental|Anti-PD-1/PD-L1 Antibody Naïve or R/R HCC (Monotherapy)|
32854891|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive HCC(Combination)|
32854892|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant HCC|
32854893|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive G/GEJ cancer|
32854894|NCT04405895|Experimental|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
32854895|NCT04405895|Active Comparator|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
32854896|NCT03941171|Experimental|Group 1|PAO+usual+PRT
32854897|NCT03941171|Active Comparator|Group 2|PRT
32854898|NCT04992000|Experimental|4-free app + PHN intervention|"The intervention group was received initial education, 4-free apps, and followed by PHN interventions.~Education, app, and PHN intervention"
32854899|NCT04992000|Experimental|4-free app alone|The apps alone group received the initial education and the 4-free Apps.
32854900|NCT04992000|No Intervention|education|Standard care group received just the initial education.
32854901|NCT04021979|Experimental|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
32854902|NCT04021979|Placebo Comparator|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
32854903|NCT04991844|No Intervention|Control group|The control group did not receive any intervention, but met at three timepoints to complete study questionnaires and provide anthropometric measurements,
32854904|NCT04991844|Experimental|Intervention Group|This group received the study intervention protocol.
32854905|NCT04021433|Experimental|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine [dose range 0.3-1.5mg/kg]
32854906|NCT04991610|Active Comparator|Adult male|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
33406738|NCT05189028|Experimental|Locally advanced bulk cervical cancer neoadjuvant chemotherapy group(NACT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:A Point dose 6Gy*4-6F~Drug: gemcitabine plus cisplatin,cisplatin Neoadjuvant chemotherapy:gemcitabine and cisplatin (GP) regimen*2 cycles Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
32960977|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
32960978|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
32960979|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
32960980|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
32960981|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
32960982|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
32960983|NCT01167504||Saliva Sample Collection|Saliva collection
32960984|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
32960985|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
32960986|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
32960987|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
32960988|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
32960989|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
32960990|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
32960991|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
32960992|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
33406739|NCT05189028|Active Comparator|Locally advanced bulk cervical cancer chemoradiotherapy group(CCRT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:APoint A dose 6Gy*4-6F~Drug: cisplatin Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
32960993|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
32960994|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
32960995|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
32960996|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
32960997|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
32960998|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
32960999|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
32961000|NCT01171794|Placebo Comparator|placebo|visually identical
32961001|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
32961002|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
32961003|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
32961004|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
32961005|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
32961006|NCT01175226|Experimental|BTA798|
32961007|NCT01175226|Placebo Comparator|Placebo|
32961008|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
32961009|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
32961010|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
32961011|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
32961012|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
32961013|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
33406740|NCT05609370|Experimental|Phase 1b: LBL-007 + Tislelizumab + Bevacizumab + Capecitabine|A modified 3+3 scheme will be used for evaluation of LBL-007 in 2 dose levels
32854907|NCT04991610|Active Comparator|Adult female|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
32854908|NCT04021745|Experimental|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
32854909|NCT04991532||Dasatinib group|the CML patient treated with dasatinib
32854910|NCT04991532||Imatinib group|the CML patient treated with imatinib
32854911|NCT04147481|Experimental|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
32854912|NCT04147481|Placebo Comparator|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
32854913|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
32854914|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
32854915|NCT04148339||Patients|Patients with Elevated Cholesterol
32854916|NCT04148261|Active Comparator|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
32854917|NCT04148261|Active Comparator|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
32854918|NCT04148261|Experimental|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
32854919|NCT04148261|Experimental|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
32854920|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
32854921|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
32854922|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
32854923|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
32854924|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
32854925|NCT03939689|Active Comparator|Enzalutamide|
32854926|NCT03939689|Experimental|I-131-1095 in combination with enzalutamide|
32854927|NCT04147091|Experimental|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
32854928|NCT04147091|Experimental|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
32854929|NCT04147091|Experimental|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
32854930|NCT04991220|Experimental|preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
32854931|NCT03932903|Experimental|Contextually-tailored Mobile Messages for Adherence|All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
32854932|NCT03932903|No Intervention|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
32854933|NCT04991064|Other|AB arm|participants allocated to this arm receive treatment A first, followed by treatment B.
32854934|NCT04991064|Other|BA arm|participants allocated to this arm receive treatment B first, followed by treatment A.
32854935|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
32854936|NCT03072108|Experimental|Bonolive|
32854937|NCT03072108|Placebo Comparator|Placebo|
32854938|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
32854939|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
32854940|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
32854941|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
32854942|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
32854943|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
32854944|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
32854945|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
32854946|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
32854947|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
32854948|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
32854949|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
32854950|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
32854951|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
32961014|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
32961015|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
32961016|NCT01181076|Experimental|Individualized Nutrition|
32961017|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
32961018|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
32961019|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
32961020|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
32961021|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
32961022|NCT01188876|Experimental|Carboplatin/Pralatrexate|
32961023|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
32961024|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
32961025|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
32961026|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
32961027|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
32961028|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
32961029|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
32961030|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
32961031|NCT01195116|Placebo Comparator|Normal Saline|
32961032|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
32961033|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
32961034|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
32961035|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
32961036|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
32961037|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
32961038|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
32961039|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
32961040|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
32961041|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
32961042|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
32961043|NCT01200030|Experimental|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
32961044|NCT01200030|Placebo Comparator|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
32961045|NCT01200030|No Intervention|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
32961046|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
32961047|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
32961048|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
32961049|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
32961050|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
32961051|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
32961052|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
32961053|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
32961054|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
32854952|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
32854953|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
32854954|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
32854955|NCT04765943||Study population|Patients with LVEF equal to or less than 40% determined by echocardiogram on the 4th day after acute myocardial infarction.
32854956|NCT04996446|Experimental|Alpps plus Tislelizumab group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
32854957|NCT04996446|Active Comparator|Alpps group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
32854958|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
32854959|NCT04147949|Experimental|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
32854960|NCT04147949|Placebo Comparator|Placebo|Matching capsules of placebo
32854961|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
32854962|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
32854963|NCT04146779|Experimental|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
32854964|NCT04146779|Experimental|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
32854965|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
32854966|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
32854967|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
32854968|NCT04147637|Experimental|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
32854969|NCT04147637|Active Comparator|FSL-A|FreeStyle Libre alone
32854970|NCT04995744|Other|Patients with closed Neer type 4 proximal humerus fractures|patients aged 50-75 years with closed Neer type 4 proximal humerus fractures
32854971|NCT04368741|Experimental|Experimental group|SANZ®KINGWILL
32854972|NCT04368741|Other|Control group|GLUCERNA SR®
32854973|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
32854974|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
32854975|NCT04995822||EUROSTEM femoral stem|All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
32854976|NCT04361643|Experimental|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
32854977|NCT04361643|Placebo Comparator|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
32854978|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
32854979|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
32854980|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
32854981|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
32854982|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
32854983|NCT04147793||Underactive sphincter|those with genuine stress incontinence
32854984|NCT04357665|Active Comparator|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
32854985|NCT04357665|Active Comparator|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
32854986|NCT04357665|Active Comparator|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
32854987|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose~Twice daily for two consecutive days out of every seven days~Cycles will last 28 days"
32854988|NCT04406051|Active Comparator|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
32854989|NCT04406051|Active Comparator|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
32854990|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
32854991|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
33406741|NCT05609370|Experimental|Phase 2: Protein Ligand -1 (PD-L1) Positive Arm A|LBL-007 + tislelizumab + bevacizumab + capecitabine
32854992|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
32854993|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
32854994|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
32854995|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
32854996|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
32854997|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
32854998|NCT03938207||other inflammation disease|Other inflammation disease were extracted from Taiwan Biobank.
32854999|NCT04991298|Active Comparator|Group M|patients will be premedicated with the undiluted IV formulation of Midazolam
32855000|NCT04991298|Active Comparator|Group F|patients will be premedicated with the undiluted IV formulation of fentanyl citrate
32855001|NCT04361175|Experimental|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
32855002|NCT04361175|Experimental|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
32855003|NCT03937973|Experimental|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
32855004|NCT03937973|Experimental|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
32855005|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
32855006|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
32855007|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
32855008|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855009|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855010|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855011|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855012|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855013|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855014|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
32855015|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
32855016|NCT04368819|Active Comparator|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
32855017|NCT04368819|Placebo Comparator|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
32855018|NCT04146311|Active Comparator|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
32855019|NCT04146311|Placebo Comparator|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
32855020|NCT04146311|Experimental|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
32855021|NCT04368585|Experimental|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
32855022|NCT04368585|Experimental|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
32903550|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
32903551|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
32903552|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
32903553|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
32903554|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
32903555|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
32903556|NCT00650936|Other|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
32903557|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
32903558|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
32903559|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
32903560|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
32903561|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
32903562|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
32903563|NCT01560182|Experimental|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
32903564|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
32903565|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
32903566|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
32903567|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
32903568|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
32903569|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
32903570|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
32903571|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
32903572|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
32903573|NCT00701714|Experimental|1|HX575, EPO HEXAL
32903574|NCT00701714|Active Comparator|2|ERYPO
32903575|NCT00655538|Experimental|Dalcetrapib|
32903576|NCT00655538|Placebo Comparator|Placebo|
32903577|NCT00656630|Active Comparator|1|Acamprosate
32903578|NCT00656630|Active Comparator|2|Naltrexone
32903579|NCT00656630|Placebo Comparator|3|
32903580|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
32903581|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
32903582|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
32903583|NCT01362998|Active Comparator|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
33320489|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
32855023|NCT04368585|Experimental|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
33320490|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
32855024|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
32855025|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
32855026|NCT04147871|Active Comparator|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
32855027|NCT04147871|Active Comparator|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
32855028|NCT04147871|Active Comparator|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
32855029|NCT04147871|Placebo Comparator|Placebo|Patients receive placebo twice a day.
32855030|NCT04357509|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
32855031|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
32855032|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
32855033|NCT04361097|Experimental|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
32855034|NCT04361097|Placebo Comparator|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
32855037|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
32855038|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
32855039|NCT04361331|Other|Toripalimab combined with lenvatinib|"Toripalimab: 240 mg, intravenous infusion, Q3W;~Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd;"
32855040|NCT04361331|Other|Lenvatinib combined with gemox|"Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd~Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
32855041|NCT04990830|Experimental|Inhalation Treatment|"Treatment: Inhaled Low molecular weight heparin + Standard COVID-19 treatment,~Inhaled Low molecular weight heparin (4000 IU given twice a day for 10 days)"
32855042|NCT04990830|Other|Control Group|Treatment: Standard COVID-19 treatment
32855043|NCT04357275||ICU admissions due to COVID-19|
32855044|NCT03926195|Experimental|Double-Blind Phase: Filgotinib|Filgotinib up to Week 13
32855045|NCT03926195|Placebo Comparator|Double-Blind Phase: Placebo|Placebo up to Week 13
32855046|NCT03926195|Experimental|Extension Phase: Open-Label Filgotinib|Participants who received double-blind filgotinib and did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) and were arthritis responders at Week 13 will enter the Extension Phase and receive open-label filgotinib up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
32855047|NCT03926195|Other|Extension Phase: Standard of Care|Participants who received double-blind placebo and participants who received double-blind filgotinib and were arthritis non-responders who did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) at Week 13 will enter the Extension Phase and receive standard of care up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
32855048|NCT03926195|Other|Monitoring Phase: Standard of Care|Participants with a prespecified decrease in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) anytime at/after Week 13 will receive standard-of-care therapy as per investigator discretion in the Monitoring Phase for up to 52 weeks or until reversibility in semen parameters is met, whichever occurs first.
32855049|NCT04361253|Experimental|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
32855050|NCT04361253|Placebo Comparator|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
32855051|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
32855052|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
32855053|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
32855054|NCT04433598|Experimental|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
32855055|NCT04433598|No Intervention|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
32855056|NCT04146623|Placebo Comparator|Normal Saline Placebo|Saline (0.9%)
32855057|NCT04146623|Experimental|CodaVax-H1N1|Live-attenuated influenza vaccine
32855058|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
32855059|NCT04361409|Experimental|Rituximab plus chemotherapy|"Drug:Rituximab~Drug:Cisplatin~Drug:Gemcitabine"
32855060|NCT04368273|Experimental|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
32855061|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
32855062|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
32855063|NCT04995354|Experimental|EGF loaded Hydrogel (Gp I)|30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
32855064|NCT04995354|Active Comparator|Hydrogel alone ( Gp II)|30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
32855065|NCT04995354|No Intervention|Control (Gp III)|30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.
32855066|NCT04357119|Active Comparator|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
32855067|NCT04357119|Active Comparator|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
32855068|NCT03906929|Experimental|Pediatric forearm fracture fixed by buried or exposed intamedullary implant|compare complication of buried or exposed intamedullary implant
32855069|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
32855070|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
32855071|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
32855072|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
32855073|NCT04146233|Other|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
32855074|NCT04146233|Other|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
32855075|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
32855076|NCT04360863||Youth smokers|Participants of Youth Quitline
32855077|NCT04148417|Experimental|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
32855078|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
32855079|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
32855080|NCT05620641|Experimental|Group 1|include 50 patients scheduled for sleeve gastrectomy
32855081|NCT05620641|Experimental|Group 2|include 50 patients scheduled for sleeve gastrectomy
32855082|NCT04148729|Active Comparator|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score. The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic.
32855083|NCT04148729|Sham Comparator|saline|"In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score.~The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic."
32855084|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
32855085|NCT04144283|Experimental|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
32855086|NCT04144283|Active Comparator|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
32855087|NCT04360785|Experimental|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
32855088|NCT04360785|No Intervention|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
32855089|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
33406742|NCT05609370|Experimental|Phase 2: Protein Ligand -1 (PD-L1) Positive Arm B|LBL-007 + bevacizumab + capecitabine
33406743|NCT05609370|Experimental|Phase 2: Protein Ligand -1 (PD-L1) Positive Arm C|bevacizumab + capecitabine
32855090|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
33406744|NCT05609370|Experimental|Phase 2: Protein Ligand -1 (PD-L1) Negative Arm D|LBL-007 + tislelizumab + bevacizumab + capecitabine
33406745|NCT05609370|Experimental|Phase 2: Protein Ligand -1 (PD-L1) Negative Arm E|bevacizumab + capecitabine
32855091|NCT04360317|Experimental|Experimental group|
32855092|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
32855093|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
32855094|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
32855095|NCT04146155|Experimental|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
32855096|NCT04146155|Active Comparator|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
32855097|NCT04367727|Experimental|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
32855098|NCT04367727|Placebo Comparator|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
32855099|NCT04367727|Experimental|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
32855100|NCT04367727|Placebo Comparator|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
32855101|NCT04367727|Experimental|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
32855102|NCT04367727|Placebo Comparator|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
32855103|NCT04145999|Experimental|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
32855104|NCT04145999|Experimental|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
32855105|NCT04145999|Experimental|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
32855106|NCT04357197|Experimental|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
32855107|NCT04990752||The ulinastatin group|In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
32855108|NCT04990752||The control group|In the control group, patients were treated with conventional treatment without ulinastatin.
32855109|NCT04142333|Other|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
32855110|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
32855111|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
32855112|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
32855113|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
32855114|NCT05585801|Experimental|Intervention Group|
32855115|NCT05585801|Active Comparator|Control Group|
32855116|NCT04367649|Experimental|Hall technique|
32855117|NCT04367649|Active Comparator|Atraumatic restorative treatment|
32855118|NCT04367649|Sham Comparator|Conventional restorative treatment|
32855119|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
32855120|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
32855121|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
32855122|NCT05585567|Experimental|V-01/V-01-B5 group|One dose of V-01/V-01-B5
32855123|NCT05585567|Experimental|V-01-351/V-01-B5 group|One dose of V-01-351/V-01-B5
32855124|NCT05585567|Experimental|V-01 group|One dose of V-01
32855125|NCT03925181|Experimental|Intervention|Recovery counselling group.
32855126|NCT03925181|No Intervention|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
32855127|NCT04356807|Experimental|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
32855128|NCT04356807|Experimental|Passive Joint Mobilizations|during 15 minutes once a day five days a week
32855129|NCT04356807|Placebo Comparator|Massage|during 15 minutes once a day five days a week
32855130|NCT05004948|Active Comparator|Resistance exercise group|This group has conducted a resistance exercise program (50-60% of 1RM, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
33320493|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
32855131|NCT05004948|Active Comparator|Aerobic exercise program|This group has conducted an aerobic exercise program ( 50-70% maxHR, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
32855132|NCT05004948|No Intervention|Metformin group|This group received only metformin without any exercise intervention.
32855133|NCT04367571|Experimental|Osteopathic Manipulative Treatment|
32855134|NCT04367571|Placebo Comparator|Manual Placebo|
32855135|NCT05584163|No Intervention|Control group|Group not using drugs used for the prevention of cardiomyopathy caused by doxorubicin, including extracorporeal shock wave
32855136|NCT05584163|Experimental|ESWT treatment group|Group receiving extracorporeal shock wave therapy
32855137|NCT04145921|Experimental|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
32855138|NCT04145921|Active Comparator|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
32855139|NCT04367493|Experimental|1. Group 55% cocoa intervention|55% cocoa intervention
32855140|NCT04367493|Experimental|2. Group White Chocolate|White chocolate
32855141|NCT04367493|No Intervention|3. Control Group|Control Group
32855142|NCT04360161|Experimental|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
32855143|NCT04145687|Active Comparator|Metformin|
32855144|NCT04145687|Placebo Comparator|Placebo|
32855145|NCT02245347||Patients with expected MDR TB|
32855146|NCT05581667|Experimental|PIR Group|PIR Group participants will be given a one-time PIR Technique for each of the neck and upper back muscles, right after the classical Swedish massage is applied to the cervical region and upper back area.
32855147|NCT05581667|Experimental|Control Group|Control group participants will receive classical Swedish massage only to the cervical and upper thoracic region.
32855148|NCT04359615|Experimental|Favipiravir|
32855149|NCT04359615|Active Comparator|Control|
32855150|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
32855151|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
32855152|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
32855153|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
32855154|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
32855155|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
32855156|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
32855157|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
32855158|NCT03924947|Experimental|Arm A|Participants will receive Pancrelipase delayed release (DR) Capsules manufactured by modernized process uniform coated pellets (MP) in treatment period 1, followed by currently marketed Pancrelipase DR Capsules in treatment period 2.
32855159|NCT03924947|Experimental|Arm B|Participants will receive currently marketed Pancrelipase DR Capsules in treatment period 1, followed by Pancrelipase DR Capsules manufactured by MP in treatment period 2.
32855160|NCT03924947|Experimental|Arm C|Participants will receive Pancrelipase DR Capsules manufactured at a Alternate Active Pharmaceutical Ingredient Site (AAPIS) in treatment period 1, followed by currently marketed Pancrelipase DR Capsules in treatment period 2.
32855161|NCT03924947|Experimental|Arm D|Participants will receive currently marketed Pancrelipase DR Capsules in treatment period 1, followed by Pancrelipase DR Capsules manufactured at an AAPIS in treatment period 2.
32855162|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
32855163|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
32855164|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
32855165|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
32855166|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
32855167|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
32855168|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
32855169|NCT00934635|Other|009|PET Scan PET Scan
32855170|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
32855171|NCT03924557|Active Comparator|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
32855172|NCT03924557|No Intervention|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
32855173|NCT04359537|Experimental|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
32855174|NCT04359537|Experimental|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
32961055|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
32961056|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
32961057|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
32961058|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
32961059|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
32961060|NCT01207908|No Intervention|Standard steroid treatment alone|Standard daily steroid treatment for DMD
32961061|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
32961062|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
32961063|NCT01208922|Experimental|Group A|Rifamycin SV-MMX® 200 mg tablets
32961064|NCT01208922|Active Comparator|Group B|Ciprofloxacin 500 mg capsules
32961065|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
32961066|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
32961067|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
32961068|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
32961069|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
32961070|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
32961071|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
32961072|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
32961073|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
32961074|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
32961075|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
32961076|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
32961077|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
32961078|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
32961079|NCT01210560|Experimental|20 mg MR|
32961080|NCT01210560|Experimental|40 mg MR|
32961081|NCT01210560|Experimental|60 mg MR|
32961082|NCT01210560|Experimental|120 mg MR|
32961083|NCT01210560|Experimental|120 mg IR|
32961084|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
32961085|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
32961086|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
32961087|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
32961088|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
32961089|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
32961090|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
32961091|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
32961092|NCT01212900|Experimental|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
32961093|NCT01212900|Active Comparator|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
32961094|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
32961095|NCT01215240|No Intervention|Standard care without PDC|
32961096|NCT01215318|Experimental|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
32961097|NCT01215318|Placebo Comparator|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
32961098|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
32961099|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
32961100|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
32961101|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
32961102|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
32961103|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
32961104|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
32961105|NCT01218672|Experimental|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
32961106|NCT01218672|Active Comparator|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
32961107|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
32961108|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
32961109|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
32961110|NCT01220466|Experimental|Refractive Error|
32961111|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
32961112|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
32961113|NCT01222494|Experimental|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
32961114|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
32961115|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
32961116|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
32961117|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
32961118|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
32961119|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
32961120|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
32961121|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
32961122|NCT01224210|Other|Ambrisentan (24 Weeks), Extension (4 Weeks)|Open Label Ambrisentan
32961123|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
32961124|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
32961125|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
32961126|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
32961127|NCT01225068|Placebo Comparator|Placebo|Placebo
32961128|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
32961129|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
32961130|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
32855175|NCT04359537|Experimental|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
32855176|NCT04359537|Placebo Comparator|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
32855177|NCT03923699|No Intervention|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
32855178|NCT03923699|Experimental|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
32855179|NCT04356651|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
32855180|NCT04356651|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
32855181|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
32855182|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
32855183|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
32855184|NCT04367259|Active Comparator|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
32855185|NCT04367259|Active Comparator|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
32855186|NCT05581121|Other|Arm A|Control arm
32855187|NCT05581121|Experimental|Arm B|Experimental arm
32855188|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
32855189|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
32855190|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
32855191|NCT05004792|Active Comparator|Intervention|Access to DermLoop Learn IT platform
32855192|NCT05004792|No Intervention|Control group|No access to DermLoop Learn
32855193|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
32855194|NCT04145063|Active Comparator|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
32855195|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
32855196|NCT04355949|Experimental|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
32855197|NCT04355949|Experimental|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
32855198|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
32855199|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
32855200|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
32855201|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
32855202|NCT05580965|No Intervention|control group|Routine procedure
32855203|NCT05580965|Experimental|Group A|1 min pressure applied
32855204|NCT05580965|Experimental|Group B|3 min pressure applied
32855205|NCT05580965|Experimental|Group C|5 min pressure applied
32855206|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
32855207|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
32855208|NCT05580887||Patients with luminal A breast cancer|
32961131|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
32961132|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
32961133|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
32961134|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
32961135|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
32961136|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
32961137|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
32961138|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
32961139|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
32961140|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
32961141|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
32961142|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
32961143|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
32961144|NCT01236300|Experimental|Cellvizio system|
32961145|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
32961146|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
32961147|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
32961148|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
32961149|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
32961150|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
32961151|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
32961152|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
32961153|NCT01240122|Active Comparator|Biotrue MPS|
32961154|NCT01240122|Experimental|Investigational MPS|
32961155|NCT01241916|Experimental|Static-progressive splint|
32961156|NCT01241916|Experimental|Dynamic Splint|
32961157|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
32961158|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
32961159|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
32961160|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
32961161|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
32961162|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
32961163|NCT01245972|No Intervention|Control|No treatment administered
32961164|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
32961165|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
32961166|NCT01246050|Experimental|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
32961167|NCT01246050|Active Comparator|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
32961168|NCT01247064|Experimental|Nebulized 3% Saline|
32961169|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
32961170|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
32961171|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
32961172|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
33320494|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
33320495|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
33320496|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
33320497|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
33320498|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
33320499|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
33320500|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
33320501|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
32855209|NCT05580887||Patients with high risk luminal B breast cancer|
32855210|NCT05580887||Patients with high pancreatic cancer|
32855211|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
32855212|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
32855213|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
32855214|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
32855215|NCT04994340||Children|From a cross-sectional perspective, children will fill out questionnaires related to their subjective physical activity levels (PAQ-C), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of children through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
32855216|NCT04994340||Adolescents|From a cross-sectional perspective, adolescents will fill out questionnaires related to their subjective physical activity levels (PAQ-A), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of adolescents through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
32855217|NCT04144985|Active Comparator|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
32855218|NCT04144985|Experimental|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
32855219|NCT04144985|Experimental|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
32855220|NCT04359381|Experimental|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
32855221|NCT04359381|Experimental|pilate exercises|pilate exercises, 3 sessions per week for 3 months
32855222|NCT04994184||Perforated duodenal ulcer|MORBIDITY AND MORTALITY
32855223|NCT03904979|Experimental|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
32855224|NCT03904979|Placebo Comparator|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
32855225|NCT03904979|No Intervention|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
32855226|NCT04359303|No Intervention|CONTROL|Base WHO recommended treatment.
32855227|NCT04359303|Experimental|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
32855228|NCT04994262|Experimental|Intervention Group|"Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.~Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form."
32855229|NCT04994262|No Intervention|Control Group|"Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly.~Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form."
33320502|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
32961173|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
32961174|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
32961175|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
32961176|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
32961177|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
32961178|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
32961179|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
32961180|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
32961181|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
32961182|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
32961183|NCT01251042|Experimental|Sangvia and retransfusion|
32961184|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
32961185|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
32961186|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
32961187|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
32961188|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
32961189|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
32961190|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
32961191|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
32961192|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
32961193|NCT01254552|Experimental|Dotarem and Xenetix 350|
32961194|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
32961195|NCT01256034|No Intervention|Group B|ordinary diet
32961196|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
32961197|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
32961198|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
32961199|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
32961200|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
32961201|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
32961202|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
32961203|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
32961204|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
32961205|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
32961206|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
32961207|NCT01262118|No Intervention|Healthy Volunteers|No intervention
32961208|NCT01263132|Experimental|F0434|
32961209|NCT01263132|Active Comparator|Gabapentin|
32961210|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
33320503|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
33320504|NCT04802174|Experimental|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
33320505|NCT04802174|Experimental|2/ Phase II|Berzosertib + lurbinectedin at MTD
32961211|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
32961212|NCT01267422|Experimental|rAAV2-ND4|injection
32961213|NCT01267656|Experimental|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
32961214|NCT01267656|Active Comparator|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
32961215|NCT01269372|Other|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
32961216|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
32961217|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
32961218|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
32961219|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
32961220|NCT01271868|Experimental|IB1001|
32961221|NCT01271946|Other|Diagnostic Procedure|
32961222|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
32961223|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
32961224|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
32961225|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
32961226|NCT01274520|Experimental|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
32961227|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
32961228|NCT01275300|Placebo Comparator|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
32961229|NCT01275300|Active Comparator|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
32961230|NCT01275300|Active Comparator|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
32961231|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
32961232|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
32961233|NCT01276860|Other|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
32961234|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32961235|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
32961236|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
32961237|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
32961238|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
32961239|NCT01282242|Experimental|IV rt-PA|open-label
32961240|NCT01282710||Pregnant, In Labor|
33320506|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
32855230|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
32855231|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
32855232|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
32855233|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
32855234|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
32855235|NCT04359225|Active Comparator|3D telemedicine|3D telemedicine system
32855236|NCT04359225|Placebo Comparator|2D telemedicine|2D telemedicine system (standard care)
32855237|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
33320507|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
33320508|NCT04775420||Group 1|Ascetic patients without spontaneous bacterial peritonitis
33320509|NCT04775420||Group 2|Ascetic patients with spontaneous bacterial peritonitis
32855242|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
32855243|NCT05004636|No Intervention|No_Mg|Ctrl Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will not receive Mg (the intervention) in the block; instead they will receive 0.3mL of sterile saline.
32855244|NCT05004636|Experimental|Mg|Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
32855245|NCT04765319||Vets|Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.
32855246|NCT04358679|Active Comparator|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
32855247|NCT04358679|Experimental|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
32855248|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
32855249|NCT04765631||Patients with Type 2 diabetes|Subjects from 3 cohorts (QUALYOR, OFELY, STRAMBO) presenting type 2 diabetes
32855250|NCT04765631||Control subjects without Type 2 diabetes|Controls patients from 3 cohorts (QUALYOR, OFELY, STRAMBO) without type 2 diabetes
32855251|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
32855252|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
32855253|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
32855254|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
32855255|NCT04144439|No Intervention|Before treatment|no intervention
32855256|NCT04144439|Active Comparator|After treatment|GABA
32855257|NCT04358601|Experimental|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
32855258|NCT04358601|Active Comparator|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
32855259|NCT04456764|Experimental|SaFTiE|The SaFTiE intervention includes: [a] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; [b] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; [c] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
32855260|NCT04456764|Placebo Comparator|Attention Placebo Control|The attention placebo control includes: [a] real-time text-message assessments of teamwork during and between scheduled shift work; [b] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; [c] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
32855261|NCT04144361|Experimental|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
32855262|NCT04144361|Active Comparator|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
32855263|NCT04456218|Experimental|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
33320510|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
33320511|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
33320512|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
32855264|NCT04456218|Experimental|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
32855265|NCT04367181|Experimental|ELGA group|"*Less than 29 weeks Gestational Age (GA) preemies (100)~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
32855266|NCT04144673|Experimental|Investigational Product|
32855267|NCT04144673|Placebo Comparator|Placebo|
32855268|NCT05004324|Experimental|Furestem-AD Inj.|"Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL~baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).~After 12 weeks, Experimental group will receive placebo."
32855269|NCT05004324|Placebo Comparator|Placebo|"Placebo~baseline (0week) Placebo comparator group will receive placebo.~After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL)."
32855270|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
32855271|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
32855272|NCT02984969||Healthy subjects|Healthy controls
32855273|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
32855274|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
32855275|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
32855276|NCT05004480|Experimental|Surgical Mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill while wearing surgical mask
32855277|NCT05004480|Experimental|Non mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill without wearing surgical mask
32855278|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
32855279|NCT04358835|Experimental|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
32855280|NCT04144829|Active Comparator|HIFU|3 cycles of HIFU treatment in 6-week intervals
32855281|NCT04144829|Active Comparator|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
32855282|NCT04994574|Experimental|tiotropium/olodaterol|
32855283|NCT04143971|Placebo Comparator|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
32855284|NCT04143971|Active Comparator|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
32855285|NCT05004558|Experimental|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
32855286|NCT04355637|No Intervention|Control|patients receiving standard of care to treat their pneumonia
32855287|NCT04355637|Experimental|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
32855288|NCT05004168|Experimental|SPF evaluation|Healthy male or female subjects with Fitzpatrick Skin Type of II-IV were included in the SPF study
32855289|NCT04144205|Experimental|Fraction of inspired oxygen setting change|
32855290|NCT05580341|Experimental|Zerun HPV-9|Subjects receive 3 doses of Zerun HPV-9 vaccine
32855291|NCT05580341|Active Comparator|GARDASIL®9|Subjects receive 3 doses of GARDASIL®9
32855292|NCT04367337||Poland|Adults, general population, N = 400
32855293|NCT04367337||Australia|Adults, general population, N = 400
32855294|NCT04367337||Canada|Adults, general population, N = 400
32855295|NCT04367337||China|Adults, general population, N = 400
32855296|NCT04367337||France|Adults, general population, N = 400
32855297|NCT04367337||Gambia|Adults, general population, N = 400
32855298|NCT04367337||Germany|Adults, general population, N = 400
32855299|NCT04367337||Israel|Adults, general population, N = 400
32855300|NCT04367337||Italy|Adults, general population, N = 400
32855301|NCT04367337||Malaysia|Adults, general population, N = 400
32855302|NCT04367337||Portugal|Adults, general population, N = 400
32855303|NCT04367337||Romania|Adults, general population, N = 400
32855304|NCT04367337||Singapore|Adults, general population, N = 400
32855305|NCT04367337||Switzerland|Adults, general population, N = 400
32855306|NCT05004090||children with ND|children with neurodevelopmental disabilities (ND) age between 3 and 24 months (chronologically or corrected in the case of children born preterm).
32855307|NCT05004090||Typical developed children (TD)|children with typical development age between 3 and 24 months (chronological).
32855308|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
32855309|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
32855310|NCT04355325|Active Comparator|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
32898847|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
33320513|NCT01314326||Normal Group|Volunteers with healthy eyes
33320514|NCT01314560|Experimental|1|experimental
32855311|NCT04355325|Placebo Comparator|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
32855312|NCT05580107|Experimental|Dose|"Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level.~If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients."
32855313|NCT04989192|Other|CT scanner 1|Patients will undergo imaging on scanner 1.
32855314|NCT04989192|Other|CT scanner 2|Patients will undergo imaging on scanner 2.
32855315|NCT04989192|Other|CT scanner 3|Patients will undergo imaging on scanner 3.
32855316|NCT04144049|Experimental|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
32855317|NCT04144049|Placebo Comparator|Placebo|Subcutaneously administered at most 50 injections per treatment.
32855318|NCT04367025|Active Comparator|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
32855319|NCT04367025|Experimental|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
32855320|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
32855321|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
32855322|NCT05620485|Experimental|prenatally diagnosed CDC|All patients received laparoscopic-assisted CDC excision and hepaticojejunostomy.
32855323|NCT04143581|Experimental|IMP|
32855324|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
32855325|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
32855326|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
32855327|NCT05620329||Pleural Fluid Registry|Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection
32855328|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
32855329|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
32855330|NCT04143815|Experimental|MBA-P01 30U|Experimental group, Dose: 30U
32855331|NCT04143815|Experimental|MBA-P01 20U|Experimental group, Dose: 20U
32855332|NCT04143815|Experimental|MBA-P01 10U|Experimental group, Dose: 10U
32855333|NCT04143815|Placebo Comparator|Placebo|Placebo group, Normal saline
32855334|NCT04987866|Experimental|group Vibration|The participants who were chose an opaque envelope containing yellow paper represented the vibration group (Group V). After 1 min of pre-treatment with the vibration device on the intravenous catheter trace, we manually injected 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunterand. Also asked the patients whether they had any discomfort. After the propofol injection, pain scores were observed during propofol injection and 20 seconds after the injection, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and after 20 seconds rocuronium injection.
32898848|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
32898849|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
32898850|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
32898851|NCT02872025|Experimental|Pembrolizumab intralesional (IL) x 2 doses + intralesional mRNA 2752 x 2-4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
32898852|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
32898853|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
32898854|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
32855335|NCT04987866|No Intervention|group Control|The participants who were chose an opaque envelope containing red paper represented the group control (Group C).Only propofol and rocuronium were given to these patients. propofol injection made manually 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Patients were observed during and after the injection of propofol for 20 seconds. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunter. During the injection of propofol, we also asked the patients whether they had any discomfort. After the propofol injection for 20 seconds, pain scores were observed, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and 20 seconds after the rocuronium injection.
32855336|NCT04355403|Experimental|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
33320515|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
33320516|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
33320517|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
33320518|NCT03773900|Experimental|Chitin-Glucan supplementation|
32855337|NCT04355403|No Intervention|No treatment|No treatment application
32855338|NCT03904043|Experimental|Radiation + FOLFOX|"Pelvic radiotherapy 5GY x 5 fractions once daily~Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).~Oxaliplatin day 1 every 14 days~Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.~5-FU bolus day 1 every 14 days~5-FU infusion day 1 every 14 days over 46 hours~Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.~An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted"
32855339|NCT05003466|Experimental|candidate vaccine|
32855340|NCT05003466|Placebo Comparator|Placebo|
32855341|NCT04355247|Experimental|Single Arm|"Patients will be admitted to a regular room in the hospital (not ICU)~They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
32855342|NCT03903809|Experimental|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
32855343|NCT03903809|Active Comparator|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
32855344|NCT04987554|Experimental|AM3 supplementation group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
32855345|NCT04987554|Placebo Comparator|Control Group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
32855346|NCT04358367|Active Comparator|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
32855347|NCT04358367|Placebo Comparator|Saline|spinal anesthesia and placebo (saline).
32855348|NCT04143269|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
32855349|NCT04143269|Sham Comparator|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
32855350|NCT04987242|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
32855351|NCT04987242|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
32855352|NCT04358523|Experimental|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
32855353|NCT04358523|Experimental|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
32855354|NCT05583383|Experimental|Cohort 1|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (< <1.25 40 mg；; 1.25-1.5 50 mg； > >1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trazumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks
32855355|NCT05583383|Active Comparator|Cohort 2|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (< <1.25 40 mg；; 1.25-1.5 50 mg； > >1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle;
32961241|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
32961242|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
32855356|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
33320519|NCT03773900|Placebo Comparator|Placebo supplementation|
32855357|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
32855358|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
32855359|NCT00936663|Placebo Comparator|placebo|placebo
33320520|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
32855360|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
32855361|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
32855362|NCT03903341|Other|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
32855363|NCT03903341|Other|Healthy subjects|bold signal in visual pathway
32855364|NCT04987086|Experimental|PSMA PET Arm|The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
32855365|NCT04354857||RT-PCR SARS-CoV-2 positive|
32855366|NCT04354857||RT-PCR SARS-CoV-2 negative|
32855367|NCT03903185|Active Comparator|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
32855368|NCT03903185|Active Comparator|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
32855369|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
32855370|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
32855371|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
32855372|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
32855373|NCT04989114|No Intervention|standard care|In this arm, oxygen inhalation will be provided without positive end expiratory pressure
32855374|NCT04989114|Experimental|nasal continuous positive airway pressure|In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure
32855375|NCT03917303|Active Comparator|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
32855376|NCT03917303|Active Comparator|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
32855377|NCT04989036|Experimental|CALCIUM HYDROXIDE™|Non-setting Calcium hydroxide Pulpotomy capping agent. Deepak. Promotion Industrial Park, Bari Brahmana, Jammu - 181133 India form : powder and liquid. application : Calcium hydroxide was mixed with saline to a thick consistency immediately before use. The paste was carefully placed on the pulp stump surface 2-3 mm thick over a small sterile wet cotton with a small condenser, and the excess material was scraped off.
32855378|NCT04989036|Experimental|Biodentine ™|Biodentine ™ Pulpotomy capping agent. Calcium Silicate-Based Material.Septodent®, Saint-Maurdes-Fosses, France form: capsule and liquid. application: According to the instructions of manufacture, Biodentine ™powder and liquid were mixed to achieve a creamy consistency, by mixing a single-unit powder part and 5 drops of a single-unit liquid part for 30 seconds by mixing device . Final mixing and adjustment were done manually to obtain the desired consistency for each case
32855379|NCT04782609|Experimental|20 mg Icapamespib cohort|Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg
32855380|NCT04782609|Experimental|dose expansion cohort|dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
32855381|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
32855382|NCT05583149|Experimental|ACALABRUTINIB and LISOCABTAGENE MARALEUCEL|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, as tolerated for one year~Liso-cel~Acalabrutinib"
32855383|NCT04366869|Active Comparator|control|traditional approach of removing denture at night
32855384|NCT04366869|Experimental|intervention 1|occlusal splint
32855385|NCT04366869|Experimental|intervention 2|Botox
32855386|NCT04989270||Patients undergoing Cesarean section|Group of patients undergoing Cesarean section between Jan'2015 to Dec'2019
32855387|NCT05583071|Experimental|combination of Tafasitamab (Minjuvi®), Lenalidomide, Rituximab and Methotrexate|All patients will receive tafasitamab (Minjuvi®) 12 mg/KG body weight and rituximab 375 mg/m² on days 0 and 5, followed by methotrexate 3,5 g/m² on day 1 as an intravenous infusion. Lenalidomide will be administered orally at 20 mg/day during the first cycle and at 25 mg/day during subsequent cycles on days 4-17 of each 21-day cycle for a total number of 4 cycles. The treatment duration per patient will be 84 days.
32855388|NCT04366635|Experimental|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
32855389|NCT04366635|Experimental|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
32855390|NCT04366635|Active Comparator|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
32855391|NCT04989348|Placebo Comparator|Antagonist group|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
32855392|NCT04989348|Active Comparator|PPOS group|"Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.~Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach >17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger."
32855393|NCT05582993|Experimental|Cohort 1: Participants With Age >=12 to <18 years|Participants with age greater than or equal to (>=) 12 to less than (<) 18 years who have received on-demand (OD) therapy or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 international units per kilogram (IU/kg) rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
32855394|NCT05582993|Experimental|Cohort 2: Participants With Age >=6 to <12 years|Participants with age >=6 to <12 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
32855395|NCT05582993|Experimental|Cohort 3: Participants With Age <6 years|Participants with age <6 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
32855396|NCT04346823|Experimental|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
32855397|NCT04346823|No Intervention|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
32855398|NCT05003232|No Intervention|Control group|
32855399|NCT05003232|Experimental|Optimal MAP group|
32855400|NCT05582837|Experimental|nortriptyline + topiramate|Nortriptyline (starting dose 7.5 mg) plus Topiramate (starting dose 10 mg) with appropriate dosage increase as necessary
32855401|NCT05582837|Active Comparator|hydrochlorothiazide + triamterene + placebo|hydrochlorothiazide (starting dose 25 mg) plus triamterene (starting dose 37.5 mg) with placebo being added in case of a dosage increase
32855402|NCT04986774|Experimental|Rescue Intracranial Stenting (RIS)|RIS in Acute Ischemic Stroke caused by intracranial large vessel occlusion
32855403|NCT04746963|Experimental|Low Dose|AXT107 0.1 mg/eye
32855404|NCT04746963|Experimental|Mid Dose|AXT107 0.25 mg/eye
32855405|NCT04746963|Experimental|High Dose|AXT107 0.5 mg/eye
32855406|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
32855407|NCT04728633|Experimental|Treatment (carmustine, ethiodized oil, gelatin sponge)|Patients undergo TACE by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats Q4W for bilobar disease or Q7W for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.
32855408|NCT04143113|No Intervention|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
32855409|NCT04143113|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
32855410|NCT05003700|Experimental|HAIC(RALOX) plus Lenvatinib and Camrelizumab|Hepatic arterial infusion of oxaliplatin and raltitrexed every 3 weeks. Lenvatinib 8 mg once daily (QD) oral dosing. Camrelizumab 200mg intravenously every 3 weeks.
32855411|NCT02982291|Active Comparator|Standard|
32855412|NCT02982291|Experimental|Individualized|
32855413|NCT05582759|Active Comparator|SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education
32855414|NCT05582759|Experimental|teleCBT-I + SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education plus cognitive cognitive behavioral therapy for insomnia
32855415|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of small volume (≤ 30 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
32855416|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of large volume (> 30 and ≤ 100 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
32855417|NCT04143191|Active Comparator|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
33320521|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
33320522|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
33320523|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
33104382|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
33104383|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
33104384|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
33104385|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
33104386|NCT00553046||family burden|chronich respiratory failure home ventilated patients
32855418|NCT04143191|Experimental|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
33104387|NCT04515901|Experimental|SPGB|Via a soft tip 20-gauge long IV catheter attached to a 3 mL syringe will be filled with 2 mL of 2% viscous lidocaine. The 2% viscous lidocaine will be administered according to the method of Barre.
33104388|NCT04515901|Placebo Comparator|Placebo|It will be adminstered the same as the experimental arm but with methylcellulose and cherry flavouring to match odour and taste.
33104389|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
33104390|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
32855419|NCT04701177||Subjective cognitive decline (SCD)|subjective perception of cognitive decline in the absence of cognitive impairment in formal neuropsychological assessment.
32855420|NCT04701177||Mild cognitive impairment (MCI)|Single or multidomain cognitive deficits with preservation of activities of daily living.
33104391|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
33104392|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
32855421|NCT04701177||Prodromal Parkinson's Disease|Parkinson's disease (PD) has a prodromal phase during which nonmotor clinical features as well as physiological abnormalities may be present.
32855422|NCT04896684||Patient screened or followed-up for IBS or IBD or colorectal cancer|Blood and colon biopsy sampling
32855423|NCT03916055|Experimental|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
32855424|NCT03916055|Active Comparator|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
32855425|NCT04896216|Experimental|Stigma Reduction Intervention|A Stigma Reduction Intervention curriculum will be developed using data generated from Stage 1 of the study.
32855426|NCT04896216|No Intervention|Control|This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
32855427|NCT04661007|Experimental|Part 1 : tafasitimab monotherapy|Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 2 groups: Group 1 will evaluate weight-based doses of tafasitamab, and Group 2 will evaluate fixed doses of tafasitamab.
32855428|NCT04661007|Experimental|Part 2 : tafasitamab combination therapy|tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
32855429|NCT04661007|Experimental|Part 3 : Dose Expansion of tafasitamab +parsaclisib|tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
32855430|NCT04661007|Experimental|Part 4: tafasitamab combination therapy|tafasitamiab in combination with lenalidomide will be further evaluated in Group 6 at RP2D determined in Part 2.
32855431|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
32855432|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
32855433|NCT04895514|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of gamma-irradiated preserved corneal tissue
32855434|NCT04640025|Experimental|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
33104393|NCT02646527|No Intervention|SPC|standard palliative care
32855435|NCT04986384|Active Comparator|Active Treatment Group|Patients will be instructed to use the anti-pruritic spray for four weeks starting from the day which informed consent was signed in active treatment group. A follow-up visit will be on week 2 for a mid-term review.
32855436|NCT04986384|Active Comparator|Wait-list Control Group|Patients will be instructed to start the treatment after two weeks from the day which consent was signed and for a duration of two weeks in wait-list control group. A follow-up visit will be on week 2 for a mid-term review and for the dispense of treating material.
32855437|NCT04765553|Active Comparator|Emapalumab|Emapalumab i.v infusion
32855438|NCT04765553|Placebo Comparator|Placebo|Saline i.v. infusion
32855439|NCT04461288|Experimental|Pride Posts|This six month intervention will be conducted on the Facebook platform. Participants will receive regular social media posts tailored to the sexual and gender minority communities (LGBTQ+). Weekly live sessions with a tobacco expert will be available. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
32855440|NCT04461288|Experimental|Pride Posts Plus|This six month intervention will include all elements of the Pride Posts arm. In addition, the intervention will include gamification, gaming elements designed to encourage participation in the program and behavior change. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
32855441|NCT04461288|Active Comparator|Usual Care Condition|Participants in this arm will be provided with a referral to smokefree.gov, a federally-funded website which provides support and digital-based interventions to assist in smoking cessation activities. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
32855442|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
32855443|NCT05582135|Active Comparator|group A|The parturients in group A were administered 2 mg morphine sulfate through the epidural catheter.
32855444|NCT05582135|Active Comparator|group B|The parturients in group B were administered 0.25mg/kg of esketamine.
32855445|NCT05582135|Active Comparator|group C|The parturients in group C were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate.
32855446|NCT05582135|Active Comparator|group D|The parturients in group D were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate.
32855447|NCT04142801|Experimental|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
32855448|NCT04142801|Placebo Comparator|Control group|Regular follow up at the memory center without cognitive training
32855449|NCT05003154|No Intervention|Conventional management group|Received conventional management based on Guidelines for GDM in China
32855450|NCT05003154|Experimental|Digitalized management group|Reveived conventional management and digitalized management
32855451|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
32855452|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
32855453|NCT04142099|Experimental|skin to skin contact 60 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.~No intervention or forced neonatal suction."
32855454|NCT04142099|Active Comparator|skin to skin contact 20 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.~No intervention or forced neonatal suction."
32855455|NCT03070704||Insulin degludec /liraglutide|
32855456|NCT04141943|Experimental|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
32855457|NCT04141943|No Intervention|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
32855458|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
32855459|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
32855460|NCT04141553|Active Comparator|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of <110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
32855461|NCT04141553|Active Comparator|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
32855462|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
33406746|NCT05609058|Experimental|Breast cancer underwent scanning in the supine position|Breast cancer patients with T1-2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist. The tumor bed (TB) was determined based on surgical clips. The Clinical target volume (CTV)consisted of the whole breast. The planning target volume (PTV) was CTV plus 0.5cm. The boost of PTV (PTVboost) was TB plus 0.5cm.
32855463|NCT04141241|Experimental|Low Dose PH100: 800mg/day|"PH100 (Ecklonia cava Phlorotannin) 200mg/tablet~PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
32855464|NCT04141241|Experimental|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
32855465|NCT04141241|Placebo Comparator|Placebo|"Placebo 200mg/tablet~Placebo 4 tablets BID during 12wks"
32855466|NCT04456062|Experimental|Caring Contacts Group|
32855467|NCT04456062|No Intervention|Standard Treatment Group|
32855468|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
32855469|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
32855470|NCT04986462||patients with bursal-side partial-thickness rotator cuff tears|Patients with bursal-side partial-thickness rotator cuff tears who underwent arthroscopic surgery and was followed up at Peking University Third Hospital.
32855471|NCT04141163|Experimental|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
32855472|NCT04141163|Placebo Comparator|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
32855473|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
32855474|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
32855475|NCT05002842|Experimental|Immediate Intervention|Those in the immediate intervention arm will begin the LovingKindess Meditation practice upon enrollment.
32855476|NCT05002842|Experimental|Delayed Intervention|Those in the deferred intervention arm will commence the LovingKindness Meditation practice intervention approximately 3 weeks (post 3 -week survey) after enrollment and participate three weeks thereafter.
32855477|NCT04141475|Active Comparator|Alpha-Lipoic Acid group|
32855478|NCT04141475|Placebo Comparator|placebo group|
32855479|NCT04986306||clinical tumor stage 1-3 (cT1-3) and nodal stage 1 (cN1) breast cancer patients|Patients who will undergo neoadjuvant chemotherapy were asked to participate in this study. Informed consent will be given. Clip will be placed over the positive lymph node by surgeon which was proven by fine-needle aspiration cytology. After completion of neoadjuvant chemotherapy, surgery of the breast and the axilla was executed in the same session. Different surgeons performed the procedure.
32855480|NCT03913715|Active Comparator|Ostomy Self-Management Training|Ostomy Self-management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
32855481|NCT03913715|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient.
32855482|NCT04544943|Experimental|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The total body surface area (BSA) dosed will be either 9% or 27% BSA. Part A will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control, applied at 9% or 27% BSA.
32855483|NCT04544943|Placebo Comparator|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients in Cohort 2. Part B will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control.
32855484|NCT04544943|Experimental|Open-Label|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients
32855485|NCT04140461|Experimental|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
32855486|NCT04140461|Active Comparator|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
32855487|NCT04988100|Experimental|Patients who undergo Splenic artery ligation|If inclusion criteria are met, these group of patients will undergo splenic artery ligation .
32855488|NCT04988100|Active Comparator|No splenic artery ligation|If inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
32855489|NCT03032757|Experimental|Resting leg of young males|
32855490|NCT03032757|Experimental|Exercising leg of young males|
32855491|NCT03032757|Experimental|Resting leg of elderly males|
32855492|NCT03032757|Experimental|Exercising leg of elderly males|
32855493|NCT04140617|Experimental|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
32855494|NCT04140617|Experimental|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
32855495|NCT05002920||cleft patients received alveolar bone grafting|alveolar bone grafting was performed when the cleft patients were aged around 9 years old. CBCT was used to analyze the bone mineral density of grafted tissue.
32855496|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
32855497|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
32855498|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
33104394|NCT04685889|Active Comparator|Icon Group|Icon® resin infiltration treatment was performed on 58 permanent central teeth with MIH and evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
33104395|NCT04685889|No Intervention|Control Group|No treatment was performed on healthy teeth. However, similar to the treated teeth, 58 healthy permanent central teeth of the same individuals were evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
33104396|NCT04206514|Experimental|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
33104397|NCT04206514|Experimental|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
33104398|NCT04206514|No Intervention|control|Participants receive the standard of care for post-abortion patients in Kenya.
33104399|NCT05504902|Experimental|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
33104400|NCT05630365|Experimental|Nasal sampling/Testing (Professional Use)|operators will collect one mid-turbinate nasal swab sample from both nostrils from each subject. The collected mid-turbinate nasal swab will be tested with the Panbio™ Rapid Panel by an operator at the study site in a Near Patient Testing setting (e.g. GP centre or hospital clinic). After the mid-turbinate nasal sampling, the operators will collect one NP swab sample from one nostril of each subject.UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, as per the laboratory manual
33104401|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
33104402|NCT04001556|Experimental|Patients reporting subjective sicca symptoms|HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
33104403|NCT04001556|Experimental|Patients without subjective sicca symptoms|HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
33104404|NCT04320589|Active Comparator|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
33104405|NCT04320589|Active Comparator|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
32855499|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
32855500|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
32855501|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
32855502|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
32855503|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
32855504|NCT04988334|Active Comparator|FAST|12 weeks of FAST, 2/week 45 minute sessions with half hour per week of education, same group of men and women
32855505|NCT04988334|Placebo Comparator|wait control|12 weeks of usual activity prior to intervention, same group of men and women
32855506|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
32855507|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
32855508|NCT00947661|Experimental|SPARC0912|Test drug
32855509|NCT00947661|Experimental|Reference0912|Reference drug
32855510|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
32855511|NCT04987632|Experimental|Letrozole combined with acupuncture and Du Meridian moxibustion group|Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
32855512|NCT04987632|Active Comparator|Letrozole group|Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
32855513|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
32855514|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
32855515|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
33104406|NCT04319458|Experimental|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
32855516|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
33104407|NCT04319458|Active Comparator|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
32855517|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
32855518|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
32855519|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
32855520|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
32855521|NCT04140227|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
32855522|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
32855523|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
32855524|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
32855525|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
32855526|NCT04355091|Experimental|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
32855527|NCT04355091|No Intervention|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
32855528|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
32855529|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
32855530|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
32855531|NCT05002686|Experimental|Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection|
32855532|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
32855533|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
32855534|NCT04985526|Experimental|Polymorphic light eruption patients|PLE patients subjected to MED testing and photoprovocation
32855535|NCT04985526|Other|Healthy subjects|Normal healthy subjects
32855536|NCT04502745|Experimental|Treatment Group|During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.
32855537|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
32855538|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
32855539|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
32898855|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
33406747|NCT05169606|Experimental|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
32855540|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
32855541|NCT04985292|Experimental|Probiotic|10^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
32855542|NCT04985292|Placebo Comparator|Placebo|Inactive substance packaged to be identical to active treatment
32855543|NCT04488861||IVF-conceived|Those who have conceived by IVF (for whatever indication); target 80 participants of which it is anticipated 20 would have conceived by frozen embryo transfer IVF.
32855544|NCT04488861||Spontaneously conceived|Those who have conceived spontaneously (within 12 months and without use of hormonal or other contraception); target 20 participants
32855545|NCT04488861||Ovulation induction-conceived|Those who have conceived by ovulation induction (after more than 12 months); target 20 participants.
32855546|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
32855547|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
32855548|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
32855549|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
32855550|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
32855551|NCT04478175|Other|Patients with advanced gastrointestinal (GI) cancers|"All patients will receive usual care including:~Chemotherapy at the investigator's choice,~Outpatient clinical visits according to the regular schedule,~Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks.~Nutritional support will consist of:~A nutrition assessment by a dieticianat W4 and W8 (plus additional visits if required),~Nutritional intervention ± oral supplementation, enteral tube feeding, and/or parenteral nutrition).~Physical activity support will consist of:~A physical condition assessment by a APA profesional including physical tests (6-minute walking test, handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance) at baseline, W4 and W8,~Personalized counselling for unsupervised home-based exercises"
32855552|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
32855553|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
32855554|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
32855555|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
32855556|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
32855557|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
32855558|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
32855559|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
32855560|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
32855561|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
32855562|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
32855563|NCT00939705|Experimental|Torrent Topiramate|
32855564|NCT00939705|Active Comparator|Topamax|
32855565|NCT05002296|Active Comparator|traditional physical therapy program|
32855566|NCT05002296|Experimental|rotatory upper cervical manipulation to both sides|
32855567|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
32855568|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
33104408|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
33104409|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
33104410|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
33104411|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
32855569|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
32855570|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
32855571|NCT05001672|Experimental|TAF arm|"54 patients will be randomized into TAF arm*. TAF 25 mg QD will be initiated 7 days before bDMARDs, and continued for up to 144-weeks.~*for patients received rituximab (anti-CD20 monoclonal antibody) will be enrolled into TAF arm, and TAF 25 mg QD will be initiated 7 days before rituximab, and continued for up to 144-weeks. Max 20 rituximab patients will be recruited."
32855572|NCT05001672|Other|Observation arm|54 patients will be randomized into observation arm initially. These patients will be closely monitored their HBV status (including qHBsAg and HBV DNA) for 48 weeks. TAF 25 mg QD will be initiated for 144 weeks in the presence of HBV reactivation, or after 48 weeks of observation.
32855573|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
32855574|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
33104412|NCT03990909|Experimental|BCAAs|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
33104413|NCT03990909|Placebo Comparator|Rice Protein|Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
32855575|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
32855576|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
33104414|NCT03990909|Placebo Comparator|Microcrystalline Cellulose|Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
33104415|NCT01252810|Experimental|GE 145 320mg I/ml injection|
33104416|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
33104417|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
33104418|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
32855577|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
33104419|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
33104420|NCT04206709|Experimental|aerobic effort|Active upper limbs pedaling
33104421|NCT04206709|Sham Comparator|passive pedaling|passive pedaling
33320524|NCT03774446|Experimental|Seliciclib|Up to 800 mg/day oral seliciclib for 4 days each week for 4 weeks
32855578|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
32855579|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
32855580|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
32855581|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
32855582|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
32855583|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
32855584|NCT03032211|Experimental|Treatment|Alfapump
32855585|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
33104422|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
33320525|NCT01309724|No Intervention|Control|No measurements are made on the control group.
33320526|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
33320527|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
32746676|NCT05032755|Experimental|VLNC Group|Participants in this condition will be provided with Spectrum NRC102/103 (nonmenthol/menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco with reported nicotine yield (ISO) of 0.03 +/- 0.01 mg and a tar yield of 9 +/- 1.5. Participants will be asked to smoke only study cigarettes for 4 weeks.
32746677|NCT05032755|Active Comparator|NNC Group|Participants in this condition will be provided with Spectrum NRC600/601 (non-menthol/menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco with reported nicotine yield (ISO) of 0.8 +/- 0.15 mg and a tar yield of 10.5 +/- 1.5.
32746678|NCT05612997||Relative Validation Arm|
32746679|NCT05473845|Experimental|Acupressure|Acupressure intervention
32746680|NCT05473845|Experimental|Reiki|Reiki intervention
32746681|NCT05473845|No Intervention|Control|No intervention.
32746682|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
32746683|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
32746684|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
32746685|NCT05192343|Experimental|Virtual Reality Glasses|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, before and during the HSG procedure, the Virtual Reality Glasses application group watched a video with a nature view with glasses.Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure. The women included in the Virtual Reality Glasses intervention group were made to watch a video with a nature view for 15 minutes before and during the HSG procedure. Each woman was shown the same video.
32746686|NCT05192343|Experimental|Music|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, a nature-based sound was played to the women in the music group before and during the HSG shooting.Listening to nature-based sound was performed for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
32746687|NCT05192343|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography.
32746688|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
32746689|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
32746690|NCT05612919|Experimental|Patients exclusively transfused with UCB-RBC|Interventional group infants arm will receive UCB-RBC bag when RBC transfusion is indicated as per standard practice, and when UCB-RBC is available within the first 6 hours of the request.
32746691|NCT05612919|Active Comparator|Patients exclusively transfused with AB-RBC|Standard treatment group infants arm will receive AB-RBC when RBC transfusion is indicated as per standard practice, and compatible UCB-RBC bag is not available.
32746692|NCT05612919|No Intervention|Non transfused patients|Patients with no indications for RBC transfusion. Their clinical management will be the usual in our neonatal unit.
32746693|NCT05612841||non metastatic castration resistant prostate cancer|
32746694|NCT05612841||metastatic castrare naïve prostate cancer|
32746695|NCT05612763|Experimental|Method of fit|Devices are fit using either a clinician completed fitting process or a patient completed fitting process. Then the alternate fitting method is used to repeat the process. The order of which method used is counterbalanced.
32746696|NCT05612061|Experimental|Treatment Group|Receives Indigenous Recovery Planning (IRP) intervention, which includes 6 weekly group intervention sessions lasting about 2 hours each.
32746697|NCT05612061|No Intervention|Waitlist Control Group|Participants in the waitlist control group do not receive the intervention until after treatment group completes the intervention. Outcomes will be compared between the 2 study arms at baseline and at follow-up, at which point the treatment group will have completed the intervention and the waitlist control group will have not yet been exposed to the intervention, thereby serving as the control group.
32746700|NCT05465967|Sham Comparator|Group I: Control Group|Patients in this group will receive ipsilateral sham ultrasound-guided block via subcutaneous injection of 1 ml of normal saline after surgery.
32746701|NCT05465967|Active Comparator|Group II:( transverse trans muscular Quadratus lumborum group).|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK(30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
32746702|NCT05465967|Active Comparator|Group III : paraspinous sagittal approach of Quadratus lumborum BLOCK|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
32746703|NCT05465889|Experimental|OSS group|Bowel preparation for colonoscopy was performed using oral sulfate solution as laxative
32961243|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
32961244|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
32961245|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
32961246|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
32961247|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
32961248|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
32961249|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
32961250|NCT01287078|Experimental|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
32961251|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
32961252|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
32961253|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
32961254|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
32961255|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
32961256|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
32961257|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
32961258|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
32961259|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
32961260|NCT01293396|Active Comparator|Insulin Aspart|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
32961261|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
32961262|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
32961263|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
32961264|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
32961265|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
32961266|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
32961267|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
32961268|NCT01298544|Other|All subjects|
32961269|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
32961270|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
32961271|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
32961272|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
32746704|NCT05465889|Active Comparator|Polyethylene glycol group|Bowel preparation for colonoscopy was performed using polyethylene glycol as laxative
32746705|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
32746706|NCT05614947|Experimental|tart cherry|two capsules daily for 60 days
32746707|NCT05614947|Placebo Comparator|placebo|two capsules daily for 60 days
32746708|NCT05611827|Experimental|Quercetin LipoMicel (250 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 250 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 250 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
32746709|NCT05611827|Experimental|Quercetin LipoMicel (500 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 500 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
32747333|NCT05545059|Active Comparator|valsartan group|The control group will be valsartan group, which patients will receive valsartan 160mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
32961273|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
32961274|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
32961275|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
32961276|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
32961277|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
32961278|NCT01304082|Placebo Comparator|normal saline|
32961279|NCT01304082|Active Comparator|lidocaine|
32961280|NCT01304082|Experimental|alkalinized lidocaine|
32961281|NCT01304238||lepirudin|lepirudin treated subjects
32747334|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
32747335|NCT05537259||Observation Group|Researchers will collect data on maternal mental health symptoms, as well as health and psychosocial factors, via short interviews (sessions 1 and 4) and via self-report questionnaires completed through REDCap at each session. Participating women will also provide one small hair sample (session 4) for measurement of the stress hormone cortisol and several finger stick blood spot samples (sessions 1,2, and 4) for measurement of immune markers.
32961282|NCT01304238||danaparoid|danaparoid treated subjects
32961283|NCT01304238||argatroban|argatroban treated subjects
32961284|NCT01304238||fondaparinux|fondaparinux treated subjects
32747336|NCT05544981|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
32747337|NCT05544981|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
32747338|NCT05698173|Experimental|Systemic Lupus Erythematosus|Diagnosis of systemic lupus erythematosus according to American College of Rheumatology (ACR) or SLICC criteria
32747339|NCT05698173|Other|Controls|Healthy controls
32747340|NCT05699343|Experimental|Bone grafting with collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with a collagen membrane (InterCollagen Guide) placed over the bone graft.
32747341|NCT05699343|Active Comparator|Bone grafting without collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with no collagen membrane placed over the graft.
32747342|NCT05536947|Active Comparator|Standard-milled Wholegrain|Bread rolls prepared using standard-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
32747343|NCT05536947|Experimental|Micro-milled Wholegrain|Bread rolls prepared using Micro-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
32747344|NCT05536947|Active Comparator|White flour fortified with standard milled Aleurone|Bread rolls prepared using a white flour and standard-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
32747345|NCT05536947|Experimental|White flour fortified with micro-milled Aleurone|Bread rolls prepared using a white flour and micro-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
32747346|NCT05544903||Mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
32747347|NCT05544903||No mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
32747348|NCT05696925|Experimental|motor imagery, observation of the action, and execution of the action (GE1)|in the sitting position, the participant will watch the recorded video to observe the action, for two minutes. Soon after, they will close their eyes, and receive the description of the action, through recorded audio of the same action, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 60 minutes of intervention.
32747349|NCT05696925|Experimental|motor imagery and execution of the action (GE2)|in the sitting position, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
32747350|NCT05696925|Experimental|action observation and action execution (GE3)|in the sitting position, the participant will watch the recorded video to perform the action observation, which will last two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
32747351|NCT05696925|Experimental|motor imagery, execution of the action, and exoskeleton (GE4)|in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes. Then, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention.
32747352|NCT05696925|Experimental|observation of the action, execution of the action, and exoskeleton (GE5)|"in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes.~Then, the participant will watch the recorded video to observe the action, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention."
32747353|NCT05536869|Active Comparator|Patient with intraperitoneal caesarean section|
32747354|NCT05536869|Experimental|patient with extraperitoneal caesarean section|Faucs technique
32747355|NCT05128773|Experimental|Amcenestrant with tamoxifen-matching placebo arm|Amcenestrant dose, once daily, continuously. Tamoxifen-matching placebo, once daily, continuously.
32747356|NCT05128773|Active Comparator|Tamoxifen with amcenestrant-matching placebo|Tamoxifen dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously.
32855586|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
32855587|NCT04354389|Experimental|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
32855588|NCT04354389|Placebo Comparator|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
32855589|NCT04354389|Experimental|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
32855590|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
32855591|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
32855592|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
32855593|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
32855594|NCT04354311|Experimental|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
32855595|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants received first/second line anticancer therapy with sorafenib before this study were assigned to Cohort A.
32855596|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who did not receive first/second line anticancer therapy with sorafenib before this study were assigned to Cohort B.
32855597|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
32855598|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
32855599|NCT04406129|Experimental|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
32855600|NCT04406129|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
32855601|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
32855602|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed > 0.8 m/s and have had no falls in the last year.
32855603|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
32855604|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
32855605|NCT04353999|Experimental|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
32855606|NCT04353999|Active Comparator|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
32855607|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
32855608|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
32855609|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
32855610|NCT04335981|Experimental|FT-CC and Swallow Exercises|
32855611|NCT04335981|Active Comparator|Swallow Exercises|
32855612|NCT05620251||COVID-19 infection-naive adolescents with type 1 diabetes|
32855613|NCT05620251||COVID-19 infection-naive healthy controls|
32961285|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
33406748|NCT05169606|Experimental|Active Isolated Stretch|Active Isolated Stretch is a specific stretching program developed by Aaron Mattes over 30 years ago. Active isolated stretch is also found to be effective to increase flexibility and improve ROM.
33406749|NCT05169606|Experimental|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients.
32961286|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
32961287|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
32961288|NCT01307748|Placebo Comparator|Placebo aroma 1|
32961289|NCT01307748|Placebo Comparator|Placebo aroma 2|
33406750|NCT05599620|Experimental|AWARE Program|The AWARE program addresses alcohol use, sexual distress and sexual revictimization risk.
33406751|NCT05599620|Placebo Comparator|General Health Promotion|The General Health Promotion program is a attention and dose-matched comparison condition.
33406752|NCT05706870|Experimental|GN 037 cream|"Psoriatic patients will receive GN037 cream in 2 to 2 to 1 ration~Application will be done twice daily, to a selected body target lesion~Psoriatic patients will receive GN037 cream twice daily,~GN037 cream will be applied as thin film layer, for 4 weeks."
33406753|NCT05706870|Active Comparator|Clobetasol 17-propianate|"Clobetasol 17-propianate cream will be applied in 2 to 2 to 1 ration~Application will be done twice daily, to a selected body target lesion~Psoriatic patients will receive Clobetasol 17 propionate cream twice daily, to a selected body target lesion~Clobetasol 17-propianate will be applied as thin film layer, for 4 weeks."
33406754|NCT05706870|Placebo Comparator|Placebo|"Placebo cream will be applied in 2 to 1 ratio twice daily,~Application will be done twice daily, to a selected body target lesion~Psoriatic patients will receive placebo cream twice daily, to a selected body target lesion~Cream will be applied as thin film layer, for 4 weeks."
33406755|NCT05706792|Experimental|Nordic Sensi Chair|Participants received three times a week one session per day of 20 minutes in the Relax for deep relaxation program of the Nordic Sensi Chair.
33406756|NCT05706792|No Intervention|Standard of care|Participants did not participate in the Nordic Sensi Chair sessions, but received, at the same time and duration, the care and activities that were part of the daily routines of the center, including group sessions of cognitive stimulation, training in activities of daily living or communication training.
33406757|NCT05061186|Experimental|Resistive Expiratory muscle Training Group|Mild Resistive Expiratory muscle Training Group
33406758|NCT05061186|Active Comparator|Conventional Breathing Exercise Group|Breathing Ex: Pursed lip Breathing, Diaphragmatic breathing ex, incentive spirometer
33406759|NCT05706480||Periodontally clinically healthy patients|In Periodontally clinically healthy patients fulfilling the eligibility criteria. The gingival tissue thickness will be measured using probe-colored periodontal probes (CPP), standard periodontal probes (SPP) and transgingival sounding with an endodontic file (ISO #20), visual judgment using photographs will be done to the three assessment methods
33406760|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
33406761|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
33406762|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
33406763|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
33406764|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
33406765|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
33406766|NCT05576376|Experimental|plantar fascia release|"plantar fascia open release Longitudinal incision at the medial heel, Exposure of the plantar fascia at its origin on the medial plantar calcaneus. Medial incision of the plantar fascia preserving the lateral portion.. Exposure of the abductor hallucis muscle. Incision of the superficial fascia of the muscle. Retraction of the muscle belly und incision of the deep portion of the fascia, decompression of the first calcaneal branch of the lateral plantar nerve (Baxter's nerve) in cases of its being compressed.~Postoperative management: Two weeks partial weight bearing. Progressively weight bearing using a shoe with a stiff sole for another 4 weeks."
33406767|NCT05576376|Experimental|Plantar fascia endoscopic release|We will draw a line distally from the posterior aspect of the medial malleolus to the intersection of the medial origin of the plantar fascia at the calcaneal tuberosity. A skin incision will be made, and medial portal will be performed at this location. Blunt dissection will be performed to clear the subcutaneous tissue from the plantar fascia with caution to avoid lesion of the calcaneal nerve medial branch.
33406768|NCT05576376|Experimental|Clacaneal osteotomy|calcaneal osteotomy skin incision will be oblique and directed from the inferoposterior edge of the lateral malleolus to the inferior edge of the calcaneal body, and subperiosteal exposure of the lateral calcaneal wall will be performed. Osteotomy will be performed from 1 cm anterior of the calcaneal attachment of the plantar fascia to 1 cm anterior of the calcaneal attachment of the Achilles tendon. After the osteotomy, approximately 5 mm plantar displacement of the proximal fragment, which include attachment of the plantar fascia, will be performed. Fixation after the osteotomy will be performed under an image intensifier using one cannulated cancellous screws 4.5 mm in diameter, which will be inserted from the infero-medial of the calcaneal tuberosity to the distal fragment
32961290|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
32961291|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
32961292|NCT01308294|Experimental|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
32961293|NCT01308294|Experimental|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
32961294|NCT01308294|Experimental|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
32961295|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
32961296|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
32961297|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
33406769|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
32961298|NCT01310400|Experimental|Inflexal 0.5 mL|
32961299|NCT01310400|Experimental|Inflexal 0.25 mL|
33406770|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
32961300|NCT01310400|Experimental|Agrippal 0.25 mL|
32961301|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
32961302|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
32961303|NCT01312038|Experimental|simethicone|125 mg tablet
32961304|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
32961305|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
32961306|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
32961307|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
32961308|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
32961309|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
32961310|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
33406771|NCT05570526|Experimental|Intervention group:|20 patients will receive oral melatonin 5mg tablets 1-hour before bedtime for 12 weeks.
32961311|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
32961312|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
32961313|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
32961314|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~Induction Dose: 2-2.5 mg/kg~Maintenance Dose: 0.1-0.2 mg/kg/min"
32961315|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
32961316|NCT01317030||Non-Contact Lens Wear|
32961317|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
32961318|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
32961319|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
32961320|NCT01318356|Experimental|Cognitive behavioral therapy|
32961321|NCT01318356|Experimental|Doxycycline|
32961322|NCT01318356|Placebo Comparator|Placebo|
32961323|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
32961324|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
32961325|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
33406772|NCT05570526|Placebo Comparator|Placebo|20 patients will receive one tablet of placebo 1-hour before bedtime for 12 weeks.
32855614|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
32855615|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
32855616|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
32855617|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
32855618|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
32855619|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
32855620|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
32855621|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
32855622|NCT04090359|Experimental|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
32855623|NCT04090359|Active Comparator|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
32855624|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
32855625|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
32855626|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
32855627|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
32855628|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
32855629|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
32855630|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
32855631|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
32855632|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
32855633|NCT05620173|Experimental|Vedea Amblyopia Therapy (VAT) then Vedea Amblyopia Therapy|"Children in this intervention arm will use the VAT for 16 weeks.~After the initial 16 weeks of treatment these children will be allowed to use the VAT for another 16 weeks."
32855634|NCT05620173|Active Comparator|Occlusion therapy then Vedea Amblyopia Therapy (VAT)|"Children in this intervention arm will adhere to a 'care as usual' regimen consisting of occlusion therapy as prescribed by their health care provider. They will do so for 16 weeks.~After the initial 16 weeks of treatment these children will crossover into the experimental arm to examine if they are still responsive to the VAT after already completing 16 weeks of traditional treatment."
32855635|NCT03585881|Experimental|window bracket positioning tray|
32855636|NCT03585881|No Intervention|conventional indirect boning tray|
32855637|NCT05620017|Experimental|A/0.8mg/kg|Drug：BAT8008 for Injection,0.8mg/kg
32855638|NCT05620017|Experimental|B/1.2mg/kg|Drug：BAT8008 for Injection,1.2mg/kg
32855639|NCT05620017|Experimental|C/2.4mg/kg|Drug：BAT8008 for Injection,2.4mg/kg
32855640|NCT05620017|Experimental|D/3.6mg/kg|Drug：BAT8008 for Injection,3.6mg/kg
32855641|NCT05620017|Experimental|E/4.8mg/kg|Drug：BAT8008 for Injection,4.8mg/kg
32855642|NCT05620017|Experimental|F/6.0mg/kg|Drug：BAT8008 for Injection,6.0mg/kg
32855643|NCT05620017|Experimental|G/7.2mg/kg|Drug：BAT8008 for Injection,7.2mg/kg
32855644|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
32855645|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
32855646|NCT03888911|Placebo Comparator|Placebo|Placebo group
32855647|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
32855648|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
32855649|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
32855650|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
33406773|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
33406774|NCT05593926|Experimental|Intervention|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
33406775|NCT05593926|No Intervention|Placebo|Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.
32855651|NCT03585803|Other|KMRC011 15μg or Placebo|Cohort 3
32855652|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 4
32855653|NCT03585803|Other|KMRC011 25μg or Placebo|Cohort 5
32855654|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
32855655|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
32855656|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
32855657|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
32855658|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
32855659|NCT03966027|Experimental|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
32855660|NCT03966027|Placebo Comparator|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
32855661|NCT05619861|Experimental|CAR-T|Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 × 106CAR-T cells/kg
33406776|NCT05343689|Experimental|Pneumatic compression group|When inducing general anesthesia, pneumatic compression is performed.
33406777|NCT05343689|No Intervention|Control group|When inducing general anesthesia, pneumatic compression is not performed.
32855664|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
32855665|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
32855666|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
32855667|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
32855668|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
32855669|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
32855670|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
32855671|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
32855672|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
32855673|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
32855674|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
32855675|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
32855676|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
32855677|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
32855678|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
32855679|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
32855680|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
32855681|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
33406778|NCT05563974|Experimental|Women who agree to receive family led postnatal care|This group will receive Family-led Postnatal Care-FPNC
33406779|NCT05563974|No Intervention|Women who receive standard of care for postnatal care|Women will get the standard of care for postnatal care
33406780|NCT05542914|Experimental|e-SBI|Electronic Screening and Brief Intervention for substance use and HIV risk reduction
32961326|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
33320528|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
32961327|NCT01322022|Experimental|Parent Training|Behavioral Intervention
32961328|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
32961329|NCT01324128|Experimental|PA21 (2.5 g tablet)|
32961330|NCT01324128|Active Comparator|Sevelamer carbonate|
32961331|NCT01324128|Other|PA21-1 (1.25 g tablet)|
32961332|NCT01324518|Experimental|Low dose of ORM-12741|
32961333|NCT01324518|Experimental|High dose of ORM-12741|
32961334|NCT01324518|Placebo Comparator|Placebo|
32961335|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
32961336|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
32961337|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
32961338|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
32961339|NCT01328184|Experimental|Reference|multiple doses of Microgynon
32961340|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
32961341|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
32961342|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
32961343|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
33320529|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
32961344|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
32961345|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
33320530|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
32961346|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
32961347|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
32961348|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
32961349|NCT01331694||COPD|copd patients 65 years and older
32961350|NCT01333098|Experimental|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
32961351|NCT01333488|No Intervention|Conventional Therapy|
32961352|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
32961353|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
32961354|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
32961355|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
32961356|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
32961357|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
32961358|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
32961359|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
32961360|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
32961361|NCT01337076|Other|cochlear implant|
32961362|NCT01337700|Experimental|Milnacipran|
32961363|NCT01337700|Placebo Comparator|Placebo|
32961364|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
33320531|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
33320532|NCT04503590|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
33406781|NCT05542914|Active Comparator|Assessment Only|These individuals complete only the screening instruments, no brief intervention
32855682|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
32855683|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
32855684|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
32855685|NCT05613387|Experimental|ZP8396|Up to 3 dose cohorts are planned with 10 subjects in each; 7 participants in each cohort will receive active treatment.
32855686|NCT05613387|Placebo Comparator|Placebo (ZP8396)|In each of the 3 dose cohorts, 3 subjects will receive placebo.
32855687|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
32855688|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
32855689|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
32855690|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
32855691|NCT03834363|Active Comparator|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
32855692|NCT03834363|Experimental|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
32855693|NCT03834363|Placebo Comparator|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
32855694|NCT05703113|Experimental|Group trained with Web 2.0 tools|Group trained with Web 2.0 tools: Web 2.0 tools were used both while making presentations to the students and at the time of evaluation. Wordaart, google form, padlet, canva, bubbl.us were used in the presentation as Web 2.0 tools. For reviews kahoot, Socrative, Bamboozle, Mentimeter and Who Wants To Be A Millionaire? application is used.
32855695|NCT05703113|No Intervention|Control Group|Lessons were taught with traditional learning method.
32855696|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
32855697|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.~Intervention:Device"
32855698|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.~Intervention: medical treatment"
32855699|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
32855700|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
32855701|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
32855702|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
32855703|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
32855704|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
32855705|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
32855706|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
32855707|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
32855708|NCT03581747||Subjects with atopic dermatitis|
32855709|NCT03581747||Controls|
32855710|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
32855711|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
32855712|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
32855713|NCT05703035|Active Comparator|waiting group during staple firing|In this group, the amount of bleeding, bleeding points, postoperative drain amount and laboratory values will be monitored during the operation.
32855714|NCT05703035|Active Comparator|staple firing group without waiting for a certain time|In this group, no further intervention will be made, and the same treatment will be given as the 1st group and comparison will be made.
32855715|NCT03711747||Post-traumatic Ankle OA|Post-traumatic ankle OA and requiring osteochondral allograft to tibia and/or talus in ankle
32855716|NCT05702957|Experimental|letrozole|Patients were given letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
32855717|NCT05702957|Active Comparator|Clomiphene citrate|Patients were given clomiphene citrate 50-150mg per day for 5 days started from 2nd day of the menses.
32855718|NCT05536401|Other|Optical Coherence Tomography (OCT)|
32855719|NCT04405505|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
32855720|NCT04405505|Active Comparator|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
32855721|NCT05492175|Experimental|proximal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
32855722|NCT05492175|Active Comparator|distal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
32855723|NCT05492175|Active Comparator|robotic practice plus conventional therapy group|60 minutes per day, 3 days per week for 6 weeks
32855724|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
32855725|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
32855726|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
32855727|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
32855728|NCT01672866|Experimental|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
32855729|NCT01672866|Experimental|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
32855730|NCT01672866|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
32855731|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
32855732|NCT03581201||No contraception|Healthy females without any contraception at all.
32855733|NCT05491551|Experimental|Mindfulness-Based Treatment|Using mindfulness and meditative strategies to control craving
32855734|NCT05491551|Experimental|Cognitive Behavioral Therapy|Thinking of negative consequences to control craving
32855735|NCT05491551|No Intervention|Control|No regulatory strategy
32855736|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
32855737|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
32855738|NCT03580733|Placebo Comparator|placebo|placebo
32855739|NCT03580733|Experimental|antifungal therapy|caspofungin
32855740|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
32855741|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
32855742|NCT05702723|Experimental|Smart-3RP|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status: curvivor (participants who have completed curative therapy) or metavivor (participants will metastatic disease), using a random plan generator with 1:1 randomization. Participants will complete study procedures as outlined:~Baseline questionnaires.~9 virtual sessions of Smart-3RP.~3-month questionnaires.~Optional collections of hair samples at enrollment and 6-month follow-up period to measure cortisol concentration.~6-month questionnaires.~Optional exit interview with study staff."
32855743|NCT05702723|Active Comparator|Enhanced Usual Care|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status (curvivor/metavivor), using a random plan generator with 1:1 randomization.~Participants will be referred to a 14-week online support group."
32855744|NCT04984746|Experimental|No Intervention: (control group)|No Intervention: (control group) The control group was assigned to lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
32855745|NCT04984746|Experimental|Experimental: intervention group|Experimental: intervention group To the intervention group was assigned the biofortificated Molibdenum lettuce and Iodine lettuce.
32855746|NCT05480085|Experimental|School-based extracurricular intervention focusing on screen media use and time spent with friends|
32855748|NCT04984824|No Intervention|No nap group|No nap opportunity will be given in this condition.
32855749|NCT04984824|Experimental|10 minute nap|Participants will be given a 10 minute nap.
32855750|NCT04984824|Experimental|30 minute nap|Participants will be given a 30 minute nap.
32855751|NCT04984824|Experimental|60 minute nap|Participants will be given a 60 minute nap.
32855752|NCT05702489|Experimental|ZX-7101A low dose group|40 mg, tablet, single oral administration when the subject screened successfully
32855753|NCT05702489|Experimental|ZX-7101A high dose group|80 mg, tablet, single oral adminitration when the subject screened successfully
32855754|NCT05702489|Placebo Comparator|Placebo control|Analog tablet with no active ingredient, single oral administration when the subject screened successfully
32855755|NCT04984434|Experimental|Experimental: Single Arm|
32855756|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
32855757|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
32855758|NCT05702411|Experimental|Protocol 1|Closed system aspiration with an expiratory pause of 10 seconds followed by hyper insufflation maneuver with the Air Stacking technique.
32855759|NCT05702411|Experimental|Protocol 2|Closed system aspiration with an expiratory pause of 10 seconds.
33406782|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
32855760|NCT05001438|Active Comparator|Hidro alone|The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
32855761|NCT05001438|Experimental|Hidro + MUA|"The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.~After the Hidrodilatation the patient is sedated and then a Movilization of the glenohumeral joint is performed."
32855762|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
32855763|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
32855764|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
32855765|NCT04939662|Experimental|Olaparib+Bevacizumab to SCLC patients|"Regimen and administration:~Administration of olaparib Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Administration of bevacizumab Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
32855766|NCT05456529|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
32855767|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
32855768|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
32855769|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
32855770|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
32855771|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
32855772|NCT05702177|Experimental|Daridorexant 25 mg|Subjects will receive a daridorexant 25 mg tablet for oral administration.
32855773|NCT05702177|Experimental|Daridorexant 50 mg|Subjects will receive a daridorexant 50 mg tablet for oral administration.
32855774|NCT05702177|Placebo Comparator|Placebo|Subjects will receive a daridorexant-matching placebo tablet for oral administration.
32855775|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
32855776|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
32855777|NCT05702099||Detorsion|The group in which only adnexal detorsion was performed during the operation (Because there is no ovarian mass)
32855778|NCT05702099||Detorsion+cystectomy|Women with an ovarian mass who underwent emergency surgery for torsion, who underwent both detorsion and cystectomy in the same session.
32855779|NCT04930380||Cases|"male and female aged 25 years or more~diagnosis of defined MS~written informed consent must be obtained before the enrolment."
32855780|NCT04930380||Controls|"male and female aged 25 years or more~written informed consent must be obtained before the enrolment no history of MS"
32855781|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
32855782|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
33320533|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
32855783|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
32855784|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
32855785|NCT05581979||68-Ga PSMA PET scan|68-Ga PSMA PET scan
32855786|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
32855787|NCT05702021|Experimental|Science of Service Laboratory implementation strategy|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
32855788|NCT05702021|No Intervention|Stepped wedge comparator|Our hybrid trial uses a unidirectional crossover stepped wedge design. All sites cross over in the same direction from usual care to intervention. All sites therefore act as their own comparison prior to the sequential roll-out of the implementation strategy.
32855789|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
32855790|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
32855791|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
32855792|NCT03901781|Experimental|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
32855793|NCT03901781|Experimental|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
32855794|NCT03901781|Experimental|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
32855795|NCT05331144|Experimental|Intensive Treatment (IT)|Lowering SBP < 120 mmHG
32855796|NCT05331144|Active Comparator|Usual Care (UC)|Participants will follow their PCP's recommendations for BP control
32855797|NCT05291247||Heavily calcified femoropopliteal disease|"Subject must be between 21 and 85 years old~Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5~Willing to comply with the specified follow-up evaluation~Written informed consent prior to any study procedures"
32855798|NCT05701943|Experimental|Sprint Interval Training|The SIT consisted of a combination of aerobic, resistance, balance, and flexibility exercises. Exercise started with 5 min of warm-up followed by bouts of 5-10 min of exercise consisting of 5-20 s all-out sprints followed by 15-45 s of low cadence recovery (1:3-1:2 work-rest ratio). The duration of the sprints and active recovery were modified throughout the program. To ensure that participants exercised at the appropriate intensity, the OMNI scale 8-10 (Stanish & Aucoin, 2007) was applied during the home intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was used during the gym intervention.
32855799|NCT05701943|Active Comparator|Continuous Aerobic Exercise Training|CAET was based on a combination of aerobic, resistance, balance, and flexibility exercises. The exercise on the cycle ergometer started with 5-min of warm-up followed by 3 bouts of continuous cycling at a steady-state intensity. The duration of the bouts (5-10 min) and the intensity (55-85% HRR) were progressively increased throughout each phase. To ensure that the participants exercised at the appropriate intensity, the OMNI scale 4-6 (Stanish & Aucoin, 2007) was used during the home-based intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was worn during the gym-based intervention.
32855800|NCT03030729||Intermediate AMD|
32855801|NCT03030729||Advanced AMD|
32855802|NCT03030729||DR without macular edema|
32855803|NCT03030729||DR with macular edema|
32855804|NCT04450524|Experimental|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
32855805|NCT04450524|Experimental|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
32855806|NCT04450524|Placebo Comparator|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
32855807|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
32855808|NCT03586895|No Intervention|Standard of care|Counties use the standard of care and there is no intervention in practices.
32855809|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
32855810|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
32855811|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
32855812|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
32855813|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
32855814|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
32855815|NCT05580185||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours after extubation
32855816|NCT05580185||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation
32855817|NCT00951561|Experimental|Vipon|
32855818|NCT00951561|Active Comparator|Ibuprofen|
32855819|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
32855820|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
32855821|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
32855822|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
32855823|NCT05585333|Experimental|Photobiomodulation Group|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
32855824|NCT05585333|No Intervention|Control Group|
32855825|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
32855826|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
32855827|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
32855828|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
32855829|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
32855830|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
32855831|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32855832|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
32855833|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
32855834|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
32855835|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
32855836|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
32855837|NCT03900923|Experimental|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
32855838|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
32855839|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
32855840|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
32855841|NCT04405427|Experimental|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
32855842|NCT04405427|Active Comparator|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
32855843|NCT05582447||Disease Cohort|Age greater than one year old Direct bilirubin level of >2 mg/dl. No known congenital red cell membrane defect
32855844|NCT05582447||Control|Age matched to disease cohort No evidence for cholestatic liver disease No known congenital red cell membrane defect
32855845|NCT02555007|Experimental|Oral Vinorelbine|
32855846|NCT04455438|Experimental|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
32855847|NCT04455438|Experimental|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
32855848|NCT04455438|Experimental|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
32855849|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
32855850|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
32855851|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
32855852|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
32855853|NCT02381535|Experimental|Treatment (onalespib, cisplatin, IMRT)|Patient receive onalespib IV over 1 hour on days -7, 3, 10, 24, 31, and 38 and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36 and 43. Patients also undergo IMRT QD, 5 days a week over 7 weeks for a total of 35 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
32855854|NCT04252950|Experimental|CB-SET Treatment|Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
32855855|NCT04252950|Active Comparator|Control|Participants randomized to this group will receive standard of care (revascularization)
32855856|NCT03897881|Experimental|mRNA-4157 and Pembrolizumab|Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
32855857|NCT03897881|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
32855858|NCT03617718|Experimental|Cystic Fibrosis|All Cystic Fibrosis participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
32855859|NCT03617718|Experimental|Asthma|All Asthma participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
32855860|NCT03617718|Experimental|Healthy Control|All Healthy Control participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
32855861|NCT05701709|Experimental|SHR-A2102|
32855862|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
32855863|NCT04982874|Experimental|Furosemide 40 mg tablet|volunteers received Furosemide 40 mg tablet with 240 mL of water
32855864|NCT04982874|Active Comparator|Lasix® 40 mg Tablet|volunteers received Lasix® 40 mg tablet with 240 mL of water
32855865|NCT05701631||non-HIV patients hospitalized for suspected PCP|non-HIV patients hospitalized for suspected PCP
32855866|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
32855867|NCT02084745|Active Comparator|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
32855868|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
33406783|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
32855869|NCT05301192|Experimental|Angiotensin-(1-7)|Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
33406784|NCT05144880|Experimental|electroacupuncture with 2Hz group|
33406785|NCT05144880|Experimental|electroacupuncture with 100Hz group|
32855870|NCT05301192|Placebo Comparator|Saline|Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.
32855871|NCT05289180||Participants undergoing Heart Catherization|Participants undergoing Heart Catherization and will complete a research survey focusing on the comfort and anxiety during procedure. Participants will be followed for 18 months after enrollment. For each clinically indicated Brachial RV-EMB Biopsy during the 18-month follow up period, data from biopsy and pre and post-procedure echocardiograms will be reviewed and recorded for research purposes. A post-procedure questionnaire and post-discharge phone call will also take place after each procedure.
32855872|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
32855873|NCT03169686|Experimental|Intervention Group|Participants in the intervention group will receive the 'WeChat WeQuit' program from the WeChat subscription account. The period for intervention was 14 weeks, including 2-week quiting preparation intervention and 12-week postquit intervention. The number of messages/pictures/audios received by participants will gradually decrease (will be intensively sent to them during 2-week prequit and 4-week postquit, and less intensively during 5-week to 12-week postquit), and follow-up questionnaires were sent only once a month in 14-28 weeks (week 16, 20, and 26 after the quit date). A WeChat group was created for answering questions from participants, and sharing the latest resources related to quitting smoking, and promoting communication between participants.
32898856|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
32961365|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
32961366|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
32961367|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
32961368|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
32961369|NCT01340586|Experimental|Group A: Apixaban|
32961370|NCT01340586|Experimental|Group B: Apixaban|
32961371|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
32961372|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
32961373|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
32961374|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
32961375|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
32961376|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
32961377|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
32961378|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
32961379|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
32961380|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
32961381|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
32961382|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
32961383|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
32961384|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
33406786|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
32961385|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
33406787|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
33406788|NCT05531214|Experimental|Intervention|Patients randomized based on their primary care clinician to a co-localized care with a telemedicine-based cardiorenal multidisciplinary team (cardiologist, nephrologist, and research coordinators) providing guidance and recommendations to the primary care clinician.
32961386|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
32961387|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
32961388|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
32961389|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
32961390|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
32961391|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
32961392|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
32961393|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
32961394|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
32961395|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
32961396|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
32961397|NCT01357356|Placebo Comparator|Placebo|Placebo
32961398|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
32961399|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
32961400|NCT01362192|Other|532 nm KTP Laser Treatment|
32961401|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
32961402|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
32961403|NCT01363050|Experimental|Ketorolac tromethamine|
32961404|NCT01363128|Experimental|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
32961405|NCT01365624|Experimental|Ketorolac tromethamine|
32961406|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
32961407|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
32961408|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
32961409|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
32961410|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
32961411|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
32961412|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
32961413|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
32961414|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
33406789|NCT05531214|No Intervention|Control|"Patients randomized to the control group will proceed with usual care with a primary care clinician making referrals to a cardiologist or nephrologist for-cause as determined by the primary care clinician, to ultimately assess the rates of improvement in the implementation of GDMT."
33406790|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
33406791|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
33406792|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
33406793|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
33406794|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
33406795|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
33406796|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
32855874|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 26 points.
33406797|NCT05706402|Experimental|N-acetylcysteine|
33406798|NCT05706402|Placebo Comparator|Placebo|
33406799|NCT05706246|Other|Children with perioperative hypersensitivity|Children with perioperative hypersensitivity
32855878|NCT03897491|Experimental|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
32855879|NCT03068208|Experimental|MB-PDT|
32855880|NCT03068208|No Intervention|Control|
32855881|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
32855882|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
32855883|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
32855884|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
32855885|NCT05104866|Experimental|Dato-DXd|Arm 1: Dato-DXd
32855886|NCT05104866|Active Comparator|Investigators Choice of Chemotherapy (ICC)|"Arm 2: ICC~Capecitabine~Gemcitabine~Eribulin mesylate~Vinorelbine"
32855887|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
32855888|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
32855889|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo stent implantation after an interval of 7±2 days.
32855890|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation.
32855891|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
32855892|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
32855893|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
32855894|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
32855895|NCT05635968|Experimental|Low-dose whole brain irradiation group 1 (4cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (4cGy/day, 2times/1wk, total 24cGy, 6 times/3wks)
32855896|NCT05635968|Experimental|Low-dose whole brain irradiation group 2 (50cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (50cGy/day, 2times/1wk, total 300cGy, 6 times/3wks)
32855897|NCT05635968|Sham Comparator|Sham RT group|Sham RT wtih general AD medication treatment (0cGy/day, 2times/1wk, total 0cGy, 6 times/3wks)
32855898|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
32855899|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
32855900|NCT05635890|Experimental|Group I|received conventional vestibular rehabilitation along with the Cawthorne Cooksey exercise protocol
32855901|NCT05635890|Active Comparator|Group II|received conventional vestibular rehabilitation only
32855902|NCT05635812||Participants Autism Spectrum Disorders (ASD)|ASD according to DSM-5 criteria
32855903|NCT05635812||Participants 22q11.2|Participants with a genetic syndrome diagnosed by FISH or CGH-array
32855904|NCT05635812||Neurotypical participants|Neurotypical development
32855905|NCT05635500|Experimental|Middle Insertion|Videolaryngoscope is inserted from the middle for endotracheal intubation.
32855906|NCT05635500|No Intervention|Right Insertion|Videolaryngoscope is inserted from the right for endotracheal intubation.
32855907|NCT05701553||Anti-PD-1/PD-L1 antibodies and S-adenosyl-methionine combination|"Drug: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months~Drug: S-adenosyl-methionine Taken orally for at least 6 months"
32855908|NCT05635422|Experimental|isokinetism test in high level triathletes practicing an endurance sport|
32855909|NCT04353375|Experimental|HMPL-453|HMPL-453 150mg QD
32855910|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
32855911|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
32855912|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
33320534|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
32855913|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
32855914|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
33320535|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
32855915|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
33320536|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
32855916|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
32855917|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
32855918|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
32855919|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
32855920|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
32855921|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
32855922|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
32855923|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
32855924|NCT03159533|Placebo Comparator|Control Group|Wait-list
32855925|NCT05269173|Active Comparator|Active group(low dose group)|Take 5 tablets each time (including 3 tablets of study drug and 2 tablets of placebo), 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
32855926|NCT05269173|Active Comparator|Active group(high dose group)|Take 5 tablets of the study drug each time, 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
32855927|NCT05269173|Placebo Comparator|Control group|Take 5 tablets of the control drug (placebo) each time, 3 times a day, 2.7g a day. Take it with warm water half an hour before meals.
32855928|NCT04405193|Experimental|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
32855929|NCT04405193|Placebo Comparator|Placebo|2 capsules of matching placebo administered once daily every morning
32855930|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
32855931|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
32855932|NCT05227833|Experimental|Vonoprazan|Vonoprazan (vonaspire 20 mg), tablets, one tablet per day before breakfast for 14 days starting from the day of band ligation.
32855933|NCT05227833|Active Comparator|Pantoprazole|Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets, one tablet per day before breakfast for 14 days, starting from the day of band ligation.
32855934|NCT05227833|Placebo Comparator|Placebo|No acid suppressive medications will be described.
32855935|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
32855936|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
32855937|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
32855938|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
32855939|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
32855940|NCT05083299||Anpl-one SR Tablet|Patients who prescribed Anpl-one SR Tablet
32855941|NCT05701475|No Intervention|Control/Single prevention|Standard pre-operative cutaneous disinfection using iodine.
32855942|NCT05701475|Experimental|Double prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine.
33320537|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
33320538|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
33320539|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
33320540|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
33320541|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
32961415|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
32961416|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
32961417|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
32961418|NCT01378416|Experimental|1|
32961419|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
32961420|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
32961421|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
32961422|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
32961423|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
32961424|NCT01387464|Experimental|ISV-303|
32961425|NCT01387464|Active Comparator|Bromday™|
32961426|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
32961427|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
32961428|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
32961429|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
32961430|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
32961431|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
32961432|NCT01391364|Experimental|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
32961433|NCT01391364|Active Comparator|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
32961434|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
32961435|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
32961436|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
32961437|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
32961438|NCT01395966|Active Comparator|DF289|Ear drops
32961439|NCT01395966|Active Comparator|DF277|Ear drops
32961440|NCT01395966|Experimental|DF289 plus DF277|Ear drops
32961441|NCT01396044|Experimental|Electronic checklist|Electronic checklist
32961442|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
32961443|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
32961444|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
32961445|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
32961446|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
32961447|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
32961448|NCT01400880||Pregnant|In Labor
32961449|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
32961450|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
32961451|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
32961452|NCT01402050|Active Comparator|CERVIDIL|
32961453|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
32961454|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
32961455|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
32961456|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
32961457|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
32961458|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
32961459|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
33320542|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
33320543|NCT01320644||vaginal mesh placement|
32961460|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
32961461|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
32961462|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
32961463|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
32961464|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
33320544|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
33320545|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
32961465|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
32961466|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
32961467|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
32961468|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
32961469|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
32961470|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
32961471|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
32961472|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
32961473|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
32961474|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
32961475|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
32961476|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
32961477|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo~The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
32961478|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
32961479|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
32961480|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
32961481|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
32961482|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
32961483|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
32961484|NCT01426230||Open Label|"Cohort by age-~- Patients >70 Yrs old"
32961485|NCT01426230||Open label|"Cohort by age-~- Patients < 70 Yrs old"
32961486|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
32961487|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
32961488|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
32961489|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
32961490|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
32961491|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
32961492|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
32961493|NCT01431300|Experimental|0.02 mmol/kg|
32961494|NCT01431300|Experimental|0.01 mmol/kg|
33320546|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
33320547|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
32961495|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
32961496|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
32961497|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
32961498|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
32961499|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
32961500|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
32961501|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
32961502|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
32961503|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
32961504|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
32961505|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
32961506|NCT01435512|No Intervention|Waitlist|Control group - no intervention
32961507|NCT01435824|Active Comparator|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
32961508|NCT01435824|Experimental|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
32961509|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
32961510|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
32961511|NCT01437852|Experimental|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
32961512|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
32961513|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
32961514|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
32961515|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
32961516|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
32961517|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
33406800|NCT05114538|Experimental|RIT Training Group|Providers in the RIT group (n=80) will receive intensive training (online tutorial, 2-day workshop, and virtual coaching and feedback in the field) in RIT and parent coaching and will be required to achieve fidelity prior to enrolling families from their caseload. They will then be asked to use the intervention with enrolled families for a minimum of 3 months. One intervention session per month for each enrolled family will be videotaped and scored for fidelity. Providers will receive monthly consultation from RIT trainers while these families are in the active treatment phase.
33406801|NCT05114538|No Intervention|Treatment as Usual|Providers in the TAU group (n=80) will have three sessions videotaped and scored for each enrolled family to assess treatment differentiation. To incentivize agency participation, RIT training will be provided to the TAU group and other providers when data collection is complete.
32961518|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
32961519|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
32961520|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
32961521|NCT01444716|Experimental|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
32961522|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
32961523|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
32961524|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (>=2.33)~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
32961525|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
32961526|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
32961527|NCT01449864|Experimental|Proton RT|Subjects receive proton radiation
32961528|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
32961529|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
32961530|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
32961531|NCT01457196|Other|Sequencing Arm|
32961532|NCT01457430|Experimental|Icatibant|Open-label study
32961533|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
32961534|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
32961535|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
32961536|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
32961537|NCT01462812|Active Comparator|Sumatriptan|
32961538|NCT01462812|Placebo Comparator|Matching placebo|
32961539|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
32961540|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
32961541|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
32961542|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
32961543|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
32961544|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
32961545|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
32961546|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
32961547|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
32961548|NCT01468584|Experimental|MP-424|
32961549|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
32961550|NCT01471626|Experimental|telematic attended polysomnography|
32961551|NCT01472718|Active Comparator|standard primary coronary intervention|
32961552|NCT01472718|Experimental|coronary thrombectomy|
32961553|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
32961554|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
32961555|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
32961556|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
32961557|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
32961558|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
32961559|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
32961560|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
32961561|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
32961562|NCT01477320|Placebo Comparator|Placebo and tube feed.|
33406802|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
32961563|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
32961564|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
32961565|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
32961566|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
32961567|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
32961568|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
32961569|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
32961570|NCT01479348|Experimental|1/Intravenous (IV) Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
32961571|NCT01479348|Experimental|2/Oral Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
32961572|NCT01479426|Experimental|EFLA400(960mg)|
32961573|NCT01479426|Placebo Comparator|Placebo(960mg)|
32961574|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
32961575|NCT01483560|Placebo Comparator|Placebo|
32961576|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
32961577|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
32961578|NCT01484652|Experimental|COV795|
32961579|NCT01484652|Placebo Comparator|Placebo|
32961580|NCT01485588|Experimental|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
32961581|NCT01485588|Experimental|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
32961582|NCT01485588|Experimental|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
32961583|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
32961584|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
32961585|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
32961586|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
32961587|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
32961588|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
32961589|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
32961590|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
32961591|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
32961592|NCT01496352|Placebo Comparator|DFA-02 placebo|
32961593|NCT01497756|Experimental|CAPP application|Patients in whom device is used
32961594|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
32961595|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
32961596|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
32961597|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
33406803|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
33406804|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
33406805|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
32855943|NCT05701475|Experimental|Triple prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine and preparation of the skin with benzoyl peroxide in the days prior to surgery.
33406806|NCT03515551|Experimental|Phase 1: Dose Escalation|Four fixed-dose, dose escalation cohorts (Cohorts 1 to 4) and 3 intrapatient dose escalation cohorts (Cohorts 5 to 7) to establish the MTD/RP2D of IMCnyeso.
32855944|NCT04897074|Experimental|AKL-T01|Digital Treatment
32855945|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
32855946|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
32855947|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
32855948|NCT05701397|Experimental|Study group|Patients undergoing surgery for lumbar spinal stenosis. Patients will have a biopsy taken from the ligamentum flavum and test for the presence of amyloid. Patients with amyloid in the ligamentum flavum will be referred for a DPD scintigraphy.
33406807|NCT03515551|Experimental|Phase 2: Dose Expansion|Three planned cohorts treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso. Phase 2 was not initiated and data were not collected.
33406808|NCT05558592|Experimental|Treatment_group|
32855951|NCT04809558|Active Comparator|Max intensity with no visual biofeedback|Tongue resistance exercises completed at maximum intensity with no visual biofeedback.
32855952|NCT04809558|Active Comparator|Progressive intensity with no visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with no visual biofeedback.
32855953|NCT04809558|Active Comparator|Max intensity with visual biofeedback|Tongue resistance exercises completed at maximum intensity with visual biofeedback of performance.
32855954|NCT04809558|Active Comparator|Progressive intensity with visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with visual biofeedback of performance.
32855955|NCT04405271|Experimental|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
32855956|NCT04405271|Placebo Comparator|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
32855957|NCT03034941|Active Comparator|metformin group|Drug: metformin
32855958|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
32855959|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
32855960|NCT04775316||Patients with fragile skin|Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.
32855961|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
32855962|NCT03020771|Active Comparator|5 mcg IM|
32855963|NCT03020771|Active Comparator|5 mcg SC|
32855964|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
32855965|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
32855966|NCT03020771|Active Comparator|10 mcg IM|
32855967|NCT03020771|Active Comparator|10 mcg SC|
32855968|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
32855969|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
32855970|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
32855971|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
32855972|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
32855973|NCT05634720|Experimental|PDAC with HA Chemotherapy|On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
32855974|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
32855975|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
32903584|NCT01362998|Active Comparator|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
33406809|NCT05558592|Active Comparator|Control_group|
33320548|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
32855976|NCT05730426|Active Comparator|Group A|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received deep dry needling on active trigger points in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
32855977|NCT05730426|Active Comparator|Group B|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received muscle energy technique (post isometric relaxation) in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
32855978|NCT05730426|Placebo Comparator|Group C|Patients receive Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors) , 3 sessions/week, for 4 weeks period.
32855979|NCT04765397|Active Comparator|Group M|Patients are in this group with monopolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
32855980|NCT04765397|Active Comparator|Group B|Patients are in this group with bipolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
32855981|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
32855982|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
32855983|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
32855984|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
32855985|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
32855986|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
32855987|NCT05730348||Patients with eating disorders|
32855988|NCT05634486|Experimental|Multidisciplinary therapeutic approach|"Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~12 physiotherapy sessions during one month (three 60-minute sessions per week) administered by a physiotherapist with experience in functional neurological disorders.~4 cognitive-behavioral therapy sessions during one month (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
32855989|NCT05634486|Sham Comparator|Psychoeducation|"Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~4 psychoeducational sessions (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
32855990|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
32855991|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
32855992|NCT05051865|Experimental|Camrelizumab Combined With SHR1020|Camrelizumab combined with SHR1020 for advanced melanoma.
32855993|NCT03589157|Experimental|Drug-coated balloon group|
32855994|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
32855995|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
32855996|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
32855997|NCT02245659|Experimental|CPAP|
32855998|NCT02245659|Other|Nasal dilator strip|Control
32855999|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
32856000|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
32856001|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
32856002|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
32856003|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
32856004|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
32856005|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
32856006|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
32856007|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
32856008|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
32856009|NCT05634330|Experimental|treatment group|treatment group: core stabilization exercises used to improve balance
32856010|NCT05634330|No Intervention|control group|this group members have continued their normal lives
32856011|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
33320549|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
33320550|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
33320551|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
33320552|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
32856012|NCT05730114||OHCA/ECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and on VA-ECMO.
32856013|NCT05730114||OHCA/nonECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
32856014|NCT05730114||nonOHCA/nonECMO|Patient with acute coronary syndrome without Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
32856015|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
32856016|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
32856017|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
32856018|NCT05634174|Experimental|Obese Group|Single dose, 100mg oral mirabegron in Obese Insulin Resistant adults
32856019|NCT05634174|Experimental|Non-Obese Group|Single dose, 100mg oral mirabegron in Non-Obese adults
32856020|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
32856021|NCT03158441||control|same patients , dynamic scan
32856022|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
32856023|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
32856024|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
32856025|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
32856026|NCT05730036|Experimental|REGN5458 or Linvoseltamab|Randomization 1:1
32856027|NCT05730036|Active Comparator|Elotuzumab/Pomalidomide/Dexamethasone (EPd)|Randomization 1:1
32856028|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
32856029|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
32856030|NCT03034395|Other|Wide Local Excision 1cm|
32856031|NCT03034395|Other|Wide Local Excision 2cm|
32856032|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
32856033|NCT05701163|Experimental|Healthy Volunteers|Healthy males with no significant comorbidities, aged 20-45 years who are able to produce a semen sample by masturbation.
32856034|NCT04904757|Other|CESM Pre and Post Survey|"Subject will be asked to complete a questionnaire that will ask you about your general attitude toward Contrast-Enhanced Spectral Mammography (CESM). Questions will include:~Thoughts regarding risk of breast cancer~Concerns regarding contrast procedures such as the CESM~Past mammogram/breast imaging experience"
32856035|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
32856036|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
32856037|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
32856038|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
32856039|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
33320553|NCT05271734|Experimental|Single arm -lid retractor placement|Placement of a lid retractor the find out if the corneal limbus is exposed to 360 degrees
32961598|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
32961599|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
33320554|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
33320555|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
33320556|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
32856040|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
32961600|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
32961601|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
32961602|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
32961603|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
32961604|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
32961605|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
32961606|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
32961607|NCT01509612|No Intervention|No intervention|No intervention
32961608|NCT01510704|Placebo Comparator|Placebo|
32961609|NCT01510704|Experimental|Low dose APD421|1mg dose level
32961610|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
32961611|NCT01510704|Experimental|High Dose APD421|20mg dose level
32961612|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
32961613|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
32961614|NCT01511640|Experimental|Pregabalin 1|Dose 1
32961615|NCT01511640|Placebo Comparator|Placebo 1|Placebo 1
32961616|NCT01511640|Experimental|Pregabalin 2|Dose 2
32961617|NCT01511640|Placebo Comparator|Placebo 2|Placebo 2
32961618|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
32961619|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
32961620|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
32856041|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
32961621|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
32961622|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
32961623|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
32961624|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
32961625|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
32961626|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
32898857|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
32898858|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
32961627|NCT01515540|Placebo Comparator|control|placebo patch
32961628|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
32961629|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
32961630|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
32961631|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
32961632|NCT01518270||Healthy Females|Healthy Females
32961633|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
32961634|NCT01519284|Experimental|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
33320557|NCT03773198|Experimental|ERCS Group|
33320558|NCT03773198|Placebo Comparator|Control Group|
32961635|NCT01519284|Experimental|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
33320559|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
33320560|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
32961636|NCT01519284|Experimental|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
32961637|NCT01519284|Experimental|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
32961638|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
32961639|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
32961640|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
32961641|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
32961642|NCT01520532|Other|Ablation|
32961643|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
32961644|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
32961645|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
32961646|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
32961647|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
32961648|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
32961649|NCT01521546|Active Comparator|eplerenone|active study drug
32961650|NCT01521546|Placebo Comparator|sugar pill|placebo
32961651|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
32961652|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
32961653|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
32961654|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
32961655|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
32961656|NCT01523808|Experimental|GRASPA 25|
32961657|NCT01523808|Experimental|GRASPA 50|
32961658|NCT01523808|Experimental|GRASPA 100|
32961659|NCT01523808|Experimental|GRASPA 150|
32961660|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
32961661|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
32961662|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
32961663|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
32961664|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
32961665|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
32961666|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
32961667|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
32961668|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
32961669|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
32961670|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
32961671|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
32961672|NCT01529502|Experimental|Fresh blood|
32961673|NCT01529502|Experimental|Old blood|
32961674|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
32961675|NCT01532700|Experimental|Ofatumumab with GSK2110183|
32961676|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32961677|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
32961678|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
32961679|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
32961680|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
32961681|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
32961682|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
32961683|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
32961684|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
32961685|NCT01537302|Experimental|Ocelot System|CTO crossing in femoropopliteal arteries using the Ocelot System
32961686|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
32961687|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
32961688|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
33320561|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
33320562|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
33320563|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
32856042|NCT05701085|Experimental|PRE-ACT Adaptation|"At the scheduled oncologic visit: consent obtained and all participants will complete the Demographics/Clinical Characteristics survey and Pre-Intervention Survey~Within 3 months of consent: tailored educational intervention and patient navigation program will take place and the scored Pre-Intervention survey will be used to generate a list of barrier for each patient. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.~Within 4 weeks of the educational video: the participant will be contacted via phone to complete a Post-Intervention Survey that assesses knowledge, attitudes, and preparation related to participation in clinical trials~Two years after intervention: chart review will be performed to assess if the patient participated in a clinical trial."
32856043|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
32856044|NCT03069222||Control|age and gender matched with patient enrolled
32856045|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
32856046|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
32856047|NCT05699915|Other|Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors|Patients are treated as standard of care
32856048|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
32856049|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
32856050|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
32856051|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid~+ empty encapsulation matrix"
32856052|NCT03027765||Egyptian children|"Population1:~Egyptian children with constructed space maintainers at Cairo University."
32856053|NCT03027765||Pediatric dentists|"Population2:~Pediatric dentists at Cairo University."
32856054|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
32856055|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
32856056|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
32856057|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
32856058|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~> 18 years of age~Non-cardiac patients~Non-obstetric patients~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
32856059|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
32856060|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
32856061|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
32856062|NCT04861233||All Participants|Participants diagnosed with constipation who have been prescribed with lubiprostone for the first time in a real-world setting will be observed prospectively and followed up for 12 months after initiation of study medication. Treatment regimen, frequency of laboratory and clinical assessments will be determined by investigator in a routine clinical practice.
32856063|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
32856064|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
32856065|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
32856066|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
32856067|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
32856068|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
33320564|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
33320565|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
33320566|NCT05254184|Experimental|Patients With NSCLC|All participants will receive the intervention.
33320567|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
32856069|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
32856070|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
33320568|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
33320569|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
33320570|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
33320571|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
32856071|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
32856072|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
32856073|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
32856074|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
33320572|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
33320573|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
33320574|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
33320575|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
32856075|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
32856076|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
33320576|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
33320577|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
32856077|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
32856078|NCT05729880||Older|16 older (>50y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
32856079|NCT05729880||Young|16 young (<40y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
32856080|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
32856081|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
32856082|NCT05698823|Experimental|Study group|"A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use.~All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss."
32856083|NCT05698823|No Intervention|Control group|A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.
32856084|NCT04573920|Experimental|Atrasentan 0.75 mg|Once daily oral administration of 0.75 mg atrasentan
33320578|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
33320579|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
33406810|NCT05706168|No Intervention|Control group|The participants in this category will not undergo any structured exercise training for the duration of the study.
33320580|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
33406811|NCT05706168|Experimental|Treadmill Group|The targeted treadmill exercise dosage will consist of 1.)a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
33406812|NCT05706168|Experimental|Cycle ergometer Group|The targeted cycling exercise dosage will consist of 1.) a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
32856085|NCT04573920|Experimental|Atrasentan 1.5 mg|Once daily oral administration 1.5 mg atrasentan (FSGS cohorts only)
32856086|NCT04836117|Experimental|Informed|"Blood draw for SomaSignal Test and laboratory assessments at baseline, and 6 months (±30 days); SomaSignal Test results to be sent to investigators as available. Review and discussion of results with the participant from baseline and 6 months within 30 days (2-4 weeks to get SomaSignal results) after blood draw. Initiation of changes in medical management as soon as test results are known and discussed with patient.~Patients will have a blood draw performed at baseline and 6 months for lipid panel, hemoglobin A1C, CBC, and BMP."
32961689|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
32961690|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
32961691|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
32961692|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
32961693|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
32961694|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
32961695|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
32961696|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
32961697|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
32961698|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
32961699|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
32961700|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
32961701|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
32961702|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
32961703|NCT01544088|Experimental|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
32961704|NCT01544088|Active Comparator|Arm 2: Group Treatment|Present Centered Group Treatment
32961705|NCT01544166|Experimental|Overall study|
32961706|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
32961707|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
32961708|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
32961709|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
32961710|NCT01548690|Experimental|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
32961711|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
32961712|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
33406813|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
33406814|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
32961713|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
32961714|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
32961715|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
32961716|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
32961717|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
32961718|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
32961719|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
32961720|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
32961721|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
32961722|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
32961723|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
32856087|NCT04836117|No Intervention|Uninformed|"Blood draw for SomaSignal Test at baseline and 6 months (+30 days). However, results will not be provided to clinician and participant until study conclusion. Patients contacted within 30 days (2-4 weeks) after baseline and 6-month visits to discuss treatment strategy (nothing, add/ remove medication, etc.) made at visit. Patients will have a blood draw performed at baseline and for lipid panel, hemoglobin A1C, CBC, and BMP~SomaSignal Test results to be sent to investigators AFTER study conclusion. Patients will be provided with SomaSignal Test results after the 6 month post-test timepoint."
32856088|NCT05698277||Cases|Singleton pregnancies affected by congenital heart disease
32856089|NCT05698277||Controls|Singleton healthy pregnancies
32856090|NCT04801797|Experimental|Standard of Care (Conventional Induction)|"Randomized participants will receive cytarabine and idarubicin [or daunorubicin) per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (or daunorubicin) on days 1-3 of induction.~Second Induction (if needed): Cytarabine on days 1-5 and idarubicin (or daunorubicin) on days 1-2 of re-induction.~Consolidation (if needed): If < 60 years, cytarabine days 1,3,5 of consolidation cycles, and if ≥60 years, cytarabine days 1-5 of consolidation cycles~Those with secondary or therapy-related AML can receive liposomal daunorubicin and cytarabine (Vyxeos) per standard of care as follows:~Induction: Liposomal daunorubicin and cytarabine (Vyxeos) on Days 1,3, 5 of induction.~Second Induction (if needed): Liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of re-induction Consolidation (if needed): liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of consolidation cycles"
32856091|NCT04801797|Experimental|Investigational (Venetoclax and Azacitidine)|Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
32856092|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
32856093|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
32856094|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
33104423|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
33104424|NCT04397692|Experimental|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
33104425|NCT04397692|No Intervention|Standard of care|Control - Standard of care
33104426|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
33104427|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
33104428|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.~After that all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
33104429|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
33104430|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
33104431|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
33104432|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
33104433|NCT03988335|Experimental|RIST4721|RIST4721 as once-daily 300mg oral solution for 28 days.
33104434|NCT03988335|Placebo Comparator|Placebo|Placebo as once-daily 300mg oral solution for 28 days.
33104435|NCT02089607|Experimental|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
32856095|NCT04453722||Oxalert in monitor only mode|Randomization will be to Oxalert in monitor-only mode
32856096|NCT04453722||Oxalert in monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
32856097|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
32856098|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
32856099|NCT01670435||Group 1|
32856100|NCT05729802|Experimental|Group A: HoloSIM (intervention)|Training by Mixed Reality Simulation
32856101|NCT05729802|Active Comparator|Group B: Mannequin (control)|Training by Mannequin Based Simulation
32856102|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
32856103|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
32856104|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
32856105|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
32856106|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
32856107|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
32856108|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
32856109|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
32856110|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
32856111|NCT01670591|No Intervention|Business as usual|
32856112|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
32856113|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
32856114|NCT04159272|Experimental|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
32856115|NCT04159272|No Intervention|Control|Participants follow their regular course curriculum.
32856116|NCT01670903||ARBs|Hypertensive patients treated with ARBs
32856117|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
32856118|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
32856119|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
32856120|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
32856121|NCT01671137|Placebo Comparator|Placebo|Placebo
32856122|NCT04410666|Experimental|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
32856123|NCT04410666|Placebo Comparator|Placebo|distilled water, in sterile glass containers.
32856124|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
32856125|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
32856126|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
32856127|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
32856128|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
32856129|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
32856130|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
32856131|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
32856132|NCT05631990|Experimental|Experimental 1|AD-209, AD-209-1 placebo
32856133|NCT05631990|Experimental|Experimental 2|AD-209-1A, AD-209 placebo
32856134|NCT05631990|Experimental|Experimental 3|AD-209-1B, AD-209 placebo
32856135|NCT05631990|Experimental|Experimental 4|AD-209-1C, AD-209 placebo
32856136|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
32856137|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
32856138|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
32856139|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
32856140|NCT01671761||young adults|19-24 years old
32856141|NCT01671761||adolescents|15-18 years old
32856142|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
32856143|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
32856144|NCT05193929|Experimental|OptiPulse™|The OptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an offloaded and shin pumping unit and the other acts as pressure reducing footwear. Both active and non-active footwear should be worn to give balanced gait.
32856145|NCT05193929|Active Comparator|Standard of care offloading device|Diabetic CAM boot
32856146|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
32856147|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
32856148|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
32856149|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
32856150|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
32856151|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
32856152|NCT05179343|Experimental|Active arm|Participants in this arm will receive the active AffeX-CT device.
32856153|NCT05179343|Sham Comparator|Sham arm|Participants in this arm will receive the sham (inactive) AffeX-CT device.
32856154|NCT03066258|Experimental|Dose 1|3E9 GC/eye of RGX-314
32856155|NCT03066258|Experimental|Dose 2|1E10 GC/eye of RGX-314
32856156|NCT03066258|Experimental|Dose 3|6E10 GC/eye of RGX-314
32856157|NCT03066258|Experimental|Dose 4|1.6E11 GC/eye of RGX-314
32856158|NCT03066258|Experimental|Dose 5|2.5E11 GC/eye of RGX-314
32856159|NCT02981745|Experimental|CT-1530|
32856160|NCT05729646|Experimental|Arm A (Chemotherapy+Toripalimab)|"Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.~Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery."
32856161|NCT05729646|Experimental|Arm B (Toripalimab monotherapy)|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
32856162|NCT05729646|Active Comparator|Arm C (Chemotherapy)|Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.
32856163|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
32856164|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
32856165|NCT03024411|No Intervention|No intervention|No intervention
32856166|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
32856167|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
32856168|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
32856169|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
32856170|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
32856171|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
32856172|NCT05132387||Out-of-hospital cardiac arrest|Patients with out-of-hospital cardiac arrest which occured in the predefined area of the city of Wroclaw.
32856173|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
32856174|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
32856175|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
32856176|NCT01672385|No Intervention|Usual Care Group|Usual Care
32856177|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
32856178|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
32856179|NCT05068973|Experimental|Luciola|Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.
32856180|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
33406815|NCT04694443|Active Comparator|Study group|The study group will receive the multidisciplinary tele-health intervention plus standard medical care
32856182|NCT05629494|Active Comparator|Repeat serum PSA test|Repeat PSA test at 6 (± 1) weeks, without any treatment
32856183|NCT05629494|Experimental|Treatment with NSAIDS|Treatment with NSAIDS (Ibuprofen 400 mg, 3 times per day or Naproxen 220 mg, twice per day for 10 days), then repeat PSA test at 6 (± 1) weeks
32856184|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
33104436|NCT02089607|Experimental|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
33104437|NCT04376242|Experimental|virtual reality then standard technology|patients randomized to this arm will first use virtual reality (VR) during and oral food challenge and then use standard technology during a second oral food challenge
33104438|NCT04376242|Active Comparator|standard technology then virtual reality|patients randomized to this arm will first use standard technology during and oral food challenge and then use virtual reality during a second oral food challenge
33104439|NCT00537693|Active Comparator|1|CRRT via Convection
33104440|NCT00537693|Active Comparator|2|CRRT via Diffusion
33104441|NCT04320316|Experimental|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
32856185|NCT04275869|Experimental|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
32856186|NCT04275869|No Intervention|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
32856187|NCT04272281|Experimental|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
32856188|NCT04272281|Active Comparator|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
32856189|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~Follow-up Evaluation-8-week visit PT session #2~Follow-up Evaluation-10-week visit PT session #3~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
32856190|NCT01672697|No Intervention|Control Group|"Control Group:~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
32856191|NCT00952653|Experimental|DVS SR|
32856192|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856193|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856194|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856195|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856196|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856197|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
32856198|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
33104442|NCT04365556|Experimental|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
33104443|NCT04365556|No Intervention|Treatment as Usual|Participants will not receive any intervention.
33104444|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
33104445|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
33104446|NCT03978117|Experimental|Freeze Dried Powder Preparation|
33104447|NCT03978117|Placebo Comparator|Placebo|
32961724|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
33104448|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
32961725|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
32961726|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
32961727|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
32961728|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
32961729|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
32961730|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
32961731|NCT01559064||Age group A|Subjects 30 to 40 years old
32961732|NCT01559064||Age group B|Subjects 40 to 50 years old
32961733|NCT01559064||Age group C|Subjects over 50 years old
32961734|NCT01559922|Placebo Comparator|Placebo|Normal Saline
32961735|NCT01559922|Experimental|Artefill|Dermal Filler
32961736|NCT01560624|Experimental|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
32961737|NCT01560624|Placebo Comparator|Placebo|Matching placebo tablets (oral)
32961738|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
32961739|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
32961740|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
32961741|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
32961742|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
32961743|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
32961744|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
32961745|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
32961746|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
32961747|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
32961748|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
32961749|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
32961750|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
32961751|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
32961752|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
32961753|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
32961754|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
32961755|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
32961756|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
32961757|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
32961758|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
32961759|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
32961760|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
32961761|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
32961762|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
32961763|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
32961764|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
32961765|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
32961766|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
32961767|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
32961768|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
32961769|NCT01573572|Experimental|Intravitreal Injections of Macugen|
32961770|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
33104449|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
32856199|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
32856200|NCT04956341|Experimental|Standard treatment from PCM or Mental Health or both + auricular acupuncture|
32856201|NCT04956341|Placebo Comparator|Standard treatment from Primary Care Manager (PCM) or Mental Health or both|
32856202|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
32856203|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
32856204|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
32856205|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
32856206|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
32856207|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
33104450|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
33104451|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
33104452|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
32856208|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
33104453|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
32856209|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
32856210|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
32856211|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
32856212|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
32856213|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
32856214|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
32856215|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
32856216|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
32856217|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
32856218|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
32856219|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
32856220|NCT01673555|Placebo Comparator|Placebo|Placebo
32856221|NCT01673633||SSc|Sacroiliitis
32856222|NCT01673633||Rheumatoid arthritis|Sacroiliitis
32856223|NCT01673633||Healthy controls|Sacroiliitis
32856224|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
32856225|NCT04781855|Experimental|Part A (ipilimumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks for up to a total of 2 years.
32856226|NCT04781855|Experimental|Part B (ipilimumab, nivolumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 7 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and nivolumab, and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks and nivolumab every 4 weeks for up to a total of 2 years.
32856227|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
32856228|NCT01673945|Experimental|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
32856229|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
32856230|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
32856231|NCT04750577|Experimental|Dose group 1: BI 685509|Low dose.
32856232|NCT04750577|Placebo Comparator|Dose group 1: Matching placebo|Matching placebo for low dose.
32856233|NCT04750577|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
33406816|NCT04694443|Placebo Comparator|Control group|The control group will receive the best standard medical care
32856234|NCT04750577|Placebo Comparator|Dose group 2: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose.
32856235|NCT04750577|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
32856236|NCT04750577|Placebo Comparator|Dose group 3: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.
32856237|NCT02235701|Experimental|aldoxorubicin|
32856238|NCT01674179||ACR diagnosis of Fibromyalgia|
32856239|NCT01674179||Patients without Fibromyalgia|
32856240|NCT04404881|Experimental|Bevacizumab|"The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.~Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Induction Period (first 3 months of bevacizumab treatment):~Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~Maintenance Period (second 3 months of bevacizumab treatment):~Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
32856241|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
32856242|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
32856243|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
32856244|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
32856245|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
32856246|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
32856247|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
32856248|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
32856249|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
32856250|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
32856251|NCT04696289|Experimental|Standardized catheterization assessment|Assessment of pulmonary veins including angiography, intravascular ultrasound, pressure assessment and compliance testing.
32856252|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
32856253|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
32856254|NCT02083835||post-surgical patients|post-surgical patients > 18 years
32856255|NCT02083835||pediatric patients post-op day 1|pediatric patients <18 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
32856256|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
32856257|NCT03156335|Experimental|Focused Ultrasound|
32856258|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
32856259|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
32856260|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
32856261|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
32856262|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
32856263|NCT03156647||idiopathic Parkinson disease|
32856264|NCT03156647||iatrogenic parkinsonian syndrome|
32856265|NCT03156647||healthy volunteers|
32856266|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
32856267|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
32898859|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
33406817|NCT05706090|Experimental|Group USP|The group using ultrasound and injection pressure manometer was named USP
33406818|NCT05706090|Experimental|Group USPN|The group using ultrasound , injection pressure manometer , and neurostimulator was named USPN
33406819|NCT04418791|Experimental|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
33406820|NCT04418791|Experimental|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
33406821|NCT05513274|Experimental|Pain Psychology Neuroscience+ Written Emotional Disclosure|Pain Neuroscience Education exercise followed by Written Emotional Disclosure
32961771|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
32961772|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
32961773|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
32961774|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
32961775|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
32961776|NCT01576536||Healthy volunteers|Normal healthy volunteers
32961777|NCT01577238|Experimental|VivaGel|
32961778|NCT01577238|Placebo Comparator|HEC Placebo|
32961779|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
32961780|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
32961781|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
32961782|NCT01580592|Experimental|Omalizumab 150mg|
32961783|NCT01580592|Experimental|Omalizumab 300mg|
32961784|NCT01580592|Placebo Comparator|Placebo|
32961785|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
32961786|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
32961787|NCT01583868|Experimental|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
32961788|NCT01583868|Experimental|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
32961789|NCT01583868|Active Comparator|PureVision2|Bausch & Lomb High definition soft contact lenses
32961790|NCT01583868|Active Comparator|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
32961791|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
32961792|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
32961793|NCT01588236|Experimental|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
32961794|NCT01588236|Experimental|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
33406822|NCT05513274|Active Comparator|Pain Psychology Neuroscience + Healthy Habits Disclosure|Pain Neuroscience Education followed by Healthy Habits writing
33406823|NCT05513274|Active Comparator|Health Behavior + Written Emotional Disclosure|Health behavior education followed by written emotional disclosure
32961795|NCT01588236|Placebo Comparator|placebo|Patients received placebo (tid)
32961796|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
32961797|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
32961798|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
32961799|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
32961800|NCT01591044|Placebo Comparator|Placebo|
32961801|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
32961802|NCT01591746|Experimental|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
32961803|NCT01591746|Placebo Comparator|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
32961804|NCT01597128|Active Comparator|Flex HD|Mesh Type
32961805|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
32961806|NCT05566860|Experimental|BMI <27|
32961807|NCT05566860|Experimental|BMI 27-32|
32961808|NCT05566860|Experimental|BMI >32|
32961809|NCT05566470||Control Group|1. Healty adults aged between 30-65 years old who do not have any pathology related to the shoulder joint and have not undergone surgery and being a volunteer to participate in the study.
32961810|NCT05566470||Patient Group|"Individuals between 30-65 years old who have been diagnosed with massive rotator cuff tear,~At least 6 months have passed after the surgery,~In the last 6 months, patients have not undergone shoulder surgery except for rotator cuff tear surgery,~Arthroscopic surgical method was performed by Prof. Dr. Gazi Huri,~The absence of another lesion involving the shoulder joint, such as SLAP (Superior Labrum Anterior Posterior), recurrent shoulder dislocation, arthroplasty, except for massive complete tear in the patient will be included in the study"
33406824|NCT05513274|Placebo Comparator|Health Behavior + Healthy Habits Disclosure|Health behavior intervention followed by healthy habits writing
33406825|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
32961811|NCT05566392||Coronavirus disease (COVID)|Pediatric patients who was diagnosed as COVID
32961812|NCT05566392||Healthy|Pediatric participants who hadn't been diagnosed COVID before
32961813|NCT05566314|Experimental|Intervention|Herbal and probiotic beverage
32961814|NCT05566314|Placebo Comparator|Placebo|Similar beverage without the probiotics and botanicals
32961815|NCT05566236|Experimental|Experimental group|The participants played the board game at least once at home every week. In addition, the 60 minutes parent-child co-learning board game was played for 4 consecutive weeks.
32961816|NCT05566236|No Intervention|Control group|The control group continued to receive health education instructions at the outpatient clinic.
32961817|NCT05566002||Patients with pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of >20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
32961818|NCT05566002||Patients without pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of ≤20 mmHg would confirm the absence of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
32961819|NCT05565924|Experimental|Group-A|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill (100% weight-bearing; n=14) 3 times/week for 12-weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
32961820|NCT05565924|Experimental|Group-B|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (70% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
32961821|NCT05565924|Experimental|Group-C|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (50% weight-bearing; n=14) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA), 3 times/week for 12 weeks plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
32961822|NCT05565924|Experimental|group-D (30% weight-bearing; n=13)|"This group received moderate-intensity aerobic exercise training (30% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
32961823|NCT05565924|Sham Comparator|group-E (control group; n=14)|"Served as a control group and participated in no aerobic exercise training on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) during the study, but received oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
32961824|NCT05565300|Experimental|Cycling combined with cognitive tasks|
32961825|NCT05565300|Active Comparator|Cycling|
32961826|NCT05565222|Experimental|Piperacillin/tazobactam or temocillin|Piperacillin/tazobactam, 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure). Piperacillin/tazobactam will be infused over 4 hours. Duration of treatment will be adjusted according to the site of infection Temocillin, 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure). Temocillin will be infused continuously. Duration of treatment will be adjusted according to the site of infection
32961827|NCT05565222|Active Comparator|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure). Meropenem will be infused over 2 hours. Duration of treatment will be adjusted according to the site of infection
32961828|NCT05564988|Experimental|Preconditionning|Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
32961829|NCT05564988|No Intervention|Control|For subjects assigned to the control group, the pneumatic cuff is placed around the upper arm, and inflation of a blood pressure to a lower pressure (50mmHg) which will result in no impairment of antegrade flow.
32961830|NCT05564910||Coffe group|Pregnant women who referred caffeine intake.
32961831|NCT05564910||Control group|Pregnant women without caffeine intake.
32961832|NCT05564832|Experimental|Pilocarpine Therapy|The right eyes of 45 patients will be treated by Biocarpine® and Vuity® eye drops. They will be considered as the case group,
32961833|NCT05564832|No Intervention|Without Pilocarpine Therapy|The left eyes of the patients will be defined as the controls.
32961834|NCT05564676|Experimental|flaxseed oil and pomegranate extract|2g daily of flaxseed oil plus 1.2g daily pomegranate dry extract
32961835|NCT05564676|Placebo Comparator|sunflower oil and microcrystalline cellulose|2g daily of sunflower oil plus 1.2g daily microcrystalline cellulose
32961836|NCT05564442|Active Comparator|Group I: Children received 20% benzocaine gel|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
32961837|NCT05564442|Active Comparator|Group II: Children received TENS stimuli|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
32961838|NCT05564442|Active Comparator|Group III: Children received EMLA gel.|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
32961839|NCT05564442|Active Comparator|Group IV: Children received ice application at injection site|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
32961840|NCT05532774|No Intervention|Ordinary defocusing frame glasses group|wear ordinary defocusing frame glasses
33406826|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
32856268|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
32856269|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
32856270|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
32856271|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
32856272|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
32856273|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
32856274|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
32856275|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
32856276|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
32856277|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
32856278|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
32856279|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
32856280|NCT04657991|Experimental|Triplet Arm|Encorafenib and Binimetinib in combination with Pembrolizumab
32856281|NCT04657991|Active Comparator|Control Arm|Pembrolizumab
32856282|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
32856283|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
32856284|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
32856285|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
32856286|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
32856287|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
32856288|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
32856289|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
32856290|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
32856291|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
32856292|NCT03032913||Non-cancer patients|Patients with no Cancer
32856293|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
32856294|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
32856295|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
32856296|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
32856297|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
32856298|NCT04642937|Experimental|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
32856299|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
32856300|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
32856301|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
32856302|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
32856303|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
32856304|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
32856305|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
32856306|NCT01676051||Chloraprep|
32856307|NCT01676051||Duraprep|
32856308|NCT01676051||Betadine only|
32856309|NCT04764851|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
32856310|NCT04764851|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
32856311|NCT04764851|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet"
32856312|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
32856313|NCT04764695|Experimental|Patients diagnosed with ALL with individualized nutritional treatment|As it is a pre-test / post-test design, the child himself will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
32856314|NCT01005459|Active Comparator|tetracaine 2mg|
32856315|NCT01005459|Active Comparator|Bupivacaine 2 mg|
32856316|NCT04764461|No Intervention|Control Group|The control group will continue with the standard practice of antenatal care using Mc Donald's rule for fundal heights measurements.
32856317|NCT04764461|Experimental|Intervention Group|Intervention group will follow the same antenatal visit plan as the control group with the use of customised GROW Charts for fundal height measurements.
32856318|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
32856319|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
32856320|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~The intensity is set to induce C-fiber response during the stimulation~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
32856321|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
32856322|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
32856323|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
32856324|NCT04599101|Other|Nasal suction devices: Nose Frida and Bulb|Nose Frida nasal suction device and bulb syringe suction device to clear nasal secretions
32856325|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
32856326|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
32856327|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
32856328|NCT01676207||1|CAD
32856329|NCT01676207||2|no CAD
32856330|NCT04747535|No Intervention|Control|Regular treatment
32856331|NCT04747535|Experimental|Auto CPAP|Auto CPAP, AirSense 10 AutoSet, ResMed Inc, max pressure 10 cm water, min pressure 5 cm water
32856332|NCT04747535|Other|CPAP since before|Patients with CPAP since before will all continue using CPAP. They will not attend the randomization process. They will be regarded as a separate group.
32856333|NCT04747223|Experimental|Retraining (RT) Group|The retraining group will receive a watch accelerometer to use for monitoring their step rate with instructions to increase their preferred step rate by 7.5% over the ten in-field training sessions.
32856334|NCT04747223|No Intervention|Control (CON) Group|The control group will receive the same device to monitor their pace but receive no instruction to change their preferred step rate over the ten in-field training sessions.
32856335|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
32856336|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
32856337|NCT01676285|Placebo Comparator|Placebo|Placebo
32856338|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
32856339|NCT01676363|Experimental|Diflunisal|
32856340|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
32856341|NCT03022071|Active Comparator|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
32856342|NCT01676441|Experimental|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
32856343|NCT04588883|Experimental|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
32856344|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
32856345|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
32856346|NCT04545983|Active Comparator|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
32856347|NCT04545983|Experimental|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
32856348|NCT04514783|Other|Group 2|Use of scalpel and a spoon-shaped metal instrument (curette).
32856349|NCT04514783|Experimental|Group 1|Use of Debritom+ micro water jet technology
32856350|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
32856351|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
32856352|NCT00957333||case|ketamine + Cystitis
32856353|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
32856354|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
32856355|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
32856356|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
32856357|NCT04353219|Experimental|research group|training program with compression stocking
32856358|NCT04353219|Active Comparator|control group|training program without compression stocking
32856359|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
32856360|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
32856361|NCT04465877|Experimental|JTT-662 5 mg|JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
32856362|NCT04465877|Experimental|JTT-662 10 mg|JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
32856363|NCT04465877|Experimental|JTT-662 20 mg|JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
32856364|NCT04465877|Placebo Comparator|Placebo|Placebo orally once daily from Day -1 to Day 28
32856365|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
32856366|NCT04453163|Experimental|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
32856367|NCT04453163|Other|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
32856368|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
32856369|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
32856370|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
32856371|NCT04451915|Experimental|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
32856372|NCT04451915|Experimental|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
32856373|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
32856374|NCT04422431|Experimental|ALXN1840|Participants will receive ALXN1840.
32856375|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
32856376|NCT04289441|Active Comparator|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Lactobacillus salivarius LS01 (DSM 22775): 10^9 CFU Bifidobacterium breve B632 (DSM 24706): 10^9 CFU Maltodextrin and silicon dioxide"
32856377|NCT04289441|Placebo Comparator|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Maltodextrin and silicon dioxide"
32856378|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
32856379|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
32856380|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
32856381|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
32856382|NCT04267133|Experimental|All Participants|
32856383|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
32856384|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
32856385|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
32856386|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.~Dose Expansion:~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
32961841|NCT05532774|Experimental|AI defocusing frame glasses group|wear defocusing frame glasses with artificial intelligence
32961842|NCT05521074|Experimental|Active tDCS administered before extinction phase|The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
32961843|NCT05521074|Experimental|Active tDCS administered during extinction phase|The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
32961844|NCT05521074|Experimental|Active tDCS administered after extinction phase|The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
32961845|NCT05521074|Sham Comparator|Sham tDCS|Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
32961846|NCT05493540|Active Comparator|Medical treatment Group|40 preterm neonates will receive Ibuprofen oral suspension
32961847|NCT05493540|Placebo Comparator|Placebo Group|40 preterm neonates will receive oral placebo
32961848|NCT05427240|Experimental|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
32961849|NCT05427240|Experimental|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
32961850|NCT05427240|Experimental|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
32961851|NCT05427240|Experimental|ARM D|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
32961852|NCT05360784|Experimental|Brimonidine tartrate preservation-free|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
32961853|NCT05360784|Active Comparator|Lumify®|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
32961854|NCT05214924|Experimental|Injectable platelet-rich fibrin injection|Each of the participants from iPRF injection group will receive two injections of iPRF with an interval of 30 days.
32961855|NCT05214924|Active Comparator|Platelet-rich plasma injection|Each of the participants from PRP injection group will receive two injections of PRP with an interval of 30 days.
32961856|NCT05672940|Experimental|Aerobic plus resistance training group|Receive three one-hour supervised group sessions weekly for 12 weeks, in which Sections 1 and 3 were AT plus RT sessions, including 5-minute warm-up, 30-minute AT exercises on a bicycle (Comfort 408, Horizon Fitness) or a treadmill (832T, Horizon Fitness), 20-minute RT, and 5-minute cool-down; whereas Section 2 was an AT-only session, including 5-minute warm up, 50-minute aerobic exercises (bicycling or treadmill walking), and 5-minute cool-down.
32961857|NCT05672940|Experimental|Stretching plus breathing training group|Receive three one-hour sessions of weekly supervised group training combining Tongtze Gymnastics (童子體操) and breathing exercises for 12 weeks.
32961858|NCT05672784|Active Comparator|C group|the patients will take standard analgesia (paracetamol 1 gm thrice daily and meloxicam (15 mg) every 24). ,with no nerve block
32961859|NCT05672784|Active Comparator|G group|the patients will take standard analgesia plus genicular nerves block
32961860|NCT05672784|Active Comparator|GI group|the patients will take standard analgesia plus genicular nerves block plusinfiltration Between Popliteal Artery and Capsule of Posterior Knee
32961861|NCT05672706||CFR and IMR group|
32961862|NCT05672628|Experimental|Oculus VR|
32961863|NCT05672472|Experimental|Sivelestat sodium|The patients in the test group were given 0.2 mg/kg. h of sivelestat sodium (0.1 g/tube, Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.) (the daily dose was added to 250 ml of 0.9% sodium chloride) intravenously for 24 hours and 5 consecutive days.
32961864|NCT05672472|Placebo Comparator|sodium chloride|The patients in the control group were given 250 ml 0.9% sodium chloride (250ml/bag, Jilin Dubang Pharmaceutical Co., Ltd.) by intravenous pump for 24 hours and 5 consecutive days.
32961865|NCT05672394|Experimental|Serratus anterior plane block:|
32961866|NCT05672394|Active Comparator|Thoracic Epidural|
32961868|NCT05672004|Active Comparator|Implementation as usual|Healthcare professionals will be instructed to implement ProMuscle in their practice as usual
32961869|NCT05672004|Experimental|PUMP-fit strategy: Implementation toolbox|Healthcare professionals receive a personal implementation toolbox, tailored to their contexts' barriers for implementation
32961870|NCT05671926||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
32961871|NCT05671926||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
32961874|NCT05651568|Experimental|Periodized resistance training|It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.
32961875|NCT05651568|Experimental|High intensity interval training|It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30-35 minutes.
32961876|NCT05607342|Experimental|Pilot Trial: Osanetant 28 Days|Pilot Trial: A single dose level (200mg twice daily, oral) will be provided for men with prostate cancer undergoing curative intent surgery. Men will undergo serum testing at baseline, days 2, 3, 7, 14, and 28 as well as 6 weeks post-treatment in order to evaluate efficacy. All men enrolled will be subject to the same study procedures and assessments, regardless of completion of the study protocol, and analysis will occur via intent-to-treat principles.
32961877|NCT05597904||Coeliac disease patients|Adult (18 years or over) patients with previous coeliac disease or dermatitis herpetiformis diagnosis
32961878|NCT05597904||Healthy controls|500 adult (18 years or over) friends or non-related family members of coeliac disease or dermatitis herpetiformis patients participating in the study, no previous coeliac disease or dermatitis herpetiformis diagnosis. In addition 1000 controls will be included from Biobank
32961879|NCT05572242|Experimental|L-PRF preservation (test)|Using L-PRF membranes inside the socket, covering with L-PRF membranes, (test group).
32961880|NCT05572242|Active Comparator|Xenogenic bone plus collagen membrane (control)|Bio-Oss® Collagen at the bone level and application of a collagen matrix (Combi-Kit). Both materials will be used for socket preservation (control).
32961881|NCT05562492|Experimental|Closed-loop insulin delivery (CamAPS FX)|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) A smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data.~Participants will use the closed-loop system for the next 26 weeks at home"
32961882|NCT05562492|Active Comparator|Conventional insulin therapy with CGM|Usual insulin therapy (injections or pump) and study CGM for 26 weeks at home.
32961883|NCT05464992|Other|Patients with glioma or brain metastases|
32961884|NCT05407818|Experimental|JNJ-63733657|Participants will receive a single dose of JNJ-63733657 as an intravenous (IV) infusion on Day 1.
32961885|NCT05392296|Experimental|Power ball|experimental group getting the power ball training with conventional treatment
32961886|NCT05392296|Active Comparator|Conventional|group will be control group getting the conventional treatment (isometric hand grip training exercises)
32961887|NCT05379972|Experimental|HR deficient cohort|Pre-identified presence of somatic or germline deleterious mutation, as determined by NGS only, in at least one gene critical to DNA repair through homologous recombination, including but not limited to: ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC.
32961888|NCT05379972|Experimental|HR proficient cohort|No identifiable somatic or germline deleterious mutation in DNA Response and Repair pathway
32961889|NCT05326464|Experimental|Tofacitinib 10 mg|Participants will take the 10mg Tofacitinib twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
32961890|NCT05274828|Experimental|H7-Coil Deep TMS Treatment|H7-Coil Deep TMS Treatment
32961891|NCT05194956|Experimental|Arm 1 - Alginate impressions followed by digital intraoral scan|The participant will have alginate impressions taken for orthodontic treatment records first. Followed by a digital intraoral scan a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
32961892|NCT05194956|Experimental|Arm 2 - Digital intraoral scan followed by alginate impressions|The participant will have a digital intraoral taken for orthodontic treatment records first. Followed by alginate impressions a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
32961893|NCT04997616|Experimental|25 mg/day dose of Happy Lane CBD (Lower Dose)|One 25 mg Happy Lane CBD gel capsule per day (25 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days.
33104454|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
33104455|NCT01352195|Active Comparator|Usual Care (UC)|This condition will comprise a single, high quality booklet that is currently in dissemination: NCI's Clearing the Air (NCI, 2003).
33104456|NCT01352195|Active Comparator|Standard Repeated Mailings (Stand-RM)|Stand-RM will be the same 8 Forever Free booklets (edited for cessation) distributed over 12 months as in our preliminary studies.
33104457|NCT01352195|Active Comparator|Intensive Repeated Mailings (Inten-RM)|Inten-RM will add two additional booklets to extend the intervention out to 18 months, plus additional monthly contacts.
33104458|NCT03974139|Experimental|Obese patients|Patients with body mass index >30
33104459|NCT04321135|Experimental|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
32856387|NCT04265651|Experimental|Infigratinib 0.25 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
32856388|NCT04404647|Experimental|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
32856389|NCT04055753||Doxorubicin|
32856390|NCT04055753||Doxil|
32856391|NCT03975647|Experimental|Tucatinib + T-DM1|Tucatinib + T-DM1
32856392|NCT03975647|Active Comparator|Placebo + T-DM1|Placebo + T-DM1
32856393|NCT03937817||1|Healthy volunteers and patients with hematologic and hemolytic diseases, including alpha and beta globin variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.
32856394|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
32856395|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
32856396|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
32856397|NCT03770273|Active Comparator|sarilumab|8 SC injections of 200 mg/1.14 ml of sarilumab over 16 weeks
32856398|NCT04764227|Experimental|Concurrent chemoradiotherapy group|"Interventions:~Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5~Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions."
32856399|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
32856400|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
32856401|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
32856402|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
32856403|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
32856404|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
32856405|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
33104460|NCT04321135|Active Comparator|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
33104461|NCT04320238|Experimental|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
32856406|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
32856407|NCT04764539|Active Comparator|Stimuli administered via 2D format on an iPad Pro|50% of participants were given the video modeling stimuli in a 2D format (iPad Pro).
32856408|NCT04764539|Active Comparator|Stimuli administered in 3D format via VR goggles and bone conduction headphones|50% of participants were given the video modeling stimuli in 3D format via VR goggles with integrated bone conduction headphones.
32856409|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
33406827|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
32856410|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
33104462|NCT04320238|Experimental|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
32856411|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
32856412|NCT04764383|Experimental|PK/PD Group|Participants in the Pharmacokinetic (PK)/pharmacodynamic (PD) Group will receive L-Histidine and Lodosyn daily for 7 consecutive days.
32856413|NCT04764383|Placebo Comparator|L-Histidine and Lodosyn followed by Placebo Group|Participants in this group will receive L-Histidine and Lodosyn daily for 2 consecutive weeks followed by Placebo for an additional 2 consecutive weeks with a 1-week wash-out period in between.
32856414|NCT04764383|Experimental|Placebo followed by L-Histidine and Lodosyn Group|Participants in this group will receive Placebo daily for 2 consecutive weeks followed by L-Histidine and Lodosyn for an additional 2 consecutive weeks with a 1 week wash out period in between.
32856415|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
32856416|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
32856417|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
32856418|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
32856419|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
32856420|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
32856421|NCT01780025||Mixed hearing loss|
32856422|NCT01012245||patients with glaucoma and ocular hypertension|
32856423|NCT03016611|Active Comparator|Chewing Ticagrelor|
32856424|NCT03016611|Experimental|Chewing Prasugrel|
32856425|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
32856426|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
32856427|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
32856428|NCT00961233|Experimental|inhaled/swallowed budesonide|
32856429|NCT00961233|Active Comparator|viscous/swallowed budesonide|
32856430|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
32856431|NCT00962871|Active Comparator|1|
32856432|NCT00962871|Experimental|2|
32856433|NCT00962871|Experimental|3|
32856434|NCT00962871|No Intervention|4|
32856435|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
32856436|NCT01014741|Experimental|Ibutilide arm|
32856437|NCT01014741|Placebo Comparator|Placebo arm|
33104463|NCT04320121|Experimental|Nelutri™ group|This group takes Nelutri™ for 12 weeks
33104464|NCT04320121|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
33406828|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
32961894|NCT04997616|Experimental|50 mg/day dose of Happy Lane CBD (Larger Dose)|Two 25 mg Happy Lane CBD gel capsules per day (50 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days. Both capsules will be taken at the same time as each other.
33406829|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
32961895|NCT04965246|Experimental|Physical activity|the physical activity intervention will be structured to increase light-intensity aerobic physical activity, to achieve a total of 150 minutes per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity
32961896|NCT04965246|Other|Usual care|Participants randomized to the usual care control group will serve as the control group for 15 weeks, and receive no intervention during this time.
32961897|NCT04887792|Active Comparator|Acetazolamide|acetazolamide capsules
32961898|NCT04887792|Active Comparator|Placebo|Identical gelatin capsules
32961899|NCT04849884|Experimental|CORI Tensioner|Subjects having a robotic TKA procedure with the CORI Surgical System including the use of the REAL INTELLIGENCE Tensioner accessory.
32961900|NCT04836858|Experimental|CMK389 high dose|Active
32961901|NCT04836858|Placebo Comparator|Placebo high dose|Placebo
32961902|NCT04836858|Experimental|CMK389 low dose|Active
32961903|NCT04836858|Placebo Comparator|Placebo low dose|Placebo
32961904|NCT04771416|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBKR03|"Cohort 1: Subjects aged >4 to <9 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 2: Subjects aged >4 to <9 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 3: Subjects aged >1 to <4 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 4: Subjects aged >1 to <4 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~*GC/g: genome copiesy per gram of estimated brain weight"
32961905|NCT04771416|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBKR03|"Cohort 5: Subjects aged >1 to <9 months Drug: PBKR03 Single dose of PBKR03, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.~*GC/g: genome copiesy per gram of estimated brain weight"
32961906|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator, we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
32961907|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
32961908|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
32961909|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
32961910|NCT04594200|No Intervention|Control Group|Participants in this group will not receive a personalized antibiotic prescribing feedback letter and they will not receive a viral prescription pad.
32961911|NCT04518228||Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
32961912|NCT04518228||Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
32961913|NCT04518228||Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
32961914|NCT04518228||Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
32961915|NCT04518228||Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
32856438|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
32856439|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
33104465|NCT04320004|No Intervention|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
33104466|NCT04320004|Active Comparator|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
33104467|NCT04320004|Active Comparator|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
33104468|NCT04320004|Active Comparator|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
33104469|NCT04320004|Active Comparator|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
33104470|NCT01229072|Experimental|1|Heparin Blausiegel
33104471|NCT01229072|Active Comparator|2|Liquemine
33104472|NCT04685733||Group 1|Comparison of blood pressure, LVET and CO/SV measures with respective Gold Standards
33104473|NCT04685733||Group 2|Comparison of blood pressure and HRV measures with respective Gold Standards
33104474|NCT04685733||Group 3|Comparison of blood pressure and CO/SV measures with respective Gold Standards
33104475|NCT01228643|Experimental|Norzyme®|
33104476|NCT01228643|Active Comparator|Creon®|
32856440|NCT00962949|Experimental|Control|Healthy controls
32856441|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
32856442|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
32856443|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
33104477|NCT04685460|Experimental|3D-printed bolus|
33104478|NCT04685460|No Intervention|Conventional bolus|
33406830|NCT05096442|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
32856444|NCT01695941|Experimental|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.~Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
32856445|NCT01244789|Active Comparator|Observation|postoperative observation only
32856446|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
32856447|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
32856448|NCT00856895||Hispanic|
32856449|NCT00856895||Non-Hispanic|
32856450|NCT05687591||Patients indicated for LAAO with the Amplatzer Amulet|All subjects who are indicated for LAAO with the Amplatzer Amulet are eligible for the study.
32856451|NCT02081807||Dabigatran|
32856452|NCT02081807||Warfarin|
32856453|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
32856454|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
33104479|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
32856455|NCT04765163||physician group with assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group using assistive equipment
32856456|NCT04765163||Physician group without assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group without assistive equipment
32856457|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 4 hours a week (4 days, 1 hour per day)."
32856458|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 4 hours a week (4 days, 1 hour per day)."
32856459|NCT03156179||Girls with type 1 diabetes|
32856460|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
32856461|NCT05729490|Experimental|Participants|
32856462|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
32856463|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
32856464|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
32856465|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
32856466|NCT05729412||Compliance|Prescription is filled for specific parameters
32856467|NCT05729412||Non-compliance|Prescription is not filled for specific parameters
32856468|NCT05729412||Not available - NA|Data not available
32856469|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
32856470|NCT04436796|Experimental|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
32856471|NCT04436796|Active Comparator|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
32856472|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
32856473|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
32856474|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (6-9 groups) administered as a single cycle.~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (1 group) administered as a single cycle.~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
32856475|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
32856476|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
32856477|NCT05582616|Experimental|Active tDCS with physiotherapy|Patients will engage in a six-week treatment protocol with 3 sessions per week (18 treatments). This was chosen to minimize discomfort and ensure the number of sessions is consistent with previous migraine literature. The primary motor cortex (M1) will be the treatment target to reduce pain sensitivity and improve motor learning. M1 will be found through measurements of the head: the point halfway between the nasion and inion and halfway between the left and right tragus will be found, we will then move down 20% of the inter-tragi distance and place the anode there. The cathode will then be placed over the super orbital region. Each electrode will be held in place with a strap and will make as much contact with the skin as possible. tDCS will be delivered via two 35cm2 surface sponge electrodes at an intensity of 2mA in the active group.
33104480|NCT00532116|Active Comparator|A|EMSAM 6mg
33104481|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
33104482|NCT04283513|Experimental|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
32961916|NCT04518228||Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
32961917|NCT04518228||Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
32961918|NCT04518228||Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
32961919|NCT04518228||Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
32961920|NCT04518228||Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:~Levofloxacin (LFX) 750mg - 1000mg q.d.~Clofazimine (CFZ) 100mg q.d.~Linezolid (LZD) 300mg - 600mg q.d.~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~Delamanid (DLM) 100mg b.i.d.~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
32961921|NCT04518228||Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
32961922|NCT04518228||Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
32961923|NCT04518228||Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
32961924|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
32961925|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
32961926|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
32961927|NCT04421352|Experimental|low-dose radiation+CS1001|low-dose radiation+CS1001
32961928|NCT04356612||Achilles Tendon Rupture|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
33320581|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
33320582|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
32961932|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
32961933|NCT03893682|Experimental|Dose Escalation and Expansion|CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
32961934|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
32961935|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
32961936|NCT03729258|Experimental|Cefpodoxime 200 (b.i.d)|
32961937|NCT03729258|Active Comparator|Cefpodoxime 400 (q.d)|
32961938|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
32961939|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
32961940|NCT03360708|Experimental|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
32961941|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
32961942|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
33104483|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
33406831|NCT05096442|Active Comparator|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
32961943|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
33406832|NCT01313143|Experimental|AOP200704, infusion|
33406833|NCT01313143|Active Comparator|Esmolol, infusion|
32961944|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
32961945|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
32961946|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
32961947|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
32961948|NCT02793492|Experimental|Misago® RX Self-expanding Stent|Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent
32961949|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously (IV) every 2 weeks (Q2W).
32961950|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered IV Q2 weeks.
32961951|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC to distant sites or lymph nodes. Cemiplimab administered IV Q3 weeks.
32961952|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered IV Q4 weeks.
32961953|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced) who received cemiplimab IV Q3W for at least 27 weeks without experiencing disease progression, will have the option to receive cemiplimab by subcutaneous (SC) injection Q3W (first 12 patients) or Q6W (next ≥ 6 patients) basis.
32961954|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
32961955|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
32961956|NCT02538666|Placebo Comparator|Placebo|Placebo
32961957|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
32961958|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
32961959|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
32961960|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
32961961|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
32961962|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
33104484|NCT03910998|Active Comparator|"Group M for Moderate muscle relaxation, low doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery."
33104485|NCT03910998|Experimental|"Group D for Deep muscle relaxation, high doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes)."
33104486|NCT04263389||control group|control group is a normal matched group.
33104487|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
33406834|NCT05499780|Experimental|Group A: treatment with Sentinox performed 3 times/day for 21 days|treatment with Investigational Medical Device (IMD) performed 3 times/day for 21 days at 8 am, 2 pm and 8 pm
33406835|NCT05499780|No Intervention|Group B:no Sentinox treatment|
33406836|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
33104488|NCT04685148|Experimental|Intervention|Estradiol patches (200 μg per day) 0-3 weeks postpartum.
33104489|NCT04685148|Placebo Comparator|Placebo|Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
33320583|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
33406837|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
32856478|NCT05582616|Sham Comparator|Sham tDCS with physiotherapy|In the sham condition, the number of sessions, placement of electrodes, and types of electrodes used will be the same, however, only a 30 second ramp up period will be administered to emulate active tDCS therapy. Patients will be able to hear the sounds of the device and will feel slight tingling for the first 30 seconds but will receive no active stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
32856479|NCT03155867|Active Comparator|Meal replacement A|
32856480|NCT03155867|Active Comparator|Meal replacement B|
32856481|NCT03155867|Active Comparator|Meal replacement C|
32856482|NCT03155867|Active Comparator|Meal replacement D|
32856483|NCT03155867|Active Comparator|Meal replacement E|
32856484|NCT03155867|Active Comparator|Meal replacement F|
32856485|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
32856486|NCT04765085|Experimental|CBIT Group|Patients in this group would only receive the CBIT treatment.
32856487|NCT04765085|Experimental|Drug therapy Group|Patients in this group would only receive the drug therapy.
33320584|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
33320585|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
33320586|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
33320587|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
33320588|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
33320589|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
33320590|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
33320591|NCT04673942|Experimental|PART 1: Dose Escalation Safety Run-In|Subjects will be treated with AdAPT-001 as a single injection, one time.
33320592|NCT04673942|Experimental|PART 2: Dose Expansion Single-Agent|6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 24 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
33320593|NCT04673942|Experimental|PART 3: Expansion|Up to 45 subjects will be enrolled in the expansion cohort to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles.
33320594|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
33320595|NCT01321190||Headache|Individuals who experience bothersome headaches.
33320596|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
33320597|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
33320598|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
33320599|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
33320600|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
33320601|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
33320602|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
33320603|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
33320604|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
33320605|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
32856488|NCT02633046|Other|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
32856489|NCT04765007|Experimental|Mindfulness group|This arm will be treated with a mindfulness-based stress reduction therapy.
32856490|NCT04765007|Other|Control group|This arm will be treated with a minimal intervention.
32856491|NCT05729334|Experimental|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria.
32856492|NCT03874793|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
32856493|NCT03874793|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
32856494|NCT04417530|Experimental|Cohort 1 AU-011 & Laser|Low dose of AU-011 + 1 laser application
32856495|NCT04417530|Experimental|Cohort 2 AU-011 & Laser|Medium dose of AU-011 + 1 laser application
32856496|NCT04417530|Experimental|Cohort 3 AU-011 & Laser|Medium dose of AU-011 + 2 laser applications
32856497|NCT04417530|Experimental|Cohort 4 AU-011 & Laser|Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 2 treatments
32856498|NCT04417530|Experimental|Cohort 5 AU-011 & Laser|AU-011/laser applications from Cohorts 1 to 3 administered weekly for 3 treatments. Up to 2 cycles of this regimen may be administered and subjects have the option of receiving a third cycle of treatment.
32856499|NCT04417530|Experimental|Cohort 6 AU-011 & Laser|High dose of AU-011/laser applications administered weekly for 3 treatments and up to 3 cycles of treatment.
32856500|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
32856501|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
32856502|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
32856503|NCT04374630|Experimental|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
32856504|NCT04374630|Active Comparator|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
32856505|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
32856506|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
32856507|NCT05540964||Single group|Study participants will be taken off antiretroviral therapy and blood samples will be collected during each clinic visit.
32856508|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)~MI TLIF at L4-5 (n=10)~XLIF at L4-5 (n=10)"
32856509|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)~MI TLIF at L5-S1 (n=10)~XLIF at L5-S1 (n=10)"
32856510|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)~MI TLIF at L4-5 and L5-S1 (n=10)~XLIF at L4-5 and L5-S1 (n=10)"
32856511|NCT04364802|No Intervention|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
32856512|NCT04364802|Experimental|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
32856513|NCT04364802|No Intervention|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
32856514|NCT04364802|Experimental|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
32856515|NCT04364802|No Intervention|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
32856516|NCT04364802|Experimental|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
32856517|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
32856518|NCT05729256|Experimental|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of PrEP, followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
32856519|NCT05729256|Active Comparator|Brief Advice and Information|Single session to provide psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis
32856520|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
32856521|NCT03155087||healthy subjects|the healthy subjects was not intervened
32856522|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
32856523|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
32856524|NCT05729178||Pediatric acute lymphoblastic leukemia patients|pediatric patients of 1-16 years old affected by acute lymphoblastic leukemia
32856525|NCT05729178||healthy subjects|cord blood from healthy donors that cannot be used for clinical purposes
33104490|NCT04258358|Experimental|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
33104491|NCT04258358|No Intervention|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
33104492|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of >12 (gender-balanced, n1=18)
33104493|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
33104494|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
33104495|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
33104496|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
33104497|NCT03888222|Placebo Comparator|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
33406838|NCT05705934|Experimental|Group 1|Participants in this group will receive holistic-based group exercise program. All evaluations in this group will be done in the form of before and after. The exercise program will be applied for 12 weeks, 3 days a week.
33104498|NCT03888222|Active Comparator|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
33104499|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
33104500|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
33406839|NCT05705934|No Intervention|Group 2|Participants in this group will continue their routine habits and nutrition programs. All assessments in this group will be done in the form of before and after.
33406840|NCT05705856||intravenous reinduction|Participants who experience a loss of response to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg. Participants will resume their standard therapy after reinduction.
33406841|NCT05705856||intravenous administration q8w|Participants who experience a loss of response to 90 mg ustekinumab maintenance treatment will receive ustekinumab intravenously at regular interval (every 8 weeks).
32856526|NCT03866603||Parkinson´s disease individuals|"The participant has been clinically diagnosed with Parkinson's disease within the last 5 years (≤ 5 years)~The participant is between 30 and 80 years old"
32856527|NCT05729100|Experimental|Oral carbohydrate-electrolyte solution|The intervention group who will receive 50 ml/kg of oral solution containing carbohydrate-electrolyte
32856528|NCT05729100|Sham Comparator|Standard clear fluid|The control group who will receive 50 ml/kg of clear fluid (i.e. water; which does not contain carbohydrate-electrolyte)
32856529|NCT05491278|Experimental|Fospropofol disodium for injection|Fospropofol disodium continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia.The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
32856530|NCT05491278|Active Comparator|propofol|Propofol continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
32856531|NCT00963105|Experimental|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
32856532|NCT00963105|Experimental|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
32856533|NCT00963105|Experimental|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
32856534|NCT03865589|Experimental|Patients Undergoing HCT|All patients enrolled will undergo US SWE at specific time points as outlined in the protocol based on disease course.
32856535|NCT05477238|Experimental|Cerebrovascular Accident|Stroke patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
32856536|NCT05477238|Other|healthy volunteer|Healthy volunteers patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
33104501|NCT04246684|Active Comparator|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
33320606|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
33406842|NCT05705856||intravenous administration q4w or q6w|Participants who experience a loss of response to 90 mg ustekinumab maintenance treatment will receive ustekinumab intravenously at shorten interval (every 4 weeks or every 6 weeks).
33406843|NCT05071794|Active Comparator|Propofol|Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
32856537|NCT05473026|Experimental|Gratitude Intervention|"Each participant will receive a gratitude journal (paperback or electronic journal based on preference) for eight weeks and will have the following journaling prompt to complete at least twice a week: There are many things in our lives, both large and small, that we might be grateful about. Think back over the day and write down on the line below all that you are grateful for today (maximum six reasons). The educational goal-setting component will be drawn from the American Cancer Society's Nutrition, Physical Activity, and Cancer toolkit. Participants will be able to choose the order in which they complete the goal-setting modules. Both exercises will be administered daily over eight weeks."
32856538|NCT05473026|No Intervention|Attention Control|"Each participant will receive a journal (paperback or electronic journal based on preference) Participants will receive the following general journaling prompt to complete at least twice a week: What are some memorable events that happened to you today, big, or small (maximum six memories). Write a brief statement about it."
32856539|NCT04879992|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
32856540|NCT04879992|Experimental|rifabutin triple therapy|Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
32856541|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
32856542|NCT03865277|Experimental|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
32856543|NCT03865277|Experimental|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
32856544|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
32856545|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
32856546|NCT04247334|No Intervention|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
32856547|NCT04247334|Experimental|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
32856548|NCT04247334|Sham Comparator|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
32856549|NCT05632523||adult patients with renal transplant|Conversion from anticalcineurin to belatacept
32856550|NCT05600712|Other|single arm|subjects who have redapt sleeved stem implant
32856551|NCT03864965|Experimental|Intervention Group|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will receive the guided advance care planning conversations with the PI
32856552|NCT03864965|No Intervention|Control Patients|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will not receive the guided advance care planning conversations with the PI
32856553|NCT05728710||Perforation|all patients with immediate or delayed perforation identified from the FECCO (NCT04592003)
32856554|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32856555|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32856556|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32856557|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
32856558|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
32856559|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
32856560|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
33406844|NCT05071794|Placebo Comparator|Placebo|Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery
33104502|NCT04246684|Experimental|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
33320607|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
33320608|NCT03772340|Experimental|Tradipitant|
33320609|NCT03772340|Placebo Comparator|Placebo|
33320610|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
32856561|NCT04188600|Experimental|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:~Responding patients: this population, defined by FSFI score > 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).~Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
32856562|NCT04188600|Active Comparator|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
32856563|NCT04181736|Experimental|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
32856564|NCT04181736|Placebo Comparator|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
32856565|NCT04404491|Active Comparator|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
32856566|NCT04404491|Placebo Comparator|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
32856567|NCT04173702|Experimental|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
32856568|NCT03861923|Experimental|Dry needling and exercise|
33320611|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
32856569|NCT03861923|Sham Comparator|Sham dry needling and exercise|
32856570|NCT04764071|Active Comparator|percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F. Pneumatic lithotripter is used for fragmentation and stone removal is accomplished with retrieval graspers through a rigid 22F nephroscope. An 18-24 F nephrostomy tube is placed at the end of the operation.
32856571|NCT04764071|Experimental|ultra-mini percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6 F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath. Then, a 9.5-F, rigid ureteroscope (KARL STORZ Medical Instruments) was introduced to the sheath. The renal stones were broken into pieces using holmium laser lithotripsy. Finally, the ureteroscope and sheath were removed and the tract site was packed for 2-3 min. then placement of double J stent will be done according to the decision of the operating surgeon for 3 to 4 weeks.
32856572|NCT03154853|No Intervention|normal foot|no intervention
32856573|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
32856574|NCT04764149||PFll Group|Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
32856575|NCT04764149||Non-PFLL Group|Patients were treated with other platinum-based chemotherapy every 21 days including: PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1. TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
33320612|NCT03778736|Experimental|Cumulase denudation|
33320613|NCT03778736|No Intervention|Hyaluronidase denudation|
32961963|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
32961964|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
33406845|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
32856576|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
32856577|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
32856578|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
32856579|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
32856580|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
32856581|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
32856582|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
32856583|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
32961965|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
32961966|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
32856584|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
32856585|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
32856586|NCT05573568|Experimental|Group A - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (5 mg, followed by 20 mg) with a 2-hour dose interval (5 subjects).
32856587|NCT05573568|Experimental|Group B - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (7.5 mg, followed by 30 mg) with a 2-hour dose interval (5 subjects).
32856588|NCT05573568|Experimental|Group C - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (10 mg, followed by 40 mg) with a 2-hour dose interval (5 subjects).
32856589|NCT05573568|Experimental|Group D - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (12.5 mg, followed by 50 mg) with a 2-hour dose interval (5 subjects).
32961967|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
32961968|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
32961969|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
32961970|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
32961971|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
32961972|NCT01893138|Experimental|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10^6 cells.
32961973|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
32961974|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
32961975|NCT00221598|Experimental|hemodialysis|
33406846|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
32856590|NCT05573568|Experimental|Group E - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (15 mg, followed by 60 mg) with a 2-hour dose interval (5 subjects).
32856591|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
32856592|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
32856593|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
32856594|NCT01672788|Experimental|Test 1|fixed dose combination tablet
32856595|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
32856596|NCT01672788|Experimental|Test 2|fixed dose combination tablet
32856597|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
32856598|NCT03851003|Experimental|Endometrial suturing|Uterine incision repair including suturing of the endometrium
32856599|NCT03851003|Experimental|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
32856600|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
32856601|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
32856602|NCT03065946||Case series|Early wakening
32856603|NCT05610059|Other|Blood Pressure Technology System M|These participants will receive information about high blood pressure, medications and strategies that can be used to take medications and manage blood pressure. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
32856604|NCT05610059|Other|Blood Pressure Technology System E|These participants receive information about high blood pressure and medications. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
32856605|NCT05549934|Experimental|PF-06651600 (Ritlecitinib)|200 mg once-daily for 8 weeks and then 100 mg once daily for the remaining 40 weeks
32856606|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
32856607|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
32856608|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
32856609|NCT03914742|Experimental|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
32856610|NCT03914742|Experimental|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator~BGB290 + TMZ at dose combination established in Phase 1"
32856611|NCT03914742|Experimental|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;~>/=12 months since last treatment~BGB290 + TMZ at dose combination established in Phase 1"
32856612|NCT03914742|Experimental|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
32856613|NCT03914742|Experimental|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
32856614|NCT04404413|Experimental|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
32856615|NCT03913728|Experimental|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
32856616|NCT03913728|No Intervention|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
32856617|NCT03913728|Experimental|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
32856618|NCT03913728|No Intervention|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
32856619|NCT03065868|Experimental|eradictaion|H. pylori eradication group
32856620|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
32856621|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
32856622|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
32856623|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
32856624|NCT03845465|Active Comparator|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
33320614|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
33320615|NCT03769454|Experimental|PP-001 low dose group|
33320616|NCT03769454|Placebo Comparator|Placebo low dose group|
33320617|NCT03769454|Experimental|PP-001 mid dose group|
32856625|NCT03845465|Experimental|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
32856626|NCT05529966|Experimental|NGENUITY|Research fellow participants utilize NGENUITY during micro-stent placement
32856627|NCT05529966|Active Comparator|Conventional microscope|Research fellow participants utilize conventional microscope during micro-stent placement
32856628|NCT03844061|Experimental|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
32856629|NCT03844061|Placebo Comparator|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
32856630|NCT05728476|Experimental|Vitrectomy group|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
32856631|NCT05728476|Active Comparator|Anti-VEGF group|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
32856632|NCT05728398|Active Comparator|Music Intervention Group|Participants randomized to receive music intervention during interventional radiology procedure.
32856633|NCT05728398|Sham Comparator|No Music Comparator Group|Participants randomized to have no music played during interventional radiology procedure.
32856634|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
32856635|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
32856636|NCT03840239|Experimental|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
32856637|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
32856638|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
32856639|NCT03834857|Other|single|Implantation of Stentrode device
32856640|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
32856641|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32856642|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32856643|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
32856644|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
32856645|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32856646|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32856647|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
32856648|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
32856649|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32856650|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
32898860|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
32898861|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
32961976|NCT05120076|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
32961977|NCT05120076|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
32961978|NCT05101122|Active Comparator|Dosing Period 1: Atomoxetine|
32961979|NCT05101122|Experimental|Dosing Period 2-4: AD313|Escalating dose of AD313
33320618|NCT03769454|Placebo Comparator|Placebo mid dose group|
33320619|NCT03769454|Experimental|PP-001 high dose group|
32856651|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
32856652|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
32856653|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
32856654|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
32856655|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
32856656|NCT05728320||Gastric bypass|Subjects submitted to gastric bypass
32856657|NCT05728320||Sleeve gastrectomy|Subjects submitted to sleeve gastrectomy
32856658|NCT05728320||Normal control subjects|Subjects not submitted to bariatric surgery with IMC < 25
32856659|NCT05728320||Obese control subjects|Subjects not submitted to bariatric surgery with IMC > 30
32856660|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
32856661|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
32856662|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
32856663|NCT03824639|Experimental|Exercise group|Structured exercise
32856664|NCT03824639|Active Comparator|Control group|Health education
32856665|NCT05504772||High-risk cancers|"One of the following two criteria must be met:~Confirmed or suspected high-risk malignancy defined as expected overall survival < 30% based on current literature for the specific cancer~Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A."
32856666|NCT05504772||Rare tumors|"At least one of the following three criteria must be met:~A rare tumor of uncertain prognosis due to rarity of disease~A rare tumor with no established treatment strategy~A cancer where routine histopathological examination has not been able to establish a diagnosis~Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment~Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating"
32856667|NCT05504772||Primary central nervous system (CNS) tumours|Patient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors
32856668|NCT05504772||Neuroblastoma|Patient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma
32856669|NCT05504772||Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL|Patient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
32856670|NCT05504772||Acute lymphoblastic leukemia (ALL)|Patient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
32856671|NCT05504772||Lymphomas|Patient is suspected or confirmed to have a lymphoma
32856672|NCT05504772||Sarcomas|Patient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT)
32856673|NCT05504772||Renal tumors|Patient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney
32856674|NCT05504772||Hepatic and biliary tree tumors|Patient is suspected or confirmed to have a liver or biliary tree tumor
32856675|NCT05504772||Thyroid and endocrine tumors|Patient is suspected or confirmed to have a thyroid or endocrine cancer
32856676|NCT05504772||Other tumors|Patient is suspected or confirmed to have a tumor which does not fit into any of the above
32856677|NCT05504772||Germline only|"One of the following two criteria must be met:~Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants/parents have consented to return of germline findings.~Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged."
32856678|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
32856679|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
32856680|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
32856681|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
32856682|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
32856683|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
32856684|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~Drug: [F-18] fluoroestradiol: [F-18]FES~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
32856685|NCT03814109|Experimental|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
32856686|NCT03814109|Active Comparator|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
32856687|NCT03814109|Active Comparator|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
32856688|NCT05491746|Experimental|Eye4|This is the arm with the Eyedaptic Device
32856689|NCT05491746|Placebo Comparator|Baseline|This is the placebo arm with the best correction the subject has
32856690|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
32856691|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
32856692|NCT03808727|Experimental|Massed Cognitive Processing Therapy (MCPT)|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. MCPT will be delivered in an intensive outpatient setting (12 sessions in 5 days) composed of both group and individual sessions.
32856693|NCT03808727|Active Comparator|Standard Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Standard CPT will be delivered in 12 one-hour sessions over 6 weeks and involves only individual sessions.
32856694|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
32856695|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
32856696|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
32856697|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
32898862|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
32898863|NCT01072331|Placebo Comparator|Placebo of MP-513|
32898864|NCT01072409|Other|Single Arm|Single arm design
32903585|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
32856700|NCT05728164|Experimental|STUDY GROUP|"The group (35 students) will be divided into 7 small groups of (5 students in each group). In addition to routine training provided for the control group, the students of the intervention group will be provided with micro learning content following the educational topics of the course in the form of short videos of cinematic films reinforcing values of resilience, empathy, and positive emotions in dealing with others.~• Pre-simulation activities will also be developed that required watching a tutorial video on how to create a plan of care for such cases. Students also will be provided with background on cinematic simulation and a summary of the characters. Learners will be assigned to one of the films characters and introduced to the assessment tool they would utilize. A pre-briefing discussion on patient confidentiality, nursing role expectations, and developing a plan of care also preceded the activity."
33320620|NCT03769454|Placebo Comparator|Placebo high dose group|
33320621|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
33320622|NCT03771950|No Intervention|Control group|Treatment as usual.
33320623|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
33320624|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
33320625|NCT04177940|Active Comparator|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
32856701|NCT05728164|No Intervention|Cintrol group|They will receive usual training based on the educational objectives of routine methods of lectures, discussion.
33320626|NCT04177940|Active Comparator|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
32856702|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
32856703|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
32856704|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
32856705|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
32856706|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
32856707|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
32856708|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
32856709|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
32856710|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
32856711|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
32856712|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
32856713|NCT05483868|Experimental|AU-011 Intramurally with or without Intratumoral Injection prior to TURBT or Cystectomy|Administration of AU-011 alone intramurally with or without intratumoral administration prior to the standard of care procedure (cystectomy or TURBT)
32856714|NCT05483868|Experimental|Intramural AU-011 with Laser Application prior to TURBT|AU-011 intramural administration with laser application prior to the standard of care TURBT
32856715|NCT05483868|Experimental|Intramural AU-011 with Laser Application prior to Cystectomy|AU-011 intramural administration with laser application prior to standard of care Cystectomy
32856716|NCT05483868|Experimental|Intermural and Intratumoral AU-011 with Laser Application prior to TURBT|AU-011 intramural and intratumoral administration with laser application prior to standard of care TURBT
32856717|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
32856718|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
32856719|NCT05481060|Experimental|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
32856720|NCT05481060|No Intervention|Control group|Online didactic education about intimate partner violence against women prepared by researchers will apply to nursing students.
32856721|NCT03802877|Active Comparator|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
32898865|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
32898866|NCT04352543|Experimental|Older adults group|Group of older adults >60 years old.
32898867|NCT04590209|Experimental|Acrosyndrome|"The blood sample, skin biopsy and other biological samples will be taken from patients~The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required."
32961980|NCT05094804|Experimental|OR2805 monotherapy and combination therapy dose-escalation phase (Part A)|"Escalating repeated doses of OR2805 by IV administration as monotherapy or in combination with cemiplimab or docetaxel in subjects with advanced solid tumors. OR2805 will be administered once every 3 weeks (Q3W) or once-weekly (QW) for 3 weeks as an IV infusion over 30 minutes.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
32856722|NCT03802877|Experimental|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
32961981|NCT05094804|Experimental|OR2805 monotherapy and combination therapy dose-expansion phase (Part B)|"OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy or in combination with cemiplimab or docetaxel in subjects with NSCLC and melanoma.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
32961982|NCT05094804|Experimental|OR2805 biological effects phase (Part C)|OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy to determine the mechanism of action and potential predictors of response and pharmacodynamic markers in subjects with liposarcoma, leiomyosarcoma, or SCCHN or are not otherwise eligible for Cohort B.
32961983|NCT05079204|Active Comparator|Conventional motivation procedure|Conventional motivation procedures defined as a presentation of the modified Bass technique on a dental teaching macro model plus intra oral instruction provided in patient's mouth with a hand mirror.
32961984|NCT05079204|Experimental|Conventional motivation procedure supported by 3D representations|Conventional motivation procedures associated with 3D intra oral procedures. A 3D intra-oral modelization will added to the previously described procedure. Then, a periodontist will show the sites contaminated by dental plaque to the patient.
32961985|NCT05030844|Experimental|Intervention Group|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
32961986|NCT05030844|No Intervention|Control Group|The control group received routine nursing care in the endocrine policlinic.
32961987|NCT05025462|Experimental|SPF|Salmon peptide fraction supplement: powder mixed in water
32961988|NCT05025462|Active Comparator|Comparator|Casein peptide fraction supplement: powder mixed in water
32961989|NCT04992312|Experimental|Glucagon Nasal Powder|A single dose of glucagon nasal powder administered intranasally.
32961990|NCT04946916|Experimental|Participant with psychiatric condition without cognitive impairment|In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.
32961991|NCT04946916|Experimental|Participant with psychiatric condition with cognitive impairment|In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.
32961992|NCT04946916|Experimental|Patients with biological Alzheimer's disease|Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.
32961993|NCT04946916|Experimental|Patient with fronto-temporal dementia|Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.
32961994|NCT04934826|Experimental|Hydrolized proteins|Group receiving hydrolyzed proteins in the postprandial metabolic test
32961995|NCT04934826|Active Comparator|Intact proteins|Group receiving intact proteins in the postprandial metabolic test
32961996|NCT04873596|Active Comparator|nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
32961997|NCT04873596|Active Comparator|nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
32961998|NCT04868760|Active Comparator|Group B: ipilimumab|Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
32961999|NCT04868760|Experimental|Group A: IBI310|IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
32962000|NCT04865952|Experimental|HA application (treatment group - HA)|periodontal surgery + HA application + buccal attached gingival (G) biopsies 24 hr after surgical procedure
32962001|NCT04865952|Other|NO HA application (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
32962002|NCT04803708|Experimental|Part A- Cohort 1|8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.
32962003|NCT04803708|Experimental|Part B- Cohort 2|"18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:~TP-102 q.d 3x weekly up to four weeks (n=12)~Placebo q.d. 3x weekly up to four weeks (n=6)~Subjects will be followed-up for 7 days."
32962004|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
32962005|NCT04651452|Active Comparator|Value Affirmation|Participants in the value affirmation condition will complete six writing prompts regarding their personal values over the course of six months. For example, participants will be given a list of values and will be asked to rate them in order of importance within their own lives and write about a time when their top value was particularly important. Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
32962006|NCT04651452|Active Comparator|Reflective Journaling|Participants in the reflective journaling condition will complete six writing prompts over the course of six months. However, the reflective journaling condition will be writing about values that are not important to them and discuss why they could be important to others. In other tasks, they will write about aspects of daily life (e.g. morning routine). Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
32962007|NCT04566978|Experimental|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
32962008|NCT04566978|Experimental|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
32962009|NCT04566978|Experimental|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
32962010|NCT04566978|Experimental|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
32962011|NCT04508166|Experimental|Dexmedetomidine|Sublingual dose of dexmedetomidine
32962012|NCT04508166|Active Comparator|Gamma-hydroxybutyrate|Oral dose of gamma-hydroxybutyrate
32962013|NCT04508166|Placebo Comparator|Placebo|Oral (saline) and sublingual (orodispersible tablet) doses
33406847|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
33406848|NCT05705778||Strabismic|
33406849|NCT05705778||Anisometropic|
33406850|NCT05705778||Isoametropic|
33406851|NCT05705778||Visual deprivation|
33406852|NCT05705778||Mixed group|
33406853|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
32962025|NCT04444440|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
32962026|NCT04444440|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
32962027|NCT04420026|Experimental|Experimental Arm|Hepatocellular tumours
32962028|NCT04342260|Experimental|Active Monitoring|Clinicians will receive symptom alerts if the survey suggests increased or worsening symptoms.
32962029|NCT04342260|Active Comparator|Passive Monitoring|Clinicians will not receive any symptom alerts.
32962030|NCT04309500|Experimental|Amyloid Positive (Tau Positive or Negative) Participants|Participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
32962031|NCT04309500|Experimental|Amyloid Negative (Tau Positive or Negative) Participants|Participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
32962032|NCT04309500|Experimental|Co-Participants of Amyloid Positive (Tau Positive or Negative) Participants|Study partners of participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
32962033|NCT04309500|Experimental|Co-Participants of Amyloid Negative (Tau Positive or Negative) Participants|Study partners of participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
32962034|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
33320627|NCT04177940|Active Comparator|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
33104503|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
33104504|NCT03883893|Active Comparator|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
33104505|NCT03883893|Placebo Comparator|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
33104506|NCT04319575|Experimental|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
33104507|NCT04319575|Active Comparator|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
33104508|NCT04227275|Experimental|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
33104509|NCT04191655|Experimental|High Definition White Light Colonoscopy|
33104510|NCT04191655|Active Comparator|Dye Spraying Chromo-colonoscopy|
33104511|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
33104512|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
33320628|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
32856723|NCT03802877|Experimental|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
32856724|NCT03802877|Experimental|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
32856725|NCT05480826|Other|Patients|"Subject suffering from (according to DSM IV criteria)~bipolar disorder~unipolar depression~schizophrenia~autism spectrum disorder~Collection of hair follicle cells"
32856726|NCT05480826|Other|Relatives|"Relatives of enrolled patients suffering from psychiatric disorder.~test to detect psychiatric disorders~blood or saliva sampling for genomic DNA extraction~Collection of hair follicle cells"
32856727|NCT03802799|Experimental|ZYN002|ZYN002 - cannabidiol Transdermal Gel
32856728|NCT04971564||Case|Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
32856729|NCT04971564||Control|Patients without cerebral hypoxia
32856730|NCT00964431|Experimental|Indomethacin Test (lower dose)|
32856731|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
32856732|NCT00964431|Active Comparator|Celecoxib 400 mg|
32856733|NCT00964431|Placebo Comparator|Placebo|
32856734|NCT05477862|Experimental|Alzheimer Disease (AD)|
32856735|NCT05477862|Experimental|Cognitively Healthy (CH)|
32856736|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
32856737|NCT05727462|Experimental|Manual Therapy with TECAR|Participants allocated to this group received 15 sessions of a manual therapy protocol applied by two resistive TECAR bracelet electrodes (one in each hand).
33104513|NCT04203017|Experimental|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
33104514|NCT05339256|Experimental|Telehealth buprenorphine induction and maintenance|Sublingual (SL) Buprenorphine and a medical management protocol adapted to the unique needs of home-based telehealth for MOUD using SL buprenorphine
33104515|NCT05339256|Active Comparator|Standard in-person SL buprenorphine induction and maintenance|In-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
33104516|NCT04192214|Active Comparator|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
33104517|NCT04192214|No Intervention|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
33104518|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
33104519|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
33104520|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
33104521|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
33104522|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
33104523|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
33104524|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
33104525|NCT01250119|Experimental|Single Arm|
33104526|NCT04682444|Experimental|Group 1 - Active Treatment|Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
33104527|NCT04682444|Placebo Comparator|Group 2 - Placebo|Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
33104528|NCT04320277|Experimental|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
33104529|NCT04320277|Active Comparator|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
32856738|NCT05727462|Active Comparator|Manual Therapy without TECAR bracelet electrodes|Participants allocated to this group received the same Manual Therapy protocol without the resistive TECAR bracelet electrodes
32856739|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness in patients with type 2 diabetes|N=21 patients with type 2 diabetes
32856740|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness for healthy individuals|N=27 healthy individuals
32856741|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
32856742|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
32856743|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
32856744|NCT05475054||Open liver resection|Non-obese or obese patients that underwent an open liver resection for all indications
32856745|NCT05475054||Minimally invasive liver resection|Non-obese or obese patients that underwent a minimally invasive liver resection for all indications
32856746|NCT04763369|Experimental|Sub-tenon injection group|In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
32856747|NCT04763369|Experimental|Suprachoroidal injection group|A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
32856748|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
32856749|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
32856750|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
32856751|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
32856752|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
32856753|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
32856754|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
32856755|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
32856756|NCT05725668|Experimental|Dual-task taj ji quan|This intervention includes training of (a) symmetrical postural tai ji quan forms/movements synchronized with breathing, (b) controlled displacement (weight-shifting) of the body's center of mass over the base of support, (c) dynamic eye-hand movements during whole-body motion, (d) multidirectional (anterior-posterior and medial-lateral) stepping, and (e) rotational ankle sway and self-induced reactive postural recovery actions. The training practices are integrated, gradually over time, with a mix of interactive, cognitively stimulating, dual-task exercises that challenge attention control, working memory, verbalization, response inhibition, processing speed, dual tasking, task switching/prioritization, and spatial orientation and postural awareness.
32856757|NCT05725668|Experimental|Standard tai ji quan|This intervention includes training of tai ji quan forms with synchronized breathing, supplemented by a set of mini-therapeutic exercises. The training involves repeated practice of (a) symmetrical, coordinated, trunk-driven tai ji quan form movements, (b) controlled displacement (weight-shifting) of the body's center of mass over varying sizes of the base of support, (c) dynamic eye-hand movements during whole-body motion, and (d) multidirectional (anterior-posterior and medial-lateral) stepping. As a balance training therapy, movement practices emphasize a dynamic interplay of stabilizing and self-induced destabilizing postural actions and balance exercises that target mobility, stability limits, and sensory integration.
32856758|NCT05725668|Experimental|Stretching exercise|This active control intervention includes light activities that consist of breathing, stretching, and relaxation exercises. Each exercise session encompasses a variety of light and static stretches for joints and muscles, performed in a seated or standing position. Exercise involves the upper body (arms, neck, upper back, shoulder, back, and chest), lower extremities (quadriceps, hamstrings/calfs, and hips), and gentle and slow trunk rotations. Also included are intermittent light walking, deep abdominal breathing exercises that emphasize inhaling and exhaling to maximum capacity, and progressive relaxation of major muscle groups.
33104530|NCT05300529|Experimental|Vestibular Rehabilitation Exercises|Vestibular Rehabilitation Exercises focused on eye stabilization and Vestibulo-Oculo Reflex (VOR). Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
32962035|NCT04265196|Experimental|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
32962036|NCT04265196|Experimental|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
32962037|NCT04265196|No Intervention|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
32962038|NCT04175964|Experimental|Group 1|PCO patients that will receive ketogenic diet only
32962039|NCT04175964|Experimental|Group 2|PCO patients that will receive caloric diet with Metformin
32962040|NCT04175964|Experimental|Group 3|PCO patients that will receive caloric diet only
32962041|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
32962042|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
32962043|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
32962044|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
32962045|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
32962046|NCT03845712|Experimental|MT1621, dC/dT|This is an open label study with all participants in a single arm. Patients will take MT1621 up to a maximum of 800 mg/kg/day (400 mg/kg/day dC and 400 mg/kg/day dT). MT1621 is deoxycytidine (dC) and deoxythymidine (dT) powders for solution for reconstitution in water or apple juice. Study drug will be supplied as powder in packets containing 0.5 or 2.0 g or 4.0 g of dC or dT, and is typically dosed three times/day. MT1621 should be administered with food.
32962047|NCT03743532|Experimental|E-Ciagrette|Participants will be asked to completely switch from cigarettes to e-cigarettes. They will receive an e-cigarette device and pods during the first 4 weeks following a scheduled switch date.
32962048|NCT03743532|Experimental|Financial Incentives + E-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes, and they will receive an e-cigarette device and pods during the first 4 weeks following a scheduled switch date. Participants will also receive weekly financial incentives for biochemically-verified cigarette abstinence during the first 4 weeks following the switch date.
32962049|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
32962050|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
32962051|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
32962052|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.~Consolidation (for all patients):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
32962053|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
33320629|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
32856759|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
32856760|NCT01017003|Experimental|1|0.6mg colchicine tablet
32856761|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
32856762|NCT04956900|Experimental|Aurase wound gel X0|Cohort 1: Aurase wound gel x0 dose concentration
32856763|NCT04956900|Experimental|Aurase wound gel X1|Cohort 2: Aurase wound gel x1 dose concentration
32856764|NCT04956900|Experimental|Aurase wound gel X1.8|Cohort 3: Aurase wound gel X1.8 dose concentration
32856765|NCT04956900|Experimental|Aurase wound gel X5|Cohort 4: Aurase wound gel X5 dose concentration
32856766|NCT04956900|Experimental|Aurase wound gel X9|Cohort 5: Aurase wound gel X9 dose concentration
32856767|NCT03793907|Active Comparator|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
32856768|NCT03793907|Experimental|Cohort 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
32856769|NCT04442724|Experimental|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement & cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
32856770|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
32856771|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
32856772|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
32856773|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
32856774|NCT04442412|Experimental|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~Schedule for VitD supplementation: 25,000 U/day starting on day -6:~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level < 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
32856775|NCT04442412|Other|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
32856776|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
32856777|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
32856778|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
32856779|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
32856780|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
32856781|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
32856782|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
32856783|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
32856784|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
32856785|NCT04445844|Experimental|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32856786|NCT03783533|Experimental|Adolescent Target Users of Behavioral Activation (BA) App|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
32856787|NCT05724342||rhTNK-tPA Thrombolysis|
32856788|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
32856789|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
32856790|NCT05713890|Experimental|VR-AOT|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation
32856791|NCT05713890|Active Comparator|VR-LO|Home-based landscape observation with virtual-reality for upper limb rehabilitation
32856792|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
32856793|NCT03783143||Cross-sectional Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
32856794|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
33320630|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
33320631|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
33320632|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
32856795|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
32856796|NCT05458596|Experimental|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
32856797|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
32856798|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
32856799|NCT05432232|Experimental|Histotripsy|HistoSonics System: non-invasive destruction of kidney tissue using histotripsy
32856800|NCT03778073|Experimental|Cohort A|Cosibelimab (TG-1501) single-agent
33320633|NCT04141592||Obese wihtout non-alcoholic steatohepatitis|Body mass index greater than 30 without liver histological evidence of non-alcoholic fatty liver disease
32856801|NCT03778073|Experimental|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
32856802|NCT03778073|Experimental|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
32856803|NCT00967941||Ancef|
32856804|NCT00967941||Vancomycin and Cefazolin|
32856805|NCT00967941||Daptomycin and Cefazolin|
32856806|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
32856807|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
32856808|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
32856809|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
32856810|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
32856815|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
32856816|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
32856817|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
32856818|NCT05395845|Experimental|value of platlet rich plasma|
32856819|NCT05395767|Experimental|endoscopic ACL reconstruction with parent allograft tendon|
32856820|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
32856821|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
32856822|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
32856823|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
32856824|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
32856825|NCT04925934|Experimental|VIB7734 SC (dosing interval 1)|
32856826|NCT04925934|Experimental|VIB7734 SC (dosing interval 2)|
32856827|NCT04925934|Placebo Comparator|Placebo SC (dosing interval 3)|
32856828|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
32856829|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
32856830|NCT03064464||CA-MRSA infection|None intervention
32856831|NCT03064464||HA-MRSA infection|None intervention
32856832|NCT03064464||CA-MSSA infection|None intervention
32856833|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
32856834|NCT05395611||Lung cancer|"Patients with primary non small cell lung cancer listed for tumor resection. EBP, plasma and lung tumor tissue will be collected for protein profiling.~Collection of EBP will be done at 2 time points before and after surgery. Collection of plasma will be done at 2 time points before and after surgery. Collection of lung/tumor tissue will be done at the time of surgery"
32856835|NCT05395611||Control|Patients without lung cancer matched according to age and smoking history (control cohort) Collection of EBP will be done at one time point. Collection of plasma will be done at one time point.
32856836|NCT05704452||Patient group|who diagnosed with dementia
32856837|NCT05704452||Control group|who diagnosed as healthy (don't have dementia)
32856838|NCT05395533|Experimental|Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)|To evaluate the safety and tolerability of TRS005 in patients with recurrent or refractory CD20-positive B-cell non-Hodgkin's lymphoma with treatment at one or more times, and to recommend the dose for phase II clinical trials (RP2D).
32856839|NCT05419518|Experimental|Palliative radiation dose escalation|The prescribed dose is 50 Gy in 10 fractions. The total dose can be reduced to 40 Gy and the total number of fractions can be reduced to 8 fractions in non-spine metastases to achieve the normal tissue constraints.
32856840|NCT05419518|No Intervention|Therapeutic benefit|Radiation will be delivered as per protocol. For participants experiencing unacceptable toxicity related to study treatment, yet obtaining therapeutic benefit, participants will be allowed to continue treatment, if well tolerated at the discretion of the investigator.
32856841|NCT05395455|No Intervention|Periodontally Healthy|Systemically and periodontally healthy
32856842|NCT05395455|Active Comparator|Stage III Grade B Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
32856843|NCT05395455|Active Comparator|Stage III Grade C Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
32856844|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
32856845|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
32856846|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
32856847|NCT05395377|Active Comparator|Registered Dietitian/Nutritionist|
32856848|NCT05395377|Active Comparator|DPP Group Classes|
32856849|NCT05395377|Active Comparator|Weight Watchers, Reimagined|
32856850|NCT05395377|Active Comparator|Pharmacological Treatment|
32856851|NCT05395377|Active Comparator|Bariatric Surgery Evaluation|
32856852|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
32856853|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
32856854|NCT02980263|Experimental|Kawasaki patients|
32856855|NCT05700474|Experimental|Intervention Arm|There is one arm of the study and this involves participating in holistic behavioral health treatment for people living with HIV and the LGBTQ+ community for a 6 month period. Specific services include individual and group therapy, case management, peer support, and behavioral health education and awareness
32856856|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
32856857|NCT05695560||Phase 1: Adult Participants|Adult participants with severe VWD (self-bleeding assessment tool [BAT] score ≥10) and their caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform.
32856858|NCT05695560||Phase 2: Pediatric Participants|Pediatric participants with severe VWD (self-pediatric bleeding questionnaire [PBQ] score of ≥3 for at least one symptom and caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform. The decision to proceed with Phase 2 will be determined following completion of Phase 1.
32856859|NCT04913220|Experimental|Cohort A: Melanoma|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32856860|NCT04913220|Experimental|Cohort B: cutaneous squamous cell carcinoma (CSCC)|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
32856861|NCT05395299|Experimental|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )|Injection at the level of the right and left prostate arteries of Squid until a complete occlusion of these arteries, and a filling of their intraprostatic branches
32856862|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
32856863|NCT03019263|Active Comparator|Control|Nutritional counseling
32856864|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
32856865|NCT05409768|Experimental|Short axis, out of plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with a short axis out of the plane method
32856866|NCT05409768|Experimental|Short axis, anteroposterior in plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with an anteroposterior short axis in-plane method
32856867|NCT05395143|Experimental|Atorvastatin and zinc|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and Zinc. Zinc tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
32856868|NCT05395143|Placebo Comparator|Atorvastatin and placebo|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and placebo. Placebo tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
32856869|NCT05408676|Experimental|Group Acu|"a surface electrode was applied in the induction room to the P6 acupoint on the dominant upper extremity, located ∼4 cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode on the opposing dorsal aspect of the forearm. When the patient enters the operating room， an investigator connected the device to both electrodes with electrical wires, set initial electric stimulating current at 1 mA with the frequency at 2 Hz(square-wave pulses of 0.2 ms), gradually increased the current intensity until the patient felt pain or reached the discomfort threshold (ranging from 6 to 20 mA), and maintained the stimulation until end of operation.~At the start of skin closure, saline (3 ml) was administered i.v."
32856870|NCT05408676|Sham Comparator|Group Gra|"Group Gra receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, granisetron (3 mg; Group Trp) was administered i.v."
33320634|NCT04141592||Obese Non-alcoholic steatohepatitis|Body mass index greater than 30 with liver histological evidence of non-alcoholic fatty liver disease
33320635|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
33320636|NCT05166512|Active Comparator|Standard DPP|Standard DPP (over 12 months)
32856871|NCT05408676|Sham Comparator|Group Dxm|"Group Dxm receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, saline (3 ml) was administered i.v."
32856872|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
32856873|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
32856874|NCT05404386|Experimental|Study group|"Study group intervention consists of a mobile application called My Fight with Incontinence structured according to the health belief model, and a 3-month follow-up."
32856875|NCT05404386|Other|Control group|"In addition to routine care, control group intervention consists of the training booklet My Fight with Incontinence which includes healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence, and a 3-month follow-up."
32856876|NCT05694858|Experimental|Lignocaine-Embedded Microneedle Patch|A biodegradable maltose microarray needle (MAN) patch loaded with 12.5 mg lignocaine will be applied on the dorsum of the participant's hand for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
32856877|NCT05694858|Active Comparator|EMLA 5% Patch|1 finger-tip unit (FTU) of EMLA containing 12.5 mg lignocaine and 12.5 mg prilocaine will be applied on the dorsum aspect of the participant's hand. This will then be covered by a Polyvinyl Alcohol (PVA)-Polyethylene Terephthalate (PET) adhesive and left in place for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
32856878|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
32856879|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
32856880|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
32856881|NCT05678400|Experimental|Hypopressive abdominal techniques|All subjects were instructed by a registered physiotherapist on how to correctly perform the hypopressive abdominal techniques (HAT) in two familiarisation sessions of 45 minutes each before any action was taken. After the two sessions, all subjects who did not learn the exercise correctly were dropped from the study. The HAT training consisted of asking subjects in a standing position to perform a spinal elongation with neutral pelvis and scapular muscle activation for three normal respiratory cycles with slow and deep exhalation, and on the last breath, an expiratory apnoea with rib expansion and elevation was requested. In this session, following the guidelines described in the familiarisation sessions, two series of four dynamic HATs in standing position were performed: dynamic HATs in right tilt, dynamic HATs in left tilt, dynamic HATs in right rotation and dynamic HATs in left rotation.
32856882|NCT05678400|Active Comparator|Stretching of proprioceptive neuromuscular facilitation|The therapist straddled that leg, and raised the other leg by placing the heel on the shoulder. The therapist then flexed the participant's hip, maintaining knee extension, to the point of discomfort indicated by the patient or the therapist's perceived end of range. In this position the leg was held straight for 10 seconds and immediately afterwards the participant was asked to perform a maximum isometric contraction for 5 seconds using the therapist's shoulder as counter resistance, thus keeping the leg straight at the same point. As soon as the contraction stops, the therapist flexes the hip again until a new range limit is reached, repeating the same protocol again. The total duration is 60 seconds, consisting of 4 passive stretches of 10 seconds each and 4 isometric contractions against resistance of 5 seconds each.
32856883|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
32856884|NCT02159703|Experimental|Single Arm Phase 2|
32856885|NCT05394753|Experimental|Unified Protocol|8-session group-based intervention
32856886|NCT05394753|No Intervention|Wait-list control|Participants in the wait-list control group will receive the same program, two months after their counterparts in the experimental group completed the intervention.
32856887|NCT05394597|Experimental|Treatment group|Receives a dose of repellent on the lower portion of the leg that is exposed
32856888|NCT05394597|No Intervention|Control group|Does not receive a dose of repellent, but subject to similar exposure period
32856889|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
33104531|NCT05300529|Sham Comparator|Conventional Rehabilitation exercises|Conventional rehabilitation exercises: stretching and walking. Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
33104532|NCT04163549|Experimental|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
33104533|NCT04163549|No Intervention|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
33104534|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
33104535|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
33104536|NCT05491876|Experimental|Chest physiotherapy with breathing exercises and ACBT|Group A will recieve chest physiotherapy with breathing exercises and ACBT.
33104537|NCT05491876|Experimental|Chest physiotherapy with breathing exercises|Group B will receive chest physiotherapy with breathing exercises.
33104538|NCT05491759|Experimental|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle The dose will be consumed orally with 250 mL water.
33104539|NCT05491759|Experimental|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle The dose will be consumed orally with 250 mL water.
32856890|NCT00974493|Active Comparator|Oral antibiotics|
32856891|NCT00974493|Active Comparator|Intravenous antibiotics|
32856892|NCT04894110|Experimental|EO2002 treatment|
32856893|NCT05366634|Experimental|Cohort 1|Single injection of MDK-703 (dose level 1) or matching placebo
32856894|NCT05366634|Experimental|Cohort 2|Single injection of MDK-703 (dose level 2) or matching placebo
32856895|NCT05366634|Experimental|Cohort 3|Single injection of MDK-703 (dose level 3) or matching placebo
32856896|NCT05653674|Experimental|Experiment|The experimental group will consist of 40 students in total, 4 groups of 10 students each, and the students will receive face-to-face psychoeducation for 6 weeks, each session for 60 minutes.
32856897|NCT05653674|No Intervention|Control|The control group will not receive any intervention during the application period and will be put on waitlist.
32856898|NCT05394285|Experimental|hetrombopag Olamine tablets|"The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were <50*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is >100*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
32856899|NCT05394285|Other|rhTPO|"The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50*109/L. When the platelet count is more than 100*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
32856900|NCT04445454|Experimental|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
32856901|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
32856902|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
32856903|NCT03018873|No Intervention|control group|routine treatment, no RIPC
32856904|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
33104540|NCT05491759|Experimental|Product 3 - Standard Fish Oil Triglyceride|"1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).~The dose will be consumed orally with 250 mL water."
33104541|NCT05295810|No Intervention|Room Air|All participants will complete an active stand breathing room air with CO2 free to fluctuate
33104542|NCT05295810|Experimental|+0mmHg CO2 Clamped at baseline|All participants will complete an active stand with their CO2 held constant at baseline
33104543|NCT05295810|Experimental|+5mmHg CO2|All participants will complete an active stand breathing +5mmHg of CO2 relative to baseline
33104544|NCT05295810|Experimental|+10mmHg|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline
33104545|NCT05295810|Experimental|+10mmHg CO2 + 50mmHg O2|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline and 50mmHg of O2
33104546|NCT04171141|Experimental|Dose Escalation|Single Agent Dose Escalation
33104547|NCT04171141|Experimental|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
33104548|NCT04171141|Experimental|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
33104549|NCT04171141|Experimental|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
33104550|NCT04171141|Experimental|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
33320637|NCT05166512|Experimental|DPP Cooks|Standard DPP plus DPP Cooks (over 12 months, with 6 active cooking sessions during the first 4 months)
33327359|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
32856905|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
32856906|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
32856907|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
32856908|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
32856909|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
32856910|NCT01672710|Experimental|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
32856911|NCT01672710|Other|waitlist|4 week waitlist with treatment as usual
32856912|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
32856913|NCT04763213||Invasive treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
32856914|NCT04763213||Medically treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
32856915|NCT04812678|Active Comparator|Physiotherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines"
32856916|NCT04812678|Experimental|Physiotherapy and Fasciatherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines, associated with Fasciatherapy Danis Bois Method"
32856917|NCT04812678|Experimental|Fasciatherapy|Fasciatherapy Danis Bois Method
32856918|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
32856919|NCT03064386|Experimental|plate group|internal fixation with the plate
32856920|NCT03064386|Experimental|screw group|internal fixation with the screw
32856921|NCT03761849|Experimental|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
32856922|NCT03761849|Experimental|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
32856923|NCT03761849|Placebo Comparator|Placebo|Placebo will be administered every 8 weeks by IT injection.
32856924|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
32856925|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
32856926|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
32856927|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
32856928|NCT05623800|Experimental|PREM-Kit group|
32856929|NCT05623800|No Intervention|Control group|
32856930|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
32856931|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
32856932|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
32856933|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
32856934|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
32856935|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
32856936|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
32856937|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
32856938|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
32856939|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
32856940|NCT04790448|Experimental|VIC regimen|"Patients will receive VIC regimen every 2 weeks:~Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 and UGT*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial)."
32856941|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
32856942|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
32856943|NCT04785066|Experimental|Study treatment|Administration of dornase alfa during intervention of thrombectomy
32856944|NCT04784052|Experimental|Depleted Stem Cell Transplant with JSP-191 Conditioning|Participants will receive an infusion of donor stem cells which have been depleted of αβ+T cells using the CliniMACS System device. Before the stem cell transplant, they will receive a reduced-intensity preparative regimen containing JSP191 in combination with rATG, cyclophosphamide, fludarabine and rituximab.
32856945|NCT04157088|Experimental|Participants treated with darolutamide|
32856946|NCT04157088|Experimental|Participants treated with enzalutamide|
32856947|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
32856948|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
32856949|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
32856950|NCT04744116|Active Comparator|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
32856951|NCT04744116|Experimental|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
32856952|NCT04744116|Experimental|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
32856953|NCT03747887|Active Comparator|School as Usual|School as usual comparison condition.
32856954|NCT03747887|Experimental|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
32856955|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
32856956|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
32856957|NCT03747809||Patients with CIEDs having Remote Monitoring|
32856958|NCT03747809||Patients with CIEDs having no Remote Monitoring|
32856959|NCT05319756|Experimental|gabapentin 600 mg single dose|
32856960|NCT05319756|Experimental|gabapentin 1200 mg single dose|
32856961|NCT05319756|Experimental|gabapentin 600 mg and oxycodone HCl 20 mg|
32856962|NCT05319756|Experimental|gabapentin 1200 mg and oxycodone HCl 20 mg|
32856963|NCT05319756|Active Comparator|oxycodone HCl 20 mg single dose|
32856964|NCT05319756|Placebo Comparator|placebo single dose|
32856965|NCT03743753|No Intervention|Control|The control group will receive the current standard educational information from the surgeon along with an information package.
32856966|NCT03743753|Experimental|Experimental|The experimental group will receive an additional educational session before their operation about what to expect during their reconstructive journey, in addition to the current standard educational information from the surgeon along with an information package.
32856967|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
32856968|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
32856969|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
32856970|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
32856971|NCT05311332|Experimental|Anterior maxillary bone augmentation using computer guided autogenous cortical shell technique.|a patient-specific guide was used to harvest a chin cortical shell which was also prepared and positioned at the (anterior horizontally atrophied maxilla) recipient site using another patient-specific positioning guide.
32856972|NCT05311332|Active Comparator|Anterior maxilla bone augmentation using free hand autogenous cortical shell technique.|the horizontally atrophic anterior maxilla was augmented with a cortical shell technique the bone was harvested from the chin without a patient-specific guide.
32856973|NCT03743051|Experimental|100mg Anamorelin HCl|
32856974|NCT03743051|Placebo Comparator|placebo|
32856975|NCT04410588|No Intervention|saline|saline for pain for nasal packing
32856976|NCT04410588|Active Comparator|levobupivacaine|levobupivacaine for pain of nasal packing
32856977|NCT04410588|Active Comparator|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
33406854|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
33406855|NCT04799327|Experimental|Treatment group A|
32856978|NCT04156620|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
32856979|NCT04156620|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
32856980|NCT05394129||SurePath™|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In SurePath™ group, subjects who underwent SurePath™ liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
32856981|NCT05394129||Conventional|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePath™ liquid cell test with the second obtained sample."
32856982|NCT03742037|Experimental|Treatment Period 1: Cenerimod 0.5 mg|"Participants will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Participants completing TP1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes the 6-month visit. This will trigger the end of treatment for all participants."
32856983|NCT03742037|Experimental|Treatment Period 1: Cenerimod 1 mg|"Participants will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Participants completing TP1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant in TP1 completes the 6-month visit. This will trigger the end of treatment for all participants."
32856984|NCT03742037|Experimental|Treatment Period 1: Cenerimod 2 mg|"Participants will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment period.~Participants completing TP1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all participants."
32856985|NCT03742037|Experimental|Treatment Period 1: Cenerimod 4 mg|"Participants will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment period 1.~Participants completing Treatment Period 1 will be re-randomized in a double-blinded fashion in Treatment Period 2 in a 1:1 ratio to placebo or cenerimod 2 mg."
32856986|NCT03742037|Placebo Comparator|Treatment Period 1: Placebo|"Participants will receive matching placebo once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Participants completing Treatment Period 1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes the 6-month visit. This will trigger the end of treatment for all participants."
32856987|NCT03742037|Experimental|Treatment Period 2: Cenerimod 2 mg (after Cenerimod 4 mg in Treatment Period 1)|"Participants completing 4 mg cenerimod in Treatment Period 1 will be re-randomized in a double-blinded fashion in Treatment Period 2 in a 1:1 ratio to cenerimod 2 mg (or to placebo).~Participants completing the 4 mg cenerimod arm in Treatment Period 1 will continue with 2 mg cenerimod in Treatment Period 2 for up to 6 additional months, or until last participant completes the 6-month visit. This will trigger the end of treatment for all participants."
32856988|NCT03742037|Placebo Comparator|Treatment Period 2: Placebo (after Cenerimod 4 mg in Treatment Period 1)|"Participants completing 4 mg cenerimod in Treatment Period 1 will be re-randomized in a double-blinded fashion in Treatment Period 2 in a 1:1 ratio to placebo (or cenerimod 2 mg).~Participants completing the 4 mg cenerimod arm in Treatment Period 1 will continue with placebo in Treatment Period 2 for up to 6 additional months, or until last participant completes the 6-month visit. This will trigger the end of treatment for all participants."
32856989|NCT03742037|Experimental|Treatment Period 2: Cenerimod 0.5 mg (after Cenerimod 0.5 mg in Treatment Period 1)|Participants completing Treatment Period 1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes their 6-month visit. This will trigger the end of treatment for all participants.
32856990|NCT03742037|Experimental|Treatment Period 2: Cenerimod 1 mg (after Cenerimod 1 mg in Treatment Period 1)|Participants completing Treatment Period 1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes their 6-month visit. This will trigger the end of treatment for all participants.
32856991|NCT03742037|Experimental|Treatment Period 2: Cenerimod 2 mg (after Cenerimod 2 mg in Treatment Period 1)|Participants completing Treatment Period 1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes their 6-month visit. This will trigger the end of treatment for all participants.
32856992|NCT03742037|Placebo Comparator|Treatment Period 2: Placebo (after Placebo in Treatment Period 1)|Participants completing Treatment Period 1 will continue their study double-blind treatment unchanged during Treatment Period 2 for up to 6 additional months, or until last participant completes their 6-month visit. This will trigger the end of treatment for all participants.
32856993|NCT05303220|Experimental|Part 1 Treatment A|
32856994|NCT05303220|Experimental|Part 1 Treatment B|
32856995|NCT05303220|Experimental|Part 1 Treatment C|
32856996|NCT05303220|Experimental|Part 1 Treatment D|
32856997|NCT05303220|Experimental|Part 2 Treatment A|
32856998|NCT05303220|Experimental|Part 2 Treatment B|
32856999|NCT05303220|Experimental|Part 2 Treatment C|
32857000|NCT05303220|Experimental|Part 3 Treatment A|
32857001|NCT05303220|Placebo Comparator|Part 3 Treatment B|
32898868|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
33104551|NCT04171141|Experimental|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
33406856|NCT04799327|Experimental|Treatment group B|
32857002|NCT04444830|No Intervention|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
33104552|NCT04171141|Experimental|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
33320638|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
32857003|NCT04444830|Experimental|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
32857004|NCT01273259|Experimental|200 mg /day arm|
32857005|NCT01273259|Experimental|25 mg/day arm|
32857006|NCT05273580||Patients|Eligible patients will be identified by the Nurse Practitioner Cancer & Palliative Care.
32857007|NCT05273580||Carers|The respective carers who are identified by the Nurse Practitioner Cancer & Palliative Care as eligible participants.
32857008|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
32857009|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
32857010|NCT04717362|Experimental|Standard Reboot with Natesto|Standard Reboot Protocol + Natesto
32857011|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
32857012|NCT04692012|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
32857013|NCT04689594|Experimental|CLS2702C/CLS2702D|
32857014|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
32857015|NCT04147884|Experimental|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
32857016|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
32857017|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
32857018|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
32857019|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
32857020|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
32857021|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
32857022|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
32857023|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
32857024|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
32857025|NCT04667520|Experimental|LPA+Fitbit|Participants in this group receive a Lifestyle Physical Activity intervention and are provided with a Fitbit to collect activity data
32857026|NCT04667520|Active Comparator|Fitbit Only|Participants in this group are provided with a Fitbit to collect activity data
32857027|NCT00976599|Experimental|CP-690,550 + methotrexate|
32857028|NCT00976599|Placebo Comparator|Placebo + methotrexate|
33104553|NCT04157153|Experimental|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 60 months.
33104554|NCT05338242|Experimental|Real-Time Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
33104555|NCT05338242|No Intervention|No Feedback|Participants will have exposure levels monitored by the same device, but it will only display the date/time and will not provide real-time feedback.
33104556|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
32962054|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
32962055|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
32962056|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
33406857|NCT04799327|Experimental|Treatment group C|
32962057|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
32962058|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
32962059|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
32962060|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
32962061|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
32962062|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
33406858|NCT04799327|Placebo Comparator|Treatment group D|
32962063|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
33320639|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33406859|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
32962064|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
32962065|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
32962066|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
32962067|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
32962068|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
32962069|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
32962070|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
32962071|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
32962072|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX~Questionnaires~Peripheral nervous system examination~Whole Genome Sequence"
32962073|NCT01843140||Young female cancer survivors|
32962076|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
32962077|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
33327360|NCT01178892|Placebo Comparator|Placebo|
33327361|NCT01178892|Experimental|Omega-3|
32962078|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
33327362|NCT01178892|Experimental|Yoga|
33327363|NCT01178892|Experimental|Exercise|
33327364|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
32962079|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
32962080|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
33327365|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
32962081|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
33327366|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
32962082|NCT01600170|Active Comparator|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
33327367|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
32962083|NCT01600170|Placebo Comparator|Placebo|Participants were given Placebo tablets for 12 weeks.
32962084|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
32962085|NCT01600482|No Intervention|Manual Compression|Manual Compression
32962086|NCT01600638|Experimental|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
32962087|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
32962088|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
32962089|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
32962090|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
32962091|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962092|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
32962093|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
32962094|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32962095|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32962096|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
32962097|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
32962098|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
32962099|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
32962100|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
32962101|NCT01610154|Experimental|Sitagliptin treatment|
32962102|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
32962103|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
32962104|NCT01612494|Placebo Comparator|Normal Saline|
32962105|NCT01612494|Experimental|Hypertonic Saline|
32962106|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
32962107|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
32962108|NCT01614210|Experimental|All patients|All patients enrolled in the study.
32962109|NCT01616082|Active Comparator|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI >27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
32962110|NCT01616082|Active Comparator|Overweight/obese with Phentermine|After screening, overweight/obese (BMI >27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
32962111|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
32962112|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
33104557|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
33104558|NCT05331456|Other|Alveolar cleft repair using autologous bone from the mandibular symphysis|
33104559|NCT05331456|Other|Alveolar cleft repair using a biphasic clacium phosphate putty|
32857029|NCT04661982||Observational (long term follow-up)|Patients undergo long term follow-up and complete questionnaires.
32857030|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
32857031|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
32857032|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
32857033|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
32857034|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
32857035|NCT03729011|Active Comparator|Volatile anesthesia group|
32857036|NCT03729011|Active Comparator|TIVA group|
32857037|NCT05264922|Active Comparator|Fibrin Glue|Single 4 milliliter (mL) injection of 0.9% normal saline and fibrin glue solution
32857038|NCT05264922|Experimental|SVF cells and Fibrin Glue|Nucleated adipose-derived cells loaded in a fibrin glue scaffold
32857039|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
32857040|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
32857041|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
32857042|NCT03727451|Experimental|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
32857043|NCT03727451|Experimental|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
32857044|NCT04444518|Experimental|VAX-MOM Intervention|
32857045|NCT04444518|Active Comparator|Standard of Care|
32857046|NCT03727061|Active Comparator|Arm A (standard of care chemotherapy at doctor's discretion)|Patients receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion
32857047|NCT03727061|Experimental|Arm B(porfimer sodium, I-PDT, SoC chemotherapy)|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later. Patients also receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion at either 7 days, 14 days, or 28 days later.
32857048|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
32857049|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
32857050|NCT04443660||Group C|with risk of complication, having a normal pregnancy
32857051|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
32857052|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
32857053|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
32857054|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
32857055|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
32857056|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
32857057|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
32857058|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate monoester|Cross-over study in 8 patients receiving single-dose oral 3-hydroxybutyrate monoester, 3-OHB salt and placebo.
32857059|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate Salt|
32857060|NCT04443426|Placebo Comparator|Single dose oral placebo|maltodextrin-based, isocaloric to ketone dosis.
32857061|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
32857062|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
32857063|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
32857064|NCT04348565|Experimental|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
33104560|NCT04107389|Active Comparator|Intervention Group|Receives Art Therapy assessment and intervention
33104561|NCT04107389|Active Comparator|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
33104562|NCT05329116|Active Comparator|Intra-articular PRP|For PRP treatment, 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection. Patients will receive a single session of PRP treatment.
33104563|NCT05329116|Active Comparator|Intra-articular PRP + periarticular mesotherapy|"In addition to single session PRP treatment, patients will receive 3 weeks of mesotherapy treatment once a week (the first session will be with PRP treatment).~Sterile and disposable needle tip (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used in mesotherapy. Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used."
33104564|NCT04107116|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
33104565|NCT04107116|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
33104566|NCT04105595||ASD patients|
33104567|NCT04105595||PFO patients|
33104568|NCT05270148|Experimental|HIIT Group|Participants are enrolled in a high-intensity interval training exercise program
33104569|NCT05270148|Active Comparator|FatMax Group|Participants who are enrolled in a moderate-intensity continuous training exercise program
33104570|NCT05270148|No Intervention|Control|Participants who do not receive an exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
33104571|NCT04096274|Experimental|LOCI (Intervention)|Agencies in the intervention group will receive leadership training and coaching in addition to training and technical assistance to implement the digital measurement based care system.
33327368|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
32857065|NCT04348565|No Intervention|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
32857066|NCT04443192|Active Comparator|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
32857067|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Single Dose|Single oral dose of placebo by mouth in the fasted state
32857068|NCT04443192|Active Comparator|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
32857069|NCT04443192|Active Comparator|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
32857070|NCT04443192|Active Comparator|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
32857071|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Two Doses|Two doses of placebo (12 h apart) by mouth in the fasted state
32857072|NCT04443192|Active Comparator|Part A Cohort 5 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
32857073|NCT04443192|Active Comparator|Part A Cohort 6 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
32857074|NCT04443192|Active Comparator|Part A Cohort 7 - ZF874 - Single Dose|Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
32857075|NCT04443192|Active Comparator|Part B Cohort 1 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
32857076|NCT04443192|Placebo Comparator|Part B Cohort 1 - Placebo to ZF874|Two doses of placebo (12 h apart) by mouth daily for 28 days.
32857077|NCT04443192|Active Comparator|Part B Cohort 2 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
32857078|NCT04443192|Active Comparator|Part B Cohort 3 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
32857079|NCT04443192|Active Comparator|Part B Cohort 4 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
32857080|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
32857081|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
32857082|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
32857083|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
32857084|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
32857085|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
32857086|NCT01670526|Placebo Comparator|Placebo|Placebo
32857087|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
32857088|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
32857089|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
32857090|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
32857091|NCT05212038|Experimental|liopsoas plane block group|Arm Description: a iliopsoas plane block before surgery
32857092|NCT05212038|Sham Comparator|sham block group|sham block before surgery
32857093|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
32857094|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
32857095|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
32857096|NCT04432740|Active Comparator|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
32857097|NCT04432740|Active Comparator|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
32857098|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
32857099|NCT03720197||Participants aged less than 14 years old|
32857100|NCT03720197||Participants aged 14 years old and older|
32857101|NCT05187156|Experimental|Intervention|Veterans will participate in a novel intervention to improve PTSD and social support
32857102|NCT05187156|Active Comparator|Treatment as usual|Veterans will participate in usual care in PCMHI
32857103|NCT05386953||Balanced group|Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery
32857104|NCT05386953||Saline group|Patients who received only normal saline during liver transplantation surgery
32857105|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
32857106|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
32857107|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
32857108|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
32857109|NCT03719573|No Intervention|control.|Usual treatment and care.
32857110|NCT05176548||Group 1|Patients in whom Cardiac Amyloidosis is confirmed
32857111|NCT05176548||Group 2|Patients in whom Cardiac Amyloidosis is ruled out
32857112|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.~Chemotherapy Regimen:~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.~Allogeneic Stem Cell Transplant if donor available and not in PD."
32857113|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).~Chemotherapy Regimen:~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
32857114|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
32898869|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
33104572|NCT04096274|Placebo Comparator|Implementation As Usual (Control)|Agencies in the control group will receive web-based leadership training in addition to training and technical assistance to implement the digital measurement based care system.
32857115|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
32857116|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
32857117|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
32857118|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
32857119|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
32857120|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
32857121|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
32857122|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
32857123|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
32857124|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
32857125|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
32857126|NCT03709043|Experimental|Kudzu|Standardized kudzu
32857127|NCT03709043|Placebo Comparator|Control|Placebo
32857128|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
32857129|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
32857130|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
32857131|NCT04763057|Experimental|indirect pulp treatment with NeoPUTTY MTA|
32857132|NCT04763057|Active Comparator|indirect pulp treatment with calcium hydroxide|
32857133|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
32857134|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
32857135|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
32857136|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
32857137|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
32857138|NCT03706625||Immunocompetent Non-Hodgkin-Lymphoma|Immunocompetent patients and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
32857139|NCT03706625||Immunocompetent Non-small cell lung cancer|Immunocompetent patients suffering from non-small cell lung cancer and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
32857140|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
32857141|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
32857142|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
33104573|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
33104574|NCT04069637||Control group|Patients with operative fractures.
32857143|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
32857144|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
32857147|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
32857148|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
32857149|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule~1 capsule daily from 28 weeks until the time of birth."
32857150|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
32857151|NCT03696797|Active Comparator|Treatment Group|Will have a Unit of blood (two cups, the same amount donated at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure your blood count to be sure you are not anemic, and blood pressure to be sure no dehydration. During or after donation, a sports drink is provided to replace the fluid loss. Phlebotomy
32857152|NCT03696797|Sham Comparator|Control Group|Will not donate blood, but will have a needle inserted into a vein in your arm. Both groups will not know which group assignment they have been randomized. Sham Phlebotomy
32857153|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
32857154|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
32857155|NCT03695237|Experimental|Participants receiving Leuprolide Acetate (LA)|Participants with Central Precocious Puberty receiving LA
32857156|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
32857157|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
32857158|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
32857159|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
32857160|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
32857161|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
32857162|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
32857163|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.~Classification ASA 2-4"
32857164|NCT03692663|Experimental|TABP EIC treatment group|Drug: TABP EIC Experimental Interventional Therapy
32857165|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
32857166|NCT02084069|Placebo Comparator|Control|Placebo
32857167|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
32857168|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
32857169|NCT05117112|Experimental|10g of nutritional product|All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
32857170|NCT04439292|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33104575|NCT04002830|Experimental|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
33104576|NCT03995771||Children and adolescents with knee pain|Children and adolescents (8-19 years old) presenting to general practice for knee pain
32857171|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
32857172|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
32857173|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
32857174|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
33104577|NCT05309031|Experimental|Immersion|This group will receive the immersion intervention
33327369|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.~other names: ''flowable composite ''"
33327370|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
32857175|NCT04438356|Experimental|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
32857176|NCT04438356|Experimental|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
32857177|NCT04628988|Experimental|CC-90011 in combination with Abiraterone and Prednisone|Oral administration (PO) of CC-90011 monotherapy administered once per week (QW), for 4 weeks. From cycle 2 onwards, all participants will receive 60 mg of CC-90011 PO QW, in combination with 100 mg of abiraterone PO daily, and 5 mg of prednisone PO every 12 hours (10mg QD)
32857178|NCT04626024|Experimental|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for > 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
32857179|NCT03682601|Placebo Comparator|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
32857180|NCT03682601|Active Comparator|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
32857181|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
32857182|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
32857183|NCT03680729|Experimental|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
32857184|NCT03680729|Active Comparator|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
33104578|NCT03921554|Experimental|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
33327371|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
33327372|NCT02525328||CT subjects|blood or saliva specimen
32857185|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
32857186|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
32857187|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
32857188|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
32857189|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
32857190|NCT03679559|Active Comparator|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
32857191|NCT03679559|Active Comparator|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
32857192|NCT04432896|Experimental|New dietary protocol|Exclusion of food containing nickel (duration: 4 weeks) + gradual weekly reintroduction of food containing nickel (duration: 4 weeks) under the supervision of a trained dietician who monitors symptoms related to systemic nickel allergy syndrome.
32857193|NCT04432896|Active Comparator|Traditional dietary protocol|Exclusion of foods containing nickel without monitoring for symptoms related to systemic nickel allergy syndrome by a trained dietician.
32857194|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
32857195|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
32857196|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
32857197|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.~Passed the safety screen for MRI~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
32857198|NCT04571580|Placebo Comparator|placebo|intracoronary infusion with saline
32857199|NCT04571580|Experimental|reteplase 9mg|intracoronary infusion with reteplase 9mg
32857200|NCT04571580|Experimental|reteplase 18mg|intracoronary infusion with reteplase 18mg
32857201|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
32857202|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
32857203|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
32857204|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
32857205|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
32857206|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
32857207|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
32857208|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
32857209|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
32857210|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
32857211|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
32857212|NCT03675737|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
32962113|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
32962114|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
32962115|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
32962116|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962117|NCT01620216|Experimental|Group II (sutinib malate)|Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962118|NCT01620216|Experimental|Group III (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962119|NCT01620216|Experimental|Group IV (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
32962120|NCT01620216|Experimental|Group V (pacritinib)|Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962121|NCT01620216|Experimental|Group VI (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962122|NCT01620216|Experimental|Group VII (idelalisib)|Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962123|NCT01621230|Active Comparator|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
32962124|NCT01621230|Placebo Comparator|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
32962125|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
32962126|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
32962127|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
32962128|NCT01622010|Experimental|Standard care with video enhancement|"Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management."
32962129|NCT01622010|Active Comparator|Standard care|Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.
32962130|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
32962131|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
32962132|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
32962133|NCT01627002|Placebo Comparator|Placebo|Placebo
32962134|NCT01628016|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.~ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
32962135|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
32962136|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
33327373|NCT02525328||subjects without CT|blood or saliva specimen
32962137|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
32962138|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
32962139|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
32962140|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
32962141|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
32962142|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
32962143|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
32962144|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
32962145|NCT01634256|Experimental|Fermented turmeric|
32962146|NCT01634256|Placebo Comparator|Placebo|
32962147|NCT01635504|Experimental|botulinum toxin A|
32962148|NCT01636206|Placebo Comparator|Placebo|Placebo
32962149|NCT01636206|Experimental|Lifitegrast|Active
32962150|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
32962151|NCT01638312||HIV infection patient and health people|The study does not have intervention
32962152|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
32962153|NCT01639872|Experimental|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
32962154|NCT01639872|Active Comparator|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
32962155|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
32962156|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
32962157|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
32962158|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
32962159|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
32962160|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
32962161|NCT01641978||ICU patients|neurological level in critical patients
32962162|NCT01642056|Experimental|EPI-743, then Placebo|Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals, then placebo three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
32962163|NCT01642056|Placebo Comparator|Placebo, then EPI-743|Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
32962164|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
32962165|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
32962166|NCT01643616|Active Comparator|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
32962167|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
32962168|NCT01644240|Experimental|TD-8954 Dose 1|
32962169|NCT01644240|Placebo Comparator|Placebo|
32962170|NCT01644240|Experimental|TD-8954 Dose 2|
32962171|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
33327374|NCT02525172|Experimental|ITT|immune modulation therapy
33327375|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
33327376|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
33327377|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
33327378|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
33406860|NCT05705622|Experimental|Experimental intervention group|"Sociodemographic information, comorbidity, habits and disease information of the patients included in the experimental group were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. After the diagnosis of oral mucositis was made, a pre-test was performed using the Oral Mucositis Knowledge Level Evaluation Form to measure the oral mucositis knowledge level of the patients. Later, the patients included in the experimental group were given training on the evaluation, prevention, care and treatment of oral mucositis, and a training booklet was given for the benefit of the patients."
32962172|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
32962173|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
32962174|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
32962175|NCT01647438|Other|Print Health Education|Participants receive print health education materials
32962176|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
32962177|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
32962178|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
32962179|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
32962180|NCT01650324|Experimental|DBPR108|
32962181|NCT01650324|Placebo Comparator|matching placebo|
32962182|NCT01650402|Experimental|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
32962183|NCT01650402|Active Comparator|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
32962184|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
32962185|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
32962186|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
32962187|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
32962188|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
32962189|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
32962190|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
32962191|NCT01652040|Experimental|Tp|Applying Testosterone patches
32962192|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
32962193|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
32962194|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
32962195|NCT01654068|Experimental|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
32962196|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
32962197|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
32962198|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
32962199|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
32962200|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
33104579|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis~Failed previous shoulder joint replacement"
33104580|NCT05307510|Active Comparator|Intervention A - prefabricated splint|A prefabricated splint is provided to the client
32857213|NCT03675737|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
33104581|NCT05307510|Experimental|Intervention B - custom orthosis|a custom orthosis (wrist splint with thumb spica) is fabricated by an occupational therapist
33104582|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
33104583|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
33104584|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
33104585|NCT05264142|Experimental|CYP2C19 Rapid Metabolizers (RM)|CYP2C19 rapid metabolizers (RM) are characterized by one normal function allele and one increased function allele
33104586|NCT05264142|Experimental|CYP2C19 Normal metabolizers (NM)|CYP2C19 normal metabolizers (NMs) harboring two normal function alleles defined by the lack of any characterized polymorphisms.
33104587|NCT05264142|Experimental|CYP2C19 Intermediate metabolizers (IM)|CYP2C19 intermediate metabolizers (IMs) are characterized by the presence of one normal function allele and one no function allele or one no function allele and one increased function allele.
32857214|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
32857215|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
32857216|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
32857217|NCT03979794|Experimental|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
32857218|NCT03979794|No Intervention|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
32857219|NCT04536480|Experimental|Control: 12 hour eating period|Control: Habitual daily eating period (no meal time restrictions)
32857220|NCT04536480|Experimental|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting).
32857221|NCT04762667|Experimental|Patients will undergo reverse shoulder arthroplasty with patient-specific instrumentation.|The patients underwent preoperative planning. A 3D model was made based on CT. The optimal position of the components of the endoprosthesis has been calculated. patient-specific instrumentation were created for each scapula and humerus using 3D modeling software. Individual guides use during operation for exact position of the components of the endoprosthesis.
32903586|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
32903587|NCT04387526|Active Comparator|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients"
32903588|NCT04387526|Active Comparator|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
32903589|NCT04387526|Active Comparator|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
32903590|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
32903591|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
32903592|NCT02997488||McGrath|McGrath Videolaryngoscope
32903593|NCT02997488||Pentax|Pentax Airwayscope
32903594|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
32903595|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
32903596|NCT04345094|Experimental|Comparator|Emulsion containing 1% Hexylresourcinol
32903597|NCT04345094|Active Comparator|Intervention|Emulsion containing 2% Hydroquinone
32903598|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
32962201|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
32962202|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
32962203|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
32962204|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
32962205|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
32962206|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
32962207|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
32962208|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
32962209|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
32962210|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
32962211|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
32962212|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
32962213|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
32962214|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
32962215|NCT01661712|Sham Comparator|Sham stimulation|One night of sham stimulation (no electrical current)
32962216|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
32962217|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
32962218|NCT01662882|Experimental|AD Subjects|
32962219|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
32962220|NCT01662882|Experimental|Healthy Controls|
32962221|NCT01662960|Experimental|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
32962222|NCT01662960|Active Comparator|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
32962223|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
32962224|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
32962225|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
32962226|NCT01667406|Experimental|Kisspeptin-54, 1.6 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
32962227|NCT01667406|Experimental|Kisspeptin-54, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
32962228|NCT01667406|Experimental|Kisspeptin-54, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
32962229|NCT01667406|Experimental|Kisspeptin-54, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
32962230|NCT01667406|Experimental|Kisspeptin-54 OHSS, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
32962231|NCT01667406|Experimental|Kisspeptin-54 OHSS, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
32962232|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
32962233|NCT01667406|Experimental|Kisspeptin-54 OHSS, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
32962234|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + 9.6|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
32962235|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + saline|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later
33406861|NCT05705622|No Intervention|No intervention control group|The first follow-up of the patients included in the control group was made in the patient's room on the day of their admission to the bone marrow transplant unit. Sociodemographic information, comorbidity, habits and disease information of the patients were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. The patients in the control group were not given training on oral mucositis and the training booklet prepared by the researcher was not given.
32739094|NCT05714267|Experimental|Passive noise cancelling|The patients corresponding to the number 2 blocks in the randomization table according to the order of operation were included in the passive noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, passive noise control headset (3M Peltor Optime II) was placed on the patient's head. The earphone was not removed until the dressing of the patient was closed at the end of the surgery. In this group, the vital signs of the patients were followed up during the surgery. At the end of each operation, the earplugs were disinfected by the researcher with an antiseptic solution containing 2% chlorhexidine and prepared for the next patient.
32962236|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
32962237|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
32962238|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
32962239|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
32962240|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
32962241|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
32962242|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
32962243|NCT01673256||SJM Confirm ICM Observational Group|
32962244|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
32962245|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
32962246|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
32962247|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
32962248|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
32962249|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
32962250|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
32962251|NCT01678794|Experimental|Candesartan|
32962252|NCT01678794|Placebo Comparator|Placebo|
32962253|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
32962254|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
32962255|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
32962256|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
32962257|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
32962258|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
32962259|NCT01680666|Active Comparator|landmark guided|central line placement
32962260|NCT01680666|Active Comparator|ultrasound guided|central line placement
32962261|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
32962262|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
32962263|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
32962264|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
32962265|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
32962266|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
32962267|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
32962268|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
32962269|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
32962270|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
32962271|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
32962272|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
32962273|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
32962274|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~HIV voluntary counseling and testing & staging~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~Substance abuse counseling~Sexually transmitted infection screening and treatment~Access to free antiretroviral therapy and adherence support~Peer community outreach"
32962275|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
32962276|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
32962277|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
32962278|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
32962279|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
32962280|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
32962281|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
32962282|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
32962283|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
32962284|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
32962285|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
32962286|NCT01695330|Experimental|Subcutaneous bortezomib|
32962287|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
32962288|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
32962289|NCT01698684|Placebo Comparator|Placebo|
32962290|NCT01698684|Experimental|Avanafil 100 mg|
32962291|NCT01698684|Experimental|Avanafil 200 mg|
32962292|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
32962293|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
32962294|NCT01699698|Experimental|Test subject|
32962295|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
32962296|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
32962297|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
32962298|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
32962299|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
32962300|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
32962301|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
32962302|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
32962303|NCT01703598|Experimental|DBS surgery|Single arm
32962304|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
32962305|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
32962306|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
32962307|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
32962308|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
32962309|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
32962310|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
32962311|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
32962312|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
32962313|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
32962314|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
32962315|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
32962316|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
32962317|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
32962318|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
32962319|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
32962320|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
32962321|NCT05711238|Experimental|Robot Assisted Therapy Group|"Investigators planned to apply robotic rehabilitation therapy with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 40 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience for the hands on the affected side of the children in the Robot Assisted Therapy Group group.~Amadeo (Tyromotion, Graz, Austria) is an end-effector device designed for the hand. It is a groove-shaped device attached to the forearm using magnets using bandages on the fingers."
32962322|NCT05711238|Active Comparator|Conventional Therapy Group|"Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.~A total of 30 sessions of treatment were planned for both groups, 5 days a week. It will be recommended that they continue with the same dose of the medical treatment they have been using during the treatment program. Children will be evaluated by a physiatrist blinded to groups before and after treatment."
32962323|NCT05711082|Active Comparator|Dopamine precursor|In the first condition, volunteers will receive a dopamine (DA) precursor (L-dopa, 100mg). L-dopa will be combined with a dose of an Aromatic amino acid decarboxylase inhibitor (Benserazide) 25mg to multiplicate its bioavailability and with a dose of domperidone 10mg (peripheral antagonist of DA) to minimize the risk of side effects.
32962324|NCT05711082|Active Comparator|D2 antagonist|In the second condition, volunteers will receive a D2 antagonist (Sulpiride, 800mg)
32962325|NCT05711082|Placebo Comparator|PLACEBO|In the third condition, volunteers will receive a placebo (lactose)
32962326|NCT05711004|Experimental|SMS group|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
32962327|NCT05711004|No Intervention|Control group|Patients in the control group will also receive the usual primary health care.
32962328|NCT05710926|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Personality Disorder as manualized by Beck, Davis, Freeman and Beck in their book (2016) will be delivered to partecipants in the active control group.
32962329|NCT05710926|Experimental|Evolutionary Systems Therapy for Schizotypy|Evolutionary Systems Therapy for Schizotypy as manualized by Cheli and colleagues in their trial (2023) will be delivered to partecipants in the experimental group.
32962330|NCT05710770|Active Comparator|Immunoadsorption|"Immunoadsorption will be conducted with the TheraSorb LIFE21 apheresis system in combination with the TheraSorb-Ig omni 5 adsorber over a period of 10 days: each participant will receive five immunoadsorption cycles treating 2.0 - 2.5 patient's plasma volumes every other day. Initial pilot studies have demonstrated this dose finding to be effective and well tolerated (Scheibenbogen et al., 2018; Tolle et al., 2020). The immunoapheresis material will be provided by the Miltenyi company at the beginning of the study.~Concerning the high effectiveness of immunoadsorption therapy in patients with other neuroimmunological diseases and the invasiveness of a sham-apheresis, a 2:1 randomization was chosen in order to ensure that more patients will receive a verum IA treatment."
32903599|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
32903600|NCT01284335|Experimental|Gemcitabine plus LY573636|
32903601|NCT01284335|Experimental|Docetaxel plus LY573636|
32903602|NCT01284335|Experimental|Temozolomide plus LY573636|
32903603|NCT01284335|Experimental|Cisplatin plus LY573636|
32903604|NCT01284335|Experimental|Erlotinib plus LY573636|
32903605|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
32903606|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
32903607|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
32903608|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
32903609|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
32903610|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
32903611|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
32903612|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
32903613|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
32903614|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
32903615|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
32903616|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
32903617|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
32903618|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
32903619|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
32907452|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
33406862|NCT05487378|Other|1st GOLIKE PLUS 3-16 2nd AA protein substitute|7 days with usual protein substitute and GOLIKE PLUS as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE followed by a 2-week washout period on their usual protein substitute, and then 7 days with AA protein substitute for all daily doses.
32857222|NCT04762667|Other|Patients will undergo conventional reverse shoulder arthroplasty.|This group of patients was examined according to the standard method, Rg and CT of the shoulder joint were performed. According to the study, the sizes of the endoprosthesis were selected. Installation of the components of the endoprosthesis during the operation was carried out using standard (included in the set) guides. Orientation was performed according to the anatomical landmarks of the glenoid and the neck of the humerus, without taking into account the individual characteristics of the bones.
32857223|NCT05376735|Experimental|Purrble intervention + Single Session Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~Initial guided reflection exercise~Short interactive psychoeducation~Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
32857224|NCT05376735|No Intervention|Treatment as usual / Waiting list|Participants in the control group will be given a Purrble & access to the online SSI intervention before the academic term ends, after 4 week follow-up questionnaires are completed.
32857225|NCT04762745|Experimental|Phase I, Cohort 1|The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
32857226|NCT04762745|Experimental|Phase I, Cohort 2|The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
32857227|NCT04762745|Experimental|Phase I, Cohort 3|The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
32857228|NCT04762745|Experimental|Phase II|The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.
32857229|NCT05373927||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
32857230|NCT05373927||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
32857231|NCT03673865|Experimental|Treatment Group|Patients undergo orbital reconstruction using pre-adjusted patient-specific orbital implants with office-based 3-dimensional printers (OB3DP)
32857232|NCT03673865|Active Comparator|Control Group|Patients undergo orbital reconstruction with non-patient-specific orbital implants (traditional approach, Control Group) which is a standard stock orbital plate
32857233|NCT05114616|Experimental|Sleep Study and Daytime MWT|Health volunteers completing one overnight sleep study followed by daytime MWT. The sleep study will include standard surface electrodes as well as EEGBuds. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
32857234|NCT05335473|Experimental|Eribulin plus Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
32857235|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
32857236|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
32857237|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
33406863|NCT05487378|Other|1st AA protein substitute 2nd GOLIKE PLUS 3-16|7 days with AA protein substitute for all daily doses followed by a 2-week washout period on their usual protein substitute, and then 7 days with usual protein substitute and GOLIKE PLUS as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE
33406864|NCT05555550|Experimental|18F-Fluciclovine|18F-Fluciclovine PET-MRI
33406865|NCT05470218|Active Comparator|Standard protein meal|Participants will receive a standard protein meal, containing about 10% of energy as protein
33406866|NCT05470218|Active Comparator|High protein meal|Participants will receive a high protein meal, containing about 50% of energy as protein
32857238|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:~≥18 years~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)~NYHA functional class I-III~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).~Able to perform an symptom limited exercise test.~Capacity and willingness to sign the informed consent form."
32857239|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
32857240|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
32857241|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
32857242|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
32857243|NCT00983541|Experimental|All patients|All participants enrolled.
32857244|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
32857245|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
32857246|NCT05323383|Experimental|Mindfulness meditation|Participants in the mindfulness meditation condition will practice one, 20-minute breath and body focused meditation.
32857247|NCT05323383|Active Comparator|Self-Hypnosis|Participants in self-hypnosis will practice one, 20-minute audio-guided hypnosis session with suggestions tailored towards enhancing positive affect and fostering decentering.
32857248|NCT05323383|Other|Control|Participants in the attention control condition will listen to a 20-minute natural history recording.
32857249|NCT05098002|Experimental|Mindful based stress classes|6 week mindfulness program
32857250|NCT05319405|Active Comparator|Sana plus Treatment as Usual|Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.
32857251|NCT05319405|No Intervention|Treatment as Usual|Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).
32857252|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
32857253|NCT05074056|Experimental|Ketorolac|A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.
32857254|NCT05074056|Placebo Comparator|Placebo|A double-blinded number of children will get one dose of intravenous placebo intraoperatively.
32857255|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
32857256|NCT03659669||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label.
32857257|NCT05061420|Experimental|Cohort A1 (sub study 01) treatment- naïve|Participants with HNSCC, who are treatment-naïve for R/M disease and have a PD-L1 Combined Positive Score (CPS) ≥1, will receive pembrolizumab followed by SAR444245. Both drugs administered by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles.
32857258|NCT05061420|Experimental|Cohort B1: (sub study 04) PD1/PD-L1 and platinum-based treatments|Participants with HNSCC who have received treatment with a PD1/PD-L1-based regimen & platinum-based regimen and have failed no more than 2 regimens for R/M disease, will receive pembrolizumab followed by SAR444244. Both drugs administered IV infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles
32857259|NCT05061420|Experimental|Cohort B2: (sub study 05) cetuximab- naïve|Participants with R/M HNSCC, who are cetuximab-naïve, have received treatment with a platinum-based regimen, and have failed no more than 2 regimens for R/M disease, will receive treatment with cetuximab followed by SAR444245. Cetuximab IV will be given on days 1, 8, and 15 of each 21 day. SAR444245 will be administered by IV infusion on Day 1 of each 21-day treatment cycle. Dosing of both drugs is to continue until disease progression, unacceptable toxicity, or withdrawal of consent.
32857260|NCT05208177|Experimental|SHR-1802 for injection combined with Camrelizumab for Injection and Famitinib Malate Capsules|
32962331|NCT05710770|Sham Comparator|Sham-apheresis|To have identical conditions to the immunoadsorption, sham apheresis will also be conducted with the TheraSorb LIFE21 apheresis system over a period of 10 days: each participant will receive five sham cycles. For the sham apheresis, a TheraSorb LIFE21 unit without an Ig adsorber will be used. The LIFE 21 apheresis unit will be placed behind a curtain ensuring that the patient and the investigator are blinded. The study nurses applying the treatment (a specific person only in charge of the patient during the treatment) cannot be blinded.
32962332|NCT05710692|Experimental|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks (available only in the optional extension part)
32962333|NCT05710614|Active Comparator|animal protein|Whey protein will be used as the active comparator for animal protein arm
32962334|NCT05710614|Experimental|plant protein|A combination of pea and soy protein will be used as the experimental arm
32962335|NCT05710458|Experimental|25 gauge 20,000 cpm Hypervit Dual Blade|New vitrectomy blade with higher cutting rate
32962336|NCT05710458|Active Comparator|25 gauge 10,000 Ultravit vitrectomy cutter|Existing vitrectomy blade with cutting rate 10,000 cut/min
32962337|NCT05710380|Experimental|All Participants (Single Arm)|All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.
32962338|NCT05710302||Patients diagnosed with acute heart failure in the emergency department|Patients with acute heart failure.
32962339|NCT05710146|Experimental|Tranexamic Acid|Patients will be injected with 15 mg/kg of tranexamic acid in 100mL of normal saline via IV access normally established for this procedure.
32962340|NCT05710146|Placebo Comparator|Placebo|Patients will be injected with 100mL of normal saline via IV access normally established for this procedure.
32962341|NCT05710068|Experimental|Conventional therapy with RF microneedle|Half face Oral tranexamic acid combined with triple combination cream with RF microneedle
32962342|NCT05710068|Active Comparator|Conventional therapy|Half face Oral tranexamic acid combined with triple combination cream
32962343|NCT05709912|Experimental|CARE App|"Participants randomized to the CARE app + usual care will complete the following:~Questionnaires at baseline, Day 10, Day 60, and Day 100 post-HCT~use the CARE app from enrollment up to 60 days post-HCT: the CARE app includes 5 contains 5 modules and a 6th optional module~receive usual care as per HCT practice which entails meeting with a transplant social worker prior to HCT and as needed for extra visits"
32962344|NCT05709912|Active Comparator|Usual Care|"Participants randomized to usual care will complete the following:~Questionnaires at baseline, Day 10, Day 60, and Day 100.~receive usual care as per HCT practice, which entails meeting with a transplant social worker prior to HCT and as needed for extra visits."
32962345|NCT05709834|Experimental|Autogenic training|It consists of patients who will receive autogenic training and conventional treatment with the frequency of 3 times per week for 4 weeks.
32962346|NCT05709834|Other|Control group|Its consists of patients who will receive conventional treatment with the frequency of 3 sessions per week
32962347|NCT05709678|Placebo Comparator|Control|Group Education (General nutrition and sport nutrition)
32962348|NCT05709678|Active Comparator|Treatment|Group Education (General nutrition and sport nutrition with athlete testimonials on impacts of RED-S on health)
32962349|NCT05709522||Pediatric brain tumor patients|The study participants will be 5 to 21 years old children with newly diagnosed brain tumors presenting with any stage, who have not undergone any treatment
32962350|NCT05709522||Blood cancer children|The study participants will be 5 to 21 years old children with newly diagnosed blood cancer presenting with any stage, who have not undergone any treatment
32962351|NCT05709444|Experimental|Subcutaneous Bremelanotide|BMT sterile aqueous solution for injection provided as a prefilled syringe, administered by subcutaneous (SQ) injection into the abdomen.
32962352|NCT05709210|Other|Memory complaint|
32962353|NCT05709210|Other|mild cognitive decline|
32962354|NCT05709210|Other|Alzheimer's Disease|
32962355|NCT05708352|Experimental|Keto-Diet|Intensive 18-week Keto Diet intervention.
32962356|NCT05708352|Placebo Comparator|Usual Diet|Usual Diet with Dietitian support
32962357|NCT05706636|Active Comparator|Early localized vitiligo on topical treatment|Cases will only receive topical steroids/ calcineurin inhibitors and targeted phototherapy
32962358|NCT05706636|Active Comparator|Early localized vitiligo on topical and systemic treatment|Cases will receive oral mini-pulse steroids, topical steroids/ calcineurin inhibitors and targeted phototherapy
32962359|NCT05703438|Experimental|Nutritionally balanced low-calorie diet|Experimental study with pre and post design
32962360|NCT05700630|Experimental|Determine the safety and feasibility of administering FT538 monotherapy|Administering FT538 monotherapy as an intravenous infusion once every 14 days for 4 consecutive doses and in combination with twice weekly vorinostat for the reduction of the HIV reservoir.
32962361|NCT05700630|Experimental|Characterize the toxicities and impact of FT538 and vorinostat|To characterize the toxicities associated with FT538 monotherapy and with vorinostat in this patient population. To determine the impact of FT538 on the persistence of low-level HIV viremia, defined as detectable HIV-1 RNA of ≤200 copies/mL despite good ART adherence.
32962362|NCT05699538|Experimental|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
32962363|NCT05699538|No Intervention|Standard of Care|Subjects will be asked to follow standard of care recommendations as prescribed by the physician.
32962364|NCT05693922|Experimental|Delta-beta tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. Stimulation will be delivered via the NeuroConn DC-STIMULATOR MC at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. The tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
32962365|NCT05693922|Sham Comparator|Active-sham tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. The active sham condition includes brief stimulation, mimicking the skin sensations associated with tACS, assisting with blinding the participant's assignment.
33406867|NCT05470218|Active Comparator|Low protein meal + leucine|Participants will receive a standard protein meal, containing about 10% of energy as protein to which leucine has been added to match the total leucine content of the high protein meal
33406868|NCT05618730|Experimental|EXP-TC punctal plug together with artificial tears|EXP-TC: A punctal plug as a delivery system for Tacrolimus. EXP-TC has 3 different sizes (Small, Medium and Big for Wide EXP-TC)
33406869|NCT05618730|Active Comparator|Artificial tears|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories)
33406870|NCT05467332||CRITICALLY ILL PATIENTS|CRITICALLY ILL PATIENTS AFTER INVASIVE MECHANICAL VENTILATION READY TO BE EXTUBATED.
33406871|NCT05029050|Experimental|Dexmedetomidine (D)|Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
32857261|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
32857262|NCT03656705|Experimental|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
32857263|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
32857264|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
32857265|NCT03965130|Experimental|Glucagon|Participants will receive glucagon or saline during the PINTA study
32857266|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
32962366|NCT05661942|Active Comparator|Calcium pre-treatment|Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl
32857267|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
32857268|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
32962367|NCT05661942|Placebo Comparator|Placebo|diluent (NS) vials
33406872|NCT05029050|Experimental|Clonidine (C)|Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
32857269|NCT03062904|Experimental|drug|
32857270|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
32857271|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
32857272|NCT05059236|Experimental|Darolutamide+ADT|Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach
32857273|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
32857274|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
32857275|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
32857276|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
32857277|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
32857278|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
32857279|NCT05056974|Experimental|UB-421 + chidamide|UB-421 + chidamide combination therapy
32857280|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
32962368|NCT05648214|Experimental|ALN-PNP Dose 1 or PB|8 participants, randomized 6:2
32962369|NCT05648214|Experimental|ALN-PNP Dose 2 or PB|8 participants, randomized 6:2
32962370|NCT05648214|Experimental|ALN-PNP Dose 3 or PB|8 participants, randomized 6:2
32962371|NCT05648214|Experimental|ALN-PNP Dose 4 or PB|8 participants, randomized 6:2
32962372|NCT05648214|Experimental|ALN-PNP Dose 5 or PB|8 participants, randomized 6:2
32962373|NCT05648214|Experimental|Optional ALN-PNP Dose 5 or PB|"8 participants, randomized 6:2~This is an optional cohort, if there is a need for additional dose characterization of ALN-PNP."
32962374|NCT05648214|Experimental|JPN ALN-PNP Dose 4 or PB|8 Japanese participants only, randomized 6:2
32962375|NCT05648214|Experimental|JPN ALN-PNP Dose 5 mg or PB|8 Japanese participants only, randomized 6:2
32962376|NCT05647824||All Subjects|Consists of people with Diabetes and people without Diabetes
32962377|NCT05641740|Experimental|Radiofrequency Therapy Group|The experimental group will receive a single-session of radiofrequency in their hands that has vasodilator action.
32962378|NCT05641740|Placebo Comparator|Placebo Comparator: Control Group|The placebo group will receive a single placebo radiofrequency session with the machine in pause mode.
32962379|NCT05639010|Active Comparator|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
32962380|NCT05639010|Experimental|hemoperfusion combined with hemodialysis|Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week
32962381|NCT05636436|Experimental|Low dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
32962382|NCT05636436|Experimental|Low dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
32962383|NCT05636436|Experimental|High dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
32962384|NCT05636436|Experimental|High dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
32962385|NCT05636436|Placebo Comparator|Placebo group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
32962386|NCT05636436|Experimental|Low dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
32962387|NCT05636436|Experimental|Low dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
32962388|NCT05636436|Experimental|High dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
32962389|NCT05636436|Experimental|High dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
32962390|NCT05636436|Active Comparator|Shingrix® group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).
32962391|NCT05636436|Placebo Comparator|Placebo group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
32962392|NCT05613426|Active Comparator|Intensive statin group|Rosuvastatin, 20 mg per day after randomization
32962393|NCT05613426|Experimental|Combined intensive statin and PCSK9 inhibitor group|Evolocumab, 140 mg twice a month after randomization, and Rosuvastatin, 20 mg per day after randomization
32962394|NCT05613426|Experimental|PCSK9 inhibitor alone group|Evolocumab, 140 mg twice a month after randomization
32962395|NCT05601492|Active Comparator|Arm 1 - Standard of Care|Participant will be given the medication with an electronic monitoring cap attached and a return appointment for a standard of care regular visit
32962396|NCT05601492|Experimental|Arm 2 - Reminder text|Participant will be given the medication with an electronic monitoring cap attached and receive weekly electronic text/email-based reporting intervention that is designed to promote better adherence to treatment (to help assure that the study have subjects who have excellent adherence. Having patients report their progress on a regular basis promotes better treatment adherence, perhaps by creating the same sense of accountability promoted by regular office visits
32962397|NCT05601492|Experimental|Arm 3 - Initial patient consult|Participant will be given the medication with an electronic monitoring cap attached and will receive an initial patient consultation intervention, which will focus on the prescribed medication education and setting expectations of what to anticipate with usage of the medication
32962398|NCT05593146|Experimental|modified anteversion angle placement (0° ± 10°) of the acetabular component|
32962399|NCT05593146|Placebo Comparator|conventional anteversion angle placement (15° ± 10°) of the acetabular component|
32962400|NCT05561556|Experimental|MitoQ|8-week MitoQ supplementation (20 mg daily capsule).
32962401|NCT05561556|Placebo Comparator|Placebo|8-week placebo matched in appearance to MitoQ supplementation (20 mg daily capsule).
32962402|NCT05518188|Experimental|Treatment Arm|MELPIDA, a gene therapy product
32962403|NCT05477784|Experimental|Group I (enhancing connections-palliative care program)|Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.
32962404|NCT05477784|Active Comparator|Group II (educational material)|Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.
32962405|NCT05471076|Experimental|Bolus Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The Bolus Delivery Arm Group 1 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
32962406|NCT05471076|Experimental|Bolus Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
32962407|NCT05471076|Placebo Comparator|Bolus Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
32962408|NCT05471076|Experimental|Fractionated Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The first dose for the Fractionated Delivery Arm Group 1 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
32962409|NCT05471076|Experimental|Fractionated Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
32962410|NCT05471076|Placebo Comparator|Fractionated Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
32962411|NCT05463354|Experimental|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
33406873|NCT05029050|Placebo Comparator|Placebo (P)|Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
32962412|NCT05463354|Active Comparator|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
32962413|NCT05463354|Experimental|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
32962414|NCT05463354|Active Comparator|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
32962415|NCT05463354|Experimental|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
32962416|NCT05463354|Active Comparator|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
32962417|NCT05449470|Experimental|CDSS and patient portal|The intervention includes the combined use of the clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction and a patient portal.
32962418|NCT05449470|No Intervention|Care as usual|Care as usual
32962419|NCT05445492|Experimental|Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders and compare the reference device measurements to the test device.
32962420|NCT05416320|Experimental|Calcipotriol Group|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
32962421|NCT05416320|Sham Comparator|Control Group|Subjects will continue to use their primary physician prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
32962422|NCT05409534|Active Comparator|Backward Walking|Participants who walk backward gait in the form of exercise program
32962423|NCT05409534|Active Comparator|Forward Walking|Participants who walk forward gait in the form of home program
33320640|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33406874|NCT05553366|Experimental|VX-548|Participants will be randomized to receive VX-548.
32962426|NCT05340504|Experimental|Group A: NAC, then Placebo Oral Capsule|Group A will receive NAC 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive Placebo Oral Capsule 2 times a day for 14 days and have another MRI exam on day 14.
32962427|NCT05340504|Experimental|Group B: Placebo Oral Capsule, then NAC|Group A will receive Placebo Oral Capsule 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive NAC 2 times a day for 14 days and have another MRI exam on day 14.
32962428|NCT05338320|Active Comparator|General anesthesia and Ultrasound Guided Erector Spinae Plane Block|
32962429|NCT05338320|Active Comparator|General anesthesia and intrathecal morphine|
32962430|NCT05338320|Other|General anesthesia using intravenous fentanyl (1µg/kg)|
33406875|NCT05553366|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will be randomized to receive HB/APAP.
32962431|NCT05330130|Active Comparator|Daily 150 IU recFSH|Follitropin beta injection 150 IU daily
32962432|NCT05330130|Active Comparator|Daily 300 IU recFSH|Follitropin beta injection 300 IU daily
32962433|NCT05293548|Experimental|NVSI-06-09 Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
32962434|NCT05293548|Active Comparator|Inactivated Vaccine Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
32962435|NCT05203770||CBP+mOUD|Chronic Back pain participants taking opioids and classified in the opioid misuse disorder group
32962436|NCT05203770||CBP+O|Chronic Back pain participants taking opioids and without opioid misuse disorder group
32962437|NCT05203770||CBP-O|Chronic Back pain participants not taking opioids
32962438|NCT05203770||Healthy Controls|Healthy control without pain or taking opioids.
32962439|NCT05199480|Experimental|E-cigarette liquid type 1|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
32962440|NCT05199480|Active Comparator|E-cigarettes liquid type 2|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
32962441|NCT05199480|No Intervention|No e-cigarettes|No e-cigarette use
32962442|NCT05197998|Experimental|Color Brave Program|The experimental group will be asked to download and complete a 6-week multi-module mobile app program designed to enhance and encourage critical conversations about race and racism among parents and their young children.
32962443|NCT05197998|Other|Wait-list Control|The wait-list control group will be placed on the wait-list for the first 6-weeks, the period in which the experimental group will complete the intervention program. Following the 6-week wait-list period they will receive the color brave program.
32962444|NCT05164926|Experimental|Experimental group, whose perineum was massaged with St. John's Wort oil during labor|St. John's Wort oil will be applied to this group during perineal massage during labor.
32962445|NCT05157360|Experimental|Treatment Arm|"Patients will be enrolled within 24 hours of diagnosis of sepsis related to a necrotizing soft-tissue infections (NSTI). HAT will be initiated within 4 hours of enrollment (thus treatment with HAT can occur no later than 28 hours from diagnosis).~Per Dr. Marik's original study, HAT consists of:~1.5 g vitamin C every 6 hours for 4 days or until ICU discharge~50 mg hydrocortisone every 6 hours for 7 days or until ICU discharge (followed by a taper over 3 days)~200 mg thiamine every 12 hours for 4 days or until ICU discharge In our study, due to the prolonged ICU course typical of most patients with NSTIs, it is not felt feasible to continue indefinitely until ICU discharge. Thus, treatment will be continued for 4 to 7 days plus a 3 day taper (respectively) as above, with no plan for a longer duration of treatment."
32962446|NCT05157360|Placebo Comparator|Control Arm|The control arm will receive the same standard ICU care for NSTI but will not receive HAT. They will receive a placebo consisting of normal saline, indistinguishable to the treatment team (blinded) but known to the pharmacy team (unblinded to treatment and placebo groups). This is so that if the treatment team elects to give stress dose steroids, they can be administered without breaking protocol (i.e. if the patient is getting HAT, it includes steroids, so if the treating team wanted to start hydrocortisone - because they didn't know if the patient was on HAT or placebo and felt steroids were indicated - the pharmacist could ensure the patient was on steroids one way or another without unblinding the providers).
32962447|NCT05136066|Experimental|Group massaged with peppermint oil|Group of experimental
32962448|NCT05106894|Experimental|smartphone application to promote nurturing care|a caregiver-directed smartphone application will directly engage first-time caregivers in providing nurturing care
32962449|NCT05106894|Active Comparator|printed caregiving materials|caregivers will receive print materials on early childhood stimulation
32962450|NCT05089656|Experimental|OAV101|OAV101 administered as a single, one-time intrathecal dose of 1.2 x 10^14 vector genomes (vg).
32962451|NCT05089656|Sham Comparator|Sham control|A skin prick in the lumbar region without any medication.
32962452|NCT04988412|Active Comparator|CoMSM LD|Participants will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
32962453|NCT04988412|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
32962454|NCT04988412|Active Comparator|Co HD|Participants will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
32962455|NCT04988412|Active Comparator|CoMSM HD|Participants will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
32962456|NCT04943874|Other|Technology Based Intervention 1 (Phase 1)|
32962457|NCT04943874|Other|Technology Based Intervention 1 (Phase 2)|
32962458|NCT04943874|Other|Technology Based Intervention 2 (Phase 2)|
32962459|NCT04874532|Experimental|Community Paramedic (CP) program and Education Materials|Subjects will receive CP home visits and telephone calls for 1 month, along with printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
32962460|NCT04874532|Active Comparator|Usual Care and Education Materials|Subjects will receive printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
32962461|NCT04873830|Experimental|Group I (VCMX)|includes 10 patients where implant placement will be performed followed by volume stable collagen matrix placement to augment the buccal defect.
32962462|NCT04873830|Experimental|Group II (control)|Will include 10 patients where implant placement will be performed followed by connective tissue grafting to augment the buccal defect.
32962463|NCT04805970||Patients with and without diabetes who were previously diagnosed with COVID-19|
32962464|NCT04676802|Experimental|NSAIDS|Following surgery will receive NSAID capsules following surgery. Will take online and phone surveys.
32962465|NCT04676802|Experimental|Opioids|Following surgery will receive opioid capsules following surgery. Will take online and phone surveys.
32962466|NCT04627896|Experimental|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
32962467|NCT04437498|Experimental|nVNS|non invasive vagal nerve stimulation
32962468|NCT04437498|Sham Comparator|sham|sham stimulation
32962469|NCT04278768|Experimental|Emavusertib (CA-4948) dose escalation|Patients receive emavusertib monotherapy PO BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962470|NCT04278768|Experimental|Emavusertib dose escalation + Azacitidine|The starting dose level for emavusertib will be 200 mg BID for 21 days (Days 1-21) of a 28-day Cycle. Anticipated emavusertib doses will be 200 and 300 mg BID. Azacitidine 75 mg/m2 intravenous (IV) or subcutaneously (SC) will be administered as 7 doses on a 28-day Cycle (e.g., 7 consecutive doses or split doses with weekend break 5-2, starting at Day 1)
32962471|NCT04278768|Experimental|Emavusertib dose escalation + Venetoclax|The starting dose level for emavusertib will be 200 mg BID for 21 days of a 28-day Cycle. Anticipated emavusertib doses will 200and 300 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
32962472|NCT04278768|Experimental|Emavusertib monotherapy dose expansion|The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 4 Cohorts and patients will be assigned to each Cohort based on baseline disease.
32962473|NCT04189614|Experimental|Cofetuzumab Pelidotin|Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
32962474|NCT04174482|Experimental|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
32962475|NCT04160130|Experimental|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
32962476|NCT04160130|Active Comparator|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
32962477|NCT04126590|Experimental|KN044 0.03 mg/kg dose group|KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles
32962478|NCT04126590|Experimental|KN044 0.1 mg/kg dose group|KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles
32962479|NCT04126590|Experimental|KN044 0.3mg/kg dose group|KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles
32962480|NCT04126590|Experimental|KN044 1 mg/kg dose group|KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles
32962481|NCT04126590|Experimental|KN044 3 mg/kg dose group|KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles
32962482|NCT04126590|Experimental|KN044 6mg/kg dose group|KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles
32962483|NCT04126590|Experimental|KN044 10mg/kg dose group|KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles
32962484|NCT04068948|Active Comparator|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
32962485|NCT04068948|Experimental|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
32962486|NCT04058652|Experimental|TENS therapy|the first step would be to administer the biologic medication in one thigh without the use of TENS therapy. Biologic medications are administered in two doses, with one in each thigh. Administering the first biologic medication injection is done to establish a control, or baseline, for how painful the injection experience is. The second step would be a study team member applying two to four TENS unit pads (made of adhesive gel) to the skin of subject's other thigh approximately two centimeters from the site where injection of the biological medication takes place. There will be no extra injection of biologic medication during this procedure. The prescribed dose will be used one time, split into two legs (which is the standard protocol for administration). The device will be turned on during the injection of the medication. Immediately after both steps, the subject will be given a brief survey to determine your pain level. The subject's involvement would last roughly 10-15 minutes.
32962487|NCT03979560|No Intervention|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
32962488|NCT03979560|Experimental|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:~Patients in this arm will benefit from 14 home interventions~7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.~7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
32962489|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
32962490|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
32962491|NCT03768570|No Intervention|Surveillance|
32962492|NCT03768570|Active Comparator|Durvalumab|
32962493|NCT03756792|Active Comparator|First Time Control|Patients with no prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
32962494|NCT03756792|Experimental|First Time Intervention|Patients with no prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
32962495|NCT03756792|Active Comparator|Previous Experience Control|Patients with prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
32962496|NCT03756792|Experimental|Previous Experience Intervention|Patients with prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
32962497|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
32962498|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
32962499|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
32962500|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
32962501|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
32962502|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
32962503|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
32962504|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
32962505|NCT03217188|Experimental|fractionated full dose re-irradiation|
32962506|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
32962507|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
32962508|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
32962509|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
32962510|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
32962511|NCT02729298|Experimental|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle~AND~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
32962512|NCT02729298|Experimental|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
32962513|NCT02729298|Experimental|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
32962514|NCT02729298|Experimental|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
33406876|NCT05553366|Placebo Comparator|Placebo|Participants will be randomized to receive placebo matched to VX-548 and HB/APAP.
33406877|NCT04690231|Experimental|Apatinib+IE|
32962515|NCT02729298|Experimental|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
32962516|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
32962517|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
32962518|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
32962519|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
32962520|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
32962521|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
32962522|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
32962523|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
32962524|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
33406878|NCT04690231|Active Comparator|IE|
33406879|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
33406880|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
32962525|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
32962526|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
32962527|NCT01074294|Experimental|Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant|Participants received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for 5 weeks. Once assigned to a stimulant by the investigator, participants remained on the same stimulant for the duration of the trial. Participants who met eligibility criteria i.e., who received prior treatment for adult ADHD and treatment-naïve participants were included in this arm group. Participants with incomplete response at the end of Phase A (Week 5) entered Phase B and rest of the participants continued to Phase A+.
33327065|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
32962528|NCT01074294|Experimental|Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant|Participants with incomplete response (with a > 0% and < 30% reduction in ADHD Symptoms Total Score {18 items} between the baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV { Conners' Adult ADHD Rating Scale-Observer: Screening Version}, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a clinical global impression - improvement scale (CGI-I) score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received Brexpiprazole 2 milligram (mg) tablet along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
32962529|NCT01074294|Placebo Comparator|Phase B (Double-blind Randomization Phase): Placebo + Stimulant|Participants with incomplete response (with a > 0% and < 30% reduction in ADHD Symptoms Total Score {18 items} between the Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a CGI-I score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received matching-placebo tablets along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
32962530|NCT01074294|Experimental|Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant|Participants with response (with a ≥ 30% reduction in ADHD Symptoms Total Score {18 items} between Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, or a CAARS-O:SV ADHD Symptoms Total Score {18 items} of < 24 at Week 5, or a CGI-I score of < 3 at Week 5) and non-response (with deterioration or no change in ADHD symptoms at Week 5) at the end of Phase A (Week 5), received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for an additional 6 weeks (up to Week 11).
32962531|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
32962532|NCT00951132|Experimental|2|Rosuvastatin
32962533|NCT00951132|Placebo Comparator|1|Placebo
32962534|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
32962535|NCT01710306|No Intervention|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
32962536|NCT01710306|Experimental|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
32962537|NCT01713660|Other|FS Corneal Incisions|
32962538|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
32962539|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
32962540|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
32962541|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
32962542|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
32962543|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
32962544|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
32962545|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
32962546|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
32962547|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
32962548|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
32962549|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
32962550|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
32962551|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
32962552|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
32962553|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
32962554|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
32962555|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
32962556|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
32962557|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
32962558|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~≥16 0.15 mg/kg/dose~Maximum dose of methadone will be 0.15 mg/kg/dose.~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
32962559|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~≥16 0.8 mg/kg/day~The maximum dose of DTO will be 0.8 mg/kg/day.~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
32962560|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
32962561|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
32962562|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
32962563|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
32962564|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
32962565|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
32962566|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
32962567|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
32962568|NCT05317338|Experimental|Intervention group|Participants randomized to this group will be enrolled to a multicomponent training for 5-7 consecutive days and will continue to receive usual hospital care. The training program consists of strength, balance and gait exercises performed within the hospital.
32962569|NCT05317338|No Intervention|Control group|Participants randomized to the control group will receive only the usual hospital care and rehabilitation, without performing multicomponent exercises.
32962570|NCT05317260||Chronic hepatitis B patients without hepatic steatosis|Patients with chronic hepatitis B will be defined as the non-steatosis group if they had histological evidence of visible lipid droplets in hepatocytes less than 5%.
32962571|NCT05317260||Chronic hepatitis B with steatosis but no steatohepatitis|Patients with chronic hepatitis B will be categorized as the steatosis but not steatohepatitis group if they had histological evidence of visible lipid droplets in hepatocytes more than 5% in the absence of steatohepatitis feature.
32962572|NCT05317260||Chronic hepatitis B patients with steatohepatitis|Patients with chronic hepatitis B will be classified as the steatohepatitis group if they had histological evidence of steatosis, hepatocyte ballooning, mixed lobular acute and chronic inflammation, and intra-acinar perisinusoidal fibrosis according to Brunt's classification.
32962573|NCT05316870|Experimental|Intervention group|The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
33327066|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
33327067|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
33327068|NCT01168830|Experimental|Investigational device|
32962574|NCT05316870|Other|Control group|The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
32962575|NCT05316792|Active Comparator|knee osteoarthritis|In patients with knee osteoarthritis, the thickness of the femoral articular cartilage will be measured with portable USG before and immediately after walking.
32962576|NCT05316792|Active Comparator|healthy volunteers|Femoral articular cartilage thickness will be measured with portable USG before and immediately after walking in healthy volunteers.
32962577|NCT05316636|Experimental|Group A|Vibrational forces from onset of treatment, from weeks 0-6; then, no vibrational forces during the rest of the treatment
32962578|NCT05316636|Experimental|Group B|From weeks 0-6, no vibrational forces. Vibrational forces starting at 6 weeks after treatment onset and applied for 6 weeks until week 12
32962579|NCT05316636|Active Comparator|Group C|Control, no vibrational forces
32962580|NCT05316480|Experimental|Nimotuzumab|nimotuzumab 200mg/week
32962581|NCT05316402|Experimental|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
32962582|NCT05316246|Experimental|CD30-positive Relapsed/Refractory NK/T-cell Lymphoma|Brentuximab vedotin will be administered as 1.8 mg/kg IV infusion on Day 1 of each 3-week cycle. PD-1 inhibitor tislelizumab will be administered as 200 mg on Day 1 of each 3-week cycle. Patients will receive maximum of 8 cycles if they do not meet the criteria for removal from the study. Patients will be assessed for overall response using the Revised Response Criteria for Malignant Lymphoma (Lugano 2014). Dedicated computed tomography (CT) scans (neck, chest, abdomen, and pelvis) will be performed at Baseline and at Cycles 2, 4 and 8, and positron emission tomography (PET) scans will be performed at Baseline and at Cycles 4 and 8.
32962583|NCT05316168|Active Comparator|isolated adductor canal block (ACB)|Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
32962584|NCT05316168|Active Comparator|isolated adductor canal block (ACB) + IPACK|ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
32962585|NCT05316090|Experimental|study group|Children in study group treated using core stability exercises program in addition to traditional program
32962586|NCT05316090|Active Comparator|control group|Children in the control group treated using traditional physical therapy program.
32962587|NCT05315856||ChAdOx1 vaccine group|AstraZeneca vaccine (chimpanzee adenovirus-vectored vaccine, 0.5 mL [5 × 1010 viral particles] per dose)
32962588|NCT05315856||BNT162b2 vaccine group|Pfizer-BioNTech vaccine (mRNA vaccine; 0.3 mL [30 μg] per dose)
32962589|NCT05315778|Experimental|Anti-BCMA CAR T-cells infusion|R/R ITP patients will accept infusion of autologous anti-BCMA CAR T-cells with a total of 1.0-2.0×10e7/Kg. The patients will be follow-up for 6 months post CAR T-cell therapy.
32962590|NCT05315466|Experimental|Non-surgical treatment|Different types of non-surgical treatments
32962591|NCT05315466|Experimental|Surgical treatment|Surgical treatment for spinal stenosis
32962592|NCT05315388|No Intervention|Group 1. Regular therapy group|Group without intervention during the study period no changes will be made in their daily routine. They will receive a weekly intervention operationalized for psychosocial risk.
32962593|NCT05315388|Experimental|Group 2A: Vitamin N therapy group - metropolitan park environment|Group with periodic outings to a neighborhood or metropolitan natural park (once a week) for approximately 2 hours for a minimum period of six months.
32962594|NCT05315388|Experimental|Group 2B: Vitamin N therapy group - forest forest environment|Group with periodic outings to a forest environment (once a week) for a time of approximately 2 hours for a minimum period of six months
32962595|NCT05315154|Experimental|No axillary surgery|
32962596|NCT05315154|Active Comparator|Sentinel lymph node biopsy|
32962597|NCT05309850|Experimental|Usage of tool|Participants get access to the tool and use it regularly
32962598|NCT05309850|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease or type 2 diabetes is followed via clinical registries.
33033444|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
33033445|NCT01963052|Experimental|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
33327069|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
33327070|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
33327071|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
32962599|NCT05257356|Experimental|Chronic Pain Patients|"All participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients.~Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals.~Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses."
32962600|NCT05257356|Experimental|Healthy Controls|"Substudy 1: Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits.~Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2).~Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1+2)."
32962601|NCT05250258||telephone peer support|Telephone peer support from experinenced father to father
32962602|NCT05250258||Routine care|Standard care as usual in child health care, one visit for fathers and nothing added
32962603|NCT05237232||Patients|Newborns, infants and children hospitalized in pediatric intensive care unit (PICU) at Trousseau Hospital, having been treated with jugulocarotid ECMO and weaned alive off ECMO.
32962604|NCT05237232||Controls|Newborns treated for hypoxic-ischemic encephalopathy in the PICU of Trousseau Hospital.
32962605|NCT05202366||Treatment group|Only one treatment group (CGB-400 Topical Gel) will be used for analysis
32962606|NCT05009706|Experimental|Self Care group|Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
32962607|NCT05009706|No Intervention|Control group|Patients who are randomized to the Control group will receive ordinary health care (from an outpatient clinic), but will also be encouraged to follow recommendation of 150 minutes/week of moderate physical activity (12 weeks). To compensate for the extra attention received by the intervention group by the advice/support, the patients in the control group will be dialed with a nurse at 3, 6 and 9 weeks to discuss their current activity.
32962608|NCT04925856|Experimental|Experimental|"4 différents cohorts:~Paclitaxel cohort (N=30)~Epirubicine - cyclophosphamide cohort (N=30)~Eribuline cohort (N=30)~Palbociclib (N=20) ou Abemaciclib (N=20) ou Ribociclib cohort (N=21)~Study diagram :~Inclusion and screening visite~Visit 1: J1C1~Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort~Visit 3 :J21C1~Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort~During these visits, we collect, before the start of treatment administration ;~Vital signs,~Concomitant treatments,~Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
32962609|NCT04894188|Experimental|Neoadjuvant RT and ADT|"Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).~Gosereline 3.6mg sc injection at week 1, week 5, and week 9"
32962610|NCT04894188|Active Comparator|Neoadjuvant ADT|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
32962611|NCT04866420||Poststroke fatigue|Participants who are experiencing fatigue post stroke.
32962612|NCT04775628|Experimental|inferior glide|Inferior glide of the right humerus till no motion is visual on the imaging
32962613|NCT04769544|Active Comparator|Medial pivot group|Device used: medial pivot total knee arthroplasty design
32962614|NCT04769544|Active Comparator|Conventional group|Device used: conventional total knee arthroplasty design
32962615|NCT04767750||HCC patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
32962616|NCT04767750||T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
32962617|NCT04767750||HCC & T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
32962618|NCT04767750||Controls|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
32962619|NCT04766502|Experimental|Blood sample (20ml) and Quality of Life Survey|
32962620|NCT04724772|Experimental|Blepharoplasty patient|Patient receives LA in one eye and LA with TXA in the other eye. They are blinded. They compare eyes without knowing which one received the TXA.
32962621|NCT04717518||Lower Anchor Survey|Patients will likely rate their pain lower.
32962622|NCT04717518||Higher Anchor Survey|Patients will likely rate their pain higher.
32962623|NCT04696614|Experimental|aerobic exercise to aerobic exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise
32962624|NCT04696614|Experimental|aerobic exercise to interval training|first 8-week: aerobic exercise second 8-week: interval training
32962625|NCT04696614|Experimental|aerobic exercise to aerobic exercise +resistance exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
32962626|NCT04696614|Experimental|interval training to interval training|first 8-week: interval training second 8-week: interval training
32962627|NCT04696614|Experimental|interval training to aerobic exercise|first 8-week: interval training second 8-week: aerobic exercise
32962628|NCT04696614|Experimental|interval training to aerobic exercise+resistance exercise|first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
32857281|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
32857282|NCT04762511|Experimental|HSV lower dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
32857283|NCT04762511|Placebo Comparator|Placebo Step 1 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
32857284|NCT04762511|Experimental|HSV low dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
32857285|NCT04762511|Placebo Comparator|Placebo Step 2 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
32857286|NCT04762511|Experimental|HSV medium dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
32857287|NCT04762511|Placebo Comparator|Placebo Step 3 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
32857288|NCT04762511|Experimental|HSV high dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
32857289|NCT04762511|Placebo Comparator|Placebo Step 4 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
32857290|NCT04762901|Experimental|Stage 1 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
32857291|NCT04762901|Experimental|Stage 1 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
32857292|NCT04762901|Experimental|Stage 1 Arm 3|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
32857293|NCT04762901|Experimental|Stage 1 Arm 4|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
32857294|NCT04762901|Experimental|Stage 2 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
32857295|NCT04762901|Experimental|Stage 2 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
32857296|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
32857297|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
32857298|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
32857299|NCT05033964|Experimental|DESyne BDS Plus Arm|DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS; DESyne BDS Plus) is loaded with Sirolimus, Rivaroxaban and Argatroban
32857300|NCT05033964|Active Comparator|DESyne X2 Arm|The DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) is loaded with Novolimus
32857301|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
32857302|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
32857303|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
32857304|NCT04491942|Experimental|Arm I (cisplatin, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32857305|NCT04491942|Experimental|Arm II (cisplatin, gemcitabine, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32857306|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
32857307|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
32857308|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
32857309|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
32857310|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
32857311|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
32857312|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
32857313|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
32857314|NCT03018483|Experimental|Variable PSV|
32857315|NCT03018483|Active Comparator|Conventional PSV|
32857316|NCT03018483|Active Comparator|Automated PSV|
32857317|NCT03018483|Active Comparator|NAVA|
32907453|NCT03850847||Multi-Methods Study|"Step 1: Semi-structured Interviews~Step 2: National Telephone Survey"
32962629|NCT04648878|Experimental|Group A - Hybrid combination|Group A (n=12) will receive 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks.
32962630|NCT04648878|Experimental|Group B - Powered Exoskeleton only|Group B (n=12) will receive 18 visits of powered exoskeleton only, three times a week for approximately 6 weeks.
32962631|NCT04648878|Experimental|Group C - Physical Therapy only|Group C (n=12) will receive 18 visits of physical therapy, three times a week for approximately 6 weeks. Upon completion of the data collection portion of the study, group C will receive 9 sessions, three times a week for approximately three weeks of powered exoskeleton therapy. Data will not be collected or reported during this phase, but but may be retained for future approved use.
32962632|NCT04602858|Experimental|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
32962633|NCT04602858|Active Comparator|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
32962634|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
33104588|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
32962635|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
32962636|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
32962637|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
32962638|NCT04513080|Experimental|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
33104589|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
33104590|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
33104591|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
33104592|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
33104593|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
32962639|NCT04513080|Experimental|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
32962640|NCT04513080|Experimental|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
32962641|NCT04513080|Experimental|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
32962642|NCT04513080|Experimental|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
32962643|NCT04513080|Experimental|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
33327072|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
33327073|NCT01169220|Experimental|Split prep|
33104594|NCT05239182|Experimental|9-ING-41 plus Retifanlimab plus Gem/Abraxane|"intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter, followed by an infusion of gemcitabine according to the gemcitabine label at a dose of 1000 mg per square meter, on days 1, 8, 15 of a 28-day cycle.~Retifanlimab 500 mg IV on day 1 of a 28-day cycle. (Retifanlimab will be administered following gemcitabine/nab-paclitaxel.)~9-ING-41 administered at a dose of 9.3 mg/kg by IV infusion twice weekly on Days 1 and 4 of each week of a 28-day cycle. (9-ING-41 will be administered following retifanlimab.)"
33327074|NCT01169220|Active Comparator|Whole prep|
32857318|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
32857319|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
32857320|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
32857321|NCT04403477|No Intervention|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
32857322|NCT04403477|Experimental|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
32857323|NCT04403477|Experimental|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
32857324|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
32857325|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
32857326|NCT03016455||Stable patients|No DSA No cAMR
32857327|NCT01677455|Experimental|HER2+ breast cancer|
32857328|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
32857329|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
32857330|NCT05010369|Experimental|non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
32857331|NCT05010369|Experimental|hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
32857332|NCT05010369|Experimental|squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
32857333|NCT05010369|Experimental|reactive|patients diagnosed with a reactive (non-cancerous) lymph node
32857334|NCT05010369|Experimental|other|none of the above. Other cancer and non-cancer conditions
32857335|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
32857336|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
32857337|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
32857338|NCT03628235||Companions of early stage HDGECs|
32857339|NCT03628235||Companions of middle stage HDGECs|
32857340|NCT03628235||Companions of late stage HDGECs|
32857341|NCT04978077|Experimental|High fat test meal first, high carbohydrate test meal second|Consumption of a high fat challenge first, consumption of a high carbohydrate challenge after two weeks wash out
32857342|NCT04978077|Experimental|High carbohydrate test meal first, high fat test meal second|Consumption of a high carbohydrate challenge first, consumption of a high fit challenge after two weeks wash out
32857343|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
32857344|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
32857345|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
32857346|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
32857347|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
32857348|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
32857349|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
32857350|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
32857351|NCT03623945||Cohort B|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.~Accrual to Cohort B is complete."
32857352|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH). Accrual to Cohort C is complete
32857353|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate. Accrual to Cohort D is complete.
33033446|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
33033447|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
33033448|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
33033449|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
32962644|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
32962645|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
32962646|NCT04442646|Experimental|ASG= Asthma School Group, with educational intervention|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
32962647|NCT04442646|No Intervention|CG= Control Group, With no educational intervention|Control group will attend control visits every three months.
32962648|NCT04420182|Other|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform~The components of the platform will include:~Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.~Symptom logs will be entered by the patients.~Feedback to the patient by the local COVID-19 care team for any action:~Two-way communication between the patient and the COVID-19 care team~Ability for team members to see all prior notes in order to have continuity of care~Reports of these interactions are transmitted to the patient's health record~Current information on COVID-19 as per the Public Health Agency of Canada"
32962649|NCT04379076|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
32962650|NCT04379076|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
32962651|NCT04320498|Active Comparator|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
32962652|NCT04320498|Experimental|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
32962653|NCT04270500|Active Comparator|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
32962654|NCT04270500|No Intervention|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
32962655|NCT04196868|Experimental|Experimental arm|
32962656|NCT04196868|Placebo Comparator|Control arm|
32962657|NCT04187742|Active Comparator|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
32962658|NCT04187742|No Intervention|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
32962659|NCT04187742|Active Comparator|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
32962660|NCT04187742|No Intervention|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
32962661|NCT04187742|Active Comparator|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
32962662|NCT04187742|No Intervention|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
32962663|NCT04168320|Active Comparator|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
32962664|NCT04168320|Experimental|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
33104595|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
33104596|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
33327075|NCT01282554|Experimental|stimulated group|stimulated group
32857354|NCT03623945||Cohort E|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III invasive breast cancer.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology.~Cohort E has 3 sub-groups. For the purposes of this study, participants with a breast cancer will be categorized as E1-malignant high risk, of E2-malignant low risk.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology, will be invited to participate.~These patients will be considered E3-benign high-risk."
32857355|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
32857356|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
32857357|NCT03617783|Active Comparator|Prebiotin|
32857358|NCT03617783|Placebo Comparator|Placebo|
32857359|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
32857360|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
32857361|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
32857362|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
32857363|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
32857364|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
32857365|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
32857366|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
32857367|NCT04438824|Experimental|Palbociclib and INCMGA00012|"Initial design (safety lead-in and expansion): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule: INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days.(No longer using this)~Amended design (Expansion only): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib and INCMGA00012 on day 1 of each cycle: 500 mg IV (flat dose) of INCMGA00012 will be administered q28 days concurrently with palbociclib 125 mg PO daily for 21 days, followed by 7 days off, q28 days."
32857368|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
32857369|NCT00004547|Experimental|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
32857370|NCT00004547|Experimental|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
32857371|NCT00004547|Experimental|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
32857372|NCT00005669|Active Comparator|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
32857373|NCT00005669|Placebo Comparator|2 - Placebo|Subjects receive placebo plus a weight loss program
32857374|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
32857375|NCT00954018||Cystic Fibrosis patients during hospitalization|
32857376|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
32857377|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
32857378|NCT03908346|Other|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
32857379|NCT02394834||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
32857380|NCT02394834||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
32857381|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
32857382|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
32857383|NCT03908268|Active Comparator|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
33406881|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
33033450|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
32857384|NCT03908268|Experimental|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
32857385|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
33406882|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
32857386|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
32857387|NCT03894618|Experimental|SL-279252|Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
32857388|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
32857389|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
32857390|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
32857391|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
32857392|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
32857393|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
32857394|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
32857395|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
32857396|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
32857397|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32857398|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
32857399|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
32857400|NCT00006101|Experimental|eflornithine|500mg/d for 12 months
32857401|NCT00006101|Placebo Comparator|Placebo|placebo for 12 months
32857402|NCT05576207|Active Comparator|Arm 1|Multiple Micronutrient Supplement for Pregnant women (UNIMMAP formulation) containing 15 nutrients all at an RDA for pregnancy to be consumed one-per-day during pregnancy
32857403|NCT05576207|Experimental|Arm 2|Balanced energy and protein (BEP) food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm all pregnant women will receive this intervention
32857404|NCT05576207|Experimental|Arm 3|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (<18.5) will receive the BEP, the rest will receive the MMS.
32857405|NCT05576207|Experimental|Arm 4|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (<18.5) and those who have inadequate gestational weight gain during pregnancy will receive the BEP, the rest will receive the MMS.
32857406|NCT05570747|Experimental|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
32857407|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
32857408|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
33104597|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
33320641|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
32857409|NCT04294134|Experimental|MIO-CPP|The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
32857410|NCT04294134|Active Comparator|CPP-only|"CPP (control) is typically offered through weekly sessions with the mother-child dyad that last 1 to 1.5 hours. The CPP control intervention will last 9 months. CPP is offered by mental health Child-Parent Specialist, who receive ongoing consultation and supervision in addition to initial training. This is the model that will be followed for the control group.~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008)"
32857411|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
32857412|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
32857413|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
32857414|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
32857415|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
32857416|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
32857417|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
32857418|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
32857419|NCT04432818|Experimental|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
33327076|NCT01282554|No Intervention|control group|Control group : non stimulated group.
32857426|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
32857427|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
32857428|NCT04224402|Other|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
33327077|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
32857429|NCT04437888|Active Comparator|Racemic Ketamine|ketamine 0.5mg/kg bolus on induction of anesthesia and 10mcg/kg/min infusion initiated prior to incision and terminated at the completion of wound closure. Maximum ketamine dose will not exceed 500mg
32857430|NCT04437888|Placebo Comparator|Saline|saline in the same volume as the study drug, administered in the exact same format.
32857431|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
32857432|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
32857433|NCT00591318|Experimental|IV Ceftriaxone|IV Ceftriaxone 2 grams/day
32857434|NCT00591318|Placebo Comparator|IV Placebo|IV Placebo (Normal Saline)
32857435|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
32857436|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
32857437|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
33327078|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
32857438|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
32857439|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
32857440|NCT04835649|Experimental|Exercise group|The group that will receive task-oriented training via telerehabilitation
32857441|NCT04835649|Placebo Comparator|Control group|The control group only will be given a home program that includes walking and balance exercises
32857442|NCT04714437|Active Comparator|F-R/L-A1/A3/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5)
32857443|NCT04714437|Active Comparator|F-R/L-A1/A5/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3)
32857444|NCT04714437|Active Comparator|F-R/L-A3/A1/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5)
32857445|NCT04714437|Active Comparator|F-R/L-A3/A5/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1)
32857446|NCT04714437|Active Comparator|F-R/L-A5/A1/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3)
32857447|NCT04714437|Active Comparator|F-R/L-A5/A3/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1)
32857448|NCT02245971|Active Comparator|Whole precutting group|
32857449|NCT02245971|Active Comparator|Partial precutting group|
32857450|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
32857451|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
32857452|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
32857453|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
32899059|NCT05449002|Experimental|Practicing the Opposite (PTO) intervention|This 30-45 minutes Qualtrics-based, digital program uses stories, interactive activities, and engaging graphics to teach youths one core principle: by practicing the positive opposite of unhelpful behaviors (e.g., engaging with rather than avoiding feared stimuli), one can, over time, change their mood, thoughts, and actions. The intervention is comprised of four main sections: 1) An introduction to PTO; (2) Testimonials from young people who have been helped by PTO; (3) Learning how to Practice the Opposite through online activities. (4) Planning how to continue to Practice the Opposite in the participant's life. Of note, after being removed from the waitlist at the clinic and contacted to begin treatment, participants will still receive treatment as usual from the clinic.
33327079|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
33327080|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
33327081|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
32962667|NCT04086732|Experimental|Temporomandibular disorder|
32962668|NCT04086732|Experimental|Healthy control|
32962669|NCT04007874|Experimental|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
32962670|NCT04007874|Active Comparator|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
32962671|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
32962672|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
32962673|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
32962674|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
32962675|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
32962676|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
32962677|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
32962678|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
32962679|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
32962680|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
32962681|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
32962682|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
32962683|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
32962684|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
32962685|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
32962686|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
32962687|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
32962688|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
32962689|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
32962690|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
32962691|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
32962692|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
32962693|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
32962694|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
32962695|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
32962696|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
32962697|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
32962698|NCT03667170|Experimental|Subjects with MSI-H/dMMR|patients receive KN035 300 mg Subcutaneously biweekly
32962699|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
32962700|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
33406883|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
33406884|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
32962701|NCT03484182|Active Comparator|Standard Home Exercise Program|
32962702|NCT03484182|Experimental|Web-based Home Exercise Program|
32962703|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
32962704|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
32962705|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
32962706|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
32962707|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
32962708|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
32962709|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen"
32962710|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen"
32962711|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
32962712|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
32962713|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
32962714|NCT02733900|Other|Control group|Patients with coxarthrosis
32962715|NCT02718300|Experimental|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
32962716|NCT02718300|Experimental|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
32962717|NCT02718300|Experimental|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
32962718|NCT02718300|Experimental|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
32962719|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
32962720|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream~application to treatment area for 5 days/week for a total of 12 weeks~dispensed at baseline visit along with patient diary"
32962721|NCT02394132|Experimental|Radiotherapy|"Radiotherapy~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution~treatment to commence within 8 weeks of randomisation"
32962722|NCT02102880|Other|Healthy Subjects|
32962723|NCT01894542|Experimental|Cod protein from presscake|
32962724|NCT01894542|Experimental|Cod protein from presscake + stickwater|
32962725|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
32962726|NCT00700596|Active Comparator|1|Salvinorin A (SA)
32962727|NCT00700596|Placebo Comparator|2|Control or Placebo SA
32962728|NCT01733238|Experimental|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
32962729|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
32962730|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
32962731|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
32962732|NCT01736358|Experimental|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
32962733|NCT01736358|Placebo Comparator|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
33327082|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
33327083|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
32962734|NCT01737684|Experimental|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
33406885|NCT05615454|Experimental|Experimental group|(BEMER activated)
32962735|NCT01737684|Experimental|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
32962736|NCT01737684|Experimental|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
32962737|NCT01740258|Experimental|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
32962738|NCT01740414|Active Comparator|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
32962739|NCT01740414|Placebo Comparator|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
32962740|NCT01740726|Experimental|Behavioral Activation|
32962741|NCT01740726|Active Comparator|Fluoxetine|
32962742|NCT01741272|Active Comparator|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
32962743|NCT01741272|Experimental|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
32962744|NCT01741350|Experimental|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
32962745|NCT01741350|Active Comparator|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
32962746|NCT01742208|Experimental|Sotagliflozin 400 mg - Pioneer Group|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
32962747|NCT01742208|Placebo Comparator|Placebo - Expansion Group|Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
32962748|NCT01742208|Experimental|Sotagliflozin 400 mg - Expansion Group|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.
32962749|NCT01742364|Experimental|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
32962750|NCT01742364|Active Comparator|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
33327084|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
33327085|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
32962751|NCT01744704|Experimental|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
32962752|NCT01744704|Experimental|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
32962753|NCT01744704|Experimental|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
32962754|NCT01744704|Experimental|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
32962755|NCT01744704|Experimental|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
33327086|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
33327087|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
33406886|NCT05615454|Placebo Comparator|Comparison group|(BEMER deactivated)
32962756|NCT01744704|Experimental|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
33406887|NCT05703204|Experimental|QLF32101|single arm with QLF32101 treatment
33406888|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
33406889|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
32962757|NCT01744704|Placebo Comparator|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
32962758|NCT01744704|Experimental|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects
32962759|NCT01744704|Experimental|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
32962760|NCT01744704|Experimental|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
32962761|NCT01744704|Placebo Comparator|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
32962762|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods"
32962763|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
32962764|NCT01745952|Experimental|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
32962765|NCT01745952|Experimental|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
32962766|NCT01745952|Sham Comparator|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
32962767|NCT01746264|Experimental|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
32962768|NCT01746420|Placebo Comparator|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
32962769|NCT01746420|Experimental|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
32962770|NCT01746420|Experimental|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
32962771|NCT01746420|Experimental|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
32962772|NCT01746420|Experimental|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
32962773|NCT01748916|Experimental|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
32962774|NCT01748916|Experimental|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
32962775|NCT01748916|Experimental|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
32962776|NCT01748916|Experimental|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
32962777|NCT01748916|Experimental|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
32962778|NCT01748916|Experimental|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
32962779|NCT01749930|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
32962780|NCT01749930|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
32962781|NCT01750086|Active Comparator|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
32962782|NCT01750086|Active Comparator|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
32962783|NCT01750398|Experimental|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
32962784|NCT01751022|Experimental|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
32962785|NCT01752426|Experimental|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
32962786|NCT01753362|Placebo Comparator|placebo|subcutaneous daily injection
32962787|NCT01753362|Active Comparator|liraglutide|subcutaneous daily injection
32962788|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
32962789|NCT01757964|Experimental|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
32962790|NCT01758432|Experimental|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
32962791|NCT01758432|Experimental|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
33406890|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
32962792|NCT01758432|Experimental|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
32962793|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
32962794|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
32962795|NCT01758432|Experimental|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
32962796|NCT01758432|Placebo Comparator|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
32962797|NCT01758588|No Intervention|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
32962798|NCT01758588|Experimental|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
32962799|NCT01759602|Experimental|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
32962800|NCT01760304|Experimental|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
32962801|NCT01760304|Placebo Comparator|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
32962802|NCT01761084|Experimental|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
32962803|NCT01761084|No Intervention|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
32962804|NCT01762722|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
32962805|NCT01763346|Active Comparator|metformin|subjects receiving metformin
32962806|NCT01763346|Experimental|gastric banding|subjects receiving LAP-BAND
32962807|NCT01763970|Experimental|Hypofractionated SBRT|800 cGy delivered in 5 fractions every day to total dose of 4000 cGy
32962808|NCT01765530|Experimental|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
32962809|NCT01765530|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
32962810|NCT01766076|Experimental|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
32962811|NCT01766076|Placebo Comparator|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
32962812|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
32962813|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
32962814|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
32962815|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
32962816|NCT01767636|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32962817|NCT01767792|Experimental|Bevacizumab|Follow participant for 2 years and assess hearing response rates
32962818|NCT01769274|Experimental|PF-05089771 1600 mg|
32962819|NCT01769274|Placebo Comparator|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
32962820|NCT01769352|Active Comparator|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
32962821|NCT01769352|Active Comparator|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
32962822|NCT01769586|Active Comparator|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
32962823|NCT01769586|Active Comparator|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
32962824|NCT01770366|Placebo Comparator|Usual Care|Patients will receive usual care from the post-surgical clinic team.
32857454|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
32857455|NCT04982640|Experimental|Yoga|12-week program, 60 minutes, twice weekly group-delivered Iyengar yoga
32857456|NCT04982640|Active Comparator|Standard Exercise|12-week, 60 minutes, twice weekly group-delivered aerobic exercise (e.g., walking) program
32857457|NCT04982328||NAFLD|patients diagnosed with NAFLD and hospitalized due to the severe COVID-19
32857458|NCT04982328||non-NAFLD|patients hospitalized due to the with severe COVID-19 without NAFLD
32857459|NCT04982016|No Intervention|Control group|There is no treatment before anesthesia induction.
32857460|NCT04982016|Experimental|Crystal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time >10min).
32857461|NCT04982016|Experimental|Colloidal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml colloidal fluid was infused (infusion time >10min).
32857462|NCT04436250|Active Comparator|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
32857463|NCT04436250|Experimental|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
32857464|NCT04436250|Experimental|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
32857465|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
32857466|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
32857467|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
32857468|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
32857469|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
32857470|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
32857471|NCT04188834|Experimental|Sensory Flicker Stimulation|"Patients will be exposed to Sensory Flicker Stimulation.~In one experiment, patients will be exposed, for about 10 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds. Each trial may include the following modalities and frequencies of flicker:~Modalities: auditory only, visual only, or audiovisual combined. Subjects may be exposed to individual pulses of light and/or sound (i.e. around or less than 1 pulse per second).~Frequencies: random, or anywhere from 5Hz to 100Hz. Subjects may be exposed to sensory flicker at a given frequency or random frequency for up to 1h at a time~In another experiment, patients will undergo a behavioral task in which they will be exposed to one of 2 flicker conditions on separate days.~Comfortable parameters (e.g., light intensity and volume intensity) for the subject will be found. If such parameters cannot be found, exposure of the patient to visual and/or auditory stimuli will be stopped."
32857472|NCT04188834|Active Comparator|Electrical Flicker Stimulation|"Patients will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Patients will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated behavioral task. Stimulation in the absence of any behavioral task will be applied in order to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during behavioral task. Stimulation during behavioral task will be applied in an attempt to affect the subject's behavior."
32857473|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
32857474|NCT04157400|Experimental|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
32857475|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
32857476|NCT00929253|Active Comparator|CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer delivered therapy.
32857477|NCT04877418|Experimental|TeleCIMT group|"One month after baseline evaluations, patients will receive a 3-week program through TeleCIMT.~Task Oriented Repetitive Training~Use of the Affected Upper Extremity~Transfer Package"
32857478|NCT04981938||Lobectomy with angioplasty|81 patients who underwent lobectomy with pulmonary artery reconstruction during oncologic lung resection from January 2001 to December 2020
32962825|NCT01770366|Experimental|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
32962826|NCT01773954|Experimental|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
32962827|NCT01778634|Placebo Comparator|Placebo (5% dextrose)|Placebo
32962828|NCT01778634|Experimental|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
32962829|NCT01779024|Experimental|ASA/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first ASA visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second ASA visit.
32962830|NCT01779024|Placebo Comparator|ASA/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first ASA visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second ASA visit
32962831|NCT01779024|Experimental|fMRI/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first fMRI visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second fMRI visit.
32962832|NCT01779024|Placebo Comparator|fMRI/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first fMRI visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second fMRI visit
32962833|NCT01780350|Experimental|ResQGARD ITD|Subjects receive a ResQGARD ITD.
32962834|NCT01781208|Experimental|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
32962835|NCT01783080|Experimental|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
32962836|NCT01783236|Placebo Comparator|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
32962837|NCT01783236|Active Comparator|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
32962838|NCT01783470|Experimental|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
32962839|NCT01783860|Experimental|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
32962840|NCT01783860|Active Comparator|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
32962841|NCT01784796|Experimental|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
32962842|NCT01784796|Active Comparator|Health education program|8 week Health Education program
32962843|NCT01785186|Experimental|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
32962844|NCT01785186|Experimental|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
32962845|NCT01785186|Experimental|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
32962846|NCT01785186|Experimental|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
32962847|NCT01785186|Active Comparator|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
32962848|NCT01785810|Experimental|Maraviroc|Phase II, single arm, single center trial, assessing the efficacy of the combination of tacrolimus, methotrexate and maraviroc as graft-versus-host disease (GVHD) prophylaxis after unrelated donor peripheral blood stem-cell transplantation in patients with hematologic malignancies. Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
32962849|NCT01786902|Experimental|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
32962850|NCT01786902|No Intervention|Non-treatment control group|Height be measured with no treatment
32962851|NCT01787604|Active Comparator|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
32962852|NCT01787604|Active Comparator|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
32962853|NCT01787916|Experimental|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
32962854|NCT01787916|Placebo Comparator|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
32962855|NCT01788150|Experimental|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
32962856|NCT01788150|Active Comparator|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
32962857|NCT01790178|Experimental|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
32962858|NCT01790178|No Intervention|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
32962859|NCT01790490|Experimental|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
33406891|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
32962860|NCT01790490|Experimental|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
32962861|NCT01790490|Experimental|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
32962862|NCT01791972|Experimental|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
32962863|NCT01791972|Experimental|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
32962864|NCT01792986|Other|water-only 24-hour fasting once per week for 6 weeks|
32962865|NCT01794312|Experimental|T4020|One drop every 2 days
32962866|NCT01794312|Placebo Comparator|Vehicle|One drop every 2 days
32962867|NCT01794702|Experimental|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
32962868|NCT01795716|Experimental|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
32962869|NCT01795716|Active Comparator|Glivec|Single and multiple oral Glivec 400mg qd
32962870|NCT01797822|Experimental|Artificial tears first, then Dexamethasone|Artificial tears four times a day both eyes for two weeks, then Dexamethasone 0.01% four times a day both eyes for two weeks
32962871|NCT01800318|Experimental|Sham NESAP with 24% oral sucrose|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
32962872|NCT01800318|Experimental|NESAP with oral water|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
32962873|NCT01800318|Experimental|NESAP with 24% oral sucrose|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
32962874|NCT01800318|Placebo Comparator|Sham NESAP with oral water|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
32962875|NCT01800786|Active Comparator|OSA-CPAP group|OSA patient will use CPAP for 3 months
32962876|NCT01800786|No Intervention|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
32962877|NCT01803204|Experimental|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
32962878|NCT01803204|No Intervention|Control|This group don't received booklet, they will be monitored during the postoperative period to control
32962879|NCT01804062||no treatment|no treatment, prospective observational
32962880|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
32962881|NCT01809054|Active Comparator|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
32962882|NCT01809054|Active Comparator|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
32962883|NCT01809834|Active Comparator|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
32962884|NCT01809834|Experimental|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
32962885|NCT01810692||Group 1|
32962886|NCT01810692||Group 2|
32962887|NCT01811004|Experimental|Botox®|Botox®
32962888|NCT01811004|Experimental|miraDry®|miraDry®
32962889|NCT01811004|Experimental|Nd: YAG laser|Nd: YAG laser 1440nm
32962890|NCT01811316|Active Comparator|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
32962891|NCT01811316|Active Comparator|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
32962892|NCT01811316|Placebo Comparator|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
33033451|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
33104598|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
32857480|NCT04981782||healthy subjects|"No intervention~Infants will be measured at different time points. At the age of 3,4,6 and 9 months."
32857481|NCT04981782||torticollis group|"No intervention~Infants will be measured at their visit to a Chiropractor. Before and after treatment."
32857482|NCT04374903|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive HCQ 600mg PO X 10 days and AZ PO 250mg DAILY X 10 days.
32857483|NCT04374903|Experimental|Study Arm B (HCQ+SIR)|Subjects will receive HCQ 600mg PO X 10 days and SIR 4mg PO X 1 day then 2mg PO DAILY X 9 days
32857484|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
32857485|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
32857486|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
32857487|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
33327088|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
33327089|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
33327090|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
33327091|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
33327092|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
32857488|NCT00995475|Experimental|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
32857489|NCT00995475|Placebo Comparator|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
33327093|NCT01166490|Experimental|1|ASG-5ME
33327094|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
32857490|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
32857491|NCT04981548||raised intracranial pressure|more than 200 mmH2O
32857492|NCT04981548||the normal intracranial pressure group|more than 80 mmH2O and no more than 200 mmH2O
32857493|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
32857494|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
32857495|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
32857496|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
33327095|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
33327096|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
33327097|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
32857497|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
32857498|NCT03500874|Experimental|Systematic Chemotherapy + HAI(FUDR)|"Patients will receive Systemic FOLFOX + HAI (FUDR) every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15.~floxuridine (FUDR) 0.12mg/Kg/d,d1-14 and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
32857499|NCT03500874|Active Comparator|Systematic Chemotherapy|"Patients will receive FOLFOX every every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15."
32857500|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
32857501|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
32857502|NCT04981314|Experimental|Treatment with echinacea|EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
32857503|NCT04981314|Placebo Comparator|Placebo|Hard caplets indistinguishable from EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
32857504|NCT04090905||Unselected cohort|Consecutive adult patients who were referred for acute abdominal surgery. Patients underwent standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
32857505|NCT04090905||Subgroup with Holter monitoring|Consecutive adult patients who were referred for acute abdominal surgery in the time interval 7 AM to 11 PM. Holter monitoring was applied on top of standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
32857506|NCT04981704|Experimental|Part 1: Itraconazole/Poziotinib Drug-drug interaction (DDI)|On Day 1 of Treatment period 1, a single oral dose of 8 milligrams (mg) poziotinib will be administered. On Day 1 of Treatment Period 2, 200 mg itraconazole oral solution will be administered twice a day (BID) followed by 200 mg itraconazole oral solution once daily (QD) for 7 consecutive days (Day 2 to Day 8) with a single oral dose of 8 mg poziotinib coadministered on Day 4.
32962893|NCT01811940|Experimental|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
32962894|NCT01811940|Placebo Comparator|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
32962895|NCT01813110|Placebo Comparator|Placebo|Identical olive oil capsules
32962896|NCT01813110|Experimental|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
32962897|NCT01813734|Experimental|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
32962898|NCT01816230|Experimental|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
32962899|NCT01816776|Experimental|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
32962900|NCT01816776|Other|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
32962901|NCT01817712|Experimental|Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of >66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
32962902|NCT01817712|Active Comparator|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
32962903|NCT01818414|Experimental|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D&E as an adjunct to same-day Dilapan-S.
32962904|NCT01818414|Placebo Comparator|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
32962905|NCT01818804|Active Comparator|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
32962906|NCT01818804|Placebo Comparator|olive oil|Olive oil
32962907|NCT01820754|Experimental|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
32962908|NCT01821300||Down syndrome|No intervention occurred as this was a cross sectional observational study.
32962909|NCT01821300||Control|No intervention occurred as this was a cross sectional observational study.
32962910|NCT01821378|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
32962911|NCT01821378|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
32962912|NCT01821378|Placebo Comparator|Placebo|Placebo Comparator 20 or 80 mg once daily
32962913|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
32962914|NCT01822548|Experimental|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
32962915|NCT01822548|Active Comparator|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
32962916|NCT01825122|Placebo Comparator|Placebo|placebo
32962917|NCT01825122|Experimental|Active, nadolol|Active
32962918|NCT01825512|Experimental|Deferiprone|75-100 mg/kg/day seven days per week
32962919|NCT01825512|Active Comparator|Deferasirox|20 to 40 mg/kg/day seven days per week
32962920|NCT01827306|Active Comparator|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
32962921|NCT01827306|No Intervention|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
32962922|NCT01827462|Experimental|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
32962923|NCT01827462|Experimental|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
32962924|NCT01827462|Experimental|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
32962925|NCT01827930|Experimental|Imatinib 600 (Randomized trial)|Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
32962926|NCT01827930|Active Comparator|Imatinib 400 (Randomized trial)|Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
32962927|NCT01827930|Other|Imatinib400 (Cohort)|Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
32962928|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
33406892|NCT05003544|Active Comparator|PENG BLOCK ( Group A)|A regional block will be applied while the patient is in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) will initially be placed in a transverse plane on the AIIS and then rotate the probe approximately 45 degrees counterclockwise to align with the pubic ramus. In this view, IPE, iliopsoas muscle and tendon, femoral artery and pectineus muscle will be observed. A 22 gauge, 80 mm needle will be inserted from lateral to medial in an in-plane approach to place the psoas tendon anteriorly and posteriorly in the musculofacial plane between the pubic ramus. Following negative aspiration, a local anesthetic solution (20ml bupivacaine 0.5%) will be injected.
32962929|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
32962930|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
32962931|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
32962932|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
32962933|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
32962934|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
32962935|NCT01833546|Experimental|Evofosfamide 240 mg|
32962936|NCT01833546|Experimental|Evofosfamide 340 mg|
32962937|NCT01833546|Experimental|Evofosfamide 480 mg|
32962938|NCT01833546|Experimental|Evofosfamide 340 mg + Gemcitabine|
32962939|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
32962940|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
32962941|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
32962942|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
32962943|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
32962944|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
32962945|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
32962946|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
32962947|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
32962948|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
32962949|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
32962950|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
32962951|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
32962952|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
32962953|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
32962954|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
33104599|NCT04682717||PI group|A cut-off value of baseline PI below which hypotension at 5 min post induction could be predicted will be the primary outcome, while positive and negative predictive values at 15 minutes will be secondary outcomes.
33406893|NCT05003544|Active Comparator|Intra-articular( Group B)|It will be applied to the intra-articular region by the surgeon at the end of the operation. A volume of 60 ml (30 ml of 0.5% bupivacaine and 30 ml of 0.9% NaCl)
32962955|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
32962956|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
32962957|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
32962958|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
32962959|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
32962960|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
32962961|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
32962962|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
32962963|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
32962964|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
32962965|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
32962966|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
32962967|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
32962968|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
32962969|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
32962970|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
32962971|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
32962972|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
32962973|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
32962974|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
32962975|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
32962976|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
32962977|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
32962978|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
32962979|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
32962980|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
32962981|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
32962982|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
32962983|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
32962984|NCT01849068|Experimental|Ezetimibe|
32962985|NCT01849068|Placebo Comparator|Placebo|
32962986|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
32962987|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
32962988|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
33327098|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
32962989|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
32962990|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
32962991|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
32962992|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
32962993|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
32962994|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
32962995|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
32962996|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
32962997|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
32962998|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
32962999|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
32963000|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
32963001|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
32963002|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
32963003|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
32963004|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
32963005|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
32963006|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
32963007|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
32963008|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
32963009|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
32963010|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
32963011|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
32963012|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
32963013|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
32963014|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
32963015|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
32963016|NCT01861002|Experimental|AML Arm|"Participants with Acute Myeloid Leukemia (AML)~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal (IT) Cytarabine"
32963017|NCT01861002|Experimental|ALL Arm|"Patients with Acute Lymphocytic Leukemia~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal Methotrexate (IT MTX)"
32963018|NCT01861704|Active Comparator|Lyric|Silver Lyric device
32963019|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
32963020|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
32963021|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
32963022|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
32963023|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
32963024|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
32963025|NCT01866150||Cohort|
32963026|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
33104600|NCT04319692|Experimental|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
32857507|NCT04981704|Experimental|Part 2: Phenytoin/Poziotinib DDI|On Day 1 of Treatment period 1, a single oral dose of 16 mg poziotinib will be administered. In treatment period 2, an oral dose of 100 mg phenytoin will be administered three times daily (TID) for 17 consecutive days (Day 1 to Day 17) with a single oral dose of 16 mg poziotinib coadministered on Day 14.
32857508|NCT04981704|Experimental|Part 3: Paroxetine/Poziotinib DDI|On Day 1 of Treatment Period 1, a single oral dose of 8 mg poziotinib will be administered. On Day 1 and Day 2 of Treatment Period 2, an oral dose of 20 mg paroxetine will be administered BID followed by 20 mg paroxetine QD for 9 consecutive days (Day 3 to Day 11) with a single oral dose of 8 mg poziotinib coadministered on Day 7.
32857509|NCT02163837|Experimental|rifaximine|
32857510|NCT04974060|Experimental|Remifentanil intervention|After the satisfactory analgesia and sedation, remifentanil will continuously infuse an escalating dose in the sequence of 0.02, 0.04, 0.06, and 0.08 μg/kg/min, each dose infusion lasting at least 30 minutes.
32857511|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
32857512|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
32857513|NCT03373032|Experimental|Stiper - A|Stiper, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
32857514|NCT03373032|Experimental|Acupuncture - B|Acupuncture with needles, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
32857515|NCT03373032|Experimental|Exercise - C|Exercise, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
32857516|NCT03373032|Experimental|Follow Up - D|Selected patients from the 3 groups Stiper / Acupuncture / Exercise. One session with a Peridell Massager
32857517|NCT03373032|Other|Observation - S|Group patients who were unable to participate in the intervention group A / B and C. In this group, only the evaluation will be performed.
32857518|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
32857519|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
32857520|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
32857521|NCT04973904|Experimental|PD-1+Paclitaxel+Cisplatin+Bevacizumab|"Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 (Q3W)~Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)"
32857522|NCT03061422|Experimental|xylitol chewing gum|intervention
32857523|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
32857524|NCT03061422|Active Comparator|Paraffin pellet|comparator
32857525|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
32857526|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
32857527|NCT04837482|Experimental|AGN-190584 Sequence 1|AGN-190584 Sequence 1 (Participants will receive AGN-190584 from Visit 2 through Visit 3 followed by Vehicle from Visit 4 through Visit 5).
32857528|NCT04837482|Experimental|AGN-190584 Sequence 2|AGN-190584 Sequence 2 (Participants will receive Vehicle from Visit 2 through Visit 3 followed by AGN-190584 from Visit 4 through Visit 5).
32857529|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
32857530|NCT04981080||Symptom of voiding dysfunction|Women with lower urinary tract symptoms including voiding symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
32857531|NCT04981080||No symptom of voiding dysfunction|Women with lower urinary tract symptoms but without cystocele or voiding symptoms who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
32857532|NCT04982094|Experimental|Mental Health First Aid and Relationship Building Training (MHFA+RBT)|Mental Health First Aid training in conjunction with Relationship Building Training.
32857533|NCT04982094|Active Comparator|Mental Health First Aid (MHFA only)|Mental Health First Aid training alone.
32857534|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
32857535|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
32857536|NCT04980924||Pulmonary Embolism without reccurence or complication|Pulmonary Embolism without reccurence or complication
32857537|NCT04980924||Pulmonary Embolism with reccurence or complication|Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension.
32857538|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
32857539|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
32857540|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
32857541|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
32857542|NCT00998517|Active Comparator|Soy/peanut fortified spread|
32857543|NCT00998517|Experimental|Milk fortified corn/soy blend|
32857544|NCT00998517|Active Comparator|Supplementary Plumpy®|
32857545|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
32857546|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
32963027|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
32963028|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
33406894|NCT05003544|Active Comparator|Quadratus lumborum block ( Group C)|The patient will be in the lateral position. A low-frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in-plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.5 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
32963029|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
32963030|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
32963031|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
32963032|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
33406895|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
32963033|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
32963034|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
32963035|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
32963036|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
32963037|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
32963038|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
32963039|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
32963040|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
32963041|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
32963042|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
32963043|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
32963044|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
32963045|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
32963046|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
33033452|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
33104601|NCT04319692|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
33406896|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
33406897|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
33406898|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
33406899|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
33406900|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
32857547|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
32857548|NCT04837248|Active Comparator|Group 1. Conventional treatment|Patients will be treated with a physiotherapy programme without digital support.
32857549|NCT04837248|Experimental|Group 2. Experimental treatment.|Patients will be treated using a digitally supported physiotherapy programme.
32857550|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
32857551|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
32857552|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
32857553|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
32857554|NCT04836546|Experimental|Self monitoring of blood glucose, then CGM System|All participants will first manage their diabetes with SMBG for 6 months followed by managing their diabetes with Eversense CGM system for the next 6 months
32857555|NCT04973592||Child with Blunt Abdominal Trauma|
32857556|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
32857557|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
32857558|NCT04973358|Experimental|BuccoTherm|buccotherm mouthwash
32857559|NCT04973358|Placebo Comparator|Placebo|placebo mouthwash
32857560|NCT04980768|Other|Root canal treatment|Root canal treatment will be provided to all the participants with the diagnosis of apical periodontitis.
32857561|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
32857562|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
32857563|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
32857564|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
32857565|NCT04428762|Experimental|I-Port use arm|
32857566|NCT04428762|No Intervention|Regular injection arm|
32857567|NCT04428216|Active Comparator|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
32857568|NCT04428216|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
32857569|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
32857570|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
32857571|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
32857572|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
32857573|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
32857574|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
33406901|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
33406902|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
33406903|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
33406904|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
32857575|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
32857576|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
32857577|NCT01669902||Cohort|
32857578|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
32857579|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
32857580|NCT04980300|Experimental|Expanded Intervention|Virtual consultation sessions with a physical therapist, focusing on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis.
32857581|NCT04980300|Active Comparator|Brief Intervention|Web-based resources on knee osteoarthritis, including an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis.
32857582|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
32857583|NCT01001559||Antidepressant alone|SSRI or SNRI alone
32857584|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
32857585|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
32857586|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
32857587|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
32857588|NCT01025427|Experimental|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
32857589|NCT03624777|Experimental|Stroll Safe Program|
32857590|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
32857591|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
32857592|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
32857593|NCT04352751|Experimental|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
32857594|NCT04972734|Experimental|NEC|premature newborns developing a NEC
32857595|NCT04972734|Active Comparator|Healthy control|premature newborns without NEC
32857596|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
32857597|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
32857598|NCT03188094||South Asians with Prediabetes|
32857599|NCT04432116|Experimental|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
32857600|NCT04432116|Experimental|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
32857601|NCT04432116|Experimental|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
32857602|NCT04972422|Experimental|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
32857603|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
32857604|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
32857605|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
32857606|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
32857607|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
33406905|NCT04972578|Active Comparator|Screw Fixation|Traditional fixation method of placing one or two screws across the syndesmosis.
33406906|NCT04972578|Active Comparator|Suture Button|Suture button implants which use a suture and anchor to repair the syndesmosis
33406907|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
33406908|NCT02104921||Healthy volunteers|
33406909|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
33406910|NCT05615220|Experimental|1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl)|Ecopipam 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 mg tablets (containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively); 1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl) target dose; oral administration daily in evenings.
32857608|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
33406911|NCT05615220|Placebo Comparator|Placebo during R/WD Phase|Matching Placebo tablets during R/WD period taken orally in the evening.
33406912|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
32857609|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
32857610|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
32857611|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
32857612|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
32857613|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
32857614|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
32857615|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:~intravenous injection~0.35 mcg/kg~in two minutes~if shivering 5 minutes after delivery"
32857616|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:~intravenous injection~0.35 mg/kg~in two minutes~if shivering 5 minutes after delivery"
32857617|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
32857618|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
32857619|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
32857620|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
32857621|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
32857622|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
32857623|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
32857624|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
32857625|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
32857626|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
32857627|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
32857628|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
32857629|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
32857630|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
32857631|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
32857632|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
32857633|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
32857634|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
32857635|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
33406913|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
32857636|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
32857637|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
32857638|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
32857639|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
32857640|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
32857641|NCT02387385|No Intervention|Standard of Care|Standard of care
33406914|NCT04957992|Active Comparator|Control Feeding Group|Milk based product
32857642|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
32857643|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
32857644|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
32857645|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
32857646|NCT02236377|Active Comparator|ERRT - Consensus Manual|Consensus Protocol, 5 sessions, includes components of ERRT and other nightmare protocols.
32857647|NCT04409457|Other|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
32857648|NCT04409457|Other|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
32857649|NCT04380363|Experimental|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
32857650|NCT04380363|Active Comparator|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
32857651|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
32857652|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
32857653|NCT01050231|Experimental|Robotic group (Type I)|Type I Robotic Therapy (Functional activities first) Participants in this group will participate in functional/task-oriented multi-joint training with the BONES robot first, followed by individual joint training with the BONES robot. A one-week break was provided between interventions.
33406915|NCT04957992|Experimental|Experimental Feeding Group|Milk based product with oligosaccharides
33406916|NCT04957992|Other|Human Milk Reference Group|Human Milk
32857654|NCT01050231|Active Comparator|Robotic group (Type II)|Type II Robotic Therapy (Individual joints first) Participants in this group will participate in individual joint training with the BONES robot first, followed by functional/task-oriented multi-joint training with the BONES robot. A one-week break was provided between interventions.
32857655|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
32857656|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
32857657|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
33406917|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
32857658|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
32857659|NCT04358133|Experimental|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
32857660|NCT04358133|Placebo Comparator|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
32857661|NCT04291209|Active Comparator|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
32857662|NCT04291209|No Intervention|Control arm with No injection|The control ear will not receive any injections
32857663|NCT01032759|Active Comparator|Memantine|
32857664|NCT01032759|Placebo Comparator|Placebo|Placebo
32857665|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
32857666|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
32857667|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
32857668|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
33406918|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
32963047|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
32963048|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.~For children <50kg:~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.~For children ≥50kg:~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.~For adults:~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
32963049|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
32963050|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
32963051|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
32963052|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
32963053|NCT01878006|Experimental|Morphine|Morphine injection 10 mg/70kg
32963054|NCT01878006|Placebo Comparator|Placebo|Saline injection
32963055|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
32963056|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
32963057|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
32963058|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
32963059|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
32963060|NCT05329272|Experimental|The VR group: the Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display [HMD] in delivering the VR intervention), audio, and motor equipment.
32963061|NCT05329272|No Intervention|The control group|The control group received usual care.
32963062|NCT05328960||Patients diagnosed before, during or after the pandemic|Patients with rectal cancer
32963063|NCT05328882||ERAF after PFA|Patients with an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
32963064|NCT05328882||no ERAF after PFA|Patients without an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
32963065|NCT05328102|Experimental|Part 1|Drug: plamotamab administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide (25mg p.o.)
32963066|NCT05328102|Experimental|Part 2|Drug: plamotamab administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide 25mg (p.o.)
32963067|NCT05328102|Active Comparator|Part 2B|Drug: tafasitamab (12 mg/kg intravenously) plus lenalidomide 25mg (p.o.)
32963068|NCT05327478||Non ECD|50-60 years old AND non ECD
32963069|NCT05327478||ECD|>60 years old or ECD
32963070|NCT05327088|Active Comparator|Group A (Dexmedetomidine group)|a bolus dose of 11ml of 0.25% bupivacaine + 0.5μg/ml preservative free dexmedetomidine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 0.5μg/ml dexmedetomidine (1ml volume) will be given when VAS score becomes 4 or more.
32963071|NCT05327088|Active Comparator|Group B (Nalbuphine group)|a bolus dose of 11ml of 0.25% bupivacaine + 10mg preservative free nalbuphine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 2mg nalbuphine (1ml volume) will be given when VAS score becomes 4 or more.
32963072|NCT05310474|No Intervention|Group C|Upon consent, patients will be randomized to receive standard of care, and not be given the active range of motion monitor (the knee glider) two weeks prior to surgery. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
33406919|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
33406920|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
33104602|NCT05238480|Active Comparator|XC-XP-XP-XC Sequence|Use of the Xtreme Conventional mouthguard (XC) while playing rugby for first and fourth weeks and the Xtreme Pro mouthguard (XP) for the second and third weeks.
33104603|NCT05238480|Active Comparator|XP-XC-XC-XP Sequence|Use of the Xtreme Pro mouthguard (XP) while playing rugby for first and fourth weeks and the Xtreme Conventional mouthguard (XC) for the second and third weeks.
33104604|NCT04319731|Experimental|Treatment|"Treatment groups:~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
33104605|NCT04682327||Responder group|"After the 4 cycles of anti-PD-1/PD-L1 mAbs treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Responders are defined as complete remission, partial remission, or stable disease."
33417260|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
32857669|NCT01033227|No Intervention|No drug|No study drug administered
32857670|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
32857673|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
32857674|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
32857675|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
32857676|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
32857677|NCT01033773|Other|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
32857678|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
32857679|NCT02167815|Experimental|Intervention ( Mepilex XT)|
32857680|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
32857681|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
32857682|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
32857683|NCT01053897|Experimental|GBT009|
32857684|NCT01053897|Placebo Comparator|Placebo|
32857685|NCT01054209|No Intervention|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
32857686|NCT01054209|Active Comparator|B: electric warming mattress|Warming with warming mattress
32857687|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
32857688|NCT04184427|Active Comparator|Group I|6 mm height of power arm
32857689|NCT04184427|Experimental|Group II|3 mm height of power arm
32857690|NCT04184427|Experimental|Group III|9 mm height of power arm
32857691|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
32857692|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
32857693|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
32857694|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
32857695|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
32857696|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
32857697|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
32857698|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
32857699|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
32857700|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
32857701|NCT03014973|Experimental|prostate cancer patients resistant to castration|
32857702|NCT03014973|Experimental|patients naif of hormonal treatment|
32857703|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
32857704|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
33104606|NCT04682327||Nonresponder group|"After the 4 cycles of anti-PD-1/PD-L1 treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Nonresponders are defined as disease progression."
33104607|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
32857705|NCT04433520||ASD/PFO cohort|Subjects indicated for atrial septal defect (ASD) closure with either the ASO or ASD-MF devices as well as subjects indicated for patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder.
32857706|NCT04433520||VSD cohort|Subjects indicated for ventricular septal defect (VSD) closure with either the MuscVSD or PIVSD occluders.
32857707|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
32857708|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
32857709|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
32857710|NCT04972032|Experimental|Estrogen Intrauterine Stent System|An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).
32857711|NCT04972032|Other|Foley balloon combined with self-cross-link sodium hyaluronate gel|Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.
32857712|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
32857713|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
32857714|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
32857715|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
32857716|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
32857717|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
32857718|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
32857719|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
32857720|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
32857721|NCT04433208|Experimental|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
32857722|NCT04433208|Experimental|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
32857723|NCT04433208|Experimental|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
32857724|NCT04432662|Active Comparator|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
32857725|NCT04432662|No Intervention|Standard of care|Standard of care: Cooling only
32857726|NCT04971330||Known HCV Ab Positive Patients|leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for positive samples.
32857727|NCT04971330||Hospitalized Patients|"leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
32857728|NCT04971330||Unselected Blood Donors|"Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status."
32857729|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
32857730|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
32857731|NCT04979208||Acute myocardial infarction (AMI) cohort|Adult patients with recent acute myocardial infarction admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis all recent AMI patients less than 24 hours old diagnosed by emergency physicians on the basis of suggestive clinical symptoms and electrocardiogram (ECG) criteria, cared in the 30 emergency units and 19 mobil intensive care unit, with a coronary angiography or a percutaneous coronary intervention (PCI) realized in the 11 cathlabs in Aquitaine
33406921|NCT05608668|Experimental|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal).~The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP."
32857732|NCT04979208||Stroke cohort|Adult patients with recent stroke admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis recent ischemic or hemorragic stroke patients with brain imaging managed in one of the 14 participating hospitals in Aquitaine (7 stroke units and 7 primary care centers).
32857733|NCT04971252||Co existance of diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease
32857734|NCT04971252||Diabetes mellitus without chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only
32857735|NCT04971252||Chronic kidney disease without diabetes mellitus|Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
32857736|NCT04970940|Experimental|Sequence 1|"Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)~Wash-out for 7 days~Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)~Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)"
32857737|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
32857738|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
32857739|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
32857740|NCT02896608||control with epilepsy|
32857741|NCT02896608||control without epilepsy|
32857742|NCT04978974|Experimental|Patients with type 2 Diabetes mellitus and Hypertension|patients with type 2 diabetes mellitus and hypertension were selected by using purposive sampling technique to apply stress management program
32857743|NCT04978896|Experimental|Intervention group: Stress-coping Program|Participants will complete an 8-day self-guided programme on stress-coping delivered via a mobile-phone application with daily exercises guided by cognitive-behavioural principles.
32857744|NCT04978896|Active Comparator|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile-phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
32857745|NCT02871726|Experimental|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
32857746|NCT02871726|Active Comparator|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
32857747|NCT02494986|Experimental|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
32857748|NCT04978194|Experimental|Online group|"Online group: online university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included:~9- video capsules (one per week)~An exchange room on each video on a private discord group"
32857749|NCT04978194|Experimental|Hybrid group|"Hybrid group: hybrid university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included: 10 lessons of 2 hours including~The viewing of the videos~A time of exchange between students, and with the teacher"
32857750|NCT04978194|No Intervention|Control group|Control group: No intervention, only two measurement times of 9 weeks apart. Nothing has changed.
32857751|NCT04970706||Healthy Volunteers|Volunteers were healthy people without ACL rupture
32857752|NCT04970706||Patients with ACL Rupture|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
32857753|NCT04152564|Active Comparator|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
32857754|NCT04152564|Active Comparator|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
32857755|NCT04970784||Patients cared for by the adult sector|Patients admitted to emergencies, non-hospitalized and cared for by the adult sector of emergencies (classical emergencies)
32857756|NCT04970784||Patients cared for by the geriatric sector|Patients admitted to emergencies, non-hospitalized and cared for by the geriatric sector of emergencies
33406922|NCT05608668|Active Comparator|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition.
33406923|NCT05586048||Exposed group|patients who received YQFM
32963073|NCT05310474|Experimental|Group B|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) close to surgery to use postoperatively (through week 4). All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
32963074|NCT05310474|Experimental|Group A|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) Receives Knee Glider 2 weeks prior to surgery to utilize through postoperative week 4. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
32963075|NCT05302050|Active Comparator|Intervention BT-001 + Standard of Care|Patients in this arm will receive the BT-001 treatment for up to 18 months.
32963076|NCT05302050|Other|Standard of Care|Patients will have access to a control mobile application for 6 months and then will have the option to use the treatment for the remainder of the 18 month study
32963077|NCT05290194|Experimental|Oligometastatic nasopharyngeal carcinoma|Patients included are going to receive radiotherapy, chemotherapy and immunotherapy. Radiotherapy includes IMRT and SBRT. IMRT is applied for primary sites and cervical lymph nodes，and SBRT following is applied for oligometastatic sites. PD-1 inhibitors: during the whole trial, intravenous, Q3W; Capecitabine: 650mg, po, bid, following the radiotherapy for a year.
32963078|NCT05279196|Experimental|Muscular response to the training|Epigenetic signature associated with different levels of muscle response induced by 6-month training
32963079|NCT05242770|Placebo Comparator|Control Arm|Educational pamphlet with resources for sexual dysfunction
32963080|NCT05242770|Experimental|Physical Therapy Arm|Physical therapy for sexual dysfunction.
32963081|NCT05228574|Active Comparator|High-salt group (group 1)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 1 will receive sodium chloride capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
32963082|NCT05228574|Placebo Comparator|Low-salt group (group 2)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 2 will receive placebo capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
32963083|NCT05062824|Experimental|Intervention|Participants in the intervention will have access to Baby Feed
32963084|NCT05062824|No Intervention|Standard Care|Participants in the standard care group will NOT have access to Baby Feed
32963085|NCT05058846||Group I: No strong family history of pancreatic cancer|Participants in Group 1 consist of BRCA, ATM and PALB2 mutation carriers without a strong family history of pancreatic cancer and can choose to undergo annual magnetic resonance imaging (MRI)/Magnetic resonance cholangiopancreatography (MRCP) screening, or they may opt out of annual MRI screening. Participants also have the opportunity to co-enroll in the University of California, San Francisco (UCSF) BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
32963086|NCT05058846||Group II: Strong family history of pancreatic cancer|Participants in Group 2 consist of BRCA, ATM and PALB2 mutation carriers with a strong family history of pancreatic cancer. Participants may undergo annual MRI/MRCP screening and may also elect to get an endoscopic ultrasound (EUS) every other year. Participants also have the opportunity to co-enroll in the UCSF BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
32963087|NCT05006040|Experimental|Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase|Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.
32963088|NCT04990440|Experimental|Part A: Bermekimab Dose 1|Participants will receive bermekimab Dose 1 or placebo as an intravenous (IV) infusion weekly from Week 0 to Week 15.
32963089|NCT04990440|Experimental|Part B: Bermekimab Dose 2|Participants will receive bermekimab Dose 2 or placebo as an IV infusion weekly from Week 0 to Week 15.
32963090|NCT04990440|Experimental|Part C: Bermekimab Dose 3|Participants will receive bermekimab or placebo at a higher or lower dose (not less than [<] Dose 1) than Part B, but with a maximum dose of Dose 3 IV weekly based on pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety analysis.
32963091|NCT04986072|Experimental|Sodium Nitroprusside Arm|Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
32963092|NCT04986072|Placebo Comparator|Placebo Arm|5% Dextrose (0.5 μg/kg/min) for 4 hours
32963093|NCT04979130|Experimental|SC semaglutide|Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.
32963094|NCT04979130|Placebo Comparator|Placebo|Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.
32963095|NCT04810338||All patients received conventional dialysis treatment|All patients received conventional dialysis treatment during an observational period of 3 years
33406924|NCT05586048||Non-exposed group|patients who didn't receive YQFM
33406925|NCT05405556|Experimental|Patients and providers only aware of study eGFR values more than 25% below baseline|Any study-related eGFR value more than 25% below the baseline measurement will be reported to the patient and treating physician.
33406926|NCT05405556|Other|Patients and providers aware of all study eGFR values|All study-related eGFR measurements will be reported to the treating physician and patient.
33406927|NCT04924998||AL-CM|
32857757|NCT04970628||Study group|Patients performed airway obstruction after anterior cervical operation
32857758|NCT04970628||Control group|Patients did not perform airway obstruction after anterior cervical operation
32857759|NCT04977960|No Intervention|Reference group|"Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:~Dexamethasone i.v. 6 mg die for consecutive 5 days~Methylprednisolone i.v. 40 mg bid for consecutive 10 days~Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice~Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask~Antibiotic therapy:~azithromycin: 500 mg/die per os for 5 days~ceftriaxone: 2 g i.v. die for 8 days"
32857760|NCT04977960|Experimental|Experimental Group|Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization
32857761|NCT01059435|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
32857762|NCT01059435|Experimental|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
32857763|NCT05593731|Other|dental implants alone|dental implants alone
32857764|NCT05593731|Active Comparator|platelet rich fibrin|platelet rich fibrin membrane around dental implants
32857765|NCT05593731|Active Comparator|melatonin gel|melatonin gel around dental implants
32857766|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857767|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
32857768|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857769|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
32857770|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857771|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
32857772|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857773|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
32857774|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857775|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
32857776|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857777|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
32857778|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857779|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
32857780|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
32857781|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
32857782|NCT05593419||Immunotherapy Group|
32857783|NCT05593263|Experimental|Clear corneal incisions|the Steep meridian will be identified and marked, One clear corneal incision will be made on one side of the steep axis using 2.4mm keratome knife then enlarged to 4mm after completion of cataract surgery & other corneal 4mm incision is added to the other side of the steep axis
32857784|NCT05593263|Experimental|Limbal relaxing incision|Single or paired LRI will be performed on the steep axis prior to phaco-emulsification procedure using a 600 μm diamond guarded blade.
32857785|NCT01062009|No Intervention|Control group|No intervention
32857786|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
32857787|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
32857788|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
32857789|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
32857790|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
32857791|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
32963096|NCT04774068|Experimental|Treatment (romidepsin, parsaclisib)|"PRE-PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION PHASE: Patients receive romidepsin IV over 4 hours on days 1,8, and 15 and parsaclisib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and parsaclisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33406928|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
33104608|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
33406929|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
33406930|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
33406931|NCT04918758|Experimental|Purastat Arm|Purastat 5ml once monthly for 3 months
33406932|NCT04918758|Other|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks
33406933|NCT04892472|Experimental|Study Arm|Pembrolizumab and TTFields
32963097|NCT04747626|Experimental|Treatment|Implantation of a physician-modified endovascular stentgraft(s) to treat the proximal aorta in subjects with aortic disease involving multiple segments.
32963098|NCT04535934||1 dose/week followed by 4 doses/week|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 1 dose/week followed by 4 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
32963099|NCT04535934||3 doses/week followed by 7 doses/week.|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 3 doses/week followed by 7 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
32963100|NCT04304742||Suspicion of hip fracture|Suspicion of hip fracture
32963101|NCT04260672|Experimental|Child-Centred Health Dialogue (CCHD)|The intervention CCHD consists of two parts 1) a universal Child Centred Health Dialog by the CHS-nurse directed in the first place to all 4-year-olds and their families (10 minutes) and 2) a targeted Family Guidance by the CHS-nurse to families where a child is identified with overweight at the age of 4 (60 minutes). All children invites to their regular 5-yrs health visit.
32963102|NCT04260672|No Intervention|usual care|Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
32963103|NCT04233138|Experimental|Intervention|The intervention group will have immediate access to the SUPPORT platform.
32963104|NCT04132362||People living with dementia, their families and carers|The cohort consists of people living with dementia. Each of them will be accompanied, throughout the study, by a family member or friend. They will take part together in a one hour music listening session, to discover their personalised playlist. Where possible, a care home staff member will join in, in order to witness the benefits of the music to the dementia resident and learn how to provide the music, as part of their care in the care home.
32963105|NCT04132206||ScS patients|Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
32963106|NCT04132206||Healthy subjects|Healthy subjects will provide one stool sample at inclusion.
32963107|NCT04103034|Experimental|BT200 0.18mg|Subjects will receive a single subcutaneous dose of BT200 0.18mg
32963108|NCT04103034|Experimental|BT200 0.6mg|Subjects will receive a single subcutaneous dose of BT200 0.6mg
32963109|NCT04103034|Experimental|BT200 1.8mg|Subjects will receive a single subcutaneous dose of BT200 1.8mg
32963110|NCT04103034|Experimental|BT200 6.0mg|Subjects will receive a single subcutaneous dose of BT200 6.0mg
32963111|NCT04103034|Experimental|BT200 12.0mg|Subjects will receive a single subcutaneous dose of BT200 12.0mg
32963112|NCT04103034|Experimental|BT200 24.0mg|Subjects will receive a single subcutaneous dose of BT200 24.0mg
32963113|NCT04103034|Experimental|BT200 24.0mg rep|Subjects will receive a single subcutaneous (SC) dose of BT200 24.0mg by gradual SC infusion
32963114|NCT04103034|Placebo Comparator|Placebo SAD|Subjects will receive a single subcutaneous dose of placebo
32963115|NCT04103034|Experimental|BT200 loading dose 24.0mg, maintenance doses of 12.0 mg|Subjects will receive an initial subcutaneous loading doses of BT200 24.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
32963116|NCT04103034|Experimental|BT200 loading doses 48.0mg, maintenance doses of 24.0 mg|Subjects will receive an initial subcutaneous loading dose of BT200 48mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
33406934|NCT03266107|Experimental|Treatment|BVN Ablation
32963117|NCT04103034|Placebo Comparator|Placebo MAD|Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
32963118|NCT04103034|Experimental|BT200 48.0mg + desmopressin challenge|Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
33406935|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
33406936|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
33406937|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
32963119|NCT04103034|Placebo Comparator|Placebo + desmopressin challenge dose|Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
32963120|NCT04103034|Placebo Comparator|Placebo infusion|Subjects will receive a single IV dose of placebo administered over 24 hours
32963121|NCT04103034|Experimental|BT200 36.0mg|Subjects will receive a single subcutaneous (SC) dose of BT200 36.0mg by gradual SC infusion
32963122|NCT04103034|Experimental|BT200 48.0 mg|Subjects will receive a single subcutaneous dose (SC) of BT200 48.0mg by gradual SC infusion
32963123|NCT03921060|No Intervention|Main Study|Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan (if not completed as standard of care within 6 months prior to research visit), micro CT, and blood collection.
32963124|NCT03921060|Experimental|Denosomab Sub-study|Approximately 10 subjects with CF that have completed the main study and have results which indicate bone disease are eligible to participate in the sub study. Subjects who consent will receive treatment with denosumab (60 mg/ml via subcutaneous injection in the upper arm, upper thigh, or abdomen every 6 months) for up to 5 years. These subjects will be asked to return every 6 months for injections and annually (+/- 6 months) for up to 5 years for a DEXA scan, micro CT, and blood collection.
32963125|NCT03916614|Experimental|START treatment|Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
32963126|NCT03916614|Active Comparator|standard of care|Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
32963127|NCT03820596|Experimental|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d~Chidamide:~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
32963128|NCT03776760||Fingerstick Point of Care GeneXpert HCV Test|Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.
32963129|NCT03776760||Treat - SOF/VEL|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir
32963130|NCT03776760||Treat - G/P|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir
32963131|NCT03423888|Experimental|High-flow nasal oxygen|
32963132|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
32963133|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
32963134|NCT03252834||Patients with endometrial or ovarian cancer|
32963135|NCT03252834||Patients with colorectal cancer|
32963136|NCT03222570|Experimental|IPT-A - possible augment with addl IPT-A|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
32963137|NCT03222570|Experimental|IPT-A - possible augment with SSRI|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
32963138|NCT03222570|Active Comparator|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI.
32963139|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
32963140|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
32963141|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
32963142|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
32963143|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
33033453|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
32963144|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
32963145|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
32963146|NCT01643460|Experimental|98% Ethanol with Paclitaxel injection|
32963147|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
32963148|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
32963149|NCT05748444||Children with cystic fibrosis|Voluntary children with cystic fibrosis aged 6-18 years with normal glucose tolerance will be included in the study.
32963150|NCT05748366|Experimental|Serratus Anterior Plane Block|Subjects will undergo serratus anterior plane block, in addition to standard of care analgesic medications at the discretion of the treatment team.
32963151|NCT05748366|Active Comparator|Standard Analgesic Medications|Subjects will receive standard of care analgesic medications at the discretion of the treatment team.
32963152|NCT05748288||Personal Equipment|Participants assigned to use technology they currently own
33406938|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
32963153|NCT05748288||HSG Equipment|Participants provided technology by the sponsor
32963154|NCT05748210|Experimental|Intervention group|Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.
32963155|NCT05748210|Active Comparator|Wait-list control group|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
32963156|NCT05748132|Experimental|trigeminal Radiofrequency|Combined conventional and pulsed radiofrequency (CCPRF) achieved comparable pain relief to PRF treatment alone in patients with chronic pain, the combination of PRF and CRF would increase the effect of CRF and reduce the need for long-duration CRF (LCRF) and its attendant side effects.
32963157|NCT05747898|Active Comparator|Cannula arm|the cannula's 18 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
32963158|NCT05747898|Active Comparator|Needle arm|The needle's 27 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
32963159|NCT05747664|Experimental|DWP16001 to normal haptic function|Normal hepatic function
32963160|NCT05747664|Experimental|DWP16001 to Child-Pugh Class A|Child-Pugh Class A
32963161|NCT05747664|Experimental|DWP16001 to Child-Pugh Class B|Child-Pugh Class B
32963162|NCT05747508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO30, 45 and 75 mcg/kg Ideal Body Weight (IBW)/hour (hr)
32963163|NCT05747508|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
32963164|NCT05747508|Active Comparator|Long Term Follow Up|Pulsed inhaled iNO30, 45 or 75 mcg/kg IBW/hr
32963165|NCT05747274||The Divat COHORT|"The DIVAT cohort (Computerized and Validated Data in Transplantation) developed by the Immunology and Nephrology Department of the University Hospital of Nantes (France) , is a bio-collection database linked to clinical data and plasma, serum, blood cells and urines of all kidney recipients from Nantes, Paris-Necker, and Lyon centres. The clinical and biological parameters are collected at 3 months, 6 months, 1 year and then every year.~All available specimens in the DIVAT cohort that:~meet inclusion and exclusion criteria of this study AND~are usable in terms of quality, integrity, and quantity. will be analysed for this study in order to maximise the power and generalisability of the results."
32963166|NCT05747118||Intervention|People with type 2 diabetes or MODY in the training group
32963167|NCT05747118||Control|People with type 2 diabetes or MODY in the control group
32963168|NCT05747040|Other|48-h monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline~t1: pre-treatment~t2: post-treatment~t3: follow-up"
33406939|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
32963169|NCT05746884|Experimental|Experimental Group with PuraStat®|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedure hemostasis at operator discretion and application of PuraStat®
32963170|NCT05746884|Active Comparator|Control Group|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedural hemostasis at operator discretion
32963171|NCT05746728|Experimental|surufatinib + tislelizumab|"Safety Lead-in Phase: Six patients with metastatic triple-negative breast cancer will be recruited to receive surufatinib in combination with tislelizumab, and DLT will be evaluated over a 28-day DLT observation period.~Dose expansion phase: Surufatinib was administered according to the dose determined in the safety run-in phase and tislelizumab is same as Safety Lead-in Phase."
32963172|NCT05743686|Experimental|Application|
32963173|NCT05727540||Noninfectious uveitis|
32963174|NCT05727540||Infectious uveitis|
33327099|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
32963178|NCT05714670|No Intervention|standard of care|patients will receive oral MMF initial dose of 1200 mg/m2/day, no more than 2000 mg/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids
32963179|NCT05714670|Experimental|Curcumin Oral Capsule group|"patients will receive oral 1000 mg of curcumin capsules daily in addition to their standard treatment for three months.~Standard treatment includes: oral MMF initial dose of 1200 mg/m2/day, no more than 2000 m g/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day~second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids"
32963180|NCT05712018|Experimental|0 ml/kg Hydroxyethyl starch coload group|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
32963181|NCT05712018|Experimental|5 ml/kg Hydroxyethyl starch coload group|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
32963182|NCT05712018|Experimental|10 ml/kg Hydroxyethyl starch coload group|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
32963183|NCT05674500|Experimental|Training Group|"Faculty participants will participate in educational training designed to teach them standardized coaching language for endoscopy instruction and strategies to promote effective communication during an endoscopy teaching. It will be comprised of:~A 15-minute-long training video demonstrating the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction)~The faculty will be given a small (10x10 cm) flash card with the recommended 14 standard terms which they can access during the second simulated encounter. To control for any potential effect of the presence of the card on the trainee during teaching, each faculty be given an identical card with 14 random words on it to hold during the first encounter"
32963184|NCT05674500|Active Comparator|Control Group|"Faculty participants will take part in 'dummy' educational training comprised of:~A 15-minute-long 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices~This group will also be provided a small (10x10cm) flash card but with random words on it (identical to the first simulated colonoscopy teaching encounter)."
32963185|NCT05671380|Active Comparator|Enhanced Usual Care: Ask-Advice-Connect (AAC)|AAC participants will receive care through their primary care provider as usual (with the caveat that providers in the clinics will be trained to provide AAC). AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
32963186|NCT05671380|Experimental|AAC + Longitudinal Proactive Outreach (LPO)|AAC+LPO participants will receive AAC plus an MI tailored outreach call at baseline and at 3, 6, and 9 months post-enrollment. AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
32963187|NCT05670132|Experimental|Neurocardiac rehabilitation program|"The home-based neuro-cardiac rehabilitation program will consist of weekly sessions of neuro-cardiac training during 12 weeks at home.~The physical activity training consists of two 1-hour sessions of adapted physical activities per week supervised by an APA educator or equal. One weekly session is held in person, at home, and the second one in videoconference. All training sessions follow the same scheme with 30 minutes of bicycle training, adapted from high-intensity training (30-33), and 30 minutes of free adapted physical activities~The neuropsychological component will consist of 2 home-based weekly 25-minute sessions of computerized cognitive training via the new platform of CogMed (standard format) for the patient and 1 weekly 30/45-min teleconsultation session of neuropsychological feedback on every-day life emotional regulation and executive functioning applied to school and family life for either the parent (for ages 17 and younger) or young adults with CHD."
32963188|NCT05670132|Active Comparator|Standard of care|The control group will follow European recommendations for cardiology care (standard of care) without introducing any additional interventions for research purposes at the exception of primary (HRQoL questionnaires) and secondary outcomes
32963189|NCT05650554|Experimental|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose|participants will receive a single dose of QIV mRNA vaccine (low dose)
32963190|NCT05650554|Experimental|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5413 medium dose|participants will receive a single dose of QIV mRNA vaccine (medium dose)
32963191|NCT05650554|Experimental|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5413 high dose|participants will receive a single dose of QIV mRNA vaccine (high dose)
32963192|NCT05650554|Active Comparator|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
32963193|NCT05650554|Active Comparator|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
32963194|NCT05650554|Active Comparator|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine (for elderly only)
32963195|NCT05645328||Intervention Hospital Administrators, Providers, and Data Monitoring Staff|"This is a health-system-level intervention, designed as single-arm intervention trial, where four participating hospitals will be offered support in the areas of training and education, cancer data collection and reporting, quality improvement and clinical peer-to-peer support.~Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year."
32963196|NCT05634954|Experimental|[18F]GEH121224 - Group 1 - Biodistribution|
32963197|NCT05634954|Experimental|[18F]GEH121224 - Group 2 - Reproducibility|
32963198|NCT05606718|Experimental|dapagliflozin group|GDMT and dapagliflozin 10mg once daily
32963199|NCT05606718|Active Comparator|control group|GDMT only
32963200|NCT05603442|Experimental|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed at second (T2), fifth (T5), ninth (T9), and twelfth (T12) thoracic vertebra. The ultrasonography is performed by using a high-frequency linear-array ultrasound transducer. A Tuohy needle is inserted in-plane to the ultrasound beam in a lateral-to-medial direction gently to contact the spinous process, into the skeletal muscle plane of the erector spinae muscle. Then, the needle tip is moved to reach the angle between the transverse process and spinous process. Subsequently, the needle tip is gently inserted and advanced for 2 mm along with the superior limit of the vertebral pedicle, until losing contact with the bone. Five ml methylene blue 1% dye (MB) are subsequently injected. The anesthetic procedure is bilaterally performed. Two continuous catheter sets were used and threaded 1 cm from the needle tip, for a bilateral continuous block. The catheters are inserted from the caudal to the cephalic direction.
32963201|NCT05594238|Active Comparator|Arm A|First stage intervention: Telephone engagement Second stage intervention: Telehealth Motivational Interviewing-Cognitive Behavioral Therapy (MI-CBT program)
32963202|NCT05594238|Active Comparator|Arm B|First stage intervention: Telephone engagement Second stage intervention: Enhanced Telephone engagement
32963203|NCT05594238|Active Comparator|Arm C|First stage intervention: Telephone engagement Second stage intervention: Not Applicable (NA), proceed directly to follow up
32963204|NCT05594238|Active Comparator|Arm D|First stage intervention: Portal Engagement Second stage intervention: NA, proceed directly to follow up
32963205|NCT05594238|Active Comparator|Arm E|First stage intervention: Portal Engagement Second stage intervention: Enhanced Portal Engagement
32963206|NCT05594238|Active Comparator|Arm F|First stage intervention: Portal Engagement Second stage intervention: Telehealth MI-CBT program
32963207|NCT05592522|Experimental|EOI group|Ultrasound-guided bilateral external oblique intercostal (EOI) using 30 ml of 0.25% bupivacaine hydrochloride and oblique subcostal transverse abdominis plane (OSTAP) block using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
32963208|NCT05592522|Experimental|OSTAP group|Ultrasound-guided bilateral oblique subcostal transverse abdominis plane (OSTAP) block using 30 ml of 0.25% bupivacaine hydrochloride and external oblique intercostal (EOI) using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
32963209|NCT05589948|Placebo Comparator|Placebo Control 1|Calm Product Form 1 - control
32963210|NCT05589948|Placebo Comparator|Placebo Control 2|Calm Product Form 2 - control
32963211|NCT05589948|Experimental|Active Product 1.1|Calm Product Form 1 - active product 1
32963212|NCT05589948|Experimental|Active Product 2.1|Calm Product Form 2 - active product 1
32963213|NCT05589948|Experimental|Active Product 2.2|Calm Product Form 2 - active product 2
32963214|NCT05588154||Cohort 1|Healthy volunteers who will donate blood, and/or bone marrow and may donate other samples
32963215|NCT05588154||Cohort 2|Healthy volunteers who will donate stool samples only
32963216|NCT05584566|Experimental|OSSIX Breeze|
32963217|NCT05584566|Active Comparator|Jason membrane|
32963218|NCT05561088|Experimental|experimental group|Mechanical thrombectomy was followed by acupuncture and guideline-based conventional treatment
32963219|NCT05561088|Experimental|control group|Conventional treatment based on guidelines was administered after mechanical thrombectomy
32963220|NCT05554926|Experimental|[4-14C] AEF0117|Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the dose administration. Up to 8 subjects will be enrolled to ensure that 6 subjects complete the study. Subjects will be admitted into the study site on Day -1. On the morning of Day 1, all subjects will receive a single oral dose of 2 mg containing approximately 100 μCi of [4-14C]AEF0117 approximately 1 hour after completion of a low-fat breakfast
32963221|NCT05550948|Experimental|alpha tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
32963222|NCT05550948|Experimental|gamma tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
32963223|NCT05550948|Experimental|sham tPBM + cognitive training|Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL)
32963224|NCT05548374|Experimental|Acupucnture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
32963225|NCT05548374|Sham Comparator|Sham Acupuncture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
33104609|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
33104610|NCT01267201|Experimental|POS formulation #1|
33104611|NCT01267201|Experimental|POS formulation #2|
33104612|NCT01267201|Active Comparator|commercial tablet|
33406940|NCT05692284|Other|routine care group|Routine clinic nursing care in hospital, no follow-up after discharge.
33406941|NCT05692284|Experimental|Care in accordance with Orem's theory group|care in accordance with Orem's theory in the hospital process and follow-up with a mobile application designed according to Orem's theory after discharge
32857792|NCT04085991|Experimental|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
32857793|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
33104613|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
33104614|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
32857794|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
32857795|NCT05592951|Placebo Comparator|Placebo once daily|1 stick pack dissolved in water once daily prior to breakfast
32857796|NCT05592951|Experimental|Test beverage once daily|1 stick pack dissolved in water once daily prior to breakfast
32857797|NCT05592951|Experimental|Test beverage twice daily|2 stick packs dissolved in water, one packet at a time twice daily (after lunch and after dinner)
32857798|NCT05592951|Experimental|Test beverage three times daily|3 stick packs dissolved in water, one packet at a time three times daily (after breakfast, lunch, and dinner)
32857799|NCT04041843|Experimental|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
32857800|NCT03952767|Experimental|Digital Physical Measures and Survey Assessments|Digital physical measure data will be collected in clinic and at home and survey assessments will be collected
32857801|NCT05592873||Patients with locally advanced rectal adenocarcinoma|Patients with histollogically confirmed locally advanced rectal adenocarcinoma (clinical T3-T4N0M0 or T(any) N+M0) treated with neoadjuvant CRT followed by curtive intent elective surgery.
32857802|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
32857803|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
32857804|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
32857805|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
32857806|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
32857807|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
32857808|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
32857809|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
32857810|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
32857811|NCT05592795||Patients with Gallbladder polyp or gallbladder adenomyosis|Patients with Gallbladder polyp or gallbladder adenomyosis In view of the difficulty in obtaining bile from normal people, our research team plans to select bile samples from patients undergoing laparoscopic cholecystectomy and patients with pathological diagnosis of gallbladder polyps or gallbladder adenomyosis as physiological bile of normal people.
32857812|NCT05592795||Patients with choledocholithiasis|Patients with choledocholithiasis The research group plans to select bile samples from patients with first episode choledocholithiasis, patients receiving ERCP treatment for the first time, and patients undergoing duodenal papillary incision during EST operation to study the biliary flora of patients with choledocholithiasis. Compared with the normal group, analyze whether there are differences, similarities and uniqueness between the groups, dynamically track changes in the structure of biliary flora before and after treatment, and whether there is specific flora related to the type of disease, and compared with the existing biliary microbiome database, to study whether there are new bacterial species.
32899060|NCT05449002|Other|Usual waitlist control group|Usual waitlist procedures involve watchful waiting for a therapist to become available, sometimes complemented by periodic check-ins from the family with clinic administrators. After being removed from the waitlist and contacted to begin treatment, participants in both study conditions will receive treatment as usual in the clinic.
32899061|NCT05422560|Experimental|Embolization of the inferior mesenteric artery|"Only one arm: Patient followed for sigmoid/rectal cancer~Pré-Selection Preoperative consultation, first information to the patient, Validation of IC / NIC, CT-TAP available~Selection Interventional radiology consultation: Consent collection + additional exams~Inclusion V1 - D0:~Follow-up visit V2 - D2: Phone call, pain assessment and analgesic treatments collection~Follow-up visit V3 - D7: Phone call, pain assessment and analgesic treatments collection~Follow-up visit V4 - D21-D30: CT-TAP~Follow-up visit V5 - D30: Digestive surgery consultation + additionnal exams~Surgery V6 - D0: Colic surgery + additional exams~Post-surgery visit V7 - D30: Last visit, additionnal exams"
32899062|NCT00176228|Experimental|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
32899063|NCT00176306|Experimental|Levofloxacin|Patients receiving levofloxacin 750mg IV
32899064|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
32899065|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
32899066|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
32899067|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
32857813|NCT05592795||Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation|Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation Bile from patients who had undergone ERCP and EST duodenal papillary incision was collected, and the long-term impact of duodenal papillary incision on biliary microecology was discussed by comparing with that of normal patients.
32857814|NCT05592717||Yutiq group|Patients will receive YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye and will be followed for 36 months after treatment.
33104615|NCT05068713|Experimental|Hihg Target Mean Arterial Pressure|Target of mean arterial pressure of 85-90 mmHg in ther first 24h after liver transplant.
33104616|NCT05068713|Active Comparator|Low Target Mean Arterial Pressure|Target of mean arterial pressure of 65-70 mmHg in ther first 24h after liver transplant.
33104617|NCT04323514|Experimental|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
33104618|NCT05198895|Experimental|Open-label, single arm with identical assessment of both biomarkers for all participants|All participants will have their glycated nail keratin assessed by infrared and blood HbA1c levels measured via an assay (based on finger prick blood drop sample)
33104619|NCT00545220|Experimental|1|PST
33406942|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
32857815|NCT05592717||traditional therapy group|Patients were treated with glucocorticoids alone or glucocorticoids combined with immunosuppressants and were followed for up to 36 months.
32857816|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
32857817|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
32857818|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
32857819|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
32857820|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
32857821|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
32857822|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
32857823|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
32857824|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
32857825|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
32857826|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
32857827|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
32857828|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
32857829|NCT05592639|Active Comparator|Videoendoscopic Inguinal Lymphadenectomy|Removal of inguinal nodes using Videoendoscopic Inguinal Lymphadenectomy
32857830|NCT05592639|Other|Open Inguinal Lymphadenectomy|Removal of inguinal nodes using Open radical inguinal lymphadenectomy
32857831|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
32857832|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
32857833|NCT01074099|Active Comparator|Control|CABG only
32857834|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
32857835|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
32857836|NCT03851601||ECP|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
32857837|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
32857838|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
33104620|NCT00545220|Sham Comparator|2|Attention Control
33104621|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
33104622|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
33104623|NCT05175573|Experimental|SuperNO2VA Et|Continuous positive airway pressure with end-tidal CO2 monitoring
33104624|NCT05175573|Active Comparator|Supplemental Oxygen Face Mask|
33104625|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
33104626|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
33104627|NCT04684680|Experimental|zamzam water|patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
33104628|NCT04684680|Active Comparator|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
33104629|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
33104630|NCT00545259|Experimental|1|AEB071
33104633|NCT05162859||Former Exercise Training|Patients that were randomized to high-intensity-interval training, moderate continuous training (OptimEx-Clin) or moderate continuous training + resistance training (Ex-DHF)
33104634|NCT05162859||Former Control|Patients that were randomized to guideline control (OptimEx-Clin) or usual care (Ex-DHF)
33104635|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
33406943|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
32857839|NCT03849963||Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
32857840|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
32857841|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
32857842|NCT01075971|Experimental|Buprenorphine hydrochloride|
32857843|NCT05589051|Experimental|Alpha Hope|Each tablet contains 10 mg PQQ and 40 mg (19% DV) magnesium as well as malic acid, dextrose, adipic acid, citric acid, natural flavor, and blackberry leaf extract
32857844|NCT05589051|Placebo Comparator|Placebo|Same formulation as experimental with 250 mg calcium carbonate replacing the magnesium and PQQ.
32857845|NCT01076049|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
32857846|NCT01076049|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
32857847|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
32857848|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
32857849|NCT05570487||N0A Group|patients with negative lymph nodes and resected lymph nodes less than 15
32857850|NCT05570487||N0B Group|patients with negative lymph nodes and resected lymph nodes no less than 15
32857851|NCT05570487||N+A Group|patients with positive lymph nodes and resected lymph nodes less than 15
32857852|NCT05570487||N+B Group|patients with positive lymph nodes and resected lymph nodes no less than 15
32857853|NCT03805581|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
32857854|NCT01266915||Control group|Normal disease free (non lupus) subjects
32857855|NCT01266915||Diseased Control|
32857856|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
32857857|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
32857858|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
32857859|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
32857860|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
32857861|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
32857862|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
32857863|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
32857864|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
32857865|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
32857866|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
32857867|NCT05539911|Active Comparator|group f|patient received 50 mic fentanyl as an adjuvant to the local anesthetic mixture applied during peribulbar block in the operative eye
32857868|NCT05539911|Placebo Comparator|group C|received the traditional mixture used
32857869|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
32857870|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
32857871|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
32857872|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
32857873|NCT01077921|Experimental|Propranolol|Drug arm
32857874|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
33104636|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
32963226|NCT05505630|Experimental|ketamine then midazolam|single intravenous infusion of ketamine (0.71 mg/kg) or an active control (midazolam, 0.025 mg/kg) in counter-balanced order
32963227|NCT05505630|Experimental|Midazolam then ketamine|single intravenous infusion of ketamine (0.71 mg/kg) or an active control (midazolam, 0.025 mg/kg) in counter-balanced order
32963229|NCT05472948|Experimental|Surufatinib and Sintilimab in Combination With Capecitabine|"Patients were given solventinib (a 3+3 design was adopted in the dose exploration phase, with two dose levels of 200mg and 250mg for dose exploration; after the recommended dose was determined in the dose exploration phase, the dose amplification phase was entered), once a day (QD) for continuous administration~sindilizumab, 200mg, iv every 3 weeks (Q3W)~Capecitabine, 1000mg/m2, twice a day (BID, once in the morning and once in the evening), orally after meals, stopped for 1 week after 2 weeks of treatment;~The three-drug combination therapy was continued every 3 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
32963230|NCT05460624|Experimental|Intervention group|Participants randomized to the intervention group will receive six premade egg-containing breakfast meals per week in the form of a 3-day rotating menu. Each meal contains 2 eggs to provide 12 eggs per week for a duration of 12 weeks.
32963231|NCT05460624|Other|Control group|Participants randomized to the control group will receive breakfast meals in the form of a 3-day rotating menu including typical foods found in American diets excluding eggs, e.g., corn flakes, milk, sausage, granola bars, fruit. Control recipes are matched to the intervention foods on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
32963232|NCT05450562|Experimental|SAR444200 - Dose Escalation Phase (Part 1A)|SAR444200 will be administered as intravenous injection as monotherapy in patients with GPC3+ solid tumors over a 21-day cycle
32963233|NCT05450562|Experimental|SAR444200 - Dose Expansion Phase (Part 2A)|SAR444200 will be administered as intravenous injection in patients with GPC3+ NSCLC over a 21-day cycle
32963234|NCT05450562|Experimental|SAR444200 and Cemiplimab combination therapy - Dose Escalation Phase (Part 1B)|SAR444200 in combination with cemiplimab will be administered as intravenous injection in patients with GPC3+ solid tumors over a 21-day cycle
32963235|NCT05414448|No Intervention|ENDOAID|CADe system will be used during withdrawal phase of colonoscopy.
32963236|NCT05414448|Experimental|ENDOAID with ENDOCUFF|CADe system and mucosal exposure device (ENDOCUFF) will be used during withdrawal phase of colonoscopy.
32963239|NCT05377554|Experimental|ALM-488-002a WLR only|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
32963240|NCT05377554|Experimental|ALM-488-002a WLR with FL Overlay|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
32963241|NCT05377554|Experimental|ALM-488-002b WLR only|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
32963242|NCT05377554|Experimental|ALM-488-002b WLR with FL Overlay|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
32963243|NCT05368896||Elderly patients with postoperative complications after major surger|Patients >80 years that will undergo major visceral or orthopedic surgery
32963244|NCT05357508|Experimental|Intervention group|Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.
32963245|NCT05357508|Active Comparator|Usual care group|Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.
32963246|NCT05350488||Stroke Survivors <1 year|Group A will include participants that are less than 1 year out from their most recent stroke.
32963247|NCT05350488||Stroke Survivors >1 year|Group B will include participants that are greater than 1 year out from their most recent
32963248|NCT05350488||Caregivers|Group C will include participants' identified caregivers.
32963249|NCT05294796|Active Comparator|Short course of antibiotherapy|Patients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)
32963250|NCT05294796|Active Comparator|Long course of antibiotherapy|Patients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (< 2 week), and until fracture healing of antibiotherapy in case of delayed infection
32963251|NCT05251896|Experimental|Plasma-free procedure|
32963252|NCT05215470|Experimental|Nivolumab+Ipilimumab|Nivolumab IV 3mg/kg 3/3w + Ipilimumab 1mg/kg 3/3w 4 doses, followed by Nivolumab IV 480mg 4/4w until progression, toxicity, or up to 2 years of use.
32963253|NCT05206500|Other|Symptomatic Patients with low Colony Count|Patients with positive urinalysis, symptomatic, and Urine Culture Colony Count <10,000 to be treated based on Next Generation Sequencing result.
32963254|NCT05198076|No Intervention|G1 ( Conventional Physical Therapy Program group)|Patients in (G1) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration was 40min to 1 hour.
33327100|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
32963255|NCT05198076|Experimental|G2 ( High Frequency rTMS group)|Patients in (G2) will be treated by high frequency repetitive transcranial magnetic stimulation (HF-rTMS) in addition to the same physiotherapy program as in G1. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration for rTMS will be 20-30 minutes, the physiotherapy session will be 40-45 min.
32963256|NCT05169372||Subjects with locally or biochemical recurrence prostate cancer|
32963257|NCT05166720|Experimental|NIDCAP care|The training core group was formed by the project team. After a one-month clinical unified training on the best evidence of NIDCAP for the VLBW nursing professional group, the best evidence of NIDCAP was applied to the intervention group.
32963258|NCT05166720|No Intervention|routine nursing care|routine nursingPerform routine care for NICU infants according to the nursing routine of each hospital
32963259|NCT05163522|Experimental|Part 1 (SAD): Participants receiving VH4004280|
32963260|NCT05163522|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
32963261|NCT05163522|Experimental|Part 2 (MAD) Non Drug-Drug Interaction (DDI) cohort: Participants receiving VH4004280|
32963262|NCT05163522|Placebo Comparator|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
32963263|NCT05163522|Experimental|Part 2 (MAD) DDI cohort: Participants receiving VH4004280 and Midazolam|
32963264|NCT05163522|Placebo Comparator|Part 2 (MAD) DDI cohort: Participants receiving Placebo and Midazolam|
32963265|NCT05163522|Experimental|Part 3 (Single dose): Participants receiving VH4004280 (new formulation)|
32963266|NCT05151588|Experimental|Induction therapy followed by surgery and postoperative therapy|Induction chemotherapy with docetaxel 75mg/m2 on day 1, cisplatin 75mg/m2 on day 1, 5-FU 750mg from day 1 to day 5, given every 3 weeks for 3 cycles and tazemetostat 800mg twice daily orally for 3 cycles, followed by radical surgery or radical chemoradiation, and maintenance tazemetostat 800mg twice daily orally for 6 months
32963267|NCT05117892|Experimental|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor"
32963268|NCT05117892|No Intervention|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished)
32963269|NCT05083416|Experimental|A: Prolonged Nightly Fasting|"Participants will be educated on Prolonged Nightly Fasting (PNF) and the mycircadianapp. Participants be allowed to choose any 10-hr period that falls between 6 AM- 6 PM, as feeding period. Participants will be recommended to follow study diet guidelines, eat to satiety and not count calories. Participants will be allowed to have water, beverages (<4 kcal) during the fasting period."
32963270|NCT05083416|Active Comparator|B: Regular Eating pattern|Participants will follow a traditional eating pattern with no time restrictions.
32963271|NCT05034354|Experimental|Remote physiological monitoring|"Patients will be recruited from inpatient and outpatient cardiology service at the Stollery Children's Hospital will be purposively selected, with 50% of the patients living at least 100km from the Stollery into one of the following groups:~Group 1: Infants <12 months of age with single ventricle physiology or biventricular cyanotic congenital heart disease.~Group 2: Patients aged 5-17 with heart failure, listed for transplant, or within 1 year of transplant."
32963272|NCT04963296|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.
32963273|NCT04963296|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.
32963274|NCT04929834|Experimental|Experimental group|All patients will receive the experimental emollients during 3 weeks.
32963275|NCT04921332|Experimental|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF and COPD patients may not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
32963276|NCT04898790|No Intervention|Feedback for Preliminary Adaptation|Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.
32963277|NCT04898790|Experimental|Adapted CHAMPS-II intervention|All participants in Aim 2, and those randomized to the physical activity intervention in Aim 3 will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
33033454|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
32963278|NCT04898790|Active Comparator|Survivorship Education Active Control Condition|Participants in Aim 3 who are randomized to the Survivorship Education active control condition will receive the survivorship education program. Testing for outcome measures will be completed, and feedback on the survivorship education program will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
32963279|NCT04894734|Experimental|EES on|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
32963280|NCT04894734|Placebo Comparator|EES off|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
32963281|NCT04886232|Experimental|VP1 Lido US - NC|Injection to the left cheek via needle and to the right cheek via canula
32963282|NCT04886232|Experimental|VP1 Lido US - CN|Injection to the left cheek via canula and to the right cheek via needle
32963283|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - NC|Injection to the left cheek via needle and to the right cheek via canula
32963284|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - CN|Injection to the left cheek via canula and to the right cheek via needle
32963285|NCT04883814|Experimental|Initial Staging|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer
32963286|NCT04883814|Experimental|Suspected disease recurrence|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence
32963287|NCT04873362|Active Comparator|Arm A: Placebo + Trastuzumab Emtansine|Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
32963288|NCT04873362|Experimental|Arm B: Atezolizumab + Trastuzumab Emtansine|Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
32963289|NCT04863924||Advanced NSCLC|Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer
32963290|NCT04856982|No Intervention|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
32963291|NCT04856982|Experimental|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive BIIB067 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
32963292|NCT04856982|Experimental|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years. Participants who received BIIB067 during Part B will receive BIIB067 100 mg on Days 1, 29, and every 28 days thereafter for up to 2 years, with a dose of placebo on Day 15 to maintain the study blind.
32963293|NCT04856982|Experimental|Part D: Open-Label Treatment|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
32963294|NCT04740918|Active Comparator|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
32963295|NCT04740918|Experimental|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
32963296|NCT04576182|Experimental|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
32963297|NCT04576182|Experimental|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
32963298|NCT04569240|Other|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
32963299|NCT04556838|Experimental|VVN001, 1%|VVN001, 1% ophthalmic solution
32963300|NCT04556838|Experimental|VVN001, 5%|VVN001, 5% ophthalmic solution
32963301|NCT04556838|Placebo Comparator|Vehicle|VVN001 Ophthalmic Solution Placebo
32963304|NCT04470804|Experimental|Sirolimus on newly diagnosed primary acquired PRCA|A prospective research of the sirolimus efficiency on newly diagnosed primary acquired PRCA patients. Sirolimus dosage: 2mg QD with plasma concentration 4-15ng/mL. Medication time should last at least 6 months
32963305|NCT04470804|Active Comparator|Cyclosporine A on newly diagnosed primary acquired PRCA|Cyclosporine A (CsA) efficiency on newly diagnosed primary acquired PRCA patients. CsA dosage: 4mg/kg QD. Medication time should last at least 6 months
32963306|NCT04431726|Experimental|Emicizumab|
32963307|NCT04418466|Experimental|DLP-114 alpha-4 (6-months)|2 360mg Risperidone Implants
32963308|NCT04418466|Experimental|DLP-114 alpha-7 (12-months)|2 435mg Risperidone Implants
32963309|NCT04389918|Experimental|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
32963310|NCT04360044|Experimental|THC ~5%|4 puffs of cannabis flower containing THC ~5% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
33327379|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
32963311|NCT04360044|Experimental|THC ~5%/CBD ~12%|4 puffs of cannabis flower containing THC ~5% and CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
32963312|NCT04360044|Experimental|CBD ~12%|4 puffs of cannabis flower containing CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
32963313|NCT04360044|Sham Comparator|Sham Cannabis|4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
32963314|NCT04339764|Experimental|Participants receiving intervention|Participants receiving intervention
32963315|NCT04337814|Experimental|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
32963316|NCT04337814|Experimental|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
32963317|NCT04337814|Placebo Comparator|Placebo Arm|Patients getting oral placebo and topical placebo
32963318|NCT04336332|Experimental|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~Azithromycin 500 mg taken by mouth on Day 1, followed by~Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
32963319|NCT04336332|Experimental|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
32963320|NCT04336332|No Intervention|Arm 3: Placebo|"Placebo pills Days 1-6.~If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
32963321|NCT04318548|Experimental|MenB+MenACWY Group|Subjects will receive 1 dose rMenB+OMV NZ given concomitantly with MenACWY at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of placebo at Day 91.
32963322|NCT04318548|Experimental|MenB Group|Subjects will receive 1 dose of rMenB+OMV NZ and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of MenACWY at Day 91.
32963323|NCT04318548|Experimental|MenACWY Group|Subjects will receive 1 dose of MenACWY and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ each at Day 61 and at Day 91.
32963324|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
32963325|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
32963326|NCT04280718|Experimental|efgartigimod PH20 SC|Patients treated with efgartigimod PH20 SC
32963327|NCT04230408|Experimental|DURVALUMAB (MEDI4736) + carboplatin-paclitaxel|"Induction chemo-immunotherapy phase:~Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.~Concurrent chemo-immuno-radiotherapy phase:~Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.~Concurrent chemo-immuno-radiotherapy:~Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses"
32963328|NCT04205838|Experimental|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
32963329|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
33327380|NCT00047008|Other|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
33327381|NCT00047008|Experimental|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
32963332|NCT03953508|Other|Menthol|Participants will smoke and rate several puffs of a menthol Camel Crush cigarette
32963333|NCT03953508|Other|Non-menthol|Participants will smoke and rate several puffs of a non-menthol Camel Crush cigarette
32963334|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
32963335|NCT03870672|Active Comparator|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
32963336|NCT03870672|Active Comparator|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
32963337|NCT03870672|Sham Comparator|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
33406944|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
33406945|NCT05550714|Experimental|General anesthesia|
33406946|NCT05550714|Active Comparator|Conscious sedation|
32963338|NCT03755154|Experimental|S65487 - initial scheme|
32963339|NCT03755154|Experimental|S65487 - alternative scheme|
32963340|NCT03734016|Experimental|Zanubrutinib|Zanubrutinib will be orally administered until disease progression or unacceptable toxicity.
32963341|NCT03734016|Active Comparator|Ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
32963342|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.~Each session will consist of:~10 minutes of warm-up: general mobilisation, walking, active stretching~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
32963343|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.~Each session will consist of the same structure as the Water-based Exercise Group including:~10 minutes warm up~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
32963344|NCT03671148|Experimental|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 208.
32963345|NCT03671148|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 208.
32963346|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
32963347|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
32963348|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
32963349|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
32963350|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
32963351|NCT03465852|Experimental|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.~."
32963352|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
32963353|NCT03360396|Experimental|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
32963354|NCT03360396|No Intervention|Control|Medically-managed control group
32963355|NCT03295344||Patients|
32963356|NCT03295344||Healthy volunteers|
32963357|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
32963358|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
33104637|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
33320642|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33320643|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
32963359|NCT02718066|Experimental|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
33104638|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
33327382|NCT01285674|Experimental|Intra-tympanic steroid injection|
33327383|NCT01179126|Experimental|complete multivessel revascularization|
32963360|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
32963361|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
32963362|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
32963363|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.
33327384|NCT01179126|Active Comparator|stress echo guided revascularization|
33327385|NCT01285752|Experimental|1|
33327386|NCT01285752|Experimental|2|
33327387|NCT01285752|Active Comparator|3|
32963364|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
32963365|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
32963366|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study(PCYC-1115-CA) who have not progressed at the time of parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
32963367|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study (PCYC-1115-CA) who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
32963368|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study (PCYC-1115-CA) and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
32963369|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the Investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (e.g., intolerability or adverse event [AE]) or prior to experiencing PD).
32963370|NCT01472562|Experimental|all patients|"Induction Phase (week 1 - 48):~Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance Phase (week 49 - progression of disease):~Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.~Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
32963371|NCT01430442|Experimental|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
32963372|NCT01430442|Experimental|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
33327388|NCT03865056|Experimental|High-Flow Nasal Cannula|
33327389|NCT03865056|Experimental|Noninvasive ventilation|
32963373|NCT01430442|Experimental|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
32963374|NCT01430442|Experimental|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
32963375|NCT01430442|Experimental|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
32963376|NCT01430442|Experimental|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
32963377|NCT01430442|Placebo Comparator|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
32963378|NCT01430442|Active Comparator|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
32963379|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32963380|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32963381|NCT00941538|Experimental|intervention|"Residents aged 30-69 years in eight screening towns in the intervention group are invited to screening marker tests - IgA antibodies to EBV VCA/IgA and EBV nuclear antigen-1 (EBNA1/IgA) by ELISA.~The trial will use two minimally acceptable false-positive rates (i.e., 10% and 3%) as the cutoffs to define medium-risk (seropositive, 0.65 ≤ score < 0.98) and high-risk participants (seropositive, score ≥ 0.98). After a blood test, participants whose EBV-based risk exceeds the predefined high-risk threshold (score ≥ 0.98) will be referred to endoscopy for clinical evaluation. Participants who are defined as medium-risk or high-risk (score ≥ 0.65) will be followed annually through blood testing and linkage to registers. The remaining participants (seronegative, score < 0.65) will be asked to return for a follow-up visit after five years."
32963382|NCT00941538|No Intervention|Control|The individuals aged 30-69 in the other eight towns will be included as controls, which is a comparable population that will not be screened for NPC.
32963383|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
32963384|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
32963385|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
32963386|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
32963387|NCT01882764|Experimental|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
32963388|NCT01882764|Placebo Comparator|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
32963389|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
32963390|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
32963391|NCT01887132|Experimental|Open-Label Donepezil|
32963392|NCT01887132|Experimental|Donepezil - Blinded|
32963393|NCT01887132|Placebo Comparator|Placebo|
32963394|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
32963395|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
32963396|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
32963397|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
33320644|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
32963398|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
32963399|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
32963400|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
32963401|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
32963402|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
32963403|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
32963404|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
32963405|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
32963406|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
32963407|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
32963408|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
32963409|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
32963410|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
32963411|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
32963412|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
32963413|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
32963414|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
32963415|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
32963416|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
32963417|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
32963418|NCT01900704|Placebo Comparator|Placebo|Placebo
32963419|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
32963420|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
32963421|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
32963422|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
32963423|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
32963424|NCT01906866|Placebo Comparator|Placebo|Placebo arm
32963425|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
32963426|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
32963427|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
32963428|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
32963429|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
32963430|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
32963431|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
32963432|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
32963433|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
32963434|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
32963435|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
32963436|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
32963437|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
32963438|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
32963439|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
32963440|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
32963441|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
32963442|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
32963443|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
32963444|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
32963445|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
32963446|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
32963447|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
32963448|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
33104639|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
33104640|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
33104641|NCT03456492||case|Hyponatremic elderly patients (>70 years) with hip fractures
33104642|NCT03456492||control|Normonatremic elderly patients(>70 years) undergoing joint replacement
33104643|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
33104644|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
33104645|NCT05154318|Experimental|Pericapsular Nerve Group Block|30ml 0.3% Ropivacaine will be injected between psoas muscle and iliopubic eminence.
33104646|NCT05154318|Active Comparator|Fascia iliaca compartment block|30ml 0.3% Ropivacaine will be injected into fascia iliaca compartment.
33104647|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
33104648|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
33104649|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
33104650|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
33104651|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
33104652|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
33104653|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
33104654|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
33104655|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
33104656|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
33104657|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
33327390|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
33104658|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
33104659|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
33104660|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
33104661|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
33327391|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
33104662|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
33104663|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
33104664|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
33104665|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
33104666|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
33104667|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
33104668|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
33104669|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
33104670|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
33327392|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
33327393|NCT01179204||Patiens operated with TKA|
32963449|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
32963450|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
32963451|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
32963452|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
32963453|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
32963454|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
32963455|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
32963456|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
32963457|NCT01935180|No Intervention|Standard colonoscopy|
32963458|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
32963459|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
32963460|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
32963461|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
32963462|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
32963463|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
32963464|NCT01937598|Experimental|Sitagliptin, then Placebo|
32963465|NCT01937598|Experimental|Placebo, then Sitagliptin|
32963466|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
32963467|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
32963468|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
32963469|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
32963470|NCT01942668|Experimental|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
32963471|NCT01942668|Experimental|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
32963472|NCT01942668|Experimental|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
32963473|NCT01942668|Experimental|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
32963474|NCT01942668|Placebo Comparator|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
32963475|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
32963476|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
32963477|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
32963478|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
32963479|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
32963480|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
33327394|NCT03365596||Subacute stroke|
33327395|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
33327396|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
33104671|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
33327397|NCT05420428|Placebo Comparator|endotracheal intubation|under general anesthesia, patients received tracheal intubation.
33327398|NCT05420428|Experimental|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
33327399|NCT03300804|Active Comparator|20-herb formulation|Active herb
33327400|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
32963481|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
32963482|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
32963483|NCT01948986|Experimental|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
32963484|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
32963485|NCT01950078||surgical patients|grouped by receiving surgery
32963486|NCT01950078||Healthy volunteers group|grouped by healthy college students
32963487|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
32963488|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
32963489|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
32963490|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
32963491|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
32963492|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
32963493|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
32963494|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
32963495|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
32963496|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
32963497|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
32963498|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
32963499|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
32963500|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
32963501|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
32963502|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
32963503|NCT05740254|Experimental|Early Time Restricted Eating|early-day TRE (7:00 to 15:00 h)
32963504|NCT05740254|Experimental|Late Time Restricted Eating|late TRE (12:00 to 20:00 h)
32963505|NCT05740098|Experimental|Best practices|Participants will receive the Five As plus a referral to a quit line.
32963506|NCT05740098|Experimental|Best practices and financial incentives|Participants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence
32963507|NCT05740098|Experimental|Best practices, financial incentives, and NRT|Participants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy.
32963508|NCT05740020|Experimental|Group (A)|Group (A) will receive virtual reality in addition to the traditional exercise program.
32963509|NCT05740020|Active Comparator|Group (B)|Group (B) will receive traditional exercise program.
32963510|NCT05739864|Experimental|Donor FMT (D-FMT)|Patients enrolled in this arm will receive donor FMT
32963511|NCT05739864|Placebo Comparator|Placebo FMT (P - FMT)|Patients enrolled in this arm will receive placebo FMT
32963512|NCT05739786|Active Comparator|Group A liquid nitrogen|liquid nitrogen In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
32963513|NCT05739786|Active Comparator|Group B intralesional Vit D3|intralesional Vit D3 Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
32963514|NCT05739708|Other|Asthma patients|
33406947|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
33406948|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
32963515|NCT05739630|Experimental|M+PTCy group|For the M-PTCy group, Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
32963516|NCT05739630|Active Comparator|BuCy group|For the BUCY group, the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
32963517|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly
32963518|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly
32963519|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
32963520|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
32963521|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the Flu-M Tetra vaccine intramuscularly
32963522|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the VaxigripTetra vaccine intramuscularly
32963523|NCT05739318|Experimental|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is collapsed
32963524|NCT05739318|Experimental|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is inflated
32963525|NCT05739162|Experimental|Endoscopic Sleeve Gastroplasty (ESG)|Participants undergo Endoscopic Sleeve Gastroplasty (ESG). Following the 6-week transitional diet after undergoing the ESG procedure, participants will start the lifestyle intervention.
32963526|NCT05739162|Active Comparator|Diet and Exercise|Participants receive lifestyle intervention only for 24 months
32963527|NCT05739084||Retrospective cohort|A total sample size of 200 patients is expected in the retrospective thanks to the NETSARC/ CONTICABASE databases (French sarcoma reference network)
32963528|NCT05739084||Prospective cohort|"To ensure an external validation, patients from NETsarc centers experiencing preoperative RT will be prospectively accrued and transcriptomic signature will be tested.~Up to 100 patients will be enrolled in this prospective cohort."
32963529|NCT05739006|Experimental|Group 1|BCD-201 200 mg by intravenous infusions once every 3 weeks
32963530|NCT05739006|Active Comparator|Group 2|Keytruda 200 mg by intravenous infusions once every 3 weeks
32963531|NCT05738772||hcc group|The study group will include 45 patients with HCC on top of liver cirrhosis. All virus-related liver cirrhosis and all BCLC stages of HCC will be accepted. Verified presence of HCC, will be assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) or based on histological validation. In patients with presence of liver cirrhosis, non-invasive diagnosis of HCC is standard, when dynamic imaging shows typical diagnostic patterns as the combination of hypervascularity in late arterial phase and washout on portal venous and/or delayed phases
32963532|NCT05738772||LC group|Will include 45 patients diagnosed with liver cirrhosis on top of HCV or HBV with an absence of focal lesions on ultrasound screening as a control group. Cirrhosis will be determined according to clinical, serological, and radiological findings
32963533|NCT05738616|Experimental|lenvatinib combined with TACE and camrelizumab|
32963534|NCT05738616|Active Comparator|lenvatinib alone|
32963535|NCT05738460||Reproductive tract GBS colonization group of mothers during pregnancy|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
32963536|NCT05738460||No reproductive tract GBS colonization group in mothers during pregnancy|No reproductive tract GBS colonization group in mothers during pregnancy
32963537|NCT05738382|Experimental|BG2109 75mg|oral, once a day
32963538|NCT05738382|Experimental|BG2109 150mg|oral, once a day
32963539|NCT05738382|Experimental|BG2109 200mg|oral, once a day
32963540|NCT05738382|Active Comparator|Cetrorelix|0.25mg, Subcutaneous injection, once a day
32963541|NCT05738304|Experimental|External Ureteral Catheter group|After RIRS, an external ureteral catheter will be placed for one day.
32963542|NCT05738304|Active Comparator|Double J group|After RIRS, a double J internal ureteral stent will be placed for 2 weeks.
32963543|NCT05738226|Experimental|EpiCare@Home|Patients with a history or suspicion of focal onset epilepsy admitted to the EMU for routine observation will be able to opt-in to using EpiCare@Home during their admission. Optionally, they will be able to continue using the device at home after EMU discharge.
32963544|NCT05737680|Active Comparator|Hydroxychloroquine arm|Hydroxychloroquine 400mg daily
32963545|NCT05737680|Active Comparator|Colchicine arm|Colchicine continued
33320645|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
32963546|NCT05737290|Active Comparator|Group A|
32963547|NCT05737290|Active Comparator|Group B|
32963548|NCT05736666|Experimental|Training Group|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side.
32963549|NCT05736666|Active Comparator|Education Group|This group will receive educational materials related to fall prevention in older adults.
32963550|NCT05736588|No Intervention|Usual care|
32963551|NCT05736588|Experimental|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
32963552|NCT05736510|Experimental|Binaural|Exposed to binaural sound (40 Hz) from the end of pneumoperitoneum until the eyes are open
32963553|NCT05736510|Active Comparator|Control|Applied silent files from the end of pneumoperitoneum until the eyes are open
32963554|NCT05736432|Experimental|Blueberries-Phase I|feeding will consist of 1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal)
32963555|NCT05736432|Placebo Comparator|Syrup-Phase I|feeding will consist of an isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani)
32963556|NCT05736432|Experimental|Blueberries-Phase II|1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
32963557|NCT05736432|Placebo Comparator|Syrup-Phase II|isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
32963558|NCT05736354||BII Subjects|Subjects with breast implants having BII manifestations.
32963559|NCT05736354||Non-BII Subjects|Subjects with breast implants with no reported BII symptoms.
32963560|NCT05736354||Subjects without Breast Implants|Subjects without breast implants.
32963561|NCT05736198||Dexmedetomidine|Dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
32963562|NCT05736198||Placebo|Normal Saline, midazolam, and fentanyl (titrated to effect) to facilitate the intubation
32963563|NCT05736042|Experimental|Lens fragmentation with miLOOP|Phacoemulsification with adjunctive lens fragmentation with the microinterventional microfilament loop device (miLOOP)
32963564|NCT05736042|No Intervention|Controls|Phacoemulsification alone (no adjunctive lens fragmentation)
32963565|NCT05735964|Experimental|ICG|Patients in this single arm will receive ICG during their surgery
32963568|NCT05735808|Active Comparator|Standart physicain based education|In this arm, patient education will be conducted by the physician as the gold standard.
32963569|NCT05735808|Experimental|VR based education|In this arm, patient education will be performed using 3D educational material presented in VR glasses.
32963570|NCT05735730|Other|Epidemiologic study|This is an epidemiologic study. No arms are considered.
32963571|NCT05735652||Subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel|This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.
32963572|NCT05735418|Experimental|GI Biome #7|The intervention consists of daily administration of probiotics GI Biome #7 for four weeks.
32963573|NCT05735418|Placebo Comparator|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
32963574|NCT05735340|Active Comparator|Diabetes Education|Participants in this arm will receive traditional diabetes education following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
32963575|NCT05735340|Experimental|T1DES|Participants in this arm will receive a emotion regulation intervention called T1DES following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
32963576|NCT05735028|Experimental|CM group|CM+PD-1/PD-L1 inhibitor
32963577|NCT05735028|Active Comparator|Control group|PD-1/PD-L1 inhibitor
32963578|NCT05734872|Experimental|Experimental group|
32963579|NCT05734872|Other|Control group|
32963580|NCT05734638|Experimental|MIM-DASH|A trained MIM provider (layperson) and a registered dietitian will deliver the MIM DASH group intervention in eight 1-hour (30 minutes MIM and 30 minutes DASH) sessions via telehealth (video and telephone access).
32963581|NCT05734638|Experimental|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers."
32963582|NCT05734638|Experimental|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
32963583|NCT05734560|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (6920 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours followed by an injection of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor at week 2, radiation, and further injections of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor.
32963584|NCT05734482|Experimental|Biosimilar Product|CMAB015 150 mg Subcutaneous injection in upper arm
32963585|NCT05734482|Active Comparator|Reference Product|Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm
32963586|NCT05733624|Experimental|SCAI-001 0.01%|Cyclosporine 0.01%
32963587|NCT05733624|Experimental|SCAI-001 0.02%|Cyclosporine 0.02%
32963588|NCT05733624|Active Comparator|Restasis|Cyclosporine 0.05%
32963589|NCT05732376|Experimental|3D Printed Endoscopy Training Model Group|
32963590|NCT05732376|Active Comparator|Ready-Made Endoscopy Training Model Group|
32963591|NCT05732220|Experimental|EMA+ group|EMA assessment + EMA-based cessation counselling
32963592|NCT05732220|Active Comparator|EMA group|EMA assessment only + Usual peer counselling
32963593|NCT05732220|Active Comparator|Control|Usual peer counselling
32963594|NCT05730972|Experimental|true TEAS|"A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral Jiaji acupoint group (EX-B2) or the ipsilateral limb acupoint group(Hegu (LI4) - Waiguan (TE5), or Zusanli (ST36) - Sanyinjiao (SP6)), so as contralateral side.~A single TEAS treatment takes 30 min. TEAS specific parameters were dilatation wave 2/100 Hz and stimulus current intensity in degrees as tolerated by the patient.~7 days was considered as 1 session. Self-controlled treatment refers to not setting an upper limit on the number of treatment times, but must have met at least 3 days or 5 times of TEAS treatment within each session.~A total of 4 sessions of treatment were administered."
32963595|NCT05730972|Sham Comparator|sham TEAS|Each step of the sham TEAS operation is the same as the TEAS group. A total of 4 sessions of treatment were administered. 10 free TEAS treatments will be given after the trial.
32963596|NCT05730582|Active Comparator|Generic Screening Invitation|Patients randomized to this study arm will receive the generic letter to inform them that they are at risk for T2D and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. The letter is signed by the patient's primary care provider and sent in both English and Spanish. This letter was previously developed and has been in use by the Parkland Diabetes Detection Program.
32963597|NCT05730582|Experimental|Targeted-Tailored Screening Invitation|Patients randomized to this study arm will receive the tailored letter, which uses messaging developed collaboratively by patients and clinical stakeholders under a prior NIH-funded research study (STU 2021-0743), in addition to available EHR data, to inform patients that they are at risk for Type 2 Diabetes based on specific clinical characteristics and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they fast and complete testing at their clinic lab within 60 days. Fasting instructions will specify nothing to eat or drink except water for at least 8 hours. The letter will be signed electronically by the patient's primary care provider and sent in both English and Spanish.
32963598|NCT05730582|No Intervention|Standard of Care|Patients randomized to this study arm will receive opportunistic screening based on routine clinical activities. Patients will be assigned a study number for tracking purposes, but no intervention activities via the Parkland Dysglycemia Detection Program will occur for this study arm.
32963599|NCT05730192|Experimental|CADDIE colonoscopy (CADDIE Arm)|CADDIE is a computer-assisted detection (CADe) device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract.
32963600|NCT05730192|Active Comparator|Standard high-definition white light colonoscopy (Control Arm)|Patients will receive a standard colonoscopy
32963601|NCT05725200|Experimental|Individualized treatment in patients with metastatic colorectal cancer|"Interventions with anti-cancer drugs having marketing authorisation in Norway will be used in this study.~The intervention will be study drugs as monotherapy or treatment with approved combinations.~This trial will facilitate access to potentially effective interventions to which they would otherwise not have access."
32963602|NCT05724966||Registration of side effects|patients are to registrer side effects prior to treatment with Bortezomib through an app.
32963603|NCT05722080|Other|simulator Eyesi - new residents|Eyesi simulator learning curve for new ophthalmology residents
32963604|NCT05722080|Other|simulator Eyesi/sleep deprivation -confirmed residents|See how experienced residents perform after sleep deprivation using the Eyesi simulator
32963605|NCT05721144|Experimental|Experimental: Treatment Group|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room. The physician will follow their own institutional weaning protocols.
32963606|NCT05721144|No Intervention|Sham Comparator: Control Group|The delivery system will be set up anyway without studying gas administration
32963607|NCT05714592|Experimental|Optical genome mapping|
32963608|NCT05712252||Fallers without a fracture|Individuals who obtain no fracture.
32963609|NCT05712252||Fallers with a fracture|Individuals who obtain one or several fractures through fall. This group can be further subgrouped according to type of fracture.
32963610|NCT05701800|Experimental|mRNA-1468: Dose 1|Participants will receive placebo by intramuscular (IM) injection on Day 1 followed with mRNA-1468 by IM injection on Day 57.
32963611|NCT05701800|Experimental|mRNA-1468: Dose 2|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
32963612|NCT05701800|Experimental|mRNA-1468: Dose 3|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
32963613|NCT05701800|Experimental|mRNA-1468: Dose 4|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
32963614|NCT05701800|Active Comparator|Shingrix|Participants will receive Shingrix by IM injection on Day 1 and Day 57.
32963615|NCT05695092|Experimental|Experimental group|PMR session will be provided a night before competition
32963616|NCT05695092|Sham Comparator|Control group|Simple ROM for upper limbs and lower limbs
32963617|NCT05685732|Experimental|Cohort 1: SDX/d-MPH in 4-5 year old|13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH
32963618|NCT05685732|Placebo Comparator|Cohort 1: Placebo in 4-5 year old|matching placebo
32963619|NCT05685732|Experimental|Cohort 2: SDX/d-MPH in 6-12 year old|26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH, 52.3 mg/10.4 mg SDX/d-MPH
32963620|NCT05685732|Placebo Comparator|Cohort 2: Placebo in 6-12 year old|matching placebo
32963621|NCT05665140|Active Comparator|Arm A (Control)|"Three cycles of induction (isatuximab, bortezomib, lenalidomide, dexamethasone, I-VRD), followed by standard of care therapy (e.g. stem cell mobilization, and apheresis with a subsequent high-dose melphalan and autologous stem cell transfusion).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
32963622|NCT05665140|Experimental|Arm B (Experimental)|"Three cycles of induction (I-VRD), stem cell mobilization, and apheresis followed by three cycles of consolidation (I-VRD).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
32963623|NCT05664750|Experimental|TNM002|If randomized to TNM002, participant will receive a single IM gluteal injection of TNM002
32963624|NCT05664750|Active Comparator|Human tetanus immunoglobulin (HTIG)|If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
32963625|NCT05653518|Experimental|Closed-loop artificial pancreas (AP)|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
32963626|NCT05653518|Experimental|Sensor Augmented Pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's current insulin therapy (i.e., either insulin pump or multiple daily injections)
32963627|NCT05649306||Patients not receiving a cystectomy - Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
32963628|NCT05649306||Patients not receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
32963629|NCT05649306||Patients receiving a cystectomy- Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
32963630|NCT05649306||Patients receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
32963631|NCT05619744|Experimental|Part 1: RO7616789 QW: Dose Escalation|Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
32963632|NCT05619744|Experimental|Part 2: RO7616789 Q3W: Dose Escalation|Participants will receive a fixed dose of RO7616789, at a dose determined in Part 1, intravenously once every 3 weeks (Q3W) on Day 1 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
32963633|NCT05619744|Experimental|Part 3: Dose Expansion|Based on emerging data from Part 1 and 2, one or more dosing regimens will be further investigated in Part 3.
32963634|NCT05606484|Experimental|Intervention Group (IG)|They will perform an intradialysis physical exercise program with non-immersive virtual reality during the first two hours of hemodialysis treatment (n = 40).
32963635|NCT05606484|Active Comparator|Control Group (CG)|They will exercise with a static pedal during the first two hour of hemodialysis treatment (n = 40).
32963636|NCT05599698|Experimental|chemotherapy|chemotherapy
32963637|NCT05574894|Experimental|GH group|Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
32963638|NCT05574894|Active Comparator|Control group|No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
32963639|NCT05567952|Experimental|nirmatrelvir plus ritonavir for 5 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
32963640|NCT05567952|Other|placebo plus ritonavir for 5 days|placebo (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
32963641|NCT05563506|Experimental|Healthy Kids +|Three times a week for 30 weeks with each session lasting 1 hour.
32963642|NCT05562570|Experimental|Physical activity intervention coupled with standard post-cancer directed treatment care group|
32963643|NCT05562570|Other|Standard post-cancer directed treatment care control group|
32963644|NCT05554614|Experimental|BTW app with reward-based feedback|Teens will install the BTW app with reward-based feedback. This tracks driving performance while providing individualized driving feedback using gamification concepts.
32963645|NCT05554614|Experimental|BTW app with situational supervised driving practice|Teens will install the BTW app the same as the app with reward-based feedback in conjunction with a situational supervised driving practice intervention for teen-parent dyads.
32963646|NCT05554614|Sham Comparator|Sham BTW app|Teens will install the sham BTW app with driving performance tracking only.
32963647|NCT05533554|Experimental|Experimental group with intervention|The experimental group will receive the intervention. First, the group will undergo a pre-intervention evaluation lasting 120 minutes. The intervention will consist of two synchronized virtual sessions of brief intervention with a cognitive-behavioral approach where various persuasive communication strategies will be implemented, definition of hazardous alcohol consumption, establishment of a consumption goal, social skills to deal with pressure to consume and plan of pleasant activities alternative to consumption, each session will last 120 minutes. Four weeks after the end of the intervention, the experimental group will carry out the post-intervention evaluation session in a virtual synchronized manner with a duration of 120 minutes.
33104672|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
33104673|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
33104674|NCT00538161|Experimental|Low tidal volume arm|
33104675|NCT00538161|Active Comparator|Conventional tidal volume arm|
33104676|NCT00545415|Experimental|1|
33104677|NCT00545415|Experimental|2|
33406949|NCT05577702|Experimental|Arm A: Tislelizumab Monotherapy|Tislelizumab on a 3-week cycle for 2 cycles, followed by surgical resection (each cycle is 21 days)
33406950|NCT05577702|Experimental|Arm B: Tislelizumab and Ociperlimab|Tislelizumab + ociperlimab on a 3-week cycle for 2 cycles, followed by surgical resection (each cycle is 21 days)
32857875|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
32857876|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
32857877|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
32857878|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
32857879|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
32857880|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
32857881|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
32857882|NCT03014505|Active Comparator|The traditional treatments|
32857883|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
32857884|NCT05498181|Experimental|sacubitril/valsartan|Participants will take sacubitril/valsartan, beginning dose of 24/26mg twice daily, with titration to target dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug and being followed for a further two weeks (total study time of 18 weeks).
32857885|NCT05498181|Placebo Comparator|placebo|Participants will take equivalent placebo, beginning equivalent dose of 24/26mg twice daily, with titration to target equivalent dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug/placebo and being followed for a further two weeks (total study time of 18 weeks).
32857886|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~All of their embryo kept in prolonged culture~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~Supernumerary blastocysts cryopreserved"
32857887|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
32857888|NCT04977882|Experimental|Abdominal drainage|19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
32857889|NCT04977882|Experimental|Postoperative antibiotico-prophylaxis|postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
32857890|NCT04977882|No Intervention|Control group|No drainage nor postoperative antibiotico-prophylaxis
32857891|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
32857892|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
32857893|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
32857894|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
32857895|NCT04970238|Experimental|Levosimendan group|
32857896|NCT04970238|Placebo Comparator|placebo group|
33104678|NCT00545415|Experimental|3|
33104679|NCT00545415|Experimental|4|
33104680|NCT00545415|Experimental|5|
33104681|NCT00545415|Experimental|6|
33104682|NCT03397667|Other|Control|Primary Care
33104683|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
33104684|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
33406951|NCT05577702|Experimental|Arm C: Tislelizumab and LBL-007|Tislelizumab + LBL-007 on a 3-week cycle for 2 cycles, followed by surgical resection (each cycle is 21 days)
33406952|NCT04279158|Experimental|patients with optic ataxia (OA)|
33406953|NCT04279158|Experimental|patients with hemispatial neglect|
33406954|NCT04279158|Experimental|patients with attention-deficit hyperactivity disorder|
32857897|NCT04970394||Intervention|"The principal investigator reviews the medical notes of all individuals they consult over a period of three years to check if they are non responders. If confirmed as non responder, they receive a three-step verbal intervention:~Your cervical cancer screening is now overdue.~The test is easy to perform and saves thousands of lives from cervical cancer every year.~Should we book an appointment for cervical screening now so that you make sure you have it done?~Those who are seen face-to-face receive a fourth intervention:~An appointment slip is given to the patient to hand to the receptionist. This includes the patient's name and the comment, book an appointment with practice nurse for cervical screening."
32963648|NCT05533554|No Intervention|Control group|The control group will participate in a pre-intervention evaluation session. Four weeks after the end of the last intra-session evaluation session, the control group will participate in the post-intervention evaluation in a virtual synchronized manner with a duration of 120 minutes.
32963649|NCT05530278|Experimental|ABBV-576 with Galicaftor + Navocaftor|Participants will receive ABBV-576 for 14 consecutive days, with navocaftor + galicaftor for the latter 7 consecutive days.
32963650|NCT05530278|Experimental|Navocaftor + Galicaftor with ABBV 576|Participants will receive Navocaftor + galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
32963651|NCT05530278|Experimental|Optional: Navocaftor with ABBV 576|Participants will receive Navocaftor for 14 consecutive days with ABBV 576 for the latter 7 consecutive days.
32963652|NCT05530278|Experimental|Optional: Galicaftor with ABBV 576|Participants will receive Galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
32963653|NCT05530278|Experimental|Optional: Midazolam with ABBV-576 + Navocaftor|Participants will receive Midazolam alone and in combination with multiple doses of ABBV-576 + navocaftor.
32963654|NCT05489484|Experimental|MD-Shoulder Medical Device|MD-Shoulder Medical Device type I collagen based
33320646|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33327401|NCT05598892|Experimental|Robot-assisted Rehabilitation|Participants will receive rehabilitation based on hand robotic exosqueleton (ROBHAND, ITAP Valladolid, Spain) Patients will perform upper limb exercises assisted by the device. Training involve 16 sessions, 2 sessions per week for 8 weeks, each lasting about 60 minutes.
32963657|NCT05459298|Active Comparator|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
32963658|NCT05459298|Experimental|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day (when feedings reach about 120 -160 mL/kg/day). At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
32963659|NCT05438628||Patients scheduled for total knee arthroplasty surgery|
32963660|NCT05436288|Experimental|Single arm active|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S), up to 6 times a day for 4 weeks.
32963661|NCT05434962|Experimental|Cardiac resynchronization therapy (CRT) obtained by stimulating the left branch area|"The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. It is strongly encouraged the designation of a single and experienced implanting physician at each center for the LBBAP implant procedures.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be <2,5V@0,5ms."
32963662|NCT05434962|Active Comparator|Cardiac resynchronization therapy (CRT) obtained by biventricular pacing|"The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study.~Investigators may use any market approved right atrial (RA) pace/sense lead, right ventricular (RV) pacing/defibrillator lead with pace/sense capabilities and any market approved unipolar/bipolar/quadripolar LV pacing lead.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º).~Acceptable LV pacing threshold should be <3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold"
32963663|NCT05417958|Experimental|Extremely Thick - Mildly Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
33104685|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
33327402|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
33327403|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
33406955|NCT04279158|Active Comparator|Healthy volunteers|
32857898|NCT04970394||Control|The control group receives standard unstructured reminders regarding their overdue status from any of the 6 other clinicians during appointments and / or reminder letters from the administration team.
32857899|NCT04970160||TSARP|Is a surgical procedure
32857900|NCT04970160||ASARP classic|Surgical procedure
32857901|NCT04970160||PSARP|Surgical procedure
32857902|NCT04970160||Modified ASARP|Surgical procedure
32857903|NCT04977570|Experimental|SYHA1805|subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.
32857904|NCT04977570|Placebo Comparator|Placebo|subjects will be randomized to receive the matching placebo tablets.
32857905|NCT04970316||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
32857906|NCT04970316||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
32857907|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
32857908|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
32857909|NCT03062670|Experimental|Retreat|A full day off-site training session
32857910|NCT03062670|No Intervention|Control|Care teams normal process
32857911|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
32857912|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
32857913|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
32857914|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
32857915|NCT02038998|Sham Comparator|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
32857916|NCT02038998|Experimental|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
32857917|NCT02038998|Experimental|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
32857918|NCT04969614||kidney transplant recipients|kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine
32857919|NCT04969536|Experimental|Branched chain amino acid supplementation|Consumption of 8 ounces of water with addition of 2.5 g of leucine, 1.25 g of isoleucine, and 1.25 g of valine immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
32857920|NCT04969536|Placebo Comparator|Placebo|Consumption of 8 ounces of a flavor matched beverage sweetened with a sucralose-based drink mix immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
32857921|NCT05486559|Experimental|The ECMO-free Protocol group|For patients assigned to the ECMO-free protocol group, the study personnel will perform the ECMO-free protocol daily from enrollment until the first of death or ECMO decannulation; results will be recorded and shared with the treatment team. Final decisions regarding decannulation will be made by treating clinicians who are aware of the results of daily ECMO-free protocolized assessments.
32857922|NCT05486559|Active Comparator|The Usual Care Group|For patients assigned to the usual care group, ECMO weaning and assessments of readiness for ECMO decannulation will be at the discretion of treating clinicians.
32857923|NCT04969458||participants|The study included individuals whose native language is Turkish, who are over the age of 18 and under the age 70, diagnosed with chronic low back pain, without Psychiatric disorder, Cognitive impairment, Dementia, or Alzheimer's and who want to participate in the study.
32857924|NCT04977258|Active Comparator|Control group|Only treadmill aerobic exercise with 60 min recovery in supine position.
32857925|NCT04977258|Experimental|Controlled hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water predetermined intake.
32857926|NCT04977258|Experimental|Ad Libitum hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water intake in an uncontrolled manner.
32857927|NCT04432194|No Intervention|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
32857928|NCT04432194|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
32857929|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
32857930|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
32963664|NCT05417958|Experimental|Extremely Thick - Mildly Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
32963665|NCT05417958|Experimental|Mildly Thick - Extremely Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
32963666|NCT05417958|Experimental|Mildly Thick - Extremely Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
32963667|NCT05383170|Experimental|Arm A: advanced or metastatic HNSCC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic HNSCC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
32963668|NCT05383170|Experimental|Arm B: advanced or metastatic melanoma|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic melanoma. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
32963669|NCT05383170|Experimental|Arm C: advanced or metastatic TNBC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic TNBC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
33406956|NCT04251156|Experimental|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
33406957|NCT04251156|Placebo Comparator|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
32963670|NCT05378568|Experimental|the selection scheme of peripheral venous access devices|To implement the selection scheme of peripheral venous access devices, based on the Clinical Practice Guideline on Infusion Therapy in Children. Then observe the appropriateness of peripheral venous access devices selection.
32963671|NCT05378568|Active Comparator|the existing nursing routine|Follow the existing nursing routine of intravenous infusion and the selection of peripheral venous access devices.
32963672|NCT05374512|Experimental|Dato-DXd|Arm 1: Dato-DXd
32963673|NCT05374512|Active Comparator|Investigator's Choice of Chemotherapy (ICC)|"Arm 2:~If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI > 12 months, paclitaxel or nab-paclitaxel~If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin."
32963674|NCT05360706||CSL220|AAV5 containing a codon-optimized human factor IX gene
32963675|NCT05359692|Experimental|Part 1: Cohort 1|INCAGN01876 every 2 weeks (Q2W) with retifanlimab every 4 weeks (Q4W).
32963676|NCT05359692|Experimental|Part 1: Cohort 2|INCAGN01876 Q2W with retifanlimab Q4W.
32963677|NCT05359692|Experimental|Part 2 (Expansion): Treatment Group A|INCAGN01876 and retifanlimab combination in participants who have been previously treated with anti-PD-(L)1 therapy.
32963678|NCT05359692|Experimental|Part 2 (Expansion): Treatment Group B|INCAGN01876 and retifanlimab combination in participants who are naive to anti-PD-(L)1 therapy.
32963679|NCT05318976|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 23 weeks.
32963680|NCT05318976|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 23 weeks.
32963681|NCT05312658|Experimental|Routine external aortic compression|The assistant surgeon or nurse places heel of the hand or fist over the abdominal aorta immediately after the baby is born while the surgeon helps the baby out, the placenta is expulsed or fetched, and the surgeon gains control over bleeding. The compression should be held until controlled bleedning, for example until the first layer of the uterine incision is sutured. Maximum time of aortic compression is 20 minutes, then a 5 minute break is required, after which compression may be reapplied.
32963682|NCT05312658|No Intervention|No external aortic compression|No routine aortic compression. If deemed vital to the mother, aortic compression should be exerted. Aortic compression may be exerted if bleeding exceeds 1000 ml.
32963683|NCT05312268|Other|Group A|Rasburicase treatment at week 1, 4 and 8 with stable dose oral urate-lowering therapy for 24 weeks.
32963684|NCT05312268|Other|Group B|Rasburicase treatment at week 12, 16 and 20 with stable dose oral urate-lowering therapy for 24 weeks.
32963685|NCT05256966|Active Comparator|Sauna|Firefighters/participants based at the station with an existing sauna will be allocated to the intervention arm/sauna group. They will include a sauna session, as per study protocol, which is the intervention.
32963686|NCT05256966|No Intervention|Non Sauna|Firefighters/participants based at the stations without a sauna will be allocated to the control arm/Non sauna group. They will not sauna, as per study protocol, as to not receive the study intervention.
32963687|NCT05245734|Experimental|Main group|"Patients receive two prophylactic doses of the Human Anti-D (rh) immunoglobulin at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery. Patients receive the second dose only in the case of the birth of an Rh-positive child.~Before and after each injection of the drug, blood will be taken to control the level of anti-Rh0 (D) antibodies. after the last injection of the drug, blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen.~15 participants from the Main group are formed the Pharmacokinetics subgroup for additional blood samples taking, to determine the pharmacokinetic parameters"
32963688|NCT05242692|Experimental|S-ketamine|S-ketamine (50 mg, 2 ml) is diluted to 50 ml (1 mg/ml) with 48 ml normal saline;
32963689|NCT05242692|Active Comparator|Dexmedetomidine|Dexmedetomidine (200 ug, 2 ml) is diluted to 100 ml (2 ug/ml) with 98 ml normal saline;
32963690|NCT05242692|Placebo Comparator|Normal saline|Control group only contains 50 ml normal saline in light of blindness
32963691|NCT05236062|Experimental|Exercise Group|"Home-based, virtually supervised via Zoom, 3x weekly for 12-weeks aerobic and resistance exercise program~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
32963692|NCT05236062|Experimental|Attention control Group|"Home-based, 12-week stretching program only with participants asked not to change their activity behavior.~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
32963693|NCT05235282|Experimental|Usual care + IQoro|The intervention group receives usual training of swallowing function along with training 3 times each day with an IQoro oral screen
32963694|NCT05235282|Active Comparator|Usual care|The comparison group receives usual training of swallowing function
33327404|NCT03336112|Experimental|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
33327405|NCT03336112|Active Comparator|Control group|Information program delivered by the Internet during 5 weeks.
33327406|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
33327407|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
33327408|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
33327409|NCT05598580|Experimental|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
32963697|NCT05211648|Experimental|Patients with Aktiia bracelet|This is a prospective open-label single arm study. Study participants will wear the Aktiia bracelet for 6 months and will continue in parallel the procedures of the Remote Hypertension Program.
32963698|NCT05193552|No Intervention|Control Group|11 subjects will be treated for 6 months at their current dose of Hizentra
32963699|NCT05193552|Experimental|Treatment Group|11 subjects will have their level of IGRT increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.
32963700|NCT05150184||Healthy adults, various ethnicities|Non-interventional
32963701|NCT05131620|Experimental|Venture in the Virtual Reality Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. After CAG, 10 minutes before the catheter extraction, the patients will be selected from videos such as park and nature walks, beach and seaside walks, underwater, museum tour, and virtual reality glasses will be put on and will be worn during the procedure. In the literature, VR glasses were put on 5-10 minutes before the procedure, continued throughout the procedure, and used for a total of 30-60 minutes. Catheter extraction takes approximately 15-20 minutes and it is planned to continue the virtual reality glasses viewing period for 30 minutes. VAS will be applied during the catheter extraction process, and VAS, SAI and PCS will be applied to all patients after catheter extraction. Vital signs of patients will be recorded before, during and after catheter extraction.
32963702|NCT05131620|Experimental|Venture in the Acupressure Group|Initiative in the Acupressure Group Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Acupressure will be applied 10 minutes before catheter extraction after CAG. Catheter extraction takes approximately 15-20 minutes. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
32963703|NCT05131620|No Intervention|Control Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Routine application will be made. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
32963704|NCT05130450|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
32963705|NCT05126472|Experimental|anti-CD40 antibody 2141-V11|Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses.
32963706|NCT05116722|Experimental|Shoulder Pacemaker Treatment|The patients will be treated using the pacemaker for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
32963707|NCT05110404|Active Comparator|Group (A): The high-volume HIIT|Exercise group A (n=30): It will include patients that will perform high-volume high-intensity interval training (HIIT), and will receive medical intervention.
32963708|NCT05110404|Active Comparator|Group (B): The low-volume HIIT|Exercise group B (n=30): will receive medical intervention. that will perform the low-volume high-intensity interval training, and will receive medical intervention.
32963709|NCT05110404|No Intervention|Group C|patients will receive medical intervention only.
32963710|NCT05087940||Resistant hypertension|The adult patients with resistant hypertension which is defined as casual blood pressure during clinical examination of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, typically an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker (CCB). All reference blood pressures will be taken as a mean of the 2nd and 3rd measurements in physician's office during a single examination, measured at least 3 min apart. The following add-on therapy is available in Serbia, where the study is conducted: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic (e.g. furosemide), a thiazide in large daily dose, an alpha 1 selective blocker and a beta 1 selective blocker.
32963711|NCT05077566|Active Comparator|Exercise at 60% vo2|This arm will receive 15 minutes of exercise at 60% VO2 max.
32963712|NCT05077566|Experimental|Exercise at 90% vo2|This arm will receive 15 minutes of exercise at 90% VO2 max.
32963713|NCT05077566|No Intervention|No intervention|No intervention
33406958|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
33406959|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
33406960|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
33406961|NCT04821726|Experimental|Drug eluting balloon (Vmoky)|A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
32857931|NCT04977492||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
32857932|NCT04977492||control group|People suffered from excessive lateral pressure syndrome with conservative treatment.
32857933|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
32857934|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
32857935|NCT04977102|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
32857936|NCT04977102|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
32857937|NCT04968756|Experimental|Treatment with the SPECTRALIS CENTAURUS device|"In Stage 1, two laser pattern will be applied in areas of the retina that require ablative laser photocoagulation.~In Stage 2, a laser pattern will be applied along and on the outside of the arcades. Furthermore, a treatment pattern will be applied to an area temporal to the fovea affected by intermediary age-related macular degeneration (AMD) and confluent soft drusen."
32857938|NCT04968600|Experimental|Posterior-cruciate-ligament-retaining (CR)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
32857939|NCT04968600|Experimental|posterior-cruciate-ligament-stabilized (PS)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
32857940|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
32857941|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
32857942|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
32857943|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
32857944|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
32857945|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
32857946|NCT03252951|Experimental|Eccentric Training|
32857947|NCT03252951|Experimental|Concentric Training|
32857948|NCT03252951|Experimental|Isometric Training|
32857949|NCT03252951|Active Comparator|Biofeedback|
32857950|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
32857951|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
32857952|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
32857953|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
32857954|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
33327410|NCT05598580|Experimental|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
33104686|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33104687|NCT05122689|Experimental|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
33104688|NCT05122689|Placebo Comparator|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
33406962|NCT04810260|Active Comparator|HIV +|Patients will have the application and use it to increase their awareness about their medical condition.
33406963|NCT04810260|Active Comparator|HIV -|Patients will have the application and use it to increase their awareness about their medical condition.
32857955|NCT05451225|Experimental|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
32857956|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
32857957|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
32857958|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
32857959|NCT05427981|Experimental|Buprenorphine|Buccal Films
32857960|NCT05427981|Placebo Comparator|Placebo|Buccal Films
32857961|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
32857962|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
32857963|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
32857964|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
32857965|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
32857966|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
32857967|NCT05409105|Experimental|Mangoes|Frozen mangoes, 2 cups per day (with 2 cups water), 2 weeks.
32857968|NCT05409105|Active Comparator|Water|Bottled water, 2 cups per day
32857969|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
32857970|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
32857971|NCT02552823|Placebo Comparator|White bread 1|Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
32857972|NCT02552823|Experimental|Pea variety 1 with rice|Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
32857973|NCT02552823|Experimental|Pea variety 2 with rice|Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
32857974|NCT02552823|Experimental|Pea variety 3 with rice|Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
32857975|NCT02552823|Experimental|Rice|Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
32857976|NCT02552823|Placebo Comparator|White bread 2|Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
32857977|NCT02552823|Experimental|Pea variety 1 with potato|Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
32857978|NCT02552823|Experimental|Pea variety 2 with potato|Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
32857979|NCT02552823|Experimental|Pea variety 3 with potato|Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
32857980|NCT02552823|Experimental|Potato|Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants
32857981|NCT05376969|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
32857982|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
32857983|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
32857984|NCT05339607|Experimental|Intervention|
32857985|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part 1A receive pembrolizumab intravenously (IV) 200 mg every three weeks (Q3W) + PEG-IFN at assigned dose subcutaneously (SC) once a week for up to ~2 years.
32857986|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 1 mg/kg Q3W for up to ~12 weeks.
32857987|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 50 mg every 6 weeks (Q6W) for up to ~24 weeks.
32857988|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 100 mg every 12 weeks (Q12W) for up to ~48 weeks.
32857989|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
32857990|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
32857991|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
32857992|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
32899068|NCT00265616|Active Comparator|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
33104689|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
33327411|NCT05598580|No Intervention|Control|Participants will continue to receive antiretroviral therapy without other intervention and be monitored for 48 weeks.
33104690|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
33406964|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
33104691|NCT03383081|No Intervention|Control groups|No intervention
33104692|NCT05120739|Experimental|Interventional|Skin preparations (the day before and the morning of the operation) with the 2% CHX cloths
33104693|NCT05120739|No Intervention|Control|Skin preparations (the day before and the morning of the operation) with the 4% CHX soap (standard of care)
32857993|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
32857994|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
33104694|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
33327412|NCT01287468||Experimental Group|
33327413|NCT01287468||Control Group|
33406965|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
32857995|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
32857996|NCT04730609|Experimental|Dexmedetomidine|IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.
32857997|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
32857998|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
32857999|NCT04730531|Experimental|Treatment Arm|Local infiltration with 0.25% bupivacaine and epinephrine
32858000|NCT04730531|Placebo Comparator|Control Arm|Placebo of equal volume injectable saline
32858001|NCT01092195|Active Comparator|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
32858002|NCT01092195|Active Comparator|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
32858003|NCT01092195|Active Comparator|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
32858004|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
32858005|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
32858006|NCT05569733||VSS|Patients with visual snow syndrome
32858007|NCT05569733||controls|healthy, screened age-matched controls
32858008|NCT05307003||Quetiapine|"Patients diagnosed with delirium who received quetiapine for treatment.~Start study medication at 25 mg daily PO ; may increase to BID (twice a day) or TID (three times a day) if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE (adverse effects) likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
32858009|NCT05307003||Trazodone|"Patients diagnosed with delirium who received trazodone for treatment.~Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
32858010|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32858011|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
32858012|NCT05293743|Active Comparator|Straight bar|This group will continue using the straight bar as part of their brace, per their current treatment.
32858013|NCT05293743|Experimental|Dynamic bar|This group will use the novel dynamic bar for 30 days instead of their standard straight bar.
32858014|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
32963714|NCT05069220|Experimental|18F-MFBG PET/CT in neuroendocrine malignancies|Each patient receive a single intravenous injection of 18F-MFBG 2-4 MBq/kg and undergo PET/CT scan after 60 min post-injection. Patients with neuroblastoma should have a routine clinical 123I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.
32963715|NCT05056506|Active Comparator|Endoscopic papillary large balloon dilation group|Endoscopic papillary large balloon dilation to extract bile duct stones
32963716|NCT05056506|Experimental|Endoscopic papillary Large balloon dilation combined with limited endoscopic sphincterotomy group|Endoscopic papillary large balloon dilation combined with limited endoscopic sphincterotomy to extract bile duct stones
32963717|NCT04993326|Other|Intervention|"emPOWERed to Change~Online Courses:~4 Critical Step to Manage Diabetes modules~Step 1 Learn about diabetes~Step 2 Know your diabetes ABCs~Step 3 Learn how to live with diabetes~Step 4 Get routine care to stay healthy Diabetes + COVID-19 Protection and Prevention modules~Introduction to understanding COVID-19 and the risks specific to T2DM~Learn preventive and protective measures to avoid COVID-19~COVID-19 Vaccine education and Discussion guide~Community resource guide to access COVID-19 testing and vaccination Stress Management modules~Understanding of the relationship between diabetes and stress~Learn stress management techniques for diabetes Ongoing Program Support: Motivation for participation, medication adherence, accountability and peer-to-peer interaction and support (bi-weekly text messages & private and closed Facebook community support group with peers and professionals)"
32963718|NCT04993326|No Intervention|Control|Usual Standard of Care as deemed by participants provider(s)
32963719|NCT04975152|Experimental|Neoadjuvant Cemiplimab Treatment|Participants will receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection. After surgery they will continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses.
32963720|NCT04964934|Experimental|AZD9833 + palbociclib or abemaciclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + anastrozole placebo ( PO, once daily) or letrozole placebo ( PO, once daily)
32963721|NCT04964934|Active Comparator|Anastrozole or letrozole + palbociclib or abemaciclib|The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125,100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + AZD9833 placebo (PO, once daily)
32963722|NCT04939038|Active Comparator|Control Arm|Standard wound care for diabetic wound ulcer
32963723|NCT04939038|Experimental|Immediate revascularization|Patient will have revascularization 0 - 7 days after initial wound assessment and then receive standard wound care for diabetic wound ulcer
33327414|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
33327415|NCT01287546|Experimental|LY2875358|
32963724|NCT04930770|Experimental|Renal/renopancreatic transplant's patients with a verified seronegativity|
32963725|NCT04926636|No Intervention|Standard Mobile App|This group will be supplied with Novidan DTC hearing aids and documentation following standard of care as a control. They will be provided with the mobile application allowing for the monitoring of data for study analysis and personal control of their hearing aids, but not Health and Wellness Coaching features.
32963726|NCT04926636|Experimental|Enhanced Mobile App with Health Coaching|This group will also be supplied with the Novidan DTC hearings aids and documentation, same as the control group, but will be supplied the enhanced mobile application that allows for participation in health coaching features. They will be assigned to a health coach and will have coaching sessions scheduled.
32963727|NCT04923048|Experimental|GB261|Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.
32963728|NCT04922658|Experimental|Surufatinib|
32963729|NCT04922658|Experimental|Surufatinib plus Vinorelbine|
32963730|NCT04915404|Experimental|pK Assessment of Berubicin and its active metabolite|The first 18 patients will undergo a pK assessment of Berubicin and it's active metabolite Berubicinol during the dosing days of the first two cycles. After 18 patients are done n intern analysis will new performed.
32963732|NCT04883346|Experimental|Liraglutide|Treated with Liraglutide
32963733|NCT04879602|Experimental|Bronchoscopy group|patients receive suction before extubation by bronchoscopy in PACU
32963734|NCT04879602|No Intervention|Control group|patients receive routine ordinary suction in PACU
32963735|NCT04862910|Experimental|Kinect Based Virtual Reality Training|Kinect-Based Virtual Reality Training. Routine Medication and routine diet will be continued.
32963736|NCT04862910|Other|Control Group|Moderate-level regular physical activity with a routine diet and routine Medication
32963737|NCT04794660|Active Comparator|Arm 1|In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.
32963738|NCT04794660|Active Comparator|Arm 2|In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy
32963739|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
32963740|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
32963741|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
32963742|NCT04767594||First-line Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy
32963743|NCT04764942|Experimental|Arm A (selinexor, dexamethasone, carfilzomib, carfilzomib)|Patients receive selinexor PO and dexamethasone PO on days 1, 8 15, and 22, carfilzomib IV on days 1, 8, and 15, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
33327416|NCT01287546|Experimental|LY2875358 + erlotinib|
33327417|NCT01287546|Experimental|LY2875358 at Part A highest dose|
33327418|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
33327419|NCT05598268|Experimental|T3011 Herpes Virus Injection|
32858015|NCT03153995|Active Comparator|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
32858016|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
32858017|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
32858018|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
32858019|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
32858020|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
32858021|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
32858022|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
32858023|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
32858024|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
32858025|NCT00967863|Experimental|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
32858026|NCT00967863|Experimental|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
32858027|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
32858028|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
32858029|NCT05186727|Active Comparator|Researcher-Group|Education delivered in a group session by a member of the research team
32858030|NCT05186727|Active Comparator|Research-One on One|Education delivered telephonically one-on-one by a member of the research team
32858031|NCT05186727|Active Comparator|Patient Ambassador-Group|Education delivered in a group session by a Patient Ambassador (a peer mentor)
32858032|NCT05186727|Active Comparator|Patient Ambassador- One on One|Education delivered telephonically one-on-one by a Patient Ambassador (peer mentor)
32858033|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
32858034|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
32858035|NCT05163717|Experimental|INP105|POD-olanzapine (INP105), 5 mg, single dose, to be delivered to each participant
32858036|NCT05163717|Placebo Comparator|Placebo|POD-placebo, single dose, to be delivered to each participant
32858037|NCT05496335|Experimental|AGN-151586, BOTOX|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
32858038|NCT05496335|Experimental|Placebo, BOTOX|Participants will receive 5 intramuscular injections of placebo in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
32858039|NCT05433935||Prospective IPMN cohort|Multi-omics analysis of 5000 prospectively collected samples.
32858040|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
32858041|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
32858042|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
32858043|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
32858044|NCT03153605|Experimental|SATISI_7|
32858045|NCT01097343|Active Comparator|75 mg clopidogrel|
32858046|NCT01097343|Active Comparator|150 mg clopidogrel|
32858047|NCT05347901||Health Control|Health children with age and sex paired with experimental group
32858048|NCT05347901||Kawasaki Disease|KD patients, with no congenital heart disease, metabolic disease or Immune deficiency disease.
32858049|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
32858050|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
32858051|NCT05347745|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue
33406966|NCT04741542|Experimental|Group A|Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
32963744|NCT04764942|Experimental|Arm B (selinexor, dexamethasone, pomalidomide)|Patients receive selinexor PO and dexamethasone PO on days 1, 8, 15, and 22, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
32963745|NCT04696146|Experimental|Berinert|Berinert 500 units
32963746|NCT04696146|Placebo Comparator|Placebo|Normal Saline in identical volume to Berinert
32963747|NCT04676646|Experimental|Open-label run-in phase|"Cohort 1 (4 weeks duration): Patients who are hyperkalemic at study entry will begin SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily).~Cohort 2 (up to 6 weeks duration): Patients who develop hyperkalemia during the uptitration of spironolactone will receive SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
32963748|NCT04676646|Experimental|Randomized withdrawal phase (6 months)|"SZC arm and Placebo arm: Patients will continue on the SZC dose they were receiving at the end of the run-in phase.~The SZC / Placebo dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
32963749|NCT04660968|Experimental|Dyadic Health Behaviour Change Intervention|The dyadic health behaviour change intervention is a 10 sessions program provided over 16 weeks. It includes nutritional, physical activity and sedentary related information, as well as couples-based adaptation of motivational interviewing, self-monitoring, goals setting, stimulus control, problem-solving, and relapse prevention as well as specific strategies to support their partner's autonomy and intrinsic motivation.
32963750|NCT04660968|Active Comparator|Dyadic nutrition counselling intervention|The couples-based nutrition counselling intervention is a 10 sessions program provided over 16 weeks. Topics are based on Dietitians of Canada's Practice-based Evidence in Nutrition discussions. Participants are also encouraged to meet the current physical activity recommendations. Both members of the couples are seen at the same, but no intervention target specifically the behaviour change process or the romantic relationship.
32963751|NCT04633200|Experimental|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
32963752|NCT04633200|No Intervention|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
32963753|NCT04594902|Experimental|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
32963754|NCT04594902|Active Comparator|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
32963755|NCT04544436|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
32963756|NCT04544436|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
32963757|NCT04543188|Experimental|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
32963758|NCT04543188|Experimental|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
32963759|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
32963760|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
32963761|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
32963762|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and prior BRAF inhibitor utilization
32963763|NCT04543188|Experimental|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
32963764|NCT04543188|Experimental|Expansion Phase Drug-Drug Interaction Substudy (Part B Optional Cohort 6)|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
33406967|NCT04741542|Experimental|Group B|Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
33406968|NCT04741542|Experimental|Group C|Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
32963765|NCT04543188|Experimental|Expansion Phase (Part B Optional Cohort 7)|PF-07284890 (at the recommended dose for expansion when administered with food) plus binimetinib in participants with BRAF V600 solid tumor
33406969|NCT04741542|Experimental|Group D|Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
32963766|NCT04538742|Experimental|Module 1- T-DXd and Durvalumab|T-DXd and Durvalumab
32963767|NCT04538742|Experimental|Module 2- T-DXd and Pertuzumab|T-DXd and Pertuzumab
32963768|NCT04538742|Experimental|Module 3- T-DXd and Paclitaxel|T-DXd and Paclitaxel
32963769|NCT04538742|Experimental|Module 4- T-DXd and Durvalumab and Paclitaxel|T-DXd and Durvalumab and Paclitaxel
32963770|NCT04538742|Experimental|Module 0- T-DXd|T-DXd
32963771|NCT04538742|Experimental|Module 5 - T-DXd and Tucatanib|T-DXd and tucatinib
32963772|NCT04538742|Experimental|Module 6 - T-DXd and Tucatinib|T-DXd and tucatinib in patients with active brain metastases (Part 2 Only)
33406970|NCT04129242|Active Comparator|"paired taVNS + Task Specific Training"|
32963773|NCT04538742|Experimental|Module 7 - T-DXd|T-DXd monotherapy in patients with active brain metastases (Part 2 Only)
32963774|NCT04441086|Experimental|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively. Intervention provided in addition to usual cardiac rehabilitation.
32963775|NCT04441086|Active Comparator|Healthy living active control|Healthy living strategies based on American Heart Association education. Intervention provided in addition to usual cardiac rehabilitation.
32963776|NCT04441086|No Intervention|Usual care|Usual cardiac rehabilitation with no additional intervention.
32963777|NCT04438902|Experimental|osimertinib combined with anlotinib|
32963778|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 8 times for adults and up to 5 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
32963779|NCT04346394|Experimental|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
32963780|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
32963781|NCT04326036|Experimental|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
32963782|NCT04326036|Experimental|Isolation & Concentration of cSVF|Isolation & Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
32963783|NCT04326036|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
32963784|NCT04326036|Other|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
32963785|NCT04326036|Other|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
32963786|NCT04309188|Experimental|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
32963787|NCT04309188|Active Comparator|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
32963788|NCT04303572|Experimental|Eloctate ITI plus Emicizumab|Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
32963789|NCT04303572|Active Comparator|Eloctate ITI|Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
32963790|NCT04282668|Experimental|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
32963791|NCT04282668|Experimental|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
32963792|NCT04275180|No Intervention|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
32963793|NCT04275180|Experimental|Argatroban group|Argatraban is used on the basis of standard medical treatment.
32963794|NCT04177602|Experimental|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
32963795|NCT04177602|Active Comparator|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
33406971|NCT04129242|Active Comparator|"unpaired taVNS + Task Specific Training"|
33104695|NCT03373916|Active Comparator|Enhanced Usual Care (EUC)|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
32858052|NCT04352829|Experimental|EXPERİMENTAL GROUP|1st day, patients were asked to use an MDI sample that didn't contain an active agent. At the same time, they filled the MDI Skill Evaluation Form, obtaining 'the scores of the 1st measurement'. Next, MDI use was explained through the video twice. After each video and explanation, the patients were asked to use the same MDI sample for 10 min. Simultaneously, the skills were marked by the researcher through observation on the form, obtaining 'the scores of the 2nd measurement'. 2nd day, they were again asked to use the MDI. While using the MDI, the form was marked and 'the scores of the 3rd measurement' were found. Later, a video session was held as on the 1st day, the video was watched twice, and after each repetition, were requested to use the MDI again. While they were using the MDI, the skills were simultaneously marked on the form and 'the scores of the 4th measurement were determined. 3rd day, all steps were repeated.
32858053|NCT04352829|No Intervention|CONTROL GROUP|20 patients were recruited to the control group. The controls received a routine training on MDI from their clinic nurses including verbal explanation of MDI use. The controls received training about MDI use in line with ethical principles and watched the video once after the 5th measurement. After the study, participants who wished to watch the training video again were provided internet links.
32858054|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
32858055|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
32858056|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
32858057|NCT04729127|No Intervention|Treatment as usual|The families keep receiving their treatment as usual
32858058|NCT04729127|Active Comparator|ImPACT at a dose of 1 hour/week|ImPACT at a dose of 1 hour/week over 6 months
32858059|NCT04729127|Active Comparator|ImPACT at 4 hours/week|ImPACT at 4 hours/week over 6 months.
32858060|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
32858061|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
32858062|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
32858063|NCT02085941|Experimental|MRI guided cryoablation +/- biopsy|Intraoperative MRI guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
32858064|NCT02085941|Experimental|PET-CT guided cryoablation +/- biopsy|Intraoperative PET-CT guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
32858065|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
32858066|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
32858067|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
32858068|NCT01098747|Experimental|Treatment A|
32858069|NCT01098747|Active Comparator|Treatment B|
32858070|NCT01098747|Active Comparator|Treatment C|
32858071|NCT01098747|Placebo Comparator|Treatment D|
32858072|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
32858073|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
32858074|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
32858075|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
32858076|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
32858077|NCT05088681||Peripheral neuropathies patients|"Peripheral neuropathies patients will be assessed at baseline, after a 20 session 2-3/w program of physical therapy and at a follow up of 3 months with:~Total Neuropathy Score-clinical version (TNSc©)~Nerve conduction studies~Short Form Health Survey 36 (SF-36)~Functional Independence Measure (FIM)~postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):centre of pressure (COP) displacement of force platform; surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)~Six Minute Walking Test (6MWT), Mini Balance Evaluation System Test (MiniBESTest) and Timed Up and Go test (TUG)."
33406972|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
32963796|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963797|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963798|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963799|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963800|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963801|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
32963802|NCT04150068|Experimental|Cohort 1A: Lenacapavir|"Participants with human-immunodeficiency virus-1 ribonucleic acid (HIV-1 RNA) ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) lenacapavir 927 mg and will initiate an OBR at Day 1 SC Visit (14 days after the first dose of oral lenacapavir). Participants will receive their subsequent SC lenacapavir injection at Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
32963803|NCT04150068|Placebo Comparator|Cohort 1B: Placebo to Lenacapavir|"Participants with HIV-1 RNA ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral lenacapavir placebo on Days 1, 2, and 8 while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral lenacapavir 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg while continuing OBR. Participants will receive their next SC injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue study in the country."
32963804|NCT04150068|Experimental|Cohort 2: Lenacapavir|"Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA < 400 copies/mL or if Cohort 1 is fully enrolled will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC lenacapavir 927 mg at Day 1 SC Visit (14 days after the first dose of oral lenacapavir) while continuing their OBR. Participants will receive their subsequent SC lenacapavir injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given the option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
32963805|NCT04148352|Experimental|Dupilumab|24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
32963806|NCT04148352|Placebo Comparator|Placebo|24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
32963807|NCT04135482||CD|patients with severe crohn's disease
32963808|NCT04084080|Experimental|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
32963809|NCT04084080|Active Comparator|Standard of care|Randomized to standard of care
32963810|NCT03992430|Experimental|Part 1: Eteplirsen|Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.
32963811|NCT03992430|Active Comparator|Part 2: Eteplirsen 30 mg/kg|Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
32963812|NCT03992430|Experimental|Part 2: Eteplirsen 100 mg/kg|Randomized participants will receive eteplirsen 100 mg/kg once weekly before the selection of the high dose occurs and then will receive the selected high dose once weekly for up to 144 weeks.
32963813|NCT03992430|Experimental|Part 2: Eteplirsen 200 mg/kg|Randomized participants will receive eteplirsen 200 mg/kg once weekly before the selection of the high dose occurs and then will receive the selected high dose once weekly for up to 144 weeks.
32963814|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
32963815|NCT03849066||Cross-Sectional PRSA|This will be a cross-sectional analysis of children with neurological impairment and polypharmacy.
32963816|NCT03847428|Experimental|Arm A|Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
32963817|NCT03847428|Experimental|Arm B|Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
32963818|NCT03847428|Placebo Comparator|Arm C|Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)
33104696|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
32963819|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
32963820|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
32963821|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
32963822|NCT03816618|Experimental|CONTROL|CONTROL GROUP
32963823|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
32963824|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
32963825|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
32963826|NCT03770598|Active Comparator|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
32963827|NCT03770598|Active Comparator|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
32963828|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
32963829|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
32963830|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
32963831|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
32963832|NCT03662646||IBD patients|
32963833|NCT03662646||Healthy controls|
32963834|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
32963835|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
32963836|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
32963837|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
32963838|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with RT for 6 -7 weeks. Each subsequent cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 26 cycles at RP2D of 200mg/m2 with a maximum dose capped at 400mg for patients with BSA ≥2.0
32963839|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
32963840|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
32963841|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
32963842|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
32963843|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
32963844|NCT03522246|Experimental|Arm A|oral rucaparib + intravenous (IV) nivolumab
32963845|NCT03522246|Experimental|Arm B|oral rucaparib+IV placebo
32963846|NCT03522246|Experimental|Arm C|oral placebo+ IV nivolumab
32963847|NCT03522246|Placebo Comparator|Arm D|Oral placebo + IV placebo
32963848|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
32963849|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
32963850|NCT03464292|Placebo Comparator|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
33104697|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
32858078|NCT05088681||Healthy age-matched subjects|"Healthy age-matched subjects will receive a postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):~centre of pressure (COP) displacement of force platform;~surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)."
33104698|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
33104699|NCT03338387|Placebo Comparator|Placebo|"Other Names:~Placebo (for Olbetam)"
33104700|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
33104701|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
33104702|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
33104703|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments~Day 2: Tasks"
33104704|NCT05112549|Experimental|intrathecal Nivolumab|"This is a prospective, interventional, open label, multicenter phase I trial in leptomeningeal disease in subjects with solid tumor that have a registered indication for intravenous treatment with PD1 antibody. Subject will undergo 6 cycles each 14 days in duration and a safety visit 7 days after the 3th dosage and 7 days after the 6th dosage. The Follow-up phase will start four weeks after the last dose and will continue monthly (up to 4 Follow-up visits in total).The study consists of two parts:~Part I dose - escalation phase (3 + 3 design) with 4 cohorts and each subject will receive an intrathecal nivolumab treatment with a fixed predefined dose (20 mg, 30 mg, 40 mg or 50 mg). On each dose level, exposure of subjects to intrathecal nivolumab will follow a staggered approach. Part II dose expansion phase: subjects will receive an intrathecal PD1 treatment with a fixe dose, depending on the results from Part I."
33104705|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
32858079|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
32858080|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
32858081|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
32858082|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
32858083|NCT05073549|Experimental|Collaborative antimicrobial stewardship group|Collaborative antimicrobial stewardship intervention will be implemented in NICUs of this group.
32858084|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
32858085|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
32858086|NCT03577301|Active Comparator|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
32858087|NCT03577301|No Intervention|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
32858088|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
32858089|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
32858090|NCT03013179||Black/African American Women and their 3-5 year old children|
32858091|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
32858092|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
32858093|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
32858094|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
32858095|NCT04762355|Experimental|Dose 1|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
32858096|NCT04762355|Experimental|Dose 2|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
32899069|NCT00265616|Active Comparator|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
32963851|NCT03464292|Active Comparator|Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
33320647|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33320648|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
33320649|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
33320650|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
33320651|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
33320652|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
33320653|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
33320654|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
33320655|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
33320656|NCT05447156|Other|Aim 2: Tailored App (pilot run of Aim 3)|All participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
33320657|NCT05447156|Experimental|Aim 3:Tailored App|Randomized subset of participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
33320658|NCT05447156|Placebo Comparator|Aim 3: Standard App|Randomized subset of participants will use the standard QuitGuide app, a smoking cessation app available to the public, downloaded to their personal phone.
33320659|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
33320660|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
33320661|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
33320662|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
33320663|NCT01335880|Active Comparator|Promotion I|Three month time horizon
33320664|NCT01335880|Experimental|Promotion II|One week time horizon
33320665|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
33320666|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
33320667|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
33320668|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
33320669|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
33320670|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
33320671|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
33033455|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
33033456|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
32858097|NCT04762355|Experimental|Dose 3|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
32858098|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
32858099|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
32858100|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
32858101|NCT05384015|Experimental|Experimental|Trial Treatment administration: at induction phase cycles will be administered every 3 weeks. For carboplatin (AUC5) and etoposide (100mg/m2) the maximum dose exposure will be 4 cycles or until reaching a discontinuation criterion. At this induction phase lenvatinib (8mg) will be orally administered daily and pembrolizumab (200mg) IV every 3 weeks. At maintenance phase lenvatinib will be administered at 20 mg dose and pembrolizumab at the same dose (200mg) until study intervention completion (total of 35 cycles of pembrolizumab/no treatment duration limit for lenvatinib) or reaching a discontinuation criterion.
32858102|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
32858103|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
32858104|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
32858105|NCT03152903|Placebo Comparator|Placebo|
32858106|NCT04728971|Experimental|Micafungin Preventing Group|
32858107|NCT04728971|Active Comparator|Others Preventing Group|
32858108|NCT04185155|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
32858109|NCT04185155|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
32858110|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
32858111|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
32858112|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
32858113|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
32858114|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
32858115|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
32858116|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
32858117|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
32858118|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
32858119|NCT01039467|Active Comparator|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
32858120|NCT01039467|Active Comparator|Search AV+|Search AV+: programmed on
32858121|NCT01102413|Experimental|Monofer|Injections or infusions
32858122|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
32858123|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
32858124|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
32858125|NCT01103505|Other|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
32858126|NCT01103505|No Intervention|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
32858127|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
32858128|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
32858129|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
32858130|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
32858131|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
32858132|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
32858133|NCT04999449|Experimental|Pharmacokinetic|Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.
33406973|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
33406974|NCT05284032|Experimental|Isatuximab (Sarclisa)|4 weekly doses of isatuximab
32858134|NCT04999449|Experimental|Chair|Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
33320672|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
32858135|NCT04973709||Delirium with dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
32858136|NCT04973709||Dementia without Delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
32858137|NCT04973709||Delirium without Dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
32858138|NCT04973709||No dementia, No delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
32858139|NCT04948515||group 1 patients with severe covid 19 respiratory infections|Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
32858140|NCT04948515||group 2 patients with non severe covid 19 respiratory infections|Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
32858141|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
32858142|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
32858143|NCT03014271|Active Comparator|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
32858144|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
32858145|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
32858146|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
32858147|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
32858148|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
32858149|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
32858150|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
32858151|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
32858152|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
32858153|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
32858154|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
32858155|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
32858156|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
32899070|NCT04351399||patient with chronic painful inflammatory rheumatism|
33104706|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
33104707|NCT00538200|Other|1|Dietary Advice
33104708|NCT00538200|Other|2|Supplements
33104709|NCT00545649|Experimental|1|Exercise and education
32858157|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
32858158|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
33104710|NCT00545649|Active Comparator|2|Education only
33104711|NCT03268382|Experimental|APR-246 + PLD|
33104712|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
33104713|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
32858159|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
32858160|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
32858161|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
32858162|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
32858163|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
32858164|NCT04814355|Experimental|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
32858165|NCT04810299|Experimental|Aromatherapy Massage Group|According to this Tisserand Institute guide chart, for a 2% dilution process, dilution will be provided with a total of 12 drops by adding 4:4:4 drops of lavender, Roman chamomile and ginger essential oils in 20 ml of sweet almond oil. Expert opinion was obtained from a phytotherapy and aromatherapy specialist physician that the oils and dilution rates used were appropriate. Foot massage will be applied on the 1st, 2nd and 3rd postoperative days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application Foot massage will be applied for 20 minutes.
32858166|NCT04810299|Experimental|Classical Foot Massage Group|Baby oil will be applied as massage oil to patients who are assigned to the classical foot massage group before the surgery. Foot massage will be applied for 20 minutes on the 1st,2nd and 3rd days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application
32858167|NCT04810299|No Intervention|Control Group|Except for routine care practices, no attempt will be made to the patients assigned to the pre-operative control group. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied on postoperative 1st, 2nd and 3rd days. The same scales will be re-evaluated 60 minutes after the first measurement. Richard-Campbell Sleep Quality Scale will be applied once
32858168|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
32858169|NCT02179047||placebo|healthy subject
32858170|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
32858171|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
32858172|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
32858173|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
32858174|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
32899071|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
32899072|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
33104714|NCT00538239|Experimental|Ridaforolimus|
33104715|NCT00538239|Placebo Comparator|Placebo|
33104716|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
33104717|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
33104718|NCT00545727|Other|HGI|High/standard glycemic index diet
33104719|NCT00545727|Experimental|LGI|Low glycemic index diet
33104720|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
33104721|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
32858175|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
32858176|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.~."
32858177|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
32858178|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
33406975|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
33406976|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
33406977|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
32858179|NCT01043133|Experimental|Intervention group|
32858180|NCT01043133|No Intervention|Control Group|
32858181|NCT01043523||Group 1|
32858182|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
32858183|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
32858184|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
32858185|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
32858186|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
32858187|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
32858188|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
32858189|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
32858190|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
32858191|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
32858192|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
32858193|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
32858194|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
32858195|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
32858196|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
32858197|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
32858198|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
32858199|NCT03015909|Other|Eutropin pen inj.|
32858200|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
32858201|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
32858202|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
32858203|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
32858204|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
32858205|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
32858206|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
32858207|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
32858208|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
32858209|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
32899073|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
33104722|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
33104723|NCT03261050||R61 (Phase 1)|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
33104724|NCT03261050||R33 (Phase 2)|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy or Interpersonal Therapy. Participants will complete target and outcome measures at pretest and posttest, including a 6-month follow-up, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
33104725|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
33104726|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
33104727|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
33104728|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
33104729|NCT03228563|No Intervention|Healthy control|Healthy volunteers were: no hypertension (Blood pressure<140/90mmHg), no diabetes (Glucose AC 70~100mg/dl), no hyperlipidemia (Cholesterol Total 130~200mg/dL、Triglyceride<150mg/dL), no urinary protein (-) and normal renal function (eGFR>90), after signing the consent form, the stool samples will be collected.
33104730|NCT01265953|Experimental|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
33104731|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
33104732|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
33104733|NCT00545805|Experimental|OM group|
33104734|NCT00545805|Active Comparator|CT group|Control group
33104735|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33104736|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
33104737|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
33104738|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
32858210|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
32858211|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
32858212|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
32858213|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
32858214|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
32858215|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
32858216|NCT01115517|Experimental|Bevacizumab|
33320673|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
33320674|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
32858217|NCT01115517|Active Comparator|Mitomycin C|
32858218|NCT04723953|Experimental|Acute myocardial infarction patient group|
32858219|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks~mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
33406978|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
33406979|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
33406980|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
33406981|NCT05683145|Experimental|Computerized Cognitive Behavioral Therapy for Insomnia|Self-guided computerized CBT-I program with assistance from a licensed mental health professional.
33406982|NCT05683145|No Intervention|Enhanced Treatment as Usual|ETU is defined as treatment per usual which is enhanced by participating in data collection related to study participation.
32963852|NCT03462342|Experimental|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
32963853|NCT03462342|Experimental|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
33406983|NCT04671342|Experimental|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with polysomnography sensors (gold standard).
33406984|NCT04764929|Experimental|Helmet CPAP|Patients in the Pediatric Intensive Care Unit (PICU) already receiving CPAP through a facemask or nasal prongs or mask for at least four hours but no more than 48 hours will be transitioned to the Vyatil nonpowered oxygen tent system (Rochester, NY) by trained respiratory therapists per the manufacture's instructions: patient's neck circumference will be measured with a soft tape measure to ensure appropriate sizing. The helmet will be connected to at least 30 liters per minute of high flow medical air with an oxygen blender. The expiratory limb will be attached to the positive end expiratory pressure (PEEP) valve (initially set at 5 centimeters of water pressure) connected to a high-efficiency particulate air (HEPA) filter to prevent any viral particles from being released into the environment. A disposable manometer will be used to measure the pressure within the helmet. Once the flow to the helmet interface is on, the helmet will be sealed and secured with the system's arm straps.
32963854|NCT03462342|Experimental|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
32963855|NCT03462342|Experimental|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
32963856|NCT03462342|Experimental|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
32963857|NCT03366480|Experimental|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
32963858|NCT03366480|Experimental|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
32963859|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
32963860|NCT03342144||Participants Receiving Venetoclax + Rituximab|Participants with CLL receiving venetoclax in combination with rituximab.
32963861|NCT03342144||Participants Receiving Venetoclax + Obinutuzumab|Participants with CLL receiving venetoclax in combination with obinutuzumab.
32963862|NCT03284892|Experimental|PED Care group|Received PED care addition to usual care
32963863|NCT03284892|Active Comparator|Control group|Received usual care only
32963864|NCT03267108|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
32963865|NCT03267108|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
32963866|NCT03267108|Other|Open Label Extension|Pulsed inhaled iNO 45 mcg/kg IBW/hr
32963867|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
32963868|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
32963869|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
33104739|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
33104740|NCT01265719||Latanoprost-treatment group|
33104741|NCT01265719||Non-topical prostaglandin analogue treatment group|
33104742|NCT03148496|Experimental|Biologic Mesh and Small Bites|Biologic mesh placement and small bites used for suturing.
33104743|NCT03148496|Experimental|Small Bites and No Biologic Mesh|Small bites used for suturing with no placement of biologic mesh
33104744|NCT03148496|Experimental|Biologic mesh and Large Bites|Biologic mesh placement and large bites used for suturing
33104745|NCT03148496|Active Comparator|Large Bites and no biologic mesh|Large bites used for suturing and no placement of biologic mesh.
32858220|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
32858221|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
32858222|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
32858223|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
32858224|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
32858225|NCT04353063|No Intervention|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
32858226|NCT04353063|Experimental|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
32858227|NCT03013023|Placebo Comparator|Routine care|Control group
32858228|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
32858229|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
32858230|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
32858231|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
32858232|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
32858233|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
32858234|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
32858235|NCT04662801|Experimental|Behavioral Weight Loss|
32858236|NCT04662801|Experimental|Behavioral Weight Loss + Medication|
32858237|NCT04634019|No Intervention|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
32858238|NCT04634019|Experimental|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
32858239|NCT04582383|Experimental|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
32858240|NCT04582383|Active Comparator|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
32858241|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
32858242|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
32858243|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
32858244|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
32858245|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
32858246|NCT01048593|Experimental|Dose 1|114ug
33104746|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
33406985|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
32858247|NCT01048593|Experimental|Dose 2|513ug
32858248|NCT01048593|Experimental|Dose 3|684ug
32858249|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
32858250|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
32858251|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
32858252|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
32858253|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
32858254|NCT03012945|Experimental|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
32858255|NCT03012945|Active Comparator|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
32858256|NCT01120197|Experimental|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
32858257|NCT01120197|Other|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
32858258|NCT01048905|Experimental|Treatment: L-glutamine|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
32858259|NCT04352283|No Intervention|palpation|Usual method to determinate needle puncture site
32858260|NCT04352283|Experimental|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
32858261|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
32858262|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
32858263|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
32858264|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
32858265|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
32858266|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
32858267|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
32858268|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
32858269|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
32858270|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
32858271|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
32858272|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
32858273|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
32858274|NCT03010371|Experimental|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
32858275|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
32858276|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
32858277|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
32858278|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
32858279|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
33104747|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
33104748|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
33104749|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
33104750|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
33104751|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
33104752|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
33104753|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
33104754|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
33320675|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
32858280|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
32858281|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
32858282|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
32858283|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
32858284|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
32858285|NCT03088137|Experimental|Primapur (Follitropin alfa)|
32858286|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
32858287|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
32858288|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
32858289|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
32858290|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
32858291|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
32858292|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
32858293|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
32858294|NCT01165983|Placebo Comparator|Placebo|
32858295|NCT01165983|Experimental|Aliskiren|
32858296|NCT05308173||Surgical Aortic Valve Replacement|Surgically replaced aortic valve. Patients with planned concomitant bypass grafting other valvular interventions, arrhythmia ablation, or left atrial appendage occlusion were excluded. Any tissue or mechanical valve implantation in an aortic position with sternotomy or minimal access was included.
32858297|NCT05308173||Transcutaneous Aortic Valve Implantation|Transfemoral aortic valve implantation. Patients with a planned concomitant percutaneous coronary intervention were excluded
32858298|NCT05307861|Active Comparator|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
32858299|NCT05307861|Active Comparator|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
32858300|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
32858301|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
32858302|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
32858303|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
32858304|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
32858305|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
32858306|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
32858307|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
33320676|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
33320677|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
32858308|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
32858309|NCT05307471||neuropathic pain|This study will be proposed to patients undergoing thoracotomy or thoracoscopy for partial or total lung resection in the service of Thoracic Surgery of Centre Jean Perrin (Prof. M. Filaire), the objective is to recruit 120 patients (for 100 evaluable patients) over a period of 18 months of inclusion
32858310|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
32858311|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
32858312|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
32858313|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
32858314|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
32858315|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
32858316|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
32858317|NCT05306847|Experimental|Experimental arm|"Sintilimab will be given intravenously at a dose of 200mg every 21 days. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.~Tumor evaluation will be conducted after treatment of the tested regimen every 2 cycles. Subsequent treatment will be determined based on the evaluation results: If the patients are not suitable for radical surgery, but the result of efficacy evaluation is CR, PR, or SD, they can continue to receive the tested regimen. If the patients are still not suitable for radical surgery after 6 cycles of the tested regimen, the standard first-line or immunotherapy after chemoradiotherapy or radiotherapy will be given. If patients are eligible for radical surgery, surgery will be performed within 4 weeks after completion of the last tested regimen."
32858318|NCT05306769||Group 1|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing (and thus potential candidates for Harrison Wing clinical studies)~Has ≥ 1 demographic identified to be underrepresented as specified in 'trial statistics'~Able and willing to provide written or witnessed informed consent to participate"
32858319|NCT05306769||Group 2|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing~Currently participating in any clinical study in which Harrison Wing is the/ a participating centre1~Able and willing to provide written or witnessed informed consent to participate"
32858320|NCT05306691|Experimental|Bio-smart Light Cured Protective Shield with bioactive S-PRG filler technology (PRG Barrier Coat)|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas
32858321|NCT05306691|Active Comparator|5% NaF varnish (Proflourid Varnish VOCO America Inc.).|The gold standard remineralizing agent recommended by the guidelines
32858322|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
32858323|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
32858324|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
32858325|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
32858326|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
32858327|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
32858328|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
32858329|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
32858330|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
32858331|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
32858332|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
32858333|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
32858334|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
32858335|NCT00597441|Experimental|I|Thymic tissue from third party donor
32963870|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
32963871|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27, or every 8 hours on day 0 and then reduced to every 12 hours on days 30-40. Patients with HLA-matched unrelated donors receive sirolimus PO QD on days -3 to 150 and then tapered to day 180.
32963872|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
32963873|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
32963874|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
32963875|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
32963876|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
32963877|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
32963878|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
32963879|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
32963880|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
32963881|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
32963882|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
32963883|NCT02534844|Experimental|Parts A/B: Sham Control|Participants receive no study drug
32963884|NCT02534844|Other|Parts A/B: Adrabetadex|Participants receive adrabetadex
32963885|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
32963886|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
32963887|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
32963888|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
32963889|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
32963890|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
32963891|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
32963892|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
32963893|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to inhaled, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past."
32963894|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
32963895|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
32963896|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
32963897|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
32963898|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
32858336|NCT01176591|Experimental|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
32858337|NCT01176591|Placebo Comparator|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
32858338|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
32858339|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
32858340|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
32858341|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
32858342|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
32858343|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
32858344|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
32858345|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
32858346|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
32858347|NCT05213715||1/Children with diparetic cerebral palsy|1/Children with diparetic cerebral palsy
32858348|NCT05213715||2/Children with hemiparetic cerebral palsy|2/Children with hemiparetic cerebral palsy
32858349|NCT05213715||3/healty peer aged children|3/healty peer aged children
32858350|NCT05197959|No Intervention|Group A-Control|Participants in this arm will not experience any intervention during a 4 week period of time. Participants will experience their standard medical care.
32858351|NCT05197959|Experimental|Group B-rTMS and sensorimotor training|Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Immediately following rTMS, participants will perform sensorimotor training. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
32858352|NCT05197959|Experimental|Group C-Sensorimotor training|Participants will perform sensorimotor training intervention. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
32858353|NCT05196243||Study Group|Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
32858354|NCT05196243||Control Group|Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa
32858355|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
32858356|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
32858357|NCT01129245|No Intervention|Control cycle|Control menstrual cycle
32858358|NCT01129245|Experimental|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
32858359|NCT01129245|Experimental|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
32858360|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
32858361|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
32858362|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
32858363|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
32858364|NCT01183923|Experimental|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
32858365|NCT01183923|Experimental|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
33104755|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
32858366|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
32858367|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
32858368|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
32858369|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
32858370|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
32858371|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
32858372|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
32858373|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
32858374|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
32858375|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
32858376|NCT01188369|Placebo Comparator|Placebo|Identical placebo
32858377|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
32858378|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
32858379|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
32858380|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
32858381|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
32858382|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
32858383|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
32858384|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
32858385|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
32858386|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
32858387|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
32858388|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
32858389|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858390|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858391|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858392|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858393|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858394|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858395|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858396|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858397|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
32858398|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
32963899|NCT02043678|Experimental|Radium-223 dichloride + Abi/Pred|Participants received 6 intravenous (IV) administrations of radium-223 dichloride 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) body weight at intervals of 4 weeks, along with oral abiraterone acetate tablets 1000 milligrams (mg) every day plus prednisone/prednisolone 5 mg twice daily (abi/pred) for 6 cycles, followed by abi/pred until an on-study symptomatic skeletal event (SSE) occurred (or other withdrawal criteria were met)
32963900|NCT02043678|Placebo Comparator|Placebo + Abi/Pred|Participants received 6 IV administrations of placebo matched to radium-223 dichloride at intervals of 4 weeks, along with abi/pred for 6 cycles, followed by abi/pred until an on-study SSE occurred (or other withdrawal criteria were met)
32963901|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
32963902|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
32963903|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
32963904|NCT01818492|Experimental|NI-0501|NI-0501 administered by IV infusion at a starting dose of 1 mg/kg.
32963905|NCT01688076|Experimental|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
32963906|NCT01688076|Active Comparator|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
32963907|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
32963908|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
32963909|NCT01372566|Experimental|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
32963910|NCT01372566|Placebo Comparator|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
32963911|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
32963912|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
32963913|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
32963914|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
32963915|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
32963916|NCT01239030|Placebo Comparator|Placebo|Placebo capsules
32963917|NCT01239030|Experimental|Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg)|Biphentin Methylphenidate Hydrochloride Extended Release Capsules (10, 15, 20, 40, 50 or 60 mg) - Open Label Phase
32963918|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
32963919|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
32963920|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
32963921|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
32963922|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
32963923|NCT01086540|Experimental|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
32963924|NCT01086540|Placebo Comparator|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
32963925|NCT00594750||Asthma|People who have been diagnosed with Asthma
32963926|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
32963927|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
32963928|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
32963929|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
32963930|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
32963931|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
32963932|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
32963933|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
32963934|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
32963935|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
32963936|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
33104756|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
33104757|NCT05548660|Experimental|PGx-guided|Pharmacogenetic testing using a 16 gene panel with a pharmacist consult providing genotype-guided recommendations for post-surgery analgesic selection based on CYP2D6 and CYP2C9 results. Pharmacist recommendations for all 16 gene results will also be provided in a detailed note.
32858399|NCT04403555|Experimental|Ivermectin|Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
33104758|NCT05548660|Other|Usual care|Pharmacogenetic testing using a 16 gene panel. Post-surgery analgesic selection will be based on usual care (not the PGx results). Pharmacist recommendations for all 16 gene results will be provided in a detailed note with a delayed return of results (30 days post surgery)
33104759|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
33104760|NCT00545922|Active Comparator|B|Minimal Telephone Contact
33104761|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
33104762|NCT01265056|Experimental|Gabapentin|Gabapentin
33104763|NCT05548231|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
33104764|NCT05548231|Placebo Comparator|Placebo|Placebo administered SC
33104765|NCT05656651|Experimental|Cancer patients|Single exercise intervention following a HIIT protocol, duration ~20 mins
33104766|NCT05656651|Active Comparator|Healthy adults|Single exercise intervention following a HIIT protocol, duration ~20 mins
33104767|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
33104768|NCT02942498|Placebo Comparator|Placebo|Placebo solution
33104769|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
33104770|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
33104771|NCT02935517|Experimental|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
33104772|NCT02935517|Experimental|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
33104773|NCT02935517|Experimental|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
33104774|NCT02935517|Experimental|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
33104775|NCT02935517|Experimental|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
32858400|NCT04403555|No Intervention|Standard of care|Standard of care treatment
32858401|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
33104776|NCT02935517|Experimental|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
33104777|NCT02935517|Experimental|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
32858402|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
32858403|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
32858404|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
32858405|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
32858406|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
32858407|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
33104778|NCT02935517|Experimental|Group 6: MTD of AGTC-402|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
33104779|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
33104780|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
33104781|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104782|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104783|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104784|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104785|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104786|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104787|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104788|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
33104789|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
33104790|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
33104791|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
33320678|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
32858408|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
32858409|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
32858410|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
32858411|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
32858412|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
32858413|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
32858414|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
32858415|NCT05347433||Tube baby pregnancy group|18-24-week pregnant women with in vitro fertilization
32858416|NCT05347433||Spontaneous pregnancy group|18-24-week pregnant women with spontaneous
32858417|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
32858418|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
32858419|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
32858420|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
32858421|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
32858422|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
32858423|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
32858424|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
32858425|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
32858426|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
32858427|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
32858428|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
32858429|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
32858430|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
32858431|NCT03547271|Experimental|Group 1|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella [MMR] vaccine) at 2, 4 and 12 to 18 months of age
32858432|NCT03547271|Active Comparator|Group 2|Licensed meningococcal vaccine (Nimenrix®), 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
32858433|NCT03547271|Experimental|Group 3|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
32963937|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
33320679|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
32858434|NCT03547271|Experimental|Group 4|MenACYW conjugate vaccine, 4 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
32858435|NCT03547115|Experimental|voruciclib monotherapy and voruciclib in combination with venetoclax|"voruciclib monotherapy - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)~voruciclib and venetoclax - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level for AML subjects"
32858436|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
32858437|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
32858438|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
32858439|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
32858440|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
32858441|NCT01191255|Placebo Comparator|Placebo|Placebo
32858442|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
32858443|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
32858444|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
32858445|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
32858446|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
32858447|NCT02078219|Other|Allopurinol|Allopurinol 200mg
32858448|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
32858449|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
32858450|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
32858451|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
32858452|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
32858453|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
32858454|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
32858455|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
32858456|NCT04726319|Experimental|Intervention|In addition to usual care, patients will be asked to answer questions about any family history through the use of a questionnaire.
32858457|NCT04726319|No Intervention|Usual Care|Patients receive usual care, which consists of health care providers inquiring about and dealing with family history as they would in usual practice.
32858458|NCT03532373|No Intervention|Control|None- normal care
32858459|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
32899074|NCT00176852|Other|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
33033457|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
33033458|NCT01963156|Experimental|Prescription synchronization|
33033459|NCT01963156|No Intervention|Control|
33033460|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
33033461|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
33033462|NCT01963221|Other|fluodeoxyglucose (18f)|
33033463|NCT01963247||Healthy Athletes|
33033464|NCT01963247||Concussed Athletes|
33033465|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
33033466|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
33033467|NCT01963299|Active Comparator|Ropivacaine alone group|
33033468|NCT01963299|Experimental|Ropivacaine/Clonidine group|
33033469|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
33033470|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
33033471|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
33033472|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
33033473|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
33033474|NCT01963351||Locally advanced and metastatic nsclc|non squamous
33033475|NCT01963364|Experimental|Intervention group|All healthy volunteers
32858460|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
32858461|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
32858462|NCT03529487|Experimental|Oxymetazoline applied intra analy|
32858463|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
32858464|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
32858465|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
32858466|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
32963938|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
32858467|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
32858468|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
32858469|NCT03527147|Experimental|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
32858470|NCT03527147|Experimental|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
32963939|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
32963940|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
32963941|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
32963942|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
32858471|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Cipros 10 association; and~1 tablet crestor placebo Oral, once a day."
32858472|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Crestor 10mg; and~1 tablet Cipros association placebo Oral, once a day."
32858473|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
32858474|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
32963943|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
32963944|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
32963945|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
32963946|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
32963947|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
32963948|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
32963949|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
32963950|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
32963951|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
32963952|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
32963953|NCT01974102|Active Comparator|lifestyle|Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
32963954|NCT01974102|Experimental|therapy|Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.
32858475|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
32858476|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
32858477|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
32858478|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
32858479|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
32858480|NCT04402931|Other|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
32858481|NCT04402931|Other|Redo Surgery|Surgical Mitral valve replacement
32858482|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
32858483|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
32858484|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
32858485|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
32858486|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
32858487|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
32858488|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
32858489|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
32858490|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
32858491|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
32858492|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
32858493|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
32963955|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
32963956|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
32963957|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
32963958|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
32963959|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
32963960|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
32963961|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
32963962|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
32858494|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
32858495|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
33406986|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
33406987|NCT05560854|Experimental|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
32858496|NCT01678469|Other|blood sample|
32858497|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
32858500|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
32858501|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
32858502|NCT01679951|Placebo Comparator|Placebo|
32858503|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
32858504|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
32858505|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
32858506|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
32858507|NCT03514589|Experimental|Arm 2|Nasal Synacthen
32858508|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
32858509|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
32858510|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
32858511|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
32858512|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
32858513|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
32858514|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
32858515|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
32858516|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
32858517|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
32858518|NCT05347277||OCB positive|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as negative for the presence of CSF OCB
32858519|NCT05347277||OCB negative|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as positive for the presence of CSF OCB
32858520|NCT01194453|Experimental|Group A|
32858521|NCT01194453|Active Comparator|Group B|
32858522|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
32858523|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
32858524|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
32858525|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
32858526|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
32858527|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
32858528|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
32858529|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
32858530|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
32858531|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
32858532|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
32858533|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
32858534|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
32858535|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
32858536|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
32858537|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
32858538|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
32858539|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
32858540|NCT03492437|Experimental|Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib|Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.
33406988|NCT05233566|Experimental|Ketamine Arm|Following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 2 hours 50 minutes.
32858544|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
33104792|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
33104793|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
33104794|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
32858545|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
32858546|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
32858547|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
32858548|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
32858549|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
32858550|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
32858551|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
32963963|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
32963964|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
32963965|NCT01981590|Experimental|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
32963966|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
32963967|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
32963968|NCT01984398|Experimental|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
32963969|NCT01984398|Experimental|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
32963970|NCT01985958|Experimental|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
32963971|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
32963972|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
32963973|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
32963974|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
32963975|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
32963976|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
32963977|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
32963978|NCT01991808|Experimental|DCE-MRI|
32963979|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
32963980|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
32963981|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
32963982|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
32963983|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
32963984|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
32963985|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
32963986|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
32963987|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
32963988|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
32963989|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
32963990|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
32963991|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
32963992|NCT02000154|Experimental|SyB L-1101|
32963993|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
32963994|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
32963995|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:~Bilateral internal jugular venous flow in supine and prone position~Bilateral internal jugular venous flow in supine and park bench position~Bilateral internal jugular venous flow in prone and park bench"
32963996|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
32963997|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
32963998|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
32963999|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
32964000|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
33406989|NCT05233566|Placebo Comparator|Control Arm|Following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.
33406990|NCT05232708|Experimental|Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL|
33406991|NCT05232708|Experimental|Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL|
33406992|NCT05230368|Experimental|1 cycle of treatment (Cohort 1 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3~romidepsin (5mg/m²) at days 4, 11, 18"
33406993|NCT05230368|Experimental|2 cycles of treatment (Cohort 2 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52"
33406994|NCT05230368|Experimental|4 cycles of treatment (Cohort 3 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37, 70, 71, 72, 105, 106, 107~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52, 73, 80, 87, 108, 115, 122"
33406995|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
33406996|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
33406997|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
33406998|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
33406999|NCT05114785||HFpEF group|Suspected HFpEF group: 80 patients will be recruited with history of dyspnoea, LV ejection fraction ≥ 50%, raised NTproBNP
33407000|NCT05114785||Control group|20 patients with suspected CAD but with no dyspnoea and normal echocardiogram.
32964001|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
32964002|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
32964003|NCT02004288|Placebo Comparator|Placebo|One chewable tablet twice per day with placebo per day
32964004|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
32739095|NCT05714267|Experimental|Active noise cancelling with music therapy|Patients corresponding to blocks numbered 3 in the randomization table according to the order of surgery were included in the music therapy group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the headset (Sony WH1000xm4) was positioned on the patient's head as shown in Figure 3.7-5 (A). iPod Touch 7th Generation music player with Spotify mobile application was used for music application. The connection between the headset and the music player was provided via Bluetooth. Music chosen by the patient; Active noise control was turned on and the patient was listened to until the dressing was removed at the end of the operation. The vital signs of the patient during the operation were followed up. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
32739096|NCT05714267|No Intervention|Control group|Patients corresponding to blocks numbered 0 in the randomization table according to the order of surgery were included in the control group. The patients, whose preoperative care was performed by clinical nurses, were transferred to the operating room and spinal anesthesia was administered. No intervention was made in this group during the surgery. The vital signs of the patients were followed up during the operation.
32739097|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
32739098|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
32739099|NCT02636907|Experimental|BI 695501|
32964005|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
32964006|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
32964007|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
32964008|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
32964009|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
32964010|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
32964011|NCT02006160|Active Comparator|treatment|dalfampridine
32964012|NCT02006160|Placebo Comparator|control|placebo
32964013|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
33104795|NCT05544565|Experimental|Experimental group: Discontinuation of treatment|For patients randomized in the experimental group, the patient receives 3-day IV therapy and the treatment is interrupted.
32964014|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
32964015|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
33407001|NCT05080621|Experimental|Escalation|"Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
33407002|NCT05080621|Experimental|Expansion|"Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
33407003|NCT05035303|Active Comparator|Nor-Epinephrine (NE)-Group|The PCNL tract is infiltrated by Nor-Epinephrine before its dilatation.
33407004|NCT05035303|Placebo Comparator|S-Group|The PCNL tract is infiltrated by Normal Saline before its dilatation.
33407005|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
33407006|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
33407008|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
33407009|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
33407010|NCT03046056|Placebo Comparator|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
33407011|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will smoke cannabis with placebo THC (.02%) ad libitum
33407012|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will smoke cannabis cigarettes with 5.9% THC ad libitum
33407013|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will smoke cannabis cigarettes with 13.4% THC ad libitum
33407014|NCT04647786|Experimental|Humidified and Augmented gas flows|
33407015|NCT04647786|Experimental|Humidified but not Augmented gas flows|
33407016|NCT04647786|Experimental|Not Humidified but Augmented gas flows|
33407017|NCT04647786|No Intervention|Neither humidified nor augmented gas flows|
33407018|NCT04647786|Experimental|Use of finalised device (SEA CtV) in final phase|
33407019|NCT04647786|No Intervention|Standard care (no SEA CtV)|
33407020|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
33407021|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
33407022|NCT04627428|Experimental|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
33407023|NCT04627428|Experimental|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
33407024|NCT04627428|Experimental|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
33407025|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
33407026|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
33407027|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
33407028|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
33407029|NCT04250545|Experimental|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33407030|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
33407031|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
33407032|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
33407033|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
33407034|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
33407035|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
33407036|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
33407037|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
33407038|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
33407039|NCT05201664||Surgical Extrusion|Patients who receive surgical extrusion treatment in maxillary premolars.
33407040|NCT04399837|Experimental|Spesolimab, treatment arm 1|
33407041|NCT04399837|Experimental|Spesolimab, treatment arm 2|
33407042|NCT04399837|Experimental|Spesolimab, treatment arm 3|
33407043|NCT04399837|Placebo Comparator|Placebo|
33407044|NCT04580394|Experimental|AD109|Oral capsule administered before sleep
33407045|NCT04580394|Active Comparator|Atomoxetine|Oral capsule administered before sleep
33407046|NCT04580394|Active Comparator|R-oxybutynin|Oral capsule administered before sleep
33407047|NCT04580394|Placebo Comparator|Placebo|Oral capsule administered before sleep
33407048|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
33407049|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
33407050|NCT03713580|Experimental|Venetoclax+BEAM x 1 cycle prior to ASCT|"Venetoclax dose escalation cohorts + BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) begin with dose level 1 (800mg on Day -7 and Day -6). The dosing cohorts are escalated in a 3 + 3 design but with increasing duration instead of increasing dosage.~Carmustine 300 mg/m2 by IV over 2 hours on Day -7.~Etoposide 100 mg/m2 by IV over 6 hours daily for 4 consecutive days, Day-6 through Day-3.~Cytarabine 200 mg/m2 by IV over 2 hours every 12 hours for 3 consecutive days, Day-6 through Day-4.~Melphalan 140 mg/m2 by IV over 30 minutes or IV push once on Day -2.~Following V+BEAM therapy, participants will receive Autologous Stem Cell Transplant (ASCT): infusion of previously collected autologous stem cells and supportive care per institutional guidelines"
33407051|NCT05683067||Fontan Survivors|The investigator will include Fontan survivors between 16-50 years of age for the study.
33407052|NCT05683067||People operated for congenital heart diseases|The investigator will include people operated for other types of congenital heart diseases such as tetralogy of Fallot, transposition of great arteries between 16 and 50 years of age
33407053|NCT05683067||Healthy volunteers|The investigator will include healthy volunteers between 16 to 50 years of age for comparison purpose.
33407054|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
33407055|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
33407056|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
33407057|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
33407058|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
33407059|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
33407060|NCT01343082|Experimental|1|DE-111 ophthalmic solution
33407061|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
33407062|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
33407063|NCT04385173|Experimental|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
33407064|NCT03677154|Experimental|Consolidation Therapy (Cohort A)|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
33407065|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Monotherapy (Cohort B)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
33407066|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
33407067|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
33407068|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
33407069|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
33407070|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
33407071|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
33407072|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
33407073|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
33407074|NCT03648840|Other|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
33407075|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
33407076|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
33407077|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
33407078|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
33407079|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
33407080|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
33407081|NCT05682911|Experimental|Zingiber Officinale L (Ginger) treated group n=20|Ginger tablets 500mg twice a day (BD) for two month
33407082|NCT05682911|Active Comparator|Simvastatin treated group n=20|Simvastatin 20 mg tablet once a day (OD) for two month
33407083|NCT05480592|Experimental|Single Ascending Dose (SAD)|Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.
33407084|NCT05480592|Placebo Comparator|Multiple Ascending Dose (MAD)|Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.
33407085|NCT04990531|Experimental|Covid-19 subjects|Childrens and adolescent with PCR-proven previous SARS-CoV-2 infection
33407086|NCT04990531|Active Comparator|Healthy controls|Healthy controls negative for previous SARS-CoV-2 infection
33407087|NCT05479890|No Intervention|Treatment as Usual (TAU)|TAU will receive no training during the intervention period.
33407088|NCT05479890|Experimental|ClientBot (CB)|CB trainees will engage in 5 weekly practice sessions with ClientBot
33407089|NCT04680390|Experimental|Active-kINSHIP navigation intervention|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
33407090|NCT04680390|Active Comparator|Control-Standard Care|The control arm will be standard-of-care, which is as-needed case management for justice-involved women.
33407091|NCT04663620|Active Comparator|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
33407092|NCT04663620|Placebo Comparator|No Saving Babies Lives Programme|Control arm
33407093|NCT04625088|Experimental|Standardized liquid test meal|
33407094|NCT04625088|Experimental|Atropine + Standardized liquid Test meal|
33407095|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
33407096|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
33407097|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
33407098|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
33407099|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
33407100|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
33407101|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
33407102|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
33407103|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg; Double-Blind|
33407104|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo; Double Blind|
33407105|NCT03259789|Experimental|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
33407106|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
33407107|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
33407108|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
32858552|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
33104796|NCT05544565|Other|Control group: Usual practice|For patients randomized in the control group, the treatment for acute pyelonephritis is based on the attending clinician's practice and according to the usual practice: 3-day IV therapy followed by a 7-day oral antibiotic therapy.
33407109|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
33407110|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
33407111|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
33407112|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
33407113|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
32858553|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
32858554|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
32858555|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
32858556|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
33407114|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
33407115|NCT03257995|Experimental|Sequence 1|A-B-C
33407116|NCT03257995|Experimental|Sequence 2|B-C-A
32858557|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
32858558|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
32858559|NCT05347121||difficult airway|
32858560|NCT01196793||febrile children, age 3 m to 5 y|
32858561|NCT03491345|Experimental|avelumab|
32858562|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
32858563|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
32858564|NCT01138917|Experimental|all participants|All participants will receive both ReCell and split-thickness skin graft
32858565|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
32858566|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
32858567|NCT02400671|No Intervention|Control|Participants will receive standard of care (no intervention)
32858568|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
32858569|NCT03454451|Experimental|Cohort 1a|CPI-006
32858570|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
32858571|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
32858572|NCT03454451|Experimental|Cohort 2a|CPI-006
32858573|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
32858574|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
32858575|NCT00089843|Active Comparator|2|Placebo Actonel (risedronate) and active testosterone patch
33407117|NCT03257995|Experimental|Sequence 3|C-A-B
33407118|NCT03257995|Experimental|Sequence 4|A-C-B
33407119|NCT03257995|Experimental|Sequence 5|B-A-C
32858576|NCT00089843|Active Comparator|3|Active Actonel (risedronate) and active testosterone patch
33407120|NCT03257995|Experimental|Sequence 6|C-B-A
33407121|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
33407122|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
33407123|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
32858577|NCT00089843|Active Comparator|4|Active Actonel (risedronate) and placebo testosterone
32858578|NCT00089843|Placebo Comparator|1|Placebo testosterone patch and placebo Actonel (risedronate)
32858579|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
32858580|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
32858581|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
32858582|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
32858583|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
32858584|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
32858585|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
32858586|NCT00089297|Experimental|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
32858587|NCT03483077|Placebo Comparator|Placebo matching BI 730460|Placebo tablet(s) matching BI 730460 tablet(s) administered orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
32858588|NCT03483077|Experimental|2 milligram (mg) - BI 730460|A single dose of 2 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
33407124|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
33407125|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
33407126|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
33407127|NCT04484922|Experimental|Dexmedetomidine|
33407128|NCT04484922|Placebo Comparator|Control|
33407129|NCT04481958|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
33407130|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
33407131|NCT04446390|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
33407132|NCT04446390|Active Comparator|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm Sodium monofluorophosphate). chew xylitol gum 2 pieces four times per day for 5 minutes after meals.
33407133|NCT04504812|Active Comparator|Phase 1: Best Practices|Participants will receive an intervention from the best practices.
33407134|NCT04504812|Active Comparator|Phase 1: Best Practices + Duloxetine|Participants will receive Duloxetine in addition to an intervention from the best practices.
33407135|NCT04504812|Active Comparator|Phase 1:Best Practices + Duloxetine + Pain coping skills|Participants will receive Duloxetine and pain coping skills training in addition to an intervention from the best practices.
33407136|NCT04504812|Active Comparator|Phase 2: Intra-Articular Injection (HA+)|Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine.
33407137|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Long Acting Blocks|Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection.
33407138|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Nerve Ablation|Participants will receive a nerve ablation procedure and steroid injection.
33407139|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
33407140|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
33407141|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
33407142|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
33407143|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
33407144|NCT04402242|Sham Comparator|"SCS Group"|"Receiving anesthesia according to routine standard care, with the use of the hidden NOL (used to compare the data at the end of anesthesia with those of the classic BIS - without monitoring of the anesthesia by the NOL (without adjustment of treatments ))"
33407145|NCT04402242|Experimental|NOL Group|Receiving anesthesia monitored by the NOL
33407146|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
33407147|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
33407148|NCT04400058|Experimental|Octagam 10%|Octagam 10%
33407149|NCT04400058|Placebo Comparator|Placebo|Placebo
33407150|NCT04782661|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive an oral solution of JNJ-70075200 or placebo in single ascending doses on Day 1 in cohorts 1, 2, 3, 4, 5a and 6 under fasted condition. Participants in cohort 5a will additionally receive the same study intervention under fed condition (Cohort 5b) after a washout period of at least 7 days.
33407151|NCT04782661|Experimental|Part 2: Multiple Ascending Dose (MAD)|After assessment of safety, tolerability and pharmacokinetics data in Part 1, participants will receive an oral solution of JNJ-70075200 or placebo twice daily in Cohorts 1 to 6 for 14 days under fasted/fed condition.
33407152|NCT04782661|Experimental|Part 3: Single-dose Oral Solid Formulation (Optional)|Participants will receive oral dose of JNJ-70075200 on Day 1 in Cohort 1 under fasted condition. Part 3 will start after obtaining a formal regulatory/ethical approval.
33407153|NCT04745845|Experimental|Noradrenalin|treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
33407154|NCT04492098||study group|women with spontaneous miscarriage
33407155|NCT04683991|Experimental|treatment group 1|At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
33407156|NCT04683991|Experimental|treatment group 2|During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
33407157|NCT05532150|Experimental|Operative group|The operative group will undergo an arthroscopic Bankart repair, which is type of surgery used to repair a dislocated shoulder.
32858589|NCT03483077|Experimental|8 mg - BI 730460|A single dose of 8 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
32858590|NCT03483077|Experimental|25 mg - BI 730460|A single dose of 25 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
32858591|NCT03483077|Experimental|50 mg - BI 730460|A single dose of 50 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
33407158|NCT05532150|Active Comparator|Non-operative group|The non-operative group will undergo physical therapy following a specific rehabilitation schedule.
33407159|NCT04173247|Experimental|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
33407160|NCT04173247|Active Comparator|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
33407161|NCT04361838|Active Comparator|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
33407162|NCT04361838|No Intervention|No Prayer|Patients will receive standard of care treatment while in the ICU.
33407163|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
33407164|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
33407165|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
33407166|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
33407167|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
33407168|NCT05571397|Experimental|Dexcom CGM|Dexcom G6
33407169|NCT05571397|No Intervention|Historical Controls|Matched historical controls
33407170|NCT03196986|Experimental|mil60|mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
33407171|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
33407172|NCT04542031|Other|Survey|Survey to be distributed at 6 and 12 months
33407173|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
32858592|NCT03483077|Experimental|100 mg - BI 730460|A single dose of 100 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
32858593|NCT03483077|Experimental|200 mg - BI 730460|A single dose of 200 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
32858594|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
33407174|NCT04531969|Active Comparator|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
33407175|NCT04531969|Active Comparator|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
33407176|NCT04507555|Experimental|Intervention|
33407177|NCT04507555|Active Comparator|Standard Care|
33407178|NCT04507555|No Intervention|Observational|
33407179|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
33407180|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
33407181|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
33407182|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
33407183|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
33407184|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
33407185|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
33407186|NCT04377919|Active Comparator|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
33407187|NCT04377919|Placebo Comparator|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
33407188|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
33407189|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
33407190|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
33407191|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
33407192|NCT04408092|Experimental|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
33407193|NCT04408092|Experimental|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
33407194|NCT05511870|Experimental|Etripamil Nasal Spray 70mg|Etripamil Nasal Spray 70mg single dose
33407195|NCT05511870|Placebo Comparator|Etripamil Placebo Nasal Spray 70mg|Etripamil Placebo Nasal Spray 70mg single dose
33407196|NCT02984124|Experimental|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
33407197|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
33407198|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
33407199|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
33407200|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
33407201|NCT04051554|Experimental|Neuromuscular and Proprioceptive Training|Myklebust's training program
33407202|NCT04051554|Active Comparator|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
33407203|NCT04051476|Experimental|3-g footbath|Footbath with 3g ginger flour per liter of water
33407204|NCT04051476|Experimental|6-g footbath|Footbath with 6g ginger flour per liter of water
33407205|NCT04051476|Experimental|12-g footbath|Footbath with 12g ginger flour per liter of water
33407206|NCT04051476|Placebo Comparator|Warm water footbath|Footbath with warm water only
33407207|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
33407208|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
33407209|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
33407210|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
33407211|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
33407212|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
33407213|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
33407214|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
33407215|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
33407216|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
33407217|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
33407218|NCT04373460|Experimental|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
33407219|NCT04373460|Active Comparator|Standard Control plasma|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
33407220|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
33407221|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
33407222|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
33407223|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
33407224|NCT03644498||Adults treated with a CPI therapy for cancer|
33407225|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
32858595|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
33407226|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
33407227|NCT04166994|Experimental|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
33407228|NCT04166994|Other|Usual Care|No exercise or diet specialization.
33407229|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~Clinical evaluation~Radiographic assessment of osteoarthritis~Magnetic resonance imaging (MRI)~Histological evaluation of the surgical piece"
33407230|NCT05471856|Experimental|BI 1703880 (Cycle 1) then BI 1703880 + ezabenlimab (Cycle 2 onwards)|
33407231|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
33407232|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
33407233|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
33407234|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
32858596|NCT03482297|Experimental|Automated Abdominal Binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (~40 mmHg) every time the participant stands up throughout the study day.
33407235|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
33407236|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
33407237|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
32858597|NCT03482297|Sham Comparator|Sham binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (~5 mmHg) every time the participant stands up throughout the study day.
32858598|NCT00088907|Active Comparator|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
32858599|NCT00088907|Experimental|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
32858600|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
32964016|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
32964017|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
32858601|NCT00088595|Experimental|Pasireotide|
33320680|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
33320681|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
33320682|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
33320683|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
33320684|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
33320685|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
33320686|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
33320687|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
33320688|NCT04026646|Experimental|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
33320689|NCT04026646|Experimental|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
33320690|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
33320691|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
33320692|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
33320693|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
33320694|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
33320695|NCT01345396|Experimental|Education|
33320696|NCT01345396|No Intervention|No education|
33320697|NCT04008004|Experimental|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
33320698|NCT04008004|Experimental|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
33320699|NCT04008004|Placebo Comparator|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
33320700|NCT04008004|Placebo Comparator|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
33320701|NCT04008004|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
33320702|NCT04008004|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
33320703|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
33320704|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
33320705|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
33320706|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
33407238|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
33407239|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
33407240|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
33407241|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
33407242|NCT01264549|Experimental|PCT guided arm|
33407243|NCT01264549|No Intervention|Control|Standard treatment
33407244|NCT05692752||Test Group|"The study group included 10 patients,~men and women~between age of 35-60 year~chest pain lasting for at least 30 minutes,~electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)"
33407245|NCT05692752||Control Group|"The study group included 10 patients,~men and women~between age of 35-60 year~having no complaint of health issue,"
33407246|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
33407247|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
33407248|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
33407249|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
33407250|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
33407251|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
33407252|NCT05508672|Experimental|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI) group|The intervention group will receive Community-Centered eHealth Smoking Cessation Intervention(CCeSCI).
33407253|NCT05508672|Active Comparator|"Traditional smoking is harmful education group"|"The control group to receive the traditional smoking is harmful education."
33407254|NCT03643406|Experimental|Mental Fatigue Condition|
33407255|NCT03643406|Placebo Comparator|Control Condition|
33407256|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
33407257|NCT04097262|Experimental|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
33407258|NCT04097262|Experimental|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
33407259|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
33407260|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
33407261|NCT04051788|Experimental|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
33407262|NCT04051788|Active Comparator|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
33407263|NCT03641534||Sepsis|
33407264|NCT03641534||Severe malaria|
33407265|NCT03641534||Uncomplicated malaria|
33407266|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
33407267|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
33407268|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
33407269|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
33407270|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
33407271|NCT05692674|Experimental|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, proton therapy.
33407272|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
33407273|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
33407274|NCT05692596||All participants|Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.
33407275|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
33407276|NCT02929329|Experimental|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations < 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and < 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and < 1000 ng/mL maintained a 25 mg BID dosing regimen.
33407277|NCT02929329|Placebo Comparator|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
33407278|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
33407279|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
32858602|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
32858603|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
33407280|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
33407281|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
33407282|NCT03240133|Experimental|Part1: BCX7353 750 mg|
33407283|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
32858604|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
32858605|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
32858606|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
32858607|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
32858608|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
32858609|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
33407284|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
33407285|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
33407286|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
33407287|NCT03642860|Experimental|Active treatment|Triheptanoin oil
33407288|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
33407289|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
33407290|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
33407291|NCT05692518|Experimental|MAGNET System, DI Bio-fragmentable|GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System
33407292|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
33407293|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
33407294|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
33407295|NCT02101944|Experimental|Treatment (dexamethasone, carfilzomib, Reolysin)|Patients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33407296|NCT05682833|Experimental|Test|NS therapy + Chlorhexidine/Hyaluronic acid subgingival gel application
33407297|NCT05682833|Placebo Comparator|Control|NS therapy + Placebo gel subgingival application
33407298|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
32858610|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
33407299|NCT05692362||Healthy People|People with solitary pulmonary nodule， without any other pulmonary diseases.
33407300|NCT05692362||Chronic Airway Diease People|People with COPD or Asthma
33407301|NCT05692362||Pulmonary fibrosis people|People were diagnosised pulmonary fibrosis by chest Computer Tomography, and restrictive ventilatory impairment by pulmonary function test.
33407302|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
33407303|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
33407304|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
33407305|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
33407306|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
33407307|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
33407308|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
33407309|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
33407310|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
33407311|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
33407312|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
33407313|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
33407314|NCT05439941|Experimental|Group 1 (1.6x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 1 participants will receive 1.6x10^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 1)
33407315|NCT05439941|Experimental|Group 2 (6.4x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 2 participants will receive 6.4x10^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 2)
33407316|NCT05439941|Experimental|Group 3 (8.0x10^10 total cells of EDP1815, 1 capsule once daily)|EDP1815-207 Cohort 4 participants will receive 8.0x10^10 total cells of EDP1815 in EDP1815-208 administered as 1 capsule once daily. (Group 3)
33407317|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
33407318|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
33407319|NCT05283668|Experimental|(LASER WITH I-PRF)|Eight sites that were treated with laser method for gingival depigmentation, followed by intra-mucosal field injection of I-PRF
33407320|NCT05283668|Active Comparator|(LASER WITHOUT I-PRF)|Eight sites that were treated with laser technique for gingival depigmentation only
33407321|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
33407322|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
32858611|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
32858612|NCT00088205|Experimental|A|
32964018|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
33407323|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
33407324|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
33407325|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33407326|NCT05326997|Experimental|Photobiomodulation (PBM) with placebo cosmetic treatment.|Participants will receive the intervention with PBM using amber light (DMC E-Light ABR), 20 J/cm² and will also receive a product for daily home topical use containing only the cosmetic base without active.
33407327|NCT05326997|Active Comparator|Photobiomodulation (PBM) sham with 5% liposomal tranexamic acid cosmetic product|Participants will receive the simulated intervention with PBM using amber light (DMC E-Light ABR) and will also receive a product for topical home use containing 5% liposomal tranexamic acid.
33407328|NCT03738852|Experimental|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
33407329|NCT03738852|Experimental|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
33407330|NCT03738852|Experimental|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
33407331|NCT05476887|Experimental|Part 1: Dose escalation Cohort 1|Participants will receive escalating and varying dose intervals of KP104 every week.
33407332|NCT05476887|Experimental|Part 1: Dose escalation Cohort 2|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
33407333|NCT05476887|Experimental|Part 1: Dose escalation Cohort 3|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
33407334|NCT05476887|Experimental|Part 2: Proof-of-concept Cohort 1|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
32858613|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.~Greater than 5 cm hiatal hernia on upper gastrointestinal study.~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~Consenting adult 19 years of age or older~Must be able to participate in follow-up evaluation.~Free of cognitive impairment"
32964019|NCT02013180||control|benign prostatic diseases in pathologic evaluation
32964020|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
32964021|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
33407335|NCT05476887|Experimental|Open-label extension (OLE)|Participants will receive KP104, who benefit from KP104 treatment in Part 1 and 2
33407336|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
33407337|NCT05263245|No Intervention|Standard regimen|Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study.
33407338|NCT05263245|Experimental|Experimental regimen|Patients will take the prior recommended dose cabozantinib with a light breakfast.
33407339|NCT05471973|Other|Quality Improvement Program|The quality improvement program will consist of development and/or refinement of participating health system's patient care pathways tailored to address the gaps and barriers around recognition and treatment of CIED infections. Interventions will be customized and modified as needed based on regular reviews and implementation progress.
33407340|NCT05468853|Experimental|MPFC-iTBS|Transcranial magnetic stimulation delivered to the medial prefrontal cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
33407341|NCT05468853|Active Comparator|Inion-iTBS|Transcranial magnetic stimulation delivered to the inion. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
33407342|NCT05465655|Experimental|TAVR|Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed notifying for New-Onset Conduction Disturbances (NOCD) using Cara Monitor.
33407343|NCT04700787|Experimental|Sulopenem|Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
33407344|NCT04783233||Packing with Gelfoam|Tympanoplasty surgery with fascia graft (either transcanal or post-auricular) will be preformed. The middle ear and external canal will then be packed with Gelfoam.
33407345|NCT04783233||Packing with Chitosan succinamide|The surgical intervention and tympanoplasty will be performed as normal. The middle ear and external canal will be packed Chitosan succinamide.
33407346|NCT05251233|Placebo Comparator|Placebo|-Visually equivalent placebo once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
33407347|NCT05251233|Active Comparator|Proton pump inhibitor|-Pantoprazole once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
33407348|NCT05248035||Patient|Adult patient hospitalized in ICU for a duration of mechanical ventilation longer than 48 hours
32858614|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
33407349|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
33407350|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
33407351|NCT04664829|Experimental|Bexarotene and Capecitabine|
33407352|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
33407353|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
33407354|NCT04622709|Experimental|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
33407355|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
33407356|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
33407357|NCT05682755|Experimental|Chidamide|
33407358|NCT01312103|Experimental|Internet Based Safety Decision Aid|
33407359|NCT01312103|Active Comparator|Control Website|
33407360|NCT05682677|Experimental|PACT+iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + intermittent theta burst stimulation (iTBS; 20 sessions over 4 weeks)
33407361|NCT05682677|Sham Comparator|PACT+sham iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + sham intermittent theta burst stimulation (sham iTBS; 20 sessions over 4 weeks)
33407362|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
33407363|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
33407364|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
32858615|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
33407365|NCT05321537|Experimental|Somatosensory training|It consists of head relocation exercises, eye tracking, gaze stability and eye-head coordination. It requires the use of special material, the pupillary glasses allow the gaze to be fixed by restricting peripheral vision and the laser pointer provides visual feedback on the positioning of the head.
33320707|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
32858616|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
33320708|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
33320709|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
33320710|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
32858617|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
32858618|NCT03448601|No Intervention|Non-tailored control group|Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.
32858619|NCT03448601|Experimental|Culturally tailored video intervention group|Participants will view a short 5-minute culturally-tailored video.
32858620|NCT03448601|Experimental|Culturally tailored brochure intervention group|Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.
32858621|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
32858622|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
32858623|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
32858624|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
32858625|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
33320711|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
33320712|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
33320713|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
33320714|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
33320715|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
33320716|NCT01321268|Active Comparator|Control|Vitamin E
33320717|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
33320718|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
33320719|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
33320720|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
33320721|NCT03988270|Experimental|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
32858626|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
32858627|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
32858628|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
32858629|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
32858630|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
32858631|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
32858632|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
32858633|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
32858634|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
32858635|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
32858636|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
33320722|NCT03988270|No Intervention|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
33320723|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
33320724|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
33320725|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
33320726|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
33320727|NCT05162066|Other|C3G cohort|Approximately 14 eligible participants with C3G will be enrolled.
33320728|NCT05162066|Other|IgAN cohort|Approximately 14 eligible participants with IgAN will be enrolled.
33320729|NCT05162066|Other|PMN cohort|Approximately 14 eligible participants with PMN will be enrolled.
33320730|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
33320731|NCT01335958|Experimental|A|
33320732|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.~Assessment of diagnoses, functioning and health services"
32858637|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
32899075|NCT00176852|Experimental|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
33320733|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.~Assessment of diagnoses, functioning and health services"
33320734|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
33320735|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
33320736|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
33320737|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
33320738|NCT04469348|Experimental|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.~If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)~If no contamination of S. Aureus: their participation stops"
33320739|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
33320740|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
33320741|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
33320742|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
33320743|NCT03770936|No Intervention|Control group|No intervention
33320744|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
33320745|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
33320746|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
33320747|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
33320748|NCT05444348|Experimental|ACT intervention|Participants will receive the ACT intervention
33320749|NCT05444348|No Intervention|control|Participants will receive no intervention only usual care.
33320750|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
33320751|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
33320752|NCT04626466||Non-metastatic prostate, rectum, canal, endometrium, cervix or vaginal cancer Radiotherapy treatment|
33320753|NCT04414202||1 GROUP|"Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery.~The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years"
33320754|NCT04058366|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
33320755|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
33320756|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
33320757|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
33320758|NCT02118610|Placebo Comparator|Sugar Pill|
33320759|NCT01561742|Experimental|Minocycline|
33320760|NCT01561742|Placebo Comparator|Placebo|
33320761|NCT03770702|No Intervention|Control group|No intervention
33320762|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
33320763|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
33320764|NCT01345552|Other|SBRT|
33320765|NCT03768596|Experimental|Nudge|receiving nudge and form
33320766|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
33320767|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
33320768|NCT04332224|Experimental|Non-shivering cooling group|Cooling devices
33320769|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
33320770|NCT04320602|Experimental|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
33320771|NCT03948022|Active Comparator|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
33320772|NCT03948022|Active Comparator|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
33320773|NCT03948022|Experimental|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
33407366|NCT05321537|Experimental|Endurance-strength training|It consists of low-load training of the craniocervical flexor muscles. This exercise is specific for the deep cervical flexor muscles, while seeking minimal activation of the superficial flexor muscles. This training consists of 5 phases, starting with a pressure of 20 mmHg, progressively increasing 2 mmHg in each phase.
33407367|NCT05241015|Active Comparator|Control Group|Patients in this group will receive standard physiotherapy program used for PD will be applied, 3 times a week for 8 weeks.
33407368|NCT05241015|Experimental|Exercises Group|In addition to standard physiotherapy programme, patients in this group will also receive sensorimotor training.
33407369|NCT04595019|Active Comparator|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
33407370|NCT04595019|Experimental|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
33407371|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
33407372|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
33407373|NCT05423379||XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System|Subjects who were implanted with XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System will be included.
33407374|NCT05228145|Experimental|Cohort 1|The study treatment is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
33407375|NCT05228145|Experimental|Cohort 2|The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
33407376|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
33407377|NCT05214807|Active Comparator|Control group receiving Synvisc-One®|
33407378|NCT05214807|Experimental|IMD group receiving KiOmedine® CM-Chitosan|
33407379|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
33407380|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
33407381|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
33407382|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
33407383|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
33407384|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
33407385|NCT05205525||Restrictive antibiotic strategy|
33407386|NCT05205525||Aggressive (immediate) antibiotic strategy|
33407387|NCT04707183|Placebo Comparator|Control Arm|1.0mg/kg/hr IV lidocaine infusion
33407388|NCT04707183|Experimental|Treatment Arm|10 mL of 2% lidocaine via ESPB
33407389|NCT04703205|Experimental|ivermectin|Ivermectin group: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state) subjects take the study drug (3 mg tablet of ivermectin) at the dose of the study drug taken once per body weight of the subject.
33407390|NCT04703205|Placebo Comparator|placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state) the control drug (ivermectin placebo tablet) at the dose of the study drug taken once per body weight of the subject.
33407391|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
33407392|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
33407393|NCT04681365||Simulation Suite|Participating staff will use BubblePAPR and evaluate its function in the non-clinical simulation suite, ensuring that simulated tasks appropriate to role can be undertaken safely whilst wearing the Bubble
33407394|NCT04681365||Low-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered low risk (ie non-COVID-19).
33407395|NCT04681365||High-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered high risk (ie suspected or confirmed COVID-19).
33407396|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
33407397|NCT05279573|Experimental|Combination of Omega-3 based product and botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
33407398|NCT05279573|Experimental|Omega-3 based product|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
33407399|NCT05279573|Experimental|Botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
33407400|NCT05279573|Placebo Comparator|Control group|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
33407401|NCT05182905|Experimental|Arm A: Recurrent Grade 4 Glioma Surgical Cohort Time Escalation|
33407402|NCT05182905|Experimental|Arm B: Recurrent Grade 4 Glioma Dose Escalation|
33407403|NCT05182905|Experimental|Arm C: Newly-diagnosed Grade 4 Glioma|
33407404|NCT05682365|Experimental|prevANS intervention|In this arm, participants will receive an online personalized intervention to prevent anxiety disorders based on a risk predictive algorithm (predictA).
33407405|NCT05682365|No Intervention|Control group|In this arm, participants will continue receiving the usual care from their health providers. However, they will not receive any intervention, but they will fill out the same questionnaires as in the intervention group.
33407406|NCT05275127||Q-SRP|Evaluation of changes of gingival crevicular fluid miRNA
33407407|NCT05275127||FM-SRP|Evaluation of changes of gingival crevicular fluid miRNA
33407408|NCT05178069|Placebo Comparator|Placebo Comparator: Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
33407409|NCT05178069|Active Comparator|Active Comparator: Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
33407410|NCT05270213|Experimental|Treatment Group A-1|For Treatment Group A-1, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418. Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
33407411|NCT05270213|Experimental|Treatment Group A-2|For Treatment Group A-2, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418 in combination with pembrolizumab 200 mg IV (administered on Day 1 and every 3 weeks). Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
33407412|NCT05270213|Experimental|Treatment Group B|After dose escalation phase is completed in both monotherapy and combination therapy setting (A-1 and A-2), an expansion treatment group will be enrolled, and subjects (n=20- 40) will be treated with a fixed dose of RBS2418 to be selected by the Sponsor in consultation with the SRC and after reviewing the totality of the dose escalation data both as monotherapy and combination therapy.
33407413|NCT04283175||Neuromuscular disease (MNM) subjects (Charcot Marie Tooth disease, CMT)|
33407414|NCT04283175||Hemiparetic subjects|
33407415|NCT04283175||Healthy subjects|
33407416|NCT05682287|Experimental|Experimental group|"Participants in the experimental group will be treated with a combination of 448kHz capacitive resistive monopolar radiofrequency and Proprioceptive neuromuscular facilitation (PNF) over the course of two weeks.~448 kHz radio frequency therapy will be carried for a duration of 15 min. Contact cream will be applied beforehand to increase the electrical conductivity in the treated area.~After the radiofrequency therapy, participants will exercise for exactly 20 minutes using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2."
33407417|NCT05682287|Active Comparator|Control group|"Participants will exercise for exactly 20 minutes, over the course of two weeks, using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2.~This is identical intervention and the second intervention in the experimental group."
33407418|NCT05642403|Active Comparator|SAD Cohort A XW001|Single inhalation of XW001
33407419|NCT05642403|Placebo Comparator|SAD Cohort A placebo|Single inhalation of placebo
33407420|NCT05642403|Active Comparator|MAD Cohort B XW001|Multiple inhalations of XW001
33407421|NCT05642403|Placebo Comparator|MAD Cohort B placebo|Multiple inhalations of placebo
33407422|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
33407423|NCT04640727||open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
33407424|NCT04640727||closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
33407425|NCT04252677|Active Comparator|Vaping and Obesity Prevention Only|"Obesity prevention and vaping~Vaping:~Factual information about vaping devices and vaping~Beliefs and attitudes about nicotine products~Refusing and avoiding vaping~Recognizing addiction and getting help~Health information:~• Factual information about healthy eating and activity (PA)~Motivation:~Personal: Create positive attitudes toward engagement in healthy eating and PA~Social: Enlisting social support to increase healthy eating and PA~Social: Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and model good health decision-making for health behaviors"
33407426|NCT04252677|Experimental|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).~Health Literacy~Functional HL: skills for reading/understanding nutrition labels and medication instructions.~Interactive HL: verbal skills for interacting with others on health issues.~Critical HL: connections between advocacy and health~Media HL: skills for accessing and identifying reliable source of media.~Health information:~• Factual information about healthy eating and activity (PA)~Motivation:~Create positive attitudes toward engagement in healthy eating and PA~Enlisting social support to increase healthy eating and PA~Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and good health decision-making for health behaviors"
33407427|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
33407428|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
33407429|NCT05682209|Active Comparator|Octreotide group|Received 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
32964022|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
33320774|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
32964023|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
32964024|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
32964025|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
32964026|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
33320775|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
33320776|NCT04345666|Experimental|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
33320777|NCT04345666|Placebo Comparator|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
33320778|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
33320779|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
33320780|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
33320781|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
33320782|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
33320783|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
33320784|NCT01336192|No Intervention|Best supportive care|Best supportive care
33320785|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
33320786|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
33320787|NCT04296890|Experimental|Treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
33320788|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
33320789|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
33320790|NCT04607200|Experimental|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
33320791|NCT04607200|Experimental|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
33320792|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
33320793|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
33320794|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
33320795|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
33320796|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
33320797|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
33320798|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
33320799|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
33320800|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
33320801|NCT01345942|Experimental|A food|
33320802|NCT01345942|Experimental|B without food|
33320803|NCT01346020||CLL|
33320804|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
33320805|NCT01346098|Active Comparator|GROUP A|
33320806|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
33320807|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
33320808|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
33320809|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
33320810|NCT04592536|Experimental|CVL-865|High dose CVL-865 (25mg) Low dose CVL-865 (7.5mg)
33407430|NCT05682209|Placebo Comparator|Control group|Received 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
32858638|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
33320811|NCT04592536|Active Comparator|Alprazolam|Active Comparator Alprazolam with extended release oral tablets; 1 tablet BID
32858639|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
33320812|NCT04592536|Placebo Comparator|Placebo|Placebo Comparator matching oral tablets for CVL-865, capsule for Alprazolam
33320813|NCT01346332||Anesthetization|
33320814|NCT01336582|Experimental|docetaxel|
33320815|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
33320816|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
33320817|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
33320818|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
33320819|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
33320820|NCT01346800|Experimental|Prasugrel 10mg po|
33320821|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
33320822|NCT03902314|Active Comparator|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
33320823|NCT03902314|Placebo Comparator|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
33320824|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
33320825|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
33320826|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
33320827|NCT03706040|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
33320828|NCT03706040|Experimental|Risankizumab 300 mg|Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
33320829|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
33320830|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
33320831|NCT04276376|Experimental|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.~1.A - Non-Small Cell Lung Cancer~1.B - Urothelial Bladder Cancer~1.C - metastatic Castration Resistant Prostate Cancer~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
33320832|NCT04276376|Experimental|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
33320833|NCT04276376|Experimental|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
33320834|NCT04276376|Experimental|Cohort 4|Clear Cell Renal Cell Carcinoma
33320835|NCT04254692|Active Comparator|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
33320836|NCT04254692|Other|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
33320837|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
33320838|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
33320839|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
33320840|NCT04398680|Experimental|Part 1, Group 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] less than or equal to [<=] Upper limit of normal [ULN]) will be administered with Belantamab mafodotin
33320841|NCT04398680|Experimental|Part 1, Group 2: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin greater than >1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin
33320842|NCT04398680|Experimental|Part 2,Group 3: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin >3 times ULN and any AST) will be administered with Belantamab mafodotin
33320843|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
33320844|NCT04033718|Experimental|Inpatient lab bundling plus navigation|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach. Additional inpatient support from a patient navigator
33320845|NCT04033718|Experimental|Inpatient lab bundling alone|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach.
33407431|NCT05258513|Placebo Comparator|Placebo|From weeks 1-4, participants will consume 150mg daily of a visually identical placebo. For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of placebo supplementation.
33407432|NCT05258513|Experimental|Geranylgeraniol Treatment|From weeks 1-4, participants will consume 150mg daily of a Geranylgeraniol (GG). For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of GG.
33407433|NCT04637841|Active Comparator|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
33407434|NCT04637841|Active Comparator|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
33407435|NCT04637841|Active Comparator|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
33407436|NCT04637841|Active Comparator|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
33407437|NCT05682131|Placebo Comparator|Control group|Oral placebo was added to conventional chemotherapy
33407438|NCT05682131|Experimental|Experimental Group|Oral RIF was added to conventional chemotherapy
33407439|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
33407440|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
33407441|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
33407442|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
33407443|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
33407444|NCT03706391||ALS and PMA Reversals|
33407445|NCT05399277|Experimental|Rivaroxaban Group|Subjects will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days following transradial access.
33407446|NCT05399277|No Intervention|Standard of Care Group|Subjects will receive the usual standard of care following transradial access.
33407447|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
33407448|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
33407449|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
33407450|NCT04608903|Experimental|Sulforaphane Group|Administration of 4g L-Sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
33407451|NCT04608903|Placebo Comparator|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
33407452|NCT02961218|Placebo Comparator|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
33407453|NCT02961218|Experimental|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
33407454|NCT05682053|Other|patients with medullary sponge kidney|Patients with medullary sponge kidney attending medical consultation
33407455|NCT05682053|Other|Patients with glomerular filtration rate > 60 mL/min/1.73m2 without kidney stone|Patients with glomerular filtration rate > 60 mL/min/1.73m2 without kidney stone attending a renal exploration.
32858640|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858641|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858642|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858643|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
33407456|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
33407457|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
33407458|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
33407459|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
33407460|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
33407461|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
33407462|NCT05216744|Experimental|Doxycycline plus ceftriaxone|Each subject will receive 100 mg doxycycline twice daily for seven days and a single dose of ceftriaxone 1000 mg intravenously
33407463|NCT05216744|Active Comparator|Doxycycline plus cefixime|Each subject will receive 100 mg doxycycline twice daily for seven days and a single oral dose of cefixime 800 mg
33407464|NCT05681897|Other|Single Spin Group|Currently, the standard operating procedures for PRP preparation in dr. Cipto Mangunkusumo National General Hospital is by performing a single-spin centrifugation at 3000 rpm for 15 minutes. This first group will received PRP treatment by single-spin centrifugation at 3000 rpm in 15 minutes in addition to topical minoxidil (5%)
33407465|NCT05681897|Active Comparator|Double Spin Group|This group will received double-spin centrifugation PRP treatment at 1500 rpm in 6 minutes and continued at 2500 rpm in 15 minutes in addition to topical minoxidil (5%)
33407466|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
33407467|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
33407468|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
33407469|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
33407470|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
33407471|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
33407472|NCT05393739|Experimental|Intermittent theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
33407473|NCT05393739|Experimental|Continuous theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
33407474|NCT05393739|Sham Comparator|Sham theta burst|The stimulus intensity in sham group is about half of that in iTBS/cTBS groups, and the subjects receive a placebo stimulation with the coil orientation tilted to 90°. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
33407475|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
33407476|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
33407477|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
33407478|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
33407479|NCT05149131||mCSPC patients in the province of Alberta|mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
33407480|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
33407481|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
33407482|NCT05389215|Experimental|DWN12088 Xmg Tablet (BID)|PRS inhibitor
33407483|NCT05389215|Placebo Comparator|Placebo 0mg Tablet (BID)|Placebo
33407484|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
33407485|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
33407486|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
33407487|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
33407488|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
33104797|NCT05543356|Active Comparator|Monovalent Pfizer-BioNTech(BNT162b2): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
33407489|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
32899076|NCT00176852|Experimental|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
33407490|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
33407491|NCT04112667||Normal Macular Health|>=60 years old with no macular disease
33407492|NCT04112667||Early Macular Degeneration|>=60 years old with early age-related macular degeneration
33407493|NCT04112667||Young Normals|20-30 years old with normal macular health
33407494|NCT05630001|Experimental|Iptacopan treatment in adult PNH patients|Subjects will receive iptacopan at a dose of 200 mg b.i.d. orally
33407495|NCT04077879|Experimental|Single ascending dose of ASP1617|This is composed of 5 sequential cohorts (cohorts 1.1 to 1.5), 6-9 participants for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5). Participants in cohorts 1.1, 1.2, 1.3, 1.4 and 1.5 will receive a single dose of 2, 10, 30, 100 and 300 milligrams (mg) ASP1617 capsules respectively under fasting conditions
33407496|NCT04077879|Placebo Comparator|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
33407497|NCT04077879|Experimental|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of 100 mg ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
33407498|NCT04077879|Experimental|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 to 2.3, 9 participants for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3). Participants in cohorts 2.1, 2.2 and 2.3 will receive 30, 60 and 110 mg ASP1617 capsules respectively twice daily for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
33407499|NCT04077879|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3.
33407500|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
33407501|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
33407502|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
33407503|NCT05372367|Experimental|BI 907828 low dose, then BI 907828 low dose + rifampicin, then BI 907828 high dose|Cycle 1: BI 907828 low dose; Cycle 2: BI 907828 low dose + rifampicin; Cycle 3: BI 907828 high dose
33407504|NCT05283434|Placebo Comparator|Double-Blind Clinical Trial- Placebo Group|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the placebo group will take the recommended doses of sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
33407505|NCT05283434|Experimental|Double-Blind Clinical Trial- Experimental Group|
33407506|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
33407507|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
33407508|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
33407509|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
33407510|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
33407511|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
33407512|NCT03642002|Experimental|Toning|Vocal Tonal Holding
33407513|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
33407514|NCT03642002|Experimental|SOK|Song of kin with lyric content
33407515|NCT03642002|Experimental|Process|Processing of experience
33407516|NCT03642002|Experimental|Holding Harmonic Container|
33407517|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
33407518|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
33407519|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
33407520|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
33407521|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
33407522|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
33407523|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
33407524|NCT03254485|Experimental|IW-1973 High Dose|
33407525|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
33407526|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
33407527|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33407528|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
33407529|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
33407530|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
33407531|NCT03641612|Experimental|one shape|single file rotary system
33407532|NCT03641612|Active Comparator|protaper next|multiple file rotary system
33407533|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
33407534|NCT01068704|Active Comparator|Lapatinib + Letrozole|
33407535|NCT00352573||Normal Volunteers|Adults over 21 years old
33407536|NCT05179759|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
33407537|NCT05179759|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
33407538|NCT05179759|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
33407539|NCT05179759|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
33407540|NCT05179759|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
33407541|NCT05179759|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
33407542|NCT05179759|Experimental|Tealeaf - Year 4: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
33407543|NCT05179759|Active Comparator|Enhanced Usual Care - Year 4: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
33407544|NCT05179681||patients with non-intubated thoracic surgery|
33407545|NCT03339401|Experimental|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.~Subjects who did NOT receive concurrent cyclosporine on Day 1:~If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).~If <48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):~1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.~2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
32858644|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858645|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858646|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
33407546|NCT03339401|Other|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
33407547|NCT05179525|Experimental|Risperidone ISM® 100 mg|Subjects will receive 4 mg oral risperidone once daily for 7 days. After the 1 week oral risperidone regimen subjects will be administered 100 mg risperidone ISM as an injectable into the gluteal muscle. A total of 4 doses of intramuscular (IM) 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. Each dose will be separated by 4 weeks.
33407548|NCT05179291|Experimental|Buzzy Group|In this group external cold and vibration-Buzzy was applied to the children during phlebotomy.
33407549|NCT05179291|Experimental|Virtual Realitiy-VR Group|In this group Virtual Realitiy-VR was applied to the children during phlebotomy.
33407550|NCT05179291|No Intervention|Control Group|In this group, children received routine phlebotomy procedure
33407551|NCT04362709||Postoperative complications|
33407552|NCT04362709||No postoperative complications|
33407553|NCT04160455||Cohort A, group A1|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase : CD4 count less than 500 cells / ml at the time of inclusion in the study
33407554|NCT04160455||Cohort A, group A2|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase: CD4 count above 500 cells / ml at the time of inclusion in the study
33407555|NCT04160455||Cohort B|20 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)
32858647|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858648|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858649|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
32858650|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
32858651|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
32858652|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
32858653|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
32858654|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
33407556|NCT04160455||Cohort C, group C1|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during primary infection (within 4 months of infection)
33407557|NCT04160455||Cohort C, group C2|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study
33407558|NCT04160455||Cohort C, group C3|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study
33407559|NCT04160455||Cohort D|20 patients who have undetectable plasma HIV RNA (HIV RNA <50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers).
33407560|NCT05692206||according to the neck disability index, mildly and moderately affected|
33407561|NCT05692206||According to the neck disability index, severely affected and very severely affected|
33407562|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
33407563|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
33407564|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
33407565|NCT05507580|Experimental|Double-Blind Treatment Period Dose A|Participants will be administered updadacitinib Dose A once daily (QD) for 12 weeks.
32964027|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
33407566|NCT05507580|Experimental|Double-Blind Treatment Period Dose B|Participants will be administered updadacitinib Dose B once daily (QD) for 12 weeks.
33407567|NCT05507580|Experimental|Single-Blinded Treatment Period Arm A|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
33407568|NCT05507580|Experimental|Single-Blinded Treatment Period Arm B|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
33407569|NCT05507580|Experimental|Single-Blinded Treatment Period Arm C|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
33407570|NCT05507580|Experimental|Single-Blinded Treatment Period Arm D|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
33407571|NCT04292197|Experimental|18-MC SAD Study|In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day.
33407572|NCT04292197|Experimental|18-MC MAD Study|In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days.
33407573|NCT05137496|Experimental|Ruxolitinib+methylprednisolone|Ruxolitinib and methylprednisolone administered as the first-line therapy
33407574|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
33407575|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
33407576|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
33407577|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
33407578|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
33407579|NCT04025359|Active Comparator|Dronabinol 2.5mg|Dronabinol 2.5mg
33407580|NCT04025359|Active Comparator|Dronabinol 5mg|Dronabinol 5mg
33407581|NCT04025359|Placebo Comparator|Placebo|Placebo
33407582|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
33407583|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
33407584|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
33407585|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
33407586|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
33407587|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
32858655|NCT00085709|Experimental|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
33407588|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
33407589|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
33407590|NCT05425277|Experimental|RIT Training Group|Providers in the RIT group (n=30) will receive an 8-hour virtual workshop (2 half-days) on RIT implementation and caregiver coaching. Each provider will invite 2 families in their caseload to participate in the study. Providers will coach families in the use of RIT. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity.
33407591|NCT05425277|Active Comparator|Daily Routines|Providers in the Routines Control group (n=30) will receive a 3-hour virtual workshop focused on helping providers coach caregivers on how to increase children's participation and social engagement during everyday home routines (i.e., snack time, bedtime, bath time, and family playtime). Each provider will invite 2 families in their caseload to participate in the study. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity to ensure contamination has not occurred and the control condition providers are not utilizing RIT strategies.
33407592|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
33407593|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
33407594|NCT05124002|Experimental|H101+HAIC|"Recombinant Human Adenovirus Type 5 (H101): intratumorally injected 3 days before HAIC. 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.~HAIC (FOLFOX): Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium"
33407595|NCT01661400|No Intervention|Control|No intervention
33407596|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
33407597|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
33407598|NCT05158166|Experimental|Administration of Daxi|Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.
33407599|NCT03676218||Elderly cancer patients|
33407600|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
33407601|NCT03666624|No Intervention|Routine medical care|No intervention
33407602|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
33407603|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
33407604|NCT05225129|Experimental|Training Group|Resistance training will be applied to the training group, equivalent to 30% of 1 maximum repetition with blood flow restricted exercise for 8 weeks , 2 days in a week.
33407605|NCT05225129|No Intervention|Control Group|Resistance training will be applied to the control group, equivalent to 30% of 1 maximum repetition without blood flow restriction for 8 weeks , 2 days in a week.
33407606|NCT04013971|Other|Game without VR, Game with VR, Traditional biofeedback Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without VR, game with VR, traditional interface
33407607|NCT04013971|Other|Game without VR, Traditional Interface, Game with VR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without VR, traditional interface, game with VR
33407608|NCT04013971|Other|Game with VR, Game without VR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with VR, game without VR, traditional interface
33407609|NCT04013971|Other|Game with VR, Traditional Interface, Game without VR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with VR, traditional interface, game without VR
32858656|NCT00085709|Other|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
32858657|NCT00085709|Active Comparator|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
32858658|NCT00085709|Active Comparator|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
32858659|NCT01201863|Experimental|Low T Intervention - Androgel Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Androgel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
33407610|NCT04013971|Other|Traditional Interface, Game without VR, Game with VR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game without VR, game with VR
33407611|NCT04013971|Other|Traditional Interface, Game with VR, Game without VR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game with VR, game without VR
33407612|NCT05691972|Experimental|Treatment|
33407613|NCT05691972|No Intervention|Control|
33407614|NCT05179213|Experimental|Azacytidine combined with chidamide|Patients in the experimental arm will received azacytidine plus chidamide treatment. This regimen was repeated every 28 days.
33407615|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
33407616|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
33407617|NCT05424276|Experimental|50mg IkT-148009|This arm will consist of thirty (30) patients on 50mg of active treatment.
33407618|NCT05424276|Experimental|100mg IkT-148009|This arm will consist of thirty (30) patients on 100mg of active treatment.
33407619|NCT05424276|Experimental|200mg IkT-148009|This arm will consist of thirty (30) patients on 200mg of active treatment. This arm is to be added to the trial following completion of an ongoing PK profile measurement.
33407620|NCT05424276|Placebo Comparator|Placebo|This arm will consist of thirty (30) patients on placebo.
33407621|NCT05499624|Experimental|MicroTrend System|MicroTrend System is placed onto the subject's cheek and the subject will actively participate in the study for up to 6 hours, with up to 4 hours of sensor monitoring.
33407622|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
33407623|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
33407624|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
33407625|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
33407626|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
33407627|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
33407628|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
33407629|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
33407630|NCT05178745||Cohort 1|Patients with metastatic colorectal cancer and liver metastases treated with FOLFIRI plus aflibercept after failure of an oxaliplatin-based regimen
33407631|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
32858660|NCT01201863|Placebo Comparator|Low T Intervention - Placebo Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Placebo gel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
32899077|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
33407632|NCT03626220||acupuncture group|acupuncture with de-chi sensation
33407633|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
33407634|NCT05571241||fast rehabilitation program|conventional rehabilitation
33407635|NCT05691894|Experimental|18F-FAPI|
33407636|NCT05691894|Experimental|68Ga-FAPI|
33407637|NCT05178511|Experimental|hydrochloric acid ensartinib|Ensatinib 225mg daily, QD, until progression or intolerance
33407638|NCT05571163|Experimental|Treatment Sequence AB|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment A) - AMG 510 as oral tablets. Period 2 (treatment B) - AMG 510 as tablets dispersed in water."
33407639|NCT05571163|Experimental|Treatment Sequence BA|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment B) - AMG 510 as tablets dispersed in water. Period 2 (treatment A) - AMG 510 as oral tablets."
33407640|NCT05423262|Experimental|Arm : TRK-950|"Solid Tumor~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. Two dose levels will be explored during this Arm."
33407641|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
33407642|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
33407643|NCT05691738|Experimental|Exercise Group|Information will be given about diabetes and its complications.Modified Otago Exercise will be applied by the physiotherapist.Participants will be given a home program
33407644|NCT05691738|Other|Control Group|Information will be given about diabetes and its complications.Participants will be given a home program
33407645|NCT05691660|Experimental|Single dose cohort|
33407646|NCT05691660|Experimental|Repeated dose cohort Once daily (QD)|
33407647|NCT05691660|Experimental|Repeated dose cohort Twice daily (BID)|
33407648|NCT03995641|No Intervention|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
33407649|NCT03995641|Experimental|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
33407650|NCT04105231|Experimental|Cannabidiol|"Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks.~AND Risperione placebo, encapsulated tablet."
33407651|NCT04105231|Active Comparator|Risperidone|"Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks~AND Cannabidiol placebo, oral suspension"
33407652|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
33407653|NCT05691582|Experimental|Single arm|All the subjects recruited have 4 access to GRAIL, in 4 different day, to test their tolerability to the proposals
33407654|NCT03557749||Immune and Microbial Reconstitution|
33407655|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
33407656|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
33407657|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
33407658|NCT03557749||Immune Response Triggered by Relapse|
33407659|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
33407660|NCT03557749||Allogeneic Related Donor Samples|
33407661|NCT03557749||Cellular Therapy Products|
33407662|NCT05691504|Experimental|Treatment (pelcitoclax, cobimetinib)|Patients receive APG-1252 IV and cobimetinib PO on study. Patients also undergo biopsy and collection of blood on study and undergo CT and/or MRI throughout the trial.
33407663|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
33407664|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
33407665|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
33407666|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
33407667|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
33407668|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
33407669|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
33407670|NCT03993457|Other|CRP<1, CRP consistent antidepressant selection|Participants with CRP<1 will be prescribed escitalopram
33407671|NCT03993457|Other|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed bupropion XL
33407672|NCT03993457|Other|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP< 1 will be prescribed bupropion XL
33407673|NCT03993457|Other|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed escitalopram
33407674|NCT05571085|Experimental|Core Stability Exercises group|"Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.~Children will be taught the abdominal cupping technique during the first two weeks of the exercises."
33407675|NCT05571085|Other|PNF Exercise Program|"PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.~Individuals will be taught the abdominal cupping technique during the first two weeks of the program."
33407676|NCT05571085|No Intervention|Control Group|No treatment program was applied. As a result of the study, an effective exercise program will be recommended to the participants.
33407677|NCT05691270|Other|Pilot Study Participants|All adolescents who engage with the IN-Control Program will be asked if they would like to formally enroll as a study participant after interaction with the navigator. However, enrollment is not required to receive support from the navigator.
33407678|NCT05571007|Experimental|True acupressure|Using three true acupoints. Acupoints: Yongquan (K1), Sayingjiao (SP6), Zusanli (ST36). Patient Position: Lying or sitting position. Time: first 2 hours of HD.
33407679|NCT05571007|Sham Comparator|Sham acupressure|Using three sham acupoints. Acupoints: Sham acupoints are located on 1 cun from the true acupoint. Patient Position: Lying or sitting position. Time: first 2 hours of HD.
33407680|NCT03348306|Experimental|All patients|
33407681|NCT05570773|Experimental|peer support program|"A researcher and peer tutors met students in an online session for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days. These sessions focused on academic problem solving and academic encouragement of students. In addition, peer tutors and students shared their contact information and continued their sharing by talking on the phone and messaging in the chat group 24/7.~Selection and education of peer tutors: 5 peers with strong communication skills and high academic achievement were selected among the 4th-year volunteer students. These 5 volunteers were selected among students who were not included in the sample, had an appropriate level of anxiety (anxiety score ≤36), and had good sleep quality (PSQI score ≤5). A theoretical and practical session was held with them. In these sessions, peer-supported education was explained and necessary information was given about its purpose and how it was performed."
33407682|NCT05570773|Experimental|progressive relaxation exercise group|The importance of the exercise and how it should be done were explained by the researcher Mixed teaching methods, including lecturing, demonstration, question-answer, and discussion were, used as education methods. The sessions were carried out online by a researcher who is an expert in the field of PRE for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days.
33407683|NCT05570773|No Intervention|control group|The students who formed the control group through randomization were given information about the research, and then they submitted informed consent. Control group students were given the same questionnaire as a pre-and-post-test applied in the intervention groups, but no intervention was applied.
33407684|NCT04677439|Experimental|Flumatinib|
33407685|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
33407686|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
33407687|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
33407688|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
33407689|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
33407690|NCT05570695|Experimental|neurofeedback|Modulation of brain activity using verum and sham neurofeedback.
33407691|NCT05689710|No Intervention|No intervention|
32858661|NCT01201863|No Intervention|Normal T|A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
32858662|NCT01202253||Anidulafungin|
32858663|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
32858664|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
32858665|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
32899078|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
33407692|NCT05689710|Experimental|Experimental|Dietary Supplement with inositols and alpha-lactalbumin
32899079|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
32899080|NCT01324453|Experimental|Post conditioning + PCI|
33407693|NCT02986789|No Intervention|Control Group|Clinicians will be performing blood transfusions using hospital standard of care procedures.
33407694|NCT02986789|Experimental|Evaluation Group|Clinicians will be guiding blood transfusions using SpHb with In vivo feature as a trigger for laboratory blood draws and PVi to inform fluid administration decisions in addition to hospital standard of care procedures.
33407695|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
33417261|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Pre and post-bronchodilator using Albuterol (BD) spirometry"
33417262|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
33407696|NCT05685498|Other|Peer-led HIV self-testing among male fisherfolk in Uganda|Men aged 15 years or older, who self-report a HIV-negative or unknown HIV status at enrolment and last tested for HIV three or more months are enrolled into the study. Enrolled men receive two HIV self-test kits from a trained community-based distributor (or peer-leader). Peer-leaders are selected from existing social networks and are trained in HIV self-testing procedures prior to distributing HIV self-test kits. The goal of the study is to assess if distribution of HIV self-test kits to men through trained local peer-leaders is feasible and acceptable in a fishing community context, and whether this approach can help to improve access to HIV testing services and, by implication, improve HIV testing uptake and subsequent linkage to appropriate HIV prevention, care and treatment services. Men are interviewed at baseline will be followed up at 1, 6 and 12 months post-baseline to determine HIV testing uptake, linkage to and retention in HIV care.
33407697|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
33407698|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
33407699|NCT05360550|Experimental|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|LSP-5415
33407700|NCT05255874|Experimental|Aromatherapy Group|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
33407701|NCT05255874|No Intervention|Standard of care|Routine treatment and care interventions will be applied to the patients included in the control group during the procedure. Patients in the control group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level.
33407704|NCT03247543|Placebo Comparator|Placebo|Placebo, qd, oral capsule
33407705|NCT03247543|Active Comparator|200mg SPN-812|200mg SPN-812, qd, oral capsule
33407706|NCT03247543|Active Comparator|400mg SPN-812|400mg SPN-812, qd, oral capsule
33407707|NCT05351190|Other|Treatment Arm|All participants will be given a rtCGM (Dexcom G6) to assess their glycemic control.
33407708|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
33407709|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
33407710|NCT05569525|Experimental|Test|Patients receiving non-surgical periodontal treatment within 1 week from enrollment.
33407711|NCT05569525|Active Comparator|Control|Patients receiving non-surgical periodontal treatment 6 months after the enrollment.
33407712|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
33104798|NCT05543356|Active Comparator|Monovalent Moderna(mRNA-1273, Spikevax®): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
33407713|NCT03246061|Active Comparator|BVN Ablation|BVN ablation with continued standard care
33407714|NCT03246061|Active Comparator|Standard Care Control|Continue with non-surgical standard care
33407715|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
33407716|NCT05569057|Experimental|SIM1811-03 Monotherapy|All participants receive SIM1811-03 alone
32899081|NCT01324453|Active Comparator|Standard PCI|
33407720|NCT01315236|Experimental|LAI 590 mg QD|LAI 590 mg QD
33407721|NCT01315236|Placebo Comparator|Placebo|placebo QD
33407722|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
33407723|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
33407724|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
33407725|NCT05203614|Other|Household Contribution|Do something thoughtful or nice for your caregiver that would provide them with tangible support
33407726|NCT05203614|Other|Outside Contribution|Do something outside your home/household that contributes to the larger society
33407727|NCT05203614|Other|Control|Keep track of your daily activities
33407728|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
33407729|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
33407730|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
33407731|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
33407732|NCT02477358|Experimental|PRF Treated|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
33407733|NCT02477358|No Intervention|Control|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
33407734|NCT04621045|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
32858666|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
32858667|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
32858668|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
32858669|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
32858670|NCT00084929|Experimental|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
32858671|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32858672|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
32858673|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
32858674|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
32858675|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
33407735|NCT04621045|Active Comparator|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
33407736|NCT01348490|Experimental|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
33407737|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
32858676|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
32858677|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
32899082|NCT01376557|Experimental|Treatment A|
32899083|NCT01376557|Experimental|Treatment B|
32899084|NCT01376557|Experimental|Treatment C|
32858678|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32858679|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
32858680|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
32858681|NCT00084617|Experimental|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
32858682|NCT04270175|Experimental|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:~(4mg orally) on days 1-21 of a 28-day cycle~Dexamethasone:~20mg IV as premedication on days 1, 8, 15, and 22~20mg orally the day after daratumumab dosing for cycles 1-2 of induction~40mg IV as premedication on days 1 and 15 on daratumumab treatment days~40mg orally on non-daratumumab days (8 and 15) for cycles 3-6~20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)~If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.~Daratumumab:~1800mg sub-cutaneously weekly x8 weeks~1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)~1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
32858683|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
33407738|NCT03232333||MIRODERM|Biologic wound graft
33407739|NCT05620914|Experimental|Patritumab deruxtecan|15 participants with surgically-resectable brain metastases from multiple solid tumor primary histologies known to express HER3 will be treated. Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of BrM. Participants will undergo specimen collection prior to and during the planned craniotomy, including tumor, blood, and cerebrospinal fluid (CSF).
33407740|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
33407741|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
33407742|NCT05618574|Active Comparator|Beet-It nitrate beverage|Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14. All participants will undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
33407743|NCT05618574|Placebo Comparator|Nitrate-depleted placebo.|Participants will receive 210 ml of nitrate-depleted placebo for 14 days. All participants will undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
33407744|NCT04080505|Active Comparator|SSKI (Potassium Iodide)|Participants randomized to receive 7 days of pre-operative SSKI
33407745|NCT04080505|No Intervention|NO SSKI|Participants randomized to not receive any drug pre-operative
33407746|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
33407747|NCT05572411||Ponseti|Ponseti treated Clubfoot participants will be asked to walk across the GAITRite Electronic Walkway.
33407748|NCT05572255|Experimental|Treatment A (Reference)|An intact 200 mg cenobamate tablet administered orally.
33407749|NCT05572255|Experimental|Treatment B (Test 1)|A crushed 200 mg cenobamate tablet in suspension administrated orally.
33407750|NCT05572255|Experimental|Treatment C (Test 2)|A crushed 200 mg cenobamate tablet in suspension administered via an NG tube
33407751|NCT05610696|Experimental|Low impact immersion|This intervention will use the principles of Ai Chi, a model defined as a low-intensity aquatic exercise strategy
33407752|NCT05610696|Experimental|Conventional aquatic physiotherapy|In this intervention, medium impact exercises will be performed, with a comfortable movement speed.
33407753|NCT05610696|Experimental|High intensity aquatic physiotherapy|In this intervention, high-impact exercises will be performed, with maximum movement speed, twice time of the medium-intensity protocol
33407754|NCT03364049|Experimental|MK-7162 25 mg +Pembrolizumab (Pembro)|Participants receive MK-7162 25 mg via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 25 mg orally QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
33407755|NCT03364049|Experimental|MK-7162 50 mg + Pembro|Participants receive MK-7162 50 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-71625 50 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
32858684|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
32858685|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
32858686|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
32858687|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
33407756|NCT03364049|Experimental|MK-7162 100 mg + Pembro|Participants receive MK-7162 100 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 100 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
33407757|NCT03364049|Experimental|MK-7162 200 mg + Pembro|Participants receive MK-7162 200 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 200 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
33407758|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
32858688|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
33407759|NCT05148156|Experimental|Urolift|This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.
32858689|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
32858690|NCT01206387|Placebo Comparator|placebo comparator|vehicle
32858691|NCT03711929|Experimental|Test Arm: DE-109 Injectable Solution|Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects).
32858692|NCT03711929|Sham Comparator|Control Arm: Sham Procedure|Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects). The sham procedure mimics an intravitreal injection without penetrating the eye.
32858693|NCT03711929|Other|Dummy Arm: DE-109 Injectable Solution|Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 40 subjects). This study arm (which has the same route of administration and frequency as the test arm).
32858694|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
33407760|NCT05606172|Experimental|PCIP for youth aged 6 to 11|This arm will receive the adapted PCIP intervention lasting from 1-4 weeks, and will complete baseline, post treatment, 1-month, and 3-month follow up assessments.
33407761|NCT05606172|Active Comparator|Waitlist Treatment as Usual|Receive standard care treatment and will complete baseline, post treatment, 1-month, and 3-month follow up assessments, and are offered PCIP treatment after conclusion of the study.
33407762|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
33407763|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
33407764|NCT05348772|Active Comparator|AmnioPul-02 Dose level 1|AmnioPul-02 Dose level 1
33407765|NCT05348772|Active Comparator|AmnioPul-02 Dose level 2|AmnioPul-02 Dose level 2
33407766|NCT05681819|Experimental|SHR-1707|Up to4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 injection
33407767|NCT05681819|Placebo Comparator|SHR-1707 placebo|Up to 4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 placebo injection
33407768|NCT05343078|Experimental|Dapagliflozin|Dapagliflozin 10mg P.O.
33407769|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
33407770|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
33407771|NCT03238963|Experimental|BI 1467335|
33407772|NCT03238963|Placebo Comparator|Placebo|
33407773|NCT05693298|Experimental|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
33407774|NCT05693298|Active Comparator|Standard Treatment|If peripheral oxygen saturation will be < 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
33407775|NCT05693220|Active Comparator|Density gradient centrifugation|Patients will undergo sperm preparation by density gradient centrifugation
32858695|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
32858696|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.~During the study, the dose of all subjects will be switched to the selected one*.~* The dose was determined to be 2.0 mg/kg/week based on the safety and efficacy data of JR-141-BR21 study."
32858697|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
32858698|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
32858699|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
33407776|NCT05693220|Active Comparator|Zymot sperm separation device|Patients will undergo sperm preparation by the Zymot sperm separation device
33407777|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
33407778|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
32858700|NCT01679639|Experimental|Aleglitazar|
32858701|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
32899085|NCT01376557|Experimental|Treatment D|
33407779|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
33407780|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
33407781|NCT05572177|Experimental|Asthma SMART|Subjects randomized to the intervention arm will be provided with the app to download to their personal iPhone or Android smartphone. Subjects will be asked to use the app every day for 6 months.
33407782|NCT05572177|No Intervention|Standard of care|Subjects randomized to the standard-of-care arm will continue to receive regular care for their condition.
33407783|NCT05439096|Experimental|Functional Exercise|"2 stretching exercises~1 yoga exercises~2 core strengthening exercises~2 pelvic area exercises~Kegel exercises~Warm up for 5 minutes the apply perform exercise 3 times a week for 8 weeks and 45 minutes duration at a time"
33407784|NCT05439096|Experimental|High Frequency Transcutaneous Electrical Nerve Stimulation|"High frequency TENS by below mentioned parameters will be applied.~Pulse waveform = Biphasic waveform~Pulse recurrence = 50 to 120 Hz~Phase duration = 100 µsec~Current amplitudes = highest tolerable intensity with continuous adjustment~Skin arrangement = flawless skin region.~Type of electrodes = Self-adhesive~Size and location of electrodes = It will be adjusted specifically to each woman according to the typical area of her pain."
33407785|NCT03683173|Experimental|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
33407786|NCT03683173|No Intervention|Control|Does not receive the multilevel intervention.
33407787|NCT05681741|Sham Comparator|current pump flow (between 2 and 2.4 l/min/m²)|the pump flow will be constant during this randomized phase
33407788|NCT05681741|Active Comparator|high pump flow (between 2.6 and 3 l/min/m²)|the pump flow will be constant during this randomized phase
33407789|NCT03964363|Experimental|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
33407790|NCT03964363|Experimental|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
33407791|NCT03964363|No Intervention|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
33407792|NCT03964363|No Intervention|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
33407793|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
33407794|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
33407795|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
33407796|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
33407797|NCT05199311|Experimental|Starting Dose -1|"CC-220/Iberdomide: 1.1 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
33407798|NCT05199311|Experimental|Dose Level 1|"CC-220/Iberdomide: 1.3 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 1 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level -1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
33407799|NCT05199311|Experimental|Dose Level 2|"CC-220/Iberdomide: 1.6 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 2 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level 1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
33407800|NCT05199311|Experimental|Dose Level -2|"CC-220/Iberdomide: 0.75 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
33407801|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
32899086|NCT01376557|Placebo Comparator|Placebo|
32899087|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
32899088|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
33407802|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
33407803|NCT05681663|Experimental|1.5 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 1.5 bar ESWT will be applied to this group.
33407804|NCT05681663|Experimental|4 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 4 bar ESWT will be applied to this group.
33407805|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
33407806|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
33407807|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
33407808|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
33407809|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
33407810|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
33407811|NCT05176535|Experimental|FertyBiotic Balance|Participants received FertyBiotic Balance one capsule a day
33407812|NCT03042312|Experimental|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
33407813|NCT03042312|Experimental|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
33407814|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
33407815|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
33407816|NCT05692986|Active Comparator|povidone betadine|
33407817|NCT05692986|Active Comparator|chlorhexidine|
33407818|NCT05166785|Active Comparator|In-person Diabetes Prevention Program (DPP)|Participants randomized to the in-person DPP intervention for 12 months
33407819|NCT05166785|Active Comparator|DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm)|Participants randomized to the DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm) intervention for 12 months.
33407820|NCT03360071|Experimental|Allergen Immunotherapy Group|
33407821|NCT03360071|Placebo Comparator|Control Group|
33407822|NCT05692908|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
33407823|NCT05692830|Experimental|Fast Condition|Participants randomized to consume study beverages at a comparatively rapid rate.
33407824|NCT05692830|Experimental|Slow Condition|Participants randomized to consume study beverages at a comparatively slow rate.
33407825|NCT05131139|Experimental|Continuous Glucose Monitoring Device|Eversense 524 CGM System and ROME CGM System.
33407826|NCT05092776|Experimental|RPH-104|"Test product group receiving RPH-104 subcutaneous (s.c.) injections:160 mg on Day 0, 80 mg on Day 7, Day 14 and every 2 weeks (q2w) thereafter.~In case marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will receive planned RPH-104 80 mg administration.~In case of a new attack on further days of treatment period until Visit 10 inclusive - the treatment group will be unblinded: the dose of RPH-104 could be escalated to 160 mg q2w; The patients already receiving RPH-104 160 mg q2w will continue to receive RPH-104 at this dose. Further dose escalation is forbidden."
33407827|NCT05092776|Placebo Comparator|Placebo|"Placebo group receiving the equivalent placebo dose also as s.c. injections on Day 0, Day 7, Day 14 and q2w thereafter.~In case the marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will be switched to active treatment with RPH-104 in SC injections at a dose of 160 mg followed by administration of 80 mg in 7 days at the Attack + 7 days Visit, and 80 mg at the next Visits.~In a case of a new attack the patients switching from placebo and receiving RPH-104 at 80 mg dose could be escalated to RPH-104 160 mg q2w; Further dose escalation is forbidden."
33407828|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
33407829|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
33407830|NCT05339100|Experimental|Anifrolumab administered using AI|Randomized participants will receive a single SC dose of anifrolumab via AI.
33407831|NCT05339100|Active Comparator|Anifrolumab administered using APFS|Randomized participants will receive a single SC dose of anifrolumab via APFS.
33407832|NCT05129891|Experimental|Part A: Oral semaglutide|Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
33407833|NCT05129891|Experimental|Part B: NNC0385-0434|Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
33407834|NCT05058924|Active Comparator|Prophylactic Low Molecular Weight Heparin (LMWH)|Prophylactic LMWH for 6 weeks postpartum
33407835|NCT05058924|Experimental|Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose Aspirin|Prophylactic LMWH for 3 weeks followed by low dose Aspirin for 3 weeks.
33407836|NCT04745507||Arm 1 / C1|This cohort (C1) consists of 180 patients who receive IEHT in the recruiting sites, fulfil inclusion criteria and gave informed consent regarding their study participation.
32858702|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
33407837|NCT04745507||Arm 2 / C2|"This cohort (C2) consist of 180 patients receiving standard inpatient care (TAU) from the IEHT delivering hospital who fulfil inclusion criteria, are identified through a propensity score (PS) function as optimal control user or rather a PS match and gave informed consent regarding their study participation"
33407838|NCT04745507||Arm 3|360 close relatives or informal caregivers living in the same household of the participating patients who gave informed consent regarding their study participation. Thereby, one relative of each patients who is participating in the trial will be assessed (C1 = 180, C2 = 180).
33407839|NCT04745507||Arm 4:|Staff members of participating study cites as well as local and political stakeholders engaged with IEHT who gave informed consent (approximately n = 100 participants overall).
33407840|NCT05051124|Experimental|Patients Enrolled in the AMPATH CDM Program|
33407841|NCT05680337|Active Comparator|Active TENS|Active will be performed with using a TENS device with an ear clip attached to the tragus of the left ear (which is innervated by auricular branch of the vagus nerve) at 20 Hz, 200ms at a current just below discomfort threshold.
33407842|NCT05680337|Sham Comparator|Sham TENS|Sham will be performed with using a TENS device with an ear clip attached to the left earlobe (which is devoid of vegas innervation) at 20 Hz, 200ms at a current just below discomfort threshold.
33407843|NCT05681429|Placebo Comparator|Opioid-based Anaesthesia|This arm will be given drugs for standard opioid-based anaesthesia.
33407844|NCT05681429|Experimental|Opioid-free Anaesthesia|"This experimental arm will be given drugs for opioid-free anaesthesia as stated below to replace opioids used:~Intravenous (IV) Lignocaine (1.5 mg/kg) Intravenous Infusion (IVI) Dexmedetomidine (0.2-0.7 mcg/kg/h) & volatile (sevoflurane) ~ Minimum Alveolar Concentration (MAC) 0.9-1.0 IV Paracetamol 1 gm (give after scalp block) IV Parecoxib 40 mg (give 30 minutes before end of surgery) IV Ondansetron 4 mg (give 30 minutes before end of surgery) IV Metoclopramide 10 mg (rescue)"
33407845|NCT05024760|No Intervention|Control|This arm will receive standard of care during dental implant insertion.
33407846|NCT05024760|Experimental|Chlorhexidine|Chlorhexidine treatment.
33407847|NCT05024760|Experimental|Hydrogen Peroxide|Hydrogen Peroxide treatment.
33407848|NCT05176067|No Intervention|drug therapy group|targeted therapy, immune, chemotherapy
33407849|NCT05176067|Experimental|drug therapy concurrent radiotherapy|drug therapy(targeted therapy, immune, chemotherapy ) combined with thoracic tumor concurrent radiotherapy
33407850|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors > 5 cm)|Paclitaxel IV plus carboplatin IV (+/- pembrolizumab IV) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (+/- pembrolizumab IV) (4 cycles total)
33407851|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors < 5 cm)|Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
33407852|NCT05020860|Active Comparator|HER2-Positive Breast Cancer|Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (or PHESGO) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)
33407853|NCT05020860|Active Comparator|Hormone Receptor Positive Breast Cancer|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
33407854|NCT05331300|Experimental|LASN01|Part A (SAD in healthy subjects) Part B (MAD in healthy subjects) Part C (MAD in patients with IPF or PF-ILD)
33407855|NCT05331300|Placebo Comparator|Placebo|Part A (SAD in healthy subjects) Part B (MAD in healthy subjects) Part C (MAD in patients with IPF or PF-ILD)
32964028|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
32964029|NCT02020278|Experimental|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
32964030|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
33407856|NCT05603832|Experimental|F14 + Multimodal Analgesia|
33407857|NCT05603832|Active Comparator|Multimodal Analgesia|
33407858|NCT04999020|Experimental|Ravulizumab|Participants will receive ravulizumab in both Parts A and B.
33407859|NCT04999020|Placebo Comparator|Placebo|Participants will receive placebo in both Parts A and B.
33407860|NCT05319522|Active Comparator|Individuals with SCI|Male and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
33407861|NCT05319522|Active Comparator|Controls (No SCI)|Male and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
33407862|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
33407863|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
33407864|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
33407865|NCT05599932|Experimental|Group 1: Healthy Control|Each healthy participant will receive a single dose of HDM201
33407866|NCT05599932|Experimental|Group 2: Mild; Child-Pugh A|Each participant with mild Child-Pugh will receive a single dose of HDM201
33407867|NCT05599932|Experimental|Group 3: Moderate; Child-Pugh B|Each participant with moderate Child-Pugh will receive a single dose of HDM201
33407868|NCT05599932|Experimental|Group 4: Severe; Child-Pugh C|Each participant with severe Child-Pugh will receive a single dose of HDM201
33407869|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
33407870|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
33407871|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
33320846|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
33320847|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
33320848|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
33320849|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
33320850|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
33320851|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
33320852|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
33320853|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
33320854|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
33320855|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
33320856|NCT03768362|Experimental|Undergoing plication strabismus surgery|
33320857|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
33320858|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
33320859|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
33320860|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
33320861|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
33320862|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
33320863|NCT01321424||Normal Eye|20 Participants
33320864|NCT05187130|Experimental|Intervention|Mindfulness-based breathing and music therapy was applied
33320865|NCT05187130|No Intervention|Control|No intervention has been made
33320866|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
33320867|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
33320868|NCT01347190|Experimental|Liquid API|
33320869|NCT01347190|Placebo Comparator|Placebo|
33320870|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
33320871|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
33320872|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
33320873|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
33320874|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
33320875|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
33320876|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
33320877|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
33320878|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
33320879|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
33320880|NCT01347268|Experimental|withdrawing GnRH agonists|
33320881|NCT01347268|Experimental|GnRH antagonist administration|
33320882|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
33320883|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
33320884|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
33320885|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
33320886|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
33320887|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
33320888|NCT05187052||Group 1 (REI group)|Group 1 included patients that were intubated using rigid endoscope-assisted orotracheal intubation (REI) (0°, 45°, and 70°), 18-cm rigid telescope (Storz, Germany), full-HD camera (Olympus, USA), and Macintosh blade.
33320889|NCT05187052||Group 2 (V-MAC Group)|Group 2 included patients that underwent endotracheal intubation using a V-MAC (Besdata, China) videolaryngoscope and Magill forceps.
33320890|NCT05187052||Group 3 (FFEI group)|Group 3 included patients that underwent flexible fiberoptic endotracheal intubation (FFEI Group, Storz, Germany).
33320891|NCT02385890|Experimental|Bagel control|100% wheat flour
33320892|NCT02385890|Experimental|Bagel with pea flour|Pea flour
33320893|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
33320894|NCT02385890|Experimental|Bagel with pea protein|Pea protein
33320895|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
33320896|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
33104799|NCT05543356|Active Comparator|Monovalent Pfizer-BioNTech(BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
33407872|NCT05409066|Experimental|Epcoritamab Dose A in Combination With R2|Participants will receive epcoritamab Dose A in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
33407873|NCT05409066|Experimental|Epcoritamab Dose B in Combination With R2|Participants will receive epcoritamab Dose B in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
33407874|NCT05409066|Active Comparator|Lenalidomide and Rituximab (R2)|Participants will receive lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
33407875|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
33407876|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
33407877|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
33407878|NCT05145725||Idiopathic scoliosis in adolescents requiring surgery|
33407879|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33407880|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33407881|NCT05177627|Experimental|Fundamental of Care Framework implementation|Educational interventions related to introduction of FoC framework and taking charge of patients and their fundamental needs will be realized during theoretical, simulation and internship learning.
33407882|NCT05177627|No Intervention|No Fundamental of Care Framework implementation|the participants of no intervention group will receive the standard training as scheduled on the curriculum
33407883|NCT05317494||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
33407884|NCT05143541||AEON Endostapler|Stapling performed with AEON Endostapler
33407885|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407886|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407887|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407888|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407889|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407890|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
33407891|NCT05546580|Experimental|Active arm|iadademstat and gilteritinib
33407892|NCT04563702|Experimental|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
33407893|NCT04563702|Experimental|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
33407894|NCT05459376|Experimental|Intervention Group|Participants in the intervention group will receive an assessment, classification as to McKenzie method (MDT) syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine ; will receive basic information about low back pain (LBP), its prevalence and prognosis; plus how and why to exercise; and types of responses that may occur in response to the exercise program. Guidance for performing the exercises at home. Dry suction cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae, bilaterally according to the acupoint boundaries, B23, B24 and B25 . This group will consist of performing MDT exercises and dry cupping with 2 suctions for 10 minutes, 2 times a week, for 8 weeks.
33407895|NCT05459376|Sham Comparator|Sham Group|The sham group will follow the same principles of evaluation, classification and intervention according to the McKenzie method (MDT) (described in the intervention group) and will have a placebo dry cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of placebo dry cupping for 10 minutes, 2 times a week, for 8 weeks. However, cups will be prepared with small holes <2 mm in diameter to release negative pressure in seconds.
33407896|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
33407897|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
33407898|NCT05155332|Experimental|Part 1 (Monotherapy): Arm A|Arm A: Intratumoral (i.t.) administration
33407899|NCT05155332|Experimental|Part 1 (Monotherapy): Arm B|Arm B: Intravenous (i.v.) administration
33407900|NCT05155332|Experimental|Part 1 (Monotherapy): Arm C|Arm C: i.t.+i.v. administration
33407901|NCT05155332|Experimental|Part 2 (Combination therapy): Arm D|Arm D: Intratumoral (i.t.) administration
33407902|NCT05155332|Experimental|Part 2 (Combination therapy): Arm E|Arm E: Intravenous (i.v.) administration
32858703|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
33320897|NCT04538560|Experimental|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
33320898|NCT04538560|No Intervention|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
33320899|NCT01337206|Experimental|Stenting Arm|Stenting Arm
33320900|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
33320901|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
33320902|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
33320903|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
33320904|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
33320905|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
33320906|NCT01347424|Experimental|Test group|
33320907|NCT01347424|Active Comparator|control group|
33320908|NCT02288702||Normal|This is the group with no neurological problems or syndrome
33320909|NCT02288702||Down syndrome|This is the group with Down syndrome
33320910|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
33320911|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
33320912|NCT01322438|Experimental|Arm 1|
33320913|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
33320914|NCT03762980|Experimental|Right hemiplegic patients|
33320915|NCT03762980|Experimental|Left hemiplegic patients|
33320916|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
33320917|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
33320918|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
33320919|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
33320920|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
33320921|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
33320922|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
33320923|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
33320924|NCT05186896||Residents of areas at high risk of environmental crisis|1000 adult males and females living in areas declared at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
33320925|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
33320926|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
33320927|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
33407903|NCT05155332|Experimental|Part 2 (Combination therapy): Arm F|Arm F: i.t.+i.v. administration
33407904|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
33407905|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
33407906|NCT05153148|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug will be orally administered QD for 12 weeks
33407907|NCT05153148|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug will be orally administered QD for 12 weeks
33407908|NCT05153148|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug will be orally administered QD for 12 weeks
33407909|NCT05153148|Placebo Comparator|Placebo|Placebo will be orally administered QD for 12 weeks
33407910|NCT05152212|Experimental|LVGN7409|Monotherapy Dose Escalation
33407911|NCT05177549|Experimental|on estrogen-progestin contraception|
32858704|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
33407912|NCT05177549|Experimental|under micro-progestational contraception|
33407913|NCT05177549|Experimental|without hormonal contraception|
32858705|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33407914|NCT05148234|Experimental|escalating dose of treatment for HR-MDS|escalating doses of BMS-986253 + DNMTi
33407915|NCT05148234|Experimental|escalating doses of treatment for LR-MDS|escalating doses of BMS-986253
33407916|NCT05148234|Experimental|phase II dose of BMS-986253 for HR-MD|phase II dose of BMS-986253 + DNMTi
33407917|NCT05148234|Experimental|phase II dose of BMS-986253 for LR-MDS|phase II dose of BMS-986253
33407918|NCT05175521|Placebo Comparator|Eucalyptus Oil Scent|Eucalyptus oil diluted in mineral oil 1:20
33407919|NCT05175521|Active Comparator|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70%
33407920|NCT04900818|Experimental|Dose Escalation: TJ033721|"Dose Escalation:: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi-weekly (Q2W)~During dose expansion, TJ033721 will be administered Q2W, starting at the highest dose to have cleared the DLT period.~After the conclusion of dose expansion TJ033721 will be administered Q2W at the MAD or RP2D."
33407921|NCT05177237|Experimental|Endostar combined with Methylprednisolone|Endostar combined with Methylprednisolone lasts for 10 weeks
33407922|NCT05309772|Experimental|Biomarker arm|"All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC).~Participants with negative or inconclusive BAT/MAT will undergo OFC."
32858706|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
33407923|NCT05309772|Active Comparator|Standard-of-care arm|All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.
33407924|NCT05177081|Experimental|Home BIA Monitoring group|Preemptive management by Body fluid monitoring system (BWA ON + App + Web)
33407925|NCT05177081|No Intervention|Control group|Usual heart failure management (Outpatient follow-up and medical treatment)
33407926|NCT05671289||Patients with confirmed bladder tumor|Patients with bladder tumor, confirmed by cystoscopy and radiology. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
33407927|NCT05671289||Healthy volunteers|Individuals with no known disease and normal urinalysis. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
33407928|NCT04747067|Experimental|High-flux Hemodialysis|patients treated by conventional hemodialysis
33407929|NCT04747067|Experimental|Hemodiafiltration|patients treated by online post-dilution hemodialysis
33407930|NCT05681273|Experimental|Group A|D1: Oral single dose of Empagliflozin 10 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Empagliflozin 10 mg and Chiglitazar 48 mg.
33407931|NCT05681273|Experimental|Group B|D1: Oral single dose of Atorvastatin 20 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Atorvastatin 20 mg and Chiglitazar 48 mg.
33407932|NCT05681273|Experimental|Group C|D1: Oral single dose of Valsartan 160 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Valsartan 160 mg and Chiglitazar 48 mg.
33407933|NCT05648435||Sepsis patients|No interventions
33407934|NCT05648435||Healthy controls|No interventions
33407935|NCT05646953|Experimental|Vasu Facial Beauty Oil|"Vasu Facial Beauty Oil blends the Traditional Beauty recipe of Kumkumadi Tailam with clinically- proven Natural Plant Actives to offer a unique product that gives a Natural Glow to face, overcoming hyper-pigmentation, age spots, wrinkles, and blemishes with Avacado, Lavender, Argan, Rapeseed.~Kumkumadi Oil is an Ayurvedic Elixir that is effective for many skincare concerns such as Hyperpigmentation, Dark spots, Age spots, Acne scars, Fine lines, Wrinkles as well as Dark circles. It is also used for Beautifying, Rejuvenating and Uplifting the skin."
33407936|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
33407937|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
32858707|NCT01207401|Experimental|Paracervical Block|
32858708|NCT01207401|No Intervention|No Paracervical Block|
32858709|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
32858710|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
33407938|NCT05176925|Experimental|Tislelizumab combined with sitravatinib|
33407939|NCT05147376|Experimental|Curcumin mouthwash|The curcumin mouthwash contains the final concentration of 1 μM curcumin, water, xylitol, and food coloring agent.
33407940|NCT05147376|Sham Comparator|Placebo mouthwash|The placebo mouthwash contains water, xylitol, and food coloring agent.
33407941|NCT05681117|No Intervention|control group|No intervention will be made in the control group.
33407942|NCT05681117|Experimental|Experimental group|Class-based nutrition education, online intervention (SMS reminders with tips for healthy eating), distribution of brochures prepared in accordance with the educational content, and a controversial supermarket tour were organized in the experimental group as multiple interventions. Class-based nutrition education was given as a 40-minute session once a week for 4 weeks. Nutrition education content has been prepared as 4 modules in line with the current literature.
33407943|NCT05007899|Active Comparator|Daily|Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
33407944|NCT05007899|Experimental|Alternate Day|Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
33407945|NCT05424042|Experimental|In-Person Caloric Restriction Arm|This group will undergo a 9-month behavioral diet intervention targeting a 20% reduction in caloric intake. During the first 6 months, participants will meet in-person one time each month individually and three times/month in a group setting with a dietitian and/or behavioral coach. During the remaining three months of intervention, there will be one group and one individual meeting each month. Participants will keep diet records using the Fitbit app on a tablet and weight using a BodyTrace™ smart scale that transmits data through a study-specific Companion App. Participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, continuously increasing their daily step count.
33407946|NCT05424042|Experimental|Remote Caloric Restriction Arm|This group will have a 20% reduction in caloric intake and meeting schedule, and physical activity goal similar to the In-Person group. However, the remote arm intervention will be delivered via video conferencing.
33407947|NCT05424042|Experimental|Time-Restricted Eating Arm|This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake. During the first 6 months, participants will meet in-person once per month individually and three times per month in a group setting with a dietitian and/or behavioral coach. During the remaining 3 months of intervention, there will be one group and one individual meeting each month. Participants in TRE will be asked to log into the study-specific Companion App each day to document the beginning and end of their feeding cycles with timing of meals/snacks consumed. As in the CR arms, participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, increasing daily step count. Continuous glucose monitoring will be used at intervals to document glucose levels over a 7-10-day period.
33407948|NCT05175131|Experimental|Mebeverine+Simethicone combination|three times a day per os
33407949|NCT05175131|Active Comparator|mebeverine|three times a day per os
32858711|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
33407950|NCT05175131|Active Comparator|simethicone|80 mg (2 capsules 40 mg) three times a day per os
33407951|NCT05147142|Experimental|Target Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the target region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
33407952|NCT05147142|Active Comparator|Control Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the control region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
33407953|NCT05147142|No Intervention|Healthy Control|25 age- and sex-matched healthy controls will be recruited and complete fMRI tasks. They will not receive low intensity focused ultrasound.
33407954|NCT05636345|Experimental|Intervention group|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
33407955|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
33407956|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
33407957|NCT05174975|Experimental|App-based Positive Psychological Intervention group|The intervention will be conducted on the app, including 2-week PPI, diabetes-related health education, physical records, and online consultation.
33407958|NCT05174975|No Intervention|control group|usual care which will educated by certificated educators in terms of self-management
33407959|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
33407960|NCT05174897|No Intervention|Control Group|The child for whom an intravenous catheter will be applied will be placed on a stretcher and pain and fear will be evaluated before the procedure. Afterwards, an intravenous catheter will be applied. Pain and fear scores will be evaluated during and after the procedure.
33407961|NCT05174897|Experimental|Experimental group|The child to whom an intravenous catheter will be applied is placed on a stretcher. After evaluating the pain and fear score before the procedure, emotional liberation technique (EFT) is performed for 10 minutes. followed by an intravenous catheter. Pain and fear scores are evaluated during and after the procedure.
33417263|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
33417264|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
32858712|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
32858713|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
33407962|NCT05233787|Experimental|Arm A: Tailored use of defunctioning stoma after TME|"The tailored use of defunctioning stoma includes two steps:~Firstly, the decision to use or not a defunctioning stoma will be based on the personalized risk of anastomotic leakage (according to AFOR score). This score is ranked from 0 to 6, and includes gender, Body Mass Index, smoking, diabetes, tumor size and preoperative radiotherapy.~Patients with AFORS equal to 0 or 1 (risk of anastomotic leakage less than 10%) will not have defunctioning stoma;~Patients with AFORS equal to or between 2 and 6 (risk of anastomotic leakage more than 20%) will have a defunctioning stoma.~Secondly, in patients with a defunctioning stoma, an early closure will be performed day 8-12 after TME if:~No fever postoperatively (≤ 38°C),~CRP at day 2 lower than 115mg/L (+/- 10 mg/L), decreasing at day 4,~CT-scan with colonic contrast retrograde enema showing no anastomotic leakage."
33407963|NCT05233787|Active Comparator|Arm B: Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 3 months after TME according to French national guidelines
33407964|NCT05232149|Experimental|Lower Dose|Orelabrutinib is a white, round, uncoated tablet
33407965|NCT05232149|Experimental|Higher Dose|Orelabrutinib is a white, round, uncoated tablet
33407966|NCT05552495|Experimental|Reference-Test1-Test2|
33407967|NCT05552495|Experimental|Reference-Test2-Test1|
33407968|NCT05552495|Experimental|Test1-Reference-Test2|
33407969|NCT05552495|Experimental|Test1-Test2-Reference|
33407970|NCT05552495|Experimental|Test2-Reference-Test1|
33407971|NCT05552495|Experimental|Test2-Test1-Reference|
33407972|NCT05229653|Experimental|Low-Dose Ketamine (LDK) Treatment Group|
33407973|NCT05229653|Placebo Comparator|Control Group|
33407974|NCT05215847|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
33407975|NCT05076227||BNT162b2/BNT162b2 - 3 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 3 weeks as boost vaccination
33407976|NCT05076227||ChAdOx1/ChAdOx1 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and also receiving AstraZeneca as boost vaccination after 12 weeks
33407977|NCT05076227||ChAdOx1/BNT162b2 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and receiving BioNTech as boost vaccination after 12 weeks
33407978|NCT05076227||BNT162b2/BNT162b2 - 6 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 6 weeks as boost vaccination
33407979|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
33407980|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
33407981|NCT05418582|Experimental|DZD9008 and itraconazole|Subjects in arm 1 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
33407982|NCT05418582|Experimental|DZD9008 and carbamazepine|Subjects in arm 2 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
33407983|NCT05551949|Other|Vaginal estrogen therapy|Participants receive Vaginal estrogen therapy.
32858714|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
32858715|NCT04761731|Experimental|ADVAGRAF®|One arm: Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
33407984|NCT05372718|Experimental|Recombinant non-immunogenic staphylokinase|"lyophilisate for preparation a solution, 5 mg (745,000 IU) in 20 ml over 1 minute through a perforated multihole catheter intrathrombally.~30 minutes after this injection, infusion of recombinant non-immunogenic staphylokinase will be continued at a dose of 1 mg/hour, maximum 10 mg (50 ml) for 10 hours through a perforated multihole catheter intrathrombally."
33407985|NCT05372718|Experimental|Surgical methods of treatment|endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
33407986|NCT05541497|Experimental|Varenicline + Self-Change Pamphlet|"Days 1-3: 0.5mg study pill once per day~Days 4-7: 0.5mg study pill twice per day~Weeks 2-8: 1mg study pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
33407987|NCT05541497|Placebo Comparator|Placebo + Self-Change Pamphlet|"Days 1-3: 0.5mg placebo pill once per day~Days 4-7: 0.5mg placebo pill twice per day~Weeks 2-8: 1mg placebo pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
33407988|NCT05283954|Experimental|Combined Regime of Fluoxetine, Prednisolone and Ivermectin|"Fluoxetine: 20mg tablet; 20 mg; once daily for 10 days; oral~Prednisolone: 25 mg tablet; 25mg; once daily for 5 days; oral~Ivermectin: 3 mg tablet; 0.4 mg/kg; once daily for 5 days; oral"
33407989|NCT05283954|Other|Combination of Vitamin C and Albendazole|"Vitamin C: 50 mg tablet; 1 tablet; Once daily for 10 days; Oral~Albendazole; 200 mg; 1 tablet; Once daily for 5 days; Oral~Vitamin C: 50 mg tablet; 0.13 tablet/kg*; Once daily for 5 days; Oral~*Same number of tablets than for Ivermectin"
33417265|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
33417266|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
33417267|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
32858716|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
32858717|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
32858718|NCT03088163|Experimental|DWI-MRI|
32858719|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
32858720|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
32858721|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
32858722|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
33320928|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
33320929|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
32858723|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
32858724|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
32858725|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
32858726|NCT03419897|Experimental|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
33320930|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
33320931|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
33320932|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
33320933|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
33320934|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
33320935|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
33320936|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
33320937|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
33320938|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
33320939|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
33320940|NCT05260346|Placebo Comparator|Placebo|Cranberry flavored drink, once daily, in a 8fl oz bottle. Identical in appearance and taste compared with the treatment.
33320941|NCT05260346|Active Comparator|Cranberry juice|100% cranberry juice, once daily, in a 8fl oz bottle.
33320942|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
33320943|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
33320944|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
33320945|NCT05244122|Experimental|Feedback X Prevalence Using Dermatology Stimuli|"In this experiment, observers (Os) completed blocks of 80 trials. On each trial, they saw an image of a spot on the skin. They classified this as a melanoma (cancer) or a nevis (benign). Blocks could be of low prevalence (20% cancer cases, 16 images) or high prevalence (50%, 40 images). Os either did received trial by trial Feedback about their performance accuracy, or they did not. Thus, there were four types of block.~Low prevalence, No Feedback Low prevalence, Feedback High prevalence, No Feedback High prevalence, Feedback Each of these four types of block was made available to Os on each of 6 days. Os could elect to view each of the four blocks each day. Our particular interest was in the effect of performing one block on performance on an immediately subsequent block."
33407990|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
33407991|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
33407992|NCT05521919|Experimental|Stress (sympathetic nervous system activation)|"Stress will be induced using the socially evaluated cold pressor test and a guided thought exercise about individuals' to-do lists.~Participants will complete three rounds of the social evaluated cold pressor test followed by a guided thought exercise about their to-do list for the coming day, week, month, and year.~The socially evaluated cold pressor test involves submerging one hand in ice-cold water for 3 minutes while participants' reactions are filmed on camera."
33407993|NCT05521919|Sham Comparator|No-stress|Participants will hold a hand in room temperature water for 3 minutes.
33407994|NCT05176145|Other|single arm|Only one arm. The urine collection from each patient will be used for VisioCyt® test and conventional cytology
33407995|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
33407996|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
33407997|NCT05143775|Experimental|new surgical plan group|The investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm in the sensitive area which is posterior superior longitudinal fasciculus or posterior arcuate fasciculus.
33407998|NCT05143775|Active Comparator|traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified, those points would be retained to avoiding language function impairment after the tumor resection.
33407999|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
33408000|NCT04982315|Experimental|Standard Acupuncture|Participants randomized to standard acupuncture will receive 8-15 acupuncture treatments over 3 months.
33408001|NCT04982315|Experimental|Enhanced Acupuncture|Participants randomized to enhanced acupuncture will receive 12-21 acupuncture treatments over 6 months.
33408002|NCT04982315|No Intervention|Usual Care|Participants assigned to the usual care arm will not receive acupuncture and will be asked to not get acupuncture over the one-year course of the study.
33408003|NCT04979117||Participants with plantar fasciitis|"Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing).~The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician.~Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement"
33408004|NCT04979117||Volunteers who has not foot complaints.|Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.
33408005|NCT05370144|Experimental|Hypofractionated neoadjuvant concurrent chemoradiotherapy|"Drug: Carboplatin and Taxol (paclitaxel)~Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously for 5 weeks on Days 1,8,15,22 and 29.~Radiation: Hypofractionated radiation"
33408006|NCT05346354|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment.~During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks."
33408007|NCT05122559|Active Comparator|N-acetyl cysteine|N-acetyl cysteine (NAC) 1200mg t.i.d.
33408008|NCT05122559|Placebo Comparator|Placebo|Placebo 1200mg t.i.d.
33408009|NCT05323656|Experimental|Setanaxib 800 mg and Pembrolizumab 200 mg|Participants will be administered Setanaxib 800 mg twice daily. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
33408010|NCT05323656|Active Comparator|Placebo and Pembrolizumab 200 mg|Participants will be administered placebo throughout the 24 month treatment period. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
33408011|NCT05309837|Active Comparator|Polydextrose (PDX)|Subject consumed a daily dose of 18g polydextrose enriched drink mixtures and biscuits (12 g from the drink mixtures and 6 g from the biscuits) providing 16.2 g dietary fibre/d.
33408012|NCT05309837|Placebo Comparator|Control (CON)|Subjects consumed placebo products, where maltodextrin replaced PDX and differed only in the amount of fibre per gram (1.7 g).
33408013|NCT04313244|Experimental|Group 1|0.5 mL Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) will be co-administered with 0.5 mL Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
33408014|NCT04313244|Experimental|Group 2|0.5 mL 9vHPV vaccine IM will be administered once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
32964031|NCT02023944|Other|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
32964032|NCT02023944|No Intervention|Control, No Intervention|"No Intervention, considered treatment as usual"
33408015|NCT04977947|Experimental|Healthy Eating for My Infant Intervention|Participants and their parents will participate in a 6 session intervention targeting healthy introduction of complementary foods, and responsive feeding and mealtime behaviors. Intervention sessions will occur when the infant is 3, 4, 5, 6, 7, and 8 months of age.
33408016|NCT04977947|No Intervention|Control|Participants and their parents will complete baseline and post-treatment study visits to assess study outcomes. They will receive no intervention.
33408017|NCT04294290|Experimental|hCT-MSC infusion|
33408018|NCT05155865|Experimental|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
33408019|NCT05155865|Active Comparator|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
33408020|NCT05279898|Experimental|Multimodal General Anesthesia (MMGA Bundle) - EEG Guided|"Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.2% ropivacaine on both sides of the sternum after anesthetic induction but before surgical incision (total of 40mL)~Ketamine (0.1 to 0.2 mg.kg/hr)~Remifentanil (0.05-0.4 mcg/kg/min)~Dexmedetomidine (0.2-0.5 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion (15 to 200 mcg/kg/min)~Postop~Standard pain management protocol~IV Acetaminophen~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~PIFB on postoperative day 1 (provided they are extubated/getting ready to be extubated)(for intervention group)~Lidocaine patches"
33408021|NCT05279898|No Intervention|Standard of Care/Control|"EEG monitoring will be blinded, and not guide anesthesiologists. Patients will receive standard/routine anesthesia practice intraoperatively.~Postoperative Propofol infusion (15 to 200 mcg/kg/min) ± Sevoflurane~Standard pain management protocol~IV Acetaminophen (1 gram) x 4 doses at 6 hour intervals starting from 1 hr after ICU arrival~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~Lidocaine patches~Parasternal block (PIFB or Transversus Thoracic Plane Block) on Postoperative day 0 - currently incorporated into standard pain management after surgery based on physician discretion"
33408022|NCT05108909||mild to moderate traumatic brain injury|patients diagnosed with mild to moderate traumatic brain injury within 1 week after onset of TBI.
33408023|NCT05108909||isolated orthopaedic trauma patients|Patients with isolated orthopaedic trauma were identified and enrolled using the same process as that for patients with TBI.
33408024|NCT05108909||healthy non-injury control|Healthy non-injured controls were recruited either via a relationship with a TRACK-TBI participant or through public advertisement within TRACK-TBI institutions, and were able to provide informed consent.
33408025|NCT05309694|Other|Group 1|Paragard® T380A Intrauterine Copper Contraceptive with new inserter Non parous and parous female subjects of child bearing potential
33408026|NCT05131529|No Intervention|Control|The 3 dining halls allocated to this arm will receive none of the three interventions during the 3 semesters of the project.
33408027|NCT05131529|Experimental|Treatment|The 3 dining halls allocated to this arm will receive one intervention during each of the 3 semesters of the project (only one intervention per semester).
33408028|NCT04784598|Experimental|Experimental group|Group 1- The intervention group I will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 32). And 2.5mm EVA cover (Shore A 28).
32858727|NCT04746599|Experimental|Patients with critic limb ischemia|"Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.~After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
32858728|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
32858729|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
32858730|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
32858731|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
32858732|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
32858733|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
32858734|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
32899089|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
32907454|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
32907455|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
33408029|NCT04784598|Sham Comparator|Sham group|Group 2- The control group will receive a slipper with a 2.5mm EVA cover (Shore A 32) identical to the one used by the intervention group, but without corrective par
33408030|NCT05507879||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at time of therapy initiation. Patients who develop cardiac toxicity may undergo additional collection of blood samples. Patients' medical records are also reviewed.
33408031|NCT05278104|Experimental|Atomoxetine|
33408032|NCT05278104|Placebo Comparator|Placebo|
33408033|NCT05100641|Experimental|AV-GBM-1|Autologous dendritic cells loaded with autologous tumor antigens cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
33408034|NCT05100641|Placebo Comparator|Autologous monocyte control (MC)|Autologous monocytes cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
33408035|NCT05273268|Active Comparator|Control Arm|The control arm (target enrollment; n=180) will receive the US government-standard guidelines for dietary advice in the form of the USDA dietary recommendations digital leaflet.
33408036|NCT05273268|Experimental|Intervention Arm|The intervention arm (target enrollment; n=180) will receive personalized dietary guidelines created by machine learning algorithms using their personal anthropometric, gut, dietary and medical information as inputs. The guidelines will be delivered in the form of a smartphone/ smart device app.
33408037|NCT05268822|Active Comparator|Movement control exercise with specific breathing techniques|Movement control exercise with specific breathing techniques (experimental group)
33408038|NCT05268822|Active Comparator|Movement control exercise without specific breathing techniques|Movement control exercise without specific breathing techniques (control group)
33408039|NCT05501561|Experimental|IIV-A Investigational|
33408040|NCT05501561|Experimental|aIIV-B Investigational|
33408041|NCT05501561|Experimental|aIIV-C Investigational|
33408042|NCT05501561|Active Comparator|Licensed IIV|
33408043|NCT05268510|Experimental|Chemotherapy plus Pembrolizumab followed by Pembrolizumab and Olaparib|"Chemotherapy plus Pembrolizumab 2 cycles à 6 weeks:~Pembrolizumab+mod FOLFOX-6:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 85 mg/m² 2h day 1, 15, 29~Leucovorin 400 mg/m² 2h day 1, 15, 29~5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29~or~Pembrolizumab+CapOx:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 130 mg/m² 2h day 1,22~Capecitabine 1.000 mg/m² bid. day 1-14, 22-35~Consolidation phase Pembrolizumab and Olaparib max 16 cycles à 6 weeks:~Pembrolizumab 400 mg 30 min. day 1~Olaparib 300 mg bid. cont. day 1 to 42"
33408044|NCT05042453||Hysteropexy using Splentis via vaginal route|Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis
33408045|NCT04191174||Adults undergoing lung resection for lung cancer|
33408046|NCT05309681||Study group|Female patients of the Department of Oral medicine diagnosed with burning mouth syndrome
33408047|NCT05309681||Control group|Age-matched female patients without oral lesions and without burning mouth syndrome
33408048|NCT05309603|Active Comparator|Unloaded Walking|Walking on a treadmill without wearing a pack
33408049|NCT05309603|Experimental|Loaded Walking High|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the high-back
33408050|NCT05309603|Experimental|Loaded Walking Mid|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the mid-back
33408051|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
33408052|NCT05060783||Oncocytoma|Patients with oncocytoma
33408053|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
33408054|NCT05033717|Experimental|Group A|Tissue Flossing Technique
33408055|NCT05033717|Active Comparator|Group B|Static Stretching exercises
33408056|NCT05030441|Experimental|Ivosidenib|-Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 17 months (approximately 18 28-day cycles), with each cycle being 28 days.
33408057|NCT05030597|Experimental|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
33408058|NCT05023655|Experimental|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
33408059|NCT04974515|Experimental|Low intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.
33408060|NCT04974515|Active Comparator|High intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.
33408061|NCT05026931|Experimental|Group A|Foam Rolling
33408062|NCT05026931|Active Comparator|Group B|Stretching exercises
33408063|NCT05477693|Experimental|Experimental Group|1200 participants(including 600 subjects aged 2~17 years,240 subjects aged 18~59 years and 360 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd
32739100|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
32739101|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
32739102|NCT05348915|Experimental|Inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
32739103|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
32739104|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
33408064|NCT05477693|Active Comparator|Control Group|600 participants(including 300 subjects aged 2~17 years,120 subjects aged 18~59 years and 180 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Merck Sharp & Dohme.
33408065|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
33408066|NCT04927325|Other|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
33408067|NCT04927325|Other|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
33408068|NCT05309447||Patients with sLSS|Patients with Symptomatic Lumbar Spinal Stenosis (n=10)
33408069|NCT05309447||Young Controls|Young healthy control subjects (n=10)
33408070|NCT05309447||Age-Matched Controls|Age-matched healthy control subjects (n=10)
33408071|NCT05020769|Experimental|SI-B001 combined with osimertinib_A|Patients with locally advanced/metastatic NSCLC progressed on 3rd generation EGFR-TKI treatment.
33408072|NCT05020769|Experimental|SI-B001 combined with osimertinib_B|Patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment and with T790M negative mutation.
32858735|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
32858736|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
33408073|NCT05020769|Experimental|SI-B001 combined with osimertinib_C|Patients with locally advanced/metastatic NSCLC and with EGFR exon20ins mutation.
33408074|NCT04952753|Experimental|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
33408075|NCT04952753|Experimental|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
33408076|NCT04952753|Active Comparator|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
33408077|NCT04952753|Experimental|Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the safety run-in part for investigational arm 2, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793 and tislelizumab to confirm the RP2D of NIS793.
33408078|NCT04952753|Experimental|Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the expansion part, participants in the investigational arm 2 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FLOFOX6 or FOLFIRI) with NIS793 and tislelizumab at the RP2D for NIS793 defined in the safety run-in
33408079|NCT05309213|Experimental|IM19 CAR-T cells|
33408080|NCT05309057||Studies with intermittent fasting|Studies with intermittent fasting strategies.
32858737|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
32858738|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
32858739|NCT03086759|Experimental|Platelet rich plasm group|
32858740|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
33408081|NCT05438303|Experimental|Arm A (midazolam and omeprazole)|Participants will receive single oral doses of midazolam and omeprazole together (Day 1 of Treatment Periods 1 and 3) and repeated doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
33408082|NCT05438303|Experimental|Arm B (Dabigatran etexilate)|Participants will receive single oral doses of dabigatran etexilate (Day 1 of Treatment Periods 1 and 2) and single oral dose of AZD9833 (Day 1 of Treatment Period 2)
33408083|NCT05438303|Experimental|Arm C (Celecoxib)|Participants will receive single oral doses of celecoxib (Day 1 of Treatment Periods 1 and 3) and repeated oral doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
33408084|NCT05434325||TESTING Particpants|All participants who were successfully randomised to the TESTING study who are still alive and have not reached kidney failure requiring dialysis.
33408085|NCT05432141|Experimental|Primary immunization group|A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group
32858741|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
32858742|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
32858743|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
32964033|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
33408086|NCT05432141|Experimental|Booster immunization group of sIPV vaccine|A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.
33408087|NCT04868279|Experimental|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
33408088|NCT04868279|No Intervention|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
33408089|NCT04859231|Active Comparator|Control|
33408090|NCT04859231|Experimental|Investigational|
33408091|NCT04859231|No Intervention|Mother's-own Breast Milk|
33408092|NCT05308823|No Intervention|Group 1|The paients in this group will receive traditional treatment of IIH for 3 months.
33408093|NCT05308823|Experimental|Group 2|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent.
33408094|NCT05308745|Active Comparator|Probiotic group|Participants within this group consumed Yakult® as research product 1 bottle/day for 24 weeks (168 days).
32858744|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
33408095|NCT05308745|Placebo Comparator|Placebo group|Participants within this group consumed placebo as research product 1 bottle/day for 24 weeks (168 days).
33408096|NCT04956809|Active Comparator|Dapagliflozin 10mg|Active arm will be 6 weeks in duration, separated by a 2-week wash-out period.
33408097|NCT04956809|Placebo Comparator|Placebo|Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period.
33408098|NCT04803227|Active Comparator|Emricasan|Emricasan
32858745|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
33408099|NCT04803227|Placebo Comparator|Placebo|Placebo
33408100|NCT04735913|Other|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
33408101|NCT04735913|Experimental|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
33408102|NCT04910867|No Intervention|Control Arm|No intervention will be administered. Usual care will be administered.
33408103|NCT04910867|Experimental|Intervention Arm|APOL1 testing program
33408104|NCT04906889|Experimental|dexmedetomidine-lidocaine|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
33408105|NCT04906889|Active Comparator|remifentanil|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy
33408106|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
33408107|NCT04723667|Experimental|Intervention|13-week multimodal intervention
32858746|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
32858747|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
32858748|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
33408108|NCT04723667|Active Comparator|Active control|5-week health education programme
33408109|NCT04883333|Experimental|Cohort A1 LEO 153339|Single ascending dose (Part 1)
33408110|NCT04883333|Experimental|Cohort A2 LEO 153339|Single ascending dose (Part 1)
33408111|NCT04883333|Experimental|Cohort A3 LEO 153339|Single ascending dose (Part 1)
33408112|NCT04883333|Experimental|Cohort A4 LEO 153339|Single ascending dose (Part 1)
33408113|NCT04883333|Experimental|Cohort A5 LEO 153339|Single ascending dose (Part 1)
33408114|NCT04883333|Experimental|Cohort A6 LEO 153339|Single ascending dose (Part 1)
33408115|NCT04883333|Experimental|Cohort A7 LEO 153339|Single ascending dose (Part 1)
33408116|NCT04883333|Experimental|Cohort B1 LEO 153339|Single ascending dose (Part 1)
33408117|NCT04883333|Placebo Comparator|All SAD cohorts placebo|Single ascending dose (Part 1), all participants receiving placebo in Cohorts A1-A7 and B1
33408118|NCT04883333|Experimental|Cohort C1 LEO 153339|Multiple ascending doses (Part 2)
33408119|NCT04883333|Experimental|Cohort C2 LEO 153339|Multiple ascending doses (Part 2)
32858749|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
32907529|NCT03399539|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33320946|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
33320947|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
33320948|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
33320949|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
33408120|NCT04883333|Experimental|Cohort C3 LEO 153339|Multiple ascending doses (Part 2)
33408121|NCT04883333|Experimental|Cohort C4 LEO 153339|Multiple ascending doses (Part 2)
33408122|NCT04883333|Experimental|Cohort C5 LEO 153339|Multiple ascending doses (Part 2)
33408123|NCT04883333|Experimental|Cohort C6 LEO 153339|Multiple ascending doses (Part 2)
33408124|NCT04883333|Placebo Comparator|All MAD cohorts placebo|Multiple ascending doses (Part 2, all participants receiving placebo in Cohorts C1-C6)
33408125|NCT05358743|Experimental|Probiotic group|
33408126|NCT05358743|Placebo Comparator|Control group|
33408127|NCT05308589|Experimental|Continuous Postoperative Pericardial Flushing|Continuous Postoperative Pericardial Flushing (inflow of 500 ml NaCl 0,9% flushing fluid into the pericardial cavity during the first 8 postoperative hours) executed with the Haermonics investigational device
33408128|NCT05308589|No Intervention|Control|Standard care
32858750|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
33408129|NCT05357105||Regional Nerve Block Patients|Patients who receive regional nerve blocks as part of the anesthetic management prior to surgery.
33408130|NCT04716959|Experimental|Prepectoral Prosthetic Breast Reconstruction|
33408131|NCT04716959|Active Comparator|Subpectoral Prosthetic Breast Reconstruction|
33408132|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
33408133|NCT04868747|Experimental|study group|The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.<120 mg/h).
33408134|NCT04868747|Placebo Comparator|control group|The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
33408135|NCT04693325|Experimental|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
33408136|NCT04684823|Experimental|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
33408137|NCT04817345|Experimental|Plerixafor|Participants will receive a subcutaneous dose of 0.24 mg/kg of plerixafor once daily (Q24hr) x 2 days.
33408138|NCT05357651|Experimental|Dose Escalation|Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard 3+3 dose escalation algorithm approach.
33408139|NCT05357651|Experimental|Safety Expansion|2-3 doses were initially selected for safety expansion, with patients with advanced solid tumors as the main research population. Each dose cohort is expected to enroll 9-12 patients.
33408140|NCT05357651|Experimental|Exploratory Expansion|The Cohort Exploratory Expansion will enroll subjects by cohort at the RP2D dose, and a total of 4 cohorts (cohorts A, B, C, D) are expected.
32858751|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
32858752|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
33408141|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
33408142|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
33408143|NCT05330273|Experimental|Period 1: KAF156 + LUM566 / Period 2: KAF156 + LUM566 + Efavirenz|"Participants enrolled will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1.~In Period 2, participants will receive an oral dose of efavirenz q.d. in the evening on Days 1 through 24 and a single dose of ganaplacide and lumefantrine combination on the morning of Day 11."
33408144|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
33408145|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
33408146|NCT05329259|Experimental|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (13vPnC)
33408147|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
33408148|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
33408149|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
33408150|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
33408151|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
33408152|NCT04519853|Experimental|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 30% carbohydrate, 20% protein.
32858753|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
33320950|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
32858754|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
32858755|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
33320951|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
33320952|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
33320953|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
33320954|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
33320955|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
33320956|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
33320957|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
33320958|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
33320959|NCT00189280|Experimental|imiqimod 5% cream|
33320960|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
33320961|NCT05217602|Experimental|AC+ARwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards only if they meditate using their anchoring plan on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
33320962|NCT05217602|Experimental|AC+RwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards if they meditate on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
33320963|NCT05217602|Active Comparator|Usual Calm Control (UC)|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; $20 incentive for completing the baseline, week 8, and week 16 surveys
33320964|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
33320965|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
33320966|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
33320967|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
33320968|NCT03198598|No Intervention|Healthy subjects|
33320969|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
33320970|NCT05203718|Experimental|Patients with Obesity|NYU Langone Health patients ≥18 to 80 years of age with a BMI ≥30.0 kg/m2
33320971|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
33320972|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
33320973|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
33320974|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
33320975|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
33320976|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
32858756|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
32858757|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
33408153|NCT05254847|Experimental|combined treatment group|Capecitabine combined with lenvatinib and tislelizumab: Lenvatinib,8mg po. qd.Tislelizumab,200mg iv. q3w. Capecitabine 1250mg/m^2 bid.d1-d14 q3w
32858758|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
32858759|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
32858760|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
32858761|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
32858762|NCT01144143|Experimental|Infliximab|
32858763|NCT01144143|Placebo Comparator|Salt Water|
32858764|NCT01144143|Active Comparator|Methylprednisolone acetate|
32858765|NCT03408665|Experimental|SBRT|Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
32858766|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
32858767|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
32964034|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
33320977|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
33320978|NCT04505098|Active Comparator|Intervention|
33320979|NCT04505098|No Intervention|Usual Care|
33320980|NCT01348126|Active Comparator|Single agent docetaxel|
33320981|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
33320982|NCT01348204|Experimental|quercetin|health food supplement
33320983|NCT00166504|Experimental|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
33320984|NCT00166504|Active Comparator|Atorvastatin|Atorvastatin 10 mg
33320985|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
33320986|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
33320987|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
33320988|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
33320989|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
33320990|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
33320991|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
33320992|NCT03137992|Active Comparator|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
33320993|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
33320994|NCT04501588|Experimental|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
33320995|NCT04501588|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
33320996|NCT04501588|Active Comparator|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
33320997|NCT04501588|Active Comparator|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
33320998|NCT04470778|Experimental|BMS-986256|
33320999|NCT04470778|Experimental|BMS-986256 + Famotidine|
33321000|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
33321001|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
33321002|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
33321003|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
33321004|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
33321005|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
32858768|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
32858769|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
33321006|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
32858770|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
32858771|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
32858772|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
32858773|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
32858774|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
32858775|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
32858776|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
33104800|NCT05543356|Active Comparator|Monovalent Moderna(mRNA-1273, Spikevax®):AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
33321007|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
33321008|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
33321009|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
33321010|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
33321011|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
33321012|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
33321013|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
33321014|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
33321015|NCT01352728|Experimental|TACE+Axitinib|
33321016|NCT01348360||NOBORI stent|
33321017|NCT03704636|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
33321018|NCT01348438|Other|Single arm study|
33321019|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
33321020|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
33321021|NCT01348516|Experimental|KM-023|
33321022|NCT01348516|Placebo Comparator|Placebo for KM-023|
33321023|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
33321024|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
33321025|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
33321026|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
33321027|NCT04470388|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
33321028|NCT04470388|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
32858777|NCT03084341|No Intervention|Control Group|No intervention
32858778|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
32858779|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
32858780|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
32858781|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
33321029|NCT03997448|Experimental|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
33321030|NCT01343134||Retinal detachment cohort|
32858782|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
32858783|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
32858784|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
32858785|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
32858786|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
32858787|NCT03405545|Experimental|HIIT|This group of subjects will perform High Intensity Interval training 3x/week for 12 weeks
33408154|NCT05249699|Experimental|Positive TSPOT results with clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
32858789|NCT03083717||Patients with compensated heart failure|
32858790|NCT03083717||Patients with decompensated heart failure|
33408155|NCT05249699|Placebo Comparator|Negative TSPOT results with clinical risk factors group|patients receive no additional therapy
33408156|NCT05249699|Experimental|Clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
33408157|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
33408158|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
33408159|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
33408160|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
33408161|NCT04509011|Experimental|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
33408162|NCT04509011|No Intervention|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
33408163|NCT04491539|No Intervention|Adaptation|Site will inform the adaptation of the FRESH intervention.
33408164|NCT04491539|Experimental|First Receipt|Site will received the adapted FRESH intervention first.
33408165|NCT04491539|Experimental|Second Receipt|Site will received the adapted FRESH intervention second.
33408166|NCT04751669|Experimental|Micronutrient dietary supplement effervescent tablet|"Tablet containing:~Retinol (Vitamin A) 700 mcg~Cholecalciferol (Vitamin D3) 10 mcg~Alpha-Tocopherol (Vitamin E) 45 mg~Ascorbic acid (vitamin C) 1000 mg~Pyridoxine (Vitamin B6) 6.5 mg~Cyanocobalamin (Vitamin B12) 9.6 mg~Folic acid 400 mg~Iron 5 mg~Zinc 10 mg~Selenium 110 mg~Copper 0.9 mg~Excipients"
33408167|NCT04751669|Placebo Comparator|Placebo dietary supplement effervescent tablet|"Effervescent tablet with only the excipients.~Sucralose 13 mg~Sodium Chloride 20 mg~Potassium Acesulfam 22.5 mg~Orange P 55 mg~Sodium Carbonate 70 mg~Betacarotene 100 mg~Malic Acid 800 mg~Citric Acid 960 mg~Sodium bicarbonate 1,000 mg~Isomalt 1,459.50 mg"
32858791|NCT03083717||Healthy subjects|
32858792|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
32858793|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
33408168|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
33408169|NCT04731233|Experimental|PRGF Arm|The PRGF experimental group will have two cc of PRGF infused into the upper joint space after the TMJ arthrocentesis procedure.
33408170|NCT04731233|Active Comparator|Steroid Arm|Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.
33408171|NCT05292053|Experimental|COPD subjects|COPD with or without asthma
33408172|NCT04461509|Experimental|ARM 1 (HIFU) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
33408173|NCT04461509|Experimental|ARM 2 (RP) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
32858794|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
32858795|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
32899090|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
32899091|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
32899092|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
33408174|NCT05227079|Active Comparator|Group A (double bite forceps)|Participants in group A will proceed to have their biopsies during endoscopy taken with the conventional double bite forceps. Meaning, they will have two biopsies taken each time the forcep is passed through the endoscope. To obtain a total of six biopsies, the forceps will be passed through the endoscope a total of three times.
33408175|NCT05227079|Experimental|Group B (multiple bite forceps)|Participants in group B will have their biopsies during endoscopy retrieved with the multiple bite forceps. Meaning, they will have six consecutive biopsies taken with each pass through the endoscope.
33408176|NCT05288621|Experimental|electroacupuncture at'four sacral points'|The participants in the electroacupuncture at'four sacral points'group will receive treatment that consists of 8 acupuncture sessions over an 4-week period after baseline (2 sessions in each week), each for 30 minutes. Hua Tuo brand disposable acupunctureneedles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.The device will be set at a frequency of 2.0 Hz, continuous wave and a moderate intensity the patient can tolerate. Electrostimulation will be performed for 30 min during each treatment. BL30 (Baihuanshu )(both sides and BL35 (Huiyang )(both sides), were selected as acupoints protocol.BL30 is located on either side of the sacrococcygeal joint, approximately 1 cm from the joint. BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
33408177|NCT05288621|Active Comparator|conventional electroacupuncture|The participants in the conventional electroacupuncture group will select RN3 (Zhongji), CV4 (Guanyuan), and ST28 (Shuidao, both sides), KL3 (Taixi).A needle measuring 0.25×40 mm will be inserted perpendicularly to a depth of 25- 40 mm to RN3, CV4 and ST28 and 0.5 cun to KL3 to induce a local sensation (distention or sourness).Subsequently, the electrodes from the SDZ-IIB electroacupuncture device will be connected to the needles at these points, with the anode connected to ST28 and RN3, the cathode connected to ST28 and CV4. The protocol includes the same duration, frequency of sessions and the parameter setting of electroacupuncture as for the'four sacral points'treatment.
33408178|NCT05306639|Experimental|Spinal magnetic stimulation|Spinal magnetic stimulation group will receive repetitive spinal magnetic stimulation sessions for a total of 12 sessions. Using the Neuro-MS/D machine, circular coil will be used to stimulate S2,3 and 4 sacral roots. The outer rim of the coil will be positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2) Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 15 Hz, burst length = 10 seconds, inter-burst interval = 30 seconds with a total of 1500 pulses
33408179|NCT05306639|Experimental|Neuromodulation|Neuromodulation group will receive 12 sessions of bilateral transcutaneous posterior tibial neuromodulation using (Myomed 632®, Enraf Nonius, Delft, Netherlands) machine, the active rubber surface was placed behind the medial malleolus and the reference electrode was placed 10 cm proximal. Adjustment of the electric current was as follows: continuous current, pulse duration 200 ms, frequency 20 Hz; each session lasts for 30 min. The current intensity was adjusted according to the tolerance of the patient or until the big toe curls into plantar flexion
33408180|NCT05207111|Experimental|Revefenacin Inhalation Solution, 175 mcg/3 mL|
33408181|NCT03256097|Experimental|XDP - VG - XDP|order of testing: XDP - VG - XDP
33408182|NCT03256097|Experimental|VG - XDP - VG|order of testing: VG - XDP - VG
33408183|NCT05199077|Placebo Comparator|placebo group|Topical administration of a drug-free placebo ointment daily for 28 days.
33408184|NCT05199077|Active Comparator|cohort A|Topical administration of a 2.5 % GM-XANTHO ointment daily for 28 days.
33408185|NCT05199077|Active Comparator|cohort B|Topical administration of a 5 % GM-XANTHO ointment daily for 28 days.
33408186|NCT05195567|Experimental|Subject glucometer measurement|
33408187|NCT04417517|Experimental|evorpacept (ALX148) + azacitidine|"Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle~Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle"
33408188|NCT04417517|Active Comparator|azacitidine|Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle
33408189|NCT04697381|Experimental|somatropin - GH naïve pediatric cohort|All participants will receive somatropin.
33408190|NCT04697381|Experimental|somatropin - GH treated pediatric cohort|All participants will receive somatropin
33408191|NCT04697381|Experimental|somatropin - adult cohort|All participants will receive somatropin
33408192|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
33408193|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
33408194|NCT04732793|Experimental|Hyruan ONE®|
33408195|NCT04732793|Active Comparator|Durolane®|
32899093|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
33408196|NCT04695977|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
33408197|NCT04695977|Experimental|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
33408198|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
33408199|NCT04644965||Control Group|age and sex matched Control Group
33408200|NCT05270759||Hospitalized patients receiving hemodiafiltration|"Adult patients hospitalized in the intensive care unit (ICU) or general ward receiving hemodiafiltration treatments as least 3 times per week with ≥1L of fluid removal per session~Exclusion criteria:~Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician~End of active care (awaiting hospital discharge)~Planned blood product transfusions during the session"
32899094|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
32899095|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
33408201|NCT05128019|Experimental|Intervention|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will offer the patients a session of unspecified length or number of consultations, to follow the conversation tool ICIT
33408202|NCT05128019|No Intervention|Control|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will however, only receive standard routine care and follow-up by their GP.
32964035|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
33408203|NCT04908761|Experimental|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
33408204|NCT04908761|Placebo Comparator|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
33408205|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
33408206|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
33408207|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
33408208|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
33408209|NCT03080129|Experimental|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
33408210|NCT03080129|No Intervention|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
32858796|NCT04278053|Experimental|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
32858797|NCT04278053|Experimental|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
32858798|NCT04278053|Placebo Comparator|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
32858799|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
32858800|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
32858801|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
32899096|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
32899097|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
33408211|NCT04762121||Patients requiring intravenous catheter insertion|Adults (>18 years old) who require intravenous catheter insertion for their operation/procedure
33408212|NCT03324581|Experimental|OPC-64005|During the titration period, participants received OPC-64005 two 10 milligram (mg) tablets, and one OPC-64005-matching placebo tablet along with two atomoxetine-matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC-64005 three 10 mg tablets, and two atomoxetine-matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.
33408213|NCT03324581|Active Comparator|Atomoxetine|"During the titration period, participants received atomoxetine one 40 mg capsule and one atomoxetine-matching placebo capsule along with three OPC-64005-matching placebo tablets, orally, QD, from Day 1 up to Day 4.~During the treatment period, participants received two atomoxetine 40 mg capsules and three OPC-64005-matching placebo tablets, orally, QD, from Day 5 up to Day 56. The dose was reduced to 40 mg if the 80 mg dose in the treatment period was not tolerable."
33408214|NCT03324581|Placebo Comparator|Placebo|Participants received three OPC-64005-matching placebo tablets and two atomoxetine-matching placebo capsules, orally, QD, from Day 1 up to Day 56.
33408215|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
33408216|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
32858802|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
32858803|NCT03083171|Placebo Comparator|Placebo|
33408217|NCT05040659||Anosmic patients|Anosmic patients will be recruited from Dr. Albers Smell Clinic at MGH and through past participation in research with known anosmia and permission to recontact. All consent and testing will occur on a phone/tablet app in the participant's home.
33408218|NCT05040659||Asymptomatic participants / Healthy participants|Asymptomatic participants recruited in a hospital setting (eg. healthcare workers and household members of symptomatic patients who are potentially COVID positive). No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
32858804|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
32858805|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
32858806|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
32858807|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
32858808|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
33104801|NCT05543356|Active Comparator|Bivalent Pfizer-BioNTech (BNT162b2 OMI): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
33104802|NCT05543356|Active Comparator|Bivalent Moderna (mRNA-1273.214): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1])."
33104803|NCT05543356|Active Comparator|Bivalent Pfizer-BioNTech (BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA."
33104804|NCT05543356|Active Comparator|Bivalent Moderna (mRNA-1273.214): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1])."
33104805|NCT00546039|Active Comparator|1|
33104806|NCT00546039|Placebo Comparator|2|
33104807|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
32858809|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
32858810|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
32858811|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
32858812|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
32858813|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
32858814|NCT05346107|Experimental|PldCHP---Nab-PHP|he patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
32858815|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
32858816|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
32858817|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
32858818|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
32858819|NCT03082703|Experimental|Text Messaging|
33408219|NCT05040659||Symptomatic participants|Symptomatic individuals will be recruited from respiratory illness clinics to evaluate smell function in patients with either SARS-CoV2, Influenza, or Adenovirus infection. All consent and testing will occur on a phone/tablet app in the participant's home.
33408220|NCT04754711|Experimental|Group with oral nutritional supplement|Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%
33408221|NCT04754711|No Intervention|Control group|"Group 2: controls receiving normal calorie intake without oral nutritional supplement"
33408222|NCT05019833|Experimental|Signals collection|Collection of sensors signals by the implanted device.
33408223|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
33408224|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
33408225|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
33408226|NCT05019677|Experimental|GP+PD-1+Tight|"Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
33408227|NCT05010785|Experimental|alveolar ridge splitting with GBR and i-PRF|alveolar ridge splitting in combination with the use of GBR with i-PRF (sticky bone) with immediate implant placement
33408228|NCT05010785|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without i-PRF (sticky bone) with immediate implant placement
33408229|NCT04291391|Experimental|Lean-normoglycemic (control)|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
33408230|NCT04291391|Experimental|Obese - normoglycemic|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
33408231|NCT04291391|Experimental|obese-glucose intolerant|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
33408232|NCT04291391|Experimental|obese with type 2 diabetes|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
33408233|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
33408234|NCT04981145|Experimental|IGU Group|
33408235|NCT04981145|Active Comparator|HCQ Group|
33408236|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
33408237|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
33408238|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
33408239|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
33408240|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
33408241|NCT04258631|Active Comparator|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
33408242|NCT04258631|Experimental|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
33408243|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~ECG~circulating sex hormones levels"
33408244|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~ECG~circulating sex hormones levels"
33408245|NCT04877015|Active Comparator|Active Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive active vCR stimulation.
33408246|NCT04877015|Sham Comparator|Sham Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive sham vCR stimulation.
33408247|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
33408248|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
33408249|NCT03638063||Control|healthy controls
33408250|NCT04869371|Experimental|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
32858820|NCT03082703|No Intervention|Control|
32858821|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
33408251|NCT04869371|Active Comparator|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
33408252|NCT02710331|Experimental|Active THC and Placebo Ethanol|
33408253|NCT02710331|Experimental|Active THC and Active Ethanol|
33408254|NCT02710331|Experimental|Placebo THC and Active Ethanol|
33408255|NCT02710331|Placebo Comparator|Placebo THC and Placebo Ethanol|
33408256|NCT02885753|Experimental|Experimental arm FOLFOX with oxaliplatin intraarterial + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intraarterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
33408257|NCT02885753|Active Comparator|Reference arm FOLFOX with oxaliplatin intravenous + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
33408258|NCT02885753|Experimental|Experimental arm mFOLFIRINOX with oxaliplatin intraarterial + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intraarterially Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
33408259|NCT02885753|Active Comparator|Reference arm mFOLFIRINOX with oxaliplatin intravenous + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intravenously Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
33408260|NCT04228523|Experimental|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
33408261|NCT04228523|Other|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
33408262|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
33408263|NCT02650895|Experimental|Efprezimod alfa|Single dose of efprezimod alfa is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in efprezimod alfa and 2 subject in placebo.
33408264|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
33408265|NCT04742231|Experimental|Cohort 1. Patients with brain lesions in non-motor areas undergoing an awake craniotomy (AC)|5 patient minimum
33408266|NCT04742231|Experimental|Cohort 2. Patients with brain lesions within or proximal to motor areas undergoing an AC|5 patient minimum
33408267|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
33408268|NCT03320057|Other|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
33408269|NCT04741139|Experimental|Scheduled post-IVIG medication|Utilization of post-IVIG medication with acetaminophen and diphenhydramine on a scheduled basis of 72 hours post-infusion.
33408270|NCT04738409|Experimental|Ov/Ob group|PCOS subjects (Overweight/Obesity)
33408271|NCT04738409|Experimental|N group|PCOS subjects (Normal weight)
33408272|NCT04738409|No Intervention|H group|Healthy control subjects
33408273|NCT03316547|No Intervention|Control|The control group received standard hospital care.
33408274|NCT03316547|Experimental|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
33408275|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
32858822|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
33408276|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
33408277|NCT02738255|Active Comparator|Polysomnogram With Varnum First, Regular Polysomnogram Second|Varnum mouthpiece, similar to a mouth tape with central opening on the first night, then a 1-week non-treatment period, then overnight sleep study with no mouthpiece.
33408278|NCT02738255|Active Comparator|Regular Polysomnogram First, Polysomnogram With Varnum Second|Baseline sleep study without Varnum mouthpiece on the first night, then a 1-week non-treatment period, then an overnight sleep study with Varnum mouthpiece on the second night.
33408279|NCT04824989|Experimental|Sleep Health|Family receives the Sleep Health In Preschoolers parenting intervention to address toddler sleep problems.
32858823|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
33408280|NCT04824989|Experimental|Behavior Health|Family receives the Family Check-Up parenting intervention to address toddler behavior problems.
32858824|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
32858825|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
33408281|NCT04824989|Experimental|Choice|Family is given the opportunity to select either the Sleep Health in Preschoolers intervention to address toddler sleep problems or the Family Check-Up intervention to address toddler behavior problems.
33408282|NCT04824989|Active Comparator|Control|Family receives a safety and hygiene active control intervention.
33408283|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
33408284|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
33408285|NCT02227199|Experimental|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
33408286|NCT04131647|Active Comparator|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
33408287|NCT04131647|Experimental|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
33408288|NCT04762433|Experimental|Kegel Exercise Pregnancy Training - App|The intervention arm will be given a mHealth app for two months duration with the usual antenatal follow-up.
33408289|NCT04762433|No Intervention|Waitlist control|The control (waitlist) group will continue their usual antenatal follow-up and the KEPT-app will be given after the study ends.
33408290|NCT04108091||Treatment for TTR amyloidosis|Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel and Vynmac.
33408291|NCT04853147|Experimental|triple therapy|Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered
33408292|NCT04853147|Other|double therapy|double combination of Palonosetron and Dexamethasone were administered
33408293|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|Racecadotril Infants Granules for Oral Suspension 10 mg (in addition to standard treatment i.e. oral rehydration solution) Racecadotril Children Granules for Oral Suspension 30 mg (in addition to standard treatment i.e. oral rehydration solution)
33408294|NCT03315689|Placebo Comparator|Vehicle|Vehicle
33408295|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
33408296|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
33408297|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
33408298|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
33408299|NCT04699799|Experimental|record brain activity while smelling odors|Record brain activity while smelling odors
33408300|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
33408301|NCT04689347|Experimental|FLIRT-bevacizumab|"Bevacizumab intravenous infusion (IV), irinotecan IV, leucovorin (LV) IV, 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU), given every 14 days, in combination with oral (PO) temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days.~The treatment will consist of an induction period of four 28-day cycles of FLIRT- bevacizumab followed by maintenance regimen of 5-FU/LV-bevacizumab administered every 14 days in combination with PO temozolomide according to dose level over days 1-5 every 28 days in patients without progressive disease at the end of the induction period."
33408302|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
33408303|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
33408304|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
33408305|NCT04685759|Active Comparator|In-Person Exercise Protocol (IPEP)|This group will receive exercise instruction and monitoring in-person from the certified Cancer Exercise Trainer (CET) in the gym facility at Moncrief Cancer Institute (MCI). Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
33408306|NCT04685759|Experimental|Virtual Exercise Protocol (VEP)|This group will receive exercise instruction and monitoring from the CET via telehealth sessions at home. Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
33408307|NCT04836221|Experimental|Intervention|Will receive mHealth support for comorbidity and support from a Community Health Worker by phone
33408308|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
32964036|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
32858826|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
32858827|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
32858828|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
33321031|NCT03602612|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
33321032|NCT03602612|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|6.0x10^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
33321033|NCT03982160|Experimental|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
33321034|NCT03982160|Placebo Comparator|Saline|Saline will be infused for 30 minutes
33321035|NCT03689920|Active Comparator|WaveWriter Settings|WaveWriter Programming
33321036|NCT03689920|Active Comparator|Conventional Settings|Conventional Programming
33321037|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
33321038|NCT01348594||Vitamin D deficient|
33321039|NCT01348594||Vitamin D sufficient|
33321040|NCT01321580|Experimental|Group A|
33321041|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
33321042|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
33321043|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
33321044|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
33321045|NCT03689608|Other|standard care (SC)|usual care
33321046|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
33321047|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
33321048|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
33321049|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
33321050|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
33321051|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
33321052|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
33321053|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
33321054|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
33321055|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
33321056|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
33321057|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
33321058|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
33321059|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
33321060|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
32858829|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
32858830|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
32858831|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
32858832|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
32858833|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
32858834|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
32858835|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
32858836|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
32858837|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
32858838|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
32858839|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
32899098|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
33321061|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
33321062|NCT05096312|Active Comparator|Zinc gluconate group|"interventions: Zinc gluconate (200g/capsule) one capsule once in the morning after breakfast for 60 days.~Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days."
33321063|NCT05096312|Placebo Comparator|Placebo group|interventions: Placebo capsule, one capsule once in the morning after breakfast for 60 days. Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.
33321064|NCT03758378|Experimental|Dietary intervention|
33321065|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
33321066|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
33321067|NCT05089916|Experimental|Osimertinib plus Radiation|Osimertinib 80 mg Radiation as per SOC
33321068|NCT05088668|Experimental|Agumented Reality combined with scapular exercises|Scapular exercises performed with glasses of augmented reality during sessions at clinic, and without glasses at home.
33321069|NCT05088668|Active Comparator|Scapular exercises|Scapular exercises performed all the time without glasses.
33321070|NCT05056844|Experimental|Diagnostic (CESM, DBT)|Patients receive iodine-based contrast agent IV then undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
33321071|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
33321072|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
33321073|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
33321074|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
33321075|NCT05004662|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with Florida Quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
33321076|NCT05004662|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
33321077|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
32899099|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
32899100|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
32899101|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
33321078|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
33321079|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
33408309|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
33408310|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33408311|NCT04674995||Stent|Patients with tracheal stenosis treated with stent placement via rigid bronchoscopy.
33408312|NCT04674995||Balloon dilatation|Patients with tracheal stenosis treated with balloon dilatation via laryngoscope.
33408313|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
33408314|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
33408315|NCT02384759|Experimental|A|Aflibercept + LV5FU2
33408316|NCT02384759|Active Comparator|B|LV5FU2
33408317|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
33408318|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
33408319|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
33408320|NCT05276843|Experimental|group A|receive Qigong exercise in addition to traditional physical therapy program
33408321|NCT05276843|No Intervention|group B|receive traditional physical therapy program only
33408322|NCT05276765|Experimental|CAD/CAM customized Socket Sealing Abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
33408323|NCT05276765|Active Comparator|Standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
33408324|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
32899102|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
33408325|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
33408326|NCT05276687|Experimental|Diluted betadine|
33408327|NCT05276687|Experimental|Powdered vancomycin|
33408328|NCT05276687|No Intervention|No intervention|
33408329|NCT04616339|Active Comparator|Formulation A (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408330|NCT04616339|Experimental|Formulation B (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation B at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408331|NCT04616339|Experimental|Formulation C (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation C at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408332|NCT04616339|Experimental|Formulation D (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation D at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408333|NCT04616339|Active Comparator|Formulation A (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408334|NCT04616339|Experimental|Formulation E (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation E at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
33408335|NCT03333941||RES (Regenerative Epithelial Suspension)|
33408336|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
33408337|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
33408338|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
32899103|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
32899104|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
32899105|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
32899106|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
32899107|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
32899108|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
33408339|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
33408340|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
33321080|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
33321081|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
33321082|NCT03758144|Active Comparator|study|
33104808|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
33321083|NCT03758144|No Intervention|CONTROL GROUP|
33321084|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
33321085|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
33321086|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
33321087|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
33321088|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
33321089|NCT04908488|Other|P1fA, then AMfA|Verofilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
33321090|NCT04908488|Other|AMfA, then P1fA|Etafilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
33321091|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
33321092|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
33321093|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
33321094|NCT04876274|Experimental|Intervention group|Patients in the intervention group received Taipei Medical University (TMU) line-oriented video education and care in addition to usual care
33321095|NCT04876274|No Intervention|Control group|Patients in the control group received usual care
33321096|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
33321097|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
33321098|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
33321099|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
33321100|NCT04865354|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
33321101|NCT04865354|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
33321102|NCT04860518|Experimental|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
33321103|NCT04860518|Active Comparator|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
33321104|NCT03110380|Experimental|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
33321105|NCT03110380|Active Comparator|DTG + F/TAF|DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
33321106|NCT03110380|Experimental|Open-label Phase B/F/TAF from B/F/TAF|Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
33321107|NCT03110380|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
33321108|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
33104809|NCT00538707|Experimental|Young subjects|
33104810|NCT00538707|Experimental|Older subjects|
33104811|NCT02905370|Experimental|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
33104812|NCT02905370|Active Comparator|Usual Care (UC)|Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care
33321109|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
33321110|NCT03473366|Experimental|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
33408341|NCT05276375|Active Comparator|Bronchipret|Bronchipret syrup (3x 5,4 ml daily, according to summary of product characteristics) until day 14
33408342|NCT05276375|No Intervention|standard of care|no study intervention
33408343|NCT04697771|Experimental|Study Group|First Evaluation - Fine Motor Skills Training - 8 week - 3 session per week - 40 minute per session - Second Evaluation
33408344|NCT04697771|Other|Kontrol Group|First Evaluation - 8 week waiting period - Second Evaluation - 8 week Fine Motor Skills Training
33408345|NCT05275985|Experimental|68Ga-FAPI PET/CT examination|Patients with suspected pancreatic lesions underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The clinicians decided the treatment methods based on the results of 68Ga-FAPI PET/CT.
33408346|NCT05275829||Control group: Face-to-Face learning of simple interrupted suturing|"The students watched a video demonstrating simple interrupted suturing, with the instructor commenting on the steps.~The students then watched the video again.~The instructor then demonstrated the procedure for the students.~The students then practiced suturing with immediate and specific feedback provided by the instructor until he and the students were satisfied with the performance."
33408347|NCT05275829||Study group: Distance learning (tele simulation) of simple interrupted suturing|"The instructor ran the interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform). The students used their personal smartphones or laptops with audio-video capabilities. The instructor ran the session through his smartphone.~The instructor shared a video demonstrating simple interrupted suturing while commenting on the steps (the same video used in the control group).~The instructor then ran the video again for the students.~The instructor then demonstrated the skill for the students by turning on his camera.~The students then practiced suturing, and periodically turned on their cameras to receive live and specific feedback from the instructor on their performance, until the instructor and the students were satisfied.~No face-to-face interactions between the students and the instructor."
33408348|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
32858840|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
33408349|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
32858841|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
33408350|NCT03332771|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
33408351|NCT03332771|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
32858842|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
32858843|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
32858844|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
32858845|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
32858846|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
32858847|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
32858848|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
32899109|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
33408352|NCT03332771|Active Comparator|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
33408353|NCT03332771|Placebo Comparator|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
33408354|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
33408355|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
33408356|NCT04123704|Experimental|Sitravatinib|Sitravatinib 120 mg daily
33408357|NCT04108104|Experimental|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
33408358|NCT04108104|Experimental|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
33408359|NCT04108104|Placebo Comparator|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
32858849|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
32858850|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
33408360|NCT05304468|Experimental|Reduced-dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo low-dose (60Gy) intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive concurrent cisplatin once every three weeks for 2 cycles.
33408361|NCT05304468|Active Comparator|Standard dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo standard-dose (70Gy) intensity modulated radiotherapy (IMRT) 5 days per week for approximately 7 weeks (33 fractions). Patients also receive concurrent cisplatin once every three weeks for 3 cycles.
33408362|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
32858851|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
32858852|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
32858853|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
32858854|NCT04401839|Active Comparator|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
32858855|NCT04401839|Active Comparator|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
32858856|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
33408363|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
33408364|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
33408365|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
32858857|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
33408366|NCT05250102|Other|Pulse oximeter sensor readings|Subjects who satisfy all of the inclusion criteria will be eligible to participate in the study, will receive intervention (the Masimo and Nellcor sensors, and their arterial blood sample will be taken in the normal course of care). This is a single arm study. Those who don't meet the inclusion/ exclusion criteria won't be eligible to participate.
33408367|NCT05275595||chronic renal disease with covid|all patients who have chronic kidney disease with COVID-19 infection
32858858|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
33408368|NCT05275595||chronic renal disease without covid|all patients who have chronic kidney disease without COVID-19 infection
33408369|NCT04582799|Active Comparator|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
33408370|NCT04582799|Experimental|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
33408371|NCT05248308|Experimental|Genicular artery embolization|Study participants will undergo genicular artery embolization (GAE) for treatment of chronic moderate to severe pain following knee arthroplasty or revision arthroplasty. Embolization will be performed using Embozene Microspheres.
33408372|NCT04236245|Other|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
33408373|NCT05246670|Experimental|Arm I (lower-dose PEA)|Patients receive PEA PO QD for 8 weeks as long as there is not any unacceptable toxicity.
33408374|NCT05246670|Experimental|Arm II (higher-dose PEA)|Patients receive PEA PO BID for 8 weeks as long as there is not any unacceptable toxicity.
33408375|NCT05246670|Placebo Comparator|Arm III (QD placebo)|Patients receive placebo PO QD for 8 weeks.
33408376|NCT05246670|Placebo Comparator|Arm IV (BID placebo)|Patients receive placebo PO BID for 8 weeks.
33408377|NCT05125302|Experimental|PK Cohort: Ubrogepant Dose A|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
33408378|NCT05125302|Experimental|PK Cohort: Ubrogepant Dose B|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
33408379|NCT05125302|Experimental|Main Study: Children Ubrogepant Low Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408380|NCT05125302|Experimental|Main Study: Children Ubrogepant High Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408381|NCT05125302|Placebo Comparator|Main Study: Children Ubrogepant Placebo|Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408382|NCT05125302|Experimental|Main Study: Adolescents Ubrogepant Low Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408383|NCT05125302|Experimental|Main Study: Adolescents Ubrogepant High Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408384|NCT05125302|Placebo Comparator|Main Study: Adolescents Ubrogepant Placebo|Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
33408385|NCT03330119|Experimental|Alternate Management|
33408386|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
33408387|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
33408388|NCT03842969|Experimental|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
33408389|NCT03842969|Experimental|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
33408390|NCT05123274|Active Comparator|Individual Care Counseling|After completing the baseline survey, each participant will receive a 20-minute individual counseling session focused on HIV medical care. The session will convey that effective HIV treatment is now available at no cost, protects health, and that most individuals who are in treatment can lead long and healthy lives. Referral will be made and assistance provided in accessing LGBT-friendly HIV medical care, mental health, substance abuse, and other services.
33408391|NCT05123274|Experimental|Social Support Mobilization|In addition to the post-baseline 20-minute individual counseling session, each participant in this arm will attend five main intervention sessions and two booster sessions that have three inter-related objectives: (1) ensuring that participants understand that viral suppression through ART maintains health and protects others; (2) increasing resilience and feelings of self-worth; and (3) guiding participants in identifying, accessing, and mobilizing social resources for both general psychosocial support and also specific supports for HIV care. For individuals who have potential supports in their social environment, the intervention will seek to mobilize or increase the frequency and quality of interactions with them. For participants who are presently socially isolated or whose social resources are not supportive of HIV care, the intervention will help to build new social ties with potentially supportive life figures.
33408392|NCT04049604||1/Cohort 1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
33408393|NCT04049604||2/Cohort 2|Women undergoing active treatment or surveillance for known malignancy
32858859|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
32858860|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
32858861|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
32858862|NCT04761185|Experimental|HIPEC using Raltitrexed|
32899110|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
32964037|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
33408394|NCT04731480|Active Comparator|CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia.
33408395|NCT04731480|Active Comparator|Marsh model group|The target-controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
33408396|NCT04731480|Active Comparator|Schnider model group|The TCI-pump will be programmed to will be programmed to Schnider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia.
33408397|NCT04731480|Active Comparator|Manual group|Propofol administration will be controlled manually using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
33408398|NCT05237388|Experimental|Baricitinib|Participants will take one pill of Baricitinib daily with their regular medications.
33104813|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
33408399|NCT05237388|Placebo Comparator|Placebo|Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.
33408400|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
33408401|NCT05261022|Experimental|Love Together, Parent Together Intervention|"Participants will take part in a 3-session writing intervention over the course of 12-week. They will complete a fact-based summary of a recent conflict and answer questions on conflict/conflict-related distress. Next, they will be asked to complete a 9-minute writing task where they reappraise the conflict they previously reported. First, they will watch an instructional video of how to engage in the writing task, by providing definitions and examples of potentially useful conflict reappraisal strategies. Writing prompts include: … Think about this disagreement … from the perspective of a neutral third party who wants the best for all involved…; …what obstacles do you face in trying to take this perspective…?;… How might you be most successful in taking this perspective … over the next 2 weeks? Participants in the intervention group will receive emails to prompt use of the reappraisal strategy between writing sessions."
33408402|NCT05261022|No Intervention|Wait-List Control Group|"Participants will take part in a waitlist control group. They will participate in the same number of assessment/sessions as the experimental group. In the sessions that correspond to the intervention (one session every 4 weeks over the course of 12 weeks as in the intervention group), the waitlist group will complete a basic writing task (identical to the intervention group, wherein they provide a fact-based summary of a recent conflict) and they will complete questions regarding conflict history and conflict-related distress. No other writing tasks will take place.~Following the 3-month assessment, they will be offered the writing intervention."
33408403|NCT03983382||HER2-Positive Breast Cancer|
33408404|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
32858863|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
32899111|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
32899112|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
33104814|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
33408405|NCT05256654|Experimental|LY3561774 Dose 1|Participants will receive LY3561774 subcutaneously (SC)
33408406|NCT05256654|Experimental|LY3561774 Dose 2|Participants will receive LY3561774 SC
33408407|NCT05256654|Experimental|LY3561774 Dose 3|Participants will receive LY3561774 SC
33408408|NCT05256654|Placebo Comparator|Placebo|Participants will receive placebo
33408409|NCT03936660|No Intervention|Control|Clinics in the control arm will be encouraged to follow guideline-based care.
33408410|NCT03936660|Active Comparator|Intervention|The cardiology clinics in the intensive educational intervention arm will receive guidance to develop an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
33408411|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
33408412|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
33408413|NCT05222178|Experimental|Low Dose Cohort|Low dose of HMI-103 delivered intravenously one time
33408414|NCT05222178|Experimental|Intermediate Dose Cohort|Intermediate dose of HMI-103 delivered intravenously one time
33408415|NCT05222178|Experimental|High Dose Cohort|High Dose of HMI-103 delivered intravenously one time
33408416|NCT05370612|Experimental|Arm 1: Continuous Glucose Monitor (CGM)|CGM for duration of pregnancy.
33408417|NCT05370612|Active Comparator|Arm 2: Point of Care Glucose Testing (POCT)|"Point of care finger sticks for glucose monitoring.~At two time points during the study - at time of enrollment and at 28-32 weeks gestation, CGM sensor will be placed and remain in place for 10 days. Participant and Physician will be blinded to CGM data."
33408418|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.~Blood and tumor sampling will also be performed at disease progression/relapse."
33408419|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:~a) Standard-of-care (SOC) + Selinexor gel, 10 μM~, b) SOC + vehicle gel c) SOC alone."
33408420|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 30 μM~SOC + vehicle gel~SOC alone."
33408421|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 70 μM~SOC + vehicle gel~SOC alone."
33408422|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408423|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408424|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408425|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408426|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408427|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
33408428|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
33408429|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
33408430|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
33408431|NCT05275283|No Intervention|Control group|Applying tidal volume 7 ml/kg without PEEP
33408432|NCT05275283|Experimental|PEEP group|Applying tidal volume 7 ml/kg with 6 cmH2O of PEEP
33408433|NCT01529034|Experimental|USL261|Intranasal midazolam 5 mg
33408434|NCT05275049|Experimental|PT+ Device|PT plus translingual stimulation device PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
33408435|NCT05275049|Active Comparator|PT + Control Device|PT plus translingual stimulation control device Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
33408436|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
33408437|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
33408438|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
33408439|NCT05107362||Symptomatic Adult and Pediatric Subjects|Untrained lay user to collect throat swab specimen and perform investigational test.
33408440|NCT05102916||Patient population|Children, adolescents and adults diagnosed with a NMD (DMD/BMD/IMD; SMA; COL-6; LAMA-2) who are treated or living in Switzerland.
33408441|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
33408442|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
33408443|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
33408444|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
33408445|NCT05099172|Experimental|Dose escalation|
33408446|NCT05099172|Experimental|Backfill|Dose Escalation and Backfill run concurrently
33408447|NCT05099172|Experimental|Dose expansion|Dose Expansion is initiated after Dose Escalation and Backfill.
33408448|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
33408449|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
33408450|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
33408451|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
33408452|NCT03038880|Experimental|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
33408453|NCT03038880|Experimental|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
33408454|NCT03038880|Active Comparator|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
33408455|NCT05211336|Experimental|1: VIPOR|VIPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in 21-day cycles for up to 6 cycles
33408456|NCT01192464|Experimental|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10^7 cells/m2~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10^7 cells/m2~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10^8 cells/m2"
33408457|NCT05038644|Experimental|Arm Z: Dose Level -1 for Group A (T-ALL, T-LBL)|0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
32858864|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
32858865|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
32858866|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
33408458|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) for Group A (T-ALL, T-LBL)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
32858867|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
32858868|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
32858869|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
32858870|NCT04401527|Active Comparator|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
32858871|NCT04401527|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
32858872|NCT04401683|Experimental|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
33408459|NCT05038644|Experimental|Arm B: Dose Level 1 for Group A (T-ALL, T-LBL)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
33408460|NCT05038644|Experimental|Arm C: Dose Level 2 Group A (T-ALL, T-LBL)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
33408461|NCT05038644|Experimental|Arm D: Dose Level 3 Group A (T-ALL, T-LBL)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
33408462|NCT05038644|Experimental|Arm Z: Dose Level -1 Group B (AML)|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
33408463|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) Group B (AML)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
33408464|NCT05038644|Experimental|Arm B: Dose Level 1 Group B (AML)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
32858873|NCT04401683|Active Comparator|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
32858874|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
32858875|NCT03080363|No Intervention|Group Control|No intervention
33408465|NCT05038644|Experimental|Arm C: Dose Level 2 Group B (AML)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
33408466|NCT05038644|Experimental|Arm D: Dose Level 3 Group B (AML)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
33408467|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
33408468|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
32858876|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
32858877|NCT01212627|Experimental|Ridaforolimus|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
33408469|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
33408470|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
33408471|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
33408472|NCT05094570|Experimental|Dupilumab treatment|Treatment with dupilumab to demonstrate decreased staph prevalence and improve microbial diversity
33408473|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
33408474|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
33408475|NCT03675516||Controls|Age, gender and primary care practice-matched controls
33408476|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
33408477|NCT05655000|Experimental|Neonatal thymus transplantation|Supermicrosurgical technique for neonatal thymus transplantation into the subject's radial forearm. The donor will be a neonate subject to corrective heart surgery via sternotomy requiring routinary partial thymectomy.
33408478|NCT04889040|Experimental|RO7496998 (AT-527)|Orally administered, 550 mg twice daily (BID) for 5 days
33408479|NCT04889040|Placebo Comparator|Placebo|The dose and regimen of the placebo will match that of AT-527.
33408480|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
33408481|NCT05655078|No Intervention|Standard of care|MPM participants who are on the standard of care watch and wait approach i.e. immediate treatment not suitable. Participants will have follow-up for 2 years (3 monthly in year 1, 4 monthly in year 2).
33408482|NCT05655078|Experimental|Proton beam therapy|MPM participants to receive 5 weeks of proton beam therapy to the hemithorax. Following completion of treatment participants will have follow-up at the referring centre for 2 years (3 monthly in year 1, 4 monthly in year 2).
33408483|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
33408484|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
33408485|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
33408486|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
33408487|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
33408488|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.~Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
33408489|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
33408490|NCT05274893|Experimental|SYHX2011(T)-Abraxane®(R)|Patients will be administrated with SYHX2011 followed by Abraxane®
33408491|NCT05274893|Experimental|Abraxane®(R)-SYHX2011(T)|Patients will be administrated with Abraxane® followed by SYHX2011
33408492|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
33408493|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
33408494|NCT05255471|Experimental|Olaparib|
33408495|NCT05255471|Active Comparator|Chemotherapy|
33408496|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
33408497|NCT03241927|No Intervention|Healthy Donors|
33408498|NCT03936751|Active Comparator|CPAP|Continuous positive airway pressure
33408499|NCT03936751|Sham Comparator|Nasal strips|Nasal Strips
33408500|NCT05571865|Other|Control subjects (non-diabetic).|"Control subjects (non-diabetic):~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
33408501|NCT05571865|Other|Diabetic Subjects|"Diabetic subjects:~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
33408502|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
33408503|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
33408504|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
33408505|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
33408506|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
33408507|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
33408508|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
33408509|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC|
33408510|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody naïve NSCLC|
33408511|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant RCC|
33408512|NCT03666143|Experimental|Metastatic or advanced RCC without prior systemic therapy|
33408513|NCT03666143|Experimental|Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC|
33408514|NCT03666143|Experimental|Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC|
33408515|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody R/R melanoma|
33408516|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC|
33408517|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, sq NSCLC|
33408518|NCT03609203||Patients|
33408519|NCT03609203||Controls|
32858878|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
32858879|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
33408520|NCT02938585|Experimental|Prophylactic treatment|
33408521|NCT02938585|Experimental|On-demand treatment|
33408522|NCT05235113|Active Comparator|Remote Exercise with tele-exergame|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
33408523|NCT05235113|Sham Comparator|home-based exercise without technology|Subjects will perform exercises at home without tele-exergaming platform twice a week.
33408524|NCT04727411|Experimental|Gel Stent implantation|XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
33408525|NCT04727411|Experimental|Trabeculectomy|Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
32858880|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
32858881|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
33408526|NCT04661267|Experimental|Supplement formula|Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
33408527|NCT04661267|Placebo Comparator|Placebo formula|Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
33408528|NCT05571709|Active Comparator|Aged individuals who perform exercise training|Aged individuals will perform an acute bout of resistance trainig (30 minutes). This training is focused on the lower limbs.
32858882|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
33408529|NCT05571709|Sham Comparator|Aged individuals who stay sedentary|Aged individuals will remain seated for 30 minutes.
33408530|NCT05571631|Experimental|Arm ergometer-balance training|Combination of arm ergometer exercise and balance training
33408531|NCT05571631|Experimental|arm ergometer|Only arm ergometer exercise training
33408532|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
33408533|NCT04565665|Experimental|Phase II Arm I (mesenchymal stem cells)|Patients receive MSCs as in the Pilot study.
33408534|NCT04565665|Active Comparator|Phase II Arm II (standard of care)|Patients receive standard of care.
33408535|NCT04565665|Experimental|Pilot study (mesenchymal stem cells)|Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
33408536|NCT05220059|Experimental|Polyphenol extract low dose|156mg single dose
33408537|NCT05220059|Experimental|Polyphenol extract medium dose|222mg single dose
33408538|NCT05220059|Experimental|Polyphenol extract high dose|333mg single dose
33408539|NCT05220059|Placebo Comparator|Placebo|Maltodextrin single dose
33408540|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
33408541|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
33408542|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
33408543|NCT05218109|Experimental|tVNS + mindfulness|Transcutaneous vagus nerve stimulation plus behavioral: mindfulness
33408544|NCT05218109|Sham Comparator|Sham + mindfulness|Sham transcutaneous vagus nerve stimulation plus behavioral: mindfulness
33408545|NCT05218109|Active Comparator|Mindfulness only|
33408546|NCT05218109|Active Comparator|Control|Control number puzzle task delivered via mobile device
33408547|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
33408548|NCT03476681|Experimental|NEO-201 in combination with pembrolizumab|Subjects will receive 3 doses NEO-201 in combination with one dose of pembrolizumab in a 42 day cycle. This course will be repeated in the absence of disease progression or unacceptable toxicity.
33408549|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
33408550|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
33408551|NCT03620825|No Intervention|Negative control|No intervention is performed
33408552|NCT01312649|Experimental|Arm 1|Healthy volunteers
33408553|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
33408554|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
33408555|NCT01312649|Experimental|Arm 4|Bipolar disorders
33408556|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
33408557|NCT01312727|Other|HTIN|HTIN
33408558|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
33408559|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
33408560|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
33408561|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
33408562|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
33408563|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
33408564|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
33408565|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
33408566|NCT04463797|Experimental|Square-stepping exercise group|Square-stepping exercise
33408567|NCT04463797|Active Comparator|Control group|Whole-body stretching and upper extremity strengthening
33408568|NCT03930121|Experimental|Experimental group|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
33408569|NCT03930121|Sham Comparator|Control group|Placebo stimulation (using sham-tDCS) combined with SLT
33408570|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
33408571|NCT04446481|Active Comparator|NC|Normal healthy Veterans
33408572|NCT01496118|Experimental|Carfilzomib and Panobinostat|"Phase I:~Carfilzomib: cycle 1 - Dose is 20 mg/m^2 IV on day 1; 27 or 36 or 45 or 56 mg/m^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m^2 IV on days 1, 2, 8, 9, 15, 16~Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19~Phase II:~Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I"
33408573|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
33408574|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
33408575|NCT05083884||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
33408576|NCT05083884||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
33408577|NCT05083884||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
33408578|NCT05083884||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
33408579|NCT04649034||86 patients ischemic DCM|A cohort of 86 patients with ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
33408580|NCT04649034||86 patients non ischemic DCM|A cohort of 86 patients with non-ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
33408581|NCT04649034||86 patients hypertrophic cardiomyopathy|A cohort of 86 patients with hypertrophic cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 55% or with an apical aneurism diagnosed in an image test
33408582|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
33408583|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
33408584|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
33408585|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
33408586|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
33408587|NCT03309605|Experimental|ELX-02|ELX-02
33408588|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
33408589|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
32858883|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
33408590|NCT02936635|Experimental|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
33408591|NCT02936635|Experimental|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
32858884|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
33408592|NCT04976322|Experimental|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol throughout the Treatment Period.
33408593|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
33408594|NCT03227029|Experimental|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
33408595|NCT03227029|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
33408596|NCT04544280|Experimental|Intervention|
33408597|NCT05571475|Experimental|Simulated competition|During the experimental condition, the participants will be competing for a reward, will be given verbal encouragement, and will receive performance feedback.
33408598|NCT05571475|No Intervention|Control|During the control condition, the participants will be asked to sprint without verbal encouragement or any performance feedback.
33408599|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
33408600|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
33408601|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
32858885|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
32858886|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
33408602|NCT05015634|Active Comparator|Active Arm|Patients will be discharged from the hospital with the telemedicine package. If the patient develops possible cardiac symptoms and seeks medical attention, the data provided by the telemedicine package will be acted upon, as appropriate, by the trial cardiology team. With remote follow up over the phone at 3, 6 and 9 months.
33408603|NCT05015634|Placebo Comparator|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
33408604|NCT05014776|Experimental|Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207|
33408605|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
33408606|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
33408607|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
33408608|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
32858887|NCT03080207|Experimental|Low Level Laser|
32858888|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
32858889|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
32858890|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
32858891|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
32858892|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
32858893|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
33321111|NCT03473366|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
33321112|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
32858894|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
32858895|NCT03152825||Viable myocardium Group|"At least ONE of the following:~Late gadolinium enhancement <75%.~Improvement in segmental function ≥1 grade during low dose dobutamine"
32858896|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~Late gadolinium enhancement ≥75%.~No improvement in segmental function during low dose dobutamine"
32858897|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
32858898|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
32858899|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
32858900|NCT05345873|Experimental|SCTV01E Group|one dose of SCTV01E, intramuscular
32858901|NCT05345873|Active Comparator|mRNA-1273|one dose of mRNA-1273, intramuscular
32899113|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
32899114|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
32899115|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
32899116|NCT03008317|Active Comparator|non metallic|PEEK denture base,
32899117|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
33321113|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
33321114|NCT01353040|Placebo Comparator|Placebo|Normal saline
33321115|NCT03766568|Experimental|Diagnostic with JGG endoscope|
33321116|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
33321117|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
33321118|NCT04851314|Active Comparator|ICU certified ventilator|Participants assigned to receive ventilation with the ICU certified ventilator
33321119|NCT04851314|Active Comparator|Non-ICU certified ventilator|Participants assigned to receive ventilation with the Non-ICU certified ventilator
33321120|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
33321121|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321122|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321123|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321124|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321125|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321126|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
33321127|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
33321128|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
33321129|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
33321130|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
33321131|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
33321132|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
33321133|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
33321134|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
33321135|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
33321136|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
33321137|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
33321138|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
33321139|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
33321140|NCT01348984|Placebo Comparator|group 2|placebo patch
33408609|NCT00604201|Experimental|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
33408610|NCT00492349|Experimental|1|Varenicline
33408611|NCT00492349|Placebo Comparator|2|Placebo
33408612|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
33408613|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
33408614|NCT03924193|Active Comparator|LDX|
33408615|NCT03924193|Active Comparator|Cognitive-Behavioral Therapy|
33408616|NCT03924193|Active Comparator|LDX and Cognitive Behavioral Therapy|
33408617|NCT04558957|Experimental|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
33408618|NCT03308825|Experimental|Group 1: 6 to < 36 Months|Children aged 6 to < 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
33408619|NCT03308825|Experimental|Group 2: 3 to < 9 Years|Children aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
33408620|NCT03308825|Experimental|Group 3: 18 to < 65 Years|Adults aged 18 to < 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
33408621|NCT03308825|Experimental|Group 4: >= 65 Years|Adults aged >= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
33408622|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
33408623|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
33408624|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
33408625|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
33408626|NCT05196503|Active Comparator|Experimental group|Surgery for disc herniation and intraoperative periradicular administration of PRF
33408627|NCT05196503|Active Comparator|Control group|Surgery for disc herniation alone (i.e. reference treatment).
33408628|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
33408629|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
33408630|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
33408631|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
33408632|NCT04879043|Experimental|HDP-101|"Participants will receive HDP-101 intravenously at one dose every 3 weeks (21 day cycle) until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.~During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered."
33408633|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
33408634|NCT05039489|Active Comparator|The schizophrenia patients with general auditory hallucinations|Drug intervention
33408635|NCT05039489|No Intervention|The healthy controls|MRI scan at baseline and no drugs treatment
33408636|NCT05039489|Experimental|Drug + cTBS intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug + cTBS intervention (the left temporoparietal cortex as the stimulation target)
33408637|NCT05039489|Active Comparator|Drug intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug intervention
33408638|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations from the fourth arm|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
32964038|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
32964039|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
32964040|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
32964041|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
33408639|NCT05008289|Active Comparator|ACTIVE|Magnetic transcutaneous spinal cord stimulation
33408640|NCT05008289|Sham Comparator|PLACEBO|
33408641|NCT04967105||elderly patients following liver resection|elderly patients (aged ≥60 years) scheduled for any type of liver resection due to benign or malignant hepatobiliary diseases
32858902|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
32858903|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
33408642|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
33408643|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
33408644|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
33408645|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
32858904|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
32858905|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
32858906|NCT05342051|Experimental|balneotherapy group|balneotherapy plus usual care
33408646|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
33408647|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
33408648|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
33408649|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
33408650|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
33408651|NCT04718441|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
33408652|NCT04229095|Active Comparator|Belsomra,(suvorexant)|20 mg single-dose administration given on an inpatient clinical research unit
33408653|NCT04229095|Placebo Comparator|Placebo|Placebo single-dose administration given on an inpatient clinical research unit
33408654|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
33408655|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
33408656|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
33408657|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
33408658|NCT04079881|Experimental|A (Pre-prandial insulin administration) : B (post-prandial insulin administration)|"VISIT 1: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.~Then VISIT 2: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal."
33408659|NCT04079881|Experimental|B (post-prandial insulin administration) : A (Pre-prandial insulin administration) :b|"VISIT 1: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.~Then VISIT 2: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal."
32858907|NCT05342051|No Intervention|control group|usual care
32858908|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
32858909|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
32858910|NCT05339087|Experimental|Riociguat|patients will undergo a titration phase starting with 1mg riociguat oral tablets tid (three times daily) up to a maximum dosage of 2.5mg tid that will be continued for the remainder of the study.
32858911|NCT05339087|Placebo Comparator|Placebo|Placebo tablets with the same treatment regimen (tid) as the verum therapy will be provided. Patients will undergo a sham titration phase with sham doses individually adjusted as in the experimental arm
32858912|NCT01145391|No Intervention|Control|Patients receive usual care.
32899118|NCT01433107|Experimental|Terbinafine|Drug
32899119|NCT01433107|Placebo Comparator|Placebo|Drug
32858913|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
32858914|NCT03150407|Active Comparator|VR101 Device|Subjects assigned to use randomly-assigned VR101 devices. Each device is to be used for 7 consecutive days, then replaced with a fresh device. Four each VR101 devices will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 Shams, each for 7 days.
32858915|NCT03150407|Sham Comparator|Sham Control Ring|Subjects assigned to use randomly-assigned Sham rings. Each Sham is to be used for 7 consecutive days, then replaced with a fresh sham. Four each Shams will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 VR101 Devices, each for 7 days.
33321141|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
32858916|NCT03150407|Other|Long-term Safety Evaluation|13-week investigation of the safety of the use of VR101 Devices
32858917|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
32858918|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
32858919|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
32858920|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
32858921|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
33321142|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
33321143|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
33321144|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
32858922|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
32964042|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
33321145|NCT03100240|No Intervention|control group|long protocol
33321146|NCT04848662|Experimental|A/B - Treatment with BDA MDI (PT027) 160/180 μg followed by treatment with Pulmicort Respules 1mg|Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 2, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3.
33321147|NCT04848662|Experimental|B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 μg|Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 3.
33321148|NCT04842500|Experimental|"Cheap Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
33321149|NCT04842500|Experimental|"Cheap Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
33321150|NCT04842500|Experimental|"Expensive Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
33321151|NCT04842500|Experimental|"Expensive Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
33321152|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
33321153|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
33321154|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
33321155|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
33321156|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
33321157|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
33321158|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
33321159|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
33321160|NCT05419622|Experimental|lung MRI|The procedure under study is lung MRI, performed on a 1.5T magnet (AERA dot 1.5T, Siemens), without anesthesia and without injection or inhalation of contrast agent.
33321161|NCT04822298|Experimental|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
33321162|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
33321163|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
33321164|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
33321165|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
33321166|NCT04351256|Experimental|Arm A (HYPO group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
33321167|NCT04351256|Active Comparator|Arm B (CON group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
33321168|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
33321169|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
33321170|NCT03700892|No Intervention|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
33321171|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
33321172|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
33321173|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
33321174|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
33321175|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
33321176|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
33321177|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
33321178|NCT03760094|Experimental|Study group|patients with lymphadenopathy
33321179|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
33321180|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
33321181|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
33321182|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
33321183|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
33321184|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
33321185|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
33321186|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
33321187|NCT04737278|Experimental|Cunermuspir|Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.
33321188|NCT04737278|Placebo Comparator|Placebo|Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm
33321189|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
32858923|NCT05688605|Experimental|MRG003+HX008|"MRG003 will be administrated via intravenous infusion at 1.5, 2.0 mg/kg (MTD=2.5 mg/kg) once on Day 1 of every 3 weeks (21-day cycle).~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day cycle)."
32964043|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
32964044|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
33033476|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
33321190|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
33321191|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
33321192|NCT03766100|No Intervention|Control group|Insomnia is untreated.
33321193|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
33321194|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
33321195|NCT03757208|No Intervention|Fasting group|
33321196|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
33321197|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
33321198|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
33321199|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
33321200|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
33321201|NCT04725500|Experimental|Auto-titrating EPAP|ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.
33321202|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
33321203|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
33321204|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
33321205|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
33321206|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
33321207|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
33321208|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
33321209|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
33321210|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
33321211|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
33321212|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
33321213|NCT04694066|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (followup; 8 hours). The sessions will be supervised by an experienced qigong master.
33321214|NCT04694066|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise only, with the same duration and frequency of supervised sessions identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
33321215|NCT04684394|Experimental|SoC + GEM103|Participants were administered SoC therapy defined as aflibercept (2 milligram [mg]/50 microliter [mcL]) first, followed by GEM103 (500 microgram [mcg]/50mcL) 15 minutes later. Administration occurred every other month (EOM) for a total of 6 doses during the 12-month study period.
33408660|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
32858924|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
32858925|NCT05312645|Experimental|Diclofenac Gel|
32858926|NCT05312645|Placebo Comparator|Control|
32858927|NCT05688449|Active Comparator|Epidural analgesia|Eeg monitoring will be implemented with Sedline monitor(Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
32858928|NCT05688449|Placebo Comparator|placebo|Eeg monitoring will be implemented with Sedline monitor (Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
32858929|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
32858930|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
32858931|NCT03158597||AMI|
32858932|NCT03158597||Control|
32858933|NCT04401137|Placebo Comparator|Placebo|
32858934|NCT04401137|Experimental|QDX 25|
32858935|NCT04401137|Experimental|QDX 50|
32858936|NCT04401137|Experimental|QDX 100|
32858937|NCT04401137|Experimental|QDX 200|
32858938|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
32858939|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
33321216|NCT04684394|Sham Comparator|SoC + Sham|Participants were administered SoC therapy defined as aflibercept (2mg/50mcL) first, followed by the Sham injection 15 minutes later. Administration occurred EOM for a total of 6 doses during the 12-month study period.
33321217|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
33321218|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
33321219|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
33321220|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
33321221|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
33321222|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
33321223|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
33321224|NCT04186832|Active Comparator|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
33321225|NCT04186832|Experimental|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
33321226|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
33321227|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
33321228|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
33321229|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
33321230|NCT04675346||Questionnaire|The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.
33321231|NCT04675346||Interviews|A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
33321232|NCT04674644|Other|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals|Dental professionals
33321233|NCT05280938|Experimental|MAAPI Intervention|The MAAPI intervention is an 8-week adapted mindfulness intervention based upon Kabat-Zinn's MBSR. The intervention includes spirituality, self-empowerment, interdependence, and story-telling which are salient to AAW. Session topics include Tasting Your Life, Seeing and Believing, The Scent of Roses, When Life Hurts, Hearing Your Own Cries, Embracing Inner Peace, Holding on, Welcoming Stillness. Each session will include an introduction, opening mindfulness practice, class responses to the previous week, review guidelines for class, guided individual reflection, group go-around/discussion, yoga, abdominal breathing, body scan, conclusion, and home practice. Face to face sessions 1, 4, 8 will be in a quiet room to allow group sitting or free floor space. Sessions 2, 3, 5, 6, are virtual on the zoom app. Participants receive practice links and a program workbook. Program attendance, type/amount of practice (weekly logs), and changes in mindfulness will be included in data analysis.
33408661|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
32858940|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
33408662|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
33408663|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
33408664|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
33408665|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
33408666|NCT03733925|Experimental|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
33408667|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
33408668|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
33408669|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
33408670|NCT05181631|Experimental|Biobanking|"If the patient consents, two tubes of blood will be collected for biobanking, at the same time as routine tubes will be collected.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in the biological resources center of Avicenne hospital ."
33408671|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
33408672|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
33408673|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
33408674|NCT05181397|Experimental|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab. No Intervention: control, participants in control group will receive regular treatment.
32858941|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
32858942|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
32858943|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
32858944|NCT05688293|Active Comparator|Connective tissue graft|Patients will receive non-surgical periodontal treatment and connective tissue graft using tunneling technique
32858945|NCT05688293|Active Comparator|Free gingival Graft|Patients will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
32858946|NCT05688293|Active Comparator|Non surgical procedure|Patients will receive non-surgical periodontal treatment only
32858947|NCT01148745|Other|ferumoxytol|FDA approved drug
32858948|NCT05685407|Experimental|Caffeine|During one of two counterbalanced experimental sessions, participants will ingest 300mg of caffeine.
32858949|NCT05685407|Placebo Comparator|Placebo|During one of two counterbalanced experimental sessions, participants will ingest placebo.
32858950|NCT04401215|Other|Technology Augmented Treatment group|Intervention Group
32858951|NCT04401215|No Intervention|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
32858952|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
32858953|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
32858954|NCT03697109|Experimental|Relacorilant (open-label phase)|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
32858955|NCT03697109|Experimental|Relacorilant (randomized-withdrawal phase)|Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
32858956|NCT03697109|Placebo Comparator|Placebo (randomized-withdrawal phase)|Placebo matched to study drug
32858957|NCT04348487|Other|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
32858958|NCT04761029|Active Comparator|grup R|Unilateral Rhomboid intercostal and subserratus block + intravenous patient-controlled analgesia
33408675|NCT05181397|No Intervention|Control|Participants in control group will receive regular treatment.
33408676|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
33408677|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
33408678|NCT02932891|Experimental|DSXS topical|active treatment
33408679|NCT04517903|Experimental|exploratory phase|eye rubbing questionnaire at baseline and 15 days later
32858959|NCT04761029|Placebo Comparator|Group P|intravenous patient-controlled analgesia
32858960|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
33408680|NCT04517903|Experimental|Confirmatory phase|eye rubbing questionnaire at baseline and at 6 month follow-up
33408681|NCT05181319||bronchopulmonary dysplasia group|infants diagnosed with bronchopulmonary dysplasia
32858961|NCT03384875|Placebo Comparator|Control|Standard of care
32858962|NCT05688137|Active Comparator|DRAINAGE GROUP (D)|This patients will take the abdominal drainage.
32858963|NCT05688137|No Intervention|NON DRAINAGE GROUP (ND)|This patients will not take the abdominal drainage.
32858964|NCT05688059|Experimental|Absorbable Suture|Absorbable suture for sacrospinous ligament suspension
32858965|NCT05688059|Experimental|Permanent Suture|Permanent suture for sacrospinous ligament suspension
33408682|NCT05181319||no bronchopulmonary dysplasia|infants not diagnosed with bronchopulmonary dysplasia
33408683|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
33408684|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
33408685|NCT05181241|Experimental|Group No. 1 (n=6) Dimolegin - 20 mg|Group No. 1 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 1 and 2 received Dimolegin (DD217) once at a dose of 20 mg
33408686|NCT05181241|Experimental|Group No. 2 (n=6) Dimolegin - 40 mg|Group No. 2 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 3 and 4 received Dimolegin (DD217) once at a dose of 40 mg
32858966|NCT05687981|Active Comparator|Patients will receive 10 ml of 0.5% bupivacaine|A 2mg dexamethasone will be added
32858967|NCT05687981|Active Comparator|Patients will receive 10 ml of 0.25% bupivacaine|A 2mg dexamethasone will be added
32858968|NCT05687825||Clinically relevant postoperative pancreatic fistula|patients who developed clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
32858969|NCT05687825||No clinically relevant postoperative pancreatic fistula|patients who did not develop clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
32858970|NCT05687747|Experimental|68Gallium-FAPI-46 PET/MRI|Patients receiving Ga68-FAPI-46 will be injected at a dose of 4mCi +/- 2mCi (0.05mCi/kg). Whole body PET scans will be acquired 45mins post injection from head to mid thighs
33408687|NCT05181241|Experimental|Group No. 3 (n=12) Dimolegin - 60 mg|Group No. 3 (n=12) consisted of 3 cohorts. Cohorts 5 and 6 included 3 volunteers per each, and Cohort 7 included 6 volunteers. All Group 3 volunteers received Dimolegin (DD217) once at a dose of 60 mg
33408688|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
33408689|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
33408690|NCT01314469||Patients with intermediate uveitis|
33408691|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
33408692|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
33408693|NCT03897673|Experimental|Early Iron|Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month.
33408694|NCT03897673|Experimental|Delayed Iron|Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.
33408695|NCT03897673|No Intervention|Community Control Children|Healthy, non-anemic community children will be enrolled from the same households and villages as the children with malaria. They will not have ZPP tested or receive iron, but they will also be under the same illness surveillance as the children with malaria.
33408696|NCT05328505|Experimental|Molecular Imaging Informed Radiation Dose Escalation and De-escalation|Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.
32858971|NCT05687669|Experimental|Group GTN|Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
32858972|NCT05687669|Experimental|Group Phentolamine|Phentolamine is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
32858973|NCT05687513|Experimental|treatment group|
32858974|NCT05687513|Placebo Comparator|control group|
32858975|NCT05687435|Experimental|Changyanning group|Changyanning tablet: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
33408697|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
33408698|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
32858976|NCT05687435|Placebo Comparator|Placebo group|Changyanning tablet placebo: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
32858977|NCT05687357|Experimental|Arm A: Tislelizumab + Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive 4 cycles of Tislelizumab 200 mg via intravenous (IV) infusion on C1D1, C2D1, C2D22, C3D1 PLUS radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C2D1~C2D5, C2D8~C2D12, C2D15~C2D19, C2D22~C2D26, C2D29~C2D33, C3D1~D14 and oxaliplatin 130mg/m^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C3D1~D14 and nab-paclitaxel, IV 100~120mg/m^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1, AND up to 16 cycles of Tislelizumab 200 mg via IV infusion on Day 1 Q3W."
32899120|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
33408699|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
33408700|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
32858978|NCT05687357|Active Comparator|Arm B: Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C2D1~C2D5, C2D8~C2D12, C2D15~C2D19, C2D22~C2D26, C2D29~C2D33, C3D1~D14 and oxaliplatin 130mg/m^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C3D1~D14 and nab-paclitaxel, IV 100~120mg/m^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
33321234|NCT05280938|Active Comparator|Educational Program|"The Education Program (attention control group) will be an 8-week educational program matched in duration and frequency to the MAAPI intervention. Session topics are:1) Perineum and Incision Care, 2) Safe Sexual Practices, 3) Understanding Infant Feeding Methods, 4) How to Communicate Effectively with your Child's Health Care Providers, 5) Healthy Eating, 6) Infant Changing and Baths, 7) Infant Safety at Home, and 8) Utilizing Support from Family and the Community.~Sessions will be given in groups by the same expert clinicians/educators for all cohorts. Subject receipt of the attention control will be monitored by attendance. Control group instructor will not include content on stress reduction or methods (yoga, meditation, etc.) taught in the MAAPI intervention. Classes will be given in the same setting as the MAAPI intervention, at the same time but on a different evening, to avoid crossover of effects."
32907530|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
33321235|NCT04668950|Experimental|Fluvoxamine|Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
33321236|NCT04668950|Placebo Comparator|Placebo|Start placebo one capsule, twice daily. May reduce dose for tolerability reasons. Will be followed in RCT for approximately 15 days.
33321237|NCT03078478|Experimental|IDeg 200 U/mL|
33321238|NCT03078478|Active Comparator|IGlar 300 U/mL|
33321239|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
33321240|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
33321241|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
33321242|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
33321243|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
33321244|NCT01349296|Experimental|BIBF 1120 + RAD001|
33321245|NCT04422964|Experimental|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
33321246|NCT04422964|No Intervention|control group|The standard procedure without the 3D obturator.
33321247|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
33321248|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
33321249|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
33321250|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
33321251|NCT03522844|Active Comparator|Escitalopram|
33321252|NCT02879578|Experimental|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
33321253|NCT02879578|Experimental|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
33321254|NCT02879578|Experimental|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
33321255|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
33321256|NCT01349374|Experimental|Group1|healthy volunteers
33321257|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
33321258|NCT01349374|Experimental|Group3|Type2 Diabetic patients
33321259|NCT01349374|Experimental|Group4|MODY patients
33321260|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
33321261|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
33408701|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
33408702|NCT02700035|No Intervention|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
33408703|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
33408704|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
33408705|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
33408706|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
33408707|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
33408708|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
33408709|NCT04495673|Experimental|tDCS with Cognitive Training|DLPFC stimulation with tDCS with simultaneous cognitive training
33408710|NCT04495673|Active Comparator|Sham tDCS with Cognitive Training|Sham tDCS with simultaneous cognitive training
33408711|NCT04270877|Experimental|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets once daily in the evening."
33408712|NCT04270877|Placebo Comparator|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
33408713|NCT04731077|Other|Avenir Complete Femoral Stem|All enrolled subjects receive the study implant
33408714|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
33408715|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
33408716|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
33408717|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
33408718|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
33408719|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
33408720|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
33408721|NCT03245723|Active Comparator|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
32858979|NCT05687357|Active Comparator|Arm C: Chemotherapy|"Neoadjuvant: S-1 initial dose depends on the body surface area, PO, bid, D1~D14，Q 3W for 6 cycles, and oxaliplatin 130mg/m^2, IV, D1 of each cycle for 6 cycles OR nab-paclitaxel, IV 100~120mg/m^2，IV，D1 and D8 for each cycle for 6 cycles.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
32858980|NCT05687201||APOE-E4 (ε2/ε4,ε3/ε4,ε4/ε4) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
32858981|NCT05687201||APOEε3(ε3/ε3) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
32858982|NCT05687123|Experimental|Treatment (sunitinib malate, lutetium Lu 177 dotatate)|Patients receive sunitinib malate PO and lutetium Lu 177 dotatate IV on study. Patients undergo a CT scan and/or MRI throughout the trial. Patients also undergo a SSR PET/CT scan during screening and blood sample collection on study.
32858983|NCT05687045|Experimental|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
33408722|NCT03245723|Placebo Comparator|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
33408723|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
33408724|NCT05003921|Experimental|Treatment Group|three intrathecal injections of 50 million cells at two-month intervals.
33408725|NCT04237649|Experimental|Arm A|KAZ954
33408726|NCT04237649|Experimental|Arm B|KAZ954 + PDR001
33408727|NCT04237649|Experimental|Arm C|KAZ954 + NIR178
33408728|NCT04237649|Experimental|Arm D|KAZ954 + NZV930
33408729|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
33408730|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
33408731|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
33408732|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
33408733|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
33408734|NCT04647617|Experimental|Quantitative Weight-bearing|Experimental wearing 0.5 kg quantitative sandbag 12~15 Repetitions/set X 5 set X 3day. Weight adjustment: After the first month of intervention, if the experimental can perform for more than 20 repetitions/set , we will asked to increase the weight of the sandbag to 1 kg until the end of the experiment
33408735|NCT04647617|Placebo Comparator|Control group|They are keep their normal live style
33408736|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
33408737|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
32858984|NCT05687045|Active Comparator|Standard Treatment|If peripheral oxygen saturation will be < 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
33408738|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
32858985|NCT05686967|Experimental|Aerobic Exercise plus MitoQ|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus experimental MitoQ, 20mg/d.~Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks."
32858986|NCT05686967|Placebo Comparator|Aerobic Exercise plus Placebo|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus matching placebo capsule/d for 10 weeks.~Matched placebo capsules."
33408739|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
33408740|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
33408741|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
33408742|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
33408743|NCT05070390|Experimental|Panel A- Moderate RI|Single dose of MK-0616 10 mg
33408744|NCT05070390|Experimental|Panel B- Healthy Controls|Single dose of MK-0616 10 mg
33408745|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
33408746|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
33408747|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
33408748|NCT03764137|Experimental|[89Zr]Panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
33408749|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
33408750|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
33408751|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
33408752|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
33408753|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
33408754|NCT03469297|Experimental|Brown Glaucoma Implant|
33408755|NCT00972738|Experimental|1|montelukast
33408756|NCT00972738|Active Comparator|2|loratadine
33408757|NCT00972738|Placebo Comparator|3|placebo
33408758|NCT03452839|Experimental|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day~for ClCr > 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.~for ClCr < 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
33408759|NCT03452839|Active Comparator|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):~for Cl-Cr > 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after~for Cl-Cr < 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
33408760|NCT04701281|Experimental|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
32858987|NCT05686967|Experimental|No Exercise plus MitoQ|No exercise plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.
32858988|NCT05686889|Experimental|Success|Symptomatic improvement present
32858989|NCT05686889|Experimental|Failure|Symptomatic improvement absent
32858990|NCT04400825|Experimental|Dry needling|Dry needling of 3 active MTrPs at most.
32858991|NCT04400825|Active Comparator|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
33408761|NCT05012670|Experimental|[14C]-Paxalisib Capsule|Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
33408762|NCT04313478||Low Birth Weight Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
33408763|NCT04313478||Normal Weight Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
33408764|NCT05180929|Experimental|Dual-M1 tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
33408765|NCT05180929|Experimental|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
33408766|NCT05180929|Sham Comparator|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
33408767|NCT04249830|Experimental|Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
33408768|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
33408769|NCT04168632|Experimental|Intervention|A new 4-week menu plan
33408770|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
33408771|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
33408772|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
33408773|NCT04907045|Experimental|Standard Implementation Plus Health Coaching|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
33408774|NCT04907045|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
33408775|NCT03345420|Experimental|Treatment (hypofractionated radiation therapy)|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
33408776|NCT04188743|Experimental|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
32858992|NCT05686811|Active Comparator|Myofascial release therapy|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
32858993|NCT05686811|Experimental|post isometric relaxation technique|This group will receive routine physical therapy with post isometric relaxation technique.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
32858994|NCT04400747|Experimental|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
32858995|NCT04400747|Experimental|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
32858996|NCT04400747|No Intervention|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
32858997|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
33408777|NCT04188743|Placebo Comparator|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
33408778|NCT04188743|No Intervention|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
33408779|NCT05282329|Experimental|tACS group|Participants receive tACS 20-min sessions in a 5-day sequence for four consecutive weeks,combined with original and stable medication. Active group participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
33408780|NCT05282329|Sham Comparator|Sham group|Controls received sham stimulation with the same protocol.
33408781|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumor
33408782|NCT04187651|Experimental|PRP gel application|PRP application for perianal fistula
33408783|NCT04180397|Active Comparator|Furosemide|Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
33408784|NCT04180397|Placebo Comparator|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
33408785|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
33408786|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
33408787|NCT04174859||NVAF patients|Start treatment with rivaroxaban at the discretion of physician.
33408788|NCT04629911|Experimental|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
33408789|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
33408790|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
33408791|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
33408792|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
33408793|NCT05065242|Experimental|Cognitive Behavioural Therapy|Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities.
33408794|NCT05065242|No Intervention|Waitlist|The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group.
33408795|NCT03295721|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
33408796|NCT03295721|Placebo Comparator|Treatment Group 2: Saline Placebo|Saline placebo
33408797|NCT03295721|Active Comparator|Treatment Group 3: Bupivacaine HCI|Bupivacaine HCl
33408798|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
32964045|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
33408799|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
33408800|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
33408801|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
33408802|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
33408803|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
33417268|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
33417269|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
32964046|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
32964047|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
33321262|NCT00045942|Experimental|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
33321263|NCT00045942|Experimental|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
33321264|NCT00045942|Experimental|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
33321265|NCT00045942|Experimental|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
33321266|NCT00045942|Experimental|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
33321267|NCT00045942|Experimental|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
33321268|NCT00045942|Experimental|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
33321269|NCT00045942|Experimental|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
33321270|NCT00045942|Experimental|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
33321271|NCT04386616|Placebo Comparator|All Placebo|Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
33321272|NCT04386616|Experimental|MSTT1041A|Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
33321273|NCT04386616|Experimental|UTTR1147A|Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
33321274|NCT00045708|Experimental|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
33321275|NCT00045708|Experimental|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
33321276|NCT00045708|Experimental|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B~Drug: ixabepilone~Other Names:~BMS-247550 epothilone B lactam Ixempra Given IV"
33321277|NCT01349452|Experimental|Ganciclovir|
33321278|NCT01349452|Sham Comparator|Artificial tear|
33321279|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
33321280|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
33321281|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
33321282|NCT00045630|Experimental|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
33321283|NCT01357252|Experimental|vildagliptin|
33321284|NCT01357252|Placebo Comparator|placebo|
33321285|NCT01349608|Experimental|Health coaching|
33321286|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
33321287|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
33321288|NCT01098552||High-risk radical prostatectomy patients|
33321289|NCT01098552||Primary external beam radiotherapy patients|
33321290|NCT01098552||Primary prostate brachytherapy patients|
33321291|NCT01098552||Hormone refractory prostate cancer patients|
33321292|NCT01098552||Active Surveillance|
33417270|NCT05190913|Experimental|Initiative group I|In the active phase of labor, perineal massage will be performed with the device at an interval of one hour.
33321293|NCT01098552||Prostate biopsy patients|
33321294|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
33408804|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
33408805|NCT04427891||Group I|"Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis.~No intervention, samples from abdominal fluid, blood, tissue, feces"
33408806|NCT04427891||Group II|Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I
33408807|NCT04427891||Group III|Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.
33408808|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
33408809|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
33408810|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
33408811|NCT03506412|Experimental|Low Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml
33408812|NCT03506412|Experimental|High Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP greater than or equal to 0.9 ng/ml
33408813|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
33408814|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
33408815|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
33408816|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
33408817|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
33408818|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
33408819|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
33408820|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
33408821|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
33408822|NCT04964778|Experimental|Arm1: SKED© only first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 1 will be in the following order: SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding
33408823|NCT04964778|Experimental|Arm 2: SKED©+Vacuum mattress first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 2 will be in the following order: SKED©+Vacuum mattress; SKED©+OSS-II©; SKED©+foam padding, SKED© only
33408824|NCT04964778|Experimental|Arm 3: SKED©+OSS-II© first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 3 will be in the following order: SKED©+OSS-II©;SKED©+Vacuum mattress; SKED© only; SKED©+foam padding
33408825|NCT04964778|Experimental|Arm 4: SKED©+foam padding first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 4 will be in the following order: SKED©+foam padding, SKED©+Vacuum mattress; SKED© only; SKED©+OSS-II
33408826|NCT04961112|Experimental|Experimental - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
33408827|NCT04961112|Experimental|Experimental - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
33408828|NCT04961112|Sham Comparator|Sham - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
33408829|NCT04961112|Sham Comparator|Sham - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
33408830|NCT02316834|Experimental|BMN 673|
33408831|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
32964048|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
33408832|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
33408833|NCT05059158||Alzheimer's Disease|Patients with a Alzheimer's Disease diagnosis
33408834|NCT05059158||Mild Cognitive Impairment|Patients with a mild cognitive impairment diagnosis
33408835|NCT05059158||Subjective Cognitive Decline|Patients with a subjective cognitive decline diagnosis
33408836|NCT05054010||Early Breast Cancer patients|Early stage breast cancer category is based on the definition of the European Society of medical Oncology and is defined as disease confined to the breast with or without regional lymph node involvement
33408837|NCT05054010||Metastatic Breast Cancer patients|Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.
33408838|NCT05054010||Healthy donors|Participants who are in good health and without history of cancer disease
33408839|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
33408840|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
33408841|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
33408842|NCT00250458|Experimental|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
33408843|NCT00250458|Placebo Comparator|2|matching placebo
33408844|NCT01965132||Biologic or targeted synthetic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biolsimilars) or a targeted synthetic DMARD
33408845|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
33408846|NCT01667133|Experimental|Phase 2 expansion|Phase 2
33408847|NCT05109741|Experimental|Internet-based Psychodynamic Therapy|"This is a 10-week treatment based on the psychodynamic SUBGAP model (Seeing, Understanding, Breaking, and Guarding Against Patterns) by Farrell Silverberg (2005). The treatment has been evaluated in two previous randomized controlled trials.~Silverberg, F. (2005). Make the leap: A practical guide to breaking the patterns that hold you back. Da Capo Press.~Andersson, G., Paxling, B., Roch-Norlund, P., Östman, G., Norgren, A., Almlöv, J., ... & Silverberg, F. (2012). Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial. Psychotherapy and psychosomatics, 81(6), 344-355.~Johansson, R., Ekbladh, S., Hebert, A., Lindström, M., Möller, S., Petitt, E., ... & Andersson, G. (2012). Psychodynamic guided self-help for adult depression through the internet: a randomised controlled trial. PloS one, 7(5), e38021."
33408848|NCT05109741|Active Comparator|Internet-based Behavioral Activation|"This 10-week treatment is based on the BATD-R (Behavioral Activation Treatment for Depression - Revised) treatment by Lejuez and others (2011).~Lejuez, C. W., Hopko, D. R., Acierno, R., Daughters, S. B., & Pagoto, S. L. (2011). Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behavior modification, 35(2), 111-161."
33408849|NCT05109741|No Intervention|Waiting-list|Participants will be in a 10-week waiting period.
33408850|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
33408851|NCT03947775|Experimental|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
33408852|NCT03947775|Active Comparator|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 12, dose #2 at month 14, and dose #3 at month 18.
33408853|NCT01891344|Experimental|Ovarian cancer|rucaparib
33408854|NCT01498770||Asenapine|
33408855|NCT01498770||Aripiprazole|
33408856|NCT01498770||Quetiapine|
33408857|NCT01498770||Risperidone|
33408858|NCT01498770||Olanzapine|
33408859|NCT01498770||Ziprasidone|
33408860|NCT01498770||Iloperidone|
33408861|NCT01498770||Paliperidone|
33408862|NCT01498770||Lurasidone|
33408863|NCT01498770||Clozapine|
33408864|NCT01498770||Amisulpride|
33408865|NCT01498770||Sertindole|
33408866|NCT01498770||Zotepine|
33408867|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Doses of bortezomib given is 1.3 mg/m2 weekly x 4 weeks given every 3 month x 8 cycles. Doses of RITUXAN given is 375 mg/m2 give weekly x 4 weeks given every 6 month for 4 cycles.
33408868|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
33408869|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
33408870|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
33408871|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
33408872|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
33408873|NCT00092118|Experimental|1|Montelukast
33408874|NCT00092118|Placebo Comparator|2|Placebo
33408875|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
33408876|NCT05167578||Patients with multimorbidity|Patients with multimorbidity who visit the public health centres in Vantaa, Southern Finland
33408877|NCT05150964|Experimental|Experimental|One group will be fit with commercially available hearing aids that will have different program settings
33408878|NCT05225688||PASC patients|Non-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19
33408879|NCT05225688||Healthy controls|Non-hospitalized covid-19 patients without residual symptoms
33408880|NCT04925154||Group A: Patients|Recruitment for this group will take place at either the radiation-oncology department or at the colorectal surgery department, at the time of consultation or at the time of diagnosis, before the treatment setting. Once clinical staging is available, the surgeon and/or radiation-oncologist and/or research assistant should identify eligible patients. Patients that comply with selection criteria (inclusion/exclusion) will be approached by a research team member. For those patients interested in participating, the e-link to the consent form for this group will be sent by email. Once a patient decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
33408881|NCT04925154||Group B: Physicians|Health professionals will be approached by the research team. The study aim will be explained, and participants that agree to participate will be provided an e-link to consent for this group. Once the health care participant decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
33408882|NCT05582928|Experimental|healthy population group|"The experimental design includes three sessions:~session 1 will be used to evaluate diagnostic using different targeted questionnaires.~sessions 2 and 3 will be decomposed into 3 consecutives parts:~Pre evaluation~Neurofeedback~Post evaluation"
33408883|NCT05582928|Experimental|ADHD population group|"The experimental design includes three sessions:~session 1 will be used to evaluate diagnostic using different targeted questionnaires.~sessions 2 and 3 will be decomposed into 3 consecutives parts:~Pre evaluation~Neurofeedback~Post evaluation"
33408884|NCT04051008|No Intervention|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
33408885|NCT04051008|Experimental|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
33408886|NCT04051008|Experimental|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
33408887|NCT04914780|Experimental|Intervention group|4 weeks training with mobile application
33408888|NCT04914780|No Intervention|Control group|No intervention will be made for 4 weeks
33408889|NCT05225142|Experimental|Modified minimally invasive surgery alone|Modified minimally invasive surgery alone for access and debridement of intrabony defect. This approach maximises wound stability. No application of regenerative biomaterial.
33408890|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative (regenerative biomaterial)
33408891|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative and bone replacement graft (regenerative biomaterial)
33408892|NCT03261947|Experimental|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
33408893|NCT03261947|Experimental|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
33408894|NCT03261947|Experimental|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
33408895|NCT03261947|Experimental|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
33408896|NCT03261947|Experimental|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
33408897|NCT05654844|Other|Digital Lateral Cephalometry|Patients justifying the indication for LC and CBCT exposure
33408898|NCT05224284|Other|BPA level|BPA (Bisfenol A) in blood and ejaculate samples
33408899|NCT05224128|Experimental|Imatinib Drug|Standard medication of liver fibrosis + Imatinib 200 mg 1 time a day.
33408900|NCT05224128|Placebo Comparator|Placebo|Standard medication of liver fibrosis + placebo as a control group.
33408901|NCT04976946||Urologists|Local and international consultant Urologists and accredited Urology trainees.
33408902|NCT04976946||Anaesthetists|Local and international consultant anaesthetists. Critical care physicians who are primarily Urological anaesthetists or have experience in complication reporting will be targeted.
33408903|NCT04976946||ICU specialists|Local and international consultant ICU specialists. Critical care physicians who are primarily Urological focused or have experience in complication reporting will be targeted.
33408904|NCT04949880|Experimental|Group A|Neurovascular Drug-Eluting Balloon Dilatation Catheter
32858998|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
32858999|NCT05686655||diabetes children|
32859000|NCT03372161|Experimental|SP-102|SP-102
33408905|NCT04050852|Experimental|SMA patients receiving nusinersen treatments|
33408906|NCT04051086|Other|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
33408907|NCT04051086|Other|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
33408908|NCT04051086|Other|Healthy Group|Subjects without cardiovascular and neurological medical history.
33408909|NCT05223660|Experimental|Low dose KT07|KT07 single dose (4 capsules) followed by multiple doses for 5 days (tid)
33408910|NCT05223660|Experimental|High dose KT07|KT07 single dose (6 capsules) followed by multiple doses for 5 days (tid)
33408911|NCT05223660|Placebo Comparator|Low dose placebo|Placebo single dose (4 capsules) followed by multiple doses for 5 days (tid)
33408912|NCT05223660|Placebo Comparator|High dose placebo|Placebo single dose (6 capsules) followed by multiple doses for 5 days (tid)
33408913|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
33408914|NCT05520138||Enzalutamide cohort|Patients with mCRPC initiating enzalutamide
33408915|NCT05520138||Abiraterone cohort|Patients with mCRPC initiating abiraterone
33408916|NCT05518968|Experimental|Acceptance and Commitment Therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
33408917|NCT05516316|Experimental|EP395 high dose|EP395 in repeated doses. Orally, once-daily administration of 3 EP395 capsules for 21 days
33408918|NCT05516316|Experimental|EP395 low dose|EP395 in repeated doses. Orally, once-daily administration of 1 EP395 capsule and 2 placebo capsules for 21 days
33408919|NCT05516316|Placebo Comparator|Placebo|Matched placebo capsule, once-daily administration of 3 placebo capsules for 21 days
33408920|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
33408921|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
33408922|NCT04896918||Cohort of adult client of public dental clinics in Region Stockholm|Tobacco use (cigarette smoking and/or snus use) will be considered as exposure. Information on tobacco use will be extracted by public dental clinic records in Stockholm Region (October 2015-January 2020). Any diagnosis of COVID-19, hospitalization, receiving intensive care, and death because of COVID-19 will be examined as outcomes. Diagnoses of COVID-19 will be obtained through record linkage with health care registers of inpatient and outpatient care (February 2020-August 2021).
33408923|NCT05223426|Experimental|Cognitive training followed by usual care|Usual care and cognitive training for 6 weeks, followed by usual care (only) for 6 weeks.
33408924|NCT05223426|Experimental|Usual care followed by cognitive training|Usual care (only) for 6 weeks, followed by cognitive training and usual care for 6 weeks.
33408925|NCT04897776|Experimental|Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at a therapeutic level established based on the physician's evaluation and patient specific parameters established at a previous visit. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
33408926|NCT04897776|Sham Comparator|Non-Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at below therapeutic threshold to control for implant and placebo effects. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
33408927|NCT04886856|Experimental|Mindful Moms|"Weekly Mindful Moms sessions"
33408928|NCT04886856|Active Comparator|Prenatal Education|Weekly prenatal education sessions
33408929|NCT04856904|Placebo Comparator|Trifarotene Vehicle Cream|
32859001|NCT03372161|Placebo Comparator|Placebo|Placebo
32859002|NCT05686577||learning database group|The results of blood cultures and the clinical elements of the patients in the first sample (1600 patients) will constitute the learning database. A supervised learning will be performed on these data in order to select a set of clinical elements allowing to define a predictive score of positive blood cultures
32859003|NCT05686577||validation database group|The score will be validated on the remaining sample (800 patients), independent of the first sample. Both samples will be constituted by randomization.
32859004|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
33408930|NCT04856904|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
33408931|NCT04852848|Experimental|Connect2Test Intervention|A brief MI intervention to motivate individuals to participate in COVID-19 testing after receiving syringe exchange services
33408932|NCT04852848|No Intervention|Control|Services as usual
33408933|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
33408934|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
33408935|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
33408936|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
33408937|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
33408938|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
33408939|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
33408940|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
33408941|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
33408942|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
33408943|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
33408944|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
33408945|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
33408946|NCT04802304|Experimental|Treatment|
33408947|NCT04802304|No Intervention|Control|
33408948|NCT05221944||Patients on antithrombotic therapy|The study aimed to investigate if perioperative bleeding complications were more common in patients on antithrombotic therapy. We retrospectively reviewed patients with IC/BPS who underwent hydrodistension during January 2010 and May 2021. Patients with and without antithrombotic drugs were identified and grouped and their medical records were reviewed.
33408949|NCT05221944||Patients without antithrombotic therapy|Patients without antithrombotic drugs were identified as controls
33408950|NCT05416827|Active Comparator|PPV group|Epiretinal membrane eyes underwent PPV
33408951|NCT05416827|Experimental|PPV+implant Group|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
33408952|NCT05472792|Active Comparator|Endocrine Therapy|Endocrine therapy will be chosen by the treating medical oncologist with an aim of 5 years duration, as tolerated by the patient.
33408953|NCT05472792|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI will consist of 5 fractions of radiation therapy delivered every other day to the lumpectomy cavity.
33408954|NCT05626803|Experimental|Open Label Sentinel|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (sentinel n=10)
33408955|NCT05626803|Experimental|Medium Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets total dose is 1×10 to the power 11 IU/dose (N=50)
33408956|NCT05626803|Experimental|High Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (N=50)
33408957|NCT05626803|Placebo Comparator|Placebo Arm|Placebo tablets (N= 25)
33408958|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
33408959|NCT04982250|Experimental|"Formal peer PrEP referral + HIVST delivery"|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
33408960|NCT04982250|No Intervention|"Informal peer PrEP referral"|Young female PrEP users will be encouraged to refer 4 peers to PrEP using informal word-of-mouth recruitment strategies and Kenya MOH-style referral cards.
33408961|NCT05416671|Experimental|Treatment group|
33408962|NCT05416671|No Intervention|Control group|
33408963|NCT05079477|Active Comparator|Calorie label|"Calorie label (control) will display a calories per package label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels. Additionally, all snack items will have a calories per serving label."
33408964|NCT05079477|Experimental|Sugar graphic warning label|"All products in this arm will also have calorie labels. Beverages with added sugar will also have sugar graphic warning labels with the text: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay along with graphics depicting the amount of sugar in the beverage."
33408965|NCT05197530|Experimental|Early RA (<1 year of disease)|In this single center study, early RA subjects (<1 year of disease) who are MTX inadequate responders or experience a flare (see inclusion criteria for detail) on MTX and are starting an anti-TNF therapy will be invited to participate to receive ICG injections at Baseline (prior to the start of medication), week 16 and week 52. NIR-ICG imaging will be done immediately post injection and 1 week later for a total of three injection/imaging visits and three imaging visits without injections. See schedule of events for more detail. Total length of participation will be up to 53 weeks (+3days).
33408966|NCT05197530|Experimental|Established RA (> 10 years of disease)|Patients with symptomatic established RA (>10 years) will be invited to participate in an ICG injections followed by NIR-ICG imaging and NIR-ICG imaging visit 1 week later. Total length of participation will be up to 1 week (+3 days)
33408967|NCT04958421|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
33408968|NCT04958421|Experimental|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
33408969|NCT04980690|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~Acceleration Stage: The initial increasing dose is 0.025 mg/kg, and the dose is increased in 100% increments. Each dose group will enroll 1 subject."
33408970|NCT04980690|Experimental|Phase Ia - Dose escalation(3+3 Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~3+3 Stage: The dose is increased in 30%-50% increments between adjacent dose groups, and the increment is determined by the investigator and the sponsor based on the safety data obtained in the previous period.Each dose group will enroll 3 to 6 evaluable subjects (evaluable: at least complete the DLT observation period), and this period continues until the maximum tolerated dose (MTD) is reached."
33408971|NCT04980690|Experimental|Phase Ib - Dose extension|"Phase Ib is an open, non-random, single-arm, multi-center research design.~When phase Ia is transformed into 3+3 stage, a certain dose group meets the conditions for increasing the next dose group (after the DLT observation period of the last subject in the dose group has passed, the safety assessment of the current dose group will be completed) , The dose extension study of this dose group can be carried out, and 6 evaluable (evaluable: at least 2 cycles of dosing and observation) subjects with advanced malignant tumors who have failed standard treatments will be included in this dose group."
33408972|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group A)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group A: Recurrent or metastatic triple-negative breast cancer that failed standard treatment."
33408973|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group B)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group B: Locally advanced/metastatic non-small cell lung cancer without driver gene mutations that failed standard treatment."
33408974|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group C)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatment."
33408975|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group D)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group D: Recurrent or metastatic peripheral T-cell lymphoma that failed standard treatment."
33408976|NCT05076513|Experimental|Arm A: Presumed Newly-Diagnosed glioblastoma|Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
33408977|NCT05076513|Experimental|Arm B: Recurrent Glioma (Grades II-IV)|Participants undergoing resection of a recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss will be treated with niraparib for 4 days prior to a planned surgical resection. Participants who proceed to the Expansion cohort will receive niraparib in 28d cycles after surgery.
33408978|NCT05450094|Active Comparator|Comparator|The comparator arm enhances school-based mental health (SBMH) with universal screening and trains voluntary school teams to use the school-wide data to plan and make intervention referrals using an evidence-based in-service training and coaching model called Team-Initiated Problem Solving (TIPS).
33408979|NCT05450094|Experimental|Enhanced|The enhanced arm involves the enhancements to school-based mental health (SBMH) of the comparator arm with the addition of 3 additional empirically supported enhancements to mental health screening: 1) voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities; 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias; and 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
33408980|NCT04958265|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
33408981|NCT04621266|Experimental|Online Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
33408982|NCT04621266|No Intervention|Standard usual care|Participants will receive standard usual care.
33408983|NCT04979910|Active Comparator|Ixekizumab|Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.
33408984|NCT04979910|Placebo Comparator|Placebo|Matching saline placebo at Week 0 (two injections), followed by one injection at Weeks 2 and 4 via subcutaneous route.
32859005|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
32859006|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
32859007|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
33408985|NCT01119183|No Intervention|1|
33408986|NCT01119183|Active Comparator|2|
32859010|NCT04279457|Active Comparator|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
32859011|NCT04279457|Active Comparator|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
32859012|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
32859013|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
32859014|NCT05686343||Treated|
32859015|NCT05686343||Untreated|
32859016|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
32859017|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
33408987|NCT01119183|Experimental|3|
33408988|NCT04978818|Active Comparator|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
33408989|NCT04978818|Active Comparator|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
33408990|NCT05422794|Experimental|Dose Escalation (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on day 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo CT or MRI scan and collection of blood samples throughout the trial.
33408991|NCT05422794|Experimental|Dose Expansion (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-7 prior to combination therapy. Patients then receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on days 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo biopsies on study, and CT or MRI scans and collection of blood samples throughout the trial.
33408992|NCT05066919|Experimental|Operative treatment|Patients treated with open plantar fasciotomy
33408993|NCT05066919|Active Comparator|Conservative treatment|Patients treated non-operatively with exercise
33408994|NCT05422482|Experimental|GC1123 30mg|30 mg of IP will be administered every 28 days for 6 patients enrolled in Group 1
33408995|NCT05422482|Experimental|GC1123 30mg + GC1123 45mg|"30 mg of IP will be administered twice every 28 days for 2 patients enrolled in Group 2~45 mg of IP will be administered twice, and any DLT occurrence will be followed-up until 4 weeks after the 2nd 45 mg dose on the 2nd patient.~DSMB will determine whether to proceed the administration after reviewing safety and tolerability data from 1) and 2).~Group 2 will continue to receive 45 mg of IP administration"
33408996|NCT05422482|Experimental|GC1123 45mg|45 mg of IP will be administered every 28 days for 4 patients enrolled in Group 3
33408997|NCT05418465|Experimental|Huangqi Guizhi Wuwu decoction group|Huangqi Guizhi Wuwu decoction
33408998|NCT05418465|Active Comparator|Dapagliflozin group|Dapagliflozin
33408999|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
33409000|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
33409001|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
33409002|NCT05400330|Experimental|Previously administered LX1001|"This is a long-term follow-up study to evaluate the safety following LX1001, a gene therapy, for participants who are APOE4 homozygotes with clinical diagnoses varying from MCI or dementia due to AD who have previously received LX1001. Study LX1001-01 was designed to assess the safety of LX1001 at 3 ascending doses (5.0 x 1010, 1.6 x 1011, 5.0 x 1011 gene copy [gc]/mL CSF), with each group consisting of approximately n=5 individuals for a total of approximately 15 participants for the entire study.~In this study, participants who have received LX1001 in the parent protocol (LX1001-01) will be followed for up to 260 weeks post gene therapy administration"
33409003|NCT05416359|Experimental|TQB3915 tablets|Take 300mg, 450mg, 600mg, 750mg, 900mg each time, once a day;Oral administration on an empty stomach, 28 days as a cycle. Duration of medication: Continue medication until disease progression or intolerable toxicity occurs.
33409004|NCT05391126|Experimental|Genocare Guided|
33409005|NCT05391126|No Intervention|Usual Care|
33409006|NCT05418309|Experimental|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
33409007|NCT05137548|Experimental|ATI-2173.|ATI-2173
33409008|NCT05137548|Experimental|Tenofovir Disoproxil Fumarate|Tenofovir disoproxil fumarate
33409009|NCT05416047||Frail and no frail|Frailty will be assessed using Rockwood Clinical Frailty Score
33409010|NCT05416047||Sarcopenia and no sarcopenia|Sarcopenia will be assessed using psoas muscle mass
33409011|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
33409012|NCT04534842|Experimental|SYNB1618|Dose ramp of SYNB1618
33409013|NCT04534842|Experimental|SYNB1934|Dose ramp of SYNB1934
33409014|NCT05044611|Experimental|Amiloride|the experimental arm will receive 5mg of amiloride twice daily during 2 months
33409015|NCT05044611|Placebo Comparator|Placebo|the control arm will receive a placebo twice daily during 2 months
33409016|NCT05091294|Active Comparator|Group S:33|120-second local anesthesic (% 0,5 Bupivacaine) injection time
33409017|NCT05091294|Active Comparator|Group F:34|15-second local anesthesic(% 0,5 Bupivacaine) injection time
33409018|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
33409019|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
33409020|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
33409021|NCT04520178|Active Comparator|Low-dose 5HTP|50mg 5-HTP in combination with 50mg carbidopa
33409022|NCT04520178|Active Comparator|High-dose 5HTP|100mg 5-HTP in combination with 50mg carbidopa
33409023|NCT04520178|Sham Comparator|Carbidopa|50mg carbidopa only
33409024|NCT04520178|Placebo Comparator|Placebo|Placebo comparator
33409025|NCT05021133|Other|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
33409026|NCT04505891|No Intervention|Usual care|
33409027|NCT04505891|Active Comparator|Education alone|
33409028|NCT04505891|Active Comparator|Education and follow-up|
33409029|NCT04872543|Experimental|ASTX727 (cedazuridine and decitabine)|Patients who meet the eligibility criteria will be treated with oral ASTX727 (INQOVI) on days 1-5 of each 21-day cycle with Pegfilgrastim support on day 7. A delay in the start of subsequent cycles due to holidays, weather, or other circumstances will be permitted up to 7 days and not considered a protocol deviation. Drug dosing will be interrupted for any Grade 4 adverse events or clinically significant laboratory abnormalities. For Grade 3 or 4 AE, if the AE returns to Grade 1 or baseline, the patient may be re-escalated.
33409030|NCT05340894|Active Comparator|Mckenzie group|"adolescents will receive 4 weeks Mckenzie exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
33409031|NCT05340894|Active Comparator|William's group|"adolescents will receive 4 weeks William's exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
33417271|NCT05190913|Experimental|Initiative group II|During the active phase of labor, manual perineal massage will be performed with an interval of one hour.
32859018|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
33409032|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
33409033|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
33409034|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
33409035|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
33409036|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
33409037|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
33409038|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
33409039|NCT05044650|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days combined with background treatment
33409040|NCT05044650|No Intervention|NON-KOVIR|Only background treatment
33409041|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
33409042|NCT05320926|Experimental|Short-term DAPT followed by clopidogrel monotherapy|atients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop aspirin and maintain clopidogrel after DAPT.
33409043|NCT05320926|Active Comparator|Short-term DAPT followed by aspirin monotherapy|Arm Description: Patients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop clopidogrel and maintain aspirin after DAPT.
33409044|NCT05415891|Experimental|Stigma-Reduction Training Arm + YouRx Prescribing Platform|"Staff working in the clinic in this arm will be offered a whole-site stigma reduction training.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
33409045|NCT05415891|Experimental|YouRx Prescribing Platform Only|"Staff working in the clinic in this arm will not be offered a whole-site stigma reduction training. However, staff will be offered this training at the conclusion of the study.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
33409046|NCT04486391|Experimental|Tislelizumab|Tislelizumab monotherapy for up to 45 months
33409047|NCT04486391|Experimental|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
33409048|NCT05418075|Experimental|Home Treatment as add on to Familiy-based Treatment|
33409049|NCT05418075|Active Comparator|Familiy-based Treatment|
33409050|NCT05418075|Active Comparator|Mindfulness based stress reduction training|
33409051|NCT04928118||Impella protected Percutaneous coronary intervention (PCI)|Patients undergoing Impella protected PCI as deemed necessary by interventional cardiologist - VCU Medical Center case based standard of care
33409052|NCT04375553|Active Comparator|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
33409053|NCT04375553|No Intervention|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
33409054|NCT05296512|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~The names of the study drugs involved in this study are:~Lenvatinib~Pembrolizumab~Treatment will continue until progression of disease or unacceptable toxicity. Participants will be followed for up to 36 months after discontinuation of study treatment."
33409055|NCT05417997|Experimental|Research Arm|"Kunamin® 20 capsules 500mg daily plus; Standard therapy interventions determined and prescribed by investigators including:~Favipiravir: 1,600 mg (8 tablets) by mouth twice daily for 5 days.~Enoxaparin: 40 mg SQ daily if D-dimer < 3000 ng/mL *or* plt < 100,000~Enoxaparin: 0.5 mg/kg SQ twice daily if D-dimer >3000 ng/mL *and* plt < 100,000~Lansoprazole: 30 mg (one tablet) by mouth, once a day for 7 days.~Paracetamol: 500 mg (one tablet) by mouth, up to one tablet every 4 to 6 hours in case of fever (100.4°F/38°C or higher).~Ceftriaxone: 500 mg IV once a day for 5-7 days.~Clarithromycin: 250 mg (one tablet) twice a day for 5-7 days.~Methylprednisolone: 80 mg/kg IV bolus, followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h."
33409056|NCT05417997|Placebo Comparator|Control arm|"According to MOH of Turkey, which required a standard treatment including the following drugs as placebo:~Favipiravir~Enoxaparin~Enoxaparin~Lansoprazole~Paracetamol~Ceftriaxone/ Clarithromycin~Methylprednisolone"
33409057|NCT04292574||Participants with Spinal Muscular Atrophy|
33409058|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
33409059|NCT03292913|Other|Control Group|Receives standard of care
33409060|NCT04871451|Experimental|ABP-450 - Between Low Dose and High Dose|ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles with investigator's determined dose within the range of low dose and high dose - 4 injection cycles at 3-month intervals.
33409061|NCT04999839|Placebo Comparator|Placebo|Placebo of NDI-034858 study drug - Approximately 50 subjects will receive placebo, orally administered QD for 12 weeks.
33409062|NCT04999839|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug - orally administered QD for 12 weeks.
33409063|NCT04999839|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug - orally administered QD for 12 weeks.
33409064|NCT04999839|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug - orally administered QD for 12 weeks.
33409065|NCT04999839|Experimental|NDI-034858 study drug - Dose 4|NDI-034858 study drug - orally administered QD for 12 weeks.
33409066|NCT04167995|Active Comparator|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks added to standard treatment
33409067|NCT04167995|No Intervention|ADHD not receiving probiotics|ADHD patient (40) on standard treatment
33409068|NCT03704844||Patients with renal congestion|
32859019|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
32859020|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
32859021|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
32859022|NCT05686265||Patients|Patients with SAH (see eligibility criteria below).
32859023|NCT05686265||Controls|Healthy controls (see eligibility criteria below).
32859024|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
33321295|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
33321296|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
32859025|NCT05686187|Experimental|AR's platform for gender empowerment|The experimental group's intervention consists of a course that embraces AR's platform for gender empowerment. The intervention course will require 50-60 minutes for preliminary planning, and participants in the experimental group can design at least three course modules to suit their learning needs.
32859026|NCT05686187|No Intervention|control group|The control group will adopt the classroom narration method.
33321297|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
33321298|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until the participant is transitioned to ixazomib through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
33321299|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
33321300|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
33321301|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
33321302|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
33321303|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
33321304|NCT01317862|Active Comparator|Transcervical foley catheter|
33321305|NCT01317862|Active Comparator|Prostaglandins|
33321306|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
33321307|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
33321308|NCT00003702|Experimental|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
33321309|NCT00003702|Experimental|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
33321310|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
33321311|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
33321312|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
33321313|NCT01098786||Healthy|
33321314|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
33321315|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
33409069|NCT03704844||Patients without renal congestion|
32859027|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
33409070|NCT04005144|Experimental|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33409071|NCT05418933|Experimental|Intervention group|Family workshops with 5 courses, with 6-7 families in one course, 2 hours per session, one time per week, for a total of 6 weeks.
33409072|NCT03291587|Experimental|Intervention|"Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)"
33409073|NCT03291587|No Intervention|Usual Care|"No training or performance coaching calls on personnel, just usual clinic practice.~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)"
33409074|NCT03856788|Placebo Comparator|Saline|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with normal saline on the ipsilateral side as the extraction site.
33409075|NCT03856788|Active Comparator|Bupivacaine|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with bupivacaine on the ipsilateral side as the extraction site.
33409076|NCT04870125|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
33409077|NCT04870125|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
33409078|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
33409079|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
33409080|NCT03210961|Experimental|PF-06826647 tablet|
33409081|NCT03210961|Placebo Comparator|Placebo tablet|
33409082|NCT03210961|Experimental|PF-06826647 oral suspension|
33409083|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
33409084|NCT04797078|Active Comparator|Transrectal fusion biopsies of the prostate|"Transrectal approach, patient in left lateral position, local anestesia 10ml lidocaine 1% at prostate base laterally and apex if indicated.~MRI-ultrasound fusion-guided biopsies with 4 biopsy cores per lesion, where clinically indicated. 18G biopsy needle.~Standard 12-core template for systematic biopsies. 18G biopsy needle.~Antibiotic prophylaxis with 750mg ciprofloxaicin, single dose p.o."
33409085|NCT04797078|Experimental|Transperineal free hand fusion biopsies of the prostate|"Men randomized to the experimental arm undergoes free-hand targeted transperineal fusion biopsies as defined below.~Patient is placed supine in the lithotomy-position. The perineal area is prepared with chlorhexidine 0,5ml/ml.~Ropivacain 7,5mg/ml is used as an anesthetic agent. Up to 40ml's (equivalent to 300mg) can be used to anestitize the skin, caudal and cranial part of the urogenital diaphragm and periprostatic tissue.~Free-hand MRI-ultrasound fusion-guided biopsies with at least 4 biopsy cores per lesion. Coaxial technique with 18G biopsy needle.~10-12 Systematic biopsies according to the modified Barzell 12-core template.~No antibiotic profylaxis unless warranted by immunosuppression, previous sepsis or urinary tract infection."
33417272|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
32859028|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
32859029|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
32859030|NCT04279379|Experimental|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
32859031|NCT05685719|Experimental|Part 1: TR|Subjects will take a single dose of test product 200mg/capsule on Day 1 of the study, then reference product 100mg/capsule on Day 8 of the study.
32859032|NCT05685719|Experimental|Part 1: RT|Subjects will take a single dose of reference product 100mg/capsule on Day 1 of the study, then test product 200mg/capsule on Day 8 of the study.
32859033|NCT05685719|Experimental|Part 1: Group 1|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 200mg of itraconazole, q.d, for 6 consecutive days (Day 4 to Day 9). The 5th dose (Day 8) of itraconazole will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
33321316|NCT00031590|Experimental|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide [IV and oral]) which will be given in the following order: AABAABAAB (total of 54 weeks)."
33321317|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
33321318|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
33321319|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
33321320|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
33321321|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
33321322|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
33321323|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
33321324|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
33321325|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
33321326|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
33321327|NCT01353820|Active Comparator|1 = Tested product|
33321328|NCT01353820|Sham Comparator|2 = Control product|
33321329|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
33321330|NCT03954054||Former therapeutic education participants|Semi-structured interviews with people who already completed the TPE programme
33321331|NCT03954054||Intervention group (current therapeutic education participants)|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
33321332|NCT03954054||Control AUD (Alcohol Use Disorder) patients|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
33321333|NCT00239681|Experimental|Rosuvastatin|Rosuvastatin 20 mg once daily
33321334|NCT00239681|Placebo Comparator|Placebo|Placebo once daily
33321335|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
33321336|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
33321337|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
33321338|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
33321339|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
33321340|NCT01354054|No Intervention|Control|Age matched controls, no intervention
33321341|NCT01354288|Experimental|Therapeutic education|
33321342|NCT01354288|No Intervention|Classical management|
33321343|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
33321344|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
33321345|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
33321346|NCT00238433|Experimental|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) > 1500 for 2 consecutive days.~Drug: busulfan~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.~Drug: melphalan~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.~Drug: thiotepa~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.~Procedure/Surgery: peripheral blood stem cell transplantation~Performed 36-48 hours following last chemotherapy dose."
33321347|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
33321348|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
33417273|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
33321349|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
33321350|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
33321351|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
33321352|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
33321353|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
33321354|NCT00045162|Active Comparator|1|
33321355|NCT00045162|Active Comparator|2|
33321356|NCT04289038|Experimental|Autogenic Relaxation|Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features.
33321357|NCT04289038|Experimental|Virtual Reality|Virtual reality: Playing games via smart phone with virtual reality glasses and headset.
33321358|NCT04289038|Other|Control Group|Routine nursing care and kidney function narration
33321359|NCT01072799|Experimental|Low dose H1N1|
33321360|NCT01072799|Experimental|Mid dose H1N1|
33321361|NCT01072799|Experimental|High dose H1N1|
33321362|NCT01072799|Placebo Comparator|Placebo|
33321363|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
33321364|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
33321365|NCT01354600|Other|Energy Balance|
33321366|NCT01354600|Other|Positive Energy Balance|
33321367|NCT01354678|Active Comparator|group of bone marrow cell therapy|
33321368|NCT01354678|Sham Comparator|group of sham therapy|
33321369|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
33321370|NCT01350466||FESS patients|
33321371|NCT01350466||Controls|
33321372|NCT00238121|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33321373|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
33321374|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
33321375|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
33321376|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
33321377|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
33321378|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
33321379|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
33321380|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
33321381|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
33321382|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
33321383|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
33321384|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
33321385|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
33321386|NCT01096212|Experimental|generic sevoflurane|
33321387|NCT01096212|Active Comparator|origianl sevoflurane|
33321388|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
33321389|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
33321390|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
33321391|NCT01099098||Patients with TB sequelae|
33409086|NCT04981509|Experimental|Treatment (bevacizumab, atezolizumab, erlotinib)|Patients receive bevacizumab IV over 30-90 minutes and atezolizumab IV over 30-90 minutes on day 1 of each cycle. Patients also receive erlotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT with contrast or CT without contrast and MRI throughout the trial. Patients may also undergo a biopsy during screening, collection of blood throughout the trial, and a brain MRI/CT scan and/or F-18 sodium fluoride PET scan with contrast as clinically indicated.
33409087|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
33409088|NCT05417919|Experimental|Solution-oriented Nursing in Violence Against Women (SONVAW)|"Initiatives for the Experimental Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected from students who did not come to school that day by telephone or by interviewing them the next day.~Before the solution-oriented approach program, the students were interviewed and the appropriate time and hours were determined for the program. Then, an online solution-oriented approach program was implemented, which lasted for 6 weeks at the specified hours and days. In the first week of the program, a guide form containing the activities related to the program to be applied was distributed to the students. At the end of the program, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the end of the program, they were asked to fill in the İSKEBE scale again as a follow-up test."
33409089|NCT05417919|No Intervention|Control|Initiatives for the Control Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected by phone calls or the next day with students who did not come to school that day. 6 weeks after the pre-test application, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the post-test application, they were asked to fill out the İSKEBE scale again as a follow-up test. At the end of the follow-up test, 45 minutes of violence against women training was given to the control group students.
33409090|NCT04792008|Experimental|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
33409091|NCT04792008|Placebo Comparator|Placebo Single dose|One-third of randomized patients will receive matching placebo
33409092|NCT05415735|Experimental|SMART Program|The Stress Management and Resiliency Training (SMART) Program is a multimodal mind-body and cognitive skills-based program that teaches participants a variety of different approaches for reducing their physiologic stress response. The program is delivered virtually (online) for 1.5 hours once a week for 8 weeks.
33409093|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
33409094|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
33409095|NCT04853667||Patients with hereditary epidermolysis bullosa|Minor patients with hereditary epidermolysis bullosa
33409096|NCT04853667||Parents|Parents of patients with hereditary epidermolysis bullosa
33409097|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
33409098|NCT04050930|Experimental|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
33409099|NCT04050930|Experimental|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
33409100|NCT05180617|Experimental|Individual music therapy (IMT)|"After baseline measures, each Participant will receive 6 x 1 weekly hour of music therapy. During music therapy the participants will be interacting both musically and verbally with the therapist.~Participants will be provided with both acoustic and electronic instruments with which they will be able to improvise with the therapist. In addition, IMT participants will be provided with the opportunity to compose and write songs, take part in preferred music lyric analysis, sing and discuss/talk with the therapist.~During session 2 and 5 EEG hyperscanning of therapist and patient will be applied.~All 5 IMT participants will do the same pre-post intervention test battery."
33409101|NCT05180617|Experimental|Group music therapy (GMT)|"During 6 x 1 weekly hour of GMT, 5 participants will be invited to take part in a range of group music making activities.~Participants will be provided with both acoustic and electronic instruments with which they will be able to improvise within the group setting. In addition, GMT participants will be provided with the opportunity to compose and write songs as a group, take part in preferred music lyric analysis, sing and take part in group discussions.~All 5 GMT participants will do the same pre-post intervention test battery."
33409102|NCT05180617|No Intervention|Control Group|"CG will receive standard treatment, which includes key work sessions, other group work programmes and clinical support (e.g. prescribing).~All 5 CG participants will do the same pre-post intervention test battery."
33409103|NCT05415579||DDC patients with Traditional Chinese medicine (TCM) treatment|"TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.~This study does not limit Western medical treatment methods. Patients commonly applied high dose of intravenous steroid treatment in the acute phase, which usually referred to intravenous administration of 1g or 500mg of glucocorticoid daily for 3 consecutive days and reduced by half every 3 days. In addition, plasma exchange and immunoabsorption are also optional treatment for the acute phase. Immunomodulatory therapies including low dose of steroid, immunosuppressants (Azathioprine, Mycophenolate, etc.), and disease-modifying therapy (fingolimod, Teriflunomide, Rituximab, Satralizumab, etc.) are necessary for the remission phase."
33409104|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
32964049|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
32859034|NCT05685719|Experimental|Part 1: Group 2|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 600mg of rifampin, q.d, for 9 consecutive days (Day 4 to Day 12). The 8th dose (Day 11) of rifampin will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
32859035|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
33321392|NCT01099098||People without TB sequelae|
33321393|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
33321394|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
33321395|NCT01327404||Depressed|Patients with Major Depressive Disorder
33321396|NCT01327404||Diabetic|Patients with Type 2 Diabetes
33321397|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
33321398|NCT01327404||Healthy Controls|
33321399|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
33321400|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
33321401|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
33321402|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
33321403|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
33321404|NCT01584258|Active Comparator|Laparoscopic Prostatectomy vs prostate SBRT|Patients for whom surgery is considered will be randomised to laparoscopic prostatectomy or prostate SBRT delivered with 36.25 Gy in 5 fractions.
33321405|NCT01584258|Active Comparator|Conventionally Fractionated RT vs Prostate SBRT|Patients for whom surgery is not considered or who refuse surgery will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 2 Gy fractions or SBRT delivered with 36.25 Gy in 5 fractions.
33321406|NCT00237809|Experimental|Drug and control CRT|D-serine/control
33321407|NCT00237809|Experimental|Drug and CRT|D-serine/cog rehab
33321408|NCT00237809|Experimental|Placebo Drug and Placebo CRT|Placebo/control
33321409|NCT00237809|Experimental|Placebo Drug and CRT|Placebo/cog rehab
33321410|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
33321411|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
33321412|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
33321413|NCT01351012|Placebo Comparator|Corn and safflower oil|
33321414|NCT01351012|Active Comparator|Canola oil|
33321415|NCT01351012|Active Comparator|High oleic acid canola oil|
33321416|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
33321417|NCT01351012|Active Comparator|Flax and safflower oil|
33321418|NCT03973775|Experimental|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
33321419|NCT03973775|Active Comparator|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
33321420|NCT01351168|Placebo Comparator|Sugar pill|
33321421|NCT01351168|Active Comparator|Levodopa|
32859036|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
32859037|NCT05685641|Experimental|Intervention group|All enrolled patients will be included in this arm of the study, patients will be administered all rapid diagnostic tests as part of their diagnostic work-up (this will constitute the main intervention of the study)
33321422|NCT01351168|Experimental|Zolpidam second dose|
33321423|NCT01351168|Experimental|Zolpidam first dose|
33321424|NCT00003498|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33321425|NCT01351246|Experimental|Intervention|
33321426|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
33321427|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
33321428|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
33321429|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
33321430|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
33321431|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
33321432|NCT03952104|Experimental|Experimental-Low Intensity Strength Training|Strength training (low intensity)
33321433|NCT03952104|Experimental|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
33321434|NCT03952104|Experimental|Experimental-High Intensity Strength Training|Strength training (high intensity)
33321435|NCT03952104|No Intervention|Control|No intervention
33321436|NCT01351558|No Intervention|Control|No intervention for 12 weeks
33321437|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
33321438|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
33321439|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
32907531|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
33321440|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
33321441|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
33321442|NCT00003492|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33321443|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
33321444|NCT01101672|Experimental|Single-port laparoscopic colectomy|
33321445|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
33321446|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
33321447|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
33321448|NCT03952260|Active Comparator|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
33321449|NCT03952260|No Intervention|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
33321450|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
33321451|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
33321452|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
33321453|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
33321454|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
33321455|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
33321456|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
33321457|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
33321458|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
33321459|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
33321460|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
33321461|NCT01317706|Active Comparator|Bishop score|
33321462|NCT01317706|Active Comparator|transvaginal ultrasound|
33321463|NCT01352026|Experimental|Metformin|
33321464|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
33321465|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
33321466|NCT00042666|Experimental|LY317615|500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles
33321467|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
33321468|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
33321469|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
33321470|NCT01357486|Other|D|patients receiving best supportive care
33321471|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
33321472|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
33321473|NCT01352104|Experimental|waiting-intervention-course|
33321474|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
33321475|NCT00042432|Experimental|cinacalcet (AMG 073)|
33321476|NCT00042432|Placebo Comparator|Placebo|
33321477|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
33321478|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
33321479|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
33417274|NCT01363375||normal foot|Subjects with normal foot structure
33417275|NCT01363375||flat foot|Subjects with flat foot structure.
33409105|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
33409106|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
33409107|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
33409108|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
33409109|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
33409110|NCT04851873|Experimental|OAV101|Participants will receive a single IV dose administration of OAV101
32859038|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
33409111|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
33409112|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
33409113|NCT05232877|Experimental|tDCS combined with simultaneous cognitive training|
33409114|NCT05232877|Sham Comparator|cognitive training with a combined sham tDCS|
33409115|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
33409116|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
33409117|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
33409118|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
33409119|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
33409120|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
33409121|NCT05415501|Experimental|Structural priming training|Participants will be enrolled in 3 sessions of structural priming training (for experiment 1-3) or up to 15 treatment sessions (for experiment 4). Each session will be about 2 hour long, consisting of a set of tasks, including repeating, making, and remembering various types of sentences. In experiment 1-3, each participant will receive two different experimental priming conditions that are being compared within each session. In experiment 4, participants will receive a structural priming treatment in a single-subject design.
33409122|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
33409123|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
32859039|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
32859040|NCT05685563||sweep rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
32859041|NCT05685563||scull rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
32859042|NCT05685563||control non-rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
32859043|NCT05480657|Experimental|Single Arm AT-1501|Single-arm, open-label trial
32859044|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
33409124|NCT04206995||Evaluation of odour capturing techniques|To evaluate two odour capturing techniques to compare VOC profiles of cancerous and healthy skin cancer.
33409125|NCT04971525||Darvadstrocel Cohort|Participants diagnosed with CD and CPAF, who administered at least one dose of darvadstrocel in fistula tract tissue under surgical environment will be observed.
33409126|NCT04971525||Matched Control Cohort: Standard of Care (SoC)|Participants diagnosed with CD and PAF with no history of administration of darvadstrocel, matched age at index date (within 3 years), time from CD diagnosis (within 1 year), and sex to individuals in the darvadstrocel cohort who received the alternative Standard of Care (SoC), which varies from country to country and according to local centre expertise will be observed.
33409127|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
33409128|NCT03625050|Experimental|Chuna + Usual care|
33409129|NCT03625050|Active Comparator|Usual care|
33417276|NCT01363375||high arch foot|Subjects with high arch foot structure.
33321480|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
32859045|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
32859046|NCT05443139|Experimental|Interactive intervention|The participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.
32859047|NCT05443139|Experimental|non-interactive intervention|Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.
32859048|NCT05443139|No Intervention|Waiting List group|The control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.
32859049|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
32859050|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
32859051|NCT05439395||STEELEX|Steelex® Sternum Set for sternal closure
32859052|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
32859053|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
32859054|NCT05428787|Active Comparator|Cardiac Resynchronization Therapy + AV node ablation|The active comparator group will be treated with CRT followed by an Atrioventricular Node Ablation.
32859055|NCT05428787|Experimental|Left Bundle Branch Area Pacing + AV node ablation|The experimental group will be treated with LBBAP followed by an Atrioventricular Node Ablation.
32859056|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
32859057|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
32859058|NCT05403827|Experimental|K-161|K-161 Ophthalmic Solution
32859059|NCT05403827|Placebo Comparator|Placebo|Vehicle Solution
32907532|NCT03385655|Experimental|WEE-1 inhibitor - ARM CLOSED|
32907533|NCT03385655|Experimental|cMET inhibitor|
33321481|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
33321482|NCT05152810|Experimental|Active Transcranial Magnetic Stimulation|
33321483|NCT05152810|Placebo Comparator|Transcranial magnetic resonance imaging placebo|
33321484|NCT01361386||1|
33321485|NCT00003474|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33321486|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
33321487|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
33321488|NCT01354834||hMG|
33321489|NCT01099410||Group 1|volunteer subjects
33321490|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
33321491|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
33321492|NCT01099566|Experimental|Prasugrel|
33321493|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
33321494|NCT01099722|Active Comparator|Inhaler|
33321495|NCT01099722|Active Comparator|inhaler|Symbicort
33321496|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
33321497|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
33321498|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
33321499|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
33321500|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
33321501|NCT00003456|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33321502|NCT03950778|Active Comparator|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
33417277|NCT01370707|Active Comparator|Metformin|
32964050|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
32964051|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
33321503|NCT03950778|No Intervention|Septic patients not receiving albumin replacement|
33321504|NCT03953664|Experimental|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
33321505|NCT03953664|Experimental|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
33321506|NCT03953664|Experimental|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
33321507|NCT03950700|Experimental|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
33321508|NCT03950700|Placebo Comparator|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
33321509|NCT01355146||Fabry's Disease under Replagal|
33321510|NCT00237185|Experimental|imatinib mesylate 400 mg|400 mg once daily
33321511|NCT00237185|Experimental|imatinib mesylate 600 mg|600 mg once daily
33321512|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
33321513|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
33321514|NCT00003222|Experimental|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
33321515|NCT00003222|Experimental|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
33321516|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
33321517|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
33321518|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
33321519|NCT01357876|Other|Type two diabetics|Type two diabetics
33321520|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
33321521|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
33321522|NCT05626062|Experimental|Intervention group|30 adults with learning disabilities with incontinence will be offered a 12-week personalised toilet training plan, which promotes prompted voiding in a toilet
33321523|NCT01581983|Experimental|Internet Mindfulness Meditation|
33321524|NCT01581983|Experimental|Individual Mindfulness Meditation|
33321525|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
33321526|NCT03951558|Experimental|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
33321527|NCT03951558|Placebo Comparator|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
33321528|NCT01319578|Active Comparator|Chewing Arm 1|
33321529|NCT01319578|Placebo Comparator|Chewing Arm 2|
33321530|NCT01319578|Active Comparator|Chewing Arm 3|
33321531|NCT01319578|Active Comparator|Chewing Arm 4|
33321532|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
33321533|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
33321534|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
33321535|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
33409130|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
33409131|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
33409132|NCT03210259|Experimental|BI 695501|
33409133|NCT03210259|Active Comparator|Humira®|
33409134|NCT04773678|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
33409135|NCT04773678|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
33409136|NCT04773678|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
33409137|NCT04812015|Other|Dose Group 1|
33409138|NCT04812015|Other|Dose Group 2|
33409139|NCT04812015|Other|Dose Group 3|
33409140|NCT04812015|Other|Dose Group 4|
33409141|NCT04812015|Other|Dose Group 5|
33409142|NCT04812015|Other|Dose Group 6|
33409143|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
33409144|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
33409145|NCT04319757|Experimental|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.~Dose Level: 1 Planned number of subjects: 1 to 6"
33409146|NCT04319757|Experimental|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 2 Planned number of subjects: 1 to 6"
33409147|NCT04319757|Experimental|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 3 Planned number of subjects: 3 to 6"
33409148|NCT04319757|Experimental|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 4 Planned number of subjects: 3 to 6"
33409149|NCT04319757|Experimental|ACE1702 Dose Level 5|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 5 Planned number of subjects: 3 to 6"
33409150|NCT04319757|Experimental|ACE1702 Dose 6|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 6 Planned number of subjects: 3 to 6"
33409151|NCT04576806|Active Comparator|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
33409152|NCT04576806|Experimental|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
33409153|NCT05180461|Experimental|Part 0 Pilot group emodepside 15mg Once a day (OD) 1 day|emodepside tablets 15 milligrams once a day for 1 day
33409154|NCT05180461|Experimental|Part 1 emodepside 30mg OD 1 day|emodepside tablets 30 milligrams once a day for 1 day
33409155|NCT05180461|Experimental|Part 1 emodepside 15mg OD 7 days|emodepside tablets 15 milligrams once a day for 7 days
32859060|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
33409156|NCT05180461|Experimental|Part 1 emodepside 15mg OD 14 days|emodepside tablets 15 milligrams once a day for 14 days
33409157|NCT05180461|Experimental|Part 1 emodepside 15mg twice a day (BID) 10 days|emodepside tablets 15 milligrams twice a day for 10 days
33409158|NCT05180461|Placebo Comparator|Part 1 placebo|matching placebo of emodepside tablets
33409159|NCT05180461|Experimental|Part 2 emodepside dose regimen A|emodepside tablets, dose regimen A selected from regimens tested in Part 1
33409160|NCT05180461|Experimental|Part 2 emodepside dose regimen B|emodepside tablets, dose regimen B selected from regimens tested in Part 1
33409161|NCT05180461|Active Comparator|Part 2 ivermectin|ivermectin, single oral dose of 150 micrograms per kilogram by weight
33409162|NCT03701646||arterial line|Pediatric patients admitted tot he ICU with a medically indicated arterial line.
33417278|NCT01370707|Experimental|CJ-30001/CJ-30002|
32859061|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
32859062|NCT01220973|Experimental|Atorvastatin and Celecoxib|
32859063|NCT05390801||Patients|Any patient ≥ 18 years old with congenital aniridia, able to respond independently to a questionnaire and patients under 18 years old with congenital aniridia, whose parents can respond for their child.
32859064|NCT05375747|Experimental|Remimazolam based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
32907534|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
33409163|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
32907535|NCT03385655|Experimental|CFI400945 PLK4 inhibitor - ARM CLOSED|
32907536|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
32907537|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
32907538|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
32907539|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
32907540|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
32907541|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
33321536|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
33321537|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
33321538|NCT04847128|Experimental|Arm I|Participants receive exercise intervention 3 times weekly for 8 weeks.
33321539|NCT04847128|No Intervention|Arm II|Participants keep sedentary life without exercise for 8 weeks.
33321540|NCT01361932|Experimental|Video of ED Discharge Instructions|
33321541|NCT01361932|No Intervention|Control (usual standard of care)|
33321542|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
33321543|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
33321544|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
33321545|NCT04775680|Experimental|ADG106 combined with PD-1 antibody Dose Escalation Level 1|
33321546|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Dose Escalation Level 2|
33321547|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Expansion Phase|
33321548|NCT01362088||CVVH patients|
33321549|NCT00003138|Active Comparator|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of >= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
33321550|NCT00003138|Experimental|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
33321551|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
33321552|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
33321553|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
33321554|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
33321555|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
33321556|NCT01099956||diabetes group|
33321557|NCT01099956||control group|
33321558|NCT05625906|Experimental|Intervention group|will receive a multi-media experiential training programme.
33321559|NCT05625906|No Intervention|control group|will NOT receive a multi-media experiential training programme
33321560|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
33321561|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
33321562|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
33321563|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
33321564|NCT00003102|Experimental|Cohort 1 50cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
33321565|NCT00003102|Experimental|Cohort 2 75cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
33409164|NCT05229861|Experimental|High-intensity Interval Training (HIIT)|Participants will complete seven HR-controlled HIIT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
33417279|NCT01363453||Patients with Ulcerative Colitis|
33417280|NCT04336735|Experimental|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
33409165|NCT05229861|Active Comparator|Moderate Continuous Training (MCT)|MCT represents the standard treatment at Valens rehabilitation clinic. Participants will complete seven HR-controlled MCT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
33409166|NCT04573530|Experimental|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
33409167|NCT04573530|No Intervention|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
33409168|NCT05415345|Experimental|Group A|Participants in this arm will be simultaneously administrated with HPV and HEV vaccine. The immunization schedule is 0,1,6 months.
33409169|NCT05415345|Active Comparator|Group B|Participants in this arm will be administrated with HPV vaccine. The immunization schedule is 0,1,6 months.
33409170|NCT05415345|Active Comparator|Group C|Participants in this arm will be administrated with HEV vaccine. The immunization schedule is 0,1,6 months.
33409171|NCT05205889|Experimental|Mobile based values intervention for people with chronic pain|
33409172|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
33409173|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
33409174|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
33409175|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
33409176|NCT05417529|Experimental|Treatement Group|Participants received music therapy intervention
33409177|NCT05417529|Active Comparator|Control Group|Patients in control group receive premedication
33409178|NCT02496611|Placebo Comparator|Weight Loss Maintenance without Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve ≥5% BMI reduction. A selection of these participants are then randomized to receive treatment with placebo.
33409179|NCT02496611|Active Comparator|Weight Loss Maintenance with Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a >/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
33409180|NCT03636295|Experimental|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
33409181|NCT03636295|Active Comparator|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
33409182|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
33409183|NCT04767048|Experimental|Experimental Arm|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
33409184|NCT04767048|Active Comparator|Control Arm|Tonsillectomy alone (unilateral or bilateral at the choice of the investigator)
33409185|NCT04566666|Placebo Comparator|Placebo of SCD-044 product|Placebo of SCD-044 study drug
33409186|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
33409187|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
33409188|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
33409189|NCT03237481|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
33409190|NCT03237481|Active Comparator|Treatment Group 2: Bupivacaine HCI|Bupivacaine HCl
33409191|NCT03237481|Placebo Comparator|Treatment Group 3: Saline Placebo|Saline placebo
33409192|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
33409193|NCT03222349|Experimental|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
33409194|NCT03222349|Experimental|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
33409195|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
33409196|NCT03543553||HC|Healthy control participants
33409197|NCT05180071|Experimental|TEMA elbow arthroplasty|
33409198|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
33409199|NCT05170165||Enrolled Subjects|Test a clinical decision support (CDS) tool that provides clinicians (cardiologists and nurse practitioners) recommendations regarding guideline directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF).
33409200|NCT04795245||patients treated with afatinib|
33409201|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
33409202|NCT05168917|Other|Ulcerative colitis in clinical and endoscopic remission|Patients with established diagnosis of ulcerative colitis (UC) in clinical and endoscopic remission defined as clinical score = 0 at enrollment with no endoscopy flare up may participate to follow up. Proctosigmoidoscopy to document endoscopic remission has to be foreseen. The patients' inclusion/exclusion criteria are based on the established diagnostic procedures for the UC, i.e. colonoscopy at the time of diagnosis, endoscopic evidence of remission and clinical significant findings.
33409203|NCT05163951|Active Comparator|Trabeculectomy|Forty-four patients with advanced primary angle closure glaucoma will receive trabeculectomy.
33409204|NCT05163951|Experimental|SPI+GSL+GT|Forty-four patients with advanced primary angle closure glaucoma will receive surgical peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT).
33409205|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
33409206|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
33409207|NCT05162781|Experimental|CICT with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
33409208|NCT05162781|Experimental|CICT without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
33409209|NCT05162781|Active Comparator|BF-HELP with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
33409210|NCT05162781|Active Comparator|BF-HELP without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
33409211|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
33409212|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
33409213|NCT05152953||Persons with HIV|Persons with HIV who are currently taking antiretroviral therapy who reside in the study's target geographical areas.
33409214|NCT05152953||Pharmacy staff members|Pharmacists, pharmacy technicians, pharmacy managers, or clerks employed at a community pharmacy who would potentially be involved in program development, scheduling, financial aspects, planning or administration of long-acting injectable antiretroviral therapy in the pharmacy.
32964052|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
32964053|NCT02032680|Active Comparator|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
32964054|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
32964055|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
33409215|NCT05152953||Clinic staff members|Physicians, clinic managers, nurses, medical assistants, social work staff or case managers, therapists, and other clinic personnel who are involved or would potentially be involved in any aspect of long-acting antiretrovirals in the clinic facility including financial aspects, planning, scheduling patients, educating patients, ordering medication, or administering medications.
33409216|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
33409217|NCT02423772|No Intervention|Treatment as Usual|
33409218|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
33409219|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
33409220|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
33409221|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
33409222|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
33409223|NCT05136729|Experimental|Face-to-face Self-Natural Posture Exercise training|Off-line training
33409224|NCT05136729|Active Comparator|Online Self-Natural Posture Exercise training|"Virtual training~This group as a wait-list control group will receive online SNPE intervention after serving as an untreated comparison group."
33409225|NCT04766034|Sham Comparator|Control|The grocery shopping simulation will not include any discounts or bundles
33409226|NCT04766034|Active Comparator|Discount|The grocery shopping simulation will include discount on eligible fruits and vegetables
33409227|NCT04766034|Active Comparator|Bundles|The grocery shopping simulation will include healthy bundle defaults with no discount
33409228|NCT04766034|Active Comparator|Bundles and Discount|The grocery shopping simulation will include healthy bundle defaults plus a discount
33409229|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
33409230|NCT04762017|Experimental|OCS-05|Once daily IV infusions of OCS-05 (n=18) for 5 consecutive days
33409231|NCT04762017|Placebo Comparator|Placebo|Once daily IV infusions of Placebo (n=18) for 5 consecutive days
33409232|NCT05114733|Experimental|InVEST|4 month treatment condition
33409233|NCT05114733|No Intervention|delayed invest|participants in delayed invest wait four months and are reassessed before taking part in the intervention
33409234|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
33409235|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
33409236|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
33409237|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
33409238|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
33409239|NCT04752267|Experimental|Diagnostic (18F-FMAU, PET/CT, mpMRI)|Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
33409240|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
33409241|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
33409242|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
33409243|NCT04864080|Active Comparator|Healthy Comparison Group|Behavioral tasks and surveys online.
33409244|NCT04864080|Experimental|Pain/Depression patients from clinic|MRI, TMS and EEG, and behavioral tasks and surveys online.
33409245|NCT05086263|No Intervention|Standard of Care (No VR) Randomization|Participants would take the same questionnaires as the VR interventional group except the RT questionnaire. Then they will proceed with their MRI.
33409246|NCT05086263|Experimental|VR Randomization|The virtual reality MRI training will be conducted immediately after completion of the questionnaires in a distraction free room. The training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Using audio/visual cues and biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure. The research subject will continue with their regularly scheduled MRI. The modified Yale Preoperative Anxiety Scale (mYPAS) is an observational measure and will be completed by research staff.
33409247|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
33409248|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
33409249|NCT04544124|Experimental|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
33409250|NCT04544124|No Intervention|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
33409251|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
33409252|NCT05100277||Single arm|All patients will have the test
33409253|NCT05417373||The development cohort|The development cohort was composed of patients diagnosed with PAH and healthy control group from 2019.1-2021.5 in RenjiH.
33409254|NCT05417373||The validation cohort|The validation cohort was composed of patients are suspected as PAH by echocardiography in 2021.5-2021.12 or suspected patients are form other medical institutions.
33409255|NCT03257267|Experimental|Experimental Therapy|Cemiplimab
33409256|NCT03257267|Active Comparator|Control Therapy|Investigator choice (IC) chemotherapy
33409257|NCT04543812|Experimental|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
33409258|NCT04543812|Placebo Comparator|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
33409259|NCT05050773||Nicorandil group|Patients who are prescribed with Nicorandil with or without other concomitant medication
33409260|NCT05050773||Non-Nicorandil group|Patients who are prescribed with antianginal drugs except Nicorandil
33409261|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
33409262|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
33409263|NCT05417295|Experimental|Inflating air into the bronchial cuff before changing position|Before changing from supine position to lateral position, inflate air into the bronchial cuff of double lumen endotracheal tube (DLT) and adjust cuff pressure to 25-30 mmHg.
33409264|NCT05417295|Placebo Comparator|Inflating air into the bronchial cuff after changing position|Do not inflate air into the bronchial cuff before changing position.
33409265|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
33409266|NCT04748757|Placebo Comparator|Placebo|Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
33409267|NCT04748757|Experimental|Low dose|50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
33409268|NCT04748757|Experimental|High dose|100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
33409269|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
33409270|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
33409271|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
33409272|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
33409273|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
33409274|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
33409275|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
33409276|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
33409277|NCT04887129|Experimental|Students and staff at Mary Cariola Center|All students enrolled at the Mary Cariola Center in Rochester, NY. All staff working at the Mary Cariola Center in Rochester, NY.
33409278|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
33409279|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
33409280|NCT04816773||Newly or previously implanted patients|Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert
33409281|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
33409282|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
33409283|NCT05089123|Experimental|Flu-M|160 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
33409284|NCT05089123|Active Comparator|Ultrix|160 volunteers were vaccinated with the Ultrix (Inactivated split influenza vaccine)
33409285|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
33409286|NCT03948035|Experimental|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
33409287|NCT03948035|Active Comparator|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
33409288|NCT04540770|Placebo Comparator|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
33409289|NCT04540770|Placebo Comparator|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
33409290|NCT04540770|Placebo Comparator|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
33409291|NCT04540770|Experimental|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in IPF subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in IPF subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.~A total of 6 IPF subjects will be enrolled in this multiple-dose cohort."
33409292|NCT03671421|Active Comparator|Quads tendon|The graft tissue will be quadriceps tendon
33409293|NCT03671421|Active Comparator|Hamstring|Semitendinosus and gracilis will be used for graft
33409294|NCT03671421|Active Comparator|BPTB|Bone patellar tendon bone graft to be used.
33409295|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
33409296|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
33409297|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
33409298|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
33409299|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
33409300|NCT04780581|Active Comparator|RECOVERY|intermediate-dose dexamethasone (6mg/24h - 10 days)
33409301|NCT04780581|Experimental|BOLUS|high-dose methylprednisolone bolus (250mg/4h - 3 days)
33409302|NCT01526135|Active Comparator|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
33409303|NCT01526135|Experimental|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
33409304|NCT03703830|Experimental|Experimental|Cerebellar transcranial current stimulation associated with locomotor training
33409305|NCT03703830|Sham Comparator|Sham comparator|Cerebellar transcranial current stimulation sham associated with locomotor training
33409306|NCT04697589|Experimental|SBRP 300 mg|300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
33409307|NCT04697589|Experimental|SBRP 600 mg|600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
33409308|NCT04697589|Placebo Comparator|Placebo|Colored maltodextrin
33409309|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
33409310|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
33409311|NCT05417139|Experimental|Immunotherapy+induction chemotherapy+radiotherapy|
33409312|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
33409313|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
33409314|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
33409315|NCT03206749|Experimental|VX-150|
33409316|NCT03206749|Active Comparator|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
33409317|NCT03206749|Placebo Comparator|Placebo|
33409318|NCT04635969|Experimental|Experimental: Children training|All registered participants in intervention group will participate in a series of trainings on sexuality education.
33409319|NCT04635969|No Intervention|Control: No intervention|All registered participants in control group will not participate in a series of trainings on sexuality education.
33409320|NCT04754646|Experimental|RHA®4 - Cannula|
33409321|NCT04754646|Active Comparator|RHA®4 - Needle|
33409322|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
33409323|NCT03255941|Active Comparator|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
33409324|NCT03255941|Active Comparator|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
33409325|NCT03255941|Active Comparator|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
32859065|NCT05375747|Active Comparator|Propofol based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
32859066|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
33409326|NCT03255941|Active Comparator|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
33409327|NCT03705468||Ketamine sedation|Ketamine sedation
33409328|NCT03705468||Propofol sedation|Propofol sedation
33409329|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
33409330|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
33409331|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo endoscopic or CT assisted biopsy and MRI on study.
33409332|NCT03705390|Experimental|ILB|ILB subcutaneous injection
33409333|NCT04805424|Active Comparator|Abdominoplasty|Standard abdominoplasty
33409334|NCT04805424|Experimental|Lipo-abdominoplasty|Abdominoplasty plus liposuction
32859067|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
32859068|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
33409335|NCT04659993||Telemental Group|The virtual group will be conducted within a secure platform such as Microsoft WebEx. Assessments (pre-, post-, mid-way) will be distributed through REDCap, a secure virtual platform, as will session handouts and forms.
33409336|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
33409337|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
33409338|NCT04250259|Placebo Comparator|Placebo|Alcoholic Cirrhosis on placebo
33409339|NCT04250259|Experimental|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
33409340|NCT04250259|No Intervention|Non-drinking Controls|Non-drinking healthy controls
33409341|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
33409342|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
33417281|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
33417282|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
33409343|NCT04226313|Active Comparator|Self-sampling device sent at home|Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
33409344|NCT04226313|Experimental|Self-sampling device sent by gynecologist(s)|Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
33409345|NCT04226313|Experimental|Self-sampling device obtained from general practitioner(s)|Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
33409346|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
33409347|NCT04221165|Active Comparator|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
33409348|NCT04221165|Experimental|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
33409349|NCT03255629|Other|Study drug (glucagon) first, placebo second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
33409350|NCT03255629|Other|Placebo first, study drug (glucagon) second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
33409351|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
33409352|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
33409353|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
33409354|NCT04622007|Experimental|A1 Tomi + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.
33409355|NCT04622007|Placebo Comparator|Pbo + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.
33409356|NCT04622007|Experimental|B1 Tomi + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.
33409357|NCT04622007|Placebo Comparator|Pbo + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.
33409358|NCT04622007|Experimental|C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive tomi plus pembrolizumab and pemetrexed (non-squamous NSCLC) or tomi plus pembro as a single agent (squamous) in accordance with the package insert.
33409359|NCT04622007|Placebo Comparator|Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive placebo plus pembrolizumab and pemetrexed (non-squamous NSCLC) or placebo plus pembro as a single agent (squamous) in accordance with the package insert.
33409360|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
33409361|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
33409362|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
33409363|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
33409364|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
33409365|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
33409366|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
33409367|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
33409368|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
33409369|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
33409370|NCT01568385|Experimental|TAK-438 20 mg QD|
33409371|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
33409372|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
33409373|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
33409374|NCT04525092|Active Comparator|Conventional Hemodialysis|Participants will receive intermittent HD for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode HD).
33409375|NCT04525092|Experimental|Pre-dilution Hemodiafiltration|Participants will receive intermittent pre-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode pre-dilution HDF).
33409376|NCT04525092|Experimental|Post-dilution Hemodiafiltration|Participants will receive intermittent post-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode post-dilution HDF).
33409377|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
33409378|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
33409379|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
33409380|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.~The web platform will be used to share participant dietary and weight data with dietitians."
33409381|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
33409382|NCT03700632|No Intervention|Control|no intervention will be done
33409383|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
33409384|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
33409385|NCT03698526|Active Comparator|Palliative care I|Palliative care
33409386|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
33409387|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
33409388|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
33409389|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
33409390|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
33409391|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
33409392|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
33409393|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
33409394|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
33409395|NCT04615455|Experimental|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
33409396|NCT04615455|Placebo Comparator|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
33409397|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
32964056|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
32964057|NCT02033382||Healthy Controls|Age and gender matched healthy controls
32964058|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
32964059|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
32964060|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
33409398|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
33409399|NCT03703284||Healthy control|Healthy individuals
33409400|NCT04614909|Experimental|Arm A Newly diagnosed glioblastoma treated with pamiparib- ARM CLOSED|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
33409401|NCT04614909|Experimental|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
33409402|NCT04614909|Experimental|Arm C Recurrent glioblastoma treated with olaparib - ARM CLOSED|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
33409403|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
33409404|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])~- Expected subject no.: 200 patients"
33409405|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
33409406|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
33409407|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
33409408|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
33409409|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
33409410|NCT03698058|Experimental|A2 Growing Up Milk|
32964061|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
32964062|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
32964063|NCT02037438|Active Comparator|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
32964064|NCT02037438|Experimental|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
32964065|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
32964066|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
32964067|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
32964068|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
33409411|NCT03698058|No Intervention|Traditional non-A2 milk|
33409412|NCT03698058|Active Comparator|Other Growing Up Milk|
33409413|NCT04613271|Experimental|Group 1|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
33409414|NCT04613271|Active Comparator|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
33409415|NCT05415189||Patients|Patients with mental illness according to Danish health registers
33409416|NCT05415189||Control individuals from the general population|Control individuals from the general population matched according to the data of diagnosis/ psychotropic medication, year of birth, sex and calendar year.
33409417|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
33409418|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
33409419|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
33409420|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
33409421|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
33409422|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
33409423|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
33409424|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
33409425|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
33409426|NCT01030575|Experimental|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
33409427|NCT01030575|Experimental|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
33409428|NCT01030575|Experimental|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
33409429|NCT01030575|Placebo Comparator|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
33409430|NCT04378023|Other|Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
33409431|NCT04352205|Experimental|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
33409432|NCT04314687|Experimental|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
33409433|NCT04314687|Experimental|UCMSCs|UCMSCs is administered via intrathecal injection
33409434|NCT04314687|Active Comparator|Standard Therapy|Physiotherapy
33409435|NCT04119843|Experimental|Mangoral|All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate [MnCl2 4H2O]).
33409436|NCT04215471|Experimental|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
33409437|NCT04561011|Experimental|Persons with Mild Traumatic Brain Injury (mTBI)|
32739105|NCT05714189|Other|Intervention group: adherence to Low FODMAP diet|Women could choose to adhere to the low FODMAP diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
32859069|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
32859070|NCT05354687|No Intervention|Control Group|No intervention will be given to participants. Students will be given pre-test and post-tests.
32859071|NCT05354687|Experimental|Small-group Teaching Group|Participants will be given training on the evaluation of pressure injuries with small-group teaching techniques.
32859072|NCT05354687|Experimental|Self-directed Learning Group|Participants will be given training on the evaluation of pressure injuries with self-directed learning technique.
33409438|NCT04065477|Experimental|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
33409439|NCT04065477|No Intervention|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
33409440|NCT04058067|Experimental|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
32859073|NCT05354141|Placebo Comparator|Treatment Arm 1|PLACEBO Normal saline 100 mL
33409441|NCT04058067|Active Comparator|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
33409442|NCT04105725|Experimental|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
33409443|NCT04105725|Active Comparator|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
33409444|NCT04101669|Experimental|EndoBarrier|Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner
33409445|NCT04101669|Sham Comparator|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.
33409446|NCT05408325||confirmed COVID 19 ptients|All patients confirmed by RT-PCR, as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who visited the emergency room and the outpatient clinic in the study period.
32859074|NCT05354141|Experimental|Treatment Arm 2|IP (ExoFlo) 15ml dose in Normal saline 85 mL, which is approximately 1.2 trillion EVs.
33409447|NCT05408325||healthy subjects|normal healthy volunteers
32859075|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
32859076|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
33321566|NCT00003102|Experimental|Cohort 3 100cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
33321567|NCT01362478||Case group|
33321568|NCT01362478||Control group|
33321569|NCT00002850|Experimental|Ciprofloxacin or ofloxacin|"Quinolone:~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
33321570|NCT00002850|Experimental|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
33321571|NCT00002850|No Intervention|No prophylaxis|The patient will receive no prophylactic antibiotics.
33321572|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
33321573|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
33321574|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
33321575|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
33321576|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
33321577|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
33321578|NCT01362634|No Intervention|Control|waitlist control condition
33321579|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
33321580|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
33321581|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
33321582|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
33321583|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
33321584|NCT01363024|Experimental|A|
33321585|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
33321586|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
33321587|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
33321588|NCT00002766|Experimental|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
33321589|NCT00002766|Active Comparator|"Standard Vincristine/Prednisone (L-20)"|See detail description
33321590|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
33321591|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
33321592|NCT01355380||Group 1|Drug (incl. Placebo)
33321593|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
33321594|NCT01355536||Preterm birth group|Women with prior preterm birth
33321595|NCT01355536||Term birth group|Women with prior term birth
33321596|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
33321597|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
33321598|NCT01355614|Experimental|QAX576|
33321599|NCT01355614|Other|Infliximab|
33321600|NCT01584414||normal samples|
33321601|NCT01584414||premalignant/carcinoma samples|
33321602|NCT01355692|Experimental|Laser therapy|
33321603|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
33321604|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
33321605|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
33409448|NCT04066023|Experimental|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
33409449|NCT04066023|Experimental|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
33409450|NCT04066023|Placebo Comparator|Placebo|Placebo microneedle system administered as two placebo patches
33409451|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
33409452|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
33409453|NCT05040217|Experimental|Gene transfer of AAV2-BDNF|Up to 12 subjects will receive open-label AAV2-BDNF
33409454|NCT02910895|Other|single arm|single tumor biopsy
33409455|NCT04971109|Active Comparator|TPOXX|Treatment Group 1: An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
33409456|NCT04971109|Placebo Comparator|TPOXX Placebo|Treatment Group 2: An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
33409457|NCT04947709|Experimental|Physical activity intervention group|The physical activity intervention will be structured to increase moderate-to-vigorous intensity aerobic physical activity, to achieve the 60-minute goal, five days per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity intervention.
33409458|NCT04947709|Other|Delayed-intervention control group|Participants randomized to the delayed-intervention control group will serve as the control group for 12 weeks, and will not receive physical activity intervention during this time and will not receive weekly support calls. After completion of the control group, participants will be offered physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations. This delayed-intervention control group design is used not only to boost recruitment, but to eventually confer the benefits of physical activity to all those who enter the trial.
33409459|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
33409460|NCT04930705|Experimental|TempSure FlexSure Applicator|Subjects will be treated with the TempSure FlexSure applicator device at each treatment.
33409461|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
33409462|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
33409463|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
33409464|NCT04927195|Experimental|Cohort 1|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10^11 cells, capsules, once daily, 14 days total
33409465|NCT04927195|Experimental|Cohort 2|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10^12 cells, capsules, once daily, 14 days total
33409466|NCT04927195|Experimental|Cohort 3|24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
33409467|NCT04927195|Experimental|Cohort 4|24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
33409468|NCT04927195|Experimental|Cohort 5|24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
33409469|NCT04888507|Experimental|Pozelimab+Cemdisiran|
33409470|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
33409471|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
33409472|NCT01428895|Active Comparator|Surgery Alone|
33409473|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
33409474|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
33409475|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
33409476|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
33409477|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
33409478|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
33409479|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
33409480|NCT03700398|Experimental|first OE|
33409481|NCT03700398|Other|First WLI|
33409482|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
33409483|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
33409484|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
33409485|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
33409486|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
33409487|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
33409488|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
32859077|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
32859078|NCT04348097|Experimental|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6~. For this study a force setting of 3 was used."
32859079|NCT04348097|Active Comparator|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
33321606|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
33321607|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
33321608|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
33321609|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
33321610|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
33321611|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
33321612|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
33321613|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
33321614|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
33321615|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
33321616|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
33321617|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
33321618|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
33321619|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
33321620|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
33321621|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
33321622|NCT02306122|Experimental|Information doctor|Physician receives nonadherence information, but there is no opportunity for pharmacist action
33321623|NCT02306122|Experimental|Choice doctor|Physician receives nonadherence information, and can choose to request pharmacist action
33321624|NCT02306122|Experimental|Default doctor|Physician receives nonadherence information; pharmacist action will be triggered unless physician cancels action
33321625|NCT00001962|Experimental|Daclizumab in participants with a bone marrow failure syndrome|daclizumab, 1 mg/kg, will be given for a total of 5 intravenous infusions. These subjects may be diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
33321626|NCT01356004|Experimental|chicken pox vaccine, efficacy|
33321627|NCT01356004|Placebo Comparator|saline, efficacy|
33321628|NCT03951714|Other|Reference|Control experience using marketed application to record medication intake without reminders from the app
33321629|NCT03951714|Experimental|Intervention|Full experience using marketed application, with all functionalities enabled
32859081|NCT04347863|Experimental|Experimental group|Group swallowing disorder diet preparation program
32859082|NCT04347863|No Intervention|Control group|No Intervention
32859083|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
33321630|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
33321631|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
33321632|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
33321633|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
33321634|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
33321635|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
33321636|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
33321637|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
33321638|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
33321639|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
33321640|NCT05625828|Experimental|SILVER XIII EQUILIBRE|Cognitive-motor 10 weeks program
33321641|NCT05625828|Active Comparator|VIVIFRAIL|Multifactorial 10 weeks program
33321642|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
33321643|NCT03950388|No Intervention|Treatment as Usual|
33321644|NCT03950388|Experimental|Intervention|
32859084|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
33409489|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
32859085|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
32859086|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
32859087|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
32859088|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
32859089|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
32859090|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
32859091|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
32859092|NCT05338619|Experimental|Lazertinib|Lazertinib 240mg, oral, QD
32859093|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
33321645|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
33321646|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
33321647|NCT01103388|Experimental|Rituximab|
33321648|NCT01103388|No Intervention|No Rituximbab|
33321649|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
33321650|NCT01327326|Active Comparator|TMD patients|"Intervention:~Drug: Naltrexone~Drug: placebo"
33321651|NCT01327326|Active Comparator|Healthy controls|"Intervention:~Drug: Naltrexone~Drug: placebo"
33321652|NCT03950544|Experimental|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
33321653|NCT05625672|Experimental|Intervention|Five modules of training on hemovigilance were given in 5 hours. A pre-test was applied at the beginning of the training. The final test was done at the end of the training. One month later, the same test was applied again to measure the permanence of the training.
33321654|NCT05625672|No Intervention|Control|No training was provided. Only the pretest was administered one week after the posttest.
33321655|NCT00028002|Experimental|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
33321656|NCT03949998|Experimental|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
33321657|NCT03949998|Active Comparator|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
33321658|NCT03949998|Active Comparator|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
33321659|NCT00256997|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
33321660|NCT00256997|Active Comparator|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
33321661|NCT00027846|No Intervention|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
33321662|NCT00027846|Experimental|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
33321663|NCT00027846|Experimental|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
33321664|NCT05627622|Experimental|Experimental group,|Receiving stone-prevention information on a monthly basis, using WhatsApp Messenger® application.
33321665|NCT05627622|No Intervention|control group|will not receive stone-prevention information
33321666|NCT00027378|Experimental|1|fluoxetine plus Treatment As Usual (TAU)
33321667|NCT00027378|Placebo Comparator|2|placebo plus Treatment As Usual (TAU)
33321668|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
33321669|NCT03950154|Experimental|Arm 1:CIK|"Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells~Bevacizumab,7.5mg/kg,intravenousinfusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; PD1-T cells, 1x10^10 (10 billion),intravenous infusion,17; Q3W,after 6 cycles; Bevacizumab, 7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2;Oral administration,d1-14; PD1-T cells,1x10^10(10 billion),intravenous infusion,d17; Q3W, maintenance treatment."
33409490|NCT03702816|Experimental|Alzheimer's Disease|"Alzheimer's Disease (N=20)~GE180 PET Scan"
33409491|NCT03702816|Experimental|Parkinson's Disease|"Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)~GE180 PET Scan"
33409492|NCT03702816|Experimental|Control|"Control Group (N=10)~GE180 PET Scan"
33409493|NCT03702816|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)~GE180 PET Scan"
33409494|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
33409495|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
33409496|NCT04387812|Experimental|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
33409497|NCT03697590|Experimental|PDT with no curettage|
33409498|NCT03697590|Active Comparator|Standard PDT|
33409499|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
33409500|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.~The duration will be matched to that during the cold exposure."
33409501|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
33409502|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
33409503|NCT04050384|No Intervention|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
33409504|NCT04050384|Experimental|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
33409505|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
33409506|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
33409507|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
33409508|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
33409509|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
33033477|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
33409510|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
33409511|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
33409512|NCT03702660|Active Comparator|GLP-1|
33409513|NCT03702660|Experimental|GLP-1 + GIP(3-30)NH2|
33409514|NCT04486950|Experimental|Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes|TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
33409515|NCT04486950|Experimental|Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes|TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
33409516|NCT04486950|Experimental|Cohort 3: TAK-951 1 mg Infusion Over 120 Minutes|TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
33409517|NCT03699852|Experimental|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
33409518|NCT03699852|Other|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
33409519|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
33417283|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
32859094|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
32859095|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
32859096|NCT03291431|Active Comparator|Active iTBS|
33409520|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
32859097|NCT03291431|Sham Comparator|Sham iTBS|
32859098|NCT03289949|Other|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
33409521|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
33409522|NCT04050696|Experimental|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
33409523|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)~Dosage form: Per Os (Oral)~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
33409524|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors~Dosage form: Per Os (Oral)~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
33409525|NCT04693416|Experimental|Intrapersonal Stigma Reduction|The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
33409526|NCT04693416|Experimental|Interpersonal Stigma Reduction|The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.
33409527|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
33409528|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
33409529|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
33409530|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
32859099|NCT03289949|Other|Project 2: Long term effects of psilocybin|"After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.~Subproject B: After baseline MRI & UCB-J PET-imaging, participants will receive one dose of oral psilocybine intervention. One week after dosing, participants will undergo post-intervention UCB-J PET-scan.~Subproject C: After baseline MR imaging, participants will receive one dose of oral psilocybine (one of two doses: 3mg or ~0.3 mg/kg). One month after dosing, participants will undergo a post-intervention MRI scan."
32859100|NCT03289949|Other|Project 3: Functional connectivity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
32859101|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
32859102|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
32859103|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
33321670|NCT03950154|Active Comparator|Arm 2: Control|"Bevacizumab & Oxaliplatin & Capecitabine~Bevacizumab,7.5mg/kg,intravenous infusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; Q3W,after 6 cycles; Bevacizumab,7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2, Oral administration,d1-14; Q3W, maintenance treatment."
33321671|NCT03949062|Experimental|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
33321672|NCT00235391|Experimental|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
33321673|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
33321674|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
33321675|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
33321676|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
33321677|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
33321678|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
33321679|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
33321680|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
33321681|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
33321682|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
33321683|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
33321684|NCT01326143||ORM Narval MRD|
33321685|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
33321686|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
33321687|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
33321688|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
32859104|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
32859105|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
32907542|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32907543|NCT04364594|Experimental|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
33321689|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
33321690|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
33321691|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
33321692|NCT02981108|Experimental|Phase 2 Extension|Oral Once-Daily Administration of HS-10296 110mg (RP2D)
33321693|NCT00234533|Experimental|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:~GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight~TS patients: up to 0.05 mg/kg bodyweight~CRI patients: up to 0.05 mg/kg bodyweight~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
33321694|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
33321695|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
33321696|NCT00026208|Experimental|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.~Radiotherapy = 20 Gy modified involved field radiotherapy"
33321697|NCT00026208|Experimental|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
33321698|NCT02955290|Experimental|Phase I (CIMAvax, nivolumab)|"LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks."
33321699|NCT02955290|Experimental|Phase II Study A and B (CIMAvax, nivolumab)|PHASE II STUDY A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.
33321700|NCT02955290|Experimental|Phase II Study C (CIMAvax, pembrolizumab)|PHASE II STUDY C: Patients with PD-L1 expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 2 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
33321701|NCT02955290|Experimental|Phase II Study D (CIMAvax, pembrolizumab)|PHASE II STUDY D: Patients with PD-L1 expression < 50% after 4 cycles of induction chemotherapy with pembrolizumab, receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
33321702|NCT03765476|Active Comparator|TAU|treatment as usual
33321703|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
33321704|NCT00025662|Experimental|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
33321705|NCT02948036|Experimental|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
33321706|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
33321707|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
33321708|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
33321709|NCT03759158|Placebo Comparator|Placebo|
33321710|NCT02922764|Experimental|Recurrent NSCLC (2nd/3rd Line Lung Cancer). Expansion|"RGX-104 in combination docetaxel~RGX104 120 mg BID (5day on/2days off)"
33321711|NCT02922764|Experimental|Newly dignosed NSCLC Cohort Expansion|"RGX104 + pembrolizumab + carboplatin/pemetrexed~RGX104 120 mg BID (5day on/2days off)"
33321712|NCT02922764|Experimental|Recurrent/Relapsed Small Cell Lung Cancer (SCLC) Expansion|"RGX-104 + docetaxel~RGX104 120 mg BID (5day on/2days off)"
33321713|NCT02922764|Experimental|Recurrent/Relapsed Endometrial Cancer Expansion|"RGX-104 combined with ipilimumab~RGX104 120 mg BID (5day on/2days off)"
33321714|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
33321715|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
33321716|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
33321717|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
33321718|NCT00025506|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33321719|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
33321720|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
33321721|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
33321722|NCT05461040|Experimental|Optic capture of Intraocular lens without anterior vitrectomy (Group 1)|
33321723|NCT05461040|Experimental|in-the-bag implantation of Intraocular lens with anterior vitrectomy (Group 2).|
33321724|NCT00024258|Experimental|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2-3 months for 1 year and then annually thereafter."
33321725|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
33321726|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
33321727|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
33321728|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
33321729|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
33321730|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
33321731|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
33321732|NCT01321658|Experimental|Geriatric intervention|
33409531|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
33409532|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
32859106|NCT04400279|Experimental|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
32859107|NCT04400279|Experimental|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
33409533|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
33409534|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
33409535|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
33409536|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
33409537|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
33409538|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
33409539|NCT04684368|Experimental|Plan A (chemotherapy, WVSCI, second-look surgery if needed)|See Outline in Detailed Description.
33409540|NCT04684368|Experimental|Plan B (chemotherapy, HDCSCR, second-look surgery if needed)|See Outline in Detailed Description.
33409541|NCT00265941|Active Comparator|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
33409542|NCT00265941|Experimental|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
33409543|NCT04367922|Experimental|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
33409544|NCT03377361|Experimental|Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib|
32859108|NCT04400279|Experimental|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
32859109|NCT04400279|No Intervention|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
32859110|NCT05329493|Experimental|Cooling digit device application|Device: Cooling digit device. The cooling finger device will be applied in the subjects on their right hand. Subjects will serve as their own control.
32859111|NCT04400045|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
32859112|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32859113|NCT05289635|Experimental|test group|vertical mattress suture
32859114|NCT05289635|Other|control group|horizontal mattress suture
32859115|NCT05288933|Active Comparator|Group (A) conventional physical therapy|20 participants will receive conventional physical therapy.TENS, the frequency of the current is 100 Hz and the duty cycle is 250 microseconds, three times per week for 4 weeks. Ultrasound waves, frequency 1 MHz with intensity 1 W/cm2, a pulsed mode for 5 minutes, three times per week for 4 weeks, passive stretching, and isometric exercises three times per week for 4 weeks.
33321733|NCT01321658|No Intervention|Control|
33321734|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
33321735|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
33409545|NCT03377361|Experimental|Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib|
33409546|NCT03377361|Experimental|Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib|
33409547|NCT03377361|Experimental|Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib|
33409548|NCT03377361|Experimental|Part 2 Cohort 5 (3L): Regorafenib|
32964069|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
32964070|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
33409549|NCT03377361|Experimental|Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib|
33409550|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
33409551|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
33409552|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
33409553|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
33409554|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
33409555|NCT04552899|Experimental|PRM-151|Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
33409556|NCT04552899|Placebo Comparator|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
33409557|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
33409558|NCT04477512|Experimental|Level 1: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 20 mg.
33409559|NCT04477512|Experimental|Level 2: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 40 mg.
33409560|NCT04477512|Experimental|Expansion: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be dependent on recommended dose found in first part of study
33409561|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
33409562|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
33409563|NCT04343430|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
33409564|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33409565|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33409566|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
33409567|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
33409568|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
33409569|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
33409570|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
33409571|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
33409572|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
33409573|NCT05378763|Experimental|Poziotinib 8 mg|Participants will receive poziotinib 8 mg, orally, BID, in 21 day cycles or until disease progression, death, intolerable adverse events (AEs), initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
33409574|NCT05378763|Active Comparator|Docetaxel 75 mg/m^2|Participants will receive docetaxel 75 mg/m^2, intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression, death, intolerable AEs, initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
33409575|NCT04462302|Experimental|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
33409576|NCT04462302|No Intervention|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
33409577|NCT03203473|Experimental|Overall cohort: Initial Primary Treatment with Nivolumab (induction phase)|"Therapy with nivolumab IV every 2 weeks~Serial imaging assessments every 8 weeks~After confirmatory scans, patients are assigned to Arm A or Arm B."
33409578|NCT03203473|Experimental|Arm A: Observation Arm (for patients with persistent response to induction nivolumab)|"Patients with persistent response (complete or partial response) to induction nivolumab are assigned to Arm A (Observation Arm).~Patients discontinued nivolumab after allocation to Arm A.~Serial imaging assessments every 8 weeks.~If scans persistently show PR/CR, patients remained on observation.~If progressive disease develops, therapy with nivolumab (480 mg IV every 4 weeks) will be resumed.~If there is subsequent progression on nivolumab monotherapy, ipilimumab (1 mg/kg IV every 3 weeks x 2 doses) is added.~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
33409579|NCT03203473|Experimental|Arm B: Nivolumab+Ipilimumab then nivolumab alone (for patients with SD/PD to induction nivolumab)|"Patients with confirmed SD/PD to induction nivolumab are allocated to Arm B (Combination Therapy Arm).~In combination therapy, patients received nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for two doses.~After then nivolumab will be continued at 480 mg IV every 4 weeks until disease progression.~Arm B patients undergo imaging at 12 weeks and then every 8 weeks."
33409580|NCT05375799||COVID-19 in use of ELMO|This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, who used the Assisted Breathing Helmet - ELMO.
33409581|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
33409582|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
33409583|NCT05420883|Active Comparator|Acupressure|One minute after the start of the Nonstress test recording, an application will be made to the Zhi yin (BL67) acupuncture point with a depth of 0.1-0.2 cm, on the outer edge of the little toe of both feet, at the nail end point. The application will be applied to both points simultaneously for 2 minutes consecutively and then repeated 2 times with a 3-minute rest period.
33409584|NCT05420883|Active Comparator|Halogen light|One minute after the start of the Nonstress Test recording, halogen light stimulation will be given from the mother's abdomen to the fetal head for 10 seconds with a flashlight device worth 1,000,000 candles. The procedure will be repeated on the same spot 10 minutes after the first halogen light stimulation.
33409585|NCT05420883|Active Comparator|Control|No action will be taken against this group.
32964071|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
33409586|NCT04665973|Experimental|Oral semi-structured interview|The oral semi-structured interview uses the principles of motivational interviewing (partnership with the patient, no judgment, altruism, evocation) and follow the content of the booklet used in the control group.
32964072|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
32964073|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
32964074|NCT02048670|Experimental|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
32964075|NCT02048670|Active Comparator|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
32964076|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
32964077|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
32964078|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
32964079|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
32964080|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
32964081|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
32964082|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
32964083|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
32964084|NCT02057952|No Intervention|Usual Care Control|No intervention.
32964085|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
32964086|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
32964087|NCT02059512|Active Comparator|Group 1|Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.
32964088|NCT02059512|Placebo Comparator|Group 0|Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.
32964089|NCT02059512|Active Comparator|Group 2|Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.
32964090|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
32964091|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
33033478|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
33104815|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
33409587|NCT04665973|Active Comparator|Booklet|The information booklet was designed by the physiotherapists at Cliniques universitaires Saint-Luc and is specifically dedicated to raise patient's awareness about the benefits of physical activity (PA) in the context of cancer.
33409588|NCT04530513|Experimental|Dose Level 1|
33409589|NCT04530513|Experimental|Dose Level 2|
33409590|NCT04530513|Experimental|Dose Level 3|
33409591|NCT04530513|Experimental|Dose Level 4|
33409592|NCT04530513|Experimental|De-escalation Level|
33409593|NCT03696654|No Intervention|Before treatment|
33409594|NCT03696654|Active Comparator|After treatment|
33409595|NCT05420571|Experimental|digital impression module|In the experimental group, digital impressions and 3D printed models were used and fitted pads were made. Patients were instructed to wear the hinge pad for 24 hours, and x-rays were taken and intraoral examinations were performed at 2 weeks and 4 weeks.
33409596|NCT05420571|Active Comparator|ordinary impression group|The control group used alginate impression and plaster model infusion to make the model and make the fitting pad. Patients were instructed to wear the pad for 24 hours, and x-rays and intraoral examinations were taken at 2 and 4 weeks.
33409597|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
33409598|NCT05420415||High-CSTME|Patients with high tumor microenvironment collagen signature
33409599|NCT05420415||Low-CSTME|Patients with low tumor microenvironment collagen signature
33409600|NCT04333524||Group A|Staging
33409601|NCT04333524||Group B|Criteria for response assessment
33409602|NCT02937571|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone|"Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.~Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16~Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days~Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23~Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
33409603|NCT03882957|Active Comparator|Video|videos of media tasks being completed
33409604|NCT03882957|Experimental|media multi-task|media tasks
33409605|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
33409606|NCT04333290|Experimental|Single Arm: Healthy subjects|The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
33409607|NCT04331340|Experimental|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
33409608|NCT04331340|Active Comparator|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
33409609|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
33409610|NCT03201211|Experimental|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
33409611|NCT03201211|Experimental|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
33409612|NCT03201211|Placebo Comparator|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
33409613|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
33409614|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
33409615|NCT04633837|No Intervention|Group 1 Control|Group 1 will undergo standard arthroscopic shoulder surgery without the ECM injection.
33409616|NCT04633837|Active Comparator|Group 2: ECM Injectable graft|Group 2 will undergo arthroscopic shoulder surgery and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
33409617|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
33409618|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
33417284|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
33033479|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
33033480|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
33104816|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
33417285|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
33104817|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
33409619|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
33409620|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
33409621|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
33409622|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
33409623|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
32859116|NCT05288933|Experimental|Group (B )IASTM and conventional physical therapy|20 participants will receive Instrument-Assisted Soft Tissue Mobilization (IASTM) and conventional physical therapy, the M2T blade will be used to find the exact areas of restriction in the upper trapezius. Then the M2T blade will be used, at an angle of 45 and using treatment planes 1, 2, and 3, to apply slow strokes along with the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. This procedure will be repeated twice a week for four weeks
32859117|NCT05288933|Experimental|Group (C) HPPT US and conventional physical therapy|20 participants will receive High Power Pain Threshold Ultrasound (HPPT US) and conventional physical therapy. For the HPPT US, ultrasound waves will be applied to trigger points of the upper trapezius in continuous mode, and the power of ultrasound will first increase to the threshold pain level at intensity (1.5-2 W/cm) according to the patient for 4-5 seconds with the probe placed directly on the trigger point and held motionlessly and then reduced to one-half of that intensity for15 seconds with the probe placed directly on the trigger point and move in a circular motion and repeat this three times. This procedure will be repeated twice a week for two weeks
33409624|NCT04871893|Other|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal|Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.
33409625|NCT05598879||Breast cancer|Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
33409626|NCT05598879||Hematological malignancies|Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
33409627|NCT05598879||Immune check point inhibitors|Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months
33409628|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
33409629|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
33409630|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
33409631|NCT04472949|Experimental|Durvalumab & thoratic radiotherapy|"Patients will start with an induction phase (part 1). Patients with CR; PR or SD after the induction phase, will transfer to the maintenance phase (part 2). Patients with PD after the induction phase will transfer to the follow-up phase.~Induction phase (part 1):~Patients will receive durvalumab in combination with carboplatin and etoposide for 4 cycles of 21 days:~Maintenance phase (part 2):~Patients will receive durvalumab treatment up to PD or max. 2 years, i.e. 26 maintenance cycles, in combination with tRT:~Follow up phase:~Patients will be followed up for 24 months, every 8 weeks."
33409632|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
33409633|NCT03696186|Experimental|Luminal type-2|Experimental treatment
33409634|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
33409635|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
32859118|NCT05286593|Other|Normal volunteers|Normal participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
32859119|NCT05286593|Other|Clinical patients|Clinical patients participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
32859120|NCT05286593|Other|Infarcts|Infarct participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
32964092|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
33033481|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
33409636|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
33409637|NCT03696186|Experimental|Atypical type-2|Experimental treatment
33409638|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
33409639|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).
33409640|NCT03336333|Experimental|Cohort 1, Arm A: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
33409641|NCT03336333|Experimental|Cohort 1, Arm B: B+R|Participants will receive bendamustine plus rituximab for up to six 28-day cycles
33409642|NCT03336333|Experimental|Cohort 1a, Arm A (China only): Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
33409643|NCT03336333|Experimental|Cohort 1a, Arm B (China only): B + R|Participants will receive bendamustine plus rituximab for up to six 28-day cycles
33409644|NCT03336333|Experimental|Cohort 2, Arm C: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
33409645|NCT03336333|Experimental|Cohort 3, Arm D: Venetoclax + zanubrutinib|Approximately 110 participants, 50 without del17p and 60 with del[17p] or TP53 mutation will receive venetoclax until unacceptable toxicity, disease progression, or for maximum of 24 cycles; Participants will also receive zanubrutinib for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first. Each cycle is 28 days.
33409646|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
33409647|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
33409648|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
33409649|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
33409650|NCT04658472|Experimental|SOC-Refractory Initial Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they will not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
33409651|NCT04658472|Experimental|SOC-Refractory Low Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility and will be given the option to roll into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
33409652|NCT04658472|Experimental|SOC-Treated|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Administration of SAR445088 with superimposing effects of SOC therapy; Weeks 13-24: SAR445088 administered. Participants who do not enroll in Part B will be asked to attend a final safety follow-up visit at 22 weeks after Week 24 (approximately Week 46).~Part B: Participants who successfully complete Part A will be reassessed for continued eligibility, given option to roll into Part B and continue receiving SAR445088 an additional 52 weeks. At the end of the Part B treatment period participants will attend a safety follow-up visit that takes place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue any time during Part C will attend safety follow-up visit that takes place 22 weeks after last SAR445088 dose."
33409653|NCT04658472|Experimental|SOC-Naive|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
33409654|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
32859121|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
32859122|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
33409655|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
33409656|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
33409657|NCT04431453|Experimental|Remdesivir (RDV)|"Participants will receive RDV up to 10 days. The RDV dose administered in each cohort is as follows:~Cohort 1: intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg daily~Cohorts 2-5: IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily~Cohort 6-7: IV RDV 2.5 mg/kg on Day 1 followed by IV RDV 1.25 mg/kg daily for up to 10 days~Cohort 8: IV RDV 200 mg on Day 1 followed by IV RDV 100 mg daily"
33409658|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
33409659|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
33409660|NCT04420221|Experimental|Half dose non-adj Group 1a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1.
33409661|NCT04420221|Placebo Comparator|Placebo Group 1b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
33409662|NCT04420221|Experimental|Full dose non-adj Group 2a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1
33409663|NCT04420221|Placebo Comparator|Placebo Group 2b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
33409664|NCT04420221|Experimental|Half dose adj Group 3a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1.
33409665|NCT04420221|Placebo Comparator|Placebo Group 3b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
33409666|NCT04420221|Experimental|Full dose adj Group 4a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61)
33409667|NCT04420221|Placebo Comparator|Placebo Group 4b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
33409668|NCT04420221|Experimental|Vaccine Group 5a|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61).
33409669|NCT04420221|Placebo Comparator|Placebo Group 5b|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
33409670|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
33409671|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
33409672|NCT04419558|Experimental|Pamrevlumab|"Treatment phase: Pamrevlumab 30 mg/kg administered by IV infusion, every 3 weeks, for a total of up to 17 infusions over 48 weeks.~Open-label extension phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks for up to 48 weeks"
33409673|NCT04419558|Experimental|Placebo|Pamrevlumab-matching placebo administered by IV infusion every 3 weeks for a total of up to 17 infusions over 48 weeks
33409674|NCT03929913|Experimental|Transcatheter Mitral Valve Cerclage Annuloplasty|"To evaluate the feasibility and safety of Transcatheter Mitral Cerclage Annuloplasty (TMCA) to treat symptomatic heart failure accompanied by mitral valve regurgitation despite optimal medical therapy.~The TMCA implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspid valve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branch of the left coronary artery."
33409675|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
33409676|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
32859123|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
32859124|NCT04278599|Experimental|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
32859125|NCT04278599|Placebo Comparator|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
32859126|NCT05277623|Active Comparator|mannitol group|
32859127|NCT05277623|Placebo Comparator|control group|
32859128|NCT01223469|Experimental|Atrial Fibrillation|
32859129|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
32859130|NCT01223703|Active Comparator|n-3 PUFAs|
32859131|NCT01223703|Placebo Comparator|Placebo|
32859132|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
33409677|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
33409678|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
33409679|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
33409680|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
33409681|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
33409682|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
33409683|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
33409684|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
33409685|NCT04648098|Experimental|Experimental: Intervention group|Discharge training and telephone counseling
33409686|NCT04648098|No Intervention|No Intervention: Control Group|Routine care
33409687|NCT04640142|Experimental|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
33409688|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
32859133|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
32859134|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
32859135|NCT05250947|Experimental|PRP Injection Arm|The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
33409689|NCT03029832|Active Comparator|Atezolizumab|
33409690|NCT04416243|Experimental|Recumbent Stepping, High-Intensity Interval Training|
33409691|NCT04412187|Other|TSPO PET imaging|All study participants will receive [18F]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
33409692|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
33409693|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
32859136|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
32859137|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
32859138|NCT04760327|Experimental|Electrochemotherapy of gynecological cancers|
32859139|NCT05235581|Experimental|BCAD's arm|The 4 interventions are in the BCAD's order.
32859140|NCT05235581|Experimental|BACD's arm|The 4 interventions are in the BACD's order.
32859141|NCT05235581|Experimental|CABD's arm|The 4 interventions are in the CABD's order.
32859142|NCT05235581|Experimental|ACBD's arm|The 4 interventions are in the ACBD's order.
32859143|NCT05232383|Active Comparator|Wp|
32859144|NCT05232383|Active Comparator|Wn|
32859145|NCT05232383|Active Comparator|Gn|
32859146|NCT05232383|Active Comparator|Gp|
32859147|NCT05232383|Active Comparator|Rp|
32859148|NCT05232383|Active Comparator|Rn|
33409694|NCT04391595|Experimental|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
33409695|NCT04252638|Experimental|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
33409696|NCT04252638|Active Comparator|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
33417286|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
33417287|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
32859149|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
32859150|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
33033482|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
33033483|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
33409697|NCT05598567||TCI Group|"Anesthesia induction will be provided by infusion of Propofol and Remifentanil with an infusion pump device called TCI (target controlled infusion). When the bispectral index (processed EEG) levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg, and 3 minutes after that, endotracheal intubation will be performed. Propofol and Remifentanil infusion and TCI-TIVA will be continued in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
33409698|NCT05598567||Sevoflurane Group|"Anesthesia induction will be provided by administration of propofol 2 mg/kg, remifentanil 1 mcg/kg . When the processed EEG levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg. 3 minutes after that, endotracheal intubation will be performed. Conventional balanced inhalation-intravenous anesthesia will be provided by administering remifentanil at 0.05 mcg/kg/min and sevoflurane 2% in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
33409699|NCT04050228|No Intervention|Standard Neoadjuvant Chemotherapy Monitoring|
33409700|NCT04050228|Experimental|Adaptive Chemotherapy Monitoring|
33033484|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
33409701|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
33409702|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
33409703|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
33409704|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
33409705|NCT03692754|Experimental|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
33409706|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
33409707|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
33409708|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
33409709|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
33409710|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
33409711|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
33409712|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
33409713|NCT04224558|Experimental|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.~Interventions include:~Stem cell mobilization~Leukopheresis~Preparative regimen~Peripheral blood stem cell infusion~Post-PBSC infusion conditioning"
33409714|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
33409715|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
33409716|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
33409717|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
33409718|NCT05598411|Experimental|Oral Glucocorticoids group|Intervention Period：oral glucocorticoids（methylprednisolone 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
33409719|NCT05598411|Placebo Comparator|Placebo group|Intervention Period：oral placebo+nasal spray（oral placebo 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
33409720|NCT05598333|Experimental|NAN-101|"Randomized in 1:1:1 into one of three groups.~Group 1: 3.25E13vg (n=30-50)"
33409721|NCT05598333|Experimental|Treatment Group 2 NAN-101|"Randomized in 1:1:1 into one of three groups.~Group 2: 6.5E13vg (n=30-50)"
33033485|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
33409722|NCT05598333|Placebo Comparator|Treatment Group 3|"Randomized in 1:1:1 into one of three groups.~Group 3: Placebo (n=30-50)"
33417288|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
33409723|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
33409724|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
33409725|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
33409726|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
33409727|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
33409728|NCT04043364|Experimental|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
33409729|NCT04043364|No Intervention|Treatment as usual|Care coordination and facilitation as usual.
32859151|NCT05224271||Observational (surveys, medical records & Fitbit collection)|Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.
32859152|NCT05217173|Experimental|Intervention group|"Rehabilitation service that will be provided remotely through information and communication technologies. It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks.~The content of the rehabilitation program will consist of e modules: 1) Information module on the disease and self-care, 2) Exercise module (Stretching, strengthening and proprioception)."
32859153|NCT05217173|No Intervention|Control group|Care service that is carried out by the Family Physician. The medical care that the patient with an ankle sprain will carry out with the Family Physician of the assigned office; Medical care will consist of the approach that the Doctor considers appropriate for the patient. The follow-up and time of disability will be the responsibility of the Physician in question
32859154|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
32859155|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
32859156|NCT05179265|Placebo Comparator|Control group|0.45 g/bottle，50 mL
32859157|NCT05179265|Experimental|test group|10 g/bottle (20%, 50 mL)
32859158|NCT01226979|Experimental|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
32859159|NCT04278287|Experimental|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
32859160|NCT05169905|Experimental|RSV_dTpa-P Group|"Healthy non-pregnant girls 9-17 years of age were scheduled to receive a single dose of RSV MAT vaccine at Day 1 and a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration).~Participants who are enrolled and are due to receive the dTpa vaccine at Day 31 will no longer receive the dTpa as part of this study, but they will be provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization outside this study."
32859161|NCT05169905|Experimental|dTpa_RSV-P Group|"Healthy non-pregnant girls 9-17 years of age were scheduled to receive a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration).~RSV MAT vaccine will no longer be administered to participants at Day 31."
32859162|NCT05169905|Experimental|RSV_dTpa-A Group|"Healthy non-pregnant adult women 18-49 years of age were scheduled to receive a single dose of RSV MAT vaccine at Day 1 and a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration).~Participants who are enrolled and are due to receive the dTpa vaccine at Day 31 will no longer receive the dTpa as part of this study, but they will be provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization outside this study."
32964093|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
33033486|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
33409730|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
33409731|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
33409732|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
33409733|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
33409734|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
33409735|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
33409736|NCT05654766||Control group|Group of healthy adult and pediatric participants, whose blood platelets will be used to evaluate normal ranges of parameters in the flow cytometry PFT.
33409737|NCT05654766||Hemorrhagic syndrome and Acute Leukemia|Group of pediatric participants with any manifestations of hemorrhagic syndrome and/or acute leukemia
33409738|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
33409739|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
33409740|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
33409741|NCT04302870|Experimental|Memantine|
33409742|NCT04302870|Experimental|Trazodone|
33409743|NCT04302870|Placebo Comparator|Placebo|
33409744|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
33409745|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
33409746|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
33409747|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
33409748|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
33409749|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
33409750|NCT04296864|Placebo Comparator|Placebo|Placebo of Dupilumab
33409751|NCT04296864|Experimental|Dupilumab|one loading dose of Dupilumab 600 mg followed by Dupilumab 300 mg weekly for a total of 16 weeks
33409752|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
33409753|NCT04059900|Experimental|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
33033487|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
33409754|NCT04059900|Placebo Comparator|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
33409755|NCT04295148|Active Comparator|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
33409756|NCT04295148|Active Comparator|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
33409757|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
33409758|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
33409759|NCT04208490|Other|HN-STAR|
33409760|NCT04208490|No Intervention|Usual Care|
33409761|NCT04207944|Experimental|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
33409762|NCT04207944|Placebo Comparator|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
33409763|NCT04203498|Experimental|Nabiximols|
33409764|NCT04203498|Placebo Comparator|Placebo|
33409765|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
33409766|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
33409767|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
33033488|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
33409768|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
33409769|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
33409770|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
33409771|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
33409772|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
33409773|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
33409774|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
33409775|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
33409776|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
33409777|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
33409778|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
33409779|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
33409780|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
33409781|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
33409782|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
33409783|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
33409784|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
33409785|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
33033489|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
33409786|NCT04059978|Active Comparator|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
33409787|NCT04059978|Placebo Comparator|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
33409788|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
33409789|NCT03199963|Placebo Comparator|Matching Placebo Gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
33409790|NCT04547257|Experimental|Treatment|Extracorporeal therapy with Seraph 100 blood filter
33409791|NCT04547257|No Intervention|Control|patients receive antibiotics only as standard of care
33409792|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
33409793|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
33409794|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
33409795|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
33409796|NCT03883581|Experimental|ALS individuals with bulbar dysfunction|Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.
33409797|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
33409798|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
33409799|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
33409800|NCT03113643|Experimental|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
33409801|NCT03113643|Experimental|SL-401+ Azacitidine + Venetoclax|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally
33409802|NCT05324397|Experimental|Experimental: Treatment|Subjects will undergo treatment with the NEUROMARK System
33409803|NCT03091491|Experimental|Nivolumab|
33409804|NCT03091491|Experimental|Nivolumab and Ipilimumab|
32907544|NCT04370600|Active Comparator|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
32907545|NCT04370600|Active Comparator|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
32907546|NCT04364204|Experimental|Kangaroo mother care with bracelet|
32907547|NCT04364204|Active Comparator|Kangaroo mother care|
32907548|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
32907549|NCT02242838||Hypertensive patients|
32907550|NCT03207347|Experimental|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
32859163|NCT05169905|Experimental|dTpa_RSV-A Group|"Healthy non-pregnant adult women 18-49 years of age were scheduled to receive a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration).~RSV MAT vaccine will no longer be administered to participants at Day 31."
32859164|NCT05164055|Experimental|Avalglucosidase alfa|Administered intravenously every other week
32859165|NCT05162027|Active Comparator|Erenumab-aooe|"Erenumab-aooe 70 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
32859166|NCT05162027|Placebo Comparator|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other name: Placebo"
32859167|NCT05160233|Active Comparator|Standard Implementation|All primary care clinics will implement reSET and reSET-O using standard implementation approach.
32859168|NCT05160233|Experimental|Standard Implementation Plus Health Coaching|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
32859169|NCT05160233|Experimental|Standard Implementation Plus Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.
32859170|NCT05160233|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
32859171|NCT05141435|Active Comparator|NCPAP|
32859172|NCT05141435|Active Comparator|NHFOV|
32859173|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
32859174|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
32859175|NCT05138471|Experimental|tDCS Active vs TENS Active|
32859176|NCT05138471|Experimental|tDCS Active vs TENS Placebo|
33409805|NCT05598255|Active Comparator|Caudal blockade (with levobupivacaine) and dexamethasone iv|Administration of levobupivacaine 0,25% 0,5 ml/kg through the hiatus sacralis lege artis. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
33409806|NCT05598255|Active Comparator|Dorsal penile nerve block (with levobupivacaine) and dexamethasone iv|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
33409807|NCT05293353||Breast Milk Fortification with NeoKare|Prospective cohort, 50 infants
33409808|NCT05293353||No Breast Milk Fortification|Retrospective, historical cohort, approx 50 infants
33409809|NCT04733235||with endometrial compaction|Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
32859177|NCT05138471|Placebo Comparator|tDCS Placebo vs TENS Placebo|
33409810|NCT04733235||without endometrial compaction|Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
33409811|NCT05598177|Experimental|Group D|The participant will be infused with dexmedetomidine during anesthesia to protect the myocardium.
33409812|NCT05598177|Placebo Comparator|Group R|The participant will use saline of the same volume as dexmedetomidine as a placebo during anesthesia.
32859178|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
32859179|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
32859180|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
32859181|NCT05136287||Diabetes mellitus 2 patients with obesity|Patients that meet criteria to start treatment with GLP-1 receptor agonists (dulaglutide; exenatide; liraglutide; lixisenatide )
32859182|NCT03278717|Experimental|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
32859183|NCT03278717|Active Comparator|Olaparib|"Patients will receive oral olaparib 300mg BD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
32859184|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
32859185|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
32859186|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
32859187|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
32859188|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
32859189|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
32859190|NCT05099237|Active Comparator|1. Colorectal Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with colorectal cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-C survey).~Report specific symptoms on an ad-hoc basis as they wish."
32859191|NCT05099237|Active Comparator|2. Lung Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with lung cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-L survey).~Report specific symptoms on an ad-hoc basis as they wish."
32859192|NCT05099237|Active Comparator|3. Haematological Cancer|"Participants (with haematological malignancy about to start treatment with CAR T-cell therapy or another cellular therapy product) will be asked to:~Wear an OURA ring and Withings ScanWatch for approx five weeks including whilst they are in hospital (prior to CAR T-cell therapy and continue for 28 days post infusion)~Wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.~Supported to take daily weights using Withings Body Scale.~Asked to complete weekly electronic quality of life surveys~Provide a series of 12 blood samples to measure inflammatory molecules at various intervals"
33409813|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
33409814|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
32859195|NCT01155999|Experimental|T1225|
32859196|NCT01155999|Active Comparator|Tobramycin|
32859197|NCT05094401|Experimental|Intervention BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
32859198|NCT05092763|Experimental|FIT4SURGERY Intervention|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls.
32859199|NCT05092763|Active Comparator|Healthy Lifestyle Control|The Healthy Lifestyle Control group engages in their usual activities and receives education about physical activity and a healthy lifestyle for ovarian cancer patients. They receive weekly check in calls.
32859200|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients >30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
32859201|NCT05087069|Experimental|BV100|BV100 intravenous infusion
32859202|NCT05087069|Placebo Comparator|Placebo|Saline intravenous infusion
32859203|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
32859204|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
32859205|NCT05071157||anorexia nervosa|girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
32859206|NCT05071157||obesity|girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
32859207|NCT05071157||normal weight|girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
32859208|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
32859209|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
32859210|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
32859211|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
32859212|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
32859213|NCT02192307|Experimental|potassium oxalate gel|Professional application
32859214|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
32859215|NCT05052281|Experimental|Intervention group|"The first MB course session and technology training will take place in-person, prior to 23 weeks gestation. The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress. Sessions are delivered 1-on-1 with a trained facilitator and are based on principles of cognitive-behavioral therapy (CBT) and attachment theory. The MB course is divided into 3 sections: 1) Pleasant Activities; 2) Thoughts; 3) Contact with Others. Throughout each module, mindfulness skills training will be integrated as a strategy to help center participants. All participants will receive a Participant Manual for Families, containing worksheets that correspond to the 12 sessions."
32859216|NCT05052281|Active Comparator|Stress monitoring (control) group|This group will not receive any additional intervention but will engage in stress monitoring via biosensors and EMA text messages through the 14 week period
32859217|NCT05004233|Experimental|Ischemic stroke patients|Patients hospitalized for an ischemic stroke.
32859218|NCT04991831||Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease|This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
32859219|NCT04989413|Active Comparator|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day
33409815|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
33409816|NCT05292105||Coronary Artery Disease (CAD)|
32859220|NCT04989413|Placebo Comparator|Placebo|"Placebo capsules will be titrated up as follow:~day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day"
32859221|NCT04986839|Active Comparator|Ibuprofen|Standard treatment arm which will provide the comparator arm to the proposed new treatment. This is routine standard of practice
33409817|NCT03740529|Experimental|Phase I Dose Escalation (Pirtobrutinib Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
33409818|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
32859222|NCT04986839|Experimental|Paracetamol|To study the efficacy of Paracetamol (proposed new treatment) in treating hsPDA in comparison to Ibuprofen (current standard treatment) in preterm infants
32859223|NCT04968587|Other|Group 1: RACD - RCA|First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED
32859224|NCT04968587|Other|Group 2 : RCA - RACD|First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED
32859225|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
32859226|NCT04962737|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
32859227|NCT04961567|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC), every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
32859228|NCT04961567|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
32859229|NCT04961567|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
32859230|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
32859231|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
32859232|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
32859233|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
32859234|NCT04937153|Experimental|Single arm|GEN1046 open label, single arm trial where GEN1046 will be administered
32859235|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
32859236|NCT01230021|Experimental|recombinant factor XIII|
32859237|NCT03266081|Experimental|0.75% bupivacaine|
33409819|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
33409820|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
33409821|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
33409822|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
33321736|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
32859238|NCT04933565|Experimental|ORG-129|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
32859239|NCT04933565|Placebo Comparator|Placebo|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
32859240|NCT04926311||Developmental Language Disorder patients|
32859241|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
32859242|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
32859243|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
32859244|NCT04925219|Experimental|Remotely supervised exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months."
32859245|NCT04925219|Active Comparator|Self-directed exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Control = electronic walking log and instructions to exercise 4 times per week for 3 months"
32859246|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
32859247|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
32859248|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
32859249|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
32859250|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.~Investigators and Operators were blinded to all other results for a sample upon data entry."
32859251|NCT04278365|Experimental|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
32859252|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
32859253|NCT04904081|Experimental|Treatment Arm (Indocyanine Green [ICG])|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
32859254|NCT04904081|No Intervention|Control Arm (Standard Care)|The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.
32859255|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
32859256|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
32859257|NCT01158651|Experimental|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
32859258|NCT03263507|Experimental|Donidalorsen|Ascending single and multiple doses of Donidalorsen administered subcutaneously
32859259|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
32859260|NCT04852679|Other|lanreotide Autogel 120 mg|Subjects will be treated with lanreotide Autogel® 120mg, every 28 days (+/- 3 days).
32859261|NCT03683069|Experimental|Epleronone Arm|
32859262|NCT03683069|Experimental|Amlodipine Arm|
32859263|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 1|"A 3+3 dose escalation design will be used to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when combined with cemiplimab.~Participants will receive ASP8374 and Cemiplimab every 3 weeks for up to 2 years. ASP8374 will be available until October 31, 2022. Subjects may continue treatment with cemiplimab alone after that date."
33033490|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
33321737|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
33321738|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
33321739|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
33321740|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
33321741|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
33321742|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
33321743|NCT00023712|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33409823|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
32859264|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 2|"Upon determination of the MTD/RP2D of ASP8374 plus cemiplimab in Cohort 1, a dose expansion will be performed in which eligible participants who are candidates for surgical resection will enroll to Cohort 2 and will be randomized into one of two treatment groups (2A-2B).~Group 2A: IV ASP8374 plus cemiplimab within 14± 5 days prior to surgery at the MTD/RP2D established in Cohort 1.~Group 2B: No immune checkpoint therapy prior to surgery.~Post-operatively, all Cohort 2 participants will receive ASP8374 plus cemiplimab every 3 weeks administered at the MTD/RP2D established by Cohort 1"
32859265|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
32859266|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
32859267|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
32859268|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
32859269|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
32859270|NCT04811729|Experimental|Experimental Group|Intervention based on the Motivational Interview, previously receiving a training program
32859271|NCT04811729|Active Comparator|Control Group|Usual care based on a health counci
32859272|NCT04791527|Experimental|Mind-body Intervention arm|Online yoga, meditation, behavior change tips, and nutrition tips
32859273|NCT04779593|Experimental|experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin."
32859274|NCT04779593|Active Comparator|control group|"Patients treated with bloodletting according to current guidelines ferritin alone"
32859275|NCT04777643|Experimental|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
32859276|NCT04777643|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
32859277|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
32859278|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
32859279|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
32859280|NCT04776161|No Intervention|Control|Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).
32859281|NCT04776161|Experimental|Cue-Reward Intervention|Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.
32859282|NCT04776161|Experimental|Cue-Reward Intervention with possible intensification.|Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.
32859283|NCT04775225|Active Comparator|Hip denervation group|This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.
32859284|NCT04775225|Placebo Comparator|control group|this group will receive saline injection subcutaneously at the same places.
32859285|NCT04775225|Active Comparator|Steroid|This group with receiving an intra-articular injection of 80mg triamcinolone
32859286|NCT04746443||STUDENTS|COLLEGE STUDENTS WITH POSITIVE COVID-19 TEST
32859287|NCT04731467|Experimental|Part A- Dose escalation of CM24 in combination with nivolumab|
32859288|NCT04731467|Experimental|Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
32859289|NCT04731467|Experimental|Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
32859290|NCT04731467|Experimental|Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
32859291|NCT04731467|Experimental|Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
32859292|NCT04731467|Active Comparator|Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine|
32859293|NCT04731467|Active Comparator|Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV|
32859294|NCT04723277|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
32859295|NCT04723277|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
33033491|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
33104818|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
33104819|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
33409824|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 7|Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
33409825|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
33409826|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
33409827|NCT03740529|Experimental|Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)|Patients to receive the recommended Phase 2 dose of pirtobrutinib
32859296|NCT04723277|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
32859297|NCT04723277|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
32859298|NCT04723277|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
32859299|NCT04723277|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
32859300|NCT04719143|Active Comparator|CBT-I|
32859301|NCT04719143|No Intervention|Waitlist Control|
32859302|NCT04717895|Experimental|1st Situation|Subjects included will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment
32859303|NCT04717895|Active Comparator|2nd Situation|Subjects included will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment
32859304|NCT04715399||Cross-sectional|
32859305|NCT04715399||Longitudinal|
32859306|NCT05182775|Experimental|experimental group|This trial is a prospective study without a control group. It is planned to recruit 15 patients with IgA nephropathy. The experimental group received fecal bacteria transplantation through FMT capsule. The researchers will judge the effectiveness and safety of fecal bacteria transplantation in the treatment of IgA nephropathy by observing the changes of monitoring indicators before and after fecal bacteria transplantation and during follow-up. Donor screening and FMT capsule preparation were completed by Dongyuan Yikang company (www.dongyuanyikang. com).The patients participating in the trial took 16 Enterobacteriaceae capsules on day 1, day 8 and day 15 respectively as a course of treatment. The researchers will collect stool samples from patients one day before taking the medicine, one week after the last taking the medicine and one month after the last taking the medicine, and analyze the intestinal flora by sequencing
32859307|NCT04685915|Experimental|Addition of copanlisib to either ibrutinib or acalabrutinib|"During the 28-day study treatment cycles, participants will:~Continue to take ibrutinib (daily) or acalabrutinib (twice a day) at a predetermined dose for as long as there are no serious side effects and disease progression~Receive intravenous infusion of copanlisib at a predetermined dose days 1, 8 and 15 for cycles 1-6."
32859308|NCT04679441|Active Comparator|Healthy individuals Skills training only|These participants will receive CFSAT training only (n = 60). They will train for 24 hours over 12 weeks.
32859309|NCT04679441|Experimental|MCI, Skills training only|These participants will receive 24 hours of CFSAT training over 12 weeks following the same training protocol as the NC sample.
32859310|NCT04679441|Experimental|MCI, Combined treatment|Participants assigned to this condition will initially train for 3 weeks @ 60 minutes twice per week on CT (Posit Science). Participants will train 90 minutes on Double Decision and 30 minutes on Hawkeye. They can train on Hawkeye in 15- minute increments and intersperse it within the Double Decision training. They will then train CFSAT for 9 weeks at the recommended dosage. Each task will be trained twice before advancing to the next task
32859311|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
32859312|NCT04399187|Experimental|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets > 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
32859313|NCT04399187|Placebo Comparator|scaling and root planing alone|scaling and root planing alone was performed
32859314|NCT04659863|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
32859315|NCT04659863|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
32859316|NCT04277897|Experimental|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
32859317|NCT04277897|Placebo Comparator|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
32859318|NCT04277897|Experimental|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
33409828|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
32859319|NCT04277897|Placebo Comparator|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
32859320|NCT04277897|Experimental|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
32859321|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
32859322|NCT03251027|Experimental|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
32859323|NCT04655495|Experimental|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
32859324|NCT04655495|Active Comparator|Balanced gluten free diet|Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.
32859325|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
32859328|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
32859329|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
32859330|NCT03240731|Experimental|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention~Conditioning~THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7~THIOTEPA: 10mg/kg/j at D-7~CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D-6 and D-5~FLUDARABINE (Fludara®): 30mg/m2 per Day from D-6 to D-2~TBI : 2GY : D -1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.~Prophylaxis of GvHD~CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4~Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
32859331|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
32859332|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
32859333|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
32859334|NCT04746365|Experimental|ivermectin|ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
32859335|NCT04746365|Experimental|hydroxychloroquine|hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days
32859336|NCT04746365|Placebo Comparator|Placebo|Unlabelled standard treatment according to the clinical condition of patients
32859337|NCT04399577|Experimental|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
32859338|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
32859339|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
32859340|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
32859341|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
32859342|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
32859343|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
32859344|NCT04399343|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
32859345|NCT04399343|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
32859346|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
32859347|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
32859348|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
33409829|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
33104820|NCT05042778|Experimental|Auriculotherapy|Indwelling fixed semipermanent needles embedded in a skin-colored adhesive tape will be used in active points around the vagus nerve stimulation area.
33104821|NCT05042778|No Intervention|No intervention|No auriculotherapy will be applied.
33104822|NCT02711969|Experimental|Apatinib mesylate|
33104823|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
33104824|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
33104825|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
33104826|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
32859349|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
32859350|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
33104827|NCT04323631|Experimental|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
32859351|NCT04277429||Normal cardiac function|Normal cardiac function
32859352|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
32859353|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
32859354|NCT04347707|Experimental|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
32859355|NCT04347707|No Intervention|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
32859356|NCT01230801|Experimental|BMN 701|IV infusion
32859357|NCT04596995|Experimental|Rozanolixizumab Treatment Arm|All study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
32859358|NCT02984345|Active Comparator|Mycoprotein beverage|
32859359|NCT02984345|Placebo Comparator|Milk protein beverage|
32859360|NCT03230435||Anorexia nervosa|Treatment settings as usual.
32859361|NCT03230435||Healthy controls|No interventions.
32859362|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
32859363|NCT01232205|Placebo Comparator|Control|
32859364|NCT04584125|Experimental|Ex vivo cross linking of donor corneal tissue|Treatment Arm: The donor corneal tissue used in the PK or DALK procedures will previously undergo ex vivo crosslinking.
32859365|NCT04584125|Sham Comparator|Non-cross-linked donor corneal tissue for keratoplasty|Control Arm: The donor corneal tissue used in the PK or DALK procedures will not previously undergo ex vivo crosslinking.
32859366|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
32859367|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
32859368|NCT04348409|Experimental|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
32859369|NCT04348409|Placebo Comparator|Placebo|Patients will receive placebo BID for 7 days
32859370|NCT01158885|Experimental|Single Arm|"A maximum of two courses of the following regimen will be administered.~Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
32859371|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
33104828|NCT04323631|Other|The control group|The control group will not receive hydroxychloroquine.
33104829|NCT00546234|Active Comparator|1|
33104830|NCT00546234|Active Comparator|2|
33104831|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
33104832|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
33104833|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
33104834|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
33104835|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
33104836|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
33104837|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
33104838|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
33104839|NCT05042037|Active Comparator|Double-blind, placebo-controlled interventional study|Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.
32964094|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
32964095|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
32964096|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
32964097|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
32964098|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
32964099|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
32964100|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
32964101|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
32964102|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
32964103|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
32964104|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
33321744|NCT00023322|Experimental|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
33321745|NCT04640168|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
32964105|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
32964106|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
32964107|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
32964108|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
32964109|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
32964110|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
32964111|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
33033492|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
33033493|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
33321746|NCT04640168|Experimental|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
33417289|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
33409830|NCT04284774|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo tumor disease evaluation with PET scan, CT scan, MRI, or MIBG scintigraphy throughout the trial. Patients may undergo bone marrow aspiration or biopsy at baseline, or if there is suspicion of bone marrow metastasis, or when a complete or partial response is identified, or if there is disease progression in the marrow suspected. Patients may undergo blood specimen collections throughout the trial.
32859372|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
32859373|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
32859374|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,~A smartphone-based symptom management app,~A print and web-based symptom management toolkit,~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
32859375|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,~Self-management strategies for symptoms,~Skills training,~A list of red flag symptoms and numbers for who to call"
32859376|NCT04574063|No Intervention|Breast cancer risk leaflet only|
32859377|NCT04574063|No Intervention|Breast cancer risk leaflet PLUS SNPs|
32859378|NCT04574063|Experimental|Lifestyle website only|
32859379|NCT04574063|Experimental|Lifestyle website PLUS SNPs|
32859380|NCT04574063|Experimental|Lifestyle website PLUS group coaching|
32859381|NCT04574063|Experimental|Lifestyle website PLUS group coaching PLUS SNPs|
32859382|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
32859383|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
32859384|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
32859385|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
32859386|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
32859387|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
32859388|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
32859389|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~progression according to IWCLL criteria or~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
32859390|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
32859391|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
32859392|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
33033494|NCT01963507|No Intervention|Control|
33033495|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
32859393|NCT04348253|Active Comparator|Berger|Bergers capsulodesis
32859394|NCT04348253|Active Comparator|3LT|Three ligament tenodesis
32859395|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
32859396|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
32859397|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
32859398|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
32859399|NCT05683847||Adults with epilepsy|User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM).
32859400|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
33409831|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
32859401|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
32859402|NCT04533503||HF-OCT imaging|Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging
32859403|NCT04533347|Active Comparator|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
32859404|NCT04533347|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
32859405|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
32859406|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
32859407|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
32859408|NCT04398875|Experimental|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
32859409|NCT04398875|Sham Comparator|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
32859410|NCT04398875|Placebo Comparator|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
32859411|NCT05680025|No Intervention|Control|Participants in the control group will be invited to attend two workshops, where they will be given and have explained a guide to physical activity and one for diet for patients with hypertension. In addition to pharmacological treatment, this is the information given as part of conventional treatment patients with hypertension receive from health care personnel.
32859412|NCT05680025|Experimental|Physical exercise intervention|Promoting physical exercise. The intervention group will have access to training videos through social networks and infographics.
32859413|NCT04279223|Active Comparator|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
32859414|NCT04279223|Sham Comparator|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
32859415|NCT01237041|Experimental|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
32859416|NCT01237041|Experimental|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
32859417|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
32859418|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
32859419|NCT01237041|Experimental|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
32859420|NCT04474925|Active Comparator|Surgical Resection followed by SRS (Non-Experimental)|Surgical Resection followed by SRS within 3 weeks of surgery date.
32859421|NCT04474925|Experimental|SRS followed by Surgical Resection (Experimental)|SRS followed by surgery within 1 week of radiotherapy end date.
32859422|NCT04279145|Experimental|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
32859423|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
32859424|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
32859425|NCT04278911||Participates|This is an observational study
32859426|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
32859427|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
32859428|NCT04474613|Experimental|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
33033496|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
32859429|NCT05673395|Experimental|EARW group|This group drink electrolyzed alkaline reduced water (EARW, pH 9.5) 10 mL/kg body weight in 10 min after exercise.
32859430|NCT05673395|Sham Comparator|PW group|PW is purified water generated from sham device, and PW group drink 10 mL/kg body weight in 10 min after exercise.
32859431|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
32859432|NCT04459559|Experimental|Intervention|Using the Tactile Cueing Device
32859433|NCT04277585|Experimental|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
33033497|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
32859434|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
32859435|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
32859436|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
32859437|NCT03362489|Other|IUI|Intrauterine insemination
32859438|NCT03634241|Active Comparator|Arm A (standard of care)|Participants receive standard of care.
32859439|NCT03634241|Experimental|Arm B (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32859440|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
32859441|NCT05664581|Experimental|Rapid Acoustic Pulse (RAP)|Participants will receive 3 separate RAP cellulite treatments sessions.
32859442|NCT04410341|Placebo Comparator|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
32859443|NCT04410341|Experimental|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
32859444|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
32859445|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
32859446|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
32859447|NCT04400669|Experimental|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
32859448|NCT04400669|Active Comparator|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
32859449|NCT04400669|Active Comparator|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
32859450|NCT04400669|No Intervention|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
32859451|NCT04746755|Experimental|Experimental: Lower back pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced lower back pain; the subjects selection was corroborated by a physiotherapist.
32859452|NCT04746755|Experimental|Experimental: Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the heels of their feet; the subjects selection was corroborated by a physiotherapist.
32859453|NCT04746755|Experimental|Experimental: Knee to Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced Knee to Heel pain; the subjects selection was corroborated by a physiotherapist.
32859454|NCT04746755|Experimental|Experimental: Arch pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the arch of their feet; the subjects selection was corroborated by a physiotherapist.
32859455|NCT01161225|Experimental|peer-led asthma self-managment program|
32859456|NCT01161225|Active Comparator|Adult-led asthma self-management program|
32859457|NCT05657561|Experimental|early mobilization|"Patients in the intervention group will be given Early Mobilization Training in the preoperative preparation unit in the preoperative period."
32859458|NCT05657561|No Intervention|routine clinical care|Patients in the control group will receive routine clinical care .Routine post-operative mobilization procedure will be delivered by clinic doctors and nurses
32859459|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
32859460|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
32859461|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
32859462|NCT01243593|Experimental|Treatment Group|
32859463|NCT01243593|Active Comparator|Control Group|
32859464|NCT05654597||Participants aged 40 or more, without diagnosis of COPD or asthma|Men and women attending aged 40 or more, without previous diagnosis of chronic obstructive pulmonary disease or asthma.
32859465|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
32859466|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
32859467|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
33409832|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
33409833|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
32859468|NCT05649839|Active Comparator|conventional garment|
33409834|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
33409835|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
33409836|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
33409837|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
33409838|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
33409839|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
33409840|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
33409841|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
33409842|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
33409843|NCT04191330|No Intervention|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
32859469|NCT05649839|Experimental|prototype garment|
32859470|NCT04362761|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
32859471|NCT01162005|Experimental|Tacrolimus|Tacrobell
32859472|NCT05639309||Case (hemodynamically significant patent ductus arteriosus)|Hemodynamically significant patent ductus arteriosus (hsPDA) diagnosed by echocardiographic criteria including pulsatile left-to-right shunt through patent ductus arteriosus, enlarged left atrium and/or left ventricle, increased left pulmonary artery velocity, absent or reversed end-diastolic flow of anterior cerebral artery and/or renal artery
32859473|NCT05639309||Control (no hemodynamically significant patent ductus arteriosus)|no hsPDA based on the same echocardiographic criteria described for the Case group
32859474|NCT04354649|Experimental|Hydroxychloroquine, plus prednisone|Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
32859475|NCT04354649|Placebo Comparator|Hydroxychloroquine-matching placebo, plus prednisone|Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
32859476|NCT01244451|Experimental|Bendofa|Bendamustine + Ofatumumab
32859477|NCT04398953|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
32859478|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
32859479|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
32859480|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
32859481|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
32859482|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
32859483|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
32859484|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
32859485|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
32859486|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
32859487|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
32859488|NCT05632211|Experimental|AVT05 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32859489|NCT05632211|Active Comparator|EU Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32859490|NCT05632211|Active Comparator|US Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32859491|NCT01245699|No Intervention|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
32859492|NCT01245699|Active Comparator|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
32859493|NCT05629871|Experimental|Single arm|Alzheimer
32859494|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
32859495|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
32859496|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
32859497|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
32859498|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
32859499|NCT04333667|Experimental|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
32859500|NCT04333667|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
32859501|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
33321747|NCT00022698|Experimental|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
33321748|NCT00022698|Experimental|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
33321749|NCT03951402|Experimental|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
33321750|NCT03951402|Experimental|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
33321751|NCT03951402|Placebo Comparator|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
32859502|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
32859503|NCT05628545|Experimental|GDKM-100 injection|"In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10^8 cells/person, 5×10^8 cells/person, 10×10^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10^8 cells/person infusions based on available safety data.~The check indexes are CT scan，intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
33409844|NCT04191330|Experimental|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
33409845|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
32859504|NCT05627375|Experimental|strategy of full-dose anticoagulant therapy alone (AC)|"The experimental group receiving full-dose anticoagulant therapy alone (AC).~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE Antiplatelet therapy will be stopped."
32859505|NCT05627375|Active Comparator|strategy of combined full-dose anticoagulant and antiplatelet therapies (AC+AP)|"The control group receiving the standard of care: Antiplatelet therapy will be combined to full-dose anticoagulant therapy.~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE~Antiplatelet (AP) therapy : Aspirin or Clopidogrel"
32859506|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
32964112|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
32964113|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
32964114|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
32964115|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
32964116|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
32964117|NCT02067000||Obstructive Sleep Apnea|
32964118|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
32964119|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
32964120|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
32964121|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy~Lesion dependent"
32964122|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
32964123|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
32964124|NCT02070276|No Intervention|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
32964125|NCT02070276|Experimental|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
32964126|NCT02070276|Experimental|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
32964127|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
32964128|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
32964129|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
32964130|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
32964131|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
32964132|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
33104840|NCT05042037|Placebo Comparator|Placebo|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.
33321752|NCT03951402|Active Comparator|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
33321753|NCT03948828|Other|Conventional treatment group|GnRHa combained with reverse addition therapy
33321754|NCT03948828|Experimental|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
33321755|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
33321756|NCT03948750||Patients with Ocular Toxoplasmosis|
32859507|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
32859508|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
33321757|NCT03948750||Patients without Ocular Toxoplasmosis|
32859509|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
32859510|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
32859511|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
32859512|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
32859513|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
32859514|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
32859515|NCT05622071|Experimental|SINGLE ARM|Tislelizumab 200 mg will be administered every 3 weeks IV. Treatment will be continued until progression or limiting toxicities, for a maximum duration of 2 years and with an average duration of 4 months
32859516|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
32859517|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
32859518|NCT05345639|Experimental|TTP group (= Transversus Thoracic Plane block = Deep PIP = Deep parasternal intercostal plane block)|At the end of the surgery, realisation of a bilateral transverse thoracic block. (20ml of Naropeine 0.2%, each side) Followed by standard analgesic treatment.
32859519|NCT05345639|Experimental|PSB group (=ParaSternal Block = Superficial PIP = Superficial parasternal intercostal plane block)|"At the end of the surgery, realisation of a bilateral parasternal block (20ml of Naropeine 0.2%, each side).~Followed by standard analgesic treatment."
32859520|NCT05345639|Sham Comparator|Control group|Standard analgesic treatment alone (without LRA) .
32859521|NCT04399109|Active Comparator|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
32859522|NCT04399109|No Intervention|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
32859523|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32859524|NCT05617313|Experimental|Experimental Group|"Pembrolizumab will be given intravenously on Day 1 of the 21 day cycle (For all cycles).~GT103 dose will be determined by the safety lead in prior to the study. Dosing calculations should be based on actual body weight where applicable. It will be taken intravenously on Day 1 of the 21 day cycle (For all cycles)."
32859525|NCT04303325|Placebo Comparator|Control|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
32859526|NCT04303325|Active Comparator|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.
32859527|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
32859528|NCT04399031|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
32859529|NCT04399031|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
32859530|NCT04399031|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
33321758|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
32859531|NCT04399031|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
32859532|NCT04399031|Experimental|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
32859533|NCT04399031|Experimental|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
32859534|NCT04399031|Experimental|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
32859535|NCT04399031|Experimental|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
32859536|NCT04399031|Experimental|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
32859537|NCT04399031|Experimental|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
32859538|NCT04399031|Experimental|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
32859539|NCT04399031|Experimental|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
32859540|NCT04399031|Experimental|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
32859541|NCT04399031|Experimental|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
32859542|NCT04399031|Experimental|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
33409846|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
33409847|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
33409848|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
33409849|NCT05212623|Experimental|Group A|"Subjects received 2 doses of 0.25 mL of quadrivalent influenza vaccine, 4 weeks apart.~Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata)."
33409850|NCT05212623|Experimental|Group B|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.(Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
33409851|NCT05212623|Active Comparator|Group C|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 type of virus strains, including BY).
33409852|NCT05212623|Active Comparator|Group D|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
33409853|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
33409854|NCT03960138|Experimental|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
33409855|NCT03960138|Experimental|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
33409856|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
33409857|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
32859543|NCT04399031|Experimental|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
32859544|NCT04399031|Experimental|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
32859545|NCT04399031|Experimental|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
32859546|NCT04399031|Experimental|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
32859547|NCT04399031|Experimental|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
32859548|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
32859549|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
32859550|NCT04248335|Experimental|In Weight Management Program|Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam
32859551|NCT04248335|Experimental|Not in Weight Management Program|Evaluate the effect of liver fat on drug metabolism of PPI's, and if applicable midazolam
32859552|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
32859553|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
32859554|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
32859555|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
32859556|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
32859557|NCT04228679|Experimental|Erbium laser treatment|Women with vaginal looseness and sexual dysfunction treated with real laser.
32859558|NCT04228679|Sham Comparator|Sham laser treatment|Women with vaginal looseness and sexual dysfunction treated with sham laser.
32859559|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
32859560|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
32859561|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
32859562|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
32859563|NCT04277039|Experimental|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
33104841|NCT02664038|Experimental|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
32859564|NCT04277039|Active Comparator|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
33104842|NCT02664038|Active Comparator|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
32859565|NCT04277039|Other|usual care|patients will continue the routine care as established by international guidelines
32859566|NCT04276961|Experimental|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
32859567|NCT04276961|Sham Comparator|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
32859568|NCT04759859||Carotid Endarterectomy (CEA)|70 participants undergoing CEA
32859569|NCT04759859||Other Peripheral Vascular Surgery|30 participants undergoing other peripheral vascular surgical procedures
32859570|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT|Patients who are MRD Negative by Flow cytometry but are MRD Positive by High Throughput Sequencing, will receive a myeloablative conditioning regimen which includes total body irradiation (TBI) followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
32859571|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT|Patients who are MRD Negative by Flow cytometry and are MRD Negative by High Throughput Sequencing, will receive a reduced intensity conditioning regimen followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
32859572|NCT04176419|Experimental|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
32859573|NCT04176419|Placebo Comparator|Control Group|"Perioperative placebo~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
32859574|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
32859575|NCT04168931|Experimental|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
33104843|NCT05038293|Experimental|Automated mouthpiece-based toothbrush|Under observation of study staff, participants assigned to the automated mouthpiece-based toothbrush will insert a properly fitted mouthpiece and use the automated device directly over the sink.
33321759|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
33321760|NCT03948594|Placebo Comparator|plain water|subject drink 250cc plain water
33321761|NCT03948594|Active Comparator|resource|subject drink 1 packet resource(237ml)
33321762|NCT03759002||Patients|Children with end stage renal disease
33321763|NCT03759002||Controls|Healthy sex- and age adjusted children
33321764|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
33321765|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
33321766|NCT03948360|Experimental|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
33321767|NCT03948360|Experimental|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
33321768|NCT03949608|Experimental|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
33321769|NCT03949608|No Intervention|Control|Usual care
33321770|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
33321771|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
33321772|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
33321773|NCT03947268|Experimental|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
33321774|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
33321775|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
33321776|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
33321777|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
33409858|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
32964133|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
33321778|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
33321779|NCT03949686|Sham Comparator|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
33321780|NCT03949686|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
33321781|NCT03946956|Active Comparator|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
33321782|NCT03946956|Placebo Comparator|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
33321783|NCT03946956|Active Comparator|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
33321784|NCT03946956|Placebo Comparator|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
33321785|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
33321786|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
33321787|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visit. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
33321788|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
33321789|NCT04061382||Group 3|Group three will consist of up to 300 participants aged 0-19 from the Black, Asian and Minority ethnic population aged 0-19 years. They will not be restricted to the post code sampling and will be recruited at a sub-set of sites depending on capacity and the demographic profile of the local population. Recruitment will be by multiple approaches, including mail outs, radio and advertising in community (e.g. community centres, religious establishments) or Pharmacies and GP practices where we have ethics approval for them to act as PICs. These can vary according to each site's experience and their contacts within their local community on how is best to approach the BAME community. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients.
33321790|NCT05573022|Experimental|Arm A1: Breast cancer patients|
33321791|NCT05573022|Active Comparator|Arm B1: Breast cancer patients|
33321792|NCT05573022|Experimental|Arm A2: Colorectal cancer patients|
33321793|NCT05573022|Active Comparator|Arm B2: Colorectal cancer patients|
33321794|NCT03949842|Experimental|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
33321795|NCT03949842|Experimental|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
33321796|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
33321797|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
33409859|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
33409860|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
33409861|NCT04059744|Experimental|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
33409862|NCT04269486||Inpatient participant|Inpatients who signed the informed consent form that she will be observed during the hospitalization period
33409863|NCT03215511|Experimental|Cancer participants <12 years|A Rolling-6 dose escalation design will be used. The starting dose for participants age < 12 years will be 25% below the highest dose level cohort divided by 1.73 m^2 cleared by the Safety Review Committee (SRC) for subjects age 12 years and older.
33409864|NCT03215511|Experimental|Cancer participants ≥12 years|A 3+3 dose escalation design will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study, enrolling 3 to 6 participants per cohort with a starting dose level of 100 mg twice daily (BID).
33409865|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
33409866|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
33417290|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
33417291|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
32859576|NCT04165967|Experimental|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
32859577|NCT04160663|Experimental|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
32859578|NCT04133987|Experimental|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
32859579|NCT04133987|Placebo Comparator|placebo|Plasma-Lyte A
32859580|NCT04110743|Other|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
32859581|NCT04110743|Other|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
32859582|NCT04110743|Other|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
32859583|NCT04098029|Experimental|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
32859584|NCT04098029|Experimental|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
32859585|NCT04098029|Other|Standard therapy|Patients with standard therapy as a control group
32859586|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
32859587|NCT04080635|Experimental|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
33409867|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
33409868|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
32859588|NCT04076657|Experimental|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (<48 hours post) injury, and will complete home therapy exercise twice daily
32859589|NCT04076657|Active Comparator|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
32859590|NCT04068155|Experimental|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
32859591|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
32859592|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
32859593|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
32859594|NCT04033211||Novosyn® CHD|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
32859595|NCT04033211||Novosyn®|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
32859596|NCT01285635|Active Comparator|Docetaxel Alone|
32859597|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
32859598|NCT01285635|Experimental|Metronomic AT-101 Arm|
32859599|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
32859600|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
32859601|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
32859602|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
32859603|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
32859604|NCT01286259|Experimental|Intervention Arm|
32859605|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
32859606|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
32859607|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
32859608|NCT04019561|Experimental|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
32859609|NCT04019561|Placebo Comparator|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
32859610|NCT04019561|Experimental|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
32859611|NCT04019561|Placebo Comparator|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
32859612|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
32859613|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
32859614|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
32859615|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
32859616|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
32859617|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
32859618|NCT01289067|Other|Satraplatin, Single Arm|
32859619|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
32859620|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
32859621|NCT03616223|Experimental|FX-322 Low Dose|Cohort of 8. Single intratympanic injection
32859622|NCT03616223|Experimental|FX-322 High Dose|Cohort of 8. Single intratympanic injection
32859623|NCT03616223|Placebo Comparator|Placebo-Low Dose|Cohort of 4. Single intratympanic injection
32859624|NCT03616223|Placebo Comparator|Placebo-High Dose|Cohort of 4. Single intratympanic injection
32859625|NCT04014179|Experimental|Dried Blood Spot (Intervention)|Blood samples will be tested for HCV RNA from dried blood spot cards.
32859626|NCT04014179|Experimental|Point-of-care RNA (Intervention)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
32859627|NCT04014179|No Intervention|Standard of Care (Control)|Sites will continue with their standard of care for hepatitis C testing.
32859628|NCT04010825|Experimental|Hypnosis Arm|"In parallel with an inpatient pulmonary rehabilitation program, nine visits will be carried out :~V0 : an inclusion visit~V1 : a randomization visit~V2 to V6 : five visits with hypnosis sessions~V7 : a end-stay visit~V8 : a 6-month post-rehabilitation visit ( by phone call)~The five hypnosis sessions (V2 to V6) will be spread over three weeks of rehabilitation program (1 to 2 hypnosis sessions per week).~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
32859629|NCT04010825|No Intervention|Control Arm|"In parallel with an inpatient pulmonary rehabilitation program, no additional intervention will be carry out and four visits will be carried out :~V0 : an inclusion visit~V1 : a randomization visit~V7 : a end-stay visit~V8 : a 6-month post-rehabilitation visit ( by phone call)~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
32859630|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
32859631|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
32859632|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
32859633|NCT03990311|Experimental|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
32859634|NCT03990311|Placebo Comparator|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
32859635|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
32859636|NCT03954899|Experimental|MCI+ Melatonin 5mg|MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months
32859637|NCT03954899|Placebo Comparator|MCI+ placebo|MCI+ individuals receiving placebo for a period of 9 months
32859638|NCT03954899|Experimental|MCI- Melatonin 5mg|MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months
32859639|NCT03954899|Placebo Comparator|MCI- placebo|MCI- individuals receiving placebo for a period of 9 months
32859640|NCT03934307|Experimental|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
32859641|NCT03934307|Placebo Comparator|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
32859642|NCT03934307|Experimental|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
32859643|NCT03934307|Placebo Comparator|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
32859644|NCT03934307|Experimental|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
32859645|NCT03934307|Active Comparator|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
32859646|NCT03934307|Experimental|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
32859647|NCT03924635|Active Comparator|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
32859648|NCT03924635|Active Comparator|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
32859649|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
32859650|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
32859651|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
32859652|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
32859653|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
32859654|NCT04398251|Experimental|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
33104844|NCT05038293|Active Comparator|Manual toothbrush|Under observation of study staff, participants assigned to the manual toothbrush will be timed brushing their teeth directly over the sink using a pre-dispensed quantity of toothpaste on bristles dampened with water.
32859655|NCT04398251|Active Comparator|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
32859656|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
33104845|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
33321798|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
33321799|NCT05561244|No Intervention|CONTROL GROUP|Control group (n = 16 nursing homes, 64 patients): Patients will be monitored as usual using the Venous International Normalised Ratio strategy. Practices will not be changed (i.e. prospective observation of real-life practices; according to recommendations, at least 1 Venous International Normalised Ratio per month will usually be performed) and patients will not receive any supplementary intervention specific to the trial. A reminder of good International Normalised Ratio practices will be provided to nurses and prescribers.
33409869|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
32859657|NCT00632203|No Intervention|Observation|Observation
32859658|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
32859659|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
32859660|NCT04398095|Experimental|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
32859661|NCT04398095|Experimental|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
32859662|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
32859663|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
32859664|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
32859665|NCT03830333|Experimental|Ceftolozane/Tazobactam + Metronidazole|Participants receive ceftolozane/tazobactam 1500 mg (ceftolozane 1000 mg + tazobactam 500 mg) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days (per protocol, ceftolozane/tazobactam may be adjusted to 500 mg/250 mg if creatinine clearance [CrCL] is 30 to ≤50 mL/min)
32859666|NCT03830333|Active Comparator|Meropenem + Placebo|Participants receive meropenem 1000 mg plus saline administered as an IV infusion every 8 hours for 4 to 14 days (per protocol, meropenem may be adjusted to every 12 hours if CrCL was 30 to ≤50 mL/min).
32859667|NCT01248741|Experimental|HDR prostate brachytherapy|An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.
32859668|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
32859669|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
32859670|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
32859671|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
32859672|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
32859673|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
32859674|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
32859675|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
32859676|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
32859677|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
32859678|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
32859679|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
33104846|NCT02599922|Experimental|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33104847|NCT02599922|Experimental|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33104848|NCT02599922|Experimental|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
32859680|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
32859681|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
32859682|NCT01253343||inpatient high aggression|
32859683|NCT01253343||inpatient low aggression|
32859684|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
32859685|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
32859686|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
32859687|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
32859688|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
32859689|NCT01290627||Control|Subjects with normal knees
32859690|NCT04398017|Active Comparator|Standard support|
32859691|NCT04398017|Experimental|Hypnosis|
32859692|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
32859693|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
32859696|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
32859697|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
32859698|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
32859699|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
32859700|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
32859701|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
32859702|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
32859703|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
32859704|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
32859705|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
32859706|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
32859707|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
32859708|NCT03245645|Experimental|100% Fructose|The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms.
32859709|NCT03245645|Placebo Comparator|100% Glucose|The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms.
32859710|NCT03245645|Active Comparator|Fructose and Glucose|The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms.
32859711|NCT03170141|Experimental|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 0.5×10^5 /kg to 2.5×10^7 /kg
32859712|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
32859713|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
32859714|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
32859715|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
32859716|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of cycle 1 and on days 1-21 of cycle 2 and subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycle 1 equals 14 days. Cycles 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32859717|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
32859718|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
32859719|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
32859720|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
32859721|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
32859722|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
32859723|NCT02974595||Affected Participants|Individuals with undifferentiated autoinflammatory diseases or genetically defined conditions, such as NOMID/CAPS, DIRA, CANDLE, SAVI, and NLRC4 MAS.
32859724|NCT02974595||Healthy Volunteer|Volunteers without known autoinflammatory disease who consent to providing blood specimen for genetic testing.
32859725|NCT02974595||Unaffected Relatives|Blood relatives of the affected patients without known autoinflammatory disease who consent to providing specimen for genetic testing.
32859726|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
32859727|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
32859728|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
32859729|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
32859730|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
32859731|NCT00630877|Experimental|NER/ASA|
32859732|NCT00630877|Experimental|NER/ASA Placebo|
32859733|NCT00630877|Experimental|NER Placebo/ASA Placebo|
32859734|NCT04557163|Experimental|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
32859735|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
32859736|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
32859737|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
32859738|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
32859739|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
32859740|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
32859741|NCT02545127|Experimental|Merotocin (a selective oxytocin-receptor agonist)|
32859742|NCT02545127|Placebo Comparator|Placebo|
32859743|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
32859744|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
32859745|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram~Total or partial gastrectomy group"
32859746|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram~Children with functional dyspepsia"
32859747|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram~Children with chronic nausea"
32859748|NCT03176927|Experimental|Control participants|"magnetogastrogram~Group without any gastrointestinal diseases."
32859749|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
32859750|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
32859751|NCT04397705|Experimental|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
32859752|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
32859753|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
32859754|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
32859755|NCT02089217|Active Comparator|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
32859756|NCT02089217|Active Comparator|Carotid Stenting (CAS)|Carotid Stenting
32859757|NCT02089217|Experimental|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
32859758|NCT02089217|Experimental|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
32859759|NCT02023073||Healthy volunteers|
32859760|NCT04397783|No Intervention|Cruciate incision|the classic cruciate incision in the colostomy construction
32859761|NCT04397783|Experimental|longitudinal incision|longitudinal incision with two proline sutures
32859762|NCT04397315|Active Comparator|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
32859763|NCT04397315|Active Comparator|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
32859764|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
32859765|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
32859766|NCT03174197|Experimental|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32859767|NCT03174197|Experimental|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
32859768|NCT03172403|Experimental|Patients with digestive cancer requiring resection surgery|"Patients with cancer of digestive system requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
32859769|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
32859770|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
32859771|NCT01200953||Confirmed or suspected exposure|Confirmed or suspected exposure to biodefense select agent, to agent of bioterrorism concern, to naturally-occurring pathogen in the environment, to EID agent, or to an individual
32859772|NCT01200953||Confirmed or suspected infection|Confirmed or suspected infection by biodefense select agent, by agent of bioterrorism concern, by naturally-occurring pathogen in the environment, or by emerging infectious disease agent
32859773|NCT01200953||Healthcare worker or healthy volunteer|Healthcare worker or healthy volunteer involved in simulation drills or exercises evaluating the Clinical Center admission, care, and infection control processes
32859774|NCT01200953||Healthcare worker surveillance|Healthcare worker surveillance of medical staff involved in the medical care of patients in the above 2 categories
32859775|NCT01176461|Experimental|A1 - Phase I Dose Escalation|Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
32859776|NCT01176461|Active Comparator|A2 - BMS-936558 Without Peptide Vaccine|Cohort 6. Each treatment cycle is comprised of 6 doses of BMS-936558 administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
32859777|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
32859778|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
32859779|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
32859780|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
32859781|NCT04557865|Experimental|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
32859782|NCT04555291|Experimental|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
32859783|NCT04555291|Placebo Comparator|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
32859784|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
32859785|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
33104849|NCT02599922|Experimental|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33104850|NCT02599922|Experimental|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33104851|NCT02599922|Experimental|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
32859786|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
32859787|NCT04275739|Experimental|Experimental: Episodic Future Thinking|
32859788|NCT04275739|Active Comparator|Control: Vivid Memory Task|
32859789|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
32859790|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
32859791|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
32859792|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
32859793|NCT04550065|Experimental|Intervention arm|Digital game
32859794|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
32859795|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
32859796|NCT04275427|Experimental|study laser group|laser therapy on knee for 2 weeks
32859797|NCT04275427|No Intervention|control group|no intervention
32859798|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
32859799|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
32859800|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
32859801|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
32859802|NCT04275115|Experimental|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
32859803|NCT04275193|Experimental|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
32859804|NCT04275193|Placebo Comparator|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
32859805|NCT00633997|Experimental|1|Healthy volunteers
32859806|NCT00633997|Experimental|2|Type II diabetics
32859807|NCT04274959|Active Comparator|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
32859808|NCT04274959|Experimental|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
32859809|NCT04559347|Experimental|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
32859810|NCT04559347|Active Comparator|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
32859811|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
32859812|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
32859813|NCT00631111|Experimental|1|
32859814|NCT00631111|Active Comparator|2|
32859815|NCT00631111|Active Comparator|3|
32859816|NCT00631111|Placebo Comparator|4|
32859817|NCT03061201|Experimental|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
33104852|NCT02599922|Experimental|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33409870|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
33409871|NCT05598099||Individual therapy over four consecutive days|Treatment will be delivered individually over four consecutive days
33409872|NCT05598099||Combined Individual and group therapy over four consecutive days|Treatment will be delivered in a mix of individual and group sessions over four consecutive days
33409873|NCT03631563|Experimental|Arm 1|ATG-F treated
33409874|NCT03631563|Active Comparator|Arm 2|ATG treated
32859818|NCT03535363|Experimental|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
32859819|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
32859820|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
33409875|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
33409876|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
33409877|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
33409878|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
33409879|NCT05077293||Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will be visible on the first screen displayed in the electronic health record and will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
33409880|NCT05077293||In-Basket Message group|Providers will receive a biweekly in-basket messages linking to a list of patients who have been seen in the past year with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, and date of last visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
33409881|NCT05077293||Control group|Patients who will receive the current standard practice of care (no alerts)
33409882|NCT05069181|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
33409883|NCT05069181|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
33409884|NCT05069181|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
32859821|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
33409885|NCT01383603|Experimental|Cat-PAD|
33409886|NCT05065203||Postpartum patients|Women booked and have delivery of their child(ren) at Lucile Packard Children's Hospital
33409887|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
33409888|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
33409889|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
33409890|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
33409891|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
33409892|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
33409893|NCT05597865|Other|Control Arm|Control arm will received Alcohol and Drug Use Risk Reduction Sessions
33409894|NCT05597865|Experimental|Intervention|Participants in the intervention arm will receive four (4) Financial Literacy (FL) training sessions and receive a Youth Development Savings account (YDA) at a financial institution accredited by the Bank of Uganda for long-term savings. Each YDA account will be opened in the name of the participant. Savings will be matched at a 1:1 rate with money from the program.
33409895|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
33409896|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
32859822|NCT04558723|Experimental|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
33321800|NCT05561244|Experimental|INTERVENTIONAL GROUP|Intervention group (n = 16 nursing homes, 64 patients): Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
33321801|NCT01102608|Experimental|1|
33321802|NCT05556174|Experimental|Intensive intraoperative lung-protective ventilation|intraoperative lung-protective ventilation with periodic lung recruitment maneuvers
33321803|NCT05556174|No Intervention|Moderate intraoperative lung-protective ventilation|intraoperative lung-protective ventilation without periodic lung recruitment maneuvers
33321804|NCT01105728|Experimental|Study arm|Endoscopic resection
33321805|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
33321806|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
33321807|NCT01102686|Experimental|Pyrimethamine|
33321808|NCT03949296|Active Comparator|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
33321809|NCT03949296|Placebo Comparator|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
33321810|NCT05499468|Other|Popular-Opinion Leader-led workshops & conversations to encourage utilization of support resources|Physicians identified by programwide Qualtrics survey item asking housestaff who in their program they respect and trust most, personally and professionally. Identified POLs were invited to join this health promotion effort as a POL to improve the culture of wellness and psychological safety among housestaff and encourage them to utilize resources at a time when they may benefit significantly. POLs were trained to endorse the benefits of mental health promotion coaching or therapy for residents training at Stanford.
33321811|NCT05499468|No Intervention|Standard Training Program Curriculum and Access to Existing Support Resources|All residents and fellows continued to have the same access to coaching and psychotherapy resources available through Stanford WellConnect, along with other educational activities in their usual training.
33321812|NCT05497908|Experimental|Transversus abdominis plane (TAP) block via lateral approach|This group receives a Transversus abdominis plane (TAP) block via lateral approach
33321813|NCT05497908|Experimental|Transversus abdominis plane (TAP) block via posterior approach|This group receives a Transversus abdominis plane (TAP) block via posterior approach
33321814|NCT05497908|No Intervention|Control group|The control group receives no TAP block.
33321815|NCT03949374|Active Comparator|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
33321816|NCT03949374|Active Comparator|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
33321817|NCT05626374|Active Comparator|Basic case management|Basic case management with bi-weekly meetings between case manager and trainees that includes check-ins, frequent visits to construction sites and monitoring of feedback forms from mentors. Case managers attempt to connect trainees with external support services as needed.
33321818|NCT05626374|Experimental|Basic case management supplemented by self-reporting distress tool (DT)|Basic case management plus access to the self-report daily distress tool. The trainees are provided web-based access to the daily distress tool and report their distress levels using a validated visual analog scale (Distress Thermometer), along with reporting their risk of missing work/class or dropping out of the program. The case manager responds to the distress tool by coordinating external support services as needed.
33321819|NCT05626374|Experimental|Basic case management supplemented by rapid access healthcare services|Basic case management supplemented by a fit-for-purpose rapid referral process for trainees with active mental health and/or substance use disorders affecting their program participation.
33321820|NCT05626374|Experimental|Basic case management supplemented by DT and rapid access healthcare services|Basic case management supplemented by both the self-report distress tool and rapid referral process for those trainees at-risk of program absence or drop-out from either mental health or addictions issues.
33321821|NCT01104012||All patients|Allergy patients, asthma and rhinitis
33321822|NCT01104168||Nursing home residents with diabetes|
33321823|NCT03949530|Experimental|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
33321824|NCT03949530|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
33321825|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
33321826|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
33321827|NCT05626140|Placebo Comparator|Diclofenac plus placebo|Oral tablet diclofeanc sodium 50 mg was given with tab folic acid 5 mg as placebo ,12 hourly for 15 days
33409897|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
33104853|NCT02599922|Experimental|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
33104854|NCT02599922|Experimental|Group 7: MTD of AGTC-401|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
32859823|NCT04558723|No Intervention|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
33409898|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
33409899|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
33409900|NCT04722549|Placebo Comparator|Placebo|Placebo (cellulose)
32859824|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
32859825|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
32859826|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
32859827|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
32859828|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
32859829|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
32859830|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
32859831|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
32859832|NCT04558801|Experimental|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
32859833|NCT04558801|Active Comparator|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
32859834|NCT04828343|Experimental|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
32859835|NCT04828343|Experimental|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
32859836|NCT04828343|Experimental|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
32859837|NCT04828343|Experimental|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
32859838|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
32859839|NCT04276649||Caltrate+Mesalazine|Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.
32859840|NCT04276649||Mesalazine|Patients in this group were received with Mesalazine 4g/d orally at least 12 months.
32859841|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
32859842|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
32859843|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
32859844|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
32859845|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
32859846|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
32859847|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
32859848|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
32859849|NCT04553419|Experimental|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
33409901|NCT04722549|Active Comparator|Butyrate|Sodium butyrate
33104855|NCT00539175|Active Comparator|2|active treatment with infrared light
33104856|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
33104857|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
33104858|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
33104859|NCT02577302|Experimental|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
33321828|NCT05626140|Active Comparator|Diclofenac plus codeine|Oral tablet diclofeanc sodium 50 mg was given with tab codeinephosphate 30 mg ,12 hourly for 15 days
33321829|NCT05626140|Experimental|Diclofenac plus lacosamide|Oral tablet diclofeanc sodium 50 mg was given with tab lacosamide 50 mg as placebo ,12 hourly for 15 days
33321830|NCT03949452|Active Comparator|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
33321831|NCT03949452|Placebo Comparator|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
33321832|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
33321833|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
32859850|NCT04553419|Placebo Comparator|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
32859851|NCT04550845|Experimental|Specific Aim 1|In specific aim 1, twelve focus group interviews (AA and rural White men with localized prostate cancer and caregivers, N = 50 dyads or N = 100 participants) will be conducted to explore comprehension of prognostic genomics as well as facilitators and barriers to genomic health literacy and to assess the acceptability and value of the revised PCLA education video.
32859852|NCT04550845|Experimental|Specific Aim 2|In specific aim 2, participants will be randomized into intervention versus control group. Twenty focus groups (AA and rural White men with localized prostate cancer and caregivers, N = 80 dyads or N = 160 participants) will be conducted to culturally conceptualize the study intervention and to provide qualitative contextual evaluation. The design for this aim is a randomized controlled, parallel group, repeated measures, non-blinded trial, with a nurse-delivered tailored prostate cancer education, communication coaching, and the prognostic genomics revised Prostate Cancer Literacy Video compared to the prognostic genomics revised Prostate Cancer Literacy Video.
32859853|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time.
32859854|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
32859855|NCT03097783|No Intervention|No intervention arm|No treatment
32859856|NCT04420819|Experimental|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
32859857|NCT04420819|Experimental|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
32859858|NCT04420819|Placebo Comparator|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
32859859|NCT04420819|No Intervention|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
32859860|NCT01920217||normal control|
32859861|NCT01920217||Sepsis group|
32859862|NCT04346407|Experimental|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
32859863|NCT04346407|Placebo Comparator|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
32859864|NCT04397549|Active Comparator|Block group|Cervical Erector Spinae Plane Block administered group
32859865|NCT04397549|Sham Comparator|Control group|Control group
32859866|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
32859867|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
32859868|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
32859869|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
32859870|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
32859871|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
32859872|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
32859873|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
32859874|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
32859875|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
32859876|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
32859877|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
32859878|NCT04551001|Experimental|Cold forcep|Cold forcep polypectomy performed for polyps <=3mm.
32859879|NCT04551001|Experimental|Cold snare|Cold forcep polypectomy performed for polyps <=3mm.
32859880|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
32859881|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
32859882|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
32859883|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
32859884|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
32859885|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
32859886|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
32859887|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
32859888|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
32859889|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
32859890|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
32859891|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
32859892|NCT05246657||intervention|EUS-guided Entero-biliary Anastomosis
32859893|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
32859894|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
32859895|NCT05244395|Experimental|Duchenne Muscular Dystrophy Gait Assessment Scale|The DMD-GAS was developed using the two-round Delphi method. After a detailed literature review, the items of scale were compiled. The DMD-GAS was designed to consist of 10 items and each item scored as 0,1,2. The DMD-GAS was presented to the expert group (10 physical therapists), who had experience in the management of patients with DMD. According to the scale items, it is classified as 2: no compensation, 1: minimal compensation, and 0: excessive compensation for the relevant body part.
32859896|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
32859897|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
32859898|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
32859899|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
32859900|NCT05249387|Experimental|A-967079 Injections + BAM8-22|
32859901|NCT05249387|Experimental|A-967079 Injections and vehicle|
32859902|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
32859903|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
32859904|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
32859905|NCT05248529|Experimental|Intervention group|Within 12-24 hours before the surgery, the demonstrative education was given based on 'Hip Replacement Adaptation Booklet' and 'Knee Replacement Adaptation Booklet' to the patients in the intervention group.
32859906|NCT05248529|No Intervention|Control gorup|Routine preoperative preparation training was performed to the patients in the control group.
32859907|NCT04550221|Experimental|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
33321834|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
33321835|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
33409902|NCT05003427|Experimental|68Ga-FAPI-04 PET/CT|The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.
32859908|NCT04550221|Active Comparator|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
32859909|NCT05248373|Experimental|rAd26 single administration|
32859910|NCT05248373|Experimental|rAd5 single administration|
32859911|NCT05248373|Experimental|prime-boost regimen with rAd26 followed rAd5 administration|
32859912|NCT05248373|Placebo Comparator|placebo|
32859913|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
32859914|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
32859915|NCT05243147|Experimental|nasal stents|using nasal stents after septoplasty
32859916|NCT05243147|Other|merocel|using merocel as nasal packing after septoplasty
32859917|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
32859918|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
32859919|NCT05241665||Group 1|
32859920|NCT05241665||Group 2|
32859921|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
32859922|NCT05240807|Experimental|Clinical Coronary CTA Cohort|Subjects scheduled for a clinically indicated coronary CTA will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT
32859923|NCT05240807|Experimental|Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort|Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT at rest and after administration of a cardiac stress agent
32859924|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
32859925|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
32859926|NCT05247047|Experimental|Device|Clusters in this arm will start using the device and use it for 6 weeks.
32859927|NCT05247047|No Intervention|Control|Clusters in this arm will not receive the device it will continue with usual care with no changes.
32859928|NCT03373981|Experimental|intervention|rTMS
32859929|NCT04759495|Experimental|rtCGM|Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
32859930|NCT04759495|Experimental|FGM|Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
32859931|NCT05247203|Experimental|Telitacicept Arm 1|Telitacicept 80mg, once a week for 24 weeks plus standard therapy
32859932|NCT05247203|Experimental|Telitacicept Arm 2|Telitacicept 160mg, once a week for 24 weeks plus standard therapy
32859933|NCT05247203|Experimental|Telitacicept Arm 3|Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy
32859934|NCT05247203|Experimental|Telitacicept Arm 4|Telitacicept 240mg, once a week for 24 weeks plus standard therapy
32859935|NCT05247203|Experimental|Telitacicept Arm 5|Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy
32859936|NCT04556305|Experimental|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
32859937|NCT04556305|Experimental|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
32859938|NCT04556305|Experimental|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
32859939|NCT04556305|No Intervention|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
32859940|NCT05245019|Experimental|cardamom group|the pH of saliva will be checked first then they r required to chew cardamom nd after 15 minutes again pH will be checked
32859941|NCT05245019|Experimental|fennel group|the pH of saliva will be checked first then they r required to chew fennel and after 15 minutes again pH will be checked
32859942|NCT01925755||Group 1|
32859943|NCT01925833|Experimental|Both insertion and withdrawal|
32859944|NCT01925833|Active Comparator|Only withdrawal|
33409903|NCT04941261|Experimental|18-59 years old group A|
32859945|NCT04746053|Other|patient with a mutation in the HNF1B gene|Patient with a mutation in the HNF1B gene and which are followed in the reference centers
32859946|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
33321836|NCT03944850|Experimental|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
33321837|NCT05497050|Experimental|Experimental group|Family education
33321838|NCT05497050|No Intervention|Control group|No training will be given.
32859947|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
32859948|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
32859949|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
32859950|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
32859951|NCT04787237|Experimental|Vestibulart socket therapy and immediate implants|A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted . A flexible cortical membrane shield that is made of cortical bone of heterologous origin was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a membrane tack or a micro screw to the alveolar bone apical to the base of the socket . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
32859952|NCT04787237|Active Comparator|Buser's technique and early implant placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
32859953|NCT04760171||Group 1|Patients diagnosed with medullary thyroid cancer (MTC) who are undergoing standard surgical treatment for their disease. This will be either hemithyroidectomy or total thyroidectomy. Patients with laryngeal amyloidosis (LA) who are undergoing standard surgical treatment of this disease. This will be microlaryngoscopy & biopsy/debulking
32859954|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
32859955|NCT04396769|Experimental|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
32859956|NCT04396769|Active Comparator|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
32859957|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
32859958|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
32859959|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
32859960|NCT05246345||Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax|Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
32859961|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
32859962|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
32859963|NCT05241587|Experimental|The chewing gum group|"Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010). Therefore, this group of patients was allowed to chew xylitol gum for 10 minutes, five times a day for six weeks."
32859964|NCT05241587|Experimental|The mouth spray group|The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
32859965|NCT05241509|Experimental|Group I (test)|included twenty patients treated with SRP and intrapocket application of 2% lemongrass oil gel.
32859966|NCT05241509|Placebo Comparator|Group II (control)|included twenty treated with SRP and intrapocket application of placebo gel.
33321839|NCT05429736|Experimental|MST + TSS|Individuals will participate in 6 training sessions of MST combined with TSS.
33321840|NCT05429736|Sham Comparator|MST + ShamTSS|Individuals will participate in 6 training sessions of MST while receiving shamTSS.
32859967|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
32859968|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
32859969|NCT05241431|Active Comparator|Intervention group|10 mg (oral) SGLT-2 inhibitor once daily
32859970|NCT05241431|Placebo Comparator|Control group|Placebo tablet encapsulated as the active treatment.
32859971|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
32859972|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
32859973|NCT05241119|Experimental|SLNB Group|undergo fluorescence SLNB
32859974|NCT05241119|Experimental|pALND Group|undergo low axillary lymph node dissection with ICBN as the boundary
32859975|NCT05241119|Experimental|ALND Group|undergo ALND
32859976|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
32859977|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
32859978|NCT05241041|Experimental|[1st year]Auricular Acupressure Experimental Group 1|auricular acupressure
32859979|NCT05241041|No Intervention|[1st year]Control Group 1|education material
32859980|NCT05241041|No Intervention|[1st year]Normal Group|Non-gamblers
32859981|NCT05241041|Experimental|[2nd&3rd year]Auricular Acupressure Experimental Group 2|auricular acupressure + group counseling
32859982|NCT05241041|Placebo Comparator|[2nd&3rd year]Placebo Group|placebo acupressure + group counseling
32859983|NCT05241041|No Intervention|[2nd&3rd year]Control Group 2|education material
32859984|NCT05600101|Experimental|care.coach Pilot|"The research study procedures include screening for eligibility, a brief call with a research assistant after tablet is given to subject, and a survey after a subject has completed the study.~3 consecutive cohorts of 6 RIC HCT patients each.~care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates. A subject uses the avatar for up to 3 weeks."
32859985|NCT05240963|Experimental|PEEK implant|Temporal PEEK implant to prevent temporal hollowing after temporalis muscle transfer
32859986|NCT05240885||Controls|"Study subjects that are eligible based on inclusion/exclusion criteria~Screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing"
32859987|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
32859988|NCT05240495|Experimental|Internet-based Cognitive-behavioural therapy group (n=61)|TThe generic iCBT program was based on contemporary CBT techniques adapted for stress-related disorders, and recovery from work training inspired by Hahn et al. [2011]. The iCBT consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week. In the first module (introduction), the participants received information about the outline of the program, stress physiology and defined individual treatment goals. During the second week participants were introduced to different recovery techniques and applied relaxation. The third and fourth week contained exercises related to behavioral activation, work-home balance, and values-based action skills. Between weeks five and ten, participants were able to choose between different exposure-based exercises. In addition, participants with insomnia could choose to focus on sleep management.
32859989|NCT05240495|Experimental|Internet-based Work-focused Cognitive-behavioural therapy group (n=61)|The internet-based and work-focused cognitive-behavioral therapy (W-iCBT) consisted of the generic treatment for stress-related disorders (iCBT), plus components focusing on work and return-to-work. These sections were integrated and represented in each of the ten modules. Work-focused CBT is built on the same conceptual framework as regular CBT. For example, CBT principles are used to change the appraisal of work stressors, change the dysfunctional behaviour, or increase health promoting behaviours. The CBT principal, exposure, is given special attention. Gradual exposure can help individuals develop more effective coping skills when dealing with work-related stressors (e.g., assertiveness) and stimulate gradual return to the work setting for individuals on a long-term sick leave [27].
32859990|NCT05240495|No Intervention|Wait-list control group (n=60)|Wait-list control group received equal and parallell assessment and eligibility procedure as the two experimental konditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
32859991|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
32859992|NCT05240261|Other|ESRAD on regular haemodialysis|30 ESRD Patients with sleep < 6 hours on regular haemodialysis . Before and after taking medications for 3 month.
32859993|NCT05240261|Other|CKD patients (predialydsis)|30 CKD Patients (predialysis) with sleep < 6 hours . Before and after taking medications for 3 month.
32859994|NCT01921543|Experimental|CI/BNST stimulation on|
32859995|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
32859996|NCT01921543|Experimental|ITP stimulation on|
32859997|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
32859998|NCT05240105||Departments for Psychosomatic Medicine at University Clinics|no study interventions, observational group
32859999|NCT05240105||Clinics specialized in Psychosomatic Medicine|no study interventions, observational group
32860000|NCT05240105||Departments for Psychosomatic Medicine at general hospitals|no study interventions, observational group
32860001|NCT05240105||Departments for Psychosomatic Medicine at psychiatric hospitals|no study interventions, observational group
32860002|NCT05241977||Anterior suprasscapular nerve block|A single researcher will perform the nerve blocks of all participants.
32860003|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
32860004|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
32860005|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
32860006|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
32860007|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
32860008|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
32860009|NCT03154307|Experimental|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
32860010|NCT05602051|Experimental|Virtual reality+Mindfulness|Intervention method combining virtual reality technology and mindfulness therapy, twice a week, lasting for 7 weeks
32860011|NCT05602051|No Intervention|Mindfulness|Intervention method of mindfulness therapy, twice a week, lasting for 7 weeks
32860012|NCT01926223|Experimental|Home visiting Group|
32860013|NCT01926223|No Intervention|Control Group|
32860014|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
32860015|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
32860016|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
32860017|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
32860018|NCT03148457|Experimental|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
32860019|NCT03148457|Other|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
32860020|NCT01921699|Other|irrelevant|
32860021|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
32860022|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
32860023|NCT05601817|Experimental|Vita (virtual reality-based cognitive restoration intervention)|Participants randomized to Vita will receive a virtual reality head-mount device (e.g., Oculus Quest) to view nature pictures for 10 minutes (1 set of 10 pictures)/day, 2-3 days/week for 8 weeks (a total of 20 sets for 200 minutes, approximately 3.3 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
32860024|NCT05601817|Experimental|Com (computerized cognitive training intervention )|Participants randomized to Com will receive a tablet computer (e.g., iPad) to complete BrainHQ training for 1 hour (6 exercises)/day, 2-3 days/week for 8 weeks (total of 20 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
32860025|NCT05601817|Experimental|Vita+Com (Both Vita and Com intervention)|Participants randomized to Vita+Com will receive both Vita and Com simultaneously. They will spend 10 minutes on Vita and then 1 hour on Com per day, 2-3 days/week for 8 weeks (a total of 23.3 hours). Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
32860026|NCT05601817|No Intervention|Usual care|Participants randomized to this control condition will continue to receive their usual care, but no interventions from the study team. We will monitor changes in their activities that may affect changes in cognitive function (e.g., starting book clubs) by weekly check-in calls during the 8 weeks of intervention phase.
32860027|NCT05601739||Lumbar degenerative disc disease|The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.
32860028|NCT05601739||Healthy|The control group was made of 44 healthy volunteers.
32860029|NCT05244551|Experimental|ABSK061|Dose escalation of oral ABSK061 will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in the subsequent cycles. If the actual elimination half-life of ABSK061 is greatly exceeding that predicted, a run-in period with a single-dose and a longer drug-free observation period could be performed in subsequent patients after the Investigator and Sponsor have discussed and agreed.
32860030|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
32860031|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
32860032|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
32860033|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
33321841|NCT05429736|Active Comparator|CAX + TSS|Individuals will participate in 6 training sessions of CAX while receiving TSS
33321842|NCT04878042|Experimental|Active|Mouth wash and nasal spray containing a diluted solution of hydrogen peroxide
33104860|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
33104861|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
33104862|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
33104863|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
33104864|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
33104865|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
32860034|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
33104866|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
33104867|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
33321843|NCT04878042|Placebo Comparator|Placebo|Mouth wash and nasal spray not containing a diluted solution of hydrogen peroxide
33321844|NCT04813614|Experimental|STYLAGE M Lidocaine|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into and/or around the lip mucosa by linear threading injection, multipoint injection, or a combination of both techniques with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
33321845|NCT04813614|Active Comparator|Active control group|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into the submucosal layer of the lip by linear threading injection or serial puncture techniques injection with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
33321846|NCT01106118||Group 1|
32860035|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
32860036|NCT05249309||Treatment|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
32860037|NCT05249309||Control|Will be checked weight, height and waist circumference and collected about 15 mL of peripheral blood.
32860038|NCT05243537||QTc time interval in former preterm neonates, or term born healthy controls|former preterms and healthy term controls are defined as described in the cohort as previously published (Salaets et al, Pediatr Res 2021; Gervais et al, Pediatr Res 2020; Bassareo et al, J Matern Fetal Neonatal Med 2011). This includes both the perinatal characteristics as well as the characteristics collected at assessment (pediatric age or young adulthood) In all cases, an ECG was collected at rest, and these individual values (preterm or healthy term controls will be pooled.
32860039|NCT05616221|Experimental|AP-PA02|Anti-pseudomonal bacteriophage
32860040|NCT05616221|Placebo Comparator|Placebo|Inactive isotonic solution
33104868|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
33104869|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
33321847|NCT01327872|Experimental|Treatment A|
33321848|NCT01327872|Experimental|Treatment B|
33321849|NCT01327872|Experimental|Treatment C|
33321850|NCT01327872|Experimental|Treatment D|
33321851|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
33321852|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
32860041|NCT04373785|Experimental|NG101m and standard treatment|"Concomittant therapy:~Radiation therapy, oral temozolomide, and oral NG101m~Adjuvant therapy:~Oral temozolomide and oral NG101m"
32860042|NCT05246267||Study group|Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
32860043|NCT05601505|No Intervention|Traditional neoadjuvant chemoradiotherapy group|"Eligible patients randomized into arm A will receive traditional neoadjuvant chemoradiotherapy, including long-course radiotherapy with a total number of 45-50.4Gy in 25-28 fractions, and with concurrent 3 times of oral capecitabine, the strategies of capecitabine are:~During radiotherapy: capecitabine 1650mg/m2/d, orally administered twice a day, d1-d14, every 3 weeks as a course; During the non-radiotherapy period: capecitabine 2000mg/m2/d, orally administered twice daily, d1-d14, every 3 weeks as a course"
32860044|NCT05601505|Experimental|ctDNA-guided neoadjuvant treatment group|"After sequencing tumor tissue, those with MSI-H/TMB-H or POLD/POLE2 mutation willed be arranged to receive immune therapy following NCRT，Terelizumab，200mg.~The others are arranged to randomly receive TNT (VAF>0.4%) or NCRT (VAF<0.4%) according to VAF value by the level of ctDNA.~TNT： Long course radiotherapy combined with 2 courses of single-agent capecitabine chemotherapy → 6 courses of CapeOX (Capecitabine 2000mg/m2/ day, twice orally, d1-14; Oxaliplatin 100-130mg/m2, intravenous infusion, d1; Every 3 weeks for a course of treatment.) chemotherapy was performed 2 to 3 weeks after the end of chemotherapy."
32860045|NCT05615597|Other|Para-discal infiltration|Single arm study
32860046|NCT05601427|Active Comparator|Anesthesiologist-Performed Adductor Canal Block (aACB)|Patients will get a pre-operative adductor canal block performed by an anesthesiologist.
32860047|NCT05601427|Experimental|Surgeon-Performed Adductor Canal Block (sACB)|Patients will get an intra-operative adductor canal block performed by the surgeon
32860048|NCT05240027|Other|Middle, High and College students within the Dallas-Fort Worth area that may Vape|The program will be going to middle school, high school, and college campuses in the Dallas-Fort Worth (DFW) area to speak with students about vaping. The program will be implemented by community outreach, as the students will be presented with information about vaping and the resources necessary to prevent or stop vaping.
32860049|NCT04396015|Placebo Comparator|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
32860050|NCT04396015|Other|open label extension|6 months of MCT oil.
32860051|NCT04396301|Active Comparator|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
32860052|NCT04396301|No Intervention|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
32860053|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
32860054|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
32860055|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
32860056|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
32860057|NCT05601349|Other|Usual Implementation of the Clinical Practice Guideline|In this group, all participants (cluster) have access to the clinical practice guideline that has been sent to the office responsible for implementing the guideline in the hospital. Due to the characteristics of the intervention in the control group it does not work as a placebo or a sham intervention.
32860058|NCT05601349|Active Comparator|Tele-education strategy|Tele-educational program consisting of a virtual course with recommendations from the CPG of lower limb amputees, with three modules: Perioperative, rehabilitation and prostheses
32860059|NCT05604755|Experimental|HQP1351 prophylactic therapy|HQP1351 prophylactic therapy after allo-hct on days 30 to 60
32860060|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
32860061|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)~β- Carotene (3 mg)~Vit C (100 mg)~Vit E (Alpha-Tocopherol Acetate): 60 IU~Vit D (500 IU)~Zinc (4 mg, elemental)~Copper (0.5 mg, elemental)~Selenium 100 µg (as Sodium Selenite)"
32860062|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
32860063|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
32860064|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
32860065|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
33104870|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
33321853|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
33409904|NCT04941261|Experimental|18-59 years old group B|
33409905|NCT04941261|Placebo Comparator|18-59 years old group C|
32860066|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
32860067|NCT05599295|Experimental|Orbactiv|ORBACTIV is infused at 15mg/kg over 3 hours for all subjects not to exceed a dose of 1200mg.
32860068|NCT05599295|Experimental|Kimyrsa|"KIMYRSA is infused at 15mg/kg over 1 hour for subjects ≥12 years old and weighing >40 kg not to exceed a dose of 1200mg.~KIMYRSA is infused at 15mg/kg over 3 hours in subjects <12 years old or weighing ≤40 kg."
32860069|NCT05599295|Active Comparator|Standard of Care|"The following SoC medications below will be administered via IV infusion, per the package insert, and according to local rules and regulations. SoC medications cannot be used in combination with one another.~Vancomycin~Teicoplanin~Clindamycin~Daptomycin~Semi-synthetic penicillins (e.g., nafcillin, oxacillin, cloxacillin)~Cefazolin~Ceftaroline"
32860070|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
32860071|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
32860072|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
32860073|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
32860074|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
32860075|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
32860076|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
32860077|NCT05601271|Placebo Comparator|Placebo|pills exactly as the drug will be delivered to participants. Instructions will be made to take the pill once a day.
32860078|NCT05601271|Active Comparator|Allopurinol|pills exactly as the placebo will be delivered to participants. Instructions will be made to take the pill once a day.
32860079|NCT03141437|Active Comparator|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
32860080|NCT03141437|Experimental|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
32860081|NCT05601193|Experimental|PRP group|Experimental: autologous PRP Bilateral ovaries autologous PRP injection under transvaginal ultrasound guidance. 3ml on each ovary.Once a month. two consecutive injections
32860082|NCT05601193|No Intervention|Control group|No intervention
32860083|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
32860084|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
32860085|NCT04347421|Experimental|Krill oil group|This group takes Krill oil for 12 weeks
32860086|NCT04347421|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
32860087|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32860088|NCT05601037|Experimental|Axilla dissection + Lymphevenous Anastomosis|Surgical bypass between lymphatic vessel and vein
32860089|NCT05601037|No Intervention|Standard surgery|Standard surgery
32860090|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
32860091|NCT05593289|Experimental|Telerehabilitation group|Participants assigned to the telerehabilitation program will complete a 3 month intervention consisting of 5 weekly sessions of 30 minutes of pre-recorded video, with a frequency of 2-3 times a day.
32860092|NCT05593289|No Intervention|Control group|The usual care group will be instructed to follow their physicians' orders during the 3-month intervention period. Baseline measurements will be made for each group, at 2 weeks, 6 weeks and 3rd month.
32860093|NCT05600959||Lymphoma group|Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment.
32860094|NCT05600959||Lymphoma-associated HLH group|Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment.
32860095|NCT05591885|Experimental|Study product gruop|Nutrilite Memory Builder Ingredients (Cistanche deserticola extract, Ginkgo biloba extract, glucose, microcrystalline cellulose, corn starch, etc.) 60 Tablets / bottle
32860096|NCT05591885|Placebo Comparator|Placebo group|Ingredients (glucose, microcrystalline cellulose, corn starch, caramel pigment, etc.) 60 Tablets / bottle
33409906|NCT04941261|Experimental|6-17 years old group A|
33409907|NCT04941261|Experimental|6-17 years old group B|
33104871|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
33409908|NCT04941261|Placebo Comparator|6-17 years old group C|
32860097|NCT05600881||ADHD|This study will recruit people aged 14-17 with ADHD who are 'Assigned Female At Birth' (AFAB). This is to include cisgender women alongside those who may not identify with womanhood such as those who are non-binary but AFAB or transgender men who have not undergone hormonal/medical transition.
32860098|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
32860099|NCT04394143|Experimental|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
32860100|NCT04394143|Placebo Comparator|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
32860101|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
32860102|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
32860103|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
32860104|NCT05586815|Active Comparator|Colistin plus Placebo|Colistin alone, 150 mg every 8 hours intravenously or according to renal function, plus Placebo
32860105|NCT05586815|Experimental|Colistin plus Minocycline|Colistin, 150 mg every 8 hours intravenously or according to renal function, plus Minocycline, 200 mg every 12 hours orally
32860106|NCT05607901|Active Comparator|Tacrolimus Group|50 patients will be treated with a thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
32860107|NCT05607901|Active Comparator|Hydrocortisone Group|50 patients will be treated with a thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.
32860108|NCT05604859|Active Comparator|non-intervening group|Standard treatment plan
32860109|NCT05604859|Experimental|intervention group|"Part A group: Patients received methylprednisolone 2mg/kg/d + IVIG 20g/d for a total of 5 days. If the disease progressed after treatment, the patients were given the dose of rescue therapy (methylprednisolone > 2mg/kg/d + IVIG 20g/d) for another 5 days.~Part B group: Patients received tocilizumab 4mg/kg once.~Part C group: Patients received low molecular weight heparin 100U/kg, q12h IH for 7 days.~All patients were followed up from the end of treatment to day 28 after completion of treatment."
32860110|NCT05586503|Experimental|ECG-gated CTA|For study's purposes, patients will undergo ECG-gated CTA scans instead of CTA scans at pre-operative planning, prior to discharge, 30 days, 6 months, 12 months in order to assess the stent stability and durability as well as the seal of the stent graft during the cardiac cycle and over time. An additional ECG-gated CTA scan may optionally be performed at 24 months if the device fixation and conformability continue up to the 12 months scan.
32860111|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
32860112|NCT04759573|Experimental|Early Vocal Contact|"The EVC will take place in the hospital room while infants are in their individual incubators or open cribs. In the intervention group, mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.~Early Vocal Contact will be performed by mothers three times a week for 2 weeks, more than one hour after afternoon feeding. It will begin when the newborns are in an active sleep state, in calm awake state or in active awake state, but not in deep sleep or crying. Preterm infants will be enrolled from 25+0 to 32+6 weeks of GA, following the established inclusion criteria."
32860113|NCT04759573|Active Comparator|Behavioral observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
32860114|NCT05607745|Active Comparator|FMT|Fecal transplantation is given 2:1 compared to placebo transplantation via gastroscopy as a fluid of 100-150ml. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
32860115|NCT05607745|Placebo Comparator|Placebo|Placebo is brown-colored water and given the same way than fecal transplantation fluid. All study subjects receive similar dietary advice based on healthy diet. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
32860116|NCT05607667|Experimental|Experimental: Treatment|Device: J-Valve® valve delivery system， Transvascularized biological aortic valve system
32860117|NCT00638963|Experimental|Temozolomide|
32860118|NCT00638963|No Intervention|Observational|
32860119|NCT01926925||1|Overweight Hispanic children/adolescents
32860120|NCT01926925||2|Lean Hispanic children/adolescents
32860121|NCT05604625|Active Comparator|Group A|12 patients will receive Van-Beek activator and a headgear
32860122|NCT05604625|Active Comparator|Group B|12 patients will receive Andresen activator
32860123|NCT05607589|Experimental|DWP213388|"Each cohort, healthy subjects will be administered DWP213388 (6 subjects per each cohort) SAD Cohort 1: DWP213388 x mg QD Cohort 2: DWP213388 x mg QD Cohort 3: DWP213388 x mg QD Cohort 4: DWP213388 x mg QD Cohort 5: DWP213388 x mg QD~MAD Cohort 6: DWP213388 x mg QD Cohort 7: DWP213388 x mg QD Cohort 8: DWP213388 x mg QD Cohort 9: DWP213388 x mg QD"
32860124|NCT05607589|Placebo Comparator|Placebo|"Each cohort, healthy subjects will be administered placebo (2 subjects per each cohort) SAD Cohort 1: Placebo QD Cohort 2: Placebo QD Cohort 3: Placebo QD Cohort 4: Placebo QD Cohort 5: Placebo QD~MAD Cohort 6: Placebo QD Cohort 7: Placebo QD Cohort 8: Placebo QD Cohort 9: Placebo QD"
32860125|NCT05604469||Group A (liver faluire patients with pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
32860126|NCT05604469||Group B (liver faluire patients without pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
32860127|NCT05604469||Group C (renal faluire patients with pruritus)|
33104872|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
33409909|NCT04941261|Experimental|3-5 years old group A|
32860128|NCT05604469||Group D (renal faluire patients without pruritus)|
32860129|NCT03047395|Experimental|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
32860130|NCT05560685|Other|Patient participants|Patients with risk factors for adjuvant endocrine therapy non-adherence or early discontinuation will complete patient-reported outcome (PRO) surveys via smart phone app at baseline and 2, 4, 8 and 12 weeks after adjuvant endocrine therapy initiation.
32860131|NCT05560685|Other|Team Member Participants|Feedback about the intervention will be obtained from patients and from members of the study teams and clinical teams caring for the patients who participate.
32860132|NCT04278677|Active Comparator|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
32860133|NCT04278677|No Intervention|No supplementation|
32860134|NCT00638027|Experimental|1|Memantine 10 mg bid
32860135|NCT00638027|Placebo Comparator|2|Placebo
32860136|NCT03548519|Experimental|Attention Training|OCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
32860137|NCT03548519|Active Comparator|Active placebo training|OCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
32860138|NCT03548519|Experimental|PSE and Attention Training|OCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
32860139|NCT04218565|Experimental|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
32860140|NCT05560607|Experimental|Intervention/ Drug|Investigation of the knockdown of hepatic HSD17B13 mRNA expression, PK, safety, and tolerability following multiple dose administration of AZD7503 in male participants and female participants of non-childbearing potential with NAFLD or NASH
32860141|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
32860142|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
32860143|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
32860144|NCT05604079|Experimental|Electrolarynx|In this single arm study, all participants will receive training in the Electrolarynx
32860145|NCT05607199|Experimental|AUR103, 25mg to 400mg|Currently planned dose levels in Part 1 are 25 mg BID, 50 mg BID, 100 mg BID, 200 mg BID and 400 mg BID
32860146|NCT05603767|Experimental|RMT+ VR|The patient selects a video with the Oculus Quest headset and music to be played live.
32860147|NCT05603767|No Intervention|Control|No intervention
32860148|NCT05606653|Other|didgeridoo players|subjects having a regular practice of didgeridoo
32860149|NCT05606653|Other|oboe players|subjects having a regular practice of the oboe
32860150|NCT05606653|Other|control|control subjects without diagnosed SAS, at low risk of SAS on the Berlin questionnaire and the STOP BANG questionnaire
32860151|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
32860152|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
32860153|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
32860154|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
32860155|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
32860156|NCT05603689|Active Comparator|Normal diet|no limitations on food consumption.
32860157|NCT05603689|Experimental|Isocaloric ketogenic diet|We defined ICKD as a daily CHOs ingestion < 30 to 50 g.d-1, without any limitation in fat consumption.
32860158|NCT05553977||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
32860159|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
32860160|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
32860161|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
32860162|NCT05541341||Acute Lymphoblastic Leukemia (ALL)|Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion
32860163|NCT05541341||Diffuse Large B-cell Lymphoma (DLBCL)|Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion
32860164|NCT05602987|Experimental|Study Group: enema|receiving enema at the night before anal surgery
32860165|NCT05602987|Active Comparator|Control Group: no enema|no enema before anal surgery
32860166|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
32860167|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
32860168|NCT03030079|Experimental|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
32860169|NCT05536895|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
32860170|NCT05536895|Active Comparator|MD-CT|An evaluation with conventional, standard of care, multi-detector CT (MD-CT)
32860171|NCT05603533|Experimental|Intervention group|On top of the regular physical therapy, the participants in the intervention group will receive a music and video-based group exercise therapy in small groups of 5. On a big screen, a video of an older woman performing exercises will be shown, the participants will have to copy these exercises. In the beginning of each session, the participants will be able to choose the music they want to move to.
32860172|NCT05603533|No Intervention|Control group|The participants in the control group will receive no additional therapy.
32860173|NCT05600335||ERAS group|
32860174|NCT05600335||Conventional group|
32860175|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
32860176|NCT04759105|Experimental|Autologous BM-MSC injection|"Two interventions:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control"
32860177|NCT04759105|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection, without placebo injection."
32860178|NCT05603221||Endovascular Group|Patients who had successful endovascular revascularization
32860179|NCT04126603|Placebo Comparator|Group A Placebo|Metformin + Placebo.
32860180|NCT04126603|Active Comparator|Group B Active|Metformin + Placebo
32860181|NCT05602909|Experimental|Guided biaxial distraction|
32860182|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
32860183|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
32860184|NCT04759261|Other|Study group|
32860185|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
32860186|NCT04124497|Experimental|Daratumumab Pomalidomide dexamethasone|"Therapy consists in cycles of the DPd combination as follows:~Pomalidomide 4 mg once daily on days 1-21;~Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22;~Daratumumab 16 mg/kg intravenously at following schedule:~cycle 1 and 2: days 1, 8, 15, and 22~cycle 3 through 6: days 1, and 15~from cycle 7 until disease progression: day 1."
32860187|NCT03831373|Experimental|Upper-limb-focused resistance training|
32860188|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
32860189|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
32860190|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
32860191|NCT04394611||Control|healthy pregnancies will be selected for the control group.
32860192|NCT04127851|Experimental|Sodium Hyaluronate 0.15% mono-therapy|HA 0.15% group was treated with HA 0.15% six times daily for 12 weeks
32860193|NCT04127851|Active Comparator|Cyclosporin 0.05% + carboxymethylcellulose (CMC) 0.5% (standard therapy)|CsA 0.05% + CMC 0.5% group was treated with CsA 0.05% two times daily and CMC 0.5% two ~ six times daily for 12 weeks.
32860194|NCT04127851|Other|HA 0.15% + CsA 0.05% (combination therapy)|HA 0.15% + CsA 0.05% group was treated with HA 0.15% six times daily and CsA 0.05% twice daily for 12 weeks.
32860195|NCT04394533|Experimental|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
32860196|NCT04394533|Active Comparator|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
32860197|NCT01928017||Hematooncology patients|No intervention
32860198|NCT04275583|Experimental|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
32860199|NCT04124653|Experimental|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
32860200|NCT04124653|Experimental|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
32860201|NCT04127695|Experimental|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
32860202|NCT04127695|Experimental|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
32860203|NCT04127695|Experimental|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
32860204|NCT04127695|Experimental|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
32860205|NCT05602831||operable treatment group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline surgical tissue will be also obtained."
33104873|NCT02236013|Experimental|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
33104874|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
32860206|NCT05602831||radical chemoradiotherapy group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline puncture tissue will be also obtained before radical chemoradiotherapy."
32860207|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
32860208|NCT04393831|Active Comparator|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
32860209|NCT04393831|No Intervention|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
32860210|NCT04394455|Experimental|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
32860211|NCT04394455|Active Comparator|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
32860212|NCT04394065||uEXPLORER total-body PET/CT|Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes
32860213|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
32860214|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
32860215|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
32860216|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
32860217|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
32860218|NCT04125823|Experimental|Video game-based physical activity training|
32860219|NCT04125823|Active Comparator|Conventional physiotherapy program|
32860220|NCT05602441|Experimental|VALID - diabetes supportive clubs|VALID - diabetes supportive clubs
32860221|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
32860222|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
32860223|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
32860224|NCT04123951|Experimental|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
32860225|NCT04123951|No Intervention|Control|"In this arm patients will continue 'as normal' with daily activities.~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
32860226|NCT04120597|Experimental|Therapy group|
32860227|NCT04120597|Placebo Comparator|Control group|
32860228|NCT04129879|Experimental|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
32860229|NCT05602129|Experimental|HSK36273 Continuous infusion|Drug:HSK36273 Administration mode:Continuous infusion
32860230|NCT05602129|Experimental|HSK36273 Bolus+Continuous infusion|Drug:HSK36273 Administration mode:Bolus+Continuous infusion
32860231|NCT05602129|Active Comparator|Heparin sodium|Drug:Heparin sodium Administration mode:Bolus+Continuous infusion
32860232|NCT05609929|Experimental|Omeprazole combined with AB-106 group|
32860233|NCT04393987|Experimental|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
32860234|NCT04393987|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
32964134|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
33321854|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
33321855|NCT04769310|Other|Patient arm|"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
33321856|NCT01108770||HED affected males|
33321857|NCT01108770||Unaffected male controls|
32964135|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
32964136|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
32964137|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
32964138|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
32964139|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
32964140|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
32964141|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
32964142|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
32964143|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
32964144|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
32964145|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
32964146|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
32964147|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
32964148|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
33321858|NCT00234065|Experimental|1|cilostazol
33321859|NCT00234065|Active Comparator|2|Aspirin
33409910|NCT04941261|Experimental|3-5 years old group B|
32964149|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
32964150|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
32964151|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
32964152|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
32964153|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
32964154|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
32964155|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
32964156|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
32964157|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
32964158|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
33409911|NCT04941261|Placebo Comparator|3-5 years old group C|
33409912|NCT04941261|Experimental|6-35 months old group A|
33409913|NCT04941261|Experimental|6-35 months old group B|
33409914|NCT04941261|Placebo Comparator|6-35 months old group C|
33409915|NCT04941261|Experimental|6-35 months old group D|
32860235|NCT05609851||experimental group|A physical performance test will be applied to the group and Questionnaires related to occupation will be made to individuals.
32860236|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
32860237|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
32860238|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
32860239|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
32860240|NCT01928563|Experimental|Udenafil|Udenafil is administered
32860241|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
32860242|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
32860243|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
32860244|NCT05609617|Experimental|Face and neck injection|"NCTF135HA intradermal injection on face and neck. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and neck."
32860245|NCT05609617|Experimental|Face and upper chest/décolleté injection|"NCTF135HA intradermal injection on face and décolleté. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and décolleté."
32860246|NCT05609617|Active Comparator|Face and neck controle|Application of Hydra Filler cream twice daily on the face and neck.
32860247|NCT05609617|Active Comparator|Face and upper chest/décolleté controle|Application of Hydra Filler cream twice daily on the face and décolleté.
32860248|NCT04129255|Other|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
32860249|NCT03044977|Experimental|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
32860250|NCT03044977|Experimental|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
32860251|NCT03044977|Experimental|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
32860252|NCT03044977|Experimental|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
32860253|NCT03044977|Experimental|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
32860254|NCT03044977|Experimental|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
32860255|NCT03044977|Experimental|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
32860256|NCT03044977|Experimental|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
32860257|NCT03422731|Experimental|Cohort I (TMLI+FLT/TMLI)|Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, on days 30 and 100, at 1 year, and at time of relapse. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days 30 and 100, at year 1, and at time of relapse. Patients also undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year. Patients undergo fluorothymidine F-18 PET, DECT, and water-fat MRI as in TMLI+FLT.
32860258|NCT03422731|Active Comparator|Cohort II (TBI)|Patients undergo collection of bone marrow at baseline, day 30, time of relapse, and at 1 year.
32860259|NCT04129489|Experimental|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
32860260|NCT04129567|Experimental|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
32860261|NCT04129567|Experimental|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
32860262|NCT04129567|Placebo Comparator|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
32860263|NCT04129567|Active Comparator|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
32860264|NCT04128787|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
32860265|NCT04128787|Experimental|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
33409916|NCT04941261|Experimental|6-35 months old group E|
33409917|NCT04941261|Placebo Comparator|6-35 months old group F|
33409918|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
33409919|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
33409920|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
33409921|NCT05597787|Active Comparator|HIV Connect|Participants randomized to this condition will complete HIV Connect, which is an online course developed by the Malaysian Society of HIV Medicine designed to educate primary care physicians in Malaysia about HIV. It consists of a series of modules featuring HIV infectious disease experts who instruct on topics including epidemiology and natural history of HIV, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), sexual history taking and STI testing, and others.
33409922|NCT05597787|Active Comparator|Project ECHO for HIV Prevention|Participants randomized to this condition will receive Project ECHO for HIV Prevention, without added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
33409923|NCT05597787|Experimental|Project ECHO for HIV Prevention + Stigma Reduction|Participants randomized to this condition will receive the Project ECHO for HIV Prevention intervention with added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
33409924|NCT05597709||Patients who diagnosed as T2DM|Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
33409925|NCT05420181|Other|Short Fast|Participants will fast overnight for a period of 10 hours
33409926|NCT05420181|Other|Long fast|Participants will fast overnight for a period of 16 hours
32860266|NCT04128787|Experimental|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
32860267|NCT04129099|Experimental|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
32860268|NCT05609227|Experimental|mobile application|Participants will get a mobile application containing information about information about all stages of stem cell transplantation process (pre, during and post).
32860269|NCT05609227|No Intervention|Control|Participants will receive routine care.
32860270|NCT04129021|Experimental|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
32860271|NCT05609149||T3 Rectal cancer|Patients with T3 rectal cancer who underwent curative surgery.
32860272|NCT04394377|Other|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):~Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);~Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
32860273|NCT04394377|Other|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
32860274|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
32860275|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
32860276|NCT04128163|Experimental|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
32860277|NCT04128163|Placebo Comparator|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
32860278|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
32860279|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
32860280|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
33104875|NCT03456999|Placebo Comparator|Placebo|Matching placebo
32860281|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
32860282|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
32860283|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
32860284|NCT05608759|Experimental|single arm|4 weeks of multimodal pre-rehabilitation
32860285|NCT04128085|Experimental|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
32860286|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
32860287|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
32860288|NCT05608603||3 months postcovid patients|"Included 100 patients, aged 18-80 years old, at 3 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
32860289|NCT05608603||9 months postcovid patients|"Included the same 100 patients, aged 18-80 years old, at 9 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
32860290|NCT04348175|Experimental|Mild impairment|
32860291|NCT04348175|Experimental|Moderate impairment|
32860292|NCT04348175|Experimental|Severe impairment|
32860293|NCT04348175|Experimental|Normal (control)|
32860294|NCT04127929|Active Comparator|Glass carbomer|
32860295|NCT04127929|Active Comparator|Tokuyama Estelite Posterior|
32860296|NCT05608525|Experimental|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
32860297|NCT05608525|Experimental|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
32860298|NCT05608525|Sham Comparator|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
32860299|NCT03301909|Experimental|PillCam™ Endoscopy System|"PillCam™ Endoscopy System consists of the following subunits:~PillCam™ Capsule products' family:~PillCam™ COLON 2~PillCam™ UGI (upper gastrointestinal)~PillCam™ SB3 (small bowel 3)~PillCam™ Crohn's capsule~Patency capsule: PillCam™ Patency capsule~All the bellow system subunits are part of the Pillcam™ systems:~PillCam™ Recorder~PillCam™ Sensor Arrays & Sensor Belt~PillCam™ Software v. 9~Workstation unit"
32860300|NCT03244189|Experimental|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
32860301|NCT03244189|No Intervention|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
32860302|NCT03130439|Experimental|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
32860303|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
32860304|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
32860305|NCT04396223|Experimental|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
32860306|NCT04127617|Experimental|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
32860307|NCT04127617|Active Comparator|Nursing Care|The conventional treatment consists in educational nursing care.
32860308|NCT04396067|Active Comparator|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
32860309|NCT04396067|Active Comparator|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
32860310|NCT04396067|Placebo Comparator|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
32860311|NCT04124419|Experimental|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
32860312|NCT05608447|Active Comparator|FMT capsules|FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
33409927|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
33409928|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
32860313|NCT05608447|Placebo Comparator|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
32860314|NCT05608213|Experimental|Len-I|
32860315|NCT05608213|Active Comparator|Len|
32860316|NCT04127461|Active Comparator|Open vessel harvesting|Arm 1 is the conventional procedure
32860317|NCT04127461|Experimental|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
32860318|NCT04274647|Experimental|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
32860319|NCT04124107|Experimental|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
32860320|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
32860321|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
32860322|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
32860323|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
32860324|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
32860325|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
32860326|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
32860327|NCT03236545|Experimental|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
32860328|NCT03236545|Experimental|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
32860329|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
32860330|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
32860331|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Recruited from community-based cohort studies - CLEAREST and ACCT~Equal recruitment across the following parameters:~Age: 3 groups <30, 30-60, >60 years~Gender~BMI: 3 groups <25, 25-30, >30 Kg/m2"
33409929|NCT05420103||Pre-ASAP|Conventional Stroke Rehabilitation Program
32964159|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
32964160|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
33409930|NCT05420103||Post-ASAP|Standardized functional assessment, standardized intensive early ambulation with modern technologies such as Knee-Ankle-Foot Orthoses and Robotic-Assisted Gait Training. In order to monitor the progress of each patient proactively, Stroke Registry and Reference Modified Rivermead Mobility Index (MRMI) Gain were developed. Stroke Registry was a longitudinal stroke rehabilitation database to monitor patients' functional outcomes and therapists' intervention compliance so as to pave the way for future clinical big data movement to bridge the gap between evidence-practice and clinical practice. Reference MRMI Gain was a clinical prediction model apply business intelligence concept to support goal-orientated approach of physiotherapists in stroke rehabilitation. Stroke treatment library, a standardized exercise prescription in video format was also developed to facilitate standardized prescription of interventions to patients with different level of ability.
33409931|NCT04868643|Other|In-Center arm|Subjects undergo In-Center treatment in Phase 2 as defined.
33409932|NCT04868643|Other|In-Home arm|"Subjects undergo In-Home treatments in Phase 4 as defined.~Subjects in Phase 2 and Phase 4 will be the same."
33409933|NCT04863885|Experimental|Phase 1 Dose Level 1|Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.
33409934|NCT04863885|Experimental|Phase 1 Dose Level 2|Participants will be treated at dose level 2: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 10 mg/kg IV will be administered days 1 and 8 every 3 weeks.
33409935|NCT04863885|Experimental|Phase 1 Dose Level -1|If dose reduction is indicated, participants will be treated at dose level -1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 6 mg/kg IV will be administered days 1 and 8 every 3 weeks
33409936|NCT04863885|Experimental|Phase 2: Treatment at Maximum Tolerated Dose (MTD)|Participants will be treated at with Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks plus the maximum tolerated dose of Sacituzumab Govitecan days 1 and 8 every 3 weeks.
33409937|NCT03631485||parents having children with cancer|No intervention.
33409938|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
33409939|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
33409940|NCT05418543|Experimental|EUS-FNA|
33409941|NCT05418543|Experimental|CH-EUS-FNA|
33409942|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
33409943|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
33409944|NCT05417841|Experimental|IDegAsp group|IDegAsp twice daily
33409945|NCT05417841|Active Comparator|IDegAsp + IAsp group|IDegAsp once daily plus IAsp twice daily
33409946|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
33409947|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
33409948|NCT05597475|Other|Patients|Patients with hypoglycemia
33409949|NCT05597475|Other|Controls|Patients without post-bariatric hypoglycemia
33409950|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
33409951|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
33409952|NCT05597397|Experimental|Repeated Low-Level Red-Light Therapy (RLRL)|Single vision spectacles (SVS) & RLRL.
33409953|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
33409954|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
33409955|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
33409956|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
33409957|NCT05597319||ERAS-in|Patients who completed ERAS program
33409958|NCT05597319||ERAS-out|Patients who dropped-out from ERAS program
33409959|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
33409960|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
32964161|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
32964162|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
32964163|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
32964164|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
32964165|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
32860332|NCT05606731|Experimental|Intervention Group|"The study's intervention is a parenting/caregiver training program that includes 1-month of weekly in-person sessions plus multi-media interactive text messaging. The weekly 1-hour-in-person sessions will be coupled with four interactive messages per week for a period of 4 weeks total, followed by booster text messages after completing the 4-week program."
32860333|NCT05606731|No Intervention|Usual Care|"Usual care for caregivers of 2- to-5-year-olds will include the Women Infant and Children services : (1) monthly vouchers for nutritious food; (2) individual nutrition counseling at least twice per year; (3) nutrition education two times per year (1:1 counseling or online health education modules); and (4) referrals to family services."
32860334|NCT04126993|Experimental|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
32860335|NCT04126993|Active Comparator|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
32860336|NCT05604781||Symfony & Synergy IOL combination|
32860337|NCT05604313|Experimental|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC)
32860338|NCT05604313|No Intervention|Do-as-usual|On the test day (crossover study), participants will play with the usual preferred chin and shoulder rest.
32860339|NCT04123483|Experimental|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
32860340|NCT04127227|Experimental|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Stage IV patients with localized disease will be treated with consolidative RT. Patients with CR or PR will receive Sintilimab maintenance therapy.
32860341|NCT05603299|No Intervention|Control Group|The Control group treats their simulated patients using standard practice and have no introduction to the new test.
32860342|NCT05603299|Experimental|Intervention Group 1 - Test Results Given|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, whether they order the test or not.
32860343|NCT05603299|Experimental|Intervention Group 2 - Test Results Optional|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, only if they choose to order the test.
32860344|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
32860345|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
32860346|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
32860347|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
32860348|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
32860349|NCT04274803|Experimental|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
32860350|NCT04274803|Active Comparator|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
32860351|NCT04127149|Experimental|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
32860352|NCT04127149|No Intervention|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
32860353|NCT03292861|Active Comparator|Thymoglobulin®|"Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.~In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation"
32860354|NCT03292861|No Intervention|No induction therapy|Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
32860355|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
32860356|NCT04126759|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
33104876|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
33104877|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
33104878|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
33104879|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
32860357|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
32860358|NCT02315989|Other|safety|proton therapy
32860359|NCT04392973|Experimental|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
32860360|NCT04392973|No Intervention|Control|Standard of Care Treatment for COVID-19 Infection
32860361|NCT03267277|Experimental|Treatment|Patient will be assessed for 10 weeks off treatment and then will receive 10 weeks of treatment. They will return at weeks 24 and 52 for safety and sustainability of efficacy assessments.
32860362|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
32860363|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
32860364|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
32860365|NCT04126369|Experimental|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
32860366|NCT04126369|Active Comparator|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
32860367|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
32860368|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
32860369|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
32860370|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
32860371|NCT04123249|Experimental|Group Propofol|In the Group P, propofol 4-6 mg/kg/h and remifentanil 0.2μg/kg/min were infused by intravenous pump separately for assisted sedation and assisted analgesia.
32860372|NCT04123249|Experimental|Group Sevoflurane|sevoflurane (concentration: 2%-3%, mixed with 50% air and 50% oxygen to keep the minimum alveolar concentration (MAC) at 1.0-1.1) was inhaled to maintain assisted sedation, and remifentanil 0.2 μg/kg/min was infused by intravenous pump for assisted analgesia.
32860373|NCT05526521|Experimental|Dupilumab|Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age
32860374|NCT04758871|Experimental|Dydrogesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using dydrogesterone 10 mg 3 times daily
32860375|NCT04758871|Active Comparator|Micronized progesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using micronized progesterone 2x200 mg twice daily vaginally
32860376|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
32860377|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
32860378|NCT03128593|Experimental|Experimental: JR-141|
32860379|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
32860380|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
32899121|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0).~With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications."
33104880|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
33104881|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
33104882|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
32860381|NCT04125901|Experimental|Pain Neuroscience Education and Exercise|Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
32860382|NCT04125901|Other|Exercise|Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
32860383|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 1)|
32860384|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 2)|
32860385|NCT03538301|Placebo Comparator|Placebo|
32860386|NCT04125979|Experimental|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
32860387|NCT04125979|Experimental|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
32860388|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
32860389|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
32860390|NCT04393675|Active Comparator|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
32860391|NCT04393675|Placebo Comparator|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
32860392|NCT05520203||Patient - cohort 1|Patients (and their parents) recruited before introduction of the NP
32860393|NCT05520203||Patient - cohort 2|Patients (and their parents) recruited after introduction of the NP
32860394|NCT05520203||Healthcare providers|Healthcare providers involved in the process of development, implementation and evaluation as well as all healthcare providers who come into close contact with the Nurse Practitioner
32860395|NCT04274413|Experimental|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
32860396|NCT04274257|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
32860397|NCT04274257|Experimental|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
32860398|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
32860399|NCT03128957|Experimental|Varying cerebral oxygenation with varying ventilation|Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen
32860400|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
32860401|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
32860402|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib, acalabarutinib)|Patients receive venetoclax PO QD and ibrutinib PO QD and acalabrutinib PO BID. Treatment repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unaccepted toxicity.
32860403|NCT03827551|Experimental|Parkinson's Patients|
32860404|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
32860405|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
32860406|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
32860407|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
32860408|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
32860409|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
32860410|NCT00632099|Placebo Comparator|Placebo|matched placebo
32860411|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
32860412|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
32860413|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
32860414|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
32860415|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
32860416|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
32860417|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
32899122|NCT01381471||COPD|Patients with a diagnosis code of COPD
32860418|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
32860419|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
32860420|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
32860421|NCT04125511|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
32860422|NCT02957929|Experimental|Cohort 1a, Period A|single intravenous dose, crossover
32860423|NCT02957929|Experimental|Cohort 1a, Period B|single oral dose, crossover
32860424|NCT02957929|Experimental|Cohort 1a, Period C|single oral dose
32860425|NCT02957929|Experimental|Cohort 1a, Period D|single oral dose, crossover
32860426|NCT02957929|Experimental|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
32860427|NCT02957929|Experimental|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
32860428|NCT02957929|Experimental|Cohort 2|Multiple oral doses
32860429|NCT02957929|Experimental|Cohort 3|Multiple oral doses
32860430|NCT02957929|Experimental|Cohort 4|Multiple oral doses in presence of CYP probe substrates
32860431|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
32860432|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
32860433|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
32860434|NCT04392739|Other|TPOXX|TPOXX 600 mg BID x 7 days
32860435|NCT04122547|Active Comparator|Roflumilast|Roflumilast 500 microgram one tab oral per day
32860436|NCT04122547|Placebo Comparator|Placebo|One tablet oral per day
32860437|NCT04122703|Experimental|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
32860438|NCT04122703|Sham Comparator|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
32860439|NCT04109911|Experimental|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
32860440|NCT04109911|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
32860441|NCT04393597|Experimental|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
32860442|NCT04393597|Experimental|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
32860443|NCT04122781|Experimental|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
32860444|NCT04122781|Active Comparator|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
32860445|NCT02957227||1|cohort 1: Older adults with memory impairment
32860446|NCT02957227||2|cohort 2: Age matched healthy controls
32860447|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
32860448|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
32860449|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
32860450|NCT04125355|Placebo Comparator|Placebo|Placebo control
32860451|NCT04125355|Experimental|Reflexology|foot reflexology
32860452|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
32860453|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
32860454|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
32860455|NCT04121923|Experimental|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
32860456|NCT04125433|Experimental|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals~Up to 400 Adults age 18 to 65~New York State Medicaid Managed Care Members~Have utilized emergency department services 6 or more times in a 12-month period~Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
32860457|NCT04125199|Experimental|experimental group|
32860458|NCT04125199|Placebo Comparator|control group|
32860459|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
32860460|NCT03826615|No Intervention|No medication|Control group
32860461|NCT04124887|Active Comparator|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
32860462|NCT04124887|Experimental|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
32860463|NCT04124887|Experimental|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
33104883|NCT01263691|Placebo Comparator|Control|Saline control
33104884|NCT02178410|Active Comparator|Vitamin D + fish oil|
32860464|NCT04124887|Experimental|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
32860465|NCT04121767|Experimental|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
32860466|NCT04121767|Active Comparator|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
32860467|NCT04121689|Experimental|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate
32860468|NCT04274569|Active Comparator|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
32860469|NCT04274569|Experimental|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
32860470|NCT04274569|Experimental|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
32860471|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
32860472|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
32860473|NCT04124731|Experimental|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
32860474|NCT04124731|Active Comparator|Control|Standard platinum-based chemotherapy
32860475|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
32860476|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
32860477|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.~The patients are examined once."
32860478|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.~The patients are examined once."
32860479|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
32860480|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
32860481|NCT04758559|Placebo Comparator|Usual care|Patients receive usual care concerning dietary advice.
32860482|NCT04758559|Experimental|myfood24|Patients receive myfood24 a new online app to support tracking of food and nutrient intakes, and allows patients and healthcare professionals to communicate, seeing results of intakes to promote healthy dietary behaviour changes.
32860483|NCT04758559|Experimental|myfood24 + diet optimisation|Personalised feedback. Patients use myfood24 with an additional feature of new technology providing guidance of how to optimise their diets against targets, using information they provide about current intakes.
32860484|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
32860485|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
33104885|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
33104886|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
33104887|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
33104888|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
32860486|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
32860487|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.~Participants in the exercise intervention will complete 24 sessions."
32860488|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
32860489|NCT03098563|Experimental|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
32860490|NCT03098563|Experimental|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
32860491|NCT03098563|Experimental|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
32860492|NCT03098563|Experimental|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
32860493|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
32860494|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
32860495|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
32860496|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
32860497|NCT04121533|Placebo Comparator|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
32860498|NCT04121533|Experimental|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
32860499|NCT04121533|Experimental|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
32860500|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
32860501|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
32860502|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
32860503|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
32860504|NCT04121143|Active Comparator|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
32860505|NCT04121143|Active Comparator|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
32860506|NCT04121143|Active Comparator|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
32860507|NCT04121143|Placebo Comparator|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
32860508|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
32860509|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
32860510|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
32860511|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
32860512|NCT04273789|Experimental|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
32860513|NCT04273789|Placebo Comparator|Placebo sleepwear|Sleepwear (shorts + tshirt)
32899123|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
32899124|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
32899125|NCT02941926|Experimental|Ribociclib + letrozole+goserelin/leuprolide|Participants will received ribociclib (orally taken, 3 weeks on/1 week off) in combination with letrozole (orally taken once daily). For men and premenopausal women, either goserelin will be given as an injectable subcutaneous implant or leuprolide will be given as an intramuscular injection.
33409961|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
32899126|NCT01329679|Experimental|Energy Drink|Energy drink, 2 oz twice daily for 7 days
32899127|NCT01329679|Placebo Comparator|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
32899128|NCT01331083|Experimental|PX-866|
32899129|NCT05422092|Experimental|Canagliflozin treatment group|Canagliflozin 100mg were given to the patients for 24 weeks
32899130|NCT05422092|Placebo Comparator|Pioglitazone treatment group|Pioglitazone 30mg were given to the patients and the dosage will be increased to 45mg 2 weeks later
32899131|NCT05421078|Placebo Comparator|Placebo|Once-daily placebo
32899132|NCT05421078|Experimental|Experimental 2.5 mg Obicetrapib|once-daily Obicetrapib
32899133|NCT05421078|Experimental|Experimental 5 mg Obicetrapib|once-daily Obicetrapib
32899134|NCT05421078|Experimental|Experimental 10 mg Obicetrapib|once-daily Obicetrapib
32899135|NCT05420844|Other|Kintsugi|Enrolled participants who will be using the Kintsugi voice journaling phone application.
32899136|NCT05448456|Active Comparator|Hexakakapron group|women with an episiotomy after vaginal delivery
32899137|NCT05448456|Placebo Comparator|control group|women with an episiotomy after vaginal delivery
32899138|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
32899139|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
32899140|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
32899141|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
32899142|NCT05448378|Experimental|D-chiro-inositol|Patients will take D-chiro-inositol. We will make two blood sampling, at the baseline and after one-month treatment
32899143|NCT05447130|Experimental|Corneal Endothelial Evaluation after Phacoemulsification in Eyes with Pseudoexfoliation Syndrome|
32899144|NCT05447130|Experimental|Corneal Endothelial Evaluation after Phacoemulsification in Eyes without Pseudoexfoliation|
32899145|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
32899146|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
32899147|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
32899148|NCT05462340|Experimental|Healthy Volunteers|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
32899149|NCT05462340|Experimental|Schizophrenia (ari, brex, risp)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
32899150|NCT05462340|Experimental|Schizophrenia (olanz)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
32899151|NCT05462340|Experimental|Schizophrenia (no med)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
32899152|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
32899153|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
32899154|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
32899155|NCT01381861|Experimental|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
32899156|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
32899157|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
32899158|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
32899159|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
32899160|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
32899161|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
32899162|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
32899163|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
32899164|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
32860514|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
32860515|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
32860516|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
32860517|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
32860518|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
32860519|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
32860520|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
32860521|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
32860522|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
32860523|NCT03064867|Experimental|V+RICE|"Venetoclax given in combination with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide)~Phase I part of this study is a 3 + 3 design, with 3 dose levels, a minimum of 6 participants (maximum of 18) will be required to identify the recommended phase 2 dose (RP2D).~Phase II involvs two stages: In stage I, a total of 16 participants will be accrued. If there are 7 or fewer complete responses (CR), the study will be stopped. Otherwise, an additional 30 participants will be accrued in stage II.~The maximum number of treatment cycles with V+RICE is three. Participants who achieve complete remission at the interim response assessment after 2 cycles may omit cycle 3 in order to proceed to subsequent consolidation therapy with autologous stem cell transplant (AHSCT).~Participants will proceeed to other treatment including RICE, other chemotherapy, peripheral blood stemm cell collection, and ASCT per institutional guidelines."
32860524|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
32860525|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR ≤ 0.80 in vessels ≥ 2.5 mm in diameter .
32860526|NCT04120987|Active Comparator|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
32860527|NCT04120987|No Intervention|Control|No treatment
32860528|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
32860529|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~real exposure: oral presentation to a panel of examiners~virtual reality : oral presentation to virtual examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
32860530|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~virtual reality : oral presentation to virtual examiners~real exposure: oral presentation to a panel of examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
32860531|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
32860532|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
33321860|NCT04732962|Experimental|AposHealth|"Following the initial consultation and calibration of the Apos device in the clinic, the patients will receive from his therapist a home-based treatment plan. This usually includes wearing the device for about 20 minutes with about 20% of weight-bearing (patient is instructed to wear the Apos and just be with the device and go about his/her daily routine). A gradual increase in usage time is prescribed reaching up to 60 min wear time with about 40% weight-bearing.~Patients are requested to return to follow-up (FU) appointments after 1, 3, 6, 9 and 12 months. In addition, patients will have a remote FU after 1-week to confirm they use AposHealth as advised. During the follow-up appointment, re-assessment of clinical outcomes and gait patterns are performed and the calibration of the Apos device is adjusted as needed. The treatment plan is adjusted, and patients are encouraged to continue to wear the device regularly at home."
33321861|NCT04732962|Active Comparator|Total Knee Replacement (TKR)|"Patients will undergo TKR according to Geisinger's policy, guidelines and care protocol.~The study baseline visit will occur 6 weeks postoperative for TKR groups."
32860533|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
32860534|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
33409962|NCT05594199|Experimental|Intervention Arm: Virtual Group|The intervention will involve participating in the study's virtual smoking cessation program. This program consists of 2 components: an e-learning module and a tailored email messaging program based on the participant's motivation to quit smoking and their Fagerstrom test for nicotine dependence score.
32860535|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
32860536|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
32860537|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
32860538|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
32860539|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
32860540|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
32860541|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
32860542|NCT04120831|Experimental|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
32860543|NCT04120831|Active Comparator|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
32860544|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
32860545|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
32860546|NCT00631163|Experimental|Deferasirox|Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.
32860547|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
32860548|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
32860549|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
32860550|NCT04120675|Experimental|Experimental group|"Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).~Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
32860551|NCT04120675|Active Comparator|Control group|10 patients will not receive treatment with Extra Virgin Olive Oil
33104889|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
32860552|NCT03056755|Experimental|Cohort A: Prior CDK 4/6 + aromatase|Patients who received any Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib 300 mg oral.+ fulvestrant 500 mg intramuscular (i.m)
32860553|NCT03056755|Experimental|Cohort B: Prior CDK 4/6 + fulvestrant|Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib 300 mg oral + letrozole 2.5 mg oral
32860554|NCT03056755|Experimental|Cohort C: Prior systemic chemo or ET|Patients who received systemic chemotherapy or endrocrine therapy (ET) , (including monotherapy or in combination with targeted therapy except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib 300 mg oral + fulvestrant 500 mg i.m.
32860555|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .~."
32860556|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
32860557|NCT04120441|Experimental|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
32860558|NCT04120441|No Intervention|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
32860559|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
32860560|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
32860561|NCT04120519|Experimental|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
32860562|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
32860563|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
32860564|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
32860565|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
32860566|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
32860567|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
32860568|NCT04392115|Experimental|Exercise Group|"The home-based exercise program called the PREPARE program.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
32860569|NCT04392115|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
32860570|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
32860571|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
32860572|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
32860573|NCT03126851|Experimental|No age range / no explicit warning|Label: No age range and no explicit warning on front display panel of medication box.
32860574|NCT03126851|Experimental|age range / no explicit warning|Label: Age range present but no explicit warning on front display panel of medication box.
32860575|NCT03126851|Experimental|age range / explicit warning in words|Label: Age range present with explicit warning in words on front display panel of medication box.
32860576|NCT03126851|Experimental|age range / explicit warning+pictogram|Label: Age range present with explicit warning in words plus pictographic warning on front display panel of medication box.
32860577|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
32860578|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
32860579|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
32860580|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
32899165|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
32860581|NCT04120207|Experimental|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
32860582|NCT04120207|Other|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
32860583|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
32860584|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
32860585|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
32860586|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
32860587|NCT04392271|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
32860588|NCT04120051|Experimental|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
32860589|NCT04120051|Placebo Comparator|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
32860590|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
32860591|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
32860592|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
32860593|NCT04120129|Experimental|TMS treatment|participants receive TMS treatment
32860594|NCT04120129|Sham Comparator|sham TMS|participants receive control TMS treatment
32860595|NCT04120129|No Intervention|non intervention|control group
32860596|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
32860597|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
32860598|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
32860599|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
32860600|NCT04758793|Other|patients without liver disease,|taking blood samples and biopsy of muscular wall
32860601|NCT04758793|Other|patient with chronic liver disease without cirrhosis,|taking blood samples and biopsy of muscular wall
32860602|NCT04758793|Other|patients with compensated cirrhosis,|taking blood samples and biopsy of muscular wall
32860603|NCT04758793|Other|patient with severe cirrhosis|taking blood samples and biopsy of muscular wall
32860604|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
32860605|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
32860606|NCT00634829|Placebo Comparator|P|Placebo-HFA
32860607|NCT04126837|Other|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
32860608|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
32860609|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
32899166|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
33409963|NCT05594199|No Intervention|Control Arm: Standard Care|"This arm will receive standard care which may or may not include brief advice to quit smoking from any of the healthcare providers.~Providing smoking cessation intervention is not mandatory in standard care and may not be provided."
32860610|NCT04125277|Experimental|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
32860611|NCT04395911|Other|SCD|Cytopheretic device
32860612|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
32860613|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
32860614|NCT04008355|Experimental|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
32860615|NCT04008355|Experimental|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
32860616|NCT04008355|Placebo Comparator|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
32860617|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
32860618|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
32860619|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
32860620|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
32860621|NCT03823807|Experimental|SH-1028|QD,Oral
32860622|NCT01920191|Experimental|IMA 950 and Poly ICLC|
32860623|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
32860624|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
32860625|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
32860626|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
32860627|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
32860628|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
32860629|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
32860630|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
32860631|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
32860632|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
32860633|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
32860634|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
32860635|NCT02921893|Experimental|Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
32860636|NCT02921893|Experimental|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
32899167|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
33409964|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
33409965|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
33409966|NCT05590767||shoulder rotators repair|Patients scheduled to undergo shoulder rotators repair surgery
33409967|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
33409968|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
33409969|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
33409970|NCT03686826||multiple sclerosis patients|
33409971|NCT03686826||healthy volunteers|
33409972|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
33409973|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
33409974|NCT03690882||Cases of unclassified acute cervical pain|
33409975|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
33409976|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
33409977|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
33409978|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
33409979|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
33409980|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
33409981|NCT03682692|Experimental|ACEI/CCB|
33409982|NCT03682692|Experimental|ACEI/DIU|
33409983|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
33409984|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
33409985|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis~Histologically confirmed solid malignancy~Positive Cytology~Baseline Brain MRI~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
33409986|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma~Clinical indication for stereostatic radiosurgery~Evaluable extracranial focus~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.~Brain MRI and PET CT"
32860638|NCT01920503||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
32860639|NCT04352049|Active Comparator|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
32860640|NCT04352049|Active Comparator|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
32860641|NCT01920581||volunteers|
32860642|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
32860643|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
32860644|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
32860645|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
32860646|NCT01920659|No Intervention|control|control
32860647|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
32860648|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
32860649|NCT01262547|No Intervention|Control|Control
32860650|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
32860651|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
32860652|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
32860653|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
32860654|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
32860655|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
32860656|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
32860657|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
32860658|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
32860659|NCT04392349|Other|NORMAL|Normal group includes eyes with healthy cornea.
32860660|NCT04392349|Other|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
32860661|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
32860662|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
32860663|NCT03009513|Experimental|single arm|
32860664|NCT04129333|Experimental|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
32860665|NCT04129333|Placebo Comparator|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
32860666|NCT03117881|Experimental|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
32860667|NCT03117881|Experimental|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
32860668|NCT03117881|Experimental|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
32860669|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
32860670|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
32860671|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
32860672|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
32860673|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
32860674|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
32860675|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
32860676|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
32860677|NCT04120753|Experimental|Treatment 1|OLOMAX 20/5/5mg
32860678|NCT04120753|Experimental|Treatment 2|OLOMAX 20/5/10mg
32860679|NCT04120753|Active Comparator|Treatment 3|Olmesartan 20 mg/Amlodipine 5 mg
32860680|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
32860681|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
32899168|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
33409987|NCT04163016|Experimental|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.~From all study participants blood samples will be drawn for pharmacokinetics during the study."
32860682|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
32860683|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
32860684|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
32860685|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
32860686|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
32860687|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
32860688|NCT01265667|Experimental|CF101 2 mg|CF101 2mg oral tablets
32860689|NCT01265667|Placebo Comparator|Placebo|Placebo oral tablets
32860690|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
32860691|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
32860692|NCT01921595|Experimental|Valanced salt colloid group|
32860693|NCT01921595|Active Comparator|Valanced salt crystalloid group|
32860694|NCT04121455|Experimental|Cohort 1: 200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
32860695|NCT04121455|Experimental|Cohort 2: 400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
32860696|NCT04121455|Experimental|Cohort 3: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
32860697|NCT04121455|Experimental|Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, bevacizumab every two weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely or not resected patients
32860698|NCT04121455|Experimental|Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6, completely resected patients
32860699|NCT04121455|Experimental|Expansion group, Arm C: 600 mg Olaptesed pegol + Radiotherapy + 200 mg Pembrolizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, pembrolizumab every three weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely resected patients
32860700|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
32860701|NCT01921907|Experimental|Active|topical treatment
32860702|NCT01921907|Placebo Comparator|Placebo|topical treatment
32860703|NCT03826771|Experimental|POWER training|high velocity strength training
32860704|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
32860705|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
32860706|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
32860707|NCT04129411|Experimental|RFA Group|
32860708|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
32860709|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
32860710|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
32899169|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
32899170|NCT01038557|Active Comparator|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
32899171|NCT01038557|Experimental|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
32964166|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
33409988|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
32964167|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
32964168|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
32964169|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
32964170|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
32964171|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
32964172|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
32964173|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
32964174|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
32964175|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
32964176|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
32964177|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
32964178|NCT02164422|Placebo Comparator|Placebo|Placebo
32964179|NCT02165124|Experimental|Intervention/Bariatric Embolization|
32964180|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
32964181|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
32964182|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
32964183|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
32964184|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
32964185|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
32964186|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
32964187|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
32964188|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
32964189|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
32964190|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
32964191|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
32964192|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
32964193|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
33409989|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
32964194|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
32964195|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
32964196|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
33321862|NCT04732962|Experimental|Post TKR traditional physical therapy (PT) and AposHealth|"Patients who have had a knee replacement and were assigned to the traditional PT+ AposHealth group will follow Geisinger post-operative rehab protocol and will also receive AposHealth and follow the rehabilitation protocol.~AposHealth will start six weeks post-op and will continue for 12 months. Patients will receive AposHealth similar to the non-invasive group, i.e., will have an initial evaluation (IE) and calibration of the Apos device, have a remote FU after one week from IE and in-clinic FUs at 1, 3 6, 9 and 12 months."
33321863|NCT04730076|Active Comparator|Standard Balloon Dilation|Patients in this group will receive standard balloon dilation therapy.
33321864|NCT04730076|Experimental|Progressive Balloon Dilation|Patients in this group will receive progressive balloon dilation therapy.
33321865|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
33321866|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
33321867|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
33321868|NCT01108848||Berinert|Patients requiring treatment with Berinert®
32964197|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
32964198|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
32964199|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
32964200|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
32964201|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
32964202|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
32964203|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
32964204|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
32964205|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
32964206|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
32964207|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
32964208|NCT02189382|Other|Water|Self Applied
32964209|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
32964210|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
32964211|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
32964212|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
32964213|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
32964214|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
32964215|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
32964216|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
32964217|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
32964218|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
32964219|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
33321869|NCT05371470|Experimental|Cardiac rehabilitation plus voice analysis|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.
33321870|NCT05371470|No Intervention|Cardiac rehabilitation only|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.
32964220|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
32964221|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
32964222|NCT02198430||Control group|Children without hemophilia
32964223|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
32964224|NCT02200536|Experimental|Test|Infant oral health promotion package
32964225|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
32964226|NCT02200536|No Intervention|Control 2|
32964227|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
32964228|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
32964229|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
32964230|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
32964231|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32964232|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
33409990|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
32964233|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
32964234|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
32964235|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
32964236|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
32964237|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~-- Complete baseline data collection, and registration~Patient Randomization~Standard transplant oncology care~-- Palliative care consults only upon request~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
32964238|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
32964239|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
32964240|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
33409991|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
33409992|NCT03926052|Active Comparator|LDX|
33409993|NCT03926052|Placebo Comparator|Placebo|
33409994|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
33409995|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
32964241|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
32964242|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
32964243|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
32964244|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
32964245|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
32964246|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
32964247|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
32964248|NCT02213250|Experimental|BeneFIX|
32964249|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
32964250|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
32964251|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
32964252|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
32964253|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
32964254|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
32964255|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
32964256|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
32964257|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
32964258|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
32964259|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
33409996|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
33409997|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
32964260|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
32964261|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
32964262|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
32964263|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
32964264|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
32964265|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
32964266|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
32964267|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
32964268|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
32964269|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
32964270|NCT02224404|Experimental|Fast Gelling Dressing|
32964271|NCT02224482|No Intervention|Control|Print materials
33409998|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
32964272|NCT02224482|Active Comparator|Intervention Group|PROGRESS
33104890|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
32860711|NCT02943733|Experimental|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
32860712|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
32860713|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
32860714|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
32860715|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
32860716|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
32860717|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
32860718|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
32860719|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
32860720|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
32860721|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
32860722|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
32860723|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32860724|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
32860725|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
32860726|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
32860727|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
32860728|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
32860729|NCT01922375|Experimental|Naftopidil dose 2|PO administration
32860730|NCT01922375|Placebo Comparator|Placebo|PO administration
32860731|NCT01922375|Experimental|Naftopidil dose 1|PO administration
32860732|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
32860733|NCT01922453|No Intervention|no music and sound|
32860734|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
33409999|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
33321871|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
33321872|NCT04696458|Experimental|EXPERIMENTAL PROBIOTIC|1 Multistrain Probiotic Capsule
33321873|NCT04696458|Placebo Comparator|Placebo|1 Identical Placebo Capsule
33321874|NCT04660812|Experimental|etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab|Participants will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.
32860735|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
32860736|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
32860737|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
32860738|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
32860739|NCT04395989|Experimental|LAR-HER2+|If patients were LAR subtype with HER2 gene activated mutation
32860740|NCT04395989|Experimental|LAR-PAM+|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
32860741|NCT04395989|Experimental|IM|If patients were IM subtype (CD8 positive T cell more than 20%)
32860742|NCT04395989|Experimental|BLIS|If patients were BLIS subtype or MES subtype and without PI3K/AKT/mTOR pathway activation
32860743|NCT04395989|Experimental|MES-PAM+|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
32860744|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
32860745|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
32860746|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
32860747|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
32860748|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
32860749|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
32860750|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32860751|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
32860752|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
32860753|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
32860754|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
32860755|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
32860756|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
32860757|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
32860758|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
32860759|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
32860760|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
32860761|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
32860762|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
32860763|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
32860764|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :~Tarnier and Chantreuil technique~or SOGC technique"
33321875|NCT04660812|Active Comparator|mFOLFOX-6 +/-bevacizumab|Participants will receive mFOLFOX-6 +/- bevacizumab by IV infusion.
33321876|NCT04660812|Active Comparator|regorafenib|Participants will receive oral regorafenib
33321877|NCT04660812|Experimental|etrumadent+ zimberelimab + AB680|Participants will receive oral etrmadenant in combination with zimberelimab +AB680 by IV infusion.
33321878|NCT04660188|Experimental|Multidisciplinary collaborative care arm|Post-treatment clinical follow-up visits will be staggered between the oncologist and a dedicated PCP. A patient navigator will be assigned to each study participant to conduct follow-up sessions over the phone regularly at an approximate interval of 3 months.
33321879|NCT04660188|No Intervention|Attentional control arm|BCS will receive follow-up care by their oncologists and any other healthcare providers under existing usual care practices at NCCS.
33321880|NCT00233987|Experimental|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
33321881|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
33321882|NCT03946644|Active Comparator|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
33321883|NCT03946644|Experimental|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
33321884|NCT03947970|Experimental|[14C] CR845|Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
33321885|NCT05322174|Experimental|Baby Sleep|Those randomized to this intervention group will receive an interactive online intervention focused on promoting infant sleep. This will include membership in a private Facebook group with support provided in the group, including weekly resources in the form of videos and tip sheets. To supplement this, they will also receive items meant to help with sleep (ex. sleep sack, baby sleep book).
33321886|NCT05322174|Active Comparator|Baby Care|The active control condition will parallel the intervention, but will be focused on general baby care and not sleep. Participants will be added to a private Facebook group in which general baby care information will be shared (e.g., bathing, play) and will receive items to help with general baby care (e.g., baby care kit with items such as nail clippers and comb; general baby care book). Topics related to sleep and feeding will not be highlighted in this group.
33321887|NCT05321394|Active Comparator|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
33321888|NCT05321394|Experimental|Tixagevimab Cilgavimab|300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections
33321889|NCT05321394|Experimental|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
33321890|NCT01106508|Experimental|LEQ506|
33321891|NCT04623242|Experimental|Gantenerumab|
33321892|NCT04623242|Experimental|Solanezumab|
33321893|NCT04623242|Placebo Comparator|Matching placebo (Gantenerumab)|
33321894|NCT04623242|Placebo Comparator|Matching Placebo (Solanezumab)|
33321895|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
33327420|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
33327421|NCT01285830|Placebo Comparator|Placebo|
33327422|NCT01285830|Active Comparator|Lactobacillus reuteri|
33327423|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
32860765|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
32860766|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
32860767|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
32860768|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32860769|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32860770|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32860771|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
32860772|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
32860773|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
32860774|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
32860775|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
32860776|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
32860777|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
32860778|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
32860779|NCT04395677|Experimental|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
32964273|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
32964274|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
32964275|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
32964276|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
32964277|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
32964278|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
32964279|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
32964280|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
32964281|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
32964282|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
32964283|NCT02232126|No Intervention|Usual Care|
32964284|NCT02232126|Experimental|Intervention|
32964285|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
32964286|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
32964287|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
32964288|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
32964289|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
32964290|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
32964291|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
32964292|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
32964293|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
32964294|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
32964295|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
32964296|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
32964297|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
32964298|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
32964299|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
32964300|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
32964301|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
32964302|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
33327424|NCT01179360||Imaging group|
33327425|NCT03631888||patients scheduled for elective laparoscopic surgery|
33104891|NCT05108844|Experimental|Early small bowel investigation|Patients in the early small bowel investigation group will undergo VCE immediately after their initial negative gastroscopy
33327426|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
33327427|NCT03859050|Experimental|LPS arm|
32860780|NCT05509907|Experimental|healthy adolescents within 12-18 years old|Adolescents aged 12-18 years who continue secondary education, do not have any chronic diseases or disabilities and volunteer to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All evaluations, training on the use of smart watches and mobile and web-based physical activity tracking applications will be carried out at the school where the adolescents receive education.
32860781|NCT05509907|Experimental|Adolescents aged 12-18 years with chronic rheumatic disease|Children with rheumatic disease who were diagnosed with chronic rheumatic disease, diagnosed at least 6 months ago, whose medical treatment was stable, and who volunteered to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All assessments and training on smartwatches and mobile and web-based physical activity tracking applications will be held at Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University.
32860782|NCT05507255|Active Comparator|Relaxation training|Females will receive relaxation training, in the form of deep breathing, 3 days per week, for 8 weeks.
32860783|NCT05507255|Experimental|The same relaxation training plus an aerobic exercise program|Females will receive the same relaxation training, in addition to 30 minutes of a moderate aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.
32860784|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
32860785|NCT05498129|Active Comparator|No school meal|
32860786|NCT05498129|Experimental|School meal|
32860787|NCT05498129|Experimental|School meal plus micronutrient powder|
32860788|NCT05337917||Case|Injury to digital nerve: thumb, digit II radial side, digit V ulnar side
32860789|NCT05337917||Control|Injury to digital nerve: digit II ulnarside, dig III, dig IV dig V radial side.
32860790|NCT05489237|Experimental|Dose Escalation (Phase I)|Participants should have advanced (metastatic and/or surgically unresectable) GIST, following failure of at least prior imatinib therapy due to progression of GIST.
32860791|NCT05489237|Experimental|(Phase 1b) Cohort 1 - Participants with GIST progression after first-line imatinib therapy|Participants with advanced GIST who have had GIST progression only after first-line imatinib only (second line therapy setting).
32860792|NCT05489237|Experimental|(Phase 1b): Cohort 2 - Participants with GIST progression after 2nd OR 3rd line TKI therapy|Participants with metastatic and/or surgically unresectable GIST following progression EITHER after sequential imatinib then sunitinib (third-line therapy setting) OR after imatinib, sunitinib, and then an additional TKI agent (i.e., regorafenib or ripretinib) (fourth-line therapy setting).
32860793|NCT05489237|Experimental|(Phase 1b): Cohort 3 - Participants with GIST progression after 4th or greater lines of TKI therapy|Participants with advanced GIST who have had GIST progression after 4th line or greater lines of TKI therapy (failure due to progression of all available agents (imatinib, sunitinib, regorafenib, ripretinib, and possibly others (> 5th line therapy setting)
32860794|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
32860795|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
32860796|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
32860797|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
32860798|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
32860799|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
32860800|NCT05486117|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 8 days
32860801|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
32860802|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
32860803|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
32860804|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
32860805|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
33104892|NCT05108844|Active Comparator|Colonoscopy|Participants with negative gastroscopy will undergo bowel preparation and colonoscopy the next day
33327428|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
33327429|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
32860806|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
32860807|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
32860808|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
32860809|NCT01929941|Experimental|Group 1 INCB047986|
32860810|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
32860811|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
32860812|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
32860813|NCT01925651|Other|Standard Risk - No bolus|No Bolus
32860814|NCT01925651|Other|Standard Risk - Alternate Bolus|Alternate 5mm Bolus
32860815|NCT01925651|Other|High Risk - Alternate Bolus|Alternate 5mm Bolus
32860816|NCT01925651|Other|High Risk - Continuous bolus|Continuous 5mm bolus
32860817|NCT01272999||1|Otitis media cases
32860818|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
32860819|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
32860820|NCT03422627|Experimental|Phase 1b|The phase 1b part of this study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 52 weeks.
32860821|NCT03422627|Experimental|Phase 2|The phase 2 portion of this study will be conducted as a single arm, multi-center, open-label trial in subjects with steroid refractory chronic graft versus Host Disease (cGVHD). All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks and will continue protocol permitted background therapy for cGVHD.
32860822|NCT01300065|Experimental|Experimental- Soflens|Bausch & Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
32860823|NCT01300065|Active Comparator|Marketed - Soflens|Bausch & Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
32860824|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
32860825|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
32860826|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
32860827|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
32860828|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
32860829|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
32860830|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
32860831|NCT04769583|Active Comparator|concomitant quadruple therapy (QC)|PPI (esomeprazole: 40 mg x 2 per day) with the amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day) for 14 days
32860832|NCT04769583|Placebo Comparator|triple therapy (TT)|PPI (esomeprazole: 40 mg x 2 per day) with amoxicillin (1 g x 2 per day) and clarithromycin (500 mg x 2 per day) AND PLACEBO for 14 days.
32860833|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
32860834|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
32860835|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
32860836|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
32860837|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
32860838|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
32860839|NCT01926197|Active Comparator|Modified FOLFIRINOX|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin.
32860840|NCT01926197|Experimental|Modified FOLFIRINOX plus Stereotactic Body Radiotherapy|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin, in combination with stereotactic body radiotherapy (SBRT)
32964303|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
32964304|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
32964305|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
32964306|NCT02241720|Experimental|Regorafenib treatment|
32964307|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
32964308|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
32964309|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
32964310|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
32964311|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
32964312|NCT02247336|Experimental|Immediate|Patients will complete a family health history platform at enrollment
32964313|NCT02247336|Active Comparator|Delayed|Patients will complete a family health history platform 12 months following enrollment
32964314|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
32964315|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
32964316|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
32964317|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
32964318|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
32964319|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
32964320|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
32964321|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
32964322|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
32964323|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
32964324|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
32964325|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
32964326|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
32964327|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
32964328|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
32964329|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
32964330|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
32964331|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
32964332|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
32964333|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
33327430|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
33327431|NCT05598034|Experimental|Left DLPFC tDCS|Participants randomized to this arm will receive tDCS at the left DLPFC brain region.
33327432|NCT05598034|Experimental|Left DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
33327433|NCT05598034|Experimental|Right DLPFC tDCS|Participants randomized to this arm will receive tDCS at the right DLPFC brain region.
33327434|NCT05598034|Experimental|Right DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
33410000|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
32860841|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
32860842|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
32860843|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
32860844|NCT01923545|Active Comparator|Leucostim®|G-CSF
32860845|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
32860846|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
32860847|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
32860848|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
32860849|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
32860850|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
33327435|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
33327436|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
32860853|NCT01305213|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32860854|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32860855|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
32860856|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
32860857|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
32860858|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
32860859|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
32860860|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
32860861|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
32860862|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
32860863|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
32860864|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
32860865|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
32860866|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
32860867|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
32860868|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
32860869|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
32860870|NCT03078803|Placebo Comparator|Placebo|Water
32860871|NCT03101501|Experimental|MMC for fibrosis prevention|no intervention is required after procedure is performed
32860872|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
32860873|NCT01923623|Placebo Comparator|NaCl|
32860874|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
32860875|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
32860876|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
32860877|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
32860878|NCT01923857|Experimental|Severe renal impairment|
32860879|NCT03495167|Experimental|SyB C-1101|
32860880|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
33410001|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
33410002|NCT03686592|Active Comparator|Volunteers|
32964334|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
32964335|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
32964336|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
32964337|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
32964338|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles~Pembrolizumab will be given at 200 mg every 21 days.~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
32964339|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
32964340|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
32964341|NCT02267226|Experimental|Octafibrin|
32964342|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
32964343|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
32964344|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
32964345|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
32964346|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
32964347|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
32964348|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
32964349|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
32964350|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
32964351|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
32964352|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
32964353|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
32964354|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
32964355|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
32964356|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
32964357|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
32964358|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
32964359|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
32964360|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
32964361|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
32964362|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
32964363|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
32964364|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
32964365|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
32964366|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
32964367|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
32964368|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
32964369|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
32964370|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
32964371|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
32964372|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
32964373|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
32964374|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
32860881|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
32860882|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
32860883|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
32860884|NCT03485729|Experimental|Biopsy-mandated|
32860885|NCT03485729|Experimental|Biopsy-optional|
32860886|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
32860887|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
32860888|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
32860889|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
32860890|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
32860891|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
32860892|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
32860893|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
32860894|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
32860895|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
32860896|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
32860897|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
32860898|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
32860899|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
32860900|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
32860901|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
32860902|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.~Dry Powder Inhaled Dose:~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
32860903|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
32860904|NCT04275947||Training|
32860905|NCT04275947||Validation|
32860906|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
32860907|NCT01925105|Placebo Comparator|Control|Treatment as usual
32860908|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
32860909|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
32860910|NCT01925729|Experimental|histamine|5 mg intranasal spray
32860911|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
32860912|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
32860913|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
32860914|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
32860915|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
32860916|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
32860917|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
32860918|NCT01926275|Active Comparator|IMT|inspiratory muscle training
32860919|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
33327437|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
33327438|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
33327439|NCT05597956|Experimental|white defects|Evaluate the infiltration of the defects.
33327440|NCT05597956|Experimental|yellow defects|Evaluate the infiltration of the defects.
33327441|NCT05597956|Experimental|Brown defects|Evaluate the infiltration of the defects.
33327442|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
32860920|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
32860921|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
32860922|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
32860923|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
32860924|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
32860925|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
32860926|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
32860927|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
32860928|NCT01926743|Experimental|NIR with ICG group|
32860929|NCT01926821|Experimental|sonifilan|Group who get sonifilan
32860930|NCT01926821|No Intervention|control|No Sonifilan administered
32860931|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
32860932|NCT04395365|Experimental|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
32860933|NCT04395365|Placebo Comparator|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
32860934|NCT04340531|Experimental|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
32860935|NCT04340531|Active Comparator|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
32860936|NCT01927133||FIBROFRANCE Project|
32860937|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
32860938|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
32860939|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
32860940|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
32860941|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
32860942|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
32860943|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
32860944|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
32860945|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
32860946|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
32860947|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
32860948|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
32860949|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
32860950|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
32964375|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
32964376|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
32964377|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
32964378|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
32964379|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
32964380|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
32964381|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
32964382|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
32964383|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
32964384|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
32860951|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
32860952|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
32964385|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
32964386|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
32964387|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
32964388|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
32964389|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
32964390|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
32964391|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
32964392|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
32964393|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
32964394|NCT02286726|Experimental|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
32964395|NCT02286726|Experimental|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
32964396|NCT02286726|Experimental|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
32964397|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
32964398|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
32964399|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
32964400|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
32964401|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
32964402|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
32964403|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
32964404|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
32964405|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
32964406|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
32964407|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
32964408|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
32964409|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
32964410|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
32964411|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
32964412|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
32964413|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
32964414|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
32964415|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
32964416|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
32964417|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
32964418|NCT02303184|Experimental|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
32964419|NCT02303184|Active Comparator|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
32964420|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
32964421|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
32964422|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
32964423|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
32964424|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
32964425|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
32964426|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
32964427|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
32964428|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
32964429|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
32964430|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
32964431|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
32964432|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
32964433|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
32964434|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
32964435|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
32964436|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
32964437|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
32964438|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
32964439|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
32964440|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
32964441|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
32964442|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
32964443|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
32964444|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
32964445|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
32964446|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
32964447|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
32964448|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
32964449|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
32964450|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
32964451|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
32964452|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
32964453|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
32964454|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
32964455|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
32964456|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
32964457|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
32964458|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
32964459|NCT02347410|Other|Investigation Group|This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.
32964460|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
32964461|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
32964462|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
32964463|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
32964464|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
32964465|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
32964466|NCT02351700|Active Comparator|IV Caldolor (ibuprofen)|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
33033498|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
32964467|NCT02351700|Placebo Comparator|standard treatment group|IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
32964468|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
32964469|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
32964470|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
32964471|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
32964472|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
32964473|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
32964474|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
32964475|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
32964476|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
32964477|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
32964478|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
32964479|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
32964480|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
32964481|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
32964482|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
32964483|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
32964484|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
32964485|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
32964486|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
32964487|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
32964488|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
33033499|NCT01963559|Other|Diabetic patients with MPP|
33033500|NCT01963559|Other|Diabetic patients without MPP|
33327443|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
33327444|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
33327445|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
33327446|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
33327447|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
33327448|NCT05597800|Experimental|Cohort A: HBV and HCV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections, such as HBV and HCV in cohort A.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
32964489|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
32964490|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
32964491|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
32964492|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
32964493|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
32964494|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
32964495|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
32964496|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
32964497|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
32964498|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
32964499|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
32964500|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
32964501|NCT02370810|Other|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
32964502|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
32964503|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
32964504|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
32964505|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
32964506|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
32964507|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
32964508|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
32964509|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
32964510|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
32964511|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
32964512|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
32964513|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
32964514|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
32964515|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
32964516|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
32964517|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
32964518|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
32964519|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met~."
32964520|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
32964521|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
32964522|NCT02377752|Experimental|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32964523|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
32964524|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
32964525|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
32964526|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
32964527|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
32964528|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
32964529|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
32964530|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
32964531|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
32964532|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
32964533|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
32964534|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
32964535|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
32964536|NCT02385240|Placebo Comparator|Placebo gel|Placebo
32964537|NCT02385318|Experimental|Test Product|Ingenol Mebutate
32964538|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
32964539|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
32964540|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
32964541|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
32964542|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
32964543|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
32964544|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
32964545|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
32964546|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
32964547|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
32964548|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
32964549|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
32964550|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
32964551|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
32964552|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
33327449|NCT05597800|Experimental|Cohort B: HIV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as HIV in cohort B.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
32964553|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
32964554|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
32964555|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
32964556|NCT02394912|Experimental|Single-arm|
32964557|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32964558|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
32964559|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
32964560|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
32964561|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
32964562|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
32964563|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
32964564|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
32964565|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
33033501|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
33033502|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
33033503|NCT01963585||Negative metacholine|Healthy control
33033504|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
32899172|NCT04352387|Experimental|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
32899173|NCT04352387|Active Comparator|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
32899174|NCT01117727|Experimental|Pilot Testing|
32899175|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
32899176|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
32899177|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
32899178|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
32899179|NCT01041209|Experimental|BPS|BPS guidance
32899180|NCT01041209|Active Comparator|Guideline|Enforced guidelines
32899181|NCT01084499|Experimental|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
32899182|NCT01084499|Experimental|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
32899183|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
32899184|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
32899185|NCT01986348|Experimental|Arm A: Selinexor 60 mg and Surgery|Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
32899186|NCT01986348|Experimental|Arm B: Selinexor 50 mg/m^2|Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
32899187|NCT01986348|Experimental|Arm C: Selinexor 60 mg|Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
32899188|NCT01986348|Experimental|Arm D: Selinexor 80 mg|Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
32899189|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
32899190|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
32899191|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
32899192|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
32899193|NCT01118273|Active Comparator|DPH 50mg|
32899194|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
32899195|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 3) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 65.64g of plant protein and fibre variety 3 (3.09g leucine), 28.6g butter, 5.12g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
32899196|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 5) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 67.78g of plant protein and fibre variety 3 (3.09g leucine), 27.79g butter, 4.63g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
32899197|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 6) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 57.66g of plant protein and fibre variety 3 (3.09g leucine), 31.72g butter, 6.62g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
32899198|NCT05420142|Active Comparator|Test meal incorporating the control comparator (whey protein isolates), plus 10g of added pea fibre.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 36.59g of unflavoured Optimum Nutrition gold standard 100% whey protein (3.09g leucine), 33.23g butter, 9.09g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
32899199|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
32899200|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
33410003|NCT05411991|Experimental|Intervention arm|"Application of a standardized diuretic schedule with following key components:~UNa assessment in spot urine sample after every bolus of loop diuretics with continuation of intravenous diuretics until absence of clinical signs of fluid overload AND UNa <80 mmol/L~Loop diuretic dosing according to estimated glomerular filtration rate (eGFR) with higher dose for lower eGFR~Upfront use of intravenous acetazolamide 500 mg OD unless hypernatremia or metabolic acidosis~Upfront use of oral chlorthalidone 50 mg OD if eGFR <30 mL/min/1.73m² OR hypernatremia~Full nephron blockade with intravenous acetazolamide 500 mg OD, intravenous bumetanide 4 mg TID, oral chlorthalidone 100 mg OD, and intravenous canrenoate 200 mg OD in case of diuretic resistance, defined as UNa <80 mmol/L and persistent clinical signs of fluid overload~Provision of 500 mL intravenous Dextrose 5% with 3 g MgSO4 and 40 mmol KCl daily during intravenous diuretics"
33410004|NCT05411991|Active Comparator|Control arm|Usual care for AHF. It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines. Urine electrolyte assessment in the control arm is not allowed as it is a key component of the studied intervention.
33410005|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
33410006|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
33410007|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
33410008|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
32860953|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
32860954|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
32860955|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
32860956|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
32860957|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
32860958|NCT01927913|Experimental|SPD602|
32860959|NCT01927913|Active Comparator|Deferasirox|
32860960|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
32860961|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
32860962|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
32860963|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
32860964|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
32860965|NCT03085979|Experimental|Burch|Burch Colposuspension
32860966|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
32860967|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
32860968|NCT04759469|Experimental|High-intensity interval training (HIIT)|A high-intensity interval training program for 3 days/week (day after day) for 12 weeks on atreadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program intensity.
32860969|NCT04759469|Active Comparator|Moderate intensity interval training (MIIT)|A moderate intensity interval training program for 3 days/week (alternate days) on a treadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program.
32860970|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
32860971|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
32860972|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
32860973|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
32964566|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
32964567|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
32964568|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
32964569|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
32964570|NCT02408796|Experimental|OTO-201|6 mg OTO-201
32964571|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
32964572|NCT02411916|No Intervention|controls|patients not receiving misoprostol
32964573|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
32964574|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
32964575|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
32964576|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
32964577|NCT05719350|Experimental|Experimental Group|Tele-rehabilitation exercises for the knee joint to reduce pain
32964578|NCT05719350|Active Comparator|Control Group|Exercises in presence for the knee joint to decrease pain
32964579|NCT05719116|Experimental|Physical exercise|Participants will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.
32964580|NCT05719038||Healthy control group|
32964581|NCT05719038||Pulmonary fibrosis after COVID-19 Pneumonia|
32964582|NCT05719038||No pulmonary fibrosis after COVID-19 Pneumonia|
32964583|NCT05718882|Experimental|Lenvatinib plus VIC-1911 combination therapy|Subjects with lenvatinib unresponsive or lenvatinib resistant hepatocellular HCC will receive Lenvatinib plus VIC-1911 combination therapy.
32964584|NCT05718804||Sepsis-associated kidney injury|Sepsis patients and acute kidney injury No intervention
32964585|NCT05718804||Sepsis but no renal impairment|Sepsis patients without acute kidney injury
32964586|NCT05718492|Experimental|HAIC|Treated by HAIC alone.
32964587|NCT05718258|Experimental|Participants with mild hepatic impairment|Venglustat single dose on Day 1
32964588|NCT05718258|Experimental|Participants with normal hepatic function|Venglustat single dose on Day 1
33410009|NCT02839707|Experimental|Arm I (PLD, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. (Closed to accrual as of February 09, 2021)
33410010|NCT02839707|Experimental|Arm II (PLD, bevacizumab, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. Patients also undergo CT on study.
32964589|NCT05718258|Experimental|Participants with moderate hepatic impairment|Venglustat single dose on Day 1
32964590|NCT05718258|Experimental|Participants with severe hepatic impairment|Venglustat single dose on Day 1
32964591|NCT05718180|Experimental|Supine|Measures are performed first in the supine position and then in a flexible sacrum position
32964592|NCT05718180|Active Comparator|Flexible|Measures are performed first in a kneeling squat position and then in the supine position
32964593|NCT05718102|Active Comparator|Pharmacist led|Pharmacists will conduct population health management for patients with COPD
32964594|NCT05718102|Active Comparator|Pulmonologist led|Pulmonologists will conduct population health management for patients with COPD
32964595|NCT05718024|Experimental|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
32964596|NCT05718024|Active Comparator|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
32964597|NCT05717946|Experimental|"Group I PRO-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
32964598|NCT05717946|Placebo Comparator|"Group II PLC-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a placebo.
33410011|NCT02839707|Active Comparator|Arm III (PLD, bevacizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also undergo CT on study.
33410012|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
33410013|NCT04140708|Experimental|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
33410014|NCT03686280|Experimental|Robot in combination with traditional reeducation|
33410015|NCT03686280|Active Comparator|Standard rehabilitation|
33410016|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
33410017|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
33410018|NCT04059354|Experimental|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
33410019|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
33410020|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
33410021|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
33410022|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
33410023|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
33410024|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
33410025|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
33410026|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
32964599|NCT05717868|Experimental|Kinesio-taping group|Kinesio-tape will be applied from the dorsal region (T1-T2) to the upper cervical region (C1-C2), two times weekly in a period of four weeks.
33410027|NCT03785964|Experimental|Double-Blind Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
33410028|NCT03785964|Placebo Comparator|Double-Blind Phase - Placebo|Placebo 150 mg by mouth, twice daily
33410029|NCT03785964|Experimental|Open-Label Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
33410030|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
33410031|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
33410032|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
33410033|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
33410034|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
33410035|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
33410036|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
32964600|NCT05717868|Experimental|Self-mobilization group|Self-SNAG technique will be applied by the participants with the help of a towel, and performed for a four week period.
33033505|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
33033506|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
33033507|NCT01963650||No treatment|
32964601|NCT05717790|Experimental|Experimental: Nimotuzumab arm|Patients will receive induction chemotherapy with nimotuzumab (200mg/w,weekly plus gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT. After 4-6 weeks of the completion of IMRT, adjuvant nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.
32964602|NCT05717790|Active Comparator|Control|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT.
32964603|NCT05717712|Experimental|Experimental Group|Single intratumoral injection of Ad-TD-nsIL12. Total dose will be 3x10^9vp, 1x10^10vp or 3x10^10 vp suspended in 1 ml according to cohort design.
32964604|NCT05717634||TAM|Patients with previous breast cancer with hormonal receptor expression that are treated with tamoxifen.
33410037|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.~Data available at: http://nhance.se/"
32964605|NCT05717634||Ais|Patients with previous breast cancer with hormonal receptor expression that are treated with Ais.
32964606|NCT05717634||No Therapy|Patients with previous breast cancer that are not treated with none hormonal therapies.
32964607|NCT05717556|Active Comparator|single attempt catheterization|successful catheterization with a single attempt number
32964608|NCT05717556|Active Comparator|multiple attempts catheterization|successful catheterization after multiple attempts
32964609|NCT05717478|Experimental|Experimental|Socket preservation after extraction with Proteo-Graft (Noricum S.L.) with a particle size of 0.25-1.00 mm, without using a barrier membrane.
32964610|NCT05717478|Active Comparator|Control|Conventional treatment (socket preservation therapy). Post-extraction socket preservation with Bio-Oss® (Geistlich Pharma AG, Switzerland) with a particle size of 0.25-1.00 mm, hereinafter BO, and protection with a barrier membrane, Bio-Gide® ( Geistlich Pharma AG, Switzerland).
32964611|NCT05716386|Experimental|Intervention|The low sodium diet will be provided low salt diet 1.5 gm/day in three main meals for three months.The food will be provided by the nutritionists and delivered directly to their home
32964612|NCT05716386|Placebo Comparator|Control|The control group will continue with their usual diet and record the food recall
32964613|NCT05711160||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~All patients have been undergoing CBCT scans for both jaws. Then, intraoral scanned of the dental arches of each patient have been taken using an intraoral scanner. Then measurements were made on digital images (CBCT & IOS) and on plaster models."
32964614|NCT05707728||totally resection of glioma using intraoperative ultrasound|totally resection of glioma using intraoperative ultrasound
33321896|NCT03946722|Other|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with one week of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
33410038|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
32964617|NCT05695716|Experimental|CSI pVAD System|clinical use of the CSI pVAD System during high risk percutaneous coronary interventions (HR-PCI)
33410039|NCT03921996|Experimental|arm A: ePLND|Radical prostatectomy with extended pelvic lymph node dissection
33410040|NCT03921996|Active Comparator|arm B: no PLND|Radical prostatectomy only
32964620|NCT05679258|Experimental|HLX15 group|Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.
33410041|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
33410042|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
33410043|NCT03779334|Experimental|Open-label Arm|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range.
32964621|NCT05679258|Active Comparator|US-sourced DARZALEX® group|Daratumumab injection
32964622|NCT05679258|Active Comparator|CN-sourced DARZALEX® group|Daratumumab injection
32964623|NCT05634876|Experimental|Treatment First - MSA|"Includes participants with MSA only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
32964624|NCT05634876|Experimental|Delayed Start - MSA|"Includes participants with MSA only~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
32964625|NCT05634876|Experimental|Treatment First - PD|"Includes participants with PD only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
32964626|NCT05634876|Experimental|Delayed Start - PD|"Includes participants with PD only.~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
33321897|NCT03946722|Experimental|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional five weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Leuprorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Leuprorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
33321898|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
32964629|NCT05632926|Experimental|CBL-514 40mg|
32964630|NCT05632926|Experimental|CBL-514 60mg|
32964631|NCT05632926|Experimental|CBL-514 80mg|
32964632|NCT05616858|Experimental|Intervention group|Group with exercise program
32964633|NCT05616858|No Intervention|Control group|Group without exercise program
32964634|NCT05609916|Active Comparator|Continued SRI|After post-phase I assessment, participants who are eligible will be randomized to 1) Continued SRI. For these participants, the medication (SRI) will be provided at a consistent dosage.
32964635|NCT05609916|Placebo Comparator|Discontinuation titration to placebo|After post-phase I assessment, participants who are eligible will be randomized to 2) Discontinuation titration to placebo. For these participants, the placebo substitution in an increasing proportion of capsules will be implemented until all drug is withdrawn.
32964636|NCT05609916|Other|Open label CBT|During Phase I, all participants will receive open label cognitive-behavioral therapy. Only those who achieve significant benefit will be able to most on to the post-phase I assessment, and then to the random assignment to Continued SRI or Discontinuation titration to placebo arms.
32964637|NCT05589792|Placebo Comparator|Placebo|Placebo capsule before bedtime for 3 nights before the studies (inclusive)
32964638|NCT05589792|Active Comparator|Acetazolamide|Acetazolamide 250 mg before bedtime 3 nights before the study, Acetazolamide 500 mg before bedtime for 2 nights before the study (inclusive)
32964639|NCT05587530|Experimental|Treatment engagement and retention intervention for suicidal clients|Participants will receive the manualized treatment engagement and retention protocol for suicidal outpatient clients (single-arm intervention pilot). The manualized treatment engagement and retention protocol will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1).
33033508|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
33033509|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
33321899|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
33321900|NCT03947658|Experimental|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
33321901|NCT03947658|Experimental|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
33321902|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
33321903|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
33321904|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
33321905|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if virally suppressed at 6 months."
33410044|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
32964640|NCT05562648|Experimental|Manual therapy techniques|Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use. These adhesions and unbalanced tissue tensions in the tissues can cause muscle weakness, numbness, pain, tingling and burning sensation. The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
32964641|NCT05562648|Active Comparator|Electrophysical agents|Evidence levels for approaches commonly used in the clinic for the treatment of chronic low back pain were generally very low to moderate. TENS (Transcutaneous Electrical Nerve Stimulation) is the most preferred application in the treatment of chronic pain in patients who receive conventional treatment in the clinic. TENS is a physiotherapy modality used to inhibit pain by stimulating the sensory nerves by applying a low frequency electrical current.
32964642|NCT05543694|Experimental|Dural Puncture Epidural Technique|"Laboring women receiving the Dural Puncture Epidural (DPE) Technique, after a lidocaine test dose, with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
32964643|NCT05543694|Active Comparator|Epidural Technique|"Laboring women receiving the Conventional Epidural Technique (EPL), after receiving a lidocaine test dose with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
32964644|NCT05542602|Experimental|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff to children with hfASD as part of their existing after-school program.
32964645|NCT05542602|No Intervention|No-treatment control|Children in the no-treatment control condition will receive no after-school social programming during the active social intervention study phase.
32964646|NCT05537142|Experimental|Group 1|Participants with Normal hepatic Function
32964647|NCT05537142|Experimental|Group 2|Participants with mild hepatic impairment: Child-Pugh A (Score 5-6)
32964648|NCT05537142|Experimental|Group 3|Participants with moderate hepatic impairment: Child-Pugh B (Score 7-9)
32964649|NCT05537142|Experimental|Group 4|Participants with severe hepatic impairment: Child-Pugh C (Score 10-15)
33410045|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
33410046|NCT03682146|Experimental|R-LRPE|robot-assisted laparoscopic prostatectomy
32964652|NCT05519748|Experimental|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week. The program is designed to be a brief, trauma-informed, dissociation-focused education package that aims to enable users to better understand and cope with their post-traumatic and dissociative reactions and related life challenges. There are specific psychoeducation elements in each session, such as: (1) safety issues planning, (2) understanding the impacts of trauma and stress, (3) understanding the concept of dissociation and integration of the personality, (4) identifying and coping with the post-traumatic and dissociative symptoms, (5) identifying trauma-related cognitive distortions.
32964653|NCT05519748|Other|Waitlist control|The waitlist control group will receive an online psychoeducational program for 8 weeks a week after the completion of the two-month follow-up in the intervention group. The psychoeducation package is identical to the program in the intervention group.
33033510|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
33410047|NCT03682146|Experimental|LRPE|conventional radical laparoscopic prostatectomy
33410048|NCT03681990|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
33410049|NCT04690413|Experimental|Persons tested with investigational device|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
33410050|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
33410051|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
33410052|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
33410053|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will not receive T-CPR."
33410054|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
33410055|NCT03580369|Experimental|Ligelizumab 120 mg|Ligelizumab 120 mg arm: 1 injection of 1.0 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
33410056|NCT03580369|Experimental|Ligelizumab 72 mg|Ligelizumab 72 mg arm: 1 injection of 0.6 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
33410057|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg arm: 2 injections of 1.2 mL omalizumab q4w
32964654|NCT05495568|Experimental|Switching CT-P17|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the CT-P17 Switching group will receive CT-P17 (40mg) at Week 13, Week 15, Week 21, Week 23 and Week 25. The Switching group will receive Humira at Week 17 and Week 19.~From Week 27, patients will receiAve CT-P17 (40 mg) EOW only as open-label up to Week 49."
32964655|NCT05495568|Active Comparator|Humira maintenance|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the Humira maintenance group will receive Humira (40mg) EOW up to Week 25.~From Week 27, patients will receive CT-P17 (40 mg) EOW only as open-label up to Week 49."
32964656|NCT05493774|Experimental|Experimental group|Virtual reality
32964657|NCT05493774|Active Comparator|Control group|High Fidelity Simulation Training
32964658|NCT05488548|Experimental|Arm 1|Patients will be assigned escalated dose according to BOIN design. The starting dose is 5 mg orally once a day for 7 consecutive days followed by 14 days of rest.
32964659|NCT05482386|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
32964660|NCT05482386|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
32964661|NCT05481762||Asymptomatic adult patients|
32964662|NCT05476536|Experimental|experimental arm|self-management skills and healthy technology APP
32964663|NCT05476536|No Intervention|control group|Health education leaflet
32964664|NCT05458050|Other|PU Sensor examination|Device:PU Sensor will assess the microcirculation in sacrum with and without pressure (subject will lay on side and after that on back) the total measurement time is 5-10 minutes
32964665|NCT05429424|Experimental|Verum acupuncture group|The study uses manual acupuncture as verum intervention.
32964666|NCT05429424|Sham Comparator|Sham control group I|The study used specific made needle with a blunt tip, Streitberger device, as sham intervention.
32964667|NCT05429424|Sham Comparator|Sham control group II|Manual acupuncture at the points unrelated to the dysphagia is another sham intervention in this study.
32964668|NCT05413824||COVID-19 survivors|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived.
32964669|NCT05413824||COVID-19 Deceased|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died.
32964670|NCT05384652||subjects with NASH|
32964671|NCT05384652||subjects with simple steatosis|
32964672|NCT05384652||healthy subjects|
32964673|NCT05367102|Experimental|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
32964674|NCT05367102|Experimental|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
32964675|NCT05365308|Experimental|Intervention: Quality Improvement tools|Quality improvement tools including: computer-assisted identification of iron deficiency anemia patients with an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education.
32964676|NCT05365308|No Intervention|Control: usual care|Physicians will be notified at the start of the study that 120 days after the study start they will receive access to the quality improvement tools available to the intervention group.
32964677|NCT05359068|Experimental|Stage 1 Arm A|Patients with essential hypertension, received SPH 3127 tablet 50 mg once daily for 12 weeks.
32964678|NCT05359068|Experimental|Stage 1 Arm B|Patients with essential hypertension, received SPH 3127 tablet 100 mg once daily for 12 weeks.
32964679|NCT05359068|Experimental|Stage 1 Arm C|Patients with essential hypertension, received SPH 3127 tablet 200 mg once daily for 12 weeks.
32964680|NCT05359068|Experimental|Stage 1 Arm D|Patients with essential hypertension, received Valsartan 80 mg once daily for 12 weeks.
32964681|NCT05359068|Experimental|Stage 2 Arm A|Patients with essential hypertension, received SPH 3127 tablet 100 mg once daily for 12 weeks.
32964682|NCT05359068|Experimental|Stage 2 Arm B|Patients with essential hypertension, received Valsartan 80 mg once daily for 12 weeks.
32964683|NCT05358834|Placebo Comparator|Daytime melatonin 0.0 mg|
32964684|NCT05358834|Experimental|Daytime melatonin 0.5 mg|
32964685|NCT05358834|Experimental|Daytime melatonin 3.0 mg|
32964686|NCT05358834|Placebo Comparator|Nighttime melatonin 0.0 mg|
32964687|NCT05358834|Experimental|Nighttime melatonin 0.5 mg|
32964688|NCT05336682|Experimental|LSTR with radicular instrumentation.|
32964689|NCT05336682|Experimental|LSTR with no radicular instrumentation.|
32964690|NCT05336682|Active Comparator|Conventional pulpectomy.|
32964691|NCT05333016|Experimental|Multimodal Exercise Intervention|12-week, twice weekly partner-based multimodal exercise program
32964692|NCT05317806|Experimental|Metformin Treatment Group|Subjects with PAI-1 deficiency with or without cardiac fibrosis, receiving daily treatment with metformin for a daily range of 500-2000mg
32964693|NCT05317806|No Intervention|Observation Group|"Subjects with PAI-1 deficiency with or without cardiac fibrosis, not receiving treatment with metformin~Subjects are allowed to switch between the two groups"
32964694|NCT05295108|Experimental|Caring Connections intervention|The Caring Connections intervention will consist of non-demanding, messages of care and concern delivered to individuals with SCI/D who had moderate to high social isolation and/or loneliness scores on the baseline survey. The caring messages will be in the form of structured, yet personalized mailed letters from one consistent peer with SCI/D, providing long-term and steady contact. Intervention participants will receive a letter every month over a 6-month period. Following a standardized set of principles, letters will contain cheerful expressions of care and micro-moments of positivity. The PI/Co-Is will provide a brief training and work with volunteer peers with SCI/D to write the letters.
32964695|NCT05295108|Active Comparator|Attention control|We will mail informational materials to individuals with SCI/D in our control group at the same timepoints over 6 months as our intervention letter mailings. The informational materials will discuss life domains that are important to a good quality of life. Topics include community living, physical/healthy living, safety and security, social/spirituality, advocacy/engagement, and employment/volunteering. We will draw information for each topic from the Knowledge Translation Center SCI Factsheets (MSKTC 2021) and the LifeCourse Nexus library (2021).
32964696|NCT05273346|Experimental|Comprehensive Conservative TCM Treatment Group|"Traditional Chinese medicinal ointment;~Acupotomy;~Cupping therapy with bamboo cup;~Oral Chinese medicine granules."
32964697|NCT05273346|Active Comparator|Modern Medicine Conservative Treatment Program Group|"Epidural Steroid Injections (ESIs);~Interferential current therapy;~Thermal therapy;~Oral painkillers."
32964698|NCT05248776|Experimental|CPL207280 60 mg|16 participants are to receive IMP at dose 60 mg.IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
32964699|NCT05248776|Experimental|CPL207280 120 mg|16 participants are to receive IMP at dose 120 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
32964700|NCT05248776|Experimental|CPL207280 240 mg|16 participants are to receive IMP at dose 240 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
32964701|NCT05248776|Experimental|CPL207280 480 mg|16 participants are to receive IMP at dose 480 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
32964702|NCT05248776|Placebo Comparator|Placebo|16 participants are to receive masking placebo tablets once daily for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
32964703|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Standard Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
32964704|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
32964705|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®) Standard Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
32964706|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
32964707|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
32964708|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
32964709|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
32964710|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
33321906|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~SoC:~HIV counseling and testing (HTC)~STI screening and treatment~TB screening and referral~Health education through peer educators and peer supported follow-up related to linkages to care~Referrals to DOH primary healthcare clinics or THC drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
33410058|NCT03580369|Placebo Comparator|Placebo|Placebo-ligelizumab arm: 2 injections of 1.0mL of ligelizumab placebo from Week 0 through Week 20; 1 injection of 1.0mL of ligelizumab 120 mg + 1 injection of 1.0 mL ligelizumab placebo from Week 24 through Week 48
32964711|NCT05226234||Experimental group|
32964712|NCT05225220|Experimental|Transcutaneous Vagus Nerve Stimulation (t-VNS)|Participants will receive 60 minutes of t-VNS stimulation every day for 10 consecutive days while wearing a fitness tracker.
32964713|NCT05218356|Experimental|Codivir treatment|20 mg administrated by subcutaneous (SC) injection, twice a day, for 7 days
32964714|NCT05218356|Placebo Comparator|Placebo treatment|Placebo administrated in subcutaneous (SC) injection, twice a day, for 7 days
32964715|NCT05211960|Experimental|Treatment|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness. Participants will receive a premium account for 1 year; the current study will evaluate outcomes over 3 months. The intervention will be delivered concurrently with treatment as usual which includes standard psychosocial care as participants are referred to their respective programs.
32964716|NCT05194254|Experimental|ASD|people with Autism Spectrum Disorders
32964717|NCT05194254|Active Comparator|TD|Typical Development) group of people
32964718|NCT05159934|Active Comparator|Nicotine|Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
32964719|NCT05159934|Placebo Comparator|saline|Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
32964720|NCT05146986||Non-surgical group|Patients will receive analgesia and symptomatic management treatment
32964721|NCT05146986||Surgical group|Patients will receive surgical treatment using RibFix Blu Thoracic Fixation System
32964722|NCT05132244|Experimental|Intensive Glucose Intervention|Participants will receive standard anti-hyperglycemic treatment as guided by an endocrinologist using a combination of data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Treatment will aim to maintain glucose levels between 4 and 10 mmol/L. Participants will have real-time access to their glucose data via the CGM.
32964723|NCT05132244|Other|Standard Care|Participants will receive standard anti-hyperglycemic treatment only if blood glucose level is above 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a CGM but will not be able to view their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
32964724|NCT05131776|Experimental|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
32964725|NCT05131074|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions.
32964726|NCT05131074|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions.
32964727|NCT05131074|No Intervention|Control Group|Patients will not receive the Collabree application.
32964728|NCT05129280|Experimental|Part I: Single Participant Cohort (SPC) Dose Escalation|In Part I, RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level.
32964729|NCT05129280|Experimental|Part II: Multiple Participant Cohort (MPC) Dose Escalation|In Part II, RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored.
32964730|NCT05129280|Experimental|Part III: Recommended Phase 2 Dose (RP2D) Expansion|Based on emerging data from Part II, an RP2D and dosing regimen will be further investigated in Part III.
32964731|NCT05118906|Experimental|BP1.4979|15 mg BID active treatment
32964732|NCT05118906|Placebo Comparator|Placebo|matching placebo
32964733|NCT05112198|Experimental|Noona web-based symptom tracking tool|In addition to usual care for their disease, patients interact with Noona system and system questioners to record their symptoms over a period of 6 months.
32964734|NCT05112198|No Intervention|Usual Care|Participants will receive the standard of care for their disease
32964735|NCT05105802|Experimental|Mindfulness Intervention|MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal. Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
32964736|NCT05105802|Active Comparator|Cognitive Sham Application + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. We consider this arm as active as participants will be assigned to a cognitive sham app (cognitive math game) delivered via the same app (same main interface as the mindfulness intervention). However, they will not take part in the MBI program for the first 4 weeks. On a daily basis, participants will be asked questions about their stress and emotions and about their symptoms.
32964737|NCT05105256|Active Comparator|Corticosteroids|Lumbar facet joint injection with corticosteroids
32964738|NCT05105256|Experimental|PRP|Lumbar facet joint injection with PRP
32964739|NCT05103072||testing all the plots|"the investigator chose the best plot of the leads for stimulation by a procedure long and exhausting for the patient and the examinator ( plot by plot )"
32964740|NCT05103072||Guide X Software|the investigator can chose the plot using a software (Guide Xt), which can delete the exhausting test
32964741|NCT05085210|Experimental|Visual Training with Noninvasive Brain Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of tRNS with visual training on the computer
32964742|NCT05085210|Experimental|Visual Training with Sham Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of sham stimulation with visual training on the computer
32964743|NCT05085210|Experimental|Noninvasive Brain Stimulation without visual training|10 daily (Monday-Friday) 20-30 minute sessions of tRNS alone
32964744|NCT05085210|Sham Comparator|Sham Stimulation without visual training|Placebo control. Simulation of tRNS without receiving any actual stimulation
32964745|NCT05083260|Experimental|NE3107|orally administered NE3107 20 mg twice daily (BID)
32964746|NCT05083260|Placebo Comparator|placebo|orally administered placebo, twice daily
32964747|NCT05081622|Experimental|ICC-T|5 days with 9 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
32964748|NCT05081622|No Intervention|Monitoring condition|No intervention
32964749|NCT05062668||iStent|POAG patient operated at the CHU of Amiens or the CH of Saint-Quentin of a combined cataract and iStent inject or inject W surgery from January 2018 to September 2020.
32964750|NCT05062668||cataract only|POAG patients operated only on cataract from January 2018 to September 2020.
32964751|NCT05058690|Experimental|Individuals who had a CCTA as part of their clinical care|Approximately 90 individuals who had a CCTA as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable;
32964752|NCT05058690|Experimental|Individuals who had a chest CT as part of their clinical care|Approximately 90 individuals who had a chest CT as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable.
32964753|NCT05047692|Experimental|Group 1: Low dose|The subject will receive a single dose of AdCLD-CoV19-1(5.0x10^10VP) as an intramuscular injection.
32964754|NCT05047692|Experimental|Group 2: High dose|The subject will receive a single dose of AdCLD-CoV19-1(1.0x10^11VP) as an intramuscular injection.
32964755|NCT05046288|Experimental|Group 1|Participants will participate to the 3-month cycle of virtual guided tour of the MMFA and will complete assessments at M0 and at M3
32964756|NCT05046288|No Intervention|Group 2|Participants will not participate to the 3-month cycle of virtual guided tour of the MMFA but will complete assessments at M0 and at M3
32964757|NCT05020626||Controls|
32964758|NCT05020626||Mild cognitive impairment|
32964759|NCT05020626||AD dementia|
32964760|NCT05016258||KONTACT MB|Adult patients needed one or multiple implant-supported fixed restoration(s)
33321907|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if not virally suppressed at 6 months."
33410059|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
32964761|NCT05002218|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
32964762|NCT05002218|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
32964763|NCT04992546|Experimental|PRN473 (SAR444727)|Multiple topical doses of PRN473 (SAR444727) for 42 days
32964764|NCT04992546|Placebo Comparator|Placebo|Multiple topical doses of placebo for 14 days, and PRN473 (SAR444727) for 28 days
32964765|NCT04981392|Experimental|Multi-component patient and provider intervention to promote COVID-19 vaccination|
32964766|NCT04981392|No Intervention|Usual care|Patients will receive usual care
32964767|NCT04967196|Experimental|Treatment (ipilimumab, nivolumab)|Patients receive ipilimumab via DoseConnect on day 1 of cycle 1 and via IV over 30 minutes on day 1 of cycles 2-4. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32964768|NCT04963062|Experimental|Participants treated with Holmium laser with the Moses laser|
32964769|NCT04963062|Experimental|Participants treated with Holmium laser with the thulium laser|
32964770|NCT04950894|Active Comparator|Active|HGN therapy activation at Month 1 - compared at Month 7 to Control group, continued stimulation through Month 13
32964771|NCT04950894|Other|Control|HGN therapy NOT activated at Month 1 - compared at Month 7 to Active group, stimulation will start at Month 7 + 1 Day and continue through Month 13
32964772|NCT04922502|Active Comparator|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
32964773|NCT04922502|Active Comparator|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
32964774|NCT04921410|Experimental|Biofeedback Sleeve Effects on Preventive Biomechanics|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive an 'active' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide haptic feedback directly associated with potentially injurious events as determined by previously established cut-off values and artificially-intelligent algorithms.
32964775|NCT04921410|Sham Comparator|Sham Biofeedback|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive a 'sham' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide random feedback at random intervals not directly associated with potentially injurious events.
32964776|NCT04916886|Experimental|50L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
32964777|NCT04916886|Experimental|500L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
32964778|NCT04916886|Experimental|800L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
32964779|NCT04916886|Experimental|800L Scale Lot 1 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964780|NCT04916886|Experimental|800L Scale Lot 2 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964781|NCT04916886|Experimental|800L Scale Lot 3 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964782|NCT04916886|Experimental|800L Scale Lot 1 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964783|NCT04916886|Experimental|800L Scale Lot 2 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964784|NCT04916886|Experimental|800L Scale Lot 3 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
32964785|NCT04907682|Active Comparator|Intravenous ribavirin|"standard treatment: Irrua regimen~100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)~25 mg/kg days 2-7~12.5 mg/kg days 8-10"
32964786|NCT04907682|Experimental|Oral favipiravir|"Oral favipiravir~Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)~Day 2-10 1200mg twice daily (BD)"
32964787|NCT04898400|Experimental|Subjects with Obesity|Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure
32964788|NCT04880304|Experimental|ADHD diagnosis and subconcussive head impacts|"ADHD Group: Individuals clinically diagnosed with ADHD, currently taking his/her prescribed ADHD medication.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
33410060|NCT05390151|Active Comparator|Laser assisted fistula closure|Group to be actively treated with laser assisted fistula surgery
32964789|NCT04880304|Experimental|No history or current diagnosis of ADHD and subconcussive head impacts|"Non-ADHD Group: Individuals with no current or prior diagnosis of ADHD.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
32964790|NCT04854096|Experimental|NS-018|Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles
32964791|NCT04854096|Active Comparator|Best Available Therapy (BAT)|Single agent per Investigator discretion or no therapy
33410061|NCT05390151|Active Comparator|Rectal advancement flap|Group to be actively treated with a rectal advancement flap.
33410062|NCT03689790|Active Comparator|liver function|liver function
33410063|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
33410064|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
33410065|NCT05567757|Experimental|Investigational|Study subjects implanted with a TRUE AVC as an arteriovenous conduit for hemodialysis
32860974|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
32860975|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
32860976|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
32860977|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
32860978|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
32860979|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
32860980|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
32860981|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
32860982|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
32860983|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
32860984|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
32860985|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
32860986|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
32860987|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
32860988|NCT05609045|Experimental|test product group|
32860989|NCT05609045|Placebo Comparator|placebo group|
32860990|NCT05607953|Experimental|SD-101|Two doses of SD-101 given over two cycles via pancreatic retrograde venous infusion (PRVI) using the PEDD method of administration.
32860991|NCT05602181|Experimental|ALL Phonics Instruction|Lessons for the treatment group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with four subskills per session (e.g., letter-sounds, sound blending, typing, and sight words). The words and subskills with rotate based on the data collected and the machine learning within the technology. The child will complete 100 lessons. The systematic instruction with subksills (e.g., sound blending, decoding) includes 10 trials per word and an instructional sequence that introduces the skill, two models, six trials of guided practice, and two trials of independent practice with corrective feedback.
32860992|NCT05602181|Active Comparator|ALL Sight Word|Lessons for the comparison group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with sight words. The child will also complete 100 lessons.No phonics instruction will be provided to this group through the ALL app.
32860993|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
32860994|NCT03052283||Patients with CF|>2000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA, Australia, Canada, Brazil, Argentina...
32860995|NCT03052283||Age-matched healthy controls|>100 in Germany >100 in each of the other participating countries
32860996|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
32860997|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
32860998|NCT05601869|Experimental|Intervention|Participants in this arm receive a new prosthesis system designed to improve footwear options.
32860999|NCT05601713|Active Comparator|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
32861000|NCT05601713|Experimental|Lower limb immersion|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
32861001|NCT05601713|Experimental|Lower limb immersion + neck cooling|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
32861002|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
32861003|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
32861004|NCT04248257|Experimental|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
32964792|NCT04842084||healthy volunteers|Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,
32964793|NCT04840992|Experimental|A1a Phase I low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
32964794|NCT04840992|Placebo Comparator|A1b Phase I placebo low 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
32964795|NCT04840992|Experimental|A2a Phase I medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
32964796|NCT04840992|Placebo Comparator|A2b Phase I placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
32964797|NCT04840992|Experimental|A3a Phase I high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
32964798|NCT04840992|Placebo Comparator|A3b Phase I placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
32964799|NCT04840992|Experimental|A4a Phase I combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
32964800|NCT04840992|Placebo Comparator|A4b Phase I placebo combine 2 doses|6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
32964801|NCT04840992|Experimental|A5a Phase I single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
32964802|NCT04840992|Placebo Comparator|A5b Phase I placebo single dose|6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
32964803|NCT04840992|Experimental|B1a Phase II low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
32964804|NCT04840992|Placebo Comparator|B1b Phase II placebo low 2 doses (18-59)|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
32964805|NCT04840992|Experimental|B2a Phase II medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
32964806|NCT04840992|Placebo Comparator|B2b Phase II placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
33410066|NCT04648293||Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. Improvement in hemodynamics is exhibited by an increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
33410067|NCT04648293||No Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. No Improvement in hemodynamics is exhibited by no increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
32964807|NCT04840992|Experimental|B3a Phase II high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
32964808|NCT04840992|Placebo Comparator|B3b Phase II placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
32964809|NCT04840992|Experimental|B4a Phase II combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
32964810|NCT04840992|Placebo Comparator|B4b Phase II placebo combine 2 doses|Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
32964811|NCT04840992|Experimental|B5a Phase II intramuscular single dose|Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
32964812|NCT04840992|Placebo Comparator|B5b Phase II placebo intramuscular single dose|placebo containing 0 vp, 1 dose Intramuscular Injection
32964813|NCT04840992|Experimental|B6a Phase II Aerogen Solo single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
32964814|NCT04840992|Placebo Comparator|B6b Phase II placebo Aerogen Solo single dose|placebo containing 0 vp, 1 dose Aerogen Solo
32964815|NCT04840056||Intestinal Metaplasia|patient with history of histologically proven gastric intestinal metaplasia
32964816|NCT04840056||Atrophic gastritis|patient with history of histologically proven atrophic gastritis
32964817|NCT04832802|Experimental|ACCESS-Vets Intervention Group|This group will receive ACCESS-Vets, a customized employment intervention adapted for use in VA healthcare.
32964818|NCT04832802|Active Comparator|IPS (Usual Care) Group|This group will receive IPS (Individual Placement and Support), the usual evidence-based supported employment program in VA.
32964819|NCT04793022|Experimental|TIVA-Propofol|Intravenous anesthesia with Propofol
32964820|NCT04793022|Active Comparator|Inhaled Anesthesia|General Inhaled Anesthesia
32964821|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm A - TAK-981 Twice Weekly (BIW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg subcutaneous (SC) injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks in Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 BIW intravenous (IV) infusion on Days 1, 4, 8, 11 and 15 in Cycle 1 and 2 (each Cycle is of 28 days) followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
32964822|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm B - TAK-981 Weekly (QW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg SC injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks from Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 QW IV infusion on Days 1, 8, 15, and 22 in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks. up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
32964823|NCT04776018|Experimental|Phase 1b, Part 2 - Lead-in Cohort: TAK-981 + Daratumumab and Hyaluronidase-fihj|"Daratumumab and hyaluronidase-fihj: 1800 mg SC injection QW once weekly in Cycles 1 and 2 , (each cycle is of 28 days) followed by every 2 weeks in Cycle 3 through 6 , followed by every 4 weeks up to Cycle 24 until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: As per dose and schedule of TAK-981 defined in Phase 1b Part 1."
33410068|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
32964824|NCT04776018|Experimental|Phase 2 - Dose Expansion: TAK-981 + Daratumumab and Hyaluronidase-fihj or Mezagitamab|TAK-981 at RP2D as determined in Phase 1b. Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycle 3 through 6, followed by every 4 weeks up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
32964825|NCT04750902|Active Comparator|0.24% Sodium Fluoride Dentifrice|Toothpaste
32964826|NCT04750902|Experimental|1.5% Arginine Dentifrice|Toothpaste
32964827|NCT04750902|Experimental|4.0% Arginine Dentifrice|Toothpaste
32964828|NCT04750902|Experimental|8.0% Arginine Dentifrice|Toothpaste
32964829|NCT04737018|Experimental|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
32964830|NCT04737018|Sham Comparator|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
32964831|NCT04711824|Experimental|Study Treatment Arm|Cycle 1 of study treatment will consist of Olaparib twice daily concurrently with stereotactic radiosurgery (SRS). Olaparib will start one week prior to SRS and continue during and following SRS (1-5 fractions) for up to 28 days total. Once the subject has recovered from SRS, Cycle 2 will be initiated with physician's choice systemic therapy and durvalumab. Cycle 2+ will equal 21 days. During Cycles 2 and 3, physician's choice systemic monotherapy will be given along with durvalumab. Each cycle will last 21 days. Imaging to evaluate intracranial and extracranial disease will be performed after Cycle 3, and subjects with response will continue with the systemic therapy and durvalumab until progression (intracranial or extracranial), unacceptable toxicity or death.
32964832|NCT04682496|Experimental|intratendon vascularization|Intratendon vascularization will be quantified using a proprietary methodology using ImageJ 1.47v image analysis software, determining the different variables related to the Doppler signal within an intratendon region of interest.
32964833|NCT04633356|Experimental|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
32964834|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
32964835|NCT04592484|Experimental|CDK-002|
32964836|NCT04567524|Active Comparator|Arm 1|"LYN-005: capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.~AND~IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
32964837|NCT04567524|Placebo Comparator|Arm 2|"LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.~AND~IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
32964838|NCT04549038|Experimental|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
32964839|NCT04549038|No Intervention|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
32964840|NCT04547790|Experimental|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
32964841|NCT04547790|Experimental|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
32964842|NCT04481412|Experimental|Study group|(33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
32964843|NCT04481412|Active Comparator|Control group|(33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
32964844|NCT04475718|Other|Fourth Trimester Mobile Tool|Fourth Trimester Mobile Tool
32964845|NCT04473066||Adenotonsillectomy (AT)|Children diagnosed with moderate-to-severe OSA (OAHI ≥3/h) and tonsillar hypertrophy (tonsil grade ≥2) at the age of 5-12 years old and underwent AT since 2012.
32964846|NCT04473066||Refused AT|Children diagnosed with moderate-to-severe OSA and tonsillar hypertrophy but refused AT in the same period.
32964847|NCT04473066||Normal control|Children reported to have no habitual snoring (less than 3 nights per week) and confirmed to have no OSA (OAHI <1/h) by overnight sleep study in the same period.
32964848|NCT04465188|Experimental|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
32964849|NCT04465188|No Intervention|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
32964850|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + MicrFlow Imaging will be immediately recorded afterwards
32964851|NCT04423068|Experimental|Overall Study|
32964852|NCT04412616|Experimental|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964853|NCT04412616|Experimental|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964854|NCT04412616|Experimental|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964855|NCT04412616|Experimental|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964856|NCT04412616|Experimental|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964857|NCT04412616|Experimental|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964858|NCT04412616|Experimental|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
32964859|NCT04317300|Experimental|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
32964860|NCT04300218|Experimental|iCBT-I + CAU|Participants of this arm will get access to the course of the online cognitive-behavioral therapy for insomnia (iCBT-I) for 2 months along with the treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment
32964861|NCT04300218|Active Comparator|CAU|Participants of this arm will get a treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment. Then provided completion of all the assessments and satisfying eligibility criteria participants of this arm will get tha access to the 2-month iCBT-I course followed by the post-treatment assessment
32964862|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
32964863|NCT04205370|Active Comparator|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
32964864|NCT04205370|Experimental|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
32964865|NCT04179552|Experimental|PAAG-OA|All subjects receive treatment with PAAG-OA
32964866|NCT04176510|Experimental|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
32964867|NCT04176510|No Intervention|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
32964868|NCT04154514|Experimental|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
32964869|NCT04145622|Experimental|Dose escalation|All participants enrolled in the dose escalation part
32964870|NCT04145622|Experimental|Dose expansion|All participants enrolled in the dose expansion part
32964871|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
32964872|NCT04138134||Group 1|Patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins
32964873|NCT04138134||Group 2|Patients with atherosclerotic obstructive disease of lower limbs
32964874|NCT04106154|Experimental|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
32964875|NCT04106154|No Intervention|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
33410069|NCT05370027|Experimental|1st Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be taken and the application will be made from the right ear. Then, the application will be performed on both ears with a 48-hour break.
32964878|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
32964879|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
32861005|NCT04248257|Active Comparator|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
33033511|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
32861006|NCT05601557||hyperbilirubinemia|Gilbert syndrome Crigler-Najjar syndrome Dubin-Johnson syndrome Rotor syndrome PFIC BIRC
32861007|NCT05601557||Wilson disease|Leipzig score system was used for diagnosis, and the total score ≥4 points could be confirmed. The total score of 3 is suspected diagnosis, which requires further examination. A total score of 2 or less is not considered for diagnosis.
32861008|NCT05601557||Hemochromatosis|① clinical manifestations of extensive skin pigmentation, bronzing; Decline to disappearance of sexual function; Mild hepatosplenomegaly, may appear jaundice; The heart is enlarged; Pain and swelling mainly in metacarpophalangeal joints; Decreased glucose tolerance and increased blood glucose; ② Serum iron was significantly increased, serum transferrin was normal or decreased, transferrin saturation was significantly increased, often more than 62%, serum ferritin was significantly increased, often more than 500ug/L; (3)/HJV/HAMP TFR2 / SLC40A1 HFE gene mutation.
32861009|NCT05601557||Glycogen accumulation disease|According to different types, there may be the following manifestations, which need specific analysis. ① Clinical manifestations of abdominal distension, fasting hypoglycemia and other symptoms; ② Laboratory examination showed metabolic acidosis, hyperlactic acidemia, hyperuricemia and hyperlipidemia; ③ Abdominal CT showed enlarged liver volume; ④ Serum glucosidase activity decreased; (5) the GAA/G6PC/SLC374A/AGL/PYG/PHK gene mutations.
32861010|NCT05601557||Other types of inherited metabolic liver disease|
32861011|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
32861012|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
32861013|NCT05601479|Experimental|Acetyl-L-carnitine group(ALC group)|At the beginning of the first chemotherapy of the oxaliplatin regimen, acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks.
32861014|NCT05601479|No Intervention|Blank Control group|No drugs for the prevention and treatment of peripheral neuropathy will be given.
32861015|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
32861016|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
32861017|NCT05601401|Experimental|Study arm|Patients receive RC48-ADC.
32861018|NCT04275245|Experimental|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
32861019|NCT01346085|Experimental|CNI-free single-group|
32861020|NCT05601245|Experimental|High voltage pulsed current|Twenty patients with chronic wounds will be managed by the high-voltage pulsed current for 45 as the total treatment duration and the polarity will be reversed after 22 minutes, three sessions per week for six weeks.
32861021|NCT05601245|Experimental|Microcurrent therapy|Twenty patients with chronic wounds will be managed by microcurrent therapy for 40 minutes, three sessions per week for six weeks.
32861022|NCT05608031||bariatric surgery|A cross-sectional study was conducted among patients that underwent bariatric surgery (laparoscopic sleeve gastrectomy). Sleep quality was assessed using the Pittsburgh sleep quality index (PSQI) scale preoperatively and at the 6th postoperative month.
32861023|NCT05607875|Experimental|The Grow to Recovery train-the-trainer group|Professionals of the train-the-trainer group will receive an online training and then conduct a recovery group.
32861024|NCT05607875|Other|Control group|Professionals of the control group will not receive training.
32861025|NCT05607797|Experimental|Patients with gout|Patients aged 18-70 with gout diagnosis in their medical record or claiming to have gout according to ACR/EULAR (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria.
32861026|NCT05607797|Experimental|Patients with CKD|"Patients aged 18-70, in dialysis or with CKD clinically diagnosed on the basis of markers of kidney damage or decreased kidney function.~Patients will be recruited in dialysis centers of Wé and Maré and during the monthly nephrology consultations in medical centers."
32861027|NCT05607797|Placebo Comparator|Control group|Persons aged 30-80 without gout or CKD. The recruitment will be done among people visiting the medical centers of Lifou and Maré for administrative or vaccination reasons.
32861028|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
32861029|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
32861030|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
32861031|NCT05607641|Other|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|
32861032|NCT05607641|Active Comparator|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|
32861033|NCT05607641|Experimental|Neospastil, solution for injection then Neospastil, film-coated tablets|
32861034|NCT05607485|Other|Crowd workers|"Crowd workers watched 10 (oiut 45 possible) random videos and assessed with a standard assessment tool.~All participants were blinded to the identity and skill level of the surgeon"
32861035|NCT05607329|Experimental|Secondary cytoreduction followed by chemotherapy|
32861036|NCT05607329|Active Comparator|chemotherapy alone|
32861037|NCT05607017|Experimental|Radiation Therapy and Losartan|Participants will receive radiation therapy 5x weekly over 1-6 weeks. Participants will receive Losartan 1x daily during radiation therapy and for up to 6 months afterward then be followed for 1 year
32964880|NCT03977922|Experimental|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:~Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).~10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.~At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.~Once per month, we will be offering a live cooking class."
33410070|NCT05370027|Experimental|2nd Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the right ear with a break for 48 hours.
32964881|NCT03977922|No Intervention|Control group|The control group will eat their usual diet for the 12-week period.
32964882|NCT03971136|Other|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
32964883|NCT03946332|Experimental|Physical exercise arm|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
32964884|NCT03946332|Active Comparator|controlled arm|patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
32964885|NCT03924102|Experimental|patients with acute decompensated systolic and diastolic heart|
32964886|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
32964887|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
32964888|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
32964889|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
33410071|NCT05370027|Experimental|3rd Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be taken and the application will be made from the left ear. Then, the application will be performed on both ears with a 48-hour break.
33410072|NCT05370027|Experimental|4th Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the left ear with a break for 48 hours.
33410073|NCT05370027|Experimental|5th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the left ear. Then, the application will be performed on the right ear with a break for 48 hours.
33410074|NCT05370027|Experimental|6th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the right ear. Then, the application will be performed on the left ear with a break for 48 hours.
33410075|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
32964890|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
32964891|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
32964892|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP (or 99mTc-HDP) scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
32964893|NCT03698994|Experimental|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32964894|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
32964895|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
32964896|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
32964897|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
32964898|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
32964899|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
32964900|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
32964901|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
32964902|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
33033512|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
33410076|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
33410077|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
33033513|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
33410078|NCT05351151|Experimental|"Regional anesthesia ALR"|The ALR group is made up of patients benefiting from the V2 and V3 ultrasound-guided ALR technique without mucosal infiltration.
33410079|NCT05351151|Active Comparator|Infiltration|"The Infiltration group is made up of patients who benefit from the infiltration technique by local anesthesia of the incision sites by the surgeon without recourse to ultrasound-guided LRA."
33410080|NCT04801849|Active Comparator|Vitamin E, 200 IU|200 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
33410081|NCT04801849|Active Comparator|Vitamin E, 400 IU|400 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
33410082|NCT04801849|Active Comparator|Vitamin E, 800 IU|800 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
33410083|NCT04801849|Placebo Comparator|Placebo|matching placebo taken once daily with breakfast
33410084|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
33410085|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
33410086|NCT01749709|Experimental|Instrumental music listening|Daily music listening
33410087|NCT01749709|Experimental|Vocal music listening|Daily music listening
33410088|NCT01749709|Active Comparator|Audiobook listening (control)|Daily audiobook listening
33410089|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
33410090|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
33410091|NCT04364269|Experimental|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
33410092|NCT04364269|Experimental|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
33410093|NCT04364269|Placebo Comparator|Placebo|Participants will be assigned to receive Placebo, Twice a day.
33410094|NCT05300763|Experimental|TEST LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the TEST Lens for the duration of the study.
33410095|NCT05300763|Experimental|CONTROL LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the CONTROL Lens for the duration of the study.
33410096|NCT04800367|Experimental|Romosozumab followed by denosumab|Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.
33410097|NCT05279859|Experimental|Dose Escalation (Part 1): ERAS-007 plus gilteritinib|ERAS-007 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
33410098|NCT05279859|Experimental|Dose Escalation (Part 2): ERAS-601 plus gilteritinib|ERAS-601 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
33410099|NCT05279859|Experimental|Dose Expansion (Part 3): ERAS-007 plus gilteritinib|ERAS-007 will be administered at the recommended dose (as determined from Part 1) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
33410100|NCT05279859|Experimental|Dose Expansion (Part 4): ERAS-601 plus gilteritinib|ERAS-601 will be administered at the recommended dose (as determined from Part 2) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
33410101|NCT05233995|Experimental|Intervention group|The patients included in the experimental group will be operated on, performing the resection of the intestinal segment affected by the dehiscence, the sectioned intestinal ends will be left without anastomosis, and open abdomen therapy will be established. After surgery, the patient will be cared for in the intensive care unit where intensive resuscitation will be carried out in order to improve the general conditions of the patient. After 48 ± 24 hours, a second surgical procedure will be performed where local conditions will be evaluated and the possibility of performing a delayed anastomosis will be evaluated.
33410102|NCT05233995|Active Comparator|Control group|The patients included in the control group will be operated on with a resection of the affected intestinal segment and a stoma with or without associated mucosal fistula will be performed at the same surgical time. After the procedure, the patient will be cared for in the intensive care unit in order to improve the general conditions of the patient.
33410103|NCT05523609|No Intervention|Control Group|20 patients will receive Letrozole only for 12 weeks.
33410104|NCT05523609|Experimental|VitD/Ca group|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks.
33410105|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
33410106|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
33410107|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
33410108|NCT04603365|Experimental|Treatment (pamiparib, temozolomide)|Patients receive PO BID on days 1-28 and temozolomide PO QD on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
33410109|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
33410110|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
32861038|NCT05606861|Experimental|Intervention group|Mindfulness Based Intervention in pediatric nurses components was applied to this group.
32861039|NCT05606861|No Intervention|Control group|No procedure was conducted the control group.
32861040|NCT05605691|Experimental|Renuvion APR System Treatment|Subject will be treated with the Renuvion APR system in the lower eyelid (periorbital) area.
32861041|NCT05603585|No Intervention|Control Group|Standard care as per current ICU feeding regime.
32861042|NCT05603585|Experimental|Interventional Group|Optimal protein supplementation to achieve 80% protein adequacy through optimised protein supplementation. The protein supplementation will be increased/decreased based on the previous day's intake to achieve 80% adequacy each day by the dietician.
32861043|NCT05603507|Experimental|inspiratory muscle training group|received both inspiratory muscle training and pulmonary rehabilitation
32861044|NCT05603507|Sham Comparator|pulmonary rehabilitation group|received only pulmonary rehabilitation and sham inspiratory muscle training
32861045|NCT05603273|No Intervention|standard wound care|normal wound care according to current clinical practice
32861046|NCT05603273|Experimental|non-weight bearing exercise + standard wound care|normal wound care according to current clinical practice with the addition of a weekly exercise routine
32861047|NCT05603039|Experimental|QL1706(5mg/kg)|QL1706(5mg/kg) Combined with Bevacizumab
32861048|NCT05603039|Experimental|QL1604|QL1604 Combined with Bevacizumab
32861049|NCT05603039|Experimental|QL1706(7.5mg/kg)|QL1706(7.5mg/kg) Combined with Bevacizumab
32861050|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
32861051|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
32861052|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
32861053|NCT04394741|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
32861054|NCT04394741|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
32861055|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.~The control group will only continue conventional physiotherapy treatment."
32861056|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
32861057|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
32861058|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
32861059|NCT05602415|Experimental|Surgery + Dose Reduced Radiotherapy + Anlotinib|"Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved.~Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction).~Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles)."
32861060|NCT05602337||Immunocompetent BCC Subjects|BCC-predominant group
32861061|NCT05602337||Immunocompetent SCC Subjects|SCC-predominant group
32861062|NCT05602337||Immunocompetent MM Subjects|Melanoma group
32861063|NCT05602337||Control|age, sex and Fitzpatrick phototype match
32861064|NCT05602337||Solid Organ Transplantation Recipient - SC|At least 5 skin cancers and at least 5 years post-transplant
32861065|NCT05602337||Solid Organ Transplantation Recipient|No more than 1 skin cancer and at least 5 years post-transplant
32861066|NCT05609669|Experimental|CADENCE program pilot|
32861067|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
32861068|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
32861069|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
32861070|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
32861071|NCT05609357|Experimental|Head-up Cardiopulmonary Resuscitation|
32861072|NCT04200053|Experimental|Reflexology massage|Reflexology massage
32861073|NCT04200053|Experimental|Reflexology massage and passive music|Reflexology massage and passive music
32861074|NCT04200053|No Intervention|Control|Control
32861075|NCT05609201||Cases|36 participants with a multidisciplinary team diagnosis of IPF or non-IPF fibrotic-ILD
32861076|NCT05609201||Healthy Control|5 Age, sex and ethnicity matched controls
32899201|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
32899202|NCT02397720|Experimental|Arm I (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32964903|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
32964904|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
32964905|NCT03437928|Experimental|Directional Deep Brain Stimulation|
32964906|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
32964907|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
32964908|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
32964909|NCT03327324|Experimental|F1U1|Sequence 1 (Facility 1/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 39 Month Sustainability.
32964910|NCT03327324|Experimental|F1U2|Sequence 2 (Facility 1/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 33 Month Sustainability
32964911|NCT03327324|Experimental|F2U2|Sequence 3 (Facility 2/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 27 Month Sustainability
32964912|NCT03327324|Experimental|F2U3|Sequence 4 (Facility 2/Unit 3): Baseline, then 3 Month SLUMBER Intervention, then 21 Month Sustainability
32964913|NCT03327324|Experimental|F2U4|Sequence 5 (Facility 2/Unit 4): Baseline, then 3 Month SLUMBER Intervention, then 15 Month Sustainability
32964914|NCT03327324|Experimental|F3U1|Sequence 6 (Facility 3/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 9 Month Sustainability
32964915|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
32964916|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
32964917|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
32964918|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
32964919|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
32964920|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
32964921|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
32964922|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 Quavonlimab + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with quavonlimab at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
33410111|NCT04543773|Experimental|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
33410112|NCT03681444|Experimental|Regular diet|no dietary restriction
33410113|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
33410114|NCT03681444|Experimental|Low residue diet|easy digestible food
32964923|NCT03179436|Experimental|Escalation: DL 2 Quavonlimab + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
32964924|NCT03179436|Experimental|Escalation: DL 3 Quavonlimab + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
32964925|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
33410115|NCT05489679|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. The participants will participate in this dose escalation arm.
32899203|NCT02397720|Experimental|Arm II (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
32899204|NCT04423848|Experimental|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
32899205|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
32899206|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
32899207|NCT05419908|Experimental|Fezolinetant|Participants received 90 milligrams (mg) fezolinetant capsules orally, twice daily (BID) for a period of 12 weeks
32899208|NCT05419908|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
32899209|NCT04265742|Experimental|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score >-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
32899210|NCT04265742|Experimental|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score >-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
32899211|NCT04265742|Experimental|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
32899212|NCT04265742|Experimental|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
32899213|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
32899214|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
32899215|NCT05419128|Active Comparator|ACHESS-C|In ACHESS-C, both the drinker and the partner will receive a smartphone, but only the drinker will receive the ACHESS-C app. The partner will receive a smartphone with contact information for standard AUD, SUD, and crisis support.
32899216|NCT05419128|Experimental|FamCHESS-C|In the FamCHESS-C arm, drinker and partner will both receive a smartphone with the FamCHESS-C app, which contains ACHESS-C services plus ABCT/ PartnerCHESS services.
32899217|NCT05419128|No Intervention|Control|Both the drinker and family partner will receive a smartphone with pre-programmed contact information for Alcoholics Anonymous (AA), Narcotics Anonymous (NA), Al-Anon, Adult Children of Alcoholics (ACOA), and crisis hot lines.
32899218|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
32899219|NCT05446350|Experimental|Experiment 1|The aim of Experiment 1 is to understand how tACS operates on the neural level
32899220|NCT05446350|Experimental|Experiment 2|The aim of Experiment 2 is to increase efficacy of tACS and, consequently, its potential to play an important role in research and everyday life applications
32899221|NCT05446350|Experimental|Experiment 3|The aim of Experiment 3 is to reveal how tACS can boost speech perception in a multi-speaker scenario.
32899222|NCT05446350|Experimental|Experiment 4|The aim of Experiment 4 is to combine established techniques to create novel opportunities to improve speech perception
32899223|NCT01439581|Experimental|Patients on mapping systems|
32899224|NCT01439581|Active Comparator|Patients not on mapping systems|
32899225|NCT01439815|Placebo Comparator|Placebo Nasal Spray|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
32899226|NCT01439815|Active Comparator|Fluticasone Propionate|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
32899227|NCT01332253|Experimental|Intravenous Ibuprofen|
32899228|NCT01332253|Placebo Comparator|Normal Saline|
32899229|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
32899230|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
32899231|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
32899232|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
32899233|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
32899234|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
32899235|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32899236|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32899237|NCT00265850|Active Comparator|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
32964926|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
32964927|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and at DL2 quavonlimab according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
32964928|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
32964929|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
32964930|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2+PDL2 Pembro Schedule 2: Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both quavonlimab and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
32964931|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
32964932|NCT03179436|Experimental|Coformulation: Pembrolizumab/Quavonlimab Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
32964933|NCT03179436|Experimental|Coformulation Phase in China: Pembrolizumab/Quavonlimab Schedule 2: Arm K|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants in mainland China with advanced solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
32964934|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
32964935|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
32964936|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA~ECG-gated CT"
32964937|NCT03116568||IBD Case|"Pregnant women with IBD~Newborns of pregnant women with IBD~Family member of pregnant women with IBD~Siblings of newborns"
32964938|NCT03116568||Control|"Pregnant women without IBD~Newborns of pregnant women without IBD~Family member of pregnant women without IBD~Siblings of newborns"
32964939|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
32964940|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.~Participants may receive treatment for 1 year (~17 cycles)."
32964941|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
32964942|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
32964943|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
33410116|NCT05475717|Experimental|20 µg group|Patients will receive alprostadil liposome injection at 20 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery).
33410117|NCT05475717|Experimental|40 µg group|Patients will receive alprostadil liposome injection at 40 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
33410118|NCT05475717|Experimental|80 µg group|Patients will receive alprostadil liposome injection at 80 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
33410119|NCT05475717|No Intervention|blank control group|Patients will receive only basic hydration therapy which the experimental groups will receive.
33410120|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
32964944|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
32964945|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
32964946|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
32964947|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
32964948|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
32964949|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
32964950|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
32964951|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
32964952|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
32964953|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
32964954|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
32964955|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
32964956|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
32964957|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
32964958|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
32964959|NCT02000934|Experimental|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
32964960|NCT02000934|Experimental|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
32964961|NCT02000934|Experimental|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
32964962|NCT02000934|Experimental|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
32964963|NCT02000934|Experimental|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
32964964|NCT02000934|Experimental|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
32964965|NCT02000934|Experimental|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
32964966|NCT02000934|Experimental|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
32964967|NCT02000934|Experimental|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
32964968|NCT01955460|Experimental|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
32964969|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
32964970|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
32964971|NCT01869114|Experimental|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32964972|NCT01869114|Experimental|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32964973|NCT01869114|Experimental|MDS or AML with prior Azacitadine therapy|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32964974|NCT01793922|Active Comparator|PD|pneumodilation
33410121|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
33410122|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
33410123|NCT05468931|Experimental|Prostate stimulation device arm|Participants will be asked to use our prostate stimulation device.
33410124|NCT04171375|Experimental|trans-spinal Electrical Stimulation (tsES)|
33410125|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
33410126|NCT05133687|Experimental|Group (0.8-G)|This group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25%
33410127|NCT05133687|Experimental|Group (1.2-G)|This group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25%
33410128|NCT05133687|Active Comparator|Group G|This group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
32964975|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
33410129|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
33410130|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
33410131|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
33410132|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
33410133|NCT04508049|Other|Early identification of fibrosis.|A pilot study to test the ability of qMT to quantify fibrosis in the post-stenotic human kidney, in comparison to innovative biomarkers of renal dysfunction and tissue damage. We will pursue the Specific Aim that qMT in stenotic human kidneys is feasible and reproducible.
33410134|NCT04109274|Experimental|Institution-Based Exercise and Self-Management (EXSM)|Eight session of supervised exercise within the cancer institution plus 8 self-management modules focusing on goal setting and action planning for safe and effective exercise strategies (this is based on our team's successful pilot intervention). Four booster sessions will be provided to this group.
33410135|NCT04109274|Experimental|Institution-Based Self-management only (SM)|Eight SM sessions for safe and effective exercise strategies will be provided to this group (described above). Four booster sessions will be provided to this group.
33410136|NCT04109274|No Intervention|Usual care|Participants in this group will receive care as normally provided by their treating oncologist. This can be heterogeneous between different physicians and centres, but usually includes oncologists encouraging their patients to 'stay active'
33410137|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
33410138|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
33410139|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
33410140|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
32964976|NCT01176006|Active Comparator|Group A|10/10 HLA Matched Related or Unrelated Donor Transplant
32964977|NCT01176006|Active Comparator|Group B|9/10 HLA Matched Related or Unrelated Donor Transplant
32964978|NCT01176006|Other|Group C|Donor (closed)
33410141|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
33410142|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
33410143|NCT05101551|Experimental|Talazoparib with topotecan and gemcitabine|Talazoparib will be administered orally on Days 1 to 5 concurrently with topotecan and a single dose of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.
33417292|NCT03060447|Experimental|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
32964979|NCT01176006|Other|Group D|Family Interview (closed)Participation in research interview
32964980|NCT01176006|No Intervention|Group E|Patient and caregiver psychosocial and QOL assessments during HSCTParticipation in interview and questionnaires
32964981|NCT01143480||ABCA1|SNP or allele of interest
32964982|NCT01143480||APOE|SNP or allele of interest
32964983|NCT01143480||APOL1|SNP or allele of interest
32964984|NCT01143480||CD14|SNP or allele of interest
32964985|NCT01143480||CD44|SNP or allele of interest
32964986|NCT01143480||IRGM|SNP or allele of interest
32964987|NCT01143480||ITIH3|SNP or allele of interest
32964988|NCT01143480||ITIH4|SNP or allele of interest
32964989|NCT01143480||MyD88|SNP or allele of interest
32964990|NCT01143480||TIRAP|SNP or allele of interest
33410144|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
32964991|NCT01143480||TLR4|SNP or allele of interest
32964992|NCT01143480||TLR5|SNP or allele of interest
32964993|NCT01143480||TNFa|SNP or allele of interest
33410145|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
33410146|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
33410147|NCT05451771|Experimental|Phase 1: Venetoclax 200 mg|Cohort 1: Venetoclax 200 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
33410148|NCT05451771|Experimental|Phase 1: Venetoclax 400mg|Cohort 2: Venetoclax 400 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
33410149|NCT05451771|Experimental|Phase 1: Venetoclax 400mg + Dexamethasone 10 mg|Cohort 3: Venetoclax 400 mg tablet, once daily and Dexamethasone 10 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
33410150|NCT05451771|Experimental|Phase 1: Venetoclax 400mg + Dexamethasone 20 mg|Cohort 4: Venetoclax 400 mg tablet, once daily and Dexamethasone 20 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
33410151|NCT05451771|Experimental|Phase 2: Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
33410152|NCT05451771|Active Comparator|Phase 2: Control Arm (Investigator's Choice)|"Participants will receive one of the following as determined by the investigator:~Daratumumab, Pomalidomide, Bendamustine, or Ixazomib (+/- dexamethasone)"
33410153|NCT02414139|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line
33410154|NCT02414139|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mg BID as second or third line
33410155|NCT02414139|Experimental|cMET GCN < 4|Pre-treated patients with cMET GCN < 4 treated with INC280 at 400mg BID as second or third line
33410156|NCT02414139|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line
33410157|NCT02414139|Experimental|cMET dysregulation - treatment-naïve|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID
33410158|NCT02414139|Experimental|cMET dysregulation - second line|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line
33410159|NCT02414139|Experimental|cMET mutations treatment-naïve|Treatment-naïve patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
33410160|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
33410161|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
33410162|NCT01383057|Experimental|Femtosecond Laser|
33410163|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
33410164|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
33410165|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
33410166|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
32964994|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
33410167|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
33410168|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
33410169|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
33410170|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
33410171|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
32964995|NCT05723562|Experimental|Dostarlimab monotherapy|
32964998|NCT05723172|Active Comparator|active tACS|40 mins tACS for 10 consecutive daily sessions
32964999|NCT05723172|Sham Comparator|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
32965000|NCT05723094|Experimental|Retention Laser Group (LG)|Before the orthodontic retention phase, the Ga-Al-As diode laser(Ilase, USA) was applied to the experimental group.
32965001|NCT05723094|Placebo Comparator|Retention Control Group (CG)|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
32965002|NCT05723016||AMH < 0.5 ng/ml|
32965003|NCT05723016||AMH 0.5-0.99 ng/ml|
32965004|NCT05723016||AMH 1.0-1.49 ng/ml|
32965005|NCT05723016||AMH 1.5-1.99 ng/ml|
32965006|NCT05723016||AMH 2.0-4.99 ng/ml|
32965007|NCT05723016||AMH > 5.0 ng/ml|
32965008|NCT05722938|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
32965009|NCT05722938|Placebo Comparator|Placebo|Human albumin 1%
32965010|NCT05722860|Experimental|L-Citrulline|L-Citrulline 10 g/day per os for 1 week
32965011|NCT05722782|Active Comparator|NSAI|Piroxicam: 20 mg per pill; one pill per day for five days
32965012|NCT05722782|Active Comparator|Acetaminophen|Paracetamol: 1000 mg per day for five days
32965013|NCT05722782|Placebo Comparator|Placebo|Placebo: one pill per day for five days
32965014|NCT05722626|Experimental|Platelet-rich plasma|PRP manufactured by T_Biyoteknoloji LTD, Turkey
32965015|NCT05722626|Placebo Comparator|Normal Saline|NaCl 0.9%
32965016|NCT05722548|Experimental|Group A|Patients will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
32965017|NCT05722548|Active Comparator|Group B|Standard Medical Treatment
32965018|NCT05722392||Two-step Radical Prostatectomy|Two-step Radical Prostatectomy
32965019|NCT05722236|Experimental|IBD Strong Peer2Peer intervention|
32965020|NCT05722236|Other|Waitlist -controls|
32965021|NCT05722002|Other|NSAID regimen|Surgical teams will elect for one of the medications within the treatment arm to which the patient is randomized.
32965022|NCT05722002|Other|Opioid regimen|
32965023|NCT05721924|Active Comparator|Pericapsular nerve group (PENG) block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule.
32965024|NCT05721924|Active Comparator|Supra-inguinal fascia iliaca compartment (S-FICB) block|A supra-inguinal fascia iliaca compartment block (S-FICB), a 3 in 1 block involving femoral nerve , lateral femoral cutaneous nerve and obturator nerve.
32965025|NCT05721846|Experimental|Experimental|"SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1~Immunotherapy:~Nivolumab 3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle Ipilimumab 1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days).~Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)"
32965026|NCT05721534||Care home residents|The intervention was offered to new residents and residents that had not yet attended a consultation focusing on pharmacological treatment in The Chronic Care Model.
32965027|NCT05721534||Community-dwelling patients with chronic disease|Patients were invited for the consultation focusing on pharmacological treatment in the month of their birthday and, thereby, included randomly and consecutively throughout the study period.
32965028|NCT05721456|Active Comparator|PCV10 (Synflorix®)|
32965029|NCT05721456|Active Comparator|PCV13 (Prevenar13®)|
32965030|NCT05721456|Experimental|12-Valent Pneumococcal Conjugate Vaccine|
32965031|NCT05721378|Experimental|Permissive Weight Bearing group|Rehabilitation following the Permissive Weight Bearing (PWB) protocol
32965032|NCT05721378|Active Comparator|Restrictive Weight Bearing group|Rehabilitation following the Restrictive Weight Bearing (RWB) protocol
32965033|NCT05721300|Experimental|experience group|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48weeks, and then continue NAs treatment"
32965034|NCT05721300|Active Comparator|control group|"patients receive NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
32965035|NCT05721222|Experimental|PRO1160|PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
32965036|NCT05721066||POST-COVID|Patients hospitalized due to acute COVID-19 pneumonia and discharged home. No residual symptoms after recovery. Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro).
32965037|NCT05721066||LONG-COVID|"Patients hospitalized due to acute COVID-19 pneumonia and discharged home. Presence of residual symptoms after recovery or new symptoms appeared after discharge not otherwise explained.~Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro)."
32965038|NCT05720988|Active Comparator|Cohort I (tagraxofusp-erzs)|Patients receive tagraxofusp-erzs IV QD over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
32965039|NCT05720988|Experimental|Cohort II (azacitidine, tagraxofusp-erzs)|Patients receive azacitidine SC daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
32965040|NCT05720910|Experimental|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;
32965041|NCT05720910|No Intervention|CONTROL ARM|Patients included in the control arm will be managed according to the standard of care.
33033514|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
33033515|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
33033516|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
32965042|NCT05720832|Experimental|Prostate Cancer Patients and their Supporters|"The WINGS smartphone application is being tested on prostate cancer patients for the first time in this pilot study. It provides easy access to prostate cancer-related information and simplifies networking with supporters, such as family and friends. The WINGS smartphone application can be easily downloaded to a personal smartphone via Google Play or the App Store and can be used at any time from home or on the go.~In addition, the WINGS smartphone application also provides supporters, such as family members and friends of prostate cancer patients with easy access to prostate cancer-related information. Moreover, it helps them to support prostate cancer patients by facilitating joint activities, tailored to the needs of the patient."
32965043|NCT05720754|Experimental|DQS+HEM|Participants in the DQS+ group used DQS 1 drop 3 times/per day with heated eye mask for 2 weeks
32965044|NCT05720754|Active Comparator|DQS|Participants in the DQS group used DQS 1 drop 3 times/per day for 2 weeks
32965045|NCT05720754|Active Comparator|HEM|Participants in the HEM group used heated eye mask 3 times/per day for 2 weeks
32965046|NCT05720598|Experimental|Patients underdoing staging laparoscopy with indocyanine green (ICG)|"Patients will undergo upper GI endoscopy one day before SL will be dissolved in sterile water, resulting in a 0.125mg/ml concentration. 2 milliliters of the solution will be injected into the submucosa of 4 peritumoral sites - 0.5ml for each site. The following day patient will undergo SL~Intraoperative application of ICG-enhanced vision will be accomplished with dedicated optical devices. Alternate usage of white light and ICG fluorescence mode will allow precise location and cT stage determination of primary tumor, followed by identification of SN and its corresponding LN station, according to Japanese Gastric Cancer Association guidelines. Identified SN will be retrieved with a high-energy device, and the LN basin will be labeled with a magnetic clip."
32965047|NCT05720442|Experimental|Tangweian Recipe Group|"Tangweian formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.~1 mosapride citratetablet per time, 3 times a day, take it with meals."
32965048|NCT05720442|Active Comparator|Mosapride Citrate Group|1 mosapride citratetablet per time, 3 times a day, take it with meals.
32965049|NCT05720364|Experimental|TP-05, Fasted Group|Single dose of TP-05 (lotilaner oral), fasted
32965050|NCT05720364|Experimental|TP-05, High-Fat Group|Single dose of TP-05 (lotilaner oral) following a high-fat meal
32965051|NCT05720364|Experimental|TP-05, Low-Fat Group|Single dose of TP-05 (lotilaner oral) following a low-fat meal
32965052|NCT05720286||Study group|There was only one group as the study was a non-comparative study
32965053|NCT05720208|Experimental|Therapeutic Arm|
32965054|NCT05720208|Sham Comparator|Sham Arm|
32965055|NCT05720052|Experimental|Single arm|dose exploration
32965056|NCT05719974|Experimental|criterion-based rehabilitation protocol|
32965057|NCT05719974|Active Comparator|conventional physical therapy program|
32965058|NCT05719896|Placebo Comparator|Placebo tablets|Posology: oral administration of 3 placebo tablets three times per day for 8 weeks.
32965059|NCT05719896|Experimental|DT01 tablets|Posology: oral administration of 3 DT01 tablets three times per day for 8 weeks.
32965060|NCT05719896|Experimental|DT01-Placebo tablets|Posology: oral administration of 2 DT01 tablets and 1 placebo tablet, three times per day for 8 weeks.
32965061|NCT05719818||Treatment initiation|patients with a satisfactory oral assessment authorizing the immediate prescription of treatment.
32965062|NCT05719818||Surgical dental care|patients requiring surgical dental care before treatment initaition.
32965063|NCT05719740||45 patients in type 1 .DM|TYPE 1 DIABETES MELLITUS
32965064|NCT05719740||and 45 patients in type 2DM|TYPE 2 DIABETES MELLITUS
32965065|NCT05719662|Experimental|Weight bearing exercises|weight bearing exercises (I.e standing on preferred foot, standing with close eyes, walking forward on a line using normal stride and heel to toe gait, stepping over response speed stick on balance beam).
32965066|NCT05719662|Experimental|Jaffrey's core stability exercises|Jaffrey's core stability exercises (I.e contracting muscles, sitting on Swiss ball, Bridging, Squatting side lying bridge etc).
32965067|NCT05719584|Experimental|hypopressive exercises|pelvic floor muscle exercises along with hypopressive exercises
32965068|NCT05719584|Active Comparator|pelvic floor muscle training|pelvic floor muscle exercises alone
32965069|NCT05719506|Sham Comparator|control group 1|control group (nebulized normal saline without drug: group C) .The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.
32965070|NCT05719506|Experimental|dexmedetomidine group 2|"that receive nebulized dexmedetomidine (3 μg/kg; group D),The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
32965071|NCT05719506|Experimental|ketamine group 3|"nebulized ketamine (3mg/kg; group K) ,The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
32965072|NCT05719428|Experimental|DRUID|Patients NGS profile will be analysed with DRUID system to generate recommendations based on predicted efficacy. Patients will subsequently receive single agent therapy based on DRUID recommendations and criteria for therapy choice.
32965073|NCT05718960|Placebo Comparator|Reassurance-alone|
32965074|NCT05718960|Active Comparator|Traditional Dietary Advice|
32965075|NCT05717322|Experimental|TENS arm|
32965076|NCT05717322|Active Comparator|non TENS arm|
32965077|NCT05717166|Active Comparator|Standard Arm (Arm 1)|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications.
32965078|NCT05717166|Experimental|Experimental Arm (Arm 2)|Consists of treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable (e.g. surgery, RFA, fractionated radiation, chemoradiation) if those are deemed to be preferable by the treating oncologists.
32965079|NCT05717010||Group self-retaining retractor|Patients used self-retaining retractor for surgery
32965080|NCT05717010||Group Hand-held retractor|Patients used hand held retractor for surgery
33410172|NCT05084313|Experimental|Manual therapy group|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include 40 healthy individuals.
33410173|NCT05084313|Active Comparator|Deep-slow breathing group|Patients in this group will do deep-slow paced breathing exercise. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
33410174|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
33410175|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
33410176|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
33410177|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
33410178|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
33410179|NCT01382979|No Intervention|Control|Control group.
33410180|NCT04281537||Patient with Fabry Disease on ERT (agalsidase alfa)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
33410181|NCT04281537||Patient with Fabry Disease on ERT (agalsidase beta)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
33410182|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on ERT
32965081|NCT05716854|Active Comparator|Part 1: Clarithromycin Administration Only|Subjects in this arm will be administered Clarithromycin only over 3 days of dosing.
32965082|NCT05716854|Active Comparator|Part 1: Pimozide Administration Only|Subjects in this arm will be administered Pimozide only over 3 days of dosing.
32965083|NCT05716854|Placebo Comparator|Part 1: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
32965084|NCT05716854|Active Comparator|Part 2: Moxifloxacin Administration Only|Subjects in this arm will be administered Moxifloxacin only for 1 day of dosing.
32965085|NCT05716854|Active Comparator|Part 2: Cobicistat Administration Only|Subjects in this arm will be administered Cobicistat only for 1 day of dosing.
32965086|NCT05716854|Active Comparator|Part 2: Moxifloxacin and Cobicistat Administration|Subjects in this arm will be administered both Cobicistat and Moxifloxacin for 1 day of dosing.
32965087|NCT05716854|Placebo Comparator|Part 2: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
32965088|NCT05716776||Group 1 short axial length (AL)|Axial length less than 21
32965089|NCT05716776||Group 2 average axial length (AL)|Axial length 21-24
32965090|NCT05716776||Group 3 long axial length (AL)|Axial length more than 24
33410183|NCT04094610|Experimental|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Safety and tolerability at different dose levels~Phase 2~Oral repotrectinib (TPX-0005): 3 cohorts~Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ALK/ROS1/NTRK alterations or fusions in tumors and ALCL"
33410184|NCT05042193||Unvaccinated SARS-CoV-2 positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
33410185|NCT05042193||Vaccinated|Participants who were vaccinated against SARS-CoV-2
32965091|NCT05716698|No Intervention|Control Group|no Pleurotus citrinopileatus intervention
32965092|NCT05716698|Experimental|D2 10ug Pleurotus citrinopileatus Group|took D2 10ug Pleurotus citrinopileatus per day for a total of 4 weeks.
32965093|NCT05716698|Experimental|D2 100ug Pleurotus citrinopileatus Group|took D2 100ug Pleurotus citrinopileatus per day for a total of 4 weeks.
32965094|NCT05716542|Experimental|Physical Activity Intervention|"Participants will complete a primarily home-based PA intervention, with the goal of safely increasing their steps/day by incorporating moderate-to-vigorous physical activity (MVPA)~Participants will receive Fitbits with heart rate capabilities to support maintenance of the prescribed intensity during home exercise sessions and participants' self-monitoring of daily steps.~Participants will strategize aerobic MVPA behaviors with the intervention PT to identify preferable and enjoyable PA modalities (e.g., walking, cycling), while also identifying alternative options to allow for flexibility if life- or cancer-specific barriers arise~During the first telehealth appointment, the intervention PT will train participants on using the Fitbit and completing home exercise logs. The PT will continue to meet with participants to support exercise maintenance, review home exercise sessions, strategize new exercises, and troubleshoot emerging chemotherapy-related health declines."
32965095|NCT05716542|No Intervention|Usual care, wait-list control condition|-Participants in the control group will proceed with their treatment regimen as prescribed by their oncologist(s). To prevent drop out and high attrition rates as well as promote healthy behavior, control group participants will receive a Fitbit at the initial set-up meeting to wear during chemotherapy, as well as an individualized home exercise program and up to two telehealth visits with a PT after chemotherapy completion.
32965096|NCT05716464|Experimental|Lifestyle medicine intervention (LM)|Participants in the LM group will receive a 6-week group-based lifestyle medicine intervention.
33410186|NCT05031429|No Intervention|Control - Standard Care|"includes a minimum 12-hour feeding window for 7 days per week~no caloric restriction will be used~will wear a continuous glucose monitor"
33410187|NCT05031429|Experimental|Intervention - Time Limited Eating|"includes an 8-hour feed/16-hour fast for 7 days per week~will be instructed to consume all of their calories in the afternoon/evening period~can consume non-caloric beverages (water, tea, coffee) during the fasting period~will wear a continuous glucose monitor~no caloric restriction will be used"
33410188|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
33410189|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
33410190|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
33410191|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
33410192|NCT04928235||All Participants|All participants will have thermal imaging of their lower extremities. The temperature values will be shared with the attending physician. The physician will be asked questions about their diagnostic confidence before and after seeing the temperature values.
33410193|NCT04092660|Experimental|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
33410194|NCT04092660|Active Comparator|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
32965097|NCT05716464|Experimental|Cognitive-behavioral therapy for depression (CBT-D)|Participants in the CBT-D group will receive a 6-week group-based cognitive-behavioral therapy for depression.
32965098|NCT05716308|Experimental|intervention group|Continuous nursing intervention was performed on the basis of the control group
32965099|NCT05716308|No Intervention|control group|discharge guidance was performed according to routine nursing intervention at the time of discharge, and the patients were informed to return to the hospital for regular review (review was performed at 1 month, 3 months, half a year, 1 year, and 2 years after discharge, respectively).
32965100|NCT05716152||Psoriasis vulgaris participants|
32965101|NCT05716152||not diseased participants|
32965102|NCT05716074|Experimental|Supervised-exercise group|This group will be given combined low-intensity exercises under the supervision of a physiotherapist.
33410195|NCT05407857|Experimental|On-site|The on-site multi-modal intervention will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol.
33410196|NCT05407857|Active Comparator|Remote|The remote intervention group is designed for reducing the chances of person-to-person contact response to the current COVID-19 pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs.
33410197|NCT05407857|Placebo Comparator|Control|The control group will also receive the same health evaluation and education as all intervention groups.
33410198|NCT03688698||PAH|
33410199|NCT03688698||Controls|
33410200|NCT04220775|Experimental|Treatment (bintrafusp alfa, SBRT)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
32965103|NCT05716074|Experimental|Home-exercise group|This group will exercise at home without the supervision of a physiotherapist.
32965104|NCT05715996|Experimental|mixed reality guided localization group|Application of mixed reality technique for percutaneous lung nodule localization.
32965105|NCT05715996|No Intervention|Computerized tomography (CT) guided localization group|Computerized tomography (CT) guided percutaneous lung nodule localization.
32965106|NCT05715840|Experimental|safety run-in Stage(single arm) and Phase 3: SG001+Platinum-based chemotherapy±Bevacizumab|SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
32965107|NCT05715840|Placebo Comparator|Phase 3: Placebo+Platinum-based chemotherapy±Bevacizumab|Placebo, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
32965108|NCT05715762||Ventilation in supine position|Patients are ventilated in supine position.
32965109|NCT05715762||Ventilation in supine position and NO inhalation|Patients are ventilated in supine position with NO inhalation for 1 hour.
32965110|NCT05715762||Ventilation in prone position for 1 hour|Patients are ventilated in prone position for 1 hour.
32965111|NCT05715762||Ventilation in prone position for 2 hours plus NO inhalation for 1 hour|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour.
32965112|NCT05715762||Ventilation in prone position for 3 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 1 hour.
32965113|NCT05715762||Ventilation in prone position for 16 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 14 hours.
32965114|NCT05715762||Ventilation in re-supine position for 3 hours|Patients are ventilated in supine position for 3 hours followed by ventilation in prone position for 16 hours.
32965115|NCT05715294|Experimental|Music Application Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the music group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied. Patients will listen to music composed in Uşşak makam for 50 minutes before going to bed every day for 7 days. After the first interview, the patients will be reminded of the music application by phone call and 2 text messages every day by the researcher. Interviews will be recorded on the Patient's Telephone Follow-up Form while Listening to Music. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients in the intervention group.
32965116|NCT05715294|No Intervention|Control Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the control group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied.No application will be made to the control group. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients.
32965117|NCT05713734||Patients|Patients with bleeding of unknown cause
32965118|NCT05713734||Controls|Healthy voluntaries without bleeding tendency
32965119|NCT05713656||Physiotherapy and bikefit|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
32965120|NCT05709288|Experimental|BBM-H901 administration group|Subjects will be administered with single dose intravenous infusion of BBM-H901.
32965121|NCT05706324|Experimental|Low dose|21~65 year old healthy subjects, received low dose of RCVi
32965122|NCT05706324|Experimental|Medium dose|21~65 year old healthy subjects, received medium dose of RCVi
32965123|NCT05706324|Experimental|High dose|21~65 year old healthy subjects, received high dose of RCVi
32965124|NCT05702814||Group A: GD1 with Low-normal Bone Disease|Participants with GD1 with low-normal bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
32965125|NCT05702814||Group B: GD1 with Mild Bone Disease|Participants with GD1 with mild bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
32965126|NCT05702814||Group C: GD1 with Severe Bone Disease|Participants with GD1 with severe bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
32965127|NCT05702814||Group D: Healthy Participants|Healthy Participants whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years.
32965128|NCT05698758|Experimental|dextrometropine group|Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).
32965129|NCT05698758|Placebo Comparator|placebo group|Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).
32965130|NCT05696184|Active Comparator|GERD patients with complaint of regurgitation and supra-esophageal reflux disease (SERD)|GERD patients with complaint of regurgitation and one of the following supra-esophageal symptoms attributed to reflux of gastric content: chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis and dental erosion i.e. SE-GERD. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
32965131|NCT05696184|Active Comparator|Age and gender matched healthy controls|Controls will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
32965132|NCT05696184|Active Comparator|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint)|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
32965133|NCT05696184|Active Comparator|Asthma patients with and without supra-esophageal symptoms|Asthma patients with and without supra-esophageal symptoms (these symptoms include chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis, and dental erosion). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
32965134|NCT05696184|Active Comparator|Age and gender matched patient controls for diagnosed Barrett's esophagus patients|Patient controls for diagnosed Barrett's esophagus patients. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
33033517|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
33033518|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
32965135|NCT05694156|Experimental|Music-based cognitive training|Music-based cognitive training sessions are derived from two Neurologic Music Therapy techniques: Musical Attention Control Training (MACT) and Musical Executive Function Training (MEFT). MACT exercises will focus on sustained and selective attention to emphasise flexibility and adaptability of the auditory attention system. MEFT exercises will provide opportunity for decision making, problem solving, reasoning, comprehending, organising, initiating, inhibiting, evaluating, analysing, and creating.
32965136|NCT05683392|Experimental|Control-IQ 2.0 Alternate Target|Participants will use t:slim X2 pump with Control-IQ technology 2.0 at an alternate target for two weeks.
33410201|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
33410202|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
32965137|NCT05683392|Experimental|Control-IQ 2.0 Standard Target|Participants will use t:slim X2 pump with Control-IQ technology 2.0 at a standard target for two weeks.
32965138|NCT05680116|Active Comparator|Home based exercise group|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. Exercise follow-up of the patients will be provided with weekly routine face-to-face checks. After an average of 6 weeks of radiotherapy, the initial evaluations will be repeated.
32965139|NCT05680116|Experimental|Home based exercise plus vibration therapy group.|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. The study group continues their home based exercise, in addition they will receive 30 minutes of Myovolt (Myovolt TM, Myovolt Limited, Christchurch, New Zealand) device which is wearable vibration therapy 2 days a week. The vibration program will continue for 6 weeks, in the form of 2 sessions per week. Intermittent and sinusoidal modes between 20-100 Hz will be used for the vibration frequency.
33410203|NCT04108299|Placebo Comparator|Wait-list Control|Standard of care
33410204|NCT04108299|Experimental|SMS Intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
33410205|NCT01382823|Experimental|Femtosecond Laser|
33410206|NCT01382043||Endeavor Segment group|
33410207|NCT01382043||Excel Segment Group|
33410208|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
33410209|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
33410210|NCT01381965|Active Comparator|Eyes with macular hole|
33410211|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
33410212|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
33410213|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
33410214|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
33410215|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
32965140|NCT05679570|Experimental|Satralizumab （Genetical Recombination）|
32965141|NCT05678322|Experimental|Patients with PSA > 0.2 ng/ml following Radical Prostatectomy|Men will be eligible for the study when their post-prostatectomy PSA level is initially observed to be PSA >0.2ng/ml. All participants will receive a baseline rhPSMA-7.3 (18F) MRI scan within a month of enrollment, and the second rhPSMA-7.3 (18F) scan will be performed within a year of the initial scan. Only those participants with rhPSMA-7.3 (18F) identifiable disease during the initial scan will be offered salvage intervention per standard of care. All participants with a negative initial rhPSMA-7.3 (18F) scan will undergo a second scan when the PSA> 0.5 ng/ml or one year after the initial PET scan. The salvage intervention will be at the discretion of the investigator.
33033519|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
33410216|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
33033520|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
33033521|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
33410217|NCT04878471|Experimental|ASP5354|Three participants in three dose levels will receive a single intravenous dose of ASP5354 on Day 1 under fasting conditions.
33410218|NCT04878471|Placebo Comparator|ASP5354 Matching Placebo|One participant in three dose levels will receive a single intravenous dose of matching placebo on Day 1 under fasting conditions.
33410219|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
33410220|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
33410221|NCT04877379|Experimental|Part 1|Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.
33410222|NCT04877379|Experimental|Part 2A|Multiple dose administration of VNRX-7145 q8h for 10 days
33410223|NCT04877379|Placebo Comparator|Part 2B|Multiple dose administration of placebo q8h for 10 days
33410224|NCT04877379|Experimental|Part 3A|Multiple dose administration of low dose VNRX-7145 + VNRX-5024
32965142|NCT05678088|Experimental|Supervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
32965143|NCT05678088|Active Comparator|Unsupervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. After the initial training there will be no further scheduled interactions with the study staff except during the follow-up telephone calls and study visits.
32965144|NCT05678088|Sham Comparator|Supervised Sham Exercises|The participant will perform sham control exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
33410225|NCT04877379|Experimental|Part 3B|Multiple dose administration of high dose VNRX-7145 + VNRX-5024
33410226|NCT04877379|Placebo Comparator|Part 3C|Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)
33410227|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
33410228|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
33410229|NCT03684330|Active Comparator|Vitamin D supplementation|
33410230|NCT03684330|Placebo Comparator|Vitamin D placebo|
33410231|NCT04857489||Patients with Relapse Remitting Multiple Sclerosis|Blood sample
33410232|NCT04857489||Healthy Controls|Blood Sample
33410233|NCT03680430|Experimental|limb soft tissue sarcoma|
33410234|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
33410235|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
33410236|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
33410237|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
33410238|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
33410239|NCT04058028|Experimental|Rozibafusp Alfa, Dose A|Investigational product solution in vial
32965145|NCT05676294|Experimental|Olanzapine|olanzapine oral tablet, 5mg, once prior to surgery
32965146|NCT05676294|Placebo Comparator|Placebo|placebo oral tablet once prior to surgery
33033522|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
33033523|NCT01963819|No Intervention|Control|Standard treatment
33033524|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
33410240|NCT04058028|Experimental|Rozibafusp Alfa, Dose B|Investigational product solution in vial
33410241|NCT04058028|Experimental|Rozibafusp Alfa, Dose C|Investigational product solution in vial
33410242|NCT04058028|Placebo Comparator|Placebo for Rozibafusp Alfa|Placebo Investigational product solution in vial
33410243|NCT03684252|Other|Control|Treatment as usual
33410244|NCT03684252|Experimental|Intervention|CBT-based intervention
33410245|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
33410246|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
32965147|NCT05665062|Experimental|SYNCAR-001 + STK-009|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with repeated sequential ascending doses of STK-009 subcutaneously (SC)~Dose extension: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with repeated doses of STK-009 SC at the RP2D"
32965148|NCT05661864|Experimental|Multi-Tiered Systems of Support for Teacher Training Evaluation|Participants will be randomized to a target practice group. The group will receive the multi-tiered systems of support (online instruction, self-monitoring, self-management) for the target practice. They will not receive instruction on the non-target practice until after study data collection concludes.
32965149|NCT05661864|No Intervention|Control|Participants will not receive intervention on the non-target practice until after study data collection concludes. This practice will serve as the comparison for the group who received intervention on the practice.
33410247|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
33410248|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
32965152|NCT05642520|Experimental|oval section abutment of a 2.9mm|"The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed.~Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland)."
32965153|NCT05642520|Placebo Comparator|circular section abutment in 3.3mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
33410249|NCT03677544||exploratory cohort (A)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
32965154|NCT05625360|Experimental|Arm 1 - eHealth Mindful Movement and Breathing Group (eMMB) Yoga|Participants will be given access to 20-minute eMMB videos (either saved as a local files on an iPad or via links to watch on their own devices) with written instructions for eMMB and to watch a video at least once before surgery (videos have the same content, one is taught in a bed and one in a chair). The yoga instructor will call participants before surgery to offer guidance upon request and meet with participants individually via a synchronous videoconference or telephone session, postoperative day 1 (the day after surgery), or as soon as feasible.
33410250|NCT03677544||exploratory cohort (B)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
33410251|NCT03468426|Experimental|BI 836880 + ezabenlimab|
33410252|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
33410253|NCT04850469||trial group|Mesenchymal Stem Cell-Derived Exosomes
33410254|NCT04850469||control group|conventional treatment
33410255|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
33410256|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
33410257|NCT04811079|Experimental|Spectacle Filter Sequence 1|(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
33410258|NCT04811079|Experimental|Spectacle Filter Sequence 2|(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
33410259|NCT04811079|Experimental|Spectacle Filter Sequence 3|(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
33410260|NCT04811079|Experimental|Spectacle Filter Sequence 4|(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
33410261|NCT04811079|Experimental|Spectacle Filter Sequence 5|(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
33410262|NCT04811079|Experimental|Spectacle Filter Sequence 6|(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
33410263|NCT04811079|Experimental|Spectacle Filter Sequence 7|(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
33410264|NCT04811079|Experimental|Spectacle Filter Sequence 8|(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
33410265|NCT04811079|Experimental|Spectacle Filter Sequence 9|(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
33410266|NCT04811079|Experimental|Spectacle Filter Sequence 10|(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
33410267|NCT01569321|Experimental|Breast cancer|
33410268|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
33410269|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
33410270|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
33410271|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
33410272|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
32965155|NCT05625360|Active Comparator|Arm 2 Life Impacts Reflection Group (LIR)|The format for interactions with an LIR interventionist, frequency of recommended home practice (brief diary entries), and home assessments will be matched to the eMMB group. LIR will not include active ingredients of eMMB (yoga).
32965156|NCT05623488|Experimental|Dose Level 1|3.00 x 10^7 CAR T cells administered intratumoral
33410273|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
33410274|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
33410275|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
33410276|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
33410277|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
33410278|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
33410279|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
33410280|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
33410281|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
33410282|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
33410283|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
33410284|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
33410285|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
33410286|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
33410287|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
33410288|NCT03861234|Experimental|BI 836880|Single Rising Dose part followed by a Multiple Rising Dose part
33410289|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
33410290|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
33410291|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
33410292|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
33410293|NCT03736213|Experimental|Visual-acoustic biofeedback|Visual-acoustic biofeedback treatment targeting /r/ distortions.
32965157|NCT05623488|Experimental|Dose Level -1|3.00 x 10^6 CAR T cells administered intratumoral
32965158|NCT05619510|Other|Wait List Control Group|This group will be randomized to wait list control. They will serve as a control for the intervention at time points 1 and 2. However after a 2-3 month period they will receive the intervention.
32965159|NCT05619510|Experimental|Intervention Group|Individuals randomized to this group will start the intervention immediately and have outcomes measured at three time points.
32965160|NCT05618808|Experimental|REGN9933|REGN9933 will be administered by intravenous (IV) infusion
32965161|NCT05618808|Active Comparator|Enoxaparin|Enoxaparin will be administered by subcutaneous (SC) administration
32965162|NCT05618808|Active Comparator|Apixaban|Apixaban will be administered orally twice a day
32965163|NCT05612802|Other|IGF|Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. In our study, in order to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.
32965164|NCT05612490||Critically ill patients undergoing RRT|Patients admitted to participating ICU and receiving renal replacement therapy.
33321908|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Receives both interventions at 6 months if non-virally suppressed."
32965166|NCT05600322|Experimental|Hexvix Blue light cystoscopy|In this study, enrolled patients will undergo standard White light cystoscopy and Blue light cystoscopy following Hexvix administration. Lesions detected during the cystoscopies will be resected or biopsied.
32965167|NCT05598918|Experimental|early passive mobilization|ıt will begin to using an orthosis with 30* flexion of the wrist,70* flexion of metacarpophalangeal (MCP) joints,full extension of IF joints.Home exercises will be performed as passive flexion and active extension exercises with rubber band 10 times per hour on postoperative 3rd day for 3 weeks.Passive flexion and extension exercises will be performed ten times a day;four times a day on MCP+PIP+IF joints.3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
32965168|NCT05598918|Experimental|early active mobilization|ıt will begin to using an orthosis that positions wrist in neutral position,MCP joints 50*-70* flexion,IF joints in full extension.After flexion active extension exercises,full passive flexion of fingers with the other intact hand and then keeping fingers in flexion position for 3-5 sec for 3 weeks.Rehabilitation program applied from 3rd week is the same as the passive group:3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
32965169|NCT05596734|Experimental|qIRV + bivalent BNT162b2 (dose level combination 1)|Administered intramuscularly into the deltoid muscle of the right arm
32965170|NCT05596734|Experimental|qIRV + bivalent BNT162b2 (dose level combination 2)|Administered intramuscularly into the deltoid muscle of the right arm
33321909|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if virally suppressed."
33410294|NCT03736213|Experimental|Ultrasound biofeedback|Ultrasound biofeedback treatment targeting /r/ distortions.
33410295|NCT03850782|Experimental|Bimatoprost SR - Dose A|"Study Eye: Participants will receive 1 - 3 Cycles of Bimatoprost SR administrations of Dose A~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
32965171|NCT05596734|Experimental|qIRV + bivalent BNT162b2 (dose level combination 3)|Administered intramuscularly into the deltoid muscle of the right arm
32965172|NCT05596734|Experimental|qIRV (dose level 1)|Administered intramuscularly into the deltoid muscle of the right arm
32965173|NCT05596734|Experimental|qIRV (dose level 2)|Administered intramuscularly into the deltoid muscle of the right arm
32965174|NCT05596734|Experimental|bivalent BNT162b2 (dose level 1) + QIV|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
32965175|NCT05582226|Experimental|ACL reconstruction utilizing stump-derived mesenchymal stem cells|This is the test group of this study. These participants will receive the augmented ACL reconstruction treatment involving extraction and injection of mesenchymal stem cells. Stem cell tissue will be harvested from each participant using the GraftNet device intraoperatively. During the intra-articular preparation phase of the reconstruction, the stem cell tissue will be applied to the ACL graft using a bovine collagen matrix.
32965176|NCT05582226|Other|Standard of care ACL reconstructive surgery|This is the control group of this study. These participants will receive standard ACL reconstructive surgery without any augmentations.
32965177|NCT05579730|Experimental|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combination ophthalmic solution, n = 75|
32965178|NCT05579730|Experimental|Ketotifen fumarate ophthalmic solution 0.035% (n = 75)|
32965179|NCT05579730|Experimental|Brimonidine tartrate ophthalmic solution 0.025% (n = 75)|
32965180|NCT05579730|Experimental|Vehicle ophthalmic solution (n = 75)|
32965181|NCT05578560|Experimental|Prehabituation group|Patients with vestibular Schwannoma are indicated for the surgery. The patients in this group undergo chemical labyrinthectomy via intratympanically installed gentamicin before the vestibular Schwannoma resection. After the operation, vestibular training under supervision will be performed.
32965182|NCT05578560|Experimental|Virtual reality group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision and in addition to this, they will be exposed to 3D optokinetic stimulation in virtual reality space.
32965183|NCT05578560|Experimental|Vestibular training group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision.
32965184|NCT05577390|Experimental|Intraneural Facilitation™ Treatment Group|Subjects will receive nine 60-minute Intraneural Facilitation™ treatments during sessions 2 through 10.
32965185|NCT05577390|Sham Comparator|Sham Control Treatment Group|Subjects will receive nine 60-minute Sham treatments during sessions 2 through 10.
32965186|NCT05573100|Experimental|CU06-1004 100mg|CU06-1004 100 mg tablets. Dosed at 100 mg (1 capsule) QD within 30 minutes after meal on each evening
32965187|NCT05573100|Experimental|CU06-1004 200mg|CU06-1004 100 mg tablets. Dosed at 200 mg (2 capsules) QD within 30 minutes after meal on each evening
32965188|NCT05573100|Experimental|CU06-1004 300mg|CU06-1004 100 mg tablets. Dosed at 300 mg (3 capsules) QD within 30 minutes after meal on each evening
32965189|NCT05570292|Active Comparator|Domperidone|
32965190|NCT05570292|Placebo Comparator|Folic acid|
32965191|NCT05558982|Experimental|BXCL701 plus Pembrolizumab|
32965192|NCT05557812|Experimental|non-eugenol based ZOE and Ferric Sulfate|non-eugenol based ZOE and Ferric Sulfate in primary molar pulpotomy procedures.
32965193|NCT05557812|Experimental|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide and Ferric Sulfate in primary molars pulpotomies procedures.
32965194|NCT05554302|Experimental|PET/CT, MRI|All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.
32965195|NCT05549466|Experimental|Apatinib plus Camrelizumab and Chemotherapy|
32965196|NCT05549466|Experimental|Apatinib plus Camrelizumab|
32965197|NCT05549466|Experimental|Camrelizumab and Chemotherapy|
32965198|NCT05549466|Active Comparator|Chemotherapy|
32965199|NCT05544318|Experimental|Intervention|Extra nutritional support
32965200|NCT05544318|No Intervention|Control|Usual care
32965201|NCT05543382||Implanted group|This group will be participants with urinary urge incontinence (UUI) who have been previously implanted with an Axonics System, are considered therapy responders (>50% reduction in UUI episodes) and are satisfied with therapy
32965202|NCT05543382||De Novo group|This group will be participants who are newly implanted with an Axonics System.
32965203|NCT05541822|Experimental|Cohort 1: ABN401|Subjects will receive ABN401 800 mg, monotherapy, administered orally once daily in 21-day cycles
32965204|NCT05540652|Experimental|Mindfulness-Based Queer Resilience (MBQR)|This is a single arm trial testing an internet delivered mindfulness-based intervention. All enrolled participants will receive the study intervention.
32965205|NCT05530980|Experimental|GameDay Ready Program|The GameDay Ready Program is a 12-week, football-themed, behavioral weight management intervention that promotes gradual increases in physical activity, reductions in sedentary time, and improvements in dietary habits through education, self-monitoring of physical activity and diet, personalized goal setting, group-based competition, social support, identifying and overcoming barriers, and including physical activity as a substantial component of meeting sessions. The program is sensitive to unique cultural influences surrounding gender, race, and rurality; and issues related to motivation are threaded throughout the program.
32965206|NCT05520450||Intervention group|Recruitment will be based on consecutive patients receiving regular home care in the ATDOM Programme by the Primary Care Team, with prior informed consent.
32965207|NCT05519436||Morbid obesity individuals|
32965208|NCT05519436||Healthy individuals|
32965209|NCT05517252|Experimental|Tele-Yoga Group|OSAS patients in the Tele-Yoga group will be taken to group-based Hathastyle Tele-Yoga sessions of 60 minutes three times a week for 12 weeks, simultaneously in groups of 4-5 people, in an internet-based telerehabilitation environment.
32965210|NCT05517252|Experimental|Control Group|OSAS patients in the control group will be taught unilateral basal and apical chest expansion exercises in the first session and will be followed as a home program. 3-4 thoracic extension exercises and 1-2 breathing control will be repeated 10 times. The patient will be asked to do the home program four times a day and keep a diary for the home program.
32965211|NCT05508360|Experimental|Lumbar Disc Nucleus Replacement|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
32965212|NCT05505162|Experimental|Zibotentan and EE/LNG|"Participants will receive two tablets of combined oral EE/LNG on Day 1 with PK samples obtained from pre-dose on Day 1 until post-dose on Day 6.~Participants will receive two capsules of zibotentan orally QD from Day 6 to Day 14. From Day 15 until Day 19 participants will continue to receive two capsules of zibotentan QD administered orally.~On Day 15, participants will receive two tablets of combined oral EE and LNG with PK samples obtained pre-dose on Day 15 until post-dose (Day 20)."
32965213|NCT05505084||Collatape (Zimmer Dental)|This material is a resorbable collagen wound dressing. They are made from bovine Achilles tendons and are a source of Type I collagen. The resorbable wound dressings are sterilized after purification with ethylene oxide.
33321910|NCT03500172|Active Comparator|ICM, SoC if Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~SoC:~HIV counseling and testing (HTC)~STI screening and treatment~TB screening and referral~Health education through peer educators and peer supported follow-up related to linkages to care~Referrals to DOH primary healthcare clinics or THC drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
33321911|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if non-virally suppressed."
33321912|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Receives both interventions at 6 months if non-virally suppressed."
33321913|NCT03973073|Experimental|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
33321914|NCT03973073|Other|blank group|Topical applications and/or NB-UVB on-demand treatment
33321915|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
33321916|NCT03972761|Active Comparator|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
32965214|NCT05505084||Cytoplast Barrier Membranes TXT-200 Singles (Osteogenics Biomedical)|Cytoplast Barrier membranes are manufactured from high-density Polytetrafluoroethylene (PTFE) which allows them to withstand exposure to the oral environment. The textured surface increases the surface area available for cellular attachment during dental bone grafting procedures thereby aiding in stabilizing the PTFE membrane. It can be removed non-surgically after at least 21 days.
32965215|NCT05505084||Ossix Plus (dantum dental)|OssixPlus is a resorbable collagen dental membrane used for Guided Bone Regeneration and Guided Tissue Regeneration. It contains a patented GLYMATRIX cross-linking technology that allows it to maintain barrier functionality for 4 to 6 months. The collagen is derived from porcine.
32965216|NCT05505084||Renovix-Plus (Salvin)|Renovix Plus is a non-cross-linked extracellular matrix containing Type I, II, and III Collagen, Fibronectin, Laminin, and Elastin. It provides architecture and barrier protection for bone regeneration and soft tissue esthetics. This membrane resorbs within six months.
32965217|NCT05505084||BioXclude (Snoasis)|BioXclude is a minimally manipulated allograft amnion chorion tissue. It is obtained from consenting mothers who donate their placentas after elective caesarian section delivery. The tissue is processed to cleanse and maintain the tissue. Following processing and dehydration, the allografts are packaged and terminally sterilized.
32965218|NCT05504304|Active Comparator|Group A: open reduction and internal fixation plus primary subtalar arthrodesis.|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
32965219|NCT05504304|Active Comparator|Group B: conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
32965220|NCT05473572|Experimental|Children who stutter|Measuring stuttering severity and cortical auditory evoked potentials in a group of children who stutter then they will receive fluency shaping exercises for a period range from 2-4 months. Reassessment of cortical auditory evoked potentials and stuttering severity after the specified period
32965221|NCT05473572|No Intervention|children who do not stutter|Measuring cortical auditory evoked potentials as a comparison group
32965222|NCT05467800|Experimental|Canakinumab|Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
32965223|NCT05461170|Experimental|Cohort 1a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for up to 88 weeks total
32965224|NCT05461170|Experimental|Cohort 1b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 88 weeks total.
32965225|NCT05461170|Experimental|Cohort 2a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for 92 weeks.
32965226|NCT05461170|Experimental|Cohort 2b1 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 24 or 48 weeks followed by VIR-3434 or VIR-3434 + VIR-2218 for an additional 44 or 68 weeks.
32965227|NCT05461170|Experimental|Cohort 2b2 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 48 weeks followed by VIR-3434 or VIR-3434 + VIR-2218 for an additional 44 weeks.
32965228|NCT05461170|Experimental|Cohort 2c (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 92 weeks total
32965229|NCT05436678|Active Comparator|PrimeC|2 PrimeC tablets (total single dose 748 mg) twice daily for 6.5 days following a meal
32965230|NCT05436678|Active Comparator|Marketed ciprofloxacin and celecoxib|750 mg of ciprofloxacin and 200 mg of celecoxib, co-administered twice daily for 6.5 days following a meal
32965231|NCT05434338|Other|Major women with HPV-related high-grade intraepithelial lesions|
32965232|NCT05433012|Other|Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T|
32965233|NCT05426772|Other|Healthy sedentary people|Muscle oxygenation and vital signs will be measured before, during, and after of 20 minutes aerobic exercise in an environment where suitable conditions are provided. After 3 days, kinesio taping will be added to the same program and the measurements will be repeated.
32965234|NCT05425056|Experimental|Treatment Arm|Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).
32965235|NCT05425056|No Intervention|Control Arm|Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.
32965236|NCT05413122|Experimental|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice. ].
33033525|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
33410296|NCT03850782|Experimental|Bimatoprost SR - Dose B|"Study Eye: Participants received 1-3 Cycles of Bimatoprost SR administrations of Dose B~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
33410297|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
32965237|NCT05413122|Experimental|Peer Support|Participants randomized to receive Peer Support will be engaged by participants' own peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
32965238|NCT05413122|Experimental|c-NRT|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.
32965239|NCT05413122|Experimental|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician according to randomization into the varenicline condition and participants will be provided with education on its use. Participants will be instructed to begin taking varenicline one week prior to participants' quit date and for 11 weeks following quit date. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and to monitor adherence; calls will taper to every other week after four weeks.
32965240|NCT05413122|No Intervention|Control|No intervention
32965241|NCT05413122|Experimental|Varenicline & c-NRT|Varenicline & c-NRT
32965242|NCT05413122|Experimental|Peer Support & Varenicline|Peer Support & Varenicline
32965243|NCT05413122|Experimental|c-NRT & Peer Support|c-NRT & Peer Support
32965244|NCT05413122|Experimental|c-NRT & Peer Support & Varenicline|c-NRT & Peer Support & Varenicline
32965245|NCT05413122|Experimental|Intensive Behavioral Counseling & Varenicline|Intensive Behavioral Counseling & Varenicline
32965246|NCT05413122|Experimental|Intensive Behavioral Counseling & c-NRT|Intensive Behavioral Counseling & c-NRT
32965247|NCT05413122|Experimental|Intensive Behavioral Counseling & Varenicline & c-NRT|Intensive Behavioral Counseling & Varenicline & c-NRT
32965248|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support|Intensive Behavioral Counseling & Peer Support
32965249|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & Varenicline|Intensive Behavioral Counseling & Peer Support & Varenicline
32965250|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & c-NRT|Intensive Behavioral Counseling & Peer Support & c-NRT
32965251|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & c-NRT & Varenicline|Intensive Behavioral Counseling & Peer Support & c-NRT & Varenicline
32965252|NCT05410548|Other|Standard-of-Care|Patient participants will receive routine standardized prosthetic follow-up care by a certified prosthetist, including evaluation of prosthesis use, prosthesis-enabled mobility, socket comfort and sock ply usage, falls, body anthropometrics, and functional mobility.
32965253|NCT05410548|Experimental|Standard-of-Care + Clinical Screening|In addition to routine, standardized prosthetic follow-up care, patient participants will receive comorbidity screening for contralateral limb peripheral arterial disease, peripheral neuropathy, major depression, and greater than low risk for persistent low back pain. Participants will be educated on clinical screening findings, provided a copy of their screening results to share with their medical providers, and their results will be securely sent to their primary care provider.
32965254|NCT05405010|Placebo Comparator|Control|Participants remain seated for 1 hour
32965255|NCT05405010|Experimental|1 min|Participants remain seated for 1 hour except for 1 minute of stair climbing and descending
32965256|NCT05405010|Experimental|3 min|Participants remain seated for 1 hour except for 3 minute of stair climbing and descending
32965257|NCT05404854||chronic low back pain patients|Physical Activity by wearing an accelerometer for 7 days before and after the rehabilitation program sedentarity by wearing an accelerometer for 7 days before and after the rehabilitation program Measurement of explicit motivation Measurement of implicit attitudes
32965258|NCT05403060|Experimental|Intervention|Educational nutritional intervention, based on the Social Cognitive Theory
33410298|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
33410299|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
32965259|NCT05403060|No Intervention|Control|Regular school education, without educational nutritional intervention
32965260|NCT05384262|Active Comparator|Cohort 1: Part A1 - AZD0780 dose 1/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
32965261|NCT05384262|Active Comparator|Cohort 2: Part A1 - AZD0780 dose 2/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
32965262|NCT05384262|Active Comparator|Cohort 3: Part A1 - AZD0780 dose 3/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
32965263|NCT05384262|Active Comparator|Cohort 4: Part A1 - AZD0780 dose 4/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
32965264|NCT05384262|Active Comparator|Cohort 5: AZD0780 dose 5/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
33321917|NCT03972761|Placebo Comparator|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
32965265|NCT05384262|Active Comparator|Cohort 6: Part B - AZD0780 dose 6/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
32965266|NCT05384262|Active Comparator|Cohort 7: Part B - AZD0780 dose 7/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
32965267|NCT05384262|Active Comparator|Cohort 8: Part B - AZD0780 dose 8/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
32965268|NCT05384262|Active Comparator|Cohort 9: Part B - AZD0780 dose 9/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
32965269|NCT05384262|Active Comparator|Cohort 10: Part B - AZD0780 dose 10/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
32965270|NCT05384262|Active Comparator|Cohort 11: Part A2 - AZD0780 dose 11/placebo tablet|A total of 5 subjects will receive single ascending doses of AZD0780 and placebo.
32965271|NCT05377320||Clinical Decision Aid Group|In this group, physicians will use standard care plus the clinical decision aid.
32965272|NCT05377320||Control Group|In this group, physicians will use standard care only.
32965273|NCT05371080|Other|LTFU Group|Participants who received at least one dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and are followed for long-term vaccine efficacy and safety in the current ZOSTER-101 study.
32965274|NCT05371080|Other|1-Additional Dose Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and one additional dose of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
32965275|NCT05371080|Other|Revaccination Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and two additional doses of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
32965276|NCT05371080|Other|Control Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.
32965277|NCT05364606||50 Subjects|50 Subjects Receiving the Patient Specific Talus Spacer.
32965278|NCT05352282|Active Comparator|Group A|
32965279|NCT05352282|Active Comparator|Group B|
32965280|NCT05343624|Other|CGM Arm|continuous glucose meter is placed on the abdomen
32965281|NCT05333328|Experimental|OFS with endocrine|Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, the patients with a genomic low risk using the multigene-assay (OncoFREE®) will be included in this arm.
32965282|NCT05322330|Experimental|XPO-1 Inhibitor+CAR-T Cells|XPO-1 Inhibitor plus CAR-T Cells
32965283|NCT05320146||CORT118335-860 Participants|This group will include patients who participated in CORT118335-860 study and received at least one dose of miricorilant.
33410300|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
33410301|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
32965284|NCT05320146||CORT118335-861 Participants|This group will include patients who participated in CORT118335-861 study and received at least one dose of miricorilant.
32965285|NCT05319990||PANDA, T1D|New participants with T1D will be enrolled at the University of Colorado and University of Washington.
32965286|NCT05319990||PANDA Sub Study, Former CROCODILE Participants|Participants will be enrolled from the existing CROCODILE study (COMIRB # 19-1282), adding longitudinal follow-up to completed kidney biopsies and baseline data and biosample acquisition.
32965287|NCT05312892|Placebo Comparator|Placebo|Subjects will received 2 weeks of capsules containing placebo.
32965288|NCT05312892|Active Comparator|Amlodipine|Subjects will received 2 weeks of capsules containing amlodipine.
32965289|NCT05312892|Experimental|Moxonidine|Subjects will received 2 weeks of capsules containing moxonidine.
32965290|NCT05311020|Placebo Comparator|Placebo drink|
32965291|NCT05311020|Experimental|Pitaya Ovule Extract Drink|
32965292|NCT05310240||Hip arthroscopy|Patients that underwent hip arthroscopy at this department between 2013 and 2021.
32965293|NCT05309616|Experimental|Talz|All participants receive Talz
32965294|NCT05307198|Experimental|Rectal Artery Infusion Chemotherapy|Patients receive 2 cycles of Capecitabine and Oxaliplatin (CapeOx) chemotherapy and evaluated with rectum Magnetic Resonance Imaging (MRI). Patients with more than 20% regression of maximum diameter of rectal tumor in MRI image will entry into next step of rectal artery infusion of Oxaliplatin and oral Capecitabine（1000mg/㎡）with anti-PD1 antibody（200mg）every 3 weeks for 2 cycles.Then those patients will receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME.
32965295|NCT05304936|Experimental|HCW9218|Experimental Arm: HCW9218
32965296|NCT05301504|Experimental|Group 1|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10^9 vp
32965297|NCT05301504|Experimental|Group 2|"n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5×10^10 vp~Note: The DSMB may recommend increasing the size of group 2 to n=9 in the event of higher than expected reactogenicity"
32965298|NCT05301504|Experimental|Group 3|n=11 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10^10 vp
32965299|NCT05301504|Experimental|Group 4|"n=25 participants vaccinated with a two doses of ChAdOx1 biEBOV at the final selected dose, based on safety data for groups1-3. The second dose is administered after 12 weeks.~Note:The dose for group 4 will be selected following a review of safety data to 28 days post vaccination for all previous participants (groups 1 to 3"
33410302|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
33410303|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
32965300|NCT05300256|Experimental|Peripheral Heating|Peripheral Heating
32965301|NCT05300256|Sham Comparator|Sham|Sham
32965302|NCT05286684|Experimental|Study process|Consultation, Cerebral and medullary MRI, lumbar puncture, CSF sampling, blood sample, collection of breast fluid
32965303|NCT05283252|Experimental|Guided Endodontic Micro-Surgery|Use of the 3-D printed guide in endodontic micro-surgery
32965304|NCT05283252|Placebo Comparator|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
32965305|NCT05281614|Experimental|Arm A|Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
32965306|NCT05281614|Experimental|Arm B|Arm B will receive 6 weeks of vedolizumab only. Final study visit at 52 weeks.
32965307|NCT05278494|Experimental|Dextromethorphan|
32965308|NCT05278494|Placebo Comparator|Placebo|
32965309|NCT05267652|Active Comparator|Preoxygenation with Non-Invasive Positive Pressure Ventilation Group|Patients assigned to preoxygenation with non-invasive positive pressure ventilation will receive non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
32965310|NCT05267652|Active Comparator|Preoxygenation with Facemask Oxygen Group|For patients randomized to preoxygenation with facemask oxygen, supplemental oxygen will be administered via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
32965311|NCT05267340|Experimental|Experimental: TARA Training|"Behavioral: Training for Awareness, Resilience, and Action (TARA)~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)"
32965312|NCT05267340|Active Comparator|Control: Psycho-Education|"Behavioral: Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components"
32965313|NCT05265312|Active Comparator|Intervention clinic|Patients with prediabetes seen for routine care at intervention clinic
32965314|NCT05265312|No Intervention|Control clinic|Patients with prediabetes seen for routine care at control clinic
32965315|NCT05251038|Experimental|Experimental Group|"Patients will either receive a combination of:~Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV)~OR~Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel~*The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician"
32965316|NCT05247918|Experimental|Digital-physical care group|Combination of digital and physical care.
32965317|NCT05247918|Active Comparator|Treatment as usual.|Treatment as usual in accordance with national guidelines.
32965318|NCT05246904|Active Comparator|audiologist arm|A research audiologist will fit the participant with the hearing devices according to usual clinical best practice procedures.
32965319|NCT05246904|Active Comparator|self-fit arm|Participants will follow manufacturer's printed instructions to complete the self-hearing test using the hearing aids and a provided app to program their hearing aids.
32965320|NCT05244096||COVID+|COVID + positive individuals from March 15 2020 to Nov 30, 2021
32965321|NCT05240898|Experimental|KSQ-4279 Monotherapy and KSQ-4279 + Combination (Dose Escalation and Expansion)|KSQ-4279 will be administered orally once daily (QD) continuously as monotherapy. Once the maximum tolerated dose (MTD) for KSQ-4279 monotherapy has been reached, KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor) and combination with a platinum-based chemotherapy. These cohorts will be enrolled in parallel.
33321918|NCT01147666|Experimental|Cohort A-1 (Roxadustat 1.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb.
33321919|NCT01147666|Experimental|Cohort A-2 (Roxadustat 1.5 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
32965322|NCT05239338||PREFACE: Vanderbilt-Ingram Cancer Center|Patient recruitment and follow-up, longitudinal collection of data and multiple biospecimen at pre-defined study timepoints, objective assessment of health behaviors/habits, individual interviews.
32965323|NCT05231304||Total Talus Replacement|
32965324|NCT05231304||Total Ankle Total Talus Replacement|
32965325|NCT05231304||Total Ankle Total Talus Replacement + Subtalar Fusion|
33410304|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
32965326|NCT05231304||Total Talus Replacement + Subtalar Fusion|
32965327|NCT05226780|Experimental|NBI-921352|106 week treatment Period
32965328|NCT05225298|Active Comparator|Static frequency|Test based screening for SARS-CoV-2 every two weeks
32965329|NCT05225298|Active Comparator|Dynamic frequency|Test based screening for SARS-CoV-2 ranging from once a week to once every four weeks anchored to county COVID-19 case rates
32965330|NCT05220306|Experimental|Device Arm|Participants will use the MouthLab device for monitoring their vital signs
32965331|NCT05219292||Adult patients followed for a recent lung transplant.|Patients will be recruited during the pre-transplant assessment by the physiotherapist, the pneumologist and/or the transplant nurse coordinator. The patient has the hospital stay of the pre-transplantation to give his answer. The protocol starts on arrival in the rehabilitation department.
32965332|NCT05218980|Experimental|Investigational|Yale Dining menu + 6 olives daily
32965333|NCT05218980|No Intervention|Standard|Yale Dining menu only
32965334|NCT05217498|Experimental|Istradefylline+low oxygen training|"Drug: Nourianz Other Names: KW6002, Istradefylline~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first low oxygen therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
33410305|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
33410306|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
32965335|NCT05217498|Active Comparator|Placebo+low oxygen training|"This is a placebo counterpart to the istradefylline drug.~Participants enrolled in this study arm will ingest a 20mg placebo tablet/day containing dextrose starting 14 days prior to the first low oxygen therapy (LOT) and continuing for 14 additional days. Participants will consume a total of 28 placebo tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
32965336|NCT05217498|Active Comparator|Istradefylline+SHAM|"Drug: Nourianz Other Names: KW6002, Istradefylline~This is a SHAM counterpart to low oxygen therapy.~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first SHAM therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Participants will breathe 15 episodes/session of SHAM via an automated air generator system (4 sessions/week x 2 weeks). The system will fill reservoir bags attached to a non-rebreathing face mask. During the 90-second episodes of SHAM, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
32965337|NCT05206422|Experimental|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
32965338|NCT05206266|Experimental|Turmeric, then Turmeric+Black Pepper|Participants first receive Turmeric (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper) for 1 week. After a 1 week washout, participants then receive Turmeric at the previous amount plus Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper 300mg/subject daily) for 1 week.
32965339|NCT05206266|Experimental|Turmeric+Black Pepper, then Turmeric|Participants first receive Turmeric+Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper at 300mg/subject daily) for 1 week. After a 1 week washout, participants then receive Turmeric daily at the previous amount for 1 week (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper).
32965340|NCT05205486|Experimental|Cefazolin 3gm Injection|Study drug will be administrated as an infusion over 30 minutes starting approximately 0.5 hours before surgery begins and following institutional guidelines on Day 1 (day of surgery). All subjects will have five (5) individual whole blood samples (4 mL each) collected for the estimation of cefazolin concentration in plasma at the following times after the start of the infusion: 0.5 (+/-10 min) end of infusion, 1 h (+/-15 min), 2 h (+/-15 min), 4 h (+/-15 min), and 8 h (+/-15 min).
32965341|NCT05203692|Experimental|DS-7011a|"Stage 1: Healthy participants who will be randomized to receive a single intravenous (IV) ascending dose of DS-7011a (starting dose 0.1 mg/kg).~Stage 2: Healthy participants who will be randomized to receive a single subcutaneous (SC) ascending dose of DS-7011a (starting dose will be centered around estimated therapeutic dose confirmed in Stage 1).~Stage 3: Healthy Japanese participants who will be randomized to receive an IV dose of DS-7011a (based on estimated therapeutic dose confirmed in Stage 1)."
32965342|NCT05203692|Placebo Comparator|Placebo|Healthy participants who will be randomized to receive a single dose of placebo.
32965343|NCT05198310|Experimental|Cohort 1 KPL-404|KPL-404 2mg/kg Subcutaneous (SC) q2wk for 12 weeks
32965344|NCT05198310|Placebo Comparator|Cohort 1 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
32965345|NCT05198310|Experimental|Cohort 2 KPL-404|KPL-404 5mg/kg SC q2wk for 12 weeks
32965346|NCT05198310|Placebo Comparator|Cohort 2 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
32965347|NCT05198310|Experimental|Cohort 3 KPL-404|KPL-404 5mg/kg SC qwk for 12 weeks
32965348|NCT05198310|Experimental|Cohort 3 KPL-404 and Placebo|KPL-404 5mg/kg SC q2wk with alternating weekly administrations of KPL-404 and placebo SC for 12 weeks
32965349|NCT05198310|Placebo Comparator|Cohort 3 Placebo|Placebo for KPL-404 SC qwk for 12 weeks
32965350|NCT05195502||Screening colonoscopy patients|Patients referred for out-patient colonoscopy in the Danish Colorectal Screening program
32965351|NCT05193786|Active Comparator|Low PEEP group|In low PEEP group, the PEEP was 5 cmH2O and inspiratory pressure was 10-20 cmH2O in noninvasive ventilation.
32965352|NCT05193786|Experimental|High PEEP group|In high PEEP group, the PEEP was 10-15 cmH2O and inspiratory pressure was 15-20 cmH2O in noninvasive ventilation.
33410307|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
33410308|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
32965353|NCT05184894|Experimental|AKI in Care Transitions (ACT) Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will participate in the ACT program which provides standardized education and assists with coordination of follow up care after hospital stay.
32965354|NCT05184894|No Intervention|Usual Care Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will receive standard of care from their inpatient and outpatient care teams.
32965355|NCT05181072|Experimental|Enhanced in-person peer-motivation|This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
32965356|NCT05181072|Experimental|Virtual peer-motivation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual.
32965357|NCT05181072|No Intervention|Self-help/Control|The participants in the control group will receive the services already in place, including a brief motivation enhancement session.
32965358|NCT05173428|Experimental|Interventional Gruop|Online motivational interviews based on the transtheoretic model with the intervention group will be held via zoom. Data collection forms will be applied to the intervention group at the first interview, at the 3rd month as an interim monitoring, and at the 6th month as the final monitoring.
32965359|NCT05173428|No Intervention|Control Gruop|No intervention will be made to the control group, and data collection forms will be applied at the first interview and 6 months after the first interview.
32965360|NCT05166018|Experimental|SuMO Patient|"92 data will be collected during the patient care episode. Among the 92 criteria, 63 are pre-operative, 29 are post-operative in order to provide an evolutionary prediction during the management of the patient.~Post-operative follow-up criteria making it possible to establish the scalability or non-scalability of the quality of life after the surgical procedure.~The results will be compared to the prediction proposed by the machine learning algorithm."
32965361|NCT05151822|Experimental|Virtual reality mask|"Realization of the following examinations with virtual reality mask :~Training session~Acceptability of the device before and after surgery~Monitoring of the device during surgery"
32965362|NCT05151666|Experimental|Hemodialysis Patients|
32965363|NCT05150340|Experimental|Epoch 1: TAK-771 Ramp up Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI will be increased from 1/3 of full dose to full dose in 3 weeks for participants who will receive TAK-771 once every 3 week, or from 1/4 of full dose to full dose in 6 weeks for participants who will receive TAK-771 once every 4 week.
32965364|NCT05150340|Experimental|Epoch 2: TAK-771 Treatment Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 24.
32965365|NCT05140044|Active Comparator|Home - Paper Intervention|Older adults who are given a 4-week paper-based balance intervention program. Performed 3days/week for 30min/day over the course of a 4-week period using printed materials with text instruction and images.
32965366|NCT05140044|Experimental|Home - Smartphone Intervention|Older adults who are given a 4-week home-based balance exercise program. Performed 3days/week for 30min/day over the course of a 4-week period using participants' smartphones.
32965367|NCT05133336|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
32965368|NCT05133336|Experimental|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
32965369|NCT05133336|Placebo Comparator|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
32965370|NCT05132478|Active Comparator|Standard Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITHOUT emotionally supportive statements
32965371|NCT05132478|Experimental|Emotionally Supportive Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITH emotionally supportive statements
32965372|NCT05132088|Experimental|oral semaglutide 50 mg once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
32965373|NCT05132088|Placebo Comparator|oral semaglutide placebo once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
32965374|NCT05119764|No Intervention|Control Group|Standard pre- and postoperative physical therapy without manual lymphatic drainage.
32965375|NCT05119764|Experimental|Manual lymphatic drainage before and after knee replacement|Manual lymphatic drainage before and after knee replacement
32965376|NCT05119764|Experimental|Manual lymphatic drainage after knee replacement|Manual lymphatic drainage after knee replacement
32965377|NCT05117970|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
32965378|NCT05117970|No Intervention|Control|Patients randomized to control will continue routine practice.
32965379|NCT05103540|Experimental|Intervention|Comprehensive theory-based suicide behavior program
32965380|NCT05103540|No Intervention|Control|No intervention will be given to the group
32965381|NCT05101044|Experimental|Acceptance-based Behavioral Therapy (ABBT) Intervention|All recruited individuals will receive ABBT intervention. ABBT involves 2 sessions delivered within about a week of each other, consisting of a 20-25 minute session 1, and a 10 minute session 2.
32965382|NCT05091372|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over about 30 minutes on Day 1 of each cycle
32965383|NCT05091372|Experimental|Lenalidomide|lenalidomide by mouth every day of each cycle
32965384|NCT05085366|Experimental|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 1, Day 57, and Day 169.
32965385|NCT05085366|Placebo Comparator|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 1, Day 57, and Day 169.
32965386|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
32965387|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
32965388|NCT05071872||Rotarex®S|Treatment performed with Rotarex®S
32965389|NCT05071872||Aspirex®S|Treatment performed with Aspirex®S
32965390|NCT05042700|Experimental|Melatonin-Placebo sequence|50% of the included patients will receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo. The treatments are blinded.
32965391|NCT05042700|Experimental|Placebo-Melatonin sequence|50% of the included patients will receive 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin. The treatments are blinded.
32965392|NCT05035602||Oesophagectomy|Patients who have undergone oesophageal cancer resection.
32965393|NCT05035602||Gastrectomy|Patients who have undergone gastric cancer resection.
32965394|NCT05035602||Control group|A cohort consisting of healthy controls who have not been diagnosed with, or have undergone treatment for oesophageal or gastric cancer.
32965395|NCT05034432|Experimental|Intra-Op Prophylactic VT ablation|Subjects will get ablation procedure as needed if they were determined to be refractory to medical antiarrhythmic control should undergo catheter-based electrophysiology study and ablation on LVAD support
32965396|NCT05034432|Active Comparator|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
32965399|NCT05027646|Experimental|Part 1 - Bioequivalence|Bioequivalence will be measured in approximately 42 healthy male and female subjects at a single center in the US to achieve at least 33 completers.
32965400|NCT05027646|Experimental|Part 2 - Adhesion|Adhesion will be measured in approximately 90 healthy male and female subjects are planned to be enrolled at a single center in the US.
32965401|NCT05006976|Active Comparator|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
32965402|NCT05006976|Experimental|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
32965403|NCT05005728|Experimental|Cohort A - AVPCa|
32965404|NCT05005728|Experimental|Cohort B - HRD/CDK12 PARP - Progressors|
32965405|NCT05005728|Experimental|Cohort C - HRD/CDK12 PARP Naïve|
32965406|NCT05005728|Experimental|Cohort D - MSI-H, MMRD or TMB-H|
32965407|NCT05005728|Experimental|Cohort E - No Targetable Mutations|
32965408|NCT05002140|Experimental|XRD-0394 40 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
32965409|NCT05002140|Experimental|XRD-0394 80 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
32965410|NCT05002140|Experimental|XRD-0394 160 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
32965411|NCT05002140|Experimental|XRD-0394 (Dose TBD)|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
32965412|NCT04988646|Experimental|Acyclovir Tablet|Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water
32965413|NCT04988646|Active Comparator|Zovirax® Tablet|Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water
32965414|NCT04983420|Experimental|non-alcoholic Pilsner|1 L non-alcoholic Pilsner per day for 2 weeks
32965415|NCT04983420|Experimental|non-alcoholic wheat beer|1 L non-alcoholic wheat beer per day for 2 weeks
32965416|NCT04983420|Active Comparator|apple spritzer|1 L apple spritzer per day for 2 weeks
32965417|NCT04983420|Placebo Comparator|lemonade|1 L lemonade per day for 2 weeks
32965418|NCT04973748|Active Comparator|Conrol|Pain: All patients will continue with standard multimodal analgesia (as above) while inpatient. The nursing staff will assess and document pain severity by Likert scale every 4 hours in EPIC, as is standard of care.
32965419|NCT04973748|Experimental|Open Label Conditioning|Conditioning therapy in the Open label conditioning (OLC) group: Patients in the OLC group will receive conditioning therapy with all doses of opioids and placebo. Given reduced sense of smell and taste and administration of medications via nasogastric or gastric tube, taste of the medication will not be a consideration for formulation of placebo. At all times that oxycodone or placebo medication is administered, the patient will undergo conditioning therapy. As described here, the patient will 1) be given time to note the similar color and appearance of the medications and 2) be given simultaneous exposure to a clove oil Sniffin' sticks, which has been shown to stimulate both olfactory and trigeminal chemoreceptors.
32965420|NCT04972110|Experimental|Phase Ib Dose Escalation|Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with Niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with Olaparib
32965421|NCT04972110|Experimental|Phase 2 Expansion Cohorts|Expansion cohort with RP-3500 (camonsertib) + Niraparib and/or Expansion cohort RP-3500 (camonsertib) + Olaparib
32965422|NCT04951206|Active Comparator|Clobetasol Group|Clobetasol propionate 0.05% ointment is the active treatment arm that will be use in women with lichen sclerosus in the study per standard clinical recommendations. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
33033526|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
33033527|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
32965423|NCT04951206|Placebo Comparator|Placebo Group|Placebo ointment is the control treatment arm. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
32965424|NCT04947462|Experimental|Chronically Implanted Neural and Muscular Interface|6 eligible participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
32965425|NCT04926948|Experimental|Treatment (SBRT, immunotherapy)|Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
32965426|NCT04924062|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
32965427|NCT04924062|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
32965428|NCT04912674||Operative|"Inclusion Criteria:~≥18 years old at time of treatment~Patient undergoing a posterior cervical instrumented fusion using the DePuy Synthes SymphonyTM OCT System for the treatment of adult cervical deformity, defined as any of below criteria:~10 degrees of overall cervical kyphosis (measured from C2-C7)~10 degrees of kyphosis across any 1 or 2 cervical segments~10 degrees of scoliosis~C2-C7 SVA >4cm~Plan for surgical correction of cervical deformity in the next 6 months~Willing to provide consent and complete study forms at baseline and follow-up intervals~Exclusion Criteria:~Active spine tumor or infection~Deformity due to acute trauma~Unwilling to provide consent or to complete study forms~Prisoner~Pregnant or immediate plans to get pregnant"
32965429|NCT04911660|Active Comparator|Empagliflozin + Placebo|1 capsule containing 25 mg empagliflozin per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing placebo for 14 days.
33410309|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
33410310|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
32965430|NCT04911660|Placebo Comparator|Placebo + Empagliflozin|1 capsule containing placebo per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing 25 mg empagliflozin for 14 days.
32965431|NCT04905264||Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries|Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded
32965432|NCT04876248|Experimental|Treatment (belantamab mafodotin, lenalidomide)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
33321920|NCT01147666|Experimental|Cohort A-3 (Roxadustat 2.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33321921|NCT01147666|Experimental|Cohort A-4 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33410311|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
33410312|NCT03398148|Placebo Comparator|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
32965437|NCT04854798|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
32965438|NCT04854798|No Intervention|Control Group|Control Group
32965439|NCT04844190|Experimental|Addition of ADM and EndoFLIP to pre-G-POEM evaluation|During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
32965440|NCT04827810|Experimental|Dose -1|Accelerated Phase: - Standard Phase: 5 mg
32965441|NCT04827810|Experimental|Dose 1|Accelerated Phase: 10 mg Standard Phase: 10 mg
33410313|NCT03398148|Experimental|Substudy 1, Induction 1: Open-label Risankizumab Dose 1|Participants receive risankizumab dose 1 administered by intravenous (IV) infusion.
33410314|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
33410315|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
32965442|NCT04827810|Experimental|Dose 2|Accelerated Phase: 20 mg Standard Phase: 20 mg
32965443|NCT04827810|Experimental|Dose 3|Accelerated Phase: 40 mg Standard Phase: 35 mg
32965444|NCT04827810|Experimental|Dose 4|Accelerated Phase: 80 mg Standard Phase: 50 mg
32965445|NCT04827810|Experimental|Dose 5|Accelerated Phase: 160 mg Standard Phase: 65 mg
32965446|NCT04827810|Experimental|Dose 6|Accelerated Phase: 320 mg Standard Phase: 85 mg
32965447|NCT04827732|Experimental|Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
32965448|NCT04827732|Experimental|Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
32965449|NCT04827732|Experimental|Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
32965450|NCT04820946||various episodic mood disturbances patient group|A group of patients with various episodic mood disturbances was used as a clinical case control group.
32965451|NCT04820946||Disruptive Mood Dysregulation Disorder (DMDD) patient group|DMDD patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors.
32965452|NCT04819464|Experimental|Group A: Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).
32965453|NCT04819464|Experimental|Group B: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).
32965454|NCT04819464|Experimental|Group C:Healthy participants|Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.
32965455|NCT04803006|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
33410316|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
33410317|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
33410318|NCT03398148|Experimental|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
33410319|NCT03398148|Placebo Comparator|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
33410320|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
33410321|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
33410322|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
33410323|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
33410324|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
33410325|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
33410326|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
33410327|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
33410328|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
32965456|NCT04803006|Experimental|Arm 2|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
32965457|NCT04803006|Experimental|Arm 3|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
32965458|NCT04789746|Experimental|Running group|Participants that will join the running program.
32965459|NCT04782336|Other|Sample Collection - Symptomatic Patients|The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study
32965460|NCT04764318||Remote patient monitoring for hypertension|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
33033528|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
33033529|NCT01963858|Experimental|Functional relaxation|Functional relaxation
33033530|NCT01963858|Active Comparator|No relaxation|No relaxation
33033531|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
32965461|NCT04764318||Remote patient monitoring with care management|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM. In addition, PCPs will receive lists of candidate patients. Care managers will assist with the outreach to patients to offer RPM when recommended by the PCP, will monitor and support patient use of the remote monitor, and will promote action on the part of the patient or PCP when uncontrolled hypertension is present.
32965462|NCT04764318||Usual care|Medicare patients from non-intervention primary care practices in Northwestern Medical Group will contribute EHR data but will not have any new procedures put in place.
33410329|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
33410330|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
33410331|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
33410332|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
33410333|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
33410334|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
33410335|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
33410336|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
33410337|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
33410338|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
33410339|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
33410340|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
33410341|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
33410342|NCT03374202|Experimental|Group 1|5 x 10 (10) vg/kg IM
33410343|NCT03374202|Experimental|Group 2|5 x 10 (11) vg/kg IM
33410344|NCT03374202|Experimental|Group 3|2.5 x 10 (12) vg/kg IM
33410345|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
33410346|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
33410347|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
33410348|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
33410349|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
33410350|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
33410351|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
33410352|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
33410353|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
33410354|NCT03193333|Experimental|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free~Package description: 5 m multidose dropper bottle.~Placebo (for~Two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
32965463|NCT04761666||static verticalization device|children with severe cerebral palsy (GMFCS IV & V) with static verticalization device
32965464|NCT04761666||non verticalization device|children with severe cerebral palsy (GMFCS IV & V) without static verticalization device
32965465|NCT04754334|Placebo Comparator|Placebo|placebo dosed QD
33410355|NCT03193333|Active Comparator|Concomitant triple therapy group|"Imot Ofteno~Drug substance: Timolol 5 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by Laboratorios Sophia S.A. de C.V.~Alphagan~Drug substance Brimonidine 2 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Allergan, Inc.~Trusopt~Drug substance: Dorzolamide 20 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Merck Sharp and Dohme Corp.~Posology: 1 drop every 12 hours for 90 days"
32965466|NCT04754334|Experimental|ORMD-0801|ORMD-0801 8 mg QD
33410356|NCT03193333|Active Comparator|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
33410357|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
32965467|NCT04749732|Experimental|WalkingPad plus Psychological Intervention - PsyWPad Group|The participants in Experimental Group 1 will receive a prescription of an HBET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
32965468|NCT04749732|Experimental|WalkingPad plus Virtual Assistant - CyberWPad Group|The participants in Experimental Group 2 will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a virtual assistant that will give motivational support.
32965469|NCT04749732|Active Comparator|Paper WalkingPad group - PaperWPad Group|The participants in the Active Control Group will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
32965470|NCT04748796|Experimental|Experimental group|2 days with landiolol IV + usual care
32965471|NCT04748796|Active Comparator|Control group|usual care according to the attending physician and following the guidelines of surviving sepsis campaign.
32965472|NCT04744194|Active Comparator|Nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
32965473|NCT04744194|Experimental|Assisted nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. During this exercise, participants are attached to a weighted pulley cable system via a chest attachment. A sufficient amount of assistance is given to allow the participant to lower to 30 degrees of knee flexion. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
32965474|NCT04732728||Safety Cohort|No intervention will be administered to subjects that comprise the safety cohort.
32965475|NCT04732728||Holter Cohort|No intervention will be administered to subjects that comprise the safety cohort.
32965476|NCT04725084||High Flow Nasal Cannula oxygen therapy treatment|Patients treated only by high flow nasal cannula oxygen therapy
32965477|NCT04725084||Non-Invasive Ventilation treatment|Patients treated by non-invasive ventilation (combined or not with HFNC)
32965478|NCT04725084||Continuous Positive Airway Pressure treatment|Patients treated by continuous positive airway pressure (combined or not with HFNC)
32965479|NCT04715958|Experimental|Diagnostic (CEUS, Definity)|Patients undergo CEUS and receive perflutren lipid microspheres IV over 10-15 minutes before NAC, after 10% of NAC, and after 30% of NAC
32965480|NCT04707846|Experimental|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
32965481|NCT04707846|Active Comparator|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
32965482|NCT04707846|No Intervention|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
32965483|NCT04704258|Experimental|TAVI + Embolic protection|Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI
32965484|NCT04681638|Experimental|Plasma|Pathogen-Reduced Plasma resuscitation
32965485|NCT04681638|Active Comparator|Crystalloid|Standardized crystalloid resuscitation
32965486|NCT04677816|Experimental|Vitamin D Supplementation Group - Deficient Levels|Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
32965487|NCT04677816|Active Comparator|Observational Arm - Vitamin D at Normal Levels|Standard of care neoadjuvant chemotherapy
32965488|NCT04676334|Experimental|Rucaparib|Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision
32965489|NCT04673994||Chronic Stroke|Individuals 40-80 years old who have had a stroke 6 months to 5 years ago.
33410358|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
33410359|NCT05241145|Experimental|IVMED-6Wk|In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)
32965490|NCT04673994||CON|Control group (CON) comprised of age- and sex-matched healthy adults.
32965491|NCT04673994||CONyoung|Healthy, young adult control group (CONyoung) who are age 18-30 years old.
32965492|NCT04661358|Experimental|Fenofibrate 160-mg|
32965493|NCT04661358|Placebo Comparator|Placebo|
33321922|NCT01147666|Experimental|Cohort A-5 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33321923|NCT01147666|Experimental|Cohort A-6 (Roxadustat 1.3 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33321924|NCT01147666|Experimental|Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
32965497|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
32965498|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
32965499|NCT04625946|Experimental|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
32965500|NCT04625946|Other|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
32965501|NCT04625244|No Intervention|Group 1: In-person therapy|Standard of care, in-person therapy with a Certified Hand Therapist (CHT)
32965502|NCT04625244|Experimental|Group 2: Home therapy program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises, starting 4 weeks after surgery.
32965503|NCT04624698|Experimental|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
32965504|NCT04609722|Experimental|intervention group|Solution-Focused Support Program will apply to the participants.
32965505|NCT04609722|No Intervention|control group|No intervention will be applied to the parents in the control group.
32965506|NCT04599816|Active Comparator|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
32965507|NCT04599816|Active Comparator|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
32965508|NCT04599816|Active Comparator|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
32965509|NCT04579380|Experimental|Tucatinib + Trastuzumab (+ Fulvestrant)|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
32965510|NCT04578834|Experimental|LNP023 200mg b.i.d|
32965511|NCT04578834|Placebo Comparator|Placebo to LNP023 200mg b.i.d|
32965512|NCT04572906|Experimental|NTX-001|NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
32965513|NCT04572906|No Intervention|Standard of Care|standard suture neurorrhaphy
32965514|NCT04572204||Conservative group|
32965515|NCT04572204||interventional group|
32965516|NCT04571970|Experimental|Single Arm|6.5 × 10^10 GC/g brain mass of RGX-121
32965517|NCT04566276|Experimental|Adult Cohort 1: 10 µg|12 healthy adults aged 18-55 years will receive 10 µg of the vaccine IM
32965518|NCT04566276|Experimental|Adult Cohort 2: 25 µg|12 healthy adults aged 18-55 years will receive 25 µg of the vaccine IM
32965519|NCT04566276|Experimental|Adult Cohort 3: 50 µg|12 healthy adults aged 18-55 years will receive 50 µg of the vaccine IM
32965520|NCT04566276|Experimental|Elderly Cohort 1 :10 µg|12 elderlies aged 56-75 years will receive 10 µg of the vaccine IM
32965521|NCT04566276|Experimental|Elderly Cohort 2: 25 µg|12 elderlies aged 56-75 years will receive 25 µg of the vaccine IM
32965522|NCT04566276|Experimental|Elderly Cohort 3: 50 µg|12 elderlies aged 56-75 years will receive 50 µg of the vaccine IM
32965523|NCT04566276|Experimental|Phase 2: ChulaCov19 vaccine Dose 50 ug|adults between 18 and 59 years of age will receive 2 IM ChulaCov19 vaccine Dose 50 ug vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
33321925|NCT01147666|Experimental|Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33410360|NCT05241145|Experimental|IVMED-16Wk|In Group 2 (IVMED-16Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
32965524|NCT04566276|Other|Phase 2: Placebo|adults between 18 and 59 years of age will receive 2 IM saline vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
32965525|NCT04563390|Experimental|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
32965526|NCT04563390|Experimental|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
32965527|NCT04563390|No Intervention|WL Control|Waiting list control group.
32965528|NCT04563078|Experimental|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
32965529|NCT04563078|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
32965530|NCT04546230|Experimental|E group|Low-Thoracic Epidural Anesthesia
32965531|NCT04546230|Active Comparator|G group|General Anesthesia
32965532|NCT04535310|Experimental|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
32965533|NCT04534218|Experimental|Experimental|"REGORAFENIB:~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.~METRONOMIC CHEMOTHERAPIES:~Capecitabine: 625mg/m²/orally twice daily continuously for 6 months~Cyclophosphamide: 50 mg per os, daily, for 6 months~ASPIRIN:~75 mg orally and daily until progression"
32965534|NCT04531878|Experimental|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
32965535|NCT04525014|Experimental|RRx-001, Temozolomide and Irinotecan|
32965536|NCT04509414|Experimental|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
32965537|NCT04509414|Active Comparator|midazolam|0.2mg/kg intranasal atomized midazolam
32965538|NCT04480554|Experimental|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
32965539|NCT04480554|Experimental|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
32965540|NCT04480554|Experimental|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
32965541|NCT04475250|Experimental|Tetragraph|
32965542|NCT04456998|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 24 weeks
32965543|NCT04456998|Placebo Comparator|Placebo|Placebo inhaled orally BID over 24 weeks
32965544|NCT04437108|Active Comparator|Li-SWT|Patients will be treated by 8 sessions of Li-SWT with one week interval. This group is subdivided into 3 subgroups according to the approach through which Li-SWT is applied; suprapubic, perineal and combined approaches
32965545|NCT04437108|Sham Comparator|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
32965546|NCT04437108|Active Comparator|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
32965547|NCT04417764|Experimental|TACE combined PD-1 knockout T cell treatment|
32965548|NCT04416984|Experimental|ALLO-501A, ALLO-647|
32965549|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
32965550|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
32965551|NCT04398966|Experimental|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
32965552|NCT04358406|Placebo Comparator|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
32965553|NCT04358406|Active Comparator|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
32965554|NCT04320342|Experimental|BDP/FF/GB - CHF 5993|Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler
32965555|NCT04320342|Active Comparator|BDP/FF - CHF 1535|Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
32965556|NCT04307862|Experimental|ZEP-3Na 0.1%|The ZEP-3Na 0.1% cream will be applied topically twice daily
32965557|NCT04307862|Experimental|ZEP-3Na 1%|The ZEP-3Na 1% cream will be applied topically twice daily
32965558|NCT04307862|Placebo Comparator|Vehicle Control|The Vehicle Control cream will be applied topically twice daily
32965559|NCT04307550|Experimental|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
32965560|NCT04307550|Placebo Comparator|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
33410361|NCT05241145|Placebo Comparator|Placebo|In Group 3 (Placebo), patients instilled IVMED-80 vehicle solution eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
32965561|NCT04299594||sickle cell disease patients|150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study
32965562|NCT04297488|Experimental|INR(oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus)|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
32965563|NCT04240314|Experimental|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
32965564|NCT04218240|Experimental|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
32965565|NCT04218240|Active Comparator|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
32965566|NCT04208412|Experimental|Part 1|Subjects received a single dose of 600 mg KVD900.
32965567|NCT04208412|Experimental|Part 2 - Sequence 1: 600 mg KVD900, Then Placebo|Subjects received a single dose of 600 mg KVD900 to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of placebo to treat the second eligible HAE attack.
32965568|NCT04208412|Experimental|Part 2 - Sequence 2: Placebo, Then 600 mg KVD900|Subjects received a single dose of placebo to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of 600 mg KVD900 to treat the second eligible HAE attack.
32965569|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
32965570|NCT04194996||Operative|"Inclusion criteria:~≥18 years old at time of treatment~Diagnosis of cervical deformity- must meet one or more of the following criteria:~C2-C7 sagittal kyphosis (Cobb > 15o)~T1S-CL > 35o~Segmental cervical kyphosis > 10o between any 2 vertebra between C2-T1 or > 15o across any 3 vertebra between C2-T1~Cervical scoliosis > 10o (Cobb angle must include end vertebra within the cervical spine)~C2-C7 SVA > 4cm~McGregor's slope > 20 degrees or CBVA > 25 degrees~Plan for surgical correction of cervical deformity in the next 6 months"
32965571|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients meeting the following Inclusion Criteria~18 years of age or greater at the time of treatment~Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity~Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)~Complex patients are defined as and meeting any one of the subsequent criteria:~a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment >7cm b. Procedural criteria: i. Posterior spinal fusion > 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age >65 years and minimum 7 levels of spinal instrumentation during surgery"
32965572|NCT04191486|Experimental|T-817MA (448 mg)|
32965573|NCT04191486|Placebo Comparator|Placebo|
32965574|NCT04164732|Experimental|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d|randomized in a 1:1 ratio: LCZ696 to placebo
32965575|NCT04164732|Placebo Comparator|Placebo to LCZ696|randomized in a 1:1 ratio: LCZ696 to placebo
32965576|NCT04156854|Experimental|Subjects with heart failure|Subjects admitted to the hospital for acute decompensation of chronic systolic heart failure will have a Quantitated Blood Volume Analysis blood test done
32965577|NCT04151550|Other|AVG LSM Procedure|Ace Vision Group LSM procedure performed on both eyes.
32965578|NCT04134000|Experimental|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
32965579|NCT04095858|Experimental|Efprezimod alfa Treatment|Efprezimod alfa: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03 mg/kg/day] or by mouth (PO) [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
32965580|NCT04095858|Placebo Comparator|Placebo|Placebo (Saline solution): 100 ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
32965581|NCT04092348||study group|children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
32965582|NCT04092348||control group|healthy age- and sex-matched children without ahistory of any malignancies
32965583|NCT04073862|Other|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
32965584|NCT04057716|Experimental|Sleep restriction followed by extension|Children will spend 8 hours in bed for one week, engage in one week of wash-out, and then spend 11 hours in bed for one week.
32965585|NCT04057716|Experimental|Sleep extension followed by restriction|Children will spend 11 hours in bed for one week, engage in one week of wash-out, and then spend 8 hours in bed for one week.
32965586|NCT04052568|Experimental|Experimental psilocybin|Participants will have up to four doses of psilocybin.
32965587|NCT04052022||1|Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
32965588|NCT04025580|Experimental|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
32965589|NCT04008108|Experimental|Patient with urinary incontinence|Patient with urinary incontinence
32965591|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
32965592|NCT03937986|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
32965593|NCT03937986|Experimental|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
32965594|NCT03937986|Experimental|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
32965595|NCT03937986|Experimental|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
33033532|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
33033533|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
32965596|NCT03911856|Experimental|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
32965597|NCT03911856|Experimental|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
32965598|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDS/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
32965599|NCT03886038|Active Comparator|RA on synthetic or biological DMARDs|RA patients tretad with syntetic or bioloogial DMARDs for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
33410362|NCT05240599|Experimental|Shaker|"Shaker exercises consist of isotonic and isometric contractions of the neck flexor muscles. Participants will be asked to lie on their back with their knees straight. Participants will first wait for 60 seconds by lifting their head and looking at their feet. He will repeat the movement three times in total, resting for 60 seconds in between. Then, the participants will raise their heads again, look at the toes, and put their head back on the bed without waiting. By repeating this movement 30 times in total, the exercise program will be completed.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
32965600|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
32965601|NCT03873402|Experimental|Nivolumab + ipilimumab|
32965602|NCT03873402|Experimental|Nivolumab + ipilimumab placebo|
32965603|NCT03851796|Active Comparator|TEENS+Parents as Coaches|"Parents are taught strategies to support and facilitate child weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on strategies to facilitate healthy weight management in their child(ren). Topics include role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen. They receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents will receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
32965604|NCT03851796|Active Comparator|TEENS+Parent Weight Loss|"Parents are given a weight loss goal of 1-2 lbs/week, and specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
32965605|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
32965606|NCT03835884|Experimental|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
32965607|NCT03835884|Experimental|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
32965608|NCT03835884|Experimental|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
32965609|NCT03835884|Experimental|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
32965610|NCT03815058|Experimental|Safety Run-in Period: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of RO7198457.
32965611|NCT03815058|Active Comparator|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with RO7198457 plus pembrolizumab (Arm B) after confirmed disease progression.
32965612|NCT03815058|Experimental|Randomized Period: Arm B: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of RO7198457.
32965613|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
32965614|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
32965615|NCT03778944|Active Comparator|M group|Mannitol infusion
32965616|NCT03778944|Active Comparator|D group|Dopamine infusion
32965617|NCT03778944|Active Comparator|C group|Adequate hydration
32965618|NCT03760926|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
32965619|NCT03738150|Experimental|Sotatercept|Each participant will receive SOC plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. (Each cycle will be 21 days.) From Cycle 2 through Cycle 9, the dose will be escalated to 0.7 mg/kg SC. Dosing will be every three weeks during the 24-week treatment period and 18-month extension period.
32965620|NCT03733080||1|ages 18 and older
32965621|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
32965622|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
32965623|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
32965624|NCT03660930|Experimental|Treatment (ABI-009, pazopanib)|Participants receive nanoparticle albumin-bound rapamycin IV on days 1 and 8 and pazopanib hydrochloride PO daily on days 1-21. Courses repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
32965625|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
32965626|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
32965627|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
32965628|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
32965629|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
32965630|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
32965631|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
32965632|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
32965633|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
32965634|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965635|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965636|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965637|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965638|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965639|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965640|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
32965641|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
33033534|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
33033535|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
32965642|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
32965643|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
32965644|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
32965645|NCT03567174|Experimental|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
32965646|NCT03567174|No Intervention|Control|No additional services provided.
32965647|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
32965648|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
32965649|NCT03546582|Experimental|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
32965650|NCT03546582|Other|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
32965651|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
32965652|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
32965653|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
32965654|NCT03534180|Experimental|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
32965655|NCT03529110|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).
32965656|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.
32965657|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
32965658|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
32965659|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
32965660|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
32965661|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
32965662|NCT03455868||Sleeve gastrectomy diabetes|70 Men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy
32965663|NCT03455868||Control without obesity or diabetes|30 Men and women who are overweight (without obesity) and without diabetes
32965664|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
32965665|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
32965666|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
32965667|NCT03436368|Active Comparator|GA group|General Anesthesia
32965668|NCT03367572|Experimental|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
32965669|NCT03367572|Experimental|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
32965670|NCT03367572|Experimental|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
33410363|NCT05240599|Experimental|Chin Tuck Against Resistance|"In this exercise, participants have to place an inflatable ball with a diameter of 12 cm between their chin and sternum. This exercise has two subcomponents, isotonic and isometric. In the isometric component, individuals must compress the ball with maximum force between their chin and sternum, hold for 60 seconds, and rest for 60 seconds. One should repeat this isometric component 3 times. In the isotonic parameter, on the other hand, the participants must slowly squeeze the ball between their chin and sternum 30 times with the maximum force they can do. Participants will perform the exercise in an upright sitting position on a back-supported chair.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
32965671|NCT03321630|Other|Lenvatinib & Pembrolizumab|
32965672|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
32965673|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
32965674|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
32965675|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
32965676|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
32965677|NCT03238326|Experimental|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
32965678|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
32965679|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months~Tremelimumab for up to 4 doses/cycles~FOLFOX"
32965680|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
32965681|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
32965682|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
32965683|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
32965684|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
32965685|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
32965686|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
32965687|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
32965688|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
32965689|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
32965690|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
32965691|NCT03055416|Other|Mobile Men App Prototype|Prototype of physical activity mobile app geared for African-American men.
32965692|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
32965693|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
32965694|NCT03042546|Active Comparator|Calcium Sulphate|
32965695|NCT03042546|Active Comparator|PMMA|
32965696|NCT03042546|Active Comparator|Nothing|
32965697|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
32965698|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
33033536|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
32965699|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
32965700|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
32965701|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
32965702|NCT02734602|No Intervention|Single PET scan|Subjects will participate in 1 PET scan (up to 2 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan.
32965703|NCT02734602|Active Comparator|PET scans and ketamine administration|"Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.~Bipolar subjects will not participate in any ketamine arms."
32965704|NCT02734602|No Intervention|PET scans for subjects undergoing ketamine treatment|"For subjects currently undergoing treatment with ketamine. Subjects will participate in 1-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. Baseline scan will occur prior to initiation of ketamine treatment. Subsequent scans will occur after several treatments with ketamine and after completion of treatment.~Bipolar subjects will not participate in any ketamine arms."
32965705|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
32965706|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
32965707|NCT02663622|Experimental|Efprezimod alfa 240 mg|Efprezimod alfa in 240 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
33410364|NCT05240599|Experimental|Chin Closure Against Resistance|This exercise will be performed in the form of closing the chin against the manual resistance to be given from the tip of the mandible, starting from the maximum voluntary mouth opening. In this way, eccentric contact will be created as the suprahyoid muscles will move from the shortest position to the longest position with resistance. Participants will perform the exercise by maintaining the upright posture in the upright sitting position on the back-supported chair.
33410365|NCT05240443|Experimental|Bariatric Surgery + Medical Management for Chronic Kidney Disease|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
32965708|NCT02663622|Experimental|Efprezimod alfa 480 mg|Efprezimod alfa in 480 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
32965709|NCT02663622|Experimental|Efprezimod alfa 960 mg|Efprezimod alfa (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
32965710|NCT02663622|Placebo Comparator|Placebo|Placebo to efprezimod alfa (saline IV injection solution) on day -1 or days -1, 14, and 28 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
32965711|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
32965712|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
33033537|NCT01963936|Experimental|Supreme LMA|
33033538|NCT01963936|Active Comparator|Facial mask|
32965713|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
32965714|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
32965715|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
32965716|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
32965718|NCT02566668||Asthmatic|1 year observational follow-up
32965719|NCT02566668||Non-Asthmatic|1 year observational follow-up
32965720|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
32965721|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
32965722|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
32965723|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
33321926|NCT01147666|Experimental|Cohort A-9 (Roxadustat 2.0 mg/kg)|Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33321927|NCT01147666|Experimental|Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
33321928|NCT01147666|Active Comparator|Cohorts A (Epoetin Alfa)|Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
32965724|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
32965725|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
32965726|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
32965727|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
32965728|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
32965729|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
32965730|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
32965731|NCT02481414|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan
32965732|NCT02481414|Active Comparator|Candin|Four injections (one every 3 weeks) of Candin
32965733|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
32965734|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
32965735|NCT02311374|Sham Comparator|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
32965736|NCT02311374|Sham Comparator|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
32965737|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
32965738|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
32965739|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.8 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
33033539|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
32965740|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.95 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965741|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.98 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965742|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.04 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965743|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.10 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965744|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.14 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965745|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.19 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965746|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.22 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965747|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.24 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
32965748|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
32965749|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
32965750|NCT02037048|Active Comparator|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
32965751|NCT02037048|Experimental|Negative Pathologic Response|Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
32965752|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
32965753|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
32965754|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
32965755|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
33410366|NCT05240443|Active Comparator|Medical Management for Chronic Kidney Disease|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
33410367|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
33410368|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
33410369|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
33410370|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
33033540|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
33410371|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
33410372|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
33410373|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
33410374|NCT03573648|Active Comparator|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
33410375|NCT03573648|Active Comparator|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
33410376|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
33410377|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
32965767|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
32965768|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
32965769|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
32965770|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week~AND, At least one of the following:~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)~Abnormal pH index (pH less than 4 for greater than 6% of study)~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
32965771|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
32965772|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
32965773|NCT01856478|Experimental|afatinib|oral intake, once daily
32965774|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
32965775|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
32965776|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
32965777|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
33321929|NCT01147666|Experimental|Cohort B-1 (Roxadustat 1.5 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
32965780|NCT01659606|Experimental|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; calcineurin-inhibitor/mycophenolate mofetil GVHD prophylaxis
32965781|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
32965782|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
32965783|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
32965784|NCT01345344|Experimental|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
32965785|NCT01345344|Active Comparator|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
32965786|NCT01345344|No Intervention|Healthy Controls|No intervention.
32965787|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
32965788|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
32965793|NCT00819546|Other|Only one arm on this study.|
33033541|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
33033542|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
32965794|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
32965795|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFOS QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
32965796|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFOS QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
32965800|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
32965801|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
32965802|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
33410378|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
33410379|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
32965803|NCT00281658|Experimental|Paclitaxel and Lapatinib (Blinded)|Paclitaxel and Lapatinib (Blinded)
32965804|NCT00281658|Active Comparator|Paclitaxel and Placebo (Blinded)|Paclitaxel and Placebo (Blinded)
32965805|NCT00281658|Other|Open Label - Monotherapy (Extension Phase)|Open Label - Monotherapy (Lapatinib)
32965806|NCT00281658|Other|Open Label - Combination Therapy (Extension Phase)|Open Label - Combination Therapy (Lapatinib and Paclitaxel)
32965807|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
32965808|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
32965809|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
32965810|NCT02417844|Active Comparator|Tamsulosin HCl|
33410380|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
32965811|NCT02417844|Active Comparator|Tamsulosin|
32965812|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
32965813|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
32965814|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
32965815|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
32965816|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
32965817|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
32965818|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
32965819|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
33033543|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
33033544|NCT01964001|Placebo Comparator|Placebo|starch
33033545|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
33033546|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
32965820|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
32965821|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
32965822|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
32965823|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
32965824|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
32965825|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
32965826|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
32965827|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
32965828|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation~Assess inflammation (PBR PET)~Follow Patients"
32965829|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
32965830|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
32965831|NCT02433366||Patients|
32965832|NCT02433366||Physicians|
32965833|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
32965834|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
32965835|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
32965836|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
32965837|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
32965838|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
32965839|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
32965840|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
32965841|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
32965842|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
32965843|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
32965844|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
32965845|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
32965846|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
32965847|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
32965848|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
32965849|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
32965850|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
32965851|NCT02452866|Experimental|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
32965852|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
32965853|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
32965854|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
32965855|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
33321930|NCT01147666|Experimental|Cohort B-2 (Roxadustat 2.0 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage >115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
32965856|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
32965857|NCT02462070|Experimental|IDP-118 Lotion|Lotion
32965858|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
32965859|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
32965860|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
32965861|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
32965862|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
32965863|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
32965864|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
32965865|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
33321931|NCT01147666|Active Comparator|Cohort B (Epoetin Alfa)|Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
33321932|NCT01147666|Placebo Comparator|Cohort B (Placebo)|Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.
33321933|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
33321934|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
32965866|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
32965867|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
32965868|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
32965869|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
32965870|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
32965871|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
32965872|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
32965873|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
32965874|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
32965875|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
32965876|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
32965877|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
32965878|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
32965879|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
32965880|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
33321935|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
33321936|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
33321937|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
33321938|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
33321939|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:~Sign an Information and Authorization form~Demographic data: gender, date of birth, ethnicity~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
33321940|NCT03947502|Experimental|Intervention Group with|Educational intervention in neurobiology of pain
33321941|NCT03947502|No Intervention|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
33321942|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
33321943|NCT03944460|Active Comparator|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
32965881|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
32965882|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
33321944|NCT03944460|Active Comparator|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
33321945|NCT03944460|Active Comparator|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
32965883|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
32965884|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
32965885|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
32965886|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
32965887|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
32965888|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
32965889|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
32965890|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
32965891|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
32965892|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
32965893|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
32965894|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
32965895|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
32965896|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
32965897|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
32965898|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
32965899|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
32965900|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
32965901|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
32965902|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
32965903|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
32965904|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
32965905|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
33321946|NCT03944460|Active Comparator|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
33321947|NCT03944460|Active Comparator|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
32965906|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
33321948|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
32965907|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike at your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
33321949|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
33321950|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
32965908|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of stroke education~45 minutes of upper extremity repetitive arm exercises"
32965909|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
32965910|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
32965911|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
32965912|NCT02500602|Experimental|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
32965913|NCT02500602|Placebo Comparator|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
32965914|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
32965915|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
32965916|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
32965917|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
32965918|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
32965919|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
32965920|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
32965921|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
32965922|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
32965923|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
32965924|NCT02508636|Experimental|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
32965925|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
33410381|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
32965926|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
32965927|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
32965928|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
32965929|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
32965930|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
32965931|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
32965932|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
32965933|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
32965934|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
32965935|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
32965936|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
32965937|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
32965938|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
32965939|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
32965940|NCT02516046|Experimental|Flortaucipir PET Scan|
32965941|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
32965942|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
32965943|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
33410382|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
33410383|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
32965944|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
32965945|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
32965946|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
32965947|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
32965948|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
32965949|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
32965950|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
32965951|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
32965952|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
32965953|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
32965954|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
32965955|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
32965956|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
32965957|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
32965958|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
32965959|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
32965960|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
32965961|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
32965962|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
32965963|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
32965964|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
32965965|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
33321951|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
33321952|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
33321953|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
33321954|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
32965966|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
32965967|NCT02530554|Experimental|CHG Cloth|3 min application time
32965968|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
32965969|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
32965970|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
32965971|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
32965972|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
32965973|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
32965974|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks~Wash-out 14 days~Placebo for 6 weeks"
32965975|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks~Wash-out 14 days~Sitagliptin 100 mg/d for 6 weeks"
32965976|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
32965977|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
32965978|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
32965979|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
32965980|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
32965981|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
32965982|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
32965983|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
32965984|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
32965985|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
32965986|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
32965987|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
32965988|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
32965989|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
32965990|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
32965991|NCT02541942|Other|Collection of specimen|
32965992|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
32965993|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
32861077|NCT04161599|Experimental|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
32861078|NCT04161599|Active Comparator|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
32861079|NCT05609123||Brain dead organ donors|Patients with clinically proven bain death were assigned to the paraclinical confirmatory investigation of the brain death and subsequently accepted into the transplantation program.
32861080|NCT04759235||neoadjuvant chemoradiotherapy of local advanced ESCC|All the patients receive paclitaxel/cisplatin chemotherapy and concurrent radiotherapy. Each patient receives radiation of 41.4 Gy / 23 fractions complied by intensity modulated radiotherapy or volumetric modulated arc therapy. Patients without disease progression after nCRT will be scheduled for surgery and patients with disease progression (PD) will continue to receive chemoradiation or additional treatments. Surgery will be performed 6 to 8 weeks after completion of chemoradiotherapy.
32861081|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
32861082|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
32861083|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
32861084|NCT05608967||G_PREHapp|Experimental group will follow a prehabilitation programme through the PREHapp platform
32861085|NCT05608967||G_Control|Control group will follow a prehabilitation programme according to usual practice
32861086|NCT05608811|Experimental|Social Skills Training-intervention group|"Intervention group: Adolescents in the training group were given 8 sessions of Social Skills Training. At the end of the training, the final evaluation was made. Initial and final assessments were made face-to-face. The training was held via Zoom."
32861087|NCT05608811|Active Comparator|One Session General Social Skills-control group|The control group was informed about general social skills in one session. When the training given to the intervention group was completed, the final evaluation was made. Initial and final assessments were made face-to-face.
32861088|NCT05608655|Experimental|DKutting|DKutting LL Scoring Balloon, DK Medtech Co Ltd
32861089|NCT05608655|Active Comparator|Chocolate|Chocolate Balloon, TriReme Medical LLC
32861090|NCT05608499|Experimental|Duobrii|Duobrii is the study treatment drug. Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii.
32861091|NCT05608499|Placebo Comparator|Placebo|Placebo
33321955|NCT01106664|Placebo Comparator|P|
32861093|NCT05601167|Experimental|JTBC00201 (nirmatrelvir/ritonavir, Skayvira)|Group 1 (n=132) received the study drug nirmatrelvir/ritonavir, tablets 300/100 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
32861094|NCT05601167|Active Comparator|Standard of care|Group 2 (n=132) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
32861095|NCT04126213|Experimental|RSV MAT 60 Group-Mother|Maternal subjects randomized to RSV MAT 60 Group received a single dose of RSV MAT (60 µg) vaccine at Day 1, and were followed up until the study end.
32861096|NCT04126213|Experimental|RSV MAT 120 Group-Mother|Maternal subjects randomized to RSV MAT 120 group received a single dose of RSV MAT (120 µg) vaccine at Day 1, and were followed up until the study end.
32861097|NCT04126213|Placebo Comparator|Control Group-Mother|Maternal subjects randomized to the Control Group received a single dose of Placebo at Day 1, and were followed up until the study end.
32861098|NCT04126213|No Intervention|RSV MAT 60 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 60 Group-Mother) who received a single dose of RSV MAT (60 µg) vaccine during pregnancy.
32861099|NCT04126213|No Intervention|RSV MAT 120 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 120 Group-Mother) who received a single dose of RSV MAT (120 µg) vaccine during pregnancy.
32861100|NCT04126213|No Intervention|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
33321956|NCT01106664|Experimental|E|
32965994|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
33321957|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
33321958|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
33321959|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
33321960|NCT04602156|Experimental|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
33321961|NCT04602156|Active Comparator|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
33321962|NCT04587882|Experimental|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
33321963|NCT04587882|Active Comparator|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
33321964|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
32965995|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
32965996|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
32965997|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
32965998|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
32965999|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
32966000|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
32966001|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
32966002|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
32966003|NCT02549040|Experimental|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
32966004|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
32966005|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
32966006|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
32966007|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
32966008|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
32966009|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
32966010|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
32966011|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
32966012|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
32966013|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
32966014|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
32966015|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
33321965|NCT01363180||Control|
33321966|NCT01363180||Trauma-exposed without PTSD|
33321967|NCT01363180||Trauma-exposed with PTSD|
33321968|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
32966016|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
32966017|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
32966018|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
32966019|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
32966020|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
32966021|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
32966022|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
32966023|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
32966024|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
32966025|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
32966026|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
32966027|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
32966028|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
32966029|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
32966030|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
32966031|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
33321969|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
33321970|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
32966032|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
32966033|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
32966034|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
32966035|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
32966036|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
32966037|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
32966038|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
32966039|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
32966040|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
32966041|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
32966042|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
32861101|NCT05609747|Experimental|TYPE 2 DIABETIC PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
32966043|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
32966044|NCT02577822|Other|Short Stem Group|Short femoral stem
32966045|NCT02577822|Other|Long Stem Group|standard-length stem
32966046|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
32966047|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
32966048|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
32966049|NCT02577978|Other|Medacta Sphere|Ball-and-socket
32966050|NCT02577978|Other|Medacta PS|Cam-and-post
32966051|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
32966052|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
32966053|NCT02583360|Active Comparator|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
32966054|NCT02583360|No Intervention|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
32966055|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
32966056|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
33321971|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
33321972|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
33321973|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
33321974|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
33321975|NCT01104948|Experimental|DA-8031|
33321976|NCT01104948|Placebo Comparator|Placebo|
32861102|NCT05609747|Experimental|HEALTHY CONTROL GROUP PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
32861103|NCT05609513|Experimental|8 HIV clinics randomized to HTN BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
32861104|NCT05609513|Experimental|8 HIV clinics randomized to HTN PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
33104893|NCT05541484|Other|Group A: Usual care followed by usual care plus dapagliflozin|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care, then undergo an insulin withdrawal visit. Subsequently, the Group A patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, followed by an insulin withdrawal visit.
33104894|NCT05541484|Other|Group B: Usual care plus dapagliflozin followed by usual care|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, then undergo an insulin withdrawal visit. Subsequently, the Group B patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily during usual care alone followed by an insulin withdrawal visit.
32861105|NCT05609513|No Intervention|Control Period for all 16 clinics|Outcome data will be collected during the control period prior to intervention roll-out in all 16 clinics.
32861106|NCT02983955|Other|SCI with Tetraplegia|
32861107|NCT05605613|Experimental|PD-1 Antibody in Addition to Bronchial Arterial Chemoembolization|Treated with BACE and PD-1 antibody as induction therapy during which BACE was performed on the first day and PD-1 antibody was given 3-5 days later, then PD-1 antibody was administered at 200mg Q3W as maintenance therapy.
32861108|NCT05605613|Active Comparator|Bronchial Arterial Chemoembolization|Bronchial artery chemoembolization (BACE) is a technique of drug delivery and embolization performed via injecting anti-tumor drugs with drug carriers and implanting the embolization agents into the tumor feeding artery
32861109|NCT05602259|Experimental|Eosinophil detection|Eosinophils will be measured in blood, sputum, bronchoalveolar lavage if available and biopsies.
32861110|NCT03035201||Cocoa extract + multivitamin|2 capsules containing 500 mg/d cocoa extract; daily MTV
32861111|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 500 mg/d cocoa extract; daily MTV placebo
32861112|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
32861113|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
32861114|NCT04393883|Experimental|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
32861115|NCT04393883|Experimental|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
32861116|NCT05604833|Experimental|experimental|they will November progressive muscle relaxation exercise
32861117|NCT05604833|No Intervention|no ıntervention|to be followed without exercise
32861118|NCT04128319|Experimental|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
32861119|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
32861120|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
32861121|NCT05604287|Experimental|SAD: ID119031166M|
32861122|NCT05604287|Experimental|MAD: ID119031166M|
32861123|NCT05604287|Placebo Comparator|SAD: Placebo|
32861124|NCT05604287|Placebo Comparator|MAD: Placebo|
32861125|NCT04273633|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
32861126|NCT04273633|Placebo Comparator|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
32861127|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
32861128|NCT05603975|Active Comparator|EsKetamine Group|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change.~Esketamine Hydrochloride Injection 2ml：50mg"
32861129|NCT05603975|Placebo Comparator|Control Group|
32861130|NCT04122859|Active Comparator|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
32861131|NCT04122859|Active Comparator|Standard of Care Sutures|Conventional sutures used for laceration repair
32861132|NCT05603663|Experimental|Intervention arm|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about their high PRS at the start of the study, calculated the overall CVD risk, and provided counseling and treatment of hypertension and/or high cholesterol if appropriate.
32861133|NCT05603663|No Intervention|Control group #1|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their high PRS only at the end of the study.
32861134|NCT05603663|No Intervention|Control group #2|Young (25-44 years) overweight adults with low (bottom 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their low PRS only at the end of the study.
32861135|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
32861136|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
32861137|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
33104895|NCT04323358|Active Comparator|IOL Master® 700|Biometry will be performed three times consecutively.
33104896|NCT04323358|Active Comparator|Pentacam®|Keratometry will be performed three times consecutively.
32861138|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
32861139|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
32861140|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
32861141|NCT05606783|Experimental|Home blood pressure monitoring|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily~Patients will be scheduled for a one-hour in-person appointment for the initial study visit where informed consent will be obtained, and for the final study visit"
32861142|NCT04121377|Experimental|Resistance exercise program|Early resistance exercise sessions and home program
32861143|NCT05603117|Experimental|Intervention|Participants received a behavioral intervention, CISBAR, via zoom sessions.
32861144|NCT04273399|Experimental|Crohn's Disease|Twelve week jumping based exercise intervention
32861145|NCT04273399|Active Comparator|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
32861146|NCT05608577||Retrospective|Up to 1,750,000 patient admissions (up to 10 years of admissions) from one National Health Service Trust (Hospital group)
32861147|NCT05608577||Prospective Hospital Cohort|Up to 87, 500 will be screened by the digital platform to identify those who may have bled during the recruitment period, of which at least 40 will be approached for their consent to retain their blood samples (collected as part of routine care).
32861148|NCT04129775|Experimental|OTO-413|
32861149|NCT04129775|Placebo Comparator|Placebo|
32861150|NCT04120363|Placebo Comparator|Placebo|single intramuscular injection of 750 mg sesame oil solution on Day 8
32861151|NCT04120363|Experimental|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
32861152|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
32861153|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
32861154|NCT01450033|No Intervention|Control group|Standard of care
32861155|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
32861156|NCT02981173|Active Comparator|Psilocybin High Dose|
32861157|NCT02981173|Active Comparator|Psilocybin Low Dose|
32861158|NCT02981173|Placebo Comparator|Placebo|
32861159|NCT04393961|Other|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
32861160|NCT04393961|Other|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
32861161|NCT04393961|Other|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
32861162|NCT04393961|Other|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
32861163|NCT04125745|Experimental|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
32861164|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
32861165|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
32861166|NCT04394039|Experimental|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
32861167|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
32861168|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
32861169|NCT04122755|Experimental|Cohort1|Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
32861170|NCT04122755|Experimental|Cohort2|Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
32861171|NCT04122755|Experimental|Cohort3|Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
32861172|NCT04122755|Experimental|Cohort4|Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
32861173|NCT04122755|Experimental|Cohort5|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
32861174|NCT04122755|Experimental|Cohort6|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
32861175|NCT04129853|Experimental|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
32861176|NCT04129853|Experimental|Case study|Comparing the cyberlegs xleg with other devices.
32861177|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
32861178|NCT04129697|Active Comparator|Dexamethasone|
32861179|NCT04129697|Active Comparator|Methylprednisolone|
32861180|NCT04129463|Active Comparator|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
32861181|NCT04129463|Active Comparator|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
32966057|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
32966058|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
32966059|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
32966060|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
32966061|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
32966062|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~X-181 reassortant of H1/A/California/7/2009~X-223A reassortant of H3/A/Texas/50/2012."
32966063|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
32966064|NCT05249556|Experimental|GNX|The suspension contains GNX (50 mg/mL), hydroxypropyl methylcellulose, polyvinyl alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, and sodium citrate at pH 3.5 to 4.2, and is sweetened with sucralose and flavored with artificial cherry.
32966065|NCT05249556|Placebo Comparator|Placebo|The PBO suspension consists of titanium dioxide, Avicel® (microcrystalline cellulose and carboxymethylcellulose sodium), sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, sodium citrate and is sweetened with sucralose and flavored with artificial cherry
32966066|NCT05249400|Experimental|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom. The trainer was not allowed to enter the procedure room and touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
32966067|NCT05249400|No Intervention|On-site assistance group|The trainer supervised the trainee's cannulation operation in the procedure room. The trainer was allowed to provide unlimited verbal instructions to the trainee on-site. The trainer was not allowed to touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
32966068|NCT05249244||observation group|huachansu oral preparation (tablet, capsule) was used.
32966069|NCT05249244||control group|huachansu was not used.
32966070|NCT05249166|Placebo Comparator|Control group|Subjects assigned to this arm will follow the habitual recommendations to develop skills for a healthy diet. No specific foods or cooking methods will be applied
32966071|NCT05249166|Experimental|ALINFA group|This group will receive, in addition to the usual recommendations, meals, and foods designed to increase the healthiness of the diet. Foods and meals have been designed to increase the fiber content, decrease sugars and saturated fats, and limit salt intake.
32966072|NCT05248698|Experimental|group 1|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
32966073|NCT05248698|Active Comparator|group 2|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
32966074|NCT05248542|Experimental|Virtual Reality group|Each participant in the experimental group received a 30 minutes of individualized VR-based simulation education in a dedicated oral skills training room.
32966075|NCT05248542|No Intervention|Control group|The control group only received repeated questionnaires and did not receive any education about geriatric oral hygiene.
32966076|NCT05248152|Placebo Comparator|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
32966077|NCT05248152|Experimental|Pregabalin|Patients will receive pregabalin 150 mg in the hour before surgery and two intravenous doses of saline before surgical incision.
32966078|NCT05248152|Experimental|Paracetamol and Ibuprofen|Patients will receive a placebo capsule in the hour before surgery and an intravenous dose of paracetamol 1 g and ibuprofen 400 mg before surgical incision.
32966079|NCT05247996|Experimental|"Transcatheter arterial chemoembolization Combined With Target Immune Therapy"|Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and multi-target drugs was used for treatment.
32966080|NCT05247996|Active Comparator|Traditional Systemic Intravenous Chemotherapy Group|Traditional systemic intravenous chemotherapy with GEMOX regimen was used for comparison.
32966081|NCT05247762|Sham Comparator|Sham acupuncture group|Use Wangbuliu Xingzi Paste on the skin, once a week, once for 20 minutes, for 24 weeks.
32966082|NCT05247762|Experimental|Acupuncture group|Use stainless steel needles on the skin, once a week, once for 20 minutes, for 24 consecutive weeks.
32966083|NCT05247684|Experimental|arm 1(AK112)|Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
32966084|NCT05247684|Experimental|arm 2(AK112+Carboplatin/cisplatin + paclitaxel)|Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
32966085|NCT05184348|Active Comparator|Narrow band Ultraviolet B phototherapy group|Patients will be treated with Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.
32966086|NCT05184348|Active Comparator|Acitretin group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months
32966087|NCT05184348|Active Comparator|Acitretin plus Narrow band Ultraviolet B phototherapy group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
32966088|NCT05184348|No Intervention|Control group|30 healthy individuals un related , age, sex , BMI matched with volunteers.
32966089|NCT05132166|Active Comparator|BAT|anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
32966090|NCT05132166|Experimental|DSC|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
32966091|NCT05081388|Experimental|REGN14256 + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1 Phase 3: (Open label) (≥12 and <18 Years)
32966092|NCT05081388|Experimental|REGN14256|Phase 1, Phase 2: Randomized 1:1:1:1:1
32966093|NCT05081388|Experimental|Imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1
32966094|NCT05081388|Experimental|casirivimab + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
32966095|NCT05081388|Experimental|Placebo|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
32966096|NCT04990986|Other|Intervention|The complex intervention will be co-developed during first phase of the study.
32966097|NCT04990986|No Intervention|Control|Half of the group will be included as control and thus not exposed to the intervention.
32966098|NCT04845828|Experimental|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
32966099|NCT04845828|Active Comparator|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
32966100|NCT04808466|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with paclitaxel): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
33321977|NCT04410562|Experimental|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
33321978|NCT04410562|Placebo Comparator|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
33321979|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
33321980|NCT01363336||Group 1|
33321981|NCT01105026|Experimental|bioactive glass|
33321982|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
33321983|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
33321984|NCT03946410|Active Comparator|Screening|Invitation to cardiovascular screening
33321985|NCT03946410|Placebo Comparator|Control|No invitation to cardiovascular screening
33321986|NCT01105104|Other|MedMinder System|
33321987|NCT01105104|Other|MedMinder System - deactivated|
32966101|NCT04808466|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
32966102|NCT04808466|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
32966103|NCT04670640|Experimental|Breath Focus|Participants receiving the breath focus study intervention.
32966104|NCT04670640|Experimental|Vibration|Participants receiving the vibration study intervention.
32966105|NCT04670640|Experimental|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
32966106|NCT04670640|Experimental|Screens Free|Participants receiving the screens free study intervention.
32966107|NCT04597554|Experimental|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
33321988|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
33321989|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
33321990|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
32966108|NCT04597554|Placebo Comparator|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
32966109|NCT04488900|Experimental|CKD-508 Capsule in Single Dose|Single dose of CKD-508 capsules
32966110|NCT04488900|Placebo Comparator|Placebo Capsule in Single Dose|Single dose of Placebo capsules
32966111|NCT04488900|Experimental|CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets
32966112|NCT04488900|Placebo Comparator|Placebo Tablet in Single Dose|Single dose of Placebo tablets
32966113|NCT04488900|Experimental|CKD-508 Tablet in Multiple Dose|Multiple dose of CKD-508 tablets
32966114|NCT04488900|Placebo Comparator|Placebo Tablet in Multiple Dose|Multiple dose of placebo tablets
33321991|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
33321992|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
33321993|NCT01357954|Experimental|Targeted Training|
32966115|NCT04003740|Experimental|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
32966116|NCT04003740|Sham Comparator|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
32966117|NCT03939234|Experimental|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
32966118|NCT03907176|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
32966119|NCT03907176|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
32966120|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
32966121|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
32966122|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
32966123|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
32966124|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
32966125|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
32966126|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1: Phenytoin (loading dose 15-20 mg/kg iv, maintenance doses 150 mg iv twice per day) PLUS one of the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam. Benzodiazepine dosing regimes should be based on national and local protocols for status epilepticus treatment~Step 2: Propofol infusion (with a maximum rate of 8 mg/kg/hour) PLUS a second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3: Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages, treatment should be guided by the EEG pattern."
32966127|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
32966128|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
33321994|NCT01357954|Other|Control|
33321995|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
32966129|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
32966130|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
32966131|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
32966132|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
32966133|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
32966134|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
33321996|NCT01105182||Radiofrequency Ablation|
33321997|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
33321998|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
33321999|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
33322000|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
33322001|NCT04617860|Experimental|WVE-120102 (Dose A)|
32861182|NCT03311555|Experimental|Recurrent PSA-only non-metastatic prostate cancer|Subjects with recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of greater than 0.2 ng/mL and less than 4 ng/mL in the absence of metastatic disease on CT and bone scans.
33104897|NCT04323358|Active Comparator|Casia II®|Keratometry will be performed three times consecutively.
33104898|NCT04323358|Active Comparator|Spectralis Anterion®|Biometry will be performed three times consecutively.
33104899|NCT05539846|Experimental|test group|
33104900|NCT05539846|No Intervention|control group|
32861183|NCT04129307|Experimental|Motor Imagery|
32861184|NCT04129307|Experimental|Double time Motor imagery|
32861185|NCT04129307|Active Comparator|Action observation|
32861186|NCT04129541|Active Comparator|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
32861187|NCT04129541|Active Comparator|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
32861188|NCT04128917|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
32861189|NCT04128917|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
32861190|NCT04128917|Active Comparator|RAPAE01|RAPAE01 Triple Therapy
32861191|NCT04128449|Experimental|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
32861192|NCT04128449|Placebo Comparator|Placebo|sunflower oil (5 dragees)
32861193|NCT04128137|Experimental|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
32861194|NCT04128137|Placebo Comparator|Placebo|placebo of flucortac and same diagram of administration
32861195|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
32861196|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
32861197|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
32861198|NCT04393727|Experimental|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
32861199|NCT04393727|No Intervention|Control|Patients will continue to receive standard therapy
32861200|NCT04127513|Experimental|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
32861201|NCT04127513|Active Comparator|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
32861202|NCT03295643|Other|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
32861203|NCT04128059|Experimental|phase 1, component 1|component 1 of vaccine
32861204|NCT04128059|Experimental|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
32861205|NCT04128059|Experimental|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
32861206|NCT04128059|Experimental|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
32861207|NCT04128059|Placebo Comparator|phase 2, placebo|vaccination with placebo with an interval of 21 days
32861208|NCT04127669|Experimental|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
32861209|NCT04127669|Placebo Comparator|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
32861210|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
32861211|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
32861212|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
33104901|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
33104902|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
32861213|NCT04127357|Other|A - Control|Brushing with 1450 ppm fluoride toothpaste.
32861214|NCT04127357|Experimental|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
32861215|NCT03823261|Experimental|CBT|
32861216|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.~Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);~Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.~Depending on B-TPS data, we establish a digital model for the individual template.~Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.~Delineation of the GTV and design planning .~Connect the source tube and 192Ir high dose rate interorganizational brinotherapy~At the end pressed to stop bleeding."
32861217|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
32861218|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
32861219|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
32861220|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
32861221|NCT02706145|Experimental|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
32861222|NCT02706145|No Intervention|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
32861223|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
32861224|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
32861225|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
32861226|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
32861227|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
32861228|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
32861229|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
32861230|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
32861231|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
32861232|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
32861233|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
32861234|NCT02697253|Experimental|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
32861235|NCT02697253|Experimental|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
32861236|NCT02697253|Placebo Comparator|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
32861237|NCT02697253|Placebo Comparator|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
32861238|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
32861239|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
33410384|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
33410385|NCT03026088|Experimental|Bisoprolol|
33410386|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
32966135|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
32966136|NCT05372562||patients with recurrent macular edema|after intravitreal injection of OZURDEX, patients with macular edema relapse during follow-up were recruited.
32966137|NCT05372562||patients without recurrent edema|after intravitreal injection of OZURDEX, patients without macular edema relapse during follow-up were recruited.
32966138|NCT05372016|Experimental|Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha),0.5mL, three doses, 0,2,6 months
32966139|NCT05372016|Active Comparator|GARDASIL ®9|GARDASIL®9 (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) ,0.5mL, three doses, 0,2,6 months
32966140|NCT05371938|Experimental|Volar Locking Plate|Surgery with volar locking plate
32966141|NCT05371938|Active Comparator|External fixation|Surgery with external fixation
32966142|NCT05371860|Experimental|Omit breast radiation|
32966143|NCT05371782||Derivation cohort|The derivation cohort will comprise about 235,000 patients with dementia, who were admitted to a hospital in Ontario from April 1st, 2009 to December 31st, 2017.
32966144|NCT05371782||Validation cohort|The validation cohort will comprise about 63,000 dementia patients, who were admitted to a hospital in Ontario from January 1st, 2018 to March 31st, 2019.
32966145|NCT05371704|Experimental|Supplementation|In this arm of the study, participants will take 1 multivitamin pill each day for 10 days. If this is the participant's first trial, they will also record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate their diet recorded from their first trial.
32966146|NCT05371704|Other|Control|In this arm of the study, participants will not supplement with any multivitamin. If this is the participant's first trial, they will record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate the diet recorded from their first trial.
32966147|NCT05371392||patient group|
32966148|NCT05371392||control group|
32966149|NCT05371158|Experimental|Online intervention|The experimental condition includes an online psychological intervention with therapist email guidance based on Acceptance & Commitment Therapy (ACT). ACT is a form of Cognitive Behavioral Therapy, which focuses on acceptance of chronic pain in order to be able to perform valuable activities, instead of attempts of avoidance and controlling (Hayes et al., 2012). The main goal of ACT is increasing psychological flexibility, which includes the ability to act effectively according to personal values, with pain. ACT can thereby play a role in creating more realistic expectations regarding expectations of future pain relief. The intervention can be worked through in the participant's own living environment. It consists of 6 modules which can be worked through in 8 weeks.
32966150|NCT05371158|No Intervention|Control condition|The control condition includes a waiting list group that can receive treatment-as-usual. Participants are placed on a waiting list and receive the online psychological ACT intervention without email guidance directly after the first follow-up measurement. Participants placed on the waiting list will not receive the ACT intervention immediately. Participants do have the opportunity to access treatment as usual (TAU). Directly after the first, 3-month follow-up measurement these participants receive the opportunity to follow the intervention without email guidance by a therapist.
32966151|NCT05365854|Active Comparator|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
32966152|NCT05365854|Active Comparator|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
32966153|NCT05365620|Active Comparator|Catheter Suction|Patients in this arm were managed for 8 hours with Catheter Suction whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's
32966154|NCT05365620|Experimental|Mechanical Inexsufflation|Patients in this are were managed for 8 hours with automatic inexsufflation treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with Catheter Suction performed only if signs of airway secretion accumulation manifested
32966155|NCT05362734||fresh embryo transfer|measure: time to live birth
32966156|NCT05362734||cryopreserved embryo transfer|measure: time to live birth
32966157|NCT05362110|Experimental|Experimental|HCP1803-3
32966158|NCT05362110|Active Comparator|Active Comparator|RLD2002
32966159|NCT05361876||Young Male|Healthy men with some sport experience
32966160|NCT05361876||Young Female|Healthy female with some sport experience
33410387|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
33410388|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
33410389|NCT03678948|Active Comparator|Mechanical Debridement|
33410390|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
33410391|NCT03678792|Experimental|Morphine|
32861240|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
32861241|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
32861242|NCT03825289|Experimental|Treatment (trametinib, hydroxychloroquine)|Patients receive trametinib PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32861243|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
32861244|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
32861245|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
32861246|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
32861247|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
32861248|NCT01450423|Experimental|Physical activity|
32861249|NCT01450423|No Intervention|Control|
32861250|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
32861251|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
32861252|NCT03822559|Experimental|DE-111A eye drops|
32861253|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
32861254|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
32861255|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
32861256|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
32861257|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
32861258|NCT04391725|Experimental|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
32861259|NCT04391725|Active Comparator|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
32861260|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
32861261|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
32861262|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
32861263|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
32861264|NCT04273321|Experimental|MP group|
32861265|NCT04273321|No Intervention|Con group|
32861266|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
32861267|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
32861268|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
32861269|NCT01450579|Placebo Comparator|Placebo|Saline
32861270|NCT01450579|Experimental|Dose -1|ASP7373
32861271|NCT01450579|Experimental|Dose -2|ASP7373
32861272|NCT01450579|Experimental|Dose -3|ASP7373
32861273|NCT01450657||Chronic Kidney Failure 3/4|
32861274|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
32861275|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
32861276|NCT04976400|Experimental|test group|Semi-individualized total knee arthroplasty
32861277|NCT04976400|Active Comparator|Control group|Zimmer standard prosthesis total knee replacement
33410392|NCT03678792|Experimental|Tramadol|
33410393|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
32966161|NCT05346276|Experimental|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
32966162|NCT05334342|Experimental|Low-GI Diet|Low Glycemic Index Diet
32966163|NCT05334342|Active Comparator|High-GI Diet|High Glycemic Index Diet
32966164|NCT05306652|Experimental|A - Home based supervised physical exercise|patients will have a home-based physical activity prescription
32966165|NCT05306652|Active Comparator|B- Unsupervised physical exercise|patients will receive a physical activity counselling, without a real prescription and supervision
32966168|NCT05120856|Experimental|Active AAT-App|Participants will receive the active AAT-App.
32966169|NCT05120856|Sham Comparator|Minimal AAT-App|Participants will receive the minimal version of AAT-App.
32966170|NCT05091060|Experimental|Erchonia HLS|635 nanometers (nm) laser application
32966171|NCT04970004||Patients Diagnosed with HSCT-TMA|
32966172|NCT04946214|Other|Smart Water Bottle Intervention Arm|Patients will receive a smart water bottle, then instructed on bowel and bladder preparation for daily standard of care radiotherapy treatments for up to 10 weeks.
32966173|NCT04945122|Experimental|Pitavastatin|Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.
32966174|NCT04945122|Active Comparator|Atorvastatin|Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.
32966175|NCT04873518||Cohort 1|These are the eldest children who entered kindergarten in September 2016.
32966176|NCT04873518||Cohort 2|These children entered kindergarten in September 2017.
32966177|NCT04873518||Cohort 3|These are the youngest children who entered kindergarten in September 2018
32966178|NCT04803630|Experimental|Treatment of depression (thermal therapy)|Patients undergo thermal therapy over 2.5 hours.
32966179|NCT04725396|Experimental|Patients undergoing PVP-assisted MR|PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized).
32966180|NCT04725396|Active Comparator|Patients undergoing conventional (i.e. without PVP) MR|Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR.
32966181|NCT04488822|Experimental|Pexidartinib|
32966182|NCT04445064|Experimental|Arm A: IO102 vaccine|Randomization between arm A and B. Patients in arm A will receive IO102 3 to 4 times prior to curative treatment
32966183|NCT04445064|No Intervention|Arm B: Control group|Randomization between arm A and B
32966184|NCT04445064|Experimental|Arm C: IO103|No randomization. Patients in arm C will receive IO103 3 to 4 times prior to curative treatment
32966185|NCT04417998|Active Comparator|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
32966186|NCT04417998|Active Comparator|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
33410394|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
32966187|NCT04227366|Experimental|Group 1|BCD-089
32966188|NCT04227366|Placebo Comparator|Group 2|Placebo
32966189|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
32966190|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
32966191|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
32966192|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
32966193|NCT03995238|Experimental|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
32966194|NCT03995238|Experimental|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
33410395|NCT03678714|No Intervention|Control|Resting control
33410396|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
32966195|NCT03995238|Active Comparator|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
32966196|NCT03963492|Active Comparator|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
32966197|NCT03963492|Experimental|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
32966198|NCT03945162|Experimental|0.7 mg/cm^2 TLD-1433 Bladder infusion and Photodynamic Therapy|A single instillation of TLD-1433 (at the therapeutic dose of 0.7 mg/cm^2) will be infused intravesically into the bladder for approximately 60 minutes. Photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. Two treatment procedures will be performed, a primary treatment at Day 0 and a secondary treatment at Day 180 post primary treatment.
32966199|NCT03917316||ADHD|
32966200|NCT03917316||Control|
32966201|NCT03869970|Active Comparator|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
32966202|NCT03869970|Active Comparator|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
32966203|NCT03869970|Active Comparator|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
32966204|NCT03869970|Active Comparator|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
32966205|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
32966206|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
32966207|NCT03560466|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
32966208|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
32966209|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
32966210|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
32966211|NCT03376698|Active Comparator|Colchicine 0.5 mg|
32966212|NCT03376698|Active Comparator|Colchicine 0.25 mg|
32966213|NCT03376698|Placebo Comparator|Placebo|
32966214|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
32966215|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
32966216|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
32966217|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
32966218|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
32966219|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
32966220|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
32966221|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
32966222|NCT02868684||mild traumatic brain injury|
32966223|NCT02868684||Healthy controls|
32966224|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
32966225|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
32966226|NCT01382082||subjects with breast cancer|
32966227|NCT01382082||subjects with lymphoma|
32966228|NCT01382082||subjects without cancer|
32966229|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
32966230|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
32966231|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
32966232|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
32966233|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
32966234|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
32966235|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
32966236|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
32966237|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
32966238|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
32966239|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
32966240|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
32966241|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
32966242|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
32966243|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
33410397|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
32966244|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
32966245|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
32966246|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
32966247|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
32966248|NCT05732064|Experimental|Dexmedetomidine and esketamine|Dexmedetomidine 0.5 microgram/kg (100 microgram/ml) and esketamine 0.2 mg/kg (25 mg/ml) are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
32966249|NCT05732064|Placebo Comparator|Normal saline|Same volumes of normal saline are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
32966250|NCT05731986|Active Comparator|Optimal stimulation (for a blood pressure response)|Stimulation will be applied during an orthostatic sit-up challenge, using the profile (stimulation site and parameters) that was chosen in the mapping sessions, for optimal modulation of systolic blood pressure.
33322002|NCT03944226|Experimental|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
33322003|NCT01106820|Active Comparator|Resistance training|
32966251|NCT05731986|Sham Comparator|Sham stimulation|Sham stimulation will be applied during an orthostatic sit-up challenge. Sham stimulation will be delivered at a predetermined spinal location. Stimulation parameters, however, will be different from those chosen for the optimal stimulation, and sensation may be different as well.
32966252|NCT05731830||Takotsubo Syndrome|Patients admitted to the Department of Cardiovascular Sciences of Fondazione Policlinico Universitario A. Gemelli IRCCS with a diagnosis of TTS. TTS will be diagnosed based on the most recent InterTAK Diagnostic Criteria. Myocarditis will be excluded based on clinical presentation (e.g.: previous flu-like symptoms, increased inflammatory biomarkers) and confirmed by cardiac magnetic resonance. We will further include all patients with a confirmed TTS diagnosis made between January 2016 and end of October 2022 (hypothetical beginning of prospective phase).
32966253|NCT05731752|Experimental|HX009|Study treatment: HX009 administered every 2 weeks (14 [±3] days) via intravenous infusion.
32966254|NCT05731674|No Intervention|Control|
32966255|NCT05731674|Experimental|Intervention|
32966256|NCT05731596|Active Comparator|Group 1 (Rosuvastatin group)|Patients will receive Rosuvastatin 20mg/day orally for 3 months
32966257|NCT05731596|Experimental|Group 2 (CoQ10 group)|Patients will receive Coenzyme Q10 100 mg/day orally for 3 months
32966258|NCT05731518|Experimental|SC0245 and irinotecan combination|SC0245 and irinotecan combination are administered one cycle that is consisted of 28 days until disease progression or death or loss of follow-up or withdrawal.
32966259|NCT05731440||Healthy participants|"Drug: [18F]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]-Pittsburgh Compound ([11C]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the [11C]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
32966260|NCT05731440||Participants with mild cognitive impairment|"Drug: [18F]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]-Pittsburgh Compound ([11C]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the [11C]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
32966261|NCT05731206|Experimental|hydrolized protein formula|hydrolysed protein formula
32966262|NCT05731206|Placebo Comparator|Control formula|commercially available hypoallergenic infant formula
32966263|NCT05731050|Experimental|NM8074|All subjects will receive a dose of 15 mg/kg NM8074 every two weeks with a total of 6 doses, from Day 1 to Day 84 during the treatment period.
33322004|NCT01106820|Active Comparator|Relaxation training|
32966264|NCT05730816|Experimental|Magnesium Sulfate|The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).
32966265|NCT05730816|Placebo Comparator|Normal Saline|Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.
32966266|NCT05730738|Active Comparator|dalfampridine|patients received dalfampridine ER 10mg twice daily
32966267|NCT05730738|Placebo Comparator|Placebo|patients received placebo
32966268|NCT05730660|Experimental|Intervention group|
32966269|NCT05730660|Placebo Comparator|Placebo group|
32966270|NCT05725434|Experimental|CT-P47 SC (tocilizumab)|CT-P47 (tocilizumab) by subcutaneous (SC) injection
32966271|NCT05712798||The children with primary ciliary dyskinesia|The children with primary ciliary dyskinesia
32966272|NCT05712798||Healthy controls|Healthy children
32966273|NCT05697276|Active Comparator|Lidocaine|Patients will receive lidocaine
32966274|NCT05697276|Experimental|Bupivacaine|Patients will receive bupivacaine
32966275|NCT05665842|Experimental|Music Application Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be applied.~After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be reapplied."
32966276|NCT05665842|Experimental|Sleep Hygiene Training Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal & Nunes, 2014; Dinis & Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
32966277|NCT05665842|No Intervention|Control Group|No attempt will be made to the adolescents who will be in the control group, and the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied on the same dates in parallel with the education and music application groups.
32966278|NCT05652270|Active Comparator|Goal Attainment Intervention|
32966279|NCT05652270|Active Comparator|Goal Development Intervention|
32966280|NCT05652270|Active Comparator|Goal Development and Tracking Intervention|
32966281|NCT05643768|Experimental|High-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
32966282|NCT05643768|Active Comparator|Low-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
32966283|NCT05629416|Experimental|Cultural safety training and behaviour change intervention|- Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples
32966284|NCT05627388|Other|Dreem 3 System|
32966285|NCT05600088|Experimental|CTS Treatment Arm|active cryotherapy of a single suitable high-risk coronary plaque lesion with CTS device
32966286|NCT05568420||Colorectal Cancer Cohort|"Stool collection prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.)~Blood sample to be collected either prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.) or during surveillance.~Tissue collection will be utilized from clinically indicated diagnostic colonoscopies/biopsies/resections. Non-diagnostically indicated tissue collections will not be performed."
32966287|NCT05568420||Healthy Control Cohort|"Tissue collection of normal colon mucosa will be utilized from clinically indicated colonoscopies or from tissue obtained from a prior colonoscopy, non-diagnostically indicated tissue collections will not be performed. Colonoscopies for indications of IBD, anemia, and/or genetic predisposition will be excluded.~Stool samples will be collected at time of colonoscopy. Samples to be collected either within 3-14 days before or at least 1 month after colonoscopy, to avoid changes in microbiome caused by colonoscopy prep.~Blood samples will be collected at time of colonoscopy.~Risk factor questionnaire will be completed at time of colonoscopy. Will also try to collect stool from healthy control patients; however, if accrual is low after 3-6 months, remainder of cohort will be filled with specimen data from the Human Microbiome Project Data Portal."
32966288|NCT05555082|Experimental|Massage|30 minutes of classical swedish massage given by a certified masseur 10 times monthly during 12 months
32966289|NCT05551728|Experimental|Intervention group|12, 1-hour ESDM-informed caregiver coaching sessions, delivered by non-specialists. Intervention materials and approach have been adapted for the South African context.
32966290|NCT05551728|No Intervention|Delayed intervention control group|Usual care.
32966291|NCT05541120|No Intervention|Living Well with Diabetes|Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.
32966292|NCT05541120|Experimental|Living Well with Diabetes + Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
32966293|NCT05518656|Experimental|Online emotion regulation training version 1|
32966294|NCT05518656|Active Comparator|Online emotion regulation training version 2|
32966295|NCT05515458|Experimental|Normal Renal Function|Subjects with normal renal function will receive a single 48 mg oral dose of Chiglitazar
32966296|NCT05515458|Experimental|Severe Renal Impairment|Subjects with severe renal impairment will receive a single 48 mg oral dose of Chiglitazar
32966297|NCT05496036|Experimental|Pembrolizumab|Study participants will undergo a tumor tissue collection biopsy prior to treatment, followed by one dose of pembrolizumab 400mg, then undergo a curative intent resection of all remaining disease 3 weeks after the initial dose of pembrolizumab. Post-operatively, subjects will receive up to 1 year of pembrolizumab 400mg every 6 weeks.
32966298|NCT05469360|Experimental|NIO752 - Dose A - Cohort 1|A single intrathecal injection of Dose A
32966299|NCT05469360|Placebo Comparator|Matching placebo - Cohort 1|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
32966300|NCT05469360|Experimental|NIO752 Dose B - Cohort 2|A single intrathecal injection of Dose B
32966301|NCT05469360|Placebo Comparator|Matching placebo - Cohort 2|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
32966302|NCT05460702||Luminal A|Breast cancer patients with immunohistochemically luminal A
32966303|NCT05460702||Luminal B|Breast cancer patients with immunohistochemically luminal B
32966304|NCT05460702||Triple negative|Breast cancer patients with immunohistochemically triple negative
32966305|NCT05460702||Control|The absence of any pathology in the breasts of healthy volunteers by mammography and/or ultrasound
32966306|NCT05446272|Experimental|NIV-NAVA|
33322005|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
33322006|NCT04608500|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
32966307|NCT05446272|Active Comparator|NS- NIPPV|
33322007|NCT04608500|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
33322008|NCT01105260||control|group with classical rehabilitation program
33322009|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
33322010|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
33322011|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
32966308|NCT05419674|Experimental|groupA: dual therapy (vonoprazan+amoxicillin)|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
32966309|NCT05419674|Experimental|group B: dual therapy (rabeprazole+amoxicillin)|rabeprazole 10mg tid and amoxicillin 1000mg tid for 10 days
32966310|NCT05419674|Active Comparator|group C: bismuth-containing quadruple therapy|rabeprazole 10 mg bid, colloidal bismuth pectin 200mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 10 days
32966311|NCT05409300|Experimental|BBIBP-CorV|Intramuscular administration of two doses of vaccine at 28 days (+/- 2 days) interval (0.5 mL/dose)
32966312|NCT05386524|Experimental|SBP group|sintilimab 200mg, ivgtt，d1， bevacizumab biosimilar 15mg/kg，ivgtt d1， pegylated liposomal doxorubicin 30mg/m2 d1，q3w
32966315|NCT05357664|Experimental|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
32966316|NCT05357664|Experimental|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
32966317|NCT05350098|Experimental|A dietary intervention of plant-protein based diets|
32966318|NCT05350098|Active Comparator|A dietary intervention of control diets|
32966319|NCT05340426|Experimental|Porcine Kidney (UKidney) transplant|In this phase I single arm study patients with acute renal failure will be transplanted with a porcine xenograft versus a human allograft-after transplantation the best practice standard of care will be followed for monitoring and immunosuppression with the exception of additional monitoring for potential porcine transmitted infections
32966320|NCT05338554|Experimental|pcTBS|The protocol is same as the previous study: pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz using repetitive transcranial magnetic stimulation device . A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
32966321|NCT05338554|Experimental|10HZ rTMS|The protocol is same as the previous study: 10HZ rTMS included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT) using repetitive transcranial magnetic stimulation device , with the inter-train interval being set to 50 seconds (1500 pulses)
32966322|NCT05318040|Experimental|Single ascending dose - CMS121|Subjects will receive a single oral dose of CMS121 under fed conditions.
32966323|NCT05318040|Placebo Comparator|Single ascending dose - placebo|Subjects will receive a single oral dose of placebo under fed conditions.
33322012|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
33322013|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
33322014|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
32966324|NCT05318040|Experimental|Multiple ascending dose - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
32966325|NCT05318040|Placebo Comparator|Multiple ascending dose - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
32966326|NCT05318040|Experimental|Multiple ascending dose - Elderly cohort - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
32966327|NCT05318040|Placebo Comparator|Multiple ascending dose - Elderly cohort - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
32966328|NCT05318040|Experimental|Food Effect - CMS121|On Day 1 of each of 2 treatment periods, a single oral dose of CMS121 will be administered following either a standard high fat/high calorie meal (Treatment A) or an overnight fast (Treatment B), as per each subject's assigned randomization sequence (AB or BA). There will be a washout of at least 7 days between doses.
32966329|NCT05252442||Pre-COVID-19|
32966330|NCT05252442||COVID-19|
32966331|NCT05252442||COVID-19 vaccination roll-out|
32966332|NCT05224986|No Intervention|Variable Schedule|Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.
32966333|NCT05224986|Experimental|Fixed Schedule|Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.
32966334|NCT05214456|Experimental|Interventional group|The interventional group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include dry needling plus sham mobilization for the lumbar spine and routine physiotherapy. The needles will be inserted to obtain local twitch responses, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Sham mobilization for the lumbar spine will be done in the same way as the real mobilization, with the difference that the mobilization will be applied only on the skin surface and less than the first degree of Maitland's mobilization. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
32966335|NCT05214456|Active Comparator|Control group|The control group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include anterior-posterior mobilization based on the Maitland technique for the lumbar spine plus sham dry needling and routine physiotherapy. Based on the findings of the patient evaluation, the severity, rhythm, time, the degree of mobilization and the place of force (spine or lamina) will be determined. For sham dry needling The needles will be inserted subcutaneously and there will be no local twitch response. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
32966336|NCT05195346||People Living with HIV (PLHIV)|Thai people living with HIV, aged 18 or above, who are on Antiretroviral Therapy (ART)
33322015|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
33322016|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
33322017|NCT03944070|Active Comparator|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
33322018|NCT03944070|Active Comparator|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
33322019|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
33322020|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
33322021|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
33322022|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
33322023|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
33322024|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
33322025|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
33322026|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
33322027|NCT05460728|Experimental|Dry needling|
33322028|NCT04585646|Experimental|Orion then Gemini|Subjects will be randomized to wear Orion daily disposable contact lens then Gemini daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
33322029|NCT04585646|Experimental|Gemini then Orion|Subjects will be randomized to wear Gemini daily disposable contact lens then Orion daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
33322030|NCT04074928|Experimental|QIVc|Cell-derived Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
33322031|NCT04074928|Active Comparator|Comparator QIV|Comparator Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
33322032|NCT04584788|Experimental|Healthy Adult Volunteers|Controlled hypoxia will be induced and Masimo O3 regional oximeter-derived tissue oxygen saturation (rSO2) readings of somatic tissue will be measured. The readings will be compared with blood reference oxygen saturation values.
33322033|NCT05460572|Other|Patients undergoing PVI procedure and who are treated with peripheral parental nutrition|Patients undergoing elective PVI procedure who will receive peripheral parental nutrition before start of the procedure.
33410398|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
33410399|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
32861278|NCT04976478||observation group|All patients will be treated with Nimotuzumab combined with radiotherapy.
32861279|NCT01454011|Active Comparator|Testosterone 250mg injection,|
32861280|NCT01454011|Active Comparator|Testosterone transdermal application|
32861281|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
32861282|NCT02979769|Experimental|Palovarotene|"All participants will receive non-flare-up based treatment of 5 mg palovarotene once daily for 24 months.~Participants who continued non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to an additional 48 months (therefore 72 months over the entire study).~Participants who start non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to 48 months.~Participants that are skeletally immature will receive weight-adjusted doses.~In the event of an eligible flare-up all participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days. Participants under the age of 18 years will receive weight-adjusted doses."
32861283|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
32861284|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
32861285|NCT04976088|Experimental|Group A Test|Test product: treated once a day (morning) with the medicated plaster containing 140 mg Diclofenac Sodium for seven days Diclofenac Sodium 140 mg medicated plaster
32861286|NCT04976088|Active Comparator|Group B Reference|Reference product: treated once a day (morning) with the medicated plaster containing DIEP 180 mg, Flector® for seven days Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®
32861287|NCT04976088|Placebo Comparator|Group C Placebo|Placebo: treated once a day (morning) with the placebo plaster for seven days
32861288|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
32861289|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
32861290|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
32861291|NCT04975854|Experimental|Virtual Reality Exposure|Participants complete three 30-40-minute sessions of exposure administered via a virtual reality headset. The exposure involve exposure to various heights and height cues in the virtual city environment. Experimental group also attends 20-minute online information session (prerecorded video).
32861292|NCT04975854|Other|Control|Control group attends a single 20-minute information session (prerecorded video) about general principles of exposure therapy and anxiety before the start of the study, but receives no exposure-based intervention.
32861293|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
32861294|NCT04975932||Study group: TACE+ICIs|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs
32861295|NCT04975932||Control group: TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
32861296|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
32861297|NCT04968132|Active Comparator|Standard care group|This group will receive standard perioperative care, surgical treatment, and pain medications.
32861298|NCT04968132|Experimental|Opioid reduction group|Patients will participate in a multicomponent pathway coordinated by a trained coordinator who will facilitate patient participation and engagement with each interventional component.
32861299|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32861300|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32861301|NCT04968444|Active Comparator|one to one traditional physiotherapy|For clarity, 1-1 physiotherapy takes the form of a private consultation between patient and therapist. A discussion of symptoms is had and an individual physical examination is undertaken to explore what is mechanically causing their pain and what can be offered to help. This is also when the initial outcome scores are taken. Treatments are then offered which can take the form of exercise therapy, massage, and manual therapy. Symptoms are regularly monitored for effectiveness of treatment and adjusted accordingly. The number of sessions that forms their treatment is variable depending on response to treatment and how they are coping. At the final session the end outcome scores will be taken.
32966337|NCT05195346||HIV Healthcare Providers|Thai healthcare providers, including but not limited to doctors, nurses, counsellors, lay providers, pharmacists, lab technicians, etc., who take care of any persons living with HIV. All aged 18 or above
33322034|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~a BW of less than 1501 gram (g)~born at a GA of 34 weeks (wk) or less and~selected infants with an unstable clinical course were included"
33322035|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
33322036|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
33322037|NCT05460494|No Intervention|Usual Care|Usual care for AD/ADRD care partners consists of a screen for stress and burden, an evaluation of needs for resources to support the patients, and a referral to AD/ADRD support agencies.
32966342|NCT05093400||Normal Saliva|"saliva from normal healthy adults."
32966343|NCT05044182|Experimental|Decompression and drainage seton|Decompress the pressure in intersphincteric space,and drainage seton will be put around the external anal sphincter.
32966344|NCT05044182|Experimental|Cutting seton|Cutting seton will be put around the internal and external anal sphincter.
32966345|NCT05024994|Experimental|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
32966346|NCT05016024|Other|Colilen IBS + Placebo|First Period: Colilen IBS Second Period: Placebo
32966347|NCT05016024|Other|Placebo + Colilen IBS|First Period: Placebo Second Period: Colilen IBS
32966348|NCT05010564|Experimental|Autologous TriCAR T-Cells and lymphodepletion chemotherapy|Three dose levels will be evaluated. The TriCAR T-cells will be administered after lymphodepletion chemotherapy with Cyclophosphamide and fludarabine.
32966349|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)|Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.
32966350|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)|Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.
32966351|NCT04998396|Experimental|Enrollment Expansion Phase: BBP-812|Participants will receive a single IV infusion of BBP-812 at the selected dose from the dose-finding phase on Day 0 in expansion phase of the study.
32966352|NCT04986540|Experimental|Cohort 1|A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects
32966353|NCT04986540|Experimental|Cohort 2|A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects
32966354|NCT04986540|Experimental|Cohort 3|A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects
32966355|NCT04986540|Experimental|Cohort 4|A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects
32966356|NCT04986540|Experimental|Cohort 5|A single subcutaneous injection of SHR-1906/placebo dose 5 in healthy subjects
32966357|NCT04986540|Experimental|Cohort 6|A single subcutaneous injection of SHR-1906/placebo dose 6 in healthy subjects
32966358|NCT04965714|Experimental|Treatment (nivolumab, pegargiminase)|Patients receive nivolumab IV over 30 minutes on day 1 and pegargiminase IM at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. A cycle is 14 days.
32966359|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
32966360|NCT04905654|Active Comparator|Levcromakalim|
32966361|NCT04905654|Placebo Comparator|Saline|
32966362|NCT04787562|Experimental|Cohort 1: normal renal function|Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
32966363|NCT04787562|Experimental|Cohort 2: Mild renal insufficiency|Participants with an eGFR 60 to <90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
32966364|NCT04787562|Experimental|Cohort 3: Moderate renal insufficiency|Participants with an eGFR 30 to <60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
32966365|NCT04787562|Experimental|Cohort 4: Severe renal insufficiency|Participants with an eGFR 15 to <30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
32966366|NCT04787562|Experimental|Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy|Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
33327450|NCT05597800|Experimental|Cohort C: Long COVID syndrome|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as Long Covid syndrome in Cohort C.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
33327451|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
32966369|NCT04780698|Experimental|Study Cohort|
32966370|NCT04762368|Active Comparator|Active + Training|Participants in this arm will be exposed to active stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
32966371|NCT04762368|Sham Comparator|Sham + Training|Participants in this arm will be exposed to sham stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
32966372|NCT04708782|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
33327452|NCT05597644|Experimental|females with adenomyosis|
32966373|NCT04708782|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
33410400|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
32966374|NCT04669236|Experimental|Intervention group|Intervention promoting healthy sleep behaviour in adolescents based on a participatory health research approach. Based on participatory session, the pupils of the action group will develop the intervention. They will participate in every step of the development to maximize their input.
32966375|NCT04669236|No Intervention|Control group|Participants in the control group will receive no intervention.
32966376|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
32966377|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.
32966378|NCT04293198||control arm|Cryoballoon PVI procedure where the freeze was initiated based on the occlusion assessed using fluoroscopy
32966379|NCT04293198||Kodex arm|Cryoballoon PVI where the freeze was initiated based on the outcome of the KODEX occlusion Viewer
32966380|NCT04266912|Experimental|Treatment (avelumab, M6620)|Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32966381|NCT04240392|Experimental|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
32966382|NCT04240392|Active Comparator|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
32966383|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
32966384|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
32966385|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
32966386|NCT04153422|Experimental|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg IVIG every 4 weeks (over 2 days, 1g/kg dose on Day 1 and 1g/kg dose on Day 2) for 24 weeks (6 doses total).
32966387|NCT04153422|Placebo Comparator|Placebo|Patients in the placebo arm will receive 0.9% NaCl infusions on the same schedule as the active treatment group (Day 1 and Day 2 every 4 weeks for 24 weeks total, (6 doses).
32966388|NCT04137510|Experimental|Orsiro|
32966389|NCT04137510|Active Comparator|Resolute Onyx|
32966390|NCT04116996|Experimental|Adults with Parkinson's disease and severe insomnia|1 arm study
32966391|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.~Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
32966392|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966393|NCT04107168||Cohort 3|Disease: Advanced renal cell carcinoma. Anti-PD-(L)1 + kinase inhibitor. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966394|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966395|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966396|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
33327453|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
33327454|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
33410401|NCT03676608|Active Comparator|Control|Usual educational care.
32966397|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966398|NCT04107168||Cohort 8|Disease: Resected renal cancer Anti-PD-(L)1 monotherapy (Durvalumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966399|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
32966400|NCT04022850|Active Comparator|Passive dissemination|Passive dissemination strategies focused on the distribution of materials, support tools and training
32966401|NCT04022850|Experimental|Intuitive de-implementation|Mindless externally imposed de-implementation strategies to discourage the non-desired behavior and to encourage the preferred/desired behavior
32966402|NCT04022850|Experimental|Reflexive de-implementation|Active de-implementation strategies targeting conscious cognition processes to discourage the non-desired behavior and to encourage the preferred/desired behavior
32966403|NCT03958344|Experimental|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
32966404|NCT03958344|Active Comparator|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
32966405|NCT03901950|Experimental|XNW7201|
32966406|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
32966407|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
32966408|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
32966409|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
32966410|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
32966411|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
32966412|NCT03740490|Experimental|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
32966413|NCT03740490|Active Comparator|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
32966414|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
32966415|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
32966416|NCT03712410|Active Comparator|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
33410402|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
32966417|NCT03712410|Experimental|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
33410403|NCT03678558|No Intervention|Vitrification medium with no supplementation|
33410404|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
32966418|NCT03712410|Experimental|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.~The third session will also take place via video."
32966419|NCT03712410|Experimental|Group 4 (PISCESplus online)|Participants in this group receive the PISCES plus intervention (the PISCES intervention with the enhancement of the positive reappraisal elements) delivered fully online. All assessments and sessions take place online.
32966420|NCT03139344|Experimental|Acute gene regulation: low frequency|Adaptations in gene regulation in response to single-session low-frequency exercise.
32966421|NCT03139344|Experimental|Acute gene regulation: high frequency|Adaptations in gene regulation in response to single-session high-frequency exercise.
32966422|NCT03139344|Experimental|Training study: low frequency|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with low-frequency exercise.
32966423|NCT03139344|Experimental|Training study: high frequency|Adaptations in gene regulation in response to training with high-frequency exercise.
32966424|NCT03139344|No Intervention|Comparator cohort|Participants will undergo selected outcome measures to provide comparison values for Experimental arms.
32966425|NCT02960646|Experimental|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
32966426|NCT02909556|Experimental|ACURATE neo AS|
32966427|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
32966428|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
32966429|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
32966430|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
32966431|NCT02678832||Cancer patients|breast cancer prostate cancer colorectal cancer
32966432|NCT02678832||Physicians|working in in- and outpatient care
32966433|NCT02678832||Oncology nurses|working in in- and outpatient care
32966434|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
32966435|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
32966436|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
32966437|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
32966438|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
32966439|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
32966440|NCT02432196|Experimental|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
32966441|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
32966442|NCT02022384||study patients|Blood sample and life quality questionnaires
32966443|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
32966444|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
32966445|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
32966446|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
32966447|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
33410405|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
32966448|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
32966449|NCT00853632|Other|Device - CEP Mitral Valve|
32966450|NCT00074412|Experimental|2A|For infants: extended treatment with NVP
32966451|NCT00074412|Placebo Comparator|2B|For infants: extended treatment with NVP placebo
32966452|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
32966453|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
32966454|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
32966455|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
32966456|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
33410406|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
33410407|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
32966457|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
33410408|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
32966458|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
32966459|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
32966460|NCT02621892|Experimental|50mg BID|Tenapanor
32966461|NCT02621892|Placebo Comparator|Placebo|Placebo
32966462|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
32966463|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
32966464|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
32966465|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
32966466|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
33410409|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
33410410|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
33410411|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
33410412|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
33410413|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
33410414|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
33410415|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
33410416|NCT03117985|Experimental|Antiretroviral therapy|Stopping antiretroviral therapy
33410417|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
32966467|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
32966468|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
32966469|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
32966470|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
32966471|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
32966472|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
33410418|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
33410419|NCT03672708|Other|Cresyl violet|
32966473|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
32966474|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
32966475|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
32966476|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
32966477|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
32966478|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
32966479|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
32966480|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
32966481|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
33410420|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
33410421|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
33410422|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
32966482|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
32966483|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
32966484|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
32966485|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
32966486|NCT05588778|Experimental|BAILAMOS™ @home/en casa|The BAILAMOS™ @home/en casa dance program is provided twice weekly for 24 weeks. Each month a new dance style is introduced by a professional dance instructor.
32966487|NCT05588778|Experimental|¡En Forma y Fuerte! @home/en casa|¡En Forma y Fuerte! @home/en casa is an exercise and health education program designed to improve arthritis-related outcomes. The classes will meet two times per week for 90 min each for 12 weeks. Each class session consists of 60 min of exercise (flexibility, aerobics and strength training) and 30 minutes of health education using group problem solving based on SCT.
32966488|NCT05588622|Experimental|Treatment Group|This single-arm study will enroll all 20 participants in the Meru Health Program.
33410423|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
33410424|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
32966489|NCT05588544|Active Comparator|SRP only|Periodontal treatment by scaling and root planning
32966490|NCT05588544|Experimental|SRP + laser|Periodontal treatment by Laser-assisted scaling and root planning
32966491|NCT05588076||normal endometrial|
32966492|NCT05588076||endometrial lesions|
32966493|NCT05587920||Non-hormonal contraceptive users|Women not using any form of hormonal contraceptive.
32966494|NCT05587920||Combined oral contraceptive pill users|Women using the oral combined oral contraceptive pill.
32966495|NCT05587920||Hormonal IUS|Women using the hormonal intrauterine system contraceptive.
32966496|NCT05587920||Hormonal implant|Women using the hormonal contraceptive implant contraceptive.
32966497|NCT05587920||Hormonal injection|Women using the hormonal injection contraceptive.
33033547|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
33410425|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
33410426|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
33410427|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
33410428|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
33410429|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
32966498|NCT05587842|Active Comparator|Non-weightbearing Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to continue non-weightbearing w/ crutches. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, the subject will continue with non-weightbearing and follow range of motion instructions. After 6 weeks, the subject will begin weightbearing as tolerated. Instructions for limited range of motion to be given, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
32966499|NCT05587842|Experimental|Early weightbearing (as tolerated) Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, subject will continue with weightbearing as tolerated in orthosis, following range of motion instructions. After 6 weeks, the subject will continue with weightbearing as tolerated, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
32966500|NCT05587686||Intubated patient during their stay in the IUCPQ-UL emergency or intensive care department|
32966501|NCT05587218|Experimental|Self-production|L2 lexical items self-produced at learning
32966502|NCT05587218|Active Comparator|Perception|L2 lexical items heard or observed an additional time at learning
32966503|NCT05585658|Active Comparator|Erythropoietin alpha Eprex®|Group/cohort/Arm 1 (participating 21 volunteers): Eprex® injection 4,000 IU will be administered subcutaneously on Day 1; and wash out for 4 weeks. GBPD002 injection 4,000 IU/1 mL will be administered subcutaneously on Day 29.
32966504|NCT05585658|Experimental|Erythropoietin alpha, GBPD002|"Group/cohort/Arm 2 (participating 21 volunteers):GBPD002 PFS (Pre-Filled Syringe) 4,000 IU/ 1 mL (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 1.And wash out for 4 weeks (28 days from the 1st injection day). Eprex® inj. (Injection) 4,000 IU (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 29.~Total 42 volunteers participated in the clinical trial."
32966505|NCT05584098|Other|qSOFA and MEWS|Modified Early Warning Score(MEWS) and quick Sequential Organ Failure Assessment(qSOFA) are used in prediction of occurrence of sepsis
32966506|NCT05533242|Experimental|Lu-177-labeled-6A10Fab-fragments|The patient will receive a predetermined dose of Lu-177-labeled- 6A10Fab-fragments via the intracavitary reservoir. Patients will receive 3 RIT-cycles with an interval of 4 weeks. The total activity, adjusted to the volume of the RC, will be injected in 3 fractions with 50%, 25% and 25% of the total activity to achieve the desired boost to the 2 cm margin.
32966507|NCT05522634|Experimental|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
32966508|NCT05510856|Experimental|Duloxetine|group 1
32966509|NCT05510856|Experimental|Gabapentin|group 2
32966510|NCT05510856|Experimental|Lacosamide|group 3
32966511|NCT05462028|No Intervention|control group|Only received conventional therapy comprised of standardized treatment and regular rehabilitation (i.e., postural training, facilitation techniques, stretching exercise, and strengthening exercise) prescribed by a rehabilitation physician and performed at 3 to 6 days after admission for five 60-minute sessions per week by the physical, occupational, and speech therapists in the rehabilitation center of the medical center.
32966512|NCT05462028|Placebo Comparator|exercise group|The exercise group will receive extra 5 days of 30-minute lower-limb ergometer exercise training in addition to the conventional therapy.
33410430|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
33410431|NCT03259074|Experimental|AIN457 150 mg/placebo|AIN457 150 mg and a matching placebo was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
32966513|NCT05462028|Sham Comparator|wearable leg vibration training group|The wearable leg vibration training group will receive extra 5 days of 30-minute wearable leg vibration of lower limbs combined with 30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
32966514|NCT05462028|Experimental|lower-extremity weight bearing vibration training group|The lower-extremity weight bearing vibration training group will receive extra 5 days of 30-minute lower-extremity weight bearing vibration combined with30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
32966515|NCT05403138|Experimental|Daratumumab|Induction Period: Participants received daratumumab (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received daratumumab (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
33033548|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
33410432|NCT03259074|Experimental|AIN457 300 mg|AIN457 300 mg (2 x 150 mg) was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
33410433|NCT03259074|Active Comparator|GP2017 40mg|GP2017 (adalimumab biosimilar) 40 mg was administered subcutaneously via pre-filled syringes at Baseline followed by dosing every 2 weeks until Week 102
33410434|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
33410435|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
33410436|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
32966516|NCT05403138|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received matching placebo (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
32966517|NCT05393466|Experimental|Phase Ia Dose Escalation|The number of patients enrolled will be determined based on the maximum number required to establish the RP2D according to a Bayesian Optimal Interval (BOIN) method and will depend on the true DLT rate. Up to 24 patients will be enrolled for the dose-finding part.
32966518|NCT05393466|Experimental|Phase Ib Expansion Study|Based on clinical data obtained from Part 1a, up to 24 patients with advanced NSCLC harboring EGFR C797S mutation will be enrolled in this dose expansion part of the study. One or more dose levels may be investigated dependent on emerging data. The sample size will be determined based on practical considerations.
32966519|NCT05393466|Experimental|Phase II Study|The phase II part will be conducted using a Bayesian Optimal Phase 2 (BOP2) method with efficacy monitoring based on cumulative information on Objective Response Rate (ORR). The BOP2 method will consist of 2 interim looks occurring when the number of evaluable patients reaches the pre-specified values of 10 and 20 and a final analysis when a total of 30 patients are evaluable.
32966520|NCT05281770||Erenumab|Patients will be treated with this drug within standard of care treatment
32966521|NCT05281770||Galcanezumab|Patients will be treated with this drug within standard of care treatment
32966522|NCT05281770||Fremanezumab|Patients will be treated with this drug within standard of care treatment
32966523|NCT05225610|Experimental|VALSALVA Group|40 Patients will perform the Valsalva manoeuvre before starting propofol injection by blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds and 5 ml saline will be administered in 5 seconds.
32966524|NCT05225610|Experimental|DEXMED Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group, patients will receive 0.5 µg/kg Dexmedetomidine diluted in 5 ml saline in 5 seconds as a sedating dose prior to injection of propofol.
32966525|NCT05225610|Placebo Comparator|CONTROL Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group and only 5 ml saline will be administered over 5 seconds.
32966526|NCT05209386|Experimental|Patient Participants|"This single-group study will recruit patients through the PI's clinical practice who are undergoing invasive neurophysiological monitoring (sEEG) with clinically necessary placement of electrodes in the supratemporal plane.~All participants will complete the same behavioral response paradigms."
33410437|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
32966527|NCT05185830|Experimental|Interactive robot|Children in the interactive robot will be mobilized for the first time with interactive robots.
32966528|NCT05185830|No Intervention|Control group|Children in the control group will be mobilized with nurses
32966529|NCT05150652|Experimental|Neoadjuvant Endocrine Therapy|Participants will begin treatment with Anastrozole. If not tolerated well, participants will discontinue and begin treatment using Letrozole. If not tolerated well, participants will discontinue and begin treatment using Exemestane. If not tolerated well, participants will discontinue and begin treatment on Tamoxifen.
32966530|NCT05133024|Active Comparator|beetroot juice|Brand: BEET IT sport NITRATE 400 concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
32966531|NCT05133024|Placebo Comparator|nitrate-depleted beetroot juice|Brand: BEET IT sport NITRATE 400 nitrate-depleted concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
32966532|NCT05079906|Other|Main study arm|All subjects will have their SFA lesion assessed with FFR measurement.
32966533|NCT05079906|Other|Sub-study|Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
32966534|NCT05069142|Experimental|Intervention group|15 participants will be randomly selected to the intervention group. These individuals will receive six weeks of pre-operative exercise instruction and education, as well as six weeks of graduated post-operative exercise instruction, beginning at three weeks post-op with the surgeons clearance.
32966535|NCT05069142|No Intervention|Control group|15 participants will be randomly selected to the control group. This group will receive pre-operative education in the form of videos regarding the procedure and pain. They will not receive exercise instruction.
32966536|NCT05058300||Patients with Chest Pain|An unselected patient-population with chest pain in emergency department
32966537|NCT04956354||Phase 1|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for 8h during daytime, for 4 consecutive days. In addition, photographs of the skin at the site of placement of the sensors will be taken before sensors placement and after removal.~Hourly axillary temperature measured by the bedside nurse (as part of routine care) will be manually recorded for each patient by the research team. A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
32966538|NCT04956354||Phase 2|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for a longer monitoring period - i.e., 96 consecutive hours. In consideration with device battery life, the devices will be replaced daily. In addition, photographs of the skin at the site of placement of the sensors will be taken at baseline, device replacement, and at 96h. The research team will also measure respirations using uncalibrated RIP belts at the level of the chest and abdomen (2 to 3 continuous hours each day). Two respiratory bands will be placed circumferentially around the infant's chest and around the abdomen to measure chest and abdominal wall movements, respectively.~Hourly axillary temperature measured by the bedside nurse (as part of routine care) will be manually recorded for each patient by the research team. A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
33033549|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
33410438|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
33410439|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
32966539|NCT04922190|Experimental|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
32966540|NCT04872660|Experimental|GSATP group|Gushen Antai Pill (GSATP, 6g* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
32966541|NCT04872660|Placebo Comparator|Placebo group|Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
32966542|NCT04835766||Symptomatic group|These patients had bladder injury during PAS surgery and had Lower urinary tract symptoms
32966543|NCT04835766||Asymptomatic group|These patients had bladder injury during PAS surgery and had no Lower urinary tract symptoms
32966544|NCT04820790|Experimental|Experimental Group 1|The efficiency of the mobile app in the follow-up of patients with home oxygen will be evaluated during 6 months
32966545|NCT04820790|No Intervention|Intervention Group 2:|Regular monitoring of the home oxygen without mobile app during 6 months
32966546|NCT04511052|Experimental|Carotenoid + Probiotic|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement~Probiotic: 1 capsule daily containing 10 x 10^9 CFU of a proprietary strain~Total duration: 10 weeks"
32966547|NCT04511052|Placebo Comparator|Carotenoid + Placebo|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement~Placebo: 1 capsule daily containing the same carrier material of the probiotic, that is also similar in size, shape, and taste.~Total duration: 10 weeks"
32966548|NCT04482582|Experimental|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
32966549|NCT04482582|Active Comparator|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
32966550|NCT04444050|Experimental|Part 1 Single Ascending Dose (SAD): Panel 1|
32966551|NCT04444050|Experimental|Part 1 SAD: Panel 2|
32966552|NCT04444050|Experimental|Part 1 SAD: Panel 3|
32966553|NCT04444050|Experimental|Part 1 SAD: Panel 4|
32966554|NCT04444050|Experimental|Part 1 SAD: Panel 5|
32966555|NCT04444050|Experimental|Part 1 SAD: Panel 6|
32966556|NCT04444050|Experimental|Part 1 SAD: Optional Split-dose Panel|
32966557|NCT04444050|Experimental|Part 2 Multiple Ascending Dose (MAD): Panel 1|
32966558|NCT04444050|Experimental|Part 2 MAD: Panel 2|
32966559|NCT04444050|Experimental|Part 2 MAD: Panel 3|
32966560|NCT04444050|Experimental|Part 2 MAD: Panel 4|
32966561|NCT04444050|Experimental|Part 2 MAD: Optional (to be determined) Panel|
32966562|NCT04444050|Experimental|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
32966563|NCT04444050|Experimental|Part 3 J-MAD: Panel 2|
32966564|NCT04444050|Experimental|Part 3 J-MAD: Panel 3|
32966565|NCT04444050|Experimental|Part 3 J-MAD: Optional (to be determined) Panel|
32966566|NCT04225416||Hemodialysis patients|Patients undergoing hemodialysis
32966567|NCT04225416||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis
32966568|NCT03693846|Experimental|Nivolumab and Ipilimumab|Treatment will consist of Nivolumab 480mg every 4 weeks and Ipilimumab 1mg/kg every 8 weeks. Subjects will continue on study therapy until disease progression, unacceptable toxicity, withdrawal of consent, or 24 months of therapy.
33410440|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
32966569|NCT03529890|Experimental|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
32966570|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
32966571|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
32966572|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
33033550|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
33410441|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
33410442|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
33410443|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
33410444|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
33410445|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
33410446|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
33410447|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
33410448|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
32861302|NCT04968444|Active Comparator|BOOST workshop group|The BOOST workshop is a novel approach whereby participants are invited to a 2.5 hour interactive session. Subjective discussion at the start is had about how people are affected and impacted by their back pain, and outcome scores are completed. Then during the 2.5 hours there is a delivery of information and a practical exercise component to better inform the participants on how to manage their back pain and understand it better. Following this on 3 separate occasions, 1 month apart further top up information is sent to ensure they remember exercises and advice on practical management if a flare up occurs or they are struggling to fit activity in to day to day routines. Finally, at 3 months, there participants are invited back to complete the outcomes scores but also to discuss any concerns they are having and be given any advice to support them continuing with managing with any ongoing symptoms.
32861303|NCT04967898|Experimental|bowen technique|group 1 will be treated with the Bowen technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up.
32861304|NCT04967898|Active Comparator|sustained stretching|group 1 will be treated with the sustained stretching technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up
32861305|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
32861306|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
32861307|NCT04964154|No Intervention|BRAVE Non-Intervention|Survey participants in the BRAVE non-intervention arm will not have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
32861308|NCT04964154|Active Comparator|BRAVE Intervention|Survey participants in the BRAVE intervention arm will have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
32861309|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
32861310|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
32861311|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
32861312|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
32861313|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
32861314|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
32861315|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
32861316|NCT04967976|Experimental|Breast Reconstruction with breast mesh|The tissue expander-implant reconstruction with TiLoop Bra mesh.
33410449|NCT03504774|Experimental|Cashew or Shrimp Oral Immunotherapy|Participants, ages 7 to 55 years, inclusive, with an allergy to Cashew or Shrimp.
33410450|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
33410451|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
33410452|NCT04059042|Experimental|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
32966573|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
32966574|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
32966575|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
32966576|NCT03441048|Experimental|Lintuzumab Ac225 Recommended Phase 2 Dose (RP2D)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
32966577|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
32966578|NCT02761200||volunteer who completion of a recent ATI|
32966579|NCT02751060||patients with coronary heart disease symptoms|
32966580|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
32966581|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
32966582|NCT02369406|Experimental|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
32966583|NCT02369406|Experimental|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive <57 days after birth (peripartum HIV infection) and who are able to initiate ART <57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
32966584|NCT02369406|No Intervention|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
33410453|NCT04059042|Placebo Comparator|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
33410454|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
32966585|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
32966586|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
32966587|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
32966588|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
32966589|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
32966590|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
32966591|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
32966592|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
32966593|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
32966594|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
32966595|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
32966596|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
32966597|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
32966598|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
32966599|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
32966600|NCT02648178|Active Comparator|HALO Triton|HALO tank model
32966601|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
32966602|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
32966603|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
32966604|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
32966605|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
32966606|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
32966607|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
32966608|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
32966609|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
32966610|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
32966611|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
32966612|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
32966613|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
32966614|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
32966615|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
32966616|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
32966617|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
32966618|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
32966619|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
32966620|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
32966621|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
32966622|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
32966623|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
32966624|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
32966625|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
32966626|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
32966627|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
32966628|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
32966629|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
32966630|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
32966631|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
32966632|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
32966633|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
32966634|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32966635|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
32966636|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
32966637|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
32966638|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
32966639|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
32966640|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
32966641|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
32966642|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
32966643|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
33410455|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
33410456|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
33410457|NCT04059120|Experimental|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
32861317|NCT04967976|Active Comparator|Breast Reconstruction without breast mesh|The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
32861318|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
32861319|NCT01454557|Experimental|Controls|Auditory stimuli for control group
32861320|NCT03061734|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
32861321|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
32861322|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
32861323|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
32861324|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
32861325|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
32861326|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
32861327|NCT01451125|Experimental|Treated|
32861328|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
32861329|NCT01454713||Veritas|Breast reconstruction with Veritas
32861330|NCT04964232|Experimental|Temperature monitoring group|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
32861331|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
32861332|NCT03059784|No Intervention|control|usual care without APP
32861333|NCT02906761|Experimental|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
32861334|NCT02906761|Placebo Comparator|Placebo|Placebo (2 tablets) twice daily for 6 months
32861335|NCT04975542|Experimental|Treatment Group|
32861336|NCT04975542|Sham Comparator|Sham Group|
32861337|NCT02905591|Experimental|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
32861338|NCT04975386|Active Comparator|spinal anesthesia|
32861339|NCT04975386|Active Comparator|lumbar plexus+sacral plexus block|
32861340|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
32861341|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
32861342|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
32861343|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
32861344|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
32861345|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
32861346|NCT04393051|Experimental|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age >75 years old) for 14 days as add-on therapy"
32861347|NCT04393051|No Intervention|Control group|Patients in the control group will continue to receive standard therapy.
32861348|NCT04964310||APAP_DILI|"（①/②）+③+④：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L ④ liver impairment is caused by acetaminophen：Russel U-Calf Causality Assessment Method(RUCAM) causality score>6"
32861349|NCT04964310||APAP_NO-DILI（NDILI）|"（①/②）not（③/④）：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：ALT or AST ≥ 1000 IU/L④ liver impairment is caused by acetaminophen：RUCAM causality score>6"
32966644|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
33410458|NCT04059120|Active Comparator|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
32966645|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
32966646|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
32966647|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
32966648|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
32966649|NCT02665728|Experimental|BLI400|BLI400 Laxative
32966650|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
32966651|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
32966652|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
32966653|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
32966654|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
32966655|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
32966656|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
32966657|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
32966658|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
32966659|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
32966660|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
32966661|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
32966662|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
32966663|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
32966664|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
32966665|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
32966666|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
33410459|NCT04059198|Experimental|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
33410460|NCT04059198|Experimental|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
32966667|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
32966668|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
32966669|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
32966670|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
32966671|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
32966672|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
32966673|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
32966674|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966675|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966676|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966677|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966678|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966679|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
32966680|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
32966681|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
32966682|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
32966683|NCT02682420|Other|endoAVF|
32966684|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
32966685|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
32966686|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
32966687|NCT02684136|Placebo Comparator|placebo|9 nights placebo
32966688|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
32966689|NCT02684604||Fertile women|44 fertile women
33410461|NCT04059198|Experimental|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
32966690|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
32966691|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
32966692|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
32966693|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
32966694|NCT02695290|Experimental|Afatinib|
32966695|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
32966696|NCT02696070|Other|Sham of Provant|Sham of Provant
32966697|NCT02696070|Other|Active Treatment|Active Provant Treatment
33410462|NCT04058964|Experimental|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
32966698|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
32966699|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
32966700|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
32966701|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
32966702|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
32966703|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
32966704|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
32966705|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
32966706|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
32966707|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
32966708|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
32966709|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
32966710|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
32966711|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
32966712|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
32966713|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
32966714|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
32966715|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
32966716|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
32966717|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
32966718|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
32966719|NCT02713230|Active Comparator|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
32861350|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
32861351|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
33410463|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
33410464|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
33410465|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
32861352|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
32861353|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
32861354|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
32861355|NCT04426890|Experimental|Arm 1|300 mg of CT-P39 as SC injections via PFS
32861356|NCT04426890|Active Comparator|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
32861357|NCT04426890|Experimental|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
32861358|NCT04426890|Active Comparator|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
32861359|NCT04426890|Experimental|Arm 3|"Treatment period 1: 150 mg of CT-P39~Treatment period 2: 300 mg of CT-P39"
32861360|NCT04426890|Active Comparator|Arm 4|"Treatment period 1: 150 mg of EU-approved Xolair~Treatment period 2: 300 mg of EU-approved Xolair"
32861361|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
32861362|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
32861363|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
32861364|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
32861365|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
32861366|NCT04975074|Experimental|Anemia Correction Group|Continue to take the current medication orally at the current dose
32861367|NCT04975074|Experimental|Anemia uncorrected group|Continue to take the current medication orally at the current dose
32861368|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
32861369|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
32861370|NCT04974918|Experimental|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of Lip defects|participants will be chosen according to liable age and information will be given about complications
32861371|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
32861372|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
32861373|NCT04964076||COPD patients in the plateau|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.
32861374|NCT04964076||COPD patients in the plain|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.
32861375|NCT04963998|Experimental|Copper oxide dressings|Treatment of diabetic ulcers that were in a stagnated stage with copper oxide containing wound dressings
32861376|NCT03148327|Experimental|Regimen A: Phase I|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
32861377|NCT03148327|Experimental|Regimen A: Phase II|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
32861378|NCT03148327|Active Comparator|Regimen B: Phase II|Radiotherapy alone
32861379|NCT04963608||non-interventional study|Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
32861380|NCT04974450|Experimental|Trigona Honey|The intervention will be given by oral route in a form of liquid of 70-gram trigona honey once daily for 8 weeks
32966720|NCT02713230|Active Comparator|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
32966721|NCT02713230|Placebo Comparator|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
32966722|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
32966723|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
32966724|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
32966725|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
32966726|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
32966727|NCT02716506||Symptomatic POP|POP surgery in year 2015
32966728|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
32966729|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
32966730|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
32966731|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
32966732|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
32966733|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
33322038|NCT05460494|Experimental|Intervention Arm 1|MCP videos alone. Care partners randomized to intervention arm 1 during Step 2 randomization will receive usual care + RELOAD-C, consisting of: 1) 6 brief (~5 minute) videos of Dr. Allison Applebaum introducing concepts from MCP for care partners of persons with AD/ADRD; and 2) written content associated with the videos, such as directions for homework assignments. The tab with links to the virtual group meetings will be removed. Participants in this arm use RELOAD-C on their own and do not have interaction with other care partners while using the platform. One video will become available for viewing each week for the first 6 weeks after step 2 randomization, and each care partner will have a unique user ID/login.
33322039|NCT05460494|Experimental|Intervention Arm 2|"MCP videos + MCP-focused virtual groups. In addition to the components that the intervention arm 1 participants receive (usual care content, 6 MCP videos, written text), the RELOAD-C platform for the intervention arm 2 participants will include links to the virtual group meetings (7 in total). The first 6 group meetings will occur weekly, during the first 6 weeks after participants are randomized in step 2. Each of the first 6 group meetings will facilitate discussion of the MCP concepts introduced in that week's video, as participants receive access to each video ~3 days prior to the group meeting. The 7th virtual meeting will be used as a booster in week 9 after step 2 randomization, and will focus on sharing how participants are using the MCP concepts in their daily lives. All meetings will be facilitated by our social worker, Katherine Henthorne, LCSW."
33322040|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
33322041|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
32966734|NCT02719938|No Intervention|Control|Usual care.
32966735|NCT02723916|Experimental|Intervention: ezParent Program|
32966736|NCT02723916|Active Comparator|Control: Health-e Kids App|
32966737|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
32966738|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
32966739|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
32966740|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
32966741|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
32966742|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
32966743|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
32966744|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
33322042|NCT05460416|Experimental|Treatment by acetylsalicylic acid|
33322043|NCT05460416|No Intervention|No treatment|
33322044|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
33322045|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
32966745|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
33410466|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
32966746|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
32966747|NCT02734056|Experimental|Music|The intervention to be administered is music
32966748|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
32966749|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
32966750|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
32966751|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
32966752|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
33410467|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
33410468|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
32966753|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
32966754|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
32966755|NCT05446584|Active Comparator|Active left frontal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the left frontal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
32966756|NCT05446584|Active Comparator|Active left temporal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the left temporal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
32966757|NCT05446584|Sham Comparator|Sham HD=tDCS|Electrodes will be placed in the same 4x1 ring configuration over the left frontal region as the active left frontal condition to ensure a useful control condition. Stimulation will consist of a 30-second ramp up period until reaching 2 mA, followed immediately by a 30-second ramp down, and off for 29 minutes. The same ramp up and down process will be repeated in the final minute of the session to help preserve masking of conditions. Sham stimulation will be applied back-to-back over three consecutive days.
32966758|NCT05446428||Any SLE Disease Activity|
32966759|NCT05446428||Moderate to severe SLE Disease Activity|
32966760|NCT05446116|Active Comparator|femoral puncture|Under local anaesthesia, the femoral artery was punctured and 6F sheath was inserted. Splenic artery was catheterized using 4- or 5-F catheters (Cobra C2 cat or Simmons II catheter Imager-Boston Scientific Natick, Massachusetts). Embolization was done using Embospheres (Biosphere Medical, Rockland, MA) 700-900 μ in diameter.
32966761|NCT05446116|Active Comparator|Radial puncture|The left radial artery was preferred due to shorter distance from the left wrist to the splenic artery in comparison to the right wrist; also the left radial access theoretically decreases the risk of cerebral emboli. Under local anaesthesia and ultrasound guidance, the radial artery was punctured and 5- or 6-F sheath was introduced. After sheath insertion, the radial cocktail (2.5 mg of verapamil, 100 μg of nitroglycerin, and 5,000 units of heparin) was injected through the sheath over one minute after dilution with 20 ml of blood to decrease the discomfort during injection.
33410469|NCT03024606|No Intervention|control group|No text messages
33410470|NCT03671928|Other|bowel ischemia|
32966762|NCT05446038|Experimental|Multifamily Guided Self-Help Family-Based Treatment (MF-GSH-FBT)|Treatment consists of up to 12 once-weekly online group sessions, where groups are made up of parents from 4-5 different families of young people with Anorexia. Group sessions will last approximately 50-60 minutes. Prior to each group session, parents watch recorded videos about how parents can help their child with Anorexia. Only parents, and not the young person with Anorexia, attend the group sessions.
32966763|NCT05445960|Active Comparator|Tourniquet|This arm will have a tourniquet placed around the thigh inflated to 250mmHg for the duration of surgery (until splint placed) or 2 hours, whichever is shorter, during ankle fracture surgery.
32966764|NCT05445960|No Intervention|No Tourniquet|This arm will have a tourniquet placed around the thigh but NOT inflated for the duration of ankle fracture surgery.
32966765|NCT05445180|Experimental|Psychosis patients with cannabis use (Abstinent)|Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
32966766|NCT05445180|No Intervention|Psychosis patients with cannabis use (Non-abstinent)|Psychosis Patients with cannabis use who will continue to use cannabis as usual
33410471|NCT03671928|Other|non-digestive abdominal pain|
33410472|NCT03675906||preoperative albumin levels <3.8|
33410473|NCT03675906||preoperative albumin level >3.8|
33410474|NCT03675906||postoperative Day 2 albumin level <2.9|
33410475|NCT03675906||postoperative Day 2 albumin level >2.9|
32861381|NCT04974450|Active Comparator|Control|The intervention will be given by oral route in a form of liquid of 70-gram artificial honey once daily for 8 weeks
32861382|NCT01451905|Active Comparator|Psoriasis|
32861383|NCT01451905|Placebo Comparator|Placebo|
32861384|NCT04974606|Experimental|Coffeeberry 100 mg beverage|Appearance-matched to the other beverages
32861385|NCT04974606|Experimental|Coffeeberry 300 mg beverage|Appearance-matched to the other beverages
32861386|NCT04974606|Placebo Comparator|Placebo beverage|Appearance-matched to the other beverages
32861387|NCT04974606|Active Comparator|Caffeine 75 mg beverage|Appearance-matched to the other beverages
32861388|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
32861389|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
32861390|NCT04967586||Preclinical medical students|
32861391|NCT04967586||Clinical medical students|
32861392|NCT01455649|Experimental|Everolimus|
32861393|NCT01455649|Active Comparator|calcineurin inhibitor|
32861394|NCT04967118|Experimental|Skin-to-skin contact|Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG, EMG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately thirty minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
32861395|NCT04967118|Experimental|Mother's heartbeats as sound and vibration|Neonates will be placed in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The platform on which the mother's heartbeat will be played will be placed under mattress of the incubator or crib. The playing of the mother's recorded heartbeats will be started thirty minutes prior the heel lance and will be continued during and thirty minutes after the blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
32861396|NCT04967118|Active Comparator|30% oral glucose|Neonates will be placed on in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The neonates will be given a 30% oral glucose solution two minutes prior the heel lance
32861397|NCT04392817|Experimental|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
32861398|NCT04974294|Active Comparator|PPV23|
32861399|NCT04974294|Active Comparator|PCV13|
32861400|NCT04974294|Placebo Comparator|Saline placebo|
32861401|NCT01452061||ASD|Participants with autism spectrum disorder.
32861402|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
32861403|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
32861404|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
32861405|NCT04963374||respiratory inpatient|respiratory inpatient with VTE
32861406|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
32861407|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
32861408|NCT04974372||HT group|Patients have echocardiography examination before and after heart transplantation.
32861409|NCT04974372||Control group|healthy volunteers who had no history of hypertension, diabetes mellitus, renal failure or other organic diseases based on physical examinations, biochemical tests, electrocardiogram, echocardiography were enrolled as control group
32861410|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
32861411|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
32861412|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
32861413|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~OSDI questionnaire score <13.~Fluorescein TBUT > 7 s in both eyes.~CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
32861414|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
32966767|NCT05445180|Experimental|Non-Psychiatric controls with cannabis use (Abstinent)|Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
32966768|NCT05445180|No Intervention|Non-Psychiatric controls with cannabis use (Non-abstinent)|Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual
32966769|NCT05445180|No Intervention|Non-Psychiatric Controls without cannabis use|Non-Psychiatric controls without cannabis use
32966770|NCT05445102|Experimental|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|
32966771|NCT05445024|Experimental|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
32966772|NCT05445024|Placebo Comparator|sufentanil group|sufentanil (1/1000* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
32966773|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab|
32966774|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D1|
32966775|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D2|
32966776|NCT05443932|Other|Washout Phase and treatment arms|"At first there will be wash-out phase I with daily placebo administration for all participants. All patients will receive blood- and 24h-urine screenings in week 0 and 6 to get baseline data and also a low-dose native CT of the urinary tract in week 6. In preparation of the HCT phase all participants will daily receive an oral placebo.~In week 7 the HCT phase will start and all patients will receive an oral therapy with 50mg of HCT daily; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 10).~After that, in washout phase II, the same test as before will be performed in week 0 and 6 (weeks 15 and 20).~At the end another therapy phase with an oral administration of 10mg dapagliflozin daily will be performed; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 25).~Finally, the same tests as before will be performed in wash-out phase III in week 0 and 6 (weeks 29 and 34)."
32966777|NCT05443854|Experimental|Aminoglycosides intervention|"Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
32966778|NCT05443854|Experimental|Lack of protective isolation intervention|Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.
32966779|NCT05443854|Other|No systematic aminoglycosides intervention|Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines - standard arm
32966780|NCT05443854|Other|Protective isolation intervention|Protective isolation will be provided systematically as currently practiced in participating centers - standard arm
32966781|NCT05443776|Experimental|Study group biomaterial 1|
32966782|NCT05443776|Experimental|Study group biomaterial 2|
32966783|NCT05443776|Experimental|Study group biomaterial 3|
32966784|NCT05443776|Experimental|Study group biomaterial 4|
32966785|NCT05443776|Experimental|Study group biomaterial 5|
32966786|NCT05443776|Experimental|Study group biomaterial 6|
32966787|NCT05443308||Alzheimer Disease|patients with presumed Alzheimer disease and no known vascular, psychiatric or other major diseases age > 60 years
33410476|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
32966788|NCT05443308||Small vessel disease|"patients diagnosed with small vessel disease of the brain by MRI and presumed cognitive dysfunction and no other known psychiatric or other major diseases.~age > 60 years"
32966789|NCT05443308||Healthy subjects|"Age-matched subjects with no known vascular, psychiatric or other major diseases.~age > 60 years"
33410477|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
32966790|NCT05443230||patients with sarcopenia|
32966791|NCT05443230||patients without sarcopenia|
32966792|NCT05443152|Experimental|Experimental Arms|Prenatal attachment scale answered. In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care. The mother attachment scale was answered at least 1 month after the birth of the women.
32966793|NCT05443152|No Intervention|No İntervention Arms|Prenatal attachment scale answered. The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research. The mother attachment scale was answered at least 1 month after the birth of the women.
33410478|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
33410479|NCT03671772||FDRs of controls|First-degree relatives of controls
33410480|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
33410481|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
32966794|NCT05442996|Experimental|HLX35+HLX10|Subjects will receive HLX35 in combination with HLX10 therapy, every 2 weeks as one treatment cycle.
32966795|NCT05442918||General Surgery|All patients undergoing either elective laparoscopic/open cholecystectomy, laparoscopic/open hiatus hernia repair, laparoscopic/open inguinal hernia repair, laparoscopic/open umbilical hernia repair or laparoscopic ventral wall hernia repair.
32966796|NCT05442918||Bariatric Surgery|Participants undergoing elective bariatric surgery (laparoscopic sleeve gastrectomy or roux-en-y gastric bypass). Those in the bariatric arm must have been on a VLCD pre operatively
32966797|NCT05442762||Global Database of Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for all vaccines. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
32966798|NCT05442762||Global Database of HPV Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for HPV vaccine. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
32966799|NCT05442528||Experimental: FIX replacement therapy.|Subject's previous treatment plan will be followed
32966800|NCT05441046|Experimental|Genakumab|genakumab plus tislelizumab 200 mg
32966801|NCT05440188||COPD|Patients over 65 years old diagnosed with COPD in GOLD II state or higher who uses Breath Detect Platform for monitoring their respiratory health status.
32966802|NCT05439564|Placebo Comparator|Group morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
32966803|NCT05439564|Active Comparator|Group morphine-Dex|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
32966804|NCT05439564|Active Comparator|Group Dex|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
32966805|NCT05429814|Experimental|Experimental|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
32966806|NCT05429814|No Intervention|control group|control group will receive standard practice
32966807|NCT05423340|Experimental|Use Own Brand of Flavored Product|Participants will use their current flavor of e cigarettes for 90 days
32966808|NCT05423340|Experimental|Use Provided Tobacco Flavor|Participants will use a new assigned flavor for 90 days
32966809|NCT05423340|Active Comparator|"Vaping Abstinence - use Tobacco Free Nicotine Pouches"|Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.
32966810|NCT05422170||Patients undergoing transfemoral TAVI|Patients receiving 125 U/kg unfractioned heparin for periprocedural anticoagulation and 500U Protamine / 1000U Heparin at the end of the procedure
33410482|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
32966811|NCT05419986|Other|Non-opioid users|
32966812|NCT05419986|Other|Active opioid users|
32966813|NCT05412264|Experimental|Website intervention|Website access: 12 Weekly emails, access to website with goal setting and recording steps
32966814|NCT05412264|No Intervention|Delayed access|Will not receive access to the program/website until they complete their 16 week assessments
32966815|NCT05404152||Ederly|Elderly Admitted to Nursing homes
32966816|NCT05394870|Experimental|study group|
32966817|NCT05394870|Active Comparator|control group|
32966818|NCT05350332|Experimental|Negative Pressure Ventilator|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with a non-invasive negative pressure ventilator. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
32966819|NCT05340270|Experimental|PD-1 inhibitor + GP Group|PD-1 inhibitor plus GP chemotherapy as Neoadjuvant Therapy followed by IMRT combined with cisplatin concurrent chemotherapy
32966820|NCT05340270|Active Comparator|GP Group|GP chemotherapy as Neoadjuvant Therapy chemotherapy followed by IMRT combined with cisplatin concurrent chemotherapy
32966821|NCT05336760||ALS Patients|Patients with confirmed amyotrophic lateral sclerosis.
32966822|NCT05336760||Relatives|Close relatives of the patients included in the study.
32966823|NCT05321472||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
32966824|NCT05321472||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
32966825|NCT05289414|Active Comparator|Radiofrequency|first group of patients will be sujected to radiofrequency treatment
32966826|NCT05289414|Active Comparator|Greater occipital nerve vlock|second group of patients will be sujected to Greater occipital nerve block
32966827|NCT05269368|Experimental|No wicking|Absence of Wicking after intervention
32966828|NCT05269368|Active Comparator|Control|Wicking after intervention
32966829|NCT05266404|Experimental|Treatment A (Test Formulation): Dapagliflozin/Sitagliptin FDC tablet|Subjects will receive single dose of dapagliflozin/sitagliptin fixed dose combination (FDC) (test formulation).
32966830|NCT05266404|Active Comparator|Treatment B (Reference Formulation): Dapagliflozin+Sitagliptin|Subjects will receive single dose of dapagliflozin 10 mg tablet + sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).
33410483|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
33410484|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
33410485|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
33410486|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
33410487|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
33410488|NCT03180619|Experimental|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
33410489|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
33410490|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
33410491|NCT03213678|Experimental|Treatment (samotolisib)|Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.
33410492|NCT05240209|Experimental|Education (Intervention) Group|In the pretest phase of the research;Education group, those who signed the Informed Voluntary Consent Form and agreed to participate in the research will fill out the questionnaire.Data collection will take approximately 20-25 minutes.Afterwards,the researcher will give training to the training group about skin cancer,skin self-examination and sun protection behaviors.The tutorials are planned as a PowerPoint demonstration.The duration of the trainings is planned to take approximately 40minutes.The content of the training was prepared in line with the literature review.As a method;It will be in the form of narration,question and answer,brainstorming.Materials used in education;Colorfulbrochures on the subject will be given to reinforce the slide show and post-training information.A follow-up period of four months will be expected after the training given.At the end of the follow-up period,the training group will have to fill out the post-test questionnaires during the post-test phase.
33410493|NCT05240209|No Intervention|Control Group|Control Group: In the pre-test phase of the study; control group parents, those who signed the Informed Consent Form and agreed to participate in the study will fill out the questionnaire. Data collection will take approximately 20-25 minutes. During the follow-up period (120 days), no intervention will be made on the control group. At the end of the follow-up period (120 days), the control group will have to fill out the post-test questionnaires during the post-test phase. Participants will be reminded of the purpose of the research. Approval of the Informed Consent Form will be received. Completing the post-test questionnaires will take approximately 20-25 minutes. A brochure training material will be distributed to the parents of the control group, in line with the principle of equality, immediately after the completion of the post-tests.
33410494|NCT05426941|Experimental|Music Imagery|MI sessions will be delivered by board-certified music therapists with specialized training in MI and the study treatment protocol.The 8-session protocol has two stages. Stage 1 (sessions 1-4) is focused on learning to use music and imagery for self-regulation. Once the Veteran has demonstrated skill in using music for self-regulation, Stage 2 (sessions 5-8) shifts to identify and deepen their inner resources and how they can use those resources for self-care.
33410495|NCT05426941|Experimental|Music Listening|Following a one-time meeting with a music therapist, an electronic playlist will be compiled for the Veteran to listen to during the 12-week treatment period.
32966831|NCT05212584|Experimental|CD7 CAR T cells|Dose escalation phase: CD7 CAR T cells will be transduced with a lentiviral vector to express a CD7 CARs. with an escalation approach, 1 e6 to 7 e6 CAR-T cells/kg
33322046|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
33322047|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
33410496|NCT05426941|No Intervention|Usual care|Participants in the usual care arm (as is the case for MI and ML groups) may receive analgesics and non-pharmacological treatments (e.g., physical therapy) for their chronic musculoskeletal pain.
32966832|NCT05206188|Experimental|Experimental|Study participants randomized to the experimental condition will receive IPS services as usual in conjunction with the MWW intervention.
32966833|NCT05206188|No Intervention|Control|Study participants randomized to the control condition will receive IPS services as usual.
32966834|NCT05191680|Experimental|Apalutamide 6 months|Participants will receive apalutamide 240 mg (4 x 60 mg tablets) orally once a day for up to 6 months.
32966835|NCT05191680|Experimental|Apalutamide 3 months + Placebo 3 months|Participants will receive apalutamide 240mg (4 x 60 mg tablets) orally once a day for up to 3 months followed by placebo to match apalutamide (4 tablets) orally once a day for up to 3 months.
32966836|NCT05191680|Placebo Comparator|Placebo 6 months|Participants will receive placebo to match apalutamide (4 tablets) orally once a day for up to 6 months.
32966837|NCT05184738|Experimental|Oligomeric nutritional formula arm (Bi1 peptidic)|Individuals will receive a Oligomeric nutritional formula.
32966838|NCT05184738|Other|Standard arm|Individuals will receive a Standard nutritional formula.
32966839|NCT05175924|Experimental|Virtual reality|In the Aquarium VR group, virtual reality headset compatible with iPhone 7 (Apple) was used to distract attention. Before use, the headsets were tested on five children for face fit and visibility of the application used. Written and verbal consent of the children and their parents was obtained to test the headsets. The children who tested the headsets were not included into the study. The headset offered a soft and comfortable experience in contact with the skin due to its leather and pad covering. It also had a wide viewing angle and an optical zoom button. Due to its noise isolation function, it did not disturb anyone or make noise.
33410497|NCT05420467|Active Comparator|TCbHP|HER2-positive breast cancer
33410498|NCT05420467|Experimental|nPCbHP|HER2-positive breast cancer
32966842|NCT05150418|Experimental|Oxygen|Oxygen 15 l/min administered with face mask with reservoir.
32966843|NCT05150418|Placebo Comparator|Room air|Room air 15 l/min administered with face mask with reservoir.
32966844|NCT05146206||Patients on RYALTRIS|Patients who are currently using RYALTRIS nasal spray.
32966845|NCT05146206||Patients on DYMISTA|Patients who are currently using DYMISTA nasal spray.
32966846|NCT05127564|Experimental|DRF: Chinese Participants|Chinese participants will receive DRF Dose 1, oral capsules, twice daily (BID), from Day 1 to Day 4 and DRF Dose 1, oral capsules, once daily (QD), on Day 5.
32966847|NCT05127564|Experimental|DRF: Caucasian Participants|Caucasian participants will receive DRF Dose 1, oral capsules, BID, from Day 1 to Day 4 and DRF Dose 1, oral capsules, QD, on Day 5.
32966848|NCT05122494|Experimental|Hemay022 and AI|Hemay022 in combination with AI will be taken orally once daily. Planned dose of Hemay022 will be 500mg daily for 21 days.
32966849|NCT05122494|Active Comparator|Lapatinib and Capecitabine|lapatinib in combination with capecitabine will be taken in suitable dose until disease progression or death, etc.
32966850|NCT05107518||children with physical disabilities|his study was designed to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire-(CSA) scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
32966851|NCT05063604|Experimental|Citalopram 20-40 mg|Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
32966852|NCT05063604|Experimental|Psychotherapy|Participants received one psychotherapy session weekly for 12 weeks.
32966853|NCT05057676|Experimental|Intervention Autoimmune Intervention Mastery Course (AIM) online course|This arm will begin the intervention immediately after randomization
32966854|NCT05057676|Other|Delayed Autoimmune Intervention Mastery Course|This is the control arm.
32966855|NCT05051514||No-Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
32966856|NCT05051514||Moderate to Severe OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour.
32966857|NCT04978428|Experimental|Epidiolex|Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
32966858|NCT04968054|Active Comparator|Propofol group|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively
32966859|NCT04968054|Experimental|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
32966860|NCT04960332|No Intervention|Standard treatment|Group A: Standard wound closure with staples and conventional wound dressing.
33322048|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
33322049|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
33322050|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
32966861|NCT04960332|Experimental|Prevena|Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
32966862|NCT04956120|Experimental|Citrate Dialysate then Standard Dialysate|Participants receiving hemodialysis using a citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a non-citrate acid concentrate dialysate (standard dialysate) for the second year of the study.
32966863|NCT04956120|Active Comparator|Standard Dialysate|Participants receiving hemodialysis using a non-citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a citrate acid concentrate dialysate for the second year of the study.
32966864|NCT04940364|Experimental|Cohort 1|Pozelimab: Single-dose SC on day 1
32966865|NCT04940364|Experimental|Cohort 2|Pozelimab: Single-dose IV on day 1
32966866|NCT04940364|Experimental|Cohort 3|Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
32966867|NCT04940364|Experimental|Cohort 4|Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
32966868|NCT04940364|Experimental|Cohort 5|Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
32966869|NCT04940364|Experimental|Cohort 6|Pozelimab: Single-dose IV on day 1
32966870|NCT04870944|Experimental|Treatment (CBL0137)|Patients receive CBL0137 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
32966871|NCT04848558|Experimental|Part 1: Single Dose Cohorts|Participants will receive subcutaneous (SC) injection or intravenous (IV) infusion of nipocalimab or placebo in single ascending doses on Day 1 in Cohorts 1-6 and SC administration in optional Cohorts 7-8.
32966872|NCT04848558|Experimental|Part 2: Multiple Dose Cohorts|Participants will receive up to 4 weekly SC injections of nipocalimab or placebo on Days 1, 8, 15, and 22 in Cohort 1 or 4 biweekly SC injections on Days 1, 15, 29, and 43 in optional Cohort 2.
33410499|NCT05420467|Active Comparator|EC-T|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
32966873|NCT04844736|Other|Radiology Treatment Planning/Review|After patient consultation and enrollment, the patient will undergo routine CT simulation to initiate the radiation treatment planning process. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes. If the initial radiology review reflects concern for inadequate target volume delineation, the case will be flagged for multidisciplinary discussion between the radiation oncologist and radiologist.
32966874|NCT04840134|Experimental|From Hardship to Hope: Financial Wellness Intervention|"From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk~Over the course of this study, the investigators will develop and pilot a financial wellness intervention to work in tandem with clinical treatment. The intervention will support individuals experiencing financial hardship and suicide risk to address their financial difficulties (e.g., debt, inability to meet basic needs) by coaching them on financial management techniques, facilitating a financial wellness plan, and connecting them with community-based financial supports (e.g., free financial counseling). The intervention will be facilitated by trained peer specialists, who are individuals with lived experience of financial hardship and suicidal ideation or suicidal behaviors who are state certified peer specialists (having met formal training and experience requirements)."
32966875|NCT04814706||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
32966876|NCT04780464|Active Comparator|Standard doxorubicin|
32966877|NCT04780464|Experimental|Metronomic doxorubicin|
32966878|NCT04780464|Experimental|Metronomic oral cyclophosphamide + prednisolone or prednisone|
32966879|NCT04722432|Experimental|Système de cathéter détachable dehors du scope (DDS)|
32966880|NCT04660422||Pre-COVID-19 ACP baseline|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~September 15, 2019 - March 14, 2020,"
32966881|NCT04660422||COVID-19 rate|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~March 15, 2020 - September 14, 2020"
32966882|NCT04660422||ACP rate|ACP rate during the implementation period, which begins December 15, 2020 and continues for six months, to the rates in the previous two control periods December 15, 2020-June 15, 2021
32966883|NCT04649580||Online Survey|
32966884|NCT04649580||One-to-one interviews|
32966885|NCT04636710|Experimental|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.~Prior to neoadjuvant chemotherapy~Day before surgery~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
32966886|NCT04601922||Emergency Medicine Consultants|
32966887|NCT04601922||General Practitioners|
32966888|NCT04601922||Acute care nursing staff|
32966889|NCT04601922||Patients presenting with suspected cardiac chest pain|
32966890|NCT04557462|Experimental|LNP023|All participants are receiving 200 mg b.i.d
32966891|NCT04521348|Experimental|RAIR-DTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
32966892|NCT04521348|Experimental|MTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
32966893|NCT04521348|Experimental|ATC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
32966894|NCT04521348|Experimental|DTC unsuitable for RAI arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
32966895|NCT04495608|Experimental|fluconazole|Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
32966896|NCT04495608|Placebo Comparator|placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
32966897|NCT04422132|Active Comparator|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
32966898|NCT04422132|Active Comparator|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
32966899|NCT04376658||Cohort 1 (Coalition I)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
32966900|NCT04376658||Cohort 2 (Coalition II)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation > 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
32966901|NCT04376658||Cohort 3 (Coalition III)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
32966902|NCT04376658||Cohort 4 (Coalition IV)|Adult hospitalized patients with proven SARS-Cov-2 infection and D-dimer above the upper limit of the normal range
32966903|NCT04376658||Cohort 5 (Coalition VI)|Adult hospitalized patients with proven SARS-Cov-2, needing oxygen supplementation to maintain SpO2 > 93%, and two or more of the following inflammatory tests: D-dimer > 1,000 ng/mL; C reactive protein (CRP) > 5 mg/dL; Ferritin > 300 mg/dL; Lactate dehydrogenase (LDH) > upper limit of normal
32966904|NCT04368702|Experimental|Phase I - Gastric Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
32966905|NCT04368702|Experimental|Phase I - Breast Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
33322051|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
32966906|NCT04368702|Experimental|Phase I - Mantle Cell Lymphoma|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
32966907|NCT04368702|Experimental|Phase I - Larynx|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
32966908|NCT04368702|Experimental|Phase I - Bladder|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
32966909|NCT04356690|Experimental|Cohort 1 - Etoposide|"Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4~If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
32966910|NCT04356690|Experimental|Cohort 2 - Etoposide|"Participants that are NOT on ventilation Etoposide 150 mg/m2 daily days 1 and 4~Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
32966911|NCT04356690|No Intervention|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
32966912|NCT04356690|No Intervention|Cohort 2 - Control|Standard of care therapy in participants that are NOT on ventilation.
32966913|NCT04352010|Experimental|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
32966914|NCT04352010|Experimental|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
32966915|NCT04352010|Experimental|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
32966916|NCT04280952|Experimental|CONVIVO|tumor tissue identification with the CONVIVO system
33410500|NCT05420467|Experimental|ddEC-wnP|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
32966917|NCT04238754|Experimental|All Participants|Each participant will receive Epidiolex oral solution and Cherry syrup oral solution (placebo) in a randomized fashion.
32966918|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as~Metabolic Syndrom~Diabetic~Obese"
32966919|NCT04193904|Experimental|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
32966920|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
32966921|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
32966922|NCT04076202|Experimental|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
32966923|NCT04017468|Active Comparator|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
32966924|NCT04017468|No Intervention|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
32966925|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
32966926|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
32966927|NCT03947814|Experimental|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [>=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
32966928|NCT03947814|Experimental|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR >=15 to less than [<]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR <15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
32966929|NCT03947814|Experimental|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR >=60 mL/min to <90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
32966930|NCT03947814|Experimental|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR >=30 to <60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
32966931|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
32966932|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
32966933|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
32966934|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
33322052|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
33322053|NCT03906994|Experimental|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
33322054|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
33322055|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
32966935|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
32966936|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
32966937|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
32966938|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
32966939|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
32966940|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
32966941|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
32966942|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
32966943|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
32966944|NCT03694626|Active Comparator|Healthy Control subjects|
32966945|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
33410501|NCT05420467|Active Comparator|TC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
32966946|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
32966947|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
32966948|NCT03694626|Active Comparator|TBI patients with photosensitivity|
32966949|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
32966950|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
32966951|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
32966952|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
32966953|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
32966954|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
32966955|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
32966956|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
32966957|NCT03567642|Experimental|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)
33410502|NCT05420467|Experimental|nPC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
33410503|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
33410504|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
32966958|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
32966959|NCT03506880|Active Comparator|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
32966960|NCT03506880|No Intervention|Control|TAU
32966961|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
32966962|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
32966963|NCT03447834|Experimental|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
32966964|NCT03447834|Other|Standard PPCI|The control group will receive routine PPCI.
32966965|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
32966966|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
32966967|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
32966968|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
32966969|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
32966970|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
32966971|NCT03018912|Experimental|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
32966972|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
32966973|NCT03012282|Experimental|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
32966974|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
32966975|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
32966976|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
33322056|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral"
33322057|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral~Patient with a liver biopsy indication as part of the treatment within 3 months."
32966977|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
32746710|NCT05611827|Experimental|Quercetin LipoMicel (1000 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 1000 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 1000 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
32966978|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
32966979|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
32966980|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
32966981|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
32966982|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
32966983|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
32966984|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
32966985|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
32966986|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
32966987|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
32966988|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
32966989|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
32966990|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
32966991|NCT01668186||Patients diagnosed with a peroxisomal disorder|Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation
32966992|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
32966993|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
32966994|NCT05452824|Experimental|Tai Chi Prehabilitation|8 weeks Tai Chi prehabilitation prior to radical prostatectomy
32966995|NCT05452824|Placebo Comparator|Usual Care|Usual care
32966996|NCT05452746|Experimental|Acupuncture|
32966997|NCT05452746|Active Comparator|Treatment as usual|
33104903|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
32966998|NCT05452590|Experimental|Ultrasound-guided wire-in-needle technique|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
32966999|NCT05452590|No Intervention|Traditional technique|A syringe will be connected to the needle. The IJV will be punctured in a long-axis in-plane or short-axis out-of-plane approach (as preferred by the anesthesiologist). When the needle tip enters the IJV, blood is aspirated using the syringe. The operator will then discontinue US-guidance, disconnect the syringe and advance the guidewire through the needle into the IJV. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
33322058|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~The existence of at least one element of metabolic syndrome~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
33322059|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
32967002|NCT05452434|Experimental|Experimental group|300 cases, mirabegron 50mg QD + behavior intervention (timed urination + left head wagging 3 times and right head wagging 3 times in urgent urination) for 12 weeks.
32967003|NCT05452434|Active Comparator|Control group|300 cases, mirabegron 50mg QD for 12 weeks
32967004|NCT05452200|Experimental|Lyon hospital employees with high risk of lung cancer.|Lyon Hospital employees meeting criteria for high risk of lung cancer according French recommendation criteria.
32967005|NCT05451888|Experimental|Celestial Floatation Pool|
32967006|NCT05451888|Experimental|Dead Sea Salt Pool|
32967007|NCT05451888|Active Comparator|Balneotherapy Control Pool|
32967008|NCT05451576|Active Comparator|Sodium selenite|200μg/d intravenous sodium selenite was dissolved in 100 ml 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
32967009|NCT05451576|Placebo Comparator|Placebo|100 ml intravenous 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
32967010|NCT05451342||ARDS|Patients who meet the diagnostic criteria of ARDS
32967011|NCT05451342||Non-ARDS|Patients without ARDS
32967012|NCT05450874||Training cohort|
32967013|NCT05450874||Validation cohort|
32967014|NCT05450484|Experimental|Durvalumab-680LT|
32967015|NCT05450328|Placebo Comparator|Normal Saline|The control group will receive a saline solution (8mL) as a placebo, before CPB start.
32967016|NCT05450328|Active Comparator|Combination of inhaled Epoprostenol and Milrinone|The experimental group will receive simultaneously 4mg of Milrinone (1mg/mL, 4mL) and 60 mcg of Epoprostenol (15 mcg/mL, 4mL) before CPB initiation.
32967017|NCT05450172||Consecutive patients scheduled for thoracic surgery|
32967018|NCT05449938|Experimental|Thick periodontal phenotype|Stage II and stage III periodontitis Patient with thick periodontal phenotype will be enrolled using probe transparency method .
32967019|NCT05449938|Active Comparator|Thin periodontal phenotype|Stage II and stage III periodontitis Patient with thin periodontal phenotype will be enrolled using probe transparency method.
32967020|NCT05449860|Experimental|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
32967021|NCT05449782|Other|Healthy participants: Cocoa flavanol - Placebo|Healthy participants receiving cocoa flavanols on first study day and placebo on second study day
33322060|NCT01364506|Experimental|Water exercise|
33322061|NCT01364506|No Intervention|Control|
33322062|NCT04575038|Experimental|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
33322063|NCT04575038|Placebo Comparator|Placebo|Placebo for Brequinar capsules x 5 days
33322064|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
33322065|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
33322066|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
33322067|NCT05372120|Experimental|ICP-192|20 mg once daily
33322068|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
32967022|NCT05449782|Other|Healthy participant: Placebo - Cocoa flavanol|Healthy participants receiving placebo on first study day and cocoa flavanols on second study day
33410505|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
32967023|NCT05449782|Other|Type 2 diabetes participants: Cocoa flavanol - Placebo|Participants with type 2 diabetes receiving cocoa flavanols on first study day and placebo on second study day
32967024|NCT05449782|Other|Type 2 diabetes participants: Placebo - Cocoa flavanol|Participants with type 2 diabetes receiving placebo on first study day and cocoa flavanols on second study day
32967025|NCT05449704|Experimental|Sequence A|
32967026|NCT05449704|Experimental|Sequence B|
32967027|NCT05449548|Experimental|Intervention with lenalidomide|All subjects will be treated with lenalidomide 10mg/day.
32967028|NCT05449158|Experimental|LAP Group|Control of left atrial pressure changes by adjusting pacemaker frequency
32967029|NCT05449158|No Intervention|Control Group|General pacemaker rate setting
32967030|NCT05449080||Cases|subjects with type 2 5-alpha reductase deficiency
32967031|NCT05448846|Active Comparator|Control|Usual care (i.e., 'Enhanced Recovery After Surgery' (ERAS) protocol)
32967032|NCT05448846|Experimental|Home-based multicomponent exercise program|Complete a home-based multicomponent exercise program from diagnosis to 3 months after surgery in addition to ERAS protocol.
32967033|NCT05448612|Experimental|Active Release Technique|In ART the particular muscle is taken from shortened to lengthened position or vice versa. Duration of treatment will be of 8-15min
32967034|NCT05448612|Experimental|Muscles Energy Technique|In METs,the protocol will perform for 3 repetitions per day and thrice a week for 5 week.
32967035|NCT05447988|Other|Two-stage reconstruction|136 participants will undergo two-stage reconstruction
32967036|NCT05447832||1/Children aged between 1-5 years from the emergency department|Children who have attended the emergency department at St Mary's Hospital, with an acute attack of wheezing. These families will be asked to use the lung function monitoring and the wheeze detection device every night for 2 weeks, while recording symptoms and medication use in the last 24 hours.
32967037|NCT05447832||2/Children aged between 1-5 years admitted electively for wheezing investigation|Children who have been admitted electively for investigations of their wheezing at the Brompton Hospital. These children/families will be asked to do the lung function monitoring and the wheeze detection device once per week for 4 months, while recording symptoms and medication use in the last 24 hours.
32967038|NCT05447754|Experimental|Combined RAGT and TBT|Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
32967039|NCT05447754|Active Comparator|TBT Only|Participants were given balance exercises (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing without an assistive device, walking on a flat surface to the forward and sideways) for 5 weeks, 5 times a week and for 40 minutes in each session. lying down while sitting and standing) will be applied.
32967040|NCT05447676|Active Comparator|Dalfampridine (4-AP)+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of 4-AP, STDP stimulation and training.
32967041|NCT05447676|Placebo Comparator|Placebo+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of placebo drug, STDP stimulation and training.
32967042|NCT05447676|Experimental|Dalfampridine (4-AP)+STDP+training for extended sessions|The long-term effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of 4-AP, STDP stimulation and training.
32967043|NCT05447364|Experimental|75 mg of Pregabalin|Participant received 1 tab of 75 mg of Pregabalin and 1 tab of placebo
32967044|NCT05447364|Active Comparator|150 mg of Pregabalin|Participant received 2 tabs of 75 mg of Pregabalin
32967045|NCT05447052|Experimental|Bio-MIMICS Stent|Helical shaped BioMimics 3D Stent
32967046|NCT05447052|Active Comparator|Innova Stent|Conventional: Nitinol Stent
32967047|NCT05446974|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
32967048|NCT05446974|No Intervention|Non-intervention|Nurses randomly assigned by applying a random selection method
32967049|NCT05446896|Experimental|AR group|participants in the AR group were guided by AR-based instructions and requested assistance with the head-mounted device.
32967050|NCT05446896|No Intervention|manual group|Participants in the manual group used a printed manual and made a phone call for assistance.
32967051|NCT05446818|Active Comparator|Flavanol first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: CF-P-CF-P-CF-P-CF-P
32967052|NCT05446818|Active Comparator|Placebo first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: P-CF-P-CF-P-CF-P-CF
32967053|NCT05445726||Healthy|Generally healthy participants that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
32967054|NCT05445726||Atrial Fibrillation Diagnosis|Participants with a diagnosis of atrial fibrillation that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
32967055|NCT05444322|Experimental|RD14-01 cell infusion|Infused i.v. in a single dose
33322069|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
33322070|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
32967056|NCT05442684|Experimental|Ad5-nCoV/O group|
32967057|NCT05442684|Experimental|Ad5-nCoV/O-IH group|
32967058|NCT05442684|Active Comparator|mRNA-based COVID-19 vaccine group|
32967059|NCT05439018|Experimental|Integrated Neuromuscular Inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique )
32967060|NCT05439018|Active Comparator|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
33322071|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
33322072|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
32861415|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
32861416|NCT02584933|Experimental|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
32861417|NCT04852458|Experimental|Intravenous hydrocortisone|
32861418|NCT04852458|No Intervention|Observational|Participants will complete assessments/surveys only.
32861419|NCT04851366|Experimental|PROCARE+ (with add-on modules)|In addition to core UP-A preventive intervention, PROCARE will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include, but not limited to social, parental, stress-related (including CoVid19 impact) risk factors, and health. Dosage (number of modules) will be included as covariate in all subsequent analyses.
32861420|NCT04851366|Experimental|PROCARE (UP-A for selective purposes)|To ensure cost-effectiveness, PROCARE core intervention will be designed as a brief 8-session child-focused programme which aims to build resilience for adolescents by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical selective preventive intervention format focused on cost-effectiveness.
32861421|NCT04851366|Active Comparator|Active control condition.|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for two alternative compare conditions to PROCARE. The U Talk programme support-based group condition will be used as active control condition."
32861422|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
32861423|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
32861424|NCT04967040|Active Comparator|group 1 : medial plantar artery flap|
32861425|NCT04967040|Active Comparator|group 2 : distally based sural artery flap|
32861426|NCT01452217|Experimental|Secretin|
32861427|NCT04966650|Experimental|Intervention group|For the intervention group, participants will receive a 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT). The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms. At the 2nd month, participants will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given a booster intervention. At 6th months, subjects will be assessed their depression symptoms and the level of physical activity changes via questionnaire.
32861428|NCT04966650|No Intervention|Control Group|A wellbeing leaflet from CHP will be provided to each participant. At the 2nd month, subjects will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given another wellbeing leaflets. At 6th months, subjects will be assessed their depression symptoms the level of physical activity changes via questionnaire.
32861429|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
32861430|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
32861431|NCT04966962||Bladder cancer|Patients who diagnosis with incident or recurrent bladder cancer
32861432|NCT04966962||benign disease of urinary system|Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
32861433|NCT04966728||suspected tear of the anterior superior labrum of the hip|One group consisted of patients with suspected tear of the anterior superior labrum of the hip.
32861434|NCT04966728||non-hip joint diseases|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
32861435|NCT04966572|Experimental|Presurgical vacuum formed nasoalveolar molding aligners group|In this group, all patients will receive 1-2 VF-NAM aligners incorporated with palatal screw in addition to taping from day 1 for 4-6 Months with follow-up every 3 weeks
32861436|NCT04966572|Experimental|conventional Grayson acrylic formed nasoalveolar molding appliances group|This group will receive conventional Grayson acrylic formed nasoalveolar molding appliances without taping except some cases, with follow up every week for activation.
32861437|NCT04966884|Experimental|A single-arm open-label pilot observational study|Patients were received a glucocorticoids (0.8mg-1mg/kg/day) and a combination with tofacitinib (at a dose of 5 mg twice daily).
32861438|NCT04962906|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
32861439|NCT04962906|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
32861440|NCT04962906|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
32861441|NCT04966806|Other|Percentage of Coma and SA to Total ocular HOA|
32861442|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
32861443|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
32861444|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
32861445|NCT04966260|Experimental|Standardized Virtual Reality|Participants in the standard virtual reality (VR) group will choose from the general library of VR experiences. Participants will be asked to select an experience they desire but have never experienced in person. The session will be facilitated by the therapeutic recreation staff on the unit.
32967061|NCT05435664|Experimental|Intervention Group|During the first interview, the nurses in the intervention group were informed about PGE in a convenient and quiet room within the hospital, face-to-face and face-to-face. Afterwards, the researcher 15 minutes of application was made with the accompaniment. In order for the participants to practice at home, a voice recording containing the PGE steps voiced by the researcher in his own voice was sent to the nurses' phones. Nurses were asked to perform the PGE exercise by listening to the audio recording file for 15 minutes once a day for 4 weeks. In addition, daily reminders were made by creating a group over the WhatsApp application in order to prevent it from being forgotten. They were asked to provide feedback on their compliance with the program. At the beginning of the study, at the beginning of the study, at the 1st, 2nd, 3rd and 4th weeks (at the end of the application), the 'Fatigue Severity Scale' was administered again through face-to-face interviews.
32967062|NCT05435664|No Intervention|Control group|"No intervention was made to the nurses in the control group. In the second and fourth weeks of the study, the Fatigue Severity Scale will be applied again through face-to-face interviews. At the end of the study, nurses will be informed about PGE and a voice recording will be sent to their phones from the WhatsApp application, containing the PGE steps, which the researcher voiced with her voice."
32967063|NCT05430750|Active Comparator|Conventional' - N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min (Low flow) and allowed to reach MAC 1.0 before incision is allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
32967064|NCT05430750|Active Comparator|'Streamed -in' N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %. When MAC 1.0 is reached incision will be allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
32967065|NCT05430750|Active Comparator|Non-N2O group|Ventilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow). The incision is allowed when MAC 1.0 is achieved .At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the O2 - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
32967066|NCT05418036|Other|Consecutive patients elegible for outpatient sotalol indication|Single Group
32967067|NCT05392920||Obese children and adolescents|Obese children and adolescent patients
32967068|NCT05381610|Experimental|Neurogenic Bowel|This is a US-Only, early feasibility, Investigational Device Exemption - Non-Significant Risk (IDE-NSR), single-center, open label study evaluating the effects of Peristeen, compared to a LVE administered into the rectum. The subjects to be analysed will be subjects with : Neurogenic Bowel Dysfunction (NBD). The NBD cohort will be broken down into two phases: LVE and Peristeen. See Statistical section 10 for more infor-mation on cohort and sub-group analyses.
32967069|NCT05378178|Experimental|Phase I：Dose escalation|HS-10381 given orally QD of various dose strengths administered in 21 day dosing cycles.
32967070|NCT05337618|Experimental|SD-Guided Care|In this arm, ECoG data will be reviewed for SDs in real-time using the bedside clinical CNS monitor. As a secondary measure, recognition of SDs will be facilitated by custom software on a laptop that receives data from the CNS monitor. Data on SD occurrence will be used to guide treatment in a tier-based therapeutic escalation and de-escalation protocol with the goal of SD suppression. Therapies to be used among the tiers include adjusted targets for MAP, CPP, PaCO2, plasma glucose, temperature, as well as ketamine pharmacotherapy. Changes between tiers are determined by the success or failure of SD suppression at the given treatment level.
32967071|NCT05337618|No Intervention|Standard ICU Care|"Management in the Standard ICU Care arm will follow published national guidelines consisting of common ICU-based targets for physiologic intervention that are thought to mitigate the development of secondary brain injuries.~Continuous ECoG monitoring will be performed for seizure monitoring, but information on the course of SDs in these patients will not be used to guide care. To enforce blinding to SD-related ECoG data, the ECoG bedside software will be locked with password protection to prevent displays with frequency filtering and time/amplitude scales that are necessary to identify SDs."
32967072|NCT05327790|Experimental|LFMT capsules + vedolizumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
32967073|NCT05327790|Placebo Comparator|Placebo capsules + vedolizumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
32967074|NCT05327790|Experimental|LFMT capsules + ustekinumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
32967075|NCT05327790|Placebo Comparator|Placebo capsules + ustekinumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
32967076|NCT05316714|Experimental|IPP Nanofat Grafting|Nanofat surgical grafting in albuginea penile tunica
32967077|NCT05292534|Active Comparator|Amplification-only|Hearing aid will be fit to prescribed participant hearing loss.
32967078|NCT05292534|Active Comparator|Amplification with added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated on the hearing aid.
32967079|NCT05292534|No Intervention|No intervention|Participants will return to their original unaided state.
33322073|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
32967080|NCT05274048|Experimental|Neratinib plus TDxD|Neratinib oral daily days 1-21 plus TDxD on day 1 administered intravenously of a 21 day treatment cycle.
32967081|NCT05273658|Placebo Comparator|Placebo|Placebo cannabis and placebo alcohol
32967082|NCT05273658|Experimental|Cannabis, No alcohol|18.16% THC, placebo alcohol
32967083|NCT05273658|Experimental|Cannabis, Low dose alcohol|18.16% THC, .07 breath alcohol concentration
32967084|NCT05273658|Experimental|Placebo cannabis, High dose alcohol|<.1% THC, .10 Breath alcohol concentration
32967085|NCT05273658|Experimental|Placebo cannabis, Low dose alcohol|<.1% THC, .07 breath alcohol concentration
32967086|NCT05249322|Experimental|Follow-up alternating between face-to-face consultation and teleconsultation every three months|Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)
32967087|NCT05234346|Experimental|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
32967088|NCT05234346|Placebo Comparator|Placebo|
32967089|NCT05194410|Experimental|Intervention|6 months of virtual, team-based exercise
32967090|NCT05194410|Other|Control|3 months of usual exercise and then 3 months of virtual, team-based exercise
32967091|NCT05190666|Experimental|PACE Weight Loss Program|Participants randomized to this arm will receive personalized diet, activity, and weight loss goals as well as tools to self-monitor behaviors and weight. To facilitate changes, participants will receive coaching calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
32967092|NCT05190666|Sham Comparator|Chronic Disease Self-Management Program|Participants randomized to this arm will receive a chronic disease self-management program including a self-management book. Participants will receive regular calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
32967093|NCT05130294|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
32967094|NCT05130294|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
33322074|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
33322075|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
32967097|NCT05079828|Active Comparator|Arm 1|Patients receive first a PET/CT with 68Ga-PSMA-11 and a second PET/CT with 18F-PSMA-1007
32967098|NCT05079828|Active Comparator|Arm 2|Patients receive first a PET/CT with 18F-PSMA-1007 and a second with 68Ga-PSMA-11
32967099|NCT05028426||Traditional method of care|Patients managed according to the traditional care protocol without an enhanced recovery program
32967100|NCT05028426||Some elements of a fast-track program|operative and postoperative techniques were modified according to a fast-track program
32967101|NCT05028426||Full enhanced recovery program|Patients were managed in an enhanced recovery program (elements of the previous fast-track program were modified and preoperative education was added)
32967102|NCT05023278|Placebo Comparator|Placebo|Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
32967103|NCT05023278|Experimental|Venlafaxine|Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
32967104|NCT05021172|Experimental|Arm I (Passport to Health booklet, ePrognosis)|Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
32967105|NCT05021172|Active Comparator|Arm II (usual care)|Participants receive usual care before scheduled primary care visit.
32967106|NCT04964466||Amount of PDGF-BB in PRF preparation vs. GEM21|The release kinetics of PDGF-BB will be assessed for one PRF preparation from each of the six individual participants and one GEM 21S sample. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
32967107|NCT04964466||PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
33033551|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
33104904|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
33104905|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
32967108|NCT04964466||: Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
32967109|NCT04964466||Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
32967110|NCT04962048|Experimental|pulse-synchronized negative pressure (PSNP) device|One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.
32967111|NCT04949568|Experimental|Diabetes Self-Management Behaviors|Self-Management Education Program The culturally tailored Diabetes Self-Management Education Program involves the following: 1) an initial 45-minute face-to-face private consultation collaboratively determining goals; followed by 2) six 2-hour weekly educational interactive sessions in a format TBD by aim 1. We will deliver culturally targeted written materials and presentations in these sessions. Participants will be asked to practice self-management behaviors concurrently and for four additional weeks.
32967112|NCT04949568|No Intervention|Usual Type 2 Diabetes Care|The usual care arm will receive the clinic's standard type 2 diabetes care and remain under their providers' care for the duration of the study.
32967113|NCT04944810||Magnetic bariatric surgery|Perform a bariatric surgery using the magnetic device like a second assitant in the steps of the surgery in order to perform the surgery with less incisions and with the same safety
32967114|NCT04928508|Experimental|SHetA2 capsule|SHetA2 (oral, BID) within a 21-days cycle
32967115|NCT04914702||Everion® only|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
32967116|NCT04914702||CORE® only|A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
32967117|NCT04914702||Everion® first, CORE® second|"Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.~Then a CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene."
32967118|NCT04914702||CORE® first, Everion® second|"A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.~Then two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene."
32967119|NCT04914702||Everion® and CORE® simultaneously|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, and one CORE® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
32967120|NCT04899804||Validity and Reliability Group|This study will be completed in two phases. In the first phase, the participants included in the study will be evaluated first by tele-assessment. One hour later, all assessments will be repeated face-to-face procedures by the researchers; thus, the validity of the tele-assessment method will be determined. Before the tele-assessment, participants will be informed about having a chair whose floor-to-seat height is 48 cm and tape measure. In the second phase of the study, to determine the reliability of the tele-assessment method, all tests will be applied to the previously tested participant by the same researcher one week later and at the same time of the day using only the tele-assessment method.
32967121|NCT04881708|No Intervention|Current Care Group|The current care group will receive the standard of care currently in place within the subspecialty practices in the Department of Surgery, Mayo Clinic Rochester. This includes postoperative inpatient care directed by the surgical team, including timing of discharge and follow-up.
32967122|NCT04881708|Active Comparator|Remote Care Group|Patients randomized to the remote monitoring arm will engage in a Connected Care Remote Patient Monitoring (RPM) Complex Care program. RPM Complex Care programs utilize established and standardized equipment, logistics/reverse logistic, engagement methods, and nursing clinical practice. Use of RPM Complex Care programs in this manner, is considered standard practice. Patients will be monitored for 30 days by the Connected Care nursing team as is standard for surgical RPM Complex Care programs.
32967123|NCT04810806|Experimental|Immediate coronary angiography group|Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
32967124|NCT04810806|Active Comparator|Delayed coronary angiography group|Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.
32967125|NCT04744428|Experimental|Autism Parent Navigators Intervention|Autism Parent Navigators Intervention is a manualized, in-home, peer support model for parents with a young child recently diagnosed with ASD.
32967126|NCT04744428|Active Comparator|Peer mentoring|Peer mentors will offer an equivalent number of in-home or telephone visits for families, providing non-manualized peer support.
32967127|NCT04727424|Active Comparator|Fluvoxamine Maleate + Budesonide Inhalation powder|"Fluvoxamine 100 mg oral tablets:~One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) after randomization (Day 0) followed by 400 mcg BID for the following 09 days"
32967128|NCT04727424|Active Comparator|Fluvoxamine Maleate|"Fluvoxamine 100 mg oral tablets:~One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days"
32967129|NCT04727424|Placebo Comparator|Placebo (mild disease)|"Placebo SC normal saline syringe (single day schedule):~Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC).~OR~Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS~Placebo Inhalation Therapy:~One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule)~OR~Placebo oral tablets (10-day schedule for patients with SPO2 < 94%):~One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)"
32967130|NCT04727424|Active Comparator|Peginterferon Lambda|"Peginterferon Lambda 180 mcg syringe:~One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration)."
32967131|NCT04727424|Active Comparator|Fluxetine + Budesonide Inhalation powder|"Fluoxetine 20 mg oral tablets:~Two tablets right after randomization (Day 0) followed by 40 mg MID for the following 06 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by 400 mcg BID for the following 06 days"
32967132|NCT04715646|Experimental|Brivaracetam|LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.
32967133|NCT04698876|Experimental|Outpatient measurement of intraocular pressure|The intervention group measures its intraocular pressure itself in their home environment for 7 days at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m. with a self-tonometer (iCareHOME).
32967134|NCT04698876|Active Comparator|Stationary measurements of intraocular pressure|The intraocular pressure of the control group is measured by means of rebound tonometry or Goldmann applanation tonometry in a clinic for minimum 24 hours at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m.
32967135|NCT04688034|Experimental|OP-724 400 mg / 20 mL / vial (20 mg / mL)|"Dose: [Cohort 1] 140 mg/m2/4 hours (starting dose) , [Cohort 2] 280 mg/m2/4 hours~Administration method: In the single administration, the safety of concomitant use with the investigational drug and antiretroviral drug will be confirmed and then the cycle administration will be started. For the single administration, at 14 days before the first cycle of administration, the dose planned for the first cycle with continuous intravenous administration for 4 hours will be administrated once. When an integrase inhibitor is used in combination as a key drug for antiretroviral drugs, it should be administered at the same time as the start of investigational drug administration only after the single administration. For the cycle administration, the continuous intravenous administration for 4 hours twice a week is defined as one cycle, and 12 cycles (12 weeks in total) will be performed."
32967136|NCT04596384|Experimental|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
32967137|NCT04596384|Active Comparator|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
32967138|NCT04588038|Experimental|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
32967139|NCT04569942|Active Comparator|Vasopressor|a restricted fluids and early vasopressor strategy
32967140|NCT04569942|Active Comparator|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
32967141|NCT04532658|Experimental|Intervention arm|Surgeons randomly assigned to the intervention arm
32967142|NCT04532658|No Intervention|Control arm|Surgeons randomly assigned to the control arm
32967143|NCT04522206|Experimental|Patients undergoing elective spine surgery|
33322076|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
33322077|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
33410506|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
32967144|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
32967145|NCT04510116|Experimental|AIM preventive intervention|Families were assigned to receive a 6 session, 12 hour prevention program in their community.
32967146|NCT04510116|No Intervention|Control|Families were assigned to no intervention control.
32967147|NCT04505592|Experimental|Tenecteplase|First 20 patients randomized to treatment will receive tenecteplase 0.25 mg/kg (maximum 25 mg). Last 20 patients randomized to treatment will receive tenecteplase 0.50 mg/kg (maximum 40 mg).
32967148|NCT04505592|Placebo Comparator|Placebo|Placebo control
32967149|NCT04491006|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
32967150|NCT04491006|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
32967151|NCT04491006|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
32967152|NCT04477200|Experimental|Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)|Mycophenolate mofetil
32967153|NCT04477200|Experimental|Phase 1 - Recurrent GBM / GS|Mycophenolate mofetil; radiation therapy
32967154|NCT04477200|Experimental|Phase 1 - Newly Diagnosed GBM / GS|Mycophenolate mofetil; radiation therapy; temozolomide
32967155|NCT04460508|Experimental|Mecapegfilgrastim|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.
32967156|NCT04460508|Active Comparator|rhG-CSF|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.
32967157|NCT04416126|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
32967158|NCT04416126|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
32967159|NCT04415892|Other|Healthy volunteers|Young, healthy male volunteers to characterize the DBF changes upon cinnamaldehyde and capsaicin, including the reproducibility.
32967160|NCT04415892|Other|Paclitaxel Patients|Group of patients after treatment with paclitaxel.
32967161|NCT04415892|Other|Paclitaxel Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
32967162|NCT04415892|Other|Oxaliplatin Patients|Group of patients after treatment with oxaliplatin.
32967163|NCT04415892|Other|Oxaliplatin Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
32967164|NCT04415892|Other|Longitudinal Paclitaxel Patients|Group of patients who are treated with paclitaxel.
32967165|NCT04415892|Other|Longitudinal Oxaliplatin Patients|Group of patients who are treated with oxaliplatin.
32967166|NCT04399044|No Intervention|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
32967167|NCT04399044|Experimental|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
32967168|NCT04322370|Active Comparator|Group A|VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
32967169|NCT04322370|Active Comparator|Group B|Standard of Care Treatment Arm- Zone 2 flexor tendon repair
32967170|NCT04320186|Active Comparator|Treatment|Participants viewed informational video content plus entertainment content
32967171|NCT04320186|Placebo Comparator|Control|Participants viewed entertainment content only
32967172|NCT04316676|Other|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
32967173|NCT04299048|Experimental|PF-06946860|subcutaneous injection
32967174|NCT04272060|Experimental|CT Angiography|Research CT angiography.
32967175|NCT04272060|Active Comparator|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
32967176|NCT04256070|Experimental|Education, tele-consultation and training booklet|"Informed Consent Form will be taken in written from those who agree to participate in the research.~In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.~24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.~In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
32967177|NCT04256070|No Intervention|Standart care, no intervention|"Informed Consent Form will be taken in writing from those who agree to participate in the research.~At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.~A training booklet for COPD management will be provided."
32967178|NCT04226118|No Intervention|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
32967179|NCT04226118|Experimental|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
32967180|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
32967181|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
32967182|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
32967183|NCT04173780|Experimental|Atropine 0.01%|
32967184|NCT04173780|Placebo Comparator|Placebo|
32967185|NCT04129554|Experimental|JNJ-73763989+ JNJ-56136379+ NA|Participants will receive fixed dose of JNJ-73763989 subcutaneous injection once every 4 weeks along with fixed dose of JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) once daily up to 48 weeks.
32967186|NCT04129554|Placebo Comparator|Placebo for JNJ-73763989+ Placebo for JNJ-56136379+ NA|Participants will receive matching placebo for JNJ-73763989 subcutaneous injection once every 4 weeks with matching placebo for JNJ-56136379 once daily and NA treatment (either ETV, TDF or TAF) once daily up to 48 weeks.
32967187|NCT04128540|Other|Control group|This group will receive fentanyl infusion only
32967188|NCT04128540|Active Comparator|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
32967189|NCT04125732|Experimental|AdVEGFXC1 at 1x10^9 vp|
32967190|NCT04125732|Experimental|AdVEGFXC1 at 1x10^10 vp|
32967191|NCT04125732|Experimental|AdVEGFXC1 at 4x10^10 vp|
32967192|NCT04125732|Experimental|AdVEGFXC1 at 1x10^11 vp|
32967193|NCT04109976|Experimental|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
32967194|NCT04109976|Experimental|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
32967195|NCT04104438|Active Comparator|Basiliximab with Delayed TAC|"Basiliximab~Dose #1: 20mg IV within 2 hours of transplant~Dose #2: 20mg IV Post-operative day #4~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol~Post-operative taper:~Post-op day 1- methylprednisolone 50mg IVP Q6H~Post-op day 2- methylprednisolone 40mg IVP Q6H~Post-op day 3- methylprednisolone 30mg IVP Q6H~Post-op day 4- methylprednisolone 20mg IVP Q6H~Post-op day 5- methylprednisolone 20mg IVP Q12H~Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
32967196|NCT04104438|Active Comparator|Basliximab, Delayed TAC with Everolimus|"Basiliximab~Tacrolimus (with basiliximab induction)~o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated~Corticosteroids (SOC): Per UCLA protocol~Everolimus (delayed)~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
32967197|NCT04104438|No Intervention|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)~Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL~Six months to one year: maintain whole blood trough concentration of 5-10ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol"
32967198|NCT04085796||Older patients|Older patients who received the ICCI while in the hospital's A&E
32967199|NCT04085796||ICCI Professional|The member of staff who delivers the ICCI at the site
32967200|NCT04069884|Experimental|Arm I (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
32967201|NCT04069884|Active Comparator|Arm II (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
32967202|NCT04007640|Other|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
32967203|NCT04007640|Other|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
32967204|NCT04007640|Other|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
32967205|NCT04007640|Other|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
32967206|NCT04007640|Other|Overweight patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
32967207|NCT03913104|Experimental|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
32967208|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
32967209|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
32967210|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
32967211|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
32967212|NCT03752970|Experimental|Spesolimab|
32967213|NCT03752970|Placebo Comparator|Placebo|
32967214|NCT03745950|Experimental|Olaparib|"The Olaparib arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
32967215|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
32967216|NCT03737604|Active Comparator|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
32967217|NCT03737604|Active Comparator|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
32967218|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
32967219|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
32967220|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
32967221|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
32967222|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
32967223|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
32967224|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
32967225|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
33322078|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
33322079|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
33322080|NCT01364974|Experimental|Group A|low dose, all male
33322081|NCT01364974|Experimental|Group B|medium dose, all male
33322082|NCT01364974|Experimental|Group C|high dose, all male
33322083|NCT01364974|Experimental|Group D|medium dose, all female
33322084|NCT01364974|Placebo Comparator|Placebo|
33322085|NCT05323214|Other|Control group|Normal saline 2 ml will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
33322086|NCT05323214|Other|Fentanyl group|Fentanyl 2 ml (100 μg) will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
32967226|NCT03689244|Experimental|Selexipag OL|All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
32967227|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
32967228|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
32967229|NCT03604302|Experimental|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
32967230|NCT03516708|Experimental|Dose Escalation Cohort|"Epacadostat at the designated dose level starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery~Epacadostat is taken by mouth twice per day every day of each 21 day cycle~Standard of care preoperative therapy will consist of a total of approximately 20-24 weeks' preoperative therapy followed by surgery. Breakdown of the 20-24 weeks of preoperative therapy are as follows:~Week 1: Short-course pelvic radiation therapy, 5 fractions over 1 week~Weeks 2-4: Treatment break for 2 to 4 weeks; for patients enrolled at Washington University only, tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts"
32967231|NCT03516708|Experimental|Dose Expansion Cohort|"Epacadostat at the designated dose level starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery~Epacadostat is taken by mouth twice per day every day of each 21 day cycle~Standard of care preoperative therapy will consist of a total of approximately 20-24 weeks' preoperative therapy followed by surgery. Breakdown of the 20-24 weeks of preoperative therapy are as follows:~Week 1: Short-course pelvic radiation therapy, 5 fractions over 1 week~Weeks 2-4: Treatment break for 2 to 4 weeks; for patients enrolled at Washington University only, tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts"
32967232|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, they will receive baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone will assess symptoms. Approximately 35% of all participants will be in this group.
32967233|NCT03494166|Experimental|High Need A-SMH or TIP-C|Participants will be mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant will be called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. Calls will last approximately 10 minutes. After 4 weeks, participants will be re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIP-C) Intervention for the subsequent 8 weeks. If the TIP-C is added, the counselor will call the participant once per week for about 35-40 minutes to assess and discuss strategies for managing symptoms, provide survivorship education, and discuss interpersonal relationships, communication, and social support. At week 13, the participant will complete the second assessment.
32967234|NCT03494166|Experimental|High Need B-TIP-C+SMH|Participant will be called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor will assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls will focus be the SMH protocol. At week 13, the second assessment will be conducted.
32967235|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
32967236|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
32967237|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
32967238|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
32967239|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
32967240|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
33104906|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33322087|NCT05323214|Other|Dexmedetomidine group|Dexmedetomidine 1 ml (100 μg) plus 1 ml normal saline will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
33322088|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
32967241|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
32967242|NCT03269136|Experimental|PF-06863135|BCMA-CD3 bispecific antibody
32967243|NCT03269136|Experimental|PF-06863135 + dexamethasone|BCMA-CD3 bispecific antibody + dexamethasone
32967244|NCT03269136|Experimental|PF-06863135 + lenalidomide|BCMA-CD3 bispecific antibody + lenalidomide
32967245|NCT03269136|Experimental|PF-06863135 + pomalidomide|BCMA-CD3 bispecific antibody + pomalidomide
32967246|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
32967247|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
32967248|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
32967249|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
32967250|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
32967251|NCT03040596|Other|voice therapy only|standard voice therapy
32967252|NCT03026712|Experimental|Real tDCS|
32967253|NCT03026712|Sham Comparator|Sham tDCS|
32967254|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
32967255|NCT03022656|Active Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
32967256|NCT03022656|Active Comparator|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
32967257|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
32967258|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
32967259|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
32967260|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
32967261|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
32967262|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
32967263|NCT02952924|Experimental|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
32967264|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
32967265|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
32967266|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
32967267|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
32967268|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
33322089|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
33322090|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
33322091|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
33322092|NCT05283746|Experimental|Open Label|All subjects in Cohorts 1-4 receive 500 mg epetraborole once; Subjects on Cohort 5 receive 500 mg epetraborole twice
33322093|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
33322094|NCT01936480|Placebo Comparator|Placebo group|Healthy volunteers with QT genotype score in the highest or lowest quintile
33322095|NCT05371496|Active Comparator|Semaglutide Treatment|Subjects will receive Semaglutide once weekly in addition to counselling on healthy lifestyle intervention
33322096|NCT05371496|Placebo Comparator|Placebo Treatment|Subjects will receive matching placebo once weekly in addition to counselling on healthy lifestyle intervention
33322097|NCT05366816|Experimental|Group A: KIT Exon 13 receiving Sunitinib|Participants with KIT mutation on exon 13 will receive Sunitinib. Participants showing disease progression after first-assigned Sunitinib therapy have the option to receive Regorafenib therapy. Total allotted time for treatment is up to 12 months.
33322098|NCT05366816|Experimental|Group B: KIT Exon 17 receiving Regorafenib|Participants with KIT mutation on exon 17 will receive Regorafenib. Participants showing disease progression after first-assigned Regorafenib therapy have the option to receive Sunitinib therapy. Total allotted time for treatment is up to 12 months.
33322099|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
33322100|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
33322101|NCT05460260||GLUCODAY21|Study subjects for 21-day study
33322102|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
33322103|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
33322104|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
33322105|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
33322106|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
33322107|NCT01575886|Other|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
33322108|NCT03755180|Experimental|Group 1|Exercise Group
33322109|NCT03755180|Active Comparator|Group 2|Compression Group
33322110|NCT01356550|Experimental|Healthy subjects|
33322111|NCT01356550|Experimental|Hepatic impairment|
33322112|NCT05460104|Experimental|Expérimental|Virtual Reality Exposure Therapy will be realised.
33322113|NCT05460104|Active Comparator|Control|Standard care without VRET
33322114|NCT02060188|Experimental|Nivolumab Monotherapy|
33322115|NCT02060188|Experimental|Nivolumab + Ipilimumab|
33322116|NCT02060188|Experimental|Nivolumab + Ipilimumab Cohort C3|
33322117|NCT02060188|Experimental|Nivolumab + Ipilimumab + Cobimetinib Cohort C4|
33322118|NCT02060188|Experimental|Nivolumab + BMS-986016 Cohort C5|
33322119|NCT02060188|Experimental|Nivolumab + Daratumumab Cohort C6|
33322120|NCT03755024||normal group|fetuses with normal growth
33322121|NCT03755024||Growth retardation group|fetuses with retarded growth
33322122|NCT04549454|Experimental|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
33322123|NCT04549454|Placebo Comparator|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
33322124|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
33322125|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
33322126|NCT01356784|Experimental|Tailored Physical Activity|
33322127|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
33322128|NCT01356784|Other|Health Counselling|
33322129|NCT03752840|Experimental|Screening|
33322130|NCT03752840|Active Comparator|Case detection|
33322131|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
33322132|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
33322133|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
33322134|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
33322135|NCT01357018||patients with rheumatoid arthritis|
33322136|NCT01357018||patients with ankylosing spondylitis|
32967269|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
32967270|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
32967271|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
32967272|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
32967273|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
33322137|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
33322138|NCT01357096|No Intervention|Comparison group|
33322139|NCT01357096|Experimental|Integrated health care team|
33322140|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
32967274|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
32967275|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
32967276|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
32967277|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
32967278|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
32967279|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
32967280|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
32967281|NCT00860730|Experimental|Perceval S|
32967282|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
32967283|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
32967284|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the rectal primary tumor
32967285|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the rectal primary tumor
32967286|NCT05454930|No Intervention|Typical Commute|Participants spend two hours in automobile, on heavily trafficked roadways, without active filtration of air pollutants
32967287|NCT05454930|Other|Typical Commute, Filtered Air|Participants spend two hours in automobile, on heavily trafficked roadways, with active filtration of air pollutants
32967288|NCT05454774|Experimental|Arm of BBM 002|1×10^13 vg/kg, Single-dose treatment.
32967289|NCT05454540|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
32967290|NCT05454540|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The sham rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
32967291|NCT05454462|Experimental|KM-001 0.3%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
32967292|NCT05454462|Experimental|KM-001 1%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
32967293|NCT05454462|Placebo Comparator|Vehicle arm|Vehicle cream will be applied to the affected area twice daily for 4 consecutive weeks.
32967294|NCT05454384||Forensic Medicine|The group of consultation records requested from the Department of Forensic Medicine
32967295|NCT05454384||Oncology|The group of consultation records requested from the Department of Oncology
32967296|NCT05454384||Neonatology|The group of consultation records requested from the Department of Neonatology
32967297|NCT05454384||Otorhinolaryngology|The group of consultation records requested from the Department of Otorhinolaryngology
32967298|NCT05454384||Neurology and Neurosurgery|The group of consultation records requested from the Department of Neurology and Neurosurgery
32967299|NCT05454384||Pediatrics|The group of consultation records requested from the Department of Pediatrics
32967300|NCT05454384||Emergency Medicine|The group of consultation records requested from the Department of Emergency Medicine
32967301|NCT05454384||Other Departments|The group of consultation records requested from the Departments such as Plastic and Reconstructive Surgery, Cardiovascular Surgery, Internal Medicine, Ophthalmology, Urology, Gastroenterology, Palliative Care, Pulmonology, Sleep Medicine, and Infectious Diseases.
32967302|NCT05454150|Experimental|TAVI with balloon-expandable valve (Sapien 3/Ultra, Edwards Lifesciences©)|
32967303|NCT05454150|Active Comparator|TAVI with self-expanding valve (Evolut R/Pro, Medtronic©)|
33322141|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
33322142|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
33322143|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
33322144|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
33322145|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
33322146|NCT01365520|Experimental|N8|
33322147|NCT05191732|Experimental|PRP augmentation ACL reconstruction group|Platelet-rich plasma (PRP) (Dosage form: APA-15)
33322148|NCT05191732|Experimental|PRP+BMC augmentation ACL reconstruction group|Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
33322149|NCT05191732|No Intervention|Traditional ACL reconstruction group|No intervention
33322150|NCT05191654||with Congenital heart diseases|
33322151|NCT05191654||without Congenital heart diseases|
33322152|NCT02930122|Experimental|Anakinra|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
33322153|NCT02930122|Placebo Comparator|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
33322154|NCT01365598|Placebo Comparator|Placebo|Non-active drug
33322155|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
33322156|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
33322157|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
33322158|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
33322159|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
33322160|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
33322161|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
33322162|NCT01365208||advanced nasopharyngeal carcinoma|
33322163|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
33322164|NCT01358032|No Intervention|Control group|no program, only care as usual
33322165|NCT04546724|Active Comparator|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
33322166|NCT04546724|Placebo Comparator|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
33322167|NCT01365286|Active Comparator|Ivabradine-Placebo|
33322168|NCT01365286|Active Comparator|Placebo-Ivabradine|
33322169|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
33322170|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
33322171|NCT03697460|Experimental|INCB018424|INCB018424 Cream
33322172|NCT05191498|Experimental|Study patients|All patients receive intratumoral holmium microsphere injections.
33322173|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
33322174|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
33322175|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
33322176|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
33322177|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
33322178|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
33322179|NCT05191342||Rheumatoid arthritis|Patients with rheumatoid arthritis (n=25).
33322180|NCT05191342||Rheumatoid arthritis complicated atrial fibrillation|Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).
33322181|NCT05191342||healthy volunteers|Healthy volunteers (n=25).
33322182|NCT01365754|Active Comparator|A|A - Fusion
33322183|NCT01365754|Active Comparator|B|B - Dynamic (new)
33322184|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
33322185|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
33322186|NCT04498832|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) high dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0.
33322187|NCT04498832|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL standard-dose quadrivalent influenza vaccine (QIV-SD), subcutaneously (SC) at Day 0.
32967304|NCT05453994||Non-bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
32967305|NCT05453994||Bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days
32967306|NCT05453838|Other|New product - Original product|All subjects will receive first product A and then product B. In addition, the reference product will also be received (three times a glucose solution during the trial).
32967307|NCT05453838|Other|Original product - New product|All subjects will receive first product B and then product A. In addition, the reference product will also be received (three times a glucose solution during the trial).
32967308|NCT05453682|Experimental|Hypo IMRT|in muscle invasive bladder cancer, hypofractionated IMRT with chemotherapy
32967309|NCT05453604|Experimental|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers, urine samples and a blood sample from pregnant women and cancer patients with solid tumors with emphasis on breast- and prostate cancer. The participants will be asked to provide a urine sample collected with the Colli-Pee® device and fill out an online questionnaire to collect usability data.
32967310|NCT05453526||Race - American Indian or Alaska Native|Being identified as American Indian or Alaska Native
32967311|NCT05453526||Race - Asian|Being identified as Asian
32967312|NCT05453526||Race - Black or African-American|Being identified as Black or African-American
32967313|NCT05453526||Race - Native Hawaiian or Other Pacific Islander|Being identified as Native Hawaiian or Other Pacific Islander
32967314|NCT05453526||Race - White|Being identified as White
32967315|NCT05453526||Ethnicity - Spanish/Hispanic/Latino|Being identified as Spanish/Hispanic/Latino
32967316|NCT05453448|Experimental|tenofovir alafenamide|tenofovir alafenamide,Gilead Sciences,capsule,25 mg,once a day,Continuous use for 48 weeks.
32967317|NCT05453448|Experimental|entecavir|entecavir,Fujian cosunter pharmaceutical co.LTD,capsule,0.5mg,once a day,Continuous use for 48 weeks.
32967318|NCT05453214|Experimental|Fludrocortisone arm|10 hospitalised COVID-19 patients meeting inclusion criteria will receive fludrocortisone 0.1 mg tablets in addition to dexamethasone 6 mg / 24 hours and standard care
32967319|NCT05452980|Active Comparator|sleeve gastrectomy|For standard sleeve gastrectomy (SG), a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
32967320|NCT05452980|Experimental|SG with reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak. Three stitches using nonabsorbable 2-0 Prolone were performed to reestablish the acute angle of His: anterior gastric fundus with esophagus, gastric fundus with left crural diaphragm, posterior gastric fundus with left crural diaphragm.
32967321|NCT05451498|Experimental|Creatine Pre-Exercise|Consumes creatine within one hour before training and placebo within one hour after training
32967322|NCT05451498|Experimental|Creatine Post-Exercise|Consumes placebo within one hour before training and creatine within one hour after training
32967323|NCT05451498|Placebo Comparator|Placebo|Consumes placebo within one hour before training and placebo within one hour after training
32967324|NCT05448300|Active Comparator|Water exchange|This group of participants receives water exchange colonoscopy with the computer-aided polyp detection system.
32967325|NCT05448300|Active Comparator|Air insufflation|This group of participants receives air insufflation colonoscopy the computer-aided polyp detection system.
32967326|NCT05444478|Experimental|Microwave ablation|Patients only accepted microwave ablation
32967327|NCT05444478|Experimental|Microwave ablation plus lenvatinib|Patients accepted microwave ablation plus lenvatinib
32967328|NCT05358132||ARM-ED group 1 - Acute toxicity group|Patients attending the Emergency Department with acute sedating drug toxicity
32967329|NCT05358132||ARM-ED group 2 - PSA group|Patients undergoing procedural sedation and analgaesia in the Emergency Department
32967330|NCT05354466|Experimental|Sugammadex as reversal agent|
32967331|NCT05354466|Active Comparator|Neostigmine as reversal agent|
32967332|NCT05347602|Other|Phase 1: double-blinded placebo-controlled Supplement vs Placebo|Phase 1 (8 weeks): Supplement and Placebo groups ingested 3 oz of Supplement and Placebo per day respectively for the first four weeks as a loading dose, and then switched to 2 oz per day for weeks 5 - 8. This phase was double-blinded.
32967333|NCT05347602|No Intervention|Washout Phase|"Phase 2 (4 weeks): Both groups underwent a month-long wash out period, during which they did not ingest any of the Supplement or Placebo. This lasted from weeks 9-12. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure."
32967334|NCT05347602|Active Comparator|Phase 3: Supplement|Phase 3 (8 weeks): Both groups took the Supplement at 3 oz per day as a loading dose for four weeks (weeks 13 - 16), and then 2 oz per day for the final four weeks (weeks 17 - 20). This phase was open labeled, as all participants and the researchers were aware that all participants were ingesting the Supplement.
32967335|NCT05346432|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
32967336|NCT05346432|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
32967337|NCT05346432|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
33033552|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
32967338|NCT05236140|Experimental|Perineal electrical stimulation (Stimulation group)|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
32967339|NCT05236140|No Intervention|Control group|Subjects in the control group will go through baseline assessment and will not receive treatment or instructions to perform pelvic floor exercises at home. After 8 weeks they will be submitted to the final assessment. After the final evaluation, they will be invited to start treatment in the urogynecological rehabilitation unit.
32967340|NCT05144490|Experimental|Bodyweight Exercise|"A standardized 11-minute bodyweight exercise session that involves a 1-minute warm-up followed by 5, 1-minute bouts of exercise at a self-selected challenging pace, interspersed with 1-minute periods of low-intensity exercise for recovery."
32967341|NCT05144490|No Intervention|Non-Exercise Control|An 11-minute period of quiet sitting.
32967342|NCT05137704||Participant With ADHD|The record available for ADHD participants in primary care-based electronic medical records in the CPRD database linked to secondary care based episodic claims data available in HES database will be assessed.
32967343|NCT04978584|Experimental|Treatment (uLTRA, CHOP)|"COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr"
32967344|NCT04971096|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
32967345|NCT04971096|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
32967346|NCT04971096|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
32967347|NCT04971096|No Intervention|Healthy Control|No intervention
33410507|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
32967349|NCT04880616|Experimental|Sequence 1|In treatment period 1 participants will receive increasing doses of NBI-827104 for 28 days. After a 14-day washout period, participants will receive matching placebo for 28 days in treatment period 2.
32967350|NCT04880616|Experimental|Sequence 2|In treatment period 1 participants will receive matching placebo for 28 days. After a 14-day washout period, participants will receive increasing doses of NBI-827104 for 28 days in treatment period 2.
32967351|NCT04837404|Other|ultrasound guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.
32967352|NCT04837404|Other|fluoroscopy guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.
32967353|NCT04792086||Inhabitants in Nord-Trøndelag 70 years of age and older|All inhabitants in Nord-Trøndelag 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
32967354|NCT04792086||Inhabitants in one area in Trondheim, 70 years of age and older|All inhabitants one area in Trondheim, 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
32967355|NCT04720404|Experimental|Mindfulness Based Stress Reduction program|Healthcare workers in the MBSR arm will be invited to participate in an adapted online MBSR program added to support as usual
32967356|NCT04720404|Active Comparator|Daily self-help mindfulness exercises via YouTube-channel|Healthcare workers in the self-help arm will be invited to follow a self-help program with mindfulness/compassion exercises of 30 minutes per day via YouTube channel
32967357|NCT04683900|Experimental|Standard of Care + Mediterranean Diet|Participants will be given standard of care for constipation (handout) plus individualized diet education on the Mediterranean diet and instructed to follow the diet during the 8-week intervention period. Diet education will be administered by a study dietitian and followed with weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
32967358|NCT04683900|Active Comparator|Standard of Care|Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period. A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
32967359|NCT04674462|Experimental|CpG-adjuvanted HBV Vaccine|
32967360|NCT04674462|Active Comparator|Traditional HBV Vaccine|
32967361|NCT04608396|Experimental|AXS-05|
32967362|NCT04608396|Placebo Comparator|Placebo|
32967363|NCT04561128|Experimental|SHR-1819|Experimental: SHR-1819
32967364|NCT04561128|Placebo Comparator|Placebo|Placebo comparator: placebo
33410508|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
32967365|NCT04095624|Experimental|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
32967366|NCT04095624|Active Comparator|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
33322188|NCT00070018|Experimental|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m^2 on day 1, doxorubicin 50 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
33322189|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
33322190|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
33322191|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
32967371|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
32967372|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
32967373|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
32967374|NCT03395340|Experimental|Ruxolitinib cream|Investigational cream to 1 location; vehicle cream to 2nd location
32967375|NCT03395340|Placebo Comparator|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
32967376|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
32967377|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
32967378|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
32967379|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
32967380|NCT02714634|Experimental|methotrexate + targeted therapy group|"Methotrexate or leflunomide +~targeted therapy chosen by investigator"
32967381|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
32967382|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
32967383|NCT02708394|Placebo Comparator|placebo|Placebo comparator
32967384|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
33322192|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
33322193|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
33322194|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
33322195|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
33322196|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
33322197|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
33322198|NCT03750734||Healthy volunteers|Healthy volunteers
33322199|NCT00231413|Active Comparator|HPV-16/18 Group|Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322200|NCT00231413|Experimental|HPV-TETRA A Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322201|NCT00231413|Experimental|HPV-TETRA B Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322202|NCT00231413|Experimental|HPV-TETRA C Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322203|NCT00231413|Experimental|HPV-TETRA D Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322204|NCT00231413|Experimental|HPV-TETRA E Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33410509|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
32967385|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
32967386|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
32967387|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
32967388|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
32967389|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
32967390|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
32967391|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
32967392|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
32967393|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
32967394|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
32967395|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
32967396|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
32967397|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
32967398|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
32967399|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
32967400|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
32967401|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
32967402|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
32967403|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
32967404|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
32967405|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
32967406|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
32967407|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
32967408|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
32967409|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
32967410|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
32967411|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
32967412|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
32967413|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
32967414|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
32967415|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
32967416|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
32967417|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
32967418|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
32967419|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
32967420|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
33410510|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
32967421|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
32967422|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
32967423|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
32967424|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
32967425|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
32967426|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
32967427|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
32967428|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
32967429|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
32967430|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
32967431|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
32967432|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
32967433|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
32967434|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
32967435|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
32967436|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
32967437|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
32967438|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
32967439|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
32967440|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
32967441|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
32967442|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
32967443|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
32967444|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
32967445|NCT05350020|Experimental|Solu-Cortef® in deltoid muscle|Solu-Cortef® in deltoid muscle
32967446|NCT05350020|Experimental|Solu-Cortef® in thigh muscle|Solu-Cortef® in thigh muscle
32967447|NCT05350020|Experimental|Hydrocortisone 100mg/ml in deltoid muscle|Hydrocortisone 100mg/ml in deltoid muscle
32967448|NCT05350020|Experimental|Hydrocortisone 100mg/ml in thigh muscle|Hydrocortisone 100mg/ml in thigh muscle
33410511|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
32967449|NCT05349942|Experimental|Intraoral scanning and data acquisition|
32967450|NCT05349786|Experimental|Intervention Group|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
32967451|NCT05349786|No Intervention|Non-Intervention Group|The individuals in the control group, were pre-tested, evaluated at the first, second, and third months, and followed up in the process without any intervention. Patients were reminded that they should continue their routine medical treatment and not start any physical activity program.
32967452|NCT05349708|Experimental|Participant|Patients who were sent home with the intervention post-surgery
32967453|NCT05349708|No Intervention|Historical controls|
32967454|NCT05349474|Experimental|Metformin Treatment|Metformin 500 mg tablets up to 2,000 mg (4 tablets) a day divided into two doses. Patients will start on 500 mg Qday and a titration to maximum dose will be attempted during the first 30 day period of the study.
32967455|NCT05349474|Placebo Comparator|Placebo Treatment|Placebo tablets identical to metformin 500 mg tablets divided into two doses. Patients will be started on 1 tablet a day and a titration to maximum dose (4 tablets) will be attempted during the first 30 day period of the study.
32967456|NCT05349396|Experimental|Eszopiclone Test Product T-1|Participants will receive one tablet of the Test T-1 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
32967457|NCT05349396|Experimental|Eszopiclone Test Product T-2|Participants will receive one tablet of the Test T-2 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
32967458|NCT05349396|Active Comparator|Eszopiclone Referent Product|Participants will receive one tablet of the marketed reference formulation containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
32967459|NCT05349084|Other|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
32967460|NCT05348694|Active Comparator|Pendulum WBF-038|Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
32967461|NCT05348694|Placebo Comparator|Pendulum Placebo|Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
32967462|NCT05348148|Active Comparator|Oral Levocetirizine|Patients in Levocetirizine group will use oral antihistamine (Levocetirizine) only
32967463|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine|Patients in combined Intranasal Mometasone Furoate with oral Levocetirizineintranasal group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine)
32967464|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|The other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline)
32967465|NCT05348070||Operated Non-Ruptured Endometrioma Group|It consists of patients who were found to have endometrioma in their clinical follow-ups and decided to operate as a result of the evaluations. The patients were operated under elective conditions.
32967466|NCT05348070||Operated Ruptured Endometrioma Group|Rupture of endometrioma, which is a rare gynecological emergency. This group consists of endometrioma patients requiring urgent/subacute operation such as acute abdominal pain, hemodynamic instability, intra-abdominal bleeding. The patients were operated after completing the necessary preparations
32967467|NCT05346120|Experimental|Intervention|Single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs) lasting approximately 30 minutes
32967468|NCT05346120|Placebo Comparator|Placebo controlled|PlasmaLyte A supplemented with 5% HSA
32967469|NCT05334732|Experimental|Sisters Informing Sisters Sessions|The intervention is peer-based and in concert with our theoretical model, builds upon positive role-modeling of the survivor coach to the patient, addresses behavioral expectations/capacities, and uses Motivational Interviewing (MI) techniques. The intervention includes a culturally relevant coach's manual and a patient workbook that will be used to facilitate the coaching sessions.
32967470|NCT05334732|No Intervention|Enhanced Usual Care|Women in the EUC arm will receive usual care that includes standardized information in the public domain (NCI treatment information booklet). This booklet was chosen to provide women with national-level recommendations regarding treatment recommendations.
32967471|NCT05272566||Infants|"30 healthy, term infants are recruited for 2 purposes:~To study the development of gut bacteria and viruses over time~To use as donors in a separate trial"
32967472|NCT05272566||Mothers|"30 healthy pregnant women are recruited along with their infants~To compare gut bacteria and viruses with those of their children~To screen for disease transferrable by breastfeeding"
32967473|NCT05266482|Experimental|Intervention group|Next to the usual care, patients also get the opportunity to download and read a personal report.
32967474|NCT05266482|No Intervention|Control group|Patients will receive the usual care.
32967475|NCT05259930|No Intervention|Chronic gastrointestinal disease (IBD and liver cirrhotic patients)|Liver cirrhotic patients to receive best practice nutritional assessment and supports
32967476|NCT05259930|Experimental|branched-chain amino acid (BCAA)|Liver cirrhotic patients to receive best practice nutritional assessment and supports in addition to a 12-week course of BCAA supplementation
32967477|NCT05259930|No Intervention|Healthy Control|Controls attending gastroenterology outpatient or endoscopy services with no chronic inflammatory GI disease.
32967478|NCT05257590|Experimental|Nivolumab + CVM-1118|"1 Cycle = 28 days~Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.~CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID.~Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3~Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
33033553|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
33033554|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
33104907|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33104908|NCT01349582|Active Comparator|flow diversion|
32967479|NCT05192226|Experimental|Counterfactual Strategy Intervention|After participants finish describing past events where they were unable to participate or engage in physical activity and have identified barriers which impacted their events they just described, participants will be randomly assigned to conditions. Participants in the counterfactual strategy condition will engage in counterfactual strategies on barriers they believe they could have reasonably acted on to increase physical activity in their described event(s) that would have led to a better outcome. After identifying the counterfactual strategies, participants will then select three counterfactual strategies they just identified that they could use at some point in the upcoming week, any obstacles to using that counterfactual strategy, ways to overcome those obstacles, their intention to use the counterfactual strategy over the next week, and how likely they think the counterfactual strategy would have happened and led to the better outcome.
32967480|NCT05192226|No Intervention|Control|Participants will be asked to describe past events where they were unable to participate or engage in physical activity. All participants will walk through the NIMHD framework with a researcher and be guided to identify barriers at various domains and levels of influence, which impacted their events they just described. After barrier identification, participants will be asked to select three barriers to talk aloud and list out additional details about the barriers identified.
32967481|NCT05457192||Moderate diabetic polyneuropathy (DPN)|65 patients of both sexes (males & females) with type II DM with moderate polyneuropathy will be included. Patients will be enrolled and assessed for their eligibility to participate in this study. Their body mass index (BMI) will range from 20:30 kg/m2, age will range from 40-60 years, postprandial blood sugar more than 200 mg/dl, duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) (score nine to 11 points), and Neuropathy Impairment Score in the lower limbs (NIS-LL) (The muscle power of the lower limbs will be more than grade 2 and less than grade 4)
32967482|NCT05456958|Experimental|Amygdala|PTSD participants will receive a neurofeedback signal reflecting amygdala activity.
32967483|NCT05456958|Experimental|Posterior cingulate cortex (PCC)|PTSD participants will receive a neurofeedback signal reflecting PCC activity.
32967484|NCT05456958|Experimental|Sham-control|PTSD participants will receive a sham neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
32967485|NCT05456568|Experimental|All participants|All participants will use IPC daily at home for 12 weeks alongside usual and standard care
32967486|NCT05456022|Experimental|Quercetin drug.|
32967487|NCT05456022|Experimental|Quercetin-encapsulated PLGA-PEG nanoparticles|
32967488|NCT05456022|Active Comparator|Doxorubicin chemotherapeutic drug|
32967489|NCT05455788||Patients undergoing Cardiac valve replacement|
32967490|NCT05455554||CLI (Critical Limb Ischemia)|CLI cohort is a population of individuals with CLI, at least one active lower extremity wound and planned lower extremity revascularization. CLI cohort patients will receive Flowmet-D measurements in addition to standard of care therapy following intervention.
32967491|NCT05455554||HBO (Hyperbaric Oxygen)|HBO cohort is a subset of the CLI cohort who will undergo hyperbaric oxygen therapy in the post-operative setting who will receive Flowmet-D measurements before and after their therapy.
32967492|NCT05455398|Experimental|Round window niche enlargement group|The round window niche was surgically removed by general anesthesia, the round window membrane was opened as entirely as possible, and the blockage of the round window membrane was carefully identified.
33410512|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
33410513|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
32967493|NCT05455398|Active Comparator|Drum chamber injection group|Methylprednisolone (40 mg) was injected via puncture in the posterior quadrant of the tympanic membrane once daily for 7 d. Patients were instructed to remain supine for 30 min to keep the drug in the tympanic chamber and to avoid swallowing to prevent drug flow from the eustachian tube.
32967494|NCT05455242|Experimental|Habit Formation Interventions|Single subject design used for individual control (A-B design). During baseline phase (A), participants completed self-care activities ratings once per week for 4 weeks. During intervention phase (B), participants engaged in weekly sessions to address goals related to diabetes self-management and guided in habit formation. Participants engaged in intervention for 10 weeks, in accordance with habit formation recommendations by Lally et al. (2010). Each weekly session were held virtually (telephone or Zoom) and lasted 30-60 minutes, beginning with administration of the SDSCA and SRBAI. Participants were instructed in ongoing context-specific implementation intention to promote occupational participation in DSM through habit formation. This instruction included continued education and context modification recommendations. At two week intervals, additional areas of DSM were added until each were covered: blood glucose monitoring, nutrition, medication management, and physical activity.
32967495|NCT05455164|Other|Without supplementation, followed by Supplementation with Dietary Fibre|"For the first two weeks, subjects were given eucaloric prepared meals typical of Indonesian diet, which has low protein and low DF contents (contain less than 15 g/d of DF and protein content less than 15% of total macronutrient distribution range).~After two weeks of washing periods, all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range). At the end of interventions, waist circumference, body weight, body composition, fasting plasma glucose, uric acid, and total cholesterol were measured again. Half of DF content in food came from natural occurring fiber from fruit, vegetables and whole grains, the other half (50%) come from IMO-based fiber supplement (FibercremeⓇ, PT. Lautan Natural Krimerindo, Mojokerto, Indonesia"
33033555|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
32967496|NCT05455086|Experimental|Arm I (pronated e-liquid, unprotonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET?CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest"
32967497|NCT05455086|Active Comparator|Arm II (unprotonated e-liquid, protonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT."
32967498|NCT05455008|Experimental|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
32967499|NCT05453916|Experimental|Nitazoxanide|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
32967500|NCT05453916|Active Comparator|Rifaximin|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days.
32967501|NCT05451420|Experimental|Group A|PegIFN α- 2b monotherapy, 180 μg/ week, 68 weeks of treatment, 24 weeks of follow-up after drug withdrawal
32967502|NCT05451420|Active Comparator|Group B|Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.
32967503|NCT05448144||Alcohol-associated liver disease|drinking, had fatty liver, hepatitis, or hepatic cirrhosis
32967504|NCT05448144||Purely drinking|drinking, but had no fatty liver and hepatitis.
32967505|NCT05448144||Healthy control|no drinking and no liver diseases.
32967506|NCT05409378|Experimental|The HLT® Meridian® TAVR Valve|Transcatheter aortic valve replacement with the HLT Meridian TAVR Valve
32967507|NCT05376150|Experimental|XEN1101 10 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day
32967508|NCT05376150|Experimental|XEN1101 20 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day
32967509|NCT05376150|Placebo Comparator|placebo|During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day
32967510|NCT05329038|Experimental|Adult group|90 subjects aged 18-59 years received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
32967511|NCT05329038|Experimental|Elderly group|90 elderly aged 60 year and older received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
32967512|NCT05324124|Experimental|Selpercatinib (Period 1)|Selpercatinib will be administered orally on Day 1 either in fast or fed state.
32967513|NCT05324124|Experimental|Selpercatinib (Period 2)|Selpercatinib will be administered orally on Day 8 either in fast or fed state.
32967514|NCT05305092||chemotherapy|Premenopausal breast cancer patients receiving chemotherapy (including preoperative neoadjuvant chemotherapy) and endocrine therapy after surgery
32967515|NCT05305092||Endocrine therapy|Premenopausal breast cancer patients receiving endocrine therapy alone after surgery
32967516|NCT05305092||Healthy control|Healthy non-cancer controls
32967517|NCT05273814|Experimental|Tislelizumab+Bevacizumab+Pemetrexed|"Bevacizumab，7.5mg/kg，d1; Pemetrexed，500mg/m2，d1; Tislelizumab，200mg，d4; Q3W for 4 cycles;~Maintenance treatment ： Tislelizumab，200mg，d1; Bevacizumab，7.5mg/kg，d1; Q3W for 2 years"
32967518|NCT05215080|Experimental|Treatment group|Group of infants aged 6-7 months that given organic formula milk three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
32967519|NCT05166486|Experimental|Calisthenic exercise|The patients in the calisthenic exercise group will be given one-to-one hands-on calisthenic exercises by the research physiotherapist. They will be asked to do these exercises 3 times a week for 8 weeks. Patients will be followed up by asking whether they do their exercises or not. They will be asked to do the exercises twice a month for 8 weeks under the control of a physiotherapist. In this way, it will be ensured that the exercises are done correctly and that the patients do it completely.
32967520|NCT05166486|No Intervention|Control|Control
32967521|NCT05132322|Active Comparator|Unlearning Only|Includes educational outreach and audit & feedback.
32967522|NCT05132322|Experimental|Unlearning + Substitution|Includes educational outreach, audit & feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.
33104909|NCT01349582|Active Comparator|Best standard treatment|
33322205|NCT00231413|Experimental|HPV-TETRA F Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
33322206|NCT03991988|Experimental|Montelukast Group|Montelukast (10, 20, or 40 mg)
32967523|NCT05103618|Active Comparator|Healthy Control Couple Pairs|All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.
32967524|NCT05103618|Active Comparator|Active Couple Pairs Parkinson's Group|"15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD.~The female subject will undergo the baseline scan. Both members of the couple will complete surveys. The active group will receive training materials in the practice of OM which they will be asked to practice for the next 2-3 months The active couple-pair will begin the OM practice initially (in between the baseline and follow up). FDOPA scans will be conducted with female members with PD the couple pair at approximately 2-3 months."
32967525|NCT05103618|Other|Waitlist Couple Pairs Parkinson's Group|15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys The waitlist period in which the female member with PD will continue to receive standard of care for those 2-3 months; who then receive follow up scan. After the follow up scan, the waitlist group may be trained in the practice of OM for the next two months (but there will not be an additional FDOPA scan). Couple-pairs in the waitlist group will be asked to complete surveys at baseline and follow up scan and again after completing the OM Meditation practice. Couple pairs will engage in OM Meditation together approximately 3-4 times a week after the baseline and follow up scans for 2-3 months but female subjects with PD will not receive and additional post OM Meditation FDOPA scan
32967526|NCT05006118|Experimental|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
32967527|NCT04948866|Experimental|Intervention Condition: ADRD-PC Program|"Dementia-specific palliative care delivered by hospital-based specialty interdisciplinary palliative care teams.~Standardized caregiver education will be provided by the palliative care team. Clinicians will share and discuss the booklet Advanced Dementia: A Guide for Families, which addresses common concerns and treatment decisions.~Transitional care will be provided by the palliative care team, including facilitation of community-based services and two post-discharge telephone calls."
32967528|NCT04948866|Active Comparator|Control Condition|Patient-family caregiver dyads randomized to the control arm will receive educational materials from the Alzheimer's Association, specifically designed for late-stage ADRD caregivers. The patient will receive usual hospital and post-acute care.
32967529|NCT04867044||STUDY GROUP|patient diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
32967530|NCT04867044||CONTROL GROUP|healthy women volunteers
32967531|NCT04800510|No Intervention|NoCDO|Participants will be evaluated without a CDO.
32967532|NCT04800510|Experimental|CDO-A|The first design variant will be designated CDO-A.
32967533|NCT04800510|Experimental|CDO-B|The second design variant will be designated CDO-B.
32967534|NCT04800510|Experimental|CDO-C|The third design variant will be designated CDO-C.
32967535|NCT04784208||Arm 1-Healthy Volunteers|"Arm 1: Subjects from the general population who are naïve to their hypothyroid status.~The Subjects will be randomly selected and will be equally stratified between genders and socio-economics statuses from places where groups of general populations are located"
32967536|NCT04784208||Arm 2- Hypothyroid treatment naïve patients|The subjects will be identified and selected from clinical settings such as hospitals, clinics and certified laboratories.
32967537|NCT04782570|Experimental|Verum TMS|ITBS (intermittent Theta Burst Stimulation) over left frontal cortex
32967538|NCT04782570|Sham Comparator|Sham TMS|Sham TMS over left frontal cortex
32967539|NCT04775004|Active Comparator|Bone marrow venting procedure (BMVP)|Subjects randomized in the OR to undergo BMVP surgical augmentation
32967540|NCT04775004|Active Comparator|Platelet rich plasma (PRP)|Subjects randomized in the OR to undergo PRP surgical augmentation
32967541|NCT04741620|Active Comparator|Capsaicin 10microM|10mL capsaicin 10microM solution 3 times/day during 14 consecutive days (2 weeks).
32967542|NCT04741620|Active Comparator|Piperine 150microM|10mL Piperine 150microM solution 3 times/day during 14 consecutive days (2 weeks).
32967543|NCT04741620|Active Comparator|Cinnamaldehyde 756,6microM + zinc 70microM|10mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
32967544|NCT04741620|Active Comparator|Citric acid 457,5microM (pH=3,5)|10mL Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
32967545|NCT04741620|Active Comparator|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5)|10mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
32967546|NCT04741620|Placebo Comparator|Placebo|10mL placebo solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
32967547|NCT04607616|Experimental|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
33322207|NCT03991988|Placebo Comparator|Placebo Group|Matched placebo pill
33322208|NCT01370122||Subjects exposed to radiation|
33322209|NCT01370122||Subjects not exposed to radiation|
33322210|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
33322211|NCT04494646|Experimental|Bardoxolone Methyl|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
33322212|NCT04494646|Placebo Comparator|Placebo|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
33322213|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
33322214|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
33322215|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
32967548|NCT04607616|Experimental|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
32967549|NCT04607616|Experimental|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
32967550|NCT04607616|Experimental|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
32967551|NCT04607616|Experimental|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
32967552|NCT04607616|Experimental|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
32967553|NCT04589286|Experimental|Pack Health's Digital Life Coaching (DLC)|Participants will receive 16 weeks of access to a trained human life coach employed by Pack Health. Coaches will communicate via phone calls, text messages, emails, and links to web-based Pack Health resources plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
32967554|NCT04589286|Active Comparator|Quasi-usual care control arm|Participants will receive usual supportive care for stem cell transplantation plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
32967555|NCT04504188|Experimental|Heart Rate Monitor Enhanced Treatment Optimization|Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.
32967556|NCT04404114||Normal renal function|Normal renal function
32967557|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
32967558|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
32967559|NCT04404114||Chronic kidney disease|Chronic kidney disease
32967560|NCT04170894|Experimental|Apnea|Patients will undergo an atrial fibrillation ablation and will have induced periods of apnea throughout the procedure.
32967561|NCT04170894|Active Comparator|Control|Patients who choose not to participate in the apnea arm will have the opportunity to consent to the control arm. These patients will undergo an atrial fibrillation ablation per standard of care without periods of apnea throughout the procedure. This data will be collected to use as a comparator to the apnea arm.
32967562|NCT04112940||Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
32967563|NCT04063956|Experimental|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
32967564|NCT04063956|Active Comparator|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
32967565|NCT04024878|Experimental|Stanfard Platinum|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
32967566|NCT04024878|Experimental|Stanfard Platinum with Surgical or Core Needle Biopsy|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.~Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
32967567|NCT04004520|Experimental|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
32967568|NCT04004520|Other|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
32967569|NCT04004520|Other|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
32967570|NCT03845010|Active Comparator|Sotalol|
32967571|NCT03845010|Active Comparator|Flecainide and verapamil|
32967572|NCT03845010|Active Comparator|Catheter ablation|
32967573|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
32967574|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
32967575|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consists of participants born between 1948-1957.
32967576|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
32967577|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
32967578|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
32967579|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).~Lifestyle intervention books for breast cancer survivors at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
32967580|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
32967581|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
32967582|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
32967583|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
32967584|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
32967585|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
32967586|NCT05101746|Experimental|Nitric oxide group|Participants in this group will receive Nitric Oxide (NO) while undergoing Cardiopulmonary bypass (CPB)
33410514|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
33410515|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
32967587|NCT05101746|Active Comparator|Standard of care cardiopulmonary bypass procedure|Participants in this group will receive standard of care
32967588|NCT04961034|Other|classic KPE|the classic management of biliary atresia as described
32967589|NCT04961034|Other|modified KPE|we added 2 sutures posterior, one on each side and two anterior. this will hang the jejunal loop to promote tension free anastomosis
32967590|NCT04951518||Van Positive|Large Vessel Occlusion Positive
32967591|NCT04951518||Van Negative|Large Vessel Occlusion Negative
32967592|NCT04945356|Experimental|upper limb virtual training|6-week virtual training of the affected upper limb using the Physiotec application
32967593|NCT04927650||Screening|Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
32967594|NCT04918290|Experimental|Tegaderm Left|After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
32967595|NCT04918290|Experimental|Transpore Right|After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
32967596|NCT04902300||Adolescent|adolescent attending high school
32967597|NCT04845282|Experimental|Graded Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with a gradation of protein over the 12 week study duration.
32967598|NCT04845282|Active Comparator|RDA Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with the recommended daily allowance of protein over the 12 week study duration.
32967599|NCT04809324|Experimental|Gross examination|measurement of the surgical margins will be done by the surgeon in the operating room using sterile scale after resection of the primary tumor .
32967600|NCT04809324|Active Comparator|Frozen section|frozen section examination of surgical margins will be done by the pathologist.
32967601|NCT04763226|Experimental|Part A Furosemide|
32967602|NCT04763226|Experimental|Part B (SAD)|Single Ascending Dose (SAD)
32967603|NCT04726566||Arthroscopic stabilization|Patient will have an anatomical surgery of chronic lateral ankle instability under arthroscopy
32967604|NCT04695678||residents and staff of all nursing homes in Solingen|each study participant receives a single nasal/pharyngeal swab
32967605|NCT04695678||staff of one single nursing home in Solingen|each study participant receives a weekly nasal/pharyngeal swab for six months
32967606|NCT04636008|Experimental|Experimental arm|Sintilimab+Hypofractionated radiotherapy
32967607|NCT04613154|Active Comparator|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4*250mg) during the day of surgery and the next 6 Days.
32967608|NCT04613154|Placebo Comparator|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
32967609|NCT04569864|Experimental|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
32967610|NCT04569864|Active Comparator|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
32967611|NCT04549428|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
32967612|NCT04527900|Experimental|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
32967613|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
32967614|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
32967615|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
32967616|NCT04449432|Experimental|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
32967617|NCT04449432|Active Comparator|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
32967618|NCT04350606|Experimental|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
33104910|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
33104911|NCT01310192|Experimental|1|Investigational Imaging Device
33104912|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
33410516|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
33410517|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
32967619|NCT04335240|Experimental|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
32967620|NCT04335240|No Intervention|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
32967621|NCT04301154|Experimental|Arm 1 (n=10): HIVIS DNA / MVA-CMDR|"Arm 1 (n=10) will receive 1500 micrograms (0.5ml) HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.~Participants who have been randomized to receive HIVIS DNA and MVA-CMDR alone (ARM 1) will be administered Cervarix after week 72, the last study follow-up visit, if required."
32967622|NCT04301154|Experimental|Arm 2 (n=10): HIVIS DNA + Cervarix/ / MVA-CMDR|Arm 2 (n=10) will receive 0.5 ml of Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
32967623|NCT04301154|Experimental|Arm 3 (n=5): Cervarix|Arm 3 (n=5) will receive 0.5 ml of Cervarix by IM needle injection at weeks 0, 4 and 24.
32967624|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
32967625|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
32967626|NCT04239846|Experimental|AC-701|AC-701 Topical Gel 0.3%
32967627|NCT04239846|Placebo Comparator|Placebo|Placebo Gel
32967628|NCT04233060|Experimental|CS3005|
32967629|NCT04193046|Other|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
32967630|NCT04171440|Experimental|Minimally Invasive Pancreaticoduodenectomy|Patients that undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology.
32967631|NCT04162470|Experimental|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)
32967632|NCT04067778|Experimental|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
32967633|NCT04067778|Other|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
32967634|NCT04040790|Experimental|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
32967635|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
32967636|NCT04027998||Control group|group of healthy controls
33322216|NCT04529096|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses
33410518|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
33410519|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
32967639|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
32967640|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
32967641|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
32967642|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
32967643|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
32967644|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
32967645|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
32967646|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
32967647|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
32967648|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
32967649|NCT03556800|Active Comparator|1.25 EstroGel|
32967650|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
32967651|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
32967652|NCT03034902|Experimental|Combined EEG and fNIRS|EEG is electroencephalography. fNIRS is functional near infrared spectroscopy. The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured.
32967653|NCT02952846|No Intervention|Before algorithm|Observational
32967654|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
32967655|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
32967656|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
32967657|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
32967658|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
32967659|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
32967660|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
32967661|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
32967662|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
32967663|NCT01685814|Experimental|tandem autologous transplant|Arm D
32967664|NCT00800514|Experimental|active|
32967665|NCT00345930||2|Individuals without drug induced liver disease
33410520|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
33410521|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
32967666|NCT00345930||1|Individuals with drug induced liver disease
32967667|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
32967668|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
32967669|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
32967670|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
32967671|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
32967672|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
32967673|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
32967674|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
32967675|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
32967676|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
32967677|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
32967678|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
32967679|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
32967680|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
32967681|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
33104913|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
33104914|NCT01129544|Experimental|Gene Transfer|open label single arm study
33410522|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
32967682|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
32967683|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
32967684|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
32967685|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
32967686|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
32967687|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
32967688|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
32967689|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
32967690|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
32967691|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
32967692|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
32967693|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
32967694|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
32967695|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
32967696|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
32967697|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
32967698|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
32967699|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
32967700|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
32967701|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
32967702|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
32967703|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
32967704|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
32967705|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
33322217|NCT04529096|Placebo Comparator|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
32967706|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
32967707|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
32967708|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
32967709|NCT02801370|Experimental|OTO-201|
32967710|NCT02801370|Sham Comparator|Control|
32967711|NCT02803164|Other|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
32967712|NCT02803164|Other|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
32967713|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
32967714|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
32967715|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
32967716|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
32967717|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
32967718|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
32967719|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
33322218|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
32967720|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
32967721|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
32967722|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
32967723|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
32967724|NCT02820324|Experimental|Treatment 1 Oliceridine|
32967725|NCT02820324|Experimental|Treatment 2 Oliceridine|
32967726|NCT02820324|Experimental|Treatment 3 Oliceridine|
32967727|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
32967728|NCT02820324|Active Comparator|Treatment 5 Morphine|
32967729|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
32967730|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
32967731|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
32967732|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
32967733|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
32967734|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
32967735|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
32967736|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
32967737|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
32967738|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
32967739|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
32967740|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
32967741|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
32967742|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
32967743|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
32967744|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
32967745|NCT02842242|Experimental|Open Label|MYK-461
33322219|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
33322220|NCT05191186|Active Comparator|grass pollen extract treatment|participants receive 3 injections with Alutard phleum pratense, ALK, grass pollen extract
33322221|NCT05191186|Placebo Comparator|Placebo|Participants receive 3 injections with saline (NaCl 0.9%)
33322222|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
33322223|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
32967746|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32967747|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
32967748|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
32967749|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
32967750|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
32967751|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
32967752|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
32967753|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
32967754|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
32967755|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
32967756|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
32967757|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
32967758|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
32967759|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
32967760|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
32967761|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
32967762|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
32967763|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
32967764|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
32967765|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
32967766|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
32967767|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
32967768|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
32967769|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
32967770|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
32967771|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
32967772|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
32967773|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
32967774|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
32967775|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
32967776|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
32967777|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
32967778|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
32967779|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
33410523|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
32967780|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
32967781|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
32967782|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
32967783|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
32967784|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
32967785|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
32967786|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
32967787|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
32967788|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
32967789|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
32967790|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
32967791|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
32967792|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
32967793|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
32967794|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
32967795|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
32967796|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
32967797|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
32967798|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
32967799|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
32967800|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
32967801|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
32967802|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
32967803|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
32967804|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
32967805|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
32967806|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
32967807|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
32967808|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
32967809|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
32967810|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
32967811|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
32967812|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
33410524|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
33410525|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
32967813|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
32967814|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
32967815|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
32967816|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
32967817|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
32967818|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
32967819|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
32967820|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
32967821|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
32967822|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
32967823|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
32967824|NCT02917278|Experimental|Meals|High-protein renal-specific meals
32967825|NCT02917278|No Intervention|Control|No Meals
32967826|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
32967827|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
32967828|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
32967829|NCT02922582|Experimental|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
32967830|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
32967831|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
32967832|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
32967833|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
32967834|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
32967835|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
32967836|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
32967837|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
32967838|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
32967839|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
32967840|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
32967841|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
33322224|NCT00231179|Experimental|Home visiting Intervention|Home visiting intervention group.
33322225|NCT00231179|Placebo Comparator|Control|Control condition did not receive any services.
33322226|NCT05459714|Experimental|MCE for obese patients|After a standardized gastrointestinal preparation, the patient will undergo MCE examination. After completing the MCE procedure, the patient is evaluated for examination comfort and can then leave the hospital on his or her own and watch for capsule excretion.
33322227|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
33322228|NCT01071785|Experimental|guar gum|guar gum
33322229|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
33322230|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
33322231|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
33322232|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
33322233|NCT04526834|Experimental|CD30 positive NHL subtypes|"(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)~Dose Level 1~Dose Level 2~Dose Level 3"
32967842|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
32967843|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
32967844|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
32967845|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
32967846|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
32967847|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
33410526|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
33410527|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
32967848|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
32967849|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
32967850|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
32967851|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
32967852|NCT02938494|Experimental|IDP-123 Lotion|Lotion
32967853|NCT02938494|Active Comparator|Tazorac Cream|Cream
32967854|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
32967855|NCT02938494|Active Comparator|Vehicle Cream|Cream
33410528|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
33410529|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
32967856|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
32967857|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
32967858|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
32967859|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
32967860|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
32967861|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
32967862|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
33410530|NCT03674658|Experimental|A drug|Rhynorm(A drug)
33410531|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
33410532|NCT03156114|Experimental|Part I - Dose--Escalation|
33410533|NCT03156114|Experimental|Part II - Dose-Expansion|
33410534|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
33410535|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
33410536|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
33410537|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
33410538|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
33410539|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
33410540|NCT02661672|Experimental|Patients with Brain Hemorrhage|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo or Artemis System for clot evacuation.
33410541|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
32967863|NCT02956044|Active Comparator|Group 1: Metformin alone|
32967864|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
32967865|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
32967866|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
32967867|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
32967868|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
32967869|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
32967870|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
32967871|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
32967872|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
32967873|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
32967874|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
32967875|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
32967876|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
32967877|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
32967878|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
33410542|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
33410543|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
33410544|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
32967879|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
33410545|NCT02594202||1|Adults (= 18 years of age) with biopsy-proven or suspected prostate cancer
33410546|NCT03674034||term|50 CTscan and MRI images of children aged at term
33410547|NCT03674034||one month|50 CTscan and MRI images of children aged one month
33410548|NCT03674034||two months|50 CTscan and MRI images of children aged two months
33410549|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
32967880|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
32967881|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
32967882|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
32967883|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
33410550|NCT03135834|Experimental|Group 1 (ACWY Naive subjects, MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
33410551|NCT03135834|Experimental|Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)|ACWY Naive subjects, rLP2086/MenACWY-CRM
32967884|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
32967885|NCT02967354|Experimental|Healthy control|Healthy control
32967886|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
32967887|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
32967888|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
32967889|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
32967890|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
33410552|NCT03135834|Experimental|Group 3 (ACWY Experienced subjects, MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
33410553|NCT03135834|Experimental|Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)|ACWY Experienced subjects, rLP2086/MenACWY-CRM
33410554|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
32967891|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
32967892|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
32967893|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
32967894|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
32967895|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
32967896|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
32967897|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
32967898|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
32967899|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
32967900|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
32967901|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
32967902|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
32967903|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
32967904|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
32967905|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
32967906|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
32967907|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
32967908|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
32967909|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
32967910|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
32967911|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
32967912|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
32967913|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
32967914|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
32967915|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
32967916|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
32967917|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
32967918|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
32967919|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
32967920|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
32967921|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
32967922|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
32967923|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
32967924|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
32967925|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
32967926|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
32967927|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
32967928|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
32967929|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
32967930|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
32967931|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
32967932|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
32967933|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
32967934|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
32967935|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
32967936|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
32967937|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
32967938|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
32967939|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
32967940|NCT03009396|Experimental|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
32967941|NCT03009396|Experimental|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
32967942|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
32967943|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
32967944|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
32967945|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
32967946|NCT03012594|Experimental|Lanreotide|Open label
32967947|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
32967948|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
32967949|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
32967950|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
32967951|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
32967952|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
32967953|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
32967954|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
32967955|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
32967956|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
32967957|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
32967958|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
33410555|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
32967959|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
32967960|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
32967961|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
32967962|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
32967963|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
32967964|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
32967965|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
32967966|NCT03033108|Experimental|Emixustat Dose 1|lowest dose of once-daily oral emixustat
32967967|NCT03033108|Experimental|Emixustat Dose 2|middle dose of once-daily oral emixustat
32967968|NCT03033108|Experimental|Emixustat Dose 3|highest dose of once-daily oral emixustat
32967969|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
32967970|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
32967971|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
32967972|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
32967973|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967974|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967975|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967976|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967977|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967978|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967979|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967980|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
33410556|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
33410557|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
32967981|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967982|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
32967983|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
32967984|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
32967985|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
32967986|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
32967987|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
32967988|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
32967989|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
32967990|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
32967991|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
33410558|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
32967992|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
32967993|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
32967994|NCT03051672|Experimental|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.~Palliative radiation: a total dose of 20 Gy in 5 fractions"
32967995|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
32967996|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
32967997|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
32967998|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
32967999|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
32968000|NCT03061812|Experimental|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
32968001|NCT03061812|Active Comparator|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m^2 on Days 1 to 5 of each 21-day cycle.
32968002|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
32968003|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
32968004|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
33322234|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
33410559|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
32968005|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
32968006|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
32968007|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
32968008|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
32968009|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
32968010|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
32968011|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
32968012|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
32968013|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
32968014|NCT03072186|Experimental|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
32968015|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
32968016|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
32968017|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
32968018|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
32968019|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
32968020|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
32968021|NCT03080142|Experimental|Group 1|Single injection of Exparel
32968022|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
32968023|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
32968024|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
32968025|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
32968026|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
32968027|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
32968028|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
32968029|NCT03092934|Experimental|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
32968030|NCT03092934|Experimental|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
32968031|NCT03092934|Experimental|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
32968032|NCT03092934|Experimental|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
33322235|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
33322236|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
33322237|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
32968033|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
32968034|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
32968035|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
32968036|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
33322238|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
32968037|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
32968038|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
32968039|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
32968040|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
32968041|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
32968042|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
32968043|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
32968044|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
32968045|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
32968046|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
32968047|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
32968048|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
32968049|NCT03124368|Experimental|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
32968050|NCT03124368|Experimental|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
32968051|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
32968052|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
32968053|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
32968054|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
32968055|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
32968056|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
32968057|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
32968058|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
32968059|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
32968060|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
32968061|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
32968062|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
32968063|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
32968064|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
32968065|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
32968066|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
32968067|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
32968068|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
32968069|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
32968070|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
32968071|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
32968072|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
32968073|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
32968074|NCT03147690|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
32968075|NCT03148236|Active Comparator|Vitamin C|
33322239|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
33322240|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
33410560|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
32968076|NCT03148236|Placebo Comparator|Placebo|
32968077|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
32968078|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
32968079|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
32968080|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
32968081|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
32968082|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
32968083|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
32968084|NCT03154710|Experimental|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
32968085|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
32968086|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
32968087|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
32968088|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
32968089|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
32968090|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
32968091|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
32968092|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
32968093|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
32968094|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
33410561|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
32968095|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
33322241|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
33322242|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
33322243|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
33322244|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
33322245|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
33322246|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
33322247|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
33322248|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4~doxorubicin 9mg/m2 iv on D1-4~dexamethasone 40mg/d po on D1-4,9-12,17-20~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
33322249|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
33322250|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
33322251|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
33322252|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
33322253|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
33322254|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
33322255|NCT00228917|Experimental|ACAC_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
33322256|NCT00228917|Experimental|ACHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33322257|NCT00228917|Experimental|HibACPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33322258|NCT00228917|Experimental|HibHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33322259|NCT00228917|Experimental|ACAC_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
32968096|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
32968097|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
32968098|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
32968099|NCT03170388|Experimental|IDP-126 Gel|Gel
32968100|NCT03170388|Active Comparator|IDP-126 Component A|Component A
32968101|NCT03170388|Active Comparator|IDP-126 Component B|Component B
32968102|NCT03170388|Active Comparator|IDP-126 Component C|Component C
32968103|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
32968104|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
32968105|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
32968106|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
32968107|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
32968108|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
32968109|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
32968110|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
32968111|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
32968112|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
32968113|NCT05364918|Experimental|Jeksung|
32968114|NCT05364918|No Intervention|Control|
32968115|NCT05364216|Other|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE and MoCA scale on one day before surgery, one day after surgery, and three months after surgery. Acute postoperative pain was was evaluated by VAS after extubation , one day after surgery, Chronic postsurgical pain was evaluated by VAS on three months after surgery.
32968116|NCT05364216|Experimental|Group T|Group T received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction.
32968117|NCT05364216|Other|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POD incidence as normal control to in Z value calculation of POD incidence to rule out learning effect.
32968118|NCT05363748||Observation group|sequential
32968119|NCT05353920|Experimental|Cognitive traiinig|
32968120|NCT05353920|Active Comparator|Active control|
32968121|NCT05304000|Active Comparator|Mindfulness Meditation|5 minutes a day of mindfulness meditation practice for 28 days (passive attention to breath) delivered remotely through a video link.
32968122|NCT05304000|Experimental|Cyclic Sighing Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of slow inhales until lungs felt full then one more inhale to maximally fill the lungs, followed up a slow exhale. Repeat this cycle for 5 minutes.
33410562|NCT03113760|Experimental|Tadekinig alfa|Patients that showed response to treatment in the SAOL phase will receive Tadekinig alfa for up to 16 weeks.
33410563|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that showed response to treatment in the SAOL phase will receive placebo comparator for up to 16 weeks.
33410564|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
32968123|NCT05304000|Experimental|Box Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of equal duration of inhale, hold, exhale, hold cycles. The duration of the cycle is determined by the participant's comfort level with holding. (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold). Repeat this cycle for 5 minutes.
32968124|NCT05304000|Experimental|Cyclic Hyperventilation with Retention|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of 30 breaths (inhale deeply through the nose and exhale passively through the mouth) and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds. Repeat this cycle for 5 minutes.
32968125|NCT05155176||Individuals with Alcohol Use Disorder|Participants who meet the criteria for Alcohol Use Disorder will complete six weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
32968126|NCT05155176||Social drinkers|Participants who have a past year history of alcohol use and do not meet the criteria for Alcohol Use Disorder will complete two weeks of smartphone monitoring. During this monitoring period, they will also complete three consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
32968127|NCT05133882|Experimental|Arm 1|Queue 1:Clifutinib Besylate:30mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:30mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
32968128|NCT05133882|Experimental|Arm 2|Queue 1:Clifutinib Besylate:40mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:40mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
32968129|NCT05133882|Experimental|Arm 3|Queue 1:Clifutinib Besylate:60mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:60mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
32968130|NCT05098080|Experimental|HutrukinTM|At least three healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), three subjects will be administered HutrukinTM.
32968131|NCT05093790|Experimental|Treatment Arm 1: Ticagrelor + BMS-986141|
32968132|NCT05093790|Experimental|Treatment Arm 2: Aspirin + BMS-986141|
32968133|NCT05093790|Experimental|Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141|
32968134|NCT05093790|Experimental|Treatment Arm 4: BMS-986141|
32968135|NCT05018286|Experimental|Apraglutide subcutaneous (SC) injections, once weekly|Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
32968136|NCT05015400|Experimental|Fluid Increase|The increased fluid intervention arm will begin on day 2 after the onset of bleeding (day 1) of their phase 1 menses through day 5. For the increased fluid intake intervention, participants will a) consume an additional 64 oz (1.89 L) of plain water only on top of habitual fluid intake and b) aim to at least urinate 5 times per day.
32968137|NCT05015400|No Intervention|Fluid Habitual|The fluid habitual non-intervention arm will a) maintain normal fluid intake volume and beverage choices and a) urination frequency.
32968138|NCT05010954|Experimental|LXI-15028 50mg group(n=200)|
32968139|NCT05010954|Active Comparator|Lansoprazole 30mg group (n=200)|
32968140|NCT04936074|Experimental|Muscle preserving selective laminectomy (L-group)|Muscle-preserving selective laminectomy with a posterior midline incision and dissection through the nuchal fascia. The spinous processes are split in the midline using a high-speed burr/ultrasound knife and without disturbing the deep extensor muscles on either side. Angulating away from the midline, the spinous processes are divided at their bases. Laminectomy is performed with a width no more than 2-3 mm wider than the dural borders. The facet joints are not exposed. Finally, the split spionous processes are sutured together. No collar or restrictions will be used in either group.
32968141|NCT04936074|Active Comparator|Laminectomy with instrumented fusion (LF-group)|Laminectomy with instrumented fusion with a midline incision over the appropriate levels defined as the same levels as the extension of laminectomy plus one level above and below but not extending beyond C3-C7. Soft tissue dissection and retraction is performed to identify osseous landmarks. Special care is taken to spare muscle attachments on C2 and C7. Spinal instrumentation is performed with lateral mass or pedicle screws (C3-C7) combined with rod fixation. Laminectomy is performed with a width not extending more than 2 mm outside the dural borders. Facet joint injury should be avoided. Special care is taken to spare the C7 spinous process and distal half of C7 lamina. The sagittal alignment is corrected before spinal fixation. No collar or restrictions will be used in either group.
32968142|NCT04933344||patients having had BJI or PJI treated with daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
32968143|NCT04866576|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER: 2 pouches per day, each pouch contains (12-15 gms of fermented soy powder)
32968144|NCT04866576|Placebo Comparator|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
32968145|NCT04847544|Experimental|ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.|
32968146|NCT04847544|Placebo Comparator|Placebo administered orally BID for up to 28 days.|
32968147|NCT05406804|Experimental|Breast milk olfactory stimulation care|Let premature babies smell their mother's breast milk
32968148|NCT05406804|Active Comparator|Routine care|Prevent premature babies from smelling their mother's breast milk
32968149|NCT05406648|Experimental|Intervention|20g of Morus nigra concentrate administration for 12 weeks
32968150|NCT05406648|No Intervention|Control|No intervention throughout the study
32968151|NCT05406492||Patients udergoing ECMO|Population who have been taking antibiotics or antiplatelets or sedatives/analgesics during Extracorporeal Membrane Oxygenation
32968152|NCT05406336|No Intervention|No Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will not include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit.
32968153|NCT05406336|Experimental|Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit about whether the algorithm predicts that the patient will have uncontrolled BP at the next visit.
32968154|NCT05405946|Experimental|Computerized Cognitive Remediation Intervention and Treatment as Usual (CCRT+TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo Computerized CRT and the usual treatment.~Three evaluations are carried out, each one divided into two sessions: an evaluation before the start of treatment, a second evaluation after finishing the Computerized CRT (after 40 sessions), and a third evaluation (follow-up) 6 months after finishing the Computerized CRT."
32968155|NCT05405946|Active Comparator|Treatment as Usual (TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo the usual treatment.~Two evaluations will be carried out, also divided into two sessions: a first baseline evaluation and a second evaluation 5 months later, after receiving the usual treatment. After this second evaluation, the Computerized CRT is then started to guarantee ethics in all patients.~The evaluation is not carried out at 6 months since they will also have received the intervention."
32968156|NCT05405712|Experimental|Marigold APP|Participants randomized to receive the APP will be enrolled in an app based peer support program
32968157|NCT05405712|No Intervention|CONTROL|In the control arm participants will receive existing standardized peer recovery support resources from SAMHSA
32968158|NCT05405634||Patients with chronic analfissure|1. Consecutive patients referred to the outpatient clinic at the Digestive Disease Centre, Bispebjerg Hospital in Denmark for botox injection for chronic anal fissure. Thus, the included patients will likely all have tried conservative treatment before referral, and are expected to represent a more homogeneous subset with longer standing disease, less spontaneous improvement, and a higher likelihood of being compliant with suggested therapy
32968159|NCT05405634||Patients with an indication for fissurectomy|Consecutive patients with an indication for revision of the fissure and anal injection of botulinum toxin in general anaesthesia
32968160|NCT05405634||Healthy volunteers|Healthy volunteers. These will be recruited among staff at the Digestive Disease Centre, Bispebjerg Hospital, Denmark.
32968161|NCT05405478|Experimental|use of omalizumab in patients with refractory nasal polyp|15 patients group with arrival criteria
32968162|NCT05405478|Experimental|control group patients with refractory nasal polyp|15 patient that with arrival criteria cant arrive in the patients group
32968163|NCT05333952|Experimental|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
32968164|NCT05333952|Other|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
32968165|NCT05276310|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
32968166|NCT05262738|Experimental|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects in this arm will be randomized to the 50 micrograms of vaginal misoprostol (intervention) group, they will be admitted to labor and delivery and undergo placement of 50 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
32968167|NCT05262738|Active Comparator|25 Micrograms Vaginal Misoprostol (Control)|Subjects in this arm will be randomized to the 25 micrograms of vaginal misoprostol (control) group, they will be admitted to labor and delivery and undergo placement of 25 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
32968168|NCT05252832|Active Comparator|Local Infitrate|
32968169|NCT05252832|Experimental|SCPB|
32968170|NCT05237466|Experimental|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive a combination of motivational interviewing and sorting practice to reduce hoarding symptoms.
32968171|NCT05237466|Active Comparator|Sorting Practice|Participants will receive sorting practice only to reduce hoarding symptoms.
32968172|NCT05233254|Experimental|Patients with L4-5 disc herniation|In the light of the reference research, it was estimated that it could reach an effect size of 0.6 according to the sample size measurement made with at least 80% power and 0.05 margin of error, and 18 individuals with LDH (9 men, 9 women) were planned to participate in this study. Since data loss was predicted to be 20%, it was decided to include a total of 22 patients for the study.
32968173|NCT05178732|Experimental|Protein and early|
32968174|NCT05178732|Experimental|Protein and late|
32968175|NCT05178732|Experimental|Protein-polyphenol and early|
32968176|NCT05178732|Experimental|Protein-polyphenol and late|
32968177|NCT05169918|Active Comparator|Control group|
32968178|NCT05169918|Experimental|Training Group|
32968179|NCT05083806|Experimental|Pompe disease|Actual condition
32968180|NCT05083806|Active Comparator|Muscular dystrophy|Different known condition
32968181|NCT05083806|Active Comparator|Healthy volunteer|Healthy control
32968182|NCT05023512|Experimental|Message 1|Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
32968183|NCT05023512|Experimental|Message 2|Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
32968184|NCT05011188|Experimental|Does Escalation|Approximately 3 dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) will also be administered on Day 2 during all treatment cycles
32968185|NCT05011188|Experimental|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) will also be administered on Day 2 during all treatment cycles.
32968186|NCT04980066|Experimental|sticky bone and EDTA|treatment of gingival recession using sticky bone after root surface biomodification with EDTA
32968187|NCT04980066|Active Comparator|Sticky bone|treatment of gingival recession using sticky bone
32968188|NCT04890366|Experimental|Alteplase plus Dimethyl Fumarate|
32968189|NCT04890366|No Intervention|Alteplase|
32968190|NCT04731714|Other|Experimental: rhythmic MNS, then arrhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
32968191|NCT04731714|Other|Experimental: arrhythmic MNS, then rhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.
32968192|NCT04723368|Experimental|Automated flying Drone carrying an Automated external defibrillator (AED)|Five drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating time benefit of drone delivery of AEDs in suspected OHCA.
32968193|NCT04639674|Experimental|AST-120|"sachet Three times a day. (2g/pack*3pack/box)~1 month"
32968194|NCT04639674|No Intervention|Control|No intervention
33410565|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
33410566|NCT03166735|Experimental|BI 1467335 dose 1|
33410567|NCT03166735|Experimental|BI 1467335 dose 2|
33410568|NCT03166735|Experimental|BI 1467335 dose 3|
32968195|NCT04601532|Active Comparator|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
32968196|NCT04601532|Experimental|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
32968197|NCT04520256|Experimental|Core Program Only|
32968198|NCT04520256|Experimental|Social Support|
32968199|NCT04520256|Experimental|Dysregulated Eating|
32968200|NCT04520256|Experimental|Social Support, Dysregulated Eating|
33410569|NCT03166735|Experimental|BI 1467335 dose 4|
32968201|NCT04520256|Experimental|Exercise|
32968202|NCT04520256|Experimental|Social Support, Exercise|
32968203|NCT04520256|Experimental|Dysregulated Eating, Exercise|
32968204|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise|
32968205|NCT04520256|Experimental|Feedback|
32968206|NCT04520256|Experimental|Social Support, Feedback|
32968207|NCT04520256|Experimental|Dysregulated Eating, Feedback|
32968208|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback|
32968209|NCT04520256|Experimental|Exercise, Feedback|
32968210|NCT04520256|Experimental|Social Support, Exercise, Feedback|
32968211|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback|
32968212|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback|
32968213|NCT04520256|Experimental|VR|
32968214|NCT04520256|Experimental|Social Support, VR|
32968215|NCT04520256|Experimental|Dysregulated Eating, VR|
33410570|NCT03166735|Placebo Comparator|Placebo|
32968216|NCT04520256|Experimental|Social Support, Dysregulated Eating, VR|
32968217|NCT04520256|Experimental|Exercise, VR|
33410571|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
32968218|NCT04520256|Experimental|Social Support, Exercise, VR|
32968219|NCT04520256|Experimental|Dysregulated Eating, Exercise, VR|
32968220|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, VR|
32968221|NCT04520256|Experimental|Feedback, VR|
32968222|NCT04520256|Experimental|Social Support, Feedback, VR|
32968223|NCT04520256|Experimental|Dysregulated Eating, Feedback, VR|
32968224|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback, VR|
32968225|NCT04520256|Experimental|Exercise, Feedback, VR|
32968226|NCT04520256|Experimental|Social Support, Exercise, Feedback, VR|
32968227|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback, VR|
32968228|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
32968229|NCT04364568|Experimental|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome >= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
32968230|NCT04364568|Experimental|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome < 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
32968231|NCT04263792|Other|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
32968232|NCT04263792|Other|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
32968233|NCT04098978|Experimental|Pharmacist Drug Therapy Management|
32968234|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
32968235|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
33410572|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
33410573|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
33410574|NCT02750605|Experimental|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
33410575|NCT02750605|Active Comparator|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
33410576|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
33410577|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
32968236|NCT03811470||1|Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
32968237|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
32968238|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
32968239|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
32968240|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
32968241|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
32968242|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
32968243|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
32968244|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
32968245|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
32968246|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
32968247|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
32968248|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
32968249|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
32968250|NCT01705626||Participants diagnosed with small fiber polyneuropathy no obvious etiology|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
32968251|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
32968252|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
32968253|NCT00404430||Stable COPD patients|Patients with stable COPD
32968254|NCT00177918||lung transplant patients|
32968255|NCT04682574|Active Comparator|vitamin C|The dose would be 30 grams a day (10 grams TDS) for 3 days with standard treatment
32968256|NCT04682574|No Intervention|Placebo|Distill water in the same dose with same standard treatment
32968257|NCT04589364|Experimental|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:~dose: 100 units ( various units each site depend on clinical )"
32968258|NCT04589364|Experimental|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:~dose: 33.33 units ( various units each site depend on clinical )"
32968259|NCT04553484|Experimental|Measuring cardiovascular performance and blood flow|
32968260|NCT04519866|Experimental|Electroacupuncture|In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
32968261|NCT04519866|Active Comparator|Manual acupuncture|In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
32968262|NCT04492488|Experimental|Solid Tumors|Phase I Dose Escalation: MRG002 will be administrated by an IV infusion of escalating doses (starting dose of 2.2 mg/kg, followed by 2.6 mg/kg) on Day 1 of every 3 weeks (21-day cycle).
32968263|NCT04492488|Experimental|Locally Advanced or Metastatic Gastric/GEJ Cancer|MRG002 will be administrated by an IV infusion on Day 1 of every 3 weeks (21-day cycle).
32968264|NCT04473924|Experimental|Body surface area-based mycophenolate dosing|Intervention group will receive mycophenolate mofetil 750 mg/m^2/day divided into twice daily dosing.
32968265|NCT04473924|Active Comparator|Standard (fixed) dosing|Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.
32968266|NCT04448106|Experimental|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
32968267|NCT04448106|Active Comparator|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
32968268|NCT04448106|Experimental|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
32968269|NCT04448106|Active Comparator|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
32968270|NCT04448106|Experimental|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
32968271|NCT04448106|Active Comparator|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
32968272|NCT04426500|Placebo Comparator|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
33410578|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
33410579|NCT05320159||Overall cohort: Secukinumab|Included all the patients treated with secukinumab
33410580|NCT05320159||Bio-naive|Included PsO patients initiating treatment with secukinumab. Bio-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the following biologic drugs of interest anytime pre-index: secukinumab, certolizumab, etanercept, adalimumab, infliximab, golimumab, ustekinumab, ixekizumab, brodalumab, abatacept, and guselkumab and risankizumab during all available history
33410581|NCT05320159||Bio-experienced|Included PsO patients initiating treatment with secukinumab. Patients had pre-index use of one or more of the biologic drugs of interest during all available history
33410582|NCT05320159||Systemic-naive|Included PsO patients initiating treatment with secukinumab. Systemic-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the biologic treatments or with any of the following systemic (i.e., oral or injectable - no topical forms) drugs of interest pre-index: methotrexate, corticosteroids, acitretin or apremilast.
33410583|NCT05320159||Systemic-experienced|Included PsO patients initiating treatment with secukinumab. Systemic-experienced patients had pre-index use of one or more of the systemic drugs of interest.
33410584|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
33410585|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
33410586|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
33410587|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
33410588|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.~Creation of a bone and arterial panorama using EndoNaut® software."
33410589|NCT05263921|Active Comparator|Treatment A: PF-07321332/ritonavir|PF-07321332 ritonavir
33410590|NCT05263921|Experimental|Treatment B: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with water
32968273|NCT04426500|Active Comparator|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
33410591|NCT05263921|Experimental|Treatment C: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with applesauce
33410592|NCT05263921|Experimental|Treatment D: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with vanilla pudding
33410593|NCT05225467||Main group|All participants taking part in this study are subsequently categorized in this group
33410594|NCT05192473|Experimental|Lithotripsy Treatment|"Pulse Intravascular Lithotripsy System~Device: Pulse Intravascular Lithotripsy Catheter"
33410595|NCT05184673|Active Comparator|hatha thermo-neutral|The hatha classes will hold each pose for 5 breaths in a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
33410596|NCT05184673|Active Comparator|hatha hot|The hatha hot classes will hold each pose for 5 breaths in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
33410597|NCT05184673|Active Comparator|flow thermo-neutral|The flow hot classes will flow from each pose (one breath per movement) a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
32968274|NCT04426500|Experimental|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
32968275|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
33410598|NCT05184673|Active Comparator|flow hot|The flow hot classes will flow from each pose (one breath per movement) in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
32968276|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
32968277|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
32968278|NCT04251546||Observational group|Patients with suspected prostate cancer with a PSA test value of 4-10 ng / mL
32968279|NCT04131192|Experimental|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
32968280|NCT04123626|Experimental|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
32968281|NCT04123626|Experimental|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
32968282|NCT04123626|Experimental|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
32968283|NCT04123626|Experimental|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
32968284|NCT04123626|Experimental|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
32968285|NCT04123626|Experimental|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
32968286|NCT03925116|No Intervention|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
32968287|NCT03925116|Experimental|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:~collect relevant medical history~provide educational material on birth control options~provide a link to bedsider.com for further information~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
32968288|NCT03923868|Experimental|dose escalation in healthy subjects|
32968289|NCT03923868|Experimental|dose escalation in hyperuricemia patients|
32968290|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
32968291|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
32968292|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
32968293|NCT03689868|Experimental|Virtual Reality|
32968294|NCT03689868|No Intervention|Control|
32968295|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
32968296|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
33410599|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
33410600|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
33410601|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
32968297|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
33410602|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
33410603|NCT02445768|Experimental|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
32968298|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
32968299|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
32968300|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
32968301|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
32968302|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
32968303|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
32968304|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
32968305|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
32968306|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
32968307|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
32968308|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.~1 capsule, b.i.d. for 12 weeks"
32968309|NCT03409614|Other|Chemo|Part 1: Chemotherapy
32968310|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
32968311|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
32968312|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
32968313|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
32968314|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
32968315|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
32968316|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
32968317|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
32968318|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
32968319|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
32968320|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
32968321|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
32968322|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
32968323|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
32968324|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
32968325|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
32968326|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
32968327|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
32968328|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
32968329|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
32968330|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
32968331|NCT00151398|Experimental|A|
32968332|NCT00151398|Experimental|B|
32968333|NCT00151398|Experimental|C|
32968334|NCT00151398|Active Comparator|D|
32968335|NCT03181308|Experimental|TRC105 plus Nivolumab|
32968336|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
32968337|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
32968338|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
32968339|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
32968340|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
32968341|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
32968342|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
32968343|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
32968344|NCT03198000|Experimental|Formula # 13418-148|
32968345|NCT03198000|Experimental|Formula # 13418-158|
32968346|NCT03198000|Active Comparator|Control Formula # PF004390|
32968347|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
32968348|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
32968349|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
32968350|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
32968351|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
32968352|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
32968353|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
32968354|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
32968355|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
32968356|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
32968357|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
32968358|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
32968359|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
32968360|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
32968361|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
32968362|NCT03219840|Experimental|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
32968363|NCT03219840|Experimental|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
32968364|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
32968365|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
32968366|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
32968367|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
32968368|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
32968369|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
32968370|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
32968371|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
32968372|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
32968373|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
32968374|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
32968375|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
32968376|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
32968377|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
32968378|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
32968379|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
32968380|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
32968381|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
32968382|NCT03239574|Experimental|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
32968383|NCT03242148|Experimental|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
32968384|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
32968385|NCT03257202|No Intervention|Control|No topical treatment
32968386|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
32968387|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
32968388|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
32968389|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
32968390|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
32968391|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
32968392|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
32968393|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
32968394|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
32968395|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
32968396|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
32968397|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
32968398|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
32968399|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
32968400|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
32968401|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
32968402|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
32968403|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
32968404|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
32968405|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
32968406|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
32968407|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
32968408|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
32968409|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
32968410|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
32968411|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
32968412|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
32968413|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
32968414|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
32968415|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
32968416|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
32968417|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
32968418|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
33410604|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
33410605|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
32968419|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
32968420|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
32968421|NCT03292692|Experimental|OurRelationship|Online Intervention
32968422|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
32968423|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
32968424|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
32968425|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
32968426|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
32968427|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
32968428|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
32968429|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
32968430|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
32968431|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
32968432|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
32968433|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
32968434|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
32968435|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
32968436|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
32968437|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
32968438|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
32968439|NCT03308058|No Intervention|Printed Educational material|Printed educational material
32968440|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
32968441|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
33410606|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
32968442|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
32968443|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
32968444|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
32968445|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
32968446|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
32968447|NCT03329352|Experimental|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
32968448|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
32968449|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
32968450|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
32968451|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
32968452|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
32968453|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
32968454|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
32968455|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
32968456|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
32968457|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
32968458|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
32968459|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
32968460|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
32968461|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
32968462|NCT03339570||Orthopedic treatment|This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.
32968463|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
32968464|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
32968465|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
32968466|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
32968467|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
32968468|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
32968469|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
32968470|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
32968471|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
32968472|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
32968473|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
32968474|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
32968475|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection~Injection of Placebo into area of scarring (forehead)"
32968476|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
32968477|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
32968478|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
32968479|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
32968480|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
32861446|NCT04966260|Experimental|Personalized Virtual Reality|There are two types of personalized VR: 1) Family/friends provide personalized content (e.g., life stories, photos, videos) that will be used during the VR session. Family/friends of participants in the personalized VR group will have the opportunity to upload custom photos, videos, life stories or capture their own 360° footage of family events using a GoPro camera that will be loaned to them for the study. This content will be uploaded to a cloud-based portal. 2) If the family/friends of those in the personalized VR arm are unavailable/unable/unwilling to provide personalized content the participant will select a video from the VR library of an experience that is personally memorable to them, such as their childhood hometown, a favourite vacation destination. The session will be facilitated by the therapeutic recreation staff on the unit.
33410607|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
33410608|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
32968481|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
32968482|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
32968483|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
32968484|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
32968485|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
32968486|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
32968487|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
32968488|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
32968489|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
32968490|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
32968491|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
32968492|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
32968493|NCT03377244|Experimental|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
32968494|NCT03377244|Active Comparator|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
32968495|NCT03377244|Other|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
32968496|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
33410609|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
33410610|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
32968497|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
32968498|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
32968499|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
32968500|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
32968501|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
32968502|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
32968503|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
32968504|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
32968505|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
32968506|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
32968507|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
32968508|NCT03395808|Other|AVE-901 50mg|IV Tramadol
32968509|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
32968510|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
32968511|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
32968512|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
32968513|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
32968514|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
32968515|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
32968516|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
32968517|NCT03410628|Experimental|gammaCore Active Device|open label
32968518|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
32968519|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
32968520|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
32968521|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
32968522|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
32968523|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
32968524|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
32968525|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
32968526|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
32968527|NCT03429270|Experimental|Urodynamics Arm|
32968528|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
32968529|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
32968530|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
32968531|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
32968532|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
32968533|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
32968534|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
32968535|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
32968536|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
32968537|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
32968538|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
32968539|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
32968540|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
32968541|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
32968542|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion will not be titrated.~Remaining care will be identical to standard therapy group."
32968543|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)~Pre-op dexamethasone~Pre-op midazolam at discretion of anesthesiologist~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~Other post-op care as per usual surgical routine"
32968544|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
32968545|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
32968546|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
32968547|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
32968548|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
32968549|NCT03457116|Active Comparator|NSAIDS|400mg of Ibuprofen
32968550|NCT03457116|Active Comparator|Opiates|Norco (hydrocodone 5mg- acetaminophen 325mg)
32968551|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
32968552|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
32968553|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
32968554|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
32968555|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
32968556|NCT03463512|Active Comparator|ORS (standard treatment)|
32968557|NCT03467412|Experimental|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
32968558|NCT03467412|Experimental|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
32968559|NCT03467412|Experimental|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
33410611|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
32968560|NCT03467412|Experimental|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
32968561|NCT03467412|Placebo Comparator|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
32968562|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
32968563|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
32968564|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
32968565|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
32968566|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
32968567|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
32968568|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
32968569|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
32968570|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
32968571|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
32968572|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
32968573|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
32968574|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
32968575|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
32968576|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
32968577|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
32968578|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
32968579|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
32968580|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
32968581|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
32968582|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
32968583|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
32968584|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
32968585|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
33410612|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
32968586|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
32968587|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
32968588|NCT03495648|Experimental|Walking Group (Low Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. Low engagers are defined as those participants who walked to the market two or fewer times during the program.
32968589|NCT03495648|Experimental|Walking Group (High Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. High engagers are defined as those participants who walked to the market three or more times during the program.
32968590|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
32968591|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
32968592|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
32968593|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
32968594|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
32968595|NCT03501264|Experimental|Intervention group|This group receives the game
32968596|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
32968597|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
32968598|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
32968599|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
32968600|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
32968601|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
32968602|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
32968603|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
32968604|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
32968605|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
32968606|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
32968607|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
32968608|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
32968609|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
32968610|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
32968611|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
32968612|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
32968613|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
32968614|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
32968615|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
32968616|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
33410613|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
32968617|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
32968618|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
32968619|NCT03541356|Placebo Comparator|Placebo|
32968620|NCT03541356|Active Comparator|L-dopa 35 mg|
32968621|NCT03541356|Active Comparator|L-dopa 70 mg|
32968622|NCT03541356|Active Comparator|L-dopa 140 mg|
32968623|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
32968624|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
32968625|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
32968626|NCT03545412|Experimental|Microfocused ultrasound with visualization|
32968627|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
32968628|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
32968629|NCT03549234|Experimental|Erector Spinae (single injection)|
32968630|NCT03549234|Active Comparator|Paravertebral (single injection)|
32968631|NCT03557658|Experimental|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
32968632|NCT03557658|Experimental|Healthy Volunteer|Subjects with normal hepatic function
32968633|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
32968634|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
32968635|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
32968636|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
32968637|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
32968638|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
32968639|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
32968640|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
32968641|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
32968642|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
33410614|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-~Oral, daily during each cycle~fludarabine-administered at standard dosing for up to 6 cycles~cyclophosphamide-administered at standard dosing for up to 6 cycles~rituximab-administered at standard dosing for up to 6 cycles"
32968643|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
32968644|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
32968645|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
32968646|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
32968647|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
32968648|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
32968649|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
32968650|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
32968651|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
32968652|NCT03613818|No Intervention|Control|Assessment only
32968653|NCT03614130|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
32968654|NCT03614130|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
32968655|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
32968656|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
32968657|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
32968658|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
32968659|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
32968660|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
32968661|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
32968662|NCT03623334|Experimental|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
32968663|NCT03623334|Experimental|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
32968664|NCT03623334|Experimental|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
32968665|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
32968666|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
32968667|NCT03633084|Experimental|RBM-007 Injectable Solution - 0.2 mg|No additional information.
32968668|NCT03633084|Experimental|RBM-007 Injectable Solution - 1.0 mg|No additional information.
32968669|NCT03633084|Experimental|RBM-007 Injectable Solution - 2.0 mg|No additional information.
32968670|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
32968671|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
32968672|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
32968673|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
32968674|NCT03638622|Experimental|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
32746711|NCT05611827|Experimental|Regular/standard Quercetin (500 mg)|Each participant receives their treatment of standard/raw Quercetin at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). A standardized lunch and dinner are served after 4h and 8h of product administration. Capillary whole blood samples are collected (after a 10hr overnight fast) at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin. A washout period of at least 7 days between each treatment will be used.
32968675|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
32968676|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
32968677|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
32968678|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
32968679|NCT03649932|Experimental|L-citrulline 100 mg/kg/day|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
32968680|NCT03649932|Experimental|L-citrulline 200 mg/kg/day|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
32968681|NCT03649932|Experimental|L-citrulline 300 mg/kg/day|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
33410615|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/Wild-Type GIST|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Gastrointestinal stromal tumor (GIST)"
32968682|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
32968683|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
32968684|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
32968685|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
32968686|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
32968687|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
32968688|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
32968689|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
32968690|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
32968691|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
32968692|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
32968693|NCT03685968|Experimental|Glidescope AVL|
32968694|NCT03685968|Experimental|King Vision Channeled VL|
33322260|NCT00228917|Experimental|ACHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33322261|NCT00228917|Experimental|HibACPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
32968695|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
32968696|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
32968697|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
32968698|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
32968699|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
32968700|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
32968701|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
32968702|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
32968703|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
32968704|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
32968705|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
32968706|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
32968707|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
32968708|NCT03704376|Active Comparator|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
32968709|NCT03704376|Active Comparator|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
32968710|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
32968711|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
32968712|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
32968713|NCT03711396|Experimental|Advance Care Planning Group Visits - amnestic Mild Cognitive Impairment|Participants with amnestic Mild Cognitive Impairment will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
33410616|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE"
32861447|NCT04966260|Active Comparator|Two-Dimensional Video|Participants in the active comparator group will choose a two-dimensional video such as a mountain view, ocean view or safari. Participants will view the two-dimensional video on an iPad and the session will be facilitated by the therapeutic recreation staff on the unit.
32861448|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
32861449|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
32861450|NCT04954560|Active Comparator|losartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
32861451|NCT04954560|Active Comparator|eprosartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
32861453|NCT04954482||The experimental group|The included specimens were used to establish a new posterior fork reconstruction procedure.
32861454|NCT04954482||The validation group|The included specimens were used to validate the new posterior fork reconstruction procedure.
32861455|NCT04962828|Experimental|Collaboration group|This group of children will have targets and vocabulary that has been designed collaboratively and then the therapist and teacher both reinforce the vocabulary during the week
32861456|NCT04962828|Active Comparator|Non-collaborative group|This group of children will have targets and vocabulary that has been designed collaboratively but they will only be practiced with the therapist during the week
32861457|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
32861458|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
32861459|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
32861460|NCT01456117|Placebo Comparator|Placebo QD|
32861461|NCT04962984|Experimental|THAL +|patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
32861462|NCT04962984|Sham Comparator|THAL -|Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
32861463|NCT04962984|Sham Comparator|Healthy volunteers|healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
32861464|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
32861465|NCT04962672|Experimental|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide.
32861466|NCT04962672|Active Comparator|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group will received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide.
32861467|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
32861468|NCT04962750|Experimental|laser therapy|
32861469|NCT04962750|Sham Comparator|Control|
32861470|NCT03829189|Active Comparator|inulin|
32861471|NCT03829189|Placebo Comparator|maltodextrin|
32861472|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
32861473|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
32861474|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
32861475|NCT04966416|Experimental|Pyrophosphate|
32861476|NCT04966416|Placebo Comparator|Placebo|
32968714|NCT03711396|Experimental|Advance Care Planning Group Visits - Care Partners|Care partners of persons with amnestic Mild Cognitive Impairment will attend group visits, with the person with Mild Cognitive Impairment, to discuss advance care planning. Group visits will last up to two hours and be help up to twice.
32968715|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
32968716|NCT03716076|Experimental|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
32968717|NCT03716076|Experimental|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
33410617|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca"
33410618|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
32968718|NCT03835728|Active Comparator|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
32968719|NCT03835728|Placebo Comparator|Treatment Placebo Arm|Saline will be used as the matching placebo
32968720|NCT03848910|Experimental|Investigational device - Sound Processor|
32968721|NCT03861780|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
32968722|NCT03861780|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.
32968723|NCT03861780|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.
32968724|NCT03889158|Experimental|Acute Inflammation|All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
32968725|NCT03889158|Experimental|Ascorbic Acid|All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)].
32968726|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
32968727|NCT04096482|Experimental|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
32968728|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
32968729|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
32968730|NCT04323852|Experimental|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
32968731|NCT04323852|Placebo Comparator|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
32968732|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
32968733|NCT04420572|Experimental|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
32968734|NCT04420572|Experimental|steroid injection group|1ml betamethasone will be used for steroid injection.
32968735|NCT04709484|Experimental|USG-guided steroid injection group|In the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
32968736|NCT04709484|Experimental|Palpation-guided steroid injection group|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
32968737|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
32968738|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
32968739|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
32968740|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
32968741|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
32968742|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
32968743|NCT04463004|Active Comparator|Intervention|Treatment infusion
32968744|NCT04463004|Placebo Comparator|Control|Placebo infusion
32968745|NCT04430634|Experimental|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
32968746|NCT04430634|Experimental|BCAD|Same as previous arm, but in a different randomization order.
32968747|NCT04430634|Experimental|CDBA|Same as previous arm, but in a different randomization order.
32968748|NCT04430634|Experimental|DACB|Same as previous arm, but in a different randomization order.
32968749|NCT04430634|Experimental|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
32968750|NCT04430634|Experimental|FGEH|Same as previous arm, but in a different randomization order.
32968751|NCT04430634|Experimental|GHFE|Same as previous arm, but in a different randomization order.
32968752|NCT04430634|Experimental|HEGF|Same as previous arm, but in a different randomization order.
32968753|NCT04429932|Experimental|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
32968754|NCT04429932|Experimental|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
32968755|NCT04429932|Experimental|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
32968756|NCT04429932|Experimental|Product use sequence DACB|Same as previous arm, but in a different randomization order.
32968757|NCT04429932|Experimental|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
32968758|NCT04429932|Experimental|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
32968759|NCT04429932|Experimental|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
32968760|NCT04429932|Experimental|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
32968761|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
32968762|NCT04399980|Active Comparator|Intervention|Treatment infusion
32968763|NCT04399980|Placebo Comparator|Control|Placebo infusion
32968764|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
32968765|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
32968766|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
32968767|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
32968768|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
32968769|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
32968770|NCT04335552|Active Comparator|Standard of care|
32968771|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
32968772|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
32968773|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
32968774|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
32968775|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
32968776|NCT04288752|Experimental|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
33410619|NCT02645851|Experimental|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
32968777|NCT04288752|Sham Comparator|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
32968778|NCT04287036|Experimental|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
32746712|NCT04936425|Experimental|OTSC Stentfix|
32746713|NCT04936425|No Intervention|Stent Suturing|
32968779|NCT04287036|Experimental|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
32968780|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
32968781|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
32968782|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
32968783|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
32968784|NCT04267770|Active Comparator|flat rates|flat basal rate
32968785|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
32968786|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
32968787|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)~Did not receive allocated conventional vitamin C (n= 0)"
32968788|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)~Did not receive allocated liposomal vitamin C (n= 0)"
32968789|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)~Did not receive allocated intervention (n= 0)"
32968790|NCT04179474|Experimental|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
32968791|NCT04179474|Experimental|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
32968792|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
32968793|NCT04174638|Experimental|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
32968794|NCT04174638|No Intervention|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
32968795|NCT04152642|Active Comparator|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
32968796|NCT04152642|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
32968797|NCT04152642|Sham Comparator|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
32968798|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
32968799|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
32968800|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
32968801|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
32968802|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
32968803|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
32968804|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
32968805|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
32968806|NCT04112160|Placebo Comparator|control|normal saline 0.9%
32968807|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
32968808|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
32968809|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
32968810|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
32968811|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
32968812|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
32968813|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
32968814|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
32968815|NCT04057248|Experimental|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
32968816|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
32968817|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
32968818|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
32968819|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
32968820|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
32968821|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
32968822|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
32968823|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
32968824|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
32968825|NCT04022694|No Intervention|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
32968826|NCT04022694|No Intervention|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
32968827|NCT04015440|Experimental|HBMT|
32968828|NCT04015440|Placebo Comparator|Placebo|
32968829|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
32968830|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
32968831|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
32968832|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
32968833|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
32968834|NCT04026750|Experimental|Pitolisant|
32968835|NCT04026750|Placebo Comparator|Matching placebo|
32968836|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
32968837|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
32968838|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
32968839|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
32968840|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
32968841|NCT03993210|Experimental|GYN Cancer Cases|"Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
32968842|NCT03993210|Active Comparator|GYN Benign Controls|"Benign gynecological (GYN) fibroids.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
32968843|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
32968844|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
32968845|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
32968846|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
32968847|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
32968848|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
32968849|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
32968850|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
32968851|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
32968852|NCT03966924|Experimental|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
32968853|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
32968854|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
32968855|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
32968856|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
32968857|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
32968858|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
32968859|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
32968860|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
32968861|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
32968862|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
32968863|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
32968864|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
32968865|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
32968866|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
32968867|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
32968868|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
32968869|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
32968870|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
32968871|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
32968872|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
32968873|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
32968874|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
32968875|NCT03882528|Experimental|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
32968876|NCT03881670|Placebo Comparator|Lotrafilcon B|
32968877|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
32968878|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
32968879|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
32968880|NCT03861000|Experimental|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
32968881|NCT03861000|Experimental|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
32968882|NCT03863496|Other|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
32968883|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
32746714|NCT05612685|Experimental|Intervention|This arm will receive a healthcare provider referral to a tax filing app
32746715|NCT05612607|Other|IGRT discontinuation|Participants will be tested to determine Switched memory B cells (SMB) levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are < 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
32968884|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
32968885|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
32968886|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
32968887|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
32968888|NCT03862482|Active Comparator|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
32968889|NCT03862482|Experimental|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
32968890|NCT03862482|Experimental|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
32968891|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968892|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968893|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968894|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968895|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968896|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968897|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968898|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968899|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968900|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968901|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968902|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968903|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968904|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968905|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968906|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968907|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968908|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
32968909|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
32968910|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
32968911|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
32968912|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
32968913|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
32968914|NCT03843372|Experimental|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
32968915|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
32968916|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
32968917|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
32968918|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
32968919|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
32968920|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
32968921|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
32968922|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
32968923|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
32968924|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
32968925|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
33322262|NCT00228917|Experimental|HibHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
33322263|NCT05190952|Active Comparator|Group 1|Control Group (Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure).
33322264|NCT05190952|Active Comparator|Group 2|Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes).
32861477|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
32861478|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
32861479|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
32861480|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
32861481|NCT04966026||COPD combined with CAP inpatients|(1) CAP meets the diagnostic criteria published in our 2016 CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in our 2013 COPD diagnosis and treatment guidelines; (2) age ≧ 18 years. Exclusion criteria: (1) age <18 years; (2) pregnancy; (3) positive human immunodeficiency virus (HIV) antibody; (4) suspected or confirmed tuberculosis or fungal infection of the lung.
32861482|NCT00989261|Experimental|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
32861483|NCT00989261|Experimental|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
32861486|NCT04966494|Experimental|BOSB Group|This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.
32861487|NCT04966494|No Intervention|Control Group|This group corresponded to hypertriglyceridemic women who does not consume BOSB
32861488|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
32861489|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
32861490|NCT04954170||RCT patients|Patients suffering from rotator cuff injury
32861491|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
32861492|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
32861493|NCT04962282||group 1|Follow-up by telephone for researching compliance of patients receiving exercise prescriptions
32861494|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
32861495|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
32861496|NCT04954404|Experimental|Transcatheter mitral valve repair/replacement|
32861497|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
32861498|NCT03829033|Experimental|Radiotherapy delivered with protons|
32861499|NCT04954092|Experimental|1/10 of full adult dose|
32861500|NCT04954092|Experimental|1/5 of full adult dose|
32861501|NCT04954092|Experimental|Selected dose for second stage of the trial|
32861502|NCT04954092|Placebo Comparator|Placebo for second stage of the trial|
32861503|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
32861504|NCT04965948|Experimental|Active group|Snack enriched with camelina sativa oil
32861505|NCT04965948|Placebo Comparator|Placebo group|Snack no enriched with camelina sativa oil
32861506|NCT01452685|Placebo Comparator|Placebo|
32861507|NCT01452685|Experimental|TAK-385 10 mg QD|
32861508|NCT01452685|Experimental|TAK-385 20 mg QD|
32861509|NCT01452685|Experimental|TAK-385 40 mg QD|
32861510|NCT01452685|Other|Leuplin|
32861511|NCT03059706|Experimental|RegenoGel-OSP™|
32861512|NCT03059706|Placebo Comparator|Placebo|
32861513|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
32861514|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
32861515|NCT04431648|Experimental|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
32861516|NCT04279925|Experimental|Locally-made Miniplate and screw|Locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia.
32861517|NCT04279925|Active Comparator|Imported Miniplate and screw|Biomet® miniplate 1.5 and screw 1.5 produced by Biomet, included in the Lorenz® Plating System Midface.
32861518|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
32861519|NCT04953858|Other|Social Network Strategy|All study participants will receive social network strategy intervention as linkage method to receive HIV testing and care
32861520|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
32861521|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
32861522|NCT04278989|Active Comparator|Anti-tumor B|1,200 mg three times a day.
32861523|NCT04278989|Placebo Comparator|Placebo|Placebo taken three times a day.
32861524|NCT04953936|Experimental|HMB|The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)
32861525|NCT04953936|Placebo Comparator|Placebo|The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.
32861526|NCT01452763|Experimental|TAK-438 10 mg QD|
32861527|NCT01452763|Experimental|TAK-438 20 mg QD|
32861528|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
32861529|NCT04127279|Experimental|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
32861530|NCT04127279|Active Comparator|Placebo Cream|Cream devoid of essential oils, self-administered
32861531|NCT04954014|Experimental|BEVACIZUMAB|Patients will receive best available treatment (BAT) for COVID-19 plus single dose bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
32861532|NCT04954014|Active Comparator|BEST AVAILABLE TREATMENT|Patients will receive best available treatment for COVID-19.
32861533|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
32861534|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
32861535|NCT04431882|Experimental|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
32861536|NCT05587075|Active Comparator|Control group|The control group was treated with filiform needle.
32861537|NCT05587075|Experimental|Observation group|The observation group was treated with long round needle.
32861538|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
32861539|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
32861540|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
32861541|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
32861542|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
32861543|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
32861544|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
32861545|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
32861546|NCT04962516||Test group|
32861547|NCT04962516||Control group|
32861548|NCT04126967|Other|allo-PBSCT patients with no NGS text|
32861549|NCT01452841|Experimental|Grapefruit Consumption|
32861550|NCT01452841|Active Comparator|Control|
32861551|NCT04962438||Tumor patients using anti-VEGF drugs|
32861552|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
32861553|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
32861554|NCT04961736||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
32861555|NCT04961736||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
32861556|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
32861557|NCT04953624||CNAQ≤28|ALS patients with CNAQ ≤ 28
32861558|NCT04953624||CNAQ>28|ALS patients with CNAQ > 28
32861559|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
32861560|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
32861561|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression~Nab-paclitaxel every 21 days"
32861562|NCT04961892||surgical treatment|Patients with CAI undergoing surgical treatment
32861563|NCT04961892||conservative treatment|Patients with CAI undergoing conservative treatment
32861564|NCT04961970|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin
32861565|NCT04961970|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and cisplatin
32861566|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
32861567|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
32861568|NCT04953546||ACL group|According to the previous clinical diagnosis, volunteers who has suffered the ACL injury.
32861569|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
32861570|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
32861571|NCT04961424||Symptomatic spinal epidural hematoma Group|Patients who performed thoracic decompression surgery and developed neurological deficit after surgery due to the symptomatic spinal epidural hematoma were enrolled into case group.
32861572|NCT04961424||Control group|hose who did not develop the symptomatic spinal epidural hematoma, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period (the same year or the following year) were randomly selected from the pool of patients.
32861573|NCT01456663|Experimental|AFQ056|
32861574|NCT04953468||ANXA2 high expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group
32861575|NCT04953468||ANXA2 low expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level <6 points were identified as the ANXA2 low expression group
32861576|NCT04953468||ANXA2 high expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group
32861577|NCT04953468||ANXA2 low expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level <2 were regarded as the ANXA2 low expression group
32861578|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
32861579|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
32861580|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
32861581|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
32861582|NCT01311687|Experimental|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
32861583|NCT01311687|Active Comparator|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
32861584|NCT04952688|Experimental|Experimental|"Inclusion~Before Anti-VEGF treatment: opht"
32861585|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
32968926|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
32968927|NCT03809052|Experimental|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
32968928|NCT03809052|Experimental|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
32968929|NCT03809052|Experimental|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
32968930|NCT03809052|Experimental|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
32968931|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
32968932|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
32968933|NCT03812328|Experimental|SelK2|I.V., single-dose
33410620|NCT02645851|Experimental|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
33410621|NCT02645851|Other|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
33410622|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
32968934|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
32968935|NCT03815292|Experimental|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
32968936|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
32968937|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
32968938|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
33410623|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
33410624|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
33410625|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
33410626|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
32968939|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
32968940|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
32968941|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
32968942|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
32968943|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
32968944|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
32968945|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
32968946|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
32968947|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
32968948|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
32968949|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
33410627|NCT02642029|Experimental|Intermittent TBS (iTBS)|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
33410628|NCT02642029|Active Comparator|Continuous TBS (cTBS)|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
33410629|NCT02642029|Sham Comparator|Sham TBS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
32968950|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
33410630|NCT04058574|Active Comparator|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
33410631|NCT04058574|Placebo Comparator|Control|Control Group: 15 healthy volunteers, athletes.
33410632|NCT04058730|Experimental|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
33410633|NCT04058730|Experimental|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
33410634|NCT04058730|Experimental|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
33410635|NCT02121132||No treatment|
33410636|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
33410637|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
33410638|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
33410639|NCT01314625||one arm|
33410640|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
33410641|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
33410642|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
32968951|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
32968952|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
32968953|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
32968954|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
32968955|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
33410643|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
32968956|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
33410644|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
32968957|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
33410645|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
33410646|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
33410647|NCT05239975|Experimental|SCTV01C|
33410648|NCT05239975|Active Comparator|Comirnaty|
33410649|NCT05239897|Experimental|postoperative delirium|We will use Confusion Assessment Method (CAM) to determine the incidence of postoperative delirium in participants twice per day. We will use the Memorial Delirium Assessment Scale(MDAS)and Mini-mental state examination(MMSE) to examine postoperative delirium severity.
33410650|NCT05239819|Experimental|Intervention group|We conducted a fully engaged inspiratory muscle training (IMT) program. The exercise group received the intervention threshold IMT from preoperative to postoperative undergoing upper abdominal surgery. The IMT was started before 3 weeks of operation and surveyed in the followed 4 weeks.
33410651|NCT05239819|Active Comparator|Usual care group|The Usual care group will receive regulated education.
33410652|NCT05006833|Experimental|Bundled clinician training and bundled text messages|Clinicians will receive bundled approach training and parents will receive bundled text messages.
33410653|NCT05006833|Experimental|Bundled clinician training and benefits text messages|Clinicians will receive bundled approach training and parents will receive benefits text messages.
33410654|NCT05006833|Experimental|Bundled clinician training and no text messages|Clinicians will receive bundled approach training and parents will not receive any intervention text messages.
32968958|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
32968959|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
32968960|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
32968961|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
32968962|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
32968963|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
32968964|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
32968965|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
32968966|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
32968967|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
32968968|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
32968969|NCT03748992|Experimental|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
32968970|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
32968971|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
32968972|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
32968973|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
32968974|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
32968975|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
32968976|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
32968977|NCT03730116||the patients with HT and concomitant stable CAD|
32968978|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
32968979|NCT03729024|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
32968980|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
32968981|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
32968982|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
32968983|NCT03727854|Other|Dietary modofication only group|Dietary modification only
32968984|NCT03544242|Active Comparator|Control group|
32968985|NCT03544242|Experimental|Pre-Isolation Infusion|
32968986|NCT03544242|Experimental|Post-Isolation Infusion|
32968987|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
32968988|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
32968989|NCT03423654|Experimental|Training Group|Spatial training
32968990|NCT03423654|Other|Control Group|Letter number matching
32968991|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
32968992|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
32968993|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
32968994|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
32968995|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
33322265|NCT05190952|Active Comparator|Group 3|Dexamethasone Group (In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes).
32968996|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
32968997|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
32968998|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
32968999|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
32969000|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
32969001|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
32969002|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
32969003|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
32969004|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
33410655|NCT05006833|Experimental|Benefits clinician training and bundled text messages|Clinicians will receive benefits approach training and parents will receive bundled text messages.
33410656|NCT05006833|Experimental|Benefits clinician training and benefits text messages|Clinicians will receive benefits approach training and parents will receive benefits text messages.
32969005|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
32969006|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
32969007|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
32969008|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
32969009|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
32969010|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
32969011|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
32969012|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
32969013|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
32969014|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
32969015|NCT02745210|Experimental|Experimental|13C Magnetic resonance (MR) spectroscopy.
33410657|NCT05006833|Experimental|Benefits clinician training and no text messages|Clinicians will receive benefits approach training and parents will not receive any intervention text messages.
33410658|NCT05006833|Experimental|Deferred-clinician training and bundled text messages|Clinicians will receive training after the study and parents will receive bundled text messages.
32969016|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
33410659|NCT05006833|Experimental|Deferred-clinician training and benefits text messages|Clinicians will receive training after the study and parents will receive benefits text messages.
32969017|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
32969018|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
32969019|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
33410660|NCT05006833|No Intervention|Deferred-clinician training and no text messages|Clinicians will receive training after the study and parents will not receive intervention text messages.
32969020|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32969021|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32969022|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32969023|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
32969024|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
32969025|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
32969026|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
32969027|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
32969028|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
32969029|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
32969030|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
32969031|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32969032|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
32969033|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
32969034|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
32969035|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
32969036|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
32969037|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
32969038|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
32969039|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
32969040|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
32969041|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
32969042|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
32969043|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
32969044|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
32969045|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
32969046|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
32969047|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
32969048|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
32969049|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
32969050|NCT02015910|Placebo Comparator|Placebo|Placebo
32969051|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
32969052|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
32969053|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
32969054|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
32969055|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
32969056|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
32969057|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
32969058|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
32969059|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
32969060|NCT01881984|Experimental|Ravicti|Open Label Study
32969061|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
32969062|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
32969063|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
32969064|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
32969065|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
32969066|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
32969067|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
32969068|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
32969069|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
32969070|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
32969071|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
32969072|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
32969073|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
32969074|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
32969075|NCT01738698|Experimental|SPD489 40mg|
32969076|NCT01738698|Experimental|SPD489 100mg|
33410661|NCT04969705|Active Comparator|Group A (spinal Dexmedetomidine)|. Spinal needles (22 G) will be introduced in sitting position after skin disinfection with povidine iodine, iliac crest will be palpated and thumb extended to meet the midline, feeling the space between L4 and L5. spinal needle penetrates through the dura matter, a pop will be felt and then after the needle puncture into the subarachnoid space and the appearance of clear cerebrospinal fluid, the intrathecal local anesthetic will be injected. All patients will be receiving 2 ml heavy bupivacaine 0.5% plus 5 µg dexmedetomidine to total volume of 2.5 ml.
33410662|NCT04969705|Active Comparator|Group B (spinal with transversus abdominus plane block)|Spinal needles (22 G) introduced in sitting position . patients receiving1.7 to 2.2 ml heavy bupivacaine 0.5%( according to weight and height ) + 1 ml normal saline = total volume of 2.5 ml then at surgery end under sonographic guide transducer placed in transverse plane above iliac crest.A 90 mm 22 G short beveled block needle inserted in-plane with transducer, in anterior-posterior direction. needle connected to syringe contains20 ml of bupivacaine 0.25%+10 µg dexmedetomidine to deposit local anesthetic deep into the fascial layer between internal oblique & transversus abdominis muscles on each side.
33410663|NCT04969705|Active Comparator|Group C ( controlled group ) Spinal Anesthesia only :|Patients will be anesthetized only with spinal anesthesia using Bupivacaine Hcl( 10 mg).
33410664|NCT04896697|Experimental|Part 1A - XTX101 Monotherapy Dose Escalation|Part 1A Dose Escalation of XTX101 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
33410665|NCT04896697|Experimental|Part 1B - Pharmacodynamic (PD) Dose Expansion|Part 1B XTX101 at the RP2D will be administered to further examine XTX101 as monotherapy in patients with select advanced solid tumors.
33410666|NCT04896697|Experimental|Part 1C - XTX101 Dose Escalation in Combination with Pembrolizumab|Part 1C Standard labeled dose of pembrolizumab followed by administration of escalating doses of XTX101 to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
33410667|NCT04896697|Experimental|Part 2- XTX101 and Pembrolizumab Combination Therapy|Part 2 will examine XTX101 and pembrolizumab combination therapy at the RP2D in patients with unresectable or metastatic melanoma
32969077|NCT01738698|Experimental|SPD489 160mg|
32969078|NCT01738698|Placebo Comparator|Placebo|
33410668|NCT03178669|Experimental|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
33410669|NCT03178669|Experimental|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
33410670|NCT03178669|Experimental|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
33410671|NCT03178669|Experimental|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
33410672|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
33410673|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
33410674|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
33410675|NCT04833127|Active Comparator|Masibambane - Gender-Enhanced|"A virtual (online) group-based interactive Gender-Enhanced (GE) Workshop (using the WhatsApp® platform). The intervention has components that are conducted by participants on their own time as well as a real-time live interactive session."
33410676|NCT04833127|Other|Individually accessed|In this condition women are given access to a PrEP video and to websites that provide information on PrEP and on contraception options.
32969079|NCT01717482|Active Comparator|Metformin|Metformin 850mg twice a day
32969080|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
32969081|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
33410677|NCT02085408|Active Comparator|A (Induction:daunorubicin/cytarabine; consolidation:cytarabine; maintenance:observation/transplant)|See Detailed Description
32969083|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
32969084|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
32969085|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
32969086|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
32969087|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
32969088|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
33410678|NCT02085408|Experimental|B (Induction: clofarabine; Consolidation: clofarabine; Maintenance: decitabine or transplant)|See Detailed Description
32969089|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
32969090|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
32969091|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
32969092|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
32969093|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
32969094|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
32969095|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
32969096|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
32969097|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
32969098|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
32969099|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
32969100|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
32969101|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
32969102|NCT01507584|Active Comparator|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
32969103|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
32969104|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
32969105|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
32969106|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
32969107|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
32969108|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
32969109|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
32969110|NCT01319760|Sham Comparator|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
32969111|NCT01319760|Experimental|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
32969112|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
32969113|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
32969114|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
32969115|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
32969116|NCT01284504|Placebo Comparator|Placebo|placebo, tab
32969117|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
32969118|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
32969119|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
32969120|NCT01169610|Experimental|Varenicline|
32969121|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
32969122|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
32969123|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
32969124|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
32969125|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
32969126|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
32969127|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
32969128|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
32969129|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
32969130|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
32969131|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
32969132|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
32969133|NCT00895284|Experimental|Robot|Robotic hysterectomy
32969134|NCT00895284|Active Comparator|Standard|Standard hysterectomy
32969135|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
32969136|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
32969137|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
32969138|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
32969139|NCT00875394|Experimental|1|sitagliptin + metformin
32969140|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
32969141|NCT00875394|Active Comparator|3|metformin
32969142|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
32969143|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
32969144|NCT00811590|Experimental|All patients|All participants enrolled.
32969145|NCT00749658|Active Comparator|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
32969146|NCT00749658|Active Comparator|upropion + Varenicline|Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline
32969147|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
32969148|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
32969149|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
32969150|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
32969151|NCT00726180|Experimental|Treatment arm|
32969152|NCT00704496|Placebo Comparator|Placebo|Placebo
32969153|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
32969154|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
32969155|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
32969156|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
32969157|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
32969158|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
32969159|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
32969160|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
32969161|NCT00679926|Experimental|Once daily|Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
32969162|NCT00680316|Experimental|Dornase alfa|
32969163|NCT00680316|Placebo Comparator|Placebo|
32969164|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
32969165|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
32969166|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
32969167|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
32969168|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
32969169|NCT00601848|Experimental|Photodynamic Therapy|PDT
32969170|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
32969171|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
32969172|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
32969173|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
32969174|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
32969175|NCT00568698|Experimental|Hydroxyurea|
32969176|NCT00568698|Placebo Comparator|Placebo|
32969177|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
32969178|NCT05600634||Kidney and skin transplataiton|
32969179|NCT05600478||Japan|A group of ICU physical therapists working in Japan.
32969180|NCT05600478||Philippines|A group of ICU physical therapists working in the Philippines.
32969181|NCT05600478||Taiwan|A group of ICU physical therapists working in Taiwan.
32969182|NCT05600400|Experimental|Arm 1|Two weekly fractions of 13.5 Gy
32969183|NCT05600400|Active Comparator|Arm 2|Five every other day fractions of 8 Gy
32969184|NCT05600166||Experimental group|Participants were treated with artificial dermal repair materials in combination with growth factors.
32969185|NCT05600166||Control group|Cases treated with a double layer of artificial dermal repair material
32969186|NCT05599542|Experimental|Solution-oriented approach group|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order.
32969187|NCT05599542|Experimental|Hypno-breastfeeding group|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
32969188|NCT05599542|Other|control group|Data were collected with the Introductory Information Form at the first interview (admission to the postpartum service) with the women in the control group. Post-test data were collected with Primiparous Breastfeeding Motivation Scale and Insufficient Milk Perception Scale at 16-24 hours postpartum.
32969189|NCT05599386||Patients Undergoing VATS|Only one group as primary endpoints are continous
32969190|NCT05599230||CF patients before (3 days) and during (14 days) ETI treatment|"Patients over 12 years old and eligible will start ETI treatment ( current standart treatment).~Morning: Elexacaftor 100 mg, Tezacaftor 50 mg, Ivacaftor 75 mg, 2 tablets~Evening: Ivacaftor 150 mg"
32969191|NCT05599152||ticagrelor/prasugrel Group|Patients with acute myocardial infarction who underwent percutaneous coronary intervention and maintained aspirin and ticagrelor/prasugrel as standard therapy.
32969192|NCT05599152||clopidogrel Group|In patients with acute myocardial infarction who underwent percutaneous coronary intervention, discontinued ticagrelor/prasugrel and switched to clopidogrel
32969193|NCT05573256|Experimental|Group 1 (Sleep hygiene education together with lavender oil inhalation)|the participants assigned to Group 1 will be given sleep hygiene education and instructed how to apply lavender oil inhalation. The participants will be provided with charts on sleep hygiene education and lavender oil inhalation and shown how to regularly keep daily records using their charts. The participants in this group will be given a copy of the sleep hygiene education brochure and lavender oil in a 10 ml bottle.
32969194|NCT05573256|Experimental|Group 2 (Sleep hygiene education)|The participants assigned to Group 2 will only be given sleep hygiene education. They will be provided with a copy of the sleep hygiene education brochure and a chart on which to record their sleep hygiene practices.
32969195|NCT05573256|Experimental|Group 3 (Lavender oil inhalation)|The participants assigned to Group 3 will only be instructed on how to apply lavender oil inhalation and keep regular daily records on the chart given. The participants in this group will be given lavender oil in a 10 ml bottle.
32969196|NCT05573256|No Intervention|Group 4 (Routine care)|"Participants assigned to Group 4 will be given routine care and no application will be made.~Patient care and follow-up are routinely performed as follows: Following the patient's admission to the clinic, the first evaluation of the patient is made by the ostomy and wound care nurses within 24 hours, and patient education is initiated accompanied by the primary caregiver from the family. Throughout the period from admission to clinic to discharge, the ostomy care and education of the patient is repeated by the ostomy and wound care nurses every 72 hours. In addition, the patient and caregiver are given the contact information of the ostomy and wound care nurses and informed that they can call them at any time when they need it after discharge from the hospital."
32969197|NCT05533476|Experimental|Multi Sensory Stimulation And Priming|8 weeks, 30 minutes per day home based MuSSAP training.
32969198|NCT05533476|Experimental|Intensive Usual Care (Upper Limb)|8 weeks, 30 minutes per day home based Intensive Usual Care (Upper Limb).
32969199|NCT05526768|Experimental|VITLS Device|The remote monitoring device (VITLS) will be placed onto the chest of consented patients in a manner that will not interfere with standard in-patient monitoring devices. Subjects will simultaneously be monitored with conventional inpatient methods per the unit routine. The providers caring for participating patients will be blinded to the data being collected by the remote monitoring system and no patient care decisions will be made based on the remote monitoring system. The remote monitoring device will automatically monitor and store the data for each subject by subject ID number. Once at least 6, but up to 72 hours of data have been recorded, the investigational device will be removed. Researchers will then retrospectively obtain the corresponding data from the current standard of care inpatient monitoring devices.
32969200|NCT05524584|Experimental|Fulvestrant + Anastrozole + Abemaciclib|"Fulvestrant, intramuscular, Initial: 500 mg on days 1 and 15; Maintenance: 500 mg once monthly.~Anastrozole, oral, 1mg tablet daily~Abemaciclib 150 mg twice daily"
32969201|NCT05522868|Other|Cohort 1|SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort
32969202|NCT05522868|Other|Cohort 2|SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort
32969203|NCT05522868|Other|Cohort 3|SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort
32969204|NCT05522868|Other|Cohort 4|SB17170 dose: 1500 mg/d per day, 3 to 6 subjects per cohort
32969205|NCT05522868|Other|Cohort 5|SB17170 dose: 2000 mg/d per day, 3 to 6 subjects per cohort
32969206|NCT05460390|Experimental|TDM based adalimumab dose optimization group|Therapeutic drug monitoring (TDM) provides an opportunity for a proactive and individualized therapy optimization based on serum drug concentration and anti-drug antibodies development.
32969207|NCT05460390|No Intervention|Standard of care|Standard of care practice for RA management is based on disease activity guided therapy adjustments.
32969208|NCT05403762|Experimental|ESENTA™ Skin Barrier Spray|In the intervention group I, standardized mild skin cleansing regimen and daily topical application of a film-forming skin protectant at the exposed skin areas will be applied by nursing staff.
32969209|NCT05403762|Experimental|Hydrophobes Basisgel DAC|In the intervention group II, standardized mild skin cleansing regimen and daily topical application of a hydrophobic skin protectant at the exposed skin areas will be applied by nursing staff.
32969210|NCT05403762|No Intervention|Standard Care|In the control group, standardized mild skin cleansing regimen without application of an additional skin protectant will be conducted by nursing staff.
32969211|NCT05356572|Active Comparator|Investigational Skin Preparation Device versus Disposable Dermal Curette|
32969212|NCT05356572|Active Comparator|Investigational Skin Preparation Device versus Abrasive Pad for Skin Preparation|
32969213|NCT05345184|Experimental|Cognitive Behavioral Suicide Prevention for psychosis (treatment group)|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
32969214|NCT05345184|Active Comparator|Services as Usual (SAU; comparison group)|Services as usual involve standard and current services that clients are eligible for receiving.
32969215|NCT05330442|No Intervention|CoCM alone|In the CoCM alone arm, participants will have access to treatment as usual from the CM.
32969216|NCT05330442|Experimental|CoCM+WET|In the CoCM+WET intervention arm, patients will be encouraged to receive WET.
32969217|NCT05291286|Experimental|BXQ-350|BXQ-350 will be administered by IV infusion
32969218|NCT05291286|Placebo Comparator|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion
32969219|NCT05288946|Experimental|local segmental control and closed kinetic chain|the patients will receive local segmental control and closed kinetic chain three times a week for four weeks
32969220|NCT05288946|Experimental|local segmental control and open kinetic chain|the patients will receive local segmental control and open kinetic chain three times a week for four weeks
32969221|NCT05288946|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for four week
33033556|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
32969222|NCT05272176|Experimental|Coping Long Term with Active Suicide Program (CLASP)|"The CLASP intervention is an adjunctive, telehealth-based behavioral intervention designed to reduce suicidal behavior among individuals at high risk for suicide going through periods of transition. CLASP is designed to intervene on four risk factor targets: ongoing treatment engagement, problem-solving, social and family support, and hopelessness. In addition to these general factors, the CLASP provider also has the flexibility to identify and target certain patient-specific risk factors (e.g., substance misuse) for intervention.~CLASP will begin after completion of the baseline assessment (prior to discharge), and will continue for 6 months post-discharge. CLASP will be comprised of: a) 3 initial sessions while participants are still inpatients (can occur post-discharge if needed); b) 12 brief telehealth sessions over 6-months post-discharge; c) 6 brief SO telehealth sessions."
32969223|NCT05272176|No Intervention|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided as part of routine care in the Veterans Health Administration (VHA) following inpatient hospitalization. Study staff will provide no additional treatment in this arm.
32969224|NCT05270460|Experimental|PCS12852 0.1mg|PCS12852 0.1mg tablet
32969225|NCT05270460|Experimental|PCS12852 0.5mg|PCS12852 0.5mg tablet
32969226|NCT05270460|Placebo Comparator|Placebo|Similar in appearance to active study drug
32969227|NCT05263830||Patient with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
32969228|NCT05164614|Experimental|RT-102 Group 1|In 15 subjects, a RaniPill capsule containing 20 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
32969229|NCT05164614|Experimental|RT-102 Group 2|In 15 subjects, a RaniPill capsule containing 80 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
32969230|NCT05164614|Active Comparator|SC Group|In 10 subjects, 20 µg of Forteo will be administered subcutaneously and serial blood samples will be collected for PK analysis.
32969231|NCT05164614|Experimental|Part 2; Group 1|In up to 7 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy post-menopausal or surgically sterile with bilateral oophorectomy women.
32969232|NCT05164614|Experimental|Part 2; Group 2|In up to 12 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy women.
32969233|NCT05145738|Experimental|C-Raven + Avatar|Computer delivered intervention with Avatar as virtual counselor plus linkage to community health worker
32969234|NCT05145738|Active Comparator|C-Raven|Computer-delivered intervention without virtual counselor, with linkage to community health worker
32969235|NCT05001048|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
32969236|NCT05001048|Experimental|Early Acclimatization to High Altitude|Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.
32969237|NCT05001048|Experimental|Late Acclimatization to High Altitude|Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.
32969238|NCT04954638||sodium hypochlorite|group 1: control group with sodium hypochlorite desinfection
32969239|NCT04954638||hyperpure chlorine dioxide|group 2: study group with hyperpure chlorine dioxide desinfection
32969240|NCT04906200|Experimental|Group A (YES portal)|Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.
32969241|NCT04906200|Active Comparator|Group B (usual care)|Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.
32969242|NCT04848870||Sjögren patients|Patients in specialized consultations for Sjögren's patients in the oral medicine department of the Charles Foix Hospital AP-HP France
32969243|NCT04810572|Active Comparator|Group 1 - composition with Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition with Silymarin (Silybum marianum), in a diary dose of 140 mg for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
32969244|NCT04810572|Active Comparator|Group 2 - composition without Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
32969245|NCT04810572|Active Comparator|Group3 - Low-mineral composition without Silymarin (L5)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
32969246|NCT04773600|Active Comparator|ARQ-151 Cream 0.15%|Active comparator
32969247|NCT04773600|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
32969248|NCT04772742|Experimental|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
32969249|NCT04772742|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
32969250|NCT04723758|Experimental|GI Genius-assisted colonoscopy (GGC)|In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
32969251|NCT04723758|Active Comparator|Standard Colonoscopy (SC)|In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
32969252|NCT04710576|Experimental|Axatilimab Dose Cohort 1|Participants will be administered axatilimab 0.3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks for up to 2 years.
32969253|NCT04710576|Experimental|Axatilimab Dose Cohort 2|Participants will be administered axatilimab 1 mg/kg IV every 2 weeks for up to 2 years.
32969254|NCT04710576|Experimental|Axatilimab Dose Cohort 3|Participants will be administered axatilimab 3 mg/kg IV every 4 weeks for up to 2 years.
32969255|NCT04702386||Focus groups|Children aged 8 years or more participating in a focus group with the study psychologist
32969256|NCT04702386||Individual interviews|All children who have an individual interview with the study psychologist
32969257|NCT04575090|No Intervention|Arm 1 (Observational Arm)|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
32969258|NCT04575090|Experimental|Arm 2 (Interventional Experimental Arm)|"Subjects with statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
32969259|NCT04575090|Experimental|Arm 3 (Interventional Control Arm)|"Subjects with no statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
32969260|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
32969261|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
32969262|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
32969263|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
32969264|NCT04302948|No Intervention|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
32969265|NCT04302948|Experimental|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
32969266|NCT04234152|Experimental|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
32969267|NCT04234152|Placebo Comparator|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
32969268|NCT04100772|Experimental|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
32969269|NCT04100772|Experimental|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
33417293|NCT03060447|Experimental|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
33417294|NCT04623567|Experimental|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
32969270|NCT04100772|Experimental|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
32969271|NCT04100772|Experimental|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
32969272|NCT04100772|Experimental|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
32969273|NCT04100772|Experimental|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
32969274|NCT04100772|Experimental|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
32969275|NCT04100772|Active Comparator|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
32969276|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
32969277|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo is a transdermal patch, applied weekly for 24 weeks"
32969278|NCT04043520|Placebo Comparator|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
32969279|NCT04012008|Active Comparator|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
32969280|NCT04012008|Experimental|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
32969281|NCT03634410||Employed|people aged +50 and currently employed
32969282|NCT03634410||Unemployed|people aged +50 and currently unemployed
32969283|NCT03634410||Early retirement|people aged +50 and currently on early retirement
32969284|NCT03634410||Disability pension|people aged +50 and currently on disability pension
32969285|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
32969286|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
32969287|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
32969288|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
32969289|NCT03466476|Experimental|Wearable Technology Group|Patients in this arm will be provided with their own Consensus TracPatch wearable device postoperatively and instructed on its use for six weeks.
32969290|NCT03466476|No Intervention|Current Standard of Care Group|Patients in this arm will not be provided with any wearable device. Participants will be evaluated as part of the study for a total of six weeks.
32969291|NCT03461406|Experimental|Fibrin Sealant Grifols|human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution)
32969292|NCT03461406|Active Comparator|EVICEL|human fibrinogen (55-85 mg/mL) and human thrombin (800-1200 IU/mL)
32969293|NCT03301038|Experimental|All Subjects|SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)
32969294|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
32969295|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
32969296|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
32969297|NCT02836470|Experimental|LB1148|Active
32969298|NCT02836470|Placebo Comparator|Placebo|Placebo
33410679|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
32969299|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
32969300|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
32969301|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
32969302|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
32969303|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
32969304|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
32969305|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
32969306|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
33410680|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
33410681|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
32969307|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
32969308|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
32969309|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
32969310|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
32969311|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
32969312|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
32969313|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
32969314|NCT00519090|Experimental|Nilotinib (AMN107)|
32969315|NCT00519090|Active Comparator|Imatinib|
32969316|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
32969317|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
32969318|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
32969319|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
32969320|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
32969321|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
32969322|NCT00386724|Experimental|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
32969323|NCT00325572|Active Comparator|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
32969324|NCT00325572|Placebo Comparator|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
32969325|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
32969326|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
32969327|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
32969328|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
32969329|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
32969330|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
32969331|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
32969332|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
32969333|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
32969334|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
32969335|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
32969336|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
32969337|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
32969338|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
32969339|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
33410682|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
32969340|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
32969341|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
32969342|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
32969343|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
32969344|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
32969345|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
32969346|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
32969347|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
32969348|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
32969349|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
32969350|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
32969351|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
32969352|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
32969353|NCT00000318|Experimental|1|Maintenance treatment with daily medication
32969354|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
32969355|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
32969356|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
32969357|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
32969358|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
32969359|NCT00000450|Active Comparator|Naltrexone Tablet|
33410683|NCT01656564||Healthy Controls|Individuals with no known history of HIV
33410684|NCT01656564||Healthy Controls - Questionnaire Group|Individuals with no known history of HIV
33410685|NCT01656564||HIV|Individuals who acquired HIV in early life
32969360|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
32969361|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
32969362|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
32969363|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
32969364|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
32969365|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
32969366|NCT00000930||B|Individuals with newly acquired HIV infection
32969367|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
32969368|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
33410686|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~Eczema vaccinatum.~Progressive vaccinia.~Severe generalized vaccinia.~Vaccinia infections in individuals who have skin conditions.~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
32969369|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
32969370|NCT00000948|Active Comparator|2|All participants will receive ART
32969371|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
32969372|NCT00001626|Experimental|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
32969373|NCT00001626|Experimental|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
32969374|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
32969375|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
32969376|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
32969377|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
32969378|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
32969379|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
32969380|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
32969381|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
32969382|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
32969383|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
33410687|NCT01099644|Experimental|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
32969384|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
32969385|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
32969386|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
32969387|NCT00002586|No Intervention|Observation|Observation
32969388|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
32969389|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
32969390|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
32969391|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
32969392|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
32969393|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
32969394|NCT00002664|Experimental|Treatment|
32969395|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
32969396|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
33410688|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
33410689|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
33410690|NCT00354120|Experimental|1|Alentuzumab
33410691|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
32969397|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
32969398|NCT00002682|Experimental|Antibiotic Treatment|
32969399|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
32969400|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
32969401|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
32969402|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
33410692|NCT03021486|Experimental|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
32969403|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
32969404|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
32969405|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
32969406|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
32969407|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
32969408|NCT05752578||Subjects with HIV infection|Both male and female subjects, over 18 years of age, on antiretroviral therapy, native speakers of Italian
32969409|NCT05752578||Healthy control subjects|Both male and female subjects, over the age of 18 years, no neurological or psychiatric conditions that would alter test performance, native speakers of Italian
32969410|NCT05752500|Experimental|BA + PA Coaching|Brief Advice to Engage in Physical Activity + FitBit Physical Activity Coaching
32969411|NCT05752500|Experimental|BA + CB-PA|Brief Advice to Engage in Physical Activity + FitBit Cognitive-Behavioral Intervention to Increase Physical Activity
32969412|NCT05752500|Experimental|BA + SS-PA|Brief Advice to Engage in Physical Activity + FitBit Social support for Physical Activity
32969413|NCT05752500|Experimental|BA + PA Coaching + CB-PA|Brief Advice to Engage in Physical Activity + FitBit Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity
32969414|NCT05752500|Experimental|BA + PA Coaching + SS-PA|Brief Advice to Engage in Physical Activity + FitBit Physical Activity Coaching Social support for Physical Activity
32969415|NCT05752500|Experimental|BA + CB-PA + SS-PA|Brief Advice to Engage in Physical Activity + FitBit Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
32969416|NCT05752500|Experimental|BA + PA Coaching + CB-PA + SS-PA|Brief Advice to Engage in Physical Activity + FitBit Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
32969417|NCT05752500|Other|BA|Brief Advice to Engage in Physical Activity + FitBit
32969418|NCT05752422|Experimental|Active transcranial Photobiomodulation (t-PBM)|Active t-PBM will be delivered to the forehead using the Niraxx Smart Headband (gen 1). Daily treatments of 40 min
32969419|NCT05752422|Sham Comparator|Sham t-PBM|To the subjects belonging to the sham arm the sham treatment sessions will be performed using the same device, during the same time but the device will not be turned on.
32969420|NCT05752266|Experimental|Probiotic Arm|Participants allocated to PRO arm will be administered personalized probiotic pills.
32969421|NCT05752266|Placebo Comparator|Placebo Arm|Participants allocated to PRO arm will be administered maltodextrin placebo pills similar in appearance to probiotic pills.
32969422|NCT05752110|Active Comparator|Ketamine|Received 0.5mg/kg IV single dose ketamine in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
32969423|NCT05752110|Placebo Comparator|Control|Received 0.05ml/kg IV % 0.9 saline in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
33410693|NCT03021486|Experimental|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
33410694|NCT03021486|Experimental|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
32969426|NCT05751954|Other|Arm Label|All patients who undergo total knee arthroplasty and met inclusion and exclusion criteria
32969427|NCT05751876||Women with adenomyosis under dienogest|Perimenopausal women with symptomatic adenomyosis receiving dienogest
32969428|NCT05751798|Experimental|OSE-279 100 mg|Dose Level 1: OSE-279 100 mg
32969429|NCT05751798|Experimental|OSE-279 300 mg|Dose Level 2: OSE-279 300 mg
32969430|NCT05751798|Experimental|OSE-279 500 mg|Dose Level 3: OSE-279 500 mg
33410695|NCT00317616||Unaffected individuals from families in which the genetic cause of ALS is known|This population would include pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
33410696|NCT04058808|Experimental|Participants with Atrial Fibrillation attending the clinic.|
33410697|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
33410698|NCT00136500||Individuals affected with ALS|This population be sporadic or familial ALS.
33417295|NCT04623567|Active Comparator|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
33410699|NCT00136500||Unaffected individuals from families in which the genetic cause of ALS is known|This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
33410700|NCT00136500||Individuals affected with an ALS-related neurodegenerative disease|This would include FTD, MSP, IBMPFD, etc.
32969431|NCT05751720|Experimental|GLP-1/GIP Arm pre and post intervention|"The adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic, who are identified as having fatty liver disease either via ultrasound or biochemical parameter of NFS.~We will aim to include minimum 30 patients fulfilling the selection criteria as below. Informed written consent will be obtained . Intervention group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide).~The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.The KPa improvement in liver stiffness and total fat estimation pre and post intervention in both groups will assessed"
32969432|NCT05751564|Experimental|"Ready to inject MSC product"|"Cryopreserved ready to inject Umbilical Cord (UC) derived MSC"
32969433|NCT05751564|Active Comparator|Resuspended MSC product|Umbilical Cord (UC) derived MSC in suspension media
32969434|NCT05751486|Experimental|JS001sc Q3W|
32969435|NCT05751486|Experimental|JS001sc long period|
32969436|NCT05751486|Experimental|JS001 IV (if applicable)|the Safety Monitor Committe (SMC) will discuss whether to conduct an IV cohort and determine the dose/frequency of the IV cohort, based on the initial safety and clinical pharmacological data of triprilimab injection in combination with the GP regimen;
32969437|NCT05751486|Experimental|Additional cohort (if applicable)|The exploration of additional dosing/frequency will be discussed by the SMC based on prior safety and clinical pharmacological data
32969438|NCT05751408||Stiff knee gait|Subjects referred to clinical 3D gait analysis because of a clinical question related to stiff knee gait
32969439|NCT05751408||Foot surgery|Subjects referred to clinical 3D gait analysis because of a clinical question related to foot surgery
32969440|NCT05751330|Experimental|patients affected by Cardioinhibitory Neurocardiogenic Syncope|
32969441|NCT05751252|Experimental|0.0625 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.0625 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude
32969442|NCT05751252|Experimental|0.025 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.025 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude.
32969443|NCT05751096|Active Comparator|LIFU - CRPS|Real LIFU application for CRPS cohort.
32969444|NCT05751096|Sham Comparator|SHAM - CRPS|Sham LIFU application for CRPS cohort.
32969445|NCT05751096|Active Comparator|LIFU - FM|Real LIFU application for FM cohort.
32969446|NCT05751096|Sham Comparator|SHAM - FM|Sham LIFU application for FM cohort.
32969447|NCT05751018|Experimental|pyrotinib|
32969448|NCT05750784|Other|total knee arthroplasty using the active robotic system using the kinematic alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
33410701|NCT00136500||Healthy controls|
33410702|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
33410703|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
33417296|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
32969449|NCT05750784|Other|total knee arthroplasty using the active robotic system using the mechanical alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
32969450|NCT05750706||Acute lymphoblastic leukemia, no invasive fungal infection|
32969451|NCT05750706||Acute lymphoblastic leukemia, invasive fungal infection|
32969452|NCT05750628|Experimental|Cohort A1: Dose Level 1 INE963|Cohort A1: Dose Level 1 INE963
32969453|NCT05750628|Experimental|Cohort A1: Dose Level 2 INE963|Cohort A1: Dose Level 2 INE963
32969454|NCT05750628|Experimental|Cohort A1: Dose Level 3 INE963|Cohort A1: Dose Level 3 INE963
32969455|NCT05750628|Experimental|Cohort B1: KAE609 + INE963|Cohort B1: KAE609 + INE963
32969456|NCT05750628|Active Comparator|Cohort B1: SoC (Coartem)|Cohort B1: SoC (Coartem)
32969457|NCT05750628|Experimental|Cohort B2: KAE609 + KLU156|Cohort B2: KAE609 + KLU156
32969458|NCT05750628|Active Comparator|Cohort B2: SoC (Coartem)|Cohort B2: SoC (Coartem)
32969459|NCT05750550|Experimental|Instrument Assisted Soft Tissue Mobilization Group|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
32969460|NCT05750472||Neck Pain Group|group evaluated with scales
32969461|NCT05750472||Healthy Group|group evaluated with scales
32969462|NCT05750394|Active Comparator|Single Layer Closure|"Single layer closure using the following technique:~a. Closure of the myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique. The endometrium should be excluded."
32969463|NCT05750394|Active Comparator|Double Layer Closure|"Double layer closure using the following technique:~Closure of the full thickness of the myometrium with one (1) Monocryl suture on a CT needle using a running locked technique. The endometrium should be excluded.~Imbrication of the first layer with one (1) Monocryl suture on a CT needle using a running un-locked technique"
32969464|NCT05750394|Active Comparator|Triple Layer Closure|"Triple layer closure of Endometrium, Myometrium and Serosa (EMS) using one of the the following two techniques:~Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~Closure of the remaining myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~or~Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~Closure of the remaining myometrium with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~Closure of the serosa with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique"
33410704|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
32969465|NCT05750316|Experimental|Freeze dried cowpea leaves mixed in jam|6g of freeze-dried cowpea leaves (equivalent to one portion of vegetables) mixed with apricot jam and spread on bread.
32969466|NCT05750316|Active Comparator|Jam with green food colour|Apricot jam mixed with green colouring and spread on bread
32969467|NCT05750160|No Intervention|Control|Given education only
32969468|NCT05750160|Experimental|Intervention|Given education and music therapy
32969469|NCT05749926|Active Comparator|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|Length of use : 1 day
32969470|NCT05749926|Experimental|VidPrevtyn® Beta vaccine (Sanofi/GSK)|Length of use : 1 day
32969471|NCT05749848|Experimental|[¹⁴C]-LY3372689|Single dose of [¹⁴C]-LY3372689 administered orally.
32969472|NCT05749692||The COVID-19 infected group|Functional dyspepsia patients infected with COVID-19
32969473|NCT05749614|Experimental|Group 1|
32969474|NCT05749614|Experimental|Group 2|
32969475|NCT05749536||Asthma|With positive asthma test
32969476|NCT05749536||Healthy|With no signs of asthma
32969477|NCT05749380|Other|1A(RT)|Patients (AmBisome, DKF-5122)
32969478|NCT05749380|Other|1B(TR)|Patients (DKF-5122, AmBisome)
32969479|NCT05749380|Other|2A(RT)|Healthy subjects (AmBisome, DKF-5122)
32969480|NCT05749380|Other|2B(TR)|Healthy subjects (DKF-5122, AmBisome)
32969481|NCT05749302|Experimental|Al18F-NOTA-FAPI PET/CT|Al18F-NOTA-FAPI PET/CT will be performed on patients with suspected or clearly diagnosed FAP positive-expressing tumors. The patients were injected with Al18F-NOTA-FAPI and underwent PET/CT scan 20~40min after the injection.
32969482|NCT05749224|Experimental|Patients Who Have Temporomandibular Joint Disorder|Helkimo index will be applied to the patients have temporomandibular disorder.
32969483|NCT05749224|Experimental|Healthy Controls|Helkimo index will be applied to healthy people.
32969484|NCT05749146|Experimental|Palliative care at home|Randomized to intervention arm
32969485|NCT05749146|Active Comparator|Augmented control|Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)
32969486|NCT05749068|Experimental|Experimental|Open label experimental arm
32969487|NCT05748990|Experimental|Schizophrenia Group|Insulin (160IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
32969488|NCT05748990|Experimental|Healthy Control Group|Insulin (160 IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
32969489|NCT05748912|Experimental|Therapeutic bronchoscopy for removal of mucus plugs|Protocol A: This protocol will study 10 patients with asthma who have CT (Computed Tomography) evidence of mucus plugs in their airways. Screening data will be reviewed to determine participant eligibility. Participants who meet all eligibility criteria will participate in a bronchoscopy done on one lung for the first 5 participants, and if single lung mucus removal is well tolerated then we will perform bronchoscopies on both lungs for the next 5 participants.
32969490|NCT05748834|Experimental|Tucatinib Experimental Treatment Arm|Participants will receive tucatinib 300mg by mouth twice daily continuously in combination with Doxil 40mg/m2 given intravenously on day 1 of each cycle. Cycles will be 28 days. Up to 36 participants will be enrolled in this Phase 2 study.
32969491|NCT05748756|Experimental|Test group|
32969492|NCT05748756|Active Comparator|Control group|
32969493|NCT05748678|Experimental|Use of the compression apparel|All participants
32969494|NCT05748522|Other|Shoulder Mobility|It is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands. This type of reach test has been described as a tool for measuring glenohumeral joint (GH) mobility through functional shoulder movements.
32969495|NCT05748522|Experimental|Diaphragmatic Breathing|The participant lies on his back. He places his hands horizontally on the lowest part of the ribs. While inhaling, he is asked to inflate his stomach towards the bottom of his hands. It is taught that during breathing, the abdomen should swell rather than the rib cage, and the ribs should open outwards. Breath is taken through the nose, blown slowly through the mouth.
32969496|NCT05746806|Experimental|Single arm|Patients with locally recurred prostate cancer will receive a ultrahypofractionated stereotactic radiotherapy to the radiologically identified lesion (Dose: 5 fractions with 7Gray every second work week day) combined with an androgen deprivation therapy (LHRH-agonist / -antagonist) for 6 months.
32969497|NCT05745402|Experimental|Mobility Checkup Intervention|45-minute Mobility checkup that includes 5 physical performance measures and education based on outcomes compared to age and gender normative values.
32969498|NCT05745246|Experimental|Intervention Group|"This arm will receive the online e-health intervention for six months.~The intervention consists of three sections:~a novel health information strategy, 90SecondFire Cancer health letters~a brief on-line course~a problem-solving asynchronous bulletin board to mobilize existing knowledge"
32969499|NCT05745246|No Intervention|waitlist control group|This group will be placed on a waitlist and will receive the online treatment program after six months.
32969500|NCT05743374|Other|Normal diet|One arm will be given dietary advice that is always given to patients with ulcerative colitis.
32969501|NCT05743374|Active Comparator|E400 elimination|The other arm will be given advice to eliminate E400 substances with special regard to carragenan, CMC and polysorbates.
32969502|NCT05743296||Cross-sectional study, no arm|"Experimental: Training with the virtual reality program (MOTOCOG)~Training consists of 26 minutes task-specific training."
33410705|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
32969503|NCT05740176|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restore kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a two level discectomy for intractable radiculopathy and/or myelopathy.
32969504|NCT05739396|Experimental|core stabalization|The core stability exercises will be used for core stabilization training of group (A) in addition to traditional physical therapy. The core stability program included 3 levels. Each exercise lasted 5 min, and the children shifted from one exercise to the next after the complete performance of the preceding exercise. The first (simple) level included supine abdominal draw-in (20 repetitions), abdominal draw-in with both knees to the chest (10-20 repetitions), and supine twist (10-20 repetitions). The second (medium) level included pelvic bridging (3e5 repetitions) and twist with a medicine ball (10e20 repetitions). Finally, the third (difficult) level included bridging with the head on a physio ball (the position was held for 3-5 s, followed by a slow relaxation phase, with 10-20 repetitions)
32969505|NCT05739396|Experimental|rebound therapy|Rebound exercises will be applied for group B. this group will receive rebound exercise training in addition to traditional physical therapy . Rebound exercises were conducted on a mini-trampoline and BOSU ball. Passive bouncing will be conducted while the child was standing with his/her feet a shoulder-width apart. The therapist will held the child's legs while applying upward and downward movement. The bouncing started slowly. The child then will progress to include the rebound exercises, starting with active bounce, where in a hands free manner the therapist will ask the child to speed up or slow down the bounce rate according to the child's abilities
32969506|NCT05739240|Other|no 3D model|
32969507|NCT05739240|Other|3D model|
32969508|NCT05731284|Active Comparator|Adjunct Platelet rich plasma (PRP) therapy|Study Interventions: PRP will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
32969509|NCT05731284|Placebo Comparator|Normal saline|Placebo: Normal saline will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
32969510|NCT05729568|Experimental|Randomized Phase: Treatment Group 1 - Lenacapavir (LEN) + Teropavimab Dose A + Zinlirvimab Dose B|Participants will receive oral LEN 600mg, subcutaneous (SC) LEN 927 mg, teropavimab Dose A, and zinlirvimab Dose B on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. The last treatment regimen will include SC LEN + teropavimab Dose A + zinlirvimab Dose B.
32969511|NCT05729568|Experimental|Randomized Phase: Treatment Group 2 - LEN + Teropavimab Dose C + Zinlirvimab Dose D|Participants will receive oral LEN 600mg, SC LEN 927 mg, teropavimab Dose C, and zinlirvimab Dose D on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. The last treatment regimen will include SC LEN + teropavimab Dose C + zinlirvimab Dose D.
32969512|NCT05729568|Experimental|Randomized Phase: Treatment Group 3 - Antiretroviral Therapy (ART)|Participants will continue their baseline oral ART through Week 52.
32969513|NCT05729568|Experimental|Extension Phase: Treatment Groups 1 and 2|At Week 52, participants who receive the study drug of LEN, teropavimab, zinlirvimab, and complete study through Week 52 with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) < 50 copies/mL will be given the option to participate in the study extension phase where they will continue to receive their randomized study drugs treatment regimen until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years.
32969514|NCT05729568|Experimental|Extension Phase: Treatment Group 3|Participants who complete study through Week 52 with HIV-1 RNA < 50 copies/mL and in the absence of confirmed virologic rebound (VR) throughout the randomized phase of the study will be given the option to participate in the extension phase and receive the study drugs of LEN, teropavimab, and zinlirvimab at the dose specified for Treatment Group 1 until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years. Treatment with study drug will begin at Week 52 and at that time the baseline oral ART will be discontinued.
32969515|NCT05729022|Active Comparator|Fluoroscopy|A local anesthetic (2% lidocaine), a 22G, 90mm needle (Quincke spinal needle) is inserted into the skin. Once the needle tip is in its target position, 0.5-5 cc of contrast (Omnipauqe) is injected. If the contrast spread along the spinal nerve into the epidural space, a mixture of 3 cc of 0.125% Marcaine and 40 mg of Depo-Medrol is injected or Diprofos (1/2 ampoule (2 ml) per level).
32969516|NCT05729022|Experimental|Ultrasound Microendoscopic|A US device with a curvilinear probe and with a microendoscope (EvoTouch+7 Star Scope), inserted into an 18G needle is used. This group will also receive one AP view fluoroscopy (as control) to check for the diffusion of the contrast material in the epidural space.
32969517|NCT05711784|Experimental|Phaseolean (White Kidney Bean Standardized Extract)1500 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
32969518|NCT05711784|Experimental|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
33322266|NCT05459480|Experimental|Intervention Group|"Online training was continued according to the jigsaw technique for a total of 6 weeks, two hours a week. In the first week, 6 subgroups of 6 people were created.~Sub-topics of the physical examination course were shared according to the systems to these groups, called the main group.~In the first week, it was aimed for the groups to get to know each other and the first lesson was used for that. In the second week, the students in the main group researched the sub-topics of the unit given to them and formed a new group by coming together with students who were researching the same subject. This group was called the expert group. In the third and fourth weeks, expert groups continued their studies to reinforce the subject.~In the fifth and sixth group the students returned to their main groups and explained the subjects they had learned in the expert groups to their main group. Students were expected to teach each other all parts of the unit in their main groups."
32969519|NCT05711784|Placebo Comparator|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
32969520|NCT05709990|Experimental|High dose vitamin D supplementation (combined with standard urotherapy)|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) and behavioral therapy for 8 weeks
32969521|NCT05709990|Active Comparator|Solifenacin succinate group (combined with standard urotherapy)|These patients will receive solifenacin (5-10 mg daily) and behavioral therapy for 8 weeks
32969522|NCT05709990|Active Comparator|standard urotherapy group|These patients will receive behavioral therapy alone for 8 weeks.
33417297|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
32969525|NCT05693064|Experimental|Wait-list followed by chiropractic|
32969526|NCT05688696|Experimental|Orelabrutinib Lower Dose|
32969527|NCT05688696|Experimental|Orelabrutinib Higher Dose|
32969528|NCT05688696|Placebo Comparator|Placebo|
32969529|NCT05688228||Abortion|Adult women performing a medical or surgical abortion
32969530|NCT05682300||Patient under regional anesthesia|patients who recieve peripheral nerve blocks as analgesic technique
32969531|NCT05677698|Experimental|Peppermint oil|Peppermint oil has an effect on menopausal symptoms
32969532|NCT05677698|Experimental|Lemon oil|Lemon oil has an effect on menopausal symptoms.
32969533|NCT05677698|Placebo Comparator|almond oil|Almond oil has an effect on menopausal symptoms.
32969534|NCT05671146|Experimental|Graded weight-bearing exercise|participants will perform exercises using an anti-gravity treadmill
32969535|NCT05671146|Active Comparator|Closed kinetic chain exercise|Exercises will be achieved in a weight-bearing position, with or without support, besides other exercises to improve knee flexors and extensors strength.
32969536|NCT05671146|Sham Comparator|open kinetic chain exercise|Exercises including stretching and strengthening exercises for knee flexors and extensors
32969537|NCT05667168|Experimental|High power laser|"The application of high-intensity laser on cervical muscles, 50J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus.~Administration of tinnitus intensity on scale 0-10 and questionary."
32969538|NCT05667168|Experimental|Low power laser|The application of low-intensity laser on cervical muscles, 4J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus. Administration of tinnitus intensity on scale 0-10 and questionary.
32969539|NCT05667168|Experimental|Radio-frequention therapy|Applying radio-frequentation current on cervical muscles, 10-50% of intensity, 0 Hz. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969540|NCT05667168|Experimental|Manual therapy of temporomandibular joint,.|A manual physiotherapeutic approach to the temporomandibular joint will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969541|NCT05667168|Experimental|Manual therapy of the cervical spine.|A manual physiotherapeutic approach to the cervical spine will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969542|NCT05667168|Active Comparator|Physical exercising.|Participants will be treated by physical exercising in closing and opening muscle chains. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969543|NCT05667168|Active Comparator|Cognitive therapy|Participants will be treated with cognitive therapy by a psychologist. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969544|NCT05667168|Placebo Comparator|Life style.|Participants will be treated only by modulation of their lifestyle. Administration of tinnitus intensity on a scale of 0-10 and questionary.
32969545|NCT05660850|Experimental|Part A: CRC Asthma atopic|Patients with CRC atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
32969546|NCT05660850|Experimental|Part A: CRC Asthma non-atopic|Patients with CRC non-atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
33033557|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
33322267|NCT05459480|No Intervention|Control Group|The subjects were explained by the instructor with the traditional e-teaching method and as in the intervention group, the lectures were conducted online for two hours a week for 6 weeks. At the end of each week, the relevant course documents were shared with the students. At the end of the sixth week, the post-tests of the learning motivation and self-confidence scales were applied in the control group simultaneously with the intervention group. In addition, an academic achievement test was applied.
33322268|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
33322269|NCT04523870|Experimental|Botanical extract|
32861586|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
32861587|NCT01456741|Experimental|1-EBNA with ROSE|
32861588|NCT01456741|Experimental|1-EBNA without ROSE|
32861589|NCT04965324||Anaesthesia Depth BIS 35|BIS 35
32861590|NCT04965324||Anaesthesia Depth BIS 50|BIS 50
32861591|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
32861592|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
32861593|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
32861594|NCT04964856|Experimental|ERAS exercise in perioperative period.|The patients take ERAS exercise from hospitalization to 30 days after operation.
32861595|NCT04964856|Sham Comparator|No ERAS exercise in perioperative period.|The patients do not take ERAS exercise in perioperative period.
32861596|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
32861597|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
32861598|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
32861599|NCT03060408||Open|Patients underwent open distal pancreatectomy
32861600|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
32861601|NCT04961268|Active Comparator|Tramadol 50|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size 000 capsules."
32861602|NCT04961268|Active Comparator|Tramadol 100|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size 000 capsules."
32861603|NCT04961268|Active Comparator|Ibuprofen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size 000 capsules."
32861604|NCT04961268|Active Comparator|Ibuprofen/acetaminophen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size 000 capsules."
32861605|NCT04961268|Placebo Comparator|Placebo|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size 000 capsules."
32861606|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
32861607|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
32861608|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
32861609|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
32861610|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
32861611|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
32861612|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
32861613|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
32861614|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
32861615|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
32861616|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
32861617|NCT01453231|No Intervention|Control|No surgery
32861618|NCT01453231|Experimental|thighplasty|
32861619|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
32861620|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
32861621|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
32861622|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
32861623|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
33322270|NCT04523870|Experimental|Major compound of the extract|
33322271|NCT04523870|Placebo Comparator|Placebo|
33322272|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
33322273|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
32969547|NCT05660850|Experimental|Part A: Unexplained Chronic Cough|Patients with Unexplained Chronic Cough will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
33322274|NCT05189626|Experimental|Group A|Muscle energy technique
33322275|NCT05189626|Experimental|Group B|Kaltonborn mobilizations
33322276|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
32969548|NCT05660850|Experimental|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease|Patients with Chronic Obstructive Pulmonary Disease will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
32969549|NCT05660850|Experimental|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis|Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
33322277|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
33322278|NCT03972683|Experimental|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
33322279|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
33322280|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
33322281|NCT01319032||I. Top-level swimmers|
33322282|NCT01319032||II. Control|Other swimmers
33322283|NCT00227903|Experimental|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
33322284|NCT00227903|Active Comparator|Brief Advice|Advice and education
32969554|NCT05656794|Experimental|Arm 1 - Investigational|Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends).
32969555|NCT05656794|Other|Arm 2 - Standard|Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks.
32969556|NCT05636358|Experimental|Home-based hypnotherapy|"The intervention includes existing home-based hypnotherapy self-exercises in MP3 format for a period of three months.~The intervention group of children with FAP or IBS in primary care receives the home-based hypnotherapy self exercises in addition to care as usual by their GP according to the guideline commissioned by the Dutch Society of GPs."
32969557|NCT05636358|No Intervention|Control|The control group of children with FAP or IBS in primary care will receive only care as usual by their GP. After the end of the study, the control group will also receive access to the home-based hypnotherapy exercises, if desired.
32969558|NCT05628870|Experimental|HRS-1358|Daily oral dosages of HR-1358
32969559|NCT05625516||Patients with acute syndesmotic injuries|The patients undergo a bilateral external torque CT.
32969560|NCT05625516||Patients with asymptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
32969561|NCT05625516||Patients with symptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
32969562|NCT05625282|Active Comparator|control|Weil osteotomy and plantar plate repair
32969563|NCT05625282|Experimental|intervention|Weil osteotomy alone
32969564|NCT05624112|Experimental|AD patients|AD patients aged ≥12 and ≤ 65
32969565|NCT05624112|No Intervention|Healthy volunteers|Non-treatment healthy volunteers
32969566|NCT05623254|Other|TAU + MINDF (Treatment-as -Usual + Mindfulness)|Treatment-as-usual combined with weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)
32969567|NCT05612022||Group 1. Patients with AVF as first line HD access option.|24 consecutive patients in need of AVF enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
32969568|NCT05612022||Group 2. Patients with AVG as first line HD access option.|20 consecutive patients in need of AVG enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
32969569|NCT05605548|Experimental|MitoQ|Participants will take 1 pill each day for 6 weeks
32969570|NCT05605548|Placebo Comparator|Placebo|Participants will take 1 pill each day for 6 weeks
32969571|NCT05597514|Active Comparator|Slide-based presention group|Received a regular learning
32969572|NCT05597514|Experimental|3D-printed presention group|Received a regular learning plus 3D printing model
32969573|NCT05595876|Experimental|Stent retriever|The patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).
32969574|NCT05595876|Sham Comparator|Contact aspiration|The patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)
32969575|NCT05588388|Experimental|Experimental Treatment|"Induction (ABCE): Atezolizumab 1200 mg, Bevacizumab 15 mg/kg, Carboplatin AUC5, Etoposide 100 mg/m2, given IV Q3weeks~Maintenance (AB): Atezolizumab 1200 mg and Bevacizumab 15 mg/kg given IV Q3weeks for 1 year, or until disease progression, or unacceptable toxicity"
32969576|NCT05581212|No Intervention|Standard of Care (Control phase)|In the current standard of care in Thailand, at time of diagnosis and tuberculosis (TB) treatment initiation, TB patients are being advised to tell their household (HH) contacts to consult at the TB clinic for screening and provision of either curative or preventive treatment - according to the screening outcome.
33410706|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
33410707|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
32861624|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
32861625|NCT04961346|Experimental|Ultrapro®|Participants received incisional hernia repair with an Ultrapro mesh in a sublay technique.
32861626|NCT04961346|Experimental|Premilene®|Participants received incisional hernia repair with a Premilene mesh in a sublay technique.
32861627|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
32861628|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
32861629|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
32861630|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
32861631|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
32861632|NCT04961502|Experimental|Elderly person|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
32861633|NCT04961502|Active Comparator|Younger adults (priority caregivers)|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
32861634|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
32861635|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
32861636|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
32861637|NCT04960800|Experimental|Intervention group|The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
32861638|NCT04960800|No Intervention|Control group|The control group will not participate in any exercise intervention. The participants in the control group will be explained the importance of a control group in RCTs and will be recommended to continue with their normal activity levels. They will however, be recommended to follow national guidelines for general exercise during pregnancy and will receive information about these guidelines (15).
32861639|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
32861640|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
32861641|NCT04953234|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care
32861642|NCT04952454|Active Comparator|External DCR|Patients treated with External DCR for functional epiphora
32969577|NCT05581212|Experimental|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase)|"In the selected provinces, individuals (≥18 years) with newly detected bacteriologically confirmed pulmonary Tuberculosis (index TB case) will be sensitized on the importance of HH contact investigation for detection and prevention of TB and stigma reduction.~Index TB cases will be asked to enumerate all persons living in their HH for ≥1 month at the date of TB diagnostic (contact list), and provide their name/age/sex and relationship with the index case.~Screening will be offered to each HH contact, using screening invitation cards that will be provided to the index TB case, to be handed over to each HH contact (or caregiver for children <13 years old).~Urban and Village Health Volunteers (U/VHV),will visit the HH to enhance awareness of the importance of screening for TB case-finding and prevention and facilitate liaison with the hospital.~If active tuberculosis has been formally excluded, they will be eligible to receive the Tuberculosis Preventive Treatment (TPT)."
32969578|NCT05574582|Experimental|Arthroscopic assisted Cancellous chips graft reconstruction|"The arthroscopic technique is potentially less invasive with minimal donor site morbidity and potentially faster time to union because of minimal trauma to the ligament structures, joint capsule, and the tenuous blood supply. It may also have advantageous osteogenic properties compared to a structural graft.~Currently, studies have reported similar union rates, patient reported outcomes score, and functional score compared to open graft technique. Results in patients with gross deformity are debated with some studies favoring conventional open structural graft and other found no difference in outcome between the techniques."
32969579|NCT05574582|Active Comparator|Open cancellous graft reconstruction|Convention open technique with debridement of the nonunion side, insertion of cancellous graft from the iliac crest and osteosynthesis with compression screw is currently commonly applied in scaphoid nonunion.
32969580|NCT05572632|Experimental|COPD Wellness|This arm, COPD Wellness gives low-intensity exercise component with pulmonary rehabilitation for individuals with moderate-to-severe COPD. COPD Wellness is a program that was built from the Better Breathing Program, that is a part of San Francisco Health Network (SFHN) standard care for COPD.
32969581|NCT05572632|Active Comparator|Usual Care|This includes access to comprehensive primary care services. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. This program consists of an evidence-based curriculum that improves disease knowledge and management skills but has no effect on symptoms or functional status. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
32969582|NCT05572632|Experimental|COPD Wellness Plus+|This arm includes COPD Wellness Plus+. This arm is built from COPD Wellness with the addition of Health Advocates (i.e. Plus+). This intervention seeks to understand the effects of addressing social needs on overall health and wellness through Zuckerberg San Francisco General Hospital's (ZSFG) Health Advocate (HA) program; participation and engagement with the HA's will serve as an adherence strategy.
32969583|NCT05570214|Experimental|Virtual Reality Group|Subjects will wear a virtual reality headset during their urological bedside vasectomy.
32969584|NCT05570214|No Intervention|Standard of Care Group|Subjects will undergo standard of care urological bedside vasectomy
32969585|NCT05563818||Arabic-speaking individuals with schizophrenia|Approximately 56-60 Arabic-speaking individuals with a DSM-5 diagnosis of schizophrenia
32969586|NCT05552196|Experimental|Treatment A: Ponesimod|Participants will receive up-titrated Ponesimod orally once daily from Day 1 to Day 15.
32969587|NCT05552196|Experimental|Treatment B: Ponesimod + Carbamazepine|Participants will receive up-titrated Carbamazepine from Day 1 to Day 7 and from Day 23 to Day 26. Participants will also receive up-titrated Ponesimod and Carbamazepine from Day 8 to Day 22.
32969588|NCT05544162|Experimental|SeND Home precision nutrition pathway|Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization. Upon discharge, participants will be given 4-weeks' worth of oral supplements to take. Adjustments may be made based on indirect calorimetry (IC) measurements by the clinical dietitian.
32969589|NCT05544162|No Intervention|Control pathway|Standard of care nutrition delivery throughout hospitalization. Upon discharge they will be sent home with standard nutrition information without Indirect Calorimetry (IC) guidance.
32969590|NCT05543850|Active Comparator|Open loop control|In this arm, the patients will use their usual diabetes therapy. Additionally, patients will wear a blinded DexcomG6 for data collection during the open loop period.
32969591|NCT05543850|Experimental|Bi-hormonal closed-loop control|In this arm, treatment consists of the bi-hormonal closed-loop system. A short acting insulin analogue (Humalog, 3 ml pre-filled cartridge, Eli Lilly) and glucagon (Glucagen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) will be administered according to the closed-loop algorithm. Additionally, patients will wear a blinded DexcomG6 for data collection during the closed loop period.
32969592|NCT05538624|Experimental|Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D|"Part 1: one of four ascending doses of AVB-001 planned for IP, single dose administration at each dose level cohort of the Dose Escalation Phase.~Part 2: a single dose of AVB-001 at the MTD/RP2D level (determined in Part 1) to be further evaluated in the Dose Expansion Phase."
32969593|NCT05535816|Experimental|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound by the same endourologist to determine the size of the largest residual fragment.
32969594|NCT05535816|No Intervention|Fluoroscopy|Standard of care, control Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
32969595|NCT05529654|Experimental|Impella Arm|Impella 5.5 with SmartAssist
33033073|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
32969596|NCT05523414|Experimental|SKY|In-person SKY sessions will be 3 hours long on each of 3 consecutive days, and participants must be willing to attend all 3 sessions. Each session comprises a combination of breathwork, emotional resilience training, yoga, and leadership skills. The SKY technique includes a unique set of standardized breathing techniques to rapidly reduce neuroendocrine stress responses and the autonomic imbalance due to sympathetic overdrive. 8 weeks of online and/or in-person sessions will be delivered to participants in the follow-up period after the initial in-person intervention. They will receive a phone call reminding them about the practice intermittently during the 8-week follow-up period. The participants will be asked to engage in daily 45-60 minute SKY sessions remotely, that is led by an instructor. Each participant will be required to log in the number of times a week they practise. In addition, weekly 90-minute reinforcement sessions will be conducted, in-person.
32969597|NCT05523414|Active Comparator|Control|Control participants will undergo HEP training, that will comprise different modules including music, active body movements, contemplation, and nature walk among others. The number of hours of training will be the same as for the SKY participants. Control participants will be encouraged to daily perform one or more of these activities during the follow-up period, and record how frequently they engage in these activities each week. They will also receive a phone call reminding them about the practice intermittently during the 8-week follow-up period. The HEP curriculum will be designed and taught by an experienced instructor.
32969598|NCT05516628|Experimental|Surgery followed by Adjuvant Atezolizumab-Bevacizumab Therapy every 3-weekly|Patient will receive adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following surgery.
32969599|NCT05515536|Experimental|Vatiquinone|Participants with FA who were previously treated with vatiquinone at an investigational site and completed participation in a prior PTC Therapeutics (PTC)-sponsored clinical study (PTC743-NEU-003-FA or PTC743-NEU-005-FA) will continue to receive the same dose/formulation of vatiquinone (unless there has been a change in age and/or weight that meets the criteria for a different dose/formulation as described below; dose/formulation will also be changed if participants meet the criteria for a different dose/formulation during study treatment): If <7 years of age, participants will receive an oral solution (100 milligrams [mg]/milliliter [mL]) 3 times a day (TID) at one of the following doses: 15 mg/kilogram (kg) if body weight <13 kg, or 200 mg if body weight ≥13 kg. If ≥7 years of age, participants will receive a capsule formulation (200 mg) orally TID at one of the following doses: 200 mg if body weight ˂25 kg, or 400 mg if body weight ≥25 kg.
32969600|NCT05506254||Patients who have previously received hLB-001|
32969601|NCT05497674|Experimental|rongliflozin and/or rifampicin|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Starting On Day 5, subjects will administer rifampicin once a day (QD) for 10 consecutive days ( Day 5 to Study Day 14) , comprising of a single dose administration of rongliflozin on Study Day 11.
32969602|NCT05497674|Experimental|rongliflozin and/or probenecid|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Probenecid will be administrated twice a day from Day 5 to Day 9, and another single dose administration of rongliflozin on Day 6.
32969603|NCT05488314|Experimental|Phase 1 (Combination Dose Selection)|Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms [kg]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
32969604|NCT05488314|Experimental|Phase 2 (Dose Expansion)|Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1.
32969605|NCT05485974|Experimental|Dose Escalation and Expansion|HBI-2438 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6-8 patients will then be enrolled in the expansion cohort at the recommended dose.
32969606|NCT05485740|Experimental|study group|the study group received the same exercise training program in addition to cognitive multisensory rehabilitation program
32969607|NCT05485740|Experimental|control group|the control group which received the selected exercise program
32969608|NCT05481528|Experimental|Part 1 - Dose group 1|Single oral dose of elinzanetant or placebo.
32969609|NCT05481528|Experimental|Part 1 - Dose group 2|Single oral dose of elinzanetant or placebo
32969610|NCT05481528|Experimental|Part 1 - Dose group 3|Single oral dose of elinzanetant or placebo
32969611|NCT05481528|Experimental|Part 1 - Dose group 4|Single oral dose of elinzanetant or placebo
32969612|NCT05481528|Experimental|Part 2: Moxifloxacin - Placebo|Participants of Dose Groups 1 and 4 will receive a single dose of moxifloxacin in Period 1 and a single dose of placebo in Period 2.
32969613|NCT05481528|Experimental|Part 2: Placebo - Moxifloxacin|Participants of Dose Groups 1 and 4 will receive a single dose of placebo in Period 1 and a single dose of moxifloxacin in Period 2.
33410708|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
33410709|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
32969616|NCT05461326|Active Comparator|Quad tendon|ACL graft harvested from the quadriceps tendon
32969617|NCT05461326|Active Comparator|BTB tendon|ACL graft harvested from the patellar tendon
32969618|NCT05458674|Experimental|Tucatinib/Eribulin/Trastuzumab|"The initial dose of trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV), unless trastuzumab was administered within the prior 4 weeks, then the initial dose of trastuzumab will be administered at a dose of 6 mg/kg. Each trastuzumab dose is given once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule~Tucatinib 300 mg orally twice daily (PO BID) every day (Days 1-21) of each 21-day cycle using a modified schedule of events. Subcutaneous trastuzumab is given only once every three weeks as there is no allowance for weekly dosing.~Eribulin will be given at a dose of 1.4 mg/M2 intravenously over a 2-5 minute period on days 1 and 8 of each 21-day cycle."
33322285|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
33322286|NCT04420546|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
32969622|NCT05437926||Light skin|Light skin Fitzpatrick 1-2 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
32969623|NCT05437926||Dark skin|Dark skin Fitzpatrick 5-6 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
32969624|NCT05437068|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
32969625|NCT05435508|Experimental|Pain Neurosicence Education + Pre-anesthetic Assessment|Pain neuroscience education + Pre-anesthetic Assessment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
32969626|NCT05435508|Other|Pre-anesthetic Assessment (Usual Care)|The pre-anesthetic assessment is the clinical study that allows evaluating the physical condition, personal, pathological and surgical history together with laboratory tests to be able to establish a surgical risk in order to define the best anesthetic plan that the patient requires according to the surgical event.
32969627|NCT05435352||Early TNBC patient Cohort A|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy.~Any approved neoadjuvant therapy can be used based on physician's choice."
32969628|NCT05435352||Early TNBC patient Cohort B|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy and blood.~Any approved neoadjuvant therapy can be used based on physician's choice."
32969629|NCT05427162|Experimental|Prostacyclin Receptor Agonist|Participants in Cohort 1-4 will receive multiple doses of prostacyclin receptor agonist of formulation 1 in treatment period 1, followed by a single dose of various other formulations (formulation 2 and 3) in treatment period 2. Cohort 4 will be optional with dose based on PK, safety and tolerability data of previous cohort 3.
32969631|NCT05416944|No Intervention|Routine management (control) group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients assigned to the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
32969632|NCT05416944|Experimental|Personalized management (intervention) group|In patients randomized to the personalized management group, intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg. The perioperative trial intervention period starts with the beginning of the induction of general anesthesia and ends two hours after surgery ends.
32969633|NCT05408910|Experimental|Treatment|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
32969634|NCT05408910|Placebo Comparator|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
32969635|NCT05403372|Experimental|InterShunt PAS-C|
32969636|NCT05400486|Active Comparator|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
32969637|NCT05400486|Experimental|Therapeutic exercise group + high frequency TENS|This group will consist of 25 participants. Initially, TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce impedance at the skin-electrode interface. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012). After the application of TENS, the same program of therapeutic exercises applied in the first group will be applied, in the same sequence, evolution, times, and repetitions.
32969638|NCT05400486|Experimental|Therapeutic exercise group + Interferential|This group will consist of 25 participants. Initially, the protocol of exercises performed in the therapeutic exercise group will be applied. In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
32969639|NCT05400252|Experimental|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
32969640|NCT05400252|Active Comparator|Health and Wellness|Health & Wellness is an educational wellness intervention
32969641|NCT05391828|Experimental|Total Knee Arthroplasty (TKA) performed using a medial congruent articular bearing surface design|
32969642|NCT05391828|Active Comparator|Total Knee Arthroplasty (TKA) performed using a posterior stabilized bearing design|
32969643|NCT05386680|Experimental|OAV-101|Single intrathecal administration of OAV101 at a dose of 1.2 x 10^14 vector genomes
32969644|NCT05377164||Vegetarian group|
32969645|NCT05377164||Omnivorous group|
32969646|NCT05377164||Low carbohydrate group|
32969647|NCT05375214|Other|Treatment Arm|Open label study, all participants will receive novel iTBS
32969648|NCT05370534||Study Population|"The investigators anticipate validating two specific actions: a box jump and walking gait. Both will be captured in two planes, coronal and sagittal. Healthy patients without musculoskeletal complaints will be voluntarily enrolled to undergo motion capture with both methods, completed during the same visit to the UAMS Human Biomechanics Laboratory.~Each patient will perform a box jump and walking gait using each of the two modalities. We anticipate 4 hrs will be required for each patient: 1 hr for setup before the patient arrives, 1 hr for testing, and 2 hrs for data cleaning and initial processing. This work will be performed at the UAMS Human Biomechanics Laboratory (off campus on Aldersgate Road), which is equipped for this type of analysis."
32969649|NCT05370300||Controls: Patients with negative screening MMG|Patients presenting to Duke Radiology for routine screening mammogram will be screened for eligibility as negative controls. Study enrollment for negative controls presumes that patients do not receive their screening mammography results immediately. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
32969650|NCT05370300||Cases: Patients with known cancer diagnosis|Patients presenting to the Duke Cancer Center for evaluation by Medical or Surgical Oncology of a newly diagnosed breast cancer will be screened for study eligibility and approached, enrolled, and consented accordingly. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
32969651|NCT05360628|Experimental|D-0120 plus Allopurinol|D-0120 dosing followed by Allopurinol and combination treatment
32969652|NCT05360628|Experimental|Allopurinol plus D-0120|Allopurinol dosing followed by D-0120 and combination treatment
32969653|NCT05339412|Experimental|Technology Based Training Tool Only|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
32969654|NCT05339412|Experimental|Technology Based Training Tool plus Live Supervision|Participants randomized to this condition will receive (in addition to the training tool described above) access to live supervision delivered remotely via commercially available video conferencing software (Zoom). Facilitators-in-training will complete two mock roleplays of curriculum activities, which can be conducted live via Zoom with PHAT Life trainers (either Dr. Floyd or Dr. Snow-Hill) or can be recorded and submitted via the app. Trainers will review for fidelity and provide feedback. During the supervision sessions, participants will have the opportunity to clarify content, ask questions, roleplay group sessions to practice difficult parts of the group sessions, and review feedback on role plays.
32969655|NCT05334420|Experimental|Healthy Dads Healthy Kids|A group-based lifestyle behavioral program for Hispanic fathers and children
32969656|NCT05334420|Other|Standard of care control|National guidelines and recommendations for healthy eating, physical activity and weight loss.
32969657|NCT05326932|Experimental|Intervention group|Mechanical thrombectomy to be initiated as soon as possible after randomisation.
32969658|NCT05326932|No Intervention|Control group|Patients assigned to the control group will avoid treating MT and only receive the standard medical treatment according to local guidelines.
32969659|NCT05326308||Waldenström's Macroglobulinemia|75 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
32969660|NCT05326308||Chronic Lymphocytic Leukemia|150 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
32969661|NCT05326308||Marginal Zone Lymphoma|75 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
32969662|NCT05321940|Experimental|Combination STAVs and DC Vaccine Group|Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
32969663|NCT05315232||Qualitative assessment|Survey (using validated quality of life assessment questionnaires) and one to one interviews of people and family members living with Glanzmanns Thrombasthenia
32969664|NCT05315232||Bleed diary|Daily bleed diary completion over 12 weeks
32969665|NCT05312112||Venetoclax|Venetoclax in newly diagnosed AML
32969666|NCT05312112||FLT3 inhibitors|FLT3 inhibitors including gilteritinib in relapsed AML
32969667|NCT05311176|Experimental|Arm 1: HER-Vaxx in combination with chemotherapy (ramucirumab plus paclitaxel)|Patients who have received an immune checkpoint inhibitor (ICI) previously will exclusively be enrolled in Arm 1 treated with HER-Vaxx (IM) in combination with chemotherapy (ramucirumab plus paclitaxel)
32969668|NCT05311176|Experimental|Arm 2: HER-Vaxx in combination with pembrolizumab|Arm 2 will investigate the combination of HER-Vaxx plus pembrolizumab in patients who are naïve to ICI treatment including patients who have had chemotherapy only treatment after progression on trastuzumab. As the combination treatment has not been investigated, Arm 2 is planned to initiate with a safety run-in phase.
32969669|NCT05309928|Experimental|Amox 1 GM|Amoxicillin 1000 mg PO
32969670|NCT05309928|Experimental|Amox 1GM + Probenecid|Amoxicillin 1000 mg PO + Probenecid 1000 mg PO
32969671|NCT05309928|Experimental|Amox 3 GM|Amoxicillin 3000 mg PO
32969672|NCT05309928|Experimental|Amox 3 GM + Probenecid|Amoxicillin 3000 mg PO + Probenecid 1000 mg PO
32969673|NCT05296278|Experimental|Cohort A|patients with only 3'ALK confirmed by NGS
32969674|NCT05296278|Experimental|Cohort B|patients with 3'ALK with retention of 5'ALK
32969675|NCT05288868|Experimental|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
32969676|NCT05288868|No Intervention|Caregiver Satisfaction|Caregivers who accompany their children with autism to the clinic will be surveyed for their comfort scores before and after the study participants' educational intervention
32969677|NCT05271552|Experimental|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
32969678|NCT05271552|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
32969679|NCT05271552|Placebo Comparator|Placebo|Sublingual Placebo film
32969680|NCT05266170||Normal adults|aerobic and anaerobic exercises
32969681|NCT05259462|Experimental|Group-active virtual reality gaming|Participants will undergo the intervention.
32969682|NCT05257668|Active Comparator|Group 1|High intensity interval training
32969683|NCT05257668|Active Comparator|Group 2|Moderate intensity training
32969684|NCT05257668|No Intervention|Group 3|Control
32969685|NCT05251428|Experimental|excision of the A1 pulley|
32969686|NCT05251428|Active Comparator|incision of the A1 pulley in the standard fashion|
32969687|NCT05248854|Experimental|Sensorimotor exercise training|SM program included combination of traditional hip and knee exercise, various balance and proprioceptive exercises.
32969688|NCT05248854|Experimental|Core Stabilization exercise training|Core stabilization exercise program contained traditional hip and knee ROM exercise combining the core stabilization as mat activities
32969689|NCT05244174|Active Comparator|Biliary stent|Biliary stent by ERCP is indicated both in palliative treatment, because of biliary duct decompression improves patient comfort by decreasing itching and jaundice, as in the treatment of the disease itself, because of it lets reach non-toxic levels of bilirubin which is necessary for chemotherapeutic treatment.
33410710|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
32969690|NCT05244174|Experimental|Biliary and pancreatic stent|During ERCP, the cannulation of the main pancreatic duct may be performed for the placement of a pancreatic duct stent, which is performed routinely as a prophylaxis of post-ERCP acute pancreatitis in patients at risk. In patients with pancreatic cancer, the placement of a pancreatic stent could improve pancreatic secretion by clearing the main pancreatic duct and thus it could improve fat digestion and nutritional status of patients, avoiding the need for PERT
32969691|NCT05242458||Participants with Crohn's Disease (CD)|Participants with moderate-to-severe active CD enrolled in ImproveCareNow (ICN) pediatric Inflammatory bowel disease (IBD) registry will be observed who are being treated with ustekinumab under real world setting and will be divided into 9 cohorts. Cohorts 1-6 for age group >=2 to <18 years (pediatric), cohorts 7-9 for young adults within age group >=18 to <26 years. Cohort 1: participants with moderate-severe CD and body weight >=40 kg, cohort 2: participants with moderate-severe CD and body weight <40 kg, cohort 3: all participants with moderate-severe CD, cohort 4: participants with active disease and body weight >=40 kg, cohort 5: participants with active disease and body weight <40 kg, cohort 6: all participants treated with ustekinumab, cohort 7: young adults with moderate-severe CD, cohort 8: young adults with active-disease; and cohort 9: all young adults treated with ustekinumab. Only data available per routine clinical practice will be collected within this study.
32969692|NCT05241522|Active Comparator|Tilmanocept Dose - 0.050 mg|
32969693|NCT05241522|Active Comparator|Tilmanocept Dose - 0.20 mg|
32969694|NCT05241522|Active Comparator|Tilmanocept Dose - 0.40 mg|
32969695|NCT05235750|Experimental|Writing|This is a single-group study with one arm only.
32969696|NCT05226858||Trauma patients with suspected blunt traumatic aortic injury (BTAI)|All trauma patients with suspected BTAI at the emergency department who require both transesophageal echocardiography (TEE) and computed tomography angiography (CTA).
32969697|NCT05218668|Experimental|Fasudil|Oral fasudil up to 240 mg/day
32969698|NCT05215626||Patients implanted with the Zimmer Reconstruction System|
33410711|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
33410712|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
33410713|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
33410714|NCT04058340|Active Comparator|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
33410715|NCT04058340|Active Comparator|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
33410716|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
33410717|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
33410718|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
33410719|NCT04058262|Experimental|Meditation presential|
33410720|NCT04058262|Experimental|Reiki|
33410721|NCT04058262|Experimental|Meditation (app)|
33410722|NCT04058262|Placebo Comparator|round of conversation|
33410723|NCT05654688|Experimental|Graston|Graston technique and traditional physical treatment (control)
33410724|NCT05654688|Experimental|Muscle energy technique|Muscle energy technique and traditional physical treatment
33410725|NCT05654688|Active Comparator|Traditional physical therapy|Traditional physical therapy treatment as heat application
33410726|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
33410727|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
33410728|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
33410729|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
33410730|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
33410731|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
33410732|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
33410733|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
33410734|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
33410735|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
33410736|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
33410737|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
33410738|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
32861643|NCT04952454|Active Comparator|Endonasal DCR|Patients treated with Endonasal DCR for functional epiphora
32861644|NCT04952454|Active Comparator|Transcanalicular DCR|Patients treated with Transcanalicular DCR for functional epiphora
32861645|NCT02908477|Experimental|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
32861646|NCT02908477|Active Comparator|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
32861647|NCT04818918||STEMI group|"Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.~Absolute coronary flow and microvascular resistance will be measured in the LAD."
32861648|NCT04818918||Control group|"Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions <90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value >0.8).~Absolute coronary flow and microvascular resistance will be measured in the LAD."
32861649|NCT04392427|Active Comparator|INTERVENTION|"*Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
32861650|NCT04392427|No Intervention|CONTROL|"B) Control group: will not receive nothing~Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )~Follow-up: to record any side effects of drugs, swab will be taken for PCR"
32861651|NCT04960878|Placebo Comparator|Placebo|1.5 g maltodextrin in a sachet once daily for 8 weeks.
33410739|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
33410740|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
33410741|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
33410742|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
33410743|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
33410744|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
33410745|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
33410746|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
33410747|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
33410748|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
33410749|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec|Talimogene Laherparepvec
33410750|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
33410751|NCT04807777|Experimental|Ruxolitinib|"In a safety lead-in of 6 patients, subjects will receive 15mg of ruxolitinib twice daily (BID). After 4 weeks, if dose-limiting toxicities (DLT) are observed in 1 or fewer patients, the study will enter stage 1 of the Simon two-stage design where all subsequent patients will receive a starting dose of ruxolitinib 15mg BID.~Subjects will have regularly scheduled study visits at the clinical site on Day 1 and Day 15 (± 3 days) of the first 2 cycles, then on Day 1 (± 3 days) of every subsequent cycle (starting cycle 3), where safety assessments, including laboratory assessments, vital signs, and physical examinations will be performed."
33410752|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
33410753|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
32861652|NCT04960878|Experimental|Synbiotic|1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10^11 CFU) , Bifidobacterium lactis HN019 (7.5×10^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.
32861653|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
32861654|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
32861655|NCT04432038||General population of adults from Poland|
32861656|NCT04432038||General population of adults from Germany|
32861657|NCT04432038||General population of adults from China|
32861658|NCT04432038||General population of adults from Vietnam|
32861659|NCT04432038||General population of adults from Spain|
32861660|NCT04432038||General population of adults from Brazil|
32861661|NCT04432038||General population of adults from Croatia|
32861662|NCT04432038||General population of adults from Ethiopia|
32861663|NCT04432038||General population of adults from France|
32861664|NCT04432038||General population of adults from Indonesia|
32861665|NCT04432038||General population of adults from Iran|
32861666|NCT04432038||General population of adults from Sri Lanka|
32861667|NCT04432038||General population of adults from USA|
32861668|NCT04432038||General population of adults from Italy|
32861669|NCT04432038||General population of adults from South Africa|
32861670|NCT04432038||General population of adults from Portugal|
32861671|NCT04432038||General population of adults from Norway|
32861672|NCT04432038||General population of adults from Lithuania|
32861673|NCT04432038||General population of adults from Romania|
32861674|NCT04432038||General population of adults from Pakistan|
32861675|NCT04432038||General population of adults from Ukraine|
32861676|NCT04432038||General population of adults from India|
32861677|NCT04432038||General population of adults from Japan|
32861678|NCT04432038||General population of adults from Russia|
33410754|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
33410755|NCT03175549|Active Comparator|Apremilast (Otezla)|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
33410756|NCT03175549|Placebo Comparator|Placebo|Identical placebo pills taken orally for 14 days
32861679|NCT04432038||General population of adults from Bangladesh|
32861680|NCT04432038||General population of adults from Nigeria|
32861681|NCT04432038||General population of adults from Egypt|
32861682|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
32861683|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
32861684|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
32861685|NCT04960566|Experimental|eCBT+|eCBT+ participants will be enrolled in 6, 45-minute sessions delivered via a secure video platform with a GI psychologist. To reinforce concepts reviewed in the sessions, participants will complete weekly home practice exercises. The targets are 1) improved maladaptive cognitive-affective processes associated with increased hypervigilance and symptom anxiety, 2) reduced behaviors associated with EHA including avoidance, increased medication/healthcare utilization and 3) reduced autonomic nervous system (ANS) arousal by increased HRV. Participants will learn to identify, question, and modify maladaptive thoughts, beliefs, and assumptions related to their symptoms (symptom anxiety). Systematic exposure to feared events are used to reduce maladaptive coping strategies (hypervigilance, PPI overuse, HCU). Specific, paced diaphragmatic breathing exercises (Resonance Frequency Breathing) designed to increase HRV are the last component (visceral hypersensitivity, reflux physiology).
32861686|NCT04960566|Sham Comparator|Sham-SOC Lifestyle Coaching|Patients randomized to the SOC condition will receive lifestyle guidance recommended for patients with GERD over a period of 6, 45-minute sessions with the GI psychologist to maintain consistency of delivery between the two intervention arms. Topics include maintaining a healthy weight, identifying triggering food and drink, making healthy food choices, eating behaviors, smoking and/or alcohol use, and timing of meals. The SOC condition will be carefully designed to not include any principles of the eCBT+ condition rather be based solely on patient education and encouragement to practice lifestyle changes on their own.
32861687|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
32861688|NCT04944264|Active Comparator|Immediate start|Behavioral: Stress Management and Resiliency Training (SMART) program
32861689|NCT04944264|Active Comparator|Delayed start|Wait time control
32861690|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
32861691|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
32861692|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
32861693|NCT04944342||Individuals who have had COVID-19.|Individuals who have had COVID-19 and who treated by a standart medical treatment at home.
32861694|NCT04944342||Individuals who have not a COVID-19 illness history.|Individuals who have not a COVID-19 illness history.
32861695|NCT02453737|Other|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
32861696|NCT02453737|Other|3D-CRT APBI|7.3 Gy x 3 fractions
32861697|NCT02453737|Other|Proton APBI|7.3 Gy x 3 fractions
32861698|NCT01455337|Active Comparator|prednisolone|
32861699|NCT01455337|Experimental|pentoxifylline|
32861700|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
32861701|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
32861702|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
32861703|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
32861704|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
32861705|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
32861706|NCT04951830||control group|NORMAL TMJ
32861707|NCT04951830||Study group|patients with TMJ internal derangement
32861708|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
32861709|NCT01312389|Experimental|Phase 2: Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
32861710|NCT01312389|Experimental|Phase 2: Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
32861711|NCT01312389|Experimental|Phase 1|3 patients will be enrolled receiving the vaccine (tumor lysate/Montanide) plus Ampligen using a 3+3 approach. If no DLTs in the first three subjects, we will move to phase II; if one 1/3 subject develops DLTs, we will enroll 3 additional subjects; if 2/6 subjects develop DLTs, we will discontinue the study. Following completion of run---in phase I (3 or 6 subjects), we will transition to Phase 2.
32861712|NCT01457599||Marking Liver|
32861713|NCT04410978|Experimental|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
32861714|NCT04410978|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
32861715|NCT02816983||SBRT for oligometastatic prostate cancer|
32861716|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
32861717|NCT01350453|Active Comparator|Standard Care|Participants received their usual care which included home exercises
32861718|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
32861719|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
32861720|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
32861721|NCT03009357||control|euthyroid, healthy adults
32861722|NCT04159038|Experimental|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
32861723|NCT04159038|Other|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
32861724|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
32861725|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
32861726|NCT04951908||control group|NORMAL TMJ
32861727|NCT04951908||Study group|Patients with TMJ internal derangement
32861728|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
32861729|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
32861730|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
32861731|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
32861732|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
32861733|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
32861734|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
32861735|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
32861736|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
32861737|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
32861738|NCT03058536|No Intervention|No intervention|Expectant management
32861739|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
32861740|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
32861741|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
32861742|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
32861743|NCT04960488|Experimental|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
32861744|NCT04960488|Active Comparator|carotid endarterectomy|carotid endarterectomy
32861745|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
32861746|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
32861747|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
32861748|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
32861749|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
32861750|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
32861751|NCT04943718|Experimental|personalized vaccine|patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
32861752|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
32861753|NCT04960410||Low air pollution|
32861754|NCT04960410||High air pollution|
32861755|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
32861756|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
32861757|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
32969699|NCT05211882|Experimental|Immediate|Participants in the intervention arm will start on the ENABLE program at point of randomization.
32969700|NCT05211882|Experimental|Wait-list (delayed)|Participants on wait-list will start ENABLE 6 months after randomization.
32969701|NCT05199246|Experimental|Lower-limb powered dermoskeleton|Patients and healthy subjects will use a lower-limb powered dermoskeleton to perform different standardised tasks
32969702|NCT05199246|No Intervention|No assistance device|Patients and healthy subjects will perform different standardised tasks without lower-limb powered dermoskeleton
32969703|NCT05182164|Experimental|Stratum 1: advanced undifferentiated pleomorphic sarcoma|Patients with advanced undifferentiated pleomorphic sarcoma will be treated by the combination of pembrolizumab + cabozantinib
32969704|NCT05182164|Experimental|Stratum 2: advanced osteosarcoma|Patients with advanced osteosarcoma will be treated by the combination of pembrolizumab + cabozantinib
32969705|NCT05182164|Experimental|Stratum 3: advanced Ewing sarcoma|Patients with advanced Ewing sarcoma will be treated by the combination of pembrolizumab + cabozantinib
32969706|NCT05167110|Experimental|Treatment group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
32969707|NCT05167110|Placebo Comparator|Placebo group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
32969708|NCT05162976|Experimental|Treatment (CC-486, nivolumab)|Patients receive azacitidine PO QD on days 1-7 and nivolumab IV over 30 minutes on day 8. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32969709|NCT05161650|Experimental|Ketone monoester (3-OHB)|
32969710|NCT05161650|Experimental|Isocaloric placebo|
32969711|NCT05161338|Experimental|FROZEN EMBRYO TRANSFER|Women who undergo an artificial cycle for frozen embryo transfer and receive luteal phase support.
32969712|NCT05141370|Experimental|hand-held femtosecond laser|Anterior capsulorhexis will be performed with a hand-held femtosecond laser named CATSYS.
32969713|NCT05133180|Experimental|Oxervate|one drop of cenegermin 20 mcg/mL will be instilled in both eyes three times daily.
32969714|NCT05133180|Placebo Comparator|Vehicle|vehicle eye one drop will be instilled in both eyes three times daily.
32969715|NCT05132400||Pre-Training Arm (Control)|To receive physical therapy treatment as usual, before PiPT occurs
32969716|NCT05132400||Post-Training Arm (Intervention)|
32969717|NCT05127330|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
32969718|NCT05127330|Active Comparator|Treatment as Usual|Individuals will receive unrestricted routine care only.
32969719|NCT05118360|Experimental|Part 1-ASC41 2mg|ASC41 2mg for 52 weeks.
32969720|NCT05118360|Placebo Comparator|Part1-placebo|Matching placebo for 52 weeks.
32969721|NCT05118360|Experimental|Part 2-ASC41 4mg|ASC41 4 mg for 52 weeks.
32969722|NCT05118360|Placebo Comparator|Part2-placebo|Matching placebo for 52 weeks.
32969723|NCT05102760|Active Comparator|Fascia Iliaca Compartment|Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED
32969724|NCT05102760|Active Comparator|PENG Block|Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
32969725|NCT05096364|Experimental|AK111 Regimen 1|AK111 Regimen 1 - subcutaneous injection every 4 weeks up to 60 weeks
32969726|NCT05096364|Experimental|AK111 Regimen 2|AK111 Regimen 2 - subcutaneous injection every 4 weeks up to 60 weeks
32969727|NCT05096364|Experimental|AK111 Regimen 3|AK111 Regimen 3 - subcutaneous injection every 4 weeks up to 60 weeks
32969728|NCT05096364|Experimental|AK111 Regimen 4|AK111 Regimen 4 - subcutaneous injection every 4 weeks up to 60 weeks
32969729|NCT05096364|Placebo Comparator|Placebo to AK111|Placebo to AK111-Placebo subcutaneous injection, then 1:1 randomized to AK111 Regimen 3 or Regimen 4 at week 12
32969730|NCT05095038|Experimental|Appethyl®|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g Appethyl®, and the daily intake is 5 g/day."
32969731|NCT05095038|Placebo Comparator|Placebo|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g placebo, and the daily intake is 5 g/day."
32969732|NCT05093634|Experimental|POMC or PCSK1 variant|1:1 Randomization
33322287|NCT04420546|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
32969733|NCT05093634|Experimental|LEPR variant|1:1 Randomization
33322288|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
33322289|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
33322290|NCT04411628|Experimental|LY3819253|Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
33322291|NCT04411628|Placebo Comparator|Placebo|Participants received single dose of Placebo as intravenous infusion.
33322292|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
33322293|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
33322294|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
33322295|NCT03973619|Active Comparator|Labial|Patients who received a labial graft as replacement of urethral tissue
32969734|NCT05093634|Experimental|NCOA1 (SRC1) variant|1:1 Randomization
32969735|NCT05093634|Experimental|SH2B1 variant|1:1 Randomization
32861758|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
32861759|NCT04943640|Experimental|kinesio taping|"The patient was advised to clean the skin with alcohol and shave the hairy areas. The standing patient was asked to take off high heels if he/she was wearing them.~The paravertebral technique was used with 5 cm x 5 m kinesio tape material. While the patient was standing in an upright position, two longitudinal pieces were cut by taking the tape and slightly rolling its corners. The patient was asked to lean forward. The lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. The patient was asked to do a slight rotation to the left, and while in this position, the tape was attached to T11-T12 without stretching at all. Kinesio tape was attached to the opposite side of the vertebrae with the same procedure."
32861760|NCT04943640|Experimental|rigid taping|The patient was asked to lean forward, and 5 cm x 5 m rigid tape material was used in the right paravertebral region. When bonding the tape, first, the lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. Then, the patient was asked to do a slight rotation to the left, and while in this position, the hypoallergenic tape (beta fix) was applied with no tension [23]. Then, rigid tape was applied upward onto the paravertebral muscles. The left paravertebral region was taped with the same procedure as the right paravertebral region .
32861761|NCT04943640|Placebo Comparator|placebo taping groups|"Placebo taping was applied to patients in this group using betafix, an elastic stabilization tape, as material. A straight line of betafix was applied to the non-painful scapular inferior alignment of the spine, right and left, while the patient was standing upright.~Treatment with taping was administered to all groups every 2 days by the same physiotherapist ."
32861762|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
32861763|NCT01353495|Experimental|APM Graft (BIOTAPE XMTM|graft applied to wound q 3 weeks for 12 weeks
32861764|NCT01353495|Active Comparator|standard wound care|Wound debridement and gels and foams applied to wound weekly for 12 weeks.
32861765|NCT04951674|Experimental|DIET|Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
32861766|NCT04951674|Placebo Comparator|CONTROL|No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
32861767|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
32861768|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
32861769|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
32861770|NCT05586919|Active Comparator|Direct Puncture Repair / Ethanol|
32861771|NCT05586919|Active Comparator|Direct Puncture Repair / Polidocanol|
32861772|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
32861773|NCT04951440|Experimental|Intervention group|"Intervention group: 30min intravenous point. Infusion of 1400 mg of tetranitrone was given to bed I with a dose of 100ml, twice a day, with an interval of 12 hours, and continued administration for 7 days, that is, a total of about 14 times.~version"
32861774|NCT04951440|Placebo Comparator|Placebo group|Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
32861775|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
32861776|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
32861777|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
32861778|NCT04951752||Hemicolectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
32861779|NCT04951752||Hemicolectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
32861780|NCT04951752||Nephrectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
32861781|NCT04951752||Nephrectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
32861782|NCT04951752||Percutaneous nephrolithotomy, Active treatment|1x30mL 0.75% Ropivacaine administered by way of transmuscular quadratus lumborum block
32861783|NCT04951752||Percutaneous nephrolithotomy, Placebo treatment|1x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
32861784|NCT04951752||Hysterectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
32861785|NCT04951752||Hysterectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
32861786|NCT04951752||Elective Caesarean section, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
32861787|NCT04951752||Elective Caesarean section, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
32861788|NCT01455493|Experimental|A|
32969736|NCT05083182|Experimental|Cohort 1: Ustekinumab|Participants will receive a weight-based dose of ustekinumab subcutaneously (SC) at Week 0, Week 4 and then every 12 weeks up to Week 52.
32969737|NCT05083182|Experimental|Cohort 2: Guselkumab|Participants without evidence of joint damage will be dosed with guselkumab at Week 0, Week 4 and then every 8 weeks up to Week 52. Participants with radiographic evidence of joint damage will be dosed with guselkumab every 4 weeks from Week 0 through Week 52. Participants at high risk of joint damage according to clinical judgement but should be considered for dosing every 4 weeks, depending upon the judgement of the study doctor.
32969739|NCT05067972|Experimental|Monotherapy dose escalation (Part 1)|Participants will receive PF-07260437
32969740|NCT05067972|Experimental|Dose Expansion (Part 2A) - Tumor specific Arm A|Participants will receive PF-07260437
32969741|NCT05067972|Experimental|Dose Expansion (Part 2B) - Tumor specific Arm B|Participants will receive PF-07260437
32969742|NCT05067972|Experimental|Dose Expansion (Part 2C) - Tumor specific Arm C|Participants will receive PF07260437
32969743|NCT05048940|Experimental|HETEROLOGOUS VACCINE|COVID-19 Vaccine Janssen, injectable suspension
32969744|NCT05048940|Active Comparator|HOMOLOGOUS VACCINE|Spikevax (Moderna), injectable dispersion
32969745|NCT05046990||RAC evaluation|Patients older than 18 years without previous history of Hp infection or eradication undergoing a gastroscopy
32969746|NCT05043090|Experimental|Arm A|savolitinib 600mg plus durvalumab 1500mg
32969747|NCT05043090|Active Comparator|Arm B|sunitinib 50mg
32969748|NCT05043090|Experimental|Arm C|durvalumab 1500mg
32969749|NCT04987164||Feminabiane CBU Consumers|Group of consumers of Feminabiane CBU : 2 tablets of Feminabiane CBU® every day, to be swallowed with a glass of water.
32969750|NCT04987164||Control group|Control group of non consumers of Feminabiane CBU
32969751|NCT04985682|Experimental|Haemophilia A Group|Participants with hemophilia A will be treated with ADVATE according to a regimen determined by the study site treating physician study site and in accordance with the national product label under standard clinical practice.
32969752|NCT04978350|Experimental|Educational Workbook Arm|Participants in the Educational Workbook Arm will receive an electronic PDF version of an educational workbook via email on cascade screening in families with Lynch Syndrome. Genetic counselors will introduce the workbook to enrolled patients with Lynch Syndrome. Patient participants will use the activities and information in the workbook to communicate about Lynch Syndrome with family members.
32969753|NCT04963920|Experimental|SoC+CytoSorb treatment|patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
32969754|NCT04963920|No Intervention|SoC|patients allocated to this group will receive only standard of care therapy according to applicable guidelines
32969755|NCT04956666|Experimental|Lyophilized S95014|"Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL.~The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water For Injection to obtain a 750 U/mL solution for single use."
32969756|NCT04945590|Experimental|Latino/Hispanic Virtual Intervention Program|Latino/Hispanic individuals will participate in culturally tailored virtual intervention program following a community-based collaborative design.
32969757|NCT04935684|Experimental|Group 1: Fecal Microbiota Transplantation (FMT)|"Patients randomized in the FMT group will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months."
32969758|NCT04935684|No Intervention|Group 2: no intervention|"The comparator group will be constituted by patients randomized in the no FMT group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time."
32969759|NCT04927806|Experimental|SilverKnight group|Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria
32969760|NCT04927806|No Intervention|Control group|The control group uses standard ventilator circuits.
32969761|NCT04919382|Experimental|Cohort I (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32969762|NCT04919382|Experimental|Cohort II (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32969763|NCT04911894|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
32969764|NCT04896372|Experimental|ACT intervention|The ACT condition (comprehensive of standard care) comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and a psychological intervention based on ACT combined with a standard psychological assessment and support to the hospitalization.
32969765|NCT04896372|Other|Standard care|The TAU comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and the standard psychological assessment and support to the hospitalization
32969766|NCT04889898||ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
32969767|NCT04889898||Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
32969768|NCT04878276||Dimet 5|"Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (liquid) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs."
32969769|NCT04878276||Hedrin Once Liquid Gel|Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
33322296|NCT03973619|Active Comparator|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
32861789|NCT04960098||patient underwent hip and knee arthroplasty|Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria.
32861790|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
33410757|NCT05239429|Experimental|Transcendental Meditation Technique|Participants are trained on the use of the Transcendental Meditation Technique. They will perform the technique twice a day for 20-minutes per session.
33410758|NCT05239429|No Intervention|Lifestyle-as-usual (control)|There is no change to the participants daily schedule and lifestyle.
33410759|NCT03174925|Experimental|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
32861791|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
32861792|NCT04943016|Experimental|CD19 Chimeric Antigen Receptor (CAR) T Cells|The dose is escalated in standard 3 +3 design with a starting dose of 1x10^6 cell/kilogram and maximum treatment dose of 5 x 10^6 cell/kilogram. The minimum number of 9 subjects would occur if no dose-limiting toxicities are observed in the 3 dose escalation cohorts. The maximum sample size of 18 subjects would be enrolled in 3 dose escalation cohorts (six in each cohort) for meeting dose-limiting toxicities request. In addition, we hypothesize that we will be able to successfully manufacture CAR T cells to meet the established release criteria at a minimum target dose of 1 X 106 +-30% cells/kilogram in this patient population using the Miltenyi CliniMACS Prodigy® closed transduction system.
32861793|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
32861794|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
32861795|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
32861796|NCT04960020||ACL injuries with e-scooter trauma|
32861797|NCT04942548|Experimental|HFpEF|Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)
32861798|NCT04942548|Experimental|PH-HFpEF|Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)
32861799|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
32861800|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
32861801|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
32861802|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
32861803|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
32861804|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
32861805|NCT04959942|Experimental|scapular stabilization exercise|the subjects will receive scapular stabilization exercise + postural correction exercise and advice three times per week for 10 weeks
32861806|NCT04959942|Experimental|postural correction exercise|the subjects will receive postural correction exercise and advice three times per week for 10 weeks
32861807|NCT04959942|Active Comparator|advice|the subjects will receive advice three times per week for 10 weeks
32861808|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
32861809|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
32861810|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
32861811|NCT04942860|Active Comparator|Methotrexate 1% gel|1% methotrexate gel applied onto a predefined limb
32861812|NCT04942860|Active Comparator|Methotrexate 0.5% gel|0.5% methotrexate gel applied onto a predefined limb
32861813|NCT04942860|Placebo Comparator|Vehicle gel|Vehicle gel applied onto a predefined limb
32861814|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
32861815|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
32861816|NCT04959786|Experimental|INTERVENTION ARM|
32861817|NCT04959786|No Intervention|standard of care|
32861818|NCT01452451|Placebo Comparator|Placebo|Placebo
32861819|NCT01452451|Active Comparator|HM11260C|HM11260C
32861820|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
32861821|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
32861822|NCT03057912|No Intervention|Control group|Observation
32861823|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The study will consist of two sequential phases: Phase 1 (validation process) and Phase 2 (data collection and NLP).
32861824|NCT04942782|Experimental|lumbopelvic stabilization exercises|the patients will receive trunk stabilization exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
32861825|NCT04942782|Experimental|Pilates exercises|the patients will receive trunk pilates exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
32861826|NCT04942782|Active Comparator|conventional therapy|the patients will receive trunk stabilization exercise three times/ week for three months
32861827|NCT04272229|Active Comparator|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
32969770|NCT04868916||Participants with X-Linked Retinitis Pigmentosa (XLRP)|Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.
32969771|NCT04867278|Experimental|External Beam Radiation (XRT) with Debridement|Patients will receive gluteus minimus debridement in the OR, which is the standard of care at Shock Trauma. If randomized to the treatment group, patients that undergo surgical fixation of an acetabular fracture via a posterior or combined anterior and posterior approach will undergo a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery. This treatment is currently the standard procedure performed for all patients who undergo a posterior or combined approach at our institution.
33322297|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
33322298|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
33410760|NCT05216107||Hospital Universitario de Álava, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
33410761|NCT05216107||Hospital Universitario de Basurto, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
33410762|NCT05216107||Hospital Universitario de Cruces, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
32969772|NCT04867278|Active Comparator|Debridement Alone (Control)|The control treatment arm will only include gluteus minimus debridement in the OR and will not receive XRT.
33410763|NCT05216107||Hospital Universitario de Donostia, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
32969773|NCT04867122|Placebo Comparator|Attention Control|"Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three friendly visits with a trained research staff person."
32969774|NCT04867122|Experimental|Problem Solving Therapy Intervention|Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.
32969775|NCT04867122|Other|In-Depth Interviews for non-FCG Stakeholders|Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.
33410764|NCT05216107||Hospital San Pedro (Logroño), Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
33410765|NCT05216107||Hospital of Navarra, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
32969779|NCT04848402|Experimental|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
32969780|NCT04848402|Experimental|Single Auto Injector|Single auto injector used to administer placebo SC.
32969781|NCT04843410|Experimental|Experimental: exercise group|"In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least three cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs who can tolerate the exercise, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study.~The experimental group will be taught an exercise program to apply regularly twice a day. The researcher will give the patient the barbed ball and barbed roller required for the exercise. In addition, visual training material will be given for the exercise program so that the patient can repeat the training whenever he wants to ensure the permanence of the patient education."
32969782|NCT04843410|No Intervention|No Intervention: Control Group|In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least 3 cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study. The routine care of the clinic will be applied to the control group.
32969783|NCT04836780|Experimental|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
32969784|NCT04836780|Active Comparator|Standard of care|Standard care therapy
33410766|NCT01314937|Experimental|Deworming at 12 months of age|
32969789|NCT04800822|Experimental|PF-07284892 monotherapy|Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
32969790|NCT04800822|Experimental|PF-07284892 in combination with lorlatinib (Part 2)|Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
32969791|NCT04800822|Experimental|Expansion Phase (Cohort 1)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
32969792|NCT04800822|Experimental|Expansion Phase (Cohort 2)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
32969793|NCT04800822|Experimental|Expansion Phase (Cohort 3)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
32969794|NCT04800822|Experimental|Expansion Phase (Cohort 4)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
32969795|NCT04800822|Experimental|Expansion Phase (Cohort 5)|PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
32969796|NCT04800822|Experimental|PF-07284892 in combination with encorafenib and cetuximab (Part 2)|Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
32969797|NCT04800822|Experimental|PF-07284892 in combination with binimetinib (Part 2)|Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
32969798|NCT04793724|Experimental|Simeox first|Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
32969799|NCT04793724|Active Comparator|PARI O PEP first|Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
32969800|NCT04782492|Experimental|Y-composite graft|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
32969801|NCT04782492|Active Comparator|aortocoronary conduit|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
32969802|NCT04779138|Experimental|Increasing Uptake of COVID-19 Vaccination|"This is a pre-experimental one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
32969803|NCT04774926|Experimental|Brolucizumab 6 mg|Participants will receive 3 monthly ocular injections followed by a q12w or q8w maintenance phase based on patient's disease activity (DA).
32969804|NCT04772898|Experimental|Hippotherapy|Both children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
32969805|NCT04759248|Experimental|Atezolizumab in combination with Trastuzumab and Vinorelbine|
32969806|NCT04740294|Experimental|Magnesium Sulfate|The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.
32969807|NCT04740294|Placebo Comparator|Placebo|The patient will receive a bolus of Normal Saline over twenty minutes.
32969808|NCT04727736|Experimental|18F-DCFPyL + PET imaging|"Participants will receive a single dose of 18F-DCFPyL and undergo a PET imaging study.~(The PET imaging may be repeated at a later date if the biopsy of the lesion is negative and if the lesion is present on follow-up imaging.)"
32969809|NCT04723680||Early dose finding cohort|People with Haemophilia who took part in the early dose finding studies
32969810|NCT04723680||Subsequent studies group cohort|People with haemophilia who took part in subsequent gene therapy studies
32969811|NCT04723680||Withdrawn/ineligible Cohort|People with haemophilia who were withdrawn or proved ineligible
32969812|NCT04723680||Not interested cohort|People with haemophilia who are definitely not interested in gene therapy
32969813|NCT04723680||Not offered cohort|People with haemophilia who are interested in gene therapy but have not been the opportunity to take part
32969814|NCT04721418||Cocaine Use Disorder|
32969815|NCT04721418||Healthy Control|
32969816|NCT04705818|Experimental|Cohort A: pancreatic cancer|Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
32969817|NCT04705818|Experimental|Cohort B: not MSI-H or MMR-deficient colorectal cancer|Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
32969818|NCT04705818|Experimental|Cohort C: metastatic solid tumor|Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
32969819|NCT04705818|Experimental|Cohort D: soft-tissue sarcoma|Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
32969820|NCT04703712|Active Comparator|Lens extraction combined with goniosynechialysis group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.
33410767|NCT01314937|Experimental|Deworming at 18 months of age|
32969821|NCT04703712|Active Comparator|Trabeculectomy Group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.
32969822|NCT04677972|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup
32969823|NCT04677972|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 28 days, with 84-day followup
32969824|NCT04676022|Experimental|Spinal Cord Stimulation|To receive Spinal Cord Stimulation programming
32969825|NCT04676022|Other|Conventional Medical Management|To receive conventional medical management
32969826|NCT04637724|Experimental|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
32969827|NCT04637724|Sham Comparator|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
32969828|NCT04626804|Experimental|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
32969829|NCT04610736|Experimental|Single arm|Temozolomide 40 mg/ml, Oral suspension
32969830|NCT04610190|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
32969831|NCT04609020|Experimental|HArmonyCA, Juvederm, BOTOX|All treatments will be administered according to the respective label and according to an agreed upon treatment plan between the subject and Health Care Provider. If required: HarmonyCA Lidocaine will be administered at Visit 1, Juvéderm filler injections (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine and/or JUVÉDERM VOLUX with Lidocaine) will be administered at Visit 3, BOTOX will be administered at Visit 5. Touch-ups may be performed as required by subject's treatment plan after each study visit.
32969832|NCT04605978|Experimental|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
33410768|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
33410769|NCT01314937|Placebo Comparator|Usual care|
33410770|NCT04718155|Active Comparator|statin group|will receive atorvastatin for 48 hours
33410771|NCT04718155|Placebo Comparator|control|will receive placebo tablets for 48 hours
33410772|NCT04668859|Active Comparator|Midodrine Arm|Patients will receive the drug Midodrine
33410773|NCT04668859|Placebo Comparator|Placebo Arm|Patients will receive placebo.
33410774|NCT04648969|Experimental|Experimental: kisspeptin, GnRH|• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
33410775|NCT04633369|Experimental|Fructo-oligosaccharide|Fructo-oligosaccharide 20g
33410776|NCT04633369|Experimental|Arabinogalactan|Arabinogalactan 12g
33410777|NCT04633369|Experimental|Glucomannan|Glucomannan 4g
33410778|NCT02320201|Experimental|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
33410779|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
33410780|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
33410781|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
33410782|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
33410783|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
33410784|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
32969833|NCT04605978|Placebo Comparator|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
32969834|NCT04595370|Experimental|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
32969835|NCT04595370|Experimental|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
32969836|NCT04595370|Experimental|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
32969837|NCT04595370|Experimental|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
32969838|NCT04591236|Experimental|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
33410785|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
32969839|NCT04591236|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
33410786|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
33410787|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
33410788|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
33410789|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
33410790|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
33410791|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
33410792|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
33410793|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
33410794|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
33410795|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
33410796|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
33410797|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
32969840|NCT04575324|Experimental|Intervention Arm|Participants will receive the telemedicine linkage intervention.
32969841|NCT04575324|No Intervention|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
32969842|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
32969843|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
32969844|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
32969845|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
32969846|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
32969847|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
32969848|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
32969849|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|"Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles.~Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3."
32969850|NCT04538664|Experimental|Arm B: Chemotherapy Alone|"Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles."
32969851|NCT04529538|Experimental|Group1: nOPV1 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of novel OPV type 1 (nOPV1) containing 10^6.5 CCID50/dose.
32969852|NCT04529538|Active Comparator|Group 2: mOPV1 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of mOPV1 containing 10^6.0 CCID50/dose.
33410798|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
33410799|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
33410800|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
33410801|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
33410802|NCT03011892|Placebo Comparator|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
33410803|NCT03011892|Active Comparator|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
32969853|NCT04529538|Experimental|Group 3: nOPV1 (OPV History)|30-50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV1 containing 10^6.5 CCID50/dose, given 28 days apart.
32969854|NCT04529538|Active Comparator|Group 4: mOPV1 (OPV History)|15-25 healthy adults fully vaccinated against polio by OPV will be administered 2 doses of mOPV1containing ≥ 10^6.0 CCID50/dose, given 28 days apart
32969855|NCT04529538|Experimental|Group 5: nOPV3 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of nOPV3 containing 10^6.5 CCID50/dose.
32969856|NCT04529538|Active Comparator|Group 6: mOPV3 (IPV History)|15-20 healthy adults fully vaccination against polio by exclusively IPV will be administered 1 vaccination of mOPV3 containing ≥ 10^5.8 CCID50/dose.
32969857|NCT04529538|Experimental|Group 7: nOPV3 (OPV History)|30-50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV3 in a dose of 10^6.5 CCID50/dose, given 28 days apart.
32969858|NCT04529538|Active Comparator|Group 8: mOPV3 (OPV History)|15-25 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of mOPV3 containing ≥ 10^5.8 CCID50/dose, given 28 days apart.
32969859|NCT04522596|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
32969860|NCT04522596|Placebo Comparator|Placebo|Placebo inhaled once a day for 14 days.
32969861|NCT04521114|Experimental|Leronlimab 700 mg|Leronlimab 700 mg SC weekly injection
32969862|NCT04521114|Experimental|Leronlimab 350 mg|Leronlimab 350 mg SC weekly injection
32969863|NCT04521114|Placebo Comparator|Placebo|Placebo SC weekly injection
32969864|NCT04519164|Experimental|Eplerenone|Participants will receive eplerenone, ranging from 25-100mg daily for one year.
32969865|NCT04519164|Active Comparator|Chlorthalidone with potassium chloride|Participants will receive chlorthalidone (6.25-25mg daily for one year) along with potassium chloride (up to 20 mEq daily for one year)
32969866|NCT04510272|Experimental|High risk critically ill patients|Critically ill patients requiring vasopressor support or mechanical ventilation will receive aloud real time ICU diary reading intervention
32969867|NCT04504500|No Intervention|Observation phase|Routine practice assessment
32969868|NCT04504500|Active Comparator|Intervention phase|Clinical practice assessment after the application of the trial's educational, behavioral and organizational interventions
32969869|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
32969870|NCT04484142|Experimental|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
32969871|NCT04471974|Experimental|Safety Cohort|Patients receive 96mg pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32969872|NCT04471974|Experimental|Cohort A: Transdifferentiated mCRPC|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32969873|NCT04471974|Experimental|Cohort B: mCRPC without evidence of transdifferentiation|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32969874|NCT04470648||hosted in the center and HCWs at the epidemic period|"people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time.~People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic"
32969875|NCT04461678|Experimental|Screening population and ASCUS referral population|"The screening population: Two cervical cytology samples will be collected from each subject. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks. In case of visible lesions under colposcopy, a biopsy of tissues at the site of the lesion will be performed; in case of no visible lesions, randombiopsy and/or ECC will be performed. Patients with histopathological results ≥ CIN2 will completed the study.~ASCUS referral population: Female subjects with an ASCUS cytology result will be recalled undergo colposcopy, the remaining samples for cytology test collected prior to enrollment will be used for BD Onclarity Assay HPV test."
32969876|NCT04452084|Active Comparator|Control|
32969877|NCT04452084|Experimental|Experimental Procedure|
32969878|NCT04450914|Other|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
32969879|NCT04450914|Other|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
32969880|NCT04450914|Other|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
32969881|NCT04416750|Experimental|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
33322299|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
33410804|NCT03011892|Experimental|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
33410805|NCT03011892|Experimental|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
33410806|NCT03011892|Experimental|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
32969884|NCT04403022|Other|Single arm|Colorectal procedure will be performed by da Vinci SP® Surgical System
32969885|NCT04389216|Experimental|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
32969886|NCT04360824|Active Comparator|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
32969887|NCT04360824|Other|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
32969888|NCT04331652|Experimental|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
32969889|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
32969890|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
32969891|NCT04261296|Experimental|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
32969892|NCT04261296|Experimental|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
32969893|NCT04261296|Experimental|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
32969894|NCT04252794|Experimental|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
32969895|NCT04252794|Active Comparator|No splenic artery ligation|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
32969896|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
32969897|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
32969898|NCT04234386|Active Comparator|Dose Level 1: 21 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
32969899|NCT04234386|Active Comparator|Dose Level 2: 24 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
32969900|NCT04234386|Active Comparator|Dose Level 3: 27 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
33410807|NCT03011892|Experimental|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
33410808|NCT03011892|Placebo Comparator|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
33410809|NCT03011892|Active Comparator|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
32969901|NCT04234386|Active Comparator|Dose Level 4: 30 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
32969902|NCT04215978|Experimental|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 8 increasing dose levels on day 1 of each 21-day cycle
32969903|NCT04215978|Experimental|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 6 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
32969904|NCT04215978|Experimental|Phase 1b:BGB-A445 Monotherapy|Dose Expansion Part A: Participants will receive recommended doses of IV BGB-A445 as determined from Phase 1a Dose Escalation; BGB-A445 will be evaluated in two tumor types
32969905|NCT04215978|Experimental|Phase 1b: BGB-A445 + Tislelizumab Combination Therapy|Dose Expansion Part B: Participants will receive recommended dose IV infusion of BGB-A445 plus 200mg tislelizumab to be evaluated in two tumor types
32969906|NCT04198350|Experimental|Islet implantation|
32969907|NCT04188990|Active Comparator|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
33410810|NCT03011892|Experimental|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
33410811|NCT03011892|Experimental|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
32969908|NCT04188990|Placebo Comparator|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
32969909|NCT04188990|Placebo Comparator|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
33322300|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
33322301|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 3 weeks|
33322302|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 4.5 weeks|
32969913|NCT04176198|Experimental|TP-3654|
32969914|NCT04174716|Experimental|IDX-1197|Patient will be receive IDX-1197HCl once daily for 28 continuous days
32969915|NCT04168710|Experimental|erector spinae plane block (ESP block) with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
32969916|NCT04168710|Placebo Comparator|ESP block with saline/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
32969917|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
32969918|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
32969920|NCT04122924|Experimental|Intervention Group|A three months home-based abdominal muscle training program.
32969921|NCT04122924|No Intervention|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
32969922|NCT04079166|Experimental|SCIB1|SCIB1 administered by intramuscular needle-free injection
33322303|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 6 weeks|
33322304|NCT04364854|Other|No Therapy 6 weeks|
33322305|NCT04945772|Experimental|vMCO-010- High Dose|Participants receive 1.2E11gc/eye of vMCO-010
33322306|NCT04945772|Experimental|vMCO-010- Medium Dose|Participants receive 0.9E11gc/eye of vMCO-010
33322307|NCT04945772|Sham Comparator|Sham Injection|Participants receive sham injection
33322308|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
33322309|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
33322310|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
33322311|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
33322312|NCT05668910||malignant group|patients diagnosed with high grade Intraepithelial neoplasia or GC (> 50% of patients in stage I and II)
33322313|NCT05668910||non-malignant group|healthy individuals and patients with non-atrophic gastritis, gastric ulcer, gastric polyp or other benign gastric diseases
33322314|NCT00227591|Experimental|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33322315|NCT01358344|Experimental|Standard Percentage|
33322316|NCT01358344|Experimental|High Percentage|
33322317|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
33322318|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
33322319|NCT01366222|Placebo Comparator|Placebo|
33322320|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
33322321|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
33322322|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
32969923|NCT04055298|Other|Patients|"The study will be performed at the Walk-in-Clinic (WIC) and Interdisciplinary Emergency Department (ED) of the cantonal hospital of Baden, Switzerland. During their stay at the WIC or ED the patients will be invited to use the triage-symptom-checker SMASS-Triage.~In this study, the patient's self-triage using a symptom checker will be compared with the urgency assessments conducted by three interdisciplinary panels of physicians (panel A, B and C). In order to appropriately reflect the complex interaction in medical decision-making, which usually leads to a low inter-rater reliability, the cases assessed to be undertriaged by panel A, are subsequently assessed a second time by two panelist of panel B. Cases which are adjudged to be undertriaged by all panelist (panel A and B), are assessed for a risk to health or life by panel C. The risk assessments of panel C will be based on the structured reports generated by the symptom-checker and the discharge summaries of the WIC/ED."
32969924|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
32969925|NCT04042038|Experimental|CBT|Intensive CBT (20 sessions in 1 month)
32969926|NCT04042038|No Intervention|Waiting-list|Waiting-list
32969927|NCT04029480|Experimental|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
32969928|NCT04029480|Experimental|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
32969929|NCT04029480|Placebo Comparator|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
32969930|NCT04026906|Experimental|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
32969931|NCT04026906|Placebo Comparator|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
32969932|NCT04016142|Experimental|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients~will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
32969933|NCT03990792|Experimental|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
32969934|NCT03990792|Active Comparator|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
32969935|NCT03984396|Experimental|Intervention - Patient and Clinician|Intervention educational materials provided to patient and family and clinician
32969936|NCT03984396|No Intervention|Delayed Intervention|Usual care
32969937|NCT03978624|Experimental|A: Pembrolizumab alone|Subjects will be administered pembrolizumab alone 200 mg IV on day 1 and day 22
32969938|NCT03978624|Experimental|B: Pembrolizumab plus Entinostat|Subjects will be administered pembrolizumab on day 1 and day 22 and entinostat 5 mg given orally on day 1, day 8 and day 15
32969939|NCT03952338|Experimental|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
32969940|NCT03952338|No Intervention|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
32969941|NCT03946800|Experimental|MEDI1191 escalation in combination with durvalumab|MEDI1191 escalation in sequential and concurrent combination with durvalumab
32969942|NCT03946800|Experimental|MEDI1191 expansion in combination with durvalumab|MEDI1191 expansion in concurrent combination with durvalumab
32969943|NCT03941106|Experimental|Left aTMS|
32969944|NCT03941106|Experimental|Right aTMS|
32969945|NCT03927690|Experimental|LKA651|LKA651 IVT
32969946|NCT03927690|Experimental|LKA651/Lucentis|LKA651/Lucentis IVT
32969947|NCT03927690|Active Comparator|Lucentis|Lucentis IVT
32969948|NCT03915678|Experimental|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
32969949|NCT03915678|Experimental|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
32969950|NCT03915678|Experimental|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
32969951|NCT03915678|Experimental|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
32969952|NCT03915678|Experimental|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
32969953|NCT03915678|Experimental|Population 6: Triple negative breast cancer|Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
33410812|NCT03011892|Experimental|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
32969954|NCT03915366|No Intervention|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
32969955|NCT03915366|Experimental|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
32969956|NCT03915366|Experimental|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
32969957|NCT03915366|Experimental|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
32969958|NCT03903666|Experimental|Cohort|47 Down syndrome patients age from 4 to 16
32969959|NCT03897036|Experimental|CX-4945 28 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
32969960|NCT03897036|Experimental|CX-4945 21 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
32969961|NCT03897036|Experimental|Expansion CX-4945 Locally Advanced BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
33410813|NCT03011892|Experimental|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
32969962|NCT03897036|Experimental|Expansion CX-4945 Metastatic BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
32969963|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
32969964|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
32969965|NCT03874338||Colchicine|
32969966|NCT03874338||Placebo|
32969967|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|All surgical procedures to be performed during this clinical trial are part of the routine procedures for lumbar spondylodesis by using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) techniques in the 1-2 levels (L4-L5 and/or L5-S1). Patients will receive surgery according to standard procedures.
32969968|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
32969969|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
32969970|NCT03838848|Experimental|Cohort A|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
33410814|NCT03017742|Experimental|Test Group|The subjects enrolled in the test group will receive the pulse oximeter
33410815|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
32969971|NCT03838848|Experimental|Cohort B|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
32969972|NCT03838848|Experimental|Cohort C|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
32969973|NCT03838848|Experimental|Cohort D|1L NSCLC (EGFR-sensitive mutation (Ex19del or L858R), progression after at least one line treatemtn of EGFR TKIs, and no prior systemic platinum-containing chemotherapy), will receive KN046 5 mg/kg Q3W in combination with pemetrexed and carboplatin
32969974|NCT03838848|Experimental|Cohort E|≥ 2L NSCLC (failure or intolerance of 1L platinum-doublet chemotherapy; and failure of PD-1/PD-L1 checkpoint inhibitor therapy), will receive KN046 in combination with ningetinib
32969975|NCT03787602|Experimental|Cohort 1, Arm 1|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
32969976|NCT03787602|Experimental|Cohort 1, Arm 1b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.
32969977|NCT03787602|Experimental|Cohort 1, Arm 2b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.
32969978|NCT03787602|Experimental|Cohort 1, Arm 3|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
32969979|NCT03787602|Experimental|Cohort 1, Arm 5|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.
32969980|NCT03787602|Experimental|Cohort 1 Expansion|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
32969981|NCT03787602|Experimental|Cohort 2, Arm 1 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
32969982|NCT03787602|Experimental|Cohort 2, Arm 2 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
32969983|NCT03787602|Experimental|Cohort 2 Expansion|KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
33322323|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
33322324|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
33322325|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
33322326|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
32969984|NCT03787602|Experimental|Cohort 3|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
32969985|NCT03787602|Experimental|Cohort 4|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
32969986|NCT03782376|Experimental|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
32969987|NCT03782376|Active Comparator|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
32969988|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
32969989|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
32969990|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
32969991|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
32969992|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
32969993|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
33322327|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
33322328|NCT05190796||women with history of recurrent pregnancy loss.|100 women who had history of recurrent pregnancy loss.
33322329|NCT05190796||women without history of recurrent pregnancy loss.|50 women who had given birth at term (>37 weeks of gestation) to healthy infants (control group)
32969994|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
32969995|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
32969996|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
32969997|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
32969998|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
32969999|NCT03701490|Experimental|Prolutex|
32970000|NCT03701490|Experimental|Progeffik|
32970001|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
32970002|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
32970003|NCT03691974|Experimental|Fasinumab|
32970004|NCT03691974|Placebo Comparator|Placebo|
32970005|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
32970006|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
32970007|NCT03662022|No Intervention|No PEP|No PEP will be distributed
32970008|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
32970009|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
32970010|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
32970011|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
32970012|NCT03580044|Experimental|ATM- AVI Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm|
32970013|NCT03580044|Active Comparator|Best Available Therapy (BAT) Comparator Treatment Arm|
32970014|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
32970015|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
32970016|NCT03525678|Experimental|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
32970017|NCT03525678|Experimental|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
32970018|NCT03525678|Experimental|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
32970019|NCT03459222|Experimental|Arm A|Relatlimab + Nivolumab + BMS-986205
32970020|NCT03459222|Experimental|Arm B|Relatlimab + Nivolumab + Ipilimumab
32970021|NCT03398304|Experimental|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
32970022|NCT03398304|Experimental|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
32970023|NCT03351348|Active Comparator|Saline + usual post-operative medications|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
32970024|NCT03351348|Experimental|Bupivacaine + usual post-operative medications|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
33410816|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
33410817|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
33410818|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
33410819|NCT03667794||PH patients|Patients with known or first diagnosis of PH
33410820|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
33410821|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
33410822|NCT04575948|Experimental|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
33410823|NCT04575948|Placebo Comparator|Base formula of mouth wash|Base formula of mouthwash
33410824|NCT04575948|Active Comparator|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
32861828|NCT04272229|Experimental|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
32861829|NCT04951128|Experimental|Tranexamic acid arm|Eyelid(s) that received tranexamic acid in the local anesthetic
32861830|NCT04951128|Active Comparator|Control|Eyelid(s) that receive local anesthetic without tranexamic acid
32861831|NCT01458301|Placebo Comparator|Placebo|
32861832|NCT01458301|Experimental|TAK-385 10 mg QD|
32861833|NCT01458301|Experimental|TAK-385 20 mg QD|
32861834|NCT01458301|Experimental|TAK-385 40 mg QD|
33410825|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
33410826|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
33410827|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
33410828|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
33410829|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
33410830|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
33410831|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
33410832|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
33410833|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
33410834|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
33410835|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
33410836|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
33410837|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
33410838|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
33410839|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
33410840|NCT03666936|Experimental|Intervention|Social-health care intervention
33410841|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
33410842|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
33410843|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
33410844|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
32861835|NCT01458301|Other|Leuplin|
32861836|NCT04959630|Other|Group A|Group A received first five patient cases and 3D models via DI and another five cases in the VR environment
32861837|NCT04959630|Other|Group B|Group B received first five patient cases and 3D models via VR and another five cases in the DI.
32861838|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
32861839|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
32861840|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
32861841|NCT04272151|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
32861842|NCT04950738|Experimental|Acupuncture with press tack needle group (Acu)|Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
32861843|NCT04950738|Placebo Comparator|Placebo group press tack placebo (Con)|Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
32861844|NCT04272307||Acute Severe Ulcerative Colitis group|
32861845|NCT04272307||Non-severe Ulcerative Colitis group|
32861846|NCT04942392|Experimental|digital dance for PD|
32970025|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
32970026|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
32970027|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
32970028|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
32970029|NCT03272022||women|never-pregnant women
32970030|NCT03272022||pregnant women|pregnant
33322330|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
33322331|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
32970033|NCT03237780|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial.
32970034|NCT03237780|Experimental|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and eribulin mesylate IV over 2-3 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial.
32970035|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to an extensive treat multiple gingival recessions in aesthetic areas
32970036|NCT03207984|Experimental|Test CM|Root coverage surgery with Mucograft® collagen matrix to treat an extensive multiple gingival recessions in aesthetic areas
32970037|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
32970038|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
32970039|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
32970040|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
32970041|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
32970042|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
32970043|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
32970044|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
32970045|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
32970046|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
32970047|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
32970048|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
32970049|NCT02850900|No Intervention|No Survey|No intervention
32970050|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
32970051|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
33322332|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
33322333|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
33322334|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
33410845|NCT04050150|Experimental|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
33410846|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game~- Focus on Paediatric Asthma and Seizure management"
33410847|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
33410848|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
33410849|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
33410850|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
33322335|NCT04512482|Experimental|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
33410851|NCT03008460|Experimental|Eziclen®/Izinova®|
33410852|NCT03008460|Active Comparator|Klean-Prep®|
33410853|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
33410854|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
33410855|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
33410856|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
33410857|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
33410858|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
33410859|NCT04057638|Experimental|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
33410860|NCT03666078||normal vaginal delivery|
33410861|NCT03666078||assisted vaginal delivery|
33410862|NCT03666078||elective cesarean delivery|
33410863|NCT03666078||emergency cesarean delivery|
33410864|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
33410865|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
33410866|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
33410867|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
33410868|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
33410869|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
33410870|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
33410871|NCT03003000|Active Comparator|ibuprofen|
33410872|NCT03003000|Placebo Comparator|placebo|
33410873|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
33410874|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
33410875|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
33410876|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
33410877|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
32970052|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
32970053|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
33410878|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
33410879|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
33410880|NCT04055454|Experimental|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
33410881|NCT04055454|Experimental|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
33410882|NCT04055454|Placebo Comparator|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
33410883|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
33410884|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
33410885|NCT04056390|Active Comparator|Substrate Modification|After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) < 0.5mV.
33410886|NCT04056390|Active Comparator|LAA Isolation|Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.
33410887|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
33410888|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
32861847|NCT04942314||Complete remission off therapy|"no clinical activity and serological activity~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
32861848|NCT04942314||Complete remission on therapy|"no clinical activity and serological activity~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
32861849|NCT04942314||Clinical remission off therapy|"no clinical activity but serological activity allowed~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
32861850|NCT04942314||Clinical remission on therapy|"no clinical activity but serological activity allowed~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
32861851|NCT04942314||Low disease activity state|(1) SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever), and no haemolytic anaemia or gastrointestinal active involvement; (2) no new lupus disease activity compared with the previous assessment; (3) a PGA ≤1; (4) a current predni- sone (or equivalent) dose ≤7.5mg/day; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
32861852|NCT04942314||Not in LDAS or Remission|At the end of follow-up, the disease state of SLE children was not in LDAS or any remissions defined above.
32861853|NCT04942314||Never in LDAS|During the follow-up, the disease state was never get LDAS.
32861854|NCT04843345||Reduced Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow
32861855|NCT04843345||Normal Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow
32861856|NCT03059160|Experimental|open label|
32861857|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
32861858|NCT04950348|Experimental|3D printed personalized TKA prosthesis|Patients in the experimental group received 3D printed personalized TKA prosthesis treatment
32861859|NCT04950348|Active Comparator|Zimmer NexGen TKA prostheses|Patients in the active comparator group received Zimmer NexGen TKA prostheses treatment
32861860|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
32861861|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
32861862|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
32970054|NCT02782104|Experimental|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
32970055|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
32970056|NCT02743494|Experimental|Nivolumab|
32970057|NCT02743494|Placebo Comparator|Placebo|
32970058|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
32970059|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
32970060|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
32970061|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
32970062|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
32970063|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
32970064|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
32970065|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
32970066|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
32970067|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
32970068|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
32970069|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
32970070|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
32970071|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
32970072|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
32970073|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
32970074|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
32970075|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
32970076|NCT01649388|Experimental|FCR001|Recipients 3-12 months post-living kidney transplantation undergo non-myeloablative conditioning followed by infusion of an enriched hematopoietic stem cell product derived from the same living donor's peripheral blood stem cells
32970077|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
32970078|NCT01394016|Experimental|LY2835219|
32970079|NCT01096368|Experimental|Arm I (chemotherapy, observation)|Patients with classic histology(WHO Grade II) supratentorial ependymoma who have undergone microscopic gross total resection (GTR1) or achieved CR either after first or second resection or after post-operative induction chemotherapy are assigned to observation. For patients without GTR1, induction chemotherapy is comprised of vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
33410889|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
33410890|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
32970080|NCT01096368|Experimental|Arm II (radiotherapy, chemotherapy)|Patients with supratentorial ependymoma (Grade II without GTR1 or Grade III) or any infratentorial ependymoma who have undergone gross or near total resection (GTR or NTR) or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks followed by maintenance chemotherapy. Maintenance chemotherapy comprised of vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
32970081|NCT01096368|Active Comparator|Arm III (radiotherapy, observation)|Patients with supratentorial ependymoma (Grade II without GTR1 or ST Grade III) or any infratentorial ependymoma (Grade II or III) who have undergone gross or near total resection or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks and then undergo observation. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
32970082|NCT01096368|Active Comparator|ARM IV (radiotherapy, chemotherapy)|Patients with subtotal resection after induction chemotherapy (see Arm I) and second surgery are nonrandomly assigned to Arm II treatment.
32970083|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
32970084|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
32970085|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
32970086|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
32970087|NCT00063882|Experimental|EBRT + Brachytherapy|External beam radiation therapy (EBRT) and transperineal interstitial permanent brachytherapy (100/110)
32970088|NCT00063882|Active Comparator|Brachytherapy Only|Transperineal interstitial permanent brachytherapy (125/145)
32970089|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
32970090|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
32970091|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
32970092|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
32970093|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
32970094|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
32970095|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
32970096|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
32970097|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
32970098|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
32970099|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
32970100|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
32970101|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
32970102|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
32970103|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
32970104|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
32970105|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
32970106|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
32970107|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
32970108|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
32970109|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
32970110|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
32970111|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
32970112|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
32970113|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
32970114|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
32970115|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
32970116|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
32970117|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
32970118|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
32970119|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
32970120|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
32970121|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
32970122|NCT00003288|Experimental|Arm I|See arm description.
32970123|NCT00003330|Experimental|Arm I|See detailed description.
32970124|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
33322336|NCT04512482|Placebo Comparator|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
33322337|NCT05456204|Other|Refralone group|Patients with recurrent AF/AFL after catheter interventions to restore SR will be cardioverted with refralon
33322338|NCT00226811|Experimental|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
33322339|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
33322340|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
33322341|NCT03936218|Experimental|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
33322342|NCT03936218|Active Comparator|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
33322343|NCT03751904|Other|AcoustiCare|Single Arm
33322344|NCT04903496||Group A: Diabetic patients with CVD, CKD or at risk|The group A includes all Patients with diagnosis of diabetes, and with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
33322345|NCT04903496||Group B: Diabetic patients without CVD, CKD or at risk|The group B includes all patients with diagnosis of diabetes, but not with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
32970125|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
33410891|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
32970126|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
32970127|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32970128|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
32970129|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32970130|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
32970131|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
33322346|NCT04903496||Group C: Non-diabetic patients with CVD, CKD or at risk|The group C includes all patients with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, but not with diagnosis of diabetes.
33322347|NCT04903496||Group D: Non-diabetic patients without CVD, CKD or at risk|The group D includes all patients without diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, and without diagnosis of diabetes.
33322348|NCT05261516|Active Comparator|Propofol|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given.~In patients in the propofol group, anesthesia will be induced and maintained with a total intravenous anesthesia pump following the model of Schnider et al, at a targeted effect-site concentration of 4 +/- 1 mcg/ml.~In patients in all groups, after induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital."
33322349|NCT05261516|Experimental|Isoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: isoflurane in this group."
33322350|NCT05261516|Experimental|Desflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: desflurane in this group."
33322351|NCT05261516|Experimental|Sevoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: sevoflurane in this group."
33322352|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
33322353|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
33322354|NCT00226655|Experimental|I|All patients will receive hCRF (XERECEPT) 2mg/day
33322355|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
32970132|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
32970133|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
32970134|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
33410892|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
33410893|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
32970135|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
32970136|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
32970137|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
32970138|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
32970139|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
32970140|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
32970141|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
32970142|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
32970143|NCT00003714|Experimental|Pyrazoloacridine|
32970144|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
32970145|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
32970146|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
33322356|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
33322357|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
33410894|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
32970147|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
32970148|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
32970149|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
33410895|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
32970150|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
32970151|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
32970152|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
32970153|NCT00003846|Experimental|Treatment|See detailed description.
32970154|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
32970155|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
32970156|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
32970157|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
32970158|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
32970159|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
32970160|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
32970161|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
32970162|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
33410896|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
32970163|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
32970164|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
32970165|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
32970166|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
32970167|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
32970168|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
32970169|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
32970170|NCT00004242|Experimental|Arm I|See detailed description.
32970171|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
32970172|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
32970173|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
33322358|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
33410897|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
32970174|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
32970175|NCT00004554|Experimental|Sertraline|sertraline
32970176|NCT00004554|Experimental|Naltrexone|naltrexone
32970177|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
32970178|NCT00004554|Placebo Comparator|Placebo|Placebo
32970179|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
32970180|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
32970181|NCT00004842|Experimental|Budesonide|Oral budesonide
32970182|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
32970183|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
32970184|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
32970185|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
32970186|NCT00004992|Placebo Comparator|Placebo|
32970187|NCT00004992|Active Comparator|Metformin|
32970188|NCT00004992|Active Comparator|Intensive Lifestyle|
32970189|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
32970190|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
32970191|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
32970192|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
32970193|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
33410898|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
32970194|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
32970195|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
32970196|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
32970197|NCT00005076|Experimental|EgFR antibody|
32970198|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
32970199|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
32970200|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
32970201|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
32970202|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
32970203|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
32970204|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
32970205|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
32970206|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
32970207|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
32970208|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
32970209|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
32970210|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
32970211|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
32970212|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
32970213|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
32970214|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
32970215|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
32970216|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
32970217|NCT00005796|Experimental|Single arm|PCV therapy
32970218|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
32970219|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
32970220|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
33410899|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
32970221|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
33410900|NCT03005106|Experimental|StrataGraft Skin Tissue|
33410901|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
33410902|NCT03546894||Any FDA Approved ALK Inhibitor Other Than Crizotinib|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
33410903|NCT01004861|Experimental|PLX3397|
33410904|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
32861863|NCT04843501|Experimental|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|The CMB curriculum is divided into four developmentally appropriate e-cigarette lessons (approximately 20-30 minutes each) for middle school aged youth (6th - 8th grade). A variety of educational strategies are used and include cooperative learning groups, large group discussions, interviews, role-play, media, reports, and goal setting. CMB will provide study materials to teachers and schools through a state-of-the art online delivery portal. A site-based management team will oversee program implementation. Teachers will be trained via webinar. Project staff will visit all participating schools to assemble and train the CATCH site-based management team, and answer questions about the study. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar with Dr. Kelder, which will be offered at multiple times to accommodate teaching schedules.
32861864|NCT04843501|Active Comparator|Texas Education Agency required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes online lessons and support materials.
32861865|NCT04942002|Placebo Comparator|Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution
32861866|NCT04942002|Experimental|Standard treatment + intervention|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + retrobulbar injection of 2 cc (40 mg/mL) to methylprednisolone acetate
32861867|NCT01458457|Active Comparator|Usual care|
32861868|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
32861869|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
32861870|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
32861871|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
32861872|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
32861873|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
32861874|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
32861875|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
32861876|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
32861877|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
32861878|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
32861879|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
32861880|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
32861881|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
32861882|NCT04959318|Experimental|Treatment group or counseling group|The treatment group will receive a counseling intervention addressing metabolic syndrome (comprised of abdominal adiposity, high blood pressure, high cholesterol, elevated fasting glucose, and elevated triglyceride level) and low vitamin D. This group will undergo baseline body composition measurements, phlebotomy, and an introduction to the digital app for recording diet and activity.
32861883|NCT04959318|Active Comparator|Control group or comparison group|Subjects randomized to the control group will undergo baseline body composition measurements, phlebotomy, and an introduction to the app for recording diet and activity. They will receive a packet of evidence-based pamphlets addressing Service-specific approaches to healthy eating and physical activity (e.g. Performance Triad). There will be no formal recurring interaction with an RD for those randomized to this control group.
32861884|NCT02520427|Experimental|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
32861885|NCT02520427|Experimental|Group 2: Minimal Residual Disease Positive (MRD+) AML|
32861886|NCT02520427|Experimental|Group 3: Myelodysplastic syndrome (MDS)|
32861887|NCT02520427|Experimental|Group 4: R/R AML with alternative pretreatment|
32861888|NCT02520427|Experimental|Group 5: R/R AML with alternative dose schedule|
32861889|NCT04941612|Experimental|Activa IM-Nail|Activa IM-Nail
32861890|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
32861891|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
32861892|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
32861893|NCT04959084|Experimental|Acupuncture|Acupuncture group A , consisting of 20 women will be received laser acupuncture therapy and pelvic floor training every other day for 30 min , 3 times per week for 12 sessions
32861894|NCT04959084|No Intervention|Medical|Medical group B, consisting of 20 women will be maintained their ordinary medical treatment
32861895|NCT04958928||Persistent AF Group|
32861896|NCT04941690||Men seen for preconception physicals|Ready to conceive, i.e. not having contraception and not having children for less than 1 year
32861897|NCT04941690||Men seen for infertility|Couples who have not used contraception and have not had children for more than 1 year
32970222|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
32970223|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
32970224|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
32970225|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
32970226|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
32970227|NCT00355680|Experimental|1|Aurolab Green Laser
32970228|NCT00355680|Active Comparator|2|Available Green Laser
32970229|NCT00356460|Experimental|1 - Part 1|Dose Group
32970230|NCT00356460|Experimental|2 - Part 1|Dose Group
32970231|NCT00356460|Experimental|3 - Part 1|Dose Group
32970232|NCT00356460|Experimental|4 - Part 1|Dose Group
32970233|NCT00356460|Experimental|5 - Part 1|Dose Group
32970234|NCT00356460|Experimental|6 - Part 1|Dose Group
32970235|NCT00356460|Experimental|1 (Part 2)|
32970236|NCT00356460|Experimental|2 (part 2)|
32970237|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
32970238|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
32970239|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
32970240|NCT00357240|Active Comparator|A1|
32970241|NCT00357240|Active Comparator|A2|
32970242|NCT00357240|Experimental|A3 I|
32970243|NCT00357240|Experimental|A3 II|
32970244|NCT00357240|Active Comparator|B1|
32970245|NCT00357240|Active Comparator|B2|
32970246|NCT00357240|Experimental|B3 I|
32970247|NCT00357240|Experimental|B3 II|
32970248|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
33410905|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
33410906|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
33410907|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
33410908|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
32970249|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
32970250|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
32970251|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
32970252|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
32970253|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
32970254|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
32970255|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
32970256|NCT00358410|Experimental|GW679769|120mg once a day
32970257|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
32970258|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
32970259|NCT00358488|Experimental|salbutamol|salbutamol
32970260|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
32970261|NCT00358488|Placebo Comparator|placebo|placebo
32970262|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
32970263|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
32970264|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
32970265|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
32970266|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
32970267|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
32970268|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
32970269|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
33410909|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
32970270|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
32970271|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
32970272|NCT00360438|Experimental|Rasburicase|
32970273|NCT00360594|Experimental|1|Acamprosate
32970274|NCT00360594|Placebo Comparator|2|Placebo
32970275|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
32970276|NCT00361530|No Intervention|No intervention|Patient has no intervention.
32970277|NCT00362778|Sham Comparator|Serum saline|
32970278|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
32970279|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
32970280|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
32970281|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
32970282|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
32970283|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
32970284|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
32970285|NCT00362934|Experimental|1|
32970286|NCT00362934|Active Comparator|2|
32970287|NCT00363714|Experimental|1|Single intravitreal injection
32970288|NCT00363714|Experimental|2|Single intravitreal injection
32970289|NCT00363714|Experimental|3|Single intravitreal injection
32970290|NCT00363714|Experimental|4|Single intravitreal injection
32970291|NCT00363714|Experimental|5|Single intravitreal injection
32970292|NCT00363714|Experimental|6|Single intravitreal injection
32970293|NCT00363948|Placebo Comparator|P|
32970294|NCT00363948|Experimental|E|
32970295|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
32970296|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
32970297|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
32970298|NCT00364104|Placebo Comparator|D|
32970299|NCT00364416||001|
32970300|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
32970301|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
32970302|NCT00364650|Placebo Comparator|I|Placebo
32970303|NCT00364650|Experimental|II|Probiotic supplement
32970304|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
32970305|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
32970306|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
32970307|NCT00366288||1|
32970308|NCT00366288||2|
32970309|NCT00366288||3|
32970310|NCT00366288||4|
32970311|NCT00366288||5|
32970312|NCT00366288||6|
32970313|NCT00366288||7|
32970314|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
32970315|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
32970316|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
32970317|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
32970318|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
32970319|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
32970320|NCT00367302|Experimental|1|Buprenorphine maintenance
32970321|NCT00367302|Active Comparator|2|Methadone maintenance
32970322|NCT00368160|Experimental|1|eszopiclone 3 mg
32970323|NCT00368160|Placebo Comparator|2|Placebo tablet
32970324|NCT00368706|Experimental|1|
32970325|NCT00368706|Active Comparator|2|
32970326|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
32970327|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
32970328|NCT00369018|Active Comparator|MAL 3|
32970329|NCT00369018|Active Comparator|MAL 12|
32970330|NCT00369018|Active Comparator|HAL 10, 3|
32970331|NCT00369018|Active Comparator|HAL 10, 12|
32970332|NCT00369018|Active Comparator|HAL 40, 3|
32970333|NCT00369018|Active Comparator|HAL 40, 12|
32970334|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
33322359|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
32970335|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
32970336|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
32970337|NCT00370110|Experimental|Itopride|
32970338|NCT00370110|Other|Placebo|
32970339|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
32970340|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
32970341|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
32970342|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
32970343|NCT00370812|Active Comparator|B|Medical treatment alone
32970344|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
32970345|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
33322360|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
33322361|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
33322362|NCT03672344|Active Comparator|Lookware TM|Lookware TM computer-based video game that requires the subject to engage in social skills related exercises during simulated social interactions with game characters.
33322363|NCT03672344|Placebo Comparator|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises.
33322364|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
33322365|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
33322366|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
33322367|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
33322368|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
33322369|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
33322370|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
33322371|NCT04520412|Experimental|GV-971|
33322372|NCT04520412|Placebo Comparator|Placebo|
33322373|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
33322374|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
33322375|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
33322376|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
33322377|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
33322378|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
32970346|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
32970347|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
32970348|NCT00371748|Experimental|Arm 1|
33410910|NCT04083599|Experimental|Monotherapy - Dose Escalation and Dose Expansion parts|Escalating doses of GEN1042 monotherapy in subjects with non-central nervous system (CNS) solid malignant tumors followed by monotherapy expansion cohorts at selected dose(s) in subjects with relapsed or refractory, advanced and/or metastatic melanoma, or non-small-cell lung cancer (NSCLC), or colorectal cancer (CRC).
32970349|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
32970350|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
32970351|NCT00371904|Experimental|1|
32970352|NCT00371904|Active Comparator|2|
32970353|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
32970354|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
32970355|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
32970356|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
32970357|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
32970358|NCT00372684||1|with severe malaria hospitalized in ICU
32970359|NCT00372684||2|with uncomplicated malaria
32970360|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
33322379|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
33322380|NCT05256368||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-80
33322381|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
33322382|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
33322383|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
33322384|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
33322385|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
33322386|NCT03946488|No Intervention|Inactive neuroprosthesis|
33322387|NCT03946488|Experimental|Active neuroprosthesis|
33322388|NCT04465812|No Intervention|Standard health counseling at baseline|Standard health counseling at baseline
33322389|NCT04465812|Experimental|Self-monitoring and personalized feedback on smartphone app|"Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete cognitive training games every week on app;~Medical staff will send health information on app"
33322390|NCT04475588|Experimental|Arm A - Itolizumab + BSC|
33322391|NCT04475588|Active Comparator|Arm B - Best supportive care (BSC)|
33322392|NCT03946254|Experimental|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
33322393|NCT03946254|Experimental|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
33322394|NCT03946020|Active Comparator|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
33322395|NCT03946020|Experimental|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
33322396|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
33322397|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
33322398|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
33322399|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
33322400|NCT03947580|Experimental|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
32970361|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
32970362|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
32970363|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
32970364|NCT00372918|Other|1|Transnasal Esophagoscopy
32970365|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
32970366|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
32970367|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
32970368|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
32970369|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
32970370|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
32970371|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
32970372|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
32970373|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
32970374|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
32970375|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
32970376|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
32970377|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
32970378|NCT00374946||D|THA. Head and shell og Alumina ceramic
32970379|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
32970380|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
32970381|NCT00375102|Experimental|Acup|Acupuncture
32970382|NCT00375102|Experimental|RR|Relaxation Response
32970383|NCT00375102|No Intervention|UC|Usual Care
32970384|NCT00375258|Experimental|1|Active
32970385|NCT00375258|Placebo Comparator|2|
32970386|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
32970387|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
32970388|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
32970389|NCT00375570|Experimental|1|ME-609
32970390|NCT00375648|Experimental|zoledronate|
32970391|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
32970392|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
32970393|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
32970394|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
32970395|NCT00375882|Other|cochlear implantation with mild hypothermia|
32970396|NCT00376272|Experimental|1|
32970397|NCT00376272|Placebo Comparator|2|
32970398|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
32970399|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
32970400|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
32970401|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
32970402|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
32970403|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
32970404|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
32970405|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
32970406|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
32970407|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
32970408|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
32970409|NCT00376896|Placebo Comparator|Placebo|Placebo
32970410|NCT00377052|Experimental|Bortezomib + Gemcitabine|
32970411|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
32970412|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
32970413|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
32970414|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
33410911|NCT04083599|Experimental|Combination Therapy - Dose Expansion Part|GEN1042 safety and efficacy will be evaluated in combination with pembrolizumab with or without chemotherapy in treatment-naive subjects with advanced or metastatic melanoma, non-small-cell lung cancer [NSCLC], head and neck squamous cell carcinoma [HNSCC], and pancreatic cancer.
33410912|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
33410913|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
33410914|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
33410915|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
33410916|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
33410917|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
33410918|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
33410919|NCT04374305|Experimental|Sub-study A (brigatinib)|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
33410920|NCT04374305|Experimental|Sub-study B (neratinib)|The first three participants treated in this arm will receive neratinib 200 mg mg by mouth daily. If these participants tolerate the medication well, subsequent participants will receive neratinib 240 mg by mouth daily.
33410921|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
33410922|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
33410923|NCT04363463|No Intervention|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
33410924|NCT04363463|Experimental|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
33410925|NCT05179109|Experimental|Robot-assisted laparoscopy|Surgery for deep endometriosis using robot-assisted laparoscopy.
33410926|NCT05179109|Active Comparator|Conventional laparoscopy|Surgery for deep endometriosis using conventional laparoscopy.
33410927|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
33410928|NCT05178953|Experimental|pentoxifylline group|"Group 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients.~These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)~Other names:~Trental"
33410929|NCT05178953|Experimental|Zinc Sulfate group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
33410930|NCT05178953|Experimental|pentoxifylline+ zinc group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
32970415|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
32970416|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
33410931|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
33410932|NCT05178875||NDNS participants|Random participants from all the UK (including England, Scotland, Wales and North Ireland)
33410933|NCT05178719|Experimental|PMA-zeolite|All subjects receive the substance 3 times per day in a measuring spoon as powder
33410934|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
33417298|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
32970417|NCT00377442|Experimental|1|
32970418|NCT00377442|Experimental|2|
32970419|NCT00377442|Experimental|3|
32970420|NCT00377598|Experimental|TAK-583 5 mg QD|
33322401|NCT03947580|Experimental|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
32861898|NCT04941690||Men who visited the clinic for their wives' miscarriage|Couples whose wives were previously pregnant but terminated the pregnancy due to fetal abortion, spontaneous abortion, biochemical pregnancy, fetal malformation or ectopic pregnancy
32861899|NCT02883673|Experimental|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
33322402|NCT03947580|No Intervention|Use of no pad|Description is not needed
33322403|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
33322404|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
33322405|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
33322406|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
33322407|NCT03947736||patients with positive HER2 amplification|
33322408|NCT03947736||patients with negative HER2 amplification|
33322409|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
33322410|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
33417299|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
32861900|NCT04949958|Experimental|Experimental: Exercise Based Manual (Supervised)|Supervised Exercises with exercise based Manual (exercise & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of different type of exercises including warm up and rest interval
32861901|NCT04949958|Experimental|Experimental: Exercise Based Manual (Home Based)|Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise & Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise.
32861902|NCT04949958|Placebo Comparator|Placebo Comparator: Control|Age matched Control Group followed for 16 weeks with General Advise to active
32861903|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
32861904|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
32861905|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
32861906|NCT04950036||Normal control group-Grade 0|Arthroscopic examination of the hip was normal, and the labrum was intact without injury or tear.
32861907|NCT04950036||Ligament injury -Grade 1|Arthroscopic examination of the hip showed labrum degeneration or injury, but no local or complete tear.
32861908|NCT04950036||Ligament tear-Grade 2|Arthroscopy of the hip revealed partial or complete loss of labrum.
32861909|NCT03058926||Chronic Pancreatitis|
32861910|NCT03058926||Diabetes|
32861911|NCT03058926||Pancreatic Cancer|
32861912|NCT04840849|Experimental|Nirsevimab|Nirsevimab single dose IM injection
32861913|NCT04840849|Placebo Comparator|Placebo|Placebo single dose IM injection
32861914|NCT04958616||Patients sensitive to HDM|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled.Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
32861915|NCT04958616||Patients not sensitive to HDM allergy.|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled .Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation).
32970421|NCT00377598|Experimental|TAK-583 25 mg QD|
32970422|NCT00377598|Experimental|TAK-583 50 mg QD|
32970423|NCT00377598|Experimental|TAK-583 100 mg QD|
32970424|NCT00377598|Placebo Comparator|Placebo QD|
32970425|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
32970426|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
32970427|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
32970428|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
32970429|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
32970430|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
32970431|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
32970432|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
32970433|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
32970434|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
32970435|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
32970436|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
32970437|NCT00379470|Experimental|NovoTTF-100A|
32970438|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
32970439|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
32970440|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
32970441|NCT00380406|Placebo Comparator|Placebo|Placebo
32970442|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
32970443|NCT00380484|Experimental|1|Budesonide
33322411|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
33322412|NCT01105338|Active Comparator|Green tea drink|Green tea drink
33322413|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
32970444|NCT00380484|Active Comparator|2|Montelukast
32970445|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
33322414|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
33322415|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
33322416|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
32970446|NCT00380562|No Intervention|Control|Usual activities
32970447|NCT00380640|Experimental|1|
32970448|NCT00380640|Experimental|2|
32970449|NCT00380796||Cohort 1|
32970450|NCT00381108|Experimental|Pomegranate Tablet|
32970451|NCT00381108|Placebo Comparator|Placebo Tablet|
32970452|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
32970453|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
32970454|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
32970455|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
32970456|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
32970457|NCT00381576|Experimental|A|12 weeks of resistance training
32970458|NCT00381654|Experimental|A|Daily oral administration of AV-412
32970459|NCT00381732|Placebo Comparator|1|placebo tablet
32970460|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
32970461|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
32970462|NCT00382356|Experimental|study drug|Open label, single arm
32970463|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
32970464|NCT00382668||A|
32970465|NCT00382668||B|
32970466|NCT00382668||C|
32970467|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
32970468|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
32970469|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
32970470|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
32970471|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
32970472|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
32970473|NCT00383136|Experimental|1|Tirofiban
32970474|NCT00383136|Active Comparator|2|Abciximab
32970475|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
32970476|NCT00383214|Placebo Comparator|Placebo|Intravenous
32970477|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
32970478|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
32970479|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
32970480|NCT00383526|Experimental|Study Group 1|
32970481|NCT00383526|Active Comparator|Study Group 2|
32970482|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
32970483|NCT00384228|Experimental|Nilotinib|
32970484|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
32970485|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
32970486|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
32970487|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
32970488|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
32970489|NCT00385086|Active Comparator|Placebo|Treatment with placebo
32970490|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
33322417|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
33322418|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
32970491|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
32970492|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
32970493|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
32970494|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
32970495|NCT00385710|Experimental|valproic acid|Depakine
32970496|NCT00385710|Placebo Comparator|Placebo|Placebo
32970497|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
32970498|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
32970499|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
32970500|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
32970501|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
32970502|NCT00421668|Experimental|Zinc|zinc
32970503|NCT00421668|Placebo Comparator|Placebo|placebo
32970504|NCT00421824|Experimental|A|
32970505|NCT00421824|Experimental|B|
32970506|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
32970507|NCT00422682|Experimental|1|BSI-201 + topotecan
32970508|NCT00422682|Experimental|2|BSI-201 + temozolomide
32970509|NCT00422682|Experimental|3|bsi-201 + gemcitabine
32970510|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
32970511|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
32970512|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
32970513|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
32970514|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
32970515|NCT00423072||1|children with cleft palate birth-24 months of age
32970516|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
32970517|NCT00423228|Active Comparator|Donepezil|Donepezil
32970518|NCT00423306|Experimental|Single Arm|
32970519|NCT01799070||CHS|
32970520|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
32970521|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
32970522|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
32970523|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
33322419|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
33322420|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
33322421|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
33322422|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
32970524|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
33410935|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
32970525|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
32970526|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
32970527|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
32970528|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
32970529|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
32970530|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
32970531|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
32970532|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
32970533|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
32970534|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
32970535|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
32970536|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
32970537|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
32970538|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
32970539|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
32970540|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
33410936|NCT05572619||Positive group|A patient diagnosed with large vessel occlusion after a non-contrast CT, CT perfusion and CT angiography
32970541|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
32970542|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
32970543|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
32970544|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
32970545|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
32970546|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
32970547|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
32970548|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
32970549|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
33322423|NCT05206656|Placebo Comparator|Eribulin mesylate|"Metastatic breast cancer patients receive eribulin mesylate injection alone. The dosage is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle. Patients receive Eribulin untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
32970550|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
32970551|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
32970552|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
32970553|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
32970554|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
32970555|NCT02992080|Other|Cystic fibrosis Patients|
32970556|NCT02992080|Other|Patients without fibrosis cystic|
32970557|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
32970558|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
32970559|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
32970560|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
32970561|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
32970562|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
32970563|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
32970564|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
32970565|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
32970566|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
32970567|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
32970568|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
32970569|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
32970570|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
32970571|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
32970572|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
32970573|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
33410937|NCT05572619||Negative group|A normal person or a patient not diagnosed with intracranial haemorrhage after a non-contrast CT, CT perfusion and CT angiography
33410938|NCT04670393|Experimental|FertyBiotic Woman Plus|Participants received FertyBiotic Woman Plus one sachet a day
32970574|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
32970575|NCT02998866|Other|Multi-center, prospective outcomes registry|The study is a multi-center, prospective outcomes registry
32970576|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
32970577|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
32970578|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
32970579|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
32970580|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
32970581|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
32970582|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
32970583|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
32970584|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
32970585|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
32970586|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
32970587|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
32970588|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
32970589|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
32970590|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
32970591|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
32970592|NCT02997618|Active Comparator|Control|"1. Usual care (control)~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:~Smoking Exercise Weight Diet"
32970593|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
32970594|NCT02997384||General practitioner|
32970595|NCT02997384||gynecologist|
32970596|NCT02997384||radiologist|
32970597|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
32970598|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
33410939|NCT04670393|Placebo Comparator|Placebo|Participants received 400 mcg of folic acid once a day
32970599|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
32970600|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
32970601|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
32970602|NCT02997150|Experimental|IL-2 low dose|
32970603|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32970604|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
32970605|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
32970606|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
33410940|NCT04080791|Experimental|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
33410941|NCT04080791|Active Comparator|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
32970607|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
32970608|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
32970609|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
32970610|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
32970611|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
32970612|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
32970613|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
33410942|NCT05178251||Control group without Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2018 to December 14, 2018 and from March 17, 2019 to December 14, 2019
33410943|NCT05178251||Test group with Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2020 to December 14, 2020
33410944|NCT05178095|Experimental|AI|Colonoscopy with AI
33410945|NCT05178095|Placebo Comparator|No AI|Colonoscopy without AI
32970614|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
32970615|NCT02996136|Experimental|Nasal Swab|Nasal Swab
32970616|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
32970617|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
33410946|NCT05572385|Active Comparator|Patients with aphasia|Patients with a clinical aphasia (20 receptive, 20 expressive) with a specific logopedic treatment, with specific EEG measurement at start and end of treatment schedule.
32970618|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.~Hyperpolarized helium 3 imaging will be performed at breath hold."
32970619|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
32970620|NCT02995200|No Intervention|Healthy Control Group|
33410947|NCT05572385|No Intervention|Patients without aphasia|Patients with comparable stroke characteristics, but without clinical aphasia.
33410948|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
33410949|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
33410950|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
33410951|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
33410952|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
33410953|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
33322424|NCT05206656|Experimental|Eribulin mesylate combined with Anlotinib|"Metastatic breast cancer patients receive Eribulin mesylate combined with Anlotinib. The dosage of Eribulin mesylate is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle.~Anlotinib dosage is 12mg per day for consecutive 14 days (21 days per cycle). Patients receive Anlotinib untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
33322425|NCT05347004|Experimental|BI 425809 fed state (Test, T) then BI 425809 fasting state (Reference, R)|
33322426|NCT05347004|Experimental|BI 425809 fasting state (Reference, R) then BI 425809 fed state (Test, T)|
33322427|NCT05171166|Experimental|HAIC-TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.
33322428|NCT05171166|Active Comparator|TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.
33322429|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
32861916|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
32861917|NCT04843423|Experimental|Cariprazine treatment|
32861918|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
32861919|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
32861920|NCT04940988||See alert|The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.
32861921|NCT04940988||Do not see alert|The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.
32861922|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
32861923|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
32861924|NCT04423302|Experimental|TOTUM-63 3 intakes per day|Experimental active diet supplement TOTUM-63 taken 3 times per day (blinded arm)
32861925|NCT04423302|Placebo Comparator|Placebo 3 intakes per day|Placebo comparator taken 3 times per day (blinded arm)
32861926|NCT04423302|Experimental|TOTUM-63 2 intakes per day|Experimental active diet supplement TOTUM-63 taken 2 times per day (open arm)
32861927|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
32861928|NCT01459003|Experimental|experimental|
32861929|NCT01459003|No Intervention|control|
32861930|NCT04949802|Experimental|laser|treated with Vialase laser
32861931|NCT01459081|Experimental|Zanamivir|
32861932|NCT01459081|Placebo Comparator|Placebo|
32861933|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
32861934|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
32861935|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
32861936|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
32861937|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
32861938|NCT04849663|Experimental|study group|Use of free fat graft to cover exposed root
32861939|NCT04849663|Active Comparator|control group|use of sub epithelial connective tissue graft to cover exposed root
32861940|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
32861941|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.~The modified multimodal analgesic regimen utilizes the following medications:~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
32861942|NCT04949334|Experimental|Dofin Breathing Strength Builder|Usual post stroke care and respiratory muscle training
32861943|NCT04949334|No Intervention|Usual post stroke care|Usual post stroke care
32861944|NCT04389931|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
32970621|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32970622|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32970623|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
32970624|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
32970625|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
32970626|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
32970627|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
32970628|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
32970629|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
32970630|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
32970631|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
32970632|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
32970633|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
32970634|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
32970635|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
32970636|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
32970637|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
32970638|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
32970639|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
32970640|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
32970641|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
32970642|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
32970643|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
32970644|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
32970645|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
32970646|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
32970647|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
32970648|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
32970649|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
32970650|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
32970651|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
32970652|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
32970653|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
32970654|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
32970655|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
32970656|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
32970657|NCT02992704|No Intervention|Control|No treatment for 72 weeks
32970658|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
32970659|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
32970660|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
32970661|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
32970662|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
32970663|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
32970664|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
32970665|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
32970666|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
32970667|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
32970668|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
32970669|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
32970670|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
32970671|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
32970672|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
32970673|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
32970674|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
32970675|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
32970676|NCT02991222|Experimental|SPARC001 type I|Treatment type I
32970677|NCT02991222|Experimental|SPARC001 type II|Treatment type II
32970678|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
32970679|NCT02991222|Active Comparator|Reference type II|Treatment type II
32970680|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
32970681|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
32970682|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
32970683|NCT02990676|No Intervention|Control group|Asked to continue as normal
32861945|NCT04389931|Experimental|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
32861946|NCT04949178||Critically ill cirrhotics with septic shock and AKI undergoing CRRT|Consecutive critically ill cirrhotics with septic shock and AKI who give written informed consent will be included in this prospective study
32861947|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
32861948|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
32861949|NCT04958460|Experimental|Probiotics group|"Probiotics~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
32970684|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
32970685|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
32970686|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
32970687|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
32970688|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
32970689|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
32970690|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
32970691|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
32970692|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
32970693|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
32970694|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
32970695|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
32970696|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
32970697|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
32970698|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
32970699|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
32970700|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
32970701|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
32970702|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
32970703|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
33322430|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
33322431|NCT04353596|Experimental|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
33322432|NCT04353596|No Intervention|Control|No intervention, which means further treatment with ACEI or ARB.
32970704|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32970705|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
32970706|NCT01270698|Experimental|IMMU-130|
32970707|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
32970708|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
32970709|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
32970710|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
32970711|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
32970712|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
32970713|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
32970714|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
32970715|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
32970716|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
32970717|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
32970718|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
32970719|NCT01272102||Glaucoma|subjects with glaucoma
32970720|NCT01272258|Experimental|Arm 1|PRO 140
32970721|NCT01272258|Placebo Comparator|Arm 2|Placebo
32970722|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
32970723|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
32970724|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
32970725|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
32970726|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
32970727|NCT01272492|No Intervention|Control|Only answers survey questions.
32970728|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
32970729|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
32970730|NCT01272648|Active Comparator|Rehabilitation|note intervention
32970731|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
32970732|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
32970733|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
32970734|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
32970735|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
32970736|NCT01273428|Active Comparator|HP011-101|
32970737|NCT01273428|Active Comparator|HP828-101|
32970738|NCT01273428|Other|Standard Care|
32970739|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
32970740|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
32970741|NCT01273662|Experimental|Axitinib|
32970742|NCT01273740|Experimental|External support|Bypass graft with external support
32970743|NCT01273740|Experimental|No external support|Bypass with graft without external support
32970744|NCT01273974|Experimental|intradermal influenza vaccine|
32970745|NCT01273974|Active Comparator|intramuscular influenza vaccine|
32970746|NCT01274130|Experimental|Ranitidine|
32970747|NCT01274130|Experimental|Verapamil|
32970748|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
32970749|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
32970750|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
32970751|NCT01274676|Active Comparator|carotid stenting with MOMA|
32970752|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
32970753|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
32970754|NCT01274754||control group|no administration of erythromycin
32970755|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
32970756|NCT01274910|Placebo Comparator|Control group|Placebo group
32970757|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
32970758|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
32970759|NCT01275612|Experimental|Cell therapy|
32970760|NCT01275690||subjects with PH undergoing right heart catheterization|
32970761|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
32970762|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
32970763|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
32970764|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
32970765|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
32970766|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
32970767|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
32970768|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
32970769|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
32970770|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
32970771|NCT01276626|Experimental|Bifidobacterium longum|
32970772|NCT01276626|Placebo Comparator|Maltodextrin|
32970773|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
32970774|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
32970775|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
32970776|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
32970777|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
32970778|NCT01277094|Experimental|1|
32970779|NCT01277094|Placebo Comparator|2|
32970780|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
32970781|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
32970782|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
32970783|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
32970784|NCT01277328||Cohort|Cohort
32970785|NCT01277406|Experimental|4SC-201+FOLFIRI|
32970786|NCT01277406|Active Comparator|FOLFIRI|
32970787|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
32970788|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
32970789|NCT01277640|Placebo Comparator|matched placebo|
32970790|NCT01277640|Placebo Comparator|universal placebo|
32970791|NCT01277640|Active Comparator|dapivirine|
32970792|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
33322433|NCT05133414|Experimental|Participants will receive stimulation of the left subclavian ansae.|Participants as self-controlled cases for the study. Human cardiac haemodynamics and electrophysiological in response to left subclavian ansae stimulation will be studied.
33322434|NCT05190562|Experimental|Zinc Sulphate|Zinc Sulphate 25 Mg once daily for one month
33322435|NCT05107596|Active Comparator|Post ST Elevation Myocardial Infarction/ Heart Attack|Image patients who have had a heart attack
33322436|NCT05107596|Active Comparator|Sarcoidosis|Image patients who have Sarcoidosis
33322437|NCT05107596|Active Comparator|Myocarditis|Image patients with Myocarditis
33322438|NCT05107596|Active Comparator|Cardiomyopathy|Image patients with cardiomyopathy
33322439|NCT05107596|Active Comparator|Infected Cardiovascular Implantable Electronic Devices|Image patients with cardiovascular implanted medical devices
32970793|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
32970794|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
32970795|NCT01278108|Experimental|1|single ascending doses
32970796|NCT01278108|Placebo Comparator|2|single dose placebo
32970797|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
32970798|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
32970799|NCT01278420|Other|Tecnis MF|
32970800|NCT01278420|Other|ReSTOR|
32970801|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
32970802|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
32970803|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
32970804|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
32970805|NCT01278810|Experimental|Icaritin|
32970806|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
32970807|NCT01279122|No Intervention|Nanoflex IOL|
32970808|NCT01279278|No Intervention|Control|
32970809|NCT01279278|Experimental|Co-signed Letter|
32970810|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis~cholestatic liver diseases~auto-immune hepatitis~NAFLD~ALD~sarcoidosis of the liver"
32970811|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
32970812|NCT01279434|Active Comparator|Vitamin E|
32970813|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
33322440|NCT05107596|Active Comparator|Healthy Volunteers|Image healthy volunteers
32970814|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
32970815|NCT01279668|Experimental|Montelukast|
32970816|NCT01279668|Placebo Comparator|Placebo|
32970817|NCT01279746||ultrasond compression of deep veins|
32970818|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~Rituximab 375 mg/M2 IV day 1~Cyclophosphamide 750 mg/M2 IV day1~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~Prednisolone 50 mg bid day 1-5, every 3 weeks"
32970819|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
32746716|NCT04870359|Active Comparator|Pre-emptive Treatment (Prednisolone and/or AZA/MMF)|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~Adjustment of the 2nd agent would be as follows:~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
32970820|NCT01279044|Placebo Comparator|2|HIV testing with information only
32970821|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
32970822|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
32970823|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
32970824|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
32970825|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
32970826|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
32970827|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
32970828|NCT01276236|Experimental|Treatment Arm (Maraviroc)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
32970829|NCT01275222|Experimental|Phase l: RAD001 20mg/week|RAD001 20 mg was given once a week.
32970830|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 600mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
32970831|NCT01275222|Experimental|Phase l: RAD001 5mg/day + Glivec 600mg/day|RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
32970832|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 800mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
32970833|NCT01275222|Experimental|Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day|All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
32970834|NCT01275222|Experimental|Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day|All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
32970835|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
32970836|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
32970837|NCT01275066|Placebo Comparator|Placebo|
32970838|NCT01275066|Experimental|BMN 110 Weekly|
32970839|NCT01275066|Experimental|BMN 110 Every Other Week|
32970840|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
32970841|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
32970842|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
32970843|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
32970844|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
32970845|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
32970846|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
32970847|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
32970848|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
32970849|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
32970850|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
32970851|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
32970852|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
32970853|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
32970854|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
32970855|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
32970856|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
32970857|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
32970858|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
32970859|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
32970860|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
32970861|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
32970862|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
32970863|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
32970864|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
32970865|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
32970866|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
32970867|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
32970868|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
32970869|NCT00249834|Experimental|Gonal-f 112.5 IU|
32970870|NCT00249834|Experimental|Gonal-f 37.5 IU|
32970871|NCT00249834|Experimental|Gonal-f 75 IU|
32970872|NCT00249834|Experimental|Gonal-f 150 IU|
32970873|NCT00249834|Experimental|Gonal-f 187.5 IU|
32970874|NCT00249834|Experimental|Gonal-f 225 IU|
32970875|NCT00249834|Experimental|Gonal-f 262.5 IU|
33322441|NCT01358422||In Patients|
32970876|NCT00249834|Experimental|Gonal-f 300 IU|
32970877|NCT00249444|Active Comparator|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
32970878|NCT00249444|Placebo Comparator|Placebo|placebo
32970879|NCT00249288|Experimental|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
32970880|NCT00249288|Placebo Comparator|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
33322442|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
33322443|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
33322444|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
32970881|NCT00248040|Experimental|reparixin group - continuous infusion|"Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.772 mg/kg/h was administered for12 hours."
32970882|NCT00248040|Experimental|reparixin group - intermittent infusion|"Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours."
32970883|NCT00248040|Placebo Comparator|placebo infusion|Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
32970884|NCT00247962|Experimental|A|
32970885|NCT00247962|Active Comparator|B|
32970886|NCT00247416|Other|1 No Dex|No Dexamethasone
33104915|NCT05106855|Other|Implants GM Acqua surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
33104916|NCT05106855|Other|Implants GM Acqua surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
33104917|NCT05106855|Other|Implants GM NeoPoros surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
33322445|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
33322446|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
33322447|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
33322448|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
33322449|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
33322450|NCT03947424|Experimental|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
33322451|NCT03947424|Experimental|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
33322452|NCT03947424|Sham Comparator|Control|Sham laser snoring treatment with no energy applied.
33322453|NCT03921580|Placebo Comparator|Control Canned Tuna|Control Canned Tuna
33322454|NCT03921580|Experimental|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
33322455|NCT03921580|Experimental|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
33322456|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
33322457|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
33322458|NCT05096286|Experimental|Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy|"A diagnostic MRI-only, simulation-free plan will be generated from diagnostic brain MRI imaging, using a semi-automated, AI-assisted plan template within the Ethos Therapy system.~The radiation prescription dose twill be 3.0 Gy daily over approximately 2 weeks for a total of 30.0 Gy (10 fractions)."
32970887|NCT00247416|Experimental|2 Dex|Dexamethasone
32970888|NCT00246090|Experimental|1|
32970889|NCT00246012|Experimental|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
32970890|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
32970891|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
32970892|NCT00246012|Experimental|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
32970893|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
32970894|NCT00246012|Experimental|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
32970895|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
32970896|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
32970897|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
32970898|NCT00245856|Experimental|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
32970899|NCT00245466|Experimental|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
32970900|NCT00245466|Experimental|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
32970901|NCT00245466|Experimental|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
32970902|NCT00244764|Experimental|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
32970903|NCT00244764|Placebo Comparator|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
32970904|NCT00244374|Experimental|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
32970905|NCT00244374|Experimental|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
32970906|NCT00244374|Experimental|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
32970907|NCT00244374|Experimental|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
32970908|NCT00242658|Experimental|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
32970909|NCT00242658|No Intervention|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
33322459|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
33322460|NCT05071326|Experimental|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
33322461|NCT05062200|Experimental|Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])|Japanese participants will receive single oral dose 1 of JNJ-77242113 (immediate-release [IR] tablet) or matching placebo on Day 1 in Cohort 1 of Part 1.
33322462|NCT05062200|Experimental|Cohort 2: JNJ-77242113 or Placebo (SAD)|Japanese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 2 of Part 1.
32970910|NCT00242580|Experimental|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
32970911|NCT00242580|Experimental|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
32970912|NCT00242580|Active Comparator|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
32970913|NCT00241644|Experimental|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
32970914|NCT00241644|Experimental|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
32970915|NCT00241644|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
32970916|NCT00245622|Experimental|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
32970917|NCT00245622|Placebo Comparator|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
32970918|NCT03800784|Experimental|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
32970919|NCT03804060|Experimental|Cooling + Recanalization|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after recanalization.
32970920|NCT03804060|Active Comparator|Recanalization only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.
32970921|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
32970922|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
32970923|NCT03809754|Experimental|OCT-guided PCI|
32970924|NCT03809754|Sham Comparator|Angiography-guided PCI|
32970925|NCT03809676||heaart transplant recipients|
32970926|NCT03809676||healthy controls|
32970927|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
32970928|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
32970929|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
33410954|NCT05572229|Experimental|Tec-Dara|For patients assigned to Cohort A (Tec-Dara), 1800 mg of daratumumab SC will be administered weekly for 8 weeks (Cycles 1 and 2); then Q2W for 16 weeks (Cycles 3 to 6); thereafter (≥Cycle 7), once Q4W until documented PD or unacceptable toxicity.
32970930|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
32970931|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
32970932|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
32970933|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
32970934|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
32970935|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
32970936|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
33410955|NCT05572229|Experimental|Tec-Len|For patients assigned to Cohort B (Tec-Len), lenalidomide administration guidance will be provided in an amendment.
33410956|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
33410957|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
32970937|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.~The number of cores taken will be decided per the physician discretion according to the clinical demand.~Additional two biopsy core will be taken the SmartBx cassette"
32970938|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
32970939|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
32970940|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
32970941|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
32970942|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
32970943|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
32970944|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
32970945|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
32970946|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
32970947|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
32970948|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
32970949|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
32970950|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
32970951|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
32970952|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
32970953|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
32970954|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
32970955|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
32970956|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
32970957|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
32970958|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
32970959|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
32970960|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
33410958|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
33410959|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
33410960|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
33410961|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
32746717|NCT04870359|No Intervention|Control|Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.
32746718|NCT02589639|Experimental|empagliflozin 10 mg|
32746719|NCT02589639|Experimental|empagliflozin 25 mg|
32746720|NCT02589639|Placebo Comparator|placebo|
32861950|NCT04958460|Placebo Comparator|Control group|"Placebo~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
32861951|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
32861952|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
32861953|NCT04940754|Other|Stabilzation of Fracture|Arthrodesis nail used for stabilzation of a fracture, single patient
32861954|NCT01892137|Other|Open label active|
32861955|NCT04940910|Experimental|Black rice bran extract group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 1 g/day)
32861956|NCT04940910|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 0 g/day)
32861957|NCT01459315|Experimental|GSK1349572|
32861958|NCT04849273|Experimental|TPX-0131|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.~The Phase 2 part of the study will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts."
32861959|NCT04940520|Active Comparator|Control group|Group A: control group, drug recommended by the Brazilian Society of Dermatology
32861960|NCT04940520|Active Comparator|Alpha-bisabolol and laser|Group B: alpha bisabolol-based product associated with low-level laser therapy
32861961|NCT04940520|Active Comparator|Alpha bisabolol|Group C: alpha bisabolol based product
32861962|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 1)|
32861963|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 2)|
32861964|NCT04948788|Experimental|GemOx (Stage 2)|
32861965|NCT04958148|Experimental|High sodium|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 4,300 mg/d sodium for 4 weeks.
32861966|NCT04958148|Placebo Comparator|Placebo|Subjects will be counseled to consume a diet with 2,300 mg/d sodium and will supplement with taking placebo pills for 4 weeks.
32861967|NCT04948242||Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection|Consecutive adult patients (> 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.
32861968|NCT04948086||TT MTHFR genotype|
32861969|NCT04948086||Non-TT (i.e. CC/CT) MTHFR genotype|
32861970|NCT04948320||Temporomandibular Disorder Group|
32861971|NCT04948320||Control Group|
32861972|NCT04940442|Experimental|Active choice|FIT or colonoscopy
32861973|NCT04940442|Experimental|Sequential choice|FIT offered first, then colonoscopy offered to those still unscreened
32861974|NCT04420728|Experimental|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
32861975|NCT04420728|Active Comparator|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
32861976|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
32861977|NCT04957446|Experimental|Group 1|Subjects will receive 3 treatments of 1mL Poly-L-Lactic Acid (Sculptra Aesthetic)
32861978|NCT04957446|Placebo Comparator|Group 2|Subjects will receive 3 treatments of 1mL Saline solution.
32861979|NCT04939896||Compliance with rehabilitation|The patients' compliance with rehabilitation was followed up at 2, 6, 8, 12 and 24 weeks after onset, respectively
32861980|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
32861981|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
32861982|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
32861983|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
32861984|NCT02431507|Experimental|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
32861985|NCT04957680|Experimental|computer-based cognitive behavioral therapy|
32861986|NCT04957680|Active Comparator|online stress management program|
32861987|NCT04957680|No Intervention|waitlist|
32861988|NCT01459471|Experimental|bleeding, leak, operative time|
32970961|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
32970962|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
32970963|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
32970964|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
32970965|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
32970966|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
32970967|NCT03806088||patients of chronic kidney disease|no interventions
32970968|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
32970969|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
33410962|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
33410963|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
32970970|NCT03805776|No Intervention|Control|
32970971|NCT03805620|Active Comparator|Phys Group|physical training group
32970972|NCT03805620|Active Comparator|Cog Group|cognitive training group
32970973|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
32970974|NCT03805620|No Intervention|Con Group|educational control group
32970975|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
32970976|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
32970977|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
32970978|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
32970979|NCT03804840|Placebo Comparator|Placebo|
32970980|NCT03804840|Active Comparator|7.5 mg THC|
32970981|NCT03804840|Active Comparator|15 mg THC|
32970982|NCT03804762|Experimental|patients received treatment of TS-RECS|
32970983|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
32970984|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
32970985|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
33033074|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
33033075|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
33033076|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
33033077|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
33033078|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
33033079|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
33033080|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
33033081|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
33033082|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
33410964|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
32970986|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
32970987|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
32970988|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
32970989|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
32970990|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
32970991|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
32970992|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
32970993|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
32970994|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
32970995|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
32970996|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan~1 tablet before renography"
32970997|NCT03803124|Placebo Comparator|Placebo|"Placebo~1 tablet before renography"
32970998|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
32970999|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
32971000|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
32971001|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
32971002|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
32971003|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
32971004|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
32971005|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
32971006|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17 : IV bolus injection twice a week~V18 to V33 : IV bolus injection once a week"
32971007|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17: IV bolus injection twice a week~V18 to V33: IV bolus injection once a week"
32971008|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
32971009|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
32971010|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
32971011|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
32971012|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
32971013|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
32971014|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
32971015|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
32971016|NCT03801018||Parents who have used the donation of gametes|
32971017|NCT03801018||Children born of gametes donation|
32971018|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
32971019|NCT03801096|Active Comparator|Health Education (HE)|
32971020|NCT03800706|Experimental|TQB2450|
32971021|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
32971022|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
32971023|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
32971024|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
32971025|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
32971026|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
32971027|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
32971028|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
32971029|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
32971030|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
32971031|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
32971032|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
32971033|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
32971034|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
32971035|NCT03808272|Experimental|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
32971036|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
32971037|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
32971038|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
32971039|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
32971040|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
32971041|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
32971042|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
32971043|NCT03803202|Experimental|Stage 1, Group 1 ASP3772 in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
32971044|NCT03803202|Active Comparator|Stage 1, Group 1 PCV13 in Adults|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
32971045|NCT03803202|Experimental|Stage 2, Group 2 ASP3772 in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
32971046|NCT03803202|Active Comparator|Stage 2, Group 2 PCV13 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
32971047|NCT03803202|Active Comparator|Stage 2, Group 3 PPSV23 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
33322463|NCT05062200|Experimental|Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])|Chinese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 3 of Part 2.
32971048|NCT03805698|Experimental|Platelet-rich Plasma (PRP) group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will be treated intraoperatively with platelet-rich plasma (PRP) (24 subjects).~Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the platelet-rich plasma (PRP)is injected into the debrided wrist"
32971049|NCT03805698|Active Comparator|Standard Treatment group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will undergo treatment, as is standard of care, followed by no treatment with platelet-rich plasma (PRP)(24 subjects).~Intervention: No platelet-rich plasma (PRP) injection into debrided wrist"
32971050|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases (normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal and reliable standard automatic perimetry, and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
32971051|NCT03804684|Experimental|Mild and Moderate Glaucoma|Subjects between 21 and 80 years of age with Mild or Moderate Glaucoma. Eyes will have a reliable standard automatic perimetry with no more than -6 mean deviation (Mild) and between -6 mean and -12 mean deviation (Moderate). Spherical refraction will be less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
32971052|NCT05318430|Experimental|Experimental group|the closed-suction drainage device will be placed subcutaneously when closing the incision
32971053|NCT05318430|No Intervention|Control group|the closed-suction drainage device will not be placed subcutaneously when closing the incision
32971054|NCT05311956|Experimental|Experimental|Patients will receive tDCS delivered over the motor cortex, at an intensity of 2mA, delivered for 20 minutes 5 times each week over eight consecutive weeks (40 applications in total).
32971055|NCT05311956|Sham Comparator|Sham Comparator|Sham treatment will consist of 30 seconds of the direct current at 2mA and 0 current for the remaining time of the 20-minute application 5 times per week over eight consecutive weeks (40 applications in total).
32971056|NCT05744154|Experimental|Audit & feedback with educational outreach and facilitation|The intervention includes: 1) refinement with end users, 2) an A&F report sent to local governing authorities presenting for each practice: performance compared to peers (simple A&F), a summary message indicating if action is required and a list of potential actions, 3) educational materials (a clinical vignette; consequences of the practice; links to practice guidelines, clinical decision rules and shared decision-making tools; a case review tool), 4) virtual educational meetings with the local trauma Medical Director, trauma program manager and data analyst, and 5) two virtual facilitation visits 2 and 4 months after the transmission of the report to support committees in preparing their action plan.
32971057|NCT05744154|Other|Simple audit & feedback|The control arm will receive the quality improvement intervention currently in place in the Québec Trauma Care Continuum (i.e. simple A&F report presenting their performance compared to peers on quality indicators measuring adherence to high-value care and risk-adjusted outcomes) with the addition of quality indicators on low-value care (already planned by provincial authorities for the 2023 evaluation cycle). Simple A&F was chosen for the control because it is standard practice in Québec and in most integrated trauma systems and the effectiveness of A&F for de-implementation has been documented.
32971058|NCT05743920|Experimental|Self-help Forest Bathing Group|Participants in the FB group will perform forest bathing activity at the Chinese University of Hong Kong for two session.
32971059|NCT05743920|Other|Wait List Group|
32971060|NCT05743764|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
32971061|NCT05743764|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
32971062|NCT05743764|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
32971063|NCT05743608||Moderate to severe COPD patients receiving Trimbow dry powder inhaler|Patients above the age of 35 years, who had been diagnosed with COPD for over a year by a pulmonologists specialist. Having a moderate or severe obstruction (30%≤FEV1<80%) and are uncontrolled despite fixed dual combination treatment (LABA/LAMA or ICS/LABA). Therapy was changed to Trimbow® 88/5/9 µg inhalation powder maximum 1 week prior to or on the day of study inclusion and irrespective of study entry (escalation of symptomatic patient to fixed triple combination as per treatment protocol)
32971064|NCT05743530|Experimental|TENS - transcutaneous electrical nerve stimulation|
32971065|NCT05743530|Placebo Comparator|Placebo|
32971066|NCT05743452|Experimental|CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
32971067|NCT05743218|Experimental|liver meridian group|Four acupoints; LR3 Taichong, LR5 Ligou, LR8 Ququan, and LR12 Jiman. Based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be in a supine position. Taichong will be punctured at a 25-mm depth using a 0.35×25-mm filiform needle, Ligou will be punctured at a 15-20-mm depth with a 0.35×25-mm filiform needle, Ququan at a 20-25-mm depth with a 0.30×40-mm filiform needle, and an acute pulse of 15-20 mm. Each acupoint will be subject to a small amount of uniform lifting and twisting to the degree of local acid distension. An auxiliary needle (0.16×13 mm) will be inserted approximately 5 mm into the needle, 2 mm proximal to the heart of each acupoint along the meridian. The negative electrode will be connected to the main point, and the positive electrode will be connected to the auxiliary needle, and connect the electroacupuncture instrument. The needles will be retained for 30 min respectively, once every other day, 36 treatments.
33033083|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
33410965|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
32971068|NCT05743218|Active Comparator|stomach meridian group|Four acupoints have been selected for the gastric meridian group, including ST42 Chongyang, ST40 Fenglong, ST36 Zusanli, and ST31 Biguan. The acupoint locations are based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be supine during the procedure, and the needles will be routinely sterilized. Straight needling will be performed in the hip region using a 0.30×50-mm-filiform needle, a 0.30×50-mm filiform needle in Zusanli, and a 0.30×40-mm filiform needle in Fenglong. A 0.35×25-mm filiform needle will be used to stimulate Chongyang for 10-15 mm, and each acupoint will be gently and evenly lifted, inserted, and twisted to local acid distension. Electroacupuncture will be applied in the same manner as for the liver meridian group. The needles will be retained for 30 min respectively, once every other day, then thrice weekly for a total of 36 treatments in the three groups.
32971069|NCT05743218|Placebo Comparator|non-acupoint acupuncture group|Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
33410966|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
32971071|NCT05742984|Experimental|25 mg Linaprazan Glurate QD|25 mg ( one 25 mg oral tablet) Linaprazan Glurate QD for 14 days
32971072|NCT05742984|Experimental|50 mg Linaprazan Glurate QD|50 mg (two 25 mg oral tablets) Linaprazan Glurate QD for 14 days
32971073|NCT05742984|Experimental|75 mg Linaprazan Glurate QD|75 mg ( three 25 mg oral tablet) Linaprazan Glurate QD for 14 days
32971074|NCT05742984|Experimental|25 mg Linaprazan Glurate BID|25 mg ( one 25mg oral tablet) Linaprazan Glurate BID for 14 days
32971075|NCT05742984|Experimental|50 mg Linaprazan Glurate BID|50 mg ( two 25 mg oral tablets) Linaprazan Glurate BID for 14 days
32971076|NCT05742984|Experimental|75 mg Linaprazan Glurate BID|75 mg ( three 25 mg oral tablet) Linaprazan Glurate BID for 14 days
32971077|NCT05742906|Other|Group A: Adults treated with SIS 1.0 Cor TRICUSPID ECM Valve|Adults (>/= 21 years of age) treated with the SIS 1.0 Cor TRICUSPID ECM Valve
32971078|NCT05742906|Other|Group B: Pediatrics treated with SIS 1.0 Cor TRICUSPID ECM Valve|Pediatrics (<21 years of age) treated with SIS 1.0 Cor TRICUSPID ECM Valve
32971079|NCT05742906|Other|Group C: Adults treated with SIS 2.0 Cor TRICUSPID ECM Valve|Adults (>/= 21 years of age) treated with the SIS 2.0 Cor TRICUSPID ECM Valve
32971080|NCT05742906|Other|Group D: Pediatrics treated with SIS 2.0 Cor TRICUSPID ECM Valve|Pediatrics (<21 years of age) treated with SIS 2.0 Cor TRICUSPID ECM Valve
32971081|NCT05742828|Active Comparator|Virtual Seating Coach|The Virtual Seating Coach is a context-aware reminding system that when set up by a clinician, directly benefits a user by reminding him or her to change position with the chair's power seating function.. Regular position changes increase independent function, reduce the risk of pressure ulcers, manage pain, and reduce swelling.
32971082|NCT05742828|No Intervention|Non Virtual Seating Coach|power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain.
32971083|NCT05742750|Experimental|Camrelizumab + apatinib and chemotherapies (gemcitabine and cisplatin)|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
32971084|NCT05742672|Experimental|Massage|In the experimental group, twice a day, in the morning and evening, and 30 minutes after the meal, for 15 minutes. Effusion, petrissage and vibration massage movements will be applied by the researcher for a certain period of time in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.
32971085|NCT05742516|Experimental|GOS|Galactooligosaccharide consumption through the prebiotic product Bimuno.
32971086|NCT05742516|Placebo Comparator|Placebo|Maltodextrin powder
32971087|NCT05742360||OSA subjects with the excessively sleepy symptom subtype treated with CPAP|Patients with the excessively sleepy symptom subtype who accept CPAP therapy
32971088|NCT05740878|Experimental|immunonutrients ONS|the intervention group received ONS which contained immunonutrients (omega 3 and anthocyanin)
32971089|NCT05740878|Active Comparator|standard ONS|the control group received standard ONS (isocaloric)
32971090|NCT05740332|Experimental|All participants|1 mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.
32971091|NCT05738850|Experimental|Part 1: ABBV-932|Participants will receive ABBV-932 on Day 1 and followed for 30 days.
32971092|NCT05738850|Placebo Comparator|Part 1: Placebo|Participants will receive placebo on Day 1 and followed for 30 days.
32971093|NCT05738850|Experimental|Part 2: Sequence 1|Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.
32971094|NCT05738850|Experimental|Part 2: Sequence 2|Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.
32971095|NCT05738850|Experimental|Part 3: Japanese Participants: ABBV-932|Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.
32971096|NCT05738850|Placebo Comparator|Part 3: Japanese Participants: Placebo|Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
32971097|NCT05738850|Experimental|Part 3: Han-Chinese Participants: ABBV-932|Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
33322464|NCT05062200|Experimental|Cohort 4: JNJ-77242113 or Placebo (SD)|Japanese participants will receive single oral dose 3 of JNJ-77242113 (delayed-release [DR] tablet) with absorption enhancer (AbE) or matching placebo on Day 1 in Cohort 4 of Part 3.
32971098|NCT05737992|Experimental|Exercise group|Patients in the intervention group will do high intensity interval training (HIIT) in water. In this study, HIIT training will be short intervals (30 seconds) of movements and 15 seconds of rest.Exercises will be done in a floating position in the deep part. The intervention will be done 3 sessions weekly. The length will be 8 weeks.
32971099|NCT05737992|No Intervention|Control group|The patients will continue their usual medication and their usual physical activity.
32971100|NCT05673096|Experimental|PACT + Management as usual|"PACT + management (MAU - see comparator intervention). PACT is a parent-mediated and video-aided intervention designed to improve socio-communicative functioning in children with ASD. The intervention is based on theory and research on pre-linguistic and early social interaction and language development. The programme focuses on changing the interaction in the parent-child dyad in order to enhance communication and language development and skills in children with ASD.~The overall focus of the intervention is to guide parents to provide a sensitive, highly adapted interaction context in which their own responses and language are matched to the child's communication competence and language comprehension. Parents learn to identify windows of opportunity to facilitate joint interactions, enhance emerging communication, elicit child intentionality and support language comprehension, thereby aiming to ameliorate abnormal developmental pathways."
32971101|NCT05673096|Active Comparator|Management as usual|"Enhanced management as usual (MAU). MAU is delivered by the regional Child and Adolescent Mental Health Center (CAMHS). All participants will have equal access to seek advice via a telephone hotline in the trial period (12 months).~Following the diagnosis of ASD, the parents will be offered psychoeducation as usual in the local CAMHS. A telephone hotline open to all participants will offer pedagogical advice and try to help the parents to collaborate and engage with their professional partners in the municipality. The parents will also be able to contact the CAMHS when needed. The hotline team will be able to consult with the responsible clinician at the CAMHS. The clinician should always be notified within the same day, if a parent describes acute worsening of the child's condition, risk of suicidality, or severe aggression. The responsible clinician will be able to refer the child to further assessment and treatment within the CAMHS without any significant delay."
32971102|NCT05650320|Experimental|0.3% OPA-15406 Ointment|The 0.3% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
32971103|NCT05650320|Experimental|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
32971104|NCT05650320|Placebo Comparator|0% OPA-15406 Vehicle|The 0% formulation of OPA-15406 venicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
32971105|NCT05604066|Experimental|Patients with myofascial-related pain diseases|Subjects diagnosed with myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
32971106|NCT05604066|Experimental|Healthy controls without myofascial-related pain diseases|Subjects without myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
32971107|NCT05561400|Active Comparator|Real tDCS|the participant receives real tDCS to the right cerebellum during behavioral intervention (CILT)
32971108|NCT05561400|Placebo Comparator|Sham tDCS|the participant receives sham tDCS to the right cerebellum during behavioral intervention (CILT)
32971109|NCT05558124|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CPX-351 in combination with Gemtuzumab Ozogamicin in participants with newly diagnosed acute myeloid leukemia. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
32971110|NCT05557266|Experimental|Mindfulness-based intervention (MBI)|A 8-week mindfulness-based intervention. From 15 to 30 minutes of practice per session, three times/week through audio guided meditations.
32971111|NCT05557266|Active Comparator|Physical exercise (PE)|A 8-week physical exercise intervention. From 15 to 30 minutes of practice per session, three times/week through workout videos.
32971112|NCT05557266|No Intervention|Wait list (WL)|The participants will continue their work activity as usual. This arm will be invited to a mindfulness training once the study finished.
32971113|NCT05543928|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|
32971114|NCT05543928|Experimental|Cohort 1 and Cohort 2 CTAP101 Capsule|
32971115|NCT05536752|Experimental|QA102 200mg group|Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 24 months
32971116|NCT05536752|Experimental|QA102 400mg group|Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 24 months
32971117|NCT05536752|Placebo Comparator|Placebo group|Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 24 months
32971118|NCT05528562|Experimental|PrEP Rapid Access|Participants who are at risk of HIV and being seen at the Victory Program's Mobile Prevention Services Van.
32971119|NCT05502978|Experimental|Intervention group|The intervention group is third trimester pregnant women with 37 weeks of gestation who received blended education. Blended education is provided by cadres and nutritionists, both online and offline. Education consists of online assistance with digital booklets, videos via WhatsApp by cadres and consultation with nutritionists as well as home visits (offline/face-to-face) by cadres and the research team. One education is done during the third trimester at 37 weeks of gestation, second education is done at 38 weeks' gestation, the third education is done when the baby is 3 months old, all three of which are done online. Mother will be visited every month by cadres and the research team from birth to 7 month old. Consultation with a nutritionist is carried out via WhatsApp calls at critical times the failure rate in IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months
33410967|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
33410968|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
32971120|NCT05497284|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 26 weeks
32971121|NCT05497284|Experimental|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 26 weeks
32971122|NCT05481684|Experimental|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
32971123|NCT05481684|Active Comparator|Low Progesterone group|Progesterone level <10 ng/mL on ET day. Grup a Rescue vaginal progesterone, Grup b Rescue subcutan progesterone
32971124|NCT05441124|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
32971125|NCT05441124|No Intervention|Control|Control
32971126|NCT05435742|Experimental|SON-080 Dose Level 1|20 µg SON-080 SC administration TIW
32971127|NCT05435742|Experimental|SON-080 Dose Level 2|60 µg SON-080 SC administration TIW
32971128|NCT05435742|Placebo Comparator|Matching Placebo|Matching placebo 20 µg SON-080 SC administration TIW
32971129|NCT05421624|Experimental|Amped-PD|6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.
32971130|NCT05421624|Active Comparator|Active-Control|6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.
33322465|NCT04734080|Experimental|Dronabinol|55 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of 5 mg of Dronabinol beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
33322466|NCT04734080|Placebo Comparator|Placebo|55 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of a non-active placebo pill beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
32971133|NCT05347992||Standard of Care|Cohort(1) of the study will collect longitudinal blood samples from participants who are on the standard of care treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
32971134|NCT05347992||Biologics|Cohort(2) of the study will collect longitudinal blood samples from participants who are on biologics treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
32971135|NCT05343468|Experimental|Experimental|Singe-arm: the assistive digital software was implemented as an intervention to all participants.
32971136|NCT05338398|Placebo Comparator|Control Group (Group 1): Standard Therapy|"Group 1 will receive standard therapy with conventional oral care to prevent oral mucositis consisting of oral hygiene and rinses/mouthwashes with saline solutions 3-5 times daily.~Half of the subjects in Group 1 will also receive Bocaliner™ devices"
32971137|NCT05338398|Experimental|Intervention Group (Group 2): Benzydamine mouthwash|Group 2 will receive benzydamine mouthwashes 3-5 times daily. Half of the subjects in Group 1 will also receive Bocaliner™ devices.
32971138|NCT05311800|Experimental|High intensity interval training - BIKE (HIIE BIKE)|10 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (37min30s)
32971139|NCT05311800|Experimental|High intensity interval training - RUN (HIIE RUN)|9 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (35min15s)
32971140|NCT05248386|Experimental|RTX-GRT7039|Participants will receive 2 intra-articular injections of RTX-GRT7039 during the 52-week double-blind treatment period.
32971141|NCT05248386|Placebo Comparator|Placebo|Participants will receive 2 intra-articular injections of placebo matching to RTX-GRT7039 during the 52-week double-blind treatment period.
32971142|NCT05245500|Experimental|Phase 1/1B|Dose Escalation/Evaluation
32971143|NCT05245500|Experimental|Phase 2|MRTX1719 RP2D administered to separate cohorts of patients with selected solid tumor malignancies with MTAP homozygous deletion to include the following: Mesothelioma, Pancreatic Adenocarcinoma, NSCLC, Malignant Peripheral Nerve Sheath Tumor, Other Solid Tumors
33410969|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
32971145|NCT05130840|Experimental|Stage IV HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
32971146|NCT05130840|Experimental|Stage II-III HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
32971147|NCT05119296|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab (Keytruda) 200 mg administered by IV infusion every 3 weeks. Participants will remain on study and receive pembrolizumab for the nominal duration of treatment (35 cycles, approximately 2 years) or until there is evidence of disease progression by RECIST, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason.
32971148|NCT05045898|Experimental|Control group|plantar massage
32971149|NCT05045898|Experimental|Intervention group|plantar massage and textured insoles
32971150|NCT04876950|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-2 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take would photos during the 30 days after randomization. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
32971151|NCT04876950|No Intervention|Standard Care|Standard post-surgical care.
33322467|NCT01358500|Experimental|Fentanyl|
32971152|NCT04853472||Early Stage Peri-Menopause|Mild cycle irregularity over the last 3-6months (minimum), variation of >6 days in length between consecutive cycles including shortened and longer cycles (but not >60 days in length)
32971153|NCT04853472||Late Stage Peri-Menopause|Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea >60 days in length (but less than 12 months)
32971154|NCT04853472||Post-Menopause|Greater than 12 months since last menstrual period
32971155|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
33322468|NCT05013450|Experimental|Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab will be administered
32971156|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
32971157|NCT04741074|Active Comparator|Semaglutide|This arm will receive semaglutide.
32971158|NCT04741074|Placebo Comparator|Placebo|This arm will receive placebo.
32971159|NCT04713228|Experimental|Pregnant with Pre-eclampsia|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
32971160|NCT04713228|Experimental|Pregnant with gestational hypertension|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
32971161|NCT04713228|Active Comparator|Pregnant without Hypertension - Control|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
32971162|NCT04699188|Experimental|Arm A|JDQ443
32971163|NCT04699188|Experimental|Arm B|JDQ443 in combination with TNO155
32971164|NCT04699188|Experimental|Arm C|JDQ443 in combination with tislelizumab
32971165|NCT04699188|Experimental|Arm D|JDQ443 in combination with TNO155 and tislelizumab
32971166|NCT04601454|Experimental|Spinal Cord Stimulation|Enrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters.
32971167|NCT04581408|Experimental|Orkambi|"Generic name: Lumacaftor/Ivacaftor~Dosage form: tablet~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor~Frequency: two tablets twice a day."
32971168|NCT04544748|Other|Cohort 1|GNR-051 (0.1 mg/kg)
32971169|NCT04544748|Other|Cohort 2|GNR-051 (0.3 mg/kg)
32971170|NCT04544748|Other|Cohort 3|GNR-051 (1 mg/kg)
32971171|NCT04544748|Other|Cohort 4|GNR-051 (3 mg/kg)
32971172|NCT04544748|Other|Cohort 5|GNR-051 (10 mg/kg)
32971173|NCT04509726|Experimental|EBV TCR-T|
32971174|NCT04446078|Experimental|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
32971175|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
32971176|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
32971177|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
32971178|NCT04384302|Experimental|Visual training|"Pre-specidied visual training methods that use: the Marsden ball, tables that uses green-red visual stimuli, physical reation in response to the visual stimuli that uses the flippers or the preselected distances.~One set of exercises per week was prepared.~Each visual training will last for 15 minutes and should be performed by the participant in their home (using the telemedicine devices to control the conduction of each exercise) 3 times a week."
32971179|NCT04295772|Experimental|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
32971180|NCT04236882|Experimental|Focus group and interview (focus group, interview)|Participants attend either a focus group or interview about the sleep intervention and sleep-related problems over 90 minutes.
33410970|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
32971181|NCT04236882|Experimental|Group I (sleep intervention, health coaching session)|Participants receive a web-based sleep intervention weekly during weeks 1-4. Participants then receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
32971182|NCT04236882|Experimental|Group II (health coaching session, sleep intervention)|Participants receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 1-4. Participants then receive a web-based sleep intervention weekly during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
32971183|NCT04236882|Active Comparator|Group III (health education material, counseling session)|Participants receive educational material on healthy homes. Participants also receive 2 web-based counseling sessions over 30-45 minutes consisting of topics such as indoor air quality, CPR and first aid, and emergency preparedness at weeks 1 and 3. Participants may optionally complete an interview over 1 hour at week 9.
32971184|NCT04218084|Experimental|Voxelotor|Voxelotor 1500mg or equivalent daily as a tablet, dispersible tablet, or as powder for oral suspension.
32971185|NCT04218084|Placebo Comparator|Placebo|Matching placebo.
32971186|NCT04209660|Experimental|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
32971187|NCT04209660|Experimental|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
32971188|NCT04188912||Observational (sample collection, survey, imaging, spirometry)|Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.
32971189|NCT04188678|Other|Interventional Arm- Bone Marrow Transplant|"Study visits will include the performance of assessments prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. Assessments include:~Physical function assessments~questionnaires about general health and current health compared to health one year ago~assessments that measure cognition, attention and memory~assessments regarding personality and psychological and social stressors~Physiological measures including~blood tests- 160 mL of blood during evaluations, and 90mL of blood at the day 180 visit.~bone marrow aspirate collected during standard of care bone marrow biopsies pre-transplant and at day 180~Saliva collections pre-transplant~ACTH Stimulation Test~Oral Glucose Tolerance Test~Holter Monitor- to record hear rate variability~MRI pre-transplant and at Day 180 in a subset of 10 subjects"
32971190|NCT04160286||ECT|Group of patients receiving ECT during their hospitalization.
32971191|NCT04160286||Non-ECT|Group of patients not receiving ECT during their hospitalization.
32971192|NCT04151940||Observational (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
32971193|NCT04148430|Experimental|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
32971194|NCT04122456|Experimental|Day Shift Work Schedule|Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
32971195|NCT04122456|Experimental|Night Shift Work Schedule|Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
32971196|NCT04096638|Experimental|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses
32971197|NCT04096638|Experimental|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses plus 1680mg every 4 weeks (Q4W) atezolizumab
32971198|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
32971199|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
32971200|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
33410971|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
33410972|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
33410973|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
33410974|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
32971203|NCT04064424|Experimental|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
32971204|NCT04064424|Active Comparator|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
32971205|NCT03888066|Experimental|Group 1: Patiromer|Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
32971206|NCT03888066|Placebo Comparator|Group 2: Placebo|Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.
32971207|NCT03655236|Experimental|K0706, low dose|
32971208|NCT03655236|Experimental|K0706, high dose|
32971209|NCT03655236|Placebo Comparator|Placebo|
32971210|NCT03620058|Experimental|CART22-65s monotherapy|
32971211|NCT03620058|Experimental|CART22-65s in combination with huCART19|
32971212|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
32971213|NCT03467256|Experimental|experimental|Patients will receive lymphodepleting chemotherapy, one hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV on day 0.
32971214|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
32971215|NCT03326388|Experimental|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
32971216|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~Two dose levels of ADXS-NEO will be explored: 1 x 10^9 and 1 x 10^8 colony forming unit (CFU)."
32971217|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored (i.e., 1 x 10^8 and 5 x 10^8 CFU) in combination with 200 mg of pembrolizumab.
32971218|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10^8 CFU in combination with 200 mg of pembrolizumab in an expansion cohort.
32971219|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
32971221|NCT03198078|Experimental|Brexpiprazole (OPC-34712)|2-4 mg/day; Start at 0.5 mg/day, titrate to max of 4 mg/day
32971222|NCT03198078|Active Comparator|Aripiprazole|10-20 mg/day; Start at 2 mg per day, titrate up to max of 20 mg/day
32971223|NCT03198078|Placebo Comparator|Placebo|Matching placebo, daily
32971224|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer (HOPE)|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention~All participants will receive :~HOPE App~The Fitbit Zip~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
32971225|NCT03022032|Other|Usual care (HOPE)|"Stage 2 will consist of arm 2-5 and will enroll 100 randomized patients.~Usual care~The app will also collect passive data from the smartphone"
32971226|NCT03022032|Experimental|Wearable accelerometer (HOPE)|"Participants will be asked to wear the Fitbit~The Hope App will measure daily steps~The app will also collect passive data from the smartphone"
32971227|NCT03022032|Experimental|Refined smartphone app (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~The app will also collect passive data from the smartphone"
32971228|NCT03022032|Experimental|Refined smartphone app and accelerometer (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~Participants will be asked to wear the Fitbit~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
32971229|NCT03022032|Experimental|SMART Study Arm|"Two smartphone apps and a wearable accelerometer (Fitbit) in 30 patients with gynecologic cancers receiving chemotherapy at two NCI Community Oncology sites.~The SMART intervention refers to the combination of both smartphone apps (SMART app and Beiwe app) and the accelerometer (Fitbit).~The SMART app is the technology that is actively collecting symptom reporting information from patients (e.g. patients are receiving surveys, recording their symptoms daily, and receiving tailored symptom management materials on their phone in response).~The Beiwe app is the technology involved in the passive data collection of participants' symptoms (GPS and accelerometer data) without their involvement."
32971230|NCT03017820|Experimental|Group A (low tumor burden) (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
33410975|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
32971231|NCT03017820|Experimental|Group B (high tumor burden) (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
32971232|NCT03017820|Experimental|Group C (VSV-IFNbeta-NIS and cyclophosphamide)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and cyclophosphamide IV over 30 minutes on day 2. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
33410976|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
32861989|NCT04948008|Experimental|Treatment group 1|The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
32861990|NCT04948008|Experimental|Treatment group 2|The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
32861991|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
32861992|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
32861993|NCT04939974|Active Comparator|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
32861994|NCT04939974|Placebo Comparator|placebo|Placebo packet same in colour, smell and constituent to that of placebo one packet daily for 24 weeks
32861995|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
32861996|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
32861997|NCT04957212|Experimental|TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; pertuzumab® (CinnaGen Co.) is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
32861998|NCT04957212|Active Comparator|TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; Perjeta® is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
32861999|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
32862000|NCT02473315|Experimental|cryotherapy|
32862001|NCT02473315|Placebo Comparator|light cryotherapy|
32862002|NCT04939194|Experimental|Fast Track Protocol|the 22 items of ERAS (Early Recovery After Surgery) society
32862003|NCT04939194|No Intervention|Conventional perioperative care program|standard perioperative care
32862004|NCT04390789|Experimental|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
32862005|NCT04390789|Active Comparator|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
32862006|NCT04947774||prophylactic cranial irradiation group|The extensive-stage SCLC patients will receive prophylactic cranial irradiation after standard first-line chemotherapy combined with immunotherapy, until disease progression or death.
32862007|NCT04947774||Observation group|Patients with extensive-stage SCLC do not receive preventive craniocerebral irradiation after standard first-line chemotherapy combined with immunotherapy until the disease progresses or death.
32862008|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
32862009|NCT04948164|Experimental|Test group|
32862010|NCT04948164|Placebo Comparator|Control group|
32862011|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
32862012|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
32862013|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
32862014|NCT04947696||1|Patients undergoing a Whipples procedure for pancreatic cancer
32862015|NCT04957056||Study object|A young patient hospitalized in the Department of Neurosurgery of the Third Hospital of Beijing University of Medicine underwent CT examination of cervical vertebrae. The patient had no cervical bony deformity, no cervical degeneration, and no history of trauma
32862016|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
32862017|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
32862018|NCT04947228|Experimental|intervention group|in addition to the usual therapy, the patients were given access to the trackPAD app
32862019|NCT04947228|No Intervention|control group|patients in this group were treated as usual in the clinic without additional interventions.
32862020|NCT04413162|Other|measurement before and after capsular distention|
32862021|NCT04947306||All subjects|"Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia at our Institution in which the administration of rocuronium for neuromuscular blockade is anticipated.~All participants will be monitored with both TOF Watch and Tetragraph neuromuscular monitors."
32862022|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
32862023|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
32862024|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
32862025|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
32971233|NCT03017820|Experimental|Group D (MM only, VSV-IFNbeta-NIS and Ipilimumab an nivolumab)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ipilimumab and nivolumab IV over 30 minutes on day -3. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
32971234|NCT03017820|Experimental|Group E (PTCL only, VSV-IFNbeta-NIS Ipilimumab and Nivolumab)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ipilimumab and nivolumab IV over 30 minutes on day -3. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
32971235|NCT03017820|Experimental|Group F (BCL)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
32971236|NCT03017820|Experimental|Group G (PTCL)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
32971237|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
32971238|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32971239|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32971240|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32971241|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32971242|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
32971243|NCT02458014|Experimental|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
32971244|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
32971245|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
32971246|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
32971247|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
32971248|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
32971249|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
32971250|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
32971251|NCT02017704|Active Comparator|IMRT and Capecitabine|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
32971252|NCT02017704|Experimental|Endo-HDR|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
33322469|NCT05225870|Other|patients with colorectal carcinoma|patients with colorectal carcinoma will undergo colectomy. their colectomy specimens will be sectioned, tissue blocks will be prepared from tumor and adjacent normal mucosa. sections will be stained immunohistochemically by antibody against cortactin.
32971255|NCT01733082||Cohort|
32971256|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
32971257|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
32971258|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
32971259|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
32971260|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
32971261|NCT05310084|Experimental|Coadministration Group|BNT162b2 and SIIV followed by placebo a month later
32971262|NCT05310084|Experimental|Separate Administration Group|Placebo and SIIV followed by BNT162b2 a month later
32971263|NCT05310006|Experimental|High Speed Resistance Exercise (HSRE)|Exercise sessions performed using eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s.
32971264|NCT05310006|Experimental|Traditional Resistance Exercise (TRE)|Exercise sessions were performed using four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s.
33322470|NCT03724942|Experimental|Brexpiprazole|
33322471|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
33322472|NCT04660526|Experimental|Intervention (Enhanced Standard of Care)|Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
33322473|NCT04660526|No Intervention|Control (Standard of Care)|Usual care, continuing standard quality improvement effort
33322474|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
33322475|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
33322476|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
33322477|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
33322478|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
33322479|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
33322480|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
32746721|NCT05611749|Placebo Comparator|control group receiving a placebo|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
32862026|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
32862027|NCT04411914|Experimental|Clavulanic Acid|9 Participants will receive 500 mg of CLAV at baseline. Subjects who can tolerate 500 mg/day for 3 days (or matched placebo) will have a dose escalation to 750 mg/day for 3 days. Subjects who can tolerate 750mg/day for three days will have a dose escalation to 1000mg for 4 days.
32862028|NCT04411914|Placebo Comparator|Placebo|"3 participants will receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
32862029|NCT04411836|No Intervention|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
32862030|NCT04411836|Experimental|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
32862031|NCT04411836|Experimental|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
32862032|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
32862033|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
32862034|NCT04946838|Experimental|TENS|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
32862035|NCT04946838|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
32862036|NCT04946682|Experimental|Group of mNGS|
32862037|NCT04946682|Experimental|Group of PCR|
32862038|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
32862039|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
32862040|NCT04431492||coronary artery bypass|
32862041|NCT04431492||thoracic surgery|
32862042|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
32862043|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
32862044|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
32862045|NCT01892761||TCL/MMF Group|
32862046|NCT01892761||CyA/MMF Group|
32862047|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
32862048|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
32862049|NCT04956822||ALS|Amyotrophic lateral sclerosis group
32862050|NCT04956822||CMT|peroneal muscular dystrophy group
32862051|NCT04956822||KD|Kennedy's disease group
32862052|NCT04956822||Control|Healthy control group
32862053|NCT04351971|Experimental|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
32862054|NCT04351971|Sham Comparator|Placebo group|A placebo dorsal mobilization technique will be applied
32862055|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
32862056|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
33322481|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
32971265|NCT05310006|No Intervention|Control Session (CS)|Participants remained seated in a comfortable chair listening to music and/or talking with study investigators for approximately 30 min.
32971266|NCT05313282|Experimental|treatment group|combination of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX7) , targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
32971267|NCT05313282|Active Comparator|control group|combination of targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
32971268|NCT05316012|Experimental|Residents|5 residents - fase 1 Intervention device: smart diaper (diaper, sensor and strips, without alerting system) 15 residents, of which 5 residents of study phase 1 Intervention device: smart diaper (diaper, sensor and strips, with alerting system)
32971269|NCT05315622|Experimental|Intervention|Bilateral vertebral manipulation of the T12-L1 vertebra
32971270|NCT05315622|Placebo Comparator|Placebo|Application of slight manual tension to the vertebra without reaching a manipulation thrust
32971271|NCT05318274|Experimental|ARM I|Radiotherapy treatment with high hypofractionation, 26 Gy in 5 fractions to the whole breast.
32971272|NCT05318274|Active Comparator|ARM II|Radiotherapy treatment with standard hypofractionation, 42.5 Gy in 16 fractions with simultaneous integrated increase of 5.5 Gy to the tumor bed in high-risk patients.
32971273|NCT05317728|Experimental|BAL-FAIOL|BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)
32971274|NCT05317728|Active Comparator|Monofocal|Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)
32971275|NCT05312502|Experimental|Experimental: Birth Ball|In the second stage, the birth ball application was made and followed. Pregnant women with a vaginal opening of 4 cm admitted to the delivery room were instructed to sit on the delivery ball for a total of 30 minutes. A stopwatch clock was used to determine these 30 minutes. The pregnant woman was not asked to sit on the ball all the time, and she could take a break for rest or other needs. The birth ball, which is suitable for women's use, was preferred in 45 cm dimensions, and the pilates circle was used as a stabilizer. Under the supervision of the researcher, the pregnant women sat upright on the ball and began to rock back and forth. Meanwhile, the researcher held the pregnant woman's hand. In order for the pregnant woman not to lose her balance, the birth ball was placed on a pilates circle and she was supported by the researcher in making the movements.
32746722|NCT05611749|Experimental|treatment group receiving 60 mg Duloxetine|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
32746723|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
32971276|NCT05312502|No Intervention|Control|A routine care was performed.
32971277|NCT05312034|Experimental|Application of an antimicrobial stewardship program in ICUs|Application of an antimicrobial stewardship program in Brazilian ICUs using machine learning techniques and an educational model
32971278|NCT05311722|Experimental|Dexmedetomidine|Inj.dexmedetomidine 0.5mcg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
32971279|NCT05311722|Experimental|Ketamine|Inj.ketamine 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
32971280|NCT05311722|Experimental|Tramadol|Inj.tramadol 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
32971281|NCT05311644||Included|All participants that cesed VIT between 2005 and 2019, and did not withdraw his consent to participate to the study.
32971282|NCT05311488||Symptomatic TTRv|Patients with known TTR mutations and neuropathy
32971283|NCT05311488||Asymptomatic TTRv|Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease
32971284|NCT05311488||Healthy controls|Age and sex matched healthy controls without neuropathy or other neurological disorder.
32971285|NCT05311254|Experimental|Fosfomycin|Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.
32971286|NCT05311254|Active Comparator|Ciprofloxacin|Oral ciprofloxacin, tablets containing 500 mg of active drug.
32971287|NCT05314062|Active Comparator|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
32971288|NCT05314062|Experimental|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
32971289|NCT05317884|No Intervention|No Contact|No reminder sent
32971290|NCT05317884|Experimental|Reminder|Reminder email with contact information to set an appointment will be sent 12 weeks before the appointment.
32971291|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
32971292|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
32971293|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
32746724|NCT04813185|No Intervention|Treatment as usual|Adults who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
32971294|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
32971295|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
32971296|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
32971297|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
32971298|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
32971299|NCT03219996||non-survivor group|
32971300|NCT03219996||survivor group|
32971301|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
32971302|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
32971303|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
32971304|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
32971305|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
32971306|NCT03219060|Experimental|Intervention group|MI based four individual sessions
33410977|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
33410978|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
33410979|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
33410980|NCT04337255|Active Comparator|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
33410981|NCT04337255|Placebo Comparator|Usual care diet intervention|3 year Intervention of usual care diet + counseling
33410982|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
33410983|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
33410984|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
33410985|NCT05571995|Experimental|Intervention|The intervention group will receive TRIMOSH
33410986|NCT05571995|No Intervention|Control|The control group will receive no intervention.
33410987|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
33410988|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
33410989|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
33410990|NCT03247517|Placebo Comparator|Placebo|Placebo, qd, oral capsule
33410991|NCT03247517|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
33410992|NCT03247517|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
32971307|NCT03219060|Active Comparator|Control group|Brief advice following 5As
33410993|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
33410994|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
33410995|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
33410996|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
33410997|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
33410998|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
33410999|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
33411000|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
33411001|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
32971308|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
32971309|NCT03218436|No Intervention|Control cohort|no intervention
32971310|NCT03218280|Active Comparator|Antioxidant Therapy|
32971311|NCT03218280|No Intervention|Antioxidant Free|
32971312|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
32971313|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
32971314|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
32971315|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
32971316|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
32971317|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
32971318|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
32971319|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
32971320|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
32971321|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
32971322|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~At least 18 years old"
32971323|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~At least 18 years old"
32971324|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
32971325|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
32971326|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
32971327|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
32971328|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
32971329|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
32971330|NCT03215862|Active Comparator|Control|
32971331|NCT03215862|Experimental|Experimental|
32971332|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
32971333|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
32971334|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
32971335|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
32971336|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
32971337|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
32971338|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
32971339|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
32971340|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
32971341|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
32971342|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
32971343|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
32971344|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
32971345|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
32971346|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
32971347|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
32971348|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
32971349|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
32971350|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
32971351|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
32971352|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
32971353|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
32971354|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
32971355|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
32971356|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
32971357|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
32971358|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
32971359|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
32971360|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
32971361|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
32971362|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
32971363|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
32971364|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
32971365|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
32971366|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
32971367|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
32971368|NCT03212820|Experimental|Biologic drilling|drilling at low speed
32971369|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
32971370|NCT03212664|Other|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
32971371|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
32971372|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
32971373|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
32971374|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
32971375|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
32971376|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
33411002|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
32746725|NCT04813185|Experimental|In-hospital intervention|Adults randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 6-months of community case management and a firearm counseling program.
32971377|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
32971378|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
32971379|NCT03211884|Experimental|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
32971380|NCT03211884|No Intervention|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
32971381|NCT03211728|Experimental|experimental group|
32971382|NCT03211728|Placebo Comparator|placebo group|
32971383|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
32971384|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
32862057|NCT04937946|Experimental|Fentanyl|Fentanyl will be given within 24 hours from the initiation of mechanical ventilation at an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
32862058|NCT04937946|No Intervention|Placebo|Will receive continuous infusion of IV fluid up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
32862059|NCT05160987|Experimental|Remimazolam Group|The patients are administered with sedation of remimazolam and analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drug before enrollment, patient would be administered with a bolus of remimazolam with 0.1-0.3mg/kg intravenously in 1 minute for the first time. And maintenance dose is 0.25-0.1mg/kg/h, meanwhile the dose of remimazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
32862060|NCT05160987|Placebo Comparator|Midazolam Group|The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
32862061|NCT01892995|Experimental|Ketamine|active arm
32862062|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
32862063|NCT01892995|Placebo Comparator|Saline|placebo
32862064|NCT04938102|No Intervention|Abnormal DI - Control|Patients' whose distensibility index is measured <2.8 will receive no intervention.
32862065|NCT04938102|Active Comparator|Abnormal DI - Botox|Patients' whose distensibility index is measured <2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
32862066|NCT04938102|No Intervention|Normal DI - Control|Patients' whose distensibility index is measured >2.8 will receive no intervention.
32862067|NCT04938102|Active Comparator|Normal DI - Botox|Patients' whose distensibility index is measured >2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
32862068|NCT04846309|Experimental|Treatment: all patients|
32862069|NCT04946448|Experimental|FIT group|Patients treated with biological treatment and the FIT diet
32862070|NCT04946448|No Intervention|Control group|Patients treated with biological treatment and the standard diet
32862071|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
32862072|NCT04946604|Other|Ashtangayoga|Participants attanded eight yoga sessions, one hour long.
32862073|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
32862074|NCT01893073|No Intervention|Waiting group|
32862075|NCT04946760|Sham Comparator|Sham Protocol|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention. To provide a sham for the OMT-WB protocol, subjects will lie supine with the physician's hands under the occiput, palms toward the table, so that the subject's head rests on the dorsal aspect of the physician's hands. The time used in the sham procedures will be approximately 20-25 minutes.
32862076|NCT04946760|Experimental|Whole-Body Protocol|"The whole-body protocol will include all the techniques in the OMT-ND protocol, but will also include techniques focused on the expected cranial dysfunctions [Rivera-Martinez 2002]. The OMT-WB protocol will last approximately 25-30 minutes.~The techniques will include:~Evaluation for strain pattern(s)~Occipitolatlantal decompression~Sphenobasilar synchondrosis decompression~Occipitomastoid suture V-spread~Temporal bone balancing~Venous sinus drainage technique"
32862077|NCT04946760|Experimental|Neck-down protocol|"The neck-down protocol takes into consideration previous relevant studies [Lopez 2011, Wells 1999]. OMT will be used bilaterally on the following areas with one or more techniques, including myofascial release, articulatory, muscle energy, and balanced ligamentous tension. The OMT-ND protocol will last approximately 15-20 minutes.~Cervical spine~Thoracic spine~Lumbar spine~Shoulder girdle~Sacroiliac joint~Innominates~Leg muscles (including psoas, piriformis, hamstring, adductors)~Ankles"
32862078|NCT02181075|Experimental|Part I|"All participants in Part I received:~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
32862079|NCT02181075|Experimental|Part II|"All participants in Part II received:~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
32862080|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
32971385|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
32862081|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
32862082|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
32862083|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
32862084|NCT04956588|Experimental|experimental group|
32862085|NCT04956588|Active Comparator|control group|
32862086|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
32862087|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
32862088|NCT04945980|Experimental|Low-MUFA ground beef|Participants consumed ground beef low in monounsaturated fatty acids.
32862089|NCT04945980|Experimental|High-MUFA ground beef|Participants consumed ground beef high in monounsaturated fatty acids.
32862090|NCT02872987||B-ALL/NHL|
32862091|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
32862092|NCT04955886|Experimental|Recurrent or Metastatic Nasopharyngeal Carcinoma.|Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.
32862093|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
32862094|NCT04271839|Experimental|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
32862095|NCT04271839|Active Comparator|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
32862096|NCT04945902|Active Comparator|Asynchronous Group|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
32862097|NCT04945902|Experimental|Synchronous Group|If you are assigned to the synchronous intervention group, you will be required to complete the asynchronous interventions on Brightspace AND attend a weekly one-hour support group. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connections and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
32862098|NCT04945902|No Intervention|Waitlist|If you are assigned to the wait-list group, you will not have access to the asynchronous or synchronous interventions during the course of this study. After this study is completed, you will have access to the asynchronous intervention on Brightspace.
32862099|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
32862100|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
32862101|NCT04945668|Other|Pericapsular nerve group block|combined ultrasound and fluoroscopy-guided technique for pericapsular nerve group block
32862102|NCT05083143||COVID-19 Testicular Cancer|Patients diagnosed with testicular cancer in the COVID-19 period
32862103|NCT05083143||PreCOVID-19 Testicular Cancer|Patients diagnosed with testicular cancer before the COVID-19 period
32862104|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
32862105|NCT04945434|Experimental|S53P4 BAG intervention group|Patients recruited and enrolled in study for treatment with S53P4 BAG
32862106|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
32862107|NCT04411758|Placebo Comparator|Placebo Group|4 capsules of 500mg/day of magnesium stearate, silicon dioxide and microcrystalline cellulose
32862108|NCT04411758|Experimental|Propolis Group|4 capsules of 500mg/day containing concentrated and standardized dry EPP-AF® green propolis extract for 2 months
32862109|NCT04408560|Active Comparator|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
32862110|NCT04408560|Sham Comparator|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
32862111|NCT04937244|Experimental|Patients with new or recurrent malignant gliomas|
32862112|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
32862113|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
32862114|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
32862115|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
32862116|NCT04936698||Hyperthyroidism|Elevated fT4, low TSH
32862117|NCT04936698||Hypothyroidism|Elevated TSH, low fT4
32862118|NCT04936698||Euthyroid|Normal TSH/fT4 level
32862119|NCT04844905|Experimental|Ivermectin Mass Drug Administration|Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
32971386|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
32971387|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
32971388|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
32971389|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
32971390|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
32971391|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
32971392|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.~formulation : curcumin powder 240mg/capsule~general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
32971393|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
32971394|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
32971395|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
32971396|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
32971397|NCT03210870|Other|Intervention|In-person nutritional education classes
32971398|NCT03210870|No Intervention|Control|no in-person nutritional education classes
32971399|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
32971400|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
32971401|NCT03210402|Active Comparator|Elevated night pacing on|
32971402|NCT03210402|Placebo Comparator|Elevated night pacing off|
32971403|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
32971404|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
32971405|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
32971406|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
32971407|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
32971408|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
32971409|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
32971410|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
32971411|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
32971412|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
32971413|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
32971414|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
32971415|NCT01830114|Experimental|Web app evaluation group|
32971416|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
32971417|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
32971418|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
32971419|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
32971420|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
32971421|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
32971422|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
32971423|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
32971424|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
32971425|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
32971426|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
32971427|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
32971428|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
32971429|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
32971430|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
32971431|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
32971432|NCT01831128||Control|No ASV treatment
32971433|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
32971434|NCT01831206|No Intervention|standard treatment|Standard treatment alone
32971435|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
32971436|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
32971437|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
32971438|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
32971439|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
32971440|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
32971441|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
32971442|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
32971443|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
32971444|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
32971445|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
32971446|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
32971447|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
32971448|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
32971449|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
32971450|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
32971451|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
32971452|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
32971453|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
32971454|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
32971455|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
32971456|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
32971457|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
32971458|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
32971459|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
32971460|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
32971461|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
32971462|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
32971463|NCT01833312|No Intervention|Control|Best medical treatment
32971464|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
32971465|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
32971466|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
32971467|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
32971468|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
32971469|NCT01833780||GBS carriage status|
32971470|NCT01833780||GBS status during labor|
32971471|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
32971472|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
32971473|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
32971474|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
32971475|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
32971476|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
32971477|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
32971478|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
32971479|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
32971480|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
32971481|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
32971482|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
32971483|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
32971484|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
32971485|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32971486|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
32971487|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
32971488|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
32971489|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
32971490|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
32971491|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
32971492|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
32971493|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
32971494|NCT01836120|Active Comparator|Docetaxel|
32971495|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
32971496|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
32971497|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
32971498|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
32971499|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
32971500|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
32746726|NCT05611593|Experimental|FOL100|Subjects will apply FOL100 lotion topically in the defined treatment area.
32971501|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
32971502|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
32971503|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
32971504|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
32971505|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
32971506|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
32971507|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
32971508|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
32971509|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
32971510|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
32971511|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
32971512|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
32971513|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
32971514|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
32971515|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
32971516|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
32971517|NCT01838928|Experimental|Bupivacaine|
32971518|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
32971519|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
32971520|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
32971521|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
32971522|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
32971523|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
32971524|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
32971525|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
32971526|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
32971527|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
32971528|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
32971529|NCT01839630||Group 1|
32971530|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
32971531|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
32971532|NCT01839942||no gap closure|no hernia gap closure
32971533|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
32971534|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
32971535|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33411003|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
32971536|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
32971537|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
32971538|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
32971539|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
32971540|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
32971541|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
32971542|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue FOLFIRINOX~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
32971543|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
32971544|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
32971545|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
32971546|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
32971547|NCT01720134||after legislation 1st july 2003|2003-2006
32971548|NCT01720134||before legislation 1st july 2003|1999-2003
32971549|NCT01720212|Experimental|Single dose group|
32971550|NCT01720212|Experimental|Multiple dose group|
32971551|NCT01720290|Experimental|Rep|
32971552|NCT01720290|Active Comparator|Met|
32971553|NCT01720290|Active Comparator|Rep + met|
32971554|NCT01720368||1st Group of 50 patients|
32971555|NCT01720368||2nd Group of 50 patients|
32971556|NCT01720914||Critically ill patient|
32971557|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
32971558|NCT01720992|Other|Group B|Group B is a wait list control
32971559|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
32971560|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
32971561|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
32971562|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
32971563|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
32971564|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
32971565|NCT01721616|Active Comparator|Cefazolin|single antibiotic
32971566|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
32971567|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
33411004|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
32971568|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
32971569|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
32971570|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
32746727|NCT05611593|Active Comparator|Propecia 1mg (oral Finasteride)|Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)
32746728|NCT05614713|Experimental|Study group|received a modified selected physical therapy program to increase sensory input.
32746729|NCT05614713|Active Comparator|Control group|received a selected physical therapy
32746730|NCT05611515||TORS|Patients operated by Trans-oral Robotic Surgery (TORS)
32971571|NCT01722084|No Intervention|Community members without intervention|
32971572|NCT01722396|Experimental|Vitamin D|
32971573|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
33411005|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
32971574|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
32971575|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
32971576|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
32971577|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
32971578|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
32971579|NCT01723098|No Intervention|Control|Sedentary pregnant women
32971580|NCT01723098|Experimental|Exercise group|
32971581|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
32971582|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
32971583|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
32971584|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
32971585|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
32971586|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
32971587|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
32971588|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
32971589|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
32971590|NCT01723878||Cohort|
32971591|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
32971592|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
32971593|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
32971594|NCT01724034|No Intervention|Control Group|
32971595|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
32971596|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
32971597|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
32971598|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
32971599|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
32971600|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
32971601|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
32971602|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
32971603|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
32971604|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
32971605|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
32971606|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
32971607|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
33411006|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
32971608|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
32971609|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
32971610|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
32971611|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
32971612|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
32971613|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
32971614|NCT01724970|Experimental|PLMA|ProSeal
32971615|NCT01724970|Experimental|SLMA|Supreme LMA
32971616|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
32971617|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
32971618|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
32971619|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
32971620|NCT01725516|Experimental|Myofascial release technique|
32971621|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
32971622|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
32971623|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
32971624|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
32971625|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
32971626|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
32971627|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
32971628|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
33411007|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
32971629|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
32971630|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
32971631|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
32971632|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
32971633|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
32971634|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
32746731|NCT05611515||TLM|Patients operated by Trans-oral Laser Microsurgery (TLM)
32746732|NCT05611515||IMRT|Patients treated by Intensity Modulated Radiation Therapy (IMRT)
32971635|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
32971636|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
32971637|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
32971638|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
32971639|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
32971640|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
32971641|NCT01726062|Other|Conventional Care (CC)|
32971642|NCT01726140|Experimental|TREATMENT|Helmet CPAP
32971643|NCT01726140|Active Comparator|CONTROL|Venturi Mask
32971644|NCT01726218||Stroke patients|
32971645|NCT01726218||Healthy Control|
32971646|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
32971647|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
32971648|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
32971649|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
32971650|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
33411008|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
33411009|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
32971651|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
32971652|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
32971653|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
32971654|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
32971655|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
32971656|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
32971657|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
32971658|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
32971659|NCT01726920|Active Comparator|naratriptan|
32971660|NCT01726920|Active Comparator|naproxen|
32971661|NCT01726998|Experimental|Lokomat Group|
32971662|NCT01726998|Active Comparator|conventional gait training group|
32971663|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32971664|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
32971665|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
32971666|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
32971667|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
32971668|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
32971669|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
32971670|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
32971671|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
32971672|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
33322482|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.~Intervention to be administered: Bordetella Pertussis B1917"
33411010|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
32971673|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
32971674|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
32971675|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
32971676|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
32971677|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
32971678|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
32971679|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
32971680|NCT01728168||Non-atopic|Subjects without atopy.
32971681|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
33411011|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
33411012|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
33411013|NCT01313975||2|Patients with severe traumatic brain injury
32862120|NCT04844905|Placebo Comparator|Placebo Mass Drug Administration|Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
32862121|NCT04418856|Experimental|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
32862122|NCT04418856|Active Comparator|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
32862123|NCT04418856|Experimental|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
32862124|NCT04418856|Active Comparator|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
32862125|NCT04418856|No Intervention|Healthy control group|The healthy control group and the breast cancer patients undergo the same assessments (questionnaires, neuropsychological assessments and actigraphy) at the same time points
32862126|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
32862127|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
32862128|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
32862129|NCT04955496||ERAS Group|Patients were treated by enhanced recovery after surgery
32862130|NCT04955496||Control Group|Patients were not treated by enhanced recovery after surgery
32862131|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
32862132|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
32862133|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
32862134|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
32862135|NCT04944966|Experimental|Group 1|"• Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis"
32862136|NCT04944966|Experimental|Group 2a|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis.~Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Maytenus senegalensis"
32862137|NCT04944966|Active Comparator|Group 2b|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Artemether 20mg/lumefantrine 120mg"
32862138|NCT04758169|Experimental|Enhanced Homestead Food Production|Participant in this arm will receive the Helen Keller's EHFP model which involves homestead food production, nutrition and WASH education and gender transformative sessions (intervention group). Participants will also receive interventions related to parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH and basic life-skill trainings.
32862139|NCT04758169|Experimental|Control|Participants in this arm will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings. This particular arm will not receive any homestead food production intervention over the course of the implementation.
32862140|NCT04936152|Active Comparator|mime therapy using tablet PC mirror application|these individuals will receive mime therapy using tablet PC mirror application
32862141|NCT04936152|Experimental|the control intervention including the mime therapy|these individuals will receive the control intervention including the mime therapy).
32862142|NCT04955106|Other|Sample for reliability|Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
32862143|NCT02678299|Experimental|Treatment|
32971682|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~Effective analgesia provided simultaneously and early (analgesia first).~Regular and frequent assessment of patient wakefulness/sedative state;~Avoidance of benzodiazepines and minimisation of use of propofol;~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
32971683|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
32971684|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
32971685|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
32971686|NCT01728948||Group 1|
32971687|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
32971688|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
32971689|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
32971690|NCT01729182||Nexium|
32971691|NCT01729260|Experimental|Mebendazole|All study participants will receive study drug; Mebendazole.
32971692|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
32971693|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
32971694|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
32971695|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
32971696|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
32971697|NCT01729650|No Intervention|Usual clinical care|
32971698|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
32971699|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
32971700|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
32971701|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
32971702|NCT01720836|Experimental|Stage IA or I/II NSCLC|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
32971703|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
32971704|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
32971705|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
32971706|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
32971707|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
32971708|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
32971709|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
32971710|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
32971711|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
32971712|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
32971713|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
32971714|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
32971715|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
32971716|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
32971717|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
32971718|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
32971719|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
32971720|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
32971721|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
32971722|NCT01048788|Experimental|OPC|
32971723|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
32971724|NCT01048242|Placebo Comparator|sugar pill|
32971725|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
32971726|NCT01046682|Active Comparator|Salsalate|
32971727|NCT01046682|No Intervention|Usual care|
32971728|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
32971729|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
32971730|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
32971731|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
32971732|NCT01043874|Experimental|Nilotinib|400 mg BID
32971733|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
32971734|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
32971735|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
33322483|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.~Intervention to be administered: Bordetella Pertussis B1917"
32971736|NCT01047540|Experimental|Dose regimen 1|
32971737|NCT01047540|Experimental|Dose regimen 2|
32971738|NCT01047540|Experimental|Dose regimen 3|
32971739|NCT01047540|Experimental|Dose regimen 4|
32971740|NCT01047540|Placebo Comparator|Placebo|
32971741|NCT01046916|Experimental|TAK-700|
32971742|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
32971743|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
32971744|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
32971745|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
32971746|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
32971747|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
32971748|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
32971749|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.~Subjects will be recruited for the study in the following groups :~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
32971750|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
32971751|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
32971752|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
32971753|NCT03408990||Healthy|Healthy children, no relevant pathologies
32971754|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
32971755|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
32971756|NCT03408288||Nurses|
32971757|NCT03408288||Urologists|
32971758|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
32971759|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
32971760|NCT03408132|Experimental|FE203799 5 mg|FE203799 5 mg subcutaneous injection
32971761|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
32971762|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
32971763|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
32971764|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
32971765|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
32971766|NCT03407898||C-mac D blade used for intubation|
32971767|NCT03407898||mcgrath X blade used for intubation|
32971768|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
32971769|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
32971770|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
32971771|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
32971772|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
32971773|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
32971774|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
32971775|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
32971776|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
32971777|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
32971778|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
32971779|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
32971780|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
32971781|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
32971782|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
32971783|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
32971784|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
32971785|NCT03405402|Other|Control group|Allo-immunization not detected
32971786|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
32971787|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
32971788|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
32971789|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
32971790|NCT03405168|Experimental|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
32971791|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
32971792|NCT03404856|Other|Treatment with ORL-1G - D-galactose|
32971793|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
32971794|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
32971795|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
32971796|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
32971797|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
32971798|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
32971799|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
32971800|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
32971801|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
32971802|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
32971803|NCT03403530|Placebo Comparator|control group|antibiotics only
32971804|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
32971805|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
32971806|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
32971807|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
32971808|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
32971809|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
32971810|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
32971811|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
32971812|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
32971813|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
32971814|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
32971815|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
32971816|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
32971817|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
32971818|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
32971819|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
32971820|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
32971821|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
32971822|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
32971823|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
32971824|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
32971825|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
32971826|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
32971827|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
32971828|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
32971829|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
32971830|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
32971831|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
32971832|NCT03401502|Placebo Comparator|Control group|Placebos
32971833|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
32971834|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
32971835|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
32971836|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
32971837|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
32971838|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
32971839|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
32971840|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
32971841|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
32971842|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
32971843|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
32971844|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
32971845|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
32971846|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
32971847|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
32971848|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
32971849|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
32971850|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
32971851|NCT03400254|Experimental|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
32971852|NCT03400254|Experimental|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
33417300|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~Signed informed consent form from adult patient or parent/guardian of pediatric patient.~Patient must have a valid mailing address within the United States to receive QOL surveys.~Ability to speak and read English.~Patients with access to a telephone."
32971853|NCT03400254|Experimental|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
32971854|NCT03400254|Experimental|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
32971855|NCT03400254|Experimental|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
32971856|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
32971857|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
32971858|NCT03408444|Experimental|EMO-114|Test Lens 1
32971859|NCT03408444|Experimental|EMO-116|Test Lens 2
32971860|NCT03408444|Experimental|EMO-118|Test Lens 3
32971861|NCT03408444|Active Comparator|EMO-117|Test Lens 4
32971862|NCT03401190|Experimental|Low Dose Group|Phase 1: Cohorts 1 & 2 will consist of 4 female and 4 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
32971863|NCT03401190|Experimental|High Dose Group|Phase 2: Cohorts 3 & 4 will consist of 8 female and 8 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
32971864|NCT03401190|No Intervention|Standard of Care|For all cohorts, patients will be randomized 3:1 to CM4620-IE plus standard of care versus standard of care alone.
32971865|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
32971866|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
32971867|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
32971868|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
32971869|NCT03400956|Experimental|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
32971870|NCT03400956|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
32971871|NCT03400956|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
32971872|NCT00012012|Experimental|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
32971873|NCT00012012|Experimental|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
32971874|NCT00010374|Experimental|NeuRx DPS|Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
32971875|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
32971876|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
33417301|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
32971877|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
32971878|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
33417302|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
32971879|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
32971880|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
32971881|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
32971882|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
32971883|NCT02240238|Experimental|NC-6004 and Gemcitabine|
32971884|NCT02240316||Follicular NHL Cohort|
32971885|NCT02240316||DLBCL Cohort|
32971886|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
32971887|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
32971888|NCT02240784||Acute Hepatic Porphyria|
32971889|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
32971890|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
32971891|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
32971892|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
32971893|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
32971894|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
32971895|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
32971896|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
32971897|NCT02241564||Malignancy post transplantation|
32971898|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
32971899|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
32971900|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
32971901|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
32971902|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
32971903|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
32971904|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
32971905|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
32971906|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
32971907|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
32971908|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
32971909|NCT02242266|Placebo Comparator|Placebo|
32971910|NCT02242344|Experimental|telmisartan - low dose|
32971911|NCT02242344|Experimental|telmisartan - high dose|
32971912|NCT02242344|Placebo Comparator|Placebo|
32971913|NCT02242422||transobturator tape|
32971914|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
32971915|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
32971916|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
32971917|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
32971918|NCT02242812|Experimental|Telmisartan|MICARDIS®
32971919|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
32971920|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
32971921|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
32971922|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
33417303|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
32971923|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
32971924|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)~Etoposide 40 mg/m2/day, on days 1 to 4~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4~Cisplatin 25 mg/m2/day, on days 1 to 4~Ara C (cytarabine) 2 g/m2, on day 5~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.~- Autologous peripheral blood stem cell transplant~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
32971925|NCT02243514||Resistant hypertension|
32971926|NCT02243514||Essential hypertension|
32971927|NCT02243514||Chronic heart failure|
32971928|NCT02243514||Control|
32971929|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
32971930|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
32971931|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
32971932|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
32971933|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
32971934|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
32971935|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
32971936|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
32971937|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
32971938|NCT02244294|Experimental|FLOMAX®|
32971939|NCT02244294|Placebo Comparator|Placebo|
32971940|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
32971941|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
32971942|NCT02244372|Placebo Comparator|Placebo|Placebo
32971943|NCT02244528|Experimental|Treatment|sildenafil treatment
32971944|NCT02244684||Pregnant women|
32971945|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
32971946|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
33417304|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
32971947|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
32971948|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
32971949|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
32971950|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
32971951|NCT02245464||Patients with essential hypertension|
32971952|NCT02245542||BPH patients|
32971953|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
32971954|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
32971955|NCT02246244|Experimental|Escitalopram|10 mg once per day
32971956|NCT02246244|Placebo Comparator|Placebo|
32971957|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
32971958|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
32971959|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
32971960|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
32971961|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
33417305|NCT01357811|Active Comparator|digoxin|
32971962|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
32971963|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
32971964|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients in the study will get a DW-MRI of the liver in addition to their standard treatment imaging prior to their surgery.
33417306|NCT01357811|Experimental|eliglustat with digoxin|
32971965|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
32971966|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
32971967|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
32971968|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
32971969|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
32971970|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
32971971|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
32971972|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
32971973|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
32971974|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
32971975|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
32971976|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
32971977|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
32971978|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
32971979|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
32971980|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
33417307|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
32971981|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
32971982|NCT02247492||Orsiro|
32971983|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
32971984|NCT02247648|Experimental|treatment|treatment: tramadol group
32971985|NCT02247648|Placebo Comparator|control|control: placebo group
32971986|NCT02247882|Experimental|Patient Education|Health Education.
32971987|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
33417308|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
32746733|NCT05612451|Experimental|non-setting calcium hydroxide|Regenerative Endodontic Procedure utilizing non-setting calcium hydroxide as intracanal medicament
32746734|NCT05612451|Experimental|modified triple antibiotic paste|Regenerative Endodontic Procedure utilizing modified triple antibiotic paste as intracanal medicament
32971988|NCT02248038|Active Comparator|open surgery|Conventional procedure
32971989|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
32971990|NCT02248116|Experimental|Alzheimer|
32971991|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
32971992|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
32971993|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
32971994|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
32971995|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
32971996|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
32971997|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
32971998|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
32971999|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
32972000|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
32972001|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
32972002|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
32972003|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
32972004|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
32972005|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
32972006|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
32972007|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
32972008|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
32972009|NCT02249286|No Intervention|No intervention|
32972010|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
32972011|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
32972012|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
32972013|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
32972014|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
32972015|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
32972016|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
32972017|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
32972018|NCT02249754|Active Comparator|Routine health education|Routine health education alone
32972019|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
32972020|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
32972021|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
32972022|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
32972023|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
32972024|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
32972025|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
32972026|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
32972027|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
32972028|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
32972029|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
32972030|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
33417309|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
32972031|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
32972032|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
32972033|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
32972034|NCT00550134||1, Non Cancer group|A noncancer control group (N=35), frequency matched on age (< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
32972035|NCT00550134||2 Breast Cancer Patients Scheduled for chemotherapy|We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
32972036|NCT00550134||3 Breast Cancer Patients Not Scheduled for Chemotherapy|We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
32972037|NCT00559962|Placebo Comparator|1|Placebo
32972038|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
32972039|NCT00559962|Active Comparator|3|5 mg AEGR-733
32972040|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
32972041|NCT00559962|Active Comparator|5|10 mg AEGR-733
32972042|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
32972043|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
32972044|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
32746735|NCT05611359|Experimental|Thermal Ablation|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, thermal ablation and chemotherapy are administered.
32972045|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
32972046|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
32972047|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
32972048|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
32972049|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
32972050|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
32972051|NCT00557622|Placebo Comparator|placebo|placebo
32972052|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
33417310|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
33417311|NCT02978781|Experimental|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
32972053|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
32972054|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
32972055|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
32972056|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
32972057|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
32972058|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
32972059|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
32972060|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
32972061|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32972062|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
32972063|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
32972064|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
32972065|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
32972066|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
32972067|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
32972068|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
32972069|NCT00559650|Placebo Comparator|Arm 1|
32972070|NCT00559650|Experimental|Arm 2|
32972071|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
32972072|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
32972073|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
32972074|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
32972075|NCT00556374|Experimental|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
32972076|NCT00556374|Other|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
32972077|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
32972078|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
33417312|NCT02978781|Experimental|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
33417313|NCT02978781|Placebo Comparator|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
32972079|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
32972080|NCT03029910|Experimental|Vibration and eccentric exercise|
32972081|NCT03029910|No Intervention|Control|
32972082|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
32972083|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
32972084|NCT00555204|Experimental|A|
32972085|NCT00555204|Experimental|B|
32972086|NCT00555204|Experimental|C|
32972087|NCT00555204|Experimental|D|
32972088|NCT00555204|Experimental|E|
32972089|NCT00555204|Experimental|F|
32972090|NCT00555204|Placebo Comparator|G|
32972091|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
32972092|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
32972093|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
32972094|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
32972095|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
32972096|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
32972097|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
32972098|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
32972099|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
32972100|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
32972101|NCT04271202|Other|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
32972102|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are stratified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants and ) as well as if previously or newly diagnosed.
32746736|NCT05611359|Active Comparator|Chemotherapy|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, chemotherapy is administered.
32972103|NCT04279548|Active Comparator|On DBS|Patients in the on mode DBS
32972104|NCT04279548|Sham Comparator|Off DBS|Patients in the off mode DBS
32972105|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
32972106|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up > 2 years
32972107|NCT04270032||normal group|women have normal images with follow up > 2 years
32972108|NCT04279392|Active Comparator|Active Infusion|At 6 weeks post surgery, 5 mg of zoledronic acid in 100 ml of saline will be infused intravenously over a 15 minute time period.
32972109|NCT04279392|Placebo Comparator|Non-active Infusion|At 6 weeks post surgery, 100 ml of saline will be infused intravenously over a 15 minute time period.
32972110|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
32972111|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
32972112|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
32972113|NCT04277910|Active Comparator|MT2004|MT2004 oral capsules treated group
32972114|NCT04277910|Placebo Comparator|Placebo|Placebo oral capsules treated group
32972115|NCT04273542|Other|Control cohort|"In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer.~They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening)."
32972116|NCT04273542|Other|Patient cohort|"In this cohort, women for who an invasive breast cancer has been diagnose will be included.~Only one liquid biopsy will be collected before any treatment."
32972117|NCT04273542|Other|Exploratory cohort|"In this cohort, women with high risk of BRCA1/2 mutation but without invasive breast cancer.~6 liquid biopsies will be collected : each year after inclusion during 5 years."
32972118|NCT04272216||Treatment with HydroPearl via radial access|all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
32972119|NCT04275570|Active Comparator|Motivational Interview.|Repeated motivational interview during prenatal care visits
32972120|NCT04275570|No Intervention|Usual intervention|Usual intervention
32972121|NCT04278846|Experimental|DepoFoam bupivacaine|local anesthetic
32972122|NCT04278846|Active Comparator|Bupivacaine hydrochloride (HCl)|local anesthetic
32972123|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
32972124|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
32972125|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
32972126|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
32972127|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
32972128|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
32972129|NCT03838770|Experimental|Active|
32972130|NCT03838770|Placebo Comparator|Sham|
32972131|NCT03839862||Responder|Patient responding to TNF-inhibition
32972132|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
32972133|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
32972134|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
32972135|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
32972136|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
32972137|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
32972138|NCT03838926|Experimental|Trichostatin A|
32972139|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
32972140|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
32972141|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
32972142|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
32972143|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
32972144|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
32972145|NCT03838614|Experimental|MPT group|Muscle power training group
32972146|NCT03838614|Other|Control group|Usual care group
32972147|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
32972148|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
32972149|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
32972150|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
32972151|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
32972152|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
32972153|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
32972154|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
32972155|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
32972156|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
32972157|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
32972158|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
32972159|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
32972160|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
32972161|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
32972162|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
32972163|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
32972164|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
32972165|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
32972166|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
32972167|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
32972168|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
32972169|NCT03835494|Experimental|Fallot patients|Fallot patients
32972170|NCT03835494|Experimental|healthy controls|healthy volunteers
32972171|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
32972172|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
32972173|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
32972174|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
32972175|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
32972176|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
32972177|NCT03834480|Experimental|• Steroid Group (S)|
32972178|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
32972179|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
32972180|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
32972181|NCT03834324|Experimental|intervention|FES
32972182|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
32972183|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
32972184|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
32972185|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
32972186|NCT03834090|Experimental|rESWT|the group receiving rESWT
32972187|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
32972188|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
32972189|NCT03833466|Experimental|metformin and chemotherapy|
32972190|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
32972191|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
32972192|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
32972193|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
33411014|NCT05571917|Experimental|ACT + MBRP Intervention|The ACT + MBRP group will follow a manualized clinical protocol. Treatment will include 12 weekly, virtual group-based sessions, each lasting 90 minutes. Group sizes will range from three to ten participants. All sessions will be audio recorded for fidelity. Over the course of the group meetings, participants identify areas of meaningful functioning that have been adversely impacted by pain, learn methods to enhance pain willingness in the service of these meaningful areas, and practice present-focused awareness skills. Group sessions include discussions of the impact of pain and distress avoidance, identifying alternatives to this avoidance and establishing plans for behavior change, demonstration and role-playing exercises, and homework assignments. Participants are provided with a treatment manual to help guide and inform practice outside of group sessions.
33411015|NCT05571917|Active Comparator|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) condition will supplement standard practices within the study sites related to chronic pain and OUD education. Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with a list of chronic pain treatment resources, signs and management of opioid overdose including naloxone, and overdose prevention, and will encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms. In addition to receiving the brochure, EUC condition participants will meet with a therapist remotely for approximately 15 minutes for a descriptive overview of the brochure. In this session, the therapist will point out the resources in the brochure and read the helpful tips out loud to the participant. This session will be audio recorded for fidelity.
32972194|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
32972195|NCT03830580|Experimental|Sung voice|
32972196|NCT03830580|No Intervention|Control|
32972197|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
32972198|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
32972199|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
32972200|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
32972201|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
32972202|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
32972203|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
32972204|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
32972205|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
32972206|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
32972207|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
32972208|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
32972209|NCT03833622|Experimental|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
33411016|NCT03637829|Placebo Comparator|Control|250 mL of water
32972210|NCT03833700|Experimental|Dose Escalation Part: E7386|Participants will receive E7386 10, 15, 20 mg (milligram) or more, tablets, orally, twice daily, in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
32862144|NCT04955262|Experimental|Part 1 Initial Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214, 3 injections of 89Zr-Df-IAB22M2C, and 6 PET/CT scans. Starting with Cycle 2, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. Once the PET/CT imaging data from Part 1 have been reviewed, Part 2 will open for enrollment.
32972211|NCT03833700|Experimental|Expansion Part|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The highest dose of E7386 which is deemed tolerable or the optimal dose based on PK or PD analysis in dose escalation part will be used.
32972212|NCT03831360|Experimental|Hatha Yoga|12 weeks of hatha yoga
32972213|NCT03831360|Experimental|Group CBT|12 weeks of group CBT
32972214|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
32972215|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
32972216|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
32972217|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
32972218|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
32972219|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
32972220|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
32972221|NCT05440734|Experimental|Melatonin|2 mg oral tablet, melatonin slow release formulation, 1x 60 min before bedtime for 15 days
32972222|NCT05440734|Placebo Comparator|Placebo|2 mg oral tablet, 1x 60 min before bedtime for 15 days
32972223|NCT05447208|Experimental|Treatment group|GH is supplemented during ovarian stimulation
32972224|NCT05447208|Active Comparator|Control group|GH is not supplemented during ovarian stimulation.
32972225|NCT05447442||Study group|Patients with anemia will be checked whether they would be assessed by protocol.
32972226|NCT05444556|Experimental|Imlunestrant + Repaglinide|Repaglinide administered orally alone on day 1 followed by imlunestrant administered orally in combination with repaglinide orally on day 3.
32972227|NCT05444556|Experimental|Imlunestrant + Omeprazole & Dextromethorphan|Omeprazole administered in combination with dextromethorphan orally on day 1 followed by imlunestrant administered orally in combination with omeprazole and dextromethorphan orally on day 3.
32972228|NCT05444556|Experimental|Imlunestrant + Quinidine|"Imlunestrant administered orally on day 1 followed by quinidine alone orally on day 15 to 17.~On day 18, imlunestrant administered orally in combination with quinidine followed by quinidine administered orally on day 19 to 24."
32972229|NCT05444556|Experimental|Imlunestrant + Rosuvastatin & Digoxin|Rosuvastatin administered in combination with digoxin administered orally on day 1 followed by imlunestrant administered orally in combination with rosuvastatin and digoxin orally on day 10.
32972230|NCT05440266|Active Comparator|First: half-sine wave stimulation; Second: rectangular shaped stimulation|"First appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency."
33411017|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
32862145|NCT04955262|Experimental|Part 2 Expansion Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214 or nivolumab, 2 injections of 89Zr-Df-IAB22M2C, and 3 PET/CT scans. In Cycle 2 and beyond, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. During Cycle 2, patients will receive 1 injection of 89Zr-Df-IAB22M2C and 1 PET/CT scan.
32862146|NCT04844125|Experimental|SHR-1209|
32862147|NCT04844125|Placebo Comparator|SHR-1209 Placebo|
32862148|NCT04944732||Patients with Creutzfeldt Jakob disease|Patients with Creutzfeldt Jakob disease
32862149|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
32862150|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
32862151|NCT04944498|Experimental|Intervention Group|Patients who received surgery with modified tarsorrhaphy technique
32862152|NCT04944498|Active Comparator|Control group|Patients who received surgery with gold weight implant technique
32862153|NCT04758013|Experimental|Laparoscopic gastric surgery with Epidural injection|Patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.
32862154|NCT04758013|Experimental|Laparoscopic gastric surgery without Epidural injection|Patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.
32862155|NCT04758013|No Intervention|Open gastric surgery|Patients with open gastric surgery.
32899238|NCT00265850|Experimental|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
32972231|NCT05440266|Active Comparator|First: rectangular shaped stimulation; Second: half-sine wave stimulation|"First appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency."
32972232|NCT05440032||Synovial fluid testing with semi-quantitative leukocyte esterase test strip|Using a drop of synovial fluid, sample will be analyzed via the point-of-care device to measure amount of leukocyte esterase in the sample
32972233|NCT05440032||Synovial fluid testing with Roche Chemstrip|Using a drop of synovial fluid, sample will be analyzed via a urine test-strip to measure amount of leukocyte esterase in the sample
32972234|NCT05445804|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
32972235|NCT05445804|Experimental|Additional Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
32972236|NCT05444400|Experimental|Strengthening of lower limbs|The participants of this group will carry out their training following the protocol described. The participants work with strength of lower limbs.
32972237|NCT05444400|Active Comparator|Conventional protocol|The participants of this group will carry out their rehabilitation following the conventional protocol.
32972238|NCT05443542|Experimental|Virtual Reality Group|Group 1 will play a VR game using an Oculus Quest 2 in a home setting
32972239|NCT05443542|Active Comparator|Active control group|The control group will be given a pamphlet containing exercises affecting working memory, attention and processing speed to be performed in a home setting
32972240|NCT05442294|Experimental|Juego de Llaves group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Juego de Llaves.~The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values"
32972241|NCT05442294|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
32972242|NCT05441904|Experimental|PXL770 500 and 750 mg|Each subject received 1 dose of PXL770 at 500 mg and 1 dose at 750 mg
32972243|NCT05441748|Experimental|Intervention treatment|Intervention treatment will contain walnuts and be consumed everyday for 3 weeks.
32972244|NCT05441748|Experimental|Intervention treatment oil|Intervention treatment will contain walnut oil in foods and be consumed everyday for 3 weeks.
32972245|NCT05441748|Placebo Comparator|Control treatment|Intervention treatment will contain corn oil in foods and be consumed everyday for 3 weeks.
32972246|NCT05441436||Allogeneic hematopoietic stem cell transplantation|Patients in waiting list for and after allogeneic hematopoietic stem cell transplantation.
32972247|NCT05441436||Solid organ transplantation|Patients in waiting list for and after solid organ transplantation.
32972248|NCT05441358||Patients undergoing open heart surgery|"Subjects scheduled for elective cardiothoracic surgery requiring a sternotomy.~Coronary artery bypass grafting (CABG)~Combined CABG and valve surgery~On-pump double or triple valve procedures~Aortic surgery or redo surgery~Off pump CABG as part of a hybrid revascularization approach"
32972249|NCT05440890|Active Comparator|Control group|Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.
32972250|NCT05440890|Experimental|Cross-education group|"Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.~Additionally a contralateral lower limb strength training."
32972251|NCT05440578||olaparib plus bevacizumab treatment group|olaparib plus bevacizumab maintenance therapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
32972252|NCT05446662|No Intervention|control group|After randomization, the patients in the control group will be given pre- and post-operative nursing care without any intervention.
32972253|NCT05446662|Experimental|case group|Patients in the case group after randomization will choose one or more of the music therapy, aromatherapy, progressive relaxation exercises and massage therapies according to their health care needs.
32972254|NCT05448690||Non-combined approach (Single or Staged)|Patients underwent transnasal approach or craniotomy approach; Patients underwent an initial surgery and a sencond staged surgery several months after the initial surgery
32972255|NCT05448690||Combined approach|Patients underwent a combined approach using transnasal approach and craniotomy approach simultaneously
32972256|NCT05446194|Experimental|Investigational Treatment 1|Investigational treatment stimulation pattern 1
32972257|NCT05446194|Experimental|Investigational Treatment 2|Investigational treatment stimulation pattern 2
32972258|NCT05441670|Experimental|Art and Physical Therapy|
32972259|NCT05441670|Active Comparator|Physical Therapy|
32972260|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
32972261|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
33411018|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
32972262|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
32972263|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
32972264|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
32972265|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
32972266|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
32972267|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
32972268|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
32972269|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
32972270|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
32972271|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
32972272|NCT01689012|Experimental|Facial Exercise|
32972273|NCT05768854|Active Comparator|Intravenous Bisphosphonates (IV-BP) -> Setrusumab|"Participants on IV-BP will continue their existing dose/regimen per investigator discretion; for participants not on IV-BP, the dose/regimen will be determined by the investigator.~After the active-controlled period, participants will receive Setrusumab during the extension period"
32972274|NCT05768854|Experimental|Setrusumab|Participants will receive Setrusumab during the active-controlled and extension period
32972275|NCT05768828||Migraine|Patients suffering from migraine based on ICHD-3 criteria
32972276|NCT05768828||Controls|Patients free of headaches or not suffering from headaches with a frequency that exceeds 1x/year
32972277|NCT05768815|Experimental|Breaking the Cycle Intervention group|
32972278|NCT05768815|Active Comparator|Maxxine Wright Intervention group|
33322484|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
32972280|NCT05768789|Experimental|Buoy Electrolyte Drops|The goal is to give 600mg of Na+ over 4 hours while measuring urine output over 6 hours. The recommended Buoy dosage is ⅓ tsp in 237 ml of water (50mg Na+) multiple times a day (Table 1). Therefore, to safely achieve a total dose 600mg Na+ (6-fold increase from single dose) we will use 2 tsps (9.84 ml) of Buoy diluted in 4% of total body water (TBW), calculated based on subject's weight. Equation will be [patient weight (kg) * 0.6 (* 0.8 for women) = total body water * 4.0% = liters of water consumed over 6h] (Ex: Assuming a male subject weighed 70 kg: 70 * 0.6 = 42 kg TBW * 4.0% = 1.68 L of water/6h). Not to exceed a threshold of 2.5 L volume total. Therefore, a 70 kg subject would consume 9.84 ml of Buoy in 1.68 L of water over 4h. They will consume 6.25% of the total volume every 15min for 4h (105 ml for a 70kg subject).
32972281|NCT05768789|Experimental|Nuun Electrolyte Tablet|The goal is to give a one-time dose of Nuun (600mg Na+) at the start of the trial, diluted in 1L water to be consumed within 30 min (similar to prior published data, Pence 2020). Then they will drink free water for the remaining 3.5 h to equaling total amount of water consumed during Visit 1 and 2. (Ex: for a 70 kg male subject for a total volume consumption of 4% TBW they will consume 1.68 L over 4 hour. The first 1L consumed with Nuun during the first 30 min, and the remaining 680 ml of electrolyte-free water consumed during the next 3.5h (49 ml free water every 15 min).
32972282|NCT05768789|Placebo Comparator|Water|Participants will ingest the same quantity of water (4% of TBW) at a rate of 6.25% of the calculated amount of water every 15 min for 4 hours. Not to exceed a threshold of 2.5 L to avoid the risk of water intoxication (see adverse events).
33322485|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
33322486|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
32972285|NCT05768763|Experimental|Precision Community Health|The Phase B precision community health intervention will consist of a three part intervention: 1) Community-enhanced reach activities 2) Person-centered care delivery; and, 3) Data-enhancement to improve precision of interventions.
32972286|NCT05768763|Active Comparator|Control|Standard of Care
32972287|NCT05768750|Experimental|Control followed by intervention phase|"All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program).~The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes."
32972288|NCT05768737||Patients wiht Hepatitis B Virus Infection|Patients with hepatitis b virus infection.
32972289|NCT05768724|Experimental|İntervention group|METAbolic Syndrome REduction in NAvarra (RESMENA) diet was applied to adolescents with PCOS
32972290|NCT05768724|Experimental|conrol group|American Heart Association (AHA) guidelines based diet was applied to adolescents with PCOS
32972291|NCT05768711|Experimental|Azacidine+Venetoclax|"Azacitidine will be administered subcutaneously at the standard dose of 75 mg/m²/d either on days 1-7 or using a 5-2-2 schedule of the 28 day-cycles.~Patiens will be exposed to Venetoclax during the first 7 or 14 days of the 28 day-cycles (number of days of Venetoclax determined during the safety run-in phase).~At cycle 1, Venetoclax will be given orally with 3-day ramp-up, at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 7 or 14 of the cycle.~At all subsequent cycles, Venetoclax will be given orally at 400 mg on days 1 to 7 or 14 of the cycle.~Treatment duration will be 24 months."
32972292|NCT05768685||Cases|Right-handed women diagnosed with obesity will be consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders will be exclusion criteria, as well as the evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars)
32972293|NCT05768685||Controls|Age-matched, right-handed, healthy women (i.e., with no history of eating disorders) will be recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
32972294|NCT05768672||Cases|Right-handed Individuals diagnosed with obesity will be recruited at the beginning of a rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
32972295|NCT05768672||Controls|Age-matched, right-handed, individuals with a healthy weight recruited outside the hospital through personal contacts of the researchers and word-of-mouth
33411019|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
32972296|NCT05768659||Cases|Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).
32972297|NCT05768659||Controls|Not-hospitalized participants with a healthy weight
32972298|NCT05768646||ALS patients|
32972299|NCT05768646||Healthy controls|
32972300|NCT05768633||Cases|Individuals diagnosed with obstructive sleep apnea (OSA) syndrome recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
32972301|NCT05768633||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
32972302|NCT05768620|Experimental|CAVE|10 immersive virtual reality sessions to train spatial memory
32972303|NCT05768620|Active Comparator|TAU|10 paper and pencil sessions to train spatial memory
32972304|NCT05768607|Other|Patients undergone Laparoscopic Extraperitoneal Burch Colposuspension|
32972305|NCT05768581|Experimental|Concurrent Training|Experimental: home-based concurrent training composed by strength and aerobic exercises within the same training session
32972306|NCT05768581|Experimental|Strength Training|Experimental: home-based resistance training mode
32972307|NCT05768581|Experimental|Aerobic Training|Experimental: home-based endurance training mode
32972308|NCT05768568|Active Comparator|Group I|Manual Toothbrush.
32972309|NCT05768568|Active Comparator|Group II|Powered Toothbrush
32972310|NCT05768555|Active Comparator|Whole body vibration intervention at 40 Hz|40 Hz frequency WBVT
32972311|NCT05768555|Active Comparator|Whole body vibration intervention at 25 Hz|25 Hz frequency WBVT
32972312|NCT05768555|Active Comparator|Whole body vibration intervention at 0 Hz|0 Hz frequency WBVT
32972313|NCT05768542|Active Comparator|Takotsubo Control|Patients with Takotsubo receiving betablockade
32972314|NCT05768542|Placebo Comparator|Takotsubo Intervention|Patients with Takotsubo receiving placebo
32972315|NCT05768542|No Intervention|Control|Control subjects
32972316|NCT05768529|Experimental|U16|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to U16 infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
32972317|NCT05768516|Experimental|Multi-level intervention|General practioners in this arm will receive the multi-level intervention composed of Stratified care, Healthcare professional education, Patient education and Interprofessional collaboration.
32972318|NCT05768516|No Intervention|Usual care|GPs in the control group will have no specific training or intervention. They will treat patients according to their usual practice.
32972319|NCT05768503|Experimental|Chidamide + Sintilimab + Bevacizumab Group|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
32972320|NCT05768503|Active Comparator|FOLFIRI + Bevacizumab Group|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
32972321|NCT05768490|Experimental|early intervention group of brain radiotherapy|the brain radiotherapy started within 1 month of almonertinib the brain radiotherapy here specifically refers to stereotactic radiotherapy
33411020|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
32972322|NCT05768490|Active Comparator|late intervention group of brain radiotherapy|Brain radiotherapy was given within 3 months after brain progression during almonertinib treatment
32972323|NCT05768477||Chronic pain patients|Chronic pain patients with a dominant nociceptive pain mechanism, a dominant neuropathic pain mechanism and a dominant nociplastic pain mechanism. They will receive different treatments: Consultations, Interventions (injections, denervations...), Bakster therapy and interdisciplinary treatment.
33411021|NCT04696835|Experimental|children with hearing aids|
33411022|NCT04696835|Sham Comparator|control group|
33411023|NCT05158127|Experimental|Treatment Group (AlloRx)|intravenous infusion and intralesional injection of 100 million cells
33417314|NCT02978781|Experimental|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
32972324|NCT05768464|Experimental|study group|"Drug: Toripalimab 240mg, intravenously every 3 weeks~Drug: Axitinib 5 mg orraly twice daily"
32972325|NCT05768451||benign|
32972326|NCT05768451||malignant|
32972327|NCT05768438|Experimental|Mulligan with upper limb movement|"This study arm will receive following therapy~.) Mulligan with upper limb movement."
32972328|NCT05768438|Experimental|Mckenzie exercises with neural mobilizations|"This study arm will receive following therapy~.) McKenzie exercises with neural mobilizations"
32972329|NCT05768425||Dementia with Lewy Bodies (DLB)|Mild cognitive impairment (MCI) to moderate dementia with probable DLB No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
32972330|NCT05768425||Alzheimers disease (AD)|MCI to moderate dementia with probable AD. No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
32972331|NCT05768425||Healthy Controls (HC)|Young healthy controls under the age of 40.
32972332|NCT05768412||All patients|All patients undergoing Radial Artery Access requiring interventional radiology.
32972333|NCT05768399||Asthma group|Children with asthma diagnosed by a respiratory physician
32972334|NCT05768399||Control group|Children without respiratory disease or inflammatory diseases
32972335|NCT05768373|Experimental|3M™ Clinpro™ Fluoride Aqueous Solution|Investigational product.
32972336|NCT05768373|Active Comparator|3M™ Vanish™|Commercialized product
32972337|NCT05768360|Experimental|Drug cocktail/Savolitinib + Drug cocktail|Subjects will receive two different interventions in two periods (Periods 1 and 2). In Period 1, the subjects will receive a single-dose of Drug cocktail components (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E). During Period 2, the subjects will receive savolitinib dose A in combination with the Drug cocktail.
32972338|NCT05768347|Experimental|Treatment with Adoptive Cell Therapy|TIL from bladder biopsies will be propagated and cultured with interleukin-2 (IL-2) to a target goal of >30 million cells. These TIL then undergo rapid clonal expansion (REP) by incubation with anti-CD3 monoclonal antibody (mAb), resulting in >500-fold expansion. After 4-6 weeks culture time intravesical TIL will be administered via intravesical infusion, consisting of up to 3.2e8 cells in 40 mL aliquot. Intravesical therapy will be administered for up to 2 hours. This treatment will occur four times (Day 0, Day 7, Day 14 and Day 21).
32972339|NCT05768334|Active Comparator|lubiprostone|50 patients
32972340|NCT05768334|Placebo Comparator|Control arm|50 patients
32972341|NCT05768308|Experimental|Internet CBT-UP intervention (iCBT-UP)|Patricipants in the experimental group will receive online cbt intervention for students with adjustment disorder (iCBT-UP).
32972342|NCT05768308|Active Comparator|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR).
32972343|NCT05768308|No Intervention|Waiting List|Participants from the waiting list condition will receive access to the choosen intervention after 6-weeks waiting period.
32972344|NCT05768295|Other|Axiom BL X3|Dental implant Axiom BL X3
32972345|NCT05768269||Cellular Therapy|Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
32972346|NCT05768256|Experimental|Advanced cancer patients|
32972347|NCT05768243|Experimental|Treated with hyaluronic acid + SRP|After scaling and root planing, hyaluronic acid (GENGIGEL®) will be applied in the following forms (one ml of 0.8% HA was injected subgingivally once every four weeks), topically (0.2 ml of 0.8% HA applied by the patient twice daily for the following 14 days after the subgingival application).
32972348|NCT05768243|Experimental|Treated with red i-PRF + SRP|The red i-PRF will be injected into the pocket at the point of interdental space after SRP. Moreover, to control bleeding due to the needle tip after the procedure, a saline-soaked sponge will be placed between the lip and the gingiva and removed after 15 minutes. A total of four sessions of i-PRF will be administered to patients at a ten-day interval.
33322487|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
32972349|NCT05768243|No Intervention|Scaling and root planing only|no adjunctive treatment will be done to scaling and root planing
32972350|NCT05768230|Experimental|treatment group A|intravenously injected levosimendan 12.5mg with 5% glucose injection 50ml configuration at 2ml/h for 24h
32972351|NCT05768230|Placebo Comparator|treatment group B|treatment group B: control group with 5% glucose injection 2ml/h for 24h
32972352|NCT05768204|Experimental|Experimental group|Prednisolone, oral, 2 mg/kg.d (maximum dose 60 mg/day), two or three times a day , 5 days.
32972353|NCT05768204|Placebo Comparator|Placebo group|The same amount of placebo was taken orally as the trial for 5 days
32972354|NCT05768191|Active Comparator|Humulin N plus Humulin R|15 subjects will receive insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals
32972355|NCT05768191|Experimental|Premix human isophane suspension plus insulin human injection|15 subjects will receive premix insulin human isophane suspension and insulin human injection twice daily
32972357|NCT05768152|Experimental|Repeated low-level red-light (RLRL) therapy|single vision spectacles & RLRL
32972358|NCT05768139|Experimental|Part 1.1: Dose Escalation (Breast)|Cohort A0: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
32972359|NCT05768139|Experimental|Part 1.2-DE: Dose expansion at MTD|"Cohort A1: Gynecologic cancers~Cohort A2: HNSCC~Cohort A3: Other solid tumors not included in Cohorts A0, A1, or A2~Mutations for Cohorts A1, A2, and A3: PI3Kα H1047X mutations or other kinase domain mutations~Cohort A4: Solid tumors expressing PI3Kα helical domain mutations (E542/E545)"
32972360|NCT05768139|Experimental|Part 1.2-DS: RP2D Selection (Breast)|"Recommended Phase 2 dose (RP2D)~Cohort A0: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations."
32972361|NCT05768139|Experimental|Part 1.3: RP2D Expansion (Breast)|Cohort A0: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
33322488|NCT03506438|Experimental|Mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
32972362|NCT05768139|Experimental|Part 2.1: RP2D Selection|Cohort B: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
32972363|NCT05768139|Experimental|Part 2.2: RP2D Expansion|Cohort B: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
32972364|NCT05768126|Experimental|Rivastigmine|Rivastigmine, transdermal administration with a dosage of 4.6 and 9.6mg. The patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
32972365|NCT05768126|Sham Comparator|Sham|Non-active patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
32972366|NCT05768113||Covixyl-V ELAH|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment
32972367|NCT05768113||Placebo|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment. This one is Placebo
33322489|NCT03506438|Placebo Comparator|Usual care|Usual ICU care
33411024|NCT05157035|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
33411025|NCT05157035|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
33411026|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
33411027|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
33411028|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
33411029|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
33411030|NCT05571605|Experimental|Exercise Training|Participants will exercise 3 times a week on a stationary bicycle. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) and increase as tolerated to a maximum of 80% of maximal heart rate reserve. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes per session.
33411031|NCT05571605|Placebo Comparator|Stretching|Participants will undergo progressive whole body stretching and balance exercises. This type of low intensity exercise is designed not to increase heart rate but rather to improve joint mobility and the ability to perform activities of daily living. This will serve as the control group to the exercise group. The control group will come in for stretching sessions 3 times per week for 20-45 minutes.
33411032|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
33411033|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
33411034|NCT05571371||Epileptic seizure|Measuring inflammatory serum biomarkers in epileptic seizure patients and psychogenic non-epileptic seizure
33411035|NCT03385265|Experimental|DIPPer Academy|Parents randomized to this group will participate in the DIPPer Academy curriculum.
33411036|NCT03385265|Active Comparator|Standard of Care Control|Parents randomized to this group will receive care as usual from their child's diabetes provider
33411037|NCT05571449|Experimental|Experimental group|Planning of tibial plateau fracture osteosynthesis by using a three-dimensional model of the fracture.
32972368|NCT05768100|Experimental|Bis-Hexanoyl (R)-1,3-Butanediol|
32972369|NCT05768100|Placebo Comparator|Placebo|
32972370|NCT05768087|Experimental|Escalated proton therapy|
32972371|NCT05768074||Therapists|20 therapists who were already trained will participate in a qualitative interview to gather perceptions and experiences of the therapists about the process of learning and practicing specific CIFFTA competencies from the therapy training platform (time 1 interview) and later, about their unique experiences related to implementation of the Evidenced Based Treatment (EBT), delivery of competencies learned, and the application of EBT in a real-world context (time 2).
32972372|NCT05768074||Agency leaders|16 agency leaders from the main study will participate in qualitative interviews to 2) gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work (time 1), and later regarding their agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness (at time 2).
33322490|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
33322491|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
32972373|NCT05768035|Experimental|Patients with acute leukemia or myelodysplastic syndrome and eligible for an haplo PT-Cy HSCT|"2 cohorts of patients will be included in the study based on the type of conditioning regimen:~The cohort A will include up to 17 patients receiving a myeloablative conditioning (MAC).~The cohort B will include up to 17 patients receiving a reduced intensity conditioning (RIC).~Enrollment of patients in each cohort will be done in parallel."
32972374|NCT05768022|Experimental|Cura kinesio-taping|100 subjects (females and males) will receive kinesio taping from origin to insertion on the superficial muscles of Quadriceps femoris (VM,VL, RF).
32972375|NCT05768022|Placebo Comparator|Placebo|100 subjects (females and males) will receive placebo kinesio-taping across quadriceps.
32972376|NCT05767983|Experimental|Fat-free milk|Treatment
32972377|NCT05767983|Experimental|Fat-free yogurt|Treatment
32972378|NCT05767983|Experimental|Low-fat cheese|Treatment
32972379|NCT05767983|Experimental|Fruit juice|Treatment
32972380|NCT05767983|Experimental|Snack skipping|Treatment
33322492|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
32972383|NCT05767957|Active Comparator|Control group|
32972384|NCT05767957|Experimental|Intervention group|
32972385|NCT05767944|Experimental|Wide Awake Local Anesthesia (WALANT)|Study arm: (WALANT) patient received local anaesthesia infiltration at site of surgery for hand flexor tendons repair.
32972386|NCT05767944|Active Comparator|Supra Clavicular- Brachial Plexus Block (SC-BPB)|Control arm:(SC-BPB): ultrasound-guided injection of local aesthetics at supra-clavicular level where brachial plexus trunks are located this will provide anesthesia for the whole upper limb distal to shoulder joint.
32972387|NCT05767892|Experimental|YK-029A Group (Arm A)|
32972388|NCT05767892|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|
32972389|NCT05767879|Experimental|Neo adjuvant BRAF/MEK inhibition in pN1c Melanoma|"Neo adjuvant BRAF/MEK inhibition (encorafenib/binimetinib).~Patients receive encorafenib 450 mg once daily for a period of 8 weeks. Patients receive 45 mg binimetinib twice daily for a period of 8 weeks. After the neo-adjuvant therapie, patients will receive encorafenib 450 mg once daily fand binimetinib 45mg twice daily for 44 weeks."
32972390|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical worsening|(PaO2/FiO2<200)
32972391|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical improvement|(PaO2/FiO2>200)
32972392|NCT05767840|Experimental|mgGap-IG|MhGap-IG intervention to be delivered to depression and self-harm cohorts
32972393|NCT05767827|Active Comparator|Group R|0.35% ropivacaine 20ml, 1.5% lidocaine with adrenaline 10ml = 30 ml
32972394|NCT05767827|Experimental|Group RD|0.35% ropivacaine and 1mcg/ kg dexmedetomidine (20 ml), 1.5% lidocaine with adrenaline (10ml) = 30 ml
32972395|NCT05767814||PsO patients at risk of PsA development|
32972396|NCT05767814||naive to treatment PsA|
32972397|NCT05767814||TNF-inhibitor resistant PsA|
32972398|NCT05767814||IL-17-inhibitor resistant PsA|
32972399|NCT05767814||TNF-inhibitor induced remission PsA|
32972400|NCT05767814||IL-17-inhibitor induced remission PsA|
32972401|NCT05767814||c-DMARDs resistant PsA|
32972402|NCT05767814||c-DMARDs resistant RA|
32972403|NCT05767801||RA patients in sustained clinical and ultrasound remission not changing treatment|
32972404|NCT05767801||RA patients in sustained clinical and ultrasound remission changing treatment|
32972405|NCT05767788|Experimental|Movement with Mobilization (MWM)|Active movement with passive mobilization gliding force
32972406|NCT05767788|Sham Comparator|Sham Movement with Mobilization (Sham MWM)|Active movement with passive light touch gliding force
32972407|NCT05767775||RA patients with BMI≥ 25 eligible to Tofacitinib|
32972408|NCT05767775||RA patients with BMI<25 eligible to Tofacitinib|
32972409|NCT05767749|Experimental|Lidocaine + epinephrine vs Ropivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of . Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 0.5ml of Naropin (ropivacaine) 0.2% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
32972410|NCT05767749|Experimental|Lidocaine + epinephrine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of lidocaine + epinephrine into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
32972411|NCT05767749|Experimental|Ropivacaine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of Naropin (ropivacaine) 0.2% into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
32972412|NCT05767736||Vumerity Cohort|Participants who have been prescribed Vumerity as a newly initiating treatment and not previously treated with Tecfidera are selected and the available data is collected retrospectively.
32972413|NCT05767736||Tecfidera Cohort|Participants who have been prescribed Tecfidera as a newly initiating treatment and not previously treated with Vumerity are selected and the available data is collected retrospectively.
32972414|NCT05767736||Vumerity/Tecfidera Switch Cohort|Participants who have been treated with Tecfidera and then switched to Vumerity as per routine medical care are selected and the available data is collected retrospectively.
32972415|NCT05767736||Selected Disease Modifying Therapies (DMTs) Treated Cohort|Participants who have been prescribed with other selected DMTs (teriflunomide, beta-interferons, or glatiramer acetate) and are not previously treated with Vumerity or Tecfidera are selected and the available data is collected retrospectively.
32972416|NCT05767723|Active Comparator|Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
32972417|NCT05767723|Experimental|Ticagrelor alone or prasugrel alone|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor (90 mg twice daily) or prasugrel alone (10 mg once daily) for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
32972418|NCT05767710|Experimental|AI telerehabilitation - Tai Chi|All sessions were conducted online, with participants practicing along with Tai Chi videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
32972419|NCT05767710|Active Comparator|general telerehabilitation - Tai Chi|All sessions were conducted in an online format, with participants practicing along with Tai Chi videos while the professional Tai Chi instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
32972420|NCT05767710|Active Comparator|traditional rehabilitation - Tai Chi|All sessions were conducted offline and implemented by professional Tai Chi instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Tai Chi group.
32972421|NCT05767710|Experimental|AI telerehabilitation - Yi Jin Jing|All sessions were conducted online, with participants practicing along with Yi Jin Jing videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
32972422|NCT05767710|Active Comparator|general telerehabilitation - Yi Jin Jing|All sessions were conducted in an online format, with participants practicing along with Yi Jin Jing videos while the professional Yi Jin Jing instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
32972423|NCT05767710|Active Comparator|traditional rehabilitation - Yi Jin Jing|All sessions were conducted offline and implemented by professional Yi Jin Jing instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Yi Jin Jing group.
32972424|NCT05767710|Experimental|AI telerehabilitation - Ba Duan Jin|All sessions were conducted online, with participants practicing along with Ba Duan Jin videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
32972425|NCT05767710|Active Comparator|general telerehabilitation - Ba Duan Jin|All sessions were conducted in an online format, with participants practicing along with Ba Duan Jin videos while the professional Ba Duan Jin instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
32972426|NCT05767710|Active Comparator|traditional rehabilitation - Ba Duan Jin|All sessions were conducted offline and implemented by professional Ba Duan Jin instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Ba Duan Jin group.
32972427|NCT05767684|Experimental|Arm 1: DCs monotherapy|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
32972428|NCT05767684|Experimental|Arm 2: DCs with booster of anti-VEGF/anti-PD-1.|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309 plus lenvatinib 10mg QD on day 43-77 and nivolumab 3mg/kg on day 43, 57 and 71.
32972429|NCT05767671|Other|Study Population Group|People in the ICU on mechanical ventilation due to a diagnosis of ARDS or any other diagnosis that requires mechanical ventilation (following surgery, sepsis without lung involvement, seizures)
32972430|NCT05767658|Experimental|Safe Sleep|
32972431|NCT05767658|Experimental|Breastfeeding|
32972432|NCT05767658|Experimental|Safe Sleep and Breastfeeding|
32972433|NCT05767658|Active Comparator|Early Brain Development and Parent -Child Relationships|
32972434|NCT05767632|Active Comparator|R reference (first dose)|Reference drugs (Vesicare & Betmiga)
32972435|NCT05767632|Experimental|T test|Test drug (Mirfenacin MR)
32972436|NCT05767632|Active Comparator|R reference (second dose)|Reference drugs (Vesicare & Betmiga)
32972437|NCT05767593||Depressed Adults|Adults with a current diagnosis of Major Depressive Episode
32972438|NCT05767593||Healthy Controls|Adults without a current or past diagnosis of Major Depressive Episode
32972439|NCT05767580||alzehimer demantia geriatric|It is a group of individuals over the age of 65, diagnosed with Alzheimer's dementia, able to walk independently, have no communication problems, and volunteer to participate in the research.
32972440|NCT05767580||healty geriatric|This is a group of healthy geriatric individuals over the age of 65 who have not been diagnosed with Alzheimer's dementia, can walk independently, have no communication problems, and volunteered to participate in the study.
32972443|NCT05767541|Experimental|Pilates group|The Pilates technique consists of a series of low-impact exercises that build strength and flexibility throughout the body. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
32972444|NCT05767541|Active Comparator|Resistance group|Resistance exercises are anaerobic physical exercises, uses low number of repetitions with adjustable intensity contribute to hypertrophy of the muscle fibers and increase in muscle strength. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
32972445|NCT05767528||Case Group|Participants who were diagnosed as MIBC and plan to receive neoadjuvant therapy before the surgery, above 18 years of age, regardless of gender
32972446|NCT05767515|Active Comparator|Metformin Group|Metformin will be used in dose of 500mg BD daily for 30 infertile female PCOS patients
32972447|NCT05767515|Experimental|Inositol isomers Group|Inositols isomers (Myo inositol and D- Chiro Inositol in its physiological ratio) will be used 2000mg BD Daily for 30 infertile female PCOS patients
32972448|NCT05767515|Experimental|Acetyl-L- Carnitine Group|Acetyl-L-Carnitine will be given in dose of 1000mgBD Daily for 30 infertile female PCOS patients
32972449|NCT05767515|Experimental|Combine Group|Inositol isomers and Acetyl-L-Carnitine will be given in dose of 2000mg and 1000mg respectively BD daily for 30 infertile female PCOS patients
32972450|NCT05767476||Newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia|
32972451|NCT05767450|Experimental|Treated|Probiotic name: Vivomixx® Form: powder Dosage: 4,4g/sachet with 450 billion of lactobacilli and bifidobacteria in a base of maltose Frequency: 1 sachet/day for children <10 year old or 2 sachets/day for children >10 year old Duration: 90 days
32972452|NCT05767450|Placebo Comparator|Untreated|Product name: Placebo Form: powder Dosage: 4,4g/sachet containing maltose Frequency: 1 sachet/day for children <10 year old or 2 sachets/day for children >10 year old Duration: 90 days
32972453|NCT05767437|Experimental|Abdominal drawing-in maneuver exercise, afterward Sham therapy(conventional physiotherapy)|Participants first received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy. Afterward a washout period of one month, they then received sham therapy (conventional therapy_release pain or upper limb mobilization) 2 times a week for 4 weeks. Each session is 40 minutes.
32972454|NCT05767437|Experimental|Sham therapy(conventional physiotherapy), afterward Abdominal drawing-in maneuver exercise|Participants first received sham therapy(release pain or upper limb mobilization)2 times a week for 4 weeks. Each session is 40 minutes. Afterward a washout period of one month, they then received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy
32972455|NCT05767385|Experimental|Single Arm|Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.
32972456|NCT05767372|Experimental|Study group|The participants will receive Inspiratory muscle trainer and Coherent breathing exercise three times per week for 12 weeks.
32972457|NCT05767372|Experimental|Control group|The participants will receive Inspiratory muscle training three times per week for 12 weeks.
32972458|NCT05767359|Experimental|Safety Run-In|"Participants will be enrolled into each of the 2 safety run-in phases in a standard 3 + 3 design.~- Participants will undergo study procedures as outlined:~Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~Stem cell collection on-site post-apheresis per standard care.~Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~Follow-up for 3 years post-treatment and up to 15 years."
32972459|NCT05767359|Experimental|Cilta-Cel Dose Expansion Cohort|"Expansion cohort of 14 participants will be enrolled after safety run-in phases, and participants will undergo study procedures as outlined:~Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~Stem cell collection on-site post-apheresis per standard care.~Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~Follow-up for 3 years post-treatment and up to 15 years."
32972460|NCT05767346|Experimental|Aficamten up to 20 mg plus placebo for metoprolol|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.
32972461|NCT05767346|Active Comparator|Metoprolol succinate up to 200 mg plus placebo for aficamten|Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.
32972462|NCT05767320|Active Comparator|open approach for perforated pectic ulcer|repair of perforated peptic ulcer by open technique (exploration)
32972463|NCT05767320|Active Comparator|lap. approach for perforated peptic ulcer|repair of perforated peptic ulcer by laparoscopy
32972464|NCT05767307||MRI-first|"Biopsy naïve men referred to MRI-first due to suspicion of PC (elevated PSA and/or suspect DRE) at one of the following three major urology/uroradiology centers in Denmark: Aarhus University Hospital (AUH), Herlev & Gentofte Hospital (HH), and Odense University Hospital (OUH), where MRI and targeted biopsy is already implemented in clinical use."
32972465|NCT05767294||Neonatal|
32972466|NCT05767294||1-3 months old|
32972467|NCT05767294||3-6 months old|
32972468|NCT05767294||6 months-1 year old|
32972469|NCT05767294||1-2 years old|
32972470|NCT05767294||2-5 years old|
32972471|NCT05767281||Children 3 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
32972472|NCT05767281||Children 5-6 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
32972473|NCT05767281||Children 7 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including only an examination of the oral cavity.
32972474|NCT05767281||Children 12 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
32972475|NCT05767281||Teenagers 15 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
32972476|NCT05767281||Teenagers 18 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
32972477|NCT05767268||treated with Lokomat|Patients perform a rehabilitation treatment of 15 or 20 sessions with lokomat + 15 or 20 sessions of physiotherapy in 3 or 4 weeks as defined by the clinician. During two or three sessions they wear a wearable device Empatica E4 that measure their electrocardiographic (ECG) activity and electrodermal activity (EDA). They also have a baseline acquisition of these signals in their room at hospital.
32972478|NCT05767255|Active Comparator|basal group bolus|"Insulin Glargine required on an in-hospital basis~Insulin Aspart required on an in-hospital basis"
32972479|NCT05767255|Experimental|insulin degludec + liraglutide ( ideglira)|16 Units once a day
32972480|NCT05767242||MEDEA BabyLab Cohort|
32972481|NCT05767229|Experimental|Carvedilol for 1.5 hrs|Carvedilol 0.2 mg/kg for 1.52 hrs
32972482|NCT05767216|Other|Down syndrome children|Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
32972483|NCT05767203|Experimental|Patients with Down syndrome or other Intellectual deficiency of genetic origin|Patients with Down syndrome or with other intellectual deficiency of genetic origin followed at the outpatients clinic of the Institut Jérôme Lejeune.
32972484|NCT05767177|Experimental|High Carbohydrate Diet vs High Fat Diet|"In the current project, the situation applies to individuals with obesity (body mass index (BMI) 35 to 45 kg/m2). In one case the diet is of the type high-carbohydrate diet and in the other case high-fat diet. The idea is that the research subjects should subsist on these diets for the respective 14 days. The energy content of the diet periods must be the same and correspond to the participants' daily needs. Each participant is drawn to one diet for 2 weeks. After a break of at least 3 weeks, the second diet is taken for 2 weeks."
32972485|NCT05767164|No Intervention|Preoperative|
32972486|NCT05767164|Experimental|postoperative (3 months)|
32972487|NCT05767164|Experimental|postoperative (6 months)|
32972488|NCT05767164|Experimental|postoperative (1 year)|
32972489|NCT05767138||Bamako Participants|301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.
32972490|NCT05767125|Experimental|APRV Group|Patients with moderate-to-severe ARDS were supported with APRV.
32972491|NCT05767125|Active Comparator|LTV Group|Patients with moderate-to-severe ARDS were supported with LTV.
32972492|NCT05767112|Active Comparator|HMB-Ca in water|Investigate whether the pharmacological form of HMB has any impact on its bioavailability and pharmacokinetic profile.
32972493|NCT05767112|Experimental|HMB-Ca in capsules|Avaliate AUC of HMB-Calcium form supplementation.
32972494|NCT05767112|Experimental|HMB-FA|Avaliate AUC of HMB-free acid form supplementation.
32972495|NCT05767099||Patient undergoing general anesthesia with videolaryngoscopy intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway.
33411038|NCT05571449|Other|Control group|Standard planning of tibial plateau fracture osteosynthesis (by plain radiography and computed tomography imaging).
33411039|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
32972499|NCT05767073|Experimental|Intervention|Lifestyle intervention
32972500|NCT05767060|Experimental|BAT7104 Injection 0.1 mg/kg|frequency: Q2W
32972501|NCT05767060|Experimental|BAT7104 Injection 0.3 mg/kg|frequency: Q2W
32972502|NCT05767060|Experimental|BAT7104 Injection 1 mg/kg|frequency: Q2W
32972503|NCT05767060|Experimental|BAT7104 Injection 3 mg/kg|frequency: Q2W
32972504|NCT05767060|Experimental|BAT7104 Injection 10 mg/kg|frequency: Q2W
32972505|NCT05767060|Experimental|BAT7104 Injection 20 mg/kg|frequency: Q2W
32972506|NCT05767060|Experimental|BAT7104 Injection 40 mg/kg|frequency: Q2W
32972507|NCT05767047|Experimental|Apremilast|Participants with a weight between ≥ 12 kg to < 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to < 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.
33322493|NCT05189548|Experimental|Adsorbed a cell-free whitening break (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine.
32972508|NCT05767034|Experimental|Secukinumab 300 mg|randomized in 1:1:1 ratio every 4 weeks
32972509|NCT05767034|Experimental|Secukinumab 150 mg|randomized in 1:1:1 ratio every 4 weeks
32972510|NCT05767034|Placebo Comparator|Placebo to secukinumab|randomized in 1:1:1 ratio every 4 weeks
32972511|NCT05767021|Experimental|Mirikizumab|Participants will receive mirikizumab intravenously (IV) and mirikizumab subcutaneously (SC).
32972512|NCT05766878|Active Comparator|machined collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and traditional machined collar. A definitive transgingival standard machined abutment will be immediately screwed. Four months later, prosthetic procedures will start."
33322494|NCT01562522|Experimental|Intervention group|
33322495|NCT01562522|No Intervention|Control group|
33322496|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
33322497|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
33322498|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
32899239|NCT00265850|Experimental|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
32899240|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
33322499|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
33322500|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
33322501|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
33322502|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
33322503|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
33322504|NCT03945942|Other|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
33322505|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
33322506|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
33322507|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
33322508|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
33322509|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
33322510|NCT05190250||Study group - women with idiopathic infertility|Endometrial biopsy during implantation window Blood analysis
33322511|NCT05190250||Control group - women with naturally conceived offspring|Endometrial biopsy during implantation window Blood analysis
33322512|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
33322513|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
33322514|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
33322515|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
33322516|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
33322517|NCT03946176|Experimental|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
33322518|NCT03946176|Placebo Comparator|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
33322519|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
33322520|NCT05258942||Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery|Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery
33322521|NCT05258942||Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)|Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)
33322522|NCT05258942||Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery|Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery
33322523|NCT05258942||Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery|Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery
33322524|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)|Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)
33322525|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Mitra Clip|Heart Failure Patients Scheduled for Transcatheter Mitra Clip
33322526|NCT05258942||Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation|Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation
33322527|NCT05258942||Heart Failure Patients Scheduled for Stellate Gangliectomy|Heart Failure Patients Scheduled for Stellate Gangliectomy
33322528|NCT05258942||Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery|Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery
33322529|NCT05258942||Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery|Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery
33322530|NCT01107522|Experimental|Arm A|Single Agent CTO
33322531|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
33322532|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
32972513|NCT05766878|Experimental|anodized collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and anodized collar. A definitive transgingival anodized abutment will be immediately screwed. Four months later, prosthetic procedures will start."
33322533|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
33411040|NCT04651439|Experimental|FILGRASTIM|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + ZARZIO@ (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)
33411041|NCT04651439|Placebo Comparator|PLACEBO|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + 20 ml GLUCOSE 5% administrated by IV route over a period of 5 consecutive days (1 injection per day during 30 minutes)
33411042|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
33411043|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
33411044|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
33411045|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
33411046|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
33411047|NCT04034225|Experimental|SNS-301 added to pembrolizumab|"SNS-301~Pembrolizumab"
33411048|NCT05571215|Experimental|Combined tDCS and PNE|This is a single-arm pilot study used to evaluate the treatment effects of combining pain neuroscience education (PNE) and transcranial direct current stimulation (tDCS). All participants will receive the same Intervention, which includes five sessions of tDCS to the left dorsolateral prefrontal cortex (DLPFC) plus PNE over two weeks.
33411049|NCT03690947|Experimental|Combination Therapy Group|
33322534|NCT03983070|Active Comparator|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
33411050|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
33411051|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
33411052|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
33411053|NCT01313741|Experimental|Single arm shoulder arthroplasty|
33411054|NCT02999178|Experimental|Nintedanib|
33411055|NCT02999178|Placebo Comparator|Placebo|
33411056|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
33411057|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
33411058|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
33411059|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
33411060|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
33411061|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
33411062|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
33411063|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
32972514|NCT05766592|Experimental|LGBTQ-affirmative CBT|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 16 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual and gender minority mental health disparities.
33411064|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
33411065|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
33411066|NCT05111990||Maternal pre-gestational BMI 18.5<25|
33411067|NCT05111990||Maternal pre-gestational BMI 25<30|
33411068|NCT05111990||Maternal pre-gestational BMI >30|
33411069|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
33411070|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
33411071|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
33411072|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
33411073|NCT03722810|Active Comparator|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
33411074|NCT03722810|Sham Comparator|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
33411075|NCT02236676|Active Comparator|Nap after rehearsal trials|A 30-minute daytime nap after training
33411076|NCT02236676|Placebo Comparator|Resting while awake|Placebo condition of 30 minutes between training and retesting in which the half hour is spent resting awake in bed.
33411077|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
33411078|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
32899241|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
33411079|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
33411080|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
32899242|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
32899243|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
33411081|NCT03618914||Non-anemic women|
33411082|NCT03618914||anemic women|anemia due to iron deficiency
33411083|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
33411084|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
33411085|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
33411086|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
33411087|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
33411088|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
33411089|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
33411090|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
33411091|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
33411092|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
33411093|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
33411094|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
33411095|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
33411096|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
33411097|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
32899244|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
32899245|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
32899246|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
33411098|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
33411099|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
33411100|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
32972515|NCT05766592|Experimental|ABFT-SGM|Individuals assigned to attachment-based family therapy for sexual and gender minorities will receive a 16-session sequence of family-based therapy delivered via telehealth. This sequence will include sessions with sexual and/or gender minority adult children alone, adult children and parent(s), and parent(s) alone. Sessions will address the quality parent-child relationship in relation to child sexual orientation and gender identity to target mental health disparities.
32972516|NCT05765968|Experimental|Double Stimulation Protocol|Double stimulations were performed during the follicular and luteal phases in the same cycle by rFSH&hmg.
32972517|NCT05765968|Active Comparator|Antagonist Stimulation Protocol|The classical antagonist protocol were performed by rFSH,hmg and antagonist.
32972518|NCT05765955|Active Comparator|POLB 001 30 mg|
32972519|NCT05765955|Active Comparator|POLB 001 70 mg|
32972520|NCT05765955|Active Comparator|POLB 001 150 mg|
32972521|NCT05765955|Placebo Comparator|Placebo|
32972522|NCT05765513|Experimental|35kDa hyaluronan fragment HA35 injection|The investigator injected 35kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg.The distribution of injection amount was determined by the location of gingival inflammation.
32972523|NCT05765214|Experimental|Intervention Group (IG)|Participants randomized to the IG will receive a customized patient-centered, culturally appropriate education program. Patients randomized to the IG will participate in eight (8) education sessions. A booklet with colorectal cancer education and nutrition education will be developed and print materials given to the participants to use as a workbook.
32972524|NCT05765214|No Intervention|Usual Care (UC)|Patients randomized to UC group will continue to receive care at the clinic without any intervention from the study team.
32972525|NCT05765019|Experimental|Spinal mobilization group|
32972526|NCT05765019|Active Comparator|Core stabilization exercise group|
32972527|NCT05764733|Experimental|Resistance Training (RT) + Bisphosphonate (BIS)|"Progressive Resistance Training (RT) and Bone-Loading Exercise~+ 70 mg/weekly dose alendronate"
32972528|NCT05764733|Experimental|No RT + BIS|"No Resistance Training~+ 70 mg/weekly dose alendronate"
32972529|NCT05764733|Active Comparator|No RT + Placebo (PL)|No Resistance Training + Weekly Placebo
32972530|NCT05764733|Active Comparator|RT + PL|Progressive RT and Bone-Loading Exercise + Weekly Placebo
32972531|NCT05764070|Experimental|Non Invasive Vagus Stimulation|Aerobic exercise + Non Invasive- Vagus Stimulation
32972532|NCT05764070|Placebo Comparator|Placebo Non Invasive Vagus Stimulation|Aerobic exercise + Placebo Non Invasive Vagus Stimulation
32972533|NCT05764031|Experimental|Clinical pilates group|The clinical pilates group received a total of 40 min of exercise training, including 5 min of warm-up exercises, 30 min of clinical pilates exercises and 5 min of cooldown exercises. Clinical Pilates training was performed as group sessions under the supervision of a physiotherapist Exercise training was provided to the clinical pilates group 2 days a week over a period of 8 weeks.
33411101|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
33411102|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
32972534|NCT05764031|Experimental|Aerobic exercise group|The aerobic exercise group received a total of 40 min of aerobic exercise training, including 5 min of warm-up exercises, 30 min of aerobic cycling exercise and 5 min of cooldown exercises. Aerobic exercises were performed individually under the supervision of a physiotherapist. Aerobic exercises were performed using an upright bike (HS-1200; Hattrick-Pro, Istanbul, Turkey). The exercises were planned as moderate-intensity exercises, at 60-70% of the maximum heart rate (MHR). Exercise training was provided to the aerobic exercise group 2 days a week over a period of 8 weeks.
32972535|NCT05762965|Experimental|GOS 1|Galacto-oligosaccharide
32972536|NCT05762965|Experimental|GOS 2|Galacto-oligosaccharide
32972537|NCT05762107|Experimental|ZT-01 7 mg|Participants receive placebo and ZT-01 7 mg each by subcutaneous injection daily for 28 days, randomized to order
32972538|NCT05762107|Experimental|ZT-01 15 mg|Participants receive placebo and ZT-01 15 mg by subcutaneous injection daily for 28 days, randomized to order
32972539|NCT05762107|Experimental|ZT-01 22 mg|Participants receive placebo and ZT-01 22 mg by subcutaneous injection daily for 28 days, randomized to order
32972540|NCT05761691|Experimental|Children treated for Early childhood caries under general anesthesia (DGA)|GA group (Study group) the dental treatment was provided as a day care surgery under general anasthesia for healthy child patients.
32972541|NCT05761691|Experimental|Children treated for Early childhood caries under Local anesthesia (LA)|LA goup (control group) the average number of dental visits was required to finish the treatment plan in local anasthesia group around five to six visits.
32972542|NCT05761431|Experimental|5 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg (8 active : 2 placebo).
32972543|NCT05761431|Experimental|10 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 10 mg (8 active : 2 placebo).
32972544|NCT05761431|Experimental|20 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 20 mg (8 active : 2 placebo).
32972545|NCT05761431|Experimental|30 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 30 mg (8 active : 2 placebo).
32972546|NCT05761431|Experimental|Octreotide long-acting release ( Sandostatin LAR®) 20 mg cohort|Subjects will be treated with single dose of octreotide long-acting release ( Sandostatin LAR®) at dose of 20 mg.
33411103|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
33411104|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
33411105|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
33411106|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
33411107|NCT03618212||Myeloma patients|
32972547|NCT05761431|Experimental|Sandostatin® 0.1mg cohort|Subjects will be treated with single dose of Sandostatin® at dose of 0.1mg.
32972548|NCT05761275|Active Comparator|Conventional Abdominal Laparoscopy|Use of conventional transabdominal laparoscopy as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
32972549|NCT05761275|Experimental|vNOTES|Use of vNOTES (Transvaginal Natural Orifice Transluminal Endoscopic Surgery) as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
32972550|NCT05761262||PATIENTS WITH SMA TYPE I|
32972551|NCT05761262||PATIENTS WITH SMA TYPE II|
32972552|NCT05761262||PATIENTS WITH SMA TYPE III|
32972553|NCT05761197||Children with history of OPC|Individuals in the non-OPC cohort will be age and sex-matched to individuals in the OPC cohort.
32972554|NCT05761197||Children without history of OPC|Individuals in the OPC cohort will be age and sex-matched to individuals in the non-OPC cohort.
32972555|NCT05760924|Active Comparator|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement will be performed in this group of patients.
32972556|NCT05760924|Experimental|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right and left ventricular pacing will be performed in this group of patients.
32972557|NCT05760924|Experimental|Cardiac Resynchronization Therapy with Combined Left Bundle Branch and Left Ventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right ventricular pacing will be performed in this group of patients.
32972558|NCT05759741|Experimental|MIYAIRI 588 group|4 tablets of MIYAIRI 588 were inserted into distal ileostomy once a week for 6 months.
32972559|NCT05759741|No Intervention|control group|The anastomosis stoma was followed up monthly in the outpatient department
32972560|NCT05759065|Experimental|Tele-Brief Behavioral Treatment for Insomnia|
32972561|NCT05759065|Active Comparator|Tele-Cognitive-Behavioral Therapy for Insomnia|
32972562|NCT05757843|Experimental|Consolidation to Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Prior to the 5th cycle the first mandatory ctDNA test will be done. If it's negative and the subsequent test 4 weeks later prior to cycle 6 is negative, then Durvalumab will be stopped otherwise subject will continue consolidation durvalumab until 2 negative ctDNA analyses performed approximately 4 weeks apart or up to 1 year of consolidation per standard medical practice is complete.
32972563|NCT05757804||Non-disease controls|
32972564|NCT05757804||PD patients|
32972565|NCT05757804||DLB patients|
32972566|NCT05757804||MSA patients|
32972567|NCT05757557|Active Comparator|Control group|Oxygen-air mixture without NO after intubation, during CPB, and six hours after surgery.
32972568|NCT05757557|Experimental|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperative after trachea intubation, during CPB, and six hours after surgery.
32972569|NCT05757427|Experimental|All patients will have an MBI scan with Wavelia #2 in addition to standard reference imaging.|Patients with an investigator assessed discrete breast abnormality of size >1cm and who attend the symptomatic breast unit for assessment as per standard of care protocol will be considered for participation in this clinical investigation.
32972570|NCT05756907|Experimental|Dose Level 1|SON-1010 Dose Level 1 + Atezolizumab
32972571|NCT05756907|Experimental|Dose Level 2|SON-1010 Dose Level 2 + Atezolizumab
32972572|NCT05756907|Experimental|Dose Level 3|SON-1010 Dose Level 3 + Atezolizumab
32972573|NCT05756907|Experimental|Dose Level 4|SON-1010 Dose Level 4 + Atezolizumab
32972574|NCT05756907|Experimental|Dose Level 5|SON-1010 Dose Level 5 + Atezolizumab
32972575|NCT05756907|Experimental|RP2D Expansion in Patients with Platinum-resistant Ovarian Cancer|RP2D Dose of SON-1010 + Atezolizumab
32972576|NCT05756907|Experimental|Randomized Arm #1 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D Alone
32972577|NCT05756907|Experimental|Randomized Arm #2 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D + Atezolizumab
32972578|NCT05756907|No Intervention|Randomized Arm #3 in Patients with Platinum-resistant Ovarian Cancer|Standard of Care
32972579|NCT05755789|Experimental|Intervention group (innovative administration scheme)|Continuous infusion of cefoxitin + Intermittent placebo
32972580|NCT05755789|Active Comparator|Control group (recommended administration scheme)|Intermittent cefoxitin + Continuous infusion of placebo
32972581|NCT05754073|Experimental|1. Intranasal Oxytocin|Intranasal oxytocin spray (30 IU twice daily) for 12 months in the double-blinded phase followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
32972582|NCT05754073|Placebo Comparator|2. Placebo|Intranasal placebo spray (30 IU twice daily (total 60 IU per day) for 12 months followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
32972583|NCT05753267|Active Comparator|Control Group|Mesalamine group will receive 1 g mesalamine three times daily for 6 months
32972584|NCT05753267|Active Comparator|Fenofibrate group|Fenofibrate group will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
32972585|NCT05751343|Experimental|TACE-HAIC plus atezolizumab-bevacizumab|transartery chemoembolization and hepatic artery infusion of FOLFOX, simultaneously followed by intravenous of 1200mg atezolizumab plus bevacizumab (15mg/kg)
32972586|NCT05750914|Experimental|Treatment Arm|Broadband light treatment using in-motion protocol
32972587|NCT05749627|Experimental|Neoantigen peptide vaccine/neoantigen-based DC treatment|Patients assigned to the neoantigen peptide vaccine/neoantigen-based DC treatment group will receive 5-6 subcutaneous injections of neoantigen peptide vaccine or neoantigen-based DC immune preparation within a 14-week treatment period.
32972588|NCT05746988|Experimental|Carrageenan-based Mouthwash|Mouthwash with Carrageenan as an active ingredient
32972589|NCT05746988|Placebo Comparator|Placebo Mouthwash|"Mouthwash without Carrageenan but similar in colour, taste, and mouthfeel to the experimental mouthwash"
32972590|NCT05742373|Experimental|Fasted exercise|Exercise training in the fasted state
32972591|NCT05742373|Active Comparator|Fed exercise|Exercise training in the fed state
32972592|NCT05742373|No Intervention|Control|No exercise training
32972593|NCT05737134|Experimental|MA_PESAN APPLICATION|"The content of MA_PESAN includes an understanding of children, children's rights, sexual understanding, the definition of CSA, forms of CSA, the prevalence of CSA, the impact of CSA, risk factors for the occurrence of CSA, the importance of communication with children, who are the perpetrators/predators of CSA, efforts to prevent CSA. The material is presented in the form of text, images, stop motion videos about the prevention of CSA and videos of the jargon TANGKIS, songs about permissible and unacceptable touches, TikTok about permissible and prohibited touches, and discussion columns. The MA_PESAN intervention was carried out for 9 days."
32972594|NCT05737134|No Intervention|common information from the school|The control group was given intervention according to the procedure at each elementary school. However, information was provided regarding preventing child sexual violence under the procedures usually carried out in each elementary school. The time spent was the same as the intervention group.
32972595|NCT05736900|Other|Patients with COVID-19|Patients admitted as in-patients with SARS-CoV-2 Infection
32972596|NCT05736718|Experimental|Champion AAT|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination. The training will be organized and delivered by vaccine champions from participating healthcare systems.
32972597|NCT05736718|Experimental|Traditional AAT|Staff in clinics randomized to this arm will also receive Announcement Approach Training (AAT). The training will be organized and delivered by outside experts.
32972598|NCT05720663||nonalcoholic steatohepatitis (NASH)|Adult patients nonalcoholic steatohepatitis (NASH)
32972599|NCT05713370|Placebo Comparator|no exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, normal sleep (8 h))
32972600|NCT05713370|Experimental|no exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, 4 h of sleep the previous night)
32972601|NCT05713370|Experimental|Exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, normal sleep (8 h))
32972602|NCT05713370|Experimental|Exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, 4 h of sleep the previous night)
32972603|NCT05712720|Experimental|Group 1 - 50 mg RZ402|
32972604|NCT05712720|Experimental|Group 2 - 200 mg RZ402|
32972605|NCT05712720|Experimental|Group 3 - 400 mg RZ402|
32972606|NCT05712720|Placebo Comparator|Group 4 - Placebo|
32972607|NCT05708417|Experimental|Weight neutral intervention|"The intervention is based on the concept of Acceptance and Commitment Therapy (ACT) and is conducted by specially trained physiotherapist and a dietician. The intervention in SDOI has the predominantly focus on each individual reflection and realization and is built upon ACT' six core processes. Specific focus on teach participant with different narrative and background and on coaching and back-and-forth dialogue with physiotherapist and dietician. The program is based on up to 13 times attendance within the 12 months intervention period. Part 1: Three to five individual coaching, Part 2: six group sessions and Part 3: one or two individual coaching.~Compliance to the intervention is classified as 'good' if the participants participate for a minimum four out of six group sessions, a minimum three out of five initial individual coaching and a minimum one out of two individual coaching post intervention."
32972608|NCT05708417|Placebo Comparator|Reference group|The reference group will not receive the intervention in the study and only participate in the test/data collection. The reference group will established consisting of participants participating in the SDOI program but, who of some reasons have refused participating in the lifestyle program. In case of insufficient recruitment of participants to the reference group, individuals meeting inclusion criteria such as age and BMI will be recruited via advertising in local newspapers and social media.
32972609|NCT05707403|Experimental|Test treatment (T) followed by Reference treatment (R)|
32972610|NCT05706610|Experimental|Tailored Program|8-week tailored program including 4 coach visits and 4 bi-weekly text check-ins
32972611|NCT05706610|Other|Feedback Program|8-week feedback program including 8 weekly texts
32972612|NCT05705544|Active Comparator|ILLUMISITE™ Platform (EMN bronchoscopy)|Participants in the ILLUMISITE™ Platform arm will undergo a diagnostic bronchoscopy with the ILLUMISITE™ Platform (EMN) machine.
32972613|NCT05705544|Active Comparator|Ion™ Endoluminal System (SSCB bronchoscopy)|Participants in the Ion™ Endoluminal System arm will undergo a diagnostic bronchoscopy with the Ion™ Endoluminal System (SSCB) machine.
32972614|NCT05702853|Experimental|Dose Level 1|1 x 10^6 transduced T cells/kg (± 20%)
32972615|NCT05702853|Experimental|Dose Level 2|1.5 x 10^6 transduced T cells/kg (± 20%)
32972616|NCT05702853|Experimental|Dose Level 3|2 x 10^6 transduced T cells/kg (± 20%)
32972617|NCT05701670|Experimental|Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the student and support in-the-moment soothing -- see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider and Prof James Gross), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~Initial guided reflection exercise~Short interactive psychoeducation~Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
32972618|NCT05701670|No Intervention|Control|Wait-list control (access to services as usual)
32972619|NCT05701137|Experimental|EMDR-RTE|Eye movement desensitization and reprocessing in its recent traumatic episode version.
32972620|NCT05701137|Active Comparator|TAU|Usual treatment by a psychologist.
32972621|NCT05701072||All participants|
32972622|NCT05700227|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
32972623|NCT05699759|Experimental|Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema
33411108|NCT05001386|Experimental|Lymphoproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
33411109|NCT05001386|Sham Comparator|Control group|Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
33411110|NCT05001386|Experimental|Myeloproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
33411111|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
32972628|NCT05693571|Experimental|Valera Pilot Study|All participants in the open-label pilot study will be provided with the Valera smart phone application and online care manager dashboard
32972629|NCT05685381||Black adults with persistent asthma in homes with gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) fueled by combustible gas.
32972630|NCT05685381||Black adults with persistent asthma in homes without gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) not fueled by combustible gas.
32972631|NCT05683418|Experimental|TOS-358 Single Agent Arm|Multiple doses of TOS-358 for oral administration.
32972632|NCT05683275|Experimental|IASTM|"In addition to the home exercise program application, IASTM application will be made for 4 weeks. IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute (Cheatham et al., 2019). The instruments will be applied to the soft tissue at 30º-60º angles, using vaseline as an intermediate, with a multidirectional stroking movement."
32972633|NCT05683275|Experimental|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application. Ultrasound gel will be used as an intermediate in the application. No anesthetic substance will be used before and after the application. Cold applications will be recommended for those who have pain after the application.
32972634|NCT05683275|Experimental|Home Exercise|Static stretching and eccentric strengthening exercises specific to the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks. For strengthening exercises, all patients will be asked to use green (medium resistance) elastic bands, hold them in a tense position for 10 seconds, let them back passively, and rest for 1 minute between sets. In the stretching exercise, they will be asked to stay in the most tense position for 30-45 seconds and rest for 30 seconds between stretching. In case of a painful situation, they will be asked to be informed about their information.
32972635|NCT05679752|Active Comparator|control group|massage therapy will be given to this group of participants
32972636|NCT05679752|Experimental|experimental group|Facial PNFtechnique will be given to this group of participants
32972637|NCT05678348|Experimental|Pyrimethamine|Pyrimethamine will be taken by mouth at a dose of 50 mg once daily for 14 days (+/-2 days) with the last dose the day prior to surgery.
32972638|NCT05677568||Prospective|"Prospective patients are identified prior to undergoing the Carillon procedure and are only enrolled after being successfully implanted with the Carillon device (prior to hospital discharge). Prospective patients will have applicable medical history and details of the Carillon implant procedure collected from medical records. After the patient is discharged, the patient's primary care specialist (cardiologist) and clinical investigation site staff will coordinate follow-up evaluations. Patients will be evaluated at one (1), six (6), twelve (12) months per standard of care and with annual contact for an additional four (4) years, for a total of five (5) years to assess long-term safety of the Carillon implant."
32972639|NCT05677568||Retrospective/Prospective|"Retrospective/Prospective patients are implanted with the Carillon device and are currently being followed-up per standard of care. These patients will have applicable data collected from their medical records, including medical history, data about the Carillon procedure and follow-up visit data done since receiving the Carillon implant. They will be evaluated prospectively per standard of care follow-up through five (5) years post-implant to assess long-term safety of the Carillon implant."
32972640|NCT05668663|Experimental|Elderly patients|"Only one group of patients will be constituted. It will be composed of 385 patients aged more than 75 years old and hospitalized in a geriatric acute care unit.~If the patient consent to participate in the study, a 4-mL blood sample will be collected concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.~No other sample will be taken., and tThe participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effectswith this blood sample collection.~No further visit is organised."
32972641|NCT05668208|Experimental|extraperitoneal surgery group - TEP inguinal hernia repair|The external sheath of the rectus muscle was seen by passing through the skin and subcutaneous tissue with a mini incision made from the umbilicus edge. A 10 mm trocar was placed in the preperitoneal area and CO2 insufflation was performed. The pressure was set to 14 mmHg. Two more 5 mm trocars were inserted between the umbilicus and the sympisis pubis under the laparoscope. The preperitoneal inguinal area was dissected with a laparoscopic dissector and grasper. The hernia sac was released. A 10x15 cm prolene mesh was spread and fixed to cover the femoral, direct and indirect hernia areas. The trocars were removed by evacuating the CO2 gas. The skin was closed and the operation was terminated.
33411112|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
33411113|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
32972642|NCT05668208|Active Comparator|transperitoneal surgery group - laparoscopic cholecystectomy|With a mini incision made under the umbilicus, the abdomen was entered with a 10 mm trocar. Pneumoperitoneum was created with CO2 gas. Intra-abdominal pressure was set to 14 mmHg. Under the guidance of the laparoscope, one 10 mm trocar from the subxiphoid area and two more 5 mm trocars from the subcostal area were inserted. The cystic artery and cystic duct were clipped and cut by exposing the Callot triangle. Then the gallbladder was separated from the liver bed and taken out of the abdomen. The CO2 in the abdomen was evacuated and the trocars were removed. The fascia defect and skin were closed and the operation was terminated.
32972643|NCT05667038|Placebo Comparator|Placebo arm|The placebo sachets containing only the excipients, i.e., maize starch and maltodextrins, weights 3g. The placebo was indistinguishable in color, smell, and taste from the probiotic formulation.
32972644|NCT05667038|Experimental|Probiotic arm|Drug being used is Hexbio sachet containing 3g / 90 billion CFU. this drug is a formulation containing six microorganism strains (Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120).
32972645|NCT05664217|Experimental|Stage 1 NKTR-255 at 1.5 µg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 1.5 µg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
32972646|NCT05664217|Experimental|Stage 1 NKTR-255 at 3.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 3.0 μg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
32972647|NCT05664217|Experimental|Stage 1 NKTR-255 at 3.0/6.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), patients will be dosed with 3.0 μg/kg NKTR-255 in Cycle 1 (C1) and continue in Cycle 2 and subsequent cycles (C+) with 6.0 μg/kg NKTR-255 (hereinafter referred to as 3.0/6.0 µg/kg NKTR-255).~NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
32972648|NCT05664217|Placebo Comparator|Placebo|Placebo is commercially available 0.9% Sodium Chloride Solution for Injection (USP). Placebo will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion. Placebo will be infused every 3 weeks for up to 7 cycles or 5 months, whichever is earlier.
32972649|NCT05662592|Experimental|Treatment Arm|Broadband light treatment will be provided on pigmented skin lesions
33411114|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
33411115|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
32972650|NCT05661058||Total number of participants|As this is not an intervention study, the investigators only have one group which the investigators will follow at two-time points to map the context of sedentary behaviour.
32972651|NCT05660486|Experimental|Aromatherapy group|Participants in this group will receive, lavender essential oil applied to their surgical mask for 5 minutes prior to scheduled standard of care interventional spine procedure.
32972652|NCT05660486|Placebo Comparator|Placebo group|Participants in this group will receive water applied to their surgical mask for 5 minutes prior to scheduled standard of care interventional spine procedure.
32972653|NCT05657548||Child with Cerebral Palsy|Children and adolescents from 4 to 17 years old with cerebral palsy GMFCS III, IV or V followed in the Physical Medicine and Rehabilitation Department, Children's Rehabilitation Unit of the University Hospital of Nîmes (Carémeau Hospital)
32972654|NCT05656378||Single Cohort|Participants aged >0 years with no upper age limit, both healthy volunteers and those with previously known and unknown disease states
32972655|NCT05655442|Experimental|early APM|early APM within 3 and 6 month knee pain symptoms
32972656|NCT05655442|Active Comparator|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
32972657|NCT05655429|Experimental|physical therapy|Physical therapy mainly include aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months.
32972658|NCT05655429|Active Comparator|arthroscopic partial meniscectomy|The torn meniscus and unstable part were removed with arthroscopic instruments.
32972659|NCT05654818|Experimental|Vitamin D|
32972660|NCT05654818|Placebo Comparator|Control|
32972661|NCT05653778|Experimental|Scrambler therapy|"Scrambler Therapy is a non-invasive neuromodulation approach using superficial electrocardiogram (ECG) electrodes in paired channels on the involved dermatomes to send non-pain information along the existing nerve pathways, which can modify peripheral and central sensitization."
32972662|NCT05653778|Active Comparator|TENS treatment|Transcutaneous electrical nerve stimulation (TENS) is a battery-powered device which delivers low-voltage electrical current through superficial electrocardiogram (ECG) electrodes placed on the surface of the skin to provide pain relief.
32972663|NCT05653050|Experimental|Fully closed-loop system with age-approved ultra-rapid insulin|"The fully closed-loop system (CamAPS HX) will consist of:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) or mylife YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland).~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), or other compatible real-time CGM sensor.~Android smartphone hosting CamAPS HX App with the Cambridge model predictive control algorithm.~Cloud upload system to review CGM/insulin data.~Participants will use an age-approved ultra-rapid insulin in the closed-loop system."
32972664|NCT05653050|Active Comparator|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), or other compatible real-time CGM sensor.~."
32972665|NCT05650710|Other|Surgical Procedure|Consented patients who meet eligibility will have a surgical procedure for management of head and neck cancer, with dissection and exposure of the relevant anatomic structures as part of regular clinical care.
32972666|NCT05648695|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
32972667|NCT05648695|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
32972668|NCT05647681|Active Comparator|"topic analgesic Douloff"|"Patients receive a tpic analgesic douloff in association with an oral treatment placebo"
32972669|NCT05647681|Active Comparator|oral paracetamol|Patients receive oral paracetamol in association with a topic placebo
32972670|NCT05646238|Experimental|intervention group|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
32972671|NCT05646238|Active Comparator|control group|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles.
32972672|NCT05645731||Lung cancer patient|Lung cancer patients or lung cancer survivors willing to refer close contacts for lung cancer screening
32972673|NCT05645731||Referred participants|Participants referred to the study by close contacts living with lung cancer.
32972674|NCT05644314|Experimental|Patients with vertebral atherosclerotic stenosis requiring stent implantation|"Referring to the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease, the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus and Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients."
32972675|NCT05644171|Other|Patients with motor complete chronic spinal cord injury|
32972676|NCT05644145|Experimental|Yellow fever seropositive vaccinated pediatric population in Argentina|Yellow fever seropositive pediatric population in Argentina after receiving the YF vaccine at 12-23 months of age.
32972677|NCT05643560||Hemophilia A patients|Hemophilia patients who had initiated damoctocog alfa pegol treatment.
32972678|NCT05642858|Experimental|Intervention Arm|The intervention arm will receive education about HIV and heart disease risk via mobile phone text messages for up to 6 months. They will receive the text messages 3-5 times per week. The messages will include information about HIV and risk of heart disease and information about how to reduce heart disease risk. The intervention arm will also receive brief monthly surveys via a digital research platform.
32972679|NCT05642858|No Intervention|Control Arm|The control arm will not receive the educational text messages. They will receive brief monthly surveys via a digital research platform.
32972680|NCT05642416|Active Comparator|Continuous Infusion|Will receive a continuous infusion of pain medication (0.2% ropivacaine at a rate of 10mL per hour- 5mL per side per hour) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
32972681|NCT05642416|Experimental|Intermittent Bolus|Will receive intermittent boluses of pain medication (30mL bolus of 0.2% ropivacaine every three hours) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
32972682|NCT05637697||Ambulatory|
32972683|NCT05637697||Limited Ambulation|
32972684|NCT05636826|Active Comparator|atherolive-drug|In each study population, the patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive) will be prescribed at a dose of 400 mg, once a day for 3 months.
32972685|NCT05636826|Placebo Comparator|atherolive-placebo|In each study population, the patient will be assigned to one of two treatments (placebo ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive-placebo) will be prescribed at a dose of 400 mg, once a day for 3 months.
33322535|NCT03983070|Experimental|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
32972688|NCT05632263||EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
32972689|NCT05631028|Experimental|Group A|Dexmedetomidine pretreatment dose was 0. The effective dose of remimazolam tosilate inhibiting cardiovascular response during double-lumen tracheal intubation in elderly patients (age > 65 years) and young patients (18 < age <65 years) was explored respectively, without the use of dexmedetomidine. The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.25 mg / kg, and the adjusted unit dose was 0.01mg.
32972690|NCT05631028|Experimental|Group B|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 0.5μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.15 mg / kg, and the adjusted unit dose was 0.01mg.
32972691|NCT05631028|Experimental|Group C|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 1μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.1 mg / kg, and the adjusted unit dose was 0.01mg.
32972692|NCT05630976|Experimental|Isavuconazole|This is a single arm study, all enrolled participants will receive the study medication.
32972693|NCT05630235|Experimental|CBD followed by placebo group|Participants in this group will receive CBD on day one followed by placebo within a two week follow-up visit.
32972694|NCT05630235|Experimental|Placebo followed by CBD group|Participants in this group will receive placebo on day one followed by CBD within a two week follow-up visit.
32972695|NCT05626777|Experimental|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
32972696|NCT05626777|Experimental|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
32972697|NCT05626218|Experimental|Stress ball group|A stress ball will be applied to pregnant women with anxiety during NST.
32972698|NCT05626218|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
32972699|NCT05625685|Experimental|Quitbuddy|Participants will be assigned to use a smartphone app (QuitBuddy) that will automatically guide NRT treatment delivery through the integration of ecological momentary assessments (EMA) and GPS into personalized relapse prevention algorithms.
32972700|NCT05625685|Active Comparator|Control|Control is intended to approximate the real-world experience where Participants will use The National Cancer Institute's smartphone app (QuitGuide) and will self-manage NRT treatment delivery based on written instructions.
32972701|NCT05623358|Experimental|Pharmacist-led HFrEF medication optimization|
32972702|NCT05623358|Other|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services.
32972703|NCT05623228|Experimental|Therapy Group A|"Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~5 individuals with schizophrenia"
32972704|NCT05623228|Experimental|Therapy Group B|"Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~2 individuals with schizophrenia"
32972705|NCT05623228|Experimental|Therapy Group C|Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972706|NCT05623228|Experimental|Therapy Group D|Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972707|NCT05623228|Experimental|Therapy Group E|Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972708|NCT05623228|Experimental|Therapy Group F|Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972709|NCT05623228|Experimental|Therapy Group G|Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972710|NCT05623228|Experimental|Therapy Group H|Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
32972712|NCT05622877|Placebo Comparator|Placebo Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and placebo granules (6g/ bag, one bag each time, twice a day after meals);
32972713|NCT05622877|Experimental|Qushi Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Qushi Formula granules (6g/ bag, one bag each time, twice a day after meals);
33411116|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
32972714|NCT05622877|Experimental|Zhu's Wenban Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Zhu's Wenban Formula granules (6g/ bag, one bag each time, twice a day after meals);
32972715|NCT05621616|Experimental|mirabegron|Participants will receive mirabegron prolonged-release microgranula-based oral suspension.
32972716|NCT05612074|Experimental|Nitric Oxide|High dose inhaled nitric oxide (200, 250 and 300 ppm) in a nitrogen-oxygen-air mixture, at two different FiO2 levels (0.21 and 0.8) will be delivered intermittently with a dedicated system and a snug-fitting facemask to healthy volunteers three times per day for 5 days. The subjects will be monitored before, during and after the administration
32972717|NCT05611047|Experimental|Active cognitive rehabilitation|
32972718|NCT05611047|Active Comparator|Sham cognitive rehabilitation|
32972721|NCT05606874|Experimental|Pre-heating of flowable resin composite .|(Filtek™ Z350Xt Flowable Restorative, 3M ESPSE, USA)
32972722|NCT05606874|Active Comparator|Conventional resin fissure sealant|(total etch), (UltraSeal XT®, Ultradent, USA)
33322536|NCT01371526|Experimental|Synacthen|active treatment
33322537|NCT03945708|Experimental|Treatment|Addition of whole blood adsorber to CPB circuit
33322538|NCT03945708|No Intervention|Control|Standard treatment
33322539|NCT05189392|No Intervention|21 patients with opsite visible|application of visible opsite plaster on the surgical wound after hip arthroplasty
33322540|NCT05189392|Experimental|21 patients with PICO|application of PICO on the surgical wound after hip arthroplasty
33322541|NCT03943992|Experimental|YYD601 40mg|Esomeprazole magnesium Dihydrate.
33322542|NCT03943992|Active Comparator|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
32972723|NCT05605704|Active Comparator|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
32972724|NCT05605704|Placebo Comparator|placebo atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
32972725|NCT05604599|Active Comparator|Intranasal dexmedetomidine group|30 patients will receive 1µg/kg dexmedetomidine diluted in 10ml 0.9% saline intranasally preoperative administered to each naris as drops 45 -60 min before the operation +infusion saline.
32972726|NCT05604599|Active Comparator|Intravenous dexmedetomidine group|30 patients will receive a dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia + intranasal saline.
32972727|NCT05602636|Active Comparator|interscalene analgesia (Group ISBPB)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The C5 to C7 or C5 to C8 nerve roots between the anterior scalene and middle scalene muscles will be visualized in the absence of the subclavian artery and 10 mL 0.125% bupivacaine will be injected around the nerve roots of the brachial plexus. The needle trajectory will be adjusted to facilitate the even distribution of the local anesthetic around each nerve root."
32972728|NCT05602636|Active Comparator|The intercostobrachial nerve block ( Group ICBN)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The ICBN block will be performed with 10 mL of 0.5% bupivacaine in the plane deep to the pectoralis minor and/or serratus anterior muscle over the second and third intercostal space."
32972729|NCT05602636|Active Comparator|Patient-Controlled Analgesia (Group PCA)|All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.
32972730|NCT05602519|Active Comparator|Group fentanyl|Patients will receive 50 mg of fentanyl 20 min before the end of surgery.
32972731|NCT05602519|Active Comparator|Group oxycodone|Patients will receive 4 mg of oxycodone 20 min before the end of surgery.
32972732|NCT05599646|Experimental|traditional pedometer group|
32972733|NCT05599646|Experimental|gamified smartphone pedometer group|
32972734|NCT05599646|No Intervention|control group|
32972735|NCT05597748|Active Comparator|Class II type A malocclusion - proclination of upper incisors indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
32972736|NCT05597748|Active Comparator|Class II type B malocclusion - proclination of upper incisors not indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
32972737|NCT05597748|Experimental|Class II type A malocclusion - proclination of upper incisors indicated - TADs|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
32972738|NCT05597748|Experimental|Class II type B malocclusion - proclination of upper incisors not indicated - TADs|CA modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines.
32972739|NCT05596994|Active Comparator|Light Intervention Therapy (LIT) then Sham LIT|The LIT will begin at the patient's home and will be presented for 10 weeks. A washout period of 1 month will be scheduled to diminish carryover effects of the first therapy arm, then patients will begin the Sham LIT.
32972740|NCT05596994|Active Comparator|Sham LIT then Light Intervention Therapy|LIT will be performed identical to Arm 1, except for switchover of active LIT and Sham. A washout period of 1 month will be scheduled to diminish carryover effects of the LIT arm.
32972741|NCT05595850|Experimental|Mindfulness|Three-week online mindfulness course followed by one-month social community online interaction.
32972742|NCT05595850|Active Comparator|Mindful Learning|Three-week online mindful learning course followed by one-month social community online interaction
32972743|NCT05594511|Experimental|Experimental Group (muscle-energy technique)|Mandibular muscle energy technique: In the supine position, the patient will open the mouth and perform isometric contractions for closure controlled by the physiotherapist. Passively, the physiotherapist will increase the range of mandibular opening. The technique consists of performing 3 sets, with 3 isometric contractions in each set of 3 seconds each. At the end of each set, the physiotherapist will passively try to gain mouth opening in order to continue the rest of the sets. At the end of all sets, gently return to the resting position.
33322543|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
32972744|NCT05594511|Sham Comparator|Control Group (sham technique)|Sham technique: In the supine position, the physiotherapist will place his hands under the patient's skull with the fingertips in contact with the suboccipital musculature for 5 minutes, without applying pressure or therapeutic intent. The objective is to provide a stimulus as similar as possible to the original Suboccipital Inhibition Technique, but without force of movement. The patient will keep the eyes closed for the duration of the technique.
32972745|NCT05593432|Experimental|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 16 weeks, followed by ruxolitinib cream BID 16-week open-label extension.
32972746|NCT05593432|Placebo Comparator|Vehicle Cream|Vehicle cream BID for 16 weeks, followed by ruxolitinib 1.5% cream BID in a 16-week open-label extension.
32972747|NCT05591911||Patients over 60 years old presenting with acute urinary tract infection symptoms|
32972748|NCT05588180|Active Comparator|Group (P)|Group (P) PPV guided group
32972749|NCT05588180|Active Comparator|Group (F)|Group (F) FVD/FAD ratio guided
32972750|NCT05587296|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
32972751|NCT05587296|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
32972752|NCT05586802|No Intervention|Design 1 (Fertility) - positive micro-dissection testicular sperm extraction (mTESE) biopsy 1|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have positive sperm retrieval (detectable spermatozoids)
32972753|NCT05586802|Experimental|Design 1 (Fertility) - negative mTESE biopsy 1, then randomized to Group A|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
32972754|NCT05586802|Experimental|Design 1 (Fertility) - negative mTESE biopsy 1, then randomized to Group B|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
32972755|NCT05586802|Active Comparator|Design 2 (Metabolic Risk) - randomized to Group C|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an active comparator by a testosterone gel
32972756|NCT05586802|Experimental|Design 2 (Metabolic Risk) - randomized to Group D|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
32972757|NCT05586802|Experimental|Design 2 (Metabolic Risk) - randomized to Group E|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
32972758|NCT05583110|Experimental|Trastuzumab-Vinorelbine-Tucatinib|Trastuzumab-Vinorelbine-Tucatinib
33411117|NCT05384444|Experimental|Fasting mimicking diet|The cyclic FMD diet consists of a 5 day regimen: day 1 diet of the diet supplies ~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
32972759|NCT05581823|Experimental|Tavapadon Followed by Tavapadon + Carbamazepine|Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.
32972760|NCT05579990|Experimental|Meal Delivery|Meal delivery intervention program designed to help low income postpartum women lose weight through weekly meal delivery and behavioral strategies.
32972761|NCT05576220|Experimental|Intervention group|Subjects being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
32972762|NCT05576220|No Intervention|Control Group|Retrospective data from the control group comprised of 105 patients directly preceding the intervention group who are underwent stem cell transplant or CAR-T therapy. Such control group information will be obtained via a research data request. Only de-identified data will be obtained for these subjects.
32972763|NCT05574699|Active Comparator|Social Risk Score and Closed Loop Referral|Patients in intervention arm will have a social risk score available through the CDS tool, which the provider can review and decide whether the patient needs more assessment. If the patient is identified as with high social needs based on the risk score in the CDS tool, the providers will refer the patient to social workers/ care managers for further in-depth assessment of the participants social needs at HCC. HCC will reach out to the patients over the phone and will perform an in-depth assessment of the patients social needs. If any social needs are identified and patient agrees to address those needs HCC staff will refer the patient to CBOs.
32972764|NCT05574699|Active Comparator|Control|Patients randomized into the control arm will be provided with the standard-of-care screening, assessment, and addressing social needs in the clinic setting. This would not include any automated mechanism of pre-collected data in the EHR. Currently providers on an ad-hoc basis apply a series of needs-assessment tools including one available within JHHS-EHR. Patients in the control arm that are identified as someone with social needs will then be referred to appropriate services through current standard-of-care mechanisms, this may include a sheet of various educational resources, or a list of organizations that can address the identified social need.
33411118|NCT05384444|No Intervention|regular diet|regular diet
33411119|NCT03617900|Placebo Comparator|Placebo|
33411120|NCT03617900|Experimental|Ginger|
33411121|NCT03617900|Active Comparator|Paracetamol|
33411122|NCT04987892|Active Comparator|Prostatic Lift|Treatment with the UroLift System
33411123|NCT04987892|Active Comparator|Medication|Treatment with Tamsulosin HCl 0.4mg
33411124|NCT05384366|Other|Neoadjuvant chemotherapy|Patients receiving neoadjuvant paclitaxel 175mg/m2 and carboplatin (AUC5) at three weekly interval by intravenous route
32972765|NCT05574504|Experimental|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|Phase II trial is designed to evaluate the combination of avelumab (800 mg IV every 2 weeks) and lurbinectedin (3·2 mg/m2 lurbinectedin administered as a 1-h intravenous infusion once every 4 weeks) for those with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC.
32972766|NCT05572840|Experimental|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (PowerPoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (PowerPoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
33322544|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
33322545|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
33322546|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
33322547|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
32972767|NCT05554874|Experimental|Case group|participants undergoing pulsed electromagnetic fields
32972768|NCT05554874|Sham Comparator|Control group|participants undergoing sham pulsed electromagnetic fields
32972769|NCT05552664|Other|Arm 1|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
32972770|NCT05552664|Other|Arm 2|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
32972771|NCT05552664|Other|Arm 3|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
32972772|NCT05552664|Other|Arm 4|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
32972773|NCT05552430|Experimental|Skills-Based VR|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
32972774|NCT05551273|Experimental|Arm A|Selgantolimod 3 mg once weekly for 24 weeks
32972775|NCT05551273|Placebo Comparator|Arm B|Matching Placebo for Selgantolimod once weekly for 24 weeks
32972776|NCT05543837|Experimental|Capsaicin .66μMol/ml|Group receiving .66μMol/ml
32972777|NCT05543837|Experimental|Capsaicin .99μMol/ml|Group receiving .99μMol/ml
32972778|NCT05537714||Vaccine hesitant|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC)
32972779|NCT05537714||Trusted community leaders|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve medical underserved individuals living in rural eastern North Carolina (ENC) .
32972780|NCT05537519|Experimental|Open Label Arm|
32972781|NCT05534867|Experimental|Mandala coloring group|Mandala painting will be applied to pregnant women who have anxiety related to pregnancy.
32972782|NCT05534867|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
32972783|NCT05532046|Experimental|Treatment arm 1|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
32972784|NCT05532046|Experimental|Treatment arm 2|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
32972785|NCT05532046|Placebo Comparator|Placebo|Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
32972786|NCT05531565|Experimental|Part A (Phase 2): BIIB059|Participants will receive BIIB059 subcutaneously (SC) once every 4 weeks (Q4W) from Week 0 to Week 20, with an additional dose of BIIB059 at Week 2 during the double-blind placebo-controlled (DBPC) treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the extended treatment period (ETP) from Week 24 to Week 48, with an additional dose of BIIB059-matching placebo at Week 26.
32972787|NCT05531565|Placebo Comparator|Part A (Phase 2): Placebo|Participants will receive BIIB059-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of BIIB59-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059 at Week 26.
32972788|NCT05531565|Experimental|Part B (Phase 3): BIIB059|Participants will receive BIIB059 SC Q4W from Week 0 to Week 20, with an additional dose of BIIB059 at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059-matching placebo at Week 26.
33322548|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
33322549|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
33322550|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
33322551|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
32972789|NCT05531565|Placebo Comparator|Part B (Phase 3): Placebo|Participants will receive BIIB059-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of BIIB59-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059 at Week 26.
32972790|NCT05526560||Patients requiring replacement of their native or prosthetic mitral valve|Patients requiring replacement of their native or prosthetic mitral valve
32972791|NCT05521958|Other|Acute tibial shaft or tibial plateau fractures without compartment syndrome|Patients with acute lower leg fractures who do not have clinical compartment syndrome.
32972792|NCT05521958|Other|Acute tibial shaft or tibial plateau fractures with compartment syndrome.|Patients with acute lower leg fractures with acute compartment syndrome.
32972793|NCT05521958|Other|Exertional compartment syndrome|Patients with a diagnosis of exertional compartment syndrome who are planning to undergo surgical procedure to release the compartment fascia will be recruited to participate prior to surgical intervention.
32972794|NCT05519982|Experimental|Sleep Treatment Education Program (STEP-1)|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Sleep Treatment Education Program (STEP-1) group will receive online instruction on making changes to sleep habits and health behaviors.~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
32972795|NCT05519982|Active Comparator|Enhanced Usual Care: Relaxation Education|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Enhanced Usual Care group will receive information on relaxation techniques to improve sleep~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
32972796|NCT05518682|Experimental|Single study arm|The Lenire device is CE marked in Europe and intended to reduce the symptoms of tinnitus. It comprises a handheld controller and an intra-oral device called a Tonguetip® Intra-Oral Device (IOD), which delivers gentle electrical stimulation to the tongue, and also comprises of a set of wireless consumer headphones that deliver audio stimulation. The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe. For this study, the device software has been modified to allow users to adjust the headphone volume to a level that is comfortable and clearly audible instead of a preset volume with limited adjustments based on the patient's audiogram.
32972797|NCT05515640||Karolinska Cohort|Observational cohort corresponding to patients treated at the Neurointensive Care Unit, Karolinska University Hospital, Stockholm, Sweden.
32972798|NCT05514769|Experimental|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty (GAP)|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the anterior of gastric stump.
32972799|NCT05514769|Active Comparator|Control|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the posterior or side of gastric stump.
32972800|NCT05514561||Patients with chronic lower gastrointestinal symptoms|We enroll adults older than 18 years with chronic lower GI symptoms for more than 1 month and are scheduled for a colonoscopy. The lower GI symptoms consist of any of the followings; lower abdominal pain, constipation, diarrhea, rectal bleeding, change in stool caliber, and abdominal bloating.
32972801|NCT05513703|Experimental|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
33322552|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
33322553|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
32972802|NCT05512000|Experimental|Contrast A|Feedback vs no feedback with massed trials
32972803|NCT05512000|Experimental|Contrast B|Feedback vs no feedback with spaced trials
32972804|NCT05512000|Experimental|Contrast C|Spaced vs massed trials without feedback
32972805|NCT05512000|Experimental|Contrast D|Spaced vs massed trials with feedback
32972806|NCT05508971|Experimental|Drug-Induced Sleep Endoscopy|DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.
32972807|NCT05508971|Active Comparator|Adenotonsillectomy|Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.
33411125|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
33411126|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
32972810|NCT05497999|Experimental|Treatment Group|With Black and White Subgroups
32972811|NCT05497999|Active Comparator|Control Group|With Black and White Subgroups
32972812|NCT05497154|Experimental|Training Arm|
32972813|NCT05496647|Experimental|Virtual Reality (VR)|Virtual Reality Application (VR) VR group patients will be shown VR videos that include landscapes such as nature and the sea, giving people a feeling of comfort and peace, and making them feel like they are inside. During the surgical procedure, VR videos will be watched for an average of 20 minutes with X-brand VR glasses. In the research, similar studies will be examined and 360o VR video, which is a licensed product with atmospheric music background, containing relaxing nature images and nature sounds will be used.
33322554|NCT01208844||Posttraumatic Stress|
32972814|NCT05496647|Experimental|Music Therapy|"Music Therapy Application During the surgical procedure, an mp3 player, and music therapy CDs of uşşak and Hüseyni will be used. (Oline will also create a list from music platforms (fizzy-Spotify, etc.)) Before starting the procedure, the patients will be asked about their music preferences and the music will be played to the patients (20 minutes) during the procedure in line with their preferences. Headphones provided by the researcher will be used for patients with headphones, and for patients without headphones.~The music authorities used (hüseyni and uşşak) will be provided and used by order, by obtaining the necessary permissions from the official site of TÜMATA."
32972815|NCT05496647|Experimental|Stress Ball Application|"Stress Ball Application A sufficient number of stress balls will be provided by the investigator for each patient to use separately before starting the study. Before starting the day-to-day gynecological surgery, patients in the stress ball group will be given a round, colored, medium-hard, compressible Knaftmed ball made of high-quality silicone. To avoid implying that the procedure is inherently stressful, it will be referred to as a squeezing ball when instructing patients about stress ball application.~During the surgical procedure, it will be said that he can squeeze the stress ball as often as he wants for about 20-25 minutes and the stress ball will be given to each patient."
32972816|NCT05496647|Experimental|Control|During the process; Women in the control group will not undergo any intervention other than routine surgery.
32972817|NCT05495581|Experimental|Mild renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
32972818|NCT05495581|Experimental|Moderate renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
32972819|NCT05495581|Experimental|Severe renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
32972820|NCT05495581|Experimental|Normal renal function|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
32972821|NCT05490329|No Intervention|Standard of Care (Control)|Research staff will provide COVID vaccine materials from the Centers for Disease Control (CDC) to those participants in the Standard of Care (SOC) arm.
32972822|NCT05490329|Experimental|TT-C Intervention|Research staff will provide access to the TT-COVID app for one-month, which will provide knowledge about the COVID-19 vaccine, address mis-information, and include multi-media digital stories from study participant's peers.
32972823|NCT05490238|Experimental|Distal radial access|Distal radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
32972824|NCT05490238|Active Comparator|Conventional radial access|Conventional radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
32972825|NCT05486026|Active Comparator|Duloxetine tablet|Patient in the first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals for 13 weeks .
32972826|NCT05486026|Active Comparator|NSAID(non steroidal anti inflammatory)|patient in the second group will receive NSAID(non-steroidal anti inflammatory) drugs for 13 weeks
32972827|NCT05483465|Experimental|NR|Treatment with oral NR (1g/day per os for 8 weeks)
32972828|NCT05483465|Placebo Comparator|Control|Visually identical placebo (daily, per os, for 8 weeks)
32972829|NCT05483036||Persons with Parkinson's disease (PwPD)|
32972830|NCT05481411|Experimental|Single Dose Olpasiran Hepatic Impairment|Participants will be enrolled in 1 of 3 hepatic impairment groups based on their hepatic impairment status, as determined by Child-Pugh classification. All participants will receive a single dose of olpasiran on Day 1.
32972831|NCT05481411|Experimental|Single Dose Olpasiran Normal Hepatic Function|Participants with normal hepatic function will be enrolled and will receive a single dose of olpasiran on Day 1.
32972832|NCT05468099|Experimental|Orthodontic debonding|
32972833|NCT05463549|Experimental|Informative video|The research group will be exposed to an informative instructional film before the procedure.
32972834|NCT05463549|No Intervention|No video|The control group will undergo amniocentesis with information given as accepted by standard-of-care.
32972835|NCT05451940|Experimental|Erythropoietin|Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period.
32972836|NCT05449587||Primary /Revision Augmentation Cohort|Patients that underwent primary and/or revision augmentation from 3 years or more postoperatively.
32972837|NCT05445596|Experimental|FCT Evaluation|This study uses single case experimental design in which participants will serve as their own control. Each participant will receive the treatment (functional communication training) and will participate in comparison conditions to evaluate the effects of the treatment. We will evaluate the effects of functional communication training during three treatment phases: initial implementation, schedule thinning, and generalization.
33322555|NCT01208844||Depression|
33322556|NCT01208844||Healthy|
33322557|NCT03127384|Experimental|No-treatment control|
33322558|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
32972842|NCT05439421|Experimental|With Claim|Package or digital marketing advertisement containing claim of interest
32972843|NCT05439421|Experimental|Without Claim|Package or digital marketing advertisement without claim of interest
32972844|NCT05438654|Other|Cohort of patients presenting to emergency department with abdominal right upper quadrant pain|This study is a single arm study analyzing a prospective population of patients presenting at the emergency department complaining of non-traumatic right upper quadrant abdominal pain. The analysis of the diagnostic approach will take place before and after the intervention on a same patient. The intervention is the use of Point of Care Ultrasound bedside.
33322559|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
33322560|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
33322561|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
32972845|NCT05438251|Experimental|Diabetic Foot Ulcers (TEXAS 3A, 3B)|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (approximately 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 12 weeks"
33322562|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
33322563|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
32972848|NCT05434364|Experimental|Facilitated Tucking|giving facilitated tucking before, during and after the procedure
32972849|NCT05434364|Experimental|Swaddling|giving swaddling before, during and after the procedure
32972850|NCT05434364|Experimental|Prone position|giving prone position before, during and after the procedure
32972851|NCT05434364|No Intervention|control|Rutin care in the neonatal intensive care unit
32972852|NCT05432570|Active Comparator|Group A - Muscle Relaxants Used|Muscle Relaxants Used
32972853|NCT05432570|Active Comparator|Group B - No Muscle Relaxants|No Muscle Relaxants
32972854|NCT05430555|Experimental|MAGE-A1 - directed TCR transduced autologous T-cells|Single-dose, intravenous infusion
32972855|NCT05419427|Experimental|Denosumab Solution for injection in single use prefilled syringe 60 mg permL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months, Route of Administration-Subcutaneous injection
32972856|NCT05419427|Active Comparator|Prolia® Solution for injection in single use prefilled syringe 60 mg per mL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months,Route of Administration-Subcutaneous injection
33322564|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
32972858|NCT05411523||Observational (spinal cord stimulation, questionnaires)|Patients receiving spinal cord stimulation therapy complete questionnaires over 30 minutes at baseline and at 3, 6, and 12 months.
32972859|NCT05411107|Experimental|Arm I (iloprost)|Patients receive Iloprost PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
32972860|NCT05411107|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
32972861|NCT05408091|Experimental|Dose Level 1 - 1 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
32972862|NCT05408091|Experimental|Dose Level 2 - 10 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
32972863|NCT05406830|Experimental|Verum acupuncture (VA)|Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
32972864|NCT05406830|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
32972865|NCT05401565|Experimental|Balovaptan|
32972866|NCT05401565|Placebo Comparator|Placebo|
32972867|NCT05397223|Experimental|Part 1: mRNA-1345|Participants will receive single intramuscular (IM) injection of mRNA-1345 on Day 1.
32972868|NCT05397223|Experimental|Part 1: mRNA-1647 2-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1 and 57.
32972869|NCT05397223|Experimental|Part 1: mRNA-1647 3-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1, 57, and 169.
32972870|NCT05397223|Experimental|Part 2: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1
32972871|NCT05397223|Experimental|Part 2: mRNA-1010|Participants will receive single IM injection of mRNA-1010 on Day 1.
32972872|NCT05397223|Active Comparator|Part 2: FLUAD®|Participants will receive single IM injection of FLUAD® on Day 1.
32972873|NCT05390645|Experimental|MFA-370|MFA-370 once daily for up to 8 x 21 days.
32972874|NCT05388357|Experimental|AI -guided PCI|based on AI-QCA measurement, a drug eluting stent of an appropriate size is inserted and then high-pressure balloon dilatation is additionally actively performed in all patients.
32972875|NCT05388357|Active Comparator|OCT-guided PCI|In the OCT group, the size of the stent is determined using intravascular optical coherence tomography, and balloon dilatation is additionally performed if necessary.
32972876|NCT05384964||Nurses|
32972877|NCT05380401|Other|DHA/ARA supplement|"DHA/ARA supplement throughout the duration of the protocol, d-on"
32972878|NCT05380401|No Intervention|No DHA/ARA supplement|"no DHA/ARA supplement throughout the duration of the protocol, d-off"
32972879|NCT05380401|Other|DHA/ARA initially then no supplement|"DHA/ARA supplement from enrollment to 31 6/7 weeks post-menstrual age (PMA) then no supplement from 32 to 36 weeks' PMA, x- on/off"
32972880|NCT05380401|Other|No supplement initially then DHA/ARA supplement|"No DHA/ARA supplement till 31 6/7 weeks' then long-chain polyunsaturated fatty acids (LCPUFA) supplement from 32 to 36 weeks PMA, x-off/on"
32972881|NCT05379686|Experimental|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise
32972882|NCT05369195|Experimental|LAAC with neuroprotection|Arm in which is used a transcatheter system to protect the cerebral circulation during the left atrial appendage closure procedures.
32972883|NCT05369195|Placebo Comparator|LAAC without neuroprotection|Arm in which the left atrial appendage closure procedures are performed without transcatheter cerebral protection.
32972884|NCT05367440|Experimental|Arm 1 (AZD5305 in combination with enzalutamide)|Patients will receive an oral dose of AZD5305 and Enzalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
32972885|NCT05367440|Experimental|Arm 2 (AZD5305 in combination with abiraterone acetate)|Patients will receive an oral dose of AZD5305 and Abiraterone Acetate once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
33322565|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
32972886|NCT05367440|Experimental|Arm 3 (AZD5305 in combination with darolutamide)|Patients will receive an oral dose of AZD5305 once daily and Darolutamide twice daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
32972887|NCT05366582|Active Comparator|Group Macintosh Laryngoscope (ML)|Macintosh laryngoscope is used for intubation after anesthesia induction
32972888|NCT05366582|Active Comparator|Group Video Laryngoscope (VL)|Video laryngoscope is used for intubation after anesthesia induction
32972889|NCT05362903||Oral LLT|Patients who newly initiated oral Lipid lowering treatment (LLT) on top of a statin
32972890|NCT05362903||Inclisiran|"Patients who newly initiated Inclisiran~Inclisiran in a PCSK9-treatment naive cohort~Inclisiran in patients with prior PCSK9-antibody treatment"
32972891|NCT05362903||Apheresis plus Inclisiran|Patients who newly initiated Inclisiran on top of lipid apheresis
32972892|NCT05362032|Experimental|Diagnostic (endorectal MRI, MRI-targeted biopsy)|Patients undergo endorectal MRI and transrectal MRI-targeted biopsy using the OmnEcoil device.
32972893|NCT05352971||Patients with multiple sclerosis|
32972894|NCT05352672|Experimental|A: fianlimab+cemiplimab dose 1|Protocol Amendment 1: 40 participants randomized 2:1:1 (Futility Analysis) Protocol Amendment 3: 140 participants randomized 2:2:2:1 Protocol Amendment 3: 1050 participants randomized 2:2:2:1 ((PFS population) Protocol Amendment 3: 360 participants randomized 1:1:1 (OS Analysis)
32972895|NCT05352672|Experimental|A1: fianlimab+cemiplimab dose 2|Protocol Amendment 3: 140 participants randomized 2:2:2:1 Protocol Amendment 3: 1050 participants randomized 2:2:2:1 ((PFS population) Protocol Amendment 3: 360 participants randomized 1:1:1 (OS Analysis)
32972896|NCT05352672|Experimental|B: pembrolizumab+placebo|Protocol Amendment 1: 40 participants randomized 2:1:1 (Futility Analysis) Protocol Amendment 3: 140 participants randomized 2:2:2:1 Protocol Amendment 3: 1050 participants randomized 2:2:2:1 ((PFS population) Protocol Amendment 3: 360 participants randomized 1:1:1 (OS Analysis)
32972897|NCT05352672|Experimental|C: cemiplimab+placebo|Protocol Amendment 1: 40 participants randomized 2:1:1 (Futility Analysis) Protocol Amendment 3: 140 participants randomized 2:2:2:1 Protocol Amendment 3: 1050 participants randomized 2:2:2:1 ((PFS population)
32972898|NCT05352386|Other|Patients with familial hypercholesterolemia, early treated|
32972899|NCT05352386|Other|Patients without familial hypercholesterolemia, late treated|
32972900|NCT05352386|Other|Healthy individuals|
32972901|NCT05350813|Experimental|PCT-guided arm|Group of patients whose duration of antibiotic therapy will depend on procalcitonin (PCT) plasma levels on days 0 and 1, then on PCT plasma level every 48 hours and on patient clinical evolution evaluated by the fever, the infected organ, and the pSOFA (Pediatric Sequential Organ Failure Assessment) score every day until cessation of antibiotics in hospital or until discharge from hospital if the patient is discharged with an antibiotic treatment.
32972902|NCT05350813|Active Comparator|standard-of-care arm|A group of patients whose duration of antibiotic therapy will be determined by the type of infection, microbiological findings and clinical, biological and/or radiological course, according to standard practice based on guidelines.
32972903|NCT05347667|Experimental|Pre-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the follicular phase of the menstrual cycle (pre-ovulation).
32972904|NCT05347667|Experimental|Post-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the luteal phase of the menstrual cycle (post-ovulation).
33322566|NCT01111578||New enteral feeding tube|
33322567|NCT03945630|Experimental|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
33322568|NCT03945630|Active Comparator|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
33322569|NCT04212598|Experimental|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
33322570|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
33322571|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
33322572|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
33322573|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
33322574|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
33322575|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
33322576|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
33322577|NCT03943524|No Intervention|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
32972905|NCT05342844|No Intervention|Group-Control|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline 0.9% for each side
32972906|NCT05342844|Active Comparator|Group-Dexmedetomidine 0.5|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline containing 0.5 mcg/kg dexmedetomidine for each side
32972907|NCT05342844|Active Comparator|Group-Dexmedetomidine1|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0. 5% plus 10 mL normal saline containing 1 mcg/kg dexmedetomidine for each side
32972908|NCT05341726|Experimental|BREATHE intervention|The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
32972909|NCT05341726|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
32972910|NCT05340959||Adult patient with single or multiple missing tooth or teeth requiring dental implants|"Adult patient with single or multiple missing tooth or teeth requiring dental implants, 40 dental implants will be placed in osteotomy sites based on radiographic findings (CBCT), the primary stability will be measured immediately after implant installation and secondary stability will be measured after 12 weeks .~Both primary and secondary stability will be measured by three devices:~Osstell®: based on Resonance Frequency Analysis (RFA).~Periotest®: based on damping effect.~AnyCheck®: based on tapping-motion."
32972911|NCT05337540|Experimental|EVI-01 - low dose|4 mL, one single EVI-01 intra-articular injection
32972912|NCT05337540|Experimental|EVI-01 - high dose|6 mL, one single EVI-01 intra-articular injection
32972913|NCT05337540|Active Comparator|Synvisc-One|6 mL, one single intra-articular injection
32972914|NCT05336136|Experimental|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
32972915|NCT05336136|Active Comparator|Current commercial mask|Current commercial mask used by the participant for administration of non-invasive ventilation
32972916|NCT05335421|Experimental|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
32972917|NCT05335421|No Intervention|Standard of Care|Control group receives standard of care only
32972918|NCT05334472||Kesimpta|Patients or caregivers of patients administered Kesimpta
32972919|NCT05333926|Experimental|MHNA-001|
33411127|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
32972920|NCT05332067|Experimental|Omalizumab|Single dose of omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
32972921|NCT05332067|Placebo Comparator|Placebo for omalizumab|Single dose of placebo for omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
32972922|NCT05331443||participents who has the intention to fast Ramadan|subjects with at least two cardiovascular risk factors according to Framingham classification or with out any risk .
32972923|NCT05331157|No Intervention|palpation group|"In lateral decubitus position, the conventional palpation technique will be used to detect the epidural space. The midline will be identified by palpation of the spinous processes. Through the Tuffier's line, L5 spine then, the two intervertebral spaces (L3-4 and L2-3) will be detected and the middle of each intervertebral space will be marked with selection of the widest space.~After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline"
32972924|NCT05331157|Experimental|Ultrasonography group|In lateral decubitus position, a curved array probe will be utilized to scan the sacrum in the longitudinal paramedian plane, then the probe will be moved upwards to detect the L5-S1, L4-5, L3-4 and L2-3 intervertebral spaces then turned 90º to the transverse plane and used to scan L3-4 and L2-3 spaces inside the 2 spaces, midline will be detected by noting the site of spinous processes with selection of the space with the best sonographic image quality. Then skin surface at the middle of the long and short axis of the probe will be marked horizontally. If the 2 spaces have the same image quality, L2-3 space will be chosen for the entrance of epidural needle. After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline
32972925|NCT05330338|Other|Congenital heart disease|
32972926|NCT05323890|Experimental|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg/m2) and Cisplatin (75 mg/m2) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
32972927|NCT05323617|Experimental|Arm 1: Previously Untreated IST|Participants with SAA/vSAA that are previously untreated with IST.
32972928|NCT05323617|Experimental|Arm 2: Refractory IST|Participants with SAA/vSAA that are refractory to IST.
33411128|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
33411129|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
33411130|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
32972929|NCT05323318||Neuropsychological Sequelae|Post-COVID-19 symptomatic patients with neuropsychological sequelae
32972930|NCT05323318||Without Neuropsychological Sequelae|Post-COVID-19 symptomatic patients Without neuropsychological sequelae
32972931|NCT05323253|Experimental|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Objective Response Rate (ORR) will be determined based on confirmed BOR following DaRT insertion.
32972932|NCT05314361|Experimental|Treatment - 1 Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered by two trained public health nurses in addition to receiving usual care.
32972933|NCT05314361|No Intervention|Control - usual care|Participants assigned to the control arm will continue to receive standard postnatal care from their healthcare providers.
32972934|NCT05312632|Experimental|Safinamide Mesilate|Participants with parkinson's disease will be administered Safinamide Mesilate 50 milligram (mg) tablet, orally, once daily as add-on therapy to levodopa for up to 2 weeks. After 2 weeks, at the discretion of an investigator, dose of Safinamide Mesilate will be increased to 100 mg tablets (two tablets of 50 mg each), orally, once daily for up to 18 weeks.
32972935|NCT05312554|Experimental|Intervention arm|Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form
32972936|NCT05312437|Experimental|Interruptive Best Practice Advisory - CDS Intervention|"Adults at Elevated Predicted Risk (>=2% predicted risk, based on our study, DOI: 10.1001/jamanetworkopen.2021.1428) at visit registration (aka check-in) will be randomized to either Interruptive Alert or Passive Prompt CDS interventions.~In the Interruptive Alert, the physician who next opens that patient's chart will be prompted to review a BPA describing the patient's risk and asking the physician to choose from the BPA options (see Interventions).~The BPA will need to be dismissed to the Epic Storyboard or completed as above to continue clinical workflow."
32972937|NCT05312437|Active Comparator|Passive Storyboard Prompt - CDS Intervention|"Adult patients in the highest predicted risk tier (>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
32972938|NCT05308199|Experimental|experimental|thoracic manipulation group
32972939|NCT05308199|Active Comparator|control|MET group
32972940|NCT05303233|Experimental|TIBIAL group|All patients allocated to the TIBIAL group will receive an adductor canal block with 20ml of ropivacaine 0.75% and a selective tibial nerve block with 5 ml of ropivacaine 0.75% prior to surgery,
32972941|NCT05303233|Active Comparator|IPACK group|All patients allocated to the IPACK group will receive an adductor canal block with 20ml of ropivacaine 0.75% and an IPACK with 20ml of ropivacaine 0.2% prior to surgery.
32972942|NCT05301608|Experimental|Psilocybin First|Psilocybin (10mg) will be administered one time orally as a capsule taken with water. Expected duration of acute effects is approximately 6 hours. After a period of a washout, participants will switch to the placebo intervention.
32972943|NCT05301608|Placebo Comparator|Placebo First|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water. After a period of a washout, participants will switch to the Psilocybin intervention.
32972944|NCT05301179|Experimental|RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
32972945|NCT05301179|Experimental|Higher than RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing more than the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
32972946|NCT05295992|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
32972947|NCT05295628|Experimental|EMBLOK™ Embolic Protection System|"Device Description:~The EMBLOK™ Embolic Protection System (EMBLOK EPS) is a sterile, single use system designed to capture and remove debris (e.g., thrombus, calcium, atheroma) dislodged during transcatheter aortic valve replacement (TAVR) procedures. The device is currently for investigational use only.~When Device Will Be Used:~Roll-in: Prior to enrollment of the first randomized subject at each site, each site will enroll 2 Roll-In subjects, who will not be randomized but will receive the EMBLOK EPS during TAVR.~Randomized: Up to 422 subjects meeting eligibility criteria will be randomized 1:1. The experimental intervention arm is utilizing EMBLOK EPS during TAVR (up to 211 subjects).~Nested registry: Up to 50 subjects who meet clinical eligibility criteria and are anatomically suitable for the EMBLOK EPS, but whose anatomy precludes the use of the SENTINEL CPS."
32972948|NCT05295628|Active Comparator|SENTINEL™ Cerebral Protection System|"Device Description:~The control comparator is the commercially-available SENTINEL™ Cerebral Protection System (SENTINEL CPS) (Boston Scientific Corp., Marlborough, MA, US), a dual-filter protection device designed to capture and remove debris dislodged during TAVR procedures.~The SENTINEL CPS is indicated for use as an embolic protection device to capture and remove thrombus/debris while performing TAVR procedures. The diameters of the arteries at the site of filter placement should be between 9.0 mm - 15.0 mm for the brachiocephalic and 6.5 mm - 10.0 mm in the left common carotid.~When Device Will Be Used:~In the randomized cohort, up to 422 subjects meeting eligibility criteria will be randomized 1:1 (stratified by operative risk and study site). The active comparator control arm is utilizing SENTINEL CPS during TAVR (up to 211 subjects)."
32972949|NCT05294302|Active Comparator|eSCCIP/eSCCIP-SP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. A stakeholder-informed Spanish-language adaption of eSCCIP (eSCCIP-SP) has been developed and will be offered to Spanish-speaking PCCC. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
33322578|NCT03943524|Experimental|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
33322579|NCT05189158|Other|HVS-|subjects with no complaint AND a Nijmegen questionnaire score of < 23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS-)
33104918|NCT05106855|Other|Implants NeoPoros surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
33104919|NCT00539565|Active Comparator|A|oral corticosteroids
33104920|NCT00539565|Placebo Comparator|B|as for active regimen
33104921|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
33104922|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
33104923|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
33104924|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
33104925|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
33104926|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
33411131|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
33411132|NCT02031926|Experimental|Positive expiratory pressure|
32899247|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
32899248|NCT00125372|Experimental|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
32899249|NCT01087541|No Intervention|Control|Usual clinical health care
32899250|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
32899251|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
32899252|NCT00125528|Experimental|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
32899253|NCT00125528|Placebo Comparator|2|placebo
32899254|NCT00125762|Experimental|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
32899255|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
32899256|NCT04346485|Experimental|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
32899257|NCT04346485|Experimental|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
32899258|NCT04346485|Active Comparator|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
32899259|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
32899260|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
32899261|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
32899262|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
32899263|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
32899264|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
32899265|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
32899266|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
32899267|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
32899268|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
32899269|NCT01334827|Other|Formulations|high volume gel; low volume gel; vaginal film
32899270|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
32899271|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
32899272|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
32899273|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
32899274|NCT01335061|Other|BeneFIX|
32899275|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
32899276|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
32972950|NCT05294302|Active Comparator|Coping Space|PCCC randomized to the patient education control condition will be given access to a website with information about psychosocial functioning, coping, and PTSS related to pediatric cancer. This website will be hosted on the same platform as the intervention, available in English and Spanish, and will consist of information modified from CopingSpace.org. CopingSpace.org is an evidence-informed website developed by Ryan's Case for Smiles, a national organization dedicated to supporting families impacted by pediatric cancer and other chronic diseases.
32972951|NCT05293223|Experimental|Group A|One dose Sputnik V + one dose Ad5-nCoV
32972952|NCT05293223|No Intervention|Group B|Samples stored at the immunology lab of the Buenos Aires University Medical School, corresponding to individuals vaccinated with 2 doses of Sputnik V.
32972953|NCT05292313|Other|Single distal femur implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
32972954|NCT05292313|Other|Dual distal femur implants|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
32972955|NCT05291091|Experimental|Adult Cohort 1|Drug: EDG-5506 Drug: Placebo
32972956|NCT05291091|Experimental|Adult Cohort 2|Drug: EDG-5506 Drug: Placebo
32972957|NCT05291091|Experimental|Adult Cohort 3|Drug: EDG-5506 Drug: Placebo
32972958|NCT05291091|Experimental|Adolescent Cohort 4|Drug: EDG-5506 Drug: Placebo
32972959|NCT05291091|Experimental|Adolescent Cohort 5|Drug: EDG-5506 Drug: Placebo
32972960|NCT05290233|Experimental|TRE+RT|Participants will confine eating between 12-8pm and fast from 8pm to 12pm daily combined with 3-4 days of supervised resistance training per week.
32972961|NCT05290233|Active Comparator|TRE+AT|Participants will confine eating between 12-8pm and fast from 8pm to 12pm daily combined with 3-4 days of supervised aerobic training per week.
32972962|NCT05285553|Experimental|MiSight 1 day|MiSight 1 day
32972963|NCT05285553|Active Comparator|Proclear 1 day|Proclear 1 day
32972964|NCT05285527|Experimental|MiSight 1 Day|MiSight 1 Day
32972965|NCT05284617|Experimental|Active Treatment: HU6 Planned doses of HU6; N = 31|
32972966|NCT05284617|Placebo Comparator|Placebo Comparator Non-active study drug N = 31|
32972967|NCT05284019|Experimental|Eptinezumab|Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
32972968|NCT05284019|Experimental|Anti-CGRP injectables|Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
32972969|NCT05284019|Experimental|Onabotulinumtoxin-A|Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
33322580|NCT05189158|Other|HVS+|subjects with complaints AND a Nijmegen questionnaire score of ≥23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS+)
33322581|NCT03942978|Active Comparator|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
33322582|NCT03942978|No Intervention|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
33322583|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
33322584|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
33322585|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
33322586|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
33322587|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
32972978|NCT05283408|Experimental|Dexmedetomidine infusion on recovey quality with radical mastectomy|Drug: Dexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
32972979|NCT05283408|Experimental|Co-administration dexmedetomidine and low-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
32972980|NCT05283408|Experimental|Combined dexmedetomidine and high-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
33411133|NCT04516746|Experimental|AZD1222|Approximately 20,000 participants randomized to the AZD1222 arm
33411134|NCT04516746|Placebo Comparator|Placebo|Approximately 10,000 participants randomized to the saline placebo arm
32972983|NCT05276622||Subjects with newly diagnosed multiple myeloma|Forty subjects with newly diagnosed multiple myeloma.
33411135|NCT03607994|Active Comparator|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
32972984|NCT05276622||Care partners of the subjects with newly diagnosed multiple myeloma|Thirty care partners of the subjects with newly diagnosed multiple myeloma.
32972985|NCT05275998|Experimental|Sentinel Group 1|10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
33411136|NCT03607994|Other|nonspecific acoustic stimulation (NCC)|Continued current care and acoustic stimulation that is not linked to brainwave activity.
33411137|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
32972986|NCT05275998|Experimental|Sentinel Group 2|10 HIV-1 infected subjects will receive one infusion of 3600 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
33411138|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
33411139|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
32972987|NCT05275998|Experimental|Sentinel Group 3|10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
32972988|NCT05275998|Experimental|Core Group 1|20 HIV-1 infected subjects will receive three infusions of each antibody, TMB-365 and TMB-380 every 8 weeks, at doses to be determined and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
32972989|NCT05275998|Experimental|Core Group 2|20 HIV-1 infected subjects will receive two infusions of each antibody, TMB-365 and TMB-380 every 12 weeks, at doses of 4800 mg each and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
32972990|NCT05275439|Experimental|SL-172154|Patients will receive intravenous administration
32972991|NCT05275439|Experimental|SL-172154 + Azacitidine|Patients will receive intravenous administration of SL-172154 and Azacitidine.
32972992|NCT05275439|Experimental|SL-172154 + Azacitidine + Venetoclax|Patients will receive intravenous administration of SL-172154 and Azacitidine plus oral venetoclax.
32972993|NCT05271162|Active Comparator|Empagliflozin|Empagliflozin, 10 mg q.d; p.o
32972994|NCT05271162|Placebo Comparator|Placebo|Placebo 1 tabl q.d; p.o
32972995|NCT05269186|Experimental|Virtual reality|Virtual reality session performed before the planning CT scan
32972996|NCT05269186|No Intervention|Normal care|Normal care without intervention
32972997|NCT05263336|Active Comparator|Intervention|Intraoperative verdye green iv administration to visualize blood supply to the anastomosis
32972998|NCT05263336|No Intervention|Control|No administration of verdye green intraoperatively
32972999|NCT05257083|Active Comparator|Arm A: DVRd + ASCT+DVRd (Standard Therapy)|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
32973000|NCT05257083|Experimental|Arm B: DVRd followed by Ciltacabtagene Autoleucel|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.~Participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6.~Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.~Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist of 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
32973001|NCT05250804|Experimental|Experimental|All registered participants in the intervention group, will receive the intramuscular injection with Helfer Skin Tap Technique.
32973002|NCT05250804|No Intervention|No intervention|All registered participants in the intervention group, will receive the intramuscular injection with Routine Technique. Routine Technique involved inserting the injection intra muscularly at 90 degree angle into Dorso gluteal muscles without tapping after cleaning with alcohol swab.
32973003|NCT05249634|Experimental|treatment|JATENZO daily for 6 months
32973004|NCT05249270||Safe and Sound Protocol Participants|Parents of children receiving the Safe and Sound Protocol (a clinical auditory therapy provided outside of the study) will complete questionnaires to assess sensory behaviors prior to therapy initiation (baseline), 1 week after therapy conclusion, and 4 weeks after therapy conclusion. The SSP typically consists of 1 hour of listening per day, for 5 consecutive days. If modifications of the typical dosage are implemented due to client needs, they will be documented by parents in the 1 week post therapy questionnaire.
32973005|NCT05247879|Active Comparator|Commercial reduced-osmolarity oral rehydration solution (ORS|
32973006|NCT05247879|Experimental|VS011, new children's ORS, a sugar-free blend of amino acids and electrolytes|
32973007|NCT05245071|Experimental|Tusamitamab ravtansine|Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).
32973008|NCT05244980|Experimental|MAD Cohorts 1-4 TDM-105795 topical solution|Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
32973009|NCT05244980|Placebo Comparator|Placebo for TDM-105795 topical solution|Multiple dose administration of Placebo forTDM-105795 Topical Solution
32973010|NCT05243433|Experimental|Procedure using the Maestro Platform|Study participants will be adults aged ≥ 18 to ≤ 75 years scheduled for a non-emergent laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy.
32973011|NCT05237284|Experimental|SAR443820|twice daily (BID) oral SAR443820
32973012|NCT05237284|Placebo Comparator|Placebo|twice daily (BID) oral placebo
32973013|NCT05236933||Neuropathic|Individuals who report pain that is categorized as neuropathic will be assigned to this group.
32973014|NCT05236933||Nociceptive|Individuals who report pain that is categorized as nociceptive will be assigned to this group.
32973015|NCT05232604|Experimental|Aerobic exercise group (AE)|The session training will be divided into a warm-up, main exercise period, and cool-down, with a total duration of 60 minutes (guided by a PT). The training will be performed on a cycle ergometer, three times per week for 12 weeks. The duration of the main AE will be between 30-45 minutes and the intensity will be based on the maximal heart rate (HRmax), heart rate reserve (HRR), and the Borg Rating of Perceived Exertion Scale (Borg Scale), which will be monitored. The intensity of the AE program will be progressively increased according to each patient's response and tolerance but will be standardized as much as possible: 1) first two weeks, low to moderate intensity (60% HRmax or 9-11 on the Borg scale); 2) 2-6 weeks, moderate-intensity (55-70% HRmax or 12-14 on the Borg scale), and 3) last 6 weeks, high intensity interval training (HIT) (75-90% HRmax or 15-17 on the Borg scale; 4 min*4 times HIT followed by 3 min of 70%HRmax in between) will be targeted per literature endorsements.
32973016|NCT05232604|Active Comparator|Neck motor control exercise group|The treatment will consist of a 12-week progressive exercise program targeted to the neck flexor and extensor muscles supervised by a physical therapist (PT). This exercise protocol has been successfully tested in subjects with NP. Low load craniocervical exercises (nodding) will be performed at early stages (first 6 weeks) guided by visual feedback from a pressure unit. Higher-load neck exercises will be performed at later stages (last 6 weeks). During the first month, subjects will receive 30-45 min of MCTF three times per week, in the second month twice per week, and in the third month once per week. This duration of treatment is commonly used in clinical settings and has proven to be sufficient to improve muscle function, clinical, and brain outcomes.
32973017|NCT05229822||Malignant ABO|60 patients with malignant acute bowel obstruction
32973018|NCT05229822||CRC without ABO (control)|60 colorectal cancer patients without acute bowel obstruction (planned operations)
32973019|NCT05229822||Benign ABO|30 patients with benign acute bowel obstruction
32973020|NCT05228691||Long COVID|"Participants will self-complete some questionnaires, while the rest of the variables will be evaluated by the evaluating physiotherapist.~After the consultation, the evaluator himself will provide the participants with some recommendations that he should make. As support, a diptych has been made with different general activities to be developed by the participant. With the purpose of track this activity, they will be informed that they will be contacted once 6 months have passed since the evaluation (via phone call or SMS)."
32973021|NCT05228366|Experimental|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
32973022|NCT05228366|Experimental|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
32973023|NCT05228366|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
32973024|NCT05225168|Active Comparator|laparoscopic burch colposuspension group|this group will only have laparoscopic burch colposuspension
32973025|NCT05225168|Active Comparator|Minisling Suburethral Sling group|this group will only have Minisling Suburethral Sling
32973026|NCT05224661||Adult patients with AML in complete remission undergoing alloHCT|Adult patients with AML in complete remission undergoing alloHCT
32973027|NCT05224102|Experimental|Faricimab|
32973028|NCT05222581|Experimental|Prototypes of Breast Shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump
32973029|NCT05217342|Experimental|PVP-Guided|Peripheral venous pressure guided therapy arm
32973030|NCT05217342|Active Comparator|Control|Standard medical therapy arm
32973031|NCT05213598||Adults with FALD|male and female subjects =18 years of age who historically underwent Fontan procedure due to a severe CHD and thus are at risk for FALD by virtue of their altered physiology
32973032|NCT05211245|Experimental|Pulse mode|Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization. The non-thermal effect of US can be explain by frequency resonance theory which states that the proteins in these structures absorbs mechanical energy thus altering the structure & function, finally resulting in stimulation of phagocytosis, increase number of free radicals, increase cell membrane permeability, cellular proliferation &acceleration of fibrinolysis
32973033|NCT05211245|Active Comparator|Continous mode|Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
32973034|NCT05202262|Experimental|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
32973035|NCT05202262|Experimental|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
32973036|NCT05202262|Experimental|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
32973037|NCT05202262|Active Comparator|Open-label Symbicort TBH 320/9 μg|Open-Label Comparator Symbicort Turbuhaler 320/9 μg
32973038|NCT05202119|Active Comparator|Active stimulation|Active stimulation at 2mA
32973039|NCT05202119|Sham Comparator|Sham stimulation|
32973040|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (8μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
32973041|NCT05199714|Active Comparator|Fiasp-alone with carbohydrate-matched boluses|The Fiasp-alone intervention will have a 14 hour duration. During which, carbohydrate counting will inform insulin bolus doses based on insulin to carbohydrate ratios.
32973042|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (10μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
32973043|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (10μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
32973044|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (8μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
32973045|NCT05198154||Advanced NSCLC patients with long-term benefit after first-line immunotherapy|For patients with advanced NSCLC who have long-term benefit (PFS 12 months) after first-line immunotherapy
32973046|NCT05197881|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
32973047|NCT05194618|Experimental|Valerian/Lavender arm|Participants in this arm will receive actives products : 420 mg per tablet of Valerian root extract and 40 mg per tablet of essential oil of Lavender
32973048|NCT05194618|Placebo Comparator|Placebo arm|Participants in this arm will receive placebo (no active product)
32973049|NCT05193370|Experimental|angiotensin II (intervention)|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert). Thereafter, angiotensin II and norepinephrine will both be titrated according to the schema in UNM Hospitals Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72h, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
32973050|NCT05193370|Active Comparator|vasopressin (standard of care)|In patients randomized to the control group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, vasopressin will be used at a fixed dose of 0.04 units/min and norepinephrine will be titrated per usual standard of care (as also outlined in the UNM Hospitals Nursing Department Titration Guideline).
32973051|NCT05188183|Experimental|M1 anodal home-based tDCS and somatosensory training|Investigators will use the Soterix Medical 1X1 tDCS mini-CT stimulator device (© Soterix Medical Inc.) an home-based tDCS device used in several clinical trials with no adverse events. It sends a low-level current from the positive electrode, anode, to the negative electrode, cathode. During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. HB-TDCS will be combined with somatosensory training that will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks.
32973052|NCT05188183|Experimental|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
32973055|NCT05181618|Experimental|Cohort 1, Hemophilia A and Without Arthropathy: Emicizumab|Cohort 1 comprises participants with severe or moderate hemophilia A and with no synovitis and no osteochondral damage (Haemophilia Early Arthropathy Detection with Ultrasound [HEAD-US] score of 0) in all index joints.
32973056|NCT05181618|Experimental|Cohort 2, Hemophilia A and with Synovitis Only: Emicizumab|Cohort 2 comprises participants with severe or moderate hemophilia A and with synovitis (HEAD-US synovitis score of ≥1) in at least one index joint and no osteochondral damage (HEAD-US bone and cartilage score of 0).
32973057|NCT05181618|Experimental|Cohort 3, Hemophilia A and with Osteochondral Damage: Emicizumab|Cohort 3 comprises participants with severe or moderate hemophilia A and with osteochondral damage (HEAD-US bone and cartilage score of ≥1) in at least one index joint with any synovitis score.
32973058|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive programmed intermittent bolus of local anaesthetic: 20mls 0.125% levobupivacaine every two hours.
32973059|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Continuous Infusion (CI)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive a continuous infusion local anaesthetic: 0.125% levobupivacaine at an infusion rate of 10 ml/hr.
32973060|NCT05180240|Experimental|CardiolRx|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
32973061|NCT05180240|Placebo Comparator|Placebo|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
32973062|NCT05178901|Experimental|PHV02 2x10^5 pfu|
32973063|NCT05178901|Experimental|PHV02 2x10^6 pfu|
32973064|NCT05178901|Experimental|PHV02 2x10^7 pfu|
32973065|NCT05178901|Placebo Comparator|Placebo|
33411140|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
32973066|NCT05178901|Experimental|PHV02 5x10^8 pfu (Boost)|
32973067|NCT05178901|Experimental|PHV02 5x10^8 pfu (Prime)|
32973068|NCT05172947|Active Comparator|Resveratrol|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months.
32973069|NCT05172947|Placebo Comparator|Placebo|"Non-interventional group, participants are receiving only Placebo once daily for 3 months.~Placebo formulated as capsule match the color and size of the active comparator,"
32973070|NCT05172947|Other|Resveratrol plus Pharmaceutical care|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months with pharmaceutical care.
32973071|NCT05172947|Other|Placebo with pharmaceutical care|Interventional group, participants are receiving placebo along with pharmaceutical care for 3 months.
32973072|NCT05170646||Participants treated with upadacitinib|
32973073|NCT05170607||PV associated atrial fibrillation|
32973074|NCT05170607||non-PV associated arrhythmic focuses|
32973075|NCT05170607||Healthy volunteers|
32973076|NCT05170269|Experimental|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
32973077|NCT05167591|Experimental|Study group|Measurements of paracetamol concentration
32973078|NCT05166889|Experimental|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
32973079|NCT05166889|Experimental|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
32973080|NCT05166889|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
32973081|NCT05158387|Experimental|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
32973082|NCT05158387|Experimental|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
32973083|NCT05158387|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
32973084|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort A|Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
32973085|NCT05156710|Other|Standard of Care (SOC) Cohort A|SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
32973086|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort B|Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
32973087|NCT05156710|Other|Standard of Care (SOC) Cohort B|SOC includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
32973088|NCT05156125|Experimental|VTX002 Dose A|VTX002 Dose A tablet administered orally once daily
32973089|NCT05156125|Experimental|VTX002 Dose B|VTX002 Dose B tablet administered orally once daily
32973090|NCT05156125|Placebo Comparator|Placebo|Placebo tablet administered orally once daily
32973091|NCT05151367|Experimental|Text message reminders|Text message reminders
32973092|NCT05151367|No Intervention|Usual Care|No reminders
32973093|NCT05147220|Experimental|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
32973094|NCT05147220|Active Comparator|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
32973095|NCT05147220|Experimental|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
32973096|NCT05147220|Experimental|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
32973097|NCT05139160|Experimental|Whey protein isolate|Whey protein isolate is the 'gold standard' of protein supplements due to being rich in essential amino acids and leucine. Leucine is a key amino acid the is required to stimulate muscle protein synthesis. Muscle protein synthesis is the major mechanism the underpins muscle growth. The whey protein would ostensibly serve as a positive control.
32973098|NCT05139160|Experimental|Plant based protein isolate|Current plant-based protein isolates available contain insufficient amounts of leucine, and are less digestible, resulting in a reduced muscle protein synthesis responses. The plant based protein would ostensibly serve as a negative control.
32973099|NCT05139160|Experimental|Plant based protein isolate + leucine|Enriching plant-based protein with leucine will increase the 'quality' of said protein source and theoretically should have similar muscle protein synthetic responses to whey protein.
33411141|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
33411142|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
32973102|NCT05127902||adolescent idiopathic scoliosis group|Female subjects aged 10 to 16 will be recruited if they are diagnosed with AIS by standard standing long X-ray examinations, with Cobb angle larger or equal to 15°, without prior treatment for their AIS and been cleared for physical activity by their doctors. Subjects were excluded if they had (i) Cobb angle larger or equal to 40°, (ii) scoliosis with any known aetiologies such as congenital, neuromuscular, metabolic, and skeletal dysplasia, (iii) known endocrine and connective tissue abnormalities, (iv) known heart condition or other diseases that could affect the safety of exercise, (v) eating disorders or gastrointestinal malabsorption disorders, and (vi) currently taking medications that affecting their bone or muscle metabolism. All subjects will be recruited in the community.
32973103|NCT05127902||Control group|Ten healthy female subjects with matched for age, height and weight will be recruited as control.
32973104|NCT05127291|Experimental|Study Group|Patients with type 2 diabetes mellitus
32973105|NCT05127291|Other|Control Group|People without type 2 diabetes and prediabetes
32973106|NCT05126030|Experimental|Primary Cohort|Device: Topaz TTVR system
32973107|NCT05124912|Other|Recurrent Tumor|Receives Laser Interstitial Thermal Therapy (LITT) followed by surveillance or Receives Laser Interstitial Thermal Therapy (LITT) followed by hypofractionated radiation therapy (RT).
33411143|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
33411144|NCT05058716||COVID-19 positive patients|
33411145|NCT05058716||COVID-19 negative patients|
33411146|NCT04057950|Active Comparator|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
33411147|NCT04057950|Placebo Comparator|vehicle|1144781 cosmetic product
32973108|NCT05124912|Other|Radiation Necrosis|Receives Laser Interstitial Thermal Therapy (LITT) and best medical management with steroids or Receives best medical management with steroids.
32973109|NCT05122832||The study Group|Population of Kazakhstan
32973110|NCT05121415||Experimental group:|patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
32973111|NCT05121415||Control group|patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
32973112|NCT05118997|Experimental|Treatment Arm #1|IRRAflow with manual tPA administration followed by Active Fluid Exchange
32973113|NCT05118997|Experimental|Treatment Arm #2|IRRAflow with continuous infusion of tPA combined with Active Fluid Exchange
32973114|NCT05118997|Active Comparator|Treatment Arm #3|Standard EVD with manual tPA administration
32973115|NCT05117242|Experimental|Arm A|Treatment with GEN1046 once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles
32973116|NCT05117242|Experimental|Arm B|Treatment with GEN1046 + Pembrolizumab once every 21 days
32973117|NCT05117242|Experimental|Arm C|Treatment with GEN1046 + Pembrolizumab once every 42 days
33411148|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~Will be able to attend each of the 10 training days."
33411149|NCT04051866|Other|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
33411150|NCT04051866|Experimental|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
32973118|NCT05099718|Experimental|Hyaluronic acid|Application 3-times per day for 7 days.
32973119|NCT05099718|Placebo Comparator|Saline solution|Application 3-times per day for 7 days.
32973120|NCT05099159|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
32973121|NCT05099159|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
32973122|NCT05095181||Experimental group:|patients with liver cirrhosis
32973123|NCT05095181||Control group|patients without liver cirrhosis
32973124|NCT05095155||Experimental group:|children with B-cell leukemia and lymphoma of Kazakhstani nationality
32973125|NCT05095155||Control group|children without B-cell leukemia and lymphoma of Kazakhstani nationality
32973126|NCT05095142||Experimental group:|patients with idiopathic osteoarthritis of the knee
32973127|NCT05095142||Control group|patients without idiopathic osteoarthritis of the knee
32973128|NCT05095129||Experimental group:|patients with idiopathic scoliosis
32973129|NCT05095129||Control group|patients without idiopathic scoliosis
32973130|NCT05090644||Experimental group:|Patients with schizophrenia
32973131|NCT05090644||Control group|Patients without schizophrenia
32973132|NCT05090631||Experimental group:|Patients with atopic dermatitis
32973133|NCT05090631||Control group|Patients without atopic dermatitis
32973134|NCT05090618||Experimental group:|Patients with Heart Attack
32973135|NCT05090618||Control group|Patients without Heart Attack
32973136|NCT05090605||Experimental group:|Patients with breast cancer
32973137|NCT05090605||Control group|Patients without breast cancer
32973138|NCT05090436|Experimental|Schroth Exercise|The Schroth Method is a nonsurgical option for scoliosis treatment. It uses exercises customized for each patient to return the curved spine to a more natural position. The goal of Schroth exercises is to de-rotate, elongate and stabilize the spine in a three-dimensional plane. it will be applied 3 session per week for 3 months.
32973139|NCT05090436|Experimental|Functional Electrical Stimulation|30 minutes of Functional Electrical Stimulation (FES) three times a week for 3 months. Two electrodes were attached on the lateral parts of the convex side of the body, and two others on the erector spinae muscles. FES (CU-FS1; Novastim, Korea) was set at a frequency of 35 Hz, with a 250-μs pulse width. Electrical stimulation lasted for 6 seconds, followed by a 6-second rest.
32973140|NCT05088512||Experimental group:|Patients with bronchial asthma
32973141|NCT05088512||Control group|Patients without bronchial asthma
32973142|NCT05088499||Experimental group:|Patients with epilepsy
32973143|NCT05088499||Control group|Patients without epilepsy
32973144|NCT05088486||Experimental group:|Patients with arterial hypertension
32973145|NCT05088486||Control group|Patients without arterial hypertension
32973146|NCT05087303|Active Comparator|Hub and Spoke|
32973147|NCT05087303|Active Comparator|Direct to Consumer|
32973148|NCT05081180|Experimental|Avelumab + Lenvatinib|
32973149|NCT05078827|Active Comparator|Comparator Arm|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
32973150|NCT05078827|Experimental|Arms and Interventions|Test Product (A): Fluorouracil Cream, 5% of Encube Ethicals Pvt. Ltd., India
32973151|NCT05078827|Placebo Comparator|Placebo Arm|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
32973152|NCT05076981||Pure Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~TVUS day 9-10 of cycle to identify dominant follicle.~Blood test for IVF1 every 24h until identification of the LH surge.~The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010).~Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days.~During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise."
33411151|NCT03616340|Experimental|Ketorolac|
33411152|NCT03616340|Experimental|Kenalog|
33411153|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
33411154|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
32973153|NCT05076981||Modified Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~TVUS day 9-10 of cycle to identify dominant follicle.~Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration.~IVF1 2h after rhCG.~IVF1 every 12h for 2 days after rhCG.~During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG."
32973154|NCT05076422|Experimental|BI 3006337 treatment group|BI 3006337
32973155|NCT05076422|Placebo Comparator|Placebo group|Placebo
32973156|NCT05075213|Experimental|QuitBet|"QuitBet is a quit smoking game delivered via a smartphone application that lasts 28 days and includes contingency management in the form of a deposit contract, integrated exhaled breath carbon monoxide (CO) testing, a social feed on which players can post and respond to messages, and a leaderboard that displays players' status (i.e., whether they are still eligible to win). A game host will post educational information about smoking cessation and serve as a discussion moderator. Participants will deposit (bet) $30 of their own money at the start of the game. Participants who submit a CO test that is 6ppm or lower (indicating no smoking) on at least 24 of the 26 days between day 3-28 will be declared winners and will split the pot of money that was deposited. All participants who submit at least 21 CO tests during the 28 day game, regardless of the CO test result, will be entered into a lottery to win a prize worth $75."
32973157|NCT05075213|Active Comparator|QuitBet-NS (no social elements)|QuitBet-NS will include the deposit contract and integrated CO testing with identical rules to QuitBet for being a winner, the $75 raffle for submitting at least 21 CO tests, a display of the participant's daily CO test results that is updated in real time, and a game feed on which only the game host has the ability to post. Players will not be able to post on this feed or respond to the host's posts. At the beginning of the game, the host will post limited information, including a list of smoking cessation resources. QuitBet-NS will NOT include the social feed, leaderboard, or any other social features.
32973158|NCT05074979|Other|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
32973159|NCT05074979|Experimental|home exercise program group|this group will implement COVID 19 home exercise program.
32973160|NCT05074979|Experimental|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
32973161|NCT05065164|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
32973162|NCT05065164|Placebo Comparator|placebo control|Placebo subcutaneous injection /6 months, twice a year
32973163|NCT05062122||vibration group|Vibration applied group in addition to conventional physiotherapy
32973164|NCT05062122||kinesiology tape group|The group in which kinesiology tape was applied in addition to conventional physiotherapy
32973165|NCT05062122||control group|Group receiving only conventional physiotherapy
32973166|NCT05062044||Multivitamins usage in pregravidal preparation|Participants start use of Elevit multiple micronutrient (MMN) before pregnancy.
32973167|NCT05062044||Multivitamins usage during pregnancy|Participants start use of Elevit multiple micronutrient (MMN) in the first trimester of pregnancy.
32973168|NCT05062044||Folic acid usage during pregnancy|Participants use folic acid in accordance with clinical guidelines.
32973169|NCT05057819|Experimental|Empagliflozin first, Placebo second|Oral empagliflozin 25 mg daily in the morning for 20 days, followed by oral placebo (daily in the morning) for 20 days after a wash-out period of 2-6 weeks
32973170|NCT05057819|Placebo Comparator|Placebo first, Empagliflozin second|Oral placebo (daily in the morning) for 20 days, followed by oral empagliflozin 25 mg daily in the morning for 20 days after a wash-out period of 2-6 weeks
33322588|NCT03943602|Experimental|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
33322589|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
33322590|NCT02523274|Experimental|Resveratrol 500 mg/day + exercise|500 mg/day resveratrol taken orally in combination with exercise
33322591|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
32973175|NCT05046834|Experimental|cold application Group|a cold gel pack will be wrapped in gauze and placed directly on the skin in an area with a radius of about 5 cm to cover the chest tube. The cold gel package will remain on the skin surface for about 20 minutes.
32973176|NCT05046834|Experimental|Cold Application Group with Thermometer|10 of cold application. After a minute, the skin temperature will be measured with an infrared thermometer if the temperature has dropped below 13.6 o C, the procedure will be terminated. If the skin temperature has not decreased below 13.6 0 C, the application will be continued, the application will be terminated when the temperature drops below the specified temperature.
32973177|NCT05046834|No Intervention|control Group|standard pain procedure.
32973178|NCT05044819|Experimental|Cannabidiol|Cannabidiol solution 100 milligrams per milliliter (mg/mL) will be administered orally at a dose level of 5 mg/kg/day for 1 week, then increase to 10 mg/kg/day by the participant or their caregiver twice each day (morning and evening).
32973179|NCT05042362|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
32973180|NCT05042362|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
32973181|NCT05041478|Experimental|Cold EMR with adjuvant STSC to margins|Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins
33322592|NCT03945474|Experimental|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
33322593|NCT03945474|Sham Comparator|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
33322594|NCT01107990||Single right ventricles|
33322595|NCT01107990||Single left ventricles|
33322596|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
32973182|NCT05041478|Active Comparator|Cold EMR|Standard Cold EMR resection technique
32973183|NCT05039645|Other|Open Arm Study - All participants|"Study is open arm with no blinding or randomisation. Patients will receive standard care including frequent clinical visits, education, and preventative foot care/podiatry as required. Patients will also be given a DFS thermovisual scanner device. Patients will be instructed to use the DFS on a daily basis, at home, to record thermovisual data about the soles of their feet.~Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment)."
32973184|NCT05039515|Experimental|IPN60130 high dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
32973185|NCT05039515|Experimental|IPN60130 low dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
32973186|NCT05039515|Placebo Comparator|Placebo|Oral capsule, swallowed whole or sprinkled onto food, once daily
32973187|NCT05038826||trial 1|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
32973188|NCT05038826||trial 2|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
32973189|NCT05038826||trial 3|RNA-polymerase-II inhibitor
32973190|NCT05038826||trial 4|Tyrosine kinases inhibitor
32973191|NCT05038826||trial 5|Tyrosine kinases inhibitor
32973192|NCT05038826||trial 6|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
32973193|NCT05037812|Placebo Comparator|Saline injection|Saline
32973194|NCT05037812|Experimental|Multimodal injections|"Superficial multimodal analgesia composition includes 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline.~Deep medial multimodal analgesia composition includes 2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline."
32973195|NCT05036083|Experimental|Diagnostic (CEM, DBT, medical record)|Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
32973196|NCT05035693|Experimental|PMCF MOVE-C|PMCF MOVE®_C is a single arm observational study with 170 patients.
32973197|NCT05035420|Experimental|Healthy Volunteer|Healthy Volunteer
33322597|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
33322598|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
32973200|NCT05033886|Experimental|fezolinetant|Participants will receive 2 tablets of fezolinetant once daily for 24 weeks.
32973201|NCT05033886|Placebo Comparator|placebo fezolinetant|Participants will receive 2 tablets of matching placebo once daily for 24 weeks.
32973202|NCT05029752|Other|Vendys II Device|Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device
32973203|NCT05029375|Experimental|immediate parental involvement|Parental involvement in training is parallel to children's training
32973204|NCT05029375|Experimental|delayed parental involvement|Parental involvement in training will be given at the end of the children's training
32973205|NCT05027802|Experimental|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
32973206|NCT05027074|Experimental|MK-2060 Low Dose|MK-2060 low dose administered via intravenous (IV) infusion as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1
32973207|NCT05027074|Experimental|MK-2060 High Dose|MK-2060 high dose administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then QW after week 1
32973208|NCT05027074|Placebo Comparator|Placebo|Placebo (normal saline) administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1
32973209|NCT05024487|Experimental|Experimental group|The correlation between blood pressure level, dermal resistance level, and subjective symptoms caused by triggered AD below the level of the lesion will be performed in a group of SCI people.
32973210|NCT05022095||SCI Patients with ongoing spasticity|SCI Patients that are either seen in clinical routine due to fillings or controls of their intrathecal injection pumps or stationary patients will be informed about the project, they are granted with enough time to decide whether they want participate or not. After giving Informed Consent they will be administered a set of questionnaires including SCI-SETde, PSFS (adapted to german), SCIM-SR in german as well as self-evaluation of spasticity severity and intensity. The SCI-SETde will be filled in again one week later to evaluate test-retest reliability. Overall, the burden for the patients is kept at minimum. There are no expected risks or harm to the patients.
32973213|NCT05019638|Active Comparator|Regional anesthesia group|Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.
32973214|NCT05019638|Experimental|Local multimodal analgesia group|Local multimodal analgesia composition will include 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
32973215|NCT05017142||Patient population|Children, adolescents and adults diagnosed with an IBrainD before age 18, who are born, treated or living in Switzerland
32973216|NCT05014191||Radiation therapy in frog leg position|
32973217|NCT05014191||Radiation therapy in straight leg position|
32973218|NCT05014139|Experimental|Enfortumab vedotin: Dose escalation cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
32973219|NCT05014139|Experimental|Enfortumab vedotin: Dose expansion cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
32973220|NCT05004389||Acute Stroke|Persons ≥ 18 years of age with acute (≤ 7 days) ischemic or intracerebral hemorrhagic stroke.
32973221|NCT04997993|Experimental|Leflunomide|Leflunomide, 20-50mg PO daily
32973222|NCT04995315||PK Deficiency Diagnosed Participants|Participants will receive online user access to the CBB. Participants will complete 2 CBB assessments on Study Day 0 and Study Day 90.
32973223|NCT04994483|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
32973224|NCT04994483|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
32973225|NCT04981821|Experimental|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
32973226|NCT04981821|Active Comparator|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
32973227|NCT04975763|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
32973228|NCT04975763|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
32973229|NCT04969926||Patients with confirmed, suspected or at risk of developing parathyroid disorder|Parathyroid (and related disorders) will be evaluated and their biospecimens collected to define the molecular signature and clinical spectrum of their disorder
32973230|NCT04964323||PK Deficiency Diagnosed|Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.
32973231|NCT04962165|Experimental|Experimental group|The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.
32973232|NCT04947033|Experimental|TJ210001 Injection|Single Arm Dose expansion
32973233|NCT04942535|Experimental|Social Incentive Gamification|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Incentive Gamification intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
32973234|NCT04942535|Experimental|Social Goals through Incentives to Charity|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Goals through Incentives to Charity intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
32973235|NCT04942535|Active Comparator|Control|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive Daily Performance Feedback during the 12 month intervention and 6 month follow up."
32973236|NCT04934124|Experimental|Cohort 1: 0.03 mg ITI-333 or placebo|
32973237|NCT04934124|Experimental|Cohort 2: 0.09 mg ITI-333 or placebo|
32973238|NCT04934124|Experimental|Cohort 3: 0.25 mg ITI-333 or placebo|
32973239|NCT04934124|Experimental|Cohort 4: 0.75 mg ITI-333 or placebo|
32973240|NCT04934124|Experimental|Cohort 5: 2.25 mg ITI-333 or placebo|
33417315|NCT02978781|Experimental|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
32973241|NCT04934124|Experimental|Cohort 6: 6.75 mg ITI-333 or placebo|
32973242|NCT04924920|Experimental|Intervention EEO_SIGH|Single arm intervention. All the patients will receive the two tests (SIGH and EEOT) in 1:1 random sequence order (6 patient-block)
32973243|NCT04924010|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy (CBT) is a talking therapy that can help patients manage problems by changing the way they think and behave. It's most commonly used to treat anxiety, depression and chronic pain conditions.
32973244|NCT04924010|Placebo Comparator|Education and Mindfulness|Education and mindfulness therapy refers to lessons on techniques to calm the mind and body - can reduce the negative effects of stress
33417316|NCT04565379|Active Comparator|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
33417317|NCT04565379|Active Comparator|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
32973247|NCT04914975|Experimental|NMES Group|Participants will receive neuromuscular electrical stimulation of the abdominal wall before defaecation for 30 minutes over the course of 16 weeks.
32973248|NCT04909723|Placebo Comparator|Stage 1 placebo arm|
32973249|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1|
32973250|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 0.5g/day|
32973251|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 10g/day|
32973252|NCT04909723|Experimental|(Optional) Stage 1 variable doses of NB1000S and NB2000P at varying dosing regimens.|Adaptive trial design supports the enrollment of additional arms with variable doses of NB1000S, NB2000P, at varying frequencies of NB1000S and NB2000P administrations.
32973253|NCT04909723|Experimental|Stage 1 NB2000P at a dose to be determined|
32973254|NCT04909723|Experimental|Stage 2 NOV-001 at dose determined in Stage 1|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive NOV-001 (consisting of NB1000S and NB2000P at a dose and regimen determined in Stage 1) for 28 days.
32973255|NCT04909723|Placebo Comparator|Stage 2 placebo arm|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive placebo for 28 days.
32973256|NCT04908735|Experimental|Ruxolitinib Treatment|
32973257|NCT04907253|Active Comparator|Quercetin|Patients receiving 500 mg quercetin twice daily
32973258|NCT04907253|Placebo Comparator|Placebo|Patients receiving placebo twice daily
33417318|NCT04565379|Placebo Comparator|Placebo|100 ml normal saline infusion
32973259|NCT04907240||Iliac|Subjects with de novo or restenotic lesions in the iliac arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973260|NCT04907240||Superficial Femoral Artery (SFA)|Subjects with de novo or restenotic lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973261|NCT04907240||Superficial Femoral Artery (SFA) In-Stent Restenosis (ISR)|Subjects with in-stent restenosis lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973262|NCT04907240||AV access|Subjects with stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access graft and in the venous outflow of dialysis access circuits, including the central veins treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973263|NCT04907240||Popliteal Artery Aneurysms|Subjects with popliteal artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973264|NCT04907240||Trauma/Injury|Subjects with traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity, or pelvis (except for aorta, coronary, innominate, carotid, vertebral, and pulmonary arteries) treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973265|NCT04907240||Visceral Artery Aneurysms|Subjects with isolated visceral artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
32973266|NCT04907240||Others|Subjects treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) but do not fit any of the cohorts listed above.
32973267|NCT04905979|Experimental|AD113|Two oral capsules administered before bed
32973268|NCT04905979|Experimental|Atomoxetine|Two oral capsules administered before bed
32973269|NCT04905017|Experimental|Treatment with the Trisol System|
32973270|NCT04902469|Experimental|Pleasant Odor|Participants in this condition will sniff the olfactory cue they rate as both pleasant (>5 on the 1-9 scale) and the most intense following cigarette cue exposure. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated as pleasant.
32973271|NCT04902469|Other|Odor Blank|Participants in this condition will sniff a neutral olfactory cue (odor blank) following cigarette cue exposure.
32973272|NCT04889859|Active Comparator|long RL group|long Roux limb Roux-en-Y reconstruction
32973273|NCT04889859|Experimental|long BPL group|long biliopancreatic limb Roux-en-Y reconstruction
32973274|NCT04885400|Experimental|iJobs|All the participants will be included in the program.
32973275|NCT04884360|Experimental|Group A: Olaparib tablets 300 mg oral twice daily (n=280).|Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
32973276|NCT04884360|Placebo Comparator|Group B: Placebo tablets 300 mg oral twice daily (n=140)|Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
32973277|NCT04881916||Sample Collection|"Participation In:~Initial data completion: Telephone collection of information on disease, treatment and testing~Medical record collection: Collection of medical records regarding cancer, testing, and treatment history~Archival tissue collection: Collection of tumor from prior standard of care procedure~Saliva collection: Saliva collection with at home kit~Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
32973278|NCT04880590||Sex Intercourse|women with a heterosexual sexual relationship after embryo transfer
32973279|NCT04880590||Non sex intercourse|women without a heterosexual sexual relationship after embryo transfer
32973280|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
32973281|NCT04870827||Healthy Controls|Females and males 18 years of age or older
32973282|NCT04867902|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
32973283|NCT04860765||TPVR|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
32973284|NCT04854512|Experimental|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
32973285|NCT04854512|Placebo Comparator|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
32973286|NCT04854512|Active Comparator|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
32973287|NCT04844970|Experimental|Anamorelin|Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
32973288|NCT04844970|Placebo Comparator|Placebo|Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
32973289|NCT04837196|Experimental|Phase 1 ASP7517 Monotherapy Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses.
32973290|NCT04837196|Experimental|Phase 1 ASP7517 + Pembrolizumab Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks starting from Cycle 1 Day 1. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
32973291|NCT04837196|Experimental|Phase 2 ASP7517 Monotherapy Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses
32973292|NCT04837196|Experimental|Phase 2 ASP7517 + Pembrolizumab Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
32973293|NCT04806854|Experimental|LUM-201 (1.6 mg/kg/day)|
32973294|NCT04806854|Experimental|LUM-201 (3.2 mg/kg/day)|
32973295|NCT04806386|Experimental|Psyllium fiber supplement treatment|All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.
33322599|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
33322600|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
32973298|NCT04804072|Experimental|Integrated health services delivered in the mobile unit and peer navigation|Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks.
32973299|NCT04804072|Active Comparator|Peer navigation to connect them to health services available at community-based agencies|Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.
32973300|NCT04803214|Other|Treatment (ReActiv8)|Market-approved ReActiv8 device
32973301|NCT04803214|No Intervention|Control (OMM)|Standard of Care
32973302|NCT04802187|Other|RADx CHCs testing intervention strategy|Six Massachusetts community health center partnerships implementing both a common testing expansion implementation strategy plus tailored strategies designed for community partner needs.
32973303|NCT04802187|Other|Usual care control|
32973304|NCT04798365|Experimental|Intervention group|The main components of the intervention are 1) two sessions of voluntary continuing medical education on the urinary tract infection program in each LTCF for physicians and nursing staff, 2) distribution of educations materials such as written guidelines on antibiotic prescribing including a smart phone friendly version, 3) implementation of the project homepage as a platform to distribute guidelines and educational videos and to enable physicians to ask questions which will be answered by an infectious disease physician.
32973305|NCT04798365|No Intervention|Control group|No intervention until end of the stuy.
32973306|NCT04797195|Experimental|CKD-PD app user group|Patients on peritoneal dialysis using the CKD-PD app and home monitoring equipment to measure and record blood pressure, body weight, and dialysis fluid removed
32973307|NCT04797195|No Intervention|Usual care group|Patients on peritoneal dialysis using handwritten notebook to record record blood pressure, body weight, and dialysis fluid removed; measurements obtained through usual method
32973308|NCT04797156|Experimental|High Dose Intravenous TXA (hTXA group)|Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
32973309|NCT04797156|Experimental|Low Dose Intravenous TXA (lTXA group)|Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
32973310|NCT04797156|Placebo Comparator|Combined Intravenous and Topical TXA group (cTXA group)|Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure
32973311|NCT04796324|Experimental|Ixabepilone|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
32973312|NCT04795089||Patients|Patients with iNPH and shunt surgery.
32973313|NCT04795089||Healthy individuals|Healthy controls with similar gender and age distribution as the patients.
32973314|NCT04788511|Experimental|Semaglutide|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
32973315|NCT04788511|Placebo Comparator|Placebo (semaglutide)|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
32973316|NCT04787302|Experimental|CVL-231|
32973317|NCT04782856|Active Comparator|Single therapy|"Levothyroxine (LT4) and placebo (a look-alike inactive substance, a sugar pill) Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation."
33033084|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
32973318|NCT04782856|Experimental|Combination therapy|"Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3."
32973319|NCT04778670|Active Comparator|Standard of Care|Standard of Care means all examinations will receive a flagging decision by: first reader and second reader radiologist as usual. However, in this paired design all participants will belong to both arms.
32973320|NCT04778670|Experimental|AI CAD combination|AI CAD combination in the primary end-point means the combination of the flagging decision of the first reader and AI CAD; in the secondary end-points it means any combination of AI alone, or AI in combination with first, second and both readers.
33322601|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
33322602|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
33322603|NCT03942822|Experimental|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
33322604|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
32973325|NCT04774445|Experimental|Intervention Group|Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
32973326|NCT04774445|No Intervention|Usual Care Group|Individuals randomized to this arm will receive the standard clinical practice.
32973327|NCT04773730|Active Comparator|Posterior transversus abdominus block|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles~Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle~The same steps will be repeated on the other side"
32973328|NCT04773730|Active Comparator|Quadratus lumborum block type 2|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle~The same steps will be repeated on the other side"
32973329|NCT04773275|Experimental|Aliya PEF treatment|
32973330|NCT04772664|Experimental|Participants with Major Depression receiving a multi-strain probiotic|Participants with Major Depression receiving a multi-strain probiotic
32973331|NCT04772664|Placebo Comparator|Participants mit Major Depression receiving a placebo|Participants mit Major Depression receiving a placebo
32973332|NCT04772664|Experimental|Healthy volunteers receiving a multi-strain probiotic|Healthy volunteers receiving a multi-strain probiotic
32973333|NCT04772664|Placebo Comparator|Healthy volunteers receiving a placebo|Healthy volunteers receiving a placebo
32973334|NCT04772651|Experimental|Mediterranean Diet and dietary coaching|Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)
32973335|NCT04772651|Placebo Comparator|Diet as usual and psychoeducation for depression|Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)
32973336|NCT04772300|Experimental|Sirolimus DCB group|Intervention with Sirolimus-coated balloon catheter
32973337|NCT04772300|Active Comparator|POBA group|Intervention with non-coated balloon catheter (POBA)
32973338|NCT04759144|Active Comparator|Faster insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with faster insulin aspart for 8 weeks.~Intervention: Use of faster insulin aspart with hybrid closed-loop insulin delivery"
32973339|NCT04759144|Active Comparator|Standard insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with standard insulin aspart for 8 weeks.~Intervention: Use of standard insulin aspart with hybrid closed-loop insulin delivery"
32973340|NCT04757701||General dentists and dental hygienists in North Carolina|This objective will be met by administering a quantitative survey to active and licensed NC dentists and dental hygienists.
33322605|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
33322606|NCT00745134|Experimental|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
32973341|NCT04757701||Directors of Service-Learning Centers and their partnering FQHCs|This objective will be met by conducting qualitative assessments with ECU's SoDM's CSLCs and their partnering community clinic/FQHCs. The investigators will interview the Directors of the eight existing CSLCs and focus groups with clinical staff at each CSLC. In collaboration with the Directors of the CSLCs, the investigators will identify key stakeholders in the co-located/partnering medical clinics, and conduct interviews with the administrators and focus groups with medical clinic staff.
32973342|NCT04756037|Experimental|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
32973343|NCT04737200|Experimental|Nighttime cycled enteral feeds first|Patients will start nighttime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start daytime cycled enteral feeds for 12 hours.
33322607|NCT00745134|Active Comparator|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
33322608|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
32973344|NCT04737200|Experimental|Daytime cycled enteral feeds first|Patients will start daytime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start nighttime cycled enteral feeds for 12 hours.
32973345|NCT04734847|Active Comparator|High-frequency rTMS|"Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT.~Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm.~Frequency: 10 Hz.~Duration: 20 Trains, 10 second duration, 50 second inter-train interval.~Total number of pulses per session: 2000.~Total number of session: 5 (one session per day for 5 consecutive days)."
32973346|NCT04734847|Sham Comparator|Sham rTMS|"Identical to the High-frequency rTMS arm except delivered with an inert sham stimulation coil."
32973347|NCT04731870||Nurses/Doctors|Covid-19 vaccine confidence and recommendation practices of nurses/doctors
32973348|NCT04731870||Minority populations living in rural south|Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
32973349|NCT04729985|No Intervention|Standard Care|A blinded CGM will be placed to review glucoses after discharge in the Standard Care arm.
32973350|NCT04729985|Active Comparator|Diabetic education and CGM monitoring|Treatment arm will get diabetic education, active CGM use with patient feedback for 14 days, active access to the PI for concerns relating to hospitalization. They will also receive a brief, 15 minute phone call from the PI on day 3-4, 6-7, 9-10 and day 14-15.
32973351|NCT04724031||One cohort|women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
32973352|NCT04715542|Experimental|Stibium metallicum praeparatum 6x|Patients are treated with Stibium metallicum praeparatum 6x (subcutaneus injection), which is authorized in Switzerland and is listed by Swissmedic as an authorized anthroposophic medicinal product.
32973353|NCT04715542|Placebo Comparator|Saline subcutaneous injection|Placebo (a saline subcutaneous injection) is chosen as comparator to the treatment group.
32973354|NCT04693403|Experimental|High-flow oxygen nasal cannula (HFNC)|In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
32973355|NCT04693403|Experimental|Continuous positive airway pressure (CPAP)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
32973356|NCT04693403|Active Comparator|Standard Low flow Oxygen Arm|Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
32973357|NCT04687969||COHORT A: PROSTATE CANCER PATIENTS|"Primary prostate cancer patients scheduled to undergo radical prostatectomy.~Twenty five (25) prostate cancer patients will undergo two [18F]DCFPyL PET/MRI scans and~Sixty (60) additional prostate cancer patients will undergo one [18F]DCFPyL PET/MRI scan."
32973358|NCT04687969||COHORT B: SOLID TUMOR PATIENTS|"Patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).~Up to fifty (50) patients will undergo up to three [18F]DCFPyL PET/MRI scans"
32973359|NCT04679376|Experimental|Group 1: Atorvastatin Treatment|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive atorvastatin for 96 weeks
32973360|NCT04679376|Placebo Comparator|Group 2: Placebo|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive a placebo for 96 weeks
32973361|NCT04678999|Experimental|Tai Chi|The intervention will delivered via a secure Zoom video platform. One of two Tai Chi instructors will teach each of the classes. Tai Chi instructors will be selected prior to study start on the basis of familiarity with our previous Tai Chi protocols and experience working with OA patients.
32973362|NCT04678999|Experimental|Wellness Education|At each session, a variety of health professionals will provide a didactic lesson on a topic relating to knee OA. An informational brochure on knee OA education is presented to all participants during the first session. Each session will last 60 minutes including a 10-minute instructor-led program of stretching or flexibility exercises via a zoom platform.
32973363|NCT04677959|Experimental|Digital System (DS)|DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard
32973364|NCT04677959|Active Comparator|Standard of Care (SoC) Group|SoC group participants will be treated with their standard of care medications
32973365|NCT04677946|Experimental|Healthy Cookie Group|All participants in the study
32973366|NCT04677920|Experimental|Healthy Cookie Group|All participants in the study
32973367|NCT04671043|Experimental|CAF+lowCHO|A drink containing caffeine and 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
32973368|NCT04671043|Active Comparator|10g CHO|A drink containing 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
32973369|NCT04671043|Placebo Comparator|placebo|A drink containing an artificial sweetener (aspartame) dissolved in 200 mL of tap water
32973370|NCT04656899|Active Comparator|Pillsy arm|Participants in the Pillsy arm will receive a prescription for buprenorphine-naloxone with an ''active'' Pillsy smart cap that will continuously collect data on pill bottle openings, missed doses, text messages sent, automated phone calls made. A participant who misses an entire day of buprenorphine-naloxone will automatically receive a survey about cravings and risk of relapse.
32973371|NCT04656899|No Intervention|Service as usual arm|Participants in the Service As Usual arm will receive a prescription for buprenorphine-naloxone with an ''inactive'' Pillsy smart cap that will track openings but will not provide reminders or any other messaging. They will receive a basic application that can deploy patient satisfaction surveys.
32973372|NCT04655196|Experimental|Internet-based self-help + weekly feedback by a coach|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text, audio and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly feedback by a coach.
32973373|NCT04655196|Experimental|Internet-based self-help + weekly automated messages|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text-, audio- and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly automated messages in order to increase motivation.
32973374|NCT04655196|No Intervention|Waiting control group|
32973375|NCT04652687||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment for discogenic low back pain.
32973376|NCT04652687||Non Surgical Management|Patients receiving non surgical management (i.e., physical therapy, transforaminal epidural steroid injection, lifestyle modification, or surgical intervention)
32973377|NCT04647760|Other|Active treatment|Participants will start the intervention immediately upon study enrollment.
32973378|NCT04647760|Other|Delayed treatment|Participants will start the intervention 4-months post enrollment.
32973379|NCT04645342|Experimental|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
32973380|NCT04645342|Active Comparator|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
32973381|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
32973382|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
32973383|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
32973384|NCT04643002|Active Comparator|for controlled substudies: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 1)|"Isatuximab dose, intravenous (IV) weekly (QW) x 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Pomalidomide dose os (PO) daily Day 1 to Day 21.~Dexamethasone dose PO QW."
32973385|NCT04643002|Experimental|isatuximab + SAR439459 + dexamethasone) (Substudy 2 terminated)|"Part 1: SAR439459 in combination with isatuximab and dexamethasone 2 dose levels (DLs) of intravenous (IV) SAR439459:~DL1 SAR439459 dose Q2W.~DL2 SAR439459 dose Q2W.~Isatuximab dose IV every week (QW) × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW per os (PO) In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).~Part 2:~SAR439459 dose, IV Q2W.~Isatuximab dose, IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW PO. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8)."
32973386|NCT04643002|Experimental|isatuximab + dexamethasone + belantamab mafodotin (Substudy 3 terminated)|"Part 1: belantamab mafodotin in combination with isatuximab and dexamethasone~1 dose level (DL) of intravenous (IV) belantamab mafodotin in Part 1 and de-escalation dose DL-1:~DL1 belantamab mafodotin dose QW4 or de-escalation dose DL-1 QW8~Isatuximab dose, intravenous (IV) weekly (QW) x 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Dexamethasone fixed dose and schedule: QW PO.~Part 2:~Isatuximab dose, intravenous (IV) weekly (QW) x 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~belantamab mafodotin dose IV Q4W or Q8W~Dexamethasone fixed dose and schedule: QW PO."
32973387|NCT04643002|Experimental|Isatuximab + SAR444245 (Substudy 4)|"Part 1- dose escalation SAR444245 in combination with isatuximab:~Up to 2 DLs of IV SAR444245 are planned to be evaluated:~DL1 will explore SAR444245 at Q2W.~DL2 will explore SAR444245 at Q2W.~In case of excessive toxicity at DL1, a de-escalation dose DL-1 will be explored at Q2W.~Isatuximab dose, IV, QW × 4 weeks, followed by Q2W (subsequent cycles).~Part 1 - dose optimization:~Isatuximab dose, IV, QW × 4 weeks, followed by Q2W (subsequent cycles).~SAR444245 at potential doses (DL A and DL B) Q2W.~Part 2 (dose expansion):~Isatuximab dose, IV, QW × 4 weeks, followed by Q2W (subsequent cycles).~SAR444245 dose, IV, Q2W."
32973388|NCT04642586|Experimental|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
32973389|NCT04642586|Experimental|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
32973390|NCT04641975|Experimental|Mirabegron Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily pediatric equivalent dose (PED) low dose of IP (Investigational Product) orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
32973391|NCT04641975|Placebo Comparator|Placebo Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
33033085|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
33322609|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
32973392|NCT04641975|Experimental|Mirabegron Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
32973393|NCT04641975|Placebo Comparator|Placebo Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
32973394|NCT04639297|Experimental|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
32973395|NCT04639297|Active Comparator|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
32973396|NCT04639050|Experimental|Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
32973397|NCT04639050|Placebo Comparator|Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
32973398|NCT04639050|Experimental|Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973399|NCT04639050|Placebo Comparator|Cohort 2: Placebo|Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973400|NCT04639050|Experimental|Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973401|NCT04639050|Placebo Comparator|Cohort 3: Placebo|Participants will receive matching placebo to dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973402|NCT04639050|Experimental|Cohort 4: Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973403|NCT04639050|Placebo Comparator|Cohort 4: Placebo|Participants will receive matching placebo to dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
32973404|NCT04637035|Experimental|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.~The Supportive Oncology Care at Home intervention consists of three key components:~Daily monitoring of patient-reported symptoms, vital signs, and body weight.~Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.~Structured communication with the oncology team regarding care delivered to ensure continuity of care."
32973405|NCT04633590|Experimental|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment (including a television if required) and receive instructions on how to use the system. Participants will be provided with a stepped training plan with exergame session durations of 19 minutes (4x 3-minutes 45-seconds of exercise interspersed with 1 minute of rest) in weeks 1 and 2; 24-minutes (4x 5-minutes of exercise interspersed with 1 minute of rest) in week 3 and 4; and 30-minutes (5x 5-minutes of exercise interspersed with 1 minute of rest) in week 5 and 6. Sessions will be set at a vigorous intensity (≥80% heart rate maximum) and participants will be provided with individualised heart rate zones to achieve in line with heart rate maximum determined during a maximal exercise test in Visit 2. Participants will be asked to train 3 times per week.
32973406|NCT04626050|Experimental|Medical Music (Phase I)|Participants will complete four medical music sessions that are 30 minutes in length each.
32973407|NCT04626050|Experimental|Narrative Writing (Phase I)|Participants will complete four narrative writing sessions that are 30 minutes in length each.
32973408|NCT04626050|Active Comparator|Interpersonal Psychotherapy (Phase II)|IPT is comprised of ten 75-minute sessions scheduled twice weekly.
32973409|NCT04626050|Active Comparator|Prolonged Exposure Therapy (Phase II)|ET is comprised of ten 75-minute sessions scheduled twice weekly.
32973410|NCT04624230|Experimental|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
32973411|NCT04618198|No Intervention|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
32973412|NCT04618198|Experimental|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
33033086|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
33033087|NCT01959256|No Intervention|Control|Control group
33322610|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
33322611|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
33322612|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
33322613|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
32973413|NCT04618198|Experimental|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
32973414|NCT04618198|Experimental|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
32973415|NCT04617925|Experimental|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
32973416|NCT04614337|Experimental|LUM-201 (0.8 mg/kg/day)|
32973417|NCT04614337|Experimental|LUM-201 (1.6 mg/kg/day)|
32973418|NCT04614337|Experimental|LUM-201 (3.2 mg/kg/day)|
32973419|NCT04614337|Active Comparator|rhGH (34 µg/kg/day)|
32973420|NCT04612920|Experimental|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
32973421|NCT04612920|No Intervention|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
32973422|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
32973423|NCT04607837|Experimental|Etrasimod 2 mg|
32973424|NCT04607837|Placebo Comparator|Placebo|
32973425|NCT04590599|Experimental|IBI310+Sintilimab|IBI310+Sintilimab
32973426|NCT04590599|Active Comparator|Placebo+Sintilimab|Placebo+Sintilimab
32973427|NCT04588116|Experimental|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
32973428|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
32973429|NCT04572841|Experimental|SAR441344|SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
32973430|NCT04572841|Placebo Comparator|Placebo|Matching placebo
32973431|NCT04570293|Experimental|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
32973432|NCT04570293|Placebo Comparator|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
32973433|NCT04569084|Experimental|MT-1186|
32973434|NCT04569084|Experimental|MT-1186 and Placebo|
32973435|NCT04566172|Experimental|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
32973436|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192~Dose Expansion Phase ICP-192"
32973437|NCT04560595|Experimental|Caffeine Reduction Manual, Immediate Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the immediate treatment group will receive the guide immediately after screening."
32973438|NCT04560595|Experimental|Caffeine Reduction Manual, Delayed Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the delayed treatment group will receive the guide seven weeks after screening."
32973439|NCT04551222|Active Comparator|Probenecid|1 gr. orally of probenecid twice daily for 180 days
32973440|NCT04551222|Placebo Comparator|Placebo|identical placebo (to probenecid tablets) for 180 days
32973441|NCT04550260|Experimental|Arm 1: Durvalumab + definitive CRT|Durvalumab + concurrent chemoradiation
32973442|NCT04550260|Placebo Comparator|Arm 2: Placebo + definitive CRT|Placebo + concurrent chemoradiation
32973443|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
32973444|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
32973445|NCT04540705|Experimental|Part 1A (Part 1): Nivolumab + Axitinib|
32973446|NCT04540705|Experimental|Part 1B (Part 1): Nivolumab + Cabozantinib|
32973447|NCT04539574|Experimental|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
32973448|NCT04531462|Experimental|Empagliflozin|
32973449|NCT04531462|Placebo Comparator|Placebo|
33322614|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
32973451|NCT04527016|Experimental|Microbiota and eosinophils phenotype based therapy|The children will be treated with different protocol(Fluticasone propionate (FP),Azithromycin,or FP+Azithromycin) according to their Blood eosinophils level and airway microbiota pattern for 3 months and follow up for 1 year.
32973452|NCT04527016|Active Comparator|Clinical guidelines based therapy|The children will be treated as directed by their paediatrician, the clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016 (FP or montelukast for 3 months，or intermittent budesonide inhalation suspension during wheezing episode) and follow up for 1 year.
33033088|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
33033089|NCT01959295|Experimental|ASP2151|
33322615|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
33411155|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
32973453|NCT04521764|Experimental|Treatment (MV-s-NAP)|Patients receive MV-s-NAP intratumorally (IT) on day 1 in the absence of disease progression or unacceptable toxicity. After 1 cycle of treatment, patients who experience disease progression proceed to follow-up. Patients who achieve CR, PR, or SD receive MV-s-NAP IT every 21 days for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity.
32973454|NCT04520139|Experimental|Phase 1 Dose Escalation|Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
32973455|NCT04520139|Experimental|Phase 2 Dose Expansion|Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.
32973456|NCT04514744|Experimental|Unilateral Immobilization|One leg will undergo 8 days of single-leg immobilization, by means of a removable knee brace.
32973457|NCT04514744|Experimental|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
33322616|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
33322617|NCT01111968|Placebo Comparator|placebo group 14|placebo
33322618|NCT03942666|Experimental|Treatment A|Single administration of CHF 6532 Dose #1
33322619|NCT03942666|Experimental|Treatment B|Single administration of CHF 6532 Dose #2
32973465|NCT04512716|Experimental|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
32973466|NCT04512105|Experimental|Dose Level -1 (DL-1)|"Patients receive Pitavastatin (PIT) 1 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~The 1 mg/day dose level will be held in reserve to allow dose reduction in those patients who cannot tolerate DL1."
32973467|NCT04512105|Experimental|Dose Level 1 (DL1)|"Patients receive Pitavastatin (PIT) 2 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~This is the starting dose level for the study."
32973468|NCT04512105|Experimental|Dose Level 2 (DL2)|"Patients receive Pitavastatin (PIT) 4 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~If DL1 is well tolerated, the next cohort will progress to this dose level."
32973469|NCT04511442||Bariatric surgery|Women with obesity, with a bariatric surgery
32973470|NCT04511442||Control|Women with obesity, without a bariatric surgery
32973471|NCT04507815|Experimental|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
33033090|NCT01959295|Placebo Comparator|ASP2151 placebo|
33033091|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
33033092|NCT01959360|Active Comparator|direct lateral|
33322620|NCT03942666|Experimental|Treatment C|Single administration of CHF 6532 Dose #3
33322621|NCT03942666|Experimental|Treatment D|Single administration of CHF 6532 Dose #4
33322622|NCT03942666|Placebo Comparator|Treatment E|Single administration of CHF 6532 Placebo
33322623|NCT03942666|Other|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
33322624|NCT04398134|Experimental|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
33322625|NCT04398134|Placebo Comparator|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
33322626|NCT01112046|Experimental|Endoscopic submucosal dissection|
33322627|NCT01112046|Active Comparator|Laparoscopic resection|
33322628|NCT04281342|Experimental|Aprocitentan 25 mg|Therapeutic dose level
33322629|NCT04281342|Experimental|Aprocitentan 100 mg|Supratherapeutic dose level
33322630|NCT04281342|Placebo Comparator|Matching placebo|
33322631|NCT04281342|Other|Moxifloxacin|
33322632|NCT04253262|Experimental|Dose Level -2|300 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
33322633|NCT04253262|Experimental|Dose Level -1|400 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
33322634|NCT04253262|Experimental|Dose Level 1|400 mg Rucaparib, 45 mg Copanlisib
33322635|NCT04253262|Experimental|Dose Level 2|500 mg Rucaparib, 45 mg Copanlisib
33322636|NCT04253262|Experimental|Dose Level 3|600 mg Rucaparib, 45 mg Copanlisib
33322637|NCT04253262|Experimental|Dose Level 4|600 mg Rucaparib, 60 mg Copanlisib
33322638|NCT01207362||Young adult|
33322639|NCT01207362||Older adult|
32973472|NCT04507815|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
32973473|NCT04505865|No Intervention|Usual care|Optimally tolerated medical therapy
32973474|NCT04505865|Experimental|Stress reduction|Optimally tolerated medical therapy and stress reduction course for 8 weeks
32973475|NCT04505254|Experimental|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
32973476|NCT04504318|Experimental|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
32973477|NCT04504318|Active Comparator|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
32973478|NCT04503499|Experimental|Study Group|The group to which the manuel therapy will be applied.
32973479|NCT04503499|No Intervention|Control Group|The control group where only the evaluations will be made.
32973480|NCT04501120|Experimental|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
32973481|NCT04501120|Experimental|APG2575+reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT in R/R AML, MPAL, BPDCN, CMML.
32973482|NCT04501120|Experimental|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT in R/R AML, MPAL, BPDCN, CMML.
32973483|NCT04501120|Experimental|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in R/R AML, MPAL, BPDCN, CMML.
32973484|NCT04501120|Experimental|APG2575+ AZA(HR-MDS.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in HR-MDS.
32973485|NCT04501120|Experimental|APG2575+ AZA(Naïve AML.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in treatment naïve AML.
32973486|NCT04497142|Experimental|Perampanel|"Participants will take a predetermined first dose of perampanel on the day before their tumor surgery~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~After surgery participants will take perampanel at a predetermined dose once a day for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone."
32973487|NCT04497142|Active Comparator|Standard of Care|"Participants will receive standard of care medication before surgery.~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~After surgery participants will take standard of care medications as predetermined by their doctor. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone.~Participants will be followed up to 12 months after completing surgery."
32973488|NCT04491877|Experimental|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
32973489|NCT04491877|Placebo Comparator|Cohort 1 (Placebo)|1 administration of placebo on Day 0
32973490|NCT04491877|Experimental|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
32973491|NCT04491877|Placebo Comparator|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
32973492|NCT04491877|Experimental|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
32973493|NCT04491877|Placebo Comparator|Cohort 3 (Placebo)|1 administration of placebo on Day 0
32973494|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
32973495|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
32973496|NCT04491877|Placebo Comparator|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
32973497|NCT04491591|Experimental|BREASTChoice|"After consent, the participant will be randomized~Depending on the clinic work-flow, the patient will be sent the link to the BREASTChoice tool by email or MyChart message~1) prior to their visit with the surgeon;~2) at the time of their visit with the surgeon;~3) after the surgeon appointment~Will receive an online survey to complete after viewing the BREASTChoice tool assessing socio-demographics, knowledge, health literacy, decisional conflict, patient engagement, health-related quality of life, preferred decision role, and usability of the website.~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
32973498|NCT04491591|Active Comparator|Attention Control Website|"After consent, the participant will be randomized~Depending on the clinic work-flow, the patient will be sent the link to the website by email or MyChart message~1) prior to their visit with the surgeon;~2) at the time of their visit with the surgeon;~3) after the surgeon appointment~Will receive an online survey to complete after viewing the website assessing socio-demographics, knowledge, preferences, health literacy, decisional conflict, measure of patient engagement, health-related quality of life, preferred decision role, consult time, and usability of the website.~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
32973499|NCT04491591|Experimental|Clinicians|"Will receive a brief virtual training on how BREASTChoice functions and the features, including placement of the patient tool summary in the electronic health record~Will complete pre-post trial survey about shared decision making"
32973500|NCT04478760||Masculinising therapy|Healthy transgender (including non-binary) adults who are on testosterone-containing hormone therapies.
32973501|NCT04478760||Feminising therapy|Healthy transgender (including non-binary) adults who are on oestrogen-containing hormone therapies.
32973502|NCT04477317|Experimental|Experimental|4% Articaine Hydrochloride with 1:100,000 Adrenaline (Alexadricaine, Alexandria Co., Egypt).
32973503|NCT04477317|Active Comparator|Control|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin (Mepicaine-L, Alexandria Co., Egypt)
32973504|NCT04469959|Experimental|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
32973505|NCT04469959|Placebo Comparator|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
32973506|NCT04441034|Experimental|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
32973507|NCT04441034|Experimental|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
32973508|NCT04438369|Active Comparator|Erector spinae block|"Group ESPB: Multimodal analgesia comprising of preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodon 1 mg/ml.~Preoperatively positioned bilateral catheters at level T7 injected with ropivacaine 2,5 mg/ml, 30 ml on each side. Postoperative maintenance treatment with injection of 2 mg/ml ropivacaine 30 ml on each side every 6 hours postoperatively. Maximum allowed bolus preoperative ropivacaine dose is 3 mg/kg body weight (BW), while the maximum 24 hour dose postoperatively is 11 mg/kg to avoid local anesthesia systemic toxicity (LAST). The catheter will be discontinued 24 hours after the original procedure. The container with ropivacaine will be masked for blinding of the personnel on the ward."
32973509|NCT04438369|Placebo Comparator|Control|"Control group with standard multimodal analgesia: Preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodone 1 mg/ml.~Insertion of bilateral catheters preoperatively. Injection of 30 ml saline preoperatively and every 6 hours postoperatively. The catheter will be discontinued 24 hours after the original procedure. The container with saline will be masked for blinding of the personnel on the ward."
32973510|NCT04434196|Experimental|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
33411156|NCT05035004|Experimental|Post exercise hot water immersion|Moderate intensity cycling for 30 minutes, followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion.
32973513|NCT04432597|Experimental|1/Arm 1A|HPV vaccine at 1x10(11) Viral Particles (VP) (DL1) and at 5x10(11) VP (DL2)
32973514|NCT04432597|Experimental|2/Arm 1B|HPV vaccine at RP2D plus M7824 at 1200 mg
32973515|NCT04432597|Experimental|3/Arm 2A|HPV vaccine at RP2D given as neoadjuvant or induction therapy
32973516|NCT04432597|Experimental|4/Arm 2B|HPV vaccine at RP2D plus M7824 at 1200 mg given as neoadjuvant or induction therapy
32973517|NCT04426461|Experimental|Behavioral activation|
32973518|NCT04426461|Experimental|Exposure-based therapy|
32973519|NCT04426461|Active Comparator|Supportive therapy|
32973520|NCT04416191|Other|Limb immobilization|Participants will undergo a 2-week leg immobilization period
32973521|NCT04415931|Experimental|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
32973522|NCT04415931|Active Comparator|Interscalene block group|This group of patients will receive interscalene block
32973523|NCT04410380|Experimental|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
32973524|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
32973525|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
32973526|NCT04395430|Active Comparator|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
32973527|NCT04395430|Experimental|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
32973528|NCT04383262|Experimental|Lexiva|Lexiva/fosamprenavir at the FDA approved and manufacturers recommended dose (1,400mg twice daily) for 12 weeks
32973529|NCT04383262|Placebo Comparator|Placebo|standard of care
32973530|NCT04382898|Experimental|Part 1 (mCRPC) - dose titration|"BNT112 monotherapy~Enrollment into this arm is completed."
32973531|NCT04382898|Experimental|Part 2 Arm 1A (mCRPC) - expansion cohort|"BNT112 in combination with cemiplimab~Enrollment into this arm is completed."
33411157|NCT05035004|Active Comparator|Exercise|Moderate intensity cycling for 30 minutes.
33411158|NCT05035004|Active Comparator|Hot water immersion|Whole-body hot water immersion for 30 minutes, followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion.
32973532|NCT04382898|Experimental|Part 2 Arm 1B [1] (mCRPC) - expansion cohort|"BNT112 monotherapy~Enrollment into this arm is completed."
32973533|NCT04382898|Experimental|Part 2 Arm 2 (LPC) - expansion cohort|BNT112 in combination with cemiplimab
32973534|NCT04382898|Experimental|Part 2 Arm 3 (LPC) - expansion cohort|BNT112 monotherapy
32973535|NCT04382898|Experimental|Part 2 Arm 1B [2] (mCRPC) - expansion cohort|"Following progression after BNT112 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy~Enrollment into this arm is completed."
32973536|NCT04381897|Experimental|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
32973537|NCT04381897|Experimental|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
33322640|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
32973539|NCT04370691||JETi Peripheral Thrombectomy System|Subjects who were treated with JETi Peripheral Thrombectomy System will be included.
33033093|NCT01959360|Experimental|minimal invasive|
33322641|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
33322642|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
33322643|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
33322644|NCT01108224|Experimental|Psychosocial support|
33322645|NCT01108224|No Intervention|Control group|
33322646|NCT01109628|Experimental|Protein drink|
33322647|NCT01109628|Placebo Comparator|Placebo drink|
33322648|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
33322649|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
33322650|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
33322651|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
33322652|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
33322653|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
33322654|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
33322655|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
33322656|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
33322657|NCT03122860|Placebo Comparator|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
33322658|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
33322659|NCT05175586|Experimental|Group 1|15 patients in the experimental group of percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan)
33322660|NCT05175586|Active Comparator|Group 2|15 patients in the experimental group of orthopaedic manual therapy (Maitland and Mulligan).
33322661|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
33322662|NCT01319188|Active Comparator|injection + photodynamic therapy|
33322663|NCT01319188|Sham Comparator|Sham injection|
33322664|NCT05167162|Active Comparator|Group 1: Compression technique|20 participants make up the compression technique group.
33322665|NCT05167162|Active Comparator|Group 2: Massage techniques|20 participants make up the massage technique group.
33322666|NCT05167162|Active Comparator|Group 3: Hydromassage|20 participants make up the hydromassage technique group.
33322667|NCT05167162|Active Comparator|Group 4: Active recovery technique.|20 participants make up the active recovery technique group.
33322668|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
33322669|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
33322670|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
32973540|NCT04344262|Active Comparator|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
32973541|NCT04344262|Experimental|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
32973542|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
32973543|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
32973544|NCT04330638|Placebo Comparator|Usual Care|
32973545|NCT04330638|Active Comparator|Anakinra|
32973546|NCT04330638|Active Comparator|Siltuximab|
32973547|NCT04330638|Active Comparator|Anakinra + Siltuximab|
32973548|NCT04330638|Active Comparator|Tocilizumab|
32973549|NCT04330638|Active Comparator|Anakinra + Tocilizumab|
32973550|NCT04325321|Other|Stress reactivity|Stress reactivity test
32973551|NCT04322084||Participants|Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
32973552|NCT04322006|Experimental|TJ004309 injection Monotherapy or Combination with Toripalimab|TJ004309 will be dose escalated in a 3+3 design in Monotherapy or combination with Toripalimab
32973553|NCT04317742|Active Comparator|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
32973554|NCT04317742|Active Comparator|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
32973555|NCT04315610|Experimental|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
32973556|NCT04315610|Active Comparator|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
32973557|NCT04304131|Experimental|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
32973558|NCT04304131|Experimental|Colon polyp|Confirmed colorectal polyp under colonoscopy
32973559|NCT04304131|Active Comparator|Healthy|Confirmed no cancer nor polyp under colonoscopy
33322671|NCT05167084|Experimental|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 2500mg/d is achieved).
32973560|NCT04298879|Experimental|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
32973561|NCT04298554|Experimental|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
32973562|NCT04298554|Placebo Comparator|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
32973563|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
32973564|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
32973565|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
32973566|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
32973567|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
32973568|NCT04288427|Experimental|Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by American Urologic Association (AUA) urinary symptom score > than 8, (suggestive of moderate LUTS) prostate size > 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
32973569|NCT04285827|Experimental|CSL889 Cohort A1 (Dose 1)|CSL889 administered as a single IV infusion
32973570|NCT04285827|Experimental|CSL889 Cohort A2 (Dose 2)|CSL889 administered as a single IV infusion
32973571|NCT04285827|Experimental|CSL889 Cohort A3 (Dose 3)|CSL889 administered as a single IV infusion
32973572|NCT04285827|Experimental|CSL889 Cohort A4 (Dose 4)|CSL889 administered as a single IV infusion
32973573|NCT04285827|Experimental|CSL889 Cohort A5 (Dose 5)|CSL889 administered as a single IV infusion
32973574|NCT04285827|Experimental|CSL889 Cohort A6 (Dose 6)|CSL889 administered as a single IV infusion
32973575|NCT04285827|Experimental|CSL889 Cohort B1 (low dose)|CSL889 administered as a single IV infusion
32973576|NCT04285827|Experimental|CSL889 Cohort B2 (high dose)|CSL889 administered as a single IV infusion
33033094|NCT01959360|Experimental|modified minimal invasive|
33033095|NCT01959373|Experimental|patients|
33033096|NCT01959373|Experimental|healthy volunteers|
32973577|NCT04280601|Other|Low vitamin level at baseline|At specific time points we will measure vitamin D status (baseline and 12-months) and re-enforcing vitamin D supplementation in those with insufficient or deficient vitamin D levels. More specifically, we will ask patients with insufficient or deficient vitamin D levels at enrollment to increase vitamin D intake by 1,000 IU units (to a maximum of 2,000 IU if the patient is already on vitamin D supplementation) for the 12 month period.
32973578|NCT04277104|Experimental|Healthy intervention|Acoustic stimulation
32973579|NCT04277104|Sham Comparator|Healthy sham|No stimulation
32973580|NCT04277104|Experimental|At risk intervention|Acoustic stimulation
32973581|NCT04277104|Sham Comparator|At risk sham|No stimulation
32973582|NCT04277104|Experimental|MCI (mild cognitive impairment) intervention|Acoustic stimulation
32973583|NCT04277104|Sham Comparator|MCI (mild cognitive impairment) sham|No stimulation
32973584|NCT04271501|No Intervention|Control|Area without surgical intervention. Ultraviolet Lamp (UVB)
32973585|NCT04271501|Active Comparator|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
32973586|NCT04271501|Experimental|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
32973587|NCT04271501|Experimental|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
32973588|NCT04271501|Experimental|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
32973589|NCT04264013|Placebo Comparator|Exercise|Exercise
32973590|NCT04264013|Active Comparator|Exercise + Diet|Exercise + eggs
32973591|NCT04263714|Experimental|Exercise|All subjects will perform both aerobic and resistance exercise
32973592|NCT04263064|Active Comparator|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
32973593|NCT04263064|Experimental|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
32973594|NCT04261751||Nurses|Nurses will be taking the Clinician Questionnaire electronically.
32973595|NCT04258449||Case|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
32973596|NCT04249466||Patient with cystic fibrosis|
32973597|NCT04248764|Experimental|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
32973598|NCT04248764|Experimental|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
32973599|NCT04248764|No Intervention|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
32973600|NCT04231669|No Intervention|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
33322672|NCT05167084|Placebo Comparator|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone.
32973601|NCT04231669|Experimental|Anzansi Family Program|In addition to bolstered care, participants(adolescent girls and caregivers) in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
32973602|NCT04228107|Experimental|Cohort|"Participants will be enrolled in medication use monitoring. Their medication use patterns will be available to themselves and their guardians via a smartphone application, and to their asthma care providers via a portal. There will be no interventions to change medication use patterns. A portion of them will be asked to participate in a semistructured interview during which they will be asked questions about their perception of their asthma, health beliefs regarding medication use, and what they feel would be the most helpful to get them to take their asthma medicines.~Additionally a small group of healthcare providers will be asked to participate in a focus group to collect qualitative data on medication use barriers and facilitators"
32973603|NCT04227899|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
32973604|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
32973605|NCT04215692|Experimental|Ultrasound Guided Fluid Therapy|
33322673|NCT03798366|Experimental|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
33322674|NCT03798366|Placebo Comparator|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
32973606|NCT04215692|No Intervention|Conventional Fluid Therapy|
32973607|NCT04210778|Experimental|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
33322675|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
33322676|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
32973608|NCT04210778|Active Comparator|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
32973609|NCT04210778|No Intervention|Treatment As Usual|This group will receive no intervention
32973610|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
32973611|NCT04195399|Experimental|Treatment (nirogacestat)|Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32973612|NCT04194541|Experimental|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
32973613|NCT04190706|Experimental|bioactive components fortified food products|
32973614|NCT04190706|Placebo Comparator|control food products|
32973615|NCT04189783|Active Comparator|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
32973616|NCT04189783|Experimental|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
32973617|NCT04189744|Placebo Comparator|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
32973618|NCT04189744|Active Comparator|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
32973619|NCT04189744|Active Comparator|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
32973620|NCT04185532|Experimental|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
32973621|NCT04185532|Active Comparator|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
32973622|NCT04183894|Experimental|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
32973623|NCT04182464|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
33322677|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
33322678|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
32973624|NCT04182464|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
33322679|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
33322680|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
33322681|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
32973628|NCT04158804|Experimental|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
32973629|NCT04158804|No Intervention|standard group|standard of care guided by current guidelines
32973630|NCT04157348|Experimental|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
32973631|NCT04157348|Active Comparator|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
32973632|NCT04153396|Experimental|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
32973633|NCT04153396|Active Comparator|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
32973634|NCT04148521|Experimental|Behavioral Health - Virtual Patient Navigation|All patients who meet eligibility criteria at sites where the virtual patient navigation behavioral health program is offered will be considered exposed to the intervention.
32973635|NCT04148521|No Intervention|Usual care Behavioral Health|All patients who meet eligibility criteria at sites where the virtual patient navigator behavioral health program is not offered will be considered exposed to usual care.
33104927|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
33104928|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
33104929|NCT00539799|Placebo Comparator|2|
33322682|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
33322683|NCT01109706||patient treated by statines|
33322684|NCT01109706||patient without normolipidemic treatment|
33322685|NCT03945396|Experimental|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
33411159|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
33411160|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
33411161|NCT03664284|Active Comparator|intervention group|
33322686|NCT03945396|Active Comparator|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
33322687|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
32973638|NCT04131309|Experimental|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
32973639|NCT04125134|Experimental|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
32973640|NCT04125134|Experimental|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
32973641|NCT04119778|Experimental|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
32973642|NCT04119778|Experimental|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
32973643|NCT04119778|No Intervention|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
32973644|NCT04117945|Experimental|Arm A (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
32973645|NCT04117945|Experimental|Arm B (cetuximab, panitumumab, irinotecan)|Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
32973646|NCT04111978|Experimental|Letrozole (aromatase inhibitor)|Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
32973647|NCT04111978|Placebo Comparator|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease
32973648|NCT04109209|Active Comparator|Usual Care Group|"60 Participants will be randomized to receive usual care for caregivers of patients with malignant brain tumors~Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
32973649|NCT04109209|Experimental|Psychosocial Intervention Group|"60 Participants of caregivers of patients with malignant brain tumors will be randomized into the psychosocial intervention arm~Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
32973650|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
32973651|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
32973652|NCT04097379|Experimental|LRX712 Arm 1|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
32973653|NCT04097379|Placebo Comparator|Placebo|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
32973654|NCT04097379|Experimental|LRX712 Arm 2|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
33322688|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
33322689|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
33322690|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
33322691|NCT01112280|No Intervention|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
33322692|NCT01328262|Experimental|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
33322693|NCT01328262|Active Comparator|Standard treatment|Intervention: Standard red blood cell transfusion
32973655|NCT04091672|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and skin graft. Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B
32973656|NCT04091217|Experimental|Atezolizumab + Bevacizumab|
32973657|NCT04090567|Experimental|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973658|NCT04090567|Experimental|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973659|NCT04084704|Other|Cingal injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
32973660|NCT04078594|Experimental|Experimental wards|Active sepsis e-alert
32973661|NCT04078594|No Intervention|Contol wards|"Masked sepsis e-alert.~The wards will have masked sepsis e-alert."
32973662|NCT04077970|Experimental|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
32973663|NCT04077970|No Intervention|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
32973664|NCT04067427|Active Comparator|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
32973665|NCT04067427|No Intervention|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
32973666|NCT04061746|Experimental|Group A Treatment|2.5 x 10^6 MSC per kg will be infused intravenously on Day 1
32973667|NCT04061746|Placebo Comparator|Group B Placebo|Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1
32973668|NCT04056221|Experimental|acupuncture|Acupuncture at the selected points.
32973669|NCT04056221|Sham Comparator|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
32973670|NCT04049110|Experimental|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
32973671|NCT04049110|Experimental|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
32973672|NCT04046900|Active Comparator|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
32973673|NCT04046900|Placebo Comparator|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
32973674|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
32973675|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
32973676|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
32973677|NCT04043442|Active Comparator|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
32973678|NCT04040959|Experimental|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
32973679|NCT04040959|Placebo Comparator|Placebo|Matched placebo capsules.
32973680|NCT04039464|Active Comparator|Monotherapy with Sildenafil Group|mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.
32973681|NCT04039464|Active Comparator|Duo Therapy with Sildenafil + Bosentan Group|duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)
33411162|NCT03664284|No Intervention|control group|
33411163|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
33411164|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
32973685|NCT04035031|Experimental|Forxiga first, placebo second|Forxiga followed by placebo
32973686|NCT04035031|Experimental|Placebo first, Forxiga second|Placebo followed by forxiga
32973687|NCT04026607|Experimental|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
32973688|NCT04026607|Experimental|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
32973689|NCT04026607|Experimental|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
32973690|NCT04018638|Experimental|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
32973691|NCT04018638|No Intervention|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
32973692|NCT04006392|Experimental|Erchonia FX-635|The Erchonia FX-635 is administered to the foot 12 times over 6 weeks (2 times each week) for 15 minutes per foot.
33411165|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
33411166|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
32973693|NCT04006392|Sham Comparator|Placebo Laser|Noise and appearance of output is the same but no active therapy applied. Treatment administration procedure is the same as with the experimental arm.
32973694|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
32973695|NCT03997617|Other|Personalized Functional Profiling|
32973696|NCT03992469|Experimental|E-B-FAHF-2|Low dose EBFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
32973697|NCT03992469|Placebo Comparator|Placebo|capsules are identical in appearance to EBFAHF-2 capsules
32973698|NCT03980561|Experimental|Varenicline|2 mg daily
32973699|NCT03980561|Placebo Comparator|Placebo|2 mg daily
32973700|NCT03965689|Experimental|Treatment (paclitaxel, carboplatin, pevonedistat)|Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
32973701|NCT03960008|Other|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
32973702|NCT03960008|Other|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
32973703|NCT03959423|Experimental|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
32973704|NCT03936998|Experimental|vancomycin plus VE416 before PNOIT|active vancomycin plus VE416 before PNOIT
32973705|NCT03936998|Experimental|Vancomycin plus VE416 with PNOIT|active vancomycin plus active VE416 with active PNOIT
32973706|NCT03936998|Experimental|Placebo plus VE416 with PNOIT|placebo vancomycin plus active VE416 with active VE416
32973707|NCT03936998|Active Comparator|Placebo plus placebo with PNOIT|placebo vancomycin and placebo VE416 with active peanut oral immunotherapy
32973708|NCT03934697|Experimental|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
32973709|NCT03930953|Experimental|Part A: Dose Escalation|
32973710|NCT03930953|Experimental|Part B: Dose Expansion|
32973711|NCT03911505|Experimental|Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule
32973712|NCT03910660|Other|Phase 1b|"Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:~If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort.~If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose.~At the 0.4mg dose:~If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO.~If 1/3 of the patients experience a DLT, the Phase 2a can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed.~Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose.~For this cohort of 6 to 9 patients:~If </=1/3 of the patients experience a DLT, the Phase 2a can commence"
33322694|NCT04327388|Experimental|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in fraction of inspired oxygen (FiO2) requirement or~Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
32973713|NCT03910660|Other|Phase 2a|After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
32973714|NCT03910660|Other|Phase 2b combination|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~• Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days."
32973715|NCT03910660|Other|Phase 2b monotherapy|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy, crossover to combination treatment is allowed."
32973716|NCT03907462|Experimental|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
32973717|NCT03907462|Experimental|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
32973718|NCT03907462|No Intervention|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
32973719|NCT03900910|Experimental|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
32973720|NCT03900910|Experimental|The acceptability and applicability of the mass screening program|Our short-term outcome is the acceptability and feasibility of this screening program, which will be evaluated by answering whether the screening quality indicators can reach the minimal requirements.
32973721|NCT03879304|Experimental|Multimodal physiotherapy program with RV|The RV intervention group receives a tele multimodal physiotherapy program with tradicional exercises of physiotherapy like stretching, aerobic, training through videos and gamification with VR glasses.
32973722|NCT03879304|Active Comparator|Traditional physiotherapy program|Traditional intervention group receives assistance of a program of physiotherapy traditional without virtual reality glasses.
32973723|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
32973724|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
32973725|NCT03855735|Experimental|TeamBaby Online Training Intervention Group Phase 2 (IG1)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group receive an interactive online training on different communication models and competencies (Phase 2).
32973726|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app prior to giving birth.
32973727|NCT03855735|Experimental|TeamBaby App Training Intervention Group Phase 3 (IG2)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group will gain access to the digital app and receive a communication training via the app (Phase 3).
32973728|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
32973729|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
32973730|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
32973731|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
32973732|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
32973733|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
32973734|NCT03834961|Experimental|Treatment (larotrectinib)|Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.
32973735|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
32973736|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
32973737|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
32973738|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
32973739|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
32973740|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, applied once daily to each axilla for 24 weeks
32973741|NCT03769181|Experimental|Phase 1: cHl/DLBCL/PTCL|Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose
32973742|NCT03769181|Experimental|Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
32973743|NCT03769181|Experimental|Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
32973744|NCT03769181|Experimental|Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
32973745|NCT03769181|Experimental|Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
32973746|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
32973747|NCT03768349|Experimental|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
32973748|NCT03768349|Experimental|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
32973749|NCT03761680|Experimental|MEDPass Group|Allocation of ONS in the MEDPass mode
32973750|NCT03761680|Active Comparator|Control Group|Patients receive ONS between meals or at their request as usual
32973751|NCT03755934|Experimental|Dose Level 1|MEDI7352
33411167|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
33411168|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
33411169|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
32973752|NCT03755934|Experimental|Dose Level 2|MEDI7352
32973753|NCT03755934|Experimental|Dose Level 3|MEDI7352
32973754|NCT03755934|Placebo Comparator|Placebo|Placebo
32973755|NCT03755934|Experimental|Dose Level 4|MEDI7352
32973756|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
32973757|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
32973758|NCT03670056|Experimental|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
32973759|NCT03667196||Observational|
32973760|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
32973761|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
32973762|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
32973763|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
32973764|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
32973765|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
32973766|NCT03654833|Experimental|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
32973767|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
32973768|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
32973769|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
32973770|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
32973771|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
32973772|NCT03636243|Other|Group of obese patients with type-2 diabetes|
32973773|NCT03636243|Other|Group of non-diabetic obese patients|
32973774|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
32973775|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
32973776|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
32973777|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
32973778|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
32973779|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
32973780|NCT03634839|Experimental|Sweet non-menthol, nicotine 36mg/ml|Sweet flavor non-menthol (Watermelon) with 36mg/ml Nicotine
32973781|NCT03634839|Experimental|Sweet menthol, nicotine 36mg/ml|Sweet flavor with menthol (Watermelon-menthol) with 36mg/ml Nicotine
32973782|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32973783|NCT03622905|Experimental|DBS On|DBS system On
32973784|NCT03622905|Sham Comparator|DBS Off|DBS System Off
32973785|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
32973786|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
32973787|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
32973788|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
32973789|NCT03596242|Experimental|High Blood Pressure Monitoring by SMS|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
32973790|NCT03596242|Active Comparator|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
32973791|NCT03564938|Experimental|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
32973792|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
32973793|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
32973794|NCT03538600||Healthy Volunteers|healthy volunteers
32973795|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
32973796|NCT03519451|Experimental|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
32973797|NCT03519451|Experimental|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
32973798|NCT03494127|Experimental|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
32973799|NCT03494127|Experimental|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
32973800|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
32973801|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
32973802|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
32973803|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
32973804|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32973805|NCT03432494|Experimental|Transcaval access and closure with the transcaval closure device (TCD) test article.|All participants undergo transcaval access for transcatheter aortic valve replacement (TAVR) followed by implantation of the transcaval closure device (TCD).
32973806|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
32973807|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
32973808|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
32973809|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
32973810|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973811|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973812|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
32973813|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
32973814|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
32973815|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
32973816|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
32973817|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
32973818|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
32973819|NCT03332667|Experimental|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
32973823|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
32973824|NCT03327623||Control|Subjects who are healthy volunteers
32973825|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Participants received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)
32973826|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
32973827|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
32973828|NCT03302611|Experimental|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
32973829|NCT03302611|Active Comparator|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
32973830|NCT03299166|Experimental|BHV-4157|
32973831|NCT03299166|Placebo Comparator|Placebo|
32973832|NCT03292315|Experimental|Semaglutide 1MG Injection [Ozempic]|20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
32973833|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
32973834|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
32973835|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
32973836|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
32973837|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
32973838|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
32973839|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
32973840|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
32973841|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
32973842|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
32973843|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
32973844|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
32973845|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
32973846|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
32973847|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
33033097|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
32973848|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
32973849|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
32973850|NCT03182244|Experimental|ASP2215|ASP2215 will be administered orally once daily.
32973851|NCT03182244|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy). Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE). In COE participants will be administered ASP2215 orally once daily.
32973852|NCT03182244|Experimental|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
32973853|NCT03181633|Experimental|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
32973854|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
32973855|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
32973856|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
32973857|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
32973858|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
32973859|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
32973860|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
32973861|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
32973862|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
32973863|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
32973864|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
33411170|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
33033098|NCT01959399|Experimental|ASP015K + rosuvastatin|
33411171|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
33411172|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
33411173|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
33411174|NCT02911116|Experimental|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
33411175|NCT02911116|Experimental|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
33411176|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
33411177|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
33411178|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
33411179|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
33411180|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
33411181|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
32973867|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
33411182|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
33411183|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
33411184|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
33411185|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
33411186|NCT04055844|Experimental|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
33411187|NCT04058496||1|Coronary artery bypass surgery off-pump (n=24)
32973868|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
33411188|NCT04058496||2|Coronary artery bypass surgery on-pump (n=16)
33411189|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
33411190|NCT04055688||Participants with known or suspected high grade gliomas|
33411191|NCT02872142|Experimental|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
33411192|NCT04057794|Active Comparator|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
33411193|NCT04057794|Active Comparator|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
33411194|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
33411195|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
33411196|NCT04882280|Experimental|Low room|Low intensity (80 lux) room light
32973869|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
33411197|NCT04882280|Experimental|Normal room|Normal intensity (150 lux) room light
33411198|NCT04882280|Experimental|Bright room|High intensity (500 lux) room light
33411199|NCT04882280|Experimental|Bright|Very high intensity (1000 lux) room light
33411200|NCT04055610|Experimental|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
33411201|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
33411202|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
33322695|NCT04327388|Experimental|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
33322696|NCT04327388|Placebo Comparator|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
33322697|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
33322698|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
33322699|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
33322700|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
33322701|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
33322702|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
33322703|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
33322704|NCT03796728|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
33322705|NCT00352534|Experimental|Stratum I (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
33322706|NCT00352534|Experimental|Stratum II (standard-risk, stage I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
33322707|NCT00352534|Experimental|Stratum III (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
33322708|NCT04323800|Experimental|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
33322709|NCT04323800|Active Comparator|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
33322710|NCT01328418|Other|Achondroplasia lengthening|
33322711|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
33322712|NCT04112862|Experimental|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
33322713|NCT03942276|Placebo Comparator|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
33322714|NCT03942276|Experimental|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
33322715|NCT03942276|Experimental|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
33322716|NCT01328106|Experimental|1|
33322717|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
32973870|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
32973871|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
32973872|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
32973873|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
32973874|NCT02997202|Experimental|Gilteritinib|Participants will take gilteritinib once daily for continuous daily dosing.
32973875|NCT02997202|Placebo Comparator|Placebo|Participants will take placebo once daily for continuous daily dosing.
32973876|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
32973877|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
32973878|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
32973879|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
32973880|NCT02989948|Experimental|Main Arm - Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
32973881|NCT02989948|Experimental|Expanded Access Arm - Physician-modified fenestrated endovascular graft.|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
32973882|NCT02983578|Experimental|Treatment (danvatirsen, durvalumab)|Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973883|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
32973884|NCT02982070|No Intervention|College as Usual|no training provided
32973885|NCT02970513|Experimental|patients operated on for colorectal cancer|
32973886|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
32973887|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
32973888|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
32973889|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
32973890|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
32973891|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32973892|NCT02853604|Placebo Comparator|Placebo|Participants with locally advanced cervical cancer at higher risk for recurrence (HRLACC) received ADXS11-001 matching placebo by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course placebo matching to either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
32973893|NCT02853604|Experimental|ADXS11-001|Participants with HRLACC received ADXS11-001 at a dose of 1x10^9 colony forming units (CFU) by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course of either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
33033099|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
33033100|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
32973894|NCT02846623|Experimental|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
32973895|NCT02846623|Experimental|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
32973896|NCT02844816|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.
32973897|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
32973898|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
32973899|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
32973900|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
32973901|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
32973902|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
32973903|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
32973904|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
32973905|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
32973906|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
32973907|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
32973908|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
32973909|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
32973910|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
32973911|NCT02811133|Experimental|Inositol|Subjects will receive inositol
32973912|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
32973913|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
32973914|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
32973915|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
32973916|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
32973917|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
32973918|NCT02759458|Experimental|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
32973919|NCT02759458|Active Comparator|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
32973920|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once every 8 weeks until vedolizumab is commercially available. (Per MM approval, dosing regimen may be modified per physician's decision).
32973921|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
32973922|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
32973923|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
32973924|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
32973925|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
32973926|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
32973927|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
32973928|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
32973929|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
32973930|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
32973931|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
32973932|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
32973933|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
32973934|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
32973935|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
32973936|NCT02591147|Active Comparator|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
32973937|NCT02591147|Placebo Comparator|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
32973938|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
32973939|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
32973940|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc."
32973941|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc."
32973947|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
32973948|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
32973949|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
32973950|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
32973951|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
32973952|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
32973953|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
32973957|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
33104930|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
32973958|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
32973959|NCT02448485||Aortic Valve Intervention|Consecutive symptomatic patients who underwent aortic valve intervention (SAVR or TAVI) for the treatment of severe AS since 2010
32973960|NCT02448485||Conservative Treatment|Asymptomatic patients with aortic stenosis followed conservatively at our department
32973961|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
32973962|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
32973963|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
32973964|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).
32973965|NCT02387203|Experimental|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
32973966|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
32973967|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
32973968|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
32973969|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
32973970|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
32973971|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
32973972|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
32973973|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:~Blood test: CA-125 biomarker at day 1 and week 6-8. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
32973974|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
32973975|NCT02288676||Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
32973976|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
32973977|NCT02264678|Experimental|Module 2 Part A1|Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
32973978|NCT02264678|Experimental|Module 2 Part A2|Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.
32973979|NCT02264678|Experimental|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
32973980|NCT02264678|Experimental|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
32973981|NCT02264678|Experimental|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
32973982|NCT02264678|Experimental|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
32973983|NCT02264678|Experimental|Module 3 Part A|Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.
32973984|NCT02264678|Experimental|Module 3 Part B|Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
32973985|NCT02264678|Experimental|Module 2 Part B5|Patients with BRCA mutant or RAD51C/D mutant (either germline or somatic) or HRD-positive status epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1 - without intervening chemotherapy following progression on a PARPi, Cohort 2 - with intervening chemotherapy following progression on a PARPi. Patients will receive ceralasertib and olaparib, at the RP2D dose, frequency and schedule established from Module 2 Part A2.
32973986|NCT02264678|Experimental|Module 4 (FE/QT)|Ceralasertib monotherapy will be administered on a number of days during Cycle 0 to assess the effect of food on ceralasertib absorption and effect of ceralasertib on ECG parameters under various conditions (fasted, fed, steady state). From C1 onwards, patients who participated in C0 will be allocated to either ceralasertib in combination with olaparib or durvalumab, or ceralasertib monotherapy and assessed for safety.
32973987|NCT02264678|Experimental|Module 5 Part A|Module 5 Part A: ascending doses of ceralasertib will be administered in combination with AZD5305 to patients to define the MTD, RP2D.
32973988|NCT02264678|Experimental|Module 5 Part B|Module 5 Part B: cohort expansions of ceralasertib in combination with AZD5305 in ovarian patients at dose, frequency and schedule from Module 5 Part A.
32973989|NCT02264678|Experimental|Module 1 Part A|Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
32973990|NCT02264678|Experimental|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
32973991|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
32973992|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
32973993|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
32973994|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
32973995|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
32973996|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
32973997|NCT02031419|Experimental|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
32973998|NCT02031419|Experimental|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
32973999|NCT02031419|Experimental|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
32974000|NCT02031419|Experimental|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
32974001|NCT02028455|Experimental|Phase 1 - Cohort 1A|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg
32974002|NCT02028455|Experimental|Phase 1 - Cohort 1B|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg
32974003|NCT02028455|Experimental|Phase 1 - Cohort 1C|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^6 CAR T cells/kg
32974004|NCT02028455|Experimental|Phase 1 - Cohort 1D|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^7 CAR T cells/kg
32974005|NCT02028455|Experimental|Phase 1 - Cohort 1F1|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
32974006|NCT02028455|Experimental|Phase 1 - Cohort 1F2|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
32974007|NCT02028455|Experimental|Phase 2|The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10^6 CAR T cells/kg following lymphodepletion if indicated.
32974008|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
32974009|NCT01992653|Experimental|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
32974010|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
32974011|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
32974012|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
32974013|NCT01992653|Experimental|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
32974014|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
32974015|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
32974016|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
32974017|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
33104931|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
33104932|NCT00546507|Placebo Comparator|A|placebo
32974018|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
32974019|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
32974020|NCT01924247|Other|Interventional Arm|Interventional Arm
32974021|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
32974022|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
32974023|NCT01861106|Active Comparator|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9/10 HLA with DQ mismatch Transplant
32974024|NCT01861106|Active Comparator|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
32974025|NCT01861106|Active Comparator|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
32974026|NCT01861106|Active Comparator|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
32974027|NCT01861106|No Intervention|Arm E (Deleted this arm per amendment O)|Donor
32974028|NCT01851395||1/Thoracic|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma
32974029|NCT01851395||2/Genitourinary|Patients with genitourinary malignancies
32974030|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
32974031|NCT01851395||4/Ovarian|Patients with ovarian cancer
32974032|NCT01851395||5/Epithelial|Patients with breast, colorectal, pancreatic, stomach or biliary cancer.
32974033|NCT01850303|Other|Surveillance|
32974034|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
32974035|NCT01763671|Active Comparator|Docetaxel|
32974036|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
32974037|NCT01750567|Experimental|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
32974038|NCT01747213|Experimental|BNC|Bisnorcymserine tartrate
32974039|NCT01747213|Placebo Comparator|Placebo|microcrystalline celluose
32974040|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
32974041|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
32974042|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
32974043|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
32974044|NCT01682083|Experimental|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
32974045|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
32974046|NCT01681264|Active Comparator|Morphine:Placebo|
32974047|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
33411203|NCT04054284|Experimental|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
32974048|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
32974049|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
32974050|NCT01681264|Placebo Comparator|Placebo:Placebo|
32974051|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
32974054|NCT01527591|Other|vaccine|pneumococcal conjugated vaccine
32974055|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
32974056|NCT01500551|Experimental|Tofacitinib|All patients will be in tofacitinib treatment group.
32974057|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
32974058|NCT01296113|Experimental|A|
32974059|NCT01199692||Age|
32974060|NCT01199692||Gender|
32974061|NCT01199692||Ethnicity|
32974062|NCT01199692||Body Mass Distribution|
32974063|NCT01199692||Dietary Habits|
32974064|NCT01199692||Exercise Habits|
32974065|NCT01199692||Medication Requirements|
32974066|NCT01199692||Disease State Burden|
33033101|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
33104933|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
33104934|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
32974067|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~206.4 Kcals~40.3 g Carbohydrate~11.5 g Protein~0.08 g Fat~0.05 g Sat fat~4.2 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~22.5 g Freeze-dried blueberry powder~5.0 g Imitation vanilla flavor~1.0 g Splenda~16 oz plastic cup with lid~Smoothie total weight - 378.5 g"
32974068|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~201.3 Kcals~40.3 g Carbohydrate~10.7 g Protein~0.08 g Fat~0.05 g Sat fat~4.3 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~5.0 g Benefiber~12.0 g Sugar~4.0 g Artificial blueberry flavor(liquid & powder)~1.5 g Red food color~0.7 g Blue food color~16 oz plastic cup with lid~Smoothie total weight - 373.2 g"
32974069|NCT00906984|Other|TheraSphere® treatment|TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
32974070|NCT00690196|Experimental|1|Tai Chi Chih
32974071|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
32974072|NCT00590122|Experimental|Randomization Group b|Parcopa at equivalent dosage to subjects current stable dose
32974073|NCT00590122|Active Comparator|Randomization Group a|Carbidopa-levodopa (Sinemet)at subjects current stable dose
32974074|NCT00557726||1|Patients with a variety of infections and inflammatory diseases.
32974075|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2"
32974076|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
32974077|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
32974078|NCT00309192|Experimental|1|Triamcinolone acetonide + Grid Laser
32974079|NCT00309192|Sham Comparator|2|Sham procedure + Grid laser
32974080|NCT00295893|Active Comparator|Docetaxel, Doxorubicin Hydrochloride, and Cyclophosphamide|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
32974081|NCT00295893|Experimental|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel and Carboplatin|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
32974082|NCT00295893|Experimental|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel, Carboplatin and trastuzumab|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
32974083|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
32974084|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
32974085|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
32974086|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
32974087|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
33411204|NCT04054284|Active Comparator|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
33411205|NCT01067196||Observation and quality of life|Central Nervous System Tumors
33411206|NCT04494438|No Intervention|Steroid tapering.|
32974090|NCT01689246|Experimental|TRx0237 250 mg/day|
32974091|NCT01689246|Placebo Comparator|Placebo|
32974092|NCT01689246|Experimental|TRx0237 150 mg/day|
32974093|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
32974094|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
32974095|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
32974096|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
32974097|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
32974098|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
32974099|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
32974100|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
32974101|NCT04823442|Active Comparator|Study A|Metabolic PET study with mirabegron
32974102|NCT04823442|Experimental|Study B|Metabolic PET study with mirabegron and bisoprolol
32974103|NCT04820244||No intervention|Otherwise healthy human volunteers, 16-55 years old, with a confirmed genetic diagnosis of Usher Syndrome type 2 or non-syndromal USH2A related retinitis pigmentosa
32974104|NCT04829292|Experimental|Open treatment|Supportive therapy followed by CBT
32974105|NCT04820634|Experimental|VR-JIT|In this arm, participants would participate in simulated interviews utilizing a software program and virtual interviewer, once a week for 90 minutes.
32974106|NCT04820634|Placebo Comparator|Wonderworks|In this arm, participants would participate in a similar intervention, also once a week for 90 minutes. However, in this arm, the intervention would be in a virtual office environment completing office tasks.
32974107|NCT04821570||Chemotherapy (IV and oral)|
32974108|NCT04821570||Immunotherapy|
32974109|NCT04821570||Chemotherapy + Immunotherapy|
32974110|NCT04821570||Cyclin- dependent kinase (CDK) 4/6 inhibitors|
32974111|NCT04821570||Stem Cell Transplant recipients|
32974112|NCT04825470|Experimental|Liver Transplantation|
32974113|NCT04821648|Experimental|Dosage group A|"Dosage group A will consist of 6 subjects, 1:1:1 (A1:A2:A3 below):~A1: 0.04 mg/injection; A2: 0.075 mg/injection; A3: 0.15 mg/injection Two subjects will be dosed in the area scheduled for resection with 5 injections of the lowest of the 3 RJV001 test article strengths (i.e., 0.04 mg/injection); the two subjects will also be dosed with a single injection of vehicle in the area scheduled for resection for a total of 6 injections. At the conclusion of a given test article dose group, if tolerated, enrollment will continue to the next higher dose after approval to advance based upon an interim safety review. This same process will be repeated for the 0.075 mg/injection dose with 2 additional subjects. Assuming the interim safety review for the mid dose (i.e., 0.075 mg/injection) is deemed acceptable, the 2 final subjects will be treated with the high dose (0.15 mg/injection)."
32974114|NCT04821648|Experimental|Dosage group B|"Dosage group B will consist of 3 subjects (if only 1 dose from Dosage group A is well tolerated) or 6 subjects (if 2 doses from Dosage group A are well tolerated), randomized 1:1 (B1:B2 below).~B1: RJV001 Solution for Injection, Dose 1 B2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Dosage group A, referred to as Dose 1 and Dose 2). Up to 13 injections (12 active and 1 vehicle) will be administered in an open label manner in the area scheduled for resection. If tolerated, enrollment will continue to Dosage group C after approval to advance based upon an interim safety review."
32974115|NCT04821648|Experimental|Dosage group C|"Dosage group C will consist of 3 subjects (if only 1 dose from dosage group B is well tolerated) or 6 subjects (if 2 doses from Dosage group B are well tolerated), randomized 1:1 (C1:C2 below).~C1: RJV001 Solution for Injection, Dose 1~C2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Cohort B, referred to as Dose 1 and Dose 2). Up to 31 injections (30 active and 1 vehicle) will be administered in an open-label manner in the area scheduled for resection."
32974116|NCT04821414||trial group|anakinra canakinumab
32974117|NCT04821414||control group|conventional treatment
32974118|NCT04829682|Experimental|ACT for Life|ACT for Life + Treatment as Usual
32974119|NCT04829682|Active Comparator|Present Centered Therapy|Present Centered Therapy + Treatment as Usual
32974120|NCT04826484|Experimental|Liposomal Bupivacaine plus 0.25% Bupivacaine|Participants will receive local wound infiltration with sequential Liposomal Bupivacaine plus 0.25% Bupivacaine
32974121|NCT04826484|Active Comparator|0.25% Bupivacaine alone|Participants will receive local wound infiltration with 0.25% Bupivacaine alone.
32974122|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
32974123|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
32974124|NCT01384396|Experimental|KW-3357|
32974125|NCT01384409|Experimental|KW-3357|
32974126|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
32974127|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
32974128|NCT01384422|Placebo Comparator|Placebo oral capsules|
32974129|NCT01384435|Experimental|KPS-0373, lowest dose|
32974130|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
32974131|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
32974132|NCT01384435|Experimental|KPS-0373, highest dose|
32974133|NCT01384435|Placebo Comparator|Placebo|
32974134|NCT01384448|Experimental|Initial Stress Echocardiography|
32974135|NCT01384448|Experimental|Initial Coronary CT Angiography|
32974136|NCT01384461||Cohort|
32974137|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
32974138|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
32974139|NCT01384487||Normal Eyes|Eyes without disease
32974140|NCT01384487||Eyes with Glaucoma|
32974141|NCT01384487||Eyes with Retinal Disease|
32974142|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
32974143|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
32974144|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
32974145|NCT01384526||history of hormone therapy|
32974146|NCT01384526||no history of hormone therapy|
32974147|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974148|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974149|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
33411207|NCT04494438|Experimental|Rituximab|Single administration of Rituximab 375 mg/mq at a rate of 0.5 to 1.5 ml/min over approximately 6 hours, following the infusion of 2.5-5 mg of intravenous chlorfenamine maleate (based on the local protocol and patient tolerance), methylprednisolone (2 mg/Kg) in normal saline and oral paracetamol (8 mg/kg).
33411208|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
32899277|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
32899278|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
32899279|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
32899280|NCT00176930|Experimental|PBSC: No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
32899281|NCT00176930|Experimental|Marrow : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
32899282|NCT00176930|Experimental|UCB : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
32899283|NCT00176930|Experimental|UCB : No TBI/Bu/Cy/ATG|Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
32899284|NCT00176930|Experimental|PBSC|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
32899285|NCT00176930|Experimental|Marrow|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
32899286|NCT00176930|Experimental|UCB|Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
32899287|NCT00176930|Experimental|Co-Enroll From MT0403|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
32899288|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
32899289|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
32899290|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
32899291|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
32899292|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
32899293|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
32899294|NCT00127790|Active Comparator|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
32899295|NCT00127790|Active Comparator|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
32899296|NCT00127790|Experimental|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia & Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
32899297|NCT00127790|No Intervention|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
32899298|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
32899299|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
32899300|NCT01120223|Experimental|LEO 80185 gel once daily application|
32974150|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974151|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974152|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974153|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974154|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
32974155|NCT01384565|Active Comparator|G-CSF+EPO|
32974156|NCT01384565|Placebo Comparator|Placebo|
32974157|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
32974158|NCT01384578|Active Comparator|Vitamin E|
32974159|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
32974160|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
32974161|NCT01384643|Experimental|Propofol group|
32974162|NCT01384643|Placebo Comparator|Control group|
32974163|NCT01384656|Experimental|GIK group|
32974164|NCT01384656|Placebo Comparator|Control group|
32974165|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
32974166|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
32974167|NCT01384682|No Intervention|No change|continue their current cART regimen
32974168|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
32974169|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
32974170|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
32974171|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
32974172|NCT01384708|Experimental|treatment|imaging with proflavine
32974173|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
32974174|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
32974175|NCT01384812|Placebo Comparator|Isoton sodium chloride|
32974176|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
32974177|NCT01384825||MS|Subjects with Multiple Sclerosis
32974178|NCT01384825||HC|Healthy Controls
32974179|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
32974180|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
32974181|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
32974182|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
33104935|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
32974183|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
32974184|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
32974185|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
32974186|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
32974187|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
32974188|NCT01384903|Experimental|KW-3357|
32974189|NCT01384903|Active Comparator|Plasma-derived antithrombin|
32974190|NCT01384916|Experimental|Yoga|
32974191|NCT01384916|Active Comparator|Health education|
32974192|NCT01384929||ICU patients|All patients present in the ICU on the selected days
32974193|NCT01384942|Experimental|Meaning-Based Bereavement Group|
32974194|NCT01384942|Active Comparator|Conventional Bereavement Group|
32974195|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
32974196|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
32974197|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
32974198|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
32974199|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
32974200|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
32974201|NCT01384994|Experimental|FOLFOX + Panitumumab|
32974202|NCT01384994|Active Comparator|FOLFOX|
32974203|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
32974204|NCT01385046|Experimental|physical activity and nutrition|
32974205|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
32974206|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
32974207|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
32974208|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
32974209|NCT01385111|Active Comparator|Arm A|EBUS centered
32974210|NCT01385111|Experimental|Arm B|EUS centered
32974211|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
32974212|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
32974213|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
33104936|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
33104937|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
32974214|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
32974215|NCT01385163|Experimental|Cognitive Processing Therapy|
32974216|NCT01385215|Placebo Comparator|Placebo|
32974217|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
32974218|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
32974219|NCT01385215|Placebo Comparator|Intramuscular Immunization|
32974220|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
32974221|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
32974222|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
32974223|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
32974224|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
32974225|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
32974226|NCT01385267||Diamniotic twin gestations|
32974227|NCT01385319|Active Comparator|bare metal stent|
32974228|NCT01385319|Experimental|Endeavor sprint stent|
32974229|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
32974230|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
32974231|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
32974232|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
32974233|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
32974234|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
32974235|NCT01385384|Other|NeuRx|
32974236|NCT01385397|Experimental|Preceptorship and virtual community|
32974237|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
33411209|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
32899301|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
32899302|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
32899303|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
32899304|NCT00178178|Placebo Comparator|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
32899305|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
32899306|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
32899307|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
32899308|NCT00178646|Experimental|1 - Low Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
32899309|NCT00178646|Active Comparator|2 - High Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
32899310|NCT00178646|Other|3 - High Volume, Low Dose|Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline
32899311|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
32899312|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
32899313|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
32899314|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
32899315|NCT01898234|Experimental|Revaclear|
32899316|NCT01898234|Experimental|Helixone high flux|
32899317|NCT01898234|Experimental|Xevonta|
32899318|NCT01898234|Experimental|Helixone low flux|
32899319|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
32899320|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
32899322|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
32899323|NCT01899482|Active Comparator|Control|One educational session in group.
32899324|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
32899325|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
32899326|NCT00128180|Active Comparator|Active|Methylprednisolone
32899327|NCT00128180|Placebo Comparator|Placebo|Placebo
32899328|NCT01899560|Other|Unique arm|Experimental and comparator
32899329|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
32899330|NCT00181610|Active Comparator|1|Placebo group normal saline twice per day
32899331|NCT00181610|Active Comparator|2|Recombinant human prolactin 60 mcg/kg every 12 hours
32899332|NCT00181610|Active Comparator|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
32899333|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
32899334|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
32899335|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
32899336|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
32899337|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
32899338|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
32862156|NCT04955418|Active Comparator|Epi-no Group|The study group was evaluated before the intervention (between 30 and 32 weeks) and 6 months after delivery.From the 34th week onwards, they performed 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device. The pregnant woman was placed in the supine position and EPI-NO® was inserted into vaginal canal. After the introduction of the deflated tube, it was minimally inflated until the perception in the vaginal canal. The first 5 minutes were for perception of the pelvic floor with 10 contractions and relaxation of the perineum in order to maintain muscle strength. After 15 minutes for stretching the perineum, the device was gradually inflated and always respecting the pregnant woman's tolerance. After a total of 20 minutes, the pregnant woman was asked to relax the pelvic floor in order for the inflated device to gently exit her vaginal cavity. The perimeter was measured using a tape measure in its largest diameter.
32862157|NCT04955418|Placebo Comparator|Control Group|The control group was evaluated only once, six month after delivery.
32862158|NCT04840927|Experimental|Cohort 1: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
32974238|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
32862159|NCT04840927|Experimental|Cohort 2: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
32862160|NCT04954950||sports injuries|Patients were classified according to self-reported years of participation in skiing and snowboarding: beginner (first season), medium (1-5 years), advanced (5-10 years) and expert (≥10 years). Date of injury was divided into weekdays and weekends/ holidays according to the Chinese government holiday arrangement.
32862161|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
32862162|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
32862163|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
32862164|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
32862165|NCT04431570|Experimental|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
32862166|NCT04431570|Experimental|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
32862167|NCT04431570|Sham Comparator|sham stimulation|
32862168|NCT04933656|Experimental|50g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
32862169|NCT04933656|Experimental|90g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
32862170|NCT04933656|Experimental|130g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
32862171|NCT04933656|Experimental|170g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
32862172|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
32862173|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
32862174|NCT04935996|Experimental|Pleuropulmonary echography|
32862175|NCT05076357|Experimental|Only diet group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein) during 8 weeks. Follow up with a registered dietitian.
32862176|NCT05076357|Experimental|Only cold exposure group|No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
32974239|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
32974240|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
32974241|NCT01385436||HPV HSIL cervical carcinoma|
32974242|NCT01385449|Experimental|interscalene block|interscalene block
32974243|NCT01385449|Experimental|interscalene catheter|interscalene catheter
32974244|NCT01385475|Experimental|Control|
32974245|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
32974246|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
32974247|NCT01385501|No Intervention|routine care|
32974248|NCT01385501|Experimental|Educational intervention group|
32974249|NCT01385514||company A-Training Base No.1|
32974250|NCT01385514||company A-Training Base No.2|
32974251|NCT01385514||company A-Training Base No.3|
32974252|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
32974253|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
32974254|NCT01385540||Task-based fMRI|
32974255|NCT01385553|Active Comparator|Individual Drug Counseling|
32974256|NCT01385553|Experimental|Fathers for Change|
32974257|NCT01385605||female patients|ICSI treatment because of male subfertility
32974258|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
32974259|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
32974260|NCT01385618||control|females with an indication for treatment because of male subfertility
32974261|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
32974262|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
32974263|NCT01385657|Experimental|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
32974264|NCT01385657|Experimental|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
32974265|NCT01385657|Experimental|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
32974266|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
32974267|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
32974268|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
32974269|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
32974270|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
32974271|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
32974272|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
32974273|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
32974274|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
32974275|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
32974276|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
32974277|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
32974278|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
32974279|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
32974280|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
32974281|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
32974282|NCT01385826|Placebo Comparator|placebo|placebo
32974283|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
32974284|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
32974285|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
32974286|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
32974287|NCT01385865|Experimental|Mulberry leaf extract|
32974288|NCT01385865|Placebo Comparator|Placebo|
32974289|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
32974290|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
32974291|NCT01385891|Experimental|children with advanced leukemia|
32974292|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
32974293|NCT01385930|No Intervention|Control group|Control group
32974294|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
32974295|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
32974296|NCT01385969||Standard Practice|
32974297|NCT01385969||Syringe recoil|
32974298|NCT01385969||Pressure Transducer|
32974299|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~Defining the levels of severity and urgency for clinically significant test results~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~Standardized policies for the time frames and nature of communication of test result alerts.~Establish criteria for appropriate ATR management by the responsible provider.~Feedback performance including provider, practice and service report cards"
32974300|NCT01386021||Prior recipients of allografts for CABG|
32974301|NCT01386034|Experimental|Citrulline/Placebo|
32974302|NCT01386034|Experimental|Placebo/Citrulline|
32974303|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
32974304|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
32974305|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
32974306|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
32974307|NCT01386073|Active Comparator|FreshKote|
32974308|NCT01386073|Placebo Comparator|Systane|
32974309|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
32974310|NCT01386099|Experimental|PSN821|
32974311|NCT01386099|Placebo Comparator|Placebo|
32974312|NCT01386112|Experimental|EUR-1100 1.5 mg|
32974313|NCT01386112|Experimental|EUR-1100 3.0 mg|
32974314|NCT01386112|Placebo Comparator|placebo|
32974315|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
32974316|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
32974317|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
32974318|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
32974319|NCT01386164|Experimental|Gardasil®|
32974320|NCT01386164|Experimental|Cervarix®|
32974321|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
32974322|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
32974323|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
32974324|NCT01386203||Lung Cancer|
32974325|NCT01386203||Lung Cancer after therapy|
32974326|NCT01386203||COPD controls|
32974327|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
32974328|NCT01386229|Active Comparator|Ketamine|
32974329|NCT01386229|Active Comparator|Etomidate|
32974330|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
32974331|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
32974332|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
32974333|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
32974334|NCT01386255|Active Comparator|baclofen|Baclofen suspension
32974335|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
32974336|NCT01386268||Group 1|
32974337|NCT01386281||Group 1|Drug (incl. Placebo)
32974338|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
32974339|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
32974340|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
32974341|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
32974342|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
32974343|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
32974344|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
32974345|NCT01386333|Placebo Comparator|Saline nasal spray|
32974346|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
32974347|NCT01386372|Experimental|Tolvaptan|
32974348|NCT01386372|Active Comparator|standard therapy|
32974349|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
32974350|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
32974351|NCT01386541|Placebo Comparator|Placebo|
32974352|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
32974353|NCT01386567|Active Comparator|Testim (topical testosterone)|
32974354|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
32974355|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
32974356|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
32974357|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
32974358|NCT01386593|Other|(A) Baseline|
32974359|NCT01386593|Other|(B) Inhibition|
32974360|NCT01386593|Other|(C) Induction|
32974361|NCT01386619|Experimental|NK cell DLI|
32974362|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
32974363|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
32974364|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
32974365|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
32974366|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
32974367|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
32974368|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
32974369|NCT01386749|No Intervention|Control|
32974370|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
32974371|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
32974372|NCT01386775||HED Affected Males|
32974373|NCT01386775||Controls|
32974374|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
32974375|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
32974376|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
32974377|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
32974378|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
32974379|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
32974380|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
32974381|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
32974382|NCT01386853|Experimental|Pitavastatin|
32974383|NCT01386853|Active Comparator|Atorvastatin|
32974384|NCT01386866|Experimental|A|
32974385|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
32974386|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
32974387|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
32974388|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
32974389|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
32974390|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
32974391|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
32974392|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
32974393|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
32974394|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
32974395|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
32974396|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
32974397|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
32974398|NCT01386996|Active Comparator|Symbicort Turbuhaler|
32974399|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
33322718|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
33322719|NCT01371916||ESAT-6 positive|
33322720|NCT01371916||ESAT-6 negative|
33322721|NCT01109862|Experimental|THA|Total hip arthroplasty
33322722|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
33322723|NCT04321460|Experimental|LRG-002|LRG-002 once daily for 14 days
33322724|NCT04321460|Placebo Comparator|Placebo|Placebo once daily for 14 days
33322725|NCT03943212|Experimental|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
32974400|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
32974401|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
32974402|NCT01387061|Experimental|hepatic resection|
32974403|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
33322726|NCT03943212|Sham Comparator|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
32974404|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
32974405|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
32974406|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
32974407|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
32974408|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
32974409|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
32974410|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
32974411|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
32974412|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
32974413|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
32974414|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
32974415|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
32974416|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
32974417|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
32974418|NCT01387126|No Intervention|Weight management program|
32974419|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
32974420|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
32974421|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
32974422|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
32974423|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
32974424|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
32974425|NCT01387243||60 mg Orlistat|Purchased by consumer
32974426|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
32974427|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
32974428|NCT01387295|Experimental|chemotherapy|
32974429|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
32974430|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
32974431|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
32974432|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
32974433|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
32974434|NCT01387321|Experimental|BYL719|
32974435|NCT01387334|Experimental|Resistance Exercise Training Program|
32974436|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
32974437|NCT01387373|Experimental|chemotherapy|
32974438|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
32974439|NCT01387412||Genital warts|Those with and without ano-genital warts
32974440|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
32974441|NCT01387425|Placebo Comparator|control group|
32974442|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
32974443|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
32974444|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
32974445|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
33104938|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
33104939|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
33322727|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
32974446|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
32974447|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
32974448|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
32974449|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
32974450|NCT01387568|Active Comparator|group L|Lidocaine group
32974451|NCT01387568|Placebo Comparator|group P|Placebo group
32974452|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
32974453|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
32974454|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
32974455|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
32974456|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
32974457|NCT01387750|Placebo Comparator|Mentholated Cream|
32974458|NCT01387750|Active Comparator|Mentholated Cream with OGT|
32974459|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
32974460|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
32974461|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
32974462|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
32974463|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
32974464|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
32974465|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
32974466|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
32974467|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
32974468|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
32974469|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
32974470|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
32974471|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
32974472|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
32974473|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
32974474|NCT01387919|Experimental|1|healthy young and lean men
32974475|NCT01387945|No Intervention|HBPM only|
32974476|NCT01387945|Experimental|HBPM+website+patient navigator|
32974477|NCT01387958|Experimental|LCQ908|
32974478|NCT01387958|Placebo Comparator|Placebo|
32974479|NCT01387971||ocular surface disorders|various ocular surface disorders
32974480|NCT01387984||Type 2 diabetes mellitus|
32974481|NCT01387997|Experimental|1|
32974482|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
32974483|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
32974484|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
32974485|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
32974486|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
32974487|NCT01388023|Active Comparator|listerine|listerine mouth wash
32974488|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
32974489|NCT01388049|Experimental|virus detection|
32974490|NCT01388062|Experimental|virus detection|
32974491|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
32974492|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
32974493|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
32974494|NCT01388088|Placebo Comparator|Placebo|
32974495|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
32974496|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
33104940|NCT00580346|Experimental|2|
32974497|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
32974498|NCT01388153|Experimental|Arm 1|
32974499|NCT01388153|Experimental|Arm 2|
32974500|NCT01388153|Active Comparator|Arm 3|
32974501|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
32974502|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
32974503|NCT01388192||Receiving pancreaticoduodenectomy|
32974504|NCT01388205|Experimental|Family-based Intervention Arm|
32974505|NCT01388205|No Intervention|Control|
32974506|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
32974507|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
32974508|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
32974509|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
32974510|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
32974511|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
32974512|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
32974513|NCT01388257|Other|Simple seton drain removal|
32974514|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
32974515|NCT01388270|No Intervention|170 H|Conventional filter
32974516|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
32974517|NCT01388296||Morbidly obese|BMI 50-60 k/m2
32974518|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
32974519|NCT01388309||Cohort|
32974520|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
32974521|NCT01388322|No Intervention|expectant management|Usual management
32974522|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
32974523|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
32974524|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
32974525|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
32974526|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
32974527|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
32974528|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
32974529|NCT01388413|No Intervention|Classic care|
32974530|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
32974531|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
32974532|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
32974533|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
32974534|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
32974535|NCT01388465|No Intervention|Control|No TM queries or feedback
32974536|NCT01388504|Experimental|sodium nitrite|
32974537|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
33104941|NCT00546663|Experimental|Open-label|
32974538|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
32974539|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
32974540|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
32974541|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
32974542|NCT01388556|No Intervention|Control Group|
32974543|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
32974544|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
32974545|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
32974546|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
32974547|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
32974548|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
32974549|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
32974550|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
32974551|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
32974552|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
32974553|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
32974554|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
32974555|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
32974556|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
32974557|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
32974558|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
32974559|NCT01388699||migraine group|female migraineurs with aura
32974560|NCT01388699||control group|healthy women without headache syndrome
32974561|NCT01388712|Placebo Comparator|Placebo|
32974562|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
32974563|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
32974564|NCT01388725||Sepsis|SIRS + infection
32974565|NCT01388738|Active Comparator|cerebrolysin|IV
32974566|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
32974567|NCT01388738|Active Comparator|citicoline|IV and per os
32974568|NCT01388751|No Intervention|no night splinting|
32974569|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
32974570|NCT01388764|Experimental|L-arginine|
32974571|NCT01388829|Experimental|formulation comparison|formulation comparison
32974572|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
32974573|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
32974574|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
32974575|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
32974576|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
32974577|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
32974578|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
32974579|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
32974580|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
32974581|NCT01388959|Experimental|Single arm|
32974582|NCT01389037|Experimental|Health Literacy-focused Self-help|
32974583|NCT01389037|Placebo Comparator|Delayed intervention control|
32974584|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
33104942|NCT00300599|Active Comparator|A|Continue positive airway pressure
32974585|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
32974586|NCT01389089|No Intervention|Control group|The Control group received ice gel packs and elevation to reduce edema.
32974587|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
32974588|NCT01389089|Experimental|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
32974589|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
32974590|NCT01389115||Liver donors|Subjects eligible for organ explant
32974591|NCT01389115||Healthy controls|
33322728|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
33411210|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
32862177|NCT05076357|Experimental|Combined diet + cold exposure group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
33411211|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
33411212|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
32862180|NCT04935918|Experimental|Study Arm 1|Children with bladder exstrophy or isolated epispadias
32862181|NCT04955028||intraoperative massive hemorrhage|blood loss of ≥200 mL with or without artery embolization (UAE) or local CSP resection by laparoscopy or laparotomy as additional interventions.
32862182|NCT04955028||the non-massive hemorrhage group|blood loss of <200 mL
33411213|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
33411214|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
32862185|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
32862186|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
32862187|NCT04935372||Subjective cognitive decline|Male and female, aged 55 to 80 years with subjective cognitive decline, either cognitively unimpaired or with mild cognitive impairment
32862188|NCT04933110||Multiple Sclerosis|Individuals with early-stage multiple sclerosis
32862189|NCT04933110||Healthy Volunteers|Healthy volunteers of similar age and sex as individuals with multiple sclerosis
32862190|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
32974592|NCT01389141||mid-reproductive age|
32974593|NCT01389141||late reproductive age-1|
32974594|NCT01389141||late reproductive age-2|
32974595|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
32974596|NCT01389167|Experimental|Vivitrol + BDRC|
32974597|NCT01389167|Experimental|Vivitrol + Medical Management|
32974598|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
32974599|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
32974600|NCT01389180|Experimental|BDRC|
32974601|NCT01389180|Experimental|EC|
32974602|NCT01389180|Other|TAU|
32974603|NCT01389193|Experimental|Ibudilast|
32974604|NCT01389193|Placebo Comparator|Placebo|
32974605|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
32974606|NCT01389219|No Intervention|Control|Control arm
32974607|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
32974608|NCT01389271||Group 1|
32974609|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
32974610|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
32974611|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
33411215|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
32974612|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
32974613|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
32974614|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
32974615|NCT01389349|Experimental|Acupuncture|
32974616|NCT01389349|Sham Comparator|Sham Control|
32974617|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
32974618|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
32974619|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
32974620|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
32974621|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
32974622|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
32974623|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
32974624|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
32974625|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
32974626|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
32974627|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
32974628|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
32974629|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
32974630|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
32974631|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
32974632|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
32974633|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
32974634|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
32974635|NCT01389466|Experimental|MG1109 - Step 1|
32974636|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
32974637|NCT01389466|Experimental|MG1109 - Step 2|
32974638|NCT01389479|Experimental|Fluviral Group|
32974639|NCT01389479|Active Comparator|Fluzone Group|
32974640|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
32974641|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
32974642|NCT01389492|Other|fresh meat|250 g of fresh meat meal
32974643|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
32974644|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
32974645|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
33322729|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
33322730|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
33322731|NCT05010590|Active Comparator|Romosozumab and denosumab|
32974646|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
32974647|NCT01389518|Placebo Comparator|Placebo|
32974648|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
32974649|NCT01389544|Experimental|Single Arm|
32974650|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
32974651|NCT01389583|Experimental|AUY922|AUY922
32974652|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
32974653|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
32974654|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
33322732|NCT05010590|Active Comparator|Romosozumab|
33411216|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
32974655|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
33411217|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
33411218|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
32862191|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
32862192|NCT04954716|Experimental|Deep Neck Flexor Massage|INTERVENTIONAL GROUP(DEEP Neck FLEXOR MASSAGE)
33411219|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
33411220|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
32862193|NCT04954716|Active Comparator|Post-Isometric Relaxation Technique|CONTROL GROUP (POST-ISOMETRIC RELAXATION TECHNIQUE)
32862194|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
32862195|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
32862196|NCT04932642|Experimental|High-intensity interval training plus resistance training (HIIT+RT)|The HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points. Second, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of as many repetitions as possible in 60 seconds, followed by 60 to 120 seconds of passive recovery.
32862197|NCT04932642|Experimental|Resistance training plus High-intensity interval training (RT+HIIT)|Firstly, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of 60 seconds, followed by 60 to 120 seconds of passive recovery, as previously reported. Secondly, in the HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points.
32862198|NCT05014737||Patients with low risk of PONV|
32862199|NCT05014737||Patients with high risk of PONV|
32862200|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
32862201|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
32862202|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
32862203|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
32862204|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
32862205|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
32862206|NCT04935294|Experimental|Group 1: Matched Control Group Of Healthy Participants|Participants received a single 200-milligram (mg) treatment on Day 1.
32862207|NCT04935294|Experimental|Group 2: Severe RI And Not On Dialysis|Participants received a single 200-mg treatment on Day 1.
32862208|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
32862209|NCT04922580||Hospitalization group|Newborns of ICP mothers require hospitalization after birth
32862210|NCT04922580||without Hospitalization group|Newborns of ICP mothers don't require hospitalization after birth
32862211|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
32862212|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
32862214|NCT04407390|Placebo Comparator|Control|Patients receiving placebo.
32862215|NCT04407390|Experimental|NR|Patients receiving nicotinamide riboside (NR-E)
32862216|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
32862217|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
32862218|NCT04921878|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 24 mg/m2, and then the dose is sequentially escalated to 30 mg/m2, 36 mg/m2 and 40 mg/m2.~Dose-expansion phase: After DLT observation, two to four dose cohorts will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection."
32974656|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
32974657|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
32974658|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
32974659|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
32974660|NCT01389648|No Intervention|usual care|
32974661|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
32974662|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
32974663|NCT01389687|Experimental|Study Group|
32974664|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
32974665|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
32974666|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
32974667|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
32974668|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
32974669|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
32974670|NCT01389739|No Intervention|Usual care|
32974671|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
32974672|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
32974673|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
32974674|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
32974675|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
32974676|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
32974677|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
32974678|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
32974679|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~Symptom and/or sign of heart failure~Lung congestion~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
32974680|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
32974681|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
32974682|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
32974683|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
32974684|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
32974685|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
32974686|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
32974687|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
32974688|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
32974689|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
32974690|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
32974691|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
32974692|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
32974693|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
32974694|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
32974695|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
32974696|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
32974697|NCT01390012|Active Comparator|Dexamethasone oral|
32974698|NCT01390012|Active Comparator|Dexamethasone intravenous|
32974699|NCT01390025|Experimental|TCN-032|
32974700|NCT01390025|Placebo Comparator|Placebo|
32974701|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
32974702|NCT01390051|No Intervention|no treatment|
32974703|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
32974704|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
32974705|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
32974706|NCT01390129|Experimental|Control|
32974707|NCT01390129|Active Comparator|Remote ischemic preconditioning|
32974708|NCT01390142|Experimental|Control|
32974709|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
32974710|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
32974711|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
32974712|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
32974713|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
32974714|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
32974715|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
32974716|NCT01390168|Active Comparator|waitlist|waitlist
32974717|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
32974718|NCT01390207|Experimental|16mm follicles|
32974719|NCT01390285|Experimental|TENS|
32974720|NCT01390285|Sham Comparator|Sham TENS|
32974721|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~No Azacitidine will be given"
32974722|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
33322733|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
33322734|NCT03942510|Experimental|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
32974723|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
33322735|NCT03942510|Experimental|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
33322736|NCT03942510|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
32974724|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
33322737|NCT03942510|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
32974725|NCT01390324|Active Comparator|Naratriptan|Naratriptan
32974726|NCT01390324|Active Comparator|Naproxen|Naproxen
32974727|NCT01390337|Experimental|AC220|
32974728|NCT01390350|Placebo Comparator|Placebo|
32974729|NCT01390350|Experimental|Canakinumab|
32974730|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
32974731|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
32974732|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
32974733|NCT01390376|Experimental|BE 1|DAAOI-1 1g
32974734|NCT01390376|Experimental|BE 2|DAAOI-1 2g
32974735|NCT01390376|Placebo Comparator|starch pill|
32974736|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
32974737|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
32974738|NCT01390480|Placebo Comparator|Placebo|peanut oil
32974739|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
32974740|NCT01390493|Experimental|neurofeedback, alpha power|
32974741|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
32974742|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
32974743|NCT01390519||Afinitor|Afinitor
32974744|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
32974745|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
32974746|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
32974747|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
32974748|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
32974749|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
32974750|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
32974751|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
32974752|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
32974753|NCT01390701|Active Comparator|felodipin|
32974754|NCT01390714|Experimental|1|
32974755|NCT01390714|Experimental|2|
32974756|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
32974757|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
32974758|NCT01390740||Echocardiography|patients with echocardiography
32974759|NCT01390753|No Intervention|Preterm formula|
32974760|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
32974761|NCT01390753|No Intervention|Breastfeeding + formula|
32974762|NCT01390753|No Intervention|Breasfeeding|
32974763|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
32974764|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
32974765|NCT01390805||Subjects with recurrent genital herpes|
32974766|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
32974767|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
32974768|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
32974769|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
32974770|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
32974771|NCT01390935||systolic heart failure|EF under 45%
32974772|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
32974773|NCT01391026|No Intervention|Usual care|
32974774|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
33104943|NCT00300599|Placebo Comparator|B|Placebo
32974775|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
32974776|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
32974777|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
32974778|NCT01391065|Other|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
32974779|NCT01391078|Experimental|Sensimed Triggerfish|
32974780|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
32974781|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
32974782|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
32974783|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
32974784|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
32974785|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
32974786|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
32974787|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
32974788|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
32974789|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
32974790|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
32974791|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
32974792|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
32974793|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
33104944|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
33104945|NCT00546741|Experimental|1|
33104946|NCT00546741|Active Comparator|2|
33104947|NCT00546741|Active Comparator|3|
33104948|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
33104949|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
32974794|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
32974795|NCT01391156|Experimental|Minoxidil|
32974796|NCT01391156|Active Comparator|MinoxidilFinasteride|
32974797|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
32974798|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
32974799|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
32974800|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
32974801|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
33411221|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
32974802|NCT01391208|No Intervention|peptide application|
32974803|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
32974804|NCT01391247||healthy age machted controls|
32974805|NCT01391247||normal tension glaucoma patients|
32974806|NCT01391247||primary open angle glaucoma patients|
32974807|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
32974808|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
32974809|NCT01391338|Experimental|Low dose ASP3652 twice daily|
32974810|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
32974811|NCT01391338|Experimental|High dose ASP3652 once daily|
32974812|NCT01391338|Experimental|High dose ASP3652 twice daily|
32974813|NCT01391338|Placebo Comparator|Placebo|
32974814|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
32974815|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
32974816|NCT01391377|Active Comparator|Niacin / Laropiprant|
32974817|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
32974818|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
32974819|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
32974820|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
32974821|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
32974822|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
32974823|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
32974824|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
32974825|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
32974826|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
32974827|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
32974828|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
32974829|NCT01391481|Experimental|Perfluorocarbon|
32974830|NCT01391481|Placebo Comparator|Sterile Water for Injection|
32974831|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
32974832|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
32974833|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
32974834|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
32974835|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
32974836|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
32974837|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
32974838|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
32974839|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
32974840|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
32974841|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
32974842|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
32974843|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
32974844|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
32974845|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
32974846|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
32974847|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
32974848|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
32974849|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
32974850|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
32974851|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
32974852|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
32974853|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
32974854|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
32974855|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
32974856|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
32974857|NCT01391650|Experimental|biomechanic of the knee|
32974858|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
32974859|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
32974860|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
32974861|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
32974862|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
32974863|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
32974864|NCT01391728|Active Comparator|Lifestyle counseling|
32974865|NCT01391728|No Intervention|Control|
32974866|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
32974867|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
32974868|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
32974869|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
32974870|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
32974871|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
32974872|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
32974873|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
32974874|NCT01391780||Group 1|Patients with stress urinary incontinence
32974875|NCT01391780||Group 2|Patients with urgency urinary incontinence.
32974876|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
32974877|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
32974878|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
32974879|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
32974880|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
32974881|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
32974882|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
32974883|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
32974884|NCT01391884||Healthy control|
33104950|NCT00546858||Survey|Patients with interstitial cystitis
33104951|NCT02467361|Experimental|Combo with Ipilimumab|
32974885|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
32974886|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
32974887|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
33322738|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
33322739|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
33322740|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
33322741|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
33322742|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
32974888|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
32974889|NCT01391975|Experimental|Surveillance and proactive intervention|
32974890|NCT01391975|No Intervention|Control and reactive intervention|
32974891|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
32974892|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
32974893|NCT01392001||Cohort|
32974894|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
32974895|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
32974896|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
32974897|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
32974898|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
32974899|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
32974900|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
32974901|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
32974902|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
32974903|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
32974904|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
32974905|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
32974906|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
32974907|NCT01392196|Other|Single arm|Renal Denervation
32974908|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
32974909|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
32974910|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
33322743|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
32974911|NCT01392235|Experimental|Drug: Famitinib|
32974912|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
32974913|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
32974914|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
32974915|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
32974916|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
32974917|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
32974918|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
32974919|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
32974920|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
32974921|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
32974922|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
32974923|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
32974924|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
32974925|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
32974926|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
32974927|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
32974928|NCT01392521|Experimental|Arm 1|
32974929|NCT01392534||Group 1|
32974930|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
32974931|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
32974932|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
32974933|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
32974934|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
32974935|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
32974936|NCT01392651||Women with urinary stress incontinence|
32974937|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
32974938|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
32974939|NCT01392716|Experimental|Single arm|
32974940|NCT01392729||Cohort|
32974941|NCT01392755|Experimental|1|
32974942|NCT01392755|Experimental|2|
32974943|NCT01392768|Experimental|Levetiracetam|
32974944|NCT01392768|Placebo Comparator|Placebo|
32974945|NCT01392781||normoweight PCOS patients|
32974946|NCT01392781||normoweight controls|
32974947|NCT01392781||overweight plus obese PCOS patients|
32974948|NCT01392781||overwqeight plus obese controls|
32974949|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
32974950|NCT01392794|Experimental|conventional tablet precedence group|
32974951|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
32974952|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
32974953|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
32974954|NCT01392820|Experimental|TC-5214|
32974955|NCT01392820|Placebo Comparator|Placebo|
32974956|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
32974957|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
32974958|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
32974959|NCT01392872|Other|sclerosis|
32974960|NCT01392898|Experimental|liraglutide|
32974961|NCT01392898|Active Comparator|insulin|
32974962|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
32974963|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974964|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974965|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
33104952|NCT02467361|Experimental|Combo with Nivolumab|
32899339|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
32907551|NCT03207347|Experimental|Cohort B (Closed to enrollment)|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
32907552|NCT04364438|No Intervention|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
32907553|NCT04364438|Experimental|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
32907554|NCT04364438|Experimental|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
32907555|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32907556|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32907557|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
32907558|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
32907559|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
32907560|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
32907561|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
32907562|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
32907563|NCT04363892|Experimental|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
32907564|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
32907565|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
32907566|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
32907567|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
32907568|NCT04370288|No Intervention|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
32907569|NCT04370288|Experimental|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
32907570|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
32907571|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
32907572|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
32907573|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
32907574|NCT04369820|Experimental|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:~Within the first 72 hours of medical care in resuscitation unit or department.~Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
32907575|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
32907576|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
32907577|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
32907578|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
32974966|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974967|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974968|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974969|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974970|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
32974971|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
32974972|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
32974973|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
32974974|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
32974975|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
32974976|NCT01392976|Experimental|CO-1.01 Formulation B|
32974977|NCT01392976|Active Comparator|CO-1.01 Formulation A|
32974978|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
32974979|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
32974980|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
32974981|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
32974982|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
32974983|NCT01393041|Other|Angio-Seal VIP|
32974984|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
32974985|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
32974986|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
32974987|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
32974988|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
32974989|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
32974990|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
32974991|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
32974992|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
32974993|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
32974994|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
32974995|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
32974996|NCT01393145|Experimental|Group 1|
32974997|NCT01393145|Active Comparator|Group 2|
32974998|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
32974999|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
32975000|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
32975001|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
32975002|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
32975003|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
32975004|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
32975005|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
32975006|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
32975007|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
32975008|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
32975009|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
32975010|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
33104953|NCT02467361|Experimental|Combo with Pembrolizumab|
32975011|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
32975012|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
32975013|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
32975014|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
32975015|NCT01393262||Healthy Escort|
32975016|NCT01393262||Hand Service patient|
32975017|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
32907579|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
32975018|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
32975019|NCT01393288|Placebo Comparator|Ondansetron|
32975020|NCT01393288|Placebo Comparator|Lorazepam|
32975021|NCT01393288|Placebo Comparator|Aprepitant|
32975022|NCT01393327|Experimental|Respiratory and exercise therapy|Early after PEA postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks.
32975023|NCT01393340|Placebo Comparator|Placebo|
32975024|NCT01393340|Active Comparator|Omalizumab|
32975025|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
32975026|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
32975027|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
32975028|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
32907580|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
32975029|NCT01393418||Subjects undergoing cardiac surgery|
32975030|NCT01393431||EBC pH|Observational study
32975031|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
32975032|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
32975033|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
32975034|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
32975035|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
32975036|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
32975037|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
32975038|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
32975039|NCT01393561|Placebo Comparator|Group 2|Placebo
32975040|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
32975041|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
32975042|NCT01393587|Experimental|Experimental|
32975043|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
32975044|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
32975045|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
32975046|NCT01393665|Placebo Comparator|Placebo|
32975047|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
32975048|NCT01393678|Experimental|PENNEL|2cap T.I.D
32975049|NCT01393678|Active Comparator|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
33322744|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
32975050|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
32975051|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
32975052|NCT01393756|Experimental|Lenalidomide dose 25 mg|
33104954|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
33104955|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
33322745|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
32975053|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
32975054|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
32975055|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
32975056|NCT01393795|Placebo Comparator|Tegaderm|
32975057|NCT01393795|Active Comparator|Qutenza|
32975058|NCT01393808|Experimental|Paricalcitol|
32975059|NCT01393808|Placebo Comparator|placebo|
32975060|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
32975061|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
32975062|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
32975063|NCT01393860||Aliskiren|Diabetic nephropathy
32975064|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
32975065|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
32975066|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
32975067|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
32975068|NCT01393925|Experimental|parecoxib, normal saline|
32975069|NCT01393938|Other|Mullerian Duct Anomaly|
32975070|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
32975071|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
32975072|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
32975073|NCT01393977|No Intervention|control|Outpatient in hospital
32975074|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
32975075|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
32975076|NCT01394029||deferasirox|
32975077|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
32975078|NCT01394055|Active Comparator|RM-131|
32975079|NCT01394055|Placebo Comparator|Placebo|
33322746|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
32975080|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
32975081|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
32975082|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
32975083|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
32975084|NCT01394120|Experimental|Tarteted Therapy|
32975085|NCT01394120|Active Comparator|Standard Chemotherapy|
32975086|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
32975087|NCT01394146|Experimental|Subjects with healthy kidney function|
32975088|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
32975089|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
32975090|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
32975091|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
32975092|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
32975093|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
32975094|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
32975095|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
32975096|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
32975097|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
32975098|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
33033102|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
32975099|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
32975100|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
32975101|NCT01394367|No Intervention|respiratory and exercise therapy|
32975102|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
32975103|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
32975104|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
32975105|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
32975106|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
32975107|NCT01394406|Experimental|Ketamine group|
32975108|NCT01394406|Placebo Comparator|Saline group|
32975109|NCT01394419|Experimental|NAC group|N-acetylcysteine
32975110|NCT01394419|Placebo Comparator|Placebo group|Saline
32975111|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
32975112|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
32975113|NCT01394445|Active Comparator|Physostigmine|
32975114|NCT01394445|Placebo Comparator|Placebo|
32975115|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
32862219|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
32975116|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
32975117|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
32975118|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
32975119|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
32975120|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
32975121|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
32975122|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
32975123|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
32975124|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
32975125|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
32975126|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
32975127|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
32975128|NCT01394575|Experimental|IMRT-SIB|
32975129|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
32975130|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
32975131|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
32975132|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
32975133|NCT01394653|Experimental|conventional tablet precedence group|
32975134|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
32975135|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
32975136|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
32975137|NCT01394731|Experimental|Paracetamol 1|
32975138|NCT01394731|Experimental|Paraceatmol 2|
32975139|NCT01394731|Active Comparator|Meperidine|
32975140|NCT01394770|Experimental|Aliskiren|
32746737|NCT05611281|Experimental|GS3-007 oral liquid|"78 subjects: Part 1 SAD 36 subjects: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD 30 subjects: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days Part 3 Food effects 12 subjects: Planned in 1.6mg/kg dose group。Once a day, a total of one dose."
32975141|NCT01394770|Active Comparator|Amlodipine|
32975142|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
32975143|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
32975144|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
32975145|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
32975146|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
32975147|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
32975148|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
32975149|NCT01394822||Ultrasound results reported|
32975150|NCT01394822||Ultrasound results NOT reported|
32975151|NCT01394835|Experimental|Alpha -1 Antitrypsin|
32975152|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
32975153|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
32975154|NCT01394848|Active Comparator|Atorvastatin 20mg group|
32975155|NCT01394848|Active Comparator|Atorvastatin 80mg group|
32975156|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
32975157|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
32975158|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
32975159|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
33411222|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
33411223|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
32975160|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
32975161|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
32975162|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
32975163|NCT01394965|No Intervention|ECG Mapping|
32975164|NCT01395069|Active Comparator|Nepafenac 0.1%|
32975165|NCT01395069|Active Comparator|Ketorolac 0.5%|
32975166|NCT01395069|Placebo Comparator|Placebo|
32975167|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
32975168|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
33033103|NCT01959555||Retrospective collection of data|
33033104|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
33033105|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
33033106|NCT01959594|Experimental|Cohort 1|
32975169|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
33322747|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
33322748|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
33322749|NCT04097028|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
32975170|NCT01395108|Placebo Comparator|Placebo|Placebo
32975171|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
32975172|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
32975173|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
32975174|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
32975175|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
32975176|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
32975177|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
32975178|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
32975179|NCT01395147|Experimental|Lu AA21004 group|
32975180|NCT01395160||Adult ADHD|
32975181|NCT01395160||Bipolar Disorder|
32975182|NCT01395160||Healthy control|
32975183|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
32975184|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
32975185|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
32975186|NCT01395199|Placebo Comparator|Starch pill|Placebo
32975187|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
32975188|NCT01395212||Cardiac stem cell therapy 5 years ago|
32975189|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
32975190|NCT01395238|No Intervention|Wait-List Group|
32975191|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
32975192|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
32975193|NCT01395264||Episodic Migraine.|
32975194|NCT01395264||menstrual migraine|
32975195|NCT01395264||Cluster Headache patients|
32975196|NCT01395264||control (non-headache group)|
32975197|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
32975198|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
32975199|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
32975200|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
32975201|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
32975202|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
32975203|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
32975204|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
32975205|NCT01395303||control group|randomly selected controls from the Tromsø study
32975206|NCT01395342|No Intervention|blood pressure and heart rate data|
32975207|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
32975208|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
32975209|NCT01395381|Placebo Comparator|Placebo|
32975210|NCT01395381|Experimental|Albendazole|
32975211|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~21~23~25"
32975212|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~18~20~22"
32975213|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~15~17~19"
32975214|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
32975215|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
32975216|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
32975217|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
32975218|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
32975219|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
32975220|NCT01395459|No Intervention|control|Care as usual is given.
33033107|NCT01959594|Experimental|Cohort 2|
32975221|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
32975222|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
32975223|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
32975224|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
32975225|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
32975226|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
32975227|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
32975228|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
32975229|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
32975230|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
32975231|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
32975232|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
32975233|NCT01395563|Experimental|1|pancreatic cancer patients
32975234|NCT01395563|Experimental|2|pancreatic cancer patients
32975235|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
32975236|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
32975237|NCT01395602|Placebo Comparator|placebo|placebo pill
32975238|NCT01395602|Active Comparator|cabergoline|cabergoline pill
32975239|NCT01395615||Cohort|
32975240|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
32975241|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
32975242|NCT01395680||cancer adolescent|
32975243|NCT01395693|Experimental|Salt Lake mask system|
32975244|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
32975245|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
32975246|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
32975247|NCT01395732|Experimental|1|
32975248|NCT01395745|Experimental|blisibimod weekly dose|
32975249|NCT01395745|Placebo Comparator|Placebo|
32975250|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
32975251|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
32975252|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
32975253|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
32975254|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
32975255|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
32975256|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
32975257|NCT01395940|Experimental|KLH-2109, lower dose|
32975258|NCT01395940|Experimental|KLH-2109, higher dose|
32975259|NCT01395953|Active Comparator|Buspirone|
32975260|NCT01395953|Placebo Comparator|Placebo|
32975261|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
32975262|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
32975263|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
32975264|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
32975265|NCT01396031|Experimental|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x ~1 month
32975266|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
32975267|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
32975268|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
32975269|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
32975270|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
32975271|NCT01396174|Active Comparator|Standard Online Support Group|
32975272|NCT01396174|Experimental|Prosocial Online Support Group|
32975273|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
32975274|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
32975275|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
32975276|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
32975277|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
32975278|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
32975279|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
32975280|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
32975281|NCT01396330|Other|Stress|
32975282|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
32975283|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
32975284|NCT01396356||ablation procedure|
32975285|NCT01396369|Active Comparator|Birth control|
32975286|NCT01396369|Experimental|Birth control plus Brevail|
32975287|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
32975288|NCT01396460||control group|morbid obese population
32746738|NCT05611281|Placebo Comparator|Placebo GS3-007 oral liquid|"Part 1 SAD: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days"
32746739|NCT04334811|Other|Arm|No arm
32975289|NCT01396473|No Intervention|control|
32975290|NCT01396473|Experimental|Policy and Environmental Change|
32975291|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
32975292|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
32975293|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
32975294|NCT01396577|Active Comparator|3 x 2-mg perampanel|
32975295|NCT01396577|Active Comparator|6mg perampanel|
32975296|NCT01396590|Active Comparator|6 x 2 mg perampanel|
32975297|NCT01396590|Active Comparator|12 mg Perampanel|
32975298|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
32975299|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
32975300|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
32975301|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
32975302|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
32975303|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
32975304|NCT01396707|Experimental|Herceptin+XELOX|
32975305|NCT01396720|Active Comparator|fluvoxamine|
32975306|NCT01396720|Active Comparator|citalopharm|
32975307|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
32975308|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
32975309|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
32975310|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
32975311|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
32975312|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
32975313|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
32975314|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
32975315|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
32975316|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
32975317|NCT01396850||Psychotic Group|
32975318|NCT01396850||Anxiety|
32975319|NCT01396850||Depressed|
32975320|NCT01396850||Control Group|
32975321|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
32746740|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
32975322|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
32975323|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
32975324|NCT01396876|No Intervention|No clown|
32975325|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
32975326|NCT01396889|Placebo Comparator|Placebo|Placebo
32975327|NCT01396902|Active Comparator|Standard of care|
32975328|NCT01396902|Experimental|Text Messaging|
32975329|NCT01396915||High or Normal Dietary Protein Intake|
32975330|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
32975331|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
32975332|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
32975333|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
32975334|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
32975335|NCT01396993||BCT|patients undergoing conservative breast surgery
32975336|NCT01397006|Experimental|Pregabalin|
32975337|NCT01397006|Placebo Comparator|Placebo|
32975338|NCT01397019|Experimental|FOLFIRINOX|
32975339|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
32975340|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
32975341|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
32975342|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
32975343|NCT01397097|Experimental|Arm 1|
32975344|NCT01397097|Active Comparator|Arm 2|
32975345|NCT01397123|Experimental|Lifestyle counseling|
32975346|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
32975347|NCT01397149|Placebo Comparator|Film coated tablet|
33033108|NCT01959594|Experimental|Cohort 3|
32975348|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
32975349|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
32975350|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
32975351|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
32975352|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
32975353|NCT01397214|Experimental|Megace F|Megace F oral suspension
32975354|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
32975355|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
32975356|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
32975357|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
32975358|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
32975359|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
32975360|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
32975361|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
32975362|NCT01397318||Experimental Group|
32975363|NCT01397318||Control Group|
32975364|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
32975365|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
32975366|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
32975367|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
32975368|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
32975369|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
32975370|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
32975371|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
32975372|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
32975373|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
32975374|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
32975375|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
32975376|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
32975377|NCT05269290|Experimental|Ingavirin®, syrup, 30 mg/5 ml|Ingavirin®, syrup, 30 mg/5 ml will be administered on top of standard therapy
32975378|NCT05269290|Placebo Comparator|Placebo|Placebo will be administered on top of standard therapy
32975379|NCT05269251||Axillary Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
32975380|NCT05269251||Infraclavicular Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
33033109|NCT01959594|Experimental|Optional Cohort 4|
33033110|NCT01959594|Experimental|Optional Cohort 5|
33033111|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
33033112|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
33033113|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
33033114|NCT01959646|Placebo Comparator|Placebo|Placebo Group
32975381|NCT05269251||Interscalene Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
32975382|NCT05269238|Other|control group patient|performing lumbar punctures by students with standard training
32975383|NCT05269238|Experimental|experimental group patient|performing lumbar punctures by students with standard training and an augmented reality simulator
32975384|NCT05269134|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotic treatment.
32975385|NCT05269134|Placebo Comparator|DAIR + Placebo + Antibiotics|Placebo will be administered in conjunction with antibiotic treatment.
32975386|NCT05269108|Experimental|Fluoroscopy-free RIRS|Patients will be treated by RIRS without fluoroscopy
32975387|NCT05269108|Active Comparator|Standard RIRS|Standard RIRS under fluoroscopy-guidance will be performed
32975388|NCT05268952|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
32975389|NCT05268913||Women with BRCA1/2 genes|
32975390|NCT05268913||Women with breast cancer|
32739106|NCT05714189|Other|Intervention group: adherence to endometriosis diet|Women could choose to adhere to the endometriosis diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
32739107|NCT05714189|No Intervention|Control group: no diet adherence|Women were asked to complete three questionnaires, once every two months. These contained the EHP-30 and GIQLI. The first questionnaire contained questions on their demographics, and whether they applied a diet before.
32975391|NCT05268913||Women with obesity|
32975392|NCT05268900|Placebo Comparator|Volume control ventilation group|Patients' lungs will be ventilated with volume control ventilation mode
32975393|NCT05268900|Active Comparator|Pressure control ventilation-volume guaranteed group|patients' lungs will be ventilated with Pressure control ventilation-volume guaranteed mode
32975394|NCT05268861|Experimental|Training with EA feedback|Subjects will undergo training with the EA-VR game that includes a 15 degree elbow flexion error.
32975395|NCT05268861|Sham Comparator|Training without EA feedback|Subjects will undergo training with the EA-VR game that does not include EA feedback.
32975396|NCT05268848|Experimental|Termography PRE|Foot thermography before lining test
32975397|NCT05268848|Experimental|Termography POST|Foot thermography after wearing 2 types of liner for three hours (one on each foot)
32975398|NCT05268848|Active Comparator|Thermographic comparations|Thermographic comparations between PRE and POST measurements
32975399|NCT05268835|Active Comparator|Clindamycin 150mg|Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours
32975400|NCT05268835|Active Comparator|Clindamycin 300mg|Patients receiving 300mg of clindamycin after surgery every 8 hours
32975401|NCT05268835|Active Comparator|Clindamycin 600mg|Patients receiving 600mg of clindamycin after surgery every 12 hours
32975402|NCT05268770||Tinnitus patients with good hearing|
32975403|NCT05268770||Healthy controls with good hearing|
32975404|NCT05268718|Experimental|Nanogel photothermal therapy|After the subjects were enrolled in the study, the eyes were coated with Au-Ag-Cu2O nano-gel once (the concentration was 26.4μg/mL, the dosage was suitable to cover the ulcer surface evenly, and the dosage was recorded). Combined with mdl-n-808-10w near-infrared laser (China changchun new industry photoelectric technology) combined with photothermal therapy (laser wavelength 808 nm, power 1.5W/cm2, temperature controlled at 40℃, lasting 10min)
32975405|NCT05268718|Active Comparator|Voriconazole eye drops|Voliconazole eye drops (once in half an hour) were also used in the control group.
32975406|NCT05268718|Placebo Comparator|Normal saline|Normal saline eye drops (once in half an hour) were also used in the control group.
32975407|NCT05268692|Active Comparator|GS|gemcitabine plus S-1
32975408|NCT05268692|Active Comparator|GnP|gemcitabine plus nab-paclitaxel
32739108|NCT04998513|Active Comparator|Medical Management Alone Arm|Antibiotics, steroids, fluids
32739109|NCT04998513|Active Comparator|Surgical Arm|Incision and drainage
32739110|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
32739111|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
32975409|NCT05268627|Active Comparator|Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections|
32975410|NCT05268627|Active Comparator|liraglutide|
32975411|NCT05268536|Active Comparator|resistance exercise|Participants will perform Squat walking with resistance band, Butt blaster, Mussel with resistance band, Hip extension with resistance band, and Ankle dorsiflexion exercises with resistance band. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
32975412|NCT05268536|Active Comparator|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
32975413|NCT05268523|Experimental|Education and Strategies Intervention Group|Participants will use a videoconferencing system to participate in the Education and Strategies Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
32975414|NCT05268523|Active Comparator|Mindfulness Skills Intervention Group|Participants will use a videoconferencing system to participate in the Mindfulness Skills Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
32975415|NCT05268523|No Intervention|No-Treatment Control Group|Participants adhere to the standard of care (no study treatment) for 8 weeks.
32975416|NCT05268484|Experimental|TBI Intervention Group|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
32975417|NCT05268484|No Intervention|TBI Control Group|No intervention is provided
32975418|NCT05268484|No Intervention|Healthy Control|No intervention is provided
32975419|NCT05268354|Experimental|Training group|6-week neuromuscular training program
32975420|NCT05268354|No Intervention|Control group|
32975421|NCT05268276|Experimental|study group|"the study group will recelve adesigned protocol of care that entails three interventions as the following1) Application of ice gel pad on perineal trauma for the first 24 hours post partum 2) Performance of pelvic floor exercises (Kegel exercises) from six hours till one week postpartum 3) Application of warm compresses after 48 hours and through the first week postpartum.~The investigator will perform demonstration and then redemonstration by the women on each intervention will be done. A designed booklet (developed previously) that explains each intervention will be given to each woman."
32975422|NCT05268276|No Intervention|control group|The control group will receive the routine hospital care only
32975423|NCT05268081|Experimental|Virtual specialist conferences|The group of general practices who participates in the virtual specialist conferences with endocrinologists.
32975424|NCT05268081|No Intervention|Standard of care|Receives the usual, standard practice.
32975425|NCT05268068|Experimental|Dose A of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.
32975426|NCT05268068|Experimental|Dose B of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
32975427|NCT05268068|Experimental|Dose C of Risankizumab for Intravenous (IV) Infusion|Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.
32975428|NCT05267977|Active Comparator|cephalosporin|cephalosporin
32975429|NCT05267977|Active Comparator|cephalosporin and aminoglycoside|the combination of cephalosporin and aminoglycoside.
32975430|NCT05267964|Active Comparator|Epping resection arthroplasty|During the Epping resection-suspension arthroplasty the trapeziectomy is performed, the flexor carpi radialis tendon is divided into two parts and one of these is stripped and cut proximally. To prevent shortening of the first ray with following loss of strength, this tendon strip is pulled through a drill hole in the base of the 1st metacarpal from ulnar palmar to radial dorsal. The rest of the tendon strip is sutured to a roll replacing the os trapezium.
32975431|NCT05267964|Active Comparator|CMC I prosthesis group|During implantation of the prosthesis the CMC joint is opened and 3 mm of the metacarpal base as well as osteophytes are resected. Following the release of the trapezium the first metacarpal and the trapezium are prepared for the prosthesis by broaching and drilling. After the test-implants have shown satisfying joint tension and anatomic conditions, the HA coated stem and cup are pressfit inserted in the appropriate size followed by the modular head.
32975432|NCT05267912|Experimental|ORGANOTREAT 01|"To assess the feasibility of timely generating chemograms from PDOs in advanced CRC.~To assess the proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram.~To assess the efficacy and safety of chemogram-driven treatment in advanced CRC."
32975433|NCT05267912|Experimental|ORGANOTREAT 02A|is a single-arm, Phase II study to evaluate the efficacy of chemogram-driven treatment in patients with advanced, pretreated solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate <50%. The primary endpoint is the Growth Modulation Index (GMI), defined as PFSn/PFSn-1, where PFSn is the -progression-free survival (PFS) time on study treatment and PFSn-1 the PFS time within the previous treatment line.
32975434|NCT05267912|Experimental|ORGANOTREAT 02B|is a randomized Phase II study to compare the efficacy of chemogram-driven treatment vs SoC in patients with advanced, pretreated solid cancers with a PDO take-on rate ≥50%. A cross-over will allow patients enrolled in the control arm to benefit from chemogram-based treatment. Patients for whom no chemogram can be obtained will not be randomized and they will be treated according to SoC. The primary endpoint will be PFS. The study will include multiple strata, each for a different tumor type (e.g., stratum 1, pancreatic ductal adenocarcinoma (PDAC); stratum 2, CRC; etc.). Each stratum will be conducted and analyzed independently from the other strata.
32975435|NCT05247333|Experimental|Patients presenting with minor ailments or requesting a non-prescription product.|"Community pharmacists working with agreed protocols with primary care physicians respond to all type of patients presenting with minor ailments or requesting a non-prescription product.~Following this consultation, patients are followed up after ten days."
32975436|NCT05246891||Rehabilitation nursing intervention|Functional respiratory rehabilitation exercise plan. Motor exercise plan. Cardiorespiratory optimization. Early diagnosis of potential problems associated.
32975437|NCT05246891||Rehabilitation nursing not intervention|General nursing care
32975438|NCT05246748|Experimental|Intervention group|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
32975439|NCT05246748|Active Comparator|Control group|The control group received solely standard education program for one sessions in prenatal period.
32975440|NCT05238090|Other|Control group|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
32975441|NCT05238090|Experimental|Experimental|Passive and active analytical stretching exercises described by Neiger and Simons , applying them to the muscle chain involved in lateral epicondylitis described by Busquet
32975442|NCT05207696||Platelet-rich fibrin (PRF)|A total of 28 sites from 12 patients who underwent papilla reconstruction with PRF placed with semilunar incision in the maxillary anterior region were included in PRF group. ( Data of 12 patients were included in the study.)
32975443|NCT05207696||Connective tissue graft (CTG)|A total of 27 sites from 8 patients who underwent papilla reconstruction with CTG placed with semilunar incision in the maxillary anterior region were included in CTG group. (Data of 8 patients were included in the study.)
32975444|NCT05186558|Experimental|penpulimab, lenalidomide, rituximab, gemcitabine and oxaliplatin（Penpulimab-R2-GemOx)）|penpulimab: 200 mg q2w, iv, drip R2-GemOx: lenalidomide 10 mg，po; Rituximab 375mg/m2, iv, drip; Gemcitabine 1000mg, po; Oxaliplatin 100mg/m2, iv, drip;
32975445|NCT05183490|Experimental|Group A: Allogenic Stem Cell Transplant Recipient (SCT)|"Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Each group will undergo independent dose escalation.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
32975446|NCT05183490|Experimental|Group B: Solid organ transplant recipients (SOT)|"In SOT recipients, the study will use higher doses of R-MVST cells, as the infused anti-viral T cells are less likely to persist long-term and cause GVHD, based on the safety profile of PyVST cells used for therapy of PML in non-HCT subjects.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
32975447|NCT05175456|Experimental|Bedjet arm|All participants will complete a baseline study period of 4 weeks and then will be provided the Bedjet system.
32975448|NCT05113810|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
32975449|NCT05113810|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
32975450|NCT05101135|Experimental|JT-001|Drug: JT-001
32975451|NCT05101135|Placebo Comparator|JT-001 Placebo|Drug: JT-001 Placebo
32975452|NCT05092698|Active Comparator|Vit_D_suppl|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube weekly followed by 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
32975453|NCT05092698|Placebo Comparator|Vit_D_placebo|Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly followed by two drops of herbal oil daily until discharge or death.
32975454|NCT05051254|Experimental|Respiratory muscle impairment|Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
32975455|NCT05038020|Experimental|AKST4290|Subjects will receive AKST4290, 400mg twice daily, for 24 weeks
32975456|NCT05038020|Placebo Comparator|Placebo|Subjects will receive matching Placebo, twice daily, for 24 weeks
32975457|NCT05009355|Experimental|experimental|A Group: Consisted of 20 patients who were treated with scaling and root planing in conjunction with 2g antioxidant Vit (C)
32975458|NCT05009355|No Intervention|Control|A Group: consisted of 20 patients who were treated with scaling and root planing.
32975459|NCT05003661|Experimental|Mother's voice|Neonates receive the intervention that recording of mother's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
32975460|NCT05003661|Experimental|Father's voice|Neonates receive the intervention that recording of father's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
32975461|NCT05003661|No Intervention|control group|When the infants undergoing heel puncture procedure, the control group were under routine care. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
32975462|NCT04986449|Experimental|Intervention group|All families will receive the culinary and nutritional intervention. Changes before-after will be assessed regarding culinary skills, knowledge and attitudes of families on cooking with plant-based foods
32975463|NCT04981587|Experimental|Intervention group|This is the group that receives strength exercise in addition to usual treatment
32975464|NCT04981587|Other|Control group|This is the group that only receives usual treatment
32975465|NCT04980807||CMT Patients|Individuals with Charcot-Marie-Tooth Disease Types 1 and 2.
32975466|NCT04980807||Healthy Controls|Healthy age-matched volunteers
32975467|NCT04980014||NesinaAct® Tablet|Participants with a diagnosis of Type 2 Diabetes who took NesinaAct® tablet, a fixed dose combination of alogliptin along with pioglitazone, as prescribed by the physician, are observed in this study.
32975468|NCT04975269|Active Comparator|Acetazolamide|Acetazolamide (active)
32975469|NCT04975269|Placebo Comparator|Placebo|Placebo
32975470|NCT04975204|Experimental|TQB3909 Tablets|Take 100-1200mg once a day; Oral administration on an empty stomach, 28 days as a cycle.
32975471|NCT04954807|Active Comparator|Human Milk Fortifier|human milk fortifier which contains protein, lipid, carbohydrate and micronutrients
32975472|NCT04954807|Placebo Comparator|placebo|Placebo is made of polysaccharides (0.9 g/1 g placebo) and maltose (0.1 g/1 g placebo) and minerals.
32975473|NCT04944745|Experimental|Myofascial release (MFR)|The pectoral MFR will be completed by an experienced registered massage therapist (RMT). They will stand on the participant's right side slightly rotated to the left facing towards the participant's left hip and apply a cross-hand MFR technique to the superficial pectoral fascia on the right side. The therapist will begin by placing the distal region of the anterior palm of the anchoring hand (therapist's right hand) on the right edge of the anterior sternum at the level of the 3rd to the 6th ribs on the skin and the draping over the pectoral fascia. They will then apply a gentle posterior pressure to hold the fascia in place. The forearm of the mobilizing hand (RMT's left hand) will be directed to the right shoulder wit hate right forearm crossing over the left and the contact of are of the mobilizing hand will be the skin superficial to the pectoral fascia and insertion of pectorals major on the anterior aspect of the humerus. This will be held for four minutes.
32975474|NCT04944745|Sham Comparator|Soft-touch Control (CON)|This control treatment will be set up the same way in regards to the RMT's hand placement, except no pressure will be applied. The RMT's hands will simply be resting over the contact points. This treatment will also be held for four minutes.
32975475|NCT04925986|Experimental|Group 1A: PD-L1 1-49%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
32975476|NCT04925986|Experimental|Group 1B: PD-L1 1-49%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
32975477|NCT04925986|Experimental|Group 2A: PD-L1 ≥ 50%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
32975478|NCT04925986|Experimental|Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
32975479|NCT04856436||Pregnant women with exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).
32975480|NCT04856436||Pregnant women without exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester
32975481|NCT04853212|Active Comparator|SPA patient|Patients with SPA
32975482|NCT04853212|Sham Comparator|Subject without SPA|Health subjects without SPA, planned to undergo a digestive endoscopy.
32975483|NCT04695054|Experimental|Buzzy and EMLA Cream|In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.
32975484|NCT04695054|Active Comparator|EMLA Cream|In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure
32975485|NCT04685902||Adult patients with tracheostomy|Adult patients who currently have a tracheostomy and receive an order for one-way speaking valve trial
32975486|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
32975487|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
32975488|NCT04604353|Experimental|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
32975489|NCT04604353|Active Comparator|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
32975490|NCT04600674|Experimental|delayed cord clamping|DCC performed at 60 sec after birth
32975491|NCT04600674|Experimental|early cord clamping|ECC performed at 15 sec after birth
32975492|NCT04598087|Experimental|Prehabilitation|- Tailored exercise prescription involving aerobic and resistance training, supported by a clinical exercise physiologist.
32975493|NCT04593784|Experimental|Cohort 1|Subjects receive 60 mg edoxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 3 hours after administering edoxaban, study drug (ciraparantag or placebo) will be intravenously administered.
32975494|NCT04593784|Experimental|Cohort 2|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
32975495|NCT04593784|Experimental|Cohort 3|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
32975496|NCT04576910|Experimental|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
32975497|NCT04576910|Experimental|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
33033115|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
33033116|NCT01959659||Cohort|
32975498|NCT04576910|Experimental|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
32975499|NCT04576910|Experimental|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
32975500|NCT04576910|Experimental|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
32975501|NCT04574089|Experimental|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
32975502|NCT04574089|Experimental|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
32975503|NCT04503603|Experimental|Lanadelumab 300 mg|Participants will receive single dose of lanadelumab 300 mg intravenous (IV) infusion on Day 1 followed by second dose on Day 4.
32975504|NCT04503603|Placebo Comparator|Placebo|Participant will receive single dose of lanadelumab matching placebo (normal saline) IV infusion on Day 1 followed by second dose on Day 4.
32975505|NCT04500756|Active Comparator|Metformin group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
32975506|NCT04500756|Placebo Comparator|Placebo Group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
32975507|NCT04500366|Active Comparator|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
32975508|NCT04500366|Experimental|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
32975509|NCT04472416|No Intervention|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
32975510|NCT04472416|Experimental|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
32975511|NCT04466540|Experimental|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
32975512|NCT04466540|Placebo Comparator|Placebo|The placebo group will follow the same regimen of administration
32975513|NCT04454918|Experimental|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
32975514|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
32975515|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
32975516|NCT04415333|Experimental|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
32975517|NCT04415333|Experimental|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
32975518|NCT04415333|No Intervention|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
32975519|NCT04366336|Experimental|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.~BFRT involves placing the pressure cuff before the start of therapeutic exercises.~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
33033117|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
33033118|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
32739112|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
32739113|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
32739114|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
32975520|NCT04366336|Active Comparator|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
32975521|NCT04364867|Experimental|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
32975522|NCT04364867|Active Comparator|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
32975524|NCT04347343|Experimental|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
32975525|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
32975526|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
32975527|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
32975528|NCT04333888|Experimental|Treatment|
32975529|NCT04333888|No Intervention|Control|
32975530|NCT04283071||Patient|Progressive MS patients administered clinical examination measures including EDSS, nine-hole PEG test, patient reported outcomes measures and kinematic assessment of upper limb function
32975531|NCT04283071||Control|Healthy volunteers administered nine-hole PEG test and kinematic assessment of upper limb function
32975532|NCT04233814|Sham Comparator|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
32975533|NCT04233814|Experimental|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
32975534|NCT04233814|Experimental|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
32975535|NCT04233814|Experimental|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
32975536|NCT04233814|Experimental|MAD Cohort 1|LTI-03 dose at 20mg once daily x 14 days via DPI
32975537|NCT04233814|Experimental|MAD Cohort 2|LTI-03 dose at 40mg once daily x 14 days via DPI
32975538|NCT04233814|Experimental|MAD Cohort 3|LTI-03 dose at 2.5 mg once daily x 14 days via DPI
32975539|NCT04233814|Experimental|MAD Cohort 4|LTI-03 dose at 5 mg once daily x 14 days via DPI
32739115|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
32975540|NCT04233814|Experimental|MAD Cohort 5|LTI-03 dose at 5 mg twice daily x 14 days via DPI
32975541|NCT04232059|Active Comparator|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
32975542|NCT04232059|Active Comparator|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
32975543|NCT04212286|Experimental|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
32975544|NCT04155216|Experimental|Guided imagery|Relaxation and guided imagery program
32975545|NCT04093596|Experimental|ALLO-647, ALLO-715, Nirogacestat|
32975546|NCT04068012|Experimental|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
32975547|NCT04023162|Experimental|Biomedical (Physiotherapy) group|Therapy Exercise and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
32975548|NCT04023162|Experimental|Biopsychosocial (Graded Activity) group|Operant Conditioning implement in Physiotherapy, Therapy Exercises and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
32975549|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapy Exercise and Back School for self-care.
32975550|NCT04002388|Experimental|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
32975551|NCT04002388|Active Comparator|Usual Care Group|The usual care group will NOT receive a FitBit
32975552|NCT03993821|Experimental|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
32975553|NCT03964545|Experimental|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
32862220|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
32862221|NCT04932876||ESKD - HD|End Stage Kidney Disease on Long Term Dialysis
32862222|NCT04932876||KTR|Kidney Transplant Recipient
32862223|NCT04351347|Experimental|Ivermectin|Ivermectin alone in larger doses
32862224|NCT04351347|No Intervention|Standard treatment|Standard of care treatment
32862225|NCT04391101|Experimental|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
32862226|NCT04391101|No Intervention|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
32862227|NCT04932564|Experimental|Leflunomide Arm|Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
32862228|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
32862229|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
32862230|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
32862231|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
32862232|NCT04932720|Experimental|experimental group|Experimental group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
32862233|NCT04932720|No Intervention|control group|Also the control group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
32862234|NCT04898673|Experimental|CP1110 Sound Processor|
32862235|NCT04898673|Active Comparator|CP1000 Sound Processor.|
32862236|NCT04932330||ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60 when discharged.
32862237|NCT04932330||no ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
32862238|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
32862239|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
32862240|NCT04921566|Other|Sequence TR|13 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32862241|NCT04921566|Other|Sequence RT|13 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
32862242|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
32862243|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
32862244|NCT04821531|Experimental|PT Pal|Experimental Arm-PT PAL Participants randomized into this arm will receive exercise instructions via Pt_PAL. PT PAL is a mobile health technology used to facilitate communications between Care teams and patients, by allowing the team to send web-based exercise routines, surveys and educational materials. The PT Pal app captures patient activity adherence and reports
32862245|NCT04821531|Active Comparator|Exercise Manual|Control Arm- Exercise Manual Participants randomized into this arm will use the exercise manual to obtain their exercise instructions
32862246|NCT02622828|Other|Behavioural|Participant-identified community based activity
32862247|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
32862248|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
32862249|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
32862250|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
32862251|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
32862252|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
32975554|NCT03964545|No Intervention|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
32975555|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
32975556|NCT03735849|No Intervention|Pre-treatment|Biopsy collected but was not randomized to any treatment group
32975557|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
32975558|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
32975559|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
32975560|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
32975561|NCT03691857|Other|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
32975562|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
32975563|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
32975564|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
32975565|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
32975566|NCT03572621|Other|Partner|Patient's partner.
32975567|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
32975568|NCT03552393|Experimental|Mircera|Mircera will be administered subcutaneously once every 4 weeks
32975569|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
32975570|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
32975571|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
32975572|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
32975573|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
32975574|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
32975575|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
33033119|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
32975576|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
32739116|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
32975577|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
32975578|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
32975579|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
32975580|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
32975581|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
32975582|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
32975583|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
32975584|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
32975585|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
32975586|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
32975587|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
32975588|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
32975589|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
32975590|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
32975591|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
32975592|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
32975593|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
32975594|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
32975595|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
32975596|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
32975597|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
32975598|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
32975599|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
32975600|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
32975601|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
32975602|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
32975603|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
32975604|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
32975605|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
32975606|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
32975607|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
32739117|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
32975608|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
32975609|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
32975610|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
32975611|NCT02801136|Experimental|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
32975612|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
32975613|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
32975614|NCT02798588|Experimental|Comatose patients in ICU|
32975615|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
32975616|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
32975617|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
33322750|NCT05193292|Experimental|Camrelizumab combined with trastuzumab and chemotherapy|Camrelizumab: 200mg, iv, 21d for a treatment cycle Trastuzumab: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle Chemotherapy will either be XELOX, mFOLFOX6, FOLFIRI, mXELIRI or mIRIS
33322751|NCT03943056|Experimental|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
33322752|NCT03943056|Experimental|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
33322753|NCT03943056|Experimental|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
33322754|NCT03943056|Experimental|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
32739118|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
32975618|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
32975619|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
32975620|NCT02607956|Experimental|B/F/TAF|B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.
32975621|NCT02607956|Active Comparator|DTG + F/TAF|DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.
32975622|NCT02607956|Experimental|Open-label Phase B/F/TAF from B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
32975623|NCT02607956|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
33033120|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
33322755|NCT03943056|Experimental|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
33322756|NCT03943056|Experimental|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
33322757|NCT03943056|Experimental|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
33322758|NCT03943056|Experimental|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
32975624|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
32975625|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
32975626|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
32975627|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
32975628|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
32975629|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
32975630|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
32975631|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
32975632|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32975633|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
32975634|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32975635|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
32975636|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
32975637|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
32975638|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
32975639|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
32975640|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
32975641|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
33411224|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
32975642|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
32975643|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
32975644|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
32975645|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
32975646|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
33411225|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
32975647|NCT01447628|Active Comparator|Ferinject or CosmoFer followed by Placebo|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours~IV Iron given at Week 0, Placebo (saline) given at Week 12."
32975648|NCT01447628|Placebo Comparator|Placebo followed by Ferinject or CosmoFer|"Placebo comparator~Placebo (saline) given at Week 0, IV Iron given at Week 12."
32975649|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
32975650|NCT01072084||Patients with food allergy|
32975651|NCT01072084||Healthy subjects|
32975652|NCT00744484|Experimental|B1|B1 - training in water
32975653|NCT00744484|Experimental|S1|S1 - training on land
32975654|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
32975655|NCT00515853|Experimental|Biofeedback|Received feedback
32975656|NCT00515853|No Intervention|No biofeedback|Did not received feedback
32975657|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
32975658|NCT00003458|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
32975659|NCT05274724|Active Comparator|Standard institutional protocol, without teleconsultation.|standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty.
32975660|NCT05274724|Active Comparator|Teleconsultation during the ambulance journey to the place of care.|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
32975661|NCT05274685|Experimental|covid positive with acute kidney injury receiving early renal replacement|
32975662|NCT05274685|Experimental|covid positive with acute kidney injury under conservative management|
32975663|NCT05274568|Experimental|[18F]UCB-2897|"Administration of Investigational Agent:~Study center personnel will administer [18F]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of [18F]UCB-2897. [18F]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures."
32975664|NCT05274490||copd patients with covid infection|
32975665|NCT05274490||non-copd patients with covid infection|
32975666|NCT05274438|Experimental|JS001+Imatinib Mesylate|Imatinib: 400mg qd po. Toripalimab: 240mg q3w ivgtt. The longest cumulative use period of the two drugs was 2 years.
33411226|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
33411227|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
32975669|NCT05274386|Other|Averaging time 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
32975670|NCT05274386|Other|Averaging time 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
32975671|NCT05274386|Other|Averaging time 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
32975672|NCT05274360|Experimental|Experimental Group|Mobile evidence-based aphasia therapy
32975673|NCT05274360|Active Comparator|Control Group|Conventional aphasia therapy
32975674|NCT05274256|Other|patients with missing teeth in maxillary aesthetic zone|
32975675|NCT05274191|Experimental|A single arm, open-label Phase II clinical study.|"All subjects enrolled will receive the following treatment：Pyrotinib±standard treatment.~Pyrotinib 400 mg/ D (once a day, at the same time each day) until the progression of disease; Chemotherapy regimens follow the programme cycle recommended by the guidelines or as determined by the investigator.~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
33033121|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
33033122|NCT01959750|Experimental|Intervention Group|
32975676|NCT05274139|Experimental|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt, temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
32975677|NCT05274139|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
32975678|NCT05274113|Active Comparator|Group 1: Block with Ropivacaine + Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
32975679|NCT05274113|Active Comparator|Group 2: Ropivacaine Block + IV Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously
32975680|NCT05274100|Experimental|Group 1: Risankizumab Dose A|Participants will receive risankizumab dose A.
32975681|NCT05274100|Experimental|Group 2: Risankizumab Dose B|Participants will receive risankizumab dose B.
32975682|NCT05274100|Experimental|Group 3: Risankizumab Dose C|Participants will receive risankizumab dose C.
32975683|NCT05274100|Experimental|Group 4: Risankizumab Dose D|Participants will receive risankizumab dose D.
32975684|NCT05274100|Experimental|Group 5: Risankizumab Dose D|Participants will receive risankizumab dose D.
32975685|NCT05274087|Experimental|Group 1|Participants will receive Regimen A (15-minute autoinjector (AI) warm-up time) in Period 1, Regimen B (30-minute AI warm-up time) in Period 2 followed by Regimen C (45-minute AI warm-up time) in Period 3.
32975686|NCT05274087|Experimental|Group 2|Participants will receive Regimen B in Period 1, Regimen C in Period 2 followed by Regimen A in Period 3.
32975687|NCT05274087|Experimental|Group 3|Participants will receive Regimen C in Period 1, Regimen A in Period 2 followed by Regimen B in Period 3.
32975688|NCT05273957|Experimental|Case Manager|Patients are followed up by a case manager
32975689|NCT05273957|Active Comparator|Standard-of-care|Patients are followed up only by the neurologist
32975690|NCT05273944|Active Comparator|Reference product-R|Caelyx® (Janssen-Cilag International NV); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Reference Product (Caelyx®) in Cycle 1, will receive the Test Product (Lipodox®) in Cycle 2. Cycle is defined as 28-42 days (RT).
32975691|NCT05273944|Experimental|Test Product-T|Lipodox® (Sun Pharmaceutical Industries Ltd.); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Test Product (Lipodox®) in Cycle 1, will receive the Reference Product (Caelyx®) in Cycle 2. Cycle is defined as 28-42 days (TR).
32975692|NCT05273866|Experimental|Virtual reality|Virtual reality video application
32975693|NCT05273866|No Intervention|control group|control group
32975694|NCT05273853|Other|Patients with high risk of hypernasality|In 1958, Gibb indicated an incidence of hypernasality (escape of air from nose as in patients with cleft palate) postadenoidectomy in approximately 1of 2000 cases. Closure pattern of velopharyngeal valve in children is veloadenoidal rather than velopharyngeal closure. Adenoid tissue is vital to velopharyngeal closure in children and its removal necessitates a change in the closure pattern of velopharyngeal valving. These changes are easily overcome if there is no anatomic abnormality
32975695|NCT05273801|No Intervention|Clinician Arm (period 1) - behavior prior to HR intervention|The investigators will monitor baseline behavior of providers in regards to sessions and how frequently heart rate (HR), rating of perceived exertion (RPE) and intensity is monitored and subsequent sessions are performed/modified through observation.
33411228|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
32975696|NCT05273801|Active Comparator|Clinician arm (period 2) & Patient arm (control - HR monitor, no feedback)|Participants will receive 1 week of HR monitoring in their group sessions where visual feedback is not provided during group session. The investigators will monitor overall HR response, mean HR and time in target HR zone, RPE and clinician behavior to HR monitor on patient during these sessions.
32975697|NCT05273801|Experimental|Clinician arm (period 3) & Patient arm (active - HR monitor, with feedback)|The same participants will receive 1 week of HR monitoring with visual feedback during group sessions. The investigators will monitor overall HR response, mean time HR and time in target zone, RPE, and clinician behavior to HR monitoring with visual feedback.
32975698|NCT05273528|Experimental|V-01-351/V-01D bivalence vaccine|
32975699|NCT05273424||no groups|A cohort of CKD patients on hemodialysis
32975700|NCT05273398|Experimental|Treatment|Single arm of treatment
32975701|NCT05273372|Experimental|Oxaloacetate|500 mg anhydrous enol-oxaloacetate in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
32975702|NCT05273372|Placebo Comparator|Placebo|500 mg white rice flour in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
32975703|NCT05273333|Other|Ultra-gyn®|ovule
32975704|NCT05273294|Experimental|Ultrasound group|Anesthesiologist will convenient color ultrasound high frequency 12MHZ array probe perpendicular to the neck, by the glottal down, until the thyroid isthmus, and ring cartilage level, ring cartilage level diameter by ultrasound, to avoid the effect of inspiration and breath on airway diameter, measurement timing should choose after anesthesia induction, mask pressure gas 1min, suspended pressure ventilation for 5s, ultrasonic measurement time is not more than 10s.Repeated measurements were averaged three times, and the maximum outer diameter of the catheter was selected, that is, the maximum outer diameter was selected closest to the measured value.
33033123|NCT01959750|No Intervention|Control Group|
33033124|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
32975705|NCT05273294|No Intervention|Control group|tracheal catheter models are usually selected through traditional experience, according to the age formula in Clinical Anesthesiology, People's Health Press (i. e., 2.5 for preterm infants, 3.5 at 1-6 months, 4.0 at 6-12 months).
32975706|NCT05273229|Experimental|Virtual Gait and Physical Exercise|"Virtual Gait and Physical Exercise Virtual Gait The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.~Physical Exercise Specific gait exercise was conducted."
32975707|NCT05273229|Sham Comparator|Documental projection and Physical Exercise|"Physical Exercise Specific gait exercise was conducted.~Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed."
32975708|NCT05273229|Experimental|Virtual Gait|only the virtual gait program will be carried out, detailed in Arm I.
32975709|NCT05273229|Sham Comparator|Virtual Gait Sham|Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
32975712|NCT05273073|Active Comparator|Probiotics group|83 participants received probiotics for 12-week
32975713|NCT05273073|Placebo Comparator|Placebo group|83 participants received placebo for 12-week
32975714|NCT05273021||participants with substance use problems|"There are 2 subgroups:~Participants without intellectual disabilities~Participants with intellectual disabilities with and without severe mental illness"
32975715|NCT05272982||Successful weaning group|Criteria of weaning included resolution of the primary cause of intubation, adequate cough without excessive tracheobronchial secretions, PaO2 > 60 mmHg with positive end-expiratory pressure ≤ 8 cmH2O, fraction of inspired oxygen ≤ 0.4, respiratory rate < 30 per minute, appropriate pH for patients' baseline respiratory status, and stable cardiovascular status.
32975716|NCT05272982||Failed weaning group|Weaning failure will be defined as a patient need for reintubation or noninvasive ventilation within 48 h after extubation due to the presence of one or more of the following criteria: altered mental status tachypnea (respiratory rate more than 35 breaths per minute), oxygen saturation less than 90% or PaO2 less than 60 mmHg on a fraction of inspired oxygen of 40%, an apparent increase in accessory respiratory muscle activity, evident facial signs of respiratory distress and hemodynamic instability (Heart rate >140 b/min, systolic blood pressure >180 or < 90mmHg )
32975717|NCT05272904|Active Comparator|Conventional closure method|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
32975718|NCT05272904|Experimental|Quilting|The implemented intervention is the quilting suture technique. The subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin. No wound drain is placed.
32975719|NCT05272839|Experimental|Hypoglycemic food group|The patient will choose 2 food products clinically validated against diabetes, at the same dosage and the same mode of preparation as in the reference clinical trials. This will be done additionally to healthcare advice and standard medication if any.
32975720|NCT05272839|Placebo Comparator|Control group|The control group will receive only dietary advice and standard medication if any.
32975721|NCT05272813|Experimental|MS-553 Low Dose|MS-553 Low Dose PO BID
32975722|NCT05272813|Experimental|MS-553 Mid Dose-1|MS-553 Mid Dose-1 PO BID
32975723|NCT05272813|Experimental|MS-553 Mid Dose-2|MS-553 Mid Dose-2 PO BID
32975724|NCT05272813|Experimental|MS-553 High Dose|MS-553 High Dose PO BID
32975725|NCT05272709|Experimental|Cohort 1M (Monotherapy dose escalation cohort)|This cohort will recruit patients with solid tumours.
32975726|NCT05272709|Experimental|Cohort 2M: mCRPC (Monotherapy expansion cohort)|This cohort will recruit patients with mCRPC only.
32739119|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
32975727|NCT05272709|Experimental|Cohort 2M: MSI/MMR defective tumours (Monotherapy expansion cohort)|This cohort will recruit patients with MSI/MMR defective tumours only.
32975728|NCT05272709|Experimental|Cohort 2M: TNBC (Monotherapy expansion cohort)|This cohort will recruit patients with TNBC only.
32975729|NCT05272540||Day case surgery|Adult patients who are operated on as outpatients in day surgery. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before and after the surgery is added.
32975730|NCT05272540||In patient surgery|Adult patients who are operated on as inpatients in hospital care. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before the surgery and every morning during hospital stay is added.
32975731|NCT05272501|Experimental|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
32975732|NCT05272501|No Intervention|Usual care|The usual care group may participate in usual activities at the nursing home e.g. physio- and occupational therapy, listening to calming music, holdning hands with care-takers.
32975733|NCT05272462|Experimental|Treatment|Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
32975734|NCT05272449|Experimental|Evaluation of a disposable sound sensor for recording respiration during sleep|PneaVoX sensor, CIDELEC
33033125|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
33033126|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
33033127|NCT01959776|Other|Vitrectomy|
32975735|NCT05272436|Experimental|Patients IVR for Upper Limb Motor Impairment Rehabilitation in children and at home trial|"For the purpose of the trial, patients had their usual OT/PT appointments but were asked to use the IVR games to do the prescribed home exercises. Before consenting to participate, each patient was offered a 5-10 minute experience of the game to familiarise themselves with how it worked and to check for problems. Written and verbal consents were taken from parents and children.~The pre-trial PedsQL was administered in the initial OT/PT appointment. Children were then asked to use the IVR system for approximately 15 minutes twice a day. Trial participation lasted three weeks during the prescribed treatment weeks.~Following the at-home trial, patients and parents returned the equipment to the clinic in the final appointment and the SUS and the post-trial Peds QL were administrated by OT/PT in person. In addition, they participated in semi-structured interviews as described above."
32975736|NCT05272436|Other|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
32975737|NCT05272410||cases|Patients colonized or infected with CPE
32975738|NCT05272410||controls|Patients not colonized or infected with CPE
32975739|NCT05272371|Experimental|Intervention arm|Chemoimmunotherapy arm.
32975740|NCT05272358||strategy 1: sarcoma MDTB before surgery and initial management in the NETSARC network|Patients who had a sarcoma-specialized multidisciplinary tumour board (MDTB) before the initial surgery and complete initial management (including surgery) in the network (also including patients who had a sarcoma-specialized MDTB after the initial surgery and complete initial management in the network) (strategy 1)
32975741|NCT05272358||strategy 2: sarcoma MDTB before surgery and initial management outside the NETSARC network|Patients who had a sarcoma-specialized MDTB before the initial surgery and initial management (including surgery) outside the network (strategy 2)
32975742|NCT05272358||strategy 3: sarcoma MDTB after surgery and initial management outside the NETSARC network|Patients who had initial management (including surgery) outside the network and a sarcoma-specialized MDTB after initial surgery (strategy 3)
32975743|NCT05272358||strategy 4: No sarcoma MDTB and initial management outside the NETSARC network|Patients who had an initial management (including surgery) outside the network, without sarcoma-specialized MDTB neither before nor after the initial surgery (strategy 4).
32975744|NCT05272215||Patient group|"Pre-BaS: Patients administered for BaS, Department of Endocrinology either Odense University Hospital, Odense, Denmark or Hospital of Southwest Jutland, Esbjerg, Denmark~Post-BaS: (3, 6, 12 months postoperatively, then yearly) Department of Surgery, Southwest Jutland, Esbjerg, Denmark~Pre-BC: Patients administered for BC, Department of Plastic Surgery, Odense University Hospital, Odense, Denmark or Department of Plastic Surgery, Southwest Jutland, Esbjerg, Denmark.~Post-BC: (3, 6, 12 months postoperatively, then yearly), department of Plastic Surgery, Odense University Hospital; Hospital of Southwest Jutland, Esbjerg.~Normative group: Reference scores of the general population from an international sample of 10 countries and country specific scores. This study sample is submitted for publication elsewhere."
32975745|NCT05272189|Experimental|Experiment|All participants are tested in all conditions of this experiment.
32975746|NCT05272163|Experimental|Main Experiment|This is a single arm study where all participants are tested on 1-2 hours of visual search.
32975747|NCT05272137||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
32975748|NCT05272124|Experimental|Hip Abductor Strengthening|This group received quadriceps and hip abductor strengthening along with patellar mobilization and stretching exercises.
32975749|NCT05272124|Active Comparator|Traditional Physical Therapy|This group received quadriceps strengthening along with patellar mobilization and stretching exercises.
32975750|NCT05272020|Other|TAVI|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment
32975751|NCT05272020|Other|AVR|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment, Myocardial + aortic valve biopsy
32975752|NCT05271981||Female who underwent uterine artery embolisation for uterine pathology|
32975753|NCT05271968|No Intervention|Control|Standard Care : The classic treatment recommended is the prescription of an oral drug, Ivermectin to be taken two times at one or 2 weeks interval. And recommendations on the need to change the clothes and the linen of the bedding the following day after taking the drug, washing them at more than 50° as well as all the clothes three days before are explained. The first course of oral treatment is swallowed at the BOPC, while the second course is given to be swallowed one week later.
32975754|NCT05271968|Experimental|Intervention|Patients in this interventional arm will come back to BOPC the following day after intake the treatment (D1 and D8) to take a shower and to receive again new clothes
32975755|NCT05271942|Experimental|Tilt and Tumble|"The patients of this group will undergo cataract surgery using the Tilt and Tumble technique."
32975756|NCT05271942|Active Comparator|Divide and Conquer|"The patients of this group will undergo cataract surgery using the Divide and Conquer technique."
32975757|NCT05271916|Experimental|Combined treatment group|Dacomitinib+Anlotinib: Patients will be treated with combined Dacomitinib and Anlotinib.
32975758|NCT05271916|Active Comparator|Dacomitinib monotherapy group|Dacomitinib: Patients will be treated with Dacomitinib.
32975759|NCT05271877||Pregnant women|Pregnant women, regardless of the gestational age.
32975760|NCT05271838|Experimental|High protein diet|High protein diet (2/g/kg/day)
32975761|NCT05271838|No Intervention|Standard Nutritional care|Standard nutritional care.
32975762|NCT05271838|Experimental|Magnesium|Magnesium oral supplementation
32975763|NCT05271838|No Intervention|Standard: No magnesium supplementation|No supplementation
32975764|NCT05271812||Mothers|All women delivered in the recruitment center
32975765|NCT05271812||Staff|All staff working in the labor and delivery areas of the recruiting center.
32975766|NCT05271786||Tracheostomized patients|Patients who underwent percutaneous tracheostomy performed for any reason
32975767|NCT05271760||S group|Single-shot Spinal group
32975768|NCT05271760||E group|Continuous Epidural
32975769|NCT05271760||C group|combined spinal-epidural
33033128|NCT01959789||Control|Standard treatment
32975770|NCT05271695||The patients with type 2 diabetes|"Patients with a diagnosis of Type 2 Diabetes Mellitus and HbA1c ≤ 7%~Patients using or not using oral antidiabetic drugs~Patients who inject insulin once or twice a day or repeated insulin injections"
32975771|NCT05271695||The healthy controls|"Patients diagnosed with Type I Diabetes Mellitus,~Patients with HbA1c > 7%~Those with gestational diabetes,~Breastfeeding diabetics,~Patients with renal dysfunction,~Patients with acute and chronic infection status"
32975772|NCT05271539|Active Comparator|The first group, Lucentis alone group|The first group received 3 monthly intravitreal injections of 0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis), aspirated from vial through 5-micron sterile filter needle (19-gauge × 1-1/2 inch), with a 1-mL syringe and injected through a 30-gauge × ½ inch sterile injection needle.
32975773|NCT05271539|Active Comparator|The second group, Lucentis dexamethasone group|The second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN).
32975774|NCT05271513|Active Comparator|real transcranial magnetic stimulation plus real transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds over the hand area plus 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for consecuative 10 days (5 days/week)
32975775|NCT05271513|Active Comparator|real transcranial magnetic stimulation with sham transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds plus sham stimulation 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for 10 consecutive days (5 sessions/week)
32975776|NCT05271500|Active Comparator|group(1)|40 post covid 19 patients will receive laser acupuncture
32975777|NCT05271500|Placebo Comparator|group(2)|40 post covid patients will receive placebo laser acupuncture in which laser will be off
32975778|NCT05271487|Experimental|Multi-Step Botanical Skin Care Regimen|The patient will be provided with and instructed to use a cleanser, toner, oil control cream, exfoliating facial scrub, clay mask, acne spot treatment, and body scrub for the duration of the study.
32975779|NCT05271461|Active Comparator|Circulatory exercises group .|Circulatory exercises.
32975780|NCT05271461|Experimental|LLLT group .|Low level laser Therapy + circulatory exercises.
32975781|NCT05271448|Experimental|Continue ACEI or ARBs|Randomized to continue on prescribed ACE1 or ARBs
32975782|NCT05271448|Active Comparator|Hold ACEI or ARBs|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-72 hours post)
32975783|NCT05271422|Experimental|Experimental Group|Dry eye disease patients (n=12)
32975784|NCT05271422|Sham Comparator|Control Group|Dry eye disease patients (n=12)
32975785|NCT05271396||Temporomandibular Joint Dysfunction Group|Being diagnosed with Temporomandibular Joint Dysfunction
32975786|NCT05271396||Healthy-matched Group|Being healthy according to WHO criteria
32975787|NCT05271370|Experimental|PRO 140 350 mg|PRO 140 350mg weekly SQ injection.
32975788|NCT05271370|Experimental|PRO 140 525 mg|PRO 140 525mg weekly SQ injection.
32975789|NCT05271370|Experimental|PRO 140 700 mg|PRO 140 700mg weekly SQ injection.
32975790|NCT05271253|Active Comparator|Group (C)|caudal group, where caudal anaesthesia was given using 1 mL/kg dose of 0.25% bupivacaine without epinephrine.
32975791|NCT05271253|Active Comparator|Group (D)|Dexmedetomidine (D) group, where Dex. (Precedex, hospira, Egypt) 0.8 μg/kg was given intravenously over 10 min as a loading dose, and then infused at a rate of 0.4 μg/kg/h
32975792|NCT05271253|Placebo Comparator|Group (P)|Placebo (P) group, where normal saline instead of Dex was given in volume (ml) and rate (ml/h) calculated related to the patient's body weight.
32975793|NCT05271227||Cardiogenic Shock Patients|"Cardiac output and Carotid Blood flow is measured before & after PLR test, then percent change is calculated were increase in cardiac output with 10 % or more is considered volume responder.~Measurements can be repeated as needed, and fluid resuscitation continues until no further response to passive leg raising is noted."
32975794|NCT05271201|Experimental|mild intensity group|Received mild intensity treadmill training according to Martti Karvonen's formula.
32975795|NCT05271201|Experimental|moderate intensity group|Received moderate intensity treadmill training according to Martti Karvonen's formula.
32975796|NCT05271188|Active Comparator|Group 1 who will receive IPACK block|This group of patients will receive IPACK block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
32975797|NCT05271188|Active Comparator|Group 2 who will receive adductor canal block|This group of patients will receive adductor canal block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
32975798|NCT05271149|Other|Control group|conventional physical therapy based on neurodevelopmental techniques, This program will be given for 1 hour, 3 days a week for 12 weeks
32975799|NCT05271149|Experimental|study group|conventional physical therapy and orthosis (Thera togs) : the child will wear the orthosis for twelve weeks, from 8 to 10 hours a day, during daily-life activities. The child's guardian (mother) will be trained and will receive a DVD recording, with a step-by-step demonstration on the fitting of TheraTogs® in the child. Markings were made in TheraTogs® to facilitate and improve fitting. All necessary support will be offered, with weekly monitoring in person to control the fitting of the orthosis, as well as for possible questions or clarifications.in addition to conventional physical therapy as the control group
32975800|NCT05271136|Active Comparator|Cell 1: Anti-aging Serum|"Dosage form: Anti-aging Serum~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum.~Study Duration: 7 days"
32975801|NCT05271136|Active Comparator|Cell 2: Anti-aging Serum and Facial Moisturizer|"Dosage form: Anti-aging Serum and Facial Moisturizer~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum, and then 2 pumps of the Facial Moisturizer to the global face.~Study Duration: 7 days"
32975802|NCT05271123||Study group|Children were evaluated using spirometer to assess forced expiratory volume at first second and peak expiratory flow and gross motor function classification system to assess the functional level.
33411229|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
33411230|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
33411231|NCT03614000|Experimental|positive screenings|
33411232|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
33411233|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
33411234|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
33411235|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
33411236|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
33411237|NCT02032082|No Intervention|Ex vivo without CO|
33411238|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
33411239|NCT04057170|Experimental|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
33411240|NCT04057170|Experimental|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
33411241|NCT03615638|Experimental|Fall prevention group|Fall prevention program
33411242|NCT03615638|No Intervention|Usual care group|Usual postoperative care
33411243|NCT03615638|No Intervention|Asymptomatic control|No intervention
33411244|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
33411245|NCT03615560||Preeclampsia (mild)|
33411246|NCT03615560||Preeclampsia (severe)|
33411247|NCT03615560||Gestational hypertension|
33411248|NCT03615560||Control group|
33411249|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
33411250|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
33411251|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT), a remotely delivered tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are interactive with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist support.
33411252|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
32975803|NCT05271110|Experimental|Treatment cohort|Adult patients (ECOG 0-1) with a resectable (or previously resected) PDAC and either synchronous or metachronous liver metastases are the target population of this study.
32975804|NCT05271058|Sham Comparator|Control group 1|23 eyes that did not receive any intraoperative steroids
32975805|NCT05271058|Active Comparator|Dexamethasone group 2|23 eyes that received intracameral dexamethasone
33411253|NCT03231371|Experimental|Study Arm|
33411254|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
33411255|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
33411256|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
33411257|NCT04057092|Experimental|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
32975806|NCT05271058|Active Comparator|Triamcinolone (TA) group 3|23 eyes that received intracameral triamcinolone (TA)
32975807|NCT05271045|Experimental|fortified canola oil with vitamins A and D and γ-oryzanol|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g & 2130 ppm γ-oryzanol/30g)
33322759|NCT05193214|Experimental|609A UPS|The 609A single-drug regimen (200mg Q3W) was used to treat unresectable or advanced undifferentiated pleomorphic sarcoma to evaluate the safety and effectiveness of 609A.
32975808|NCT05271045|Active Comparator|fortified canola oil with vitamins A and D|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
32975809|NCT05271045|Placebo Comparator|fortified sunflower oil with vitamins A and D|daily intake of fortified sunflower oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
32975810|NCT05270954|Active Comparator|Group 1 (Phase 1)|All volunteers randomized to Group 1 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
32975811|NCT05270954|Active Comparator|Group 2 (Phase 1)|All volunteers randomized to Group 2 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
32975812|NCT05270954|Active Comparator|Group 3 (Phase 2)|All volunteers randomized to Group 3 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
32975813|NCT05270954|Active Comparator|Group 4 (Phase 2)|All volunteers randomized to Group 4 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
32975814|NCT05270954|Placebo Comparator|Group 5 (Phase 2)|Volunteers randomized to Group 5 will be administered a placebo reference drug (0.9% aqueous sodium chloride solution), twice, within a 28-day period.
32975815|NCT05270941|Active Comparator|Control Groups|"Control groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups"
32975816|NCT05270941|Experimental|Test Group|"Test groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups Intervention: Procedure: test groups"
32975817|NCT05270915|Experimental|Family supportive EOLC|The intervention 'family supportive EOLC' was developed based on the international guidelines of family-centered care (25) with additional aspects of care and support. The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
33322760|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
33322761|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
33322762|NCT02529774|Active Comparator|Systemic Chemotherapy|
33322763|NCT04459598|Experimental|Efavirenz 600 mg + Quizartinib 60 mg|Participants who received efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg on Day 15 concurrently with efavirenz.
33322764|NCT04459598|Active Comparator|Quizartinib 60 mg|Participants who received a single, oral dose of quizartinib 60 mg on Day 1.
33322765|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
33322766|NCT05167006|Experimental|Group A:|Participants will be treated with routine physical therapy for 20 minutes, five days a week for 12th weeks. Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation.
33322767|NCT05167006|Active Comparator|Group B|The participants will be treated with Perfetti's method and routine physical therapy for 35 minutes, five times a week for 12th weeks. Each participant will receive his/her arms training therapy.
33322768|NCT01114230|Experimental|Dose Level 1|
33322769|NCT01114230|Experimental|Dose Level 2|
33033129|NCT01959789||2 days|bleaching treatments made in 2 days
33033130|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
33104956|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
33322770|NCT01114230|Experimental|Dose Level 3|
33322771|NCT01114230|Experimental|Dose Level 4|
33322772|NCT01114230|Experimental|Dose Level 5|
33322773|NCT01114230|Experimental|Dose Level 6|
33322774|NCT01114230|Experimental|Dose Level 7|
33104957|NCT02302742||Triple Negative Breast Cancer patients|No intervention
33104958|NCT02302742||Germline HBOC Mutation Carriers|No intervention
33322775|NCT01114230|Experimental|Dose Level 8|
33322776|NCT01114230|Experimental|Dose Level 9|
33322777|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
33322778|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
33322779|NCT03942354|Experimental|Intervention arm|A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
32975818|NCT05270915|Active Comparator|The standard EOLC|The standard EOLC included the international guidance of palliative care and EOLC in neonatology (21-23). In China, parents are often the decision-makers of their infant's treatment and the NICU clinicians usually respect the parent's decision (24). After parents have decided to withdraw treatment, standard EOLC is initiated and includes monitoring of vital signs and withholding or withdrawing rescue procedures such as intubation and intravenous infusion. Unnecessary lines are removed and pain management is provided by analgesia. Comfort care is provided by nurses including basic care such as skin care and oral care. After the infant died, the NICU physician informs the parents by phone.
32975819|NCT05270889|Experimental|Tislelizumab+Zanidatamab|
32975820|NCT05270824|Experimental|radical surgery after neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)|After randomization, patients received radical surgery after the neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)
32975821|NCT05270824|Active Comparator|radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)|After randomization, patients received radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)
32975822|NCT05270772|Experimental|CAR-T-19 Cells|The patients with CD19+ relapse or refractory B-ALL will receive a single infusion of autologous CAR-T-19 cells, with the escalated dose ranging from 0.5×10^6/kg to 5.0×10^6/kg CAR+ cells.
32975823|NCT05270720|Experimental|experimental group|This arm will evaluate the safety of administering a total dendritic cell dose of 5x106. A total of 3 to 6 patients will be enrolled. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
32975824|NCT05270681|Experimental|Individuals with HD|Participants with a confirmed diagnosis of Huntington's disease
32975825|NCT05270681|Experimental|Care Partners|Participants' care partners
32975826|NCT05270642|Experimental|HCC patients guided by Plan for Microwave Thermal Field|The plan for HCC patients undergoing microwave ablation would be refer to Plan for Microwave Thermal Field system
32975827|NCT05270629||Lower limb lymphedema patients|This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled.
32975828|NCT05270616|Experimental|robotic surgery group|minimally invasive lung surgery using the Davinci robotic system to assist.
32975829|NCT05270616|Active Comparator|uniport surgery group|VATS minimally invasive lung surgery under the uniportal status.
32975830|NCT05270616|Active Comparator|multiple- port surgery group|VATS minimally invasive lung surgery under the multiple- port status.
32975831|NCT05270590||group A|periareolar approach
32975832|NCT05270590||group B|submamary approach
32975833|NCT05270577|Experimental|Prehabilitation|Prehabilitation with physical exercise, psychological support, nutritional support and smoking/alchohol stop
32975834|NCT05270577|Active Comparator|Standard care|Standard preoperative recomendations
32975835|NCT05270564|Active Comparator|Drain|Surgical drains used as routine
32975836|NCT05270564|Experimental|No drain|No surgical drain used
33322780|NCT03942354|Active Comparator|Standard therapy|72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
32975837|NCT05270551|Active Comparator|Group 1|Without augmentation
32975838|NCT05270551|Active Comparator|Group 2|With augmentation
32975839|NCT05270538|Active Comparator|comparison of clinical and gasometric parameters between the study group and the control group|"To carry out the study, we defined a control group and a study group distributing them between the two groups. The control group will perform the exercise, without using a mask, while the study group will perform the exercise using Masks Zero Mask Sewing Virus Bac-Off Lupo® for the duration of the exercise.~The exercise consisted of 15 minutes of treadmill without inclination interspersing every 2 minutes at speeds 10 Km/h and 12 Km/h, being by definition of a dynamic aerobic exercise of intensity 4 of 5 in the Borg scale- classification of the intensity of physical exercise. Physical activity was performed in water deprivation and fasting at least 30 minutes before the start of activated."
32975840|NCT05270486||Group A|group A undergoing TELD (transforaminal endoscopic lumbar discectomy) with electromagnetic navigation system
32975841|NCT05270486||Group B|group B undergoing TELD with X-ray fluoroscopy (gold standard)
32975842|NCT05270447|Experimental|Total laparoscopic hysterectomy (TLH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
32975843|NCT05270447|Other|Total laparoscopic hysterectomy (TLH) control group|routine care+ advising
32975844|NCT05270447|Experimental|Total abdominal hysterectomy (TAH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
32975845|NCT05270447|Other|Total abdominal hysterectomy (TAH) control group|routine care+ advising
32975846|NCT05270434|Experimental|Endoscopic group <12h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
32975847|NCT05270434|Active Comparator|Endoscopic group 12-36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12-36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
33104959|NCT00546975|Experimental|1|Resource Support® Novartis
33411258|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
33104960|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
32975848|NCT05270434|Active Comparator|Endoscopic group >36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP is greater than 36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
32975849|NCT05270421|Experimental|Intervention Group|"40 mg of furosemide IV + IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
32975850|NCT05270421|Active Comparator|Control Group|"IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
32975851|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 1|A mouthwash contains cetylpyridinium chloride and pH adjuster 1.
32975852|NCT05270382|Placebo Comparator|Placebo 1|A mouthwash without cetylpyridinium chloride and pH adjuster 1
32975853|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 2|A mouthwash contains cetylpyridinium chloride and pH adjuster 2.
32975854|NCT05270382|Placebo Comparator|Placebo 2|A mouthwash without cetylpyridinium chloride and pH adjuster 2
32975855|NCT05270369|Experimental|digital cognitive behavioural therapy for insomnia (CBTI)|The digital CBTI group will receive 6-session on their smartphone application
32975856|NCT05270369|Experimental|group cognitive behavioural therapy for insomnia (CBTI)|The group CBTI will receive 6-session CBTI in group
32975857|NCT05270369|No Intervention|waitlist|The waitlist group will receive treatment sessions after about 10 weeks' time
32975858|NCT05270343|Experimental|Vitamin D|In 99 subjects of 3-18yr with newly-onset T1D, oral administration of 140IU/kg qd of cholecalciferol will be given until the serum 25(OH)D3 was maintained at the upper limit of normal range(50-80 ng/ml[125-200 nmol/L], ≤100 ng/ml[≤250 nmol/L]) for the loading peroid. And then oral administration of 70IU/kg qd of cholecalciferol for the maintenance period, meanwhile combined with intensive Insulin therapy for 12 months.
32975859|NCT05270343|No Intervention|Insulin|In 99 subjects of 3-18yr with newly-onset T1D, only intensive insulin therapy will be given for 12 months.
32975860|NCT05270252|No Intervention|Control group|no intervention
32975861|NCT05270252|Experimental|Intervention group|Interdisciplinary educational intervention with a combination of active educational methods.
32975862|NCT05270226|Experimental|Group A|After being randomly allocated, group A participants had first evaluation (out of 3, pre-intervention) and immidiatlly recived Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE).
32975863|NCT05270226|Experimental|Group B|After being randomly allocated, group B participants had first evaluation (out of 4), then waiting-phase of 10-11 weeks, and after second evaluation (pre-intervention) start Work-MATE intervention process.
32975864|NCT05270187|Experimental|Scanning Gorup|"Patients in this group will receive facial massage, facial expression exercises and a Multiwave Locked System Laser with energy density 10 J/cm2. Laser will scan the affected side after calculating the distance and the total energy delivered to the one side of the face.~The average treatment area is 50 cm2. The energy density was 10 J/cm2 with a total energy of 500 J and the treatment time is approximately 15 minutes. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles."
32975865|NCT05270187|Experimental|Point laser Group|Patients in this group will received facial massage, facial expression exercises and laser at predetermined eight points on the affected side of the facial muscles. the hand piece is positioned perpendicular to 8 points which is located on the superficial roots of the facial nerve of the affected side. Each point will receive an energy density of 10 J/point with total energy delivered to the patient during one session of 80 joules. The time of application 90 sec/point. laser is calibrated by the manufacture company before the starting the experiment and periodically during the sessions. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles.
32975866|NCT05270187|Placebo Comparator|Control Group|patients in this group will receive only facial massage, facial expression exercises and placebo laser. Facial expression exercises include active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
32975867|NCT05270161|Experimental|Test Group 1 (T1)|Multiple gingival recessions in the anterior region of the mandible treated with the tunnel technique.
32975868|NCT05270161|Experimental|Test Group 2 (T2)|Isolate gingival recessions in the anterior region of the mandible treated with the laterally closed tunnel technique.
32975869|NCT05270161|Active Comparator|Control Group 1 (C1)|Multiple gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
32975870|NCT05270161|Active Comparator|Control Group 2 (C2)|Isolate gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
32975871|NCT05270161|Experimental|Gel Group (G)|The donor area on the palate will be treated using hyaluronic acid gel and green tea applied by the participant 3 times a day for 7 days.
32975872|NCT05270161|Active Comparator|Clot Group (CO)|No material will be placed in the donor area, only the clot will be kept in position by means of sutures.
32975873|NCT05270135|No Intervention|Control|Control pharmacies will not receive the intervention training, coaching or materials. They will track the sale of syringes upon request and they will participate in the surveys.
32975874|NCT05270135|Experimental|ASAP Intervention|ASAP intervention pharmacies will receive the CEU training, coaching from research staff, ASAP materials and tracking for the sale of syringes. They will also participate in surveys.
32975875|NCT05270083|Active Comparator|Athletes with mild to moderate traumatic brain injury (mTBI) and good outcome|Young athletes who have sustained one or more concussions without persistent cognitive complaints at least one year post-injury
33104961|NCT00546975|Placebo Comparator|3|
33104962|NCT02232620|Experimental|BBI503|
32975876|NCT05270083|Active Comparator|Athletes with persistent cognitive deficits due to mild to moderate traumatic brain injury (mTBI)|Young athletes who have sustained one or more concussions with persistent cognitive complaints at least one year post-injury in spite of medical and cognitive treatment intervention.
32975877|NCT05270070||Digital Booking|Patients bookings done through digital booking system.
32975878|NCT05270070||Traditional Booking|Patients bookings done through traditional booking like telephone or secure email.
32975879|NCT05270031|Experimental|Eustachian tube dilation|Surgical Eustachian tube dilation in general anaesthesia
32975880|NCT05270031|No Intervention|Control Group|nasal saline spray
32975881|NCT05270018|Experimental|Bacterial Lysate group|Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days
32975882|NCT05270018|Placebo Comparator|Control group|Oral / gastric administration of normal saline once a day, 14.0ml each time
32975883|NCT05270005||Asymptomatic carotid artery stenosis|Patients with an asymptomatic carotid artery stenosis, defined by 30% to 69% narrowing of the carotid artery according to conventional duplex measurements in the absence of ipsilateral retinal or cerebral ischemia in the preceding 6 months.
32975884|NCT05269979|Experimental|Intervention (the Vislanda district)|435 women living in Vislanda responded to a detailed survey and participated in physical exercise and received lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
32975885|NCT05269979|No Intervention|Control (the Tingsryd/Emmaboda districts)|415 women living in Tingsryd and 395 women living in Emmaboda responded to the same detailed survey as the 435 women living in Vislanda.
32975886|NCT05269940|Experimental|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily
32975887|NCT05269940|Experimental|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily
32975888|NCT05269940|Experimental|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily
32975889|NCT05269940|Experimental|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily
32975890|NCT05269940|Experimental|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily
32975891|NCT05269927|Experimental|TD (typically developing) infants|Typically developing infants, infants without familiar risk for ASD or LD.
32975892|NCT05269927|Experimental|HR (high risk) for LD infants|Infants at high risk for language disorders
32975893|NCT05269927|Experimental|HR for ASD infants|Infants at high risk for autism spectrum disorder
32975894|NCT05269914|Experimental|Autologous anti-CD19 CAR-T cell injection|with 1.00×106 CAR+T cells/kg, 3.00×106 CAR+T cells /kg and 9.00×106 CAR+T cells/kg
32975895|NCT05269719||Digital nerve injury, surgical treatment, isolated injury|Patient over the age of 18 with an isolated injury to a digital nerve.
32975896|NCT05269719||Digital nerve injury, surgical treatment, concomittant flexor tendon injury|Patient over the age of 18 with an injury to a digital nerve and a concomittant flexor tendon injury.
32975897|NCT05269693|Experimental|the Brief Hope Intervention group|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions in-between.
32975898|NCT05269693|No Intervention|wait-listed control group|Usual community care
32975899|NCT05269654|Experimental|injectable poly-L-lactic acid|One side of the subject's hips will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
32975900|NCT05269654|Sham Comparator|Normal Saline|One side of the subject's hips will be treated with injectable normal saline
33322781|NCT05165992|Active Comparator|Nebulized Fentanyl|Intervention group (n=100): Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
33322782|NCT05165992|Placebo Comparator|Nebulized 0.9% Saline Solution|Control group (n=100): Administration of nebulized 0.9% saline solution (5 ml of normal saline), over 15 minutes, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
32975901|NCT05269641|Experimental|Almonds|Daily consumption of almonds.
32975902|NCT05269641|Placebo Comparator|Control Snack|Daily non-nut snack will be consumed.
32975903|NCT05269524|Experimental|Treatment|Therapist-guided internet treatment.
32975904|NCT05269524|Active Comparator|Attention control|Non-directive supportive contact via email.
32975905|NCT05269485|Experimental|High-dose hypofraction Arm|Irradiation of 60-68Gy/15-17f is administered followed by one-year immunotherapy maintenance.
32975906|NCT05269485|Experimental|Low-dose hypofraction Arm|Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.
32975907|NCT05269420|Experimental|SAS-J|single anastomosis sleeve Jejunal Bypass as a revisional bariatric procedure after restrictive bariatric procedures
32975908|NCT05269342|Experimental|the nurse-led counseling and after intervention exercise|"The NUCAI aims to help patients manage themselves physically and psychologically by giving support, education, and exercise tracking.~The participants in the control group were care as usual.Intervention group were the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC."
32975909|NCT05269329|Experimental|XC8, film-coated tablets, 20 mg/day|
32975910|NCT05269329|Experimental|XC8, film-coated tablets, 40 mg/day|
32975911|NCT05269329|Experimental|XC8, film-coated tablets, 80 mg/day|
32975912|NCT05269329|Placebo Comparator|Placebo|
32975913|NCT05262673|Experimental|CART/CTL/DCvac cells to treat B-ALL|
32975914|NCT05259982|Experimental|Vital root resection|Root resective surgery aiming to preserve pulp vitality
33322783|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
33322784|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
33322785|NCT03942432|Experimental|Patients with dysmetabolic iron overload syndrome|
33322786|NCT01367548|Experimental|Arm 1|
33322787|NCT01367548|Placebo Comparator|Arm 2|
33322788|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
33322789|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
32975915|NCT05254769|Experimental|Neurofeedback Intervention in children with Autism Spectrum Disorder|Neurofeedback therapy will be provided to 35 children with Autism Spectrum Disorder 30 sessions each and cognitive domains will be assessed before and after intervention.
32975916|NCT05254392|No Intervention|Usual Care|Participants in the UC arm received the usual/conventional care offered by the hospitals which included: hospital visits on appointment or a sick day, consultations with the physicians, prescription of drugs and routine laboratory tests, review of diagnosis and medications, refilling of prescriptions by patients and referral.
32975917|NCT05254392|Experimental|Pharmacists' Intervention|Participants in the PI arm received routine usual care plus pharmacists' interventions for 12 months. The PI arm received usual care plus face-to-face education on CKD, hypertension as a co-morbidity and its management, and antihypertensive medication adherence at baseline (group education), 6 months and 12 months (individualized according to each patient's needs), CKD patient educational infographic leaflet at baseline, a calibrated sphygmomanometer digital BP monitor (Chidalex®) for HSMBM, a BP logbook at baseline for the recording of BP values daily and hands-on training on BP self-measurement. Also, antihypertensive medication adherence and HSMBM reminder cell phone text messages were sent biweekly throughout the trial period, while phone-in inquiries from the participants and phone-out reinforcement interventions were utilized throughout the trial period
32975918|NCT05253846|Experimental|SCRT--> FOLFOXIRI--> SURGERY|"SHORT-COURSE RT~FOLFOXIRI~IRINOTECAN 165 mg/sqm iv over 60 minutes, day 1 followed by~OXALIPLATIN 85 mg/sqm iv over 2 hours, day 1 in two-way with~LEDERFOLIN 200 mg/sqm iv over 2 hours, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm 48 h-continuous infusion, starting on day 1. The chemotherapy treatment will be repeated every 2 weeks up to 8 cycles.~Surgery with TME should be performed after 4 weeks after the last cycle of chemotherapy"
32975919|NCT05253625|Experimental|lullaby mother|The participant will listen to a lullaby recorded with his mothers voice.
32975920|NCT05253625|Experimental|lullaby female|The participant will listen to a lullaby recorded with a foreign female voice.
32975921|NCT05253625|No Intervention|no lullaby|The participant will not listen to a lullaby.
32975922|NCT05252897|Active Comparator|Endoscopic step-up approach|"After endoscopic drainage of WON, patients will be reassessed 72 hours after the procedure. If there is no clinical improvement 72 hours after drain placement, a CECT is performed to check the adequacy of the drainage. Irrigation of the WON via a nasocystic drain or endoscopic irrigation (step 1) is performed in case of inadequate drainage. If a nasocystic drain is inserted, 500ml of normal saline, twice a day will be used to irrigate the WON. If endoscopic irrigation is performed, only irrigation with normal saline without necrosectomy is allowed.~Patients are again evaluated 72 hours after step 1. In case of improvement, treatment is conservative; otherwise step 2 will be initiated, which is endoscopic necrosectomy. Further endoscopic necrosectomy will be performed until there is clinical improvement."
32975923|NCT05252897|Active Comparator|Direct endoscopic necrosectomy approach|Patients in the DEN group will undergo an immediate endoscopic necrosectomy after LAMS placement and balloon dilatation. A 10Fr 5cm double pigtail plastic stent will be inserted within the LAMS after necrosectomy. Patients will be assessed in 72 hours after the procedure. If there is no clinical improvement, a CECT is performed to check the adequacy of the drainage. DEN will be repeated in case of inadequate drainage. Patients will be reassessed every 72 hours and DEN repeated until there is clinical improvement. Subsequently, necrosectomy is performed weekly until a reassessment CECT at 3 weeks.
32975924|NCT05252468|Experimental|TaffiX™|TaffiX™ is a Nasal powder personal spray that blocks viruses particles from entering the nasal cells.
32975925|NCT05252468|Placebo Comparator|Lactose powder|Lactose nasal powder will be used as a placebo. It has an identical appearance as TaffiX™ (white powder in an identical bottle).
32975926|NCT05250739|Experimental|Strength training|Participants completed 16 training sessions of strength training during eight weeks.
32975927|NCT05250739|Experimental|Neuromuscular training|Participants completed 16 training sessions of neuromuscular training during eight weeks.
32975928|NCT05250739|No Intervention|Control group|The Control group received no intervention.
32975929|NCT05250583|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring.
32975930|NCT05250193|Experimental|DK ScoreTM Coronary Scoring Balloon (DK Score)|DK ScoreTM Coronary Scoring Balloon Manufactured by DK Medical Technolgy CO.,LTD
32975931|NCT05250193|Active Comparator|Non-Slip Element Coronary Dilatation Catheter (NSE)|Non-Slip Element Coronary Dilatation Catheter Manufactured by GOODMAN CO.,LTD
32975932|NCT05250141|Experimental|Levodopa and Carbidopa Test Product|Participants will receive one tablet of the test formulation containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
32975933|NCT05250141|Experimental|Levodopa and Carbidopa Referent Product|Participants will receive one tablet of the marketed reference containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
32975934|NCT05248724|Experimental|Intervention,|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride (10mg/ml Kabi Fresenius Kabi Norway AS),150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride (10mg/ml Braun Medical SA Spain), 30 mg of ketorolac tromethamine (Normon Spain), 300 micrograms of adrenaline (epinephrine Braun Medical SA Spain), and saline 0.9% till reaching 50 ml of volume
32975935|NCT05248724|Placebo Comparator|placebo|Participants in the placebo group received a periarticular infiltration of 50 ml of saline 0.9%.
32975936|NCT05237310|Active Comparator|Standard Colonoscopy followed by CAD-EYE|Subjects will undergo standard colonoscopy immediately followed by CAD-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
32975937|NCT05237310|Active Comparator|CAD-EYE followed by Standard Colonoscopy|Subjects will undergo CAD-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
32975938|NCT05237310|Active Comparator|Standard Colonoscopy followed by combined CAD-EYE and G-EYE colonoscopy|Subjects will undergo standard colonoscopy immediately followed by combined CAD-EYE and G-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
32975939|NCT05237310|Active Comparator|Combined CAD-EYE and G-EYE colonoscopy followed by Standard Colonoscopy|Subjects will undergo combined CAD-EYE and G-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
32975940|NCT05235893|Experimental|Reflexology Group|The newborns who have applied Reflexology to soles three minutes before and during 5-7 minutes of painful procedure by a physiotherapist, certificated in reflexology.
32975941|NCT05235893|Active Comparator|Sucrose Group|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
32975942|NCT05235893|Active Comparator|Kangaroo Care Group|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
32975943|NCT05235893|Active Comparator|Music Group|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
32975944|NCT05235893|No Intervention|Control Group|Control arm
32975945|NCT05235737|Active Comparator|Treatment arm 1|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 of body surface area (BSA) daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
32975946|NCT05235737|Active Comparator|Treatment arm 2|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
32975947|NCT05235737|No Intervention|Treatment arm 3|n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
32975948|NCT05232006|Experimental|Niraparib|PARP-inhibitor, Niraparib Dosage : starting 300 mg/day for patients with body weight ≥77kg and platelet counts ≥ 150 000/µl or 200 mg when body weight inferior to 77kg and/or platelet counts ≤ 150 000/µl and > 100 000/µl Pharmaceutical form : 100 mg capsules Posology : single dose daily Route of administration : oral Administration procedures : oral, daily single dose Duration of treatment : 12 cycles of 28 days each
32975949|NCT05231408|Experimental|Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
32975950|NCT05231408|Sham Comparator|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
32975951|NCT05231395|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
32975952|NCT05231395|Sham Comparator|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
32975953|NCT05225051|Experimental|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
32975954|NCT05225051|Experimental|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
32975955|NCT05225051|Experimental|human control cell lines, Unmutated Huntingtin|human control cell lines, Unmutated Huntingtin
32975956|NCT05224583||Simultaneous Liver-Kidney Transplant patients population at MDMC|Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).
32975957|NCT05224297||breast|
32975958|NCT05224297||thorax|
32975959|NCT05224297||skin|
32975960|NCT05224297||abdomen|
32975961|NCT05224297||skull|
32975962|NCT05224297||head and neck|
32975963|NCT05224297||pelvis male|
32975964|NCT05224297||pelvis female|
32975965|NCT05224297||extremities|
32975966|NCT05224193||Paediatric Patients with Inflammatory Bowel Disease|
32975967|NCT05220904|Placebo Comparator|Placebo Comparator:placebo practice+spectacles|Patients will take placebo practices with spectacles every two days.
32739120|NCT05003193|Experimental|Using a pedometer|The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
32975968|NCT05220904|Experimental|Experimental： perceptual learning practice+spectacles|Patients will take perceptual learning practices with spectacles every two days.
32975969|NCT05215678||INKA participants|Individuals eligible and accepting participation in the INKA trial (NCT05172843)
32975970|NCT05215678||n-INKA participants|Individuals eligible and declining participation in the INKA trial (NCT05172843)
32975971|NCT05214885||the ccRCC patient group|The age and gender of patients are not limited. The patient was preliminarily diagnosed as renal carcinoma by imaging examination and finally diagnosed as clear cell renal cell carcinoma by pathology.
32975972|NCT05214885||the healthy control group|The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
33322790|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
33322791|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
33322792|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
33322793|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
33322794|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
33322795|NCT05118412|Experimental|Lucerne protein concentrate|Lucerne protein concentrate powder presented in the form of a shake.
33322796|NCT05118412|Experimental|Whey protein concentrate|Whey protein concentrate powder presented in the form of a shake.
33322797|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
33322798|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
32975973|NCT05214885||the benign kidney disease group|The age and sex of this group were matched with that of ccRCC patient group. The patient did not have any tumor but had one of the benign kidney diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. The functions of the liver and heart were normal.
32975974|NCT05211362|Experimental|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
32975975|NCT05211362|Active Comparator|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
32975976|NCT05209841|Experimental|Catheter sealing with low dose heparin|Catheters will be sealed with 3mL of Fibrillin Ⓡ (heparin 20UI/mL)
32975977|NCT05209841|Active Comparator|Catheter sealing with normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
32975978|NCT05207280|Experimental|Noradrenaline plus Terlipressin|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours. Solution for infusion (Intravenous). And: Terlipressin with dose 1 mg every 6 hours diluted in a 50 mL serum to pass in 15-30 minutesin injectable solution. Intravenous (diluted in a 50 mL serum to pass in 15-30 minutes)
32975979|NCT05207280|Placebo Comparator|Noradrenaline plus placebo|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours in solution for infusion (Intravenous), and placebo with solution in vial with the same external appearance as terlipressin. 1 mg every 6 hours, diluted in a 50 mL serum to pass in 15-30 minutes in injectable solution Route of administration: Intravenous, diluted in a 50 mL serum to pass in 15-30 minutes
32975980|NCT05205772|Experimental|medial prefrontal cortex - control site - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
32975981|NCT05205772|Experimental|medial prefrontal cortex - dorsolateral prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
32975982|NCT05205772|Experimental|dorsolateral prefrontal cortex - medial prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
32975983|NCT05205772|Experimental|dorsolateral prefrontal cortex - control site - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
32975984|NCT05205772|Experimental|control site - medial prefrontal cortex - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
32975985|NCT05205772|Experimental|control site - dorsolateral prefrontal cortex - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
32975986|NCT05203978||Virtual reality colonoscopy|using virtual reality with glasses and sound no anaesthesia
32975987|NCT05203978||General anaesthesia colonoscopy|gold standard
32975988|NCT05202899|Experimental|Sugammadex Group|rocuronium-induced general anesthesia，use of sugammadex antagonism
32975989|NCT05202899|No Intervention|Control Group|general anesthesia without rocuronium
33322799|NCT05192980|Other|Peripheral neuroblastic tumors (ganglioneuroma, ganglioneuroblastoma and neuroblastoma)|
33322800|NCT05192902|Experimental|Student-administered|
33322801|NCT05192902|Placebo Comparator|Dentist-administered|
33322802|NCT01211808|Experimental|Treatment A (BMS-914832)|
33322803|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
33322804|NCT05192824|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39
33322805|NCT05192824|Experimental|Orthokeratology lenses group 1|Subjects wearing orthokeratology lenses of 5mm optical zone.
33322806|NCT05192824|Experimental|Orthokeratology lenses group 2|Subjects wearing orthokeratology lenses of 5.5mm optical zone.
33322807|NCT05192824|Experimental|Orthokeratology lenses group 3|Subjects wearing orthokeratology lenses of 6mm optical zone.
33322808|NCT05192824|Experimental|Orthokeratology lenses group 4|Subjects wearing orthokeratology lenses of 6mm optical zone and the increased height of peripheral reverse curve.
33322809|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
32975990|NCT05202379|Experimental|SAD cohort 1A|first dose level with 6 active and 2 placebo healthy participants
32975991|NCT05202379|Experimental|SAD cohort 1B|second dose level with 6 active and 2 placebo healthy participants
32975992|NCT05202379|Experimental|SAD cohort 1C|third dose level with 6 active and 2 placebo healthy participants; food-effect cohort
32975993|NCT05202379|Experimental|SAD cohort 1D|fourth dose level with 6 active and 2 placebo healthy participants
32975994|NCT05202379|Experimental|MAD cohort 2A|first dose level with 6 active and 2 placebo healthy participants dose x 14 days
32975995|NCT05202379|Experimental|MAD cohort 2B|second dose level with 6 active and 2 placebo healthy participants dose x 14 days
32975996|NCT05202379|Experimental|MAD cohort 3B|third dose level with 6 active and 2 placebo healthy participants dose x 14 days
32975997|NCT05192707||Healthy Volunteers|TcPO2 measurement in the upper limb of healthy volunteers
32975998|NCT05192707||Patients with arterial disease in the upper limb and wound|Patients with arterial disease in the upper limb and wound (retrospective setting, research on data)
32975999|NCT05191537|Experimental|spinal mobilization with arm movement|conventional treatment and of spinal mobilization with arm movement
32976000|NCT05191537|Active Comparator|positional SNAGs|conventional treatment and positional SNAGs
32976001|NCT05189834|Other|Treatment sequence A|"Patients will follow the following treatment sequence:~Treatment with Gelsectan® (30 days)~Washout period (15 days)~Treatment with placebo (30 days)"
32976002|NCT05189834|Other|Treatment sequence B|"Patients will follow the following treatment sequence:~Treatment with placebo (30 days)~Washout period (15 days)~Treatment with Gelsectan® (30 days)"
32976003|NCT05186922|Experimental|CM326 55 mg, once every two weeks (Q2W)|55mg for 6 doses, every 2 weeks, subcutaneous (SC)
32976004|NCT05186922|Experimental|CM326 110 mg, once every two weeks (Q2W)|110mg for 6 doses, every 2 weeks, subcutaneous (SC)
32976005|NCT05186922|Experimental|CM326 110 mg, once every four weeks (Q4W)|110mg for 3 doses, every 4 weeks, subcutaneous (SC)
32976006|NCT05186922|Experimental|CM326 220 mg, once every two weeks (Q2W)|220mg for 6 doses, every 2 weeks, subcutaneous (SC)
32976007|NCT05186922|Experimental|CM326 220 mg, once every four weeks (Q4W)|220mg for 3 doses, every 4 weeks, subcutaneous (SC)
32976008|NCT05186922|Placebo Comparator|Placebo|Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)
32976009|NCT05182827|Experimental|Euthymic patients with history of suicide attempt (suicide attempters)|Currently euthymic patients with at least one lifetime major depressive episode and a history of suicide attempts
32976010|NCT05182827|Experimental|Euthymic patients without any history of suicide attempt (affective controls)|Currently euthymic patients with at least one lifetime major depressive episode and with no history of suicide attempts
32976011|NCT05182346|Experimental|Acupressure of classical acupoints|Acupressure is applied on four acupoints: Pressure was applied to large intestine 10 (LI10) (large intestine meridians): It is located on the dorsal radial side of the forearm, 2 Cun below the transverse cubital crease. Hegu (large intestine meridians, LI 4): It is in the middle of the 2nd metacarpal bone on the radial side. TE5 (Triple energizer): It is located 2 cun proximal to the dorsal wrist crease between the radius and the ulna. SI3 (small intestine meridians): It is located at the ulnar end of the distal palmar crease proximal to the 5th metacarpal phalangeal joint. These acupoints are commonly used in the treatment of cervical myofascial pain syndrome.
32976012|NCT05182346|Experimental|Ischemic compression release of myofascial trigger points|Ischemic compression was gradually applied pressure to the trigger point with your thumb. The patient will likely feel referred pain in a question mark pattern (along the back of the neck, around the side of the head, and then a focused pain right behind the eye). Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points will be treated. Then apply a few effleurage strokes to flush out the area and follow up with a passive stretch to the muscle.
32976013|NCT05175911||premature infants|premature infants less than 31 weeks of gestation or weighting less than 1300 g
32976014|NCT05173142|Experimental|dose escalation phase of HMPL-453 monotherapy or combination therapy|HMPL-453 monotherapy or combination therapy
32976015|NCT05173142|Experimental|indication specific dose expansion phase of HMPL-453 combination therapy|HMPL-453 combined with chemotherapy or anti-PD-1 antibody, in patients with IHCC, G/GEJ, or UC harboring specific FGFR gene alterations
32976016|NCT05171348|Experimental|CM326 55mg Q2W|55mg for 6 doses, SC, Q2W
32976017|NCT05171348|Experimental|CM326 110mg Q2W|110mg for 6 doses, SC, Q2W
32976018|NCT05171348|Experimental|CM326 220mg Q2W|220mg for 6 doses, SC, Q2W
32976019|NCT05171348|Experimental|CM326 220mg Q4W|220mg for 3 doses, SC, Q4W
32976020|NCT05171348|Placebo Comparator|Placebo|Placebo
32976021|NCT05167929|Experimental|Intervention Group|
33322810|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
33322811|NCT05192746|Experimental|"group A Control group"|"Twenty two patients will receive conventional treatment hot pack and exercise (control group).~."
33322812|NCT05192746|Experimental|"group BExtracorporeal shock wave group:"|Twenty two patients will receive Radial Extra corporeal Shock Wave Therapy plus conventional treatment hot pack and exercise.
33322813|NCT05192746|Experimental|"Group CHigh power pain threshold ultrasound group:"|Twenty two patients will receive High-Power Pain Threshold Ultrasound therapy plus conventional treatment hot pack and exercise
33322814|NCT05192668|Experimental|Quiet time care|Reduce noise and centralize medical or nursing operations in the NICU
33322815|NCT05192668|No Intervention|Routine nursing care|Perform routine nursing care for the VLBWIs in the NICU
33322816|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
33322817|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
33322818|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
33411259|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
32976022|NCT05167929|Experimental|Intervention PLUS Group|
32976023|NCT05167929|Active Comparator|Comparison Group|
32976024|NCT05167435|Experimental|Group A (Intervention)|"Myofascial release (Following Cross-hand release techniques of myofascial release in a manner of 2 minutes approach:~Cross-Hand Release of Back [For Thoracolumbar Fascia] Cross-Hand Release of the Lumbosacral Junction [L5-S1] Cross-Hand Release of Lateral low back area [for quadratus lumborum]) will be provided with conventional therapy including stretching exercises (Stretching of Latissimus Dorsi [10 seconds hold, 10 reps, 2 sets], Quadratus Lumborum Stretching [10 seconds hold, 3 reps, 1 set bilaterally], Lower Back Stretching [10 seconds hold, 10 reps, 2 sets], Hamstring Stretching [10 seconds hold, 10 reps, 2 sets bilaterally], Tensor Fasciae Latae Stretching [10 sec hold, 10 reps, 2 sets bilaterally] with duration rest will be of thirty seconds after five minutes) and Thermotherapy will be given for 20 minutes"
32976025|NCT05167435|Active Comparator|Group B (Control)|Posterior-anterior glide: Grade 1-4 [depending on tolerance] (120 oscillations per minute x 3 sets, Duration of rest between each set: 30 seconds) will be provided with the same conventional therapy as in Group A (Intervention)
32976026|NCT05166746|Active Comparator|Clindamycin + LACTIN-V (L.crispatus)|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
32976027|NCT05166746|Active Comparator|Clindamycin + placebo LACTIN-V|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V placebo (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
33411260|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
33411261|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
32976028|NCT05166746|Placebo Comparator|Placebo clindamycin + placebo LACTIN-V|Matching clindamycin placebo 2 times per day for 7 days followed by LACTIN-V placebo (Osel Inc.) until completion of the clinical pregnancy scan at week 7-9.
32976029|NCT05165875|Other|Randomized: Steroid injection|1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
32976030|NCT05165875|Other|Randomized: Splint|a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks
32976031|NCT05163860||Youth|TGGD youth age 12-17 will answer a survey regarding demographics (gender identity, sex assigned at birth, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism, degree of family conservatism/liberalism, ethnicity), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (ADO-BED, previous Eating Disorder diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (ARQ), adequacy of physical activity (PACE+), bodyweight (BMI, BMI%ile, %mBMI), and previously diagnosed psychiatric and neurodevelopmental disorders
32976032|NCT05163860||Young Adults|TGGD young adults age 18-25 will answer a survey regarding demographics (gender identity, sex assigned at birth, country of residence, ethnicity, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (SCOFF, ADO-BED, previous ED diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (RRBQ), bodyweight (BMI), malnutrition risk (MST), and previously diagnosed psychiatric and neurodevelopmental disorders.
32976033|NCT05163860||Parents|Parents of TGGD youth will answer a survey with information regarding demographics (religion, degree of religiosity, degree of conservatism/liberalism, country of residence, ethnicity, gender identity, sex assigned at birth, sexual orientation, education, marital status, household size, income), anxiety (GAD-7), depression (PHQ-9), family gender environment (FGE), food insecurity (HVS), height and bodyweight (BMI).
32976034|NCT05163457||aged of 75 and more living at home|"aged of 75 and more living at home group: patients aged of 75 and more living at home"
32976035|NCT05162313|Other|all patients undergoing tracheal intubation procedure|"In current practice, the endotracheal intubation procedure includes the systematic use of the capnometer, which is immediately connected to the tube after its insertion by direct laringoscopy. Confirmation of the correct tube positioning is established by color change of the capnometer from violet to yellow. Then, the colorimetric capnometer is usually removed before connecting the endotracheal tube to the flow-sensor of the ventilator.~For the purpose of our study, after the tube insertion the care provider will connect in line both the capnometer and the ventilator flow-sensor to the tracheal tube."
32976036|NCT05162118|Experimental|Single Arm|"Intratumoral injection of VG161 - 1.5*10^8 on D1 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2, D3 + Nivolumab on D8, D22"
33104963|NCT05030220||Phase 1|51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.
33411262|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
33411263|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
33411264|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
33411265|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
33411266|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
33411267|NCT04844684||Obese/non-diabetic patients undergoing gastric bypass surgery|
32976037|NCT05159310|Other|Cast|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
32976038|NCT05159310|Other|Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
32976039|NCT05158556|Experimental|myofascial release technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. deep pressure will be applied and glided medially towards the thoraco-lumbar region.ins
32976040|NCT05158556|Experimental|Instrument Assisted Soft Tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
32976041|NCT05155917|Experimental|basal insulin and insulin pump|Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.
32976042|NCT05155917|No Intervention|insulin pump|Patients in the control group did not receive placebo injections.
32976043|NCT05154708||Patient Group - Phase 1|15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
32976044|NCT05154708||Health Professionals Group - Phase 1|15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
32976045|NCT05154708||Patient Group - Phase 2|50 à 60 patients were expected to test a systematic electronic assessment
32976046|NCT05153291|Experimental|Bachmann's bundle area pacing|Lead placement in Bachmann's bundle area
32976047|NCT05153291|Active Comparator|Right atrial appendage pacing|Lead placement in the right atrial appendage
32976048|NCT05150041|Active Comparator|iPRo2 only (Control group)|- The Control group will go through target lifestyle coaching including diet and exercise and they will undergo 24 weeks of follow-up period.
32976049|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week treatment (Treatment group 1)|Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.
32976050|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week on /3 weeks off (2cycles) (Treatment 2)|- Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
32976051|NCT05142267|Other|Adults with chronic non-cancer low back pain|
32976052|NCT05139940||Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
32976053|NCT05139940||Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
32976054|NCT05138029|Experimental|Anti-VEGF treatment group|Visual acuity and center thickness of the macula
32976055|NCT05138029|Experimental|Inner limiting membrane stripping group|Visual acuity and center thickness of the macula
32976056|NCT05138029|Experimental|Glucocorticoid treatment group|Visual acuity and center thickness of the macula
32976057|NCT05137119|No Intervention|Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)|"Vancomycin or Daptomycin - Standard Therapy Arm~Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function."
32976058|NCT05137119|Experimental|Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)|"Vancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm~In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted."
32739121|NCT05003193|No Intervention|Not using a pedometer|The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.
33322819|NCT05192356|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(3) - A single oral dose of 1 tablet under fasting condition"
32976059|NCT05137119|No Intervention|Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
32976060|NCT05137119|Experimental|Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)|"Cefazolin - Interventional Arm~Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted."
32976061|NCT05137119|No Intervention|Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
32976062|NCT05137119|Experimental|Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)|"Benzylpenicillin - Interventional Arm~Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted."
32976063|NCT05137119|No Intervention|No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|"No adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA~Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm."
32976064|NCT05137119|Experimental|Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|Adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours for 5 days. No dosage adjustment is needed to renal impairment.
32976065|NCT05137119|No Intervention|Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm|"Backbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
32976066|NCT05137119|Experimental|Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.|"Switch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days).~Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
32976067|NCT05135039|Experimental|Lifestyle interventions + Canagliflozin|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of canagliflozin 100mg.
32976068|NCT05135039|Placebo Comparator|Lifestyle interventions + Placebo|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of placebo 100mg.
33322820|NCT05192356|Experimental|Sequence 2|"Period 1: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
33322821|NCT03940638||Patients with septic non-union of the tibia|
32976071|NCT05128591|Experimental|Arm A-Rivaroxaban|Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
32976072|NCT05128591|Experimental|Arm B-Rivaroxaban|Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
32976073|NCT05127681|Experimental|severe hemophilia A or B patients|30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.
32976074|NCT05127681|Other|healthy men|"Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the Institut national de la santé et de la recherche médicale (INSERM) research unit associated."
32976075|NCT05123560||women attending first-trimester ultrasound|All women attending their first-trimester ultrasound and meeting the inclusion criteria will be invited to participate
32976076|NCT05121701|Active Comparator|Videolaryngoscopy|The patients were intubated with the C-MAC PM-Karl Storz Video laryngoscope.
32976077|NCT05121701|Active Comparator|Laryngoscopy|The patients were intubated with the Macintosh laryngoscope.
32976078|NCT05120388|Experimental|Dietary addition of extra virgin olive oil|WHO diet with a daily addition of extra virgin olive oil
32976079|NCT05120388|No Intervention|No addition of extra virgin Olive Oil|WHO diet
33322822|NCT05192278|Active Comparator|Group 20 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 10 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 7 ml saline 0.9% (total 20 ml with bupivacaine 0.25%).
33322823|NCT05192278|Active Comparator|Group 30 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 15 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 12 ml saline 0.9% (total 30 ml with bupivacaine 0.25%).
33322824|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
33322825|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
32976080|NCT05118815|Active Comparator|Conventional straight esthetic abutment|After implant surgery, 30 patients will have a 3 mm high conventional straight esthetic abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N.
32976081|NCT05118815|Experimental|Slim (New Slim) transepithelial abutment|After surgery, 30 patients will have a 3 mm high transepithelial New Slim abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N
32976082|NCT05116319||Chinese people with no known history of diabetes|
32976083|NCT05111327|Experimental|Intervention|Students in the interventional groups will receive structured simulation guideline
32976084|NCT05111327|No Intervention|Control|Students in the control groups will receive standard treatment.
32976085|NCT05110508|Experimental|Physical Activity Self-Regulation|Participants will receive multiple weekly text messages. Texts will contain wear reminders, encouragements, congratulatory content, and behavior change messages based on the Garmin data. Some text message content asks for a response from the participant to help tailor later messages for behavior change support.
32976086|NCT05109806|Experimental|Experimental group|Problem prevention therapy will be given as per intervention. a group of parents will be included for a group session for narration of their problems in relevance to health related quality of life .After the assessment the next session the solution to these problems would be given to them.
32976087|NCT05109806|Other|control group|for this group only a general education regarding disease will be conducted and no further interventions will be provide to them .
32976088|NCT05096052|Experimental|ProLectin M|Active chewable tablets containing galectin inhibitor complex carbohydrate
32976089|NCT05096052|Placebo Comparator|PLACEBO|Placebo chewable tablets not containing galectin inhibitor complex carbohydrate
32976090|NCT05093595|No Intervention|Group A|The tracheal tube was routinely fixed with a teeth pad and adhesive tape (3M).
32976091|NCT05093595|Experimental|Group B|The tracheal tube was fixed by the trans-nasal Silicone Foley Catheter (SFC) and adhesive tape.
32976092|NCT05092932||Normal Control Data|"Normal adults with no history of neuromusculoskeletal disease will be recruited for this study. Participants will be independent walkers (no walking aid needed) and will not have needed a walking aid for injury over the past 5 years.~Participants will walk 200 m under 4 randomized conditions: non-weightbearing ambulation using crutches, a walker, a wheeled knee walker, and unaided walking. An in-shoe sensor will measure stance limb plantar force, a stopwatch will time each walk, perceived exertion will be reported using the BORG CR-10 scale, and device preference will be identified."
32976093|NCT05089331||Participants will be recruited from the GERFHS/ROSE Study|Participants will be recruited who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study/Recovery and Outcomes from Stroke study, who live in the area of University of Cincinnati, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, Baptist Health Louisville and Houston Methodist. The participant's age must be18 years or greater. The participant or legal representative must be able to provide informed consent, and the racial/ethnic category of participants should be Caucasian, African American or Hispanic.
32976094|NCT05088928|Experimental|Interventional Arm|Ecru (Apixaban )Tablets
32976095|NCT05088928|Active Comparator|Comparator/control|Rivascot (Rivaroxaban)
32976096|NCT05087771|Active Comparator|Oral naltrexone|patients will receive a 30 day supply of oral naltrexone 50 mg daily at hospital discharge. This medication was FDA approved in 1984 for the treatment of alcohol use disorder
32976097|NCT05087771|Experimental|injectable naltrexone|patient will receive 360 mg injection of naltrexone prior to hospital discharge
32976098|NCT05078762|Experimental|iVR|The intervention group will train on a bronchoscopy simulator in an iVR environment with Virtual Reality Goggles (HTC IVE Pro Eye, HTC corporation, Taiwan) while using the bronchoscopy simulator.
32976099|NCT05078762|No Intervention|Non iVR|The control group will train on a bronchoscopy simulator without VR goggles.
32976100|NCT05075122|Experimental|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
32976101|NCT05075122|Other|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
32976102|NCT05069922|Active Comparator|Fresh Frozen Plasma|At 6-8 hours, Initiate FFP infusion
32976103|NCT05069922|Active Comparator|Albumin|At 7 hours, Initiate 5% Albumin infusion
32976104|NCT05067439|Other|Period 1|In Period 1, all the participants will receive single doses of the probe drugs, including caffeine 100 mg, efavirenz 50 mg and omeprazole 10 mg, together on Day 1.
32976105|NCT05067439|Other|Period 2|In Period 2, participants will receive abrocitinib 200 mg once daily (QD) on Day 1-10, single dose of omeprazole on Day 2 and single dose of probe drugs together on Day 8.
33322826|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
33322827|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
33322828|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
32976106|NCT05064176|Experimental|Reconstructive lymphatic surgery|"The intervention treatment is reconstructive lymphatic surgery and consists of the application of lymphovenous anastomosis (LVA), lymph node transfer (LNT) or a combination of both. The choice of reconstructive technique(s) is determined by the surgeon and is based on the algorithm for reconstructive lymphatic surgery of lymphoedema.~Additionally, all patients receive usual care (i.e. maintenance decongestive lymphatic therapy)"
32976107|NCT05064176|Active Comparator|No surgery|All patients receive usual care (i.e. maintenance decongestive lymphatic therapy)
32976108|NCT05064137|Experimental|Curodont Repair® ( monomeric self - assembling peptide P11-4 )|Self assembling peptide P11-4 as Curodont Repair® can remineralize WSLs in a deeper manner than fluoride by guided enamel regeneration by forming a three-dimensional matrix within the subsurface body of an initial carious lesion to which calcium and phosphate ions found in natural saliva can bind and build de novo hydroxyapatite crystals.
32976109|NCT05064137|Experimental|Clinpro white varnish® ( Tricalcium Phosphate Fluoride Varnish, 5% F- )|Tri-calcium phosphate can be hydrolyzed rapidly to form calcium hydroxyapatite (HAp). The processes of hydrolysis and formation of HAp are accelerated by the presence of NaF ions as in case of Clinpro white varnish®. Moreover, the HAp formed by such hydrolysis tends to have a greater uptake of fluoride than conventional HAp.
32976110|NCT05064137|Active Comparator|Voco-profluorid® fluoride varnish (5% sodium fluoride)|Fluoride varnish is the gold standard for treating WSLs.
32976111|NCT05063097||CCU patients|All consecutive patients over 18 years admitted to the CCU.
32976112|NCT05059743|Experimental|[14C]-Larotinib|Patients will receive single dose of [14C]-Larotinib (Suspension, 350mg/100μCi).
32976113|NCT05057364|Experimental|Heart Smart Group|Receives Heart Smart Intervention
32976114|NCT05057026||Adult mental health support program|The investigators will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.
32976115|NCT05055986||CBCT Dicom files of patients|CBCT Dicom files of patients will be used for measurements of mandibular bone volume by open-source software.
32976116|NCT05053022|Experimental|Microneedling with Skinpen Precision System|"Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit.~Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use."
32976117|NCT05052528|Experimental|Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
32976118|NCT05052528|Experimental|Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
32976119|NCT05052528|Experimental|Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
32976120|NCT05052528|Experimental|Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
32976121|NCT05052528|Experimental|Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
32976122|NCT05052528|Experimental|Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
32976123|NCT05051150|Active Comparator|epinephrine 0.03 mcg|
32976124|NCT05051150|Active Comparator|epinephrine 0.05 mcg|
32976125|NCT05051150|Active Comparator|epinephrine 0.07 mcg|
32976126|NCT05045313|Experimental|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
32976127|NCT05045313|Experimental|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
32976128|NCT05045313|Experimental|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
32976129|NCT05044572|Experimental|Open chain kinetic exercises|
32976130|NCT05044572|Experimental|Forward head posture correction exercises|
32976131|NCT05044156||Case group|vaginal candidiasis
32976132|NCT05044156||Control group|healty women
33411268|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
33411269|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
33322829|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
33411270|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
33411271|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
32976135|NCT05032872|Experimental|Social Exergame Treatment Group|The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go&Grow fitness app for 6 weeks.
32976136|NCT05032872|Active Comparator|Control Group|The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go&Grow fitness app without the social features for 6 weeks.
32976137|NCT05030922|Experimental|Diet intervention|Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.
32976138|NCT05030922|No Intervention|Control|Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.
32976139|NCT05030051|Experimental|SkinPen Precision System|This proof of concept study is being conducted over the course of 60 days followed by a 3-month post-treatment visit to assess the efficacy and tolerability of the Sponsor's SkinPen device when used to treat men and women with signs of aging on the dorsum of the hands. Overall assessment of clinical outcome and safety will be based on the evaluation of pre- and post-treatment photos comparing baseline to final visit. The subject's assessment of satisfaction will also be evaluated at Visit 3 and Visit 4. Finally, both the clinician's and subject's assessment will be characterized using a clinician assessment scale at the 3 month post-treatment visit.
32976140|NCT05012826|Experimental|Osteopathic Manipulative Treatment (OMT)+ Physiotherapy (PT) Group|Participants in this group will receive OMT in addition to the same interventions of PT group for the same 2- month period. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
32976141|NCT05012826|Active Comparator|Physiotherapy Group (PT)|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 2 months. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council. the treatment provided will be registered on each participant's clinical notes and a summary of main interventions will be reported.
32976142|NCT05012241||Czech patients with multiple sclerosis|Czech patients with multiple sclerosis will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test. Video of their performance will be obtained.
32976143|NCT05009394|Active Comparator|Targeted Muscle Reinnervation (TMR)|In this surgical procedure, the residual peripheral nerve is transferred to an available muscle in the stump that has been deinnervated from its native nerve. The surgical procedure includes three core steps: preparation of the residual nerve; motor nerve identification from the targeted muscle; and coaptation. To prepare the residual nerve, the surgeon identifies the injured nerve that has developed a painful neuroma and cuts the nerve back to healthy fascicles. Next, the surgeon dissects the motor nerve to a nearby target and thereby denervates a native muscle. Lastly, the injured nerve where the neuroma was excised is transferred and coapted to the newly severed motor nerve stump innervating the targe muscle. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
32976144|NCT05009394|Active Comparator|Regenerative Peripheral Nerve Interface (RPNI)|The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. The surgeon first identifies the injured nerve and excises the terminal neuroma. Then, this peripheral nerve is transected into several intraneural fascicles. Next, autologous muscle grafts are harvested from a healthy donor site and the transected nerve endings are placed in the middle part of each muscle graft, in parallel to the muscle fibres. The muscle graft is wrapped around the distal transected nerve ending and anchored by epimysial sutures, and an RPNI is created. This is repeated for each group of fascicles obtained from splitting a transected nerve. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
32976145|NCT05009394|Active Comparator|Standard neuroma treatment, neuroma transposition|The standard neuroma treatment, also called neuroma transposition, includes excision of the terminal neuroma and burying the nerve into an adjacent deep muscle. As in the TMR and RPNI procedure, the surgeon starts with finding the injured nerve and excises the terminal neuroma into healthy fascicles. Next, the surgeon identifies a deep nearby muscle which is away from joint motion and has limited output opportunities for the nerve. The nerve is then channelled inside to the deep muscle without applying any tension on it and secured by sutures. The surgery time is approximately 1-2 hours and it takes place in the hospital. The patient can leave the hospital the same day.
32976146|NCT05007561|Experimental|Naltrexone|50mg naltrexone HCL once daily for seven days by mouth
32976147|NCT05007561|Placebo Comparator|placebo|sugar pill once daily for seven days by mouth
32976148|NCT05002738|Experimental|Overall Cohort|Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days
32976149|NCT05001724|Experimental|Cohort 1: KN046 plus Lenvatinib RP3D.|Experimental arm: Cohort 1: KN046 5mg/kg every 2 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
33322830|NCT05192044|Experimental|Group A|Fast track Care (Enhanced recovery after)pancreatico-duodenectomy
33411272|NCT04057326|Active Comparator|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
33411273|NCT04057326|Placebo Comparator|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
33411274|NCT04573829|Experimental|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
32976150|NCT05001724|Experimental|Cohort 2: Lenvatinib RP3D|Cohort 2 lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
32976151|NCT05001724|Active Comparator|Docetaxel|Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
32976152|NCT04983394|Experimental|Virtual Realty|Participants will play a motion-controlled video game with Microsoft XBox One Kinect for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance exercises
32976153|NCT04983394|Active Comparator|Conventional|Participants will do aerobic exercises for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance
32976154|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - telemedicine self exam before face-to-face evaluation|First care will be performed via telemedicine with a clinical physician, guiding self-examination guided by telemedicine. After the remote consultation, a face-to-face evaluation will be performed with an orthopedist, according to institutional protocol.
32976155|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - only face-to-face evaluation|Face-to-face care with an orthopedist, according to institutional protocol.
32976156|NCT04974567||Women recently diagnosed with breast cancer who have not undergone any treatment.|Tear sample collection
32976157|NCT04970914|Experimental|Anlotinib+Penpulimab|
32976158|NCT04968808|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
32976159|NCT04968808|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
32976160|NCT04967677||Czech healthy occupational therapy students|Czech healthy occupational therapy students will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test. Video of their performance will be obtained.
32976161|NCT04966559|Placebo Comparator|Placebo treatment|"Film-coated matched placebo-tablets consisting of:~Core:~Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
32976162|NCT04966559|Active Comparator|Naldemedine treatment|"Film-coated matched active-tablets consisting of:~Core:~Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
32976163|NCT04965402|Experimental|Panel 1: Dose 1|
32976164|NCT04965402|Experimental|Panel 2: Dose 2|
32976165|NCT04965402|Placebo Comparator|Placebo|
32976166|NCT04961801|Experimental|Acalabrutinib in combination with tacrolimus and methotrexate|"Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.~Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate."
32976167|NCT04954131|Experimental|SCB-2019 vaccine|Investigational SCB-2019 vaccine contains 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants, in each 0.5 mL dose
32976168|NCT04954131|Placebo Comparator|Placebo|Saline solution (0.9%)
32976169|NCT04938388|Active Comparator|Oral Semaglutide (OS) with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the OS dose will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the OS tablet whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
32976170|NCT04938388|Placebo Comparator|Oral Semaglutide (OS) Placebo with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the Placebo will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the Placebo will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of Placebo will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the Placebo will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the matched OS Placebo whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
33322831|NCT05192044|Active Comparator|Group B|Conventional Care pancreatico-duodenectomy.
33322832|NCT01114464||young women with breast cancer|
33411275|NCT04839146|Experimental|Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant|In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
32976171|NCT04935723|Experimental|EFFECT OF REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the reiki/sham reiki group were taken to a quiet single room and reiki/sham reiki was applied for approximately 25-30 minutes. will be applied. Reiki application will be applied by a researcher who has Reiki I and Reiki II level training.
32976172|NCT04935723|Placebo Comparator|EFFECT OF SHAM REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. Sham Reiki will be applied by a health professional who has not received Reiki training.
32976173|NCT04935723|No Intervention|ANXIETY, FEAR PAIN LEVELS AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|The control group will be given routine post-operative care without any intervention and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
32976174|NCT04935619|Other|Non-Contingency Reinforcement Group|Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
32976175|NCT04935619|Experimental|Contingency Reinforcement Group|Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
32976176|NCT04935008|Experimental|Effect of recruitment maneuver on intracranial pressure|A recruitment maneuver will be performed in patients with decreased oxygen saturation due to atelectasis by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
32976177|NCT04931264|Experimental|YuWell YE660D and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE660D Electronic Sphygmomanometer (YuWell YE660D) and with Desk Mercury Sphygmomanometer.
32976178|NCT04930406||Historical control group|
32976179|NCT04930406||Intervention group|
32976180|NCT04919564|Experimental|Furosemide|Low dose continuous furosemide 2 mg/hour for a period of 12 hours since anesthetic induction
32976181|NCT04919564|Placebo Comparator|Control|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
32976182|NCT04918823|Other|Single arm|All subjects will receive Restasis in this study
32976183|NCT04914611||HBsAg Positive|Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
32976184|NCT04910932|Experimental|Breathing Exercises group|Breathing exercises will be applied via teleconference by a physiotherapist 1 day a week. Individuals will perform exercises by themselves at their homes on the remaining 6 days of the week. Exercise program will be applied for 4 weeks. Individuals will also be informed about COVID-19 for once at baseline.
32976185|NCT04910932|Other|Control group|Individuals will be informed about COVID-19 for once at baseline.
32976186|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
32976187|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
32976188|NCT04909372|No Intervention|No labelling|Food products without any label in the virtual supermarket.
32976189|NCT04909372|Experimental|Environmental labelling|Food products with an environmental label in the virtual supermarket.
32976190|NCT04908826|Active Comparator|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
32976191|NCT04908826|Active Comparator|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
32976192|NCT04908826|Active Comparator|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
32976193|NCT04902248|Experimental|Over-the-scope clips|"The OTSC® System Set is an instrument for flexible endoscopy~The OTSC® System Set consists of an applicator cap with a mounted OTSC® clip, thread, thread retriever and a hand wheel for clip release.~The OTSC® clip is delivered by means of an applicator cap mounted to the tip of gastroscopes or colonoscopes. The clip is released by tightening the thread with the hand wheel.~The OTSC® clip for flexible endoscopy is a superelastic Nitinol device for compression and approximation of tissue in the digestive tract"
32976194|NCT04902248|Experimental|angiographic embolization|"The procedure was performed in the angiographic suite and under local anaesthetics to the patient's groin. The celiac and then gastroduodenal artery or the left gastric artery was selectively cannulated depending on ulcer location.~Coils were deposited distal to the bleeding point. Gel foam particles were then packed into the artery and its collaterals. This was followed by further coils deposited in its proximal portion until complete cessation of arterial flow. Our protocol requested empiric embolisation of the artery even in the absence of active contrast extravasation or a pseudoaneurysm."
33033131|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
32976195|NCT04897425|Experimental|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"The participant can choose between one, two, or five interventions per week depending on their availability.~Steps of each intervention:~Pain Evaluation: Numeric Rating Scale (NRS)~Functional Assessments (1st, 5th, 10th, and last sessions)~Preparation:~Locate participant in a comfortable position for training (comfortable chair, about a meter distance to the screen, pleasant arm position)~Placement of the surface electrodes~Positioning of the feedback wearable device over the affected body part~Placement of the brain modulation cap~Treatment modalities:~Motor training~Sensory training~Sensorimotor training~Assessments~Step 4 is repeated for different phantom movements, initially one at a time, progressing to several joints simultaneously. A treatment session lasts 2 hours."
32976196|NCT04894786|Experimental|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization & Sleeper Stretch
32976197|NCT04894786|Active Comparator|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique and Sleeper Stretch
33411276|NCT04839146|Experimental|Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant|In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411277|NCT04839146|Experimental|Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant|In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411278|NCT04839146|Experimental|Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant|In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411279|NCT04839146|Experimental|Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant|In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411280|NCT04839146|Experimental|Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411281|NCT04839146|Experimental|Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
33411282|NCT04628507||Patients undergoing IVF|
33411283|NCT02870348|Experimental|Alpha-1 MP|Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.
33411284|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
33411285|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
33411286|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
33411287|NCT03613610|Active Comparator|Three needles group|
33411288|NCT03613610|Active Comparator|Single needle group|
33411289|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
33411290|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
33411291|NCT05384210|Active Comparator|Milnacipran|Patients will receive Milnacipran as a mono-therapy will be administered in increment doses for 3 months
33411292|NCT05384210|Active Comparator|Gabapentin|patients will receive Gabapentin as a mono-therapy will be administered in increment doses for 3 months
33411293|NCT05384210|Active Comparator|Combined gabapentin/milnacipran|Patients will receive combined gabapentin and milnacipran as a combination therapy will be administered in increment doses for 3 months
33411294|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
33411295|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
33411296|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.~Transportation assistance for medical home appointments.~Electronic Prompts/Reminders to Encourage Completion of Goals."
33411297|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
33411298|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
33411299|NCT04804592|Experimental|Group A: SiHy CL|Silicone hydrogel (SiHy) CL wear at least 3 days per week and at least 8 hours per day;
33411300|NCT04804592|Experimental|Group B: RGP CL|Rigid gas permeable (RGP) CL wear at least 3 days per week and at least 8 hours per day;
33411301|NCT04804592|Experimental|Group C: no CL wear|No current CL wear for at least 3 months;
33411302|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
33411303|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
32976226|NCT04886817|No Intervention|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
32976227|NCT04886817|Experimental|Intervention|"Intervention group participants will receive a 6-month behavioral intervention with the following components:~A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, and a children's book about water consumption, as well as instructions for other intervention components (how to view video, download app, and prepare for calls)~A 5-minute educational video that introduces parents to healthy drink choices for the family.~Ready, Set Gulp! A smartphone application for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water.~A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices."
32976228|NCT04886479|Experimental|Daily Disposable Silicone Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Silicone Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
32976229|NCT04886479|Active Comparator|Habitual Daily Disposable Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
32976230|NCT04886479|Active Comparator|Non-lens wearers|Subjects with no previous history of contact lens wear
32976231|NCT04886284|Experimental|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
32976232|NCT04886284|Placebo Comparator|Placebo|Saline placebo infused daily over 2 hours x 5 days
32976233|NCT04881825|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
32976234|NCT04876703|Experimental|Excite group (Group A)|The experimental group (Group A) will receive standard motor retraining of the affected upper extremity in addition to functional electrical stimulation provided by means of Xcite system 4 days per week for 30 minutes for two weeks.
32976235|NCT04876703|Active Comparator|Standard motor training group (Group B)|The control group (Group B) will receive standard motor retraining of the upper extremity.
32976236|NCT04871815|Experimental|Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray|This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.
32976237|NCT04870333|Active Comparator|Niclosamide|"INN: Niclosamide Ethanolamine Chemical name (IUPAC): 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide.2 aminoethanol CAS registry number: 1420-04-8 Lab code: UNI911~The IMPs niclosamide Nasal Spray 1% and matching Nasal Spray Placebo will be provided in 20 mL amber glass vials with nasal spray pumps, containing 8.5 mL of the respective solution, delivering 140 μL per spray shot. It is an isotonic and euhydric aqueous solution with red colour."
32976238|NCT04870333|Placebo Comparator|Placebo niclosamide|Placebo to match niclosamide will be supplied, stored, labelled, dispensed and dosed as for the active formulation. The placebo product is formulated to have the same appearance as the active solution.
32976239|NCT04870333|Active Comparator|Ciclesonide|"Chemical name (IUPAC): 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacycloicosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate CAS registry number: 141845-82-1~It is a pressurised solution, intended for inhalation use and commercialised under the brand Alvesco. The recommended dose of ciclesonide is 160μg once daily, which leads to asthma control in the majority of patients. However, this may be increased if necessary to 320μg twice daily, in severe asthma."
32976240|NCT04870333|Placebo Comparator|Placebo ciclesonide|Matched placebo contains the same solvent and propellant as the active product but no drug substance.
32976241|NCT04870333|Experimental|Sotrovimab|Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion Colourless or yellow to brown, liquid solution 20 mM histidine, 7% sucrose (w/v), 0.04% PS80 (w/v), 5 mM L-methionine at pH 6.0
32976242|NCT04870333|Placebo Comparator|Placebo sotrovimab|This will be in the form of 0.9% sodium chloride 50mL for infusion and will be sourced from commercially available stock by the site. It may be procured and stored as per sites usual procedures and only requires handling as an IMP upon dispensing and labelling.
32976243|NCT04867018||Orthopaedic Trauma, Pediatrics and Joint Patients|Patients will have an additional 9ml of blood drawn during their normal course of care for this study up to 4 times. Intraoperatively, we will request a tissue sample of the debrided injured muscle from the area where the surgeon is operating. There will be no additional tissue sample taken during the surgery, but what is removed in the normal course of the operation will be used for analysis in our study.
32976244|NCT04867018||Healthy Volunteer|Blood will be taken from healthy, nonpregnant adults who weigh at least 110 pounds. All volunteers will have a single blood draw of 100ml at the time of consent.
32976245|NCT04861610|Experimental|Brief mindfulness based program|A four session program, each last for 2.5 hours. Brief mindfulness exercises promote stress reduction, with an introduction of mindfulness to caregivers and home practice is encouraged with guidance.
32976246|NCT04861610|Active Comparator|Psychoeducation|A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
32976247|NCT04861610|No Intervention|Treatment-as-usual|
32976248|NCT04861025||Users Group|Patients admitted to any Hospitalization Unit belonging to Geriatrics Department
33322833|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
33322834|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
33322835|NCT01209858|Experimental|Experimental 1|
33322836|NCT01209858|Experimental|Experimental 2|
33322837|NCT05191888|Active Comparator|14-day vonoprazan high-dose two-in-one therapy|vonoprazan 20mg bid and amoxicillin 750mg qid
33322838|NCT05191888|Active Comparator|14-day vonoprazan triple therapy|vonoprazan 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid
33322839|NCT05191888|Active Comparator|14th Rabeprazole reverse mixed therapy|first 7 days rabeprazole 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid and metronidazole 500mg bid Next 7 days rabeprazole 20mg bid and amoxicillin 1gm bid
33322840|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
33322841|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
33322842|NCT05170906|Experimental|Experimental Group|"The subject will be placed on a stretcher with the torso uncovered. Once the spectroscopy helmet is in place, a recording of the resting activity will be started, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation on the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure on the pectoral area in the pattern of the reflex swing locomotion complex in its first phase. For this, the subject will be placed in supine decubitus aligned with respect to the axial axis, with the arms alongside the body, the lower extremities in extension and the head extended with a rotation of approximately 30º to one side of the stimulation. Manual stimulation pressure will be exerted in the space between the 6th-7th or 7th-8th ribs below the mammary line, with a force of about 2 kg."
33322843|NCT05170906|Sham Comparator|Control Group|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg"
33322844|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
33322845|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
32976249|NCT04861025||Health Professionals Group|All health professionals working at some Hospitalization Unit belonging to CSAPG Institution
32976250|NCT04860271|Active Comparator|Filiform Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 6 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first treatment, after the third treatment, after the sixth treatment and at 2 weeks after the sixth treatment.
33033132|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
33033133|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
33033134|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
33033135|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
33033136|NCT01959906||R0|Complete resection
32976251|NCT04860271|Active Comparator|Press Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
32976252|NCT04859699|No Intervention|Control Group|This arm will include schools and the enrolled families assigned as the control group, who will not receive the COVID-19 Health Education Comic Books and video intervention until the end of the school year.
32976253|NCT04859699|Active Comparator|COVID-19 Comic Books|This arm will include schools that are randomized to receive an intervention of Health Education comic books focused on the benefits of COVID-19 topics such as masking, social distancing and COVID-19 testing.
33411304|NCT04802798|Experimental|Placebo, Fibre 1, Fibre 2|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
32976255|NCT04857099||Macular edema|
32976256|NCT04856696|Experimental|combined non-invasive PGT-A & PGT-A|Infertility women who underwent both non-invasive PGT-A and PGT-A
32976257|NCT04856696|Experimental|non-invasive PGT-A|Infertility women who underwent non-invasive PGT-A only
32976258|NCT04856696|Active Comparator|PGT-A|Infertility women who underwent PGT-A only
32976259|NCT04854278||Pilot study|Pilot study with 22 cases, no intervention
32976260|NCT04854278||Baseline measurement|Baseline measurement of +/- 100 cases, no intervention
32976261|NCT04854278||Post measurement|Post measurement of +/- 100 cases after implementation of a Massive Open Online Course
32976262|NCT04853459|Experimental|Retention|After Border modeling by traditional and light cure. Amount of force required to dislodge.
32976263|NCT04853459|Experimental|Vestibular depth measurement|Casts By using Ney Surveyor
32976264|NCT04851847|Experimental|MatrixflexTM resorbable collagen membrane|Experimental arm using the Matrixflex Resorbable Collagen Membrane for treatment of periodontal intrabony defects
32976265|NCT04851847|Active Comparator|control group membrane|Control arm using the Comparator Xenograft Resorbable Collagen Membrane or treatment of periodontal intrabony defects
32976266|NCT04837534|Experimental|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
32976267|NCT04837534|Experimental|SMS and phone call reminder group:|In this group after the children have been examined, treatment plan and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol
32976268|NCT04837534|No Intervention|Routine standard care group|In this group, the children will undergo ocular examination, and treatment plan. They will be discharged from the department and advised accordingly including a routine follow-up schedule as per hospital protocol.
32976269|NCT04835402|Experimental|Intervention|Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
32976270|NCT04834648|Experimental|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
32976271|NCT04834648|No Intervention|Control Arm|General Counseling, which included saying you need to visit the hospital and you have involvement in the eyes due to diabetes, providing a health education leaflet.
32976272|NCT04817579|Active Comparator|Conventional visual shade matching|Patients requiring single crown in the esthetic zone treated with Conventional visual shade matching (Ivoclar Classic shade guide)
32976273|NCT04817579|Experimental|Spectrophotometer|Patients requiring single crown in the esthetic zone treated with Spectrophotometer (Vita Easy Shade)
32976274|NCT04817579|Experimental|Digital photography combined with eLABor_aid shade analyzing software.|Patients requiring single crown in the esthetic zone treated with Digital photography combined with eLABor_aid shade analyzing software.
32976275|NCT04813120|Experimental|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
32976276|NCT04813120|Experimental|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
32976277|NCT04813120|Experimental|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
32976278|NCT04813120|Active Comparator|Traditional MT using a mirror box|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
33033137|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
33033138|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
33033139|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
32976279|NCT04810988|Active Comparator|Unsupported|"Participants in this arm will receive a 12-week Unified Protocol intervention delivered via the same web platform. Each week, participants will complete the following content:~depression survey,~anxiety survey,~information about their symptom change over time,~psychoeducational text~practice exercises,~home practice instructions,~writing exercise,~home practice worksheets.~In the first week, participants will receive an emailed welcome message followed by a link to the first week's content. For every following week, participants will receive an email at the start of the week with automatically generated feedback on intervention usage, behavior change, and symptom change, as well as the link to the new week's intervention content."
32976280|NCT04810988|Experimental|Partially Supported|Participants in the partially supported arm will receive all aspects of the intervention described above, with no differences between arms for the first seven weeks of the intervention (Modules 1-6). Participants will be introduced to their study therapist in week 8, at the start of Module 7 via email. During Module 7 (exposure; weeks 8-11), participants will receive four video therapy sessions. Session content will be based on principles of exposure therapy (developing a personalized exposure hierarchy, live demonstrations of exposure exercises, in-session exposure practices, post-exposure processing, home practice assignments, and therapist feedback).
32976281|NCT04805255||Hypofractionated Stereotactic Radiotherapy (HF-SRT)|"A prospective cohort study addressing both neurocognitive outcome measures and oncological endpoints will be carried out for treating newly-diagnosed brain oligometastases with a pre-defined course of hypofractionated stereotactic radiotherapy (HF-SRT) in cancer patients with a fair/satisfactory performance status.~Either a limited number of brain metastases or oligometastatic brain disease refers to that the number of brain metastatic lesions (both post-resected and intact) at enrollment should be limited to three or fewer and that the greatest diameter of any metastatic lesion (either a tumor bed post-surgical resection or an intact brain metastasis) should be no more than 4 cm."
32976282|NCT04801641|Placebo Comparator|Placebo|Placebo
32976283|NCT04801641|Experimental|Low-Dose Nabilone|pms-nabilone titrated to 2 mg daily
32976284|NCT04801641|Experimental|High-Dose Nabilone|pms-nabilone titrated to 6 mg daily
32976285|NCT04800718|Experimental|Door-to-door screening|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
33322846|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
33322847|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
33322848|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
33322849|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
32976286|NCT04800718|No Intervention|Routine awareness activities,Control Arm|The control arm VC will continue its routine awareness activities & health talk sessions in the community.
32976287|NCT04800276|Experimental|APA with consideration of ischemia localization|
32976288|NCT04800276|Experimental|APA without consideration of ischemia localization|
32976289|NCT04791813||Exposure group|group of surgically treated unilateral cleft lip and palate Egyptian children aged 9_12years
32976290|NCT04791813||Control group|group of healthy Egyptian children aged 9_12years
32976291|NCT04783376|Active Comparator|Arm 1 (usual treatment)|intervention A
32976292|NCT04783376|Active Comparator|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
33322850|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
33322851|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
32976293|NCT04783376|Active Comparator|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
32976294|NCT04783285|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
32976295|NCT04783285|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.
32976296|NCT04772560|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
32976297|NCT04772560|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
32976298|NCT04768829|Active Comparator|Placebo group|Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity
32976299|NCT04768829|Experimental|Moringa group|Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity
32976300|NCT04760912|Experimental|Experimental group general anesthesia without rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring. After induction with Propofol and Sufentanil ( doses adjusted according to weight and age) anesthesia was maintained with sevorane. Muscle strength measured on three occasions with Yamar dinamometar for hand grip strength, before induciran to anesthesia and immediate after Salingeru from anesthesia, then again measured in first 24 hours.
33033140|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
33033141|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
32976301|NCT04760912|Active Comparator|Active comparator: general anesthesia with rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring with train-of-four (TOF). After induction with Propofol and Sufentanil (doses adjusted according to weight and age) and rocuronium 0,6 mg per kg, anesthesia maintained with sevorane. Muscle strength neasured with Yamar dinamometar for hand grip strength before induction to anesthesia and immediate after awakening from anesthesia, then again measured in first 24 hours.
32976302|NCT04758702|Experimental|GROUP 1|L-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
32976303|NCT04758702|Experimental|GROUP 2|H-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
32976304|NCT04758702|Experimental|GROUP 3|A surgical stent will be delivered to cover the surgical site and apply pressure on the wound site.
32976305|NCT04758208||Healthy CALIPER Participants|Healthy community children and adolescents recruited through the CALIPER initiative as well as healthy children and adolescents recruited from outpatient clinics at the Hospital for Sick Children through the CALIPER initiative. Blood samples from these participants will be tested on the Mindray BC-6800Plus device to measure hematology parameters and establish reference intervals.
33411305|NCT04802798|Experimental|Placebo, Fibre 2, Fibre 1|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
33411306|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
33411307|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
33411308|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
33411309|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
33411310|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
33411311|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
33411312|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
33411313|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
32976306|NCT04743479||New Onset Diabetes|"New Onset Diabetes must meet one of the following criteria:~Documented diabetes diagnosed within the past 3 years.~Definite new-onset diabetes based on recent fasting blood glucose (FBG) values ≥126 mg/dl (7.0 mmol/L) or Hemoglobin A1c (HbA1c) ≥ 6.5%. All glycemic parameters must be measured in an outpatient setting."
33033142|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
32976307|NCT04743479||Familial pancreatic cancer|"Familial pancreatic cancer must meet one of the following criteria:~≥ 2 blood relatives with pancreatic cancer (includes 1st-3rd degree relatives)~One 1st degree relative with PDAC diagnosed before age 60"
32976308|NCT04743479||Inherited syndromes associated with pancreatic cancer|"Family history includes with inherited syndromes associated with pancreatic cancer ( ≥ 2 blood relative, includes 1st-3rd degree relatives).~Inherited syndromes must meet one of the following criteria:~Hereditary pancreatitis~Familial atypical multiple mole and melanoma syndrome~Hereditary nonpolyposis colon cancer~Peutz-Jeghers syndrome~Hereditary breast and ovarian cancer syndromes"
32976309|NCT04743479||Pancreatic Cystic Neoplasm|Pancreatic Cystic Neoplasm, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which are defined by endoscopic ultrasound or serial imaging.
32976310|NCT04743479||Chronic pancreatitis|Chronic pancreatitis, defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist.
32976311|NCT04743284||tele-assessment|The balance evaluations will be applied by the tele-assessment method.
32976312|NCT04743284||face-to-face assessment|The balance evaluations will be applied by the face-to-face assessment method in a clinical setting
32976313|NCT04738448|Experimental|Art Therapy Group|
32976314|NCT04738201|Active Comparator|Control group|Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle.
32976315|NCT04738201|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
32976316|NCT04734613|Experimental|Tai Chi intervention|Tai Chi exercise intervention provided twice a week for one hour for 12 weeks
32976317|NCT04734613|Active Comparator|self management|self management program provided 6 sessions (one hour per session) for 12 weeks
32976318|NCT04732481||interventional group|passive leg lift test
32976319|NCT04732481||control group|no intervention (SOC)
32976320|NCT04729816|Experimental|Dietary Intervention|All participants will stay weight stable while undergoing 5 phases of a dietary intervention that lasts 62 days.
32976321|NCT04720196|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
32976322|NCT04720196|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
32976323|NCT04717401|Experimental|Strain-counterstrain Group A|Strain Counterstrain (SCS) is a passive positional technique which aims to relieve musculoskeletal pain and dysfunction by indirect manipulation .
32976324|NCT04717401|Experimental|Muscle Energy Technique Group B|MET is a gentle manual therapy for the restricted mobility of the spine and extremities and is an active procedure in which the corrective force is regulated by the patient, not the clinician. This technique requires the patient to perform voluntary muscle contractions of varying intensity, in a specific direction, while the clinician uses a counter-force that does not allow movement to occur The physiological mechanism underlying SCS is unknown though. It has hypothesized that muscle tone inhibition occurs by stimulation of the target muscle's Golgi tendon organ by physical approximation of muscle origin and insertion.
32976325|NCT04715516|Experimental|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
32976326|NCT04715516|Other|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
32976327|NCT04712604|Experimental|MSOS Group|The participants in this group will receive the MSOS Intervention for 4 consecutive weeks.
32976328|NCT04710641|Experimental|MTL-CEBPA in combination with sorafenib|Intravenous infusion of MTL-CEBPA 130mg/m2 given once every 3 weeks. Oral sorafenib 400mg twice a day will commence C1D8.
32976329|NCT04710641|Active Comparator|Sorafenib alone|Oral sorafenib 400mg twice a day commencing Day1
32976330|NCT04706767|Experimental|Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery|
32976331|NCT04706767|Experimental|Effect of Dexmedetomidine infusion on Quality of Recovery|
32976332|NCT04706767|Experimental|Effect of Lidocaine infusion on Quality of Recovery|
32976333|NCT04706767|Experimental|Effect of saline infusion on Quality of Recovery|
32976334|NCT04706481||Healthy Control|Healthy subjects who have provided consent for specimen collection
32976335|NCT04706481||Cancer or Other Diseases|Diseased subjects who have provided consent for specimen collection
32976336|NCT04706468|Experimental|40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
32976337|NCT04706468|Experimental|80 mg TG-1000|Participants received 80 mg of TG-1000 orally on Day 1 and 40 mg of placebo on Day 3.
32976338|NCT04706468|Experimental|40 mg TG-1000+40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of TG-1000 on Day 3.
32976339|NCT04706468|Placebo Comparator|Placebo|Participants received 80 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
32976340|NCT04705298|Placebo Comparator|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
32976341|NCT04705298|Experimental|Prebiotic|Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
32976342|NCT04704700|Active Comparator|patient with inspace device|
32976343|NCT04704700|Placebo Comparator|patient without inspace device|
32976344|NCT04702139|Active Comparator|patient with game-ready splint|Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
32976345|NCT04702139|Placebo Comparator|patient with standard splint|Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
32976346|NCT04701827|Experimental|Intervention group|AWARE intervention
32976347|NCT04701827|No Intervention|Control group|Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)
32976348|NCT04700215|Active Comparator|Group 01 Effectiveness of BiPAP in reducing post CABG pulmonary complications|Bilevel positive airway pressure device after every 6 hours
32976349|NCT04700215|Active Comparator|Group 02 Effectiveness of IS in reducing post CABG pulmonary complications|Incentive spirometry for 15 minutes after every 4 hours
32976350|NCT04699656|Experimental|Plazomicin Injection|plazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD
32976351|NCT04698304||Group A：TASC C lesion group|Multiple stenoses or occlusions totaling >15cm or recurrent stenoses or occlusions that need treatment after endovascular interventions (300 cases)
32976352|NCT04698304||Group B：TASC D lesion with common femoral artery involved|Chronic total occlusions >20cm with common femoral artery involved (100 cases)
32976353|NCT04698304||Group C：TASC D lesion with proximal popliteal artery involved|Chronic total occlusions >20cm with proximal popliteal artery involved (300 cases)
32976354|NCT04698304||Group D：TASC D lesion with distal popliteal artery involved|Chronic total occlusions >20cm with distal popliteal artery involved (200 cases)
32976355|NCT04698304||Group E：TASC D lesion with popliteal artery and proximal trifurcation vessels involved|Chronic total occlusion of popliteal artery (P1-3 segment) with proximal trifurcation vessels involved (100 cases)
32976356|NCT04697810|Experimental|Namodenoson|Namodenoson capsules orally 25 mg every 12 hours for 36 weeks
32976357|NCT04697810|Placebo Comparator|Placebo|Matching placebo capsules orally 25 mg every 12 hours for 36 weeks
32976358|NCT04693364||Observational (questionnaire, 3D breast model, discussion)|Patients complete questionnaire over 5 minutes about difficulties in making decision about breast cancer treatment, then participate in a consultation with regular care doctor and study doctor/study staff using the 3D breast model. Patients then complete questionnaires over 5-10 minutes about their opinions on the breast model and different breast surgical treatment options available.
32976359|NCT04691037||CCTA|
32976360|NCT04690686|Experimental|LW-02 device immunopheresis combined with atezolizumab|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus atezolizumab 1200 milligrams (mg) q3w until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first [N=8]
32976361|NCT04690686|Experimental|LW-02 device immunopheresis combined with weekly paclitaxel|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus paclitaxel 80 mg/m2 /week × 6 followed by 2 weeks rest until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
32976362|NCT04690686|Experimental|LW-02 device immunopheresis|LW-02 column immunopheresis treatments ~3x/week for 16 weeks alone until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
32976363|NCT04688866||Pregnant women with cervical insufficiency (Cases)|Pregnant women with a shortened (<25 mm) or dilated cervix in the second trimester (or late first trimester)
32976364|NCT04688866||Pregnant women without cervical insufficiency (Controls)|Pregnant women with a normal-length (>= 25 mm) and closed cervix in the second trimester (or late first trimester)
32976365|NCT04688411|Other|MED-Go app Intervention|Participants will use MED-Go app intervention for a total of 12 weeks
32976366|NCT04688411|No Intervention|Control Arm|Standard of care
32976367|NCT04685369||Active smokers with wet AMD|
32976368|NCT04682977|Experimental|IPROACTIF|12 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
32976369|NCT04682977|Other|Usual care|Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.
32976370|NCT04682626|Experimental|VD3 group|"Dietary Supplement: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg once weekly for 8 weeks.~."
32976371|NCT04682626|No Intervention|Control group|none has been administered
32976372|NCT04676607|Experimental|treatment group|SHR7390
32976373|NCT04675411|Other|usual care|After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
32976374|NCT04675411|Experimental|Smart Care Model|"The smart care model (SCM) will contain the components of geriatric assessment, continuous rehabilitation, and discharge planning.~Sensors will be installed in bedrooms and living areas of the patient's home to receive signals from the smart clothing. Instant alerts and feedbacks from research nurses to family caregivers about the patient's condition and activity level will be provided."
32976375|NCT04665622|Other|Fronto-temporal Dementia|10 subjects
32976376|NCT04665622|Other|Alzheimer's Dementia|20 subjects
32976377|NCT04665622|Other|Parkinson's Disease|20 subjects
32976378|NCT04665622|Other|Healthy volunteers|20 subjects
32976379|NCT04656236|Experimental|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
32976380|NCT04656236|Placebo Comparator|Control|3 hours of continuously intravenous infusion of saline (NaCl).
32976381|NCT04654546|Experimental|Abdominal scans|Participants who performed an abdominal CT exam up to one month prior to the experimental ultrasound exam.
32976382|NCT04652609|Experimental|PRESIONA|An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
32976383|NCT04652609|No Intervention|Control group|Patients undergoing usual medical treatment
32976384|NCT04647513|Experimental|Art Filler Fine Lines (forehead)|Injection of Art Filler Fine Lines in Forehead wrinkles
32976385|NCT04647513|Experimental|Art Filler Fine Lines (upper lip)|Injection of Art Filler Fine Lines in upper lip wrinkles
32976386|NCT04647513|Experimental|Art Filler Fine Lines (cheek folds)|Injection of Art Filler Fine Lines in cheek folds
32976387|NCT04647513|Experimental|Art Filler Fine Lines (crow's feet)|Injection of Art Filler Fine Lines in crow's feet
32976388|NCT04647513|Experimental|Art Filler Universal (lips volume)|Injection of Art Filler Universal in lips
32976389|NCT04647513|Experimental|Art Filler Universal (nasolabial folds)|Injection of Art Filler Universal in nasolabial folds
32976390|NCT04647513|Experimental|Art Filler Lips (lips volume)|Injection of Art Filler Lips in lips
32976391|NCT04647513|Experimental|Art Filler Lips (very deep nasolabial folds)|Injection of Art Filler Lips in very deep nasolabial folds
32976392|NCT04645576|Other|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
32976393|NCT04645576|Other|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
32976394|NCT04645576|Other|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
32976395|NCT04645576|Experimental|Chin|The chin will only receive one injection of Art Filler Volume.
32976396|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
32976397|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
32976398|NCT04644159||Staff of health care institutions|Staff of health care institutions
32976404|NCT04623372|Experimental|suture|
32976405|NCT04623372|Experimental|Directed wound healing|
32976406|NCT04621682|Active Comparator|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
32976407|NCT04621682|Active Comparator|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
32976408|NCT04616846|No Intervention|Control cohort|
32976409|NCT04616846|Experimental|Infected cohort|
32976410|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
32976411|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
32976412|NCT04614142|Experimental|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
32976413|NCT04613739|Experimental|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
32976414|NCT04613739|No Intervention|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
32976415|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
32976416|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
32976417|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
32976418|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
32976419|NCT04604691|Experimental|Blinatumomab Treatment|
32976420|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
32976421|NCT04594525|Experimental|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
32976422|NCT04594525|No Intervention|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
32976423|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
32976424|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as > 11 infusions per year
32976425|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
32976426|NCT04579848|Active Comparator|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.~Additional Folic acid 1mg prescribed daily."
32976427|NCT04579848|Placebo Comparator|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.~Additional Folic acid 1mg prescribed daily."
32976428|NCT04575792||C group|C group: control group, children who do not practice oral habits.
32976429|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
32976430|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
32976431|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
32976432|NCT04561154|Experimental|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
32976433|NCT04548245||Term|
32976434|NCT04548245||Preterm|
32976435|NCT04542564|Experimental|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
32976436|NCT04542564|Placebo Comparator|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
32976437|NCT04542317|Experimental|REACH VN|A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
32976438|NCT04542317|Placebo Comparator|Enhanced control|A single session focused on education about the nature of dementia.
32976439|NCT04537884|Experimental|Treatment with UBX1325|UBX1325, single intravitreal injection, ascending dose
32976440|NCT04535349|Other|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
32976441|NCT04535349|Other|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
32976442|NCT04535349|Other|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
32976443|NCT04534686|Experimental|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
32976444|NCT04534686|Experimental|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
32976445|NCT04530006|Experimental|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
32976446|NCT04526925|Active Comparator|standard CPET|Standard CPET will be performed without in-line filter
32976447|NCT04526925|Experimental|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
32976448|NCT04519320|Other|SARS-COV 2 Patients|
32976449|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
32976450|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
32976451|NCT04508647|Experimental|Treatment|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed. Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
32976452|NCT04505020|Experimental|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
32976453|NCT04505020|Other|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
32976454|NCT04500795|Experimental|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
32976455|NCT04500795|No Intervention|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
32976456|NCT04496245|Active Comparator|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
32976457|NCT04496245|Experimental|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
32976458|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
32976459|NCT04492410|Experimental|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
32976460|NCT04476745|Experimental|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
32976461|NCT04476745|No Intervention|Control group|Control group No intervention was given
32976462|NCT04471545|Experimental|Interventional group|Intervention arm: PECS II block with ropivacaine
32976463|NCT04471545|Placebo Comparator|Control group|Control arm: PECS II block with placebo (saline)
32976464|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
32976465|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
32976466|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
32976467|NCT04468971|Placebo Comparator|Arm 1|Excipient
32976468|NCT04468971|Experimental|Arm 2|CK0802: 1x10^8 cells
32976469|NCT04468971|Experimental|Arm 3|CK0802: 3x10^8 cells
32976470|NCT04458805|Experimental|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
33104964|NCT05030220||Phase 2|Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.
33104965|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
33104966|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
33104967|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
33104968|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
32976471|NCT04458805|Placebo Comparator|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
32976472|NCT04458753|Experimental|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
32976473|NCT04458753|Active Comparator|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
32976474|NCT04458441|Active Comparator|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
32976475|NCT04458441|No Intervention|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
32976476|NCT04450888|Other|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
32976477|NCT04450888|Other|Model B|Average CVD-free life expectancy gain per year.
32976478|NCT04450888|Other|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
32976479|NCT04450888|Other|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
32976480|NCT04448951||sepsis/septic shock|target population
32976481|NCT04448951||non-septic critically ill|demographically-matched control group
32976482|NCT04448951||healthy control|control group
32976483|NCT04444076|Experimental|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
32976484|NCT04444076|No Intervention|Standard of Care|Supraspinatus tendon repair.
32976485|NCT04443751|Experimental|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
32976486|NCT04436042|Experimental|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
32976487|NCT04433390|Experimental|Naloxegol group|naloxégol tablet by oral route
32976488|NCT04433390|Placebo Comparator|Placebo group|inert tablet by oral route
32976489|NCT04432272|Experimental|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
32976490|NCT04432272|Experimental|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
32976491|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
32976492|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
32976493|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
32976494|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
32976495|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
32976496|NCT04407806|Active Comparator|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
32976497|NCT04407806|Active Comparator|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
32976498|NCT04399746|Experimental|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
32976499|NCT04399746|No Intervention|Control|No intervention
32976500|NCT04391608|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
32976501|NCT04391608|No Intervention|TDF dose reduction|TDF dose reduction
32976502|NCT04383756|Experimental|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
32976503|NCT04383756|Active Comparator|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
32976504|NCT04368299|Experimental|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
32976505|NCT04368299|Active Comparator|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
32976506|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
32976507|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
32976508|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
32976509|NCT04337931|Experimental|Cohort 1|APX005M every 3 weeks
32976510|NCT04337931|Experimental|Cohort 2|APX005M every 2 weeks
32976511|NCT04337931|Experimental|Cohort 3|APX005M every 2 weeks plus radiation therapy
32976512|NCT04331379|Experimental|Nasal Elevator|
32976513|NCT04331379|Active Comparator|Taping Alone|
32976514|NCT04329715|Experimental|Expedited instructions|
32976515|NCT04329715|Active Comparator|Restricted instructions|
32976516|NCT04328090|Experimental|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
32976517|NCT04328090|No Intervention|Standard of care|Teams in the control arm will continue with usual standard clinical care.
32976518|NCT04324021|Active Comparator|Emapalumab|Emapalumab i.v. infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
32976519|NCT04324021|Active Comparator|Anakinra|Anakinra i.v. infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
32976520|NCT04324021|No Intervention|Standard of care|Standard of care according to local practice
32976521|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
32976522|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
32976523|NCT04318821|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
32976524|NCT04318821|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
32976525|NCT04318808|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
32976526|NCT04318808|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
32976527|NCT04311437|Experimental|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
32976528|NCT04311437|Placebo Comparator|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
32976529|NCT04310956|Experimental|Y-Knot group|Patients use Y-Knot all-suture anchor
32976530|NCT04310956|Active Comparator|Biocomposite suture anchor|Patients use Biocomposite suture anchor
32976531|NCT04309513|Active Comparator|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
32976532|NCT04309513|Experimental|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
32976533|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
32976534|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
32976535|NCT04304729||Diabetics|Girls and boys aged 14-18 years old, living with Type 1 Diabetes.
32976536|NCT04304729||Control|Age and sex matched adolescents without any type of diabetes
32976537|NCT04302168|Active Comparator|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
32976538|NCT04302168|Placebo Comparator|Placebo Group|Placebo pill twice daily for total of 8 weeks.
32976539|NCT04301271|Experimental|Simvastatin|Simvastatin and Escitalopram
32976540|NCT04301271|Placebo Comparator|Placebo|Placebo and Escitalopram
32976541|NCT04300738|Other|Patients undergoing CT scann for CCS determination|
32976542|NCT04287049|Experimental|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
32976543|NCT04265365|Experimental|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
32976544|NCT04265365|Experimental|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
32976545|NCT04265365|Sham Comparator|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
32976546|NCT04265365|Experimental|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
32976547|NCT04265365|Experimental|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
32976548|NCT04265365|Sham Comparator|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
32976549|NCT04265365|Experimental|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
32976550|NCT04265365|Experimental|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
32976551|NCT04265365|Sham Comparator|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
32976552|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
32976553|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
32976554|NCT04260945|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
32976555|NCT04260932|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
32976556|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
32976557|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
32976558|NCT04249557|Experimental|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 6-18 patients per group (class size may be limited by social distancing policy in Hong Kong), homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise. (If sports center are closed by the Government, the classes will be conducted online)
32976559|NCT04248751|Experimental|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
32976560|NCT04248751|Active Comparator|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
32976561|NCT04246008|Experimental|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
32976562|NCT04246008|Active Comparator|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
32976563|NCT04238845|Active Comparator|SMC + Vitamin A alone|Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone
32976564|NCT04238845|Experimental|SMC+ Vitamin A + Plumpy'Doz|Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation
32976565|NCT04238845|Experimental|SMC+ Vitamin A + Zinc|Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation
32976566|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
32976567|NCT04232202|Experimental|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
32976568|NCT04232202|Active Comparator|Control|Standard extraction procedure.
32976569|NCT04228822|Experimental|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
32976570|NCT04228822|No Intervention|Control|Standard diet defined as 45-65% total energy intake
32976571|NCT04223037|Active Comparator|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
32976572|NCT04223037|Experimental|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
32976573|NCT04218838|Active Comparator|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
32976574|NCT04218838|Active Comparator|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
32976575|NCT04213365|Other|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
32976576|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
32976577|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
32976578|NCT04211753|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
32976579|NCT04211753|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
32976580|NCT04210661|Active Comparator|classic prediction software|test with classic precition software
32976581|NCT04210661|Experimental|prediction software with spell checker|test with prediction software with spell checker
33322852|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
33322853|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
32976582|NCT04209621|Other|Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Duvelisib with ibrutinib will be administered for the first six 28-day (± 7) cycles followed by duvelisib alone until disease progression or intolerance. Duvelisib is an orally administered at 15 mg twice a day (dose level 1) or 25 mg twice day (dose level 2). Subjects will continue the same dose of ibrutinib prior to study enrollment for the first six 28-day cycles. Ibrutinib is an orally administered and provided as 140 mg white opaque capsules or tablets in 4 strengths: 140 mg, 280 mg, 420 mg, and 560 mg.
32976583|NCT04207983|Experimental|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
32976584|NCT04207983|Experimental|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
32976585|NCT04186663|Experimental|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
32976586|NCT04180267|No Intervention|Control Group|Subject assigned to Control Group will not receive LMHFV
32976587|NCT04180267|Active Comparator|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
32976588|NCT04179734|Experimental|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
32976589|NCT04179734|Placebo Comparator|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
32976590|NCT04176302|Active Comparator|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
32976591|NCT04176302|Active Comparator|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
32976592|NCT04176302|Placebo Comparator|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
32976593|NCT04158219|Experimental|Treatment|Behavioral activation for health and depression (BA-HD)
32976594|NCT04156217|Experimental|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
32976595|NCT04155853|Active Comparator|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
32976596|NCT04155853|Active Comparator|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
32976597|NCT04155437|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
32976598|NCT04155437|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
32976599|NCT04154423|Active Comparator|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
32976600|NCT04154423|Active Comparator|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
32976601|NCT04154371|Experimental|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
32976602|NCT04152824|Experimental|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
32976603|NCT04152824|No Intervention|Control Group|Leaders in the control group will be usual practice
32976604|NCT04131959|Experimental|Pharmacodynamic population|Single arm
32976605|NCT04121559|Experimental|Intervention|A&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
32976606|NCT04121559|No Intervention|Control|Comparison areas: standard activities at government primary schools
32976607|NCT04112654|Active Comparator|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
32976608|NCT04112654|Experimental|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
32976609|NCT04108026|Experimental|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
32976610|NCT04101253|Experimental|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
32976611|NCT04098406|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
32976612|NCT04098406|Experimental|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
33322854|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
33322855|NCT03940794|Experimental|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
33322856|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
33322857|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
33322858|NCT05118256|No Intervention|No intervention - standard of care|A group of patients with PMF will be treated per standard of care on site
32976613|NCT04095104|Experimental|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
32976614|NCT04095104|Placebo Comparator|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
32976615|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
32976616|NCT04086966|Experimental|Metastatic Prostate Cancer Arm|[68Ga]PSMA-11 PET/MRI or PET/CT for guiding the radiation treatment plan in patients with known or suspected locally metastatic prostate cancer
32976617|NCT04084990|Experimental|aPAP|Nightly use of aPAP when sleeping through the date of delivery
32976618|NCT04084990|No Intervention|No aPAP|No use of aPAP (standard of care)
32976619|NCT04067622|Other|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
32976620|NCT04067622|Other|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
32976621|NCT04067284|Active Comparator|Education|Nutrition education on dietary diversity.
32976622|NCT04067284|Experimental|Yogurt|A combination of similar education plus daily supplementation of homemade yogurt
32976623|NCT04067284|Active Comparator|Control|Control group.
32976624|NCT04061564|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
32976625|NCT04061564|Sham Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
32976626|NCT04045405|Experimental|CDR132L|
32976627|NCT04045405|Placebo Comparator|Saline|
32976628|NCT04044729|Active Comparator|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~CBD"
32976629|NCT04044729|Placebo Comparator|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~placebo"
32976630|NCT04012944|Experimental|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
32976631|NCT04011150|Experimental|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
32976632|NCT04011150|Active Comparator|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
32976633|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (<) 60 kg, orally, once daily as per routine clinical practice.
32976634|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
32976635|NCT03995589|Experimental|Walking Group|
32976636|NCT03995589|Active Comparator|Control|
32976637|NCT03983343|No Intervention|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
32976638|NCT03983343|Active Comparator|intervention group|Closing the perineal skin using adhesive glue- exofin® (Octyl-2-cyanoacrylate)
32976639|NCT03979547|Experimental|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
32976640|NCT03979547|No Intervention|Standard of Care|Subjects are instructed to maintain their current activity level.
32976641|NCT03979534|Experimental|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
32976642|NCT03979534|No Intervention|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
32976643|NCT03978000|Active Comparator|IBP-9414|
32976644|NCT03978000|Placebo Comparator|Placebo|
32976645|NCT03977779|Experimental|Prophylactic biodegradable pancreatic stent placement|
32976646|NCT03974243|Experimental|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.~Intervention: Drug: Chiauranib and Chidamide"
32976647|NCT03970109|Active Comparator|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
32976648|NCT03970109|Active Comparator|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
32976649|NCT03970109|Placebo Comparator|Matched Placebo|2 placebo tablets once a day
32976650|NCT03967925|Active Comparator|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
32976651|NCT03967925|Placebo Comparator|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
32976652|NCT03958006|Experimental|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
32976653|NCT03954743|Experimental|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
32976654|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
32976655|NCT03954223|Experimental|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
32976656|NCT03954223|Experimental|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
32976657|NCT03954223|Experimental|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
32976658|NCT03952663|Experimental|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
32976659|NCT03952663|Active Comparator|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
32976660|NCT03932318|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
32976661|NCT03925584|Experimental|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
32976662|NCT03915327|Experimental|Intravenous iron group|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
32976663|NCT03915327|No Intervention|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
32976664|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
32976665|NCT03911830|Experimental|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
32976666|NCT03911128||Participants with newly diagnosed ALL|
32976667|NCT03905148|Experimental|Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.|Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day
32976668|NCT03905148|Experimental|Part B: Group 1|Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants
32976669|NCT03905148|Experimental|Part B: Group 2|Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants
32976670|NCT03905148|Experimental|Part B: Group 3|Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants
32976671|NCT03897439|Active Comparator|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
32976672|NCT03897439|Experimental|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
32976673|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of <8 hours per day ii. Self-perceived insufficient sleep during school days
32976674|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of >=8 hours per day ii. Self-perceived sufficient sleep during school days
32976675|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
32976676|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
32976677|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
32976678|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
32976679|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
32976680|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
32976681|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
32976682|NCT03880565|Other|Standard ACLS Resuscitation|Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
32976683|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
32976684|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
32976685|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
32976686|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
32976687|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
32976688|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
32976689|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
32976690|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
32976691|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
32976692|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
32976693|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
32976694|NCT03867643||Hepatitis B vaccine booster|Children with anti-HBs at a level of<10mIU/mL or [10,100) mIU/mL before booster.
32976695|NCT03867643||Observation|Children with anti-HBs at a level of >100mIU/mL or [10,100) mIU/mL before booster.
32976696|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
32976697|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
32976698|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
32976699|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
32976700|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
32976701|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
32976702|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
32976703|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
32976704|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
32976705|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
32976706|NCT03788993|Experimental|Blue-depleted evening light condition|
32976707|NCT03788993|Active Comparator|Normal light condition|
32976708|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
32976709|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
32976710|NCT03782792|Experimental|Spesolimab|
32976711|NCT03782792|Experimental|Placebo|
32976712|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
32976713|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
32976714|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
32976715|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
32976716|NCT03762161|Experimental|Intervention TAS-102|
32976717|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
32976718|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
32976719|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
32976720|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
33322859|NCT05118256|Experimental|Experimental - Pirfenidone plus standard of care|A group of patients with PMF will be treated with pirfenidone plus standard of care on site
32976722|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
32976723|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
33322860|NCT03940716|Experimental|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
33322861|NCT03940716|No Intervention|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
33322862|NCT05057182|Experimental|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
33322863|NCT01114542|Experimental|IDeg 0.4 U/kg|
33322864|NCT01114542|Experimental|IDeg 0.6 U/kg|
33322865|NCT01114542|Experimental|IDeg 0.8 U/kg|
33322866|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
33322867|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
33322868|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
33322869|NCT01367938||OMNI Apex Ultracongruent Knee Device|
33322870|NCT05135494|Experimental|Experimental Group|Experimental Group: Inspiratory Muscle Training + rehabilitation program
32976724|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
32976725|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
32976726|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
32976727|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
32976728|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
32976729|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
32976730|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
32976731|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
32976732|NCT03733119|Experimental|Akt/ERK inhibitor ONC201|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32976733|NCT03733119|Experimental|Akt/ERK inhibitor ONC201, methionine-restricted diet|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32976734|NCT03724669|Placebo Comparator|waiting list|
32976735|NCT03724669|Experimental|Benzodiazepines and Z-drugs knowledge|
32976736|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
32976737|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
32976738|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
32976739|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
32976740|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
33411314|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
33322871|NCT05135494|Other|Control Group|Control Group: rehabilitation program
33322872|NCT01210092||Macintosh #3 Laryngoscope|
32976741|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
33322873|NCT01210092||Glidescope|
33322874|NCT01210092||Ambu Pentax AWS|
33322875|NCT01210092||McGrath|
33322876|NCT01210092||Airtraq|
33322877|NCT01210092||Storz C-MAC|
33322878|NCT05121220|Experimental|fixed mandibular lingual rectangular retainer 0.673 x 0.268 mm|0.673 x 0.268 mm 8-stranded wire Bond A Braid (Reliance Orthodontic Products, USA) will be bonded in mandible canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
32976742|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
32976743|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
32976744|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
32976745|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
32976746|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
32976747|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
32976748|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
32976749|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
32976750|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
32976751|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
32976752|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
32976753|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
32976754|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
32976755|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
32976756|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
32976757|NCT03664765|Active Comparator|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
32976758|NCT03664765|Sham Comparator|Control arm|Daily sham exercises
32976759|NCT03663829||Participants RA who have received a TNFi|
32976760|NCT03663829||Participants with RA who have received abatacept|
32976761|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
32976762|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
32976763|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
32976764|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
32976765|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
32976766|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
32976767|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
32976768|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
32976769|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
32976770|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
32976771|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
32976772|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
32976773|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
32976774|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
32976775|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
32976776|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
32976777|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
32976778|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
32976779|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
32976780|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
32976781|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
32976782|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
32976783|NCT03634124|Experimental|interventional group|
32976784|NCT03633461|Active Comparator|OC-02 (simpinicline) spray spray, 11.1 mg/ml|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
32976785|NCT03633461|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
32976786|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
32976787|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
32976788|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
32976789|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
32976790|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
32976791|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
32976792|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeks
32976793|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeks
32976794|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
32976795|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
32976796|NCT03620968|No Intervention|Group 1|Control, no intervention
32976797|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
32976798|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
32976799|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;~Maintenance I (1 cycle = 56 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);~Maintenance II (1 cycle = 84 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
32976800|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
32976801|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
32976802|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
32976803|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
32976804|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
32976805|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
32976806|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
32976807|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
32976808|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
32976809|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
32976810|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
32976811|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
32976812|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
32976813|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
32976814|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
32976815|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
32976816|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
32976817|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
32976818|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
32976819|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
32976820|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
32976821|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
32976822|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
32976823|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
32976824|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
32976825|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
32976826|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
32976827|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
32976828|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
32976829|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
32976830|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
32976831|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
32976832|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
32976833|NCT03498495|Experimental|SMART Intervention|
32976834|NCT03498495|No Intervention|Usual Care|
32976835|NCT03496597||Patients|type 1 diabetes patients
32976836|NCT03496597||Healthy controls|non diabetic control subjects of the same age
32976837|NCT03496597||Dyslipidemic controls|non-diabetic control participants with familial dyslipidemia
32976838|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
32976839|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
32976840|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
32976841|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
32976842|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
32976843|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
32976844|NCT03468556|Experimental|test drug|2 tabs of SNP-610
32976845|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
32976846|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
32976847|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
32976848|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
32976849|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
32976850|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
32976851|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
32976852|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
32976853|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
32976854|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
32976855|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
32976856|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
32976857|NCT03424343||cancer survivor, parents, sibling|
32976858|NCT03416088|Experimental|Beverage consumption|Drink 300ml red wine (alcohol concentration:12.5%), 300ml coffee (caffeine concentration 72 mg), or 300ml water.
32976859|NCT03416088|Experimental|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading.
32976860|NCT03416088|Experimental|Body motion|Exercise and body postural changes.
32976861|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
32976862|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
32976863|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
32976864|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
32976865|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
32976866|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
32976867|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
33411315|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
32976868|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
32976869|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
32976870|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
32976871|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
32976872|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
32976873|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
32976874|NCT03369431|Other|Vivomixx, then placebo|This group starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
32976875|NCT03369431|Other|Placebo, then Vivomixx|This group starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
32976876|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
32976877|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
32976878|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
32976879|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
32976880|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
32976881|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
32976882|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
32976883|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
32976884|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
32976885|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
32976886|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
32976887|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
32976888|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
32976889|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
32976890|NCT03344744||Control|Healthy volunteers
32976891|NCT03336866|Placebo Comparator|Placebo|Normal saline
32976892|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
32976893|NCT03336411|Active Comparator|mHealth|
32976894|NCT03336411|Experimental|Personalized mHealth|
32976895|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
32976896|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
32976897|NCT03332173|Experimental|Zanubrutinib|Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity
32976898|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
32976899|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
32976900|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
32976901|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
32976902|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
32976903|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
32976904|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
32976905|NCT03317405|Experimental|Cohort I (endoxifen hydrochloride)|Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
32976906|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
32976907|NCT03315039|Experimental|Liposomal annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
32976908|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
32976909|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
32976910|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
32976911|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
32976912|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
32976913|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
32976914|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
32976915|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
32976916|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
32976917|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
32976918|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
32976919|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
32976920|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
32976921|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
32976922|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
33411316|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
33411317|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
33411318|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
33411319|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
33411320|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
33411321|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
33411322|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
33411323|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
33411324|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
33411325|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
33411326|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
33411327|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
33411328|NCT01068912|Placebo Comparator|Placebo|Placebo
33411329|NCT04563143|Other|Novel stimulation|All subjects will undergo periods of stimulation using novel stimulation patterns
33411330|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
33411331|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
33411332|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
33411333|NCT03614546|Other|A（surgery） group|Hepatectomy
33411334|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
33322879|NCT05121220|Experimental|fixed mandibular lingual round retainer 0.40 mm|0.40 mm round 6-stranded wire (Forestadent, Germany) will be bonded on 6 mandibular frontal teeth, canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
33322880|NCT05121220|Active Comparator|removable mandibular retainer|Group without fixed retainer will be wearing removable thermoplastic vacuum-formed Essix retainer
33322881|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
33322882|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
33322883|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
32976923|NCT03252314||Subjects with ruptured aneurysms|
33322884|NCT05188924|Experimental|DKF-306|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
33322885|NCT05188924|Placebo Comparator|Placebo|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
33322886|NCT03941886|No Intervention|Non-intervention group|Participants receive routine prenatal care
33322887|NCT03941886|Experimental|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
33322888|NCT05045014||Patient group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task. In addition, X-ray images taken during routine follow-ups will be used to determine the location, type of curvature and Cobb angle of the scoliosis. The degree of rotation will be measured with a mobile application called Scoliodetector. Quality of life is planned to be evaluated with the Scoliosis Research Society-22 questionnaire.
32976924|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
32976925|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
32976926|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
32976927|NCT03227081|No Intervention|Sleep|Sleep
32976928|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
32976929|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
32976930|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
32976931|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
32976932|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
32976933|NCT03180294|Experimental|Bupropion 150 mg|One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule daily for 8 weeks; one placebo capsule daily for one 1 week (titration off).
32976934|NCT03180294|Experimental|Bupropion 300 mg|One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
32976935|NCT03180294|Placebo Comparator|Placebo|One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
32976936|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
32976937|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months~Bicalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
32976938|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months~Abiraterone acetate by mouth once/day for 6 months~Prednisone by mouth once/day for 6 months~Apalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
32976939|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
32976940|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
32976941|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
32976942|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
32976943|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
32976944|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
32976945|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
32976946|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
32976947|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
32976948|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
32976949|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
32976950|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
32976951|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
32976952|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
32976953|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
32976954|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
32976955|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
32976956|NCT03079024|No Intervention|Treatment as Usual (TAU)|Treatment as Usual
32976957|NCT03078855|Experimental|Vitamin D plus rituximab|
32976958|NCT03078855|Placebo Comparator|Placebo plus rituximab|
32976959|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
32976960|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
32976961|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
32976962|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
32976963|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
32976964|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
32976965|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
32976966|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
32976967|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
32976968|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
33322889|NCT05045014||Control group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task.
33322890|NCT05009290|Experimental|Treatment group：SHR3680 + ADT|
32976969|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
32976970|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
32976971|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
32976972|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
32976973|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
33322891|NCT05009290|Placebo Comparator|Treatment group : Placebo + ADT|
33322892|NCT01208298|Experimental|# 1727|Cold sore Patch
33322893|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
33322894|NCT03942198|Experimental|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
32976974|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
32976975|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
33322895|NCT03942198|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
33322896|NCT01359514|Active Comparator|Duloxetine|
33322897|NCT01359514|Active Comparator|Pregabalin|
32976976|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
32976977|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
33322898|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
33322899|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
32976978|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
33322900|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
33322901|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
33322902|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
33322903|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
33322904|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
33322905|NCT01114776||Controls|
33322906|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
33322907|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
33322908|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
33322909|NCT01368094|Active Comparator|Standard drainage|
33322910|NCT01368094|Experimental|Short drainage|
33322911|NCT05188846|Experimental|SDF|
33322912|NCT05188846|Active Comparator|SDF + ART ( SMART technique )|
33322913|NCT01110486|Experimental|Monotherapy, once daily|
33322914|NCT01110486|Experimental|Combination with carboplatin|
32976979|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
32976980|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
32976981|NCT03011775|Experimental|Pioglitazone + Standard Care|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
32976982|NCT03011775|Other|Standard Care|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
32976983|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
32976984|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
32976985|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
32976986|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
32976987|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
32976988|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
32976989|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
32976990|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
32976991|NCT02951104|Experimental|USCOM|
32976992|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
32976993|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
32976994|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
32976995|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
32976996|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
32976997|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
32976998|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
32976999|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
32977000|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
32977001|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
32977002|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
32977003|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
32977004|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
32977005|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
32977006|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
32977007|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
32977008|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
32977009|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
33322915|NCT01110486|Experimental|Combination with docetaxel|
33322916|NCT01110486|Experimental|Monotherapy, twice daily|
33322917|NCT01110486|Experimental|IV Monotherapy, once daily|
32977010|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
32977011|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
32977012|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
32977013|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
32977014|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
32977015|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
32977016|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
32977017|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
32977018|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
32977019|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
32977020|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
32977021|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
32977022|NCT02797964|Experimental|Open label|
32977023|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
32977024|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
32977025|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
32977026|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
33322918|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
33322919|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
32977029|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
32977030|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for >1 year"
32977031|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
32977032|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
32977033|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
32977034|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
32977035|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
32977036|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
32977037|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care~(N=7 participants in this group)"
33033143|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
33322920|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
33322921|NCT04890028|Experimental|F-DOPA PET/CT|Drug: 18 F-DOPA Radiation: F-DOPA PET CT
33322922|NCT01359670|Experimental|Tadalafil|
33322923|NCT01359670|Experimental|Sildenafil|
33322924|NCT03942588|Experimental|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
33322925|NCT03942588|No Intervention|Control|Usual activities for 10 weeks
33322926|NCT04784806|Experimental|Consumption of ground beef|Consuming 106g of cooked ground beef (85% lean) to deliver 20g of protein.
32977038|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.~(N=7 participants in this group)"
32977039|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
32977040|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
32977041|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
32977042|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
32977043|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
32977044|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
32977045|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
32977046|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
32977047|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
32977048|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
32977049|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
32977050|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
33411335|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
33411336|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
33411337|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
32977051|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
32977052|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
32977053|NCT02636322|Experimental|Arm I (RLI WITH EPOCH)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
33411338|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
33411339|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
33411340|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
33411341|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
33411342|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
33411343|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
33411344|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
33411345|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
33411346|NCT01314131|Experimental|Intervention group|
33411347|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy
32977054|NCT02636322|Experimental|Arm II (RLI WITH R-CHOP)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
32977055|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
32977056|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
32977057|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
32977058|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
32977059|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
32977060|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
32977061|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
32977062|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
32977063|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
32977064|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
32977065|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
32977066|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
33322927|NCT04784806|Experimental|Consumption of ground pork|Consuming 118g of cooked ground pork (72% lean) to deliver 20g of protein.
33322928|NCT04784806|Experimental|Consumption of tofu burger|Consuming 113g of cooked tofu to deliver 20g of protein.
33322929|NCT04784806|Experimental|Consumption of Beyond Meat burger|Consuming 113g of Beyond Meat burger to deliver 20g of protein.
33322930|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
33322931|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
33322932|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
33322933|NCT04688944||patients|(1) age ≥ 45 years, (2) diagnosed LSS through a combination of clinical history, physical examination and radiological changes showing spinal canal stenosis on magnetic resonance imaging
33322934|NCT04688944||healthy people|(1) age ≥ 45 years; (2) without chronic low back pain (LBP)
32977067|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
32977068|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
32977069|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
32977070|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
32977071|NCT02556450|No Intervention|Control group|Only background treatment
32977072|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
32977073|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
32977074|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
32977075|NCT02527681|Experimental|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
32977076|NCT02526017|Experimental|Phase 1a Monotherapy Dose Escalation|Cabiralizumab administered at 2 mg/kg every 2 weeks (Q2W), 4 mg/kg Q2W and 6 mg/kg Q2W in participants with any solid tumor.
32977077|NCT02526017|Experimental|Phase 1a Combination Therapy Dose Escalation|Nivolumab 3 mg/kg Q2W + cabiralizumab at the following doses: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 6 mg/kg Q2W. Also nivolumab 3 mg/kg + cabiralizumab 4 mg/kg every 3 weeks (Q3W). Participants with any solid tumor.
32977078|NCT02526017|Experimental|Phase 1b Combination Therapy Dose Expansion|The expansion phase would use the recommended dose determined in Phase 1a: cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Q2W. Participants are enrolled for the following advanced cancer types: non-small cell lung cancer (anti-programmed cell death 1 [PD1] targeted drug naïve), non-small cell lung cancer (prior treatment with anti-PD-1), pancreatic cancer, ovarian cancer, renal cell cancer, glioblastoma, and melanoma.
32977079|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
32977080|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
32977081|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
32977082|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
32977083|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
32977084|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
33322935|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
33322936|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
32977087|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
32977088|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
32977089|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
32977090|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
32977091|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
33322937|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
33322938|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
32977092|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
32977093|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
32977094|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
32977095|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
32977096|NCT02354079|Other|genetic analysis|
32977097|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
32977098|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
32977099|NCT02333708||GCA group|
32977100|NCT02333708||Inflammatory syndrome (without GCA) group|
32977101|NCT02333708||Without inflammatory syndrome and without GCA group|
32977102|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
32977103|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
32977104|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
32977105|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32977106|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
32977107|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
32977108|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
32977109|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
32977110|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
33411348|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
33411349|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
33411350|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
32977111|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
32977112|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
32977113|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
32977114|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
32977115|NCT02078206|No Intervention|Treatment as usual|
33104969|NCT05006313|Experimental|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
32977116|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
32977117|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
32977118|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
32977119|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
32977120|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
32977121|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
32977122|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
32977123|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
32977124|NCT01982630|Experimental|Part 1: MK-8521 64/120 μg/day|Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.
32977125|NCT01982630|Experimental|Part 1: MK-8521 34/72 μg/day|T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.
32977126|NCT01982630|Active Comparator|Part 1: Liraglutide 0.6/1.2/1.8 mg/day|T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.
32977127|NCT01982630|Placebo Comparator|Part 1: Placebo for MK-8521|T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.
32977128|NCT01982630|Experimental|Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM|T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.
32977129|NCT01982630|Active Comparator|Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM|T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.
32977130|NCT01982630|Placebo Comparator|Part 2: Placebo for MK-8521-T2DM|T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.
32977131|NCT01982630|Experimental|Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese|Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.
32977132|NCT01982448|Experimental|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
32977133|NCT01982448|Experimental|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
32977134|NCT01951469|Experimental|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) chemotherapy or Pemetrexed (D1)+nedaplatin (D1) chemotherapy, every 28 days
32977135|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
32977136|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32977137|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
32862253|NCT04934514|Experimental|Ia stage-Dose escalation|"Using the 3+3 model, 1 subject was included in the 6 mg/kg dose group, and then 3 to 6 patients with HER2-positive advanced solid tumors that failed standard treatment were included in the fixed 3 dose groups (10 mg/kg, 15 mg/kg, and 20 mg/kg) ."
32862254|NCT04934514|Experimental|Ib stage-Dose extension|In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
32862255|NCT04934514|Experimental|IIa stage-Single-agent study (cohort 1)|After the completion of the dose escalation in the 20 mg/kg dose group (Phase Ia), a total of 30 patients with HER2-positive advanced biliary system tumors who have failed standard treatment will be enrolled in the 20 mg/kg dose group. Every 3 weeks is a cycle, and the drug is administered once on the first day of each cycle, and the treatment is continued until any end-point event occurs.
32862256|NCT04934514|Experimental|IIa stage - IAH0968 combined GP regimen study (cohort 2)|After the completion of the dose escalation in the 20 mg/kg dose group (phase Ia), a total of 30 patients with newly treated HER2-positive advanced biliary system tumors will be enrolled in the 20 mg/kg dose group combined with the GP regimen (gemcitabine + cisplatin) . Every 3 weeks is a cycle, treatment until any end-point event occurs.
32862257|NCT05586841|Experimental|Dalpiciclib + Chidamide|Dalpiciclib will be administered in a dose of 100 mg/d or 125 mg/d. Chidamide shall be designed in a dose of 25 mg/BIW or 20 mg/BIW
32862258|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
32862259|NCT01365819|Placebo Comparator|Sugar pill|Placebo
32862260|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
32862261|NCT04932174|Experimental|High-intensity Interval Training|Group 2: the included 15 subjects will participate in High intensity Interval training exercise running on treadmill for 12 weeks, 3 times / week.
32862262|NCT04932174|Active Comparator|Low-intensity Continuous Training|Group 1: the included 15 subjects will participate in low intensity continuous exercise on treadmill for 12 weeks, 3 times / week
32862263|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
32862264|NCT04932408|Experimental|Hip Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed around the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
32862265|NCT04932408|Experimental|Chest Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
32862266|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
32862267|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
32862268|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
32862269|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
32862270|NCT04931940|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
32862271|NCT04931940|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
32862272|NCT04847479|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to their close contacts.
32862273|NCT04847479|Active Comparator|Test referral distribution|Participants in the test referral arm receive text messages providing testing information to send to their close contacts.
32862274|NCT04673019|Experimental|Immediate Intervention|"The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months:~Months 1- 3 (Approximately Day 1-Day 90)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator. We are interested in learning whether the phone calls are necessary or if the Nurse AMIE platform can stand alone and see the same effect.~Months 4-6 (Approximately Day 91-180) o Participant will continue to use Nurse AMIE, but without phone calls from study facilitator"
32862275|NCT04673019|Other|Delayed Intervention|"The delayed intervention group will receive the intervention 3 months after consent (3 months of no intervention followed by with 3 months of intervention, for a total of 6 months); the participant will follow the pattern listed below:~Months 1- 3 Approximately (Day 1-Day 90)~o No use of Nurse AMIE~Months 4-6 (Approximately Day 91-180)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator"
32862276|NCT04931784|Active Comparator|Nitrate Group|with administration of intra-coronary nitrate before percutaneous coronary intervention
32862277|NCT04931784|Placebo Comparator|Control Group|without administration of intra-coronary nitrate before percutaneous coronary intervention
32862278|NCT04352361|Experimental|TVB-2640 tablets|
32862279|NCT04352361|Placebo Comparator|placebo|
33104970|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
33104971|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
32862280|NCT04934202||Patients from the 1st epidemic wave|"One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC 1st wave in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above."
32862281|NCT04934202||Patients from the 2nd epidemic wave|"As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:~During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms~During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation."
32862282|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
32862283|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
32862284|NCT04404036|Experimental|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
32862285|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
32862286|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
32862287|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
32862288|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
32862289|NCT04934280|Other|2D transvaginal ultrasonography|
32862290|NCT04931706||N-Sleve patients|Patient that were selected for surgery
32862291|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
32862292|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
32862293|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
32862294|NCT04931004|Experimental|0.075% Cetylpyridinium Chloride|
32862295|NCT04931004|Experimental|1.5% Hydrogen peroxide|
32862296|NCT04931004|Experimental|Chlorhexidine gluconate|
32862297|NCT04931004|Placebo Comparator|Water rinse|Control for impact on viral load changes from mechanical rinsing
32862298|NCT04492215|Experimental|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
32862299|NCT04492215|No Intervention|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
32862300|NCT02763319|Experimental|Tafasitamab and bendamustine|Tafasitamab and bendamustine
32862301|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
32862302|NCT04931160|Active Comparator|Sjögren patients|patients diagnosed Sjögren
32862303|NCT04931160|Other|Non-Sjögren witnesses|patients diagnosed no Sjögren
32862304|NCT04921020||Normal participants|
32862305|NCT04921020||Patients with blepharoptosis|
32862306|NCT04921020||Patients with blepharospasm|
32862307|NCT04921020||Patients with dry eye disease|
32862308|NCT04921020||Patients with Graves' disease|
32862309|NCT04933578||Children|"The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children.~The children's preferences for the appearance of dentists were determined in the second part.~Routine dental examinations of children with a dental mirror and artificial light were completed by an experienced pediatric dentist according to the World Health Organization (WHO) guidelines and criteria."
32862310|NCT04933578||Parents|"The questionnaire including demographic information (age, sex, and medical and dental history) was applied to the parents.~In the second section, the MDAS was administered to parents, differently from children.~The parents' preferences for the appearance of dentists were determined in the second part."
32862311|NCT04841473|Active Comparator|Standard Concussion Education|Participants will receive standard concussion education materials (online training) focused on concussion prevention in youth sport.
32862312|NCT04841473|Experimental|TRAIN Concussion Education|After receiving the standard concussion education materials (online training), participants will receive an additional module, the TRAIN concussion education module.
33104972|NCT01263496|Experimental|Alogliptin 25 mg QD|
33104973|NCT01263496|Experimental|Alogliptin 50 mg QD|
33104974|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
32977138|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32977139|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
32977140|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32977141|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
32977142|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
32977143|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
32977144|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
32977145|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
32977146|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
32977147|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
32977148|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be taken orally each morning for 6 months.
32977149|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
32977150|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
32977151|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
32977152|NCT01752920|Experimental|Low Dose Group|Patients who received derazantinib orally at dose levels from 25 mg every other day (QOD) - 200 mg daily (QD) on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
32977153|NCT01752920|Experimental|Middle Dose Group|Patients who received derazantinib orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
32977154|NCT01752920|Experimental|High Dose Group|Patients who received derazantinib orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
32977155|NCT01752920|Experimental|Expanded Cohort Group|Patients who received derazantinib orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
32977156|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
32977157|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
32977158|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
32977159|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
32977160|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
33322939|NCT01368172|No Intervention|Control|
33104975|NCT00547014|Experimental|Cohort 1 1mg|
33104976|NCT00547014|Experimental|Cohort 2|
33104977|NCT00547014|Experimental|Cohort 3|
33104978|NCT00547014|Experimental|Cohort 4|
33104979|NCT00547014|Experimental|Cohort 5|
33322940|NCT05188768|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
33322941|NCT05188768|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
33322942|NCT01110564||1|COPD patients
33322943|NCT01368328|Placebo Comparator|Placebo|
33322944|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
33322945|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
33322946|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
33322947|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
32977161|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
32977162|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
32977163|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
32977164|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
32977165|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
32977166|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
32977167|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
32977168|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
32977169|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
32977170|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
32977171|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
32977172|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
32977173|NCT01597583|Experimental|Use of MobileMedMinder|
32977174|NCT01597583|No Intervention|Usual care|
33411351|NCT05181215|Experimental|Bafiertam|190 mg (2 x 95 mg) delayed-release capsules
33411352|NCT05181215|Active Comparator|Vumerity|462 mg (2 x 231 mg) delayed-release capsules
33411353|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
33411354|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~Evaluate its ability to locate and assess the volume of the endometriosic lesion~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
33411355|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
33411356|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
33411357|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
33411358|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
33411359|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
32977175|NCT01595620|Active Comparator|THC 0.01 mg/kg|
32977176|NCT01595620|Placebo Comparator|Placebo|
32977177|NCT01595620|Active Comparator|THC 0.03 mg/kg|
32977178|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
33411360|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
33411361|NCT05384054||Low Erythroferron group|The lower concentration group will be Group1.
32977179|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
32977180|NCT01591629|Placebo Comparator|Placebo and Placebo|
32977181|NCT01591629|Experimental|Active Naloxone and Placebo|
32977182|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
32977183|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
33411362|NCT05384054||High Erythroferron group|The higher concentration group will be Group2.
32977184|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
32977185|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
32977186|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel Cycle 1: paclitaxel administered on Day 1 of 2-week cycle. Cycle 2 and beyond : ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
32977187|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4- week cycle.~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
32977188|NCT01515098|Experimental|Blueberry Group|37 grams of dehydrated blueberries daily for 6 months
32977189|NCT01515098|Placebo Comparator|Placebo Group|37 grams of dextrose powder daily for 6 months
32977190|NCT01515098|No Intervention|Reference Group|No intervention
32977191|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
32977192|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
33411363|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
33411364|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
33411365|NCT03662100|Experimental|LY3074828 Reference 1|Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm
33411366|NCT03662100|Experimental|LY3074828 Reference 2|Solution formulation in PFS administered as SC injection in thigh
33411367|NCT03662100|Experimental|LY3074828 Reference 3|Solution formulation in PFS administered as SC injection in abdomen
33411368|NCT03662100|Experimental|LY3074828 Test 1|Solution formulation administered SC via an auto-injector (AI) in arm
33411369|NCT03662100|Experimental|LY3074828 Test 2|Solution formulation administered SC via an AI in thigh
33411370|NCT03662100|Experimental|LY3074828 Test 3|Solution formulation administered SC via an AI in abdomen
33411371|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
33411372|NCT03612986|Placebo Comparator|B: Placebo|"Placebo~1 tablet/day, oral administration"
32977193|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
32977194|NCT01431157|Placebo Comparator|No nasal oxygen|
33411373|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
33411374|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
33411375|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
32977195|NCT01423851|Experimental|Intervention: Drug: NS-018|In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
32977196|NCT01397929|Experimental|Drug: BAL101553 at MTD|
32977197|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
32977198|NCT01366404||FFR|Patients who had FFR measurement
32977199|NCT01360593|Other|Gem, Xeloda, SBRT|
32977200|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
32977201|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
32977202|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
32977203|NCT01317875|Experimental|Stratum -1|Participants with baseline Platelet counts of 75-99 x10^9/L
32977204|NCT01317875|Experimental|Stratum -2|Participants with baseline Platelet counts of 50-74 x10^9/L
32977205|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
33411376|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
33411377|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
33411378|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
33411379|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
33411380|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
32977206|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
32977207|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
32977208|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
32977209|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
32977210|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
32977211|NCT01194362||45 specimens collected from BAV patients|
32977212|NCT01194362||45 specimens collected from TAV patients|
32977213|NCT01194362||15 specimens collected from CABG pts|
32977214|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
32977215|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
33322948|NCT01212120||All patients|All patients
33322949|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
33322950|NCT03940248|Experimental|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
33322951|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
33322952|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
33322953|NCT01212198||Korean type 2 diabetic patients|
33322954|NCT01212198||Koreans at high risk for diabetes|
33322955|NCT01212198||Korean gestational diabetic patients|
33322956|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
33322957|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
33322958|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
33322959|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
33322960|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
33322961|NCT01110720|Experimental|Davunetide 30 mg BID|
33322962|NCT01110720|Placebo Comparator|Placebo|
33322963|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone & extremities
33322964|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
33322965|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
33322966|NCT04576936|Experimental|AIRVO Device|All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months
33322967|NCT04535674|No Intervention|Standard of Care|
33322968|NCT04535674|Experimental|Standard of Care + Asunercept 25 mg|
33322969|NCT04535674|Experimental|Standard of Care + Asunercept 100 mg|
33322970|NCT04535674|Experimental|Standard of Care + Asunercept 400 mg|
33322971|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
32977216|NCT00962988|Experimental|Cost-Free Group|
32977217|NCT00962988|Other|Prescription Only Group|
32977218|NCT00949312||Stage II unresected Colon Cancer|
32977219|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
32977220|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
32977221|NCT00883597||Controls|Patients with ileostomy.
32977222|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
32977223|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
32977224|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
32977225|NCT00768820|Experimental|1|
32977226|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
32977227|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
32977228|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
32977229|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
33104980|NCT04681937|Experimental|Hyaluronic Acid + Physical Therapy|4 ml hyaluronic acid (subacromial)
33411381|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
32977230|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
32977231|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
32977232|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
32977233|NCT00500071|Experimental|1|
32977234|NCT00447122|Experimental|treatment 1|Gemcitabine 1000mg/m2 with lapatinib 1000mg/d weekly x 3 weeks
32977235|NCT00447122|Experimental|treatment 2|Gemcitabine 1000mg/m2 with lapatinib 1500mg/d weekly X 3 weeks
32977236|NCT00447122|Experimental|treatment 3|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1000 mg/d
32977237|NCT00447122|Experimental|treatment 4|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1500 mg/d
32977238|NCT00430040|Experimental|carvedilol|carvedilol
32977239|NCT00430040|Active Comparator|lisinopril|lisinopril
32977240|NCT00382252|Experimental|18F-FDG PET/CT + RFA|"18F-FDG PET/CT: I.V. injection of 5 to 15 mCi (185 to 555 MBq) of 18F-FDG. Capture time of 60 to 90 minutes. Acquisition of images: A whole body CT scan with normal breathing will be performed for attenuation correction with 5mm thick slices. A whole body PET acquisition of 6 or 7 steps will be done from the upper third of the thighs to the base of the skull. PETC/CT performed at inclusion, 1 month et 3 months after RFA.~RFA: Treatment procedure: the location under scanner allows to place the electrode in the center of the tumor. The treatment then lasts 15 to 20 minutes.~CT scanner: The CT examination will be performed in spiral acquisition without or after injection of contrast medium (70 ml at 2 or 3 ml/sec). On a 16-slice scanner, the examination is performed with 1.25 mm slices every 0.9. Constants generally used 120kV, 350 mA. Ct scanner performed at inclusion, 48H post-RFA, 1 month, 3 months, 6, 9 and 12 months after RFA."
32977241|NCT00290251|Active Comparator|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
32977242|NCT00290251|Active Comparator|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
32977243|NCT00290251|Placebo Comparator|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days
32977244|NCT00290251|No Intervention|Pre-ulipristal acetate 10 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
32977245|NCT00290251|No Intervention|Pre-ulipristal acetate 20 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
32977246|NCT00290251|No Intervention|Pre-placebo|Subjects were studied during one baseline cycle without any intervention before entering placebo arm
32977247|NCT00066963|No Intervention|Counseling Only|Counseling Only
32977248|NCT00066963|Experimental|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
32977249|NCT00066963|Experimental|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
32977250|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
32977251|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
32977252|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
32977253|NCT01397500|No Intervention|control group|No Intervention.
32977254|NCT01397513|Active Comparator|Aspirin 75mg|
32977255|NCT01397513|Active Comparator|Aspirin 320mg|
32977256|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
32977257|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
32977258|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
32977259|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
32977260|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
32977261|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
32977262|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
33104981|NCT04681937|Experimental|Platelet-Rich-Plasma (PRP) + Physical Therapy|4 ml platelet-rich-plasma (subacromial)
33104982|NCT04681937|Experimental|Steroid + Physical Therapy|methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) (subacromial)
33104983|NCT04681937|Experimental|Placebo (serum saline) + Physical Therapy|4 ml serum saline (subacromial)
32977263|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
32977264|NCT01397630|Experimental|Accelerated Oxytocin Titration|
32977265|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
32977266|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
32977267|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
33411382|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
33411383|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
33411384|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
33411385|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
33411386|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
33411387|NCT05383898|Experimental|Phase 1a Dose escalation of D-1553|Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation
33411388|NCT05383898|Experimental|Phase 1b Dose expansion of D-1553|Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.
33411389|NCT05383898|Experimental|Phase 2 of D-1553 monotherapy|Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.
33411390|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
32977268|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
32977269|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
32977270|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
32977271|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
32977272|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
32977273|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
33411391|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
33411392|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
33411393|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
33411394|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
33411395|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
33411396|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
33411397|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
32977274|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
32977275|NCT01397773||Control group|Healthy subjects
32977276|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
32977277|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
32977278|NCT01397838|Experimental|Pro-Bone|
33411398|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
33411399|NCT03612128|Other|control group|Children continued their traditional physiotherapy
33411400|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
33411401|NCT03660852||Before dedicated MRI|
33411402|NCT03660852||After dedicated MRI|
32977279|NCT01397864||Hereditary Angioedema|
32977280|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
33322972|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
33411403|NCT04691102||Stroke group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411404|NCT04691102||Traumatic Brain Injury group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411405|NCT04691102||Mild Cognitive Impairment group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411406|NCT04691102||Parkinson Disease group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411407|NCT04691102||Multiple Sclerosis group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411408|NCT04691102||Healthy subjects groups|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
33411409|NCT03612752|Experimental|Active arm|CMI-168
33411410|NCT03612752|Placebo Comparator|Placebo arm|Placebo
32977281|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
32977282|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
32977283|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
32977284|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
32977285|NCT01397955||Group 1|Drug (incl. Placebo)
32977286|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
32977287|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
32977288|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
32977289|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
33411411|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
33411412|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
32977290|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
32977291|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
32977292|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
32977293|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.~treatment of the target lesion with the paclitaxel-coated balloon"
32977294|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
32977295|NCT01398046|Active Comparator|Dasatinib|
32977296|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
32977297|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
32977298|NCT01398072|Active Comparator|Moxifloxacin|
32977299|NCT01398072|Active Comparator|Azithromycin|
32977300|NCT01398072|Active Comparator|Doxycycline|
32977301|NCT01398072|Placebo Comparator|Placebo|
32977302|NCT01398098|Experimental|COLOKIT®|
32977303|NCT01398111|Active Comparator|Treatment R2|
32977304|NCT01398111|Active Comparator|Treatment R1|
32977305|NCT01398111|Placebo Comparator|Placebo|
32977306|NCT01398111|Experimental|Treatment T|
32977307|NCT01398137||Ragweed allergic subjects|
32977308|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
32977309|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
32977310|NCT01398163|Experimental|1 = Tested product|
32977311|NCT01398163|Active Comparator|2 = Control product|
32977312|NCT01398163|No Intervention|3 = No product|
33411413|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
32977313|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
32977314|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
32977315|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
32977316|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
32977317|NCT01398202|Placebo Comparator|Placebo|
32977318|NCT01398215||transvaginal NOTES|
32977319|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
32977320|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
32977321|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
32977322|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
32977323|NCT01398241|Experimental|Active|
32977324|NCT01398241|Placebo Comparator|Placebo|
32977325|NCT01398254|Other|TRA|Transradial Access
32977326|NCT01398254|Other|TFA|Transfemoral Access
32977327|NCT01398267|Experimental|1|
32977328|NCT01398267|Placebo Comparator|2|
32977329|NCT01398293|Experimental|A|
32977330|NCT01398293|Experimental|B|
32977331|NCT01398293|Active Comparator|C|
32977332|NCT01398293|Placebo Comparator|D|
32977333|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
32977334|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
32977335|NCT01398345|Active Comparator|Exercise and Respiratory Training|
32977336|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
32977337|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
32977338|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
32977339|NCT01398384|Placebo Comparator|Placebo|inhalation gas
32977340|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
32977341|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
32977342|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
32977343|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
32977344|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
32977345|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
32977346|NCT01398462|Experimental|CWP232291|
32977347|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
32977348|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
32977349|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
32977350|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
32977351|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
32977352|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
32977353|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
32977354|NCT01398553|Experimental|Armeo Spring|
32977355|NCT01398553|Active Comparator|conventional physiotherapy|
33411414|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
32977356|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
32977357|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
32977358|NCT01398592|Experimental|Vildagliptin|Experimental
32977359|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
32977360|NCT01398605|Experimental|moderate exercise training|
32977361|NCT01398605|Experimental|intensive exercise training|
32977362|NCT01398605|No Intervention|Control|
32977363|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
32977364|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
32977365|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
32977366|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
33411415|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
32977367|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
32977368|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
32977369|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
32977370|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
32977371|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
32977372|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
32977373|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
32977374|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
33411416|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
33411417|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
32977375|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
32977376|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
32977377|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
32977378|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
32977379|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
32977380|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
32977381|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
32977382|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
32977383|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
32977384|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
32977385|NCT01398891|Experimental|Positive Psychology Exercises|
32977386|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
33411418|NCT04715438|Experimental|Cohort A: Individuals without cancer|A cohort of individuals without a cancer diagnosis is included for comparison. Because age is an important predictor of the ability to mount an effective immune response to vaccination, partners of patients in cohort B, C, and D.
33411419|NCT04715438|Experimental|Cohort B: patients receiving immunotherapy|Cancer patients receiving immunotherapy
33411420|NCT04715438|Experimental|Cohort C: patients receiving chemotherapy|Cancer patients receiving chemotherapy
32977387|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
32977388|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
33411421|NCT04715438|Experimental|Cohort D: patients receiving chemo-immunotherapy|Cancer patients receiving chemo-immunotherapy
33411422|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
32977389|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
32977390|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
32977391|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
32977392|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
32977393|NCT01398969|Experimental|Fresh FMT|Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
32977394|NCT01398969|Experimental|Frozen-and-Thawed FMT|Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
32977395|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
32977396|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
32977397|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
32977398|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
32977399|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
32977400|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
32977401|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
32977402|NCT01399073||Patients with Neglect|
32977403|NCT01399073||Patients with Hemianopsia|
32977404|NCT01399073||Healthy age-matched controls|
32977405|NCT01399086||Fulvestrant|
32977406|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
32977407|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
32977408|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
32977409|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
32977410|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
32977411|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
32977412|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
32977413|NCT01399216|Experimental|Fucoidan supplement|
32977414|NCT01399216|Placebo Comparator|Placebo|
32977415|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
32977416|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
32977417|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
32977418|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
32977419|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
32977420|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
33411423|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
33411424|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
33411425|NCT03661242|No Intervention|Standard of care|No intervention
32977421|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
32977422|NCT01399307|Other|Elective Liposuction|
32977423|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
32977424|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
32977425|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
32977426|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
32977427|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
32977428|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
32977429|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
32977430|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
32977431|NCT01399450|Experimental|paliperidone add on|paliperidone add on
32977432|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
32977433|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
32977434|NCT01399476|Experimental|Endoscopic Myotomy|
33322973|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
33322974|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
32977435|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
32977436|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
32977437|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
32977438|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
32977439|NCT01399515|Active Comparator|Valproic acid|
32977440|NCT01399515|No Intervention|Control|
32977441|NCT01399528||Beaumont Hospital, Dublin, Ireland|
33322975|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
32977442|NCT01399528||St. James' Hospital, Dublin, Ireland|
33322976|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
33411426|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
33411427|NCT05383820|Placebo Comparator|Placebo|Placebo (calcined magnesia) in capsules, one capsule every 8 hours for 5 days.
32977443|NCT01399528||Hôpital Erasme, Brussels, Belgium|
33411428|NCT05383820|Experimental|Ketorolac|Ketorolac 10 mg capsules, one capsule every 8 hours (30 mg daily) for 5 days.
32977444|NCT01399528||Duke Medical Centre, North Carolina, USA|
32977445|NCT01399528||The Institute of Neurology/University College London, UK|
32977446|NCT01399541||Under and over 65 years|
32977447|NCT01399554|No Intervention|Assessment Only|
32977448|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
32977449|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
32977450|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
32977451|NCT01399606|Experimental|BF2.649|
32977452|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
32977453|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
32977454|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
32977455|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
32977456|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
32977457|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
32977458|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
32977459|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
32977460|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
32977461|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
32977462|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
32977463|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
32977464|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
32977465|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
32977466|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
32977467|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
32977468|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
32977469|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
32977470|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
32977471|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
32977472|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
32977473|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
32977474|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
32977475|NCT01399879||Healthy Volunteers|
32977476|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
32977477|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
32977478|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
32977479|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
32977480|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
32977481|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
32977482|NCT01399996|Experimental|Probiotic added post fermentation.|
32977483|NCT01399996|Experimental|Probiotic added pre-fermentation.|
33322977|NCT01372540|Experimental|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
32977484|NCT01399996|Experimental|A capsule containing the probiotic.|
32977485|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
32977486|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
32977487|NCT01400022|Active Comparator|Cortisone|
32977488|NCT01400022|Experimental|UVA1 phototherapy|
32977489|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
32977490|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
32977491|NCT01400048|Placebo Comparator|Placebo|
32977492|NCT01400061||normal|body mass index: 19-24
32977493|NCT01400061||overweight|body mass index: 25-29
32977494|NCT01400061||obesity|body mass index: 30-40
32977495|NCT01400061||modbid obes|body mass index: over 40
32977496|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
32977497|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
32977498|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
32977499|NCT01400087|Placebo Comparator|Regular colonoscopy|
33322978|NCT01368484|Placebo Comparator|Sunflower oil|
33322979|NCT01368484|Experimental|Docosahexanoic acid|
33322980|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
33322981|NCT04394884||COVID-19 + BTK|will receive BTK therapy
33322982|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
32977500|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
32977501|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
32977502|NCT01400152|Active Comparator|Passive warming with additional active warming|
32977503|NCT01400152|No Intervention|Passive warming|
32977504|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
32977505|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
32977506|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
32977507|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
32977508|NCT01400191|Active Comparator|Heterozygote OCT1|
32977509|NCT01400191|Active Comparator|Homozygote OCT1 variant|
32977510|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
32977511|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
32977512|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
32977513|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
32977514|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
32977515|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
33411429|NCT05383820|Active Comparator|Paracetamol|Paracetamol capsules of 500 mg, one capsule every 8 hours (1.5 g per day) for 5 days.
33411430|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
32977516|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
32977517|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
32977518|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
32977519|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
32977520|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
33411431|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
32977521|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
32977522|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
32977523|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
32977524|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
32977525|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
32977526|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
32977527|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
32977528|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
32977529|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
32977530|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
32977531|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
32977532|NCT01400386|Experimental|Soluble coffee 1|
32977533|NCT01400386|Experimental|Soluble coffee 2|
32977534|NCT01400386|Experimental|Soluble coffee 3|
32977535|NCT01400386|Experimental|Soluble coffee 4|
32977536|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
32977537|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
32977538|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
32977539|NCT01400490|Active Comparator|DHA 1800 mg/day|
32977540|NCT01400490|Active Comparator|EPA 1800 mg/day|
32977541|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
33322983|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
33411432|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
33411433|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
33411434|NCT04660214|Active Comparator|Vessel sealing device|Endoscopic diverticulectomy is performed with the LigaSure (TM) device
32977542|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
32977543|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
32977544|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
32977545|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
32977546|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
32977547|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
32977548|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
32977549|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
32977550|NCT01400581|No Intervention|Usual Care|Observational
32977551|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
32977552|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
32977553|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
32977554|NCT01400620|Placebo Comparator|Placebo rinse|
32977555|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
32977556|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
32977557|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
32977558|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
32977559|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
32977560|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
32977561|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
32977562|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
32977563|NCT01400724|Experimental|Inofolic NRT|
32977564|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
32977565|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
32977566|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
32977567|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
32977568|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
32977569|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
32977570|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
32977571|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
32977572|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
32977573|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
32977574|NCT01400854||Effentora®|Single group prospective treatment cohort
32977575|NCT01400867|Experimental|Ceftaroline fosamil|
32977576|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
32977577|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
32977578|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
32977579|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
32977580|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
32977581|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
32977582|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
32977583|NCT01401114||Group 1|Drug (incl. Placebo)
32977584|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
32977585|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
32977586|NCT01401140|Active Comparator|St Thomas|
33411435|NCT04660214|Active Comparator|Dissecting Knife device|Endoscopic diverticulectomy is performed with the SB-Knife(TM) device
33411436|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
33411437|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
33411438|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
33411439|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
32862313|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
32862314|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
32862315|NCT04930926||INFECTION DISEASE PATIENTS WITH PNEUMONIA OR SARHS COVID19|NO SPECIFIC INTERVENTION
32862316|NCT01323153|Experimental|Dalcetrapib|
32862317|NCT01323153|Placebo Comparator|Placebo|
32862318|NCT04920786|Experimental|TB006 70 mg - 5000 mg IV|TB006 infused intravenously over 1 hour
32862319|NCT04920786|Placebo Comparator|Placebo|0.9% normal saline infused intravenously over 1 hour
32862320|NCT04912986|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
32862321|NCT04912986|Experimental|Experimental group|The intervention was implemented in accordance with the Early Lung Rehabilitation Training Programme for Adult Double Lung Transplant Patients
32862322|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
32862323|NCT04920708|Experimental|Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
32862324|NCT04920708|Active Comparator|Palbociclib + Fulvestrant (Comparison arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
32862325|NCT04920708|Active Comparator|Standard of Care (No ctDNA observational arm)|Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
32862326|NCT04920708|Active Comparator|Standard of Care (Low ctDNA observational arm)|Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
32862327|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
32862328|NCT02846389|No Intervention|Control Group|No exercise
32862329|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
32862330|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
32862331|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
32862332|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
32862333|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
32862334|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
32862335|NCT04930848|Experimental|Intervention Arm|Euphorbia hirta
32862336|NCT04930848|Placebo Comparator|Placebo Arm|Terminalia arjuna and Terminalia bellerica
32862337|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
32862338|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
32862339|NCT04920552|Placebo Comparator|Placebo binder first|"Participants in this arm will wear the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
32862340|NCT04920552|Active Comparator|Elastic abdominal binder first|"Participants in this arm will wear the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
32862341|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
32977587|NCT01401140|Experimental|Custodiol|
32977588|NCT01401179|Active Comparator|cefazolin|
32977589|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
32977590|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
32977591|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
32977592|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
32977593|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
32977594|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
32977595|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
32977596|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
32977597|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
32977598|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
32977599|NCT01401244|Experimental|Norditropin®|
32977600|NCT01401244|Active Comparator|Genotropin®|
32977601|NCT01401270|No Intervention|Treatment Group A|Standard Care
32977602|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
32977603|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
32977604|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
32977605|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
32977606|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
32977607|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
32977608|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
32977609|NCT01401335|Other|Trauma counseling|
32977610|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
32977611|NCT01401374||Controls|Individuals without vitiligo vulgaris
32977612|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
32977613|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
32977614|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
32977615|NCT01401413|Placebo Comparator|1|placebo control nightly
32977616|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
32977617|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
32977618|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
32977619|NCT01401491|Active Comparator|clozapine + fluvoxamine|
32977620|NCT01401491|Placebo Comparator|clozapine + placebo|
32977621|NCT01401504|Experimental|ASP3026|
32977622|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
32977623|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
32977624|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
32977625|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
32977626|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
32977627|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
32977628|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
32977629|NCT01401634|Experimental|Oral Fluids|
32977630|NCT01401660||Group A|Subjects who do not currently have low back pain.
32977631|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
32977632|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
32977633|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
32977634|NCT01401712|Active Comparator|Thoracic epidural catheter|
32977635|NCT01401725|Experimental|Hamilton General Hospital|
32977636|NCT01401725|Active Comparator|Juravinski Hospital|
32977637|NCT01401725|Other|St. Joseph's Hospital|
32977638|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
32977639|NCT01401764|Other|Platform II, PASS, ARG 100|
32977640|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
32977641|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
33322984|NCT01110954|Experimental|PD L 506|
32977642|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
33322985|NCT01113138|No Intervention|Baseline|
32862342|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
32862343|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
32862344|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
32862345|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
32862346|NCT04405596|Experimental|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
32862347|NCT04405596|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
32862348|NCT05586451|Other|Resistance Trained|Resistance-trained individuals are considered those who report performing structured moderate to intense resistance exercise for at least three days per week for at least 2 years prior to study start.
32862349|NCT05586451|Other|Untrained|Untrained individuals are considered those that report less than two days per week of structured (> 30 minutes) moderate to vigorous-intensity aerobic exercise and less than two days per week of structured resistance training for the 3 months prior to study start.
32862350|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
32862351|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
32862352|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
32862353|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
32862354|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
32862355|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
32862356|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
32862357|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
32862358|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
32862359|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
32862360|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
32862361|NCT04345107|Experimental|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
32862362|NCT04345107|Experimental|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
32862363|NCT04345107|Experimental|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
32862364|NCT04345107|Experimental|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
32862365|NCT04345107|Experimental|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
32862366|NCT04345107|Experimental|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
32862367|NCT04345107|Placebo Comparator|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
32862368|NCT04912752|Other|Case-Control|Copy number variation
32862369|NCT04912752|Experimental|Case-Control 1|Gene expression
32862370|NCT04238637|Experimental|Arm 1|Durvalumab
32862371|NCT04238637|Experimental|Arm 2|Durvalumab in combination with Tremelimumab
32862372|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
32977643|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
33322986|NCT01113138|Active Comparator|Mablet|
33322987|NCT01113138|Active Comparator|Magnesium sulfate|
33322988|NCT01210404|Experimental|1.0|
32977644|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
33322989|NCT03940482|Experimental|Single Arm|Subjects will act as their own controls
33322990|NCT03940170||vistacam|
33322991|NCT03940170||ICDAS II|
33322992|NCT03940170||Fissurotomy|
33322993|NCT05188612||Male|Non-interventional patient registry
32977645|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
32977646|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
32977647|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
32977648|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
32977649|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
32977650|NCT01401855||In Vivo Probe Prediction|
32977651|NCT01401855||Cytology Results|
32977652|NCT01401868|Experimental|single arm|dose escalation
32977653|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
32977654|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
32977655|NCT01401933|Experimental|Linifanib|
32977656|NCT01401946|Active Comparator|soy isoflavones|
32977657|NCT01401946|Placebo Comparator|Placebo|
32977658|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
32977659|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
32977660|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
32977661|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
32977662|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
32977663|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
32977664|NCT01402076|Experimental|Steady State PK Group|
32977665|NCT01402076|Experimental|No steady state PK|
32977666|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
32977667|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
32977668|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
32977669|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
32977670|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
32977671|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
32977672|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
33322994|NCT05188612||Female|Non-interventional patient registry
33322995|NCT05188612||Elderly|Non-interventional patient registry
33322996|NCT05188612||Hypertension|Non-interventional patient registry
33322997|NCT05188612||Diabetes|Non-interventional patient registry
33322998|NCT05188612||Dyslipidemias|Non-interventional patient registry
33322999|NCT05188612||Smoking|Non-interventional patient registry
33323000|NCT05188612||Kidney Disease|Non-interventional patient registry
33323001|NCT05188612||Heart Diseases|Non-interventional patient registry
33323002|NCT05188612||Vascular diseases|Non-interventional patient registry
32977673|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
32977674|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
32977675|NCT01402219|Active Comparator|Iopamiro-370|
32977676|NCT01402219|Active Comparator|Visipaque 320|
32977677|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
32977678|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
32977679|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
32977680|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
32977681|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
32977682|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
32977683|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
32977684|NCT01402323|Other|early or late tooth extraction|
32977685|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
32977686|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
32977687|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
32977688|NCT01402362||Ethiopians participating in previous study, year 2000|
32977689|NCT01402388|Experimental|Lifestyle intervention group.|
32977690|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
32977691|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
32977692|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
32977693|NCT01402440|Experimental|AEB071|
32977694|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
32977695|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
32977696|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
33411440|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
33411441|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
33411442|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
32977697|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
32977698|NCT01402479|Active Comparator|ramipril|open label single arm trial
32977699|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
32977700|NCT01402518||Per-oral endoscopic myotomy|
32977701|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
32977702|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
32977703|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
32977704|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
32977705|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
32977706|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
32977707|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
32977708|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
33411443|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
33411444|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
33411445|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
33411446|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
33411447|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
32977709|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
32977710|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
32977711|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
32977712|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
32977713|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
32977714|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
32977715|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
32977716|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
32977717|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
32977718|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
32977719|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
32977720|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
32977721|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
32977722|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
32977723|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
32977724|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
32977725|NCT01402739|Active Comparator|standard of care transfusions|control arm
32977726|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
32977727|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
32977728|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
32977729|NCT01402778||Cather fixation by tunneling and suture|
32977730|NCT01402778||Catheter fixation by adhesive tape|
32977731|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
32977732|NCT01402804||Stable CAD, ASA, NSAID|
32977733|NCT01402804||Stable CAD, ASA|
32977734|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
32977735|NCT01402843|Experimental|pitavastatin + valsartan|
32977736|NCT01402843|Placebo Comparator|pitavastatin + placebo|
32977737|NCT01402843|Placebo Comparator|valsartan + placebo|
32977738|NCT01402843|Placebo Comparator|placebo|
32977739|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
32977740|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
32977741|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
32977742|NCT01402882|Experimental|Tranexamic acid|
32977743|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
32977744|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
32977745|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
32977746|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~ankle pressure: 10 mmHg~calf pressure : 23 mmHg"
32977747|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~ankle pressure: <5 mmHg~calf pressure : <7 mmHg"
32977748|NCT01402934|Experimental|fluid infusion|
32977749|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
32977750|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
32977751|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
32977752|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
32977753|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
32977754|NCT01403025||Liraglutide|
32977755|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
32977756|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
32977757|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
32977758|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
32977759|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
32977760|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
32977761|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
32977762|NCT01403077|Experimental|Scaffold Treatment|
32977763|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
32977764|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
32977765|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
32977766|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
32977767|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
32977768|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
32977769|NCT01403168|Placebo Comparator|conventional analgesic treatments|
32977770|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
32977771|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
32977772|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
32977773|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
32977774|NCT01403233|Experimental|cogniVida™ 50 mg/day|
32977775|NCT01403233|Experimental|cogniVida™ 100 mg/day|
32977776|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
32977777|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
32977778|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
32977779|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
32977780|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
32977781|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
32977782|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
32977783|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
32977784|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
32977785|NCT01403363|Experimental|fentanyl patch|
32977786|NCT01403389|Experimental|Eculizumab|
32977787|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
32977788|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
32977789|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
32977790|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
32977791|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
32977792|NCT01403454|No Intervention|usual care|
32977793|NCT01403454|Active Comparator|Health Communication Application|
32977794|NCT01403467|Experimental|NIPPV|
32977795|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
32977796|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
32977797|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
32977798|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
32977799|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
32977800|NCT01403519||Control group|Blood and CSF samples
32977801|NCT01403519||FTD patients|Blood ad CSF samples
32977802|NCT01403532|Active Comparator|Traditional|
32977803|NCT01403532|Experimental|Sequential|
32977804|NCT01403532|Experimental|Sequential Plus|
32977805|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
32977806|NCT01403545|Placebo Comparator|5% Glucose|
32977807|NCT01403558|Experimental|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
32977808|NCT01403558|No Intervention|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
32977809|NCT01403571|Experimental|Salba supplement|30g/1000kal
32977810|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
32977811|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
32977812|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
32977813|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
32977814|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
32977815|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
32977816|NCT01403662|Experimental|Minocycline|
32977817|NCT01403675|Experimental|Ovarian autotransplantation|
32977818|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
32977819|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
32977820|NCT01403701|No Intervention|routine care|Standard postoperative visits
32977821|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
32977822|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
32977823|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
32977824|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
32977825|NCT01403740||Acquired haemophilia patients|
32977826|NCT01403753||Non-clinical sample of children|
32977827|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
32977828|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
32977829|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
32977830|NCT01403792|Experimental|Up to 7mg P2G12|
32977831|NCT01403792|Experimental|Up to 14mg P2G12|
32977832|NCT01403792|Experimental|Up to 28mg P2G12|
32977833|NCT01403792|Placebo Comparator|Placebo (saline solution)|
32977834|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
32977835|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
32977836|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
32977837|NCT01403831|No Intervention|Control|
32977838|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
32977839|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
32977840|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
32977841|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
32977842|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
32977843|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
32977844|NCT01403896|Active Comparator|Plerixafor Group|
32977845|NCT01403896|Experimental|Plerixafor + G-CSF group|
32977846|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
32977847|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
32977848|NCT01403922|Experimental|1|TC-5214
32977849|NCT01403922|Experimental|2|TC-5214 with placebo
32977850|NCT01403922|Experimental|3|TC-5214 with placebo
32977851|NCT01403922|Experimental|4|TC-5214
32977852|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
32977853|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
32977854|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
32977855|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
32977856|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
32977857|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
32977858|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
32977859|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
32977860|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
32977861|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
32977862|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
32977863|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
32977864|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
33323003|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
33323004|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
32977865|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
32977866|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
32977867|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
32977868|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
32977869|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
32977870|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
32977871|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
32977872|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
33323005|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
33323006|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
33323007|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
32977873|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
32977874|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
32977875|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
32977876|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
32977877|NCT01404143|Active Comparator|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
32977878|NCT01404143|Experimental|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
33104984|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
33104985|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
33323008|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
33323009|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
33323010|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
33323011|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
33323012|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
33323013|NCT01359982|Experimental|RRx-001|
33323014|NCT01111032||Treadmill test|
33323015|NCT05188534||BOLD-fMRI|Identifying the language functional cortex in glioma patients with BOLD-fMRI
33323016|NCT05188534||ZOOMit-fMRI|Identifying the language functional cortex in glioma patients with ZOOMit-fMRI
32977879|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
32977880|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
32977881|NCT01404169|Experimental|1|
32977882|NCT01404169|Placebo Comparator|2|
32977883|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
32977884|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
32977885|NCT01404195|No Intervention|Control|without supplementation
32977886|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
32977887|NCT01404273|Experimental|Meditation/Relaxation Response Training|
32977888|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
32977889|NCT01404286|No Intervention|Control group|
32977890|NCT01404299|Experimental|Supplementary Group|
32977891|NCT01404299|No Intervention|Control Group|
32977892|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
32977893|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
32977894|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
32977895|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
32977896|NCT01404351|Experimental|PEAK PlasmaBlade|
32977897|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
32977898|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
32977899|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
32977900|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
32977901|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
32977902|NCT01404390|Experimental|Arm 1|
32977903|NCT01404390|Experimental|Arm 2|
32977904|NCT01404403|Other|Stroke patients|
32977905|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
32977906|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
32977907|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
32977908|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
32977909|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
32977910|NCT01404468|Active Comparator|pulsed|
32977911|NCT01404468|Sham Comparator|control|
32977912|NCT01404468|Active Comparator|continuous|
32977913|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
32977914|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
32977915|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
32977916|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
32977917|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
32977918|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
32977919|NCT01404520|No Intervention|Control Group|Control group receives usual care
32977920|NCT01404533|Experimental|Iron supplement without food|
32977921|NCT01404533|Experimental|Iron supplement with food|
32977922|NCT01404533|Experimental|Iron fortificant with food|
33104986|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
32977923|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
32977924|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
32977925|NCT01404598|Experimental|naproxcinod 750 mg bid|
32977926|NCT01404598|Experimental|naproxcinod 3000 mg od|
32977927|NCT01404598|Active Comparator|naproxen 500 mg bid|
32977928|NCT01404637|Experimental|Tamsulosin 0.4mg|
32977929|NCT01404637|Active Comparator|tamsulosin 0.2mg|
32977930|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
32977931|NCT01404676|Experimental|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
32977932|NCT01404676|Active Comparator|Glimepiride + Metformin|Adding Glimepiride to metformin users
32977933|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
32977934|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
32977935|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
32977936|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
33411448|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
33104987|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
33104988|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
33104989|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
33104990|NCT01775423|Experimental|BBI608|
32977937|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
32977938|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
32977939|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
32977940|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
32977941|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
32977942|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
32977943|NCT01404780|Experimental|The GlideScope (GVL)|
32977944|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
32977945|NCT01404793||Liver transplant recipient|
32977946|NCT01404806|Experimental|GSK1349572|
32977947|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
32977948|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
32977949|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
32977950|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
33104991|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
33104992|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
33411449|NCT02954510|Experimental|Intervention|Single arm utilizing ferumoxytol
32977951|NCT01404858||Patients undergoing IVF|
32977952|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
32977953|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
32977954|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
32977955|NCT01404897|Experimental|Dietary Intervention: Control Diet|
32977956|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
32977957|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
32977958|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
32977959|NCT01404962|Other|Group 1|
32977960|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
33411450|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
32977961|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
32977962|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
32977963|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
32977964|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
32977965|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
32977966|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
32977967|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
32977968|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
32977969|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
32977970|NCT01405118|Experimental|Metformin/CP-690,550|
32977971|NCT01405131|Experimental|methylprednisolone suspension|
32977972|NCT01405131|Active Comparator|methylprednisolone tablets|
32977973|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
32977974|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
32977975|NCT01405157|Experimental|methylprednisolone suspension|
32977976|NCT01405157|Active Comparator|methylprednisolone tablets|
32977977|NCT01405170|Experimental|methylprednisolone suspension|
32977978|NCT01405170|Active Comparator|methylprednisolone tablets|
32977979|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
32977980|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
32977981|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
32977982|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
32977983|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
32977984|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
32977985|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
32977986|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
32977987|NCT01405248|Placebo Comparator|control|Placebo
32977988|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
32977989|NCT01405261|Experimental|NNC 0113-987 (coated)|
32977990|NCT01405261|Experimental|NNC 0113-987 (i.v)|
32977991|NCT01405274|Experimental|Physiotherapy intervention|
32977992|NCT01405274|No Intervention|standard care|
32977993|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
32977994|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
32977995|NCT01405300|Experimental|Peanut|
32977996|NCT01405300|Placebo Comparator|Control|
32977997|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
32977998|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
32977999|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
32978000|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
32978001|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
32978002|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
32978003|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
32978004|NCT01405365|Experimental|Metronidazole|
32978005|NCT01405365|Placebo Comparator|Placebo|
32978006|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
32978007|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
32978008|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
32978009|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
32978010|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
32978011|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
33104993|NCT00900809|Experimental|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
32978012|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
32978013|NCT01405430|Experimental|Bevacizumab + blood samples|
32978014|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
32978015|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
32978016|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
32978017|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
32978018|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
32978019|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
33411451|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
32978020|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
32978021|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
32978022|NCT01405521|Experimental|M01ZH09 vaccine|
32978023|NCT01405521|Placebo Comparator|Vaccine placebo|
32978024|NCT01405521|Other|Ty21a vaccine|Positive control
32978025|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
32978026|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
32978027|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
32978028|NCT01405599|Experimental|Control|Healthy subjects
33411452|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
33411453|NCT02032784|Other|no octreotide|No Octreotide
33411454|NCT04055376|Experimental|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
33411455|NCT04055376|Sham Comparator|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
33411456|NCT03611426|Experimental|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
33411457|NCT03611426|Placebo Comparator|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
33411458|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
33411459|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
33411460|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
33411461|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
33411462|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
32978029|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
32978030|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
32978031|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
32978032|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
32978033|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
32978034|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
32978035|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
32978036|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
32978037|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
33411463|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
33411464|NCT04612868|Experimental|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
32862373|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
32862374|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
32862375|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
32862376|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
32862377|NCT04352595|Experimental|1% Hemay808|
32862378|NCT04352595|Experimental|3% Hemay808|
32862379|NCT04352595|Experimental|7% Hemay808|
32862380|NCT04352595|Placebo Comparator|vehicle|
32862381|NCT02744287|Experimental|Arm 1: Phase 1 Dose Escalation|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
32862382|NCT02744287|Experimental|Arm 2: Phase 2 Dose Expansion|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
32862383|NCT04920240|Placebo Comparator|routine group|"In accordance with the intensive care unit hospital infection prevention and control norms requirements"
32862384|NCT04920240|Experimental|Experimental group|Implement a multi-center unified ICU high-frequency contact surface standardized cleaning and disinfection mode
32862385|NCT04930224||Proliferative Diabetic retinopathy|40 patients with proliferative diabetic retinopathy
32862386|NCT04930224||Non-Proliferative Diabetic retinopathy|40 patients with non-proliferative diabetic retinopathy
32862387|NCT04930224||Healthy individuals|40 healthy persons
32862388|NCT05024305|Experimental|Dose Escalation Cohort|Four dose levels of TWP-102 injection will be tested by BOIN study design.
32862389|NCT05024305|Experimental|Dose Expansion Cohort|Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.
32862390|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
32862391|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
32862392|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
32862393|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
32862394|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
32862395|NCT04912440||MSE-ERCP|Group of patients, that received motorized spiral enteroscopy assisted ERCP in altered anatomy at the single study center
32862396|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
32862397|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
32862398|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
32862399|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
32862400|NCT04919850|Active Comparator|Intervention group|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
33417319|NCT03074318|Experimental|Phase 1 (1.5 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
32862401|NCT04919850|Placebo Comparator|Placebo group|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
32862402|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
32862403|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
32862404|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
32862405|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
32862406|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
32862407|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
32862408|NCT02734615|Experimental|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
32862409|NCT04912362|Experimental|YAG iridotomy+CLASS|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
32862410|NCT04912362|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery only
32862411|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
32862412|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
32862413|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy~MLN9708 -oral on predetermined days per cycle~Cytarabine, continuous infusion for predetermined duration and dosage~Daunorubicin short IV infusion or rapid injection for predetermined~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
32862414|NCT04919694|Experimental|combination of orbital compression and strabismus surgery|orbital compression and strabismus surgery are performed at the same time
32862415|NCT04919694|Active Comparator|perform strabismus surgery after orbital compression|Firstly, perform orbital compression, after about 3 to 6 months ,strabismus surgery is done.
32862416|NCT04912284||General population|Questionnaire administered to adult population
32862417|NCT04912284||Health care workers|Questionnaire administered to adult health care workers
32862418|NCT05021809|No Intervention|Group A|control group will not receive any intracanal medication
32862419|NCT05021809|Active Comparator|Group B|Calcium hydroxide intracanal medication without iodoform (Metapaste )
32862420|NCT05021809|Active Comparator|Group C|Calcium hydroxide intracanal medication with iodoform (Metapex)
32862421|NCT04930146|Experimental|Intervention group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
32862422|NCT04930146|No Intervention|Control group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
32862423|NCT04930146|Experimental|Intervention group (Moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
32862424|NCT04930146|No Intervention|Control group (moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
32862425|NCT02730715||Thymoglobulin|blood specimen collection
32862426|NCT02730715||Basiliximab|blood specimen collection
32862427|NCT04919616|Experimental|Single-arm|
32862428|NCT04125693|Experimental|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
32862429|NCT04063995|Experimental|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
32862430|NCT04063995|Experimental|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
32862431|NCT04063995|Sham Comparator|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
32862432|NCT04919460|Other|clinical observation combined with pathological biopsy|Clinical observation (including inspection and palpation) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
32907581|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
32978038|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
32978039|NCT01405651|Experimental|E|ONO-6950
32978040|NCT01405651|Placebo Comparator|P|Placebo
32978041|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
32978042|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
32978043|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
32978044|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
32978045|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
32978046|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
32978047|NCT01405703||open plate fixation|large transverse incision
32978048|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
32978049|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
32978050|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
32978051|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
32978052|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
32978053|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
32978054|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
32978055|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
32978056|NCT01405846|Other|Gefitinib|Single arm study
32978057|NCT01405859||TS controls|10
32978058|NCT01405859||Non TS Controls|11
32978059|NCT01405859||TS remission|0
32978060|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
32978061|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
32978062|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
32978063|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
32978064|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
32978065|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
32978066|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
32978067|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
32978068|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
32978069|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
32978070|NCT01405976|Active Comparator|1|NIV for severe OSA group
32978071|NCT01405976|Active Comparator|2|CPAP for severe OSA group
32978072|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
32978073|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
32978074|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
32978075|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
32978076|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
32978077|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
32978078|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
32978079|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
32978080|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
32978081|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
32978082|NCT01406054|No Intervention|control|
32978083|NCT01406067|Experimental|Social Skills Training|
32978084|NCT01406067|Active Comparator|Play group|
32978085|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
32978086|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
32978087|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
32978088|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
32978089|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
32978090|NCT01406119|Experimental|ABT-806 Arm|
32978091|NCT01406132|Experimental|ASP015K|
32978092|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
32978093|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
32978094|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
32978095|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
32978096|NCT01406158|Experimental|Treatment A|
32978097|NCT01406158|Experimental|Treatment B|
32978098|NCT01406158|Experimental|Treatment T|
32978099|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
32978100|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
32978101|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
32978102|NCT01406236|Other|Transradial PCI|
32978103|NCT01406236|Other|Transfemoral PCI|
32978104|NCT01406249|Active Comparator|S-1,Cisplatin|
32978105|NCT01406249|Experimental|Capecitabine, Cisplatin|
32978106|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
32978107|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
32978108|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
32978109|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
32978110|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
32978111|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
32978112|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
32978113|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
32978114|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
33323017|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
32978115|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
32978116|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
32978117|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
32978118|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
32978119|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
32978120|NCT01406379|Active Comparator|Detachable snare|Detachable snare
32978121|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
32978122|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
32978123|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
32978124|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
32978125|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
32978126|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
32978127|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
32978128|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
32978129|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
32978130|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
32978131|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
32978132|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
32978133|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
32978134|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
32978135|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
32978136|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
32978137|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
32978138|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
32978139|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
32978140|NCT01406483|Other|CABG|
32978141|NCT01406496|Experimental|Timing of insulin administration|
32978142|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
32978143|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
32978144|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
32978145|NCT01406522|Experimental|Oral tacrine|Oral tacrine
32978146|NCT01406587|Experimental|PP4001 50 mg|
32978147|NCT01406587|Experimental|PP4001 100 mg|
32978148|NCT01406587|Experimental|PP4001 200 mg|
32978149|NCT01406587|Placebo Comparator|Placebo|
32862433|NCT04919460|Experimental|Clinical observation, in vivo staining combined with pathological biopsy|Clinical observation (including inspection and palpation), in vivo staining (reagent: toluidine blue) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
33411465|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
32862434|NCT04930068|Experimental|ultra-sound|ultrasonic cavitation applied on abdominal region for 30 minutes, 2 times per week for 6 weeks.
32862435|NCT04930068|Experimental|aerobic exercise|aerobic exercises through treadmill (60-70% of VO2 max.) for 30 minutes, 2 times per week for 6 weeks
32862436|NCT04049643|Active Comparator|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
32862437|NCT04049643|Experimental|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
32862438|NCT04049643|Experimental|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
32862439|NCT04929756||Fixation PRL|Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
32862440|NCT04929756||Smooth Pursuit PRL|Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
32862441|NCT04929756||Saccade PRL|Visual feedback will be provided to train subjects to attend to a PRL for saccadic eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on an abruptly shifting dot. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Saccadic eye movement behavior will be measured with an eye tracker.
32862442|NCT04929756||Scotoma Awareness PRL|Subjects are often unaware of their scotomas because they are filled in with the surrounding background texture. The investigators will exploit this filling in to increase awareness of the scotoma by surrounding the scotoma with a visible disk that will be perceptually completed across the scotoma, rendering the scotoma visible. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Scotoma Awareness Disk at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
32862443|NCT04929756||Meta-Guidance PRL|Oculomotor control can be promoted in the location around our hands. The investigators will exploit this meta-guidance advantage by asking subjects to move their hand and their PRL to an on-screen target. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Hand Movement at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
32862444|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
32862445|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
32862446|NCT04037241|Active Comparator|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
32978150|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
32978151|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
33411466|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
33411467|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
33411468|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
33411469|NCT03611192|Experimental|Multicomponent exercise group|
33411470|NCT03611192|Active Comparator|Home-program exercise group|
33411471|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
33411472|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
33411473|NCT05383586|Experimental|Creative Music Therapy|20 minutes of infant-directed singing in lullaby-style accompanied with the monochord for preterm infant and parent during kangaroo-care
33411474|NCT04056000|Experimental|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
33411475|NCT04056000|Experimental|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
33411476|NCT04056000|Experimental|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
33411477|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
33411478|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
33411479|NCT02879864|Experimental|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
33411480|NCT02879864|Active Comparator|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
33411481|NCT04055532||Mild Cognitive Impairment|
33411482|NCT04055532||Alzheimer's Disease|
33411483|NCT04055532||Dementia with Lewy Bodies|
32907582|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
32907583|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
32907584|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
32907585|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
32907586|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
32907587|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
32907588|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities as a mechanism for reducing distress and improving overall well-being. Participants will use an online web tool to select and schedule activities they deem will be rewarding and fulfilling. They will then track their engagement in these activities on a weekly basis.
32907589|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills. Participants will receive bibliotherapy handouts describing various means of managing their distress and solving caregiving-related problems.
32907590|NCT02243618|Active Comparator|Rebamipide group|
32907591|NCT02243618|Active Comparator|Polaprezinc group|
32907592|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
32907593|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
32907594|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
32907595|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
32907596|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
32907597|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
33411484|NCT04055532||Frontotemporal Lobar Dementia|
33411485|NCT04055532||Parkinson's Disease with Dementia|
33411486|NCT04055532||Transient Epileptic Amnesia|
33411487|NCT04055532||Temporal Lobe Epilepsy|
33411488|NCT04055532||Spinocerebellar Ataxia|
33411489|NCT04055532||HIV-Associated Neurocognitive Disorder|
33411490|NCT04055532||Amyotrophic Lateral Sclerosis|
33411491|NCT04055532||Primary Lateral Sclerosis|
33411492|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
33411493|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
33411494|NCT04055064|Experimental|Intervention|patients received nutrition education and nutritional supplements
33411495|NCT04055064|No Intervention|Control|patients did not receive any intervention
33411496|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
33411497|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
33411498|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
33411499|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
33411500|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
33411501|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
33411502|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
33411503|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
33411504|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
33411505|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
33411506|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
33411507|NCT03045744|Experimental|incomplete SCI patients|
33411508|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
32739122|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
32978152|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
33104994|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4~Period 2: placebo administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
33411509|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
33411510|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
33411511|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
33411512|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
33411513|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
33411514|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
33411515|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
33411516|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
33411517|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
33411518|NCT05180747|Other|Burst group|Patients received two physical therapy sessions weekly for 6 weeks.
33411519|NCT05180747|Other|Spaced Group|Patients received one physical therapy sessions every 2 weeks for 6 months.
33411520|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
33411521|NCT05179889|Experimental|Arm A|FOLFOXIRI
33411522|NCT05179889|Active Comparator|Arm B|mFOLFOX 6
33411523|NCT03208127|Experimental|Treatment with Direct Acting Antiviral (DAA) Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
33411524|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
33411525|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
33411526|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
32978153|NCT01406626|Experimental|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
32978154|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
32978155|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
32978156|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
33323018|NCT04231396|Other|HA and CI Users using Audiobooks for Hearing Loss for Auditory Training|"study participants will be seen weekly for 12 weeks and will use the Audiobooks for HL App for the final 6 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:~First 6 weeks:~• Partial BKB-SIN will be administered~Final 6 weeks:~Partial BKB-SIN will be administered~Conduct a comprehension test.~Address any usability issues the participant brings up.~Review and set new weekly goals Final session: Conduct Final Usability survey"
33323019|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
33323020|NCT01113294|Experimental|ablation|
32978157|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
32978158|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
32978159|NCT01406704|No Intervention|Control|
32978160|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
32978161|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
32978162|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
32978163|NCT01406730|Experimental|exercise|16 weeks of running exercise
32978164|NCT01406730|No Intervention|control|
32978165|NCT01406743||EOS™ Acquisition|
32978166|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
32978167|NCT01406808|Other|standard of care plus genetic information|
32978168|NCT01406808|No Intervention|usual standard of care without genetic information|
32978169|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
32978170|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
32978171|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
32978172|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
32978173|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
32978174|NCT01406886|Experimental|Energy density|Low or high energy density meal
32978175|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
32978176|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
32978177|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
33323021|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
33323022|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
32978178|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
32978179|NCT01406925|Placebo Comparator|Control|Placebo control
32978180|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
32978181|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
32978182|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
32978183|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
32978184|NCT01406951||sepsis|SIRS + infection
32978185|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
32978186|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
32978187|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
32978188|NCT01407016|Experimental|1.0|
32978189|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
32978190|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
32978191|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
32978192|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
32978193|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
32978194|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
32978195|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
32978196|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
32978197|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~intensity: 100% of resting motor threshold~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~number of stimulations per session: 300, 900 or 1800 per session~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
32978198|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
32978199|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
32978200|NCT01407159||Control group|"historical control group fulfilling the following criteria:~Age +/- 3 years~Sex matched~Same follow-up period"
32978201|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
32978202|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
32978203|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
32978204|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
32978205|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
32978206|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
32978207|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
32978208|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
32978209|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
32978210|NCT01407224|No Intervention|Control|No intervention such as training or supervision
32978211|NCT01407237||HIV-infected Individuals|
32978212|NCT01407237||non-HIV-infected Individuals|
32978213|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
32978214|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
32978215|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
32978216|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
32978217|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
32978218|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
32978219|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
32978220|NCT01407393|Experimental|Glucosanol|Glucosanol
32978221|NCT01407393|Placebo Comparator|Placebo|Placebo
32978222|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
32978223|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
32978224|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
32978225|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
32978226|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
32978227|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
32978228|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
33104995|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
32862447|NCT04037241|Active Comparator|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
32862448|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
32907598|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
32907599|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
32907600|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
32907601|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
32907602|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
32907603|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
32907604|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
32907605|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
32907606|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
32907607|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
32907608|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
32907609|NCT02244008|Placebo Comparator|manual contact|
32907610|NCT03102125|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
32907611|NCT03102125|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
32907612|NCT03102125|Experimental|Cardiac allograft vasculopathy|Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
32907613|NCT03102125|Experimental|ACR/AMR|Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
32907614|NCT04347278||Patients receiving treatment for COVID19|
32907615|NCT04369586|Experimental|meplazumab dose 1|0.06mg/kg for single dose
32907616|NCT04369586|Experimental|meplazumab dose 2|0.12mg/kg for single dose
32907617|NCT04369586|Experimental|meplazumab dose 3|0.2mg/kg for single dose
32907618|NCT04369586|Experimental|meplazumab dose 4|0.3mg/kg for single dose
32907619|NCT04369586|Experimental|meplazumab dose 5|0.42mg/kg for single dose
32907620|NCT04369586|Experimental|meplazumab dose 6|0.56mg/kg for single dose
32907621|NCT04369586|Experimental|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
32978229|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
32978230|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
32978231|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
32978232|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
32978233|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
32978234|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
32978235|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
32978236|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
32978237|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
32978238|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
32978239|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
32978240|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
32978241|NCT01407484|Placebo Comparator|Placebo|Placebo
32978242|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
32978243|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
32978244|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
32978245|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
32978246|NCT01407510|Experimental|Arm 1|
32978247|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
32978248|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
32978249|NCT01407588|Experimental|Magnetic navigation|
32978250|NCT01407588|Experimental|Manual navigation|
32978251|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
32978252|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
32978253|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
32978254|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
32978255|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
32978256|NCT01407640|Experimental|1|Allergy tests
32978257|NCT01407653|Experimental|virtual reality|
32978258|NCT01407653|Other|usual care|
32978259|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
32978260|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
32978261|NCT01407679|Experimental|Alitretinoin|
32978262|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease~30 to 80 years of age~Ability of volunteers to tolerate 1 hr examination"
32978263|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~Clinical and Radiographic evidence of cervical spondylotic myelopathy~18 to 80 years of age~Safe and stable clinical scenario to undergo imaging~Awake, alert patient able to cooperate with physical examination~Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~Have signs or symptoms consistent with spinal cord injury.~Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
32978264|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
32978265|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
32978266|NCT01407783|No Intervention|Enhanced Referral|
32978267|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
32978268|NCT01407809|Experimental|Intervention|
32978269|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
32978270|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
33104996|NCT00547209|Active Comparator|1|ventilation with air and oxygen
32978271|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations~Positive control~Negative control"
32978272|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
32978273|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
32978274|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
32978275|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
32978276|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
33323023|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
32978277|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
32978278|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
32978279|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
32978280|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
32978281|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
32978282|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
32978283|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
32978284|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
32978285|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
32978286|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
32978287|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
32978288|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
32978289|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
32978290|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
32978291|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
32978292|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
32978293|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
32978294|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
32978295|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
32978296|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
32978297|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
32978298|NCT01408121||African-American on clopidogrel|
32978299|NCT01408121||African-American on prasugrel|
32978300|NCT01408121||Caucasian on clopidogrel|
32978301|NCT01408121||Caucasian on prasugrel|
32978302|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32978303|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
32978304|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
32978305|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
32978306|NCT01408199|Experimental|Lenalidomide Group|
32978307|NCT01408212|Experimental|Acupuncture therapy|
32978308|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations~Positive control~Negative control"
32978309|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
32978310|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
32978311|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
32978312|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
32978313|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
33323024|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
33323025|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
33323026|NCT04154644|Experimental|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
33323027|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
33323028|NCT01210638|Active Comparator|Opana|Tablet
33323029|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
33323030|NCT01115478|Active Comparator|Vitamin A|
33323031|NCT01115478|Active Comparator|Zinc|
32978314|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
32978315|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
32978316|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
32978317|NCT01408342|Other|Rituximab, Alemtuzumab|
32978318|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
32978319|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
32978320|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
32978321|NCT01408368|Experimental|Total thyroidectomy|
32978322|NCT01408381|No Intervention|Control|No cell therapy
32978323|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
32978324|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
32978325|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
32978326|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
32978327|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
32978328|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
32978329|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
32978330|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
32978331|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
32978332|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
32978333|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
32978334|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
32978335|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
32978336|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
32978337|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
32978338|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
32978339|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
32978340|NCT01408511|Experimental|Arm 1|
32978341|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
32978342|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
32978343|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
32978344|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
33323032|NCT01115478|Active Comparator|Vitamin A + Zinc|
32978345|NCT01408589|Placebo Comparator|Sugar Pill|
32978346|NCT01408589|Experimental|Atomoxetine 40 mg|
32978347|NCT01408589|Experimental|Atomoxetine 60 mg|
32978348|NCT01408589|Experimental|Atomoxetine 80 mg|
32978349|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
32978350|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
32978351|NCT01408602|Placebo Comparator|Placebo|Placebo
32978352|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
32978353|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
32978354|NCT01408667|Placebo Comparator|Placebo|
32978355|NCT01408667|Active Comparator|TRC150094|
32978356|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
32978357|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
32978358|NCT01408680|Placebo Comparator|Placebo|
32978359|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
32978360|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
32978361|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
32978362|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
32978363|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
32978364|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
32978365|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
32978366|NCT01408797|Experimental|Clonal deletion|
32978367|NCT01408797|Experimental|Drugs Added When Needed|
32978368|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
32978369|NCT01408823||Idiopathic Scoliosis|
32978370|NCT01408823||Non-idiopathic Scoliosis|
32978371|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
33323033|NCT01115478|Placebo Comparator|Placebo|
33323034|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
33323035|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
32978372|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
32978373|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
32978374|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
32978375|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
32978376|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
32978377|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
32978378|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
32978379|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
32978380|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
32978381|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
32978382|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
32978383|NCT01409018|Experimental|Itraconazole|
32978384|NCT01409044|Experimental|Music|Research participant listened to music
32978385|NCT01409057||No heart lung machine|Coronary-artery-disease
32978386|NCT01409057||Heart lung machine|Coronary artery disease
32978387|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
32978388|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
32978389|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
32978390|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
32978391|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
32978392|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
32978393|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
32978394|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
32978395|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
32978396|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
32978397|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
33323036|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
33323037|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
33323038|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
33323039|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
33323040|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
33411527|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
32978398|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
32978399|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
32978400|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
32978401|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
32978402|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
32978403|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
32978404|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
32978405|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
32978406|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
32978407|NCT01409226|Experimental|MRI|
32978408|NCT01409252||Hemorrhagic stroke patients|
32978409|NCT01409265||No treatment|
32978410|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
32978411|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
32978412|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
32978413|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
32978414|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
32978415|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
32978416|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
32978417|NCT01409343|Experimental|TrasGEX|A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.
32978418|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
32978419|NCT01409369|Experimental|1|
32978420|NCT01409369|Active Comparator|2|
32978421|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
32978422|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
32978423|NCT01409408|Active Comparator|Aliskiren|
32978424|NCT01409408|Active Comparator|Amlodipine|
32978425|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
32978426|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
32978427|NCT01409421|No Intervention|standard care|standard care for glaucoma
32978428|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
32978429|NCT01409460|Experimental|True Obturator Nerve Block|
32978430|NCT01409460|Sham Comparator|Sham Block|
32978431|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
32978432|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
32978433|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
32978434|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
32978435|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
32978436|NCT01409525||cardiac surgery patients|
32978437|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
32978438|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
32978439|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
32978440|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
32978441|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
32978442|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
32978443|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
32978444|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
32978445|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
32978446|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
32978447|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
32978448|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
32978449|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
32978450|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
32978451|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
32978452|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
32978453|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
32978454|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
33323041|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
32978455|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
32978456|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
32978457|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
32978458|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
32978459|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
32978460|NCT01409668|Experimental|L. Amylovorus|
32978461|NCT01409668|Experimental|L. Fermentum|
32978462|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
32978463|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
32978464|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
32978465|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
32978466|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
32978467|NCT01409733|Experimental|Stage IV melanoma patients|
32978468|NCT01409746||twins|twin pairs
32978469|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
32978470|NCT01409759|Other|Full thickness graft|
32978471|NCT01409772||Intestinal Rehab|
32978472|NCT01409785||LMA Supreme|
32978473|NCT01409785||LMA unique|
32978474|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
32978475|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
32978476|NCT01409850|Active Comparator|Aqualizer|
32978477|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
33104997|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
32978478|NCT01409850|No Intervention|Counselling|
32978479|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
32978480|NCT01409876|Experimental|Brachytherapy|
32978481|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
32978482|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
32978483|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
32978484|NCT01410019|Experimental|1|Gene transfer
32978485|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
32978486|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
32978487|NCT01410045|Experimental|Surgery|Ovariectomy
32978488|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
32978489|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
32978490|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
32978491|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
32978492|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
32978493|NCT01410162|Active Comparator|Advagraf|
32978494|NCT01410162|Active Comparator|Prograf|
33323042|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
32907622|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
32907623|NCT02231177|Active Comparator|BI 1744 CL|
33323043|NCT01111344|Experimental|Glizigen + Viusid|
33323044|NCT01111344|Placebo Comparator|Placebo|
33323045|NCT01208688|Experimental|FES Therapy|FES Therapy
32907624|NCT02231177|Active Comparator|Tiotropium|
32907625|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
32907626|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
32907627|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
32907628|NCT02223689|Experimental|Skin Affix|Surgical adhesive
32907629|NCT04369118|Experimental|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
32907630|NCT04369118|Active Comparator|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
32907631|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
32907632|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
32907633|NCT04363190||Cases|
32907634|NCT04363190||Controls|
32907635|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained~MRI Tracker is used during catheter positioning with serial MR imaging during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
32907636|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained~Standard process is used with serial MR imaging to evaluate catheter position during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
32907637|NCT02706197|Experimental|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
32907638|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
32907639|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
32907640|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
32907641|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
32907642|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
32907643|NCT02249117|Experimental|BIWH 3|single escalating dose
32907644|NCT02249117|Placebo Comparator|Placebo|
32907645|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
32907646|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
32907647|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
32907648|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
32907649|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
32907650|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
32907651|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
32907652|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
32907653|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
32907654|NCT04362020|Experimental|Group-1|No anticoagulation
32907655|NCT04362020|Active Comparator|Group-2|ACT-guided anticoagulation
32907656|NCT04368572|Experimental|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
32907657|NCT04368572|Active Comparator|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
32907658|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
32907659|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
33323046|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
32907660|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
33323047|NCT05365204|Experimental|Voluven diluted indocyanine green|This arm participants uses Voluven diluted ICG for sentinel lymph node mapping.
33323048|NCT05365204|Active Comparator|Distilled-water diluted indocyanine green|This arm participants uses Distilled-water diluted ICG for sentinel lymph node mapping.
33323049|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
33323050|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
33323051|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
33323052|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
33323053|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
33323054|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
33323055|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
33323056|NCT01368952|No Intervention|Baseline|No intervention for sleep position
33323057|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
33323058|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
33323059|NCT05188378|Experimental|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33323060|NCT05188378|Active Comparator|EU-approved RoActemra|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
33323061|NCT05358730|Experimental|IASTM + Standard Exercise Group|Patients were applied IASTM in combination with standard exercise program two days a week for six weeks. The IASTM technique was performed using six titanium-plated instruments in different sizes, shapes and treatment styles. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
33323062|NCT05358730|Active Comparator|Standard Exercise Group|Patients were given a standard exercise program two days a week for six weeks. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
33323063|NCT03939702|Active Comparator|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
33323064|NCT03939702|Active Comparator|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
33323065|NCT05188300|Experimental|Dorsal intercostal artery (DICA) perforator flaps|Retrograde dissection of free style perforator arising from DICA according to region of dorsal spine and identification of paraspinal muscle where perforator vessel was found
33323066|NCT05188300|Experimental|Trapezius musculocutaneous perforator flaps|Retrograde dissection of a free style perforator arising as a trapezius myocutenous perforator where the trapezius muscle is identified and a perforator vessel was isolated.
33323067|NCT05188300|Experimental|Lumbar artery perforators flaps|Retrograde dissection of free style perforator arising from lumbar artery according to region of lumbar spine and identification of lumbar fascia where perforator vessel was found
33323068|NCT05357638|Experimental|Physical Training Group 1 (n=16)|High Intensity Interval Training
33323069|NCT05357638|Experimental|Physical Training Group 2 (n=16)|Continuous Aerobic Training
33323070|NCT05357638|Experimental|Physical Training Group 3 (n=16)|Movement Advice
33323071|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
33323072|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
33323073|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
32862449|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
33411528|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
33411529|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
32907661|NCT04368650|Experimental|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
32907662|NCT04368650|Active Comparator|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
32907663|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
32907664|NCT04367948|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
32907665|NCT04367948|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
32907666|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
32907667|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
32907668|NCT04368182|Experimental|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
32907669|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
32907670|NCT01632215|Placebo Comparator|sugar pill|Placebo group
32907671|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
32907672|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
32907673|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate.
32907674|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
32907675|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
32907676|NCT04376450|Experimental|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
32907677|NCT04376450|Active Comparator|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
32907678|NCT04376294|Experimental|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
32907679|NCT04376294|Active Comparator|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
32907680|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
32907681|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
32907682|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
32907683|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
32907684|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
32907685|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
32907686|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
32907687|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
32978495|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
32978496|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
33411530|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
33411531|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function.
32907688|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
32907689|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
32907690|NCT04362332|Active Comparator|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
32907691|NCT04362332|Active Comparator|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
32907692|NCT04362332|No Intervention|Supportive care only|3. Supportive care only.
32907693|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
32907694|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
32907695|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
32907696|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
32907697|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
32907698|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
32907699|NCT04367558|Experimental|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
32907700|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
32907701|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
32907702|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
32907703|NCT04362098|Experimental|Nurse home visits|Nurse home visits biweekly.
32907704|NCT04362098|No Intervention|Usual care|Usual care.
32907705|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
32907706|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
32907707|NCT02224313|No Intervention|1.Premenopausal women|No treatment
32907708|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
32907709|NCT04362410|Experimental|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
32907710|NCT04362410|Experimental|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
32907711|NCT04362410|Experimental|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
32907712|NCT04362410|Placebo Comparator|Placebo|Placebo single dose subcutaneously injection.
32907713|NCT04361708|Experimental|High Risk UGT1A1 genotype|
32907714|NCT04361708|Experimental|Intermediate Risk UGT1A1 genotype|
32907715|NCT04361708|Experimental|Low Risk UGT1A1 genotype|
32907716|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 3 years).
32978497|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
33323074|NCT03938064|Active Comparator|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
33323075|NCT03938064|Placebo Comparator|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
33323076|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
33323077|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
33323078|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
33323079|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
32978498|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
32978499|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
32978500|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
32978501|NCT01410253|Experimental|Group 1|
32978502|NCT01410253|Experimental|Group 2|
32978503|NCT01410253|Experimental|Group 3|
32978504|NCT01410253|Placebo Comparator|Group 4|
32978505|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
32978506|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
32978507|NCT01410292|Experimental|meal D|low fiber and low GI
32978508|NCT01410292|Experimental|meal C|low Fiber and High GI
32978509|NCT01410292|Experimental|meal B|high Fiber and low GI
32978510|NCT01410292|Experimental|meal A|high fiber and high GI meal
32978511|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
32978512|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
32978513|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
32978514|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
32978515|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
32978516|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
32978517|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
32978518|NCT01410370|Active Comparator|control|Radiotherapy
32978519|NCT01410383|Placebo Comparator|Placebo|
32978520|NCT01410383|Experimental|Eprotirome I|
32978521|NCT01410383|Experimental|Eprotirome II|
32978522|NCT01410422||COPD|COPD
32978523|NCT01410422||Bronchiectasis|Bronchiectasis
32978524|NCT01410435|Experimental|Treatment|
32978525|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
32978526|NCT01410487||Obese group|
32978527|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
32978528|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
32978529|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
32978530|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
32978531|NCT01410526||Control group|Patients suffering major abdominal surgery
32978532|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
32978533|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
32978534|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
32978535|NCT01410578||sepsis|SIRS + infection
32978536|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
32978537|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
32978538|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
32978539|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
32978540|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
32978541|NCT01410630||FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
32978542|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
32978543|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
32978544|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
32978545|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
32978546|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
32978547|NCT01410669|Experimental|Motivational Interviewing (MI)|
32978548|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
32978549|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
32978550|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
32978551|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
32978552|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
32978553|NCT01410747||tacrolimus group|Oral
32978554|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
32978555|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
32978556|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
32978557|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
32978558|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
32978559|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
32978560|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
32978561|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
32978562|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
32978563|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
32978564|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
32978565|NCT01410877||Inhaler naive healthy volunteers|
32978566|NCT01410903|Experimental|TheraSorb Ig|
32978567|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
32978568|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
32978569|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
32978570|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
32978571|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
32978572|NCT01411007||Non-Smokers|
32978573|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
32978574|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
33323080|NCT05339932|Experimental|Manual wheelchair skills training|
33323081|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
33323082|NCT05336110||Patient with a positive preoperative SARS-CoV-2 test|Patient with a positive preoperative SARS-CoV-2 test
33323083|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
33323084|NCT05303116||Control|Patients with COVID who are NOT experiencing altered mental status
33323085|NCT05303116||COVID patients|COVID patients who are experiencing confusion,
33323086|NCT03938142||patients with chronic pain|
33323087|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
32862450|NCT04037241|Active Comparator|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
32862451|NCT04037241|Active Comparator|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
32862452|NCT04912128||Anlotinib group|Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1~14, 21d/cycle. All patients received SBRT for brain metastases.
32862453|NCT04912128||SBRT group|Patients in SBRT group took no anti-angiogenic drugs. All patients received SBRT for brain metastases.
32862454|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
32862455|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
32862456|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
32862457|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
32862458|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
32862459|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
32862460|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
32862461|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
32862462|NCT02621034|Experimental|Control|K-file hand instrumentation
32862463|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
32862464|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
32862465|NCT04911738|Experimental|Plane A for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane A, which corresponds to the following order: verticality perception (Baseline, effect during the intervention, post-effect), then active vertical body orientation (Baseline, effect during the intervention). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
32862466|NCT04911738|Experimental|Plane B for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane B, which corresponds to the following order: active vertical body orientation (Baseline, effect during the intervention), then verticality perception (Baseline, effect during the intervention, post-effect). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
32862467|NCT02572453|Experimental|ALK+ ALCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
32862468|NCT02572453|Experimental|Relapsed MCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
32862469|NCT02572453|Experimental|BCL6+ DLBCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
32862470|NCT04929990|Experimental|Inpiratory and expiratory muscle training|The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively. The intensity was adjusted to add 5% of resistance each week
32978575|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
32978576|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
32978577|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
32978578|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
32978579|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
32978580|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
32978581|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
32978582|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
32978583|NCT01411033||Newly diagnosed diabetes mellitus type 1|
32978584|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
32978585|NCT01411059|Experimental|yoga|32 weeks of yoga training
32978586|NCT01411072|Experimental|Gemcitabine|
32978587|NCT01411072|Experimental|5-fluorouracil|
33323088|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
32978588|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
32978589|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
32978590|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
32978591|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
32978592|NCT01411124|Active Comparator|diphenhydramine|50 mg
32978593|NCT01411124|Placebo Comparator|placebo|placebo to match
32978594|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
32978595|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
32978596|NCT01411189|Other|Menthol|20 mL NPO-11
32978597|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
32978598|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
32978599|NCT01411254|Experimental|1|
32978600|NCT01411254|Experimental|2|
32978601|NCT01411254|Sham Comparator|3|
32978602|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
32978603|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
32978604|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
32978605|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
32978606|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
32978607|NCT01411358|Experimental|AdimFlu-S 2011-2012|
32978608|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
33323089|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
33323090|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
33323091|NCT01115712|Placebo Comparator|Placebo|Placebo
33323092|NCT01360294||Asthma with small airway disease|
33323093|NCT01360294||Asthma without small airway disease|
33323094|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
33323095|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
33323096|NCT03939936|Active Comparator|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
33323097|NCT03939936|Placebo Comparator|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
33323098|NCT05197972|Experimental|Experimental group|Classic management of the preoperative period with a cardiac coherence program coupled with hypnosis.
33323099|NCT05197972|No Intervention|Control group|Classic management of the preoperative period
33323100|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
33323101|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
33323102|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
33323103|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
33323104|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
33323105|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
33323106|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
33323107|NCT01115790|Experimental|Prexasertib|
33323108|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
33323109|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
33323110|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
33323111|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
33323112|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
33323113|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
33323114|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
33323115|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
33323116|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
33323117|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
32862471|NCT04929990|Active Comparator|Inspiratory muscle training|The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
32862472|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
32862473|NCT04929444|Active Comparator|Training group|The professionals of the primary care teams that are in Intervention group would receive the training at the beginning of the study
32862474|NCT04929444|No Intervention|Common Practice|The professionals of the primary care teams that are in Control group will be offered the training after the conclusion of the study
32862475|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
32862476|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
32862477|NCT04918914|Other|Intervention|
32862478|NCT04911504||Questionnaire survey group|All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
32862479|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
32862480|NCT04911114|Experimental|Intervention Arm|This is a single arm pilot study of group base exercise
32862481|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
32862482|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
32862483|NCT04918524||The Antiphospholipid syndrome (APS)|The cohort includes that patients who meet the proposed Sydney criteria.
32862484|NCT04918524||Undifferentiated connective tissue disease (UCTD)|The cohort includes the patients who are diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibodies (aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting CTD ,while not fulfilling any classification criteria of a defined CTD.
32862485|NCT04911426|No Intervention|Treatment as usual|Individuals in the treatment as usual condition will participate in substance use treatment as part of the standard police opioid diversion program model.
32862486|NCT04911426|Experimental|Treatment plus telehealth|Individuals in the treatment plus telehealth condition will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
32862487|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 1|
32862488|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 2|
32862489|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
32862490|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
32862491|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
32862492|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
32862493|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
32862494|NCT04929288|Experimental|Males|Participants in this group will be adult male drinkers.
32862495|NCT04929288|Experimental|Females|Participants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
32862496|NCT05026489||G6PD Deficiency|In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity < 6.8NBT were positive, and G6PD deficiency is confirmed.
32862497|NCT05026489||Normal|The G6PD activity ranged from 6.8 to 20.5 NBT and the G6PD activity is normal.
32862498|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
32862499|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
32862500|NCT05586763|Active Comparator|Metoclopramid|IM Metoclopramid 10mg
33104998|NCT00186992|Other|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
33104999|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
33105000|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
33411532|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
33411533|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
33411534|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
33411535|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
32862501|NCT05586763|Active Comparator|Promethazine|IM Promethazine 25mg
32862502|NCT05586763|Active Comparator|prochloraperazine|IM prochloraperazine 12.5mg
32862503|NCT01328769|Active Comparator|Febuxostat|Investigational
32862504|NCT01328769|Placebo Comparator|Placebo|Placebo
32862505|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:~prolonged chest pain > 10 minutes,~recent infectious context <7 days~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.~This is an observational study that does not affect the management of patients."
32862506|NCT04030299|Experimental|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
32862507|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
32862508|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
32862509|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
32862510|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
32862511|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
32862512|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
32862513|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
32862514|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
32862515|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
32862516|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
32862517|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
32862518|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
32862519|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
32862520|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
32862521|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
32862522|NCT04929522|Active Comparator|IANB/inferior alveolar nerve block|patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
32862523|NCT04929522|Active Comparator|IANB+IO|patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
32862524|NCT04929522|Active Comparator|IANB+PDL|patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
32862525|NCT04929522|Active Comparator|IANB+BI|patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
32978609|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
33411536|NCT03941093|Experimental|Arm A|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
33411537|NCT03941093|Placebo Comparator|Arm B|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
32978610|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
32978611|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
32978612|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
32978613|NCT01411423||Group 1|
32978614|NCT01411436||Group 1|
32978615|NCT01411449||Group 1|
32978616|NCT01411462||VIBE-DEB|
33105001|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
33105002|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
33323118|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
33411538|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
32978617|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
32978618|NCT01411514|Experimental|Prednisone|
32978619|NCT01411514|Placebo Comparator|Placebo|
32978620|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
32978621|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
32978622|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
32978623|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
32978624|NCT01411566|Experimental|Treatment|
32978625|NCT01411566|Active Comparator|Control|
32978626|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
32978627|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
32978628|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
32978629|NCT01411618|Experimental|free alcohol essential oil moutwash|
32978630|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
32978631|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
32978632|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
32978633|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
32978634|NCT01411670|Experimental|Human protein C concentrate|
32978635|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
32978636|NCT01411670|Placebo Comparator|Placebo|Standard treatment
32978637|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
32978638|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
32978639|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
32978640|NCT01411709|Active Comparator|Vitano|
32978641|NCT01411709|No Intervention|Control|No tablets - control group
32978642|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
32978643|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
32978644|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
32978645|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
32978646|NCT01411748|Active Comparator|nystatin|
32978647|NCT01411761|Experimental|Saccharomyces boulardii|study group
32978648|NCT01411761|Placebo Comparator|placebo|serum physiologic
32978649|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
33411539|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
32978650|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
32978651|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
32978652|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
32978653|NCT01411813||Alprazolam|Patients receiving Alprazolam.
32978654|NCT01411826|Active Comparator|Information|
32978655|NCT01411826|Experimental|Information + Narratives + Support group|
32978656|NCT01411865|Experimental|Intervention|
32978657|NCT01411865|Other|Control|
32978658|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
32978659|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
32978660|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~MagProbe (TM)~Diagnosed or suspected leukemia~Non-leukemia patients~MagProbe (TM)~Requiring bone marrow biopsy"
32978661|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
32978662|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
32978663|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
32978664|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
32978665|NCT01411969||External nasal dilator, decongestion|
32978666|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
32978667|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~After admission of each case in the pre-operative period.~Immediately post- operative.~24 hours post- operative."
32978668|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
32978669|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
32978670|NCT01412099|Experimental|Feedback report plus peer counseling|
32978671|NCT01412099|Experimental|Feedback report|
32978672|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
32978673|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
32978674|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
32978675|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
32978676|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
32978677|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
32978678|NCT01412216|Placebo Comparator|Placebo|Placebo control
32978679|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
32978680|NCT01412294|Experimental|Capecitabine, Cisplatin|
32978681|NCT01412307|Experimental|lenalidomide plus bendamustine|
32978682|NCT01412320|Experimental|Flavanol rich cocoa|
32978683|NCT01412320|Experimental|Flavanol poor|
32978684|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
32978685|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
32978686|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
32978687|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
32978688|NCT01412398||Group 1|Drug (incl. Placebo)
32978689|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
32978690|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
32978691|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
32978692|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
32978693|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
32978694|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
32978695|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
32978696|NCT01412476||case group|Subjects with metabolic syndrome
32978697|NCT01412476||control group|Healthy individuals
32978698|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
32978699|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
32978700|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
32978701|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
32978702|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
32978703|NCT01412528|Other|Eight different allergens will be standardized in this study|
32978704|NCT01412567|Active Comparator|Vaccine+HBIG|
32978705|NCT01412567|Placebo Comparator|Vaccine+Placebo|
32978706|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
32978707|NCT01412593|Experimental|Stem cell transplant|
32978708|NCT01412593|No Intervention|Control|
32978709|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
32978710|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
32978711|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
32978712|NCT01412645|Placebo Comparator|Placebo|
33411540|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
32978713|NCT01412645|Experimental|High-dose Resveratrol|
32978714|NCT01412645|Experimental|Low-dose Resveratrol|
32978715|NCT01412658|Experimental|Milk Peptides|
32978716|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
32978717|NCT01412671||Group 1|
32746741|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
32978718|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
32978719|NCT01412697|No Intervention|Control Group|control group received the standard health information
32978720|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
32978721|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
32978722|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
32978723|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
32978724|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
32978725|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
32978726|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
32978727|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
32978728|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
32978729|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
32978730|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
32978731|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
32978732|NCT01412827|Other|Comparison of radioisotope dosing|
32978733|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
32978734|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
32978735|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
32978736|NCT01412853|Experimental|MR-spectroscopy|
32978737|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
32978738|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
32978739|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
32978740|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
32978741|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
32978742|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
32978743|NCT01413009||ICU patients|
32978744|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
32978745|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
32978746|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
32978747|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
32978748|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
32978749|NCT01413048|Experimental|AGSCT101|
32978750|NCT01413048|Active Comparator|Carvedilol|
32978751|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
32978752|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
32978753|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
32978754|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
32978755|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
32978756|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
32978757|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
32978758|NCT01413126|No Intervention|No peanuts (control)|
32978759|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
32978760|NCT01413152|Experimental|0|
32978761|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
32978762|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
32978763|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
33323119|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
33323120|NCT03941340|Experimental|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
33323121|NCT01117740||Thoracoscopy Group|
33323122|NCT01117740||Indwelling Pleural Catheters|
33323123|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
33323124|NCT01372852||Non-diabetic Control Group|
33323125|NCT01117818|Active Comparator|A: AFFITOPE AD02|
33323126|NCT01117818|Active Comparator|B: AFFITOPE AD02|
33323127|NCT01117818|Active Comparator|C: AFFITOPE AD02|
33323128|NCT01117818|Active Comparator|D: Placebo control|
32978764|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
32978765|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
32978766|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
32978767|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
32978768|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
32978769|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
32978770|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
32978771|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
32978772|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
32978773|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
32978774|NCT01413386|Active Comparator|Covered Metal Stent|
32978775|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
32978776|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
32978777|NCT01413477|Active Comparator|Calcipotriol ointment|
32978778|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
32978779|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
33411541|NCT04603157|No Intervention|Standard of Care Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will continue to follow the treatment recommendations of the primary care physician
32978780|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
32978781|NCT01413555|Experimental|Blood Culture QI Program|
32978782|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
32978783|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
32978784|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
32978785|NCT01413581|Placebo Comparator|Placebo|Placebo
32978786|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
32978787|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
32978788|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
32978789|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
32978790|NCT01413620|Experimental|Vitamin E Treated|
32978791|NCT01413620|No Intervention|Untreated|
32978792|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
32978793|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
32978794|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
32978795|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
32978796|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
32978797|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
32978798|NCT01413698||Patient with chronic cough|
32978799|NCT01413711|Experimental|Vigabatrin|
32978800|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
32978801|NCT01413763|Active Comparator|Imiquimod cream|
32978802|NCT01413763|Placebo Comparator|Placebo cream|
32978803|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
32978804|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
32978805|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
32978806|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
32978807|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
32978808|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
32978809|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
32978810|NCT01413854|Active Comparator|diclofenac|
32978811|NCT01413854|Placebo Comparator|sugar pill|
32978812|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
32978813|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
32978814|NCT01413893|Experimental|linifanib|
32978815|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
32978816|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
32978817|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
32978818|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
33323129|NCT01372930|Experimental|Etanercept|
33323130|NCT01372930|Placebo Comparator|saline|
33323131|NCT05126524||Loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery|Patients with loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery are eligible for this study
32978819|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
32978820|NCT01413997||Chronic Low Back Pain|
32978821|NCT01413997||No Low Back Pain|
32978822|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
32978823|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
32978824|NCT01414049|Experimental|On-pump CABG|
32978825|NCT01414049|Experimental|Off-pump CABG|
32978826|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
32978827|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
32978828|NCT01414088|Placebo Comparator|glucose|glucose 5 %
32978829|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
32978830|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
32978831|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
32978832|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
32978833|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
32978834|NCT01414140||Group 1|
32978835|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
32978836|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
32978837|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
32978838|NCT01414283|Experimental|Arm 1|
32978839|NCT01414296|Experimental|Arm 1|
32978840|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
32978841|NCT01414322||Group 1: Patients ages 0 - 3|
32978842|NCT01414322||Group 2: Patients ages 3 - 7|
32978843|NCT01414322||Group 3: Patients ages 7 - 15|
33411542|NCT04603157|Experimental|Hybrid Exercise Training Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will follow a hybrid exercise training program
32978844|NCT01414335|Placebo Comparator|placebo|
32978845|NCT01414335|Active Comparator|amino acid composition|
32978846|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
32978847|NCT01414348|Experimental|Novel rehabilitation approach|
32978848|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
32978849|NCT01414374|Active Comparator|Iron|
32978850|NCT01414374|Experimental|Herbal|
32978851|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
32978852|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
32978853|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
32978854|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
32978855|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
32978856|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
32978857|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
32978858|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
32978859|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
32978860|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
32978861|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
32978862|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
32978863|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
32978864|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
32978865|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
32978866|NCT01414530|Experimental|oral contraceptive|
32978867|NCT01414530|Active Comparator|NSAID|
32978868|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
32978869|NCT01414543|Other|Seeking consent|
32978870|NCT01414543|Other|Interview Participant|
32978871|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
32978872|NCT01414556|Experimental|hyperglycemia|
32978873|NCT01414556|Experimental|fasting glycemia|
32978874|NCT01414556|Experimental|hypoglycemia|
32978875|NCT01414569|Active Comparator|8 mg dexamethasone|
32978876|NCT01414569|Placebo Comparator|Placebo, saline|
32978877|NCT01414569|Experimental|40 mg dexamethasone|
32978878|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
32978879|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
32978880|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
32978881|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
32978882|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
32978883|NCT01414621||CABG patients|atrial tissue samples from CABG patients
32978884|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
32978885|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
32978886|NCT01414647|Experimental|C|Control diet with restricted berry consumption
32978887|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
32978888|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
32978889|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
32978890|NCT01414673|Other|spontaneous LH|
32978891|NCT01414673|Experimental|HCG|
32978892|NCT01414686|Experimental|Immediate Treatment Group|
32978893|NCT01414686|No Intervention|Delayed Treatment Group|
32978894|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
32978895|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
32978896|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
32978897|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
32978898|NCT01414712||prostate cancer patients|
32978899|NCT01414725|Experimental|Core Stability Training|
32978900|NCT01414725|Placebo Comparator|Relaxation|
32978901|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
32978902|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
32978903|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
32978904|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
32978905|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
32978906|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
32978907|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
32978908|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
32978909|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
32978910|NCT01414816||Group 1|
32978911|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
32978912|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
32978913|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
32978914|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
32978915|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
32978916|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
32978917|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
32978918|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
32978919|NCT01414907|Active Comparator|Health Promotion activities|
32978920|NCT01414907|No Intervention|No Intervention|
32978921|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
32978922|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
32978923|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
32978924|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
32978925|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
32978926|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
32978927|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
32978928|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
32978929|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
32978930|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
32978931|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
32978932|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
32978933|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
32978934|NCT01415050|Active Comparator|Alendronate|
32978935|NCT01415050|Active Comparator|Raloxifane|
32978936|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
32978937|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
32978938|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
32978939|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
32978940|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
32978941|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
32978942|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
32978943|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
32978944|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
32978945|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
32978946|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
32978947|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
32978948|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
32978949|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
32978950|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
32978951|NCT01415193|Experimental|Selective Tibial Nerve Block|
32978952|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
32978953|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
32978954|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
32978955|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
32978956|NCT01415219|No Intervention|conventional care|community based physiotherapy
32978957|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
32978958|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
32978959|NCT01415271|Experimental|Internet Intervention|
32978960|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
32978961|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
32978962|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
32978963|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
32978964|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
32978965|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
32978966|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
32978967|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
32978968|NCT01415414||Group 1|
32978969|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
32978970|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
32978971|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
32978972|NCT01415479|Experimental|Quantitative|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
32978973|NCT01415479|Experimental|Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
32978974|NCT01415479|Experimental|Quantitative + Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
32978975|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
32978976|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
32978977|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
32978978|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
32978979|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
32978980|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
32978981|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
32978982|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
32978983|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
32978984|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
32978985|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
32978986|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
32978987|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
32978988|NCT01415596|Placebo Comparator|Placebo|
32978989|NCT01415596|Active Comparator|Salbutamol|
32978990|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
32978991|NCT01415622|Other|standard care|standard care of Ulcera crurum
32978992|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
32978993|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
32862526|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
32862527|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
32862528|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
32862529|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
32862530|NCT04911192|No Intervention|systemic thrombolysis group|patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).
32862531|NCT04911192|Active Comparator|mechanical fragmentation group|patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.
32862532|NCT04911192|Active Comparator|In Situ thrombolysis group|patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
32862533|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
32862534|NCT04910802|Experimental|HPV-vaccination|Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.
32862535|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
32862536|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
32862537|NCT02414269|Experimental|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
32862538|NCT04918680||EcoFit® Total Hip System with implacross® E Polyethylene|Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
32862539|NCT04918446|Experimental|T-POSE|Technology based brief educational intervention for hospitalized patients that will be discharged with an opioid prescription.
32862540|NCT04918446|Other|Usual Care|Standard discharge instructions provided.
32862541|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
32862542|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
32862543|NCT02538991|Experimental|Bulkamid|
32862544|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
32862545|NCT04910490||Patients received stereotaxic aspiration|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
32862546|NCT04910490||Patients received conservative therapy|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
32862547|NCT05022823|Active Comparator|Standard of Care|Group A (Control). Home decongestive exercise regimen + daytime use of a compression sleeve (12 hours per day)
32862548|NCT05022823|Experimental|DPRE + compression sleeve during exercise|Group B. Decongestive Progressive Resistance Exercise + compression sleeve use during exercise + daytime use of a compression sleeve (12 hours per day)
32862549|NCT05022823|Experimental|DPRE + AC garment during exercise|Group C. Decongestive Progressive Resistance Exercise + Adjustable Compression (AC) garment use during exercise + daytime use of a compression sleeve (12 hours per day).
32862550|NCT04910646|Experimental|orange peel fermentation|
32862551|NCT04910646|Placebo Comparator|placebo|
32862552|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
32862553|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
32862554|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
33411543|NCT05458271|Experimental|VCMX|"All patients will be treated by scaling/root planing to obtain infection control if needed. In addition, patients will receive oral hygiene instructions.~The test group will be treated with add of VCMX. Following the local anesthesia, a split thickness flap will be raised-up to uncover the implant screw. Care will be taken to preserve pre-existing KT amount. A mesio-distal and apical partial thickness dissection will be performed to release residual muscle tension and allow the passive apical displacement of the flap. The randomisation envelope will be then opened. In test group the VCMX will be gently shaped and secured under the flap with suture. Care will be applied to completely cover the xenograft."
32978994|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
32978995|NCT01415661|Experimental|obese patient|
32978996|NCT01415661|Experimental|non obese patient|
32978997|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
32978998|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
32978999|NCT01415700|Experimental|Stimulator|
32979000|NCT01415700|Active Comparator|Orthosis|
32979001|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
32979002|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
32979003|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
32979004|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
32979005|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
32979006|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
32979007|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
32979008|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
32979009|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
32979010|NCT01415804|Active Comparator|stentgraft|Stentgraft
32979011|NCT01415804|No Intervention|Medical management|Antihypertensive medication
32979012|NCT01415817|No Intervention|Baseline Data collection|
32979013|NCT01415817|Experimental|Randomization and Training Arm|
32979014|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
32979015|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
32979016|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
32979017|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
32979018|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
32979019|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
32979020|NCT01415895|Experimental|ATNC05 - a study drug capsule|Naltrexone and Clonidine Combination (ATNC05)
32979021|NCT01415895|Placebo Comparator|placebo|
32979022|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
32979023|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
32979024|NCT01415999||patient|adult survivors of childhood malignancies
32979025|NCT01415999||control|healthy age-matched individuals
32979026|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
32979027|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
32979028|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
32979029|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
32979030|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
32979031|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
32979032|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
32979033|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
32979034|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
32979035|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
32979036|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
32979037|NCT01416103|Experimental|Intervention group|Intervention group
32979038|NCT01416103|Placebo Comparator|Intervention control|Control group
32979039|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
32979040|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
32979041|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
32979042|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
32979043|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
32979044|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
32979045|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
32979046|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
32979047|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
32979048|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
32979049|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
32979050|NCT01416324|Experimental|GSK2330672|experimental study drug
32979051|NCT01416324|Placebo Comparator|Placebo|placebo
32979052|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
32979053|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
32979054|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
33323132|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
32979055|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
32979056|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
32979057|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
32979058|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
32862555|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
32862556|NCT04928976||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32862557|NCT04928976||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32862558|NCT04928976||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32979059|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
32979060|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
32979061|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
32979062|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
32979063|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
32979064|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
32979065|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
32979066|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
32979067|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
32979068|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
32979069|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
32979070|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
32979071|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
32979072|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
32979073|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
32979074|NCT01416493|Experimental|bIAP treatment|
32979075|NCT01416506||Group 1|
32979076|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
32979077|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
32979078|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
32979079|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
32979080|NCT01416597||Cross-Protection Studies|
32979081|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
32979082|NCT01416662|Other|gemcitabine|gemcitabine
32979083|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
32979084|NCT01416701|Placebo Comparator|Placebo (cellulose)|
32979085|NCT01416714||Gastric Cancer|
32979086|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
32979087|NCT01416714||Esophageal Cancer|
32979088|NCT01416714||Pancreas Cancer|
32979089|NCT01416714||Hepatocellular Cancer|
32979090|NCT01416714||Biliary Cancer|
33411544|NCT05458271|Active Comparator|CTG|The control group patients will be treated by flap surgery with add of CTG. In the control group (APF) a CTG harvested from palate will be secured under the flap with suture.
32979091|NCT01416714||Neuroendocrine Cancer|
32979092|NCT01416714||Peritoneal Mesothelioma|
32979093|NCT01416714||Anal Cancer|
32979094|NCT01416714||Colorectal Cancer|
32979095|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
32979096|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
32979097|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
32979098|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
32979099|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
32979100|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
32979101|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
32979102|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
32979103|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
32979104|NCT01416779|No Intervention|No Intervention|Non Writing Group
32979105|NCT01416792|Experimental|Multiple-pass hemofiltration|
33411545|NCT05453747|Experimental|Ankle injury basketball player|Athletes included in the study; They were divided into two groups as those with and without ankle injury . The same exercise program was applied to the same group in both groups.
33411546|NCT05453747|Active Comparator|Basketball player|The same exercise program was applied to the same group in both groups.
33411547|NCT05432687|Other|patient before Robotic-assisted Radical Prostatectomy|evaluation of deep abdominal wall before surgery : cough test + ulstrasonography of transversus abdominis
32862559|NCT04928976||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32862560|NCT02710435||Arm 1 - Prospective|Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Neovasc Reducer System implant procedure
32862561|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Neovasc Reducer System during the COSIRA study and agree to participate in this long term follow up study
32862562|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Neovasc Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study~Arm 3 has been closed to enrollment-June 2017"
32862563|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
32862564|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
32862565|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
32862566|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
32862567|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
32862568|NCT04928586|Experimental|Pirfenidone group|CTD-ILD patients treated with DMARDs and pirfenidone
32862569|NCT04928586|Active Comparator|No-Pirfenidone group|CTD-ILD patients treated with DMARDs, without pirfenidone
32862570|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
32862571|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
32862572|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
32862573|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
32862574|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
32862575|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
32862576|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
32862577|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
32862578|NCT04918368||Pregnant women between 18-45 years old, being in second and third trimester of a singleton pregnancy|
32862579|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
32862580|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
32862581|NCT03054012||CAS group|computer-assisted surgery group
32862582|NCT04910256|Experimental|HuaTuo ZaiZao group|"In this arm, patients take 8g of HuatuoZaizao pill three times a day. Besides，participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
32862583|NCT04910256|Active Comparator|Control group|"participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
32862584|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
32862585|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
32862586|NCT04928274|Other|ball retained mandibular over denture|each patient in this group received 3 implant installed in mandible and 3 ball attachments for retention of over denture
32862587|NCT04928274|Other|locator retained mandibular over denture|
32862588|NCT04928274|Other|telescopic retained mandibular over denture|
32979106|NCT01416818|Experimental|group 1|
32979107|NCT01416818|Active Comparator|group 2|
32979108|NCT01416818|Placebo Comparator|group 3|
32979109|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
32979110|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
32979111|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
32979112|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
32979113|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
32979114|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
32979115|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
32979116|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
32979117|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
32979118|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
32979119|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
32979120|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
32979121|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
33411548|NCT03917381|Experimental|Dose escalation|GEN1046 Open label, single arm trial where GEN1046 will be administered as monotherapy
32979122|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
32979123|NCT01416948|Placebo Comparator|Sugar Pill|
32979124|NCT01416948|Active Comparator|Galantamine|
32979125|NCT01416948|Experimental|Methylphenidate|
32979126|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
32979127|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
32979128|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
32979129|NCT01417052|Experimental|50 mg LX3305 QD|
32979130|NCT01417052|Experimental|100 mg LX3305 QD|
32979131|NCT01417052|Experimental|150 mg LX3305 QD|
32979132|NCT01417052|Experimental|200 mg LX3305 QD|
32979133|NCT01417052|Experimental|250 mg LX3305 QD|
32979134|NCT01417052|Experimental|300 mg LX3305 QD|
32979135|NCT01417052|Experimental|400 mg LX3305 QD|
32979136|NCT01417052|Experimental|250 mg LX3305 BID|
32979137|NCT01417052|Experimental|500 mg LX3305 QD|
32979138|NCT01417052|Placebo Comparator|Placebo|
32979139|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
32979140|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
32979141|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
32979142|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
32979143|NCT01417130||Placebo|Original assignment in the ADAPT trial
32979144|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
32979145|NCT01417169|Experimental|Micafungin|
32979146|NCT01417182|Experimental|Melanoma|
32979147|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
32979148|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
32979149|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
32979150|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
32979151|NCT01417260||Nocebo|Told breastfeeding may worsen pain
32979152|NCT01417260||No treatment|Told nothing
32979153|NCT01417260||Placebo|Told will improve pain
32979154|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
32979155|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
32979156|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
32979157|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
32979158|NCT01417312|Active Comparator|Green tea extract|
32979159|NCT01417312|Placebo Comparator|Placebo|
32979160|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
33411549|NCT03917381|Experimental|Expansion|GEN1046 Open label, single arm trial where GEN1046 will be administered as monotherapy (or in combination with docetaxel or in combination with pembrolizumab or in combination with pembrolizumab and standard chemotherapy in separate expansion cohorts)
33411550|NCT03913949|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
32979161|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
32979162|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
32979163|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
32979164|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
32979165|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
32979166|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
33411551|NCT03913481|Experimental|ANH|Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
33411552|NCT03913481|Other|Standard care|No ANH
33411553|NCT05404139|Other|Arm 1 - Standard of Care|Participants in this group will receive standard of care radiation treatment and ADT. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.).
33411554|NCT05404139|Experimental|Arm 2 - Study Treatment|Participants in this group will receive standard of care radiation treatment and ADT, plus enzalutamide. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.). In addition, participants will take enzalutamide orally (by mouth) daily for 8 months. Participants will start the first pill within a month of enrollment. This pill can be taken around the same time of day with or without food.
33411555|NCT02864498|Experimental|1g DS107|1g DS107 (2 DS107 capsules and 2 placebo capsules) orally administered once-daily for 8 weeks.
33411556|NCT02864498|Experimental|2g DS107|2g DS107 (4 DS107 capsules) orally administered once-daily for 8 weeks.
33411557|NCT02864498|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 8 weeks.
33411558|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
33411559|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
33411560|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
33411561|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
33411562|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
32979167|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
32979168|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
32979169|NCT01417416||with combat training stress|
32979170|NCT01417416||without combat training stress|
32979171|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
32979172|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
32979173|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
32979174|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
32979175|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
32979176|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
32979177|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
32979178|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
32979179|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
32979180|NCT01417546|Experimental|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
32979181|NCT01417546|Experimental|2|NHS-IL12 escalating doses on a 2 week schedule
32979182|NCT01417546|Experimental|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
32979183|NCT01417572|Experimental|lidocaine|
33323133|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
33323134|NCT05102812|Experimental|Breakfast Group Intervention|The intervention will be piloted at Sheffield Teaching Hospitals for 1-2 weeks. Then will be refined and piloted at tow further stroke wards (Rotherham Hospitals NHS Foundation Trust and Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust)
33323135|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
33323136|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
33323137|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
33323138|NCT01116180|Active Comparator|Candesartan|
33323139|NCT01116180|Placebo Comparator|Placebo|
33323140|NCT01117974|Experimental|Liposuction|
32979184|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
32979185|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
33105003|NCT01263106|Experimental|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
32979186|NCT01417598|No Intervention|Control group|
32979187|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
32979188|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
32979189|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
33105004|NCT01263106|Experimental|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
33105005|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
33105006|NCT00547326|Placebo Comparator|2|Treatment with placebo
33105007|NCT05534971|Active Comparator|Standard technique|The conventional hollow bore needle on a syringe will be used
33105008|NCT05534971|Experimental|Peripheral IV|A peripheral intravenous catheter will be used to obtain initial central venous access
33323141|NCT05008744||Patients presenting with TTTS|Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome
33323142|NCT01116258|Experimental|1|
33323143|NCT01116258|Placebo Comparator|2|
33323144|NCT04875052|Active Comparator|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
33411563|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
32979190|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
32979191|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
32979192|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
32979193|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
32979194|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
32979195|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
32979196|NCT01417663|Other|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
32979197|NCT01417676|Experimental|Radiation|
32979198|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
32979199|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
32979200|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
32979201|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
32979202|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
32979203|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
32979204|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
32979205|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
33411564|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
32979206|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
33411565|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
32979207|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
32979208|NCT01417754|Other|Toremifene|
32979209|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
32979210|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
32979211|NCT01417793|Experimental|Smoking Cessation Program|
32979212|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
32979213|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
32979214|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
32979215|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
32979216|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
32979217|NCT01417858|Active Comparator|brimonidine 0.2%|
32979218|NCT01417858|Active Comparator|brimonidine 0.1%|
32979219|NCT01417871||case goup|Lifestyle counseling, ABC program
32979220|NCT01417871||control group|usual care
32979221|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
32979222|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
32979223|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
32979224|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
32979225|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
32979226|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
32979227|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
32979228|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
32979229|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
32979230|NCT01417962||Fetuses|Still birth and Termination of pregnancies
32979231|NCT01417962||Children|Includes Newborns, Infants and Children
32979232|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
32979233|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
32979234|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
32979235|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
32979236|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
32979237|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
32979238|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
32979239|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
32979240|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
32979241|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
32979242|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
32979243|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
32979244|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
32979245|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
32979246|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
32979247|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
32979248|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
32979249|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
32979250|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
32979251|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
32979252|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
32979253|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
32979254|NCT01418157|Active Comparator|Acetazolamide|
32979255|NCT01418157|Placebo Comparator|Placebo|
32979256|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
32979257|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
32979258|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
32979259|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
32979260|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
32979261|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
32979262|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
33411566|NCT03884855|Active Comparator|Classical Cardiac Rehabilitation|Patients benefit from a classic cardiac rehabilitation cycle during 3 months.
33105009|NCT01263028|Experimental|Ergocalciferol supplementation|
33411567|NCT03884855|Experimental|Karate Rehabilitation|Patients benefit from cardiac rehabilitation cycle with traditional karate during 3 months.
33411568|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
33411569|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
33411570|NCT02097121|Experimental|Botox 25 U|Participants randomized to receive 25 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
33411571|NCT02097121|Experimental|Botox 50 U|Participants randomized to receive 50 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
33411572|NCT02097121|Experimental|Botox 100 U|Participants randomized to receive 100 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
33411573|NCT05320445|Experimental|Supportive-expressive group therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
33411574|NCT05320445|No Intervention|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
33411575|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
33411576|NCT05298215|Experimental|5 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
33411577|NCT05298215|Experimental|10 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
33411578|NCT05298215|Placebo Comparator|Placebo|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
33411579|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
33411580|NCT02747420|Sham Comparator|Sham Group|
33411581|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
33411582|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
33411583|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
33411584|NCT05256095|Experimental|Immediate Assignment to Intervention Group|This group will begin to receive the intervention immediately upon entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
33411585|NCT05256095|Experimental|Waitlist Assignment to Intervention Group|The Waitlist group will begin to receive the intervention 10 weeks after entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
33411586|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
33411587|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
33411588|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
33411589|NCT05206643||A cohort as an area probability sample of Shanghai City|
33411590|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
33411591|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33105010|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
33105011|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
32979263|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
32979264|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
33411592|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
33411593|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
32979265|NCT01418274|Experimental|Single arm|
33411594|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
33411595|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
32979266|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
32979267|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
32979268|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
32979269|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
32979270|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
32979271|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
32979272|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
32979273|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
32979274|NCT01418326||Propofol|Propofol exposure for cancer surgery
32979275|NCT01418391|Experimental|morphine consumption|
32979276|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
32979277|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
32979278|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
32979279|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
32979280|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
32979281|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
32979282|NCT01418430|Experimental|CHOP-daclizumab|
33411596|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
33411597|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
33411598|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
33411599|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
33411600|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
32979283|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
32979284|NCT01418456|No Intervention|Non antibiotic group|
32979285|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
32979286|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
32979287|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
32979288|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
32979289|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
32979290|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
32979291|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
32979292|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
32979293|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
32979294|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
32979295|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
32979296|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
32979297|NCT01418573|Experimental|Palaeolithic-type meal 1|
32862589|NCT04927728|Experimental|Audio MP|Participants of the audio mental practice (MP) group will complete MP via audio-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
32979298|NCT01418573|Experimental|Palaeolithic-type meal 2|
32979299|NCT01418573|Placebo Comparator|The reference meal|
32979300|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
32979301|NCT01418651|Experimental|Milnacipran|Drug
32979302|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
32979303|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
32979304|NCT01418677|Active Comparator|Cohort 1|
32979305|NCT01418677|Active Comparator|Cohort 2|
32979306|NCT01418677|Active Comparator|Cohort 3|
32979307|NCT01418690||Non-invasive near infra-red device (NIRS)|
32979308|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
32979309|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
32979310|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
32979311|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
32979312|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
32979313|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
32979314|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
32979315|NCT01418768|Experimental|Rehabilitation|
32979316|NCT01418781||Gout|Patients with ICD-9 for gout
32979317|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
32979318|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
32979319|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
32979320|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
32979321|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
32979322|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
32979323|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
32979324|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
32979325|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
32979326|NCT01418846||adult hematology patients|
32979327|NCT01418846||pediatric patients age 5-18years|
32979328|NCT01418846||adult pneumology patients|
32979329|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
32979330|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
32979331|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
33105012|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
32979332|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
32979333|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
32979334|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
32979335|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
32979336|NCT01418885||normal controls|normal elderly controls
32979337|NCT01418898|Experimental|Nutrient Fortified Beverage|
32979338|NCT01418898|Placebo Comparator|Control|
32979339|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
32979340|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
32979341|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
32979342|NCT01418963|Experimental|Active|
32979343|NCT01418963|Placebo Comparator|Placebo|
32979344|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
32979345|NCT01418989|Experimental|1|
32979346|NCT01418989|Experimental|2|
32979347|NCT01419002|Experimental|Neoadjuvant RTx|
32979348|NCT01419002|Active Comparator|Surgery|
32979349|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
32979350|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
32979351|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
32979352|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
32979353|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
32979354|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
32979355|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
32979356|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
32979357|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
32979358|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
32979359|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
32979360|NCT01419145|Experimental|Multimodal intervention|
32979361|NCT01419145|Active Comparator|Standard Care|
32979362|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
32979363|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
32979364|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
32979365|NCT01419262|Experimental|2000 IU per day vitamin D|
32979366|NCT01419262|Active Comparator|400 IU per day vitamin D|
32979367|NCT01419288|Active Comparator|No Body weight support|
32979368|NCT01419288|Experimental|Body weight support|
32979369|NCT01419327||Group 1|Drug (incl. Placebo)
32979370|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
32979371|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
32979372|NCT01419379||1|
32979373|NCT01419392|Experimental|Sildenafil citrate|
32979374|NCT01419392|Placebo Comparator|placebo|
32979375|NCT01419405|Experimental|Pregabalin/placebo|
32979376|NCT01419405|Active Comparator|placebo/remifentanil|
32979377|NCT01419405|Placebo Comparator|placebo/placebo|
32979378|NCT01419405|Experimental|Pregabalin/Remifentanil|
32979379|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
33411601|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
32979380|NCT01419431||Colon cancer patients|Laparoscopic resection
32979381|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
32979382|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
32979383|NCT01419457|Experimental|Group 1|Normal hepatic function
33411602|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
32979384|NCT01419457|Experimental|Group 2|Mild hepatic impairment
32979385|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
32979386|NCT01419457|Experimental|Group 4|Severe hepatic impairment
32979387|NCT01419470|Experimental|YHD1044 I|
32979388|NCT01419470|Experimental|YHD1044 III|
32979389|NCT01419470|Experimental|YHD1044 V|
32979390|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
32979391|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
32979392|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
32979393|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
32979394|NCT01419613|Experimental|Motivational Interviewing|
32979395|NCT01419613|Active Comparator|Physical Activity Counseling|
32979396|NCT01419652|Active Comparator|continue hypglycemic meds|
32979397|NCT01419652|No Intervention|control - hold drug|
32979398|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
32979399|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
32979400|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
32979401|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
32979402|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
32979403|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
32979404|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
32979405|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
32979406|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
32979407|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
32979408|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
32979409|NCT01419756||Single Arm|Imaging comparison study. No intervention.
32979410|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
32979411|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
32979412|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
32979413|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
32979414|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
32979415|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
32979416|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
32979417|NCT01419847|Placebo Comparator|Placebo|
32979418|NCT01419886||Dysphagia|
32979419|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
32979420|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
32979421|NCT01419912|Experimental|soy milk|
32979422|NCT01419912|Experimental|cow's milk|
32979423|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
32979424|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
32979425|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
32979426|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
32979427|NCT01419938|Active Comparator|Light therapy for two weeks|
32979428|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
32979429|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
33411603|NCT05034029|Experimental|Metformin|Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/day for the first two weeks, 1 g/day for the next 2 weeks, and then 2 g/day until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researchers can determine whether the subject needs to reduce or stop the drug based on their discretion.
33411604|NCT05034029|Placebo Comparator|Placebo|Placebo will administer the same as the experimental drug.
33411605|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
33411606|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
33411607|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
33411608|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
33411609|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
33411610|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
33411611|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
33411612|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
33411613|NCT05121077|Experimental|Moderate continuous training|Participants will continuously exercise at a workload between 50-60% of VO2peak on a bicycle ergometer.
33411614|NCT05121077|Experimental|Interval training|Participants will exercise at a varying workload between 50-60% of VO2peak during recovery and 80-90% of VO2peak during bouts of interval training on a bicycle ergometer.
33411615|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):~40mg RZL-012 -administered at 8 sites~80mg RZL-012 - administered at 16 sites~120mg RZL-012 - administered at 24 sites~180mg RZL-012 - administered at 36 sited"
33411616|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
33411617|NCT03829241|Experimental|Troriluzole|"Randomization phase (Weeks 1 through 8): Participants received troriluzole 100 mg capsules twice daily (BID) orally for up to 8 weeks in the double-blind (DB) randomization phase.~Extension phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed open-label (OL) treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
33411618|NCT03829241|Placebo Comparator|Placebo|"Randomization Phase (Weeks 1 through 8): Participants received troriluzole matching placebo capsules BID orally for up to 8 weeks in the DB randomization phase.~Extension Phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed OL treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
33411619|NCT05210959||Preterm or term born infants|Premature or term born infants between the aged 3-18 months were recruited in this study.
33411620|NCT05090423|Experimental|Experimental: balance training alone|The subjects will receive the balance training twice a week for 6 weeks.
32979430|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
32979431|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
32979432|NCT01419964|Experimental|Group 01|ACH24
32979433|NCT01419964|Placebo Comparator|Group 02|Placebo
32979434|NCT01419990|Experimental|GLPG0634 capsules|
32979435|NCT01419990|Placebo Comparator|Placebo capsules|
32979436|NCT01420003|Experimental|Allergen Challenge|
33411621|NCT05090423|Experimental|Experimental: balance training and neurodynamic intervention for the common peroneal nerve|The subjects will receive the balance training and neurodynamic intervention for the common peroneal nerve twice a week for 6 weeks.
33411622|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
33411623|NCT05056493|Experimental|Clinical Providers|Clinical provider site champions will be invited to participate in web-based quantitative surveys and a semi-structured interview
33411624|NCT05056493|Experimental|Parent/Caregivers|Patient and parent/caregiver subjects from the participating clinic sites will be enrolled. These participants are all adults - parents or caregivers of children and youth with special health care needs (CYSHCN) and adult patients with multiple chronic conditions (MCC) who are already receiving care at Duke Health.
33323145|NCT04875052|Experimental|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
33323146|NCT04875052|Experimental|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
32979437|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
32979438|NCT01420042|Experimental|NNZ-2566|
32979439|NCT01420055|Experimental|fingolimod|
32979440|NCT01420094|Experimental|Arm 1|
32979441|NCT01420094|Active Comparator|Arm 2|
32979442|NCT01420094|Placebo Comparator|Arm 3|
32979443|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
32979444|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
32979445|NCT01420159|Experimental|Methoxyflurane|
32979446|NCT01420159|Placebo Comparator|Normal Saline|
32979447|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
32979448|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
32979449|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
32979450|NCT01420211|Experimental|Primovist|
33323147|NCT01113528|Experimental|Regenerative therapy|
33323148|NCT01113528|Placebo Comparator|Sugar pill|
33323149|NCT01213446|Experimental|Biostate|
33323150|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
33323151|NCT01113606|Active Comparator|Standard of Care|
33323152|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
33323153|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
33323154|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
33323155|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
33323156|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
33323157|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
33323158|NCT03939780|Experimental|Cohort 1|Subjects will be scanned twice (once with each of the tracers [18F]RO-948 and [18F]MK-6240)
32979451|NCT01420224||Healthy volunteers|
32979452|NCT01420224||Chuvash polycythaemia|
32979453|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
32979454|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
32979455|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
32979456|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
32979457|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
32979458|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
32979459|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
32979460|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
32979461|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
32979462|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
32979463|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
32979464|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
32979465|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
32979466|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
32979467|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
32979468|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
33411625|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
33411626|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
33411627|NCT04230395|Experimental|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
33411628|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
33411629|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
33411630|NCT01330693|Placebo Comparator|Placebo|Sugar pill
33411631|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
33411632|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
32862590|NCT04927728|Experimental|Video MP|Participants of the video mental practice (MP) group will complete MP via video-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
32862591|NCT04927728|Experimental|Repetitive-Task Practice|Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
32862592|NCT04927728|Active Comparator|Traditional Therapy|The control group received traditional occupational therapy stroke rehabilitation.
32862593|NCT04918056||beta thalassemia patients|
32862594|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
33411633|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
33411634|NCT01330771||hMG-HP/r-FSH|Patients with a condition
33411635|NCT03164551|Active Comparator|GERI+ Incubator|
33411636|NCT03164551|Other|Conventional incubator|
33411637|NCT02863328|Experimental|14 mg oral semaglutide|
33411638|NCT02863328|Active Comparator|25 mg empagliflozin|
33411639|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
33411640|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
33411641|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
33411642|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
33411643|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
33411644|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
33411645|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
33411646|NCT05186623||Patients with confirmed ulcerative colitis|Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.
33411647|NCT01330849|Experimental|Toolkit intervention|
32862595|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
32862596|NCT04404660|Experimental|AUTO1|
32862597|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
32862598|NCT05586295|Placebo Comparator|Placebo|
32862599|NCT05586295|Experimental|EX plus|
32862600|NCT02255383|Other|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
32862601|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
32862602|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
32862603|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
32862604|NCT05023369|Experimental|Dexamethasone group|Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis
32862605|NCT05023369|No Intervention|Routine care|In this group only routinely performed anaesthesia protocol will be provided
32862606|NCT04431180|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
32862607|NCT04431180|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
32862608|NCT04431180|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
33411648|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
33411649|NCT04602845|Experimental|Remimazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 3 mg/2ml remimazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Remimazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
32979469|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
33411650|NCT04602845|Active Comparator|Midazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 2.5 mg/2ml midazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Midazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
33411651|NCT01330927|Experimental|VA106483 0.5 mg|
33411652|NCT01330927|Experimental|VA106483 1 mg|
33411653|NCT01330927|Experimental|VA106483 2 mg|
33411654|NCT01330927|Experimental|VA106483 4 mg|
33411655|NCT01330927|Placebo Comparator|Sugar pill|
33411656|NCT04966325|Experimental|Treatment T (Therapeutic dose)|Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.
33411657|NCT04966325|Experimental|Treatment ST (Supratherapeutic dose)|Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).
33411658|NCT04966325|Placebo Comparator|Treatment P (Placebo)|Single oral dose of 3 × placebo tablets.
33411659|NCT04966325|Active Comparator|Treatment M (positive control)|Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)
33411660|NCT05096377||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
33411661|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
33411662|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
33411663|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
33411664|NCT05089669|Experimental|interactive e-book|The experimental group will read an interactive e-book for 90 minutes to learn nasogastric tube feeding.
33411665|NCT05089669|Active Comparator|comparison group|The comparison group will read a paper textbook for 90 minutes to learn nasogastric tube feeding.
33411666|NCT04108819|Experimental|Ketogenic Diet|Participants will receive the ketogenic diet.
33411667|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
33411668|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
33411669|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
33411670|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
33411671|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
33411672|NCT04902365|Active Comparator|Patients group 1|This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome
32979470|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
32979471|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
32979472|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
32979473|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
33411673|NCT04902365|Placebo Comparator|Patients group 2|This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome
33411674|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-Sub-crestal
33411675|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
33411676|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
33411677|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
33411678|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
33411679|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
33411680|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
33411681|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
33411682|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
33411683|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
33411684|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
33411685|NCT01572337|Experimental|NIV|Non-invasive ventilation
32862609|NCT04431180|Placebo Comparator|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
32862610|NCT05020405|Experimental|ARS with GBR and SMV|alveolar ridge splitting in combination with the use of GBR with SMV with immediate implant placement
33411686|NCT01572337|Other|Best available treatment|
33411687|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
33411688|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
33411689|NCT02860130|Experimental|Prismocitrate 18|
33411690|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
33411691|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
33411692|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
32862611|NCT05020405|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without SMV with immediate implant placement
32862612|NCT04909944|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation and ventilation
32862613|NCT04909944|Experimental|laryngeal tube suction disposable supraglottic insertion for oxygenation|laryngeal tube suction disposable insertion for oxygenation and ventilation
32862614|NCT04917978||beta thalassemia patients|
32862615|NCT04909632|Experimental|To establish metabolite pattern and biomarkers of tongue fur in DM|
32862616|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
32862617|NCT02390869|Active Comparator|R-MANT|A) Rituximab
32862618|NCT04909866|Experimental|TACE+Lenvatinib+Camrelizumab|
32862619|NCT04909476||Severe COVID pneumonia with ET|Severe COVID 19 pneumonia undergoing endotracheal intubation
32862620|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
32862621|NCT04757779|Experimental|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
32862622|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
32862623|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
32862624|NCT04757467|Active Comparator|Standard physiotherapy neuro-rehabilitation|Control Group: Patients included in the control group will receive standard physiotherapy neurorehabilitation protocols.
32862625|NCT04757467|Experimental|Repetition-CIMT|In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr
32862626|NCT04757467|Experimental|Hour-CIMT|The task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours.
32862627|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
32979474|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
33411693|NCT05051605||Vaccinated group|Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.
33411694|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
33411695|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
32979475|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
32979476|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
32979477|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
33411696|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + MK-4830|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS MK-4830 800 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. MK-4830 will be administered by IV infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
33411697|NCT04938817|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) administered by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
33411698|NCT04114994||Alzheimer's Disease|
33411699|NCT04114994||Mild Cognitive Impairment|
33411700|NCT04114994||Frontotemporal Dementia|
33411701|NCT04114994||Vascular Dementia|
33411702|NCT04114994||Parkinson Disease|
32979478|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
32979479|NCT01420484||different blood pressure intervals|
32979480|NCT01420497|Active Comparator|methylprednisolone,infiltration|
32979481|NCT01420497|Active Comparator|epidural injection|
32979482|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
32979483|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
32979484|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
32979485|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
32979486|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
33411703|NCT04114994||Traumatic Brain Injury (TBI)|
33411704|NCT04114994||Multiple Sclerosis|
33411705|NCT04114994||No diagnosis|
33323159|NCT03939780|No Intervention|Cohort 2A|No PET scans will be done. Previous [18F]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
33323160|NCT03939780|Experimental|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
33323161|NCT03939780|Experimental|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
33411706|NCT03013543|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
33411707|NCT02502266|Active Comparator|Phase II Arm I (reference regimen)|Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
33411708|NCT02502266|Experimental|Phase II Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
33411709|NCT02502266|Experimental|Phase II Arm III (cediranib maleate)|Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
33411710|NCT02502266|Experimental|Phase II Arm IV (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
32979487|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
32979488|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
32979489|NCT01420588||gastric cancer|
32979490|NCT01420588||gastritis|
32979491|NCT01420588||gastric ulcer|
32979492|NCT01420588||normal|
32979493|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
32979494|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
32979495|NCT01420640|Active Comparator|Tai Chi|
32979496|NCT01420640|Active Comparator|Aerobic Exercise Training|
32979497|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
32979498|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
32979499|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
32979500|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
32979501|NCT01420692|Active Comparator|Gliclazide MR|
32979502|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
32979503|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
32979504|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
32979505|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
32979506|NCT01420744|Experimental|BT086 infusion|
32979507|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
32979508|NCT01420757|Active Comparator|open|open incisional hernia repair
32979509|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
32979510|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
33323162|NCT03939780|Experimental|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
33323163|NCT03939780|Experimental|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
33323164|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
33323165|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
33323166|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
33323167|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
33323168|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
32979511|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
32979512|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
32979513|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
32979514|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
32979515|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
32979516|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
32979517|NCT01420861|Experimental|1000 mg GTx-758|subjects will receive daily doses of 1000 mg GTx-758
32979518|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
32979519|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
32979520|NCT01420900|Active Comparator|ABG II / Trident|
32862628|NCT04757623|No Intervention|Group B : conventional primary closure|allileostomies are reversed with conventional method
32862629|NCT04757623|Experimental|Group A: Purse string closure|the ileostomy reversal circular incision used with stitches of continuous and non-absorbable. The wound of skin was closed by using (Proline No. 1) that leaving 0.5 cm defect on middle in the skin.
32862630|NCT05029219|Experimental|Virtual reality group|To become proficient in lumbar transforaminal epidural blocks, participants receive additional training using virtual reality programs after audiovisual education.
33323169|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
33323170|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
32862631|NCT05029219|Active Comparator|Self study group|In order to become proficient in lumbar transforaminal epidural block, participants have self-study time using books and videos after audiovisual education.
32862632|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
32979521|NCT01420900|Active Comparator|CLS / Trilogy|
33323171|NCT03941418|Experimental|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
32862633|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
33323172|NCT03941418|Placebo Comparator|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
33323173|NCT03941028|Experimental|bone defects caused by trauma|Large bone defects (>6cm) caused by trauma
33323174|NCT03941028|Experimental|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
33323175|NCT03941028|Experimental|bone defects caused by tumor|Large bone defects caused by benign tumor
33323176|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
33323177|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
33323178|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
33323179|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
33323180|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
33323181|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
33323182|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
33323183|NCT01116570|Other|control|None intervention
33323184|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
33323185|NCT01113996|No Intervention|Standard treatment - usual care|
33323186|NCT01113996|Experimental|Protein supplementation|
33323187|NCT01113996|Experimental|Protein supplementation and strength training|
33323188|NCT03937518|Other|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
33323189|NCT03937518|Other|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
33323190|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
33323191|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
33323192|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
33323193|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
33323194|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
33323195|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
33323196|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
33323197|NCT01114074||Control group|Healthy controls
33323198|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
33323199|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
33323200|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
33323201|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
33323202|NCT03937440|Experimental|Deep neuromuscular block group|
33323203|NCT03937440|Experimental|Moderate neuromuscular block group|
33323204|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
33323205|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
33323206|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
33323207|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
33323208|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
33323209|NCT01118286||Group 1|
33323210|NCT01211652||1|
33323211|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
33323212|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
33323213|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
33323214|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
33323215|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
33323216|NCT01585506||Questionnaire responders|
33323217|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
33323218|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
33323219|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
33323220|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
33323221|NCT03937674|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
33323222|NCT03936036||2nd generation sulfonylureas|Reference group
33323223|NCT03936036||Linagliptin|Exposure group
33323224|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
33323225|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
33323226|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
33323227|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
33323228|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
33323229|NCT03939546|No Intervention|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
33323230|NCT03939546|Active Comparator|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
33323231|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
33323232|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
33411711|NCT02502266|Active Comparator|Phase III Arm I (reference regimen)|Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
32979522|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
32979523|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
32979524|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
32979525|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
32979526|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
32979527|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
32979528|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
32979529|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
32979530|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
32979531|NCT01421043|Experimental|triazolam liquid oral drops|
32979532|NCT01421043|Active Comparator|triazolam tablets|
32979533|NCT01421082|Experimental|LVRC Treatment|
32979534|NCT01421108|Experimental|Loss-framed messages|
32979535|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
32979536|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
32979537|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
32979538|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
32979539|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
32979540|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
32979541|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
32979542|NCT01421199|Other|Myringotomy|On arm
32979543|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation []"
32979544|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care []"
32979545|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
32979546|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
33411712|NCT02502266|Experimental|Phase III Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
32979547|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
32979548|NCT01421394||single group study|
32979549|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
32979550|NCT01421407|No Intervention|Control group|
32979551|NCT01421420||Alzheimer's Disease|
32979552|NCT01421420||Mild Cognitive Impairment|
32979553|NCT01421420||Other forms of Dementia, not AD|
32979554|NCT01421420||Normal Elderly Individuals|
32979555|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
32979556|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
32979557|NCT01421485|Experimental|Integrated treatment Program|
32979558|NCT01421485|Active Comparator|Treatment as Usual|
32979559|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
32979560|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
32979561|NCT01421563|Active Comparator|Anplag|
32979562|NCT01421563|Experimental|DP-R202|
32979563|NCT01421576|Active Comparator|High fat meal|
32979564|NCT01421576|Experimental|DP-R202|under fed condition
33411713|NCT02502266|Experimental|Phase III Arm III (single-agent cediranib maleate)|Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
32979565|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
32979566|NCT01421615|Experimental|lactobacilli capsule|
32979567|NCT01421615|Experimental|lactobacilli capsules|
32979568|NCT01421628|Experimental|exercise|
32979569|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
32979570|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
32979571|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
32979572|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days"
32979573|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
32979574|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
32979575|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
32979576|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
32979577|NCT01421758|Experimental|online social network|
32979578|NCT01421758|Active Comparator|web education control|
32979579|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
32979580|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
32979581|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
32979582|NCT01421823|Experimental|alpha agonist ointment|
32979583|NCT01421823|Placebo Comparator|Placebo|
32979584|NCT01421836|Active Comparator|ERCP guided stent insertion|
32979585|NCT01421836|Active Comparator|EUS guided stent insertion|
32979586|NCT01421901|Experimental|Ertapenem|
32979587|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
32979588|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
32979589|NCT01421927|Experimental|lenalidomide|
32979590|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
32979591|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
32979592|NCT01421953|Experimental|Patients|
32979593|NCT01421966|Experimental|CureXcell®|
32979594|NCT01421966|Sham Comparator|Sham injection|
32979595|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
32979596|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
32979597|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
32979598|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
32979599|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
32979600|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
32979601|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
32979602|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
32979603|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
32979604|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
32979605|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
32979606|NCT01422109|Experimental|Group A|
32979607|NCT01422109|Active Comparator|Group B|
32979608|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
32979609|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
32979610|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
32979611|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
32979612|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
32979613|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
32979614|NCT01422265||Cohort|
32979615|NCT01422291|Active Comparator|morphine|
32979616|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
32979617|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
32979618|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
32979619|NCT01422330|Experimental|Etravirine|
32979620|NCT01422343||1|
32979621|NCT01422395|Experimental|freezing|
32979622|NCT01422395|No Intervention|No freezing|
32979623|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
32979624|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
33323233|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
33323234|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
33323235|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
33323236|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
33323237|NCT01215864|Experimental|TCD-717|
33323238|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
33323239|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
33323240|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
33323241|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
33323242|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
33323243|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
33323244|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
33323245|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
33323246|NCT01118910|Experimental|Vusion ointment|
33323247|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
33323248|NCT01121796|Active Comparator|Vitamin D|
33323249|NCT01121796|Placebo Comparator|Placebo|
33323250|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
33323251|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
33323252|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
33323253|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
33323254|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
33323255|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
33323256|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
33323257|NCT01116960||CRNAs|Full time CRNAs working within the department
33323258|NCT01116960||Residents|Residents working within the department
33323259|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
33323260|NCT03937284||Control group|Subject matched for sex, age and BMI
33323261|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
33323262|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
32862634|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
32862635|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
32862636|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
33323263|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
33323264|NCT01119144|Active Comparator|Control|Control group with titanium mesh
33323265|NCT01117038|Experimental|enalapril and avanafil|
33323266|NCT01117038|Experimental|amlodipine and avanafil|
33323267|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
33323268|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
33323269|NCT01119300|Active Comparator|Standard care|Standard care
33323270|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
33323271|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
33323272|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
33323273|NCT03938922|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
33411714|NCT05012917|Other|Patient/Proxy-SSPedi Administered First|"Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first period and then co-SSPedi as a second period."
33411715|NCT05012917|Other|Co-SSPedi Administered First|"Parent/child dyads will complete co-SSPedi as the first period and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second period."
33411716|NCT00788671|Experimental|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
32862637|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
33411717|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
33411718|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
33411719|NCT01366729|Experimental|TheraTogs|
33411720|NCT01366729|Active Comparator|Cane walking|
33411721|NCT04485325|Active Comparator|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
33411722|NCT04485325|Active Comparator|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
33411723|NCT03610178|Active Comparator|very tight glycemic targets|
33411724|NCT03610178|Active Comparator|tight-moderate glycemic targets|
33411725|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
33411726|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
33411727|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
33411728|NCT04491110|Experimental|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
32862638|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
32862639|NCT02389309|Experimental|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
32862640|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
32862641|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
32862642|NCT04927026|Experimental|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|Solution-focused brief therapy (SFBT) involving psychoeducation and structured life review therapy, as well as mindfulness-based training
32862643|NCT04927026|No Intervention|Control|No intervention
32862644|NCT04917666|Experimental|Treatment|Participants joined a 8-session horticultural therapy group program (60 minutes per session) over 8 weeks.
32862645|NCT04917666|Other|Comparison|Participants joined 4 sessions of individual, parallel, and table-top activities of their own interest, e.g. reading, drawing, coloring.
32862646|NCT02489695|Experimental|axitinib + pembrolizumab|axitinib 10mg twice a day
32862647|NCT03053778|Experimental|Intervention|Early follow-up after discharge
32862648|NCT04917198|Experimental|median sternotomy|median sternotomy in penetrating cardiac trauma and hemodynamically unstable patients, does it affect morbidity and mortality.
32862649|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
32862650|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
32862651|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
32862652|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
32862653|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
32862654|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
32862655|NCT04926480|Experimental|low flow Anesthesia group|Antioxidant parameters are measured in the low flow anesthesia group.
32862656|NCT04926480|Active Comparator|high flow Anesthesia gruop|Antioxidant parameters are measured in the high flow anesthesia group.
32862657|NCT04917276||Training Group|The training cohort that used to built the response prediction model
32862658|NCT04917276||Validation Group|The validation cohort that used to validate the response prediction model
32862659|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
32862660|NCT04917432|Active Comparator|IVUS guided CTO revascularization|To assess the effects of IVUS usage in CTO revascularization compared to conventional non-IVUS guided CTO-PCI as regard technical success and procedural success, MACE within 6 months.
32862661|NCT04917432|Active Comparator|Non-IVUS guided CTO revascularization|To compare this conventional non-IVUS guided CTO-PCI arm with the other IVUS guided arm as regard technical success and procedural success, MACE within 6 months.
32862662|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
32862663|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
33411729|NCT04491110|Sham Comparator|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
33411730|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
33411731|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
33411732|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
33411733|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
33411734|NCT00367003|Experimental|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
33411735|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
33411736|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.~Intervention: Pt will be given verbal instruction to collect urine"
33411737|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
33411738|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
33411739|NCT03660462|Experimental|FePO4 fortified rice test meal|
33411740|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
33411741|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
33411742|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
33411743|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
33411744|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
33411745|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
33411746|NCT04859257||Disease Group|Cohort 1 (Disease Group) of the study will collect blood and urine samples from participants who are either diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific inclusion criteria.
33411747|NCT04859257||Control Group|Cohort 2 (Control Group) of the study will collect blood and urine samples from participants who have NOT been diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific exclusion criteria.
33411748|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
33411749|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
33411750|NCT03661008||Adolescents with paternal involvement|
33411751|NCT03661008||Adolescents without paternal involvement|
33411752|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
33411753|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
33411754|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
33411755|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
33411756|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
32862664|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
32862665|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
32862666|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
32862667|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
32862668|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
33411757|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
33411758|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
33411759|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
33411760|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
33411761|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
33411762|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
33411763|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
33411764|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
33411765|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
33411766|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
33411767|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
33411768|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
33411769|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
33411770|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
33411771|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
33411772|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
33411773|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
33411774|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
33411775|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
33411776|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
33411777|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
33411778|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
33411779|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
33411780|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
33411781|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
33411782|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
33411783|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
33411784|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
33411785|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
33411786|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
33411787|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
33411788|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
33411789|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
33411790|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
33411791|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
33411792|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
33411793|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
32979625|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
33411794|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
33411795|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
33411796|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
33411797|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
33411798|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
33411799|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
32979626|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
32979627|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
32979628|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
32979629|NCT01422525||Trabeculectomy RNFL thickness OCT|
32979630|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
32979631|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
32979632|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
32979633|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
32979634|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
32979635|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
32979636|NCT01422590|Active Comparator|Sitagliptin|
32979637|NCT01422590|Active Comparator|Mitiglinide|
32979638|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
32979639|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
32979640|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
32979641|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
32979642|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
32979643|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
32979644|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
32739123|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
33411800|NCT04473222|Experimental|Sleep Well! Intervention|Participants in this condition will begin the Sleep Well! intervention after initiating baseline, daily diary, and actigraph procedures. Sleep Well! will be provided over approximately 6-8 weeks and will include 3 sessions. Intervention sessions will typically last about an hour, but session length may vary.
33411801|NCT04473222|Other|Enhanced Usual Care|The enhanced usual care condition will occur between 6 and 8 weeks. At randomization to this condition, participants will be provided with an evidence-based sleep guidelines for young children from the CHOP Parent Family Education manual. Participants in this condition will also be able to consult with their primary care physician for management of child sleep. Consistent with usual care in the CHOP system, the primary care physician may manage the sleep concern or choose to make a referral to the CHOP sleep center or to other behavioral health services internal or external to the CHOP system. Of note, the CHOP Parent Family Education handouts provide contact information for the CHOP Sleep Center and direct readers to follow-up with their primary care provider for further guidance.
33411802|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
33411803|NCT03609476|Active Comparator|Standard of care group|No saline instillation
33411804|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
32739124|NCT05455853|Experimental|bilateral transcutaneous tibial nerve stimulation,exercise and advices|•They will receive bilateral transcutaneous tibial nerve stimulation three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise and bowel care advices.
32979645|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
32979646|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
32979647|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
32979648|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
32979649|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
32979650|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
33411805|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
33411806|NCT04549610|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.~HMB will be administered in the form of blinded capsules containing 0.5 g HMB per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
32979651|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
32979652|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
32979653|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
32979654|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
32979655|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
32979656|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
32979657|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
32979658|NCT01422811|Experimental|Intervention|
32979659|NCT01422811|Other|Control|No Intervention
32979660|NCT01422863|Experimental|Lifestyle Intervention|
32979661|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
32979662|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
32979663|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
32979664|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
32979665|NCT01422941|Experimental|CAVU Attune Device|
32979666|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
32979667|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
32979668|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
32979669|NCT01422967|Active Comparator|Osteoarthritis group|
32979670|NCT01422967|Active Comparator|without osteoarthritis|
32979671|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
32979672|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
32979673|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
32979674|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
32979675|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
32979676|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
32979677|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
32979678|NCT01423032|Experimental|Bendamustine|
32979679|NCT01423032|Active Comparator|Fludarabine|
32979680|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
32979681|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
32979682|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
32979683|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
32979684|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
32979685|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
32979686|NCT01423175|Experimental|ClAraC|
32979687|NCT01423175|Active Comparator|FLAMSA|
32979688|NCT01423188|Experimental|RVX000222, 200 mg daily|
32979689|NCT01423188|Placebo Comparator|Placebo|
32979690|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
32979691|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
32979692|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
32979693|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
32979694|NCT01423240|Experimental|Lurasidone 20 mg|
32979695|NCT01423240|Experimental|Lurasidone 60 mg|
32979696|NCT01423240|Placebo Comparator|Placebo|
32979697|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
32979698|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
32979699|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
33411807|NCT04549610|Placebo Comparator|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
33411808|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
33411809|NCT01068678|Active Comparator|IGlar OD|
33411810|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
33411811|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
33411812|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
33411813|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
33411814|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
33411815|NCT03334435|Placebo Comparator|Responders and Partial Responders (RPR)-Placebo|Responders or partial responders (RPR) [Investigator's Global Assessment (IGA) of (0,1, or 2) at entry to study JAHN and never rescued in originating study] participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive placebo orally.
33411816|NCT03334435|Experimental|RPR-Bari 1-milligram (mg)|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM were assigned to remain in this arm to receive Baricitinib 1 mg orally.
33411817|NCT03334435|Experimental|RPR-Bari 2-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 2 mg orally.
33411818|NCT03334435|Experimental|RPR-Bari 4-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 4 mg orally.
33411819|NCT03334435|Experimental|Non-responders (NR): Bari 1 mg to 2 mg|Non-responder (NR) [those not meeting definition of RPR] participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
33411820|NCT03334435|Experimental|NR: Bari 1 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
33411821|NCT03334435|Experimental|NR: Bari 2 mg to 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
32862669|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
32979700|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
32979701|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
32979702|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
32979703|NCT01423318|Experimental|A|
33411822|NCT03334435|Experimental|NR: Bari 2 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
33411823|NCT03334435|Experimental|NR: Bari 4 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 4 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
33411824|NCT03334435|Experimental|NR: Placebo to Bari 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 2 mg orally.
33411825|NCT03334435|Experimental|NR: Placebo to Bari 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 4 mg orally.
33411826|NCT03334435|Placebo Comparator|Placebo|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive placebo orally.
33411827|NCT03334435|Experimental|Bari 1 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) were randomized or assigned to this arm to receive Baricitinib 1 mg orally.
32739125|NCT05455853|Experimental|Exercises and advices|They will perform abdominal muscle training and breathing exercise three times per week, for 4 weeks in addition to bowel care advices.
32739126|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
32739127|NCT02479841|No Intervention|Control group|
32739128|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
32739129|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
32739130|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
32739131|NCT04991181|Experimental|BIA 5-1058|Capsules; 400 mg; single dose; oral administration.
32979704|NCT01423318|Placebo Comparator|B|
33411828|NCT03334435|Experimental|Bari 2 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 2 mg orally.
33411829|NCT03334435|Experimental|Bari 4 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 4 mg orally.
33411830|NCT03334435|Experimental|Bari 2-mg Open-Label Addendum|Participants were directly enrolled to this open-label arm to receive Baricitinib 2-mg orally.
33411831|NCT03636971|Experimental|hyaluronic acid with mannitol|
33411832|NCT03636971|Experimental|hyaluronic acid with sorbitol|
33411833|NCT03636971|Active Comparator|saline|
33411834|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
33411835|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
33411836|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
33411837|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
33411838|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
32862670|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
32862671|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
33411839|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
33411840|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
33411841|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
33411842|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
33411843|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
33411844|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
33411845|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
33411846|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
33411847|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
33411848|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
33411849|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
33411850|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
33411851|NCT03635905|Placebo Comparator|Placebo|
33411852|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
33411853|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
33411854|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
33411855|NCT04850365|Other|Abdominal sacral hysteropexy|The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.
33411856|NCT04850365|Other|Vaginal sacrospinous hysteropexy|"This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.~The outcomes will be obtained as follow;"
33411857|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
33411858|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
33411859|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
33411860|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
33411861|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
33411862|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
33411863|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
33411864|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
33411865|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
33411866|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
33411867|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
33411868|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
32862672|NCT02380573|Experimental|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
33411869|NCT04458324|Experimental|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
33411870|NCT04458324|Placebo Comparator|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
33411871|NCT04458324|Sham Comparator|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
32862673|NCT02380573|Placebo Comparator|Healthy Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
33411872|NCT04458324|Active Comparator|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
33411873|NCT02858154|Other|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
33411874|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
33411875|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
33411876|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off~ABI-009 is given intravenously on days 1, 8, and 15~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
33411877|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
33411878|NCT02684214|Experimental|Food secure families|high and marginal household food security
33411879|NCT02684214|Experimental|Food insecure families|low and very low household food security
33411880|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
33411881|NCT03657498|No Intervention|Control Group I|No intervention
33411882|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
33411883|NCT03657186|Experimental|ProbioSatys™|
33411884|NCT03657186|Placebo Comparator|Placebo|
33411885|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
33411886|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
33411887|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
32862674|NCT04917510|Active Comparator|Control|Will not receive erector spinae block. Will be administered 30 mL of 0.5% Marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
32862675|NCT04917510|Experimental|Study|Will receive an erector spinae block prior to surgery using 30-45 mL of 0.25 bupivacaine w/ epinephrine and 5 mL of dexmedetomidine. Will be administered 30 mL of 0.5% marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
32862676|NCT04926870|Experimental|PACS group|PACS administration during teaching
32862677|NCT04926870|Active Comparator|Traditional group|Traditional teaching without PACS
32862678|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
32862679|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
32862680|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
32862681|NCT04917354||hepatic lesion|
32862682|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
32862683|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
32979705|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
32979706|NCT01423357|No Intervention|Business as usual|
32979707|NCT01423370|Experimental|Group A|
32979708|NCT01423370|Experimental|Group B|
33411888|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
33411889|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
32979709|NCT01423370|Experimental|Group C|
32979710|NCT01423370|Active Comparator|Group D|
33411890|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
33411891|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
33411892|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
33411893|NCT04357158|Other|Patients referred for colonoscopy|
32979711|NCT01423370|Placebo Comparator|Group E|
32979712|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
33411894|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
33411895|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
33411896|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
33411897|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
33411898|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
33411899|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
33411900|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
33411901|NCT04309578|Experimental|treatment arm|Single arm
33411902|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
33411903|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
33411904|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
32979713|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
32979714|NCT01423409|Sham Comparator|usual VAS|VAS
32979715|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
32979716|NCT01423435|Experimental|Japanese|
32979717|NCT01423435|Experimental|Chinese|
32979718|NCT01423435|Experimental|South Korean|
32979719|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
32979720|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
32979721|NCT01423474|Experimental|Short treatment time (11 days)|
32979722|NCT01423474|Experimental|Long treatment time (29 days)|
32979723|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
32979724|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
32979725|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
32979726|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
32979727|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
32979728|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
32979729|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
33411905|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
33411906|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
33411907|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
32979730|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
32979731|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
32862684|NCT04926402|No Intervention|Standard of care|The control group received standard routine care
32862685|NCT04926402|Experimental|Kangaroo care education program|The experimental group received a maternal kangaroo care education program
33411908|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
33411909|NCT02237976|Active Comparator|Routine practice|No specific intervention
32979732|NCT01423539|Active Comparator|A|
33411910|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
33411911|NCT02981472|Experimental|Apixaban|
33411912|NCT02981472|Active Comparator|LMWH/VKA|
33411913|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
33411914|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
33411915|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
33411916|NCT04298034|Experimental|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
33411917|NCT04298034|No Intervention|No-treatment|
33411918|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
33411919|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
33411920|NCT00849667|Active Comparator|Farletuzumab (1.25 mg/kg)|Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel [175 milligram per meter square {mg/m^2}] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain area under curve [AUC] 5-6 milligram per milliliter per minute [mg/mL/minute]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression.
33411921|NCT00849667|Active Comparator|Farletuzumab (2.5 mg/kg)|Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel [175 mg/m^2] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression.
32862686|NCT04916808||Ductal Carcinoma In Situ (DCIS)|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
32862687|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
32862688|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
32862689|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
32862690|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
32862691|NCT02463877|Experimental|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
32862692|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
32862693|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
32862694|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
32862695|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
32862696|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
32862697|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
32862698|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
32862699|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
32862700|NCT03055182|No Intervention|Control subjects|No intervention administered
32862701|NCT04272541|Active Comparator|Psychoeducation program|The intervention program consists of psychopharmacology (standard intervention in mental health services) + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program is implemented for three months, allocated in several sessions.
32862702|NCT04272541|Active Comparator|Habitual intervention|Intervention program consists of psychopharmacology (standard intervention in mental health services). This program is implemented for three months.
32979733|NCT01423539|Experimental|B|
32979734|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
32979735|NCT01423565|Experimental|Deep Brain Stimulation|
32979736|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
32979737|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
32979738|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
32979739|NCT01423591|Experimental|infliximab|
32979740|NCT01423591|Placebo Comparator|inactive powder|
32979741|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
32979742|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
32979743|NCT01423656|Experimental|LEO 29102|
32979744|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
32979745|NCT01423669||Community dwelling adult population|
32979746|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
32979747|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
32979748|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
32979749|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
32979750|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
32979751|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
32979752|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
33411922|NCT00849667|Placebo Comparator|Placebo|Participants will receive farletuzumab-matched placebo (0.9 percent [%] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel [175 mg/m^2] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression.
32979753|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
32979754|NCT01423786|Other|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.~No other information is available."
32979755|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
32979756|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
32979757|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
32979758|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
33411923|NCT03201419|Experimental|FE 201836 500 μg (Randomized Treatment Period)|FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
33411924|NCT03201419|Experimental|FE 201836 350 μg (Randomized Treatment Period)|FE 201836 350 μg oral solution and placebo ODT, administered once daily
32979759|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
32979760|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
32979761|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
32979762|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
32979763|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
32979764|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
32979765|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
32979766|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
32979767|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
32979768|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
32979769|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
32979770|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
32979771|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
32979772|NCT01423994|Active Comparator|implantable loop recorder|
32979773|NCT01423994|Active Comparator|pacemaker|
32979774|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
33323274|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
33323275|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
33323276|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
33323277|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
32862703|NCT04909398|Experimental|Dynamic pupillometry sessions|"It is planned to include 60 participants divided into different groups:~15 healthy subjects, called controls.~15 patients with retinitis pigmentosa.~15 patients with Leber's hereditary optic neuropathy.~15 patients with Stargardt's disease."
33323278|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
33323279|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
33323280|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
33323281|NCT03938766|Other|PSMA PET/CT|Repeat PSMA PET/CT after ADT
32862704|NCT05021263|Experimental|Magnesium Group|The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
33323282|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
33323283|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
33323284|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
33323285|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
33323286|NCT01117116|Active Comparator|budesonide and formoterol|
33323287|NCT01117194|Experimental|shoulder training, rehabilitation robot|
32862705|NCT05021263|Placebo Comparator|Control Group|The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
32862706|NCT04916964|Experimental|Test & Exercise home-based program (T&E)|Eight home-based physiotherapy sessions will occur in two months, once a week
32862707|NCT05028673|Experimental|Lu AG06466 Capsule, Fasted State|Participants will receive 1 capsule of Lu AG06466 in a fasted state.
33323288|NCT01117194|No Intervention|control group|
33323289|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
33323290|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
33323291|NCT01119612|Active Comparator|Iron|
33323292|NCT01119612|Placebo Comparator|Placebo|
33323293|NCT03937206|Experimental|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
33323294|NCT03937206|Experimental|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
32862708|NCT05028673|Experimental|Lu AG06466 Tablet, Fasted State|Participants will receive 1 tablet of Lu AG06466 in a fasted state.
32862709|NCT05028673|Experimental|Lu AG06466 Tablet, Fed State|Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).
32862710|NCT05028673|Experimental|Lu AG06466 Tablet + Antacid, Fasted State|Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.
32862711|NCT04925310||RSV Bronchiolitis Group|hospitalized children with confirmed RSV infection between the first month of life and second year of life
32862712|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
32862713|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
32862714|NCT04916652||Infant Cohort|"aged from 1.5-6 months. Includes predominantly breastfed infants and formula-fed infants.~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
33323295|NCT03937206|Experimental|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
33323296|NCT03937206|Placebo Comparator|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
33323297|NCT01216488|Active Comparator|40 ml of Xylocaine|
33323298|NCT01216488|Experimental|25 ml of Xylocaine|
33323299|NCT01119690|Active Comparator|Rapeseed oil|
33323300|NCT01119690|Active Comparator|Milk fat|
33323301|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
33323302|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
33323303|NCT01213212|Experimental|Caloric restriction|Caloric restriction
32979775|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
32979776|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
32979777|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
32979778|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
32979779|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
32979780|NCT01424059||fear of labor|Parous women with fear of labor
32979781|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
32979782|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
32979783|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
32979784|NCT01424111||Healthy Control|Those not receiving treatment.
32979785|NCT01424124|Experimental|YHD001 dose level 1|
32979786|NCT01424124|Experimental|YHD001 dose level 2|
33323304|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
33323305|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
33323306|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
33323307|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
33323308|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
33323309|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
33323310|NCT01216566|Experimental|I. Patients with chronic neck pain|
33323311|NCT01120002|Placebo Comparator|Placebo pill|
33323312|NCT01120002|Active Comparator|Tamibarotene|
33323313|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
33323314|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
33323315|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
33323316|NCT02529384||malignant group|The lesion which is malignant tumors in breast
33323317|NCT02529384||begin group|The lesion which is begin lesion in breast
33323318|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
33323319|NCT03963414|Experimental|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
33323320|NCT03963414|Experimental|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
33323321|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
33323322|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
32979787|NCT01424124|Active Comparator|Singulair|
32979788|NCT01424124|Placebo Comparator|Placebo|
32979789|NCT01424137|Other|Easyhaler type A|
32979790|NCT01424137|Other|Easyhaler type B|
32979791|NCT01424137|Other|Diskus inhaler|
33323323|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
33323324|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
33323325|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
33323326|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
33323327|NCT01120080|Placebo Comparator|Practical Counseling|
33323328|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
33323329|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
33323330|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
33323331|NCT01369654|Experimental|Computerized decision aid|
33323332|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
33323333|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
33323334|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
33323335|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
33323336|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
33323337|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
32862715|NCT04916652||Toddler Cohort|"aged from 9-15 months. Includes follow-up formula-fed / growing-up milk-fed infants & toddlers.~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
32862716|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
32862717|NCT04909164||Immunotherapy group|Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
32862718|NCT04909164||Cytotoxic chemotherapy group|Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
32862719|NCT02368405|Active Comparator|Control|Control group will receive standard of care
32862720|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
32862721|NCT04916574|Active Comparator|BioBlock® concentration 0.2 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
32862722|NCT04916574|Active Comparator|BioBlock® concentration 0.1 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
32862723|NCT02460445|Experimental|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
32862724|NCT02460445|Active Comparator|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
32862725|NCT04908540|Active Comparator|MARPE/ Conventional (Control) (Group A)|patients will open the appliance in its conventional way; 2 quarter turn (0.2 mm) in the morning, and 2 quarter turn in the evening until overcorrection achieved.
32862726|NCT04908540|Experimental|MARPE/ ALT-RAMEC (Group B)|Patients will open 2 quarter turn (0.2mm) in the morning, and 2 in the evening in the first week, then alternate with closing 2 quarter turn in the morning and 2 in the evening in the second week. And then continuing opening and closing till end with opening in the 7th week and continue opening until overcorrection achieved.
32862727|NCT02455687|Active Comparator|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
32862728|NCT02455687|Placebo Comparator|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
32862729|NCT02455687|Active Comparator|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
32862730|NCT02455687|Placebo Comparator|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
32862731|NCT04908618|Active Comparator|digital impression with normal abutment for dental implant|digital impression using a ready-made abutment for dental implant
32862732|NCT04908618|Experimental|digital impression with scan abutment for dental implant|digital impression with scan body abutment for dental implant
32862733|NCT04908618|Experimental|open tray conventional dental implant impression|Digitized open tray dental implant impression
32862734|NCT04908618|Experimental|closed tray impression for dental implant|Digitized closed tray dental implant impression
32862735|NCT04908696||TLM treatment for LC and PHC patients with early stage|TLM group: Laryngeal carcinoma (LC) (supraglottic type and glottic type) and hypopharyngeal carcinoma (HPC) (pyriform sinus and posterior pharyngeal wall) patients with T1 and T2 stages can be treated with transoral laser microsurgery (CO2 laser resection) for proper indications (NCCN 2020).
32862736|NCT04908696||OPL treatment for LC and PHC patients with T1, T2, and T3 stages|OPL group: Open partial laryngectomy with laryngeal function preservation is performed for patients with laryngeal carcinoma (LC) (supraglottic type, glottic type, and subglottic type) and hypopharyngeal carcinoma (PHC) (pyriform sinus, postcricoid, and posterior pharyngeal wall) with proper indications (NCCN 2020).
32862737|NCT04908696||R treatment for LC and PHC patients with early stage|R group: radiotherapy is treated for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications (NCCN 2020).
32862738|NCT04908696||TORS treatment for LC and PHC patients with early stage|TORS group: transoral robotic surgery is performed for proper laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications.
32862739|NCT04908696||SPA treatment for LC and PHC patients with advanced stage|SPA group: surgical treatment (S) ± postoperative adjuvant (PA) therapy is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
32862740|NCT04908696||CCR treatment for LC and PHC patients with advanced stage|CCR group: concurrent chemoradiotherapy (CCR) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
32862741|NCT04908696||ARC treatment for LC and PHC patients with advanced stage|ARC group: neoadjuvant therapy (A) + radiotherapy/chemoradiotherapy (RC) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
33323338|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
33323339|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
33323340|NCT05188066||Normal, pathological IVG|We will use placenta and fetal memebranes collected from first trimester termination of pregnancy. This will constitute group IVG.
33323341|NCT05188066||Normal and pathological term|We will also use the same specimens collected from third trimester pregnancies . We will call this group normal and pathological..... à finaliser
32979792|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
32979793|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
32979794|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
32979795|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
32979796|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
32979797|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
32979798|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
32979799|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
32979800|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
32979801|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
32979802|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
32979803|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
32979804|NCT01424254|Experimental|Push Enterosopy|
32979805|NCT01424267||1|
32979806|NCT01424280|Experimental|Active drug|
33411925|NCT03201419|Experimental|FE 201836 250 μg (Randomized Treatment Period)|FE 201836 250 μg oral solution and placebo ODT, administered once daily
33411926|NCT03201419|Experimental|FE 201836 150 μg (Randomized Treatment Period)|FE 201836 150 μg oral solution and placebo ODT, administered once daily
33411927|NCT03201419|Experimental|FE 201836 100 μg (Randomized Treatment Period)|FE 201836 100 μg oral solution and placebo ODT, administered once daily
32979807|NCT01424280|Placebo Comparator|Placebo|
32979808|NCT01424319|Experimental|ABT-627, Low dose|
32979809|NCT01424319|Experimental|ABT-627, High dose|
32979810|NCT01424319|Placebo Comparator|ABT-627, Placebo|
32979811|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
32979812|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
33411928|NCT03201419|Experimental|FE 201836 50 μg (Randomized Treatment Period)|FE 201836 50 μg oral solution and placebo ODT, administered once daily
33411929|NCT03201419|Experimental|Placebo (Randomized Treatment Period)|Placebo oral solution and placebo ODT, administered once daily
32979813|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
32979814|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
32979815|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
32979816|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
32979817|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
32979818|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
32979819|NCT01424358|Experimental|Web-based Educational|
33411930|NCT03201419|Experimental|Desmopressin 25 μg (Randomized Treatment Period)|Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)
33411931|NCT03201419|Experimental|Desmopressin 50 μg (Randomized Treatment Period)|Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)
32979820|NCT01424371||Adjuvanted Vaccine Group|
32979821|NCT01424371||Unadjuvanted Vaccine Group|
32979822|NCT01424371||Unvaccinated Elderly|
32979823|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
32979824|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
32979825|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
32979826|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
32979827|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
32979828|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
33411932|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
33411933|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
33323342|NCT04816162|Placebo Comparator|Control group|21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
33323343|NCT04816162|Active Comparator|ketofol group|21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
33323344|NCT04816162|Active Comparator|dexmedetomidine group|21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
33323345|NCT01214148|Other|ORSIRO|
33323346|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
33323347|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
33323348|NCT04959760|Experimental|BinaxNow Covid-19 Antibody test|The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.
33323349|NCT03935334|Experimental|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
33323350|NCT03935334|Active Comparator|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
33323351|NCT04934566|Experimental|patients|patients receiving temporary veno-arterial assistance whose weaning, or transfer to a heart transplant, or to long-term assistance or discontinuation is envisaged.
33323352|NCT01122420|Experimental|Goal-Setting Tool|
33323353|NCT01122420|Active Comparator|Health Web Sites|
33323354|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
33323355|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
33323356|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
33323357|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
33323358|NCT01360372|Active Comparator|Methylnaltrexone|
33323359|NCT01360372|Placebo Comparator|saline placebo injection|
33323360|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
33323361|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
33323362|NCT01360528||Low birth weight|Between 1500-2500 gram
33323363|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
33323364|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
33323365|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
33323366|NCT04812262|Experimental|Group A1 - Single Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
33323367|NCT04812262|Experimental|Group A2, Single Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
33323368|NCT04812262|Experimental|Group A3, Single Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
33323369|NCT04812262|Experimental|Group A4, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
33323370|NCT04812262|Experimental|Group B2 - Multiple Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323371|NCT04812262|Experimental|Group B3 - Multiple Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323372|NCT04812262|Experimental|Group B4 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323373|NCT04812262|Experimental|Group B5 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323374|NCT04812262|Experimental|Group B6 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323375|NCT04812262|Experimental|Group A5, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
33323376|NCT04812262|Experimental|Group A6, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
33323377|NCT04812262|Experimental|Group A7, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
33323378|NCT04812262|Experimental|Group A8, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
33323379|NCT04812262|Experimental|Group B7 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323380|NCT04812262|Experimental|Group B8 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
33323381|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
33323382|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
33323383|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
33323384|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
33323385|NCT01122498|Experimental|1|
33323386|NCT01122498|Experimental|2|
33323387|NCT01122498|Experimental|3|
33323388|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
33323389|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
33323390|NCT01120314|Experimental|Severe renal impairment population|
32979829|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
32979830|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
32979831|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
32979832|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
32979833|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
33323391|NCT01120314|Experimental|Moderate renal impairment population|
33323392|NCT01120314|Experimental|Mild renal impairment population|
33323393|NCT01120314|Experimental|Healthy population|Healthy matched subjects
33323394|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
33323395|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
33323396|NCT01328886|Experimental|Omalizumab|
33323397|NCT01360606|Other|SBRT|
33323398|NCT01120392|Experimental|Treatment group - Nintendo wii.|
33323399|NCT01120392|Active Comparator|conventional - Physical Therapy|
33323400|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
33323401|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
33323402|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
33323403|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
33323404|NCT04624984|Experimental|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
33323405|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
33323406|NCT05187754|Experimental|Intervention Group|
33323407|NCT05187754|No Intervention|Control Group|
33323408|NCT01214382|Experimental|Sertraline|
33323409|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
33323410|NCT01373476|Placebo Comparator|Placebo|Placebo group
33323411|NCT01216956|Experimental|Extended release nicotinic acid|
33323412|NCT01216956|Placebo Comparator|Placebo|
33323413|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
33323414|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
33323415|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
33323416|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
33323417|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
33323418|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
33323419|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
33323420|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
33323421|NCT01373554|Placebo Comparator|Placebo|
33323422|NCT01373554|Experimental|Oltipraz|
33323423|NCT02529150|Experimental|exercise|
33323424|NCT01319344|Experimental|Eplerenone|
33323425|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
33323426|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
33323427|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
33323428|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
33411934|NCT04689529|Experimental|Breast cancer patients undergoing mastectomy after neoadjuvant chemotherapy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) after receiving neoadjuvant chemotherapy
33411935|NCT04689529|Active Comparator|Breast cancer patients without neoadjuvant chemotherapy and undergoing mastectomy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) even in patients who did not receive neoadjuvant chemotherapy as a control group.
33411936|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
33411937|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
33411938|NCT01764633|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
33411939|NCT01764633|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
33411940|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
33411941|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
33411942|NCT05440981|Experimental|Temporarily implanted nitinol device (iTind) group|Subjects will undergo iTind for the treatment of male LUTS.
33411943|NCT04850573|Experimental|EAA|Participants in this arm will take part in eight weekly thirty minute sessions of equine facilitated learning where they interact with a horse and learn basic horsemanship skills.
33411944|NCT04850573|No Intervention|Control|
33411945|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
33411946|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
33411947|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
33411948|NCT01331707|Active Comparator|Promus Element|
33411949|NCT01331707|Active Comparator|Resolute Integrity|
33411950|NCT02956447|Experimental|Kisspeptin Bolus|Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
33411951|NCT02956447|No Intervention|Baseline|Blood sampling every 10 minutes
33411952|NCT02956447|Experimental|Pulsatile kisspeptin|Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
33411953|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
33411954|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
33411955|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
33411956|NCT03953807|Experimental|Ozurdex|OZURDEX implant 700 μg
33411957|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
33411958|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
33411959|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
32979834|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
33411960|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
32979835|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
32979836|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
33411961|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
33411962|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
33411963|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
33411964|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
32979837|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
32979838|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
32979839|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
33411965|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
32979840|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
32979841|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
32979842|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
33411966|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
33411967|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
33411968|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
33411969|NCT05435131|Experimental|Periodontal Health|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
33411970|NCT05435131|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
32979843|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
32979844|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
33411971|NCT05435131|Experimental|Stage II grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
33411972|NCT05435131|Experimental|Stage III grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
32739132|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
32739133|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
32739134|NCT04998357|Experimental|Transplantation|Endovascular infusion
32979845|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
33411973|NCT05435131|Experimental|Stage III grade C Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
33411974|NCT01314209|Experimental|dexmedetomidine|
33411975|NCT05434429|Experimental|Intervention|Participants have access to short-term and long-term interventions.
33411976|NCT05434429|No Intervention|Control|Given access to all interventions at the end of the 5 weeks of the trial.
33411977|NCT04732325|Experimental|Burst / kHz / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
33411978|NCT04732325|Experimental|Burst / Sham / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
33411979|NCT04732325|Experimental|kHz / Sham / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
32979846|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
32739135|NCT04492319|Active Comparator|control group|
32739136|NCT04492319|Active Comparator|neostigmine group|
32739137|NCT02483663||27 Monozygotic Pairs|
32739138|NCT02483663||27 Dizygotic Pairs|
32739139|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
32739140|NCT05713955|Active Comparator|study group|For the study group, a unit of autologous BioMatrix OBSiDiAN will be produced. Blood sample (120ml) will be taken after randomization at the ending of the abdominal phase of the surgery. The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. Around 1-2ml of autologous BioMatrix OBSiDiAN will be applied on the distal/or proximal resection stump before the stapled anastomose will be created. After firing the standard circular device and creation of a functional anastomosis, a further 2.5-3ml OBSiDiAN must be applied circumferentially on the outside on the anastomosis. Once application is completed, a 30 seconds waiting period is required before putting the esophagus back into the surgical field (study specific). A methylene blue leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected or the completed procedure has to be done again.
33411980|NCT04732325|Experimental|kHz / Burst / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
33411981|NCT04732325|Experimental|Sham / Burst / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
33411982|NCT04732325|Experimental|Sham / kHz / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
32862742|NCT04908696||ASRC treatment for LC and PHC patients with advanced stage|ASRC group: neoadjuvant therapy (A) + surgery (S) + radiotherapy (R) or chemoradiotherapy (C) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
32862743|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
33323429|NCT01219374||egg donors|anonymous egg donors
33323430|NCT04570774|Experimental|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
32862744|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
32862745|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
33411983|NCT05431075|Experimental|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid
33411984|NCT05431075|Active Comparator|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid
33411985|NCT04709393|Experimental|Pre-screening|Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk
33411986|NCT04709393|No Intervention|Control|Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk
33411987|NCT03758417|Experimental|LCAR-B38M Chimeric Antigen Receptor T Cell|"Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).~In addition, participants will enroll in additional cohort to further characterize the safety profile and accumulate efficacy data of LCAR-B38M CAR-T cells."
33411988|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
33411989|NCT01329835|No Intervention|standard care|standard prenatal care
33411990|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
33411991|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
33411992|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
33411993|NCT04892173|Experimental|Arm A|NBTXR3, as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. NBTXR3 is given as a single intratumoral injection as a dose of 33% of the Gross Tumor Volume
33411994|NCT04892173|Active Comparator|Arm B|Investigator's choice of RT alone or RT in combination with cetuximab
33411995|NCT03199391|Experimental|BioWick SureLock Implant|All subjects are part of a single arm. All subjects received the BioWick SureLock implant.
33411996|NCT01329913|Experimental|GT1-HCV 200 mg|
33411997|NCT01329913|Experimental|GT1-HCV 400 mg|
33411998|NCT01329913|Experimental|GTI-HCV 800 mg|
33411999|NCT01329913|Experimental|GT3-HCV 200 mg|
32862746|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
32862747|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation, or with high risk prostate cancer.
32862748|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
32862749|NCT02449837||Immunotherapy|Melanoma or metastatic NSCLC scheduled to receive ipilimumab, nivolumab, and/or pembrolizumab.
32862750|NCT02449837||Head and Neck Induction chemotherapy|Locally advanced head and neck cancer (HNSCC) scheduled to receive induction chemotherapy followed by radiotherapy.
32862751|NCT02449837||Metastatic Breast Cancer|Patients scheduled to receive any treatment, including radiation therapy, and/or systemic/hormonal therapy
33323431|NCT04570774|Active Comparator|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
33412000|NCT01329913|Experimental|GT3-HCV 400 mg|
33412001|NCT01329913|Experimental|GT3-HCV 800 mg|
33412002|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
33412003|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
33412004|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
33412005|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
32979847|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
32979848|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
32979849|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
33323432|NCT04570774|Experimental|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
33323433|NCT04570774|Active Comparator|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
33323434|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
32979850|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
32979851|NCT01424553|Other|Cohort|All patients
32979852|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
32979853|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
32979854|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
32979855|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
32979856|NCT01424605|Experimental|DLT intubation|
33323435|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
33323436|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
33323437|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
33323438|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
33323439|NCT04562974|Experimental|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
33323440|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
33323441|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
33323442|NCT01124760|Experimental|1|AZD9742
33323443|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
33323444|NCT03936582|Experimental|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
33323445|NCT03936582|Active Comparator|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
33323446|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
33323447|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
33323448|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
33323449|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
33323450|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
33323451|NCT01217502|Experimental|Self management|
33323452|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
33323453|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
33323454|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
33323455|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
33323456|NCT01120548|No Intervention|Rehabilitation Only Group|
32979857|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
32979858|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
32979859|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
32979860|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
32979861|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
32979862|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
33323457|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
33323458|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
33323459|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
33323460|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
33323461|NCT01219530||Gestational Carriers|
33323462|NCT01219530||Intended Parents|
33323463|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
33323464|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
33323465|NCT05187676|Experimental|Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)|ScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
33323466|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
33323467|NCT02699554||Orthopaedic surgery|
33323468|NCT01217736|Experimental|VTP-27999|
33323469|NCT01217736|Active Comparator|aliskiren|
33323470|NCT01217736|Placebo Comparator|placebo|
33323471|NCT01373710|Experimental|Trastuzumab intrathecal|
33323472|NCT03935412|Active Comparator|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
33323473|NCT03935412|Sham Comparator|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
33323474|NCT01360918|Active Comparator|Usual care|
33323475|NCT01360918|Active Comparator|Pulmonary vein isolation|
33323476|NCT04162600|Experimental|Group 1|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^9 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
33323477|NCT04162600|Experimental|Group 2|"Volunteers will receive a standalone dose of ChAdOx2 RabG 2.5 x 10^10 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
33323478|NCT04162600|Experimental|Group 3|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^10 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
33323479|NCT03935022|Experimental|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
33323480|NCT03935022|Experimental|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
33323481|NCT03935022|Sham Comparator|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
33323482|NCT04134910|Experimental|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
33323483|NCT03936504|Active Comparator|Control Group|Group received conventional exercise rehabilitation programs (CERP).
33323484|NCT03936504|Experimental|Experimental Group|Group received Tai Chi cardiac rehabilitation program(TCCRP).
33323485|NCT04109014|Other|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
33412006|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
33412007|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
33412008|NCT04532515|Experimental|Seal G / Seal-G MIST|"Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach.~Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach."
33412009|NCT04005651|Experimental|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
33412010|NCT04005651|Active Comparator|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
33412011|NCT04005651|Active Comparator|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
33412012|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
33412013|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
33412014|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
33412015|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
33412016|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
33412017|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
33412018|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
33412019|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
33412020|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
33412021|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
33412022|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
33412023|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
33412024|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
33412025|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
33412026|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
33412027|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
33412028|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
33412029|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
32862752|NCT02449837||Endometrial Cancer|Patients with stage III endometrial cancer, being treated with adjuvant radiation
32862753|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
32862754|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
32862755|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
32862756|NCT04924686||Crohn's disease|The fecal and plasma were collected
32862757|NCT04924686||Ulcerative colitis|The fecal and plasma were collected
32862758|NCT04924686||Diabetes mellitus, type 2|The fecal and plasma were collected
32862759|NCT04924686||Atherosclerotic cardiovascular disease|The fecal and plasma were collected
32979863|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
32979864|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
33412030|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
32979865|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
32979866|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
32979867|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
32979868|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
32979869|NCT01424748|Placebo Comparator|Placebo|Placebo juice
32979870|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
32979871|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
33412031|NCT03980535|Experimental|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
33412032|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
33412033|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
32739141|NCT05713955|No Intervention|standard group|The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. A methylene blue leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected.
32979872|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
32979873|NCT01424761|Experimental|Placebo|Placebo:starch
32979874|NCT01424761|Experimental|Coenzyme Q10|
32979875|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
32979876|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
32979877|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
32979878|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
32979879|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
32979880|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
32979881|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
32979882|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
32979883|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
32979884|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
33412034|NCT01331785|Experimental|Midodrine|
33412035|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
33412036|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
32979885|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
32979886|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
32979887|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
32979888|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
32979889|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
32979890|NCT01424917||Heart Transplant|Heart Transplant subjects
33412037|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
32979891|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
32979892|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
32979893|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
32979894|NCT01425008|Experimental|MLN2480|
32979895|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
32979896|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
32979897|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
32979898|NCT01425047||Females ingesting mangosteen juice|
32979899|NCT01425047||Males ingesting mangosteen juice|
32979900|NCT01425060|Experimental|Contraceptive management program|
32979901|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
32979902|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
32979903|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
32979904|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
33412038|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
33412039|NCT03682757||Healthy Controls|Uninjured healthy volunteers
32979905|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
32979906|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
32979907|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
32979908|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
32979909|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
32979910|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
32979911|NCT01425151|Active Comparator|i-Gel|
32979912|NCT01425151|Experimental|ProSeal|
32979913|NCT01425164|Active Comparator|Carvedilol|
32979914|NCT01425164|Experimental|Ivabradine|
32979915|NCT01425177|Experimental|Normal saline irrigation|
32979916|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
32979917|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
32979918|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
33412040|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
33412041|NCT04495621|Experimental|MEN1611|MEN1611 + Cetuximab
32979919|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
33323486|NCT03935256|Experimental|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
32979920|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
32979921|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
32979922|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
33323487|NCT01122654||Control|
33323488|NCT01122654||Experimental 1|
33323489|NCT01122654||Experimental 2|
33323490|NCT04073446|Active Comparator|Dorsal Column (DC) Perception|Use of DC Perception based programming
33323491|NCT04073446|Active Comparator|Dorsal Root (DR) Perception|Use of DR Perception based programming
33323492|NCT04073446|Active Comparator|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
33323493|NCT04073446|Active Comparator|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
33323494|NCT04055116|Experimental|Unbuffered Lidocaine, then Buffered Lidocaine|Subjects will receive an injection of non-buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
33323495|NCT04055116|Experimental|Buffered Lidocaine, then Unbuffered Lidocaine|"Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion.Subjects will receive an injection of this buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.~We will use 8.4% Sodium Bicarbonate manufactured by Hospira, Inc. Lake Forest, IL"
33323496|NCT03937882|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
33323497|NCT03937882|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
33323498|NCT01125384|No Intervention|nurse swabbing|
33323499|NCT01125384|Experimental|"accurate swabbing by a physician"|
33323500|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
33323501|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
33323502|NCT03909178|Active Comparator|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
33323503|NCT03909178|Active Comparator|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
33323504|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
33323505|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
33323506|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
33323507|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
33323508|NCT03753490|Other|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
33323509|NCT03753490|Other|Standard care|Management according to local practice, national and international guidelines.
33323510|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
33323511|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
33323512|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
33323513|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
33323514|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
33323515|NCT03685240|No Intervention|Control|No camera detection
33323516|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
33323517|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
33323518|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
33323519|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
33323520|NCT01219608|Placebo Comparator|Enteral Nutrition|
33323521|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
33323522|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
33323523|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
33323524|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
33323525|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
33412042|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
33412043|NCT01384227|Experimental|Proflavine Hemisulfate|
33323526|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
33412044|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
32739142|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
33323527|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
33323528|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
33323529|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
33323530|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
33323531|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
33323532|NCT03934788|Experimental|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
33323533|NCT03934788|Active Comparator|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
33323534|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
33323535|NCT01123044|Experimental|corneal stem cell transplant|
33323536|NCT01123044|No Intervention|conservative medical therapy|
33323537|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
33323538|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
33323539|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
33323540|NCT03116698|Experimental|Low dose DFD07 once daily|
33323541|NCT03116698|Experimental|High dose DFD07 once daily|
33323542|NCT03116698|Experimental|High dose DFD07 twice daily|
33323543|NCT03116698|Placebo Comparator|Placebo twice daily|
33323544|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
33323545|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
33323546|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
33323547|NCT02565004||2|Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.
33323548|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
33323549|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
33323550|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
33323551|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
33323552|NCT03936426|Experimental|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
33323553|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
33323554|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
33323555|NCT01217970|Active Comparator|Ibudilast 20mg BID|Ibudilast 20mg oral BID 7 days
33323556|NCT01217970|Active Comparator|Ibudilast 50mg BID|Ibudilast 50mg oral BID 7 days
33323557|NCT01217970|Placebo Comparator|Placebo|Placebo oral BID 7 days (0mg ibudilast)
33323558|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
33323559|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
33323560|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
33323561|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
33323562|NCT01123122|Active Comparator|Strict glucose control|
33323563|NCT01123122|No Intervention|Standard glucose control|
33323564|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
33323565|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
33323566|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
32979923|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
32979924|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
32979925|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
32979926|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
33323567|NCT03932838|Experimental|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
33323568|NCT03936348|Experimental|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
32979927|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
32979928|NCT01425398|Experimental|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
32979929|NCT01425398|Placebo Comparator|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5
32979930|NCT01425411|Experimental|Valsartan treatment|
33323569|NCT03936348|Experimental|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
33323570|NCT03936348|No Intervention|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
33323571|NCT01125696|Active Comparator|Standard of Care|
33323572|NCT01125696|Experimental|Tenofovir|
32979931|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
32979932|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
33323573|NCT03932916|Experimental|experimental group 1|HHT201 17mg injection
32979933|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
32979934|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
32979935|NCT01425450|Experimental|HF1020|
32979936|NCT01425450|Placebo Comparator|Placebo|
32979937|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
32979938|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
32979939|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
32979940|NCT01425489||Observation|Patients with Krabbe Disease
32979941|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
32979942|NCT01425554|No Intervention|Diagnostic study|
32979943|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
32979944|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
32979945|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
32979946|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
33323574|NCT03932916|Experimental|experimental group 2|HHT201 34mg injection
33323575|NCT03932916|Active Comparator|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
33323576|NCT03931980|Experimental|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
33323577|NCT03931980|Experimental|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
33323578|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
33323579|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
33323580|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
33323581|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
33323582|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
33323583|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
33323584|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
33323585|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
33323586|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
33323587|NCT01218282|No Intervention|Control|
33323588|NCT00226499|Experimental|MMRV Group|Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
33323589|NCT00226499|Experimental|OKAH Group|Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.
33412045|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
33412046|NCT04631835|Experimental|HS-10352|There are five escalating dose cohorts
33412047|NCT04646369|Active Comparator|"screening as usual"|"Participants in the screening as usual' group will have a symptoms scores report of results sent to their provider based on their Screening Wizard responses."
33412048|NCT04646369|Experimental|Screening Wizard 2.0|Participants in the Screening Wizard 2.0 Report group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses.
33412049|NCT04646369|Experimental|Screening Wizard 2.0 + SOVA|Participants in the Screening Wizard 2.0 + SOVA group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses. This group will also receive access to the SOVA website aimed at addressing perceptions about mental health providing support to teens through peer interaction.
33412050|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
33412051|NCT02888119|Active Comparator|Mild Osteoarthritis|
33412052|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
33105013|NCT04323319|Experimental|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
33412053|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
33412054|NCT04916197|Experimental|Dexmedetomidine prolonged group|Dexmedetomidine 0.1~1.0 μg/kg/h for 24h after patients finished mechanical thrombectomy and returned to ICU. Maintain Ramsay score 2-3.
33412055|NCT04916197|Placebo Comparator|placebo group|Placebo（Equal dose of saline）24h after patients finished mechanical thrombectomy and returned to ICU. If Ramsay Sedation score was 1, midazolam was given 0.02 ~ 0.1mg/kg. If the dose of midazolam was more than 0.2mg/kg within 1 hour after operation, the Ramsay Sedation score was still 1, propofol was given to maintain sedation.
33412056|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
33412057|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
33412058|NCT04505059|Experimental|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
33412059|NCT04505059|Active Comparator|Conventional cardiac anesthesia|Institutional standard of care.
33412060|NCT01382433|Experimental|Chronic Cannabis Users|
33412061|NCT01382433|Experimental|Control|Neurotypical subjects
33412062|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
33412063|NCT01333657||Sepsis|"sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
33412064|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
33412065|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
33412066|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
32739143|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
32739144|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
33412067|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
33412068|NCT04297761|Placebo Comparator|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
33412069|NCT04297761|Experimental|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
33412070|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
33412071|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
33412072|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
33412073|NCT04243863|Experimental|VNRX-7145|Oral dosing
33412074|NCT04243863|Placebo Comparator|Placebo|Oral dosing
33412075|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
33412076|NCT03197129|Experimental|SADE waiting room|children that will wait in the SADE waiting room
33412077|NCT03197129|No Intervention|Traditional waiting room|children that will wait in the traditional waiting room
33412078|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
33412079|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
33323590|NCT00226499|Active Comparator|MMR Group|Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
32862760|NCT04924686||Colorectal cancer|The fecal and plasma were collected
32862761|NCT04924530|Sham Comparator|Maltodextrin|Glucose polymer; a common sugar substitute
32862762|NCT04924530|Active Comparator|Sucrose|Fructose-glucose disaccharide
32862763|NCT04924530|Experimental|Lactose|Galactose-glucose disaccharide
32862764|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
32862765|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
32862766|NCT05586139|Experimental|Microbiome-directed food (MDF) - MAM|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks of supplementation
32862767|NCT05586139|Active Comparator|Ready-to-use supplementary food (RUSF)|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks of supplementation
32862768|NCT05586139|Active Comparator|Locally available Food|Each (MAM) child will receive a basket of food ingredients to prepare a complementary food at home. The quantity of ingredients is based on child's weight. The food is given a maximum duration of 12 weeks.
32862769|NCT05586139|Experimental|Microbiome-directed food (MDF) - SAM|Each (SAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks of supplementation.
32862770|NCT05586139|Active Comparator|Ready-to-use therapeutic food (RUTF)|Each (SAM) child will receive a daily ration of RUTF corresponding to his weight, for maximum 12 weeks of supplementation
32862771|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
32862772|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
32862773|NCT05586061|Experimental|RC48 Plus Tislelizumab and S-1(RCTS)|Disitamab Vedotin: 2.5mg/kg, ivdrip, d1, (every 3 weeks) Q3W； Tislelizumab: 200mg, ivdrip, d1, (every 3 weeks) Q3W； S-1: 40-60mg(according to patients' body surface area), po, bid, d1-14 and discontinued for 7 days in each cycle; until progressive disease (PD) or intolerable toxicity
32862774|NCT04916184|Active Comparator|aerobic exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
32862775|NCT04916184|Active Comparator|Combined exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
32862776|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
32862777|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
32862778|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
32862779|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
32862780|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
32862781|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
32862782|NCT04916262||TSH < 30uIU/mL group|Clinical information was collected from patients with TSH < 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
32862783|NCT04916262||TSH ≥ 30uIU/mL group|Clinical information was collected from patients with TSH ≥ 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
32862784|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
32862785|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
32862786|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
32862787|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
32862788|NCT04908384|Experimental|IMPACT Intervention|IMPACT health application and wearable device
32862789|NCT04908384|No Intervention|Usual care control|Usual care control.
32979947|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
32979948|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
32979949|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
32979950|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
32979951|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
32979952|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
32979953|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
32979954|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
32979955|NCT01425684||schizophrenia|smokers and nonsmokers
32979956|NCT01425684||control|smokers and nonsmokers
32979957|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
32979958|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
32979959|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
32979960|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
32979961|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
32979962|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
32979963|NCT01425762|Experimental|Choice Group|
32979964|NCT01425762|Active Comparator|No Choice Group|
32979965|NCT01425775|Active Comparator|Vitamin D|
32979966|NCT01425775|Placebo Comparator|Placebo|
32979967|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
32979968|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
32979969|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
32979970|NCT05386940||PKN1 Tertile 1|
32979971|NCT05386940||PKN1 Tertile 2|
32979972|NCT05386940||PKN1 Tertile 3|
32979973|NCT05386862|No Intervention|Naturalistic Group|This group will followed as they follow their naturalistic cannabis use.
33323591|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
32979974|NCT05386862|Experimental|THC Reduction Group|This group will be asked to reduce the THC content and increase CBD content of their cannabis products to study the effect of PTSD symptom severity.
32979975|NCT05386823|Experimental|HF1K16|"Up 32 subjects, comprised of up to 4 cohorts of 8 subjects each, will receive a single IV dose of study drug. Six of the 8 subjects in each cohort will receive HF1K16 and 2 subjects will receive placebo in a blinded manner Cohort 1: up to 3 mg/m2 of HF1K16 or placebo~Cohort 2: up to 6 mg/m2 of HF1K16 or placebo~Cohort 3: up to 10 mg/m2 of HF1K16 or placebo~Cohort 4: up to 13 mg/m2 of HF1K16 or placebo"
32979976|NCT05386823|Placebo Comparator|Placebo|"Up 32 subjects, comprised of up to 4 cohorts of 8 subjects each, will receive a single IV dose of study drug. Six of the 8 subjects in each cohort will receive HF1K16 and 2 subjects will receive placebo in a blinded manner Cohort 1: up to 3 mg/m2 of HF1K16 or placebo~Cohort 2: up to 6 mg/m2 of HF1K16 or placebo~Cohort 3: up to 10 mg/m2 of HF1K16 or placebo~Cohort 4: up to 13 mg/m2 of HF1K16 or placebo"
32979977|NCT05386667||Control|Patients were not given anything after FGG.
32979978|NCT05386667||Flurbiprofen|Oral spray containing 0.075 g flurbiprofen administered after FGG
32979979|NCT05386667||Hypochlorous acid|Oral spray containing hypochlorous acid applied after FGG
32979980|NCT05386667||Hyaluronic acid|An oral spray containing the main component of the product is hyaluronic acid (sodium salt) with a high molecular weight of 30 mg / 100 g was given to patients after FGG
32979981|NCT05386615||Exablate|Observational study of Exablate treatment.
32979982|NCT05386511||UTD1|UTD1 monotherapy or UTD1 based therapy
32979983|NCT05386498|Experimental|Precure composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
33323592|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
33323593|NCT01400776|Experimental|WC3011 Estradiol Vaginal Cream (2 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
33323594|NCT01400776|Placebo Comparator|Vehicle (2 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
33323595|NCT01400776|Experimental|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
33323596|NCT01400776|Placebo Comparator|Vehicle (3 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
33323597|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
33323598|NCT01220076|Experimental|Tamoxifene|
32903620|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
33323599|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
33323600|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
33323601|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
33323602|NCT03932994|Experimental|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
33323603|NCT03932994|No Intervention|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
33323604|NCT01220232|Active Comparator|Abacavir/Lamivudine|
33323605|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
33323606|NCT05174494|Active Comparator|Full mouth non surgical periodontal treatment|Each selected subject underwent to full mouth SRP.
33323607|NCT05174494|Placebo Comparator|Control|Each selected subject underwent full mouth traditional oral hygiene.
33323608|NCT03972215|Experimental|Berberine treatment|
33323609|NCT03972215|Placebo Comparator|Placebo control|
33323610|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
33323611|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
33323612|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
33323613|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
33323614|NCT03972293|Experimental|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
33323615|NCT03972293|Experimental|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
33323616|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
33323617|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
33323618|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
33323619|NCT01126008|Experimental|weekly docetaxel and cisplatin|
33323620|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
33323621|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
33323622|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
33323623|NCT01361074|Experimental|In Vivo Exposure|
33323624|NCT01361074|Experimental|Augmented Reality Exposure|
33323625|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
33323626|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
33323627|NCT03974009|Experimental|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
32862790|NCT04431102|Experimental|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
32862791|NCT04431102|No Intervention|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
32862792|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
32862793|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
32862794|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
32862795|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
32862796|NCT04430868|Experimental|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
32862797|NCT04430868|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
32862798|NCT04907994||Older patients and/or with chronic diseases|Retrospective cohort study of exposed/unexposed individuals in the national health data system (SNDS). The study population is composed of individuals aged 70 years or older and patients with a chronic disease. Exposure to containment is defined as the period between 17 March 2020 (beginning of week 12, start of containment) and 10 May 2020 (end of week 19, end of containment). The end of monitoring is set at 12 months after the start of the containment, on 17 March 2021. The unexposed group consists of random samples of comparable individuals (aged 70 years or older and/or chronically ill) for the two years prior to the outbreak (2015 and 2016). The second study period (May 10, 2020 to March 17, 2021) may be subdivided depending on the evolution of the health crisis and the governmental measures adopted. Measurement of the outcome measures and comparison between exposed and unexposed will be carried out at the end of each of the two periods.
32862799|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
32862800|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
32862801|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
32862802|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
32862803|NCT04924218|Active Comparator|rigid cystoscopy|Group undergoing endoscopic urethral procedure with rigid cystoscopy after radical prostatectomy
32862804|NCT04924218|Active Comparator|flexible cystoscopy|Group undergoing endoscopic urethral procedure with flexible cystoscopy after radical prostatectomy
32862805|NCT04924218|Active Comparator|semi-rigid ureterorenoscopy|Group undergoing endoscopic urethral procedure with semi-rigid ureterorenoscopy after radical prostatectomy
32862806|NCT04346719|Experimental|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
32862807|NCT04346719|Experimental|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
32862808|NCT04346719|Sham Comparator|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
32862809|NCT04924296|Experimental|Treatment group A|
32862810|NCT04924296|Placebo Comparator|Treatment group B|
32862811|NCT03056430|Experimental|Training Group 1|Slackline training
32862812|NCT03056430|Experimental|Training Group 2|Slackline training
32862813|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
32862814|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
32862815|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
32862816|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
32862817|NCT04924452|Experimental|Er:YAG laser therapy|Er:YAG laser will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment.
32862818|NCT04924452|Active Comparator|Conventional therapy|Conventional rotary instruments will be used for caries treatment.
32862819|NCT04915794|Experimental|Simulation based education|Simulation is a technique that creates a situation or environment that allows people to experience the representation of a real event, practice, learn, evaluate, test, or gain an understanding of systems or human actions
32862820|NCT04915794|No Intervention|Traditional education|Necessary procedures explained theoretically
32862821|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
32862822|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
32862823|NCT04923906|Experimental|Aumolertinib and platinum-based chemotherapy|
32862824|NCT04923906|Active Comparator|Aumolertinib|
32862825|NCT04908150|Experimental|Core Group|The Core Group carried out core stability exercises. Their training consisted of the following exercises: bridge, Klapp, front plank and lateral plank
32862826|NCT04908150|Active Comparator|Abdominal Group|The Abdominal Group performed traditional exercises: trunk flexion or abdominal crunch, trunk extensions, lower abdominals with hip lifts and crunch with crossed legs
32862827|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
32862828|NCT04907604|Other|First intervention group|Clusters 1 and 2 (group 1) will start the intervention at month 1, immediately after completing the baseline assessment. After 7 weeks of using the app and having access to the EMPOWER website (with material related to the anti-stigma campaign and recommendations for employees to deal with psychosocial risk factors), they will answer a post-treatment assessment protocol through the app.
32862829|NCT04907604|Other|Second intervention group|Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
32862830|NCT04907604|Other|Third intervention group|Clusters 5 and 6 (group 3), that serve as control group of group 1 and 2, will also complete the assessment at T2. Clusters 5 and 6 (group 3) will start the intervention in step 3. All clusters will answer a total of five assessments
32862831|NCT01380639|Experimental|Rehabilitation with vibration training|
32862832|NCT01380639|No Intervention|Rehabilitation without vibration training|
32862833|NCT04915716||healthy pregnant woman|healthy pregnant woman
32862834|NCT04915716||pregnant women with GDM|pregnant women with gestational diabetes mellitus
32862835|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
32862836|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
32862837|NCT04915638|Experimental|Intervention group|Schoolchildren received enriched cookies containing a multiple micronutrients formula. Enriched cookies (20g) with a daily dose of 0.33g of organic mix formula were given in the morning during 4-weeks. The formulation is an industrial secret of UNAM.
32862838|NCT01382901|Experimental|Intravenous (IV) Iron|
32862839|NCT01382901|Placebo Comparator|Placebo|
32862840|NCT04907760|Experimental|With a personalized care program|The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months
32862841|NCT04907760|No Intervention|Without a personalized care program|The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator.
32862842|NCT04915482|Experimental|Combined use of eltrombopag with low-dose rituximab|The starting dose of eltrombopag is 75mg daily. Before or within 4 weeks after the treatment, rituximab 375mg/m2 will be used once. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance. If the continuous application of 75 mg once a day of eltrombopag for 6 weeks is still ineffective, discontinue the use of eltrombopag.
32862843|NCT04915482|Active Comparator|The best available therapy other than combined use of eltrombopag with rituximab|The best available therapy except for combined use of eltrombopag with rituximab includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists other than eltrombopag, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
32862844|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
32862845|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
32862846|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
32862847|NCT04907448|Experimental|IsoK-ST group|Participants in this group received the usual physical rehabilitation program in addition to an IsoK-ST program.
32862848|NCT04907448|Active Comparator|Control group|Participants in this group received the usual physical rehabilitation program only.
32862849|NCT04907838|Experimental|Type 2 diabetics|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
32862850|NCT04907838|Experimental|Healthy controls|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
32862851|NCT04923204||Bipolar depression pharmacogenetics|Patients 18 years and older, with a diagnosis of bipolar disorder with an index episode of depression with or without associated psychotic symptoms (according to the Diagnostic Manual of Mental Disorder 4th Edition Text Revision, DSM-IV-TR), who attended the Bipolar Disorder Program of the Psychiatry Service of the Hospital Clínic de Barcelona (Spain).
33323628|NCT03974009|Active Comparator|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
33323629|NCT03934710|Placebo Comparator|Placebo|Placebo
33323630|NCT03934710|Experimental|Serotonin agonist|13ug of serotonin agonist
33323631|NCT03938194|Experimental|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
33323632|NCT01073423|Experimental|Yoga|
33323633|NCT01073423|Active Comparator|Music Therapy|
33323634|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
33323635|NCT05169424||Stiolto initiators|Chronic obstructive pulmonary disease (COPD) patients who initiated with Stiolto Respimat (Tiotropium + Olodaterol (5/5 micrograms (mcg)) between 15 September 2017 and 31st March 2020.
33323636|NCT05169424||Trelegy initiators|COPD patients who initiated with Trelegy Ellipta (Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg) between 15 September 2017 and 31st March 2020.
33323637|NCT01123590||Thymoma|Patients with thymoma
33323638|NCT01123590||Control|Normal controls
33323639|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
33323640|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
33323641|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
33323642|NCT01218360||Participants|All participants enrolled
33323643|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
33323644|NCT03934476|Experimental|Ketogenic diet|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction"
33323645|NCT03934476|Experimental|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
33323646|NCT03934476|Experimental|Ketogenic diet + Exercise HIIT|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction~Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
33323647|NCT03934476|No Intervention|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
33323648|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
33323649|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
33323650|NCT01215474||NSCLC Stadium III-IV|
33323651|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~Subjects should have at least one of the following problems~Presence of hemophagocytosis in tissue or bone marrow~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~Age > 18 years~Written informed consents~Subjects receive steroids and etoposide"
33323652|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
33323653|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
33323654|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
33323655|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
33323656|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
33323657|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
33323658|NCT03936114|Experimental|SMART|
33323659|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
33323660|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
33323661|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
33323662|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
32979984|NCT05386498|Experimental|Contact Making Instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
32979985|NCT05386498|Active Comparator|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
32979986|NCT05386446||Drug: Interferon Gamma|Ingaron (INN: recombinant human interferon gamma, lyophilisate for solution for intranasal administration 100,000 IU) in the regime of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles)
32979987|NCT05386446||Control: No intervention|Любой профилактический метод, включающий различные фармакологические методы лечения COVID-19, наряду с применением противовирусных и иммуномодулирующих средств, за исключением препаратов, назначаемых не по назначению или в исследовательских целях, а также IFN-G.
32979988|NCT05386433|Placebo Comparator|standard-of-care|Standard-of-care of COVID-19 includes oxygen inhalation, antibiotics, traditional medicine, etc.
32979989|NCT05386433|Experimental|standard-of-care plus Paxlovid|standard-of-care of COVID-19 plus Paxlovid
32979990|NCT05386407|Experimental|telemedically assisted guided oropharyngeal + nasal (OP+N) self-sampling (GSS): OP+N GSS|After performing the telemedically assisted OP+N GSS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP.
32979991|NCT05386407|Experimental|unsupervised OP+N self-sampling (USS): OP+N USS|"Written instructions on how to perform a self-test will be provided, representing the instructions that come along with a commercially available rapid test set. An instructional online video tutorial or similar would also account as the latest state of the art.30 However, this has not yet been implemented comprehensively with all available test sets.~After performing the OP+N USS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP."
32979992|NCT05386381||Decompression alone|Patients undergone decompression surgery alone
32979993|NCT05386381||Decompression with fusion|Patient undergone decompression and lumbar fusion surgery
32979994|NCT05386316|Experimental|Intervention counties|Birthing persons who live in Kent County or Genesee County, Michigan, USA at the time of delivery.
32979995|NCT05386316|Active Comparator|Control counties|Birthing persons who live in the other Michigan, USA counties at the time of delivery.
32979996|NCT05386290||UC patients|Patients who were diagnosed moderate-to-severe ulcerative colitis (UC) and intend to be treated by biological agents (infliximab or vedolizumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
32979997|NCT05386290||CD patients|Patients who were diagnosed moderate-to-severe Crohn's Disease (CD) and intend to be treated by biological agents (infliximab or ustekinumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
32979998|NCT05386251|Experimental|Behavioral Parent Training/Organization Skills Training|Parents will receive 8 weeks of a 90 minute behavioral parent training protocol that focuses on supporting academic and behavioral success in adolescents with ADHD. Teens will receive a simultaneous 8 weeks of a 90 minute organization skills training group. Both groups will be delivered via telehealth.
32979999|NCT05386251|Sham Comparator|Peer support|Parents and teens will each participate in 8 weeks of a 90 minute peer support group focused on exchange of shared experience and group problem-solving difficulties. Both groups will be delivered via telehealth.
32980000|NCT05386212||control|regular nursing care instructions
32980001|NCT05386212||Expirement|web app healthcare instructions for relieving back pain
32980002|NCT05386186|Experimental|Glimepiride|All participants have background therapy of metformin 1500mg-2000mg, glimepiride1-4mg were added in the patients randomised to this arm considering the baseline HbA1c of the participants.
32980003|NCT05386186|Active Comparator|Sitagliptin|All participants have background therapy of metformin 1500mg-2000mg, Sitagliptin 100mg were added in the patients randomised to this arm regardless of the baseline HbA1c level in this arm.
32980004|NCT05386173||Fetal intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria
32980005|NCT05386173||Fetal non-intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group
32980006|NCT05386160|Active Comparator|Cataract phacoemulsification combines Ranibizumab|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
32980007|NCT05386160|Active Comparator|Cataract phacoemulsification|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
32980008|NCT05386121|Active Comparator|Erector spinae plane block (ESPB) group|30 child will receive a preoperative unilateral single shot US-guided erector spinae plane block at the level of T9 vertebra in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
32980009|NCT05386121|Active Comparator|Quadratus lumborum block (QLB) group|30 child will receive a preoperative unilateral single shot US-guided quadratus lumborum block at the level of L2 spinous process in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
32980010|NCT05386056|Experimental|Experimental: Pembrolizumab plus photodynamic therapy (PDT)|"Interventions:~Drug: Pembrolizumab~Drug: sinoporphyrin sodium (DVDMS)~Photodynamic therapy (PDT)"
32980011|NCT05386017||Young adults who were included in the PRALIMAPINES trial as adolescents|The population is all young adults who were included in the PRALIMAPINES trial as adolescents (n=1419); we estimated 852 young adults participated in the follow-up visit (T3). This visit was proposed to investigate long-term social, economic, educational/professional and health (in particular weight) trajectories in adolescents in the PRALIMAP-INÈS intervention
32980012|NCT05386004|Experimental|BSSC group|Participants in the experimental group were allowed to focus with BSSC during uterine contractions in the first stage of labor.
32980013|NCT05386004|No Intervention|control group|The participants in the control group were provided with routine care in the first stage of labor. No intervention was made.
32980014|NCT05385939||Time period 1|Time period one included infants admitted to the current traditional, open bay NICU.
32980015|NCT05385939||Time period 2|Time period 2 included infants admitted to the private, single family room NICU.
32980016|NCT05385913||"Placebo"|AB high group; SUVR >1.11
32980017|NCT05385913||"Treatment"|AB low group; SUVR ≤1.11
32980018|NCT05385913||Study Partners|Each participant will also have a stud partner that will be enrolled.
32980019|NCT05385900|Experimental|Penpulimab in combination with anlotinib and chemotherapy|After receiving the corresponding neoadjuvant therapy for 3 cycles according to the established treatment plan, surgery should be performed within 3-6 weeks after drug withdrawal.
32980020|NCT05385887|Active Comparator|Antibiotic treatment|Two kinds of antibiotics: Ciprofloxacine 500mg 2dd & Metronidazole 500mg 3dd
32980021|NCT05385887|Placebo Comparator|Placebo|Placebo tabletes
32980022|NCT05385874||Training cohort|The training cohort will be used for model development.
32980023|NCT05385874||Testing cohort|The testing cohort, a new cohort compared with the training cohort, will be used for model external validation.
32980024|NCT05385861|Experimental|nal-IRI (ONIVYDE®) and Carboplatin|nal-IRI (ONIVYDE®) and Carboplatin
32980025|NCT05385848|Experimental|PRP Injection Arm|"All patients recruited will come down to KKIVF Centre on Day 2-3 of the menstrual cycle to do blood tests (Anti-Mullerian Hormone (AMH)) and an ultrasound scan (Antral Follicular Count (AFC)). In the same menstrual cycle/month, autologous PRP injection will be done on Day 5-15 of the cycle.~Patients will return to KKIVF Centre 1-3 months after the PRP injection on Day 2-3 of the menstrual cycle to repeat blood tests (AMH) and Ultrasound scan (AFC).~IVF stimulation cycle as per KKIVF protocol will be started within 6 months from PRP injection. Patients will be followed up as per routine, with no more additional visits pertaining specifically to the study."
32980026|NCT05385835||1Nurses|"The research is a pre-post-test observation study without a control group, aiming to determine the effect of the training given to nurses on the knowledge and practices of brachial artery blood pressure measurement.~The research is carried out with a group of 60 nurses."
32980027|NCT05385822|No Intervention|Control|The control group will not recieve any training in the trial period but will have to answer the same questionnaires on erectile function (IIEF-EF) and international prostate symptom score (IPSS).
32980028|NCT05385822|Experimental|Pelvic Floor Muscle Training|Participants who are randomized to pelvic floor training will then undergo instruction in the anatomy, function and training of the pelvic floor muscles.
32980029|NCT05385757||Childhood Uveitis|Children <18 years old newly diagnosed with non-infectious uveitis
32980030|NCT05385744|Experimental|BCD-132|IV infusion every 24 weeks in combination with daily placebo tablets. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with BCD-132 in combination with the daily placebo tablets)
32980031|NCT05385744|Active Comparator|Teriflunomide, 14 mg orally|Teriflunomide, 14 mg orally daily, in combination with intravenous placebo infusions. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with intravenous placebo infusions in combination with daily teriflunomide tablets).
32980032|NCT05385731|Experimental|Nordic Walking (NWG)|"The Nordic Walk program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion."
32980033|NCT05385731|Active Comparator|Free walking (FWG)|"The free walking program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.~Intervention administered:~24 sessions will be held twice a week, with each session taking an average of 60 minutes."
32980034|NCT05385731|No Intervention|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
32980035|NCT05385627||Ankle block|Any participant receiving an ankle block (local infiltration analgesia).
32980036|NCT05385614|No Intervention|Control|Control group that will receive the app after primary endpoint was assessed.
32980037|NCT05385614|Experimental|Intervention|Experimental group that will receive the app at the start of their participation
32980038|NCT05385445|Experimental|Audit and Feedback Group 1|"The intervention Group 1 received the standard feedback report with a one-page summary of the CWC recommendations of interest. Group 1 did not receive any data specific to their prescribing."
32980039|NCT05385445|Experimental|Audit and Feedback Group 2|"Intervention Group 2 received the standard feedback report, CWC recommendation summary and practice-specific data related to their prescribing rates for the CWC recommendations of interest, compared to rates for other providers at their clinic, in their health region and in the province."
32980040|NCT05385445|No Intervention|Control|The control group received the standard feedback report with no information related to CWC.
32980041|NCT05385419|Other|Patients subjected for bronchoscopy or medical thoracoscopy|Bronchoscopic and thoracoscopic biopsies will be sent for both frozen section and permenant paraffin section
32980042|NCT05385341|Experimental|Telerehabilitation (Tele RCV)|Experimental group (Tele-RCV): the treatment will consist of 20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training (the first session in center to form the patient) associated with 8 educative sessions.
32980043|NCT05385341|Active Comparator|Rehabilitation (RCV)|Group control (RCV) : 20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
32980044|NCT05385276|Experimental|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above the umbilicus after maximum retraction of the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment.
32980045|NCT05385276|Experimental|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
32980046|NCT05385250|Other|Bone sparring radiotherapy|Observational arm of bone-sparing radiotherapy
32980047|NCT05385237|Experimental|4D-MRI assessment for patients with liver diseases|patients with chronic liver diseases, acute liver inflammation or cardiac blood congestion to the liver will be assessed by MRI
33412080|NCT04217135|Active Comparator|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
32980048|NCT05385237|Experimental|4D-MRI assessment for healthy volunteers (control group)|healthy control subjects will be assessed by MRI
32980049|NCT05385211||People living with type 1 diabetes|Participants will be separated into two groups based on the levels of their exocrine pancreatic enzymes levels.
32980050|NCT05385198|Experimental|VOICE care|"The VOICE conversations contain minimal 5 consecutive conversations with parents. The conversations are not rigid or strictly protocolized but rather focus on issues related to the situation of the admission period of the infant and the conversations should be individualized based on the parent needs. Thus, depending on the situation of the infant and the home situation of the parents.~The content of the VOICE conversations is built up based on the admission pathway of the infant. Every VOICE conversation has its own focus, and these are presented in the 5 VOICE conversation guides. Basically, every VOICE conversation is about the support of parents and infant.~The principles of the VOICE conversations are Values, Opportunities, Integration, Control and Evaluation. The VOICE program focuses on a systematic and planned communications with parents during the NICU admission and follow-up 2-4 weeks after NICU discharge."
32980051|NCT05385198|No Intervention|Standard care|Standard care is defined as the standard family centered care (FCC) practices currently implemented in the NICU. Parents are allowed to visit the NICU for 3 hours every day and provide basic care to their infant. Standard care involves meetings with the doctors three times a week and the content is mainly directed to the medical condition and treatments of the infant. No other meetings between parents and doctors/nurses exists. The FCC principles implicate that parents and NICU staff work closely together on the NICU. This also involves unscheduled information and communication contact moments where short questions of parents will be addressed.
32980052|NCT05385185|Experimental|Leptomeningeal metastases received PD-1 inhibitor and recombinant human endostatin|Camrelizumab 200mg intravenously, once every 21 days or envafolimab 150mg subcutaneous injection,once a week Endostatin 30mg/d was administered intravenously for 7 days (d1-d7). The interval between Endostatin and next was 2 weeks.
32980053|NCT05385172||18-65 years old women|
32980054|NCT05385146|Experimental|qigong group|The qigong group received Chan-Chuang qigong therapy with breathing meditation for 15 weeks.Qigong training program consisted of a warm-up, Chan-Chuang qigong, and breathing meditation. The whole process takes about 20 minutes.The qigong was monitored in terms of muscle elasticity and heart rate variability. After practicing the Chan-Chuang qigong, meditation with breathing was conducted for 10 minutes. In the meanwhile, sit down while relaxing with slow breathing and focus on the present feelings, with brain wave (NeuroSky's, Australia) to monitor and confirm that the eSense (attention and relaxation).
32980055|NCT05385146|No Intervention|control group|those in the control group received usual care during the same study period.
32980056|NCT05385133|Experimental|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
32980057|NCT05385133|Experimental|Manual condylar position|post-osteotomy condylar position was performed using the conventional free hand approach
32980058|NCT05385120|Experimental|Group A-Shunt group|Patients who undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
32980059|NCT05385120|No Intervention|Group B-No Shunt group|Patients who donot undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
32980060|NCT05385081|Other|genomic profiling|"After informed consent a PET/CT scan is performed to determine disease spread and the best location for core needle biopsi. Genomic profiling is performed using Next Generation Sequencing, NGS, genpanel analysis by Oncomine Comprehensive vs 3 The result of NGS is discussed at weekly local and national tumor board meeting to decide a possible targeted treatment offer based on genomic profiling or a possibly treatment offer in a clinical trial.~Timelines in the course of investigation will be calculated using date of informed consent, PET/CT scan, biopsy, tumor board and date of start of next treatment, progression and death.~If the genomic profiling results in a targeted treatment offer the Growth Modulation Index is calculated from progressions-free survival on recent and current treatment. Treatment given without an actionable target is likewise evaluated for efficacy."
32980061|NCT05385068|Experimental|Niraparib combined with Anlotinib|Participants received Niraparib 200mg or 300mg QD PO continually and Anlotinib 10mg QD PO on Days 1-14 (21 days/cycle) .
32980062|NCT05385029||Thyroid functions in neonates born to COVID 19 positive mothers|thyroid hormone or antithyroid drugs
32980063|NCT05385029||Neonates born to mothers without COVID 19 infection|Thyroid drugs if indicated
32980064|NCT05385003|Experimental|Dietary Supplement: anserine|Subjects are instructed to take one capsule of anserine daily for a total of 3 months
32980065|NCT05385003|Experimental|Dietary Supplement: Sunflower peptide|Subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months
32980066|NCT05385003|Placebo Comparator|Dietary Supplement: Placebo control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
32980067|NCT05384990|Experimental|Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test while receiving stochastic resonance stimulation on legs and hip.
32980068|NCT05384990|No Intervention|No Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test without receiving any electrical stimulation.
32980069|NCT05384977|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
32980070|NCT05384639|Experimental|Dual-task Group|
32980071|NCT05384639|Active Comparator|Cycling Group|
32980072|NCT05384639|Active Comparator|Cognitive Group|
32980073|NCT05383755|Experimental|Digital intervention|Digital intervention for pregnant adolescents living with HIV.
32980074|NCT05379413||Early BoNT treatment|Patients with PSS treated with BoNT within the first Quartile of injection timing distribution
32980075|NCT05379413||Late BoNT treatment|Patients with PSS treated with BoNT within the third Quartile of injection timing distribution
32980076|NCT05379413||Not treated with BoNT|Natural controls with PSS not treated with BoNT
32980077|NCT05379374|Active Comparator|Bupivacaine group|0.25% bupivacaine 20 ml in TAP block
32980078|NCT05379374|Experimental|Bupivacaine morphine group|0.25% bupivacaine 20 ml with 3 mg morphine in TAP block
32980079|NCT05376007|Experimental|Playing serious game 'Broodles'|"The participants allocated to this group will play the newly developed serious game 'Broodles' after pre-test assessment. Children will play the serious game without the parent or the help of a caregiver. Parents and children will make complementary worksheets together and parents will read an information brochure.~Concomitant care as usual is allowed during the study.~A parent-child pair is labelled as one participant."
32980080|NCT05376007|No Intervention|Waitlist control group|"The participants allocated to this group will play the serious game 'Broodles' after follow-up assessment.~Concomitant care as usual is allowed during the study."
32980081|NCT05375708|Active Comparator|Systemic maintenance therapy|
32980082|NCT05375708|Experimental|Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)|
32980083|NCT05375474|Experimental|oral anticoagulation therapy group|
32980084|NCT05375474|Active Comparator|double antiplatelet therapy group|
32980085|NCT05375279||LSGB vs EMB|Patients who already underwent EMB within the last six months with confirmed Amyloid Transthyretin -wild type (ATTRwT) will undergo LSGB.
32980086|NCT05372965|Experimental|Experimental: periodontitis|Our study will include 42 people with periodontitis patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
32980087|NCT05372965|Active Comparator|Control: clinical healthy|Our study will include 42 people with clinical healthy patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
32980088|NCT05339633|Other|Single Dose|All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast
32980089|NCT05336279|Experimental|Treatment group TR|T - R
32980090|NCT05336279|Experimental|Treatment group RT|R -T
32980091|NCT05335174||HPI monitor|
32980092|NCT05312060|Experimental|Pneumatic Compression (PC)|The PC will undergo two daily 30-minute sessions of sequential pneumatic compression.
32980093|NCT05312060|Active Comparator|Antithromboembolic exercises (AE)|AE will perform two supervised antithromboembolic exercises sessions daily lasting 30 minutes.
32980094|NCT05308979|Experimental|1 Injection Site|100u Botox® injected at one intradetrusor site
32980095|NCT05308979|Active Comparator|10 Injection Sites|100u Botox® injected at 10 intradetrusor sites
32980096|NCT05299697|Experimental|TG103 15 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 15 mg.
32980097|NCT05299697|Experimental|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 22.5 mg.
32980098|NCT05299697|Placebo Comparator|Placebo|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks.
32980099|NCT05296980|Experimental|REMINDER program online|The REMINDER program in this arm will be delivered by videoconferencing. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
32980100|NCT05296980|Experimental|REMINDER program face-to-face|The REMINDER program in this arm will be delivered face to face. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
32980101|NCT05296980|Sham Comparator|Brain psychoeducation program|The control condition will have the same length as the experimental harms, including 20 psychoeducation sessions, with information regarding dementia modifiable risk factors, information on healthy lifestyles, and brain health promotion.
32980102|NCT05296655||Laryngopharegeal reflux symptoms patients|patients with symptoms of laryngopharyngeal reflux detected at an outpatient appointment with an ENT doctor
32980103|NCT05296655||Asymptomatic laryngopharegeal reflux patients|patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist
32980104|NCT05294653||Type 1 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
32980105|NCT05294653||Type 2 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
32980106|NCT05286918|Experimental|The intervention (CRP-guided) group|"Standard usual care (following GOLD initiative, including bronchodilator, and systemic steroid).~The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to <5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
32980107|NCT05286918|No Intervention|The usual care (control) group|Patients in the control arm will be treated with usual care (GOLD initiative). No CRP would be measured.No CRP would be measured.
32980108|NCT05259254|Placebo Comparator|Standard Direct Observed Therapy (DOT)|After a patient was diagnosed with TB, they will be provided TB therapy which is consist of health education and anti-TB medication. Patient that is not in life-threatening condition typically will be treated as outpatient. Patient will receive medication that will be monitored closely through DOT, which is either by health facilities (by healthcare staff), or community (by family members or community members). Observation of medication will be conducted daily, and the health care staff will sign the DOT diary provided to the patient to verify the medication consumption.
32980109|NCT05259254|Active Comparator|Mobile application DOT|The mobile application will be consisting of four basic modules which are: 1) reminder system, 2) visual observed therapy, 3) feedback, and 4) health education. Researcher will teach patient on how to record, and send video of every dose of medication ingested every day. Participants also required to show their mouth is empty by opening their mouth and sticking out their tongue. The participants also are required to record and send the self-recorded video of ingesting the medication daily. Researcher will subsequently view the video through a password protected website. The observation of taking medication will be completed until the end of study period.
32980110|NCT05252624|Active Comparator|Active Comparator: Henagliflozin|Single 5 mg tablet, administered orally once daily for 6 months
32980111|NCT05252624|Placebo Comparator|Placebo Comparator: Placebo|Single 5 mg tablet, administered orally once daily for 6 months
32980112|NCT05237622|Other|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data lung volume changes will be measured using electrical impedance tomography.
32980113|NCT05235958|Experimental|Training intervention|8 weeks of non-linear periodized aerobic exercise; 3 sessions per week; 1 hour per session; standardized warm-up; individual training intensity according to cardiorespiratory fitness level
32980114|NCT05235958|Sham Comparator|Control Intervention|Recommendation to continue with current lifestyle (especially physical activity habits) during the following 8 weeks. At the final assessment after 8 weeks, individualized exercise recommendations according to established standard procedures in exercise medicine and offer to attend the standard medical follow-up in our outpatient clinics subsequent to study termination
32980115|NCT05234411||Observational group|Eligible participants will be female patients aged 13 years or older, with regular menstrual cycle, who have been undergoing a KDT for at least 3 months and thus previously diagnosed with Drug resistant epilepsy or GLUT1DS.
32980116|NCT05216484|Experimental|two doses CoronaVac group|the third does was given 6 months after two doses CoronaVac group
32980117|NCT05216484|Experimental|two doses BBIBP-CorV|the third does was given 6 months after two doses BBIBP-CorV
32980118|NCT05216484|Experimental|first does CoronaVac and second does BBIBP-CorV|the third does was given 6 months after first does CoronaVac and second does BBIBP-CorV
32980119|NCT05216484|Experimental|first does BBIBP-CorV and second does CoronaVac|the third does was given 6 months after first does BBIBP-CorV and second does CoronaVac
32980120|NCT05214469||Case Group|Individuals diagnosed with knee-osteoarthritis
32980121|NCT05214469||Control Group|Individuals who do not have a chronic disease and are not diagnosed with osteoarthritis
32980122|NCT05210439|Experimental|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment from the date of the last positive blood culture
32980123|NCT05210439|Active Comparator|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture
32980124|NCT05210088|Experimental|PHASE 1- Dose escalation protocol|"4-step dose-escalation protocol with increasing doses of intermittent hypoxia and continuous reassessment of safety criteria (primary endpoint).~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored: 90% for stage 1 (n=1 patient), 85% for stage 2 (n=3 patients), 80% for stage 3 (n=3 patients), 75% for stage 4 (n=3 patients)."
33412081|NCT04217135|Active Comparator|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
33412082|NCT01337401|Experimental|Blinded Cediranib|
33412083|NCT01337401|Placebo Comparator|Blinded Placebo|
33412084|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
32980125|NCT05210088|Active Comparator|PHASE 2 - Intermittent hypoxia group|"Group exposed to an intermittent hypoxic stimulus (n=20, target pulsed saturation in dioxygen 75%).~The device used is a gas mixer already in use in the unit and used in current clinical practice and research in our team (Altitrainer®, Sport and Medical TEChnologies S.A. (SMTEC S.A.), Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the FiO2 will be set individually to achieve the targeted level of desaturation."
32980126|NCT05210088|Sham Comparator|PHASE 2 - Sham (Normoxia) group|Normoxia group (n=10, FiO2 = 21%). The same setting will be used as in the Intermittent hypoxia group, but subjects will breathe ambient air throughout the conditioning procedure.
33412085|NCT04178603|Experimental|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
33412086|NCT04178603|Experimental|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
33412087|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
32980127|NCT05201976|Active Comparator|Intervention|Virtual cardiac rehab program delivered through the CardaHealth platform.
33412088|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
33323663|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
32980128|NCT05201976|Active Comparator|Control|Clinically ordered standard of care cardiac rehab program (in-person).
32980129|NCT05194345|Experimental|Autism Eats nutrition intervention|Autism Eats intervention lessons (10 lessons + 2 booster sessions) integrate ASD-specific feeding strategies such as repeated exposures, food chaining, and making regular mealtime routines and behaviorally-focused nutrition content and activities utilizing goal setting, healthy meal planning, monitoring progress, strategies to overcome barriers, and creating healthy home food environment. The early intervention (EI) providers will be trained to implement the lessons. EI providers are well-trained to use personalized intervention and coaching approach in their EI services, which will be applied to Autism Eats activities as well. Each intervention lesson will take 25-30 minutes within one hour EI services, and parent-child dyads will participate in the intervention as part of their regular EI services. The Autism Eats lesson manual will be provided to the EI providers and the parent handbook will be distributed to the parent participants.
32980130|NCT05194345|Active Comparator|We Can! enhanced usual care control|Enhanced usual care (EUC) control group materials are from the evidence-based materials that are already developed and available online (in both English and Spanish): https://www.nhlbi.nih.gov/health/educational/wecan/index.htm. We will download one to two handouts and email early intervention providers to distribute them to parent-child dyads. Materials will be distributed each week for 10 weeks and additional monthly handouts for two months after the first 10 weeks (parallel to the intervention schedule).
32980131|NCT05188664|Experimental|LM-302 monotherapy dose escalation|LM-302 monotherapy dose escalation (part Ia). Accelerated titration combined with traditional 3+3 design will be used for monotherapy dose escalation (part Ia).
32980132|NCT05188664|Experimental|LM-302 in combination therapy dose escalation|LM-302 in combination therapy dose escalation (part Ib).Accelerated titration combined with traditional 3+3 design will be used for LM-302 in combination with fixed dose Toripalimab dose escalation (part Ib).
32980133|NCT05188664|Experimental|LM-302 Dose Expansion|SMC will select appropriate dose(s) and/or tumor types for dose expansion study.
32980134|NCT05176379|Experimental|fluconazole|fluconazole tablet/pill 150 mg, single acute dose
32980135|NCT05176379|Placebo Comparator|Placebo|250 mg pill microcrystalline Cellulose, single acute dose
32980136|NCT05168982||Chronic liver disease (CLD) patients at stage A0 of liver inflammation|
32980137|NCT05168982||Chronic liver disease (CLD) patients at stage A1 of liver inflammation|
33412089|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
33412090|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
32980138|NCT05168982||Chronic liver disease (CLD) patients at stage A2 of liver inflammation|
32980139|NCT05168982||Chronic liver disease (CLD) patients at stage A3 of liver inflammation|
32980140|NCT05168982||Chronic liver disease (CLD) patients at stage F0 of liver fibrosis|
32980141|NCT05168982||Chronic liver disease (CLD) patients at stage F1 of liver fibrosis|
32980142|NCT05168982||Chronic liver disease (CLD) patients at stage F2 of liver fibrosis|
32980143|NCT05168982||Chronic liver disease (CLD) patients at stage F3 of liver fibrosis|
32980144|NCT05168982||Chronic liver disease (CLD) patients at stage F4 of liver fibrosis|
32980145|NCT05168982||healthy subjects|
32980146|NCT05167656|Experimental|Intraoral Manual Therapy plus exercise and education.|Six sessions of intraoral manual therapy plus exercise and counselling.
33323664|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
33323665|NCT01126164|Experimental|parent handbook|parent handbook
33323666|NCT01126164|Experimental|peer basics|peer delivered basics
33323667|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
33323668|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
33323669|NCT01361230|No Intervention|Control|Standard practice
33323670|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
33323671|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
33323672|NCT01215552|Experimental|HT-0712|
33323673|NCT01123902|Experimental|hand-held fan|
33323674|NCT01123902|Placebo Comparator|wristband|
33323675|NCT05759962|Experimental|Part A: Single Ascending Dose (SAD) LQT-1213|In Part A, 4 dosing cohorts will receive a single oral dose of LQT-1213. The highest dose of LQT-1213 to be administered is 1.67 mg/kg.
33323676|NCT05759962|Experimental|Part A: Food Effect LQT-1213|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
33323677|NCT05759962|Experimental|Part B: Multiple Ascending Dose (MAD) LQT-1213|In Part B, 3 dosing cohorts will receive LQT-1213 in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
33323678|NCT05759962|Placebo Comparator|Part A: Single Ascending Dose (SAD) Placebo|In Part A, 6 dosing cohorts will receive a single oral dose of placebo.
33323679|NCT05759962|Placebo Comparator|Part A: Food Effect Placebo|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
33323680|NCT05759962|Placebo Comparator|Part B: Multiple Ascending Dose (MAD) Placebo|In Part B, 3 dosing cohorts will receive placebo in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
33323681|NCT01215630||Healthy subjects|Men Women Age; 18-75
33323682|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
33323683|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
33323684|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
33323685|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
33323686|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
33323687|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
33323688|NCT03933150|Other|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
33323689|NCT03933150|Other|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
33323690|NCT05129644|Experimental|P1101 24 mcg|A total of 6 subjects received single dose of 24 mcg P1101
33323691|NCT05129644|Experimental|P1101 48 mcg|A total of 6 subjects received single dose of 48 mcg P1101
33323692|NCT05129644|Experimental|P1101 90 mcg|A total of 6 subjects received single dose of 90 mcg P1101
33323693|NCT05129644|Experimental|P1101 180 mcg|A total of 6 subjects received single dose of 180 mcg P1101
33323694|NCT05129644|Experimental|P1101 225 mcg|A total of 6 subjects received single dose of 225 mcg P1101
33323695|NCT05129644|Experimental|P1101 270 mcg|A total of 6 subjects received single dose of 270 mcg P1101
33323696|NCT05129644|Active Comparator|Pegasys 180 mcg|A total of 12 subjects received single dose of 180 mcg Pegasys
33323697|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
33323698|NCT00255047|Experimental|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
33323699|NCT00255047|Experimental|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
33323700|NCT00255047|Experimental|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
33323701|NCT00255047|Experimental|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
33323702|NCT01220622|Active Comparator|Nimodipine|
33323703|NCT01220622|Placebo Comparator|Placebo|
33323704|NCT05123170|Active Comparator|Group I|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml
33323705|NCT05123170|Active Comparator|Group II|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.
33323706|NCT05123170|Active Comparator|Group III|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml
33323707|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
33323708|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
32980147|NCT05167656|Experimental|Extraoral Manual Therapy plus exercise and education.|Six sessions of extraoral manual therapy plus exercise and counselling.
32980148|NCT05167656|Active Comparator|Exercise and education.|Exercise and counselling alone without any manual therapy treatment.
32980149|NCT05165186|Experimental|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video
32980150|NCT05165186|No Intervention|Control Arm|For participants randomized to the control group arm, participants will review an informational sheet, which covers the same information as the videos shown to the intervention arm.
32980151|NCT05154656||patients with early stage of liver fibrosis|
32980152|NCT05154656||subjects with no liver fibrosis|
32980153|NCT05122715|Other|OMNI PET/CT scan first|
32980154|NCT05122715|Other|DMI PET/CT scan first|
32980155|NCT05115422|Experimental|"Coping with Brain Fog intervention"|
32980156|NCT05113615|Active Comparator|tiotropium bromide|tiotropium bromide inhaler (Spiriva Respimat) will be used once daily (2 puffs) for a total of 8 days
32980157|NCT05113615|Placebo Comparator|Matching placebo|matching placebo inhaler will be used once daily (2 puffs) for a total of 8 days
32980158|NCT05098717||UIP patients|Patients with pulmonary fibrosis and UIP pattern undergoing mechanical ventilation for acute respiratory failure
32980159|NCT05098717||ARDS patients|Patients with ARDS undergoing mechanical ventilation for acute respiratory failure
32980160|NCT05096208|Experimental|RSVpreF vaccine Group 1|RSVpreF
32980161|NCT05096208|Experimental|RSVpreF vaccine Group 2|RSVpreF
32980162|NCT05096208|Experimental|RSVpreF vaccine Group 3|RSVpreF
32980163|NCT05096208|Placebo Comparator|Placebo dose|Placebo
32980164|NCT05074186|Experimental|neurological thrombectomy device|Revascularization device is an investigational device.
32980165|NCT05061030|Active Comparator|Wharton's jelly derived mesenchymal stromal cells (Protrans)|Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).
32980166|NCT05061030|Placebo Comparator|Placebo|Placebo (saline) is given intravenously over a period of 20-40 min.
32980167|NCT05041855|Experimental|Community based childhood obesity intervention|A novel family-inclusive childhood obesity treatment program consisting of 12 family group sessions delivered in English and Spanish by health educators at community recreation centers, followed by three group booster sessions occurring every 6 months.
32980168|NCT05041855|Active Comparator|Primary care based childhood obesity intervention|A healthy lifestyle counseling intervention delivered by trained primary care providers and health educators at visits occurring every 3 months.
32980169|NCT05041504|Experimental|Intervention|Participants assigned to the intervention arm will receive the True North Peer Navigation intervention.
32980170|NCT05041504|Other|Active Waitlist Control|Participants assigned to the control arm will receive usual care and access to an online health resource library. After completion of the study, they will receive the True North Peer Navigation intervention.
32980171|NCT05037630|Experimental|Self-guided Digital Tool for Problematic Alcohol Use|Self-guided Digital Tool for Problematic Alcohol Use during 8 weeks with clinical telephone interviews pre ant post intervention.
32980172|NCT05030233|Experimental|Nurse-Administered Touch Intervention|Preterm infants will receive the nurse-administered touch intervention during one episode of essential nursing care.
32980173|NCT05030233|No Intervention|Standard Care|Preterm infants will receive one episode of essential nursing care delivered as standard care.
32980174|NCT05013957||Retrospective analysis|Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated
33323709|NCT01215708|Placebo Comparator|placebo|placebo capsule
32980175|NCT05013957||Prospective analysis|Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated
32980176|NCT04987034||Direct and indirect PPG measurements|Measuring the portalsystemic pressure gradient in patients directly using the EchoTip® Insight™ and indirectly through the HVPG procedure.
32980179|NCT04981977|Experimental|Care Transitions Intervention|Patient participants in this arm will receive the Care Transition Intervention.
32980180|NCT04981977|Experimental|Care Transition Intervention and Peer Support|Patient participants in this arm will receive the Care Transition Intervention.
32980181|NCT04981977|Other|Usual Care|Patient participants in this arm will receive the usual discharge/transition care provided by the hospital.
32980182|NCT04975893|Other|CMV-seropositive and CMV-seronegative Participants|CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.
32980183|NCT04971018|Experimental|Active ta-VNS|
32980184|NCT04971018|Placebo Comparator|Sham ta-VNS|
32980185|NCT04931199|Active Comparator|CBT|
32980186|NCT04931199|Experimental|CBT+App|
32980187|NCT04893863|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
33323710|NCT05114278|Experimental|Oral Iron + IV Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.
33323711|NCT05114278|Active Comparator|Oral Iron only|Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
33323712|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
32980188|NCT04893863|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
32980189|NCT04883944|Experimental|Intervention group|All the enrolled infants will receive the heel stick procedure with the maternal involvement after mother will be trained on the application of the non-pharmacological techniques during the performance of the procedure.
32980190|NCT04883944|Active Comparator|Standard care|All the enrolled infants will receive the heel stick procedure according to local protocol without the maternal involvement. The non-pharmacological techniques will be performed by a second nurse not involved in the heel stick procedure itself.
32980191|NCT04868695|Experimental|Bilateral Spheno-Ethmoidectomy:|
32980192|NCT04868695|Experimental|Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b|
32980193|NCT04868695|Experimental|Draf Typ 3|
33323713|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
33323714|NCT05095168|Experimental|Single Ascending Dose (SAD)|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). Additional subjects may be added in any cohort if necessary.
33323715|NCT05095168|Placebo Comparator|placebo|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). In higher dose levels, subjects will be randomized to receive the treatment or placebo.
33323716|NCT00225251|Experimental|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
33323717|NCT00225251|Placebo Comparator|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
32980194|NCT04862572|Experimental|People with tinnitus|People with tinnitus will undergo all interventions (audiology test, MRI scans, tinnitus-related questionnaires).
32980195|NCT04862572|Experimental|People without tinnitus|People with tinnitus will undergo most of all interventions (audiology test, MRI scans) except filling up the tinnitus-related questionnaires.
32980196|NCT04857775|Experimental|Intervention group|A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups. Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal.
32980197|NCT04850378|No Intervention|Coagulation profile in Nephrotic syndrome|Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.
32980198|NCT04850378|Experimental|Nephrotic syndrome|Nephrotic patients without diabetes.
32980199|NCT04850378|Experimental|Membranous nephropathy and nephrotic syndrome|Membranous nephropathy and nephrotic syndrome.
32980200|NCT04850378|Active Comparator|Atrial fibrillation|Atrial fibrillation with no kidney disease.
33323718|NCT01220700|Experimental|Triclosane|triclosan coated suture material
33323719|NCT01220700|Active Comparator|Control|ordinary suture material
32980203|NCT04834882||Healthcare workers|Medical and paramedical staff in Reims University Hospital and EPSM Marne working in COVID-19 units and non COVID-19 units
32980204|NCT04830527|Experimental|Intervention group|Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
32980205|NCT04830527|Active Comparator|Control group|"Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study."
32980206|NCT04818385||Participants Receiving Risankizumab|Participants will receive risankizumab as prescribed by their physician.
32980207|NCT04818385||Participants Receiving All Other Biologics|Participants will receive all other biologics as prescribed by their physician.
32980208|NCT04818359|Experimental|Interventional Arm|Supervised exercise program: MoviS Training. Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
32980209|NCT04818359|No Intervention|Control Arm|Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
32980210|NCT04818047|Experimental|Experimental: VID-KIDS Intervention Program Group|Experimental: VID-KIDS Intervention Program Group RN review photos of infant engagement/ disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
33323720|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
33323721|NCT01220778|Experimental|Exercise|
33323722|NCT01220778|No Intervention|Control|
33323723|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
33323724|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
33323725|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
33323726|NCT00254501|Active Comparator|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
33323727|NCT00254501|Experimental|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
33323728|NCT05045716|Experimental|Lecanemab 10 mg/kg|Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.
33323729|NCT05045716|Experimental|Lecanemab 700 mg|Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.
33323730|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
33323731|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
32862852|NCT04923438|Experimental|telerehabilitation|The exercises will be applied twice a week for a total of 12 weeks, and each program will last roughly 30 minutes.
32862853|NCT04923438|Active Comparator|control|The same exercise program will be prepared and given as a printout and they will be asked to do their exercises at home. This group will also be included in the study as a control group.
32862854|NCT04915092|Experimental|Intervention group|The app is explained and installed during the recruitment to the family in the intervention group. Some families in this group will be selected to take part to the qualitative research.
32862855|NCT04915092|No Intervention|Control group|Every months during the first year of study a newsletter is sent only to the members of the control group.
32862856|NCT04915326||Retrospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The first step will be a retrospective and exploratory analysis of FFPE slides retrieved from the pathology archives testing a panel of molecular marker exploring the immune reaction to the cancer (i.e. antigen presenting cells and T lymphocytes activation).
32862857|NCT04915326||Prospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The second step will be a prospective and validating analysis. Tissue samples will be obtained from normal rectal mucosa adjacent to the cancer at the time of the trans anal or trans abdominal resection. In patients with early rectal cancer, the combination of immunological markers on healthy rectal mucosa adjacent to the cancer obtained in the part 1a of the study will be validated to identify the patients that will have not any nodal metastasis.
32862858|NCT03056274|Active Comparator|Metformin arm|Metformin
32862859|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
32862860|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
32862861|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
32862862|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
32862863|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
33323732|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
33323733|NCT03932058||osteosarcoma|
33323734|NCT03932058||chondrosarcoma|
33323735|NCT03932058||enchondroma|
33323736|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
33323737|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
33323738|NCT05005312|Experimental|Cohort 1|Healthy Volunteer
33323739|NCT05005312|Experimental|Cohort 2|Hepatic Impairment
33323740|NCT03972059|Experimental|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
33323741|NCT03972059|No Intervention|Control group|No intervention for 12 weeks, participants perform all tests.
33323742|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
33323743|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
33323744|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
33323745|NCT02531789||Observation|45 patients receiving elective colorectal surgery
33323746|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
33323747|NCT01126320|Active Comparator|Control|routine mechanical ventilator
33323748|NCT03971981|Experimental|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
32980211|NCT04809103|Experimental|Intratumoral Cisplatin Arm|Single arm approach. There is no comparator or placebo group. Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
32980212|NCT04804371|Other|18F-FDG PETCT scan|18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous
32980213|NCT04797234|Experimental|Control|There will be no intervention to the control group.
32980214|NCT04797234|Experimental|Experiment|The experimental group will be trained for 6 weeks.
32980215|NCT04791267|Experimental|Intervention|Community health navigator program for six months
32980216|NCT04791267|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program
32980217|NCT04790604|Experimental|Intervention|Community health navigator program for six months.
32980218|NCT04790604|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program.
32980219|NCT04781296|Experimental|Subject's Scanned with Investigational Device|
32980220|NCT04776031|Experimental|Laser Treatment|Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
32980221|NCT04772040|Experimental|Young loading dose group|Participants (18-35) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the old group.
32980222|NCT04772040|Experimental|Old loading dose group|Participants (60y+) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the young group.
32980223|NCT04772040|Experimental|Young constant dose group|Participants (18-35y) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
32980224|NCT04772040|Experimental|Old constant dose group|Participants (60y+) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
32980225|NCT04771052||CORE program|Patients admitted to a dedicated COVID-19 units (CHUS Hôtel-Dieu de Sherbrooke - CIUSSS de L'Estrie - CHUS) with medical clearance (physical deconditioning; hemodynamically stable; oxygen therapy by nasal cannula < 4 L/min for saturation > 92%; resting respiratory rate < 24; and heart rate between 50 and 120 beats per minute).
32980226|NCT04771052||Control|Patients admitted to a dedicated COVID-19 units (CHAUR de Trois-Rivières, CIUSSS de la Mauricie-et-du-Centre-du-Québec) receiving usual care, matched to CORE a patient with similar characteristics (sex, age, preadmission provenance).
32980227|NCT04765371|Active Comparator|DEXAMETHASONE Arm|Patients will take 6 mg per day of Dexamethasone during 10 days
33105014|NCT04323319|Experimental|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
33412091|NCT04853875|Experimental|Group A (Tetracycline, Metronidazole, and Bismuth)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg
33412092|NCT04853875|Active Comparator|Group B (Amoxicillin, Metronidazole, and Clarithromycin)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g
32980228|NCT04765371|Active Comparator|PREDNISOLONE Arm|Patients will take 60 mg per day of Prednisolone during 10 days
32980229|NCT04750356||Cohort A1|Healthcare workers and patients that have previously undertaken a swab or serology test to detect for the presence of SARS-CoV-2. Without the need to seek retrospective consent for the SARS CoV 2 Longitudinal Study, residual samples and derivatives from the Crick COVID -9 Consortium Testing centre and data will be used for the study
32980230|NCT04750356||Cohort A2|3,000 SARS-CoV-2 positive and 3,000 SARS-CoV-2 negative participants (randomly selected) from cohort A1 will be prospectively consented to the study. In addition, vaccine status will also be used to stratify the participants and recruit to the study.
32980231|NCT04750356||Cohort B|Employees at participating centres including but not limited to UCLH and The Francis Crick Institute who have their serology tested and/or are swabbed for viral (SARS-CoV-2 and seasonal viruses) detection as well as participants who are vaccinated will be prospectively consented to the study.
32980232|NCT04750356||Cohort C|Individuals recruited to other REC approved research studies where their samples are processed by the Crick COVID 19 Consortium Testing centre will also be consented in their existing study to allow the use of leftover study samples already collected and to be collected, for use in this longitudinal study.
32980233|NCT04746781|Active Comparator|Risk notification/education arm|We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
32980234|NCT04746781|Experimental|Mobile 360° Video intervention arm|After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
32980235|NCT04746781|Experimental|Motivation and Problem Solving (MAPS) arm|After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
32980236|NCT04744363|Experimental|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32980237|NCT04744363|Active Comparator|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32980238|NCT04744363|Active Comparator|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
32980239|NCT04736316|Experimental|Early CCLAD|Early community client-led ART delivery groups
32980240|NCT04729517|Active Comparator|Azelastine Hydrochloride|Patients that will receive azelastine hydrochloride are defined as the active control arm.
32980241|NCT04729517|Experimental|AI201901|Patients that will receive AI201901 are defined as the test arm.
32980242|NCT04727541|Experimental|Neoadjuvant therapy with Bintrafusp alfa|1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.
32980243|NCT04698525|Active Comparator|Valproate group|This is a well know antiepileptic drug with efficacy as a preventive tic treatment in episodic migraine
32980244|NCT04698525|Active Comparator|Memantine|This is a possible preventive treatment in episodic migraine
32980245|NCT04696133|Experimental|conventional training|children in this group will receive conventional program including stretching and strengthening exercise in addition to exercises to enhance fine motor skills for one hour for each child, three times per week along a period of three months
32980246|NCT04696133|Experimental|sensory integration training|Children in this group will receive designed sensory integration program, one hour for each child, three times per week along a period of three months. The program includes tactile, vestibular and proprioceptive stimulation and heavy work activities in addition to fine motor skills.
32980247|NCT04684576|Experimental|Explorer Mini First (AB Arm)|Children randomized into this arm will first trial a Permobil Explorer Mini powered mobility device over an 8-week intervention period, then trial a modified ride-on car over a second 8-week intervention period in their home and community environments.
32980248|NCT04684576|Active Comparator|Modified Ride On Car First (BA Arm)|Children randomized into this arm will first trial a modified ride-on car over an 8-week intervention period, then trial a Permobil Explorer Mini powered mobility device over a second 8-week intervention period in their home and community environments.
32980249|NCT04673162|Experimental|A SOC plus MP|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3
32980250|NCT04673162|Active Comparator|B SOC plus Pb|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo
32980251|NCT04665375|Experimental|DOR/3TC/TDF|100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)
32980252|NCT04658082|Other|Non invasive glucose monitor|Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab
32980253|NCT04650607||PHA SA CO|patients having a severe infection treated by injection of phages, with or without surgery
32980254|NCT04650607||PhageRESPONSE|ancillary study : Establish a biobanking of serums, plasmas and PBMC (Peripheral Blood Mononuclear Cells) of patients who have been treated with phage therapy for a bacterial infection.
32980255|NCT04647071|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
32980256|NCT04647071|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
32980257|NCT04638660|Experimental|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
32980258|NCT04638660|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
32980259|NCT04638244|Experimental|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
32980260|NCT04638244|Active Comparator|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
32980261|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
32980262|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
32980263|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
33412093|NCT03196973|Experimental|DF289 plus DF277|Otic solution
33412094|NCT03196973|Active Comparator|DF289|Otic solution
33412095|NCT03196973|Active Comparator|DF277|Otic solution
32980264|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
33105015|NCT04323319|Experimental|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
33105016|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
32980265|NCT04572568||experimental group|"Ruptured AVMs:~AVMs not involved vital eloquent areas, or more than 5 mm away from functional fiber bundles, microsurgery or hybrid surgery can be performed;~Targeted embolization for hemorrhagic predictors could be considered as a monotherapy; embolization can be used as an adjunctive strategy to reduce flow or volume before microsurgery or stereotactic radiosurgery (SRS).~SRS for patients with a volume less than 10ml and not in the acute phase(< 3months) of hemorrhage. Volume-stage or dose-stage can be used for giant AVMs involving important eloquent areas.~Conservation can be used for AVMs that are prone to severe disability due to intervention.~Unruptured AVMs:~Interventions are recommended if unruptured AVMs are assessed as being at high rupture risk, or have refractory epilepsy or acceptable postoperative neurological deficits, otherwise conservative treatment is recommended. The choice of intervention strategy was the same as for ruptured AVM."
32980266|NCT04572568||control group|Patients who had not received a multidisciplinary assessment to develop a treatment plan were included in the control group. It should be noted that the multidisciplinary team for AVM was formed in June 2018, so the prospective AVM cohort from August 2011 to June 2018 and the AVM cohort after June 2018 without comprehensive evaluation of treatment regimens by the multidisciplinary team served as the control group.
32980267|NCT04566081|Active Comparator|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
32980268|NCT04566081|Active Comparator|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
32980269|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
32980270|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
32980271|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
32980272|NCT04560036|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
32980273|NCT04531566|Experimental|Oral Feed Intervention Group|
32980274|NCT04531566|Active Comparator|Usual care|
32980275|NCT04524221|Experimental|PTG-100|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
32980276|NCT04524221|Placebo Comparator|Placebo|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
32980277|NCT04521179|Experimental|KN026 combined with KN046|KN026 combination therapy
32980278|NCT04504253|Experimental|Creatine monohydrate|"Week 1: Creatine monohydrate 5g PO QID~Week 2 up to Week 6: Creatine monohydrate 5g PO qday"
32980279|NCT04504253|Placebo Comparator|Placebo|"Week 1: Placebo 5g PO QID~Week 2 up to Week 6: Placebo 5g PO qday"
32862864|NCT04915170|Experimental|High intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
32980280|NCT04500951|Experimental|Optimized resting environment|"The optimized resting environment will consist of the following complex intervention.~Technically assisted noise control in regards of alarms in the patient room~Visual signing reminding staff that the patient is not to be disturbed during rest~Individual optimization of room environment according to information received from relatives~Individual optimization of room environment and positioning according to systematized knowledge on best practice in the intervention ward including auditory and visual stimuli"
32980281|NCT04500951|Other|Standard resting environment|Standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward.
32980282|NCT04487678|Experimental|Low-dose KE|141 mg/kg bodyweight of ketone esters
32980283|NCT04487678|Experimental|High-dose KE|282 mg/kg bodyweight of ketone esters
32980284|NCT04487249|Experimental|Vision Therapy|Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.
32862865|NCT04915170|Experimental|Low intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
32862866|NCT04922892|Experimental|Total Parathyroidectomy Alone|Total Parathyroidectomy Alone , without autotransplantation
32862867|NCT04922892|Active Comparator|Total Parathyroidectomy With Autotransplantation|Total Parathyroidectomy With Autotransplantation
32862868|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
32862869|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
32862870|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
33412096|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
32980285|NCT04487249|No Intervention|Observation|Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.
32980286|NCT04452175|Experimental|HIGH 5%|
32980287|NCT04452175|Active Comparator|LOW 1.7%|
32980288|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
32980289|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
32980290|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
32980291|NCT04444687||Control|Control patients, SARS-CoV-2-negative
32980292|NCT04431622|Experimental|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
32980293|NCT04430257|Experimental|PrEP for health|Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
32980294|NCT04430257|Active Comparator|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
32980295|NCT04425902|Experimental|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram [mg], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.
32980296|NCT04421677|Experimental|Phenylbutyrate|Open-label phenylbutyrate
32980297|NCT04418414|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
32980298|NCT04413240|Experimental|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
32980299|NCT04413240|Active Comparator|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
32980300|NCT04401943|Experimental|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
32980301|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
32980302|NCT04399200||Control group|Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)
32980303|NCT04380038|Active Comparator|Dupilumab|The dupilumab dose regimen selected for this study (300 mg q2w after an initial loading dose of 600 mg)
32980304|NCT04380038|Placebo Comparator|Placebo|A harmless substance that looks like the study drug, but which should have no effect. The placebo formulation used in this study contains all the ingredients present in the active drug, except the active ingredient (IL-4α antibody). Therefore, the risk related to this formulation should be no greater than the risk associated to the active drug.
32980305|NCT04370093|Experimental|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
32980306|NCT04370093|Experimental|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
32980307|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
32980308|NCT04347538|No Intervention|Control Group, No intervention|control group, no nasal irrigation
33412097|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
32980309|NCT04347538|Experimental|Saline Nasal Irrigation|Nasal irrigation BID with normal saline
32980310|NCT04347538|Experimental|Saline with Baby Shampoo Nasal Irrigation|Nasal irrigation BID with normal saline and 1/2 teaspoon baby shampoo
33105017|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
33105018|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
33412098|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
33323749|NCT03971981|Experimental|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
33323750|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
32980311|NCT04340206|Experimental|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
32980312|NCT04340206|Experimental|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
33323751|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
33323752|NCT03971903|Experimental|Attention bias modification treatment|12-session of ABMT
33323753|NCT03971903|Placebo Comparator|Placebo controls|12-session of placebo(i.e.,sham) training
33323754|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
33323755|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
33323756|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
32980313|NCT04340206|Experimental|Experimental Control|"Experimental Control:~Control group, no intervention (one third of the participants is randomly assigned to this group)"
33323757|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
32980314|NCT04334031|Experimental|IMMINeNT cohort|
32980315|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
32980316|NCT04330963||Healthy controls|Healthy control subjects without complaints of EDS and /or H.
32980317|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
33323758|NCT01126398||Ankle / dist. tibia fracture fixation|
33323759|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
33323760|NCT00253643|Experimental|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
33323761|NCT00253643|Experimental|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
33323762|NCT00253643|Experimental|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
33323763|NCT00253643|Placebo Comparator|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
33323764|NCT01222650|Experimental|KSO-0400 Low Dose|
33323765|NCT01222650|Experimental|KSO-0400 High Dose|
33323766|NCT01222650|Experimental|Silodosin|
33323767|NCT01222650|Placebo Comparator|Placebo|
33323768|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
33323769|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
33323770|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
33323771|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
33323772|NCT04856488|Experimental|Iodine Potassium Iodide solution|Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment
33323773|NCT04856488|No Intervention|No intervention|Participants continue with standard preoperative treatment
33323774|NCT01126554||Critically ill patients|
33323775|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
32980318|NCT04330963||Pediatric Hypersomnolence group|Pediatric group aged 10-18. Same criteria for inclusion and exclusion apply as for the adult group.
32980319|NCT04323501|Experimental|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
32980320|NCT04323501|Active Comparator|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
32980321|NCT04318951|Experimental|Intensive communicative-pragmatic social interaction.|Intensive Language-Action Therapy (ILAT).
32980322|NCT04318951|Other|Standard care.|All participants will receive standard care.
32980323|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
32980324|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
32980325|NCT04293757|Experimental|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
32980326|NCT04293757|No Intervention|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
32980327|NCT04293601|Experimental|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:~appropriate use of hydrocolloid, headbands, masks and prongs~frequently assess skin integrity~humidity and heat gases"
32980328|NCT04293601|Other|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
32980329|NCT04257565|Active Comparator|Control group|The Control Group will receive usual and customary care from their vascular specialist.
32980330|NCT04257565|Experimental|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
32980331|NCT04247880|Experimental|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
32980332|NCT04247880|No Intervention|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
32980333|NCT04226053|Experimental|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
32980334|NCT04226053|No Intervention|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
32980335|NCT04223362|Experimental|Pulmonary rehabilitation + Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
32980336|NCT04223362|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates physical activity recommendations.
32980337|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
32980338|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
32980339|NCT04203472|Experimental|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
32980340|NCT04203472|Active Comparator|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
32980341|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
32980342|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
32980343|NCT04166071|Active Comparator|Naltrexone|
32980344|NCT04166071|Placebo Comparator|Placebo|
32980345|NCT04165213|Experimental|Online training site|"Ten participating Trinity PACE Organizations will participate via webinar in a brief orientation/ training to the study and project logistics. Next, Trinity Health PACE organizations will be randomized into two groups using the re-randomization procedures described in the paragraph below; 5 PACE organizations will serve as the control site in which training will be provided via the traditional high intensity face-to-face.; 5 PACE organizations will serve as the comparison and be trained through the online training site. Prior to randomization, we will carefully examine PACE organizations on important variables such as size, location (urban; rural) percent of persons with dementia, and staff: participant ratio. In each site, one occupational therapist (OT) and one nurse (RN) will be trained (e.g., 5 OTs and 5 RNs in traditional sites; 5 OTS and 5 RNS in online training sites for a total of 10 OTs and 10 RNs or 20 health providers)."
33412099|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
33412100|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
33412101|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
33412102|NCT01337557|Experimental|Bepotastine|
33412103|NCT01337713|Experimental|Swedish Massage|
33412104|NCT01337713|Sham Comparator|Light Touch|
33412105|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
33412106|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
33412107|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
33412108|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
33412109|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
32980346|NCT04165213|Experimental|COPE-PACE participant outcomes with online training|The efficacy of the COPE program training on PACE participant outcomes by type of COPE training will be evaluated in this arm. Each of the PACE organizations will enroll 5 persons with dementia and their caregivers in the study. This will yield 50 family dyads or 100 subjects (25 dyads in traditional training sites and 25 dyads in online training sites). Dyads will be followed for 4 months. Non-inferiority analysis will be used to assess whether dyads will yield the same or better outcomes regardless of how PACE staff were trained.
33105019|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
33105020|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
33105021|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
33105022|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
33412110|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
33412111|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
33412112|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
33412113|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
33412114|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
33412115|NCT04403737|No Intervention|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
33412116|NCT04403737|Experimental|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
33105023|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
33412117|NCT05186389||"Control Group"|"15 non-obese participants considered metabolically-healthy : control group"
33412118|NCT05186389||Obese group (Ob)|"15 severely obese participants, candidates for bariatric surgery, but without T2D: obese group (Ob)"
33412119|NCT05186389||Obese and Type 2 Diabetes group (ObD)|"15 participants who are both severely obese, candidates for bariatric surgergy and diagnosed with T2D: obese and diabetic group (ObD)."
33412120|NCT04360837|Experimental|PEEP incremental-decremental alveolar recruitment|"installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters~implementation of recruitment:~increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O~decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20~end inspiratory hold manoeuvre at every PEEP level~recording closing parameters~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
33105024|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
33412121|NCT01337791|No Intervention|control|
33412122|NCT01337791|No Intervention|telbivudine|
32980347|NCT04134871|Experimental|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
32980348|NCT04134871|No Intervention|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
32980349|NCT04105660|Experimental|Intervention arm|EEG monitoring in addition to standard monitoring (clinical parameters and BIS index)
32980350|NCT04105660|Active Comparator|Control arm|Standard monitoring including clinical parameters and BIS index
32980351|NCT04076735|Experimental|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
32980352|NCT04076735|Active Comparator|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
32980353|NCT04072146|Experimental|Varenicline oral tablet 1mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|OC-01 0.12 mg was administered intranasally 50 ul into each nostril in a fasted state
33323776|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
32980354|NCT04072146|Active Comparator|OC-01 (varenicline solution) nasal spray 0.12 mg, then Varenicline oral tablet 1 mg|Varenicline oral tablet 1mg was administered orally in a fasted stated with 200 ml water
32980355|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
32980356|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
32980357|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
33323777|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
33323778|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
33323779|NCT04855474|Experimental|Low Protein|0.2 g/kg/day of protein provided as crystalline amino acid made after egg protein.
33323780|NCT04855474|Experimental|Moderate Protein|1.2g/kg/day of protein provided as crystalline amino acid made after egg protein.
33323781|NCT04855474|Experimental|High Protein|2.0 g/kg/day of protein provided as crystalline amino acid made after egg protein.
33323782|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
32980358|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
32980359|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
32980360|NCT04062214|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
33323783|NCT04813900|Experimental|Patient suspected to suffer from interstitial syndrome needing an arterial blood gas analysis|
33323784|NCT01126788||PADnet + testing|
33323785|NCT01126788||Parks Flo-lab Test|
33323786|NCT04806802|Experimental|APIOC Sphere or Astigmatism|Single Vision Spherical or Toric Contact Lens
33323787|NCT03934320|Other|FAMCAT|
33323788|NCT01376830||COPD patients|
33323789|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
33323790|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
33323791|NCT04674436|Experimental|6 minute walking break|Participants will walk casually for 6 minutes following one hour of game play, then continue play for one more hour.
33323792|NCT04674436|Experimental|6 minute rest break|Participants will rest supine for 6 minutes following one hour of game play, then continue play for one more hour.
33323793|NCT04674436|No Intervention|Continuous play|Participants will play continuous for 2 hours.
33323794|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
33323795|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
32980361|NCT04062214|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
32980362|NCT04058847|Experimental|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
32980363|NCT04058847|No Intervention|Control|The control group uses standard regime (business as usual).
32980364|NCT04040153|Experimental|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
32980365|NCT04040153|No Intervention|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
32980366|NCT04001972|Experimental|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
32980367|NCT04001972|Active Comparator|Control group|Brief advice (AWARD model) + regular SMS
32980368|NCT03996265|Experimental|Arm I (bupropion hydrochloride controlled-release)|Patients receive bupropion hydrochloride controlled-release PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
32980369|NCT03996265|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
32980370|NCT03987906|Experimental|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
32980371|NCT03987906|No Intervention|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
32980372|NCT03963570|Experimental|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
32980373|NCT03963570|Other|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
32980374|NCT03945084|Experimental|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
32980375|NCT03945084|Other|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
32980376|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
32980377|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
32980378|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
32980379|NCT03914846|Experimental|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
32980380|NCT03914846|Experimental|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted [at the discretion of the treating physician] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
32980381|NCT03914846|Experimental|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
32980382|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
32980383|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
32980384|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
32980385|NCT03886467|No Intervention|Control|community development activities only.
33323796|NCT00221195|Other|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
33323797|NCT00221195|Other|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
33323798|NCT05760820|Experimental|Intervention Group|Access to the digital intervention post-baseline questionnaire and randomization.
33323799|NCT05760820|No Intervention|Control Group|Control group will gain access to the digital intervention after the 3-month follow-up.
33323800|NCT03933930|Experimental|Lactate-directed therapy|
33323801|NCT03933930|Experimental|Goal-directed therapy|
33323802|NCT04646590|Experimental|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
33323803|NCT04646590|Placebo Comparator|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
33323804|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
33323805|NCT03931668|Experimental|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
33323806|NCT03931668|Experimental|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
33323807|NCT03931668|Experimental|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
32980386|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
33323808|NCT03931668|Experimental|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
33323809|NCT03931668|Experimental|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
33412123|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
33323810|NCT03931668|Experimental|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
33323811|NCT03931668|Experimental|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
33323812|NCT04595188|Experimental|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
33323813|NCT00220805|Experimental|Group 1|
33323814|NCT00220805|Placebo Comparator|Group 2|
33323815|NCT01220934||Cohort|
33323816|NCT05760742|Placebo Comparator|Placebo group|2 capsules of Maltodextrin per day
33323817|NCT05760742|Experimental|MicAlgae100|2 capsules per day containing 100mg of microalgae based ingredient
33323818|NCT05760742|Experimental|MicAlgae250|2 capsules per day containing 250mg of microalgae based ingredient
33323819|NCT05760742|Experimental|MicAlgae500|2 capsules per day containing 500mg of microalgae based ingredient
33323820|NCT00220727|Experimental|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
33323821|NCT00220727|Experimental|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
33323822|NCT01221012||men wearing Semipermeable garment|
33323823|NCT01221012||air permeable garment type BP2|
33323824|NCT01221012||air permeable garment type BP3|
33323825|NCT01221012||air permeable garment type MO|
33323826|NCT01221012||air permeable garment type BP1|
33323827|NCT01225770|Experimental|Green tea|Gargling with green tea
33323828|NCT01225770|Active Comparator|water|Gargling with water
33323829|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
33323830|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
33323831|NCT04495816|Active Comparator|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
33323832|NCT04495816|Sham Comparator|Placebo/Control|2 softgels per day for 6 weeks
33323833|NCT03971747|Experimental|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
33323834|NCT03931824|Experimental|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times."
33323835|NCT03931824|Sham Comparator|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
33323836|NCT04485286|Experimental|Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy|Lung cancer or pancreatic cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
33323837|NCT03971357|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
33323838|NCT03971357|Placebo Comparator|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
33323839|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
33323840|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
33323841|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
33323842|NCT03971513|No Intervention|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
33323843|NCT03971513|Experimental|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
33323844|NCT04439734|Experimental|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
33323845|NCT04439734|No Intervention|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
33323846|NCT04424212|Experimental|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
32980387|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
32980388|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
32980389|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
32980390|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
32980391|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
32980392|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
32980393|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
32980394|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
32980395|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
32980396|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
32980397|NCT03771612|Active Comparator|Naproxen|
32980398|NCT03771612|Placebo Comparator|Placebo|
32980399|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
32980400|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
32980401|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
32980402|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
32980403|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
32980404|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
32980405|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
32980406|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
32980407|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
33412124|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
33412125|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
33412126|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
33412127|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
33412128|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
33412129|NCT01334203|Experimental|Ranolazine|
32980408|NCT03734211|Experimental|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
32980409|NCT03734211|Placebo Comparator|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
32980410|NCT03730974|Experimental|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
32980411|NCT03730974|Experimental|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
32980412|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
32980413|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
32980414|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
32980415|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
32980416|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
33412130|NCT01334203|Placebo Comparator|Placebo|
32980417|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
32980418|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
32980419|NCT03695068|Experimental|RISE Intervention|Reading Instruction for Students who are English Learners (El) with Reading Difficulties (RISE): The RISE intervention is a multi-phase treatment that first accelerates basic skills through an emphasis on word reading (e.g., multi-syllable words, morphology, high-frequency words commonly misread; Phase 1), and then provides a longer-term emphasis on fluency and comprehension through systematically varying text difficulty and genre (Phase 2). To assure that students have minimal loss during the summer, RISE adds a summer Book Club that includes provision of books with comprehension activities for students in the RISE intervention arm (Phase 3). This entire approach takes two full academic years and two summers to be replicated across two cohorts.
33105025|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
33323847|NCT04424212|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
33323848|NCT01221324||Patients after open resection of colorectal cancer|
33323849|NCT05760430|Experimental|Experimental Group|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
33323850|NCT05760430|Active Comparator|Control group|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
33323851|NCT05760352|No Intervention|Control group|Self-paced exercise
33323852|NCT05760352|Experimental|Intervention Group: eccentric cycling exercise|Received eccentric cycling exercise
33323853|NCT05760352|Experimental|Intervention Group: eccentric cycling exercise with helmet ventilation|Eccentric cycling exercise combined with helmet ventilation
33323854|NCT04331158|Experimental|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
33323855|NCT04331158|Placebo Comparator|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
33323856|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
33323857|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
33323858|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
33323859|NCT04310566|Experimental|Test/Control|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
33323860|NCT04310566|Experimental|Control/Test|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
33323861|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
33323862|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
33323863|NCT01221402|Experimental|Extended-release niacin|
33323864|NCT01221402|Placebo Comparator|Placebo|
33323865|NCT04215952|Experimental|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
33323866|NCT04215952|Active Comparator|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
33323867|NCT01221480||Beta Blocker Use|
33323868|NCT01221480||No beta blocker use|
33323869|NCT04214860|Experimental|APR-246|APR-246 4.5 g/day
33323870|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
33323871|NCT04165408|Experimental|Device Use|Only one arm
33323872|NCT01126866|Experimental|preoperative chemotherapy|
33323873|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
33323874|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
33323875|NCT04103554|Experimental|sacubitril/valsartan|
33323876|NCT04103554|Active Comparator|Standard of care|Standard of care for treating blood pressure per center protocols
33323877|NCT03931434|Active Comparator|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
33323878|NCT03931434|Placebo Comparator|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
33323879|NCT05760196|Experimental|Recurrent or metastatic advanced head and neck malignancy|Patients with a clear pathological diagnosis, imaging diagnosis, and history, no clear recommended standard treatment or inability to tolerate standard treatment, and a clear measurable lesion
33323880|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
33323881|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
33323882|NCT00252239|Active Comparator|1|tenecteplase
33323883|NCT00252239|Active Comparator|2|tissue plasminogen activator, tPA
33323884|NCT04097158||Upper Motor Neuron predominant ALS|
33323885|NCT04097158||Lower Motor Neuron predominant ALS|
33323886|NCT04097158||Bulbar predominant ALS|
33323887|NCT04097158||Generalized ALS|
33323888|NCT01126944|Experimental|system heart mate II|left ventricular assist device
32980420|NCT03695068|No Intervention|Business as Usual Comparison Condition|Participants assigned to the Business as Usual (BAU)or comparison condition will participate in an elective class that includes such options as music, cooking, film, study time, or high stakes test preparation.
32980421|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
32980422|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
32980423|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
32980424|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
32980425|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
32980426|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
32980427|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
32980428|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
32980429|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
32980430|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
32980431|NCT03578393|Experimental|Intervention|Will visualize an Educational Virtual Reality video in preoperative period to reduce perioperative anxiety.
32980432|NCT03578393|No Intervention|Usual treatment|Will be applied the usual treatment (provide information on the anaesthetic-surgical process).
32980433|NCT03569449|Experimental|Group 1- Goat|Clinic-based visit, usual care, standard pediatric surveillance, and structured visits
32980434|NCT03569449|Experimental|Group 2- Cow|Clinic-based visit, usual care, enhanced pediatric surveillance, and structured visits
32980435|NCT03569449|Experimental|Group 3- Horse|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and structured visits
32980436|NCT03569449|Experimental|Group 4- Pig|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and structured visits
32980437|NCT03569449|Experimental|Group 5- Sheep|Clinic-based visit, usual care, standard pediatric surveillance, and individually-tailored visits
32980438|NCT03569449|Experimental|Group 6- Llama|Clinic-based visit, usual care, enhanced pediatric surveillance, and individually-tailored visits
32980439|NCT03569449|Experimental|Group 7- Cat|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and individually-tailored visits
32980440|NCT03569449|Experimental|Group 8- Dog|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and individually-tailored visits
32980441|NCT03569449|Experimental|Group 9- Donkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and structured visits
32739145|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
32980442|NCT03569449|Experimental|Group 10- Bear|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and structured visits
32980443|NCT03569449|Experimental|Group 11- Tiger|Clinic and community visits, technology enhanced care coordination, standard pediatric surveillance, and structured visits
32980444|NCT03569449|Experimental|Group 12- Lion|Clinic and community visits, technology enhanced care coordination, enhanced pediatric surveillance, and structured visits
32980445|NCT03569449|Experimental|Group 13- Monkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and individually-tailored visits
32980446|NCT03569449|Experimental|Group 14- Zebra|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and individually-tailored visits
32980447|NCT03569449|Experimental|Group 15- Elephant|Clinic and community visits, technology-enhanced care, standard pediatric surveillance, and individually-tailored visits
32980448|NCT03569449|Experimental|Group 16- Giraffe|Clinic and community visits, technology-enhanced care, enhanced pediatric surveillance, and individually-tailored visits
32980449|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
32980450|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
33105026|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
33412131|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
33412132|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
33412133|NCT04262791|Experimental|Healthy Volunteers|Healthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
33412134|NCT04262791|Experimental|Participants With Atopic Dermatitis (AD)|Participants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
33412135|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
33412136|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
33105027|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
33105028|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
33412137|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
33412138|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
33412139|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
33412140|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
33412141|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
33412142|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
32980451|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
32980452|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
33412143|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
33412144|NCT01569165|No Intervention|no fluoride therapy|control group
33412145|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
33412146|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
33412147|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
33412148|NCT04259749|Active Comparator|Status Quo|The StoreLab power wall will display all tobacco products.
33412149|NCT04259749|Experimental|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
33412150|NCT04259749|Experimental|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
33412151|NCT01382355||Kidney transplant|
33412152|NCT03575793|Experimental|Phase I (Dose Escalation): nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.~Plinabulin escalation is as follows:~Level -1 : 13.5mg/m^2~Level 1 (start) : 20mg/m^2~Level 2 : 30mg/m^2"
33412153|NCT03575793|Experimental|Phase II: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
33412154|NCT02535091|Experimental|YKP3089|Multiple dose
33412155|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
33412156|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
33412157|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
33412158|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
32980453|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
32980454|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
32980455|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
32980456|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
32980457|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32980458|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
32980459|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
32980460|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
32980461|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
32980462|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
32980463|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
32980464|NCT03495713|Experimental|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
32980465|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
32980466|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
32980467|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
32980468|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
32980469|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
32980470|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
32980471|NCT03444753|Experimental|Arm A|BMS-986299
32980472|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
32980473|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
32980474|NCT03360838||CogCheck application|Performance in the application
32980475|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
32980476|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
32980477|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
32980478|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
32980479|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
32980480|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
32980481|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
32980482|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
32980483|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
32980484|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
32980485|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
32980486|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
32980487|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
32980488|NCT03203694|Experimental|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
32980489|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
32980490|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
32980491|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
32980492|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
32980493|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
32980494|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
32980495|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
32980496|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
32980497|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
32980498|NCT03076723|Sham Comparator|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
32980499|NCT03076723|Experimental|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
32980500|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980501|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980502|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980503|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980504|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980505|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
32980506|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
32980507|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
32980508|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss as well as 3, 4, 5 and 6 years post loss.
32980509|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) as well as 3, 4, 5 and 6 years post loss.
32980510|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
32980511|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
32980512|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
33323889|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
32980513|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
32980514|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
33105029|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
33323890|NCT05760118||Diabetes Mellitus Patients|Patients diagnosed with diabetes mellitus.
33323891|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
33323892|NCT04086550|Experimental|Investigational arm|Application of LIQOSEAL after closure of dura mater
33323893|NCT04086550|Active Comparator|Control arm|Application of Adherus or DurSeal after closure of dura mater
33323894|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
32980515|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
32980516|NCT02884323|Experimental|geko device arm|
32980517|NCT02786875|Experimental|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
32980518|NCT02786875|Active Comparator|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
32980519|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
32980520|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
32980521|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
32980522|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
32980523|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
32980524|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
32980525|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
32980526|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
32980527|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
32980528|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
32980529|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
32980530|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
32980531|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
32980532|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
32980533|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
32980534|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
32980535|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
32980536|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32980537|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
32980538|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
32980539|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
32980540|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
32980541|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
32980542|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
32980543|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
32980544|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
32980545|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.~Fermented red clover isoflavones in aglycone form"
32980546|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.~Fermented red clover isoflavones in aglycone form"
32980547|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt~Fermented red clover isoflavones in aglycone form"
32980548|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid~Fermented red clover isoflavones in aglycone form"
32980549|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones~Unfermented glycosides (as aglycone equivalents)"
32980550|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
32980551|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
32980552|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
32980553|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
32980554|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
32980555|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
32980556|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
32980557|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
32980558|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
32980559|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
32980560|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
32980561|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
32980562|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
32980563|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
32980564|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
32980565|NCT01596621|Experimental|Bendamustine|Participants will receive bendamustine hydrochloride administered at 120 milligrams (mg)/square meter (m^2) intravenously (IV) as a 60-minute infusion, and not more than 120 minutes, on Days 1 and 2 in each 21-day treatment cycle for 6 planned cycles and up to 8 total cycles.
32980566|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
32980567|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
32980568|NCT01231906|Experimental|Arm A (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9."
32980569|NCT01231906|Experimental|Arm B (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19."
32980570|NCT01079325|Experimental|SB-509|
32980571|NCT01079325|Placebo Comparator|Placebo|Saline
32980572|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
32980573|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
32980574|NCT00787865||Control|Children with no disease and normal enzyme levels
32980575|NCT00787865||Motor Disability|Children at risk of developing motor disability
32980576|NCT00704561|Active Comparator|DES - Zotarolimus Drug eluting stents|Zotarolimus Drug eluting stents in overlap
32980577|NCT00704561|Active Comparator|BMS -Bare metal stent|Bare metal stent
32980578|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
32980579|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
32980580|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
32980581|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
32980582|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
32980583|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
32980584|NCT01425905|Experimental|Depression Prevention|
33323895|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
32980585|NCT01425905|Active Comparator|Health Education|
32980586|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~Parent education sessions once a week for 2 hours each session over the 5-month period."
32980587|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
32980588|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
32980589|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
33323896|NCT05200000|Experimental|SygeLIX-Coll-T|Extract of umbilical cord lining constituted of Wharton's jelly put in suspension in microvials. Instillation by the patient in the sick eye of 1 drop 5 times a days (morning, noon, afternoon, evening and bedtime) for 40 days.
32980590|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
32980591|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
32980592|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~* The dosage regimen would be escalated gradually until MTD had been found out."
32980593|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
32980594|NCT01426022|Experimental|Ambiance|"Pleasant ambiance~Unpleasant ambiance"
32980595|NCT01426035|Experimental|GROUP 1|
32980596|NCT01426035|Active Comparator|GROUP 2|
32980597|NCT01426048||Patients operated on with the TVT|
32980598|NCT01426061|Experimental|Reflexology plus conventional treatment|
33323897|NCT01221558|Experimental|6mg lycopene|
32980599|NCT01426061|Experimental|Homeopathy plus conventional treatment|
32980600|NCT01426061|No Intervention|Conventional treatment|
32980601|NCT01426087|Experimental|endoscopic and somatostatin treatment|
32980602|NCT01426087|Other|endoscopic therapy|
32980603|NCT01426100|Experimental|CKD-828 40/2.5mg|
32980604|NCT01426100|Experimental|CKD-828 40/5mg|
32980605|NCT01426100|Active Comparator|Telmisartan 80mg|
32980606|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
32980607|NCT01426139|Experimental|Biotronik Orsiro DES|
32980608|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
32980609|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
32980610|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
32980611|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
32980612|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
33417320|NCT03074318|Experimental|Phase 1 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
32980613|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
32980614|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
32980615|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
32980616|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
32980617|NCT01426282|No Intervention|control|
32980618|NCT01426282|Experimental|nurse education|
32980619|NCT01426295|Experimental|Caphosol|
32980620|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
32980621|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
32980622|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
32980623|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
32980624|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
32980625|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
32980626|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
32980627|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
32980628|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
32980629|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
32980630|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
32980631|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
32980632|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
32980633|NCT01426490|Other|Vitamin C|Vitamin C as control group.
32980634|NCT01426490|Experimental|Vitamin B6|
32980635|NCT01426490|Experimental|Folic acid|
32980636|NCT01426490|Experimental|Vitamin B6 plus folic acid|
32980637|NCT01426542|Experimental|Topiramate|
32980638|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
32980639|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
32980640|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
32980641|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
32980642|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
33105030|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
33105031|NCT04682171|Experimental|Low level Laser Therapy|Low Level Laser Therapy and Conventional Exercise therapy
32980643|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
32980644|NCT01426633|Experimental|Gemcitabine + Trabectedin|
32980645|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
32980646|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
32980647|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
32980648|NCT01426659|Active Comparator|"no stimulation say and do"|
32980649|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
32980650|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
32980651|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
32980652|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
32980653|NCT01426776|Other|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
32980654|NCT01426802|Experimental|Vildagliptin 50 bid|
32980655|NCT01426815|Placebo Comparator|Placebo|
32980656|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
32980657|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
32980658|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
32980659|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
32980660|NCT01426906|Experimental|Study A|
32980661|NCT01426906|Experimental|Study B|
32980662|NCT01426919||Suspected traumatic brain injury with head CT|
32980663|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
32980664|NCT01426971|Active Comparator|Ibuprofen|2 capsules
32980665|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
32980666|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
32980667|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
32980668|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
32980669|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
32980670|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
32980671|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
32980672|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
32980673|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
32980674|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
32980675|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
32980676|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
32980677|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
32980678|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
32980679|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
32980680|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
32980681|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
32980682|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
32980683|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
32980684|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
32980685|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
32980686|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
32980687|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
32980688|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
32980689|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
32980690|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
32980691|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
32980692|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
32980693|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
32980694|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
32980695|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
32980696|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
32980697|NCT01427244|Experimental|Trastuzumab|Open Label
32980698|NCT01427257|Active Comparator|PB1023 Formulation A|
32980699|NCT01427257|Active Comparator|PB1023 Formulation B|
32980700|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
32980701|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
32980702|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
32980703|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
32980704|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
32980705|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
32980706|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
32980707|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
33412159|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
32980708|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
32980709|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
32980710|NCT01427335|Experimental|calcium|Calcium intravenous infusion
32980711|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
32980712|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
32980713|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
32980714|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
32980715|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
32980716|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
32980717|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
32980718|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
32980719|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
32980720|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
32980721|NCT01427439||Major Depressive Disorder|
32980722|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
32980723|NCT01427465|Experimental|Consult|Consult
32980724|NCT01427465|Experimental|Newsletter|Newsletter
32980725|NCT01427465|Experimental|Parent Letter|Parent Letter
32980726|NCT01427465|Active Comparator|Control|Control
33105032|NCT04682171|Active Comparator|Conventional ExerciseTherapy|Conventional ExerciseTherapy
33105033|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
32980727|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
32980728|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
32980729|NCT01427491|Active Comparator|Aquacel® Ag|
32980730|NCT01427491|Active Comparator|Mepilex® Border Ag|
32980731|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
32980732|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
32980733|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
32980734|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
32980735|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
32980736|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
32980737|NCT01427621|Experimental|RIPCcom group|
32980738|NCT01427621|No Intervention|Control group|
32980739|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
32980740|NCT01427634|Other|Control|Usual Care
32980741|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
32980742|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
32980743|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
32980744|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
32980745|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
32980746|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
32980747|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
32980748|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
32980749|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
32980750|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
32980751|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
32980752|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
32980753|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
32980754|NCT01427816|Placebo Comparator|Placebo|
32980755|NCT01427829|Experimental|Intervention (CaPRA)|
32980756|NCT01427829|No Intervention|Control (usual care)|
32980757|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
32980758|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
32980759|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
32980760|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
32980761|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
32980762|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
32980763|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
32980764|NCT01427868|Experimental|LB80380 maleat salt|
32980765|NCT01427868|Active Comparator|LB80380 free base|
32980766|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
32980767|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
32980768|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
32980769|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
32980770|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
33105034|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
32980771|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
32980772|NCT01427998|Placebo Comparator|placebo|matched placebo
32980773|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
32980774|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
32980775|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
32980776|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
32980777|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
32980778|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
32980779|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
32980780|NCT01428141|Experimental|E7050|
32980781|NCT01428154|Experimental|Darbepoetin alfa|
32980782|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
32980783|NCT01428180||Indomethacin|Infants treated with Indomethacin
32980784|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
32980785|NCT01428180||Ligation|Infants undergoing surgical ligation
32980786|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
32980787|NCT01428206|No Intervention|control|Usual care is performed for the control group
32980788|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
32980789|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
32980790|NCT01428232|No Intervention|usual care|
32980791|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
32980792|NCT01428284|Experimental|001|Canagliflozin/Probenecid
32980793|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
32980794|NCT01428297|Experimental|Part 2 BPR277|
32980795|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
32980796|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
32980797|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
32980798|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
32980799|NCT01428349|Experimental|Attention to Context|
32980800|NCT01428349|Experimental|Affective Cognitive Control|
32980801|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
32980802|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
32980803|NCT01428388|Active Comparator|Bevacizumab|
32980804|NCT01428388|Active Comparator|Ranibizumab|
32980805|NCT01428401|Experimental|Arm A|
32980806|NCT01428401|Placebo Comparator|Arm B|
32980807|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
32980808|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
32980809|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
32980810|NCT01428440|Other|no treatment|
32980811|NCT01428466|Experimental|GSK2585823|external preparation
32980812|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
32980813|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
32980814|NCT01428466|Placebo Comparator|Vehicle|external preparation
32980815|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
32980816|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
32980817|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
32980818|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
33105035|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
33323898|NCT01221558|Experimental|15mg lycopene|
33323899|NCT01221558|Placebo Comparator|placebo|
33323900|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
33323901|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
32980819|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
32980820|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
32980821|NCT01428505|Other|no treatment|
32980822|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
32980823|NCT01428531||Patients prescribed fondaparinux|
32980824|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
32980825|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
32980826|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
32980827|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
32980828|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
32980829|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
32980830|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
32980831|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
32980832|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
32980833|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
32980834|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
32980835|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
32980836|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
32980837|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
32980838|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
32980839|NCT01428674|Experimental|10 minutes reading|
32980840|NCT01428674|Experimental|20 minutes touch|
32980841|NCT01428674|Experimental|20 minutes reading|
32980842|NCT01428674|Experimental|10 minutes touch|
32980843|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
32980844|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
32980845|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
32980846|NCT01428726|Placebo Comparator|Placebo|
32980847|NCT01428726|Experimental|NT-KO-003 low dose|
32980848|NCT01428726|Experimental|NT-KO-003 high dose|
32980849|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
32980850|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
32980851|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
32980852|NCT01428817|Active Comparator|Carbetocin 20mcg|
32980853|NCT01428817|Active Comparator|Carbetocin 40mcg|
32980854|NCT01428817|Active Comparator|Carbetocin 60mcg|
32980855|NCT01428817|Active Comparator|Carbetocin 80mcg|
32980856|NCT01428817|Active Comparator|Carbetocin 100mcg|
32980857|NCT01428830|Experimental|7-day catheterization|
32980858|NCT01428830|Active Comparator|14-day catheterization|
32980859|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
32980860|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
32980861|NCT01428869||statin+ASA+dutasteride|
32980862|NCT01428869||statin+ASA|
32980863|NCT01428869||dutasteride+statin|
32980864|NCT01428869||dutasteride+ASA|
32980865|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
32980866|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
32980867|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
32980868|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
33105036|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
33105037|NCT00547560|Other|GSI+Placebo|
32980869|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
32980870|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
32980871|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
32980872|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
32980873|NCT01428960|Experimental|Palm Mid Fraction|
32980874|NCT01428960|Experimental|Shea Butter|
32980875|NCT01428960|Experimental|High Oleic Sunflower Oil|
32980876|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
32980877|NCT01428986||No maraviroc|Those who do not take maraviroc
32980878|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
32980879|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
32980880|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
32980881|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
32980882|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32980883|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
32980884|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
32980885|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
32980886|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
32980887|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
32980888|NCT01429129|Experimental|Nicotine Replacement Therapy|
32980889|NCT01429129|No Intervention|Control|
32980890|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
32980891|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
32980892|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
32980893|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
32980894|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
32980895|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
32980896|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
32980897|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
32980898|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
32980899|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
32980900|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
32980901|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
32980902|NCT01429324||Cardiac disease|Aortic arch surgery
32980903|NCT01429337|Experimental|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
32980904|NCT01429337|Experimental|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
32980905|NCT01429337|Experimental|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
32980906|NCT01429337|Experimental|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
32980907|NCT01429337|Experimental|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
32980908|NCT01429363|Experimental|Targeted disc decompression|
32980909|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
32980910|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
32862871|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
32980911|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
32980912|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
32980913|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
32980914|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
32980915|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
32980916|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
32980917|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
32980918|NCT01429480|Active Comparator|TAP Block|
32980919|NCT01429480|Active Comparator|II/IH Block|
32980920|NCT01429480|Active Comparator|Control Group|
32980921|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
32980922|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
32980923|NCT01429519|Experimental|Treatment|
32980924|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
32980925|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
32980926|NCT01429571||Systemic and local antibiotics|
32980927|NCT01429571||Local antibiotics|
32980928|NCT01429571||No antibiotics|
32980929|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
32980930|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
32980931|NCT01429636|Experimental|Applied Relaxation (AR)|
32980932|NCT01429636|Experimental|Modified Relaxation (MR)|
32980933|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
32980934|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
32980935|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
32980936|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
32980937|NCT01429675|Active Comparator|Bonviva|
32980938|NCT01429675|Experimental|DP-R206|
32980939|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
32980940|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
32980941|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
32980942|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
32980943|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
32980944|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
32980945|NCT01429740|Experimental|PF-05180999|
32980946|NCT01429740|Placebo Comparator|Placebo|
32980947|NCT01429753|Active Comparator|Standard LV lead placement|
32980948|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
32980949|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
32980950|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
32980951|NCT01429818|Experimental|Glimepiride/metformin|
32980952|NCT01429818|Active Comparator|Metformin|
32980953|NCT01429831|Experimental|Aripiprazole|
32980954|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
32980955|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
32980956|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
32980957|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
32980958|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
32980959|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
32980960|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
32980961|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
32980962|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
32980963|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
32980964|NCT01429935|Active Comparator|Ginger powder|
32980965|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
32980966|NCT01429935|Placebo Comparator|placebo|capsules contain starch
32980967|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
32980968|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
32980969|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
32980970|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
32980971|NCT01429974||volunteers|
32980972|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
32980973|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
32980974|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
32980975|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
32980976|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
32980977|NCT01430065|Experimental|Tacrolimus and ASP015K|
32980978|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
32980979|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
32980980|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
32980981|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
32980982|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
32739146|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
32980983|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
32980984|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
32739147|NCT05374187|Experimental|Active eTNS|Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.
32980985|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
32980986|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
32980987|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
32980988|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
32980989|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
32980990|NCT01430208|Active Comparator|mini-resectoscope|
32980991|NCT01430208|Active Comparator|tradiorional resectoscope|
32980992|NCT01430208|Active Comparator|bettocchi resectoscope|
32980993|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
32980994|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
32980995|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
32980996|NCT01430247|Other|Amblyopia screening|
32980997|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
32980998|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
32980999|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
32981000|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
32981001|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
32981002|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
32981003|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
32981004|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
32981005|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
32981006|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
32981007|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
32981008|NCT01430338||BAT|brown adipose tissue detected, undetected
32739148|NCT05374187|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.
32739149|NCT03202381|Experimental|Degarelix|
32981009|NCT01430364|Active Comparator|BIOSS implantation|
32981010|NCT01430377|Experimental|SB predilatation|
32981011|NCT01430416|Experimental|AEB071|
32981012|NCT01430429|Experimental|NI-0801|
32981013|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
32981014|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
32981015|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
32981016|NCT01430494||No treatment|
32981017|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
32981018|NCT01430507|Experimental|High Dose|High Dose Revamilast
32981019|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
32981020|NCT01430507|Experimental|Low dose|Low dose Revamilast
32981021|NCT01430520|Active Comparator|Escitalopram|
32981022|NCT01430520|Placebo Comparator|Placebo|
32981023|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
32981024|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
32981025|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
32981026|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
32981027|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
32981028|NCT01430650|Experimental|Oral strogen|
32981029|NCT01430650|Experimental|Transdermal strogen|
32981030|NCT01430663||Hematological patients with proven or probable aspergillosis|
32981031|NCT01430663||Hematological patients with possible aspergillosis|
32981032|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
32981033|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
32981034|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
32981035|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
32981036|NCT01430715|Experimental|Outside play|
32981037|NCT01430715|Experimental|Active video game|
32981038|NCT01430728||Very low birthweight infants|
32981039|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
32981040|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
32981041|NCT01430780||control group|placebo
32981042|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
32981043|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
32981044|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
32981045|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
32981046|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
32981047|NCT01430806|Other|Dronedrone Arm|
32981048|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
32981049|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
32981050|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
32981051|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
32981052|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
32981053|NCT01430884||Aspirate Blood|
32981054|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
32981055|NCT01430910|Active Comparator|2|500mg Avibactam
32981056|NCT01430910|Active Comparator|3|2000mg Ceftazidime
32981057|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
32981058|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
32981059|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
32981060|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
32981061|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
32981062|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
32981063|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
32981064|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
32981065|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
32981066|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
33323902|NCT05199766|Experimental|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks, in case of discontinuation due to patient's wishes and/or adverse event above grade 2 : 1000mg during 14 days then complete discontinuation if no resolution. In case of sudden discontinuation a therapeutic phlebotomy will be authorized.
32981067|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
32981068|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
32981069|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
32981070|NCT01431053|Experimental|Exemestane + Aspirin|
32981071|NCT01431053|Active Comparator|Exemestane|
33323903|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
33323904|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
33323905|NCT01221636|Other|Low Metal Abatacept|Reference
33323906|NCT01221636|Experimental|High Metal Abatacept|
33323907|NCT05731804|Experimental|Cohort 1 of Part A|Subjects with mild renal impairment(SIM0417 600 mg; Ritonavir100 mg )
33323908|NCT05731804|Experimental|Cohort 2 of Part A|Subjects with moderate renal impairment(SIM0417 375 mg; Ritonavir100 mg )
33323909|NCT05731804|Experimental|Cohort 3 of Part A|Subjects with normal renal function(SIM0417 600 mg; Ritonavir100 mg )
33323910|NCT05731804|Experimental|Cohort 4 of Part A|Subjects with normal renal function(SIM0417 375 mg; Ritonavir100 mg )
33323911|NCT05731804|Experimental|Cohort 5 of Part B|Subjects with moderate hepatic impairment (SIM0417 750 mg; Ritonavir100 mg )
33323912|NCT05731804|Experimental|Cohort 6 of Part B|Subjects with normal hepatic function(SIM0417 750 mg; Ritonavir100 mg )
32739150|NCT05713721||SMC DYT/PARK-TAF1|Symptomatic mutation carriers (SMC) of the TAF1 gene, which is associated with X-linked Dystonia-Parkinsonism, will be examined.
32981072|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
32981073|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
32981074|NCT01431092|Experimental|Melatonin|
32981075|NCT01431092|Placebo Comparator|Placebo|
32981076|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
32981077|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
32981078|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
32981079|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
32981080|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
32981081|NCT01431222|Active Comparator|percutaneous treatment|
32981082|NCT01431222|No Intervention|optimal medical treatment|
32981083|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
32981084|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
32981085|NCT01431248||Azithromycin|Azithromycin 1gm PO once
32981086|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
32981087|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
32981088|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
32981089|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
32981090|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
33105038|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
33323913|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
33105039|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
33323914|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
33323915|NCT05199376|Experimental|Percutaneous cryotherapy|Cryoablation of the tumor
33323916|NCT05198986||ECMO Prone Position|After baseline assessment in supine position, patients will be positioned in prone position to assess modification of lung mechanics, aeration and hemodynamics
33323917|NCT03932292|Active Comparator|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
33323918|NCT03932292|Active Comparator|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
33323919|NCT05729542|Active Comparator|Arthrex Tightrope|Syndesmosis fixation performed with ARthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
33323920|NCT05729542|Experimental|Synthes Fibulink|Syndesmosis fixation perforemd with Synthes Fibulink device. This is a high-tension fixation with a screw based anchor system.
33323921|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
33323922|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
33323923|NCT05727514|Other|enrolled participants|participation in 4-session music composition program with optional viewing of performance at the end
33323924|NCT01127178|Experimental|E7016 + TMZ|
33323925|NCT05715580|Active Comparator|Intervention group|The nursing intervention will consist of providing information to the patient with a KT about the importance of following the prescribed therapeutic regimen, at the same time the information they may have about healthy lifestyle habits will be expanded, with special emphasis on those areas in which there has been detected, through the administered questionnaires, a lack of adherence.
33323926|NCT05715580|Placebo Comparator|Control group|The control group will be informed of the same aspects following the usual clinical practice, which consists of providing the information in the immediate post-transplant period, and resolving any doubts that the patient may have during the subsequent time.
33323927|NCT01226394|No Intervention|surveillance|
33323928|NCT01226394|Experimental|laparotomy plus HIPEC.|
33323929|NCT03932604|No Intervention|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
33323930|NCT03932604|Active Comparator|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
33323931|NCT05198440|Experimental|Neuromodulation of vection|
33323932|NCT01223430|Experimental|Si-Ni-Tang|
33323933|NCT01223430|Placebo Comparator|Placebo|
33323934|NCT05707078|Other|Surgery|Based on PET/CT scan patients will undergo neck dissection.
33323935|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
33323936|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
33323937|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
33323938|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
33323939|NCT05198206||The First Affiliated Hospital of Chongqing Medical University|
33323940|NCT05198206||West China Hospital|
33323941|NCT05198206||the First Affiliated Hospital of Xi'an Jiaotong University|
33323942|NCT05198206||Guangdong Provincial People's Hospital|
33323943|NCT05198206||Xiangya Hospital of Central South University|
33323944|NCT05198206||The Second Affiliated Hospital of Harbin Medical University|
33323945|NCT05198206||Yan'an Hospital of Kunming City|
33323946|NCT05198206||Zhongshan Hospital|
33323947|NCT05198206||Gansu Provincial People's Hospital|
33323948|NCT05198206||Qilu Hospital of Shandong University|
33323949|NCT05198206||Shanxi Provincial Cardiovascular Hospital|
33323950|NCT05198206||West China Second Hospital|
33323951|NCT05198206||The First Affiliated Hospital of Jilin University|
33323952|NCT05198206||Xinqiao Hospital, Army Medical University|
33323953|NCT05198206||The First Affiliated Hospital of Guangzhou Medical University|
33323954|NCT05198206||the Second Xiangya Hospital of Central South University|
33323955|NCT05198206||Shengjing Hospital of China Medical University|
33323956|NCT05198206||The Second Affiliated Hospital of Nanchang University|
33323957|NCT05198206||Henan Provincial People's Hospital|
33323958|NCT05198206||Southwest Medical University Hospital|
33323959|NCT05198206||The First Affiliated Hospital of Gannan Medical University|
33323960|NCT05198206||University-town Hospital of Chongqing Medical University|
33323961|NCT05198206||Chongqing Health Center for Women and Children|
33323962|NCT05198206||Kunhua Hospital|
33323963|NCT05198206||Changdu People's Hospital of Tibet|
33323964|NCT05198206||The Sixth People's Hospital of Chengdu|
33323965|NCT05198206||Chongqing Bishan District People's Hospital|
33323966|NCT05198206||Sichuan Guangyuan People's Hospital|
33323967|NCT05198206||Xinjiang Military Region General Hospital|
33323968|NCT05198206||Xinjiang Uygur Autonomous Region People's Hospital|
33323969|NCT05198206||The First Affiliated Hospital of Anhui Medical University|
33323970|NCT05198206||Yantai Yuhuangding Hospital|
32981091|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
32981092|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
32981093|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
32981094|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
32981095|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
32981096|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
32981097|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
32981098|NCT01431404|Experimental|HD203, prefilled syringe|
32981099|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
32981100|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
32981101|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
32981102|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
32981103|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
32981104|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
32981105|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
32981106|NCT01431443|Experimental|Dark chocolate|
32981107|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
32981108|NCT01431456|Active Comparator|Dabigatran|Dabigatran
32981109|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
32981110|NCT01431456|Active Comparator|Nadroparin|Nadroparin
32981111|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
32981112|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
32981113|NCT01431495|Active Comparator|plavix|patient treated by the princeps
32981114|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
32981115|NCT01431547|Experimental|Part 1: Dalotuzumab|
32981116|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
32981117|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
32981118|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
32981119|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
32981120|NCT01431599|Experimental|short-course|
32981121|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
33412160|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
33412161|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
33412162|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
33412163|NCT01337869|Active Comparator|Limberg Flap Technique|
32981122|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
32981123|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
32981124|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
32981125|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
32981126|NCT01431651|Experimental|probiotic, lifestyle counseling|
32739151|NCT05713721||AMC DYT/PARK-TAF1|Asymptomatic mutation carriers (AMC) of the TAF1 gene will be examined.
33105040|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
33323971|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
33323972|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
33323973|NCT05702710||Neonates Undergoing PIRS|All children <28 days of age undergoing PIRS for inguinal hernia repair
33323974|NCT03932526|Active Comparator|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
33323975|NCT03932526|Experimental|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
33323976|NCT03932214|Experimental|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
33323977|NCT03932214|No Intervention|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
33323978|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
33323979|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
33323980|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
33323981|NCT03932370||f-URS|
33323982|NCT03932370||mini-PCNL|
33323983|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
33323984|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
33323985|NCT05691244|Active Comparator|Normal Saline + Standard of care|Normal saline will be used as a comparator. It will be available in a 5.0 mL vial. Three doses will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
33323986|NCT05691244|Experimental|Sovateltide + Standard of care|The test product is sovateltide. It is available as a lyophilized injection containing 30 µg of sovateltide in a 5.0 mL vial. Three doses of 0.3 μg/kg will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
33323987|NCT03928470|Experimental|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
33323988|NCT03928470|Active Comparator|Nexium Tab. 20mg|Nexium Tab. 20mg
33323989|NCT03927924|Experimental|High-intensity focused ultrasound|
33323990|NCT01223586||Regression|Patients with regression of plaque volume by statin
33323991|NCT01223586||Non regression|Patients without regression of plaque volume by statin
33323992|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
33323993|NCT01127412|No Intervention|Control|
33323994|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
33323995|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
33323996|NCT03931590|Experimental|Healthy Male Subjects|Single oral dose of 150 mg of [14C] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
33323997|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
33323998|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
33323999|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
33324000|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
33324001|NCT05675098|Experimental|Methylphenidate|Participants in this group will receive 2.5mg Methylphenidate and 100mg placebo (Modafinil shape) in addition to physical therapy program
33324002|NCT05675098|Experimental|Modafinil|Participants in this group will receive 100mg Modafinil and 2.5mg placebo (Methylphenidate shape) in addition to physical therapy program
33324003|NCT05675098|Placebo Comparator|Placebo|Participants in this group will receive 2.5mg placebo (Methylphenidate shape) and 100mg placebo (Modafinil shape) in addition to physical therapy program
33324004|NCT01223742|Experimental|ACETYL-L-CARNITINE|
33324005|NCT01223742|Placebo Comparator|placebo|
33324006|NCT03928002|Experimental|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
33324007|NCT03928002|Active Comparator|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
33412164|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
32981127|NCT01431690|Experimental|Warfarin and Epanova|
32981128|NCT01431690|Active Comparator|Lovaza|
32981129|NCT01431729||mucositis|
32981130|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
32981131|NCT01431781|Experimental|stilamin+common daily treatment|
32981132|NCT01431781|Active Comparator|common daily treatment|
32981133|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
32981134|NCT01431833|Experimental|Moderate hepatic|
32981135|NCT01431833|Experimental|Severe Hepatic|
32981136|NCT01431833|Experimental|Matched control|
32981137|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
32981138|NCT01431859|Active Comparator|Birch pollen immunotherapy|
32981139|NCT01431872||Post menopausal breast cancer patients|
32981140|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
32981141|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
32981142|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
32981143|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
33412165|NCT04221997|Experimental|sertraline|90 patients will be randomized to sertraline
32981144|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
32981145|NCT01431937|Active Comparator|GSK2018682|Active Drug
32981146|NCT01431937|Placebo Comparator|Placebo Control|Placebo
32981147|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
32981148|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
32981149|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
32981150|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
33324008|NCT05671354|Experimental|The auto-wrapping commode chair|The experimental group will use the auto-wrapping commode chair for 7 days.
33324009|NCT05197816|Experimental|Deep brain stimulation|All patients will undergo adaptive deep brain stimulation with results compared before and after stimulation
33324010|NCT03931122|No Intervention|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
32981151|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
32981152|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
32981153|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
32981154|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
32981155|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
32981156|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
32981157|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
33105041|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
33324011|NCT03931122|Experimental|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )~Based on these ear measurements, nearest smaller LMA size will be selected."
32981158|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
32981159|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
32981160|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
32981161|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
32981162|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
32981163|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
32739152|NCT05713721||SMC DYT/PARK-GCH1|Symptomatic mutation carriers (SMC) of the GCH1 gene, which is associated with dopa-responsive Dystonia, will be examined.
32739153|NCT05713721||AMC DYT/PARK-GCH1|Asymptomatic mutation carriers (AMC) of the GCH1 gene will be examined.
32981164|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
32981165|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
32981166|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
32981167|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
32981168|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
32981169|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
32981170|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
32981171|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
32981172|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
32981173|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
32981174|NCT01432353|Experimental|Single Arm|
32981175|NCT01432392||1|
32981176|NCT01432418|Experimental|wheelchair training|
32981177|NCT01432418|No Intervention|Control|Standard of care only
32981178|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
32981179|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
32981180|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
32981181|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
32981182|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
32981183|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline~Intramuscular epinephrine~Intranasal epinephrine"
32981184|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
32981185|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
32981186|NCT01432639|No Intervention|Control group|Usual medical care
32981187|NCT01432652||vascular surgery|Patients undergoing vascular surgery
32981188|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
32739154|NCT05713721||SMC PARK-Parkin/PARK-PINK1|Symptomatic mutation carriers (SMC) of the Parkin or PINK1 genes, which is associated with Parkinsonism, will be examined.
32739155|NCT05713721||AMC PARK-Parkin/PARK-PINK1|Asymptomatic mutation carriers (SMC) of the Parkin or PINK1 genes will be examined.
33412166|NCT04221997|Placebo Comparator|Placebo|30 patient will be randomized to placebo
32981189|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
32981190|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
32981191|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
32981192|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
32981193|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
32981194|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
32981195|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
32981196|NCT01432691|Other|Surgery|RSA study on hemi
32981197|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
32981198|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
32981199|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
32981200|NCT01432717|Placebo Comparator|Placebo|
32981201|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
33412167|NCT04221997|No Intervention|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
32981202|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
32981203|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
32981204|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
32981205|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
32981206|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
32981207|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~4 gliding aids~2 stocking butlers, one with and without handle~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
32981208|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
32981209|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
32981210|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
32981211|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
33324012|NCT05179330|Experimental|Group A (no visual feedback-visual feedback)|Participants in group A (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® without visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® plus visual feedback
33324013|NCT05179330|Experimental|Group B (visual feedback-no visual feedback)|Participants in group B (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® plus visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® without visual feedback
33324014|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
32739156|NCT05713721||Control group|A healthy control group will be examined.
32981212|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
32981213|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
32981214|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
32981215|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
32981216|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
32981217|NCT01432873|Placebo Comparator|Placebo|Oral placebo
32981218|NCT01432912|No Intervention|Patients|
32981219|NCT01432925|Other|evaluation surgical intervention at week 8|
32981220|NCT01432925|Other|evaluation surgical intervention at week 14|
33105042|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
33324015|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
33324016|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
33324017|NCT01129518|Experimental|Control Group|Zero dose MenC priming
33324018|NCT05176132||OBESE (BMI>30)|BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.
33324019|NCT05176132||CONTROL Normal weight (BMI 20-25)|100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age
33324020|NCT05176132||CONTROL Overweight (BMI 25-30)|100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
33324021|NCT01226784|Active Comparator|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
33324022|NCT01226784|Active Comparator|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
33324023|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
33324024|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
33324025|NCT03924960|Experimental|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
33324026|NCT03924960|Active Comparator|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
33324027|NCT03924960|Other|Control|Usual care control group
33324028|NCT01223820|Experimental|Capsaicin|
33412168|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
33412169|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
32981221|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
32981222|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
32981223|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
32981224|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
32981225|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
32981226|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
32981227|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
32981228|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
32981229|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
32981230|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
32981231|NCT01433068|Experimental|NBTXR3|
33324029|NCT03931044|Experimental|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
33324030|NCT03931044|No Intervention|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
33324031|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
33324032|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
33324033|NCT03924726|Other|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
33324034|NCT03924726|Other|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
33324035|NCT03924726|Other|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
33324036|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
33324037|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
33324038|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
33324039|NCT01129596||1|
33324040|NCT04799158|Experimental|Run-In Period|Participants will receive vonoprazan 20 mg once daily for up to 4 weeks.
33324041|NCT04799158|Experimental|Vonoprazan 10 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 10 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
33324042|NCT04799158|Experimental|Vonoprazan 20 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 20 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
33324043|NCT04799158|Experimental|Vonoprazan 40 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 40 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
33324044|NCT04799158|Placebo Comparator|Placebo: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take a placebo when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
33324045|NCT05175820||Dentists|"Graduated from the Faculty of Dentistry,~Continuing/not continuing dental education (master, doctor, doctorate) after graduation,~Working in practice or outpatient clinic, private or public hospital, private polyclinic or public health or university hospital,~Dentists who registered in Turkish Dental Association"
33324046|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
33324047|NCT05665426|Other|AW group|(1) AW group: acupuncture at Weizhong point,
33324048|NCT05665426|Other|AC group|(2) AC group: acupuncture at Chize point,
33324049|NCT05665426|Other|MW group|(3) MW group: moxibustion at Weizhong point,
33324050|NCT05665426|Other|MC group|(4) MC group: moxibustion at Chize point.
33324051|NCT04797520|Other|Treatment|All participants will have placement of ETT confirmed using both Core stethoscope and point-of-care ultrasound
33412170|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
32981232|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
32981233|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
32981234|NCT01433120|Experimental|Probiotic L. casei F19|
32981235|NCT01433120|Experimental|Flax seed fibres|
32981236|NCT01433120|Placebo Comparator|Placebo|
32981237|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
32981238|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
32981239|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
32981240|NCT01433198|Active Comparator|Aquatic exercise group|
32981241|NCT01433198|No Intervention|Control group|
32981242|NCT01433211||No treatment|
32981243|NCT01433276|Experimental|Totilac|
32981244|NCT01433276|Active Comparator|Ringer's lactate|
32981245|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
32981246|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
32981247|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
32981248|NCT01433302||Punch Biopsy|
32981249|NCT01433341||Young athletes|
32981250|NCT01433367||CerPass® Total Disc Replacement|
32981251|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
32981252|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
32981253|NCT01433393|Experimental|TAK-875 25 mg|
32981254|NCT01433393|Experimental|TAK-875 50 mg|
32981255|NCT01433393|Placebo Comparator|Placebo|
32981256|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
32981257|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
32981258|NCT01433419|Experimental|TAK-875 25 mg|
33412171|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
32739157|NCT05002647||exposure group|Data from electronic clinical pharmacist records of two infectious disease hospitals
32739158|NCT05002647||Non-exposure group A|Data from medical records of the hospital with no clinical pharmacy.
32981259|NCT01433419|Experimental|TAK-875 50 mg|
32739159|NCT05002647||Non-exposure group B|Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
32981260|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
32981261|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
32981262|NCT01433445|Experimental|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981263|NCT01433445|Experimental|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981264|NCT01433445|Experimental|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981265|NCT01433445|Experimental|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981266|NCT01433445|Experimental|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981267|NCT01433445|Experimental|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
32981268|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
32981269|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
32981270|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
32981271|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
32981272|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
32981273|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
32981274|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
32981275|NCT01433523|Placebo Comparator|Placebo|
32981276|NCT01433523|Experimental|ALK HDM AIT 6 DU|
32981277|NCT01433523|Experimental|ALK HDM AIT 12 DU|
32981278|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
32981279|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
32981280|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
32981281|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
32981282|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
32981283|NCT01433536||Control|Healthy individuals
32981284|NCT01433562|Experimental|DLBS1425|
32981285|NCT01433562|Placebo Comparator|Placebo|
32981286|NCT01433575|Experimental|A|
32981287|NCT01433575|Experimental|B|
32981288|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
32981289|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
32981290|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
32981291|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
33412172|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
32981292|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
32981293|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
32981294|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
32981295|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
32981296|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
32981297|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
32981298|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
32981299|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
32981300|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
32981301|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
32981302|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
32981303|NCT01433653|Experimental|CG-CBT|
32981304|NCT01433653|No Intervention|wait list control|
32981305|NCT01433666|Experimental|roflumilast 100ug|
32981306|NCT01433666|Experimental|roflumilast 300ug|
32981307|NCT01433666|Experimental|roflumilast1000ug|
32981308|NCT01433666|Placebo Comparator|placebo|
32981309|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
32981310|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
32981311|NCT01433692|Experimental|intervention group|
32981312|NCT01433692|Other|control group|
32981313|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
32981314|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
32981315|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
32981316|NCT01433718|Experimental|ACL prevention training|
32981317|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
32981318|NCT01433744|No Intervention|Periodontally healthy|
32981319|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
33324052|NCT04680598||high HBV-DNA group|patients with HBV-DNA >500 IU/ml
33324053|NCT04680598||low HBV-DNA group|patients with HBV-DNA≤500 IU/ml
33324054|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
33324055|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
33324056|NCT04677244|Experimental|Portal vein blood sample|
32981320|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
32981321|NCT01433770|Experimental|Alefacept action on memory T cells|
32981322|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
32981323|NCT01433835|Placebo Comparator|Placebo|
32981324|NCT01433835|Experimental|MBX-400|
32981325|NCT01433848||Child A liver cirrhosis|
32981326|NCT01433848||Child B liver cirrhosis|
32981327|NCT01433848||Child C liver cirrhosis|
32981328|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
32981329|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
32981330|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
32981331|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
32981332|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
32981333|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
32981334|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
32981335|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
32981336|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
32981337|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
32981338|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
32981339|NCT01433952|Placebo Comparator|0 mg Thiamine|
32981340|NCT01433952|Experimental|100 mg Thiamine|
32981341|NCT01433952|Experimental|500 mg Thiamine|
32981342|NCT01433952|Experimental|1500 mg Thiamine|
32981343|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
32981344|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
32981345|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
33324057|NCT01223898|Experimental|Nilotinib|
33324058|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
33324059|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
33324060|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
33324061|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
33324062|NCT01228344||Artemether-lumefantrine|
32981346|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
32981347|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
32981348|NCT01434043||Myocardial ischemia patients|
32981349|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
32981350|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
32981351|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
32981352|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
32981353|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
32981354|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
32981355|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
32981356|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
32981357|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
32981358|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
32981359|NCT01434160|Experimental|Arm 1|
32981360|NCT01434173||Group 1|
32981361|NCT01434173||Group 2|
32981362|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
32981363|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
32981364|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
32981365|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
32981366|NCT01434238|Experimental|Intervention participant|
32981367|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
32981368|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
32981369|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
32981370|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
32981371|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
32981372|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
33324063|NCT03924570|Experimental|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
33324064|NCT03924570|No Intervention|Control|Until randomization this arm will continue running hands offs per usual care.
33324065|NCT03927456|Experimental|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
33324066|NCT03927456|Placebo Comparator|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
32981373|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
32981374|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
32981375|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
32981376|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
32981377|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
33105043|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
33324067|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
33324068|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
33412173|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
33412174|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
33412175|NCT03635827|Active Comparator|NBTX-001|
33412176|NCT03635827|Placebo Comparator|Placebo|
33412177|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
33412178|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
33412179|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
33412180|NCT04530201|Other|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
33412181|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
33412182|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
33412183|NCT04095403|Experimental|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
33412184|NCT04095403|Sham Comparator|Passive cooling|Supine lying
33412185|NCT01332175|Active Comparator|Provent|
33412186|NCT01332175|Placebo Comparator|Placebo-Provent|
33412187|NCT01332175|Active Comparator|CPAP|
32981378|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
32981379|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
32981380|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
32981381|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
33412188|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
33412189|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
33412190|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
33412191|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
33412192|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
33412193|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
33412194|NCT01338103|Experimental|Rituximab|
33412195|NCT03369665|Experimental|Mavenclad®|
33412196|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
33412197|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
33412198|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
33412199|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
33412200|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
32981382|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
32981383|NCT01434459|Experimental|Gemcitabine with TheraSphere|
32981384|NCT01434485||Nexium|
32981385|NCT01434524|No Intervention|Control|normal dietary
32981386|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
32981387|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
32981388|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
32981389|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
32981390|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
32981391|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
32739160|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
32981392|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
32981393|NCT01434576|Experimental|HGS1025 2 mg/kg|
32981394|NCT01434576|Experimental|HGS1025 10 mg/kg|
32981395|NCT01434576|Placebo Comparator|Placebo|
32981396|NCT01434589|No Intervention|Wait list control|
32981397|NCT01434589|Experimental|STICA Intervention|
32981398|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
32981399|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
32981400|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
32981401|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
32981402|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
32981403|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
32981404|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
32981405|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
32981406|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
32981407|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
32981408|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
32981409|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
32981410|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
33324069|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
32981411|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
32981412|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
32981413|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
33105044|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
33105045|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
33324070|NCT01129752||children at risk for depression|children at familial risk for depression
33324071|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
33324072|NCT01228422||1|test interferon - blausiegel
33324073|NCT01228422||2|reference interferon - Roferon A (Roche)
33324074|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
33324075|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
33324076|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
33324077|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
33324078|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
33324079|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
33324080|NCT05633290||ICU Survivors of Sepsis|ICU survivors of sepsis who would routinely attend ICU follow-up.
33324081|NCT01129986|Experimental|Dermastream|
33324082|NCT04545112|Experimental|XABG|
33324083|NCT03931278|Other|persons with Multiple Sclerosis (MS)|
33324084|NCT03931278|Other|Healthy controls|
32981414|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
32981415|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
32981416|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
32981417|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
32981418|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
32981419|NCT01434836|Active Comparator|active tDCS and working memory training|
32981420|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
32981421|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
32981422|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
32981423|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
32981424|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
32981425|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
32981426|NCT01434888|Active Comparator|Tafluprost 0.0015%|
32981427|NCT01434888|Active Comparator|Timolol 0.5%|
32981428|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
32981429|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
32981430|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
32981431|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
32981432|NCT01434914|Active Comparator|verum|
32981433|NCT01434914|Placebo Comparator|Placebo|
32981434|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
32981435|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
32981436|NCT01434940|Experimental|Depression|Patients suffering from depression
32981437|NCT01434940|Experimental|Healthy|Healthy volunteers
32981438|NCT01434953|Experimental|Labeled|
32981439|NCT01434953|Active Comparator|Unlabeled|
32981440|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
32981441|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
32981442|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
32981443|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
32981444|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
32981445|NCT01434992||H. pylori gastritis|
32981446|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
32981447|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
33324085|NCT01227096||Electro-acupuncture, Control|
32981448|NCT01435057|Active Comparator|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
32981449|NCT01435057|Active Comparator|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
32981450|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
32981451|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
32981452|NCT01435096|Experimental|BN80927|
32981453|NCT01435109|No Intervention|Usual Care|
32981454|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
32981455|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
32981456|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
32981457|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
32981458|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
32981459|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
32981460|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
32981461|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
32981462|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
32981463|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
32981464|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
32981465|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
32981466|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
32981467|NCT01435213|Experimental|Atipamezole|
32981468|NCT01435213|Experimental|Atomoxetine|
32981469|NCT01435213|Experimental|Ketamine|
32981470|NCT01435213|Experimental|Insulin-induced hypoglycemia|
33412201|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
32981471|NCT01435213|Experimental|Cold pressor test|
32981472|NCT01435213|Experimental|Placebo|
32981473|NCT01435239|Experimental|resting volume group|
32981474|NCT01435239|Active Comparator|maximum volume group|
33412202|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
33412203|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
32981475|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
32981476|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
32981477|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
32981478|NCT01435291|Experimental|Advagraf|
32981479|NCT01435291|Active Comparator|Prograf|
32981480|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
32981481|NCT01435330|Experimental|BVS857|
32981482|NCT01435330|Placebo Comparator|Placebo|
32981483|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
32981484|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
33324086|NCT01227096||Preconditioning, No preconditioning|
33412204|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
32981485|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
32981486|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
33324087|NCT05416606|Active Comparator|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
33324088|NCT05416606|Active Comparator|open prostatectomy|open surgical transvesical prostatectomy
33324089|NCT01224132|No Intervention|Probiotics|
32739161|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
32981487|NCT01435486|Active Comparator|caffeine Citrate|
32739162|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
32981488|NCT01435486|Placebo Comparator|Normal saline|
33324090|NCT01224132|No Intervention|skim milk powder, dextrose|
33324091|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
32981489|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
32981490|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
32981491|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
32981492|NCT01435525||Nexium|
32981493|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
32981494|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
32981495|NCT01435564|Active Comparator|pedometer|
32981496|NCT01435564|Experimental|Mobile phone physical activity intervention|
32981497|NCT01435629||Norditropin®|
32981498|NCT01435642||A|
33324092|NCT05615974|Experimental|LM101 Dose Escalation|
33324093|NCT05615974|Experimental|LM101 combination therapy exploratory|
32739163|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
32739164|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
32739165|NCT05002725|Experimental|PENG|An ultrasound guided PENG catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
32981501|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
32981502|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
32981503|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
32981504|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
32981505|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
32981506|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
32981507|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
32981508|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
32981509|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
32981510|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
32981511|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
32981512|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
32981513|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
32981514|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
32981515|NCT01435811|Placebo Comparator|Sterile water|
32981516|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
32981517|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
32981518|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
33324094|NCT05615974|Experimental|LM101 combination expansion|
33324095|NCT03924258|Experimental|HEART FAILURE|Patients with Heart Failure diagnosis
33324096|NCT05415904||HANTA-NE|All adult patient hospitalized for hantavirus infection between 01/01/2013 and 31/12/2022 in North Eastern France
33324097|NCT03927534|Experimental|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
32981519|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
32981520|NCT01435863|Experimental|SP-02L|
32981521|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
32981522|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
32981523|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
32981524|NCT01435876|Active Comparator|Surgical|
32981525|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
32981526|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
32981527|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
32981528|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
32981529|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
32981530|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
32981531|NCT01435980|No Intervention|basal treatment|basal treatment
32981532|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
32981533|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
32981534|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
32981535|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
32981536|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
32981537|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
32981538|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
32981539|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
32981540|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
32981541|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
32981542|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
32981543|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
32981544|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
32981545|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
32981546|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
32981547|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
32981548|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
32981549|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
32981550|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
32981551|NCT01436214|Experimental|APC-100|
32981552|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
32981553|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
32981554|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
32981555|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
32981556|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
32981557|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
32981558|NCT01436409|Other|only vaginal touch|
32981559|NCT01436409|Experimental|vaginal touch +echography|
32981560|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
32981561|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
32981562|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
32981563|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
32981564|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
32981565|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
32981566|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
32981567|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
32981568|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
32981569|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
32981570|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
32981571|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
32981572|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
32981573|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
32739166|NCT05002725|Active Comparator|Femoral Block|An ultrasound guided Femoral Nerve catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
32981574|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
32981575|NCT01436604|Other|LV dysfunction group|Cardiac MRI
32981576|NCT01436604|Other|Control group|Cardiac MRI
32981577|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
32981578|NCT01436669|Experimental|Home Monitoring|All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
32981579|NCT01436695||Epicall group|patients will be connected to Epicall sensor
33105046|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
32981580|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
32981581|NCT01436734|Experimental|GIP|
32981582|NCT01436747|Active Comparator|Paricalcitol|
32981583|NCT01436747|Placebo Comparator|Matching placebo|
32981584|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
32981585|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
32981586|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
32981587|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
32981588|NCT01436786|No Intervention|Control group|continues usual plan of care
32981589|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
32981590|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
32981591|NCT01436825||Group 1|
32981592|NCT01436838||Group 1|
32981593|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
32981594|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
33105047|NCT00547794||CRT-D + AVJ Ablation|
33105048|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
32981595|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
32981596|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
32981597|NCT01436890|Experimental|Low dose|Low dose revamilast
32981598|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
32981599|NCT01436890|Experimental|High dose|High dose Revamilast
32981600|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
32981601|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
32981602|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
33412205|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
33412206|NCT04527575|Experimental|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
32981603|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
32981604|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
32981605|NCT01436942|Experimental|Exercise group|
32981606|NCT01436942|No Intervention|Control group|
32981607|NCT01436955|Experimental|A|
33412207|NCT04527575|Experimental|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
33412208|NCT04527575|Placebo Comparator|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
32981608|NCT01436955|Placebo Comparator|B|
32981609|NCT01436981||CABG with papaverine|Patients with CABG procedure
32981610|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
32981611|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
32981612|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
32981613|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
32981614|NCT01437046|Placebo Comparator|Placebo|Placeno
32981615|NCT01437059|Active Comparator|ALN-PCS02|
32981616|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
32981617|NCT01437072||Total study population|
32981618|NCT01437137|Active Comparator|LMA group|
32981619|NCT01437137|Experimental|I-gel group|
32981620|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
32981621|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
32981622|NCT01437163|Sham Comparator|Red Incandescent light source|
32981623|NCT01437163|Active Comparator|TopHat 655|
32981624|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
32981625|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
32981626|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
32981627|NCT01437215|Experimental|Fenestrated Endografting|
32981628|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
32981629|NCT01437228|Placebo Comparator|CONTROL|
32981630|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
32981631|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
32981632|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
32981633|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
32981634|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
32981635|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
32981636|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
32981637|NCT01437332||Diabetes|
32981638|NCT01437332||Nerve injury|
32981639|NCT01437332||Other|
32981640|NCT01437358||intensive care unit|
32981641|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
32981642|NCT01437371|Other|usual care|
32981643|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
32981644|NCT01437410||EUS-FNA|
32981645|NCT01437436||obesity|otitis media patient with obesity
33412209|NCT03318861|Experimental|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 autologous anti-B-cell maturation antigen (BCMA) CAR T cells at a dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
33412210|NCT03318861|Experimental|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
32981646|NCT01437436||non obesity|otitis media patient with non obesity
32981647|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
32739167|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
32739168|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
32739169|NCT05713643|Active Comparator|ESPB group|
32739170|NCT05713643|Active Comparator|TPVB group|
32739171|NCT05713643|Active Comparator|QLB group|
32981648|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
32981649|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
32981650|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
32981651|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
32981652|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
32981653|NCT01437527|Active Comparator|control arm|Body image therapy as usual
32981654|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
32981655|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
32981656|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
32981657|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
33105049|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
33105050|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
33105051|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
32981658|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
32981659|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
32981660|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
32981661|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
32981662|NCT01437592|Experimental|IDeg|
32981663|NCT01437618||BRAF mutant mCRC|
32981664|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
32981665|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
32981666|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
32981667|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
32981668|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
32981669|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
32981670|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
32981671|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
33324098|NCT03927534|No Intervention|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
33324099|NCT01329276|Other|Symbicort® forte Turbohaler®|
32739172|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
32739173|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
32981672|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
32981673|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
32981674|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
32981675|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
32981676|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
32981677|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
32981678|NCT01437800|Experimental|Glimepiride / Extended release Metformin|Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions
32981679|NCT01437813|Experimental|Group A: Glimepiride / Extended Release Metformin|Pharmaceutical Form: Tablets Dosage: 4 mg / 850 mg Administration way: Oral
32981680|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
32981681|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
32981682|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
32981683|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
32981684|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
33324100|NCT01329276|Placebo Comparator|Placebo (lactose)|
33324101|NCT01224366|Experimental|Vildagliptin|
33324102|NCT01224366|Placebo Comparator|Placebo|
32862872|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
32981685|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
32981686|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
33324103|NCT05415826|Active Comparator|PPV group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling.
33324104|NCT05415826|Experimental|PPV+implant group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling and slow-release dexamethasone implant.
32862873|NCT04922970|Experimental|Strength training|"In this arm participants will go through the Strength training intervention."
32862874|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
33324105|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
33324106|NCT01227330|No Intervention|Control|No intervention
33324107|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
32862875|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
32862876|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
32862877|NCT04351503||SARSCoV-infected patients (cases)|
32862878|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
32862879|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
32862880|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
32862881|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
32862882|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
32862883|NCT04922814|No Intervention|Control group(group A)|Only sedation for mechanically ventilated COVID patients
32862884|NCT04922814|Experimental|Muscle relaxant group(group B)|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
32862885|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
32862886|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
32862887|NCT03012399|Experimental|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
32862888|NCT03012399|Active Comparator|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
32862889|NCT04914624|Placebo Comparator|Regular ACBT training|Including quitting smoking, ACBT training, cough practicing.
32862890|NCT04914624|Experimental|Positive expiratory pressure therapy|Use acpella®PEP therapeutic system and regular nursing care.
32862891|NCT04914624|Experimental|External diaphragm pacemaker|Patients are trained to use external diaphragm pacemaker and receive regular nursing care.
32862892|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
32862893|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
32862894|NCT04906512|Experimental|Tegaderm CHG Dressing|Tegaderm CHG dressing is used to cover and protect insertion catheter sites and to secure devices to skin. It is available in a variety of shapes and sizes. Tegaderm CHG Dressing is intended to reduce skin colonization and catheter colonization and to suppress regrowth of microorganisms commonly related to bloodstream infections. Tegaderm CHG dressing is intended to reduce catheter-related bloodstream infections (CRBSI) in patients with central venous or arterial catheters.
32862895|NCT04906512|Active Comparator|Tegaderm Standard Dressing|Tegaderm Standard Dressing is used to cover and protect insertion catheter sites and to secure devices to skin.
32862896|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
32862897|NCT03077399|Experimental|control|Healthy individuals (patients without stroke), application of SCALA
32862898|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
32862899|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
32862900|NCT04914936|Experimental|Part 1: ACP-196 and Calcium carbonate|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and a single oral dose of calcium carbonate 1 g tablet coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 2.
32862901|NCT04914936|Experimental|Part 2: ACP-196 and Omeprazole|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of omeprazole 40 mg capsules once daily (QD) for 5 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 5 of Period 2.
32862902|NCT04914936|Experimental|Part 3: ACP-196 and Rifampin|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of rifampin 600 mg capsule QD for 9 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 and Day 9 of Period 2.
32981687|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
32981688|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
32981689|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
32981690|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
32981691|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
32981692|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
32981693|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
32981694|NCT01438086|Active Comparator|mecasermin low dose|
32746742|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
32981695|NCT01438086|Active Comparator|mecasermin high dose|
32981696|NCT01438086|Placebo Comparator|saline placebo|
32981697|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
32981698|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
32981699|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
32981700|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions~Mitomycin C~Interferon~Valrubicin~Gemcitabine"
32981701|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
32981702|NCT01438125|Active Comparator|Standard surgical wound closure|
32981703|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
33412211|NCT03318861|Experimental|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 3 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
33412212|NCT03318861|Experimental|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^9 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
32981704|NCT01438164||oncologic patients|initial staging
32981705|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
32981706|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
32981707|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
32981708|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
32981709|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
32981710|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
32981711|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
32981712|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
32981713|NCT01438255||Alvesco|
32981714|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
32981715|NCT01438281|Experimental|SYL1001|
32981716|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
32981717|NCT01438333|Experimental|Lactobacillus brevis|
32981718|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
32981719|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
33105052|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
32981720|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
32981721|NCT05607927|Other|Parks surgery group|The CRII patients received Parks surgery
32981722|NCT05607927|Experimental|PE-Bacon surgery group|The CRII patients received PE-Bacon surgery
33324108|NCT05415748|Experimental|Tamsulosin 0.4 mg or 0.8 mg, Then Placebo|Participants first received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
32981723|NCT05607433|Experimental|Air Q ILA group|Air Q supraglottic device will be placed in the participants in this group .
32981724|NCT05607433|Experimental|Ambu AuraGain group|Ambu AuraGain supraglottic device will be placed in the participants in this group .
32981725|NCT05607212|Experimental|Kettlebell Swing Group|Participants will perform two-handed kettlebell swings
32981726|NCT05607212|Active Comparator|Active Comparator Group|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals.
32981727|NCT05607212|Other|Control group|participants will be educated on the benefit of a kettlebell swing.
32981728|NCT05606991|No Intervention|CPAP on|Participants will continue with their usual continuous positive airway pressure (CPAP) therapy as advised by their treating physician.
32981729|NCT05606991|Experimental|CPAP off|Participants will be weaned off their usual continuous positive airway pressure (CPAP) therapy and enter a 2-week period of non-treatment.
32981730|NCT05605028|Experimental|Mental Health lifestyle intervention|The intervention will focus on identifying risk factors for depression and anxiety and will quantitate the educational component of the POWER Obesity group intervention delivered by mental health professionals that are currently presenting for 30 min during the Monday session to address the root causes of obesity as well as to encourage positive lifestyle changes (e.g. sleep, diet, sun exposure, circadian rhythms, and addictions). The previously published hypothesis identifies triggers, that combined, could cause mental health problems. The 10 groups of triggers are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
32981731|NCT05605028|Active Comparator|Dietitian-led|A group of participants that visit a dietitian will be the control.
32981732|NCT05604001|Experimental|Symptomatic submucosal myoma|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy with laser ablation of the myoma.
32981733|NCT05597085||Adult relapsed or refractory B Cell ALL|Adult patients whose B Cell ALL has occurred again after the last treatment or patients who never responded to prior treatment
32981734|NCT05596370||biliary cancer|cholangiocarcinoma gallbladder cancer
32981735|NCT05596370||pancreatic tumor|pancreatic cancer pancreatic ductal adenocarcinoma pancreatic neuroendocrine tumor
32981736|NCT05596110|Experimental|TENS and KT|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
33324109|NCT05415748|Experimental|Placebo, Then Tamsulosin 0.4 mg or 0.8 mg|Participants first received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
32981737|NCT05596110|Sham Comparator|TENS and sham taping|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
33324110|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
33324111|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
33324112|NCT03924024|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
33105053|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
33324113|NCT05415670||[Training set, N=80] Benign/Malignant Pulmonary Nodule|This is a prospective training-set cohort study. A stratified case-cohort design will be used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will receive chest CT or low-dose computed tomography (LD-CT) scanning and detection of serum tumor markers, and receive Whole-genome methylation sequencing at baseline. GM-seq will perform methylation analysis to build a prediction model for benign and malignant classification.
33324114|NCT05415670||[Verification set, N=40] Benign/Malignant Pulmonary Nodule|This is a prospective validation-set cohort study. A stratified case-cohort design was used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will verify the benign and malignant differentiation model based on GM-seq methylation analysis, and compare the results with histopathological benign and malignant results, so as to develop a clinical benign and malignant differentiation model.
33324115|NCT05415514|Other|Instrumented assessment of muscle function|During the instrumented evaluations, the investigators will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
33324116|NCT01228578|Experimental|Multivitamins (B,C,E)|
33324117|NCT01228578|Placebo Comparator|Placebo|
33324118|NCT03923946|Experimental|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
33324119|NCT03923946|No Intervention|Control|Treatment as usual arm
32862903|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
32862904|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
32862905|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
32862906|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
32862907|NCT04914390|Experimental|Tislelizumab + Anlotinib + Chemotherapy|Participants receive Tislelizumab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + AT regimen (Q3W) x 6 cycles as neoadjuvant therapy prior to surgery.
32862908|NCT04759391|Experimental|Exercise group|Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group
32862909|NCT04759391|Active Comparator|Control group|Lifestyle recommendations will be given to the control group
32862910|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
32862911|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
32862912|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
32862913|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
32862914|NCT04914468||TMVR|Patients undergoing Transcatheter Mitral Valce Replacement (TMVR)
32862915|NCT04914468||TEER|Patients undergoing mitral Transcatheter Edge-to-Edge Repair (TEER) after screening for TMVR
32862916|NCT04914468||Surgery|Patients undergoing mitral valve surgery (repair or replacement) after screening for TMVR
32862917|NCT04914468||Medical therapy|Patients undergoing medical therapy after screening for TMVR
32862918|NCT04906590|Experimental|Study Drug|All participants will receive PI-2620.
32862919|NCT04906356||Study group|Single group observational study
32862920|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
32862921|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
32862922|NCT04914156|Experimental|Personalised, genetic-based advice for sport performance|This group will receive personalised nutrition advice for sports performance based on their genetic test results and tailored to their current dietary intake.
32862923|NCT04914156|Active Comparator|Personalised nutrition advice for sport performance based on population-based evidence|This group will receive personalised nutrition advice on key nutrients relating to sports performance based on current best practice, population-based sport nutrition guidelines. These will be tailored to their current dietary intake
32862924|NCT04904094|Experimental|Intervention group|This group will receive casting of the lower limb for approximately 2 weeks combined with a passive stretching program of the knee flexors, followed by a homebased stretching exercise program for the plantar flexors and hamstrings for 4 weeks after casting.
32862925|NCT04904094|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.
32862926|NCT04903938||Criminal-Antisocial Personality Disorder|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
33105054|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
33105055|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
33412213|NCT03318861|Experimental|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single intravenous infusion of KITE-585 anti-autologous BCMA CAR T cells at a tolerable dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
33412214|NCT01381341|Experimental|linifanib|
33412215|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
33412216|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
32746743|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
32746744|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
32862927|NCT04903938||Non-criminal group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
32862928|NCT04903938||Control group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
32862929|NCT04913844||Skiers group|"The skiers group was formed from licensed ski athletes (17 male, 17 female) who have been active in sports for at least the last 2 years.~There will be no interventions. Physical performance tests and observational assessments will be conducted."
32862930|NCT04913844||Control group|"The control group was composed of non-athletic and age-matched participants (17 male, 17 female) with no skiing experience.~There will be no interventions. Physical performance tests and observational assessments will be conducted as in the Skiers Group."
32862931|NCT04904016|Experimental|Intervention FlowOx treatment|Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
32862932|NCT04398888|Experimental|BXD treatment|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, Banxia Xiexin Decoction (BXD), and the additional syndrome-specific herbs.~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
32862933|NCT04398888|No Intervention|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
32862934|NCT04397250|Experimental|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
32862935|NCT04397250|No Intervention|Control|Participants will be asked to continue their habitual lifestyle
32862936|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
32862937|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
32862938|NCT04905966|Experimental|Nutrition education + Physical activity intervention|Physical Activity and Nutrition Education: An additional 45 minute weekly physical education class and 5 weekly active break sessions of 10 minutes each will be added to the provisions of the children's curriculum. In addition, schools will receive high intensity nutrition education, that is, 3 weekly nutrition education classes of one hour in each session over a period of 6 months.
32862939|NCT04905966|No Intervention|Control|Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
32862940|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
32862941|NCT04906044|Experimental|Total Neoadjuvant Treatment combined with Tilelimumab|
32862942|NCT04906122|Experimental|Experimental group|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
32862943|NCT04906122|No Intervention|Control Group|Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
32862944|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
32981738|NCT05596110|Sham Comparator|KT and sham TENS|KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
32981739|NCT05596110|Sham Comparator|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
32981740|NCT05578859|Experimental|AMG510|Each participant will receive a single oral dose of AMG510 on Day 1 after an overnight fast.
32981741|NCT05569486|Experimental|Green light-emitting diode (GLED)|Subjects randomized to this arm will be exposed to GLED 2 hours a day for 10 weeks
32981742|NCT05569486|Placebo Comparator|White light-emitting diode (WLED)|Subjects randomized to this arm will be exposed to WLED 2 hours a day for 10 weeks
32981743|NCT05568355|No Intervention|Standard Hospital-Based Care Coordination|Patients and families randomized to this arm will receive best practice standard of care hospital-based transition planning in the hospital with routine outpatient care team follow-up post-discharge.
32981744|NCT05568355|Experimental|GET2HOME Intervention|The GET2HOME intervention includes: 1) a pre-discharge telehealth huddle with the family, inpatient team, primary care team, and home care nursing; 2) a visual discharge task tracker (DTT) to monitor progress across care management tasks; and if desired by family and primary care 3) a post-discharge telehealth huddle 2-7 days after discharge with the family, inpatient team, primary care team, and home care nursing
32981745|NCT05566873|Active Comparator|PA Education|"Participants will continue to receive the remote light touch physical activity education program that they have been receiving for the past several years."
32981746|NCT05566873|Experimental|PA Education plus Our Voice citizen science|"Participants will receive the remote light touch physical activity education program in combination with the remote Our Voice citizen science program aimed at identifying and addressing physical and social environmental barriers to and enablers of regular physical activity."
32981747|NCT05563389|Placebo Comparator|PLACEBO|
32981748|NCT05563389|Active Comparator|statin|
32981749|NCT05557539|Other|all patients|The intervention consists of taking blood samples, urine sample and naso-pharyngeal sample at two different time points (at inclusion and at week8-12).
32981750|NCT05557071|Experimental|Intervention|An online, asynchronous, self-paced, 6-week long, physical activity intervention.
32981751|NCT05557071|No Intervention|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 6 weeks following all measurements.
32981752|NCT05556954||Infected DFU cohort|25 participants that have an infected DFU will be enrolled.
32981753|NCT05556954||Non-infected DFU cohort|75 non-infected participants with DFU will be enrolled.
32981754|NCT05554393|Experimental|ARM I (daunorubicin, cytarabine, venetoclax)|Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
32981755|NCT05554393|Experimental|ARM II (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
32981756|NCT05554393|Active Comparator|ARM III (daunorubicin, cytarabine)|Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
32981757|NCT05548946|Other|General population|In this group, younger adults (18-64) and older (from 65 and older) from the general population are included. The participants fill in questionnaires.
32746745|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
32981758|NCT05548946|Other|Clinical Population|In this group, in- and outpatients from the clinical population are included. This are older adults, from the age of 65 with varying psychological pathologies (such as anxiety disorders, mood disorders, substance use disorders, developmental disorders, personality pathology, grief, trauma-related disorders, psychosocial problems, psychosis and schizophrenia-related disorders and somatic disorders). The patients fill in questionnaires and a randomly selected smaller group of patients will conduct a clinical interview.
32981759|NCT05543265|No Intervention|Control|Routine postpartum care
32981760|NCT05543265|Experimental|Facilitated Transition|Behavioral science informed interventions to assist in the transition from postpartum to primary care providers
32981761|NCT05539209|Active Comparator|The Standard Helpline Care (SC) group|The SC group will receive standard Oklahoma Smoking Cessation Helpline care AND complete daily check-ins and weekly surveys for 27 weeks.
32981762|NCT05539209|Active Comparator|OKquit group|The OKquit group will receive SC plus daily check-ins and weekly surveys for 27 weeks. In addition, the OKquit group will receive tailored smoking cessation messages in the smartphone application following completion of each survey. Further, the OKquit group will have access to on-demand smoking cessation content through the app.
32981763|NCT05539027|Active Comparator|Group 1 (Treatment group)|
32746746|NCT04333485|Active Comparator|Home-based Active Case Finding (HACF)|
32981764|NCT05539027|Active Comparator|Group 2 (Control group)|
32981765|NCT05525013|Experimental|Simvastatin|Simvastatin as an intracanal medication
32981766|NCT05525013|Active Comparator|Calcium hydroxide|Calcium hydroxide intracanal medication
32981767|NCT05518370|Experimental|Hippotherapy simulator training group|Hippotherapy simulator training group will receive a traditional physiotherapy and hippotherapy simulator training, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes hippotherapy simulator training).
32981768|NCT05518370|Active Comparator|Traditional physiotherapy group|Traditional physiotherapy group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
32981769|NCT05515328|Experimental|Part A: Arm 1|
32981770|NCT05515328|Experimental|Part B: Arm 1 - Reference|
33412217|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
32981771|NCT05515328|Experimental|Part B: Arm 2 - Treatment|
33412218|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
33412219|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
33412220|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
33412221|NCT03183609|Active Comparator|Gluten|30 grams of gluten flour daily in protein shake
33412222|NCT03183609|Placebo Comparator|Placebo|30 grams of rice flour daily in protein shake
33412223|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
33412224|NCT05422599|Experimental|Lemon balm|300mg Lemon balm and Maltodextrin
33412225|NCT05422599|Placebo Comparator|Placebo|Placebo
33412226|NCT04152213|Experimental|Low GI diet group|"The components of the Low GI diet group include:~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
33412227|NCT04152213|Placebo Comparator|Control group|"The components of the control group include:~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
33412228|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
33412229|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
33412230|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
33412231|NCT03187301|Placebo Comparator|Placebo|Placebo
33412232|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
33412233|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
33412234|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
33412235|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
33412236|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
33412237|NCT01381263|Experimental|Behavioural medicine|
33412238|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
33412239|NCT02963285||0 to 6 months|
33412240|NCT02963285||7 months to less than 1 year|
33412241|NCT02963285||1 to less than 2 years|
33412242|NCT02963285||2 to less than 6 years|
33412243|NCT02963285||6 to 12 years|
33412244|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
33412245|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
33412246|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
32862945|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
33412247|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
33412248|NCT03977571|Experimental|Deferred nephrectomy|Surgery after induction therapy with IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
33412249|NCT03977571|Active Comparator|No surgery|Induction therapy wih IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
33412250|NCT02946047|Experimental|Ixazomib 1 mg|Cohort A: Patients will receive ixazomib 1mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
33412251|NCT02946047|Experimental|Ixazomib 2 mg|Cohort B: Patients will receive ixazomib 2mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
33412252|NCT02946047|Experimental|Ixazomib 3 mg|Cohort C: Patients will receive ixazomib 3 mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
33412253|NCT02946047|Experimental|Ixazomib 4 mg|Cohort D: Patients will receive ixazomib 4mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
33412254|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
33412255|NCT05422443||Chronic pain group|Children with chronic pain
32862946|NCT04903782||Children and adolescents with newly diagnosed malignancy|
32862947|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
32862948|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
32862949|NCT04913688||suspected DVT group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, the patients become eligible for study subjects.
33412256|NCT05422443||Health group|children without chronic pain
33412257|NCT05422287|Experimental|Virtual Reality Glasses (VRG) Group|The participants in this group were started to watch videos by wearing virtual reality glasses about 2 minutes before the catheterization process was started and the process was continued until the end. Then, catheterization was performed by detecting the tourniquet by the emergency department nurse. Upon completion of the catheterization procedure, VRG was removed from the procedure area by the researcher. This process took an average of 5 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
33412258|NCT05422287|Experimental|Thermomechanical Stimulation Device (Buzzy ®) Group|1 minute before starting the catheterization procedure in this group, a cold and vibration application was placed in the operation area by the researcher using the apparatus of the Buzzy ® device and started. The procedure was performed after evaluating the vein and determining the appropriate right or left arm. At the end of this time, the Buzzy ® has been shifted approximately 5 cm above the processing zone. Then, catheterization was performed. Upon completion of the catheterization procedure, Buzzy ® was removed from the procedure area by the researcher. This process took an average of 4 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
32981772|NCT05511766|Placebo Comparator|PLACEBO|Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
32981773|NCT05511766|Active Comparator|Allopurinol|Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
32981774|NCT05511766|Active Comparator|Simvastatin|Group 3: (atorvastatin n=50) who will receive oral atorvastatin 20 mg daily for 6 months
32981775|NCT05502601|No Intervention|Control|The control group will be comprised by those who will not receive any specific oral care intervention. For ethical reasons, the control group will receive periodontal therapy at the Endo of the study (after 6 months). In those cases presenting periodontal disease progression in a single tooth, the patients will be treated and withdrawn from the study
32981776|NCT05502601|Active Comparator|Non-surgical periodontal treatment|"Periodontal treatment will be performed with scaling and root planning (SRP).SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (patient education and motivation to control plaque and calculus accumulation)"
32981777|NCT05497830|No Intervention|Standard care|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored.
32981778|NCT05497830|Experimental|RISKINDEX|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored. In the intervention group, physicians will be presented with the RISKINDEX. Subsequently, self-report will again be initiated to evaluate the physicians' response to the ML score and possible policy changes due to the intervention.
32981779|NCT05496855|Active Comparator|Conventional follow-up|Conventional follow-up strategy with blood tests and face-to-face visits at the hospital every 6 months
32981780|NCT05496855|Experimental|Remote monitoring|Monthly remote monitoring of patient-reported outcomes and triage of patients using an algorithm will guide healthcare providers in scheduling patients for a video consultation or face-to-face hospital visits.
33412259|NCT05422287|No Intervention|Control group|Peripheral intravenous catheterization was performed by the same emergency department nurse in accordance with the procedure. The process took an average of 3 minutes. There was no application to the patients in the control group except for the standard procedure. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
33412260|NCT05422131||Patients Prescribed Clozapine|
32981781|NCT05489432|Experimental|prehabilitation group|care as usual and pre habilitation intervention
32981782|NCT05489432|No Intervention|control group|care as usual
32981783|NCT05485688||Sleep apnea|60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese [BMI>=27] & 30 non-obese [BMI<27])
32981784|NCT05485688||Control|40 age-, gender-, BMI-matched controls without OSA.
32981785|NCT05484830|Active Comparator|Individualised HDR-approach|HMS Plus® Hemostasis Management System (Medtronic International, Tolochenaz, CH).
32981786|NCT05484830|Active Comparator|Conventional ACT-approach|ACT Hemostasis Management
32981787|NCT05473884||lesion preparation with POBA in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by plain old balloon angioplasty followed with DCB.
32981788|NCT05473884||lesion preparation with debulking devices in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by other lesion preparation devices, like Chocolate balloon, Shockwave balloon, TurboHawk, Jetstream and Rotarex and then followed by DCB.
32981789|NCT05472311|Other|Treat with thermal ablation|Women who screen positive for pre-cancer lesions of the cervix will be offered treatment with thermal ablation and the process of implementation evaluated using implementation science RE-AIM framework
32981790|NCT05470036|Other|Educational intervention|In-clinic or virtual educational session on germline testing in prostate cancer with a trained educator.
33412261|NCT05421897|Experimental|Rapid infusion of dinutuximab with chemotherapy|Patients will receive chemotherapy and dinutuximab via rapid infusion
33412262|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
33412263|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
33412264|NCT01377675||Usual curriculum education program|Third year internal medicine residents
33412265|NCT01380951|Experimental|telbivudine|
33412266|NCT01377597|Experimental|ranibizumab intravitreal injection|
33412267|NCT05421351||Experimental|All patients with overt HE in ACLF of any etiology.
32981791|NCT05465174|Experimental|Group 1, Arm A: Neoadjuvant nivolumab|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected recommended phase 2 dose (RP2D) for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
33105056|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
32981792|NCT05465174|Experimental|Group 1, Arm B: Neoadjuvant DAY101|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of DAY101 within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent . Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
32981793|NCT05465174|Experimental|Group 1, Arm C: Neoadjuvant combination nivolumab and DAY101|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one dose of DAY101 (7days +/- 2 days prior) to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
32981794|NCT05465174|Experimental|Group 2, Arm A: Neoadjuvant nivolumab|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent. If participants are eligible based on archival tissue alone, these participants will go directly on to receive combination therapy only.
32981795|NCT05465174|Experimental|Group 2, Arm B: Neoadjuvant DAY101|Participants with recurrent craniopharyngioma will receive one (1) dose of DAY101 within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent.
32981796|NCT05465174|Experimental|Group 2, Arm C: Neoadjuvant combination nivolumab and DAY101|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one (1) dose of DAY101 (7 days +/- 2 days) prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent.
32981797|NCT05465174|Experimental|Group 2, Arm D: Non-biopsy/resection participants|Non-biopsy/resection participants with recurrent disease will receive combination maintenance therapy of nivolumab given every 2 weeks and DAY101 once weekly at the respected RP2D for each agent.
32981798|NCT05463757||Oral hedgehog inhibitor|Oral hedgehog inhibitors vismodegib (Erivedge) or sonidegib (Odomzo)
32981799|NCT05451446|Experimental|proprietary water|Participants in this group will consume a proprietary water blend for 5-free living days and then throughout their heat stress environment day.
32981800|NCT05451446|Active Comparator|carbohydrate-electrolyte drink|Participants in this group will consume a commercial carbohydrate-electrolyte drink for 5-free living days and then throughout their heat stress environment day.
32981801|NCT05451446|Placebo Comparator|distilled water|Participants in this group will consume distilled water for 5-free living days and then throughout their heat stress environment day.
32981802|NCT05426447|Experimental|Reduced protein diet|"A 6-week eucaloric dietary intervention of reduced protein intake (~1g protein/kg body mass). The diet will, hence, contain ~7E% protein, ~63E% carbohydrate, and ~29E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
32981803|NCT05426447|Active Comparator|Normal protein diet|"A 6-week eucaloric dietary intervention of normal protein intake (~2g protein/kg body mass). The diet will, hence, contain ~16E% protein, ~53E% carbohydrate, and ~30E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
32981804|NCT05418088|Experimental|Cohort A (lymphodepletion; anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0."
32981805|NCT05418088|Experimental|Cohort B (lymphodepletion, anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0 and 7."
32981806|NCT05403554|Experimental|NI-1801|
32981807|NCT05399966|Experimental|Monarda Didyma extract|Monarda Didyma extract
32981808|NCT05399966|Placebo Comparator|Placebo|Maltodextrin
32981809|NCT05390034|Experimental|ART|Developed by Berking and Whitley (Berking & Whitley, 2014), this transdiagnostic program aims to improve general emotion regulation skills, and more specifically by increasing participants' emotion regulation flexibility. ART targets several skills, such as acceptance, tolerance, non-judgmental awareness, self-support, analysis of the causes of emotions and emotional modification. This intervention consists of 9 sessions (2 hours each), each of which starts with the presentation of a vicious circle for psycho-education. This vicious circle is then transformed into a virtuous circle by introducing an emotion regulation skill. Participants are invited to reflect, discuss and practice this skill. Exercises are also recommended at home, with the help of audios and a written workbook made available. All the material was translated into French for the purpose of this research.
33412268|NCT05421351||Disease Control Group|"Diseased Control patients with Acute-on-Chronic Liver Failure with no Hepatic Encephalopathy~Diseased Control patients with Decompensated Cirrhosis with no Hepatic Encephalopathy"
33412269|NCT05421351||Control Group 2|Healthy Control without any liver disease
33412270|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
32981810|NCT05390034|Active Comparator|Relaxation|The relaxation group will be based mainly on the intervention developed by Dominique Servant (Relaxation and meditation, 2021), adapted for this research for the group format and divided into 9 modules (2 hours each). This intervention proposes an added psycho-education part similar to the dedicated session of the ART program, followed by the teaching of different relaxation techniques to the participants, who are invited to test them in session and then to practice them at home. This control group focuses on a specific component present in the ART group (relaxation), allowing us to assess the impact of the other components of the ART program and thus explore our flexibility hypothesis (requiring several emotion regulation skills). Note that the mindfulness meditation components were removed from the program for this study, as they were considered a second emotion regulation skill.
32981811|NCT05387525|Experimental|Tirbanibulin 10 milligram per gram (mg/g) ointment|Participants will apply tirbanibulin ointment 10 mg/g once daily to the treatment field (TF) for 5 consecutive days beginning Day 1. At subsequent visits, participants will have the option of an additional 5-day course(s) (with at least 16 weeks between starting date of treatment courses) at the discretion of the investigator if actinic keratosis (AK) lesions are present in the TF and physical treatment is not appropriate.
32981812|NCT05387525|Active Comparator|Diclofenac Sodium 3% Gel|Participants will apply diclofenac sodium 3% gel twice daily to the TF for 60 to 90 days beginning Day 1, with the option of further courses every 6 months (with at least 6 months between starting date of treatment courses) if lesions are found to be present in the TF at follow up visits and physical treatment is not appropriate.
32981813|NCT05384041|Active Comparator|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.
32981814|NCT05384041|Placebo Comparator|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
32981815|NCT05382312|Experimental|Participants receiving GSK3036656+bedaquiline|
32981816|NCT05382312|Experimental|Participants receiving GSK3036656+delamanid|
32981817|NCT05382312|Experimental|Participants receiving bedaquiline+delamanid|
32981818|NCT05382312|Experimental|Participants receiving RIFAFOUR e-275|
32981819|NCT05376891||Advanced Non-small Cell Lung Cancer with METex14 skipping alterations|Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
32981820|NCT05373316|Experimental|MR-guided hypofractionated focal boost radiotherapy|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MR
32981821|NCT05371275|Experimental|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
32981822|NCT05370794||standard IVM: urinary purified gonadotropins (uFSH and uhCG)|"uhCG = Pregnyl®, 5000IU/ vial, Organon-Merck: final concentration 100mIU/ml + uFSH = Menopur® 75mIU/ml, Ferring: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
32981823|NCT05370794||Experimental IVM: recombinant gonadotropins (rFSH and rhCG)|"rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono : final concentration 100mIU/ml + rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
32981824|NCT05343507|Experimental|Ketalar arm|Patients will receive ketamine (sold in the form of Ketalar) intravenously, up to 0.75 µg/ml concentration, for a maximum of 90' minutes. Ketalar concentration will be increased slowly in a step-wise manner unless new signs of consciousness are evident.
32981825|NCT05343507|Placebo Comparator|Placebo arm|Patients will receive placebo (saline solution)
32981826|NCT05340712|Experimental|IT formula|The test product (IT formula) is an infant formula based on cow's milk proteins containing a high level of lactose, a prebiotic, a high concentration of magnesium and a mix of probiotics.
32981827|NCT05340712|Placebo Comparator|Standard formula|The control product is a standard infant formula based on cow's milk proteins containing usual lactose and magnesium content, no prebiotic nor probiotic.
32981828|NCT05325151|Experimental|Arm I (GCPP intervention)|Patients receive GCPP intervention consisting of a series of educational videos on pre-genetic test information.
32981829|NCT05325151|Active Comparator|Arm II (conventional genetic counseling)|Patients receive conventional genetic counseling.
32981830|NCT05321914|No Intervention|Control|Habitual physical activity
33412271|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
33412272|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
32981831|NCT05321914|Experimental|Morning exercise|Exercise training in the morning (6:00-10:00am)
33412273|NCT03204695|Experimental|LAA Occlusion|
32981832|NCT05321914|Experimental|Evening exercise|Exercise training in the evening (4:00-8:00pm)
32981833|NCT05321784|Experimental|Group I (smartphone dermatoscope)|Patients perform self-skin exams using naked-eye criteria and smartphone dermatoscope at home for 4 months.
32981834|NCT05321784|Active Comparator|Group II (naked-eye skin exam)|Patients perform self-skin exams using naked-eye criteria at home for 6 months.
32981835|NCT05309941|Experimental|Internal Cues Messaging|Participants will view a five-minute video focusing on intuitive eating principles.
32746747|NCT04333485|Active Comparator|Telephonic Active Case Finding (TACF)|
32746748|NCT05350215|Placebo Comparator|Placebo oral capsules|Placebo (2 pills) before sleep for a week
32746749|NCT05350215|Active Comparator|Atomoxetine and DAW2020 oral capsules|DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
32746750|NCT05083923|Experimental|Diroximel Fumarate (DRF)|Japanese and Chinese participants will initiate treatment with DRF 231 milligrams (mg), oral capsule, twice daily on Day 1 through Day 7, followed by DRF 462 mg, oral capsules, twice daily from Day 8 up to Week 48.
32981836|NCT05309941|Active Comparator|External Cues Messaging|Participants will view a five-minute video focusing on traditional nutrition education principles.
32981837|NCT05303298|Experimental|Anti-reflux Oesophageal Stent Group (AOSG)|All patients randomised to this arm will receive an anti-reflux fully covered self-expanding metal oesophageal stent
32981838|NCT05303298|Active Comparator|Conventional Oesophageal Stent Group (COSG)|All patients randomised to this arm will receive a conventional fully covered self-expanding metal oesophageal stent that does not contain an anti-reflux mechanism
32981839|NCT05295927|Experimental|Group A: EPI-7386 + Abiraterone Acetate Plus Prednisone (AAP)|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive EPI-7386 + AAP to determine the recommended phase 2 dose (RP2D) dose of EPI-7386 in combination with AAP in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with AAP.
32981840|NCT05295927|Experimental|Group B: EPI-3786 + Apalutamide|Participants with mCRPC will receive EPI-7386 + apalutamide to determine RP2D dose of EPI-7386 in combination with apalutamide in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with apalutamide.
32981841|NCT05292482|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose.
32981842|NCT05292482|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
32981843|NCT05290883|Experimental|Group A: Yoghurt drink (polar lipid) intervention|
32981844|NCT05273281|Experimental|TAQLA|Transabdominal plain block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
32981845|NCT05273281|Experimental|TAQLB|Quadratus lumborum block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
32981846|NCT05273281|No Intervention|TAQLC|Control group. Pain relief only with intravenous and peroral drugs.
32981847|NCT05264480|Experimental|Test group|Test patients receive bone augmentation and selective decorticalisation (corticotomy) and 1 week postop. OTM.
32981848|NCT05264480|Active Comparator|Control group|Control subjects receive bone augmentation without decorticalisation (corticotomy) and 1 week postop. OTM.
32981849|NCT05258578|Experimental|Tele-CBT Group|"Participants will receive 6 weekly Tele-CBT sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration. Briefly, the Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets). Five clinical psychology graduate students will work as study therapists under the supervision of Drs. Cassin and Sockalingam and will have biweekly case supervision meetings."
32981850|NCT05258578|Active Comparator|Self-Help Resources Group|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation. Participants in the control arm will receive weekly check-in/reminder emails for the duration of the intervention period.
33105057|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
33412274|NCT03979391|Experimental|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
33412275|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
33412276|NCT03382301|Placebo Comparator|NaCl preconditioning|
33412277|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
33412278|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
33412279|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
33412280|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
33412281|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
33412282|NCT04542785|Experimental|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
33412283|NCT04542785|Active Comparator|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate < 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
33412284|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 4-6 weeks interval (6-7 weeks if combined with systemic chemotherapy).
33412285|NCT03881059|Placebo Comparator|Part A: Placebo|
33412286|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
33412287|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
33412288|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
33412289|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
33412290|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
32981851|NCT05243394|Experimental|Gamified virtual reality environtment + tDCS + treadmill gait training|The first group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill. They will also receive tDCS for the first 20 minutes of each session.
32981852|NCT05243394|Experimental|Gamified virtual reality environtment + treadmill gait training|The second group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill.
32981853|NCT05243394|Active Comparator|Treadmill gait training|The third group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last.
32981854|NCT05228847|Active Comparator|Human milk-derived HMF|Fortification with human milk-derived product
32981855|NCT05228847|Other|Bovine milk-derived HMF|Current standard practice: Fortification with bovine milk-derived product
32981856|NCT05226962|Active Comparator|Ketone|An acute bout of exercise performed after the ingestion of a commercial ketone monoester supplement.
32981857|NCT05226962|Placebo Comparator|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
32981858|NCT05215210|Experimental|Bitter-gourd|dried bitter-gourd supplements
32981859|NCT05215210|Active Comparator|Cucumber|dried cucumber supplements
32981860|NCT05213832|Experimental|Inhalatory group|Patience with severe SAH (WFNS > 3) are enrolled in the study. In these patients we administered a inhalatory dose of Isofluorane
32981861|NCT05197439|Active Comparator|DEX group|Dexmedetomidine will be given at the beginning of the second step of DBS and last for 48 hours by electronic pump.
32981862|NCT05197439|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively and postoperatively the same duration just like the DEX group would do.
33412291|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
33412292|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
32981863|NCT05196620||EAUS|Patients with EAUS pre and postpartum
32981864|NCT05186064|Experimental|whole genome sequencing after standard of care resection at first relapse|
32981865|NCT05175651|Experimental|Subjects identified by Optum Health|10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.
32981866|NCT05166395|Experimental|Er:YAG laser Group|The study is a split-scar model. Participants will have half of their lesion receive a total of three sessions using 2940 nm Er:YAG laser spaced over a 4-week study participation interval.
32981867|NCT05166395|No Intervention|Control (No Intervention) Group|The study is a split-scar model. Participants will serve as their own control and have half of their lesion receive no intervention.
32981868|NCT05164159|Active Comparator|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 ~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
32981869|NCT05164159|Experimental|remimazolam group|Arm Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
32981870|NCT05164146|Active Comparator|propofol group|During the induction, propofol was controlled according to sedline (Psi target 40)
32981871|NCT05164146|Experimental|remimazolam group|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
33412293|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
33412294|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
32981872|NCT05156333|Placebo Comparator|Placebo|Daily oral administration of 1 capusle of placebo, composed of: hydroxypropylmethylcellulose; Anti-caking agent: Magnesium salts of fatty acids, Dioxide of silicon; Dye: E171.
32981873|NCT05156333|Active Comparator|Probiotic|Daily oral administration of 1 capsule of mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).
32981874|NCT05153070|Experimental|Ciclosporin/ILT-101|Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months
32981875|NCT05153070|Placebo Comparator|Ciclosporin/placebo|Ciclosporin during 2 months (for all patients) followed by placebo during 10 months
32981876|NCT05136417|Experimental|left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)|100 patients undergoing LAA closure with the WATCHMAN FLX utilizing an intra-procedural ICE probe under moderate sedation.
32981877|NCT05135728|Experimental|Unstuck and On Target-Preschool|"UOT-P is based on the foundational principles of UOT for improving EF as well as evidence-based teaching methods (e.g., positive behavior supports, visual aids). Through this program, children, teachers and parents develop a shared self-regulatory vocabulary that enables children to improve EF at home and school through adult modeling and gradual scaffolding. The self-regulatory vocabulary (e.g., Flexible, Make a New Plan, Unstuck) becomes a contagious common language. We hypothesize this is the mechanism of change by which children will show improved EF skills, leading to increased academic readiness, improved social competence and reduced externalizing behaviors."
33105058|NCT04686474|Experimental|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment will be used twice daily for 12 weeks
32981878|NCT05135728|Active Comparator|Treatment As Usual|Children at one site may be placed in Arm 2, in which they will receive usual social skills intervention provided by school staff. Intervention is based on previously established effective treatments for preschoolers with behavioral difficulties.
32981879|NCT05132517||Stroke Patients|Ischemic-/hemorragic stroke patients, who admitted on the stroke unit.
32981880|NCT05130008|Experimental|Intervention|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker and oriented to the digital platform ( mobile app, digital weight scale, digital blood pressure monitor, biosensor with armband). Participants will have access to the community health worker and the digital platform throughout the 30-day study interval.
32981881|NCT05130008|Active Comparator|Usual CHW Care|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker. Participants will have access to the community health worker throughout the 30-day study interval.
32981882|NCT05129748|Experimental|Standard Cisplatin-based Chemotherapy + Sodium Thiosulfate + Mannitol|Participants will receive the standard of care (cisplatin-based chemotherapy) plus the experimental treatment of Sodium Thiosulfate and Mannitol. Both drugs will be administered IV 4 - 8 hours following chemotherapy treatment, as part of post-chemotherapy hydration.
32981883|NCT05129748|No Intervention|Standard Cisplatin-based Chemotherapy|Participants will receive the standard of care (cisplatin-based chemotherapy) only.
32981884|NCT05128383|Experimental|Dupilumab Subcutaneous Injection|"600 mg at initial visit and 300mg every 2 weeks until week 22~Each subject will receive 600mg of Dupilumab at baseline visit and 300mg of Dupilumab as a subcutaneous injection every 2 weeks for a total of 9 doses over 22 weeks."
32981885|NCT05123742||DHCW Subjects in POC Offices|Dental Health Care Workers recruited in point of care offices.
32981886|NCT05123742||Patient Subjects in POC Offices|Dental patients recruited in point of care offices.
32981887|NCT05123742||DHCW Subjects in LAB Offices|Dental Health Care Workers recruited for lab-based testing.
32981888|NCT05123742||Patient Subjects in LAB Offices|Dental patients recruited for lab-based testing.
32981889|NCT05114447||Clinical sample|a) clinical cases of severe/uncontrolled asthma attending hospital specialist centres already included in the online RItA Registry and b) new clinical cases of severe/uncontrolled asthma attending the clinical centres and not yet included in the online RItA Registry, with the following characteristics: adult subjects with a diagnosis of asthma since at least one year with a) uncontrolled asthma, despite regular treatment with GINA (Global Initiative for Asthma) step 4 level, in the last three months or b) controlled asthma with a step 5 level treatment according to GINA (Global Initiative for Asthma).
32981890|NCT05114447||Epidemiological sample|a) epidemiological cases of severe/uncontrolled asthma from a general population Pisa cohort already inserted in the online RItA Registry and b) new epidemiological cases of severe/uncontrolled asthma from pre-existing Pisa cohort not yet included in the online RItA Registry, with the following characteristics: adult subjects with at least one asthma attack in the last 12 months or wheezing and/or asthma therapy in the last 12months.
32981891|NCT05111548|Experimental|Active stimulation + cognitive training|Participants receive 10 sessions of 'active' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
32981892|NCT05111548|Sham Comparator|Inactive stimulation + cognitive training|Participants receive 10 sessions of 'inactive' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
32981893|NCT05111431|Experimental|Dexmedetomidine Hydrochloride Nasal Spray|
32981894|NCT05111431|Placebo Comparator|Dexmedetomidine hydrochloride nasal spray blank preparation|
32981895|NCT05093426||Insomnia in Breast cancer cohort|A single cohort will be observed in Stage 1 to assess the prevalence of insomnia suffered by participants who suffer from breast cancer. A subset of participants will continue to Stage 2 to use a digital sleep diary app for an observational period of 3 weeks.
32981896|NCT05072275||Subjects receiving care from Scripps Health physicians in Cardiology and Primary Care|A confidential data request will be submitted to screen the Scripps Health EHR system for individuals meeting study inclusion criteria and having seen a participating study physician in the past two years.
33412295|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
33412296|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
32981897|NCT05061810|Experimental|Group A: Arm 1|Arm 1, group A will receive standard respiratory outpatient care such as routine virtual visits to the respiratory clinic at 6 and 12 months along with the use of a smartphone app self-management programme with follow up monthly phone calls. They will be asked to use the spirobank spirometer (measures lung function, FEVI), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
32981898|NCT05061810|Experimental|Group B: Arm 2|Those allocated to the intervention groups B will receive standard respiratory outpatient care such as routine virtual visits at 6 and 12 months to the respiratory outpatient clinic along with the use of a smartphone app self-management programme. They will be asked to use the spirobank spirometer (measures lung function, FEV1), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), their step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
33105059|NCT04686630||Single group|Only observational study
33105060|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
33105061|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
33412297|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
33412298|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
33412299|NCT03167255|Experimental|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
33412300|NCT03167255|Experimental|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
33412301|NCT03140969|Experimental|QR-110|Administered every 3 months
33412302|NCT05426993||Patients diagnosed with lymphedema with metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
33412303|NCT05426993||Patients diagnosed with lymphedema without metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
32862950|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
32862951|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
32862952|NCT04902924|Experimental|Repeated cold-water immersion|In this arm, the participants undergo repeated cold water immersion at 10°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crest
32862953|NCT04902924|Active Comparator|Repeated warm-water immersion|In this arm, the participants undergo repeated warm water immersion at 40°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crestParticipants will be immersed up to the iliac crest.
32862954|NCT04902924|Other|Control|In this arm, the participants undergo the control intervention which comprises to remain seated for 12.5 min. The participants, that will perform the muscle damaging protocol under hypoxia will also be treated with the control condition.
32862955|NCT04903158|Experimental|Test group|Test formulation of SHR3680
32862956|NCT04903158|Other|Reference group|Reference formulation of SHR3680.
32862957|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
32862958|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
32862959|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
32862960|NCT04905576|Experimental|Relaxation training following daily radiation|All relaxation sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving relaxation will learn exercises to release tension through muscle relaxation, breathing, and imagery
32862961|NCT04905576|Experimental|Healing touch therapy following daily radiation|All Healing Touch sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving Healing Touch will receive a series of standardized therapeutic techniques designed to promote optimal flow of energy throughout the body.
32862962|NCT04905576|Active Comparator|No intervention|The no intervention group will receive no special intervention other than standard medical care, which includes the regular medical care given by the patient's physician and health care professionals.
32862963|NCT04905030|Experimental|Immigrant mother stratum|The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.
32862964|NCT04905030|Experimental|Educ 1 stratum|The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.
32862965|NCT04905030|Experimental|Educ 2 stratum|The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.
32862966|NCT04905030|Experimental|Educ 3 stratum|The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree
32862967|NCT04905030|Experimental|Educ 4 stratum|The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education
32862968|NCT04913454|Experimental|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).
32862969|NCT04913454|Active Comparator|Cognitive training only|Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).
32862970|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
32862971|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
32862972|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
32862973|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
32862974|NCT04904874|Other|flourescein staining, miboscore|
32981899|NCT05061810|Active Comparator|Group C: Arm 3 Control group|Participants in group C the control group will receive standard outpatient respiratory care which involves attending the routine visits as outlined above and informing the research team of an GP visits and or hospital admissions relating to an exacerbation of COPD. They will complete questionnaires on quality of life, m MRC scale and self-efficacy at these visits over the phone.
32981900|NCT05060731|Active Comparator|Oral iron supplementation|Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
32981901|NCT05060731|Active Comparator|Intravenous iron supplementation|Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
32981902|NCT05056090|Experimental|Patients will receive MV in PP|Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met
32981903|NCT05056090|No Intervention|Patients will receive MV in SP|
32981904|NCT05044325|Experimental|Part 1 Cohort 1: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 1) + Placebo; in period 2: GSK3884464 (Dose 2) + Placebo and in period 3: GSK3884464 (Dose 3) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
32981905|NCT05044325|Experimental|Part 1 Cohort 2: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 4) + Placebo; in period 2: GSK3884464 (Dose 5) + Placebo and in period 3: GSK3884464 (Dose 6) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
32981906|NCT05044325|Experimental|Part 1 Cohort 3: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 7) + Placebo; in period 2: GSK3884464 (Dose 8) + Placebo and in period 3: GSK3884464 (Dose 9) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
32981907|NCT05044325|Experimental|Part 2 Cohort 4: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose X) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1.
32981908|NCT05044325|Experimental|Part 2 Cohort 5: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose Y) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.
32981909|NCT05044325|Experimental|Part 2 Cohort 6: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose Z) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.
32981910|NCT05040893|Experimental|Outpatient Physiotherapy Intervention|POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
32981911|NCT05035199||Patients with psychiatric disorders|Patients with psychiatric disorders of the affective spectrum.
32981912|NCT05030909|Experimental|transdiagnostic group protocol|The study will run two gender-specific treatment groups (8 participants each) recruited from the community, with one individual session (for information, consent and initial data collection) and 5 group sessions. Both groups will receive the same intervention.
32981913|NCT05029713||liver transplanted patients without sarcopenic obesity (controls)|All liver transplanted patients followed as outpatients at out clinic, which lack at least one of the two conditions (muscle strenght and muscle mass) used to identify sarcopenic obesity.
32981914|NCT05029713||liver transplanted patients with sarcopenic obesity (cases)|All liver transplanted patients followed as outpatients at out clinic, with both muscle strenght and muscle mass.
32981915|NCT05016232|Experimental|Strength Based Case Management (SBCM)|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
32981916|NCT05016232|Experimental|PrEP adherence training and counseling|"Stage 2: Stepped Intervention:~Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
32981917|NCT05016232|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to local PrEP clinic
32981918|NCT05016232|No Intervention|Standard of Care: Stage 2|Stage 2: Standard clinical PrEP care: Doctor visit every three months to assess for side effects, do blood work, and receive a HIV test.
32981919|NCT05015543|Experimental|Patients paticipating in the Personal Training Program|The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)
32981920|NCT04975568|Experimental|Therapeutic Exercise Controlled Through App With face-to-face|3 months treatment using app for HTEP and 6 people therapeutic exercise group every 15 days
32981921|NCT04975568|Active Comparator|Therapeutic Exercise Controlled Through App|3 months treatment using app for HTEP
32981922|NCT04965298|Experimental|Active treatment arm|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
32981923|NCT04965298|Placebo Comparator|Matched-Placebo arm|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
32981924|NCT04956939||Group 1|PD patients receiving low frequency dose of levodopa.
32981925|NCT04956939||Group 2|PD patients receiving high frequency dose of levodopa.
32981926|NCT04956939||Control Group|Spouses of PD patients without PD diagnosis
32746751|NCT04752358|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
32862975|NCT04904796|Experimental|Constraint-induced Movement Therapy With Home-based Hand-arm Bimanual Intensive Therapy|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours), and 2-hour home-based HABIT sessions, 3 days/week for 5 weeks (30 hours).
32862976|NCT04904796|Active Comparator|Constraint-induced Movement Therapy only|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours).
32862977|NCT03399981||Tysabri (TOUCH Cohort)|Participants from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
32862978|NCT03399981||Tysabri (EU MS Cohort)|Participants from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
32862979|NCT04902534|Experimental|Naoqingzhiming Tablets|"Naoqingzhiming Tablets, specification:500mg(contains echinacoside 180mg) Single dose ascending. Qualified subjects will enter 6 dose groups in order from low to high: 180mg, 360mg, 720mg, 1080mg, 1620mg and 2160mg, with increasing dose design The first group (180mg) is a pre-experiment. Two subjects were selected and all received the test drug.~Groups 2 to 6 received the experimental drug in 8 patients per group. Multi-dose ascending was divided into two groups: 360mg and 720mg. 10 subjects in each group received the test drug 3 times a day for 14 consecutive days."
32862980|NCT04902534|Placebo Comparator|placebo (without active ingredients echinoside)|Placebo Tablets, specification: 500mg(without echinoside) Single dose. Groups 2 to 6 received the placebo in 2 patients per group. Multi-dose ascending. Two people in each group received placebo 3 times a day for 14 consecutive days.
32862981|NCT04913532|Experimental|Hypofractionation with SIB|Hypofractionation with SIB
32862982|NCT01332981||Cohort|
32862983|NCT04913376|Experimental|Hilotherapy|
32862984|NCT04913376|No Intervention|Standard care|
32862985|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
32862986|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
32862987|NCT04904640||CLS stem|CLS Zimmer stem implantation (single wedge, tapered stem) using the 3D CT based software for surgical pre-operative planning
32862988|NCT04904640||Wagner cone stem|Wagner cone Zimmer stem implantation (conical tapered stem) using the 3D CT based software for surgical pre-operative planning
32862989|NCT04904640||Aptafix stem|Aptafix Ortho stem implantation (anatomical stem) using the 3D CT based software for surgical pre-operative planning
32862990|NCT04894344|Experimental|Educational program|"Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.~Urine samples of 24 h before and after the Intervention will be analyzed."
32862991|NCT04894344|No Intervention|Control group|Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
32862992|NCT04904328|Active Comparator|Lumishade® active lens|Treatment of photosensitive migraine with a Lumishade® active device.
32862993|NCT04904328|Sham Comparator|Lumishade® sham lens|Treatment of photosensitive migraine with a Lumishade® sham device.
32862994|NCT04902222||Patients undergoing primary hip or knee arthroplasty|Patients undergoing primary hip or knee arthroplasty
32862995|NCT04902456|Experimental|Power Chain and Crimpable hook for En-masse retraction|"Retraction will start on a 0.017x0.025 Stainless Steel wire using elastomeric chain ( force applied will be 212 g per side ) extending between the crimpable hooks and the miniscrew"
32862996|NCT04902456|Experimental|T-loop|"Closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine."
32862997|NCT04894422||No face mask|Volunteers who did not wear a face mask
32862998|NCT04894422||Cotton face mask|Voluntarily wearing a cotton face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
32862999|NCT04894422||Surgical face mask|Voluntarily wearing a surgical face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
32863000|NCT04904406|Experimental|dolutegravir/lamivudine|50 mg dolutegravir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
32863001|NCT04904406|No Intervention|dolutegravir/abacavir/lamivudine|50 mg dolutegravir, 600 mg abacavir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
32863002|NCT00985751|Experimental|Group 1|
32863003|NCT00985751|Experimental|Group 2|
32863004|NCT00985751|Experimental|Group 3|
32863005|NCT00985751|Experimental|Group 4|
32863006|NCT00985751|Experimental|Control Group|
32863007|NCT04884828||one group|patients from the Pulmonology Service of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) who met the following criteria: over 18 years of age, hospital admission for acute chronic respiratory failure, home NIV (single-limb system with intentional leakage) users for more than 6 months with adequate compliance (greater than or equal to 5 hours/night). Patients with underlying psychiatric disease were excluded. The study was conducted during the patient's predischarge phase (the same day or the day before)
32863008|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
32863009|NCT04901832|Experimental|Experimental Group|The intervention in this group is stretching exercises with the aim of prevention and reduction of leg muscle cramps among patients undergoing hemodialysis
32863010|NCT04901832|No Intervention|Control Group|The participants in this group used as reference group
32863011|NCT02435173|Experimental|Part I: CDZ173|Participants consecutively received CDZ173 10 mg twice a day (b.i.d.) from Day 1 to Day 28, CDZ173 30 mg b.i.d. from Day 29 to Day 56 and CDZ173 70 mg b.i.d. from Day 57 to Day 84.
32863012|NCT02435173|Experimental|Part II: CDZ173|Participants received CDZ173 70 mg b.i.d. from Day 1 to Day 85.
32863013|NCT02435173|Placebo Comparator|Part II: Placebo|Participants received Placebo b.i.d. from Day 1 to Day 85.
32863014|NCT04901520|Experimental|High Intensity Training (HIT)|Participants trained at 80-90% of 1RM for 12 weeks, twice per week.
32981927|NCT04955470|Experimental|Intravenous ketamine|Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
32981928|NCT04955470|Active Comparator|Intravenous midazolam|Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
32981929|NCT04955470|Placebo Comparator|Intravenous saline|Infusion of 0.9% saline over 40 minutes.
32981930|NCT04944121|Experimental|RSLV-132|RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
32981931|NCT04944121|Placebo Comparator|Placebo|Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
32981932|NCT04938557|Experimental|An Automated Closed-loop Insulin Delivery (AiD) System.|The intervention being evaluated in this trial is automated closed-loop insulin delivery (AiD). The closed-loop system comprises of three components: an insulin pump, a continuous glucose monitor (CGM) and a computer-based model predictive control (MPC) algorithm to compute information from the CGM into a recommended insulin dose.
32981933|NCT04938557|Active Comparator|A Standard Insulin Delivery System|This can include either: an insulin pump (Continuous Subcutaneous Insulin Infusion - CSII) or multiple daily injections (MDI) without closed-loop.
32981934|NCT04927390|Experimental|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
32981935|NCT04927390|No Intervention|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
32981936|NCT04925401|Experimental|Information brochure Arm|The experimental group will receive an information brochure on fever in children and how to deal with a febrile episode and usual medical management.
32981937|NCT04925401|No Intervention|Habitual care|The control group will receive the usual medical management
32981938|NCT04922645|Experimental|Ferric citrate (commercially available, Auryxia)|Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
32981939|NCT04922645|Active Comparator|Standard of care phosphate lowering therapy|Non-Auryxia phosphate-lowering therapy administered as standard of care.
32981940|NCT04922567|Experimental|lenalidomide + CHOP regimen|
32981941|NCT04922567|Active Comparator|CHOP regimen|
32981942|NCT04906278|Other|Amniotomy group|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip.
32981943|NCT04906278|Other|No-amniotomy group|No-amniotomy will be done
32981944|NCT04899882|No Intervention|Control group|
32981945|NCT04899882|Experimental|KinHémo group|
32981946|NCT04893447|Experimental|SPI+: Safety Planning Intervention plus structured phone-based follow-up|The Safety Planning Intervention (SPI+) includes safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus a structured telephone-based intervention from a suicide prevention hotline
32981947|NCT04893447|Experimental|Caring Contacts: Safety Planning Intervention plus Caring Contacts (SP+CC)|SP+CC will include safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus caring text messages or emails from a suicide prevention hotline.
32981948|NCT04873232|Experimental|Engensis|Patients who have received Engensis in protocol VMDN-003-2
32981949|NCT04873232|Placebo Comparator|Placebo|Patients who have received Placebo in protocol VMDN-003-2
32981950|NCT04863664|Experimental|Intervention/Treatment|Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
32981951|NCT04855799|Experimental|Aquamin®|
32981952|NCT04851704|Experimental|Intervention: Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
32981953|NCT04851704|No Intervention|Control: Business as usual|"Control groups have business as usual, and then get offered the intervention program after 6 months follow-up assessment."
32981954|NCT04850222|Experimental|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
33412304|NCT02836925|Experimental|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
32981955|NCT04850222|Active Comparator|Subjects randomized to get Calcium Supplmentation|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
32981956|NCT04835363|No Intervention|Control group|Usual care.
32981957|NCT04835363|Experimental|OT intervention.|Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.
33412305|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
33105062|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
33105063|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
33105064|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
33412306|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
33412307|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
33412308|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
33412309|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
33412310|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
32863015|NCT04901520|Experimental|Moderate Intensity Training (MIT)|Participants trained at 65-75% of 1RM for 12 weeks, twice per week.
32863016|NCT04901520|Experimental|Low Intensity Training (LIT)|Participants trained at 50-60% of 1RM for 12 weeks, twice per week.
32863017|NCT04901520|No Intervention|Control Group (CG)|Participants did not participate in any training and they advised to do their daily activity
32863018|NCT04901286|No Intervention|Seated Rest|Behavioral: Seated Rest In the seated rest control condition, participants will sit on the bike for 30 minutes. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
32863019|NCT04901286|Active Comparator|Exercise Only|Behavioral: Exercise Only In the exercise-only condition, participants will complete a total of 30-minutes on the stationary bike. This will include a) 5-min warm-up at low resistance, b) 20 minutes of moderate-vigorous intensity cycling, and c) a 5-min cool-down at low resistance. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
32863020|NCT04901286|Experimental|Exercise + Non-Immersive Virtual Reality|"Behavioral: Exercise + Non-Immersive Virtual Reality In the exercise with non-immersive Virtual Reality condition, participants will complete a total of 30-minutes on the stationary bike while watching a video on an iPad. The cycling session will be identical to that in the Exercise Only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, a YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]) will play on an iPad placed on the front of the bike. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
32863021|NCT04901286|Experimental|Exercise + Immersive Virtual Reality|"Behavioral: Exercise + Immersive Virtual Reality In the exercise with immersive virtual reality condition, participants will complete a total of 30-minutes on the stationary bike while wearing Oculus Quest 2 goggles. The bout of cycling will be identical to the prescription given in the exercise only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, the Oculus YouTubeVR app will play a 360° version of the YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]). Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart Rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
32863022|NCT04893330||patients|children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
32863023|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
32863024|NCT02429557|Experimental|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
32863025|NCT02429557|Sham Comparator|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
32863026|NCT02429557|Experimental|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
32863027|NCT02429557|Active Comparator|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
32863028|NCT04893642|Active Comparator|Abdominal suture rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
32863029|NCT04893642|Active Comparator|Abdominal resection rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
32863030|NCT04893642|Active Comparator|Perineal Delorme|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
32863031|NCT04893642|Active Comparator|Perineal Altemeier|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
33105065|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
33412311|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
32863032|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
32863033|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
32863034|NCT05027269|Experimental|Part A Single Dose: AOC 1001 Dose Level 1|AOC 1001 will be administered once.
32863035|NCT05027269|Placebo Comparator|Part A Single Dose: Placebo|Saline will be administered once.
32863036|NCT05027269|Experimental|Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4|AOC 1001 will be administered three times.
32863037|NCT05027269|Placebo Comparator|Part B Multiple Ascending Dose: Placebo|Saline will be administered three times.
32863038|NCT04901130|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through colonoscopy examination with the assitance of AQCS.
32863039|NCT04901130|No Intervention|Control group|Patients in control group will go through conventional standard colonoscopy examination without the assistance of the AQCS.
32863040|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
32863041|NCT04901052|Experimental|n-3 supplementation group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
32863042|NCT04901052|Placebo Comparator|Placebo group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus placebo capsules (2 capsules per day made from sunflower oil)
32863043|NCT05021185|Experimental|Interactive Mobile Doctor (iMD) Intervention|Participants will receive up to a total of 3 iMD sessions prior to their completion of radiation therapy; each session will take about 10-15 minutes and includes: 1) computerized assessments that will be delivered on the screen via text with accompanying audio and participants will respond directly on the tablet 2) tailored videos that deliver messages specific to patient's responses to selected assessment questions and 3) a summary printout
32863044|NCT05021185|No Intervention|Control Group|Participants will complete questionnaires and receive a handout containing tobacco cessation resources.
32863045|NCT04884516|Other|Intervention arm|Participants take retinol gummy once a day
32863046|NCT05027035|Active Comparator|Surgical plication|Surgical plication of the diaphragm
32863047|NCT05027035|Active Comparator|Mechanical ventilation|Non-invasive ventiatilatory support
32863048|NCT04884282|Experimental|Arm A - tedopi + docetaxel|Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.
32863049|NCT04884282|Experimental|Arm B - tedopi + nivolumab|Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal
32863050|NCT04884282|Other|Arm C - docetaxel|Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).
32863051|NCT04346329|Placebo Comparator|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
32863052|NCT04346329|Experimental|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
32863053|NCT04892784|Experimental|Press tack needle acupuncture|
32863054|NCT04892784|No Intervention|Control|
32863057|NCT04884048||Benign bone tumors|Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.
32863058|NCT04884048||Malignant bone tumors|Patients with malignant lesions confirmed by histology.
32863059|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
32907717|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 3 years).
32981958|NCT04835077|Experimental|Structured Aerobic Exercises|"Following the training on aerobic exercise content and effectiveness;~First Week; participants 5 minutes warm-up, 20 minutes of aerobic exercise with 60-70% of maximum heart rate, and 5 minutes of cool down.~In the following weeks, the aerobic exercise duration of all participants will be increased by 5 minutes compared to the previous week.~The duration of the sessions in the 7th and 8th weeks will progressively progress to 40 minutes and the intensity to 75-80% of the maximum heart rate."
32981959|NCT04835077|Experimental|Postural Stabilization Exercises|"Exercises; It will consist of postural exercises to be done in prone, supine, side lying, crawling, sitting and standing positions. All exercises will be done in 2 sets per day, the number of repetitions will be determined individually and progressed.~Breathing exercises~Four-way stretching and strengthening of the neck muscles~Shoulder girdle stretching and strengthening exercises~Hip flexors, hamstring, itb, lumbar extensor stretching and strengthening~Lying down exercises in the crawling position~Shuttle movement~Plank movement~Toe taps~Bridging~Straight leg lift~Straight leg raises in side-lying~Prone knee flexion"
32981960|NCT04835077|No Intervention|Control|The individuals without any treatment will continue their normal lives and will be included in the study as a control group. Exercise will be given after 8 weeks.
32981961|NCT04809350|Active Comparator|Adjustable Human Milk Fortification|Human milk fortification based on blood urea levels
32981962|NCT04809350|Experimental|Targeted Human Milk Fortification|Human milk fortification based on milk analysis
32981963|NCT04801966|Experimental|Treatment|"All participants will have an individualised treatment plan. The possible treatments that can be prescribed are as follows, they may be given as a single agent or in combination~Trametinib 2 mg/day~Cobimetinib 60 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Binimetinib 45 mg/ twice a day~Alpelisib 300 mg/day~Vemurafenib 960 mg twice a day~Dabrafenib 150 mg twice a day~Encorafenib 450 mg/day~Palbociclib 125 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Ribociclib 600 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off~Abemaciclib 150 mg twice a day~Olaparib 300 mg twice a day~Talazoparib 1 mg/day~Nivolumab 240 mg IV once every two weeks~Atezolizumab 1200 mg IV on day 1 of a 21 day cycle~Pembrolizumab 200 mg IV on day 1 of a 21 day cycle"
32981964|NCT04801745|Experimental|Healthy Vegan Diet|Education on healthy vegan diet
32981965|NCT04801745|Experimental|Healthy Vegan Diet with Amla fruits|Education on healthy vegan diet, 3g of powdered amla fruits per day
32981966|NCT04801745|Active Comparator|My Plate - Low Purine|"Education on My Plate diet with emphasis on choosing low purine protein options."
32981967|NCT04801745|Experimental|My Plate - Low Purine with Amla Fruits.|"Education on My Plate diet with emphasis on choosing low purine protein options and with an addition of 3g of amla powder per day."
32981968|NCT04800692|Experimental|Tetrahydrobiopterin Dose 1 (Day 0 to 44)|All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
32981969|NCT04800692|Experimental|Tetrahydrobiopterin Dose 2 (Day 45 to 90)|All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.
32981970|NCT04792892||Patients with a new diagnosis of anal cancer|All patients identified at our national tumour board will be offered to participate
32981971|NCT04788368||Patients treated with TEM - transanala microsurgery|Early rectal cancer treated with TEM - full thickness resection
32981972|NCT04788368||Patients treated with ESD|Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection
32981973|NCT04788368||Patients treated with EMR|Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection
32981974|NCT04787848|Experimental|HIV negative without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
32981975|NCT04787848|Experimental|HIV negative with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
32981976|NCT04787848|Experimental|HIV positive without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
32981977|NCT04787848|Experimental|HIV positive with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
32981978|NCT04787523||Patients with pathological response to treatment|Response evaluated using the pathology report
33412312|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
33412313|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
33412314|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
33412315|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
33412316|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
33412317|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
33412318|NCT03136055|Experimental|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first).
33412319|NCT03136055|Experimental|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first) and chemotherapy treatment of 125 mg/m^2 of irinotecan via IV on days 1 and 8 of each 21-day cycle or paclitaxel via IV on days 1, 8, and 15 of each 21-day cycle per physician discretion
33412320|NCT01380873|Experimental|Group1|
33412321|NCT01380873|Experimental|Group2|
33412322|NCT01380873|Experimental|Group3|
33412323|NCT03789045||Obese men and women|Metabolic thresholds and fat oxidation points relationship in Obese males and females, age 18-60y, body fat > 30%
33412324|NCT03789045||Male and female athletes|Metabolic thresholds and fat oxidation points relationship in Athletic males and females, age 18-60y.
33412325|NCT03789045||Sedentary females and males|Metabolic thresholds and fat oxidation points relationship in Sedentary females and males, age 18-60y,
33412326|NCT05421273|Experimental|Active recharge burst stimulation|
33412327|NCT05421273|Experimental|Passive recharge burst stimulation|
33412328|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
33412329|NCT05240417|Experimental|Study group|"Pontic-shield will be performed as ridge preservation technique."
33412330|NCT05240417|Active Comparator|Positive control (ridge preservation)|Deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction.
33412331|NCT05240417|No Intervention|Negative control (fresh socket)|No intervention will be performed after tooth extraction. Blood clot will be maintained after extraction.
33412332|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
33412333|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
33412334|NCT05421117||transumbilical (TU) routes|For the TU group, a surgical glove was created bag during the operation as follows: a sterile, surgical latex glove (size 8.5) was double tied at the level of the wrist, the fingers were removed, and a 75-cm purse-string suture was made using a symmetrical knot to form a bag. The glove bag took an average of 10 min to make. It was lubricated with normal saline to remove the talcum powder and then introduced through the 10-mm umbilical port (optic port). The fingers of the glove were removed to facilitate its insertion with the 10-mm trocar and for ease of movement in the abdominal cavity.
32907718|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
32907719|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
32907720|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
32907721|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
32907722|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
32907723|NCT04361552|Experimental|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
32907724|NCT04361552|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
32907725|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
32907726|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
32907727|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
32907728|NCT04367324||Control|No low-level laser application
32907729|NCT02862353||patients with thrombocytopenia drug|
32907730|NCT04361630|Experimental|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
32907731|NCT04376216|No Intervention|Control|No treatment
32907732|NCT04376216|Active Comparator|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
32907733|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
32907734|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
32907735|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
32907736|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
32907737|NCT01635101|Experimental|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
32907738|NCT01635101|Experimental|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
33417321|NCT03074318|Experimental|Phase 1 (1.2 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
32981979|NCT04783467|Experimental|Time Restricted Eating (TRE) Schedule|For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
32981980|NCT04783467|No Intervention|Control Schedule|For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.
32981981|NCT04783402|Experimental|e-OTCAT|The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.
32981982|NCT04783402|Other|Control Group|At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.
32981983|NCT04780217|Experimental|Phase 1|T3011 Single Agent Dose Escalation in participants with solid tumors
32981984|NCT04776746|Experimental|Drug - trofinetide|trofinetide oral solution
32981985|NCT04765774|Experimental|The Effect of Expressive Touch Applied After Lumbar Disc Herniation Surgery|Expressive touch reduces pain and keeps vital signs and NIRS values within normal limits by touching the arms and hands of the patients through energy transfer.
32981986|NCT04765774|Experimental|The Effect of Music Applied After Lumbar Disc Herniation Surgery|Patients listening to music are distracted and their pain is reduced, vital signs and NIRS values are kept within normal limits.
32981987|NCT04765774|No Intervention|Pain, vital signs and NIRS values of patients after lumbar disc hernia surgery|No intervention is applied to the patients in this group and the effectiveness of the interventions used on the patients in the other group is measured.
32981988|NCT04764474|Experimental|Treatment|All patients will be administered HMPL-306 orally QD
32981989|NCT04763902|Experimental|Time Restricted Eating (TRE) Schedule|For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).
32981990|NCT04763902|No Intervention|Control Schedule|For 4 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals, and a standardized breakfast and snacks menu. All meals and snacks will be culturally competent, and meal plans will be individualized to meet weight maintenance energy requirements.
32981991|NCT04760353|Experimental|Probiotic|one powder portion bag of the probiotic mixture (OMNi-BiOTiC STRESS) containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51 Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12), self-administered orally twice a day for 8 weeks
32981992|NCT04760353|Placebo Comparator|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~Powder portion bags are suitable for participants with intolerance to yeasts or lactose~Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
32981993|NCT04715061|Experimental|Cancer patients with MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
32981994|NCT04715061|Experimental|Cancer patients without MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
32981995|NCT04715061|Active Comparator|Healthy patients|9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
32981996|NCT04705441|Experimental|SMART intervention|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions over 10-12 weeks. The intervention sessions are held over Zoom.
32981997|NCT04705441|No Intervention|Waitlist|Individuals randomized to WL will continue in their usual care. After they complete their 13-week and 6-month assessments, they will begin participating in the SMART program.
32981998|NCT04700774|Experimental|mBA|Motor enhanced behavioral activation. 10 sessions.
32981999|NCT04700774|Experimental|BA|Standard behavioral activation. 10 sessions.
32982000|NCT04700774|No Intervention|Waitlist|10 week waitlist.
32982001|NCT04690595|Experimental|BAFFR-CAR T cells|B-cell activating factor receptor-Chimeric antigen receptor T cells
32982002|NCT04670510|Experimental|Aerobic Exercise|The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
33324120|NCT03923712|No Intervention|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
33324121|NCT03923712|Experimental|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
33324122|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
33324123|NCT03102034|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
33324124|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
33324125|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
33324126|NCT03923634|Experimental|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
33324127|NCT05415436|No Intervention|Group A- propofol given at FDA approved administration speed|
33324128|NCT05415436|Experimental|Group B- propofol given over 120 seconds|
33324129|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
33324130|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
33324131|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
33324132|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
32907739|NCT01635101|Placebo Comparator|Placebo|Participants receive matching placebo (IV) for 24 hours
32907740|NCT04925232|Experimental|One group|All participants will undergo 2 weeks (5 times each week) of repetitive TMS
32907741|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
32907742|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
32907743|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
32907744|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
32907745|NCT00932438|Experimental|LC Beads loaded with Irinotecan and FOLFOX6|"Device: LC Beads loaded with 100mg Irinotecan~Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician"
32907746|NCT00932438|Active Comparator|FOLFOX6 and Bevacizumab|Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
32907747|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
32907748|NCT04375826|Active Comparator|Epidural analgesia|Only Epidural analgesia is used for this group
32907749|NCT04375826|Active Comparator|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
32907750|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
32907751|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
32907752|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
32907753|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
32907754|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
32907755|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
32907756|NCT01637207|Experimental|palpation|
32907757|NCT01637207|Experimental|ultrasound|
32907758|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
32907759|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
32907760|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
32907761|NCT01555697|Active Comparator|Memantine/high|memantine 20 mg
32907762|NCT01555697|Placebo Comparator|Placebo/high|placebo comparator for memantine 20 mg
32907763|NCT01555697|Active Comparator|Memantine/low|memantine 10 mg
32907764|NCT01555697|Placebo Comparator|Placebo/low|placebo comparator for memantine 10 mg
32907765|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
32907766|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
32907767|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.~Part C were Japan participants. Part C were Japan participants."
32907768|NCT04358120|Other|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
32907769|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
32907770|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
32907771|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
32907772|NCT04932798||High-Risk group|: Montreal Heart Institute biobank participants with a high specific genome-wide polygenic risk scores for atrial fibrillation G
32907773|NCT04932798||Low-Risk group|Montreal Heart Institute biobank participants with a low specific genome-wide polygenic risk scores for atrial fibrillation G
32907774|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
32907775|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
32907776|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
32907777|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
32907778|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
32907779|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
32907780|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
32907781|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
32907782|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
32982003|NCT04670510|Active Comparator|Social Engagement|The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities will be scheduled throughout the 6-month period (e.g., movie club, cooking, cultural perspectives on aging), with a gradual decline in frequency of meetings. This condition will involve twice weekly, 1-hour-long on-site meetings for the first 6-weeks of the intervention, weekly group meetings during weeks 7-12, and bi-weekly meetings during weeks 13-26 (grand total of 25 sessions).
32982004|NCT04662580|Experimental|ARX517 Part 1 (Dose Escalation)|Subjects will be administered ascending dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will be enrolled into escalating dose levels during the Dose Escalation period of the study.
32982005|NCT04662580|Experimental|ARX517 Part 2 (Dose Expansion)|Subjects will be administered maximum dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will receive the maximum tolerated dose during the Dose Expansion period of the study.
32982006|NCT04660799|Active Comparator|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
32982007|NCT04660799|Experimental|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
32982008|NCT04654104||Healthy never smokers|Clinical evaluation of immune check points expression. A prospective study
32982009|NCT04654104||Smokers with normal lung function|evaluation of immune check points expression
32982010|NCT04654104||Lung cancer|evaluation of immune check points expression
32982011|NCT04654104||COPD|evaluation of immune check points expression
32982012|NCT04653285|Experimental|motor skill practice + aerobic exercise|bout of aerobic exercise following motor skill practice
32982013|NCT04653285|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
32982014|NCT04651465|Experimental|Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
32982015|NCT04651465|No Intervention|Business as usual|"control groups have business as usual, and then get offered the intervention program after one year follow-up assessment."
32982016|NCT04636632|Experimental|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
32982017|NCT04636632|Active Comparator|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
32982018|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
32982019|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
32982020|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
32982021|NCT04632225|Active Comparator|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
32982022|NCT04632225|Placebo Comparator|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
32982023|NCT04631562|Experimental|ALXN1820|Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
32982024|NCT04631562|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
32982025|NCT04629131|Experimental|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
32982026|NCT04629131|Experimental|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
32982027|NCT04629131|Experimental|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
32982028|NCT04629131|Experimental|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
32982029|NCT04625673|Active Comparator|Group A|Group A will wear the OsciPulse device for the first 24 hours then switch to the standard IPC device for the second 24 hours.
32982030|NCT04625673|Active Comparator|Group B|Group B will wear the standard IPC device for the first 24 hours then switch to the OsciPulse device for the second 24 hours.
32982031|NCT04597372|Experimental|Tamsulosin|"10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
33324133|NCT02928952|No Intervention|DSME alone|Usual care control
33324134|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
33324135|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
32982032|NCT04597372|Placebo Comparator|Placebo|"10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
32982033|NCT04588688|Experimental|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
32982034|NCT04585542|Experimental|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
32982035|NCT04585542|Experimental|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
32982036|NCT04585542|Experimental|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
32982037|NCT04585542|Experimental|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
32982038|NCT04583358|Active Comparator|AMT-101|AMT-101 Tablet
32982039|NCT04583358|Placebo Comparator|Placebo|Placebo Tablet
32982040|NCT04580485|Experimental|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
33324136|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
32982041|NCT04580485|Experimental|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
32982042|NCT04576650|Experimental|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
32982043|NCT04569734||Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
32982044|NCT04545060|Experimental|VIR-7831 (Sotrovimab)|Participants received 500 mg sotrovimab administered intravenously (IV)
32982045|NCT04545060|Placebo Comparator|Placebo|Participants received placebo administered intravenously (IV)
32982046|NCT04531917|Experimental|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
32982047|NCT04531917|Active Comparator|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
32982048|NCT04527913|Experimental|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
32982049|NCT04527913|Experimental|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
32982050|NCT04527913|Experimental|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
32982051|NCT04527913|Experimental|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
32982052|NCT04502602|Experimental|Dose Level -1|Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
32982053|NCT04502602|Experimental|Dose Level 1|Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
32982054|NCT04502602|Experimental|Dose Level 2|Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
32982055|NCT04502602|Experimental|Dose Level 3|Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
32982056|NCT04502602|Experimental|Dose Level 4|Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
32982057|NCT04502602|Experimental|Phase 1b: Platinum Resistant Expansion Cohort|This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
32982058|NCT04495543|Experimental|Brief-Skills for Safer Living (Brief-SfSL)|Participants with current suicidal ideation (Beck Suicide Scale >10) will undergo Brief-SfSLtherapy
32982059|NCT04481321||Patient with benign gynaecologic disease|Patients consulting for endometriosis, pelvic pain, abnormal uterine bleeding and/or infertility, or for a pelvic mass,
32982060|NCT04469270|Experimental|Engensis|16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
32982061|NCT04469270|Placebo Comparator|Placebo|16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
32982062|NCT04455152|Experimental|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
32982063|NCT04455152|No Intervention|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
32982064|NCT04421235|Other|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
32982065|NCT04411849|Experimental|Group I (early intervention)|During year 2, participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation. Participants then complete a satisfaction survey and have their medical record reviewed. During years 3-5, this intervention is repeated among women who remain unscreened/underscreened.
32982066|NCT04411849|Active Comparator|Group II (delayed intervention)|During year 2, participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer. During years 3-5, participants receive the HPV self-testing intervention described for Group I.
32982067|NCT04404777||Patients with local recurrence|
32982068|NCT04395053|Experimental|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
32982069|NCT04395053|Experimental|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
32982070|NCT04382391|Experimental|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
32982071|NCT04382391|Active Comparator|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
32982072|NCT04376346|Experimental|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
32982073|NCT04376346|No Intervention|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
32982074|NCT04375202|Experimental|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
32982075|NCT04375202|No Intervention|Current care alone|Current care
32982076|NCT04365205||severe asthma|"Diagnosis of severe asthma according to the American Thoracic Society / European Respiratory Society task force.~Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in Forced expiratory volume forced expiratory volume at one second (FEV1) within 12 months before enrollment.~Documented blood eosinophils ≥ 300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1."
32982077|NCT04365205||non-severe asthma|• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
32982078|NCT04365205||non-asthmatic controls|"No prior history of any chronic respiratory disease including asthma.~No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.~No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.~Normal lung function with FEV1 > 90%."
32982079|NCT04364373|Active Comparator|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
32982080|NCT04364373|Experimental|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
32982081|NCT04345744|Experimental|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
32982082|NCT04345744|Experimental|Test group 2|administration of chlorhexidine 0.2% mouth rinse
32982083|NCT04345744|Active Comparator|Control Group|No administration of mouth rinses after surgery
32982084|NCT04343885|Experimental|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
32982085|NCT04343885|Other|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
32982086|NCT04340895|Experimental|Intervention arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 [PRO-2] scoring).~The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms."
32982087|NCT04340895|Active Comparator|Reference arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only.~The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice."
32982088|NCT04332393|Experimental|metformin group|
32982089|NCT04332393|No Intervention|No treatment group|
32982090|NCT04329572|Experimental|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
32982091|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
32982092|NCT04325529||Control subjects|healthy control subjects
32982093|NCT04323137|No Intervention|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
32982094|NCT04323137|Experimental|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
32982095|NCT04323137|Experimental|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
32982096|NCT04323137|Experimental|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
32982097|NCT04323137|No Intervention|Sub-threshold patients|Patients in this group is in the top 11-20% of risk for flu and complications, slightly lower risk than those included in the intervention, who are in the top 10% of risk for flu and complications. This group of patients does not receive an intervention, but are monitored for flu shots as a comparison to target patients.
32982098|NCT04323137|No Intervention|Household members|This group of patients share an address with target high-risk patients (in arms 1-4). This group does not receive an intervention but is monitored for spillover effects of the intervention.
32982099|NCT04322552|Experimental|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
32982100|NCT04322305|Experimental|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
32982101|NCT04322305|Placebo Comparator|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
32982102|NCT04321148|Other|standard of care PCI|
32982103|NCT04321148|Experimental|Impella-protected PCI|
32982104|NCT04316104|Experimental|CuidaTXT|This intervention, CuidaTXT [Spanish for self-care and texting], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
32982105|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
32982106|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
32982107|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
32982108|NCT04240717|Experimental|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
32982109|NCT04240717|No Intervention|Treatment As Usual|Patients receive medical consultation.
32982110|NCT04234061|Experimental|Single|ibrutinib and Tisagenlecleucel
32982111|NCT04219826|Experimental|CK-3773274 - Cohort 1 (Obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
32982112|NCT04219826|Placebo Comparator|Placebo - Cohort 1 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
32982113|NCT04219826|Experimental|CK-3773274 - Cohort 2 (Obstructive HCM)|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
32982114|NCT04219826|Placebo Comparator|Placebo - Cohort 2 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
32982115|NCT04219826|Experimental|CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM)|Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
32982116|NCT04219826|Experimental|CK-3773274 - Cohort 4 (non-obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
32982117|NCT04209842|Experimental|gastric ballon placement|will receive gastric balloon placed via endoscopy
32982118|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
32982119|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
32982120|NCT04179695|Experimental|consultation with Parkinsun|
32982121|NCT04179695|Active Comparator|consultation as usual without Parkinsun|
32982122|NCT04156334|Experimental|computer-controlled intraosseous anaesthesia|Patients will receive the local anaesthetic using computer-controlled intraosseous anaesthesia (Quicksleeper 5) before the tooth extraction in general anaesthesia.
32982123|NCT04156334|Experimental|infiltrative or conductive local anaesthesia|Patients will receive a local anaesthetic using carpule before the tooth extraction in general anaesthesia.
32982124|NCT04133233|Experimental|active treatment|"IL-2 (ILT-101) Sub-cutaneous~1 million UI/j"
32982125|NCT04133233|Placebo Comparator|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
32982126|NCT04092764|Experimental|Participants Receiving Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks.
32982127|NCT04083170|Experimental|Regimen A (fludarabine, cyclophosphamide, TBI, dilanubcel)|Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
32982128|NCT04083170|Experimental|Regimen B (anticancer drugs, TBI, dilanubicel)|Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
32982129|NCT04078906|No Intervention|Control group|Conventional IVLE (Intralipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
32982130|NCT04078906|Experimental|Experimental group|n3-LCPUFA enriched IVLE (SMOFlipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
32982131|NCT04036968|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how participants are feeling and to complete cognitive tasks.
32982132|NCT03980171|Experimental|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
32982133|NCT03979365|Active Comparator|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
32982134|NCT03979365|Active Comparator|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
32982135|NCT03972891|Experimental|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
32982136|NCT03972891|No Intervention|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
32982137|NCT03952559|Experimental|Baricitinib Open Label High Dose|Baricitinib administered orally.
32982138|NCT03952559|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
32982139|NCT03952559|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
32982140|NCT03952559|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
33324137|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
33324138|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:~Lack the immunophenotype of interest,~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
32982141|NCT03952559|Placebo Comparator|Placebo|Placebo administered orally. Matching placebo administered orally to maintain the blind.
32982142|NCT03945292|Experimental|Fazirsiran (also referred to as TAK-999 or ARO-AAT)|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
32982143|NCT03945292|Placebo Comparator|Placebo|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
32982144|NCT03945292|Experimental|Open-Label Fazisiran (also referred to as TAK-999 or ARO-AAT)|After all enrolled participants completed the Week 16 visit, an interim analysis was performed to select a single dose level (25, 100 or 200 mg) for the open-label phase of the study. Fazirsiran 200 mg was the selected dose and all participants with fibrosis at Screening who completed the post-dose liver biopsy at Week 48 (or Week 72 or 96) receive this dose every 12 weeks for the duration of the study (open-label phase).
32982145|NCT03926013|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
32982146|NCT03926013|Experimental|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
32982147|NCT03925883|Active Comparator|Patient Navigation|Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.
33324139|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
32982148|NCT03925883|No Intervention|Usual Care|Patients will receive usual care screening opportunities
32982149|NCT03901339|Experimental|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
32982150|NCT03901339|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from one of the following single-agent treatment:~Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)~Eribulin: 1.4 mg/m^2 for North American sites, 1.23 mg/m^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle~Capecitabine: 1000-1250 mg/m^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle~Gemcitabine: 800-1200 mg/m^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution~Vinorelbine: 25 mg/m^2 via IV on Day 1 weekly cycle per institution"
32982151|NCT03881631|Experimental|Mindfulness Based Stress Reduction (MBSR) Program|The MBSR program is an eight-week-long course designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
32982152|NCT03881631|Active Comparator|Living Well (LW) Program|LW is an eight-week course of group presentations and discussions on topics related to the promotion of health and well-being in the context of dementia caregiving. LW is designed to teach participants how to improve their physical and emotional health as a complement to traditional medical treatments.
32982153|NCT03881631|No Intervention|Usual Care|The usual care arm is a no intervention group wherein participants experience their usual circumstances.
32982154|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
32982155|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Transportation will be facilitated to assist participants in attending appointments and medically indicated ultrasounds will be paid for (as in the intervention group).
32982156|NCT03861195||Da Vinci Robotic Surgical System|
32982157|NCT03861195||conventional laparoscopic surgery|
32982158|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
32982159|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
32982160|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
32982161|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
32982162|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
32982163|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
32982164|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
32982165|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.~Oral Hygiene Instruction (OHI)~Professional supragingival scaling and polishing"
32982166|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
32982167|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
32982168|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
32982169|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
32982170|NCT03814746|Experimental|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants will receive Crizanlizumab (SEG101) at 5.0 mg/kg
32982171|NCT03814746|Experimental|Crizanlizumab (SEG101) at 7.5 mg/kg|Participants will receive Crizanlizumab (SEG101) at 7.5 mg/kg
32982172|NCT03814746|Placebo Comparator|Placebo|Participants will receive the placebo drug.
32982173|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
32982174|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
32982175|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
32982176|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
32982177|NCT03729206|Experimental|Sublingual microscopy|
32982178|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
32982179|NCT03707366|No Intervention|Control group|Services as usual
33324140|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
33324141|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
33324142|NCT05370820|Experimental|Cesarean Delivery|
33324143|NCT05370820|Experimental|Vaginal Delivery|
33324144|NCT05370820|Experimental|Morbidly Obese|
33324145|NCT05370820|No Intervention|No TXA|
33324146|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
32982180|NCT03697512|Experimental|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 56;~Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.~Induction PART B, from Day 57 to Day 196.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 196;~Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.~Maintenance PART C, from Day 197 to Day 730.~Patients will be treated with:~- Ibrutinib 560 mg/day continuously up to Day 730."
32982181|NCT03687411|Experimental|ULTRA-SINE (phases 1-4)|"There will be four phases in this proposed uSINE system. In first phase attending anaesthetist will use the automated spinal landmark system for neuraxial needle insertion to place the neuraxial anaesthesia in non-obese patients.~For the second phase, obese patients will have ultrasound scan of their lumbar back and no needle insertion is involved.~In third phase, conventional ultrasonography is used prior to the needle insertion, and needle insertion is conducted manually as per routine practice. The images collected in the system will be used for annotation and evaluation which serves as training material for uSINE to optimize its algorithm to improve landmark identification for obese patients. The fourth phase will have uSINE system used prior to the needle insertion, with the neuraxial needle insertion conducted manually as per routine practice. The identification accuracy and first-attempt puncture success rate of uSINE will be determined."
32982182|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
32982183|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
32982184|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
32982185|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
32982186|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
32982187|NCT03670004||Non-Impaired|Able-bodied controls
32982188|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
32982189|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
32982190|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
32982191|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
32982192|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
32982193|NCT03612804|No Intervention|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
32982194|NCT03612804|Experimental|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
32982195|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).~Follow-up testing will be conducted after one year to evaluate learner retention.~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
32982196|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
32982197|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
32982198|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
32982199|NCT03570177||all subject|the all population (described in eligibility criteria)
32982200|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
32982201|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
32982202|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
33324147|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
33324148|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
32982203|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24)."
32982204|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning post-release, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in this branch will include youth exiting the adult justice system (ages 18-24) and youth exiting the juvenile justice system (ages 16-18).
32982205|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
32982206|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
32982207|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
32982208|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
32982209|NCT03524612|Other|eltrombopag|Participants will be treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of ≥ 100×10^9/L (CR), after 1st line steroids have failed.
32982210|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
32982211|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
32982212|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
32982213|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
32982214|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
32982215|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)~temozolomide 75 mg/m2/d during radiotherapy~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
32982216|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
32982217|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
32982218|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
32982219|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
32982220|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.~Time period: From March 2017 to end of study"
32982221|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
32982222|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
32982223|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
32982224|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
32982225|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
32982227|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
32982228|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
32982229|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
32982230|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
32982231|NCT03255070|Experimental|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
32982232|NCT03255070|Experimental|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
32982233|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
32982234|NCT03250975|Experimental|Medical Therapy|medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days
32982235|NCT03250975|Placebo Comparator|Placebo Control|Placebo control medication for 14 days
32982236|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
32982237|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
32982238|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
32982239|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
32982240|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
32982241|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
32982242|NCT03203512|Active Comparator|Intervention|Fish oil capsules
32982243|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
32982244|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
32982245|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
32982246|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
32982247|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
33324149|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
33324150|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
33324151|NCT05353972|Experimental|Cohort 1|Single dose of IMG or placebo solution, intravenously administered
33324152|NCT05353972|Experimental|Cohort 2|Single dose of IMG or placebo solution, intravenously administered
33324153|NCT05353972|Experimental|Cohort 3|Single dose of IMG or placebo solution, intravenously administered
33324154|NCT05353972|Experimental|Cohort 4|Single dose of IMG or placebo solution, intravenously administered
33324155|NCT05353972|Experimental|Cohort 5|Single dose of IMG or placebo solution, intravenously administered
33324156|NCT05353972|Experimental|Cohort 6|Single dose of IMG or placebo solution, intravenously administered
33324157|NCT05353972|Experimental|Cohort 7|Single dose of IMG or placebo solution, intravenously administered
33324158|NCT03923478|Experimental|ABI-M201|"Cohort A: 1 capsule one time a day~Cohort B: 1- 5 capsules one time a day"
33324159|NCT03923478|Placebo Comparator|Placebo|"Cohort A: 1 capsule one time a day~Cohort B: 1-5 capsules one time a day"
33324160|NCT03690466|Experimental|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
33417322|NCT03074318|Experimental|Phase 2 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
32982248|NCT03141736|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32982249|NCT03141736|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32982250|NCT03141736|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32982251|NCT03141736|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
32982252|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
32982253|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
32982254|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
32982255|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
32982256|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
32982257|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
32982258|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
32982259|NCT03036423|Active Comparator|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
32982260|NCT03036423|Active Comparator|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
32982261|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
32982262|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
32982263|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
32982264|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
32982265|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
32982266|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
33412335|NCT05421117||transvaginal (TV) routes|A curette was placed into the uterine cavity and stabilized with a tenaculum for manipulation of the uterus. After separation of the adnexal mass ligaments, the manipulator was removed to perform TV retrieval. A vaginal retractor was inserted into the vagina to view the cervix and allow removal of the mass via the TV route. The posterior lip of the cervix was grasped with an Allis forceps and then pulled superiorly to expose the posterior vaginal dome. The sampler was inserted into the vagina and pushed gently against the vaginal wall to define the posterior fornix between the uterosacral ligaments. A 1-2-cm transverse TV posterior colpotomy was performed under laparoscopic control using a 3-mm monopolar hook. The sample was pulled into the vagina by holding the bag mouth from the colpotomy with ring forceps. The bag mouth was opened in the vaginal canal and the sample was transferred from the vagina.
33412336|NCT05385575|Experimental|Cohort 1|Participant will receive 0.1mg of single dose by subcutaneous injection of KN056
32982267|NCT02920892|Experimental|AFQ056 group with language intervention|12 month treatment phase during which subjects are randomized to AFQ056. The initial dose of AFQ056 will be 25 mg BID. If the subject has no side effects the dose will be titrated (mandatory titration if no side effects) to the next level, 50 mg BID, 75 mg BID and 100 mg BID in order. A flexible dose design will mimic practice, and allow use of maximum tolerated dose (MTD) which is likely to be most effective. The dose can be adjusted weekly through week 7. After 7 weeks the dose will be fixed, and at the 2 month visit all subjects will initiate the language intervention, remaining on a stable AFQ056/placebo dose for the next 6 months.
32982268|NCT02920892|Placebo Comparator|Placebo group with language intervention|12-month treatment phase during which subjects are randomized to placebo. At the 2 month visit (language intervention baseline visit) all subjects will initiate the language intervention, remaining on placebo dose for the next 6 months.
32982269|NCT02863718|No Intervention|Watch & wait|Watch & wait
32982270|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
32982271|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
32982272|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
32982273|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
32982274|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
32982275|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
32982276|NCT02813850|No Intervention|control|standard medical care
32982277|NCT02813850|Experimental|oxygen therapy|
32982278|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
32982279|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
32982280|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
32982281|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
32982282|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
32982283|NCT02605785|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
32982284|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
33412337|NCT05385575|Experimental|Cohort 2|Participant will receive 0.3mg of single dose by subcutaneous injection of KN056
32982285|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
32982286|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
32982287|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
32982288|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
32982289|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
32982290|NCT02360891||neurological controls|patients with other neurological disease
32982291|NCT02360891||healthy controls|age matched healthy controls
32982292|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
32982293|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
32982294|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
32982295|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
33412338|NCT05385575|Experimental|Cohort 3|Participant will receive 1.0mg of single dose by subcutaneous injection of KN056 or placebo
33412339|NCT05385575|Experimental|Cohort 4|Participant will receive 3.0mg single subcutaneous dose of KN056 or placebo
32982296|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
33324161|NCT03690466|Sham Comparator|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
33324162|NCT03923166|Experimental|pyrotinib+ capecitabine|
33324163|NCT03923244|Experimental|cohorte 1|"Normal patient consultation schedule for cataract surgery with:~Preoperative appointment scheduled for the patient~Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
33324164|NCT05332210|Experimental|HBM9161 Drug Product (680mg)|"HBM9161 680mg: subcutaneous injection, 6 times per treatment cycle, once a week; the second cycle of treatment may start 4 weeks after the last dose of the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL < 3 points compared with the previous treatment cycle), and the next treatment cycle can start.~The dose may be reduced to 340 per investigator's discretion. Return to the dose of 680 mg is not permitted after a dose reduction is made."
33324165|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
33324166|NCT01224756|Placebo Comparator|Placebo TID|
33324167|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
33324168|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
33324169|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
33324170|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
33324171|NCT05308732|Experimental|Copaiba arm|It will consist of the group of patients who will use copaiba mouthwash. It will be subdivided into 6 consecutive cohorts.
33324172|NCT03926832|Experimental|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
33324173|NCT01224834|Placebo Comparator|1|
33324174|NCT01224834|Experimental|2|
33324175|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
33324176|NCT01130298|Experimental|1|
33324177|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
33324178|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
33324179|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
33324180|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
33324181|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
33324182|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
33324183|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
33324184|NCT03923088|Experimental|jacobson's progressive muscle relaxation technique|
33324185|NCT03923088|Experimental|audiovisual distraction technique|
33324186|NCT03923088|No Intervention|conventional|
33324187|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
33324188|NCT03923010|Experimental|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
33324189|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
33324190|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
33324191|NCT01329354|Experimental|Autologous effector lymphocytes|
33324192|NCT03926676|Experimental|Grandio blocks|Nano hybrid composite blocks
33324193|NCT03926676|Active Comparator|E max|ceramic blocks
32982297|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
32982298|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:~Patients aged 75 years or above~Cr-Cl 30-50 ml/min~Patients who receive concomitant verapamil~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:~Patients with moderate renal impairment~Patients with gastritis, esophagitis or gastroesophageal reflux~Other patients at increased risk of bleeding"
32982299|NCT02067182|No Intervention|No Oral Anticoagulation|
33324194|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
32982300|NCT02003612||All subjects|All subjects
32982301|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
32982302|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
32982303|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
32982304|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
32982305|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
32982306|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
32982307|NCT01940341|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
32982308|NCT01940341|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
32982309|NCT01940341|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
32982310|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.~Day Treatment~-22 Alemtuzumab 3mg IV (test dose)~-21 Alemtuzumab 10mg IV~-20 Alemtuzumab 15mg IV~-19 Alemtuzumab 20mg IV~-8 Fludarabine 30mg/m2 IV~-7 Fludarabine 30mg/m2 IV~-6 Fludarabine 30mg/m2 IV~-5 Fludarabine 30mg/m2 IV~-4 Fludarabine 30mg/m2 IV~-3 Melphalan 140mg/m2 IV~-2 Rest Day~-1 Rest Day~0 Stem Cell Infusion"
32982311|NCT01781468|Experimental|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
32982312|NCT01781468|Placebo Comparator|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
32982313|NCT01781468|Experimental|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
32982314|NCT01624142|Experimental|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
32982315|NCT01539746|Experimental|TAVI without predilation|
32982316|NCT01539746|Active Comparator|Standard TAVI procedure|
32982317|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique."
32982318|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
32982319|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
32982320|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
32982321|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32982322|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32982323|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
32982324|NCT01286038|Experimental|Eltrombopag Treatment|Phase I: Dose Escalation
32982325|NCT01253707|Experimental|Dose Escalation|
32982326|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
32982327|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
32982328|NCT00722046|Experimental|PF-04360365 1 mg/kg|
32982329|NCT00722046|Placebo Comparator|Placebo|
32982330|NCT00722046|Experimental|PF-04360365 3 mg/kg|
32982331|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
32982332|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
32982333|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
32982334|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
33412340|NCT05385575|Experimental|Cohort 5|Participant will receive 6.0mg of single dose by subcutaneous injection of KN056 or placebo
32982335|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
32982336|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
32982337|NCT00345839|Experimental|Cinacalcet|
32982338|NCT00345839|Placebo Comparator|Placebo|
32982339|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
32982340|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
32982341|NCT00113763|Experimental|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
32982342|NCT00113763|Other|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
32982343|NCT00102323|Placebo Comparator|Placebo|
32982344|NCT00102323|Experimental|AMG 531|Active Investigational Product
32982345|NCT01438359|Experimental|PA21 and Furosemide with food|
32982346|NCT01438359|Experimental|No PA21; Furosemide with food|
32982347|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
32982348|NCT01438372|Experimental|Intravenous iron sucrose arm|
32982349|NCT01438372|Active Comparator|Oral ferrous sulfate|
32982350|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
32982351|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
32982352|NCT01438437|Active Comparator|Percutaneous acetic acid|
32982353|NCT01438437|Active Comparator|Radiofrequency ablation|
32982354|NCT01438450|No Intervention|Supportive|Supportive therapy
32982355|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
32982356|NCT01438463|Placebo Comparator|placebo|
32982357|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
32982358|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
32982359|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
32982360|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
32982361|NCT01438502||HyperHAES|
32982362|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
32982363|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
32982364|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
32982365|NCT01438567|Experimental|OXN PR tablets|
32982366|NCT01438567|Active Comparator|OxyPR tablets|
32982367|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
32982368|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
32982369|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
32982370|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
32982371|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
32982372|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
32982373|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
32982374|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
32982375|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
33412341|NCT05385575|Experimental|Cohort 6|Participant will receive 12.0mg of single dose by subcutaneous injection of KN056 or placebo
33412342|NCT05421039||Group (1)|With the exposure
33412343|NCT05421039||Group (2)|Without the exposure
33412344|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
32982376|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
32982377|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
32982378|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
33412345|NCT05353829|Active Comparator|Per oral|Drug:per oral Methotrexate Tablets dosage 5-30mg once weekly.
32982379|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
32982380|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
32982381|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~Volunteers who are reside in Goyang city"
32982382|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
32982383|NCT01438632|Active Comparator|conventional insulin pen|
32982384|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
32982385|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
32982386|NCT01438658||All|A cohort of all the patients.
32982387|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
32982388|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
32982389|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
32982390|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
32982391|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
32982392|NCT01438723|Experimental|metformin|
32982393|NCT01438723|Placebo Comparator|placebo|
32982394|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
32982395|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
32982396|NCT01438749|Active Comparator|A|
33412346|NCT05353829|Active Comparator|Subcutaneous|Drug: subcutaneous Methotrexate Injection dosage 5-30mg once weekly.
32982397|NCT01438749|Placebo Comparator|B|
32982398|NCT01438749|Experimental|C|
32982399|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
32982400|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
32982401|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
32982402|NCT01438788|Experimental|All patients on a low protein diet|
32982403|NCT01438801|Experimental|NutropinAq|
32982404|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
32982405|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
32982406|NCT01438827|Placebo Comparator|Injection with no active grass component|
32982407|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
32982408|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
32982409|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
32982410|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
32982411|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
32982412|NCT01438892||tDMARDs Group|traditional DMARDs
32982413|NCT01438892||Biologics group|Biologics used in RA
32982414|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
32982415|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
33412347|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
32982416|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
32982417|NCT01438918|Active Comparator|200 mg|High dose active comparator
32982418|NCT01438918|Active Comparator|50 mg|Low dose active comparator
32982419|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
32982420|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
32982421|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
32982422|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
32982423|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
32982424|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
32982425|NCT01438983||breastfeeding infants|
32982426|NCT01438983||bottle feeding infants|
32982427|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
32982428|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
32982429|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
32982430|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
32982431|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
32982432|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
33324195|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
33412348|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
32982435|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
32982436|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) had been defined, expansion cohorts were conducted at the MTD dose. Overall up to 32 subjects were planned to be enrolled in the expansion cohort:~Ovarian Carcinoma, 20 subjects~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
32982437|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
32982438|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
32982439|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
32982440|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
32982441|NCT01439191|Experimental|combination agent group|
32982442|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
32982443|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
32982444|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
32982445|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
32982446|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
32982447|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
32982448|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
32982449|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
32982450|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
32982451|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
32982452|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
32982453|NCT01439334|Experimental|Online Program Brief|Online Program Brief
32982454|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
32982455|NCT01439334|Active Comparator|Control|Control
32982456|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
32982457|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
32982458|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
32982459|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
32982460|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
32982461|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
32982462|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
32982463|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
32982464|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
32982465|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
32982466|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
32982467|NCT01439451|Experimental|experimental|perturbation training during walking
32982468|NCT01439451|Active Comparator|controls|treadmill walking
32982469|NCT01439464|Active Comparator|Control device|
32982470|NCT01439464|Experimental|Investigational device|
32982471|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
32982472|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
32982473|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
32982474|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
32982475|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
32982476|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
32982477|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
32982478|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
32982479|NCT01439542|Experimental|Radiotherapy|
32982480|NCT01439607|Experimental|Bone marrow and blood sampling|
32982481|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
33412349|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
33412350|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
32982482|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
32982483|NCT01439685||Biliary Stent group|Biliary Stent group
32982484|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
32982485|NCT01439737||asthma|
32982486|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
32982487|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
32982488|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
32982489|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
32982490|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
32982491|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
32982492|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
32982493|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
32982494|NCT01439841|No Intervention|Control|No intervention
32982495|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
32982496|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
32982497|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
32982498|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
32982499|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
32982500|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
32982501|NCT01439984|Placebo Comparator|placebo|
32982502|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
32982503|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
32982504|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
32982505|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
32982506|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
32982507|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
32982508|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
32982509|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
32982510|NCT01440088|Active Comparator|Doxorubicin|
32982511|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
32982512|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
33324196|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
33324197|NCT03922776|Experimental|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~at diagnosis, before chemotherapy (pre-CT)~after chemotherapy (post-ct)~Intervention : Collection of two blood samples (5mL)~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
33324198|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
33324199|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
33324200|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
33324201|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
33324202|NCT03926442|Experimental|Active1|Italian Herb in active breakfast meal
33324203|NCT03926442|Experimental|Active2|Cinnamon in active breakfast meal
33324204|NCT03926442|Experimental|Active3|Pumpkin Spice Mix in active breakfast meal
33324205|NCT03926442|Placebo Comparator|Placebo Comparator|Placebo Breakfast
32982513|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
32982514|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
32982515|NCT01440140|Experimental|Closed loop (algorithm)|
32982516|NCT01440140|Placebo Comparator|Open loop|
32982517|NCT01440153|Experimental|Active Intervention|
32982518|NCT01440153|Active Comparator|passive intervention|
32982519|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
32982520|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
32982521|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
32982522|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
32982523|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
32982524|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
32982525|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
32982526|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
32982527|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
32982528|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
32982529|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
32982530|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
32982531|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
32982532|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
33324206|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
32982533|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
33324207|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
32982534|NCT01440231|Placebo Comparator|Arm 1|
33324208|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
32982535|NCT01440231|Experimental|Arm 2|
33324209|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
32982536|NCT01440231|Experimental|Arm 3|
32982537|NCT01440231|Experimental|Arm 4|
32982538|NCT01440231|Experimental|Arm 5|
32982539|NCT01440257|Placebo Comparator|Placebo (Group A)|
32982540|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
32982541|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
32982542|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
32982543|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
32982544|NCT01440348|Experimental|Achilles allograft|
32982545|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
32982546|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
32982547|NCT01440400|No Intervention|Conventional spinal anesthesia|
32982548|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
32982549|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
32982550|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
32982551|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
33324210|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
33324211|NCT03930108||Mortality outcome|
33324212|NCT01225224|Experimental|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
33324213|NCT01225224|Experimental|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
33324214|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
33324215|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
32982552|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
32982553|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
32982554|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
32982555|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
32982556|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
32982557|NCT01440530|Experimental|Educational Intervention|
32982558|NCT01440530|Active Comparator|Control Group (usual care)|
32982559|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
32982560|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
32982561|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
32982562|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
32982563|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
32982564|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
32982565|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
32982566|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
32982567|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
32982568|NCT01440673|Active Comparator|Aprepitant 80 mg|
32982569|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
32982570|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
32982571|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
32982572|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
32982573|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
32982574|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
32982575|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
32982576|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
32982577|NCT01440738|Experimental|health workshops|Health promotion group intervention
32982578|NCT01440738|No Intervention|comparison group|usual care
32982579|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
32982580|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
32982581|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
32982582|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
32982583|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
32982584|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
32982585|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
32982586|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
32982587|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
32982588|NCT01440842|Active Comparator|Open loop (Standard treatment)|
32982589|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
33324216|NCT01225224|Experimental|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
33324217|NCT01225224|Placebo Comparator|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
32982590|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
32982591|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
32982592|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
32982593|NCT01440894||Body Analysis|
32982594|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
32982595|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
32982596|NCT01440933|Active Comparator|Magnesiumsulphate|
33324218|NCT03922386|Other|JX model|Subjects implanted with an RA XFINE lead (JX model)
32982597|NCT01440933|Placebo Comparator|Physiologic saline|
32982598|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
32982599|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
32982600|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32982601|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
32982602|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
32982603|NCT01441024|Experimental|1|DAS181
32982604|NCT01441024|Placebo Comparator|2|Placebo
32982605|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
32982606|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
32982607|NCT01441141||Arm 1|Subjects with SCD
32982608|NCT01441141||Arm 2|Subjects without SCD
32982609|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
32982610|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
32982611|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
32982612|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
32982613|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
32982614|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
32982615|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
32982616|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
32982617|NCT01441232|Experimental|Treatment A|
32982618|NCT01441232|Experimental|Treatment C|
32982619|NCT01441232|Active Comparator|Treatment B|
32982620|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
32982621|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
33324219|NCT03922386|Other|TX model|Subjects implanted with an RV XFINE lead (TX model)
33324220|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
33324221|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
33324222|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
33324223|NCT01225302|Experimental|Arm A|
33324224|NCT01225302|Experimental|Arm B|
33324225|NCT03922152|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
32982622|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
32982623|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
32982624|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
32982625|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
32982626|NCT01441297|Experimental|study arm|BIBF 1120 study arm
32982627|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
32982628|NCT01441323|No Intervention|Control (C)|
32982629|NCT01441323|Experimental|Nutrition (N)|
32982630|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
32982631|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
32982632|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
32982633|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
32982634|NCT01441375||Sickle cell patients non-transfused|
32982635|NCT01441375||Sickle cell patients transfused with no ICT|
33412351|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
32982636|NCT01441375||Sickle cell patients transfused with ICT|
32982637|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
32982638|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
32982639|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
32982640|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
32982641|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
32982642|NCT01441427|Experimental|G-CSF|
32982643|NCT01441427|Experimental|EPO|
33412352|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
32982644|NCT01441427|Experimental|G-CSF and EPO|
32982645|NCT01441427|Placebo Comparator|Placebo|
32982646|NCT01441453|Other|Preoperative FibroScan|
32982647|NCT01441518|Experimental|Home care|
32982648|NCT01441518|Active Comparator|Hospital care|
32982649|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
32982650|NCT01441531|Placebo Comparator|Placebo sugar pill|
32982651|NCT01441544|Experimental|VAREITY|
32982652|NCT01441544|Experimental|NON-VARIETY|
32982653|NCT01441583|Active Comparator|RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
32982654|NCT01441583|Active Comparator|RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
32982655|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
32982656|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
32982657|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
32982658|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
32982659|NCT01441622|Experimental|AL539|Device AL539
32982660|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
32982661|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
32982662|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
33412353|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
32982663|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
32982664|NCT01441700|Active Comparator|Prone position|
32982665|NCT01441700|Active Comparator|Supine position|
32982666|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
32982667|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
32982668|NCT01441726||Training of staff|
33412354|NCT04232384|Active Comparator|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
32982669|NCT01441726||No training of staff|
32982670|NCT01441739||NEC suspected - Final diagnosis NEC|
32982671|NCT01441739||NEC suspected - Final diagnosis no NEC|
32982672|NCT01441739||Controls|
33412355|NCT04232384|Experimental|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
33412356|NCT02285192|Experimental|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
32982673|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
32982674|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
32982675|NCT01441778|Active Comparator|NSS irrigation salt|
32982676|NCT01441778|Experimental|BHS nasal irrigaiton salt|
32982677|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
32982678|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
32982679|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
32982680|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
32982681|NCT01441817|Other|Surgery|
32982682|NCT01441830|Sham Comparator|sham rESWT|
32982683|NCT01441830|Active Comparator|rESWT|
32982684|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
32982685|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
32982686|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
32982687|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
33412357|NCT05420493|Experimental|Intravenous of CAR-T|Infusion of CAR-T cells by dose of 3-10 x105 cells/kg
32982688|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
32982689|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
32982690|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
32982691|NCT01441908|No Intervention|Control Group|Control Group
32982692|NCT01441908|Active Comparator|Statin|Receiving Statin
32982693|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
32982694|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
32982695|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
32982696|NCT01441934|Placebo Comparator|Sugar pill|
32982697|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
32982698|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
32982699|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
32982700|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
32982701|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
32982702|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
32982703|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
32982704|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
32982705|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
32982706|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
32982707|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
33412358|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
32982708|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
32982709|NCT01442116|Experimental|Hypertensives|
32982710|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
32982711|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
32982712|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
32982713|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
32982714|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
32982715|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
32982716|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
32982717|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
32982718|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
32982719|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
32982720|NCT01442259|Experimental|All study subjects|
32982721|NCT01442272|No Intervention|Habitual medication withuot additional|
32982722|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
32982723|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
32982724|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
32982725|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
32982726|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
32982727|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
32982728|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
33412359|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
33412360|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
32982729|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
32982730|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
32982731|NCT01442363|Experimental|BLI-1300 (low dose)|Low dose BLI-1300
32982732|NCT01442363|Experimental|BLI-1300 (high dose)|High dose BLI-1300
32982733|NCT01442363|Placebo Comparator|placebo|placebo (vehicle)
32982734|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
32982735|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
32982736|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
32982737|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
32982738|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
32982739|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
32982740|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
32982741|NCT01442441||chronic pancreatitis|
32982742|NCT01442454||Chronic Pancreatitis|
32982743|NCT01442467||Mild to Severe MAC|
32982744|NCT01442467||No to mild MAC|
32982745|NCT01442480|Experimental|Fish oil|
32982746|NCT01442480|Experimental|Olive oil|
32982747|NCT01442506||Barrett|
33324226|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
33324227|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
33324228|NCT03922230||Normal group|Confirmed as the normal by health checkups.
32982748|NCT01442519|Active Comparator|Intravesical BCG alone|
32982749|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
32982750|NCT01442532|Experimental|1|
32982751|NCT01442532|Experimental|2|
32982752|NCT01442532|Experimental|3|
33324229|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
33324230|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
33324231|NCT03926286|Experimental|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
32982753|NCT01442532|Placebo Comparator|4|
32982754|NCT01442532|Experimental|5|
32982755|NCT01442545|Experimental|001|
32982756|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
32982757|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
32982758|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
32982759|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
32982760|NCT01442571|Placebo Comparator|Saline Injection|
32982761|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
32982762|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
32982763|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
32982764|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
32982765|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
32982766|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
32982767|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
32982768|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
32982769|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
32982770|NCT01442662|Experimental|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
32982771|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
33324232|NCT03926364||Patients|Referred pain
33324233|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
33324234|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
33324235|NCT01130454|Active Comparator|SCIO Test Group|
33324236|NCT01130454|Placebo Comparator|SCIO Placebo Group|
33324237|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
32982772|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
32982773|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
32982774|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
32982775|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
32982776|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
32982777|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
32982778|NCT01442766|Experimental|Donepezil|
32982779|NCT01442766|Placebo Comparator|Placebo|
32982780|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
32982781|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
32982782|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
32982783|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
32982784|NCT01442831|Experimental|Human ADME|
32982785|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
32982786|NCT01442870|Experimental|Metformin|Metformin
32982787|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
32982788|NCT01442883||treatment resistant hypertensives with CKD 3-5|
32982789|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (<510um),~Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy~For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery~Best corrected visual acuity of 20/40 or better at enrollment"
32982790|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg~o Normal appearing optic disc and no evidence of optic disc damage"
33324238|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
33324239|NCT03929484|Experimental|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
33324240|NCT03929484|Experimental|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
33324241|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
33324242|NCT03929406|Experimental|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
33324243|NCT03922074|Experimental|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
33324244|NCT03922074|Active Comparator|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
33324245|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
33324246|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
33324247|NCT03921684|Experimental|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
33324248|NCT03925974|Experimental|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
33324249|NCT03925974|Experimental|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
33324250|NCT03929094|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
33324251|NCT01228032|Experimental|Intervention|
33324252|NCT01228032|No Intervention|Control|referral only
33324253|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
32982791|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
32982792|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
32982793|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
32982794|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~irinotecan 180 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
32982795|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
32982796|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~irinotecan 150 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
32982797|NCT01442948||Acute coronary syndrome|
32982798|NCT01442948||Stable Angina|
32982799|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
32982800|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
32982801|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
32982802|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
32982803|NCT01442987|Active Comparator|Irbesartan|
32982804|NCT01442987|Active Comparator|Atorvastatin A|
32982805|NCT01442987|Placebo Comparator|Placebo|
32982806|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
32982807|NCT01442987|Active Comparator|Atorvastatin B|
32982808|NCT01443013||Cohort of Renal Transplant recipients|
32982809|NCT01443039|Experimental|phenotypical approach|phenotypical approach
32982810|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
32982811|NCT01443052||healthy subjects|Aged 65 to 80 years
32982812|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
32982813|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
32982814|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
32982815|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
32982816|NCT01443091|Experimental|Colostrum|
32982817|NCT01443091|Placebo Comparator|Sterile water|
32982818|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
32982819|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
32982820|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
32982821|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
33324254|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
33324255|NCT03921762|Experimental|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
33324256|NCT03921762|Experimental|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
33324257|NCT03921918|Other|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
33324258|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
33324259|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
33324260|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
32982822|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
33412361|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
32982823|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
33412362|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
33412363|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
33412364|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
33412365|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
33412366|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
33412367|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
33412368|NCT05336357|Experimental|Goal-Directed Therapy Group|Patients allocated to the Goal-Directed Therapy group will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours after randomization, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously.
33412369|NCT05336357|No Intervention|Conventional Therapy Group|Patients allocated to the Conventional Therapy Group will be treated according to the assistant team of the Emergency Unit, where will be measured the following parameters: invasive or non-invasive blood pressure (decided by the assistant team), peripheral oximetry, heart and respiratory rate, urinary output, in association with clinical history, complete physical examination and laboratory and imaging tests.
33412370|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
33412371|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
33412372|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
33412373|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
33412374|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
33412375|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
33412376|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W~• TCS = topical corticosteroids"
33412377|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
33412378|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
33412379|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
33412380|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
33412381|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
33412382|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
33412383|NCT01334593||Rectal Cancer|
33412384|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
33412385|NCT00406783|Experimental|5-mg Desloratadine tablet|
33412386|NCT00406783|Placebo Comparator|Placebo tablet|
33412387|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
33412388|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
33412389|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
32982824|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
32982825|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
32982826|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
32982827|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
32982828|NCT01443169|Experimental|Sequence 1|
32982829|NCT01443169|Experimental|Sequence 2|
32982830|NCT01443169|Experimental|Sequence 3|
32982831|NCT01443169|Experimental|Sequence 4|
32982832|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
32982833|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
32982834|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
32982835|NCT01443208|Experimental|50 mg|
33324261|NCT03925896|Experimental|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
33324262|NCT03929328|No Intervention|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
32982836|NCT01443208|Experimental|100 mg|
32982837|NCT01443208|Experimental|200 mg|
33324263|NCT03929328|Experimental|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
33324264|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
33324265|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
33324266|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
33324267|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
32982838|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
32982839|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
32982840|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
32982841|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
32982842|NCT01443247|Experimental|platelet support + anti-d|
32982843|NCT01443247|No Intervention|platelet support|
32982844|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
32982845|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
32982846|NCT01443325|Experimental|lidocaine patch|
32982847|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
33324268|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
33324269|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
33324270|NCT01225536|Experimental|ARQ 736|
32982848|NCT01443338|Active Comparator|Acitretin|
32982849|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
32982850|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
32982851|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
32982852|NCT01443429|Experimental|subjects with normal renal function|
32982853|NCT01443429|Experimental|patients with mild renal impairment|
32982854|NCT01443429|Experimental|patients with moderate renal impairment|
32982855|NCT01443429|Experimental|patients with severe renal impairment|
32982856|NCT01443455|Experimental|VideoDance|
32982857|NCT01443455|Active Comparator|Brisk Walking|
32982858|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
32982859|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
32982860|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
32982861|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
33324271|NCT03925818|Experimental|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
33324272|NCT03925818|Active Comparator|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
32982862|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
32982863|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
32982864|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
32982865|NCT01443520|Placebo Comparator|Placebo|
32982866|NCT01443520|Active Comparator|Duloxetine|
32982867|NCT01443520|Active Comparator|Venlafaxine|
32982868|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
32982869|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
32982870|NCT01443559|Experimental|Xenogenic cornea|
32982871|NCT01443559|Active Comparator|human cornea|
33412390|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
32982872|NCT01443572|Experimental|desflurane group|
32982873|NCT01443572|Active Comparator|sevoflurane group|
32982874|NCT01443611||Infants with first episode of Febrile Convlusions|
32982875|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
32982876|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
32982877|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
32982878|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
32982879|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
32982880|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
32982881|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
32982882|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
32982883|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
32982884|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
32982885|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
32982886|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
32982887|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
32982888|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
32982889|NCT01443702|Placebo Comparator|Placebo|
32982890|NCT01443702|Active Comparator|Lapis judaicus|
32982891|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
32982892|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
32982893|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
32982894|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
32982895|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
32982896|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
32982897|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
32982898|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
32982899|NCT01443806|Experimental|Oseltamivir, genetic testing|
32982900|NCT01443832||iron absorption|
32982901|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
32982902|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
32982903|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
32982904|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
32982905|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
32982906|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
32982907|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
32982908|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
32982909|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
32982910|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
32982911|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
32982912|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
32982913|NCT01443988|Active Comparator|Drug|Travoprost drops
32982914|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
32982915|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
32982916|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
32982917|NCT01444014|Experimental|YF476|
32982918|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
32982919|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
32982920|NCT01444066|Placebo Comparator|dilation to 27 French|
32982921|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
32982922|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
32982923|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
32982924|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
32982925|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
32982926|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
32982927|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
32982928|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
32982929|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
32982930|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
32982931|NCT01444170|Experimental|dicreatinol sulfate|
32982932|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
32982933|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
32982934|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
32982935|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
33324273|NCT03925740|Experimental|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
33324274|NCT03925740|Experimental|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
33324275|NCT03925740|Active Comparator|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
32982936|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
32982937|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
32982938|NCT01444248|Experimental|Amaryl MEX|
32982939|NCT01444248|Active Comparator|Amaryl M|
32982940|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
32982941|NCT01444261|Other|Control|No intervention
32982942|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
32982943|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
32982944|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
32982945|NCT01444326|Experimental|Dairy diet|
32982946|NCT01444326|Placebo Comparator|Control diet|
32982947|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
32982948|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
32982949|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
32982950|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
32982951|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
32982952|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
32982953|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
32982954|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
32982955|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
32982956|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
32982957|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
32982958|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
32982959|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
32982960|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
32982961|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
32982962|NCT01444469|Placebo Comparator|Placebo|Placebo
32982963|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
32982964|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
32982965|NCT01444508|Active Comparator|crystalloid|
32982966|NCT01444508|Placebo Comparator|colloid|
32982967|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
33324276|NCT01130688|Experimental|single arm of experimental drug combination|
32982968|NCT01444534|Experimental|use of the diabetes application|
32982969|NCT01444534|Active Comparator|Control arm without app (usual care)|
32982970|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
32982971|NCT01444560||Cutaneous Melanoma|
32982972|NCT01444560||Cutaneous Melanoma Metastases|
32982973|NCT01444560||Benign Melanocytic Nevi|
32982974|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
32982975|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
32982976|NCT01444586||Group 1|
32982977|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
32982978|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
32982979|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
32982980|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
32982981|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
32982982|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
32982983|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
32982984|NCT01444664|Experimental|Aneurysm|
32982985|NCT01444677|Experimental|MB12066 300mg|single dose
32982986|NCT01444677|Active Comparator|MB12066 400mg|single dose
32982987|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
32982988|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
32982989|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
32982990|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
32982991|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
32982992|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
32982993|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
32982994|NCT01444729||xiapex|Subject treated with Xiapex
32982995|NCT01444729||Surgery|Fasciotomy or fasciectomy
32982996|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
32982997|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
32982998|NCT01444807|Experimental|Sorafenib|Active Arm
32982999|NCT01444807|No Intervention|Best Supportive Care|Comparator
32983000|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
32983001|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
32983002|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
32983003|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
32983004|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
32983005|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
32983006|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
32983007|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
32983008|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
32983009|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
32983010|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
32983011|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
32983012|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
32983013|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
32983014|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
32983015|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
32983016|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
32983017|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
32983018|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
32983019|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
32983020|NCT01445015|Experimental|Stress management program|
32983021|NCT01445015|Active Comparator|peer viewed movies|
32983022|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
32983023|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
32983024|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
32983025|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
32983026|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
32983027|NCT01445197|Experimental|Biostate|
32983028|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
32983029|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
32983030|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
32983031|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
32983032|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
32983033|NCT01445236|Experimental|Weaning patients|
32983034|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
32983035|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
32983036|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
32983037|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
32983038|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
32983039|NCT01445392|Experimental|1|Multi-cycle cohort
32983040|NCT01445392|Experimental|2|Single cycle cohort
32983041|NCT01445418|Experimental|Arm 1|Standard dose escalation
32983042|NCT01445418|Experimental|Arm 2|Expanded cohort
32983043|NCT01445431|Experimental|Virgin Coconut Oil|
32983044|NCT01445431|Active Comparator|Mineral Oil|
32983045|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
32983046|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
32983047|NCT01445561|Experimental|1|100,000 international units/m2 SQ daily for 5 days
32983048|NCT01445561|Experimental|2|200,000 international units/m2 SQ daily for 5 days
33324277|NCT03928938|Experimental|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
33324278|NCT03925662|Active Comparator|Folfox with avastin|Folfox with avastin only
33324279|NCT03925662|Experimental|Mebendazole|Folfox with avastin with mebendazole
32983049|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
32983050|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
32983051|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
32983052|NCT01445639|Experimental|Dexmedetomidine group|
32983053|NCT01445639|Placebo Comparator|Placebo group|
32983054|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
32983055|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
32983056|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
32983057|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
32983058|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
32983059|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
32983060|NCT01445756|Placebo Comparator|Placebo|Placebo
32983061|NCT01445782|Experimental|1|AZD2115
32983062|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
32983063|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
32983064|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
32983065|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
32983066|NCT01445834||Incontinent women|
32983067|NCT01445860|Experimental|Treatment|
32983068|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
32983069|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
32983070|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
32983071|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
32983072|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
32983073|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
32983074|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
32983075|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
32983076|NCT01445964|Experimental|1|SLCO2B1 wild type allele
32983077|NCT01445964|Experimental|2|SLCO2B1 variant allele
32983078|NCT01446029|No Intervention|Usual Care|
32983079|NCT01446029|Active Comparator|Intervention Device|
32983080|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
32983081|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
32983082|NCT01446068|Experimental|Lean Subjects|
32983083|NCT01446068|Experimental|Obese subjects|
32983084|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
32983085|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
32983086|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
32983087|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
32983088|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
32983089|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
32983090|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
32983091|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
32983092|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
32983093|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
32983094|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
32983095|NCT01446172||cognitive, schema focused, guided mastery, exposure|
32983096|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
32983097|NCT01446198||AHPV positive and negative subjects|
32983098|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
33324280|NCT03921450|Experimental|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
32983099|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
32983100|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
32983101|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
32983102|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
32983103|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
32983104|NCT01446263|Active Comparator|Radial access|
32983105|NCT01446263|Active Comparator|Femoral access|
32983106|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
32983107|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
32983108|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
32983109|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
32983110|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
32983111|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
32983112|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
32983113|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
32983114|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
32983115|NCT01446328|Active Comparator|Amisulpride|
32983116|NCT01446328|Active Comparator|Aripiprazole|
32983117|NCT01446328|Active Comparator|Olanzapine|
32983118|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
32983119|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
32983120|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
32983121|NCT01446380||Pseudoxanthoma elasticum|
32983122|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
32983123|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
32983124|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
32983125|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
32983126|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
32983127|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
33324281|NCT03921450|Active Comparator|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.~total of 15 sessions in 3 weeks"
33324282|NCT03921450|Placebo Comparator|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
33324283|NCT03921450|No Intervention|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
33324284|NCT01225614|Experimental|bipap ventilation|
33324285|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
33324286|NCT03921606|Experimental|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
33324287|NCT03921606|Other|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
32983128|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
32983129|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
32983130|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
32983131|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
32983132|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
32983133|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
32983134|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
32983135|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
32983136|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
32983137|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
32983138|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
32983139|NCT01446549|Experimental|Deep Brain Stimulation|
32983140|NCT01446549|Experimental|Locomotor Exercise|
32983141|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
32983142|NCT01446588|Experimental|Yoga|Yoga group
32983143|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
32983144|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
32983145|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
32983146|NCT01446627||metal staples|
32983147|NCT01446627||Insorb vicryl staples|
32983148|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
32983149|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
32983150|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
32983151|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
32983152|NCT01446679||atrovastatin group|Who receive atrovastatin
32983153|NCT01446692||Patients with suboptimal response|
32983154|NCT01446692||Patients with symptomatic remission|
32983155|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
32983156|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
32983157|NCT01446731|Active Comparator|Arm B|Docetaxel alone
32983158|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
32983159|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
32983160|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
32983161|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
32983162|NCT01446783|Active Comparator|Mecasamin + healthy control|
32983163|NCT01446783|Placebo Comparator|Saline + healthy control|
32983164|NCT01446822|Experimental|Bipolar transurethral resection|
32983165|NCT01446822|Active Comparator|Monopolar transurethral resection|
32983166|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
32983167|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
32983168|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
33412391|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
32983169|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
32983170|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
32983171|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
32983172|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
32983173|NCT01446900|Experimental|Rituximab cladribine|
33324288|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
32983174|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
32983175|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
32983176|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
32983177|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
32983178|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
32983179|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
32983180|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
32983181|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
32983182|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
32983183|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
32983184|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
32983185|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
32983186|NCT01446939||Essential tremor|Patients with essential tremor
32983187|NCT01446939||Healthy volunteers|Healthy volunteers
32983188|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
32983189|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
32983190|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
32983191|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
33324289|NCT01229202|Active Comparator|bevacizumab arm|
32983192|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
32983193|NCT01447043||Group 1|
32983194|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
32983195|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
32983196|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
32983197|NCT01447082||Quetiapine XR group|
32983198|NCT01447082||Non-quetiapine comparison group|
32983199|NCT01447095|Active Comparator|Low dose prostacyclin|
32983200|NCT01447095|Active Comparator|High dose prostacyclin|
32983201|NCT01447095|Placebo Comparator|Placebo|
33324290|NCT03928860|Experimental|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
33324291|NCT03921372|Experimental|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
33324292|NCT03921372|Experimental|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
33324293|NCT01329510|Experimental|methylphenidate|
33324294|NCT01229280|Experimental|Darisec(R) 7.5 mg|
33324295|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
33324296|NCT03929172|Experimental|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
33324297|NCT03929172|Placebo Comparator|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
33324298|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
33324299|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
33324300|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
33324301|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
33324302|NCT01130766|No Intervention|observation|
33324303|NCT03920124|Experimental|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
33324304|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
33324305|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
33324306|NCT03919890|Experimental|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
33412392|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
33412393|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
33412394|NCT02973815|Experimental|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
32983202|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
32983203|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
32983204|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
32983205|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
32983206|NCT01447147|Placebo Comparator|Placebo (Group A)|
32983207|NCT01447147|Experimental|CCX140-B (Group B)|
32983208|NCT01447147|Experimental|CCX140-B (Group C)|
32983209|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
32983210|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
32983211|NCT01447173|Experimental|2000 IU vitamin D Daily|
32983212|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
32983213|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
32983214|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
32983215|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
33412395|NCT02973815|No Intervention|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
33412396|NCT01338727|Experimental|Breastfeeding Peer Counseling|
33412397|NCT01338727|No Intervention|Standard Care|
33412398|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
33417323|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
32983216|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
32983217|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
32983218|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
32983219|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
32983220|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
32983221|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
32983222|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
32983223|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
32983224|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
32983225|NCT01447264|No Intervention|Control group|No intervention will be recommended
33324307|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
33324308|NCT03919890|Experimental|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
33324309|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
33324310|NCT03919890|Experimental|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
32983226|NCT01447277|Experimental|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
32983227|NCT01447277|Other|Femoral Block Only|Administration of a femoral nerve block prior to surgery
32983228|NCT01447290||Women being evaluated for preeclampsia|
32983229|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
32983230|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
32983231|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
32983232|NCT01447329|Placebo Comparator|standard|placebo
32983233|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
32983234|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
32983235|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
32983236|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
32983237|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
32983238|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
32983239|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
32983240|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
32983241|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
32983242|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
32983243|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
32983244|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
32983245|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
32983246|NCT01447498|No Intervention|Control group|
32983247|NCT01447498|Active Comparator|Screening and risk assessment|
32983248|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
32983249|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
32983250|NCT01447550||Bosentan|Bosentan
32983251|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
32983252|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
32983253|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
32983254|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
32983255|NCT01447615|Experimental|Bridges|
32983256|NCT01447615|Experimental|Bridges PLUS|
32983257|NCT01447615|Other|Usual Care|
32983258|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
32983259|NCT01447654|Active Comparator|Losartan|
32983260|NCT01447654|Placebo Comparator|Placebo|
32983261|NCT01447680||Blood samples, low risk population|
32983262|NCT01447680||Blood samples, high risk population|
32983263|NCT01447680||Blood samples, known HIV positive|
32983264|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
32983265|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
32983266|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
32983267|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
32983268|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
32983269|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
32983270|NCT01447784|Placebo Comparator|Placebo|
32983271|NCT01447784|Experimental|ToleroMune HDM Dose 1|
32983272|NCT01447784|Experimental|ToleroMune HDM Dose 2|
32983273|NCT01447784|Experimental|ToleroMune HDM Dose 3|
32983274|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
32983275|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
32983276|NCT01447810|Experimental|Treatment|
32983277|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
32983278|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
33324311|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
33324312|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
33324313|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
33324314|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
33412399|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
32983279|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
32983280|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
32983281|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
32983282|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
32983283|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
32983284|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
32983285|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
32983286|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
32983287|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
32983288|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
32983289|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
32983290|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
32983291|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
32983292|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
32983293|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
32983294|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
32983295|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
32983296|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
32983297|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
32983298|NCT01448070|Experimental|NN729 manufacturing process|
32983299|NCT01448070|Active Comparator|Current manufacturing process|
32983300|NCT01448083||Neuroendocrine tumor patients|
32983301|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
32983302|NCT01448109|Active Comparator|Hydrocortisone|
32983303|NCT01448109|Placebo Comparator|Sterile air filled vial|
32983304|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
32983305|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
32983306|NCT01448135|Experimental|Vital AF|
32983307|NCT01448135|Active Comparator|Osmolite 1.2|
32983308|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
32983309|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
32983310|NCT01448148|No Intervention|no contact control group|waiting list
32983311|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
32983312|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~follow-up for 30 weeks (measurement of body weight every week)."
32983313|NCT01448174|No Intervention|The controls (healthy volunteers)|
32983314|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
32983315|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
32983316|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
32983317|NCT01448226||proven or probable aspergillosis|
32983318|NCT01448226||possible aspergillosis|
32983319|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
32983320|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
32983321|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
32983322|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
32983323|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
32983324|NCT01448278|Experimental|All-inside technique|
32983325|NCT01448278|Active Comparator|Classical technique|
32983326|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
32983327|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
32983328|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
32983329|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
32983330|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
32983331|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
32983332|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
32983333|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
32983334|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
32983335|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
32983336|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
32983337|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
32983338|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
32983339|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
32983340|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
32983341|NCT01448395|Experimental|1|
32983342|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
32983343|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
32983344|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
32983345|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
32983346|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
32983347|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
32983348|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
32983349|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
32983350|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
32983351|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
32983352|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
32983353|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
32983354|NCT01448538||Group 1|
32983355|NCT01448551|Experimental|Text Messaging|
32983356|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
32983357|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
32983358|NCT01448564|Placebo Comparator|Placebo Laser therapy|
32983359|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
32983360|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
32983361|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
32983362|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
32983363|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
32983364|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
32983365|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
32983366|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
32983367|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
32983368|NCT01448629|Experimental|River|
32983369|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
32983370|NCT01448642|Active Comparator|Atorvastatin|
33412400|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
32983371|NCT01448642|Placebo Comparator|Placebo|
32983372|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
32983373|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
32983374|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
32983375|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
32983376|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
32983377|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
32983378|NCT01448720|Experimental|Paliperidone palmitate|
32983379|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
32983380|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
32983381|NCT01448772|Active Comparator|Marinol|
32983382|NCT01448772|Experimental|oral solution|
32983383|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
32983384|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
32983385|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
32983386|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
32983387|NCT01448811|Experimental|AEP monitoring|
32983388|NCT01448811|Active Comparator|RSS monitoring|
32983389|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
32983390|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
33417324|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
32983391|NCT01448863||CONTROL|Fertile women (egg-donors)
32983392|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
32983393|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
32983394|NCT01448876||chlamydia care as usual|
32983395|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
32983396|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
32983397|NCT01448902|Experimental|OC000459|
32983398|NCT01448902|Placebo Comparator|Placebo|
32983399|NCT01448928||Group 1|
32983400|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
32983401|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
32983402|NCT01448954|Experimental|ADC3680B oral|
32983403|NCT01448954|Placebo Comparator|Placebo oral|
32983404|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
32983405|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
32983406|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
32983407|NCT01448993|Active Comparator|AZI|
32983408|NCT01449019|Active Comparator|intravenous infusion|
32983409|NCT01449019|Experimental|intraduodenal perfusion|
32983410|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
32983411|NCT01449032|Placebo Comparator|Saline|
33324315|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
33324316|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
33324317|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
32983412|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
32983413|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
32983414|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
32983415|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
32983416|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
32983417|NCT01449097|Experimental|Adductor-Canal-Blockade|
32983418|NCT01449097|Active Comparator|The femoral nerve block|
32983419|NCT01449097|Placebo Comparator|Placebo|
32983420|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
32983421|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
32983422|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
32983423|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
32983424|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
32983425|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
32983426|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
32983427|NCT01449136|Experimental|antibacterial cement|
32983428|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
32983429|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
32983430|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
32983431|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
32983432|NCT01449201|Experimental|PF-00299804|
32983433|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
32983434|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
32983435|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
32983436|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
32983437|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
32983438|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
32983439|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
32983440|NCT01449318|No Intervention|Patients undergoing hysterectomy|
32983441|NCT01449344|Experimental|R-HAD + Bortezomib|
32983442|NCT01449344|Active Comparator|R-HAD|
32983443|NCT01449357|Experimental|zalutumumab|
32983444|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
32983445|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
32983446|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
32983447|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
32983448|NCT01449396|Other|Control|Bed Rest
32983449|NCT01449422|Experimental|URGO 310 3082|
32983450|NCT01449422|Active Comparator|Aquacel|
32983451|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
32983452|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
32983453|NCT01449474|Experimental|Group 1|Patient matched instruments
32983454|NCT01449474|Experimental|Group 2|Jig based instruments
32983455|NCT01449487|Active Comparator|PPC-5650|
32983456|NCT01449487|Placebo Comparator|Placebo|
32983457|NCT01449500|Placebo Comparator|Placebo|Placebo
32983458|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
32983459|NCT01449552|Experimental|Group A|No clamp and placebo
32983460|NCT01449552|Experimental|Group B|Tranexamic acid
32983461|NCT01449552|Experimental|Group C|Drain clamping
32983462|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
32983463|NCT01449565|Active Comparator|Naltrexone|
32983464|NCT01449565|Placebo Comparator|Placebo|
32983465|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
32983466|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
32983467|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
32983468|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
32983469|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
32983470|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
32983471|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
32983472|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
32983473|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
32983474|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
32983475|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
32983476|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
32983477|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
32983478|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
32983479|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
32983480|NCT01449656||LMA proseal|
32983481|NCT01449656||LMA Supreme|
32983482|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
32983483|NCT01449695|Experimental|e health|An individual web based entry
33324318|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
33324319|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
33324320|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
33324321|NCT01131858|Placebo Comparator|Placebo|Placebo
33324322|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
33324323|NCT01130922|Experimental|Moxifloxacin IV|
33324324|NCT01130922|Active Comparator|Moxifloxacin oral|
33324325|NCT01131000|Experimental|Ibuprofen|
33324326|NCT01131000|Placebo Comparator|Saline|Normal Saline
33324327|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
33324328|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
32983484|NCT01449695|No Intervention|usual care|Usual care
32983485|NCT01449760|No Intervention|No treatment|
32983486|NCT01449760|Active Comparator|Physical Therapy|
32983487|NCT01449760|Experimental|Wii Balance group|
32983488|NCT01449773|Experimental|n-3 PUFAs|
32983489|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
32983490|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
32983491|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
32983492|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
32983493|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
32983494|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
32983495|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
32983496|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
32983497|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
32983498|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
32983499|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
32983500|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
32983501|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
32863060|NCT04892550|Experimental|Traction group|"Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.~In addition, the participants in the intervention group will receive the Denneroll™ thoracic traction orthosis. All participants will begin at 3-minutes per session of DTTO application, each visit they will be encouraged to increase the duration by 2-3 minutes, until such time they will be able to reach the goal of 15-20 minutes per session."
32863061|NCT04892550|Active Comparator|Control group|Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises. The multimodal program will be delivered by the same physiotherapist, with 10 years of experience and training in the specific manual techniques in order to minimize inter-therapist variation and enhance fidelity.
32863062|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
32863063|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
32863064|NCT04883736|Experimental|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32863065|NCT04883736|Active Comparator|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32863066|NCT04883736|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
32863067|NCT02312557|Experimental|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
32863068|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
32863069|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
32863070|NCT04883658|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(2) - A single oral dose of 1 tablet under fasting condition"
32863071|NCT04883658|Experimental|Sequence 2|"Period 1: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
32863072|NCT02412787|Experimental|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
32863073|NCT04883190||1. after SARS-CoV-2 infection|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
32863074|NCT04883190||2. control group with negative antibody test|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
32863075|NCT02411773|Active Comparator|Exercise Training/Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
32863076|NCT02411773|Active Comparator|Exercise Training/Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
32863077|NCT02411773|Active Comparator|Stretching/Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
32863078|NCT02411773|Placebo Comparator|Stretching/Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
32863079|NCT02411773|No Intervention|Control|Healthy subjects without CKD will not receive any interventions.
32863080|NCT04883580|Experimental|experimental group|
32863081|NCT04883580|Active Comparator|control group|
33324329|NCT03925428|Experimental|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33324330|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
32863082|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
32863083|NCT04883034|Placebo Comparator|pain management post total knee arthroplasty with analgetic oral|Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.
32863084|NCT04883034|Active Comparator|pain management post total knee arthroplasty with adductor canal block|On postoperative day 14 (POD 14), the ACB was performed for ACB group
32863085|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
32863086|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
32863087|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
32863088|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
32863089|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
32863090|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
32863091|NCT05585905|Experimental|Virtual Reality|The virtual reality system being used for research purposes is the RelievRx by AppliedVR which is an immersive virtual reality device that includes a goggle headset and remote control. The VR experience will be an immersive experience where the child will interact with the system and navigate their way through a game that will involve bright colors, cartoon-like characters, and settings with age-appropriate content.
32863092|NCT05585905|Active Comparator|Basic Behavior Guidance Techniques|The control sample will include basic behavior guidance techniques and is standard of care. The use of basic behavior guidance techniques is common in pediatric dentistry and is not unique to this study.
32863093|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
32863094|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
32863095|NCT04745767|Experimental|Group 1: A1(T1), B(T2), C(T2 Fed)|Participants will be randomly placed into 6 sequences within Group 1. All participants in Group 1 will receive TAK-994 as Treatment A1 (T1 Formulation) and Treatment B (T2 Formulation) under fasted conditions and Treatment C (T2 Formulation) under fed conditions at different times within three periods.
32863096|NCT04745767|Experimental|Group 2: A2(T1), D(T3), E(T3 Fed)|Participants will be randomly placed into 6 sequences within Group 2. All participants in Group 2 will receive TAK-994 as Treatment A2 (T1 Formulation) and Treatment D (T3 Formulation) under fasted conditions and Treatment E (T3 Formulation) under fed conditions at different times within three periods.
32863097|NCT04745767|Experimental|Group 3: A3(T1), F(T4), G(T4 Fed), H(T5)|Participants will be randomly placed into 6 sequences within Group 3. Participants in Group 3 will receive TAK-994 as Treatment A3 (T1 Formulation), Treatment F (T4 Formulation), and Treatment F (T5 Formulation) under fasted conditions and Treatment G (T4 Formulation) under fed conditions at different times within 4 periods.
32863098|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
32863099|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
32863100|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
32863101|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
32863102|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
32863103|NCT02396251|Experimental|HA experimental|HA experimental only
32863104|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
32863105|NCT04899960|No Intervention|Observational Group|
33324331|NCT01229514||Exposure to anesthesia|
32863106|NCT04899960|No Intervention|Control (Validation) Group|
32863107|NCT04899960|Experimental|İnterventional Group|
32863108|NCT04892394|Experimental|Video Group|Detailed visual video information was given to the video group patients before endodontic treatment by the clinician.
32863109|NCT04892394|Experimental|Control Group|Basic verbal information was given to the control group patients before endodontic treatment by the clinician.
33324332|NCT01229514||Normal controls|
33324333|NCT03920592|Experimental|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).~Every pupil will watch the 4 types of video content randomly."
33324334|NCT03920514|Active Comparator|GROUP 1|IUI 24 hours after hCGadminstration
33324335|NCT03920514|Active Comparator|GROUP 2|IUI 36 hours after hCG adminstration
33324336|NCT03920514|Active Comparator|GROUP 3|IUI 48 hours after hCG adminstration
33324337|NCT03920514|Active Comparator|GROUP 4|IUI at time of hCG adminstration
32863110|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
33412401|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
33417325|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
33417326|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
33417327|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
32863111|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
32863112|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
32863113|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
32863114|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
32863115|NCT04900194|Experimental|MBSC group|counseling group
32863116|NCT04900194|No Intervention|Control group|standard care group
32863117|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
32863118|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
32863119|NCT04883268|Experimental|Intervention Group|Participants in the intervention group completed the Expand Your Horizon programme (Alleva et al., 2015).
32863120|NCT04883268|No Intervention|Comparison Group|Participants in the comparison group did not complete any intervention (i.e., this was a waitlist comparison group).
32863121|NCT05024539||Regorafenib group|Patients were given only regorafenib orally
32863122|NCT05024539||Joint group|The patient was treated with regorafenib orally and in combination with other medications
32863123|NCT04892316||Junior doctor group|Patients receive assisting devices fitting services from junior doctors
32863124|NCT04892316||Senior doctor group|Patients receive assisting devices fitting services from senior doctors
32863125|NCT04892316||Algorithm assisted group|Patients receive assisting devices fitting services from junior doctors assisted by the machine learning model
32863126|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
32863127|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
32863128|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
32863129|NCT02616900|Experimental|eSight Eyewear|Main arm
32863130|NCT04882956|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
32863131|NCT04882956|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
32863132|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
32863133|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
32863134|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
32863135|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
32863136|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
32983502|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
33412402|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
32983503|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
32983504|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
32983505|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
32983506|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
32983507|NCT01449903||Rebilda DC|
32983508|NCT01449903||Clearfil Core DC / Plus|
32983509|NCT01449903||Multicore Flow|
32983510|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
32983511|NCT01449916|Active Comparator|Usual care|Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.
32983512|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
32983513|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
32983514|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
32983515|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
32983516|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
32983517|NCT01449981|Experimental|Cognitive Behavioral Therapy|
32983518|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
32983519|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
32983520|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
32983521|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
32983522|NCT01450163|Active Comparator|Pregabalin|
32983523|NCT01450163|Placebo Comparator|Placebo|
32983524|NCT01450267|Placebo Comparator|Physiological solution|
32983525|NCT01450267|Experimental|Reduced Inhaled Glutathione|
32983526|NCT01450436||preterm infants (<35 weeks gestation)|
32983527|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
32983528|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
32983529|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
32983530|NCT01450995|Active Comparator|Treximet|
32983531|NCT01450995|Active Comparator|Imitrex and Aleve|
32983532|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
32983533|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
32983534|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
32983535|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
32983536|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
32983537|NCT01451489|Active Comparator|Cyclophosphamide|CTX
32983538|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
32983539|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
32983540|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
32983541|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
32983542|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
33417328|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
33412403|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
33412404|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
32983543|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
32983544|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
32983545|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
32983546|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
32983547|NCT01452256|Experimental|Propofol|
32983548|NCT01452373|Placebo Comparator|Control (placebo)|
32983549|NCT01452373|Experimental|DHEA + Acolbifene|
32983550|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
33412405|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
33412406|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
32983551|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
32983552|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
32983553|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
32983554|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
32983555|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
33412407|NCT05185765|Active Comparator|Brown bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412408|NCT05185765|Active Comparator|Wholemeal bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412409|NCT05185765|Active Comparator|Wholemeal bread without crust (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412410|NCT05185765|Active Comparator|White bread, water based (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412411|NCT05185765|Active Comparator|White hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
33412412|NCT05185765|Active Comparator|Brown hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
33412413|NCT05185765|Active Comparator|White soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
33412414|NCT05185765|Active Comparator|Brown soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
33412415|NCT05185765|Active Comparator|Ciabatta (commercially available)|Participants consume half a mini ciabatta, and masticate and expectorate half of 1 cm thick slice
33412416|NCT05185765|Active Comparator|Croissant (commercially available)|Participants consume half a croissant, and masticate and expectorate half of 1 cm thick slice
32983556|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
32983557|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
32983558|NCT01452958|Experimental|Endotoxin|
32983559|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
32983560|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
32983561|NCT01453608|Placebo Comparator|Placebo (saline)|
32983562|NCT01454128|Active Comparator|Non-EPB|with exercise
32983563|NCT01454128|Experimental|EPB with exercise|with exercise
32983564|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
32983565|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
32983566|NCT01454375|No Intervention|Control Arm|No change in current practice
32983567|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
32983568|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
32983569|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
32983570|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
32983571|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
32983572|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
32983573|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
33412417|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
32983574|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
32983575|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
33412418|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412419|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
32983576|NCT01454869|Active Comparator|Standard care|nac + salotamul
32983577|NCT01454869|Experimental|heparin group|heparin group
32983578|NCT01454973||Healthy obese individuals|
32983579|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
32983580|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
32983581|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
32983582|NCT01455272|Experimental|high-risk leukemia|
32863137|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
33412420|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412421|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412422|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
33412423|NCT03160573|Active Comparator|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
33412424|NCT03160573|Active Comparator|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
33412425|NCT03160573|Placebo Comparator|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
33412426|NCT03160573|Placebo Comparator|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
33412427|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
33412428|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
33412429|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
33412430|NCT05185687|Experimental|First Come, First Served|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the First Come, First Served plan description."
33417329|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
33417330|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
32863138|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
32983583|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
32983584|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
32983585|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
33412431|NCT05185687|Experimental|Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Random plan description."
33412432|NCT05185687|Experimental|Disadvantaged Priority & Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Disadvantaged Priority & Random plan description."
32983586|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
32983587|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
32983588|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
32983589|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
32983590|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
32983591|NCT01456078|Experimental|177Lu-DOTA-TATE|
32983592|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
32983593|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
32983594|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
32983595|NCT01456520|Experimental|A: single dose Vycavert (Test)|
32983596|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
32983597|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
32983598|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
32983599|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
32983600|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
32983601|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
32983602|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
32863139|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
32863140|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
32863141|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
32983603|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
32983604|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
32983605|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
32983606|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
32983607|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
32983608|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
32983609|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
32983610|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
32983611|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
32983612|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
32983613|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
32983614|NCT01457534||liver transplantation|
33412433|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
33412434|NCT01334905|Experimental|Part A group|fasted condition then fed condition
33412435|NCT01334905|Experimental|Part B group|fed condition then fasted condition
33412436|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
33412437|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
32863142|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
32863143|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
32983615|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
32983616|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
32983617|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
32983618|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
32983619|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
32983620|NCT01458145|Experimental|Home visits|
32983621|NCT01458145|No Intervention|routine primary care at community health center|
32983622|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
32983623|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
32983624|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
32983625|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
32983626|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
32983627|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
32983628|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
32983629|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
32983630|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
32983631|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
32983632|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
32983633|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
33412438|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
33412439|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
33412440|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
33412441|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
33412442|NCT05095337|Experimental|[14C]SHR1459|
33412443|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
33412444|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
32983634|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
32983635|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
33412445|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
33412446|NCT05030129|Experimental|Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP)|Ergoloid mesylates (EM) 1 mg three times daily and 5-hydroxytryptophan (5-HTP) 100 mg three times daily for 4 weeks
32863144|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
32863145|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
32863146|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
32863147|NCT04891848||migraine with aura|51 patients with MA
32863148|NCT04891848||migraine without aura|51 patients with migraine without aura
32863149|NCT04891848||tension type headache|48 patients with tension type headache
32863150|NCT04891848||healthy controls|80 healthy participants
32863151|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
32863152|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
32863153|NCT01404429|Experimental|Methotrexate 15 mg per week|
32863154|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
32863155|NCT05404711|Other|CGM use for T2D risk evaluation|All participants will complete a standard 2-hour oral glucose tolerance test (OGTT), wear a CGM for 10 days, complete at-home glucose challenge, and provide qualitative feedback about their experiences with both OGTT and CGM use for risk evaluation.
32863156|NCT04816188|Experimental|Exercise and Activity Modification|
32863157|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
32863158|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
32863159|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
32863160|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
32863161|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
32863162|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
32863163|NCT02008903||EoE active disease|Inflammation as defined by >15 eos / HPF
32863164|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
32863165|NCT02008903||normal control|No inflammation
32863166|NCT04892160|Other|Guided Imagery First/Virtual Reality Second|Patients will be played a guided imagery experience first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the virtual reality intervention.
32863167|NCT04892160|Experimental|Virtual Reality First/Guided Imagery Second|Patients will have the VR interactive experience played first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the guided imagery intervention.
32863168|NCT02006095||Neuroimaging Correlates|
32863169|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
32863170|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
32863171|NCT05026567|Active Comparator|Reference Product A|
32863172|NCT05026567|Experimental|Experimental B|
32863173|NCT05026567|Experimental|Experimental C|
32863174|NCT05026567|Experimental|Experiment D|
32863175|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
33412447|NCT05030129|Placebo Comparator|Placebo|2 placebo capsules three times daily for 4 weeks
33412448|NCT05030129|Experimental|Ergoloid mesylates (EM) and placebo|Ergoloid mesylates (EM) 1 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
33412449|NCT05030129|Experimental|5-hydroxytryptophan (5-HTP) and placebo|5-hydroxytryptophan (5-HTP) 100 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
33412450|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
33412451|NCT05017025|Experimental|Treatment (osimertinib, aurora A kinase inhibitor LY3295668)|Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
33412452|NCT05239559||bubble CPAP arm|"Oxygen will be delivered by Bubble CPAP device, which will have three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit: short nasal prongs are generally used to deliver nasal CPAP. They must be carefully fitted to minimize leakage of air (otherwise, CPAP will not be achieved) .~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure: in bubble CPAP, the positive pressure is maintained by placing the far end of the expiratory tubing in water. The pressure is adjusted by altering the depth of the tube under the surface of the water."
33412453|NCT03260023|Experimental|TG4001/Avelumab|
33412454|NCT03260023|Experimental|Avelumab|Applicable for Phase II part 2.
33412455|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
33412456|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
33412457|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
32983636|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
32983637|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
33412458|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
33412459|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
33412460|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
33412461|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
32983638|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
33412462|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
33412463|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
33412464|NCT05239481|Experimental|intervention|Before the examination, the nurse chose the appropriate colonoscopy position size sheet according to the patient's age and body size and spread it on the examination bed; instructed the patient to lie in the designated area according to the body size.Description: ① take off your shoes; ② follow the bed chart; ③ fade your pants to your knees.
33412465|NCT05239481|Placebo Comparator|control|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient, the following: ① please remove the shoes; ② please sit on the end of the bed mattress; ③ please lie to the left side; ④ please put the head close to the pillow; ⑤ please fade the pants to the knee; ⑥ please put the knee close to the abdomen.
33412466|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
33412467|NCT05224895||General Anesthesia in Trendelenburg position for robotic prostatectomy|
32983639|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
33412468|NCT01335373||Group 1|
33412469|NCT05221463|Experimental|Educational group|Video-assisted breastfeeding training was given to the educational group.
33412470|NCT05221463|Other|Control group|Only the hospital's routine general breastfeeding training was given to the control group, and no other intervention was made.
33412471|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
33412472|NCT03204721|No Intervention|Controll|No procedure
33412473|NCT05218811|Experimental|Treatment group|Patients underwent Cryotheapy assisted partial nephrectomy
33412474|NCT05185219|Experimental|Valerian|generic name: XIE CAO CONC dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
33412475|NCT05185219|Placebo Comparator|Control|generic name: placebo (Caramel Colors dyed starch) dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
33412476|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
33412477|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
33412478|NCT01315483|No Intervention|Control|Usual care
32983640|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
32983641|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
32983642|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
32983643|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
32983644|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
32983645|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
32983646|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
32983647|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
32983648|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
32983649|NCT01459874||Cardiac Implantable Device recipients|
32983650|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
32983651|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
32983652|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
32983653|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
32983654|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
32983655|NCT01460030|Experimental|KRN1493|
32983656|NCT01460043|Placebo Comparator|placebo|
33412479|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
33412480|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
33412481|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
33412482|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
33412483|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
33412484|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
33412485|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
32983657|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
32983658|NCT01460056||Peritoneal dialysis|
33417331|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
33417332|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
32983659|NCT01460069|Active Comparator|Victoza treatment|
32983660|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
32983661|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
32983662|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
32983663|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
32983664|NCT01460121|Experimental|SpotOn's corrective elements|
32983665|NCT01460121|Placebo Comparator|Placebo corrective elements|
32983666|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
32983667|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
32983668|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
32983669|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
32983670|NCT01460147|Other|DXA scan + MRI|
32983671|NCT01460173|Other|Normal subjects|
32983672|NCT01460173|Other|OSA Patients|
32983673|NCT01460186|Experimental|Blood samples|
32983674|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
32983675|NCT01460199|Experimental|CTP-499|
33417333|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
33417334|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
32983676|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
32983677|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
32983678|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
32983679|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
32983680|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
32983681|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
32983682|NCT01460316||Conotruncal cardiac defects patients|
32983683|NCT01460316||Mothers of patients|
32983684|NCT01460329||USCOM Cardiac index|
32983685|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
32983686|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
32983687|NCT01460394||Healthy adolescents and young adults|
32983688|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
32983689|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
32983690|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
32983691|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
32983692|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
32983693|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
32983694|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
32983695|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
32983696|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
33412486|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
33417335|NCT02074280|No Intervention|control|conventional treatment
33417336|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
33417337|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
32983697|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
32983698|NCT01460550|Experimental|gastrointestinal reconstruction|
32983699|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
32983700|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
32983701|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
32983702|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
32983703|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
32983704|NCT01460641||CT perfusion|
32983705|NCT01460667|Active Comparator|IV acetaminophen|
32983706|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
32983707|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
32983708|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
32983709|NCT01460680||Healthy controls|Healthy controls
32983710|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
32983711|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
32983712|NCT01460706|Experimental|68Ga-DOTATOC|
32983713|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
32983714|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
32983715|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
32983716|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
32983717|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
32983718|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
32983719|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
32983720|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
32983721|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
32983722|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
33324338|NCT03919812|Experimental|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
33324339|NCT03919656|Experimental|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
32983723|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
32983724|NCT01460823|Experimental|Use of image guided surgery|
32983725|NCT01460836||Tobramycin Solution|
32983726|NCT01460836||Aztreonam lysine|
33324340|NCT03919656|Placebo Comparator|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
33324341|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
33324342|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
33324343|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
32983727|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
32983728|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
32983729|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
32983730|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
33324344|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
33324345|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
33324346|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
33324347|NCT05402670||Dermatomyositis group|patient with dermatomyositis
33324348|NCT05402670||control group|health check-up population
33324349|NCT01231776|No Intervention|control group|
33324350|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
33324351|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
32983731|NCT01460888|Active Comparator|RT alone|
33324352|NCT01132404|Experimental|TAK-448 Dose 1|
33324353|NCT01132404|Experimental|TAK-448 Dose 2|
33324354|NCT01132404|Active Comparator|Leuprorelin|
33324355|NCT01134354||TEFTOM|Patient outcome measure
33324356|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
33324357|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
33324358|NCT01229670|No Intervention|control|home exercise group
33324359|NCT03919500|Experimental|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
33324360|NCT03919500|Placebo Comparator|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
33324361|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
33324362|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
32983732|NCT01460953|Experimental|training intervention|Students participating in didactic training
32983733|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
32983734|NCT01460966|Active Comparator|Thrombus aspiration catheter|
32983735|NCT01460979|Experimental|Temsirolimus|
32983736|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
32983737|NCT01461018|Experimental|IgPro20|
32983738|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
32983739|NCT01461070||Controls|Controls
32983740|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
32983741|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
32983742|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
32983743|NCT01461161|Experimental|20 mg bardoxolone methyl|
32983744|NCT01461161|Experimental|60 mg bardoxolone methyl|
32983745|NCT01461161|Experimental|80 mg bardoxolone methyl|
32983746|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
32983747|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
32983748|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
32983749|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
32983750|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
32983751|NCT01461200||Non allergics|
32983752|NCT01461200||allergics|
33324363|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
32983753|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
32983754|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
32983755|NCT01461226|Experimental|Exercise training|
32983756|NCT01461226|Other|Usual Care|
32983757|NCT01461239|Active Comparator|cast post and core|
32983758|NCT01461239|Experimental|fiber post - self-adhesive cement|
33324364|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
33324365|NCT01231854|Active Comparator|Ciclosporingroup|
32983759|NCT01461239|Experimental|fiber post - conventional cement|
32983760|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
33324366|NCT01231854|Active Comparator|Alitretinoingroup|
33324367|NCT05402436||Women attending Breast Cancer Screening in England with an atypia diagnosis|Women attending Breast Cancer Screening in England with an atypia diagnosis between 1st January 2003 and 30th June 2018
33324368|NCT05402358||Specific-Diagnosis|
33324369|NCT05402358||Mixed-Diagnosis|
33324370|NCT05402280|No Intervention|Qualitative study|15 nurses (direct care nurses, nurse managers) and 5 patients, to investigate experiences and compare attitudes and opinions concerning the need for and quality of sleep in hospitalized patients.
33324371|NCT05402280|No Intervention|Prospective quantitative study|diagnosing predisposition to sleep disturbances: 400 inpatients staying in gene-ral wards: Patients will undergo a serial of structured and standardized questi-onnaires during scheduled: FIRST: on the day of admission and RCSQ during their hospital stay (record length of up to 7 days).
33324372|NCT05402280|No Intervention|Retrospective quantitative study|subjective assessment of factors affecting sleep: 600 hospitalized patients (360 patients in general wards, 240 patients in intensive care wards). On the day of discharge, patients will retrospectively assess disruptive factors that could in-fluence the quality of their sleep during their hospital stay by standardized que-stionnaire.
33324373|NCT05402280|Other|Interventional study|(subjective and objective assessment of sleep, quality of sleep with respect to delirium, baseline - routine care: PRE phase) implementation of sleep protocol and assess effectiveness (POST phase: determining the effectiveness of imple-mented sleep measures): overal: 2240 patients (1480 general ward, 760 inten-sive care wards.
33324374|NCT03920436|Experimental|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
32983761|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
32983762|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
32983763|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
32983764|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
32983765|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
32983766|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
32983767|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
32983768|NCT01461382|Experimental|Phase I|Entered Study May 2008.
32983769|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
32983770|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
32983771|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
32983772|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
32983773|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
33324375|NCT03920436|Sham Comparator|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
33324376|NCT01132638|Active Comparator|Magnesium Pantoprazole|
32983774|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
32983775|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
32983776|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
32983777|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
32983778|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
32983779|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
32983780|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
32983781|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
32983782|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
32983783|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
32983784|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
32983785|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
32983786|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
32983787|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
32983788|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
32983789|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
32983790|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
32983791|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
32983792|NCT01461460|Experimental|TR-701 FA 1200 mg|
32983793|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
32983794|NCT01461460|Placebo Comparator|Placebo|
32983795|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
32983796|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
32983797|NCT01461486|No Intervention|Hygiene sleep care|Control group
32983798|NCT01461512|Placebo Comparator|Placebo|
32983799|NCT01461512|Experimental|Heme arginate treatment|
32983800|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
32983801|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
32983802|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
32983803|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
32983804|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
32983805|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
32983806|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
32983807|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
32983808|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
32983809|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
32983810|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
32983811|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
32983812|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
32983813|NCT01461642|Experimental|Asthma - ICT support.|
32983814|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
33324377|NCT01132638|Active Comparator|Magnesium Esomeprazole|
33324378|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
33324379|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
33324380|NCT05484570||Diagnosed|Patients who are diagnosed with a DNA Repair Disorder
33324381|NCT05484570||Control|Healthy family members of enrolled diagnosed participants.
33324382|NCT05483946|Experimental|CPM#1|Compartment compressibility ratio measurement using the CPM#1 device
33324383|NCT05402124|Other|ASA 81mg|Acetylsalicylic acid delayed release tablets (81mg), single tablet taken once per day for 90 days.
33324384|NCT01134432|Experimental|Prednisolone + Rituximab|
33324385|NCT01134432|Active Comparator|Prednisolone|
33324386|NCT01232010|Experimental|Healthy Volunteers|
33324387|NCT01232010|Experimental|Patients with severe renal impairment|
33324388|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:~Still Disease,~Recurrent pericarditis,~Neutrophilic dermatosis,~Schnitzler,~Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),~Inflammation of unknown origin,~Chronic/recurrent osteitis."
33324389|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
33324390|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
33324391|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
32983815|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
32983816|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
32983817|NCT01461694|Active Comparator|IPL|Half face treated with IPL
32983818|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
32983819|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
32983820|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
32983821|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
32983822|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
32983823|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
32983824|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
32983825|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
32983826|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
32983827|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
32983828|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
32983829|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
32983830|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
32983831|NCT01461876||HIV-infected cohort|
32983832|NCT01461876||HIV-uninfected control group|
32983833|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
32983834|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
32983835|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
32983836|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
32983837|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
32983838|NCT01461967|Experimental|Part 1a|
32983839|NCT01461967|Placebo Comparator|Part 1b|
32983840|NCT01461967|Experimental|Part 2|
32983841|NCT01462006|Experimental|Sirolimus|
32983842|NCT01462006|Placebo Comparator|Placebo|
32983843|NCT01462019|No Intervention|Control|
32983844|NCT01462019|Experimental|Photobiomodulation|
32983845|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
32983846|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
32983847|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
33412487|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
32983848|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
32983849|NCT01462071||Chronic kidney disease|
32983850|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
32983851|NCT01462136|Experimental|ACHN-490 Injection|
32983852|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
32983853|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
32983854|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
32983855|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
32983856|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
32983857|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
32983858|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
32983859|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
32983860|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
32983861|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
32983862|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
32983863|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
32983864|NCT01462409|Experimental|heated humidification|
33324392|NCT05402046|Experimental|ProRodinki application test|Patients scheduled for excisional biopsy of skin lesion(s) will be invited to participate in this study. Photo-documentation of the skin neoplasm(s) in the ProRodinki application will be performed, and the generated report will be sent for evaluation by artificial intelligence. Following this procedure, an excisional biopsy of the lesion(s) will be scheduled. From the moment of inclusion in the study until the excisional biopsy, an interval of no more than 2-4 weeks is allowed. After excisional biopsy of the skin neoplasm(s), a routine intravital pathological examination with hematoxylin and eosin staining will be performed, if necessary, immunohistochemical and molecular genetic tests will be performed. The selected biosamples (paraffin blocks) will then be analyzed centrally by a morphologist.
33324393|NCT05401812|No Intervention|Control|Standard care without glucocorticoid therapy.
32983865|NCT01462409|Experimental|No Humidification|
32983866|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
32983867|NCT01462422|Other|Primary prevention|
32983868|NCT01462422|Other|Secondary Prevention|
32983869|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
32983870|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
32983871|NCT01462474|Experimental|Drug: Famitinib|
33324394|NCT05401812|Experimental|Low dose and long treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 5 days, followed by 0.25 mg/kg/day for 5 days.
33324395|NCT05401812|Experimental|Low dose and short treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 4 days,, followed by 0.25 mg/kg/day for 3 days.
33324396|NCT05401812|Experimental|Moderate dose and long treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 5 days, followed by 0.5 mg/kg/day for 5 days.
33324397|NCT05401812|Experimental|Moderate dose and short treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 4 days, followed by 0.5 mg/kg/day for 3 days.
33324398|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
33324399|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
33324400|NCT05401734||Cohort 1|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
33324401|NCT05401734||Cohort 2|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
33324402|NCT05401734||Cohort 3|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
33324403|NCT01137552|Experimental|A|Dose Escalation
33324404|NCT01137552|Experimental|B|Dose Expansion
33412488|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
32983872|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
33412489|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
32983873|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
32983874|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
33412490|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
33412491|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
33412492|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
32983875|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
32983876|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
32983877|NCT01462513|Placebo Comparator|Placebo|Placebo
32983878|NCT01462526||Control|Participants who do not have glaucoma in either eye
33412493|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
32983879|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
32983880|NCT01462539||OSAS group|
32983881|NCT01462539||Non-OSAS group|
32983882|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
32983883|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
32983884|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
32983885|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
32983886|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
32983887|NCT01462617|Experimental|Pi3K|Experimental
32983888|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
32983889|NCT01462643|Experimental|variant1|topical ointment, once daily application
32983890|NCT01462643|Experimental|variant 2|topical ointment, once daily application
32983891|NCT01462643|Experimental|variant 3|topical ointment, once daily application
32983892|NCT01462643|Experimental|variant4|topical ointment, once daily application
32983893|NCT01462643|Experimental|variant 5|topical ointment, once daily application
32983894|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
32983895|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
32983896|NCT01462656||Patients with urinary retention|Patients with urinary retention
32983897|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
32983898|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
32983899|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
32983900|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
32983901|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
32983902|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
32983903|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
32983904|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
32983905|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
32983906|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
32863176|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
32863177|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
32863178|NCT04899570|Experimental|Zanubrutinib combined with R-CHOP|"The experimental arm will be treated zanubrutinib combined with R-CHOP regimen for 8 cycles. The interim evaluation will be performed after 4 cycles, and the patients who can't achieve PR or CR will be withdrawn from this trial and receive salvage regimens.~After 8 cycles of ZR-CHOP, the patients will be followed for 2 years to evaluate the PFS."
32863179|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
32863180|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
32863181|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
32863182|NCT04892004|No Intervention|Control group|Standard information defined as the standard care, unplanned, provided for Heart Failure patients and not personalized.
32863183|NCT04892004|Experimental|Interventional group|A nurse provides the intervention with expertise in Heart Failure and addresses reinforcements on: a) an explanation on signs and symptoms of Heart Failure and how to recognise them; b) importance on daily fluid management, by planning 1.5-2 litres of liquids per day (e.g., soup, milk, coffee, water, tea and yoghurts); and c) when doctors or nurses should be contacted (when symptoms escalation or a weight gain of 2 kg in three days or 5 kg in a week were detected).
32863184|NCT05585749|Experimental|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
32863185|NCT05585749|No Intervention|Control group|Routine maintenance will be applied.
32863186|NCT04397016|No Intervention|Arm 1: Usual Care|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure."
32863187|NCT04397016|Experimental|Arm 2: Option Grid|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure."
32863188|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
32863189|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
32863190|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
32863191|NCT03049722|Experimental|AVOPT Patient|
32863192|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
32863193|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
32863194|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
32863195|NCT04891926|Experimental|Hormonal therapy|Patients choosing to start hormoanl treatment using ural or transdermal estrogen.
32863196|NCT02267863|Experimental|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
32863197|NCT04892238||Treatment-naïve|Subjects without previous experience of treatment provided for H.pylori infection
32863198|NCT04892238||treatment experienced|Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test
32863199|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
32863200|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
32863201|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
32863202|NCT01391325|Other|Allopurinol|Treatment.
32863203|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
32863204|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
32863205|NCT04899726|Experimental|Intervention|Oncology patients candidate for rectal surgery (tumors located up to 15 cm from the anal margin) and meet inclusion criteria. Rectoscope (P201630551) allows the identification of the distal section margin.
32863206|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
32863207|NCT04899648|Experimental|Behavioral Intervention|Receives nutrition and exercise intervention classes
32863208|NCT04899648|No Intervention|Control Group|Does not receive any intervention classes
32863209|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
32863210|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
32983907|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
32983908|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
32983909|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
32983910|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
32983911|NCT01462825|Experimental|tomato ketchup meal|
32983912|NCT01462825|Placebo Comparator|Placebo meal|
32983913|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
32983914|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
32983915|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
32983916|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
32983917|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
32983918|NCT01462903|Experimental|Drug, T cell immunoterhapy|
32983919|NCT01462916||honey, no honey|
32983920|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
32983921|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
32983922|NCT01462994|No Intervention|Single arm|
32983923|NCT01463020|Experimental|Smartphone delivered BA|
32983924|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
32983925|NCT01463046|Experimental|Panobinostat|
32983926|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
32983927|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
32983928|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
32983929|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
32983930|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
32983931|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
32983932|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
32983933|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
32983934|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
32983935|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
32983936|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
32983937|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
33412494|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
33412495|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
32863211|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
32863212|NCT04891458|Experimental|Patients received lighter sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 0-2.
32863213|NCT04891458|Experimental|Patients received heavier sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 3-5.
32863214|NCT04891458|Experimental|Patients received lighter sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 0-2.
32863215|NCT04891458|Experimental|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 3-5.
32863216|NCT01975597||Bone marrow aspirates and biopsy|
32863217|NCT04899414|Experimental|Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma|4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT
32863218|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
32863219|NCT04899258|Other|Pre-surgery and post-surgery|femtosecond assisted LASIK
32863220|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
32863221|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
32863222|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
32863223|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
32863224|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
32863225|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
32863226|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
32863227|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
32863228|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
32863229|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
32863230|NCT04756921||Patients cohort|Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.
32863231|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
32863232|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
32863233|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
32863234|NCT01335789|Active Comparator|Oxytocin|intranasal administration
32863235|NCT01335789|Placebo Comparator|saline|intranasal administration
32863236|NCT04390321|Experimental|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
32863237|NCT04891536|Experimental|Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy|
32863238|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
32863239|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
32863240|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
32863241|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
32907884|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
32983938|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
32983939|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
33412496|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
33412497|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
33412498|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
33412499|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
33412500|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
33412501|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
32983940|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
32983941|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
32983942|NCT01463189|Experimental|painACTION: Arthritis|
32983943|NCT01463189|No Intervention|treatment as usual|
32983944|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
32983945|NCT01463228|Experimental|Treatment Sequence AB|
32983946|NCT01463228|Experimental|Treatment Sequence BA|
33412502|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)~Three-drug-regimen:~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
33412503|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
32983947|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
32983948|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
32983949|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
32983950|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
32983951|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
32983952|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
32983953|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
32983954|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
32983955|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
32983956|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
32983957|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
32983958|NCT01463371|No Intervention|Control|without azithromycin
32983959|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
32983960|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
32983961|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
32983962|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
32983963|NCT01463462||Electronic Catheter Stethoscope|
32983964|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
32983965|NCT01463488|Experimental|SAR113945 - Dose 1|
32983966|NCT01463488|Experimental|SAR113945 - Dose 2|
32983967|NCT01463488|Experimental|SAR113945 - Dose 3|
32983968|NCT01463488|Placebo Comparator|Placebo|
32983969|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
32983970|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
32983971|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
32983972|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
32983973|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
33412504|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
33412505|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
33412506|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
33412507|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
33417338|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
32907885|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
32907886|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
32907887|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
32907888|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
32907889|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
32907890|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
32907891|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
32907892|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
32907893|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
32907894|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
32907895|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
32907896|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
32907897|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
32907898|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
32907899|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
32907900|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
32907901|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
32907902|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
32907903|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
32907904|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
32907905|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
32907906|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
32907907|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
32907908|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
32907909|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
32907910|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
32907911|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
32907912|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
32907913|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
32907914|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
32907915|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
32907916|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
32907917|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
32907918|NCT04943094||TURBT alone|Patients treated with TURBT without adjuvant instillation therapy
32907919|NCT04943094||TURBT and mitomycin C|Patients treated with TURBT followed by six adjuvant instillations with mitomycin C
32907920|NCT04943094||TURBT and bacillus Calmette-Guerin|Patients treated with TURBT followed by six adjuvant instillations with BCG
32907921|NCT04931394|Experimental|Organoid-Guided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
32907922|NCT04931394|No Intervention|Physician-decided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
32907923|NCT04942938|Experimental|Neubie Treatment|"Participants in this study will participate in intervention treatment with the Neubie for 6 weeks. Outcome measures objective and subjective will be collected at the beginning and end of the study. The treatments will include:~Manual activations to underactive, spastic or limited in sensory muscles/regions~Neubie Mapping mode scanning process to scan for 1) spots that stimulate movement they couldn't do before per initial assessment, 2) spots that allow movement which is a greater range than available before per initial assessment, 3) spots that lead to decreased spasticity, and 4) diminished sensation areas - drive signal to increase sensory nerves and become metabolically active.~Train using physical therapy exercises with Neubie in training mode and Hz current adjusted for tolerance (perceived 7/10) and ability to work through or decrease spasticity in (500 Hz) in the areas which show spasticity, contraction, are dead/diminished sensation, and hot spots."
32907924|NCT04942626|Other|Chemoradiotherapy with Anakinra followed by either TME surgery or Watch and Wait|Capecitabine 500 mg/m2 bid or Capecitabine 650 mg/m2 bid or Capecitabine 825 mg/m2 bid combined with Radiotherapy and Kineret
32907925|NCT04942470|Experimental|Experimental:Intervention Arm|For the experimental group patients, sponges prepared by impregnating cream containing Aloe Vera and Propolis will be sterilized in the sterilization device. If any contamination occurs in the wound area of the patient (in the presence of feces, discharge), the product is applied to the wound bed after cleaning the wound with 0.9% isotonic sodium chloride washing solution. And the effects of the product on the wound will be monitored. The solution will be applied 2 times a day for the first 10 days. The second 10 days will be applied daily 1x1. Application results will be recorded and wound healing status will be monitored. In order to prevent and maintain pressure injury, the experimental group patients will be given an in-bed position every 2 hours. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure, etc.), necessary treatment and care is performed.
32907926|NCT04942470|No Intervention|No Intervention:Control Arm|In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
32907927|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
32907928|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
32907929|NCT00942578|Experimental|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
32907930|NCT04653818|Active Comparator|DAAs group|Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
32907931|NCT04653818|Active Comparator|Postponed DAAs group|Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.
32907932|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
32907933|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
32907934|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
32907935|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
33412508|NCT03144687|Experimental|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been < 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
33412509|NCT03144687|Experimental|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
33412510|NCT04335890|Experimental|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
33412511|NCT01624532|Experimental|GC1109|"Step1: GC1109 0.3 mL or 0.5 mL or 0.1mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
33412512|NCT01624532|Placebo Comparator|Placebo of GC1109|"Step1: Placebo of GC1109 0.5mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: Placebo of GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
33412513|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
33417339|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
33417340|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
33417341|NCT02077946||Liraglutide / Sitagliptin|
32863242|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
32863243|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
32863244|NCT01957267||Normal Group|Volunteers with healthy eyes
32863245|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863246|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863247|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863248|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863249|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863250|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
32863251|NCT05585281|Experimental|Participants receiving Fluzoparib+ QL1101|Participants will be administered QL1101 7.5 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Fluzoparib will be administered orally twice daily continuously throughout each 21-day cycle. On Day 1 of each cycle, fluzoparib will be administered upon completion of QL1101 infusion. The starting dose of fluzoparib will be based on the participant's Baseline actual body weight or platelet count.
32863252|NCT01335867|Experimental|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
32863253|NCT01335867|Placebo Comparator|Placebo|Identical placebo daily for three weeks
32863254|NCT02249923||Pulmonary Arterial Hypertension|
32863255|NCT04891146||Inhalation anesthesia|Sevoflurane for opioid remifentanyl used
32983974|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
33417342|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
33417343|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
32863256|NCT04891146||Total Intravenous Anesthesia|Propofol for opioid remifentanyl used
32863257|NCT04890990|Active Comparator|Black girl, control (BC)|~120-second video of a Black adolescent girl, without depression
32863258|NCT04890990|Active Comparator|Black girl, depressed (BD)|~120-second video of a Black adolescent girl, depressed
32863259|NCT04890990|Active Comparator|Black girl, depressed, adjusted (BDa)|~120-second video of a Black adolescent girl, depressed - adjusted for the specifics of being a Black girl (as informed by a focus group of Black girls and women)
32863260|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
32863261|NCT01949311|Experimental|Dupilumab|Participants will receive repeat doses of dupilumab
32863262|NCT01336413|Active Comparator|Arm 1|Pregnenolone
32863263|NCT01336413|Placebo Comparator|Arm 2|Placebo
32863264|NCT04275401||patients|patients with clinical presentions of change in muscle tone
32863265|NCT04275401||volunteers|healthy volunteers with normal muscle tone
32863266|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
32863267|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
32863268|NCT00985439|Active Comparator|Celecoxib 400 mg|
32863269|NCT00985439|Placebo Comparator|Placebo|
32863270|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
32863271|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
32863272|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
32863273|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
32863274|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
32863275|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
32863276|NCT01535131|Active Comparator|Furlow palatoplasty|standard procedure
32863277|NCT01535131|Experimental|modified Furlow palatoplasty|standard procedure plus modification
32863278|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
32863279|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
32863280|NCT04412148|Active Comparator|Intralesional Steroids|
32863281|NCT04412148|Placebo Comparator|Control|
32863282|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
32863283|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
32863284|NCT04890522|Experimental|Experimental group|5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days, and intravenous infusion of cisplatin 80 mg/m2 on day 1 and day 28, and intravenous infusion of JS001 240mg on day 1 and day 21, every 60 days.
32863285|NCT04890522|Active Comparator|Control group|gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1, and intravenous infusion of JS001 240mg on day 1, every 21 days.
32863286|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
32863287|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
32863288|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
32863289|NCT04898946||BNT162b2|Subjects who receive mRNA vaccine BNT162b2.
32863290|NCT04898946||CoronaVac|Subjects who receive inactivated vaccine, CoronaVac.
33412514|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
33412515|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
32983975|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
32983976|NCT01463540|Experimental|Gastrostomy after gastropexy|
32983977|NCT01463553|No Intervention|wedge resection|
33412516|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
33412517|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
33412518|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
32983978|NCT01463553|Experimental|Wedge resection and pleurodosis|
32983979|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
32983980|NCT01463579|Experimental|Exercise programme|
32983981|NCT01463579|Other|Standard Care|
32983982|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
32983983|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
32983984|NCT01463592|Experimental|Group I|ORAL RENESSANS
32983985|NCT01463605|Other|radiotherapy|It is just a single group assignment
32983986|NCT01463644|Active Comparator|mepolizumab|
33412519|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
33412520|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
33412521|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
33412522|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~Octreotide LAR 30mg~Lanreotide 120mg~Weekly Pegvisomant (40-120mg/week)"
32983987|NCT01463644|Placebo Comparator|placebo|
32983988|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
32983989|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
32983990|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
32983991|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
32983992|NCT01463748|Experimental|Placebo|starch
32983993|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
32983994|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
32983995|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
32983996|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
32983997|NCT01463787|Experimental|inguinal group|
32983998|NCT01463787|Active Comparator|sub-inguinal group|
32983999|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
32984000|NCT01463800|No Intervention|Control group|No structured exercise training
32984001|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
32984002|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
32984003|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
32984004|NCT01463826||Children with bruxism|14 children with bruxism
32984005|NCT01463826||children without bruxism|19 children without bruxism
32984006|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
32984007|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
32984008|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
32984009|NCT01463865|Active Comparator|ropivacaine|Naropin
32984010|NCT01463891||Eribulin Mesylate|
32984011|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
32984012|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
32984013|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
32984014|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
32984015|NCT01463930|Active Comparator|Medical verbal information|
32984016|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
32984017|NCT01463943|Active Comparator|Floratil®|
32984018|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
32984019|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
32984020|NCT01463969||PCOS patients|
32984021|NCT01463969||Control group|
32984022|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
32984023|NCT01464008||chronic hepatitis C|
32984024|NCT01464047||Patients with CML or Ph+ ALL|
32984025|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
32984026|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
32984027|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
32984028|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
32984029|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
32984030|NCT01464086|No Intervention|Standard arm|standard follow-up
32984031|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
32984032|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
32984033|NCT01464099|Experimental|Insulin aspart 200U/mL|
32984034|NCT01464112|Experimental|001|
32984035|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
32984036|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
32984037|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
33324405|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
33324406|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
33324407|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
33324408|NCT01137708|Experimental|Treatment Sequence 1|
33324409|NCT01137708|Experimental|Treatment Sequence 2|
33324410|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
33324411|NCT01233414|Experimental|Parent Training|
32984038|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
32984039|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
32984040|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
32984041|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
32984042|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
32984043|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
32984044|NCT01464294||nano-composite|crowns and onlays
32984045|NCT01464294||ceramic|crowns & onlays
32984046|NCT01464320|Experimental|ABT-614|
32984047|NCT01464320|Placebo Comparator|Placebo Comparator|
32984048|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
32984049|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
32984050|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
32984051|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
32984052|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
33324412|NCT01233414|Active Comparator|Psychoeducation|
33324413|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
33324414|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
33412523|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Daily Pegvisomant (15-60mg/day)"
32984053|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
32984054|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
32984055|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
32984056|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
32984057|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
32984058|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
32984059|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
33324415|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
33324416|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
33324417|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
33324418|NCT03918954|Active Comparator|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
33324419|NCT03918954|Experimental|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
33324420|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
33324421|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
33324422|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
33324423|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
33324424|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
32984060|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
32984061|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
32984062|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
32984063|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
33412524|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Weekly Pegvisomant (40-120mg/week)"
32984064|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
32984065|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
32984066|NCT01464476|Placebo Comparator|Placebo|
32984067|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
32984068|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
32984069|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
32984070|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
32984071|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
32984072|NCT01466634||permanent polymer DES|
32984073|NCT01466634||bioabsorbable polymer DES|
32984074|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
32984075|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
32984076|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
32984077|NCT01466738|Experimental|HRV-16 (100 TCID50)|
32984078|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
32984079|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
33412525|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
33412526|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
32984080|NCT01466777|Experimental|Robotic assisted operation type|
32984081|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
32984082|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
32984083|NCT01466816|Experimental|Saturated fatty acid test meal|
33412527|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
32984084|NCT01466816|Experimental|Monounsaturated fatty acid meal|
32984085|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
32984086|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
32984087|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
32984088|NCT01466842|Other|Catheter ablation|
32984089|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
32984090|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
32984091|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
32984092|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
32984093|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
32984094|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
32984095|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
32984096|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
32984097|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
32984098|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
33412528|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
33412529|NCT03630861||GBM|Primary glioblastoma (GBM)
33412530|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
32984099|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
32984100|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
32984101|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
32984102|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
32984103|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
32984104|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
32984105|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
32984106|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
32984107|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
32984108|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
32984109|NCT01467050|Active Comparator|Application of STOPP/START criteria|
32984110|NCT01467050|No Intervention|Control|
32984111|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
32984112|NCT01467102||Patients|> 18 years of age
32984113|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
32984114|NCT01467128|Active Comparator|Structured expert pharmacist review|
32984115|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
32984116|NCT01467141|Experimental|IAsp|
32984117|NCT01467141|Active Comparator|HI|
33412531|NCT03630861||Brain metastases|Brain metastases (BM)
32984118|NCT01467154||Control group|
32984119|NCT01467154||NAC group|
32984120|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
32984121|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
32984122|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
32984123|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
32984124|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
32984125|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
32984126|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
32984127|NCT01467206|Experimental|Long term follow up program|
32984128|NCT01467206|Active Comparator|Standard care|
32984129|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
32984130|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
32984131|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
32984132|NCT01467258|Experimental|Amantadine|Single dose
32984133|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
32984134|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
32984135|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
32984136|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
32984137|NCT01467310|Experimental|GSK1120212|
32984138|NCT01467323|Experimental|A|
32984139|NCT01467323|Active Comparator|B|
32984140|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
32984141|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
32984142|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
33324425|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
33324426|NCT05401500|Experimental|familial aortopathy|
33324427|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
32984143|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
32984144|NCT01467362|Experimental|V0034CR01B|
32984145|NCT01467362|Placebo Comparator|Vehicle cream|
32984146|NCT01467375|Experimental|A|
33105066|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
33412532|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
32984147|NCT01467388||phacic|Study patients who still have their own ocular lens
32984148|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
32984149|NCT01467401|Experimental|A|
33412533|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
32984150|NCT01467401|Active Comparator|B|
32984151|NCT01467414|Experimental|NN1250|
32984152|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
32984153|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
32984154|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
32984155|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
32984156|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
32984157|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
32984158|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
32984159|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
32984160|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
32984161|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
32984162|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
32984163|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
32984164|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
32984165|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
32984166|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
32984167|NCT01467674||Healthy|
32984168|NCT01467674||Chronic Periodontitis|
32984169|NCT01467674||Better Controlled T2DM|
32984170|NCT01467674||Poor Controlled T2DM|
32984171|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
32984172|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
32984173|NCT01467726|Experimental|Dose regimen 1|Varied doses
32984174|NCT01467726|Experimental|Dose regimen 2|Varied doses
32984175|NCT01467726|Experimental|Placebo|Matching placebo
32984176|NCT01467739|Active Comparator|Ambu ® aScope®|
32984177|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
32984178|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
32984179|NCT01467765|Active Comparator|Elemental diet|
32984180|NCT01467765|Placebo Comparator|Liquid nutrient|
32984181|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
32984182|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
32984183|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
32984184|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
32984185|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
32984186|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
32984187|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
32984188|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
33412534|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
33412535|NCT03609164|Active Comparator|single-row repair|
33417344|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
33417345|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
33417346|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
32863291|NCT04898868|Experimental|vaginal delivery with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
32863292|NCT04898868|Experimental|vaginal delivery with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
32863293|NCT04898868|Experimental|CS with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
32863294|NCT04898868|Experimental|CS with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
32863295|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
32863296|NCT04882254|Experimental|Normothermic machine perfusion|Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.
32863297|NCT04882254|No Intervention|Standard-of-care|Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.
32863298|NCT04389619|Experimental|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
32863299|NCT04389619|Active Comparator|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
32863300|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
32863301|NCT04882176|Experimental|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 2.5mg QD, n=1;"
32863302|NCT04882176|Experimental|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 5mg QD, n=3;"
32863303|NCT04882176|Experimental|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 10mg QD, n=3;"
32863304|NCT04882176|Experimental|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 20mg, n=3;"
32863305|NCT04882176|Experimental|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 30mg, n=3;"
32863306|NCT04882176|Experimental|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 40mg, n=9;"
32863307|NCT04882176|Experimental|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~seventh dose: 60mg, n=15;"
32863308|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
32863309|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
32863310|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
32863311|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
32863312|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
32863313|NCT04881942|Experimental|e-Vapor Product A|Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion [2.5% nicotine by weight {NBW}])
32863314|NCT04881942|Experimental|e-Vapor Product B|Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic [4.0% NBW])
32863315|NCT04881942|Experimental|e-Vapor Product C|Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint [3.5% NBW])
32863316|NCT04881942|Experimental|e-Vapor Product D|Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol [4.0% NBW])
32863317|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
32863318|NCT03074045|Active Comparator|Reference|COC (Yarina)
32863319|NCT01336959|Experimental|Open Label - BCT197 Part A|10mg single dose of BCT197
32863320|NCT01336959|Experimental|BCT197 Part B|Single dose of 50mg BCT197
32863321|NCT01336959|Placebo Comparator|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
33417347|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
33412536|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
33412537|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
33412538|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
33412539|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
33412540|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
32863322|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
32863323|NCT03072251||Anyone|Any individual may complete this survey
33412541|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
33412542|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
32863324|NCT04882020||AHI ≤ 5|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
33417348|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
32863325|NCT04882020||AHI ≥ 30|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
32863326|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
32863327|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
32863328|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
32863329|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
32863330|NCT04881864|Experimental|Tele-EF|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
32863331|NCT04126811|Experimental|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
32863332|NCT04126811|Active Comparator|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
32863333|NCT04126811|Active Comparator|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
32863334|NCT04881786|No Intervention|Untreated teeth control group|Premolars without orthodontic forces
32863335|NCT04881786|Experimental|Moderate force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 45º with a force of 56 g. Forces were measured with an orthodontic dynamometer. For 7 days
32863336|NCT04881786|Experimental|Severe force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 90º with a force of 224 g. Forces were measured with an orthodontic dynamometer. For 24 hours
32863337|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
32863338|NCT04127201|Experimental|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
32863339|NCT04127201|Active Comparator|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
32863340|NCT04127201|No Intervention|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
32863341|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
32863342|NCT02236429|Experimental|recurrent bacterial vaginitis|
32863343|NCT04126655|Experimental|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
33412543|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
33412544|NCT05351775|Experimental|Interventional AF detection arm|The patients will be monitored during index hospitalization according normal practice and additionally with a bed sensor, smartphone app, and patch-holter ECG. In addition, patients will have PDL monitoring device during hospitalization. During the index hospitalization, patients will download the CardioSignal app to their own smartphone or if patient does not have a smartphone one can be provided to the patient by the study group. Patients are asked to do the first recordings at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period. When discharged home, the study subject will have the bed sensor for home-based use up to 3 months. If the average pulse rate in the bed sensor recordings have increased with 20% or the device has recorded rhythm irregularity lasting over 5 minutes (could be longer to reduce false alarms), a 12-lead ECG will be taken, and in the case of a normal ECG, a 7-day Holter monitoring is performed.
32984189|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
33412545|NCT05351775|No Intervention|Standard of care treatment arm|Patient will be followed as in routine clinical practice.
33412546|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
33412547|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
33412548|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
33412549|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
33412550|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
33412551|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
33412552|NCT04292652||OR group|Individuals undergoing open repair. n=40
33412553|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
33412554|NCT01569399|Placebo Comparator|sham rTMS|
33412555|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
33412556|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
33412557|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
33412558|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
33412559|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
33412560|NCT03655860|Experimental|SIMEOX|
33412561|NCT02906007|Experimental|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week on Monday, Wednesday, and Friday.
33412562|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
33412563|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
33412564|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
33412565|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
33412566|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
33412567|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
33412568|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
33412569|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
33412570|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
33412571|NCT03654222||Cardiac surgery|Direct procedures in heart
33412572|NCT03654222||Organ preservation|Mainly renal autograft
33412573|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
32984190|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
32984191|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
32984192|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
33412574|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
33412575|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
33412576|NCT03654222||Other|Any surgery that does not include the previous ones
33412577|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
33412578|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
32984193|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
33412579|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
33417349|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
33417350|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants~Measurement of the amount of left atrial fibrosis"
33417351|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
32863344|NCT04126655|Active Comparator|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
32863345|NCT04377126|Active Comparator|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
32863346|NCT04377126|Placebo Comparator|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
32863347|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
32863348|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
32863349|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
32863350|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
32863351|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
32863352|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
32863353|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
32863354|NCT04376502|Other|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
32863355|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
32863356|NCT00981461|Sham Comparator|control device|control device
32863357|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
32863358|NCT04881552||Group 1|non-spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade 0-II)
32863359|NCT04881552||Arm 2|spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade III)
32863360|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
32863361|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
33412580|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
33412581|NCT01430390|Experimental|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
32863362|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
32863363|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
32863364|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
32863365|NCT04881474|Active Comparator|ibuprofen and paracetamol|
32863366|NCT04881474|Active Comparator|paracetamol only|
32863367|NCT00981149|Experimental|duloxetine study drug|Drug
32863368|NCT00981149|Placebo Comparator|Placebo|Placebo
32863369|NCT04881006|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
32863370|NCT04881006|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
32863371|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
32863372|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
32863373|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
32863374|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
32863375|NCT04395131|Other|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
32863376|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
32863377|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
32863378|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
32863379|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
32863380|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
32863381|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine for patients undergoing hip arthroscopy
32863382|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
32863383|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
32863384|NCT04898712|Experimental|Tranexamic Acid Arm|"Participants in the experimental arm will receive tranexamic acid (TXA) during surgery for CSDH evacuation with a single 1000mg intraoperative intravenous (IV) dose. Participants with a body weight 60-100kg will also receive a post-operative dose regimen of 500 mg TXA orally, 3 times a day (TID).~Weight deviations from this body weight range will be considered with a dose adjustment of 1000mg TXA two times a day (BID) for a body weight >100 kg, and 500 mg TXA BID for body weight <60kg."
32863385|NCT04898712|Placebo Comparator|Placebo Control Arm|Participants in the control arm will placebo according to the same administration regimen.
32863386|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
32863387|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
32863388|NCT01906957|Experimental|coronary patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
32863389|NCT01906957|Experimental|heart failure patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
32863390|NCT04409808|Experimental|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
32863391|NCT04409340||Training cohort|"All patients enrolled will undergo:~Magnetic Resonance Viscoelastography~Quantitative ultrasound (QUS)"
33412582|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
33412583|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
33412584|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
33412585|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
33412586|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
33412587|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
33412588|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
33412589|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
33412590|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
33412591|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:~verbal description of location~telephone-assisted CPR"
33412592|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~automated geolocalisation~video-assisted CPR"
33417352|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
32863392|NCT04409340||Validation cohort|"All patients enrolled will undergo:~• Quantitative ultrasound (QUS)"
32863393|NCT04898556|Active Comparator|Active Treatment|Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.
32863394|NCT04898556|Placebo Comparator|Control Group|Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.
32863395|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
32863396|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
32863397|NCT04898088|Experimental|Conventional Therapy|
32863398|NCT04898088|Experimental|Conventional Therapy with Add-On MSC therapy|
32863399|NCT05583643|Other|Phase 1 therapy|
32863400|NCT05583643|Active Comparator|Phase 1 therapy with atorvastatin loaded into cubosomal in-situ gel|
32863401|NCT05583643|Active Comparator|Phase 1 therapy with atorvastatin loaded into in-situ gel|
32863402|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
32863403|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
32863404|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks~30 mg/kg eteplirsen for 28 weeks"
32863405|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
32863406|NCT02225275|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
32863407|NCT04890756||Reliability Group|100 Healthy Adults
32863408|NCT04890756||Validity Group|45 Healthy Adults
32863409|NCT04881084|Experimental|Digital storytelling group (Group 1)|Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
32863410|NCT04881084|Active Comparator|Social marketing/fundraising group (Group 2)|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
32863411|NCT04389697|Experimental|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
32863412|NCT04389697|No Intervention|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
32863413|NCT04890678|Experimental|22 residentsat risk for PU development|"22 residents at risk for PU development, defined by a Braden score < 12 and/or a Braden subscale 'Mobility' score ≤ 2 and/or the presence of non-blanchable erythema in the sacral area.~aged 65 years or over"
32863414|NCT04890678|Experimental|18 residents at least one PU category III-IV in the sacral area|18 residents at least one PU category III-IV in the sacral area aged 65 years or over
32863415|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
32863416|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
32863417|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
32863418|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
32863419|NCT04890288|Experimental|Intervention group - High flow|High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.
32863420|NCT04890288|Experimental|Intervention group - Low flow:|Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.
32863421|NCT04890288|No Intervention|Conventional|Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.
32863422|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32863423|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32863424|NCT04430556|Other|Volumetric changes in response to sertraline or escitalopram|
32863425|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
32863426|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
32863427|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
32863428|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
32863429|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
32863430|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
32863431|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
32863432|NCT04890210|Experimental|Early Diet Group|"1st diet: 100 ml of clear fluid (1 hour after esophageal variceal ligation)~2nd diet: 100 ml of clear fluid (4 hours after the 1st diet)~3rd diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 4 hours after the 2nd diet~4th diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 3rd diet~5th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 4th diet~6th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 5th diet~7th diet: soft rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 6th diet~8th diet: regular rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 7th diet"
32863433|NCT04890210|Active Comparator|Late Diet Group|"1st diet : 100 ml of clear fluid (6 hours after esophageal variceal ligation)~After the 1st diet (Day 1): 6x100 ml of clear fluid for 24 hours~Day 2: soft porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 3: porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 4: soft rice (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 5: regular rice (the amount will be calculated according to patient's caloric needs) for 24 hours and beyond"
32863434|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
32863435|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
32863436|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
32863437|NCT04757077||GROUP 1|Patients 6-24 weeks after delivery with postpartum PGP (Patients with symptoms and signs of PGP, PGP confirmed with dedicated functional tests).
32863438|NCT04757077||GROUP 2|Patients 6-24 weeks after delivery, with no symptoms and signs of PGP.
32863439|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
32863440|NCT04897854|Active Comparator|Immediate treatment|The treatment schedule will be direct (start within 3 weeks of bate of diagnosis) FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
32863441|NCT04897854|Active Comparator|Delayed treatment|"The treatment schedule will be delayed treatment (based on symptoms) with FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.~Chemotherapy will start as soon as one of the following criteria is met:~Decline in performance status to ECOG < 1 or Karnofsky < 80%~Weight loss more than 5% of the total body weight from the time of study entry~Persistent nausea requiring medication~Pain requiring regular narcotic analgesics~Development of clinically significant third-space fluid collections~Liver function deterioration in the presence of progressive liver metastases"
32863442|NCT01894945||Patients with suspected lymphoma.|
32863443|NCT04897932|Active Comparator|Adult nocturia|Use of device over 28 days
33412593|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
33412594|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
33412595|NCT04203290|Active Comparator|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
33412596|NCT04203290|Active Comparator|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
33412597|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
33412598|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
33412599|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
33412600|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
33412601|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
33412602|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
33412603|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
33412604|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.~Frequency and intensity are individually assigned."
33412605|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
33412606|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
33412607|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
33412608|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
33412609|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
33412610|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
33412611|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
33412612|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
33412613|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
33412614|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
33412615|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
33412616|NCT02980224|Experimental|OmegaD|OmegaD Softgels
33412617|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
33412618|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
33412619|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
33412620|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
33412621|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
33412622|NCT03654144|Experimental|Study group|women will receive dienogest
33412623|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
32863444|NCT04897932|Active Comparator|Adult urge urinary incontinence|Use of device over 28 days
32863445|NCT04897932|Active Comparator|Adult frequency urinary incontinence|Use of device over 28 days
32984194|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
32984195|NCT01467856||chronic tetraplegia|
32984196|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
32984197|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
32984198|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
32984199|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
32984200|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
32984201|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
32984202|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
32984203|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
32984204|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
32984205|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
32984206|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
32984207|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
32984208|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
32984209|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
32984210|NCT01468064|Experimental|BMSCs group|
32984211|NCT01468064|Experimental|EPCs group|
32984212|NCT01468064|Placebo Comparator|Control group|
32984213|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
32984214|NCT01468103|Experimental|PACS|primary angle closure suspects
32984215|NCT01468103|Experimental|PAC|primary angle closure
33412624|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
32984216|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
33412625|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
33412626|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
32984217|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
32984218|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
32984219|NCT01468129|Active Comparator|Cell Saver|
33412627|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
33412628|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles~Patients with CR, PR, or SD by irRC will then be treated with:~For Squamous Carcinoma:~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
32984220|NCT01468129|No Intervention|Non Cell Saver|
32984221|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
32984222|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
32984223|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
32984224|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
32984225|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
32984226|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
32984227|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
32984228|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
32984229|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
32984230|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
32984231|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
32984232|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
32984233|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
32984234|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
32984235|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
32984236|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
32984237|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
33412629|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
32984238|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
33412630|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
33412631|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
33412632|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
33412633|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
33412634|NCT04215588|Active Comparator|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
33412635|NCT04215588|Active Comparator|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
33412636|NCT03608228||Parkinson's Disease|
32863446|NCT04897932|Active Comparator|Adult functional incontinence|Use of device over 28 days
32863447|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
32863448|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
32863449|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
32863450|NCT01399827|Placebo Comparator|Placebo|
32863451|NCT04897386|Experimental|Duvalizumab Combined With Neoadjuvant Chemotherapy|
32863452|NCT04755985|Experimental|ARM 1|Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)
32863453|NCT04755985|Experimental|ARM 2|Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)
32863454|NCT04879836||Teething Ring + Teething Gel|
32863455|NCT04879836||Teething Ring|
32863456|NCT05050591|Experimental|Single-Arm Study|This is a prospective trial of the clinical utility of a patient-specific silicone stent implant for patients with complex airway disease, requiring an airway stent. The aim of this study is to observe the outcomes associated with the implants. Current stents have been suboptimal for treating benign stenosis of the airway and we are seeking to create a better treatment option. We hypothesize, based on the previous compassionate-use cases, that placing a patient-specific silicone stent will effectively alleviate symptoms associated with stenosis of the airway. The main measure of effectiveness will be patient-reported outcomes.
32863457|NCT04889820|Active Comparator|The Control group|- The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).
32863458|NCT04889820|Experimental|The Experimental group|- The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months.
32863459|NCT02213107|Experimental|Enzalutamide and dutasteride|Two oral drugs.
32863460|NCT04879758|No Intervention|Control Group|The control group will receive a Fitbit device and general lifestyle advice e-leaflet, which includes information about T2D, health impacts of T2D and lifestyle advice on 4 major risk markers of T2D (e.g., PA, diet, smoking, weight management) as recommended by the World Health Organization.
32863461|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk of T2D in addition to the Fitbit and e-leaflet.
32863462|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
32863463|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
32863464|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
32863465|NCT04879446|Experimental|A-PRF Test Group|Advanced Platelet Rich Fibrin liquid applied into the implant cavity and implant surface. That is the only difference between A-PRF control group and A-PRF test group.
32863466|NCT04879446|Experimental|CGF Test Group|Concentrated growth factor liquid applied into the implant cavity and implant surface. That is the only difference between CGF control group and CGF test group.
32863467|NCT04879446|Experimental|A-PRF Control Group|Dental implant applications were made with traditional methods.
32863468|NCT04879446|Experimental|CGF Control Group|Dental implant applications were made with traditional methods.
32863469|NCT04897308|Active Comparator|Suprascapular nerve block|This group will include will under go suprascapularnerve block as following :10 ml of .5% bupivacaine and 2 ml of methylpradnisolon 40mg/ml
32863470|NCT04897308|Active Comparator|Hydrodilatation of shoulder capsule|This group will undergo intraarticular hydrodilatation by injection of :first lidocaine10ml%followed by 1ml of methylprednisolon 40mg/ml and finally 20ml of .9 % sodium chloride slowly in the gleno humeral joint
32863471|NCT04897308|Active Comparator|Hydrodilatation of shoulder interval|This group will undergo interval hydrodilatation by injection of :first mepivacaine 10ml folowed by 20ml of sterile water slowly in the shoulder interval
32984239|NCT01468298|Active Comparator|Isostretching|
32984240|NCT01468298|Active Comparator|Global Posture Reeducation|
33412637|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
33412638|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
32984241|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~If OH is negative value , we will not change dry weight."
32984242|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
33412639|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
33412640|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
32984243|NCT01468376|Experimental|GLU-01|
33412641|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
33412642|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
33412643|NCT04699149|Active Comparator|real stimulation|The PD patients randomized in the experimental group will receive VBT each time preceded by a real rTMS stimulation.
33412644|NCT04699149|Sham Comparator|sham stimulation|The PD patients randomized in the control group will receive VBT each time preceded by a sham TMS.
33412645|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
33412646|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
33412647|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
32984244|NCT01468376|Experimental|GLU-02|
33412648|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
33412649|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
32984245|NCT01468376|Experimental|GLU-03|
32984246|NCT01468376|Experimental|GLU-04|
32984247|NCT01468376|Experimental|GLU-05|
33412650|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
32984248|NCT01468376|Experimental|GLU-06|
32984249|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
32984250|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
32984251|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
32984252|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
32984253|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
32984254|NCT01468467|Experimental|AC220|
32984255|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
32984256|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
32984257|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
32984258|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
32984259|NCT01468493||steroid-sensitive FSGS|
32984260|NCT01468493||steroid-dependent and resistant FSGS|
32984261|NCT01468493||Healthy volunteers|
32984262|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
32984263|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
32984264|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
32984265|NCT01468545||Group 1|
32984266|NCT01468545||Group 2|
32984267|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
32984268|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
32984269|NCT01468610|Active Comparator|Workers with MDD|
32984270|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
32984271|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
32984272|NCT01468636|Active Comparator|Oral Zinc|
32984273|NCT01468636|Placebo Comparator|Placebo|
32984274|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
32984275|NCT01468662||STEMI|
32984276|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
32984277|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
32984278|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
32984279|NCT01468727|Experimental|xylitol wipe|
32984280|NCT01468727|Placebo Comparator|placebo wipe|
32984281|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
32984282|NCT01468766|Active Comparator|Resistance training|
32984283|NCT01468766|Active Comparator|Relaxation training|
32984284|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
32984285|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
32984286|NCT01468961|Experimental|Internet-based CBT|
32984287|NCT01469026|Active Comparator|Early PET/CT|
32984288|NCT01469026|Active Comparator|Conventional diagnostics including CT|
32984289|NCT01469078|Active Comparator|100 mg Monofer®|
32984290|NCT01469078|Active Comparator|200 mg Monofer®|
32984291|NCT01469078|Active Comparator|500 mg Monofer®|
32984292|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
32984293|NCT01469091|No Intervention|Controlgroup|
32984294|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
32984295|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
32984296|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
32984297|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
32984298|NCT01469143|Experimental|NN1218|
32984299|NCT01469143|Active Comparator|insulin aspart|
32984300|NCT01469169|Experimental|Arm 1|
32984301|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
32984302|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
32984303|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
32984304|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
32984305|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
32984306|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
32984307|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
32984308|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
32984309|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
33412651|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
33412652|NCT01379079|Experimental|aspirin at bedtime|
33412653|NCT01379079|Active Comparator|aspirin on awakening|
32984310|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
32984311|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
32984312|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
32984313|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
32984314|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
33412654|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle~Cisplatin: 75mg/m2,IV on 21 day cycle"
32984315|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
32984316|NCT01469351|Placebo Comparator|placebo|non active intervention
33412655|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
32984317|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
32984318|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
32984319|NCT01469416|Active Comparator|Rosuvastatin|
33412656|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
33412657|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
32984320|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
33412658|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
33412659|NCT03607760||ECMO|severe respiratory failure with ECMO
32984321|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
32984322|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
32984323|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
32984324|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
32984325|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
33412660|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
33412661|NCT01380561|Experimental|Single Arm Study|asimadoline
33412662|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
32984326|NCT01469442|No Intervention|without external biliary duct stent|
33412663|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
33412664|NCT05182983||People with digestive tract diseases|
33412665|NCT05182983||Healthy people|
33412666|NCT02522429|Experimental|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
32984327|NCT01469455|Experimental|DT01|
32984328|NCT01469468|Experimental|Single arm, fixed sequence dosing|
32984329|NCT01469481|Experimental|1|
32984330|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
32984331|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
32984332|NCT01469507|Experimental|V0220|
32984333|NCT01469507|Active Comparator|Hyaluronan|
32984334|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
32984335|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
33412667|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
32984336|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
32984337|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
32984338|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
32984339|NCT01469559|Active Comparator|Novolin Toronto insulin|
32984340|NCT01469559|Placebo Comparator|Normal saline|
32984341|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
32984342|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
32984343|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
32984344|NCT01469624|Experimental|Test group|This group receives pentoxifylline
32984345|NCT01469624|No Intervention|Control group|
32984346|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
32984347|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
32984348|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
32984349|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
32984350|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
32984351|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
32984352|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
32984353|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
32984354|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
32984355|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
33412668|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
33412669|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
33412670|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
33412671|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
33412672|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
32984356|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
32984357|NCT01469689|No Intervention|Control|Control areas. No Intervention
32984358|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
32984359|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
32984360|NCT01469754||Lymphoma Survivors|
32984361|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
32984362|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
32984363|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
32984364|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
33412673|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
33412674|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
32863472|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.~For Arm B Patients (pre-HSCT): TAA-T will be infused any time > 7 days after previous therapy for relapsed disease.~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
32863473|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
32863474|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
32863475|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
32863476|NCT01882153|Experimental|Developmentally Based Intervention|
32863477|NCT01882153|Experimental|Behaviorally Based Intervention|
32863478|NCT04897230|Active Comparator|Hatha Yoga Condition|An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
32863479|NCT04897230|Placebo Comparator|Control Condition|Participants in the control condition were watching a neutral video on a television.
32863480|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
32863481|NCT04897464|Experimental|Treatment|
32863482|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
32863483|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
32863484|NCT01444105|Active Comparator|SLT|Laser treatment
32863485|NCT04896996|Experimental|Whole eggs (WE)|consume 10 additional eggs per week
32863486|NCT04896996|Experimental|Egg substitute (ES)|consume the yolk-free egg substitute equivalent to 10 eggs per week
32863487|NCT04896996|No Intervention|Control group|Regular school meals
32863488|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
32863489|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
32863490|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
32863491|NCT04889586|Experimental|Experimental Group|The subjects were clinically assessed with a define clinical protocol. After that, the subjects executed the device test with EMG-biofeedback wearable armband.
32863492|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
32863493|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
32863494|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
32863495|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
32863496|NCT01858285||Epilepsy, genetics|
32863497|NCT04889742|Experimental|Hyperthermia|Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
32984365|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
32984366|NCT01469845|Active Comparator|hypertonic saline and usual care|
33412675|NCT04932005|Experimental|DZD2269|This study includes two parts. In Part A, a single dose of DZD2269 at different dose levels will be given. In Part C, DZD2269 at selected dose levels will be given twice daily for 7 days.
33412676|NCT04932005|Placebo Comparator|Placebo|In Part A, a single oral dose of placebo will be given. In Part C, placebo will be given twice daily for 7 days.
33412677|NCT05177211|Experimental|Treatment with Fedratinib|Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.
33412678|NCT04889495||Participants receiving Zirabev|Participants receiving Zirabev
33412679|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
33412680|NCT05083611|No Intervention|Control group|The control group will receive an information session on phantom limb pain (1 hour) and will continue with the usual treatment received.
33412681|NCT05083611|Experimental|Experimental group|The experimental group will receive an educational session on phantom limb pain and the previously designed GraMI protocol through a systematic review and validation through a study with Delphi methodology. This protocol contains the three techniques with their defined intensity, frequency, duration and progression.
33412682|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
33412683|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
33412684|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
33412685|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
33412686|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
33412687|NCT03172481|Placebo Comparator|Placebo Treatment|
33412688|NCT03653598||AF patients|Patients with Atrial Fibrillation
33412689|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
33412690|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
33412691|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
33412692|NCT03535545|Experimental|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
33412693|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
33412694|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
33412695|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
33412696|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
33412697|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
33412698|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
33412699|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;~Cabazitaxel 25 mg/m2 IV every 3 weeks"
33412700|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
33412701|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
33412702|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
33412703|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
33412704|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
33412705|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
33412706|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
33412707|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
33412708|NCT01376973||group A|Not received any oral device (Control)
33412709|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
33412710|NCT03608072|Experimental|Dose group 1|
33412711|NCT03608072|Experimental|Dose group 2|
33412712|NCT03608072|Experimental|Dose group 3|
33412713|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
33412714|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
33412715|NCT04054986|Experimental|Breast Cancer|Breast cancer
33412716|NCT03653286|Experimental|NMES and Run|NMES and run
33412717|NCT03653286|Other|Only Run|Only Run
33412718|NCT01208090|Experimental|Investigational drug - Dose 1|
33412719|NCT01208090|Experimental|Investigational drug - Dose 2|
33412720|NCT01208090|Placebo Comparator|Matching placebo|
33412721|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
33412722|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
33412723|NCT04210050|Other|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
33412724|NCT04210050|Active Comparator|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
33412725|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
33412726|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
33412727|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
33412728|NCT03215771|Experimental|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
33412729|NCT04266990|Experimental|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
33412730|NCT04266990|Active Comparator|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
33412731|NCT01380483|Experimental|A|Subjects received the Par formulated product
33412732|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
33412733|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
33412734|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
33412735|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
33412736|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
33412737|NCT04265586|No Intervention|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI<15).
33412738|NCT04265586|Experimental|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Intervention is iCBT for participants with insomnia (7-16 weeks).
32984367|NCT01469845|Active Comparator|usual care (oxygen therapy)|
32984368|NCT01469858|Experimental|study group|fMRI
32984369|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
32984370|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
32984371|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
32984372|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
32984373|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
32984374|NCT01469910|Experimental|Simotinib|
32984375|NCT01469910|Placebo Comparator|Placebo|
32984376|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
32984377|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
32984378|NCT01469936|Experimental|PERMEAPROTECT|
33412739|NCT04265586|Experimental|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Sleep hygiene education (approximately 1 hour)
33412740|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
33412741|NCT03622008|Placebo Comparator|Placebo|placebo IV
33412742|NCT03225183||1|Framingham Heart Study participants
33412743|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
33412744|NCT01378845|Placebo Comparator|Prostavasin|
32984379|NCT01469936|Placebo Comparator|PLACEBO|
32984380|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
32984381|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
32984382|NCT01469949||Control group|Subjects receiving measurement with intervention
32984383|NCT01469962||obese patients|
32984384|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
32984385|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
32984386|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
32984387|NCT01469988|Experimental|Testosterone|
32984388|NCT01469988|Placebo Comparator|Placebo|
32984389|NCT01470014||IVNC|
32984390|NCT01470014||differential diagnosis to IVNC|
32984391|NCT01470040|Experimental|discontinuation of aspirin therapy|
32984392|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
32984393|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
32984394|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
32984395|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
32984396|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
33412745|NCT01378845|Active Comparator|Prostavasin + Bosentan|
33412746|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
32984397|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
32984398|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
32984399|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
32984400|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~Must have stable disease on medication at time of enrollment"
32984401|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
33105067|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
33105068|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
33412747|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
32984402|NCT01470209|Experimental|Combination of BKM120 and everolimus|
32984403|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
33105069|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
33105070|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
33412748|NCT05016219|Active Comparator|Active Intervention plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
33412749|NCT05016219|Active Comparator|Active Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
33412750|NCT05016219|Active Comparator|Placebo Light plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
32984404|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
32984405|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
32984406|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
32984407|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
32984408|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
32984409|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
32984410|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
32984411|NCT01470287|Experimental|Arm 1|
32984412|NCT01470300|Experimental|Standard ED|100% energy density
32984413|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
32984414|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
32984415|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
32984416|NCT01470313|Experimental|PD-0360324|
32984417|NCT01470313|Placebo Comparator|Placebo|
32984418|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
32984419|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
32984420|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
32984421|NCT01470352|Placebo Comparator|Placebo|
33412751|NCT05016219|Placebo Comparator|Placebo Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
33412752|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
33412753|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
33412754|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
33412755|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
33412756|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
33412757|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
33412758|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
33412759|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
33412760|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
33412761|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
33412762|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
33412763|NCT04951635|Experimental|Almonertinib|
32984422|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
32984423|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
32984424|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
32984425|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
32984426|NCT01470391|Experimental|Adductor-Canal-Blockade|
32984427|NCT01470391|Active Comparator|Femoral Nerve Block|
32984428|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
32984429|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
32984430|NCT01470430||ROP infants treated with retinal laser photocoagulation|
32984431|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
32984432|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
32984433|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
32984434|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
32984435|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
32984436|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
32984437|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
32984438|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
32984439|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
32984440|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
32984441|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
32984442|NCT01470534|Experimental|Normal body weight|
32984443|NCT01470534|Experimental|Obese|
32984444|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
32984445|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
32984446|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
32984447|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
32984448|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
32984449|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
33412764|NCT04951635|Placebo Comparator|Placebo Almonertinib|
33412765|NCT03984968|Experimental|CAR-T cells infusion combined with feeding T cells (FTCs)|
33412766|NCT04884399|Experimental|CMAB818|0.5 mg by intravitreal injection once on the first day.
32984450|NCT01470586|No Intervention|Controls|Controls
32984451|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
32984452|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
32984453|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
32984454|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
32984455|NCT01470703|Experimental|ECMO arm|
32984456|NCT01470703|Active Comparator|conventional arm|
32984457|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
32984458|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
32984459|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
32984460|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
32984461|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
32984462|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
32984463|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
32984464|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
33412767|NCT04884399|Active Comparator|Lucentis®|0.5 mg by intravitreal injection once on the first day.
33412768|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
33412769|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
33412770|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
33412771|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
32984465|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
32984466|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
32984467|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
32984468|NCT01470820|Active Comparator|Distance 29 cm|
32984469|NCT01470820|Active Comparator|Distance 38 cm|
32984470|NCT01470820|Active Comparator|Distance 47 cm|
32984471|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
32984472|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
32984473|NCT01470846|Experimental|APD|patient with epidural analgesia
32984474|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
32984475|NCT01470885||glucose value|glucose value
32984476|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
33412772|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
32984477|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
32984478|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
32984479|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
32984480|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
32984481|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
32984482|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
32984483|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
32984484|NCT01470963|No Intervention|Control|Normal referral pattern
32984485|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
32984486|NCT01470976|Active Comparator|Standard Protocol|
32984487|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
32984488|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
32984489|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
32984490|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
32984491|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
32984492|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
32984493|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
32984494|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
32984495|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
32984496|NCT01471132|Experimental|HIPEC|
32984497|NCT01471145|Experimental|Depot Naltrexone|
32984498|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
32984499|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
32984500|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
32984501|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
32984502|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
32984503|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
32984504|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
32984505|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
32984506|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
33412773|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
32984507|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
32984508|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
32984509|NCT01471262||Elderly|Patients more or equal to 70 years old
32984510|NCT01471262||Young|Patients less than 70 years old
32984511|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
32984512|NCT01471275|Active Comparator|metformin|
32984513|NCT01471288|Active Comparator|Group3|Normal controls
32984514|NCT01471288|Placebo Comparator|Group4|Normal controls
32984515|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
32984516|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
32984517|NCT01471314||Spontaneous migraine|
32984518|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
32984519|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
32984520|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
32984521|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
32984522|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
32984523|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
32984524|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
32984525|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
32984526|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
32984527|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
33412774|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
32984528|NCT01471418|Experimental|Disease population|
32984529|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
32984530|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
32984531|NCT01471470|Experimental|neoadjuvant|
32984532|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
32984533|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
32984534|NCT01471509|Placebo Comparator|Control|240 ml water
32984535|NCT01471509|Active Comparator|glucose|50 g glucose
32984536|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
32984537|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
32984538|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
32984539|NCT01471548|Experimental|TKI258|dose escalation
32984540|NCT01471587||Patients with COPD|
32984541|NCT01471600|No Intervention|No intervention|Group overnight fasting
32984542|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
32984543|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
32984544|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
32984545|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
32984546|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
32984547|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
32984548|NCT01471652|Placebo Comparator|Placebo|
32984549|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
32984550|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
32984551|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
32984552|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
32984553|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
32984554|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
32984555|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
32984556|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
32984557|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
32984558|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
32984559|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
32984560|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
32984561|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
32984562|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
32984563|NCT01471730|Placebo Comparator|Saline solution|
32984564|NCT01471730|Active Comparator|Fibrinogen|
32984565|NCT01471730|Active Comparator|Prothrombin complex|
32984566|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
32984567|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
32984568|NCT01471756|Experimental|iSnare with Gonak solution|
32984569|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
32984570|NCT01471756|Experimental|iSnare with saline solution|
32984571|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
32984572|NCT01471769|Experimental|pain management video|Experimental
32984573|NCT01471769|Placebo Comparator|falls prevention video|placebo
32984574|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
32984575|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
32984576|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
32984577|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
32984578|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
32984579|NCT01471821|Active Comparator|Continue with current treatment|
32984580|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
32984581|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
32984582|NCT01471860|Experimental|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:~Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.~Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
32984583|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
32984584|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
32984585|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
32984586|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
32984587|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
32984588|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
32984589|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
32984590|NCT01471925|Active Comparator|Nexium®|
32984591|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
32984592|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
32984593|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
32984594|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
32984595|NCT01471951|Experimental|single embryo transfer|
32984596|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
32984597|NCT01471977|Experimental|education, counselling, default tracer|
32984598|NCT01471990|Active Comparator|PACAP38|
32984599|NCT01471990|Active Comparator|VIP|
32984600|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
32984601|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
32984602|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
32984603|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
33412775|NCT04868721|No Intervention|control side|Conventional side Canine retraction was commenced without micro-osteoperforations.
32984604|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
32984605|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
32984606|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
32984607|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
32984608|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
32984609|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
32984610|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
32984611|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
33412776|NCT04868721|Experimental|single Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed for one time only distal to the maxillary canine before starting retraction.
33412777|NCT04868721|Experimental|Multiple Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed on repeated basis distal to the maxillary canine evey 28 days before canine retraction.
33412778|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
33412779|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
33412780|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
32984612|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
32984613|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
32984614|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
32984615|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
33412781|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
32984616|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
32984617|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
32984618|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
32984619|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
32984620|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education~CGM Family Teamwork Intervention"
32984621|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
32984622|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
32984623|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
32984624|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
32984625|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
32984626|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
32984627|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
32984628|NCT01472263|Experimental|Pentoxifylline|
32984629|NCT01472263|Placebo Comparator|Placebo|
32984630|NCT01472276|No Intervention|Control|
32984631|NCT01472276|Active Comparator|Web-based program|
32984632|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
32984633|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
33412782|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
33412783|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
32984634|NCT01472315|Active Comparator|medroxyprogesterone acetate|
32984635|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
32984636|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
32984637|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
32984638|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
32984639|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
32984640|NCT01472393|Experimental|Creatine supplementation|
32984641|NCT01472393|Placebo Comparator|Placebo|
32984642|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
32984643|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
32984644|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
33412784|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
33412785|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
33412786|NCT03170609|Placebo Comparator|Placebo|Saline control
33412787|NCT03264404|Experimental|Pembrolizumab|Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
32984645|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
32984646|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
32984647|NCT01472484|Experimental|lpa with high polyphenol|
32984648|NCT01472484|Experimental|lpa with low polyphenol|
32984649|NCT01472484|Experimental|control bean with low polyphenol|
32984650|NCT01472484|Experimental|control bean with high polyphenol|
32984651|NCT01472497|Experimental|glymepiride|
32984652|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
33412788|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
33412789|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
32984653|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
32984654|NCT01472523||Controls|
32984655|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
32984656|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
33412790|NCT01314755|Experimental|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
33412791|NCT01314755|Active Comparator|control arm|iso-nitrogenous, iso-caloric control feed
33412792|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
33412793|NCT03605108|Placebo Comparator|Placebo|Rice flour only
33412794|NCT04904549|Experimental|Stage 1: SARS-CoV-2 vaccine|2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22
33412795|NCT04904549|Placebo Comparator|Stage 1: Placebo|2 injections of placebo at Day 1 and Day 22
33412796|NCT04904549|Experimental|Stage 2: SARS-CoV-2 vaccine|2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22
33412797|NCT04904549|Placebo Comparator|Stage 2: Placebo|2 injections of placebo at Day 1 and Day 22
32984657|NCT01472536|No Intervention|Control|No intervention
32984658|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
32984659|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
32984660|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
32984661|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
32984662|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
32984663|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
32984664|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
32984665|NCT01472614|Experimental|DLBS3233|
32984666|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
32984667|NCT01472640|Active Comparator|Liraglutid|Liraglutid
33412798|NCT03605030|Active Comparator|Novel Lead Based Armboard|
32984668|NCT01472640|Placebo Comparator|Placebo|Placebo
32984669|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
32984670|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
32984671|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
32984672|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
32984673|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
32984674|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
32984675|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
32984676|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
32984677|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
32984678|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
32984679|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
32984680|NCT01472783|Experimental|Veliparib|
32984681|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
32984682|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
32984683|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
32984684|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
32984685|NCT01472848|Experimental|Cohort 1|
32984686|NCT01472848|Experimental|Cohort 2|
32984687|NCT01472848|Experimental|Cohort 3|
32984688|NCT01472848|Experimental|Cohort 4|
32984689|NCT01472848|Experimental|Cohort 5|
32984690|NCT01472848|Active Comparator|Cohort 6|
33412799|NCT03605030|Placebo Comparator|Standard Armboard|
32984691|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
32984692|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
32984693|NCT01472900|Experimental|Er:YAG laser|
32984694|NCT01472900|Active Comparator|BP gel|
32984695|NCT01472913|Active Comparator|Fibrin Sealent|
32984696|NCT01472913|Placebo Comparator|Saline water|
32984697|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
32984698|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
32984699|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
32984700|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
32984701|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
32984702|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
32984703|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
32984704|NCT01473030||Placebo|No PCa at Year 2 or Year 4
32984705|NCT01473056|Experimental|Dose 1 JTK-853|
32984706|NCT01473056|Experimental|Dose 2 JTK-853|
32984707|NCT01473056|Experimental|Dose 3 JTK-853|
32984708|NCT01473056|Experimental|Dose 4 JTK-853|
32984709|NCT01473056|Placebo Comparator|Placebo|
32984710|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
32984711|NCT01473069|Experimental|Dose 2 JTK-853|
32984712|NCT01473069|Experimental|Dose 3 JTK-853|
32984713|NCT01473069|Experimental|Dose 4 JTK-853|
32984714|NCT01473069|Placebo Comparator|Placebo|
32984715|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
32984716|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
32984717|NCT01473121||Group 1|
32984718|NCT01473147|Active Comparator|GLP-1|
32984719|NCT01473147|Placebo Comparator|Normal saline|
32984720|NCT01473173|Experimental|CJ-12420 50mg|"Single dose~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
32984721|NCT01473173|Experimental|CJ-12420 100mg|"Single dose~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
32984722|NCT01473173|Experimental|CJ-12420 200mg|"Single dose~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
32984723|NCT01473173|Experimental|CJ-12420 400mg|"Single dose~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
32984724|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses~100mg is the anticipated dose~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
32984725|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses~200mg is the anticipated dose~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
32984726|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
32984727|NCT01473225|Experimental|Calorie label|
32984728|NCT01473225|Active Comparator|No calorie label|
32984729|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
32984730|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
32984731|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
32984732|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
32984733|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
32984734|NCT01473264|Placebo Comparator|Control|
32984735|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
32984736|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
32984737|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
33412800|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
33412801|NCT04770935|Experimental|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
33412802|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
32984738|NCT01473277|Active Comparator|Triamcinolone acetonide|
32984739|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
32984740|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
32984741|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
32984742|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
32984743|NCT01473316|Experimental|A|
32984744|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
32984745|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
32984746|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
32984747|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
32984748|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
32984749|NCT01473446|Experimental|Goal directed fluid therapy|
32984750|NCT01473459|Active Comparator|IVM Treatment|
32984751|NCT01473459|Active Comparator|Antagonist Protocol|
32984752|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
32984753|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
32984754|NCT01473485|Experimental|ExAblate Transcranial Device|
32984755|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
32984756|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
32984757|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
33412803|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33412804|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
32984758|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
32984759|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
32984760|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
32984761|NCT01473537|Placebo Comparator|placebo|
32984762|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
33412805|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33105071|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
32863498|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over 1-15 minutes on days 1-2, bleomycin sulfate IV over 10 minutes or SC on days 1 and 8, vincristine sulfate IV over 1 minute on days 1 and 8, etoposide IV over 60-120 minutes on days 1-3, prednisone PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV over 30-60 minutes on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
32863499|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV over 1 minute on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
32863500|NCT04889196|Active Comparator|control group|The group that have caries in primary molars and treat them with hall technique
32863501|NCT04889196|Experimental|experimental group|the group that have caries in primary molars and treat them with silver diamine fluoride (SDF) solution would exert a prevention result in managing early childhood caries ECC
32863502|NCT04878978|Active Comparator|Routine care|Women who present with PPROM or threatened PTL and have routine care
32863503|NCT04878978|Experimental|Amniocentesis and biofire directed antibiotic use|Women who present with PPROM or threatened PTL and randomised to amniocentesis and biofire directed antibiotic treatment
32863504|NCT00980057|Experimental|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
32863505|NCT00980057|Active Comparator|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
32863506|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
32863507|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
32863508|NCT04896528|Experimental|Avatrombopag|"Avartripopa is a new generation of oral TPO receptor agonist that simulates the biological effects of TPO in vitro and in vivo.~TPO stimulates megakaryocytes through binding and activation of TPO receptor, which is expressed in hematopoietic stem cells, megakaryotic cell lines and platelets.~By binding to the transmembrane region of the thrombopoietin receptor, Ava Tripopa activates the thrombopoietin receptor in humans, stimulates signal transduction and mimics the biological effects of thrombopoietin, leading to an increase in platelet count."
32863509|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
32863510|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
32863511|NCT04896294|Active Comparator|Group 1 - HAP-containing toothpaste|"The use of HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
32863512|NCT04896294|Experimental|Group 2 - Zn Mg HAP-containing toothpaste|"The use of Zn Mg HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Zn-Mg-hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
32863513|NCT04896294|Experimental|Group 3 - FAP-containing toothpaste|"The use of FAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Fluorapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene."
32863514|NCT04888806|Experimental|Camrelizumab+ablation +chemotherapy|The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.
32863515|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
32863516|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
32863517|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
32863518|NCT04126265|No Intervention|Routine colonoscopy group|The patient underwent routine colonoscopy.
32863519|NCT04126265|Experimental|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
33412806|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33412807|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33412808|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33412809|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
32863520|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
32863521|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
32863522|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
32863523|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
32863524|NCT04125797|Active Comparator|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
32863525|NCT04125797|Active Comparator|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
32863526|NCT04125797|Active Comparator|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
32863527|NCT01413087|Experimental|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
32863528|NCT01413087|Experimental|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
32863529|NCT04896138||ILD Cohort|Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
32863530|NCT04896138||Control Cohort|Control group of patients and family members of those with an Interstitial Lung Disease
32863531|NCT02158195||Patients|
32863532|NCT02158195||controls|
32863533|NCT04125875||Patients with cirrhosis of esophageal varices|
32863534|NCT04125875||Patients with gastric polyps|
32863535|NCT04878744|Experimental|Noticing the good things about green spaces|"The intervention condition will prompt participants once a day to notice the good things about green spaces, write notes about the 'good things in nature' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of species variety).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation.~Both the intervention and active control conditions are based on gratitude interventions. Practicing gratitude in controlled psychological intervention settings has been shown to have lasting effects on dispositional gratitude and psychological wellbeing (Seligman et al. 2005)."
32863536|NCT04878744|Active Comparator|Noticing the good things about built spaces|"In the control condition, participants will not be prompted to notice nature, rather they will be prompted to record the good things about the built environment, write notes about the 'good things in built spaces' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of the area being built-up).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation."
32863537|NCT04393415|Active Comparator|patients receiving LGF|
32863538|NCT04393415|No Intervention|patients not receiving LGF nor PRP|
32863539|NCT04393415|Active Comparator|patients receiving Platelet rich plasma|
32863540|NCT04745923||Patients with chronic kidney disease|Having been diagnosed with chronic kidney disease
32863541|NCT04745923||Healthy individuals|Healthy individuals without chronic disease
32863542|NCT04888728|Experimental|DWN12088 and Nebivolol|Period 1 - Nebivolol A mg, Tablet, oral, once daily, Period 2 - DWN12088 X mg, Tablet, oral, twice daily, Period 3 - 1) Nebivolol A mg, Tablet, oral, once daily & DWN12088 X mg, Tablet, oral, twice daily, 2) DWN12088 X mg, Tablet, oral, once daily
32863543|NCT04888728|Experimental|DWN12088 and Paroxetine|Period 1 - DWN12088 X mg, Tablet, oral, once daily , Period 2 - Paroxetine B mg, Tablet, oral, once daily, Period 3 - 1) DWN12088 X mg, Tablet, oral, once daily & Paroxetine B mg, Tablet, oral, once daily, 2) Paroxetine B mg, Tablet, oral, once daily
32863544|NCT04125719|Experimental|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
32863545|NCT04125719|Experimental|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
32863546|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
33412810|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
32863547|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
32863548|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
32863549|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
32863550|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
32863551|NCT04878588||patients receiving esophagectomy|the patients receiving esophagectomy during perioperative period. They receive barium examination and high resolution impedance manometry at the same time
32863552|NCT04125329|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
32863553|NCT04888962||Prospective cohort group|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
32863554|NCT04888962||Control group|This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
32863555|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
32863556|NCT01475175|Experimental|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
32863557|NCT04125641||Elxaban group|AF patients taking Elxaban
32863558|NCT04888650||angiodema hereditary patients|Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire
32863559|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
32863560|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
32863561|NCT04125407|Experimental|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
32863562|NCT04125407|No Intervention|Control|Control group will receive neither orthotic nor other supplementary intervention.
32863563|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
32863564|NCT03006185|Experimental|Split-Person Design: Ablative Fractional Carbon Dioxide (CO2) Laser vs Microdermabrasion|WIthin each participant, two 50 cm2 adjacent test areas were randomized to laser or microdermabrasion pretreatment prior to daylight photodynamic therapy.
32863565|NCT04877886|Experimental|Ultrasound with IV contrast|use ultrasound with IV contrast to perform in acute flank pain patient
32863566|NCT04877886|Active Comparator|CT with IV contrast|to compare with ultrasound with IV contrast in acute flank pain patient
32863567|NCT04877886|Active Comparator|Ultrasound without IV contrast|baseline for the Ultrasound with IV contrast
32863568|NCT04877886|Active Comparator|CT without IV contrast|baseline for the CT with IV contrast
32863569|NCT01421095|Experimental|Basal Testing|
32863570|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
32863571|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
32863572|NCT04877964||pediatric patients with scoliosis|Patients aged 3-14 years with scoliosis and who request epidural analgesia
32863573|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
32863574|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
32863575|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
32863576|NCT04393571|Experimental|conventional follow up patients|
32863577|NCT04393571|Experimental|Mobile app follow up patients|
32863578|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
32863579|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
32863580|NCT04124627|Experimental|Single arm study|Ultrasound plus radiographic guidance
32984763|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
32984764|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
33412811|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
33412812|NCT04709627||60 minute surgery|Patients completing at least 60 minutes of surgery
33412813|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
33412814|NCT00145145|Experimental|MAGE-3.A1 Peptide mixed with CpG 7909|Patients were vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 mcg) mixed with CpG 7909 (5 mg) was administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs.
33412815|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
33412816|NCT00004445|Experimental|Implanted Neuroprosthesis|"Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.~Interventions include:~Procedure/Surgery Rehabilitation/Exercise~Device includes:~IRS-8 Stimulating Electrodes External Controller"
33412817|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
33412818|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
33412819|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
33412820|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
33412821|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
33412822|NCT05167955|Experimental|Experimental Randomized controlled waitlist|n=20 (will receive Mindfulness-based cognitive intervention)
33412823|NCT05167955|Other|Waitlist Randomized controlled waitlist|waitlist Randomized controlled waitlist n=20 (will not receive Mindfulness-based cognitive intervention for 1 month)
33412824|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
33412825|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
33412826|NCT05134259|Active Comparator|Study Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy in addition to repetitive transcranial magnetic stimulation sessions for 4 weeks.
32984765|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
32984766|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
32984767|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
32984768|NCT01473641||New users of Nexplanon|
32984769|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
32984770|NCT01473654|No Intervention|Control|
32984771|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
32984772|NCT01473667|Active Comparator|Local Infiltration|
32984773|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
32984774|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
32984775|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
33412827|NCT05134259|No Intervention|Control Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy for 4 weeks.
33412828|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
33412829|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
33412830|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
33412831|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
33412832|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
33412833|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
33412834|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
33412835|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
32984776|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
32984777|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
32984778|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
32984779|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
32984780|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
32984781|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
32984782|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
32984783|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
32984784|NCT01473797|Experimental|cladribine|
32984785|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
32984786|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
32984787|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
32984788|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
32984789|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
32984790|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
32984791|NCT01473888|Other|T89|
32984792|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
32984793|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
32984794|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
32984795|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
32984796|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
32984797|NCT01473927||1|Crohn's Disease patients
32984798|NCT01473927||2|Ulcerative colitis patients
32984799|NCT01473966|No Intervention|standard of care|patients receive standard care
32984800|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
32984801|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
32984802|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
32984803|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
32984804|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
32984805|NCT01474031||Control group|healthy volunteers
32984806|NCT01474044|Placebo Comparator|Placebo|
32984807|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
32984808|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
33105072|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
32984809|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
32984810|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
32984811|NCT01474096|No Intervention|Conventional intervention|
32984812|NCT01474161|Placebo Comparator|Matching placebo|
32984813|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
32984814|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
32984815|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
32984816|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
32984817|NCT01474226|Experimental|Lysine Amino Acid|
32984818|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
33412836|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
32984819|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
32984820|NCT01474265|Placebo Comparator|varenicline placebo|
32984821|NCT01474265|Active Comparator|varenicline|
32984822|NCT01474265|Active Comparator|Nicorette TX|
32984823|NCT01474265|Active Comparator|Nicorette TX optional|
32984824|NCT01474265|No Intervention|control group smokers|
32984825|NCT01474278|Experimental|1|
32984826|NCT01474278|Placebo Comparator|2|
32984827|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
32984828|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
32984829|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
32984830|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
32984831|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
32984832|NCT01474343|Experimental|SAF-301|
32984833|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
33412837|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
32984834|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
32984835|NCT01474369|Experimental|TAK-438 10 mg QD|
32984836|NCT01474369|Experimental|TAK-438 20 mg QD|
32984837|NCT01474369|Placebo Comparator|Placebo QD|
32984838|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
32984839|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
32984840|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
32984841|NCT01474395|Placebo Comparator|Placebo D-serine|
32984842|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
32984843|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
32984844|NCT01474408|Other|control|routine measurements, no exercise
32984845|NCT01474447|Experimental|Grinberg Method|
32984846|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
32984847|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
32984848|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
32984849|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
32984850|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
32984851|NCT01474499|Active Comparator|Glycerine|
32984852|NCT01474525|Experimental|Telemonitoring|
32984853|NCT01474525|Active Comparator|Usual Care|
32984854|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
33412838|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
32907936|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
32907937|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
32907938|NCT04356482|Experimental|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
32907939|NCT04641104|Experimental|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
32907940|NCT04641104|Placebo Comparator|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
32907941|NCT01695473|Experimental|Neoadjuvant BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in operating room (OR) scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
32907942|NCT04359680|Active Comparator|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
32907943|NCT04359680|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks.
32907944|NCT02237417|Other|Healthy Control|
32907945|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
32907946|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
32907947|NCT04603898|Experimental|Controlled Dietary Study|Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.
32907948|NCT04580420|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
32907949|NCT04356170|Active Comparator|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
32907950|NCT04356170|Experimental|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
32907951|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
32907952|NCT04567550|No Intervention|Observation Control Arm|Observation Control
32907953|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
32907954|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
32907955|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
32907956|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
32907957|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
32907958|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
32907959|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
32907960|NCT02245490|Experimental|Tamsulosin|
32907961|NCT02245490|Placebo Comparator|Placebo|
32907962|NCT04356092|Experimental|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
32907963|NCT04355936|Experimental|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
32907964|NCT04355936|No Intervention|CONTROL|Patients in this group will receive standard care.
32907965|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
32907966|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
32984855|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
32984856|NCT01474603||1|overweight or obese diabetic
33412839|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
32984857|NCT01474616|Other|Sit-to-Stand Activity|
32984858|NCT01474629|Active Comparator|probiotic-based dietary supplement|
32984859|NCT01474629|Placebo Comparator|placebo|
32984860|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
32984861|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
32984862|NCT01474668|Experimental|A|Experimental
32984863|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
32984864|NCT01474707|Experimental|Group two|Group two will view the motivational video only
32984865|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
32984866|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
32984867|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
32984868|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
32984869|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
32984870|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
32984871|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
32984872|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
32984873|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
32984874|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
32984875|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
32984876|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
32984877|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
32984878|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
32984879|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
32984880|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients > 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
32984881|NCT01474902|No Intervention|No-treatment|
32984882|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
32984883|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
32984884|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
32984885|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
33412840|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
32984886|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
32984887|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
32984888|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
32984889|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
32984890|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
32984891|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
32984892|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
32984893|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
32984894|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
32984895|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
32984896|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
32984897|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
32984898|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
32984899|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
32984900|NCT01475045||Turbuhaler inhaler use|
32984901|NCT01475045||Discus inhaler use|
32984902|NCT01475045||Elpenhaler inhaler use|
32984903|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
32984904|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
32984905|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
32984906|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
32984907|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
32984908|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
32984909|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
32984910|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
32984911|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
32984912|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
32984913|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
32984914|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
32984915|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
32984916|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
32984917|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
32984918|NCT01475266|Experimental|EO9 (Apaziquone)|
32984919|NCT01475266|Placebo Comparator|Placebo|
32984920|NCT01475292|Experimental|RV568 treatment group low dose|
32984921|NCT01475292|Experimental|RV568 treatment group high dose|
32984922|NCT01475292|Placebo Comparator|Placebo treatment group|
32984923|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
32984924|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
32984925|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
32984926|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
32984927|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
32984928|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
32984929|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
32984930|NCT01475396|Experimental|Aerobic Exercise|
32984931|NCT01475396|Experimental|Anaerobic Exercise|
32984932|NCT01475396|No Intervention|Unchanged condition|
33105073|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
32984933|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
32984934|NCT01475422|Experimental|Conversation Maps Diabetes Education|
32984935|NCT01475422|Active Comparator|Usual Care|
32984936|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
32984937|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
32984938|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
33105074|NCT00547950|Experimental|1|drug
32984939|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
32984940|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
32984941|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
32984942|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
33412841|NCT03606902|Active Comparator|(Group f):|"Intervention:~Procedure: Epidural catheter insertion~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
33412842|NCT03606902|Active Comparator|(Group Lf):|"Intervention:~Procedure:Epidural catheter insertion~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
33412843|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
33412844|NCT03604094||Group I|0-1 month old newborns
33412845|NCT03604094||Group II|1 month-2 year-old pediatric patients
33412846|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
33412847|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
33412848|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
33412849|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
33412850|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
33412851|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
33412852|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
33412853|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
33412854|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
33412855|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
33412856|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
33412857|NCT03219333|Experimental|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
33412858|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
33412859|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
33412860|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
33412861|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33412862|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
33412863|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
33412864|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
32984943|NCT01475526|No Intervention|Control|No intervention. Business as usual
32984944|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
32984945|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
32984946|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
32984947|NCT01475552|Experimental|abciximab|
32984948|NCT01475552|Active Comparator|control|
32984949|NCT01475565||African-American women|Observational study--no intervention
32984950|NCT01475565||Caucasian women|Observational study--no intervention
32984951|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
32907967|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
32984952|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
32984953|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
32984954|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
32984955|NCT01475604|Sham Comparator|Sham|
32984956|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
32984957|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
32984958|NCT01475630|Other|control|information, avoiding parafunctions
32984959|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
32984960|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
32984961|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
32984962|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
32984963|NCT01475669|Placebo Comparator|Placebo|
32984964|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
32984965|NCT01475695|Experimental|Single cohort|14C GSK2251052
32984966|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
32984967|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
32984968|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
32984969|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
32984970|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
32984971|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
32984972|NCT01475760|No Intervention|Standard of Care|
32984973|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
32984974|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
32984975|NCT01475812||COPD hyperinflation|
32984976|NCT01475864||Incomplete biliary stone extraction.|
32984977|NCT01475877||Nepafenac|
32984978|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
32984979|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
32984980|NCT01475903||sleeve gastrectomy|
32984981|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
32984982|NCT01475929|Placebo Comparator|Placebo|
32984983|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
32984984|NCT01475942|Active Comparator|Probiotic|Lactobacillus
32984985|NCT01475942|Placebo Comparator|Placebo|Sucrose
32984986|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
32984987|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
32984988|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
32984989|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
32984990|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
32984991|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
32984992|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
32984993|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
32984994|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
32984995|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
32984996|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
32984997|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
32984998|NCT01475981|Placebo Comparator|Placebo|
32984999|NCT01475994|Experimental|Challenge with grass pollen|
32985000|NCT01475994|Placebo Comparator|Challenge with clean air|
32985001|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
32985002|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
32985003|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
32985004|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
32985005|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
32985006|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
32985007|NCT01476046|Experimental|GSK1995057|Single intravenous dose
32985008|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
33412865|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
32985009|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
32985010|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
32985011|NCT01476072|No Intervention|no treatment|MRI scans only
32985012|NCT01476085|No Intervention|no treatment|no treatment
32985013|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
32985014|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
32985015|NCT01476111||Group 1|Patients with primary invasive breast cancer
32985016|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
32985017|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
32985018|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
32985019|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
32985020|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
32985021|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
32985022|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
32985023|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
32985024|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
32985025|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
32985026|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
32985027|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
32985028|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
32985029|NCT01476150||Dongcheng|
32985030|NCT01476150||Haidian|
32985031|NCT01476150||Xicheng|
32985032|NCT01476150||Chaoyang|
32985033|NCT01476150||Chongwen|
32985034|NCT01476150||Tongzhou|
32985035|NCT01476150||Fengtai|
32985036|NCT01476150||Xuanwu|
32985037|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
32985038|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
32985039|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
32985040|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
32985041|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
32985042|NCT01476215|Experimental|Fast dissolution suspension|
32985043|NCT01476215|Experimental|Medium dissolution suspension|
32985044|NCT01476215|Experimental|Slow dissolution suspension|
32985045|NCT01476215|Active Comparator|Marketed suspension|
32985046|NCT01476228|Experimental|study group|EEG recording
32985047|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
32985048|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
32985049|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
32985050|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
32985051|NCT01476280|Sham Comparator|Palonosetron|
32985052|NCT01476280|Sham Comparator|Ramosetron|
32985053|NCT01476306|Placebo Comparator|In-patient care|
32985054|NCT01476306|Experimental|Telemedicine care|
32985055|NCT01476319|No Intervention|control|
32985056|NCT01476319|Experimental|video|
32985057|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
32985058|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
32985059|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
32985060|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
32985061|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
32985062|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
32985063|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
32985064|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
32985065|NCT01476384|Placebo Comparator|Placebo|250 ml water
32985066|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
32985067|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
33105075|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
32985068|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
32985069|NCT01476423||A|
33412866|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
32985070|NCT01476436|Experimental|LCHF diet|Advice of a diet low in carbohydrate
32985071|NCT01476436|Active Comparator|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
32985072|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
32985073|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
32985074|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
32985075|NCT01476527|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
32985076|NCT01476540|Experimental|Deep Brain Stimulation|Deep Brain Stimulation
32985077|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
32985078|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
32985079|NCT01476566|No Intervention|Control group|
32985080|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
32985081|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
32985082|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
32985083|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
32985084|NCT01476605|No Intervention|Waitlist|
32985085|NCT01476605|Active Comparator|Platelet rich plasma|
32985086|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
32985087|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
32985088|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
32985089|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
32985090|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
32985091|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
32985092|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
32985093|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
32985094|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
32985095|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
32985096|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
32985097|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
32985098|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
32985099|NCT01476774|Active Comparator|Tramadol CR|
33412867|NCT04850391|Active Comparator|Lean-overweight|BMI 18.5 - 30 kg/m2
33412868|NCT04850391|Active Comparator|Obese|BMI > 30 kg/m2
33412869|NCT04850391|Active Comparator|Obese OSA|OSAS patients with BMI > 30 kg/m2
32985100|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
32985101|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
32985102|NCT01476800|Experimental|YM178 OCAS alone|
32985103|NCT01476800|Active Comparator|Ketoconazole alone|
32985104|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
32985105|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
32985106|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
32985107|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
32985108|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
32985109|NCT01476865||Healthy|normal, healthy people
32985110|NCT01476865||RA|rheumatoid arthritis patients
32985111|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
32985112|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
32985113|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
32985114|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
33412870|NCT04163718|Experimental|Treatment with Umbralisib|
33412871|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
33412872|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
32985115|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
32985116|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
32985117|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
32985118|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
32985119|NCT01476956||Rheumatoid Arthritis|
32985120|NCT01476969|Experimental|Manual Tourniquet|
32985121|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
32985122|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
32985123|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
32985124|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
32985125|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
32985126|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
32985127|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
32985128|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
32985129|NCT01477047||Patients receiving primary hip or knee arthoplasty|
32985130|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
32985131|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
32985132|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
32985133|NCT01477073|Experimental|FSH-GEX 75 IU|follitropin epsilon 75 IU QD
32985134|NCT01477073|Experimental|FSH-GEX 150 IU|follitropin epsilon 150 IU QD
32985135|NCT01477073|Experimental|FSH-GEX 150 IU QAD|follitropin epsilon 150 IU QAD
32985136|NCT01477073|Active Comparator|recombinant FSH|Gonal-f 150 IU QD
32985137|NCT01477073|Active Comparator|urinary FSH|Bravelle 150 IU QD
32985138|NCT01477073|Placebo Comparator|Placebo|Placebo QD
32985139|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
32985140|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
32985141|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
32985142|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
32985143|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
32985144|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
32985145|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
32985146|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
32985147|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
32985148|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
33412873|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
32985149|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
32985150|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
32985151|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
32985152|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
32985153|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
32985154|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
32985155|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
32985156|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
32985157|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
32985158|NCT01477203|No Intervention|Remitted Patients|
32985159|NCT01477203|No Intervention|Healthy Controls|
32985160|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
32985161|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
32985162|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
32985163|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
32985164|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
32985165|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
32985166|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
32985167|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
32985168|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
32985169|NCT01477242|Experimental|Ondansetron|Ondansetron use group
32985170|NCT01477242|Placebo Comparator|Placebo|Placebo group
32985171|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
33412874|NCT01378689|No Intervention|No video|
32985172|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
32985173|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
32985174|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
32985175|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
32985176|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
32985177|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
32985178|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
32985179|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
32985180|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
32985181|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
32985182|NCT01477372|Experimental|Exercise group|Supervised exercise program
32985183|NCT01477372|No Intervention|Control|Sedentary pregnant woman
32985184|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
32985185|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
32985186|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
32985187|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
32985188|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
32985189|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
32985190|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
32985191|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
33412875|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~No SMS intervention"
32985192|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
32985193|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
32985194|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
32985195|NCT01477437|Experimental|Intervention (experimental) Group|
32985196|NCT01477437|No Intervention|Control group|
32985197|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
32985198|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
32985199|NCT01477489|Experimental|Treatment|
32985200|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
32985201|NCT01477502|Other|standard prophylaxis|
32985202|NCT01477515||End stage renal disease patient|
32985203|NCT01477515||Matched controls|
32985204|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
32985205|NCT01477541|No Intervention|Control|
32985206|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
32985207|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
32985208|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
32985209|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
32985210|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
32985211|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
32985212|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
33417353|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
32985213|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
32985214|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
32985215|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
32985216|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
32985217|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
32985218|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
32985219|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
32985220|NCT01477580|Placebo Comparator|Placebo|
32985221|NCT01477593|Experimental|Group I|
32985222|NCT01477593|Active Comparator|Group II|
32985223|NCT01477593|Active Comparator|Group III|
32985224|NCT01477606|Experimental|Midostaurin|
32985225|NCT01477619|Experimental|Smokers|Split into BMI categories
32985226|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
32985227|NCT01477619|Experimental|Elderly|
32985228|NCT01477632|Experimental|A|
32985229|NCT01477632|Experimental|B|
32985230|NCT01477632|Active Comparator|C|
32985231|NCT01477645||Leaded ammunition|
32985232|NCT01477645||Non-leaded ammunition|
32985233|NCT01477645||Modified non-leaded ammunition|
32985234|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
32985235|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
32985236|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
32985237|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
32985238|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
32985239|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
32985240|NCT01477723|No Intervention|No Product|
32985241|NCT01477736|Active Comparator|Botulinum toxin A|
32985242|NCT01477736|Active Comparator|oxybutynin|
32985243|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
32985244|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
33412876|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~Offer of Individually customized SMS~Monthly reminder SMS: to pick up ART~SMS communicating VL result"
32985245|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
32985246|NCT01477801|Experimental|CHOLECALCIFEROL|
32985247|NCT01477801|Placebo Comparator|PLACEBO|
32985248|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
32985249|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
32985250|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
32985251|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
32985252|NCT01477840|Experimental|Misoprostol|
32985253|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
32985254|NCT01477866|Active Comparator|conventional therapy|conventional therapy
32985255|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
32985256|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
32985257|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
32985258|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
32985259|NCT01477931|Experimental|Wellbutrin XL|
32985260|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
32985261|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
32985262|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
32985263|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
32985264|NCT01477996|Active Comparator|Group 1|27-gauge needle
32985265|NCT01477996|Active Comparator|Group 2|30-gauge needle
32985266|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
32985267|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
32985268|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
33412877|NCT04153539|Experimental|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
33412878|NCT04153539|Active Comparator|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
32985269|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
32985270|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
32985271|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
32985272|NCT01478126|Placebo Comparator|Placebo|
32985273|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
32985274|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
32985275|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
32985276|NCT01478165|Placebo Comparator|Tiva group (Group T)|
32985277|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
32985278|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
32985279|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
32985280|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
32985281|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
32985282|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
32985283|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
32985284|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
32985285|NCT01478334|Experimental|Exercise then control|
32985286|NCT01478334|Experimental|Control then exercise|
32985287|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
32985288|NCT01478386|Experimental|Off-loading knee brace|
32985289|NCT01478386|Experimental|Viscosupplementation and knee brace|
32985290|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
32985291|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
32985292|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
32985293|NCT01478425|Experimental|Active|Lipidic Microemulsion
32985294|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
32985295|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
32985296|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
32985297|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
32985298|NCT01478451|No Intervention|Control|control shoulder (randomized)
32985299|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
32985300|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
32985301|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
32985302|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
32985303|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
32985304|NCT01478503|Experimental|Treatment Arm A|mirabegron
32985305|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
32985306|NCT01478516|Experimental|Plasmin|eyes with macular edema
32985307|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
32985308|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
32985309|NCT01478568|Experimental|mirabegron / desipramine|
32985310|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
32985311|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
32985312|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
32985313|NCT01478633|Experimental|Galantamine|
32985314|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
32985315|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
32985316|NCT01478659|Active Comparator|Control bar and yogurt|
32985317|NCT01478659|Experimental|Fiber bar and yogurt|
32985318|NCT01478672|No Intervention|Standard care|
32985319|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
32985320|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
32985321|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
32985322|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
32985323|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
32985324|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
32985325|NCT01478724|Placebo Comparator|Placebo|Animal proteins
32985326|NCT01478724|Experimental|Milk protein fraction dose 1|
32985327|NCT01478724|Experimental|Milk protein fraction dose 2|
32985328|NCT01478737|Sham Comparator|Sham|Vitrectomy only
32985329|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
32985330|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
32985331|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
32985332|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
32985333|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
32985334|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
32985335|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
32985336|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
32985337|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
32985338|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
32985339|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
32985340|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
32985341|NCT01478815|Placebo Comparator|Standard Care|
32985342|NCT01478815|Experimental|Contingency management for abstinence from drugs|
32985343|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
32985344|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
32985345|NCT01478867||Celiac patients|
32985346|NCT01478880|Experimental|cTBS|
32985347|NCT01478880|Sham Comparator|Sham cTBS|
32985348|NCT01478893|Experimental|SEL-068|
32985349|NCT01478893|Placebo Comparator|Saline|
32985350|NCT01478906||elderly ,adult|
32985351|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|
32985352|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
32985353|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
32985354|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
32985355|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
32985356|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
32985357|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
32985358|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
32985359|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
32985360|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
32985361|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
32985362|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
32985363|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
33412879|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
32985364|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
32985365|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
33105076|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
33417354|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
32985366|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
32985367|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
32985368|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
32985369|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
32985370|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
32985371|NCT01479062|Placebo Comparator|Control|Usual care
32985372|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
32985373|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
32985374|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
32985375|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
32985376|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
33105077|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
32985377|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
32985378|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
32985379|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
32985380|NCT01479114|No Intervention|control group|
32985381|NCT01479114|Experimental|G-CSF group|
32985382|NCT01479114|No Intervention|Non-GCSF group|
32985383|NCT01479153|Active Comparator|Subclavian catheterization|
32985384|NCT01479153|Active Comparator|Internal Jugular catheterization|
32985385|NCT01479153|Active Comparator|Femoral Catheterization|
33412880|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
32985386|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
32985387|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
32985388|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
32985389|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
32985390|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
32985391|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
32985392|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
33417355|NCT02080052|Experimental|Robot-assisted prostate biopsy|
32985393|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
32985394|NCT01479218|Other|PDA Occluder|single arm
32985395|NCT01479231|Experimental|dexlansoprazole|
32985396|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
32985397|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
32985398|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
33417356|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
33417357|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
32985399|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
32985400|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
32985401|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
32985402|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
32985403|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
32985404|NCT01479387||Group 1|
32985405|NCT01479400||infants who were exposed to antipsychotics as fetus|
32985406|NCT01479400||infants who were not exposed to antipsychotics as fetus|
32985407|NCT01479413||Schizophrenia|
32985408|NCT01479452|Other|Bariatric surgery|Bariatric surgery
32985409|NCT01479452|Other|Controls|Usual care
32985410|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
32985411|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
32985412|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
32985413|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
32985414|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
32985415|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
32985416|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
32985417|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
32985418|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
32985419|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
32985420|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
32985421|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
33412881|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
32985422|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
32985423|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
32985424|NCT01479660|Placebo Comparator|Control|
33412882|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
32985425|NCT01479660|Experimental|Probiotic|
32985426|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
32985427|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
33412883|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
33412884|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
33412885|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
33412886|NCT04053972|Experimental|treatment group|adjuvant lenvatinib
33412887|NCT04053972|No Intervention|control group|no intervention
33412888|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
33412889|NCT04054518|Experimental|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
33412890|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
33412891|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
32985428|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
32985429|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
32985430|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
32985431|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
32985432|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
32985433|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
32985434|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
32985435|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
32985436|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
32985437|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
32985438|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
32985439|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
33105078|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
32985440|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
32985441|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~A thermographic sequence will be captured from each eye.~After 20 minutes, a second pair of thermographic sequences will be captured.~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
32985442|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
32985443|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
32985444|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
32985445|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
32985446|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
32985447|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
33412892|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
33412893|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
32985448|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
32985449|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
32985450|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
32985451|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
33105079|NCT00534768|Active Comparator|2|
33412894|NCT04591275|Experimental|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
33412895|NCT04591275|Active Comparator|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
33412896|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
33412897|NCT04565847|Active Comparator|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
33412898|NCT04565847|Placebo Comparator|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
33412899|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5<apnea hypopnea index (AHI)< 15) to moderate (16 < AHI < 30) OSAS.
33412900|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
33412901|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
33412902|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
33412903|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
33412904|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
33105080|NCT00547989|Active Comparator|1|control
33105081|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
33105082|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
33412905|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
32985452|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
32985453|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
32985454|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
32985455|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
32985456|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
32985457|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
32985458|NCT01479933|Placebo Comparator|Placebo|
32985459|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
32985460|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
32985461|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
32985462|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
32985463|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
32985464|NCT01479972|Experimental|VPM1002|
32985465|NCT01479972|Active Comparator|BCG|
32985466|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
32985467|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
32985468|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
33412906|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
33412907|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
33412908|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
33412909|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
33412910|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
33412911|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
33412912|NCT03759951|Experimental|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
32985469|NCT01480037||Elderly|Individuals between 60 and 70 years-old
32985470|NCT01480037||Long-lived|Individuals above 85 years-old
32985471|NCT01480037||Young|Individuals between 20 and 30 years-old
32985472|NCT01480050|Experimental|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels~For all Levels:~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
32985473|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
32985474|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
32985475|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
32985476|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
32985477|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
32985478|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
32985479|NCT01480180|Experimental|Prophylaxis|
32985480|NCT01480180|Experimental|On-demand|
32985481|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
32985482|NCT01480193|Experimental|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
32985483|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
32985484|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
32985485|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
32985486|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
32985487|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
32985488|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
32985489|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
32985490|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
32985491|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
32985492|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
32985493|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
32985494|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
32985495|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
32985496|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
32985497|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
32985498|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
32985499|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
32985500|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
32985501|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
32985502|NCT01480310|Experimental|A|
32985503|NCT01480310|Experimental|B|
32985504|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
32985505|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
32985506|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
32985507|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
32985508|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
32985509|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
32985510|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
32985511|NCT01480388|Placebo Comparator|Placebo|
32985512|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
32985513|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
32985514|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
32985515|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
32985516|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
32985517|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
32985518|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
32985519|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
32985520|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
32985521|NCT01480492|No Intervention|therapy|
32985522|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
32985523|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
32985524|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
32985525|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
32985526|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
32985527|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
32985528|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
32985529|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
32985530|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
32985531|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
32985532|NCT01480635||Incomplete Colonoscopy|
32985533|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
32985534|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
32985535|NCT01480661|Active Comparator|Roflumilast|
32985536|NCT01480661|Placebo Comparator|Placebo|
32985537|NCT01480687|Experimental|Omega-3 fatty acid|
32985538|NCT01480687|Active Comparator|Ciprofibrate|
32985539|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
32985540|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
32985541|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
32985542|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
32985543|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
32985544|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
32985545|NCT01480739|Experimental|2|Placebo twice daily for 7 days
32985546|NCT01480752|Active Comparator|Lornoxicam|
32985547|NCT01480752|Placebo Comparator|normal saline|
32985548|NCT01480752|Placebo Comparator|no injection|
32985549|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
32985550|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
32985551|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
32985552|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
32985553|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
32985554|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
32985555|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
32985556|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
32985557|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
32985558|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
32985559|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
32985560|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
32985561|NCT01480830|No Intervention|Standard colonoscopy|
32985562|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
33412913|NCT03759951|Experimental|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
32985563|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
32985564|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
32985565|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
32985566|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
32985567|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
32985568|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
32985569|NCT01480895|No Intervention|Post GDM follow-up group.|
32985570|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
32985571|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
32985572|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
32985573|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
32985574|NCT01480921|Experimental|home based exercise training|
32985575|NCT01480921|Active Comparator|supervised exercise training|
32985576|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
32985577|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
32985578|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
32985579|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
32985580|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
32985581|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
32985582|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
32985583|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
32985584|NCT01480999||Laparotomy (open surgery)|
32985585|NCT01480999||Laparoscopic surgery|
32985586|NCT01480999||Robotic assisted surgery|
32985587|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
32985588|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
32985589|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
32985590|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
32985591|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
32985592|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
32985593|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
33412914|NCT03759951|Experimental|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
33412915|NCT03759951|Experimental|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
33412916|NCT04563065|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
33412917|NCT04563065|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
33412918|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
32985594|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
32985595|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
32985596|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
32985597|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
32985598|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
32985599|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
32985600|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
32985601|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
32985602|NCT01481142|Experimental|Adacolumn|
32985603|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
32985604|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
32985605|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
32985606|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
32985607|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
32985608|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
32985609|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
32985610|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
32985611|NCT01481220|Experimental|Azacitidine + Eltrombopag|
32985612|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
32985613|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
32985614|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
32985615|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
32985616|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
32985617|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
32985618|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
32985619|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
32985620|NCT01481298||controls|24 healthy controls
32985621|NCT01481311||Patients before dialysis treatment|
32985622|NCT01481311||Patients after dialysis treatment|
32985623|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
32985624|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
32985625|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
32985626|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
32985627|NCT01481389|Active Comparator|Theobromine drink|
32985628|NCT01481389|Active Comparator|Cocoa drink|
32985629|NCT01481389|Placebo Comparator|Placebo drink|
32985630|NCT01481389|Active Comparator|Cocoa and theobromine drink|
32985631|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
32985632|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
33412919|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
32985635|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
32985636|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
32985637|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
32985638|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
32985639|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
32985640|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
32985641|NCT01481467|No Intervention|Control|Usual care.
32985642|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
32985643|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
32985644|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
32985645|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
32985646|NCT01481506|Experimental|Telemonitoring|
32985647|NCT01481506|No Intervention|Usual care|
32985648|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
32985649|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
32985650|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 18 patients with Crotoxin doses of 0.12 to 1.16 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 48 hour intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 35 treatment days (15 dose levels).
32985651|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
32985652|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
32985653|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
32985654|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
32985655|NCT01481597|Experimental|deuteporfin 1mg/kg|
32985656|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
32985657|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
32985658|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
32985659|NCT01481597|Placebo Comparator|placebo|
32985660|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
32985661|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
32985662|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
32985663|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
32985664|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
32985665|NCT01481662||retrospective|cases retrospectively reported the last 20 years
32985666|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
32985667|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
33412920|NCT04538573|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during during burn treatment, dressing changes and hydrotherapy.
33412921|NCT04538573|Active Comparator|Standard Treatment|Standard treatment during burn treatment, dressing changes and hydrotherapy.
33412922|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
33412923|NCT04418739|No Intervention|Control Arm|Standard intraoperative fluid regime
33412924|NCT04418739|Experimental|Treatment Arm|Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
33412925|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
33412926|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
33412927|NCT04483115|Experimental|TPN171H 2.5mg group|TPN171H 2.5mg tablet + Placebo 10mg tablet
33412928|NCT04483115|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg tablet
33412929|NCT04483115|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet
33412930|NCT04483115|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg tablet
33412931|NCT04483115|Active Comparator|tadalafil 20mg group|tadalafil tablet 20mg
33412932|NCT04483115|Active Comparator|tadalafil 40mg group|tadalafil tablets 20mg *2
33412933|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
33412934|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
33412935|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
33412936|NCT04054362|Experimental|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
33412937|NCT04054362|Experimental|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
33412938|NCT04467281|Experimental|89Zr-DFO-daratumumab PET/CT|"Pre treatment evaluation: 1) Standard of Care (SoC) labs, imaging, blind bone marrow biopsy. 2) Baseline research 89 Zr DFO daratumumab PET/CT 3) Possible biopsy of 89 Zr DFO daratumumab avid lesion Treatment: Daratumumab containing combination therapy (up to 12 cycles, 4 weeks/cycle). SoC labs, imaging, and blind bone marrow biopsies until complete response (CR) is suspected or 12 cycles are completed.~Post treatment evaluation:1) SoC labs, imaging, and blind bone marrow biopsy 2) SoC minimal residual disease (MRD) analysis by next generation sequencing 3) Follow up research 89 Zr DFO daratumumab PET/CT 4) Possible biopsy of 89 Zr DFO daratumumab avid lesion"
33412939|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
33412940|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
33412941|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
33412942|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
33412943|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
33412944|NCT04315467|Experimental|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
33412945|NCT03556683|Experimental|Hypertonic Saline|Subjects will inhale hypertonic saline before having a Mucociliary Clearance (MCC) scan
33412946|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
33412947|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
33412948|NCT05073107|Experimental|Test: With Dental Monitoring|"Dental Monitoring (DM) Kit + 2-month DM subscription~Required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2)~There is a window period of +1 day for the intra-oral videos."
33412949|NCT05073107|No Intervention|Control: Without Dental Monitoring|No DM Kit
33412950|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
33412951|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
33412952|NCT02853344|Experimental|Cohort A: Clear Cell RCC|Participants with clear cell RCC receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
32985668|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
32985669|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
33412953|NCT02853344|Experimental|Cohort B: Non-clear Cell RCC|Participants with non-clear cell RCC receive pembrolizumab 200 mg IV Q3W for up to 35 doses (approximately 24 months).
33412954|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
32985670|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
32985671|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
32985672|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
32985673|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
32985674|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
32985675|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
32985676|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
32985677|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
32985678|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
32985679|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
32985680|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
32985681|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
32985682|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
33412955|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
33412956|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
32985683|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
32985684|NCT01481818|Experimental|radioprotector|
32985685|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
32985686|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
32985687|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
32985688|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
32985689|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
33412957|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
33412958|NCT05028413|No Intervention|Participants Blinded to BrAC reading (Control)|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will complete a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive and be blinded to their breath alcohol readings with the BACtrack Mobile Pro device.
32985690|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
32985691|NCT01481857|Experimental|Thoracolumbar proprioception|
32985692|NCT01481857|Experimental|Segmental Stabilization|
32985693|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
32985694|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
32985695|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
32985696|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
32985697|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
32985698|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
32985699|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
32985700|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
32985701|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
32985702|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
32985703|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
32985704|NCT01481961|Experimental|rTMS arm|
32985705|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
32985706|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
32863581|NCT04895826||Back pain and no back pain|Participants with and without back pain will be included in the study and they will be asked to perform standard functional movements that would be used for a physiotherapy assessment for a back condition. The participants will also perform these movements in front of a camera for video recordings to be analysed by the CV system. The measurements by the CV system will be compared to the measurements by the physiotherapist. Additionally, participants will perform and record videos of the same set of movements at home to test the feasibility of the CV system in a home environment.
32863582|NCT04124783|Experimental|Cooling Bolero|
32863583|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
33412959|NCT05028413|Experimental|Participants Aware of their BrAC reading|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will be shown their breath alcohol readings with the BACtrack Mobile Pro device before completing a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
33412960|NCT04110405|Experimental|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
32863584|NCT04888260||Coronary Artery Disease Group|Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
32863585|NCT04888260||Control Group|The control group consisted of healthy people with normal coronary arteries angiographically
32863586|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
32985707|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
32985708|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
32985709|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
32985710|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
32863587|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
32863588|NCT04395222|Experimental|ATG Group I|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
33412961|NCT04110405|Active Comparator|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
33412962|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
33412963|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
33412964|NCT04054206|Active Comparator|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
33412965|NCT04054206|Active Comparator|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
33412966|NCT04054206|Active Comparator|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
33412967|NCT04054206|Active Comparator|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
33412968|NCT04054206|Active Comparator|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
33412969|NCT04054206|Active Comparator|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
33412970|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
33412971|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
33412972|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
33412973|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
33412974|NCT04428671|Experimental|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
33412975|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
33412976|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
33412977|NCT03603782|Experimental|1|
33412978|NCT03603782|Experimental|2|
33412979|NCT03603782|Experimental|3|
33412980|NCT03603782|Experimental|4|
32863589|NCT04395222|Experimental|ATG Group II|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
32863590|NCT04395222|Experimental|ATG Group III|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
32863591|NCT04395222|Experimental|ATG Group IV|"Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
32863592|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
32863593|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
32863594|NCT04124003|Experimental|rosuvastatin + BMS-963272|
32863595|NCT03237377|Experimental|Durvalumab with Radiation|"Drug: Durvalumab Other Names: MEDI4736~MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction~Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
32907968|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
32907969|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
32907970|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
32907971|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
32907972|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
33412981|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
33412982|NCT03967340||Lung transplant|
33412983|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
33412984|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
33412985|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
33412986|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
33412987|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
33412988|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
33412989|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
33412990|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
33412991|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
33412992|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
33412993|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
33412994|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
33412995|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
33412996|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
32907973|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
32907974|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
32907975|NCT01699373|No Intervention|Manual Palpation|
32907976|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
32907977|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
32907978|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
32907979|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
32907980|NCT04355468|Active Comparator|Control group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
32907981|NCT04355468|Experimental|Opioid Free Aneasthesia group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
32907982|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
32907983|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
32907984|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
32907985|NCT04355000|Active Comparator|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
32907986|NCT04355000|Active Comparator|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
32907987|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
32985711|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
32985712|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
32985713|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
32985714|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
32985715|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
32985716|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
32985717|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
32985718|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
32985719|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~Number of singleton or multiple pregnancy~Parity of parturients~Anesthetic technique (spinal or epidural)~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
32985720|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
32985721|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
32985722|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
32985723|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
32985724|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
32985725|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
32985726|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
32985727|NCT01482143|Experimental|All Study subjects|
32985728|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
32985729|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
32985730|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
32985731|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
32985732|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
32985733|NCT01482247|Active Comparator|L-arginine|
32985734|NCT01482247|Placebo Comparator|Placebo Supplement|
32985735|NCT01482260||Primary Cutaneous Malignant Melanoma|
33412997|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
32907988|NCT01613339|Experimental|Body awareness therapy|
32907989|NCT01613339|No Intervention|Control|
32985736|NCT01482260||Cutaneous Malignant Melanoma Metastases|
32985737|NCT01482260||Benign Melanocytic Nevi|
32985738|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
32907990|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
32907991|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
32907992|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
32985739|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
32985740|NCT01482299|Experimental|RAD001 (everolimus)|
32985741|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
33412998|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
33412999|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
33413000|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
33413001|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
32985742|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
32985743|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
32985744|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
32985745|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
32985746|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
32985747|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
32985748|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
32985749|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
32985750|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
32985751|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
32985752|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
32985753|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
32985754|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
32985755|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
32985756|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
32985757|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
32985758|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
32985759|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
32985760|NCT01482520||Renal cell carcinoma|
32985761|NCT01482520||Hepatocellular carcinoma patients|
32985762|NCT01482533||Revision Total Hip Arthroplasty|
32985763|NCT01482533||Revision Total Knee Arthroplasty|
32985764|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
32985765|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
32985766|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
32985767|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
32985768|NCT01482572||Gene profiling Success|
32985769|NCT01482585||early stage lung adenocarcinoma|
32985770|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
32985771|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
32985772|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
32985773|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
32985774|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
32985775|NCT01482624|Other|Standard arthroscopic meniscal surgery|
33413002|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
32985777|NCT01482650|Experimental|Baska mask|
32985778|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
32985779|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
32985780|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
32985781|NCT01482676||1|controls (normal bladder function)
32985782|NCT01482676||2|acontractile bladder
32985783|NCT01482676||3|overactive bladder
33413003|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
33413004|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
32985784|NCT01482676||4|bladder pain syndrome
32985785|NCT01482689|Experimental|Fish oil capsule|
32985786|NCT01482689|Experimental|Multivitamin tablet|
32985787|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
32985788|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
33413005|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
32985789|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
32985790|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
32985791|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
32985792|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
32985793|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
32985794|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
32985795|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
33413006|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
33413007|NCT03330561|Experimental|PRS-343|
33413008|NCT03603626|Experimental|Preemptive pregabalin|
32985796|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
32985797|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
32985798|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
32985799|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
32985800|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
32985801|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
32985802|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
32985803|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
33413009|NCT03603626|Placebo Comparator|Placebo|
32985804|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
32985805|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
32985806|NCT01482845|Experimental|Group 1|
32985807|NCT01482845|Experimental|Group 2|
32985808|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
32985809|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
32985810|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
32985811|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
32985812|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
32985813|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
32985814|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
32985815|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
32985816|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
32985817|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
32985818|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
32985819|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
32985820|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
32985821|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
32985822|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
32985823|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
32985824|NCT01482988||Critical care patients antipated to stay more than 72 hours|
32985825|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
32985826|NCT01483014|Experimental|imatinib|
32985827|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
32985828|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
32985829|NCT01483066|Experimental|ShapeMatch Instrumentation|
32985830|NCT01483066|Active Comparator|Usual Instrumentation|
32985831|NCT01483092|Experimental|inulin|
32985832|NCT01483092|Placebo Comparator|maltodextrin|
32985833|NCT01483131|Experimental|Low intensity resistance training|
32985834|NCT01483131|Experimental|High intensity resistance training|
32985835|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
32985836|NCT01483157|Experimental|low intensity with vascular occlusion|
32985837|NCT01483157|Experimental|high intensity resistance training|
32985838|NCT01483157|No Intervention|no exercise training|
32985839|NCT01483170|Experimental|Fexinidazole|
32985840|NCT01483170|Placebo Comparator|Placebo fexinidazole|
32985841|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
32985842|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
32985843|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
32985844|NCT01483222|No Intervention|Blank Control|Receiving no intervention
32985845|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
32985846|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
33413010|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
32985847|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
32985848|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
32985849|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
32985850|NCT01483261|No Intervention|Waiting List Control|
32985851|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
32985852|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
32985853|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
32985854|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
32985855|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
32985856|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
32985857|NCT01483326||Cohort|
32985858|NCT01483339|Experimental|Metacognitive Therapy|
32985859|NCT01483339|Experimental|Exposure and Response Prevention|
32985860|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
32985861|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
32985862|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
32985863|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
32985864|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
32985865|NCT01483430|Placebo Comparator|Placebo|
32985866|NCT01483430|Experimental|Ginseol Kg1, high dose|
32985867|NCT01483430|Experimental|Ginseol Kg1, low dose|
32985868|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
32985869|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
32985870|NCT01483456|Other|Usual care|
32985871|NCT01483469|Active Comparator|Concept Proof|
32985872|NCT01483469|Experimental|Receptor Occupancy|
32985873|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
32985874|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
32985875|NCT01483508|Active Comparator|Flavanol and procyanidins|
32985876|NCT01483508|Experimental|Flavanols only|
32985877|NCT01483508|Experimental|Procyanidins only|
32985878|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
32985879|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
32985880|NCT01483547||Neurosurgical|
32985881|NCT01483547||Non-neurosurgical|
32985882|NCT01483573|Experimental|straight leg raise|stretch the muscle
32985883|NCT01483573|Experimental|neural mobilization|stretch the nerve
32985884|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
32985885|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
32985886|NCT01483638|Experimental|Experimental|axitinib
32985887|NCT01483638|Placebo Comparator|control|placebo
32985888|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
32985889|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
32985890|NCT01483716|No Intervention|Control|NIV alone
32985891|NCT01483716|Experimental|Intervention|Rehabilitation arm
32985892|NCT01483729|Active Comparator|Part 1 A|
32985893|NCT01483729|Experimental|Part 1 B|
32985894|NCT01483729|Experimental|Part 1 C|
32985895|NCT01483729|Active Comparator|Part 2 D|
32985896|NCT01483729|Experimental|Part 2 E|
32985897|NCT01483729|Experimental|Part 2 F|
32985898|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
32985899|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
32985900|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
32985901|NCT01483781|Experimental|Canagliflozin|
32985902|NCT01483781|Placebo Comparator|Placebo|
33413011|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
33413012|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
32985903|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
32985904|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
33413013|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
32985905|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
32985906|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
32985907|NCT01483846|Experimental|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.~--------------------------------------------------------------------------------"
32985908|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
32985909|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
32985910|NCT01483885|Experimental|TENS 4Hz|
32985911|NCT01483885|Experimental|Interferential Current 4Hz|
32985912|NCT01483885|Placebo Comparator|TENS|
32985913|NCT01483885|Placebo Comparator|Interferential Current|
32985914|NCT01483885|Experimental|Manual Acupuncture|
32985915|NCT01483885|Experimental|TENS 100 Hz|
32985916|NCT01483885|Experimental|Interferential Current 100Hz|
32985917|NCT01483911|Experimental|ALX-0171|
32985918|NCT01483911|Placebo Comparator|Placebo|
32985919|NCT01483950||Patients with hypercholesterolaemia|
32985920|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
32985921|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
32985922|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
32985923|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
32985924|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
32985925|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
32985926|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
32985927|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
32985928|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
32985929|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
32985930|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
32985931|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
32985932|NCT01484106|Active Comparator|Control|Standard of Care
32985933|NCT01484145|Active Comparator|6 mA.min, 20 mins|
32985934|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
33413014|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
33413015|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
32985935|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
32985936|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
32985937|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
32985938|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
32985939|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
33413016|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
32985940|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
32985941|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
32985942|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
32985943|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
32985944|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
32985945|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
32985946|NCT01484262||Liraglutide|
33413017|NCT01377909|Experimental|statin|
33413018|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
33413019|NCT01765218|Active Comparator|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
32985947|NCT01484262||Any insulin|
32985948|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
32985949|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
32985950|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
32985951|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
32985952|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
32985953|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
32985954|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
32985955|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
32985956|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
32985957|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
32985958|NCT01484444||gastrointestinal cancer|
32985959|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
32985960|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
32985961|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
32985962|NCT01484483||Cohort|
32985963|NCT01484509||Intermittent claudication|
33413020|NCT04053660|No Intervention|Control|Periodontally healthy group
33413021|NCT04053660|Experimental|Chronic Periodontitis|Patients with chronic periodontitis
33413022|NCT05764473|Experimental|A (Med/UCLP)|"Following the Mediterranean Diet for six weeks, then following the Ultimate Cholesterol Lowering Plan for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
32985964|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
32985965|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
32985966|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
33413023|NCT05764473|Experimental|B (ULCP/Med)|"Following the Ultimate Cholesterol Lowering Plan for six weeks, then following the Mediterranean Diet for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
32985967|NCT01484535|Other|Ankle aspiration|ankle aspiration
32985968|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
32985969|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
32985970|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
32985971|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
32985972|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
32985973|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
32985974|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
32985975|NCT01484587|Experimental|001|
32985976|NCT01484587|Placebo Comparator|002|
32985977|NCT01484600|Experimental|Group 1|
32985978|NCT01484600|Experimental|Group 2|
32985979|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
32985980|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
32985981|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
33413024|NCT01731522|Experimental|EF condition|
33413025|NCT03651882|Active Comparator|Oxytocin|
33413026|NCT03651882|Active Comparator|Carbetocin|
33413027|NCT05463159|Experimental|Group A|participants in this group will be given with TENS to spastic Hams, Adductor and TA along with stretchings and ROM as baseline treatment
32985982|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
32985983|NCT01484678||Age Matched Controls|"Age matched non-affected (non-DMD) boys * This arm is full~Age matched non-affected men, matched for men with Becker MD *Recruiting"
32985984|NCT01484678||Boys/Men with DMD|This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. *Recruiting
32985985|NCT01484678||Adults with Becker MD|This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. * Recruiting
32985986|NCT01484704||No treatment|
32985987|NCT01484704||MRI|
32985988|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
32985989|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
32985990|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
32985991|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
32985992|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
32985993|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
32985994|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
32985995|NCT01484795|Experimental|Continuous positive airway pressure|
32985996|NCT01484795|Experimental|BILEVEL|
32985997|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
32985998|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
32985999|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
32986000|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
32986001|NCT01484860|Experimental|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
32986002|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
32986003|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
32986004|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
32986005|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
32986006|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
32986007|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
32986008|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
32986009|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
32986010|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
32986011|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
32986012|NCT01484990|Experimental|1|
32986013|NCT01485016||ambulatory epilepsy subjects|
32986014|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
33413028|NCT05463159|Active Comparator|Group B|participants in this group will be given with TENS to opposite of spastic muscles, i.e. quards, abductor and dorsiflexors along with stretchings and ROM as baseline treatment
32986015|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
32986016|NCT01485068|Experimental|Danubio|
32986017|NCT01485081|Experimental|Danubio|
32986018|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
32986019|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
32986020|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
32986021|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
32986022|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
32986023|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
33413029|NCT05463159|Active Comparator|Group C|participants in this group will be given with TENS to both spastic muscles and opposite of spastic muscle along with stretchings and ROM as baseline treatment
32986024|NCT01485159||All|All subjects enrolled in the study
32986025|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
32986026|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
32986027|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
32986028|NCT01485185|Placebo Comparator|Placebo|Placebo
32986029|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
32986030|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
32986031|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
32986032|NCT01485224|Experimental|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
32986033|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
32986034|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
32986035|NCT01485289||Investigational Stabilimax|
32986036|NCT01485289||Control, Posterolateral Fusion|
32986037|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
32986038|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
32986039|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
32986040|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
32986041|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
32986042|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
32986043|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
32986044|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
32986045|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
33413030|NCT05463159|Active Comparator|Group D|participants in this group will be given with stretchings and ROM as baseline treatment
32986046|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
32986047|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
32986048|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
33413031|NCT03222128|Experimental|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
33413032|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
32986049|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
32986050|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
32986051|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
32986052|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
32986053|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
32986054|NCT01485432||C group|Group C: Conventional fluid management
32986055|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
32986056|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
32986057|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
32986058|NCT01485458|Experimental|Early surgery|
32986059|NCT01485458|Active Comparator|Delayed surgery|
32986060|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
32986061|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
32986062|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
32986063|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
32986064|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
32986065|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
32986066|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
32986067|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
32986068|NCT01485575||Filter use during vitrectomy|
32986069|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
32986070|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
33413033|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
32986071|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
32986072|NCT01485679|Experimental|positrons emission tomography|
32986073|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
32986074|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
32986075|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
32986076|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
32986077|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
32986078|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
32986079|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
32986080|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
32986081|NCT01485757|Experimental|L-arginine|
32986082|NCT01485809|Experimental|Gefitinib|
32986083|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
32986084|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
32986085|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 100 mg/m²~Cohort 2: 100 mg/m²~Cohort 3: 120 mg/m²~Cohort 4: 144 mg/m²~Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 1.0 mg/m²~Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~Cohort 1, 2, 3, 4, 5: 20 + 20 mg~Day of and following bortezomib"
32986086|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
32986087|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
32986088|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
32986089|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
32986090|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
32986091|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
32986092|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
32986093|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
32986094|NCT01485939|Placebo Comparator|placebo patch|
32986095|NCT01485939|Active Comparator|lidocaine patch|
32986096|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
32986097|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
32986098|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
32986099|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
32986100|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
32986101|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
32986102|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
32986103|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
32986104|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
32986105|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
32986106|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
32986107|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
33105083|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
33105084|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
33413034|NCT05462067|Active Comparator|Binocular EDOF IOL|Binocular EDOF IOL for treatment of cataract
32863596|NCT03237377|Experimental|Durvalumab and Trememlimumab with Radiation|"Drugs: Durvalumab + Tremelimumab Other Names: MEDI4736 and CP-675 MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles + CP-675 206 75mg via IV infusion every 4 weeks up 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
32863597|NCT04888182|Active Comparator|intervention|Individual nutritional guidance of a protein intake of ≥25 E%.
32863598|NCT04888182|No Intervention|control|Free diet
32863599|NCT04124081|Experimental|Drug group|
32863600|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
32863601|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
32863602|NCT04895124||Healthy volunteers|
32863603|NCT04895124||Healthy smokers|
32863604|NCT04895124||COPD GOLD I|
32863605|NCT04895124||COPD GOLD II|
32863606|NCT04895124||COPD GOLD III/IV|
32863607|NCT04123925|Experimental|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
32863608|NCT04894578|Active Comparator|Group A|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy
32863609|NCT04894578|Active Comparator|Group B|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints
32863610|NCT04759079|Experimental|Acupuncture Needles and Antiemetic Drug|
32863611|NCT04759079|Active Comparator|Antiemetic Drug|
32863612|NCT02144467||Large-sample healthy participants|MRI scanning.
32863613|NCT04123769|Experimental|Drug group|
32863614|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
32863615|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
32863616|NCT04393025|Other|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
32863617|NCT04393025|Active Comparator|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
32863618|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
32863619|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
32863620|NCT04122989|Experimental|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
32863621|NCT04122989|No Intervention|Control|Usual care
32863622|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
32863623|NCT05257980|Experimental|Dietary supplement (ONS)|All patients will receive standardised dietary advice in addition to the ONS prescribed daily for 28 days. The ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The ONS prescribed will be the same throughout the 28 days and will be taken orally.
32863624|NCT04123301|Active Comparator|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
32863625|NCT04123301|Sham Comparator|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
32863626|NCT05580445|Experimental|Dose-escalation and dose-expansion|Dose-escalation study is designed to determine the dose-limiting toxicity (DLTs) and recommended phase II dose (RP2D). Dose-expansion study is designed to evaluate the antitumor activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.
32863627|NCT04123145|Experimental|CDK-ND|
33413035|NCT05462067|Experimental|Combined Edof and Trifocal IOL|Combined EDOF and Trifocal IOL - EDOF in the distance dominant eye / Trifocal in the non-dominant eye
33413036|NCT05461911||The Study Group|30 adult patients aged 30-75 years to receive a specialized tube feeding product Nutrison Advanced Cubison (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
32986108|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
32986109|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
32986110|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
32986111|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
32986112|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
32986113|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
32986114|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
32986115|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
32986116|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
32986117|NCT01486121|Other|S.O.S.-V|
32986118|NCT01486121|No Intervention|Standard|
32986119|NCT01486134|Experimental|procedure|
32986120|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
32986121|NCT01486147|Other|Table|Group provided nutrition information using table format
32863628|NCT05257902|Active Comparator|Treatment group|Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants.
32986122|NCT01486160||nursing home residents|participants in this group are nursing home residents
32986123|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
32986124|NCT01486173||Premature infants with a GA < 32 Weeks|
32986125|NCT01486173||New born with a GA > 37Weeks|
32986126|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
32986127|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
32986128|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
32986129|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
32986130|NCT01486225|Other|Other than Innothera's brand|
32986131|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
32986132|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
32986133|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
32986134|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
32986135|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
32986136|NCT01486329|Placebo Comparator|Placebo|Placebo control
32986137|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
32986138|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
32986139|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
32986140|NCT01486368|Experimental|PF-03446962|
32986141|NCT01486381|Experimental|BIAsp 30|
32986142|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
32986143|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
32986144|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
33413037|NCT05461911||The Control Group|30 patients aged 30-75 years to receive a standard (available in the clinic) tube feeding product (energetically similar to the product in group 1) with a standard content of arginine, vitamins and minerals from calculating the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
33413038|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
32863629|NCT05257902|Placebo Comparator|Control Group|Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.
32863630|NCT04123223|Experimental|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
32863631|NCT04123223|Experimental|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
32863632|NCT04123223|Placebo Comparator|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
32863633|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
32863634|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
32863635|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
32863636|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
32863637|NCT04122911|Experimental|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
32863638|NCT02990897|No Intervention|Control Group|Patients with Stage 3,4, or 5 CKD who are randomized to the control arm will receive standard care.
32863639|NCT02990897|Experimental|Intervention Group|Patients with Stage 3,4, or 5 CKD who are randomized to the intervention group will receive care from a physician who has been exposed to the intervention: a clinical decision support message. This clinical decision support message shows the patient's risk of kidney failure over the next 5 years.
32863640|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
32863641|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
32863642|NCT01895803||smoking woman 18-60 years old|
32863643|NCT04122599|Other|Melatonin versus standard care|Melatonin is tested versus standard care
32863644|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
32863645|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
32863646|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
32863647|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
32863648|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
32863649|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
32863650|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
32863651|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
32863652|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
32863653|NCT04122521||Glioma|Patients suspected of glioma
32863654|NCT04755829||Group 1|Normal screening mammogram (BIRADS 1 or 2)
32863655|NCT04755829||Group 2|Abnormal screening mammogram (BIRADS 3 to 6)
32863656|NCT04887636||Normal women group|I. Women of childbearing age who are physically and mentally healthy, have regular menstruation and are between 20-45 years old; II. Women who are evaluated as normal by vaginal microbiome morphological characterization; III. Women who agree to participate in this study and have signed an informed consent form; IV. Those who have full capacity for civil and legal conduct; V. The quality of vaginal samples meets the evaluation requirements of this program.
32863657|NCT04122365|Experimental|Interventional group|Chest Wall Mobilization Program
32863658|NCT04122365|Other|Control Group|Routine limbs exercises and education
32863659|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
32863660|NCT05393323|Experimental|Distraction technique|conventional physical therapy with distraction technique
32863661|NCT05393323|Experimental|Traction technique|conventional physical therapy with traction technique
32986145|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
32986146|NCT01486420|Active Comparator|Open surgery|
33413039|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
32986147|NCT01486420|Active Comparator|Corticosteroid Injection|
32986148|NCT01486433|Experimental|Epanova and Simvastatin|
32986149|NCT01486433|Active Comparator|Simvastatin|
32986150|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
32986151|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
32986152|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
32986153|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
32986154|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
32986155|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
32986156|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
32986157|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
32986158|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
32986159|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
32986160|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
32986161|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
32986162|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
32986163|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
32986164|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
32986165|NCT01486628|Placebo Comparator|levodopa and carbidopa|
32986166|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
32986167|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
32986168|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
32986169|NCT01486654|Active Comparator|Anodal stimulation|
32986170|NCT01486654|Active Comparator|Cathodal stimulation|
33413040|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
32986171|NCT01486654|Placebo Comparator|Sham stimulation|
32986172|NCT01486667|Placebo Comparator|sugar pill|
32986173|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
32986174|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
32986175|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
32986176|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
33413041|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
33413042|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
33413043|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
32986177|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
32986178|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
32986179|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
32986180|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
32986181|NCT01486745||Normal colonoscopy|
32986182|NCT01486745||Colonic polyps|
32986183|NCT01486745||Colorectal cancer patients|
32986184|NCT01486745||Breast & Prostate Cancer patients|
32986185|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
32986186|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
32986187|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
32986188|NCT01486797|Experimental|NOX-A12|
32986189|NCT01486823|Experimental|Cohort A|
32986190|NCT01486823|Experimental|Cohort B|
32986191|NCT01486836||ICD therapy|
32986192|NCT01486862|Experimental|BIAsp 30|
32986193|NCT01486875||BIAsp 30|
32986194|NCT01486888|Experimental|Formulation A|
32986195|NCT01486888|Active Comparator|Formulation B|
33413044|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
32986196|NCT01486901|Experimental|Formulation A|
32986197|NCT01486901|Active Comparator|Formulation B|
32986198|NCT01486914|Experimental|NN2000|
32986199|NCT01486914|Active Comparator|IAsp|
32986200|NCT01486940|Experimental|Basal/bolus regimen 1|
32986201|NCT01486940|Active Comparator|Basal/bolus regimen 2|
32986202|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
32986203|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
32986204|NCT01486979|Experimental|Low dose|
32986205|NCT01486979|Active Comparator|High dose|
32986206|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
32986207|NCT01487005||elderly subjects|Healthy
32986208|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
32986209|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
32986210|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
32986211|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
32986212|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
32986213|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
32986214|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
32986215|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
32986216|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
32986217|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
32986218|NCT01487122|Experimental|Continuous Microwave|
32986219|NCT01487122|Experimental|Pulsed Microwaves|
32986220|NCT01487122|Sham Comparator|sham microwaves|
32986221|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
32986222|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
32986223|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
32986224|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
32986225|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
32986226|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
32986227|NCT01487213|Other|Home self test|Intervention
32986228|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
32986229|NCT01487252|Active Comparator|Healthy Controls|
32986230|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
32986231|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
32986232|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
33413045|NCT05463003|Active Comparator|OCT1 and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 and CYP2D6 wildtype genotypes. The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm (cohort) 1 and arm (cohort) 2 and 3, respectively.
32986233|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
32986234|NCT01487304||Low dose HRT|
32986235|NCT01487317|Experimental|Rivastigmine transdermal patch|
32986236|NCT01487317|Placebo Comparator|placebo|
32986237|NCT01487330|Experimental|Subjects receiving TAVI valve|
32986238|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
32986239|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
32986240|NCT01487369||Insulin Aspart|
32986241|NCT01487382||Insulin Aspart|
32986242|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
32986243|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
32986244|NCT01487408||Insulin Aspart|
32986245|NCT01487421||SIT|
32986246|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
32986247|NCT01487447|Experimental|Intervention|
32986248|NCT01487447|Active Comparator|Control|
32986249|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
32986250|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
32986251|NCT01487460|Experimental|TAP311 and Simvastatin|
32986252|NCT01487460|Experimental|TAP311 in Patients|
32986253|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
32986254|NCT01487473|No Intervention|Waitlist Control|
32986255|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
32986256|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
32986257|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
32986258|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
32986259|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
32986260|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
32986261|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
32986262|NCT01487538|Experimental|intervention group|
32986263|NCT01487538|Active Comparator|Standard Advice Group|
32986264|NCT01487551|Experimental|paquinimod|
32986265|NCT01487564|Experimental|Hydromorphone 16 mg|
33413046|NCT05463003|Active Comparator|OCT1 deficient and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 deficient and CYP2D6 wildtype genotype.
32986266|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
32986267|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
32986268|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
32986269|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
32986270|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
32986271|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
32986272|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
32986273|NCT01487642|Experimental|Telephone counselling|
32986274|NCT01487642|Experimental|Proactive telephone counselling|
32986275|NCT01487642|Experimental|web-based smoking cessation programme|
32986276|NCT01487642|Active Comparator|Self-help material|
32986277|NCT01487655||healthy age matched controls|
32986278|NCT01487655||normal tension glaucoma patients|
32986279|NCT01487655||primary open angle glaucoma patients|
32986280|NCT01487681||Invasive cervical cancer|
32986281|NCT01487681||Cervical intraepithelial neoplasia 2/3|
32986282|NCT01487681||Cervical intraepithelial neoplasia 1|
32986283|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
32986284|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
32986285|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
32986286|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
32986287|NCT01487707|Experimental|VHW program plus Folk Media Activities|
32986288|NCT01487720|Experimental|GEMOX|GEMOX treatment
32986289|NCT01487746||treatment|Stroke patients
32986290|NCT01487746||Controls|healthy controls
32986291|NCT01487759|Active Comparator|Prebiotic|
32986292|NCT01487759|Placebo Comparator|Placebo|
32986293|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
32986294|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
32986295|NCT01487798|Experimental|Treatment period 1|
32986296|NCT01487798|Active Comparator|Treatment period 2|
32986297|NCT01487811|Experimental|Formulation 1|
32986298|NCT01487811|Active Comparator|Formulation 2|
32986299|NCT01487824||Preterm-born Young Adults|
32986300|NCT01487824||Term-born Young Adults|
32986301|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
32986302|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
32986303|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
32986304|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
32986305|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
32986306|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
32986307|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
32986308|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
32986309|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
32986310|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
32986311|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
32986312|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
32986313|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
33413047|NCT05463003|Active Comparator|OCT1 wildtype and CYP2D6 deficient genotypes|In this group, the participants are OCT1 wildtype and CYP2D6 deficient genotype.
32986314|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
32986315|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
32986316|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
32986317|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
32986318|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
32986319|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
33413048|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T~Period 2: CKD-380 10mg Tab. 1T"
32986320|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
32986321|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
32986322|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
32986323|NCT01488058|Other|Group 2|Waitlist control
32986324|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
32986325|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
32986326|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
32986327|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
32986328|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
32986329|NCT01488123|Experimental|Ayurvedic Intervention|
32986330|NCT01488136|Active Comparator|Diazoxide|Oral diazoxide 7 mg/kg
32986331|NCT01488136|Placebo Comparator|Placebo|Matched placebo
32986332|NCT01488162||Cohort|
32986333|NCT01488175|Active Comparator|with tourniquet|
32986334|NCT01488175|Placebo Comparator|without tourniquet|
32986335|NCT01488201|Experimental|KHK4827|
32986336|NCT01488201|Placebo Comparator|Placebo|
32986337|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
32986338|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
33413049|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T~Period 2: D308 10mg Tab. 1T"
33413050|NCT03163667|Active Comparator|CB-839 + Everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
33413051|NCT03163667|Placebo Comparator|Placebo + Everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
33105085|NCT02908022|Experimental|Interaction|"Phase 1:~Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
33105086|NCT02908022|Experimental|No Interaction|"Phase 1:~The clinician and the patient will first be introduced at the MRI sessions.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
33413052|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
33413053|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
32863662|NCT04121975|Experimental|Chemoradiotherapy|"Radiation:~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
32863663|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
32863664|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
32863665|NCT02140021|Experimental|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
32863666|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
32863667|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
32863668|NCT03830957|Active Comparator|Ivabradine|
32863669|NCT03830957|Active Comparator|metoprolol|
32863670|NCT05257122|Experimental|Arm A|Monotherapy of Fruquintinib
32863671|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
32863672|NCT04121663|Experimental|Full seam anchor|
32863673|NCT04121663|Active Comparator|Polyether ether ketone bone anchor|
32863674|NCT05198700|Experimental|Experimental Group|Participants in this group will be randomized to receive the probiotic formulation for 4 weeks.
32863675|NCT05198700|Placebo Comparator|Control Group|Participants in this group will be randomized to receive the placebo for 4 weeks.
32863676|NCT04121819|Experimental|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
32863677|NCT01476267|Experimental|Single Arm|
32863678|NCT04887714|Experimental|Mask|cloth mask wearing
32863679|NCT04887714|No Intervention|control|control, without mask.
32863680|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
32863681|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
32863682|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
32863683|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
32863684|NCT05189730|Experimental|Total neoadjuvant therapy|The patients would receive neoadjuvant chemoradiotherapy treatment firstly. And then evaluated efficacy according to RECIST 1.1. If patients with cCR would receive surgery treatment after 4-6 weeks. After surgery, patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy alone treatment. If patients evaluated as PD, they would receive new treatment regimen after MDT discussed. Other patients with PR and SD would receive 2 cycles of neoadjuvant immunochemotherapy. And then, Efficacy of immunochemotherapy would be evaluated according to RECIST 1.1. For patients suitable for surgery, surgery should be performed after 4-6 weeks of immunotherapy. After surgery, the patients with R0 resection would divided into two groups, if patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy treatment. Other patients without R0 resection would receive new treatment regimen after MDT discussed.
32863685|NCT05379673|Active Comparator|"Conservative O2 Supplementation"|Oxygen administration will be titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
32863686|NCT05379673|Experimental|"Liberal O2 Supplementation"|Oxygen administration will be titrated to an SpO2 > 96%.
32863687|NCT04121273|Experimental|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
32863688|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
32863689|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
32863690|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
32863691|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
32863692|NCT04042961|Experimental|Reactive balance training|
32863693|NCT04042961|Active Comparator|Aerobic and strength training|
32863694|NCT01406977|Experimental|BPS804 dose escalation|BPS804 IV Setrusumab given in escalating doses from 5mg/Kg to 20mg/Kg
32863695|NCT05179200|Experimental|"Group 1: Frequent plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis three times every 2 weeks for 16 weeks.
32863696|NCT05179200|Active Comparator|"Group 2: Regular plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis once every 14 days for 16 weeks.
32863697|NCT05179200|Placebo Comparator|"Group 3: Regular whole blood donors"|Donors will donate 450 ml (405-495 ml) whole blood every 3 months for 16 weeks.
32863698|NCT04121039|Experimental|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32863699|NCT04121039|Active Comparator|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
32863700|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
32863701|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
32863702|NCT04887090|Experimental|Acupuncture and drug compound technology group|Routine perioperative management and transcutaneous electrical acupoints stimulation treatment
32863703|NCT04887090|Other|Control group|Routine perioperative management
32863704|NCT05364775||Focus Groups with International Nurses|It is anticipated that there will be four focus groups, each comprised of 6-8 participants
32863705|NCT05364775||Interviews with Nursing Staff|Interviews with qualified and unqualified staff who work with international nurses
32863706|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
32863707|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
32863708|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
32863709|NCT04120571|Experimental|experimental|Sleep Audiological Intervention Device (SleepAID)
32863710|NCT04120571|Sham Comparator|control|no sound
32863711|NCT05256576|No Intervention|Control Group 1|Historic control group from both study sites: patients who took part in the FRAILTY study at Charité University hospital Berlin, as well as patients who were treated for OC at Evangelische Kliniken Essen Mitte during the same time period. Retrospective analysis looking at some of the main outcome variables will be conducted.
32863712|NCT05256576|No Intervention|Control Group 2|Prospective control group: patients who undergo treatment for OC at both sites. Main outcomes are determined while under standard hospital care before start of the change management and implementation of the new intervention.
32863713|NCT05256576|No Intervention|Control Group 3|Control group for health economical analysis to determine the cost-effectiveness of the new intervention.
32863714|NCT05256576|Experimental|Intervention Group|Intervention Group undergoing the new multi-modal perioperative care pathway, including the implementation of ERAS pathway, in combination with a tri-modal prehabilitation program following a comprehensive frailty assessment.
32863715|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
32863716|NCT01401543|Experimental|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
32863717|NCT01401543|Experimental|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
32863718|NCT01401543|Experimental|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
32863719|NCT05358379|Experimental|Phase 1 Dose Escalation|Phase 1 = CYC140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
32863720|NCT05358379|Experimental|Phase 2|Phase 2 = Recommended CYC140 phase 2 dose and schedule administered orally in 28-day cycles.
32863721|NCT02985749|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
32863722|NCT05256498|Experimental|Amber UI Stimulation|Short-duration pudendal nerve stimulation
32863723|NCT05027815|Experimental|cePolyTregs 100 x10^6 cells Open Label|single dose of 100 x 10^6 cells by IV infusion
32863724|NCT05027815|Experimental|cePolyTregs 200 x10^6 cells Open Label|single dose of 200 x 10^6 cells by IV infusion
32863725|NCT05027815|Experimental|cePolyTregs 400 x10^6 cells Open Label|single dose of 400 x 10^6 cells by IV infusion
32863726|NCT04887168|Experimental|Compressed|Treatment delivered at higher intensity - twice weekly
32863727|NCT04887168|Experimental|Spaced|Treatment delivered at lower intensity - once weekly
32863728|NCT04120259|Active Comparator|Group 1|Intervention: Metformin Tablet oral 750 mg OD
32986339|NCT01488227|Experimental|Vitamin D|Vitamin D
32863729|NCT04120259|Experimental|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
32863730|NCT04392102|Experimental|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
32863731|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
32863732|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
32863733|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~Confirmatory fingerprick HIV testing~TB symptom screening~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
32863734|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
32863735|NCT05256420|Experimental|Kinesiotape|Application of a kinesiotape bandage on the knee.
32863736|NCT05256420|Sham Comparator|Sham Bandage|Application of a sham bandage on the knee.
32863737|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
32863738|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
32863739|NCT04758845|Experimental|Cocktail|Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.
32863740|NCT04758845|Experimental|CGI314|Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.
32863741|NCT04758845|Experimental|CSI08|Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.
32863742|NCT04758845|Experimental|MIT411|Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.
32863743|NCT04758845|No Intervention|Placebo|Subjects will consume 1 capsule containing maltodextrin for 45 days.
32863744|NCT05256342|Active Comparator|Duloxetine|Eight weeks treatment, one pill a day. Week 1st - 30 mg a day. Weeks 2nd - 8th - 60 mg a day.
32863745|NCT05256342|Active Comparator|Etoricoxib|Eight weeks treatment. 60 mg daily pill ; from the second week adding omeprazol 20 mg daily
32863746|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
32863747|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
32863748|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
32863749|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
32863750|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
32863751|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
32863752|NCT04123847|Experimental|Stand, Step and Voluntary Training|
32863753|NCT04754022|Active Comparator|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <75 g/L (<7.5 g/dL; <4.7mmol/L) intraoperatively and/or postoperatively.
32863754|NCT04754022|Active Comparator|Liberal Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <95 g/L (<9.5 g/dL; <5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or <85 g/L (< 8.5 g/dL; <5.3mmol/L) on the ward.
32863755|NCT04123379|Experimental|Cohort A|NSCLC: Nivolumab + BMS-813160
32863756|NCT04123379|Experimental|Cohort B|NSCLC: Nivolumab + BMS-986253
32863757|NCT04123379|Experimental|Cohort C|HCC: Nivolumab
32863758|NCT04123379|Experimental|Cohort D|HCC: Nivolumab + BMS-813160
32863759|NCT04123379|Experimental|Cohort E|HCC: Nivolumab + BMS-986253
32863760|NCT04887012|Experimental|CAR-NK019|All subjects were intravenously administrated with CAR-NK019
32863761|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
32863762|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
32863763|NCT04125953|Experimental|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
32863764|NCT04125953|Placebo Comparator|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
32863765|NCT04698330|Experimental|Group A|LADA patients are assigned to receive berberine and inulin for 3-month.
32863766|NCT04698330|Experimental|Group B|LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
32863767|NCT04698330|Experimental|Group C|LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
32863768|NCT04698330|Placebo Comparator|Group D|LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
32863769|NCT01797055|Experimental|human apotransferrin|intravenous apotransferrin every 4-8 weeks
32863770|NCT04124549|Sham Comparator|Stand of Care|Patients in the control group received usual care with sham exercise.
32863771|NCT04124549|Experimental|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
32863772|NCT04430244|Experimental|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
32863773|NCT04430244|Active Comparator|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
32863774|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
32863775|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
32863776|NCT05256186|Experimental|Basketball pre-injury attack program|The intervention group carried out a program for 24 weeks. The participant had to perform the program 3 days per week for 12-15' each day (training days with the team, prior to group activation).
32863777|NCT05256186|No Intervention|Control|The control group performed only the initial, follow-up (12 weeks) and final (24 weeks) evaluations.
32863778|NCT04274543|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
32863779|NCT04274543|Active Comparator|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
32863780|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
32863781|NCT04886778|Experimental|Group A or Trial group|Group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations.
32863782|NCT04886778|Placebo Comparator|Group B or Placebo control group|Group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment.
32863783|NCT05256030|Experimental|Control-Traditional Rehabilitation Group|"This group will receive a 6-week neurorehabilitation program that includes stretching for spasticity inhibition, strengthening of the antagonist muscle, autogenic inhibition methods, as well as conscious-unconscious balance training and gait training, which are routinely applied in physical therapy and rehabilitation units. The treatment will be applied 5 days a week.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
32863784|NCT05256030|Experimental|Study-Neurodevelopmental Therapy Group|Function-oriented Neurodevelopmental Therapy will be applied to the subjects included in the study and randomly assigned to the study group in different positions such as supine, prone, sitting, standing for 6 weeks, 5 sessions per week, and the goal will be to achieve the task at different speeds. Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
32863785|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
32863786|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
32863787|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
32863788|NCT05255796|Experimental|one-piece|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
32863789|NCT05255796|Experimental|plate-haptic|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
32986340|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
33413054|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
33413055|NCT03603548|Active Comparator|Advagraf|
33413056|NCT03603548|Experimental|Envarsus|
33413057|NCT03954782|Experimental|Nintedanib|Oral treatment of Nintedanib 150 mg soft capsule
33413058|NCT03954782|Placebo Comparator|Placebo|Oral treatment of placebo soft capsule
33413059|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
33413060|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
33413061|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
33413062|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
33413063|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
33413064|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
33413065|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
33413066|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
33413067|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
33413068|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
33413069|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
33413070|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
33413071|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
32986341|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
32986342|NCT01488266|Experimental|aripiprazole augmentation|
32986343|NCT01488266|Active Comparator|different class of antidepressant|
32986344|NCT01488292|Experimental|RECAP social skills and reading program|
32986345|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
33413072|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
33413073|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
33413074|NCT03603470|Other|Patients with previous prothesis instability|
33413075|NCT03603470|Other|Patients without prothesis instability|
33413076|NCT00107250|Experimental|AZD2171 + Standard chemotherpay regimens|
33413077|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
33413078|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
33413079|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
33413080|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
33413081|NCT03167411|Experimental|Bexagliflozin alone|
33413082|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
32986346|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
32986347|NCT01488305|Experimental|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
32986348|NCT01488305|Experimental|MNP added in AAMA|It is actually a intervention arm
32986349|NCT01488331||Cohort|
32986350|NCT01488344|Experimental|BIBF 1120|
32986351|NCT01488357||Early stage breast cancer patients receiving mastectomy|
32986352|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
32986353|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
32986354|NCT01488396|Experimental|0.05%cyclosporin eye drop|
32986355|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
32986356|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
32986357|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
32986358|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
32986359|NCT01488461||patients ataxic|
32986360|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
32986361|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
32986362|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
32986363|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
32986364|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
32986365|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32986366|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
32986367|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
32986368|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
32986369|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
32986370|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
32986371|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
32986372|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
32986373|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
32986374|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
32986375|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
32986376|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
32986377|NCT01488643||CONTROL TEAM BMI <35|
32986378|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
32986379|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
32986380|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
32986381|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
32986382|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
32986383|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
32986384|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
32986385|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
32986386|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
32986387|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
32986388|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
32986389|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
32986390|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
32986391|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
32986392|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
32986393|NCT01488747|Experimental|Coromega Nectar|12.22 g
32986394|NCT01488747|Experimental|Barleans Swirl|17.45 g
32986395|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
32986396|NCT01488760||Nineteen women with low back pain|
32986397|NCT01488760||Twenty pain-free women|
32986398|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
32986399|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
32986400|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
32986401|NCT01488799|Active Comparator|MI-CBT|
32986402|NCT01488799|Active Comparator|CBT alone|
32986403|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
32986404|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
32986405|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
32986406|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
32986407|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
32986408|NCT01488864|Experimental|Applied Relaxation (AR)|
32986409|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
32986410|NCT01488903||Premenopausal Women|600 health premenopausal Women
32986411|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
32986412|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
32986413|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
32986414|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
32986415|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
32986416|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
33413083|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
32986417|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
32986418|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
32986419|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
33413084|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
33413085|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
32986420|NCT01488968|Experimental|Hypofractionated|Hypofractionated
32986421|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
32986422|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
32986423|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
32986424|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
32986425|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
32986426|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
32986427|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
32986428|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
32986429|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
32986430|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
32986431|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
32986432|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
32986433|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
32986434|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
32986435|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
32986436|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
32986437|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
32986438|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
32986439|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
32986440|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
32986441|NCT01489137|Experimental|neurosurgery with fixation|
32986442|NCT01489163|Experimental|Lifestyle Counseling|
32986443|NCT01489163|No Intervention|Control|
32986444|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
32986445|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
32986446|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
32986447|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
33413086|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
32986448|NCT01489215|No Intervention|Control Group|
32986449|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
32986450|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
32986451|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
32986452|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
32986453|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
32986454|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
32986455|NCT01489241|Experimental|Telemonitoring|
32986456|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
32986457|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
32986458|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
32986459|NCT01489293||non-atopic subjects|Control group without atopic diseases.
32986460|NCT01489306|Experimental|MDT-637|Active formulation
32986461|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
32986462|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
32986463|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
32986464|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
32986465|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
32986466|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
32986467|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
32986468|NCT01489345|Experimental|Arm 1: Experimental|
32986469|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
32986470|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32986471|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
32986472|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
32986473|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
32986474|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
32986475|NCT01489397|Experimental|Gastric intestinal metaplasia|
32986476|NCT01489397|Placebo Comparator|Normal|
32986477|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
32986478|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
32986479|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
32986480|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
32986481|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
32986482|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
32986483|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
32986484|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
32986485|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
32986486|NCT01489488|Experimental|Arm 1|
32986487|NCT01489488|Experimental|Arm 2|
32986488|NCT01489488|Experimental|Arm 3|
32986489|NCT01489488|Experimental|Arm 4|
32986490|NCT01489488|Experimental|Arm 5|
32986491|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
32986492|NCT01489514||Peanut allergic subjects|
32986493|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
32986494|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
32986495|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
32986496|NCT01489566|Placebo Comparator|the placebo|
32986497|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
32986498|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
33413087|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
33413088|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
32986499|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
32986500|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
32986501|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
32986502|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
32986503|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
32986504|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
32986505|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
32986506|NCT01489644|Experimental|Treatment period 1|
32986507|NCT01489644|Experimental|Treatment period 2|
32986508|NCT01489644|Experimental|Treatment period 3|
32986509|NCT01489644|Active Comparator|Treatment period 4|
32986510|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
32986511|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
32986512|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
32986513|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
32986514|NCT01489709||Vesicare group|Who receive vesicare
32986515|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
32986516|NCT01489735||1|
33413089|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
32986517|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
32986518|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
32986519|NCT01489774|Placebo Comparator|Placebo|
32986520|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
32986521|NCT01489787|Experimental|Phase I : HIFU|
32986522|NCT01489787|Experimental|Phase IIa : HIFU|
32986523|NCT01489787|Experimental|Phase IIb : HIFU|
32986524|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
32986525|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
32986526|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
32986527|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
32986528|NCT01489852|Active Comparator|Estrogen pre-treatment|
32986529|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
32986530|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
32986531|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
32986532|NCT01489878||macrolides|
32986533|NCT01489878||fluoroquinolones|
32986534|NCT01489878||synergistins|
32986535|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
32986536|NCT01489904|No Intervention|Control Treatment|No intervention
33413090|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
32986537|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
32986538|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
32986539|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
32986540|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
32986541|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
32986542|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
32986543|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
32986544|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
32986545|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
32986546|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
32986547|NCT01489995|Experimental|Reference|Fasted
32986548|NCT01489995|Experimental|Glucose Drink|Fed
32986549|NCT01489995|Experimental|Before High Fat Meal|Fed
32986550|NCT01489995|Experimental|Before Light Meal|Fed
32986551|NCT01489995|Experimental|After Light Meal|Fed
32986552|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
32986553|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
32986554|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
32986555|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
32986556|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
32986557|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
32986558|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
32986559|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
32986560|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
32986561|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
32986562|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
32986563|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
32986564|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
32986565|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
32986566|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
32986567|NCT01490099|Experimental|Treatment period 1|
33413091|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
32986568|NCT01490099|Active Comparator|Treatment period 2|
32986569|NCT01490112||IAsp|
32986570|NCT01490164||scoliosis|young adults requiring surgical correction
32986571|NCT01490177|Experimental|One|
32986572|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
32986573|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
32986574|NCT01490216|Other|lisdexamfetamine|open label
32986575|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
32986576|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
32986577|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
32986578|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
32986579|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
32986580|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
32986581|NCT01490281|Experimental|water-based exercise intervention|
32986582|NCT01490281|Experimental|land-based exercise intervention|
32986583|NCT01490281|No Intervention|Control group|
32986584|NCT01490307|Experimental|FCU offered|
32986585|NCT01490307|No Intervention|No feedback or services offered|
32986586|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
32986587|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
32986588|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
32986589|NCT01490333|Experimental|2500 IU Vitamin D3|
32986590|NCT01490333|Active Comparator|400 IU Vitamin D3|
32986591|NCT01490346||ART treated individuals|
32986592|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
32986593|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
32986594|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
32986595|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
32986596|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
32986597|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
32986598|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
32986599|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
32986600|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
32986601|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
32986602|NCT01490424||sepsis|SIRS plus inflammation
32986603|NCT01490424||Control|normal person under medical examination
32986604|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
32986605|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
32986606|NCT01490489|Other|Pregnent women with blood sample|
32986607|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
32986608|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
32986609|NCT01490541||Gastric intestinal metaplasia patient|
32986610|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
32986611|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
32986612|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
32986613|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
32986614|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
33413092|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
33413093|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
33413094|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
33413095|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
33413096|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
32986615|NCT01490606|No Intervention|conventional PT|
32986616|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
32986617|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
32986618|NCT01490645||one group (all patients)|
32986619|NCT01490658|Experimental|Treatment period 1|
32986620|NCT01490658|Experimental|Treatment period 2|
32986621|NCT01490658|Active Comparator|Treatment period 3|
32986622|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
32986623|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
33413097|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
33413098|NCT03601676|Active Comparator|Intervention|
33413099|NCT03601676|No Intervention|Control|
33413100|NCT05461833|Experimental|Fecal transplantation group|Fecal transplantation of frozen prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
32986624|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
32986625|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
32986626|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
32986627|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
32986628|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
32986629|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
32986630|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
32986631|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
32986632|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
32986633|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
32986634|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
32986635|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
32986636|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
32986637|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
32986638|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
32986639|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
32986640|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
32986641|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
32986642|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
32986643|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
32986644|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
32986645|NCT01490944|Active Comparator|Iron and Folic Acid|
32986646|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
32986647|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
32986648|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
32986649|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
32986650|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
32986651|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
32986652|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
32986653|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
32986654|NCT01491061|Placebo Comparator|Placebo|Placebo
32986655|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
32986656|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
32986657|NCT01491087|Experimental|PENTAXIM® vaccine group|
32986658|NCT01491100||Group 1|
32986659|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
32986660|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~Drug: cisplatin 80mg/m2 (day 1)~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~Drug: olaparib~Drug: Cisplatin~Radiation"
32986661|NCT01491152|Experimental|WBV Training|
32986662|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
32986663|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
32986664|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
32986665|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
32986666|NCT01491204|Experimental|paclitaxel +HM30181|
32986667|NCT01491230||25 autologous/25 allogeneic patients|
32986668|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
32986669|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
32986670|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
32986671|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
32986672|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
32986673|NCT01491269|No Intervention|Control condition|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
32986674|NCT01491282||No treatment|
32986675|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
32986676|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
32986677|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
33413101|NCT05461833|Active Comparator|Standard-care group|FODMAP diet, Otilonium Bromide, oral, (40mg, 1 tablet TID) and a multi-strain probiotic, oral, (1 capsule BID)
32986678|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
32986679|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
33413102|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
33413103|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
33413104|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
33413105|NCT05462847|Experimental|Volume loading|
33413106|NCT05462847|Active Comparator|Control|
33413107|NCT05764395|Experimental|Treatment (Rigosertib, pembrolizumab)|Patients receive rigosertib PO plus pembrolizumab IV throughout the study. Patients undergo CT or MRI and blood sample collection at screening and on study, and may also undergo tissue biopsy at screening and on study.
33413108|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
33413109|NCT05462691|Experimental|Patients without tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture with suturing of the tuberosities
33413110|NCT05462691|Active Comparator|Patients with tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture without suturing of the tuberosities
33413111|NCT03597152|Experimental|Treatment|WelTract
33413112|NCT03597152|Placebo Comparator|Control|Inert Placebo
33413113|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
33413114|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
33413115|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
33413116|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
33413117|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
33413118|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
33413119|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
33413120|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
33413121|NCT03596528|Other|Lung biopsy|Lung biopsy
33413122|NCT05462535||Single arm, Single group(No interventional)|Observational
33413123|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
33413124|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
33413125|NCT05461443|Active Comparator|Wild-type|Supplementation with the wild-type of the LGG strain
33413126|NCT05461443|Experimental|Low-pill|Supplementation with the low-pili LGG strain
33413127|NCT05461443|Experimental|High-pili|Supplementation with the high-pili LGG strain
33413128|NCT03593720||Hypospadias|Patients with hypospadias
33413129|NCT03593720||Control|Patients without hypospadias
33413130|NCT05461365|Experimental|intranasal insulin|For each selected participant (n=27), a baseline olfactory measurement was performed with Sniffin Sticks® (12 items) and a capillary glucose measurement was obtained with Dextrostix® NF before and after the intervention, in order to guarantee patient safety and reduce the risk of hypoglycemia. The initial and final measurements were divided into three subsections with a different number of correct answers for each section Subsequently, Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
33413131|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
32986680|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
32986681|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
33413132|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
33413133|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
32986682|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
32986683|NCT01491347||alcohol dependent|
32986684|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
32986685|NCT01491373|Experimental|rhBMP-2/ACS|
32986686|NCT01491373|Active Comparator|Autograft|
32986687|NCT01491386|Experimental|rhBMP-2/ACS|
32986688|NCT01491386|Active Comparator|Autogenous Bone|
32986689|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
32986690|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
32986691|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
32986692|NCT01491425|Experimental|rhBMP-2/ACS|
32986693|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
32986694|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
32986695|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
32986696|NCT01491451|Experimental|rhBMP-2/ACS|
32986697|NCT01491451|Active Comparator|Autogenous bone|
32986698|NCT01491464|Experimental|rhBMP-2/ACS|
32986699|NCT01491464|Active Comparator|Autogenous bone|
32986700|NCT01491477|Experimental|INFUSE™ Bone Graft|
32986701|NCT01491477|Active Comparator|Autogenous bone|
32986702|NCT01491503|Experimental|Montelukast and levocetirizine|
32986703|NCT01491503|Active Comparator|Montelukast|
32986704|NCT01491503|Active Comparator|Levocetirizine|
32986705|NCT01491542|Experimental|rhBMP-2 / ACS|
32986706|NCT01491542|Active Comparator|Autogenous bone|
32986707|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
32986708|NCT01491555||Control Group|35 healthy boys ages 2 through 30
32986709|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
32986710|NCT01491581|Placebo Comparator|control arm|normal bar
32986711|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
32986712|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
32986713|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
32986714|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
32986715|NCT01491685||Pregnant|
32986716|NCT01491685||Non- Pregnant|
32986717|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
32986718|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
32986719|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
32986720|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
32986721|NCT01491724||pCLE images|
32986722|NCT01491750|Experimental|GUIDED IMAGERY|
32986723|NCT01491750|Placebo Comparator|AUDIO BOOK|
32986724|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
32986725|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
32986726|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
32986727|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
32986728|NCT01491906|No Intervention|Usual Care|This group will receive usual care
33033558|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
33033559|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
32986729|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
32986730|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
32986731|NCT01492010|Experimental|25 g protein|25 g whey protein
32986732|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
32986733|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
32986734|NCT01492023||control|control group: no intervention
32986735|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
32986736|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
33324428|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
33324429|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
32986737|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
32986738|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
33324430|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
33324431|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
32986739|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
32986740|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
32986741|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
32986742|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
32986743|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
32986744|NCT01492153||NovoLet® device|
32986745|NCT01492166||Novolet®|
32986746|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
32986747|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
32986748|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
32986749|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
32986750|NCT01492205||Human insulin|
32986751|NCT01492218||NovoLet®|
32986752|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
32986753|NCT01492244||Patients with knee pain and a known diagnosis|
32986754|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
33033560|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
33033561|NCT01964144|Experimental|Dovitinib arm|
33033562|NCT01964157|Experimental|LDK378 arm|
32986755|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
32986756|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
32986757|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
32986758|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
32986759|NCT01492283||cirrhosis|Patients with liver cirrhosis
32986760|NCT01492283||Kontrol groups|Healthy control subjects
32986761|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
32986762|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
32986763|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
32986764|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
32986765|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
32986766|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
32986767|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
32986768|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
32986769|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
32986770|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
32986771|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
32986772|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
32986773|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
32986774|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
32986775|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
32986776|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
32986777|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
32986778|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
32986779|NCT01492465|Active Comparator|AMG 876|
32986780|NCT01492465|Placebo Comparator|Placebo|
32986781|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
32986782|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
32986783|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
32986784|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
33033563|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
33033564|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
33033565|NCT01964183|Experimental|treatment group|
33033566|NCT01964196|Experimental|ASP1517 low dose group|Oral
33033567|NCT01964196|Experimental|ASP1517 middle dose group|Oral
33033568|NCT01964196|Experimental|ASP1517 high dose group|Oral
32986785|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
32986786|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
32986787|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
32986788|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
32986789|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
32986790|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
32986791|NCT01492556|Experimental|Etoposide|Etoposide Capsules
32986792|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
32986793|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
32986794|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
32986795|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
32986796|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
32986797|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
32986798|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
32986799|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
32986800|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
32986801|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
32986802|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
32986803|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
32986804|NCT01492725|Active Comparator|Standard care iv tPA|
32986805|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
32986806|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
32986807|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
32986808|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
32986809|NCT01492764||Control Group|This group receives traditional ablation for this disorder
32986810|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
32986811|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
32986812|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
32986813|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
32986814|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
32986815|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
32986816|NCT01492855|Experimental|Operative treatment|
32986817|NCT01492855|Experimental|Conservative treatment|
32986818|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
32986819|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
32986820|NCT01492894|Active Comparator|Rapamune|
32986821|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
32986822|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
32986823|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
32986824|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
32986825|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
32986826|NCT01492959||Insulin human|
32986827|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
32986828|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
32986829|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
32986830|NCT01492985|Experimental|Vaccine arm|
32986831|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
32986832|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
32986833|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
32986834|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
32986835|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
32986836|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
32986837|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
32986838|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
32986839|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
32986840|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
32986841|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
32986842|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
32986843|NCT01493128||stable sinus rhythm|
32986844|NCT01493128||permanent atrial fibrillation|
32986845|NCT01493128||paroxysmal atrial fibrillation|
32986846|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
32986847|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
32986848|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
32986849|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
32986850|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
32986851|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
32986852|NCT01493193|Active Comparator|Endurance training with constant work load|
32986853|NCT01493193|Experimental|Pyramid-Training|
32986854|NCT01493193|Experimental|High-intensity interval training|
32986855|NCT01493206|Experimental|intraoperative radiotherapy|
32986856|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
32986857|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
32986858|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
32986859|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
32986860|NCT01493245|Experimental|JNS020QD|
33033569|NCT01964196|Placebo Comparator|Placebo group|Oral
32986861|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
32986862|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
32986863|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
32986864|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
32986865|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
32986866|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
32986867|NCT01493323|Experimental|Control|
32986868|NCT01493323|Experimental|Depressive attempters|
32986869|NCT01493336|Experimental|Capecitabine RTD|
32986870|NCT01493336|Active Comparator|Xeloda|
32986871|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
32986872|NCT01493349||Uncomplicated diverticular disease|
32986873|NCT01493349||History of complicated diverticular disease|
32986874|NCT01493349||Current complicated diverticular disease|
32986875|NCT01493362||1|Participants with Bulimia Nervosa
32986876|NCT01493362||2|Participants who are healthy controls
32986877|NCT01493388||A|
32986878|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
32986879|NCT01493440|Other|Atosiban|
32986880|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
32986881|NCT01493466||Normal|normal person under physical examination
32986882|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
32986883|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
32986884|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
32986885|NCT01493466||death|sepsis patients within 48 hours before death
32986886|NCT01493479|Experimental|Fractionated Initial Zevalin|
32986887|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
32986888|NCT01493492||sepsis|"Sepsis~sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
32986889|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
32986890|NCT01493518|Placebo Comparator|PLACEBO|
32986891|NCT01493518|Experimental|AMG 557|
32986892|NCT01493570|Experimental|BI 409306 low dose|Film-coated tablet
32986893|NCT01493570|Experimental|BI 409306 low dose II|Film-coated tablet
32986894|NCT01493570|Experimental|BI 409306 medium dose|Film-coated tablet
32986895|NCT01493570|Experimental|BI 409306 high dose|Film-coated tablet
32986896|NCT01493570|Experimental|Placebo|Film-coated tablet
32986897|NCT01493583||severely obese women|
32986898|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
32986899|NCT01493583||lean women|
32986900|NCT01493609|No Intervention|Waitlist Control|
32986901|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
32986902|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
32986903|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
32986904|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
32986905|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
32986906|NCT01493648|Experimental|Vitamin D|
32986907|NCT01493648|Placebo Comparator|Placebo|
32986908|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
32986909|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
32986910|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
32986911|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
32986912|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
32986913|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
32986914|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
32986915|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
32986916|NCT01493726|Experimental|ALKS 9072, Low dose|
32986917|NCT01493726|Experimental|ALKS 9072, Med dose|
32986918|NCT01493726|Experimental|ALKS 9072, High dose|
32986919|NCT01493726|Placebo Comparator|Placebo|
32986920|NCT01493739||lymphadenopathy|
32986921|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
32986922|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
32986923|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
32986924|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
32986925|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
32986926|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
32986927|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
32986928|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
32986929|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
32986930|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
32986931|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
32986932|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
32986933|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
32986934|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
32986935|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
32986936|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
32986937|NCT01493882|Placebo Comparator|Placebo|
32986938|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
32986939|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
32986940|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
32986941|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
32986942|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
32986943|NCT01493908|Active Comparator|High price|
32986944|NCT01493908|Active Comparator|Low price|
32986945|NCT01493908|Active Comparator|Low price participants aware paying part|
32986946|NCT01493908|Active Comparator|No price|
32986947|NCT01493908|Active Comparator|Free of charge|
32986948|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
32986949|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
32986950|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
32986951|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
32986952|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
32986953|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
32986954|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
32986955|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
32986956|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
32986957|NCT01494025|Experimental|Diet and Exercise|
32986958|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
32986959|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
32986960|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
32986961|NCT01494090|Active Comparator|Rosuvastatin|
32986962|NCT01494090|Placebo Comparator|placebo|
32986963|NCT01494116|Experimental|10 mL syringe size|
32986964|NCT01494116|Experimental|20 mL syringe size|
32986965|NCT01494116|Experimental|30 mL syringe size|
32986966|NCT01494116|Experimental|60 mL syringe size|
32986967|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
32986968|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
32986969|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
32986970|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
32986971|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
32986972|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
32986973|NCT01494194|Placebo Comparator|placebo for food challenge|
32986974|NCT01494194|Experimental|ASP Skin prick solution|
32986975|NCT01494194|Experimental|ASP sorbet|
32986976|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
32986977|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
32986978|NCT01494246|Experimental|electronic mail|
32986979|NCT01494246|No Intervention|brief advise|
32986980|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
33033570|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
33033571|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
33033572|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base~Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
33033573|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
33033574|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
33033575|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
33033576|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
33033577|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
33033578|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
33033579|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
33033580|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
32986981|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
32986982|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
32986983|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
32986984|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
32986985|NCT01494285|Experimental|ARK-E021 5% foam|
32986986|NCT01494285|Experimental|ARK-E021 10% foam|
32986987|NCT01494285|Placebo Comparator|Placebo foam|
32986988|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
32986989|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
32986990|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
32986991|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
32986992|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
32986993|NCT01494389||sepsis|SIRS + infection
32986994|NCT01494389||Normal|not SIRS and have no infection
32986995|NCT01494402|Experimental|D961S|2 way crossover
32986996|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
32986997|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
32986998|NCT01494428|Experimental|rhBMP-2/ACS|
33324432|NCT05436366|Experimental|Soleus Loading Response Experimental|Participants in this one arm will be administered the soleus loading response protocol by applying an ankle joint rotation during treadmill walking
32986999|NCT01494428|Active Comparator|Autogenous Bone|
32987000|NCT01494441|Experimental|rhBMP-2/BCP|
32987001|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
32987002|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
32987003|NCT01494454|Experimental|rhBMP-2/BCP|
32987004|NCT01494454|Active Comparator|Autograft|
32987005|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
32987006|NCT01494493|Experimental|rhBMP-2/ACS|
32987007|NCT01494493|Active Comparator|Autogenous Bone|
32987008|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
32987009|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
32987010|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
32987011|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
32987012|NCT01494571||90 pediatric, 7 to 14 year old subjects|
32987013|NCT01494571||30 pediatric, 5 to 6 year old subjects|
33324433|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
33324434|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
32987014|NCT01494571||30 pediatric, 3 to 4 year old subjects|
32987015|NCT01494571||30 pediatric, 1 to 2 year old subjects|
32987016|NCT01494571||30 pediatric, 6 to 12 month old subjects|
32987017|NCT01494571||30 pediatric, 4 to 6 month old subjects|
32987018|NCT01494571||30 pediatric, 2 to 4 month old subjects|
32987019|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
32987020|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
33033581|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
33324435|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
33324436|NCT01138176|No Intervention|Standard care|
33324437|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
33324438|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
33324439|NCT01132950|Active Comparator|Didactic Educational Counseling|
33324440|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
33324441|NCT01135290|Other|B|
33324442|NCT01135290|Active Comparator|A|
33324443|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
32987021|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
32987022|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
32987023|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
32987024|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
32987025|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
32987026|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
32987027|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
32987028|NCT01494701|Experimental|Cohort 1 (n=6)|
32987029|NCT01494701|Experimental|Cohort 2 (n=6)|
32987030|NCT01494701|Experimental|Cohort 3 (n=6)|
32987031|NCT01494701|Experimental|Cohort 4 (n=10)|
32987032|NCT01494714|Experimental|Closed-patch test|
32987033|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
32987034|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
32987035|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
32987036|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
32987037|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
32987038|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
32987039|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
32987040|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
32987041|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
32987042|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
32987043|NCT01494805|Active Comparator|Control - ranibizumab only|
32987044|NCT01494831|Experimental|TF-CBT|
32987045|NCT01494831|No Intervention|Waiting List control|
32987046|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
32987047|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
32987048|NCT01494883|No Intervention|Treatment as usual|
32987049|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
32987050|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
32987051|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
32987052|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
32987053|NCT01494948|Placebo Comparator|placebo|skin test negative
32987054|NCT01494948|Active Comparator|allergic|Skin test positive
32987055|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
32987056|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
32987057|NCT01494974|Active Comparator|FP7 implant|
32987058|NCT01494974|Active Comparator|FP8 implant|
32987059|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
32987060|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
32987061|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
32987062|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
32987063|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
32987064|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
32987065|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
32987066|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
32987067|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
32987068|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
32987069|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
32987070|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
32987071|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
32987072|NCT01495104|Experimental|Single Arm|
32987073|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
32987074|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
32987075|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
32987076|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
32987077|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
32987078|NCT01495156|Experimental|Lithium/Adjunctive SGA|
32987079|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
32987080|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
32987081|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
32987082|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
32987083|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
32987084|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
32987085|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
32987086|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
32987087|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
32987088|NCT01495208|Experimental|aflibercept|
32987089|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
32987090|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
32987091|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
32987092|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
32987093|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
32987094|NCT01495299||cataract patients with glaucoma|
32987095|NCT01495312|Experimental|SLT|
32987096|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
32987097|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
32987098|NCT01495338|Experimental|AC-170 0.17%|
32987099|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
32987100|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
32987101|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
32987102|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
32987103|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
32987104|NCT01495364|Placebo Comparator|placebo|matching placebo
32987105|NCT01495377|Active Comparator|Remifentanil|
32987106|NCT01495377|Placebo Comparator|Placebo|
32987107|NCT01495377|Experimental|Technetium|
32987108|NCT01495377|Experimental|Dynamometer|
32987109|NCT01495403|Experimental|hydroxychloroquine|
32987110|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
32987111|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
32987112|NCT01495442|Active Comparator|modified Handihaler DPI|
32987113|NCT01495442|Placebo Comparator|standard Handihaler DPI|
32987114|NCT01495455||Knee osteoarthritis|
32987115|NCT01495455||No knee pain/osteoarthritis|
32987116|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
32987117|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
32987118|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
32987119|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
32987120|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
32987121|NCT01495533|Placebo Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
32987122|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
32987123|NCT01495546|Experimental|Early loading|
32987124|NCT01495546|Active Comparator|late loading|
32987125|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
32987126|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
32987127|NCT01495650|Experimental|Intervention arm|
32987128|NCT01495650|No Intervention|Control arm|Routine practice
32987129|NCT01495663|Other|Single Group|I-131-CLR1404
32987130|NCT01495715|Experimental|Idebenone|
32987131|NCT01495715|Placebo Comparator|Placebo|
32987132|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
32987133|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
32987134|NCT01495754|Experimental|coffee3|
32987135|NCT01495754|Experimental|coffee6|
32987136|NCT01495754|Placebo Comparator|water|
32987137|NCT01495767||females, males|females: patients of female sex males: patients of male sex
32987138|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
32987139|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
32987140|NCT01495806|Placebo Comparator|Placebo|
32987141|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
32987142|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
32987143|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
32987144|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
32987145|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
32987146|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
32987147|NCT01495897|Other|Healthy|Healthy volunteers
32987148|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
32987149|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
32987150|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
32987151|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
32987152|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
32987153|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
32987154|NCT01495949|Active Comparator|etomidate|
32987155|NCT01495949|Active Comparator|thiopentone|
32987156|NCT01495962|Active Comparator|Botulinum Toxin A injection|
32987157|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
32987158|NCT01496001|Experimental|Cohort|
32987159|NCT01496027||term newborns|
32987160|NCT01496027||Preterm Newborns (32-37 GA)|
32987161|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
32987162|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
32987163|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
32987164|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
32987165|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
32987166|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
32987167|NCT01496092|No Intervention|usual protein diet|
32987168|NCT01496105|Active Comparator|lidocaine spray 10%|
32987169|NCT01496105|Placebo Comparator|Saline|
32987170|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
32987171|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
32987172|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
32987173|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
32987174|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
32987175|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
32987176|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
32987177|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
32987178|NCT01496196|Placebo Comparator|tranexamic|placebo arm
32987179|NCT01496209|Sham Comparator|Placebo control|
32987180|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
32987181|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
32987182|NCT01496235|Placebo Comparator|White chocolate|
32987183|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
32987184|NCT01496261|Experimental|Coprigerl|
32987185|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
32987186|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
32987187|NCT01496326|Experimental|Ibuprofen|
32987188|NCT01496326|Placebo Comparator|Placebo|
32987189|NCT01496339|Active Comparator|Traditional therapy control|
32987190|NCT01496339|Experimental|Stem cell infusion|
32987191|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
32987192|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
32987193|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
32987194|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
32987195|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
32747357|NCT05536635|Experimental|breathing techniques|The patients in the intervention group will be taught and practiced breathing technique. Breathing techniques will be taught face-to-face by the researcher to the patients in the intervention group. The participant will breathe through one nostril at a natural rate and depth, while the other nostril will be closed with the thumb or forefinger. After the act of breathing, it will open the closed nostril, close the open nostril and breathe naturally. As explained later, they will continue the cycle with the act of breathing. This process is described as a loop.
32987196|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
32987197|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
32987198|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
32987199|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
32987200|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
32987201|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
32987202|NCT01496495|Experimental|ARRY-614|
32987203|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
32987204|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
32987205|NCT01496521|Experimental|Aspirin|
32987206|NCT01496521|Experimental|Tea Polyphenols|
32987207|NCT01496521|No Intervention|Control|
32987208|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
32987209|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
32987210|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
32987211|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
32987212|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
32987213|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
32987214|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
32987215|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
32987216|NCT01496677|Experimental|Elderly subjects (65 or older)|
32987217|NCT01496677|Experimental|Younger adults (18-45 years old)|
32987218|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
32987219|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
32987220|NCT01496703||renal transplantation with MMF from day 1|
32987221|NCT01496716||Hip Osteoarthritis|
32987222|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
32987223|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
32987224|NCT01496742|Experimental|Bevacizumab+MetMAb|
32987225|NCT01496742|Active Comparator|Bevacizumab+Placebo|
32987226|NCT01496742|Experimental|Pemetrexed+MetMAb|
32987227|NCT01496742|Active Comparator|Pemetrexed+Placebo|
32987228|NCT01496755|Placebo Comparator|Placebo|
32987229|NCT01496755|Experimental|RG7667|
32987230|NCT01496768|Experimental|Leucine|
32987231|NCT01496768|Placebo Comparator|Alanine|
32987232|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
32987233|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
32987234|NCT01496794||Endophthalmitis cultures|
32987235|NCT01496820|Experimental|GO2KA1|
32747358|NCT05536635|No Intervention|treatment as usual|The control group will continue his/her usual treatment as advised by the physician.
32987236|NCT01496820|Placebo Comparator|Placebo|
32987237|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
32987238|NCT01496859|Experimental|Baska|
32987239|NCT01496911|Experimental|Levocetirizine (5 mg)|
32987240|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
32987241|NCT01496911|Placebo Comparator|Placebo|
32987242|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
32987243|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
32987244|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
32987245|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
32987246|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
32987247|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
32987248|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
32987249|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
32987250|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
32987251|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
32987252|NCT01497002|Active Comparator|standard arm|standard treatment arm
32987253|NCT01497002|Experimental|OSHO - intensified consolidation|Intermediate dose AraC
32987254|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
32987255|NCT01497028||Plicated Gastric Banding|
32987256|NCT01497028||Standard Gastric Banding|
32987257|NCT01497080||1|
32987258|NCT01497080||activity level|
32987259|NCT01497080||no treatment|
32987260|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
32987261|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
32987262|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
32987263|NCT01497119|Experimental|JNJ-39758979, 300 mg|
32987264|NCT01497119|Experimental|JNJ-39758979, 100 mg|
32987265|NCT01497119|Placebo Comparator|Placebo|
32987266|NCT01497132|Experimental|Vitamin D3|
32987267|NCT01497132|Placebo Comparator|Placebo|
32987268|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
32987269|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
32987270|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
32987271|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
32987272|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
32987273|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
33324444|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
33324445|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
32747359|NCT05096949|No Intervention|Clinic visit arm|Patient will receive Cabenuva injection at the clinic
32987274|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
32987275|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
32987276|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
32987277|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
32987278|NCT01497236|No Intervention|no supplement|
32987279|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
32987280|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
32987281|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
32987282|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
32987283|NCT01497301|No Intervention|Standard Individual Medical Appointment|
32987284|NCT01497301|Active Comparator|Group Visits|
32987285|NCT01497314|Other|Low Lactose Infant Formula|
32987286|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
32987287|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
32987288|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
32987289|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
32987290|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
32987291|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
32987292|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
32987293|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
32987294|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
32987295|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
32987296|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
32987297|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
32987298|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
32987299|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
33324446|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
33324447|NCT03918174|Experimental|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
33324448|NCT03918174|Experimental|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
32987300|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
32987301|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
32987302|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
32987303|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
32987304|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
32987305|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
32987306|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
32987307|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
32987308|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
32987309|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
32987310|NCT01497535|Experimental|Insulin detemir|
33324449|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
33324450|NCT01230294||control|participants without structural heart disease
32987311|NCT01497535|Active Comparator|Insulin glargine|
32987312|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
33324451|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
33324452|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
32987313|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
32987314|NCT01497561|Experimental|insulin detemir|
33324453|NCT05401422|Active Comparator|Pulsed dye laser|Laser
33324454|NCT05401422|Active Comparator|Doxycycline|Drug
32747360|NCT05096949|Experimental|Home visit arm|Patient will receive Cabenuva injection at home
32987315|NCT01497561|Active Comparator|insulin NPH|
32987316|NCT01497574|Experimental|Insulin detemir|
32987317|NCT01497574|Active Comparator|Insulin glargine|
32987318|NCT01497587|Experimental|Insulin detemir|
32747361|NCT05699265||Fabry Disease Follow-Up Patients|
32987319|NCT01497600|Experimental|insulin detemir|
32987320|NCT01497600|Active Comparator|insulin NPH|
32987321|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
32987322|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
32987323|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
32987324|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
32987325|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
32987326|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
32987327|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
32987328|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
32987329|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
33324455|NCT05401422|Active Comparator|Brimonidine gel 0.33%|Topical drug
33324456|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
33324457|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
33324458|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
33324459|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
33324460|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
33324461|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
33324462|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
33324463|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
33324464|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
33324465|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
33324466|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
32987330|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
32987331|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
32987332|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
32987333|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
32987334|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
32987335|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
32987336|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
32987337|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
32987338|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
32987339|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
32987340|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
32987341|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
33324467|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
32987342|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
32987343|NCT01497210|Experimental|EASH|
32987344|NCT01497847||travelers to tropical destinations|
32987345|NCT01497873|Experimental|Belotecan|Camtobell Injection
32987346|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
32987347|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
32987348|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
32987349|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
32987350|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
32987351|NCT01497925|Experimental|ADI-PEG 20|
32987352|NCT01497951|Experimental|Aminolaevulinic acid|
32987353|NCT01497951|Placebo Comparator|Placebo|
32987354|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
32987355|NCT01497977|Experimental|soya phytoestrogens|
32987356|NCT01497977|Experimental|red clover phytoestrogens|
32987357|NCT01497977|No Intervention|No drugs|
32987358|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
32987359|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
32987360|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
32987361|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
32987362|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
32987363|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
33324468|NCT01138410|Experimental|SCIB1|
33324469|NCT01135602|Experimental|Topiramate|1 group
33324470|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
33324471|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
33324472|NCT05401344||dry nose patients|
33324473|NCT05401344||normal controls|
33324474|NCT05401188|Active Comparator|hospitalization group|Patients in the hospitalization group, once the surgical intervention was finished, were transferred to the postoperative recovery unit and later they were discharged to the usual hospital ward. Patients received adequate intravenous fluid resuscitation based on their individual hemodynamic parameter and fluid balance, and they received analgesia according to personal requirement. In the hospital ward, the usual patient management protocols were followed until a complete recovery and consequently discharged according to the usual criteria.
32987364|NCT01498055||CIK therapy group|
32987365|NCT01498055||control group|
32987366|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
32987367|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
32987368|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
32987369|NCT01498081|Placebo Comparator|Single doses of placebo|
32987370|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
32987371|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
32987372|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
32987373|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
32987374|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
32987375|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
32987376|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
32987377|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
32987378|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
32987379|NCT01498172|Experimental|NMIBC at high risk of progression|
32987380|NCT01498172|Experimental|NMIBC at low risk of progression|
32987381|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
32987382|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
32987383|NCT01498211|Experimental|Biopsy|
32987384|NCT01498224|Active Comparator|Suture|Suture application
32987385|NCT01498224|Experimental|ReSure Sealant|Sealant application
32987386|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
32987387|NCT01498250||basal cell carcinoma|
32987388|NCT01498250||non-lesional skin|
32987389|NCT01498315||Women following hysterecomy|
32987390|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
32987391|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
32987392|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
32987393|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
32987394|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
32987395|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
32987396|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
32987397|NCT01498432|Experimental|Heliox21|
32987398|NCT01498432|Active Comparator|Air O2|
32987399|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
32987400|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
32987401|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
32987402|NCT01498523|Experimental|raw camel milk|
32987403|NCT01498523|Experimental|camel milk powder solution|
32987404|NCT01498523|Active Comparator|raw cow milk|
32987405|NCT01498523|Active Comparator|Glucose solution|
32987406|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
32987407|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
32987408|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
32987409|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
32987410|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
32987411|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
32987412|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
32987413|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
32987414|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~Age greater than 18 years~No evidence of ischemic cerebrovascular injury"
32987415|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
32987416|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
32987417|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
32987418|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
32987419|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
32987420|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
32987421|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
32987422|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
32987423|NCT01498796|Experimental|Ketorolac|
32987424|NCT01498796|Placebo Comparator|Placebo|
32987425|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
32987426|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
32987427|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
32987428|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
32987429|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
32987430|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
32987431|NCT01498874|Placebo Comparator|Placebo|
32987432|NCT01498874|Experimental|low dose gevokizumab|
32987433|NCT01498874|Experimental|high dose gevokizumab|
33413134|NCT05763303|Experimental|intervention group|"received interventional program which will consist of :~-The educational part: will be four sessions (about one hour for each session at 1-week interval) which are delivered by researcher to group of participants (15 participants for each group) after data collection and blood analysis by simplified manner via lectures, group discussions, questions and answers, and slideshows in the study's clinic.~Training part: We will invite every participant to join this part of the program which will be performed in the fitness center of the faculty of physical education, Assiut University. The entire duration of the 8-week exercise training program is closely supervised by 2 qualified personnel. The exercise session includes running or walking on treadmill, and cycling on bicycle ergometer, about 30 minutes, 3 times per week,"
33413135|NCT05763303|Other|control group|traditional care: the participants will received traditional care in health facility but nothing by researcher
32987434|NCT01498900||Repaglinide|
32987435|NCT01498913||Repaglinide|
32987436|NCT01498926|Experimental|Glycerol|
32987437|NCT01498926|Active Comparator|Mannitol|
32987438|NCT01498939|Experimental|IDet 0.2 U/kg|
32987439|NCT01498939|Experimental|IDet 0.4 U/kg|
32987440|NCT01498939|Experimental|IDet 0.8 U/kg|
32987441|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
32987442|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
32987443|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
32987444|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
32987445|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
32987446|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
32987447|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
32987448|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
32987449|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
32987450|NCT01499069|Experimental|Antimuscarinic agents|
32987451|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
32987452|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
32987453|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
32987454|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
32987455|NCT01499212|Experimental|I:E ratio 1:1|
32987456|NCT01499225|Experimental|YH14642 A-I|
32987457|NCT01499225|Experimental|YH14642 A-II|
32987458|NCT01499225|Experimental|YH14642 A-III|
32987459|NCT01499225|Active Comparator|Active Comparator B|
32987460|NCT01499225|Active Comparator|Active Comparator C|
32987461|NCT01499225|Placebo Comparator|Placebo|
32987462|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
32987463|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
32987464|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
32987465|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
32987466|NCT01499264|Active Comparator|Traditional Dressing|
32987467|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
32987468|NCT01499316|Experimental|Room Air|
32987469|NCT01499329||Patient receiving stent therapy|
32987470|NCT01499381||Routine prostate biopsy patients|
32987471|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
32987472|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
33413136|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
33413137|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
32987473|NCT01499407|Active Comparator|Standard abciximab bolus|
32987474|NCT01499407|Experimental|ClearWay-infused abciximab|
32987475|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
32987476|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
32987477|NCT01499433|Experimental|caspofungin|
32987478|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
32987479|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
32987480|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
32987481|NCT01499446|Placebo Comparator|Placebo|
32987482|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
32987483|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
32987484|NCT01499472|Other|normal wound care|standard of care intervention
32987485|NCT01499485|Experimental|Acetazolamide|
32987486|NCT01499485|Placebo Comparator|placebo|
32987487|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
32987488|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
32987489|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
32987490|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
32987491|NCT01499589||RA in block room|Performing regional anesthesia in the block room
32987492|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
32987493|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
32987494|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
32987495|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
32987496|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
32987497|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
32987498|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
32987499|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
32987500|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
32987501|NCT01499641|Experimental|None epidural steroid|
32987502|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
32987503|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
32987504|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
32987505|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
32987506|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
32987507|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
32987508|NCT01499719||Surgical checklist|Compliance for surgical checklist
32987509|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
32987510|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
32987511|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
32987512|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
32987513|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
32987514|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
33413138|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
32987515|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
32987516|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
32987517|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
32987518|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
32987519|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
32987520|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
32987521|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
33413139|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
32987522|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
32987523|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
32987524|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
32987525|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
32987526|NCT01499901|Experimental|sequential|implantation bilateral sequential
32987527|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
32987528|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
32987529|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
32987530|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
32987531|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
32987532|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
32987533|NCT01499966|Experimental|group POP|PLASTER OF PARIS
32987534|NCT01499966|Experimental|TG|TUBIGRIP
32987535|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
32987536|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
32987537|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
32987538|NCT01499992|No Intervention|standard care|
32987539|NCT01500005|Experimental|vitamin D|Baby D3 drops
32987540|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
32987541|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
32987542|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
32987543|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
32987544|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
32987545|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
32987546|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
33413140|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
32987547|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
32987548|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
32987549|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
32987550|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
32987551|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
33413141|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
33413142|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
33413143|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
32987552|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
32987553|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
32987554|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
32987555|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
32987556|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
32987557|NCT01500148|Experimental|Intevention-PMVr Procedure|
32987558|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
32987559|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
32987560|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
32987561|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
32987562|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
32987563|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
32987564|NCT01500291||Anesthesiologist|
32987565|NCT01500291||Nurse anesthetist|
32987566|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
32987567|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
32987568|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
32987569|NCT01500343|Experimental|Saccharomyces boulardii|
32987570|NCT01500343|Placebo Comparator|Placebo|
32987571|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
32987572|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
32987573|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
32987574|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
32987575|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
33413144|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
33413145|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
33413146|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
32987576|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
32987577|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
32987578|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
32987579|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
32987580|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
32987581|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
32987582|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
32987583|NCT01500473|Experimental|Females with CCHS > 16 years old on desogetrel|
32987584|NCT01500486||PenMate device|
32987585|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
32987586|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
32987587|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
32987588|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~Device: anodal tDCS~Other: motor Training during physiotherapy"
32987589|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
32987590|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
32987591|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
32987592|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
32987593|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
32987594|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
32987595|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
32987596|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
32987597|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
32987598|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
32987599|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
32987600|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
32987601|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
32987602|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
32987603|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
32987604|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
32987605|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
32987606|NCT01500785|Active Comparator|levosimendan|
32987607|NCT01500785|Placebo Comparator|placebo|
32987608|NCT01500798|Placebo Comparator|Placebo|
32987609|NCT01500798|Experimental|Bardoxolone methyl|
32987610|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
32987611|NCT01500824|Experimental|Crizotinib|
32987612|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
32987613|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
32987614|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
32987615|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
32987616|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
32987617|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
32987618|NCT01500863|Active Comparator|hCG|
32987619|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
32987620|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
32987621|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
32987622|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
32987623|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
32987624|NCT01500876|Experimental|Study Arm|Single Arm
32987625|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
32987626|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
32987627|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
32987628|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
32987629|NCT01500915|Experimental|ranibizumab|
32987630|NCT01500941|Active Comparator|probiotics|
32987631|NCT01500941|Placebo Comparator|maltodextrin|
32987632|NCT01500954||squamous cell carcinoma|
32987633|NCT01500954||non-lesional skin|
32987634|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
32987635|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
32987636|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
32987637|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
32987638|NCT01500980|Active Comparator|Sporozoite negative vaccine|
32987639|NCT01500980|Active Comparator|Primaquine placebo|
32987640|NCT01500980|No Intervention|malaria challenge|
32987641|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
32987642|NCT01500993|Experimental|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
32987643|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
32987644|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
32987645|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
32987646|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
32987647|NCT01501045|Experimental|healthy subjects|healthy subjects
32987648|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
32987649|NCT01501058|Experimental|case group|
32987650|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
32987651|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
32987652|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
32987653|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
32987654|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
32987655|NCT01501097|No Intervention|Control group|
32987656|NCT01501097|Experimental|early HV-crrt|
32987657|NCT01501123|Experimental|Haloperidol|IM Haloperidol
32987658|NCT01501123|Active Comparator|IM Midazolam|
32987659|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
32987660|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
32987661|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
32987662|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
32987663|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
32987664|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
32987665|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
32987666|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
32987667|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
32987668|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
32987669|NCT01501214|Active Comparator|Atosiban|
32987670|NCT01501214|Placebo Comparator|Placebo|Normal saline
32987671|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
32987672|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
32987673|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
32987674|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
32987675|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
33413147|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
32987676|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
32987677|NCT01501266||Faslodex|
32987678|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
32987679|NCT01501279|No Intervention|no nerve block|Control group without nerve block
32987680|NCT01501292||Immature oocytes (GV, M-I)|
32987681|NCT01501292||Mature oocytes (M-II)|
32987682|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
32987683|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
32987684|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
32987685|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
32987686|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
32987687|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
32987688|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
32987689|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
32987690|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
32987691|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
32987692|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
32987693|NCT01501409|Experimental|Group I|
32987694|NCT01501409|Active Comparator|Group II|
32987695|NCT01501409|Active Comparator|Group III|
32987696|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
32987697|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
32987698|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
32987699|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
32987700|NCT01501448|Active Comparator|OCP|
32987701|NCT01501448|Active Comparator|Oral estradiol valerate|
32987702|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
32987703|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~TAC chemotherapy~TC chemotherapy~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
32987704|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
32987705|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
32987706|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
32987707|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
33413148|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
33413149|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
33413150|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
32863790|NCT04632888|Experimental|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
32863791|NCT04632888|No Intervention|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.~The control group will be called to fill in the scales for monitoring purposes."
32863792|NCT03048396|Experimental|Uterus transplantation|
32863793|NCT04886466|Experimental|The trunk movement coordinated and legs coordination during walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in post-stroke patients (study group).
32863794|NCT04886466|Experimental|The coordinated movement of the trunk and legs during fast walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in patients with back pain syndrome, but without neurological deficits (control group).
32863795|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
32863796|NCT04537962|Placebo Comparator|Colgate Periogard and Peroxyl®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution
32863797|NCT04537962|Placebo Comparator|Colgate Periogard®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;
32863798|NCT04537962|Placebo Comparator|Colgate Peroxyl®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution
32863799|NCT04537962|Placebo Comparator|Colgate Total 12®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate
32863800|NCT04537962|Active Comparator|Toothpaste with sodium monofluorophosphate|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate
32863801|NCT04537962|Active Comparator|Toothpaste with sodium fluoride and zinc|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin
32863802|NCT04537962|Active Comparator|Toothpaste with tin fluoride|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum
32863803|NCT05240976|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
32863804|NCT05240976|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
32863805|NCT04886076||Participants with RBD|Participants with REM Sleep Behavior Disorder
32863806|NCT04886076||Participants without RBD|Age- and gender-matched controls, without REM Sleep Behavior Disorder
32863807|NCT05205252|Active Comparator|Arm 1-Tazemetostat plus tafasitamab-cxix (CD19 Ab)/lenalidomide in subjects with R/R DLBCL|Patients will receive tazemetostat, tafasitamab, and lenalidomide for approximately 1 year. After approximately 1 year, patients will receive tazemetostat and tafasitamab.
32863808|NCT05205252|Active Comparator|Arm 2-Tazemetostat plus lenalidomide in subjects with R/R DLBCL|Patients will receive tazemetostat and lenalidomide for approximately 1 year. After approximately 1 year, patients will receive tazemetostat alone.
32863809|NCT05205252|Active Comparator|Arm 3-Tazemetostat plus acalabrutinib in subjects with R/R mantle cell lymphoma|Patients will receive tazemetostat and acalabrutinib for the entire study.
32863810|NCT05205252|Active Comparator|Arm 4-Tazemetostat plus daratumumab/pomalidomide/dexamethasone in subjects with R/R multiple myeloma|Patients will receive tazemetostat, daratumumab, pomalidomide, and dexamethasone for the entire study. Daratumumab may be given intravenously or subcutaneously during this study.
32863811|NCT05205252|Active Comparator|Arm 5-Tazemetostat plus mosunetuzumab (CD20/CD3 BsAb) in subjects with R/R follicular lymphoma|Patients will receive tazemetostat and mosunetuzumab for approximately 1 year. After approximately 1 year, patients will receive tazemetostat alone.
32863812|NCT04519086|Experimental|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI > 30 Laparoscopic appendectomy
32863813|NCT04486560|Experimental|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
32863814|NCT04126733|Experimental|Regorafenib + Nivolumab|
32863815|NCT04387734|Experimental|Ocrevus|
32863816|NCT04387734|Active Comparator|Other Disease Modifying Treatments|Other Disease Modifying Treatments will consist of FDA-approved injectable and oral medications for multiple sclerosis.
32863817|NCT04128605|Experimental|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
32863818|NCT04128605|Active Comparator|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
33413151|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
33413152|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
32987708|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
32987709|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
32987710|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
32987711|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
32987712|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
32987713|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
32987714|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
32987715|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
32987716|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
32987717|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
32987718|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
32987719|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
32987720|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
32987721|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
32987722|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
32987723|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
33413153|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
32987724|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
32987725|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
32987726|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
32987727|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
32987728|NCT01501643|Active Comparator|Spirometry|Spirometry
32987729|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
32987730|NCT01501669|No Intervention|Capecitabine alone arm|X arm
33413154|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
32987731|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
32987732|NCT01501682||primary suture|operated with primary suture
32987733|NCT01501682||other mesh|operated with insertion of another mesh
32987734|NCT01501682||ventralex|operated with insertion of ventralex mesh
32987735|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
32987736|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
32987737|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
32987738|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
32987739|NCT01501721|Experimental|Exercise|Home-based exercise program
32987740|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
33413155|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
33413156|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
32987741|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~200 patients will visit the outpatient clinic for congestive heart failure.~Approximately 30% will be eligible for this study."
32987742|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
32987743|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
32987744|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
32987745|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
32987746|NCT01501773|Experimental|Autologous bone marrow stem cell|
32987747|NCT01501773|No Intervention|Control|
32987748|NCT01501786|Sham Comparator|control|propofol and saline are administered
32987749|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
32987750|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
32987751|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
32987752|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
32987753|NCT01501799|Placebo Comparator|Vehicle Gel|
32987754|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
32987755|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
32987756|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
32987757|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
32987758|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
32987759|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
32987760|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
32987761|NCT01501825|Experimental|four channels|"Four channels:~10 Hz over the left PFC.~1 Hz over the right PFC.~10 Hz over the left parietal cortex.~1 Hz over the right parietal cortex."
32987762|NCT01501864|Experimental|School Support Group|School Support Intervention
32987763|NCT01501864|No Intervention|Control|No school support
32987764|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
33324475|NCT05401188|Experimental|outpatient group|Patients in the outpatient group , once operated, were transferred to the surgery unit without admission and were later discharged home if they met the ALDRETE criteria in less than 23 hours after the intervention (following the surgery criteria without admission stages). If the patient was operated during the night shift, following the advice of major outpatient surgery where overnight stays are allowed, the patient was admitted to the post-anesthetic recovery unit and discharged the next day, always in less than 23 hours. In case of being discharged after 23 hours or not meeting ALDRETE criteria, it was considered a failure of the outpatient treatment.
33324476|NCT05308212|Experimental|FLU-M Tetra w/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (with preservative) intramuscularly
32987765|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
32987766|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
32987767|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
32987768|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
32987769|NCT01501903|Other|Fanning|Biopsy using fanning technique
32987770|NCT01501916|Experimental|vitamin d|
32987771|NCT01501916|Placebo Comparator|Placebo|
32987772|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
32987773|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
32987774|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
32987775|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
32987776|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
32987777|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
32987778|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
32987779|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
32987780|NCT01502020|Active Comparator|Zyclara™|
32987781|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
32987782|NCT01502020|Placebo Comparator|Vehicle Cream|
32987783|NCT01502046|Experimental|Sativex|
32987784|NCT01502046|Placebo Comparator|Placebo|
32987785|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
32987786|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
32987787|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
33324477|NCT05308212|Experimental|FLU-M Tetra w/o/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (without preservative) intramuscularly.
33324478|NCT05308212|Active Comparator|Ultrix|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Ultrix vaccine.
33324479|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
32987788|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
32987789|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
32987790|NCT01502124|Active Comparator|Lyophilized|
32987791|NCT01502124|Experimental|Liquid|
32987792|NCT01502137|Experimental|ESRD patients|
32987793|NCT01502137|Experimental|Healthy subjects|
32987794|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
32987795|NCT01502163|No Intervention|Control|"No prewarming~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~Passive insulation with Thermoflect™ material.~All fluids administrated intraoperative will be warmed."
32987796|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
32987797|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
32987798|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
32987799|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
32987800|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
32987801|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
32987802|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
32987803|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
32987804|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
32987805|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
32987806|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
32987807|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
32987808|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
32987809|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
32987810|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
32987811|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
32987812|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
32987813|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
32987814|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
32987815|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
32987816|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
32987817|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
32987818|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
32987819|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
32987820|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
32987821|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
32987822|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
32987823|NCT01502475||Veteran Attitudes toward CAM|
32987824|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
32987825|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
32987826|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
32987827|NCT01502566|No Intervention|Control group|This group will receive no intervention
32987828|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
32987829|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
32987830|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
32987831|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
32987832|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
32987833|NCT01502670|Experimental|Lung Nodule|
32987834|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
32987835|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
32987836|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
32987837|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
32987838|NCT01502696|Experimental|PEG IFN alfa-2b|
32987839|NCT01502696|No Intervention|Observation|
32987840|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
32987841|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
32987842|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
32987843|NCT01502735|Experimental|DENV-1 PIV (high dose)|
32987844|NCT01502735|Experimental|DENV-1 PIV (low dose)|
32987845|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
32987846|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
32987847|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
32987848|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
32987849|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
32987850|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
32987851|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
32987852|NCT01502826||Group A|less insulin-resistant
32987853|NCT01502826||Group B|severely insulin-resistant
32987854|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
32987855|NCT01502852||OEF/OIF Veterans with TBI|
32987856|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
32987857|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
32987858|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
32987859|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
32987860|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
32987861|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
32987862|NCT01502891|No Intervention|Normal care|
32987863|NCT01502904|Active Comparator|Cypher group|
32987864|NCT01502904|Experimental|Nobori group|
32987865|NCT01502904|Active Comparator|Pravastatin group|
32987866|NCT01502904|Active Comparator|Pitivastatin group|
32987867|NCT01502904|Active Comparator|Non-ARB group|
32987868|NCT01502904|Experimental|ARB group|
32987869|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
32987870|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
32987871|NCT01502930|No Intervention|REG|Registration only
32987872|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
32987873|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
32987874|NCT01502943|Experimental|Qi deficiency and blood stasis G|
32987875|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
32987876|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
32987877|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
32987878|NCT01502982|Experimental|Chemoimmunotherapy|
32987879|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
32987880|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
33413157|NCT03602534||cases with variable acne severity scores|"group will include 50 females~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~Assessment of body mass index (BMI)~blood serum samples will be collected from all patients to do thyroid function test"
33413158|NCT03602534||healthy controls|"group will include 29 females~Assessment of body mass index (BMI)~blood serum samples will be collected from all healthy controls to do thyroid function test"
33413159|NCT05764161|Experimental|Ruxolitinib 1.5% Cream|Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
33413160|NCT05764161|Placebo Comparator|Vehicle Cream|Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
33413161|NCT02972801||Testicular tissue biopsy|Testicular biopsy
33413162|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
33413163|NCT04788017|Active Comparator|ziresovir|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
33413164|NCT04788017|Placebo Comparator|placebo|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
33413165|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
33413166|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
33413167|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
33413168|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
33413169|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
33413170|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
33413171|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
33413172|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
33413173|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
33413174|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
33413175|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
33413176|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
33413177|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
33413178|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
33413179|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
33413180|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
33413181|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
33413182|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
33413183|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
33413184|NCT04896827||Healthy participants|Healthy participants (n=144)
33413185|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
33413186|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
33413187|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
33413188|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
33413189|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
33413190|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
33413191|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
32987881|NCT01503008|Experimental|Sustained Behavior Change system support|
32987882|NCT01503008|Active Comparator|Control|
32987883|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
33413192|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
33413193|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
32987884|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
32987885|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
32987886|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
32987887|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
32987888|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
32987889|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
32987890|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
32987891|NCT01503073|Active Comparator|Real stimulation|real NIBS
32987892|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
32987893|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
32987894|NCT01503099||Controls India|Healthy subjects serving as controls
32987895|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
32987896|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
32987897|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
32987898|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
32987899|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
32987900|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
32987901|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
32987902|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
32987903|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
32987904|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
32987905|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
32987906|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
32987907|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
32987908|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
32987909|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
33413194|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
32987910|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
32987911|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
32987912|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
32987913|NCT01503255|Experimental|cognitive behavioral group therapy|
32987914|NCT01503255|Active Comparator|health education group|
32987915|NCT01503268|Active Comparator|Percutaneous ablation|
32987916|NCT01503268|Active Comparator|Surgical ablation|
32987917|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
32987918|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
32987919|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
32987920|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
32987921|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
32987922|NCT01503320|Experimental|Enteral glutamine|
32987923|NCT01503320|Placebo Comparator|Placebo|
33413195|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
33413196|NCT05266677|Experimental|EXPL|Liquid oral supplement comprising a blend of glycerides at certain proportions
32987924|NCT01503346|Experimental|herbal medicine|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
32987925|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
33413197|NCT05266677|Other|CTRL|Liquid oral supplement comprising glycerides used in current formulas
32987926|NCT01503359|Placebo Comparator|Placebo|Control Group
32987927|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
32987928|NCT01503372|Active Comparator|Arm B: FLO|
32987929|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
32987930|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
32987931|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
32987932|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
32987933|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
32987934|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
32987935|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
32987936|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
32987937|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
32987938|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
32987939|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
32987940|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
32987941|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
32987942|NCT01503502|Experimental|flumatinib 400mg qd|
32987943|NCT01503502|Experimental|flumatinib 600 mg qd|
32987944|NCT01503502|Active Comparator|imatinib|
32987945|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
32987946|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
32987947|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
32987948|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
32987949|NCT01503567||Subjects 6 to 18 years old without inhibitors|
33413198|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
32987950|NCT01503567||Subjects 6 to 18 years old with inhibitors|
32987951|NCT01503567||Subjects above18 years old without inhibitors|
32987952|NCT01503567||Subjects above 18 years old with inhibitors|
32987953|NCT01503580|Experimental|antimuscarinic drug|
32987954|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
32987955|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
32987956|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
32987957|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
32987958|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
32987959|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
32987960|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
32987961|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
32987962|NCT01503736|Placebo Comparator|Placebo|
32987963|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
32987964|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
32987965|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
32987966|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
32987967|NCT01503775||TRUFILL® DCS Orbit Galaxy|
32987968|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
32987969|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
32987970|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
33413199|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
33413200|NCT03171129|Experimental|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
33413201|NCT03171129|Active Comparator|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
33413202|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
33413203|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
33413204|NCT05232669|Active Comparator|Cocoa extract + multivitamin|
33413205|NCT05232669|Active Comparator|Cocoa extract + multivitamin placebo|
33413206|NCT05232669|Active Comparator|Cocoa extract placebo + multivitamin|
33413207|NCT05232669|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
33413208|NCT05214105||Patients with sickle cell anemia|Prospective longitudinal study of patients with sickle cell anemia
33413209|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
33413210|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
33413211|NCT03590834|Active Comparator|Active Control|Active comparison group
33413212|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
33413213|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
33413214|NCT05082597|Experimental|ESWT|Receive low energy extracorporeal shock wave therapy
33413215|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
33413216|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
33413217|NCT05050617||Acute Pulmonary Embolism|Subjects in this single cohort will undergo point-of-care echocardiography at the time of presentation and subsequent follow up to assess for short term adverse events or complications.
33413218|NCT03913286|Experimental|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
33413219|NCT04856943|Experimental|smartconsent group|Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
33413220|NCT04856943|Placebo Comparator|control group|Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
33413221|NCT03599336|Other|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
33413222|NCT03599336|Other|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
33413223|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
33413224|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
33413225|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
33413226|NCT02237924|Experimental|endostar + IMRT|
33413227|NCT02237924|Active Comparator|DDP + IMRT|
33413228|NCT04855227||Laparoscopic ventral hernia repair|These subjects will undergo a laparoscopic primary umbilical or incisional hernia repair.
33413229|NCT04855227||Robotic-assisted ventral hernia repair|These subjects will undergo a robotic-assisted primary umbilical or incisional hernia repair.
33413230|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
33413231|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
32987971|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
32987972|NCT01503814|No Intervention|Control (Usual Care)|Control
33413232|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
33413233|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
33413234|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
32863819|NCT04345068|Experimental|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., ~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
32863820|NCT04345068|Active Comparator|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., ~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
32863821|NCT04311606|Experimental|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
32863822|NCT04311606|Experimental|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
32863823|NCT04311606|Placebo Comparator|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
32863824|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
32863825|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
32863826|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
32863827|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
32863828|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
32863829|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
32863830|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
32863831|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
32863832|NCT03997799|Experimental|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
32863833|NCT03997799|Experimental|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
32863834|NCT03825965|Experimental|MPL-001 (CBD: THC 25:1)|125mg CBD/5 mg THC oil for oral use
32863835|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
32863836|NCT04885842|Experimental|Study Group|injection I-PRF with brackets
32863837|NCT04885842|No Intervention|Control Group|applying brackets only
32863838|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
32898602|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
32898603|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
32898604|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
32898605|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
32898606|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
32987973|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
32987974|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
32987975|NCT01503827|No Intervention|Observation|No Intervention
32987976|NCT01503840|Active Comparator|Sugammadex|
32987977|NCT01503840|Placebo Comparator|Sodium chloride solution|
32987978|NCT01503866|Experimental|20 mg bardoxolone methyl|
32987979|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
32987980|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
32987981|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
32987982|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
32987983|NCT01503918|Experimental|Valaciclovir/Aciclovir|
32987984|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
32987985|NCT01503918|No Intervention|control|
32987986|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no other psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
32987987|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
32987988|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
32987989|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
32987990|NCT01503970|Experimental|Chondrocyte implantation|
32987991|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
32987992|NCT01503996||glaucoma|hospitalized glaucoma patients
32987993|NCT01503996||controls|hospitalized patients without glaucoma
32987994|NCT01504009|Experimental|Muscle strength|
32987995|NCT01504022|No Intervention|Control group.|Control group.
32987996|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
32987997|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
32987998|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
32987999|NCT01504048|Experimental|Chromoendoscopy|
32988000|NCT01504061|Experimental|Mederma Ultra Gel|
32988001|NCT01504061|Active Comparator|Mederma N&I|
32988002|NCT01504074||Patients suffering on CME secondary to cataract surgery|
32988003|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
32988004|NCT01504087||patient without deep venous thrombosis|
32988005|NCT01504100||femoral internal rotation|
32988006|NCT01504100||no femoral internal rotation|
32988007|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
32988008|NCT01504113||Study 2 case group|Patients who have received targeted therapy
33413235|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
32988009|NCT01504113||study 2 control group|Psoriasis patients without target therapy
32988010|NCT01504126|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32988011|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
32988012|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
32988013|NCT01504139|Experimental|LH in the luteal phase|
32988014|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
32988015|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
32988016|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
32988017|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
32988018|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
32988019|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
32988020|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
32988021|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
32988022|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
33413236|NCT04851795|Experimental|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
33413237|NCT04851795|Other|unsupervised physical exercise sessions|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
33413238|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
33413239|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
33413240|NCT02260193|Experimental|AKB-6548, starting dose 1|
33413241|NCT02260193|Experimental|AKB-6548, starting dose 2|
33413242|NCT02260193|Experimental|AKB-6548, starting dose 3|
33413243|NCT05763147|Experimental|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)
33413244|NCT05763147|Active Comparator|PosiFlush™ Pre-filled Flush Syringes (BD, USA)|PosiFlush™ Pre-filled Flush Syringes (BD, USA)
33413245|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
33413246|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
33413247|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
33413248|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
33413249|NCT04819035||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
33413250|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
33413251|NCT04306029|No Intervention|Pre-Intervention|
33413252|NCT04306029|Experimental|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
33413253|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
33413254|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
33413255|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.~Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.~Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
33413256|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.~Patients who are due to commence maintenance Niraparib treatment."
33413257|NCT02238158||Chronic Obstructive Pulmonary Disease|
33413258|NCT02238314|Experimental|Tipranavir low dose|
33413259|NCT02238314|Experimental|Tipranavir high dose|
33413260|NCT05764005|Experimental|Intervention website|
33413261|NCT05764005|Active Comparator|Control MUSIC website|This is usual care and all urologists are encouraged to refer their patients to the patient educational materials on the MUSIC website (http://www.musicurology.com/patientmaterials/).
33413262|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
33413263|NCT03587168||Healthy Controls|Healthy People
33413264|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
33413265|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
33413266|NCT04752657|Experimental|Experimental Group|The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
33413267|NCT04752657|Active Comparator|Control Group|The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
33413268|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
32988023|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
32988024|NCT01504191|Experimental|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
32988025|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
32988026|NCT01504230||health older adults|
32988027|NCT01504230||Osteoporosis participants|
32988028|NCT01504243||Control|normal person under medical examination
32988029|NCT01504243||sepsis|SIRS plus inflammation
32988030|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
32988031|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
32988032|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
32988033|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
32988034|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
32988035|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
33324480|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
33413269|NCT04703595||50 non-smoking patients with chronic cough|50 non-smoking patients aged between 30 and 99 years with chronic and / or refractory cough as the only manifestation or associated with gastroesophageal reflux
33413270|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
32988036|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
32988037|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
32988038|NCT01504321|Active Comparator|Active|
32988039|NCT01504321|Placebo Comparator|Placebo|
32988040|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
32988041|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
32988042|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
32988043|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
32988044|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
32988045|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
32988046|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
32988047|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
32988048|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
32988049|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
32988050|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
32988051|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
32988052|NCT01504438|Other|STAR Total Ankle Replacement|
32988053|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
32988054|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
32988055|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
32988056|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
32988057|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
32988058|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
32988059|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
32988060|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
32988061|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
32988062|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
32988063|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
32988064|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
33324481|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
33324482|NCT01138488|Experimental|NN5401|
33324483|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
32988065|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
32988066|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
32988067|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
32988068|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
32988069|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
32988070|NCT01504581|Experimental|HM10660A|
32988071|NCT01504581|Active Comparator|Pegasys|
32988072|NCT01504581|Placebo Comparator|HM10660A Placebo|
32988073|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
32988074|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
32988075|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
32988076|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
32988077|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
32988078|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
32988079|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
32988080|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
32988081|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
32988082|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
32988083|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
32988084|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
32988085|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
32988086|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
32988087|NCT01504698|Experimental|Treatment with manipulation|
32988088|NCT01504698|Active Comparator|Treatment without manipulation|
32988089|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
32988090|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
32988091|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
32988092|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
32988093|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
32988094|NCT01504750|No Intervention|control room|Normal lighted patient room
32988095|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
32988096|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
32988097|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
32988098|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
32988099|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
32988100|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
32988101|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
32988102|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
32988103|NCT01504932|Experimental|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
32988104|NCT01504932|Other|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
32988105|NCT01504945|Active Comparator|RBC transfusion|
32988106|NCT01504945|Placebo Comparator|Normal saline infusion|
32988107|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
32988108|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
33413271|NCT04119375|Active Comparator|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
33413272|NCT04119375|Experimental|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
32988109|NCT01505023|Active Comparator|Partial meal replacement|
32988110|NCT01505023|Experimental|Partial meal replacement with inulin|
32988111|NCT01505023|Active Comparator|Inulin|
32988112|NCT01505023|No Intervention|No intervention|
32988113|NCT01505036|Experimental|SMARTCARE service|U-Health service
32988114|NCT01505036|No Intervention|Usual care|Usual care
32988115|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
32988116|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
32988117|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
32988118|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
32988119|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
32988120|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
32988121|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
32988122|NCT01505101|Active Comparator|Conventional Support Group (SG)|
32988123|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
32988124|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
32988125|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
32988126|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
32988127|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
32988128|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
32988129|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
32988130|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
32988131|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
32988132|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
32988133|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
32988134|NCT01505257|Experimental|END-DSD Intervention|
32988135|NCT01505257|No Intervention|Control|
32988136|NCT01505270||Autistic Children|
32988137|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
32988138|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
32988139|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
32988140|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
32988141|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
32988142|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
32988143|NCT01505322||Thoracic surgery|Lung cancer patients
32988144|NCT01505335||Implant osteotomy measurements|Drilled implant locations
32988145|NCT01505348|Experimental|Fasting|Overnight fast
32988146|NCT01505348|No Intervention|Feeding|Normal breakfast
32988147|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
32988148|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
32988149|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
32988150|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
32988151|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
33413273|NCT04119375|Experimental|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
32988152|NCT01505439|Experimental|Solifenacin group|Once daily
32988153|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
32988154|NCT01505517||individuals with low back pain|
32988155|NCT01505517||healthy controls|
32988156|NCT01505543||chronic obstructive pulmonary disease|
32988157|NCT01505543||healthy matched controls|
32988158|NCT01505556||Diaphragm paresis|
32988159|NCT01505556||Healthy controls|
32988160|NCT01505582|Experimental|Inspiratory muscle training|
32988161|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
32988162|NCT01505595|Experimental|Proprioceptive training|
32988163|NCT01505595|Sham Comparator|Sham proprioceptive training|
32988164|NCT01505621||Young|Healthy adults 18-30 years old
32988165|NCT01505621||Elderly|Healthy adults greater than 65 years old
32988166|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
32988167|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
32988168|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
32988169|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
32988170|NCT01505751||cervical cancer|
32988171|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
32988172|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
32988173|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
32988174|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
32988175|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
32988176|NCT01505790|Experimental|CLOPIDOGREL GROUP|
32988177|NCT01505790|Active Comparator|PRASUGREL GROUP|
32988178|NCT01505803|Active Comparator|Zinc supplement|
32988179|NCT01505803|Active Comparator|Omega 3 supplement|
32988180|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
32988181|NCT01505803|Placebo Comparator|Placebo supplement|
32988182|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
32988183|NCT01505829||Biological validation cohort 1|
32988184|NCT01505829||Response assessment cohort 2|
32988185|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
32988186|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
32988187|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
32988188|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
32988189|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
32988190|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
32988191|NCT01505894|Experimental|BI 409306 low dose|Film-coated tablet
32988192|NCT01505894|Experimental|BI 409306 medium dose|Film-coated tablet
32988193|NCT01505894|Experimental|BI 409306 high dose|Film-coated tablet
32988194|NCT01505894|Experimental|BI 409306 high dose II|Film-coated tablet
32988195|NCT01505894|Placebo Comparator|Placebo|Film-coated tablet
32988196|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
32988197|NCT01505907|Experimental|CXB909 30mg|
32988198|NCT01505907|Experimental|CXB909 60mg|
32988199|NCT01505907|Experimental|CXB909 120mg|Dose
32988200|NCT01505907|Experimental|CXB909 250mg|
32988201|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
32988202|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
32988203|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
32898607|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
32898608|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
32898609|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
32898610|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
32898611|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
32898612|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
32898613|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
32898614|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
32898615|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
32898616|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
32898617|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
32898618|NCT00103844|Experimental|1|Active Comparator
32898619|NCT00103844|Experimental|2|Active Comparator
32898620|NCT01402141|Experimental|Chungkookjang|
32898621|NCT01402141|Placebo Comparator|Placebo|
32898622|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
32898623|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
32898624|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
32898625|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
32898626|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
32898627|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
32898628|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
32898629|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
32898630|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
32898631|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
32898632|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
32898633|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
32898634|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
32898635|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
32898636|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
32898637|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
32898638|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
32898639|NCT01351753|Active Comparator|Metformin|
32898640|NCT01351753|Experimental|Metformin + Orlistat|
32898641|NCT01351753|Experimental|Metformin + Topiramate|
32898642|NCT01351753|Experimental|Topiramate|
32898643|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
32898644|NCT01351753|Placebo Comparator|Placebo|
32898645|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
32898646|NCT01353079|Placebo Comparator|Glycero-COCAs|
32898647|NCT00104234|Other|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
32898648|NCT00104234|Other|Placebo/rhASB|
32898649|NCT01303939|Other|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
32898650|NCT01303939|Other|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
32898651|NCT00104858|Experimental|Treatment|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
32898652|NCT01354015|Experimental|Use of messaging system|Use of DRMS
32898653|NCT01354015|No Intervention|Usual Care|Usual Care
32898654|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
33413274|NCT04119375|Experimental|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.~Further details of the intervention can be found in the study protocol section."
32988204|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
32988205|NCT01505959|Experimental|Conventional|
32988206|NCT01505959|Active Comparator|Telemedicine|
32988207|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
32988208|NCT01505985|Placebo Comparator|Placebo|
32988209|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
32988210|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
32988211|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
32988212|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
32988213|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
32988214|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
32988215|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
32988216|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
32988217|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
32988218|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
32988219|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
32988220|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
32988221|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
32988222|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
32988223|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
32747362|NCT05699187|Experimental|Face Transplant Recipient|The procedure will be carried out simultaneously by two teams of transplant surgeons for each face transplanted in the operation. The teams will be divided between the functions of tissue recovery (donor operation) and transplant surgery (recipient operation). In most cases the facial graft will include the entire nose; the soft tissues of the mid-face, including all its blood vessels, muscles, and nerves; and a significant portion of the mid-facial skeleton.
32988224|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
32988225|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
32988226|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
32988227|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
32988228|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
32988229|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
32988230|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
32988231|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
32988232|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
32988233|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
32988234|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
32988235|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
32988236|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
32988237|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
32988238|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
32988239|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
32988240|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
32988241|NCT01506232||ADHD|Youth diagnosed with ADHD.
32988242|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
32988243|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
32988244|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
32988245|NCT01506245|No Intervention|Control|
32988246|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
32988247|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
32988248|NCT01506258|Experimental|Patients infused with stem cells|
32988249|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
33413275|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
32988250|NCT01506310|No Intervention|Diet alone|
32988251|NCT01506310|Experimental|Behavioral therapy|
32988252|NCT01506310|Experimental|Exercise|
32988253|NCT01506310|Experimental|Behavioral therapy and exercise|
32988254|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
32988255|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
32988256|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
32988257|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
32988258|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
32988259|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
32988260|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
32988261|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
32988262|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
32988263|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
32988264|NCT01506414|Experimental|combination treatment|
32988265|NCT01506427|Experimental|[F-18] HX4|
32988266|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
32988267|NCT01506466|Other|additional examinations/measurements|
32988268|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
32988269|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
32988270|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
32988271|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
32988272|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
32988273|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
32988274|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
32988275|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
32988276|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
32988277|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
32988278|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
32988279|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
32988280|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
32988281|NCT01506557|Experimental|choecalciferol|
32988282|NCT01506557|Placebo Comparator|placebo|
32988283|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
32988284|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
32988285|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
32988286|NCT01506583||General population|This group of participants is primarily an out-patient population.
32988287|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
32988288|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
32988289|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
32988290|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
32988291|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
32988292|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
32988293|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
33413276|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
33413277|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
33413278|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
33413279|NCT05762055|Experimental|Intervention Group|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted for participants in this group
33413280|NCT05762055|Experimental|Control Group|Participants in this arm will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology.
33413281|NCT04749017|Experimental|Experimental group|Avena Sativa L. consumption of 900 mg for 60 days.
33413282|NCT04749017|Placebo Comparator|Control group|Identically appearing placebo capsules consumed for 60 days.
33413283|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
33413284|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
33413285|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.~Frequency: 26g per day.~Total duration: 6-month."
33413286|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
33413287|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
33413288|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
33413289|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
33413290|NCT04658693|Experimental|Multi contact electrode implant and implanted electromyography recording electrodes|"Fifteen subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
33413291|NCT03975621|Experimental|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
33413292|NCT03975621|Experimental|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
33413293|NCT01413815|Active Comparator|L-arginine|L-Arginine
33413294|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
33413295|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
33413296|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
33413297|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
33413298|NCT03968679|Experimental|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
33413299|NCT04646603|Experimental|MRG-001|Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
33413300|NCT04646603|Placebo Comparator|Placebo|Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
33413301|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
33413302|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
32988294|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
32988295|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
32988296|NCT01506687|Experimental|Navigator intervention|
32988297|NCT01506687|Active Comparator|Usual Care Control|Usual care
32988298|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
32988299|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
32988300|NCT01506739|Active Comparator|1|
33324484|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
33324485|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
32988301|NCT01506739|Active Comparator|2|
32988302|NCT01506739|Active Comparator|3|
32988303|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
32988304|NCT01506752|Active Comparator|E2020 current 10 mg without water|
33324486|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
32988305|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
32988306|NCT01506752|Active Comparator|E2020 current 10 mg with water|
32988307|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
33413303|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
32988308|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
32988309|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
32988310|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
32988311|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
32988312|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
32988313|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
32988314|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
32988315|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
32988316|NCT01506817||Controls|healthy aged matched pain-free controls
32988317|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
32988318|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
32988319|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
32988320|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
32988321|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
32988322|NCT01505972|Experimental|Six and three time schedule|
32988323|NCT01505972|Experimental|Four and two time schedule|
32988324|NCT01506869||Type 2 diabetes|
32988325|NCT01506869||Prediabetes|
32988326|NCT01506869||Normal glucose regulation|
32988327|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
32988328|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
32988329|NCT01506921|Active Comparator|Racemic ketamine|
32988330|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
32988331|NCT01506934|Experimental|linifanib|Single Doses
32988332|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
32988333|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
32988334|NCT01506999||control group|subjects without ischemic heart disease (IHD)
32988335|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
32988336|NCT01507012|Placebo Comparator|Placebo|
32988337|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
33324487|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
33413304|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
32988338|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
32988339|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
32988340|NCT01507038|Experimental|Group A|
32988341|NCT01507038|Experimental|Group B|
33413305|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
32988342|NCT01507038|Experimental|Group C|
32988343|NCT01507038|Placebo Comparator|Group D|
32988344|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
32988345|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
32988346|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
32988347|NCT01507077|Experimental|ZGN-440|
32988348|NCT01507116||People with Diabetes|
32988349|NCT01507116||Family Members|
32988350|NCT01507116||Healthcare Professionals|
32988351|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
32988352|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
32988353|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
32988354|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
32988355|NCT01507168|Placebo Comparator|Placebo|
32988356|NCT01507168|Experimental|GC33 (RO5137382)|
32988357|NCT01507194|Active Comparator|Ondansetron 4 mg|
32988358|NCT01507194|Experimental|Vestipitant 6 mg|
32988359|NCT01507194|Experimental|Vestipitant 12 mg|
32988360|NCT01507194|Experimental|Vestipitant 18 mg|
32988361|NCT01507194|Experimental|Vestipitant 24 mg|
32988362|NCT01507194|Experimental|Vestipitant 36 mg|
32988363|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
32988364|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
32988365|NCT01507272|Placebo Comparator|Placebo|
32988366|NCT01507285|Experimental|NNC 90-1170|
32988367|NCT01507285|Placebo Comparator|Placebo|
32988368|NCT01507311|Experimental|NNC 90-1170|
32988369|NCT01507311|Placebo Comparator|Placebo|
32988370|NCT01507337|Experimental|Elderly|
32988371|NCT01507337|Experimental|Young|
32988372|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
32988373|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
32988374|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
32988375|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
33413306|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
32988376|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
32988377|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
32988378|NCT01507389|Experimental|Mild|
32988379|NCT01507389|Experimental|Moderate|
32988380|NCT01507389|Experimental|Severe|
32988381|NCT01507389|Experimental|Normal|
32988382|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
32988383|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
32988384|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
32988385|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
32988386|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
32988387|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
32988388|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
32988389|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
32988390|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
32988391|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
32988392|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
32988393|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
32988394|NCT01507454||Local treatment|
32988395|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
32988396|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
32988397|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
32988398|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
32988399|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
32988400|NCT01507519|Experimental|BioMime™|BioMime™ DES
33413307|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
33413308|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
33413309|NCT01314833|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
33413310|NCT01314833|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
32898655|NCT00047060|Experimental|Stem Cell Transplant Therapy With Campath-1H|Recipients received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x106 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).
32898656|NCT01304407|Other|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
32898657|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
32898658|NCT00106106|Placebo Comparator|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
32898659|NCT00106106|Experimental|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
32898660|NCT01304641||Atorvastatin Initiators|
32898661|NCT01304641||Simvastatin Initiators|
32898662|NCT00107744|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
32898663|NCT00107744|Active Comparator|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
32898664|NCT00107744|Active Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
32898665|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
32898666|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
32898667|NCT04545320|Placebo Comparator|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
32898668|NCT04545320|Experimental|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
32898669|NCT04545320|Experimental|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for ~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
32898670|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
32898671|NCT04442438|Experimental|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
32898672|NCT04442438|Other|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
32898673|NCT04442438|Other|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
32898674|NCT04442438|Other|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
32898675|NCT04442438|Other|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
32898676|NCT04442438|Other|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
32898677|NCT04753112|Experimental|Treatment|"All the subjects will receive sacubitril/valsartan from weeks 6 to 12. From weeks 1-6 and 12-18 patients will be treated with standard therapy for HFpEF according to PA pressures (diuretics and systemic vasodilators if concomitant hypertension).~All the subjects will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).~Device: Patients eligible for this study are those with an already implanted CardioMEMS device.~Drug: Sacubitril/Valsartan Target dose:97/103mg bid"
32898678|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
32898679|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
32898680|NCT04770194|Experimental|Cohort 1: 200mg SP-8008 Prototype Capsule A|Treat 200 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32898681|NCT04770194|Experimental|Cohort 2: 400mg SP-8008 Prototype Capsule A|Treat 400 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32898682|NCT04770194|Experimental|Cohort 3: 800mg SP-8008 Prototype Capsule A|Treat 800 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32988401|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
32988402|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
32988403|NCT01507571|Experimental|Dignity Therapy|
32988404|NCT01507597|Other|Healthy Subjects|
32988405|NCT01507597|Other|T2DM|
32988406|NCT01507597|Other|T1DM|
32988407|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
32988408|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
32988409|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
32988410|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
32988411|NCT01507649|No Intervention|Control|
32988412|NCT01507649|Experimental|Telephone-based intervention|
32988413|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
32988414|NCT01507701|Experimental|Clonidine|
32988415|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
32988416|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
32988417|NCT01507727|Experimental|Drug: Tolvaptan|
32988418|NCT01507727|Placebo Comparator|Drug: Placebo|
32988419|NCT01507740||1|Control group n=20
33413311|NCT01314833|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
32988420|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
32988421|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
32988422|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
32988423|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
32988424|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
32988425|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
32988426|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
32988427|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
32988428|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
32988429|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
32988430|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
32988431|NCT01507844|Sham Comparator|ventilation|
32988432|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
32988433|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
32988434|NCT01507870|Active Comparator|prophylactic onlay mesh|
32988435|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
32988436|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
32988437|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
32988438|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
32988439|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
32988440|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
32988441|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
32988442|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
32988443|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
32988444|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
32988445|NCT01507974|No Intervention|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
32988446|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
32988447|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
32988448|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
32988449|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
32988450|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
32988451|NCT01508065||controlled type one diabetes mellitus.|
32988452|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
32988453|NCT01508104|Experimental|BEZ235 and Everolimus|
33324488|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
33413312|NCT05763927|Experimental|Fruquintinib& Toripalimab& SRT|"Induction treatment:~Fruquintinib 5mg d1-d14； Toripalimab 240 mg intravenously d1；~Consolidation treatment:~SRT: 25 Gy in 5 fractions d22-d26； Fruquitinib 5mg d22-d35，43-56,64-77； Toripalimab 240 mg intravenously d22、43、64；~Surgery: Surgical resection will be performed according to the principles of TME(total mesorectal excision) 2-4 weeks after the last dose administration of Fruquintinib；~Adjuvant chemotherapy: Standard chemotherapy or observation according to the judgement of Principle Investigator and patients' willing."
33413313|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
33413314|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
33413315|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
32988454|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
32988455|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
32988456|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
32988457|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
32988458|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
32988459|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
32988460|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
32988461|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
32988462|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
32988463|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
32988464|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
32988465|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
32988466|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
32988467|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
32988468|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
32988469|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
32988470|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
33413316|NCT04577781|Experimental|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
32988471|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
32988472|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
33413317|NCT04577781|Placebo Comparator|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
33413318|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
33413319|NCT02737826|Active Comparator|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
33413320|NCT02737826|Placebo Comparator|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
33413321|NCT02737826|Experimental|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
33413322|NCT05761977||Patient with extensive small-cell lung cancer|extensive small-cell lung cancer
33413323|NCT03367715|Experimental|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
33413324|NCT03963063|Active Comparator|Non Goal-directed Care Group|
33413325|NCT03963063|Experimental|Goal-directed Care Group|
33413326|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
33413327|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
33413328|NCT05762913|Experimental|Diaphragm release|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
33413329|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
33413330|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
33413331|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
33413332|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
33413333|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
33413334|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
33413335|NCT04064931||general population|Women of childbearing age in general examination.
33413336|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
33413337|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
33413338|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
33413339|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
33413340|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
33413341|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
33413342|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
33413343|NCT05761899|Experimental|Gene-Corrected Macrophages|Autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments.
33413344|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
32988473|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
33413345|NCT05437679||Active Surveillance (AS) Controls|Patients with low or very low risk prostate cancer who have been on active surveillance for 5 or more years with a stable PSA or on active surveillance for 2 or more years with negative multiparametric MRI (mpMRI) or mpMRI with a fusion biopsy(ies) confirming low risk disease.
32988474|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
32988475|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
32988476|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
32988477|NCT01508338|Placebo Comparator|Placebo|
32988478|NCT01508338|Experimental|HMB|
33413346|NCT05437679||High Risk Localized Prostate Cancer (HRLPC)|Men with high-risk localized prostate cancer, defined as stage pT3a or Gleason score greater than or equal to 8 and/or pre-prostatectomy PSA of greater than or equal to 20 ng/mL.
32988479|NCT01508338|Experimental|ATP and HMB|
32988480|NCT01508338|Experimental|ATP|
32988481|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
32988482|NCT01508364||Group 1|
32988483|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
32988484|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
32988485|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
32988486|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
32988487|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
32988488|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
32988489|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
32988490|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
32988491|NCT01508481||Diabetes high risk group|
32988492|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
32988493|NCT01508494|Placebo Comparator|placebo|placebo
32988494|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
32988495|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
32988496|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
32988497|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
32988498|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
32988499|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
32988500|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
32988501|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
32988502|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
32988503|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
32988504|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
32988505|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
32988506|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
32988507|NCT01508624|No Intervention|Control|participants will receive standard usual care
32988508|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
32988509|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
33413347|NCT05437679||Biochemically Recurrent Localized Prostate Cancer (BCRLPC)|Systemic and/or hormonal treatment naive men with localized prostate cancer (pathological stages pT2, pT3a or pT4 with TNM N0 or N1 and M0 disease) who have clinical suspicion of biochemical recurrence 2 - 5 months following radical prostatectomy and are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days.
32988510|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
32988511|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
32988512|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
32988513|NCT01508637|Experimental|Diesel Exhaust + placebo|
32988514|NCT01508637|Sham Comparator|Filtered Air + terazosin|
32988515|NCT01508637|Sham Comparator|Filtered air + placebo|
32988516|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
32988517|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
32988518|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
32988519|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
32988520|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
32988521|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
32988522|NCT01508728|Experimental|Active vibration|
32988523|NCT01508728|Placebo Comparator|Placebo Vibration|
32988524|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
32988525|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
32988526|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
32988527|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
32988528|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
32988529|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
32988530|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
32988531|NCT01508793|No Intervention|Control|
32988532|NCT01508793|Experimental|Optimize Sleep|
32988533|NCT01508806|Experimental|Normal renal function|
32988534|NCT01508806|Experimental|Mild renal impairment|
32988535|NCT01508806|Experimental|Moderate renal impairment|
32988536|NCT01508806|Experimental|Severe renal impairment|
32988537|NCT01508806|Experimental|End-stage renal disease|
32988538|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
32988539|NCT01508819||2|no intervention
32988540|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
32988541|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
32988542|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
32988543|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
32988544|NCT01508858|Experimental|Treatment period 1|
32988545|NCT01508858|Placebo Comparator|Treatment period 2|
32988546|NCT01508871||Cardiomyopathy|
32988547|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
32988548|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
32988549|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
32988550|NCT01508897|Experimental|Phase 2 formulation|
32988551|NCT01508897|Experimental|Phase 3 formulation|
32988552|NCT01508923|Experimental|Treatment period 1|
32988553|NCT01508923|Placebo Comparator|Treatment period 2|
32988554|NCT01508949|Experimental|NNC 90-1170|
32988555|NCT01508949|Placebo Comparator|Placebo|
32988556|NCT01508975|Experimental|white rice|White rice
32988557|NCT01508975|Experimental|Brown rice|Brown Rice
32988558|NCT01508975|Experimental|Glucose|Glucose
32988559|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
32988560|NCT01508988|Experimental|Eye drops 1 µg/mL|
32988561|NCT01508988|Experimental|Eye drops 3 µg/mL|
32988562|NCT01508988|Experimental|Eye drops 10 µg/mL|
32988563|NCT01508988|Experimental|Eye drops 20 µg/mL|
32988564|NCT01508988|Experimental|Eye drops 30 µg/mL|
32988565|NCT01508988|Experimental|Eye drops placebo|
32988566|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
32988567|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
32988568|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
32988569|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
32988570|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
32988571|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
32988572|NCT01509027|Placebo Comparator|Standard Care|standard care
32988573|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
32988574|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
32988575|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
32988576|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
32988577|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
32988578|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
32988579|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
32988580|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
32988581|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
32988582|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
32988583|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
32988584|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
32988585|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
32988586|NCT01509196|Experimental|HIP0901|Fenofibric acid
32988587|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
32988588|NCT01509209|Placebo Comparator|Placebo|placebo
32988589|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
32988590|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
32988591|NCT01509222|No Intervention|Control|No intervention, control group.
32988592|NCT01509235|Experimental|1. Exercise testing and self drainage session|
32988593|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
32988594|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
32988595|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
32988596|NCT01509274|Experimental|Plasma|
32988597|NCT01509274|Sham Comparator|Saline|
32988598|NCT01509274|Active Comparator|Physiotherapy + heel cap|
32988599|NCT01509300|Experimental|HAPLO|
32988600|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
32988601|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
32988602|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
32988603|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
32988604|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
32988605|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
32988606|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
32988607|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
32988608|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
32988609|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
32988610|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
32988611|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
32988612|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
32988613|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
32988614|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
32988615|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
32988616|NCT01509456|Active Comparator|Potassium Bicarbonate|
32988617|NCT01509456|No Intervention|Control|
32988618|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
32988619|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
32988620|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
32988621|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
32988622|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
32988623|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
32988624|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
32988625|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
32988626|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
32988627|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
32988628|NCT01509521|Active Comparator|Ephedrine|
32988629|NCT01509521|Active Comparator|Phenylephrine|
32988630|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
32988631|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
32988632|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
32988633|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
32988634|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
32988635|NCT01509651|Experimental|Sugammadex|
32988636|NCT01509703|Experimental|High flow therapy|
32988637|NCT01509729|Placebo Comparator|Sham operation|
32988638|NCT01509729|Active Comparator|Knee arthroscopic surgery|
32988639|NCT01509742|Experimental|NNC 90-1170|
32988640|NCT01509742|Placebo Comparator|Placebo|
32988641|NCT01509755|Placebo Comparator|Placebo|
32988642|NCT01509755|Experimental|0.045 mg|
32988643|NCT01509755|Experimental|0.225 mg|
32988644|NCT01509755|Experimental|0.45 mg|
32988645|NCT01509755|Experimental|0.60 mg|
32988646|NCT01509755|Experimental|0.75 mg|
32988647|NCT01509755|Active Comparator|Glim|
32988648|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
32988649|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
32988650|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
32988651|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
32988652|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
32988653|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
32988654|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
32988655|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
32988656|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
32988657|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
32988658|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
32988659|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
32988660|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
32988661|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
32988662|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
32988663|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
32988664|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
32988665|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
32988666|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
32988667|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
32988668|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
32988669|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
32988670|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
32988671|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
32988672|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
32988673|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
32988674|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
32988675|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
32988676|NCT01510041|Experimental|Inspiratory muscle training group|
32988677|NCT01510041|Experimental|Respiratory exercise group|
32988678|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
32988679|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
32988680|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
32988681|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
33413348|NCT05437679||Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC)|Patients with evidence of non-metastatic castration-resistant prostate cancer (i.e. localized prostate cancer patients with clinical symptoms of disease progression and/or evidence of a rising PSA following hormone therapy) who are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days and who have not started a new therapy for treatment of their castration-resistant prostate cancer.
33413349|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
33413350|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
32988682|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
32988683|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
32988684|NCT01510171|Active Comparator|Prasugrel loading dose|
32988685|NCT01510171|Active Comparator|Ticagrelor Loading dose|
32988686|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
32988687|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
32988688|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
32988689|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
32988690|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
32988691|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
32988692|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
32988693|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
32988694|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
32988695|NCT01510288|Experimental|Ipilimumab and GVAX|
32988696|NCT01510301|Other|Self-report|
32988697|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
32988698|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
32988699|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
32988700|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
32988701|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
32988702|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
33413351|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
33413352|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
32988703|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
32988704|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
32988705|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
32988706|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
32988707|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
32988708|NCT01510496||Patients who had inguinal herniorraphy.|
32988709|NCT01510496||Patients who had hysterectomy.|
32988710|NCT01510496||Patients who had thoracotomy.|
32988711|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
33413353|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
32988712|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
32988713|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
32988714|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
32988715|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
32988716|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
32988717|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
32988718|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
32988719|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
32988720|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
32988721|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
32988722|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
32988723|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
32988724|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
32988725|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
32988726|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
32988727|NCT01510626|Experimental|One|
32988728|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
32988729|NCT01510639|No Intervention|Cuff repair Control|No intervention
32988730|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
32988731|NCT01510639|No Intervention|NEER Control|No intervention
32988732|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
32988733|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
32988734|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
32988735|NCT01510691||Epiretinal membrane|
32988736|NCT01510691||diabetic macular edema|
32988737|NCT01510691||vein occlusion|
32988738|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
32988739|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
32988740|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
32988741|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
32988742|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
32988743|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
32988744|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
32988745|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
32988746|NCT01510795|No Intervention|retrospective control|
32988747|NCT01510795|Active Comparator|spironolactone|
32988748|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
32988749|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
32988750|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
32988751|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
32988752|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
32988753|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
32988754|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
32988755|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
32988756|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
32988757|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
32988758|NCT01510886||1|
32988759|NCT01510899|Experimental|Healthy Subjects Arm|
32988760|NCT01510899|Experimental|Renal Impaired Subjects Arm|
32988761|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
32988762|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
32988763|NCT01510951|Placebo Comparator|PLACEBO|
32988764|NCT01510951|Experimental|AMG 811|
32988765|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
32988766|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
32988767|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
32988768|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
32988769|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
32988770|NCT01511003|Experimental|Tacrolimus group|oral
32988771|NCT01511029|Experimental|Dexpramipexole|
32988772|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
32988773|NCT01511029|Active Comparator|Moxifloxacin|
32988774|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
32988775|NCT01511120|Active Comparator|Tetraspan|
32988776|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
32988777|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
32988778|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
32988779|NCT01511159|Experimental|NNC 90-1170, initial dose|
32988780|NCT01511159|Experimental|NNC 90-1170|
32988781|NCT01511159|Active Comparator|Insulin|
32988782|NCT01511159|Experimental|NNC 90-1170, final dose|
32988783|NCT01511172|Experimental|NNC 90-1170 + Met|
32988784|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
32988785|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
32988786|NCT01511172|Active Comparator|Met + Glim|
33413354|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
32988787|NCT01511185|Experimental|NNC 90-1170|
32988788|NCT01511185|Placebo Comparator|Placebo|
32988789|NCT01511185|No Intervention|Healthy|
32988790|NCT01511198|Experimental|0.045 mg|
32988791|NCT01511198|Experimental|0.225 mg|
32988792|NCT01511198|Experimental|0.45 mg|
32988793|NCT01511198|Experimental|0.60 mg|
32988794|NCT01511198|Experimental|0.75 mg|
32988795|NCT01511198|Active Comparator|Met|
32988796|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
32988797|NCT01511211|Active Comparator|Ropivacaine-Only Block|
32988798|NCT01511224||Colistin monotherapy|
32988799|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
32988800|NCT01511224||Non-colistin containing regime|
32988801|NCT01511224||Glycopeptide with colistin combination|
32988802|NCT01511224||Colistin with loading dose|
32988803|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
32988804|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
32988805|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
32988806|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
33413355|NCT05763849|Experimental|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance, food exposure, and body image exposure.
33413356|NCT05763849|Active Comparator|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) focuses on parent-enforced contingencies, increasing value of eating, and decreasing the value of food avoidance.
32988807|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
32988808|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
32988809|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
32988810|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
32988811|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
32988812|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
32988813|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
32988814|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
32988815|NCT01511341|Experimental|Telenursing|
32988816|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
32988817|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
32988818|NCT01511367|Active Comparator|Flutiform|
32988819|NCT01511367|Active Comparator|Seretide|
32988820|NCT01511367|Active Comparator|Flixotide|
32988821|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
32988822|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
32988823|NCT01511393||Questionnaire|None. Non-interventional study.
32988824|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
32988825|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
32988826|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
32988827|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
32988828|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
32988829|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
32988830|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
32988831|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
32988832|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
32988833|NCT01511497|Experimental|PF-04427429|
32988834|NCT01511497|Placebo Comparator|Placebo|Normal saline
32988835|NCT01511510|Experimental|PF-04958242|
32988836|NCT01511510|Placebo Comparator|Placebo|
32988837|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
32988838|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
32988839|NCT01511549|Experimental|Dose 1|SAR113945 low dose
32988840|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
32747363|NCT05536479|Experimental|Autogenous stored mineralized dentin graft (ASMDG)|Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction
32988841|NCT01511549|Experimental|Dose 3|SAR113945 high dose
32988842|NCT01511549|Placebo Comparator|Placebo|Placebo
32988843|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
32988844|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
32988845|NCT01511627|Active Comparator|General Anesthesia|
32988846|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
32988847|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
32988848|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
32988849|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
32988850|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
32988851|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
32988852|NCT01511692|Experimental|Lira --> placebo|
32988853|NCT01511692|Placebo Comparator|Placebo --> glim|
32988854|NCT01511692|Active Comparator|Glim --> lira|
32988855|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
32988856|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
32988857|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
32988858|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
32988859|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
32988860|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
32988861|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
32988862|NCT01511744|No Intervention|Blank control|
32988863|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
32988864|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
32988865|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
32988866|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
32988867|NCT01511783|Experimental|E2609|E2609 at ascending doses
32988868|NCT01511783|Placebo Comparator|Placebo|
32988869|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
32988870|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
32988871|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
32988872|NCT01511822|Placebo Comparator|Placebo|
32988873|NCT01511835|Experimental|Myo-inositol powder|
32988874|NCT01511835|Experimental|Myo-inositol soft gel capsules|
32988875|NCT01511835|Placebo Comparator|Folic acid|
32988876|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
32988877|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
32988878|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
32988879|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
32988880|NCT01511887|No Intervention|No treatment|No treatment
32988881|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
32988882|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
32988883|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
32988884|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
32988885|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
32988886|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
32988887|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
32988888|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
32988889|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
32988890|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
32988891|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
32988892|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
32988893|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
32988894|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
32988895|NCT01512017|Active Comparator|Veloderm|
32988896|NCT01512017|Placebo Comparator|Vaseline|
32988897|NCT01512043|Experimental|1. Breathing control|Description ...
32988898|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
32988899|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
32988900|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
32988901|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
33105087|NCT02908022|Experimental|Longitudinal|"Phase 2:~Prior to first MRI session, both clinician and patient will go through a training visit.~During the first MRI session, the patient will receive experimental pressure pain to the left leg via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief.~Following the first MRI session, the patient will attend biweekly acupuncture treatment sessions with the clinician (6 treatments total). During the first session the clinician will be introduced to the patient and do a general intake in addition to the acupuncture treatment.~The final MRI session will be identical to the first. The patient will receive experimental pressure pain via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief."
32988902|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
32988903|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
32988904|NCT01512082|Experimental|Active pulsed electromagnetic field|
32988905|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
32988906|NCT01512095|Experimental|Norditropin®|
32988907|NCT01512095|Active Comparator|Nutropin AQ®|
32988908|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
32988909|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
32988910|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
32988911|NCT01512173|Experimental|propranolol gel|
32988912|NCT01512173|Placebo Comparator|Placebo|
32988913|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
32988914|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
32988915|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
32988916|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
33413357|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
32988917|NCT01512238||Pharmaceutical care|
32988918|NCT01512238||Control|
32988919|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
32988920|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
32988921|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
33413358|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
33413359|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
32988922|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
32988923|NCT01512290|Placebo Comparator|sham treatment|
32988924|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
32988925|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
33413360|NCT01330745|Other|aortic valve replacement|
33413361|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
32988926|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
32988927|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
32988928|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
33413362|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
32988929|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
32988930|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
32988931|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
32988932|NCT01512355|Experimental|dexmedetomidine|
32988933|NCT01512355|Placebo Comparator|placebo|
32988934|NCT01512381|Experimental|CRT|
32988935|NCT01512381|Active Comparator|pacemaker|
32988936|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
32988937|NCT01512394|Experimental|No bowel prep|No bowel prep
32988938|NCT01512420||Cohort|
32988939|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
32988940|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
32988941|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
32988942|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
32988943|NCT01512472|Active Comparator|10 month degarelix therapy|
32988944|NCT01512472|Active Comparator|4 month degarelix therapy arm|
32988945|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
32988946|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
32988947|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
32988948|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
32988949|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
33413363|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
33413364|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
33413365|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
33413366|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
33413367|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
33413368|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
32988950|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
32988951|NCT01512537|Active Comparator|UVB|UVB exposed group
32988952|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
32988953|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
32988954|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
32988955|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
32988956|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
32988957|NCT01512563|Active Comparator|Covered Metal Stent|
32988958|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
32988959|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
32988960|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
32988961|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
32988962|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
32988963|NCT01512615|Experimental|Control group|Usual care
32988964|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
32988965|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
32988966|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
32988967|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
32988968|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
32988969|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
32988970|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
32988971|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
32988972|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
32988973|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
32988974|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
33413369|NCT05762757|Experimental|Colposcopy educational material|Participants will complete a 9-question quiz that will assess knowledge of colposcopy. They will then view the colposcopy educational material and answer the same 9-question quiz to assess their knowledge of colposcopy. Participants will complete the Acceptability Intervention Measure, the Intervention Appropriateness Measure, and the Feasibility of Intervention Measure. Participants will also be asked whether the educational material influences their intention to adhere to colposcopy.
33413370|NCT03636191|Experimental|Probiotic|
33413371|NCT03636191|Placebo Comparator|Placebo|
33413372|NCT05763771|Experimental|Part 1|Participants will use the app for 4 weeks, during which participants will follow a smoking schedule on the app to help you reduce your cigarette consumption
32988975|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
32988976|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
32988977|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
32988978|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
32988979|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
32988980|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
32988981|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
32988982|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
32988983|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
32988984|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
32988985|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
32988986|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
32988987|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
32988988|NCT01512732||Parkinson's disease patients|(n=30).
32988989|NCT01512732||Major depressive disorder patients|(n=30).
32988990|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
32988991|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
32988992|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
32988993|NCT01512823|Experimental|Didactic educational intervention|Education alone
32988994|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
32988995|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
32988996|NCT01512862|Experimental|Calcitriol|
32988997|NCT01512862|No Intervention|Placebo|
32988998|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
32988999|NCT01512901|Experimental|1|
32989000|NCT01512901|Experimental|2|
32989001|NCT01512901|Sham Comparator|3|
32989002|NCT01512914|Placebo Comparator|CONTROL group|
32989003|NCT01512914|Experimental|PREOPERATIVE nebulization|
32989004|NCT01512914|Experimental|POSTOPERATIVE nebulization|
32989005|NCT01512914|Active Comparator|INSTILLATION group|
32989006|NCT01512927||ESRD with regular hemodialysis|
32989007|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
32989008|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
32989009|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
32989010|NCT01512992|Experimental|Home telehealth|
32989011|NCT01512992|No Intervention|Usual care|
32989012|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
32989013|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
32989014|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
32989015|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
32989016|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
32989017|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
32989018|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
32989019|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
32989020|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
32989021|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
32989022|NCT01513083|Experimental|Mild hepatic dysfunction|
32989023|NCT01513083|Experimental|Moderate hepatic dysfunction|
32989024|NCT01513083|Experimental|Normal hepatic function|
32989025|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
32989026|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
32989027|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
32989028|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
32989029|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
32989030|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
32989031|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
33413373|NCT05763771|Experimental|Part 2|"Participants will also use the app for the duration of the study (about 3 months).~Participants will be asked to record your smoking using the app and complete online surveys"
32989032|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
32989033|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
32989034|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
33413374|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
32989035|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
32989036|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
32989037|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
32989038|NCT01513252|Experimental|1|Gröber and Buschke test
32989039|NCT01513265|Active Comparator|RASP|
32989040|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
32989041|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
32989042|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
32989043|NCT01513304|Experimental|Chiropractic manual therapy|
32989044|NCT01513343|Experimental|Parent and child classes|Parent and child groups focused on self-regulation of eating
32989045|NCT01513343|No Intervention|Treatment as usual|Treatment as usual
32989046|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
32989047|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
32989048|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
32989049|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
32989050|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
32989051|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
32989052|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
32989053|NCT01513421||Active vacuum pressure drainage|
32989054|NCT01513421||Free drainage|
32989055|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
32989056|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
32989057|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
32989058|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
32989059|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
32989060|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
32989061|NCT01513525|Experimental|Abdomen|
32989062|NCT01513525|Experimental|Thigh|
32989063|NCT01513525|Experimental|Upper arm|
32989064|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
32989065|NCT01513577|Experimental|Minimal invasive pedicular screw|
32989066|NCT01513577|Experimental|Standard open insertion|
32989067|NCT01513603|Experimental|CLAG-M|
32989068|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
32989069|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
32989070|NCT01513642|Other|Incentive spirometry|
32989071|NCT01513642|No Intervention|Breath Stacking|
32989072|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
32989073|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
32989074|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
32989075|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
32989076|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
32989077|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
32989078|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
32989079|NCT01513707||Hemodialysis group|Hemodialysis group
32989080|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
32989081|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
32989082|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
32989083|NCT01513733|Experimental|Tasquinimod single dose|
32989084|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
32989085|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
32989086|NCT01513772|Placebo Comparator|Control|
32989087|NCT01513772|Active Comparator|Dexmedetomidine|
32989088|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
32989089|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
32989090|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
32989091|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
32989092|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
32989093|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
32989094|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
32989095|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
32989096|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
32989097|NCT01513850|Experimental|Hepabulin IV|
32989098|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
32989099|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
32989100|NCT01513863|Placebo Comparator|Placebo|
32989101|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
32989102|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
32989103|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
32989104|NCT01513954||IVF population|Long Lupron IVF Population
32989105|NCT01513954||IUI patients|Patients undergoing IUI
32989106|NCT01513980|No Intervention|Control group|Treatment as usual
32989107|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
32989108|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
32989109|NCT01513993|No Intervention|Control group|Treatment as usual
32989110|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
32989111|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
32989112|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
32989113|NCT01514019|Placebo Comparator|Placebo|
32989114|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
32989115|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
32989116|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
32989117|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
32989118|NCT01514071|Experimental|Pop-up picture|
32989119|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
32989120|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
32989121|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
32989122|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
32989123|NCT01514097||Fractures reduced|
32989124|NCT01514097||Fractures splinted|
32989125|NCT01514110|Experimental|RAD001|
32989126|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
32989127|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
32989128|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
32989129|NCT01514188|Active Comparator|Doxorubicin|
32989130|NCT01514188|Experimental|INNO-206|
32989131|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
32989132|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
32989133|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
32989134|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
32989135|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
32989136|NCT01514253|Experimental|infant formula|Materna RTF stage 1
32989137|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
32989138|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
32989139|NCT01514266|Placebo Comparator|Placebo|
32989140|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
32989141|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
32989142|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
32989143|NCT01514409|Experimental|5-Hydroxytryptophan|
32989144|NCT01514409|Placebo Comparator|Placebo|
32989145|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
32989146|NCT01514487|Experimental|pH 7.7|
32989147|NCT01514487|Experimental|pH 7.9|
32989148|NCT01514487|Experimental|pH 8.15|
32989149|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
32989150|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
32989151|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
32989152|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
32989153|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
32989154|NCT01514578|Experimental|TRV130A|
32989155|NCT01514578|Placebo Comparator|Dextrose in Water|
32989156|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
32989157|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
32989158|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
33105088|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
33413375|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
33413376|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
33413377|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
33413378|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
33413379|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
33413380|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
33413381|NCT01130519|Experimental|1|All patient will be receiving fixed starting dose of bevacizumab (10 mg/kg IV every 2 weeks) and erlotinib (150 mg/day PO)
33413382|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
33413383|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
33413384|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
33413385|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
33413386|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
33413387|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
33413388|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
33413389|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
33413390|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
33413391|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
33413392|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
33413393|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
33413394|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
33413395|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
32989159|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
33105089|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
33413396|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
33413397|NCT02970942|Experimental|Semaglutide 0,1 mg|
33413398|NCT02970942|Experimental|Semaglutide 0,2 mg|
33413399|NCT02970942|Experimental|Semaglutide 0,4 mg|
33413400|NCT02970942|Placebo Comparator|Placebo 1|
33413401|NCT02970942|Placebo Comparator|Placebo 2|
33413402|NCT02970942|Placebo Comparator|Placebo 3|
33413403|NCT04359069|Experimental|Urinary catheter removal on postoperative day 1|
33413404|NCT04359069|Active Comparator|Urinary catheter removal on postoperative day 3|
33413405|NCT05433311|Active Comparator|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
33413406|NCT05433311|No Intervention|Routine|Only routine treatment
33413407|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
33413408|NCT05429723|Experimental|HS-10383|HS-10383 was administered at 8 am on the first day, 4 dose levels
32989160|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
32989161|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
32989162|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
32989163|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
32989164|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
32989165|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
32989166|NCT01514695|Experimental|Fentanyl|Fentanyl arm
32989167|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
32989168|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
32989169|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
32989170|NCT01514747||ELBW infants|
32989171|NCT01514773||ICD placement|Those subjects who have an ICD.
32989172|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
32989173|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
32989174|NCT01514799|Experimental|Long BP limb|200 cm BP limb
32989175|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
32989176|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
32989177|NCT01514825|Experimental|YM150 low dose group|
32989178|NCT01514825|Experimental|YM150 middle dose group|
32989179|NCT01514825|Experimental|YM150 high dose group|
32989180|NCT01514825|Placebo Comparator|placebo group|
32989181|NCT01514838|Experimental|1941 group|Once daily over a 24-week treatment period
33413409|NCT05429723|Placebo Comparator|HS-10383 Placebo|Matching placebo to HS-10383 was administered at 8 am on the first day, 4 dose levels
32989182|NCT01514838|Active Comparator|acarbose group|Once daily over a 24-week treatment period
32989183|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
32989184|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
32989185|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
32989186|NCT01514890||Telaprevir|
32989187|NCT01514890||Boceprevir|
32989188|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
32989189|NCT01514903|Experimental|HIP0908|
32989190|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
32989191|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
32989192|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
32989193|NCT01514929|Placebo Comparator|Placebo|Placebo
32989194|NCT01514942|Other|Insulin resistant patients|
32989195|NCT01514942|Other|Non-insulin resistant patients|
32989196|NCT01514968|Experimental|DNV/r+cyclosporine|
32989197|NCT01514968|Active Comparator|cyclosporine|
32989198|NCT01514968|Active Comparator|danoprevir+ritonavir|
32989199|NCT01514981|Experimental|AMG 761|
32989200|NCT01514981|Placebo Comparator|Placebo|
32989201|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
32989202|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
32989203|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
32989204|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
32989205|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
32989206|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
32989207|NCT01515085||biopsy proven glioma, no prior treatment|
32989208|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
33413410|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
32989212|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
32989213|NCT01515163|Experimental|Exercise|3-month exercise training program
32989214|NCT01515163|No Intervention|Control|Control group
32989215|NCT01515163|Experimental|Healthy control|
32989216|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
32989217|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
32989218|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
33413411|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
32989219|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
32989220|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
32989221|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
32989222|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
32989223|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
33105090|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
32989224|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
32989225|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
32989226|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
32989227|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
32989228|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
32989229|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
32989230|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
32989231|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
33413412|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
33413413|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
33413414|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
33413415|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
33413416|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
32989232|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
32989233|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
32989234|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
32989235|NCT01515384|Experimental|Type 1 Diabetes|
32989236|NCT01515384|Experimental|Type 2 Diabetes|
32989237|NCT01515384|Experimental|Healthy Controls|
33413417|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
32989238|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
32989239|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
32989240|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
32989241|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
33413418|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
32989242|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
32989243|NCT01515553|Experimental|Formulation 4|
32989244|NCT01515553|Experimental|Final formulation 4|
32989245|NCT01515579|Experimental|Formulation 3|
32989246|NCT01515579|Experimental|Formulation 4|
32989247|NCT01515592|Experimental|15 mcg/kg|
32989248|NCT01515592|Experimental|20 mcg/kg|
32989249|NCT01515592|Experimental|25 mcg/kg|
32989250|NCT01515631||Study|Patients with alagille syndrome
33105091|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
33105092|NCT00548067|Active Comparator|1|
33105093|NCT00548067|Active Comparator|2|
33105094|NCT00548067|Active Comparator|3|
33105095|NCT00548067|Experimental|4|
33413419|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
33413420|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
33413421|NCT05763693|Active Comparator|Azithro-Azithro|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
33413422|NCT05763693|Active Comparator|Azithro-Placebo|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of matching placebo at the day 21 follow-up
33413423|NCT05763693|Active Comparator|Placebo-Azithro|A single oral dose of placebo at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
33413424|NCT05763693|Placebo Comparator|Placebo-Placebo|A single oral dose of placebo at baseline and a single oral dose of matching placebo at the day 21 follow-up
33413425|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
33413426|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
33413427|NCT03995121||Schizophrenia and other psychotic disorders|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
33413428|NCT03995121||Cannabis Use Disorder|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
33413429|NCT03995121||Healthy Control|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
33413430|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
33413431|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
33413432|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
33413433|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
33413434|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
33413435|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
33413436|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
33413437|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
33413438|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
33413439|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
33413440|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
33413441|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
33413442|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
33413443|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
33413444|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
33413445|NCT04873817||IonicRF Generator and compatible accessories|IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.
33413446|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
33413447|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
33413448|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
32898683|NCT04770194|Experimental|Cohort 4: 800 mg SP-8008 Prototype Capsule B|Treat 800 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32898684|NCT04770194|Experimental|Cohort 5: 1200 mg SP-8008 Prototype Capsule B|Treat 1200 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32898685|NCT04770194|Experimental|Cohort 6: 1800 mg SP-8008 Prototype Capsule B|Treat 1600 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
32898686|NCT05606588|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for the duration of their medical therapy, in addition to usual care.
32898687|NCT05606588|No Intervention|Control group|The control group receives treatment as usual. The control group will be given the opportunity to participate in the intervention after therapy.
32989251|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
33413449|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
33413450|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
33413451|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
33413452|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
33413453|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
33413454|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
33413455|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
33413456|NCT05202717|Experimental|PHENIX U4+|Electrical stimulation treatment for patients with urinary incontinence using a new type of pelvic floor therapy instrument
33413457|NCT05202717|Active Comparator|Traditional pelvic floor electrical stimulation therapy instrument|Electrical stimulation treatment for patients with urinary incontinence using traditional pelvic floor therapy instrument
33413458|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
33413459|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
33413460|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
33413461|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
33413462|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
33413463|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
33413464|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
33413465|NCT03574922|No Intervention|Control|Assessments only
33413466|NCT04869137|Experimental|Lenvatinib plus Pembrolizumab|Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab.
33413467|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
33413468|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
33413469|NCT00364637|Active Comparator|Total intravenous anesthesia|
33413470|NCT00364637|Experimental|sevoflurane|
33413471|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
33413472|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
33413473|NCT01989104||Children|6-12 years of age
33413474|NCT01989104||Adolescents|13-17 years of age
33413475|NCT01989104||Young adults|18-20 years of age
33413476|NCT03077789|Experimental|TRABECULOTOMY|
33413477|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
32989252|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
33413478|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
33413479|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
33413480|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
33413481|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
33413482|NCT02903238|Experimental|Placebo|placebo capsule
33413483|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
33413484|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
33413485|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
33413486|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
33413487|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
33413488|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
33413489|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
33413490|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
33413491|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
33413492|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
32989253|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
32989254|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
33413493|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
32989255|NCT01515683|Experimental|An anaesthetic nurse|
32989256|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
32989257|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
32989258|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
32989259|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
32989260|NCT01515722|Experimental|Health education intervention (HEI)|
32989261|NCT01515722|No Intervention|No intervention|
32989262|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
32989263|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
32989264|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
32989265|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
32989266|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
32989267|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
32989268|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
32989269|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
32989270|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
32989271|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
32989272|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
32989273|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
32989274|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
32989275|NCT01515852|Other|Stress level after general anesthesia|
32989276|NCT01515852|Other|Stress level after local anesthesia|
32989277|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
32989278|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
32989279|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
32989280|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
32989281|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
32989282|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
32989283|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
32989284|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
32989285|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
32989286|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
32989287|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
32989288|NCT01516021|Experimental|low fat yoghurt intake|
32989289|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
32989290|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
33324489|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
33413494|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
32989291|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
32989292|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
32989293|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
32989294|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
32989295|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
32989296|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
32989297|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
32989298|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
32989299|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
32989300|NCT01516151|Other|Group D|Standard of care
32989301|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
32989302|NCT01516164|Active Comparator|MacIntosh|
32989303|NCT01516164|Active Comparator|McGrath MAC direct|
32989304|NCT01516164|Active Comparator|McGrath MAC indirect|
32989305|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
32989306|NCT01516229||Somatropin|
32989307|NCT01516242||NovoPen® 4|
32989308|NCT01516255|Experimental|Double-blind / liraglutide|
32989309|NCT01516255|Placebo Comparator|Double-blind / placebo|
32989310|NCT01516255|Active Comparator|Open-label / moxifloxacin|
32989311|NCT01516255|Placebo Comparator|Open-label / placebo|
32989312|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
32989313|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
32989314|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
32989315|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
32989316|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
32989317|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
32989318|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
32989319|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
32989320|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
32989321|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
32989322|NCT01516359||patients with cardiac surgery|
32989323|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
32989324|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
32989325|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
32989326|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
32989327|NCT01516385||spinal cord injury|
32989328|NCT01516385||other neurological conditions|
32989329|NCT01516398||Preterm infants|No interventions were performed. Group consisted of preterm infants enrolled in the study.
32989330|NCT01516398||Term control infants|No interventions were performed. Group consisted of term infants enrolled in the study to serve as controls for the preterm infant group.
32989331|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
32989332|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
32989333|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
33324490|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
33324491|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
32989334|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
32989335|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
32989336|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
32989337|NCT01516463|Active Comparator|Collagenase Santyl|
32989338|NCT01516463|Sham Comparator|Bacitracin|
32989339|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
32989340|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
32989341|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
32989342|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
32989343|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
32989344|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
32989345|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
32989346|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
32989347|NCT01516502|Active Comparator|laser to acupoint|
32989348|NCT01516502|Sham Comparator|sham laser to acupoint|
32989349|NCT01516502|Active Comparator|laser to trigger point|
32989350|NCT01516502|Sham Comparator|sham laser to trigger point|
32989351|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
32989352|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
32989353|NCT01516528||All|All subjects enrolled in the study
32989354|NCT01516554|Experimental|Testosterone undecanoate|
32989355|NCT01516554|Placebo Comparator|Sugar pill|
32989356|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
32989357|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
32989358|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
32989359|NCT01516645|Experimental|KHK2898|
32989360|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
32989361|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
32989362|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
32989363|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
32989364|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
32989365|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
32989366|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
32989367|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
32989368|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
33324492|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
33324493|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
33324494|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
33324495|NCT05295498|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
32989369|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
32989370|NCT01516788|Experimental|Phototesting|
32989371|NCT01516801|Experimental|PSA flyer|
32989372|NCT01516801|No Intervention|Control|
32989373|NCT01516814|Experimental|Arm 1|
32989374|NCT01516814|Active Comparator|Arm 2|
32989375|NCT01516814|Active Comparator|Arm 3|
32989376|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
32989377|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
32989378|NCT01516840|Experimental|Arm 1|
32989379|NCT01516840|Experimental|Arm 2|
32989380|NCT01516840|Active Comparator|Arm 3|
32989381|NCT01516840|Active Comparator|Arm 4|
32989382|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
32989383|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
32989384|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
32989385|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
32989386|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
32989387|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
32989388|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
32989389|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
32989390|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
33413495|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
33413496|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
33413497|NCT03650946||2|men with rising PSA after local definitive treatments
33413498|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
33413499|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
33413500|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
33413501|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
33413502|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
33413503|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
32989391|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
32989392|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
32989393|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
32989394|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
32989395|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
32989396|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
32989397|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
32989398|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
32989399|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
32989400|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
32989401|NCT01517165|Experimental|Group 1|
32989402|NCT01517165|Placebo Comparator|Group 2|
32989403|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
32989404|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
32989405|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
32989406|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
32989407|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
32989408|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
33413504|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks.
33413505|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, and then every 4 weeks through Week 21.
33413506|NCT01329887|Other|administration of ketanserin|
33413507|NCT01334099|Experimental|Radiation combined with CP-675,206|
33413508|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
33413509|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
32898688|NCT01409239|Active Comparator|Subcutaneous Insulin|
32898689|NCT01409239|Experimental|Intravenous insulin|
32898690|NCT00108524|Experimental|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
32898691|NCT00108524|Active Comparator|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
32898692|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
32898693|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
32898694|NCT05606354|Experimental|Intervention group (Group A)|"STRECHING EXERCISES:~A. HAMSTRING MUSCLE STRECHING.~B. CALF MUSCLE STRECHING:~2. STRENGTHENING EXCERCISES: 2 exercises will be performed on targeted muscle group Quadriceps. A. QUADRICEP MUSCLE (with ankle weight). B. QUADRICEP MUSCLE (straight leg raise).~3. KNEE RANGE OF MOTION EXERCISES: (FLEXION AND EXTENSION)~4. FUNCTIONAL EXERCISES:~A. SIT TO STAND:~B. CLIMBING STAIRS:~KINESIO TAPING The following KT application techniques will be used for intervention group after identifying the goal. Goal - A: Proprioception Stimulation and Mechanical Correction Tape Technique-A: (Strip Cutting Shape: One Y-shaped + two I-shaped strips).~Goal B: Lymphatic Correction and Muscle Correction Tape Technique-B: (Strip Cutting Shape: Two Y-shaped + two I-shaped strips)."
32898695|NCT05606354|Other|control group (Group.B)|GROUP.B - (CONTROL) - EXERCISES ONLY WITHOUT KINESIO TAPE The exercise types and dosage will be exactly the same for control group (as in experimental group (as mentioned above) But no kinesio tape will be given to this group.
32898696|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
32898697|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
32898698|NCT05606276|Active Comparator|Cycling exercise|Cycling on a cycle ergometer instead of doing the experimental eccentric exercise.
32898699|NCT05606276|Experimental|Eccentric exercise|Perform 2 sets of maximal eccentric contractions as the single session exercise intervention.
32898700|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy.
32898701|NCT00052442|Experimental|135 mg/m^2 Pralatrexate 1/2 weeks|Pralatrexate (PDX) 135 mg/m^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.
32898702|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 3/4 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.
32898703|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 6/7 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
32898704|NCT00052442|Experimental|45 mg/m^2 Pralatrexate 6/7 weeks|PDX 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
32898705|NCT00052442|Experimental|270 mg/m^2 Pralatrexate 2/4 weeks|PDX (270 mg/m^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.
32898706|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
32898707|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
32898708|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
32898709|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:~Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~text message, email, or visual cue dose reminders"
32898710|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
32989409|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
32989410|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
32989411|NCT01517256|Experimental|Early Intervention Group|
32989412|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
32989413|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
32989414|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
32989415|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
32989416|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
32989417|NCT01517321|Experimental|E|
32989418|NCT01517321|Placebo Comparator|P|
32989419|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
32989420|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
32989421|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
32989422|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
32989423|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
33413510|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
33413511|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
32989424|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
32989425|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
32989426|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
32989427|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
32989428|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
32989429|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
32989430|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
32989431|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
32989432|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
32989433|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
32989434|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
32989435|NCT01517490||Healthy|Healthy volunteers.
32989436|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
32989437|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
32989438|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
32989439|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
32989440|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
32989441|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
32989442|NCT01517555|Experimental|Liraglutide|
32989443|NCT01517555|Placebo Comparator|Placebo|
32989444|NCT01517568|Experimental|Liraglutide|
32989445|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
32989446|NCT01517607||Mesalazine|
32989447|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
32747364|NCT05536479|Active Comparator|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze
32747365|NCT05544825|Experimental|Ice plant group|This group takes ice plant extract for 12 weeks.
32989448|NCT01517620|No Intervention|no intervention|
32989449|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
32989450|NCT01517646|No Intervention|Fat Reduction|
32989451|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
32989452|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
32989453|NCT01517789|Experimental|Patients|
32989454|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
32989455|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
32989456|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
32989457|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
32989458|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
32989459|NCT01517854|Active Comparator|Revatio|
32989460|NCT01517854|Placebo Comparator|Placebo|
32989461|NCT01517906|Experimental|Cognitive behavioral counseling|
32989462|NCT01517906|Active Comparator|Supportive therapy|
32989463|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
32989464|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
32989465|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
32989466|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
32989467|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
32989468|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
32989469|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
32989470|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
32989471|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
32989472|NCT01518010|Experimental|GamePlay|
32989473|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
32989474|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
32989475|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
32989476|NCT01518036|Experimental|Low dose|
32989477|NCT01518036|Experimental|High dose|
32989478|NCT01518062|Experimental|Low dose|
32989479|NCT01518062|Experimental|Medium dose|
32989480|NCT01518062|Experimental|High dose|
32989481|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
32989482|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
32989483|NCT01518088|Experimental|Low dose dietary fiber|
32989484|NCT01518088|Experimental|High dose dietary fiber|
32989485|NCT01518088|Placebo Comparator|No added fiber|
32989486|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
32989487|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
32989488|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
32989489|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
32989490|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
33105096|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
32989491|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
33413512|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
33413513|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
32989492|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
32989493|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
32989494|NCT01518166|Experimental|Trial period A|
32989495|NCT01518166|Experimental|Trial period B|
32989496|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
32989497|NCT01518179|Other|Control|Routine follow up and treatment
32989498|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
32989499|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
32989500|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
32989501|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
32989502|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
32989503|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
32989504|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
32989505|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
32989506|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
33413514|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
32989507|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
32989508|NCT01518348|Experimental|Patch Test|
32989509|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
32989510|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
32989511|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
32989512|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
32989513|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
32989514|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
33413515|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
33413516|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
33413517|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
33413518|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
32989515|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
32989516|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
32989517|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
32989518|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
32898711|NCT01410565|Active Comparator|Apaziquone|
32898712|NCT01410565|Placebo Comparator|Placebo|Placebo
32898713|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
32898714|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
32898715|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
32898716|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
32898717|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
32898718|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
32898719|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
32898720|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
32898721|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
32898722|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
32898723|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
32898724|NCT01309867|Experimental|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
32898725|NCT01309867|Active Comparator|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
32898726|NCT04351633||osteoporosis patient|
32898727|NCT01357525|Other|Stereotactic Body Radiotherapy|
32898728|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
32898729|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
32898730|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
32898731|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
32898732|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
32898733|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
32898734|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
32898735|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
32898736|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
32898737|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
32898738|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
32898739|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
32898740|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
32898741|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
32898742|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
32898743|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
32898744|NCT01362127|Active Comparator|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
32898745|NCT01362127|Active Comparator|Chemotherapy|Arm II: Chemotherapy + surgery
32898746|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
32898747|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
32898748|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
32898749|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
33324496|NCT05295498|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
32989519|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
32989520|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
32989521|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
32989522|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
33324497|NCT05401032|Active Comparator|Control arm|tamsulosin 0.4mg (once a day) for 6 months.
33324498|NCT05401032|Experimental|Experimental arm|5-hidroxitriptophan 100 mg (3 times a day) for 6 months.
32989523|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
32989524|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
32989525|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
32989526|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
33324499|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
32989527|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
32989528|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
32989529|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
32989530|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
32989531|NCT01518634|Experimental|Imipramine treatment|
32989532|NCT01518634|Placebo Comparator|Placebo|
32989533|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
32989534|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
32989535|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
32989536|NCT01518660|Experimental|Training|
32989537|NCT01518660|No Intervention|Control|
32989538|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
32989539|NCT01518712|Experimental|Treatment Sequence AB|
32989540|NCT01518712|Experimental|Treatment Sequence BA|
32989541|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
32989542|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
32989543|NCT01518738|Experimental|breath attention training|
32989544|NCT01518738|Active Comparator|working memory attention training|
32989545|NCT01518738|No Intervention|no training|
32989546|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
32989547|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
32989548|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
32989549|NCT01518790|Experimental|Polyethylene glycol 3350|
32989550|NCT01518803|Active Comparator|Mediterranean-style breakfast|
32989551|NCT01518803|Active Comparator|Western-style breakfast|
33324500|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
33324501|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
33413519|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
33413520|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
32989552|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
33324502|NCT03768726|Experimental|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
33324503|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
32989553|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
32989554|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
32989555|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
32989556|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
32989557|NCT01518881|Experimental|TKM-100201|
32989558|NCT01518881|Placebo Comparator|Placebo|
32989559|NCT01518894|Experimental|PF-04958242|
32989560|NCT01518894|Placebo Comparator|Placebo|
32989561|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
32989562|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
32989563|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
32989564|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
33324504|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
33324505|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
33324506|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
33324507|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
33324508|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
33324509|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
33324510|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
33324511|NCT01139034|Experimental|shoulder FES treatment|
33324512|NCT01136070||Burn Trauma Patients|
33324513|NCT03917940|Experimental|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
33324514|NCT03917940|Placebo Comparator|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
33324515|NCT05291598|Active Comparator|Ketorolac group|Participants will receive the institution specific joint replacement pain protocol.
33324516|NCT05291598|Experimental|IV meloxicam group|Participants will be given IV meloxicam for pain management post total knee and hip arthroplasty.
33324517|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
33324518|NCT05287542|Experimental|Hypnotic suggestion|During the first phase of the study, two groups will receive identical hypnotic inductions followed by targeted suggestion for one group and non-targeted suggestion for the other. The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
33324519|NCT05287542|Active Comparator|Mindfulness|The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
33324520|NCT05287542|No Intervention|No treatment|The passive control group receives no intervention
33324521|NCT01232244||Healthy young males|
33324522|NCT03917862|No Intervention|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
33324523|NCT03917862|Active Comparator|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
33324524|NCT05400876|Experimental|TQB2618 injction+penpulimab injection|TQB2618 injection with penpulimab injection, 21 days as a treatment cycle
33324525|NCT01232322||Pulmicort Respules|Those with an exposure
33324526|NCT05192538|Experimental|Endoscopic endoloop pre-test treatment|Endoscopic endoloop pre-test treatment is a less invasive reversible endoscopic treatment to predict whether the gastroesophageal reflux can be alleviated in order to ultimately decide whether to undergo irreversible surgery or endoscopic treatment.
33324527|NCT03917784|Experimental|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
33324528|NCT03917784|Placebo Comparator|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
33324529|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
33324530|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
33324531|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
32989565|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
32989566|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
32989567|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
32989568|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
33105097|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
33105098|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
32989569|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
32989570|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
32989571|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
32989572|NCT01518920|Experimental|PF-04958242|
32989573|NCT01518920|Placebo Comparator|Placebo|
33324532|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
32989574|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
32989575|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
32989576|NCT01518959|Placebo Comparator|Placebo|no treatment
32989577|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
32989578|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
32989579|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
32989580|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
32989581|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
32989582|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
32989583|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
32989584|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
32989585|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
32989586|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
32989587|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
32989588|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
32989589|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
32989590|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
33105099|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
33105100|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
32989591|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
32989592|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
32989593|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
32989594|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
32989595|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
32989596|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
32989597|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
32989598|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
32989599|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
32989600|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
32989601|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
33105101|NCT00534885|Experimental|1: Healive® Lot 1|
33324533|NCT01233882|Experimental|Healthy Volunteers|
32989602|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
32989603|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
32989604|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
32989605|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
32989606|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
32989607|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
32989608|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
32989609|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
33413521|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33413522|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
32989610|NCT01519180||Control group|Healthy volunteers
32989611|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
32989612|NCT01519193|Experimental|Narrative Exposure Therapy|
32989613|NCT01519193|No Intervention|No treatment control|
32989614|NCT01519219||Hepatic Irradiation|
33413523|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
33413524|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
33413525|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
33413526|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
33413527|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
32747366|NCT05544825|Placebo Comparator|Placebo group|This group takes a placebo for 12 weeks.
32989615|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
32989616|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
32989617|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
32989618|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
32989619|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
32989620|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
32989621|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
32989622|NCT01519336|Active Comparator|A danoprevir|
32989623|NCT01519336|Placebo Comparator|B darunavir|
32989624|NCT01519336|Experimental|C danoprevir/darunavir|
32989625|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
32989626|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
32989627|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
32989628|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
32989629|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
32989630|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
32989631|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
32989632|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
32989633|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
32989634|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
32989635|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
32989636|NCT01519492|Experimental|AFN-12520000|100 mg tablet
32989637|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including~Individual intervention, OR~Group intervention"
32989638|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
33413528|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
33413529|NCT03574766|No Intervention|Control Group|Routine lactation support.
32989639|NCT01519531|Experimental|VIA-3196|
32989640|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
32989641|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
32989642|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
32989643|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
32989644|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
32989645|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
32989646|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
32989647|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
32989648|NCT01519609|Active Comparator|Phosphoral|Bowel prep
32989649|NCT01519622||Sick elderly in community|
32989650|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
32989651|NCT01519726|Experimental|Morbidly obese patients|
32989652|NCT01519739|Experimental|MediGuide Arm|
32989653|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
32989654|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
32989655|NCT01519752|Placebo Comparator|Placebo|
32989656|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
32989657|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
32989658|NCT01519843|Active Comparator|Real|Real tDCS
32989659|NCT01519843|Placebo Comparator|sham|Sham tDCS
32989660|NCT01519856||tablet|
32989661|NCT01519895|No Intervention|Existing care|routine existing care
32989662|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
32989663|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
32989664|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
32989665|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
32989666|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
32989667|NCT01519999|Experimental|Shared Decision Making|
32989668|NCT01519999|No Intervention|Comparison (control)|
32989669|NCT01520012|Experimental|Sequence 1|
32989670|NCT01520012|Experimental|Sequence 2|
32989671|NCT01520012|Experimental|Sequence 3|
32989672|NCT01520012|Experimental|Sequence 4|
32989673|NCT01520012|Experimental|Sequence 5|
32989674|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
32989675|NCT01520051|Experimental|Mepolizumab|
32989676|NCT01520051|Placebo Comparator|Saline|
32989677|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
32989678|NCT01520103|Experimental|Vinorelbin and Everolimus|
32989679|NCT01520103|Other|standard therapy|Vinorelbin
32989680|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
32989681|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
32989682|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
32989683|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
32989684|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
32989685|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
32989686|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
32989687|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
32989688|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
32989689|NCT01520142|Experimental|Treatment|
32989690|NCT01520142|Placebo Comparator|Placebo|
32989691|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
32989692|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
32989693|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
32989694|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
32989695|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
32989696|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
32989697|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
32989698|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
32989699|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
32989700|NCT01520259||cases|Women from the cohort with gallbladder cancer
32989701|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
32989702|NCT01520259||controls|Women from the cohort with gallstones
32989703|NCT01520285|Active Comparator|Zanidip|tablets
33105102|NCT00534885|Experimental|2: Healive® Lot 2|
32989704|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
32989705|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
32989706|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
32989707|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
32989708|NCT01520337||patients undergoing outpatient colonoscopy|
32989709|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
32989710|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
32989711|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
32989712|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
32989713|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
32989714|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
32989715|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
32989716|NCT01520415|Active Comparator|bupivacaine|
32989717|NCT01520415|Placebo Comparator|saline|
32989718|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
32989719|NCT01520428|Active Comparator|E-Mail-support|
32989720|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
32989721|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
32989722|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
32989723|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
32989724|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
32989725|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
32989726|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
32989727|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
32989728|NCT01520584|Active Comparator|vitamale|
32989729|NCT01520584|Placebo Comparator|sham pill|
32989730|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
32989731|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
32989732|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
33105103|NCT00534885|Experimental|3: Healive® Lot 3|
33105104|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
33105105|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
33105106|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
33105107|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
33105108|NCT00548106|Placebo Comparator|2|Nan HA infant formula
33105109|NCT02907749|Active Comparator|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
33105110|NCT02907749|Experimental|Spironolactone and carvedilol|"Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose~Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
32989733|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
32989734|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
32989735|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
32989736|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
32989737|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
32989738|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
32989739|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
32989740|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
32989741|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
32989742|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
32989743|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
32989744|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
32989745|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
32989746|NCT01520753|Experimental|BIAsp 70|
32989747|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
32989748|NCT01520766|Experimental|glass fiber|
32989749|NCT01520766|Experimental|titanium|
32989750|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
32989751|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
32989752|NCT01520792|Experimental|Paracetamol|
32989753|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
32989754|NCT01520818|Experimental|BIAsp 50 or 70|
32989755|NCT01520818|Active Comparator|BHI 30|
32989756|NCT01520831|Experimental|BIAsp 30|
32989757|NCT01520831|Experimental|BIAsp 50|
32989758|NCT01520831|Experimental|BIAsp 70|
32989759|NCT01520831|Active Comparator|Insulin aspart|
32989760|NCT01520844|Other|Cohort study|Blood sampling
32989761|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
32989762|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
32989763|NCT01520883||DEcisional conflict|
32989764|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
32989765|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
32989766|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
32989767|NCT01520935||Cohort Group|
32989768|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
32989769|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
32989770|NCT01520961||Hueter Anterior Approach|
32989771|NCT01520961||posterolateral approach|
32989772|NCT01520974|Active Comparator|Probiotic tablet|
32989773|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
32989774|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
32989775|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
32989776|NCT01521013|Active Comparator|Supported self-care|
32989777|NCT01521013|Active Comparator|Unsupported self-care|
32989778|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
32989779|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
32989780|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
32989781|NCT01521078|No Intervention|Control|No invention control group
32989782|NCT01521130|No Intervention|Healthy Control|Healthy Control
32989783|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
32989784|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
32989785|NCT01521156|Active Comparator|1 = Control product|
32989786|NCT01521156|Experimental|2 = Tested product|
32989787|NCT01521169|Active Comparator|1 = Tested product dose 1|
32989788|NCT01521169|Active Comparator|2 = Tested product dose 2|
32989789|NCT01521169|Sham Comparator|3 = Control product|
32989790|NCT01521182|Active Comparator|1 = Tested product|
32989791|NCT01521182|Placebo Comparator|2 = Control product|
32989792|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
32989793|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
32989794|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
32989795|NCT01521221|Experimental|Patients|Patients with autonomic failure.
32989796|NCT01521221|Experimental|Healthy subjects|Control group
32989797|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
32989798|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
32989799|NCT01521247|No Intervention|Control group|Usual care.
32989800|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
32989801|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
32989802|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
32989803|NCT01521273|Experimental|high iron bean partially dephytinized|
32989804|NCT01521273|Experimental|normal iron bean partially dephytinized|
32989805|NCT01521273|Experimental|high iron bean totally dephytinized|
32989806|NCT01521273|Experimental|normal iron bean totally dephytinized|
32989807|NCT01521286||Group A|Subjects presenting with HZ episode.
32989808|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
32989809|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
32989810|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
33105111|NCT00534924|Placebo Comparator|1|No intervention after IR injury
33105112|NCT00534924|Experimental|2|Postconditioning
33105113|NCT00534924|Experimental|3|Vit. C
33105114|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
32989811|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
32989812|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
32989813|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
32989814|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
32989815|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
32989816|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
32989817|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
32989818|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
32989819|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
32989820|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
32989821|NCT01521416||Cohort Group|
32989822|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
32989823|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
32989824|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
32989825|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
32989826|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
32989827|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
32989828|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
32989829|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
32989830|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
33105115|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
33105116|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
33105117|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
33105118|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
33105119|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
32989831|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
33413530|NCT04098393|Experimental|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
32989832|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
32989833|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
32989834|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
32989835|NCT01521533|Experimental|NOX-A12|
32989836|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
32989837|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
32989838|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
32989839|NCT01521585|Placebo Comparator|Placebo tablet|
32989840|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
32989841|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
32989842|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
32989843|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
32989844|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
32989845|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
32989846|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
32989847|NCT01521676|Experimental|breast cancer|blood and tumor sample
32989848|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
32989849|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
32989850|NCT01521702|Active Comparator|surgery|surgery
32989851|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
32989852|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
32989853|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
32989854|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
32989855|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
32989856|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
32989857|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
32989858|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
32989859|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
32989860|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
32989861|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
32989862|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
32989863|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
32989864|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
32989865|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
32989866|NCT01521832|Experimental|Dose Group A|
32989867|NCT01521832|Experimental|Dose Group B|
32989868|NCT01521832|Experimental|Dose Group C|
32989869|NCT01521832|Experimental|Dose Group D|
32989870|NCT01521832|Experimental|Dose Group E|
32989871|NCT01521832|Experimental|Dose Group F|
32989872|NCT01521832|Experimental|Dose Group H|
32989873|NCT01521832|Experimental|Dose Group I|
32989874|NCT01521832|Experimental|Dose Group J|
32989875|NCT01521832|Experimental|Dose Group K|
32989876|NCT01521832|Experimental|Dose Group L|
32989877|NCT01521910|Experimental|Low protein diet|
32989878|NCT01521910|Active Comparator|Normal protein diet|
32989879|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
32989880|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
32989881|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
32989882|NCT01521962|Placebo Comparator|Insulin|injection
32989883|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
32989884|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
32989885|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
32989886|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~Examination by cardiologist 8-12 weeks after discharge."
32989887|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
32989888|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
32989889|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
32989890|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
32989891|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
32989892|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
32989893|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
32989894|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
32989895|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
32989896|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
33324534|NCT01233882|Experimental|Mild Renal Impairment|
33324535|NCT01233882|Experimental|Moderate Renal Impairment|
32989897|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
32989898|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
32989899|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
32989900|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
32989901|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
32989902|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
32989903|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
32989904|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
32989905|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
32989906|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
32989907|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
33324536|NCT01233882|Experimental|Severe Renal Impairment|
33324537|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
33324538|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
33324539|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
33324540|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
33324541|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
33324542|NCT05608824|Experimental|Acute Compartment Syndrome|Shear wave elastography and microvascular flow imaging.
33324543|NCT05608824|Experimental|Chronic Exertional Compartment Syndrome|Needle pressure measurement, shear wave elastography and microvascular flow imaging.
33324544|NCT05608824|Experimental|Musculoskeletal injury|Shear wave elastography and microvascular flow imaging.
32989908|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
32989909|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
32989910|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
32989911|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
32989912|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
32989913|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
32989914|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
32989915|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
32989916|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
32989917|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
32989918|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
32989919|NCT01522482|Experimental|High saturated fat meal|
32989920|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
32989921|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
32989922|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
32989923|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
32989924|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
32989925|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
32989926|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
32989927|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
32989928|NCT01522521|Experimental|1.|
32989929|NCT01522521|Placebo Comparator|2.|
32989930|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
32989931|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
32989932|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
32989933|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
32989934|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
32989935|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
32989936|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
32989937|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
32989938|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
32989939|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
32989940|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
32989941|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
32989942|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
32989943|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
32989944|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
32989945|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
32989946|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
32989947|NCT01522625|Placebo Comparator|Placebo|
32989948|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
32989949|NCT01522638||Healthy subjects|
32989950|NCT01522664|Experimental|Single group|
32989951|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
32989952|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
32989953|NCT01522729|Experimental|Fentanyl|
32989954|NCT01522729|Experimental|Placebo|
32989955|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
32989956|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
32989957|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
32989958|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
32989959|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
32989960|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
32989961|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
32989962|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
32989963|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
32989964|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
32989965|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
32989966|NCT01522833||Cohort A|EGFR Wild Type patients
32989967|NCT01522833||Cohort B|EGFR mutation patients
32989968|NCT01522846||Heparin|
32989969|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
32989970|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
32989971|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
32989972|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
32989973|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
32989974|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
32989975|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
32989976|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
32989977|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
32989978|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
32989979|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
32989980|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
32989981|NCT01523002|Active Comparator|Arm A: Metoprolol DDI and Pyramax 90-day re-dosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of Pyramax followed by 1 day of Pyramax + metoprolol and then a 87 day follow-up period. Subjects will then receive Pyramax once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
32989982|NCT01523002|Active Comparator|Arm B: Pyramax 60-day re-dosing|Subjects will take Pyramax once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take Pyramax once daily for 3 days followed by a 40 day follow-up period.
32989983|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
32989984|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
32989985|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
32989986|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
32989987|NCT01523028|Experimental|200 mL black coffee|
32989988|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
32989989|NCT01523041|Experimental|BIAsp 70 final formulation|
32989990|NCT01523041|Experimental|BIAsp 50 final formulation|
32989991|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
32989992|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
32989993|NCT01523067|Active Comparator|Vasomera (PB1046)|
32989994|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
32989995|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
32989996|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
32989997|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
32989998|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
32989999|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
32990000|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
32990001|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
32990002|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
32990003|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
32990004|NCT01523145|Experimental|Intervention|
32990005|NCT01523145|Experimental|Control gruop|
32990006|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
32990007|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
32990008|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
32990009|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
32990010|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
32990011|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
32990012|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
32990013|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
32990014|NCT01523262|Active Comparator|Preconditioning and normal treatment|
32990015|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
32990016|NCT01523288||Prader-Willi patients|
32990017|NCT01523288||Control group|Control group for ultrasound scan
32990018|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
32990019|NCT01523314|Active Comparator|Avastin/Laser|
32990020|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
32990021|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
32990022|NCT01523340||Erlotinib treatment|
32990023|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
32990024|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
32990025|NCT01523405||1|
32990026|NCT01523418||Group 1|
32990027|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
32990028|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
32990029|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
33324545|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
33324546|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
33324547|NCT01230606||overnight|Subjects that stay overnight at the hospital.
32990033|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
33324548|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
33324549|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
33324550|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
33324551|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
33324552|NCT02528760|Experimental|Metaclopromide group|
33324553|NCT02528760|Experimental|Erythromycin group|
33324554|NCT02528760|Placebo Comparator|Placebo group|
33324555|NCT05594472|Experimental|Ozonated olive oil|ozonated oil will be applied to on one lesion followed by gauze for 5 consecutive days.
32990034|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
32990035|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
32990036|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
32990037|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
32990038|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
32990039|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
32990040|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
32990041|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
32990042|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
32990043|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
32990044|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
32990045|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
32990046|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
32990047|NCT01523600|Experimental|Whole body vibration training|
32990048|NCT01523600|Active Comparator|Wellness group|
32990049|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
32990050|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
32990051|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
32990052|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
32990053|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
32990054|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
32990055|NCT01523678|Experimental|Filgrastim|
32990056|NCT01523691|Experimental|repeated sleep restriction and recovery|
32990057|NCT01523691|Experimental|control sleep|
32990058|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
32990059|NCT01523730|Placebo Comparator|Sham rTMS|
32990060|NCT01523769|No Intervention|Control|Control group, the cord was not milked
32990061|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
32990062|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
32990063|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
32990064|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
32990065|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
32990066|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
32990067|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
32990068|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
32990069|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
32990070|NCT01523925|Active Comparator|Control intervention group|Control intervention
32990071|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
32990072|NCT01523925|Experimental|BAT|bilateral arm treatment
32990073|NCT01523938|Experimental|Hypnotherapy|
32990074|NCT01523938|No Intervention|No Hypnotherapy|
32990075|NCT01523951||Healthy volunteers|
32990076|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32863839|NCT04885140|Experimental|Feedback-based health education health education and Routine health education|"Feedback-based health education:(1) Implementation of the feedback method includes information transmission, patient feedback, clarification and correction, and confirmation of understanding.① One day before surgery: Health education team members provided bedside one-on-one education for patients, 15-20 min per session, twice a day.~② One week after surgery: One-on-one education on rehabilitation exercise was conducted for the patients by the health education team members, 15-20 min per session, twice a day.~③ Two to four weeks after surgery: The health education group members guided the patients through functional rehabilitation exercises via WeChat. Each intervention lasted 20-30 min. The patients interacted once through WeChatB1, and their questions were answered at any time.~④ Five to 12 weeks after surgery: The health education group members guided patients through the functional rehabilitation exercises via WeChat."
32863840|NCT04885140|Experimental|Routine health education|"Routine health education:~Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method."
33324556|NCT05594472|Active Comparator|Topical garamycin cream|conventional topical treatment will be applied to a comparable lesion followed by gauze for 5 consecutive days.
33324557|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
32863843|NCT04871724|Experimental|EDP-938 and Fluconazole interaction|
32863844|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
32863845|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
32863846|NCT04871802|Experimental|Taxifolin Aqua group|Taxifolin Aqua 30 mg per day in addition to standard therapy
32863847|NCT04871802|No Intervention|Control group|No intervention
32863848|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
32863849|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
32863850|NCT04871880|Experimental|Dietitian led life style modification intervention.|Lifestyle changes supervised by dietitians
32863851|NCT04871880|Experimental|Conventional care (control)|Receive routine care
32863852|NCT04871646|Experimental|CKD-314|Treatment with CKD-314 + SOC
32863853|NCT04871646|Placebo Comparator|CKD-314 Placebo|Treatment with CKD-314 Placebo + SOC
32863854|NCT02976077|Experimental|RC2S+|"RC2S+~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Social Cognition (ERF-CS)~Psychoeducation about social cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 22):~Paper-and-pencil session~Simulation session~Home-based task~Transfer sessions (sessions 23 & 24):~Transfer of skills in dayly life - generalization~Assessment of the achievement of objectives"
32863855|NCT02976077|Active Comparator|Control therapy|"Control therapy~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Neurocognition~Psychoeducation about cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 24):~Paper-and-pencil session~Simulation session~Home-based task"
32863856|NCT04871334|Experimental|Dose Escalation Cohort|Six dose levels of TWP-101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
32863857|NCT04871334|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
32863858|NCT04759001|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
32863859|NCT04759001|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
32863860|NCT04871256|Experimental|Inver|"Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.~Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered"
32863861|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
32863862|NCT04871178|No Intervention|Control Group|Care as usual: (i.e. best medical treatment)
32863863|NCT04871178|Experimental|Mindfulness-Based Intervention|Care as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based educational and training program.
32863864|NCT04758923|Active Comparator|Two-Stage|Two-stage approach The treatment process commenced with an intial treatment phase. This will be udertaken Under General anaesthesia and entailed ERCP and endoscopic sphincterectomy
32863865|NCT04758923|Active Comparator|Single stage|Single stage approach Under General anaesthesia a5 trocar method will be used to access the abdominal cavity. Aconventional approach to laparoscopic cholecystectomy will be first udertaken with dissection of calot's triangle. The cystic duct will be pulled laterally to facilitate exposure of the anterior wall of the CBD, and the CBD will be opened longitudinally for a distance of approximately 1 to 1.5 cm using laparoscopic scissors. A5 mm flexible choledoscope will be used to identify the cbd stone which will be removed by flushing with sterile saline, passing a stone basket or electrohydroulic lithotripsy as neccesary to clear the CBD. A T-tube will be inserted into the CBD via the choledochotomy which will be closed by interrupted resorbable sutures before completing the cholecystectomy.
33324558|NCT05205018|Experimental|Motivational Interviewing Arm|This Arm will receive a remote intervention (via videacalls) based on motivational interviewing to improve self-care. The intervention will be delivered seven time over 12 months.
33324559|NCT05205018|No Intervention|Standard care Arm|This Arm will receive the standard of care.
33105120|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy~Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
33105121|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
33105122|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
32863866|NCT04758455|Experimental|P53 IHC|P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
32863867|NCT04758455|Experimental|Ki67 IHC|Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
32863868|NCT04758455|Experimental|Cyclin A IHC|Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).
32863869|NCT02962661|Experimental|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
32863870|NCT02962661|Experimental|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
32863871|NCT02962661|Active Comparator|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
32863872|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
32863873|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
32863874|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
32863875|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts~Dose Expansion Phase: Consists of 5 Cohorts~Dose Extension Phase: Consists of 2 Cohorts"
32863876|NCT04168242|Experimental|Experimental arm|Patients have scalp cooling during the chemotherapy period
32863877|NCT04168242|Placebo Comparator|Control arm|Patients do not have scalp cooling during the chemotherapy period
32863878|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
32863879|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
32863880|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
32863881|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
32863882|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
32863883|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
32863884|NCT03910530|Experimental|INCMGA00012|Single-agent INCMGA00012.
32863885|NCT03910530|Experimental|INCB001158 75 mg|Single-agent INCB001158.
32863886|NCT03910530|Experimental|INCB001158 100 mg|Single-agent INCB001158.
32863887|NCT03910530|Experimental|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
32863888|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
32863889|NCT03748680|Active Comparator|A|Intensified follow-up schedule
32863890|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
32863891|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
32863892|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
32863893|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
32863894|NCT04274387|Experimental|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
32863895|NCT04274387|No Intervention|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
32863896|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
32863897|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
33105123|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
33105124|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
33105125|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
33324560|NCT05199012|Placebo Comparator|Placebo|Placebo is maltodextrin, delivered as 2 capsules.
32747367|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers (Adenocarcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
32747368|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers (squamous cell carcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
32747369|NCT05536323|Experimental|Bolus|Anesthetic induction with bolus remimazolam administration
32747370|NCT05536323|Experimental|Continuous|Anesthetic induction with continuous remimazolam administration
32747371|NCT05536011||Pitolisant-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
32747372|NCT05536011||Unexposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant or a comparator product at any time during pregnancy
32747373|NCT05536011||Comparator-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to comparator products at any time during pregnancy
32747374|NCT05536011||Pitolisant-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
32747375|NCT05536011||Comparator-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to a comparator product at any time during pregnancy
32747376|NCT04809051|No Intervention|Condition 1: Combined Transplant Pictograph|"Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a survival rate pictograph corresponding to all patients at the center who received transplants."
32747377|NCT04809051|Experimental|Condition 2: Stratified Transplant Pictograph|"Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
32747378|NCT04809051|Experimental|Condition 3: Combined Transplant SRTR|"Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a quintile score corresponding to all patients at the center who received transplants."
32747379|NCT04809051|Experimental|Condition 4: Stratified Transplant SRTR|"Participants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
33413531|NCT04098393|Experimental|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
33413532|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
33413533|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
33324561|NCT05199012|Active Comparator|Active|The active comparator is black pepper extract, delivered as 2 capsules.
32747384|NCT05535933|Experimental|HMPL-523|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
32747385|NCT05535933|Placebo Comparator|Placebo|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
32747386|NCT05544513|Experimental|- Group I|participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
32747387|NCT05544513|Active Comparator|Group II|participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
32747388|NCT05544513|Experimental|Group III|participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
32747389|NCT04015869|Active Comparator|allopregnanolone|allopregnanolone
32747390|NCT04015869|Placebo Comparator|placebo|placebo
32747391|NCT05544435|Experimental|Motivational Interviewing|Intervention In addition to the care they always received, MI sessions were conducted by the researcher for the participants in the experimental group. This intervention was conducted as 30-45 minutes of 12 sessions in total for each patient for a period of 3 months by the academic nurse. In these sessions, the agenda was created in accordance with the nature of MI intervention, efforts were made to resolve the ambivalent feelings in the patient, the patient's change phase was determined, the patient's self-confidence for change was determined, it was questioned how much the patient cared for change and the patient was helped in determining the change plan. In addition, during the sessions, the problems patients experienced about self-care activities, the causes of these problems and the barriers in maintaining self-care activities were discussed and efforts were made to create awareness in patients.
32990077|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32990078|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
33105126|NCT03767907|Experimental|Online Cognitive Behavioural Therapy|Computer-based training for cognitive behavioural therapy (CBT4CBT) consists of seven modules, and includes a series of interactive videos presenting characters portrayed by professional actors struggling with real-life situations. These characters first experience a common risky situation or problem and then demonstrate the application of a targeted skill. The program further comprises games and interactive exercises to teach and model effective use of skills and strategies.
33105127|NCT03767907|Active Comparator|Treatment as Usual|Treatment as usual consists of weekly group and/or individual psychotherapy as determined by the clinical team. Psychotherapy will include structured relapse prevention, include cognitive and behavioural techniques, motivational enhancement, mindfulness, and specialized topics (e.g., vocational training, rainbow services) as appropriate.
33105128|NCT04682249|Experimental|Systemic Chemotheray, Apatinib plus Sintilimab|
32990079|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32990080|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32990081|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32990082|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
32990083|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
33105129|NCT00548379|Active Comparator|1|Vitamin D
32990084|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
32990085|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
32990086|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
33105130|NCT00548379|Placebo Comparator|2|
33105131|NCT04682054|Experimental|surgically-removed eye tissue|
32990087|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
32990088|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
32990089|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
32990090|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
32990091|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
32990092|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
33105132|NCT04972617||observational group|"In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.~The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.~In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined."
33105133|NCT04682210|Experimental|Arm A|sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W
32990093|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
33105134|NCT04682210|No Intervention|Arm B|Active surveillance
33105135|NCT00548457||A|
33105136|NCT04682015|Experimental|Intervention|The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
33105137|NCT04682015|No Intervention|Control|Control group will receive usual care and follow up in hospitals and community health centers.
33105138|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
33105139|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
33105140|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
33413534|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
33413535|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
33413536|NCT05763537|Experimental|Standard Doula Care Plus the PMAD Intervention|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training in addition to PMAD-specific care from their doulas.
33413537|NCT05763537|Active Comparator|Standard Doula Care|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training.
33413538|NCT05763537|No Intervention|Standard Maternal Care|In this arm participants will receive standard perinatal medical care and will not receive care from a doula.
33413539|NCT04886999|Experimental|Inhaler A CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator."
33413540|NCT04886999|Active Comparator|Inhaler B CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator"
33413541|NCT05762523|Experimental|"Group 1 VAC∆6: оnce at a dose of 10⁶ PFU (plaque-forming units)"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
33413542|NCT05762523|Experimental|"Group 2 VAC∆6: once at a dose of 10⁷ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
33413543|NCT05762523|Experimental|"Group 3 VAC∆6: twice at a dose of 10⁶ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
33413544|NCT05762523|Experimental|"Group 4 OspaVir® + live smallpox vaccine"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
33413545|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
33413546|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
33413547|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
33413548|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
33413549|NCT01569711||Deep brain stimulation|
33413550|NCT05202171|Experimental|Exercise group|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
33413551|NCT05202171|Active Comparator|Standard treatment group|Standard treatment group will be given preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks.
33413552|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
33413553|NCT05763459|Experimental|ABBV-CLS-7262|ABBV-CLS-7262 + Digoxin + Rosuvastatin
33413554|NCT04079712|Experimental|Treatment (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
33413555|NCT05763381|Active Comparator|The Usual Care + PBM Group|Participants that are assigned to this group will receive active treatment with PBM 3 times a week for 3 weeks for a total of 9 treatments.
33413556|NCT05763381|Placebo Comparator|The Usual Care + Sham (Placebo) PBM Group|Participants that are assigned to this group will receive Sham PBM therapy 3 times a week for 3 weeks for a total of 9 treatments. Sham PBM therapy is an inactive harmless treatment that is intended to mimic the active PBM treatment.
33413557|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
32908200|NCT05466032||Master of Science TouroCOM students|Students enrolled in the Master of Science in Interdisciplinary Studies in Biological and Physical Sciences at TouroCOM complete almost all of the same courses as the osteopathic medical students, but are not exposed Osteopathic Manual Manipulation (OMM). This cohort will act as the control as they undergo similar environmental stress, but will not learn about common osteopathic dysfunctions or their treatments.
33105141|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
33105142|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
33324562|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
32863898|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
32863899|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
32863900|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
32863901|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
32863902|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
32863903|NCT04885374||Amyotrophic lateral sclerosis patients|Amyotrophic lateral sclerosis patients with traditional Chinese medicine
32863904|NCT03827681|Experimental|TIPS + Vasoactive Drug|
32863905|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
32863906|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
32863907|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
32863908|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
32863909|NCT04884984|Experimental|CLL1 positive relapsed or refractory acute myeloid leukemia|
32863910|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
32863911|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32863912|NCT02956499|Experimental|Cohort 1|single intravenous dose
32863913|NCT02956499|Experimental|Cohort 2|single intravenous dose
32863914|NCT02956499|Experimental|Cohort 3|single intravenous dose
32863915|NCT02956499|Experimental|Cohort 4|single intravenous dose
32863916|NCT02956499|Experimental|Cohort 5|single intravenous dose
32863917|NCT02956499|Experimental|Cohort 6|single intravenous dose
32863918|NCT02956499|Experimental|Cohort 7|multiple intravenous doses
32863919|NCT02956499|Experimental|Cohort 8|multiple intravenous doses
32863920|NCT02956499|Experimental|Cohort 9|multiple intravenous doses
32863921|NCT02956499|Experimental|Cohort 10|multiple intravenous doses
32863922|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
32863923|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
32863924|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
32863925|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
32863926|NCT04884906|Experimental|Camrelizumab combined with radiotherapy and chemotherapy|
32863927|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
32863928|NCT04885062|Experimental|UH-Participant|Potential participants with suspected OSA will be identified from the schedule of the UH Beachwood and Bolwell sleep labs.Those subjects who satisfy the study inclusion and exclusion criteria will be approached and invited to participate in the study.
32863929|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
32863930|NCT03046758|Experimental|Participants|
32863931|NCT04382664|Experimental|UV1 vaccination + nivolumab and ipilimumab|UV1 vaccination + nivolumab and ipilimumab
32863932|NCT04382664|Active Comparator|Nivolumab and ipilimumab|nivolumab and ipilimumab
32908315|NCT05073458|Placebo Comparator|Group B: Placebo followed by Parsaclisib|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive parsaclisib in the 24 week open-label period. Participants may then continue to receive parsaclisib in a long-term extension period.
32908316|NCT03032978|Experimental|Calcium silicate|intervention
32908317|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
32908318|NCT03030092|No Intervention|Control group|Today's standard care
32908319|NCT03030092|Experimental|Intervention group|Maximal Strength Training
32747392|NCT04744467|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
32908320|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
32908321|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
32908322|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
32908323|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
32908324|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
32908325|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
32908326|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
32908327|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
32908328|NCT03032744|Experimental|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment & management'), and receive the morning dose of their daily asthma controller medication at school on school days.
32908329|NCT03032744|Active Comparator|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
32908330|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
32908331|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
32908332|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
32908333|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
32908334|NCT04959188||Bereaved family caregivers|Bereaved family caregivers (parents or spouses/partners) of individuals who died from complications associated with dyskeratosis congenita or a related telomere biology disorder.
32908335|NCT04959188||Caregivers|Family and/or caregivers of individuals with dyskeratosis congenita or a related telomere biology disorder.
32908336|NCT04959188||Patients|Individuals with dyskeratosis congenita or a related telomere biology disorder.
32908337|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
32908338|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
32908339|NCT04857476|Other|skin psoriasis participants|Single arm study
32908340|NCT04815590||Sublocade|The only group consists of participants with moderate to severe OUD who will be starting treatment with extended-release injectable buprenorphine as part of standard of care. While individual treatment regimens may vary, these will often consist of 2 once-monthly 300 mg subcutaneous injections followed by 4 once-monthly 100 mg subcutaneous injections. However, participants may receive once-monthly 300 mg subcutaneous injections in place of 100 mg subcutaneous injections for as many months as is deemed necessary by their prescribing physician.
32908341|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
32908342|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
32908343|NCT03017690||lanreotide group (Somatuline Depot®)|
32908344|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
32908345|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
33324563|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
32863933|NCT04392479|Active Comparator|Aflibercept-FOLFIRI (arm 1)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),~5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),~5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+49.5: End of treatment administration"
32863934|NCT04392479|Experimental|Aflibercept-mFOLFIRI3 (arm 2)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,~5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+50: End of treatment administration"
32863935|NCT04870398|Active Comparator|MTA partial pulpotomy|Profound local anesthesia of the tooth and the surrounding tissues will be achieved The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of MTA. After the placement of MTA, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
32863936|NCT04870398|Active Comparator|Total Fill partial pulpotomy|The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of Total Fill BC. After the placement of the material, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
32863937|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
32863938|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
32863939|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
32863940|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
32863941|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
32863942|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
32863943|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
32863944|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
32863945|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
32863946|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
32863947|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
32863948|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
32863949|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
32863950|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
32863953|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.~Melasma on the face~Fitzpatrick phototypes I-IV~Presenting facial melasma~In good health condition"
32863954|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
32863955|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
32863956|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
32908346|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
32908347|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
32908348|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
32990094|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
32990095|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
32990096|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
32990097|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
32990098|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
32990099|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
33324564|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
33324565|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
32990100|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
32990101|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
33324566|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
32990102|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
32990103|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
32990104|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
32990105|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
32990106|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
32990107|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
32990108|NCT01524042|Experimental|group 2|study group:double pants group
32990109|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
32990110|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
32990111|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
32990112|NCT01524068|Experimental|Arm B - Experimental Treatment|
32990113|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
32990114|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
32990115|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
32990116|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
32990117|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
32990118|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
32990119|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
32990120|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
32990121|NCT01524107||Urgent Caesarian Section|
32990122|NCT01524107||Elective Caesarian Section|
32990123|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
32990124|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
32990125|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
32990126|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
32990127|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
32990128|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
32990129|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
32990130|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
32990131|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
32990132|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
32990133|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
32990134|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
32990135|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
32990136|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
32990137|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
32990138|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
32990139|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
32990140|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
32990141|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
32990142|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
32990143|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
32990144|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
32990145|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
32990146|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
32990147|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
32990148|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
32990149|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
32990150|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
32990151|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
32990152|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
32990153|NCT01524393||IVF pregnancy|
32990154|NCT01524406|Experimental|HPP593|
32990155|NCT01524406|Placebo Comparator|Placebo|
32990156|NCT01524419||women after vaginal birth|
32990157|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
32990158|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
32990159|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
32990160|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
32990161|NCT01524471|Experimental|POEM|Endoscopic Myotomy
32990162|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
32990163|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
32990164|NCT01524497|Active Comparator|Trazodone|
32990165|NCT01524497|Placebo Comparator|Placebo|
32990166|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
32990167|NCT01524562||Rakai Community Cohort|HIV Patients
32990168|NCT01524562||Rakai HIV Care Program|HIV Patients
32990169|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
32990170|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
32990171|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
32990172|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
32990173|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
32990174|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
32990175|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
32990176|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
33033582|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
33413558|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
33413559|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
33413560|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
32747393|NCT04738617|Experimental|Warm-up based on small-sided games|Intervention A is based on football-specific small-sided games (SSGs), consisting of 4 versus 4 matches (with mini-goals), performed in a 30 m by 24 m court (Giménez et al., 2018), using five sets of 90 seconds of work interspersed with 30 seconds of pause, in a total duration of 10 minutes.
33413561|NCT04053348|Experimental|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
33413562|NCT04053348|Active Comparator|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
33413563|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
33413564|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
33413565|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
33413566|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
33413567|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
33413568|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
33413569|NCT05201625|Active Comparator|control group|Healthy control group
32747395|NCT04677855|Experimental|PCUR-101 Dose Escalation|PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
32747396|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 1|PCUR-101 dosed orally once per day in 28 day cycles
32747397|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 2|PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
32747398|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 3|PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
32908349|NCT02981732|No Intervention|the control group|the control group,there is no intervention
32908350|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
33413570|NCT05201625|Active Comparator|ICU COVID 19 patients|ICU COVID 19 patients
33413571|NCT05201625|Active Comparator|non-ICU covid 19 patients|non-ICU covid 19 patients
33413572|NCT04053114||Retrospective cohort|Tissue samples
33413573|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
33413574|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
33413575|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
33413576|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
33413577|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
32747394|NCT04738617|Experimental|Warm-up based on potentiation principles (e.g., speed, change of direction, plyometrics)|"Intervention B is based on speed, COD and plyometrics (i.e., a potentiation protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last ~10 minutes and will be applied in the football field."
32990177|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~Starch 60mg~Red color[1mg/ml] 10 µl~Yellow color [1mg/ml] 5 µl~Xanthum Gum (1% solution) 300 µl~Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
32990178|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
32990179|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
32990180|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 DM participants will be instructed on an AHA/ADA meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual HBA1Cs between 6.7 and 7.3% throughout the trial.
32990181|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
32990182|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
32990183|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
32990184|NCT01524731|Placebo Comparator|Placebo|Placebo group
32990185|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
32990186|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
32990187|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
32990188|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
32990189|NCT01524757|Experimental|pantoprazol|
32990190|NCT01524757|Placebo Comparator|placebo|
32990191|NCT01524809|Experimental|Treatment period 1|
32990192|NCT01524809|Experimental|Treatment period 2|
32990193|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
32990194|NCT01524848|Other|Open label|Single arm pazopanib
32990195|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
32990196|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
32990197|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
32990198|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
32990199|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
32990200|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
32990201|NCT01524939|Experimental|Investigational product|
32990202|NCT01524952|Experimental|Active|cTEMS
32990203|NCT01524965|Experimental|Immediate mobilisation|
32990204|NCT01524965|Active Comparator|Standard mobilisation|
32990205|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
32990206|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
32990207|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
32990208|NCT01525043|Active Comparator|Naproxen|
32990209|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
32990210|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
32990211|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
32990212|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
32990213|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
32990214|NCT01525108|Experimental|Home-based blood pressure monitoring|
32990215|NCT01525108|Active Comparator|Usual care|
32990216|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
33033583|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
32990217|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
32990218|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
32990219|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
32990220|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
32990221|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
32990222|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
32990223|NCT01525199||Case|
32990224|NCT01525199||Control|
32990225|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
32990226|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
32990227|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
32990228|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
32990229|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
32990230|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
32990231|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
32990232|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
32990233|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
32990234|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
32990235|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
32990236|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
32990237|NCT01525355||EUS prior to ERCP|
32990238|NCT01525368||cognitive intervention group|
32990239|NCT01525368||active control group|
32990240|NCT01525394|Experimental|Lenvatinib Capsules|
32990241|NCT01525394|Active Comparator|Moxifloxacin tablets|
32990242|NCT01525394|Placebo Comparator|Placebos|
32990243|NCT01525433|No Intervention|Control|
32990244|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
32990245|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
32990246|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
32990247|NCT01525459||Glioma patients|
32990248|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
32990249|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
32990250|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
32990251|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
32990252|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
32990253|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
32990254|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
32863957|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
32863958|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
32863959|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
32863960|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
32863961|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
32863962|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
32863963|NCT03825263|No Intervention|Control|Participants receive normal treatment
32863964|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
32863965|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
32863966|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
32863967|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
32863968|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
32863969|NCT03824873|Active Comparator|cesarean hysterectomy|
32863970|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
32863971|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
32863972|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
32863973|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
32863974|NCT04392557|Active Comparator|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
32863975|NCT04392557|Active Comparator|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
32863976|NCT04392557|Active Comparator|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
32863977|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
32863978|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
32863979|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
32863980|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MM|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.~Dosage of Mitomycin (MM) fixed at 40mg per instillation."
32863981|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
32863982|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
32863983|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
32863984|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
32863985|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
32863986|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
32863987|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
32863988|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
32863989|NCT05323825|Experimental|Experimental group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
32863990|NCT05323825|Placebo Comparator|Control group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
32863991|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
33033584|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
33413578|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
33413579|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
33105143|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
33105144|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
33105145|NCT04971876|Experimental|Group 1 - Lips Enhancement|Participants treated with HLR-1 for lip enhancement, with optional Touch-Up (TU) 4 weeks afterwards
33105146|NCT04971876|Experimental|Group 2 - Nasolabial Fold Correction|Participants treated with HLR-2 for nasolabial folds (NLFs) correction, with optional Touch-Up (TU) 4 weeks afterwards
33413580|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
33413581|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
33413582|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
33413583|NCT01813929|Experimental|Metformin|
33413584|NCT01813929|Placebo Comparator|Placebo|
32863992|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
32863993|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
32863994|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
32863995|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
32863996|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
32863997|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
32863998|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
32863999|NCT02945579|Experimental|Cohort A|"Neoadjuvant chemotherapy therapy~Biopsy: if no disease remaining - stay on the study and receive radiation (skip breast surgery)~H&P and Imaging every 6 months~Treatment (whole breast irradiation, EBRT) Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation."
32864000|NCT02945579|Experimental|Cohort B|"Neoadjuvant endocrine therapy for 6 months~Radiation if there is less than 25% tumor increase~Biopsy: if negative - additional endocrine therapy under the guidance of medical oncologist (skip breast surgery)~H&P and Imaging every 6 months~Cohort B Radiation:~Treatment (Stereotactic ablative radiotherapy -SABR) Following 3-6 months of endocrine therapy, if less than 25% tumor increase, patients undergo SABR irradiation over 10 fractions every other business day."
32864001|NCT02945579|Experimental|Cohort C|"Optional biopsy for nanomechanical biomarker assessment~Neoadjuvant chemotherapy therapy~Surgery (& optional biopsy nanomechanical biomarker assessment): if no disease remaining - stay on the study and skip radiation~H&P and Imaging every 6 months"
32864002|NCT02076061||GOLD stage I|
32864003|NCT02076061||GOLD Stage II|
32864004|NCT02076061||GOLD Stage III|
32864005|NCT02076061||GOLD Stage IV|
32864006|NCT02076061||Smokers/ex-smokers w/o COPD|
32864007|NCT02076061||non-Smokers w/o COPD|
32864008|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
32864009|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
32864010|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
32864011|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
32864012|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
32864013|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
32864014|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
33413585|NCT05284968|Experimental|Cell injection|Cell injection
33413586|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
33413587|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
32864015|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
32864016|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
32864017|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
32864018|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
32864019|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
32864020|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
32864021|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
32864022|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
32864023|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
32864024|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
32864025|NCT04392713|Active Comparator|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
32864026|NCT04392713|No Intervention|Control arm|This arm will only receive chloroquine as per existing policy of hospital
32864027|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
32864028|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
32864029|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
32864030|NCT02061787||cardiopulmonary exercise testing|patients diagnosed with pulmonary hypertension, including pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension, were evaluated by cardiopulmonary exercise testing before and after medical or balloon pulmonary angioplasty treatment
32864031|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
32864032|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.~Surgery:~2-3weeks after Neoadjuvant chemotherapy~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
32864033|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
32864034|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
32864035|NCT02863991|Experimental|ONC201|Single agent ONC201.
32864036|NCT01326715|Active Comparator|mangafodipir|see protocol
32864037|NCT02860091||Ropivacaine infusion|Patients receiving continuous ropivacaine infusion for approximately 7 days via paravertebral nerve block or erector spinae catheter managed according to existing institutional protocols.
32864038|NCT01736059|Experimental|Stem cell treated|
32864039|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
32864040|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
32864041|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
32864042|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
32864043|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
33413588|NCT04059822|Experimental|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum ~20 weeks if enrolment at 20 weeks gestation until ~40 weeks gestation birth)
33413589|NCT04053738|No Intervention|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
33413590|NCT04053738|Experimental|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
32990255|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
33413591|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
32990256|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
32990257|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
32990258|NCT01525576|No Intervention|Control group|No offer of booster program.
32990259|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
32990260|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
32990261|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
32990262|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
32990263|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
32990264|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
32990265|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
32990266|NCT01525719|Experimental|RAD001|
32990267|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
32990268|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
32990269|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
32990270|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
32990271|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
32990272|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
32990273|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
32990274|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
33413592|NCT04052880|Experimental|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
33413593|NCT05761353|Experimental|Group A (endermologie group)|This group includes 34 patients who will receive 30 min Endermologie 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks.
32990275|NCT01525797||Control|
32990276|NCT01525797||Rejection|
32990277|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
32990278|NCT01525823|Experimental|BMS-754807 + Metformin|
32990279|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
32990280|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
32990281|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
32990282|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
32990283|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
32990284|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
32990285|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
32990286|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
32990287|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
32990288|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
32990289|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
32990290|NCT01525992|Experimental|Community Pharmacy-based Program|
32990291|NCT01525992|Active Comparator|Usual care|
32990292|NCT01526005||Active agent (nicotine patch)|
32990293|NCT01526005||Placebo patch|
32990294|NCT01526018||Novel bottle|
32990295|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
32990296|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
32990297|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
32990298|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
33413594|NCT05761353|Experimental|Group B (Negative pressure therapy group)|This group includes34 patients who will receive 30min negative pressure therapy 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks
33413595|NCT04052802|Experimental|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
33413596|NCT04052802|Experimental|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
32990299|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
32990300|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
32990301|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
32990302|NCT01526083|Other|Single dose of Warfarin|
32990303|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
32990304|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
32990305|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
32990306|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
32990307|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
32990308|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
32990309|NCT01526122|Experimental|G0041(75/100mg)|
32990310|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
32990311|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
32990312|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
32990313|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
32990314|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
32990315|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
32990316|NCT01526187||Sub-Saharan Africa|
32990317|NCT01526187||Asia|
32990318|NCT01526187||Latin America|
32990319|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
32990320|NCT01526226|Experimental|HFNC|High flow nasal cannula
32990321|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
32990322|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
32990323|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
32990324|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
32990325|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
32990326|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
33033585|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
33033586|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
33033587|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
33413597|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
33413598|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
33413599|NCT03648684|No Intervention|Control|
33413600|NCT03647982|Experimental|botulinum toxin 1U|
33413601|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
33413602|NCT03647982|Experimental|botulinum toxin 5U|
33413603|NCT03647982|Experimental|botulinum toxin 10U|
33413604|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
33413605|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
33413606|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
32864044|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
32864045|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
32864046|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
32864047|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
32864048|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
32864049|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
32864050|NCT02848703|Experimental|healthy volunteers|
32864051|NCT02839265|Experimental|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary or extrapulmonary lesion as well as FLT3 immunotherapy.~FLT3 Ligand Therapy (CDX-301)~Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.~Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).~Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
32864052|NCT00988247|Experimental|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
32864053|NCT00988247|Placebo Comparator|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
32864054|NCT01260402|Active Comparator|Epicardial|
32864055|NCT01260402|Experimental|Endocardial|
32864056|NCT04381806|Experimental|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
32864057|NCT04144842|Experimental|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
32864058|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
32864059|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
32864060|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
32864061|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
32864062|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
32864063|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
32864064|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
32864065|NCT00987545|Placebo Comparator|Placebo|
32864066|NCT00987545|Experimental|QAX576|
32864067|NCT04430166|Experimental|PD-1 monoclonal antibody|
32864068|NCT00985127|Experimental|40 mg|40 mg BCX4208
32864069|NCT00985127|Experimental|80 mg|BCX4208
32864070|NCT00985127|Experimental|120 mg|BCX4208
32864071|NCT00985127|Placebo Comparator|sugar pill|
32864072|NCT00985127|Experimental|160mg|BCX4208
32864073|NCT00985127|Experimental|240mg|BCX4208
32864074|NCT00985127|Experimental|320mg|BCX4208
32864075|NCT04430478|Experimental|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
32864076|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
32864077|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
32864078|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
32864079|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
32864080|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
32864081|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
32864082|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
32864083|NCT04877496||Immunocompetent controls|Participants aged at least 18 years, no history of COVID19, no history of anti-CD20 treatment
32864084|NCT04877496||Patients with a treatment history of rituximab|Participants aged at least 18 years, no history of COVID19, history of at least 1 dose of anti-CD20 treatment received since 01/01/2010
32864085|NCT04877340|Other|Standard FNA 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a standard FNA 22G needle
32864086|NCT04877340|Experimental|Franseen 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a FNB 22G needle. The sequence of the use of needles will be randomized.
32864087|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
32864088|NCT02765789|Experimental|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
32864089|NCT04877106|Active Comparator|Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®)|JANUMET®, 50mg/850mg, batch no. M047893, manufactured by MSD Pharma (Singapore) Pte.Ltd
32864090|NCT04877106|Experimental|Sitagliptin Phosphate/metformin Hydrochloride Tablets|50mg/850mg, batch no. 161006, manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd.
32864091|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
32864092|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
32864093|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
32864094|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
32864095|NCT04876716|Active Comparator|Azole monotherapy|"Azole monotherapy~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care."
32864096|NCT04876716|Experimental|Azole + Anidulafungin|"Azole + Anidulafungin~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.~Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade."
32864097|NCT04865640||Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
32864098|NCT04865640||Pathologic Cohort|The target population for this cohort is adult patients who have been diagnosed with cardiopulmonary conditions. These can include chronic pulmonary conditions, chronic cardiac conditions, and those who are taking diuretic medications, living with heart failure, Chronic Obstructive Pulmonary Disorder (COPD), or recovering from coronary-artery disease-related events. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders as well as conditions outlined above (e.g. at least 5 each of COPD, HF, recovering from a coronary artery disease-related event, and taking diuretic medication)
32864099|NCT04870008|Active Comparator|2 mm|The side of patient's scar that will receive the sutures placed at 2 mm from wound edge.
32864100|NCT04870008|Active Comparator|5 mm|The side of patient's scar that will receive the sutures placed at 5 mm from wound edge.
32864101|NCT04865484|Experimental|SRES group|Surgical resection plus endoscopic stricturotomy for multiple fibrous stenosis
32864102|NCT04865484|Active Comparator|SRS group|Surgical resection plus strictureplasty for multiple fibrous stenosis
32864103|NCT04865250|Experimental|treatment|ATEZOLIZUMAB; Carboplatin; Nab-Paclitaxel
32864104|NCT04870242||pediatric surgery patients|all pediatric surgery patients, aged from 6 months up to 18 years, underwent surgery between January 2017 to December 2018
32864105|NCT04869774|Active Comparator|Virtual Monitoring|Patients discharged from hospital after colorectal surgery will have virtual monitoring of their surgical incision and symptoms, using the mobile application How2Trak, post-operatively.
32864106|NCT04869774|No Intervention|Standard of Care|Patients discharged from hospital after colorectal surgery will receive standard of care with no virtual monitoring of their surgical incision and symptoms.
32864107|NCT04876872||pediatric patients|whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
32864108|NCT04876404||Parkinson's Disease|Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)
32864109|NCT04876404||Healthy Controls|Healthy control individuals with no neurological or mood disorders.
32864110|NCT04429698|Other|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
32864111|NCT04429698|No Intervention|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
32864112|NCT04876482|Sham Comparator|Control|Without the willingness of surgery, those participants waiting for oral appliance (Device), losing weights and using continuous positive airway pressure (Device) were distribute to control group.
32990327|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
32990328|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
32990329|NCT01526278|Other|Maxmarvil®|single-arm study
32990330|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
32990331|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
32990332|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
32990333|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
32990334|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
32990335|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
32990336|NCT01526330|Experimental|Group A|
32990337|NCT01526330|Experimental|Group B|
32990338|NCT01526330|Experimental|Group C|
32990339|NCT01526330|Placebo Comparator|Group D|
32990340|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
32990341|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
32990342|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
32990343|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
32990344|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
32990345|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
32990346|NCT01526421|Experimental|monetary reinforcer|
32990347|NCT01526421|No Intervention|no reinforcer|
32990348|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
32990349|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
32990350|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
32990351|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
32990352|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
32990353|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
32990354|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
32990355|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
32990356|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
32990357|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
32990358|NCT01526499|Active Comparator|T|Docetaxel
32990359|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
32990360|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
33105147|NCT04971876|Experimental|Group 3 - Treatment of Midface Volume Deficit|Participants treated with HLR-3 for treatment of midface volume deficit, with optional Touch-Up (TU) 4 weeks afterwards
33105148|NCT02907554|Placebo Comparator|control group|control group receives a placebo
32990361|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
32990362|NCT01526564|Active Comparator|ALC|ALC
32990363|NCT01526564|Placebo Comparator|Placebo|
32990364|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
32990365|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
32990366|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
33324567|NCT03917550|Experimental|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
32990367|NCT01526642|No Intervention|Long Term Oxygen Therapy|
32990368|NCT01526642|Active Comparator|Non Invasive Ventilation|
32990369|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
32990370|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
32990371|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
32990372|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
32990373|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
32990374|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
32990375|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
32990376|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
32990377|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
32990378|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
32990379|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
32990380|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
32990381|NCT01526798|Experimental|Therlite hemodialysis|
32990382|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
32990383|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
32990384|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
32990385|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
32990386|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
32990387|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
32990388|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
32990389|NCT01526863|Placebo Comparator|Placebo|
32990390|NCT01526863|Active Comparator|HA egg|
32990391|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
32990392|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
32990393|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
32990394|NCT01526941|Experimental|Treatment period 1|
32990395|NCT01526941|Experimental|Treatment period 2|
32990396|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
32990397|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
32990398|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
32864113|NCT04876482|Experimental|Transoral robotic surgery (TORS)|The participants underwent TORS. TORS is a kind of surgery that the surgeons would remove the tonsils and the fat tissue of tongue base and suspend the soft palate.
32864114|NCT04876482|Experimental|TORS+OPR|The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
32864115|NCT04865328||OAB group|Group with diagnosed overactive bladder.
32864116|NCT04876170|Active Comparator|VS-EFP Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, participants will receive musical feedback driven by their own VS-EFP
32864117|NCT04876170|Sham Comparator|Yoked sham Neurofeedback|"Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, the musical feedback will be provided based on another participant's VS-EFP signal. Hence, each participant from the sham group is paired with a participant from the test group, thus receiving feedback based on the paired test participant. This way, both groups are exposed to the exact proportion of sound manipulation that indicates their success level. To account for a possible contribution of the temporal order of feedback presentation, in half of the control participants, the feedback pattern will be replayed forward (maintaining the original temporal pattern of VS-EFP that the paired participant has received), and in half - backward (flipping the original temporal pattern right-to-left)."
32864118|NCT04869852|Experimental|Mango|85g mango, 4x/week
32864119|NCT04869852|No Intervention|No Mango|No mango intake
32864120|NCT04865562|Experimental|testosterone|7mg testosterone propionate
32864121|NCT04865562|Placebo Comparator|placebo|125 mg 0.5% cholorbutanol, 50mg saline, pH5
32864122|NCT04876326|Active Comparator|Autologous Adipose MSC Group|This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month
32864123|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.
32864124|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC and Adipose Secretome Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month.
32864125|NCT04865094|Active Comparator|cyclic merocyanine|long-UVA absorber
32864126|NCT04865094|Placebo Comparator|placebo|
32864127|NCT04876560|Active Comparator|CDSS (intervention) group|Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
32864128|NCT04876560|Other|Control group|"General lifestyle advice: based on the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention via scheduled phone interviews every 15 days."
32864129|NCT04876014|Experimental|GMBPMI group|Participants in the experimental group will receive GMBPMI. A new participant (a pregnant woman in the second trimester) is expected to complete the 6 EBMI lessons in 6 weeks, and do the mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. Participants will also be asked to keep log of daily mindfulness practice from T0 to T3 using Google Form. The project RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice. The RA is backed up by the PI and co-I's who are experienced mental health practitioner and mindfulness teacher. One of them is an obstetrics and gynaecology specialist.
32864130|NCT04876014|Active Comparator|Perinatal Psycho-education group|To control for attention and placebo effects, every new participant in the control group will receive weekly web-based psychoeducation program for perinatal care. The project RA will also be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences of the psychoeducation program.
32864131|NCT04865172||Patient-caregiver dyads, patients with behavioural variant frontotemporal dementia|20 patient-caregiver dyads, patients with behavioural variant frontotemporal dementia
32864132|NCT04865172||Patient-caregiver dyads, patients with Alzheimer disease|20 patient-caregiver dyads, patients with Alzheimer disease
32864133|NCT04865172||Healthy control dyads|20 healthy control dyads
32864134|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
32864135|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
32864136|NCT04864938||Patients: ICU treated covid-19 patients|Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
32864137|NCT04864938||Control group 1, covid-19 patients treated in the regular wards|As above, without 6 minute walk test or routine chest x-ray
32864138|NCT04864938||Control group 2, persons with covid-19 without hospitalization|As above, but without respiratory testing
32864139|NCT04864938||Control group 3, non-covid controls|As control group 2
32864140|NCT04875546|Active Comparator|Standard treatment|"A 5'A' and '5'R' models~STAR method for quitting"
32864141|NCT04875546|Active Comparator|Integrated Intervention|"A 5'A' and '5'R' models~Receive brief advice on alcohol use based on the FRAMES model~Complete the Alcohol Use Disorders Identification Test"
32864142|NCT04875546|Sham Comparator|Control|Participants will receive two leaflets.
33105149|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
33105150|NCT03657303||Healthy volunteers|
32990399|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
32990400|NCT01526980|Experimental|Treatment period 1|
32990401|NCT01526980|Active Comparator|Treatment period 2|
32990402|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
32990403|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
32990404|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
32990405|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
32990406|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
32990407|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~Persistent sepsis or symptoms~Worsening of clinical condition~Failure to thrive~Complications of SAP or PCD"
32990408|NCT01527097|Experimental|Atorvastatin|
32990409|NCT01527097|Placebo Comparator|Placebo|
32990410|NCT01527123|Experimental|GSK2585823|External Preparation
32990411|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
32990412|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
32990413|NCT01527188|Experimental|100IR|
32990414|NCT01527188|Experimental|300IR|
32990415|NCT01527188|Experimental|500IR|
32990416|NCT01527188|Placebo Comparator|Placebo|
32990417|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
32990418|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
32990419|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
32990420|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
32990421|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
32990422|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
32990423|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
33324568|NCT03917550|Active Comparator|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
33324569|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
32990424|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
33105151|NCT03657303||Osteoarthritis patients|
33324570|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
33324571|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
33324572|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
33324573|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
33324574|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
33324575|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
33324576|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
33324577|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
33324578|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
33324579|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
32990425|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
32990426|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
32990427|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
32990428|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
32990429|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
33033588|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
33324580|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
33324581|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
33324582|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
33324583|NCT05571462||Activity monitor group|No intervention will be applied. All patients will have activity monitors placed at the distal part of the femur and on the torso. Normal rehabilitation will be performed as usual.
33324584|NCT03917628|Experimental|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
33324585|NCT03917628|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
33324586|NCT01232634||All Subjects|
32990430|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
32990431|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
32990432|NCT01527305|Experimental|Paliperidone palmitate|
32990433|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
32990434|NCT01527331|No Intervention|control group|usual care
32990435|NCT01527331|Experimental|Video decision aid arm|
32990436|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
32990437|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
32990438|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
32990439|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
32990440|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
32990441|NCT01527539|Experimental|BIAsp 30|
32990442|NCT01527552|Experimental|Formulation A|
32990443|NCT01527552|Experimental|Formulation B|
32990444|NCT01527565|Experimental|Formulation A|
32990445|NCT01527565|Experimental|Formulation B|
32990446|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
32990447|NCT01527604|Placebo Comparator|Refined flour muffin|
32990448|NCT01527617|Active Comparator|Cranberry beverage|
32990449|NCT01527617|Placebo Comparator|Non-cranberry beverage|
32990450|NCT01527630|Experimental|Formulation A|
32990451|NCT01527630|Experimental|Formulation B|
32990452|NCT01527643|Experimental|Formulation A|
32990453|NCT01527643|Experimental|Formulation B|
32990454|NCT01527656|Experimental|Formulation A|
32990455|NCT01527656|Experimental|Formulation B|
32990456|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
32990457|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
32990458|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
32990459|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
32990460|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
32990461|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
32990462|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
32990463|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
32990464|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
32990465|NCT01527734|Placebo Comparator|Placebo|
32990466|NCT01527734|Experimental|Tetrodotoxin, TTX|
32990467|NCT01527747|Placebo Comparator|Placebo|Placebo arm
32990468|NCT01527747|Experimental|Saxagliptin|Active drug arm
32990469|NCT01527773||COPD cohort|Cohort of patients with proven COPD
32990470|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
32990471|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
32990472|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
32990473|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
32990474|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
32990475|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
32990476|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
32990477|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
33033589|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
32990478|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
32990479|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
32990480|NCT01527864|Experimental|pegylated endostatin|
32990481|NCT01527864|Placebo Comparator|Control|
32990482|NCT01527877|Experimental|BKM120|
32990483|NCT01527903|Active Comparator|Propofol|
32990484|NCT01527903|Active Comparator|Midazolam|
32990485|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
32990486|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
32990487|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
32990488|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
32990489|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
32990490|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
32990491|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
32990492|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
32990493|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
32990494|NCT01528007|Placebo Comparator|Placebo pill.|
32990495|NCT01528007|Active Comparator|50mg Naltrexone when needed|
32990496|NCT01528020|Experimental|Dialectical Behavior Therapy|
32990497|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
32990498|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
32990499|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
32990500|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
32990501|NCT01528098||PEG 4L|Those who taken PEG 4L alone
32990502|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
32990503|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
32990504|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
32990505|NCT01528176|Other|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
32990506|NCT01528189|Placebo Comparator|Standard glucose management|
32990507|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|
32990508|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
32990509|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
32990510|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
32990511|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
32990512|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
32990513|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
32990514|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
32990515|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
32990516|NCT01528306|Experimental|HP802-247|
32990517|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
32990518|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
32990519|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
32990520|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
32990521|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
32990522|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
32990523|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
32990524|NCT01528423||Men 16 - 18yrs|
32990525|NCT01528423||Men 30 - 32 yrs|
32990526|NCT01528423||Men 70 yrs +|
32990527|NCT01528423||Women 16 - 18 yrs|
32990528|NCT01528423||Women 30 - 32 yrs|
32990529|NCT01528423||Women 70 yrs +|
32990530|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
32990531|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
33033590|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
33105152|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
32990532|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
32990533|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
32990534|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
32990535|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
32990536|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
32990537|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
32990538|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
32990539|NCT01528501|Experimental|I|
32990540|NCT01528514|Active Comparator|Curcuminoids|
32990541|NCT01528514|Placebo Comparator|Placebo|
32990542|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
32990543|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
32990544|NCT01528553|Active Comparator|Staples|Old implant type
32990545|NCT01528553|Active Comparator|8plate|New implant type
32990546|NCT01528566|Experimental|Tai Chi|
32990547|NCT01528566|Placebo Comparator|Attentation control|
32990548|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
32990549|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
32990550|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
32990551|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
32990552|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
32990553|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
32990554|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
32990555|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
32990556|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
32990557|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
32990558|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
32990559|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
32990560|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
32990561|NCT01528670||Skull Base|
32990562|NCT01528670||Lower GI|
32990563|NCT01528670||Prostate|
32990564|NCT01528670||Pelvic Region|
32990565|NCT01528670||Head-and-Neck|
32990566|NCT01528670||Upper GI|
33413607|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
32990567|NCT01528670||Brain|
32990568|NCT01528670||Other|
32990569|NCT01528683|Experimental|Carbon Ion Radiotherapy|
32990570|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
32990571|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
32990572|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
32990573|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
33413608|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
33413609|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
33413610|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
33413611|NCT04053036|Experimental|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
32990574|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
32908351|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
32908352|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
33413612|NCT04053036|Experimental|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
33413613|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
33413614|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
32990575|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
32990576|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
32990577|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
32990578|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
32990579|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
32990580|NCT01528800|Placebo Comparator|Placebo|Microcrystalline Methylcellulose
32990581|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
32990582|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
32990583|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
32990584|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
32990585|NCT01528839|Placebo Comparator|Pill|
32990586|NCT01528839|Experimental|L-Thyroxine as addon|
32990587|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
32990588|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
32990589|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
33105153|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
32908353|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
33413615|NCT05202951||Patients with hemophilia|all adult patients follow-upin Hospital for hemophilia
32990590|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
32990591|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
32990592|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
32990593|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
32990594|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin~Amikacin is provided for inhalation via nebulization.~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~Administration time is approximately 20 minutes.~Amikacin will be administered for 2 years."
32990595|NCT01528943|Experimental|Prostacyclin|Treatment with prostacyclin
32990596|NCT01528943|Placebo Comparator|Isotonic saline|Treatment with isotonic saline
32990597|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
32990598|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
32990599|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
32990600|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
32990601|NCT01529021||control|standard care procedures were used during the vaccination
32990602|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
32990603|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
32990604|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
32990605|NCT01529073|Experimental|Nitazoxanide|
32990606|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~. A rise in PSA from nadir at any time post-nadir~. PSA change from baselin >0.2 mg/ml at any time post-baseline~. Abnormal DRE at any time post-baseline~. Free-PSA <12% at any time post-baseline~. At least one of the above 4 criteria~Subjects on Dutasteride that do not meet the above criteria"
32990607|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~Abnormal DRE at any time post-baseline~Change from baseline PSA ≥ 0.35 at any time post-baseline~Change from baseline PSA ≥ 0.75 at any time post-baseline~PSA ≥ 2.5 at any time post-baseline~PSA ≥ 4.0 at any time post-baseline~Percent Free PSA < 12% at any time post-baseline~At least one of the above 7 criteria.~Subjects on placebo that do not meet the above criteria"
32990608|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
32990609|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
32990610|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
32990611|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
32990612|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
32990613|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
32990614|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
32990615|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
32990616|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
32990617|NCT01529151|No Intervention|Control Group|
32990618|NCT01529164|Experimental|treatment|
32990619|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
32990620|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
32990621|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
32990622|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
32990623|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
32990624|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
32990625|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
32990626|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
32990627|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
32990628|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
32990629|NCT01529255|Experimental|ROADMAP|
32990630|NCT01529255|Active Comparator|SOC (Standard of Care)|
32990631|NCT01529281|Experimental|BCAA|Branched chain amino acid
32990632|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
32990633|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
32990634|NCT01529307|Experimental|TAS266|
32990635|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
32990636|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
32990637|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
32990638|NCT01529372|Experimental|Percutaneous renal denervation|
32990639|NCT01529398|Active Comparator|sensorimotor training (SMT)|
32990640|NCT01529398|Active Comparator|Resistance training (RT)|
32990641|NCT01529398|Sham Comparator|Control group (CG)|
32990642|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)~+ best suportive care, with regards clinical practice."
32990643|NCT01529411|Other|Best suportive care|Best suportive care
32990644|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
32990645|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
32990646|NCT01529463||Disease Management|
32990647|NCT01529476|Experimental|Nemonoxacin 500 mg|
32990648|NCT01529476|Active Comparator|Levofloxacin 500 mg|
32990649|NCT01529489|Active Comparator|Interval physical training Control group|
32990650|NCT01529489|Experimental|Resisted/Aerobic physical training group|
32990651|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
32990652|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
32990653|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
32990654|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
32990655|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
32990656|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
32990657|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
32990658|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
32990659|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
33105154|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
32990660|NCT01529567|Active Comparator|CBT without exposure|
32990661|NCT01529567|Experimental|CBT with exposure|
32990662|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
32990663|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
32990664|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
32990665|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
32990666|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
32990667|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
32990668|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
33105155|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
32864143|NCT04864860|Experimental|intervention arm|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). This dose was selected to be similar to previous studies that shows no harm or sever adverse effect on participants (12, 14)."
32864144|NCT04864860|Placebo Comparator|placebo arm|"The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
32864145|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
32864146|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
32864147|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
32864148|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
32864149|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
32864150|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
32864151|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
32864152|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
32864153|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
32864154|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
32864155|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
32864156|NCT04864782|Experimental|Cohort A|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)
32864157|NCT04864782|Experimental|Cohort B-arm1|On Day 1 of each 21-day cycle, participants receive an IV infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
32864158|NCT04864782|Experimental|Cohort B-arm2|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
32864159|NCT04875702|Active Comparator|TTT-SU|The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level < 6.0 mg/dL.
32864160|NCT04875702|Active Comparator|TTASx|Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.
32864161|NCT04864704|Active Comparator|Infraspinatus|Subjects infraspinatus stiffness was measured and observed
32864162|NCT04864704|Active Comparator|Erector spinae|Subjects erector spinae stiffness was measured and observed
32864163|NCT04864704|Active Comparator|Gastrocnemius|Subjects gastrocnemius stiffness was measured and observed
33105156|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
32990669|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
32990670|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
32990671|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
32990672|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
32990673|NCT01529684|Experimental|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906~Part B: (Optional) OSI-906 (non-labeled)"
32990674|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
33413616|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
32990675|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
32990676|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
32990677|NCT01529710|Active Comparator|Praziquantel|Tablets
32990678|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
32990679|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
32990680|NCT01529840|Experimental|High dose 66 mcg/kg/day|
32990681|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
32990682|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
32990683|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
32990684|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
32990685|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
32990686|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
32990687|NCT01529944|Experimental|High dose 66 mcg/kg/day|
32990688|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
32990689|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
32990690|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
32990691|NCT01529957|Placebo Comparator|placebol|placebol
32990692|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
32990693|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
32990694|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
32990695|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
32990696|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
32990697|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
32990698|NCT01529970||parkinson's disease, young onset|
32990699|NCT01529970||Normal|
32990700|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
32990701|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
32990702|NCT01530035|Active Comparator|soccer training intervention|
32990703|NCT01530035|Other|strength training intervention|
32990704|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
32990705|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
32990706|NCT01530048|Experimental|U200|
32990707|NCT01530048|Active Comparator|U100|
32990708|NCT01530074|Experimental|Study Group|
32990709|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
32990710|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
32990711|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
32990712|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
32990713|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
32990714|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
32990715|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
32990716|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
32990717|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
32990718|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
32990719|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
32990720|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
32990721|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
32990722|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
33413617|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
33413618|NCT05761743||PHPT and DM Patients, Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that decided with their physician/surgeon to continue with a parathyroidectomy (independent of research).
33413619|NCT05761743||PHPT and DM Patients, NO Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that have decided with their physician/surgeon to be managed medically with no parathyroidectomy.
33413620|NCT05200689|Experimental|Thoracotomy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, alongside the KT protocol.
32990723|NCT01530230|Other|Oxytocin 5 units|
32990724|NCT01530230|Other|Oxytocin 10 units|
32990725|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
32990726|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
33413621|NCT05200689|Experimental|Thoracoscopy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, alongside the KT protocol.
32990727|NCT01530295|No Intervention|contol|control group
32990728|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
32990729|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
32990730|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
32990731|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
32990732|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
32990733|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
32990734|NCT01530321|Other|High dose massage|18 visits for light massage
32990735|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
32990736|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
32990737|NCT01530386|Experimental|Lacosamide|300 mg/day
32990738|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
33413622|NCT05200689|No Intervention|Thoracotomy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, without the KT protocol.
33413623|NCT05200689|No Intervention|Thoracoscopy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, without the KT protocol.
32990739|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
32990740|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
32990741|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
32990742|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
32990743|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
32990744|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
32990745|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
32990746|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
32990747|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
32990748|NCT01530490|No Intervention|Hemoes|
32990749|NCT01530490|Experimental|Cabergoline|cabergoline
33413624|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
33413625|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
32908354|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
32908355|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
32908356|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
32908357|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
32908358|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
32908359|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
32908360|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
32908361|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
32908362|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
32908363|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
32908364|NCT03017222|Active Comparator|Ondansetron group|
32908365|NCT03017222|Experimental|Ramosetron group|
32908366|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
32908367|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
32908368|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
32908369|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
32908370|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
32908371|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
32908372|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
32908373|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
32908374|NCT03017144||Resuscitation team|Resuscitation pit crew model is educated to the resuscitation team.
32908375|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
32908376|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
32908377|NCT00952718|No Intervention|Control|No intervention.
32908378|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
32908379|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
32908380|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
32908381|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
32908382|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
32990750|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
32990751|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
32908383|NCT02245802||Low risk group|CU Prediction model < 3
32908384|NCT02245802||High risk group|CU Prediction model >=3
32990752|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
32990753|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
32990754|NCT01530529|Experimental|PF-05180999 Immediate-Release|
32990755|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
32990756|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
32990757|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
32990758|NCT01530542|Experimental|Treatment A|
32990759|NCT01530542|Experimental|Treatment B|
32990760|NCT01530542|Experimental|Treatment C|
32990761|NCT01530542|Experimental|Treatment D|
32990762|NCT01530542|Experimental|Treatment E|
32990763|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
32990764|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
32990765|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
32990766|NCT01530581|Experimental|G-BM Transplant|
32990767|NCT01530581|Other|G-PB Transplant|G-PB Transplant
32990768|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
32990769|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
32990770|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
32990771|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
32990772|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
32990773|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
32908385|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
32908386|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
32990774|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
32990775|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
32990776|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
32990777|NCT01530672|Experimental|ANC clients|
32990778|NCT01530685|Experimental|Glycabiane, gelule|
32990779|NCT01530685|Placebo Comparator|Placebo|
32990780|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
32990781|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
32990782|NCT01530711|Experimental|terlipressin|
32990783|NCT01530724|Experimental|low fat diet|Weight-loss diet strategy
32990784|NCT01530724|Experimental|low carb diet|Weight-loss diet strategy
32990785|NCT01530737|Placebo Comparator|Control Group|
32990786|NCT01530737|Experimental|Active Antithrombin Group|
32990787|NCT01530750||Post cardiac surgery|
32990788|NCT01530763|Experimental|Ceftaroline fosamil|
32990789|NCT01530763|Active Comparator|Ceftriaxone|
32990790|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
32990791|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
32990792|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
32990793|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
32990794|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
32990795|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
32990796|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
32990797|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
32990798|NCT01530854||Septic|
32990799|NCT01530854||Healthy|
32990800|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
33105157|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
33324587|NCT05560464|Experimental|Cohort 1: Mild Hepatic Impairment|Participants will receive multiple doses of VX-548 every 12 hours (q12h) from Day 1 through Day 14.
32903621|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
32903622|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
32903623|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
32903624|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
32903625|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
32903626|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
32903627|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
32903628|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
32903629|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
32903630|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
32903631|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
32903632|NCT01196117|Placebo Comparator|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
32903633|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
32903634|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
32903635|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
32903636|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
32903637|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
32903638|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
32903639|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
32903640|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
32903641|NCT04387058|Other|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
32903642|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
32903643|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
32903644|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
32903645|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
32903646|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
32903647|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
32903648|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
32903649|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
32903650|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
32903651|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
32990801|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
32990802|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
32990803|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
32990804|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
32990805|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
32990806|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
32990807|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
32990808|NCT01530958|Active Comparator|CKD Registry|
32990809|NCT01530958|Active Comparator|ATSM + Health Coach|
32990810|NCT01530958|Placebo Comparator|Usual Care (no interventions)|
32990811|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
32990812|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
32990813|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
32990814|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
32990815|NCT01531010|Active Comparator|Pressure-limited ventilation|
32990816|NCT01531010|Active Comparator|Volume-targeted ventilation|
32990817|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
32990818|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
32990819|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
32990820|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
32990821|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
32990822|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
32990823|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
32990824|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
32990825|NCT01531062|Placebo Comparator|Placebo|
32990826|NCT01531075|Experimental|ENGERIX-B|
32990827|NCT01531075|Experimental|Sci-B-Vac|
32990828|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
32990829|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
32990830|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
32990831|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
32990832|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
32990833|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
32990834|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
32990835|NCT01531127||ADHD Medication Treatment|Control group
32990836|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
32990837|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
32990838|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
32990839|NCT01531166||Chronic hepatitis B|
32990840|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
32990841|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
32990842|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
32990843|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
32990844|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
32990845|NCT01531218|Placebo Comparator|placebo|placebo 500mg
32990846|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
32990847|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
32990848|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
32990849|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
32990850|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
32990851|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
32990852|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
32990853|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
32990854|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
32990855|NCT01531283|Placebo Comparator|saline|saline
32990856|NCT01531309|Experimental|Mild Hepatic Impaired Participants|Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.
32990857|NCT01531309|Experimental|Moderate Hepatic Impaired Participants|Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.
32990858|NCT01531309|Experimental|Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)|Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.
32990859|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
32990860|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
32990861|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
32990862|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
32990863|NCT01531361|Experimental|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
32990864|NCT01531361|Experimental|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
32990865|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
32990866|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
32990867|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
32990868|NCT01531426||NIRS continuous monitoring|
32990869|NCT01531452|Experimental|treatment|oxaliplatin+s1
32990870|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
32990871|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
32990872|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
32990873|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
32990874|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
32990875|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
32990876|NCT01531517|Experimental|Pedyphar|Ointment
32990877|NCT01531517|Active Comparator|Panthenol|Ointment
32990878|NCT01531530|Experimental|Vaccine-recipients|
32990879|NCT01531530|Placebo Comparator|Placebo|
32990880|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
32990881|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
32990882|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
32990883|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
32990884|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
32990885|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
32990886|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
32990887|NCT01531634|No Intervention|No Additional Intervention|
32990888|NCT01531647|Active Comparator|Period 1 Control|
32990889|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
32990890|NCT01531660|Experimental|training|step up jogging program
32990891|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
32990892|NCT01531751|Experimental|High Cut-off Hemodialysis|
32990893|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
32990894|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
32990895|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
32990896|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
32990897|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
32990898|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
32990899|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
32990900|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
32990901|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
32990902|NCT01531868|Other|Auditory qualitative|
32990903|NCT01531868|Other|Auditory absolute risk|
32990904|NCT01531868|Other|Auditory relative risk|
32990905|NCT01531868|Other|Visual qualitative|
32990906|NCT01531868|Other|Visual relative risk|
32990907|NCT01531868|Other|Visual absolute risk|
32990908|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
32990909|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
32990910|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
32990911|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
32990912|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
32990913|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
32990914|NCT01531933|Experimental|DLBS3233|
32990915|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
32990916|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
32990917|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
32990918|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
32990919|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
32990920|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
32990921|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
32990922|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
32990923|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
32990924|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
32990925|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
32990926|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
32990927|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
32990928|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
32990929|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
32990930|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
32990931|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
32990932|NCT01532115|Experimental|BIA 9-1067|
32990933|NCT01532115|Placebo Comparator|Placebo|
32990934|NCT01532115|Active Comparator|moxifloxacin|
32990935|NCT01532180|Experimental|THN Therapy|
32990936|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
32990937|NCT01532193|No Intervention|Control group|Conventional culture conditions
32990938|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
32990939|NCT01532206|No Intervention|Standard of care|Standard of care
32990940|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
32990941|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
32990942|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
33413626|NCT05207007||posterior polar cataracts|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
33413627|NCT05207007||posterior lenticonus|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
33413628|NCT05284734|Experimental|Caudal block group|A 22 gauge 50 mm echogenic block needle placed through the sacrococcygeal membrane into the sacral canal in the longitudinal position, using the in-plane technique Negative aspiration was then performed 0.125% bupivacaine at a dose of 1 ml/kg was administered
33413629|NCT05284734|Experimental|Erector spinae block group|The erector spinae muscle and the transverse process were identified, and a 22 G, 80 mm echogenic block needle was advanced towards the transverse process until contact. Following hydrodissection, 1 ml/kg of 0.125% bupivacaine was injected deep into the erector spinae muscle
33413630|NCT05206851|Experimental|Manual Lymphatic Drainage and Hot pack|
33413631|NCT05206851|Active Comparator|Hot Pack|
33413632|NCT04023708||Cohort I: CYD-TDV exposed pregnant women and offspring|Pregnant women of any age and their offspring who were inadvertently exposed to CYD-TDV anytime during the pregnancy or in the 30 days preceding their LMP
33413633|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
33413634|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
33413635|NCT05185713||Ctrl HPV (-)|Patients with normal cervix and HPV negative
33413636|NCT05185713||Ctrl HPV (+)|Patients with normal cervix and HPV positive
33413637|NCT05185713||LSIL group|Patients with low-grade squamous Intraepithelial lesion
33413638|NCT05185713||HSIL group|Patients with high-grade squamous Intraepithelial lesion
33413639|NCT05185713||ICC group|Patients newly diagnosed invasive cervical cancer
33413640|NCT05762289|Experimental|Change in range of motion and within the weight bearing group|. Subjects in Group A or treatment group were seated and given thrust manipulation using belt. Cervical spine was placed in neutral position and belt was stabilized on C4-C5 which is the part that causes most stiffness and pain and lost of range. Patient placed belt in left hand for left sided thrust and caudal force was applied , therapist held other end of the belt and applied stretch in the line of eye ball. The cervical spine of patient was guided in left rotation until resistance was felt and than thrust of high velocity low amplitude was given by therapist . This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day. Therapist performing manipulation was skilled in giving belt thrust manipulation.
33413641|NCT05762289|Active Comparator|Control|While Group B received manipulation in supine position by maitland's traditional thrust. Where the neck is slightly flexed by therapist hand on the occipit where therapist is standing behind the head. Neck is guided in right side flexion and opposite rotation and at the end of rang high velocity low amplitude thrust is applied. This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day
33413642|NCT05174949|Experimental|Anodal stimulation|Anodal stimulation targeting hemisphere
33413643|NCT05174949|Experimental|Cathodal stimulation|Cathodal one at the contralesional hemisphere
33413644|NCT05174949|Experimental|Sham stimulation|Sham stimulation to the brain
33413645|NCT05200611||Fecal Immunochemical Test|People in this group with positive fecal immunochemical test results were further examined by colonoscopy.
32990943|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
32990944|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
32990945|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
33413646|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
33413647|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
33413648|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
33413649|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
33413650|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
33413651|NCT05206461||Hemiparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Hemiparetic CP
33413652|NCT05206461||Diparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Diparetic CP
33413653|NCT05206305|Experimental|AD Patients|Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
33413654|NCT05206149|Experimental|Intranasal Administration of Glucagon|Intranasal administration of glucagon in healthy subjects
33413655|NCT05206149|Placebo Comparator|Intranasal Administration of Placebo|Intranasal administration of placebo (isotonic saline solution) in healthy subjects
33413656|NCT05206071|Experimental|SL 19+22 CAR-T|
32990946|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
32990947|NCT01532271||Concussed|Patients with recent concussion
33413657|NCT05170893|Experimental|Intervention group|Oral Coenzyme Q10 capsules daily for 12 weeks.
33413658|NCT05170893|Placebo Comparator|Control group|Oral capsules similar to the intervention daily for 12 weeks.
32864164|NCT04875858|Active Comparator|healthy old adults aged 70-75 years who received PPSV23|Recruitment of 254 healthy 70-75-year healthy old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
32864165|NCT04875858|Experimental|old adults who have diabetes mellitus aged 70-75 years who rec|Recruitment of 254 healthy 70-75-year diabetic old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
32864166|NCT03047850||Study Group|All patients included in this study.
32990948|NCT01532271||Matched controls|Athletes with no recent concussion
32864167|NCT04865016|Active Comparator|MIOL Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with a low add (+2.75 Diopters [D]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group).
32864168|NCT04865016|Active Comparator|EDOF Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with an EDOF (Tecnis Symfony [ZXR00]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
32864169|NCT04385940|Experimental|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
32864170|NCT04385940|Active Comparator|Low dose vitamin D|Vitamin D3 1000IU
32864171|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
32864172|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
32864173|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
32864174|NCT04864314|Placebo Comparator|Control group|Group supplemented with a daily dose of placebo
32864175|NCT04864314|Experimental|Experimental group|Group supplemented with a daily dose of TetraSOD®
32864176|NCT04875312|Experimental|Group USC|Effect of ultrasound cavitation sessions on sex hormones in obese infertile patients with poly cystic ovarian syndrome
32864177|NCT04875312|Experimental|Group EA|Effect of electro acupuncture on sex hormones in obese infertile patients with poly cystic ovarian syndrome
32864178|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
32864179|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
32864180|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
32864181|NCT02760485|Experimental|itacitinib + ibrutinib|
32864182|NCT04875468|Active Comparator|Zirconia crown cemented by adhesive resin cement|MultiRein link adhesive resin cement (non MDP, non-calcium and fluoride releasing cement)
32864183|NCT04875468|Experimental|Zirconia crown cemented by self-adhesive resin cement|TheraCem self-adhesive resin cement (MDP, calcium and fluoride releasing cement)
32864184|NCT04875000|Active Comparator|UltraEZ|"Group of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA) after teeth bleaching"
32864185|NCT04875000|Experimental|Arginine|Group of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
32864186|NCT04875000|Experimental|Nano-hydroxyapatite|Group of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
32864187|NCT04874844|Other|Test drug group|Phase II Dose Addition Stage JY025 12MG / KG and 16mg / kg Q3W Givenate Combined EGFRTKI (Gifan Totibi 250mg or Erlotini 150mg) QD scheme, 6 cases of each dose group in group (Gifanibini 3 cases of Erlotini); 1 or 2 doses of JY025 in dose expansion phase Q3W administration combined with EGFR-TKI (50mg or Ellotini 150mg) QD scheme, each dose group 6 Examples of subjects (3 cases of Gifeng Tinib and Ellotini).
32864188|NCT04874844|Active Comparator|Group type|Phase III 396 patient JY025 injection and placebo combined with Notes Totibi / Erlotini (Gifeng Totibi 250mg or Erlotini 150mg) Q3W QD treatment group is randomly packet in 1: 1 ratio (in each group) Gifanibi and Erlotini are 2: 1)
32864189|NCT02740985|Experimental|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
32864190|NCT02740985|Experimental|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
32864191|NCT02740985|Experimental|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
32864192|NCT02740985|Experimental|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
32864193|NCT02740985|Experimental|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
32864194|NCT02740985|Experimental|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
32864195|NCT02740985|Experimental|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
32864196|NCT02740985|Experimental|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
33033591|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
32864197|NCT02740985|Experimental|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
33105158|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
33105159|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
33105160|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33105161|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33105162|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33324588|NCT05560464|Experimental|Cohort 2: Matched Healthy Participants|Healthy participants matched to cohort 1 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
33324589|NCT05560464|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
32864198|NCT02740985|Experimental|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
32864199|NCT02740985|Experimental|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
32864200|NCT02740985|Experimental|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
32864201|NCT02740985|Experimental|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
32864202|NCT02740985|Experimental|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
32864203|NCT02740985|Experimental|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
32864204|NCT02740985|Experimental|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
32864205|NCT02740985|Experimental|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
32864206|NCT02740985|Experimental|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
32864207|NCT04430088|Experimental|VVZ-149 Injections|
32864208|NCT04430088|Placebo Comparator|Placebo|
32864209|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
32864210|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
32864211|NCT04349124|Other|Treatment Group|The treatment group will be provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
32990949|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
32990950|NCT01532284|No Intervention|No Polar Body Biopsy|
32990951|NCT01532297|Active Comparator|HD treated with standard dialysate|
32990952|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
32990953|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
32990954|NCT01532297|Experimental|HD treated with citrate dialysate|
32990955|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
32990956|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
32990957|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
32990958|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
32990959|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
32990960|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
32990961|NCT01532375|Experimental|Kochujang(32g)|
32990962|NCT01532375|Placebo Comparator|placebo(32g)|
32990963|NCT01532401|Experimental|chlorure de sodium|
32990964|NCT01532401|Placebo Comparator|Methylcellulose|
32990965|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
32990966|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
32990967|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
32990968|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
32990969|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
32990970|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
32990971|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
32990972|NCT01532492||Shoulder instability|Shoulder instability
32990973|NCT01532518|Experimental|Cohort 3|Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days
32990974|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days
32990975|NCT01532518|Experimental|Cohort 1|Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days
32990976|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
32990977|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
32990978|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
32990979|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
32990980|NCT01532583||Patients operated on with the TOT|
32990981|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
32990982|NCT01532596|No Intervention|Wait-List|
32990983|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
32990984|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
32990985|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
32990986|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
32990987|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
32990988|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
32990989|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
32990990|NCT01532713|Experimental|non-block side|
32990991|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
32990992|NCT01532739|Experimental|Cognitive training|
32990993|NCT01532739|No Intervention|No cognitive training|
32990994|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
32990995|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
32990996|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
32990997|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
32990998|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
32990999|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
32991000|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
32991001|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
32991002|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
32991003|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
32991004|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
32991005|NCT01532882|Experimental|Diosmin|
32991006|NCT01532882|Placebo Comparator|Placebo|
32991007|NCT01532895||Hydromorphone HCI OROS|
32991008|NCT01532947|Experimental|post restoration|
32991009|NCT01532947|No Intervention|no post restoration|no post placement
33413659|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
33413660|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
32991010|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
32991011|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
32991012|NCT01533012|No Intervention|FOB evaluation|FOB evaluation for the optimal position of tubes
32991013|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
32991014|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
32991015|NCT01533051||Chronic hepatitis B|
32991016|NCT01533064||Psychiatric Outpatients|
32991017|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
32991018|NCT01533090|Experimental|PEG low volume with bisacodyl|
32991019|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
32991020|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
32991021|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
32991022|NCT01533142||Morbid obesity|
32991023|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
32991024|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
32991025|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
32991026|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
32991027|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
32991028|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 3 days"
32991029|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 3 days"
32991030|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
32991031|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
32991032|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
32991033|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
32991034|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
32991035|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
32991036|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
32991037|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
32991038|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
32991039|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
32991040|NCT01533298|Experimental|CombiflexOmega peri|
32991041|NCT01533298|Active Comparator|SmofKabiven peripheral|
32991042|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
32991043|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
32991044|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
32991045|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
32991046|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
32991047|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
32991048|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
32991049|NCT01533389|Experimental|Silodosin|8mg QD
32991050|NCT01533389|Placebo Comparator|Placebo|8mg QD
32991051|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
32991052|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
33413661|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
33413662|NCT05761041|Experimental|Naf + MI|Sodium Fluoride Varnish 5% (Applied biannually) + two MI sessions: baseline face-to-face session and phone call after 3months.
32991053|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
32991054|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
32991055|NCT01533441|Placebo Comparator|placebo low VKA|
32991056|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
32991057|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
32991058|NCT01533441|Active Comparator|Vitamin K2 high VKA|
32991059|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
32991060|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
32991061|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
32991062|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
32991063|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
32991064|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
32991065|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
32991066|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
32991067|NCT01533532|Experimental|KLH-2109, low dose|
32991068|NCT01533532|Experimental|KLH-2109, medium dose|
32991069|NCT01533532|Experimental|KLH-2109, high dose|
32991070|NCT01533532|Placebo Comparator|placebo|
32991071|NCT01533545|Active Comparator|Plain mepivacaine|
32991072|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
32991073|NCT01533558||caspofungin|caspofungin dosing
32991074|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
32991075|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
32991076|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
32991077|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
33413663|NCT05761041|Active Comparator|SDF|Silver Diamine fluoride 38% (Applied biannually)
33413664|NCT05166057|Experimental|Telerehabilitation Group (TG)|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
33413665|NCT05166057|Experimental|Video Group (VGr)|After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent and the participants will be asked to do exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
32991078|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
32991079|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
32991080|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
32991081|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
32991082|NCT01533675|Experimental|Hydrogen peroxide|
32991083|NCT01533675|Active Comparator|Saline|
32991084|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
32991085|NCT01533727|Active Comparator|Group B|chemotherapy alone
32991086|NCT01533766|Experimental|CombiflexOmega|
32991087|NCT01533766|Active Comparator|SmofKabiven|
32991088|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
32991089|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
32991090|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
32991091|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
32991092|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
32991093|NCT01533818|Placebo Comparator|Sugar Syrup|
32991094|NCT01533844||Neonates|Neonates with CDAD
32991095|NCT01533857|Experimental|Black tea|black tea
32991096|NCT01533857|Placebo Comparator|placebo|
32991097|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
32991098|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
33105163|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33105164|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33231706|NCT04102566|Experimental|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Ibuprofen 600mg every 6 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~Patient Education (Figures 2 & 3)~The multi-modal group will receive the following prescriptions on discharge:~Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs~Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
32864212|NCT04349124|No Intervention|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the severe range (>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
32864213|NCT04874688|Active Comparator|IYCF-Only|Infants in the IYCF-only arm will receive white maize and SQ-LNS daily from 6 months of age, and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
32864214|NCT04874688|Experimental|IYCF-Plus|Infants in the IYCF-plus arm will receive orange provitamin A-fortified maize and SQ-LNS daily from 6 months of age, plus powdered NUA-45 sugar beans, moringa leaf powder, and powdered whole egg; and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
32864215|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
32864216|NCT04874298|Experimental|Intervention Arm 1 (Ginger Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use ginger oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
32864217|NCT04874298|Experimental|Intervention Arm 2 (Peppermint Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
32864218|NCT04874298|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
32864219|NCT04874142|Experimental|A Group|Two cohort, single sequence
32864220|NCT04874142|Experimental|B Group|Two cohort, single sequence
32864221|NCT02730299|Experimental|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
32864222|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
32864223|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
32864224|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
32864225|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
32864226|NCT04869150||those with myocardial bridges|
32864227|NCT04869150||those without myocardial bridges|
32864228|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
32864229|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
32864230|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
32864231|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
32864232|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
32864233|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
32864234|NCT04553003|Experimental|glucocorticoid+hepatoprotectant group|glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d
32864235|NCT04553003|Active Comparator|hepatoprotectant group|hepatoprotectant for 7d
32864236|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
32864237|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
32864238|NCT02928341|No Intervention|No intervention|Current water supply access
32864239|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
32864240|NCT04395209|Experimental|stroke individuals|
32864241|NCT04395209|Active Comparator|healthy individuals|
32864242|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
32864243|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
32864244|NCT04868448||Vaccinated participants|Participants who received 1or 2 doses of the Covid-19 vaccines
32864245|NCT04868448||Unvaccinated participants|Participants who have not received any dose of the Covid-19 vaccines
32864246|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
32864247|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
32864248|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
32864249|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
32864250|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
32864251|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
32864252|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
32864253|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
32864254|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
32864255|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
32864256|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
32864257|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
32864258|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
32864259|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
32864260|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
32864261|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
32864262|NCT02926079||Pregnant women diagnosed with gestational diabetes|
32864263|NCT02926079||Pregnant women with normal pregnancy|
32903652|NCT04270448|Active Comparator|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
33413666|NCT05166057|Experimental|Standard pulmonary rehabilitation group (SGr)|The SGr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and participants will be asked to do exercises at home for 1 day. The exercise period will be 8 weeks for both groups.
33413667|NCT05156619||Cohort#1|new annual breast cancer cases and cases of recurrence at Hadassah University hospital between 2018-2021 (700)
33413668|NCT05156619||Cohort#2|Retrospective study - all clinical trial patients in the Sharett institute of oncology between 1.1.12-30.6.21 (300)
32903653|NCT04270448|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
32903654|NCT04270448|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
32903655|NCT04270370|Experimental|LY3478045 (Part A)|LY3478045 administered orally.
32903656|NCT04270370|Placebo Comparator|Placebo (Part A)|Placebo administered orally
32903657|NCT04270370|Experimental|LY3478045 (Part B)|LY3478045 administered orally.
32903658|NCT04270370|Placebo Comparator|Placebo (Part B)|Placebo administered orally
32903659|NCT04270370|Experimental|LY3478045 + Atorvastatin (Part B)|LY3478045 co-administered with atorvastatin orally.
32903660|NCT04270370|Placebo Comparator|Placebo + Atorvastatin|Placebo co-administered with atorvastatin orally.
32903661|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
32903662|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
32903663|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
32903664|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
32903665|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
32903666|NCT02995850|Experimental|anti-cancer drug|
32903667|NCT01288859|Experimental|encapsulated curcumin|
32903668|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
32903669|NCT01288859|Active Comparator|free cocoa polyphenol|
32903670|NCT01288859|Placebo Comparator|control|
32903671|NCT01288859|Experimental|encapsulated cocoa polyphenols|
32903672|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
32903673|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
32903674|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
32903675|NCT00659828|Experimental|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
32903676|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
32903677|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
32903678|NCT04387214||Veterinary students and researchers|
32903679|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
32903680|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
32903681|NCT00660530|Active Comparator|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
32903682|NCT00660530|Experimental|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
32903683|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
32903684|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
32903685|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
33231707|NCT04106778|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
33413669|NCT05156619||Cohort#3|all newly diagnosed recurrent/metastatic disease during the study period (200)
32991099|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
32991100|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
32991101|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
32991102|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
32991103|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
32991104|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
32991105|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
32991106|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
32991107|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
32991108|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
32991109|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
32991110|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
32991111|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
32991112|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
32991113|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
32991114|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
32991115|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
32991116|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
32991117|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
32991118|NCT01534130|Experimental|acupuncture|
32991119|NCT01534130|Sham Comparator|sham acupuncture|
32991120|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
32991121|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
32991122|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
32991123|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
32991124|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
32991125|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
32991126|NCT01534234|Experimental|SonR group|SonR CRT Optimization
32991127|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
32991128|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
32991129|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
32991130|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
32991131|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
32991132|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
32991133|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
32991134|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
32991135|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
32991136|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
32991137|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
33231708|NCT04106778|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
33231709|NCT00916110|Experimental|1.5mgSC|ATN-103
33231710|NCT00916110|Experimental|4mgSC|ATN-103
33231711|NCT00916110|Experimental|10mgSC|ATN-103
33231712|NCT00916110|Experimental|25mgSC|ATN-103
33231713|NCT00916110|Experimental|25mgIV|ATN-103
33231714|NCT00916110|Experimental|50mgSC|ATN-103
33231715|NCT00916110|Experimental|100mgSC|ATN-103
33231716|NCT00916110|Experimental|200mgSC|ATN-103
33231717|NCT00916110|Experimental|200mgIV|ATN-103
33231718|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
33231719|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
33231720|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
33231721|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
33033592|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
32903686|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
32903687|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
32903688|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
32903689|NCT01235897|Experimental|Maximum tolerated dose|
32903690|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
32903691|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
32903692|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
32903693|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
32903694|NCT02994368||Primary Cohort|No intervention
32903695|NCT02994368||Expansion Cohort|No intervention
32903696|NCT02996708||Group with teleconsultation - before period|
32903697|NCT02996708||Group without teleconsultation - before period|
32903698|NCT02996708||Group with teleconsultation - after period|
32903699|NCT02996708||Group without teleconsultation - after period|
32903700|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
32903701|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
32903702|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
32903703|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
32903704|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
32903705|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
32903706|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
32903707|NCT02997878|Experimental|AIH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
32903708|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
32903709|NCT01237301|Experimental|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
32903710|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
32903711|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
32903712|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
32903713|NCT02999750|Other|individual therapy|individual therapy
32903714|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
32903715|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
32903716|NCT00706784|Experimental|A|
32903717|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
32903718|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
32991138|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
33324590|NCT05560464|Experimental|Cohort 4: Matched Healthy Participants|Healthy participants matched to cohort 3 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
33324591|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
33324592|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
33324593|NCT03917238|Other|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
33324594|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
32991139|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
32991140|NCT01534364|No Intervention|control|Ad libitum alimentation
33413670|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
32991141|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
32991142|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
32991143|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
32991144|NCT01534390|Experimental|Use of in-line microfilters|
32991145|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
32991146|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
32991147|NCT01534442|Active Comparator|Atropin|Atropin
32991148|NCT01534442|Placebo Comparator|Placebo|Saline
32991149|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
32991150|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
32991151|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
32991152|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
32991153|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
33413671|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
32991154|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
32991155|NCT01534494|Experimental|psilocybin|
32991156|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
32991157|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
32991158|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
32991159|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
32991160|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
32991161|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
32991162|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
32991163|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
33413672|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
32991164|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
32991165|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
32991166|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
32991167|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
33324595|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
33324596|NCT01329588|Placebo Comparator|Sugar pill|
33324597|NCT01329588|Experimental|Treatment arm|
33324598|NCT01136694||RA patients who are new bDMARD users|
33324599|NCT01136694||RA patients who are existing DMARD users|
33324600|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
33324601|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
32991168|NCT01534702|Experimental|Treatment|
32991169|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
32991170|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
32991171|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
32991172|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
32991173|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
32991174|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
32991175|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
32991176|NCT01534780|Experimental|fixation with Protack|
32991177|NCT01534780|Experimental|fixation with Securestrap|
32991178|NCT01534780|Experimental|fixation with Glubran|surgery
32991179|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
32991180|NCT01534806|Experimental|ketorolac|
32991181|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
32991182|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
32991183|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
32991184|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
32991185|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
32991186|NCT01534884|Active Comparator|MabThera|rituximab
32991187|NCT01534884|Active Comparator|CT-P10|rituximab
32991188|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
32991189|NCT01534936||Schizophrenic outpatients with affective symptoms.|
32991190|NCT01534949|Experimental|CT-P10|rituximab
32991191|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
33324602|NCT05088252|Experimental|Desflurane Inhalational Anesthesia|
33324603|NCT05088252|Active Comparator|Propofol Total Intravenous Anesthesia|
33324604|NCT05054244||control group|The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
33324605|NCT05054244||HBOT group|"The patients in HBOT group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue.~The HBOT sessions will be performed 5 days a week in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires as in control group."
33324606|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
33324607|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
33324608|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
33413673|NCT03629301|Other|Wait-list Group|
33413674|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fasted (Without Food)|Oral Dose
33231722|NCT04103658|No Intervention|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
33413675|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fed (With food)|Oral Dose
33413676|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 2 x 7.5 and 2 x 5.0 mg tablets, Fasted (Without Food)|Oral Dose
32991192|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
32991193|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
32991194|NCT01535079|Placebo Comparator|Placebo|
32991195|NCT01535079|Experimental|V0498TA01A 15 mg|
32991196|NCT01535079|Experimental|V0498TA01A 25 mg|
32991197|NCT01535079|Experimental|V0498TA01A 35 mg|
32991198|NCT01535079|Other|Strefen|Positive control
33413677|NCT05056779|Experimental|Nemolizumab|
33413678|NCT05056779|Experimental|Placebo|
33413679|NCT05129163|Placebo Comparator|Exercise|The control group received weekly one-hour group exercise training for 3 months.
33413680|NCT05129163|Experimental|Exercise and nutrition|The intervention group had weekly one-hour group exercise training the same as the control and an additional weekly one-hour group nutrition session for 3 months.
33413681|NCT05205837|Placebo Comparator|Active Comparator - placebo|Intervention: Intramuscular injection - placebo Intervention: Drug: placebo
33413682|NCT05205837|Active Comparator|Active comparator - treatment|Intervention: intramuscular injection - hCG Intervention: Drug: Letrozole
33413683|NCT05761665||Alzheimer|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
33413684|NCT05761665||Physically Fragile|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
32991199|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
32991200|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
32991201|NCT01535105||Obese Adolescents|
32991202|NCT01535144|Experimental|degradable metallic device|
32991203|NCT01535144|Active Comparator|non-degradable metallic device|
32991204|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
32991205|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
32991206|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
32991207|NCT01535183|Experimental|Irinotecan|
32991208|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
32991209|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
32991210|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
32991211|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
32991212|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
32991213|NCT01535300||Elective pediatric surgery|
32991214|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
32991215|NCT01535313|Experimental|Powered|
32991216|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
32991217|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
32991218|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
32991219|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
33413685|NCT05761665||Healthy|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
33413686|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
32991220|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
33413687|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
32991221|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
32991222|NCT01535404|Active Comparator|Right ventricular apex pacing|
32991223|NCT01535404|Experimental|Left ventricular apex pacing|
32991224|NCT01535417|Experimental|GCSB|
32991225|NCT01535417|Active Comparator|Celebrex|
32991226|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
32991227|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
32991228|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
32991229|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
32991230|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
32991231|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
32991232|NCT01535521|Other|SPT in patients with MAD|
32991233|NCT01535547|Experimental|isavuconazole and tacrolimus|
32991234|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
32991235|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
32991236|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
32991237|NCT01535625|Other|Momo stent|Patients with PCI
32991238|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
32991239|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
32991240|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
32991241|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
32991242|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
32991243|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
32991244|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
32991245|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
32991246|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
32991247|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
32991248|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
32991249|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
32991250|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
32991251|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
32991252|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
32991253|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
32991254|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
32991255|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
32991256|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
32991257|NCT01535794||18-26 year old men who have sex with men|
32991258|NCT01535820|Experimental|Treatment sequence AB|
32991259|NCT01535820|Experimental|Treatment sequence BA|
32991260|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
33413688|NCT05205603|Placebo Comparator|Biologics group|"Biologics including infliximab and vedolizumab. infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks."
32991261|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
32991262|NCT01535846|No Intervention|Control|
32991263|NCT01535859|Experimental|Cabergoline|
32991264|NCT01535859|Placebo Comparator|Placebo|
32991265|NCT01535872|Experimental|DHEA treatment|
32991266|NCT01535872|No Intervention|No treatment|
32991267|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
32991268|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
32991269|NCT01535989|Experimental|intravenous|dose escalation
32991270|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
32991271|NCT01536028|Active Comparator|BIAsp 30|
32991272|NCT01536028|Experimental|BIAsp 50|
32991273|NCT01536028|Experimental|BIAsp 70|
32991274|NCT01536028|Active Comparator|IAsp|
32991275|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
32991276|NCT01536080||Reflux esophagitis (RE)|
32991277|NCT01536080||Non-erosive reflux disease (NERD)|
32991278|NCT01536080||Functional heartburn (FH)|
33324609|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
33324610|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
32991279|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
32991280|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
32991281|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
32991282|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
32991283|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
32991284|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
32991285|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
32991286|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
32991287|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
32991288|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
32991289|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
32991290|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
32991291|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
32991292|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
32991293|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
32991294|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
33324611|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
33324612|NCT03917004|Experimental|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
33324613|NCT03917004|No Intervention|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
33324614|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
33324615|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
33324616|NCT03916926|Experimental|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
32991295|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
32991296|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
32991297|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
32991298|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
32991299|NCT01536353|Experimental|AGSAV301|
32991300|NCT01536353|Active Comparator|Exforge 10/160|
32991301|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
32991302|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
32991303|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
32991304|NCT01536444|Experimental|Micrografting|
32991305|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
32991306|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
32991307|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
32991308|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
32991309|NCT01536509|Experimental|Telehealth Behavioral Treatment|
32991310|NCT01536509|Active Comparator|Education Only|
32991311|NCT01536548|Experimental|Skin drawing|
32991312|NCT01536548|Active Comparator|No skin drawing|
32991313|NCT01536600||BIAsp 30 users|
32991314|NCT01536613||BIAsp 30 users|
32991315|NCT01536626||BIAsp 30 users|
32991316|NCT01536639||BIAsp 30 users|
32991317|NCT01536652||BIAsp 30 users|
32991318|NCT01536665|Experimental|Low|
32991319|NCT01536665|Experimental|Medium|
32991320|NCT01536665|Experimental|High|
32991321|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
32991322|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
32991323|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
32991324|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
32991325|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
32991326|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
32991327|NCT01536730|Experimental|Homework Intervention Strategy|
32991328|NCT01536730|No Intervention|Control|
32991329|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
32991330|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
32991331|NCT01536756|Other|Wait List Control Group|
32991332|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
32991333|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
33033593|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
33033594|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
33033595|NCT01964482|No Intervention|Usual care|Usual care
33033596|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
33033597|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
33033598|NCT01964573|Experimental|Rotigotine group|
33033599|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
33033600|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
33033601|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
33033602|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
33413689|NCT05205603|Experimental|5-ASA group|"5-ASA combined with biologics (including infliximab and vedolizumab). infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks.~mesalazine: at a dose of 4-6g/d systemic or topical therapy"
32991334|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
33413690|NCT05043285|Experimental|20 µg dose, 18-59 years of age (phase 1/2)|
33413691|NCT05043285|Experimental|20 µg dose, ≥60 years of age (phase 1/2)|
33413692|NCT05043285|Experimental|40 µg dose, 18-59 years of age (phase 1/2)|
33413693|NCT05043285|Experimental|40 µg dose, ≥60 years of age (phase 1/2)|
33413694|NCT05043285|Placebo Comparator|Placebo, 18-55 years of age (phase 1/2)|
33413695|NCT05043285|Placebo Comparator|Placebo, ≥60 years of age (phase 1/2)|
32991335|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
32991336|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
32991337|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
32991338|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
32991339|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
32991340|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
32991341|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
32991342|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
32991343|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
32991344|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
32991345|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
32991346|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
32991347|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
32991348|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
32991349|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
32991350|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
32991351|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
32991352|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
32991353|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
32991354|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
32991355|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
32991356|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
32991357|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32991358|NCT01537146|Active Comparator|Femoral Block|
33413696|NCT05042115|Experimental|Education in pain neurosciences and clinical hypnosis|Pain neuroscience education and clinical hypnosis
32991359|NCT01537146|Active Comparator|Local Infiltration Anagesia|
32991360|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
32991361|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
32991362|NCT01537172|Placebo Comparator|Placebo|
32991363|NCT01537224|Other|neurostimulation|
32991364|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
33413697|NCT05042115|Active Comparator|Education in pain neurosciences and clinical hypnosis plus Osteopathic manipulative treatment|Pain neuroscience education and clinical hypnosis, associated with osteopathic manipulative treatment
32991365|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
32991366|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
32991367|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
32991368|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
32991369|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
32991370|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
32991371|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
32991372|NCT01537289|Experimental|Pigtail catheter|
32991373|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
32991374|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
32991375|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
32991376|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
32991377|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
32991378|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
32991379|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
32991380|NCT01537380|Experimental|Cefazoline|
32991381|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
32991382|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
32991383|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
32991384|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
32991385|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
32991386|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
32991387|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
32991388|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
32991389|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
32991390|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
32991391|NCT01537510|Active Comparator|Usual Care|
32991392|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
32991393|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
32991394|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
32991395|NCT01537523|No Intervention|control|
32991396|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
32991397|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
32991398|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
33413698|NCT05762211|Experimental|Oral pooled fecal microbiotherapy - MaaT033|3 capsules per day
32991399|NCT01537575|Placebo Comparator|saline solution|
32991400|NCT01537575|Experimental|intravenous immunoglobulins|
33413699|NCT05762211|Placebo Comparator|Placebo capsule|3 capsules per day
33413700|NCT04380519|Experimental|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
32991401|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
32991402|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
33413701|NCT04380519|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
33413702|NCT04380519|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
32991403|NCT01537588|No Intervention|Normal matched|
32991404|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
32991405|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
32991406|NCT01537614|Experimental|COLIMYCINE injectable|
32991407|NCT01537614|Experimental|COLIMYCINE inhalation|
33413703|NCT05760963||Adult with lumbar echography indication|Adult with lumbar echography indication will be included.
33413704|NCT05004051||Patients who are booked for and then subsequently have undergone endovascular repair.|
33413705|NCT05004051||Patients with infrarenal AA without indications for repair undergoing serial monitoring|
32991408|NCT01537627|Active Comparator|Low-intensity training (LT)|
32991409|NCT01537627|Active Comparator|High-intensity training (HT)|
32991410|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
32991411|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
32991412|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
32991413|NCT01537653|Placebo Comparator|Placebo|Placebo
32991414|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
32991415|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
32991416|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
32991417|NCT01537679|Other|Meditation Intervention|
32991418|NCT01537679|Other|Relaxation Intervention|
32991419|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
33413706|NCT01569867||statin|
32991420|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
32991421|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
32991422|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
32991423|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
33413707|NCT04980573|Experimental|Intervention|Participants receive a bottle of plant-based oil to inhale twice daily for 14 days.
33413708|NCT04980573|Placebo Comparator|Placebo|Participants receive a bottle of inert oil to inhale twice daily for 14 days.
33413709|NCT05761587||cancer patients|Questionnaires
33413710|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
33413711|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
33413712|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
32991424|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
32991425|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
32991426|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
32991427|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
32991428|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
32991429|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
32991430|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
32991431|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
32991432|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
32991433|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
33033603|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
33033604|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
33413713|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
33413714|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
32991434|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
32991435|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
32991436|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
32991437|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
32991438|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
32991439|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
32991440|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
32991441|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
32991442|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
32991443|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
32991444|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
32991445|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
32991446|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
32991447|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
32991448|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
32991449|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
32991450|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
32991451|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
33033605|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
33413715|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
32991452|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
32991453|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
32991454|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
32991455|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
33413716|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
33413717|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
33413718|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.~Teach session will occur prior and during administration of chemo~A small quiz will be conducted to asses understanding of the educational binder"
33413719|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
33413720|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
33413721|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
33413722|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
33413723|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
33413724|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
33413725|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
33413726|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
32991456|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
32991457|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
32991458|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
32991459|NCT01538069|No Intervention|Control group|
32991460|NCT01538069|Experimental|Exercise group|
32991461|NCT01538069|Experimental|CPAP group|
32991462|NCT01538069|Experimental|Exercise and CPAP group|
32991463|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
32991464|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
32991465|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
32991466|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
32991467|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
32991468|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
32991469|NCT01538121||Controls|Patients with normal pregnancies at term.
32991470|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
32991471|NCT01538134||Control|Patients with normal pregnancies at term.
32991472|NCT01538147||Cases|Patients with Severe preeclampsia
32991473|NCT01538147||Control|Patients with normal pregnancies at term
32991474|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
32991475|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
32991476|NCT01538186||PCI without treating the side branch|
32991477|NCT01538186||PCI with treating the side branch|
32991478|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
32991479|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
32991480|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
32991481|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
32991482|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
32991483|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
32991484|NCT01538277|Active Comparator|Standard|Standard ablation arm
32991485|NCT01538316|Active Comparator|Quercetin supplement|
32991486|NCT01538316|Active Comparator|Genistein supplement|
32991487|NCT01538316|Placebo Comparator|Placebo|
32991488|NCT01538329|Experimental|Amantadine|Patients with amantadine
32991489|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
32991490|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
32991491|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
32991492|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
32991493|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
32991494|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
32991495|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
32991496|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
32991497|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
32991498|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
32991499|NCT01538381|Other|Observation|No treatment only observation
32991500|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
32991501|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
32991502|NCT01538407|No Intervention|Control group|No intervention group
32991503|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
32991504|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
32991505|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
32991506|NCT01538433||biopsy-proven IgA nephropathy|
32991507|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
32991508|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
33413727|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
32991509|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
32991510|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
33413728|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
32991511|NCT01538485|Experimental|Cholecalciferol|
32991512|NCT01538511|Experimental|BIAsp 70|
32991513|NCT01538511|Experimental|BIAsp 30|
32991514|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
32991515|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
32991516|NCT01538576||Insulin aspart users|
32991517|NCT01538589||Insulin aspart users|
32991518|NCT01538602||PCOS patients|
32991519|NCT01538602||Healthy volunteers|
32991520|NCT01538641|Experimental|1|
32991521|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
32991522|NCT01538667|Experimental|Arm 1|
32991523|NCT01538667|Experimental|Arm 2|
32991524|NCT01538667|Experimental|Arm 3|
32991525|NCT01538667|Experimental|Arm 4|
32991526|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
32991527|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
32991528|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
32991529|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
32991530|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
32991531|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
32991532|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
32991533|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
32991534|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
32991535|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
32991536|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
32991537|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
32991538|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
32991539|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
32991540|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
32991541|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
32991542|NCT01538836|Active Comparator|Weight loss with normal protein intake|
32991543|NCT01538836|Experimental|Weight loss with protein supplementation|
32991544|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
32991545|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
32991546|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
32991547|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
32991548|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
32991549|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
32991550|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
32991551|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
32991552|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
32991553|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
32991554|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
33324617|NCT03916926|Active Comparator|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
33324618|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
32991555|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
32991556|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
32991557|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
32991558|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
32991559|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
32991560|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
32991561|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
32991562|NCT01538940|Other|HIV-, ID vaccine|
32991563|NCT01538940|Other|HIV-, IM vaccine|
33324619|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
33324620|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
33324621|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
33324622|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
33324623|NCT01133886|Experimental|Decitabine|
32991564|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
32991565|NCT01538953|Experimental|handwashing and water treatment|
32991566|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
32991567|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
32991568|NCT01538953|No Intervention|Control|
32991569|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
32991570|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
32991571|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
32991572|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
32991573|NCT01538992|No Intervention|medical thrapy|medical treatment
32991574|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
32991575|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
32991576|NCT01539031|Experimental|10 mg group|
32991577|NCT01539031|Active Comparator|23 mg group|
32991578|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
32991579|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
32991580|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
32991581|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
32991582|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
33413729|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
32991583|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
32991584|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
32991585|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
32991586|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
32991587|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
32991588|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
32991589|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
32991590|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
32991591|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
32991592|NCT01539200|Placebo Comparator|Control|
32991593|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
32991594|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
32991595|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
32991596|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
32991597|NCT01539265|Experimental|silodosin, arm 1|
32991598|NCT01539265|Experimental|silodosin, arm 2|
32991599|NCT01539265|Placebo Comparator|placebo|
32991600|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
32991601|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
32991602|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
32991603|NCT01539304|Placebo Comparator|Placebo|Placebo
32991604|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
32991605|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
32991606|NCT01539369|Experimental|High fibre diet|
32991607|NCT01539369|Active Comparator|Healthy eating diet|
32991608|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
32991609|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
32991610|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
32991611|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
32991612|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
32991613|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
32991614|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
32991615|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
33231723|NCT04103658|Experimental|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
33413730|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
33413731|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
32903719|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
32903720|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
32903721|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
32903722|NCT01238549||Spinal Cord Injury|Participants with SCI
32903723|NCT01241435|Experimental|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
32903724|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
32903725|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
32903726|NCT02194439||hematopoietic stem cell transplant|procedure
32903727|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
32903728|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
32903729|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
32903730|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
32903731|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
32903732|NCT02195921|Experimental|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
32903733|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
32903734|NCT04387292|Experimental|Ophthalmologic exam|
32903735|NCT02189213|Active Comparator|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
32903736|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
32903737|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
32903738|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
32903739|NCT01241513|Placebo Comparator|Placebo|placebo
32903740|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
32903741|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
32903742|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
32903743|NCT01241903|Experimental|Crestor|
32903744|NCT01241903|Placebo Comparator|sugar pill|
32903745|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
32903746|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
32903747|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
32991616|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
32991617|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
32991618|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
32991619|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
32991620|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
32991621|NCT01539551||1|sepsis and septic shock patients
32991622|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
33413732|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
33413733|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
32991623|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
32991624|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
33413734|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
33413735|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
33413736|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
32991625|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
32991626|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
32991627|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
32991628|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
32991629|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
32991630|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
32991631|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
32991632|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
32991633|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
32991634|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
32991635|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
32991636|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
32991637|NCT01539681||Group 1|
32991638|NCT01539707|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
32991639|NCT01539707|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
32991640|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
32991641|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
32991642|NCT01539733|Experimental|Olanzapine|
32991643|NCT01539733|Active Comparator|Haloperidol|
32991644|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.~."
33413737|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
33413738|NCT03576638|Experimental|AP CD/LD|
32991645|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
32991646|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
32991647|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
32991648|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
32991649|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
32991650|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
32991651|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
32991652|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
32991653|NCT01539902|Placebo Comparator|Cyclophosphamide|
32991654|NCT01539915|Experimental|BCT194|
33413739|NCT04284657|No Intervention|ARM I: Control group|Standard therapy alone
33413740|NCT04284657|Active Comparator|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
33413741|NCT04284657|Active Comparator|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
33413742|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
33413743|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
33413744|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
33413745|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
33413746|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
33413747|NCT05205135||Caregivers|Caregivers of persons with dementia supported by the Carer Matters programme
33413748|NCT05205135||Nurses|Ward nurses who collaborate with the Carer Matters team
33413749|NCT05205135||Programme facilitators|Facilitators of programmes organised through Carer Matters
33413750|NCT05205135||Care Support Nurses|Nurses trained to deliver support and assistance as part of Carer Matters Programme
33413751|NCT05205135||Community partners and hospital leaders|Key policy makers and community leaders who partner with the Carer Matters programme to ensure its success
33413752|NCT05205135||Other clinicians (e.g. Social workers, Physiotherapists, doctors)|Other clinicians who refer caregivers to the Carer Matters programme
33413753|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
33413754|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
33413755|NCT04894773|Experimental|Imaginary Resisted Exercises|Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
33413756|NCT04894773|Experimental|Physical Resisted Exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
33413757|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
33413758|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
33413759|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
33413760|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
33413761|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
33413762|NCT05758233|Experimental|Grup 1: Transversalis Fascia Plane Block (TFPB)|Transversalis Fascia Plane Block (TFPB)
33413763|NCT05758233|Experimental|Grup 2: Transversus Abdominis Plane Block (TAPB)|Transversus Abdominis Plane Block (TAPB)
33413764|NCT03578510|Active Comparator|SHD|Standard hemodialysis
33413765|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
33413766|NCT04876677|Experimental|CHF5993|Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation
33413767|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
33413768|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
33413769|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
33413770|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
33413771|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
33413772|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
33413773|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
33413774|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
33413775|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
33413776|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
33413777|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
32903748|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
33413778|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
32903749|NCT01242527|Placebo Comparator|placebo|
32903750|NCT01242527|Experimental|Epanova 2 g|
32903751|NCT01242527|Experimental|Epanova 3 g|
32903752|NCT01242527|Experimental|Epanova 4 g|
32903753|NCT00667004|Experimental|1|ecabet ophthalmic solution
32903754|NCT00667004|Placebo Comparator|2|Placebo comparator
32903755|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
32903756|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
32903757|NCT02991014|Experimental|participant-selected non-modulated music|
32903758|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
32903759|NCT01204853|Experimental|Sitaxentan treatment|
32903760|NCT01028846|Active Comparator|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
32903761|NCT01028846|Placebo Comparator|Placebo|Intravenous normal saline during pancreatic clamp study
32903762|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
32903763|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
32903764|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
32903765|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
32903766|NCT00714272|Experimental|A|Granulocytapheresis treatment
32903767|NCT00714272|Placebo Comparator|B|Sham device treatment
32903768|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
32903769|NCT01205399||AlloMax Surgical Graft Group|
32903770|NCT04386122|Experimental|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
32903771|NCT04386122|Active Comparator|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
32903772|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
32903773|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
32903774|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
32903775|NCT02995460|No Intervention|controls|No change in diet and training habits
32903776|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
32903777|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
32903778|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
32903779|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
32903780|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
32903781|NCT02990858|Experimental|PRO 140|
32903782|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32903783|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
32903784|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
32903785|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
32903786|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
32903787|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
32903788|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
32903789|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
32903790|NCT02995226|Other|Controls (with no eating disorder)|Other
32903791|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
32903792|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
32903793|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
32903794|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
32903795|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
32903796|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
32903797|NCT03830684|Placebo Comparator|placebo group|control group
32903798|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
32903799|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
32903800|NCT00727064|Active Comparator|DVS/VEN|
32903801|NCT00727064|Active Comparator|VEN/DVS|
32903802|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
32903803|NCT00727220||Insulin Injections|Children remaining on insulin injections.
32903804|NCT01294163|Experimental|Xenon|
32903805|NCT01294163|Active Comparator|Sevoflurane|
32903806|NCT01294163|Active Comparator|Total intravenous anaesthesia|
32903807|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
32903808|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
32903809|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
32903810|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
32903811|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
32903812|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
32903813|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
32903814|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
32903815|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
32903816|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
32903817|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
32903818|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
32903819|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
32903820|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
32903821|NCT01244477|Experimental|CPT-C|Participants in group CPT-C
32903822|NCT01244477|No Intervention|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
32903823|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
32908387|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
32991655|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
32991656|NCT01539941|Experimental|Medication Integration Protocol|
33413779|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
33413780|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
32991657|NCT01539954||Youth 9-18 years of age|
32991658|NCT01539993||1|
33413781|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
32991659|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
32991660|NCT01540032|No Intervention|Control|
32991661|NCT01540032|Experimental|Diet|
32991662|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
32991663|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
32991664|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
32991665|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
32991666|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
32991667|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
32991668|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
32991669|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
32991670|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
32991671|NCT01540149||ICD implant|
32991672|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
32991673|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
32991674|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
32991675|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
32991676|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
32991677|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
32991678|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
32991679|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
32991680|NCT01540240|Active Comparator|low dosage zidovudine|
32991681|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
32991682|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
32991683|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
32991684|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
32991685|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
32991686|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
32991687|NCT01540318|No Intervention|No Abdominal Ultrasound|
32991688|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
32991689|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)~CRS and HIPEC~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
33413782|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
33413783|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
33413784|NCT04155333|Experimental|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
32991690|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
32991691|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
32991692|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
32991693|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
32991694|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
32991695|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
33413785|NCT04155333|Experimental|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
33413786|NCT04155333|Sham Comparator|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
32991696|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
32991697|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
32991698|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
32991699|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
32991700|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
32991701|NCT01540461|Experimental|Arm: Brivanib|
32991702|NCT01540500|Experimental|Steady State PK Group|
32991703|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
32991704|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
32991705|NCT01540539|Experimental|Dosing cohort 1|
32991706|NCT01540539|Experimental|Dosing cohort 2|
32991707|NCT01540539|Experimental|Dosing cohort 3|
32991708|NCT01540539|Experimental|Dosing cohort 4|
32991709|NCT01540539|Experimental|Dosing cohort 5|
32991710|NCT01540539|Experimental|Dosing cohort 6|
32991711|NCT01540539|Experimental|Dosing cohort 7|
32991712|NCT01540539|Experimental|Dosing cohort 8|
32991713|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
32991714|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
32991715|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
32991716|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
32991717|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
32991718|NCT01540604|Experimental|CRD007 10 mg tablet|
32991719|NCT01540617||Persons with low back pain|
32991720|NCT01540617||Healthy persons|
32991721|NCT01540643||Abdominal aortic aneurysm|
32991722|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
32991723|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
32991724|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
32991725|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
32991726|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
32991727|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
33231724|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
33413787|NCT05204979||Misopristol|Group A: vaginal misoprostol will be taken Group B: sublingual misoprostol will be taken
33105165|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
33413788|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
33413789|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
33413790|NCT05759871|Experimental|FSH only (no GnRH antagonist)|Women receive only FSH starting on day 2 of the cycle. The starting dose of FSH is 225-300 IU s.c. for the first 4 days adjusted thereafter according to the ovarian response.
33413791|NCT05759871|Active Comparator|FSH + GnRH antagonist|Women receive 225-300 IU s.c. FSH, and a GnRH antagonist from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day. The GnRH antagonist in group 2 is injected each time immediately after the injection of FSH.
33413792|NCT02239952|Experimental|sunitinib|
33413793|NCT02239952|Experimental|vandetanib|
33413794|NCT02239952|Experimental|Erlotinib|
33413795|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
33413796|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
33413797|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
33413798|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
33413799|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
33413800|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
33413801|NCT04739475|Other|Non surgical Periodontal Therapy NPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
33413802|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
33413803|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
33105166|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
33105167|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
33231725|NCT04102176|Active Comparator|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
33231726|NCT04102176|Experimental|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
32991728|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
32991729|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
32991730|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
32991731|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
33324624|NCT03917082|Experimental|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
33324625|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
33324626|NCT01140126|Experimental|Antibody (UB-421)|
33324627|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
33324628|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
33324629|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
33324630|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
33324631|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
33324632|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
33324633|NCT01133964|Experimental|milk|skim milk
33324634|NCT01133964|Experimental|casein drink|
33324635|NCT01133964|Experimental|whey drink|
33324636|NCT01133964|Sham Comparator|water|
32991732|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
32991733|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
32991734|NCT01540747|Experimental|Inofolic plus|178 patients
32991735|NCT01540747|Active Comparator|Inofolic|180 patients
32991736|NCT01540760|Experimental|MCAF5352A|
32991737|NCT01540760|Placebo Comparator|Placebo|
32991738|NCT01540786|Experimental|Part 1: OAB subjects|
32991739|NCT01540786|Experimental|Part 2: Healthy subjects|
32991740|NCT01540786|Experimental|Part 2: OAB subjects|
32991741|NCT01540799|Experimental|Treatment|
32991742|NCT01540799|Other|Other|Stimulation not able to be felt
32991743|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
32991744|NCT01540877|Experimental|Capsaicin application|application of 0.6%
32991745|NCT01540877|Experimental|Local anesthetics application|application of EMLA
32991746|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
32991747|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
32991748|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
32991749|NCT01540890||opioids|patients on opioid medication without withdrawal
32991750|NCT01540890||opioid-free|patients with chronic pain without opioid medication
32991751|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
32991752|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
32991753|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
32991754|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
32991755|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
32991756|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
32991757|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
32991758|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
32991759|NCT01540955|Experimental|Group Intervention program|
32991760|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
32991761|NCT01540968|Experimental|Nutrition & physical exercise|
32991762|NCT01540968|No Intervention|Control|
32991763|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
32991764|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
33413804|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
33413805|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
32991765|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
32991766|NCT01541020||Healthy individuals|
32991767|NCT01541020||Individuals with low back pain|
32991768|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
32991769|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
32991770|NCT01541033||Control|Typically developing children
32991771|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
32991772|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
32991773|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
32991774|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
32991775|NCT01541072|Experimental|Pegfilgrastim|
32991776|NCT01541072|Active Comparator|Filgrastim|
32991777|NCT01541085||Darunavir/Ritonavir (DRV/r)|
32991778|NCT01541085||Efavirenz (EFV)|
32991779|NCT01541098|Active Comparator|Licensed Plasma|
32991780|NCT01541098|Experimental|Lyophilized Plasma|
32991781|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
32991782|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
32991783|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
32991784|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
32991785|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
32991786|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
32991787|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
32991788|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
32991789|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
32991790|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
32991791|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
32991792|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
32991793|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
32991794|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
32991795|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
32991796|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
32991797|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
32991798|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
32991799|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
32991800|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
32991801|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
32991802|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
33413806|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
32991803|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
32991804|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
32991805|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
32991806|NCT01541319||Healthy volunteers|
32991807|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
32991808|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
32991809|NCT01541436|Sham Comparator|Capsaicin, UV-B|
32991810|NCT01541449||RA patients treated with plaquenil|
32991811|NCT01541449||Patients who do not use plaquenil|
32991812|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
32991813|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
32991814|NCT01541475|Experimental|Escitalopram + Bupropion|
32991815|NCT01541475|Active Comparator|Escitalopram|
33413807|NCT04721769|Active Comparator|Endoscopic strip craniectomy with the use of lateral osteotomies|Patients will have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
32991816|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
32991817|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
33413808|NCT04721769|Experimental|Endoscopic strip craniectomy without the use of lateral osteotomies|Patients will NOT have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
33413809|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
33413810|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
33413811|NCT04716699|Experimental|Health services research (lidocaine, surgery)|Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.
33413812|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
33413813|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
33413814|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
33413815|NCT03576170|Active Comparator|aromatherapy-scent|
33413816|NCT03576170|Active Comparator|aromatherapy-touch|
33413817|NCT03576170|No Intervention|wait-list control|
33413818|NCT01566747|Experimental|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
33413819|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
32991818|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
32991819|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
32991820|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
32991821|NCT01541540|Experimental|e-Counseling plus Usual Care|
32991822|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
32991823|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
32991824|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
32991825|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
32991826|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
32991827|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
32991828|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
32991829|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
33413820|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
33413821|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
32991830|NCT01541605|Active Comparator|methylphenidate|
32991831|NCT01541605|Placebo Comparator|placebo|
32991832|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
32991833|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
32991834|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
33413822|NCT05204901|Experimental|Magnetic tracking|This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
33413823|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
33413824|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
32991835|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
32991836|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
32991837|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
32991838|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
32991839|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
32991840|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
32991841|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
32991842|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
32991843|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
32991844|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
32991845|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
32991846|NCT01541774|Experimental|Phoenix Atherectomy System|
32991847|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
32991848|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
32991849|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
32991850|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
32991851|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
32991852|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
32991853|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
32991854|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
32991855|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
32991856|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
32991857|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
32991858|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
32991859|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
32991860|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
32991861|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
33231727|NCT04101864|Experimental|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
33231728|NCT04101864|Active Comparator|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
32991862|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
32991863|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
32991864|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
32991865|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
32991866|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
32991867|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
32991868|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
32991869|NCT01542060||BIAsp 30 users|
32991870|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
32991871|NCT01542086|Active Comparator|Myocardial SPECT|
32991872|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
32991873|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
32991874|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
32991875|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
32991876|NCT01542112|Experimental|No treament|Usual routine in the department
32991877|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
32991878|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
32991879|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
32991880|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
32991881|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
32991882|NCT01542190|Active Comparator|ketorolac tromethamine|
32991883|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
32991884|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
32991885|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
32991886|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
32991887|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
32991888|NCT01542268|Active Comparator|pentoxifylline|
32991889|NCT01542268|Placebo Comparator|pentoxifylline placebo|
32991890|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
32991891|NCT01542281|Active Comparator|Prehab exercise|
32991892|NCT01542294|Experimental|treatment|s1+oxaliplatin
32991893|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
32991894|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
32991895|NCT01542346|Experimental|wound closure with subcutaneous adaption|
32991896|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
32991897|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
32991898|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
32991899|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
33324637|NCT04938726|Experimental|Ketone Monoester|The ketone used is from KetoneAid and is commercially available as KE4 and will be consumed at 30 mL twice daily (15 g / dose)
32991900|NCT01542411||recurrent pregnancy loss|
32991901|NCT01542411||thrombophilia, aspirin|
33324638|NCT04938726|Placebo Comparator|Placebo|A placebo is being manufactured by KetoneAid to match the taste and other characteristics of the ketone supplement for blinding purposes
33324639|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
32991902|NCT01542411||heparin|
32991903|NCT01542424||BIAsp 30 users|
32991904|NCT01542424||IDet users|
32991905|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
32991906|NCT01542450|Experimental|Treatment period 1|
32991907|NCT01542450|Active Comparator|Treatment period 2|
32991908|NCT01542463||IDet users|
33324640|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
32991909|NCT01542476||IDet users|
32991910|NCT01542489||IDet + IAsp users|
32991911|NCT01542489||IDet + HI users|
32991912|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
33324641|NCT01234194|Active Comparator|Group 1|
33324642|NCT01234194|Active Comparator|Group 2|
32991913|NCT01542554|Experimental|Low glycaemic index diet|
32991914|NCT01542554|Active Comparator|Usual diabetic diet|
32991915|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
32991916|NCT01542567|Placebo Comparator|placebo suppositories|
32991917|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
32991918|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
32991919|NCT01542619|Experimental|rVIIa-FP|
32991920|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
32991921|NCT01542658||uterine myoma|
32991922|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
32991923|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
32991924|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
32991925|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
32991926|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
32991927|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
32991928|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
32991929|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
32991930|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
32991931|NCT01542775|Placebo Comparator|Control|
32991932|NCT01542775|Active Comparator|Exercise|
32991933|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
32991934|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
32991935|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
32991936|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
32991937|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
32991938|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
32991939|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
32991940|NCT01542892|Experimental|Supplement|
32991941|NCT01542892|Sham Comparator|Placebo|
32991942|NCT01542892|Experimental|Exercise|
32991943|NCT01542905|Experimental|Korean Red Ginseng|
32991944|NCT01542905|Placebo Comparator|Placebo|
32991945|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
32991946|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
32991947|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
32991948|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
32991949|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
33413825|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
33413826|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
32991950|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
32991951|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
32991952|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
32991953|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
32991954|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
32991955|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
32991956|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
32991957|NCT01543022|Experimental|Symphony system|
32991958|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
32991959|NCT01543048||Women with CIN3 treated by conization|
32991960|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
32991961|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
32991962|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
32991963|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~Patient's age ≥18 yo,~Patients having signed the specific consent of the study."
33413827|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
33413828|NCT03574064|Placebo Comparator|Placebo|Placebo
32991964|NCT01543113|Other|melanoma|melanoma
32991965|NCT01543126||pleural effusion|patients with pleural effusion
32991966|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
32991967|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
32991968|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
32991969|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
32991970|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
32991971|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
32991972|NCT01543191|Experimental|PUR118|
32991973|NCT01543191|Placebo Comparator|Placebo|
32991974|NCT01543217|Active Comparator|Control|Ususal care.
32991975|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
32991976|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
32991977|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
32991978|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
32991979|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
32991980|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
32991981|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
32991982|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
32991983|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
32991984|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
32991985|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
32991986|NCT01543308||coronary heart disease|
32991987|NCT01543308||healthy control group|
32991988|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
32991989|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
33413829|NCT05204745||Case|Subjects with subjective gait impariment according to questionnaire answers.
32991990|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
32991991|NCT01543347|Experimental|Temocillin|Treatment group
33413830|NCT05204745||Control|Subjects without subjective gait impariment according to questionnaire answers.
32991992|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
32991993|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
32991994|NCT01543373|Experimental|CRE8 arm|
32991995|NCT01543373|Active Comparator|Vision/Multilik8 arm|
32991996|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
32991997|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
32991998|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
32991999|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
32992000|NCT01543438|No Intervention|Control|current standard of care
32992001|NCT01543438|Experimental|Intervention Group|receives video prescription
32992002|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
32992003|NCT01543477||Single group|
32992004|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
32992005|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
32992006|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
32992007|NCT01543529|Experimental|RO4917838 + alcohol|
32992008|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
32992009|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
32992010|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
32992011|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
32992012|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
32992013|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
32992014|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
32992015|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
32992016|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
32992017|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
32992018|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
32992019|NCT01543724|Experimental|Lithium|
32992020|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
32992021|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
32992022|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
32992023|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
32992024|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
32992025|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
32992026|NCT01543802|Experimental|Pazopanib|
32992027|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
32992028|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
32992029|NCT01543815|No Intervention|CM|Standardized Care Management
32992030|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
32992031|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
32992032|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
32992033|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
32992034|NCT01543867||Users of somatropin|
32992035|NCT01543880||Users of somatropin|
33231729|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
33231730|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
32992036|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
32992037|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
32992038|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
32992039|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
32864264|NCT04863690|Experimental|Sleep Intervention System - No Coaching|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations), as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks.
32992040|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
32992041|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
32992042|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
33413831|NCT03918408|Experimental|Pulsed, accelerated|18 mW, 5 sec, 5 sec off, 10 minutes of illumination
33413832|NCT03918408|Active Comparator|Conventional|9 mW, continuous 10 minutes of illumination
33413833|NCT03573986|Experimental|Arm A|
32864265|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will also work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
32992043|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
32992044|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
32992045|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
32992046|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
32992047|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
32992048|NCT01543984|Other|Reference group|Health Counselling (1,5h)
32992049|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
32992050|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
32992051|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
32992052|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
32992053|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
32992054|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
32992055|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
32992056|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
32992057|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
32992058|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
32992059|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
32992060|NCT01544101|Experimental|Vegan Diet|
32992061|NCT01544101|Placebo Comparator|Supplement|
32992062|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
32992063|NCT01544192|Active Comparator|retinal nerve fiber thickness|
32992064|NCT01544192|Active Comparator|Mean Deviation|
32992065|NCT01544192|Active Comparator|Pattern Standard Deviation|
32992066|NCT01544192|Active Comparator|ganglion cell count|
32992067|NCT01544192|Active Comparator|c/d ratios|
32992068|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
32992069|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
32992070|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
32992071|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
32992072|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
32992073|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
32992074|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
32992075|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
32992076|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
32992077|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
32992078|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
32992079|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
32992080|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
32992081|NCT01544296|Experimental|KHK6188, high dose|
32992082|NCT01544296|Experimental|KHK6188, low dose|
32992083|NCT01544296|Placebo Comparator|Placebo|
32992084|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
32992085|NCT01544374|No Intervention|Control- no intervention|Usual Care
32992086|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
32992087|NCT01544387|Other|Activity|Activity
32992088|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
32992089|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
33413834|NCT05204433||normal control|healthy volunteers
32992090|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
32992091|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
32992092|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
32992093|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
32992094|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
32992095|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
32992096|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
32992097|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
32992098|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
32992099|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
32992100|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
32992101|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
32992102|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
33413835|NCT05204433||adenoma|pathologically reported colorectal adenoma
32992103|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
33413836|NCT05204433||colorectcal cancer|pathologically reported colon cancers
33413837|NCT05204433||High risk group|pathologically reported inflammatory bowel diseases
32992104|NCT01544621||Successful quitters Sustained smokers|Successful quitters
32992105|NCT01544634|Experimental|Propranolol + Low dose Qvar|
32992106|NCT01544634|Active Comparator|Placebo + high dose Qvar|
32992107|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
32992108|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
32992109|NCT01544660||Scanning|no treatment
33413838|NCT03573674|Experimental|Cognitive ergonomics Intervention|
32992110|NCT01544660||scanning|no treatment
32992111|NCT01544673|Active Comparator|Arm A|
32992112|NCT01544673|Placebo Comparator|Arm B|
32992113|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
32992114|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
32992115|NCT01544699|Active Comparator|Real stimulation|real tDCS (well, that's the way it is I am not gonna change it)
32992116|NCT01544699|Sham Comparator|Sham|sham tDCS
32992117|NCT01544712|Active Comparator|Control|Core decompression
32992118|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
32992119|NCT01544725|Experimental|Ketamine-propofol|
32992120|NCT01544725|Active Comparator|Ketamine alone|
32992121|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
32992122|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
32992123|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
32992124|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
32992125|NCT01544751|Active Comparator|Atorvastatin|20 mg day
32992126|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
32992127|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
32992128|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
32992129|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
32992130|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
32992131|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
32992132|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
32992133|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
32992134|NCT01544803|No Intervention|Control group|
32992135|NCT01544803|Experimental|Web based self-monitoring|
32992136|NCT01544803|Active Comparator|Web based self-help|
32992137|NCT01544816|Placebo Comparator|Control Food Product|Control food product
33413839|NCT03573674|Active Comparator|Stress management Intervention|
32992138|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
32992139|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
32992140|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
32992141|NCT01544829|Active Comparator|Multiple servings of theobromine|
32992142|NCT01544829|Placebo Comparator|Placebo capsules|
32992143|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
32992144|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
32992145|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
32992146|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
32992147|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
32992148|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
32992149|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
32992150|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
32992151|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
33033606|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
33413840|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
32992152|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
32992153|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
32992154|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
32992155|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
33324643|NCT04913922|Experimental|Combination therapy|"5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1~repeat day 28"
33324644|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
33324645|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
33324646|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
32992156|NCT01544946|Experimental|sucrose po|
32992157|NCT01544946|Placebo Comparator|placebo po|
32992158|NCT01544959|Active Comparator|fentanyl|
32992159|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
32992160|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
32992161|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
32992162|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
32992163|NCT01544985|Placebo Comparator|placebo po|sterile water
32992164|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
32992165|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
32992166|NCT01545024||DPP-IV inhibitor|
32992167|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
32992168|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
32992169|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
32992170|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)|
32992171|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)|
33324647|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
33324648|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
33324649|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
33324650|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
33324651|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
33324652|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
33324653|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
33324654|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
33324655|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
33324656|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
33324657|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
33324658|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
33324659|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
33324660|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
33324661|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
33324662|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
33324663|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
33324664|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
33324665|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
33324666|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
33413841|NCT03959592|Active Comparator|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
33413842|NCT03959592|Placebo Comparator|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
33413843|NCT04087395|Experimental|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
33413844|NCT04087395|Experimental|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
33413845|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
32992172|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)|
32992173|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)|
33413846|NCT03621618|Other|dobutamine|Cardiac failure
33413847|NCT03621618|Other|norepinephrine|Sepsis
33413848|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
32992174|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
32992175|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)|
32992176|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
32992177|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
32992178|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
33413849|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
32992179|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
32992180|NCT01545154||Prostate Cancer|
32992181|NCT01545167||African Americans with pancreatitis|pancreatitis
32992182|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
32992183|NCT01545206||acute STEMI, Primpary PCI|
33413850|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
32992184|NCT01545219|Experimental|Prebiotic|
32992185|NCT01545219|Experimental|Probiotic|
32992186|NCT01545219|Experimental|Synbiotic|
32992187|NCT01545219|Placebo Comparator|Placebo|
32992188|NCT01545245||Treated|Palivizumab treated
32992189|NCT01545245||Untreated|Palivizumab untreated
32992190|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
32992191|NCT01545258|No Intervention|Control|
32992192|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
32992193|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
32992194|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
32992195|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
32992196|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
32992197|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
32992198|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
32992199|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
32992200|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~Facilitation and support of the staff in these clinics so that they may implement the interventions"
32992201|NCT01545401|No Intervention|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
32992202|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
32992203|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
32992204|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
32992205|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
32992206|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
32992207|NCT01545440|Experimental|lebrikizumab - highest dose|
32992208|NCT01545440|Experimental|lebrikizumab - lowest dose|
33413851|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
33413852|NCT03944304|Experimental|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
33413853|NCT05204277|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
32992209|NCT01545440|Experimental|lebrikizumab - middle dose|
32992210|NCT01545440|Placebo Comparator|placebo|
32992211|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
32992212|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
32992213|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
32992214|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
32992215|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
32992216|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
32992217|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
32992218|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
32992219|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
32992220|NCT01545531||Iohexol GFR|
32992221|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
32992222|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
32992223|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
32992224|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
32992225|NCT01545609|Experimental|Text messaging|Text messaging
32992226|NCT01545609|No Intervention|No intervention|No intervention
32992227|NCT01545635|Active Comparator|Coagulation factor concentrates|
32992228|NCT01545635|Active Comparator|Fresh Frozen Plasma|
32992229|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
32992230|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
32992231|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
32992232|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
32992233|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
32992234|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
32992235|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
32992236|NCT01545739||CRT pacemaker implantation|
32992237|NCT01545752|No Intervention|coventional group|Teaching just by book
32992238|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
32992239|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
32992240|NCT01545778||Tapentadol IR|
32992241|NCT01545778||Oxycodone IR|
32992242|NCT01545791||Insulin detemir users|
32992243|NCT01545804|Experimental|Lenalidomide|
32992244|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
32992245|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
32992246|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
32992247|NCT01545869|Experimental|Fractional carbon dioxide laser|
32992248|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
32992249|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
32992250|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
32992251|NCT01545921|Experimental|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
32992252|NCT01545921|Experimental|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
32992253|NCT01545921|Experimental|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
32992254|NCT01545921|Experimental|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
32992255|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
32992256|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
32992257|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
32992258|NCT01545960||Healthy Volunteers|
32992259|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
32992260|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
32992261|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
32992262|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
32992263|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
32992264|NCT01546025|Placebo Comparator|Relaxation training|
32992265|NCT01546025|Active Comparator|Brief Motivational Counseling|
33413854|NCT05204277|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA)
33413855|NCT05204277|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
33413856|NCT05204277|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
32992266|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
32992267|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
32992268|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
32992269|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
32992270|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
32992271|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
32992272|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
32992273|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
32992274|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
32992275|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
32992276|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
32992277|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
32992278|NCT01546116|Experimental|Adefovir and lamivudine combination|
32992279|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
32992280|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
32992281|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
32992282|NCT01546181||Age-related macular degeneration|
32992283|NCT01546181||inherited retinal dystrophies|
32992284|NCT01546181||retinal trauma|
32992285|NCT01546181||toxic retinopathies|
32992286|NCT01546181||arterial hypertensive patients|
32992287|NCT01546181||diabetic patients|
32992288|NCT01546181||inflammatory diseases|
32992289|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
32992290|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
32992291|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
32992292|NCT01546233||Conventional education|Lung cancer patient will be received standard education
32992293|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
32992294|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
32992295|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
32992296|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
32992297|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
32992298|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
32992299|NCT01546311||lower limb amputees|
32992300|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
32992301|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
32992302|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
33413857|NCT05204277|Active Comparator|In-office bleaching + Remineralization|In-office bleaching was applied followed by MI-Paste Plus®
32992303|NCT01546363||Validation|
32992304|NCT01546363||Testing|
32992305|NCT01546376||HIV-cancer patients who recived RT|
32992306|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
32992307|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
32992308|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
32992309|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
32992310|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
32992311|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
32992312|NCT01546415|Experimental|Desferasirox|
32992313|NCT01546428|Experimental|INC280|
32992314|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
32992315|NCT01546441|Active Comparator|usual care|Usual care in family practice
32992316|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
32992317|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
32992318|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
32992319|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
32992320|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
32992321|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
32992322|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
32992323|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
32992324|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
32992325|NCT01546506|No Intervention|No treatment|
32992326|NCT01546545||Enrollment Group|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
32992327|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:~Period 1, metformin 1000 mg bid on Days 1-5~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
32992328|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:~Period 1, metformin 500 mg bid on Days 1-5~Period 2, metformin 850 mg bid on Days 6-10~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
32992329|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
32992330|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
32992331|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
32992332|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
32992333|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
32992334|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
32992335|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
32992336|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
32992337|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
32992338|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
32992339|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
32992340|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
32992341|NCT01546753|Experimental|Walnut Protein Powder|146 weeks for active treatment subjects
32992342|NCT01546753|Placebo Comparator|Oat Powder|184 weeks for placebo
32992343|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
32992344|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
32992345|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
32992346|NCT01546779|Experimental|lung function|
32992347|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
32992348|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
32992349|NCT01546805|Placebo Comparator|Placebo|
32992350|NCT01546805|Experimental|Zinc Group|
32992351|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
32992352|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
32992353|NCT01546870||pediatric heart transplant recipients|
32992354|NCT01546896|Experimental|buspirone+alprazolam|
32992355|NCT01546896|Active Comparator|alprazolam|
32992356|NCT01546896|No Intervention|healthy controls|
32992357|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
32992358|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
32992359|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
32992360|NCT01546974|Experimental|HME filter|
32992361|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
32992362|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
32992363|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
32992364|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
32992365|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
32992366|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
32992367|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
32992368|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
32992369|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
32992370|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
32992371|NCT01547078|Active Comparator|Licensed Plasma|
32992372|NCT01547078|Experimental|Lyophilized Plasma|
32992373|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
32992374|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
32992375|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
32992376|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
32992377|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
32992378|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
32992379|NCT01547156|No Intervention|Control group|Control group received usual care
32992380|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
32992381|NCT01547169|Placebo Comparator|Saline|
32992382|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
32992383|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
32992384|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
32992385|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
32992386|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
32992387|NCT01547195|Experimental|Group-swimming|
32992388|NCT01547195|Active Comparator|Control-walk|
32992389|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
32992390|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
32992391|NCT01547221|Active Comparator|3% boric acid|control
32992392|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
32992393|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
32992394|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
32992395|NCT01547273|Experimental|no bone graft|no bone graft
32992396|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
32992397|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
32992398|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
32992399|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
32992400|NCT01547325|Experimental|NanoDOX Hydrogel|
32992401|NCT01547325|Placebo Comparator|Placebo Hydrogel|
32992402|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
32992403|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
32992404|NCT01547364|Placebo Comparator|Caudal Saline|
32992405|NCT01547364|Active Comparator|Caudal Dextrose|
32992406|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
32992407|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
32992408|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
32992409|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
32992410|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
32992411|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
32992412|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
32992413|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
32992414|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
32992415|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
32992416|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
32992417|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
32992418|NCT01547494|Placebo Comparator|Dietary Supplement|
32992419|NCT01547494|Experimental|Vegan Diet|
32992420|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
32992421|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
32992422|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
32992423|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
32992424|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
32992425|NCT01547546|Experimental|Single Arm|
32992426|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
32992427|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
32992428|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
32992429|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
32992430|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
32992431|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
32992432|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
32992433|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
32992434|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
32992435|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
32992436|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
32992437|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
32992438|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
32992439|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
32992440|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
32992441|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
32992442|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
32992443|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
33413858|NCT05204277|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
32992444|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
32992445|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
32992446|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
33413859|NCT05204277|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by inoffice bleaching and lastly MI-Paste Plus®
33413860|NCT05204277|No Intervention|Control|no treatment (control)
32992447|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
32992448|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
32992449|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
32992450|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
32992451|NCT01547884||1|Latent TB positive with helminth positive
32992452|NCT01547884||2|Latent TB positive with helminth negative
32992453|NCT01547897|Active Comparator|NOX-E36|
33413861|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
33413862|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
33413863|NCT05204121|Experimental|Elpida 40 mg once weekly|elsulfavirine 40mg orally once weekly for 8 weeks
33413864|NCT05204121|Experimental|Elpida 80 mg once weekly|elsulfavirine 80mg orally once weekly for 8 weeks
32992454|NCT01547897|Placebo Comparator|Placebo|
32992455|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
32992456|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
32992457|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
32992458|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
32992459|NCT01547949|Experimental|tart cherry juice|
32992460|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
32992461|NCT01547962|Experimental|Split-mouth design: Treatment|
32992462|NCT01547962|Active Comparator|Split-mouth design: Control|
32992463|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
32992464|NCT01547988|No Intervention|Reference Group|
32992465|NCT01548001|Experimental|Iguratimod monotherapy|
32992466|NCT01548001|Experimental|Iguratimod and MTX combination|
32992467|NCT01548001|Active Comparator|MTX monotherapy|
32992468|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
32992469|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
32992470|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
32992471|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
32992472|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
32992473|NCT01548079|No Intervention|Control|Untreated controls
32992474|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
32992475|NCT01548092|Experimental|Autologous SVF|Intralesional application
32992476|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
32992477|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
32992478|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
32992479|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
32992480|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
33413865|NCT05204121|Experimental|Elpida 160 mg once weekly|elsulfavirine 160mg orally once weekly for 8 weeks
33413866|NCT04697901|Experimental|Active Stimulation|Active tDCS stimulation will be applied.
33413867|NCT04697901|Sham Comparator|Sham Stimulation|Sham tDCS stimulation will be applied.
33413868|NCT04671615||Patients with metastatic, HR+/HER2- breast cancer.|Patients who initiated first or subsequent lines of treatment with palbociclib
33413869|NCT05758077|Experimental|SCD + CKRT Arm|In addition to standard of care CKRT therapy for these subjects, these subjects will have up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) in-line with their existing CKRT circuit.
33413870|NCT05758077|Other|CKRT Alone Arm (standard of care)|This arm will receive standard of care CKRT therapy for their condition as appropriate.
32992481|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
32992482|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
32992483|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
32992484|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
32992485|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
32992486|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
33413871|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
33413872|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
33413873|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
33413874|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
33413875|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
33413876|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
33413877|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
33413878|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
33413879|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
33413880|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
33413881|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
33413882|NCT05284344||patients with newly diagnosed type 2 diabetes|Newly diagnosed, drug-naïve, Chinese patients with type 2 diabetes.
33413883|NCT05284344||Non-diabetic control subjects|
32992487|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
32992488|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
32992489|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
32992490|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
32992491|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
32992492|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
32992493|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
32992494|NCT01548157|Experimental|HCP1007|HCP1007
32992495|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
32992496|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
32992497|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
32992498|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
32992499|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
32992500|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
32992501|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
32992502|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
32992503|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
33413884|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
33413885|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
33413886|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
33413887|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
33413888|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
33413889|NCT03646266|No Intervention|Control|Standard of care
33413890|NCT02899338|Experimental|BI695501 Autoinjector|
33413891|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
33413892|NCT04052100|Active Comparator|Usual care|Patients following the standard preoperative policies of opur institution
33413893|NCT04052100|Experimental|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
33413894|NCT04052178|Active Comparator|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
33413895|NCT04052178|Active Comparator|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
33413896|NCT04052178|Active Comparator|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
33413897|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
33413898|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
32992504|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
32992505|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
32992506|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
32992507|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
32992508|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
32992509|NCT01548235||BIAsp 30 users|
32992510|NCT01548248||Levemir® users|
32992511|NCT01548261||Health people.|
32992512|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
32992513|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
32992514|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
32992515|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
32992516|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
33413899|NCT05284266|Active Comparator|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, includng Compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician"
32992517|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
32992518|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
32992519|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
32992520|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
32992521|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
32992522|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
32992523|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
32992524|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
32992525|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
32992526|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
32992527|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
32992528|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
32992529|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
32992530|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
32992531|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
32992532|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
32992533|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
32992534|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
32992535|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
32992536|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
32992537|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
32992538|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
32992539|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
32992540|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
32992541|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
32992542|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32992543|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
32992544|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
32992545|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
32992546|NCT01548495||No rHuEPO treatment|
32992547|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
32992548|NCT01548508|Sham Comparator|SHAM|
32992549|NCT01548521|Experimental|Oxytocin|
32992550|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
32992551|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
32992552|NCT01548547|Experimental|LP mastery learning group|
32992553|NCT01548547|Active Comparator|IV mastery learning group|
32992554|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
32992555|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
32992556|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
32992557|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
32992558|NCT01548586|Active Comparator|Anodal tDCS|
32992559|NCT01548586|Active Comparator|Cathodal tDCS|
32992560|NCT01548586|Placebo Comparator|Placebo type tDCS|
32992561|NCT01548612|Experimental|Sodium nitroprusside|
32992562|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
32992563|NCT01548625||Healthy middle-aged human volunteers|
32992564|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
32992565|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
32992566|NCT01548677|No Intervention|observation|18 weeks
32992567|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
32992568|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
32992569|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
32992570|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
32992571|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
32992572|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
32992573|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
32992574|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
32992575|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
32992576|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
33413900|NCT05284266|Experimental|Standard treatment plus additional lymphedema treatment|"Standard Conservative treatment consisiting of:~Physical therapy, includng Compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician Additional lymphedema treatment consising of intermittent pneumatic compression (IPC)"
33413901|NCT05284266|Experimental|Surgical group: Liposuction|Early liposuction, 6-9 months after inclusion in study.
32908388|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
32908389|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
32908390|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
32908391|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
32908392|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
32908393|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
32908394|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
32908395|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
32908396|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
32908397|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
32908398|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
32908399|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
32908400|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
32908401|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
32908402|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
32908403|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
32908404|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
32908405|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
32908406|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
32908407|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
32908408|NCT05710601||Tissue sealers|Procedures performed using a 5 mm diameter, 35 cm length curved branch radiofrequency tissue sealer connected to a dedicated electric generator
32908409|NCT05710601||Bipolar forceps|Procedures performed using a 5 mm diameter, 35 cm classic rotating bipolar forceps
32908410|NCT05710523|Experimental|I-ACE training|Participants will receive twenty-two sessions on the non-pharmacological therapies' methodology and on awareness of body language.
32908411|NCT05710523|Active Comparator|Standard non-pharmacological therapies (NPT) training|Participants will receive twelve sessions on the non-pharmacological therapies' methodology.
32908412|NCT05710523|No Intervention|As usual control group|Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
32908413|NCT05218733|Active Comparator|G1 Group: (Erector Spinae Plane Block (ESPB) Group)|
32908414|NCT05218733|Active Comparator|G2 Group: (Intra thecal morphine (ITM) Group)|
32908415|NCT05218733|Other|G3 Group: (Control Group)|
32908416|NCT05214599|Experimental|Group 1|Low dose
32908417|NCT05214599|Experimental|Group 2|Middle dose
32908418|NCT05214599|Experimental|Group 3|High dose
32908419|NCT05207267|Experimental|testing arm|ventilated with different VT using an EIT monitor (PulmoVista® 500, Dräger, Lübeck, Germany)
32908420|NCT01011218|Experimental|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~Armodafinil 150 mg/day by mouth."
32908421|NCT01011218|Experimental|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~Armodafinil 150 mg/day by mouth."
32908422|NCT01011218|Sham Comparator|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~No pharmaceutical intervention."
32908423|NCT01011218|Placebo Comparator|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~No pharmaceutical intervention."
32908424|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
32908425|NCT02245217|Experimental|PET/CT Imaging arm|
32992577|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
33413902|NCT05284266|Active Comparator|Srugical group: Control|Late liposuction, 18-21 months after inclusion. This group functions as a control group for 1 year before enrolment in the Liposuction group.
33413903|NCT05284422|Active Comparator|Traditional technique|Peripheral venous catheters inserted to the participants in this arm are inserted with a palpation/visualization guided technique in their hand, arm, foot or head.
33413904|NCT05284422|Experimental|Ultrasound-guided technique|Peripheral venous catheters inserted to the participants in this arm are inserted with an ultrasound-guided technique in their forearm.
33413905|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
32992578|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
32992579|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
32992580|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
32992581|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
33413906|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
33413907|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
33413908|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
33413909|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
33413910|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
33413911|NCT05204043|Experimental|Peter Hess® sound massage|Peter Hess® sound massage using bowls dedicated to this technique.
33413912|NCT05204043|Experimental|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation.
33413913|NCT03611790|Experimental|Intervention|NeVa VS
32992582|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
32992583|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
32992584|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
32992585|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
32992586|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
32992587|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
32992588|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
32992589|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
32992590|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
32992591|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
32992592|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
32992593|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
32992594|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
32992595|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
32992596|NCT01549080||research|biological research on the effects of yisuishengxuegranule
32992597|NCT01549080||clinical research|clinical research on thalassemia
32992598|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
32992599|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
32992600|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
32992601|NCT01549106|Experimental|IPI-145|
32992602|NCT01549106|Placebo Comparator|Placebo|
32992603|NCT01549119|Experimental|Low dose VAC-3S|
32992604|NCT01549119|Experimental|Medium dose VAC-3S|
32992605|NCT01549119|Experimental|High dose VAC-3S|
32992606|NCT01549119|Placebo Comparator|Placebo|
32992607|NCT01549119|Experimental|Double-dose VAC-3S|
32992608|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
32992609|NCT01549158|Experimental|Torasemide PR 10 mg|
32992610|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
32992611|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
32992612|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
32992613|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
32992614|NCT01549197||ICU staff and relatives|
32992615|NCT01549249|No Intervention|vitrectomy|
33413914|NCT05757921|Experimental|Non-surgical mechanical treatment with Perisolv® (A)|The test group will receive the following treatment: In the deepened pockets to be treated, Perisolv is initially applied according to the manufacturers recommendation.Then subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation. In addition an aliquot of Perisolv was left after final debridement.
33413915|NCT05757921|Active Comparator|Non-surgical mechanical treatment without Perisolv® (B)|The control group will receive the following treatment: In the deepened pockets to be treated, subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation.
33413916|NCT03946761|Experimental|Cancer goggle system|"The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG & visualization of biliary/liver anatomy using the cancer goggles system~The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG & will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.~Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
33413917|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
33413918|NCT02964234|Experimental|Education|Behavior: Education
33413919|NCT03921255|Active Comparator|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
33413920|NCT03921255|Placebo Comparator|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
33413921|NCT03921255|Placebo Comparator|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
33413922|NCT05757687|Experimental|Omega procedure|
33413923|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
33413924|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
33413925|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
33413926|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
33413927|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.~Cohort dosing will be as follows:~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
33413928|NCT05757609|Experimental|tDCS combined with active physiotherapy|"transcranial Direct Current Stimulation (tDCS) will be applied for 20 min at an intensity of 2 mA with anodal stimulation targeting the left dorsolateral prefrontal cortex (DLPFC).~This will be done during a cycling session and will be followed by a physiotherapy program including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
33413929|NCT05757609|Sham Comparator|Sham tDCS combined with active physiotherapy|"Sham transcranial Direct Current Stimulation (tDCS) will be applied for 20 min and this induces similar sensations for the patients, but no change in excitability.~This will be done during a cycling session and will be followed by a physiotherapy programme including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
32992616|NCT01549262|Active Comparator|Standard Incubator|
32992617|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
32992618|NCT01549288|Experimental|modified Atkins diet|
32992619|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
32992620|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
32992621|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
32992622|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
32992623|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
32992624|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
33413930|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
33413931|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
32992625|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
32992626|NCT01549353|Experimental|chewing gum|
32992627|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
32992628|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
33413932|NCT05203809||Observation group|Group of participants wearing continuous temperature monitoring device
33413933|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
32992629|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
32992630|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
32992631|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
32992632|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
32992633|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
32992634|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
32992635|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
32992636|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
32992637|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
33413934|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
32992638|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
32992639|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
32992640|NCT01549483||Asthma|asthmatic subjects
32992641|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
32992642|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
32992643|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
32992644|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
32992645|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
32992646|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
32992647|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
32992648|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
32992649|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
32992650|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
32992651|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
32992652|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
32992653|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
33413935|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
33413936|NCT03644940|Experimental|Subpopulation-specific Algorithm|
32992654|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
32992655|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
32992656|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
32992657|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
33413937|NCT03644940|No Intervention|Control Algorithm|
32992658|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
32992659|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
32992660|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
32992661|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
32992662|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
32992663|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
32992664|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
32992665|NCT01549743|Experimental|Celecoxib|
32992666|NCT01549743|Experimental|Rebamipide|
32992667|NCT01549743|Experimental|Celecoxib plus Rebamipide|
32992668|NCT01549756||Qualitative Research|Experiential/opinion based research
32992669|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
32992670|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
32992671|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
32992672|NCT01549808|Experimental|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~An 8 month observation phase.Current practice relatede to mobilize is measured.~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
32992673|NCT01549847|Experimental|L-carnitine and piracetam|
32992674|NCT01549847|Placebo Comparator|Placebo|
32992675|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
32992676|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
32992677|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
32992678|NCT01549912||Rotator cuff tear|
32992679|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
32992680|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
32992681|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
32992682|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
32992683|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
32992684|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
32992685|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
32992686|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
32992687|NCT01550055|Experimental|CMAB009 plus Irinotecan|
33413938|NCT03864081|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
33413939|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
32992688|NCT01550055|Active Comparator|Irinotecan-only and sequential-CMAB009|
32992689|NCT01550068|Experimental|Experimental Arm|Echocardiographic screening
33413940|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
33413941|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
33413942|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
33413943|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
33413944|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
33413945|NCT05746299|Experimental|Immediate Congruent|Participants will learn and be tested on two different semantic categories with the same structure that dictates the co-occurrence of different features.
33413946|NCT05746299|Experimental|Immediate Incongruent|Participants will learn and be tested on two different semantic categories with different structures that dictate the co-occurrence of different features.
33413947|NCT05746299|Experimental|Awake Incongruent|Participants will learn two different semantic categories, neither of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
32908517|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
32908518|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
32908519|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
32908520|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
32908521|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
32908522|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
32908523|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
32908524|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
32908525|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
32908526|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
32908527|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
32908528|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
32908529|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
32908530|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
32908531|NCT04930692|Experimental|Preoperative SLNs mapping provided by CT-lymphography method|Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.
32908532|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
32908533|NCT05708651|Experimental|Use of investigational device during sedation|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep levels of steady-state sedation [I-II], and during procedural sedation according to SOC for scheduled colonoscopy [III] or ureteral catheterisation [IV].
32908534|NCT05708651|Active Comparator|Use of comparator during sedation|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock [I-II] or no device [II-IV]) in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep levels of steady-state sedation [I-II], and during procedural sedation according to SOC for scheduled colonoscopy [III] or ureteral catheterisation [IV].
32908535|NCT04924283|Experimental|Cognitive Interference Task|Participants in this arm will complete random assessments of alcohol use and cravings on their phone, and be prompted to play Tetris on their phone after reporting cravings for alcohol.
32908536|NCT04924283|Active Comparator|Assessment Only|Participants in this arm will complete random assessments of alcohol use and cravings on their phone.
32992690|NCT01550068|No Intervention|Control Arm|No echocardiographic screening
32992691|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
32992692|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
32992693|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
32992694|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
32992695|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
32992696|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
32992697|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
32992698|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
32992699|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
32992700|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
32992701|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
32992702|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
32992703|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
32992704|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
32992705|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
32992706|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
32992707|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
32992708|NCT01550211||Students|Healthy students from Bar-Ilan University
32992709|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
32992710|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
32992711|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
32992712|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
32992713|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
32992714|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
32992715|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
32992716|NCT01550276|Experimental|The combination of both treatments|
32992717|NCT01550276|Placebo Comparator|control group|
32992718|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
32992719|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
33413948|NCT05746299|Experimental|Awake Congruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
32992720|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
32992721|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
32992722|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
32992723|NCT01550380|Experimental|All participants|
32992724|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
32992725|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
32992726|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
32992727|NCT01550419|Experimental|Atorvastatin(50 characters)|
32992728|NCT01550419|Placebo Comparator|Placebo(50 characters)|
32992729|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
32992730|NCT01550458|Experimental|Mibefradil|
32992731|NCT01550458|Placebo Comparator|Placebo|
32992732|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
32992733|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
32992734|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
32992735|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
32992736|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
32992737|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
32992738|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
32992739|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
32992740|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
32992741|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
32992742|NCT01550614|No Intervention|Arm B|Standard of care angina medication
32992743|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
32992744|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
32992745|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
32992746|NCT01550640|No Intervention|standard|control standard group
32992747|NCT01550653|Experimental|Liraglutide|"See Intervention"
32992748|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
32992749|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
32992750|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
32992751|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
32992752|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
32992753|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
32992754|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
32992755|NCT01550770|Experimental|proprofol|
32992756|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
33033607|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
33033608|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
32992757|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
32992758|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
32992759|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
32992760|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
32992761|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
32992762|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
32992763|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
32992764|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
32992765|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
32992766|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
32992767|NCT01550887|No Intervention|Impulsivity evaluation|
32992768|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
32992769|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
32992770|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
32992771|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
32992772|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
32992773|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
32992774|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
32992775|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
32992776|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
32992777|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
32992778|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
32992779|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
32992780|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
32992781|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
32992782|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
32992783|NCT01551017||c-treatment|test group
32992784|NCT01551017||standard cooling|comparison group
32992785|NCT01551043|Experimental|Arm 1|
32992786|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
32992787|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
32992788|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
32992789|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
32992790|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
32992791|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
32992792|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
32992793|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
32992794|NCT01551147|Experimental|Experimental 200 mg dose|
32992795|NCT01551147|Active Comparator|Active Comparator|
32992796|NCT01551147|Placebo Comparator|Placebo Comparator|
32992797|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
32992798|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
32992799|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
32992800|NCT01551238|Experimental|Protein intake of 5 energy percent|
32992801|NCT01551238|Experimental|Protein intake of 30 energy percent|
32992802|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
32992803|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
33413949|NCT05746299|Experimental|Sleep Incongruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the non-Modular category, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
33413950|NCT05746299|Experimental|Sleep Congruent (SWS)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during slow wave sleep (SWS), participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
32992804|NCT01551277|Placebo Comparator|Control Group|
32992805|NCT01551277|Experimental|BREATH STACKING|
33413951|NCT05746299|Experimental|Sleep Congruent (REM)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during rapid eye movement (REM) sleep, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
33413952|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
33413953|NCT03644316|Experimental|BandGrip|Topical skin closure device
33413954|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
33413955|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
32992806|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
33413956|NCT05283876|Active Comparator|Active psoriasis|
33413957|NCT05283876|Active Comparator|Stable psoriasis|
32992807|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
32992808|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
32992809|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
32992810|NCT01551329|Experimental|Drug: Ketamine|
32992811|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
32992812|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
32992813|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
32992814|NCT01551381|Experimental|EV-077|Oral administration
32992815|NCT01551381|Placebo Comparator|Placebo|Oral administration
32992816|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
32992817|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:~ampicillin + gentamicin (SOC regimen 1) and~cefotaxime + gentamicin (SOC regimen 2)."
32992818|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
32992819|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
32992820|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
32992821|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
32992822|NCT01551485|Experimental|Zolpidem|
32992823|NCT01551485|Placebo Comparator|Placebo|
32992824|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
32992825|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
32992826|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
32992827|NCT01551511|Placebo Comparator|Placebo|
32992828|NCT01551524|Experimental|Intravenous Erwinia|
32992829|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
32992830|NCT01551576||photoacoustic imaging (PAI)|Men seen in the urology clinic for elevated PSA and/or abnormal digital rectal exam (DRE) will be offered PAI at the time of transrectal ultrasound guided biopsy, which is standard of care. In addition, patients with a biopsy proven prostate cancer may also be approached for this PAI scan
32992831|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
33033609|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
33413958|NCT05759715||2-0 darkbown-green (2-0 bg)|Those with distinctively dark brown in the central area, slightly green in the peripheral area,
33413959|NCT05759715||1-0 lightbrown-green (1-0 bg).|Those with slightly dark brown in the central area and green in the peripheral area,
33413960|NCT05759715||dark brown (1-1 db)|Eyes with the same color structure in the central iris and the peripheral iris.
33413961|NCT05759715||light brown (1-1 lb)|Eyes with the same color structure in the central iris and the peripheral iris.
32992832|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
32992833|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
32992834|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
32992835|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
32992836|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
32992837|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
33413962|NCT05759715||dark brown (2-0 b)|Those with distinctively dark brown in the central iris area compared to the periphery .
33413963|NCT05759715||slightly dark brown (1-0 b)|Those with slightly dark brown (1-0 b) in the central iris area compared to the periphery .
32992838|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
32992839|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
33413964|NCT03644784||Yamaguchi University Hospital|
32992840|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
32992841|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
32992842|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
32992843|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
32992844|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
32992845|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
32992846|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
32992847|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
32992848|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
32992849|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
32992850|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
32992851|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
32992852|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
32992853|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
32992854|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
32992855|NCT01551706|Placebo Comparator|Exicipient pill|
32992856|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
32992857|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
32992858|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
32992859|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
32992860|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
32992861|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
32992862|NCT01551784||1|
32992863|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
32992864|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
32992865|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
32992866|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
32992867|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
32992868|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
32992869|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
32992870|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
32992871|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
32992872|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
32992873|NCT01551875||subjects who are meeting the inclusion criteria|
32992874|NCT01551901|Experimental|Luna Interbody System|
32992875|NCT01551914|Experimental|ultrasonic scissors|
32992876|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
32992877|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
32992878|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
32992879|NCT01551953|Experimental|tai chi exercise|
33413965|NCT03644784||Erasmus Medical Center|
33413966|NCT03644784||Academic Medical Center - Amsterdam|
32992880|NCT01551953|Experimental|mind-body breathing|
33413967|NCT03644784||Segeberger Kliniken Gruppe|
33413968|NCT03644784||McGill University - Montreal|
32992881|NCT01551953|Active Comparator|education|
32992882|NCT01551966|Experimental|video capsule endoscopy|
33413969|NCT05283798|Experimental|rate of missed threads in the first 6 weeks|To compare efficacy safety & side effects of multiload 375 IUD versus copper T 380 IUD when inserted during elective CS
33413970|NCT05283798|Other|number of bleeding days in first 6 weeks|compare numbers of bleeding days in first 6 weeks and first 6 month
33413971|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
33413972|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
33413973|NCT05262348|Active Comparator|Phase 1a - conventional stimulation|Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
33413974|NCT05262348|Experimental|Phase 1b - adaptive stimulation|Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
33413975|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
33413976|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
33413977|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
33413978|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
33413979|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
33413980|NCT03740919|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) administered subcutaneously (SC), 0 to 2 minutes before each meal with once or twice daily basal insulin. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
33413981|NCT03740919|Experimental|LY900014|Participants received 100 U/mL LY900014 administered SC, 0 to 2 minutes before start of the meal.
33413982|NCT03740919|Experimental|LY900014 Postmeal|Participants received 100 U/mL LY900014 administered SC, up to 20 minutes after the start of the meal.
33413983|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
33413984|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
33413985|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
33413986|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
33413987|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
32992883|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
32992884|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
32992885|NCT01552005||Population of patients treated with Saxagliptin|
32992886|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
32992887|NCT01552018|Placebo Comparator|Placebo|Placebo
32992888|NCT01552031||Observational group|
32992889|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
32992890|NCT01552044|Placebo Comparator|Placebo|placebo tablets
33324667|NCT04910022|Experimental|Phase 1_Dose escalation and MTD expansion cohort|Patients with diffuse gliomas
33324668|NCT04910022|Experimental|Phase 1_Glioblastoma expansion cohort|Patients with IDH wild type recurrent glioblastoma
33324669|NCT04910022|Experimental|Phase 2_Arm A_NMS-03305293+TMZ|Patients with IDH wild type recurrent glioblastoma
33324670|NCT04910022|Active Comparator|Phase 2_Arm B_Lomustine|Patients with IDH wild type recurrent glioblastoma
32992891|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
32992892|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
32992893|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
32992894|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
33324671|NCT05485662|Other|MIH-bearing tooth block exposed to HAP toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the HAP toothpaste
32992895|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
32992896|NCT01552122|Experimental|Odanacatib|
32992897|NCT01552122|Active Comparator|Alendronate|
32992898|NCT01552135||Healthy|Healthy men above 50 years old
32992899|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
32992900|NCT01552148|Other|Group Control|
32992901|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
32992902|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
32992903|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~Patients informed of the objectives of the survey and agreeing to participate.~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
32992904|NCT01552187|Placebo Comparator|Placebo|Placebo
32992905|NCT01552187|Active Comparator|Colchicine|Colchicine
32992906|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
32992907|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
32992908|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
32992909|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
32992910|NCT01552239|Experimental|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
32992911|NCT01552252|Placebo Comparator|0% POs-Ca|
32992912|NCT01552252|Active Comparator|0.5% POs-Ca|
32992913|NCT01552252|Active Comparator|1% POs-Ca|
32992914|NCT01552252|Active Comparator|1.5% POs-Ca|
32992915|NCT01552252|Active Comparator|2% POs-Ca|
32992916|NCT01552265||single-group MCI patients|
32992917|NCT01552291|Active Comparator|Glutamin|
32992918|NCT01552291|Placebo Comparator|Placebo|
32992919|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
32992920|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
32992921|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
32992922|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
32992923|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
32992924|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
32992925|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
32992926|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
32992927|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
32992928|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
33324672|NCT05485662|Other|MIH-bearing block exposed to Sodium Fluoride toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the sodium fluoride toothpaste
33324673|NCT01134120|Experimental|LY2784544|
33324674|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
33324675|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
33324676|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
33324677|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
32992929|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
32992930|NCT01552447|Other|Standard of care|Compression bandaging
32992931|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
33413988|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
33413989|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
32992932|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
32992933|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
32992934|NCT01552486|Other|Usual Care|
32992935|NCT01552499|Other|Control|
32992936|NCT01552499|Experimental|Treatment|
32992937|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
32992938|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
32992939|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
32992940|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
32992941|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
32992942|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
32992943|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
32992944|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
32992945|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
32992946|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
32992947|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
32992948|NCT01552616|Experimental|Activation Treatment|
32992949|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
32992950|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
32992951|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
32992952|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
32992953|NCT01552642|Active Comparator|Intervention Group|Intervention Group
32992954|NCT01552642|No Intervention|Control Group|Control Group
32992955|NCT01552655|Other|Dual-time PET/CT|
32992956|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
32992957|NCT01552668|Placebo Comparator|Placebo|
32992958|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
32992959|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
32992960|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
32992961|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
32992962|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
32992963|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
32992964|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
32992965|NCT01552785||Healthy adults|
32992966|NCT01552798|Experimental|Arm 1|
32992967|NCT01552798|Active Comparator|Arm 2|
32992968|NCT01552798|Placebo Comparator|Arm 3|
32992969|NCT01552811||Type 1 diabetes|
32992970|NCT01552811||healthy controls|
32992971|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
32992972|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
32992973|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
32992974|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
33413990|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
33413991|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
33413992|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
33413993|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
33413994|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
33413995|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
33413996|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
32992975|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
32992976|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
32992977|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
32992978|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
32992979|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
32992980|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992981|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992982|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992983|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992984|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992985|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
32992986|NCT01552941|Experimental|Vagal Nerve Stimulation|
32992987|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
32992988|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
32992989|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
32992990|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
32992991|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
32992992|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
32992993|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
32992994|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
32992995|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~will be receiving adjuvant chemotherapy"
32992996|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \~will not be receiving adjuvant chemotherapy"
32992997|NCT01553097||Healthy control|healthy education-age-matched women without cancer
32992998|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
32992999|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
32993000|NCT01553123|Experimental|Ulipristal with iron|
32993001|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
32993002|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
32993003|NCT01553266||MDET intervention|
32993004|NCT01553266||Control group|Patients who have not received the MDET intervention.
32993005|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
32993006|NCT01553305|No Intervention|Unsupervised exercise programme|
33033610|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
32993007|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
32993008|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
32993009|NCT01553370|Active Comparator|Alternate Intake-time|
32993010|NCT01553370|Experimental|Immediately post-exercise|
32993011|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
32993012|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
32993013|NCT01553422|Active Comparator|before fluid Therapy|
32993014|NCT01553422|Active Comparator|after fluid Therapy|
32993015|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
32993016|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
32993017|NCT01553487|Experimental|Excercise|The forearm vibration training
32993018|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
32993019|NCT01553500|Experimental|glucomannan|
32993020|NCT01553500|Placebo Comparator|placebo|
32993021|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
32993022|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
32993023|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
32993024|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
32993025|NCT01553526||Orsiro DES|
32993026|NCT01553552||Infected by Schistosoma haematobium|
32993027|NCT01553552||Not infected by Schistosoma haematobium|
32993028|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
32993029|NCT01553565|Experimental|Cold polypectomy|
32993030|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
32993031|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
32993032|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
32993033|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
32993034|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
32993035|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
32993036|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
32993037|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
32993038|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
32993039|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
32993040|NCT01553643|Placebo Comparator|Placebo|
32993041|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
32993042|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
32993043|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
32993044|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
32993045|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
32993046|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
32993047|NCT01553695|Active Comparator|general population|
32993048|NCT01553695|Experimental|ADHD Patient|
32993049|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2~Phase IIb Experimental : Udenafil"
32993050|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo~Phase IIb Placebo Comparator : Placebo"
32993051|NCT01553760|Experimental|Tri-MICS|
32993052|NCT01553760|Active Comparator|Conventional Phaco|
32993053|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
32993054|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
32993055|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
32993056|NCT01553799||US check tube|
32993057|NCT01553799||US check tube, Endobronchial|
32993058|NCT01553825||Pathologically diagnosed carcinoma|
32993059|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
32993060|NCT01553877|Active Comparator|Pushti Packet|
32993061|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
32993062|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
32993063|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
32993064|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
32993065|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
32993066|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
32993067|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
32993068|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
32993069|NCT01553929|Experimental|Physical and cognitive activity group|
32993070|NCT01553929|Active Comparator|Physical activity group|
32993071|NCT01553929|Placebo Comparator|control group|
32993072|NCT01553942|Experimental|Afatinib|Afatinib
32993073|NCT01553968|Other|Endurance Trained Subjects|
32993074|NCT01553968|Other|Untrained Subjects|
32993075|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
32993076|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
32993077|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
32993078|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
32993079|NCT01554020|Active Comparator|Multiherb product|Herbal product
32993080|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
32993081|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
32993082|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
32993083|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
32993084|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
32993085|NCT01554085|Experimental|ALS-002158|
32993086|NCT01554085|Placebo Comparator|Placebo|
32993087|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
32993088|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
32993089|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
32993090|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
32993091|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
32993092|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
32993093|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
32993094|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
32993095|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
32993096|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
32993097|NCT01554189|Experimental|Panel A (GT1 10 mg)|
32993098|NCT01554189|Experimental|Panel B (GT1 50 mg)|
32993099|NCT01554189|Experimental|Panel C (GT1 100 mg)|
32993100|NCT01554189|Experimental|Panel D (GT1 200 mg)|
32993101|NCT01554189|Experimental|Panel E (GT3 10 mg)|
32993102|NCT01554189|Experimental|Panel F (GT3 50 mg)|
32993103|NCT01554189|Experimental|Panel G (GT3 100 mg)|
32993104|NCT01554189|Experimental|Panel H (GT3 200 mg)|
32993105|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
32993106|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
32993107|NCT01554189|Placebo Comparator|Placebo Panel|
32993108|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993109|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993110|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993111|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993112|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993113|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993114|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993115|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993116|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
32993117|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
32993118|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
32993119|NCT01554228||Bariatric Surgery|
32993120|NCT01554254|Experimental|300mcg/kg/day for 28 days|
32993121|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
32993122|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
32993123|NCT01554293|Experimental|PBL 1427 capsules|
32993124|NCT01554293|Placebo Comparator|Matching placebo|
32993125|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
32993126|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
32993127|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
32993128|NCT01554332|Active Comparator|Active stimulation|
32993129|NCT01554332|Sham Comparator|Sham stimulation|
32993130|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
32993131|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
32993132|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
32993133|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
32993134|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
32993135|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
32993136|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
32993137|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
32993138|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
32993139|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
32993140|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
32993141|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
32993142|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
32993143|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
32993144|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
32993145|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
32993146|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
32993147|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
32993148|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
32993149|NCT01554501||Community sample|
32993150|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
32993151|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
32993152|NCT01554553|Experimental|Posterior crural repair|
32993153|NCT01554553|No Intervention|No posteriorcrural repair|
32993154|NCT01554566|Experimental|honey, no honey|
32993155|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
32993156|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
32993157|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
32993158|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
32993159|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
32993160|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
32993161|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
32993162|NCT01554657|Experimental|5 Days|
32993163|NCT01554657|Placebo Comparator|7 days|
32993164|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
33324678|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
32993165|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
32993166|NCT01554709|Experimental|CardioGard Cannula|
32993167|NCT01554709|Active Comparator|Reference Cannula|
32993168|NCT01554722|Experimental|in plane needle placement|
32993169|NCT01554722|Experimental|out of plane needle placement|
32993170|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
32993171|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
32993172|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
32993173|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
32993174|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
32993175|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
32993176|NCT01554787|Placebo Comparator|Placebo|
32993177|NCT01554800|Experimental|ACP-501|
32993178|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
32993179|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
32993180|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
32993181|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
32993182|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
32993183|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
33324679|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
32993184|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
32993185|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~Induction treatment:~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~CTD regimen - cyclophosphamide, thalidomide, dexamethasone~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~Consolidation treatment (depending on response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~High-dose therapy and stem cell transplant~Maintenance treatment:~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
32993186|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~Induction treatment~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~Consolidation treatment (depending on participant's response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~Maintenance treatment~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
33324680|NCT04811040|Experimental|Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
33324681|NCT04811040|Experimental|LEN, Teropavimab, Zinlirvimab Dose D|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
33324682|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
33324683|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
33324684|NCT03916536|Active Comparator|Holmium Laser|holmium laser enucleation of the prosteate
33324685|NCT03916536|Active Comparator|Thulium Laser|Thulium laser enucleation of the prosteate
33324686|NCT03916536|Active Comparator|Bipolar Enucleation|Bipolar enucleation of the prosteate
33324687|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
32993187|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
32993188|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
32993189|NCT01554878||knee surgery|
32993190|NCT01554917|Experimental|Iguratimod|
32993191|NCT01554930|Active Comparator|Western therapy|
32993192|NCT01554930|Experimental|Xiyanping injection plus western therapy|
32993193|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
32993194|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
32993195|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
32993196|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
32993197|NCT01554995|Experimental|LCB01-0371|active
32993198|NCT01554995|Experimental|Linezolid|comparator
32993199|NCT01555008|Experimental|Treatment A|
32993200|NCT01555008|Placebo Comparator|LX4211 Placebo|
32993201|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the TAU group will provide saliva samples for future GWAS analysis."
33324688|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
33324689|NCT04751604|Experimental|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide [1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)] for 4 weeks
33324690|NCT04751604|Placebo Comparator|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
33324691|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
33324692|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
33324693|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
32993202|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the AGT group will provide saliva samples for future GWAS analysis."
32993203|NCT01555034|Active Comparator|intervention plus therapy|
32993204|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
32993205|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
32993206|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
33324694|NCT05402982|Other|GROUP A|Fluid administration in the form of lactated ringer will be managed by Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2(10). Rohrich formula represents fluid maintinance,deficit and replacement fluid ( 0.25 ml crystalloid given for each 1 ml above 4 litre of lipoaspirate).
33324695|NCT05402982|Other|GROUP B|Patients will receive fluid maintenance of lactated ringer 2 ml/kg/h, cardiometry guided SVV will be measured before and after induction then every 30 min ,it ranges between 5-15%, fluid bolus of lactated ringer 4 ml /kg over 15 min will be administered if SVV ˃ 15% .
33324696|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
32993207|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
32993208|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
32993209|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
32993210|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
32993211|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
32993212|NCT01555099|Experimental|AZD5423|New study drug
32993213|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
32993214|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
32993215|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
32993216|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
32993217|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
32993218|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
32993219|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
32993220|NCT01555203|Experimental|liveWell: A healthy foundation for life|
32993221|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
32993222|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
32993223|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
32993224|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
32993225|NCT01555242|Experimental|Aneustat (OMN54)|
32993226|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
32993227|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
32993228|NCT01555307|Experimental|Balance group|Typical plus balance exercises
32993229|NCT01555307|Other|Typical group|Typical exercises
32993230|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
32993231|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
32993232|NCT01555333|Experimental|Arbaclofen|Open Label Study
32993233|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
32993234|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
32993235|NCT01555359||Patients undergoing stem cell collection|
32993236|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
32993237|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
32993238|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
32993239|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
32993240|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
32993241|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
32993242|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
32993243|NCT01555424|Active Comparator|High dose|
33324697|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
33324698|NCT04867668|Experimental|Digital intervention|Participants will be randomized to receive variable levels of exposure (including no exposure control) of digital anti-vaping and anti-smoking messages. We will evaluate the effects of experimental condition and exposure on outcomes (tobacco product use).
32993244|NCT01555424|Active Comparator|Reference dose|
32993245|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
32993246|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
32993247|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
32993248|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
32993249|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
32993250|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
32993251|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
32993252|NCT01555528||Growth Disorders|
32993253|NCT01555580|Experimental|GM-CSF|
32993254|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
32993255|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
32993256|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
32993257|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
32993258|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
32993259|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
32993260|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
32993261|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
32993262|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
32993263|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
32993264|NCT01555684|Placebo Comparator|Control - no treatment|
32993265|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
33033611|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
33324699|NCT04867668|No Intervention|Control|No exposure control condition
33324700|NCT04851678||Individuals with Tourette syndrome (TS)|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
33324701|NCT01234428|Other|surgery|
32993266|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
32993267|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
32993268|NCT01555736|Active Comparator|perennial immunotherapy scheme|
32993269|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
32993270|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
32993271|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
32993272|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
32993273|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
32993274|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
32993275|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
32993276|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
32993277|NCT01555827|Experimental|Alzheimer Disease|
32993278|NCT01555827|Active Comparator|Control|
32993279|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
32993280|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
32993281|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
32993282|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
32993283|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
32993284|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
32993285|NCT01555866|Experimental|Part 1 Healthy Subjects|
32993286|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
32993287|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
32993288|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
32993289|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
32993290|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
32993291|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
32993292|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
32993293|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
32993294|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
32993295|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
32993296|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
32993297|NCT01555996|Experimental|Early and intensive OT|
32993298|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
32993299|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
32993300|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
32993301|NCT01556035|Experimental|Lenalidomide treatment|
32993302|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
32993303|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
32993304|NCT01556074|Experimental|Yoga treatment|
32993305|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
32993306|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
32993307|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
32993308|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
32993309|NCT01556126|Experimental|Amphilimus eluting stent (Cre8)|Sirolimus formulated coronary eluting stent
32993310|NCT01556152|Active Comparator|Treatment Arm 1|
32993311|NCT01556152|Active Comparator|Traetment Arm 2|
32993312|NCT01556152|Placebo Comparator|Treatment Arm 3|
33413997|NCT04466163|Experimental|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen & Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
32993313|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
32993314|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
32993315|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
32993316|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
32993317|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
32993318|NCT01556217|Experimental|JNJ-39393406|
32993319|NCT01556217|Placebo Comparator|Placebo|
32993320|NCT01556282|Experimental|Therasphere|
32993321|NCT01556295||Experimental|
32993322|NCT01556295||Control|
32993323|NCT01556308|Experimental|DM-EBS|
32993324|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
32993325|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
32993326|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
32993327|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
32993328|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
32993329|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
32993330|NCT01556373||severe sepsis|patients with severe sepsis
32993331|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
32993332|NCT01556386||Pharmacogenetic analysis, ALL|
32993333|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
32993334|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
32993335|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
32993336|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
32993337|NCT01556477|Active Comparator|azacitidine|
32993338|NCT01556477|Experimental|azacitidine + lenalidomide|
32993339|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
32993340|NCT01556516||Women with Pompe Disease|
32993341|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
32993342|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
32993343|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
32993344|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
32993345|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
32993346|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
32993347|NCT01556607|Active Comparator|Experimental: MDT-637|
32993348|NCT01556607|Placebo Comparator|Placebo|
32993349|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
32993350|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
32993351|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
32993352|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
32993353|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
32993354|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
32993355|NCT01556698|Experimental|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
32993356|NCT01556698|Placebo Comparator|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
32993357|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
32993358|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
32993359|NCT01556737|Experimental|Supplement|
32993360|NCT01556737|Placebo Comparator|Placebo|
32993361|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
32993362|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
32993363|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
32993364|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
32993365|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
32993366|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
32993367|NCT01556841|Placebo Comparator|Placebo|
32993368|NCT01556867|Active Comparator|dry cord care|
32993369|NCT01556867|Active Comparator|antiseptic care|
32993370|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
32993371|NCT01556880|No Intervention|Standard usual care|
32993372|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
32993373|NCT01556919||Mucosal Impedance Probe|
32993374|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
32993375|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
32993376|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
32993377|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
32993378|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
32993379|NCT01556958||Active Wheezing - age 5-12|
32993380|NCT01556958||Active Wheezing - under age 5|
32993381|NCT01556958||No Wheezing|
32993382|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
32993383|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
32993384|NCT01556984||DSA group|
32993385|NCT01556984||control group|
32993386|NCT01557010|Experimental|Treatment A|
32993387|NCT01557010|Experimental|Treatment B|
32993388|NCT01557010|Experimental|Treatment C|
32993389|NCT01557010|Placebo Comparator|Treatment D|
32993390|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
32993391|NCT01557023|Active Comparator|Yasmin®|
32993392|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
32993393|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
32993394|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
32993395|NCT01557062|Other|Polysomnography|
32993396|NCT01557062|Other|Temperature measure|
32993397|NCT01557062|Other|Fibromyalgia Impact questionary|
32993398|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
32993399|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
32993400|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
32993401|NCT01557101|Other|OPTICAL COLONOSCOPY|
32993402|NCT01557114|Experimental|radiation therapy with Ipilimumab|
32993403|NCT01557127||Group 1|
33413998|NCT04466163|No Intervention|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert & Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
32993404|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
32993405|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
32993406|NCT01557153|Experimental|Amlodipine|
32993407|NCT01557153|Placebo Comparator|Placebo|
32993408|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
32993409|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
32993410|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
32993411|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
32993412|NCT01557218|Experimental|Cucumber|
32993413|NCT01557218|Experimental|Pepper|
32993414|NCT01557218|Experimental|Tomato|
32993415|NCT01557218|Experimental|Vegetable variety|
32993416|NCT01557218|Experimental|Apple|
32993417|NCT01557218|Experimental|Peach|
32993418|NCT01557218|Experimental|Pineapple|
32993419|NCT01557218|Experimental|Fruit variety|
32993420|NCT01557231||No treatment|OA
32993421|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
32993422|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
32993423|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
32993424|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
32993425|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
32993426|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
32993427|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
32993428|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
32993429|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
32993430|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
32993431|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
32993432|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
32993433|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
32993434|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
32993435|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
32993436|NCT01557413|Experimental|Locked plate|Locked plate
32993437|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
32993438|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
32993439|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
32993440|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
32993441|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
32993442|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
32993443|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
32993444|NCT01557608|Experimental|Photon stimulation|
32993445|NCT01557608|Placebo Comparator|Placebo treatment|
32993446|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
32993447|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
32993448|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
32993449|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
32993450|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
32993451|NCT01557647|Experimental|inhaled treprostinil|
32993452|NCT01557647|Placebo Comparator|placebo|
32993453|NCT01557660|Experimental|inhaled treprostinil|
32993454|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
32993455|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
32993456|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
32993457|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
32993458|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
32993459|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
32993460|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
32993461|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
32993462|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
32993463|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
33413999|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
32993464|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
32993465|NCT01557816|Active Comparator|Naproxen|
32993466|NCT01557816|Sham Comparator|Placebo|
32993467|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
32993468|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
32993469|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
32993470|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
32993471|NCT01557933||ECT|All study subjects have consented to receive ECT.
32993472|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
32993473|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
32993474|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
32993475|NCT01557998|Other|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
32993476|NCT01557998|Experimental|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
32993477|NCT01557998|Other|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
32993478|NCT01558011|Experimental|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
32993479|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
32993480|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
32993481|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
32993482|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
32993483|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
32993484|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
32993485|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
32993486|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
32993487|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
32993488|NCT01558050|Placebo Comparator|placebo|placebo capsules
32993489|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
33414000|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
32993490|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
32993491|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
32993492|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
32993493|NCT01558154|Experimental|acupuncture|
32993494|NCT01558154|Experimental|Psychotherapy|
32993495|NCT01558154|Experimental|physiotherapy|
32993496|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
32993497|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
32993498|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
32993499|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
32993500|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
32993501|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
32993502|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
32993503|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
32993504|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
32993505|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
32993506|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
32993507|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
32993508|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
32993509|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
32993510|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
32993511|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
32993512|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
32993513|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
32993514|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
32993515|NCT01558336|Experimental|Praziguantel|tablet single dose
32993516|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
32993517|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
32993518|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
32993519|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
32993520|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
32993521|NCT01558388|Experimental|Vaginal lactobacilli|
32993522|NCT01558388|Placebo Comparator|Placebo|
32993523|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
32993524|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
33414001|NCT04462965|Experimental|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
32993525|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
32993526|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
32993527|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
32993528|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
33324702|NCT04849104||COPD high-risk patients|age <70 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
32993529|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
32993530|NCT01558453|Experimental|Eloxatin|Oxaliplatin
32993531|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
32993532|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
32993533|NCT01558479||Case|Has a diagnosis of Parkinson's disease
32993534|NCT01558479||Control|No diagnosis of Parkinson's disease
32993535|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
32993536|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
32993537|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
32993538|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
32993539|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
32993540|NCT01558557|Experimental|Gluten Free Diet|
32993541|NCT01558570||Schizophrenia|
32993542|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
32993543|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
32993544|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
32993545|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
32993546|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
32993547|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
32993548|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
32993549|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
32993550|NCT01558622|Placebo Comparator|vitamin c|
32993551|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
32993552|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
32993553|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
32993554|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
32993555|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
32993556|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
32993557|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
32993558|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
32993559|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
32993560|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
32993561|NCT01558726|Experimental|Case management|
32993562|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
32993563|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
32993564|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
32993565|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
32993566|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
32993567|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
32993568|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
32993569|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
32993570|NCT01558843||traumatic brain injury|
32993571|NCT01558843||aneurysmal subarachnoid hemorrhage|
33414002|NCT04462965|Placebo Comparator|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
33414003|NCT01339585|Experimental|Timing of tDCS|
33414004|NCT01339585|Experimental|Alternative timing of tDCS|
33414005|NCT04004325|Experimental|Cohort A|
33414006|NCT04004325|Experimental|Cohort B|
33414007|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
33414008|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
32903824|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
32903825|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
32903826|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
32903827|NCT01244633|Experimental|Ecopipam|Active treatment
32903828|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
32903829|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
32903830|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
32903831|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
32903832|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
32903833|NCT01210079|Experimental|Gabapentin|
32903834|NCT01210079|Placebo Comparator|Placebo|
32903835|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
32903836|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
32903837|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
32903838|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
32903839|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
32903840|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
32903841|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
32903842|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
32903843|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
32903844|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
32903845|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
32903846|NCT01276340||1|women with urinary incontinence
32903847|NCT01276418|Experimental|Treatment|
32903848|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
32903849|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
32903850|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
32908563|NCT05395988|Experimental|Reward plus instruction-only group|"The reward plus instruction group receives a screen next to each sink in kindergarten.~On the screen, hand washing instructions are shown during hand washing. If hands are washed correctly (time and soap usage), a reward (animal animation) is shown on the screen.~After a defined time period, the screen only shows instructions, the reward is not shown anymore.~After a defined time period, the screen is removed."
32993572|NCT01558843||intracerebral hematoma|
32993573|NCT01558843||brain tumor|
32993574|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
32993575|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
32993576|NCT01558869|Experimental|Arm 1|
32993577|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
32993578|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
32993579|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
32993580|NCT01558908|Experimental|Intramuscular injection of ERC|
32993581|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
32993582|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
32993583|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
33414009|NCT05185063||Out of Hospital Cardiac Arrest|
32993584|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
32993585|NCT01558973||Cocaine dependent|
32993586|NCT01558973||Opioid dependent|
33414010|NCT05745207|Experimental|Part A, Cohort 1: E2086 1 mg or Placebo|Participants will receive 1 milligram (mg) (2*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32993587|NCT01558973||Alcohol dependent|
32993588|NCT01558973||Healthy controls|
32993589|NCT01558973||Adolescents|
32993590|NCT01558973||Pathological gamblers|
32993591|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
32993592|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
32993593|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
32993594|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
32993595|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
32993596|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
32993597|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
32993598|NCT01559077|Active Comparator|ALN-TTR02|
32993599|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
32993600|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
32993601|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
32993602|NCT01559142|Active Comparator|IFX TG|
32993603|NCT01559142|Active Comparator|IFX alone|
32993604|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
32993605|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
32993606|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
32993607|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
32993608|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
32993609|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
32993610|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
32993611|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
32993612|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
32993613|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
32993614|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
32993615|NCT01559233|Experimental|FPlus|
33414011|NCT05745207|Experimental|Part A, Cohort 2: E2086 2.5 mg or Placebo|Participants will receive 2.5 mg (5*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
33414012|NCT05745207|Experimental|Part A, Cohort 3: E2086 5 mg or Placebo|Participants will receive 5 mg (1*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32993616|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
32993617|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
32993618|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
32993619|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
32993620|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
32993621|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
32993622|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
32993623|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
32993624|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
32993625|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
32993626|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
32993627|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
32993628|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
32993629|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
32993630|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
32993631|NCT01559376||Endoscopic radial artery harvest|
32993632|NCT01559376||Conventional open radial artery harvest|
32993633|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
32993634|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
32993635|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
32993636|NCT01559415|Experimental|Very Low Calorie Diet|
32993637|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
32993638|NCT01559428|Experimental|Plant sterol-enriched margarine|
32993639|NCT01559428|Experimental|Plant stanol-enriched margarine|
32993640|NCT01559428|Placebo Comparator|Control margarine|
32993641|NCT01559441|Experimental|Beetroot juice|
32993642|NCT01559441|Placebo Comparator|Carbohydrate control drink|
32993643|NCT01559467|Other|Routine clinical care plus early CMR|
32993644|NCT01559467|No Intervention|Routine clinical care|
32993645|NCT01559467|Other|Routine clinical care plus early CTA|
32993646|NCT01559480|Active Comparator|Desogestrel|
32993647|NCT01559480|Placebo Comparator|Placebo|
32993648|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
32993649|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
32993650|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
32993651|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
32993652|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
32993653|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
32993654|NCT01559558||cystocele|
32993655|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
32993656|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
32993657|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
32993658|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
32993659|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
32993660|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
32993661|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
32993662|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
33414013|NCT05745207|Experimental|Part A, Cohort 4: E2086 10 mg or Placebo|Participants will receive 10 mg (2*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32993663|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
32993664|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
33414014|NCT05745207|Experimental|Part A, Cohort 5: E2086 25 mg or Placebo|Participants will receive 25 mg (1*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32908564|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
32908565|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
32908566|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
32908567|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
32908568|NCT00963638|Experimental|MagTabSR|
32908569|NCT00963638|Placebo Comparator|Sugar Pill|
32908570|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
32908571|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
32908572|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
32908573|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
32908574|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
32908575|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
32908576|NCT05395676|Experimental|Cognitive dual task training (CDT) Group|The CDT group (n = 20) will participate in games on Xbox one consoles that require a higher cognitive demand compared to those of the BDT group. The training sessions will include five different games that require participants to stand and use their hand reach function to interact with different cognitive (i.e. dual-tasking) skills, such as working memory, problem solving, Stroop effect, planning, attention and response time.
32908577|NCT05395676|Active Comparator|Balance dual task (BDT) training Group|The BDT group (n = 20) will participate in the conventional training programme on Wii consoles that have been used by previous studies (Barcala et al. 2013; Chao et al. 2015; Kannan et al. 2019), to improve balance performance. The training sessions will include five different games that require participants to stand and use their weight shift to control the game while maintaining balance.
32908578|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
32908579|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
32908580|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
32908581|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
32908582|NCT05705765|Experimental|Suspension|Exercise with suspension devices.
32908583|NCT05705765|Active Comparator|Balance|Exercise over instability surfaces.
32908584|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
32908585|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
32908586|NCT00964496|Active Comparator|Thalidomide Group|
32908587|NCT00964496|Other|Iron-controlled Group|
32908588|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
32908589|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
32993665|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
32993666|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
32993667|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
32993668|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
32993669|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
32993670|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
32993671|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
32993672|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
32993673|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
32993674|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
32993675|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
33414015|NCT05745207|Experimental|Part A, Cohort 6: E2086 50 mg or Placebo|Participants will receive 50 mg (2*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32993676|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
32993677|NCT01559766||4-6 years old group|
32993678|NCT01559766||7-9 years old group|
32993679|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
32993680|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
32993681|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
32993682|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
32993683|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
32993684|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
32993685|NCT01559909|Experimental|Socket wall height|
32993686|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
32993687|NCT01559974|Active Comparator|Vitamin D|
32993688|NCT01559974|Placebo Comparator|Placebo|
32993689|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
32993690|NCT01559987|Other|Test|MTB + Floss
32993691|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
32993692|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
32993693|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
32993694|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
32993695|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
32993696|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
32993697|NCT05570669|Experimental|full dose|"Group A delayed full-dose regimen (study arm): intake of two large A sachets and 2 small B sachets from 20:30 to 22:00 the evening before the exam. Taking the remaining 2 envelopes A large e 2 small B envelopes from 10.30 pm to midnight the evening before the exam."
32993698|NCT05570669|Other|split dose|"Group B split-dose regimen (control arm): intake of two large A sachets and two small B sachets from 20.30 to 22:00 the evening before the exam. The remaining two large A envelopes and two small B envelopes will be taken 5 hours earlier than the time when the exam is scheduled on the same day as the exam."
32993699|NCT05570643|Experimental|LPS group|Healthy male volunteers that will receive an intravenous administration of LPS (2ng/kg) twice.
32993700|NCT05570643|Placebo Comparator|Placebo group|Healthy male volunteers that will receive an intravenous administration of placebo (NaCl 0.9%).
32993701|NCT05570604|Experimental|Cognitive Training|As tested in the investigator's pilot, the Brain HQ program is designed to enhance specific areas of cognitive functioning that will be tested in this study. The goals of the Brain HQ program are to improve visual processing speed, learning and memory and attention. The exercises include time-order judgment, discrimination, spatial-match, forward-span, instruction-following, and narrative-memory tasks. This program systematically reduces the stimulus duration during a series of increasingly difficult information-processing tasks presented via computer. The exercises automatically adjust to user performance to maintain an 85% correct rate. The program will include 4 hours per week over a 10-week period for a total of up to 40 hours. The study team has support from the original developer and Posit Science. For the purposes of this trial, any participants who do not complete the total of up to 40 hours will not be counted as deviations.
32993702|NCT05570604|Placebo Comparator|Attention Control|Control participants will be asked to complete activities on the computer. The program offers a choice of activities that will consist of crossword puzzles and word jumbles. The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation. Training: Participants will be instructed to perform this active attention control intervention 4 hours per week over 10 weeks for a total of up to 40 hours, the same as BrainHQ.
32993703|NCT05570565|Experimental|Erector spinae plane group|"The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear ultrasound transducer will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 20 mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected. The procedure will be repeated following the same steps on the other side.~The surgical intervention will be then allowed 20 minutes after finishing the block procedure"
32993704|NCT05570565|Active Comparator|local field block|For the preincisional local field block, a 23-gauge needle is used to infiltrate 20mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected in the subcutaneous space and in the paravertebral muscles on each side of the spinous processes of the presumed surgical approach.
32993705|NCT05570552|Experimental|mHealth arm|mHealth arm will receive mobile phone based behavior change communication intervention to exclusively use clean fuel LPG for domestic cooking.
32993706|NCT05570552|No Intervention|Control arm|Control arm will receive no mHealth based intervention.
32993707|NCT05570539|Active Comparator|Immediate Release formulation|IR Formulation
32993708|NCT05570539|Experimental|Extended Release formulation|ER formulation
32993709|NCT05570474|Experimental|Protein|Daily protein shake during 6 months after surgery
32993710|NCT05570474|Placebo Comparator|Control|Daily placebo shake during 6 months after surgery
32993711|NCT05570461|Experimental|Experimental Group|Experimental group will receive Modified Constraint-Induced Movement Therapy and traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the Modified Constraint-Induced Movement Therapy group will be constrained by wearing a mitten during the treatment session
32993712|NCT05570461|Active Comparator|Control Group|Control group therapy will consist of increasing upper limb function with the use of both hands. The session include active or active assistive range of motion exercises, unilateral and bimanual activities, balance and strength training or coordination exercises depending on the severity of motor impairment. Similar to group A, daily therapy will be conducted for 40 min/day, 6 days/ week for upto 2 weeks.
32993713|NCT05570448|Active Comparator|Anti-reflux mucosal ablation (ARAT)|ablation in the gastric cardia using hybrid argon plasma coagulation
32993714|NCT05570448|Sham Comparator|No treatment|no ablation
32993715|NCT05570435|Experimental|YIYANG TangLv milk powder|30g of milk powder (Nestle YIYANG TangLv milk powder) containing 789 mg Reducose® extract, standardized to contain 1% 1-deoxynojirimycin (1-DNJ), 10% of an oil mix and 8% of soluble fiber reconstituted with 180 ml of warm water.
32993716|NCT05570435|Active Comparator|skimmed milk|25g of commercially available skimmed milk powder reconstituted with 180 ml of warm water.
32993717|NCT05570409|Experimental|Immunosuppressive treatment|Mycophenolate mofetil (MMF) 1g bid and prednisolone at initially 1mg/kg in a step-down regime
32993718|NCT05570409|Placebo Comparator|Placebo|Mycophenolate mofetil (MMF) and prednisolone Placebo
32993719|NCT05570383|Placebo Comparator|In the control group|Half of the subjects（30 subjects）will be assigned to the control group，they will be using the Mometasone furoate nasal spray (Nasonex).
32993720|NCT05570383|Experimental|The experimental group|Half of the subjects (30) will be assigned to the experimental group. Received sublingual dust mite drops (trade name: Changdi, Zhejiang Wuwu Biotechnology Co., LTD.) for sublingual immunotherapy.
32993721|NCT05570370||ADAD family members, mutation carriers|asymptomatic and presymptomatic individuals
32993722|NCT05570370||ADAD family members, non-mutation carriers|age-matched family members (non-mutation carriers) relative to the asymptomatic/presymptomatic group
32993723|NCT05570357|Active Comparator|Intervention|
32993724|NCT05570357|Placebo Comparator|Placebo|
32993725|NCT05570318|Active Comparator|Polyethylene glycols|"This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence.~Their PEG dosage will be adjusted to the ideal dose for the individual child (this will be evaluated by a health care professional), with the minimum dosage being the maintenance dose of 0,5mg/kg/day, and the maximum dosage being the disimpaction dose of 1,5mg/kg/day"
32993726|NCT05570318|Experimental|Polyethylene glycols and low volume trans anal irrigation|This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence. PEG dose will be adjusted in the same manner as in group a, but this group will also receive daily treatment with low volume trans anal irrigation.
32993727|NCT05570266||Cases|"Cases are taken by recruiting women who:~have no first degree family history of breast or ovarian cancer~are or had been diagnosed with primary breast cancer or tested positive for high penetrance genes (e.g. BRCA 1/2)~menarche age >12 years old~premenopausal"
32993728|NCT05570266||Cohort|"Controls are taken from clients who visited Breast Cancer Care Alliance (BCCA) and:~have no family history of breast or ovarian cancer~premenopausal~menarche age >12 years old~asymptomatic~do not have any first-degree relationship with the cases~consented for the study and follow up"
32993729|NCT05570253|Experimental|SDX-7320 plus Eribulin (safety run-in period)|During the safety run-in period, the first 15 patients enrolled will be assigned to received study drug SDX-7320 plus Eribulin. Not randomized.
32993730|NCT05570253|Experimental|SDX-7320 plus Eribulin|Patients randomized to SDX-7320 plus Eribulin.
32993731|NCT05570253|Placebo Comparator|Eribulin Plus Placebo|Patients randomized to the control arm will receive placebo plus Eribulin.
32993732|NCT05570240||OA group|Knee osteoarthritis patients who were scheduled to receive elective total knee replacement surgery which need spinal anesthesia.
32993733|NCT05570240||Control group|Control group patients were scheduled to receive elective general surgery or urological surgery with spinal anesthesia.
32993734|NCT05570201|Experimental|Experimental Group|By visiting the women who met the research criteria, the purpose of the study was explained and their written informed consent was obtained. This study was conducted in two sessions using pre- and post-tests. The Personal Information Form, the SFQ, and the HADS were filled out using the face-to-face interview method by the researcher for the women included in the music and training on the day of their hospitalization, which lasted for 30-45 minutes.
32993735|NCT05570175|Experimental|intervention group|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks.
32993736|NCT05570175|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
32993737|NCT05570136|Experimental|Treatment|Participants in the treatment group will receive the 12-week STEP by a trained interventionist. In the first four weeks, the interventionist will focus on building participants' selfefficacy and health literacy and help participants learn the STEP exercise and principles. In the following four weeks, the interventionist will help the older adults to be more independent in prescribing exercise activities for themselves. In the last four weeks, participants will be fulling knowledgeable and independent on functional exercising; the interventionist will allocate community resources for long-term maintenance. After program completion, trained raters will administer at post-tests. There will also be a 3-month and 6-month follow-up evaluation after program completion.
32993738|NCT05570136|Sham Comparator|Control|Participants in the control group will receive weekly health newsletters and will not get any suggestions or encouragement to do exercise from the research team. A staff member will call the control group participants weekly to document any new exercise programs from usual community services. At this stage, participants will not be excluded from the study if they join an exercise program, but we will document what kind of exercise they are conducting. Trained raters will administer at post-tests and two follow-ups.
32993739|NCT05570110|Experimental|enoxolone|100 mg enoxolone in a capsule
32993740|NCT05570110|Placebo Comparator|placebo|Placebo in a capsule
33324703|NCT04849104||Early-stage COPD patients|"those who are younger than 70 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:~Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) <lower limit of normal value (LLN, 80%);~CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;~FEV1 drops rapidly (≥60 mL/year);"
32993743|NCT05570084|Active Comparator|Tamsulosin|0.4mg daily for 4 weeks
32993744|NCT05570084|Experimental|Silodosin|8mg daily for 4 weeks
32993745|NCT05570058|Experimental|Cohort 1|12:4 (RXC007 : Placebo) Dose level 1: 12 weeks (84 days) dosing
32993746|NCT05570058|Experimental|Cohort 2|12:4 (RXC007 : Placebo) Dose level 2: 12 weeks (84 days) dosing
32993747|NCT05570058|Experimental|Cohort 3|12:4 (RXC007 : Placebo) Dose level 3: 12 weeks (84 days) dosing
32993748|NCT05570058|Experimental|Cohort 1B|16:2 (RXC007 : Placebo) Dose level 1; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy
32993749|NCT05570058|Experimental|Cohort 3B|16:2 (RXC007 : Placebo) Dose level 3; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy
32993750|NCT05570045|No Intervention|Usual Diet|(n=300): Children eat usual dietary (not using nutrient products) for 3 months. After that, they will use the products
32993751|NCT05570045|Experimental|Colos Gain Dietary Supplement|(n=300): Children eat usual dietary, but with 2 glasses of the nutrient product as the side meals. The product provides GOS(Galactooligosaccharides), Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.
32993752|NCT05570006|Experimental|ABBV-668|Participants will receive ABBV-668 twice daily approximately at same time each day for 16 weeks.
32993753|NCT05569993|Active Comparator|Glutamine group|30 patients will recieve .3 mg/kg of glutamine for first 7 days in ICU
32993754|NCT05569993|Placebo Comparator|Placcebo group|30 patients will recieve placcebo for first 7 days in ICU
32993755|NCT05569967|Experimental|Group 1|Individuals in this group will receive spinal stabilization training through telerehabilitation.
32993756|NCT05569967|Active Comparator|Group 2|Individuals in this group will receive spinal stabilization training face-to-face.
32993757|NCT05569863||Hypospadias group|Patients with hypospadias diagnosis
32993758|NCT05569863||Control group|Patients without hypospadias
32993759|NCT05569850|Experimental|Recently introduced toothpaste|Brushing twice a day with a recently introduced toothpaste.
32993760|NCT05569850|Active Comparator|Commercial toothpaste|Brushing twice a day with a commercially available toothpaste.
32993761|NCT05569824||Prospective Study Pathway|Child or young person undergoing a Broncho-alveolar Lavage (BAL) for suspected pulmonary Invasive Fungal Disease (IFD) and consent obtained.
32993762|NCT05569798|No Intervention|Standard care|Thirty patients will receive standard care (regular ICU treatment without any restriction to usual medical care). INSIGHT scans will not be performed on these patients. However, other forms of ultrasound scanning will be permitted in this group. For example, departmental ultrasound scans (full echocardiography, liver, or vascular ultrasound assessment); transoesophageal echocardiography; transcranial doppler; any form of PoCUS other than the INSIGHT scan.
32993763|NCT05569798|Experimental|Standard care + the INSIGHT intervention|Thirty patients will receive standard care + the INSIGHT intervention. The INSIGHT intervention is described in detail in section 5.7.1. INSIGHT scans will be performed by staff trained in the INSIGHT Training and Competency Programme on days 1 (0-36 hours), 3 (72-96 hours) and 7 (6 to 8 days) from ICU admission. Scans will only be performed at these timepoints if the patient is still admitted to the ICU.
32993764|NCT05569785|Active Comparator|Group 1 Resistance Exercise Therapy Feasibility|One group who have been randomised to receive 4 weeks of Resistance Exercise Therapy to explore the feasibility of introducing such a programme in the bariatric population.
32993765|NCT05569785|No Intervention|Group 2 Standard Care|This group have been randomised to receive standard care post surgery.
32993766|NCT05569720|Experimental|ApTOLL treatment|Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.
32993767|NCT05569707|Other|MelaDiff|Patients with melanoma of the extremities included in the protocol. Preoperative, patients will receive two MRI-scans and a magnetic tracer injection at the primary tumor site. During surgery, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with Magtrace®, in addition to the standard procedure.
32993768|NCT05569668||Neoadjuvant chemotherapy group|Standard NAC comprised 2 cycles. Platinum plus paclitaxel or docetaxel was repeated once every 3 weeks. Cis-platinum was administered at a total dose of 75 mg/m2 by continuous infusion on d1 or equal divided on Days 2-4 or Days 1-3. Paclitaxel, 175 mg/m2, d1, or paclitaxel, 87.5 mg/m2, d1, d8. If the docetaxel was adopted, it was given as 75 mg/m2 on Day 1. Then surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients.
32993769|NCT05569668||Primary surgery group|The patients would receive primary surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients. .
32993770|NCT05569655|Experimental|Subjects in group A|For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide: 20mg-40mg/d).
32993771|NCT05569655|Active Comparator|Subjects in group B|Subjects in group B receive standard therapy (including furosemide: 20mg-40mg/d).
32993772|NCT05569629|Experimental|Pre & post-EBBx/BB group|BW will be performed once before endobronchial biopsy and bronchial brushing, and once after endobronchial biopsy and bronchial brushing
32993773|NCT05569629|No Intervention|Post-EBBx/BB group|BW will be performed once after endobronchial biopsy and bronchial brushing
32993774|NCT05569616|Experimental|Hand massage group|Based on the hand massage procedure, hand massage with baby oil will be applied for 20 minutes, three times a week (12 times in total) for 4 weeks.
32993775|NCT05569616|Experimental|Play activity group|It will be played in groups of two for one hour once a week. The application will take 4 weeks.
32993776|NCT05569616|No Intervention|Control group|These elderly people in the control group will benefit from the standard care practices offered in the institution, and no intervention will be given to these elderly people by the researcher.
32993777|NCT05569603|Experimental|Chronobiology-guided lifestyle interventions group|A multimodal program that includes (1) timed bright light therapy, (2)guidance on meal timing, and (3) sleep hygiene education.
32993778|NCT05569603|No Intervention|wait-list control group|The participants in the wait-list group will be told that they are on a waiting list during the first 2 weeks to serve as the no-treatment control. Chronobiology-guided lifestyle interventions will be conducted after the posttest is completed.
32993779|NCT05569590|Active Comparator|Control|One visit three application of bleaching agent (hydrogen peroxide 35%) will be performed and desensitizing agent (fluoride varnish) will be applied for 10 minutes after bleaching.
32993780|NCT05569590|Experimental|Propolis|One sitting vital tooth bleaching procedure will be performed. Three application each of 15 minutes of bleaching agent (hydrogen peroxide 35%) will be applied and desensitizing agent propolis in paste form will be applied for 10 minutes.
32993781|NCT05569590|Experimental|Propolis mixed with bleaching agent|One visit vital tooth bleaching procedure will be performed. three application each of 15 minutes of Propolis mixed with bleaching agent (hydrogen peroxide 35%) will be applied.
32993782|NCT05569577|Experimental|Additional hCG injection|An additional hCG injection of 2000-5000IU would be performed 48 hours following routine hCG trigger on the basis of supplementation of estrogen and dydrogesterone in IHH patients.
32993783|NCT05569577|Placebo Comparator|No additional hCG injection|Only estrogen and dydrogesterone would be given for luteal phase support in IHH patients.
32993784|NCT05569564|Experimental|Osseodensification with ridge splitting|Ridge splitting followed by osseodensification using osseodensifying burs .
32993785|NCT05569564|Active Comparator|Osseodensification|osseodensification will be performed using osseodensifying burs.
32993786|NCT05569538|Experimental|Cohort A (Patients refractory to, relapsed or intolerant of ruxolitinib):|"Bomedemstat : The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort A. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10^9/L.~Ruxolitinib: Patients will continue their prior, stable dose of ruxolitinib. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
32993787|NCT05569538|Experimental|Cohort B (Cohort B will consist of 10 patients who are JAK inhibitor naïve):|"Bomedemstat: The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort B. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10^9/L.~Ruxolitinib: Patients will start treatment with ruxolitinib at Initial Treatment Period Cycle 1 Day 1. The starting dose of ruxolitinib will be 10 mg BID. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
32993788|NCT05569473|Experimental|Test group|Intrabony defect filled with VCMX after along with open flap debridement [OFD+VCMX])
32993789|NCT05569473|Experimental|control group|OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
32993790|NCT05569460||Numeric Rating Scale (NRS) score after surgery <4|
32993791|NCT05569460||Numeric Rating Scale (NRS) score after surgery ≥ 4|
32993792|NCT05569434|Experimental|68Ga-P16-093 and MRI scan|Within 1 week, each patient underwent MRI scan and PET/CT scan after intravenous administration of 68Ga-P16-093, respectively.
32993793|NCT05569408||EVUSHELD Arm|Individuals given EVUSHELD for prophylaxis
32993794|NCT05569408||Concurrent Control Arms|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
32993795|NCT05569369|Experimental|angioplasty with stenting|
32993796|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Prospective)|
32993797|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Retrospective)|
32993798|NCT05569343||Textbook outcome group|Achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
32993799|NCT05569343||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
32993800|NCT05569330|Other|Arm 1|Two of the four participating day care units are allocated in arm 1
32993801|NCT05569330|Other|Arm 2|Two of the four participating day care units are allocated in arm 2
32993802|NCT05569304|Experimental|Endoscopic Sleeve Gastroplasty Arm|Prospective cohort of patients with classes 1 and 2 obesity that had consented to undergo endoscopic sleeve gastroplasty.
32993803|NCT05569304|No Intervention|Retrospective cohort|Retrospective cohort of patients with classes 1 and 2 obesity who did not undergo endoscopic sleeve gastroplasty and had been put on GLP-1 analogues
32993804|NCT05569291|Experimental|Automated Coaching Program (ACP)|The ACP will use the application as developed for patients with COPD and tested to be effective in this population (Demeyer et al., 2017). The program includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit; wrist or waist worn) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention; 3) smartphone coaching application, installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient. 4) phone calls by the coaches initiated in pre-defined situations.
32993805|NCT05569291|Experimental|Manual Coaching Program (MCP)|The MCP includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit, wrist or waist worn), that will be linked with a smartphone using the Fitbit application providing direct feedback. Patients can access the Fitbit application if they want to, but they will not receive personal feedback; 3) weekly phone calls by the coaches, interviewing patients on their progress, performance (steps) and feedback. The first goal is based on the physical activity level at the beginning of the coaching intervention (median of 4 days). The individual activity goal (expressed as daily step count) will be revised based on the patient's willingness to increase.
32993806|NCT05569239|Experimental|OVX836 480µg|Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein in the influenza virus. One single administration intramuscularly of 480µg dose on Day1.
32993807|NCT05569239|Placebo Comparator|Placebo|Saline solution (B. Braun Ecoflac Plus) Saline solution (Nacl 0.9%), B. Braun Ecoflac Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day1.
32993808|NCT05569213||DBS latency/MEP latency|Each patient will serve as control and test. Control will be latency of hand MEP generated by DBS stimulation of the corticospinal tract. The test condition will be the latency of hand MEP generated by conventional MEP acquisition.
32993809|NCT05569200|Experimental|Haifu Focused Ultrasound tumor therapeutic System|
32993810|NCT05569135||Debridement only|Debridement of the pilonidal cyst through pits was performed in this group. After the removal of hair and necrotic tissues through pits, the surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
32993811|NCT05569135||Debridiment with laser ablation|This group underwent the same procedure as the debridement group. After the removal of hair and necrotic tissues through pits, a diode laser at 1470 wavelength was inserted and the pilonidal cavity was ablated in a continuous fashion. The surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
32993812|NCT05569109||av fistula patency loss with hperphosphatemia|hemodialysis patients with av fistula patency loss by doppler ultrasound and hyperphosphatemia
32993813|NCT05569109||av fistula patency loss with normal phosphate level|hemodialysis patients with av fistula patency loss by doppler ultrasound and normal phosphate level
32993814|NCT05569031|Active Comparator|venlafaxidine|venlafaxine 75-225 mg per day.
32993815|NCT05569031|Active Comparator|Lofixidine|Lofixidine 1.6 to 2.4 per day.
32993816|NCT05568966|Experimental|Blood Draw|"Venous blood draw up to 24mL and/or 6 capillary fingersticks~Interventions:~Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick"
32993817|NCT05568953|Experimental|Arm 1 (JE-YF17D vaccine followed by YF17D vaccine)|28 subjects will receive one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units [PFU])) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU) ) on Day 28.
32993818|NCT05568953|Experimental|Arm 2 (YF17D vaccine followed by JE-YF17D vaccine)|28 subjects will receive one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 0 followed by one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units [PFU]) on Day 28.
32993819|NCT05568953|Experimental|Arm 3 (Inactivated JE vaccine followed by YF17D vaccine)|14 subjects will receive one dose of the inactivated JE vaccine (Ixiaro, Valneva, 0.5mls) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 28.
32993820|NCT05568914|Experimental|Assessments|"In this single-arm trial, each participant undergoes the following measurements/assessments:~Physical: Body weight (before and after dialysis), length Biophysical: NRS2002, GLIM, Bio-electrical Impedance Analysis Metabolic: Indirect Calorimetry Nutritional: dietary anamnesis, 3-days nutritional diary"
32993821|NCT05568875|Experimental|e-self-management intervention|12-week e-self-management intervention consisting of exercise videos and videos with information about recommended treatment
32993822|NCT05568875|Active Comparator|Treatment as usual|Treatment as usual
32993823|NCT05568823|Other|"Patients responding to treatment after 8 weeks of treatment"|"Patients responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is beneficial."
32993824|NCT05568823|Other|"Patients non-responding to treatment after 8 weeks of treatment"|"Patients non-responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is not satisfactory."
32993825|NCT05568771|Experimental|Core exercise group|In the study, the exercise group was set as Istanbul University Club Basketball Team, and the control group was set as Galatasaray Basketball Club. While the 1st group, which is the exercise group, applied the additional warm-up program to the core training program to be included in the routine training of the team, for 8 weeks,
32993826|NCT05568771|No Intervention|Control group|the 2nd group, the control group, continued their routine training programs.
32993827|NCT05568732|Experimental|Test group|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
32993828|NCT05568732|Active Comparator|Control group|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
32993829|NCT05568693|Experimental|mRNA-enhanced immunoem|1 dose of 0.3 ml of mRNA vaccine
32993830|NCT05568680|Experimental|SynKIR-110|Single dose gravity drip IV administration
32993831|NCT05568628||lacating femals|screening of breast lesions in lactating female
32993832|NCT05568628||pregnant|screening of breast lesions in pregnant female
32993833|NCT05568251|Active Comparator|Active tDCS combined with Cognitive Training|
32993834|NCT05568251|Sham Comparator|Sham tDCS combined with Cognitive Training|
32993835|NCT05568108||nerve transfer|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
32993836|NCT05568108||nerve and free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
32993837|NCT05566249||ArtiSential group|Patients undergoing laparoscopic surgery using ArtiSential
32993838|NCT05566249||Robot group|Patients undergoing robotic surgery
32993839|NCT05564975||Hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
32993840|NCT05564975||No-hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
32993841|NCT05564741|Active Comparator|15 s injection time|Patients in group A will be given the spinal anesthesia with an injection time of 15 s
32993842|NCT05564741|Active Comparator|90 s injection time|Patients in group B will be given the spinal anesthesia with an injection time of 90 s
32993843|NCT05563402|Experimental|Treatment arm|"Therefore, the investigators propose an, open, non-randomized study. This study protocol includes 12 one-hour RAGT training sessions for 4 weeks, three times a week, under the supervision of a qualified rehabilitation team.~Informed consent will be obtained from patients before inclusion in the study, which will be carried out in accordance with the Declaration of Helsinki.~With the aim of describing Usability as the main objective, and Safety as a secondary objective and functional changes at the level of balance, walking speed and quality of life."
32993844|NCT05561257|Placebo Comparator|Group 1 (control group)|300 ml NaCl infusion
32993845|NCT05561257|Experimental|Group 2 (750 mg Vitamin C)|295 ml NaCl + 5 ml (750 mg) Vitamin C
32993846|NCT05561257|Experimental|Group 3 (7.5 g Vitamin C)|250 ml NaCl + 1 x 50 ml (7.5 g) Vitamin C
32993847|NCT05561257|Experimental|Group 4 (15 g Vitamin C)|200 ml NaCl + 2 x 50 ml (2 x 7.5 g) Vitamin C
32993848|NCT05560880|Experimental|High Intensity Interval gait training|subjects will receive 3x/week high intensity interval training for 20 minutes over a 4 week period
32993849|NCT05560880|Active Comparator|Moderate intensity continuous gait training|subjects will receive 3x/week moderate intensity continuous gait training for 20 minutes over a 4 week period
32993850|NCT05556629||NATPARA: Participants|Paticipants who have been approved for NATPARA and a part of the special use program (SUP) prior to survey implementation will participate in the survey via telephone or internet.
32993851|NCT05556629||NATPARA: Healthcare Provider (Prescribers)|Healthcare provider (HCPs)/Prescriber who can provide a 10-digit National Provider Identifier (NPI) number and who are certified in the NATPARA risk evaluation and mitigation strategy (REMS) by successfully completing the NATPARA REMS program training module for prescribers, including the knowledge assessment, and submitting a NATPARA REMS Program Prescriber Enrollment Form will participate in the survey via telephone or internet.
32993852|NCT05545540|Experimental|Intervention arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The intervention arm will be issued the first movement (8 minutes, 22 seconds) of Mozart's Sonata for Two Pianos in D Major, K448. They will be exposed to it once a day during wakefulness for two consecutive months.
32993853|NCT05545540|Placebo Comparator|Control arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The control arm will receive the first movement (8 minutes, 34 seconds) of Mozart's Fantasia for Piano in C Minor, K 475. Although from the same composer, the control sonata has been found not to have neurostimulating properties. They will be exposed to it once a day during wakefulness for two consecutive months.
32993854|NCT05542498|Active Comparator|Mindfulness Training|5-lesson audio-guided mindfulness training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
32993855|NCT05542498|Active Comparator|Relaxation Training|5-lesson audio-guided relaxation training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
32993856|NCT05541653|Experimental|Intervention|"At the individual level, participants in the intervention arm receive place-based and financial well-being interventions.~These include, at the individual level:~Tax preparation~Access to public benefits~Financial counseling and microgrants~At the neighborhood level:~Abandoned house remediation~Trash cleanup~Vacant lot greening~Tree planting"
32993857|NCT05541653|No Intervention|Control|Participants in the control arm will not receive any of the listed interventions.
32993858|NCT05531305|Experimental|Study intervention|
32993859|NCT05531084|Experimental|Thoracoabdominal aortic aneurysm extent I-III|Thoracoabdominal aortic aneurysm extent I-III (proximal seal can be from the left carotid artery to directly after the left subclavian artery):
32993860|NCT05531084|Experimental|Failed EVAR|Failed EVAR (defined as type IA endoleak or increase in aneurysm sac size in the setting of proximal seal loss)/juxtarenal/Pararenal/paravisceral/thoracoabdominal aortic aneurysm extent IV-V:
33414016|NCT05745207|Experimental|Part A, Cohort 7: E2086 100 mg or Placebo|Participants will receive 100 mg (4*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
32993862|NCT05524753|Experimental|AquOTic|Dose of 10 weeks of aquatic occupational therapy
32993863|NCT05524753|No Intervention|Control|No intervention
32993864|NCT05522582|Experimental|methotrexate+anti-PD-1 antibody+radiotherapy|Tablets with 5mg methotrexate are taken orally twice a week during radiotherapy. With anti-PD-1 monoclonal antibody, 200mg, Q3W.
32993865|NCT05502770||Natural cycle children|Children born from frozen embryo transfer with natural cycle protocol
32993866|NCT05502770||Modified natural cycle children|Children born from frozen embryo transfer with modified natural cycle protocol
32993867|NCT05502770||Artificial cycle children|Children born from frozen embryo transfer with artificial cycle protocol
32993868|NCT05491304|Experimental|Non-severe DXM group|Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
32993869|NCT05491304|Experimental|Non-severe Ruxo group|Ruxolitinib(Ruxo): body weight (BW)<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; >20kg: 10mg Bid; Orally for 4 weeks.
32993870|NCT05491304|Experimental|Severe HLH-94 group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8."
32993871|NCT05491304|Experimental|Severe HLH-94 plus ruxolitinib group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8.~Ruxolitinib(Ruxo): body weight (BW)<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; >20kg: 10mg Bid; Orally for 4 weeks."
32993872|NCT05461794|Experimental|Arm A: Sitravatinib + Tislelizumab|Sitravatinib administered orally and tislelizumab administered intravenously
32993873|NCT05461794|Experimental|Arm B: Sitravatinib|Sitravatinib administered orally
32993874|NCT05461794|Experimental|Arm C: Investigator-chosen Chemotherapy|Docetaxel or Irinotecan
32993875|NCT05453643|Experimental|Sleep deprivation|healthy volunteers
32993876|NCT05453136|Experimental|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
32993877|NCT05453136|Experimental|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
32993878|NCT05453136|Placebo Comparator|Placebo|Period in which participants received repeated doses of placebo prior to bedtime
32993879|NCT05435417|Experimental|Manual segmentation technique of CBCT images of the condyles.|Using the manual edition built in tool, first a brush of small size will be used to demarcate the outline of the condyle in the sagittal cuts. Then shading the demarcated condylar area with a brush of larger size in each slice. The outline of the condyle will be refined on all cuts. The software built in tool 'create surface' will be used to create the segmented 3D volume
32993880|NCT05435417|Experimental|Semiautomatic segmentation technique of CBCT images of the condyles.|Using the water shed built in tool, first a brush of small size will be used to demarcate the outline of the condyle by the 'background' option in all planes. Then using the 'foreground' option, a brush of larger size will be used to shade the condylar area. The software built in tool 'expand water shed' will be used to include the whole condyle. At last, 'create surface' option will be used to create the segmented 3D volume.
32993881|NCT05435417|No Intervention|Actual physical measurements of the condyles on the dry mandibles|"For linear measurements, actual physical measurements will be done on the dry mandibular condyles, using digital caliper, as mentioned before.~For volumetric measurements, water displacement technique will be used. The mandibular condyle will be immersed in a graduated beaker containing water till the level of the glued gutta percha. The volume of the displaced water will be measured and will represent the actual volume of the condyle"
32993882|NCT05434013|Experimental|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
32993883|NCT05434013|Experimental|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
32993884|NCT05434013|Experimental|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
32993885|NCT05424380|Experimental|Part 1: Dose escalation|Part 1 will evaluate a dosing schedule for a total of 28 days in each cycle. The starting dose for Cycle 1 will be escalated in the next dose escalation cohort until MTD is reached.
32993886|NCT05424380|Experimental|Part 2: Dose expansion|Part 2 will evaluate efficacy after an induction phase. The induction phase consists of a treatment regimen at RP2D determined in Part 1.
32993887|NCT05423145|Experimental|acupressure intervention|Receives access to the acupressure intervention
32993888|NCT05423145|No Intervention|wait list control|No access to the acupressure intervention during the study period
32993889|NCT05419570||Patients Undergoing Pancreaticoduodenectomy|
32993890|NCT05416138|Experimental|TMS over the left prefrontal cortex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the left dorsolateral prefrontal cortex (DLPFC) at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing and stimulation per session is approximately 40 minutes (in 4 blocks with breaks in-between).
33414017|NCT05745207|Experimental|Part B, Cohort 8: E2086 25 mg or Placebo|Participants will receive 25 mg (1*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
33324704|NCT04849104||patients with mild to moderate COPD|Patients with mild to moderate COPD: age <75 years, FEV1/FVC<70%, FEV1 predicted value ≥50%
32993891|NCT05416138|Sham Comparator|TMS over the head vertex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the head vertex at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing per session is approximately 40 minutes (in 4 blocks with breaks in-between).
32993892|NCT05400499||Parkinson's disease with DBS|This is the only group. The patients in this group will have bilateral subthalamic region deep brain stimulator. They will be recruited after they are therapeutically optimized on stimulation as well as medical therapy.
32993893|NCT05399381|Experimental|Frontoparietal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
32993894|NCT05399381|Experimental|Frontoparietal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
32993895|NCT05399381|Experimental|Parietofrontal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
32993896|NCT05399381|Experimental|Parietofrontal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
32993897|NCT05391555|Experimental|Noninteractive, then Interactive|Participants undergo the infusion under noninteractive conditions, followed by a second drug infusion under interactive conditions.
32993898|NCT05391555|Experimental|Interactive, then Noninteractive|Participants undergo the infusion under interactive conditions, followed by a second drug infusion under noninteractive conditions.
32993899|NCT05388773|Experimental|Arm S (Low Risk)|"Low risk patients are defined as T1-T2 AND 0 or 1 metastatic lymph nodes AND <3 cm AND clear (≥3mm) margins AND no extracapsular extension (ECE) AND no perineural invasion AND no lymphovascular invasion.~Patients will undergo transoral surgical resection of the oropharyngeal tumor."
32993900|NCT05388773|Experimental|Arm RT (Intermediate Risk)|"Intermediate risk patients are defined as having any of the following features: One or more close (<3mm) margins, OR minimal ≤1 mm ECE OR 1 or more metastatic lymph nodes >3 cm in diameter OR 2-4 lymph nodes positive (≤ 6 cm in diameter), OR perineural invasion OR lymphovascular invasion~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT five times a week for 3 weeks."
32993901|NCT05388773|Experimental|Arm CRT (High Risk)|"High risk patients are defined as having any of the following features: One or more positive margins OR >1 mm ECE OR ≥ 5 metastatic lymph nodes.~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT six times a week and a weekly chemotherapy infusion (cisplatin or carboplatin) during radiation therapy.~Patients will receive 2 Gy/fraction, 6 fractions per week with at least a 6-hour interfraction interval between each treatment:~PTV-P50 or PTV-N50: 50 Gy in 25 fractions (2 Gy/fx)~PTV-N45: 45 Gy in 25 fractions (1.8 Gy/fx) with simultaneous integrated boost to the PTV-P50 volume.~PTV-P30 or PTV-N30: 30 Gy in 15 fractions (2 Gy/fx)"
32993902|NCT05388656|Experimental|Estradiol, Then Placebo|Participants will first receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. After a washout period of 3 weeks, participants will then receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
32993903|NCT05388656|Experimental|Placebo, Then Estradiol|Participants will first receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. After a washout period of 3 weeks, participants will then receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
32993904|NCT05387798|Experimental|RAD011|
32993905|NCT05384457|Experimental|High intensity training (HIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The experimental group will perform a multimodal HIT protocol. Cardiorespiratory training will consist of a high-intensity interval training protocol on a cycle ergometer. After a five-minute warm-up, interval training will start, consisting of five one-minute bouts (110 RPM at 100% VO2max workload), separated by one minute of active rest (75 RPM at 50% VO2max workload). Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 80% of the one repetition maximum. Core muscle training will consist of a circuit of six static core exercises (glute bridge, glute clam, superman back extension, adapted plank, adapted side plank, shoulder retraction with hip hinge) at 60% of the maximal voluntary contraction.
32993906|NCT05384457|Active Comparator|Moderate intensity training (MIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The control group will perform a multimodal MIT protocol. Cardiorespiratory training will consist of a moderate-intensity continuous training protocol on a cycle ergometer. After a five-minute warm up, participants start continuous training comprising of 14 minutes of moderate-intensity cycling (90RPM at 60%VO2max workload). The duration will increase weekly with 1'40'' up to 22'40''. Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 60% of the one repetition maximum. Core muscle training will be identical to the protocol described in 'Core muscle training HIT' with the exception of the exercise intensity. Only exercises with low relative core muscle activation will be used.
33033612|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
33033613|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
32993907|NCT05382598|Active Comparator|Early renal replacement therapy (RRT) group|"In this group of patients, RRT will be initiated if the patient either presents with or develops AKI, while mechanically ventilated, provided that he is in stage 2 according to KDIGO classification.~RRT will not be delayed till the presence of an urgent indication for the procedure.~A trial of furosemide stress test will be applied before proceeding towards early RRT after volume optimization."
32993908|NCT05382598|Active Comparator|Late renal replacement therapy (RRT) group|"This group of patients will receive RRT if they develop any of the following indications:~Severe hyperkalemia (> 6.5 mEq/L).~Oliguria with failed response to diuretics in the presence of life-threatening pulmonary edema requiring high ventilatory settings i.e. PEEP >10 in addition to FiO2 > 50%.~Severe metabolic acidosis (PH <7.15).~Uremic pericarditis, encephalopathy or coagulopathy."
32993909|NCT05378113|Experimental|Ondansetron premedication Group|The ondansetron group will receive ondansetron 0.15mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
32993910|NCT05378113|Active Comparator|Lidocaine premedication Group|The lidocaine group will receive lidocaine 2% 1mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
32993911|NCT05372393|Other|Local infiltration anaesthesia|The investigators allocate 59 patients in this arm. It serves as the control group, who receives local infiltration anaesthesia.
32993912|NCT05372393|Experimental|Local infiltration anaesthesia and distal median nerve block|The investigators allocate 59 patients in this arm. It serves as the experimental group, who receives local infiltration anaesthesia and distal median nerve block.
32993913|NCT05371717|Experimental|Trial Group|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment application
32993914|NCT05371717|Active Comparator|Control group|Domiciliary use of Biorepair Total Protection
32993915|NCT05355012|Experimental|5A-QUIT-N intervention|"The 5A-QUIT-N intervention can be defined as multilevel, i.e., it is based on a territorial organization with expected results at the level of professional practice (structuring of practices around the 5A method) and therefore of the care of pregnant women who smoke tobacco.~This project is based on three strategic axes:~A gradation of the care offer~Personalized care by developing specific treatment paths~Coordination of territorial resources to support pregnant women in quitting smoking.~These elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
32993916|NCT05355012|No Intervention|5A-QUIT-N control|Usual care in the care of pregnant women who smoke tobacco.
32993917|NCT05320471||healthy young adults|between 20-40 years
32993918|NCT05320471||healthy older adults|between 50-75 years
32993919|NCT05306275|Experimental|CSL312 AI Abdomen|CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)
32993920|NCT05306275|Experimental|CSL312 AI Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI
32993921|NCT05306275|Experimental|CSL312 AI Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI
32993922|NCT05306275|Experimental|CSL312 NSD Abdomen|CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)
32993923|NCT05306275|Experimental|CSL312 NSD Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD
32993924|NCT05306275|Experimental|CSL312 NSD Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD
32993925|NCT05299515|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
32993926|NCT05299515|No Intervention|Treatment As Usual|Participants in the TAU group will receive treatment as usual (weekly group and individual counseling with an addiction counselor in addition to referral to other available services in the community through study contact).
32993927|NCT05258435||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE G140154 and followed in the post-approval study NCT04630626.
32993928|NCT05256615|Experimental|Diabetes|Participants recruited to this arm have been clinically diagnosed with either gestational, pre- or type 2 diabetes.
32993929|NCT05256615|Experimental|Non-diabetes|Participants recruited to this arm of the study do not have gestational, pre- or type 2 diabetes.
32993930|NCT05234632|Experimental|PICO 14 Any Wound|Any wound treated with PICO 14. For closed Surgical incisions this will be for 14 days post surgery and with a 30 day follow up. For chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
32993931|NCT05234632|Experimental|PICO 14 Closed Incisions|Any Closed incision treated with PICO 14, for closed Surgical incisions this will be for 14 days post-surgery and with a 30 day follow up.
32993932|NCT05234632|Experimental|PICO 14 Chronic/Dehisced Surgical Wounds|Any Chronic/Dehisced Surgical wound treated with PICO 14, for chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
32993933|NCT05230004|Experimental|Phase I|Phase I involves testing the comfort and feasibility of our adjustable prosthetic system for children. This arm will involve in-lab testing only to arrive at a final design. Feedback will be obtained verbally and through the PEQ questionnaire to determine comfort, stability and feasibility of the adjustable system.
32993934|NCT05230004|Active Comparator|Phase II|Phase II involves a two month home trial to determine the comfort and utility of an adjustable prosthetic system for children. Children will be fit at several different locations by their prosthetist with the adjustable socket. They will complete several questionnaires on their current device, as well as have internal socket pressures and a gait analysis completed. They will return one month later to complete the same outcome measures on their conventional device. They will also be given activity monitors to track their activity through the duration of the project.
32993935|NCT05229965|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
33033614|NCT01964703|Placebo Comparator|control|
33324705|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
32993936|NCT05229965|Active Comparator|Codeine Group|The patient receives an envelope containing association of Paracetamol and Codeine at the dose of 2 times /day + follow-up sheet + appointment card.
32993937|NCT05229965|Active Comparator|Cafeine Group|The patient receives an envelope containing association of Paracetamol and Cafeine at the dose of 2 times /day + follow-up sheet + appointment card.
32993938|NCT05223413|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning (RIC): Patients will undergo weekly RIC during the entire span of the chemotherapy period. Each RIC session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation
32993939|NCT05223413|Sham Comparator|simulated RIPC (Sham)|Control group (Sham): Patients will undergo weekly simulated RIC (sham) during the entire span of the chemotherapy period. Each sham session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation.
32993940|NCT05216081|Experimental|Elder adults in emergency department setting with cognitive impairment|Elder mistreatment in an Emergency Department setting with cognitive impairment.
32993941|NCT05204472|Experimental|Burst DBS first, Tonic DBS second|10 days of Burst-stimulation followed by 10 days of active tonic stimulation (Burst-DBS -> tonic-DBS)
32993942|NCT05204472|Active Comparator|Tonic DBS first, Burst DBS second|10 days of active tonic stimulation followed by 10 days of Burst-stimulation (tonic-DBS -> Burst-DBS)
32993943|NCT05197634||Children with Autism Spectrum Disorder|The orofacial trauma history, dietary habits and lifestyle changes of children aged 3-14 years diagnosed with autism in Istanbul University Department of Child Psychiatry evaluated through a questionnaire to be applied to their families.
32993944|NCT05197634||Healthy children|The orofacial trauma history, dietary habits and lifestyle changes of healthy children aged 3-14 years applying to Istanbul University Faculty of Dentistry Department of Pediatric Dentistry will be evaluated through a questionnaire to be applied to their families.
32993945|NCT05196750||Normal vaginal delivery|Maternal delivery of delivery via normal vaginal delivery
32993946|NCT05196750||Lower segment Caesarean section (LSCS)|Maternal delivery of delivery via lower segment Caesarean section (LSCS)
32993947|NCT05192122|Other|Bone marrow MRD-negative VGPR or CR|Discontinue maintenance therapy after at least three years
32993948|NCT05192122|Other|Bone marrow MRD-positive VGPR or CR|Continue maintenance therapy as per SOC
32993949|NCT05190744|Experimental|Polyuric subjects with Hereditary Nephrogenic Diabetes Insipidus|Polyuric subjects with hereditary nephrogenic diabetes insipidus with loss of function of AVPR2 or AQP2 will be treated with PB
32993950|NCT05190744|Experimental|Polyuric subjects with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan|Polyuric subjects with autosomal dominant polycystic kidney disease on chronic tolvaptan treatment will be treated with PB
32993951|NCT05190744|Experimental|Polyuric subject secondary to lithium administration|Polyuric subject post lithium administration will receive PB
32993952|NCT05166811|Active Comparator|75 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
32993953|NCT05166811|Active Comparator|50 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
32993954|NCT05166811|Placebo Comparator|Placebo|For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
32993955|NCT05159765|Placebo Comparator|Control|Contact lens with refractive correction, single vision optic
32993956|NCT05159765|Experimental|Treatment|Contact lens with refractive correction, multifocal optic
32993957|NCT05137080|Active Comparator|Treatment A|24mg dexamethasone i.v. perioperatively and 24mg dexamethasone i.v. on the first postoperative day
32993958|NCT05137080|Active Comparator|Treatment B|24mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
32993959|NCT05137080|Placebo Comparator|Treatment C|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
32993960|NCT05112575||Early imaging: within 36 hours postoperatively.|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular within 36 hours after neurosurgical procedure.
32993961|NCT05112575||Late imaging: between 36 and 72 hours postoperatively|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular between 36 and 72 hours after neurosurgical procedure.
32993962|NCT05099835|Active Comparator|Botulinum Toxin|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
32993963|NCT05099835|Active Comparator|steroid|injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml
32993964|NCT05098522|Experimental|Arm 1: IRL201104|IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
32993965|NCT05098522|Placebo Comparator|Arm 2: Placebo|Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
32993966|NCT05095779|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
32993967|NCT05095779|Experimental|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care for completing counseling calls.
32993968|NCT05094245|Active Comparator|Stellate ganglion block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
32993969|NCT05094245|No Intervention|Conventional|Mecobalamin Tablets oral Mecobalamin Tablets tid-8
32993970|NCT05092321|Experimental|Aquatic Occupational Therapy|Group-based aquatic occupational therapy with 1:1 swim buddy for safety.
32993971|NCT05056753|Active Comparator|Investigational Device|The HWBV chair consists of a custom-made saddle-seat type of chair. The vibration actuators are embedded into the underside design of the chair. The base contains two vibrators, one for each side of the chair, and the chair is split in half vertically so that the vibrating actuators are able to send a harmonic vibration at alternating frequencies, upwards through each side of the chair. The HWBV system is considered a non-significant and non-substantial risk device.
32993972|NCT05056753|Sham Comparator|Control Device|The Control device is identical in construction to the Active device. The vibration mode, however, is a significantly different setting than that used by the Active version, so that the mechanoreceptors in the cervical spine are not effectively stimulated.
32993973|NCT05046899|Experimental|BIOpH+ Psoriasis Medical Bath|BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
32993974|NCT05046899|Active Comparator|Comparative device|Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
32993975|NCT05046886|Other|Usual Care Control (UCC)|Baseline advice about the Mediterranean-style diet and attention control.
32993976|NCT05046886|Active Comparator|Standardized|One-size-fits-all dietary counseling to follow a Mediterranean-style diet
32993977|NCT05046886|Active Comparator|Personalized|Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
32993978|NCT05043415|Active Comparator|Immediate endoscopic necrosectomy|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Then in this group, endoscopic necrosectomy will be performed immediately following index EUS-guided drainage of the necrotic collection, during the same session
32993979|NCT05043415|Active Comparator|Step-up endoscopic intervention|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. In this group, only EUS-guided drainage of the necrotic collection will be performed, and endoscopic necrosectomy will be performed at a separate session at a later time as needed.
32993980|NCT05015491|Experimental|Noom Healthy Weight Program|"The Noom platform uses a cognitive behavioral approach to weight loss that integrates set content with interaction with live coaches to support client efforts at behavior change. The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. It has 52 weeks of curriculum with 1-3 articles to read per day (Reading level: Grade 6-8)."
32993981|NCT05010018|Experimental|Intervention|We will pilot the BUD app in 19 intervention corner stores over an 8-month period in East Baltimore. During this time, we will collect data from corner store owners, producers, whole salers, and consumers.
32993982|NCT05010018|No Intervention|Control|We will collect data from 19 control corner stores over the same 8-month period. They will not receive any form of intervention or delay intervention.
32993983|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
32993984|NCT04988815|Experimental|Ropeginterferon alfa-2b|Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.
32993985|NCT04980378||Simplify Disc|Extended follow-up of IDE Subjects treated at two continuous levels with the Simplify Cervical Artificial Disc during IDE G150206
32993986|NCT04979572|Experimental|Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg|Single dose of TS-172 or placebo before breakfast
32993987|NCT04979572|Experimental|Part B (multiple dose) : Step 5: TS-172 90 mg|Multiple dose of TS-172 or placebo before breakfast and dinner
32993988|NCT04970147|Other|there are not arm for this study.|there is not a control group for this study.
32993989|NCT04938180|Experimental|Cohort A|Low-Dose AMB-05X Each subject will receive a low dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
32993990|NCT04936061|Experimental|High flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
32993991|NCT04936061|Experimental|Low flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
32993992|NCT04936061|Sham Comparator|Sham flow ambient air|15 minute transnasal air flow therapy with the CoolStat sham device as an abortive treatment for migraine attack.
32993993|NCT04927351|Experimental|Intervention|New electronic medical record based discharge medication order set.
32993994|NCT04927351|No Intervention|Control|Usual Care
32993995|NCT04926831|Experimental|Cohort A|Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day
32993996|NCT04926831|Experimental|Cohort B|Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
32993997|NCT04922112|Experimental|Research group|Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.
32993998|NCT04905615|No Intervention|Baseline Measures|The first two-weeks within each school children's baseline physical activity data will be collected. Children will be blinded to the data, receiving no feedback. Teachers will be instructed not to change normal school practices or encourage children's physical activity.
32993999|NCT04905615|Experimental|Data-Driven Strategy Based Intervention|During the following 2-weeks teachers will be implementing strategies to improve their class' physical activity. These are individualised strategies which will be co-developed during semi-structured interviews where teachers will discuss data visualisations with the researcher which depicts their class' physical activity over the 2-week baseline period. Teachers will then implement these strategies over the subsequent 2-weeks. During this time teachers are able to share the physical activity data with their pupils if they wish.
32994000|NCT04903925|Experimental|Group 1|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a probiotic for 21 days (2 tablets/day).
32994001|NCT04903925|Placebo Comparator|Group 2|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a placebo of the probiotic for 21 days (2 tablets/day).
32994002|NCT04889300|Experimental|Best Possible Self|Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. This procedure is known to reliably generate positive affect and positive future expectations (Carrillo et al., 2019). Orientated at Flink et al. (2015) the BPS condition was adapted for a pain population.
32994003|NCT04889300|Active Comparator|Typical Day|In the control condition, participants are asked to describe and visualize a typical day (TD). We adapted the TD condition in order to take possible changes in participants´ TD due to the COVID-19 pandemic into account.
32994004|NCT04873323|Experimental|TS-142 10 mg|TS-142 therapeutic dose oral tablet (low dose)
32994005|NCT04873323|Experimental|TS-142 30 mg|Description: TS-142 supratherapeutic dose oral tablet (high dose)
32994006|NCT04873323|Experimental|Moxifloxacin 400 mg|Moxifloxacin tablet
32994007|NCT04873323|Experimental|Placebo|Placebo oral tablet
32994008|NCT04871295|No Intervention|Wait List|
32994009|NCT04871295|Experimental|Noom Healthy Weight|
32994010|NCT04856085|Experimental|Cohort 1a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
32994011|NCT04856085|Experimental|Cohort 2a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
32994012|NCT04856085|Experimental|Cohort 3a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
32994013|NCT04856085|Experimental|Cohort 4a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
32994014|NCT04856085|Experimental|Cohort 5a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
32994015|NCT04856085|Experimental|Cohort 6a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
32994016|NCT04856085|Experimental|Cohort 7a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
32994017|NCT04856085|Experimental|Cohort 8a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
32994018|NCT04856085|Experimental|Cohort 1b (VIR-3434)|Subjects will receive multiple doses of VIR-3434 for 44 weeks
32994019|NCT04856085|Experimental|Cohort 2b (VIR-3434)|Subjects will receive multiple doses of VIR-3434 for 20 weeks
32994020|NCT04856085|Experimental|Cohort 1c (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
32994021|NCT04856085|Experimental|Cohort 2c (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks
32994022|NCT04837495|Active Comparator|Stellate Ganglion block group|will include 20 patients: each one will receive 10 ml lidocaine 2% right stellate ganglion block (RSGB) under sonar guidance
32994023|NCT04837495|No Intervention|Control group|will include 20 patients: a control group
32994024|NCT04834960|Other|MOV Intervention|Pre-intervention and post-intervention design
32994025|NCT04818034|Experimental|Study Drug|The study drug Dapagliflozin
32994026|NCT04814771|Experimental|[14C] TS-142|Participants will receive oral [14C] TS-142 under fasted conditions
32994027|NCT04798924|Experimental|Training in the blind field|Training in the blind field using specialized software
32994028|NCT04798924|Experimental|Training in the intact field|Training in the intact field using specialized software
32994029|NCT04792554||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
32994030|NCT04787731|Active Comparator|Lidocaine|Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
32994031|NCT04787731|Active Comparator|Bupivacaine|Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product. It exists in liquid form in cartridges. Bupivacaine is a FDA approved marketed anesthetic drug and meets IND Exemption.
32994032|NCT04777344|Experimental|Intervention group|The intervention group will receive the multi-component intervention (counseling with intake assessment, follow-up, help obtaining nicotine replacement therapy, and CF-specific smoke exposure education)
32994033|NCT04777344|No Intervention|Control group|The control group will receive usual care plus CF-specific smoke exposure education.
32994034|NCT04753580|Experimental|group 1|healthy adult 20-35 years old
32994035|NCT04753580|Experimental|group 2|healthy elderly 65+ years old
32994036|NCT04753580|Experimental|group 3|Frail elderly 65+ years old
33324706|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
33105168|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
33231731|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
33324707|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
32864266|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching plus Human Coaching|The procedure will be identical to Group 2 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
32864267|NCT04863690|No Intervention|Control|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery), plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and (depending on group), sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
32864268|NCT04275167|Experimental|Feasibility of TCE and TNE|Feasibility is measured by the number of participants that we have successfully deployed the Trans-nasal imaging device/Tethered capsule device in.
32864269|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
32864270|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
32864271|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.~Patients can seek a physician anytime after the first assessment with the physiotherapist."
32864272|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.~Patients can seek a physiotherapist anytime after the first assessment with the physician."
32864273|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
32864274|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
32864275|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
32864276|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
32864277|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
32864278|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
32864279|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
32864280|NCT04863456|Experimental|HIPA group of Puget grade 1|the tumor abuting or displacing the hypothalamus in the preoperative MR images
32864281|NCT04863456|Experimental|HIPA group of Puget grade 2|hypothalamic involvement (the hypothalamus is no longer identifiable) in the preoperative MR images
32864282|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
32864283|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
32864284|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
32994037|NCT04753268|Experimental|Treatment group: Noom Healthy Weight Program|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging.
32994038|NCT04748965||Tibial Vessel Involvement in Patients with peripheral artery disease and CLI|The primary goal is to establish a protocol for performing optimal OCT in below-the-knee vessels. OCT images will be analyzed for lesion characteristics, lesion sizing pre- and post-intervention. This will be analyzed against QVA and IVUS (latter if applicable).
32994039|NCT04746105|Experimental|TS-142|Period in which subjects received TS-142 10 mg or The night when subjects received TS-142
32994040|NCT04746105|Experimental|Placebo|Period in which subjects received placebo or The night when subjects received matched placebo
32994041|NCT04731675|Experimental|AMB-05X|"Subjects will receive an injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).~Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose."
32994042|NCT04718168|Experimental|Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial|
33414018|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
32994043|NCT04718168|Experimental|Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial|
32994044|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial|
32994045|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial|
32994046|NCT04715100||Experimental group|"The inclusion criteria to participate in the present study are patients: with a diagnosis of hemophilia A and B; adults; and on a prophylactic or on-demand treatment regimen with FVIII / FIX concentrates.~For their part, patients with: neurological or cognitive alterations that impede understanding of the questionnaires will be excluded from the study; Dependent patients who require help from a third person to get around; patients who have developed a hemarthros in the 4 weeks prior to the study; and those who have not signed the informed consent document.~For inclusion in the study, patients will continue to be administered the dose of FVIII / FIX concentrates, following the guidelines of the medical criteria established by their reference hematologist. Throughout this study, the medical criteria for drug treatment, the dosage, and the replacement treatment periods will not be changed."
32994047|NCT04713358|Experimental|Nalmefene group|for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
32994048|NCT04713358|Placebo Comparator|Control group|Intravenous injection of normal saline 1ml immediately after surgery
32994049|NCT04707872||Heart transplant protocol and for cause biopsies|The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment.
32994050|NCT04707066|Experimental|1|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
32994051|NCT04707066|Experimental|2|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
32994052|NCT04707066|Experimental|3|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
32994053|NCT04707066|Experimental|4|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
32994054|NCT04707066|Experimental|5|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
32994055|NCT04707066|Experimental|6|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
32994056|NCT04705051|Experimental|Venglustat|Participants were to be treated with venglustat 15 milligrams once daily orally for 24 months or until venglustat was commercially available, whichever came first.
32994057|NCT04699942|Active Comparator|Conventional|Conventional low-flow Oxygen Delivery
32994058|NCT04699942|Experimental|Revoxa|Oxygen Delivery via Revoxa Oxygen Rebreather Device
32994059|NCT04696952|Experimental|TS-142 10 mg|Period in which subjects received TS-142 10 mg
32994060|NCT04696952|Experimental|TS-142 20 mg|Period in which subjects received TS-142 20 mg
32994061|NCT04696952|Experimental|Zopiclone 7.5 mg|Period in which subjects received Zopiclone 7.5 mg
32994062|NCT04696952|Experimental|Placebo|Period in which subjects received placebo
32994063|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
32994064|NCT04631276|Experimental|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
32994065|NCT04631276|Experimental|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
32994066|NCT04627506|No Intervention|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
33414019|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
32994067|NCT04627506|Experimental|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
33414020|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
33414021|NCT01335841|Experimental|3D fluoroscopy and navigation station|
33414022|NCT01335841|Active Comparator|2D and anatomical landmarks|
33414023|NCT03737565||Coronary Artery Disease|
33414024|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
32994068|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
32994069|NCT04599062|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
32994070|NCT04586647|Experimental|Noom Health Weight Program|
32994071|NCT04586647|No Intervention|Wait List Control|
32994072|NCT04575883|Experimental|MedBIKE HIIT|MedBIKE HIIT Exercise Program
32994073|NCT04573725|Experimental|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
32994074|NCT04573725|Experimental|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
32994075|NCT04573725|Experimental|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
32994076|NCT04573725|Placebo Comparator|Placebo|Period in which participants received single placebo prior to bedtime
32994077|NCT04571619|Active Comparator|Pain Coping Skills Training|
32994078|NCT04571619|No Intervention|Usual Care|
32994079|NCT04571619|Active Comparator|Buprenorphine|
32994080|NCT04571619|No Intervention|No Buprenorphine|
32994081|NCT04571502|Experimental|Full Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
32994082|NCT04571502|Active Comparator|Minimal Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes but only a paper version of the newly developed AAC app.
32994083|NCT04570709|No Intervention|Control|Patients in the control arm will receive standard of care and no intervention.
32994084|NCT04570709|Experimental|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
32994085|NCT04528693|Experimental|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
32994086|NCT04528693|No Intervention|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
32994087|NCT04506424|Experimental|CT-Based Program for First Year of CI Use|"The Flat Panel CT scan will take place after a CI has been implanted and prior to the CI device activation.~The CI device will be activated using a CT-based program. The participant may continue to use this program for 1 year. Speech and music perception abilities will be monitored at regular intervals (approx. at 1, 3, 6, and 12 months post-activation).~After the 1 year of experimental program use, the participant may be switched over to a program that uses only the clinical default settings for 1 month; after which the participant will again complete the speech and music test battery.~At the end of the 13 month study the participant may choose whether to use the CT-based program or the clinical default program moving forward."
32994088|NCT04500041|Active Comparator|Casting|Subjects will be treated with serial casting
32994089|NCT04500041|Active Comparator|Bracing|Subjects will be treated with full-time orthotics (braces)
32994090|NCT04496999|Experimental|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
32994091|NCT04492722|Experimental|AZD5718 Dose 1 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 1 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
32994092|NCT04492722|Experimental|AZD5718 Dose 2 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 2 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
32994093|NCT04492722|Experimental|AZD5718 Dose 3 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 3 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
32994094|NCT04492722|Placebo Comparator|Placebo + Dapagliflozin 10 mg|Participants will receive once daily oral dose of placebo matched to AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
32994095|NCT04489238||Young onset Colorectal Cancer Participants|(Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.
32994096|NCT04489238||Average onset Colorectal Cancer Participants|"(Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls.~Stool collection cohort only."
32994097|NCT04476225||Individuals with Hirschsprung Disease|Individuals with Hirschsprung disease
32994098|NCT04476225||Unaffected Relatives|Unaffected relatives of individuals with Hirschsprung disease
32994099|NCT04474366|Sham Comparator|Saline|Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
32994100|NCT04474366|Experimental|Ropivacaine|Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
32994101|NCT04469023|Experimental|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
32994102|NCT04469023|Experimental|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
32994103|NCT04469023|Experimental|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
32994104|NCT04469023|Experimental|Placebo|Period in which participants received single placebo prior to bedtime
33033615|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
32994105|NCT04464421|Experimental|Contingency management (CM)|Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.
32994106|NCT04464421|Experimental|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.
32994107|NCT04464265|Experimental|Functional Magnetic Resonance Imaging|"While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion."
32994108|NCT04462497|No Intervention|Control Group|Participants will receive the existing method of head support (sponge and towel stack) intraoperatively.
32994109|NCT04462497|Experimental|Study Group|Participants will receive the prototype head and neck support device intraoperatively.
32994110|NCT04437303|Active Comparator|Continuation of oral anticoagulants|
33324708|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
32994111|NCT04437303|Active Comparator|Interruption of oral anticoagulants|
32994112|NCT04424511|Placebo Comparator|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
32994113|NCT04424511|Active Comparator|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.~Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
32994114|NCT04424511|Active Comparator|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml (20 mg) / kg child weight.~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
32994115|NCT04423939|Experimental|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
32994116|NCT04423939|Experimental|Caregivers|20 HCT patients caregivers at Duke
32994117|NCT04421079|Placebo Comparator|Placebo|Comparable placebos
32994118|NCT04421079|Active Comparator|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
32994119|NCT04421079|Active Comparator|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
32994120|NCT04421079|Active Comparator|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
32994121|NCT04416802|Experimental|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
32994122|NCT04413214|Experimental|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
32994123|NCT04410406|Active Comparator|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
32994124|NCT04410406|Active Comparator|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
32994125|NCT04410406|Active Comparator|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
32994126|NCT04410406|Active Comparator|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
32994127|NCT04401813|Experimental|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
32994128|NCT04393506|Other|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
32994129|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
32994130|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
32994131|NCT04349826|Active Comparator|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
33033616|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
33414025|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
33231732|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
33414026|NCT05757531|Experimental|[¹⁴C]-LY3437943|Single dose of [¹⁴C]-LY3437943 administered subcutaneously (SC).
33414027|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
33414028|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
32864285|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
32864286|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
32864287|NCT05296681|Experimental|NM108 Drinks|"NBT-NM108 Drinks four times daily before meals and 2 hours after dinner for 56 days.~Beginning 5 days before starting chemotherapy, patients receive NBT-NM108 PO QID for 56 days. Patients receive irinotecan-based chemotherapy per standard of care."
32864288|NCT05296681|No Intervention|No Microbiome Support|"No microbiome~Patients receive irinotecan-based chemotherapy per standard of care."
32864289|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
32864290|NCT02035813|Experimental|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
32864291|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
32864292|NCT04273841|Active Comparator|Caffeine Group|This group will receive caffeine gum.
32864293|NCT04273841|Placebo Comparator|Placebo|This group will receive gum without caffeine.
32864294|NCT01724437|Active Comparator|Loss of pace capture|"Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved~catheter based pulmonary vein isolation"
32864295|NCT01724437|Active Comparator|Conventional|"Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.~catheter based pulmonary vein isolation"
32864296|NCT04273763|Experimental|Group A|Treatment group
32864297|NCT04273763|Active Comparator|Group B|Control group
32864298|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
32864299|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
32864300|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
32864301|NCT01718743|Experimental|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32864302|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
32864303|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
32864304|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
32864305|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
32864306|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
32864307|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
32864308|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
32864309|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
32994132|NCT04349826|Placebo Comparator|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
32994133|NCT04346433|Experimental|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
32994134|NCT04346433|Experimental|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
32994135|NCT04340258|Experimental|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
32994136|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
32994137|NCT04314635|Active Comparator|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
32994138|NCT04314635|Experimental|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (~45-60 minutes per session).
33414029|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
33414030|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
33414031|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
33414032|NCT04399473||Control group: Usual PT Care|
33414033|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
33414034|NCT01339741|Active Comparator|Vitamin D|
33414035|NCT01339741|Placebo Comparator|Placebo|
33414036|NCT05184829|Active Comparator|systemic lymph node dissection group|systemic lymph node dissection group
33414037|NCT05184829|Experimental|selective lymph node dissection|selective lymph node dissection
33414038|NCT01482195|Experimental|Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
33414039|NCT01482195|No Intervention|fellow eye without intervention|fellow eye without intervention
33414040|NCT01341613|Experimental|Cardioviva™ supplement capsule|
33414041|NCT01341613|Placebo Comparator|Placebo capsule|
33414042|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
33414043|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
33414044|NCT05208255|Experimental|Exercise Group1|"The telerehabilitation-based neurocognitive exercise group~6 weeks, 2 sessions per week Session duration: 60 minutes"
33414045|NCT05208255|Experimental|Exercise Group2|"The telerehabilitation-based neurocognitive exercise+motor imagery training group~6 weeks, 2 sessions per week Session duration: 60 minutes (45 minutes-neurocognitive exercise; 15 minutes-motor imagery training)"
33414046|NCT05208255|Active Comparator|Control Group|"The medication group - Participants who voluntarily participated in the study but did not want to participate in exercise groups.~6 weeks of medication use"
33414047|NCT02963922|Experimental|liraglutide 3.0 mg|
33414048|NCT02963922|Placebo Comparator|Placebo|
33414049|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
33414050|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
32994139|NCT04298853|Active Comparator|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
33324709|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
33324710|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
33324711|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
33324712|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
33414051|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
33324713|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
33324714|NCT01231698|Experimental|esmolol|
33324715|NCT01231698|Other|control|
33324716|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
32994140|NCT04298853|Experimental|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
33414052|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
33414053|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
33414054|NCT05207787|Experimental|HS-10365|There are five escalating dose cohorts.
33414055|NCT03643380|Experimental|Investigational SNS device|
33414056|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
33414057|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
33414058|NCT05214261|Experimental|TAP block group|Patiens undergo laparoscopic-guided TAP block installation for laparoscopic clolorectal surgery
33414059|NCT05214261|Active Comparator|Epidural analgesia group|Patients undergo epidural catheters placement for laparoscopic colorectal surgery
33414060|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
33414061|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
32908623|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
32908624|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
33414062|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
33414063|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
33414064|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
33414065|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
33414066|NCT02881567|Experimental|Daclizumab|
33414067|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
33414068|NCT02962674|Other|Treatment|
33414069|NCT03280797|Other|Control|
33414070|NCT03280797|Other|Rheumatoid arthritis patients|
33414071|NCT05184595|Active Comparator|Carfilzomib delivered in OH only|"Patients receive the whole treatment in OH. Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
33414072|NCT05184595|Experimental|Carfilzomib delivered in OH and HaH combined|"Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.~For the HaH patients group, the first injection of each cycle is delivered in OH. The rest of the cycle is delivered at home by HaH after a clinical examination (by nurse or general practitionner).~Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
32908625|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
32908626|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
32908627|NCT05677919|Experimental|Treatment (pirtobrutinib and venetoclax)|Patients receive pirtobrutinib and venetoclax PO on study. Patients also undergo CT, MRI, and PET scans during screening and on study. Patients also undergo bone marrow aspiration and bone marrow biopsy, and collection of blood, tissue, stool, and saliva samples on study.
32908628|NCT04810091|Experimental|Arm A (telotristat ethyl, SSA)|Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
32908629|NCT04810091|Active Comparator|Arm B (placebo, SSA)|Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
32908630|NCT04802759|Active Comparator|Cohort 1: Giredestrant Monotherapy|
32908631|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib|
32908632|NCT04802759|Experimental|Cohort 1: Giredestrant + Ipatasertib|
32908633|NCT04802759|Experimental|Cohort 1: Giredestrant + Inavolisib|
32908634|NCT04802759|Experimental|Cohort 1: Giredestrant + Ribociclib|
32908635|NCT04802759|Experimental|Cohort 1: Giredestrant + Everolimus|
32908636|NCT04802759|Experimental|Cohort 1: Giredestrant + Samuraciclib|
32908637|NCT04802759|Experimental|Cohort 1: Giredestrant + Atezolizumab|
32908638|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib + Atezolizumab|
32908639|NCT04802759|Active Comparator|Cohort 2: Giredestrant + PH FDC SC|
32908640|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Abemaciclib|
32908641|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Palbociclib|
32908642|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
32908643|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
32908644|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
32908675|NCT05643911|Experimental|HFNC (Hight-flow oxygen therapy)|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes. Oxygen will be passed through a heated humidifier and continuously delivered through medium or large nasal cannulas (OptiflowTM, Fisher and Paykel Healthcare) depending on patient anatomy, with a gas flow of 50 litres per minute and the FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
32908676|NCT05643911|Active Comparator|Non-invasive ventilation (NIV)|In the NIV Group, patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance. The pressure-support level will be adjusted with the aim of an expired tidal volume of 6 to 8 ml per kilogram of predicted body weight, with a positive end-expiratory pressure (PEEP) of 5 cmH2O. The FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
32994141|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
32994142|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
32994143|NCT04280549||Type 2 Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
32994144|NCT04261712|Experimental|Paltusotine|
33414073|NCT05213793||ischemic stroke|The cohort includes patients with acute stroke who underwent CTP, multi-delay ASL, DWI, CTA or TOF-MRA scanning.All patients will be examined within 24 hours of onset. CBF, CBV, MTT and Tmax cerebral blood flow parameter images of CTP will be obtained. CBF, CBV and ATT cerebral blood flow parameter images in multi-delay ASL will be obtained by the quantitative evaluation system. The volume of reversible ischemic tissue will be calculate according to CTP and multi-delay ASL respectively.
33414074|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
32994145|NCT04243499|Experimental|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
32994146|NCT04243499|Experimental|IV ICT01 + IV Pembrolizumab|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
32994147|NCT04238793|Experimental|Cohort 1|KLS-2031 low dose(1x10^11 VG/DRG) or Placebo
32994148|NCT04238793|Experimental|Cohort 2|KLS-2031 medium dose(1x10^12 VG/DRG) or Placebo
32994149|NCT04238793|Experimental|Cohort 3|KLS-2031 high dose(1x10^13 VG/DRG) or Placebo
32994150|NCT04232683|Experimental|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
32994151|NCT04232683|Placebo Comparator|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
32994154|NCT04227483|Active Comparator|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
32994155|NCT04227483|Experimental|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
32994156|NCT04219904|Experimental|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
32994157|NCT04216810|Active Comparator|Exercise group|Exercise group
32994158|NCT04216810|Experimental|Exercise group and dry cupping|Exercise and dry cupping
32994159|NCT04201028|Experimental|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
32994160|NCT04201028|Experimental|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
32994161|NCT04200547|Experimental|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
32994162|NCT04200547|Active Comparator|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
32994163|NCT04197102|Active Comparator|CBD Isolate|300 mg/day of CBD isolate
32994164|NCT04197102|Active Comparator|CBD Broad Spectrum|300 mg/day of CBD Broad Spectrum Oil
32994165|NCT04197102|Placebo Comparator|Placebo oil|Matched Placebo Oil
32994166|NCT04189939||subjects with treatment-resistant depression|approximately 48 subjects with treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
32994167|NCT04189939||healthy subjects|approximately 48 healthy subjects will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
32994168|NCT04189939||subjects with non treatment-resistant depression|approximately 48 subjects with non-treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
32994169|NCT04184661||hypophosphatemic rickets patients|30 hypophosphatemic rickets patients older than 2 years will be included in this study
32994170|NCT04184661||controls patients|10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study
32994171|NCT04183023||Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
33414075|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
32994172|NCT04182672|Experimental|Zilretta|
32994173|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
32994174|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
32994175|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
32994176|NCT04169906|Placebo Comparator|Placebo|
32994177|NCT04169906|Experimental|TS-142 10 mg|
32994178|NCT04169906|Experimental|TS-142 20 mg|
32994179|NCT04169906|Experimental|TS-142 30 mg|
32994180|NCT04169893|Placebo Comparator|Arm Title: Placebo (fasting)|fasting
32994181|NCT04169893|Placebo Comparator|Placebo (feeding)|after meal
32994182|NCT04169893|Experimental|TS-142, 1 mg|fasting
32994183|NCT04169893|Experimental|TS-142, 3 mg|fasting
32994184|NCT04169893|Experimental|TS-142, 10 mg (fasting)|fasting
32994185|NCT04169893|Experimental|TS-142, 10 mg (feeding)|after meal
32994186|NCT04169893|Experimental|TS-142, 30 mg|fasting
32994187|NCT04112784|Experimental|INVSENSOR00039|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00039 sensor.
32994188|NCT04110756|Experimental|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
32994189|NCT04110756|No Intervention|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
32994190|NCT04108351|Experimental|Zopiclone|
32994191|NCT04108351|Placebo Comparator|Placebo|
32994192|NCT04104776|Experimental|Phase 2 Cohort M1|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M1: Open to patients with urothelial carcinoma or other advanced/metastatic solid tumors (with known ARID1A mutation)"
32994193|NCT04104776|Experimental|Phase 2 Cohort M2|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M2: Open to patients with ovarian clear cell carcinoma (with known ARID1A mutation)"
32994194|NCT04104776|Experimental|Phase 2 Cohort M3|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M3: Open to patients with endometrial carcinoma (with known ARID1A mutation)"
32994195|NCT04104776|Experimental|Phase 2 Cohort M4|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M4: Open to patients with peripheral T-cell lymphoma (PTCL) and patients with diffuse large B-cell lymphoma (DLBCL), including patients with documented germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) with at least 1 EZH2 hotspot mutation"
32994196|NCT04104776|Experimental|Phase 2 Cohort M5|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M5: Open to patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss"
32994197|NCT04104776|Experimental|Phase 2 Cohort M6|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M6: Open to patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
32994198|NCT04101227|Experimental|Treatment Arm|AD04 (ondansetron)
32994199|NCT04101227|Placebo Comparator|Placebo Arm|Matching Placebo
32994200|NCT04096781|Experimental|Shared Decision Making Tool (SDMT)|
32994201|NCT04096781|Active Comparator|Usual Care|
32994202|NCT04087707|Experimental|Step 1;TS-142|
32994203|NCT04087707|Experimental|Step 2;TS-142|
32994204|NCT04087707|Placebo Comparator|Step 2;Placebo|
32994205|NCT04077567|Experimental|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
32994206|NCT04077567|Experimental|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
32994207|NCT04066946|Experimental|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
32994208|NCT04066946|Active Comparator|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
32994209|NCT04066894|Experimental|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
32994210|NCT04049617|Experimental|Cohort 1: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
32994211|NCT04049617|Experimental|Cohort 2: Evixapodlin 700 mg (Phase 1)|Participants will receive Evixapodlin 700 mg once daily for 21 days of each cycle.
32994212|NCT04049617|Experimental|Cohort 3: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
33414076|NCT05184517|Experimental|Arm I|Oph1 0.5% CsA ophthalmic formulation followed by Restasis 0.05% CsA ophthalmic formulation
33414077|NCT05184517|Experimental|Arm II|Restasis 0.05% CsA ophthalmic formulation followed by Oph1 0.5% CsA ophthalmic formulation
33414078|NCT05207475|Experimental|RIC group|RIC treatment and regular treatment.
33414079|NCT05207475|No Intervention|Regular treatment|Regular treatment alone.
33414080|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
32994213|NCT04049617|Experimental|Cohort 4: Evixapodlin 1500 mg (Phase 1)|Participants will receive Evixapodlin 1500 mg once daily for 21 days of each cycle.
32994214|NCT04049617|Experimental|Cohort 5: Evixapodlin 1000 mg (Phase 1)|Participants are planned to receive Evixapodlin 1000 mg twice daily (BID) for 21 days of each cycle.
32994215|NCT04049617|Experimental|Cohort 1 Substudy: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
32994216|NCT04049617|Experimental|Cohort 2 Substudy: Evixapodlin 700 mg (Phase 1)|Participants are planned to receive Evixapodlin 700 mg once daily for 21 days of each cycle.
32994217|NCT04049617|Experimental|Cohort 3 Substudy: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
32994218|NCT04049617|Experimental|Dose Expansion (Phase 2)|Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.
33414081|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
33414082|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
32994219|NCT04047004|Experimental|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
32994220|NCT04008576|Other|Group Blended Transdiagnostic treatment|
32994221|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
32994222|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
32994223|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
32994224|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
32994225|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
32994226|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
32994227|NCT03954002|Experimental|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
32994228|NCT03944798|Active Comparator|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
32994229|NCT03944798|Experimental|Surveillance Arm II|Clinical assessment and CXR every three months for two years
32994230|NCT03944798|Experimental|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
32994231|NCT03944798|Experimental|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
32994232|NCT03914664||Tourette Syndrome|Adults (>18 years of age) with diagnosis of Tourette syndrome
32994233|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
32994234|NCT03911154|Experimental|SmartSleep Continuous Fixed Interval modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Continuous Fixed Interval stimulation modality during sleep relative to the SHAM condition. The Continuous Fixed Interval is the delivery of auditory tones a 1 Hz inter-tone interval stimulation."
32994235|NCT03911154|Experimental|SmartSleep Block modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Block stimulation modality during sleep relative to the SHAM condition. The Block is the delivery of auditory tones for 5 seconds on versus 5 seconds off."
32994236|NCT03911154|Experimental|SmartSleep In-Phase Adjustable modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep In-Phase Adjustable stimulation modality during sleep relative to the SHAM condition. The In-Phase Adjustable is the constant stimulation with auditory tones delivered during each upstate of the slow wave."
33033617|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
33033618|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
33414083|NCT01336153|Placebo Comparator|Placebo|
33414084|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
32994237|NCT03911154|Sham Comparator|SHAM condition|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm is the SHAM condition, during which participants wore the SmartSleep device, however no auditory tones were delivered."
32994238|NCT03898310|Experimental|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
32994239|NCT03898310|Placebo Comparator|Placebo Capsules|
32994240|NCT03893435|Experimental|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
32994241|NCT03893435|Active Comparator|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
32994242|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
32994243|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
32994244|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
32994245|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
32994246|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
32994247|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
32994248|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
32994249|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
32739174|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
32994250|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
33414085|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
33414086|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
32994251|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
33414087|NCT03644082|Experimental|Epilepsy Patients|
32994252|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
32994253|NCT03813121|Experimental|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
32994254|NCT03813121|Placebo Comparator|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
32994255|NCT03813121|Experimental|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
32994256|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
32994257|NCT03784521|Experimental|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
32994258|NCT03784521|Active Comparator|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
32994259|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
32994260|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
32994261|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
32994262|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
32994263|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
32994264|NCT03769259|Active Comparator|Present-Centered Therapy|
32994265|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
32994266|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:~Are suspected of the same cancer or part of an at risk-group~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
32994267|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
32994268|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
32994269|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
32994270|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
32994271|NCT03718325|Other|Burst-SCS/sham SCS|First, participants will receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation. Then, participants will have their stimulation adjusted to receive sham (no) SCS. Study evaluations will be completed prior to and after this sham.
32994272|NCT03718325|Other|Sham SCS/Burst-SCS|First, participants will receive sham (no) SCS. Study evaluations will be completed prior to and after this sham. Then, participants will have their stimulation adjusted to receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation.
32994273|NCT03710590|Active Comparator|Cigarette smokers|
32994274|NCT03710590|Active Comparator|Electronic cigarette users|
32994275|NCT03691714|Experimental|Durvalumab and Cetuximab|Durvalumab 500mg as a 120-minute intravenous infusion every two weeks. Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues until progression and Cetuximab may continue as maintenance
32994276|NCT03676725|Experimental|All subjects|All subjects get the lidocaine taste test
32994277|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
32994278|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
32994279|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
32994280|NCT03624816|No Intervention|Control|no-treatment control
32994281|NCT03607825|Experimental|Neurapheresis System|CSF filtration
32994282|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
32994283|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
32994284|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
32994285|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
32994286|NCT03572049|Experimental|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
32994287|NCT03572049|Active Comparator|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
32994288|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
32994289|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
33033619|NCT01964742|Experimental|HIV-HCV co-infected patients|
33033620|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
33033621|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
33033622|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
33033623|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
32994290|NCT03566615|Experimental|CAP-daisy|"A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.~Note:~IRB Approval date for the use of Endocuff at St. Barbara Hospital, Iglesias (CA), Italy, was obtained on 3/8/2017.~IRB Approval date for the use of Endocuff at Evergreen General Hospital, Taipei, Taiwan, was obtained on 3/18/2021."
32994291|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
32994292|NCT03540732|No Intervention|1. Control|"Standard physiotherapy~Empiric formula directed feeding (daily caloric requirement calculated by 25 kcal/kg/day)"
32994293|NCT03540732|Active Comparator|2. Intervention|"Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.~Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)"
32994294|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
32994295|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
32994296|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
32994297|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
32994298|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
32994299|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
32994300|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
32994301|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
32994302|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
32994303|NCT03471507|Experimental|Bonipar|
32994304|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
32994305|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
32994306|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
32994307|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
32994308|NCT03465722|Experimental|avapritinib|300 mg PO QD
32994309|NCT03465722|Active Comparator|regorafenib|160 mg PO QD
32994310|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
32994311|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
32994312|NCT03425279|Experimental|BA3011|Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.
32994313|NCT03425279|Experimental|Combination Therapy|Phase 2: BA3011 in combination with PD-1 inhibitor.
32994314|NCT03413592|Other|Driving test|
32994315|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
32994316|NCT03360019|Active Comparator|Resident in independent living setting|
32994317|NCT03360019|Other|Care Partners|
32994318|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
32994319|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
32994320|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
32994321|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
33033624|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
32994322|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
32994323|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
32994324|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
32994325|NCT03298737||Correct to normal vision population|
32994326|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
32994327|NCT03267303|Experimental|TS-091 5mg|
32994328|NCT03267303|Experimental|TS-091 10mg|
32994329|NCT03267303|Placebo Comparator|Placebo|
32994330|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
32994331|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
32994332|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
32994333|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
32994334|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
32994338|NCT03192267||No treatment|No treatment
32994339|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
32994340|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
32994341|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
32994342|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
32994343|NCT03122821|Experimental|Group 1|Real Trans-cranial direct stimulation + Mental Imagery
32994344|NCT03122821|Active Comparator|Group 2|Sham Trans-cranial direct stimulation + Mental imagery
32994345|NCT03104400|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
32994346|NCT03104400|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
32994347|NCT03104400|Active Comparator|Adalimumab|"Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks.~Period 2: Participants continue to receive adalimumab 40 mg every other week."
32994348|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
32994349|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
32994350|NCT03104374|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
32994351|NCT03104374|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
32994352|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 15 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 15 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
32994353|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 30 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 30 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
32994354|NCT03073603|Active Comparator|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
32994355|NCT03073603|Experimental|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
32994356|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
32994357|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
33033625|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
33033626|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
32994358|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
32994359|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
32994360|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
32994361|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
32994362|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
32994363|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
32994364|NCT03002155|No Intervention|Control|Usual care.
32994365|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
32994366|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
32994367|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
32994368|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
32994369|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
32994370|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
32994371|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
32994372|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
32994373|NCT02909686|Experimental|Boswellia Serrata|400-800mg in capsule form by mouth every day
32994374|NCT02909686|Experimental|Curcumin|1000-2000mg in capsule form by mouth every day
32994375|NCT02909686|Experimental|Epimedium|1000-2000mg in capsule form by mouth every day
32994376|NCT02909686|Experimental|Fisetin|200-800mg in capsule form by mouth every day
32994377|NCT02909686|Experimental|Luteolin|200-400mg in capsule form by mouth every day
32994378|NCT02909686|Experimental|Nettle|435-1305mg in capsule form by mouth every day
32994379|NCT02909686|Experimental|Pycnogenol|200-400mg in capsule form by mouth every day
32994380|NCT02909686|Experimental|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
32994381|NCT02909686|Experimental|Resveratrol|200-600mg in capsule form by mouth every day
32994382|NCT02909686|Placebo Comparator|Placebo|in capsule form by mouth every day
32994383|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
32994384|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
32994385|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
32994386|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
32994387|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
32994388|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
32994389|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks Phase 1: N=39 adults single arm Phase 2: N=42 adults
32994390|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks Matched for Phase 2: N=42 adults
32994391|NCT02829099|Experimental|JNJ-64457107|In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
32994392|NCT02815254|Active Comparator|Low dose exercise intervention|
32994393|NCT02815254|Experimental|High dose exercise intervention|
32994394|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
32994395|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
32994396|NCT02719847|Experimental|EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
32994397|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
32994398|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
32994399|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic~Intervention #1 - Clinical algorithm: the EHMRG30-ST risk score which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation during a short stay hospital admission (3 days or less), or emergency department discharge.~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48-72 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
32994400|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
32994401|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
32994402|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
32994403|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
32994404|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
32994405|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
32994406|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
32994407|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
32994408|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
32994409|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
32994410|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
32994411|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
32994412|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32994413|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
32994414|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
32994415|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
32994416|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
32994417|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
32994418|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
32994419|NCT02282007|No Intervention|No Intervention:Control group|
32994420|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
32994421|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
32994422|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
32994423|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
32994424|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
32994425|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
32994426|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
32994427|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
32994428|NCT02063165|Experimental|Linoleic Acid|
32994429|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
32994430|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
32994431|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
32994432|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32994433|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
32994434|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
32994435|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
32994436|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
32994437|NCT01016613||Matched Control Group|Healthy controls
32994438|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
32994439|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
32994440|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
32994441|NCT00700882|Experimental|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32994442|NCT00641186|Experimental|Xyrem in Parkinson disease|sodium oxybate 4.5 to 9.0 gms per night
32994443|NCT00623389|Experimental|A|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
32994444|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
32994445|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
32994446|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
32994447|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
32994448|NCT01561612|No Intervention|Control|Usual care
32994449|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
32994450|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
32994451|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
32994452|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
32994453|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
32994454|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
32994455|NCT01562184|Active Comparator|Active tDCS|Active tDCS
32994456|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
32994457|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
32994458|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
32994459|NCT01562574|Experimental|Activated recombinant human factor VII|
32994460|NCT01562574|Placebo Comparator|Placebo|
32994461|NCT01562587|Experimental|Adults|
32994462|NCT01562587|Experimental|Paediatric|
32994463|NCT01562704|Experimental|paracetamol|
32994464|NCT01562704|Placebo Comparator|placebo|
32994465|NCT01562821|Experimental|Low dose|
32994466|NCT01562821|Experimental|High dose|
32994467|NCT01562821|Placebo Comparator|Placebo|
32994468|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
32994469|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
32994470|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
32994471|NCT01563445|Experimental|activated recombinant human factor VII|
32994472|NCT01563445|Placebo Comparator|Placebo|
32994473|NCT01563458|Experimental|High dose|
32994474|NCT01563458|Experimental|Low dose|
32994475|NCT01563458|Placebo Comparator|Placebo|
32994476|NCT01563471|Experimental|Treatment sequence 1|
32994477|NCT01563471|Experimental|Treatment sequence 2|
32994478|NCT01563471|Experimental|Treatment sequence 3|
32994479|NCT01563471|Placebo Comparator|Treatment sequence 4|
32994480|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
32994481|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
32994482|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
32994483|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
32994484|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
32994485|NCT01563523|Experimental|Activated recombinant human factor VII|
32994486|NCT01563523|Placebo Comparator|Placebo|
32994487|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
32994488|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
32994489|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
32994490|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
32994491|NCT01564186||MulitPoint Pacing|
32994492|NCT01564186||BiV Conventional|
32994493|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
32994494|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
32994495|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
32994496|NCT01564420||Control group|
32994497|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
32994498|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
32994499|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
32994500|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
32994501|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
32994502|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
32994503|NCT01565005||FANCONI ANEMIA|
32994504|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
32994505|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
32994506|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
32994507|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
32994508|NCT01565473||Parkinson disease patients|
32994509|NCT01565473||Healthy normal controls|
32994510|NCT01565863|Experimental|Progressive Goal Attainment Program|
32994511|NCT01565863|No Intervention|VA employment services|
32994512|NCT01566292|Experimental|BOTOX|
32994513|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
33414088|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
32994514|NCT01566344|No Intervention|Routine heart failure therapy|
32994515|NCT01566357|No Intervention|Fluoride-free toothpaste|
32994516|NCT01566357|Active Comparator|Fluoride toothpaste|
32994517|NCT01566357|Active Comparator|Milk|
32994518|NCT01566357|Active Comparator|Fluoridated milk|
32994519|NCT01566357|Active Comparator|CPP-ACP|
32994520|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
32994521|NCT01566357|Active Comparator|Fluoride mouthrinse|
32994522|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
32994523|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
32994524|NCT01566760|Experimental|Treatment A, Cohort 1|
32994525|NCT01566760|Experimental|Treatment B, Cohort 2|
32994526|NCT01566760|Experimental|Treatment C, Cohort 1|
32994527|NCT01566760|Experimental|Treatment D, Cohort 2|
32994528|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
32994529|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
32994530|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
32994531|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
32994532|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
32994533|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
32994534|NCT01566929|No Intervention|IVF only|IVFtreatment
32994535|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
32994536|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
32994537|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
32994538|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
32994539|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
32994540|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
32994541|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
32994542|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
32994543|NCT01567631|Experimental|intrahepatic Glisson's approach|
32994544|NCT01567631|Active Comparator|classical hepatectomy|
32994545|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
32994546|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
32994547|NCT01568190|Experimental|AVANZ|AVANZ Mites
32994548|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
32994549|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
32994550|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
32994551|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
32994552|NCT01569347||1: Cocaine users|Adults, cocaine users
32994553|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
32994554|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
32994555|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
32994556|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
33033627|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
32994557|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
32994558|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
32994559|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
32994560|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
32994561|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
32994562|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
32994563|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
32994564|NCT01570088|Active Comparator|Folic acid|
32994565|NCT01570088|Experimental|L-5-MTHF|
32994566|NCT01570088|Placebo Comparator|Placebo|
32994567|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
32994568|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
32994569|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
32994570|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
32994571|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
32994572|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
32994573|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
32994574|NCT01570153||ADHF patients|
32994575|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
32994576|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
32994577|NCT01570179|Experimental|deep block ideal body weight|
32994578|NCT01570179|Active Comparator|deep block real body weight|
32994579|NCT01570179|Experimental|moderate block ideal body weight|
32994580|NCT01570179|Active Comparator|moderate block real body weight|
32994581|NCT01570205|Experimental|XG-102 10 µg/kg|
32994582|NCT01570205|Experimental|XG-102 40 µg/kg|
32994583|NCT01570205|Experimental|XG-102 80 µg/kg|
32994584|NCT01570205|Placebo Comparator|placebo|
32994585|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
32994586|NCT01570218|No Intervention|Control|
32994587|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
32994588|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
32994589|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
32994590|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
32994591|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
33414089|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
32994593|NCT01570374|Experimental|iCBT|Receives treatment.
32994594|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
33414090|NCT01340287|Active Comparator|1 = Tested product|
33414091|NCT01340287|Sham Comparator|2 = Control product|
32994595|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
33414092|NCT05207319|Experimental|the MRDI group (Moral Reasoning Development Intervention)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
33414093|NCT05207319|No Intervention|the control group|The control group is the Treatment as Usual (TAU).
32994596|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
32994597|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
32994598|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
32994599|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
32994600|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
32994601|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
32994602|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
32994603|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
32994604|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
32994605|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
32994606|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
32994607|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
32994608|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
32994609|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
33414094|NCT01341691|Placebo Comparator|Placebo 20mg|
33414095|NCT01341691|Active Comparator|K2CG 60 mg extender|
33414096|NCT01341691|Active Comparator|K2CG 60 mg|
33414097|NCT01341691|Active Comparator|K2CG 20mg extender|
33414098|NCT01341691|Active Comparator|K2CG 20mg|
33414099|NCT01341691|Placebo Comparator|Placebo 60mg|
33414100|NCT05244486|Experimental|Treatment Arm|Men will begin utilizing PTT 30-60 minutes daily for 5-7 days weekly beginning 1 month post-prostatectomy until 6 months. After 6 months, they will have the option to continue to use the therapy for 3 additional months or discontinue at their discretion.
33414101|NCT05244486|Active Comparator|Control|Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.
33414102|NCT05213403||Patient G1|Correlation between surgery and scoring system
33414103|NCT05213403||Patients G2|Incongruence between surgery and scoring system
32994610|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
32994611|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
32994612|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
32994613|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
32994614|NCT01570543||orthopedic implants, no treatment|
32994615|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
32994616|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
32994617|NCT01570569|Active Comparator|Omeprazole|
32994618|NCT01570569|Active Comparator|Losartan|
32994619|NCT01570569|Active Comparator|Dextromethorphan|
32994620|NCT01570569|Active Comparator|Caffeine|
32994621|NCT01570569|Active Comparator|Midazolam|
33414104|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
33414105|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
32994622|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
32994623|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
32994624|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
32994625|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
33414106|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
33414107|NCT05213325||Cases|Children with acute diarrhea
32994626|NCT01570608|Active Comparator|combined treatment arm|
32994627|NCT01570647||Healthy controls|
32739175|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
32739176|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
32994628|NCT01570647||Chronic low back pain|
32994629|NCT01570647||restricted hamstrings|
32994630|NCT01570647||systemic scleroderma|
32994631|NCT01570647||joint hyperlaxity|
32994632|NCT01570660|No Intervention|control group|parallel group without intervention
32994633|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
32994634|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
32994635|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
32994636|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
32994637|NCT01570712|Experimental|Housing First Program|
32994638|NCT01570712|Active Comparator|traditional French services|
32994639|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
32994640|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
32994641|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
32994642|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
32994643|NCT01570777|Experimental|Renal denervation|
32994644|NCT01570777|Other|optimized medication regimen|optimized medication regimen
32994645|NCT01570790|Experimental|Cohort 1|
32994646|NCT01570790|Experimental|Cohort 2|
32994647|NCT01570790|Experimental|Cohort 3|
32994648|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
32994649|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
32994650|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
32994651|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
32994652|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
33414108|NCT05213325||Control|Healthy control children
33414109|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
33414110|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
32739177|NCT03315533|Placebo Comparator|Placebo|
33324717|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
32994653|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
32994654|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
32994655|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
32994656|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
32994657|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
32994658|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
32994659|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
33324718|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
33324719|NCT01237938|Experimental|Low Glycemic Diet|
33324720|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
32994660|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
32994661|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
32994662|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
32994663|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
32994664|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
32994665|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
32994666|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
32994667|NCT01571050|Placebo Comparator|Purified water|
32994668|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
32994669|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
32994670|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
32994671|NCT01571063|Experimental|Vitamin D3|
32994672|NCT01571063|Placebo Comparator|Placebo|
32994673|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
32994674|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
32994675|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
32994676|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
32994677|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
32994678|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
32994679|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
32994680|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
32994681|NCT01571141|Experimental|Monogin|
32994682|NCT01571141|No Intervention|No intervention|
32994683|NCT01571167|Placebo Comparator|Placebo|
32994684|NCT01571167|Active Comparator|Varenicline 2 mg|
32994685|NCT01571167|Active Comparator|Varenicline 1 mg|
32994686|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
32994687|NCT01571206|Active Comparator|CT-P13|infliximab
32994688|NCT01571219|Experimental|CT-P13|
32994689|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
32994690|NCT01571258|No Intervention|Control|
32994691|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
32994692|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
32994693|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
32994694|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
32994695|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
32994696|NCT01571323|Active Comparator|Misoprostol|
32994697|NCT01571323|Active Comparator|Oxytocin|
32994698|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
32994699|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
32994700|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
32994701|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
32994702|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
32994703|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
32994704|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
32994705|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
32994706|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
32994707|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
32994708|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
32994709|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
32994710|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
32994711|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
32994712|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
32994713|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
32994714|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
32994715|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
32994716|NCT01571466|Placebo Comparator|Placebo|
32994717|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
32994718|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
32994719|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
32994720|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
32994721|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
32994722|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
32994723|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
32994724|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
32994725|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
32994726|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
32994727|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
32739178|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
32994728|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
32994729|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
32994730|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
32994731|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
32994732|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
32994733|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
32994734|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
32994735|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
32994736|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
32994737|NCT01571609|Experimental|Carriers|
32994738|NCT01571609|Experimental|Non-carriers|
32994739|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
32994740|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
32994741|NCT01571648|Experimental|Oral azacitidine|
32994742|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
32994743|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
32994744|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
32994745|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
32994746|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
32994747|NCT01571661|Placebo Comparator|Placebo|Placebo
32994748|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
32994749|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
32994750|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
32994751|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
32994752|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
32994753|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
32994754|NCT01571700||Study|Patients with pulmonary hypertension.
32994755|NCT01571700||Control|ASD patients or patients with normal hearts
32994756|NCT01571713||Study|Pediatric patients with pulmonary hypertension
32994757|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
32994758|NCT01571765|No Intervention|no added MNCH activities|
32994759|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
32994760|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
32994761|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
32994762|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
32994763|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
32994764|NCT01571817|Experimental|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
32994765|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
32994766|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
32994767|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
32994768|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
32994769|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
32994770|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
32994771|NCT01571869|Experimental|1 = Tested product|
32994772|NCT01571869|Placebo Comparator|2 = Control product|
32994773|NCT01571882|Experimental|1 = Tested product 1|
32994774|NCT01571882|Experimental|2 = tested product 2|
32994775|NCT01571882|Active Comparator|3 = Active control product|
32994776|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
32994777|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
32994778|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
32994779|NCT01571921|Active Comparator|TRF|
32994780|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
32994781|NCT01571947|Active Comparator|SFA|
32994782|NCT01571947|Active Comparator|MUFA|
32994783|NCT01571947|Active Comparator|PUFA|
32994784|NCT01571947|Active Comparator|CARB|
32994785|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
32994786|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
32994787|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
32994788|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
32994789|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
32994790|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
32994791|NCT01571973|No Intervention|control group|outpatients receiving usual care
32994792|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
32994793|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
32994794|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
32994795|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
32994796|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
32994797|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
32994798|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
32994799|NCT01572025|Experimental|DHEA supplementation|
32994800|NCT01572025|Placebo Comparator|Control|
32994801|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994802|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994803|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994804|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994805|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994806|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994807|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
32994808|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
33324721|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
33324722|NCT03739710|Experimental|Part 1: Participants receiving feladilimab and ipilimumab|
32994809|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
32994810|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
32994811|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
33324723|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448|
32994812|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
32994813|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
32994814|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
32994815|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
32994816|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
32994817|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
32994818|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
32994819|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
32994820|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
32994821|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
32994822|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
32994823|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
32994824|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
32994825|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
32994826|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
32994827|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
32994828|NCT01572220|Other|stress echocardiography|Comparative effectiveness
32994829|NCT01572220|Other|Myocardial SPECT|CER
32994830|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
32994831|NCT01572233|No Intervention|usual care|waiting list group with usual care
32994832|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
32994833|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
32994834|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
32994835|NCT01572259|Experimental|interruption of the growth hormone treatment.|
32994836|NCT01572259|Experimental|Patients traited by grouth hormone|
33324724|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448 plus GSK6097608|
32994837|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
32994838|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
32994839|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
32994840|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
33324725|NCT03739710|Active Comparator|Part 2: Participants receiving SoC: docetaxel|
33324726|NCT03739710|Experimental|Part 2: Participants receiving feladilimab and docetaxel|
33324727|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
33324728|NCT04722978|Active Comparator|Experimental group|Gemcitabine combined with carboplatin plus moxifloxacin
33324729|NCT04722978|Placebo Comparator|Control group|Gemcitabine combined with carboplatin plus placebo
33324730|NCT04698018|Experimental|Faster aspart|Subjects will receive 2 injections of a single dose of faster aspart at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
33324731|NCT04698018|Active Comparator|NovoRapid®|Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
32994841|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
32739179|NCT05002491|Experimental|High protein feeding|Two isocaloric feeding phases of 2 weeks followed by an ad-libitum feeding phase of 3 months
32739180|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
32994842|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
32994843|NCT01572324|Experimental|Arterial infusion|
32994844|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
32739181|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
32994845|NCT01572350|Experimental|Triamcinolone 4 mg|
32994846|NCT01572350|Experimental|Bevacizumab|
32994847|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
32994848|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
32994849|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
32994850|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
32994851|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
32994852|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
32994853|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
32994854|NCT01572519|Experimental|JNJ-40346527|
32994855|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
32994856|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
32994857|NCT01572545|Experimental|Denosumab|
32994858|NCT01572545|Experimental|Zoledronic Acid|
32994859|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
32994860|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
32994861|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
32994862|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
32994863|NCT01572610|Experimental|RTA 402|
32994864|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
32994865|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
32994866|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
32994867|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
32994868|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
32994869|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
32994870|NCT01572688|Experimental|autologous stem cell transplant|
32994871|NCT01572701|Experimental|20 (±3) mCi of study drug|
32994872|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
32994873|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
32994874|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
32994875|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
32994876|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
32994877|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
32994878|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
32994879|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
32994880|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
32994881|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
32994882|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
32994883|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
32994884|NCT01572805|Active Comparator|melatonin 3mg|
32994885|NCT01572805|Active Comparator|melatonin 6mg|
32994886|NCT01572805|Placebo Comparator|placebo|
32994887|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
33324732|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
32994888|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
32994889|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
32994890|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
32994891|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
32994892|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
32994893|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
32994894|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
32994895|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
32994896|NCT01572896|Experimental|Taking Charge Experimental Group|
32994897|NCT01572896|Active Comparator|Control Group|
32994898|NCT01572961|Active Comparator|Aspirin|Aspirin
32994899|NCT01572961|Placebo Comparator|Placebo|Placebo
32994900|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
32994901|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
32994902|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
32994903|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
32994904|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
32994905|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
32994906|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
32994907|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
32994908|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
32994909|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
32994910|NCT01573065|Experimental|Single arm|
32994911|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
32994912|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
32994913|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
32994914|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
32994915|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
32994916|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
32994917|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
32994918|NCT01573143|Placebo Comparator|Sugar pill|Placebo
32994919|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
32994920|NCT01573156|Experimental|VTP treatment to small renal mass|
32994921|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
32994922|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
32994923|NCT01573221||stroke|
32994924|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
32994925|NCT01573234|Active Comparator|Traditional Dressing|
32994926|NCT01573247|Experimental|AKN-028|
32994927|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
32994928|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
32994929|NCT01573299|Active Comparator|Early vertical positioning|
32994930|NCT01573299|Active Comparator|Progressively vertical positioning|
32994931|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
32994932|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
32994933|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
33324733|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
33324734|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
33324735|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
33033628|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
32739182|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
32739183|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
32864310|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
32864311|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
32864312|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
32864313|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
32864314|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
32864315|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
32864316|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
32864317|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
32864318|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
32864319|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
32864320|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
32864321|NCT03820115|Experimental|Elastic abdominal binder|
32864322|NCT03820115|No Intervention|No binder|
32864323|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
32864324|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
32864325|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
32864326|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
32864327|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
32864328|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
32864329|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
32864330|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
32864331|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
32864332|NCT04391933|Other|MRI colon cancer|MRI scan of patients with colon cancer
32864333|NCT03829007|Experimental|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
32864334|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
32864335|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
32864336|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
32864337|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
32864338|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
32864339|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
32864340|NCT04863378|Experimental|Walkers|Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
32864341|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
32864342|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
32864343|NCT04873440|Experimental|Manganese plus Radiotherapy|Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
33414111|NCT05207241||Control group|Under the professional guidance of doctors, participating women (1) breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding
32994934|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
32994935|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
32994936|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
32994937|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
32994938|NCT01573403|Placebo Comparator|Treatment III|
32994939|NCT01573416|Placebo Comparator|Control group|
32994940|NCT01573416|Active Comparator|Intervention group|
32994941|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
32994942|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
32994943|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
33414112|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
33414113|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
33414114|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
33414115|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
33414116|NCT03642756|Placebo Comparator|20 gauge|
33414117|NCT03642756|Active Comparator|22 gauge|
33414118|NCT03642756|Active Comparator|24 gauge|
33414119|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
33414120|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
33414121|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
33414122|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
33414123|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
33414124|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
33414125|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
33414126|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
33414127|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
32994944|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
32994945|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
32994946|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
32994947|NCT01573520|No Intervention|usual care|
32994948|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
32994949|NCT01573546|Experimental|Aerobic Exercise|
32994950|NCT01573546|Experimental|DASH diet|
32994951|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
33414128|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
33414129|NCT03641352|Placebo Comparator|Placebo|Placebo
33414130|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
33414131|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
33414132|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
33414133|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
33414134|NCT03643926|Experimental|Arthroscopic Brostrom|
33414135|NCT03643926|Active Comparator|Open Brostrom|
33414136|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
33414137|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
32994952|NCT01573546|Active Comparator|Health education control|
32994953|NCT01573559||ClearView/Predicate|
32994954|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
32994955|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
32994956|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
32994957|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
32994958|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
32994959|NCT01573611|Experimental|Grape Powder|
32994960|NCT01573611|Placebo Comparator|Placebo Powder|
32994961|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
32994962|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
32994963|NCT01573663|Experimental|Ambroxol and Levodropropizine|
32994964|NCT01573663|Active Comparator|Ambroxol|
32994965|NCT01573663|Active Comparator|Levodropropizine|
32994966|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
32994967|NCT01573715|Active Comparator|severe ARDS patients|
32994968|NCT01573715|Active Comparator|control group|
32994969|NCT01573715|Experimental|moderate SDRA patients|
32994970|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
32994971|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
32994972|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
32994973|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
32994974|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
32994975|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
32994976|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
32994977|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
32994978|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
32994979|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
32994980|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
32994981|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
32994982|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
32994983|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
32994984|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
32994985|NCT01573845|Active Comparator|Healthy Eating Campaign|
32994986|NCT01573845|No Intervention|Control/Delayed Intervention|
32994987|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
32994988|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
32994989|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
32994990|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
32994991|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
32994992|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
32994993|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
32994994|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
32994995|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
32994996|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
32994997|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
32994998|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
32994999|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
32995000|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
32995001|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
33033629|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
32995002|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
32995003|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
32995004|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
32995005|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
32995006|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
32995007|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
32995008|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
32995009|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
32995010|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
32995011|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
32995012|NCT01574131|Placebo Comparator|Sugar pill|pill
32995013|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
32995014|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
32995015|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
32995016|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
32995017|NCT01574209||Healthy subjects|Healthy subjects as control group
32995018|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
32995019|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
33414138|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
32995020|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
33414139|NCT05193084||Work Stream 1 (WS1)|"The general aim of this work stream is to assess the hypothesis can the volumes measured by the Heartfelt device be useful in titrating and optimising drug management for patients undergoing home-IV diuretics and after completion of IV-diuretic treatment.?~We will characterise the data collected by the Heartfelt device in the participants' home, correlating it to weight readings (either from the scales or paper weight diary) and medical observations recorded while patients are being treated with IV Diuretics.~Patients from WS1 will be invited to keep the device in their home for 3 months in total, which will therefore cover periods during which they do not receive IV diuretics, but are still at relatively high risk of decompensation. That data will be analysed in the same fashion as the data collected in WS2."
33414140|NCT05193084||Work Stream 2 (WS2)|"The general aim of WS2 is to assess the hypothesis can the Heartfelt device be used to monitor heart failure stability and detect fluid overload in patients recently discharged after an episode of decompensated heart failure?.~This work stream will also aim to examine whether the Heartfelt device gives an indication of the number of days prior to hospital admissions that the Heartfelt device can detect changes in foot volume. This will be achieved by comparing the data collected by the Heartfelt device in the participants' home, and correlating it to weight readings and medical observations. Hospital admissions will be a particularly useful correlation point as it would provide information on the detection of the forming oedema leading up to this event. In future, the information collected during this study will be used to design and power an interventional study to demonstrate the effectiveness of such data in providing a leading indicator of hospitalisation."
33414141|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
33414142|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
32995021|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
32995022|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
32995023|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
32995024|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
32995025|NCT01574339|Experimental|Treatment Arm|
32995026|NCT01574365|Experimental|RTA402|
32995027|NCT01574365|Experimental|RTA402 Low|
32995028|NCT01574365|Experimental|RTA402 Medium-low|
32995029|NCT01574365|Experimental|RTA402 Medium-high|
32903890|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
32903891|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
32903892|NCT01270022|Experimental|Implementation|
32903893|NCT01270022|Active Comparator|dissemination|
32903894|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
32903895|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
32903896|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
32903897|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
32903898|NCT01270100|Experimental|Recovery management intervention|
32903899|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
32903900|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~Patient Health Questionnaire (PHQ-9)~Depression Anxiety and Stress Scale (DASS-21)~Diabetes Distress Scale (DDS-17)~Life events questions (Inter-Heart Study)~Diabetes Empowerment Scale (C-DES 20)~Summary of Diabetes Self Care Activities (SDSCA-15)~Euroqol-5D (EQ-5D)"
32903901|NCT01270178||Entecavir|
32903902|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
32903903|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
32903904|NCT01277588||Patient|
32903905|NCT01277588||Physcician|
32903906|NCT01270334||ph above cutoff|
32903907|NCT01270334||PH under cutoff|
32903908|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
32903909|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
32903910|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
32903911|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
32903912|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
32903913|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
32903914|NCT00729482|Experimental|1|Treatment Arm (RAD001)
32903915|NCT01270490|Experimental|Interferon-gamma|
32903916|NCT01270490|No Intervention|No intervention|No adjunctive treatment
32903917|NCT01278056|Experimental|Exjade|
32903918|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
32903919|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
32903920|NCT01270646|Experimental|Intraventricular Electrical Activation|
32903921|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
32903922|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
32903923|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
32903924|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
32903925|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
32903926|NCT00710840|Experimental|1|
32903927|NCT00710840|Active Comparator|2|
32903928|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
32903929|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
32903930|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
32903931|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
32903932|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
32903933|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
32903934|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
32903935|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
32903936|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
32903937|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
32903938|NCT00575432||1|
32995030|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
32995031|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
32995032|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
32995033|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
32995034|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
32995035|NCT01574417|Experimental|Plant stanol-enriched margarine|
32995036|NCT01574417|Placebo Comparator|control margarine|
33324736|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
33324737|NCT01238016|Other|device|Device implant and EEG recording
32995037|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
32995038|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
32995039|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
32995040|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
32995041|NCT01574456||13 patients with mild cognitive impairment|
32995042|NCT01574456||19 healthy controls|
32995043|NCT01574469|Active Comparator|1 = Tested product|
32995044|NCT01574469|Placebo Comparator|2 = Control product|
32995045|NCT01574482|Experimental|1 = Tested product|
33324738|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
32995046|NCT01574482|Placebo Comparator|2 = Control product|
32995047|NCT01574495|Experimental|Error Augmentation-Control|
32995048|NCT01574495|Experimental|Control-Error Augmentation|
32995049|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
32995050|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
32995051|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
33324739|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
33324740|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
32995052|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
32995053|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
32995054|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
32995055|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
32995056|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
32995057|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
32995058|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
32995059|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
32995060|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
32995061|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
32995062|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
32995063|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
32995064|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
32995065|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
32995066|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
32995067|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
32995068|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
32995069|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
32995070|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
32995071|NCT01574664||Subjects scheduled to undergo lumpectomy|
33324741|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
33324742|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
33231733|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
33231734|NCT05527392|Experimental|HINT Synchronous Intervention Group (HINT-S)|a virtual, synchronous version of the 5 HINT-S navigator sessions + HINT booklet
33231735|NCT05527392|Experimental|HINT Asynchronous Intervention Group (HINT-A)|a prerecorded, asynchronous version of the 5 HINT-S navigator sessions + HINT booklet
32995072|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
32995073|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
32995074|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
32995075|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
33231736|NCT05527392|No Intervention|Enhanced Usual Care|HINT Booklet
33231737|NCT00789360|Experimental|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
32995076|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
32995077|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
32995078|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
32995079|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
32995080|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
32995081|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
32995082|NCT01574781||Pregnant women|
32995083|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
32995084|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
32995085|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
32995086|NCT01574820|Placebo Comparator|placebo|
32995087|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
32995088|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
32995089|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
32995090|NCT01574846||Vantas|
32995091|NCT01574859||hypopituitarism|group of patients with hypopituitarism
32995092|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
32995093|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
32995094|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
32995095|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
33231738|NCT00789360|Experimental|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
32995096|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
32995097|NCT01574898|Active Comparator|V0118 - B mg|
32995098|NCT01574898|Experimental|V0474 - C mg|
32995099|NCT01574898|Experimental|V0474 - B mg|
32995100|NCT01574898|Experimental|V0474 - A mg|
32995101|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
32995102|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
32995103|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
32995104|NCT01574924||Medical residents|
32995105|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
32995106|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
32995107|NCT01574963||Control Patients|Patients without CAD
32995108|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
32995109|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
32995110|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
32995111|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
32995112|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
32995113|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
32995114|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
33414143|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
33414144|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
32995115|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
32995116|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
32995117|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
32995118|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
32995119|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
32995120|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
32995121|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
32995122|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
32995123|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
32995124|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
32995125|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
32995126|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
32995127|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
32995128|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
32995129|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
32995130|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
32995131|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
32995132|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
32995133|NCT01575158|Experimental|citalopram|citalopram
32995134|NCT01575158|Active Comparator|clomipramnine|clomipramine
32995135|NCT01575158|Placebo Comparator|placebo|placebo
32995136|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
32995137|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
32995138|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
32995139|NCT01575210|Experimental|Group A_ washing procedure 1|This group will apply washing technique 1.
32995140|NCT01575210|Experimental|Group B_washing procedure 2|This group will apply washing technique 2.
32995141|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
32995142|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
32995143|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
32995144|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
32995145|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
32995146|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
32995147|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
32995148|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
32995149|NCT01575288|Placebo Comparator|Maltose|
32995150|NCT01575288|Experimental|High-dose trehalose|
32995151|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
32995152|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
32995153|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
33414145|NCT01069692|Placebo Comparator|Arm 1|Placebo
33414146|NCT01069692|Experimental|Arm 3|
32995154|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
32995155|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
32995156|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
32995157|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
32995158|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
32995159|NCT01575366|Experimental|Slow tracking training|
32995160|NCT01575366|Experimental|Fast tracking training|
32995161|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
32995162|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
32995163|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
32995164|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
32995165|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
32995166|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
32995167|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
32995168|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
32995169|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
32995170|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
32995171|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
32995172|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
32995173|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
32995174|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
32995175|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
32995176|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
32995177|NCT01575587|Experimental|Treatment A|
32995178|NCT01575587|Experimental|Treatment B|
32995179|NCT01575587|Experimental|Treatment C|
32995180|NCT01575587|Experimental|Treatment D|
32995181|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
32995182|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
32995183|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
33414147|NCT01069692|Experimental|Arm 2|
33414148|NCT01069692|Experimental|arm 4|SBR759A
32995184|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
32995185|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
32995186|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
32995187|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
32995188|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
32995189|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
32995190|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
32995191|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
32995192|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
32995193|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
32995194|NCT01575678|Active Comparator|Melatonin|
32995195|NCT01575678|Placebo Comparator|Lactose|
32995196|NCT01575704|Experimental|Sport|
32995197|NCT01575704|Other|Control|
32995198|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
32995199|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
32995200|NCT01575717|No Intervention|No Intervention|
32995201|NCT01575743|Experimental|Aerobic Exercise|
32995202|NCT01575743|Other|healthy controls|
32995203|NCT01575782|Experimental|Chloroquine|
32995204|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
32995205|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
32995206|NCT01575821|Experimental|Eucalyptus honey ,|75 children
32995207|NCT01575821|Experimental|Labiatae honey|75 children allocated
32995208|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
32995209|NCT01575821|Experimental|Citrus honey|75 children allocated
32995210|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
32995211|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:~None."
33414149|NCT01069692|Experimental|arm 5|
33414150|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
33414151|NCT03621228|No Intervention|Control|Standard care only
32995212|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
32995213|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
32995214|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
32995215|NCT01575951|Experimental|All patients|All participants enrolled.
32995216|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
32995217|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
32995218|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
32995219|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
32995220|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
32995221|NCT01576094|Active Comparator|Levosimendan|
32995222|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
32995223|NCT01576107|Experimental|Stress-management|Stress-management training
32995224|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
32995225|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
32995226|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
33414152|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
32995227|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
32995228|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
32995229|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
32995230|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
32995231|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
32995232|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
32995233|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
32995234|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
32995235|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
32995236|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
32995237|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
32995238|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
32995239|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
32995240|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
32995241|NCT01576354|Active Comparator|Prolonged-release Fampridine|
32995242|NCT01576354|Placebo Comparator|Placebo|
32995243|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
32995244|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
32995245|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
32995246|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
32995247|NCT01576419|Experimental|PG201 tablet|
32995248|NCT01576419|Active Comparator|Celecoxib capsule|
32995249|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
32995250|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
32995251|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
32995252|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
32995253|NCT01576445|Experimental|Mid-vastus approach|
32995254|NCT01576445|Experimental|medial parapatellar approach|
32995255|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
32995256|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
32995257|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
33231739|NCT04022538|Experimental|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
33414153|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
32995258|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
32995259|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
32995260|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
32995261|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
32995262|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
33033630|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
33324743|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
33324744|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
33324745|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
33324746|NCT04624776|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
33324747|NCT04624776|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
33324748|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
33324749|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
33324750|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
33324751|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
33324752|NCT02528838||Patients receiving Revlimid according to clinical practice|
33324753|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
33324754|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
33324755|NCT01236612|Experimental|Immunization + bloodstage challenge|
33324756|NCT01236612|Active Comparator|Immunization + mosquito challenge|
33324757|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
33324758|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
33324759|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
33324760|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
33324761|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
33324762|NCT05382000|Other|Intervention|"Inclusion in the study will be proposed to all patients who come to the Emergency Department of the Gynecology and Obstetrics Service~The planned procedures for this group are as follows:~Obtaining informed consent.~Sequential triage - Patients will be evaluated sequentially using the MAT system according to standard practice. Next, another professional from the center, trained in the use of the Mediktor Hospital ® tool, will perform the advanced triage in the same space, both professionals being blind to the result of each of the tools.~Once the sequential triage is finished, the patient's care will be carried out according to usual clinical practice, following the triage assessment carried out with the MAT system.~Retrieval and introduction of data in DRF - Data of the study variables will be retrieved from the emergency report issued in the Gynecology and Obstetrics Emergency area and will be entered into an electronic DRF for subsequent analysis and processing."
33324763|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
33324764|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
33324765|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
33324766|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
33324767|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
33324768|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
33324769|NCT04578288|Active Comparator|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
33324770|NCT04578288|Experimental|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
33324771|NCT01140984|Experimental|treatment|
33324772|NCT01145040||Partition 1|Overt primary hypothyroidism
33324773|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
33324774|NCT01145040||Partition 3|Overt primary hyperthyroidism
33324775|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
33324776|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
33324777|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
33324778|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
33414154|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
33414155|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
33414156|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
33414157|NCT05183178|Active Comparator|Ticagrelor|Current standard of care
33414158|NCT05183178|Experimental|Prasugrel|New standard of care
33414159|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
33414160|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
33414161|NCT00026312|Active Comparator|Arm I (isotretinoin) (closed to accrual as of 4/16/2009)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
33414162|NCT00026312|Experimental|Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
33414163|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
33414164|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
33414165|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
33414166|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
33414167|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
33414168|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
33414169|NCT02846324|Placebo Comparator|Placebo|Parts A and B
33414170|NCT02240342|Experimental|Poor ovarian reserve women|
33414171|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
33414172|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
33414173|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
32995263|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
32995264|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
32995265|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
32995266|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
32995267|NCT01576627|Experimental|zinc citrate|
33414174|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
33414175|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
33414176|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
33414177|NCT02847650|Placebo Comparator|Placebo|
33414178|NCT02847650|Experimental|PF-06649751|
33414179|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
33414180|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
32995268|NCT01576627|Active Comparator|zinc gluconate|
32995269|NCT01576627|Active Comparator|zinc oxide|
32995270|NCT01576640|Other|Replapse Prevention Therapy|
32995271|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
32995272|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
32995273|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
32995274|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
32995275|NCT01576679|Placebo Comparator|Placebo|Saline
32995276|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
33414181|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
32995277|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
32995278|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
32995279|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
32995280|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
32995281|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
33414182|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
32995282|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
32995283|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
32995284|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
32995285|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
32995286|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
32995287|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
32995288|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
32995289|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
32995290|NCT01576887|Placebo Comparator|Placebo|
32995291|NCT01576887|Experimental|Bardoxolone Methyl|
32995292|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
32995293|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~* Patients will be randomized and assigned to each group at the ratio of 1:1."
32995294|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
32995295|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
32995296|NCT01576926||surgery|patients with obstructive sleep apnea
33033631|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
33033632|NCT01964872|Experimental|JNJ-38877618|
33033633|NCT01964872|Placebo Comparator|Placebo|
33414183|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
33414184|NCT03575858|Active Comparator|Tapered interdental brushes|control group
32995297|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
32995298|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
32995299|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
32995300|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
32995301|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
32995302|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
32995303|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
32995304|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
32995305|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
32995306|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
32995307|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
32995308|NCT01577056|Active Comparator|Fish oil|
33414185|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
33414186|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
33414187|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
32995309|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
32995310|NCT01577082|Experimental|CHF 1535 200/6µg|
33414188|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
33414189|NCT04606355||PDI Check & Conventional|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS) and Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
33414190|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
32995311|NCT01577082|Active Comparator|BDP 100µg|
32995312|NCT01577095|Experimental|EA + Rosiglitazone|
32995313|NCT01577095|Placebo Comparator|Rosiglitazone|
32995314|NCT01577121|Placebo Comparator|placebo|
32995315|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
32995316|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
32995317|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
32995318|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
32995319|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
32995320|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
32995321|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
32995322|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
32995323|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
32995324|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
32995325|NCT01577264||Cimzia treatment|
32995326|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
32995327|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
32995328|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
32995329|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
32995330|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
32995331|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
32995332|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
32995333|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
32995334|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
32995335|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
32995336|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
32995337|NCT01577342|No Intervention|No antibiotic use|
32995338|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
32995339|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
32995340|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
32995341|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
32995342|NCT01577407|Experimental|Nefopam|
32995343|NCT01577407|Placebo Comparator|placebo|
32995344|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
32995345|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
32995346|NCT01577420|No Intervention|Group C|Control; no foot sessions
32995347|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
32995348|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
32995349|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
32995350|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
32995351|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
32995352|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
32995353|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
32995354|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
32995355|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
32995356|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
32995357|NCT01577485|Experimental|Probiotic pastille|Test group
32995358|NCT01577485|Active Comparator|Control pastille|Control group
32995359|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
32995360|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
32995361|NCT01577524|Placebo Comparator|Normal Saline Wash|
32995362|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
32995363|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
32995364|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
32995365|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
32995366|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
32995367|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
32995368|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
32995369|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
32995370|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
32995371|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
32995372|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
32995373|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
32995374|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
32995375|NCT01577602|No Intervention|Standard practice|
32995376|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
32995377|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
32995378|NCT01577602|Experimental|Combined intervention|
32995379|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
32995380|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
32995381|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
33033634|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
33033635|NCT01964885|Placebo Comparator|Placebo|One tablet daily
33033636|NCT01964911|Experimental|Ropivacaïne|
33231740|NCT04022538|Active Comparator|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
33414191|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
33414192|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
33414193|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
33324779|NCT04521426||Lung Fibrosis|"probable or confirmed diagnosis of interstitial pulmonary fibrosis (IPF) or other fibrotic lung disease of unknown origin.~being listed for lung transplantation"
33414194|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
33414195|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
33414196|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
33414197|NCT05186441|Active Comparator|DMPFC iTBS|DMPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
33414198|NCT05186441|Active Comparator|DLPFC iTBS|DLPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
33414199|NCT05186441|Sham Comparator|placebo|The placebo research received similar pseudo-stimulation treatment, which was the same as the treatment site and method of true stimulation, but during stimulation, the coil used B65 8 zigzag coil, which was flipped 180 degrees, and only produced stimulation sound during treatment, but did not produce irritating magnetic field. It can produce a placebo effect.
32903939|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
32903940|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
32903941|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
32903942|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
32903943|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
32903944|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
32903945|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32903946|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
32903947|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
32903948|NCT00730964|Other|Phase 4|Open Label
32903949|NCT00731198|Experimental|1|Drotaverine hydrochloride
32903950|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
32903951|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
32903952|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
32903953|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
32903954|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
32903955|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
32903956|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
32903957|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
32903958|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
32903959|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
32995382|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
32995383|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
32995384|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
32995385|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
32995386|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
32995387|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
32995388|NCT01577719|Placebo Comparator|Usual Care|usual care
32995389|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
32995390|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
32995391|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
32995392|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
32995393|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
32995394|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
32995395|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
32995396|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
32995397|NCT01577823|No Intervention|No foley catheter|
32995398|NCT01577823|Active Comparator|Foley Catheter|
32995399|NCT01577849|Active Comparator|Vitamin D3|
32995400|NCT01577849|Experimental|DP-R206|
32995401|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
32995402|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
32995403|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
32995404|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
32995405|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
32995406|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
32995407|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
32995408|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
33324780|NCT04521426||COPD standard therapy|"COPD: GOLD stage III or IV~being listed for lung transplantation~did not underwent LVR surgery or endoscopic LVR~not being treated with chronic NIV"
33324781|NCT04521426||COPD with long-term NIV|"COPD: GOLD stage III or IV~being listed for lung transplantation~did not underwent LVR surgery or endoscopic LVR~being treated with chronic NIV before lung transplantation (at least 1 months, at least 4 hours per day)."
33324782|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33324783|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
33324784|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
33324785|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
33324786|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
33324787|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
33324788|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
33324789|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
33324790|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
33324791|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
33324792|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
33324793|NCT01585974||Group 1|
33324794|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
33324795|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
33324796|NCT03684564|Active Comparator|Warfarin (Control Arm)|
33324797|NCT01141218||Never-smokers with lung cancer|
33324798|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
33324799|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
33324800|NCT01235208|Experimental|Eurodiet treatment|
32995409|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
32995410|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
32995411|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
32995412|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
32995413|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
32995414|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
32995415|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
32995416|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
32995417|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
32995418|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
32995419|NCT01578018|Other|Lung Cancer|Diagnostic
32995420|NCT01578018|Other|Lung Disease|Diagnostic
32995421|NCT01578057|Experimental|tasimelteon + placebo ethanol|
32995422|NCT01578057|Experimental|ethanol + placebo tasimelteon|
32995423|NCT01578057|Experimental|tasimelteon + ethanol|
32995424|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
32995425|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
32995426|NCT01578070|Experimental|0.2μg Act-HIB®|
32995427|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
32995428|NCT01578070|Experimental|2μg Act-HIB®|
32995429|NCT01578070|Active Comparator|10μg Act-HIB®|
32995430|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
32995431|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
32995432|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
32995433|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
32995434|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
32995435|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
32995436|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
32995437|NCT01578148|Experimental|Noxipoint Therapy|
32995438|NCT01578148|Active Comparator|Physical Therapy|
32995439|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
32995440|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
32995441|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
32995442|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
32995443|NCT01578174|Placebo Comparator|Control|
32995444|NCT01578174|Active Comparator|Dexmedetomidine|
32995445|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
32995446|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
32995447|NCT01578213|Experimental|Imatinib|
32995448|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
32995449|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
32995450|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
32995451|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
32995452|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
32995453|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
32995454|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
32995455|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
32995456|NCT01578304|Experimental|Imidafenacin|
32995457|NCT01578304|Active Comparator|Fesoterodine|
32995458|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
32995459|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
33414200|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
32995460|NCT01578369|No Intervention|Control|Usual care
32995461|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
32995462|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
32995463|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
32995464|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
32995465|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
32995466|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
32995467|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
32995468|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
32995469|NCT01578421|Other|FX 100 dialyzer|
32995470|NCT01578421|Other|Polyflux 210 H dialyzer|
32995471|NCT01578421|Other|FXCorDiax 100 dialyzer|
32995472|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
32995473|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
32995474|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
32995475|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
32995476|NCT01578447|Other|Intramuscular DMPA|
32995477|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
32995478|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
32995479|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
32995480|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
32995481|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
32995482|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
32995483|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
32995484|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
32995485|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
32995486|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
32995487|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
32995488|NCT01578564|Experimental|SOR-C13|
32995489|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
32995490|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
32995491|NCT01578603|Experimental|sugar substituted chewing gum A|
32995492|NCT01578603|Experimental|Sugar substituted chewing gum B|
32995493|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
32995494|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
32995495|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
32995496|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
32995497|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
32995498|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
32995499|NCT01578668|Experimental|erlotinib|
32995500|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
32995501|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
32995502|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
32995503|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
32995504|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
32995505|NCT01578733|Experimental|protein intake|different levels of protein intake
32995506|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
32995507|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
33414201|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
33414202|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
33414203|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
33414204|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
33414205|NCT03572270|Experimental|case|PLWH
32995508|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
32995509|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
32995510|NCT01578811|Placebo Comparator|Placebo|
32995511|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
32995512|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
33414206|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
33414207|NCT02554253|Active Comparator|ketamine|Ketamine induction
32995513|NCT01578824|Active Comparator|Healthy Control|
32995514|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
32995515|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
32995516|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
32995517|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
32995518|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
32995519|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
32995520|NCT01578876|Experimental|CSWT for 3 month|A group
32995521|NCT01578876|Experimental|CSWT for 1 month|B group
32995522|NCT01578876|No Intervention|Control group|C group
32995523|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
33414208|NCT02554253|Active Comparator|Propofol|Propofol induction
33414209|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
33414210|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
33414211|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
33414212|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
33414213|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
33414214|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
33414215|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
33414216|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
33414217|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
33414218|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
33414219|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
32995524|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
32995525|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
32995526|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
32995527|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
32995528|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
32995529|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
32995530|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
32995531|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
32995532|NCT01578915||Controls|Women with only one sexual partner during the past year
32995533|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
32995534|NCT01578941|Placebo Comparator|Placebo|
32995535|NCT01578941|Active Comparator|Treximet|
32995536|NCT01579019|Active Comparator|1000 mg 24 weeks|
32995537|NCT01579019|Active Comparator|1000 mg 26 weeks|
32995538|NCT01579019|Experimental|1500 mg 24 weeks|
32995539|NCT01579019|Experimental|1500 mg 26 weeks|
32995540|NCT01579032||CKD patients|
32995541|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
32995542|NCT01579058|Placebo Comparator|placebo|placebo
32995543|NCT01579071|Experimental|CO2 sufflation group|
33324801|NCT04478292|Experimental|Group A|"Group A1： tumor is completely resected at diagnosis and receives no adjuvant chemotherapy（well differentiated fetal [WDF] histology HB) ；~Group A2：tumor is completely resected followed by 2 cycles of standard dose cisplatin monotherapy （non-well differentiated fetal histology HB)"
33324802|NCT04478292|Experimental|Group B|"Patients will be randomized to one of 2 arms: Arm CDDP or Arm CDDP plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy (6 cycles of standard dose cisplatin monotherapy with or without STS). All the patients in 2 arms will receive 6 cycles chemotherapy in total.~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
33324803|NCT04478292|Experimental|Group C|"Patients in Group C will have locally advanced tumors including PRETEXT I-III tumors with a positive VPEFR annotation factor and all PRETEXT IV tumors.~Patients will be randomized to one of 2 arms: Arm C5VD or Arm C5VD plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy. All the patients in 2 arms will receive 6 cycles chemotherapy in total.~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
33324804|NCT04478292|Experimental|Group D|"These patients have metastatic disease, suspected HB patients ≥ 8 years of age, or have an AFP ≤ 100 at diagnosis.~Patients will receive initial chemotherapy according to the cisplatin-intensive SIOPEL-4 induction regimen. Resection (including transplant) of the primary tumor should be completed after induction Block 3, but primary tumor resection can be planned any time after completing induction therapy.~Following 3 blocks of induction chemotherapy, patients will be stratified into 2 risk groups: Group D1 includes patients who either have a chemotherapy-induced lung CR or are rendered a lung CR by surgical metastasectomy. These patients will have chemotherapy consolidation with carboplatin/doxorubicin. In Group D2, patients will have not yet achieved a lung CR at the end of induction Block 3. These patients will get intensified consolidation therapy of carboplatin/doxorubicin with vincristine/irinotecan.~Resection of pulmonary nodules should be considered in Group D2."
33324805|NCT01141296|Active Comparator|Fenofibrate|
33324806|NCT01141296|Placebo Comparator|sugar pill|
33324807|NCT01238328|Experimental|Transplantation|
33324808|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
33324809|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
33324810|NCT03724890|Experimental|Part A: M3814 + Avelumab|
33324811|NCT03724890|Experimental|Part B: M3814 + Avelumab + Radiotherapy (RT)|
33324812|NCT03724890|Experimental|Part FE: M3814 + Avelumab (fasted/fed state)|
33324813|NCT01145664|Active Comparator|Western therapy|
33324814|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
33324815|NCT01145664|Experimental|Reduning Injection plus western therapy|
32995544|NCT01579071|Experimental|Room air sufflation group|
32995545|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
32995546|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
32995547|NCT01579110|Experimental|prednisolone + levamisole|
32995548|NCT01579110|Active Comparator|Prednisone|
32995549|NCT01579123|Active Comparator|Laser atherectomy|
33324816|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
33324817|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
32995550|NCT01579123|Active Comparator|Angioplasty|
32995551|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
32995552|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
32995553|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
32995554|NCT01579149|Placebo Comparator|Placebo|
32995555|NCT01579175|No Intervention|Standard postoperative care|
32995556|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
32995557|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
32995558|NCT01579188|Placebo Comparator|Placebo|Placebo
32995559|NCT01579201|Experimental|Carbetocin|
32995560|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
32995561|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
32995562|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
32995563|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
32995564|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
32995565|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
32995566|NCT01579240|Experimental|program visits|visits to intervention program
32995567|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
32995568|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
32995569|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
32995570|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
32995571|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
32995572|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
32995573|NCT01579292|Active Comparator|Pedometer only|Pedometer only
32995574|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
32995575|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
32995576|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
32995577|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
32995578|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
32995579|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
32995580|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
32995581|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
32995582|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
32995583|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
32995584|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
32995585|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
32995586|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
32995587|NCT01579396|Other|standard therapy|standard therapy according to local practice
32995588|NCT01579409|Other|1-25th percentile of the PNNS score|
32995589|NCT01579409|Other|75-100th percentile of the PNNS score|
32995590|NCT01579422|Experimental|social cognitive training|
32995591|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
32995592|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
32995593|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
32995594|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
32995595|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
32995596|NCT01579461|Experimental|mild hepatic impairment|
32995597|NCT01579461|Experimental|moderate hepatic impairment|
32995598|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
32995599|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
32995600|NCT01579500|Active Comparator|botulinum toxin A|
32995601|NCT01579500|Placebo Comparator|normal saline|
32995602|NCT01579526|Experimental|FP01 Dose 1|Drug
32995603|NCT01579526|Experimental|FP01 Dose 2|Drug
33324818|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
32995604|NCT01579526|Experimental|FP01 Dose 3|Drug
32995605|NCT01579526|Active Comparator|Comparator|Drug
32995606|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
32995607|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
32995608|NCT01579591|Placebo Comparator|Placebo|
32995609|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
32995610|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
32995611|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
32995612|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
32995613|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
32995614|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
32995615|NCT01579643|Experimental|LALAK|
32995616|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
32995617|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
32995618|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
32995619|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
32995620|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
32995621|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
33324819|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
32995622|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
32995623|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
32995624|NCT01579695||Exposed Group will receive Tesamorelin|
32995625|NCT01579695||Control Group will not receive Tesamorelin|
32995626|NCT01579708|Experimental|Program SI! educational intervention|
32995627|NCT01579708|No Intervention|Control|
32995628|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
32995629|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
32995630|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
32995631|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
32995632|NCT01579760|Experimental|aflibercept every 2 months|
32995633|NCT01579760|Experimental|aflibercept monthly|
32995634|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
32995635|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
32995636|NCT01579799|Active Comparator|Dose 0.5|
32995637|NCT01579799|Active Comparator|Dose 7.5|
32995638|NCT01579799|Active Comparator|Dose 3|
32995639|NCT01579799|Active Comparator|Dose 1.2|
32995640|NCT01579825|Experimental|Buffer|
32995641|NCT01579825|No Intervention|Control|
32995642|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
32995643|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
32995644|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
32995645|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
32995646|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
32995647|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
32995648|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
32995649|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
32995650|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
32995651|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
32995652|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
32995653|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
32995654|NCT01579955||eptacog alpha users|
32995655|NCT01579968||eptacog alpha users|
32995656|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
32995657|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
32995658|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
32995659|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
32995660|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
32995661|NCT01580228|Experimental|Dinaciclib|
32995662|NCT01580228|Active Comparator|Ofatumumab|
32995663|NCT01580280|Experimental|Thrust manipulation|
32995664|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
32995665|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
32995666|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
32995667|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
32995668|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
32995669|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
32995670|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
32995671|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
32995672|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
32995673|NCT01580735|Experimental|ARQ 197|
32995674|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
32995675|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
32995676|NCT01581034|Active Comparator|Padma|
32995677|NCT01581034|Placebo Comparator|Placebo|
32995678|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
32995679|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
32995680|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
32995681|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
32995682|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
32995683|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
32995684|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
32995685|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
32995686|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
32995687|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
32995688|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
32995689|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
32995690|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
32995691|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
32995692|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
32995693|NCT01581957|Active Comparator|Specific Enteral formulation|
32995694|NCT01581957|Placebo Comparator|Standard enteral formulation|
32995695|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
32995696|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
32995697|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
32995698|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
32995699|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
32995700|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
32995701|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
32995702|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
32995703|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
32995704|NCT01583075|Other|Circumferential ablation|
32995705|NCT01583075|Experimental|Single ring ablation|
32995706|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
32995707|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
32995708|NCT01583309|No Intervention|low-flux hemodialysis|
32995709|NCT01583309|Experimental|online pre-dilution hemofiltration|
32995710|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
32995711|NCT01583335|Experimental|Improved lifestyle|
32995712|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
32995713|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
32995714|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
32995715|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
32995716|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
32995717|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
32995718|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
32995719|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
32995720|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
32995721|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
32995722|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
32995723|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
32995724|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
32995725|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
32995726|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
32995727|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
32995728|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
32995729|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
32995730|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
32995731|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
32995732|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
32995733|NCT01584453|Experimental|Sodium Nitrite|
32995734|NCT01584453|Placebo Comparator|Placebo|
32995735|NCT01584713|Experimental|Adipose derived Stem Cells|
32995736|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
32995737|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
33414220|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
32995738|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
32995739|NCT01584921|Active Comparator|Low dose Erythropoietin|
32995740|NCT01584921|Active Comparator|High dose Eryhropoietin|
32995741|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
32995742|NCT01585493|Active Comparator|Care coordinator|
32995743|NCT01585493|Experimental|CHANGE|
32995744|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
32995745|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
32995746|NCT01585844||Women with sleep apnea|
32995747|NCT01585844||Women without sleep apnea|
32995748|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
32995749|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
32995750|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
32995751|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
32995752|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
32995753|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
33324820|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
33324821|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
33324822|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
33324823|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
33324824|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
33324825|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
33324826|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
33324827|NCT01145820|Experimental|Juice Plus|
33324828|NCT01145820|Placebo Comparator|Placebo|
33324829|NCT00219557|Active Comparator|Gemcitabine|
33324830|NCT00219557|Experimental|Axitinib [AG-013736] plus gemcitabine|
33324831|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
33324832|NCT01235286|Experimental|remote ischemic preconditioning|
33324833|NCT05282940|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
33324834|NCT05282940|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the test marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
33324835|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
33324836|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
33324837|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
33324838|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
33324839|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
33324840|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
33414221|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
32995754|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
32995755|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
32995756|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
32995757|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
32995758|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
32995759|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
33414222|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
33414223|NCT04563611|No Intervention|Muscle strength|Participants hamstring muscle strengths will be evaluated with ISOMED 2000 isokinetic dynamometer
33414224|NCT04563611|No Intervention|Hamstring Flexibility|In this study, Individuals' evaluations of hamstring flexibility will be assessed by the active knee extension test (ICC: 0.96) with maximum hip flexion.
33414225|NCT04563611|No Intervention|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control, and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated with the computer assisted CNSVS test battery
33414226|NCT04563611|No Intervention|Injury risk|Injury risk analysis of individuals will be made using the strength differences between the two sides, H: Q ratios (conventional and functional ratio) and functional movement screen (FMS), which will be obtained from the isokinetic measurement results.
32995760|NCT01586715|Experimental|Autologous Stem Cells|
32995761|NCT01586780|Experimental|Reference meal|
32995762|NCT01586780|Experimental|Whey protein|
32995763|NCT01586780|Experimental|Whey + 5 amino acids|
32995764|NCT01586780|Experimental|Whey + 6 amino acids|
32995765|NCT01586780|Experimental|Soy protein drink|
32995766|NCT01586780|Experimental|Soy + 5 amino acids|
33414227|NCT04563611|Experimental|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
33414228|NCT04563611|Experimental|Supine Sliding Leg Curls|The persons will be started to exercise in the hook position, with hands-on their back, with their knees next to the body, in a flexion position of approximately 60 °. Participants will be asked to first build a bridge, then maintain this position and slowly slide the slippery apparatus under their feet to bring their knees to full extension.
33414229|NCT04563611|Experimental|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
33414230|NCT04563611|No Intervention|Agility|Agility performances of individuals will be evaluated with the Agility T-test.
33414231|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
33414232|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
32995767|NCT01586780|Experimental|Soy + 6 amino acids|
32995768|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
32995769|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
32995770|NCT01586845|Experimental|Voclosporin|Voclosporin
32995771|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
32995772|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
32995773|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
32995774|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
32995775|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
32995776|NCT01586988|No Intervention|Control|Standard care.
32995777|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
32995778|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
32995779|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
32995780|NCT01587378|Experimental|metformin|
32995781|NCT01587378|Placebo Comparator|placebo|
32995782|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
32995783|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
33324841|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
33324842|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
33324843|NCT05269056||Stage I-II gastric cancer|Cell-free DNA collected from plasma samples of 200 patients with stage I-II gastric cancer will undergo whole-genome sequencing
33324844|NCT05269056||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
33324845|NCT01329666|Experimental|50,000 IU Vitamin D3|
33324846|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
33324847|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
33324848|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
33324849|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
33324850|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
33324851|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
33324852|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
33324853|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
33324854|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
33324855|NCT05255484|Experimental|LM-108 Dose Escalation|Drug: LM-108 Administered intravenously
33324856|NCT05255484|Experimental|LM-108 Dose Expansion|Drug: LM-108 Administered intravenously
33324857|NCT05255484|Experimental|LM-108 Combination Dose Escalation|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
33324858|NCT05255484|Experimental|LM-108 Combination Dose Expansion|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
33324859|NCT01141998|Placebo Comparator|Placebo|
33324860|NCT01141998|Active Comparator|Vitamin D administered orally|
33324861|NCT01141998|Experimental|Vitamin D administered via UVB|
33324862|NCT05632302|Experimental|TBI-ICP monitoring|Optical signals acquisition from the nICP probe stuck to the patient's forehead
33324863|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
33324864|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
33324865|NCT05251272||Training cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
33324866|NCT05251272||Validation cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
33324867|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
33324868|NCT01235364|Experimental|Speculum|
33324869|NCT01236924|Experimental|Lifestyle counseling|
33324870|NCT01238718|Active Comparator|lidocaine|
33324871|NCT01238718|Placebo Comparator|normal saline|
33324872|NCT04284072|Experimental|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
33324873|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
33324874|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
33324875|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
33324876|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
33324877|NCT01235520|Experimental|1|
33324878|NCT01235520|Experimental|2|
33324879|NCT01235520|Placebo Comparator|3|
33324880|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
33324881|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
33324882|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
33414233|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses~More specifically the regimens will be as follows:~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux <50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, >100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; <50kg, 5000IU, 50-70kg, 7.500 IU, >70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
32995784|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
32995785|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
32995786|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
32995787|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
32995788|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
32995789|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
33414234|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
33414235|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
33414236|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
32995790|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
32995791|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
32995792|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
32995793|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
32995794|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
32995795|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
32995796|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
32995797|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
32995798|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
32995799|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
32995800|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
32995801|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
32995802|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
32995803|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
32995804|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
32995805|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
32995806|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
32995807|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
32995808|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
32995809|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
33414237|NCT02259842|Placebo Comparator|Placebo|
33414238|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
33414239|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
33414240|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
33414241|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
33414242|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
33414243|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
33414244|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
33414245|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
32995810|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
33414246|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
33414247|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
32995811|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
33414248|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
33414249|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
33414250|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
32995812|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
32995813|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
32995814|NCT01588873|Active Comparator|Oral contraceptive pill|
32995815|NCT01588873|Active Comparator|Contraceptive ring|
32995816|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
32995817|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
32995818|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
32995819|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
32995820|NCT01589432|Experimental|ABT-639|
32995821|NCT01589432|Placebo Comparator|Placebo|
32995822|NCT01589432|Active Comparator|Lidocaine|
32995823|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
32995824|NCT01589458|Experimental|NaF/SiO2 toothpaste|
32995825|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
32995826|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
32995827|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
32995828|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
32995829|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
32995830|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
32995831|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
32995832|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
32995833|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
32995834|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
32995835|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
33414251|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
33414252|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
33414253|NCT01337765|Experimental|BEZ235 + MEK162|
33414254|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
33414255|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
33414256|NCT02842736|Experimental|Endometrial Cryoablation|
33414257|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
33414258|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
33414259|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
33414260|NCT04446143|Other|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
33414261|NCT04446143|Active Comparator|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
32864344|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
32864345|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
32864346|NCT04863066|Experimental|CAR-T-cell therapy|Four patients with plasma HIV RNA <50 copies/ml and CD4+T cell count more than 350 cells/μl receiving at least one-year antiviral treatment are injected intravenously with 1×10^5 CAR-T cells/kg body weight. If the dosage of 1×10^5 CAR-T cells/kg body weight is well tolerated, 5×10^5 CAR-T cells/kg body weight will be infused for another 4 subjects who meet the inclusion and exclusion criteria.
32864347|NCT04867980|Experimental|ABCD|Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be >= 5 days between each dose.
32864348|NCT04867980|Experimental|BDAC|Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be >= 5 days between each dose.
32864349|NCT04867980|Experimental|CADB|Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be >= 5 days between each dose.
32864350|NCT04867980|Experimental|DCBA|Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be >= 5 days between each dose.
32864351|NCT03821675|Active Comparator|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
32864352|NCT03821675|Sham Comparator|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
32864353|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
32864354|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
32864355|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
32864356|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
32864357|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
32864358|NCT04868058|Experimental|1 AF SAPB|Atrial fibrillation. Serratus anterior plane block
32864359|NCT04868058|Experimental|2 AF ESPB|Atrial fibrillation. Erector spinae plane block
32864360|NCT04868058|Experimental|3 VT SAPB|Ventricular Tachycardia.Serratus anterior plane block
32864361|NCT04868058|Experimental|4 VT ESPB|Ventricular Tachycardia. Erector spinae plane block
32864362|NCT04868058|Experimental|5 ISNT SAPB|Inappropriate Sinus node tachycardia. Serratus anterior plane block
32864363|NCT04868058|Experimental|6 ISNT ESPB|Inappropriate Sinus node tachycardia. Erector spinae plane block
32864364|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
32864365|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
32864366|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
32864367|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
32864368|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching"
32864369|NCT01314157|No Intervention|Patients remained on the waiting list|Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with control group.
32864370|NCT04391621|Experimental|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
32864371|NCT04391621|Active Comparator|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.~This will be a single dose infiltration of 40mg/cubic centimetres."
32864372|NCT04391465|Experimental|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:~600 msec (100 bpm)~500 msec (120 bpm)~400 msec (150 bpm)~350 msec (171 bpm)"
32995836|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
32995837|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
33324883|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
33324884|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
33324885|NCT01142154|Experimental|oral, liquid solution|
33324886|NCT05667636|Experimental|single arm, non randomized|SBRT 30 Gy/ 5 fractions
33324887|NCT05667636|Experimental|radiation, SBRT|SBRT 30 Gy/5 fractions to the prostatic bed +/- 25 Gy/5 fractions to the pelvic lymphnodes
33324888|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
33324889|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
33324890|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
33324891|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
33324892|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
33324893|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
32995838|NCT01589965|No Intervention|Control group|
33324894|NCT05158998|Other|propofol group|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Propofol infusion will be stopped at the end of surgery.
33324895|NCT05158998|Other|sevoflurane group|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
32995839|NCT01589965|Experimental|Treatment group T1|High Lottery reward
32995840|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
32995841|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
32995842|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
32995843|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
32995844|NCT01590030|Experimental|Laparoscopic mesial incision|
32995845|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
32995846|NCT01590043||Control|Healthy 3-18 years old participants
32995847|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
32995848|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
32995849|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
32995850|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
32995851|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
32995852|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
32995853|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
32995854|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
32995855|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
32995856|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
32995857|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
32995858|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
32995859|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
32995860|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
32995861|NCT01590173|Active Comparator|COH for IVF|
32995862|NCT01590199|Experimental|RAD001 + SOM230|
32995863|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
32995864|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
32995865|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
32995866|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
32995867|NCT01590290|Active Comparator|pay for performance|
32995868|NCT01590290|No Intervention|no pay for performance|
32995869|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
32995870|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
32995871|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
32995872|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
32995873|NCT01590329|Experimental|Micrografting|
32995874|NCT01590342|Active Comparator|Diclofenac|
32995875|NCT01590342|Placebo Comparator|Placebo|
32995876|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
32995877|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
32995878|NCT01590381||personnel in medical training - COURSE 1|
32995879|NCT01590381||personnel in medical training - COURSE 2|
32995880|NCT01590381||personnel in medical training - COURSE 3|
32995881|NCT01590381||personnel in medical training - COURSE 4|
32995882|NCT01590381||personnel in medical training - COURSE 5|
32995883|NCT01590381||personnel in medical training - COURSE 6|
32995884|NCT01590381||personnel in medical training - COURSE 7|
32995885|NCT01590381||personnel in medical training - COURSE 8|
32995886|NCT01590381||personnel in medical training - COURSE 9|
32995887|NCT01590381||personnel in medical training - COURSE 10|
32995888|NCT01590407|Experimental|ALS-002200|
32995889|NCT01590407|Placebo Comparator|Placebo|
32995890|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
32995891|NCT01590446|Placebo Comparator|Placebo|
32995892|NCT01590446|Active Comparator|BMN 111|
32995893|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
32995894|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
32995895|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
32995896|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
32995897|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
32995898|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
32995899|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
32995900|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
32995901|NCT01590537||Group 1|
32995902|NCT01590537||Group 2|
32995903|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
32995904|NCT01590589||REGISTRY participants|"Individuals~with manifest HD~unaffected but known to carry the HD mutation~unaffected but at risk of carrying the HD mutation~from HD families known not to carry the HD mutation~from outside HD families acting as control research participants (e.g., spouses)"
32995905|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
32995906|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
32995907|NCT01590641|Experimental|0.3mg GS-9620|
32995908|NCT01590641|Experimental|1mg GS-9620|
32995909|NCT01590641|Experimental|2mg GS-9620|
32995910|NCT01590641|Experimental|4mg GS-9620|
32995911|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
32995912|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
32995913|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
32995914|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
32995915|NCT01590654|Experimental|0.3mg GS-9620|
32995916|NCT01590654|Experimental|1mg GS-9620|
32995917|NCT01590654|Experimental|2mg GS-9620|
32995918|NCT01590654|Experimental|4mg GS-9620|
32995919|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
32995920|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
32995921|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
32995922|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
32995923|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
32995924|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
32995925|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
32995926|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
32995927|NCT01590732|Experimental|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32995928|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
32995929|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
32995930|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
32995931|NCT01590836|Experimental|IDeg-->IDegAsp|
32995932|NCT01590849|No Intervention|No hormonal contraception|
32995933|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
32995934|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
32995935|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
32995936|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
32995937|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
32995938|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
32995939|NCT01590927||20 healthy women|
32995940|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
32995941|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
32995942|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
32995943|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
32995944|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
32995945|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
32995946|NCT01591057|Experimental|2 Portions|
32995947|NCT01591057|Experimental|5 portions|
32995948|NCT01591057|Experimental|8 portions|
32995949|NCT01591070|No Intervention|vehicle twice weekly|
32995950|NCT01591070|Experimental|tacrolimus once weekly|
32995951|NCT01591070|Experimental|tacrolimus twice weekly|
32995952|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
32995953|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
32995954|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
32995955|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
32995956|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
32995957|NCT01591122|Experimental|Abiraterone acetate and prednisone|
32995958|NCT01591122|Active Comparator|Placebo and prednisone|
32995959|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
32995960|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
32995961|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
32995962|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
32995963|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
32995964|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
32995965|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
32995966|NCT01591187||Cancer|Participants with a diagnosis of cancer.
32995967|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
32995968|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
32995969|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
32995970|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
32995971|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
32995972|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
32995973|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
32864373|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
32864374|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
32864375|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
32864376|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
32864377|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
32864378|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
32864379|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
32864380|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
32864381|NCT01310023||Static Cohort- closed to enrollment and follow-up|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
32864382|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
32864383|NCT01310023||Reference Cohort- closed to enrollment and follow-up|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
32864384|NCT01310023||Young Adult Cohort- closed to enrollment and follow-up|Former Dynamic and Static Cohort participants ≥ 18 years of age.
32864385|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
32864386|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
32864387|NCT04873284|Experimental|Fosaprepitant|Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion
32864388|NCT04873284|Experimental|Aprepitant|Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant
32864389|NCT04872972|Other|Before/After|Before and after simulation; Institutional faculty and facilities
32864390|NCT05566483|Experimental|Exercise|
32864391|NCT05566483|No Intervention|Control|
32864392|NCT01450709||Dialysis patients|
32864393|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
32864394|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
32864395|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
32864396|NCT01308619|Active Comparator|placebo|placebo
32864397|NCT01451177|Experimental|Treated|
32864398|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
32864399|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
32864400|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
32864401|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
32864402|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
32864403|NCT04758689|Experimental|Laser acupuncture and aerobic exercise|
32864404|NCT04758689|Experimental|Aerobic exercise|
32864405|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
32864406|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
32864407|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
32864408|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
32864409|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
32864410|NCT01451801|Other|HBsAg|
33105169|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
33105170|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
33105171|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
33105172|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
33105173|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
33105174|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
33105175|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
33105176|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
33414262|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
33414263|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
33414264|NCT04475705|Active Comparator|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
33414265|NCT04475705|Active Comparator|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
33414266|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
33414267|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
33414268|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
33414269|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
33414270|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
33414271|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
33414272|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
33414273|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
33414274|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
33414275|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
32864411|NCT05458843|Experimental|Fluid replacement|
33105177|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
33105178|NCT04323280|Active Comparator|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg) for 3 months
33414276|NCT01334567|Experimental|Tenofovir DF|
33414277|NCT03570398|Other|Abdominal CT|
33414278|NCT03570398|Other|Abdominal Ultrasound|
33414279|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
33414280|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
32864412|NCT05458843|Sham Comparator|No fluid replacement|
32864413|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
32995974|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
32995975|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
32995976|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
33324896|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
33324897|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
32995979|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
32995980|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
32995981|NCT01591278|Experimental|Pulp dressing agent|
32995982|NCT01591278|Active Comparator|Pulp dressing|MTA
32995983|NCT01591291|Experimental|Ondansetron|
32995984|NCT01591291|Placebo Comparator|Placebo|
32995985|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
32995986|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
32995987|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
32995988|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
32995989|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
32995990|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
32995991|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
32995992|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
32995993|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~negative rapid urease test~negative histology for Hp infection on both initial and follow-up endoscopy~negative serology test~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
32995994|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
32995995|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
32995996|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
32995997|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
32995998|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
32995999|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
32996000|NCT01591538||lifestyle condition|
32996001|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
32996002|NCT01591564|Other|therapy|All participants will receive the intervention.
32996003|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
32996004|NCT01591603|Experimental|Group 1|
32996005|NCT01591603|Experimental|Group 2|
32996006|NCT01591668|Experimental|0.3mg GS-9620|
32996007|NCT01591668|Experimental|1mg GS-9620|
32996008|NCT01591668|Experimental|2mg GS-9620|
32996009|NCT01591668|Experimental|4mg GS-9620|
32996010|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
32996011|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
32996012|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
32996013|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
32996014|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
32996015|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
32996016|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
33324898|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
33324899|NCT03993678|Experimental|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
33324900|NCT05120466|Active Comparator|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
32996017|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
33414281|NCT05354804|Placebo Comparator|Standard|Patients randomized to standard care will be sampled at admission and after 1 hour (and furthermore as clinically indicated). High sensitive Troponin T (cTnT) and standard laboratory tests will be measured in the central hospital laboratory using Cobas e801 from Roche Diagnostics and eligibility for rule-out will be judged in accordance with the ESC 0/1 hour rule-out algorithm for cTnT. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If NSTE-ACS is low risk based on the cTnT algorithm, HEART< 4 and non-ischemic ECG, patients will be investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnoses. Patients will be admitted or discharged based on the clinical judgement of the attending physician.
33414282|NCT05354804|Active Comparator|POC|Blood samples will be obtained at admission, standard blood tests will be measured at the central laboratory whilst high sensitive troponin I at 0 and 1 hour will be analyzed using a POC instrument from Siemens Healthineers in the ED. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If the cTnI concentration at admission and the 1-hour delta is below a pre-specified concentration, the HEART- score < 4, and the ECG is non-ischemic the patients will be allocated to the rule-out of NSTEMI group and investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnosis. Finally, patients will be admitted or discharged based on the clinical judgement of the attending physician.
33414283|NCT04398329|Experimental|Phase 1b (Cohort 1)|Fixed dose of HTX-034.
33414284|NCT04398329|Experimental|Phase 1b (Cohort 2)|Individualized dose of HTX-034.
33414285|NCT04398329|Experimental|Phase 2 (Expansion): Low Dose|Fixed dose of HTX-034.
33414286|NCT04398329|Experimental|Phase 2 (Expansion): High Dose|Individualized dose of HTX-034.
33414287|NCT04398329|Active Comparator|Phase 1b and Phase 2|Bupivacaine HCl.
33414288|NCT05354726||CKD group|"Inclusion Criteria for Volunteers (Inclusion Criteria):~6-18 age range,~According to the Chronic Kidney Disease Assessment and Classification Guide prepared by the National Kidney Foundation- Kidney Disease Outcomes Quality Initiative (NKF-KDOQI); Stage 2, glomerular filtration rate 60-89 ml/min/1.73 m2, Stage 3, glomerular filtration rate 30-59 ml/min/1.73 m2, Stage 4, glomerular filtration rate 15-29 ml/min/1.73 m2,~Presence of kidney transplantation was determined as inclusion criteria.~Exclusion Criteria for Volunteers:~acute infection,~Ongoing dialysis,~Congenital heart disease,~Hypertension that cannot be controlled with dual antihypertensive medication,~Neurological and/or genetic musculoskeletal disease,~The presence of orthopedic and cognitive problems that prevented the tests from being performed were determined as exclusion criteria."
33414289|NCT05354726||Control Group|"Inclusion Criteria for Control Volunteers:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease~Not having orthopedic and cognitive problems that prevent testing~The patient's and/or family's willingness to participate in the study"
33414290|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
33414291|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
33414292|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
33414293|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
33414294|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
33414295|NCT03571880|Experimental|CNSLBP group|
33414296|NCT03571880|Active Comparator|Healthy control group|
33414297|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
33414298|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
33414299|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
33414300|NCT04373915|No Intervention|Standard Bedside Rounding|
33414301|NCT04373915|Experimental|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
33414302|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
33414303|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
33414304|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
33414305|NCT05754801|Experimental|Active treatment (Yunzhi Essence)|Subjects will take 2 Yunzhi capsules, 4 times daily, for 6 months.
33414306|NCT05754801|Placebo Comparator|Placebo|Subjects will take 2 placebo capsules, 4 times daily, for 6 months
33414307|NCT01331993|Experimental|1|Treatment order : A, B, C
33414308|NCT01331993|Experimental|2|Treatment order : B, C, A
33414309|NCT01331993|Experimental|3|Treatment order : C, A, B
33414310|NCT01331993|Experimental|4|Treatment order : A, C, B
33414311|NCT01331993|Experimental|5|Treatment order : B, A, C
33414312|NCT01331993|Experimental|6|Treatment order : C, B, A
33414313|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
32996018|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
32996019|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
32996020|NCT01591759|Placebo Comparator|Placebo|
32996021|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
33105179|NCT04323280|Experimental|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg)
33105180|NCT04323007|Other|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
32864414|NCT01699243||Epidural|subjects under epidural anesthesia
32864415|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
32864416|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
32864417|NCT01305499|Experimental|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
32864418|NCT01305499|Experimental|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
32864419|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
32864420|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
32864421|NCT04429230|Active Comparator|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
32864422|NCT04429230|Sham Comparator|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
32864423|NCT01452035|Experimental|Exercise|
32864424|NCT01452035|No Intervention|Sedentary Control|
32864425|NCT05417113|Active Comparator|Bupivacaine only|bupivacaine 0.25% in ESP blocks
32864426|NCT05417113|Experimental|Liposomal Bupivacaine and Bupivacaine|liposomal bupivacaine in addition to 0.25% bupivacaine in ESP blocks
32864427|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses~Intervention: multimodal evoked potentials"
32864428|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~Aged 18 to 58 years old, inclusive, at the time of informed consent.~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~Have no comorbid condition (ie neuropathy) that could affect testing.~Intervention: multimodal evoked potentials"
32864429|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
32864430|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
32864431|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
32864432|NCT02611362|Experimental|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
32864433|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
32864434|NCT04391699|Experimental|CPAP + Heated humidification|CPAP + Heated humidification
32864435|NCT04391699|No Intervention|CPAP alone|CPAP
32864436|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
32864437|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
32864438|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
32864439|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
32864440|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
32864441|NCT00608725|Other|Patients|Patients with orthostatic intolerance
32864442|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
32864443|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
32864444|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
33414314|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
33414315|NCT01340365|Other|Usual Care|
33414316|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
33414317|NCT01337999||HE-4 levels, healthy premenopausal women|
32864445|NCT05272111|Experimental|Fascia Therapy|Group A will receive Fascia therapy
32864446|NCT05272111|Experimental|Facial Manipulation|Group B will receive Facial manipulation
32864447|NCT01452659|Experimental|TAK-385 10 mg QD|
32864448|NCT01452659|Experimental|TAK-385 20 mg QD|
32864449|NCT01452659|Experimental|TAK-385 40 mg QD|
32864450|NCT01452659|Placebo Comparator|Placebo|
32864451|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
32864452|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
32864453|NCT04872738||Vaccinated Breast Cancer Patients|Patients who enroll in the trial and decided to get the COVID-19 vaccine will complete surveys to indicate their experiences, side effects, location of vaccination (i.e. right arm, left arm, or leg). This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
32864454|NCT04872738||Unvaccinated Breast Cancer Patients|Patients who enroll in the trial and did not choose to receive the COVID-19 vaccine once it was available to them with complete a survey to indicate why they chose not to receive the vaccine. This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
32864455|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
32864456|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
32864457|NCT04867824|Active Comparator|Control|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
32864458|NCT04867824|Experimental|Case|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
32864459|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
32864460|NCT01452815|Placebo Comparator|1|Drug: placebo
32864461|NCT01452815|Experimental|2|10mg TZP-102
32864462|NCT01452815|Experimental|3|20mg TZP-102
32864463|NCT04867512|Experimental|Intervention Group|Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
32864464|NCT04755517|Active Comparator|A1|Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2
32864465|NCT04755517|No Intervention|A2|infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.
32864466|NCT04755517|Active Comparator|C|The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.
32864467|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise~regular rehabilitation programe~alternative video-teaching materials"
32864468|NCT03045432|Other|control group|"regular passive ROM exercise~regular rehabilitation programe~regular oral-teaching materials"
32864469|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
32864470|NCT01452893||Addison's disease|Adult patients with Addison's disease
32864471|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
32864472|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
32996022|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
32996023|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
32996024|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
33105181|NCT04323085|Active Comparator|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
33105182|NCT04323085|Active Comparator|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
33105183|NCT04323085|No Intervention|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
33105184|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
33105185|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
33105186|NCT05519488|Experimental|Intervention group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
33105187|NCT05519488|Active Comparator|Control group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music of their own choice that they believe to be stress reducing
33105188|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
33105189|NCT02907281||Healthy volunteers|Healthy volunteers
33105190|NCT04323241|No Intervention|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
33105191|NCT04323241|Experimental|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
33105192|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
33105193|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
33105194|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
33105195|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
33414318|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
33414319|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
33105196|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
33105197|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
33105198|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
33105199|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
33105200|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
33105201|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
33105202|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
33105203|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
33414320|NCT01341769|Placebo Comparator|Control Test Food|Snack base
33105204|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
33105205|NCT01262677|Experimental|pregabalin CR 330 mg|
33105206|NCT01262677|Experimental|pregabalin CR 165 mg|
33105207|NCT01262677|Placebo Comparator|Placebo|
33105208|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:~Information about health risks for night workers~Dietetic intake~Leisure physical activities~Sleep and alertness~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)~That's a current practice in France for Occupational physicians."
33414321|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
33105209|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
33105210|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
33414322|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
33414323|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
33414324|NCT04344431|Experimental|HBO group|
33414325|NCT04344431|No Intervention|Non-HBO group|
33414326|NCT05709080|Experimental|family-professional collaboration practice model|"Physical therapists in the family-professional collaboration practice model group will receive instructions in the collaborative intervention, following the process and the strategies of the family-professional collaboration practice model to enhance the collaboration during physical therapy sessions.~The instruction conducted online in two sessions for six hours (3 hours per session).~the therapists in this group will treat the children according to steps of family-professional collaboration practice model: Step 1: Mutually agreed-upon goals, Step 2: shared planning, Step 3:Shared implementation, and Step 4: Shared evaluation of child and family outcomes."
33414327|NCT05709080|No Intervention|conventional therapy|"Physical therapists in the conventional therapy group will not receive any instructions related to the collaborative intervention process.~the therapists in this group will treat the children as conventional therapy"
33414328|NCT05184127|Experimental|MIR 19 ®|Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
33414329|NCT05184127|Active Comparator|Standard COVID-19 therapy|In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
33414330|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
33105211|NCT02899364|Placebo Comparator|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
33105212|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
33105213|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
33414331|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
33414332|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
33414333|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
33414334|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
33414335|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
33414336|NCT04328129|Experimental|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
32864473|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
32864474|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
32864475|NCT03045354|Experimental|French fries|Eggs with a side of French fries
32864476|NCT03045354|Experimental|Beans|Eggs with a side of beans
32864477|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
32864478|NCT03045354|Experimental|Breakfast skipping|No breakfast
32864479|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
32864480|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
32864481|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
32864482|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
32864483|NCT04872816|Experimental|Continuous airway positive pressure|All participants in continuous airway positive pressure arm will use CPAP (model S10-Resmed®) with expiratory relief and nasal mask.
32864484|NCT04872816|Sham Comparator|SHAM continuous airway positive pressure|Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
32864485|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
32864486|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
32864487|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
32864488|NCT00588211||4|Queens Hospital Center with 800 patients.
32864489|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
32864490|NCT04862598|No Intervention|Control|The patient will be positioned on the operating table and have routine monitoring attached (ECG, blood pressure, O2 saturations, end tidal carbon dioxide monitoring (ETCO2). A surgical safety time out will be performed. The patient will receive routine operative and nursing care. The study team member will record highest and lowest heart rate and blood pressure as well as lowest O2 saturation and the total intra-operative dose of fentanyl and midazolam administered to the patient. At the end of the procedure, the patient is assisted into a wheelchair and will return to the recovery area. After 15 minutes of recovery, a member of the study team will give them the post-operative questionnaires which will consist of answering how anxious they felt during the procedure and the 11 question Iowa Satisfaction with Anesthesia scale (ISAS). The patient will then be free to leave once they have met the standard discharge criteria.
32864491|NCT04862598|Experimental|VR Group|The patient wears the VR headset after being positioned on the table and the surgical time out has been completed. The VR scene and accompanying music will continue until the end of the procedure or until the patient wishes for it to be removed. The patient will receive standard operative and nursing care. The study team member will record the intra-operative vitals as detailed in the control group procedure. At the end of the procedure, the patient will be moved to recovery and will receive standard care. At 15 minutes, they will be provided with the anxiety questionnaire and the ISAS. Additional questions will be asked; their level of VR immersion and if they would like to receive the VR technology again if they were to undergo another procedure in the future. They will then be free to leave once they have met the standard discharge criteria.
32864492|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
32864493|NCT00580489|Active Comparator|Arm C Morphine|Morphine given to trauma patients transported by helicopter
32864494|NCT00580489|Active Comparator|Arm D Fentanyl|Fentanyl given to trauma patients transported by helicopter
32864495|NCT04872504|Experimental|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen
32864496|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
32864497|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
32864498|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
32864499|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
32864500|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
32864501|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
32864502|NCT01652833||Round 1|survey of 150 oncologists
32864503|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
32864504|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
32864505|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
32864506|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
32864507|NCT01453907|Sham Comparator|placebo|
32864508|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
32864509|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
32996025|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
33414337|NCT04328129|Experimental|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
33414338|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
33414339|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
33414340|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
33414341|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
33414342|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
33414343|NCT04266665|Active Comparator|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
33414344|NCT04266665|Placebo Comparator|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
33414345|NCT05182021||Case group|The case group represented by 50 primigravida women aged 35 y or more during their pregnancy or at the time of delivery
33414346|NCT05182021||Control group|The control group represented by 50 primigravida women aged 20 y : 34 y during their pregnancy or at the time of delivery
33414347|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
33414348|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
33414349|NCT01338311|Active Comparator|salbutamol|
33414350|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
33414351|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
33414352|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
33414353|NCT00501800||Caucasian|
33414354|NCT00501800||African American|
33414355|NCT00501800||Chinese|
33414356|NCT00501800||Latina (Mexican or Central American)|
33414357|NCT00501800||Filipina|
33105214|NCT04206865|Experimental|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
33414358|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
33414359|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
33414360|NCT05354492|Experimental|Active Program Participant|You will actively take part in the group program via Zoom with our program facilitators.
33414361|NCT05354492|No Intervention|Program Wait List|You will be placed on a wait list to take part in the program.
33414362|NCT01315717||Group 1|Healthy subjects
33414363|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
33414364|NCT01315717||Group 3|Patients with Mild AD
33414365|NCT01315717||Group 4|Patients with Moderate AD
33414366|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
33414367|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
33414368|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
33414369|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
33414370|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
33414371|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
33414372|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
33414373|NCT05181943|Experimental|Laser irradiation (Test group)|laser irradiation over lesion
33414374|NCT05181943|Active Comparator|Conventional treatment (Control group|
33414375|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
33414376|NCT01340443||Cohort|
33414377|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
33414378|NCT05184049|Experimental|Epalrestat|oral epalrestat (50mg/ time, 3 times/day) + conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
33414379|NCT05184049|Experimental|The control group|conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
33414380|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:~NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
33414381|NCT03570086||migraineurs without aura|
32996026|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
32996027|NCT01591850|Experimental|1 Ketoconazole DDI|
32996028|NCT01591850|Experimental|2 Rifampicin DDI|
32996029|NCT01591850|Experimental|3 ATZ/r DDI|
33414382|NCT03570086||health controls|
33414383|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
32996030|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
32996031|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
32996032|NCT01591889|Active Comparator|tindamax|500 mg tablet
32996033|NCT01591889|Active Comparator|tinidazole|500 mg tablet
33414384|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
33414385|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
32996034|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
32996035|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
32996036|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
32996037|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
32996038|NCT01591915|No Intervention|Standard care|
32996039|NCT01591928||Infants with heterotaxy syndrome|
32996040|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
32996041|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
32996042|NCT01591967|No Intervention|Control|Control -- no intervention
32996043|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
32996044|NCT01591967|Experimental|Activator treatment|Treatment with Activator
32996045|NCT01591980|Experimental|Pregabalin 100 mg|
32996046|NCT01591980|Experimental|pregabalin 150 mg|
32996047|NCT01591980|Sham Comparator|Placebo|
32996048|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
32996049|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
32996050|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
32996051|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
32996052|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
32996053|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
32996054|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
32996055|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
32996056|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
32996057|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
32996058|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
32996059|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
32996060|NCT01592123||The participants with septal deviation|
32996061|NCT01592149||Group 1|
32996062|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
32996063|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
32996064|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
32996065|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
32996066|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
32996067|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
32996068|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
32996069|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
32996070|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
32996071|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
32996072|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
32996073|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
32996074|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
32996075|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
32996076|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
32996077|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
32996078|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
32996079|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
32996080|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
32996081|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
32996082|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
32996083|NCT01592266||AML|patients with AML prior and after treatment
32996084|NCT01592279|Experimental|liraglutide|
32996085|NCT01592279|Active Comparator|Insulin injections|
32996086|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
32996087|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
32996088|NCT01592305|Experimental|S2 P1 ATZ/r|
32996089|NCT01592318|Active Comparator|DNV + r reference|
32996090|NCT01592318|Experimental|DNV/r fixed dose combination|
32996091|NCT01592331|Placebo Comparator|Placebo|
32996092|NCT01592331|Experimental|RO5508887|
32996093|NCT01592357|Experimental|Tai Chi|
32996094|NCT01592357|Sham Comparator|Sham Exercise|
32996095|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
32996096|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
32996097|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
32996098|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
32996099|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
32996100|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
32996101|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
32996102|NCT01592513|No Intervention|Control|
32996103|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
32996104|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
33414386|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
32996105|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
32996106|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
32996107|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
32996108|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
32996109|NCT01592539||Control|Age and sex matched healthy controls.
32996110|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
32996111|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
32996112|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
32996113|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
32996114|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
32996115|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
32996116|NCT01592617|Experimental|S-488410|
32996117|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
32996118|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
32996119|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
32996120|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
32996121|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
32996122|NCT01592669|No Intervention|control|supine baseline position
32996123|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
32996124|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
32996125|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
32996126|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
32996127|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
32996128|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
32996129|NCT01592890|Experimental|[14C]-labeled RO4917523|
32996130|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
32996131|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
32996132|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
33414387|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~4 days per week of MICT for 50 minutes per session~1 day per week of HIIT for 35 minutes per session~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
32996133|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
32996134|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
32996135|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
32996136|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
32996137|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
32996138|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
32996139|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
32996140|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
32996141|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
32996142|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
32996143|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
32996144|NCT01593033|Experimental|Micronutrient Supplementation|
33414388|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT~5 days per week of MICT for 50 minutes per session~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
32996145|NCT01593033|Placebo Comparator|Placebo|
32996146|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
32996147|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
32996148|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
32996149|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
32996150|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
32996151|NCT01593059||Orsiro DES|
32996152|NCT01593072|Active Comparator|AVI-7537|AVI-7537
32996153|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
32996154|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
32996155|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
32996156|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
32996157|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
32996158|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
32996159|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
32996160|NCT01593137|Experimental|Liraglutide + metformin|
32996161|NCT01593137|Active Comparator|glimepiride + metformin|
33414389|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
32996162|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
32996163|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
32996164|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
32996165|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
32996166|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
32996167|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
32996168|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
32996169|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
32996170|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
32996171|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
32996172|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
32996173|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
32996174|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
32996175|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
32996176|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
32996177|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
32996178|NCT01593319|Active Comparator|ropivacaine|
33105215|NCT04206865|Active Comparator|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
33105216|NCT02899247|Experimental|No Surface Sealant|Resin composite only
33105217|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
33105218|NCT02899403|Experimental|healthy subjects|
33105219|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
33324901|NCT05120466|Experimental|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
33105220|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
33105221|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
33105222|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
33105223|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
33105224|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
33105225|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
33105226|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
33105227|NCT04684290|Active Comparator|Alcohol Septal Ablation|
33105228|NCT04684290|Active Comparator|Surgical Septal Myectomy|
33105229|NCT02899520|Active Comparator|Group A|Reference method
33105230|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
33105231|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
33105232|NCT00535197|Experimental|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
32904000|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.~Multimodal peripheral nerve block injection."
32904001|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
32904002|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
32904003|NCT00719576|Active Comparator|Microfracture|Microfracture
32904004|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
32904005|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
32904006|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
32904007|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
32904008|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
32904009|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
32904010|NCT01272206|Experimental|A|
32904011|NCT01272206|Experimental|B|
32904012|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
32904013|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
32904014|NCT04385810|Experimental|Ophthalmologic exam|
32904015|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~500 mg IM on Day 1~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
32904016|NCT04385186|Experimental|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
32864510|NCT04391543|Experimental|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :~comprehensive interview~cognitive tests~anthropometric measures~postural balance test~critical force test~Astrand-Ryhming test~self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~actimetry~clinical and biological characteristics~determination of inflammatory markers~skeletal muscle index"
32864511|NCT04391387|Active Comparator|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
32864512|NCT04391387|Experimental|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
32864513|NCT04391231|Experimental|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
32864514|NCT04391231|Placebo Comparator|Placebo Arm|Placebo (SyrSpend SF only)
32864515|NCT04867356|Active Comparator|Spinal Stabilization Exercises (SSE)|
32864516|NCT04867356|Experimental|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|
32864517|NCT01453985|Experimental|Full-Thickness-Gastroplication|
32864518|NCT04861974||Robotic Distal Pancreatectomy|
32864519|NCT04861974||Laparoscopic Distal Pancreatectomy|
32864520|NCT04861974||Robotic Gastrectomy|
32864521|NCT04861974||Laparoscopic Gastrectomy|
32864522|NCT04861974||Robotic Funduplication|
32864523|NCT04861974||Laparoscopic Funduplication|
32864524|NCT04861974||Robotic Hernioplasty|
32864525|NCT04861974||Laparoscopic Hernioplasty|
32864526|NCT04861974||Robotic Rectal Resection|
32864527|NCT04861974||Laparoscopic Rectal Resection|
32864528|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
32864529|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
32864530|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
32864531|NCT04872270|Active Comparator|Caffeine Group|2 week supply of 100mg caffeine + aspirin 325mg + standard pain regimen (experimental)
32864532|NCT04872270|Active Comparator|No Caffeine Group|aspirin 325mg + standard pain (control)
32864533|NCT04861506||acute or subacute thromboembolic occlusions of lower extremity|The patients are confirmed with acute or subacute thromboembolic occlusions of lower extremity, and which are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as PMT pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
32864534|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
32864535|NCT04872192|Active Comparator|transversus|patients received transversus thoracic muscle plane block and injection of 15 ml bupivacaine 0.25% on each side.
32864536|NCT04872192|Sham Comparator|general anaesthesia group|the same bilateral technique was done on both sides and 15 ml saline was injected during each side of TTPB technique.
32864537|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
32864538|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
32864539|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
32864540|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
32864541|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
32864542|NCT04872114|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
32864543|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
32864544|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
32864545|NCT01454765||Sperm sample from healthy volunteers|
32864546|NCT03042234|Experimental|Group Insulin-resistant|Insulin-resistant obese adolescents
32864547|NCT03042234|Experimental|Group Insulin-sensitive|Insulin-sensitive obese adolescents
32864548|NCT00518167|Experimental|1|Intensive lifestyle intervention
32864549|NCT00518167|No Intervention|2|Standard counselling at baseline
32864550|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
32864551|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
32864552|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
32996179|NCT01593319|Placebo Comparator|Natrium chloride|
32996180|NCT01593332|Active Comparator|Rituximab|
32996181|NCT01593332|Active Comparator|Methotrexate|
32996182|NCT01593345|Experimental|Mentor|
32996183|NCT01593345|Active Comparator|Guidebook|
32996184|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
32996185|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
33414390|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
32996186|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
32996187|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
32996188|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
32996189|NCT01593423|Active Comparator|plant-based Homestead Food Production|
32996190|NCT01593423|Sham Comparator|Control|
32996191|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
32996192|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
32996193|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
32996194|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
32996195|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
32996196|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
32996197|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
32996198|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
32996199|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
32996200|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
32996201|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
32996202|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
32996203|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
32996204|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
32996205|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
32996206|NCT01593540|Experimental|metal-free interdental brushes.|
32996207|NCT01593540|Active Comparator|metal-core interdental brushes|
32996208|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
32996209|NCT01593553|No Intervention|Control group|Standard of care
32996210|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
32996211|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
32996212|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
32996213|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
32996214|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
32996215|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
32996216|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
32996217|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
32996218|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
32996219|NCT01593631|Active Comparator|3300 FCC acid lactase|
32996220|NCT01593631|Active Comparator|9000 FCC acid lactase|
32996221|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
32996222|NCT01593631|Placebo Comparator|Placebo|
32996223|NCT01593644|Experimental|adenosine + dypiridamole|
32996224|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
32996225|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
32996226|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
32996227|NCT01593709||Cohort 1|Healthy adults; age 18 or older
32996228|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
32996229|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
32996230|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
32996231|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
32996232|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
32996233|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
32996234|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
32996235|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
32996236|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
32996237|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
32996238|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
32996239|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
32996240|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
32996241|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
32996242|NCT01593826|Active Comparator|Symbicort Turbuhaler|
32996243|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
32996244|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
32996245|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
32996246|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
32996247|NCT01593878|Experimental|TV|Test taken with TV on
32996248|NCT01593878|No Intervention|Control|test taken in quiet
32996249|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
32996250|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
32996251|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
32996252|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
32996253|NCT01593943|No Intervention|Control Condition|
32996254|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
32996255|NCT01593956|Other|Concussed athletes|
32996256|NCT01593956|Other|Healthy controls|
33414391|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
32996257|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
32996258|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
32996259|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
32996260|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
32996261|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
32996262|NCT01593995|Experimental|EGF ointment|
32996263|NCT01594021|Experimental|High pre-emptive volume loading|
32996264|NCT01594021|Active Comparator|Low pre-emptive volume loading|
32996265|NCT01594034||no treatment|
32996266|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
32996267|NCT01594047|Experimental|ketamine/morphine|patients received a balance anaesthesia supplemented by low dose of ketamine and Morphine by PCA device for postoperative pain
32996268|NCT01594047|Experimental|zero/metadone|patients received a standard balance anaesthesia and methadone by PCA device for postoperative pain
32996269|NCT01594047|Experimental|ketamine/methadone|Patients received a balance anaesthesia supplemented with low dose of ketamine and Methadone by PCA device for postoperative pain
32996270|NCT01594060|Active Comparator|sliding scale|
32996271|NCT01594060|Active Comparator|basal bolus|
32996272|NCT01594086|Experimental|green tea powder|Natural green tea powder
32996273|NCT01594099|Active Comparator|Radiotherapy alone|
32996274|NCT01594099|Experimental|Radiotherapy plus cisplatin|
32996275|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
32996276|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
32996277|NCT01594138||Suicidal Subjects|Suicidal Subjects
32996278|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
32996279|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
32996280|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
32996281|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
32996282|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
32996283|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
32996284|NCT01594242|Experimental|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
32996285|NCT01594255|Experimental|AEB071 300 mg|
32996286|NCT01594255|Experimental|AEB071 900 mg|
32996287|NCT01594255|Placebo Comparator|Placebo to AEB071|
32996288|NCT01594255|Active Comparator|Moxifloxacin|
32996289|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
32996290|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
32996291|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
32996292|NCT01594320|Experimental|Group A|
32996293|NCT01594320|Experimental|Group B|
32996294|NCT01594320|Experimental|Group C|
32996295|NCT01594320|Experimental|Group D|
32996296|NCT01594320|Experimental|Group E|
32996297|NCT01594320|Experimental|Group F|
32996298|NCT01594346|Placebo Comparator|Sugar Pill|
32996299|NCT01594346|Active Comparator|Alpha-Tocopherol|
32996300|NCT01594359|Active Comparator|High iron bean|High-iron bean
32996301|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
32996302|NCT01594437|Experimental|TCN-202|
32996303|NCT01594437|Placebo Comparator|Placebo|
32996304|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
32996305|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
32996306|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
32996307|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
32996308|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
32996309|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
32996310|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
32996311|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
33414392|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
33414393|NCT05187481|Experimental|Experimental Group|The experimental group will take Jianpi Huatan dispensing granule while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
32996312|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
32996313|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
32996314|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
32996315|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
32996316|NCT01594541||Patients Treated with CerefolinNAC®|
32996317|NCT01594541||Patients Not Treated with CerefolinNAC®|
32996318|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
32996319|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
32996320|NCT01594593|No Intervention|treatment as usual|
32996321|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
32996322|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
32996323|NCT01594619|Experimental|A|Single dose naloxegol 25mg
32996324|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
32996325|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
32996326|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
32996327|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
32996328|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
32996329|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
32996330|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
32996331|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
32996332|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
32996333|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
32996334|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
32996335|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
32996336|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
32996337|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
32996338|NCT01594697|Experimental|metformin|
32996339|NCT01594710||Apparently Health People|
32996340|NCT01594736|Active Comparator|ORSIRO|
32996341|NCT01594736|Active Comparator|XIENCE PRIME DES|
32996342|NCT01594775|Active Comparator|nasal spray|
32996343|NCT01594775|Placebo Comparator|Placebo|
32996344|NCT01594801|No Intervention|Control|Subject continue their routine therapy
32996345|NCT01594801|Experimental|Test|Subjects using the InsuPad device
32996346|NCT01594814||RFA of AVNRT of AVRT|
32996347|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
32996348|NCT01594840|Active Comparator|Control|Normal diapers
32996349|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
32996350|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
32996351|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
32996352|NCT01594892|Experimental|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
32996353|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
32996354|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
32996355|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
32996356|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
32996357|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
32996358|NCT01594996||Seroquel XR group|
32996359|NCT01595009|Experimental|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
32996360|NCT01595022|Placebo Comparator|Flexi ring FR01|
32996361|NCT01595022|Placebo Comparator|Flexi ring FR20|
32996362|NCT01595022|Placebo Comparator|Ultra low dose LCS|
32996363|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
32996364|NCT01595035|No Intervention|Control|Standard care
32996365|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
33324902|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
32996366|NCT01595087|Experimental|Osteodex, infusion|Osteodex
32996367|NCT01595126||Patients with Central Nervous System Tumors|
32996368|NCT01595139||NF-1 without evidence of glioma|
32996369|NCT01595139||NF-1 with evidence of glioma|
32996370|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
32996371|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
32996372|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
32996373|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
32996374|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
32996375|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
32996376|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
32996377|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
32996378|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
32996379|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
32996380|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
32996381|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
32996382|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
32996383|NCT01595256|Experimental|walking group|
32996384|NCT01595256|No Intervention|usual care|
32996385|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
32996386|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
32996387|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
32996388|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
32996389|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
33033637|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
32996390|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
32996391|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
32996392|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
32996393|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
32996394|NCT01595360|Placebo Comparator|Placebo|Placebo
32996395|NCT01595360|Experimental|TT-173|TT-173
32996396|NCT01595373|Active Comparator|Ghrelin|Ghrelin
32996397|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
32996398|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
32996399|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
32996400|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
32996401|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
32996402|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
32996403|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
32996404|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
32996405|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
32996406|NCT01595464|Experimental|Mind-Body Skills Groups|
32996407|NCT01595464|No Intervention|Control Group|
32996408|NCT01595477|Experimental|Mind-Body Skills Groups|
32996409|NCT01595477|No Intervention|Control Group|
32996410|NCT01595490|Experimental|Mind-Body Skills Groups|
32996411|NCT01595490|No Intervention|Control Group|
32996412|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
32996413|NCT01595542|No Intervention|Control|Did not receive intervention materials
32996414|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
32996415|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
32996416|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
32996417|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
32996418|NCT01595594|Active Comparator|Systemic Doxycycline|
32996419|NCT01595594|Experimental|aPDT+ Placebo|
32996420|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
32996421|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
32996422|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
32996423|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
32996424|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
32996425|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
32996426|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
32996427|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
32996428|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
32996429|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
32996430|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
32996431|NCT01595698|Sham Comparator|Control|
32996432|NCT01595698|Experimental|Physical Exercise|
32996433|NCT01595711||Thoracotomized patients|
32996434|NCT01595724||Group 1|
32996435|NCT01595737|Experimental|Levosimendan|
32996436|NCT01595737|Placebo Comparator|Placebo|
32996437|NCT01595750|Placebo Comparator|Placebo|
33414394|NCT05187481|Placebo Comparator|Control Group|The experimental group will take Placebo granule (containing 1/10 of the formula dose of Jianpi Huatan Granule) while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
33414395|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
33414396|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
33414397|NCT00383435|Experimental|MF MDI 400 mcg BID|
33414398|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
33414399|NCT00383435|Placebo Comparator|Placebo MDI BID|
33414400|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
33414401|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
33414402|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
33414403|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
33414404|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
33414405|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
33414406|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
32996438|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
32996439|NCT01595763||Deep Vein Thromobosis signs or symptoms|
33414407|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
33414408|NCT01335035|Experimental|ICL670|
33414409|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
33414410|NCT05164315|Experimental|Tailored surgery|Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
33414411|NCT05164315|Active Comparator|Total mesorectal excision (TME)|Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
33414412|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
33414413|NCT05183815|Experimental|massage|
33414414|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
33414415|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
33414416|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
33414417|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
33414418|NCT05164003|Experimental|CORETOX®|
33414419|NCT05164003|Active Comparator|BOTOX®|
33414420|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 1200 mg, 1200 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 1200 mg, 1200 mg) during daily therapy with 2NRTIs for 12 weeks
33414421|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 900 mg, 900 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 900 mg, 900 mg) during daily therapy with 2NRTIs for 12 weeks
33414422|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 600 mg, 600 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 600 mg, 600 mg) during daily therapy with 2NRTIs for 12 weeks
32996440|NCT01595776|Experimental|single arm: autologous EPCs|
32996441|NCT01595789|Placebo Comparator|Placebo + metformin|
32996442|NCT01595789|Active Comparator|Liraglutide + metformin|
32996443|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
32996444|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
33414423|NCT05163535|Other|ELPIDA®|ELPIDA®, 20 mg capsules and 2NRTIs, daily therapy for 12 weeks
33414424|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
33414425|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
33414426|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
33414427|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
32996445|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
32996446|NCT01595867|Placebo Comparator|Treatment A|Placebo
32996447|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
32996448|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
32996449|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
33324903|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
33324904|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
32996450|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
32996451|NCT01595893|Experimental|Vitamin D3|
32996452|NCT01595893|Placebo Comparator|Placebo|
33033638|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
33324905|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
33324906|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.~Participants will receive at least 1 LDCT scan at baseline."
33324907|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
33324908|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
33324909|NCT05632380|Experimental|ASCT and C-CAR088|Patients will undergo ASCT followed by C-CAR088 single dose infusion.
33324910|NCT01237158||healthy controls|
33324911|NCT01237158||bipolar disorder type I|
33324912|NCT01144260|Experimental|Bafetinib|
33324913|NCT05667558||Study grup|
33324914|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
33324915|NCT01235988||Eltrombopag & standard of care|
33324916|NCT01235988||Standard of care|
33324917|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
33324918|NCT01237236|Experimental|LEE011|
33324919|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
33324920|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
33324921|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
33324922|NCT05631366|Active Comparator|Spaced AAT|AAT-S participants will receive 4 AAT sessions totalling 1200 trails but spaced out over four weeks (one AAT session per week)
33324923|NCT05631366|Active Comparator|Massed AAT|AAT-M participants will receive 4 AAT sessions (each with 300 trials) within the space of 8 days (which totals 1200 trails).
33324924|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
33324925|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
33324926|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
33324927|NCT00251927|Active Comparator|1|Surgery
33324928|NCT00251927|Experimental|2|Esomeprazole (NEXIUM) therapy
33324929|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
33324930|NCT01237392|Active Comparator|Standard Sharp Debridement|
33324931|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
33324932|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
33324933|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
33324934|NCT03971201|Experimental|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
33324935|NCT03971201|Active Comparator|sorafenib only|sorafenib only
33324936|NCT01236144|Experimental|AC220 Intervention|
33324937|NCT01236144|Experimental|Plerixafor Intervention|
33324938|NCT01236144|Experimental|Ganetespib|
33324939|NCT03971435||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360)
33324940|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
33324941|NCT04935762|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
33324942|NCT04935762|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 and matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
32864553|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
32864554|NCT04429776|Experimental|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
32864555|NCT04429776|Active Comparator|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
32864556|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
32864557|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
32864558|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
32864559|NCT04867200|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
32864560|NCT04867200|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
32864561|NCT01455077||Obese patients|BMI > 35
32864562|NCT00505063|Other|A|Immunization Schedule patients <7 years.
32864563|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
32864564|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
32864565|NCT00473941|Experimental|1|Writing in a journal 15 minutes a day
32864566|NCT00473941|Placebo Comparator|2|Control Writing in a journal 15 minutes a day
32864567|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
32864568|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
32864569|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
32864570|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
32864571|NCT01455623||Health Care Provider|A person working within the field of CMT.
32864572|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
32864573|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
32864574|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines~Permissive Hypertension up to 220~Antipletelets therapy:~ASA 81 mg PO daily or~Plavix 75 mg PO daily or~Aggrenox 225mg PO twice daily~Anti-inflammatory therapy:~Lipitor 80 mg PO daily or~Crestor 20 mg PO daily"
32864575|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
32864576|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
32864577|NCT01456091|Experimental|AIM 4 Teen Moms|
32864578|NCT01456091|No Intervention|Control|
32864579|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
32864580|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
32864581|NCT01456247|Experimental|TAK-438 10 mg QD|
32864582|NCT01456247|Experimental|TAK-438 20 mg QD|
32864583|NCT01456247|Active Comparator|AG-1749 15 mg QD|
32864584|NCT00452023|Experimental|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week.
32864585|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
32864586|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
32864587|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
32864588|NCT05053867|Experimental|Group A: Inhaled tranexamic acid|will receive 500 mg/5ml nebulized tranexamic acid every 8 hours for at least 3 days, and up to 5 days
32864589|NCT05053867|Other|Group B: Usual Care|usual care
32864590|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
32864591|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
32864592|NCT01598935|Placebo Comparator|Control|placebo
33414428|NCT01336777||Insulin resistant group|there is no intervention
33414429|NCT01336777||Insulin sensitive group|There is no intervention
32996453|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~Three consecutive days including 3 scenarios:~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
32996454|NCT01595919|Experimental|1% Milk|
32996455|NCT01595919|Experimental|Regular Cola|
32996456|NCT01595919|Experimental|Diet cola|
32996457|NCT01595919|Experimental|Orange juice|
32996458|NCT01595919|Placebo Comparator|Water|
32996459|NCT01595932|Placebo Comparator|placebo|
32996460|NCT01595932|Experimental|α-galactosidase|
32996461|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
32996462|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
32996463|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
32996464|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
32996465|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
32996466|NCT01595971|Placebo Comparator|Usual Care|usual care
32996467|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
32996468|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
32996469|NCT01595997|Placebo Comparator|Placebo|
32996470|NCT01595997|Experimental|DLX105|
32996471|NCT01596010|Experimental|New formulation|
32996472|NCT01596010|Active Comparator|Old formulation|
32996473|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
32996474|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
32996475|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
32996476|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
32996477|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
32996478|NCT01596101||acute burns|
32996479|NCT01596101||rehab patients|
32996480|NCT01596114|Experimental|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
32996481|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
32996482|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
32996483|NCT01596153|Placebo Comparator|Placebo|BID
32996484|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
32996485|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Ketorolac 0.5 mg/kg (max 30 mg) IV"
32996486|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Placebo (normal saline)"
32996487|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
32996488|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
32996489|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
33105233|NCT04684407|Active Comparator|calcium hydroxide|calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication
33414430|NCT04434209|Experimental|NephroCheck-guided interventions|
33414431|NCT04434209|Active Comparator|Standard of Care|Standard of Care assessment and treatment
33414432|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
33414433|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
33414434|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
32864593|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
32864594|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
32864595|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
32864596|NCT04866732|Experimental|Needs assessment and feasibility group|Based on our target population's needs/preferences, an existing Physical Activity (PA) program will be modified and tailored to the needs of the target population. We anticipate that this PA program will include the following components: a) PA component - ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to CVD risk factors prevention; c) daily diary to record if they are facing any barriers in completing various components of the intervention; d) problem-solving sessions
32864597|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
32864598|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
32864599|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
32864600|NCT04866498||Analgosedation in ICU patients after head and neck tumor resection in general anesthesia|Head and neck tumor resections were performed in general anesthesia. Midazolam and etomidate or propofol were used in introduction and then anesthesia was maintenance with sevoflurane. Patients received intravenous continuous infusion of oxycodone as an analgesic component and sedatives (propofol/dexmedetomidine/midazolam) during analgosedation in ICU.
32864601|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
32864602|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
32864603|NCT04866654|Experimental|Study group|Nivolumab, total dose 5760 mg milligram
32864604|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
32864605|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
32864606|NCT01197625|Experimental|DC-vaccine|
32864607|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
32864608|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
32864609|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
32864610|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
32864611|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
32864612|NCT01546987|Active Comparator|ADT + GnRH agonist + dose escalated radiation|Patients receive standard androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).
32864613|NCT01546987|Experimental|ADT + GnRH agonist + dose escalated radiation + TAK-700|Patients receive the same standard ADT with a GnRH agonist and oral antiandrogen. In addition, patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.
32864614|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
32864615|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
32864616|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
32864617|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
32864618|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
32864619|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
32864620|NCT01456793|No Intervention|Usual care services|
32864621|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
32864622|NCT01457027|Experimental|All subjects|
32864623|NCT04866966|Experimental|Intervention Group|The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
32864624|NCT04866966|No Intervention|Control Group|The control group will have their measurements done at the beginning and end of the study. They will continue with usual medicare care during the study and will not receive any education from the investigators during the study. They will be offered the option of a delayed intervention after the completion of the study.
32864625|NCT01457105|Experimental|ComVi biliary stent|
32996490|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
32996491|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
32996492|NCT01596205|No Intervention|Control group|
32996493|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
32996494|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
32996495|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
32996496|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
32996497|NCT01596296|Active Comparator|Transcervical foley catheter|
33414435|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
32996498|NCT01596296|Active Comparator|Dinoprostone|
32996499|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
32996500|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
32996501|NCT01596322||UARTO|
32996502|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
32996503|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
32996504|NCT01596400|Experimental|Sancuso Arm|
32996505|NCT01596400|Active Comparator|IV Granisetron Arm|IV
32996506|NCT01596413|Experimental|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
32996507|NCT01596413|Active Comparator|IV Granisetron|"Aqueous solution for IV administration~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
32996508|NCT01596426|Experimental|Sancuso Arm|patch
32996509|NCT01596426|Active Comparator|IV granisetron|IV
32996510|NCT01596465|Active Comparator|Control|Control arm
32996511|NCT01596465|Active Comparator|Intervention|Intervention arm
32996512|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
32996513|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
32996514|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
32996515|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
32996516|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
32996517|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
32996518|NCT01596530|Active Comparator|AZD8931|AZD8931
32996519|NCT01596530|Placebo Comparator|Placebo|Placebo
32996520|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
32996521|NCT01596556|Experimental|smokers|This arm consists of smokers.
32996522|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
32996523|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
32996524|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
32996525|NCT01596608|Experimental|Magnetic Seizure Therapy|
32996526|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
32996527|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
32996528|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
32996529|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
33033639|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
33414436|NCT01338545||Cohort|
32996530|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
32996531|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
32996532|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
32996533|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
32996534|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
32996535|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
32996536|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
32996537|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
32996538|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
32996539|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
32996540|NCT01596725|Experimental|Group A|
32996541|NCT01596725|Experimental|Group B|
32996542|NCT01596725|Experimental|Group C|
32996543|NCT01596725|Experimental|Group D|
32996544|NCT01596725|Experimental|Group E|
32996545|NCT01596725|Experimental|Group F|
32996546|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
32996547|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
32996548|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
32996549|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
32996550|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
32996551|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
32996552|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
32996553|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
32996554|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
32996555|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
33105234|NCT04684407|Experimental|Triple antibiotic paste|"Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 .~TAP paste is combined with propylene glycol and placed as intra canal medication."
32996556|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
32996557|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
32996558|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
32996559|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
32996560|NCT01596816|Experimental|Boost by CyberKnife|
32996561|NCT01596816|Experimental|Boost by linear accelerator|
32996562|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
32996563|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
32996564|NCT01596855|Experimental|FG-4592|Active Drug
32996565|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
32996566|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
32996567|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
32996568|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
32996569|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
32996570|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
32996571|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
32996572|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
32996573|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
32996574|NCT01596920|Active Comparator|Grafix®|
32996575|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
32996576|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
32996577|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
32996578|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
32996579|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
32996580|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
32996581|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
32996582|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
33033640|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
33105235|NCT04942080|Experimental|CALRSUIVI cohort|
33414437|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
33414438|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
33414439|NCT01338623|Experimental|Tansulosine|
32996583|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
32996584|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
32996585|NCT01596998|Experimental|Levobupivacaine with epinephrine|
32996586|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
33414440|NCT01340833|Experimental|Study Medication|GSK2118436
32996587|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
32996588|NCT01597024|Experimental|Phase 1: Breakfast Study|
32996589|NCT01597024|Experimental|Phase 2: fMRI Study|
32996590|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
32996591|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
32996592|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
32996593|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
32996594|NCT01597063||low risk pregnancies|
32996595|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
32996596|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
32996597|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
32996598|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
32996599|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
32996600|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
32996601|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
32996602|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
32996603|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
32996604|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
32996605|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
32996606|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
32996607|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
32996608|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
32996609|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
32996610|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
32996611|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
32996612|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
32996613|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
32996614|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
32996615|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
32996616|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
32996617|NCT01597362|Other|Veress needle technique|
32996618|NCT01597362|Other|Direct trocar technique|
32996619|NCT01597362|Other|Open technique|
32996620|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
33105236|NCT00548730||Observation|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy
33414441|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
32996621|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
32996622|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
32996623|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
32996624|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
32996625|NCT01597453|Other|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
32996626|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
32996627|NCT01597466|Active Comparator|Loss of resistance technique|
32996628|NCT01597518|Experimental|Riluzole|
32996629|NCT01597518|Placebo Comparator|Placebo|
32996630|NCT01597531|Active Comparator|Liraglutide only|
32996631|NCT01597531|Active Comparator|Orlistat only|
32996632|NCT01597531|Active Comparator|Liraglutide + Orlistat|
32996633|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
32996634|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
32996635|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
32996636|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
32996637|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
32996638|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
32996639|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
32996640|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
32996641|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
32996642|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
32996643|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
32996644|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
32996645|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
32996646|NCT01597713|Experimental|Part 2, cross-over|
32996647|NCT01597726|Active Comparator|Misoprostol|
32996648|NCT01597726|Experimental|Laminaria|
32996649|NCT01597739|Experimental|JNJ-40346527|
32996650|NCT01597739|Placebo Comparator|Placebo|
32996651|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
32996652|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
32996653|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
32996654|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
32996655|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
32864626|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
32864627|NCT04861662|No Intervention|Keratinized Mucosa Sufficient (KMS)|Implants exhibiting the width of keratinized mucosa (KM) ≥2 mm at the midbuccal aspect
32864628|NCT04861662|No Intervention|Keratinized Mucosa Deficient (KMD)|Implants exhibiting KM<2 mm at the midbuccal aspect
32864629|NCT04861662|Experimental|Free Gingival Graft (FGG)|Implants with KM<2 mm initially and having surgically increased keratinized mucosa with free gingival graft after prothesis delivery
32864630|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
32864631|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
32864632|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
32864633|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
32864634|NCT04778293|Experimental|Experimental Group|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized (random.org), in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
32864635|NCT04778293|No Intervention|Control Group|No intervention
32864636|NCT01457495|Experimental|DTPa 1 Group|
32864637|NCT01457495|Active Comparator|DTPa 2 Group|
32864638|NCT04861194|Experimental|Neurovascular-sparing 5x7.25 Gy MRgRT|MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb
32864639|NCT04778137|Experimental|CMAB007|75mg×2
32864640|NCT04778137|Active Comparator|Xolair|150mg
32864641|NCT04778215|Experimental|Intervention group|progressive, 8 week lumbar stabilizing program
32864642|NCT04778215|No Intervention|Control group|Continue as usual
32864643|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
32864644|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
32864645|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
32864646|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
32864647|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
32864648|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
32864649|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
32864650|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
32864651|NCT03815929|Active Comparator|Standard replacement therapy regimen|100 mcg transdermal estradiol patch (or equivalent oral dose)
32864652|NCT03815929|Active Comparator|Titrated replacement therapy regimen|Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level
32864653|NCT03815929|No Intervention|Timed Control Group|Healthy age-matched subjects not on hormone therapy
32864654|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
32864655|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
32864656|NCT01457807|Placebo Comparator|3|Placebo
32864657|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
32864658|NCT00401791|Experimental|1|
32864659|NCT00401791|No Intervention|2|
32864660|NCT01457963||pulmonary embolism, deep venous thrombosis|
32864661|NCT04858308|Active Comparator|Test Group|Take both YYC506 and Placebo(Control)
32864662|NCT04858308|Active Comparator|Control Group|Take both Contral and Placebo(YYC506)
32864663|NCT04391153|Active Comparator|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
32864664|NCT04391153|Active Comparator|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
32864665|NCT04391075||Exposed|Pudendal nerve block provided
32864666|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
32864667|NCT02893397|Experimental|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
32864668|NCT02893397|Experimental|Group II (fitbit)|Patients wear a fitbit.
32864669|NCT00394147|Experimental|Pemetrexed and gemcitabine|pemetrexed 500mg/m2 and gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
32864670|NCT01458041||Group 1|
32864671|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
32996656|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
32996657|NCT01597830|Experimental|active shoe|
33324943|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
33324944|NCT01329744|Experimental|Treatment|Recombinant IGF-I
33324945|NCT01329744|Placebo Comparator|Placebo|
33414442|NCT05162287||Patients who are treated in the acute ward of the child and adolescent psychiatry|All children and adolescents aged 12 to 18 years who are treated in the acute ward of the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics at the University Medical Center Hamburg-Eppendorf are recruited.
32864672|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
32864673|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
32864674|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
32864675|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
32864676|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
32864677|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
32864678|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
32864679|NCT01458197|Placebo Comparator|Placebo|Group 3
32864681|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
32864682|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
32864683|NCT04858464||Patients group|Individuals with primary Sjögren's syndrome
32864684|NCT05587049||Venetoclax + Azacitidine Participants|Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
32864685|NCT01896505|Experimental|Arm 1 - Treatment A, B, C, D|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 1, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D~(Note that recruitment has been completed for this arm)"
32864686|NCT01896505|Experimental|Arm 2 - Treatment B, A, D, C|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 2, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C~(Note that recruitment has been completed for this arm)"
32864687|NCT01896505|Experimental|Arm 3|"To evaluate tumor response in sarcoma patients (RECIST v1.1 criteria) on KCP-330.~(Note that recruitment has been completed for this arm)"
32864688|NCT01896505|Experimental|Arm 4 - Treatment A, B, C|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 4, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C"
32864689|NCT01896505|Experimental|Arm 5 - Treatment C, A, B|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 5, the following order will be utilized:~Week 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment B"
32864690|NCT01896505|Experimental|Arm 6 - Treatment B, C, A|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 6, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment C Week 3, day 1: Treatment A"
32864691|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
32864692|NCT01458509||Web EASP|Web Group with Nurse Intervention
32864693|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
32864694|NCT01458509||Web No EASP|Web Group without nurse intervention
32864695|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
32864696|NCT00332605|Placebo Comparator|Placebo|"Inactive placebo (sugar pill)"
32864697|NCT01458665|Experimental|PRP group|
32864698|NCT01458665|Placebo Comparator|Conventional group|
32864699|NCT01540071|Experimental|NRX 194204|This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
32864700|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
32996658|NCT01597830|Sham Comparator|Control|
32996659|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
32996660|NCT01597895|Active Comparator|Maraviroc|
32996661|NCT01597895|Experimental|Maraviroc + Boceprevir|
32996662|NCT01597895|Experimental|Maraviroc + Telaprevir|
32996663|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
32996664|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
32996665|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
32996666|NCT01597947|Experimental|Arm A|
32996667|NCT01597947|Placebo Comparator|Arm B|
32996668|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
32996669|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
32996670|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
32996671|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
32996672|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
32996673|NCT01598012|Placebo Comparator|placebo|
32996674|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
32996675|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
32996676|NCT01598077|Experimental|Dose escalation and dose expansion|
32996677|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
32996678|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
32996679|NCT01598155|Experimental|Supragingival biofilm control|
32996680|NCT01598155|Experimental|Supra- and subgingival biofilm control|
32996681|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
32996682|NCT01598181|Experimental|active tDCS|
32996683|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
32996684|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
32996685|NCT01598220|Placebo Comparator|attentional task|
32996686|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
32996687|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
32996688|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
32996689|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
32996690|NCT01598259|Placebo Comparator|placebo|
32996691|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
32996692|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
32996693|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
32996694|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
32996695|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
32996696|NCT01598337|Active Comparator|Aspirin alone|
32996697|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
32996698|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
32996699|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
32996700|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
32996701|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
32996702|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
32996703|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
32996704|NCT01598389|Experimental|Low energy-dense preload|
32996705|NCT01598389|Experimental|High energy-dense preload|
32996706|NCT01598389|Experimental|No preload|
32996707|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
33033641|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
33033642|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
32996708|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
32996709|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
32996710|NCT01598415|Placebo Comparator|Placebo|
32996711|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
32996712|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
32996713|NCT01598454|Experimental|Racotumomab|
32996714|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
32996715|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
32996716|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
32996717|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
32996718|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
32996719|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
32996720|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
32996721|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
32996722|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
32996723|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
32996724|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
32996725|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
32996726|NCT01598597||Cohort|
32996727|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
32996728|NCT01598623|Experimental|Oxytocin + Social Skills training|
32996729|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
32996730|NCT01598623|Experimental|Placebo + Social Skills Training|
32996731|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
32996732|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
32996733|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
32996734|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
32996735|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
32996736|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
32996737|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
32996738|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
32996739|NCT01598714|Other|Darco shoe|Darco walking shoe provided
32996740|NCT01598714|Other|Podalux Shoe|Podalus shoe
32996741|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
32996742|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
32996743|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
32996744|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
32996745|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
32996746|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
32996747|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
32996748|NCT01598857|Experimental|Blisibimod|
32996749|NCT01598857|Placebo Comparator|Placebo|
32996750|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
32996751|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
32996752|NCT01598883|Active Comparator|ACT after first intervention less than 450|
32996753|NCT01598909|Active Comparator|Arnica ointment|
32996754|NCT01598909|Placebo Comparator|Placebo ointment|
32996755|NCT01598909|No Intervention|Control|
32996756|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
32996757|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
32996758|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
32996759|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
32996760|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
32996761|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
32996762|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
32996763|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
32996764|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
32996765|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
32996766|NCT01599013|Other|Vinflunine plus Gemcitabine|
32996767|NCT01599013|Other|Vinflunine plus Carboplatin|
32996768|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
32996769|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
32996770|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
32996771|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
32996772|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
32996773|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
32996774|NCT01599065||Magnet|group treated by disabling ICD during procedure
32996775|NCT01599065||Off-On|Group having ICD turned off during the procedure
32996776|NCT01599078|Placebo Comparator|Placebo|
32996777|NCT01599078|Active Comparator|Paclitaxel|
32996778|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
32996779|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
32996780|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
32996781|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
32996782|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
32996783|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
32996784|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
32996785|NCT01599169|Experimental|B-Back® verum|
32996786|NCT01599169|Placebo Comparator|B-Back® placebo|
32996787|NCT01599182||High-Risk Prostate Cancer|
32996788|NCT01599182||Intermediate-Risk Prostate Cancer|
32996789|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
32996790|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
32996791|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
32996792|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
32996793|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
32996794|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
32996795|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
32996796|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
32996797|NCT01599247||Suicidal ideation/behavior|
33105237|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
33105238|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
33105239|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
33105240|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
33105241|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
33105242|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
33105243|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
33105244|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
33324946|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
33324947|NCT01745796||Intubated ICU patients|
33324948|NCT03971123|Experimental|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
33324949|NCT03971123|Experimental|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
33324950|NCT03971123|Experimental|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
33324951|NCT03971123|Experimental|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
32864701|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
32864702|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
32864703|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
32864704|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
32864705|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
32864706|NCT04346173|Experimental|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
32864707|NCT04777903||underweight woman with twin pregnancy|underweight (BMI < 18.5 kg/m2)
32864708|NCT04777903||normal weight woman with twin pregnancy|normal (BMI: 18.5-23.9 kg/m2)
32864709|NCT04777903||overweight and obese woman with twin pregnancy|overweight and obese (BMI ≥24 kg/m2)
32864710|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
32864711|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
32864712|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
32864713|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
32864714|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
32864715|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
32864716|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
32864717|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
32864718|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
32864719|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
32864720|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
32864721|NCT01417455||Controls|Healthy donors age and sex matched to the patients
32864722|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
32864723|NCT00198991|Experimental|All patients|All patients are treated upfront according to one arm
32864724|NCT01459289|Active Comparator|leaflet|
32864725|NCT01459289|Active Comparator|counseling|
32864726|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
32864727|NCT01540773|Placebo Comparator|Placebo|Non-Active
32864728|NCT01459367|Experimental|TAK-438 10 mg QD|
32864729|NCT01459367|Experimental|TAK-438 20 mg QD|
32864730|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
32864731|NCT04777825|Experimental|HRV biofeedback training|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist. This group of patients will also benefit from the HRV biofeedback training.
32864732|NCT04777825|Other|control|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist.
32864733|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
32864734|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
32996798|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
32996799|NCT01599273|Experimental|Triam inj|
32996800|NCT01599273|No Intervention|observation group|
32996801|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
32996802|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
32996803|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
32996804|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
32996805|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
32996806|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
32996807|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
32996808|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
32996809|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
32996810|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
32996811|NCT01599377|Experimental|Cohort 1|
32996812|NCT01599377|Experimental|Cohort 2|
32996813|NCT01599390||Influenza Group|
32996814|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
32996815|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
32996816|NCT01599403|Experimental|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
32996817|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
33324952|NCT03971123|Experimental|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
33324953|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
33324954|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
32996818|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
32996819|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
32996820|NCT05691231||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE study NCT03123549 and followed in the post-approval study NCT04980378.
32996821|NCT05691218|Active Comparator|Control - Standard Nebulization|
32996822|NCT05691218|Experimental|A-Vibrating mesh Nebulization|
32996823|NCT05691218|Experimental|B-Vibrating mesh Nebulization and High-flow nasal cannula heated and humidified oxygen|
32996824|NCT05691205|Experimental|PEEP-LuTX|Within 48h after LuTX we will evaluate the effects of three levels of PEEP (14>10>6 cmH2O) upon: - lung and chest wall mechanics, - intrapulmonary shunt fraction; - distribution of ventilation and perfusion; - gas exchange.
32996825|NCT05691153|Experimental|Dose Level 1|ThisCART19A，2×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
32996826|NCT05691153|Experimental|Dose Level 2|ThisCART19A，3×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
32996827|NCT05691140|Experimental|Cognitive Behavioural Therapy|
32996828|NCT05691140|No Intervention|Treatment as Usual|
32996829|NCT05691088|Experimental|Group A|Paracetamol injection
32996830|NCT05691088|No Intervention|Group B|Equivalent physiological saline
32996831|NCT05691075||Metatarsophalangeal arthrodesis of the hallux with large diameter screws|Patient who can benefit from first-line arthrodesis using large-diameter screws
32996832|NCT05691075||Metatarsophalangeal arthrodesis of the hallux by plate|Patient who can benefit from a first intention arthrodesis by dorsal plate
32996833|NCT05691062|Experimental|PEEK|Medtronic Capstone
32996834|NCT05691062|Experimental|Titanium|Medtronic Adaptix
32996835|NCT05691049|Experimental|Profhilo® Structura treatment group|"Treatment of acne scars of the face by using a subcision+injection technique: the needle (25 G) or cannula (25 G) (wider areas are treated with the cannula) is inserted into the skin and made to move with a back-and-forth motion in order to detach scar collagen bundles. Then 1 syringe (2 ml) of Profhilo® Structura is injected.~Day 0: Information and consent form provided, Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~First treatment of Profhilo® Structura (refer to study protocol).~Day 30 (1 month after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~Second treatment of Profhilo® Structura (refer to study protocol).~Day 120 (4 months after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~NO treatment, Self-evaluation questionnaire."
32996836|NCT05691036||Pregnant women with ICP|Case: Pregnant women with consistent pruritus or on medication for pruritus associated with an elevated level of serum transaminase alanine transaminase(ALT)>40 IU/L or aspartate transaminase(AST)>37 IU) and raised serum bile acids ≥10µmol/L will be eligible for the inclusion in the study.
32996837|NCT05691036||Pregnant women without ICP|Controls: Healthy pregnant women of the same gestational age with routine physical examinations will be enrolled as a control group.
32996838|NCT05691023||Vivistim|All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment.
33324955|NCT03971045|Experimental|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
33324956|NCT00162773|Placebo Comparator|Placebo|water injection
32996839|NCT05691010|Experimental|Participants with Endometrial Cancer|Participants have stage III endometrial cancer
32996840|NCT05690984|Experimental|Isatuximab in combination with lenalidomide and dexamethasone.|The isatuximab, lenalidomide, and dexamethasone (IsaRD) therapy will be administered on an outpatient basis.
32996841|NCT05690971|Experimental|Horizons mobile app|"Participants randomly assigned to the Horizons group, will use the Horizons app over an eight-week period in addition to receiving usual care from transplant team.~Participants will complete study questionnaires at the time of enrollment (baseline) and at eight and sixteen weeks after enrollment"
32996842|NCT05690971|Active Comparator|Usual Care|"Participant in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.~Participants will complete study questionnaires at the time of enrollment (baseline) nad at eight and sixteen weeks after enrollment"
32996843|NCT05690945|Experimental|QL1706+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive QL1706, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 or QL1706 combined with pemetrexed.
32996844|NCT05690945|Active Comparator|Tiselizumab+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive tiselizumab, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with tiselizumab or tiselizumab combined with pemetrexed.
32996845|NCT05690906|Experimental|ReSpace™ & gauze packing|All of the subjects will undergo palcement of ReSpace™ hydrogel together with gauze packing in the vagina before brachytherapy
32996846|NCT05690906|Active Comparator|gauze packing|All of the subjects will undergo palcement of gauze packing alone in the vagina before brachytherapy
32996847|NCT05690867|Other|Group 1|group 1 starts with volume controlled ventilation
32996848|NCT05690867|Other|Group 2|group 2 starts with pressure controlled ventilation
33324957|NCT00162773|Experimental|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
33324958|NCT00209339|Experimental|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
32996849|NCT05690802|Experimental|Palonosetron hydrochloride capsules|The recommended dose for adults is 0.5mg (1 capsule) for a single oral dose about 1 hour before chemotherapy.
33324959|NCT03970889|No Intervention|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
33324960|NCT03970889|Experimental|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
33324961|NCT03968003|Experimental|Inulin|Group A (intervention group) will receive inulin 10 g.
32996850|NCT05690776||Patients who received the Quattro X BroadBand|No specific interventions will be administered.
32996851|NCT05690711|Experimental|HRS8179|
32996852|NCT05690711|Placebo Comparator|Placebo|
33324962|NCT03968003|Placebo Comparator|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
33324963|NCT03968003|Active Comparator|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
32996855|NCT05690685|Experimental|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|Subjects will undergo treatment of their chronic or acute wound (Pressure ulcer, and Donor sites) as indicated in the instructions for use with Silver I Non-Woven Dressing
32996856|NCT05690672|Active Comparator|3D-CAM screening|
32996857|NCT05690672|Active Comparator|4AT screening|
32996858|NCT05690659|Experimental|cavitation ultrasonic lipolysis|on abdomen 2 sesions / week for 10 sessions , Treatment head was griped perpendicular to abdomen, and make slow circular motion with marked pressure.2 sesions / week for 10 sessions
32996859|NCT05690659|Experimental|RUSI guided core muscle exercise|"2 sesions / week for 10 sessions For diaphragm muscle the transducer was placed on the sub costal region to visualize diaphragm muscle on the screen aiming to use US as a visual feedback procedure. instructed to have 5 seconds to contract the diaphragm muscle by deep breathing and hold the contraction. At the end of the 5-second period, the image was saved on the screen, and the measurement of the resultant increase in thickness was performed. Each subject performed a total of 10 contractions (intervention session) For transverse abdominis exercise,. draw in your umbilicus toward the spine without moving back or pelvis, while comfortably breathing in and out, for 10 seconds hold and then 15 seconds rest in between, it was repeated 3 sets of ten while keeping the transducer perpendicular to the surface of the skin in a transverse plane halfway between the ASIS and the lower ribcage along the anterior axillary line"
32996860|NCT05690659|Experimental|combination of cavitation and RUSI|combination of cavitation and RUSI 2 sesions / week for 10 sessions
32996861|NCT05690646|Experimental|NR group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
32996862|NCT05690646|Experimental|UA group|ursodeoxycholic acid group, 15mg/kg/day bid for5 days
32996863|NCT05690646|Experimental|combination group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days and ursodeoxycholic acid group, 15mg/kg/day bid for5 days
32996864|NCT05690646|No Intervention|control group|No intervention
32996865|NCT05690633|Experimental|Oropharyngeal oximetry|The use of a pulse oximeter in the oropharynx on either an oral airway or a tongue blade.
32996866|NCT05690620|Experimental|Laughter Yoga|In a systematic review study, it was determined that it was appropriate to practice laughter yoga for at least 4 weeks. Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
33324964|NCT03970577|Experimental|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
32864735|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
32864736|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
32864737|NCT04777591|Active Comparator|Control - plain bupivacaine|Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively
32864738|NCT04777591|Experimental|Experimental - Liposomal bupivacaine|Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively
32864739|NCT04390841|Experimental|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
32864740|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
32864741|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
32864742|NCT04390919||high group|high group: monocyte count≥0.445×10*9 cells/L
32864743|NCT04390919||low group|low group: monocyte count<0.445×10*9 cells/L;
32864746|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
32864747|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
32864748|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
32864749|NCT01459835|Active Comparator|Nutrition intervention|diet advice
32864750|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
32864751|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
32864752|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
32864753|NCT04776889|Active Comparator|Control/statin non-users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy.
32864754|NCT04776889|Experimental|Interventional/statin users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy and administered rosuvastatin 20 mg/day for 6 months
32864755|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
32864756|NCT01459991|Active Comparator|MyPyramid|
32864757|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
32864758|NCT04777123|Active Comparator|sitting position|patients will be left in the sitting position
32864759|NCT04777123|No Intervention|supine position|patients will lie down immediately after injection
32864760|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
32864761|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
32864762|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
32864763|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
32864764|NCT04776967|Active Comparator|Compression Profile 4|Compression Profile/Schedule 4 = 10 minute linear, Total Time Interval of Compression to treatment depth = 10 minutes, Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at treatment depth 45 fsw
32864765|NCT04776967|Active Comparator|Compression Profile 3|Compression Profile/Schedule 3 = 10 minute non-linear, Total Time Interval of Compression to treatment depth = 10 minutes Rate (slope) of compression = Non-Linear rate of compression = 3 fsw/min to a depth of 17 fsw, then 5 fsw/min up to a depth of 38.5 fsw, then 6.5 fsw/min to arrival at the treatment depth of 45 fsw
32864766|NCT04776967|Active Comparator|Compression Profile 2|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
32864767|NCT04776967|Active Comparator|Compression Profile 1|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
32864768|NCT01456481|Active Comparator|midodrine hydrochloride pills|
32864769|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
32904017|NCT04385186|Active Comparator|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
32996867|NCT05690620|Active Comparator|Control|"No intervention will be applied to the students in the control group. Students will be followed for four weeks. Before the study, data collection tools will be applied to the students. Again, after the study starts and the study ends, all other data collection tools except the Student Information Form will be applied."
32996868|NCT05690607||HIV: Phase 1|People (over 18 years) living with HIV-1 attending London Mortimer Market Centre for routine blood tests as part of their HIV care.
32996869|NCT05690607||HIV: Phase 2|Subset of HIV participants sent TINIES test kit to use in home environment
32996870|NCT05690607||HBV: Phase 1|People (over 18 years) living with HBV patients attending London Mortimer Market Centre for routine blood tests as part of their HBV care.
32996871|NCT05690607||HBV: Phase 2|Subset of participants sent TINIES test kit to use in home environment
32996872|NCT05690568|Other|Pre-intervention and post-intervention FMS scores|multimodal chiropractic care with FMS scores assessed pre- and post-intervention
32996873|NCT05690542||patients from intensive care units|patients with hemostasis disorders (coagulation and/or platelets), antiplatelet and/or anticoagulant treatment
32996874|NCT05690542||controls|healthy people
32996875|NCT05690529||No recurrence|No recurrence of AF
32996876|NCT05690529||Recurrence|Recurrence of AF
32996877|NCT05690490|Experimental|endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
32996878|NCT05690490|Active Comparator|endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe), the lesion will be resected through the submucosal plane using the eb-block principle, after which the patient will be monitored.
32996879|NCT05690425|Experimental|BC3402 treatment group|BC3402 as a single agent via intravenous infusion once every 3-weeks
32996880|NCT05690321|Active Comparator|Active treatment|Administration of opium tincture (Dropizol)
32996881|NCT05690321|Placebo Comparator|Placebo treatment|Administration of placebo (identical to opium tincture in taste and appearance)
32996882|NCT05690308|Experimental|Experimental visual perturbation treadmill training|Participants assigned to the experimental intervention will receive 6 weeks, 2x per week of visual perturbation treadmill training using the GRAIL system. This will consist of maximum 30 minutes of walking on the treadmill while translations and rotations of the projected environment are applied.
32996883|NCT05690308|Sham Comparator|Control treadmill training|Participants assigned to the control intervention will receive 6 weeks, 2x per week of treadmill only training. This will consist of maximum 30 minutes of walking on the treadmill without any visual perturbations.
32996884|NCT05690282|No Intervention|Standard oral hydrocodone-acetaminophen post-op management|
32996885|NCT05690282|Active Comparator|Multimodal pain post-op management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|
32996886|NCT05690256|Experimental|Intervention|Resilience Clinic
32996887|NCT05690256|Active Comparator|Control|Enhanced pediatric primary care
32996888|NCT05690243|Experimental|Group therapy delivered via video telehealth|Nine sessions of 60 min each group therapy delivered via telehealth
32996889|NCT05690243|Other|Group therapy delivered via video telehealth - wait list control|Nine sessions of 60 min each group therapy delivered via telehealth after a waiting period.
32996890|NCT05690230|Experimental|Intervention 1: Virtual reality|
32996891|NCT05690230|No Intervention|Control 1|Standard of care without change, in parallel with intervention 1: Virtual reality.
32996892|NCT05690230|Experimental|Intervention 2: Environmental changes|
32996893|NCT05690230|No Intervention|Control 2|Standard of care without change, in parallel with intervention 2: Environmental changes.
32996894|NCT05690217||COPD group|There are 40 chronic obstructive pulmonary disease (COPD) patients in the COPD group.
32996895|NCT05690217||Healthy control group|There are 40 age-matched healthy participants in the healthy control group.
32996896|NCT05690204|Experimental|Placebo versus SAP 001|Placebo arm
32996897|NCT05690204|Experimental|SAP001 first study drug group|SAP001 10 mg
32996898|NCT05690204|Experimental|SAP001 second study drug group|SAP001 30 mg
32996899|NCT05690204|Experimental|SAP001 third study drug group|SAP001 60 mg
32996900|NCT05690191||Chidamide in combination with rituximab and lenalidomide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses); Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle; Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
32996901|NCT05690165|Experimental|Exercise Group|Participants will exert a heart rate controlled aerobic walking training 3-5 times per week for 30-45 minutes per training. This exercise as well as the daily amount of steps will be assessed via smartwatch.
32996902|NCT05690165|No Intervention|No Exercise Group|Participants receive no demands regarding the daily exercise. Their daily amount of steps will be assessed via smartwach.
32996903|NCT05690152|Experimental|Single Arm|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
32996904|NCT05690139||Obese patients|Obese patients received LSG surgery approval
32996905|NCT05690113||Clinical population|250 children aged from 7 to 17 will be recruited in 6 clinical departments (child and adolescent psychiatry, forensic medicine, psychotraumatism centers) They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
33033643|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
33033644|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
32904018|NCT04385420|Experimental|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
32904019|NCT04385420|Experimental|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
32904020|NCT04385420|Experimental|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
32904021|NCT04385420|Experimental|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
32904022|NCT04385420|Placebo Comparator|Placebo (SAD)|Placebo once (morning)
32904023|NCT04385420|Experimental|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
32904024|NCT04385420|Experimental|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
32904025|NCT04385420|Experimental|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
32904026|NCT04385420|Placebo Comparator|Placebo (MAD)|Placebo once daily (morning) for 7 days
32904027|NCT00737360|Experimental|1|
32904028|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
32904029|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
32904030|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
32904031|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
32904032|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
32904033|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
32904034|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
32904035|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
32904036|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
32904037|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants with an eGFR of >50 to <80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
32904038|NCT01275170|Experimental|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
32904039|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
32904040|NCT01275170|Experimental|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
32904041|NCT01275170|Experimental|Panel E Severe Renal Impairment|Participants with an eGFR <30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
32904042|NCT01275170|Experimental|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
32904043|NCT01275170|Experimental|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
32904044|NCT01275170|Experimental|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
32904045|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
32904046|NCT04385654|Experimental|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
32904047|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
32904048|NCT01272674|No Intervention|control|sedentary lifestyle
32904049|NCT01272674|No Intervention|healthy control|
32904050|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
32904051|NCT00400634|Sham Comparator|2|Sham Neurosurgery
32904052|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
32904053|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
32904054|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
32996906|NCT05690113||Non-clinical population|250 children aged from 7 to 17 will be recruited in schools They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
32996907|NCT05690061|Active Comparator|Sequence 1: Grain-Fed, Grass-Fed, Impossible|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
32996908|NCT05690061|Active Comparator|Sequence 2: Grass-Fed, Grain-Fed, Impossible|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
32996909|NCT05690061|Active Comparator|Sequence 3: Impossible, Grass-Fed, Grain-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
32996910|NCT05690061|Active Comparator|Sequence 4: Impossible, Grain-Fed, Grass-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
32996911|NCT05690061|Active Comparator|Sequence 5: Grain-Fed, Impossible, Grass-Fed|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
32996912|NCT05690061|Active Comparator|Sequence 6: Grass-Fed, Impossible, Grain-Fed|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
32996913|NCT05690022|No Intervention|Before sleeve gastrectomy|Gastroesophageal Reflux Disease (GERD) will be evaluated before surgery. EndoFlip, gastroscopy, pH-study and GERD-Health-Related Quality of Life Questionnaire will be realized for all patients.
32996914|NCT05690022|Experimental|Sleeve gastrectomy|After the surgical intervention, new onset or worsening of GERD will be evaluated.
32996915|NCT05689996|Experimental|Infective keratitis|"Preparation of nanostructure lipid carriers (NLCs):~The emulsification-solvent evaporation technique was used to prepare the NLCs. The method was followed by ultrasonication as reported [1]. In brief, the lipid phase was composed of stearic acid (solid lipid, 300 mg and oleic acid (liquid lipid, 300 mg) dissolved in ethanol (2 mL, 1:1, v/v) at 70oC. In total, 20 mL of the distilled water containing 2% of the Tween® 80 were heated at 70 oC to prepare the aqueous phase. Then, both phases, aqueous and lipid phases, were mixed at the same temperature using 2000 rpm stirring for 15 min. The resulting pre-emulsion obtained from the mixture of the aqueous and lipid phases was sonicated by a probe-type sonicator (Cole-Parmer, Vernon Hills, IL, USA) for 10 min at pulse-ON for 3 s and pulse-OFF for 5 s (40 W). The obtained dispersion was allowed to cool to RT under continuous stirring for 60 min at 1000 rpm for 1 h to obtain the NLCs dispersions."
32996916|NCT05689983|Active Comparator|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
32996917|NCT05689983|Placebo Comparator|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
32996918|NCT05689970||STE patients|Patients with ST segment elevation (STE) and coronary arteries without significant lesions and without a serum troponin curve suggestive of acute necrosis (group without acute myocardial necrosis).
32996919|NCT05689970||STEMI patients|Patients with ST segment elevation with acute occlusion of at least one epicardial coronary artery and TIMI flow 0 or I (group with acute myocardial necrosis of ischemic origin), that meet the definition of myocardial infarction (STEMI) with an acute cardiac necrosis curve verified by measurement of troponin I or troponin T.
32996920|NCT05689957|Experimental|deep neuromuscular block group|Group 1 (Induction with Rocuronium 0.6mg/kg + maintenance with intravenous Rocuronium rocuronium 8-12mcg/kg/minute (0.48-0.72 mg/kg/hour maintain PTC 0-1(deep block). (Study Group) intraoperatively
32996921|NCT05689957|Active Comparator|moderate neuromuscular block group|Group 2 (Induction with intravenous Rocuronium 0.6mg/kg + maintenance with intermittent intravenous Rocuronium 0.2mg/kg bolus. maintain PTC >1, TOF 0-2). Moderate block. (Control Group) intraoperatively
32996922|NCT05689944|No Intervention|Control group|Patients in the control group will not participate in any art-therapy or yoga interventions. They will be asked to complete pain and sleep diaries, questionnaires and pain, fatigue and mood scales at the same times and for the same duration as the other groups.
32996923|NCT05689944|Experimental|Dance-therapy group|Patients in the dance-therapy group will attend a weekly session of dance-therapy between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
32996924|NCT05689944|Experimental|Art-therapy group|Patients in the art-therapy group will attend a weekly session of art-therapy (drawings, collages…) between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
32996925|NCT05689944|Experimental|Yoga group|Patients in the yoga group will attend a weekly session of Vinyasa yoga between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
32996926|NCT05689931||Asthma patients initiating Mepolizumab treatment|Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection
33105245|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
32864770|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
32864771|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
32864772|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
32864773|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
32864774|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
32864775|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
32864776|NCT04776577|Other|Study arm|"Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2.~Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3)"
32864777|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
32864778|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
32864779|NCT04776655|Experimental|Bevacizumab in combination with FOLFIRI chemotherapy|"Bevacizumab will be administrered at a dose of 5 mg/kg iv every 2 weeks. The first dose of Bevacizumab will be administered over 90 minutes. Then, if the first infusion is well tolerated without infusion-related reaction, the second dose will be administered over 60 minutes. Then, if the second dose is also well tolerated without an infusion reaction, all subsequent doses will be administered over 30 minutes.~Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
32864780|NCT04776655|Active Comparator|Cetuximab in combination with FOLFIRI chemotherapy|Cetuximab will be administered at a dose of 500 mg/m² iv every 2 week (14 days/cycle) Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
32864781|NCT01455233|Active Comparator|besivance|ocular antibiotic
32864782|NCT01455233|Active Comparator|vigamox|ocular antibiotic
32864783|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
32864784|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
32864785|NCT04776733|Experimental|prepackaged group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
32864786|NCT04776733|Active Comparator|restricted diet group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
32864787|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
32864788|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
32864789|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
32864790|NCT04776343|Experimental|Telemedecine follow-up|
32864791|NCT04776343|No Intervention|Hospital follow-up|
32864792|NCT04776421||ileostomy group|
32864793|NCT01455857|Experimental|ITCA 650 40 mcg/day|
32864794|NCT01455857|Experimental|ITCA 650 60 mcg/day|
32864795|NCT01455857|Placebo Comparator|ITCA placebo|
32864796|NCT04753645|Experimental|HBCC and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
32864797|NCT04753645|Experimental|No HBCC project and no soap|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
32864798|NCT04753645|Experimental|Soap received but no HBCC|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
32996927|NCT05689931||Asthma patients already on Mepolizumab treatment|Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections
32996928|NCT05689931||Asthma patients without Mepolizumab treatment|Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections
32996929|NCT05689931||Healthy non-asthmatic control subjects|Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling
32996930|NCT05689905||Common HLA antigens with the lung donor|Children who have common HLA antigens with the lung donor of their mother
32996931|NCT05689905||No common HLA antigens with the lung donor|Children without common HLA antigens with the lung donor of their mother.
32996932|NCT05689892|Experimental|Intervention group|Participants who have been diagnosed with IBD and are recommended a new biologic therapy will be recruited to this arm. Participants and their families will be referred to a decision coach (DC), who will provide support in gaining knowledge of treatment and care options. They will also be given decision aids (DA) as outlined in the study description.
32996933|NCT05689892|No Intervention|Comparator group|Participants who have been recommended a new biologic therapy within the last 12 months and have commenced treatment will be recruited to this arm.
32996934|NCT05689853|Experimental|AK119 in combination with AK112|AK119 and AK112, IV, every 3 weeks
32996935|NCT05689840||Covid-19 infection group|Patients who have been infected with Covid-19 before elective surgery.
32996936|NCT05689840||Control group|Patients who were not infected with COVID-19 before elective surgery.
32996937|NCT05689814|Experimental|Paraffin based Denture Fixative|Participants will use the paraffin-based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
32996938|NCT05689814|Active Comparator|Polydecene based Denture Fixative|Participants will use the polydecene based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
32996939|NCT05689814|No Intervention|No Denture Fixative Control|Participants will continue to wear their dentures for 4 days and will not use any denture fixative as part of this study arm.
32996940|NCT05689801|Experimental|Patient on conventional hemodialysis then on optimized hemodialysis|
32996941|NCT05689788|Experimental|HILT + stretching exercise|High-intensity laser therapy (HILT) will be applied with the punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used. Laser therapy will be applied with the participant in the prone position.The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
32996942|NCT05689788|Sham Comparator|Sham HILT + stretching exercise|The group will receive a sham treatment of high-intensity laser therapy (HILT). The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
32996943|NCT05689775||Patients|Patients over 18 years of age operated for locally advanced anal or rectal cancer with robot-assisted abdomino-perinal resection and robot-assisted reconstruction of pelvic floor and/or vagina with vertical rectus abdomínis muscle flap.
32996944|NCT05689749||Participants with Sjögren's syndrome|Participants with the diagnose of Sjögren's syndrome; Patients with a confirmed diagnosis who are being followed and treated by a rheumatologist.
32996945|NCT05689749||Volunteers who has not dry eye complaints and Sjögren's syndrome diagnosis.|Voluntary participants without any rheumatic disease diagnosis, without Sjögren's syndrome diagnosis, without dry eye complaints will constitute the other group.
32996946|NCT05689723|Experimental|Manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
32996947|NCT05689723|Sham Comparator|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
32996948|NCT05689697|Placebo Comparator|Placebo group|Patients will recieve matched by taste and color shot of 25 ml liquid in ampules
32996949|NCT05689697|Experimental|Active treatment group|Patients will recieve shot of PanTrek 25 ml in anpules
32996950|NCT05689684|Active Comparator|Hybrid Product: Aarabinogalactan (AG)+xylan-oligosaccharides (XOS) +AXOS|Daily 2x 5g Hybrid Product, produced by Carbiotix AB. Hybrid Product is available as powder, which can be easily dissolved in water.
32996951|NCT05689684|Placebo Comparator|Placebo|Daily 2x 5g maltodextrin. Maltodextrin is available as powder, which can be easily dissolved in water.
32996952|NCT05689671|Experimental|Pemetrexed-free Immunochemotherapy (Arm A)|Atezolizumab 1200 mg q3w, carboplatin AUC 5-6 q3w, nab-paclitaxel 100 mg/m2 qw (administered for 4 cycles with subsequent maintenance with atezolizumab monotherapy 1200 mg q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
32996953|NCT05689671|Active Comparator|Pemetrexed-based Immunochemotherapy (Arm B)|Pembrolizumab 200 mg q3w, cisplatin 75 mg/m2 q3w OR carboplatin AUC 5-6 (each) q3w, pemetrexed 500 mg/m2 q3w (administered for 4 cycles with subsequent maintenance with pembrolizumab 200 mg AND pemetrexed 500 mg/m2 (each) q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
33033645|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
32996954|NCT05689645|Experimental|F573 for injection groups|"The first stage : The dose of 1/2 grade DILI patients was 0.5, 1.0, 2mg / kg, the dose of CHB patients was based on the efficacy and safety results of DILI patients, The second stage:The dose was determined by the comprehensive consideration of the efficacy and safety trial results in the first stage ,both the dose volume was 2 mL, intramuscular injection (IM), once a day for 14 consecutive days, and the dose was calculated by the weight results of the last visit. basic treatment: receive Diammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~The Third stage: The dose of the Screen eligible subjects was determined by the results of the efficacy and safety trials in the first and second stages. The dose volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days. The dose was calculated by the body weight results of the last visit. basic treatment: receive acetylcysteine injection (NAC),the dose was 8 g/d, once a day."
33324965|NCT03970577|Active Comparator|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
33324966|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
32996955|NCT05689645|Placebo Comparator|Placebo Comparator|"The first stage: the 1/2 grade DILI patients and CHB patients and The second stage: the 2/3 grade DILI patients and CHB patients were treated with Sterilizing water for injection , the dose volume was 2 mL, intramuscular injection (IM), once a day for 14 consecutive days, and the dose was calculated by the weight results of the last visit. Basic treatment: receive Diammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~The third stage: the Screen eligible subjects were treated with Sterilizing water for injection. The dose volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days. The dose was calculated by the body weight results of the last visit. Basic treatment: receive acetylcysteine injection at a dose of 8 g / d once a day."
32996956|NCT05689632|Placebo Comparator|Placebo|Placebo - Medium-chain triglyceride
32996957|NCT05689632|Active Comparator|Vitamin D3|Vitamin D3 - 7000 IU daily
32996958|NCT05689632|Experimental|Vitamin D3 + K2-MK7|Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily
32996959|NCT05689619|Experimental|Silibinin|Silibinin (STAT3 inhibitor) 1 g/day taken orally every day
32996960|NCT05689619|Placebo Comparator|Placebo|Placebo 1 g/day taken orally every day
32996961|NCT05689606|Experimental|Exercise group|The exercise group performs acute high-intensity interval training.
32996962|NCT05689606|No Intervention|Control group|The Control group includes the same participants. In this session, they do not exercise, and they watch a nature documentary.
32996963|NCT05689580|Experimental|Patients received ketogenic diet then Balanced diet|subjects will be educated by dietitian and receive two months of ketogenic diet. Then, followed by three months of washout period. Finally, they will receive dietary education and follow balanced diet for two months.
32996964|NCT05689580|Experimental|Patients received Balanced diet then ketogenic diet|subjects will receive dietary education and follow balanced diet for two months first, then followed by three months of washout period. At last, they will receive dietary education of ketogenic diet and need to follow the ketogenic diet for two months.
32996967|NCT05689554|Experimental|Intervention|Educational intervention
32996968|NCT05689554|No Intervention|Usual Care|Usual care
32996969|NCT05689515|Experimental|Mobile Health App group|Mobile health app to increase rates of engagement in care in youths living with HIV
32996970|NCT05689515|No Intervention|Control group|Standard of care for youths living with HIV
32996971|NCT05689502|Experimental|Treatment|
32996972|NCT05689489|Experimental|Puzzle|
32996973|NCT05689489|Active Comparator|control group|
32996974|NCT05689463|Experimental|Patient with prurit|
32996975|NCT05689437||ILD Silent Mode|The ILD model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
32996976|NCT05689437||ILD Prospective Mode|Following successful silent mode, the ILD model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
32996977|NCT05689437||SGR Silent Mode|The SGR model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
32996978|NCT05689437||SGR Prospective Mode|Following successful silent mode, the SGR model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
32996979|NCT05689437||CBCT Silent Mode|The CBCT model will be run on patients receiving routine on-treatment imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
32996980|NCT05689437||CBCT Prospective Mode|Following successful silent mode, The CBCT model will be run on patients receiving routine on-treatment imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
33033646|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
33033647|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
32996981|NCT05689411|Experimental|Musical Toy Group|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
32996982|NCT05689411|No Intervention|Control Group|No distraction technique was applied to the children in the control group before the vascular access procedure. After the procedure was explained according to the child's developmental level, the researcher applied the procedure to open a vascular access in accordance with the institutional policies.
32996983|NCT05689385|Experimental|eHealth-based cardiac rehabilitation|Participants receive a 12-wk case manager-led eHealth-based cardiac rehabilitation program with follow-up at 12 week, 6 months and 12 months.
32996984|NCT05689385|No Intervention|Usual care|Participants receive usual care.
32996985|NCT05689372||Participants with type 2 diabetes|Participants will be treated with Ozempic (solution for injection 1.34 milligrams per milliliter [mg/ml] (Semaglutide subcutaneous [s.c.]) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the Korean package insert (K-PI).
32996986|NCT05689333|Experimental|27 GA Vista Ophthalmics vitrector|The vitrectomy will be performed through the pars plana using the 27 GA Vista Ophthalmics vitrector.
32996987|NCT05689320|Experimental|Intervention|The intervention group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The intervention group participants should complete at least two EMA surveys in a day and need to comply with the intervention at least 85% of the time.
32996988|NCT05689320|No Intervention|Control|The control group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The conrol group participants should complete at least two EMA surveys in a day and No intervention will be provided after completing the 21 consecutive days EMA documentation.
32996989|NCT05689268|Other|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
32996990|NCT05689242|Experimental|Group I|Receive initial loading dose of (Dexmedetomidine 1 μg/kg I.V) diluted up to 10 ml with normal saline infused over 10 min, followed by a continuous infusion of 0.2-0.8 μg/kg/h through a 50 ml syringe and an electronic infusion pump
32996991|NCT05689242|Experimental|Group II|Receive (Nalbuphine 0.1 to 0.2 mg/kg I.V) diluted up to 10 ml with normal saline infused slowly over 10 min.
32996992|NCT05689229|Active Comparator|Colistin IV|
32996993|NCT05689229|Active Comparator|Colistin Aerosolized|
32996994|NCT05689229|No Intervention|Control|
32996995|NCT05689216|Experimental|Awake timed prone and repositioning group|Patients' cumulative prone and repositioning time is encouraged to reach 8-10 hours per day for 4 days following a timed prone and repositioning strategy.
32996996|NCT05689216|No Intervention|Standard care group|Patients can change their positions freely according to their own needs. Health providers do not take the initiative to give guidance on prone and repositioning.
32996997|NCT05689203|Experimental|QLS1128|QLS1128 will be administered orally for 5 days.
32996998|NCT05689203|Placebo Comparator|Placebo|Placebo matching to QLS1128 will be administered orally for 5 days.
32996999|NCT05688046||IA group|Immune checkpoint inhibitors plus angiogenesis inhibitors group
32997000|NCT05688046||NIA group|Immune checkpoint inhibitors without angiogenesis inhibitors group
32997001|NCT05687812|Experimental|Diabetic group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
32997002|NCT05687812|Experimental|Non-diabetic obese group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
33033648|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
33033649|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
33105246|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
33105247|NCT03429894|Experimental|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
33105248|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
33105249|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
33105250|NCT04686669|Experimental|Subjects receiving treatment sequence ABC|Subjects will receive treatment sequence ABC on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
33105251|NCT04686669|Experimental|Subjects receiving treatment sequence BCA|Subjects will receive treatment sequence BCA on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
33105252|NCT04686669|Experimental|Subjects receiving treatment sequence CAB|Subjects will receive treatment sequence CAB on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
33105253|NCT04686669|Experimental|Subjects receiving treatment sequence ACB|Subjects will receive treatment sequence ACB on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
32864799|NCT04753645|Experimental|Both HBCC project and Soap received|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
32864800|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
32864801|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
32864802|NCT04866030||NostraData Database|All prescriptions for Intuniv available in the NostraData database in Austrialia will be analyzed in this study.
32864803|NCT04866030||Physician Survey|Physician will collect medical record data of 100 participants who have been prescribed Intuniv at least once during the study period to treat participants with ADHD.
32864804|NCT04595305|Other|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
32864805|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
32864806|NCT04272905||Maternity patients|"> 18 years~Post-natal following any form of delivery~Between 4 and 48 hours after delivery~Able to understand English adequately to give consent and complete the questionnaire"
32864807|NCT04272905||Maternity Unit Staff|"Doctors, midwives and other staff~Work on labour ward"
32864808|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
32864809|NCT04096417|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
32864810|NCT04849637|Experimental|Standard of care plus adjunctive virgin coconut oil supplementation|Standard of care plus virgin coconut oil
32864811|NCT04849637|No Intervention|COVID-19 Standard of care treatment|Standard of care
32864812|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
32864813|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
32864814|NCT04844021|Experimental|Nudge|"Clinics randomized to the Nudge condition will receive the EHR prompt only. The investigators will add default language to the standard Well Child Visit workflow to serve as a reminder and allow for tracking of S.A.F.E. Firearm implementation. The clinician will be asked to denote whether the program was delivered (e.g., whether conversation around firearm storage was conducted, whether cable firearm lock was offered) to the parent during the visit. This EHR prompt will remain turned on from active implementation through the sustainment period."
32864815|NCT04844021|Experimental|Nudge+|This arm consists of Nudge as described above, as well as facilitation. Facilitation (i.e., external support delivered by health system employees not employed within the clinic site) will be offered for 12 months to each clinic, in keeping with other implementation trials. The investigators will use a train-the-trainer model to train facilitators at both health systems to ensure they achieve facilitator core competencies with an eye toward implementation of S.A.F.E. Firearm. The role of the facilitator is to engage with study clinics, to assist each clinic in setting change and performance goals around the implementation of S.A.F.E. Firearm, and to troubleshoot implementation barriers.
32864816|NCT04843631|Experimental|Arm A: BFI-751|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
32864817|NCT04843631|Active Comparator|Arm B: EU-STELARA®|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
32864818|NCT04843631|Active Comparator|Arm C: US-STELARA®.|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
32864819|NCT01419249|Other|Retrospective cohort|
32864820|NCT04845737|Other|Fibromyalgia patient group|Sympathetic skin response measurements will be made in patients who meet the diagnosis criteria of fibromyalgia. Vitamin D levels will be measured and hemogram values will be checked in these patients.
32864821|NCT04845737|Other|Control Group|The participant in this group will be chosen from healthy volunteers. Sympathetic skin response will be measured of the participants. Vitamin D levels and hemogram values will be recorded.
32864822|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
32864823|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
32864824|NCT04849715|Active Comparator|Treatment Group A|Participants will be administered parsaclisib once daily and will receive Bendamustine and Rituximab periodically for 6 months.
32997003|NCT05687812|Experimental|Non-diabetic and non-obese healthy group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
32997004|NCT05686252|Active Comparator|30 degrees|Baby is held at 30 degrees during kangaroo mother care in the NICU
32997005|NCT05686252|Active Comparator|60 degrees|Baby is held at 60 degrees during kangaroo mother care in the NICU
32997006|NCT05684471|Active Comparator|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients randomized to receive suprainguinal fascia iliaca block
32997007|NCT05684471|Active Comparator|Ultrasound Guided Anterior quadratus lumborum block|Patients randomized to receive anterior quadratus lumborum block
32997008|NCT05683158||chronic stroke|The subject consisted of the physician's confirmation of chronic hemiplegia onset ≥ 6 months Mini-mental state examination≥25 Biceps ≤2, Triceps≤2 Ability to Sit on a chair alone FMA upper extremity score ≥ 21points, FMA upper extremity score ≤ 66 points The symptom is mild or moderate level (MAS≤2) and can sit alone. The subject reaches to target by affected arm in 3 directions(medial_45, forward_90 and lateral_120 degrees)
32997009|NCT05683158||Healthy|"Matching aged people, not having neurological system or orthopedic disease on Upper extremity.~The subject reaches to target by non-dominant arm in 3 directions(medial_45, forward_90 and lateral_120 degrees)"
32997010|NCT05682118|Experimental|tested using the roadmap system|tested using the roadmap system
32997011|NCT05682118|Active Comparator|tested without using the roadmap system|tested without using the roadmap system.
32997012|NCT05680246||DHOPE-PRO|Outcomes of recipients who underwent liver transplantation of donor organs that were perfused with prolonged (>4 hours) DHOPE.
32997013|NCT05678166||NTM-LD|Diagnosis is made on the basis of the guidelines produced by the American Thoracic Society . Briefly, Patients have pulmonary symptoms with identified chest image and fit with the microbiology criteria.
32997014|NCT05678166||NTM pulmonary colonizers and others|Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC or patients infected with NTM other than MAC species.
32997015|NCT05678166||Pulmonary tuberculosis (TB)|Those with respiratory specimen culture positive for Mycobacterium tuberculosis or typical TB pulmonary pathology.
32997016|NCT05678166||Healthy control|Healthy control
32997017|NCT05678140|Experimental|soft tissue mobilization+conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
32997018|NCT05678140|Placebo Comparator|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area.
32997021|NCT05676125||chronic ankle instabilty group|females with previous history of ankle sprain
32997022|NCT05676125||control group|healthy feamles
32997023|NCT05675930|Active Comparator|Adult and pediatric patients who received an allogeneic stem cell transplant (allo-HCT)|Participants are Allo-HCT recipients
32997024|NCT05675930|Placebo Comparator|Adult and pediatric patients who received a placebo treatment|Participants are Allo-HCT recipients
32997025|NCT05674552|Experimental|Study group|Children receiving exogenous ketone esters + standard of care
32997026|NCT05674552|No Intervention|Control group|Children receiving only standard of care
32997027|NCT05670847|Experimental|Study group|Children receiving exogenous ketone esters + standard of care
32997028|NCT05670847|No Intervention|Control group|Children receiving only standard of care
32997029|NCT05650021|Other|SpaceOAR Vue and fiducial marker|After enrollment, patients will be treated per the standard of care, including the use of daily CBCT for image guided radiotherapy. The investigator will review the CBCT on the first day of treatment and align in such a way that the fiducials match up but also that the radio-opaque SpaceOAR lines up to within 5mm. If the SpaceOAR does not line up to within 5mm, the investigator will consider an intervention such as having the patient get off the table to pass gas, have a bowel movement, additional counseling about diet and bowel movement habits, or potentially even re-simulation. These daily CBCT images are aligned to the CT simulation images by way of aligning the fiducial markers on the respective imaging data sets. The CBCT images acquired during their first five fractions of radiotherapy will be imported into MIM software.
32997030|NCT05646563|Experimental|Cohort 1|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg weekly for 4 weeks. Patients will then discontinue Soliris treatment and be administered NM8074 at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
32997031|NCT05646563|Experimental|Cohort 2|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg for 4 weeks. Patients will then continue receiving Soliris while being administered NM8074 as a combination therapy at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
32864825|NCT04849715|Placebo Comparator|Treatment group B|Participants will be administered placebo once daily and will receive Bendamustine and Rituximab periodically for 6 months.
32864826|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
32864827|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
32864828|NCT04776109|Active Comparator|(Group of continous thoracic epidural bupivacaine infusion [CEI])|Group I : An epidural catheter will be inserted via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T8 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine (sunny-bupivacaine) infusion. Proper placement of the catheter will be verified through an aspiration test and a test dose (2 ml) of lidocaine 2% with adrenaline. At the end of surgery, a 0.2 ml/kg bolus of bupivacaine 0.25% will be administered through the catheter and then an infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h will be administered immediately postoperative and continued for 48 hours.
32864829|NCT04776109|Active Comparator|(Group of continous bilateral erector spinae bupivacaine infusions[CESI])|Group II : Bilateral erector spinae catheters will be placed at T8 level. Surface anatomy or ultrasound (counting up from the 12th rib) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. Then a high frequency linear-array ultrasound transducer (Sono Site MW, Bothell, WA, USA) covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine will be infiltrated .
32864830|NCT04860648|Experimental|LUS group|patients receive lung ultrasound examination, and doctors give the treatment according to the LUS results
32864831|NCT04860648|No Intervention|Control group|patients receive no lung ultrasound examination and other intervention
32864832|NCT04776187|Active Comparator|Gadodiamide|"Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.~Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide)."
32864833|NCT04776187|Experimental|Gadoteric Acid Meglumine Salt|"Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.~Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt)."
32864834|NCT04847843|Experimental|Mindfulness Orientated Recovery Enhancement (MORE) Intervention|8-week MORE intervention adapted for preventing weight regain
32864835|NCT04847843|Active Comparator|Control Intervention|8-week control intervention based on the Diabetes Prevention Program's Prevent T2 for Life program.
32864836|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
32864837|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
32864838|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
32864839|NCT04783831||Biodegradable stent|
32864840|NCT04783831||Non-biodegradable stent|
32864841|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
32864842|NCT04487041|Active Comparator|Young HIV negative group|HIV uninfected participants that are 18-35 years of age will receive the standard dose flu vaccine. Participants who did not respond to the standard dose flu vaccination, as defined by less than a four-fold increase in flu antibody titer from baseline, will then receive the high dose flu vaccination 1 year after initial standard dose flu vaccination. Participants who respond to the standard dose flu vaccination will not receive the high dose flu vaccination.
32864843|NCT04487041|Experimental|Young HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 18-35 years of age, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
32864844|NCT04487041|Experimental|Old HIV negative group|HIV uninfected participants that are 65 years and older will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
32864845|NCT04487041|Experimental|Old HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 65 years and older, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
32864846|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
32864847|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
32864848|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
32864849|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
32864850|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
32864851|NCT04783909||PEX|42 eyes with PEX syndrome and coexisting cataract
32864852|NCT04783909||Control|38 eyes with cataract only
32864853|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
32864854|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
32864855|NCT04857294|Experimental|Discectomy|Unilateral Discectomy
32864856|NCT04783753|Experimental|EDP-514 and Itraconazole interaction (Part 1)|
32864857|NCT04783753|Experimental|EDP-514 and Carbamazepine interaction (Part 2)|
32864858|NCT04783753|Experimental|EDP-514 and Quinidine interaction (Part 3)|
32864859|NCT04845191|Experimental|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
32864860|NCT04845191|Experimental|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
32864861|NCT04860570||Open Appendectomy (OA) + Double-ring wound-edge protector (2RWEP)|Intervention group: Patients with diagnosis of acute appendicitis treated by open appendectomy using a double-ring wound-edge protector.
32864862|NCT04860570||Laparoscopic Appendectomy (LA)|Control group: Patients with diagnosis of acute appendicitis treated by laparoscopic appendectomy.
32864863|NCT03008265||Colonic cancer resection|
32864864|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
32864865|NCT04849962|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
32864866|NCT04849962|Experimental|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
32864867|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
32864868|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
32864869|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
32864870|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
32864871|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
32864872|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
32864873|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
32864874|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
32864875|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
32864876|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
32864877|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
32864878|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
32864879|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
32864880|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
32864881|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
32864882|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
32864883|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
32864884|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
32864885|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
32864886|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
32864887|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
32864888|NCT04849494||Late preterm AGA infants/Group 1|According to the new BALLARD scoring system gestational age was 34-36 6/7 and those who were at the 10-90th percentile according to the Fenton growth curves
32864889|NCT04849494||Newborns with Intrauterine growth restriction/Group 2|Term or preterm infants below 10th percentile according to the values calculated according to Fenton growth curves
32864890|NCT04849494||Control/Group 3|the healthy term (gestation week 38-42 weeks), AGA newborns, who born between January 2006 and December 2008
32864891|NCT04775563||Rheumatic diseases outpatients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.
32864892|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
32864893|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
32864894|NCT04783129|Experimental|Face-to-face group|Face-to-face group (FFG), in which participants, in groups of 10 persons, followed a multidisciplinary health education program composed of 10 monthly face-to-face lectures
32864895|NCT04783129|Active Comparator|Remote group|Remote group (RG), in which individuals followed 10 monthly remote lectures
32997032|NCT05646524|Experimental|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at 20 mg/kg every two weeks.
32997033|NCT05646524|Experimental|Cohort 2|6 subjects will receive an intravenous (IV) infusion of NM8074 at 10 mg/kg weekly for four weeks followed by a 20 mg/kg dose of NM8074 every two weeks for the remainder of the treatment period.
32997034|NCT05641688|Experimental|PI-2620 PET Scan|
32997035|NCT05641519|Placebo Comparator|Enhanced Standard Intervention|Families randomized to enhanced standard intervention (ESI) will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care. At 12, 24, and 36 months they will be asked to return for in person follow-up to collect bio measures again and complete follow up surveys at the UCI FQHC in Santa Ana or during scheduled community data collection events. All adults will be asked to take their blood pressure with the device once a week.
32997036|NCT05641519|Experimental|SERVE OC Intervention|"In the SERVE OC intervention, participants will receive AHA informational materials, access to the app/web portal, and will be assigned a CHW to work with over the 3 years of the study. The CHW will facilitate the intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations. All adults will be asked to take their blood pressure with the device once a week."
32997038|NCT05637177|Experimental|Cognitive behavioral therapy (CBT)|"We used the Aging Wisely program for seniors living in the community, which uses elements of CBT and is specifically designed for older people over the age of 65 living in the community who may be in a worried, anxious or depressed mood. The program focuses on psychoeducation to manage these feelings. Seniors learn to change the ways they think and behave that maintain depression and anxiety. The sessions include education on the process of aging, coping with loneliness, improving sleep, coping with worry and avoidance, coping with loss and death. During the sessions, participants learn to track mood, motivation to change, goal setting, planning pleasant activities, identifying thoughts, working with useless thoughts, and practice techniques to replace useless thoughts. The last two sessions are dedicated to assertiveness and communication, and preventing recurrence of problems."
32997039|NCT05637177|Experimental|Reminiscence therapy|Reminiscence is a method of working with memories. Remembering has an irreplaceable place in every person's life. It is a natural activity that can encourage people, make them aware of their own achievements, different moments in life, point out their value, promote self-esteem and contribute to the development of relationships. Self-remembering is a natural form of cognitive stimulation.
32997040|NCT05637177|Experimental|Music therapy|The aim of music therapy is to optimize the quality of life, and to improve psychological, social, communication, emotional and mental health and well-being. Music therapy brings psychological and physical relaxation, reduces stress, improves mood, alleviates anxiety, improves memory and attention, develops and facilitates communication, enables self-expression. For this purpose, a number of activities are used, such as listening to music, singing, playing simple rhythmic instruments, playing the body and a number of other activities that will be carried out with seniors as part of the intervention.
32997041|NCT05637177|Experimental|memory training|"Cognitive training is targeted and structured exercise of cognitive functions (learning, memory, attention, speech, visual-spatial functions, ability to solve problems, plan or manage various tasks and correctly recognize one's surroundings). Regular exercise of cognitive abilities can create a cognitive reserve that can delay the potential aggravation of problems in memory or attention and improve quality of life.~The content of the intervention will be activities developing cognitive functions (primarily memory, attention, imagination, spatial orientation and decision-making speed), practical training and motivation for long-term regular strengthening of cognitive functions using the comprehensive training program MENTEM."
32997042|NCT05637177|Experimental|creation of educational modules (mental health, neural diseases …)|Educational activities will focus on disease prevention in three main directions - cardiovascular diseases, mental health and neurological diseases. Educational activities will take place within the University of the Third Age LF OU.
32997043|NCT05634109|Experimental|Whole Blood|Leukoreduced whole blood with a platelet-sparing filter. Participants will be transfused with 3 whole blood units. If the participant requires, an additional transfusion pack composite by 3 whole blood units will be administered.
32997044|NCT05634109|Active Comparator|Blood Components Therapy|1:1:1 ratio of red blood cells unit, plasma unit, and platelets unit. Participants will be transfused with 3 red blood cell units, 3 fresh frozen plasma units, and 3 platelets units. A second intervention with the same ratio can be transfused to participants if they require it.
32997045|NCT05633992|Experimental|V116 Treatment|Participants receive a single intramuscular (IM) injection of V116 on Day 1.
32997046|NCT05633992|Active Comparator|PPSV23 Treatment|Participants receive a single IM injection of PPSV23 on Day 1.
32997047|NCT05632237|Experimental|Family strengthening program|
32997048|NCT05632237|No Intervention|Care as usual|These participants have already been receiving case management from the Child Reintegration Centre prior to the study, and they will continue to receive care as usual, which is to receive normal case management visits without this added Family Strengthening Program component. Case management consists of a social work staff alternating between visiting children at home or at school each month to provide supervision, coaching, counseling, assessments, and identification of additional support needs.
32997049|NCT05618366|Experimental|Tazemetostat and Venetoclax|All participants will receive a combination of oral 800 mg tazemetostat BID and oral venetoclax. Since this is a phase 1 trial, the dose of venetoclax will be determined by the investigators per a sequential dose escalation (3+3). Participants will be provided study drug in the form of pills to take at home. Study participants will need to regularly come to the clinic for blood work, imaging, and to monitor and side effects. Participants may receive study drug until their cancer progresses or for up to 24 months.
32997050|NCT05618132|Experimental|Vasospastic angina|Interventional diagnostic protocol
32997051|NCT05610072|Experimental|n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine 4 times per day.
32997052|NCT05610072|Placebo Comparator|Placebo|Subjects will receive oral placebo 4 times per day.
32997053|NCT05609409|Experimental|Digital Intervention|Eight 20-30 minute sessions of an online, multimedia application
32997054|NCT05606406|Active Comparator|Healthy Control Group|Individuals without lung disease will receive oxygen for a period of four hours
32997055|NCT05606406|Active Comparator|Nocturnal hypoxemia group|Individuals with lung disease will receive oxygen for a period of four hours
32997056|NCT05596422||Cohort 1: Participants With Biologics Discontinuation|Participants with IBD (UC or CD) who had received biologic treatments for at least 6 months after the initial confirmed diagnosis of IBD, and with at least 3 months follow-up period after biologics discontinuation will be observed retrospectively.
32997057|NCT05596422||Cohort 2: Participants Treated With Biologics|Participants with IBD (UC or CD) who had any dose of biologic for IBD treatment after the initial confirmed diagnosis of IBD will be observed retrospectively.
32997058|NCT05593497|Experimental|Single Arm|neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy
32997059|NCT05589883|Experimental|EMPOWER-Latinx intervention|Informal caregivers will meet with the interventionist one-on-one via telepsychiatry (e.g., WebEx, Zoom) for 6, 15-20 minute modules to be completed within about 2-3 days from initiation of the first module, not including the booster modules. Informal caregivers will complete study assessments as per the schedule of assessments.
32997060|NCT05589623|Experimental|Copenhagen adduction exercise|The CAE is a body-weight exercise that mainly works the groin and hip adductors. It has a significant eccentric component, meaning the muscles work while lengthening. The CAE is a simple isolated eccentric exercise that does not require special equipment. Due to the heaviness and the high dynamic demands of CAE, a modified progressive Copenhagen adduction (MPCA) program has been created. The MPCA exercise was adapted from the original CAE to lessen the risk of delayed onset muscle soreness (DOMS) and facilitate high participant compliance. An experienced physical therapist will include the MPCA in the usual rehabilitation program for eight weeks, twice weekly. Sessions will last between 30 and 120 minutes.
32997061|NCT05589623|Active Comparator|Usual rehabilitation program|The rehabilitation program will be an active exercise based on the available literature and considers the clinical experience in managing groin injuries. An experienced physical therapist will supervise the rehabilitation program for two sessions weekly for eight weeks, with difficulty and volume progressing incrementally. Sessions will last between 30 and 120 minutes.
32997062|NCT05585606|Placebo Comparator|Placebo|Volume Matched Placebo (normal saline)
32997063|NCT05585606|Experimental|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
32997064|NCT05585606|Experimental|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) injection(s) over 2 minutes~- 3.8 mg/kg"
32997065|NCT05576974|Active Comparator|Part 1 - Cohort A|In Part 1 the single dose of 1 mg/kg of pegsitacianine given 6-100 hours prior to surgery will be used to image primary tumors in patients with HNSCC to evaluated to verify the diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes.
32997066|NCT05576974|Active Comparator|Part 2 - Cohort B|In Part 2, pegsitacianine the single dose of 1 mg/kg of given 6-100 hours prior to surgery will be used to in patients with unknown primary cancer of the head and neck. These patients typically undergo exam under anesthesia with a laryngoscopy as well as panendoscopy for identifying the source of the metastatic cancer found in the cervical nodes. The diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes in these patients will be evaluated. All the available data to date will be used to decide the additional tumor type(s), number of patients per tumor type, and number of Group(s) to be enrolled.
32997067|NCT05567848|Experimental|repetitive Transcranial Magnetic Stimulation (rTMS)|repetitive Transcranial Magnetic Stimulation (rTMS) in a iTBS pattern to the cerebellum at 100% of resting motor threshold
32997068|NCT05566678|Active Comparator|Cigarette|Smokers who self-selected to continue smoking cigarettes.
32997069|NCT05566678|Active Comparator|Tobacco Heating System|Smokers who self-selected to switch to THS use.
32997070|NCT05566678|Active Comparator|Smoking Abstinence|Smokers who self-selected to abstain from smoking.
32997071|NCT05565599|Experimental|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
32997072|NCT05553808|Active Comparator|Docetaxel|
32997073|NCT05553808|Experimental|Feladilimab plus Docetaxel|
32997074|NCT05553691|Experimental|Test Cohort|Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.
32997075|NCT05553691|Experimental|Control Cohort|Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.
32997076|NCT05549388|No Intervention|No label|In this arm, participants will view images of packaged food or beverage products without a front-of-pack label and respond to questions about the products.
32997077|NCT05549388|Experimental|Multiple Traffic Light (MTL)|In this arm, participants will view images of packaged food or beverage products which have multiple traffic light labels displayed on the front-of-pack and respond to questions about the products.
32997078|NCT05549388|Experimental|Nutri-Score|In this arm, participants will view images of packaged food or beverage products which have a Nutriscore front-of-pack label and respond to questions about the products.
32997079|NCT05549388|Experimental|Warning Label|In this arm, participants will view packaged food or beverage products which have front-of-pack warning labels if the product is high in one or more nutrients of concern and respond to questions about the products.
33033650|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
33033651|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
33033652|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
32997080|NCT05544890|Active Comparator|Therapeutic exercise Group (ET)|The ET group is going to follow a program of core stabilization through specific therapeutic exercise. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each session will have a duration of 60 minutes. All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.
32997081|NCT05544890|Active Comparator|Manual Therapy group (ETmanualtherapy)|Prior the core exercise previously exposed in group ET, group ETmanualtherapy will lay on the stretcher, where the physiotherapist will work on a manual therapy thrust. The participant will receive a high velocity and low range impulse technique in lateral position on both sides.
32997082|NCT05544890|Active Comparator|Kinesiotape Group (ETkinesiotape)|"The ETkinesiotape will go previously through physiotherapy, where a kinesiotape band will be applied (Kinesiotape Nondolens 5cmx5cm black color), in Y technique, by applying the kinesiotape base in neutral position of the lumbar spine without any tension on the tape. The participants realize the same exercise program than the other groups plus the kinesiotape applied."
32997083|NCT05540184|Experimental|Hydration plus Trimetazidine|Hydration plus Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
32997084|NCT05540184|Experimental|Hydration ,Trimetazidine & allopurinol|Hydration plus Trimetazidine 35mg once daily will be given to patients before the procedure and up to 24 hours after the procedure and allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
32997085|NCT05540184|Placebo Comparator|Hydration|Hydration only will be given to the patients normal saline at the rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
32997086|NCT05533268|Experimental|Mental Training|mindfulness meditation for 6-weeks.
32997087|NCT05533268|Experimental|Physical Training|Continuous moderate-intensity training for 6-weeks.
32997088|NCT05533268|Experimental|Mental and Physical Training|Combination of mindfulness meditation and continuous moderate-intensity training for 6 weeks.
32997089|NCT05533268|Active Comparator|DASH Diet Plan|Dietary Approaches to Stop Hypertension for 6-weeks.
32997090|NCT05529264|Experimental|Invasive EEG (electrodes are implanted in a participant's brain)|Patients with intracranial electrodes (electrodes are implanted in a participant's brain) undergoing pre-surgical evaluation for clinical reasons will be asked to participate in various study tasks with the recording of intracranial EEG (recording of brain waves via electrodes implanted in a participant's brain) during these tasks.
32997091|NCT05529264|Experimental|Scalp EEG (electrodes are placed on a participant's scalp)|Patients with non-invasive scalp electrodes who are admitted to the hospital for clinical reasons will be asked to participate in various study tasks with the recording of their EEG (recording of brain waves via electrodes attached to a participant's scalp) during these tasks.
32997092|NCT05529264|Active Comparator|Normal Controls|Normal controls will be recruited from family members of patients, from advertisements, or from online tools. There will be no EEG recordings obtained from these participants.
32997093|NCT05529264|Active Comparator|Online Controls|Certain control subjects will be recruited through Amazon Mechanical Turk. These participants will be given their task on the online platform using Qualtric survey function. The task design will be identical to normal controls who are recruited in-person, with the exception of identifiers. There will be no EEG recordings obtained from these participants.
32997094|NCT05523271|No Intervention|Patients undergoing White Light Endoscopy (standard of care)|All subjects in Experimental Arm A will undergo SOC (white-light endoscopy).
32997095|NCT05523271|Experimental|Patients undergoing CAD EYE endoscopy|All subjects in Experimental Arm B will undergo CADEYE endoscopy.
32997096|NCT05522777|Experimental|Test product consumption group|Drink one bottle of Yakult a day
32997097|NCT05514236|Experimental|Virtual reality group|"Participants assigned to the Visual reality group will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
32997098|NCT05514236|Experimental|Music group|"Participants in the music group will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the sound according to her comfort."
32997099|NCT05514236|No Intervention|Control group|While participants in the control group will not be given any Virtual reality or music device.
32997100|NCT05512884|Experimental|Speeded anomia therapy|21h of anomia therapy
32997101|NCT05512884|No Intervention|Standard care|Participants' typical daily routine
32997102|NCT05506852|Experimental|Strategy Training|Participants will play the Breakfast Game with training strategy.
32997103|NCT05506852|Active Comparator|Regular Approach|Participants will play the Breakfast Game without training strategy.
32997104|NCT05503771|Experimental|Intervention Group: ISA-MI|"The ISA-MI study condition involves, in addition to the standard of care described for the SOC group, a clinician training activity related to using the ISA (Infant Sleep Assessment) tool. Clinicians assigned to the ISA-MI Group will view a 20-30-minute recorded video training session on infant safe sleep (including its epidemiology, risk factors and recommendations), use of the ISA tool, and use of motivational interviewing-inspired (MI) communication skills to respond to ISA parent responses. The ISA tool builds on the 2022 AAP infant sleep recommendations and will be implemented at the 2-month WBV.~Parents/patients of physicians in the ISA-MI study condition will also be given several infant safe sleep related products that facilitate compliance with safe sleep recommendations, namely, a portable crib, a sleep sack and a pacifier."
33414443|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
32997105|NCT05503771|Other|Control Group: Standard of Care (SOC)|The SOC study condition consists of WBVs that follow the usual practice of American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age- and developmentally based anticipatory guidance. As part of their training, pediatric residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
32997106|NCT05493761|Experimental|"Denosumab"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive denosumab.
32997107|NCT05493761|Active Comparator|"Alendronate"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive alendronate.
32997108|NCT05488769||Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
32997109|NCT05487248|Experimental|Unresectable locally advanced or metastatic colorectal cancer patients|"● Samples collection:~Collection of blood samples 6 x 9 ml at day 1~Collection of blood samples 4 x 9 ml at day 15 and day 29~Collection of blood samples 4 x 9 ml at week 8 or 12 and every 8 or 12 weeks thereafter (+/- 7 days) until evidence of progressive disease by RECIST 1.1 (according to local assessment)"
32997110|NCT05475483|Experimental|SOM3355 300 mg BID|Administration of SOM3355 in up-titration for 3 weeks up to the maintenance dose of 300 mg BID (twice daily) administered for 7 additional weeks, and down-titration for 2 weeks.
32997111|NCT05475483|Experimental|SOM3355 200 mg BID|Administration of SOM3355 in up-titration for 2 weeks up to the maintenance dose of 200 mg BID (twice daily) administered for 8 additional weeks, and down-titration for 2 weeks.
32997112|NCT05475483|Placebo Comparator|Placebo BID|Administration of matching Placebo BID (twice daily) for 12 weeks.
32997113|NCT05473195|Experimental|Arm 1|BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250)
32997114|NCT05473195|Active Comparator|Arm 2|Isoniazid 300 mg po OD (INH)
32997115|NCT05473195|Experimental|Arm 3|BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125)
32997116|NCT05473195|Experimental|Arm 4|BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250)
32997117|NCT05473195|Experimental|Arm 5|BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
32997118|NCT05473195|Experimental|Arm 6|Ethionamide 250 mg po OD (Eto250)
32997119|NCT05473195|Experimental|Arm 7|Ethionamide 750 mg po given in a single or divided dose daily (Eto750)
32997120|NCT05465616|No Intervention|Placebo|Participants with HbA1c levels between 5.7% and 8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
32997121|NCT05465616|Experimental|Viome's Precision Nutrition Program (VPNP)|Participants with HbA1c levels between 5.7% and 8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
32997122|NCT05463406|Experimental|The PLUS algorithm|"The PLUS clinical management algorithm:~EDs having switched to the intervention period (intervention group) will manage their patients using the PLUS algorithm.~The PLUS algorithm starts with a validated pneumonia clinical prediction score (score of Van Vugt), followed by LUS. In case of positive results of any of these tests, PCT is measured to identify patients who will most likely benefit from antibiotics. A validated clinical severity score will ensure the safety of the intervention in those with discordant results (LUS consolidation and low PCT)."
32997123|NCT05463406|Other|Usual care|Usual care: management as usual
32997124|NCT05462704|Experimental|IV Iron|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.
32997125|NCT05462704|Active Comparator|Oral Iron|Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.
32997126|NCT05462106|Placebo Comparator|Placebo for Study Part 1 (Prodromal AD)|Prodromal AD participants receive placebo at predefined time points over 48 weeks
32997127|NCT05462106|Experimental|ACI-24.060 at Dose A|Prodromal AD participants receive dose A of ACI-24.060 at predefined time points over 48 weeks
32997128|NCT05462106|Experimental|ACI-24.060 at Dose B (Optional)|Prodromal AD participants receive dose B of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
32997129|NCT05462106|Experimental|ACI-24.060 at Dose C (Optional)|Prodromal AD participants receive dose C of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
32997130|NCT05462106|Experimental|ACI-24.060 at Dose D (Optional)|Prodromal AD participants receive dose D of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
32997131|NCT05462106|Placebo Comparator|Placebo for Study Part 2 (Down syndrome)|Participants with Down syndrome receive placebo at predefined time points over 74 weeks
32997132|NCT05462106|Experimental|ACI-24.060 at Dose X|Participants with Down syndrome receive dose X of ACI-24.060 at predefined time points over 74 weeks. Dose X will be a dose already tested in Study Part 1.
32997133|NCT05462106|Experimental|ACI-24.060 at Dose Y (Optional)|Participants with Down syndrome may optionally receive a dose Y of ACI-24.060 at predefined time points over 74 weeks.
32997134|NCT05460520|Sham Comparator|Group 1: VOR readaptation with full-field OKS|This group to undergo VOR readaptation with full-field OKS. Groups 1 will be treated with stationary OKS (sham). (Group 1, n=50).
32997135|NCT05460520|Sham Comparator|Group 2: VOR readaptation with VR googles|This group to undergo VOR readaptation with VR googles. Groups 2 will be treated with stationary OKS (sham). (Group 2, n=50)
32997136|NCT05460520|Active Comparator|Group 3: Supplemental VOR habituation|This group to undergo VOR readaptation with full-field OKS combined with a habituation protocol. (Group 3, n=30)
32997137|NCT05460520|Active Comparator|Group 4: Visual desensitization treatment|This group to undergo VOR readaptation with full-field OKS combined with visual desensitization protocol. (Group 4, n=30)
32997138|NCT05460520|Active Comparator|Group 5: Treatment of gravitational pull with OKS with full-field setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a full-field (Group 5, n=20) .
32997139|NCT05460520|Active Comparator|Group 6: Treatment of gravitational pull with OKS with VR setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a VR setting (Group 6, n=20).
32997140|NCT05458817|Experimental|1. Digital diary|75 participants in the group
32997141|NCT05458817|Active Comparator|2. Paper diary|75 participants in the group
32997142|NCT05458817|Experimental|3. Digital: diary and headache nurse|75 participants in the group
32997143|NCT05458817|Active Comparator|4. Paper diary and conventional headache nurse|75 participants in the group
32997144|NCT05458817|Experimental|5. Digital: diary, headache nurse and clinal psychologist|75 participants in the group
32997145|NCT05458817|Active Comparator|6. Paper diary, conventional headache nurse and conventional clinical psychologist|75 participants in the group
32997146|NCT05458817|Experimental|7. Digital: diary, headache nurse, clinal psychologist and physiotherapist|75 participants in the group
32997147|NCT05458817|Active Comparator|8. Paper diary, conventional: headache nurse, clinal psychologist and physiotherapist|75 participants in the group
32997148|NCT05450952|Active Comparator|Active|Dietary Supplement (Theanine Formulation)
32997149|NCT05450952|Placebo Comparator|Placebo|Placebo Tablet
32997150|NCT05449418|Active Comparator|Enhanced Usual Care|Distribution of COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention [CDC] or other national organization with limited distribution support at long-term care centers.
32997151|NCT05449418|Experimental|Full Intervention|Development of materials co-designed with and tailored to language/cultural affinity groups and distributed with assistance from co-design participants who will serve as peer advocates.
32997152|NCT05442216|Experimental|Experimental Group|"During Cycle 1 and Cycle 2:~Tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-5 of Cycle 1-2 (Cycle is 21 days)~During Cycles 3-12:~Subjects with a marrow CR after Cycle 2 will continue tagraxofusp ONLY for Cycles 3-12 (up to a year of treatment) on Days 1-5 of a 28 day cycle.~For subjects without a marrow CR, azacitidine will be administered intravenously (75 mg/m2) on days 1-7 of Cycle 3-12 (Cycle is 28 days) and tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-3 of Cycle 3-12 (Cycle is 28 days).~Subjects who achieve a marrow CR receiving tagraxofusp only after Cycle 4, will continue tagraxofusp at 12 mcg/kg IV for 5 consecutive days every 28 days until Cycle 12. Subjects who continue to achieve an overall response (CR, CRi, PR, MLFS, marrow CR) receiving tagraxofusp and azacitidine will continue tagraxofusp at 12 mcg/kg IV for 3 consecutive days and azacitidine 75 mg/m2 SQ or IV on Days 1-7 every 28 days until Cycle 12."
32997153|NCT05433103|Experimental|Low-Load Exercise with Blood Flow Restriction|The BFR intervention will combine low-load resistance training with between 60%-80% blood flow occlusion under the supervision of a licensed physical therapist.
32997154|NCT05433103|Active Comparator|Low-Load Exercise Control|The control group with consist only of low-load resistance training under the supervision of a licensed physical therapist.
32997155|NCT05430919|Experimental|REGN5713-5714-5715|3-mAb
32997156|NCT05430919|Experimental|REGN5713-5715|2-mAb
32997157|NCT05430919|Experimental|REGN5715|1-mAb
32997158|NCT05430919|Placebo Comparator|Matching Placebo|
32997159|NCT05427461|Other|Patient with leiomyosarcoma|
32997160|NCT05422053|Experimental|t:slim X2 insulin pump with Control-IQ technology|Adults with type 1 diabetes will use the t:slim X2 insulin pump with Control-IQ technology 1.5 for 3-months of outpatient use. Meal and exercise challenges will be performed.
32997161|NCT05421715|Experimental|ALL ADOLESCENTS|For all adolescents, the proposed treatment consists, in addition to conventional care,an individual digital care and education(TELEDUC-DIAB)for 6 months using digital devices (myDiabby + Kidia).
32997162|NCT05419505|Experimental|Cohort 1: CCH-aaes Dose Evaluation|Participants will be administered CCH-aaes at different doses. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997163|NCT05419505|Experimental|Cohort 2: CCH-aaes Concentration Evaluation|Participants will be administered CCH-aaes at different concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997164|NCT05419505|Experimental|Cohort 3: CCH-aaes Injection Depth Evaluation|Participants will be administered CCH-aaes using different injection depths. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997165|NCT05419505|Experimental|Cohort 4: CCH-aaes Injection Method Evaluation|Participants will be administered CCH-aaes using different injection methods. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997166|NCT05419505|Experimental|Cohort 5: CCH-aaes and Diluent Additive Evaluation|Participants will be administered CCH-aaes and diluent additive. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32864896|NCT04783129|Sham Comparator|Control group|Control group (CG), in which participants followed no education program (lectures)
33414444|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
33414445|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
33414446|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
33414447|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
33414448|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
33414449|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
33414450|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
33414451|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
33414452|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
33414453|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
33414454|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
33414455|NCT05162209|Experimental|Synbiotic|Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
33414456|NCT05162209|Placebo Comparator|Placebo|Oral sachet daily for 12 weeks
33414457|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
33414458|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
33414459|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
33414460|NCT01342237|Experimental|topotecan|
33414461|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
33414462|NCT03157037|Experimental|Imlifidase|Imlifidase 0.25 mg/kg body weight intravenous infusion
33414463|NCT04830943|Experimental|Olfactory and gustatory disorders after covid 19 infection (n = 150)|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 40 treatments (for at least 8 weeks after presentation), after which the cycle was repeated again according to the each patient response to therapy for a maximum of 24 weeks.
33414464|NCT04830943|No Intervention|control group (n = 100)|no drug intervention, just olfactory training using at least 4 strong odors to smell twice daily for at least 15 minutes (every time), for at least 8 weeks after presentation.
33414465|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
33414466|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
33414467|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
32864897|NCT04849572|Active Comparator|Sleep Education|Also referred to as Arm 1. Arm 1 receives sleep education initially.
32864898|NCT04849572|Active Comparator|Delayed Sleep Education|Also referred to Arm 2. Arm 2 receives no initial sleep education.
33033653|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
33414468|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
33414469|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
33414470|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
33414471|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
33414472|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
33414473|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
33414474|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
33414475|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
33414476|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
33414477|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
33414478|NCT04429321|Experimental|Ipilimumab +Nivolumab with Embolization|"Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.~Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently."
33414479|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
33414480|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
33414481|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
33414482|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
33414483|NCT04455295|Experimental|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
33414484|NCT04455295|Placebo Comparator|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
33414485|NCT04455295|Placebo Comparator|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
33414486|NCT04455295|Placebo Comparator|Nonstimulation|Placement of electrode without any stimulation.
33414487|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
33414488|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
33414489|NCT05186701|Experimental|Kinesio taping and Conventional Physical Therapy|Standardized therapeutic kinesio taping (I shaped with 50-100% tension for 72 hours on both shoulders) along with Conventional Physical Therapy including Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
33414490|NCT05186701|Active Comparator|Conventional Physical Therapy|Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
33414491|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
33414492|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
33414493|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
33414494|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
33414495|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
33414496|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
33414497|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
32904055|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
33033654|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
33033655|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
32904056|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
32904057|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
32904058|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
32904059|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
32904060|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
32904061|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
32904062|NCT01272986|Placebo Comparator|Healthy patients|
32904063|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
32904064|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
32904065|NCT01272908|Experimental|Single arm|
32904066|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
32904067|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
32904068|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
32904069|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
32904070|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
32904071|NCT01279538|Experimental|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
32904072|NCT01279538|Experimental|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
32904073|NCT01279538|Experimental|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
32904074|NCT01279538|Experimental|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
32904075|NCT01279538|Placebo Comparator|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
32904076|NCT00741026|Placebo Comparator|Placebo|Placebo
32904077|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
32904078|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
32904079|NCT01273298|Experimental|Bisoprolol|
32904080|NCT01273298|Placebo Comparator|Sugar pill|
32904081|NCT01273376|Experimental|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
32904082|NCT01273376|Experimental|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
32904083|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
32904084|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
32904085|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32904086|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
32904087|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
32904088|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
32904089|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
32904090|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
32904091|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
32904092|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
32904093|NCT04386434|Experimental|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
32904094|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
32904095|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
32904096|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
32904097|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
32904098|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
33105254|NCT04686669|Experimental|Subjects receiving treatment sequence BAC|Subjects will receive treatment sequence BAC on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
33105255|NCT04686669|Experimental|Subjects receiving treatment sequence CBA|Subjects will receive treatment sequence CBA on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
33105256|NCT04207450|Placebo Comparator|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
33414498|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
33414499|NCT04835857||Experimental-Arm|"For the same subject,~ViTrack wrist cuff is applied on one of the wrist~Standard Oscillometric cuff is applied to the brachial artery / wrist of the same arm~Auscultatory cuff is applied to the brachial artery of the same arm"
33414500|NCT05183269|Experimental|Virtual reality|Normal procedure with the use of a virtual reality monitor
33414501|NCT05183269|No Intervention|no virtual reality|Normal procedure without the use of a virtual reality monitor
33414502|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
33414503|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
33414504|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
33414505|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
33414506|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
33414507|NCT01332539||drug-resistant partial epilepsy|
33414508|NCT01332539||controlled partial epilepsy|
33414509|NCT04414735|No Intervention|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
33414510|NCT04414735|Experimental|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
33105257|NCT04207450|Experimental|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
33414511|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
33414512|NCT05182957|Experimental|Anti-PD-1 monoclonal antibody+Lenalidomide+Azacitidine|Anti-PD-1 monoclonal antibody plus Lenalidomide, Azacitidine
33414513|NCT02840474|Experimental|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
33414514|NCT02840474|Experimental|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
33414515|NCT04777981|Experimental|CBDRA60 supplement|Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
33414516|NCT04777981|Placebo Comparator|Placebo|Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
33414517|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
33414518|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
33414519|NCT04889599|Experimental|BH009 (Docetaxel Injection)|Patients will receive single dose BH009 75 mg/m2, as a 1-hour IV infusion.
33414520|NCT04889599|Active Comparator|Docetaxel Injection|Patients will receive single dose Docetaxel Injection 75 mg/m2, as a 1-hour IV infusion.
33414521|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
32904174|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
32904175|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
32904176|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
32904177|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
32904178|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904179|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904180|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904181|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904182|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904183|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
32904184|NCT00246740|Placebo Comparator|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
32997167|NCT05419505|Experimental|Cohort 6: CCH-aaes Dose, Concentration, and Treatment Schedule Evaluation|Participants will be administered CCH-aaes using a different treatment schedule and different doses and concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997168|NCT05419505|Experimental|Cohort 7: CCH-aaes and Antifibrinolytic Agent|Participants will be administered CCH-aaes and an antifibrinolytic agent. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
32997169|NCT05418127|Placebo Comparator|30 Participants receiving Placebo product.|Solution of filtered water, Calcium Carbonate powder, and coconut extract.
32997170|NCT05418127|Active Comparator|30 Participants receiving Active product.|Traditionally-fermented coconut milk kefir.
32997171|NCT05414240|Active Comparator|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
32997172|NCT05414240|Placebo Comparator|Inactive placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
32997173|NCT05413473|Experimental|MR guided radiotherapy|"MR-guided radiotherapy using the Alberta linac-MR P3 system. Contemporary radiotherapy techniques and fractionation schedules will be conducted in the following graduated stages with overlap between stages allowed:~Stage 1: Parallel-opposed pair treatments (palliative) Stage 2: 4 field box and breast treatments (curative or palliative) Stage 3: Radical treatments - multi-field 3DCRT (curative) Stage 4: Radical treatments - multi-field IMRT (curative)"
32997174|NCT05405803|Experimental|Intervention Group|Participants will be asked to visit WPAPP-K at least two times a week for 12 months.
32997175|NCT05405803|Active Comparator|Control group|Participants will have access to a link of the CDC website from baseline and during the duration of the study (12 months).
32997176|NCT05403502|Experimental|t:slim X2 insulin pump with Control-IQ technology utilizing insulin Lyumjev®|Current Control-IQ technology users with type 1 diabetes, age 6-80, will use the t:slim X2 insulin pump with Control-IQ technology 1.5 and Lyumjev insulin for 3-months of outpatient use.
32997177|NCT05400122|Experimental|Experimental Infusion|"Preparative Regimen Administration:~Fludarabine will be given at a dose of 30mg/m2 intravenously daily~Cyclophosphamide will be given at a dose of 500mg/m2 intravenously daily~Investigational Agent Administration:~NK Cell Product will be given as two doses by intravenous infusion on Days 0 (+2 days acceptable) and 14 (+/- 3 days acceptable)~IL-2 will be administered at a flat dose of 6 million units subcutaneously starting on the same day as the first NK cell infusion and will be administered three times weekly (dose level 1) or twice weekly (dose level -1) for up to four weeks total~Vactosertib will be administered at a dose of 200mg twice daily for 5 consecutive days per week, for up to four weeks total."
32997178|NCT05383872|Experimental|Exablate BBBD|Using Exablate Model 4000 Type 2 for liquid biopsy in subjects with Glioblastoma
32997179|NCT05380037||Veterans with chronic stroke|Veterans with chronic stroke (n=50) must 1) have ischemic or hemorrhagic stroke, primary intracerebral hematoma, or subarachnoid hemorrhage with at least 6 month chronicity; 2) demonstrate ability to perform the interview and complete questionnaires and 3) endorse mild to severe psychosocial impairment
32997180|NCT05380037||Caregiver/Loved ones|Caregiver/Loved ones (n=25) must be familiar with the trajectory of function and recovery of the identified Veteran with chronic stroke
32997181|NCT05380037||Rehabilitation providers|Rehabilitation providers (n=25) of Veterans with chronic stroke must provide stroke-related care in the VA Healthcare system including (but not limited to) physical, speech, and occupational therapists, neurologists, and neuropsychologists
32997182|NCT05364242|Experimental|VLA2001|
32997183|NCT05360056|Experimental|Dexcom CGM|
32997184|NCT05355792|Experimental|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive an OmniTaper EV implant system available in the following sizes: diameter 3.4, 3.8, 4.5 and 5.5 mm and lengths 8, 9.5, 11, 13, 15 and 18 mm.
32997185|NCT05349760|Experimental|AMB-05X|AMB-05X will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
32997186|NCT05349760|Placebo Comparator|Placebo|Placebo will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
32997187|NCT05344911|Active Comparator|remifentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with remifentanil）
32997188|NCT05344911|Experimental|alfentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with afentanil
32997189|NCT05344417|No Intervention|Arm 1: Standard of Care|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with neostigmine. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
32997190|NCT05344417|Experimental|Arm 2A: Conventional Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
33033656|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
33033657|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
32997191|NCT05344417|Experimental|Arm 2B: AirSeal® Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with AirSeal® trademark (TM) system under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
33324967|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
33324968|NCT03970499|Experimental|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
32997192|NCT05344417|Experimental|Arm 3A: Conventional Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with conventional insufflation under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
32997193|NCT05344417|Experimental|Arm 3B: AirSeal® Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with AirSeal® TM system under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
32997194|NCT05339438|Experimental|Epileptic patients|Epileptic patients with anterior temporal lobe epilepsy
32997195|NCT05339438|Experimental|Healthy volunteers|Healthy volunteers
32997196|NCT05338021|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
32997197|NCT05338021|Experimental|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
32997198|NCT05338008|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
32997199|NCT05338008|Experimental|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
33324969|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
33324970|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
32997200|NCT05334680||COVID-19|Individuals experiencing COVID-19 like symptoms.
32997201|NCT05334680||Healthy Controls|Individuals without any known significant health problems
32997202|NCT05332509|Experimental|C-BRACE/SCO|The patient is first fitted during 2 months with the C-BRACE orthosis, them, after 2 weeks wash-out period, the patient is fitted with its Stance Controlled Orthosis (SCO).
32997203|NCT05332509|Other|SCO/C-BRACE|The patient is using its Stance controlled orthosis (SCO) during 2 months, then, after 2 weeks wash-out period, the patient is fitted with the C-BRACE orthosis.
32997204|NCT05332145|Experimental|Intervention development and testing|"Phase 1 participants (N=12) will complete the MAP to Health online interview and rate the ease of use, usefulness, intention to use, and theoretical fidelity of the intervention.~Phase 2 participants (N=35) will participate in a proof-of-concept pilot trial via a double-pretest single group design. Participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 week period."
32997205|NCT05325112||FFR-CT Group|Sites who have CCTA and FFR-CT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit.
32997206|NCT05325112||Control Group|Sites who have CCTA but not FFR-CT incorporated into the ED/observation unit.
32997207|NCT05323097||Drowning-related OHCA|Drowning-related OHCA: YES
32997208|NCT05323097||All other OHCA|Drowning-related OHCA: NO
32997209|NCT05322590|Experimental|BXQ-350|BXQ-350 will be administered by IV infusion
32997210|NCT05322590|Placebo Comparator|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion (Stage 2 only)
33033658|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
33324971|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR <2 attended at ED because of Head Injury and with a Head CT performed.
33414522|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
32997211|NCT05320419|Active Comparator|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
32997212|NCT05320419|Active Comparator|Physiotherapy (PT group )|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
33414523|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
33414524|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
33414525|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
33414526|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
32997213|NCT05319691|Active Comparator|Yoga Now (Treatment Group)|An initial 12-week Treatment Phase of weekly virtual yoga classes (Yoga Now) followed by a 12-week Follow-up Phase.
32997214|NCT05319691|No Intervention|Yoga Later (Wait List Control Group)|A wait-list control group (Yoga Later) will receive usual care. After the 24 week study period, participants in Yoga Later will be offered the yoga intervention in a non-study format.
32997215|NCT05314023|Experimental|9 to 19 Years Old: Day 1, Months 2 and 6|Chinese males 9 to 19 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
32997216|NCT05314023|Experimental|9 to 14 Years Old: Day 1, and Month 6|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 6
32997217|NCT05314023|Experimental|9 to 14 Years Old: Day 1 and Month 12|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 12
32997218|NCT05310565|Experimental|Chiropractic Adjustment|Chiropractic high velocity low amplitude adjustment
32997219|NCT05310565|Active Comparator|Light touched-based intervention|Light touch with low amplitude low-velocity intervention to back
32997220|NCT05308797|Active Comparator|Erector Spinae Plane Block|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
32997221|NCT05308797|Active Comparator|Combine Serratus Anterior Plane Block|Combine Serratus Anterior Plane block will be performed at the level of 5th costa with 30 mL of 0.25% bupivacaine (15 mL superficial serratus plane block and 15 mL deep serratus plane block) solution under ultrasound guidance before the operation.
32997222|NCT05306600||Breast cancer|300 patients with locally advanced HER2-positive breast cancer who underwent neoadjuvant therapy followed by breast surgery.
32997223|NCT05306600||Prostate cancer|250 patients with metastatic prostate cancer
32997224|NCT05305638|Experimental|Experimental Group|
32997225|NCT05305638|Experimental|Control Group|
32997226|NCT05303545||All subjects with poliomyelitis sequelae|
32997227|NCT05282992|Experimental|Native type II collagen|Native type II collagen
32997228|NCT05282992|Placebo Comparator|Placebo|Placebo
32997229|NCT05281328|Experimental|CAM2029 once weekly|0.5 mL CAM2029 10 mg, subcutaneous (SC) injection, once weekly
32997230|NCT05281328|Experimental|CAM2029 once every 2 weeks|0.5 mL CAM2029 10 mg, SC injection, every 2 weeks and 0.5 mL placebo, SC injection, once every 2 weeks (alternating with CAM2029 dosing)
32997231|NCT05281328|Placebo Comparator|Placebo|0.5 mL placebo, SC injection, once weekly
32997232|NCT05271656|Experimental|C-Scan System|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
32997233|NCT05267626|Experimental|AU-007 Monotherapy|AU-007 (Q2w) will be administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort
32997234|NCT05267626|Experimental|AU-007 combined with an aldesleukin loading dose|AU-007 (Q2w) will be administered at a fixed dose in combination with a single dose of aldesleukin with the initial AU-007 dose. The aldesleukin dose will be escalated with each Dose Escalation Cohort
32997235|NCT05267626|Experimental|AU-007 combined with aldesleukin given concomitantly|AU-007 will be administered at a fixed dose in combination with a aldesleukin, both administered Q2w. The aldesleukin dose will be escalated with each Dose Escalation Cohort
32997236|NCT05265208|Experimental|Capecitabine combined with SIRT|Patients in the experimental arm will be treated with capecitabine combined with Selective Internal Radiotherapy (SIRT) before surgery.
32997237|NCT05265208|Other|Surgery only|Patients in the control group will receive surgery only.
32997238|NCT05251376|Experimental|LYN-014 Extended-Release Levomethadone HCl|Extended-release levomethadone HCl 187 mg administered orally once on Day 8 of the study.
32997239|NCT05249257||No Treatment - previously treated in parent study|Participants who completed the parent study EN3835-224 (NCT04580303) will be eligible for this study.
32997240|NCT05248555||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.
32997241|NCT05221398||Immune checkpoint inhibitors based adjuvant therapy|Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
32997242|NCT05221398||Without adjuvant therapy|Patients in this arm will not receive any adjuvant therapy.
32997243|NCT05219097||Cell Based Assay (CBA)|Use AChR/MuSK Ab CBA Kit (Tianjin New Terrain Biological Technology Co., Ltd, China) to detect AChR and MuSK Ab of myasthenia gravis
32997244|NCT05219097||RIPA Assay|Use AChR and MuSK Ab radioimmunoassay kit (RSR Limited, UK) to detect AChR and MuSK Ab of myasthenia gravis
32997245|NCT05219097||ELISA Assay|Use AChR Ab ELISA Kit (RSR Limited, UK) and MuSK ELISA kit (IBL Limited, Germany) to detect AChR and MuSK Ab of myasthenia gravis
32997246|NCT05217459|Experimental|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
32997247|NCT05213234|Other|Morning Medication Administration|Subjects are directed to take their medication between 06:00 and 10:00.
32997248|NCT05213234|Other|Night Medication Administration|Subjects are directed to take their medication between 18:00 and 22:00.
32997249|NCT05208866|Experimental|Lixivaptan|Lixivaptan capsules 100-200mg twice daily
32997250|NCT05207033|Active Comparator|Unregulated ad condition|This arm will include exposure to unregulated e-cigarette ads or ads as they appear in modern media.
32997251|NCT05207033|Experimental|Regulated ad condition|This arm will include exposure to regulated e-cigarette ads or ads where we have taken out the appealing features.
32997252|NCT05204459||RRMS, SPMS, PPMS, CIS or RIS|Multiple Sclerosis (relapsing-remitting, primary or secondary progressive forms), clinically isolated syndrome, or radiologically isolated syndrome
32997253|NCT05204459||NMOSD|Neuromyelitis optica spectrum disorders
32997254|NCT05204459||MOGAD|Myelin oligodendrocyte glycoprotein antibody disorders
32997255|NCT05204459||Neurological disorder other than MSRD|Neurological disorders due to neurodegenerative, vascular, or headache conditions that are not related to multiple sclerosis or related disorders.
32997256|NCT05204459||Healthy controls|Healthy controls with no known neurological conditions
32997257|NCT05201287|Experimental|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.
32997258|NCT05196906||Modified Broström operation group|Patients who accept a modified Broström operation
32997259|NCT05196906||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
32997260|NCT05191797|Experimental|Treatment (bomedemstat, atezolizumab)|Patients receive bomedemstat PO QD on days 1-21 and atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32997261|NCT05191446|Experimental|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
32997262|NCT05191446|Active Comparator|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
32997263|NCT05189483|Experimental|Albumin-bound paclitaxel plus camrelizumab therapy arm|Enrolled patients will receive the following treatment: 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks.
32997264|NCT05188820|Active Comparator|Corticosteroid group|Patients will receive intra-articular z-joint injection of cortisone
32997265|NCT05188820|Experimental|PRP group|Patients will receive intra-articular z-joint injection of PRP
32997266|NCT05177055|Experimental|n=17, sleep-school 6 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep-school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997267|NCT05177055|Experimental|n=18, sleep-school 6 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997268|NCT05177055|Active Comparator|n=35 Six-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997269|NCT05164354|Experimental|Aromatherapy|Aromatherapy will be done in the form of a 20-minute application period for three days.
32997270|NCT05164354|Experimental|music concert|"Music concert will be performed in the form of a 20 minute daily practice period for three days."
32997271|NCT05163613|Experimental|Patients with COVID - 19, who we were treated with magnetic stimulation.|"The study group included patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetic stimulation in addition to a standard therapy.~Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization."
32997272|NCT05163613|Experimental|Patients with COVID - 19, who we were treated without magnetic stimulation.|The control group included patients receiving a comprehensive treatment without magnetic stimulation. The patients were in a moderately severe condition.
32997273|NCT05156723|Experimental|Group 1: Subunit recombinant vaccine for the prevention of coronavirus infection|5 volunteers have been vaccinated with a single dose (Stage I)
32997274|NCT05156723|Experimental|Group 2: Subunit recombinant vaccine for the prevention of coronavirus infection|15 volunteers have been vaccinated with a single dose (Stage I)
32997275|NCT05156723|Experimental|Group 3: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers will be vaccinated with the coronavirus vaccine intramuscularly twice (Stage II)
32997276|NCT05156723|Experimental|Group 4: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers have been vaccinated with a single dose of the coronavirus vaccine intramuscularly and then treated with a single dose of placebo (Stage II)
32997277|NCT05156723|Placebo Comparator|Group 5: Placebo|45 volunteers have been vaccinated with placebo intramuscularly twice (Stage II)
32997278|NCT05156281|Experimental|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
32997279|NCT05156281|Active Comparator|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
32997280|NCT05156281|Experimental|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
32997281|NCT05156281|Experimental|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
32997282|NCT05149313|Experimental|Lebrikizumab|Lebrikizumab administered subcutaneously (SC), 250 milligram (mg) dose once every two weeks (Q2W) in the induction period for 16 weeks. Participants achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab 250 mg once every four weeks (Q4W) after Week 20 up to Week 36. Participants not achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16 and 18, followed by 1 injection of lebrikizumab 250 mg Q2W after Week 20 up to Week 52.
32997283|NCT05149313|Placebo Comparator|Lebrikizumab-matching Placebo|Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections each of 250 mg lebrikizumab-matching placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab- matching placebo 250 mg Q4W after Week 20 up to Week 36.
32997284|NCT05147298|Experimental|Environmental group intervention (E only)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment
32997285|NCT05147298|Experimental|Individual-level eHealth phone program intervention (I only)|An automated telephone-based physical activity program.
32997286|NCT05147298|Experimental|Combined group (E and I interventions)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment and an automated telephone-based physical activity program.
32997287|NCT05147298|No Intervention|Control group (no interventions)|No interventions for residents to increase activity levels.
32997288|NCT05147246|Experimental|Intervention Schools - School Staff|
32997289|NCT05147246|Experimental|Intervention Schools - Parent-Child Pairs|
32997290|NCT05147246|No Intervention|Wait-List Control Schools - School Staff|
32997291|NCT05147246|No Intervention|Wait-List Control Schools - Parent-Child Pairs|
32997292|NCT05145036|Active Comparator|Tai Chi exercise|In addition to standard of care participants will be asked to apply Tai Chi. There are 8 movements. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: Ward-off, Rollback, Push, Press, Grab, Split, Elbow strike, and shoulder strike.
32997293|NCT05145036|Active Comparator|Comprehensive training|In addition to standard of care participants will be asked to apply Comprehensive training. There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: stretch exercise, strengthening exercise, and balance exercise.
32997294|NCT05127954|Experimental|Ubrogepant Dose A (12 to 17 Years Old)|Participants will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
32997295|NCT05127954|Experimental|Ubrogepant Dose B (6 to 11 Years Old)|Participants will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
32997298|NCT05122676|Experimental|MI-CARE program|Those automatically identified as eligible and randomized to the MI-CARE arm are outreached by a study nurse care manager and offered the 12-month long virtual Collaborative Care program by telephone or video visits. Individuals are free to accept or decline the offer (e.g., stop/restart, not accept right away) during the 12 months after their randomization date.
32997299|NCT05122676|No Intervention|Usual care|Those identified as eligible and randomized to the usual care arm have no contact with the study. All outcome data for both study arms are collected from secondary, electronic sources.
32997300|NCT05121974|Experimental|Tebipenem-pivoxil arm (Pilot study)|Oral Tebipenem-pivoxil in children with shigellosis
32997301|NCT05121974|Active Comparator|Azithromycin arm (Pilot study)|Oral Azithromycin in children with shigellosis
32997302|NCT05121974|Experimental|Tebipenem-pivoxil arm (Main trial)|Oral Tebipenem-pivoxil in children with shigellosis
32997303|NCT05121974|Active Comparator|Ceftriaxone arm (Main trial)|Intravenous Ceftriaxone in children with shigellosis
32997304|NCT05119270|Experimental|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|Participants suffering from cataract who are candidates for femtosecond laser assisted cataract surgery
32997305|NCT05119270|Experimental|Standard phacoemulsification with the Active Sentry handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the new Active Sentry handpiece
32997306|NCT05119270|Experimental|Standard phacoemulsification with the OZil handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the traditional OZil handpiece
32997307|NCT05111964|Experimental|HIFU Treatment of STS or Intra-abdominal Desmoid Tumour|All participants receive HIFU to their target tumour, hence this is a single arm study with 4 recruitment pathways.
32997308|NCT05107336|Experimental|Cohort 1: AZD2693|Japanese Participants will receive Dose A of AZD2693.
32997309|NCT05107336|Experimental|Cohort 2: AZD2693|Japanese Participants will receive Dose B of AZD2693.
32997310|NCT05107336|Experimental|Cohort 3: AZD2693|Japanese Participants will receive Dose C of AZD2693.
32997311|NCT05107336|Experimental|Cohort 4: AZD2693|Non-Asian Participants will receive Dose C of AZD2693
32997312|NCT05107336|Placebo Comparator|Placebo|Japanese and Non-Asian Participants will receive placebo matching Dose A, B, and C to AZD2693.
33033659|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
33105258|NCT04207450|Experimental|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
32864899|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
32864900|NCT01542645|Experimental|Methadone|Long-acting opioid
32864901|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
32864902|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
32864903|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
32864904|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
32864905|NCT04857450|Sham Comparator|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
32864906|NCT04857450|Active Comparator|Ketamine-Etomidate|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
32864907|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
32864908|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
32864909|NCT04857216||Infraclavicular Group|Block Characteristics of Ultrasound Guided Infraclavicular Block with the Perfusion Index
32864910|NCT04857216||Costoclavicular Group|Block Characteristics of Ultrasound Guided costoclavicular Block with the Perfusion Index
32864911|NCT04782583||CAS|
32864912|NCT04782583||TEMOIN|
32864913|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
32864914|NCT04849182|Active Comparator|Vertistop D|Patients with deficiency (<20 ng/mL, <50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D
32864915|NCT04849182|Active Comparator|Vertistop L|Patients with normal vitamin D levels (>30 ng/mL, >75 nmol/L)
32864916|NCT04849182|No Intervention|Control group|Patients meeting the inclusion criteria with normal levels of vitamin D (>30 ng/mL, >75 nmol/L)
32864917|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
32864918|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
32864919|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
32864920|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
32864921|NCT04840901|Experimental|Lebrikizumab - Pre-Filled Syringe with Needle Safety Device|Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).
32864922|NCT04840901|Experimental|Lebrikizumab - Autoinjector|Lebrikizumab administered SC via autoinjector (AI).
32864923|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
32864924|NCT04849793|Experimental|Experimental|Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
32864925|NCT04849793|No Intervention|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
32864926|NCT04849026|Experimental|Group A|"Period 1: WID-CLZ18~Period 2: Clozaril 100 mg (Clozapine)"
32864927|NCT04849026|Experimental|Group B|"Period 1: Clozaril 100 mg (Clozapine)~Period 2: WID-CLZ18"
32864928|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
32864929|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
32864930|NCT04848155|Active Comparator|Older adults with MCI|
32864931|NCT04848155|Active Comparator|Caregivers|
32864932|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
32864933|NCT04775251|Experimental|one group|The treatment program consisted of upward rotation exercises for 3 sessions/week, for 6 weeks.
32864934|NCT04846127||CanGaroo Envelope|Participants who receive a CanGaroo envelope during their CIED implant.
32864935|NCT04846127||No Envelope|Participants who do not receive an envelope of any kind during their CIED implant.
32864936|NCT04844957|Other|Clinical Study of Vitamin D in Children With NMS|Correlation between vitamin D and symptoms severity of autonomic nervous mediated syncope child and it 's RAAS
33033660|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
33414527|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
32904185|NCT00246740|Experimental|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
32904186|NCT00748982|Experimental|1|
32904187|NCT00748982|Placebo Comparator|2|
32904188|NCT01274858||lung cancer surgery|
32904189|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
32904190|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
32904191|NCT01274936|Experimental|Qishe|
32904192|NCT01274936|Placebo Comparator|Control|Qishe Placebo
32904193|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
32904194|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
32904195|NCT00761930|Experimental|C|fluoride/herbal toothpaste
32904196|NCT00245102|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32904197|NCT01275014|Placebo Comparator|Placebo|
32904198|NCT01275014|Experimental|Dexamethasone|
32904199|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
32904200|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
32904201|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
32904202|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
32904203|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
32904204|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
32904205|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
32904206|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
32904207|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
32904208|NCT03807830|Other|One arm feasbility study|
32904209|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
32904210|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
32904211|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
32904212|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
32904213|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
32904214|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
32904215|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
32904216|NCT00244712|Experimental|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
32904217|NCT00244712|Active Comparator|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
32904218|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
33324972|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
32997313|NCT05106192|Experimental|Cutaneous T-cell lymphomas (CTCL) Participants|"The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas)~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
32997314|NCT05106192|Experimental|Cutaneous B-cell lymphomas (CBCL) Participants|"The first plaque will be treated using standard of care intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas).~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
32997315|NCT05082831|Active Comparator|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.
33324973|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
33324974|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
33324975|NCT00161213|Experimental|Gemcitabine and Imatinib|
33324976|NCT03970187|Experimental|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
32997316|NCT05082831|No Intervention|microfracture surgery only|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the microfracture surgery (standard of care).
32997317|NCT05071820|Experimental|Mobile application program|
32997318|NCT05071820|Active Comparator|Traditional program|
32997319|NCT05070247|Experimental|Dose Escalation: TAK-500 Single Agent (SA) (dosed Q3W or Q2W)|TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (every 2 weeks, Q2W), for up to 1 year.
32997320|NCT05070247|Experimental|Dose Escalation: TAK-500 (dosed Q3W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year, along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.
32997321|NCT05070247|Experimental|Dose Expansion: TAK-500 (dosed Q3W and/or Q2W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Days 1 and 22 (Q3W), or once on Days 1, 15, and 29, in a 42-day treatment cycle (once every 2 weeks, Q2W) with pembrolizumab 200 mg infusion, intravenously, once on Days 1 and 22, in a 42-day treatment cycle (Q3W) for up to 1 year. The dose of TAK-500 for the Dose Expansion arm will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
32997322|NCT05065866|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CC-486 in combination with Duvelisib in patients with lymphoid malignancy. Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 6 dose levels will be used.
32997323|NCT05064878|Experimental|ZX008 0.8 mg/kg/day|Part 1: ZX008 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]) with or without food.
32997324|NCT05064878|Placebo Comparator|Placebo|Part 1: Matching ZX008 placebo will be administered twice a day (BID) in equally divided doses with or without food.
32997325|NCT05064878|Experimental|ZX008|Part 2: Open-label ZX008 will be administered using a flexible dosing regimen, up to ZX008 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]). ZX008 will be administered twice a day (BID) in equally divided doses with or without food.
32997326|NCT05064397|Experimental|Eptinezumab|Participants will receive 4 intravenous (IV) infusions with eptinezumab at Baseline (Day 0) and at the end of Weeks 12, 24, and 36.
32997327|NCT05062265|Active Comparator|Tight Rope Fixation|
32997328|NCT05062265|Active Comparator|tight rope fixation w/ AITFL repair augmentation with an internal brace|
32997329|NCT05048979|Experimental|Exercise|Prospective pre-post pilot study design. (N=54)
32997330|NCT05048979|No Intervention|No exercise|Prospective cohort study design. (N=100)
32997331|NCT05047406|Experimental|Probiotic|2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
32997332|NCT05047406|No Intervention|Control (No Probiotic)|patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
33033661|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
32997333|NCT05042544||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. In settings with high anticipated HCV antibody prevalence (>15%; e.g. drug treatment, prisons, needle and syringe programs), people who have previously been told they have HCV infection, or people who have previously received HCV treatment, testing will be performed using point-of-care HCV RNA testing. In settings with a low anticipated HCV antibody prevalence (<15%; e.g. mental health, homelessness), testing will be performed using point-of-care HCV antibody testing and if positive, point-of-care HCV RNA testing will be performed.
32997334|NCT05035082|Experimental|oral semaglutide|All participants are given tablets used in addition to metformin.
32997335|NCT05035082|Active Comparator|other oral glucose lowering medication|All participants are given tablets used in addition to metformin.
32997336|NCT05026541|Sham Comparator|Nap Practitioners|This is an observational arm of regular nappers. Individuals that take naps at least three times a week will be invited to undergo all of the study procedures for one weekend of data collection.
32997337|NCT05026541|Active Comparator|Shoonya Meditators|This is intervention arm. Participants will learn and practice the fifteen minute shoonya meditation - described as a process of conscious non-doing- and shakti chalana kriya, which is a set of breathing exercises designed as a preparatory practice to shoonya meditation. Participants will practice shoonya meditation twice a day for two months. A weekend of data collection will happen at baseline and two months after they learn the practice.
32997338|NCT05026541|Placebo Comparator|Control Meditators|This is the waitlisted control arm. Participants will practice alternate nostril breathing (sukha kriya) for two months, then will learn shoonya meditation and practice for two months. A weekend of data collection will happen at baseline, two months, and four months.
32997339|NCT05017337||BASILICA-A|"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) patients recruited both retrospectively and prospectively.~Pre- and post-operative (3m and 12m) blood samples taken from prospectively recruited patients. Patients undergoing surgery + neo-adjuvant chemotherapy will be invited to donate an additional blood sample following the end of their neo-adjuvant chemotherapy.~Diagnostic pathology: Where possible fresh seroma aspirate / capsular tissue will be obtained, if not possible the FFPE embedded seroma or tissue block will be requested.~Post-operative pathological FFPE tissue samples obtained from all recruited patients."
32997340|NCT05017337||BASILICA-C|"Patients undergoing capsule related surgery (any-grade of capsular contracture, irradiated and unirradiated capsules) recruited prospectively.~Pre- and post-operative (3m) blood samples taken from all patients. Intra-operative tissue sampling (capsular washings, 2 samples of ADM and 2 samples of non-ADM capsule) from all patients."
32997341|NCT05017337||BASILICA-N|"Implant naive patients undergoing implant insertion surgery recruited prospectively.~Pre- and post-operative (3m and 12 m) blood samples taken from all patients."
32997342|NCT05012904|Experimental|Parent involvement Group|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
32997343|NCT05012904|No Intervention|Control Group|Routine venipuncture procedure was applied to the control group. The parent was present in the child's room but did not participate in the procedure.
32997344|NCT05011565||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50~Having undergone Fontan operation in our hospital or another center~Clinical stability of the patients (preserved ventricular function),~No change in ongoing drug therapy that adversely affects clinical stability,~At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data~Neurological and/or genetic musculoskeletal disease~Having orthopedic and cognitive problems that prevent testing~The patient's and/or family's unwillingness to participate in the study"
32997345|NCT05011565||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease~Not having orthopedic and cognitive problems that prevent testing~The patient's and/or family's willingness to participate in the study"
32997346|NCT04997395|Experimental|MediCabilis Cannabis sativa 50|"The medicinal cannabis used for this study is MediCabilis Cannabis sativa 50, a full spectrum CBD dominant plant based medicinal cannabis containing 50 mg/ml CBD and 2 mg/ml THC.~On commencing the oral medication, it will be titrated over a 2 week period to a dose of 1 ml twice a day (total dose 2 ml = 100 mg CBD and 4 mg THC). Participants will be given a written titration schedule at the initial clinic visit. There will be the potential for a further dose increase to a total dose of 3 ml per day (150 mg CBD and 6 mg THC) at the 1-month follow-up visit."
32997347|NCT04997161|Experimental|SZC arm with enhanced dietary advice|Participants will continue taking Sodium Zirconium Cyclosilicate (SZC), which can be titrated up or down to maintain S-K+ in the range 3.5-5.5 mmol/L; participants will also receive enhanced nutritional advice to consume fruit and vegetables. Advice will be provided by dietitians at study visits and by Noom app between visits.
32997348|NCT04997161|Other|SoC arm with standard dietary advice|SZC will be withdrawn and participants will receive SoC as per site practice, including dietary K+ restriction. Dietary advice will be given by dietitians at study visits and by Noom app between study visits.
32997349|NCT04994977|Experimental|Intra-arterial Chemotherapy|Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
32997350|NCT04984291|Experimental|Zimmer Biomet Total Shoulder Arthroplasty System|Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
32997351|NCT04983797|Experimental|OPTRELL Mapping Catheter|Participants diagnosed with cardiac arrhythmias who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for Atrial and ventricular procedures will be using multi-electrode OPTRELL mapping catheter.
32997352|NCT04969250|Experimental|Group I1|Immediate, one dose. Vaccination at study entry
32997353|NCT04969250|Experimental|Group I2|Immediate, two doses. Vaccination at study entry and Week 4
32997354|NCT04969250|Experimental|Group D1|Deferred, one dose. Vaccination at Week 12 only
32997355|NCT04969250|Experimental|Group D2|Deferred, two doses. Vaccination at Week 12 and Week 16
32997356|NCT04966104|Experimental|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consisted of:~Automated digital counselling resources (educational pages, videos, tools, and trackers)~Chatrooms available 24/7~Weekly 30-minute webcasts led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months)."
32997357|NCT04966104|No Intervention|eUC|eUC provided educational HF self-care resources that are available to the public on professional heart health websites (e.g., Heart Failure Society of Canada, American Heart Association, European Society of Cardiology, Health Canada). Patients were provided with unlimited access to these resources. Subjects were invited by weekly emails to partake in these resources. Self-reported assessments are administered at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months).
32997358|NCT04965077|Experimental|MIL97|
32997359|NCT04956016|Active Comparator|classic rTMS treatment|Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy
32997360|NCT04956016|Active Comparator|treatment with deep rTMS|Arm B: treatment with deep rTMS (use of the H1-shaped coil (helmet)) and standard therapies
32997361|NCT04954027||Patients with a use-related disorder weaning for a substance|
32997362|NCT04950426|Experimental|Treatment with reconsolidation therapy|Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
32997363|NCT04949087|Experimental|Corticosteroid Injection Group|80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection
32997364|NCT04949087|Active Comparator|Platelet-Rich Plasma Injection Group|15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP
32997365|NCT04947917|Experimental|Lymph Node SpotTM Tattoo|"Spot™ ink tattooing will be administered once prior to surgery.~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling."
32997366|NCT04938609|Experimental|Pembrolizumab + SBRT + Surgery|Pembrolizumab administration (3 dose) every 3 weeks and 1 dose before radiation (5 days) therapy followed by an additional administration of Pembrolizumab (2 doses) prior to restaging and surgical resection followed by risk-adapted adjuvant therapy, per standard of care. Patient will then be treated with adjuvant pembrolizumab every 3 weeks for 14 additional doses (17 doses total)
32997367|NCT04935411||nAMD patients|patients diagnosed with Neovascular Age-Related Macular Degeneration
32997368|NCT04934007|Experimental|Active stimulation|Active rTMS stimulation , 2 session per day during 10 days.
32997369|NCT04934007|Sham Comparator|Sham Stimulation|Sham rTMS stimulation , 2 session per day during 10 days.
32997370|NCT04925479|Experimental|Asciminib|"This arm consists of 2 groups:~The pediatric formulation group where the dose is based on body weight (1.3mg/kg)~The adult formulation group where participants will receive a flat dose of 40mg BID"
32997371|NCT04917419|Experimental|Luminotherapy and Psychoeducation Program|
32997372|NCT04917419|Active Comparator|Psychoeducation Program|
32997373|NCT04914000|Experimental|Self Help Materials|Participants will receive a smoking cessation booklet/pamphlet corresponding to their cancer type.
32997374|NCT04899024|Experimental|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
32997375|NCT04899024|Active Comparator|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
32997376|NCT04898062|Active Comparator|CRP-apheresis|Patients randomized to this group will undergo apheresis treatments with treatments every 24 ± 12 h each lasting 4-7 hours, until the CRP value does not rise to ≥ 30 mg/l within 96 h after the last treatment
32997377|NCT04898062|No Intervention|Control|Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease
32997378|NCT04896320|Experimental|Gemcitabine + Tucatinib + Trastuzumab|Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
32997379|NCT04896320|Experimental|Vinorelbine + Tucatinib + Trastuzumab|Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
32997380|NCT04891354|Experimental|Part I: single ascending dose (SAD)|In Part I, each subject will receive a 30 minute i.v. infusion of placebo followed by a 1-hour i.v. infusion of PDNO in parallel with a carrier sodium bicarbonate buffer, the infusion of which will start 5 minutes prior to start of placebo infusion and continue until 15 minutes after end of PDNO infusion. Between the end of placebo infusion and prior to the start of PDNO infusion, there will be a 20-minute stabilisation period with infusion of sodium bicarbonate buffer only.
32997381|NCT04891354|Experimental|Part II: ascending doses of PDNO|In Part II, each subject will receive a 30 minute i.v. infusion of placebo followed by 2 x 30 minute infusions of PDNO at 2 ascending dose levels and one 3-hour infusion of PDNO at a third dose level.
32997382|NCT04886531|Experimental|A|"Weeks 1-3* patients receive either (a) Neratinib, (b) Letrozole or Anastrozole or (c) Neratinib + Letrozole or Anastrozole Weeks 4-24 patients receive Neratinib + Letrozole or Anastrozole and Trastuzumab~*Starting drug intervention varies for the first 3 weeks depending on arms: a, b, and c by randomization."
33414528|NCT05709002|Experimental|MASP+ app & NRT|"MASP+ is an intervention designed to assist Black smokers with HIV who experience elevated anxiety sensitivity to quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.~Nicotine patches will be made available to provide adjunctive support."
32997383|NCT04885491|Experimental|Treatment with PDNO|"Placebo treatment administered during the 120-minute observation period, followed by PDNO infusion. PDNO administered as an i.v. infusion of 5-15 minutes, respectively, for the increased planned dose titration steps: 3, 10 and thereafter steps of max 10 nmol/kg/min until the target effect on the mean pulmonary arterial pressure/pulmonary vascular resistance (MPAP/PVR) or a maximal dose of 120 nmol/kg/min is reached.~After 4 patients have been treated, the internal safety review committee (iSRC) will decide if the start dose will be increased. The new start dose could be in the interval 1 to 5 nmol/kg/min."
33414529|NCT05709002|Active Comparator|QuitGuide app + NRT|"The QuitGuide app is a standard-of-care app that allows users to track nicotine cravings and provides motivational messages.~Nicotine patches will be made available to provide adjunctive support."
33414530|NCT04384393|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
32997384|NCT04883957|Experimental|Cohort A: R/R NHL|Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose [MAD]) and the RP2D can be determined.
32997385|NCT04883957|Experimental|Cohort B: R/R CLL/SLL (low tumor burden)|Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined.
32997386|NCT04883957|Experimental|Cohort C: R/R CLL/SLL (high tumor burden)|Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B.
32997387|NCT04873557|Experimental|Copper Intervention|Intervention with copper-based surfaces plus copper-enriched linen
32997388|NCT04873557|No Intervention|Control Group|Control group without copper intervention
32997389|NCT04866511|Experimental|NET intervention|This study will follow a single case design and will involve delivering and evaluating the child-friendly protocol of NET. Therefore, there will only be one arm (NET intervention) and no comparators.
32997390|NCT04858126|Experimental|Single Group Assignment|ECOM endotracheal cardiac output monitor in patients undergoing cardiac and liver surgery.
32997391|NCT04856566|Experimental|Low Dose THC + 0.05 BAC Alc|Participants will receive low dose of THC along with alcohol leading to a BAC of 0.05.
32997392|NCT04856566|Experimental|High Dose THC + 0.05 BAC Alc|Participants will receive high dose of THC along with alcohol leading to a BAC of 0.05.
32997393|NCT04856566|Experimental|Placebo Drug + 0.05 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.05.
32997394|NCT04856566|Experimental|Placebo Drug + 0.08 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.08.
32997395|NCT04855760|Experimental|REL-1017 25 mg|Participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
32997396|NCT04848337|Experimental|Study Treatment Arm|Lenvatinib 20 mg Orally Day1-21 with Pembrolizumab 200 mg Intravenously (IV) over 30 minutes Day 1. Each cycle = 21 days
32997397|NCT04830995|Experimental|diet program|moderate restricted diet (1800-2000 kcal/day) for four weeks, 3 sessions weekly
32997398|NCT04830995|Experimental|high intensity interval training|high intensity interval training for four weeks, 3 sessions weekly
32997399|NCT04826874|Experimental|Affect Labeling_direct|Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
32997400|NCT04826874|No Intervention|Wait-list|Randomized to a two-week wait-list control
32997401|NCT04812457|Experimental|Physiological cures using pure hyaluronic acid (Hialucic®)|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding
32997402|NCT04812457|Active Comparator|Control group using traditional cure (Betadine Gel).|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure.
32997403|NCT04810871|Experimental|Treatment (surgery)|Patients undergo surgery as indicated clinically when applicable.
32997404|NCT04808505|Experimental|Cohort 1: Cipaglucosidase Alfa/Miglustat in ERT-experienced pediatric IOPD subjects|Pediatric IOPD subjects 6 months to <18 years experiencing clinical decline
32997405|NCT04808505|Experimental|Cohort 2: Cipaglucosidase Alfa/Miglustat in ERT-naïve pediatric IOPD subjects|Pediatric IOPD subjects <6 months
32997406|NCT04801212|Experimental|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
32997407|NCT04801212|Active Comparator|core stability exercises alone|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
32997408|NCT04799587|Active Comparator|P6 Accupressure Group|The pressure point will be stimulated by the presence of the magnet when positioned properly on the P6 acupressure point. Additional pressure may be applied as desired by the study subject but is not necessary for P6 stimulation.
32997409|NCT04799587|Sham Comparator|Sham Pressure Point|The sham pressure point (distal to the P6 acupressure point).
33105259|NCT04322929|Experimental|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
33105260|NCT04686396|Experimental|Interpositional Group|Demineralized bone matrix
33105261|NCT04686396|No Intervention|Control|Without demineralized bone matrix
33105262|NCT04322773|Experimental|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
33105263|NCT04322773|Experimental|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
33105264|NCT04322773|Experimental|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
33105265|NCT04322773|Active Comparator|Standard care|Management as usual
33105266|NCT04322812|Active Comparator|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
33105267|NCT04322812|Placebo Comparator|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
33105268|NCT04070443|Experimental|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
33105269|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
33105270|NCT02888782|No Intervention|Control|Receive regular physician follow up
33105271|NCT04686591|Experimental|AZD9977|"In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL).~In Period 2, one 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)."
33105272|NCT04043494|Other|SR I/II: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~maintenance therapy"
33105273|NCT04043494|Experimental|SR I/II: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment Phase (protocol M)~maintenance therapy"
33105274|NCT04043494|Other|SR: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
32864937|NCT04782115|Experimental|1.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
32864938|NCT04782115|Experimental|1.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 1.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
33105275|NCT04043494|Experimental|SR: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
33105276|NCT04043494|Other|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
33105277|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
32864939|NCT04782115|Experimental|2.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
32864940|NCT04782115|Experimental|2.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
32864941|NCT04782115|Experimental|control group|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of Conbercept every 4 weeks, for 3 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
32864942|NCT01421589|Experimental|Growth Hormone|
32864943|NCT04856670||Control patients undergoing manual cataract surgery|As above
32864944|NCT04856670||Control patients undergoing FLACS|Femtosecond laser assisted cataract surgery
32864945|NCT04856670||Diabetic patients undergoing manual cataract surgery|As Above
32864946|NCT04856670||diabetic patients undergoing FLACS|As Above
32864947|NCT04841057|Experimental|Standard BP limb length|50 cm BP limb length
32864948|NCT04841057|Experimental|Medium BP limb length|100 cm BP limb length
32864949|NCT04841057|Experimental|Long BP limb length|150 cm BP limb length
32864950|NCT04774861||CCTA Group|This is an all-comers group, of all ages and ethnicities who have been evaluated with a CCTA from 2017-2020.
32864951|NCT04848948|Experimental|F.X.Mayr & Biofeedback|two weeks of F.X. Mayr diet and biofeedback
33105278|NCT04043494|Experimental|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
32997410|NCT04793880|Experimental|Medication checklist with cost information|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist with cost information intervention.
32997411|NCT04793880|Active Comparator|Medication checklist|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist without cost information.
32997412|NCT04791709|Experimental|HOLA Group|Participants in this group will receive a multicomponent intervention for 16 weeks.
32997413|NCT04789616|Experimental|Maraviroc (Celsentri)|Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
32997414|NCT04789616|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks)."
32997415|NCT04785300|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
32997416|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
32997417|NCT04757519|Experimental|DPP-GLB Standard|Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
32997418|NCT04757519|Experimental|DPP-GLB Enhanced|Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
32997419|NCT04753216|Experimental|Treatment (bevacizumab, irinotecan sucrosofate)|Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32997420|NCT04742634|Experimental|Phase I Dose Level 1: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle."
32997421|NCT04742634|Experimental|Phase I Dose Level 2: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1-4 of a 28 day cycle."
32997422|NCT04742634|Experimental|Phase II MRD Positive: DEC-C|"35 mg decitabine/100 mg cedazuridine taken by mouth once daily per the schedule determined in the Phase I portion of the study. Cycle 1 Day 1 may take place between Day 42 and Day 100 post-transplant. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation.~Bone marrow biopsy with MyeloSeq-HD will be obtained on Day 180 post-transplant. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C."
32997423|NCT04742634|Active Comparator|Phase II MRD Negative: Observation Arm|"In phase II, up to 77 patients who do not have MRD positivity on Day 30 post-transplant (i.e., the absence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%) will be placed on the observation arm and treated with standard of care.~Patients on the observation arm will be followed every 3 months for 2 years and every 6 months for 3 years for progression and survival"
32997424|NCT04740567|Experimental|Cognitive Intervention|During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.
32997425|NCT04740567|No Intervention|Usual Care|Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.
32997426|NCT04734990|Experimental|Treatment (azacitidine, seclidemstat)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33033662|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
33033663|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
33414531|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
33414532|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
33414533|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
33414534|NCT03155945|Experimental|Olorinab 25 mg TID|Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks
33414535|NCT03155945|Experimental|Olorinab 100 mg TID|Participants received olorinab 100 mg oral tablets TID for 8 weeks
33414536|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
33414537|NCT01342705|Experimental|phlebotomy|
33414538|NCT01342705|No Intervention|control|
33414539|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
33414540|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
33414541|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
33414542|NCT01335815||elective knee and limb endoprothesis|
33414543|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
33414544|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
33414545|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
32864952|NCT04848948|Active Comparator|F.X.Mayr|two weeks of F.X. Mayr diet
32864953|NCT04848948|Experimental|VLCD & Biofeedback|two weeks of very low calorie diet and biofeedback
32864954|NCT04848948|Active Comparator|VLCD|two weeks of very low calorie diet
32864955|NCT04846595|Other|Self questionnaire|The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.
32864956|NCT04774705|Experimental|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|
32864957|NCT04774705|Placebo Comparator|Control group|For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
32864958|NCT04860180|Experimental|A, surgery|adrenalectomy
32864959|NCT04860180|No Intervention|B, observation|conservative follow up
32864960|NCT04390997|No Intervention|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
32864961|NCT04390997|No Intervention|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
32864962|NCT04390997|Other|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
32864963|NCT01422135|Experimental|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.~Intervention: AG200-15 patch"
32864964|NCT01422135|Experimental|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.~Intervention: AG200-15 patch"
32864965|NCT01422135|Experimental|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.~Intervention: AG200-15 patch"
32864966|NCT01422135|Experimental|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen~Intervention: AG200-15 patch"
32864967|NCT01422135|Experimental|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.~Intervention: AG200-15 patch"
32864968|NCT01422135|Experimental|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.~Intervention: AG200-15 patch"
32864969|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
32864970|NCT04390685|Experimental|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
32864971|NCT04390685|No Intervention|Control|
32864972|NCT04848324|Active Comparator|Intervention group|14 patients (14 hands) who received US-guided corticosteroid hydrodissection
32864973|NCT04848324|Active Comparator|Control group|14 patients (14 hands) who received US-guided corticosteroid injection
32864974|NCT04848246|Experimental|Bupropion|
32864975|NCT04848246|Experimental|Behavioural Change Communication|
32864976|NCT04848246|No Intervention|Control|
32864977|NCT04842071|Experimental|18F-NaF eligible patients|
32864978|NCT04782193|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
32864979|NCT04856514|Experimental|Treatment Group|Participation in 16 week telehealth administration of the PEERS protocol for teens (parallel teen and parent/caregiver groups)
32898750|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
32864980|NCT02852213|Experimental|Single treatment arm|"Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency.~6 subjects will be divided in 2 groups of 3. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes.~Subjects will be enrolled into 2 dose groups. Group 1 of 3 subjects will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dosing intervals will be 90 days between the first 3 subjects. Group 2 dosing level will be determined by Group 1 results."
32864981|NCT04038619|Experimental|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
33105279|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
33105280|NCT04686357|Experimental|Intervention group (mET)|Microbiome-driven embryo transfer of a single vitrified blastocyst in an HRT cycle according to the EMMA/ALICE test results.
33105281|NCT04686357|Active Comparator|Control group (FET)|Frozen embryo transfer of a single vitrified blastocyst in an HRT cycle according to the clinical standard practice.
33414546|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
32864982|NCT04807296|Active Comparator|TFLEP|Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.
32864983|NCT04807296|Active Comparator|m-HoLEP|The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
32864984|NCT04774939|Active Comparator|EVLA only|Only main trunk/trunks with venous reflux will be treated
32864985|NCT04774939|Active Comparator|EVLA and sclerotherapy of tributaries|Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy
32864986|NCT04807218|Active Comparator|Nutritional Ketosis Intervention Referral|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
32864987|NCT04807218|Active Comparator|CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention|All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).
32864988|NCT04840277|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
32864989|NCT04840277|No Intervention|Control group|Traditional hearing aid adjustment
32864990|NCT04774783|Experimental|Low-Level Laser Therapy|Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
32864991|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
32864992|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
32864993|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
32864994|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
32864995|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
32864996|NCT04781569||Patients with S. aureus infection|
32864997|NCT04781569||healthy participants|
32864998|NCT04844411|Experimental|Arm A: JNJ-67835989 (Oral Suspension)|Participants will receive a single oral suspension dose of JNJ-67835989 on Day 1 in Part 1 and Part 2.
32864999|NCT04844411|Placebo Comparator|Arm B: Placebo|Participants will receive a single oral solution placebo on Day 1 in Part 1 only (except food effect cohorts).
32865000|NCT04844411|Experimental|Arm C: JNJ-67835989 (Oral Solid Dose)|Participants will receive a single oral solid dose (tablet) of JNJ-67835989 on Day 1 in Part 3.
32865001|NCT04390607||Subjects undergoing revision joint surgery|
32865002|NCT04774471||Women with breast lesions|Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.
32865003|NCT04841837|Experimental|Time-restricted feeding|Restrict all calorie intake within a self-selected 10-hours window for 12 weeks, without necessarily altering diet quality and quantity
32865004|NCT04755127|Active Comparator|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
33105282|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
33105283|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
32865005|NCT04755127|Experimental|arthroscopic synovectomy|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
32865006|NCT04142658|Experimental|Apixaban|Apixaban 5 mg twice daily(BID) or 2.5 mg BID
32865007|NCT04142658|Active Comparator|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
32865008|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
32865009|NCT01545141|Experimental|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
32865010|NCT01545141|Experimental|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
32865011|NCT01545141|Experimental|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
32865012|NCT04756219|Experimental|Contact Video|Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
32865013|NCT04756219|Experimental|Contact Text|Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
32865014|NCT04756219|Experimental|Education Video|Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
32865015|NCT04756219|Experimental|Education Text|Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
32865016|NCT04756219|Placebo Comparator|Control Contact|Participants randomized to this group will read a personal story of a person who survived a heart attack.
32865017|NCT04756219|Placebo Comparator|Control Education|Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
32865018|NCT04856280|Experimental|The kinesiological taping (KT) group (n=15)|6 sessions of taping was applied to the kinesiological taping group, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended. Using the KT ligament technique, it was applied to the supra pubic region with 100% tension in order to reduce contraction in the uterus
32865019|NCT04856280|Active Comparator|The aerobic exercise (AE) group (n=15)|"In the AE group, walking and climbing stairs were given during the menstrual cycle, 45 minutes session per day, 3 days a week over 3 weeks. The exercise protocol consists of 5 minute warm up, 35 min AE and 5 minute cool-down exercises. Warm-up and cool-down exercises include an active range of motion (ROM) exercises for upper and lower extremity. Aerobic exercise includes 30 min of moderate walking and climbing stairs. The aerobic exercise was performed in accordance with the definition of moderate-intensity exercise of the World Health Organization; It was given to the participants that during moderate exercise, the individual should walk with a tempo in a way that he can speak but cannot sing"
32865020|NCT04856280|No Intervention|The control group (n=15)|No intervention was applied to the control group.
32865021|NCT02849639|Placebo Comparator|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
32865022|NCT02849639|Active Comparator|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
32865023|NCT04755751||Pediatric Pompe patients|A retrospective - prospective study evaluating pediatric patients with Pompe before and 2 days after ERT on multiple occasions and different dosing. Evaluation included cardiopulmonary exercise testing (CPET), 6 minute-walking test (6MWT), motor function test (GMFM-88) and self-collected blood samples (on a Guthrie card) for enzyme blood levels.
32865024|NCT01482351|Experimental|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
32865025|NCT01482351|Experimental|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
32865026|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
32865027|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
32865028|NCT04754971|Experimental|Table|
33105284|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
32997427|NCT04733118|Experimental|Patient HER 2+ IHC 3+|Patients ≥18 years of age with previously untreated HER2-positive (HER2[+]) (Immunohistochemistry [IHC] 3+) invasive carcinoma according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and tumor size between >5 to 25 mm by breast magnetic resonance imaging (MRI) and node-negative status by clinical exam, MRI, and ultrasound. Patients must have not been previously treated with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy (ET) for invasive breast cancer. Patients with metastatic disease are not eligible. In patients with suspected axillary node involvement, a negative fine needle aspiration biopsy (FNAB) will be mandatory
32997428|NCT04732884|Experimental|Weight sensor with biofeedback|Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.
32997429|NCT04732884|Experimental|Weight sensor without biofeedback|Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.
32997430|NCT04717466|Experimental|Psoriasis Group|Psoriasis participants will be given Secukinumab for a total of 4 months. This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
32997431|NCT04717466|No Intervention|Healthy Group|Healthy participants will not receive any intervention.
32997432|NCT04714619|Experimental|CB-103 + NSAI therapy|Hormone Receptor (HR)-positive and HER2-negative advanced breast cancer, including metastatic (ABC).Approximately 80 patients
32997433|NCT04690855|Experimental|Study Treatment Arm|"All patients will be treated with induction talazoparib of 1mg PO daily starting Day 1. Patients will then receive 8 Gy x 3 fractions to 1-4 metastatic lesions beginning Day 12,13, or 14 and given QOD. 840 mg of atezolizumab will be given intravenously (IV) on Day 15 of the 1st cycle and then on Day 1 and Day 15 of the remaining cycles. The sequence of administration is not specified on the days in which talazoparib and atezolizumab are given on the same day. Each cycle equals 28 days. Treatment will continue until progression or severe toxicity.~A safety lead in of up to 6 patients will be performed. Immune-related and non-immune related adverse events will be tracked up to 12 weeks post initiation of atezolizumab, as the majority of treatment-related toxicities from talazoparib, radiation, and atezolizumab occur within this time period."
32997434|NCT04689945||Morphine|30 patients who received intravenous morphine intraoperatively, without regional block application
32997435|NCT04689945||Erector Spinae Block|30 patients who had preoperative esp block but did not use morphine during or after surgery
32997436|NCT04689945||Control|30 patients who received multimodal analgesia methods other than ESP block or IV morphine
32997437|NCT04684537|Active Comparator|Shockwave group|each subject will receive extracorporeal shockwave therapy
32997438|NCT04684537|Active Comparator|Injection group|each subject will receive ultrasound-guided piriformis corticosteroid injection
32997439|NCT04682483||Cardiogenic Shock Patients|"Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below.~Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP < 60mmHg or a >30mmHg drop in MAP from baseline, SBP < 90mmHg or a >30mmHg drop in SBP from baseline, Pulse > 100, Cardiac Index < 2.2, Cardiac Power Output ≤ 0.6 or PAPI < 1.0.~Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets."
32997440|NCT04643574|Experimental|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
32997441|NCT04643366|Experimental|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
32997442|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
32997443|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
32997444|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
32997449|NCT04600154|Experimental|MS-20|4ml, twice, daily
32997450|NCT04600154|Placebo Comparator|Placebo|4ml, twice, daily
32997451|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
32997452|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value~Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
32997453|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
32997454|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
33105285|NCT04322461|Experimental|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
33105286|NCT04322461|Experimental|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
33105287|NCT00535275|Experimental|A|
33105288|NCT00535275|Active Comparator|B|Docetaxel monotherapy
33105289|NCT04322344|Experimental|oral escin group|Standard therapy+Escin tablet 40mg*3, os for 12 days
33105290|NCT04322344|Sham Comparator|control group|standard therapy
32865029|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
32865030|NCT04855968|Active Comparator|control (CON)|will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
32865031|NCT04855968|Experimental|Mindfulness/Meditation (MM)|will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)
32865032|NCT00913471||Acute-Longitudinal SCI|
32865033|NCT00913471||Chronic SCI|
32865034|NCT00913471||Healthy volunteers|
32865035|NCT04428840|Experimental|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
32865036|NCT04428840|No Intervention|Off-day|No use of the self-measurement kiosk
32865037|NCT04773847|Experimental|MimetikOss 3D|
32865038|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
32865039|NCT04856124||Treatment resistant depressed outpatients|Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.
32865040|NCT04028479||Validation Cohort|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
32865041|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
32865042|NCT04028479||Retrospective Chart Review Cohorts|"This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms. Because most RWD has been traditionally obtained through retrospective methods, this is also considered the control arm. Data in this arm will be collected without any patient identifiers. This arm is optional."
32865043|NCT05024903|Active Comparator|Control Group: (PWG 1.0)|Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
32865044|NCT05024903|Active Comparator|Intervention group: PWG 2.0|Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead
32865045|NCT04847700|Active Comparator|Minimally invasive vestibular neurectomy|
32865046|NCT04847700|Active Comparator|Tenotomy of the stapedius and tensor tympani muscles|
32865047|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
32865048|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
32865049|NCT05027009|Experimental|Group I (low dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 3 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
32865050|NCT05027009|Experimental|Group II (middle dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 4 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
32865051|NCT05027009|Experimental|Group III (high dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 6 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
32865052|NCT04773769|Experimental|Overall Statistical design|We will treat 9 patients of each tumor type with a tea made of Graviola Leaves. If no responses are observed then the trial will be closed for that particular histological type. Should a response occur, then the trial will continue to the second stage for that cell type until 24 patients are accrued. If 3 or more responses are observed out of 24 cases, then the result will be considered promising.
32865053|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
32865054|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
32865055|NCT05027477|Active Comparator|Radical Prostatectomy|Patients in this group will undergo Radical prostatectomy. There will be about 67 people in this group.
32865056|NCT05027477|Experimental|TULSA Procedure|Patients in this group will undergo TULSA Procedure. There will be about 134 people in this group.
32865057|NCT04847622||Target Population|Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.
32865058|NCT04781803|Experimental|Arm 1|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.
32865059|NCT04781803|No Intervention|Arm 2|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4
32865060|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
32865061|NCT04860024||ADHD|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
32739184|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
32865062|NCT04860024||Healthy|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
32865063|NCT04773691|Experimental|test group|
32865064|NCT04773691|Placebo Comparator|control group|
32865065|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
32865066|NCT04781101|Experimental|conventional therapy|conventional therapy
32865067|NCT04781101|Experimental|RoboGait®|Group 1 (n = 13) received conventional therapy (65 min, 2 days/week ×8) and group 2 (n = 13) received 25 minutes of robot-assisted gait training (RoboGait®) in addition to conventional therapy (40 min, 2 days/week ×8).
32865068|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
32865069|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
32865070|NCT05023343|Active Comparator|Active|Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine
32865071|NCT05023343|Placebo Comparator|Placebo|Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline
32865072|NCT04773535||healthy Volunteers|Adult (>18y) healthy volunteers without previous injuries or pathologies of the hand and upper extremity
32865073|NCT04847076|Experimental|m-health version of WWWT intervention|Include: a) Psychoeducational information for understanding and managing infant behavior and on parenting. This information will be delivered through instant messaging service for mobile phones (i.e., Whatsapp) 3 times a week for four-week period. Each module will include a very brief video offering information regarding a specific topic, a proposed personal exercise and the invitation to assess the perceived usefulness of the information received. Some modules include links to external, complementary information from the Chilean Infancy Policy. b) Contact with the program facilitator. It will allow mothers to ask questions that arise from the topics addressed in the psychoeducational videos. The answers seek to promote the understanding and elaboration of the contents, and operate by providing expert support; c) A virtual group meeting.
32865074|NCT04847076|Other|TREATMENT AS USUAL|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
32865075|NCT04773613|Experimental|Experimental SLP|Infant placed in a SLP on the researcher's lap. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
32865076|NCT04773613|Other|Experimental SEP|Infant placed in a SEP on the researcher's lap. The head rests on the researcher's hand. Shoulder girdle higher than the pelvic girdle, head and back in a straight line at an angle of 30-45° to the ground - slight, natural body bend is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
32865077|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
32865078|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
32865079|NCT04855890|Active Comparator|Cryo-Ablation|Cryo-Balloon (Arctic Front Advance ProTM, Medtronic, Minneapolis, MN, USA) will be advanced to the LA and navigated to the PV's using an inner-lumen circular mapping catheter (Achieve AdvanceTM, Medtronic, Minneapolis, MN, USA). After confirming complete PV sealing by the CB using occlusion angiograms cryothermal energy will be applied for min 120 seconds aiming at PV isolation of all PV's according to the clinical standard.
32865080|NCT04855890|Active Comparator|High Power Short Duration-Ablation|"A detailed electroanatomical map of the left atrium during sinus rhythm will be acquired using Ensite (Abbott, St. Paul, MN, USA).~Upon completion of the LA map, a second transseptal puncture will be performed in order to insert an ablation catheter. To achieve antral PVI irrigated radiofrequency current ablation will be performed using a power of 70W and a flush rate of 8-30ml/min with a duration of 5 seconds for the anterior and 7 seconds for the posterior LA. Ablation catheters used will contain Flexibilty (Abbott, St. Paul, MN, USA) and TactiFlex (Abbott, St. Paul, MN, USA)."
32865081|NCT05024513|Experimental|BD-HAIC (Biliary drainage & HAIC)|The patients enrolled in this arm would receive external percutaneous biliary drainage plus 3Cir-OFF hepatic arterial infusion chemotherapy （HAIC）with oxaliplatin and 5-fluorouracil.
32865082|NCT05024513|Active Comparator|BD-BSC (Biliary Drainage & Best supportive care)|The patients enrolled in this arm would receive biliary drainage, biliary stents,or biliary stents with Iodine-125 seed strands, plus best supportive care.
32898751|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
32898752|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
32904219|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
32739185|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
32904220|NCT00243932|Experimental|2,700 mg CoQ10|
32904221|NCT00243932|Placebo Comparator|placebo|
32904222|NCT00243932|Experimental|1,800 mg CoQ10|
32904223|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
32904224|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
32904225|NCT00243386|Active Comparator|1|Standard prophylaxis
32904226|NCT00243386|Experimental|2|PK-driven prophylaxis
32904227|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
32739186|NCT05437835|Experimental|Diffusion length and anesthetic effect|diffusion length of local anesthetics in the subparaneural space could predict anesthetic effect and duration of analgesia
32904228|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
32739187|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
32739188|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
32739189|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
32739190|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
32739191|NCT05436197|Experimental|PLAYshop Intervention|Participants will receive a 60 minute virtual physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
32739192|NCT05436197|No Intervention|Control|Participants will receive the 60 minute virtual physical literacy workshop, equipment goody-bag, and access to the digital app after completing the follow-up measures.
32739193|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
32904229|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
32904230|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
32904231|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
32904232|NCT00762710|Experimental|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
32904233|NCT00762710|Placebo Comparator|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
32904234|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
32904235|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
32739194|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
32739195|NCT05002179|Experimental|Treatment group|"Treatment group, 3 x 2 Echinaforce chewable tablets (EC, 3x800mg) daily during prevention and 5 x 2 EC (5x800mg) during acute viral Respiratory tract infection vRTIs"
32739196|NCT05002179|No Intervention|Control Group|"No treatment Comparison group. Participants are free to take none or any preventive measure. Participants are requested not to take any Echinacea products"
32739197|NCT05429489|Experimental|Bilevel erector spinae plane block|Bilevel erector spinae block at 3rd and 5th thoracic vertebral levels
32739198|NCT05429489|Experimental|Single level erector spinae plane block|single level erector spinae plane block at 5th thoracic vertebral levels
32739199|NCT05429489|Active Comparator|Intravenous morphine|Intravenous morphine 0.1 mg/ kg
32739200|NCT03107299|Other|Control|
32739201|NCT03107299|Other|Send sms to patients|
32739202|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
32898753|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
32898754|NCT00052910|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
32898755|NCT00052910|Experimental|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
32898756|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
32898757|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
32898758|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
32898759|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
32898760|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
32898761|NCT00112112|Active Comparator|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
32898762|NCT00112112|Placebo Comparator|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
32898763|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
32898764|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
32898765|NCT00115076|Experimental|psoriasis|moderate to severe plaque psoriasis
32898766|NCT05605808|Experimental|Aerobic exercises and diet protocol group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week in addition to the diet protocol specific diet designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
32898767|NCT05605808|Active Comparator|Diet protocol group|The participant will be managed by a specific diet protocol designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
32898768|NCT05605808|Active Comparator|Aerobic exercises group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week for twelve weeks as a total treatment time.
32898769|NCT00254072|Active Comparator|Smaller Stapler|3.5 mm Circular Stapler
32898770|NCT00254072|Active Comparator|Larger Stapler|4.8 mm Circular Stapler
32898771|NCT00151814|Experimental|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
32898772|NCT00153842|Experimental|Bexarotene|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
32898773|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
32898774|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
32904236|NCT04384640||Patients seated after Intra-Tympanic injection|
32904237|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
33105291|NCT04322344|Experimental|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
33414547|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
32997455|NCT04583501|Experimental|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
32997456|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
32997457|NCT04582045||low risk, border bandage|low risk, border bandage
32997458|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
32997459|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
32997460|NCT04571138|Experimental|SCRI-CAR22v2|Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
32997461|NCT04570371|Experimental|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
32997462|NCT04570371|No Intervention|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
32997463|NCT04563494|Active Comparator|IV Dexmethsone and oral placebo|
32997464|NCT04563494|Active Comparator|Oral dexamethasone and IV placebo|
32997465|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
32997466|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
32997467|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
32997468|NCT04552288|Experimental|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
32997469|NCT04549025|Experimental|JTX-4104|Drug: JTX-4014
32997470|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 1)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
32997471|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 2)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
32997472|NCT04542343|Experimental|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
32997473|NCT04541173|Active Comparator|Arm A|TARE alone
32997474|NCT04541173|Experimental|Arm B|TARE then Bevacizumab and Atezolizumab
32997475|NCT04539795|Placebo Comparator|Placebo oral tablet|placebo
32997476|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
32997477|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
32997478|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 3|MPH966
32997479|NCT04536077|Experimental|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
32997480|NCT04536077|Experimental|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
32997481|NCT04530747|Experimental|Metformin + PAP|"Subjects randomized to this arm will be orally given 2000 mg metformin daily. Metformin dosage will be slowly increased to improve tolerance.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
33105292|NCT04322422|Experimental|ICS/LABA plus Montelukast|
32997482|NCT04530747|Placebo Comparator|Placebo oral capsule + PAP|Subjects randomized to this arm will receive placebo matching study drug. Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
32997483|NCT04494633|Experimental|Intervention|Participants will complete the pre-assessments, use the intervention, complete the assessments, wait 2-4 weeks, and complete the assessment a 3/final time.
32997484|NCT04494633|Other|Wait Group|Participants will complete the pre-assessments, wait 2-4 weeks, complete the assessments, use the intervention, complete the assessment a 3/final time.
32997485|NCT04493242|Placebo Comparator|Placebo|Normal saline 100 mL
32997486|NCT04493242|Experimental|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.
32997487|NCT04493242|Experimental|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.
32997488|NCT04483440|Experimental|4D-110 Dose 1|4D-110 IVT injection
32997489|NCT04483440|Experimental|4D-110 Dose 2|4D-110 IVT injection
32997490|NCT04464174|Experimental|Ipatasertib plus capecitabine|Arm A: Ipatasertib (GDC-0068) 400 milligrams (mg) tablets administered orally once a day (noon) on Days 1-14 of each 21-day cycle plus capecitabine 1000 mg/m2 tablets orally twice a day (morning and evening; equivalent to 2000 mg/m2 total daily dose), for 14 days (followed by a 7-day rest period) every 21-day cycle.
32997491|NCT04464174|Experimental|Ipatasertib plus Eribulin|Arm B: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.
33033664|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
33033665|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
33414548|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
33414549|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
33414550|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
33414551|NCT01343719|Experimental|BI 661051 low dose|tablet
33414552|NCT01343719|Experimental|BI 661051 medium dose|tablet
33414553|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
33414554|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
32904238|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
32904239|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
32904240|NCT00243230|Experimental|Double-Blind - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks.
32904241|NCT00243230|Experimental|Double-Blind - Vicriviroc 20 mg|Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
32904242|NCT00243230|Placebo Comparator|Double-Blind - Placebo|Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
32904243|NCT00243230|Experimental|Open-label - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months.
32904244|NCT00243074|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32904245|NCT00241358|Active Comparator|Subcutaneous (SC) Treatment Plan - Donor|"Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
32904246|NCT00241358|Experimental|Intravenous (IV) Treatment Plan - Donor|"Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis~Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
32904247|NCT00241358|Other|Recipients|"Conditioning Regimen~Cyclophosphamide 60mg/kg/day on Days -3 and -2~TBI 550cGy on Day -1~GVHD prophylaxis~*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100~PBSC transplant on Day 0"
32904248|NCT00241280|Active Comparator|Control|etafilcon A contact lens being worn 7 days/6 nights.
32904249|NCT00241280|Experimental|Test|galyfilcon A contact lens being worn 7 days/6 nights.
32904250|NCT00240500|Experimental|HBV-1 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
32904251|NCT00240500|Experimental|HBV-2 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
32904252|NCT00240500|Experimental|HBV-3 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
32904253|NCT00240500|Experimental|HBV-4 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
32904254|NCT00240500|Experimental|HBV-5 Group|neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
32904255|NCT00240500|Experimental|HBV-6 Group|neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
32904256|NCT01275716|Experimental|Patients who are shown the images|
32904257|NCT01275716|No Intervention|Patients who are not shown the images|
32904258|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
32904259|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
32904260|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
32904261|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
32904262|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
32904263|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
32904264|NCT03809390|Experimental|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
32904265|NCT03809390|No Intervention|Control group|Managed based on the standard practice in the study site
32904266|NCT01212107|Experimental|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904267|NCT01212107|Experimental|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904268|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
32904269|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904270|NCT01212107|Experimental|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32997492|NCT04464174|Experimental|Ipatasertib plus carboplatin plus gemcitabine|Arm C: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus carboplatin AUC5 on Day 1 administered intravenously plus gemcitabine 1000 mg/m2 administered intravenously over 30 minutes on Days 1 and 8, every 21-day cycle.
32997493|NCT04463498|Experimental|n=20, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997494|NCT04463498|Experimental|n=20, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997495|NCT04463498|Active Comparator|n=40 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
32997496|NCT04463251|Experimental|RPH-104 80 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
32997497|NCT04463251|Experimental|RPH-104 160 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
32997498|NCT04463251|Placebo Comparator|Placebo|subjects will receive subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
32997499|NCT04456296|Active Comparator|AVEED (Testosterone Undecanoate Injection)|Fixed dosage level of 750 milligrams (mg)/3 milliliters (mL) administered by intramuscular injections.
32997500|NCT04456296|Active Comparator|FORTESTA (Testosterone Gel)|40 mg once daily topical gel administration.
32997501|NCT04456296|Active Comparator|TESTIM (Testosterone Gel)|50 mg once daily topical gel administration.
32997502|NCT04429984||VPRIV: All Participants|Participants with type 1 Gaucher disease who as part of standard or routine clinical practice, have already received VPRIV retrospectively and will further receive VPRIV therapy according to the investigator's judgment for approximately 12 months will be observed prospectively in this PMS study.
32997503|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
32997504|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
32997505|NCT04420598|Experimental|Trastuzumab deruxtecan (DS-8201a)|"Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);~Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;~Cohort 3: HER2-positive BC with progressing BMs after local treatment;~Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;~Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
32997506|NCT04419779|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
32997507|NCT04419779|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.
32997508|NCT04417231|Experimental|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is <10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
32997509|NCT04417231|No Intervention|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
32997510|NCT04412837|Experimental|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
32997511|NCT04412837|Placebo Comparator|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
32997512|NCT04408118|Experimental|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
32997513|NCT04403321|Placebo Comparator|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved.
32997514|NCT04403321|Experimental|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved. Tacrolimus will be given at 1mg bid with the target trough concentration of 4-10 ng/mL throughout the study.
32997515|NCT04369729||Post-Traumatic Headache|Individuals who have post-traumatic headache attributed to mild traumatic brain injury according to ICHD-3 diagnostic criteria
32997516|NCT04369729||Healthy Control|Healthy controls will have no history of traumatic brain injury and no history of migraine or other headaches
32997517|NCT04332744|Active Comparator|Control Arm (Arm A)|Patients will receive enzalutamide capsules orally once daily continuously (160 mg) in addition to standard ADT (unless surgical castration).
32997518|NCT04332744|Experimental|Interventional Arm (Arm B)|Patients will receive enzalutamide capsules 160 mg in combination with talazoparib (PF-06944076) capsules 0.5 mg, both orally daily and continuously in 28-day cycle, in addition to standard ADT (unless surgical castration).
33033666|NCT01965301|Placebo Comparator|Placebo|Single oral dose
33105293|NCT04322422|Active Comparator|ICS/LABA only|
33324977|NCT03970187|No Intervention|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.~Phase 2 (home training): waitlist"
33324978|NCT01075529|No Intervention|fluoxetine|
32997519|NCT04331444|Experimental|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
32997520|NCT04331444|Experimental|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
32997521|NCT04331444|Active Comparator|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
33324979|NCT01073891|Active Comparator|Arm 1|
33324980|NCT01073891|Experimental|Arm 2|
33324981|NCT01073891|Experimental|Arm 3|
32997525|NCT04302740|Active Comparator|LEAP|Housing First plus LEAP
32997526|NCT04302740|No Intervention|Service-As-Usual|Housing First
32997527|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
32997528|NCT04265755|Experimental|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
32997529|NCT04260984|Active Comparator|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
32997530|NCT04260984|Active Comparator|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
32997531|NCT04251221|Experimental|Social Drinkers|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08.
32997532|NCT04246372|Experimental|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
32997533|NCT04246320|Experimental|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
32997534|NCT04231981|Experimental|Interventional arm|Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.
32997535|NCT04230512|Experimental|Locked|The prototype mechanical system is locked from compressing
32997536|NCT04230512|Experimental|Unlocked|The prototype mechanical system is free to compress normally
32997537|NCT04229771|Experimental|Participants who received proparacaine hydrochloride solution in left eye and placebo in right eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in left eye and a drop of basic salt solution (BSS, placebo) in the right eye prior to probing and irrigation.
32997538|NCT04229771|Experimental|Participants who received proparacaine hydrochloride solution in right eye and placebo in left eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in right eye and a drop of basic salt solution (BSS, placebo) in the left prior to probing and irrigation.
32997539|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
32997540|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
32997541|NCT04219956|Experimental|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
32997542|NCT04219956|No Intervention|Control|Usual Diet plus two snacks
32997543|NCT04217278|Active Comparator|R1: Intermediate dose Cytarabine|First Randomisation (closed to recruitment) - control arm: Intermediate dose Cytarabine (1g/m^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
32997544|NCT04217278|Experimental|R1: Vyxeos|First Randomisation (closed to recruitment) - experimental arm: Vyxeos (29mg/65mg/m^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
32997545|NCT04217278|Active Comparator|R2: FB4|Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
32997546|NCT04217278|Experimental|R2: TBF|Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
33324982|NCT03970031|Active Comparator|MSDC-0602K|MSDC-0602K one tablet per day taken orally
33324983|NCT03970031|Placebo Comparator|Placebo|Placebo one tablet per day taken orally
33324984|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
33324985|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
33324986|NCT00208325|Active Comparator|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
33324987|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
32997547|NCT04217278|Active Comparator|R3: FB2|Third Randomisation - 55 years and over (or under 55 with comorbidities) - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
33414555|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
33414556|NCT01316731|Experimental|Exercise|
33414557|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
32997548|NCT04217278|Experimental|Mini-TBF|Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
32997549|NCT04192409|Experimental|Intervention-Smartphone Application|Patients will install a smartphone application that custom-developed for the study and learn to use it with the help of researchers. The application will have the following functions: 1) providing health education information about glycemic control, postoperative management and important of drug compliance; 2) providing alert & record service on patients' DM and CAD medication treatment; 3) aiding patients to conduct self-evaluate by providing questionnaire about patients' recent basic health parameters on times. The information will be interpreted automatically by application and brief feedback will be provided to patients; 4) recording patients' fasting plasma glucose value that input by patients and generate a recent glycemic control report.
32997550|NCT04192409|No Intervention|Control|Patients will receive no additional intervention from researchers except the usual care provided by hospital.
32997551|NCT04190862|Experimental|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
32997552|NCT04190862|Experimental|Cell Therapy Treatment Part B|Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy. E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
32997553|NCT04182334|Experimental|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
32997554|NCT04182334|Sham Comparator|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
32997555|NCT04180904|Active Comparator|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
32997556|NCT04180904|Active Comparator|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
32997557|NCT04180904|No Intervention|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
32997558|NCT04169295|Experimental|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
32997559|NCT04169295|Sham Comparator|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
32997560|NCT04167540|Experimental|Earlier stage PD|
32997561|NCT04167540|Experimental|Later stage PD|
32997562|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
32997563|NCT04146441|Active Comparator|control|chemotherapy
32997564|NCT04144127|Experimental|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
32997565|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
32997566|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
32997567|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
32997568|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
32997569|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
32997570|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
32997571|NCT04124380|Experimental|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
33105294|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
33414558|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
33414559|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
33414560|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
32865083|NCT04855734|Experimental|FACE-Rare Intervention|"FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.~Sessions 1&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.~Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions."
32865084|NCT04855734|No Intervention|Treatment-as-Usual (TAU) Control|To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
32865085|NCT04753801|Experimental|Best Possible Self (writing only)|Participants are asked to think and write about their best possible future self (15 min).
32865086|NCT04753801|Experimental|Best Possible Self (writing+imagining)|Participants are asked to think and write about their best possible future self (15 min) and, then to imagine their positive future (5 min).
32865087|NCT04753801|Experimental|Best Possible Self (writing+mindfulness)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief mindfulness sequence (5 min).
32865088|NCT04753801|Experimental|Best Possible Self (writing+recall)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief recall imagination task about the past two days (5 min).
32865089|NCT04753801|Active Comparator|Writing about the past|Participants are asked to think and write about activities of the past two days (15 min).
32865090|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
32865091|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
32865092|NCT05029193|Experimental|Stroke survivors - Mindfulness intervention|Participants who have had a stroke who are receiving the mindfulness intervention immediately after enrollment (no wait period).
32865093|NCT05029193|No Intervention|Stroke survivors - Waitlist control|Participants who have had a stroke who are assigned to the waitlist.
32865094|NCT05029193|Experimental|Caregivers - Mindfulness intervention|Participants caring for someone who have had a stroke and receiving the mindfulness intervention immediately after enrollment (no wait period).
32865095|NCT05029193|No Intervention|Caregivers - Waitlist control|Participants caring for someone who have had a stroke assigned to the waitlist.
32865096|NCT05023109|Experimental|GP+PD-1+Tight|"Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
32865097|NCT04781413|Experimental|Experimental|"The phase I trial is a dose escalation design with standard 3+3 followed by expansion cohorts.~Level Nab-PTX S-1 Sintilimab~80 mg/m2 80mg/m2 200mg~100 mg/m2 80mg/m2 200mg~120 mg/m2 80mg/m2 200mg~We start at level 1. The recommended dose (RD) is defined as dose equal to the maximum tolerated dose (MTD). If 1 of three patients experiences dose-limiting toxicities (DLT), three more patients will be enrolled at the same dose level. The MTD is defined as the dose level at which two or more of three patients, or at least two of 4-6 patients, have DLTs during one cycle."
32865098|NCT05027789|Active Comparator|Self-Guided Group|Subjects in this group will be provided education on memory support strategies and healthy lifestyles. Participants will decide how they want to implement this information into their daily lives. The study will also provide information on various commercially available digital and other tools that might help participants implement healthy changes their lives. One in every three participants will be enrolled in this group (selected randomly).
32865099|NCT05027789|Active Comparator|Structured Group|Subjects in this group will will be provided with specific recommended behavior targets (e.g., like how much exercise you should engage in each week). Participants will also receive an iPad to use throughout the study and follow up period with the digital application installed. Subjects will be asked to use the digital application to record their activity and to receive reminders to complete this information. Two in every three participants will receive the iPad and digital application. Participants in this group will receive training on how to use the digital application. The researchers can install the digital application on the subjects' personal iPad or smartphone if they prefer.
32865100|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
32865101|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
32865102|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
32865103|NCT04859790|Active Comparator|Active SCAR Intervention|In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.
32865104|NCT04859790|No Intervention|Waitlist Control|Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
32997572|NCT04124380|Experimental|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
32997573|NCT04124380|Active Comparator|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
32997574|NCT04124380|Experimental|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
32997575|NCT04124380|Experimental|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
32997576|NCT04123444|Experimental|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
32997577|NCT04123444|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
32997578|NCT04120025|No Intervention|Control Group|Subject will continue standard of care for GERD symptoms
32997579|NCT04120025|Experimental|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
32997580|NCT04111900|Experimental|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
32997581|NCT04111900|No Intervention|Usual Care|Usual care within intensive care unit
32997582|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
32997583|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
32997584|NCT04105530|Placebo Comparator|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
32997585|NCT04098250|Experimental|Erenumab|140 mg erenumab
32997586|NCT04098250|Placebo Comparator|Placebo|placebo comparator
32997587|NCT04072926|Experimental|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
32997588|NCT04072926|Experimental|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
32997589|NCT04072926|Active Comparator|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
32997590|NCT04072926|Active Comparator|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
32997591|NCT04064567|Active Comparator|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
32997592|NCT04064567|Experimental|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
32997593|NCT04049695|Experimental|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
32997594|NCT04049695|Active Comparator|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
32997595|NCT04041375|Experimental|iNSPiRED|Peer coaching intervention
32997596|NCT04041375|Active Comparator|Usual Care|Directory of resources and encouragement to follow-up with Primary Care Physician
32997597|NCT04040751|Experimental|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
33324988|NCT00208325|Active Comparator|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
33324989|NCT00160667|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day.
33324990|NCT00160667|Experimental|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day).
33324991|NCT00160667|Experimental|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day).
33324992|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
33324993|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
33324994|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
33324995|NCT00160199|Experimental|1|
33324996|NCT00160199|Active Comparator|2|
33324997|NCT00157157|Experimental|Single Arm - All Participants|All subjects enrolled in the study who meet the eligibility criteria.
33324998|NCT00203411|Experimental|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
32865105|NCT04781023|Experimental|Intervention (Colpofix)|intravaginal gel with carboxymtheyl beta-glucan and polycabophil
32865106|NCT04781023|No Intervention|Control|No intervention (standard of care)
32865107|NCT05026463|Experimental|Inspiratory support level with PMI equal to -2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
32865108|NCT05026463|Experimental|Inspiratory support level with PMI equal to 0|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
32865109|NCT05026463|Experimental|Inspiratory support level with PMI equal to +2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
32865110|NCT04859634||Zhongshan Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
32865111|NCT04859634||Shenzhen Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
32865112|NCT04859634||Beijin Tongren Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
32865113|NCT04859634||Xudong Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
32865114|NCT04859634||IKang Physical Examination Center|The participant only needs to take an ultra-widefield fundus image as usual.
32865115|NCT04859634||Yangxi General Hospital People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
32865116|NCT04859634||Guangdong Provincial People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
32865117|NCT05023811|Experimental|[14C]RIST4721|[14C]RIST4721 oral solution
32865118|NCT04859556|Experimental|10k 25G cutter|New cutter, with a 10,000 cut per minute blade
32865119|NCT04859556|Active Comparator|5k 25G cutter|Traditional cutter, with a 5,000 cut per minute blade
32865120|NCT04781335|Active Comparator|Dexycu|
32865121|NCT04781335|Active Comparator|Standard Care Post operative drops|
32865122|NCT04773301|Experimental|LEVOBUPIVACAINE|Patients treated with Levobupivacaine Altan 7.5 mg / ml solution for injection and infusion
32865123|NCT04773301|Experimental|ROPIVACAINE|Patients treated with Ropivacaine Altan 2 mg / ml solution for infusion
32865124|NCT05023031|Experimental|NVP-2102|NVP-2102
32865125|NCT05023031|Active Comparator|NVP-2102-R|NVP-2102-R
32865126|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
32865127|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
32865128|NCT04846998|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
32865129|NCT04846998|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
32865130|NCT04846998|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
32865131|NCT04846998|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
32865132|NCT04846998|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
32865133|NCT04846998|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
32865134|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
32865135|NCT04780867|No Intervention|Routine vaccination (Control)|
32865136|NCT04780867|Experimental|Delay vaccination (Experimental)|
32865137|NCT04846842|Experimental|Gimatecan group|In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
32865138|NCT04780945|Experimental|Olaparib monotherapy|Patients, irrespective of BRCA status, will be treated with olaparib tablet 300 mg bid
32865139|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32865140|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
32865141|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
32865142|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
32865143|NCT04859478|Other|All eligible patients|All patients undergo the same CT protocol in addition to standard care.
32865144|NCT04773223||Open surgery group|Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
32865145|NCT04773223||Endovascular group|Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
32865146|NCT04846686||preeclampsia group|"25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.~Placenta pathological examination will be performed."
33414561|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
33414562|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
33414563|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
33414564|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
32997598|NCT04040751|Active Comparator|Control Carepartners|"Carepartners in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The carepartner will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
32997599|NCT04040751|Experimental|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
32997600|NCT04040751|Active Comparator|Control Stroke Survivors|"Stroke survivors in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. Carepartners of the stroke survivors will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
32997601|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
32997602|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
32997603|NCT04003103|Experimental|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
32997604|NCT04003103|Experimental|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
32997605|NCT04003103|Placebo Comparator|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
32997606|NCT04002115|Experimental|Clofarabine 30 mg/m^2|Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.
32997607|NCT03998748|Experimental|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
32997608|NCT03998748|Active Comparator|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
32997609|NCT03997916|Other|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
32997610|NCT03987503|Experimental|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
32997611|NCT03987503|Active Comparator|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
32997612|NCT03981718|Active Comparator|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
32997613|NCT03981718|Experimental|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
33414565|NCT01316965|Experimental|multifaceted prevention program|
33414566|NCT01316965|No Intervention|usual care|
33414567|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
33414568|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
33414569|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
33414570|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
33414571|NCT01342939||Healthy control subjects|
32865147|NCT04846686||control group|"10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.~Placenta pathological examination will be performed."
32865148|NCT04780633|Experimental|Precede-Proceed based Training Program|The experimental group is the group in which five training sessions interventions are applied.
32865149|NCT04780633|No Intervention|Control group|The control group is the group in which have no educational intervention.
32865150|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
32865151|NCT05025527|Experimental|bpMRI|Man receive the bpMRI for Prostate cancer(PCa) screening
32865152|NCT05025527|Active Comparator|PSA|Man receive the PSA blood test for Prostate cancer screening
32865153|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
32865154|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
32865155|NCT04773145||Femoral neck fracture|Patients over 80 years when suffering of femoral neck fracture with at least one year follow-up.
32865156|NCT05020379|Sham Comparator|Group N|"The patients in Group N will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol. The pain intensity will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS are the simple and most commonly used scales.11 The numerical scale is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable."
32865157|NCT05020379|Experimental|Group ESPB|The patients in the group ESPB will be placed in sitting pozition. A convex probe ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS)
32865158|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
32865159|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
32865160|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
32865161|NCT05021315|Experimental|Iodine group|50 women who received preoperative vaginal cleansing with 10% povidone-iodine.
32865162|NCT05021315|No Intervention|Control group|50 women who did not receive preoperative vaginal cleansing even with tap water.
32865163|NCT04780711||Diagnostic Group|Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided.
32865164|NCT03041610|Experimental|Walking intervention|
32865165|NCT03041610|No Intervention|Control|
32865166|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
32865167|NCT02835989|No Intervention|Control|Usual Care
32865168|NCT00858793|Experimental|A|
32865169|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
32865170|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
32865171|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
32865172|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
32997614|NCT03978598|Experimental|Immediate insertion group|Immediate insertion in the first 24 hours after delivery ENG implant insertion Intervention.
32997615|NCT03978598|Active Comparator|Standard Postpartum Insertion Group|Insertion of the Etonogestrel implant 4-6 weeks postpartum Intervention.
32997616|NCT03977181|Experimental|Health Club|A group-based community health club akin to an ART adherence club
32997617|NCT03977181|Experimental|One-on-one|One-on-one adherence counselling and support
32997618|NCT03977181|No Intervention|Medication pick-up|Community-based medication dispensary
32997619|NCT03974503|Experimental|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
32997620|NCT03974503|Active Comparator|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
32997621|NCT03967197|Experimental|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
32997622|NCT03967197|Placebo Comparator|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
32997623|NCT03954184|No Intervention|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
32997624|NCT03954184|Experimental|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
32997625|NCT03949725|Experimental|Hans Kai program|The Hans Kai program is a peer-led, preventative, self-sustaining, community-based health promotion program for adults of all ages, genders, and socioeconomic circumstances who wish to maintain or improve their health. Hans Kai empowers individuals to take control of their own health and provides a unique opportunity for participants to have an active role in improving or maintaining their health and wellbeing.
32997626|NCT03949725|No Intervention|Wait list control|Participants in the waitlist control group will remain as close to a 'typical' community member as possible as they will be able to receive any health programming normally available to them in Winnipeg, except the Hans Kai program. Standard of care is made available to all members of the control group as related to the healthcare rights of Canadians and Manitobans holding a Manitoba health card. NorWest staff will provide support to the community members without a Manitoba health card in obtaining one. The only deviation from standard care in the waitlist control group will be the pre- and post-intervention visits during which the control participants will fill out self-report questionnaires and undergo physical assessments.
32997627|NCT03944876|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
32997628|NCT03944876|Placebo Comparator|Controls|placebo injections
32997629|NCT03938454|Experimental|Crizanlizumab|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51
32997630|NCT03935646|Experimental|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
32997631|NCT03926026|Experimental|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
32997632|NCT03926026|Placebo Comparator|Placebo QD|Placebo once daily for 14 days
32997633|NCT03926026|Experimental|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
32997634|NCT03926026|Placebo Comparator|Placebo BID|Placebo twice daily for 14 days
32997635|NCT03917251|Other|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
32997636|NCT03917251|Other|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
32997637|NCT03892720|Experimental|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
32997638|NCT03875885|Other|CONNECT Intervention Group - Group A|A web-based intervention (CONNECT) to empower and connect caregivers of newly diagnosed cancer patients to supportive care resources A randomized pilot study will be conducted to assess feasibility and acceptability and obtain data on caregiver and patient outcomes. CONNECT e-tool, re-education and optional referral (2 weeks post CONNECT e-tool). Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
32997639|NCT03875885|Other|CONNECT Comparison Group - Group B|Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
32997640|NCT03875573|Experimental|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy).
33414572|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
33414573|NCT01315535||Fast Titration|
33414574|NCT01315535||Regular Titration|
33414575|NCT01315535||Fast Tritation Including Mandibular Exercises|
33414576|NCT01315535||Regular Tritation Including Mandibular Exercises|
33414577|NCT04376983|No Intervention|Control|Patients will get no intervention
33414578|NCT04376983|Experimental|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
32997641|NCT03875573|Experimental|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w.
32997642|NCT03875573|Experimental|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w and the addition of the anti-CD73 antibody oleclumab IV 3000 mg q2w for 4 administrations, followed by q4w for 3 administrations.
33414579|NCT01332695|Experimental|ST101|ST101 oval tablets
32997643|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
32997644|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
32997645|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
32997646|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
32997647|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
32997648|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
32997649|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
32997650|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
32997651|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
32997652|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
32997653|NCT03732768|Experimental|Radspherin|
32997654|NCT03731000|Experimental|PHIL® device|Using device
32997655|NCT03713619|Active Comparator|secukinumab 1|Secukinumab 300mg every 2 weeks
32997656|NCT03713619|Active Comparator|secukinumab 2|Secukinumab 300mg every 4 weeks
32997657|NCT03713619|Placebo Comparator|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
32997658|NCT03713619|Placebo Comparator|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
32997659|NCT03710109||Concussion|Individuals who have sustained a recent concussion
32997660|NCT03710109||Control Healthy Volunteers|No Intervention
32997661|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
32997662|NCT03672630|Active Comparator|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
32997663|NCT03672630|Active Comparator|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
33414580|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
33414581|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
33414582|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
32997664|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
32997665|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
32997666|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
33414583|NCT04376437|Experimental|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
33414584|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
32997667|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
32997668|NCT03643224|Experimental|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
32997669|NCT03624543|Experimental|Cohort 1: TNBC|N=9 to 24 patients
32997670|NCT03624543|Experimental|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
32997671|NCT03624543|Experimental|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
32997672|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
32997673|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
32997674|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
32997675|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
32997676|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:~Child interactive intervention (dialogic reading and play intervention)~Family Empowerment (positive parenting and grandparenting)~Access to Community Hub and its services~Enhancement to the kindergartens~Health education, screening, and support"
32997677|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
32997678|NCT03596177|Experimental|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
32997679|NCT03596177|Placebo Comparator|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
32997680|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
32997681|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
32997682|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
32997683|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
32904271|NCT01212107|Experimental|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904272|NCT01212107|Experimental|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904273|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32997684|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
32997685|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
32904274|NCT01212107|Experimental|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
32904275|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
33414585|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
32904276|NCT01212107|Experimental|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904277|NCT01212107|Experimental|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
32904278|NCT03808064|Experimental|Intervention arm|After randomization, the FCHVs in the intervention arm will receive training, health education materials and a recording register. After receiving training, they will educate women of their respective ward on cervical cancer screening and prevention through home visits and maintain records in their service register.
32904279|NCT03808064|No Intervention|Control arm|There won't be any intervention in the control arm.
32904280|NCT03801356|Other|Selective Nerve Root Block|Patient will receive a Selective Nerve Root Block injection at the target level prior to surgical intervention.
32904281|NCT04271306|Experimental|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
32904282|NCT04271306|Experimental|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
32904283|NCT04271306|Experimental|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
32904284|NCT04271306|Experimental|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
32904285|NCT04271306|Experimental|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
32904286|NCT04271306|Experimental|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
32904287|NCT01246895||Experimental|Microfracture with BST-CarGel
32904288|NCT01246895||Control|Microfracture without BST-CarGel
32904289|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
32904290|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
32904291|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
32904292|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
32904293|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
32904294|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
32904295|NCT04345484|Experimental|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
32904296|NCT04345484|Active Comparator|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
32904297|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
32904298|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
32904299|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
32904300|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
32904301|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
32904302|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
32904303|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
32904304|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
32904305|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
32904306|NCT03806894||Arab populations|Muslim, Christian, Druze
32904307|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
32904308|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
32904309|NCT01300949|Active Comparator|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
32904310|NCT01300949|Active Comparator|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
32904311|NCT01300949|Active Comparator|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
32904312|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
33414586|NCT01339169|Experimental|YF476 treatment|
32904313|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
32904314|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
32904315|NCT00758420|Placebo Comparator|2|Agitated saline
32904316|NCT00779870||1|healthy volunteers
32904317|NCT00779870||2|mild asthmatics
32904318|NCT00779870||3|moderately-severe asthmatics
32904319|NCT00779870||4|severe asthmatics
32904320|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
32904321|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
32904322|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
32904323|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
32904324|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
32904325|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
32904326|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
32904327|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
32904328|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
32904329|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
32904330|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
32904331|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
32904332|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
32904333|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
32904334|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
32904335|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
32904336|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
32904337|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
32904338|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
32904339|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
32904340|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
32904341|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
32904342|NCT03809546|Placebo Comparator|Placebo|
32904343|NCT03809546|Active Comparator|7.5 mg THC|
32904344|NCT03809546|Active Comparator|15 mg THC|
32904345|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
32904346|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
32904347|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
32904348|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
32904349|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
32904350|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
32904351|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
32904352|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
32904353|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
32904354|NCT00780494|Experimental|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
32904355|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
32904356|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
32904357|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
32904358|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
32904359|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
32904360|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
32904361|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
32904362|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
32904363|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
32904364|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
32904365|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
32904366|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
32904367|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
32904368|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
32904369|NCT01214759|Other|Truvada and Raltegravir|Single arm
32904370|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
32904371|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
32904372|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
32904373|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
32904374|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
32904375|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
32904376|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
32904377|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
32904378|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
32904379|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
32904380|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
32904381|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
32904382|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
32997686|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
32997687|NCT03536728|Experimental|Part 1|Dose escalation of AMXT1501 with a fixed low dose of DFMO will follow a 3 + 3 dose escalation design. The AMXT 1501 starting dose administered in the first cohort will be 80 mg (2 capsules); each capsule contains 40 mg of active drug. The dose will be given orally, once daily, fasted state alone for 14 days, and starting on Day 15 AMXT 1501 80 mg given in combination with fixed low-dose oral DFMO at 250mg 2x per day (BID), for an additional 14 days; for a total 28 days of treatment per cycle. Cycle 2 includes AMXT1501 + DFMO that will be administered for 28 days. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of AMXT1501 alone will increase per Part 1 cohort.
32997688|NCT03536728|Experimental|Part 2|"Dose escalation of DFMO with the Part 1 AMXT1501 RP2D fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be one level below the AMXT 1501 Part 1 RP2D with 500 mg DFMO BID. The morning dose will be given orally of both AMXT1501 and DFMO, in a fasted state. The evening dose of DFMO alone will be given prior to bed-time for 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per Part 2 cohort."
32997689|NCT03536728|Experimental|Expansion|The expansion cohort will include up to 14 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by Part 2 to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
32997690|NCT03485326||Safety|Safety
32997691|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
32997692|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
32997693|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
32997694|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
32997695|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
32997696|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
32997697|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
32997698|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
32997699|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
32997700|NCT03462251|Active Comparator|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
32997701|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
32997702|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
32997705|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
32997706|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
32997707|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
32997708|NCT03430479|Experimental|Cohort A|
32997709|NCT03430479|Experimental|Cohort B|
32997710|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32997711|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32997712|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
32997713|NCT03418038|Experimental|Arm D (ascorbic acid)|Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
32997714|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
32997715|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
32997716|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
32997717|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)~Osimertinib are to be administered orally on a daily basis"
33414587|NCT05251441|Experimental|F50|Patients in the group in which fortification was started when enteral nutrition reached 50 cc/kg
33414588|NCT05251441|Active Comparator|F100|Patients in the group in which fortification was started when enteral nutrition reached 100 cc/kg
32997718|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
32997719|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
32997720|NCT03340766|Experimental|Cohort Ia: Blinatumomab 9/28 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion (CIVI) for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days then 28 µg/day for the remaining days of treatment.~Starting on Day 15 participants also received 200 mg pembrolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) until disease progression or for up to 35 cycles."
32997721|NCT03340766|Experimental|Cohort IIa: Blinatumomab 9/28/56 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 56 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
32997722|NCT03340766|Experimental|Cohort IIIa: Blinatumomab 9/28/112 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 112 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
32997723|NCT03340766|Experimental|Expansion Cohort|This cohort will test the maximum tolerated dose of blinatumomab in combination with pembrolizumab identified in Part 1 of the study.
32997724|NCT03327857|Experimental|Neihulizumab (ALTB-168)|Intravenous doses of Neihulizumab (ALTB-168)
32997725|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
32997726|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
32997727|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
32997728|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks~Cycles/courses ≥4:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
32997729|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
32997730|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.~Day -4: Cyclophosphamide and Fludarabine~Day -3: Cyclophosphamide and Fludarabine~Day -2: Fludarabine~Day -1: Rest~Day 0: GINAKIT cells"
32997731|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
32997732|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
32997733|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
32997734|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
32997735|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
32997736|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
32997737|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
32997738|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
33414589|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
33414590|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
33414591|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
33414592|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
33414593|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
33414594|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
33414595|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
32865173|NCT04859322|Experimental|Healthy Participants|20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention
33414596|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
32865174|NCT02835287|Experimental|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
32865175|NCT02835287|Active Comparator|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
32865176|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
32865177|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
32865178|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
32865179|NCT03041376|Experimental|Walking intervention|
32865180|NCT03041376|No Intervention|Control|
32865181|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
32865182|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
32865183|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
32865184|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy.~Mothers~1 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy."
32865185|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
32865186|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
32865187|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
32865188|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
32865189|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
33414597|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
33414598|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
32865190|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
32865191|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
32865192|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
32865193|NCT04846452|Experimental|NSCLC patients with negative driver genes|Patients with negative driver genes advanced or metastatic NSCLC will receive sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens as first-line treatment.
32865194|NCT04772677|Experimental|BEAM - Infant|BEAM Infant will be delivered via mobile application to mothers with a 6-17 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
32865195|NCT04772677|Experimental|BEAM - Preschool|BEAM Preschool will be delivered via mobile application to mothers with a 18-36 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting Videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
32865196|NCT05029349|Other|VOC analysis|VOC analysis in exhaled air in patients hospitalised for stable severe COPD
32865197|NCT04780243|No Intervention|Pre-intervention group|Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group
32865198|NCT04780243|Experimental|postintervention group|Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.
32865199|NCT05023733||1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1|One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.
32865200|NCT04859244|Experimental|Part 1: GS-441524 (QD, 7 days)|750 mg GS-441524 administered QD for 7 days
32865201|NCT04859244|Experimental|Part 2: GS-441524 (TID, 3 days)|750 mg GS-441524 administered TID for 3 days
32865202|NCT04772833||Autopsy group|Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.
32865203|NCT05025449|Experimental|Non-enhanced FAST exam followed by BEFAST exam|Participants in the emergency department with hemodynamically stable blunt abdominal trauma will receive the standard of care Focused Assessment with Sonography for Trauma (FAST) exam followed by a Bubble-Enhanced FAST exam.
32865204|NCT04845906||Healthy volunteers|There will be 4 separate StatLock™ devices being tested, which will be randomly applied to the participants on their inner (ventral) forearms. Each participant will have 2 separate devices applied, one to each arm. Those participants who have the StatLock ™ Arterial Plus, StatLock™ Dialysis II, or the StatLock IV Select, will also have the foam strip applied.
32865205|NCT05022251||Lumbar radiculopathy|Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
32865206|NCT05022251||Healthy controls|Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.
32865207|NCT04846062|Active Comparator|Intervention|Intervention arm will receive nutrition behavior Children's mothers/caregivers will receive explanatory education and behavior about micronutrient essentiality and utilization. Also, dietary diversification and demonstration in the process of enriching child complimentary food will be given for participants every month for the consecutive six months. Posters and video shows will be used.
32865208|NCT04846062|Active Comparator|control|Control arm will not receive nutrition behavior
32865209|NCT05028725|Experimental|Esophageal Squamous Cell Carcinoma (ESCC) Cases|Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
32865210|NCT05028725|Experimental|Non-ESCC, Esophageal squamous dysplasia (ESD) Cases|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
32997739|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
33414599|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
32865211|NCT05028725|Experimental|Non-ESCC, Control Group|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
32865212|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
32865213|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
32865214|NCT04780165|Experimental|Single-arm|
32865215|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
32865216|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
32865217|NCT05022719|Experimental|PillCam Colon2 procedure with MB-MMX|PillCam Colon2 procedure with MB-MMX
32865218|NCT04772443|Experimental|DWJ1506|
32865219|NCT04772443|Experimental|DWJ1507|
32865220|NCT04772443|Active Comparator|DWC202011|
32865221|NCT04772443|Active Comparator|DWJ1177|
32865222|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
32865223|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
32865224|NCT05026151||non-CO|Consecutive persistent critically ill patients requiring more than 10 days of mechanical ventilation, admitted just before the first COVID-19 wave
32865225|NCT05026151||COVID|Consecutive persistent critically ill COVID-19 patients requiring more than 10 days of mechanical ventilation, admitted during the first COVID-19 wave
32865226|NCT04840524|Other|Conventional preparation design (Chamfer finish line with Butt joint incisal preparation design)|conventional treatment
32865227|NCT04840524|Experimental|New preparation design (Feather edge finish line with feather edge incisal preparation design)|New preparation design
32865228|NCT04779853||Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM|serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).
32865229|NCT04855110|Active Comparator|Day 2 warfarin group|warfarin will be administered on day 2 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
32865230|NCT04855110|Active Comparator|Day 5 warfarin group|warfarin will be administered on day 5 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
32865231|NCT04272749|Experimental|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
32865232|NCT05027867|Experimental|Arm 1|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
32865233|NCT05027867|Experimental|Arm 2|KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
32865234|NCT01485393|Experimental|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
32865235|NCT01485393|Experimental|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
32865236|NCT04772521|Experimental|Intervention|Personalized chat-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for intervention group
32865237|NCT04772521|Placebo Comparator|Control|Regular text-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for control group
32865238|NCT04854876|Experimental|Vaccinated with 1st dose of COVID-19 Vaccine & treated with 5-ALA Phosphate/SFC|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and that will be treated with 150mg 5-ALA Phosphate/SFC for 28 days
32865239|NCT04854876|No Intervention|Vaccinated with 1st dose of COVID-19 Vaccine|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control)
32865240|NCT04772287|Experimental|Toripalimab|
32865241|NCT04772287|Placebo Comparator|Placebo|
32865242|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
32865243|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
32865244|NCT04797390|Active Comparator|Advanced Pneumatic Compression Device (APCD)|Daily self-administered treatment with the Flexitouch® Plus system (FT)
32865245|NCT04797390|Active Comparator|Usual Care|Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
32865246|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
32865247|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
32997740|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
32997741|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
32997742|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
32997743|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
32997744|NCT05705531||Observational (Specimen Collection, Clinical Measures, Patient Surveys)|Archived blood samples will be obtained prior to therapy initiation and at the end of therapy. Subsequent samples will be collected in conjunction with cMRI imaging. Blood samples will be obtained at two study time points, separated by a year. Additional data from patient surveys and basic laboratory tests will be completed.
32997745|NCT05705492|Experimental|Arm I (olanzapine, optional biospecimen collection)|Patients receive olanzapine PO for six weeks on study. Patients may also undergo an optional CT scan and blood sample collection on the study.
32997746|NCT05705492|Placebo Comparator|Arm II (placebo, olanzapine, optional biospecimen collection)|Patients receive placebo PO for six weeks and then receive olanzapine PO for 6 weeks. Patients also undergo an optional CT scan and collection of blood samples on study.
32997747|NCT05705479|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
32997748|NCT05705479|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
32997749|NCT05705466|Experimental|Navtemadlin in combination with pembrolizumab|"Navtemadlin will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
32997750|NCT05705466|Placebo Comparator|Navtemadlin placebo in combination with pembrolizumab|"Navtemadlin placebo will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
32997751|NCT05705453|Experimental|Volitional EMG power|Assessing the change in volitional EMG power during the Brain Motor Control Assement (BMCA) between nonstimulation baseline and stimulation.
32997752|NCT05705414|Experimental|Treatment group Valine then EEA|Valine will be administered as two 4 gm packets administered on dialysis treatment day followed by a washout period and then EEA
32997753|NCT05705414|Experimental|Treatment group EEA then Valine|EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine
32997754|NCT05705388|Active Comparator|POSE2.0 Procedure|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
32997755|NCT05705388|Active Comparator|Liraglutide|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
32997756|NCT05705375|Experimental|waterpipe regular smokers|waterpipe regular smokers will be invited for 3 lab visits where they are allocated (random order) to smoke 3 waterpipe different sizes.
32997757|NCT05705362|Experimental|Simple crossover arm|This arm will receive the main vessel stenting only (with proximal optimization technique).
32997758|NCT05705362|Active Comparator|Side branch opening arm|This arm will receive a side branch opening procedure after the main vessel stenting.
32997759|NCT05705336|Active Comparator|1. Tranexamic Acid Oral Product (n=30 cases)|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.
32997760|NCT05705336|Placebo Comparator|2. Placebo (30 cases)|Nursery team would provide 100ml of water, and 3 tablets of placebo pills administered 2 hours prior to surgery.
32997761|NCT05705323|Experimental|Internet-delivered cognitive behavioral therapy for tinnitus|An 8-week modular cognitive behavioral therapy
32997762|NCT05705323|Experimental|Internet-delivered mindfulness-based therapy for tinnitus|An 8-week mindfulness-based stress reduction.
32997763|NCT05705323|No Intervention|Waiting-list control|The waiting list for 8 weeks.
32997764|NCT05705310|Experimental|Intervention Group|
32997765|NCT05705310|No Intervention|Control Group|Individuals in the control group will receive usual care
32997766|NCT05705284|Experimental|Patients participating in structured multidisciplinary medication review|Patients participating in structured multidisciplinary medication review
32997767|NCT05705245||recruitment|Patients who received alveolar recruitment manouever during bariatric surgery
32997768|NCT05705245||non recruitment|patients who did not receive alveolar recruitment manoeuver during bariatric surgery
32997769|NCT05705219|Experimental|3-dimensional multi-parametric ultrasound imaging (3D-MPUS)|Patients receive sulfur hexafluoride IV and undergo 3D-MPUS imaging over 20 minutes.
32997770|NCT05705180||A Retrospective samples|"Retrospective (samples already stored, CoVaKo study cohort): Retrospective samples were consecutively collected during March 2020 and March 2022 (n=420).~Group 1A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 1B: no RZV (control arm)"
33324999|NCT00203021|Experimental|Glatiramer Acetate: Delayed Start|Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
33325000|NCT00203021|Experimental|Glatiramer Acetate: Early Start|Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.
33325001|NCT00201851|Active Comparator|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
32997771|NCT05705180||B Prospective samples|"Prospective (samples to be recruited, CoVaKo study cohort): Prospective samples will be collected April 2022 to July 2022 (n=180).~Group 2A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 2B: no RZV (control arm)"
32997772|NCT05705167|Experimental|Plitidepsin 2.5 mg|"Best available supportive care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) and plitidepsin (administered as a 1-hour intravenous (IV) infusion, daily for 3 consecutive days, at a dose of 2.5 mg) will be administered to participants of the following groups:~Group 1 - Participants receiving immune-suppression due to hematopoietic or organ transplantation.~Group 2 - Participants receiving B-cell depleting therapies.~Group 3 - Participants receiving other immune-suppressive therapies.~Group 4 - Other situations with immune deficiencies."
32997773|NCT05705167|No Intervention|Control|"Best available supportive care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) will be administered to participants of the following groups:~Group 1 - Participants receiving immune-suppression due to hematopoietic or organ transplantation.~Group 2 - Participants receiving B-cell depleting therapies.~Group 3 - Participants receiving other immune-suppressive therapies."
32997774|NCT05705154|Active Comparator|Standard treatment|"Standard treatment consists of virtual MDT discussion with referrer and advice signposting into local services for specific issues. If a patient is severely affected enough to be seen face to face, they are offered an interdisciplinary consultation, and tailored input from PT OT and psychological services.~Access to standardised information covering the following topics: sleep, pacing, activity management, school reintegration, managing friendships, eating well and emotional wellbeing.~More complex or severely affected patients will receive one to one treatment with members of the MDT as required."
32997775|NCT05705154|Experimental|Intervention|"As above standard intervention plus the new co-designed intervention.~Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~Identifying the connections between body and mind to address anxiety and breathlessness~Coping skills for managing anxiety using principles from narrative therapy and mindfulness~Online materials to improve self-efficacy with home practice~Social connection with other CYP for peer support, and resource sharing~Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
32997776|NCT05705141||Combined metabolic syndrome|HBeAg-positive CHB patients with metabolic syndrome
32997777|NCT05705141||Uncombined with metabolic syndrome|HBeAg-positive CHB patients without combined MS
32997778|NCT05705089|Experimental|Rivaroxaban-based antithrombotic regimen|All patients assigned to the rivaroxaban-based antithrombotic regimen will receive rivaroxaban (15 mg once daily, orally) plus clopidogrel (75 mg daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
32997779|NCT05705089|Active Comparator|warfarin-based antithrombotic regimen|All patients assigned to the warfarin-based antithrombotic regimen will receive warfarin (overlapping with enoxaparin until reaching an INR goal of 2-2.5) plus clopidogrel (75 mg once daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
32997780|NCT05705076|Placebo Comparator|Placebo without anticoagulation|Without any anticoagulation
32997781|NCT05705076|Active Comparator|Low Dose Direct Oral Anticoagulation|Apixaban 2.5 mg twice Rivaroxaban 10 mg plus placebo
32997782|NCT05705063|Experimental|Bipolar Patients|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
32997783|NCT05705037|Sham Comparator|Group A (CPP-ACPF mousse + sham light therapy)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
33033667|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
33325002|NCT00201851|Experimental|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
33325003|NCT00201851|Other|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
32997784|NCT05705037|Placebo Comparator|Group B (placebo mousse + PBMT)|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
32997785|NCT05705037|Experimental|Group C (CPP-ACPF + PBMT)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
32997786|NCT05705024|Active Comparator|Medium dose of allogenic MSC drops|Dose of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL.
32997787|NCT05705024|Sham Comparator|Control Group|For the control group, 50 µL of the freezing media (vehicle) will be injected.
32997788|NCT05704998|Experimental|Posterior Edentulous Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
32997789|NCT05704998|Experimental|Fully Toothed Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
32997790|NCT05704972||Operation Room Nurses|
32997791|NCT05704959|Other|Measurement|
32997792|NCT05704946|Experimental|experiment group|The patients will be given a standard brand of lavender oil by the researcher, and they will be informed about how to use it (they should drop 2 drops of lavender oil on the right side of their pillow and 2 drops on the left side of their pillow every evening for a month after discharge).
32997793|NCT05704946|No Intervention|control group|Standard care will be applied.
32997794|NCT05704920|Experimental|IA Group|Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
32997795|NCT05704920|Other|Group not IA analysis|Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
32997796|NCT05704894|Experimental|Intervention group|"Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between <12g/dL.~Every week (1 to 12), the study medication will be administered 3 times, according to the proposed treatment, for those allocated in the intervention group. All assessments, procedures and notes must be recorded in a source document and in a CRF."
32997797|NCT05704894|No Intervention|Control Group|For the control group, the procedures will be performed according to the institution's standard treatment (Vitamin B12 and folic acid). The use of Iron, Vitamin B12 and folic acid will be allowed both in the intervention arm and in the control arm. Doses should be prescribed at the physician's discretion.
32997798|NCT05704881||Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease|Patient admitted for acute Exacerbation of COPD. The measurement of EtCO2 will be performed at the emergency department
32997799|NCT05704868|Experimental|UniVRse + TAU|UniVRse is a Virtual Reality (VR) intervention targeting social anxiety in First Generation Students (FGS) using cognitive behavioural therapy (CBT) techniques - specifically graded exposure. Participants will have access to UniVRse for a month post-randomisation and it is recommended they complete 6 sessions each 30-minutes long over this period. Exposure to the intervention will be reached if participants complete 2 30-minute sessions. UniVRse is a self-help intervention meaning that participants can engage in the intervention independently. Participants will be supported to progress through the UniVRse programme by a virtual mentor called Sam that will take on the role traditionally undertaken by the 'therapist'. Sam's function will be to provide psychoeducation, provide instruction on how to use the VR kit and interact with the virtual environment, and provide support and encouragement. Participants will be able to complete the intervention either on campus or at home.
32997800|NCT05704868|No Intervention|Waitlist + TAU|We will be using a wait list control group. The wait list control group will receive treatment as usual for the duration of the trial. Treatment as usual may include active monitoring, meetings with academic advisors, psychiatric medication, and/or support from an NHS mental health team. We will not withhold treatment from the control group, but prospective participants may not be eligible to take part if they have current or confirmed plans to receive a psychology therapy (see exclusion criteria). Once the trial has ended, the participants in the control arm will be the first to be offered UniVRse when it is taken up by university support services.
33325004|NCT03969485|Experimental|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
33325005|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
33325006|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
33325007|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
33325008|NCT03967769|No Intervention|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
33325009|NCT03967769|Experimental|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
33325010|NCT03967769|Experimental|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
33325011|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
33325012|NCT03129100|Experimental|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
32865248|NCT04854720|Experimental|Group 1 (Fuji II LC-Fuji Triage)|In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
32997801|NCT05704855|Experimental|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) items each week. Participants will also participate in bi-weekly, 30-40 minute, remotely-delivered behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). The program will be taught by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
32997802|NCT05704855|Active Comparator|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
32997803|NCT05704842|Other|Exercise|Intervention: Subject will be assessed by a Physical Therapist. Based on the assessment, the Physical Therapist will provide the patient with a home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises. Patients will be asked to complete a symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
32997804|NCT05704842|No Intervention|Control|Subject will not be provided an exercise program but will be asked to complete the symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
32997805|NCT05704829|Experimental|T-DXd: HER2+ and low-intermediate risk for recurrence|12 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
32997806|NCT05704829|Experimental|T-DXd: HER2+ and intermediate-high risk for recurrence|18 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
32997807|NCT05704829|Other|Control: HER2+ and low-intermediate risk for recurrence|Standard-of-Care-Treatment: 12 weeks PAC+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
32997808|NCT05704829|Other|Control: HER2+ and intermediate-high risk for recurrence|Standard-of-Care-Treatment: 18 weeks PAC/DOC+Carbo+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
32997809|NCT05704816||Quincke (Q)-25 Gauge|
32865249|NCT04854720|Experimental|Group 2 (Clinpro XT Varnish-Fuji Triage)|In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
32997810|NCT05704816||Quincke (Q)-26Gauge|
32997811|NCT05704816||Quincke (Q)-27 Gauge|
32997812|NCT05704816||Pencil-point (P)-25Gauge|
32997813|NCT05704816||Pencil-point (P)-26Gauge|
32997814|NCT05704816||Pencil-point (P)-27Gauge|
32997815|NCT05704790|Experimental|Intervention|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
32997816|NCT05704777|Experimental|exercise|The intervention (endurance + resistance training) group will perform 48 training sessions (24 weeks, twice per week). In each session, they will perform the leg and arm cycling exercises during the first half of the session (15 minutes of leg cycling and 15 minutes of arm cycling) and resistance training exercises involving the lower-body (e.g., squat) and upper-body (e.g., a variety exercises performed against the resistance imposed by elastic bands) during the second half of the session.
32997817|NCT05704777|No Intervention|control|The control group will not perform any supervised training program, and will follow standard care.
32997818|NCT05704764|No Intervention|Minimally Enhanced TAU|Participants assigned to the minimally enhanced treatment-as-usual condition will receive an educational pamphlet about internalized stigma to read at their leisure and will be encouraged to continue in all their customary HIV- and substance use-related services.
32997819|NCT05704764|Experimental|ESS-HSU|Using the materials developed during study year one, up to nine approximately 60-90 minute sessions will be carried out with groups of 8-10 participants at a time randomized to receive ESS-HSU. Each by session will be administered by two facilitators and will be carried out over a virtual platform (e.g., Zoom, Teams). Any session hand-outs will be mailed and/or emailed to participants prior to each session and shared onscreen. Participants in the ESS-HSU condition may also receive study-provided tablet computers with data plans to facilitate their engagement in the intervention (as needed).
32997820|NCT05704699|Experimental|eTRE|participants allocated to this group are required to consume food during 0800h and 1600h.
32997821|NCT05704699|Active Comparator|eTRE with BISC|participants allocated to this group are required to consume food during 0800h and 1600h as well as complete 3 sessions of BISC per week.
32997822|NCT05704660|Experimental|Adjusted and modified Cognitive-Biased Modification Task|The intervention is based on a Go/No-Go task.
32997823|NCT05704660|Placebo Comparator|Normal Cognitve-Biased modification Task|The Sham-intervention is based on a Go/No-Go task.
32997824|NCT05704634|Experimental|Cohort A : EGFR-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
32997825|NCT05704634|Experimental|Cohort B: LKB1-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
33325013|NCT03129100|Experimental|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
33325014|NCT03129100|Placebo Comparator|Placebo|Participants received subcutaneous dose of placebo.
32997826|NCT05704608|Experimental|Experimental Group|Aerobic training program was performed by participants.
32997827|NCT05704608|No Intervention|Control group|No intervention was performed by the participants.
33414600|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
32997828|NCT05704595|Other|Initial outpatient management strategy, including outpatient IV diuretics in clinic|
32997829|NCT05704595|Other|Initial hospitalization-based management strategy|
32997830|NCT05704413||digestive cancer or IBD|Patient with digestive cancer or IBD having surgery with intestinal resection planned in the Visceral Surgery Department of St Antoine Hospital
32997831|NCT05704400|Experimental|single arm|
32997832|NCT05704387|Active Comparator|restrictive fluid therapy group|Patients in this group will have a restrictive fluid therapy (1 ml/kh/h) from anesthesia induction until end of liver resection.
32997833|NCT05704387|Experimental|individualized GDFT group|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommendation of the AFM software in order to optimize patient's stroke volume (SV)
33414601|NCT05708690|Experimental|Tranexamic Acid Topical|The treatment of interest was application of Topical Tranexamic Acid (5 gram in 50 mL warm normal saline). The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure)
33414602|NCT05708690|Placebo Comparator|Placebo|The control group is given 100 mL of warm normal saline. The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure).
33414603|NCT01343875||surgery, biceps tear|
32997834|NCT05704374|Experimental|Fibromyalgia group|"In the first phase of the experiment, the effect of sympathetic tone change on T- and H-reflexes will be evaluated.~In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to these patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes."
32997835|NCT05704374|Other|Healthy control group|The effect of sympathetic tone changes on T- and H-reflexes will be evaluated in healthy cases.
32997836|NCT05704348|Active Comparator|No gastropexy|Sleeve gastrectomy without gastropexy.
32997837|NCT05704348|Experimental|Gastropexy|Sleeve gastrectomy with gastropexy
32997838|NCT05704322|No Intervention|Usual care group|The control group will not receive any intervention, they will receive usual care and only participate in the pre and post tests.
32997839|NCT05704322|Experimental|Wim Hof Method - breathing and mindset exercise|The first intervention group will practice the breathing and mindset exercise.
32997840|NCT05704322|Experimental|Wim Hof Method - breathing and mindset exercise and cold exposure|The second intervention group will also practice the cold exposure (i.e, breathing, mindset and cold exposure)
32997841|NCT05704283|Experimental|Diagnostic (3D-US)|Patients undergo 3D-US on study. Patients who have an ALN clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.
32997842|NCT05704270|Experimental|Adaptive cognitive training|This arm is the intervention arm. Participants randomized to this arm will use a tablet to receive the multi-domain adaptive cognitive training, which will be delivered 30 minutes at least 5 times a week for 12 weeks.
32997843|NCT05704270|Active Comparator|Active control|This arm is the control arm. Participants randomized to this arm will use the same tablet to receive the cognitive training of low difficulty level with no adaptive change. The intervention dosage will be the same, which is 30 minutes each time, at least 5 times a week for 12 weeks.
32997844|NCT05704257|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
32997845|NCT05704231|Experimental|Experimental: Intervention Group|Motivational Interviewing with WhatsApp video call The individuals in the intervention group will be given a smoking cessation education and motivational interview with a WhatsApp video call for 3 months. The motivational interview will be applied every two weeks, 6 times in total. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the intervention. tumor recurrence and progression will be checked by cystoscopy at 3rd and 12th months
32997846|NCT05704231|No Intervention|No Intervention: Control Group|the control group received the routine care/education provided in the hospital. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the routin hospital care. Both intervention and control groups' tumor recurrence and progression will be checked by cystoscopy at the 3rd and 12th months
32997847|NCT05704218|Other|domestic HP|"All the patients will be in the same arm until obtention of the final diagnosis.~The final diagnosis will be used to compare data of serology to determine thresholds"
32997848|NCT05704179||Patients who undergo cesarean section|Obstetric comorbidity index will be calculated for all patients, obstetric quality of recovery score will be evaluated in postpartum period( on the first and second day postpartum)
32997849|NCT05704166|Experimental|Pirfenidone|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
32997850|NCT05704166|Placebo Comparator|Placebo|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
32997851|NCT05704153|Sham Comparator|Sham|Control group to be subjected to sham stimulation.
32997852|NCT05704153|Experimental|30 hertz (Hz) Stimulation|Group of patients treated via 30Hz transcutaneous electrical nerve stimulation
32997853|NCT05704153|Experimental|1Hz Stimulation|Group of patients treated via 1Hz transcutaneous electrical nerve stimulation
32997854|NCT05704140||catheter based dialysis|All patients receiving catheter based dialysis in Vienna as of November 2022
33414604|NCT04851821|Experimental|Quercetix group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
33414605|NCT04851821|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
33414606|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
33414607|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
32997855|NCT05704127|Experimental|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
32997856|NCT05704127|Experimental|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
32997857|NCT05704114|Experimental|Treatment Arm|This is a single arm study. All participants are receiving the treatment.
32997858|NCT05704101||Asthma patients (n=20) out of them 10 with mild, controlled and 10 with severe, uncontrolled asthma|"Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~OSA severity: defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h~Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~Assessment of systemic inflammation in blood samples."
32997859|NCT05704101||Controls (n=10) (and in a group of healthy controls [2:1] matched for age, sex and BMI).|"Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~OSA severity: defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h~Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~Assessment of systemic inflammation in blood samples."
32997860|NCT05704088|Active Comparator|study group|Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one year.
32997861|NCT05704088|Placebo Comparator|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
32997862|NCT05704075|Other|Control Group|Conventional Treatment: Dressing + Negative Pressure Wound Therapy
32997863|NCT05704075|Experimental|TTT Group|Dressing + Negative Pressure Wound Therapy + Transverse Tibial Transport
32997864|NCT05704023|Experimental|Mobile app (WIapp) group|"Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between;~Mobile app with instructions on exercise at home and daily reminder to exercixse"
32997865|NCT05704023|No Intervention|Control group|Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between, written instructions on exercises at home
32997866|NCT05703997|Experimental|Maintenance treatment with cyclic, 5-day calorie restriction plus atezolizumab|"The experimental maintenance treatment will consist of:~triweekly cycles of 5-day calorie restriction (on days -2 through 2 of each cycle) in combination with~atezolizumab (at a dose of 1200 mg, administered intravenously on day 0 of each cycle)~The experimental maintenance treatment will be administered until the occurrence of unacceptable toxic effects, disease progression, consent withdrawal or patient death.~Patients interrupting cyclic calorie restriction for any reason other than disease progression may continue the maintenance treatment with atezolizumab alone, if clinically indicated."
32997867|NCT05703984|Experimental|GC2129A + Reference drugs|Period 1: GC2129A Period 2: Individual Components
32997868|NCT05703984|Experimental|Reference drugs + GC2129A|Period 1: Individual Components Period 2: GC2129A
32997869|NCT05703945|Experimental|Training group|Participants benefit from an 8-week training program of muscle strengthening
32997870|NCT05703945|Sham Comparator|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
32997871|NCT05703932|No Intervention|Group One|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD
32997872|NCT05703932|Active Comparator|Group Two|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD ;and will take exercise program including; joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises . Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
32997873|NCT05703906|Experimental|Telerehabilitation|"All patients will receive a kit home-based consisting of a tablet home, an exercise equipment and access to a daily individualized training program based on their needs (i.e., motor, language and/or cognitive training programs).~The exercise program and patients' sessions will be remotely supervised by therapists."
32997874|NCT05703893||Syndromic TAA|Patients presenting either clinical or genetic phenotype referring to a syndrome related to Thoracic Aortic Aneurysms
32997875|NCT05703893||Non-syndromic TAA|Patients presenting Thoracic Aortic Aneurysms
32997876|NCT05703854|Experimental|Chemotherapy and NK Cell Infusion|Participants will be assigned to a dose level of NK cells. A computer will decide by chance which of the dose level you will receive, and this will not be based on the doctor's or patient's decision. Up to 5 dose levels of NK cells will be tested. Each new patient will receive a different dose. If any dose shows to be not tolerable, this dose and the higher doses will not be given anymore.
32997877|NCT05703828||chronic ankle sprain group|
32997878|NCT05703828||health subjects group|
32997879|NCT05703802||Sepsis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997880|NCT05703802||SIRS|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997881|NCT05703802||Adiposity|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997882|NCT05703802||Granulomatosis with polyangiitis / microscopic polyangiitis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997883|NCT05703802||Pre-eclampsia|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997884|NCT05703802||Healthy controls|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
32997885|NCT05703789|Experimental|Oral rehabilitation|Name Oral rehabilitation. Patients receiving dental treatment will be allocated to one of two different treatment groups based on individual treatment need and proven experience. Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
32997886|NCT05703789|Other|Waiting list|Name: Waiting list. Patients in waiting list will receive no treatment. After four months they will be offered to be included in the oral rehabilitation arm.
32997887|NCT05703776|Experimental|Nordic Walking|2 weekly sessions of supervised Nordic Walking in a city park with trees, grass, and ponds. Exercise intensity was set at 65%-75% of age-predicted maximal heart rate. The length of training was consecutive 10 weeks
32997888|NCT05703776|No Intervention|control|no intervention
32997889|NCT05703750||CEPH group|CEPH was defined when at least one following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT >12 cm) with a low platelet count (<100,000/mm3).
32997890|NCT05703750||non-CEPH group|Non-CEPH was defined when none of the following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT >12 cm) with a low platelet count (<100,000/mm3).
32997891|NCT05703724|Other|Subjects|A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
32997892|NCT05703711|No Intervention|Enhanced Usual Care|In the Enhanced Usual Care arm, all healers are invited to participate in an interactive session reviewing ways to reduce inhumane and potentially harmful treatments in practices at their camps.
32997893|NCT05703711|Experimental|M&M Intervention Package|M&M is a 8-week long combination of mHealth designed to train healers to deliver basic psychosocial interventions while preserving human rights with pharmacotherapy delivered directly to their patients via visiting nurse.
32997894|NCT05703698|Experimental|Cognitive Behavioural Therapy for psychosis|CBTp will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
32997895|NCT05703672|Experimental|Varenicline and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive 1mg varenicline to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
32997896|NCT05703672|Placebo Comparator|Placebo and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive placebo pills to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
32997897|NCT05703672|Other|Open label electronic cigarette|All participants will receive an initial 6-week supply of the study electronic cigarette.
32997898|NCT05703659|Experimental|HMO consuming bacteria|Infants will given a daily HMO consuming probiotic (B. infantis) for four weeks
32997899|NCT05703659|Experimental|Non-HMO consuming bacteria|Infants will be given a daily non-HMO consuming probiotic (L. reuteri) for four weeks
32997900|NCT05703620|Experimental|Chronic Kidney Disease|Renal Denervation
32997901|NCT05703620|Experimental|Heart Failure|Renal Denervation
32997902|NCT05703620|Experimental|End stage renal disease|Renal Denervation
32997903|NCT05703594|Other|Dokuz Eylul University|Dokuz Eylul University Clinic
32997904|NCT05703581||PD(TRIANGLE)|"Patients with pancreatic head cancer or periampullary cancer underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with Pancreatoduodenectomy and standard lymphadenectomy"
32997905|NCT05703581||PD(non-TRIANGLE)|Patients with pancreatic head cancer or periampullary cancer underwent pancreatoduodenectomy with standard lymphadenectomy
32997906|NCT05703581||DP(TRIANGLE)|"Patients with carcinoma of the body and tail of the pancreas underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with distal pancreatectomy and standard lymphadenectomy"
32997907|NCT05703581||DP(non-TRIANGLE)|Patients with carcinoma of the body and tail of the pancreas underwent distal pancreatectomy with standard lymphadenectomy
32997908|NCT05703555|Experimental|Tusamitamab ravtansine 100mg/m2|Tusamitamab ravtansine 100 mg/m2 IV Q2W
32997909|NCT05703529|Experimental|Positive Psychotherapy group|
32997910|NCT05703529|Other|Control group|Usual Care means treating as usual, including a regular home visit.
32997911|NCT05703516||Capmatinib|Participants will be treated with capmatinib as per locally approved label
32997912|NCT05703477|Experimental|FMT Responder|
32997913|NCT05703477|Experimental|FMT non-Responder|
32997914|NCT05703425|Experimental|Sulfasalazine|Pregnant persons will receive sulfasalazine daily with 500 mg/daily and increasing by 500 mg/day every week until they reach a therapeutic dose of 1,000 mg twice daily. Drug will be started at 24 weeks estimated gestational age and ended at 36 weeks or earlier if preterm birth occurs.
32997915|NCT05703425|No Intervention|Standard Care|Pregnant persons will receive standard care in pregnancy.
32997916|NCT05703373|Experimental|Multiple Micronutrient Supplement (MMS) supplied to clinic|
32997917|NCT05703347|Active Comparator|Condition 1|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997918|NCT05703347|Active Comparator|Condition 2|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
32997919|NCT05703347|Active Comparator|Condition 3|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997920|NCT05703347|Active Comparator|Condition 4|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
32997921|NCT05703347|Active Comparator|Condition 5|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997922|NCT05703347|Active Comparator|Condition 6|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
32997923|NCT05703347|Active Comparator|Condition 7|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997924|NCT05703347|Active Comparator|Condition 8|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
32997925|NCT05703347|Active Comparator|Condition 9|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997926|NCT05703347|Active Comparator|Condition 10|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
32997927|NCT05703347|Active Comparator|Condition 11|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997928|NCT05703347|Active Comparator|Condition 12|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
32997929|NCT05703347|Active Comparator|Condition 13|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997930|NCT05703347|Active Comparator|Condition 14|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
32997931|NCT05703347|Active Comparator|Condition 15|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
32997932|NCT05703347|Experimental|Condition 16|Core intervention, Sleep goal, Sleep guidance messaging, Caregiver-directed loss-framed incentive, Supportive feedback.
32997933|NCT05703334|Experimental|Kinesio tap|group (A) mean age (21.03+3.6 years), and mean BMI values (27.6+.9 kg/m2 Group(A) 30 subjects were treated by kinesio tap therapy 2sessions per week.
32997934|NCT05703334|Experimental|Myofascial release|group (B) mean age (21.9+3.8 years),and mean BMI values (27.8+1.3 kg/m2 Ground(B) 30 subjects were treated by myofascial release therapy 3 sessions per week .
32997935|NCT05703334|No Intervention|Control group|
32997936|NCT05703308|Experimental|MenSCs group|Study group, treated with autologous intra-ovarian MenSCs injection and monitored for spontaneous pregnancy for 3 months after intervention. ICSI was used in cases where the pregnancy did not occur naturally.
32997937|NCT05703308|No Intervention|ICSI group|Control group, monitored for spontaneous pregnancy for 3 months after their last ovarian stimulation for ICSI or IVF. ICSI was used in cases where the pregnancy did not occur naturally.
32997938|NCT05703282|Experimental|Renal Impairment 1|Test Drug: AD-104-A
32997939|NCT05703282|Experimental|Renal Impairment 2|Test Drug: AD-104-A
32997940|NCT05703282|Experimental|Renal Impairment 3|Test Drug: AD-104-A
32997941|NCT05703282|Experimental|Normal|Test Drug: AD-104-A
32997942|NCT05703256|Experimental|Amygdala real-time fMRI neurofeedback|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
32997943|NCT05703256|Sham Comparator|Sham feedback|Yoked sham - participants will see the amygdala activity of another subject who completed the intervention. Two sessions will be performed one week apart.
32997944|NCT05702320|Experimental|Reference Group|Patients in this group will be warmed for 15 minutes with a full-body blanket belonging to the air-blown heater device before surgery. The heating will be Decelerated until he is taken to the operating table, and after the preparations are completed, the lower extremities will continue to be heated with a half-body blanket belonging to the heating device. After the patient is taken to the post-anesthesia care unit, the soaked blankets will be removed and the whole body will continue to be warmed with a blanket as in the preoperative period. When the patient's body temperature rises above 36 °C, the heating process will be terminated and when he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
33325015|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
33325016|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
33327455|NCT05597566||Elderly depression patients with suicidal ideation|Conformity: Age 60-85 years old; meet DSM-5 diagnostic criteria for major depressive disorder; currently in acute phase, HDRS-17 ≥ 24; history of suicide attempt in this depressive episode; current suicidal ideation, SIOSS ≥ 12.Exclusions: Patients with unstable physical diseases; patients currently suffering from acute inflammatory infection or chronic inflammatory disease; participated in another interventional clinical study within the past 1 month; previous or current diagnosis of other psychiatric diseases by DSM-IV ; abuse of alcohol and active drugs within 12 months, except for nicotine; severe aphasia, visual and hearing impairment, etc. unable to complete the scale evaluation; MECT treatment contraindications; pregnant, lactating women or planning pregnancy; allergic to propofol and succinylcholine chloride.
32865250|NCT04854720|Experimental|Group 3 (Beautiful Flow- Fuji Triage)|In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
32865251|NCT02822573|Active Comparator|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
32865252|NCT02822573|Placebo Comparator|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
32865253|NCT04795908|Experimental|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
32865254|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
32865255|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
32865256|NCT04854330|Active Comparator|Ketone ester|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml. Immediately following ingestion of the ketones, participants will be given 20 ml of calorie-free sparkling spring water (The Holywell Water Company Ltd, UK) in an attempt to remove any remaining flavour of the supplement.
32865257|NCT04854330|Placebo Comparator|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
32865258|NCT04854252|Experimental|Inflammatory response to opioid vs opioid free anesthesia|Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.
32865259|NCT04854174|Experimental|Healthy Volunteer|Healthy Volunteer
32865260|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
32865261|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
32865262|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
32865263|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
32865264|NCT04390295|Experimental|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
32865265|NCT04390295|Experimental|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
32865266|NCT04390295|Experimental|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
32865267|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
32865268|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
32865269|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
32865270|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
32865271|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
32865272|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
32865273|NCT03030235|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
32865274|NCT03030235|Placebo Comparator|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
32865275|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
33414608|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
32865276|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
32865277|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
32865278|NCT04853784||Totally laparoscopic colon surgery|Totally laparoscopic colon surgery/intracorporeal anastomosis
32865279|NCT04853784||Laparoscopic-assited colon surgery|Laparoscopic-assited colon surgery/extracorporeal anastomosis
32865280|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
32865281|NCT04845672|Experimental|2% chlorhexidine gluconate|4% Chlorhexidine gluconate solution and one to one water will be used to create a 2% Chlorhexidine gluconate solution.
32865282|NCT04845672|Active Comparator|soap-free body cleaning solution|It supports and protects the natural barrier function of the skin's natural protective layer.
32865283|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
32865284|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
32865285|NCT04444141|Experimental|AK104|AK104 450mg IV every 2 weeks (Q2W)
32865286|NCT04845594|Experimental|MySmileBuddy|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will receive a family-focused intervention called MySmileBuddy.
32865287|NCT04845594|No Intervention|Control|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will not receive any intervention.
32865288|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
32865289|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
32865290|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
32865291|NCT04845204|Active Comparator|Relaxation Treatment|Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
32865292|NCT04845204|Active Comparator|Standard Exercises|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
32865293|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
32865294|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
32865295|NCT04845360|Experimental|pregnancy and differences in gender can be found in the radial arterial pulse|Establishing the meridian through harmonics of blood pressure waves could be a powerful tool to qualitatively and quantitatively indicate physiologic and pathologic factors.
32865296|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
32865297|NCT04845438|Active Comparator|hand-sewn gastroenteroanastomosis|
32865298|NCT04845438|Active Comparator|stapler gastroenteroanastomosis|
32865299|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
32865300|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
32865301|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
32865302|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
32865303|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
32865304|NCT04845048||Health care professionals between 18 and 59 years old|
32865305|NCT04845048||General population 75 years old or more|
32865306|NCT04845048||General population 60 and 74 years old|
32865307|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
32865308|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
32997945|NCT05702320|Experimental|intervention group|The patients in this group will be wrapped with a reflective blanket from the neck to the whole body with the reflective side facing the patient for 15 minutes before the operation, so that only the surgical gown is on the patients in this group. After a layer of operating room cover is placed on the patient's lower extremities on the operating table in accordance with the hospital procedure, a reflective blanket will be wrapped on it with the reflective side facing the patient. After the patient is taken to the post-anesthesia care unit, the soaked covers will be removed and the entire body of the patient will be wrapped with a reflective blanket, as in the preoperative period. When the patient's body temperature rises above 36 °C and he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
32997946|NCT05702320|No Intervention|control group|No heating procedure will be performed by the researcher in this group of patients during the perioperative period, only the number of covers provided for heating in the post-anesthesia care unit will be recorded. The duration of stay in the post-anesthesia care unit, the transfer of the patient to the clinic and the follow-up in the clinic will be carried out according to the hospital procedure.
32997947|NCT05702216|Other|Cardiac rehabilitation|
32997948|NCT05702216|Other|Cardiac Tele-rehabilitation|Tele cardiac rehabilitation in hybrid form
32997949|NCT05702190|Active Comparator|Opium tincture|Administration of opium tincture (Dropizol)
32997950|NCT05702190|Placebo Comparator|Placebo|Administration of placebo (identical to opium tincture in taste and appearance)
32997951|NCT05701371||Centenarian cohort|
32997952|NCT05701124|Active Comparator|Aggressive ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
32997953|NCT05701124|Active Comparator|Type 1 prethreshold ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
33414609|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
32997955|NCT05700071|Experimental|MRI examination|
32997956|NCT05699980||Patient aged 60 or over presenting to their general practitioner|Patient aged 60 or over presenting to his general practitioner (among the 20 general practitioners recruited in Lorraine (eastern France))
32997957|NCT05699889||Patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.|
32997958|NCT05699889||Patients in intensive care without SARS-CoV 2 infection with severe respiratory impairment.|
32997959|NCT05696015|Active Comparator|Standard education|Standard education group will be carried out at discharge, discharge orientation of the patient with diabetes and application of the Diabetes Self-Care Activity Questionnaire (QAD). For this group, a new contact will be made within 30 days after discharge, where the QAD will be applied again.
32997960|NCT05696015|Experimental|Amplied education|Amplied education group will be performed at the time of discharge, guidance for discharge of patients with diabetes. This group will receive 3 contacts, the first will be carried out within 72 hours after discharge, the second contact within 10 days after the first contact and the third within 30 days after discharge, where diabetes education guidelines will be given to the patient in all contacts. At the time of discharge, and in the third contact, 30 days, the QAD will also be applied.
32997961|NCT05694676||Mothers|Mothers aged 18 to 40 years, who have singleton pregnancy.
32997962|NCT05694676||Infants|Infants were born at 36-42 weeks of gestation without complication.
32997963|NCT05693649|Experimental|Arm 1A: Usual Care|Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial.
32997964|NCT05693649|Experimental|Arm 2A: Colonoscopy Only and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm will not receive visit-based interventions.
32997965|NCT05693649|Experimental|Arm 2B: Colonoscopy Only and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
32997966|NCT05693649|Experimental|Arm 3A: Sequential Choice and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm will not receive visit-based interventions.
32997967|NCT05693649|Experimental|Arm 3B: Sequential Choice and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
33414610|NCT05251285||Prophylactic Nipple-Sparing Mastectomy|
33105295|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
33105296|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
33105297|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
33105298|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
33105299|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
33105300|NCT05516836|Experimental|Multicomponent exercise program + Telemedicine|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.~A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence"
33105301|NCT05516836|Active Comparator|Multicomponent exercise program|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
33105302|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
33105303|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
33105304|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
33105305|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
33105306|NCT04322227|Experimental|Healthy|
33105307|NCT04322227|Experimental|PD|
33105308|NCT03999229|Active Comparator|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
33105309|NCT03999229|Placebo Comparator|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of the SNO agent at 20-40 parts per million, will occur during the transfusion."
33105310|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
33105311|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
33105312|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
33105313|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
33105314|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
33105315|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
33105316|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
33105317|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
33105318|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
33105319|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
33105320|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
33105321|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
33105322|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
33105323|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
32997968|NCT05692037|Experimental|Yttrium-90 carbon microspheres|Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Ten Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available).
32997969|NCT05688085|Experimental|Irbesartan High/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan High/Amlodipine FDC in a crossover design
32997970|NCT05688085|Experimental|Co-administration of Irbesartan High and Amlodipine|participants will receive one table each of Irbesartan High and Amlodipine in a crossover design
32997971|NCT05673291||Active working group|For the study group, dentists who have completed at least 1 year in the profession, actively working in their professional life, and 4th and 5th-year of intern dentistry students
32997972|NCT05673291||Control group|In the study, 3rd-grade dentistry students who have not yet started the clinical education process will be selected as the control group.
32997973|NCT05669911|Experimental|Teal Health Self-Collection Device Group|This group will use the Teal Health Self-Collection Device to evaluate the instructions for use, usability, and satisfaction with the self-collection device. Participants will also undergo a Pap smear performed by a clinician. Self-collected and clinician-collected research samples will undergo HPV testing and cytological analysis using tests that are FDA-approved for use for HPV and Pap cytology.
32997974|NCT05645380|Active Comparator|High sTILs (≥30%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles.
32997975|NCT05645380|Active Comparator|Intermediate sTILs (5-29%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for six cycles.
32997976|NCT05645380|Active Comparator|Low sTILs (<5%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles followed by Doxorubicin (60 mg/m2) + Cyclophosphamide (600 mg/m2) + Pembrolizumab (200 mg) every 14 or 21 days for four cycles.
32997977|NCT05641246|Active Comparator|Control Arm|"Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet 2-3 times daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~Each Capecitabine (XELODA ®) cycle lasts for 21 days.~Capecitabine (XELODA ®) dose :2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress"
32997978|NCT05641246|Active Comparator|Intervention Arm|"Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet twice daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~Each Capecitabine (XELODA ®) cycle lasts for 21 days.~Capecitabine (XELODA ®) dose: 2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress Plus~Topical diclofenac (VOLTAREN®) Emulgel 1% 2-4g (2g = 4 fingertip Units (FTU)) twice daily 2 hours away from Urea-based cream (CARBAMIDE®) for 14 days starting from the first cycle and dose of Capecitabine.~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks)."
32997979|NCT05627453|Active Comparator|Normal gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will walk side by side without contact and without instructions about gait synchronisation. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
32997980|NCT05627453|Experimental|Arm-in-arm gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will be asked to walk arm-in-arm while synchronizing their steps. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
32997981|NCT05610735|Experimental|Combination of DOXIL and Ashwagandha|"The study contains two parts. In part 1 (Phase I), 18 patients with recurrent ovarian cancer will be recruited and administered IV with liposomal doxorubicin (DOXIL) 40 mg/m2 on day 1 of 28 days cycle for 4 cycles. Ashwagandha will be administered on daily basis for 2 years. Three doses of Ashwagandha (2 g, 4 g or 8.0 g) will be administered orally with water every day for two years to evaluate a tolerable dose of Ashwagandha. Six patients will be recruited for each dose.~In part 2 Phase II), 54 additional patients with recurrent ovarian cancer will be recruited and administered with DOXIL IV (40 mg/m2) and maximum tolerable dose of Ashwagandha (determined from part 1) in the form tables orally with water on daily basis for two years. The survival rate (SR), complete response (CR) and partial response (PR) will be evaluated."
32997982|NCT05610254|Active Comparator|Cold-Warm|Trial day 1: Participants receive Ringer's lactate cold (15°C, 59°F), Trial day 2: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F)
32997983|NCT05610254|Active Comparator|Warm-Cold|Trial day 1: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F) Trial day 2: Participants receive Ringer's lactate cold (15°C, 59°F),
32997984|NCT05600946||Patients|Affected individuals that meet inclusion criteria
32997985|NCT05593107|Experimental|[68Ga]N188|Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
32997986|NCT05591989|Experimental|Treatment|Subjects will undergo treatment with the NEUROMARK System
32997987|NCT05584709|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
32997988|NCT05576441|Experimental|test group: VCMX|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
32997989|NCT05576441|Experimental|Control group:SCTG|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
33414611|NCT03379727|Experimental|Midostaurin|Induction phase - D8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles Maintenance phase - D1 to D28 up to 12 cycles
32997990|NCT05575869|Experimental|Experimental group: Access to online PRONEtect educational material|A website with educational material (simulation video, protocol, checklist).
32997991|NCT05575869|Active Comparator|Control group: Classic one-hour lecture|Didactive presentation by the usual nursing school lecturer.
32997992|NCT05568381|Experimental|Digital Cognitive Behavioural therapy for insomnia|"Participants will receive a commercially available 6-week, online media-rich course of CBT-I delivered by an animated virtual therapist (Sleepio). Treatment content of this intervention includes behavioural components (sleep restriction, stimulus control, and relaxation), cognitive components (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, and 'putting the day to rest') and educational components (psychoeducation and sleep hygiene). Each of the 6 sessions lasts ~ 30 minutes and incorporates an initial progress review in relation to individualised goals, and exploration of self-reported diary data relating to the participant's current sleep status and pattern. The full program can be accessed via a website or iOS app. Participants will have access to the intervention for up to 12 weeks."
32997993|NCT05568381|Active Comparator|Sleep Health Education wait-list control|"Those in the control group will have access to three modules of the Sleep Health Education package following completion of baseline questionnaires. Each module will be delivered fortnightly with basic information about sleep health (e.g. the impact of sleep on health, creating a sleep-conducive bedroom, sleep and mood). Participants will receive a link to access each module as they are made available.~At trial completion (week 12), control participants will be offered the opportunity to engage with digital CBT-I."
32997994|NCT05568030|Experimental|Mindfulness|
32997995|NCT05568030|Active Comparator|Psycho-education|
32997996|NCT05562349|Experimental|Clavulanic Acid|Participants may receive 500 mg of CLAV at baseline. Subjects who are using cocaine once per week or more and who can tolerate 500 mg/day for 4 weeks, will have a dose escalation to 750 mg/day. If tolerated, 750mg/day will be maintained for 8 weeks, otherwise the dose will decrease to 500mg/day.
32997997|NCT05562349|Placebo Comparator|Placebo|"Participants may receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
32998000|NCT05558904|Experimental|Diagnostic (Me-4FDG PET/CT)|Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
32998001|NCT05521906|Experimental|Treatment Condition|The PRYSHM program is theoretically grounded, follows best practices for effective health behavior prevention, and includes nine, one hour sessions co-facilitated by 2 LGBTQ+ adults.
32998002|NCT05521906|No Intervention|Control|Check-ins/provision of resources
32998003|NCT05517707||Nasogastric tube group|Neonates age 0-18 weeks post-partum at enrollment with gestational age > 28 weeks will have the Gravitas Feeding Tube placed using standard technique. Tube placement will be verified by the institution standard of care. Study tubes are to remain in place up to 30 days.
32998004|NCT05511519|Experimental|ATI-450|ATI-450 50mg oral tablet BID
32998005|NCT05511519|Placebo Comparator|Placebo|Placebo oral tablet BID
32998006|NCT05506098||Healthy|Subjects without periodontitis
32998007|NCT05506098||Periodontitis|Subjects with periodontitis
32998008|NCT05504486|Experimental|Arm 1|Brexpiprazole
32998009|NCT05502835|Experimental|conventional fluid management group|patients will do elective open colonic mass resection and anastomosis will receive Infusion of 6 ml/kg/hr. Ringer's solution.
32998010|NCT05502835|Active Comparator|ppv group|patients will do elective open colonic mass resection and anastomosis. Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
32998011|NCT05480995|Experimental|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
32998012|NCT05479630|Experimental|Adolescents and their parent of the intervention group|Adolescents and their parent who are participating in TWAH
32998013|NCT05479630|No Intervention|Adolescents and their parent of the control group|Adolescents and their parent who are not participating in TWAH
32998014|NCT05476939|Active Comparator|everolimus|"Tablets of 2.5 mg or 10mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10mg once daily. Treatment will be continued until unacceptable toxicity, tumor progression, and/or withdrawal of patient, parents or legal representative consent.~At the time of centrally confirmed relapse or progression, patients will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa) after confirmed disease progression (real-time central review blinded to the treatment allocation), the treatment will also be continued until unacceptable toxicity, tumor progression, and/or withdrawal of patient, parents or legal representative consent."
32998015|NCT05476939|Experimental|ONC201|"Capsules of 125mg. 375mg/m2 per dose, day 1 and day 2 of each week. Dose will be capped at 625mg per dose. Treatment will be continued until unacceptable toxicity, tumor progression, and/or withdrawal of patient, parents or legal representative consent.~At the time of centrally confirmed relapse or progression, patients will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa) after confirmed disease progression (real-time central review blinded to the treatment allocation), the treatment will also be continued until unacceptable toxicity, tumor progression, and/or withdrawal of patient, parents or legal representative consent."
32998016|NCT05470621|Experimental|Playground Curriculum Arm|Staff (after-school staff, recess aides, and physical education teachers) receive training to implement a playground curriculum in an after-school program; children receive a training to use the curriculum during recess
32998017|NCT05470621|No Intervention|Program As Usual|Staff and students receive no training and participate in after-school programs and recess as usual
32998018|NCT05465057|Active Comparator|HIIT + lifestyle intervention|Allocation of HIIT training in conjuction with lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
32998019|NCT05465057|Active Comparator|Lifestyle intervention|Allocation of lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
32998020|NCT05460676|Experimental|Active tDCS + Mindfulness|
32998021|NCT05460676|Sham Comparator|Sham tDCS + Mindfulness|
32998022|NCT05458232||5mg tadalafil once daily for 14 days|
32998023|NCT05447598|Experimental|Intervention|Remote monitoring program
32998024|NCT05447598|Active Comparator|Usual care|Current clinical pratice at the participating hospitals
32998027|NCT05437393|Experimental|Deep brain stimulation|"Deep Brain stimulation using a novel device: Bioinduction Picostim Deep Brain Stimulation system."
32998028|NCT05429502|Experimental|Phase I-part A: Ribociclib+TOTEM|Participants with r/r NB, MB, HGG, MRT or RMS will be treated with ribociclib in combination with TOTEM to determine MTD and/or RP2D. Ribociclib dose will be scalated while topotecan and temozolomide will be administered at a fixed dose.
32998029|NCT05429502|Experimental|Phase I- Part B: r/r NB Cohort|Participants with r/r NB will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
32998030|NCT05429502|Experimental|Phase I- Part B: r/r MB Cohort|Participants with r/r MB will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
32998031|NCT05429502|Experimental|Phase I-Part B: r/r HGG Cohort|Participants with r/r HGG will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
32998032|NCT05429502|Experimental|Phase I-Part B: r/r MRT Cohort|Participants with r/r MRT will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
32998033|NCT05429502|Experimental|Phase I- Part B: r/r RMS Cohort|Participants with r/r RMS will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
32998034|NCT05429502|Experimental|Phase II- Ribociclib+TOTEM|Participants with r/r NB will be treated with ribocilib in combination with TOTEM at the RP2D defined from Phase I part A.
32998035|NCT05429502|Placebo Comparator|Phase II: Placebo+TOTEM|Participants with r/r NB will be treated ribociclib matching placebo in combination with TOTEM
32998036|NCT05412693|Experimental|Functional orthosis|Use of a functional orthosis device (AirCast Air-Stirrup) for 6 weeks. Weightbearing as tolerated will be allowed in both groups immediately after application of the cast or orthosis.
32998037|NCT05412693|Active Comparator|Cast immobilization|Use of a below-the-knee cast circular cast (3M scotch cast) for 6 weeks.
32998038|NCT05404594|Experimental|Very preterm infant|Preterm infant below 33 weeks of GA
32998039|NCT05404594|Active Comparator|Full term neonate|Term neonate from a gestational age of 37 weeks.
32998040|NCT05396846|Active Comparator|Eating Plan 1|This group will receive a pamphlet from the American Institute for Cancer Research (AICR) on dietary prevention and the results of their own breath test, Veggie Meter score and anthropometric measures.
32998041|NCT05396846|Experimental|Eating Plan 2|This group will receive the MyBestGI App and User Manual that encourages limiting four food groups: three or less foods each day made with refined flour, no more than 8% of calories from added sugars, no processed meats and less than 18 oz./week red meat. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
32998042|NCT05396846|Experimental|Eating Plan 3|This group will receive a version of the MyBestGI App and User Manual that encourages meeting 11 food group goals: four food groups to limit and seven food groups to encourage. The 7 groups to encourage are: 3-4 cups/day fruits and vegetables, at least one dark orange or dark green vegetable daily, daily allium and culinary herbs, 3-6 oz./day whole grains, 6-8 oz./week foods high in omega-3 fatty acids, 8-10 tsp./day olive oil or the equivalent from other foods high in monounsaturated fats and at least ½ cup/day of legumes or 1 TB/day nut butter. Some of the goals are personalized based on calculated energy needs. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
32998043|NCT05396768||Novices|Junior residents from the departments of surgery, pneumology or emergency medicine. These participants are in their first or second year of residency, and have observed or placed less than 5 CTIs in their career.
32998044|NCT05396768||Experienced|Faculty members from Ghent University Hospital from the departments of surgery, pneumology or emergency medicine. These participants must have finished their residency training, and must be involved in resident education.
32998045|NCT05389124||Experimental gingivitis|Group will wear a splint during oral hygiene to cover one quadrant of their dentition. They will develop gingivitis over 3 weeks. They will practise normal oral hygiene in the rest of their mouth (with minor restrictions, e.g. no mouthwash) and one other quadrant will act as an internal control for the gingivitis. After 3 weeks, normal oral hygiene will be restored throughout the mouth and subjects will continue to be monitored for a further 3 weeks.
32998046|NCT05383274|Experimental|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
32998047|NCT05382702|Other|High Fat Yogurt - Low Fat Yogurt|Participants will eat yogurt described as 'high fat' at Study Visit 2 and yogurt described as 'low fat' at Study Visit 3.
32998048|NCT05382702|Other|Low Fat Yogurt - High Fat Yogurt|Participants will eat yogurt described as 'low fat' at Study Visit 2 and yogurt described as 'high fat' at Study Visit 3.
32998049|NCT05367661|Experimental|Part A: Healthy Volunteers: Single ascending doses|Six dose groups ranging from 15mg to 500mg, under fasting condition.
32998050|NCT05367661|Experimental|Part A: Healthy Volunteer: Single Ascending dose under fed condition|60mg under fed condition.
32998051|NCT05367661|Experimental|Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose|125mg, under fasting condition.
32998052|NCT05367661|Experimental|Part B: Healthy Volunteers: Multiple Ascending doses|5 dose groups with doses ranging from 30mg to 500mg. Given daily for 14 days, under fasting condition.
32998053|NCT05364840|Experimental|STI-1558|Subjects will receive in each part either a single ascending dose (SAD): 300 mg, 600 mg, 1200 mg, 2000 mg on Day1 or as part of the multiple ascending dose (MAD): 300 mg, 600 mg, and 800 mg twice a day for 7.5 days
32998054|NCT05364840|Placebo Comparator|Placebo|Subjects will receive placebo orally following either the SAD or MAD dosing schedule
32998055|NCT05341622|Experimental|Arm 1: Box + Text + Reminder|Box + Text + Reminder
32998056|NCT05341622|Experimental|Arm 2: Box + Text + No Reminder|Box + Text + No Reminder
32998057|NCT05341622|Experimental|Arm 3: Box + No Text + Reminder|Box + No Text + Reminder
32998058|NCT05341622|Experimental|Arm 4: Box + No Text + No Reminder|Box + No Text + No Reminder
32998059|NCT05341622|Experimental|Arm 5: Standard Mail + Text + Reminder|Standard Mail + Text + Reminder
32998060|NCT05341622|Experimental|Arm 6: Standard Mail + Text + No Reminder|Standard Mail + Text + No Reminder
32998061|NCT05341622|Experimental|Arm 7: Standard Mail + No Text + Reminder|
32998062|NCT05341622|Experimental|Arm 8: Standard Mail + No Text + No Reminder|Standard Mail + No Text + No Reminder
32998063|NCT05337150|Experimental|Lifestyle Modification with a Balanced Calorie Deficit Diet|Lifestyle modification intervention with a balanced calorie deficit diet (i.e., participants will be prescribed a calorie goal and will track their dietary intake in order to meet this goal).
32998064|NCT05337150|Experimental|Lifestyle Modification with an Ad Libitum Whole Food Plant-Based Eating Plan|Lifestyle modification intervention with an ad libitum whole food plant-based diet (i.e., participants will eat, ad libitum, fruits, vegetables, starches, legumes, and whole grains, and will avoid eating processed foods, refined oils, and animal products)
32998065|NCT05324709|Experimental|Experimental|The program will be carried out one day a week for four weeks. Yin yoga practices will be applied in the program. Each session will last a total of 40 minutes. The first 20 minutes of yin yoga sessions. Participants will be given training on stress management, breathing and yin yoga. Afterwards, each session of Yin yoga exercises will be started with pranayama (breathing) exercises for 2 minutes, followed by Suryanamaskar-A (Sun Salute-A) for warming up and Yin yoga exercises will be done. The program will be completed by applying the focus on Moment in the last 5 minute. In addition, the participants will be given homework related to the subject of each week. The training booklet will be distributed to the participants before the program. Stress management sessions of the Adolescent Health Promotion-Physical Activity, Nutrition, Stress Management (COPE HEALTH- TEEN ) program will be used in the stress management training to be explained in the program.
32998066|NCT05324709|No Intervention|No Intervention|"The control group will be given 60 minutes of in the moment and stress management training."
32998067|NCT05319964|Experimental|anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~Participants were provided 30 minutes 30% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
32998068|NCT05319964|Active Comparator|conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
32998069|NCT05319964|Other|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks
32998070|NCT05318508||patients with low back pain|
32998071|NCT05318508||patients without low back pain|
32998072|NCT05292950|Experimental|ARO-MUC5AC|ARO-MUC5AC Inhalation
32998073|NCT05292950|Placebo Comparator|Placebo|(0.9% NaCl)
32998074|NCT05288413||Goldstandard DVT diagnostic through specialist sonographer|Patients with DVT symptomatic of lower limb which present at the DVT Clinic the Bays at St. Mary's Hospital will receive Goldstandard Scan through specialist.
32998075|NCT05288413||DVT diagnostic with Ultrasound probe with AutoDVT Software|Above patients will receive a second Ultrasound scan by a non-specialist with AutoDVT device.
32998076|NCT05288413||Retrospective data evaluation|result of AutoDVT is equivalent to diagnosis of specialist sonographer. Results specifically highlighted in patients with adipositas or malignant disease.
32998077|NCT05279118|Experimental|Ketogenic diet arm|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
32998078|NCT05279118|Active Comparator|ACTH arm|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
32998079|NCT05278663|Experimental|Cohort 1: E6742 100 mg or Placebo|Participants will receive E6742 100 milligram (mg) tablet or E6742-matched placebo tablet, orally, twice daily for up to 85 days.
32998080|NCT05278663|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg tablets (two tablets of each 100 mg) or E6742-matched placebo tablets, orally, twice daily for up to 85 days.
32998081|NCT05274243|Experimental|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
32998082|NCT05274243|Placebo Comparator|Placebo|Matching placebo (provided as three capsules) three times per day for 4 weeks
32998083|NCT05273879|Other|decompression group|minimally invasive decompression without fusion
32998084|NCT05273879|Other|fusion group|minimally invasive decompression with trans-foraminal interbody fusion
32998085|NCT05271799|Experimental|Participants receiving gepotidacin powder for oral suspension followed by tablet|
32998086|NCT05271799|Experimental|Participants receiving gepotidacin tablet followed by powder for oral suspension|
32998087|NCT05270733|Experimental|Treatment|Patients will be treated with ustekinumab (90mg at week 0 and week 4 by subcutaneous injection) for 8 weeks followed by treatment with guselkumab (100mg at week 0 and week 4 by subcutaneous injection) or risankizumab (150mg at week 0 and week 4 by subcutaneous injection)
32998088|NCT05261841||TYPE 2 DIABETES|Patients affected by type 2 diabetes
32739203|NCT04997967|Experimental|Ketofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
32998089|NCT05253417|Experimental|50 mg CBD|50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)
32998090|NCT05253417|Experimental|100 mg CBD|100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.
33325017|NCT05294692|Experimental|Financial Health Incentives|"fter registration on the Caterpillar App, participants will be instructed to 'carry their phone' as much as possible during a 5-day baseline period to assess their daily step counts. In Month 1, participants will earn daily rewards (3¢ per day personalized daily step goal met; BE present bias). In Month 2, users will earn weekly rewards (25¢ per week goal met 5+ times; BE fresh start). In Month 3, users will earn team-based rewards (35¢ per week if 10+ goals are reached collaboratively with someone they know e.g., friend; BE herd mentality). Participants are expected to earn $1.25 CAD (or 0.75 British pounds) over the course of the 12-week intervention (about $5/person/yr). Rather than offer daily incentives indefinitely, Caterpillar will offer daily incentives as a temporary feature-moving to larger, less frequent, less certain (team-based) incentives as PA becomes habitual."
33325018|NCT03100006|Experimental|Nivolumab and Oregovomab|
32998091|NCT05253417|Placebo Comparator|Placebo|Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.
32998092|NCT05250570|Experimental|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
32998093|NCT05250570|Active Comparator|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.
32998094|NCT05247866|Experimental|Study Group|"30 patients will be given dupilumab (dose based on current approved doses or used in current EoE clinical trial, q weekly dosing) and monitored for clinical response after 12 weeks of therapy)~Dosing:~>12 years of age > 40 kg 300 SQ weekly 30- 40 kg 300 mg SQ Q2 weeks 15-29.9 kg 200 mg SQ Q2 weeks~6-11 years of age 5-15 kg 100 mg SQ Q2W 15-30 kg 200 mg SQ Q2W >30-60 kg 300 mg SQ Q2W"
33325019|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
33325020|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
33325021|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
32998095|NCT05242744||Metastatic prostate cancer|Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background. Only individuals who can understand and give informed consent will be eligible to participate in this study.
32998096|NCT05241613|Experimental|AC176 Dose Escalation as Single Agent|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
32998097|NCT05241353|Active Comparator|Standard Self-Monitoring Group|Standard behavioral treatment with a standard (full-frequency) self-monitoring prescription.
32998098|NCT05241353|Experimental|Reduced-Frequency Group|Standard behavioral treatment with a reduced-frequency self-monitoring prescription.
32998099|NCT05229263|Experimental|Healthy volunteers|
32998100|NCT05229263|Experimental|CKD patients|
32998101|NCT05213195|Experimental|NKG2D CAR-NK|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation
32998102|NCT05207748||patients with a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
32998103|NCT05207748||patients without a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
32998104|NCT05205005|Experimental|Dietary supplementation of glycocalyx precursors (DSGP)|Participants will daily ingest 3,712mg (i.e., six capsules) of DSGP for eight weeks. DSGP, commercially available as Endocalyx (Microvascular Health Solutions LLC, Alpine, UT), include glucosamine sulfate, fucoidan, superoxide dismutase, and high molecular weight hyaluronan.
32998105|NCT05205005|Placebo Comparator|Placebo|Participants will daily ingest 6 capsules daily of placebo
33105324|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
32998106|NCT05204030|Experimental|Narrative|The intervention condition will present narrative-focused messages about HPV and the HPV vaccine that includes important parent focused exemplar language and cultural norms on Twitter told through stories and characters (i.e., pseudo-parents).
32998107|NCT05204030|Active Comparator|Non-Narrative|The non-narrative condition will present scientific-focused messages about HPV and the HPV vaccine that includes important information relayed with numbers and facts.
32998108|NCT05200416|Experimental|Test Product - Heylo|The arm includes the test product Heylo
32998109|NCT05200416|Active Comparator|Standard of Care|The arm includes Standard of Care
33325022|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
33325023|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
33325024|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:~filgotinib + lanraplenib placebo + tirabrutinib placebo~lanraplenib + filgotinib placebo + tirabrutinib placebo~tirabrutinib + filgotinib placebo + lanraplenib placebo"
33325025|NCT05239780|Experimental|Participants with depression|Participants with depression to undergo brain stimulation
33325026|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
33325027|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
32998116|NCT05193877|Active Comparator|treatment with autologous bone marrow aspirate concentrate|autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint
32998117|NCT05193877|Sham Comparator|control|control group given analgesics only
32998118|NCT05184803|Experimental|treatment|treatment arm(docetaxel, oxaliplatin, S-1)
32998119|NCT05184582|No Intervention|Standard|Routine information on the benefit of physical activity
32998120|NCT05184582|Experimental|Intervention|High-intensity interval and strength training during neoadjuvant chemotherapy
32998121|NCT05175196|Experimental|Pediatric Participants with GAS|"Children age 5-17 years old diagnosed via standard Rapid Antigen Detection Test with acute pharyngitis caused by Group A Streptococcus (GAS), along with their parent or legal guardian (aka caregiver)."
32998122|NCT05166798|Experimental|Intervention group|Cognitive control training: The adaptive Paced Auditory Serial Addition Task (aPASAT) is a Cognitive Control Training where participants need to click on the sum of the last two heard digits. Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control. Five intervention groups will each receive a different amount of sessions.
32998123|NCT05166798|No Intervention|Control group|Waitlist control group: Participants randomized to the control group will not perform the cognitive control training during the study, but will be given the opportunity to follow the training afterwards.
32998124|NCT05165173|Experimental|Intervention|Based on estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the nanoparticle group.
32998125|NCT05165173|Active Comparator|Comparator|Based on the estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the microparticle group.
32998126|NCT05143671||Hybrid coronary revascularization strategy (HCR)|Patients who undergo a combination of coronary artery bypass grafting and PCI.
32998127|NCT05143671||Hybrid valve and coronary disease correction|Patients who undergo a combination of surgical valve replacement and PCI.
32998128|NCT05143671||Hybrid coronary and carotid artery disease treatment|Patients who undergo a combination of coronary artery bypass grafting and carotid stenting.
32998129|NCT05131451|No Intervention|Usual care with educational reinforcement|Standard of care referral to Eye Care Provider (ECP) for the diabetic eye exam with educational reinforcement
32998130|NCT05131451|Experimental|Diabetic Retinopathy Exam|Point of care (POC) Diabetic Retinopathy Exam using Autonomous AI on non-mydriatic fundus camera
32998131|NCT05114629||Active|Individuals in the active group will meet or exceed the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
32998132|NCT05114629||Inactive|Individuals in the inactive group are those who do not meet the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
32998133|NCT05085470|Experimental|Reinfection group|Participants will be exposed three times to 20 male Schistosoma mansoni cercariae (weeks 0, 9, and 18)
32998134|NCT05085470|Active Comparator|Infection control group|12 participants who will undergo a placebo mock infection with water twice (weeks 0 and 9) and will be exposed once to 20 male Schistosoma mansoni cercariae (week 18)
32998135|NCT05071846|Experimental|MVX-ONCO-2|
32998136|NCT05062083|Other|One arm|All particpants will receive the same tests
32998137|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in a separate parent trial
32998138|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) low dose|The participants will receive the low dose of BCD-250
32998139|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) high dose|The participants will receive the high dose of BCD-250
32998140|NCT05037188|Experimental|Cohort 1/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
32998141|NCT05037188|Placebo Comparator|Cohort 1/Placebo|The participants will receive placebo
32998142|NCT05037188|Experimental|Cohort 2/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
32998143|NCT05037188|Placebo Comparator|Cohort 2/Placebo|The participants will receive placebo
32998144|NCT05032365|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
32998145|NCT05032365|Active Comparator|Conventional|Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.
33417358|NCT02078258|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
32998146|NCT05030506|Experimental|Belzutifan + Lenvatinib|Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
32998147|NCT05030506|Experimental|Belzutifan + Lenvatinib + Pembrolizumab|Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
32998148|NCT05029102|Experimental|TAS-102 and Anlotinib|TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
32998149|NCT05028933|Experimental|EPCAM CAR-T|"The first stage: single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose.~The first dose group is 3×10^5/kg, allowing 10% dose error.~The second dose group is 1×10^6/kg, allowing 10% dose error.~The third dose group is 3×10^6/kg, allowing 10% dose error. Each dose group must complete the DLT observation before entering the next dose group; when the first subject in the same dose group has no DLT observed for at least 14 days after cell infusion, the subsequent subjects can receive cell infusion.~The second stage: combined radiofrequency/microwave ablation for the treatment of advanced digestive system malignant tumors with liver metastases"
32998150|NCT05024058|Experimental|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
32998151|NCT05024058|Experimental|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
32998152|NCT05024058|Placebo Comparator|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
32998153|NCT05024058|Experimental|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
32998154|NCT05024058|Experimental|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
32998155|NCT05024058|Placebo Comparator|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
32998156|NCT05024058|Experimental|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
32998157|NCT05024058|Placebo Comparator|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
32998158|NCT05008549|Experimental|First Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.
32998159|NCT05008549|Experimental|Second Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
32998160|NCT05008549|Experimental|Third Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
32998161|NCT05008549|Experimental|Fourth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
32998162|NCT05008549|Experimental|Fifth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
32998163|NCT05008549|Experimental|Sixth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
32998164|NCT05008328|Experimental|Music Therapy plus Standard Care|Music therapy intervention in addition to standard hospital care during an SBT.
32998165|NCT05008328|Active Comparator|Standard Care|Standard hospital care during an SBT.
32998166|NCT04989517|Experimental|AT193|Topical applied daily
32998167|NCT04989517|Placebo Comparator|Placebo|Topical applied daily
32998168|NCT04979052|Active Comparator|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
32998169|NCT04979052|No Intervention|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
32998170|NCT04966247||Patients with Aortic Arch Pathology|Patients undergoing aortic arch surgery for aortic arch pathologies, such as aortic aneurysm and aortic dissection.
32998171|NCT04957290|Experimental|Part 1: Dose Cohort 1: NOX66 800 mg|
32998172|NCT04957290|Experimental|Part 1: Dose Cohort 2: NOX66 1200 mg|
32998173|NCT04957290|Experimental|Part 1: Dose Cohort 3: NOX66 1600 mg|
32739204|NCT04997967|Active Comparator|Propofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
32998174|NCT04957290|Experimental|Part 1: Dose Cohort 4: NOX66 2400 mg|
32998175|NCT04957290|Experimental|Part 2: Arm 1: Patients with mCRPC (RP2D NOX66)|
32998176|NCT04957290|Experimental|Part 2: Arm 2: Patients with BC or NSCLC (RP2D NOX66)|
32998177|NCT04955808||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.
32739205|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
32739206|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
32998178|NCT04955379|Other|Measurements|Subjects will be tested with the Autorefractor and the EQ103 device
32998179|NCT04948619|Other|Arm A - Single booster vaccines|Those subjects randomized to Arm A, single dose vaccine boosters, will receive non live vaccine boosters at the 3 and 12 month visits. Boosters for live vaccines will be given at the 6 month visit. Boosters will only be given as applicable for low titers tested at the baseline assessment visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
32998180|NCT04948619|Other|Arm B - Staged revaccination series|Those subjects randomized to Arm B, the full revaccination series, will receive applicable vaccines when titers are low (below normal range) at baseline. When indicated, non-live vaccines will be given at the 3, 6, 9, and 12 month visits, live vaccines will be given at the 6 and 9 month visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
32998181|NCT04948333|Experimental|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
32998182|NCT04944940||Healthy Volunteers|Healthy male participants who are age and sex matched to the SBMA participants
32998183|NCT04944940||Patients with Spinal and bulbar muscular atrophy (SBMA)|Male participants with genetically confirmed SBMA
32998184|NCT04935359|Experimental|Safety run-in part: NIS793+gemcitabine+nab-paclitaxel|In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
32998185|NCT04935359|Experimental|Randomized part: NIS793+gemcitabine+nab-paclitaxel|Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel
32998186|NCT04935359|Placebo Comparator|Randomized part: placebo+gemcitabine+nab-paclitaxel|Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel
32998187|NCT04929028|Experimental|High-risk stratum (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32998188|NCT04929028|Experimental|Low-risk stratum (mitomycin|Patients receive mitomycin IV on day 1 and either fluorouracil IV on day 1 or capecitabine PO BID on Monday-Friday until the completion of radiation therapy at the discretion of the treating physician. Patients also undergo IMRT QD for 20-23 treatment sessions over 6 weeks.
32998189|NCT04917848||Older adults with cancer|Participants will be 70 years old or older with a diagnosis of gastrointestinal or gynecological cancer. Participants will be receiving or about to receive medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)
32998190|NCT04911621|Experimental|Stratum A (newly diagnosed)|Dendritic cell vaccination plus temozolomide-based chemoradiotherapy
32998191|NCT04911621|Experimental|Stratum B (prior treatment)|Dendritic cell vaccination plus optional conventional anti-glioma treatment (in line with standard-of-care practice, at the investigator's discretion)
32998192|NCT04900428|Experimental|COVI-DROPS|10 mg or 20 mg of COVI-DROPS administered intranasally
32998193|NCT04900428|Placebo Comparator|Placebo|1 mL administered intranasally
32998194|NCT04881240|Experimental|Group A|Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
32998195|NCT04881240|Experimental|Group B|Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
32998196|NCT04877522|Experimental|Asciminib single agent group|Participants with CML or ALL, from Novartis sponsored asciminib studies, including but not limited to ABL001A2301, ABL001X2101 and ABL001A2202 studies, that were receiving asciminib
32998197|NCT04877522|Other|Bosutinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301, that were receiving bosutinib
32998198|NCT04877522|Experimental|Bosutinib-asciminib switch group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301 that were receiving bosutinib treatment and switched to asciminib when entering this study or during the course of this study
32998199|NCT04877522|Experimental|Asciminib in combination with imatinib group|Participants with CML from Novartis sponsored asciminib studies ABL001E2201 or CABL001X2101 that were receiving asciminib combined with imatinib
32998200|NCT04877522|Experimental|Asciminib in combination with nilotinib group|Participants with CML or ALL from Novartis sponsored asciminib studies ABL001E2201or CABL001X2101 that were receiving asciminib combined with nilotinib
32998201|NCT04877522|Other|Imatinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving imatinib
32998202|NCT04877522|Other|Nilotinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving nilotinib
32998203|NCT04877522|Experimental|Asciminib in combination with dasatinib group|Participants with CML from Novartis sponsored study ABL001X2101 that were receiving asciminib with dasatinib
32998204|NCT04873492|Other|Retrospective Aggressive MS patients|Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
32998205|NCT04873492|Other|Retrospective Non Aggressive MS patient|Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
33417359|NCT02078258|Active Comparator|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
32998206|NCT04873492|Other|Healthy volunteers|Prospective arm use as comparator.
32998207|NCT04873492|Other|Prospective MS patients|MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
32998208|NCT04869319||MyChart message|MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
32998209|NCT04869319||No MyChart message|No message
32998210|NCT04855266|Experimental|Iron Sucrose Group|Subjects will receive intravenous iron sucrose during a tilt table test
32998211|NCT04855266|Placebo Comparator|Placebo Group|Subjects will receive intravenous placebo during a tilt table test
32998212|NCT04852172|Active Comparator|Arm 1 (L-citrulline)|25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
32998213|NCT04852172|Active Comparator|Arm 2 (L-citrulline)|50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
32998214|NCT04852172|Active Comparator|Arm 3 (L-citrulline)|100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
32998215|NCT04852172|Active Comparator|Arm 4 (L-citrulline)|100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
32998216|NCT04852172|Active Comparator|Part 2 Arm 1 (L-citrulline)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
32998217|NCT04852172|Placebo Comparator|Part 2 Arm 2 D5 1/2NS|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.
32998218|NCT04846920|Experimental|Belzutifan 160 mg BID|Participants will receive belzutifan 160 mg orally twice daily (BID). Treatment will continue until progressive disease or discontinuation.
32998219|NCT04846920|Experimental|Belzutifan 160 mg TID|Participants will receive belzutifan 160 mg orally three times daily (TID). Treatment will continue until progressive disease or discontinuation.
32998220|NCT04846920|Experimental|Belzutifan 200 mg TID|Participants will receive belzutifan 200 mg orally TID. Treatment will continue until progressive disease or discontinuation.
32998221|NCT04846920|Experimental|Belzutifan 120 mg QD|Participants will receive belzutifan 120 mg orally once daily (QD). Treatment will continue until progressive disease or discontinuation.
32998222|NCT04845620|Experimental|ARQ-151 Cream 0.05%|Active comparator
32998223|NCT04845620|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
32998224|NCT04830124|Experimental|Advanced Cutaneous Melanoma Subcutaneous Dosing (Cohort 1)|Patients with unresectable and/or metastatic cutaneous melanoma
32998225|NCT04830124|Experimental|Advanced mucosal melanoma with IV Dosing (Cohort 2)|Patients with unresectable and/or metastatic mucosal melanoma
32998226|NCT04830124|Experimental|Advanced Cutaneous Melanoma with Less Frequent IV Dosing (Cohort 3)|Patients with unresectable and/or metastatic cutaneous melanoma
32998227|NCT04829331|Experimental|Restrata with a split-thickness skin graft|
32998228|NCT04829331|No Intervention|Split-thickness skin graft alone|
32998229|NCT04825288|Active Comparator|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
32998230|NCT04825288|Placebo Comparator|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
32998231|NCT04818580|Experimental|Right-Sided Progressive Tension Sutures|
32998232|NCT04818580|Active Comparator|Left-Sided Progressive Tension Sutures|
32998233|NCT04804605|Experimental|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
32998234|NCT04804215|Experimental|The experimental group in Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~Intraductal transanastomotic stent was used during biliary reconstruction"
32998235|NCT04804215|Experimental|The controled group in non-Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~No stent was used during biliary reconstruction"
32998236|NCT04802707|Experimental|dC/dT100-400 Arm|Children & Adult (0-60 Y), who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
32998237|NCT04781127|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
32998238|NCT04764643|Active Comparator|sodium thiosulfate solution arm|20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
32998239|NCT04764643|Experimental|N-acetylcysteine solution arm|20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe
32998240|NCT04727827|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
33417360|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
32998241|NCT04706429|Active Comparator|Trientine|Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
32865309|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
32865310|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
32998242|NCT04706429|Placebo Comparator|Placebo|The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
32998243|NCT04677595|Experimental|Cohort 1|Treatment Naive participants
32998244|NCT04677595|Experimental|Cohort 2|Participants received one or two prior lines of treatment
32998245|NCT04657900||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
32998246|NCT04657705|Experimental|High power ablation|High power ablation parameters (50-55 W)
32998247|NCT04657705|Active Comparator|Standard ablation power|Standard ablation power parameters (40-45 W)
32998248|NCT04625803|Experimental|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
32998249|NCT04610047|Experimental|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
32998250|NCT04610047|Placebo Comparator|Placebo|Placebo oral capsules, twice daily for 7 days
32998251|NCT04602611|No Intervention|Standard of Care|Standard of Care
32998252|NCT04602611|Experimental|Oncology Nurse Navigation|Standard of Care + Oncology Nurse Navigation
32998253|NCT04601571|Active Comparator|Feeding Tube Placement using CORTRAK stylet|Subjects will already have a feeding tube placed and are undergoing X-rays for placement confirmation.
32998254|NCT04601571|No Intervention|Feeding Tube Placement using X-Ray|Routine X-ray is used to confirm feeding tube placement
32998257|NCT04585191|Experimental|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
32998258|NCT04585191|Active Comparator|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
32998259|NCT04577599|Other|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
32998260|NCT04563234|Experimental|COFLEX training|Neurocognitive training, delivered via a mobile device app
32998261|NCT04563234|Active Comparator|Crossword group|Access to crossword puzzles via a mobile device app
32998262|NCT04558892|Experimental|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
32998263|NCT04558892|Experimental|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
32998264|NCT04558892|Active Comparator|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
32998265|NCT04558476|Experimental|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
32998266|NCT04558476|Other|Standard of care|Standard of care according the last gold standards
32998267|NCT04551885|Experimental|FT516 in combination with avelumab|
32998268|NCT04524000|Experimental|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
32998269|NCT04524000|Experimental|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
32998270|NCT04524000|Experimental|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
32865311|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
32865312|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
32865313|NCT04844580|Placebo Comparator|Standard Treatment + Placebo|Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
32998271|NCT04512690|Experimental|Epidural electrical stimulation of the cervical spinal cord|Individuals with prior subcortical stroke and hemiparesis of the upper extremity.
32998272|NCT04506359|No Intervention|control group|Control Group: Usual care +case manager care, UC group or Control group
32998273|NCT04506359|Experimental|experimental group|The experimental group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1) - usually patients visited hospital in 2 weeks, 1 month, 2 months, 3 months and 6 months (T2-6) after surgery. Patients will receive (a) nurse-guided touch-screen computer screening (assessment) for their psychological and physical distress and care needs during current week; (b) the screening /assessment results will immediately show as the outcome (we are developing a calculation system to sum those scores).
32998274|NCT04484532|Experimental|Supportive Care (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
32998275|NCT04452877|Experimental|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
32998276|NCT04449276|Experimental|Dose Escalation CVnCoV|"Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated.~Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg."
32998277|NCT04449276|Placebo Comparator|Dose Escalation Placebo|Participants will be given placebo on Day 1 and Day 29.
32998278|NCT04427709|Other|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
32998279|NCT04427709|Other|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
32998280|NCT04408963|Experimental|Group 1|5 mg/kg IV
32998281|NCT04408963|Experimental|Group 2|5 mg/kg SC
32998282|NCT04402073|Other|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.~Criteria: Post pubertal < 18 y SHH (p53wt) M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
32998283|NCT04402073|Experimental|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
32998284|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
32998285|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
32998286|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
32998287|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
32998288|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
32998289|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamide|Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
32998290|NCT04381832|Active Comparator|Stage 2: enzalutamide|Participants will receive standard oral enzalutamide
32998291|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + docetaxel|Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
32998292|NCT04381832|Active Comparator|Stage 2: docetaxel|Participants will receive standard dose of IV docetaxel
32998293|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab|Oral etrumadenant in combination IV zimberelimab
32998294|NCT04381832|Experimental|Stage 2: Etrumadenant + zimberelimab + quemliclustat|Participants will receive oral etrumadenant in combination with IV zimberelimab and IV quemliclustat
32998295|NCT04381832|Experimental|Stage 2: Etrumadenant + quemliclustat|Participants will receive oral etrumadenant in combination with IV quemliclustat
32998296|NCT04381832|Experimental|Stage 1: Etrumadenant + zimberelimab PK Sub-Study|Participants will receive oral etrumadenant in combination with IV zimberelimab
32998297|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + SG|Participants will receive oral etrumadenant in combination with IV SG.
32998298|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + Zimberelimab + SG|Participants will receive oral etrumadenant in combination with IV zimberelimab and SG.
32998301|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
32998302|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
32998303|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
32998304|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
32998305|NCT04338685|Experimental|RO7119929|Participants will receive RO7119929 every week in 3-week cycles. In Part A (dose-escalation on a weekly schedule) maximum tolerated dose (MTD) and/or recommended dose for expansion cohorts (RDE) will be determined. Following determination of MTD and/or RDE, treatment will commence at up to three different doses in specific expansion cohorts of participants for extended PD analysis (Part B).
32998306|NCT04304820|Experimental|SAA|Subjects with SAA treated with early initiation of oral treatment
32998307|NCT04288830|Experimental|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
32998308|NCT04288830|Active Comparator|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
32998309|NCT04288271|Experimental|Adherence Intervention|"The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.~HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events."
32998310|NCT04288271|Other|Healthy Living Education Intervention|Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
32998311|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils <300/mm3 in blood and <3% in induced sputum
32998312|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils >300/mm3 in blood and/or >3% in induced sputum
32998313|NCT04243356|Experimental|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
32998314|NCT04243356|Other|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
32998315|NCT04233788||Sequence optimization (Healthy Control Group 1 (10 Persons))|"The MEGA-based editing sequences as well as the SLOW-EPSI sequence will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used for optimization of the pulse sequences.~Aim: find those sequence parameters to obtain best spectral quality data (SNR, spatial resolution versus measurement time)."
32998316|NCT04233788||Healthy Control Group 2 (15 Persons)|"The best performing sequence which will be applied to this group using a 7T Terra scanner. Data will be used normative data for glutamate/glutamine and GABA levels in healthy controls.~Aim: normal reference data for future studies."
32998317|NCT04233788||Patient Group 1: Comparison of 5 different spectral editing sequences (30 Patients)|Two editing pulse sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The sequences being compared are MEGA-semiLASER-SVS, MEGA-semiLASER based MRSI (on both 3T and 7T) and SLOW-EPSI (on 7T only).
32998318|NCT04233788||Patient Group 1: Comparison of 4 different CEST sequences (30 Patients)|"Two different CEST sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The CEST performance will be compared between 3T and 7T, as well which of the two types in the best on each scanner.~Aim: which of the four sequence predicts the IDH-mutation status best."
32998319|NCT04231877|Experimental|Treatment (polatuzumab vedotin, combination chemotherapy)|Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
32998320|NCT04225533|Experimental|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
32998321|NCT04204538||Urban|Young adults living in urban communities of Rwanda
32998322|NCT04204538||Rural|Young adults living in rural communities of Rwanda
33417361|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment~OR~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
33417362|NCT01353833|Placebo Comparator|IL2-4|
32998323|NCT04202705|Experimental|SYD1875|5T4-targeting Antibody-Drug Conjugate
32998324|NCT04199728|Experimental|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention. Liraglutide will be administered by injection pen.
32998325|NCT04199728|Placebo Comparator|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
32998326|NCT04166435|Experimental|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
32998327|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
32998328|NCT04156802|Experimental|Real TBS to the mPFC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
32998329|NCT04156802|Sham Comparator|Sham TBS to the mPFC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
32998330|NCT04156802|Experimental|Real TBS to the MC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
32998331|NCT04156802|Sham Comparator|Sham TBS to the MC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
32998332|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
32998333|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
32998334|NCT04146051|Placebo Comparator|Phase IIb Randomized Control Trial|Generalized Myasthenia Gravis
32998335|NCT04119648|Experimental|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
32998336|NCT04077515|Active Comparator|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
32998337|NCT04077515|Experimental|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
32998338|NCT04060927|Experimental|Group 1|Freebreathing SBRT with SGRT
32998339|NCT04060927|Experimental|Group 2|Breath hold SBRT with SGRT
32998340|NCT04060927|Experimental|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
32998341|NCT04039191|Placebo Comparator|SMS survey|Subject to receive SMS survey.
32998342|NCT04039191|Active Comparator|SMS survey with education|Subject to receive SMS survey with education.
32998343|NCT04037527|Experimental|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
32998344|NCT04026711|Active Comparator|MitoQ|MitoQ 40 mg per day for 12 weeks
32998345|NCT04026711|Placebo Comparator|Placebo|placebo daily for 12 weeks
32998346|NCT04022616||Immediate Surgery|Adult patients with breast malignancy.
32998347|NCT04022616||Neo-adjuvant Chemotherapy|Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
32998348|NCT04022616||Lymph Node Tissue|Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
32998349|NCT04022616||Metastatic Breast Cancer|Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).
32998350|NCT04021589|Experimental|WLS-intervention group|chemotherapy + WLS
32998351|NCT04021589|Active Comparator|the control group|chemotherapy
32998352|NCT04009044|Experimental|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 3 to 5 weeks and then undergo core needle biopsies of both breasts.
32998353|NCT03999515|Experimental|Treatment (abiraterone acetate, enzalutamide, erdafitinib)|Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
32998354|NCT03980769|Experimental|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.
32998355|NCT03980184|Experimental|Study Medication|guanfacine 3mg/day (GUA)
32998356|NCT03980184|Placebo Comparator|placebo|placebo (PBO)
32998357|NCT03975907|Experimental|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
32998358|NCT03975829|Experimental|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:~Patients who received monotherapy of either of dabrafenib or trametinib~Patients who received combination of dabrafenib and trametinib~Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
32998359|NCT03970200|Active Comparator|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
33414612|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
33414613|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
32998360|NCT03970200|Experimental|Upper gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
32998361|NCT03970200|Experimental|Lower gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
32998362|NCT03959982|Experimental|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
32998363|NCT03959982|Active Comparator|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
32998364|NCT03958461|Other|Calculus removement|Anti-infective treatment of teeth
32998365|NCT03955055|Experimental|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
32998366|NCT03955055|No Intervention|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
32998367|NCT03953898|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood throughout the study.
32998368|NCT03936153|Experimental|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
32998369|NCT03928808|Experimental|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
32998370|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
32998371|NCT03922217|Experimental|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
32998372|NCT03921008|Experimental|Paclitaxel and Radiation|"All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks.~Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
32998373|NCT03919773|Active Comparator|Treatment IVIG Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
32998374|NCT03919773|Placebo Comparator|Treatment Albumin Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
32998375|NCT03914612|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity."
32998376|NCT03914612|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity."
32998377|NCT03879161|Experimental|Device Arm|Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
33414614|NCT01343953|Experimental|Cord Blood Transplantation|
33414615|NCT05140291|Experimental|Dry needling|Experimental Group
33414616|NCT05140291|Sham Comparator|Sham Needling|Sham Group
32998378|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
32998379|NCT03851705|Experimental|Part 1 - Inclisiran|Participants who received a dose of 300 milligram (mg) inclisiran sodium for injection administered by SC injection on Day 1 and Day 90.
33414617|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
32998380|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants who received a dose of placebos administered by SC injection on Day 1 and Day 90.
32998381|NCT03851705|Experimental|Part 2 - Inclisiran|Participants who received a dose of 300 mg inclisiran sodium for injection administered by SC injection on Day 270, Day 450 and Day 630. In addition, participants who were assigned to the placebo arm in Part 1 will receive a dose of 300 mg inclisiran sodium administered by SC injection on Day 180 after completion of Part 1.
32998382|NCT03841110|Experimental|FT500 Monotherapy|FT500 administered once weekly for 3 weeks as a monotherapy
32998383|NCT03841110|Experimental|FT500 in Combination with Immune Checkpoint Inhibitor|FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
32998384|NCT03841110|Experimental|FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor|FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
32998385|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.~Patients will receive standard of care palliative radiation therapy"
32998386|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
32998387|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
32998388|NCT03808389|Experimental|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
32998389|NCT03808389|Sham Comparator|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
32998390|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
32998391|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
32998392|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
32998393|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
32998394|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
32998395|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
32998396|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
32998397|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
32998398|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
32998399|NCT03775213|Experimental|Standard Treatment Options + Active Monitoring|Participants explore decision support tool that includes current standard treatment options for DCIS, as well as active monitoring.
32998400|NCT03775213|Active Comparator|Standard Treatment Options|Participants explore decision support tool that includes current standard treatment options for DCIS.
32998401|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
32998402|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
32998403|NCT03736863|Experimental|Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）
33414618|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
33414619|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
32998404|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
32998405|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
32998406|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
32998407|NCT03710564|Experimental|Brolucizumab|Brolucizumab 6 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
32998408|NCT03710564|Active Comparator|Aflibercept|Aflibercept 2 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
32998409|NCT03703492|Experimental|Research Arm|Directed breast PET/MRI with 18F-FES; 18F-FES uptake of the known malignancy to be measured on the PET/MRI examination
32998410|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
32998411|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
32998412|NCT03624127|Experimental|BMS-986165|
32998413|NCT03624127|Placebo Comparator|Placebo|
32998414|NCT03624127|Active Comparator|Apremilast|
32998415|NCT03623139|Active Comparator|Standard nutritional education|Control group
32998416|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
32998417|NCT03616912|Placebo Comparator|Placebo|Participants received two placebo tablets: one matching baricitinib 4 milligram (mg) and one matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
32998418|NCT03616912|Experimental|2 mg Baricitinib|Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
32998419|NCT03616912|Experimental|4 mg Baricitinib|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
32998420|NCT03616912|Placebo Comparator|Placebo Maximum Extended Enrollment (MEE)|Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.
32998421|NCT03616912|Experimental|2 mg Baricitinib (MEE)|Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
32998422|NCT03616912|Experimental|4 mg Baricitinib (MEE)|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
32998423|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
32998424|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
32998425|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
32998426|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
32998427|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
32998428|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
33417363|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
32998432|NCT03499899|Experimental|LAG525 + PDR001|Participants received LAG525 and PDR001 administered as infusion once every 3 weeks
32998433|NCT03499899|Experimental|LAG525 + PDR001 + carboplatin|Participants received LAG525, PDR001 and carboplatin administered as infusion once every 3 weeks.
33417364|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
33327456|NCT05597488|Experimental|EUS guided portal pressure gradient measurement|At index OGD, the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded. After endoscopic treatment of varices, recruited patients would undergo 1st measurement of EUS-PPG within 10-14 days after index OGD. The patients would then be enrolled into a variceal surveillance program and be started on B-blockers if not already prescribed. The patients would then be scheduled for another follow-up OGD at 3 months with measurement of the 2nd EUS-PPG. Finally, a third follow-up OGD and EUS-PPG would be performed in 1-year after 1st EUS-PPG. Endoscopic findings attributed to chronic cirrhosis would be assessed in the 3 months and 1 year OGD and the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded.
33417365|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
32998434|NCT03499899|Experimental|LAG525 + carboplatin|Participants received LAG525 and carboplatin administered as infusion once every 3 weeks
32998435|NCT03481634|Experimental|Brolucizumab 3 mg|"Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
32998436|NCT03481634|Experimental|Brolucizumab 6 mg|"Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
32998437|NCT03481634|Active Comparator|Aflibercept 2 mg|"Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
33417366|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
32998438|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
32998439|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
32998440|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
32998441|NCT03475108|Other|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
32998442|NCT03461354|Experimental|A|Mucolox Arm
32998443|NCT03461354|Active Comparator|B|Sodium Bicarb Control Arm
32998444|NCT03460756|Experimental|Ganaxolone|Oral
32998445|NCT03460756|Placebo Comparator|Placebo|Oral
32998446|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
32998447|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
32998448|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
32998449|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
32998450|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
32998451|NCT03373461|Placebo Comparator|Placebo|Placebo identical to LNP023 twice a day
32998452|NCT03373461|Experimental|LNP023 10 mg BID|10 mg taken twice a day.
32998453|NCT03373461|Experimental|LNP023 50 mg BID|50 mg taken twice a day.
32998454|NCT03373461|Experimental|LNP023 100 mg BID - Part 2|100 mg taken twice a day.
32998455|NCT03373461|Experimental|LNP023 200 mg BID|200 mg taken twice a day.
32998456|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
32998457|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
32998458|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
32998459|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
32998460|NCT03355209|Experimental|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
32998461|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
32998462|NCT03355209|Experimental|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
32998463|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
32998464|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
32998465|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32998466|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
32998467|NCT03251508|Experimental|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
32739207|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
33105325|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
33105326|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
33105327|NCT00535431|Experimental|A|AER 001
33105328|NCT00535431|Placebo Comparator|P|sterile saline
33105329|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
33105330|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
32998468|NCT03245151|Experimental|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
33105331|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
33105332|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
33105333|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
33105334|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
33105335|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
33105336|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
33105337|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
33105338|NCT04680884|Experimental|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
33105339|NCT04680884|Experimental|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
33414620|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
32739208|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
32739209|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
32739210|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
32739211|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
32739212|NCT04991415|Experimental|Treatment|30 minutes of manual therapy three times a week for two weeks (six total sessions).
32739213|NCT04991415|No Intervention|Control|No intervention
32739214|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
32739215|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
32739216|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
32739217|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
32739218|NCT04990947||Bariatric surgery (Roux-en-Y Gastric Bypass)|Patients who are eligible for RYGB
32739219|NCT04990947||Lifestyle group|Patients with a BMI > 30 who will start a lifestyle program
32739220|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
32739221|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
32739222|NCT03071991||Study group|Preincisional bupivacain will be used
32739223|NCT03071991||Control group|No preincisional anesthetic drug will be used
32998469|NCT03245151|Experimental|Phase 2: Cohort 1, Ewing sarcoma/pPNET|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
32998470|NCT03245151|Experimental|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
32998471|NCT03245151|Experimental|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
32998472|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
32998473|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
32998474|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
32998475|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
32998476|NCT03171025|Experimental|Nivolumab, all patients|
32998477|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
32998478|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
32998479|NCT03148275|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 52 cycles in the absence of disease progression or unacceptable toxicity.
32998480|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
32998481|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
32998482|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
32998483|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
32998484|NCT03074617|Experimental|LTE field|
32998485|NCT03074617|Sham Comparator|sham field|
32998486|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32998487|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
32998488|NCT03040973|Experimental|Capmatinib|Starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
32998489|NCT03040973|Experimental|Capmatinib + Nazartinib|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
32998490|NCT03040973|Experimental|Capmatinib + Gefitinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
32998491|NCT03040973|Experimental|Capmatinib + Osimertinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
33105340|NCT04680884|Experimental|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
32998492|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
32998493|NCT02990806|Experimental|Stages 1, 2 and 3: NI-071 Group|Participants received intravenous (IV) infusion of NI-071 at a dose of 3 milligrams/kilograms (mg/kg) at Weeks 0, 2, 6, 14 during stage 1 and at Weeks 22, 30, 38, 46, and 54 during stage 2. Participants were followed up to Week 62 (Stage 3).
32998494|NCT02990806|Experimental|Stage 1: Remicade-US Group|Participants received IV infusion of Remicade-US (infliximab) at a dose of 3 mg/kg at Weeks 0, 2, 6, 14 during stage 1.
32998495|NCT02990806|Experimental|Stage 2 and Stage 3: Remicade US to Remicade-US Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 to continue Remicade-US dose 3 mg/kg from Week 22 through Week 54 with every 8 weeks dosing intervals. Participants were followed up to Week 62 (Stage 3).
33105341|NCT04680884|Other|Best standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
32998496|NCT02990806|Experimental|Stage 2 and Stage 3: Remicade US to Switch Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 and received IV infusion of NI-071 at Week 22 followed by Remicade-US at Week 30, followed by NI-071 at Weeks 38, 46, and 54. Participants were followed up to week 62 (Stage 3).
32998497|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
32998498|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
32998499|NCT02980887||Pulmonary Hypertension|Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension
32998500|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
32998501|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
32998502|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
32998503|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
32998504|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
32998505|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
32998506|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
32998507|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
32998508|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
32998509|NCT02938442|Active Comparator|Control Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
32998510|NCT02938442|Experimental|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
32998511|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
32998512|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
32998513|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
32998514|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
32998515|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time intravenous (IV) Infusion of up to 5 x 10^6 allogeneic human mesenchymal stem cells per kilogram of body weight (hMSCs/kg). A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
32998516|NCT02814916|Experimental|Dalbavancin, single dose|
32998517|NCT02814916|Experimental|Dalbavancin, two doses|
32998518|NCT02814916|Active Comparator|Comparator|
32998519|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
32998520|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
32998521|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
32998522|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
32998523|NCT02650271|Active Comparator|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
32998524|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
32998525|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
32998526|NCT02578875||Sample|Discarded patient samples and autopsy material
32998527|NCT02567409|Experimental|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
32739224|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
32739225|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
32865314|NCT04844580|Experimental|Standard Treatment + Inhaled Aviptadil|In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
32865315|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.~The patients involvement will then be finished in the study and will be cared for as per clinical practice.~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
32865316|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.~Maximal hyperaemia FFR will be recorded during adenosine infusion.~An FFR ratio of <0.80 will be regarded as a positive result."
32865317|NCT04844502|No Intervention|Control Group|Frequent life activities.
32865318|NCT04844502|Experimental|Intervention Group|Protocol of physical exercises
32865319|NCT02815553|Experimental|Cardiac tumors|
32865320|NCT04844112|Experimental|Experimental arm|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
32865321|NCT01890941|Experimental|KCT-0809 Lower Dose|
32865322|NCT01890941|Experimental|KCT-0809 Higher Dose|
32865323|NCT01890941|Placebo Comparator|Placebo|
32865324|NCT04375722|Experimental|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
32865325|NCT04375722|Experimental|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
32865326|NCT04375722|Sham Comparator|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
32865327|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
32865328|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
32865329|NCT04374474|Sham Comparator|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
32865330|NCT04374474|Experimental|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
32865331|NCT04374474|Experimental|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
32865332|NCT04272515|Experimental|BA patients and their parents|"Collection of blood samples from BA patients and their parents~Collection of explanted liver tissue and skin biopsy of BA patients"
32865333|NCT02811601|Experimental|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery
32865334|NCT04272437|Experimental|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
32865335|NCT04272437|Placebo Comparator|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
32865336|NCT04373928|Experimental|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
32865337|NCT04373928|No Intervention|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
32865338|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide~Dosage:~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.~peripheral stem cell collection after cycle 1 or 2"
32865339|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
33105342|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
33105343|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
33105344|NCT02898428||New mothers|New mothers with type 1 diabetes
33105345|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
33105346|NCT00549159|Experimental|Cavaterm|
33325028|NCT05211076|Experimental|Music Group|"In the selection of the music to be played,Rast,Uşşak,Kürdi,Muhayyer modes were chosen by taking expert opinion.Before starting the music application,the selected music will be sent to the mothers in this group by the researcher over the internet to the mother's phone and it will be ensured that the mother listens to the music transmitting the sound from her own phone in each session.~Music practice will take place in mothers' rooms or in the NICU.~The room will be quiet and your mother will be alone.~To make the mother listen to music;The mother will be asked to sit on the bed/seat in a comfortable position.~At the same time,the mother will be asked to close her eyes and be relaxed.~Later, music will be turned on from the mother's phone, allowing the mother to listen to music for 30 minutes~While the mother listening to the music,at the 16th minute of the music,researcher will manually express each breast separately for at least 15 minutes until no milk comes out"
33417367|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
32865340|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
32865341|NCT04272125|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
32865342|NCT04853706|Other|Delirium|
32865343|NCT04341025|Other|Single Arm|Patients are compared to themselves before and after the treatment.
32865344|NCT04271891|Experimental|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
32865345|NCT04271891|Placebo Comparator|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
32865346|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
32904383|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
32904384|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
32904385|NCT04384874|Active Comparator|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
32904386|NCT04384874|Experimental|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
32904387|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
32904388|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
32904389|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
32904390|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
32904391|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
32904392|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
32904393|NCT00781898|Active Comparator|Depot Naltrexone|
32904394|NCT00781898|Placebo Comparator|Placebo|
32904395|NCT03800732|Experimental|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
32998528|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
32998529|NCT02557438||Roux-en-Y Gastric Bypass|Males and females aged 13-25 undergoing Roux-en-Y gastric bypass (RYGB) surgery
32998530|NCT02557438||Vertical Sleeve Gastrectomy|Males and females aged 13-25 undergoing vertical sleeve gastrectomy (VSG) surgery
32998531|NCT02557438||Non-surgical Obese Controls|Males and females aged 13-25 who are obese and not undergoing weight loss surgery
32998532|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
32998533|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
32998534|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32998535|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
32998536|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
32998537|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
32998538|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
32998539|NCT02438436|No Intervention|empty control|
32998540|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
32998541|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
32998542|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
32998543|NCT02398773|Experimental|Diagnostic (FES PET/CT)|Between 0 to 30 days before start of endocrine therapy, patients receive F-18 16 alpha-fluoroestradiol IV over 2 minutes and undergo PET/CT. Patients may undergo a second FES-PET/CT study at least 24 hours after the first study and no later than 10 days after the initial study.
32998544|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
32998545|NCT02229084|Experimental|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
32998546|NCT02229084|Experimental|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
32998547|NCT02229084|Experimental|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
32998548|NCT02229084|Experimental|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
32998549|NCT02229084|Experimental|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
32998550|NCT02229084|Experimental|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
32998551|NCT02229084|Experimental|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
32998552|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
32998553|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
33105347|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
33325029|NCT05211076|Experimental|Marmet Technique Group|Marmet Technique is one of the non-pharmacological methods used to increase milk production.The Marmet Technique is a combined method that includes breast massage and manual milking.The Marmet Technique will be performed in the mothers' rooms or in the Breastfeeding Room of the Neonatal Intensive Care Unit. It will be ensured that the mother is comfortable by paying attention to her privacy. Mothers will be manually milked into the hopper in their own milking set. In addition, the reservoir will be used after washing with hot water. This technique consists of two stages, these stages are emptying the milk ducts and stimulating the milk stroke reflex (massage).
33325030|NCT05211076|Experimental|control group|On the other hand, no application will be made to the control group, and the milking process will be carried out manually by the researcher for at least 15 minutes until the milk does not come.
33325031|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
33325032|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
32998554|NCT02177162|Other|Intervention= education peer review group|For this controlled trial a group of physiotherapists will recieve specific education about optimal exercise therapy for patioents with knee OA in early stage
33325033|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
33325034|NCT03099304|Experimental|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
33325035|NCT03099304|Experimental|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
33417368|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
32998555|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
32998556|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
32998557|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
32998558|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
32998559|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32998560|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
32998561|NCT02039063|Experimental|1|E6011 2 mg/kg
32998562|NCT02039063|Experimental|2|E6011 5 mg/kg
32998563|NCT02039063|Experimental|3|E6011 10 mg/kg
32998564|NCT02039063|Experimental|4|E6011 15 mg/kg
32998565|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
32998566|NCT01950520|Experimental|Cohort 2|Interventions, in random order, will be administered during one of the six one-day stays
32998567|NCT01950520|Experimental|Cohort 3|Interventions, in random order, will be administered during one of the four overnight inpatient stays
32998568|NCT01950520|Experimental|Low Temperature 1st|Low temperature before 27c (Cohort 1 only)
32998569|NCT01950520|Experimental|Low Temperature 2nd|Low temperature after 27c (Cohort 1 only)
32998570|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
32998571|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
32998572|NCT01746173|Experimental|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
32998573|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
33105348|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
32998574|NCT01679275||measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
32998575|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
32998576|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
32998577|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
32998578|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
32998579|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
32998580|NCT00843791|Active Comparator|pioglitizone|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
32998581|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
32998582|NCT00001177||healthy volunteers|healthy females
32998583|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
32998584|NCT03229031|Experimental|ES135|
32998585|NCT03229031|Placebo Comparator|Placebo|
32998586|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
32998587|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
32998588|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
32998589|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
32998590|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
32998591|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
32998592|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
32998593|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
32998594|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
32998595|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
32998596|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
32998597|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
32998598|NCT03136731||Healthy family members of celiac disease|Celiac disease screening, no intervention.
32998599|NCT03136731||Celiac disease index cases|Assessment of disease related factors, no intervention.
32998600|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
32998601|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
32998602|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
33105349|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
32998603|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
32998604|NCT03092297||ICU patients with anaemia|At admission to the ICU all patients, or their legal representatives, expected to stay at the ICU for longer than 24 hours will be asked to participate in the study and will be asked informed consent. ICU patients with anaemia in whom a central venous catheter is already in place and in whom a red cell transfusion is planned, will be included in the study.
32998605|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
32998606|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
32998607|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
32998608|NCT03033992|Experimental|Treatment (Concurrent Optune/focal radiation therapy followed by Optune-only therapy)|Patients must have newly diagnosed DIPG (a typical DIPG on MR imaging, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, without histologic confirmation; atypical DIPG undergoing a biopsy and the tumor is a diffuse glioma WHO Grade II-IV with OR without H3 K27M mutation; or pontine lesions that do not meet these MR imaging criteria with histologically confirmed diffuse glioma WHO Grade II-IV with H3 K27M- mutation). This arm will consist of two parts: a phase I component to evaluate the safety and tolerability of concurrent Optune and RT, and a phase II component to evaluate the feasibility of concurrent Optune and RT and the efficacy associated with this approach compared to historical controls.
32998609|NCT03032822||All Patients|All cystectomy patients who consent for the study
32998610|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
32998611|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
32998612|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
32998613|NCT02994043|Active Comparator|MBRP|
32998614|NCT02994043|Active Comparator|RP|
32998615|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
32998616|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
32998617|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg~Each medication is taken daily. Treatment cycles are 28 days long."
32998618|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg~Each medication is taken daily. Treatment cycles are 28 days long."
32998619|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
32998620|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
32998621|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
32998622|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
32998623|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
32998624|NCT02891603|Experimental|Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~Pacritinib will begin the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant.~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
32998625|NCT02876107|Experimental|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
32998626|NCT02876107|Experimental|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
32998627|NCT02872844|Experimental|Heat-stress|
32998628|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
32998629|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
32998630|NCT02855229||Phase 2 Participants [Methylphenidate]|Phase 2 participants that are randomly assigned to take methylphenidate.
32998631|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
33414621|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
33414622|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
33414623|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
32998632|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
32998633|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
32998634|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
32998635|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
32998636|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
32998637|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
32998638|NCT02727803|Experimental|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
32998639|NCT02727803|Experimental|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
32998640|NCT02727803|Experimental|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
32998641|NCT02702492|Experimental|KPT-9274|"Part A: [CLOSED TO ENROLLMENT]~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
32998642|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|"Part B:[CLOSED TO ENROLLMENT]~500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
32998643|NCT02702492|Experimental|KPT-9274 + Nivolumab|"Part C:~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.~Nivolumab 480 mg IV administered Day 1 during each 28 day cycle."
32998644|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
33105350|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
33105351|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
32904396|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
32904397|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
32904398|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
32904399|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
32904400|NCT05316896|Experimental|Internal perturbation|The people included in this group did 6 internal perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
32904401|NCT05316896|Experimental|Eksternal perturbation|The individuals included in this group performed 6 external perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
32904402|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
32904403|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
32904404|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
32904405|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
32904406|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
32904407|NCT05316428|Experimental|alcohol plus TPN171H|0.5 g/Kg alcohol plus 10 mg TPN171H tablet
32904408|NCT05316428|Experimental|alcohol|0.5 g/kg alcohol
32904409|NCT05316428|Experimental|TPN171H|10 mg TPN171H tablet
32904410|NCT05315960||Qualitative study|Consenting participants will complete a form asking about basic characteristics including age, sex, ethnicity, marital status etc. People living in long-term care and family carers will participate in an individual interview and professional staff will participate in an individual interview or focus group (between 5 and 10 participants) depending on their preference. The interview or focus group is expected to last 30-60 minutes. Sessions will be conducted in-person or online (using MS Teams), depending on preference and COVID-19-related restrictions. All sessions will be audio-recorded and transcribed.
32904411|NCT05315960||Cross-sectional study|"Procedures:~Consent will be obtained from residents, for those who have mental capacity to give informed consent, or from a nearest relative or caregiver as consultee, for those who lack capacity. Once consent is obtained, the LTC resident will be asked to complete a form asking about their characteristics and a questionnaire about their social connections which is expected to take approximately 15 minutes. The proxy will be asked to complete a sociodemographic form about themselves along with a number of questionnaires regarding the LTC resident's dementia severity, neuropsychiatric symptoms, activities of daily living and quality of life for comparison. Data collection for the proxy is expected to take approximately 30-60 minutes. Anticipated sample size 150 between Canada and the UK."
32904412|NCT05310968|Experimental|Tirofiban group|"This group will receive tirofiban and aspirin. Day 1: Tirofiban injected intravenously for 24 hours and aspirin of 100-300 mg. Tirofiban will be injected at 4 ug/kg/ min for the first 30 minutes and 0.1 ug/kg/min for the next 24 hours.~Day 2-90: Aspirin 100mg per day."
32904413|NCT05310968|Placebo Comparator|Tirofiban placebo group|"This group will receive tirofiban placebo and aspirin. Day 1: Tirofiban placebo injected intravenously for 24 hours and aspirin of 100-300 mg. The placebo will be injected at the same rate with Tirofiban group.~Day 2-90: Aspirin 100mg per day."
32904414|NCT05316506|Other|Anticipated Discomfort Group|Participants will be prompted using anticipated discomfort language during the standard of care hysteroscopy.
32904415|NCT05316506|Other|Objective Description Group|Participants will be prompted using objective description language during the standard of care hysteroscopy.
32904416|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
32904417|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
32904418|NCT05318378|Experimental|student|Twenty fifth-year medical students were asked to participate in the study
32904419|NCT05318378|Active Comparator|senior surgeon|As controls, we asked 3 independent board-certified orthopedic surgeons to participate in the study following the same conditions as described previously.
32904420|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
32904421|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
32904422|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
32904423|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
32904424|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
32904425|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
32904426|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
32904427|NCT03808532|Experimental|High-Risk with Moisturizer|
32904428|NCT03808532|No Intervention|High-Risk without Moisturizer|
32904429|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
33105352|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
33105353|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
33105354|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
33105355|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
33105356|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
33105357|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
33105358|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
33105359|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
33105360|NCT00549315|Experimental|1|
33105361|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
33105362|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
33105363|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
33105364|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
33105365|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
33105366|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
33105367|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
33105368|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
33105369|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
33105370|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
33105371|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
33105372|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
33105373|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
33105374|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
33105375|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
33105376|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
33105377|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
32904430|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
32904431|NCT05744258|Other|IBS patients|
32904432|NCT05744258|Other|Healthy volunteers|
32904433|NCT02189915|Experimental|Creatine monohydrate|
32904434|NCT04385030|Active Comparator|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
32904435|NCT04385030|Sham Comparator|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
32904436|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
32904437|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
32904438|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
32904439|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
32904440|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
32904441|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
32904442|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
32904443|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
32904444|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
33414624|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
33414625|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
33414626|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
33414627|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
32904445|NCT05744102|Other|Adult patients having MRI planned at Paul Brousse Hospital|Evaluate new MRI sequences on a population of patients undergoing MRI as part of their usual care
32904446|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
32904447|NCT01305473||Sepramesh Group|
32904448|NCT00760526|Active Comparator|1|continuous glucose monitoring
32904449|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
32904450|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
32904451|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
32904452|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
32904453|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
32904454|NCT01215929|Active Comparator|Dextroamphetamine|
32904455|NCT01215929|Placebo Comparator|Placebo|
32904456|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
32904457|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
32904458|NCT05744024|Experimental|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, a controller and a headphone. The application SyncVR Relax & Distract will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
32904459|NCT05744024|Experimental|Music Therapy (Intervention group 2)|In addition to the standard wound care procedure, the Music Therapy group (intervention group 2) will be hearing their preferred audio, chosen by patient to be relaxing and to offer distraction, through headphones during wound care. This group wears the headphone with music 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
32904460|NCT05744024|No Intervention|Care as usual (control group/group 3)|The care as usual group (control group) will receive the care as usual. This group receives neither VRT nor MT during wound care.
32904461|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
32904462|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
32904463|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
32904464|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
32904465|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
32904466|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.~Subjects will wear the tape for as long as possible up to 5-7 days."
32904467|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.~Subjects will wear the tape for as long as possible up to 5-7 days."
32904468|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
32904469|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
32904470|NCT04345406|Experimental|ACEIs|ACEIs with conventional treatment for COVID19
32904471|NCT04345406|Experimental|Conventional treatment of COVID19|Conventional treatment of COVID19
32904472|NCT05621174|Other|Magisterial Dexamphetamine|Magisterial Dexamphetamine
32904473|NCT05621174|Other|Tentin|Tentin
32904474|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
32904475|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
32865347|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
32865348|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
32865349|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
32865350|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
32865351|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
32865352|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
32865353|NCT04771585|No Intervention|Study Part A|Aerosol number and size spectrum characterization of 30 subjects, stratified by age groups, including 10 professional singers. Subjects will be examined twice within 14 days to assess reproducibility of aerosol emission.
32865354|NCT04771585|Experimental|Study Part B|From the 30 subjects of Part A, the 10 highest-emitting subjects will be assessed a third time, wearing four different classes of face masks consecutively with increasing aerosol filtering capacity.
32865355|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
32865356|NCT04771507|Experimental|Intermittent ibrutinib|Intermittent treatment with ibrutinib.
32865357|NCT01891565|Experimental|Activity Feedback|Feedback
32865358|NCT01891565|No Intervention|No Feedback|
32865359|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
32865360|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
32865361|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
32865362|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
32865363|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
32865364|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
32865365|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
32865366|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
32865367|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
32865368|NCT04779463||Mechanical Ventilated patients|All patients are invasively mechanically ventilated at least 24 hours, and are clinically stable as ready to undergo a spontaneous breathing trial.
32865369|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
32865370|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
32865371|NCT04389983|Active Comparator|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
32904476|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
32904477|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
32904478|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
33105378|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
33414628|NCT04660279|Other|Validate|D-WB PET/CT scans + arterial blood sampling.
32998645|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
33414629|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
33414630|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
33414631|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
32998646|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
32998647|NCT02601950|Experimental|Open-label Tazemetostat|All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhabdoid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma, Cohort 5 - Epithelioid sarcoma, Cohort 6 - Epithelioid sarcoma undergoing mandatory tumor biopsy and Cohort 7 - Poorly differentiated chordoma (or other chordoma with Sponsor approval)] will receive 800 mg oral Tazemetostat BID x 28 days
33414632|NCT05185193|Experimental|radiofrequency stimulation|Participants received radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
33414633|NCT05185193|Sham Comparator|sham stimulation|Participants received a sham stimulation similar to a radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
32998648|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
32998649|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
32998650|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
32998651|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
32998652|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
32998653|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
32998654|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
32998655|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
32998656|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
32998657|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
32998658|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
32998659|NCT02525783|Experimental|Hemi Shoulder Arthroplasty|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
32998660|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
32998661|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
33105379|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
33105380|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
33105381|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
33417369|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
32904479|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
32904480|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
32904481|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
32904482|NCT05743868|Experimental|IR participants with standardized dinner|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
32904483|NCT05743868|Experimental|IR participants with standardized dinner and premeal exercise|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~DNL will be assessed in all participants after a single day with short bouts of premeal exercise with a standardized dinner.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
32904484|NCT04278872|Experimental|SJX-653|Participants will receive SJX-653
32904485|NCT04278872|Placebo Comparator|Placebo|Participants will receive placebo
32904486|NCT04276610|No Intervention|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
32904487|NCT04276610|Experimental|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
32904488|NCT04276610|Experimental|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
32904489|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
32904490|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
32904491|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
32904492|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
32904493|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
32904494|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
32904495|NCT05623046|Experimental|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes.
32904496|NCT05743790|Experimental|Group A: RS2 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
32904497|NCT05743790|Experimental|Group B: RS4 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
32998662|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
32998663|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
32998664|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
32998665|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
32998666|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
32998667|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
32998668|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
32998669|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
32998670|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
32998671|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
32998672|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
32998673|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
32998674|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
32998675|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
32998676|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
32998677|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
32998678|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
32998679|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
32998680|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
32998681|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
32998682|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
32998683|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
32998684|NCT02019641|Active Comparator|No AET|control will not engage in AET.
32998685|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
32998686|NCT02015078||African Americans|Targets are family members attending African American family reunions.
32998687|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
33105382|NCT00535665|Experimental|1: 10 ug, 14 days|
33105383|NCT00535665|Experimental|2: 5 ug, 28 days|
33105384|NCT00535665|Experimental|3: 10 ug, 28 days|
33105385|NCT00535665|Experimental|4: 15 ug, 28days|
33417370|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
32904498|NCT05595356|Experimental|Active tDCS|Participants will receive 30 daily sessions of tDCS. Each session lasts 20 minutes, and delivers a current of 2mA.
32904499|NCT05595356|Sham Comparator|Sham tDCS|Participants will receive 30 daily sessions of sham tDCS. Each session lasts 20 minutes, and the sham programming delivers 3 ramps of 30 seconds of active current, the first in the first minute of the session, the second after 10 minutes and the third at the last minute of the session.
32904500|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
32904501|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
32904502|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
32904503|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
32904504|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
32904505|NCT05743712|Experimental|SMART-Wrap|SMART-Wrap is a prototype measurement and feedback software system tailored to Wraparound service model (WSM) for emotional disorders to provide measurement-based care in care coordination for youth behavioral health.
32904506|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
32904507|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
32904508|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
32904509|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
32904510|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
32904511|NCT05743634|Experimental|Treatment Group|Single injection with YY001 in glabellar lines
32904512|NCT05743634|Active Comparator|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
32904513|NCT05743634|Placebo Comparator|Placebo-Controlled Group|Single injection with placebo in glabellar lines
32904514|NCT05743478|Experimental|Forging Hopeful Futures|Forging Hopeful Futures uses a group discussion format with activities that explore race, gender, class, identity, relationships, and multiple forms of violence. Forging Hopeful Futures is a 12 session curriculum for youth ages 14-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
32904515|NCT05743478|Active Comparator|Wellness Check-ins|Youth in neighborhoods randomized to the control group will receive individual wellness checks. This will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
32904516|NCT05583188|Experimental|Aliya PEF ablation|Pulsed electric field treatment using the Aliya System
32904517|NCT05581784|Experimental|Pain neuroscience education.|This consists of generating elements from neurobiology and neurophysiology for the understanding of pain from the development of metaphors.
32904518|NCT05581784|Other|Conventional treatment or Usual Care|Pharmacological treatment and indications estimated by a specialist in palliative care and pain.
32904519|NCT05743322|Experimental|3D printing arm|A bi-atrial 3D printed model will be manufactured before the procedure
32904520|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
32904521|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
32904522|NCT05743244|Experimental|Abrocitinib|Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
32904523|NCT05743244|Experimental|Ritlecitinib|Ritlecitnib will be self-administered via oral administration as a 100-mg capsule daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
32904524|NCT05743244|Placebo Comparator|Placebo|200 mg tablet or 100 mg capsule matching either abrocitinib or ritlecitinib will be self-administered via oral administration daily for 52 weeks (12 months). The final product is to be labeled to protect the blind.
32904525|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
32904526|NCT03803618||Control|Age and sex matched neighborhood controls
32904527|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
32904528|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
32904529|NCT01337687|Experimental|Oxytocin|
32904530|NCT01337687|Placebo Comparator|Placebo|
32904531|NCT04351919|Experimental|HCQ Arm|
32904532|NCT00769808|Experimental|Technolas 217z Excimer Laser|Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
32904533|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
32904534|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
33417371|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
32998688|NCT01953926|Experimental|Neratinib monotherapy|Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, and lung cancers containing EGFR exon 18 mutations.
32998689|NCT01953926|Experimental|Neratinib and Trastuzumab|Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers.
32998690|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
32998691|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with CDK4/6i naïve) breast cancers.
32998692|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
32998693|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
32998694|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
32998695|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
32998696|NCT01843374|Experimental|Tremelimumab|Tremelimumab
32998697|NCT01843374|Placebo Comparator|Placebo|Placebo
32998698|NCT01753089|Other|WDVAX|Treatment
32998699|NCT01705067|Other|Journey II BCS TKA|Subjects having TKA with Journey II BCS Total Knee System
32998700|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
32998701|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
32998702|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
32998703|NCT01028144|Active Comparator|General Health|General health education after-school program
32998704|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
32998705|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
32998706|NCT01025726|Active Comparator|General Health|General Health Education Intervention
32998707|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
32998708|NCT00073801||Chronic Pelvic Pain and Endometriosis|Women with chronic pelvic pain and endometriosis found at study surgery
32998709|NCT00073801||Chronic Pelvic Pain and No Endometriosis|Women with chronic pelvic pain and NO endometriosis found at study surgery
32998710|NCT00073801||Healthy Volunteers|Women without no chronic pelvic pain and no symptoms of endometriosis
32998711|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
32998712|NCT01599455||Outpatient|Youths visiting outpatient clinics
32998713|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
32998714|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
32998715|NCT01599468|Placebo Comparator|placebo|
32998716|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
32998717|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
32998718|NCT01599507|Experimental|FG-4592|Active Drug
32998719|NCT01599507|Placebo Comparator|Placebo|
32998720|NCT01599533|Other|abdominal aortic aneurysms|
32998721|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
32998722|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
32998723|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
32998724|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
32998725|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
32998726|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
33325036|NCT03099304|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
32998727|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
32998728|NCT01599624|Experimental|iPad-based SRTS|
32998729|NCT01599624|Experimental|iPad-based PMR program|
32998730|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
33417372|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
33105386|NCT03971110|Experimental|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
33105387|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
33105388|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
33105389|NCT00549432|Experimental|1|
33105390|NCT05651737|Active Comparator|Sui App+ (peer guided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~One of the active study groups, the Sui App+ condition, receives the Sui app plus a peer who will guide them online. They receive weekly individual messages from their peer within the chat of the app."
33325037|NCT03099304|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
33417373|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
33417374|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
32904535|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
32904536|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
32904537|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
32904538|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
32904539|NCT05743010|Experimental|APL-1401|On Day 1, patients will be randomized to receive either APL-1401 or placebo in a 5:1 ratio. Patients will receive APL-1401 orally once daily (QD) during the 28-day treatment period.
32904540|NCT05743010|Placebo Comparator|Placebo|Identically matching placebo capsules once daily for 28 days
32904541|NCT01309451|Active Comparator|Bevacizumab alone|
32904542|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
32904543|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
32904544|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
32904545|NCT00787904||Healthy|Healthy matched pre-menopausal controls
32904546|NCT05509400|Experimental|Rimegepant|"Rimegepant - Double-blind (DB) Phase: One dose of rimegepant 75 mg Oral Disintegrating Tablet (ODT)~Rimegepant/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT as needed for a qualifying acute migraine. A qualifying migraine is an attack of moderate or severe headache pain intensity. Migraine headache pain intensity will be measured on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe)"
32904547|NCT05509400|Placebo Comparator|Placebo|"Placebo - Double-blind (DB) Phase: One dose of matching placebo~Placebo/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT for a qualifying migraine"
32904548|NCT04351841|Placebo Comparator|control|15 g maltodextrin per day consumed in the morning
32904549|NCT04351841|Experimental|Active|15 g arabinogalactan per day consumed in the morning
32904550|NCT05621018|Active Comparator|Intervention group|Patients will be introduced to Maze Out in an information meeting with the investigators and will afterwards receive a link with the game and a username. Each patient has to choose a code to start playing the game. The code will not be available for the investigators.
32904551|NCT05621018|Active Comparator|Control group|Patients will be introduced to Maze Out. 15 weeks later they will follow the same procedure as intervention group.
32904552|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
32904553|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
32904554|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
32904555|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
32904556|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
32904557|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
32904558|NCT01255865||E - 21 years and older|Age group older than 21 years
32904559|NCT05492162|Other|paramedic students|para-experimental arm
32904560|NCT05491226|Experimental|Pembrolizumab with Radiation Therapy and Axatilimab|
32904561|NCT04383704|Experimental|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
32904562|NCT04383704|Active Comparator|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
32904563|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
32904564|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
32904565|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
32904566|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
32904567|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
32904568|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
33325038|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
32998731|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
32998732|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
32998733|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
32998734|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
32998735|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
32998736|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
32998737|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
32998738|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
32998739|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
32998740|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
32998741|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
32998742|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
32998743|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
32998744|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
32998745|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
32998746|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
32998747|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
32998748|NCT01599845||Nanoparticle exposed|
32998749|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
32998750|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
32998751|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
32998752|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
32998753|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
32998754|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
32998755|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
32998756|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
32998757|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
32998758|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
32998759|NCT01599923|Experimental|Alacramyn|
32998760|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
32998761|NCT01599949|Experimental|Ibrutinib|
32998762|NCT01599962|Experimental|Cinacalcet|
32998763|NCT01599962|Placebo Comparator|Sugar pill|
32998764|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
32998765|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
32998766|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
33325039|NCT05165368|Experimental|Intraneural Facilitation (INF) + Dietary Education|The INF+ group will receive dietary education reviewed by a physician with weekly follow-up by a physical therapist either in person, or via email. The INF+ group will additionally receive meal preparation ideas and sample menus promoting a whole plant foods lifestyle.
32998767|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
32998768|NCT01600157|Experimental|Laparoscopic Nephrectomy|
32998769|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
32998770|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
32998771|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
32998772|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
32998773|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
32998774|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
32998775|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
32998776|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
32998777|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
32998778|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
32998779|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
32998780|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
32998781|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
32998782|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
32998783|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
32998784|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
32998785|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
32998786|NCT01601028|Placebo Comparator|Placebo|Placebo
32998787|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
32998788|NCT01601301|Experimental|PRECICE System|
32998789|NCT01601457|Experimental|Activated recombinant human factor VII|
32998790|NCT01601457|Placebo Comparator|Placebo|
32998791|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
32998792|NCT01601587|Other|Introduction Seminar|Psychoeducational group
32998793|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
32998794|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
32998795|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
32998796|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
32998797|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
32998798|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
32998799|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
32998800|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
32998801|NCT01602237||Bakery workers|
32998802|NCT01602705|Placebo Comparator|Usual care|
32998803|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
32998804|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
32998805|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
32998806|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
32998807|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
32998808|NCT01602796|Experimental|School-based intervention|
32998809|NCT01602796|No Intervention|Control|
33414634|NCT04783519|Experimental|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
32998810|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
32998811|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
32998812|NCT01602874|Experimental|A. Tigecycline|
32998813|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
32998814|NCT01602887|Active Comparator|Reference|This is the reference formulation
32998815|NCT01602887|Experimental|NF1|This is a test formulation
32998816|NCT01602887|Experimental|NF2|This is a test formulation
32998817|NCT01602887|Experimental|SOL|This is a test formulation
32998818|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
32998819|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
32998820|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
32998821|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
32998822|NCT01603264|Experimental|A|PF-05280014
32998823|NCT01603264|Active Comparator|B|Trastuzumab-EU
32998824|NCT01603264|Active Comparator|C|Trastuzumab-US
32998825|NCT01603485|Experimental|Lersivirine|
32998826|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
32998827|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
32998828|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
32998829|NCT01603537||No PHTLS|Not exposed to PHTLS
32998830|NCT01603589|Active Comparator|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
32998831|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
32998832|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
32998833|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
32998834|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
32998835|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
32998836|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
32998837|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
32998838|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
32998839|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
32998840|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
32998841|NCT01604213|Active Comparator|Metformin only|Oral metformin only
32998842|NCT01604538||patients with acute pulmonary embolism|
32998843|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
32998844|NCT01604798||Healthy Controls|Healthy volunteers
32998845|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
32998846|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
32998847|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
32998848|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
32998849|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
32998850|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
32998851|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
32998852|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
32998853|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
32998854|NCT01606072|Experimental|Desmopressin|
32998855|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
32998856|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
32998857|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
32998858|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
32998859|NCT01606904|Other|Control|Short term weight loss counseling, control group
32998860|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
32998861|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
32998862|NCT01607242||patients|patients undergoing total thyroidectomy
32998863|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
32998864|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
32998865|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
32998866|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
32998867|NCT01607983|Experimental|inhaled nitric oxide|
32998868|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
32998869|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
32998870|NCT01608425|No Intervention|Control|Control group. Regular treatment.
32998871|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
32998872|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
32998873|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
32998874|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
32998875|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
32998876|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
32998877|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
32998878|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
32998879|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
32998880|NCT01609140|Experimental|A|
32998881|NCT01609140|Experimental|B|
32998882|NCT01609140|Experimental|C|
32998883|NCT01609140|Experimental|D|
32998884|NCT01609140|Experimental|E|
32998885|NCT01609140|Placebo Comparator|F|
32998886|NCT01609153|Active Comparator|Olanzapine or Placebo|
32998887|NCT01609153|Active Comparator|Amisulpride or Placebo|
32998888|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
32998889|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
32998890|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
32998891|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
32998892|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
32998893|NCT01609608|Experimental|vibration|
32998894|NCT01609608|Placebo Comparator|placebo|
32998895|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
32998896|NCT01609725|Other|Community treatment|Control treatment group
32998897|NCT01609751|Experimental|Yakult 62 ml daily|
32998898|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
32998899|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches."
32998900|NCT01610024|Active Comparator|Beetroot|
32998901|NCT01610050|Experimental|LFA102|
32998902|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
32998903|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
32998904|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
32739226|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
32998905|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
32998906|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
32998907|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
32998908|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
32998909|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
32998910|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
32998911|NCT01610232|Active Comparator|Exercise Group|Treadmill training
32998912|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
32998913|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
32998914|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
32998915|NCT01610323|Experimental|Exercise group|Exercise intervention
32998916|NCT01610323|Other|Control group|Standard care
32998917|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
32998918|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
32998919|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
32998920|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
32998921|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
32998922|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
32998923|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
32998924|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
32998925|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
32998926|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
32998927|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
32998928|NCT01610401|No Intervention|No pretreatment.|no intervention
32998929|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
32998930|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
32998931|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
32998932|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
32998933|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
32998934|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
32998935|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
32998936|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
32998937|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
32998938|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
32998939|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
32998940|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
32998941|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
32998942|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
32998943|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
32998944|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
32998945|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
32998946|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
32998947|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
32998948|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
32998949|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
32998950|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
32998951|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
32998952|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
32998953|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
32998954|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
32998955|NCT01610726|Active Comparator|enhanced recovery|
32998956|NCT01610726|No Intervention|conventional recovery|
32998957|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
32998958|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
32998959|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
32998960|NCT01610778|Placebo Comparator|Placebo|
32998961|NCT01610778|Experimental|Supplement|
32998962|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
32998963|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
32998964|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
32998965|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
32998966|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
32998967|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
32998968|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
32998969|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
32998970|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
32998971|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
33417375|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
33417376|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
32739227|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
32904569|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
32904570|NCT05742698|Active Comparator|Nabilone|"Weeks 1-2 Nabilone and placebo will be taken orally by the patient as per the schedule provided by the research team. All patients will start with one 0.5mg capsule per day, taken before bed for the first week and then increase administration to the 1mg capsule taken before bed for the second week.~Weeks 3-4 Two weeks after the start of the trial patients and study partners will attend an in person or remote Interim Assessment. If remission is not achieved and no clinically significant adverse drug reactions are reported then the dose schedule will increase to 2 capsules per day (2mg/day), 1 capsule in the morning and 1 before bed.~Weeks 5-6 Four weeks after the start of the trial there will be a second in person or remote Interim Assessment identical to the first. If remission of agitation has not been achieved and no adverse drug reactions are reported the dose schedule will increase to 4 tablets per day (4mg/day), with 2 tablets in the morning and 2 before bed."
33417377|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
33417378|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
33417379|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
32904571|NCT05742698|Placebo Comparator|Placebo|"Weeks 1 and 2 Participants will receive one capsule per day to be taken orally before bedtime.~Weeks 3-4 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~Weeks 5-6 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~The placebo dosing regimen is designed to be as similar as possible to the nabilone dosing regime, including using identical capsules."
32904572|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
32904573|NCT03802838|Other|Amisulpride|Amisulpride only.
32904574|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
32904575|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
32904576|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
32904577|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
32904578|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
32904579|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
32904580|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
32904581|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
32904582|NCT05742620|Experimental|anlotinib+CAPEOX/SOX|Adjuvant treatment of locally advanced gastric cancer and colorectal cancer
32904583|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
32904584|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
32904585|NCT01339013|Active Comparator|AnaConDa|
32904586|NCT03834506|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
32904587|NCT03834506|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
32904588|NCT01339091|Experimental|Dalbavancin|
32904589|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
32904590|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
32904591|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
32904592|NCT03832010|Active Comparator|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
32904593|NCT03832010|Placebo Comparator|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
32904594|NCT03832010|Sham Comparator|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
32904595|NCT05742542|Experimental|High intensity interval training with high time spent near VO2max|"Participants performed high intensity interval training with high time spent near VO2max three times a week for two weeks.~All training sessions consisted of five times 2 minutes of work and 1 minute of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with low time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
32904596|NCT05742542|Experimental|High intensity interval training with low time spent near VO2max|"Participants performed high intensity interval training with low time spent near VO2max three times a week for two weeks.~All training sessions consisted of ten times 1 minutes of work and 30 seconds of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with high time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
32904597|NCT03837314|Experimental|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
32904598|NCT04383236|Experimental|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
32904599|NCT04383236|Active Comparator|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
32904600|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
32904601|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
32904602|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
32904603|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
32904604|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
32904605|NCT05742464|Experimental|Treatment|
32904606|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1~1 tablet, oral dosing"
32904607|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2~1 tablet, oral dosing"
32904608|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
32904609|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
32904610|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
32904611|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
32904612|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
32904613|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
32904614|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
32904615|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
32904616|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
32904617|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
32865372|NCT04389983|Active Comparator|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
32865373|NCT04389983|Active Comparator|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
32865374|NCT04779619||Non-clinical Control|people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services
32865375|NCT04779619||Clinical Group A|people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)
32865376|NCT04779619||Clinical Group B|people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)
32865377|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
32865378|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
32865379|NCT04771039||patients with chronic inflammatory bowel disease who consulted in ophthalmology|
32865380|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
32865381|NCT04770883|Experimental|Internet based cognitive behavioral therapy group|80 patients will be randomized to receive iCBT. Psychological therapy is effective in IBS patients. The treatment takes 10 weeks and is divided into five successive steps. Patients have to report that they have worked through a treatment step to get access to the next. The patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half of the treatment on step 5, in which exposure exercises are introduced. A psychologist/CBT therapist will manage the online therapeutic contact with the patients.
32865382|NCT04770883|Experimental|Low FODMAP group|80 patients will then be randomized to receive Low FODMAP diet. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates including fructose (in excess of glucose), lactose, polyols, fructans and galacto-oligosaccharides. The concept of considering all these molecules collectively as a treatment for IBS is relatively new. Understanding of FODMAPs comprises mechanisms of action such as luminal distension from their osmotic effect and rapid fermentation to hydrogen. These findings have led to increased application of the low FODMAP diet to manage IBS symptoms. Treatment will undergo 10 weeks supervised monotherapy with low FODMAP diet. This will be done with the help of professional dieticians in Örebro region, who will meet the patients and inform them how this diet works as well as follow up.
32865383|NCT04770883|Active Comparator|Control group|The control Group (40 patients) will wait for 10 weeks before being randomised to treatment with either iCBT or low FODMAP diet.
32865384|NCT04390061|Experimental|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
32865385|NCT04390061|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
32865386|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
32865387|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
32865388|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
32865389|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
32865390|NCT04754659|Experimental|Suprarenal|Individuals that are treated with a suprarenal stentgraft for a previously diagnosed AAA.
32865391|NCT04754659|Active Comparator|Infrarenal|Individuals that are treated with an infrarenal stentgraft for a previously diagnosed AAA.
32865392|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
32865393|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
32865394|NCT04770649||COVID-19 vaccine recipients|Subjects who have an appointment to receive a COVID-19 vaccine, and are able to provide samples prior to and after their first vaccine dose.
32865395|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
32865396|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
32865397|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
32998972|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
32998973|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
32998974|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
32998975|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
32998976|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
32998977|NCT01610934|Experimental|liraglutide|
32998978|NCT01610934|Active Comparator|glimepiride|
32998979|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
32998980|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
32998981|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
32998982|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
32998983|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
32998984|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
32998985|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
32998986|NCT01610986|Experimental|Water|Participants will take only water during training sessions
32998987|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
32998988|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
32998989|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
32998990|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
32998991|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
32998992|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
32998993|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
32998994|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
32998995|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
32998996|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
32998997|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
32998998|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
32998999|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
32999000|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
32999001|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
32999002|NCT01611142|Experimental|KW-0761|
32999003|NCT01611168|No Intervention|Usual Care|
32999004|NCT01611168|Experimental|Intervention Group, treatment algorithms|
32999005|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
32999006|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
32999007|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
32999008|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
32999009|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
32999010|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
32999011|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
32999012|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
32999013|NCT01611246||Anesthetization|Anesthetization
32999014|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
32999015|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
32999016|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
32999017|NCT01611311|Experimental|BI 409306 BS medium dose|Film-coated tablet
32999018|NCT01611311|Experimental|BI 409306 BS high dose|Film-coated tablet
32999019|NCT01611311|Placebo Comparator|Placebo|Film-coated tablet
32999020|NCT01611324|Experimental|Alkalinised anesthetic solution|
32999021|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
32999022|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
32999023|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
32999024|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
32999025|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
32999026|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
32999027|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
32999028|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
32999029|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
32999030|NCT01611389|Experimental|Long AV delay.|
32999031|NCT01611389|Active Comparator|Short AV delay.|
32999032|NCT01611415|Experimental|ipragliflozin|
32999033|NCT01611415|Experimental|furosemide|
32999034|NCT01611415|Experimental|ipragliflozin & furosemide|
32999035|NCT01611428|Experimental|Ipragliflozin - oral|open label
32999036|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
32999037|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
32999038|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
32999039|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
32999040|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
32999041|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
32999042|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
32999043|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
32999044|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
32999045|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
32999046|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
32999047|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
32999048|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
32999049|NCT01611610|Other|Ambulant SMA|
32999050|NCT01611610|Other|Non-ambulant SMA|
32999051|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
32999052|NCT01611649|Experimental|Dairy lipids and plant oils|
32999053|NCT01611649|Experimental|Plant oils|
32999054|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
32999055|NCT01611649|No Intervention|Human milk|
32999056|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
32999057|NCT01611688|Experimental|Active|
32999058|NCT01611688|Placebo Comparator|Placebo|
32999059|NCT01611701|Active Comparator|Cryoballoon group|
32999060|NCT01611701|Active Comparator|RF group|
32999061|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
32999062|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
32999063|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
32999064|NCT01611714|No Intervention|Control|Arm 4: Control
32999065|NCT01611727|Experimental|Cisplatin|
32999066|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
32999067|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
32999068|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
32999069|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
32999070|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
32999071|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
32999072|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
32999073|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
32904618|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
32904619|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
32904620|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
32904621|NCT03802292|Placebo Comparator|Single Dose Placebo|
32904622|NCT05477108|Experimental|Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
32904623|NCT05477108|Experimental|Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
32904624|NCT01258049|Experimental|ArTiMist|
32904625|NCT01258049|Active Comparator|Quinine|
32904626|NCT05741528|Experimental|SEP-363856|
32904627|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
32904628|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
32904629|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
32904630|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
32904631|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
32904632|NCT04384016|Experimental|Evaluating the Safety of Skyvaricella Inj.|"The main target:~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
32904633|NCT04384016|Experimental|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
32904634|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
32904635|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
32904636|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
32904637|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
32904638|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
32904639|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
32904640|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
32904641|NCT05414006|Experimental|Group E1|S-ketamine was administered intravenously after delivery，patient controlled epidural analgesia（PCEA）was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
32904642|NCT05414006|Experimental|Group E2|S-ketamine was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA) was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
32904643|NCT05414006|Placebo Comparator|Group C1|placebo was administered intravenously after delivery，patient controlled epidural analgesia（PCEA) was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
32904644|NCT05414006|Placebo Comparator|Group C2|placebo was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA） was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
32904645|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
32904646|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
32904647|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
32904648|NCT05380388|Experimental|Malaria Vaccine|PvRII/Matrix-M month 0, month 1, month 6
32904649|NCT05380388|Other|control|HBV vaccine month 0, month 1, month 6
32904650|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
32999074|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
32999075|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
32999076|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
32999077|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
32999078|NCT01611818|Other|Improved treatment as usual by GP|
32999079|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
32999080|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
32999081|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
32999082|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
32999083|NCT01611896|Active Comparator|Selenium|
32999084|NCT01611896|Placebo Comparator|Placebo|
32999085|NCT01611909|Experimental|2% PMDO|
32999086|NCT01611909|Experimental|5% PMDO|
32999087|NCT01611909|Active Comparator|Mupirocin|
32999088|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
32999089|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
32999090|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
32999091|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
32999092|NCT01611961|Active Comparator|Taxotere|Commerical Product
32999093|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
32999094|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
32999095|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
32999096|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
32999097|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
32999098|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
32999099|NCT01612026||Ultrasound|
32999100|NCT01612026||Fluoroscopy|
32999101|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
32999102|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
32999103|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
32999104|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
32999105|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
32999106|NCT01612078|Placebo Comparator|placebo, tablet|
32999107|NCT01612091|Experimental|Monitoring Messenger|
32999108|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
32999109|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
32999110|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
32999111|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
32999112|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
32999113|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
32999114|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
32999115|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
32999116|NCT01612143|Experimental|D: STV tablet (fasted state)|
32999117|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
32904651|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
32904652|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
32904653|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
32904654|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
32904655|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
32904656|NCT05734820|Experimental|HD-colonoscopy + AI-HD colonoscopy|This group is comprised by patients >45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy will be performed followed by an HD-colonoscopy with artificial intelligence assistance. The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
32904657|NCT05734820|Experimental|AI-HD colonoscopy + HD-colonoscopy|This group is comprised by patients >45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy assisted by artificial intelligence will be performed followed by an HD-colonoscopy alone.The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
32904658|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
32904659|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
32904660|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
32904661|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
32904662|NCT05721950||Brigatinib 90 mg/180mg|Participants with ALK positive locally advanced or metastatic NSCLC will be observed ambispectively (retrospective plus prospective) after receiving recommended dose of brigatinib, 90 mg orally once daily for first 7 days followed by 180 mg once daily for up to 36 months as their first line of treatment as part of routine medical care up to approximately 16 months. Data will be collected every 3 months after their first dose until the 36 month or participant death, loss to follow-up, or withdrawal from the study for any reason in the real-world setting from September 1, 2022 and December 31, 2026.
32904663|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
32904664|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
32904665|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~Cohort 1: clevidipine 250 µg (0.5 mL)~Cohort 2: clevidipine 500 µg (1 mL)~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
32904666|NCT03009383|Experimental|A bedside portable endoscopy|
32904667|NCT05721482|Experimental|MIM-DASH|A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth.
32904668|NCT05721482|No Intervention|Attention Control|A trained interventionist will deliver the Caregiver Training. Participants in this group will attend eight 1-hour group lessons via telehealth for 8 weeks. We will use Alzheimer's Association caregiver training resources on topics such as Healthy Living for Your Brain and Body: Tips from the Latest Research; Dementia Conversations: Driving, Doctors Visits, Legal and Financial Planning; and Understanding and Responding to Dementia-Related Behavior. Similar to the MIM DASH group, participants will receive educational materials so they can follow along using videoconferencing or phone.
32904669|NCT00791102|Active Comparator|1|Topical ASP-1001
32904670|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
32904671|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
32904672|NCT05317052|Experimental|Massage|Massage therapy
32904673|NCT05317052|Experimental|Music|Music therapy
32904674|NCT05317052|No Intervention|Control|Control
32904675|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
32904676|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
32904677|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
32904678|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
32904679|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
32904680|NCT04383548|Experimental|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
32904681|NCT04383392|Experimental|Rate adaptive pacing|Turn on Rate adaptive pacing
32904682|NCT04383392|Active Comparator|No Rate adaptive pacing|Turn off Rate adaptive pacing
32904683|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
32904684|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
32904685|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
32904686|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
32904687|NCT02192879|Active Comparator|Thoracic Epidural|
32904688|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
32904689|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
32904690|NCT04351763|Experimental|Amiodarone|"Amiodarone - administered intravenously~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.~Oral administration~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
32904691|NCT04351763|Experimental|Verapamil|"Verapamil - administered intravenously~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.~Oral administration~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
32904692|NCT04351763|No Intervention|Usual Care|
32904693|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
32904694|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
32904695|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
32904696|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
32904697|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
32904698|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
32904699|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
32904700|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
32904701|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
32904702|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
32904703|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
32904704|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
32904705|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
32904706|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
32904707|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
32904708|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
32904709|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
32904710|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
32904711|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
32904712|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
32999118|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
32999119|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
32999120|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
32999121|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
32999122|NCT01612195|Experimental|Anal fistula plug|
32999123|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
32999124|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
32999125|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
32999126|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
32999127|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
32999128|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
32999129|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
32999130|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
32999131|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
32999132|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
32999133|NCT01612312|Active Comparator|Thrombectomy|
32999134|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
32999135|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
32999136|NCT01612338|Experimental|Targeted|Targeted letter and booklet
32999137|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
32999138|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
32999139|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
32999140|NCT01612377|Experimental|prednisolone-dipyridamole|
32999141|NCT01612377|Active Comparator|prednisone 5mg|
32999142|NCT01612377|Active Comparator|prednisone 7.5mg|
32999143|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
32999144|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
32999145|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
32999146|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
32999147|NCT01612416|Sham Comparator|Normal subjects|
32999148|NCT01612416|Active Comparator|Primary open angle glaucoma|
32999149|NCT01612416|Active Comparator|Normal tension glaucoma|
32999150|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
32999151|NCT01612442|Experimental|Integrated education|
32999152|NCT01612442|No Intervention|Control|
32999153|NCT01612442|Experimental|Nutrition education|
32999154|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
32999155|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
32999156|NCT01612468|Experimental|Liraglutide|
32999157|NCT01612468|Placebo Comparator|Placebo|
32999158|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
32999159|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
32999160|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
32999161|NCT01612507|Experimental|B|Placebo 1 h infusion
32999162|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
32999163|NCT01612507|Experimental|D|Placebo 2 h infusion
32999164|NCT01612520|Active Comparator|telecoaching|
32999165|NCT01612520|No Intervention|control|
32999166|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
32999167|NCT01612611||a cohort using Shenmai injection|
32999168|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
32999169|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
33414635|NCT04783519|Active Comparator|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
33417380|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
33417381|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
32999170|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
32999171|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
32999172|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
32999173|NCT01612689|Experimental|Physiologic Data Collection|
32999174|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
32999175|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
32999176|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
32999177|NCT01612741||Group 1|
32999178|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
32999179|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
32999180|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
32999181|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
32999182|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
32999183|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
32999184|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
32999185|NCT01612832|Active Comparator|Control|no liryca treatment
32999186|NCT01612845|Experimental|PRF|the group in which the PRF was administered
32999187|NCT01612845|Active Comparator|Control|repair without PRF
32999188|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
32999189|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
32999190|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
32999191|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
33417382|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
33417383|NCT01350713|Experimental|povidone iodine|
32999192|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
32999193|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
32999194|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
32999195|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
32999196|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
32999197|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
32999198|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
32999199|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~Documented preexisting musculoskeletal injury/disease before onset of obesity~Hypothyroidism/Hyperthyroidism~Hyperparathyroidism~Osteopenia/Osteoporosis~Nicotine dependence~Alcohol dependence~Eating disorders (anorexia nervosa, bulimia nervosa)~Cancer requiring chemotherapy or radiation therapy~Status-post gastrectomy~Status-post bilateral oophorectomy~Crohn's Disease~Ulcerative Colitis~Celiac Disease~Cushing's Disease~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
32999200|NCT01613040|Experimental|Treatment A|
32999201|NCT01613040|Experimental|Treatment B|
32999202|NCT01613040|Placebo Comparator|Treatment C|
32999203|NCT01613040|Placebo Comparator|Treatment D|
32999204|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
32999205|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
32999206|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
32999207|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
32999208|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
32999209|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
32999210|NCT01613105||Group 1|
32999211|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
32999212|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
32999213|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
32999214|NCT01613183|Placebo Comparator|placebo group|
32999215|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
32999216|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
32999217|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
32999218|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
32999219|NCT01613261|Experimental|TAK-733 and alisertib|
32999220|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
33417384|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
32999221|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
32999222|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
32999223|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
32999224|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
32999225|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
33414636|NCT04783519|No Intervention|Assessment Only Control|Participants in Assessment Only Control (AOC) condition will complete all assessments (including survey, daily, actigraphy) at the same time as participants in the 2 active interventions. AOC will also attend an in-person meeting to verify identity, provide rationale for daily monitoring, control for time/attention, and participants in all conditions including AOC will receive referrals for community services to address alcohol and MJ use, sleep, and other mental health concerns. No participants will be deprived of services; use of outside services will be tracked to assist with interpretation of outcomes. AOC condition will be offered BASICS + SLEEP after 3-month follow-up.
33414637|NCT05185115|Experimental|Intervention group (A)|Patients treated with 3 liters per minute oxygen delivered via nasal cannula duration hospitalization
32999226|NCT01613365|Experimental|chlorhexidine gluconate|
32999227|NCT01613365|Experimental|placebo|
33414638|NCT05185115|Other|Control group (B)|No oxygen therapy during hospitalization
32999228|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
32999229|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
32999230|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
32999231|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
32999232|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
32999233|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
32999234|NCT01613443||Control|Healthy volunteers without medication
32999235|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
32999236|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
32999237|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
32999238|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
32999239|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
32999240|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
32999241|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
32999242|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
32999243|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
32999244|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
32999245|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
32999246|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
32999247|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
32999248|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
32999249|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
32999250|NCT01613586|Experimental|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
32999251|NCT01613586|Experimental|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
32999252|NCT01613586|Experimental|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
32999253|NCT01613586|Placebo Comparator|Placebo|Matching placebo twice daily for 12 weeks
32999254|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
32999255|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
32999256|NCT01613625|Experimental|Elastography|
32999257|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~born from mothers living in Brittany at delivery~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
32999258|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
32999259|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
32999260|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
32999261|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
32999262|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
32999263|NCT01613677|Experimental|BKM120|
32999264|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
32999265|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
32999266|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
32999267|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
32999268|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
32999269|NCT01613703|Experimental|Experimental|
32999270|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
33414639|NCT04580953|Experimental|Treatment with CardiaCareTM RR2|
32999271|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
33414640|NCT02248064|No Intervention|Fixed flow oxygen|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
32999272|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
32999273|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
32999274|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
32999275|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
32999276|NCT01613794|No Intervention|No intervention|
32999277|NCT01613794|Experimental|Rosuvastatin|
32999278|NCT01613807|Experimental|Mix 50/50|Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
32999279|NCT01613807|Active Comparator|Usual insulin regimen|Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
32999280|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
32999281|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
32999282|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
32999283|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
32999284|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
32999285|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
32999286|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
32999287|NCT01613872|No Intervention|Control|Wait List Control
32999288|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
32999289|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
32999290|NCT01613898||CTX Group|
32999291|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
32999292|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
32999293|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
32999294|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
32999295|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
32999296|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
32999297|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
32999298|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
32999299|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
32999300|NCT01614015|Experimental|Observation Based Supervision|Behavioral
32999301|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
32999302|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
32999303|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
32999304|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
33105391|NCT05651737|Active Comparator|Sui App (unguided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~The second active study group receives the app as a standalone intervention. They use whatever content they are interested in and receive weekly push-notifications in case they were not active."
32999305|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
33325040|NCT05165368|Active Comparator|Intraneural Facilitation (INF)|"INF™ is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle."
33325041|NCT05164666|Experimental|TAK-103 Cohort 1|TAK-103, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
32999306|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
32999307|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
32999308|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
32999309|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
32999310|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~2 mg/m2 vincristin i.v.~55,0 Gy Posterior cranial fossa (M0)~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
32999311|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
32999312|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
32999313|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~willingness to comply with the protocol (4 visits)~45 - 80 years, informed consent~acute N-AION (< 7 d)~D-BCVA > 0.1 (2/20)~RAPD ≥ 0.3 logE steps (neutral density filters)"
32999314|NCT01614184|Experimental|All patients|All patients enrolled in study.
32999315|NCT01614197|Experimental|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
32999316|NCT01614197|Experimental|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
32999317|NCT01614197|Experimental|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
32999318|NCT01614197|Experimental|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
32999319|NCT01614223|Active Comparator|ACP treatment|
32999320|NCT01614223|Active Comparator|Corticosteroid treatment|
32999321|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
32999322|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
32999323|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
32999324|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
33325042|NCT05164666|Experimental|TAK-103 Cohort 2|TAK-103, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
32999325|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
32999326|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
33414641|NCT02248064|Experimental|Auto-titrating arm|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
32999327|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
32999328|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
32999329|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
32999330|NCT01614288|Active Comparator|HTO Alone|
32999331|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
32999332|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
32999333|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
32999334|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
32999335|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
32999336|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
32999337|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
32999338|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
32999339|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
32999340|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
32999341|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
32999342|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
32999343|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
32999344|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
32999345|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
32999346|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
32999347|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
32999348|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
32999349|NCT01614444|Active Comparator|Acupressure Treatment|
32999350|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
32999351|NCT01614522|Experimental|HER-2 Amplified|
32999352|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
32999353|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
32999354|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
32999355|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
33325043|NCT05164666|Experimental|TAK-103 Cohort 3|TAK-103, 5 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
32999356|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~The recurrence required treatment (surgery or pessary)"
32999357|NCT01614587||Controls|"Sacrocolpopexy during the same period~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
32999358|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
32999359|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
32999360|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
32999361|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
33105392|NCT05651737|No Intervention|Waitlist control group|The control arm is a waitlist control group that receives access to the app after eight weeks.
33105393|NCT02897882|Experimental|Lung transplant|Pain evaluation
32999362|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
32999363|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
33325044|NCT05164666|Experimental|TAK-103 Cohort 4|TAK-103, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
32999364|NCT01614691|Experimental|SPARC1203 low dose|
32999365|NCT01614691|Experimental|SPARC1203 mid dose|
32999366|NCT01614691|Experimental|SPARC1203 high dose|
32999367|NCT01614691|Placebo Comparator|Placebo|
32999368|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
32999369|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
32999370|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
32999371|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
32999372|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
32999373|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
32999374|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999375|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999376|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999377|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999378|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999379|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999380|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
32999381|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
32999382|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
32999383|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
32999384|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
32999385|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
32999386|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
32999387|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
32999388|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
32999389|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
32999390|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
32999391|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
32999392|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
33325045|NCT05149768|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous
33325046|NCT05127382||untreated patients with advanced EGFR positive non-small cell lung cancer|
33325047|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
33325048|NCT05078320|Experimental|Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder|Cognitive-behaviour therapy, Exposure and response prevention (ERP)
33325049|NCT05064904|Active Comparator|never received RAAS blockers or multidiscipline consultation before AKI.|The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
33325050|NCT05064904|Active Comparator|had received RAAS blockers and multidiscipline consultation before AKI.|"All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.~Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D)."
32999393|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
32999394|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
32999395|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
32999396|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
32999397|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
32999398|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
33325051|NCT05060848||ADRD|"Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory.~Subgroups based on sex and race categories will also be examined."
33325052|NCT05060848||Control|Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory
32999399|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
33325053|NCT05047354||1|Subjects with Smith-Lemli-Opitz syndrome
33325054|NCT05047354||2|Subjects with Disorders of cholesterol synthesis and metabolism
32999400|NCT01614951|Experimental|Pulmonary perfusion|
32999401|NCT01614951|Experimental|Pulmoplegia|
32999402|NCT01614951|Other|Control group|
32999403|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
32999404|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
32999405|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
32999406|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
32999407|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
32999408|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
32999409|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
32999410|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
33325055|NCT05029414|Experimental|Intervention group: EVT + BMT|Patients randomized to the EVT arm will undergo endovascular therapy (EVT) in addition to best medical treatment (BMT). All decisions regarding EVT device and EVT technique will be made by the treating physician.
33325056|NCT05029414|No Intervention|Control group: BMT|Patients randomized to the control arm will NOT undergo EVT but will get best medical treatment (BMT) including intravenous thrombolysis (IVT) or antiplatelet therapy if indicated under current international guidelines and according to routine clinical practice.
32904713|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
32999411|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
32999412|NCT01615055|Experimental|Fluoxetine tablets|
32999413|NCT01615055|Placebo Comparator|Placebo tablets|
32999414|NCT01615068||Cohort|
32999415|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
32999416|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
32999417|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
32999418|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
32999419|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
32999420|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
32999421|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
32999422|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
32999423|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
32999424|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
32999425|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
32999426|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
32999427|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
32999428|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
32999429|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
32999430|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
32999431|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
32904714|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
32904715|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
32999432|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
32999433|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
32999434|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
32999435|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
32999436|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
32999437|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
32999438|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
32999439|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
32999440|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
32999441|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
32999442|NCT01615302|Active Comparator|Mucosa advancement flap|
32999443|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
32999444|NCT01615354|Placebo Comparator|Placebo|
32999445|NCT01615354|Experimental|Treatment|
32999446|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
32999447|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
32999448|NCT01615393|Active Comparator|Ribavirin capsule arm|
32999449|NCT01615393|Experimental|Ribavirin tablet arm|
32999450|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
32904716|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
32904717|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
32999451|NCT01615419||Cohort|
32999452|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
32999453|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
32999454|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
32999455|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
32999456|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
32999457|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
32999458|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
32999459|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
32999460|NCT01615523||Children/adolescents born preterm|
32999461|NCT01615523||Control children and adolescents|
32999462|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
32999463|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
32999464|NCT01615549|Active Comparator|Free training|
32999465|NCT01615549|Experimental|Proficiency-based training|
32999466|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
32999467|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
32999468|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
32999469|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
32999470|NCT01615588|Experimental|honey|Manuka honey
32999471|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
32999472|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
32999473|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
32999474|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
32999475|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
32999476|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
32999477|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
32999478|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
32999479|NCT01615653|Active Comparator|EUS 1|
32904718|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
32904719|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
32904720|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
32904721|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
32999480|NCT01615653|Active Comparator|EUS 2|
32999481|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
32999482|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
32999483|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
32999484|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
32999485|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
32999486|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
32999487|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
32999488|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
32999489|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
32999490|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
32999491|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
32999492|NCT01615744||Surgical ORIF calcaneal fx|
32999493|NCT01615744||Conservative treatment calcaneal fx|
32999494|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
32999495|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
32999496|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
32999497|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
32999498|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
32999499|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
33105394|NCT03932812|Experimental|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
33325057|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
32999500|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
32999501|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
32999502|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
32999503|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
32999504|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
32999505|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
32999506|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
32999507|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
32999508|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
32999509|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
32999510|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
32999511|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
32999512|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
32999513|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
32999514|NCT01615900|Other|Teleconsultation|
32999515|NCT01615900|Other|Standard consultation|
32999516|NCT01615913|Experimental|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
32999517|NCT01615913|Experimental|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
32999518|NCT01615913|Experimental|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
32999519|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
32999520|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
32999521|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
32999522|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
32999523|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
32999524|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
32999525|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
32999526|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
32999527|NCT01616004|Sham Comparator|Air|
32999528|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
32999529|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
33325058|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
33325059|NCT05016856|Active Comparator|Reminder Only Condition|To promote adherence, participants will receive generic reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone.
32999530|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
32999531|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
32999532|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
32999533|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
32999534|NCT01616095||Healthy Controls|matched for BMI, age, and gender
32999535|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
32999536|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
32999537|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
32999538|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
32999539|NCT01616134|Placebo Comparator|placebo contating constarch|
32999540|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
32999541|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
32999542|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
32999543|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
32999544|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
32999545|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
32999546|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
32999547|NCT01616212|Experimental|TX4|Drug Education for adolescents
32999548|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
32999549|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
32999550|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
32999551|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
32999552|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
32999553|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
32999554|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
32999555|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
32999556|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
32999557|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
32999558|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
32999559|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
32999560|NCT01616277|Placebo Comparator|1|
32999561|NCT01616277|Placebo Comparator|2|
32999562|NCT01616277|Placebo Comparator|3|
32999563|NCT01616277|Placebo Comparator|4|
33414642|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
33414643|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
33414644|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
32999564|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
32999565|NCT01616277|Placebo Comparator|6|
32999566|NCT01616277|Placebo Comparator|7|
32999567|NCT01616316|Experimental|subfascial flap|
32999568|NCT01616316|Experimental|Subplatysmal flap|
32999569|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
32999570|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
33414645|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
33414646|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
32999571|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
33414647|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
32999572|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
32999573|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
32999574|NCT01616394||children with congenital heart disease|
32999575|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
32999576|NCT01616420|No Intervention|Delayed aPS|
32999577|NCT01616420|Experimental|Immediate aPS|
32999578|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
32999579|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
32999580|NCT01616446||remission|Nephrotic patients in remission
32999581|NCT01616446||relapse|Nephrotic patients in recidive
32999582|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
32999583|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
32999584|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
32999585|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
32999586|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
32999587|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
32999588|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
32999589|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
32999590|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
32999591|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
32999592|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
32999593|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
32999594|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
32999595|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
32999596|NCT01616511||Pathway CH-1 Subjects|
33105395|NCT03932812|No Intervention|Control|These individuals will receive the typical standard of care treatment from clinics
33325060|NCT05016856|Experimental|Smart Adherence Support Condition|To promote adherence, participants will receive reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone. In this condition, participants will receive adaptive and tailored reminders based on dynamic algorithms that deploy reminders in a way that considers participant preferences, days and times of previous successful assessments, the success of previous reminder attempts, and answers to brief questions contained within reminder prompts. Parameter weights for these variables will be adjusted dynamically over a 6-month assessment period to ensure that reminders are deployed when they are most likely to be acted upon.
32999597|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
32999598|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
32999599|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
32999600|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
32999601|NCT01616602|Placebo Comparator|Left-sided Position|
32999602|NCT01616602|Experimental|Prone Position|
32999603|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
32999604|NCT01616615|Placebo Comparator|PLACEBO|
32999605|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
32999606|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
32999607|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
32999608|NCT01616641||control group|75 healthy women
32999609|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
32999610|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
32999611|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
32999612|NCT01616719|Other|DTRAX graft|
32999613|NCT01616732|Active Comparator|testosterone|against placebo
32999614|NCT01616732|Placebo Comparator|placebo|
32999615|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
33325061|NCT05015530||Test Medical Device|Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
33325062|NCT00883480|Experimental|2|The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
33325063|NCT00883480|Experimental|1|The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor
33325064|NCT04992598|Experimental|Hypnosis group|
33325065|NCT04992598|Placebo Comparator|Control group|
33325066|NCT05418946||Treatment group|Patient in treatment with Dapagliflozin 10 mg/day
33325067|NCT05418790|Experimental|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
33325068|NCT03097588|Experimental|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
33325069|NCT05418556|Active Comparator|Conventional Arm|After PCI, patients are prescribed aspirin at a daily dose of 100 mg PO plus a P2Y12 inhibitor [clopidogrel or ticagrelor or prasugrel according to the clinical diagnosis] for 12 months after the index PCI.
33325070|NCT05418556|Experimental|Tailored Arm|The antiplatelet regimens post-PCI are 1-month DAPT (aspirin plus clopidogrel) followed by 11-months clopidogrel alone for CCS, and 3-months DAPT (aspirin plus P2Y12 inhibitor [ticagrelor, prasugrel]) followed by 9-months P2Y12 inhibitor alone for ACS.
33325071|NCT04956640|Experimental|LY3537982 (Dose Escalation)|LY3537982 administered orally.
33325072|NCT04956640|Experimental|LY3537982 (Dose Expansion)|LY3537982 administered orally either alone or with another investigational agent.
33325073|NCT05418478|Experimental|Intervention group|"Study group intervention: 7 sessions of transtheoretical model-based interview (2 in the first month, a total of 7 times, once a month), a structured disease education through transtheoretical model-based telehealth practices, and 6-month follow-up.~After the participants are included in the study, a health education structured according to the Transtheoretical model will be given to the patients in the study group through tele-health applications.~The patients in the intervention group will be trained through tele-health practices for at least 25-30 minutes on a transtheoretical basis, every 2 weeks in the first month and once a month in the following months. Tele-health applications include phone monitoring, SMS notification and application applications.~In the 6-month follow-up, there will be 2 follow-ups as pre-test (1st month) and post-test (6th month).~Behavioral: 7 sessions of behavior change training based on the transtoerytic model"
33325074|NCT05418478|No Intervention|Control|"No notification will be made to the relatives of the patients in the control group. Control group patients will be called for routine control in line with their usual plans. After a total of 6 months from the beginning, the self-care and treatment compliance levels of the patients in the control group will be examined.~There will be 2 follow-ups as pre-test (1st month) and post-test (6th month)."
33414648|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
33414649|NCT03566888||Single Group|85 eligible study participants
32999616|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
32999617|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
33414650|NCT05250817||Cohort 1|Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)
32999618|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
32999619|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
32999620|NCT01616810||observation|Healthy participants
32999621|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
32999622|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
32999623|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
32999624|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
32999625|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
32999626|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
32999627|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
32999628|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
32999629|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
32999630|NCT01616901|Experimental|Spontaneous breathing trial|
32999631|NCT01616914||delirium group|patients with delirium during ICU stay
32999632|NCT01616914||non-delirium group|patients without delirium during ICU stay
32999633|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
32999634|NCT01616927|Experimental|Lanreotide|
32999635|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
32999636|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
32999637|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
32999638|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
32999639|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
32999640|NCT01616992||Interstitial Cystitis|
32999641|NCT01616992||Myofascial Pelvic Pain|
32999642|NCT01616992||Healthy|
32999643|NCT01616992||First Degree Relative|
32999644|NCT01617018||Exposed group|Biotherapy
32999645|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
32999646|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
32999647|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~+ vitamin C-250 mg chewable tab~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
32999648|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~+ vitamin C-250 mg chewable tab~+ placebo (identical capsule)"
32999649|NCT01617057|Experimental|Skelid|tiludronic acid
32999650|NCT01617057|Placebo Comparator|Control|Placebo
32999651|NCT01617109|Placebo Comparator|Placebo|
32999652|NCT01617109|Experimental|Ca/Vit D|
32999653|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
32999654|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
32999655|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
32999656|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
32999657|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
32999658|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
32999659|NCT01617200|Experimental|Asenapine 2.5 mg BID|
32999660|NCT01617200|Experimental|Asenapine 5 mg BID|
32999661|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
32999662|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
32999663|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
33414651|NCT05250817||Cohort 2|Participants from the general population
33414652|NCT01344265||consecutive patients|there is only one group in our study
33414653|NCT03159611|Experimental|Tenoten for children|
33414654|NCT03159611|Placebo Comparator|Placebo|
32999664|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
32999665|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
32999666|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
32999667|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
32999668|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
32999669|NCT01617252|Experimental|Optiflow|
32999670|NCT01617252|Experimental|Facial mask|
32999671|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
32999672|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
32999673|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
32999674|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
32999675|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
32999676|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
32999677|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
32999678|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
32999679|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
32999680|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
32999681|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
32999682|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
32999683|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
32999684|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
32999685|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
32999686|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
32999687|NCT01617343|Experimental|HEP-OKS|
32999688|NCT01617356|Active Comparator|Dextrose Injection|
32999689|NCT01617356|Active Comparator|Sterile Water Injection|
32999690|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
32999691|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
32999692|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
32999693|NCT01617486|Experimental|BALANCE|
32999694|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
32999695|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
32999696|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
32999697|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
32999698|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
32999699|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
32999700|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
32999701|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
32999702|NCT01617564|Active Comparator|Bupivacain|
32999703|NCT01617564|Sham Comparator|Sodium Chloride|
32999704|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
32999705|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
32999706|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
32999707|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
32999708|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
32999709|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
32999710|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
32999711|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
32999712|NCT01617707|Active Comparator|conventional sedation group|midazolam
32999713|NCT01617707|Experimental|BPS group|midazolam plus propofol
32999714|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
32999715|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
32999716|NCT01617746|Experimental|Bosentan|62.5mg bosentan
32999717|NCT01617746|Placebo Comparator|Placebo|
32999718|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
32999719|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
32999720|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
32999721|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
32999722|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
32999723|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
32999724|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
32999725|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
32999726|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
32999727|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
32999728|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
32999729|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
32999730|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
32999731|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
32999732|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
32999733|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
32999734|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
32999735|NCT01617928|Experimental|veliparib (ABT-888)|
32999736|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
32999737|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
32999738|NCT01617954||Subjects with MammaPrint Result|
32999739|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
32999740|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
32999741|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
32999742|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
32999743|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
32999744|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
32999745|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
32999746|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
32999747|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
32999748|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
32999749|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
32999750|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
32999751|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
32999752|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
32999753|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
32999754|NCT01618084|Experimental|Tritanium cup|
32999755|NCT01618084|Active Comparator|Trident HA cup|
32999756|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
32999757|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
32999758|NCT01618110|Active Comparator|Treatment Group|
32999759|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
32999760|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
32999761|NCT01618136|Experimental|E7449|
32999762|NCT01618136|Active Comparator|E7449 plus TMZ|
32999763|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
32999764|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
32999765|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
32999766|NCT01618188|Experimental|Formulation A|
32999767|NCT01618188|Experimental|Formulation B|
32999768|NCT01618188|Active Comparator|Insulin Aspart|
32999769|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
32999770|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
32999771|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
32999772|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
32999773|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
32999774|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
32999775|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
32999776|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
32999777|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
32999778|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
32999779|NCT01618370|Experimental|Radium-223 dichloride|
32999780|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
32999781|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
32999782|NCT01618409|No Intervention|Control|Usual care
32999783|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
32999784|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
32999785|NCT01618448|Experimental|Placebo|Placebo once daily
32999786|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
32999787|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
32999788|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
32999789|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
32999790|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
32999791|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
32999792|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
32999793|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
32999794|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
32999795|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
32999796|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
32999797|NCT01618513|Experimental|SA monitored by GH|
32999798|NCT01618513|Experimental|SA monitored by IGF-I|
32999799|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
32999800|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
32999801|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
32999802|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
32999803|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
32999804|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
33105396|NCT04322266|Experimental|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
32999805|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
32999806|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
32999807|NCT01618591|Experimental|Acute Watery Diarrhea|
32999808|NCT01618591|Experimental|Acute Dysentery/Febrile|
32999809|NCT01618604||Healthy|26 healthy voluntary probands
32999810|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
32999811|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
32999812|NCT01618617|Placebo Comparator|Placebo|Placebo
32999813|NCT01618630|Experimental|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
32999814|NCT01618630|Placebo Comparator|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
32999815|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
32999816|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
32999817|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
32999818|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
32999819|NCT01618747||Cohort|
32999820|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
32999821|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
32999822|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
32999823|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
32999824|NCT01618812||Pes plano valgus|Children with painful flatfeet
32999825|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
32999826|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
33105397|NCT04322266|Experimental|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
32999827|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
32999828|NCT01618877|Placebo Comparator|Placebo infusion|
32999829|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
32999830|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
32999831|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
32999832|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
32999833|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
32999834|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
32999835|NCT01618981|Experimental|first active|
32999836|NCT01618981|Experimental|first inactive|
32999837|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
32999838|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
32999839|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
32999840|NCT01619007||Group 1|
32999841|NCT01619007||Group 2|
32999842|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
32999843|NCT01619020|Placebo Comparator|Placebo|Capsules
32999844|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
32999845|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
32999846|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
33105398|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
33105399|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
33105400|NCT03932032|Experimental|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
33105401|NCT03932032|Sham Comparator|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
32904722|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
32904723|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
32904724|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
32904725|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
32904726|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
32904727|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
32904728|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
32904729|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
32904730|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
32904731|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
32904732|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
32904733|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
32904734|NCT01316315|Experimental|Active|N6022 - 5 mg
32904735|NCT01316315|Placebo Comparator|Placebo|Placebo
32904736|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
32904737|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
32904738|NCT01262105|No Intervention|No device|
32904739|NCT01262105|Experimental|Device deployed|
32904740|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
32904741|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
32904742|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
32904743|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
32904744|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
32904745|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
32904746|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
32904747|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
32904748|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
32904749|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
32904750|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
32904751|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
32904752|NCT01318577|Experimental|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
32904753|NCT01318577|Active Comparator|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
32904754|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
32904755|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
32904756|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
32904757|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
32904758|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
32904759|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
32904760|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
32904761|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
32904762|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
32904763|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
32904764|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
32904765|NCT01268111|Placebo Comparator|Placebo|
32904766|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
32904767|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32904768|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
32904769|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
32904770|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
32904771|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
32904772|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
32904773|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
32904774|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
32904775|NCT01321151|Experimental|Resveratrol|Intervention
32904776|NCT01350947|Experimental|All patients|All participants enrolled.
32904777|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
32904778|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
32904779|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
32904780|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
32904781|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
32904782|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
32904783|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
32904784|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
32904785|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
32904786|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
32904787|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
32904788|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
32904789|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
32904790|NCT04383860|Experimental|5-0 suture|5-0 suture administration during surgery
32904791|NCT04383860|Active Comparator|4-0 suture|4-0 suture administration during surgery
32904792|NCT05708924|Experimental|IP FT538 monotherapy|Level -1: IP FT538 monotherapy 5 x 10^7 cells/dose Level 1: IP FT538 monotherapy 1 x 10^8 cells/dose Level 2: IP FT538 monotherapy 3 x 10^8 cells/dose Level 3: IP FT538 monotherapy 1 x 10^9 cells/dose Level 4: IP FT538 monotherapy 1.5 x 10^9 cells/dose
32904793|NCT05708924|Experimental|IP FT538 + Enoblituzumab|Level 5: IP FT538 at the safe dose (MTD-1) + Enoblituzumab Level 6: IP FT538 at the highest dose (MTD) + Enoblituzumab
32999847|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
32999848|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
32999849|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
32999850|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
32999851|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
32999852|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
32999853|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
32999854|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
32999855|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
32999856|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
32999857|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
32999858|NCT01619163|Experimental|prednisolone|
32999859|NCT01619163|Placebo Comparator|Placebo|
32999860|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
32999861|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
32999862|NCT01619189|Experimental|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
32999863|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
32999864|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
32999865|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
32999866|NCT01619228||Premature Infants|Infants born at < 37 weeks gestational age
32999867|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
32999868|NCT01619228||Adults|Adults are parents of infants enrolled in the study
32999869|NCT01619241||advanced non-small cell lung cancer|
32999870|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
32999871|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
32999872|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
32999873|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
32999874|NCT01619267||device associated infection|patients with proven device associated infection
32999875|NCT01619267||control group|patients without device associated infection
32999876|NCT01619280|Experimental|Nebulized sodium nitroprusside|
32999877|NCT01619293||Epidural H.|patients with hematoma epidurale
32999878|NCT01619293||Subdural H.|patients with hematoma subdurale
32999879|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
32999880|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
32999881|NCT01619293||E. cerebri|patients with edema cerebri
32999882|NCT01619293||Concussion|patients with concussion
32999883|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
32999884|NCT01619319|Active Comparator|computer games|computer games
32999885|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
32999886|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
32999887|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
32999888|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
32999889|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
32999890|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
32999891|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
32999892|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
32999893|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
32999894|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
32999895|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
32999896|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
32999897|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
32999898|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
32999899|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
32999900|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
32999901|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
32999902|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
32999903|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
32999904|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
32999905|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
32999906|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
32999907|NCT01619540|Other|acute heart failure|control arm
32999908|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
32999909|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
32999910|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
32999911|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
32999912|NCT01619592|No Intervention|control group|standard care
32999913|NCT01619605|Experimental|Shrim|
32999914|NCT01619631|Experimental|12-week Tai Chi intervention|
32999915|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
32999916|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
32999917|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
32999918|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
32999919|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
32999920|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
32999921|NCT01619670|No Intervention|no intervention|standard wound care
32999922|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
32999923|NCT01619683|Experimental|Androxal|
32999924|NCT01619683|Placebo Comparator|Placebo|
32999925|NCT01619696|Experimental|Intervention|
32999926|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
32999927|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
32999928|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
32999929|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
32999930|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
32999931|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
32999932|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
32999933|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
32999934|NCT01619761|Experimental|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
32999935|NCT01619761|Experimental|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
32999936|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
32999937|NCT01619813|Active Comparator|Docetaxel and Prednisone|
32999938|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
32999939|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
32999940|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
32999941|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
32999942|NCT01619904|Experimental|Goal-Directed Therapy|
32999943|NCT01619904|Active Comparator|Standard Therapy|
32999944|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
32999945|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
32999946|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
32999947|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
32999948|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
32999949|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
32999950|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
32999951|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
32999952|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
32999953|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
32999954|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
32999955|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
32999956|NCT01619969|Experimental|Celgosivir|
32999957|NCT01619969|Placebo Comparator|Placebo|
32999958|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
32999959|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
32999960|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
32999961|NCT01620034|Active Comparator|11 Day Arm|
32999962|NCT01620034|Experimental|4 Day Arm|
32999963|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
32999964|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
32999965|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
33417385|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
32904794|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
32904795|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
32904796|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
32904797|NCT05287724|Experimental|N-acetyl Cysteine then Placebo|Subjects will be treated with N-acetyl cysteine twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take the placebo.
32904798|NCT05287724|Experimental|Placebo then N-acetyl Cysteine|Subjects will be treated with placebo twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take N-acetyl cysteine.
32904799|NCT01321541|Experimental|Pixantrone + Rituximab|Pixantrone and Rituximab
32904800|NCT01321541|Active Comparator|Gemcitabine + Rituximab|Gemcitabine and Rituximab
32904801|NCT05286242||Healthy control|Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
32904802|NCT05286242||Disease control|"Disease controls (individuals with a qualifying autoimmune condition, but not treated with any immunomodulator).~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
32904803|NCT05286242||B-cell depleted|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
32904804|NCT05286242||Other immunomodulator|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
32904805|NCT05282186|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
32904806|NCT05282186|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health.
32904807|NCT05689190||patients|Duplex ultrasound, angiogram, PTA intervention
32904808|NCT05281094|Placebo Comparator|Placebo|One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57.
32904809|NCT05281094|Experimental|Experimental|One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57.
32904810|NCT01270529|Experimental|CKD Stages 1-4|
32904811|NCT01270529|Experimental|ESRD on Dialysis|
32904812|NCT01270529|Experimental|Kidney Transplant recipients|
32904813|NCT05254262||Elderly patients|Patients age 70 or older, who are admitted in hospital for surgical operation (elective or emergency surgery)
32904814|NCT04351607|Experimental|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
32904815|NCT04351607|No Intervention|Control group|no intervention
32904816|NCT04351607|Other|Patient with menstral bleeding - subcollective A|verum or control
32904817|NCT04351607|Other|Patient without menstral bleeding - subcollective B|verum or control
32904818|NCT03801434|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
32904819|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
32904820|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
32904821|NCT05680298|Experimental|AD patients|Pediatric patients (≥6 and <12 years of age) with moderate-to-severe AD will receive a SC injection of dupilumab depending on the body weight
32904822|NCT05680298|No Intervention|Healthy volunteers|Except for IMPs administration, skin barrier function assessments for healthy volunteers are conducted at the same time and in the same measurement conditions as for AD patients.
32904823|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
32904824|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
32904825|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
32904826|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
32904827|NCT05676008|No Intervention|Waitlist control|
32904828|NCT05676008|Experimental|Treatment|
33417386|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
33417387|NCT02075294||youth|"<45years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
32904829|NCT01271543|Active Comparator|MacIntosh group|
32904830|NCT01271543|Experimental|Shikani optical stylet|
32904832|NCT05655572|Experimental|Action Observation therapy|This group will perform exercises in stages. First stage consists of movements to improve balance in sitting position with exercises upright the pelvis, move weight forward, move weight to the left and right and rotate right and left. Second stage consist of sit to stand movements with exercises upright the pelvis in sitting position, move weight forward from a sitting position and stand up from a sitting position. Third stage consist of standing movements to improve balance with exercises move weight right and left, forward weight shift with right foot and left foot (lateral view) and forward weight shift with right foot and left foot (front view). Fourth stage consist of walking side ways to left and then towards right. Therapist will perform these tasks and video will be made which will play in front of patients.
32904833|NCT05655572|Active Comparator|Functional Training Group|participants including in this group will perform the tasks including lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor, and stair walking
32904834|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
32904835|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
32904836|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
32904837|NCT05652608||Particpants|participating in Immune Strength, a multi-week wellness program
32904838|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
32904839|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
32904840|NCT05201612|Experimental|Pembrolizumab plus olaparib|"Treatment cycles will be 21 days in length. All participants will receive treatment as follows:~Olaparib 300 mg, orally (po), twice a day (BID) continuously. Pembrolizumab 200 mg, intravenously (IV), every 21 days. Treatment will be continued in the absence of disease progression, unacceptable toxicity, withdrawal of consent or death. Pembrolizumab will be administered up to a maximum of 2 years (35 cycles)."
32904841|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
32904842|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
32904843|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
32904844|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 0°
32904845|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 45°
32904846|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 90°
32904847|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 135°
32904848|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
32904849|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
32904850|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
32904851|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
32904852|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
32904853|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
32904854|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
32999966|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
32999967|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
32999968|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
32999969|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
33414655|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
32999970|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
32999971|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
32999972|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
32999973|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
32999974|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
32999975|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
32999976|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
32999977|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
32999978|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
32999979|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
32999980|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
32999981|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
32999982|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
32999983|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
32999984|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
32999985|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
32999986|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
32999987|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
32999988|NCT01620333|Experimental|Treatment period 1|
32999989|NCT01620333|Experimental|Treatment period 2|
32999990|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
33105402|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
33105403|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
33105404|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
33414656|NCT04323943|Experimental|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
33414657|NCT04323943|Active Comparator|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
32999991|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
32999992|NCT01620359|Experimental|ExAblate|
32999993|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
32999994|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
32999995|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
32999996|NCT01620385|Experimental|ciPDA|
32999997|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
32999998|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
32999999|NCT01620411|Experimental|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
33000000|NCT01620411|Experimental|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
33000001|NCT01620424|Experimental|Dosing visit 1|
33000002|NCT01620424|Experimental|Dosing visit 2|
33000003|NCT01620437|Experimental|Formulation A|
33000004|NCT01620437|Experimental|Formulation B|
33000005|NCT01620450|Experimental|NN2000|
33000006|NCT01620450|Active Comparator|NN-X14|
33000007|NCT01620463|Experimental|NNC 90-1170|
33000008|NCT01620463|Placebo Comparator|Placebo|
33000009|NCT01620476|Experimental|5 mcg/kg|
33000010|NCT01620476|Experimental|10 mcg/kg|
33000011|NCT01620476|Experimental|15 mcg/kg|
33000012|NCT01620502|Active Comparator|EPA 3.5 g/day|
33000013|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
33000014|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
33000015|NCT01620554|Experimental|BF2.649 5mg|
33414658|NCT04323943|No Intervention|Without orthosis (NO)|No orthosis - patient will wear only their shoes
33000016|NCT01620554|Experimental|BF2.649 10mg|
33000017|NCT01620554|Experimental|BF2.649 20mg|
33000018|NCT01620554|Experimental|BF2.649 40mg|
33000019|NCT01620554|Placebo Comparator|Placebo|
33000020|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
33000021|NCT01620580|Active Comparator|Dietary Information|Control arm
33000022|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
33000023|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
33000024|NCT01620606|Active Comparator|ES|Education and Support
33000025|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
33000026|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
33000027|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
33000028|NCT01620645||COPD, GOLD II severity or above|
33000029|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
33000030|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
33000031|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
33000032|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
33000033|NCT01620697||Perirenal fat|
33000034|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
33000035|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
33000036|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~breastfeeding is a parental task~skin to skin contact during the first three days~frequent breastfeeding at least 8 times a day~good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
33000037|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
33000038|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
33000039|NCT01620749|Experimental|MEL050|
33105405|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
33105406|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
33414659|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
33414660|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
33414661|NCT03635359||positive for fetal aneuploidy|
33000040|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
33000041|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
33000042|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
33000043|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
33000044|NCT01620801|Experimental|Low dose|AAV8-hFIX19
33000045|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
33000046|NCT01620801|Experimental|High dose|AAV8-hFIX19
33000047|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
33000048|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
33000049|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
33000050|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
33000051|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
33000052|NCT01620840||Lacosamid-i.v. treatment|
33000053|NCT01620866|Experimental|EMDR|
33000054|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
33000055|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
33000056|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
33000057|NCT01620931|Experimental|RO5469754|
33000058|NCT01620931|Placebo Comparator|Placebo|
33000059|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
33000060|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
33000061|NCT01620957||Coma patients|
33000062|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
33000063|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
33000064|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
33000065|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
33414662|NCT03635359||negative for fetal aneuploidy|
33414663|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
33000066|NCT01621035||elderly (> 70 y)|
33000067|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
33000068|NCT01621061||High altitude control|Healthy highlanders
33000069|NCT01621061||Low altitude control|Healthy lowlanders
33000070|NCT01621074|Active Comparator|Sodium bicarbonate|
33000071|NCT01621074|Placebo Comparator|Placebo|
33000072|NCT01621087|Experimental|Safflower oil|
33000073|NCT01621087|No Intervention|Control group (no diet instruction)|
33000074|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
33000075|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
33000076|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
33000077|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
33000078|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
33000079|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
33000080|NCT01621165|Placebo Comparator|Placebo|
33105407|NCT04322110|Experimental|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
33105408|NCT04322110|Active Comparator|Control group|Subjects undergoing treatment with low calorie diet
33000081|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
33000082|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
33000083|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
33000084|NCT01621256|Experimental|Ancrod|Ancrod
33000085|NCT01621256|Placebo Comparator|Saline solution|Saline solution
33000086|NCT01621269|Experimental|Fingolimod|
33000087|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
33000088|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
33000089|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
33000090|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
33000091|NCT01621321|Experimental|Steroid group|
33000092|NCT01621321|Experimental|Voriconazole group|
33000093|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
33000094|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
33000095|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
33000096|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
33000097|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
33000098|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
33000099|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
33000100|NCT01621399|Experimental|Product 55394|Treatment with product 55394
33000101|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
33000102|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
33000103|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
33000104|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
33000105|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
33000106|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
33000107|NCT01621516||Healthy controls|10 healthy volunteers
33000108|NCT01621516||Solitary small bowel transplant patients|3
33000109|NCT01621516||Liver/small bowel transplant patients|3
33000110|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
33000111|NCT01621620|Experimental|yohimbin|
33000112|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
33000113|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
33000114|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
33000115|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
33000116|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
33000117|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
33000118|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
33000119|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
33000120|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
33000121|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
33000122|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
33000123|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
33000124|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
33000125|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
33000126|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
33000127|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
33000128|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
33000129|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
33000130|NCT01621841||Glaucoma subjects|
33000131|NCT01621841||heathly subjects|
33000132|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
33000133|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
33417388|NCT02075294||middle age|"≥45years and<65years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
33000134|NCT01621867|Placebo Comparator|Placebo|
33000135|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
32865398|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
32904855|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
32904856|NCT05636852|Experimental|Altropane (123I) Injection|
32904857|NCT04865978|Experimental|Apixaban|LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
32904858|NCT04865978|Active Comparator|Warfarin|LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5
32904859|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
32904860|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
32904861|NCT05168462|Experimental|Reduced noradrenaline (MAP ≥ 55 mmHg)|
32904862|NCT05168462|No Intervention|Usual care (MAP ≥ 65 mmHg)|
32904863|NCT04383782|Active Comparator|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
32904864|NCT04383782|Experimental|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
32904865|NCT04383782|Placebo Comparator|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
32904866|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
32904867|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
32904868|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
32904869|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
32904870|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
32904871|NCT01354691|Experimental|ladostigil hemitartrate|Ladostigil capsules 80 mg
32904872|NCT01354691|Placebo Comparator|Placebo|Placebo capsules
32904873|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
32904874|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
32904875|NCT04024670|Active Comparator|Patients on a high-risk obstetrics unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly sewing and embroidery interactions with a professional artist in residence.
32904876|NCT04024670|Active Comparator|Patients on a bone marrow transplant unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly visits with a professional storyteller.
32904877|NCT04024670|No Intervention|HRO Standard of Care|SOC
32904878|NCT04024670|No Intervention|BMT Standard of Care|SOC
32904879|NCT01355471|Experimental|CD07805/47 gel|
32904880|NCT01355471|Placebo Comparator|Placebo|
32904881|NCT04853108||Remote Monitoring of COVID-19|Patients with COVID-19 who completed acute clinical monitoring of at least 30 days from symptom onset or positive COVID-19 test.
32904882|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
32904883|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
32904884|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~Aspirin: 81 or 325 mg daily oral~Pegfilgrastim subcutaneous on Day 2"
33000136|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
33000137|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
33000138|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
33000139|NCT01621958|Experimental|Motor training|
33000140|NCT01621958|Placebo Comparator|Intensity control|
33000141|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
33000142|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
33000143|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
33000144|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
33000145|NCT01621997|Experimental|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
33000146|NCT01621997|Experimental|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
33000147|NCT01621997|Experimental|usual care|Patients in the usual care group did not receive any retraining
33000148|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
33000149|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
33000150|NCT01622036||Cancer patients undergoing first medical oncology visit.|
33000151|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
33000152|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
33000153|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
33000154|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
33000155|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
33000156|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
33000157|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
33000158|NCT01622127||incisional hernias|
33000159|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
33000160|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
33000161|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
33000162|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
33000163|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
33000164|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
33000165|NCT01622192|Experimental|Automated probe|
33000166|NCT01622205|Experimental|Active|Early supported discharge
33000167|NCT01622205|Other|Control|Ordinary rehabilitation
33105409|NCT05516524|Experimental|HSAT prior to clinical sleep study|Participants will be randomized to undergo HSAT before receiving their clinical, in-lab polysomnography
33000168|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
33000169|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
33000170|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
33000171|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
33417389|NCT02075294||elderly|"≥65 years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
33000172|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
33000173|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
33000174|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
33000175|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
33000176|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
33000177|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
33000178|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
33000179|NCT01622374|Experimental|Music for the mind|
33000180|NCT01622374|Experimental|Mozart music|
33000181|NCT01622374|Experimental|Iranian traditional music|
33000182|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
33000183|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
33000184|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
33000185|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
33000186|NCT01622413|Experimental|Endscopy|
33000187|NCT01622413|Active Comparator|Microsurgery|
33000188|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
33000189|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
33000190|NCT01622439|Experimental|Single, open labeld.|
33105410|NCT05516524|Active Comparator|PSG first Participants will be random|Participants will be randomized to undergo HSAT after receiving their clinical, in-lab polysomnography.
33000191|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
33000192|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
33000193|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~Clinically negative-node after NAC~Clinically positive-node after NAC"
33000194|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
33000195|NCT01622504|Experimental|Test Product Dose 1|
33000196|NCT01622504|Experimental|Test Product Dose 2|
33000197|NCT01622504|Active Comparator|Comparator Product|
33000198|NCT01622530||Amputees|upper limb amputees
33000199|NCT01622530||Non-amputees|No longer recruiting non-amputees
33000200|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
33000201|NCT01622608|Experimental|Kiosk Users|
33000202|NCT01622608|No Intervention|Non-Kiosk Users|
33000203|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
33000204|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
33000205|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
33000206|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
33000207|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
33000208|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
33000209|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
33000210|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
33000211|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
33000212|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
33000213|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
33000214|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
33105411|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
33105412|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
33105413|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
33417390|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
33417391|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
33417392|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
33000215|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
33000216|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
33325075|NCT04939792|Placebo Comparator|Placebo|"Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo.~During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle"
33000217|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
33000218|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
33000219|NCT01622777|Placebo Comparator|Placebo|
33000220|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
33000221|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
33000222|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
33000223|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
33000224|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
33000225|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
33000226|NCT01622829|No Intervention|group 3|control, usual physiotherapy
33000227|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
33000228|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
33000229|NCT01622855|No Intervention|Standard care|Receipt of standard services
33000230|NCT01622881|Active Comparator|Nefopam|
33000231|NCT01622881|Placebo Comparator|Control|
33000232|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
33000233|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
33000234|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
33000235|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
33000236|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
33000237|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
33000238|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
33000239|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
33000240|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
33000241|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
33000242|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
33000243|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
33000244|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
33000245|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
33000246|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
33000247|NCT01623024|Active Comparator|Lifestyle counseling|
33000248|NCT01623063|Experimental|Infertile|patients from our human reproduction center
33000249|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
33000250|NCT01623089||severe asthma|
33000251|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
33000252|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33000253|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
33000254|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
33000255|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
33000256|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
33000257|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
33000258|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
33000259|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
33000260|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
33000261|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
33000262|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
33000263|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
33000264|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
33000265|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
33000266|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
33000267|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
33000268|NCT01623258||Research|SOC with sentinel lymph node analysis
33000269|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
33000270|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
33000271|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
33000272|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
33000273|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
33000274|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
33000275|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
33000276|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
33000277|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
33000278|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
33000279|NCT01623375|Experimental|s.c.|
33000280|NCT01623375|Experimental|i.v.|
33000281|NCT01623388||Phase I|
33000282|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
33000283|NCT01623414||Healthy schoolchildren|
33000284|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
33000285|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
33000286|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
33000287|NCT01623453||Low dose group|Group1. Low dose group
33000288|NCT01623453||High dose group|Group2. High dose group
33000289|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
33000290|NCT01623505|Experimental|Champix|
33000291|NCT01623505|Experimental|Long & Combination patch treatment|
33000292|NCT01623505|Experimental|Standard patch treatment|
33000293|NCT01623518|Experimental|ChAdOx1-NP+M1|
33000294|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
33414664|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
33000295|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
33000296|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
33000297|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
33000298|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
33000299|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
33000300|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
33000301|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
33000302|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
33000303|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
33000304|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
33000305|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
33000306|NCT01623622|Experimental|HC-58 low dose|Low dose
33000307|NCT01623622|Experimental|HC-58 high dose|High dose
33000308|NCT01623622|Placebo Comparator|Placebo|
33000309|NCT01623635|Experimental|Case - adnexal|
33000310|NCT01623635|Placebo Comparator|placebo - adnexal|
33000311|NCT01623635|Experimental|case - uterine|
33000312|NCT01623635|Placebo Comparator|placebo - uterine|
33000313|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
33000314|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
33000315|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
33000316|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
33000317|NCT01623687|Active Comparator|Regenerex|
33000318|NCT01623687|Active Comparator|Lub cup|
33000319|NCT01623687|Active Comparator|SP II|
33000320|NCT01623687|Active Comparator|Corail|
33000321|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
33000322|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
33000323|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
33000324|NCT01623713|Active Comparator|Risperidone|
33000325|NCT01623713|Experimental|iloperidone|
33000326|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
33000327|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
33000328|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
33000329|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
33000330|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
33000331|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
33000332|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
33000333|NCT01623804|Sham Comparator|Sham ultrasound|
33000334|NCT01623817|No Intervention|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
33000335|NCT01623817|Experimental|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
33000336|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
33105414|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
33325076|NCT04939792|Experimental|L-Cysteine|LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
33325077|NCT04939792|Experimental|Vitamin D3|VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
33325078|NCT04939792|Experimental|Vitamin D3 and L-Cysteine|VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
33325079|NCT04900792|Experimental|Cohort 1 (starting)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatments 6, 25, and 31 (± 1 radiation treatment)~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
33000337|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
33000338|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
33000339|NCT01623908|Experimental|Zoledronate|
33000340|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
33000341|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
33000342|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
33000343|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
33000344|NCT01623934||Phase 1: Pregnant women|
33000345|NCT01623934||Phase 2: Mother-offspring dyad|
33000346|NCT01623947|Placebo Comparator|Placebo|
33000347|NCT01623947|Active Comparator|2.8 g Sustamine|
33000348|NCT01623947|Active Comparator|19.6 g Sustamine|
33000349|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
33000350|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
33000351|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
33000352|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
33000353|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
33000354|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
33000355|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
33000356|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
33000357|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
33000358|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
33000359|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
33000360|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
33000361|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
33000362|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
33000363|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
33000364|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
33000365|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
33000366|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
33000367|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
32865399|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
32865400|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
32865401|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
32865402|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
32865403|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
32865404|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
32865405|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
32865406|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
32865407|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
32865408|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
32865409|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
32865410|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
32865411|NCT00684619|Experimental|Arm A|Nelarabine
32865412|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
32865413|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
32865414|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
32865415|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
32865416|NCT04770961|Sham Comparator|Cryoablation|1. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.
32865417|NCT04770961|Experimental|ESP + Cryoablation|2. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.
32865418|NCT04758221|Experimental|Single arm : Composite coronal build up strip crown|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
32865419|NCT04753489|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
32865420|NCT04753489|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
32865421|NCT04753567|Experimental|Actual pain patch|
32865422|NCT04753567|Placebo Comparator|Sham patch|
32865423|NCT02791997|Experimental|Brain-damaged patients|
33000368|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
33000369|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
33000370|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
33000371|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
33000372|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
33000373|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
33000374|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
33000375|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
33000376|NCT01624272|No Intervention|Control|Usual care
33000377|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
33000378|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
33000379|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
33000380|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
33000381|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
33000382|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
33000383|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
33000384|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
33000385|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
33000386|NCT01624376|Placebo Comparator|Placebo Injection|
33000387|NCT01624389|Experimental|F18-AV45|
33000388|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
33000389|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
33000390|NCT01624428|Active Comparator|varenicline|
33000391|NCT01624428|Placebo Comparator|Placebo|
33000392|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33000393|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
33000394|NCT01624454|Active Comparator|Osmotic|
33000395|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
33000396|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
33000397|NCT01624519|Other|1|
33000398|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
33000399|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
33000400|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
33000401|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
33000402|NCT01624571|Experimental|Group 1|300mg/day
33000403|NCT01624571|Experimental|Group 2|600mg/day
33000404|NCT01624571|Experimental|Group 3|900mg/day
33000405|NCT01624571|Placebo Comparator|Placebo|Control Group
33000406|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
33000407|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
33000408|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
33000409|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
33000410|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
33000411|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
33000412|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
33000413|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
33105415|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
33105416|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
33000414|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
33000415|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
33000416|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
33000417|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
33000418|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
33000419|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
33000420|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
33000421|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
33000422|NCT01624766|Experimental|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
33000423|NCT01624766|Experimental|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
33000424|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
33000425|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
33000426|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
33000427|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
33000428|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
33000429|NCT01624844|Experimental|Calculation of dural sac volume|
33000430|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
33000431|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
33000432|NCT01624935|Experimental|psychotherapy|psychotherapy
33000433|NCT01624935|Other|treatment as usual|TAU control
33000434|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
33000435|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
33000436|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
33000437|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
33000438|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
33000439|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
33000440|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
33000441|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
33000442|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
33000443|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
33000444|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
33000445|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
33000446|NCT01625052|Experimental|Baska|
33000447|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
33000448|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
33000449|NCT01625078|Experimental|Baska mask|
33000450|NCT01625117|No Intervention|Control Group|
33000451|NCT01625117|Experimental|A variant of Narrative exposure therapy|
33000452|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
33000453|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
33000454|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
32865424|NCT02791997|Experimental|Control participants|
32865425|NCT02791997|Experimental|Migraine patients|
32865426|NCT04753333|Experimental|Experimental|The participants in the experimental group will receive Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for four weeks.
32865427|NCT04753333|Placebo Comparator|Control|The participants in the experimental group will receive Sham EMG-BF guided isometric quadriceps strengthening without patellar taping five days a week for four weeks.
32865428|NCT04754347|No Intervention|Control|Routine Colonoscopy
32865429|NCT04754347|Experimental|Experimental|Routine Colonoscopy with the use of Skout
32865430|NCT02791685|Experimental|Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
32865431|NCT02791685|Experimental|Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
32865432|NCT02791685|Active Comparator|Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
32865433|NCT04769557|Experimental|Paracetamol|Paracetamol
32865434|NCT04769557|Placebo Comparator|Placebo|placebo
32865435|NCT04757987||Pain-free|Report persistent pain at enrolment
32865436|NCT04757987||Persistent pain|Report no pain at enrolment
32865437|NCT04758299|No Intervention|Standard care|information from an FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test
32865438|NCT04758299|Experimental|Decision science-based design|Information from a decision science-based design (of similar length to the FDA authorized home test kit information) for what actions to take for a negative or positive COVID-19 test
32865439|NCT04757909|Experimental|Monthly Haemoglobinometry|
32865440|NCT04757909|No Intervention|Routine monitoring|
32865441|NCT05606497||Early-onset FGR|
32865442|NCT05586893|Experimental|Electroacupuncture|The acupuncture electrical stimulation was performed by the EL 608 electroacupuncture device (NKL, Brusque - SC, Brazil, ANVISA 80191680002). For the stimulation of the acupuncture points, we selected a biphasic wave, 2 HZ of frequency, 6 mA of wavelength, and 5 seconds at resting time. The total stimulation time was 20 minutes.
32865443|NCT05586893|Experimental|Acupuncture therapy|"The acupuncture points were bilaterally punctured by a stainless steel acupuncture needle (length 30mm x diameter 0.25) (Dongbang, Boryeong, Chungnam- Korea). We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
32865444|NCT05586893|No Intervention|Control Group|Infrared images were captured at the first assessment (P0), 10 minutes later (P10), 20 minutes later (P20) and 30 minutes after the first assessment (P30). All analyzes were performed using QuickReport software, version 1.2 (FLIR Systems). No application of interventions between assessments.
32865445|NCT04778995|Experimental|Manager nurses (Experimental group)|Manager nurses who participated in the structured training program based on qualitative data. Web based training program was the intervention for this group.
32865446|NCT04778995|No Intervention|Manager nurses (Control group)|Manager nurses who were not included to the structured training program based on qualitative data. No intervention was performed for this group.
32865447|NCT05606419|Experimental|Group 1-Remission|Crohn's Disease Exclusion Diet (CDED)+Partial Enteral Nutrition (PEN)+dairy products: Patients with asymptomatic disease will follow the first stage diet (CDED+50%PEN) for 4 weeks and will continue with CDED + 25%PEN + dairy products for another 4 weeks. Total duration: 8 weeks.
32865448|NCT05606419|Active Comparator|Group 2 - Remission|Partial Enteral Nutrition (PEN) + usual nutritional care: Patients with asymptomatic disease will be given PEN plus the usual advice for a healthy dietary pattern. PEN will cover the 50% of total energy requirements for the first 4 weeks. During the second 4 weeks, PEN will cover the 25% of the total energy requirements.Total duration: 8 weeks
32865449|NCT05606419|Experimental|Group 1 - Active Disease|Crohn's Disease Exclusion Diet (CDED)+Partial Enteral Nutrition (PEN)+dairy products: Patients with active disease will follow the first stage diet (CDED + 50%PEN) for 6 week and then, the responders will continue with adding the advised dairy products for 4 more weeks (CDED+25%PEN+dairy products).
32865450|NCT05606419|Active Comparator|Group 2 - Active Disease|Partial Enteral Nutrition (PEN) + usual nutritional care: Patients with symptomatic disease will be given PEN plus the usual advice for a low residue diet. PEN will cover the 50% of total energy requirements for the first 6 weeks. During the next 4 weeks, PEN will cover the 25% of the total energy requirements.Total duration: 10 weeks
32865451|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
32865452|NCT05606341|Experimental|CpG 1018 0.1 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.1mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
32865453|NCT05606341|Experimental|CpG 1018 0.25 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.25 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
32865454|NCT05606341|Experimental|CpG 1018 0.5 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.5 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
33000455|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
33000456|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
33000457|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
33000458|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
33000459|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
33000460|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
33000461|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
33000462|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
33000463|NCT01625273|No Intervention|IF (Infant formula)|
33000464|NCT01625273|Experimental|IF with L. paracasei strain F19|
33000465|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
33000466|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
33000467|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
33000468|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
33000469|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
33000470|NCT01625325||extremely obese|BMI ≥35kg/m2
33000471|NCT01625325||obese|BMI 30-34.9kg/m2
33000472|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
33000473|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
33000474|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
33000475|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
33000476|NCT01625403|Active Comparator|standard of care|standard of care
33000477|NCT01625429|Experimental|neoadjuvant|
33000478|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
33000479|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
33000480|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
33000481|NCT01625468|No Intervention|Control|Participant receives usual care
33000482|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
33000483|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
33000484|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
33000485|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
33000486|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
33000487|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
33000488|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
33000489|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
33000490|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
33000491|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
33000492|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
33000493|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
33000494|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia~total intravenous anaesthesia with propofol 5-10 mg / kg / h,~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~use of a bispectral index~monitoring with a target range of 40-60~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~puncture with a Tuohy 18 G- needle, Lost of resistance technique~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
33000495|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~Bispektralindex monitoring with a target range of 40-60~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~ultrasound visible needles, a special pin detection software~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
33000496|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~we use a of BIS monitoring with a target range of 40-60~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~Morphine-patient-controlled-analgesia-device"
33000497|NCT01625585||Consecutive patients undergoing SBE for OGIB|
33000498|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
33000499|NCT01625624|Placebo Comparator|Control Food Product|
33000500|NCT01625624|Experimental|Experimental Food Product|
33000501|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
33000502|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
33000503|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
33000504|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
33000505|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
33000506|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
33000507|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
33000508|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
33000509|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
33000510|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
33000511|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
33000512|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
33000513|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
33000514|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
33000515|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
33000516|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
33000517|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
33000518|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
33000519|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
33000520|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
33000521|NCT01625806|Active Comparator|RO4602522|
33000522|NCT01625806|Experimental|RO4602522 + ketoconazole|
33000523|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
33000524|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
33000525|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
33000526|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
33000527|NCT01625832|Experimental|1|CSO first
33000528|NCT01625832|Experimental|2|CSO second
33000529|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
33000530|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
33000531|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
33000532|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
33000533|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
33000534|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
33000535|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
33000536|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
33417393|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
33000537|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
33000538|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
33000539|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
33000540|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
33000541|NCT01626053|No Intervention|control group|
33000542|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
33000543|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
33000544|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
33000545|NCT01626131|Experimental|Stretching treatment|
33000546|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
33000547|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
33000548|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
33000549|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
33000550|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
33000551|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
33000552|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
33000553|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
33000554|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
33000555|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
33000556|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
33000557|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
33000558|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
33000559|NCT01626261||cardiac pacemaker|
33000560|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
33000561|NCT01626287|Experimental|Black tea bag|
33000562|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
33000563|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
33000564|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
33000565|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
33000566|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
33000567|NCT01626430|Experimental|200 mg gd-TRF|
33000568|NCT01626430|Experimental|400 mg gd-TRF|
33000569|NCT01626430|Experimental|Placebo|
33000570|NCT01626443|Active Comparator|Folic acid|
33000571|NCT01626443|Experimental|Inofolic Combi|
33325080|NCT04900792|Experimental|Cohort 2 (-1 dose level)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatment 25 (± 1 radiation treatment)~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
33325081|NCT05418244|Experimental|Inhaled Isopropyl Alcohol|If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pad, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian. The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the Emergency Department (ED) stay.
32865455|NCT05606341|Placebo Comparator|Placebo|3 injections of sterile saline at Day 1, Week 4, and Week 8, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.
32865456|NCT01893437|Experimental|Single oral dose group|
32865457|NCT04778917|Experimental|Small dose low molecular weight heparin|Low molecular weight heparin calcium 100 units / kg/day, subcutaneous injection, 5-10 days of treatment or D-dimer recovery normal.
32865458|NCT04778917|Experimental|High dose of low molecular weight heparin|low molecular weight heparin calcium 200 units /kg/day, subcutaneous injection, treatment for 7 days or D-dimer return to normal.
32865459|NCT04778917|Placebo Comparator|Vacuity contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
32865460|NCT04778917|No Intervention|contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
32865461|NCT05606263|Experimental|Caldonirimab and nimotuzumab|Caldonirimab combined with nimotuzumab therapy
32865462|NCT04778683|Experimental|VR Group|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing.
32865463|NCT04778683|No Intervention|Control Group|The same evaluations were performed in children in the control group who received routine clinical care.
32865464|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score >10, high microsatellite instability, tumor mutation burden >15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
32865465|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
32865466|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
32865467|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
32865468|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
32865469|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
32865470|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
32865471|NCT02213289|Other|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
32865472|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32865473|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32865474|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32865475|NCT02779751|Experimental|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
32865476|NCT05606185|Active Comparator|Two step retraction|teeth will be retracted in two stages
32865477|NCT05606185|Experimental|En masse retraction|teeth will be retracted in one stage
32865478|NCT05606107|Active Comparator|Glucocorticoid group|
32865479|NCT05606107|Experimental|Tofacitinib group|
32865480|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
32865481|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
32865482|NCT04778605||Patients with septic shock stabilized between H6 and H24 of treatment under noradrenaline.|
32865483|NCT00053989|Experimental|All patients|All patients enrolled on study
32865484|NCT05606029||Patients who underwent cholecystectomy for benign conditions|In those who underwent cholecystectomy for benign conditions, the histopathological analysis showed the malignancy.
32865485|NCT05605717||Pre specified group|Fibroscan Abdominal ultrasound Lab investigation
32865486|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
32865487|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
33000572|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
33000573|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
33000574|NCT01626482|Placebo Comparator|Sham tape|
33414665|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
33000575|NCT01626482|Experimental|Kinesio Tape|
33000576|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
33000577|NCT01626508||breast milk|breast milk used without any treatment, directly by children
33000578|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
33000579|NCT01626534|Active Comparator|clopidogrel group|
33000580|NCT01626534|Experimental|tricagrelor group|
33000581|NCT01626560|Other|Daptomicina|
33000582|NCT01626560|Other|Vancomycin|
33000583|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
33000584|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
33000585|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
33000586|NCT01626612|Experimental|a strategy based on de-escalation|
33000587|NCT01626612|Active Comparator|a conservative strategy|
33000588|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
33000589|NCT01626625|Active Comparator|autograft|
33000590|NCT01626638|Experimental|Experimental|
33000591|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
33000592|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
33000593|NCT01626677|Active Comparator|Microfracture|conventional treatment method
33000594|NCT01626703|Experimental|intervention|remiding call
33000595|NCT01626703|No Intervention|Control|No intervention
33000596|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
33000597|NCT01626716|No Intervention|control|usual care
33000598|NCT01626729|Experimental|Traffic Light|
33000599|NCT01626729|Experimental|Traffic Light+|
33000600|NCT01626729|Experimental|Facts Up Front|
33000601|NCT01626729|Experimental|Facts Up Front+|
33000602|NCT01626729|Placebo Comparator|No front of package label|
33000603|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
33000604|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
33000605|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
33000606|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
33000607|NCT01626768||Enrolled patients|
33000608|NCT01626794|Experimental|VARIVAX™ VEP|
33000609|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
33000610|NCT01626807|Experimental|Walking school bus|
33000611|NCT01626807|No Intervention|Usual care|
33000612|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
33000613|NCT01626833|Placebo Comparator|Placebo|Placebo
33000614|NCT01626846||NF1 teenagers|
33000615|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
33000616|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
33000617|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
33000618|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
33000619|NCT01626924|Experimental|2-Iminobiotin|
33000620|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
33414666|NCT04377997|Experimental|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
33414667|NCT04377997|Active Comparator|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
33414668|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
33414669|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
33414670|NCT01336049|Experimental|Nimotuzumab|
33414671|NCT04758949|Experimental|FL-101 Monotherapy|30 patients will receive FL-101 prior to surgery.
33414672|NCT04758949|Experimental|FL-101 + Nivolumab|30 patients will receive FL-101 and Nivolumab prior to surgery.
33414673|NCT04758949|Active Comparator|Nivolumab + Placebo|30 patients will receive Nivolumab and placebo prior to surgery.
33414674|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
33414675|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
33414676|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
33414677|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
33414678|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
33414679|NCT04320979|Experimental|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
33414680|NCT04320979|Active Comparator|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
33000621|NCT01626937|Active Comparator|conventional medical treatment|
33414681|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
33414682|NCT05099107|Active Comparator|Treatment|congenital myopathy patients in this group will receive daily oral salbutamol, three times daily.
33414683|NCT05099107|No Intervention|Non treatment|Congenital myopathy patients in this group will not receive any salbutamol nor placebo.
33414684|NCT05708456|Experimental|Intervention Group|Application of data collection forms for the initial evaluation. Teaching the use of the mobile application, monitoring the use of the mobile application in the experimental group by the researcher for 12 weeks, and applying the data collection forms to the patients in the 6th and 12th weeks.
33414685|NCT05708456|No Intervention|Control Group|Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the 6th and 12th weeks. No intervention will be made to the patients in the control group other than the routine service provided in the outpatient clinic.
33414686|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
33414687|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
33414688|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
33414689|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
33414690|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
33414691|NCT01344421||hip dysplasia|Patients with hip dysplasia
33414692|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
33000622|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
33000623|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
33105417|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
33414693|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
33414694|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
33414695|NCT04312711|Experimental|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
33414696|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
33414697|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
32865488|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
32865489|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
32865490|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
32865491|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
32865492|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
32865493|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
32865494|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
32865495|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
32865496|NCT02752685||triple negative breast cancer (TNBC)|
32865497|NCT02752685||hormone receptor (HR)-positive cohort|(currently not recruiting for this group)
32865498|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
32865499|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
32865500|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
32865501|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
32865502|NCT02737787|Experimental|ESO-1 Vaccine and Nivolumab|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
32865503|NCT02732171|Other|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.
32865504|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
32865505|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
32865506|NCT02725463|Experimental|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
32865508|NCT01893593|Other|Control|Usual care
32865509|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
32865510|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
32865511|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
32865512|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
32865513|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
32865514|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
32865515|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
32865516|NCT02705495|Other|Control|Recommendation for use of cranberry products only
33000624|NCT01626963|Experimental|SPA|Single-port access surgery
33000625|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
33414698|NCT04302103|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
33414699|NCT04302103|Experimental|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
33000626|NCT01626976|Experimental|Cohort 1|
33414700|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
33414701|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
33000627|NCT01626976|Experimental|Cohort 2|
33000628|NCT01626976|Experimental|Cohort 3|
33000629|NCT01626976|Experimental|Cohort 4|
33000630|NCT01626976|Experimental|Cohort 5|
33000631|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
33000632|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
33000633|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
33000634|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
33000635|NCT01627054|Experimental|AT7519M|
33000636|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
33000637|NCT01627106|Experimental|Vernakalant|
33000638|NCT01627106|Active Comparator|Amiodarone|
32865517|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
32865518|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
33000639|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
33000640|NCT01627132|Experimental|dasatinib|
33000641|NCT01627145|Experimental|antimuscariniz drug|
33000642|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
33000643|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
33000644|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
33000645|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
33000646|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
33000647|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
33414702|NCT01333007||Cohort|
33414703|NCT04256005|No Intervention|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
33414704|NCT04256005|Experimental|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
32865519|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
32865520|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
33000648|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
33000649|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
33000650|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
33000651|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
33105418|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33105419|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
33417394|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
33414705|NCT04256005|Experimental|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
33000652|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
33000653|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
33000654|NCT01627236|Experimental|glucocorticoid treatment group|
33000655|NCT01627236|No Intervention|conventional treatment|
33000656|NCT01627262|Placebo Comparator|Placebo|
33000657|NCT01627262|Experimental|Mesalamine|
33000658|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
33000659|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
33000660|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
33000661|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
33000662|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
33000663|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
33000664|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
33000665|NCT01627392|Experimental|Smoking abstinence|
33000666|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
33000667|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
33000668|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
33000669|NCT01627444|Experimental|ear acupuncture|
33000670|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
33000671|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
33000672|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
33000673|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
33000674|NCT01627483|No Intervention|Controll|
33000675|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
33000676|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
33000677|NCT01627522|No Intervention|Control|Control
33000678|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
33000679|NCT01627561|Experimental|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
33000680|NCT01627561|Active Comparator|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
33000681|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
33000682|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
33000683|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
33000684|NCT01627613|Experimental|AP301|Treatment group
33000685|NCT01627613|Placebo Comparator|saline solution|Placebo group
33000686|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
33000687|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
33000688|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
33000689|NCT01627639|Placebo Comparator|Placebo|Placebo
33325082|NCT05418244|Active Comparator|Oral Ondansetron|If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.
33325083|NCT05418244|Placebo Comparator|Inhaled Placebo|If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.
33325084|NCT05418166||pro-Evo|Patients regularly take Ticagrelor and Aspirin for five days.Platelet activity was test before inject Evolocumab.
33325085|NCT05418166||24h-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 24h after inject.
33000690|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
33000691|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
33000692|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
33000693|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
33000694|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
33000695|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
33000696|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
33000697|NCT01627704|Other|Fluoroestradiol (18F)|
33000698|NCT01627717|Experimental|Maraviroc Boceprevir|
33000699|NCT01627730|Experimental|3th year medical students|
33000700|NCT01627730|Experimental|nurses in critical care units|
33000701|NCT01627743||COPD patients grade C and D|
33000702|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
33000703|NCT01627756|Active Comparator|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
33000704|NCT01627769||second degree blisters patients|blister fluids of second degree burns
33000705|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
33000706|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
33000707|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
33000708|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
33000709|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
33000710|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
33000711|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
33000712|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
33000713|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
33000714|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
33000715|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
33000716|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
33000717|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
33000718|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
33000719|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
33000720|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
33000721|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
33000722|NCT01627964||normal heart function|normal heart function
33000723|NCT01627964||abnormal heart function|abnormal heart function
33000724|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
33000725|NCT01628003|Active Comparator|healthy persons|
33000726|NCT01628003|Experimental|patients after moderate-severe TBI|
33325086|NCT05418166||1w-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 1 week after inject.
33000727|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
33000728|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
33000729|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
33000730|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
33000731|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
33000732|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
33000733|NCT01628133||blood transfusion group|
33000734|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
33000735|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
33000736|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
33000737|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
33000738|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
33000739|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
33000740|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
33000741|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
33000742|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
33000743|NCT01628276|Experimental|Rehab first|
33000744|NCT01628276|Experimental|Rehab Second|
33000745|NCT01628276|No Intervention|Non Rehab|
33000746|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
33000747|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
33000748|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
33000749|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
33000750|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
33000751|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
33000752|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
33000753|NCT01628341||Patients with diabetes (type 1 and 2)|
33000754|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
33000755|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
33000756|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
33000757|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
33000758|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
33000759|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
33000760|NCT01628445|Placebo Comparator|Placebo injection|
33000761|NCT01628458|Experimental|radiofrequency ablation|
33000762|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
33000763|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
33000764|NCT01628497||Positive filariasis test|Those testing positive for filariasis
33000765|NCT01628497||Filariasis negative|
33000766|NCT01628536|Experimental|Black cohosh|
33000767|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
33000768|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
33000769|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
33000770|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
33000771|NCT01628627|Sham Comparator|Control|
33000772|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
33000773|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
33000774|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
33000775|NCT01628679|Experimental|physical therapy treatment|
33000776|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
33000777|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
33000778|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
33000779|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
33325087|NCT04852588|Experimental|Treatment Arm|Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).
33325088|NCT05417542|Experimental|Exposition I|preterm neonates between 28 and 30 wGA Exposition to music during the NICU period
33325089|NCT05417542|Experimental|Exposition II|preterm neonates between 32 and 34 wGA Exposition to music during the NICU period
33000780|NCT01628744||Patients with mycobacterial infection|
33000781|NCT01628757||neoadjuvant chemotherapy|
33000782|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
33000783|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
33000784|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
33000785|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
33325090|NCT05417542|Active Comparator|Control I|preterm neonates between 28 and 30 wGA
33325091|NCT05417542|Active Comparator|Control II|preterm neonates between 32 and 34 wGA
33000786|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
33325092|NCT05417542|Active Comparator|Control III|preterm neonates between 36 and 40 wGA
33325093|NCT04846036|Experimental|Sonlicromanol|Paediatric-equivalent dose (as determined by Physiologically Based Pharmacokinetics (PBPK) modelling and the results of the Adaptive PK study) of sonlicromanol twice daily administered as an oral liquid for 26 weeks
33000787|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
33000788|NCT01628822|Experimental|Active relaxation|
33000789|NCT01628822|Placebo Comparator|Placebo relaxation|
33000790|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
33000791|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
33000792|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
33000793|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
33000794|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
33325094|NCT04846036|Placebo Comparator|Placebo|Matching placebo twice daily orally for 26 weeks
33325095|NCT04845178|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
33325096|NCT04845178|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles.
33000795|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
33000796|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
33000797|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
33000798|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
33000799|NCT01628952|Experimental|TAP|
33000800|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
33000801|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
33000802|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
33000803|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
33000804|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
33000805|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
33000806|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
33000807|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
33000808|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
33000809|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
33000810|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
33000811|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
33000812|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
33000813|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
33000814|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
33000815|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
33000816|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
33000817|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
33000818|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
33000819|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
33000820|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
33000821|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
33000822|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
33000823|NCT01629199|Placebo Comparator|placebo|BID
33000824|NCT01629212|Experimental|Tiropramide HCl|
33000825|NCT01629212|Active Comparator|Octylonium bromide|
33000826|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
33000827|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
33000828|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
33000829|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
33000830|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
33000831|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
33000832|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
33000833|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
33000834|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
33000835|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
33000836|NCT01629316|Active Comparator|Standard of care - control arm|
33000837|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
33000838|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
33000839|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
33000840|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
33000841|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
33000842|NCT01629368|Experimental|Dosing Period 1|
33000843|NCT01629368|Experimental|Dosing Period 2|
33000844|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
32865521|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
32865522|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
32865523|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
32865524|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
32865525|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
32865526|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
32865527|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
32865528|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
32865529|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
32865530|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
32865531|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
32865532|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Treatments repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
32865533|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
32865534|NCT02686697|Placebo Comparator|Placebo|matching placebo
32865535|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
32865536|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
32865537|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
32865538|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
32865539|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
32865540|NCT02670707|Experimental|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
32865541|NCT02670707|Active Comparator|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
32865542|NCT02669069|Active Comparator|PS1|
32865543|NCT02669069|Active Comparator|PS2|
32865544|NCT02669069|Active Comparator|PS3|
32865545|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
32865546|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
32865547|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
33000845|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
33000846|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
33000847|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
33000848|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
33000849|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
33000850|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
33000851|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
33000852|NCT01629407||Glaucoma|Patients with glaucoma
33000853|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
33000854|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
33000855|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
33000856|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
33000857|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
33000858|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
33000859|NCT01629472|Active Comparator|VSLA only: control|
33000860|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
33000861|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
33000862|NCT01629511|Experimental|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
33000863|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
33000864|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
33000865|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
33000866|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
33000867|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
33000868|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
33000869|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
33000870|NCT01629576|No Intervention|control group|
33000871|NCT01629576|Experimental|low reward|economic incentive
33000872|NCT01629576|Experimental|high reward|economic incentive
33000873|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
33000874|NCT01629628|Experimental|Adalimumab|
33000875|NCT01629628|Active Comparator|6-mercaptopurine|
33000876|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
33000877|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
33000878|NCT01629680|Experimental|Healthy subjects I|
33000879|NCT01629680|Placebo Comparator|Healthy subjects II|
33000880|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
33000881|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
33000882|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
33325097|NCT04845178|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.
33417395|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
33417396|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
33417397|NCT02870855|No Intervention|Control group|blastocyst transfer
33000883|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
33000884|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
33417398|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
33000885|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
33000886|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
33000887|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
33000888|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
33000889|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
33000890|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
33000891|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
33000892|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
33000893|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
33000894|NCT01629875|Experimental|DWP450|
33000895|NCT01629875|Active Comparator|Botox|
33000896|NCT01629888|Experimental|1 = Tested product|
33000897|NCT01629888|Placebo Comparator|2 = Control product|
33000898|NCT01629927||HED-affected males|Male subjects affected by HED
33000899|NCT01629927||Male controls|Male subjects not affected by HED
33000900|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
33000901|NCT01629940||Male controls|Male subjects not affected by HED
33000902|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
33000903|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
33000904|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
33000905|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
33000906|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
33000907|NCT01630018|Active Comparator|Topotecan|Topotecan
33000908|NCT01630018|Active Comparator|Camtobell|Belotecan
33000909|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
33000910|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
33000911|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
33000912|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
33000913|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
33000914|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
33000915|NCT01630083|Active Comparator|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
33105420|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
33105421|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
33105422|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
33000916|NCT01630083|Experimental|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m^2 intravenously on day 1 of cycle 1 followed by 600 mg/m^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
33417399|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
33000917|NCT01630083|Experimental|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
33000918|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
33000919|NCT01630096|No Intervention|Control|Standard of care.
33000920|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
33000921|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
33000922|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
33000923|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
33000924|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
33000925|NCT01630187|Active Comparator|Carbetocin 100 mcg|
33000926|NCT01630187|Experimental|Carbetocin 50 mcg|
33000927|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
33000928|NCT01630239|Experimental|Visualise Thermal Therapy System|
33000929|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
33000930|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
33000931|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
33000932|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
33000933|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
33000934|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
33000935|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
33000936|NCT01630278|No Intervention|Small ductus|
33000937|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
33000938|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
33000939|NCT01630291|Experimental|Electrical stimulation|
33000940|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
33000941|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
33000942|NCT01630317|Experimental|Peripheral acces|
33000943|NCT01630317|Placebo Comparator|Central access|
33325098|NCT04738942|Experimental|Vedolizumab 300 mg in UC cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
33000944|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
33000945|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
33000946|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
33000947|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
33000948|NCT01630356|Experimental|Intervention group|
33000949|NCT01630356|Active Comparator|Control group|
33000950|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
33000951|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
33000952|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
33000953|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
33000954|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
33000955|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
33000956|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
33000957|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
33000958|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
33000959|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
33000960|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
33325099|NCT04738942|Experimental|Vedolizumab 300 mg in CD cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
33325100|NCT05417230|Experimental|RC48-ADC plus envafolimab|
33325101|NCT04713670|Experimental|(A) T-V14|
33325102|NCT04713670|Experimental|(B) T-V7|
33325103|NCT04713670|Experimental|(C) D-V14|
33325104|NCT04713670|Experimental|(D) HD-V14|
33000961|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
33000962|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
33000963|NCT01630512|Experimental|MBCT|
33000964|NCT01630512|Experimental|CBT|
33000965|NCT01630512|No Intervention|Waitlist|
33000966|NCT01630525||Prodromal AD participants|
33000967|NCT01630525||Typical AD participants|
33000968|NCT01630525||Control participants|
33000969|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
33000970|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
33000971|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
33000972|NCT01630564|Experimental|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
33000973|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
33000974|NCT01630603||mother infants pairs|
33000975|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
33000976|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
33000977|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
33000978|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
33325105|NCT04713670|Experimental|(E) BQ-V14|
33000979|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
33000980|NCT01630681|No Intervention|Standard care|
33000981|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
33000982|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
33000983|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
33000984|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
33000985|NCT01630746|Experimental|TAK-438 20 mg/day|
33000986|NCT01630746|Experimental|TAK-438 40 mg/day|
33000987|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
33000988|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
33000989|NCT01630798|Experimental|Application of peptide|
33000990|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
33000991|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
33000992|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
33000993|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
33000994|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
33000995|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
33000997|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
33000998|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
33325106|NCT04713670|Experimental|(F) RH-V14|
33325107|NCT04713670|Experimental|(G) BQ-L14|
33325108|NCT04713670|Experimental|(H) T-L14|
33000999|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
33001000|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
33001001|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
33001002|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
33001003|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
33001004|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
33001005|NCT01630954|Active Comparator|Single evacuation of mole,|
33001006|NCT01630954|Active Comparator|Double evacuation of mole|
33001007|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
33001008|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
33001009|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
33001010|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
33001011|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
33001012|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
33001013|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
33001014|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
33001015|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
33001016|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
33001017|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
33001018|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
33001019|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
33001020|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
33001021|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
33001022|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
33001023|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
33001024|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
33001025|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
33001026|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~continuous maintenance therapy by gemcitabine if response disease~switch maintenance therapy by pemetrexed if stable disease"
33001027|NCT01631162|No Intervention|lung disease|
33001028|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
33001029|NCT01631201|Experimental|Rifalazil 25 milligram|
33001030|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
33001031|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
33001032|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
33001033|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
33001034|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
33001035|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
33001036|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
33001037|NCT01631279|Experimental|PR610|
33001038|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
33325109|NCT01631214|Active Comparator|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
33325110|NCT01631214|Experimental|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
33325111|NCT04688398|Experimental|Seal oil|Daily intake of 15 ml of seal oil containing 534 mg of EPA + 1129 mg of DHA + 530 mg of DPA during 12 weeks
33001039|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
33001040|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
33001041|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
33001042|NCT01631357|Experimental|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
33001043|NCT01631357|Active Comparator|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
33001044|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
33001045|NCT01631383|Placebo Comparator|Placebo|
33001046|NCT01631383|Active Comparator|l-THP|
33001047|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
33001048|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
33001049|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
33001050|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
33001051|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~The patients for whom MAAMT is effective.~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
33001052|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
33001053|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
33001054|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
33001055|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
33001056|NCT01631422|Experimental|Single Arm|
33001057|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
33001058|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
33001059|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
33001060|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
33001061|NCT01631461||3. Control group|No pain or other breastfeeding problems
33001062|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
33001063|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
33001064|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
33001065|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
33325112|NCT04688398|Active Comparator|Control|Daily intake of vegetable oil during 12 weeks
33325113|NCT04684108|Experimental|SG301|Study treatment: SG301 administered every week via intravenous infusion
33001066|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
33001067|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
33001068|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
33001069|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
33001070|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
33001071|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
33001072|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
33001073|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
33001074|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
33001075|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
33001076|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
33001077|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
33414706|NCT05353946|Active Comparator|Elective Rotational Atherectomy|"Operators can decide elective use of rotational atherectomy (RA) or conventional angioplasty according to the calcification patterns of the coronary lesion evaluated by Intravascular ultrasound (IVUS) or by angiography if the IVUS cannot cross the lesion.~Procedure is performed with a Rotablator system, consisting of a rotating olive-shaped burr whose leading hemisphere is coated with microscopic diamond chips. The proximal end of the device has a housing unit containing the burr advancer, a fiberoptic tachometer cable, an irrigation port, and a nitrogen gas delivery hose, which permits the rapidly rotating of the burr. The RA catheter is introduced into the coronary artery over a stainless steel 0.09-inch wire to cross the lesion, then advanced with a slow pecking motion at a speed of 160,000 to 190,000 rpm with each ablation run <15 seconds is performed. Burr size was with a burr/vessel ratio of 0.7. After RA, all patients received IVUS-guided percutaneous coronary intervention."
32865548|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
32865549|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
32865550|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
32865551|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
32865552|NCT05586581|Experimental|People living with treated suppressed HIV infection (PLWH)|"40 PLWH participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 millicurie (mCi) of [11C], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.~A subset of PLWH (n=20) will participate in TSPO (11C-PBR28) PET scans on the same day as the baseline SV2A PET scan. For a TSPO PET, up to 20 mCi of [11C], PBR28 will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes."
32865553|NCT05586581|Experimental|HIV-Negative Control (HIV-)|30 HIV-Negative Control (HIV-) participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 mCi of [11C], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.
32865554|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
32865555|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
32865556|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
32865557|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
32865558|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
32865559|NCT02663219|Experimental|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
32865560|NCT02663219|No Intervention|Control|Standard of care
32865561|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
32865562|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
32865563|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
32865564|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
33414707|NCT05353946|Active Comparator|Bailout Rotational Atherectomy|The operators began with conventional angioplasty (non-compliant balloon dilatation) regardless of the calcification patterns in the coronary lesion, and rotational atherectomy (RA) can be used only as a bailout.
33001078|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
33001079|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
33414708|NCT05085613|Active Comparator|Vaccine Corrective Control|A message that explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how the vaccines are evaluated as safe and effective by FDA.
33001080|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
33001081|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
33001082|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
33414709|NCT05085613|Experimental|Vaccine corrective with economic recovery framing|"The content of the control message with the addition of the text, If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. The message will also include a picture of an open for business sign."
33414710|NCT05085613|Experimental|Vaccine corrective with freedom framing|"The content of the control message with the addition of the text, Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. The message will also include a picture of an American flag."
33414711|NCT05085613|Experimental|Vaccine corrective with humor|"The content of the control message with the addition of the text, Unfortunately, everyone getting vaccinated means leaving the house again. The message will include a meme of a cat being pulled/rescued from a window with text boxes labeling the cat as People at home working in sweatpants and the rescuer as COVID Vaccines."
33001083|NCT01631669|Experimental|Celebrex|Receive Celebrex
33001084|NCT01631669|No Intervention|Control|no placebo administered
33001085|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
33414712|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
33001086|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
33001087|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
33001088|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
33001089|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
33001090|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
33001091|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
33001092|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
33001093|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
33001094|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
33001095|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
33001096|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
33001097|NCT01631838|Experimental|Placebo|
33001098|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
33001099|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
33001100|NCT01631890|Active Comparator|standard endotherapy|
33001101|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
33001102|NCT01631903|Experimental|Arm 2 (3mg)|
33001103|NCT01631903|Experimental|Arm 3 (6 mg)|
33001104|NCT01631903|Experimental|Arm 4 (12 mg)|
33001105|NCT01631903|Experimental|Arm 5 (24 mg)|
33001106|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
33325114|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
33001107|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
33001108|NCT01631916|No Intervention|Control|No intervention
33325115|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
33001109|NCT01631942|Experimental|Low dose (healthy subjects)|
33001110|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
33001111|NCT01631942|Experimental|High dose (subjects with haemophilia)|
33001112|NCT01631955||Cystitis|female with cystitis symptoms
33001113|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
33001114|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
33001115|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
33001116|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
33001117|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
33001118|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
33001119|NCT01632007|Experimental|SYR-472 100 mg|
33001120|NCT01632007|Active Comparator|Alogliptin 25 mg|
33001121|NCT01632007|Placebo Comparator|Placebo|
33001122|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
33001123|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
33001124|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
33001125|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
33001126|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
33001127|NCT01632072|No Intervention|No nutritional counceling|
33001128|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
33001129|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
33001130|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
33001131|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
33001132|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
33001133|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
33001134|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
33001135|NCT01632254||Patients with ≥70% carotid artery stenosis|
33001136|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
33001137|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
33001138|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
33001139|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
33001140|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
33001141|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
33001142|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
33001143|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
33001144|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
33001145|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
33001146|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
33001147|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
33001148|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
33325116|NCT04663750|Experimental|Arm A - Surgery with aflibercept|Surgery with aflibercept at the end of surgery, with post-operative review day 1 and week 1 (day 7)
33325117|NCT04663750|Active Comparator|Arm B - Aflibercept monotherapy|Aflibercept monotherapy commencing at baseline.
33325118|NCT04619524|Experimental|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
33417400|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
33417401|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
32865565|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
32865566|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
32865567|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
32865568|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
32865569|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
32865570|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
32865571|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
32865572|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
32865573|NCT02649959|Experimental|Open Label|CM-AT
32865574|NCT02607228|Experimental|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
32865575|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
32865576|NCT02607228|Experimental|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
32865577|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
32865578|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
32865579|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
32865580|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
32865581|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
32865582|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
32865583|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
32865584|NCT02638883|Experimental|Implanted|Subjects will be implanted with the Hybrid SRW cochlear implant.
32865585|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
32865586|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
32865587|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
32865588|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
32865589|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
32865590|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
32865591|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
32865592|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
32865593|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
32865594|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
33001149|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
33001150|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
33001151|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
33001152|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
33001153|NCT01632449|Experimental|1|Test product
33001154|NCT01632449|Experimental|2|Reference product
33001155|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
33001156|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
33001157|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
33001158|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
33001159|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
33001160|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
33001161|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
33001162|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
33001163|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
33001164|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
33001165|NCT01632540||Perennial Allergic Rhinitis patients|
33001166|NCT01632553||Cases|women who have experienced DVA
33001167|NCT01632553||Controls|women who have not experienced DVA
33001168|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
33001169|NCT01632592|Placebo Comparator|Placebo|
33001170|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
33001171|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
33001172|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
33001173|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
33001174|NCT01632670|No Intervention|No music therapy|
33001175|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
33001176|NCT01632722|Active Comparator|ArmA|
33001177|NCT01632722|Active Comparator|ArmB|
33001178|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
33001179|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
33001180|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
33001181|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
33001182|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
33001183|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
33001184|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
33001185|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
33325119|NCT04619524|Experimental|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
33325120|NCT04605718|Experimental|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
33325121|NCT04605718|Experimental|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo once-daily for 10 days (3:1 ratio of active:placebo treatment).
33325122|NCT04605718|Experimental|Part 3 (Elderly)|In this cohort, a minimum of 4 participants and a maximum of 12 participants will receive a single IV dose of RO7223280 or placebo (3:1 ratio of active:placebo treatment).
33325123|NCT05415280|Experimental|Mindfulness based stress reduction|mindfulness based stress reduction intervention was used to treat psychological and addiction problems of the individuals
33325124|NCT05415280|Other|Relaxation Exercise|the control group was provided with the relaxation technique.
32865595|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
32865596|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
32865597|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
32865598|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
32865599|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
32865600|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
32865601|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
32865604|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
32865605|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
32865606|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
32865607|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
32865608|NCT04840290|Experimental|Sintilimab Plus Platinum Doublet Chemotherapy|Specified dose on specified days Sintilimab
32865609|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
32865610|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
32865611|NCT02630069|No Intervention|Healthy control|No intervention
32865612|NCT04843956|Experimental|Patients with solid pancreatic lesions|Patients who will undergo endoscopic ultrasound biopsy. Samples of at least 3 passes will be obtained, each pass obtained with a different technique (capillary with suction, capillary without suction and wet suction)
32865613|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
32865614|NCT01431339|Experimental|Dalbavancin|
32865615|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
32865616|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016~initially treated with curative intent~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
32865617|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
32865618|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
32865619|NCT04843878||Positive|Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
32865620|NCT04843878||Negative|Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
32865621|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
32865622|NCT02611427|Active Comparator|Education|Booklet about physical activity
32865623|NCT04853160||All Participants With Gout|Participants with gout, initiating febuxostat therapy on or after 01 June 2016 will be included in the study.
32865624|NCT04852380||Patients treated by PRP injection|
32865625|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.~Patients undergo a second bronchoscopy during week 5."
32865626|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.~Patients undergo a second bronchoscopy during week 5."
32865627|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
32865628|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
32898775|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
33001186|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
33001187|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
33001188|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
33001189|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
33001190|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
33001191|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
33001192|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
33001193|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
33001194|NCT01632852|Experimental|CSL362|See Intervention Description
33001195|NCT01632865|Experimental|recanalization and stenting|
33001196|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
33001197|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
33001198|NCT01632943|Experimental|Symplicity renal denervation system|
33001199|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
33001200|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
33001201|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
33001202|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
33001203|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
33001204|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
33001205|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
33001206|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
33001207|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
33001208|NCT01633073|Active Comparator|LMA Supreme|
33001209|NCT01633073|Active Comparator|i-gel|
33001210|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites~nd gel: maleic/ascorbic acids"
33001211|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline~nd gel: maleic/ascorbic acids"
33001212|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
33001213|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
33001214|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
33001215|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
33001216|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
33001217|NCT01633151||20 volunteers|
33001218|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
33001219|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
33001220|NCT01633177|Active Comparator|Vitamin D and Omega-3|
33001221|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
33001222|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
33001223|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
33001224|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
33001225|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
33001226|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
33001227|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
33001228|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
33001229|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
33001230|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
33001231|NCT01633281|Experimental|acupuncture treatment|
33001232|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
33001233|NCT01633294|No Intervention|Control group|
33001234|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
33001235|NCT01633307|No Intervention|Control group|No teaching program
33001236|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
33001237|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
33001238|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
33001239|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
33001240|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
33001241|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
33001242|NCT01633385||Control Group|age- and sex matched to subject-group
33001243|NCT01633437|Placebo Comparator|Sugar pill|
33001244|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
33001245|NCT01633450|Experimental|Zinc biofortified rice|
33001246|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
33001247|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
33001248|NCT01633476|No Intervention|No additional treatment|No additional treatment
33001249|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
33001250|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
33001251|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
33001252|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
33001253|NCT01633554||Cirrhosis|Patients with liver cirrhosis
33001254|NCT01633554||Control Group|Control Group: Healthy Volunteers
33001255|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
33001256|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
33001257|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
33001258|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
33001259|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
33001260|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
33001261|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
33001262|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
33001263|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
33001264|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
33001265|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
33001266|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
33001267|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
33001268|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
33001269|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
33001270|NCT01633684||Control|Age and sex matched control subjects
33001271|NCT01633697|Experimental|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
33001272|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
33001273|NCT01633723|Experimental|DA-6886|
33001274|NCT01633723|Placebo Comparator|DA-6886 placebo|
33001275|NCT01633736|Experimental|home progressive resistance exercise|
33001276|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
33001277|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
33001278|NCT01633775||Ahmed glaucoma implant|
33001279|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
33001280|NCT01633801|Other|High flows|
33001281|NCT01633801|Other|oxygen therapy|
33001282|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
33001283|NCT01633840|Placebo Comparator|Elemental E028|
33001284|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
33001285|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
33001286|NCT01633879|No Intervention|print materials|brochures to parents
33001287|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
33001288|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
33001289|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
33001290|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
33001291|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
33001292|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
33001293|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
33001294|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
33001295|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
33001296|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
33001297|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
33001298|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
33001299|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
33001300|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
33001301|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
33001302|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
33001303|NCT01634009|No Intervention|Standard RUTF|Will act as control
33001304|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
33001305|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
33001306|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
33001307|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
33001308|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
33414713|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
33414714|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
33414715|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
33001309|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
33001310|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
33001311|NCT01634126|Active Comparator|1 FIT kit|
33001312|NCT01634126|Active Comparator|2 FIT kit|
33001313|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
33414716|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
33417402|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
33001314|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
33001315|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
33001316|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
33001317|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
33001318|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
33001319|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
33001320|NCT01634282|Experimental|OPC-262|
33001321|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
33001322|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
33001323|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
33001324|NCT01634308|Active Comparator|Bio-oss|
33001325|NCT01634321|Experimental|Luphere|
33001326|NCT01634334|Experimental|Real-time Intervention|
33001327|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
33001328|NCT01634347|Experimental|Propranolol and memory reactivation|
33001329|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
33001330|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
33001331|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
33001332|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
33001333|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
33001334|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
33001335|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
33001336|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
33001337|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
33001338|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
33001339|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
33001340|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
33001341|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
33001342|NCT01634464||Control group|women with 18.5 > BMI < 25
33001343|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
33001344|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
33001345|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
33001346|NCT01634477||HIV-infected patients group|HIV positive
33001347|NCT01634477||HIV-uninfected patients group|HIV negative
33001348|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
33001349|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
33001350|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
33001351|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
33414717|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
33414718|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
33414719|NCT05065879|Experimental|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
33414720|NCT05065879|Experimental|Diabetes group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
33414721|NCT05065879|Experimental|Combined Diseases group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
33414722|NCT05065879|Active Comparator|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
33414723|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
33001352|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
33001353|NCT01634503|Experimental|1mg of GX-188E by electroporation|
33414724|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
33414725|NCT01344577||Group3#|control group
33414726|NCT05353868||Early PD|"Recruited in the baseline study as a subject of the Early PD group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
33414727|NCT05353868||iRBD|"Recruited in the baseline study as a subject of the iRBD group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
33414728|NCT05353868||First degree relatives of patient with iRBD|"Recruited in the baseline study as a subject of the 'First degree relatives of patients with iRBD' group~Completed baseline assessment and stool sample collection~Not cohabiting with iRBD proband"
33414729|NCT05353868||Health control|"Recruited in the baseline study as a subject of the 'healthy controls' group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
33001354|NCT01634503|Experimental|2mg of GX-188E by electroporation|
33001355|NCT01634503|Experimental|4mg of GX-188E by electroporation|
33414730|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
33001356|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
33001357|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
33001358|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
33001359|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
33001360|NCT01634542||Cohort|
33001361|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
33001362|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
33001363|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
33001364|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
33001365|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
33001366|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
33414731|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
33001367|NCT01634672||hemodialysis patients|
33001368|NCT01634672||Peritoneal dialysis patients|
33001369|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
33001370|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
33001371|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
33001372|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
33001373|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
33001374|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
33001375|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
33001376|NCT01634750|Experimental|ManNac|
33001377|NCT01634750|Placebo Comparator|Placebo|
33414732|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
33414733|NCT01344655|Placebo Comparator|Matched Placebo|
33414734|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
33414735|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
32904885|NCT05136092|Experimental|Cohort 1: HFCS (fructose-fed)|"Day Before Surgery between 09:00 pm and 10:00 pm~Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm. Subjects will be reminded the day before the surgery to drink the solution."
32904886|NCT05136092|Experimental|Cohort 2: D-Xylose (xylose-fed)|"Day Before Surgery between 09:00 pm and 10:00 pm~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm. Subjects will be reminded the day before the surgery to drink the solution."
32904887|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
32904888|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
32904889|NCT01274585|Sham Comparator|No active treatment|
32904890|NCT01274585|Experimental|stimulation/treatment|
32904891|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~VAS and dental cleaning at the first query.~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
32904892|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
32904893|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
32904894|NCT04814186|Experimental|Chinese participants treated with Tafamidis|treatment group with tafamidis
32904895|NCT04382378|No Intervention|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
32904896|NCT04382378|Experimental|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
32904897|NCT04382378|Experimental|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
32904898|NCT04932824|No Intervention|Subjects Without Treatment Cross-over|these subjects will not receive any vaccination during this study.
32904899|NCT04932824|Experimental|Subjects With Treatment Cross-over (From 1st Dose of Active Study Vaccine Onwards)|Once the treatment assignments of study CLO-SCB-2019-001 are unblinded, those subjects who have received placebo and provided there is active study vaccine available, will be given the option to receive 2 doses of active study vaccine 21 days apart (ie, treatment cross-over)
32904900|NCT04932824|Experimental|Subjects who will receive Booster Vaccine|For subjects out of those who received SCB-2019 CpG/Alum-adjuvanted vaccine in study CLO-SCB-2019-001: the subjects will receive a booster dose.
32904901|NCT05135000|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 24 weeks
32904902|NCT05135000|Placebo Comparator|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
32904903|NCT05118854|Experimental|Sotorasib in Combination with Cisplatin/Carboplatin and Pemetrexed|4 cycles of at least one dose of sotorasib plus cisplatin (or carboplatin) and pemetrexed can be administered safely
32904904|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
32904905|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
32904906|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
32904907|NCT04000880|Experimental|Project 1: Diet-Exercise|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
33001378|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
33001379|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
33001380|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
33001381|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
33001382|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
33001383|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
33001384|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
33001385|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
33001386|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
33001387|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
33001388|NCT01634815|Experimental|lactate group|
33001389|NCT01634828||Minimal blood loss patients|
33001390|NCT01634828||Moderate to heavy blood loss patients|
33001391|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
33001392|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
33001393|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
33001394|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
33001395|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
33001396|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
33001397|NCT01634906|Experimental|Discontinuation of statin therapy|
33001398|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
33001399|NCT01634932|Experimental|regular-iron millet|
33001400|NCT01634932|Experimental|iron-biofortified millet|
33001401|NCT01634932|Experimental|Post-harvest iron-fortified millet|
33001402|NCT01634945|Placebo Comparator|Placebo|Placebo
33001403|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
33001404|NCT01634945|Experimental|IPT of malaria|
33001405|NCT01634945|Experimental|FeFum porridge|
33001406|NCT01634945|Experimental|FePP porridge|
33001407|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
33001408|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
33001409|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
33001410|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
33001411|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
33001412|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
33001413|NCT01635010|No Intervention|Control|
33001414|NCT01635010|Experimental|Obstructive sleep apnea|
33001415|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
33001416|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
33001417|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
33001418|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
33001419|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
33001420|NCT01635075|Experimental|Exercise|1-mile treadmill walk
33001421|NCT01635075|Placebo Comparator|Passive|20 min inactivity
33001422|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
33001423|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
33001424|NCT01635114|Active Comparator|resVida (resveratrol)|
33001425|NCT01635114|Placebo Comparator|Placebo|
33001426|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
33001427|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
33001428|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
33001429|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
33001430|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
33001431|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
33001432|NCT01635192|Active Comparator|VSL#3|
33001433|NCT01635192|Placebo Comparator|Inactive treatment|
33001434|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
33001435|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
33001436|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
33001437|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
33001438|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
33414736|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
33414737|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
33001439|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
33001440|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
33001441|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
33414738|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
33001442|NCT01635296|Experimental|A: Previously untreated|
33001443|NCT01635296|Experimental|B: Relapse/Refractory|
33001444|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
33001445|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
33001446|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
33001447|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
33001448|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
33001449|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
33001450|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
33001451|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
33001452|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
33001453|NCT01635387|Experimental|Aliskiren|
33001454|NCT01635387|Placebo Comparator|Placebo|
33001455|NCT01635400|Other|UGT1A1 wild type (6/6)|
33001456|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
33001457|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
33001458|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
33001459|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
33001460|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
33001461|NCT01635426|Active Comparator|Aspirin|
33001462|NCT01635426|Active Comparator|Clopidogrel|
33414739|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
33414740|NCT04734535|Experimental|investigational|HEMOBLAST™ Bellows
33414741|NCT04734535|Active Comparator|control|absorbable gelatin sponge with thrombin
33414742|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
33414743|NCT01333163|Active Comparator|GLP-1|
33414744|NCT01333163|Placebo Comparator|Placebo|
33001463|NCT01635452||Patients treated with Esmya|
33001464|NCT01635465||Observation group:vinorelbine plus capecitabine|
33001465|NCT01635465||Control group:docetaxel plus capecitabine|
33001466|NCT01635517||Tolvaptan|Tolvaptan administration
33001467|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
33001468|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
33001469|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
33001470|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
33001471|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
33001472|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
33001473|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
33414745|NCT04734379|Experimental|Treatment|Oral fasudil 180 mg/day
33414746|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
33414747|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
33417403|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
33001474|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
33001475|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
33001476|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
33001477|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
33001478|NCT01635621|Experimental|OKZ 120 mg|
33001479|NCT01635621|Experimental|OKZ 240 mg|
33001480|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
33001481|NCT01635621|Placebo Comparator|Placebo|
33001482|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
33001483|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
33001484|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
33001485|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
33001486|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
33001487|NCT01635660|Active Comparator|C-MAC System|
33001488|NCT01635660|Active Comparator|AP Advance|
33001489|NCT01635660|Active Comparator|King Vision|
33001490|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
33001491|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
33001492|NCT01635686|Experimental|DWP422|
33001493|NCT01635686|Active Comparator|ENBREL|
33001494|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
33001495|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
33001496|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
33001497|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
33001498|NCT01635738|Placebo Comparator|Placebo|
33001499|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
33001500|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
33001501|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
33001502|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
33001503|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
33001504|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
33001505|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
33001506|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
33001507|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
33001508|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
33001509|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
33001510|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
33001511|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
33001512|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
33001513|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
33001514|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
33001515|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
33001516|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
33001517|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
33001518|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
33001519|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
33001520|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
33001521|NCT01635985|Experimental|1|AZD5423 iv
33325125|NCT05413564|Other|optimized self-exclusion procedure A|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months
33325126|NCT05413564|Other|standard procedure|standard self-exclusion procedure B
33001522|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
33001523|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
33001524|NCT01635985|Experimental|4|AZD5423 oral
33001525|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
33001526|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
33001527|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
33001528|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
33001529|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
33001530|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
33001531|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
33001532|NCT01636050|Experimental|Training group|
33001533|NCT01636050|Experimental|Control group|
33001534|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
33001535|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
33001536|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
33001537|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
33001538|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
33001539|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
33001540|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
33001541|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
33001542|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
33001543|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
33001544|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
33001545|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
33001546|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
33001547|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
33001548|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
33001549|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
33001550|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
33001551|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
33001552|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
33001553|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
33001554|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
33001555|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
33001556|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
33001557|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
33001558|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
33001559|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
33001560|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
33001561|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
33327457|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.~the intervention : is breaking the septation within the loculated empyema"
33001562|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
33001563|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
33001564|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
33001565|NCT01636401|Active Comparator|aclidinium bromide|
33001566|NCT01636401|Placebo Comparator|Placebo|
33001567|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
33001568|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
33001569|NCT01636492|Experimental|Bitopertin|
33001570|NCT01636492|Placebo Comparator|Placebo|
33001571|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
33001572|NCT01636505|Active Comparator|long protocol|
33001573|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
33001574|NCT01636531|Experimental|HCLF|
33001575|NCT01636531|Active Comparator|LyoF|
33001576|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
33001577|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
33001578|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
33001579|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
33001580|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
33001581|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
33001582|NCT01636609|Experimental|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33001583|NCT01636609|Experimental|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
33001584|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
33001585|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
33001586|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
33001587|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
33001588|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
33001589|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
33001590|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
33001591|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
33001592|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
33001593|NCT01636752|No Intervention|Control|
33001594|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
33001595|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
33001596|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
33001597|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
33001598|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
33001599|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
33001600|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
33001601|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
33001602|NCT01636869|Experimental|bupicavaine|
33001603|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
33327458|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
33001604|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
33001605|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
33001606|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
33001607|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
33001608|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
33001609|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
33001610|NCT01637038|No Intervention|Control Group|no intervention
33001611|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
33001612|NCT01637103|Experimental|Cognitive therapy of depression|
33001613|NCT01637103|Experimental|Bright light therapy|
33001614|NCT01637103|No Intervention|Waiting list|
33001615|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
33001616|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
33001617|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
33001618|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
33001619|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
33001620|NCT01637155|Experimental|Cholecalciferol|
33001621|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
33001622|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
33001623|NCT01637181|Active Comparator|EVLA 940 nm|
33001624|NCT01637181|Active Comparator|EVLA 1470 nm|
33001625|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33001626|NCT01637220||case, control|Blood volume collected specifically for this study
33001627|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
33001628|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
33001629|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
33001630|NCT01637259|Active Comparator|NRTI + PI|arm 1
33001631|NCT01637259|Active Comparator|PI + maraviroc|arm 2
33001632|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
33001633|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
33001634|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
33001635|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
33001636|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
33001637|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
33001638|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
33001639|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
33001640|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
33001641|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
33001642|NCT01637350||total gastrectomy, jejunal interposition|
33001643|NCT01637350||total gastrectomy , Roux-en-Y|
33001644|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
33001645|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
33001646|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
33001647|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
33001648|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
33001649|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
33327459|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
33001650|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
33001651|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
33001652|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
33001653|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
33001654|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
33001655|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
33001656|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
33001657|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
33001658|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
33001659|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
33001660|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
33001661|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
33001662|NCT01637532|Other|Group 1|Carboplatin/Caelyx
33001663|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
33001664|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
33001665|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
33001666|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
33001667|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
33001668|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
33001669|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
33001670|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
33001671|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
33001672|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
33001673|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
33001674|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
33001675|NCT01637636|Experimental|Rifampin|
33001676|NCT01637636|Experimental|Ketoconazole|
33001677|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
33001678|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
33001679|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
33001680|NCT01637662|Experimental|Healthy subjects|
33001681|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
33001682|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
33001683|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
33001684|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
33001685|NCT01637714|Experimental|Multi-strain probiotics|
33001686|NCT01637714|Placebo Comparator|Placebo powder|
33001687|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
33001688|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
33001689|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
33001690|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
33001691|NCT01637753|Experimental|Carmustine Sustained Release Implant|
33001692|NCT01637753|Sham Comparator|Surgical control group|
33105423|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
33105424|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
33327460|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
33327461|NCT03864666|Other|Sequence 1|Treatment RTRT
33414748|NCT05352620|Experimental|Implant assisted maxillary overdenture|Horseshoe Maxillary Complete overdenture construction (Stabilizing and connecting the Smart Box housing)
33414749|NCT04163887|Other|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
33001693|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
33414750|NCT04163887|Other|open liver resection|standard of care
33001694|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
33001695|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
33001696|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
33001697|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
33001698|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
33001699|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
33001700|NCT01637805|Experimental|AAV-DC-CTL|
33001701|NCT01637818|Other|Lichtenstein's Operation|
33001702|NCT01637818|Other|Mesh Plug Repair|
33001703|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
33001704|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
33001705|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
33001706|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
33001707|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
33001708|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
33001709|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
33001710|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
33001711|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
33001712|NCT01637909|Active Comparator|general management|
33001713|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
33001714|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
33001715|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
33001716|NCT01637948|No Intervention|Negative control|without intervention
33001717|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
33001718|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
33001719|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
33001720|NCT01637987|Active Comparator|Unassisted vein visualization|
33001721|NCT01637987|Active Comparator|Wee Sight Transilluminator|
33001722|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|
33001723|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
33001724|NCT01638039|Active Comparator|Diarrheal disease|
33001725|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
33001726|NCT01638065||Standard|Standard IV Access without device
33001727|NCT01638065||VeinViewer|IV access with VeinViewer device
33001728|NCT01638078|Active Comparator|Thalidomide|Thalidomide
33001729|NCT01638078|Placebo Comparator|Placebo|Placebo
33001730|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
33001731|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
33001732|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33414751|NCT01333241|Experimental|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
33414752|NCT01333241|Sham Comparator|Control group|Disaster Preparedness/Home Safety group education and teaching
33417404|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
33001733|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
33001734|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001735|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
33001736|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
33001737|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001738|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001739|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001740|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001741|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
33001742|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
33001743|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
33001744|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
33001745|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
33001746|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
33001747|NCT01638117|Placebo Comparator|Placebo|Saline
33001748|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
33001749|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
33001750|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
33001751|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
33001752|NCT01638169||20 children with DMD|
33001753|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
33001754|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
33001755|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
33001756|NCT01638195|Experimental|Externally Focused Ultrasound|
33001757|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
33001758|NCT01638208|No Intervention|Healthy Controls|Healthy controls
33001759|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
33001760|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
33001761|NCT01638234|Placebo Comparator|Starch pill|
33001762|NCT01638234|Experimental|Melatonin|
33001763|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
33001764|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
33001765|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
33001766|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
33001767|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
33001768|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
33001769|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
33001770|NCT01638286||Eperisone|
33001771|NCT01638286||Aceclofenac|
33001772|NCT01638286||Eperisone hydrochloride, Aceclofenac|
33001773|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
33001774|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
33001775|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
33001776|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
33001777|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
33001778|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
33001779|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
33001780|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
33001781|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
33001782|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
33001783|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
33325127|NCT05185986|Experimental|Home based Pilates exercises|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
33327462|NCT03864666|Other|Sequence 2|Treatment TRTR
33327463|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
33001784|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
33001785|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
33001786|NCT01638403|Placebo Comparator|Placebo|
33414753|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Part A:~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects~Part B: 8 subjects (randomised to one of four treatment sequences)"
33001787|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
33001788|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
33001789|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
33001790|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
33001791|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
33001792|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
33001793|NCT01638572||neuroblastoma patients|
33001794|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
33001795|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
33001796|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
33001797|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
33001798|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
33001799|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
33001800|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
33001801|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
33001802|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
33001803|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
33001804|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
33001805|NCT01638637||Specimen Collection|
33001806|NCT01638650|Experimental|Single Arm|
33001807|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
33001808|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
33001809|NCT01638676|Experimental|Vemurafenib and Metformin|
33001810|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
33001811|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
33001812|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
33001813|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
33001814|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
33001815|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
33001816|NCT01638728||Endotracheal tube|
33001817|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
33001818|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
33001819|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
33001820|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
33001821|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
33001822|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
33001823|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
33001824|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
33001825|NCT01638845|Active Comparator|continuous perineural catheter|
33001826|NCT01638845|No Intervention|Control|
33001827|NCT01638858|Experimental|Lucentis (Ranibizumab)|
33001828|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
33001829|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
33001830|NCT01638884|Experimental|Young Healthy Subjects|
33001831|NCT01638884|Experimental|Middle age Healthy Subjects|
33001832|NCT01638884|Experimental|Elderly Healthy Subjects|
33001833|NCT01638884|Experimental|Mild Cognitive Impairment patients|
33001834|NCT01638884|Experimental|Alzheimer Disease patients|
33001835|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
33001836|NCT01638923|Experimental|Arm 1|
33001837|NCT01638923|Placebo Comparator|Arm 2|
33001838|NCT01638936|Experimental|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
33001839|NCT01638949|Experimental|Young controls|
33001840|NCT01638949|Experimental|Middle age controls|
33001841|NCT01638949|Experimental|Elderly controls|
33001842|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
33001843|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
33001844|NCT01638949|Experimental|Mild Cognitive Impairment patients|
33001845|NCT01638949|Experimental|Alzheimer Disease patients|
33001846|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
33001847|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
33001848|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
33001849|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
33001850|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
33001851|NCT01638988|Experimental|Metformin|
33001852|NCT01638988|Active Comparator|Clomiphene Citrate|
33001853|NCT01639014|Experimental|F2695|
33001854|NCT01639014|Placebo Comparator|placebo|
33001855|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
33001856|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
33001857|NCT01639053||Gel Participants|
33001858|NCT01639053||Control Participants|
33001859|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
33001860|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
33001861|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
33001862|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
33001863|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
33001864|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
33001865|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
33001866|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
33001867|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
33001868|NCT01639196|Experimental|Self-compassion writing|
33001869|NCT01639196|Active Comparator|Self-efficacy writing|
33001870|NCT01639209|Experimental|Vitrectomy|
33001871|NCT01639209|Experimental|Pneumatic retinopexy|
33001872|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
33001873|NCT01639274|Other|COPD|
33001874|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
33001875|NCT01639287||Painful|Painful synovitis group
33001876|NCT01639300|Experimental|GNbAC1|
33001877|NCT01639300|Placebo Comparator|GNbAC1 placebo|
33001878|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
33001879|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
33001880|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
33001881|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
33001882|NCT01639391|Experimental|patients|
33001883|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
33001884|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
33001885|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
33001886|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
33001887|NCT01639482||Citalopram|Patients with bipolar disorder
33001888|NCT01639482||Placebo|Patients with bipolar disorder
33001889|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33001890|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33001891|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
33001892|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
33001893|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
33001894|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
33001895|NCT01639625|Experimental|CIGB300|
33001896|NCT01639638|Placebo Comparator|Placebo|
33001897|NCT01639638|Experimental|CIGB-300 - 5 mg|
33001898|NCT01639638|Experimental|CIGB-300 - 15 mg|
33001899|NCT01639651|Active Comparator|Control Group|
33001900|NCT01639651|Experimental|Mobilization Group|
33001901|NCT01639677|Experimental|Laparoscopic gastric bypass|
33001902|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
33001903|NCT01639716||Lymphoma group|
33001904|NCT01639716||healthy group|
33001905|NCT01639716||IL-10 high|
33001906|NCT01639716||IL-10 low|
33001907|NCT01639716||IL-4 high|
33001908|NCT01639716||IL-4 low|
33001909|NCT01639716||lymphopenia|
33001910|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
33001911|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
33001912|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
33001913|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
33001914|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
33001915|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
33001916|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
33001917|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
33001918|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
33001919|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
33001920|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
33001921|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
33001922|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
33001923|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
33001924|NCT01639859|Experimental|Elastography|
33001925|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
33001926|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
33001927|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
33001928|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
33001929|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
33001930|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
33001931|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
33001932|NCT01640119|Placebo Comparator|no intervention|
33001933|NCT01640119|Experimental|Bicarbonate|
33001934|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
33001935|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
33001936|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
33001937|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
33001938|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
33001939|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
33001940|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
33001941|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
33001942|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
33001943|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
33001944|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
33001945|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
33001946|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
33001947|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
33001948|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
33001949|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
33001950|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
33001951|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
33001952|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
33001953|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
33001954|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
33001955|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
33001956|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
33001957|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
33001958|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
33001959|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
33001960|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
33001961|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
33414754|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
33001962|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
33001963|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
33001964|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
33001965|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
33001966|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
33001967|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
33001968|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
33001969|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
33001970|NCT01643148||breast cancer patients (cases)|36 subjects
33001971|NCT01643148||controls|36 subjects
33001972|NCT01643291|Experimental|Ultrasound|
33001973|NCT01643434|Active Comparator|Spironolactone|
33001974|NCT01643434|Active Comparator|Clonidine|
33001975|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
33001976|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
33001977|NCT01643941|Experimental|1|SA4Ag vaccine low dose
33001978|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
33001979|NCT01643941|Experimental|3|SA4Ag vaccine high dose
33001980|NCT01643941|Experimental|4|SA3Ag vaccine
33001981|NCT01643941|Placebo Comparator|5|Placebo
33001982|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
33001983|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
33001984|NCT01644123||Nursing home residents|
33001985|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
33001986|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
33001987|NCT01644318||authoimmıne thyroiditis and habitual abortus|
33001988|NCT01644318||authoimmune thyroiditis|
33001989|NCT01644318||healthy controls|
33001990|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
33001991|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
33001992|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
33001993|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
33001994|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
33001995|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
33001996|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
33001997|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
33001998|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
33001999|NCT01645137|Other|control|patients under usual medical care
33002000|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
33002001|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
33002002|NCT01645566|No Intervention|Control|No instructions
33002003|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
33002004|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
33002005|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
33002006|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
33002007|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
33105425|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
33325128|NCT05185986|Experimental|Combination of Home-based Pilates exercises and Home-based Cognitive Rehabilitation exercises|In addition to performing home-based Pilates exercises described in arm 1, this group will also perform home-based cognitive rehabilitation exercises for 8 weeks and 3 sessions per week. The interval between each session is at least 48 hours and each session will take between 30 to 45 minutes. Cognitive rehabilitation exercises are in pen and paper and each session includes two exercises in the areas of planning, cognitive organization, cognitive flexibility and working memory. All exercises will be explained to the subjects by a cognitive rehabilitation specialist, and in addition, explanations of all the exercises in each session will be available for participants in the separate voices. During the intervention period, in addition to the Pilates specialist, the cognitive rehabilitation specialist contacts the group 2 participants on a weekly basis and monitors their rehabilitation exercises.
33325129|NCT05185986|Other|Waiting list group|This group is the waiting list group and acts as a control group and will be instructed to maintain their preintervention physical and cognitive activity levels during the intervention. After 8 weeks of intervention, Pilates exercises and cognitive rehabilitation exercises will be provided to the participants of this group for their own use.
33325130|NCT04604548|Experimental|Open Label treatment|Oral administration of 100 mg KH176 twice daily
33325131|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
33002008|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
33002009|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
33002010|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
33002011|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
33002012|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
33002013|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
33002014|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
33002015|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
33002016|NCT01646749|Experimental|Protein intake of 15 En%|
33002017|NCT01646749|Experimental|Protein intake of 30 En%|
33002018|NCT01646840|Experimental|PF-04958242 capsule|
33002019|NCT01646840|Active Comparator|PF-04958242 oral solution|
33002020|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
33002021|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
33002022|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
33002023|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
33002024|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
33002025|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
33002026|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
33002027|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
33002028|NCT01647997|No Intervention|study 1b|basal whole body lactate production
33002029|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
33325132|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
33325133|NCT04601038|Other|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
33325134|NCT04601038|Other|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
33325135|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
33002030|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
33002031|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
33002032|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
33414755|NCT05353790|Experimental|Avocado mango meal plan|2 meals and snacks per day, including 1 avocado + 1 cup of mango, covering 75% of daily calories needs,
33414756|NCT05353790|Other|Control meal plan|2 meals and snacks per day, without avocado and mango, covering 75% of daily calories needs
33414757|NCT01339949|Experimental|24 Gy radiation|
33414758|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
33414759|NCT04693429|Experimental|PRO-172|PRO-172 Ophthalmic Solution QID (four times per day). Single arm.
33414760|NCT05353712|Experimental|Group T: ABCDEF|Participants will receive all six blind-coded samples, in the order A, B, C, D, E, F. There will be a minimum of 7 days washout between samples.
33414761|NCT05353712|Experimental|Group V: FABCDE|Participants will receive all six blind-coded samples, in the order F, A, B, C, D, E. There will be a minimum of 7 days washout between samples.
33414762|NCT05353712|Experimental|Group W: EFABCD|Participants will receive all six blind-coded samples, in the order E, F, A, B, C, D. There will be a minimum of 7 days washout between samples.
33414763|NCT05353712|Experimental|Group X: DEFABC|Participants will receive all six blind-coded samples, in the order D, E, F, A, B, C. There will be a minimum of 7 days washout between samples.
33414764|NCT05353712|Experimental|Group Y: CDEFAB|Participants will receive all six blind-coded samples, in the order C, D, E, F, A, B. There will be a minimum of 7 days washout between samples.
33414765|NCT05353712|Experimental|Group Z: BCDEFA|Participants will receive all six blind-coded samples, in the order B, C, D, E, F, A. There will be a minimum of 7 days washout between samples.
33414766|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
33002033|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
33002034|NCT01648465|Experimental|Everolimus|
33002035|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
33002036|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
33002037|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
33002038|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
33002039|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
33002040|NCT01648816||control|caucasian mothers without depression
33002041|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
33002042|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
33002043|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
33002044|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
33002045|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
33002046|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
33002047|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
33002048|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
33002049|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
33002050|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
33002051|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
33002052|NCT01650012|Placebo Comparator|Placebo|Matching placebo
33414767|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
33417405|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
33002053|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
33002054|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
33002055|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
33002056|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
33002057|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
33002058|NCT01650129|Experimental|BIAsp|
33002059|NCT01650129|Experimental|BHI|
33002060|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
33002061|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
33002062|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
33002063|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
33002064|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
33002065|NCT01650168||NOMAC-E2|New users of NOMAC-E2
33002066|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
33002067|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
33002068|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
33002069|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
33002070|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
33002071|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
33002072|NCT01650220||Veterans with a history of PTSD|
33002073|NCT01650220||Veterans without a history of PTSD|
33002074|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
33002075|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
33002076|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
33002077|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
33002078|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
33002079|NCT01650337|No Intervention|Usual primary care|
33002080|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
33002081|NCT01650363|Placebo Comparator|homeopathic placebo medication|
33002082|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
33002083|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
33002084|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
33002085|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
33002086|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
33002087|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
33002088|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
33002089|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
33325136|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
33325137|NCT04593862|Experimental|Exercise Group|The exercise intervention will consist of 36 high-volume high-intensity interval sessions over a 12-week period. The exercise frequency will be three times per week during the 6 weeks of intravesical therapy and the 6 weeks of recovery (total 12 weeks) prior to a surveillance cystoscopy.
33325138|NCT04593862|No Intervention|Usual Care:|Patients randomized to the control group will be asked not to initiate any exercise program or to increase their exercise level from baseline during the 12-week study. After the post-intervention assessments and 3-month cystoscopy, patients in the control group will be offered a 4-week supervised exercise program at the Behavioural Medicine Fitness Centre, University of Alberta.
33325139|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
33325140|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
33325141|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
33417406|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
33002090|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
33002091|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
33002092|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
33002093|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
33002094|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
33002095|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
33002096|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
33002097|NCT01650480|Experimental|Intervention group|
33002098|NCT01650480|No Intervention|Control group|
33002099|NCT01650493||Group A|Clinpro 5000
33002100|NCT01650493||Group B|MI Paste Plus
33002101|NCT01650493||Group C|Toms of Maine
33002102|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
33002103|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
33002104|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
33002105|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
33002106|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
33002107|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
33002108|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
33002109|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
33002110|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
33002111|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
33002112|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
33002113|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
33002114|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
33002115|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
33002116|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
33002117|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
33002118|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
33002119|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
33002120|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
33002121|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
33002122|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
33002123|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
33002124|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
33002125|NCT01650818|Experimental|Aerobic exercise training|
33002126|NCT01650818|Active Comparator|Standard physical therapy|
33325142|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
33002127|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
33002128|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
33325143|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
33325144|NCT05413486||SCH, OB|People with obesity (BMI > 30 kg/m2) and a medical diagnosis of schizophrenia spectrum disorder.
33002129|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
33002130|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
33002131|NCT01650896|No Intervention|General Medicine|
33002132|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
33002133|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
33002134|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
33002135|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
33002136|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
33002137|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
33002138|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
33002139|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
33002140|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
33002141|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
33002142|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
33002143|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
33002144|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
33002145|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
33002146|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
33002147|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
33002148|NCT01651091|Experimental|Meditation Awareness Training|
33002149|NCT01651091|Active Comparator|Treatment as Usual|
33002150|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
33002151|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
33002152|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
33002153|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
33002154|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
33325145|NCT05413486||BD, OB|People with obesity (BMI > 30 kg/m2) and a medical diagnosis of bipolar spectrum disorder.
33325146|NCT05413486||Control, OB|Control group with obesity. People with obesity (BMI > 30 kg/m2) without psychiatric disease or sleep disorders.
33325147|NCT05413486||Control, non-OB|Normal weight (BMI 18.5 - 25kg/m2) control group without psychiatric disease.
33002155|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
33002156|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
33002157|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
33002158|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
33002159|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
33002160|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
33002161|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
33002162|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
33002163|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
33002164|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
33002165|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
33002166|NCT01651234|Experimental|Active|
33002167|NCT01651234|Placebo Comparator|Placebo|
33325148|NCT01236222|No Intervention|Control group|
33325149|NCT01236222|Experimental|Cycling to school|
33325150|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
33325151|NCT01146132|Other|conventional + wine|conventional Diet with red wine
33325152|NCT01146132|Other|conventional|conventional diet without wine
33325153|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
33002168|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
33002169|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
33002170|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
33002171|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
33325156|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
33002172|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
33002173|NCT01651273|Placebo Comparator|Arm 4: Placebo|
33002174|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
33002175|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
33002176|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
33002177|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
33002178|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
33002179|NCT01651364|Placebo Comparator|Placebo|
33002180|NCT01651364|Active Comparator|Cabergoline|
33002181|NCT01651377|Placebo Comparator|Placebo|
33002182|NCT01651377|Active Comparator|Pramipexole|
33002183|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
33002184|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
33002185|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
33002186|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
33002187|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
33002188|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
33002189|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
33002190|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
33002191|NCT01651468|Experimental|HEMOFIX|3 grams a day
33002192|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
33002193|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
33002194|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
33002195|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
33002196|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
33325157|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
33325158|NCT04909242|Experimental|single oral dose of DZD9008|single dose of DZD9008 (50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
33002197|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
33002198|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
33002199|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
33002200|NCT01651520|Other|healthy volunteers|healthy volunteers
33002201|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
33002202|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
33002203|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
33002204|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
33002205|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
33002206|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
33002207|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
33002208|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
33002209|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
33002210|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
33002211|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
33002212|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
33002213|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
33002214|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
33002215|NCT01651663|Experimental|Arbidol (Umifenovir)|
33002216|NCT01651663|Placebo Comparator|placebo|
33002217|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
33002218|NCT01651663|Placebo Comparator|placebo prophylaxis|
33002219|NCT01651676|Experimental|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
33002220|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
33002221|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
33002222|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
33002223|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
33002224|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
33002225|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
33002226|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
33002227|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
33002228|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
33002229|NCT01651754|Other|Seasonal influenza vaccination|
33002230|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
33002231|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
33002232|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
33002233|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
33002234|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
33002235|NCT01651832|No Intervention|usual care|routine care and case management
33002236|NCT01651832|Experimental|SCAN-Intervention|
33002237|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
33002238|NCT01651858|Experimental|Nurigra Chewable tablet|
33002239|NCT01651858|Active Comparator|Viagra|
33002240|NCT01651884|Experimental|High-Definition tDCS|
33002241|NCT01651884|Experimental|Sponge tDCS|
33002242|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
33002243|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
33002244|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
33002245|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
33002246|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
33002247|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
33002248|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
33002249|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
33002250|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
33002251|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
33002252|NCT01651975|Other|Thickenup|
33002253|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
33002254|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
33002255|NCT01652014|Experimental|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
33002256|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
33002257|NCT01652027||Previously Untreated Patients with Hemophilia A|
33002258|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
33002259|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
33002260|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
33002261|NCT01652079|Experimental|Treatment Arm|CRLX101
33002262|NCT01652105|Experimental|Diet|New developed diet
33002263|NCT01652105|Active Comparator|Prodimed|Standard VLCD
33002264|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
33002265|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
33002266|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
33002267|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
33002268|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
33002269|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
33002270|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
33002271|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
33002272|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
33002273|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
33002274|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
33002275|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
33002276|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
33002277|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
33002278|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
33002279|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
33002280|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
33002281|NCT01652274||Mother|study objectives to Mother only
33002282|NCT01652274||Father|study objectives to Father only
33002283|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
33002284|NCT01652300|Other|control|received no education
33002285|NCT01652313|Experimental|Rasagiline|
33002286|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
33002287|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
33002288|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
33002289|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
33002290|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
33002291|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
33002292|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
33002293|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
33002294|NCT01652365|No Intervention|Control|
33002295|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
33002296|NCT01652378||Control Participants|healthy control volunteers
33002297|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
33002298|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
33002299|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
33002300|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
33002301|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
33002302|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
33002303|NCT01652430||PTSD cohort|
33002304|NCT01652430||No PTSD cohort|
33002305|NCT01652456|Experimental|Group A|
33002306|NCT01652456|No Intervention|Group B|
33002307|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
33002308|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
33002309|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
33002310|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
33002311|NCT01652534|Placebo Comparator|placebo|Sugar Pill
33002312|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
33105426|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33002313|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
33002314|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
33002315|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
33002316|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
33002317|NCT01652599|Experimental|Eltrombopag and dexamethasone|
33002318|NCT01652612|No Intervention|Control|zero PEEP
33002319|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
33002320|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
33002321|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
33002322|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
33002323|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
33002324|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
33002325|NCT01652651|Experimental|Psychological Intervention|
33002326|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
33002327|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
33002328|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
33002329|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
33002330|NCT01652742|Experimental|BI 135585 XX|one single dose
33002331|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
33002332|NCT01652755||non-AKI group|patients without AKI during study period
33002333|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
33002334|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
33002335|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
33002336|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
33002337|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
33002338|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
33002339|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
33002340|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
33002341|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
33002342|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
33002343|NCT01652859|Active Comparator|AmBisome|RLD
33002344|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
33002345|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
33002346|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
33002347|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
33002348|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
33002349|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
33002350|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
33002351|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
33002352|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
33002353|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
33002354|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
33002355|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
33002356|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
33002357|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
33002358|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
33002359|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
33002360|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
33002361|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
33002362|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
33002363|NCT01653002||Lung cancer with lymph node involvement|
33002364|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
33002365|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
33002366|NCT01653041|Experimental|Everolimus|Single arm
33002367|NCT01653054|Experimental|IBD patients ON Immunosuppression|
33002368|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
33002369|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
33002370|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
33002371|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
33002372|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
33002373|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
33002374|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
33002375|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
33002376|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
33002377|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
33002378|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
33002379|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
33002380|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
33002381|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
33002382|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
33002383|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
33002384|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
33002385|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
33002386|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
33002387|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
33002388|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
33002389|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
33002390|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
33105427|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
33105428|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
33414768|NCT03916549|Experimental|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
33414769|NCT05353634||Infected patients with mNGS|If the patient is suspected of infection, mNGS is performed for testing.
33414770|NCT05353634||Infected patients without mNGS|The patient is suspected of being infected, and no mNGS test was performed, only other tests were performed.
33002391|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
33002392|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
33002393|NCT01653314|Experimental|Megavec|
33002394|NCT01653314|Active Comparator|Glivec|
33002395|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
33002396|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
33002397|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
33002398|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
33002399|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
33002400|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
33002401|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
33002402|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
33002403|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
33002404|NCT01653457|Placebo Comparator|Placebo|
33002405|NCT01653457|Active Comparator|Memantine|
33002406|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
33002407|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
33002408|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
33002409|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
33002410|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
33002411|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
33002412|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
33002413|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
33002414|NCT01653522|Experimental|Triptan|
33002415|NCT01653522|Experimental|Doxycycline|
33002416|NCT01653522|Experimental|Triptan + Doxycycline|
33002417|NCT01653522|No Intervention|Control|
33325159|NCT04909242|Placebo Comparator|single oral dose of placebo|single dose of placebo (matching placebo, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
33325160|NCT04909242|Experimental|single oral dose of DZD9008 (300 mg, tablet)|
33325161|NCT04909242|Experimental|single oral dose of DZD9008 (100 mg, tablet or suspension)|
33325162|NCT04545814|Experimental|Stereotactic Radiosurgery|SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.
33325163|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
33002418|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
33002419|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
33002420|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
33002421|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
33002422|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
33002423|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
33002424|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
33002425|NCT01653626|Experimental|package|
33002426|NCT01653639|Experimental|Arm 1|
33002427|NCT01653639|Experimental|Arm 2|
33002428|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
33002429|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
33002430|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
33002431|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
33002432|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
33002433|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
33002434|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
33002435|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
33002436|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
33002437|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
33002438|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
33002439|NCT01653756|Active Comparator|IPI-145|Capsules
33002440|NCT01653756|Placebo Comparator|Placebo|Capsules
33002441|NCT01653795|Active Comparator|LMA Unique|
33002442|NCT01653795|Active Comparator|LMA Supreme|
33002443|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
33002444|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
33002445|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
33002446|NCT01653834|Experimental|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
33002447|NCT01653860|Experimental|The Brøset anger management model|Group treatment
33002448|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
33002449|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
33002450|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
33325164|NCT05359276||Cohort 1|Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France
32739228|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position~Apply elastic bandages to both legs without tension.~Maintain supine position after injecting propofol.~After 3 minutes from propofol injection, remove elastic bandages~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
33002451|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
33002452|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
33002453|NCT01653938|No Intervention|control group|
33002454|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
33002455|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
33002456|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
33002457|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
33002458|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
33325165|NCT04540354|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
33002459|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
33002460|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
33002461|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
33002462|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
33002463|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
33002464|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
33002465|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
33002466|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
33002467|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
33002468|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
33002469|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
33002470|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
33002471|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
33002472|NCT01654120|Experimental|liraglutide plus insulin|Patients were randomized to receive liraglutide plus insulin (LIRA) for 12 months.
33002473|NCT01654120|Active Comparator|Insulin titration only|Patients were randomized to receive insulin only (control) for 6 months. The controls were then crossed over to receive liraglutide plus insulin for 6 months after the initial control period.
33325166|NCT04540354|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
33325167|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
33002474|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
33002475|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
33002476|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
33002477|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
33002478|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
33002479|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
33002480|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
33002481|NCT01654198||Psoriatic arthritis|
33002482|NCT01654211|Experimental|Part 1: iv danoprevir|
33002483|NCT01654211|Placebo Comparator|Part 1: placebo|
33002484|NCT01654211|Experimental|Part 2 A: iv danoprevir|
33002485|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
33002486|NCT01654211|Active Comparator|Part 2 C: ritonavir|
33002487|NCT01654211|Experimental|Part 3 D: iv danoprevir|
33002488|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
33002489|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
33002490|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
33002491|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
33002492|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
33002493|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
33002494|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
33002495|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
33002496|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
33002497|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
33002498|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
33002499|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
33002500|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
33002501|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
33002502|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
33002503|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
33002504|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
33002505|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
33002506|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
33002507|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
33002508|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
33002509|NCT01654484|Experimental|High Dose DE-117|Monotherapy
33002510|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
33002511|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
33002512|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
33002513|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
33002514|NCT01654484|Placebo Comparator|Placebo|Monotherapy
33002515|NCT01654497|Experimental|Dexanabinol|
33002516|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
33002517|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
33002518|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
33002519|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
33002520|NCT01654575|Experimental|Methotrexate|25mg/week orally
33002521|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
33002522|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
33002523|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
33002524|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
33002525|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
33002526|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
33002527|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
33002528|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
33002529|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
33002530|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
33002531|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
33002532|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
33002533|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
33002534|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
33417407|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC
33417408|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
33002535|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
33002536|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
33002537|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
33002538|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
33002539|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
33002540|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
33002541|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
33002542|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
33002543|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
33002544|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
33002545|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
33002546|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
33002547|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
33002548|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
33002549|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
33002550|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
33002551|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
33002552|NCT01654926||Heart Failure patients|
33002553|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
33002554|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33002555|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
33002556|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
33002557|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
33002558|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
33002559|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
33002560|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
33002561|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
33002562|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
33002563|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
33002564|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
33002565|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
33002566|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
33002567|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
33002568|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
33002569|NCT01655095|Experimental|PEG and Prucalopride|
33002570|NCT01655095|Experimental|Picosalax and Prucalopride|
33002571|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
33002572|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
33105429|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
33417409|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
33417410|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
33002573|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
33002574|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
33002575|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
33002576|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
33002577|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
33002578|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
33002579|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
33002580|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
33002581|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
33002582|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
33002583|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
33002584|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
33002585|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
33002586|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
33002587|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
33002588|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
33002589|NCT01655251|No Intervention|Control|
33002590|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
33002591|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
33002592|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
33002593|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
33002594|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
33002595|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
33002596|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
33002597|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
33002598|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
33002599|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
33002600|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
33002601|NCT01655342||formocresol|
33002602|NCT01655355||Revison of the hip joint|
33002603|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
33002604|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
33002605|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
33002606|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
33002607|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
33002608|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
33002609|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
33417411|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
33002610|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
33002611|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
33002612|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
33002613|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
33002614|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
33002615|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
33002616|NCT01655472|Active Comparator|healthy parents|
33002617|NCT01655472|Active Comparator|schizophrenic parents|
33002618|NCT01655485|Experimental|Patient teaching|ipad application for social script book
33002619|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
33002620|NCT01655511|Experimental|Period 2|480 mg arm
33002621|NCT01655511|Experimental|Period 3|TBD dose
33002622|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
33002623|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
33002624|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
33002625|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
33002626|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
33002627|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
33002628|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
33002629|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
33002630|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
33002631|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
33002632|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
33002633|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
33002634|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
33002635|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
33002636|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
33002637|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
33002638|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
33002639|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
33002640|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
33002641|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
33105430|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33002642|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
33002643|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
33002644|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
33002645|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
33002646|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
33002647|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
33002648|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
33002649|NCT01655771|Experimental|Younger|TD-1211 Dose 2
33002650|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
33002651|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
33002652|NCT01655810|Active Comparator|Vitamin D 4000 IU|PO daily
33002653|NCT01655810|Active Comparator|Vitamin D 600 IU|PO daily
33002654|NCT01655849|Experimental|Z160|375mg BID
33002655|NCT01655849|Placebo Comparator|placebo|matching placebo control
33002656|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
33002657|NCT01655875|Experimental|bone marrow transplant|
33002658|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
33002659|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
33002660|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
33002661|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
33002662|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
33002663|NCT01655940||Cardiac bypass patients|
33002664|NCT01655953|Experimental|Campaign 1|
33002665|NCT01655953|Experimental|Campaign 2|
33002666|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
33002667|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
33002668|NCT01655979|Experimental|MEP-1|
33002669|NCT01655979|Experimental|MEP-2|
33002670|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
33002671|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
33002672|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
33002673|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
33002674|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
33002675|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
33002676|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
33002677|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
33002678|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
33002679|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
33002680|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
33002681|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
33002682|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
33002683|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
33002684|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
33002685|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
33002686|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
33002687|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
33002688|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
33002689|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
33325168|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
33325169|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
33002690|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
33002691|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
33002692|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
33002693|NCT01656070|Placebo Comparator|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
33002694|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
33002695|NCT01656083||Non-SM intervention group: varenicline|varenicline only
33002696|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
33002697|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
33002698|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
33002699|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
33002700|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
33002701|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):~Day 0: 20mg IV ≤2h prior to surgery~Day 4: 20mg IV~Prednisolone:~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~Day 1: 125mg IV~Day 2 - 14: 20mg/day oral~Week 3 - 4: 15mg/day oral~Week 5 - 8: 10mg/day oral~Week 9 - 12: 5mg/day oral~Week 13 - 14: 2.5mg/day oral~Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~Day -1 - 14: 2g/day oral~Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~Day -4 - 14: 3-12ng/ml~Week 3 - 12: 3-10ng/ml~Week 13 - 36: 3-8ng/ml~Week 37 - Study End: 3-6ng/ml"
33002702|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
33002703|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
33002704|NCT01656174||No Treatment|
33002705|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
33002706|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
33002707|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
33002708|NCT01656226|Other|Sunscreen SPF 50+|
33002709|NCT01656265|Experimental|ARQ 197|
33002710|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
33002711|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
33002712|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
33002713|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
33002714|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
33002715|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
33002716|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
33002717|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
33002718|NCT01656356|Placebo Comparator|Placebo|
33105431|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
33325170|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
33325171|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
33325172|NCT01239810||Control group|Receiving no treatment
33325173|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
33325174|NCT01568086||AFFITOPE AD03 with adjuvant|
33325175|NCT01568086||AFFITOPE AD03 without adjuvant|
33325176|NCT01239888|Active Comparator|Oxytocin|
33325177|NCT01239888|Active Comparator|Oxytocin and Tibolone|
33325178|NCT01239888|Placebo Comparator|Placebo|
33325179|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
33325180|NCT01318486|Experimental|Heparin free dialysis with Evodial|
33325181|NCT04226586|Active Comparator|Treatment Group|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
33325182|NCT04226586|Placebo Comparator|Placebo|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
33325183|NCT03663790|No Intervention|Control|No intervention
33325184|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
33002719|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
33002720|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
33002721|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
33002722|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
33002723|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
33002724|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
33002725|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
33002726|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
33002727|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
33002728|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
33002729|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
33002730|NCT01656525|Experimental|1|
33002731|NCT01656525|Experimental|2|
33002732|NCT01656525|Experimental|3|
33002733|NCT01656525|Experimental|4|
33002734|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
33002735|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
33002736|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
33002737|NCT01656616||EMS cyanide exposure patients|
33002738|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
33002739|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
33002740|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
33002741|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
33002742|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
33325185|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
33417412|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
33414771|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
33414772|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
32907993|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
32907994|NCT01614743|Experimental|IncobotulinumtoxinA|
32907995|NCT01614743|Placebo Comparator|Placebo|
32907996|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
32907997|NCT01701011|No Intervention|Routine care control|Questionnaires
32907998|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
32907999|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
32908000|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
32908001|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
32908002|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
32908003|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
32908004|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
32908005|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
32908006|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
32908007|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
32908008|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
32908009|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
32908010|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
32908011|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
32908012|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
32908013|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
32908014|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
32908015|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
32908016|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
32908017|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
32908018|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
32908019|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
32908020|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
32908021|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
32908022|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
32908023|NCT01703663|No Intervention|control|
32908030|NCT04251026|Experimental|Cohort A|Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II
32908031|NCT04251026|Experimental|Cohort B|A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.
32908032|NCT04251026|Experimental|Cohort C|A consistent dose level in participants with neuronopathic MPS II
32908033|NCT04251026|Experimental|Cohort D|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
32908034|NCT04251026|Experimental|Cohort E|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
32908035|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
33002743|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
33002744|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
33002745|NCT01656655||PTSD group|Patients with PTSD
33002746|NCT01656655||Control Group|non PTSD group
33002747|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
33002748|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
33002749|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
33002750|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
33002751|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
33002752|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
33002753|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
33002754|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
33002755|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
33002756|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
33002757|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
33002758|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
33002759|NCT01656798|Experimental|fasted condition|
33002760|NCT01656798|Experimental|fec condition|
33002761|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
33002762|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
33002763|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
33002764|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
33002765|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
33002766|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
33002767|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
33002768|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
33002769|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
33002770|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
33002771|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
33325186|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
33325187|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
33325188|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
33002772|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
33002773|NCT01656915||Healthy men|Healthy male subjects with normal weight
33002774|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
33002775|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
33414773|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
33414774|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
33002776|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
33002777|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
33414775|NCT03564548|Experimental|PPP001|Inhaled cannabinoids (PPP001)
33002778|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
33002779|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
33002780|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
33002781|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
33002782|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
33002783|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
33002784|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
33002785|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
33002786|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
33002787|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
33002788|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
33002789|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
33002790|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
33002791|NCT01657071|Experimental|Group A|
33002792|NCT01657071|Active Comparator|Group B|
33002793|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
33002794|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
33002795|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
33002796|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
33002797|NCT01657097|Placebo Comparator|Placebo|Placebo
33002798|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
33002799|NCT01657123|Placebo Comparator|placebo|
33002800|NCT01657123|Experimental|hydrocortisone stress dosage|
33002801|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
33002802|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
33002803|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
33002804|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
33002805|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
33002806|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
33002807|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
33002808|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
33002809|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
33002810|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
33002811|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
33002812|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
33325189|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
33325190|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
33002813|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
33002814|NCT01657227|Other|Control|Patients receive usual care
33002815|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
33325191|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
33325192|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
33325193|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
33002816|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
33002817|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
33002818|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
33002819|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
33002820|NCT01657357||PAO, osteoarhritis, THA|
33002821|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
33002822|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
33002823|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
33002824|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
33002825|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
33002826|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
33002827|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
33002828|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
33002829|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
33002830|NCT01657448|Experimental|Methenamine, Methylthioninium|
33002831|NCT01657448|Active Comparator|Phenazopyridine|
33002832|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
33002833|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
33002834|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
33002835|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
33002836|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
33002837|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
33002838|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
33002839|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
33002840|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
33002841|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
33002842|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
33002843|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
33002844|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
33002845|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
33002846|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
33002847|NCT01657565||open appendectomy|
33002848|NCT01657565||laparscopic appendectomy|
33002849|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
33002850|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
33002851|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
33002852|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
33002853|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
33002854|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
33002855|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
33002856|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
33002857|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
33002858|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
33002859|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
33002860|NCT01657708|Other|Shared Desicion Making Model|
33002861|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
33002862|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
33002863|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
33002864|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
33325194|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
33325195|NCT03436108||PCOS group|patients who have PCOS
33325196|NCT03436108||control group|patients who donnot have PCOS
33325197|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
33325198|NCT02969824|No Intervention|Usual Care Group|Following a brief period of physical and cognitive rest (typically1-7 days, depending on symptom severity and timing of spontaneous symptom abatement), the physician advises participants to increase their activity levels gradually with minimal head movement (predominantly involving a stationary bike) and progressively increase levels of exertion while remaining under the threshold of symptom exacerbation. Subsequently, exercise progressed to include a progression of head movements, visual and cognitive burdens, sport-specific activities, and heavy resistance, in that order, all below the symptom exacerbation threshold.
33414776|NCT03564548|Active Comparator|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
33002865|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
33002866|NCT01657747|No Intervention|Not applicable (imaging study)|
33002867|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
33002868|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
33002869|NCT01657786|Experimental|Ondansetron administration group|
33002870|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
33002871|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
33414777|NCT03159455|Experimental|BI 1467335|
33414778|NCT03159455|Placebo Comparator|Placebo|
33414779|NCT05353010|Experimental|Period 1: A; Period 2: B and C|A: Oral Administration of Tacrolimus 5mg once / B: Oral Administration of IN-A001(Tegoprazan) 50mg QD for 7 days / C: Oral Administration of IN-A001(Tegoprazan) 50mg + Tacrolimus 5mg once
33414780|NCT05352854|Experimental|Health control|emmetropia/low myopia (equivalent spherical lens > -3.00d, astigmatism ≤ 1.5d), best corrected visual acuity ≥1.0
33414781|NCT05352854|Experimental|High myopia|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm
33002872|NCT01657812|Placebo Comparator|control|Drug: normalsaline
33002873|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
33002874|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
33002875|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
33002876|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
33002877|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
33002878|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
33002879|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
33002880|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
33002881|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
33002882|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
33002883|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
33002884|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
33002885|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
33002886|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
33002887|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
33002888|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
33002889|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
33002890|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
33002891|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
33002892|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
33002893|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC<4×109 /L at d12-d14 );
33002894|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
33002895|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
33002896|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
33002897|NCT01657981|Experimental|Treatment arm 1|
33002898|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
33002899|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
33002900|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
33002901|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
33002902|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
33002903|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
33002904|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
33002905|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
33002906|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
33002907|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
33002908|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
33414782|NCT05352854|Experimental|Primary open angle glaucoma|emmetropia/low myopia (equivalent spherical lens > -3.00d, astigmatism ≤ 1.5d), diagnosed as POAG
33414783|NCT05352854|Experimental|HM-POAG|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm，diagnosed as POAG
33414784|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
33002909|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
33002910|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
33414785|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
33414786|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
33414787|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
33414788|NCT05184647||Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie
33414789|NCT05184647||Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie
33414790|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
33414791|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
33414792|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
33414793|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
33002911|NCT01658176|Active Comparator|Exemestane|Exemestane alone
33002912|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
33414794|NCT05708300||chronic rhinosinusitis with nasal polyps with bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps with bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
33414795|NCT05708300||chronic rhinosinusitis with nasal polyps without bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps without bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
33414796|NCT05708378|Experimental|Experimental Group|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Isometric Strengthening Exercises of calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between."
33002913|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
33002914|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
33002915|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
33002916|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
33002917|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
33002918|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
33002919|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
33002920|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
33002921|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
33002922|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
33002923|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33002924|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
33002925|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib~Drug: Lipo-Dox"
32908036|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
32908037|NCT04154072|Active Comparator|NLY01 (2.5 mg)|NLY01 2.5 mg injection
32908038|NCT04154072|Active Comparator|NLY01 (5.0 mg)|NLY01 5.0 mg injection
32908039|NCT04154072|Placebo Comparator|Vehicle|inactive drug, injection
32908040|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
32908041|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
32908042|NCT04136132|Experimental|Biological collection|"Biological collection~For all the patients include in the study :~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
32908043|NCT04111172|Experimental|Arm A (low dose)|Patients receive low dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
32908044|NCT04111172|Experimental|Arm B (medium dose)|Patients receive medium dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
32908045|NCT04111172|Experimental|Arm C (high dose)|Patients receive high dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
32908046|NCT04359524|Active Comparator|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
32908047|NCT04359524|Placebo Comparator|Control|Received placebo (oil capsules).
32908048|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
32908049|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
32908050|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
32908051|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
32908052|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
32908053|NCT04359290|Experimental|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
32908054|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
32908055|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
32908056|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
32908057|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
32908058|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
32908059|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
32908060|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
32908061|NCT03875144|Experimental|association of PIPAC and systemic chemotherapy|4 PIPAC of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks alternating with standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
32908062|NCT03875144|Active Comparator|systemic chemotherapy alone|6 cycles of Cisplatin 75mg/m² + Pemetrexed 500mg/m²
32908063|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
32908064|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
32908065|NCT04358978|Active Comparator|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
32908066|NCT04358978|Active Comparator|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
32908067|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
32908068|NCT04358666|Active Comparator|surgery and focal radiosurgery of the surgical site|
32908069|NCT04358666|Active Comparator|hypofractionned radiosurgery|
32908070|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
32908071|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
32908072|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
32908073|NCT04358822|Active Comparator|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
32908074|NCT04358822|Active Comparator|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
32908075|NCT04354844||Cyanotic and acyanotic group|questinnaire
32908076|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
33002926|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
33002927|NCT01658371||efavirenz|HIV patients on efavirenz
33002928|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
33002929|NCT01658397|Experimental|Fasting|Ten day fast
33002930|NCT01658410|Active Comparator|BQ-123|
33002931|NCT01658410|Placebo Comparator|NaCl|
33002932|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
33002933|NCT01658449|Experimental|group A|
33002934|NCT01658449|Experimental|group B|
33002935|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
33414797|NCT05708378|Other|Control Group|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Strengthening Exercises calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk balance exercise (flexion, extension of lower and upper trunk, rotation of lower and upper trunk, forward and lateral reach) on plain surface."
33414798|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
33002936|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
33002937|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
33002938|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
33002939|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
33002940|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
33002941|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
33002942|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
33002943|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
33002944|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
33002945|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
33002946|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
33002947|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
33002948|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
33002949|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
33002950|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
33002951|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
33002952|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
33414799|NCT05340452|Experimental|Test Group|Single oral dose of 20 ml of Test (Klaribact 125mg/5ml Suspension) will be given with the aid of graduated cup.
33002953|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
33002954|NCT01658670|Active Comparator|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
33002955|NCT01658670|Experimental|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
33002956|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
33002957|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
33002958|NCT01658709||Ankle Injured|Volunteers with an ankle injury
33002959|NCT01658709||Healthy|Healthy Volunteers
33002960|NCT01658722||Observational|Long term follow-up
33002961|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
33002962|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
33414800|NCT05340452|Active Comparator|Reference Group|Single oral dose of 20 ml of Reference (Klaricid 125mg/5ml Suspension) will be given to volunteers with the aid of graduated cup.
33414801|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
33414802|NCT02835092|Active Comparator|Self-directed Control|
33414803|NCT02835092|Experimental|Take Shape For Life Program|
33414804|NCT02835092|Experimental|Medifast Direct Program|
32908077|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
32908078|NCT04355078|Experimental|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
32908079|NCT04355078|Experimental|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion & Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
32908080|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
32908081|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
32908082|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
32908083|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
32908084|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
32908085|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.~CPPopt information is recorded but hidden for the treating clinicians."
32908086|NCT02981810|Active Comparator|control|tonsillectomy
32908087|NCT02981810|Experimental|coblation|coblation of the tonsills
32908088|NCT04358354|Experimental|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
32908089|NCT04358354|Active Comparator|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
32908090|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
32908091|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
32908092|NCT03516968|Experimental|Monthly bolus arm|
32908093|NCT03516968|Active Comparator|Daily arm|
32908094|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
32908095|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
32908096|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
32908097|NCT04355156|Experimental|Axitinib|small molecule multi-kinase inhibitor
32908098|NCT04355156|Placebo Comparator|Placebo|
32908099|NCT04358510||COViage|Machine learning intervention
32908100|NCT03320018|Experimental|Hydrogen/Minocycline|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, TID for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
32908101|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
32908102|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
32908103|NCT03318380|Experimental|Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)|Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.
32908104|NCT03199274|Experimental|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.
33002963|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
33002964|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
33002965|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
33002966|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
33002967|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
33002968|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
33002969|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
33002970|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
33002971|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
33002972|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
33002973|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
33002974|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
33002975|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
33002976|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
33002977|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
33002978|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
33002979|NCT01658891|Experimental|CHF 1535 50/6 µg|
33002980|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
33002981|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
33002982|NCT01658956|No Intervention|No intervention|
33002983|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
33002984|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
33002985|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
33002986|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
33002987|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
33002988|NCT01659060|Experimental|Dark chocolate|
33002989|NCT01659060|Placebo Comparator|Placebo chocolate|
33002990|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
33002991|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
33002992|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
33002993|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
33002994|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
33002995|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
33002996|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
33002997|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
33002998|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
33002999|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
33003000|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
33003001|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
33003002|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
33003003|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
33003004|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
33003005|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
33003006|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
33003007|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
33003008|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
33003009|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
33003010|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
33003011|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
33003012|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
33003013|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
33003014|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
33003015|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
32908105|NCT03199274|Active Comparator|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
32908106|NCT04354610|Other|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:~Clinical examination~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
32908107|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
32908108|NCT04354376||Telmisartan|Exposure group
32908109|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
32908110|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
32908111|NCT03032432|Experimental|Dynamic elastic garment and injection|
32908112|NCT03032432|Active Comparator|Corticosteroid injection|
32908113|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
32908114|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
32908115|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
32908116|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMDD group only) on acoustic startle response across the menstrual cycle. Sertraline 50 mg tablets are administered daily from ovulation until menses onset.
32908117|NCT02777372|No Intervention|Control|No intervention.
32908118|NCT04354142|Experimental|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
32908119|NCT04354142|No Intervention|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
32908120|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
32908121|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
32908122|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
32908123|NCT04354298|Experimental|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
32908124|NCT04354298|Experimental|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
32908125|NCT04354298|No Intervention|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
32908126|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
32908127|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
32908128|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
32908129|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
32908130|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
32908131|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
32908132|NCT05620082||Malnourished older adults in hospital|Participants will be given oral nutritional supplementation twice per day for 4 days, in addition to normal meals, in a crossover design. The products will be offered in-between breakfast and lunch, and after dinner. Products will include traditional sip-feeds (an anonymous ready-made drink supplement, 125g, 306kcal, 18.3g protein) and a new fortified porridge (Adams Vital Nutrition Ltd. High Protein Oats, 157g, 230kcal, 15g protein).
32908133|NCT01623323|Other|Fluticasone|
32908134|NCT05620004|Experimental|Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate plus Bifidobacterium Bifidum Oral Product daily
32908135|NCT05620004|No Intervention|without Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate without Bifidobacterium Bifidum Oral Product daily
32908136|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
32908137|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
32908138|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
32908139|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
32908140|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
32908141|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
32908142|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
32908143|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
32908144|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
33003016|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
33003017|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
33003018|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
33003019|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
33003020|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
33003021|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
33003022|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
33003023|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
33003024|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
33003025|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
33003026|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
33003027|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
33003028|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
33003029|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
33003030|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
33003031|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
33003032|NCT01659411||Adult CHD Patients|observational
33003033|NCT01659424|Other|Single Arm|This is a single arm study.
33003034|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
33003035|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
33003036|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
33003037|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
33003038|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
33003039|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
33003040|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
33003041|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
33003042|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
33003043|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
33003044|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
33003045|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
33003046|NCT01659580|Experimental|T89 high dose|T89 225mg bid
33003047|NCT01659580|Experimental|T89 low dose|T89 150mg bid
33003048|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
33325199|NCT02969824|Experimental|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
33325200|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
33003049|NCT01659580|Placebo Comparator|Placebo|225mg bid
33003050|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
33003051|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
33003052|NCT01659619|Experimental|erythromycin|
33325201|NCT03633916|Active Comparator|Control|School-level sensitization activities only
33417413|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
33417414|NCT02080442||Chronic Obstructive Pulmonary Disease|
33003053|NCT01659619|No Intervention|saline|
33003054|NCT01659645|Experimental|FACBC|
33003055|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
33003056|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
33003057|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
33417415|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
33417416|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
33417417|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
33003058|NCT01659697||Intensive Lifestyle counseling|
33003059|NCT01659697||usual lifestyle counseling|
33417418|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
33003060|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
33003061|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
33003062|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
33003063|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
33003064|NCT01659762|Experimental|autologous mesenchymal stromal cells|
33003065|NCT01659775|Experimental|Sancuso patch|
33003066|NCT01659775|Active Comparator|Zofran|
33003067|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
33003068|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
33003069|NCT01659814||Individuals with Major Depressive Disorder|
33003070|NCT01659814||Healthy Control Individuals|
33003071|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
33003072|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
33003073|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
33003074|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
33003075|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
33003076|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
33003077|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
33003078|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
33003079|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
33003080|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
33003081|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
33003082|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
33003083|NCT01659918|Active Comparator|Singulair|10 mg Tablet
33003084|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
33003085|NCT01659931|Active Comparator|Singulair|10 mg Tablet
33003086|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
33003087|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
33003088|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
33003089|NCT01659970||Cohort|
33003090|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
33003091|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
33003092|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
33003093|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
33003094|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
33325202|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
33003095|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
33003096|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
33003097|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
33003098|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
33003099|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
33003100|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
33003101|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
33325203|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
33325204|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
33417419|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
33003102|NCT01660126|Placebo Comparator|Placebo|Matched placebo
33003103|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
33003104|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
33003105|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
33003106|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
33003107|NCT01660165||Observational|Pregnant women
33003108|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
33003109|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
33003110|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
33003111|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
33003112|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
33003113|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
33003114|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
33003115|NCT01660308||Tumor induced osteomalcia|
33003116|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
33003117|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
33003118|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
33003119|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
33003120|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
33003121|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
33003122|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
33003123|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
33003124|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
33003125|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
33003126|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
33414805|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
33414806|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
33003127|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
33003128|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
33003129|NCT01660464|Experimental|ADHD-Team|Intervention
33003130|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
33003131|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
33003132|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
33414807|NCT03145207|Other|name brand patch|name brand lidocaine patch
33414808|NCT03145207|Other|generic patch|generic lidocaine patch
33414809|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
33414810|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
33414811|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
33414812|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
33414813|NCT03145207|Other|both patches|brand name and generic lidocaine patch
33414814|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
33414815|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
33414816|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
33414817|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
33414818|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
33414819|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided~transmitting the results to the Smart Care Server via Smartphone~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
33414820|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided~recording in a self diary of body weight and the number of steps"
33414821|NCT01344889||Cohort|
33414822|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
33414823|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
33414824|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
33003133|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
33003134|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
33003135|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
33003136|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
33003137|NCT01660516||Tea|Black tea ingestion
33414825|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
33417420|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
33417421|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
33417422|NCT02080520|Placebo Comparator|Placebo|Oral placebo matched nattokinase daily
33417423|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
33003138|NCT01660529|Experimental|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
33003139|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
33003140|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
33003141|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
33003142|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
33003143|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
33003144|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
33105432|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
33003145|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
33003146|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
33003147|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
33003148|NCT01660646|No Intervention|control|
33003149|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
33003150|NCT01660659|No Intervention|standard cooking|standard way of cooking
33003151|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
33003152|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
33003153|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
33003154|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
33003155|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
33003156|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
33003157|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
33003158|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
33003159|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
33003160|NCT01660776||healthy volunteers|healthy volunteers
33003161|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
33003162|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
33003163|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
33003164|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
33003165|NCT01660841|Experimental|Arm 1|
33003166|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
33003167|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
33003168|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
33003169|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
33003170|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
33003171|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
33003172|NCT01660919|Placebo Comparator|placebo|placebo
33003173|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
33003174|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
33003175|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
33003176|NCT01660932|Placebo Comparator|placebo|placebo
33003177|NCT01660932|Active Comparator|omega 1|omega 1 gm
33003178|NCT01660932|Active Comparator|omega 2|omega 2 gm
33003179|NCT01660932|Active Comparator|omega 4|omega 4 gm
33003180|NCT01660945|Placebo Comparator|placebo|placebo
33003181|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
33003182|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
33003183|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
33003184|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
33003185|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Infant phase. Routine care - no early learning intervention"
33003186|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets~Caregivers receive early learning messaged delivered at home biweekly for one year"
33003187|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
33003188|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
33003189|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
33003190|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
33003191|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
33003192|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
33003193|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
33003194|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
33003195|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
33003196|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
33003197|NCT01661153||Cohort|
33414826|NCT05065099|Experimental|OnTRACK Intervention|"In the intervention condition, HCPs will be trained in the usage of the OnTRACK system.~They will be oriented to the educational videos, the symptom tracking, and the interpretation of the data that is provided by the patients and families, and the associated management strategies based on that data. Additionally, patients and parents will be trained to use the OnTRACK smartphone app on their phone from diagnosis to recovery (or 12 weeks if not recovered), including daily exertional monitoring symptom ratings and use of the educational videos. School personnel will be introduced to the OnTRACK app and the data summary features in the school dashboard and the associated supports that can be provided to the student based on that data."
33414827|NCT05065099|No Intervention|Treatment as Usual|"In the control condition, the HCP provides usual/standard care to the patients and parents as is the practice within the specific clinic. The OnTRACK app and the educational modules are not provided."
33003198|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
33003199|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
33414828|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
33414829|NCT05250661|Experimental|Aqueous propolis extract|The individuals in the intervention group were asked to gargle with 5 ml aqueous propolis extract four times a day after meals (morning, noon, evening and night before bedtime) and wait average one minute in the mouth and then spit, in addition to the standard practice of the clinic. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. The patients were followed for 21 days. The 21-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
33414830|NCT05250661|No Intervention|Control|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
33414831|NCT04176913|Experimental|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
33414832|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
33414833|NCT05050279|Placebo Comparator|Placebo|Delgocitinib placebo capsule
33414834|NCT05050279|Experimental|Active dose 1|Delgocitinib capsule (Dose 1)
33414835|NCT05050279|Experimental|Active dose 2|Delgocitinib capsule (Dose 2)
33414836|NCT05050279|Experimental|Active dose 3|Delgocitinib capsule (Dose 3)
33414837|NCT05050279|Experimental|Active dose 4|Delgocitinib capsule (Dose 4)
33414838|NCT04635787||Healthy Adults|Adults 18 years or older
33414839|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
33003200|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
33003201|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
33003202|NCT01661244|Experimental|Part A - Single dose escalation|
33003203|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
33003204|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
33003205|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
33105433|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
33414840|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
33414841|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
33414842|NCT04072861|Experimental|Cohort 1|9 mg RBT-9, single dose
33003206|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
33003207|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
33003208|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
33003209|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
33003210|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
33003211|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
33414843|NCT04072861|Experimental|Cohort 2, Healthy Volunteers|27 mg RBT-9, single dose
33414844|NCT04072861|Experimental|Cohort 3, Healthy Volunteers|90 mg RBT-9, single dose
33003212|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
33003213|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
33003214|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
33003215|NCT01661361||vancomycin cohort|
33003216|NCT01661374||Mechanically Ventilated|
33003217|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
33003218|NCT01661387||Plenadren|Modified release hydrocortisone
33003219|NCT01661387||Other Glucocorticoid Replacement Therapy|
33003220|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
33003221|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
33003222|NCT01661452||patients in UAB ER,|
33003223|NCT01661478||Emergency Department personnel|survey
33003224|NCT01661478||Department of Psychiatry personnel|survey
33003225|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
33003226|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
33003227|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
33003228|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
33003229|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
33003230|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
33003231|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
33003232|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
33003233|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
33003234|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
33003235|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
33003236|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
33003237|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
33414845|NCT04072861|Experimental|Cohort 4, Subjects with CKD Stage 3|27 mg RBT-9, single dose
33414846|NCT04072861|Experimental|Cohort 5, Subjects with CKD Stage 3|90 mg RBT-9, single dose
33414847|NCT04072861|Experimental|Cohort 6, Subjects with CKD Stage 4|27 mg RBT-9, single dose
33414848|NCT04072861|Experimental|Cohort 7, Subjects with CKD Stage 4|90 mg RBT-9, single dose
33414849|NCT05250349||Isolated HF Group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) and clinical symptoms (NYHA I-III).
33414850|NCT05250349||HF + CS group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) with NYHA I-III symptoms, who were diagnosed with flow limiting Carotid Stenosis on carotid Doppler ultrasound.
33003238|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
33003239|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
33414851|NCT05250349||Control group|A cohort of patients without Heart Failure or other significant cardiac pathology and without Carotid Stenosis (a paired propensity match will be performed).
33003240|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
33003241|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
33003242|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
33003243|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
33003244|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
33003245|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
33003246|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
33003247|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
33003248|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
33003249|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
33003250|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
33003251|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
33003252|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
33003253|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
33414852|NCT04044781|Experimental|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
33003254|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
33003255|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
33003256|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
33003257|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
33003258|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
33003259|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
33003260|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
33003261|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
33003262|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
33003263|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
33003264|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
33003265|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
33003266|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
33003267|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
33003268|NCT01661855|Active Comparator|Riluzole|
33003269|NCT01661855|Placebo Comparator|Placebo|
33003270|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
33003271|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
33003272|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
33003273|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
33003274|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
33003275|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
33003276|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
33003277|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
33003278|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
33003279|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
33003280|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
33003281|NCT01661998||Harms Study Group|
33003282|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
33003283|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
33003284|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
33003285|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
33003286|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
33003287|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
33003288|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
33003289|NCT01662128|Experimental|Xeloda|Xeloda
33003290|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
33003291|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
33003292|NCT01662167|Experimental|Multiple dose mtx|mtx
33003293|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
33003294|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
33003295|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
33003296|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
33003297|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
33003298|NCT01662193|Placebo Comparator|placebo|placebo
33003299|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
33003300|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
33003301|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
33003302|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
33003303|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
33003304|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
33417424|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
33003305|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
33003306|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
33003307|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
33003308|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
33003309|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
33003310|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
33003311|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
33003312|NCT01662284||Prostate|124I-NM404 in prostate cancer
33003313|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
33003314|NCT01662284||Gastric|124I-NM404 in gastric cancer
33003315|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
33003316|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
33003317|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
33003318|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
33417425|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
33417426|NCT01358045|Active Comparator|Solaraze|
33414853|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
33417427|NCT01358045|Active Comparator|Solaraze + Silkis|
33417428|NCT01358045|Active Comparator|Silkis|
33003319|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
33003320|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
33003321|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
33003322|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
33003323|NCT01662375||MIII|
33003324|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
33003325|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
33003326|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
33003327|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
33003328|NCT01662414|Active Comparator|HMS 90®|
33003329|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
33003330|NCT01662427||Questionniare|
33003331|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
33003332|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
33003333|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
33003334|NCT01662544|Experimental|HHFNC|Heated High Flow arm
33003335|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
33003336|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
33003337|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
33003338|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
33003339|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
33003340|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
33003341|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
33003342|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
33003343|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
33003344|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
33003345|NCT01662687|Experimental|Sancuso patch|
33003346|NCT01662687|Active Comparator|Kytril|
33003347|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
33003348|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
33003349|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
33105434|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33325205|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
33003350|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
33003351|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
33325206|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
33417429|NCT01358045|No Intervention|No treatment|
33417430|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
33417431|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
33417432|NCT01353989||>60 years|
33003352|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
33003353|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
33003354|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
33003355|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
33003356|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
33003357|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
33003358|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
33003359|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
33003360|NCT01662934|Sham Comparator|Sham|Using not functioning device
33003361|NCT01662934|Experimental|Experimental|Using functioning device
33003362|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
33003363|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
33003364|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
33003365|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
33003366|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
33003367|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
33003368|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
33003369|NCT01663038|Experimental|Copidogrel|
33003370|NCT01663051||Stent|Stent
33003371|NCT01663064|Experimental|Endovascular|Endovascular treatment
33003372|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
33325207|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.~Nicotine discrimination thresholds"
33325208|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.~Nicotine discrimination thresholds"
33325209|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
33325210|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
33325211|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
33325212|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
33003373|NCT01663090|Experimental|Nanoparticle enhanced MRI|
33003374|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
33003375|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
33003376|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
33003377|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)~Systemic Lupus Erythematosis~Juvenile Dermatomyositis~Scleroderma~Overlap Syndromes~Sjogren's syndrome~Sarcoidosis~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~Other rheumatic disease"
33003378|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
33003379|NCT01663142||Patients who receive surgical resection for intestinal in CD|
33003380|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
33003381|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
33003382|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
33003383|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
33003384|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
33003385|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
33003386|NCT01663207||obese individuals with prediabetes|
33003387|NCT01663220||obese individuals with type 2 diabetes mellitus|
33003388|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
33003389|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
33003390|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
33003391|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
33003392|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
33003393|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
33003394|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
33003395|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
33003396|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
33003397|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
33003398|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
33003399|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
33003400|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
33003401|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
33003402|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
33003403|NCT01663415|Experimental|Enzalutamide|
33003404|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
33003405|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
33003406|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
33003407|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
33003408|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
33417433|NCT01353989||< 40 years|
33414854|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
33414855|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
33414856|NCT04634383|Experimental|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
33414857|NCT01345279||cisplatin|
33414858|NCT01345279||cisplatin + topotecan|
33414859|NCT01345279||cisplatin + paclitaxel|
33414860|NCT05232019||Infertile females|No less than 20 years old who were attending our clinical center for the first time were enlisted
33414861|NCT00577577|Experimental|rhIGF-I/rhIGFBP-3|
33414862|NCT00577577|Placebo Comparator|Placebo|
33414863|NCT02833844|Experimental|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
33414864|NCT02833844|Placebo Comparator|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
33414865|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
33414866|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
33414867|NCT05014789|Experimental|Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pump|"Each subject will use different combinations of new features of the system each week, in random order, over the next 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0.~The first 5 subjects in the study will complete a 48 hour session with multiple challenges during use of Control-IQ technology 2.0, before moving on the outpatient portion of the trial."
33414868|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
33414869|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~taking telemedicine through video telephone instead of visiting hospital"
33003409|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
33003410|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
33414870|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided~Self-monitoring Blood Glucose (SMBG)"
33414871|NCT04611763|Experimental|Pre FA Group|
33414872|NCT04611763|Active Comparator|Post FA Group|
33414873|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
33414874|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
33414875|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
33003411|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
33003412|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
33003413|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
33003414|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
33003415|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
33003416|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
33003417|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
33003418|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
33105435|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
33003419|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
33003420|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
33003421|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
33003422|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
33003423|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
33003424|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
33003425|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
33003426|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
33003427|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
33003428|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
33003429|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
33003430|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
33003431|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
33003432|NCT01663688||Normative Data Collection|
33003433|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
33003434|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
33003435|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
33003436|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
33003437|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
33003438|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
33003439|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
33003440|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
33325213|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
33325214|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
33325215|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
33003441|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
33003442|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
33003443|NCT01663831|Experimental|Topical Repellent & LLIN|
33003444|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
33003445|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
33003446|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
33003447|NCT01663883|Experimental|Healthy subjects|
33003448|NCT01663909|No Intervention|Standard care|
33003449|NCT01663909|Experimental|Guided imagery|
33003450|NCT01663948||Patients with Plastic bronchitis|
33003451|NCT01663961|Experimental|YM178 OCAS + digoxin|
33003452|NCT01663974||Bipolar disorder patients|
33003453|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
33003454|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
33325216|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
33003455|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
33414876|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
33414877|NCT03564002||obese subjects|
33414878|NCT03564002||lean subjects|
33414879|NCT05329064|Other|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®)|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose. Two doses will be given at 2 months apart between doses.
33003456|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
33003457|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
33003458|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
33003459|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
33003460|NCT01664143|Placebo Comparator|Placebo|
33003461|NCT01664143|Experimental|RO5508887|
33003462|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
33003463|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
33003464|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
33003465|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
33003466|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
33003467|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
33003468|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
33003469|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
33003470|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
33003471|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
33414880|NCT05186935|Experimental|Single arm|This is a multi-center, pivotal, non-randomized, prospective, open-label clinical investigation.
33414881|NCT04568629|Experimental|Algorithm Arm|Participants received prognostic advice from a prognostic algorihm.
33414882|NCT04568629|Experimental|Clinician arm|Participants recieved prognostic advice from another clinician.
33414883|NCT04973917|Experimental|conventional ventilation mode|respiratory support after cardiac surgery. Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
33414884|NCT04973917|Experimental|intelectual mode - Intelivent ASV|closed loop mode of mechanical ventilation Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
33414885|NCT03985033|Experimental|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
33414886|NCT03985033|No Intervention|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
33003472|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
33003473|NCT01664520|Experimental|Dexmedetomine infusion|
33003474|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
33003475|NCT01664572||Healthy subjects|
33003476|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to~Motivate and teach participants for postural and motor control and strengthening exercises~Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
33003477|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
33003478|NCT01664598|Experimental|RoActemra/Actemra|
33003479|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
33003480|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
33003481|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
32907846|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
32907847|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
32907848|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
32907849|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
32907850|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
32907851|NCT01598831|Active Comparator|ART-123|
32907852|NCT01598831|Placebo Comparator|Placebo|
32907853|NCT00841685|Experimental|1|Goldlock
32907854|NCT00841685|Active Comparator|2|Visicoil smallest size
32907855|NCT00841685|Active Comparator|3|Visicoil larger size
32907856|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
32907857|NCT00841685|Active Comparator|5|Bard goldmarker larger size
32907858|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
32907859|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
32907860|NCT01640327|Experimental|TIVf|
32907861|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
32907862|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
32907863|NCT05111093|Experimental|all participants|All participants will be provided with the ARC-IM Investigational System (implantable and non-implantable parts)
32907864|NCT05066711||ACP System|
32907865|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
32907866|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
32907867|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
32907868|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
32907869|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
32907870|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
32907871|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
32907872|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
32907873|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
32907874|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
32907875|NCT01604291||Cohort|
32907876|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
32907877|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
32907878|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
32907879|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
33414887|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
33414888|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
33414889|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
33003482|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
33003483|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
33003484|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
33003485|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
33003486|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
33003487|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
33003488|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
33003489|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
33003490|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
33003491|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
33003492|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
33003493|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
33003494|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
33003495|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
33003496|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
33003497|NCT01664728|Experimental|Abiraterone acetate|
33003498|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33003499|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
33003500|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
33003501|NCT01664780||Patients after liver transplantation|
33003502|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
33003503|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
33003504|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
33003505|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
33003506|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
33003507|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
33003508|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
33003509|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
33003510|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
33003511|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
33003512|NCT01664962||Patients|Women with severe Vulvodynia
33003513|NCT01664962||Healthy controls|Women without vulvodynia
33003514|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
33003515|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
33003516|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
33003517|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
33414890|NCT01345747|Experimental|endotracheal tube|
33414891|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
33414892|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
33325217|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
33003518|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
33003519|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
33003520|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
33003521|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
33003522|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
33003523|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
33003524|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
33003525|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
33003526|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
33003527|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
33003528|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
33003529|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
33003530|NCT01665131|Experimental|Subcutaneous ICD group|
33003531|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
33003532|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
33003533|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
33003534|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
33003535|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
33003536|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
33003537|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
33003538|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
33003539|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
33003540|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
33003541|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
33003542|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
33003543|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
33003544|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
33003545|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
33003546|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
33325218|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
33325219|NCT01442194||Fingolimod|non-interventional
33325220|NCT01442194||parallel cohort|non-interventional
33325221|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
33325222|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
33325223|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive sugar pill
33325224|NCT01374880||Dyspnea cohort|Dyspnea cohort
33325225|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
33325226|NCT01374880||Valvular heart disease|Valvular heart disease
33325227|NCT01374880||Ventricular assist device|Ventricular assist device
33325228|NCT01374880||Cardiac arrest|Cardiac arrest
33325229|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
33414893|NCT05150509||Patients with Progressive Disease and without Progressive Disease|"Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease.~Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease."
33414894|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
33003547|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
33003548|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
33003549|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
33003550|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
33003551|NCT01665404|Experimental|Dosing Period 1|
33003552|NCT01665404|Experimental|Dosing Period 2|
33003553|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
33003554|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
33003555|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
33003556|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
33003557|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
33003558|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
33003559|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
33003560|NCT01665482|Active Comparator|Saturated fat rich diet|
33003561|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
33003562|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
33003563|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
33003564|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
33003565|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
33003566|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
33003567|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
33003568|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
33003569|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
33003570|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
33003571|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
33003572|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
33003573|NCT01665612|Experimental|MPDS1|Contact lens care solution
33003574|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
33003575|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
33003576|NCT01665625|Experimental|regional interventional chemotherapy group|
33003577|NCT01665625|No Intervention|systemic chemotherapy|
33003578|NCT01665638|Experimental|Treatment Sequence Group AB|
33003579|NCT01665638|Experimental|Treatment Sequence Group BA|
33003580|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
33003581|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
33003582|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
33414895|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
33003583|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
33003584|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
33003585|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
33003586|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
33003587|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
33003588|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
33003589|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
33003590|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
33003591|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
33003592|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
33003593|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
33003594|NCT01665755|Experimental|Precompression|Control arm
33003595|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
33003596|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
33003597|NCT01665781|No Intervention|Control|No erythropoietin
33003598|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
33003599|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
33003600|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
33003601|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
33003602|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
33003603|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
33003604|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
33003605|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
33003606|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
33003607|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
33003608|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
33003609|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
33003610|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
32907880|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
32907881|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
33003611|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
33003612|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
32907882|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
32907883|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
33414896|NCT03952429|Active Comparator|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
33003613|NCT01665976|Experimental|A: film coated tablets, fasted condition|
33003614|NCT01665976|Experimental|B: film coated tablets, fed condition|
33414897|NCT03952429|Placebo Comparator|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
33414898|NCT05107531||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
33414899|NCT05107531||Parkinson's Patients Without Motor Freeze|Individuals with Parkinson's Disease without motor freeze were included in this group.
33414900|NCT05107531||Healthy Controls|Healthy individuals who did not have any neurological problems that would affect gait were included.
33414901|NCT01345825|Experimental|resistance training|
33414902|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
33414903|NCT05063149|Active Comparator|Broncho-Vaxom treatment|Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.
33414904|NCT05063149|Placebo Comparator|Placebo|Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.
33414905|NCT01341470|Experimental|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
33414906|NCT01341470|Experimental|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
33414907|NCT01341470|Experimental|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
33003615|NCT01665976|Experimental|C: hard gelatin capsules|
33414908|NCT01341470|Experimental|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
33003616|NCT01665976|Experimental|D: oral suspension|
33414909|NCT01341470|Placebo Comparator|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
33414910|NCT01341470|Placebo Comparator|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
33414911|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
33414912|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
33414913|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
33414914|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
33003617|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
33003618|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
33003619|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
33003620|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
33003621|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
33003622|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
33003623|NCT01666041|Placebo Comparator|placebo|placebo
33003624|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
33414915|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
33414916|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
33414917|NCT02677298|Experimental|Botulinum toxin A Open Label Extension Arm|"Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles.~20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area."
33414918|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
33414919|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
33414920|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
33003625|NCT01666041|Active Comparator|fenofibrate|fenofibrate
33003626|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
33003627|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
33003628|NCT01666067|Active Comparator|placebo|placebo
33003629|NCT01666067|Active Comparator|vytorin|vytorin
33003630|NCT01666067|Active Comparator|simvastatin|simvastatin
33003631|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
33003632|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
33003633|NCT01666132|Experimental|Intramyocardial injection of BM cells|
33003634|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
33003635|NCT01666132|Other|control|
33003636|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
33003637|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
33003638|NCT01666223|Experimental|Colesevelam|
33003639|NCT01666223|Experimental|Chenodeoxycholic acid|
33003640|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
33003641|NCT01666223|Experimental|Placebo|
33003642|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
33003643|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
33003644|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
33003645|NCT01666262|Placebo Comparator|Stabilizer|
33003646|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
33003647|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
33414921|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
33003648|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
33003649|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
33003650|NCT01666327|Experimental|MT-1303|
33003651|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
33003652|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
33003653|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
33003654|NCT01666379|Experimental|Fentanyl|
33003655|NCT01666379|Placebo Comparator|placebo|
33003656|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
33003657|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
33003658|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
33003659|NCT01666418|Other|Pazopanib/Paclitaxel|
33003660|NCT01666431|Other|Lapatinib|
33003661|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
33003662|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
33003663|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
33003664|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
33003665|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
33325230|NCT05197738||High risk OSA|"Cohort of individuals found to sleep have scores categorized as High risk, on the Berlin questionnaire."
33003666|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
33003667|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
33003668|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
33003669|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
33003670|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
33003671|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
33003672|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
33003673|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
33003674|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
33003675|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
33003676|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
33003677|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
33003678|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
33003679|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
33003680|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
33003681|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
33003682|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
33003683|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
33003684|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
33003685|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
33003686|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
33003687|NCT01666613|Experimental|1|AZD8683 iv
33003688|NCT01666613|Experimental|2|AZD8683 oral
32865629|NCT04852770|Experimental|Trial-Based Cognitive Therapy|TBCT (de Oliveira, 2008) is a novel transdiagnostic approach (Wenzel, 2017). It has been shown to be effective for depression (Hemanny et al., 2019), social anxiety disorder (Neufeld et al., 2020; Caetano et al., 2018; de Oliveira et al., 2011; Powell et al., 2013), and PTSD (Duran et al., 2020). TBCT differs from other CBT approaches in that it introduces a new, organized, and systematic approach to change dysfunctional negative core beliefs, and allows cognitive, emotional, and experiential work to be done simultaneously (de Oliveira, 2016). Interestingly, it incorporates a courtroom metaphor to challenge dysfunctional core beliefs conceptualized as self-accusations (de Oliveira, 2016). TBCT is an example of assimilative psychotherapy integration that relies on Beckian CBT (de Oliveira, 2016). It incorporates and integrates components of other psychotherapies (Delavechia et al., 2016).
33003689|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
33414922|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
33003690|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
33414923|NCT01345981|Placebo Comparator|normal saline|2 ml
33003691|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
33003692|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
33003693|NCT01666639|Active Comparator|Control Group|
33003694|NCT01666639|Experimental|Intervention Group|
33003695|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
33003696|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
33003697|NCT01666678|Experimental|Arm 1|
33003698|NCT01666678|Active Comparator|Arm 2|
33003699|NCT01666678|Active Comparator|Arm 3|
33003700|NCT01666678|Experimental|Arm 4|
33003701|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
33003702|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
33003703|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
33003704|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
33003705|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
33003706|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
33003707|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
33003708|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
33003709|NCT01666704|Placebo Comparator|Treatment C: Placebo|
33414924|NCT04541797|Placebo Comparator|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
33003710|NCT01666717||Healthy controls (HC)|HC
33003711|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
33003712|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
33003713|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33003714|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
33003715|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
33003716|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
33003717|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
33003718|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
33003719|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
33003720|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
33003721|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
33003722|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
33003723|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
33003724|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
33003725|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
33003726|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
33003727|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
33003728|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
33003729|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
33003730|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
33003731|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
33003732|NCT01667003||Orsiro DES|
33003733|NCT01667016||Orsiro DES|
33003734|NCT01667042||Without Interstitial lung disease (ILD)|
33003735|NCT01667042||With Interstitial lung disease (ILD)|
33003736|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
33003737|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
33003738|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
33003739|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
33003740|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
33003741|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
33003742|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
33003743|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
33003744|NCT01667172|Other|point-of-care test for CRP|
33003745|NCT01667185||Pediatric subjects with diabetes mellitus|
33003746|NCT01667198|Experimental|Train the leaders course|
33003747|NCT01667198|Active Comparator|Audit and feedback|
33003748|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
33003749|NCT01667237|Experimental|Pulmonary rehabilitation|
33003750|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
33003751|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
33003752|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
33414925|NCT04541797|Experimental|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
33003753|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
33003754|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
33003755|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
33003756|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
33003757|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
33003758|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
33003759|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
33003760|NCT01667367|Placebo Comparator|Placebo|
33003761|NCT01667367|Experimental|RG1662|
33003762|NCT01667380||Cohort|
33003763|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
33003764|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
33003765|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
33003766|NCT01667445|Active Comparator|spinal analgesia|spinal alone
33003767|NCT01667458||Cohort|
33003768|NCT01667484|Placebo Comparator|Placebo|treatment group #1
33003769|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
33003770|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
33003771|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
33003772|NCT01667497|Placebo Comparator|Placebo|non-drug
33003773|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
33003774|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
33003775|NCT01667523|Experimental|Capsaicin|
33003776|NCT01667523|Experimental|Cinnamaldehyde|
33003777|NCT01667523|Placebo Comparator|Placebo|Physiological saline
33003778|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
33003779|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
33003780|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
33003781|NCT01667588||Pre-Dialysis|
33003782|NCT01667588||Dialysis|
33003783|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
33003784|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
33003785|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
33003786|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
33003787|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
33003788|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
33003789|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
33003790|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
33003791|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
33003792|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
33003793|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
33003794|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
33003795|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
33003796|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
33003797|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
33003798|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
33003799|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
33003800|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
33003801|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
33003802|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
33003803|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
33003804|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
33003805|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
33003806|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
33003807|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
33003808|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
33003809|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
33003810|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
33003811|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
33003812|NCT01667835|Experimental|Yoga Intervention|
33003813|NCT01667835|No Intervention|Control|
33003814|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
33003815|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
33003816|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
33003817|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
33003818|NCT01667913|No Intervention|6 minutes walking test|
33003819|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
33003820|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
33003821|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
33003822|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
33003823|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
33003824|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
33003825|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
33003826|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
33003827|NCT01668069|Experimental|Ondansetron|study drug
33003828|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
33003829|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
33003830|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
33003831|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
33003832|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
33003833|NCT01668134|Experimental|Stereotactic radiation|
33003834|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
33003835|NCT01668199|Experimental|14C TZP-101|
33003836|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
33003837|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
33003838|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
33003839|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
33003840|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
33003841|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
33003842|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
33003843|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
33003844|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
33003845|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
33003846|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
33003847|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
33325231|NCT05197738||Low risk OSA|"Cohort of individuals found to sleep have scores categorized as Low risk, on the Berlin questionnaire."
33003848|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
33003849|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
33003850|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
33003851|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
33003852|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
33003853|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
33003854|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
33003855|NCT01668342|No Intervention|Control|Standard of care
33003856|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
33003857|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
33003858|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
33003859|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
33003860|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
33003861|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
33325232|NCT05197738||Short sleepers|Cohort of individuals found to have average sleep duration of < 7 hours per night. Individuals who sleep on average less than 6 hours per night will further be sub-categorized as very short sleeprs.
33325233|NCT05197738||Long sleepers|Cohort of individuals found to have average sleep duration of >9 hours per night.
33325234|NCT05197738||Average lengths leepers|Cohort of individuals found to have an average sleep duration between 7 and 9 hours per night
33003862|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
33003863|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
33003864|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
33003865|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
33003866|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
33003867|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
33003868|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
33003869|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
33003870|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
33003871|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
33003872|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
33003873|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
33003874|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
33003875|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
33003876|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
33003877|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
33003878|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
33003879|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
33003880|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
33003881|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
33003882|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
33003883|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
33003884|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
33003885|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
33003886|NCT01668680|No Intervention|observation|observation only
33003887|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
33003888|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
33003889|NCT01668706||Methadone maintenance treatment (MMT)|
33003890|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
33003891|NCT01668706||Medication-free ex-addicts(MF)|
33003892|NCT01668706||Normal control (NC)|
33003893|NCT01668732||community heroin addicts|
33003894|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
33003895|NCT01668745|No Intervention|Control|
33003896|NCT01668810||Beijing region|include six hospitals
33003897|NCT01668810||Guangdong Province|include 3 hospitals
33003898|NCT01668810||Jiangsu province|include 3 hospitals
33003899|NCT01668810||Hebei province|include 6 hospitals
33003900|NCT01668810||Hubei Province|include 7 hospitals
33003901|NCT01668810||Shanxi province|include 3 hospitals
33003902|NCT01668810||Jiangxi province|include 3 hospitals
33003903|NCT01668810||Jilin province|include 6 hospitals
33003904|NCT01668810||Sichuan province|include 3 hospitals
33003905|NCT01668810||Shaanxi province|include 3 hospitals
33003906|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
33325235|NCT05197738||Regular sleepers|Cohort of individuals whose standard deviation of sleep duration falls within 1 standard deviation of their mean sleep duration.
33003907|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
33003908|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
33003909|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
33003910|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
33003911|NCT01668888||Apparently Helathy Subjects|
33003912|NCT01668901|Experimental|warfarin|medication
33003913|NCT01668901|Active Comparator|aspirin|medication
33003914|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
33003915|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
33003916|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
33003917|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
33003918|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
33003919|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
33003920|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
33003921|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
33003922|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
33003923|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
33003924|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
33003925|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
33003926|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
33003927|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
33003928|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
33003929|NCT01669057||Congenital heart defect（CHD） group|
33003930|NCT01669057||Normal control group|
33003931|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
33003932|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
33003933|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
33003934|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
33003935|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
33003936|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
33003937|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
33003938|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
33003939|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~1 weekly class (90 minutes)"
33003940|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
33003941|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
33003942|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
33003943|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
33003944|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
33003945|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
33003946|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
33003947|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
33003948|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
33003949|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
33414926|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
33003950|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
33003951|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
33003952|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
33003953|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
33003954|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
33003955|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
33003956|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
33003957|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
33003958|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
33003959|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
33003960|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
33003961|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
33003962|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
33003963|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
33003964|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
33003965|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
33003966|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
33003967|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
33003968|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
33003969|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
33003970|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
33003971|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
33003972|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
33003973|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
33003974|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
33003975|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
33003976|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
33003977|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
33003978|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
33105436|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
33414927|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
33414928|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
33414929|NCT04920331|Experimental|Erenumab|Subjects with episodes of status migrainosus will receive a single dose of IV erenumab
33414930|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
33414931|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
33414932|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
33414933|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
33003979|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
33003980|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
33003981|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
33003982|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
33003983|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
33003984|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
33003985|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
33003986|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
33003987|NCT01669551||Structural or Valvular Heart Disease|
33003988|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
33003989|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
33003990|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
33003991|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
33003992|NCT01669590||old (60-75yr)|
33003993|NCT01669590||young (18-35y)|
33003994|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
33003995|NCT01669681||Included in the cohort COBRA|
33003996|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
33003997|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
33003998|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
33003999|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
33004000|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
33004001|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
33004002|NCT01669746|Experimental|Treatment|
33004003|NCT01669759||fatigue|
33004004|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
33004005|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
33004006|NCT01669824||Group 1|
33004007|NCT01669837||Patient group|Administration of surgical tissue glue.
33004008|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
33004009|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
33004010|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
33004011|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
33004012|NCT01669889||Cohort|
33004013|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
33105437|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
33105438|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33004014|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
33004015|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
33004016|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
33004017|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
33325236|NCT05197738||Irregular sleepers|Cohort of individuals whose standard deviation of sleep duration falls greater than 1 standard deviation of their mean sleep duration
33325237|NCT05197738||Severe insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as severe
33325238|NCT05197738||Moderate insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as moderate
33414934|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
33004018|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
33414935|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
33414936|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
33414937|NCT04537039|Other|All the participants.|This study only includes 1 arm.
33004019|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
33414938|NCT00442897|Experimental|1|
33414939|NCT00442897|Active Comparator|2|
33004020|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
33414940|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
33004021|NCT01669967|Active Comparator|Lidocaine|
33004022|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
33004023|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
33004024|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
33004025|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
33004026|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
33004027|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
33004028|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
33004029|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
33004030|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
33004031|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
33004032|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
33004033|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
33004034|NCT01670916||Control|Probiotics never given
33004035|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
33004036|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
33004037|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
33004038|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
33004039|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
33004040|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
33004041|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
33004042|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
33325239|NCT05197738||No insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as low
33325240|NCT05197738||Increased social jet lag|Individuals who are more than 1 hour less or more of sleep on weekdays compared to average weekend sleep.
33414941|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
33414942|NCT02834390|Experimental|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
33414943|NCT02834390|Experimental|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
33414944|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
33414945|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
33004043|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Cisplatin: 60 mg/ m2/day, i.v., day 1~Every 3 weeks"
33004044|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Oxaliplatin: 130 mg/ m2/day, i.v., day 1~Every 3 weeks"
33004045|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
33004046|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
33004047|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
33414946|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
33414947|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
33004048|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
33414948|NCT01317433|Active Comparator|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
33414949|NCT01358708|Experimental|LACTEOL® 340 mg|
32865630|NCT04852770|Active Comparator|Mindfulness-Based Health Promotion|The Mindfulness-Based Stress Reduction (MBSR) program was created by Jon Kabat-Zinn and colleagues at the University of Massachusetts Medical Center in 1979, and it is an intervention whose effects on mental health and quality of life has produced several studies worldwide, both in clinical and non-clinical populations. Several protocols have been developed based on the MBSR aimed at specific publics, such as the Mindfulness-Based Health Promotion (MBHP) program developed by the Mente Aberta - Brazilian Center for Mindfulness and Health Promotion. The MBHP program was inspired by the original MBSR model but adapted to the context of the Brazilian Health Care (SUS) system, addressing chronic conditions and mental disorders as well (TROMBKA et al., 2018; LOPES et al., 2019; SALVO et al., 2018).
33004049|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
33004050|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
33004051|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
33004052|NCT01671826||above 65 years old|
33004053|NCT01671917|Experimental|Educational and exercise program|
33004054|NCT01671917|Active Comparator|Usual care|
33004055|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
33325241|NCT05197582|Active Comparator|Tele-monitoring group|The researchers called the patients in the experimental group on the first day of the quarantine and explained the topics covered in the COVID 19 patient education booklet to the patients. Patient education and follow-up in quarantine took approximately 25-30 minutes for each patient in the experimental group. The patients in quarantine were followed up by the researchers two more times, on the 5th and 9th days of the quarantine. On the 10th and last day of the quarantine, post-test online questionnaires were sent to the patients for the second time, and the data collection phase was ended.
33414950|NCT01358708|Placebo Comparator|PLACEBO|
33004056|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
33414951|NCT01346449|Active Comparator|Visual cue absent|
33414952|NCT01346449|Experimental|Calorie information present|
33414953|NCT01346449|Active Comparator|Calorie information absent|
33414954|NCT01346449|Experimental|Visual cue present|
33004057|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
33004058|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
33004059|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
33004060|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~Common challenges in the transition to parenthood and in the relationship~Couple communication~Session 2 (33 weeks gestation):~Expectations in relation to birth~The normal course of labour~Obstetric intervention~Pain relief,coping strategies~Partner support~Session 3 (35 weeks gestation):~Feeding a newborn~Interpreting the newborn's signs, symptoms and behaviour~Taking care of a newborn~Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~Birth experiences~Mood swings, postnatal depressive symptomatology~The first time at home with a newborn~Couplehood - partner support, communication, division of household tasks"
33004061|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
33004062|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
33004063|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
33004064|NCT01672645|Experimental|PF-05402536|
33004065|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
33004066|NCT01672645|Placebo Comparator|Placebo|Intramuscular
33004067|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
33004068|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
33004069|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
33004070|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
33004071|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
33004072|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
33004073|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
33004074|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
33004075|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
33004076|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
33414955|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~HbA1C ≤ 8 for greater than 3 months32, 33.~All women will have confirmed singleton pregnancies.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
33414956|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
33414957|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
33004077|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
33004078|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
33004079|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
33004080|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
33004081|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
33004082|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
33004083|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
33004084|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
33004085|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
33004086|NCT01674335|Active Comparator|Operant Learning|
33004087|NCT01674335|Active Comparator|Energy Conservation|
33004088|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
33004089|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
33004090|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
33004091|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
33004092|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
33004093|NCT01674595|Experimental|Immunotherapy|AVANZ
33004094|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
33004095|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
33004096|NCT01675271|Active Comparator|individual exercise|individualized exercise program
33004097|NCT01675271|Active Comparator|general exercise|general exercise program
33004098|NCT01675271|No Intervention|control|No exercise and dietary counselling
33004099|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
33004100|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
33004101|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
33004102|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
33004103|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
33004104|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
33325242|NCT05197582|No Intervention|Plasebo group|The patients in the control group were called by the researchers on the first day of the quarantine and asked to fill in the online pre-test forms. On the 10th day, the last day of the quarantine, the patients were called and the online post-test forms were sent for the second time, and the data were collected. There was no telephone follow up in the control group and the patients received only routine care in the home
33325243|NCT05197114|Experimental|Intervention|There will be one arm to the study, and all participants will be receiving the intervention.
33325244|NCT05196880||ARM 1|Patients with negative clinical suspicion of Biofilm containing wounds(CSB-).
33325245|NCT05196880||ARM 2|Patients with positive clinical suspicion of Biofilm containing wounds(CSB+)
33004105|NCT01675713|No Intervention|Controls|No treatment, waiting list
33004106|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
33004107|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
33004108|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
33325246|NCT05196802|Experimental|mHeart.4u|The mHEART.4U intervention includes the use of an online Clinical Decision Support System (CDSS) for remote patient monitoring. According to the patient needs and profile, the CDSS will suggest a monitoring plan for the patient. The mHEART.4U kit will include mobile apps and wearables, such as heart rate, blood pressure, peripheral oxygen saturation (SpO2), sleep and step trackers, symptoms, lifestyle self-monitoring tools, medication reminders or motivational resources. The intervention length will be 6 months and will take into account the most recent guidelines on Cardiac Rehabilitation.
33414958|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
33414959|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
33004109|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
33004110|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
33004111|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
33004112|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
33004113|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
33414960|NCT01317511|Experimental|Protein|Protein drink
33004114|NCT01677039|Active Comparator|Treatment A|
33004115|NCT01677039|Experimental|Treatment B|
33004116|NCT01677039|Experimental|Treatment C|
33004117|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
33004118|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
33004119|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
33004120|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
33004121|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
33004122|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
33004123|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004124|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004125|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
33004126|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004127|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004128|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004129|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
33004130|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
33004131|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
33325247|NCT05196802|No Intervention|Standard care|This arm will receive treatment and care according to the prevailing practice at each of the cardiac hospital units.
33325248|NCT05196724|Experimental|Mentalization Based Therapy (MBT)|MBT for foster carers is a 12 session therapeutic intervention that will be offered to foster families by municipal foster care consultants
33004132|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
33004133|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
33004134|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
33004135|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
33004136|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
33325249|NCT05196724|Active Comparator|Usual care|the control group will receive the usual care offered to foster families such as supervision
33325250|NCT05196646||(1) 5 preterm infants spontaneously breathing in-room air with no respiratory support|"Respiratory acoustic signals will be collected and compared with airflow measurements obtained using a pneumotachometer, i.e. the gold standard. Inclusion of these infants is necessary to demonstrate the reliability of the respiratory acoustic sensor in capturing airflow when compared to the gold standard pneumotachometer.~Data will be collected for 10 minutes."
33325251|NCT05196646||(2) 10 preterm infants spontaneously breathing in-room air with no respiratory support|"Respiratory acoustic signals will be collected and compared with airflow measurements obtained using a nasal temperature sensor. In addition, measurements of respiratory efforts will be obtained using respiratory inductive plethysmography, electrical activity of the diaphragm, and transthoracic impedance. The inclusion of these infants will allow for better description of the properties of the breath sounds in a stable cohort of infants, without interference from the CPAP noise.~Data will be collected for 3 hours."
33004137|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
32739229|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position~Apply elastic bandages to both legs without tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
32739230|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position~Apply elastic bandages to both legs with tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
32739231|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
32739232|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
32739233|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
33004138|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
33004139|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
33004140|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
33004141|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
33004142|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
33004143|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
33004144|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
33004145|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
33004146|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
33004147|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
33004148|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
33004149|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
33004150|NCT01679145||Control group|Age- and gender matched healthy controls
33004151|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
33004152|NCT01679210|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
33004153|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
33004154|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
33325252|NCT05196646||(3) 10 preterm infants on continuous positive airway pressure (CPAP) with cardiorespiratory events|"Respiratory acoustic signals will be collected. In addition, measurements of respiratory efforts will be obtained using respiratory inductive plethysmography, electrical activity of the diaphragm, and transthoracic impedance. The inclusion of infants on CPAP will allow for detection of both breath sounds and airflow coming from the transmitted CPAP pressure in a cohort of infants at higher risk of cardiorespiratory events.~Data will be collected for 3 hours."
33325253|NCT05196568|No Intervention|control|no dietary intervention
33414961|NCT01317511|Placebo Comparator|Placebo|water
33004155|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
33004156|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
33004157|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
33004158|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
33004159|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
33004160|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
33004161|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
33004162|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
33004163|NCT01679743|Experimental|A|Breast Cancer Cohort
33004164|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
33004165|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
33004166|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
33004167|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
33004168|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
33004169|NCT01680120|Experimental|Continuous spinal anaesthesia|
33004170|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
33004171|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
33004172|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
33004173|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
33004174|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
33004175|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
33004176|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
33004177|NCT01680315|Experimental|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
33414962|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
33414963|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
33414964|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
33414965|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
33414966|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
33414967|NCT01347697|Experimental|Porcine collagen implant (biological mesh)|Reconstruction with an acellular porcine dermal collagen implant (biological mesh).
33414968|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
32739234|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
33414969|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
33414970|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
33417434|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
32739235|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
32739236|NCT04907565||Obese patients|BMI >30kg/m2
32739237|NCT04907565||non obese patients|BMI between 18 to 29kg/m2
33004178|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
33004179|NCT05597202|Experimental|Treatment arm|Will receive semaglutide treatment for 6 months, at the highest tolerable dose, up to a maximum of 2.0mg weekly.
33004180|NCT05597111||Blood DHA levels of patients with PCOS|The patients diagnosed as PCOS according to Rotterdam criteria will be the study group. The DHA leves in blood sample of the patients will be recorded
32739238|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
32739239|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
33004181|NCT05597111||BloodDHA levels of the control group|The patients without PCOS will be control group. The DHA leves in blood sample of the patients will be recorded
32739240|NCT05459909|Experimental|Synbiotic supplementation|Synbiotic supplementation
33004182|NCT05597072|Experimental|Intervention|In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention).
33004183|NCT05597072|Active Comparator|Control|The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons).
33004184|NCT05597033|Experimental|Morning-AM|Before 10AM
33004185|NCT05597033|Experimental|Evening-PM|After 4PM
33004186|NCT05597007|Experimental|Treatment|Clinic participation
33004187|NCT05596981||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after Allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
33004188|NCT05596981||non-sorafenib group|FLT3-ITD+ AML patients who do not receive sorafenib maintenance therapy after Allo-HSCT.
33004189|NCT05596968||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
33004190|NCT05596942|Experimental|Albumin Chana Striata Extract|
33004191|NCT05596942|Active Comparator|Human Albumin|
33004192|NCT05596916|Experimental|Low frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 5 days a week during 6 weeks
33004193|NCT05596916|Active Comparator|High frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 3 days a week during 6 weeks
33004194|NCT05596903|Experimental|EMDR 2.0|EMDR 2.0 Online Group protocol will be administered.
33004195|NCT05596903|Active Comparator|Control|Mental Health Gap Action Programme (mhGAP) will be administered.
33004196|NCT05596890|Experimental|Neoadjuvant immunochemotherapy +/- short-term radiotherapy|Tislelizumab + cisplatin/carboplatin + albumin-bounded paclitaxel +/- radiotherapy
33004197|NCT05596864||Experimental group|Patients with gastric cancer underwent contrast-enhanced CT scan and gastric filling ultrasound, respectively.
33004198|NCT05596812|Experimental|Intervention (Risk Stratification Pathway)|"Those randomized to Intervention (Risk Stratification Pathway) will have their demographic and clinical data entered into the risk stratification screening calculator, and will be assigned to either Low Risk (Novel (Low Impact) Care Pathway) or High Risk (Routine Care Pathway) groups.~Women in the Routine Care Pathway group will be followed in the DIP clinic according to routine care protocols and will provide bi-weekly glucometer data.~Women in the Novel (Low Impact) Care Pathway group will be followed in the New Care Pathway, which will include continuation of lifestyle and dietary modification, continuation of capillary self blood glucose monitoring, and routine prenatal care."
33004199|NCT05596812|No Intervention|Control (Routine Care)|Those randomized to Control (Routine Care) will continue in-person and virtual visits as per routine care protocols. This group will also provide bi-weekly glucometer data.
32739241|NCT05459909|Experimental|Dietary intervention|Dietary intervention
33004200|NCT05596786|Experimental|Rituximab|
33004201|NCT05596786|Placebo Comparator|Placebo|
33105439|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
33417435|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
33417436|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
33325254|NCT05196568|Experimental|DMD|administration of Fasting Mimicking Diet
33325255|NCT05196490||Micro-CT|Samples were scanned before and after air polishing with a high-resolution micro-CT device. The scanning conditions were 100 kVp; 100-mA, 0.5-mm Al/Cu filter; 13.1-μm pixel size; and rotation at 0.2 steps. According to the manufacturer's instructions, each sample was rotated 360°. The mean scanning time was around 1hour.
33325256|NCT05196490||CAD/CAM|The teeth surfaces were digitalized before and after air polishing with an intraoral scanner. The mean scanning time was around 10 second. The virtual images of the scanned teeth were saved in stereolithography (STL) format.
32739242|NCT05459909|Experimental|Synbiotic supplementation & dietary intervention|Synbiotic supplementation & dietary intervention
33004202|NCT05596760|Experimental|Jumpstart Guide|The Jumpstart Guide is developed using automated methods. It summarizes the presence/absence of POLST, advance directives and DPOA documentation. The Jumpstart Guide also provides tips for conducting discussion about goals of care.
33004203|NCT05596760|No Intervention|Usual Care|Clinicians of patients in the Usual Care arm will not receive a Jumpstart Guide.
33004204|NCT05596669|Active Comparator|Effect of Ketamine on Postoperative Morphine Consumption|cases in Group I received infusion of 0.15 mg/kg/h for the duration. Following a parenteral bolus dose of magnesium and ketamine (0.3mg/kg),
33004205|NCT05596669|Active Comparator|Effect of Ketamine Magnesium on Postoperative Morphine Consumption|cases in Group II received Ketamine Magnesium group were given a continuous infusion of (0.15mg/kg/h) of ketamine and (10mg/kg/h) of magnesium
33004206|NCT05596643||Patients diagnosed with Familial Mediterranean Fever|
33004207|NCT05596643||Healthy Controls|
33004208|NCT05596617|No Intervention|Standard of Care|Standard of care management of severe Covid-19 patients
33004209|NCT05596617|Experimental|Oral bedtime melatonin|Standard of care with oral bedtime melatonin
33004210|NCT05596591|Experimental|Intervention|Participants will receive four sessions over four consecutive weeks (one per week) of focused extracorporeal shockwave therapy.
33004211|NCT05596591|No Intervention|Control|Participants will receive the conventional treatment for bone marrow lesions, which includes avoidance of weight bearing and anti-inflammatory medications.
33004212|NCT05596565|Experimental|Experimental group 1|Supervised Exercise by a physiotherapist via face to face Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
33004213|NCT05596565|Experimental|Experimental group 2|Supervised Exercise by a physiotherapist via video conference Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
33004214|NCT05596565|No Intervention|Control group|No Intervention: Control group: Unsupervised exercise Home based exercises will be explained to the patients and they will be asked to perform these exercises 2 days a week for 6 weeks.
33004215|NCT05596552|Active Comparator|Bupivacaine-Dexmedetomidine group|
33004216|NCT05596552|Active Comparator|Bupivacaine-Fentanyl group|
33004217|NCT05596526|Experimental|MS patients on anti-CD20|Participants aged 18 and above will receive two doses of the recombinant Zoster vaccine (Shingrix®)
33004218|NCT05596526|Experimental|Healthy controls|Healthy participants aged 50 to 59 will receive two doses of the recombinant Zoster vaccine (Shingrix®)
33004219|NCT05596500|Experimental|Blueberry-protein gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract with 20 grams rice-pea protein in a gel.
33004220|NCT05596500|Active Comparator|Blueberry gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract in a gel.
33325257|NCT05196256|Experimental|Dural Puncture Epidural group (DPE)|Dural puncture with a 25 Gauge needle, then placement of the epidural catheter (Tuohy 18 Gauge). The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractionated bolus of 20 mL will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
33325258|NCT05196256|Active Comparator|Epidural group (EP)|Placement of an epidural catheter through a 18 Gauge Tuohy needle. The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent boluses mode (PIB) and patient controlled epidural analgesia (PCEA); An initial fraction bolus of 20ml will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
33004221|NCT05596500|Placebo Comparator|Placebo|All proximate matched ingredients except for the blueberry polyphenols and plant protein.
33004222|NCT05596487|Experimental|experimental: repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students.
33004223|NCT05596487|No Intervention|control grup|
33004224|NCT05596448|Active Comparator|Cocygeal nerve radiofrequency ablation group|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
33004225|NCT05596448|No Intervention|Conservative treatment group|This group includes patients receiving conservative treatment such as nonsteroidal anti-inflammatory group drugs, physical therapy, and exercise for coccygeal pain.
33004226|NCT05596435||Stage I-III pancreatic cancer|Cell-free DNA collected from plasma samples of 260 patients with stage I-III pancreatic cancer will undergo whole-genome sequencing
33004227|NCT05596435||Pancreatic disease|Cell-free DNA collected from plasma samples of 80 patients with pancreatic benign disease will undergo whole-genome sequencing
33417437|NCT02080754|Experimental|sellick arm|effective sellick maneuver
33417438|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
33414971|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
33414972|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
33004228|NCT05596435||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
33004229|NCT05596396|Experimental|LifeHack|Participants assigned to this arm will receive a 6-week guided e-health intervention to increase positive mental health and well-being.
33004230|NCT05596396|Active Comparator|LifeHack-C|Participants assigned to this arm will receive the same intervention, delivered over 2 to 6 weeks.
33414973|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
33414974|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
33004231|NCT05596383|Experimental|Intervention group|Vitamin D, dosage form chewable tablet, dosage 5000 IU, frequency every day, duration six months
33004232|NCT05596383|Placebo Comparator|control group|Placebo (microcrystalline,calcium carbonate, sodium starch), dosage form chewable tablet, frequency every day, duration six month
33004233|NCT05596305|Experimental|undergraduate medical students|an educational anti-stigma intervention delivered to undergraduate medical students comparing the outcomes of the study before and after the intervention at two time intervals
33004234|NCT05596279|Experimental|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
33004235|NCT05596279|Experimental|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
33004236|NCT05596266|Experimental|CD5 CAR-T|This cohort will be administrated with T cells transduced with lentivirus vectors expressing CD5 CAR.
33414975|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
33414976|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
33004237|NCT05596240|Experimental|Dry Needling|Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation
33004238|NCT05596240|Placebo Comparator|Sham Dry Needling|Individuals with shoulder pain will receive sham dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula
33004239|NCT05596227|Placebo Comparator|control group|Patients will not recieve either erector spinae plane block nor thoracolumbar interfascial plane block
33004240|NCT05596227|Active Comparator|Erector spinae plane block|Patients will recieve ultrasound guided erector spinae plane block.
33004241|NCT05596227|Active Comparator|Thoracolumbar interfascial plane block|Patients will recieve ultrasound guided thoracolumbar interfascial plane block.
33004242|NCT05596214|Experimental|Curcumin-Berberine (coptis) therapy|Cur-Berberine (Coptis) treatment will consist: 2 capsules of 500 mg Berberine (Coptis) before breakfast (a total of 1.0gr Berberine) and 3 capsules of 500mg curcumin before dinner (a total of 1.5gr curcumin).
33004243|NCT05596214|Placebo Comparator|Placebo|2 capsules of 500 mg placebo before breakfast and 3 capsules of 500mg placebo before dinner.
33004244|NCT05596175|No Intervention|Usual Care|Patients will continue Usual Care, which will include having medication optimised for adequate heart-rate control, anti-arrhythmic therapy, and anti-coagulation (for stroke-risk) instituted by their treating Cardiologist if indicated by their CHA₂DS₂-VASc Score. Patients who remain significantly symptomatic despite attempts to optimise medical therapy may be referred for further rhythm management strategies, including cardioversion(s) and/or ablation(s) - as per current standard clinical practice. The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with guidance.
33004245|NCT05596175|Experimental|Super Rehab plus Usual Care|12-month Super Rehab programme involving supervised dietary review sessions, 1-to-1 high-intensity exercise sessions and 3-monthly clinical review of AF risk factors, alongside Usual Care (defined above)
33004246|NCT05596162|Experimental|Blood Flow Restriction Group|"Patient specific tourniquet settings to achieve 80% occlusion.~Weight- 20% of 1 rep max, 4 sets 30-15-15-15 reps with 30 second rests between sets~Exercises: The first phase will focus on active and passive range of motion of the ankle as well as non-weighted concentric exercises. Phase two will progress with gastrocnemius and soleus stretches along with body weight and light resistance band concentric and eccentric exercises focusing on posterior, anterior and lateral muscle groups of the lower limb. Phase three will introduce weighted, dynamic and proprioceptive exercises."
33004247|NCT05596162|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
33004248|NCT05596149|Active Comparator|Toothpaste without fluoride|A group of participants that will be using toothpaste without fluoride.
32739243|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
33414977|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
33414978|NCT01347853|Experimental|Ketorolac tromethamine|
33414979|NCT01347853|Placebo Comparator|Placebo|
33414980|NCT01346917|Experimental|Lidocaine|
33004249|NCT05596149|Experimental|Toothpaste with sodium fluoride|A group of participants that will be using toothpaste with sodium fluoride.
33004250|NCT05596149|Experimental|Toothpaste with sodium monofluorophosphate|A group of participants that will be using toothpaste with sodium monofluorophosphate.
33004251|NCT05596149|Experimental|Toothpaste with amine fluoride|A group of participants that will be using toothpaste with amine fluoride.
33004252|NCT05596097|Experimental|experimental group|According to the initial treatment plan of the patients, the patients were divided into R-CHOP and R-chemo groups. Both groups received zanubrutinib 160 mg bid p.o. d1-28 maintenance treatment for 12 months after induction and consolidation therapy reached the maximum efficacy.
33004253|NCT05596071|Experimental|Sufentanyl+Epidural analgesia|Combined use of sufentanil and ropivacaine for intraoperative and postoperative analgesia
33004254|NCT05596071|Sham Comparator|Epidural analgesia|Only use of ropivacaine for intraoperative and postoperative analgesia
33004255|NCT05596019|Experimental|neurodynamics specific exercise group|"The experimental group will perform a multimodal therapeutic physical exercise program. The components of balance, walking, cardiovascular endurance, strength and flexibility will be worked globally, in addition to including respiratory exercises.~Specific neurodynamic exercises oriented to the treatment of the main nerves of the brachial plexus will be included as part of the exercise sessions. The specific neurodynamic program will consist of the following exercises:~Opening of the cervical conjunction holes with cranio-cervical and cervical flexion movements, cervical lateroflexions and lateral vertebral sliding self-mobilizations.~Opening of the thoracic passages of the brachial plexus with stretching of the scalene muscles, opening of the costoclavicular space and stretching of the pectoralis minor muscles.~Specific exercises of neurodynamic sliding of the nerves of the upper limb: median, radial and ulnar nerves."
33004256|NCT05596019|Active Comparator|The nonspecific exercise group|The nonspecific exercise group performed balance, cardiovascular endurance, stability, upper and lower limb strength, flexibility, and breathing exercises.
33414981|NCT01346917|Placebo Comparator|Placebo|
33414982|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
33414983|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
33004260|NCT05595941|Experimental|TELEYOG'AVC Group|The subjects of the experimental group will be invited to participate in 60-minute tele-yoga sessions, twice a week, for 12 weeks. The sessions will take place via the Zoom videoconference software, in small groups (maximum 5 people) in order to adapt the practice to the possibilities of each subject. In addition, an additional weekly session, independently at home, will be recommended to participants, accompanied by a pre-recorded video support hosted on YouTube.
33004261|NCT05595941|No Intervention|Wainting list Group|The subjects in the control group will be asked not to change their habits during the entire experimental phase (T0-T1). They will be able to benefit in turn from the tele-yoga program (free of charge), if they wish, once the evaluations in T1 are completed.
33004262|NCT05595928||Supine|supine
33004263|NCT05595928||15° left-lateral tilt position|15° left-lateral tilt position.
33004264|NCT05595928||30° left-lateral tilt position.|30° left-lateral tilt position.
33004265|NCT05595915|Experimental|Experimental Group|All subjects recruited in this study will be in the experimental group receiving the oral supplement, COMP-4, twice daily for 14 days.
33004266|NCT05595824|Experimental|JCBC00101 (Molnupiravir, Esperavir)|Group 1 (n=120) received the study drug JCBC00101, capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study
33004267|NCT05595824|Active Comparator|Standard of care|Group 2 (n=120) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study by decision of the investigator and taking into accountthe availability of drugs at the study site (Favipiravir, Umifenovir, IFN α, used incombination with each other).
33004268|NCT05595811||Inuit|
33004269|NCT05595811||Danish|
33004270|NCT05595759|Experimental|Male patients with a diagnosis of alcohol and substance abuse|Male patients with a diagnosis of alcohol and substance abuse
33004271|NCT05595759|Other|Routine service operation|Male patients with a diagnosis of alcohol and substance abuse
33004272|NCT05595746|Experimental|equicrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed equicrestally (I) are in group A-I.
33004273|NCT05595746|Experimental|subcrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed subcrestally (II) are in group A-II.
33004274|NCT05595746|Experimental|equicrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed equicrestally (I) are in group B-I.
33414984|NCT03563612|Active Comparator|cpap first, differential ventilation later|
33414985|NCT03563612|Active Comparator|differential ventilation first, cpap late|
33414986|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
33414987|NCT05708222||Self Reported Assessment|This group of patients will self report their answers to the MINI assessment.
33414988|NCT05708222||Clinician Interview Assessment|This group of patients will complete the MINI assessment via an interactive interview conducted by a qualified clinician.
33414989|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
33414990|NCT01343173|Experimental|Patients|
33414991|NCT05309954||Observational (With Bone Scan)|Individuals with a Family history of Paget's disease of bone (PDB) affecting first degree relative such as a parent or sibling that have not already diagnosed with PDB
33414992|NCT05309954||Observational (Without Bone scan)|Individuals, that are spouses, friends and/or non blood relatives of the individuals with a family history of PDB.
33004275|NCT05595746|Experimental|subcrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed subcrestally (II) are in group B-II.
33004276|NCT05595733|No Intervention|conventional group|Using conventional mode to compare mechanical ventilation day with experimental group
33004277|NCT05595733|Experimental|experimental group|Using neurally adjusted ventilatory assist mode to compare mechanical ventilation day with conventional group
33004278|NCT05595707|Experimental|Early Percutaneous dilatational tracheostomy|PDT reccomended for patients with high risk for prolonged mechanical ventilation.
33414993|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
33414994|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
33414995|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
33004279|NCT05595681|Experimental|Treatment group|20 x 1000000 C2C_ASCs on top of standard care.
33414996|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
33414997|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
33004280|NCT05595681|No Intervention|Control group|Control group with standard care.
33004281|NCT05595590|Experimental|Tislelizumab + Pulse radiation|Participants receive pulsed radiationtherapy concurrent with 3 cycles of Tislelizumab followed by an additional 32 cycles of Tislelizumab alone as maintenance therapy.
33004282|NCT05595564|Experimental|Hypoxia|Participant developed running activity on a treadmill in hypoxic condition, submitted or not to photobiomodulation therapy.
33004283|NCT05595564|Active Comparator|Normoxia|Participant developed treadmill running activity in normoxic condition, submitted or not to photobiomodulation therapy.
33004284|NCT05595538|Experimental|Intubated COVID-19 patients admitted to the ICU.|Participants intubated who consent immediately before intubation to receive more than one dose of COVID-19 convalescent plasma.
33004285|NCT05595525|Experimental|Group A = right side face treated with 1064nm and left with 755nm|subject will have their right half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, left half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
33004286|NCT05595525|Experimental|Group B = left side face treated with 1064nm and right with 755nm|subject will have their left half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, right half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
33004287|NCT05595473|Experimental|Cohort 1|
33004288|NCT05595473|Experimental|Cohort 2|
33004289|NCT05595473|Experimental|Cohort 3|
33004290|NCT05595473|Experimental|Cohort 4|
33004291|NCT05595447|Experimental|Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1|Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles
33004292|NCT05595421|Experimental|The right cerebellum (anode) and the left OFC (cathode) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH) with two rubber electrodes placed inside two 5 × 7 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). Electrodes will be placed on the basis of the international 10-20 electrodes placement system. The cathode will be placed over the left OFC on the FP1 point according to the EEG international reference. The anode will be placed over the right cerebellum 3 cm below the inion and 1 cm right from the midline. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
33004293|NCT05595421|Experimental|The bilateral pre-SMA (cathode) and right deltoid (reference) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to two rubber electrodes which are placed inside two sponge electrodes soaked in a saline solution (0.9% NaCl), respectively. The active electrode (cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
33105440|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
33105441|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
33414998|NCT01347151|Experimental|Glide scope|
33414999|NCT01347151|Experimental|Pentax airway scope|
33415000|NCT01348243|Experimental|Clodronate 200 mg|
33415001|NCT01348243|Active Comparator|Clodronate 100 mg|
33415002|NCT01348321|Experimental|Azithromicine plus levamisole|
33415003|NCT01348321|Experimental|Azithromicin|
33415004|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
33415005|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
33415006|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
33004294|NCT05595421|Experimental|The left OFC (cathode 1), bilateral pre-SMA (cathode 2), and right deltoid (reference) tDCS|Stimulation sessions are carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to a 2 × 1 wire adaptor (Equalizer Box, NeuroConn) that links three rubber electrodes placed inside sponge electrodes soaked in a saline solution (0.9% NaCl) will be applied. One active electrode (the 1st cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The other active electrode (the 2nd cathode) is 5×7 cm and placed over the left OFC on the FP1 point according to the EEG international system. The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
33004295|NCT05595408||adjuvant chemotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant chemotherapy
33004296|NCT05595408||adjuvant immunotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant immunotherapy
33415007|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
33415008|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
33415009|NCT01317589|Experimental|methadone|active pain treatment with methadone
33415010|NCT01347385|Experimental|Barbed suture|
33004297|NCT05595369|Experimental|Paxlovid|PAXLOVID dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet). All three tablets (two of nirmatrelvir and one of ritonavir) must be taken together and no more than 15 minutes apart. All three tablets are taken together twice daily by mouth for 15 days.
33004298|NCT05595369|Placebo Comparator|Placebo|The control formulation includes two placebo tablets and one ritonavir tablet.
33004299|NCT05595200||Study Group|All subjects diagnosed with pulmonary hypertension by right heart catheterization agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
33004300|NCT05593822|Other|patient with STEMI|
33004301|NCT05577455|Experimental|administration for 2 menstrual cycles group|This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.
33004302|NCT05577455|Active Comparator|administration for 3 menstrual cycles group|This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.
33004303|NCT05571683||recovered from covid-19, 2 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
33004304|NCT05571683||no covid anamnese, 2 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
33004305|NCT05571683||recovered from covid-19, 4 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
33004306|NCT05571683||no covid anamnese, 4 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
33004307|NCT05568264|Experimental|Physical Therapy Intervention|Infants enrolled in this arm will receive the intervention in addition to standard of care
33004308|NCT05568264|No Intervention|Standard of Care|Infants enrolled in this arm will receive standard of care
33004309|NCT05567822|Active Comparator|esmolol group|loading dose of esmolol 0.05 mL/kg and maintenance dose of esmolol 0.3 mL/kg/h
33004310|NCT05567822|Placebo Comparator|placebo group|loading dose of 0.9% sodium chloride 0.05 mL/kg and maintenance dose of 0.9% sodium chloride 0.3 mL/kg/h
33004311|NCT05561491|Experimental|ONCOS-102|ONCOS-102 will be administered by intratumoral (IT) injection at 1.0×10^12 VP/dose with the potential to de-escalate dosing to 3.0×10^11 VP/dose.
33004312|NCT05561491|Experimental|ONCOS-102 and balstilimab|ONCOS-102 will be administered by IT injection at 3.0×10^11 VP/dose with planned dose escalation to 1.0×10^12 VP/dose. Balsitilmab will be administered at a fixed dose of 300 mg by intravenous (IV) injection.
33004313|NCT05557253|Experimental|remimazolam group|General anesthesia is induced and maintained with remimazolam.
33004314|NCT05557253|Active Comparator|balanced group|General anesthesia is induced with propofol and maintained with desflurane.
33415011|NCT01347385|Active Comparator|Traditional suture material|
33415012|NCT01348399||XIENCE PRIME stents|
33415013|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
33415014|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
33415015|NCT01347463||Traditional|
33004315|NCT05551975|Experimental|Experimental Product|Study Human Milk Fortifier added to human milk feedings
33004316|NCT05551975|Active Comparator|Control Product|Control Human Milk Fortifier added to human milk feedings
33004317|NCT05546372|Experimental|Endobiliary RFA + stent placement|
33004318|NCT05546372|Active Comparator|Stent placement only|
33004319|NCT05543577||Pharmacists|community, hospital and clinical pharmacists
33004320|NCT05543577||Medical interns|Medical interns of both sexes
33004321|NCT05543200||All Participants|All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention.
33004322|NCT05539924|Active Comparator|Group P|The patients in this group will receive 150 mg pregabalin tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
33004323|NCT05539924|Active Comparator|Group G|The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
33004324|NCT05539924|Placebo Comparator|Group C|The patients in this group will receive vitamin B12 (100µg) as placebo tablets P.O hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
33004325|NCT05530096||MRD level group|Participants will be defined as diagnosed with multiple myeloma
33004326|NCT05528250||İndividuals with do regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to individuals with do regular physical activity is declared.
33004327|NCT05528250||Sedentary individuals with do not have regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to sedentary individuals with do not have regular physical activity is declared.
33004328|NCT05514782|Active Comparator|Anti-Aging Daily Serum|Daily serum composed of a patent-pending botanical extract, bioavailable peptide, antioxidants, postbiotic(s), short term and long-term moisturizers. New product in development.
33004329|NCT05514782|Placebo Comparator|Placebo-Control|Vehicle control of the anti-aging daily serum.
33004330|NCT05512065|Experimental|Ultrasound|Ultrasound will be used to measure velocimetric indices of both right and left uterine arteries and umbilical artery.
33004331|NCT05510700|Experimental|Acupuncture group|"Participants will be given sleep hygiene instructions. Participants will receive acupuncture treatment at Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62). Among the above acupoints, Nei Guan (PC 6), Shen Men (HT 7), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) are all taken from both sides.~Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 12 sessions over the course of four weeks. The follow-up observation will be recorded on week 8 and 16."
33004332|NCT05510700|Sham Comparator|Sham acupuncture group|"Participants will be given sleep hygiene instructions. To match the true acupuncture points, sham treatment at sham Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) will be used.~Participants will have the same needle retention time, treatment time, and follow-up time as the acupuncture group."
33004333|NCT05501925|Experimental|GlideSheath Slender®|Placement of 6 French GlideSheath Slender® for cardiovascular intervention via distal radial artery
33004334|NCT05501925|Active Comparator|Conventional Sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II ) for cardiovascular intervention via distal radial artery
33004335|NCT05496543|Experimental|Acupuncture group|"Participants will receive acupuncture treatment at Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) bilaterally.~Each treatment will last 30 minutes and participants will receive the treatment 3 times per week (every other day) for 8 weeks, 24 sessions in total. Follow-up time is week 4 and week 12 after treatment (ie, week 12 and week 20)."
33004336|NCT05496543|Placebo Comparator|Sham acupuncture group|"Participants will receive sham acupuncture treatment on bilateral sham Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) that match real acupuncture points.~The duration of needle retention, treatment period, and follow-up in the control group is the same as that in the intervention group."
33004337|NCT05490277|Active Comparator|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
33004338|NCT05490277|Sham Comparator|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
33105442|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
33105443|NCT02889250|Experimental|Open Label DBS|6 months of DBS
33105444|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
33105445|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
33415016|NCT03715153|Experimental|BUMETANIDE/S95008|
33415017|NCT03715153|Placebo Comparator|PLACEBO|
33415018|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
33415019|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
33415020|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
33415021|NCT05708144|Experimental|Indocyanine green-Sacituzumab govitecan-hziy (ICG-SG)|The fresh excision breast cancer tissues were completely soaked in the ICG-SG incubation solution for about 10 minutes, followed by 5 minutes of rinsing with PBS buffer and drying with the use of absorbent paper. Then fluorescence imaging was performed with the DPM NIR-II system. And the result was analyzed to identify the tumor area and distinguish the tumor boundary.
33415022|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
33415023|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
33415024|NCT01348555|Experimental|V0162|
33415025|NCT01348555|Placebo Comparator|Placebo|
33004339|NCT05488847|Experimental|Multimodal, Non-Narcotic|This group will be given the preoperative, intraoperative, and discharge meds described below. This group will NOT receive any opioid-containing meds. Preoperative meds: Celecoxib: 400 mg by mouth, Pregabalin: 75 mg by mouth, Tramadol: 50 mg by mouth. Intraoperative meds: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge meds: Dexamethasone: 4 mg by mouth twice per day for 4 days (for same day discharge only), 10 mg IV on postoperative day 1 (for overnight patients only), Pregabalin: 75 mg by mouth twice per day for 14 days, Tizanidine: 2 mg by mouth every 6 hours for 14 days, Magnesium: 200 mg by mouth twice per day for 14 days, Ibuprofen: 600 mg by mouth every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg by mouth every 8 hours not to exceed 3000 mg per day for 1 month.
33004340|NCT05488847|Active Comparator|Multimodal Plus Narcotic|This group will be given the preop, intraop, and discharge meds described below. They will also be given 35 pills of oxycodone hydrochloride 5mg to be taken every 6 hours as needed at discharge. Preoperative: Celecoxib: 400 mg PO, Pregabalin: 75 mg PO, Tramadol: 50 mg PO. Intraoperative: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge: Dexamethasone: 4 mg PO twice per day for 4 days (for same day discharge only), 10 mg IV on postop day 1 (for overnight patients only), Pregabalin: 75 mg PO twice per day for 14 days, Tizanidine: 2 mg PO every 6 hours for 14 days, Magnesium: 200 mg PO twice per day for 14 days, Ibuprofen: 600 mg PO every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg PO every 8 hours not to exceed 3000 mg per day for 1 month.
33415026|NCT04437277|Experimental|Patients consenting|
33415027|NCT00687986|Active Comparator|primary surgery|primary surgical resection
33415028|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
33415029|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
33004341|NCT05487846|Experimental|Arm I (peer navigation)|Patients receive assistance from a peer navigator during genetic evaluation processes. Peer navigators help patients schedule counseling appointments, discuss questions and concerns about testing, assist in sample collection, schedule a post-test disclosure visit, and do a results and recommendations debrief.
33004342|NCT05487846|Active Comparator|Arm II (best practice)|Patients receive standard care during genetic evaluation processes. Patients receive genetic counseling, undergo genetic testing, schedule a post-test disclosure visit, and receive their genetic test results and recommendations per standard care.
33004343|NCT05479370|Experimental|Frequently vaccinated Group 1: QIV-R|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
33004344|NCT05479370|Experimental|Frequently vaccinated Group 2: QIV-E|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
33004345|NCT05479370|Experimental|Frequently vaccinated Group 3: QIV-C|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
33004346|NCT05479370|Experimental|Infrequently vaccinated Group 4: QIV-R|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
33004347|NCT05479370|Experimental|Infrequently vaccinated Group 5: QIV-E|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
33004348|NCT05479370|Experimental|Infrequently vaccinated Group 6: QIV-C|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
33004349|NCT05479136|Experimental|PET study|Single intravenous administration of 18F fluciclovine for PET Scan
33105446|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
33105447|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
33105448|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
33105449|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
33325259|NCT05196256|Active Comparator|Combined Spinal-Epidural group (CSE)|Spinal injection through a 25 Gauge needle of Levobupivacaine 2.5mg and Sufentanyl 2.5 mcg in a total volume of 2 mL, placing an epidural catheter through a Tuohy 18 Gauge needle. The epidural medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL. The epidural medication is administered on a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractioned bolus of 20 mL will be administered epidurally 30 min after the intrathecal injection, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20min, all along the dilatation and expulsion period.
33325260|NCT05196178|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
33325261|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
33325262|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
33325263|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
33325264|NCT05195554|Experimental|Intervention group|The intervention groups will involve a psycho-educational intervention and will consist of between 10 and 12 people led by two professionals, one of whom must be a psychologist, while the other may be any professional in the center (usually social workers).
33325265|NCT05195554|No Intervention|Control group|Participants in the control group will receive information on suicide and advice if the suicidal ideation increases.
33325266|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle pain induced by the tourniquet pain model~cognitive tests~recording of brain activity by use of 64 channel cap"
33325267|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle induced pain by the tourniquet pain model~cognitive tests~brain activity by use of a 64 channel cap"
33325268|NCT05195086||Cyc group|
33325269|NCT05195086||MMF group|
33325270|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
33325271|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
33325272|NCT05194852|Active Comparator|group 1|Group I received ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach
33325273|NCT05194852|Experimental|group 2|group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach
33325274|NCT05194774||GT overgrowth group|pediatric patients with greater trochanter overgrowth
33325275|NCT05194306|Experimental|Perla® Cold Preservation solution|Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient.
33325276|NCT05194150|Experimental|Rayone EMV|Patient will receive the non-diffractive monofocal IOL during cataract surgery
33325277|NCT05194150|Experimental|Acrysof IQ Vivity|Patient will receive the standard EDOF IOL during cataract surgery
33325278|NCT05193838||Allopurinol|we plan to follow up effect of Allopurinol on left ventricular function in children with dilated cardiomyopathy for 6 months
33325279|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
33325280|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
33325281|NCT05193604|Experimental|TQB2858 injection|"Cohort 1: TQB2858 injection administered intravenously on day 1 of each 21-day cycle.~Cohort 2: TQB2858 injection administered intravenously on day 1 of each 21-day cycle, gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle.~Cohort 3: TQB2858 injection administered intravenously on day 1 of each 21-day cycle，gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle，Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)."
33325282|NCT05186116|Experimental|LDLT recipients|Patients that undergo LDLT for CRLM in the study period
33325283|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
33325284|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
33325285|NCT05173558|Experimental|Uninterrupted motionless standing|20minutes of uninterrupted motionless standing
33325286|NCT05173558|Experimental|Uninterrupted motionless sitting|20 minutes of uninterrupted motionless sitting
33325287|NCT05173558|Experimental|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
33325288|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
33415030|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
33415031|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
33415032|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
33415033|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
33415034|NCT00306098|Experimental|Islet transplantation|
33415035|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
33415036|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
33415037|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
33004354|NCT05478369|Experimental|storybook|anxiety and fear
33004355|NCT05478369|No Intervention|control|not anxiety and fear
33004356|NCT05478213|Experimental|Monophasic Action Potential (MAP) Catheter|Participants undergoing ventricular tachycardia ablation per standard of care will also have cellular action potential of the ventricular myocardium assessed with the MAP catheter.
33004357|NCT05475821|Experimental|Group 1|Participants will receive ABBV-990 Dose A or matching placebo.
33004358|NCT05475821|Experimental|Group 2|Participants will receive ABBV-990 Dose B or matching placebo.
33004359|NCT05475821|Experimental|Group 3|Participants will receive ABBV-990 Dose C or matching placebo.
33004360|NCT05475821|Experimental|Group 4|Participants will receive ABBV-990 Dose D or matching placebo.
33004361|NCT05475821|Experimental|Group 5|Participants will receive ABBV-990 Dose E or matching placebo.
33004362|NCT05468242|Experimental|Neoadjuvant Chemotherapy Plus Tislelizumab + Bevacizumab|Patients in experimental group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab + Bevacizumab and concurrent chemoradiotherapy plus anlotinib.
33004363|NCT05468242|Active Comparator|Neoadjuvant Chemotherapy Plus Tislelizumab|Patients in this group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab and concurrent chemoradiotherapy.
33004364|NCT05459636|Active Comparator|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
33004365|NCT05459636|Sham Comparator|Very-low resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
33004366|NCT05454098|Experimental|Fed states in healthy subjects|A single 40mg dose of Clifutinib administered in a fed state.
33004367|NCT05454098|Experimental|Fasted states in healthy subjects|A single 40mg dose of Clifutinib administered in a Fasted state.
33004368|NCT05451901|Experimental|Immediate necrosectomy|Endoscopic necrosectomy will be conducted in the same session of EUS-guided drainage (or at least within 72 hours of randomization) and be repeated until clinical success.
33004369|NCT05451901|Active Comparator|Step-up approach|Step-up treatment will be conducted if a patient's condition does not improve after EUS-guided drainage. The step-up approach includes increasing the number of stents, adding another EUS-guided drainage, and performing percutaneous drainage after 72-96 hours of the initial drainage. Endoscopic necrosectomy is considered when clinical improvement is not observed even after two times of step-up treatment.
33004370|NCT05451602|Experimental|HEC169096|Multiple doses of HEC169096
33004371|NCT05433402|Active Comparator|Control|
33004372|NCT05433402|Experimental|Chloropromazine|
33004373|NCT05431881|Placebo Comparator|Control|A silent state (a wave file made without sound) is applied for at least 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume (at a volume corresponding to 60 dB in the experimental group), and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
33004374|NCT05431881|Experimental|Binaural beat|In the experimental group, the binaural sound, which was produced by the beat of 2Hz difference, is applied for 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume corresponding to 60 dB, and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
33415038|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
33004375|NCT05423951|Experimental|Remimazolam|
33004376|NCT05423951|Active Comparator|Propofol|
33004377|NCT05418153||Synergy IOL|Patients implanted with the Synergy IOL in both eyes.
33004378|NCT05416957|Experimental|SF001 ODT administered under fasting condition|Investigational product administration under fasting condition
33415039|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
33415040|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
33004379|NCT05416957|Experimental|SF001 ODT administration under fed condition|Investigational product administration under fed condition
33004380|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg
33004381|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg
33004382|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg
33004383|NCT05416515|Experimental|Carpal Tunnel Syndrome|Adult men and post-menopausal women who have a clinical diagnosis for Carpal Tunnel Syndrome (CTS) will receive Fisetin for 2 day periods for 2 months
33004384|NCT05415488|Active Comparator|IBS dietary advice according to the NICE guidelines|The traditional dietary advice according to the NICE guidelines and the systematic reviews performed by the British dietetic association (BDA) include having regular meals and to take time to eat, not to skip meals or eat too much at ones. The diet also limits intake of known trigger foods, such as coffee, alcohol, fizzy drinks, spicy foods, fatty foods etc. People who experience loose stools are recommended to avoid sweeteners (-ol), and people with wind/bloating are recommended to eat soluble fibers such as oats and flaxseeds.
33004385|NCT05415488|Sham Comparator|A healthy diet according to the Swedish dietary guidelines|This diet includes eating 500 grams of vegetables and fruits/day, fish approximately 3 times/week, 70 grams of wholegrain/day and to limit intake of red meat.
33004386|NCT05414097||Phase 1 : 24 Women|HIV-positive, previously screened forcervical cancer , HIV-positive, not previously screened for cervical cancer, HIV-negative, previously screened for cervical cancer, HIV-negative, not previously screened for cervical cancer
33004387|NCT05414097||Phase 1: 16 Men|Male partners in 4 focus groups, referred by women previously screened or treated for cervical cancer and referred by women not previously screened for cervical cancer
33004388|NCT05414097||Phase 1: 12 Key stakeholders|Women's groups, Women's health providers, laboratory personnel, NGOs and public health organization
33004389|NCT05414097||Phase 2:300 women|Women 18 years of age and older will be eligible for participation
33004390|NCT05414097||Phase 3: 36 Women, women's health providers, and policy makers.|Adults 18 years and older will be eligible for participation. Up to 12 women previously screened for the study, up to 12 women's health providers and up to 12 policy makers
33004391|NCT05406596|Experimental|LiquID GCE Use|
33004392|NCT05406076|Active Comparator|Oral Motor Therapy/ABA|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The experimental group was first treated with 2 months of ABA + oral motor therapy, followed by 2 months of ABA treatment.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
33004393|NCT05406076|Active Comparator|ABA/Oral Motor Therapy|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The control group was treated with 2 months of ABA followed by 2 months of ABA + oral motor therapy.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
33004394|NCT05405621|Experimental|Cohort 1|Experimental: BAT8009 for Injection 0.6 mg/kg (frequency: Q3W)
33004395|NCT05405621|Experimental|Cohort 2|Drug: BAT8009 for Injection 1.2 mg/kg (frequency: Q3W)
33004396|NCT05405621|Experimental|Cohort 3|Drug: BAT8009 for Injection 2.4 mg/kg (frequency: Q3W)
33004397|NCT05405621|Experimental|Cohort 4|Drug: BAT8009 for Injection 3.6mg/kg (frequency: Q3W)
33004398|NCT05405621|Experimental|Cohort 5|Drug: BAT8009 for Injection 4.8mg/kg (frequency: Q3W)
33004399|NCT05405621|Experimental|Cohort6|Drug: BAT8009 for Injection 6.0mg/kg (frequency: Q3W)
33004400|NCT05405621|Experimental|Cohort 7|Drug: BAT8009 for Injection 7.2mg/kg (frequency: Q3W)
33004401|NCT05405621|Experimental|Cohort 8|Drug: BAT8009 for Injection 8.4mg/kg (frequency: Q3W)
33004402|NCT05400395|Experimental|GNX|GNX / 80mg / BID / PO
33004403|NCT05400395|Placebo Comparator|Placebo|Placebo / BID / PO
33004404|NCT05389722|Experimental|Part 1|
33004405|NCT05389722|Experimental|Part 2|
33004406|NCT05389722|Experimental|Part 3|
33004407|NCT05383196|Experimental|DOSE ESCALATION ONVANSERTIB + PACLITAXEL|"In the phase 1b, dose escalation/de-escalation will be managed using a BOIN design to identify the RP2D.~The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~Onvansertib~Paclitaxel"
33004408|NCT05383196|Experimental|DOSE EXPANSION RP2D ONVANSERTIB + PACLITAXEL|"The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~Onvansertib~Paclitaxel"
33004409|NCT05374941|Experimental|Stimulation not synchronized with breathing|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable without a breathing sensor.
33105450|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
33415041|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
33004410|NCT05374941|Experimental|Stimulation during inhalation only|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable with a breathing sensor.
33004411|NCT05372068|Experimental|Concrete household floor|
33004412|NCT05372068|No Intervention|Non-intervention|
33415042|NCT05708066|Experimental|Lavender Aromatherapy Tab|If part of the experimental group, participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations. After the lavender patch has been in place for 5 minutes, participants will receive the same visual analogue scale (VAS) anxiety questionnaire.
33415043|NCT05708066|Placebo Comparator|Non-scented Tab|If part of the placebo comparator group, participants will have an unscented tab placed on the chest, according to manufacturer recommendations. Participants in this group will only receive the initial visual analogue scale (VAS) anxiety questionnaire.
33415044|NCT04014842|Other|RapidShock|Patients receiving xseries device with rapid shock enabled
33004413|NCT05371665|Experimental|Culturally Adapted Compass for Courage|All youth will receive the culturally adapted Compass for Courage from Native American providers in the school setting.
33004414|NCT05359783|Experimental|Sentinel node detection with 0.1mL SPIO|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.1mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola
33004415|NCT05359783|Experimental|Sentinel node detection with 0.25mL SPIO|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.25mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola
33004416|NCT05359783|Experimental|Sentinel node detection with 0.5mL SPIO|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.5mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola
33004417|NCT05353218|Active Comparator|Group intermediate cervical plexus block (GI)|Patients anesthetized with intermediate cervical plexus block.
33004418|NCT05353218|Active Comparator|Group deep cervical plexus block (GD)|Patients anesthetized with deep cervical plexus block.
33415045|NCT04014530|Experimental|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
33415046|NCT04014530|Experimental|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
33415047|NCT04014530|Experimental|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
33415048|NCT05212610|Experimental|Pfizer-BioNTech mRNA COVID-19 vaccine or Moderna mRNA COVID-19 vaccine|Subject will receive an initial or additional dose of either the Pfizer-BioNTech (Comirnaty) mRNA COVID-19 vaccine or the Moderna (Spikevax) mRNA COVID-19 vaccine
33415049|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
33415050|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
33415051|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
33417439|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
33004419|NCT05351541|Experimental|Psilocybin in combination with zolpidem and modafinil|Single dose of Psilocybin (1mg-25mg) in combination with zolpidem and modafinil
33004420|NCT05351541|Experimental|Psilocybin in combination with zolpidem|Single dose of Psilocybin (1mg-25mg) in combination with zolpidem
33004421|NCT05351541|Experimental|Psilocybin in combination with modafinil|Single dose of Psilocybin (1mg-25mg) in combination with modafinil
33004422|NCT05351541|Experimental|Psilocybin in combination with placebo|Single dose of Psilocybin (1mg-25mg) in combination with placebo
33004423|NCT05351333|Experimental|Conditioning Open-Label Placebo|Days 1 to 3 will include the acquisition phase where the opioid medication will be prescribed on a schedule of 3-4 times per day and paired with an open-label placebo. Day 4 and 6 will be the evoked phase, and patients will receive only the open-label placebo pill. On day 5 the opioid medication will be re-introduced as pharmacological reinforcement.
33004424|NCT05351333|No Intervention|Treatment as usual|Patients in the standard of care group will receive their analgesic treatment through Spaulding Pharmacy as prescribed by their treating physicians. The treatment regime will include an opioid medication at the standard recommended dosage. Participants in this group will receive the treatment orally for 6 consecutive days.
33004425|NCT05350696|Active Comparator|Erector Spinae Plane block group|(30 patients) will receive bilateral ultrasound guided erector spinae plane block using plain bupivacaine 100 mg diluted to volume using normal saline to achieve 50% concentration ( 50 mg plain pubivicaine in each side ).
33004426|NCT05350696|Active Comparator|Intravenous Morphine group|(30 patients) will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
33004427|NCT05348252|Experimental|Interventional group (Patient Journey App)|The interventional group will receive all information and instructions on discontinuing PPI use through the Patient Journey App.
33004428|NCT05348252|Active Comparator|Control group (Conventional Care)|The control group will receive all information and instructions on discontinuing PPI use through email as a digital information folder.
33415052|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
33004429|NCT05339828||unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. Next, a local anesthetic agent comprising a solution of lidocaine (20 mg/mL) and adrenaline (0.0125 mg/mL) was diluted with distilled water in a 1:2 ratio and applied. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing.
33415053|NCT03835598||Patients with cardiac biological prosthesis|
33415054|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
33415055|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
33415056|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
33004430|NCT05339672||Morphine|The participating patients are treated with morphine before start of enzalutamide (according to label).
33004431|NCT05339672||Edoxaban|The participating patients are treated with edoxaban before start of enzalutamide (according to label).
33004432|NCT05332002|Other|4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),|"A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:~Odd Cycles (e.g. 1, 3, 5, etc…) - mFOLFOX6 initiated on days 1 & 15: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Even Cycles (e.g. 2,4,6, etc…) - FOLFIRI initiated on days 1 & 15: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Nivolumab (optional, in-line with labelled approval) - 240 mg every 2 weeks"
33004433|NCT05322200|Active Comparator|Active drug|Oral Semaglutide + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
33004434|NCT05322200|Placebo Comparator|Placebo|placebo (same dose and administration route) + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
33004435|NCT05303974|Experimental|Novices|Measurement of competence
33004436|NCT05303974|Experimental|Intermediates|Measurement of competence
33004437|NCT05303974|Experimental|Experts|Measurement of competence
33004438|NCT05301361|Active Comparator|Methylphenidate|
33004439|NCT05301361|Placebo Comparator|Placebo|
33004440|NCT05299346||Post ICU covid survivors|Patients having survived and discharged from ICU care as a result of Covid 19
33004441|NCT05291156|Experimental|Cetuximab + avelumab|"Cetuximab + avelumab (115 patients) - cetuximab at 400 mg/m2, as loading dose, and, subsequently, at 250 mg/m2 weekly, and avelumab was given intravenously at flat dose of 800 mg, once every 2 weeks.~Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol."
33004442|NCT05291156|Active Comparator|Cetuximab|Cetuximab only (58 patients) - cetuximab at 400 mg/m2 intravenously, as loading dose, and, subsequently, at 250 mg/m2 weekly. Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol.
33004444|NCT05267899|Experimental|WGI-0301|
33004445|NCT05261477|Experimental|Intervention group|Intervention group receives one in person education session using the 1stBIEN booklet, video education via mobile phones and care coordination from a bilingual Patient Navigator-PN for 3-months. PN follow up patients weekly for the first month and once a month for two months. Video education is done weekly. Videos cover problem solving training, brain injury concepts, rehabilitation treatments and school resources individualized to patient and family needs. PNs facilitate transition to outpatient care, follow-up with specialists and primary care providers; use of community resources; and communication with teachers and school administrators. PN provides observational and experiential learning opportunities for parents, using three way calls for scheduling of services and interactions with clinics and schools. PN calls use a problem-solving training format, to reinforce parental experiential learning and improve self-efficacy. Expert MD providers (Co-investigators) will supervise PNs.
33004446|NCT05261477|No Intervention|Attention Control group|Attention Control group receives one in person education session using the 1stBIEN booklet, monthly well-child texts and usual post-injury care including routine follow-up by specialists and primary care providers, per guidelines at each recruiting institution. Control patients have access to a list of community resources included in the 1stBIEN booklet. While education using the 1stBIEN booklet is not part of the current usual care at participating institutions, providing all families with initial education at the time of discharge addresses ethical and practical considerations. It standardizes discharge processes at participating institutions while delineating differences in the intensity of education and care coordination activities.
33004447|NCT05256355|Other|MSUS novices|Measurement of competence
33004448|NCT05256355|Other|MSUS intermediates|Measurement of competence
33004449|NCT05256355|Other|MSUS experts|Measurement of competence
33004450|NCT05253118|Experimental|Treatment|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed. And pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
33004451|NCT05226923|Experimental|KSP-1007 single ascending dose|Single, ascending intravenous dose of KSP-1007
33004452|NCT05226923|Placebo Comparator|Placebo single dose|Single dose of placebo (0.9% normal saline)
33004453|NCT05226923|Experimental|KSP-1007 multiple ascending dose|Multiple, ascending, intravenous doses of KSP-1007
33004454|NCT05226923|Placebo Comparator|Placebo multiple dose|Multiple doses of placebo (0.9% saline)
33415057|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
33415058|NCT05066984|Experimental|structured, multidisciplinary and personalized post-ICU care|structured, multidisciplinary and personalized post-ICU care
33004455|NCT05226923|Experimental|KSP-1007 multiple ascending dose + Meropenem multiple dose|Multiple, ascending intravenous doses of KSP-1007 and multiple doses of meropenem (fixed dose)
33004456|NCT05226923|Placebo Comparator|Placebo + Meropenem multiple dose|Multiple doses of placebo (0.9% normal saline) plus multiple doses of meropenem (fixed dose)
33004457|NCT05216666|Active Comparator|Lateral approach|290 participants receive their hip prosthesis through a lateral approach. The anterior third of m. gluteus medius along with the corresponding part of m. vastus lateralis are detached from the greater trochanter and the anterior capsule is excised for the exposure of the hip joint. After implant insertion, the gluteus medius is reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
33004458|NCT05216666|Active Comparator|Posterior approach|290 participants receive their hip prosthesis through a posterior approach. The m. piriformis gemelli and obturator internus are detached from the greater trochanter and the posterior capsule is incised for the exposure of the hip joint. After implant insertion, the posterior capsule as well as m piriformis and the external rotators are reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
33004459|NCT05209464|Experimental|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via a mobile application.
33004460|NCT05209165|Experimental|Semaglutide|
33004461|NCT05209165|Placebo Comparator|Placebo|
33004462|NCT05204680|Experimental|Aerobic Exercise|"The participant will work with the physical therapist on an exercise regimen and first session will be supervised with the therapist. Exercise protocols will include a 15-minute warmup and cooldown session as well. To allow for increased participation and accessibility, the means of aerobic exercise will not be restricted and any safe mechanism of exercise will be allowed e.g., treadmill, stationary bike, etc.~Subjects will be provided an activity monitor (Phillips HealthBand Monitor) for the duration of study participation and receive training on how to use it, including marking events with start and stop of exercise sessions and tracking heart rate. The device can track type of activity as well as cardio fitness index and VO2max."
33004463|NCT05202769||Healthy Volunteers|20 healthy volunteers above the age of 18 in a laboratory setting with video clips taken under varying conditions of lighting, distance between the cameras and the participants' faces and with various positions and limb movements involved.
33004464|NCT05202769||ICU patients|Group/Cohort Description: 20 patients above the age of 18 years and able to provide consent, admitted to the ICU with various underlying conditions and comorbidities. Video clips are taken under varying conditions of lighting, positions and with ongoing care and procedures.
33415059|NCT05066984|No Intervention|Ususal care|Usual care
33004465|NCT05199454|Experimental|Exercise training|Aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session.
33004466|NCT05199454|No Intervention|Control (standards of care)|This arm will receive brochures for healthy lifestyle recommendations. No intervention will be conducted.
33415060|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
33415061|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
33004467|NCT05183776|Experimental|Study patients|study patients will receive holmium radioembolization using a novel administration device.
33004468|NCT05180279|Experimental|Sleep Lab|
33004469|NCT05174702||Percutaneous surgery|Patient will have a percutaneous hallus valgus surgery
33004470|NCT05174702||conventional surgery|Patient will have a conventional hallus valgus surgery
33004471|NCT05172297|Experimental|Immediate Intervention Group|The immediate intervention group will take part in the online parent training program called the Parent Web (PW). This immediate intervention group are parents of PATHS children who took part in a social emotional curriculum (PATHS) at age 4 to 5 years old and during the PW trial will be 11 to 13 years old. Parents are participating in the Parent Web.
33004472|NCT05172297|Other|Wait-List Control Group|This is a group of parents who are in a wait-list control group and will receive the Parent Web, after pre and post testing.
33004473|NCT05170984|Experimental|CACIPLIQ20®|Treatment of the target wound with CACIPLIQ20® in addition to optimal local care
33004474|NCT05158933|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33004475|NCT05158205|Experimental|Yoga postures or slow, deep breathing|
33004476|NCT05158205|Sham Comparator|Control|
33004477|NCT05158114|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33004478|NCT05158101|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33105451|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
33415062|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
33415063|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
32865631|NCT04852770|Active Comparator|Positive psychotherapy|Positive psychotherapy (PPT) seeks to understand positive emotions, psychological potentialities and healthy human / social / institutional functioning, and to apply this knowledge to help people and institutions, with a focus on prevention and promotion of mental health (SELIGMAN et al., 2005). Originally, PP focused on happiness and subjective well-being (SELIGMAN, 2010; SELIGMAN; CSIKSZENTMIHALYI, 2000). Then, the studies gained a broader view of psychological well-being and another similar proposal entitled PERMA, which is composed of the following five spheres: positive emotions - P; engagement - E; relationships - R; meaning - M; and achievement - A. (RYFF, 2013; SELIGMAN, 2012). Although positive psychology aims to be a way of looking at life, some psychotherapeutic proposals, such as positive psychotherapy (PPT), have been developed, and clinical studies have been replicated in different clinical and cultural contexts (RASHID; SELIGMAN, 2019; RICHES et al., 2016).
33105452|NCT02897609||A simple questionary filled|
32865632|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium~all patients are hospitalized for a week during which they do not sleep on alternating nights~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
32865633|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
32865634|NCT05586425|Experimental|Emotion Regulation Skills + Treatment as Usual|Emotion Regulation Skills (ERS), a version of Dialectical Behaviour Therapy Skills Training, is a type of skills-focused therapy for individuals who experience severe emotion dysregulation.
33105453|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
33105454|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
33105455|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c <58mmols/mol, and family members.
33105456|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and <100mmols/mol, and family members.
33105457|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
33105458|NCT03898180|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. Lenvatinib may be continued past 35 cycles until a discontinuation criterion is met.
33105459|NCT03898180|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. Placebo may be continued past 35 cycles until a discontinuation criterion is met.
33105460|NCT03898180|Experimental|Pembrolizumab monotherapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) until progressive disease or discontinuation.
33105461|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
33105462|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
33105463|NCT04680962|Experimental|MabionCD20 / MabionCD20|Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
33105464|NCT04680962|Active Comparator|EU-Rituximab / EU-Rituximab|Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
33105465|NCT04680962|Active Comparator|US-Rituximab / MabionCD20|Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26.
33105466|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
33105467|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
33415064|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
33415065|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
33415066|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
33415067|NCT05052476|Experimental|Open label Bactecal® D Liquid 1 dose|Patients will receive 1 dose of Bactecal® D Liquid by day which corresponds to 2 ml of product
33415068|NCT05052476|Experimental|Open label Bactecal® D Liquid 2 doses|Patients will receive 2 doses of Bactecal® D Liquid by day which correspond to 4 ml of product.
33415069|NCT05036720|Experimental|LTP+Dads|Participants in this arm will be offered the LTP+Dads intervention. The intervention will be delivered by trained Community Health Workers (CHWs). This will be co-facilitated by LTP+ master trainers.
33105468|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
33105469|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
33105470|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
33105471|NCT03881098|Other|Squamous Cell Carcinoma Pre-Malignant Lesions|The prospective SCC-PML cohort is envisioned to provide a well-matched group of high-risk subjects that will provide clinically comparable subjects with lesional sites representing progressive and non-progressive disease.
33105472|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
33105473|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
33105474|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
33105475|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
33105476|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
33105477|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
33415070|NCT05036720|Other|Wait-list control:|Participants in this arm will be offered the intervention once the LTP+ arm have completed their outcome assessment. For example, in each Union Council (UC) once the LTP+ arm has completed the intervention and 4th month outcome assessment the wait-list control group in the same UC will be offered the intervention.
33415071|NCT05036720|Other|Optional mothers component|To facilitate changes in co-parenting and optimize impact on child development, the partners of fathers who participate will be offered optional LTP+ group sessions running parallel to LTP+Dads.
33415072|NCT05017298|Experimental|Study Group|Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.
33415073|NCT05017298|Placebo Comparator|Control Group|The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.
33415074|NCT04705766||COVID-19 Negative|Control group to measure progression of AKI/kidney injury overtime
33415075|NCT04705766||COVID-19 Positive|Study group to assess AKI trajectory/progression and associated risk factors of kidney injury with SARS-CoV-2 infection
33415076|NCT04763720||Dyadic Developmental Psychotherapy|Families being treated with DDP at either of the centres
33415077|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
33415078|NCT05310110|Experimental|10% lidocaine spray and cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
33415079|NCT05310110|Experimental|10% lidocaine spray and placebo of cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1.25 mg/kg.
33415080|NCT05310110|Experimental|Placebo of lidocaine spray and cisatracurium group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
33415081|NCT05310110|Placebo Comparator|Placebo group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 2 mg/kg.
33415082|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
33415083|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
33105478|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
33105479|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
33105480|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
33105481|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
33105482|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
33415084|NCT05294588|Experimental|Experimental arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the experimental arm receive the recommended two doses of BEXSERO™ prior to bacterial challenge and control vaccines (FLULAVAL™ and TDVAX™) in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
33417440|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
33105483|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
33105484|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
33415085|NCT05294588|Other|Control arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the control arm receive control vaccines that have no relevance to N. gonorrhoeae infection (FLULAVAL™ and TDVAX™) prior to bacterial challenge and then receive two doses of BEXSERO™ in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
33415086|NCT04697576|Experimental|Cohort I (quadrivalent inactivated influenza vaccine)|Patients receive influenza vaccine IM on day 0 and intratumorally on days 2 and 14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 28.
33004479|NCT05152615|Experimental|New Onset Rheumatoid Arthritis (NORA) Patient|NORA patients receiving methotraxate as first line therapy (standard of care) will take additional oral SCFA supplementation for the purposes of the study.
33004480|NCT05152368|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33004481|NCT05152290|Experimental|Treatment Group (AlloRx)|intravenous infusion and intrathecal injection (total of 100 million cells)
33004482|NCT05147701|Experimental|Treatment Group (AlloRx)|intravenous and sub-tenon delivery (total dose of 100 million cells)
33004483|NCT05147675|Experimental|Treatment Group (AlloRx)|Intravenous infusion and intraarticular injection (total dose of 100 million cells)
33004484|NCT05137275|Experimental|Anti-5T4 CAR-raNK Cells|
33004485|NCT05136807||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.
33004486|NCT05135546|Experimental|Experimental|Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
33004487|NCT05135546|Placebo Comparator|Placebo control|Placebo
33004488|NCT05126316|Experimental|Lu AG09222 Low Dose|Participants will receive Lu AG09222 injection at a low dose level 3 times with 4 weeks between each administration.
33004489|NCT05126316|Experimental|Lu AG09222 High Dose|Participants will receive Lu AG09222 injection at a high dose level 3 times with 4 weeks between each administration.
33004490|NCT05126316|Placebo Comparator|Placebo|Participants will receive placebo matching to Lu AG09222 injection 3 times with 4 weeks between each administration.
33004491|NCT05098327|Active Comparator|Prostate cancer on ADT receiving pioglitazone|Subjects will receive a 12-week supply of pioglitazone 30 mg dose 1 tab daily
33004492|NCT05098327|Placebo Comparator|Prostate cancer on ADT receiving placebo|Subjects will receive a 12 week supply of placebo pills containing cellulose
33004493|NCT05098327|No Intervention|Prostate cancer not on ADT|No intervention will be done in this group
33004494|NCT05094713|Other|Flossing - control|Control group where flossing wrapping pressure is between 20 and 30 mmHg
33004495|NCT05094713|Experimental|Flossing with medium wrapping pressure|A flossing band will be applied over tight musculature with medium wrapping pressure
33004496|NCT05093842|Experimental|Sedentary Behavior Reduction Intervention|Biweekly virtual health coaching, height-adjustable work station, and fitbit - targetting decreasing sedentary behavior, increasing standing, and increasing steps per day. Printable information on physical activity recommendations also provided.
33004497|NCT05093842|Active Comparator|Usual Care Control|Printable information on physical activity recommendations only
33004498|NCT05086250|Experimental|Arm A: Ketamine Followed by Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
33004499|NCT05086250|Experimental|Arm B: Placebo Followed by Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
33004500|NCT05084222|Experimental|Buventol® Easyhaler® 200 µg/inhalation dmDPI|400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.
33004501|NCT05084222|Experimental|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.
33004502|NCT05084222|Active Comparator|Ventoline® Evohaler® 100 µg/inhalation pMDI|400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.
33004503|NCT05076838|Experimental|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
33004504|NCT05071729|Experimental|Moderate renal impairment|Participants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m^2
33004505|NCT05071729|Experimental|Severe renal impairment|Participants with eGFR < 30 mL/min/ 1.73 m^2
33004506|NCT05071729|Experimental|Normal renal function|Participants with ≥ 90 mL/min/1.73 m^2
33004507|NCT05059886||lower limb amputee|No intervention, pure observational study
33004508|NCT05057949|Experimental|Part A, Treatment Sequence(Larotinib-Larotinib/Rifampin)|Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.
33004509|NCT05057949|Experimental|Part B, Treatment Sequence(Larotinib-Larotinib/itraconazole)|Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.
33004510|NCT05056311|Experimental|Parent Utilization of Decision Aid Website|All enrolled parents will view the decision aid website for as long and as frequently as they wish before the initial visit to the urologist.
33415087|NCT04697576|Experimental|Cohort II (quadrivalent inactivated influenza vaccine)|Patients receive influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care ipilimumab, nivolumab, or pembrolizumab.
33415088|NCT04676906|Experimental|Study compound 1|Up to 6 volunteers will receive one dose of study compound 1
33415089|NCT04676906|Experimental|Study compound 2|Up to 6 volunteers will receive one dose of study compound 2
33415090|NCT04676906|Experimental|Study compound 3|Up to 6 volunteers will receive one dose of study compound 3
33415091|NCT04748510|Active Comparator|Functionally aligned Total Knee Arthroplasty|Knee arthroplasty performed using a functional alignment theory
33415092|NCT04748510|Active Comparator|Mechanical axis aligned Total Knee Arthroplasty|Knee arthroplasty performed using a mechanical alignment theory
33004511|NCT05048368|Experimental|Cohort A-Larotinib|Cohort A:Healthy participants with normal hepatic function （match to subjects with mild hepatic impairment_cohort B）
33004512|NCT05048368|Experimental|Cohort B-Larotinib|Subjects with mild hepatic impairment
33004513|NCT05048368|Experimental|Cohort C-Larotinib|Healthy participants with normal hepatic function （match to subjects with moderate hepatic impairment_cohort D）
33004514|NCT05048368|Experimental|Cohort D-Larotinib|Subjects with moderate hepatic impairment.
33004515|NCT05047640|Experimental|BNT162b2 vaccine|Participants in this arm will receive one booster dose of the BNT162b2.
33004516|NCT05047640|Experimental|JNJ-78436735 vaccine|Participants in this arm will receive one booster dose of the JNJ-78436735
33004517|NCT05047159|Experimental|drug therapy group|Drug: drug therapy There is no restriction on the choice of therapeutic drugs.
33004518|NCT05047159|Experimental|drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group|"Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
33004519|NCT05047159|Experimental|drug therapy combined with light therapy group|"Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
33004520|NCT05047159|Experimental|drug therapy combined with electroconvulsive therapy (ECT) group|"Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
33004521|NCT05047159|Experimental|drug therapy combined with magnetic seizure therapy (MST) group|"Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
33004522|NCT05033431|Experimental|Group 1 [Healthy Chinese Participants]|Participants will receive a single intravenous (IV) infusion of brazikumab dose 1 on Day 1.
33004523|NCT05033431|Experimental|Group 2 [Healthy Chinese Participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
33004524|NCT05033431|Experimental|Group 3 [Healthy Chinese Participants]|Participants will receive a single subcutaneous (SC) injection of brazikumab dose 3 on Day 1.
33004525|NCT05033431|Experimental|Group 4 [Healthy Chinese Participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
33004526|NCT05033431|Experimental|Group 5 [healthy White participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
33004527|NCT05033431|Experimental|Group 6 [healthy White participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
33004528|NCT05023616|Experimental|Real-time home CPR training|Online real-time home CPR(cardiopulmonary resuscitation) training will be provided to participants
33004529|NCT05023616|Active Comparator|Conventional CPR training|Conventional CPR training will be provided to participants
33004530|NCT05018858|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33004531|NCT05018845|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33004532|NCT05018819|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004533|NCT05018767|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004534|NCT05016817|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004535|NCT05016804|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004536|NCT05011331|Experimental|MedCline Shoulder Relief System|Patients who will receive the MedCline Shoulder Relief System pillow
33004537|NCT05011331|Active Comparator|Control|Patients who will not receive the MedCline Shoulder Relief System pillow
33004538|NCT05010993||Czech healthy people|Czech healthy men and women will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test.
33004539|NCT05009121||Czech adult people after stroke|Czech adult people after stroke will be asked basic questions about present feelings according to their condition using a questionnaire. Then they will be tested by the Box and Block Test in only one session. Video of their performance will be obtained. The Box and Block Test will be done during their regular rehabilitation by occupational therapist.
33004540|NCT05009108||Czech adult patients after a stroke|Czech adults patients after a stroke will be asked to fill in a informed agreement and as well to answer short questionnaire. Then they will be tested by the Purdue Pegboard Test in only one session. Video of their performance will be obtained as well.
33004541|NCT05003960|Experimental|Treatment Group|One intravenous infusion of 100 million cells
33004542|NCT05003947|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004543|NCT05003934|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004544|NCT05003388|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
33004545|NCT05001581|Active Comparator|Treatment with biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps augmentation after its tenodesis
33415093|NCT05238584|No Intervention|Total omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and total omentectomy.
33415094|NCT05238584|Experimental|Partial omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and partial omentectomy.
33415095|NCT04730570|Experimental|Essential Coaching for Every Mother Intervention|Women in the intervention arm will receive the Essential Coaching for Every Mother messages up to six-weeks postpartum. No changes in standard care.
33415096|NCT04730570|No Intervention|Standard care|Women in the control group will receive no content messages. No changes in standard care.
33415097|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
33415098|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
33415099|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
33415100|NCT03562754|Active Comparator|Control|
33415101|NCT03562754|Experimental|Prometheus System|
33415102|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
33415103|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
33415104|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
33415105|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
33415106|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
33415107|NCT04353674|Sham Comparator|Control|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo standard of care
33415108|NCT04353674|Active Comparator|SLEDD with a L-MOD|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
33415109|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
33415110|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
33415111|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
33415112|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
33415113|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
33415114|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
33415115|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
33415116|NCT04541888|Experimental|Experimental Group|322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
33415117|NCT04541888|Placebo Comparator|Control group|322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
33415118|NCT01354964|Experimental|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
32865635|NCT05586425|Active Comparator|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
32865636|NCT04843644|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
33415119|NCT01354964|Placebo Comparator|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
33415120|NCT03562676|Experimental|weightlessness|
33415121|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
33415122|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
33415123|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
33415124|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
33415125|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
33415126|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
33415127|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
33415128|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
33415129|NCT04164134||Retinoblastoma patients (children)|Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
33415130|NCT04164134||Controls (children)|Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
33004546|NCT05001581|Active Comparator|Treatment without biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps tenotomy
33004547|NCT04980365|Experimental|Mindfulness|Participants will be asked to use the app Mindfulness Coach 10 minutes for 14 days.
33004548|NCT04980365|Experimental|Gratitude|Participants will be asked to use the app Grateful 10 minutes for 14 days.
33004549|NCT04980365|Active Comparator|Control|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
33004550|NCT04976959|Experimental|Parkinson's patients|Parkinson's patients who will receive a high fiber supplement
33004551|NCT04976959|No Intervention|Control subjects|no supplement will be given
33004552|NCT04975776|Experimental|Sleep restriction therapy|Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.
33004553|NCT04975776|Active Comparator|Sleep hygiene|Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.
33004554|NCT04969718|Experimental|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
33004555|NCT04969718|Experimental|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
33004556|NCT04969718|Experimental|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
33004557|NCT04969718|Active Comparator|Educational poster|The control group will be exposed to the six educational posters.
33004558|NCT04969718|Experimental|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents). This includes both presentations and videos.
33004559|NCT04959162|Experimental|E-learning preparation|Will receive e-learning prior to a hands-on course in musculoskeletal ultrasound
33004560|NCT04959162|Active Comparator|Conventional preparation|Will receive standard information (time, place etc) prior to a hands-on course in musculoskeletal ultrasound
33004561|NCT04936620|Active Comparator|Duroplasty|Duroplasty (includes Surgery with Laminectomy)
33004562|NCT04936620|Active Comparator|No duroplasty|No duroplasty (but includes surgery with Laminectomy)
33004563|NCT04927364|Experimental|Active dTMS|Participants will receive 30 dTMS treatments, administered 3 times per day over 10 consecutive business days, Each treatment visit will last approximately 30 minutes in total.
33004564|NCT04925960|Experimental|Epalrestat|Epalrestat will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
33004565|NCT04925960|Placebo Comparator|Placebo|Placebo will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
33004566|NCT04912648||Women age 18 years and older|"baseline anthropometry~bloods for metabolic phenotype; targeted and nontargeted Metabolomics~saliva and urine for steroid Metabolomics~bioimpedance~muscle biopsy for transcriptomics"
33004567|NCT04909125|Active Comparator|Hypofractionation Arm|40Gy / 15 fractions, 2.67Gy per fraction, over 3.5 week (9 fractions per fortnight)
33004568|NCT04909125|Other|Standard /Conventional fractionation Arm|50Gy / 25 fractions, 2Gy per fraction, over 5.5 week (9 fractions per fortnight)
33004569|NCT04904432|Other|young ACS patients|
33004570|NCT04902326|Active Comparator|Enhanced Usual Care (EUC)|Receives one intervention: automated educational text messages
33004571|NCT04902326|Experimental|Financial Incentives|Receives two interventions: automated educational text messages and financial incentives.
33004572|NCT04902326|Experimental|Tailored Messages|Receives two interventions: autonomy-supportive automated educational text messages and tailored text messages.
33004573|NCT04902326|Experimental|Combo Arm-Financial Incentives Plus Tailored Messages Arm|Receives three interventions: autonomy-supportive automated educational text messages, tailored text messages, and financial incentives.
33004574|NCT04901312|Experimental|Enhanced A-CRA (E-ACRA)|Higher intensity
33004575|NCT04901312|Experimental|Assertive Community Support (ACS)|Lower intensity
33004576|NCT04897893|Experimental|Experimental Treatment|All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.
33004577|NCT04897347|Experimental|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
33004578|NCT04897347|Active Comparator|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
33004579|NCT04892303|Other|High-risk thyroid cancer patients|All study patients will have histologically confirmed recurrence of thyroid cancer that is incompletely responsive to initial surgery.
33004580|NCT04886297|Placebo Comparator|placebo|"The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).~Intervention: Drug: Mega Resveratrol® capsules"
33415131|NCT04164134||Retinoblastoma survivors (adults)|"Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past.~Blood will be collected and a short questionnaire has to be filled."
33415132|NCT04164134||Controls (adults)|Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
33415133|NCT04164134||Retinoblastoma survivors with Secondary primary malignancies|"Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy.~Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery."
33004581|NCT04886297|Experimental|100mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
33415134|NCT02259998|Experimental|Persantin® new formulation|
33415135|NCT02259998|Active Comparator|Persantin® commercial formulation|
33415136|NCT04009460|Experimental|Part A dose escalation|ES101 will be escalated in patients with advanced solid tumors.
33415137|NCT04009460|Experimental|Part B expansion|Subjects with solid tumors will be treated with single-agent ES101 at either specified dose levels or RP2D.
33415138|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
33004582|NCT04886297|Experimental|300mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
33004583|NCT04886297|Experimental|600mg/d resveratrol|"During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
33415139|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
33004584|NCT04836624|Experimental|Co-designing personalised aids of daily living|Participants will be involved in up to 6 interactive sessions spread over 3 months with the researcher. Participants will work with the researcher to help develop their own assistive device to overcome challenges of daily living they experience.
33415140|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
33415141|NCT02035826|No Intervention|Arm 4|Control Arm
33415142|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
33415143|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
33415144|NCT04110080|Experimental|Enhanced recovery after surgery|Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
33415145|NCT04110080|Active Comparator|Standard of care|Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
33415146|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
33415147|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
33415148|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
33415149|NCT05707832|Experimental|Amphotericin B cholesteryl Sulfate Complex for Injection|Subjects will receive ABCD intravenous injection.
33415150|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
33004585|NCT04830410|Experimental|Fructan powder|2 g of fructan powder 3 times per day for 7 days
33004586|NCT04830410|Placebo Comparator|Placebo|2g of placebo (maltodextrin) 3 times per day for 7 days.
33004587|NCT04818216|Placebo Comparator|Placebo Group|Placebo capsules will be administered 2 capsules twice daily for 10 days
33004588|NCT04818216|Experimental|Nicotinamide Riboside Group|Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
33004589|NCT04810793||Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group|Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
33004590|NCT04810793||Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group|Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33004591|NCT04810793||Tetracycline-Furazolidone-Esomeprazole-containing quadruple group|Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33004592|NCT04810793||Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
33004593|NCT04810793||Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33415151|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
33415152|NCT05707754|Active Comparator|High dose with unilateral administration|High dose (3ml) with unilateral administration of bupivacaine
33004594|NCT04810793||Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
33004595|NCT04798664|No Intervention|Basic Usual Care|Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
33004596|NCT04798664|Active Comparator|Enhanced Usual Care|Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
33004597|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives|Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
33004598|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives plus Mobile Health Application|"Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the future is now between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner."
33004599|NCT04797832|Active Comparator|Treatment|100 patients receiving IV Iron during index hospitalisation.
33004600|NCT04797832|No Intervention|No treatment|100 patients not receiving IV Iron above standout treatment.
33004601|NCT04781140|Placebo Comparator|Placebo|Placebo, qd
33004602|NCT04781140|Experimental|SPN-812|SPN-812, qd
33004603|NCT04754672|Experimental|Continuous aerobic and resistance exercise (AE+RE)|"Two 60 min moderate-to-high intensity exercise sessions per week supervised by a physiotherapist.~Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Resistance exercise (25 min): 6 exercises targeting large muscle groups vertical row, squat, bench press, pull over, abdominal crunch, and lunge. 2 sets of 10 repetitions at 70-80% of 1 RM. To ensure adequate training load over time, tests are repeated every 3/4 weeks aligned with the chemotherapy cycle.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
33004604|NCT04754672|Experimental|Continuous aerobic and aerobic interval exercise (AE+AI)|"Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Aerobic interval (25 min): cycling with high intensity intervals alternated with recovery intervals. Intensity of the interval: between 85% and 95% of estimated maximum heart rate, adjusted to Borg 16-18 'hard - very hard'. In between the intervals, light intensity cycling will be performed for active recovery at 30% of Wmax estimated from Steep ramp test and adjusted to Borg < 12.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
33004605|NCT04754672|No Intervention|Usual care control group|Patients in the usual care group receive care as usual. In addition, a brochure with exercise guidelines for cancer survivors is provided
33004606|NCT04753190|Placebo Comparator|Dim Room Light Control|Participants in the dim room light control group will not receive any bright light exposure.
33004607|NCT04753190|Experimental|Morning Bright Light Only (MBL)|"Participants in the morning bright light (MBL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive mornings in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
33004608|NCT04753190|Experimental|Afternoon Light Only (ABL)|"Participants in the afternoon bright light (ABL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive afternoons in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
33004609|NCT04753190|Experimental|Morning + Afternoon Light (MBL+ ABL)|"Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
33415153|NCT05707754|Active Comparator|High dose with bilateral administration|High dose (3ml) with bilateral administration of bupivacaine
33415154|NCT05707754|Active Comparator|Low dose with unilateral administration|Low dose (1ml) with unilateral administration of bupivacaine
33415155|NCT05707754|Active Comparator|Low dose with bilateral administration|Low dose (1ml) with bilateral administration of bupivacaine
33415156|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
33415157|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
33415158|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
33415159|NCT05707910|Experimental|Treatment Cohort|EBV immunological agent administration on day 1,7,14,28 and 60 for Intradermal Injection
33415160|NCT05707676|Experimental|Dose Escalation|"Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard BOIN dose escalation algorithm approach."
33417441|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
33417442|NCT01351181|Experimental|Exercise advice|Behavioural
33417443|NCT01351181|Other|Normal Care|Normal care
33325289|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
33325290|NCT05172154||15 subjects testing themselves|15 subjects 14 years of age and older
33004613|NCT04742647|Experimental|Single Cerclage|Standard single cervical cerclage will be placed
33004614|NCT04742647|Experimental|Double Cerclage|Double cerclage placement
33004615|NCT04732533|Experimental|tDCS|Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
33004616|NCT04709783|Experimental|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
33004617|NCT04709575|Experimental|REGN5713-5714-5715|REGN5713-5714-5715 administered subcutaneously
33004618|NCT04709575|Placebo Comparator|Placebo Only|Placebo matching REGN5713-5714-5715 administered subcutaneously
33004619|NCT04708717|Experimental|Stimulation Rate|
33004620|NCT04708717|Active Comparator|Electrode Location|
33004621|NCT04705896|Active Comparator|20-25% Albumin fluid|100 mL 20-25% Albumin fluid at the initiation of continuous renal replacement therapy (CRRT), prolonged intermittent renal replacement therapy (PIRRT), or intermittent hemodialysis (IHD) and another 100 mL 20-25% Albumin fluid and halfway through RRT sessions in ICU.
33004622|NCT04705896|Placebo Comparator|Normal Saline|100 mL at the initiation of CRRT, SLED or IHD and another 100 mL 0.9% Normal Saline halfway through RRT sessions in ICU.
33004623|NCT04684511|Experimental|TRM-201 (Rofecoxib)|1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
33004624|NCT04684511|Placebo Comparator|Placebo|1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II
33004625|NCT04680897|Other|Standard Group|Participants may resume vaginal penetration at 6 weeks.
33004626|NCT04680897|Other|Early Group|Participants may resume intercourse at 2 weeks
33004627|NCT04679311|Experimental|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with 2 units of fresh frozen plasma that have been preselected to contain ACE activity ≥50 U/L
33004628|NCT04679311|Placebo Comparator|Normal Saline|Subjects will be treated with normal saline 500 cc.
33004629|NCT04676373|Experimental|Alglucosidase Alfa|A dose of 20 mg/kg body weight once every 2 weeks for a minimum of 52 weeks
33004630|NCT04673149|Experimental|GLS-5310 0.6mg [Group 1a]|0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
33004631|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
33004632|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1c]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.
33004633|NCT04673149|Placebo Comparator|Placebo [Group 2a]|Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).
33004634|NCT04673149|Experimental|GLS-5310 1.2mg [Group 2b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).
33004635|NCT04669652|No Intervention|ICSI|Traditional microinjection (ICSI) is performed on oocytes.
33004636|NCT04669652|Experimental|Piezo-ICSI|Microinjection (ICSI) is performed using the Piezo-ICSI technique.
33004637|NCT04658537|Active Comparator|Standard Arm|8 Gy / 1 Fraction
33004638|NCT04658537|Experimental|Single Fraction Dose Escalation|8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction
33004639|NCT04653064|Experimental|Placebo Cream first|"Each participant will undergo thermal pain tasks after being administered a treatment cream to one of eight body sites."
33004640|NCT04653064|Experimental|Control Cream first|"Each participant will undergo thermal pain tasks after being administered a control cream to one of eight body sites."
33004641|NCT04650841|Experimental|Naloxone Group|Participants will receive 4mg naloxone nasal spray.
33004642|NCT04650841|Experimental|Saline Group|Participants will receive saline in the nasal spray.
33004643|NCT04649125|Active Comparator|standard|standard radiotherapy 5 fractions
33004644|NCT04649125|Experimental|single fraction dose escalation|8Gy to Planned Target Volume, 12Gy to Clinical Target Volume +/- 14Gy to Gross Target Volume
33004645|NCT04646460|Experimental|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
33325291|NCT05172154||15 subjects testing someone else|15 adult subjects testing individuals ages 2-13
33325292|NCT05167552|Experimental|Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells|Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
33325293|NCT05167552|Experimental|Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells|Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
33325294|NCT05167552|Active Comparator|Patients with allergic rhinitis receiving standard treatment|Group 3: Patients with allergic rhinitis receiving standard treatment
33325295|NCT05167552|Active Comparator|Patients with chronic polypous rhinosinusitis receiving standard treatment|Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment
33325296|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
33004646|NCT04646460|Experimental|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
33004647|NCT04646460|Experimental|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
33004648|NCT04646460|Experimental|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
33004649|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
33004650|NCT04637438|Active Comparator|Fecal Microbiota Transplantation|
33004651|NCT04637438|Placebo Comparator|Plasebo|
33004652|NCT04636164|Experimental|DNN group|using deep neural networks for skin lesion diagnosis
33004653|NCT04636164|No Intervention|Control group|conventional diagnosis
33004654|NCT04624854|Placebo Comparator|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
33004655|NCT04624854|Experimental|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
33004656|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
33004661|NCT04602598|Experimental|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
33325297|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
33325298|NCT05603962|Active Comparator|Stop training group|Home-base prism training during week 1-6 --> then stop training during week 7-12 --> endpoint data collected at week 12
33004664|NCT04586712|Experimental|Active CBD-extract high dose|High Dose (1000mg/30mL hemp extract = 62.5mg/day)
33004665|NCT04586712|Experimental|Active CBD low dose|Low Dose (500mg/30mL hemp-extract = 25mg/day)
33004666|NCT04586712|Placebo Comparator|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
33004667|NCT04565171|Experimental|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
33004668|NCT04565171|Experimental|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
33325299|NCT05603962|Experimental|Continune training group|Home-base prism training during week 1-12 --> endpoint data collected at week 12
33004670|NCT04528238|Experimental|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
33004671|NCT04528238|No Intervention|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
33004672|NCT04505449||Left heart catheterization|Symptomatic patients who underwent left heart catheterization and coronary angiography.
33004673|NCT04504331|Experimental|Cohort 1: Infigratinib (100mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
33004674|NCT04504331|Experimental|Cohort 1: Infigratinib (125mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + + 20 mg/ day tamoxifen
33004675|NCT04504331|Experimental|Cohort 1: Infigratinib (75mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
33004676|NCT04499612||"Group Single-chamber CIED (A1)"|50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).
33004677|NCT04499612||"Group Dual-chamber CIED (A2)"|50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).
33004678|NCT04499612||"Group Dual-chamber CIED + Atrial fibrillation (A3)"|50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).
33004679|NCT04499612||"Group CIED Replace (B)"|50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).
33004680|NCT04499612||"Group Conservative (C)"|50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).
33004681|NCT04497727||Patients undergoing routine colonoscopy|Patients with and without hypertension who routinely undergo colonoscopy
33415161|NCT05707676|Experimental|Single Drug Expansion|To further evaluate the safety, tolerance and preliminary clinical efficacy of LB4330 single drug in specific tumor species, the planned expanded cohort and number of subjects are as follows: Cohort A: LB4330 single drug therapy, 10 patients with advanced gastric and gastroesophageal junction adenocarcinoma with Claudin 18.2 expression;Cohort B: LB4330 single drug therapy, 5 patients with advanced pancreatic ductal adenocarcinoma with Claudin 18.2 expression; Cohort C: LB4330 single drug therapy, other advanced solid tumor patients with Claudin 18.2 expression, a total of 8-15 cases.
33004682|NCT04485221||Children with a TECPR2 mutation|"Children with a TECPR2 mutation, age 18 months to 12 years old.~Assessments will include collection of genetic mutation reports, functional assessments, and questionnaires. There will be a singular blood draw and skin biopsy."
33004683|NCT04472026|Experimental|Intervention group|Counseling using the electronic conversation aid
33004684|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
33004685|NCT04463719|Active Comparator|Control Group|Routine counseling only
33004686|NCT04463368|Experimental|Arm A|Patients will be treated with IHP followed by 4 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
33004687|NCT04463368|Experimental|Arm B|Patients will be treated with 1 course of ipilimumab 3mg/kg and nivolumab 1mg/kg followed by IHP after 3 weeks and then another 3 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
33004688|NCT04462159|Experimental|Risk Reduction Program|All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.
33004690|NCT04452344|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
33004691|NCT04452344|Active Comparator|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
33105485|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
33415162|NCT03972956||Colorectal cancer or gastric cancer patient|Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
33415163|NCT03972956||Non-malignant disease patient|Patients suffering from non-malignant disease scheduled to have surgery.
33415164|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
33415165|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415166|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415167|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415168|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415169|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415170|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of >=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415171|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415172|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
33415173|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
33415174|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
33415175|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
33415176|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
33415177|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
33415178|NCT03903536||Thrombectomy|Patients with thrombosed external hemorrhoids undergoing thrombectomy
33415179|NCT03903536||Local excision/ Hemorrhoidectomy|Patients with thrombosed external hemorrhoids undergoing local excision/ hemorrhoidectomy
33415180|NCT05707520||MPA|Immunosuppressant with enteric-coated mycophenolate sodium
33415181|NCT05707520||None MPA|Immunosuppressant without enteric-coated mycophenolate sodium
33415182|NCT04412785|Experimental|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
33004692|NCT04450407|Experimental|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 milligrams per deciliter (mg/dL).
33415183|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
33004693|NCT04450407|Experimental|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
33415184|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
33004694|NCT04450407|Active Comparator|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose same as basal insulin dose prior randomization, during the 26-week treatment period, to achieve target fasting blood glucose of <=100 mg/dL.
33004695|NCT04447703|Experimental|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
33004696|NCT04447703|Active Comparator|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
33004697|NCT04447703|Experimental|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
33004698|NCT04432506|Experimental|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
33004699|NCT04418765|Placebo Comparator|Placebo|Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
33004700|NCT04418765|Experimental|Eptinezumab 100 mg|Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
33004701|NCT04418765|Experimental|Eptinezumab 300 mg|Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
33004702|NCT04414397|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.
33004703|NCT04414397|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 3.
33004704|NCT04408508|Other|Amoxicillin administration|Oral amoxicillin administered to study patients
33004705|NCT04396886|Experimental|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
33004706|NCT04388826|Experimental|Veru-111 18 mg|Veru-111 18mg capsules
33004707|NCT04388826|Placebo Comparator|Placebo|Placebo capsules
33004708|NCT04342806||HCWs currently working in the US, and their families and communities|"The HERO Registry will include HCWs currently working across the United States, and their families and communities. For the purposes of this study, a healthcare worker is defined as an individual who currently works in a setting where individuals receive healthcare. (Note: individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as housekeeping, food service, etc.)"
33004709|NCT04336202|Other|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
33004710|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
33004711|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
33004712|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
33415185|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
33415186|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
33004713|NCT04309292|Experimental|Treatment Arm|protein supplementation plus prebiotic supplementation
33004714|NCT04309292|Placebo Comparator|Placebo Arm|Protein supplementation plus placebo
33004715|NCT04306601|Experimental|Low-Intensity focused ultrasound brain stimulation|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
33004716|NCT04301544|Experimental|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risk management
33415187|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
33415188|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
33417444|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
33004717|NCT04301544|Active Comparator|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risk management
33004718|NCT04298255|Experimental|ROSI only|Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
33004719|NCT04298255|Experimental|Half ROSI-half Sperm Donor Fertilization|Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
33004720|NCT04284319|Experimental|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
33004721|NCT04281017|Experimental|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
33004722|NCT04281017|Active Comparator|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
33004723|NCT04267185|Experimental|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
33004724|NCT04267185|No Intervention|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
33004725|NCT04265430|Experimental|Cohort I (MRI after radiation therapy)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.
33004726|NCT04265430|Experimental|Cohort II (MRI after surgery)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
33004727|NCT04257136|Experimental|Treatment|Treatment with VBI-S
33004728|NCT04256941|Experimental|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004729|NCT04256941|Active Comparator|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004730|NCT04249843|Experimental|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO)
33004731|NCT04249843|Experimental|Phase 1b, Group 1: Dose Expansion|BGB-3245 administered orally (PO)
33004732|NCT04231838|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
33004733|NCT04231838|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS
33004734|NCT04218266|Experimental|BAY2433334 50mg+Apixaban matching placebo|
33415189|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
33415190|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
33004735|NCT04218266|Experimental|BAY2433334 20mg+Apixaban matching placebo|
33004736|NCT04218266|Active Comparator|BAY2433334 matching placebo+Apixaban|Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
33415191|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
33415192|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
33415193|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
33415194|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
33415195|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
33004737|NCT04184791|Experimental|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
33004738|NCT04184791|Experimental|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
33415196|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
33417445|NCT02080910|No Intervention|Usual care|
33004739|NCT04179799||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
33004740|NCT04172363|No Intervention|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
33004741|NCT04172363|Experimental|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
33004742|NCT04155684||HIV + with COPD|COPD will be defined as Subjects with FEV1/FVC<0.70 or FEV1 and DLco < 80% predicted
33004743|NCT04155684||HIV+ normal|Normal PFT's
33004744|NCT04152603|No Intervention|Control Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment before implementation of the BRIEF intervention.
33004745|NCT04152603|Experimental|BRIEF Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment after implementation of the BRIEF intervention.
33004746|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
33004747|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
33004748|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
33004749|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
33004750|NCT04087304|No Intervention|Low Risk Group|
33004751|NCT04087304|No Intervention|Mild Risk Group|
33004752|NCT04087304|Active Comparator|Moderate Risk Group|
33004753|NCT04087304|Active Comparator|High Risk Group|
33004754|NCT04074603|Experimental|Group A|needle-free before needle
33004755|NCT04074603|Experimental|Group B|needlebefore needle-free
33004756|NCT04068246|Placebo Comparator|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
33004757|NCT04068246|Experimental|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
33004758|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
33004759|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
33004760|NCT04061915|Experimental|Infographic Intervention|Participants in the intervention arm will view an HIV self-testing infographic.
33004761|NCT04061915|Active Comparator|Control|Participants in the control arm will read paper-based HIV self-testing instructions.
33004762|NCT04038255|Active Comparator|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
33004763|NCT04038255|Experimental|Craving-to-Quit app|"Participants in this group will receive one in-person orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
33004764|NCT04038255|Experimental|In-person Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with >4 years of training in MT).
33004765|NCT04037605|Experimental|Control Condition|"8 am - Saline Solution for Injection~10 am - Placebo oral capsule~1 pm - Saline Solution for Injection~4 pm - Placebo oral capsule & start hourly blood sampling~7 pm- Gonadorelin (GnRH) and Corticorelin (CRH) injections~9 pm - Saline Solution for Injection & last blood sample"
33004766|NCT04037605|Experimental|Hypothalamic Condition|"8 am -Ganirelix~10 am - Placebo oral capsule~1 pm - Dexamethasone injection~4 pm- Placebo oral capsule and start of hourly blood sampling~7 pm - GnRH and CRH injections~9 pm - Saline Solution for Injection and last sample blood sample"
33004767|NCT04037605|Experimental|Pituitary Condition|"8 am - Saline Solution for Injection~10 am - Ketoconazole Pill~1 pm - Saline Solution for Injection~4 pm - Ketoconazole Pill & start of hourly blood sampling~7 pm - GnRH and CRH~9 pm - Hydrocortisone Injection and last blood sample"
33004768|NCT04037605|Experimental|Adrenal/Testis Condition|"10 pm - Ganirelix Injection & Dexamethasone Pills (night before)~8 am - Start of hourly blood sampling~10 am - Dexamethasone Pills~11 am - Last hourly blood sample taken~11:30 am - Start of blood sampling every 10 minutes~1 pm - Recombinant Human Luteinizing Hormone (rhLH) Injection~3 pm - rhLH Injection~5 pm - rhLH Injection~5 pm - Cosyntropin Injectable product~7 pm - GnRH and CRH Injections~9 pm - Last blood sample"
33004769|NCT04012333|Experimental|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
33004770|NCT04012333|No Intervention|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
33004771|NCT03993184|Experimental|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
33004772|NCT03993184|Experimental|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
33004773|NCT03993184|No Intervention|Control|This group will maintain their current physical activity for 12 weeks.
33415197|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
33004775|NCT03954717||Participants in the Shepherd CAN DO Program|People with MS enrolled into the Shepherd CAN DO Program.
33004776|NCT03954717||Control Group-Shepherd (CG-S)|People with MS who are current patients of the MS Institute at the Shepherd Center.
33004777|NCT03954717||Control Group-iConquerMS (CG-iCMS)|iConquerMS members
33004778|NCT03954717||Support partners of CAN DO|Support partners of the participants in the Shepherd CAN DO Program group
33004779|NCT03954717||CG-S support partners|Support partners of the people with MS in the CG-S group.
33004780|NCT03954717||CG-iCMS|Support partners of the people with MS in the CG-iCMS group
33004781|NCT03928093|Experimental|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
33004782|NCT03928093|Experimental|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
33004783|NCT03926819|Active Comparator|Single Ascending Dose|
33004784|NCT03926819|Active Comparator|Multiple Ascending Dose|
33004785|NCT03923322|Experimental|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
33004786|NCT03923322|Placebo Comparator|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
33004787|NCT03910959|Experimental|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
33004788|NCT03910959|Active Comparator|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
33004789|NCT03909204|Other|LAPEC|Patients with cecal percutaneous catheter placement.
33004790|NCT03907800|Experimental|Nab-paclitaxel + Carboplatin ± Herceptin|
33004791|NCT03905330|Experimental|Maralixibat|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
33004792|NCT03905330|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
33004793|NCT03900117|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
33105486|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered~A hippocampal sparing approach will be used when possible~Dose will be 30 Gy in 10 fractions"
33004794|NCT03894904|Experimental|Papaverine plus heparin during procedure, with rescue papaverine as needed|1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
33004795|NCT03894904|Active Comparator|Heparin during procedure, with rescue papaverine as needed|1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
33415198|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
33415199|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
33415200|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
33415201|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
33415202|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
33415203|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
33004796|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
33004797|NCT03811158|Experimental|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
33004798|NCT03811158|Sham Comparator|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
33004799|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
33415204|NCT01352767|No Intervention|CONTROL|no treatment
33004800|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
33004801|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
33004802|NCT03777267|Experimental|Experimental: Active CR|For this single arm, open label, exploratory trial this will be the intervention arm using active CR.
33004803|NCT03774082|Experimental|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
33004804|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
33004805|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
33004806|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
33004807|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
33004808|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
33004809|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
33004810|NCT03738410|Active Comparator|Control Arm|The control arm will receive standard of care.
33004811|NCT03738410|Experimental|Mobile Health Messaging Arm|The Mobile Health Messaging Arm will receive standard of care, as well as the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
33004812|NCT03738410|No Intervention|Focus Group Arm|The results of the focus groups will contribute to the wording and design of the intervention.
33004813|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
33004814|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
33004815|NCT03705169|Experimental|Arm A, Cohort 1A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.
33004816|NCT03705169|Experimental|Arm A, Cohort 1B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
33004817|NCT03705169|Experimental|Arm A, Cohort 2A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
33004818|NCT03705169|Experimental|Arm A, Cohort 2B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
33004819|NCT03705169|Experimental|Arm A, Cohort 3A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
33004820|NCT03705169|Experimental|Arm A, Cohort 3B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
33004821|NCT03705169|Experimental|Arm A, Cohort 4A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
33004822|NCT03705169|Experimental|Arm A, Cohort 4B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
33004823|NCT03705169|Experimental|Arm B, Cohort 5: SAR441236|Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
33004824|NCT03705169|Experimental|Arm B, Cohort 6: SAR441236|Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
33004825|NCT03705169|Experimental|Arm B, Cohort 7: SAR441236|Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
33004826|NCT03705169|Experimental|Arm B, Cohort 8: SAR441236|Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
33004827|NCT03705169|Experimental|Arm B, Cohort 9: SAR441236|Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
33004828|NCT03705169|Experimental|Arm C, Cohort 10A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.
33004829|NCT03705169|Experimental|Arm C, Cohort 10B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.
33004830|NCT03705169|Experimental|Arm C, Cohort 11A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
33004831|NCT03705169|Experimental|Arm C, Cohort 11B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
33004832|NCT03699345||Edwards CENTERA THV|
33004833|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
33004834|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
33004835|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
33004836|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
33004837|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
33004838|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
33004839|NCT03671525|Experimental|Nimodipine|One 60mg capsule of nimodipine on first or second study visit
33004840|NCT03671525|Placebo Comparator|Placebo|One placebo capsule on first or second study visit
33004841|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
33004842|NCT03650374|Experimental|Group 2|experimental strength training
33004843|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33004844|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33004845|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33004846|NCT03578198|Experimental|Rituximab + MG4101|"Drug: Rituximab + MG4101~Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
33004847|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco>80% predicted after adjustments for Hgb and Co
33004848|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco <80% predicted after adjustments for Hgb and Co.
33004849|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
33004850|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
33004851|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
33004852|NCT03523559||Interstitial Cystitis|
33004853|NCT03523559||normal|
33004854|NCT03518086|Placebo Comparator|Placebo Intravenous (IV) Every 4 Weeks (Q4W)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
33004855|NCT03518086|Experimental|300 Milligram (mg) Mirikizumab IV Q4W|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
33004856|NCT03518086|Placebo Comparator|Placebo IV Q4W Maximum Extended Enrollment (ME2)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
33004857|NCT03518086|Experimental|300 mg Mirikizumab IV Q4W ME2|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
33415205|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004858|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
33004859|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
33004860|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
33004861|NCT03512002|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
33415206|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
33415207|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
33415208|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
33415209|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
33415210|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
33415211|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
33415212|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
33004862|NCT03512002|Other|Continued Current Care|Participants will continue their current care.
33004863|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
33004864|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
33004865|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
33004866|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
33004867|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
33004868|NCT03478384|Experimental|Coaching group|Patient coaching
33004869|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
33004870|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).~Non responders will be switched to mepolizumab arm."
33004871|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).~Non responders will be switched to omalizumab arm."
33004872|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
33004873|NCT03410667|Other|Standard Care|Standard of care arm
33004874|NCT03410667|Experimental|Intervention Arm|Intervention arm
33415213|NCT02815670|Experimental|Idarucizumab|
33415214|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
33417446|NCT04300985|Sham Comparator|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
33004875|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33004876|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
33004877|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
33004878|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
33004879|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
33004880|NCT03362515|Experimental|Furosemide|
33004881|NCT03362515|Placebo Comparator|Placebo|
33415215|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
33415216|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
33415217|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
33415218|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
33004882|NCT03340129|Active Comparator|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
33415219|NCT03816098||elderly patients with dysphagia|
33105487|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
33415220|NCT03816098||elderly patients without dysphagia|
33415221|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin~Day of surgery:~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Give bolus of insulin according to treatment algorithm"
33415222|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide~Day of surgery: withhold own insulin, stop oral glucose lowering tablets~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.~In case of nausea graded higher than minimal, the patient will be excluded from the study~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.~Measure glucose every 60 minutes, start 30 min prior to surgery~Adjust according to bolus algorithm of BR group"
33415223|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.~Calculate the insulin amount in the GIK infusion according to the formula:~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Adjust glucose > 8 mmol/l according to treatment algorithm"
33415224|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
33415225|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
33415226|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
33415227|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
33415228|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
33415229|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
33415230|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
33415231|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
33415232|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
33415233|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
33004883|NCT03340129|Active Comparator|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
33004884|NCT03314987|Active Comparator|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
33004885|NCT03314987|Placebo Comparator|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
33004886|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
33004887|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
33004888|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.~Cemiplimab will be administered via IV infusion every 3 weeks."
33004889|NCT03294083|Experimental|Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
33004890|NCT03294083|Experimental|Part 2-Arm B, Cemiplimab|"Cemiplimab will be administered via IV infusion every 3 weeks.~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks."
33004891|NCT03294083|Experimental|Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
33004892|NCT03294083|Experimental|Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
33004893|NCT03230890|Experimental|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
33004894|NCT03225287|Experimental|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
33004895|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33004896|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33004897|NCT03222076|Experimental|Arm C (ipilimumab, nivolumab)|Patients receive ipilimumab and nivolumab as in Arm B. Patients undergo post-treatment biopsy on day 1 of week 7, then receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks up to 2 years in the absence of disease progression or unacceptable toxicity.
33004898|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
33004899|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
33004900|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
33004901|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
33004902|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
33004903|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
33004904|NCT03128775|No Intervention|Control|without any activity
33004905|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
33004906|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
33415234|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
33415235|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
33415236|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
33004907|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
33004908|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
33415237|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
33415238|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
33415239|NCT01353001|Experimental|Diet Only|
33415240|NCT01353001|Experimental|Diet plus Aerobic Training|
33415241|NCT01353001|Experimental|Diet plus Resistance Training|
33415242|NCT02047760||MS patients|All MS sub-types
33415243|NCT02047760||Controls|sex- and age-matched controls
33415244|NCT01349023|Experimental|Standard Energy content/Standard ED|
33415245|NCT01349023|Experimental|Standard Energy content/Reduced ED|
33415246|NCT01349023|Experimental|Reduced Energy content/Standard ED|
33415247|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
33415248|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
33415249|NCT02036606||control|Questionary and neuropsychological tasks will be administered
33415250|NCT01353157||patients with elective cardiac surgery|
33415251|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
33415252|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
33004909|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
33004910|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
33004911|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
33004912|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
33004913|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
33004914|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
33004915|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
33004916|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
33004917|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004918|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004919|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33004920|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
33004921|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
33004922|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
33004923|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
33004924|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
33004925|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
33004926|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
33004927|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
33004928|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
33004929|NCT02975037|Experimental|sildenafil+clarithromycin|Sildenafil 25 mg PO (single dose); Clarithromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Clarithromycin 250 mg PO (single dose)
33004930|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
33004931|NCT02970591|Experimental|Diet A|Low carbohydrate diet
33004932|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
33004933|NCT02970591|Experimental|Diet B|Traditional dietary advice and low FODMAP content
32865637|NCT04843644|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
32865638|NCT04843644|Placebo Comparator|control|Routine care to encourage oral care three times a day.
32865639|NCT02588105|Experimental|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
32865640|NCT04840368|Experimental|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
32865641|NCT04840368|Active Comparator|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min, and a cool down of 10 min (muscle stretching and relaxation). They will be performed individually, outside, at a self-selected intensity, with no supervision.
32865642|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
32865643|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
32865644|NCT02586623|Experimental|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
32865645|NCT02586623|Placebo Comparator|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
32865646|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
32865647|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
32865648|NCT01490073|Active Comparator|Active nitroglycerin ointment|
32865649|NCT01490073|Placebo Comparator|Placebo ointment|
32865650|NCT04852536||HD-tDCS4x1|All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
32865651|NCT04839666||Propofol|
32865652|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
32865653|NCT04041336|Experimental|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
32865654|NCT04852146||Professional|The sample of professionals will be made up of doctors and nurses of the emergency structures (pre and intra-hospital), doctors and nurses of interventional cardiology and ambulance drivers practising in an establishment of the 7 participating SAMU zones
32865655|NCT04852146||Patient|The patient sample will consist of patients included in the REANIM registry during the study period (the entire period of the stepped wedge randomised controlled trial).
32865656|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
32865657|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
32865658|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
32865659|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
32865660|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
32865661|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
32865662|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
32865663|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
32865664|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
32865665|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
32865666|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
32865667|NCT04851990|Experimental|Large Patch|"To Better Days Large Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
32865668|NCT04851990|Experimental|Small patch|"To Better Days Small Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
32865669|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
32865670|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
32865671|NCT04843098|Experimental|Single arm, open label|Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
32865672|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
32865673|NCT04842942|Experimental|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
32865674|NCT04843020|Experimental|Drug subcutaneous injection|Monthly injection of ION 682884, administered subcutaneously at a dose of 45 mg.
32865675|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
32865676|NCT04839432||Crystalloids group|Patients had only a balanced crystalloid solution in the priming of the cardiopulmonary bypass (pre interventional group)
32865677|NCT04839432||albumin group|Patients had only a 4% albumin solution in addtion to a very low volume of a balanced crystalloid solution in the priming of the cardiopulmonary bypass (post interventional group)
32865678|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
32865679|NCT02562365|No Intervention|B: Follow-up|No interevention
32865680|NCT04851756|Experimental|CRet Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis
32865681|NCT04851756|Sham Comparator|CRet Sham Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis with turned on CRet device at power 0
32865682|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
32865683|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
32865684|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
32865685|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
32865686|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
32865687|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
32865688|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
32865689|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
32865690|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
32865691|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
32865692|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
32865693|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
32865694|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
32865695|NCT04839276|Experimental|Injection Laryngoplasty with PRF and Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is added to 4 mL of PRF and is smoothed by pushing it back and forth 15 times on a 2-tube 10 mL piston tube connected to a three-way connector. 3 mL of the mixture of fat and PRF is injected using a 12 G laryngoplasty syringe until medialization is achieved.
32865696|NCT04839276|Active Comparator|Injection Laryngoplasty with Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is mashed by pushing it back and forth 15 times in a container of 2 piston tubes (10 mL) connected to a three-way connector. The crushed fat is injected as much as 3 mL using a 12 G laryngoplasty syringe until medialization is achieved.
32865697|NCT04851600||Early introduction|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
32865698|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
32865699|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
32865700|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
32865701|NCT04839198|Experimental|Adaptive Treatment plus usual care|
32865702|NCT04839198|Active Comparator|Usual care|
32865703|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
32865704|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
32865705|NCT04839120|Active Comparator|MDPK67b|
32865706|NCT04839120|Placebo Comparator|Placebo|
32865707|NCT04851054||Patients after surgery for colon cancer with intention to cure|Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention
33004934|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
33004935|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
33004936|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
33004937|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
33415253|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
33415254|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
33004938|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
33415255|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
33415256|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
33004939|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
33415257|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
33004940|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
33004941|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
33004942|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
33004943|NCT02812862|Experimental|Treatment group|"20 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.~Patients will be treated with Spiolto® Respimat® (the LABA/ LAMA combination)"
33004944|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
33004945|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
33004946|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
33004947|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
33004948|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
32865708|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
32865709|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
32865710|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
32865711|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
32865712|NCT04842396|Experimental|Experimental: Motorized cycle ergometer|"The exercise group cycles 20 minutes per session on the MOTOmed Muvi 3 days per week for 6 weeks at an intensity guided by the perception of effort.~A cycling cadence is fixed between 25 and 30 rpm for all sessions since that cadence is comfortable for every participant. Researchers adjust resistance on the motorized cycle to increase the external load until it reached the level required to reach the intensity of effort programmed by the OMNI-RPE. The six weeks are programmed in the form of two intensity-differentiated training phases of three weeks. In the first training phase (i.e., the first three weeks), participants are requested to cycle simultaneously with the upper and lower limbs at an intensity equivalent to a perception of 3 (i.e., easy to somewhat moderate) on the OMNI-RPE (0-10)."
32865713|NCT04842396|No Intervention|Control group|Participants are evaluated the week before and the week after the experimental group finishes the training period (pre- vs. postintervention) to facilitate an examination of the changes in body composition, functional performance, and resting cardiovascular state.
32865714|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
32865715|NCT04838730|Experimental|single-arm|Hanita CleaRing device (CE approved; AMAR Certificate)
32865716|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
32865717|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
32865718|NCT04842474|Experimental|Gaze stability and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
32865719|NCT05586347|Experimental|group N|Nicardipine was infused after initiation of CPB
32865720|NCT05586347|Placebo Comparator|group C|Give the same volume of normal saline
32865721|NCT04842318|Experimental|BR+R|Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
32865722|NCT04842318|Experimental|RCHOP+R|Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
32865723|NCT04842318|Experimental|R2+R2|Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
32865724|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
32865725|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
32865726|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
32865727|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
32865728|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
32865729|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
32865730|NCT04842240||Patients undergoing implant based immediate breast reconstruction.|Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
32865731|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
32865732|NCT01437501|Placebo Comparator|Placebo beverage|
32865733|NCT04842162|Experimental|Patients with head and neck cancer|
33004949|NCT02658656|Active Comparator|Exoskeleton + Standard of Care (SOC)|Patient will receive exoskeletal-assisted walking device for in home use for 4 months
33004950|NCT02658656|No Intervention|Standard of Care (SOC)|Patient will receive standard of care (wheelchair use)
33004951|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
33004952|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
33004953|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
33004954|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
33004955|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
33004956|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
33417447|NCT04300985|Active Comparator|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
33417448|NCT04300985|Active Comparator|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
33004957|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
33004958|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
33004959|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
33004960|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
33004961|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
33004962|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
33004963|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
33004964|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
33004965|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
33004966|NCT02536300|Experimental|Idelalisib 150 mg Continuously|"Participants will receive idelalisib 150 mg twice daily continuously.~For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily."
33004967|NCT02536300|Experimental|Idelalisib 100 mg|"Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.~As of protocol amendment 5, enrollment to this arm has been closed."
33004968|NCT02536300|Experimental|Idelalisib 150 mg 28-Day Cycles|Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
33004969|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
33004970|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
33004971|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
33004972|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
33004973|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
33004974|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
33004975|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
33004976|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
33004977|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
33004978|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
33004979|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months"
33004980|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months"
33004981|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months"
32865734|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
32865735|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
32865736|NCT01560975|Experimental|Sensimed Triggerfish|
32865737|NCT04851132|Experimental|Exprimental Arm|IMRT plus Durvalumab
32865738|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
32865739|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade >1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
32865740|NCT04850976|Experimental|Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group|The self-assembled modified Macintosh videolaryngoscope (SAM-VL) used in this study was constructed from a portable video camera with Wi-fi connection (Wi-fi Endoscope Video Camera model YPC99) attached to a no. 4 Macintosh Laryngoscope blade (Riester® no.7040). The video signal is transmitted to an Android-based mobile phone (Android version 7.0). The portable 2 megapixels video camera is 8 mm in diameter with 8 Light Emitting Diode (LED) lights for adjustable lighting level and 3 meters cable length. Video resolution output is 640x480 pixels (VGA) and 1280x720 pixels (HD). The camera has 70º visual angle with focus length of 4- 6cm and is water-resistant. The camera was taped to the Macintosh blade at a distance of 5 cm from the distal end of the blade, using transparent waterproof Leukofix® tape.
32865741|NCT04850976|Active Comparator|McGrath MAC® videolaryngoscope (McGrath) group|The McGrath MAC® videolaryngoscope used in this study was equipped with disposable blade no.4
32865742|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
32865743|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
32865744|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
32865745|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
32865746|NCT01494753|Active Comparator|Prostaglandin|One drop.
32865747|NCT01494753|Experimental|T2345|One drop
32865748|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
32865749|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
32865750|NCT04757597|Experimental|RIC group|RIC treatment and regular treatment.
32865751|NCT04757597|No Intervention|Regular treatment|Regular treatment alone.
32865752|NCT04841928|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
32865753|NCT04841928|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
32865754|NCT04841928|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
32865755|NCT04841928|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
32865756|NCT04841928|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
32865757|NCT04841928|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
32865758|NCT04841928|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
32865759|NCT04841928|Experimental|Mindful attention + Decentering + Value-based action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
33417449|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
33004982|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
33004983|NCT02246413|No Intervention|Usual Care|Usual Care.
33004984|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
33004985|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.~Will be prescribed to 14 Gy in 2 Gy fractions"
33325300|NCT05403892||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar heel pain, metatarsalgias, etc);~athletes who have undergone surgery on their lower limb."
33325301|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
33325302|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
33325303|NCT05348122|Experimental|TG103, 15 mg,Q2W|TG103 (15 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
33004990|NCT02116764||Cross Sectional|3 years after Transplant
33004991|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
33004992|NCT02116764||Prospective|Prior to Transplant Conditioning
33004993|NCT02116764||Retrospective|1 year after Transplant
33004994|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
33004995|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
33004996|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
33004997|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
33004998|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.~resistant patients were defined as patients reached PD after first month administration and first three months administration"
33004999|NCT01878435|Experimental|SMS reminder|
33005000|NCT01878435|Experimental|SMS reminder and Travel subsidy|
33005001|NCT01878435|No Intervention|Control|
33005002|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
33005003|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
33005004|NCT01785316|No Intervention|BAC|Best alternative care
33005005|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
33005006|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
33005007|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
33005008|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
33105488|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
33105489|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
33105490|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
33325304|NCT05348122|Experimental|TG103, 22.5 mg,Q2W|TG103 (22.5 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
33325305|NCT05348122|Placebo Comparator|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
33005009|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
33005010|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
33415258|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
33005011|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
33005012|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
33415259|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
33415260|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
33005013|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
33005014|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
33417450|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
33005015|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
33005016|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
33005017|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
33005018|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
33005019|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
33005020|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
33005021|NCT01026077||Fibromyalgia/prospective pregnancies|Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
33005022|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
33005023|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
33005024|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
33005025|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
33005026|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
33005027|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
33005028|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
33005029|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
33005030|NCT01680822||NTM patient|confirmed NTM patient
33005031|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
33005032|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
33005033|NCT01681017|Other|Facilitators|Receive appropriate HBB training
33005034|NCT01681017|Other|Learners|Receive appropriate HBB training
33005035|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
33005036|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
33005037|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
33005038|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
33005039|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
33005040|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
33005041|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
33005042|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
33005043|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
33415261|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
33415262|NCT03686930|Active Comparator|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
33417451|NCT01358279|Experimental|migraine|
33005044|NCT01681602|No Intervention|Control group|Usual care.
33005045|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
33005046|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
33005047|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~CT angiography for an anterolateral thigh flap or an epigastric inferior flap~A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
33005048|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
33005049|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
33005050|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
33005051|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
33005052|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
33005053|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
33005054|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
33005055|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
33005056|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
33005057|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
33005058|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
33005059|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
33005060|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
33005061|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
33005062|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
33005063|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
33005064|NCT01682707|Active Comparator|Track Light|
33005065|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
33005066|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
33005067|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
33005068|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
33005069|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
33005070|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
33005071|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
33005072|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
33005073|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
33005074|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
33005075|NCT01683760|Experimental|Population PK|
33005076|NCT01684124|Placebo Comparator|standard care|normal treatment
33005077|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
33005078|NCT01684150|Experimental|EPZ-5676 Extension cohort|
33415263|NCT03686930|Placebo Comparator|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
33415264|NCT03686930|Active Comparator|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
33415265|NCT03686930|Placebo Comparator|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
33005079|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
33005080|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
33415266|NCT03686930|Active Comparator|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
33005081|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
33005082|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
33005083|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
33415267|NCT03686930|Placebo Comparator|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
33005084|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
33005085|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
33005086|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
33005087|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
33005088|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
33005089|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
33005090|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
33417452|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
33005091|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
33005092|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
33005093|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
33005094|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
33005095|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
33005096|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
33005097|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
33005098|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
33005099|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
33005100|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
33005101|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
33005102|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
33005103|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
33005104|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
33005105|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
33005106|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
33005107|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
33005108|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
32865760|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
32865761|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
32865762|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
32865763|NCT04841850||Hazelnut allergic children under oral immunotherapy|"Children Under eighteen years of age~Convincing clinical history of hazelnut allergy~Positive hazelnut prick test or specific IgE~Under IOT hazelnut protocol in pneumology and allergology-paediatric departement of the Mother and Child Hospital in Bron"
32865764|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
32865765|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
32865766|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
32865767|NCT04850742|Experimental|Cryopreserved aorta|After resection of a segment of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
32865768|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
32865769|NCT04850586|Experimental|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
32865770|NCT04850586|No Intervention|Control Group|Routine education was given to the patients in the control group. Routine education was administered by a nurse working in the clinic after the patients were admitted to the hospital. The patients in this group were not trained by a multidisciplinary team. In the routine training, patients were only informed about preoperative preparation.
32865771|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
32865772|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
32865773|NCT04850430|Experimental|Gastric venous congestion following total pancreatectomy|The gastric venous outflow will be reconstructed after TP. The patients will be assessed concerning gastric venous congestion and gastric ischemia intraoperatively before and after venous outflow reconstruction through onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral imaging.
32865774|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
32865775|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
32865776|NCT04850664|Experimental|CBOT + TAU|CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting ~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
32865777|NCT04850664|Sham Comparator|Sham + TAU|Sham is a CBOT device that uses artificially-scented compressed room air instead of olfactory stimulants and has no OFC cognitive tasks. Similar to the CBOT, sham will be used daily for 45 minutes. TAU is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
32865778|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
32865779|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
32865780|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
32865781|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
32865782|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
32865783|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
32865784|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
32865785|NCT04850352|Experimental|Heukcha Extracts|Take Heukcha Extracts capsule once daily for 8 weeks.
32865786|NCT04850352|Placebo Comparator|Placebo|Take placebo capsule once daily for 8 weeks.
32865787|NCT04841694|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day
33105491|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
33105492|NCT04686162|Experimental|Group using the smartphone application bae|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months.
33105493|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
33105494|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
33105495|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
33105496|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
33105497|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
33105498|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
33105499|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
33105500|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
33105501|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
33105502|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
33415268|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age~Postnatal age <72 hours;~Parental informed consent;~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
33415269|NCT01353235|Sham Comparator|usual care|
33415270|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
33415271|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
33415272|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
33415273|NCT05701046||Anterior and oblique interbody fusion (ALIF, OLIF + Posterior fixation (open or MIS) or stand-alone)|
33105503|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
33105504|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
33105505|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
33105506|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
33105507|NCT02888938||Patients suspected of SpA|
33105508|NCT04322032|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
33105509|NCT04322032|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
33105510|NCT04320082||Elderly cohort|Patients >70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
33105511|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
33105512|NCT02897258||Without anticoagulant/antiplatelet|
33415274|NCT05701046||Posterior interbody fusion (TLIF or PLIF) (open or MIS)|
32865788|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
33105513|NCT02897258||Treated with antiplatelet only|
33105514|NCT02897258||Treated with anticoagulant only|
33105515|NCT02897258||With antiplatelet/anticoagulant|
33105516|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
33105517|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
33105518|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
33105519|NCT04321798|Experimental|Physical Activity|Promoting Engagement in Physical Activity
33105520|NCT05532982||Parkinson's disease patients|
33105521|NCT05532982||Parkinson's disease patients' care-givers|
33105522|NCT05532982||Clinicians|
33105523|NCT05532982||Community stakeholders|
33105524|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
33105525|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
33105526|NCT04321642|Experimental|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
33105527|NCT04321642|Active Comparator|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
33105528|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
33415275|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
33415276|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
33415277|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
33325306|NCT05348122|Experimental|TG103, 7.5 mg,QW|TG103 (7.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
33415278|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
32865789|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
32865790|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
33325307|NCT05348122|Experimental|TG103, 15 mg,QW|TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
32865791|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
32865792|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
32865793|NCT02424617|Active Comparator|Arm A|designed to determine the maximum dose of bemcentinib that can be safely administered in combination with erlotinib administered at the approved oral dose level of 150 mg daily. It is anticipated that a maximum of three bemcentinib dose levels will be evaluated, with up to approximately 18 participants enrolled. In the absence of unacceptable toxicity, participants will be allowed to continue receiving bemcentinib in combination with erlotinib until disease progression.- (Arm completed)
32865794|NCT02424617|Active Comparator|Arm B|will incorporate a Simon-like two-stage design with relaxed stopping for futility to evaluate the safety, pharmacokinetics and clinical activity of bemcentinib in combination with erlotinib in participants with an activating EGFR mutation who have progressed after receiving prior EGFR TKI inhibitors or who have progressed after osimertinib.
33325308|NCT05348122|Placebo Comparator|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
33325309|NCT05348122|Active Comparator|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
33325310|NCT05125276|Experimental|Interventional arm|No aspirin
33325311|NCT05125276|Active Comparator|Control arm|Aspirin (75-100 mg once daily)
33325312|NCT05054842|Experimental|treatment group A|
33325313|NCT05054842|Placebo Comparator|treatment group B|
33325314|NCT05038618|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33325315|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
33325316|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
32865795|NCT02424617|Active Comparator|Arm C|will evaluate the safety, pharmacodynamics and clinical activity of bemcentinib when administered in combination with erlotinib in participants with an activating EGFR mutation who have received at least twelve weeks of erlotinib without disease progression (Open to enrolment).
32865796|NCT02424617|Other|Run in Arm|The primary goal of the Run-in Cohort is to establish the safety and tolerability of bemcentinib administered as a single agent. Eligible participants will have either exhausted existing licensed therapies or be unsuitable for treatment with existing licensed therapies for NSCLC. bemcentinib will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter (Arm completed)
32865797|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
32865800|NCT04346303|Other|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
32865801|NCT04757441|Experimental|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire (ELDOA)|Participants will receive conventional treatment along with ELDOA stretching exercises protocol at L5, S1.
32865802|NCT04757441|Other|Group B: Conventional treatment|Participants will receive only conventional treatment (Control)
32865803|NCT04745741||IB-positive group|Patients with level IB metastasis and histologically confirmed positive by biopsy.
32865804|NCT02382965||ultrasound|
32865806|NCT02379377|Experimental|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
32865807|NCT02379377|Experimental|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
32865808|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
32865809|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
32865810|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
32865811|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
33415279|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
33415280|NCT02037308|Placebo Comparator|Control white bread|
33005109|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
33415281|NCT02037308|Experimental|Beetroot bread|
33415282|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
33415283|NCT02048306|Experimental|Family-based PR group|
33415284|NCT02048306|Active Comparator|Conventional PR group|
33415285|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
33415286|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
33005110|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
33005111|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
33005112|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
33005113|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
33005114|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
33005115|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
33005116|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
33005117|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
33005118|NCT01686594|No Intervention|No maintenance treatment|observation
33005119|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
33005120|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
33005121|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
33005122|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
33005123|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
33005124|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
33005125|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
33005126|NCT01687517|Active Comparator|Volunteer|100 volunteers
33005127|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
33005128|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
33005129|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
33005130|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
33415287|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
33415288|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
33415289|NCT01353391|Active Comparator|Metformin|
33415290|NCT01353391|Placebo Comparator|Placebo|
33415291|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
33415292|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
33415293|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
33415294|NCT02048462||Cyclists|
33415295|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
33415296|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
33415297|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
33415298|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
33415299|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
33005131|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
33005132|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
33005133|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
33415300|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
33415301|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
33005134|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
33005135|NCT01687881|No Intervention|Control group|No intervention: Control group.
33005136|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
33005137|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
33005138|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
33005139|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
33005140|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
33005141|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
33005142|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
33005143|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
33005144|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
33005145|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
33005146|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
33005147|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
33005148|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
33005149|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
33005150|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
33415302|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
33415303|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
33005151|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
33005152|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
33005153|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
33005154|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
33005155|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
33005156|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
33005157|NCT01690013||Klinefelter|Men with Klinefelter syndrome
33005158|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
33005159|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
33415304|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
33415305|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
33005160|NCT01690026|Other|Standard intervention|Standard intervention condition
33005161|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
33415306|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
33415307|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
33415308|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
33005162|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
33415309|NCT02050256|Other|general practioner|
33415310|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
33415311|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
33005163|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
33005164|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
33005165|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
33005166|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
33005167|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
33005168|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
33005169|NCT01690104|Placebo Comparator|Placebo|Placebo daily
33005170|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
33005171|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
33005172|NCT01690169|Experimental|NNC0113-0987|
33005173|NCT01690169|Placebo Comparator|Placebo|
33005174|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
33005175|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
33005176|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
33005177|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
33005178|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
33415312|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
33415313|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
33415314|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
33415315|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
33415316|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
33415317|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
33417453|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
33417454|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
33415318|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
33415319|NCT02050412|Other|Cat fur scratch test|
33415320|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
32865812|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
32865813|NCT01561053|Experimental|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
32865814|NCT01561053|Experimental|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
32865815|NCT01561053|Experimental|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
33105529|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
33415321|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
33415322|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
32865816|NCT01561053|No Intervention|Control (sham) group|Simulated plasma exchange procedure
32865817|NCT02366039||EMR|patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study
32865818|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
32865819|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
32865820|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
32865821|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32865822|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
32865823|NCT02328599||Surgical|Prior Bariatric surgery
32865824|NCT02328599||Non-surgical|Medical / Lifestyle management
32865825|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32865826|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32865827|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
32865828|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
32865829|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
32865830|NCT02607306|Active Comparator|Insulin degludec OD|
32865831|NCT02607306|Active Comparator|Liraglutide OD|
32865832|NCT02315885|Placebo Comparator|placebo alcohol|<0.05% alcohol
32865833|NCT02315885|Active Comparator|alcohol middle dose|alcohol dose=0.45g/kg for women and 0.5g/kg for men
32865834|NCT02315885|Active Comparator|alcohol high dose|alcohol dose=0.90g/kg for women and 1.0g/kg for men
32865835|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
32865836|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
32865837|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
32865838|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
32865839|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
33415323|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
33415324|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
33415325|NCT02047526||1|
33005179|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
33005180|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
33005181|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
33005182|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
33005183|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
33005184|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
33005185|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
33005186|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
33005187|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
33005188|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
33005189|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
33005190|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
33005191|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
33005192|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
33005193|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
33005194|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
33005195|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
33005196|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
33005197|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
33005198|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
33005199|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
33005200|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
33005201|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
33415326|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
33415327|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
33415328|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
33415329|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
33415330|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
33415331|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
33415332|NCT03561974|Experimental|Humidification|
33415333|NCT03561974|No Intervention|Control group without humidification|
33415334|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
33005202|NCT01690377|Experimental|1|PDC or myDC
33415335|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
33005203|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
33005204|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
33005205|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
33005206|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
33005207|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
33005208|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
33005209|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
33005210|NCT01690429|Other|OSA Patients|
33005211|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
33005212|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
33005213|NCT01690455||Cohort|
33005214|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
33005215|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
33005216|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
33005217|NCT01690507|Other|DCAG plus HLI|
33005218|NCT01690533||Group 1|
33005219|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
33005220|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
33005221|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
33005222|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
33005223|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
33005224|NCT01690598|Experimental|Veliparib and Topotecan|
33005225|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
33005226|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
33005227|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
33005228|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
33415336|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
33005229|NCT01690637|Placebo Comparator|Placebo|
33005230|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
33005231|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
33005232|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
33005233|NCT01690689|Experimental|Surgery|Implant surgery
33005234|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
33005235|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
33005236|NCT01690715||Hepatocellular carcinoma underwent surgery|
33005237|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
33005238|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
33005239|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
33005240|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
33415337|NCT02049008|Experimental|Photodynamic Therapy|
33415338|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
33417455|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
33417456|NCT01351493|Active Comparator|Nitric oxide gel|
33415339|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
33415340|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
33415341|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
33415342|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
33415343|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
33415344|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
33415345|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
33415346|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
33415347|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
33415348|NCT02049086|No Intervention|No Additional Referral|No intervention.
33415349|NCT02049242|Active Comparator|Triple tourniquet|
33415350|NCT02049242|Active Comparator|Single tourniquet|
33105530|NCT05532709|Experimental|Plyometric training|The plyometric training program progressed from level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
33415351|NCT02049320||Remifentanil|Patients sedated using Remifentanil
33415352|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
33415353|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
33415354|NCT02260076|Experimental|PEG 400|multiple rising doses
33415355|NCT02260076|Placebo Comparator|Placebo|
33415356|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
33415357|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33415358|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33415359|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33105531|NCT05532709|Experimental|circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
33415360|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33415361|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33415362|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33105532|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
33105533|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
32865840|NCT02315027|Experimental|1 dose of 1 × 10(7) MSCs|Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)
32865841|NCT02315027|Experimental|2 doses of 5 × 10(7) MSCs|Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later
32865842|NCT02315027|Experimental|2 doses of 1 × 10(8) MSCs|Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later
32865843|NCT02315027|Experimental|10 doses of 5 x 10(7) (±20%) MSCs|Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
32865844|NCT02315027|Experimental|10 doses of 2.5 x 10(7) (±20%) MSCs|Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
33105534|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
33105535|NCT04321603|Other|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
33105536|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
33105537|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
32865845|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
32865846|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
32865847|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
32865848|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
32865849|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
32865850|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
32865851|NCT03040128|Placebo Comparator|placebo|normal saline infusion
32865852|NCT03040128|Experimental|minocycline|intravenous minocycline
32865853|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
32865854|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
32865855|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
32865856|NCT04850040|Experimental|Camrelizumab+Apatinib Mesylate+Oxaliplatin|An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
32865857|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
32865858|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
32865859|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
32865860|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
32865861|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
32865862|NCT04850118|Active Comparator|Group 1: Low Dose|Male subjects 8-50 years of age treated by subretinal injection with the low dose of AGTC-501
32865863|NCT04850118|Active Comparator|Group 2: High Dose|Male subjects 8-50 years of age treated by subretinal injection with the high dose of AGTC-501
32865864|NCT04850118|Other|Group 3: Control|Male subjects 8-50 years of age in the untreated control group. Subjects randomized to the untreated control group will be followed for a minimum of 12 months. After this time, they will be treated by subretinal injection with the high dose of AGTC-501.
32865865|NCT02301611|Experimental|Treatment|autologous TLPLDC (active vaccine)
32865866|NCT02301611|Placebo Comparator|Placebo|unloaded YCWP + autologous DC (control)
32865867|NCT04023318|Experimental|Integrated Lifestyle Intervention|
32865868|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32865869|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
33005241|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
33005242|NCT01690780|Active Comparator|Ibuprofen|
33005243|NCT01690780|Experimental|Oral morphine|
33005244|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
33005245|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
33005246|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
33005247|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
33005248|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
33005249|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
33005250|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
33005251|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
33005252|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
33005253|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
33005254|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
33005255|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
33005256|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
33005257|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
33005258|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
33005259|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
33005260|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
33005261|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
33005262|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
33005263|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
33005264|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
33005265|NCT01690949|Experimental|PUR118 low dose|
33005266|NCT01690949|Experimental|PUR118 mid dose|
33005267|NCT01690949|Experimental|PUR118 high dose|
33005268|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
33005269|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
33005270|NCT01690975|Placebo Comparator|Placebo|Placebo Control
33005271|NCT01690975|Experimental|Benzonatate|Benzonatate Active
33005272|NCT01691001|Experimental|dexmedetomidine|
33005273|NCT01691001|Placebo Comparator|placebo group|normal saline
33005274|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
33005275|NCT01691053|Active Comparator|Spironolactone|
33005276|NCT01691053|Placebo Comparator|Placebo|
33005277|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
33005278|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
33005279|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
33005280|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
33005281|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
33005282|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
33005283|NCT01691144||recently treated patients|
33005284|NCT01691144||2-3 years after treatment|
33005285|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
33005286|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
33005287|NCT01691170|Active Comparator|Quadriceps Strengthening|
33005288|NCT01691170|Active Comparator|Stretching Hamstring|
33005289|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
33105538|NCT04321720|Experimental|3-g footbath|Footbath with 3g mustard flour per liter of water
33325317|NCT05031052|Experimental|Normothermic machine perfusion (NMP)|End-ischemic NMP will be performed immediately after arrival of the allocated and static cold stored ECD kidney graft. The study protocol aims a duration of 4 hours. Machine perfusion will be performed with a combination of patient's blood group matched packed red blood cells (RBC) and a special manufactured solution with the currently only certified device in Europe (XVIVO - KidneyAssist®). After 4 hours of perfusion and viability assessment, the kidney allograft will be disconnected from the device immediately prior to transplantation and flushed with three litres of Custodiol HTK solution via the renal artery. Then transplantation will be performed in typical method.
33325318|NCT05031052|Active Comparator|Statical cold storage (SCS)|Conventional method kidney transplantation of statical cold stored and transported ECD kidney allograft. The allocated kidney allograft will be flushed with Custodiol HTK solution during back table preparation with the aim of immediate implantation into recipient.
33005290|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
33005291|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
33005292|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
33005293|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
33005294|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
33005295|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
33005296|NCT01691274|Experimental|PF-04895162|
33005297|NCT01691274|Placebo Comparator|Placebo|
33005298|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
33005299|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
33005300|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
33005301|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
33005302|NCT01691365|Active Comparator|vitamins pills|"antioxidant and B vitamins vitamins vitamin~--------------------------------------------------------------------------------"
33005303|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
33005304|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
33005305|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
33005306|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
33005307|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
33005308|NCT01691417|Experimental|Pneumatic Sleeves|
33005309|NCT01691417|Experimental|Congestive Heart Failure Patients|
33005310|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
33005311|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
33005312|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
33005313|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
33005314|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
33005315|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
33005316|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
33005317|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
33005318|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
33005319|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
33005320|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
33005321|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
33005322|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
33005323|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
33005324|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
33005325|NCT01691638||Periodontitis|
33005326|NCT01691638||Control|
33105539|NCT04321720|Experimental|6-g footbath|Footbath with 6g mustard flour per liter of water
33105540|NCT04321720|Experimental|12-g footbath|Footbath with 12g mustard flour per liter of water
33105541|NCT04321720|Placebo Comparator|Warm water footbath|Footbath with warm water only
33415363|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33415364|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
33417457|NCT01351493|Placebo Comparator|placebo|
33417458|NCT02829671|Other|Patients with major depressive disorders|
33005327|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
33005328|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
33005329|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
33005330|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
33005331|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
33005332|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
33005333|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
33005334|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
33005335|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
33005336|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
33005337|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
33005338|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
33005339|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
33005340|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
33005341|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
33005342|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
33005343|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
33005344|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
33005345|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
33005346|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
33005347|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
33005348|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
33417459|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
33417460|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
33417461|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
33005349|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
33005350|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
33005351|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
33005352|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
33005353|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
33005354|NCT01691989|Experimental|aleglitazar|
33005355|NCT01691989|Experimental|placebo|
33005356|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
33005357|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
33005358|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
33005359|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
33005360|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
33325319|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
33005361|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
33005362|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
33005363|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
33005364|NCT01692067||D0|Not deployed
33005365|NCT01692067||D1|Deployed to combat-related regions once
33005366|NCT01692067||D2|Deployed to combat related regions more than once
33005367|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
33005368|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
33005369|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
33005370|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
33005371|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
33005372|NCT01692132||Prucalopride|
33005373|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
33005374|NCT01692145|Placebo Comparator|Placebo|
33005375|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
33005376|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
33005377|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
33005378|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
33005379|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
33005380|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
33005381|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
33005382|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
33005383|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
33105542|NCT04321837|Active Comparator|Coral calcium complex and ibandronate|
33105543|NCT04321837|Active Comparator|Ibandronate and vitamin D|
33325320|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
33005384|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
33005385|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
33005386|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
33005387|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
33005388|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
33005389|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
33005390|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
33005391|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
33005392|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
33005393|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
33005394|NCT01692327|Other|Control Group|Control Group + fat overload intake
33005395|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
33005396|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
33005397|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
33005398|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
33005399|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
33005400|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
33005401|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
33005402|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
33005403|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
33005404|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
33005405|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
33005406|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
33005407|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
33005408|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
33005409|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
33005410|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
33005411|NCT01692431|Experimental|EPA|High fat meal containing EPA.
33005412|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
33005413|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
33005414|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
33005415|NCT01692483||Abiraterone acetate plus prednisone|
33005416|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
33005417|NCT01692522|Experimental|Ambu Aura-i|intubation
33005418|NCT01692522|Active Comparator|AirQ|intubation
33005419|NCT01692535|Experimental|GlideScope|intubation
33005420|NCT01692535|Experimental|Airtraq|intubation
33005421|NCT01692535|Experimental|McGrath MAC|intubation
33005422|NCT01692535|Experimental|King Vision|intubation
33005423|NCT01692535|Experimental|A.P. Advance|intubation
33005424|NCT01692535|Experimental|C-MAC|intubation
33005425|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
33005426|NCT01692548|No Intervention|Control|
33005427|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
33005428|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
33005429|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
33005430|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
33005431|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
33105544|NCT04321837|Active Comparator|Coral calcium complex|
33005432|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
33005433|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
33005434|NCT01692587|No Intervention|Control|No changes in dietary group
33005435|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
33005436|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
33005437|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
33005438|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
33005439|NCT01692652|Active Comparator|warm compress only group|warm compress only group
33005440|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
33005441|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
33005442|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
33005443|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
33005444|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
33005445|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
33005446|NCT01692795||MI patients|
33005447|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
33005448|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
33005449|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
33005450|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
33005451|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
33005452|NCT01692821|Experimental|100% oxygen breathing|
33005453|NCT01692821|Experimental|15% oxygen in N2 breathing|
33005454|NCT01692821|Experimental|12% oxygen in N2 breathing|
33005455|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
33005456|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
33005457|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
33005458|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
33005459|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
33005460|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
33005461|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
33005462|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
33005463|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
33005464|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
33005465|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
33005466|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
33005467|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
33005468|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
33005469|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
33005470|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
33005471|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
33005472|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
33005473|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
33005474|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
33005475|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
33005476|NCT01692977|Active Comparator|control|healthy control subjects.
33005477|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
33005478|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
33105545|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
33005479|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
33415365|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
33005480|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
33005481|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
33005482|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
33005483|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
33005484|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
33005485|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
33005486|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
33005487|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
33005488|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
33005489|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
33005490|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
33005491|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
33005492|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
33005493|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
33005494|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
33005495|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
33005496|NCT01693172|No Intervention|Standard|Standard rehabilitation care
33005497|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
33005498|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
33005499|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
33005500|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
33415366|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
33005503|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
33005504|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
33005505|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
33005506|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
33005507|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
33005508|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
33005509|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
33005510|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
33005511|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
33005512|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
33005513|NCT01693328||PecFent®|
33005514|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
33005515|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
33005516|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
33005517|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
33005518|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
33005519|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
33005520|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
33005521|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
33005522|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
33005523|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
33005524|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
33005525|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
33005526|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
33005527|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
33005528|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
33005529|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
33005530|NCT01693471||SEARCH Study Group|
33005531|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
33005532|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
33005533|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
33005534|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
33005535|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
33005536|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
33005537|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
33005538|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
33005539|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
33005540|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
33005541|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
33005542|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
33005543|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
33005544|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
33325321|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
33325322|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
33325323|NCT05564104|Experimental|Participants with normal hepatic function|Participants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
33325324|NCT05564104|Experimental|Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
33325325|NCT05564104|Experimental|Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
33325326|NCT05564104|Experimental|Participants with severe hepatic impairment|Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1
33325327|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
33325328|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
33325329|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
33325330|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
33325331|NCT01245348||Schizophrenia|Patient with schizophrenia
33005545|NCT01693640|Experimental|abatacept|
33005546|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
33325332|NCT01245348||Bipolar|Patient with bipolar disorder
33417462|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
33417463|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
33005547|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
33005548|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
33005549|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
33005550|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
33005551|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
33005552|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
33005553|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
33005554|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
33005555|NCT01693744||Control group|Patients with normal renal functions
33005556|NCT01693757||BPTB group|Bone-patellar tendon-bone
33005557|NCT01693757||STG group|Semitendinosus and gracilis tendon
33005558|NCT01693757||Control|Healthy
33005559|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
33005560|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
33005561|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
33005562|NCT01693835||Patients|Patients with metastatic colorectal cancer
33005563|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
33005564|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
33005565|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
33005566|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
33005567|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
33325333|NCT04999306|Experimental|Hypnosis group|"the sessions will be conducted following the same dynamics and the same exercises (safe place, reification, anchoring): introduction of the session (conversational hypnosis in order to probe the patient's perceptions of his or her illness and fatigue, discussion of myths and realities); induction with the creation of a safe place that will be used for each session; visualization; deepening of the trance with work on metaphors (reification technique); making specific suggestions on sensations of fatigue, on regaining energy; then instruction for self-hypnosis or anchoring."
33417464|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
33005568|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
33005569|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
33005570|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
33005571|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
33005572|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
33005573|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
33005574|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
33005575|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
33005576|NCT01693952|Experimental|blood samples|
33005577|NCT01693965|Other|sputum samples|
33005578|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
33005579|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
33005580|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
33005581|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
33005582|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
33005583|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
33005584|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
33005585|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
33005586|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
33005587|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
33005588|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
33005589|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
33005590|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
33005591|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
33005592|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
33005593|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
33005594|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
33005595|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
33005596|NCT01694095||Patients with geographic atrophy|
33005597|NCT05289752|Active Comparator|Group I|GroupI: The retentive caps will be picked up by the indirect method on the cast first, then by the direct method.
33005598|NCT05289752|Active Comparator|Group II|GroupII: The retentive caps will be picked up by the direct method on the cast first, then by the indirect method.
33005599|NCT05289726|Experimental|Traditional chinese medicine TDX105|"Experimental group Traditional chinese medicine TDX105 (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~Basic care was the same in both groups, including routine care such as topical use of urea ointment"
33005600|NCT05289726|Placebo Comparator|placebo|"The control group received placebo granules mixed with dextrin and food coloring (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~- Basic care was the same in both groups, including routine care such as topical use of urea ointment"
33005601|NCT05289713|Active Comparator|Surgery|In the surgery group, patients undergo laparoscopic appendectomy within 18 hours after randomization.
33005602|NCT05289713|Active Comparator|Symptomatic treatment|Symptomatically treated patients are hospitalized for at least 24 hours, and receive intravenous fluids and analgesics according to standard clinical practice.
33005603|NCT05289700|Experimental|HBOT intervention group (2 ATA, 95 min, FIO2=1)|Hyperbaric Oxygen Therapy (HBOT) is the administration of oxygen at a pressure higher than atmospheric pressure (2 ATA). By breathing pure oxygen at twice the atmospheric pressure, its concentration in the blood is multiplied by nearly ten times. This allows a greater oxygen concentration in poorly vascularised areas of the body.
33005604|NCT05289700|Placebo Comparator|placebo group (1.3 ATA, 95 min, FIO2=0.21)|Hyperbaric chamber is the same chamber used for HBOT, but with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers.
33005605|NCT05289609||Prospective Cohort|Liver Transplant Recipients from High-volume centers (i.e., performing >= 65 LTs per year)
33005606|NCT05289609||Retrospective Cohort|Liver Transplant Recipients from Low-to-medium volume centers (i.e., performing <65 LTs per year) and High-volume centers
33005607|NCT05289557|Active Comparator|Bonjesta|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
33415367|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
33005608|NCT05289557|Placebo Comparator|Placebo|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
33005609|NCT05289531||Rectal resection patients|Four Turkish centers participated in data collection in 2016. The inclusion criteria were rectal adenocarcinoma within 15 cm from the anal verge and LAR with either PME or TME. All patients had bowel continuity restored for at least 18 months when invited for the study. Exclusion criteria included failed R0 surgery, recurrence or dissemination, having intestinal stoma, previous cancer (except minor skin cancers) dementia and inability to speak Turkish (i.e., the need for a translator during treatment). A research assistant at each center identified the consecutive series of eligible patients for each participating consultant surgeon
33005610|NCT05289531||52 patients re-questioned to answer the same questionaire as control group|"The test-retest reliability of the LARS score was evaluated by asking 52 randomly selected subgroup of eligible patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response. Agreement between tests for the LARS score category and for each of the five LARS score items is presented as proportions with 95% confidence intervals. We considered it a perfect agreement if the patient ticked the exact same response category at both tests, a moderate agreement if responses differed by one category, while 'no agreement' was applied to patients whose responses differed by two or more categories.~The intraclass correlation coefficient was used to evaluate the agreement between the initial test and the retest. The limit of agreements was calculated by using the Bland-Altman method. An ICC between 0.61 and 0.80 is considered strong agreement. A p value less than 0.05 was considered significant."
33005611|NCT05289518|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 3 months.
33005612|NCT05289518|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 3 months.
33005613|NCT05289466|Other|Single-arm|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
33005614|NCT05289453|Experimental|study group|patients wit acute congestive glaucoma and treated bt lens extraction by phacoemulsification after IOP control
33005615|NCT05289401|Active Comparator|ESPB|Unilateral erector spinae block will be performed in the lateral position . 0.5 mL/Kg of bupivacaine 0.125% will be injected taking care not to exceed the maximum recommended dose (2 mg/kg of bupivacaine)
33005616|NCT05289401|Active Comparator|CB|caudal block performed in lateral position . bolus of 1.2 ml/Kg bupivacaine 0.125% .
33005617|NCT05289336|Experimental|Transoral Laser Microsurgery|Transoral Laser Microsurgery
33005618|NCT05289219|Experimental|Intervention Group|The duration of the program is 16-weeks, 3-times a week, for up to 50 minutes per session, starting 1 month after surgery, based on the recommendations of the WHO and the ACSM, because the guidelines for morbidly obese patients undergoing bariatric surgery are not defined. Information on exercises for morbidly obese adults is limited, so the exercise programs will follow the guidelines for adults aged 18 to 65 years healthy, with chronic diseases or disabilities
33005619|NCT05289219|No Intervention|Control Group|
33005620|NCT05289128|Experimental|Experimental Group/ Active HD-tDCS|Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
33105546|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
33105547|NCT02897414||Overall group that includes all prescription opioids except|
33415368|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
33415369|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
33005621|NCT05289128|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
33005622|NCT05289115|Experimental|Experimental Group/ Active HD-tDCS|Patients who will be randomly enrolled in this group. They will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
33005623|NCT05289115|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
33005624|NCT05289102|Experimental|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks postpartum, and one later at 7 weeks postpartum.
33005625|NCT05289102|Active Comparator|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
33005626|NCT05289076||Colorectal liver metastsis|Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos.
33005627|NCT05289011||Patients with spondyloarthritis without Inflammatory bowel disease|
33005628|NCT05288959|Experimental|Healthy participants|"All participants participate in five core sessions. Session 1 consists of MRI scans (T1-weighted, T2-weighted, diffusion MRI, resting-state fMRI). Thereafter, there are four TMS-EEG sessions. Session 2 delivers uni-focal spTMS to various cortical targets while EEG is recorded to determine inter-regional conduction delays. Thereafter, Sessions 3 - 5 deliver bi-focal TMS (PAS), each session using a different asynchrony (shorter, equal to, or longer than the conduction delay). The three PAS sessions are at least one week apart. Each of the PAS sessions have three segments: (a) TMS-EEG-behavioral recordings before PAS, (b) the PAS modulation, and (c) TMS-EEG-behavioral recordings after PAS.~In addition to these core sessions, some participants may be invited for additional sessions for parameter optimization and for assessing test-retest repeatability."
33005629|NCT05288881|Experimental|ANX105|
33005630|NCT05288881|Placebo Comparator|Placebo|
33005631|NCT05288829|Experimental|ALXN1210 SC|Participants received ALXN1210 SC.
33005632|NCT05288829|Experimental|ALXN1210 IV|Participants received ALXN1210 IV.
33005633|NCT05288829|Placebo Comparator|Placebo SC|Participants received placebo SC.
33005634|NCT05288816|Experimental|Cohort 1: ALXN1210 400 mg (Single)|A single dose of ALXN1210 was administered intravenously.
33005635|NCT05288816|Experimental|Cohort 2: ALXN1210 800 mg (Single)|A single dose of ALXN1210 was administered intravenously.
33005636|NCT05288816|Experimental|Cohort 3: ALXN1210 800 mg (Multiple)|ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses.
33005637|NCT05288803||Control cohort|The investigators will collect outcomes for 100 Veterans treated with usual care rehabilitation after total knee arthroplasty. Data will be collected at all participating clinical locations. Data collection for these Veterans will precede data collection for the intervention cohort.
33005638|NCT05288803||Intervention cohort|The investigators will implement the clinical decision support tool in all participating clinic locations. We will collect outcomes for 100 Veterans treated in rehabilitation with use of the clinical decision support tool. Data collection for these Veterans will occur after data collection is complete for the Control cohort.
33005639|NCT05288738|Active Comparator|Group D1|PCA morphine 1mg/ml
33005640|NCT05288738|Active Comparator|Group D2|PCA morphine 1mg/ml
33005641|NCT05288725|Experimental|Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.
33005642|NCT05288725|Experimental|Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.
33005643|NCT05288725|Experimental|Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.
33005644|NCT05288725|Active Comparator|Corticosteroid injection|Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day.
33005645|NCT05288686|Experimental|SPIO arm|Superparamagnetic iron oxide guided sentinel lymph node mapping
33005646|NCT05288686|Active Comparator|Control arm|Conventional radioisotope and blue dye guided sentinel lymph node mapping
33005647|NCT05288673|Experimental|ALXN1210 400 mg|Participants received ALXN1210 every 28 days.
33005648|NCT05288673|Experimental|ALXN1210: 800 mg|Participants received ALXN1210 every 28 days.
33415370|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
33415371|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
33005649|NCT05288673|Placebo Comparator|Placebo|Participants received placebo every 28 days.
33415372|NCT02051660|Experimental|Manualized CALM Intervention|
33415373|NCT02051660|Active Comparator|Non-manualized supportive intervention|
33415374|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
33005650|NCT05288660|Experimental|ALXN1210 200 mg|ALXN1210 was administered intravenously.
33415375|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
33415376|NCT02050880||Normal eyes|Eyes without pathology.
33415377|NCT02050880||Glaucoma|Eyes with Glaucoma.
33415378|NCT02050880||Retinal|Eyes with Retinal Disease.
33415379|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
33415380|NCT02050958|Experimental|OXP001|OXP001
33415381|NCT02050958|Active Comparator|Ibuprofen|Brufen
33415382|NCT02037464|Experimental|Capsaicin Supplement|
33415383|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
33415384|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
33005651|NCT05288660|Experimental|ALXN1210 400 mg|ALXN1210 was administered intravenously.
33005652|NCT05288660|Placebo Comparator|Placebo|Placebo was administered intravenously.
33005653|NCT05288465|Experimental|Hair repigmentation during Cerebrolysin treatment for neurological diseases|Patients prescribed for Cerebrolysin treatment due neurological diseases.
33005654|NCT05288426||participant post first BNT162b2 vaccination|Patients which developed myocarditis after the first dose of BNT162b2 vaccination
33005655|NCT05288426||participant post second BNT162b2 vaccination|Patients which developed myocarditis after the second dose of BNT162b2 vaccination
33005656|NCT05288426||participant post third BNT162b2 vaccination|Patients which developed myocarditis after the third dose of BNT162b2 vaccination diagnosed with MIS
33005657|NCT05288426||participant post COVID-19|Patients which developed myocarditis after COVID-19 infection
33005658|NCT05288387|Experimental|Spinal cord stimulation in heart failure patients with hypotension|"Adhesive patches are applied to subjects' back skin. Single stimuli are delivered in order to define the stimulation threshold under the guidance of neuromyography. Vascular access is performed (jugular or subclavian) according to conventional preparation to right heart catheterization. Invasive hemodynamic measures are performed as usual.~High-frequency spinal cord stimulation at T5 level is initiated, and repeated hemodynamic measures performed within 2 minutes. Stimulation lasts for 5-10 minutes, and then ceased. Following a 5-minutes waiting period, repeat hemodynamic measures are performed. The same sequence of steps applies for stimulation levels T7-8 and a combination of T5 and T7-8.~Then the procedure is completed and data are analysed."
33005659|NCT05288374|Experimental|Celecoxib|Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
33005660|NCT05288374|Placebo Comparator|Placebo|A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
33005661|NCT05288270|Experimental|Aramis Group|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
33005662|NCT05288270|Active Comparator|Conventional Group therapy|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
33415385|NCT02049554|No Intervention|Usual Care|
33415386|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
33415387|NCT02049710|Active Comparator|Sexual Behavior Intervention|Video based intervention based on changing risky behavior associated with sexual behavior.
33415388|NCT02049710|Active Comparator|Driving behavior intervention|Video based intervention based on changing risky behavior associate with driving
33415389|NCT01353625|Experimental|CC-115|
33415390|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
33005663|NCT05288244|Experimental|foot bath|"It will be applied to the patients in group A (foot bath) every evening between 21.00-21.20 for 14 days. The steps of the procedure are as follows:~To be used in the footbath, a footbath tub, water at 38-40°C, a thermometer to measure the temperature of the water, foot towels, clean socks, gloves are prepared.~With the water temperature adjustment button in the foot bath tub, wait until the temperature of the water reaches 38-40 °C~Between 21:00 and 21:20, the feet are kept in water with a constant temperature of 38-40 °C for 20 minutes. (While the process is in progress, the water temperature is checked intermittently with a laser thermometer.)"
33105548|NCT02897414||Comparator Group taking benzodiazepines|
33105549|NCT02897414||Comparator Group taking IR hydrocodone|
33005664|NCT05288244|Experimental|lavender oil snuff|"The L group (lavender oil sniffing) will be applied, the lavender oil sniffing process will be applied every evening between 21.00-21.05 for 14 days, and the process steps will be as follows;~Essential lavender oil to be used for the enterprise is obtained from a company that has business registration and TS EN ISO 9001: 2008 quality certificates with the number G06-3231 from the Ministry of Food, Agriculture and Livestock.~3 drops of the obtained lavender oil are dripped onto the cotton pad.~The prepared cotton pad is fixed on the patient's clothing in the upper chest and shoulder area with a locked needle and the patient is asked to sniff for 5 minutes (Özkaraman et al., 2018)."
33005665|NCT05288244|Experimental|foot bath and lavender oil snuff|AL group (both foot bath and lavender oil sniffing),for 14 days, every evening between 21.00-21.20, foot bath and lavender oil sniffing between 21.00-21.05 will be applied together.
33005666|NCT05288192|Active Comparator|Suprachoroidal triamcinolone injection|Eyes treated with suprachoroidal injection of triamcinolone acetonide.
33005667|NCT05288192|No Intervention|Non-treated eyes|Eyes that are receiving no interventions during the study period.
33005668|NCT05288179|Experimental|Pirfenidone group|Patient takes pirfenidone 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
33005669|NCT05288179|Placebo Comparator|placebo group|Patients take a placebo 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
33005670|NCT05288140|No Intervention|usual ICU practice|The patient's evolution is reported verbally to the family.
33005671|NCT05288140|Experimental|ICU diary|Made a diary
33005672|NCT05288127|Experimental|Talazoparib Single Agent|"The study will have 1 treatment group. Patients will receive a single oral dose of talazoparib (Talzenna®) 1mg/day daily for 28-day cycles until progressive disease, limiting toxicities, intercurrent medical issues, patient withdrawal of consent, death, or end of trial whichever occurs first. Treatment will be administered on an outpatient basis. Talazoparib should be taken orally once daily (i.e., continuous daily dosing) at approximately the same time each day (preferably in the morning). Talazoparib will be swallowed whole and may be taken with or without food. If a subject vomits a dose, the subject should not take a second dose that calendar day. The subject should resume daily dosing the next day.~Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered if the evidence of response or clinical benefit to talazoparib is noted."
33005673|NCT05291585|Experimental|the dedicated venous sinus thrombectomy stent|Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.
33005674|NCT05291585|Active Comparator|balloon catheter thrombectomy|Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product
33005675|NCT05291572|Active Comparator|Group A|will be treated by speech therapy only (fluency shaping).
33005676|NCT05291572|Active Comparator|Group B|will be treated by speech therapy (fluency shaping) plus Hyperbaric oxygen therapy.
33005677|NCT05291572|Active Comparator|Group C|will be treated by speech therapy (fluency shaping) plus medical treatment (brain stimulant).
33005678|NCT05291481|Experimental|CAPAS Youth Parenting Intervention|11-week CAPAS-Youth culturally adapted intervention
33005679|NCT05291481|No Intervention|Wait-list control|Participants allocated to this condition receive the intervention until all assessments are completed for both arms in each cohort
33005680|NCT05291455|Experimental|Lacosamide|Lacosamide will be given.
33005681|NCT05291455|Active Comparator|Phenobarbitone|Phenobarbital will be given
33005682|NCT05291429|Active Comparator|VR - coaching arm|30 individuals to be enrolled in the intervention arm that also includes coaching sessions to support and encourage VR use (VR+coaching arm).
33005683|NCT05291429|Active Comparator|VR only - no coaching|30 individuals to be enrolled in the intervention arm without coaching (VR arm)
33005684|NCT05291429|No Intervention|No intervention - control arm|30 individuals to be enrolled in the control arm with no active intervention (comparator 2; control arm)
33005685|NCT05291416||1|healthy children aged between 4-16 years
33005686|NCT05291416||2|children aged between 4-16 years, suffering from juvenile idiopathic arthritis
33005687|NCT05291377||high disbility group|Group scored more than half of the score of the neck disability index
33005688|NCT05291377||low disability group|Group scored less than half of the score of the neck disability index
33005689|NCT05291338||HCC patients|100 hepatocellular carcinoma patients underwent TACE
33005690|NCT05291312|Other|endoscopic assisted coblation|
33005691|NCT05291312|Other|conventional curettage|
33005692|NCT05291260|Experimental|Cast immobilization|Cast immobilization to immobilize the thumb for 4 weeks. After 2 weeks the thumb will be re-examined to determine if surgery is required. It is expected that at re-evaluation at 2 weeks after starting the cast treatment about 1 in 10 patients will still need surgery.
33005693|NCT05291260|Active Comparator|Surgery|The intervention is compared to surgery, which is standard treatment for complete ulnar collateral ligament ruptures.
33005694|NCT05291195|Experimental|Laser-devices group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite. Afterwards, depending on allocations, in the laser devices group, adjuvant treatment approaches were be performed by means of laser devices either photodynamic therapy (HELBO, Photodynamic Systems GmbH), or high power diode laser (940nm, Biolase).
33005695|NCT05291195|Experimental|Sodium hypochlorite|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
33415391|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
33415392|NCT02051894||HIE Group|
33415393|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
33415394|NCT01357681|Placebo Comparator|Placebo|Placebo
33105550|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
33105551|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
33105552|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
33105553|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
33105554|NCT00549666|Experimental|Lurasidone 40 mg|
33105555|NCT00549666|Placebo Comparator|Placebo|
33105556|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
33105557|NCT04680923|Experimental|CPPLAI|Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
33105558|NCT04680923|Placebo Comparator|Placebo|Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
33105559|NCT04680806|Experimental|Er,Cr:YSGG laser 2780 nm|Group A was treated by an Er,Cr:YSGG laser 2780 nm cylindrical tip (tip 600 μm, 45 millijoule /pulse, average power 2.25 W, frequency 50 Hz, pulse duration 60 µs, energy density 43 J/cm2, water 50%, and air 40%). The procedure was performed completely without anesthesia with the laser tip at angulation ~30° and distance of ~1 mm from the gingival tissue. The laser tip was advancing in scanning movement from in the cervical-apical direction in all pigmented areas. The following settings was used to achieve hemostasis in case of the bleeding was present (tip 600 μm, 30 millijoule /pulse, average power 1.5 W, frequency 50 Hz, pulse duration 700 µs, energy density 28.7 J/cm2, water 10%, and air 20%).
33105560|NCT04680806|Experimental|Diode laser 940 nm|Group B was treated with diode 940 nm Laser. The procedure was performed with a pencil-sized handpiece containing a 400 µm lasing fiber (400 μm initiated tip, average power 0.8 watts, Pulsed mode, Duty cycle 20%, Pulse duration 10 μs, energy density 636.9 J/cm2 per second, no water or air). Infiltration anesthesia was injected for B group . The laser tip was placed in angle ~30° with the gingival surface. Short light paint brush strokes were used in the cervical-apical direction in all pigmented areas.
33105561|NCT04933383|Experimental|AQ001S 0.125 mg/ml|AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.
33105562|NCT04933383|Active Comparator|budesonide inhalation suspension 0.125 mg/ml|Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.
33105563|NCT04680767|Experimental|[¹⁴C]-LY3502970|A single dose of LY3502970 and [¹⁴C]-LY3502970 administered orally.
33105564|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
33105565|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
33325334|NCT04999306|Experimental|CBT group|"This program will work specifically on the psychosocial determinants of fatigue.~The first session will be patient education on cancer-related fatigue. S2 will address the concept of perceived control and allow the patient to understand what factors accentuate this condition. S3 will allow the patient to work on the emotions associated with cancer and will be complemented by a hypnosis audio. S4 will address the notion of social support and how the patient can learn to delegate or ask for help. S5 will address the notion of coping strategies, the patient will then be able to identify what he/she puts in place, what is productive and what is not. Finally, the S6 will be a synthesis session that will allow to come back to the points that deserve to be deepened."
33325335|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
33105566|NCT04680494|Experimental|Rest|Participants rest quietly for 30 minutes, sitting on a chair. They may read magazines not involving motion-related elements
33105567|NCT04680494|Experimental|Moderate intensity exercise|Participants cycle on a cycle ergometer during 30 minutes at 65% of their maximal cardiac frequency
33105568|NCT04680494|Experimental|High intensity exercise|Participants cycle on a cycle ergometer during 15 minutes at 75% of their maximal cardiac frequency. This session also includes 3 minutes of warm-up and three minutes of cool down at 50% of their maximal cardiac frequency
33105569|NCT03694522|Experimental|Bemarituzumab + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
33105570|NCT03694522|Placebo Comparator|Placebo + mFOLFOX6|Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
33105571|NCT04891419|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants will be treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel in temple. Participants are eligible for touch up treatment
33105572|NCT04891419|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 6.
33325336|NCT05558644|Experimental|single arm for all patients|"single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
33325337|NCT04976140|Experimental|Low dose group|The investigational product is intravenously administered according to the planned dose.
33325338|NCT04976140|Experimental|Intermediate dose group|The investigational product is intravenously administered according to the planned dose.
33325339|NCT04976140|Experimental|High dose group|The investigational product is intravenously administered according to the planned dose.
33325340|NCT05537038|Experimental|BNT164a1|Escalating dose levels
33325341|NCT05537038|Experimental|BNT164b1|Escalating dose levels
33415395|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
33417465|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
33005696|NCT05291195|Experimental|Essential oil|"Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).~Depending on allocations, in the essential oil group, the canals were be treated with adjuvant essential oil of Cymbopogon martinii and Thymus vulgaris (Herba oils, Herba doo, Belgrade, Serbia)"
33005697|NCT05291182|Experimental|Dose-escalation|The study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835.
33005698|NCT05291130||Plasmafit® Vitelene® Vitamin E ceramic femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and bioceramic femoral heads
33005699|NCT05291130||Plasmafit® Vitelene® Vitamin E metal femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and metal femoral heads
33005700|NCT05291130||Plasmafit® polyethylene metal femoral heads|Plasmafit® Acetabular Cup System with polyethylene and metal femoral heads
33005701|NCT05291104|No Intervention|Placebo|Interventions are not received any treatments.
33005702|NCT05291104|Experimental|Intervention|Interventions are received folic acid or choline
33005703|NCT05291065|Experimental|Fasted exercise|Fasted prior to exercise
33005704|NCT05291065|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
33005705|NCT05291065|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
33005706|NCT05291052|Experimental|TIS combined therapy|All patients will be treated with the combination of tisleizumab , lenvatinib and XELOX regimen (oxaliplatin combined with capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
33005707|NCT05291039|Active Comparator|Infliximab.|group 1 (n=20): patients will receive IFX,
33005708|NCT05291039|Active Comparator|Adalimumab.|group 2 (n=20): patients will receive ADA
33005709|NCT05291013|Experimental|Gastric bypass with T2DM|
33005710|NCT05291013|Experimental|Gastric bypass without T2DM|
33005711|NCT05291013|No Intervention|Control group|
33005712|NCT05291000|Experimental|RoT-ReWiH|First, pre-tests were applied to the patients in the training and reminder by watch group at first home visit.Second home visits were conducted participants 12th weeks after the first home visit.One of the researchers presented the education program to individuals with hypertensive.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes.For the patients in this group, the alarm time was set according to the time when blood pressure medication was taken, the cord was adjusted according to the arm, and then information was given about the use of the watch. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
33005713|NCT05291000|Experimental|Training group|First, pre-tests were applied to the patients in the training group at first home visit.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes. In addition, other drugs used by individuals at home (such as painkillers, antibiotics) were also evaluated during the home visit, and a red label was made on the antihypertensive drug box to distinguish antihypertensive drugs from other drugs. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
33005714|NCT05291000|No Intervention|Control group|Pre-tests was applied to the patients in the control group.No intervention was be applied to the patients in this group and second home visit 12th weeks after the first home visit and were readministered the post-tests.
33005715|NCT05290948|Active Comparator|investigate of the effect of intravitreal injection of bevacizumab with acetazolamide tablets|
33005716|NCT05290948|Active Comparator|Investigate the effect of intravitreal injection of bevacizumab alone|
33005717|NCT05290935|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
33005718|NCT05290909|Experimental|The protocol of blended and problem-based learning|The experimental group will accept the protocol of blended and problem-based learning in the professional ethics course, 2 hours /per week, for 18 weeks
33005719|NCT05290909|Active Comparator|The traditional problem-oriented teaching model|The control group will accept the traditional problem-oriented teaching model in the professional ethics course, 2 hours /per week, for 18 weeks
33005720|NCT05290896|Other|Lens star biometry|Biometry done prior to phacoemulsification
33005721|NCT05290870||Subjects implanted with hydrophilic acrylic IOLs|Subjects were implanted with a HydroSmart IOL (FEMTIS, LENTIS or VISIOTIS)
33005722|NCT05290870||Subjects implanted with hydrophobic acrylic IOLs|Subjects were implanted with an ACUNEX IOL
33005723|NCT05290857|Experimental|High thrombotic risk|For patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis after GI bleeding.
33105573|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
33105574|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
33105575|NCT03686215|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015.
33105576|NCT03686215|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
33105577|NCT04931901|Experimental|Stimpod NMX450X|
33105578|NCT04931901|Active Comparator|Datex-Ohmeda E-NMT|
33105579|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
33105580|NCT04207645||Latin American|patients originating from Mexico (5 centres)
32865870|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
32865871|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
32865872|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
32865873|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
33105581|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
33105582|NCT04207645||European|patients originating from Spain (11 centres).
33105583|NCT05512585|Active Comparator|awake prone positioning with room air|Participants will stay in the prone position
33105584|NCT05512585|Experimental|awake prone positioning with high-flow nasal cannula|Participants will stay in the prone position and breathe with high-flow nasal cannula
32865874|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
32865875|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
33105585|NCT05512585|Experimental|awake prone positioning with continuous positive airway pressure|Participants will stay in the prone position and breathe with continuous positive airway pressure via face mask
32865876|NCT04838886|Experimental|Exercise group|The intervention group will be received telerehabilitation-based pilates training three times a week for 6 weeks.
32865877|NCT04838886|No Intervention|Waitlist|The control group will be a wait-list group without any additional specific treatment.
32865878|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
32865879|NCT04372992|Experimental|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
33105586|NCT05512585|No Intervention|supine position with room air|Participants will stay in the supine position
33105587|NCT05512585|Active Comparator|supine position with high-flow nasal cannula|Participants will stay in the supine position and breathe with high-flow nasal cannula
33105588|NCT05512585|Active Comparator|supine position with continuous positive airway pressure|Participants will stay in the supine position and breathe with continuous positive airway pressure via face mask
33105589|NCT04207723|Experimental|TENS Therapy|Tens therapy + placebo drug therapy
33105590|NCT04207723|Sham Comparator|Control|Standard treatment (paroxetine 20 mg) + sham therapy
33105591|NCT04207723|Experimental|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
33105592|NCT02896790||Stage 1|Patients without therapeutic education
33105593|NCT02896790||Stage 2|Patients with therapeutic education
33325342|NCT05537038|Experimental|Placebo|Isotonic NaCl solution (0.9%)
33325343|NCT05529472|Experimental|CSI Peripheral Orbital Atherectomy System (OAS)|Treatment with OAS followed by POBA (pre-dilation) and DCB (Medtronic IN.PACT Admiral)
33325344|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
33325345|NCT00603642|Placebo Comparator|Placebo|
33325346|NCT05520346|Experimental|Device|Patients use toilet device to measure fluid output and self-report event types
33415396|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
33415397|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
32865880|NCT04372992|Active Comparator|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
32865881|NCT02278601|Experimental|MPIB modified programmed intermittent bolus|Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
32865882|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
32865883|NCT02278601|Active Comparator|patient controlled epidural analgesia with basal infusion|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
32865884|NCT04833738|Active Comparator|Electrotherapy|
32865885|NCT04833738|Active Comparator|corticosteroid|
32865886|NCT04833738|Active Comparator|hyaluronic acid|
32865887|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
32865888|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
32865889|NCT02271815||Oral Hygiene|Oral Hygiene
32865890|NCT02270411||Healthy Subjects|Healthy subjects.
32865891|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
32865892|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
32865893|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
32865894|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
32865895|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
32865896|NCT04371588||Deep neuro-muscular blockade|
32865897|NCT04371588||Moderate neuro-muscular blockade|
32865898|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
32865899|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
32865900|NCT04371198|Experimental|Organoid|
32865901|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
32865902|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
32865903|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
32865904|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
32865905|NCT04838340|Active Comparator|Standart care|Standart care group will leave in the hospital's usual care and no intervention will be applied.
32865906|NCT04838340|Experimental|Hypnobirthing group|Hypnobirthig training intervention will be applied to the Hypnobirthing group for 4 weeks and 3 hours a week and usual care will be provided by healthcare professionals.
32865907|NCT05585723||students at the university|
32865908|NCT05585723||teenagers|
32865909|NCT05585723||parents of teenagers|
32865910|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
32865911|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
32865912|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
32865913|NCT04369326|Experimental|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
33415398|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
33415399|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
33005724|NCT05290857|Experimental|Moderate thrombotic risk|For patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis after GI bleeding.
33415400|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
33415401|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
33415402|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
33415403|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
33415404|NCT02037698|No Intervention|Control group|Control
33005725|NCT05290831|Experimental|Main study group|
33005726|NCT05290766|Active Comparator|Control group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on 4 implants that were placed according to the All on four concept."
33005727|NCT05290766|Active Comparator|Study group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on two implants placed according to All On two concept."
33005728|NCT05290714|Experimental|Mentalization Based Treatment for Children (MBT-C)|Mentalization Based Therapy for Children (MBT-C) is a transdiagnostic time-limited (12 weekly sessions) and manualized treatment for children aged between 5 to 12 years old with the main aim of increasing mentalization and restoring epistemic trust. Parallel parental work takes place to increase parental mentalization.
33005729|NCT05290714|Active Comparator|Parenting and Social Skills Group|"Parenting groups will run for 12 weeks with 10 parents per group. They will involve activities to help parents develop effective parenting skills via working on a family genogram, providing information on child development, developing acceptance and empathy, setting boundaries and anger regulation.~The social skills groups will run for 12 weeks and will be conducted with 10 children per group. They will involve activities on self-presentation, peer communication, play skills, empathy and anger management."
33005730|NCT05290636|Experimental|single arm trial|A single-arm trial was designed. (Two-hour sessions per week for 18 weeks). The value of classroom learning and practical experience for the study subjects is emphasized in this intervention course. The case analysis teaching technique will be used extensively in the classroom, and the school's digital action learning platform will support instructional activities relevant to senior nursing and elderly nursing practice. In each section of the course, combine classroom instruction with case analysis (2 hours each, 20-30 minutes for topic teaching, 70-80 minutes for case discussion and feedback)
33005731|NCT05290571|Experimental|Intervention Group|Intervention Group will be asked to follow the actions in the provided video. It lasts for approximately 30 minutes, with 5-minute warm-up and cool-down exercises respectively, a 4-minute song repeating for 4 times and a 1-minute rest in between each repetition. Videos, in the form of a YouTube link, will be distributed for the Intervention Group, as well as the leaflets.
33005732|NCT05290571|Active Comparator|Control Group|Control Group will receive a leaflet on 10 actions extracted from mOEP, 2 actions from conventional OEP and 1 action from Mini-BESTest. The participants will perform 8-16 repetitions for each action, with 3-5 seconds of rest between actions.
33005733|NCT05290545|Experimental|Haplo-PBSC+Cord group|The third party UCB will be infused the day after infusion of PBSCs from HID.
33005734|NCT05290545|Active Comparator|Haplo-PBSC+BM group|The BMSCs from the same HID will be infused the day after infusion of PBSCs.
33005735|NCT05290532|Other|Individualized exercise training|Exercise training. Individual program training 2 days per week during 4 week, after one week of discharge
33005736|NCT05290532|No Intervention|No Intervention: Control|Usual care including rehabilitation when necessary
33005737|NCT05290519|Experimental|Group A|plant protein for 4 weeks than animal protein for 4 weeks
33005738|NCT05290519|Experimental|Group B|animal protein for 4 weeks than plant protein for 4 weeks
33005739|NCT05290506|Active Comparator|Prediabetes Low GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
33005740|NCT05290506|Active Comparator|Prediabetes High GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
33005741|NCT05290506|Active Comparator|Diabetes Low GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
33005742|NCT05290506|Active Comparator|Diabetes High GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
33005743|NCT05290480|Experimental|Expiratory muscle training|participant performed expiratory muscle training with threshold device
33005744|NCT05290480|Experimental|Insentive spirometry|participant performed deep breathing exercise with insentive spirometry device
33005745|NCT05290441|Active Comparator|None involement|In the pathological examination, the group of patients without EGFR involvement in the biopsy material.
33005746|NCT05290441|Active Comparator|Mild|In the pathological examination, the group of patients mild EGFR involvement in the biopsy material.
33005747|NCT05290441|Active Comparator|Moderate|In the pathological examination, the group of patients moderate EGFR involvement in the biopsy material.
33005748|NCT05290441|Active Comparator|Severe|In the pathological examination, the group of patients severe EGFR involvement in the biopsy material
33005749|NCT05290428||Retrospective part|This part will enroll at least 120 cases in previously preserved samples.
33005750|NCT05290428||Prospective part|This part will enroll at least 339 cases.
33415405|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
33005751|NCT05290376|Active Comparator|Control group|Group I (control): patients who would be delivered mandibular implant overdenture retained by two RTx locator attachments using conventional loading protocol
33005752|NCT05290376|Active Comparator|Study group|Group II (study): patients who would be delivered mandibular overdenture retained by two RTx locator attachments using early loading protocol.
33005753|NCT05290337|Experimental|ZR-CHOP|
33005754|NCT05290324|Experimental|MIdazolam Group|Following surgery Immediately after shifting in ICU, midazolam infusion were administered as 0.25 mg/kg/min.
33005755|NCT05290324|No Intervention|Propofol Group|Following surgery after Immediately shifting in ICU propofol infusion was started at 10µg/kg/min.
33005756|NCT05290311||COMB|The 'combined' or 'COMB' group received cognitive behavioural therapy next to pharmacotherapy for ADHD in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
33005757|NCT05290311||PHA|The 'pharmacotherapy' group or 'PHA' received pharmacotherapy for ADHD only in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
33005758|NCT05290298|Experimental|NITRATE|Multi-component nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid)
33005759|NCT05290298|Placebo Comparator|PLACEBO|Placebo (2.5 grams of inulin)
33005760|NCT05290272|Experimental|ViFIVE Digital Care Program|AI based digital care program that is individually tailored for each user depending on need. ViFive DCP includes illustration, voice guidance, and pose correction features of AI coach. Participants will required to complete the program.
33005761|NCT05290103|Experimental|Game intervention|Participants in this arm will receive the game intervention including 15-30 minutes of digital health game playing at school and 2 weeks of free usage of the game during free time and a 30-minute debriefing session with a researcher.
33005762|NCT05290103|No Intervention|No intervention|The participants in this arm will receive no intervention.
33005763|NCT05290090|Experimental|Rituximab, lenalidomide, zanubrutinib and RCHOP|"Rituximab, lenalidomide, zanubrutinib for 2 cycles: rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~RCHOP for 4 cycles: rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
33005764|NCT05290051|Experimental|Patients referred for cytogenetic analysis|Analysis of patient DNA with Optical Genome Mapping (Bionano®) and long read Sequencing (Nanopore®) in search for chromosome abnormalities (aneuploidies and SV)
33005765|NCT05290012|Experimental|Dark Chocolate|Participants consumed 18 grams of dark chocolate (36 g/day, 400 mg/day of flavanols) twice daily.
33005766|NCT05290012|No Intervention|Control|No intervention was made
33005767|NCT05289986|Experimental|immediate switch arm|"Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks.~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
33005768|NCT05289986|Active Comparator|delayed switch arm|"Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks).~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
33005769|NCT05289921|Experimental|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
33005770|NCT05289921|Active Comparator|Clostridium botulinum type A|Clostridium botulinum type A Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
33005771|NCT05289895||1|Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer)
33005772|NCT05289895||2|Sequence 2 (Non-interventional prospective study, sample and information collection in patients with pancreatic cancer)
33005773|NCT05289895||3|Sequence 3 (Non-intervention study, healthy subjects sample and information collection)
33005774|NCT05289843|Experimental|Experimental|Rosmarinus officinals will be used as root canal irrigant in treating aysymptomatic mandibular premolars.
33005775|NCT05289843|No Intervention|Control Group|Sodium Hypochlorite used as control in root canal irrigations in treating a asymptomatic mandibular premoalrs.
33005776|NCT05293028|Experimental|Drug:F527|F527 is dose-escalated sequentially by accelerated titration and i3+3 design.
33005777|NCT05293015|Experimental|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
33005778|NCT05293015|No Intervention|Regular diabetes management|The patient would go to the endocrinology outpatient clinic before hospitalization to regulate blood glucose, and be managed by by orthopedic medical staff through hospitalization. If necessary, the endocrinologist is consulted. And after the hospital, patients would be followed up by orthopedic medical staff.
33005779|NCT05292963|Experimental|Fatherhood Works Program delivered in-person|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
33005780|NCT05292963|Experimental|Fatherhood Works Program delivered virtually|Participants receive 26 hours of Nurturing Fathers curriculum, delivered virtually over Zoom. Participants also receive employment supports, case management, and financial literacy training.
33005781|NCT05292924|Experimental|Early SSC|Cesarean delivery and SSC within the first 30 minutes of birth
33005782|NCT05292924|No Intervention|Control|Cesarean delivery and SSC one hour after birth
33005783|NCT05292768||Patients with AID|
33005784|NCT05292768||Control patients with mastocytosis|
33005785|NCT05292768||Control patients with normal digestive biopsy|
33005786|NCT05292768||Control patients with renal biopsy|
33005787|NCT05292768||Control patients with inflammatory disease|
33005788|NCT05292768||Healthy control from healthcare workers|
33005789|NCT05292742|Experimental|A|Pyrotinib: 400 mg/day (once daily, orally at the same time every day), every 3 weeks for one year Capecitabine: 1000 mg/m2 orally twice daily every 3 weeks for 6 cycles Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase)
33005790|NCT05292742|Active Comparator|B|Patients in the control group will continue neoadjuvant targeted therapy, trastuzumab or trastuzumab in combination with pertuzumab. In case of neoadjuvant trastuzumab monotherapy, trastuzumab combined with pertuzumab targeted therapy is allowed in the adjuvant phase.
33005791|NCT05292677|Experimental|Intervention (Steroid/Anesthetic Mixture)|The steroid/anesthetic mixture will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
33005792|NCT05292677|Placebo Comparator|Placebo (Normal Saline)|The placebo (Normal Saline) will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
33005793|NCT05292651|Experimental|PSP technique|"The definitions of the PSP technique are:~Predilatation is mandatory with a balloon diameter equal to or maximally 0.5 mm less than the distal reference vessel diameter. We hypothesize that this lesion preparation and fracture of the calcium may result in better stent apposition, less recoil and higher minimal stent area (MSA) Also see endpoints.~The DES should be deployed at 2 atm. above the nominal pressure. This relatively low stent deployment pressure may prevent stent edge dissections.~The postdilatation is mandatory with a shorter length and (at least 0.25mm) larger diameter non-compliant balloon at 16 atm. The apposition, minimal stent area (MSA) and recoil may improve with this large, high pressure postdilatation. The slightly shorter balloon can prevent edge dissections."
33005794|NCT05292651|Active Comparator|Direct Stenting|• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator. Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
33005795|NCT05292573|Experimental|metformin group|"During the intervention period, metformin is given 500 mg tablet b.i.d.~We will deliver education for exercise and weight control to all eligible participants"
33005796|NCT05292573|No Intervention|Observation group|only exercise and weight control to all eligible participants
33005797|NCT05292547|Active Comparator|Arm 1|Subjects receive 20 rTMS sessions in 2 weeks
33005798|NCT05292547|Active Comparator|Arm 2|Subjects receive 20 rTMS sessions in 4 weeks
33005799|NCT05292547|Active Comparator|Arm 3|Subjects receive 20 rTMS sessions in 5 weeks
33005800|NCT05292495|Experimental|Cohort one: mild renal insufficiency|
33005801|NCT05292495|Experimental|Cohort two: moderate renal insufficiency|
33005802|NCT05292495|Experimental|Cohort three: severe renal insufficiency|
33005803|NCT05292495|Experimental|Cohort four: end-stage renal disease|
33005804|NCT05292495|Experimental|Cohort five: normal renal function|
33005805|NCT05292430||Biobank|Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included.
33005806|NCT05292170|Experimental|Males|10 consecutive day heat acclimation in males
33005807|NCT05292170|Experimental|Females + high hormones|10 consecutive day heat acclimation in females with high hormonal dose
33005808|NCT05292170|Experimental|Females + low hormones|10 consecutive day heat acclimation in females with low hormonal dose
33005809|NCT05292157||Reverse total shoulder arthroplasty|Patients who have received a reverse total shoulder arthroplasty with more than 2 years of follow-up in a temporal frame going from 2016 to 2022.
33005810|NCT05292027|Experimental|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
33005811|NCT05292027|No Intervention|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
33005812|NCT05291910|Experimental|Inetetamab+ Toripalimab+ Albumin-Bound Paclitaxel|Drug: Inetetamab Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks Drug: Toripalimab 240mg intravenously every 3 weeks Drug: Albumin-Bound Paclitaxel 130mg/m2, IV , D1, D8, q3w
33005813|NCT05291793|No Intervention|NSAID group|Group 1, patients only received non-steroid anti-inflammatory oral and topical treatment for 3 weeks. (ibuprofen 2x800 mg (1600 mg daily), 1% nimesulide + 5%Lidocain (3 times a day))
33005814|NCT05291793|Active Comparator|Tenoxicam|Group 2, patients received intraarticular tenoxicam ( 20 mg) once.
33005815|NCT05291793|Active Comparator|Methylprednisolone|Group 3, patients received intraarticular methylprednisolone once(40mg).
33005816|NCT05291793|Sham Comparator|Saline|Group 4, patients received an intraarticular sterile saline injection(4ml).
33325347|NCT05520346|No Intervention|Control|Collection in standard hats + nurses visually assessing fluid volumes
33325348|NCT00246324|Experimental|Single Arm|Interferon beta 1a, oral doxycycline
33325349|NCT05507788|Experimental|Cushion|Three seating conditons (Quadtro Select 10cm, Starlock 10cm, and Starlock 13cm)
33325350|NCT00102336|Experimental|AMG 531|Active investigational product
33325351|NCT00102336|Placebo Comparator|Placebo|
33325352|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
33325353|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
33325354|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
33325355|NCT05483218|Experimental|wrist orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand only
33325356|NCT05483218|Experimental|wrist-hand-finger orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand and the fingers
33325357|NCT05152680|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
33325358|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
33005817|NCT05291780|Experimental|SABR in unresectable LA-NSCLC|Patients fit for chemotherapy will be enrolled to sequential chemotherapy-stereotactic ablative radiotherapy (SABR), while patients unfit for chemotherapy will be enrolled to exclusive stereotactic ablative radiotherapy (SABR).
33325359|NCT05479552||MCI-AD|Will be diagnosed using 'preclinical AD' criteria of mild cognitive impairment supported by a positive biomarker for AD. MCI defined as: 1. History of cognitive decline, noticed by either the patient, family member(s) or a medical practitioner but still independent in most complex daily activities. 2. Documentation of cognition not normal e.g., by MoCA or neuropsychological testing; 3. Does not meet the definition of dementia with MOCA <18 or global CDR 1 or greater (although exceptions may exist with appropriate justification). 4. Supportive AD biomarker (has positive biomarkers for both Aβ and neuronal injury using CSF or neuroimaging).
33325360|NCT05479552||MCI-DLB|Will be diagnosed as prodromal probable MCI-DLB based on consensus criteria using 2 or more core clinical features of DLB (with or without the presence of biomarkers) or 1 or more core clinical features with 1 or more indicative biomarkers (reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET reduced Iodine-MIBG uptake on myocardial scintigraphy, PSG confirmation of REM without atonia).
33325361|NCT01586130|Other|isokinetic exercises in eccentric mode|
33325362|NCT01586130|Other|isokinetic exercises in concentric mode|
33005818|NCT05291741|Active Comparator|Very Low Calorie Diet (VLCD)|VLCD
33005819|NCT05291741|Placebo Comparator|Standard care|Standard care
33005820|NCT05291702|Other|Multitract PCNL patients|Assessment of the multitract PCNL procedure in removal of large renal stones using pneumatic or laser lithotripsy.
33325363|NCT05470114|Experimental|LEO 138559|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
33325364|NCT05470114|Active Comparator|Dupixent®|Participants will receive injections of Dupixent® from Week 0 (baseline) to Week 16 (end of treatment).
33325365|NCT04860726|Experimental|GROUP A|Joint mobilization
33325366|NCT04860726|Experimental|GROUP B|Myofascial release
33005825|NCT05295160|Other|type 2 diabetes - less than 4 years duration|Patients with a duration of less than 4 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
33005826|NCT05295160|Other|type 2 diabetes - more than 8 years|Patients with a duration of more than 8 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
33005827|NCT05295134|Placebo Comparator|Placebo|Maltodextrin
33005828|NCT05295134|Active Comparator|Lipase: Low-Dose|Candida cylindracea lipase (75,000 FIP per serving)
33005829|NCT05295134|Active Comparator|Lipase: Medium-Dose|Candida cylindracea lipase (150,000 FIP per serving)
33005830|NCT05295134|Active Comparator|Lipase: High-Dose|Candida cylindracea lipase (225,000 FIP per serving)
33005831|NCT05295121|Experimental|XC221, fasted|Administration of XC221 in fasted state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
33005832|NCT05295121|Experimental|XC221, fed|Administration of XC221 in fed state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
33005833|NCT05295069|Experimental|The intervention group|To reduce postpartum depression among the primiparous puerperal women in the intervention group, and a nursing care program was implemented under the guidance of Levine's model. This program was applied with 7 home visits between the 8th and 80th postpartum days. Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
33005834|NCT05295069|No Intervention|The control group|In the control group women received routine postpartum care. No interventions were conducted other than routine postpartum care.
33005835|NCT05295056||Permanent atrial fibrillation|Known to have permanent atrial fibrillation
33005836|NCT05295056||Paroxysmal atrial fibrillation, or high risk of atrial fibrillation|Known to have episodes of paroxysmal, non-permanent, atrial fibrillation or to have at least 2 of the following risk factors: Congestive heart failure, hypertension, diabetes, history of stroke or transient ischemic attack, history of myocardial infarction, peripheral arterial disease or aortic plaque
33005837|NCT05295056||Healthy control|Known not to have atrial fibrillation and no more than 1 of the following risk factors: Congestive heart failure, hypertension, diabetes, history of stroke or transient ischemic attack, history of myocardial infarction, peripheral arterial disease or aortic plaque
33005838|NCT05295030|Active Comparator|Breast Milk-Fed Group|The infants will be breastfed during the study.
33005839|NCT05295030|Experimental|Breast Milk Simulated Formula Group|Kieember Infant formula, Ruibuen®: Infants will be fed Kieember infant formula(Phase I) from baseline (about 0-14 days) to 12 weeks old.
33005840|NCT05295030|Experimental|Traditional Formula Group|Yashili Infant formula, Ruibuen®: Infants will be fed Yashili infant formula (Phase I) from baseline (about 0-14 days) to 12 weeks old.
33005841|NCT05294952|Experimental|preeclampsiapregnant women|"Inclusion criteria~A total of 41 women in third trimester pregnancy complicated with PE showing:~Blood pressure ≥140/90 mmHg and~Proteinuria ≥300 mg/24 hours with or without~Edema in pregnant woman after week 20 of gestation (American Congress of Obstetricians and Gynecologists (ACOG2013) (17)~B-Exclusion criteria~Patients with autoimmune, acute inflammatory, and chronic diseases, are excluded from the study."
33005842|NCT05294952|No Intervention|normal pregnant women|This will include age matched 41 normal pregnant women in their third trimester of pregnancy with normal blood pressure, absence of proteinuria, and without any other systemic or endocrine disorder.
33005843|NCT05294926|Active Comparator|deep neuromuscular blockade|
33005844|NCT05294926|Active Comparator|moderate neuromuscular blockade|
33005845|NCT05294913|Experimental|Intervention group|
33005846|NCT05294913|Placebo Comparator|Placebo control group|
33005847|NCT05294887|Experimental|bisoprolol first, diltiazem second|Crossover Design: bisoprolol first, diltiazem second, placebo third
33325367|NCT04860726|Experimental|GROUP C|Joint Mobilization & Myofascial release
33325368|NCT04876690||All Participants|Participants diagnosed with CD and CPF in the Portuguese routine clinical practice will be assessed. Retrospective data on healthcare resource utilization related with CPF management in the previous three years will be obtained from the medical records.
33325369|NCT04801108|No Intervention|Medical management group|COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.
33325370|NCT04801108|Experimental|Intervention group|COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
33325371|NCT04801108|Experimental|Crossover group|Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.
33325372|NCT01245660|Experimental|Patient|
33325373|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
33325374|NCT04743778|Experimental|Virtual Diabetes Self-Management Education and Support|Participants randomized into the virtual empowerment-based DSME/S group will receive one hour of DSME/S delivered by a Certified Diabetes Care and Education Specialist (CDCES) per week for 10 weeks delivered via the Zoom for Health at U-M service may be used for Protected Health Information (PHI, regulated by HIPAA). To ensure treatment fidelity, three DSME/S sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
33325375|NCT04743778|Active Comparator|Control Group|Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
33325376|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
33325377|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
33325378|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
33325379|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
33325380|NCT04627168|Experimental|Spinal cord injured persons|Persons living with spinal cord injury presenting with constipation due to neurogenic bowel dysfunction.
33325381|NCT04627168|Experimental|Persons without neurogenic bowel dysfunction|Abled-bodied persons with chronic constipation.
33325382|NCT04530682||SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)|200 SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the COVID-RIC-1 cohort.
33325383|NCT04530682||Control group|100 health professionals participating in the COVID-BIOTOUL cohort will be selected to be matched on age, gender, and the time between the date of infection with Covid-19 and the first serology of CIR patients.
33325384|NCT04818840||Resurfaced/non patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
33325385|NCT04818840||un-resurfaced patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
33325386|NCT04461964|Experimental|treatment group|Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints
33325387|NCT03913806|Experimental|Treatment group|Bevacizumab-IRDye800CW
33325388|NCT04807608||Healthy Users|Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
33325389|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :~For Crohn's disease :~Harvey Bradshaw Index ≥ 4~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis~Partial Mayo score ≥ 2~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
33325390|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
33325391|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
33325392|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
33325393|NCT01241526|Experimental|Disease management program|
33325394|NCT01241526|Active Comparator|Usual site management|
33325395|NCT05417464|Other|Management of conductive disorders after TAVR|Evaluation of efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR
33325396|NCT04778982||dose-escalation Phase|KN026 20 mg/kg + palbociclib125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
33325397|NCT04778982||parallel-group expansion Phase|KN026 20 mg/kg + palbociclib +Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )
33325398|NCT03913338|Other|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
33005848|NCT05294887|Experimental|bisoprolol first, placebo second|Crossover Design: bisoprolol first, placebo second, diltiazem third
33005849|NCT05294887|Experimental|diltiazem first, bisoprolol second|Crossover Design: diltiazem first, bisoprolol second, placebo third
33005850|NCT05294887|Experimental|diltiazem first, placebo second|Crossover Design: diltiazem first, placebo second, bisoprolol third
33005851|NCT05294887|Experimental|placebo first, bisoprolol second|Crossover Design: placebo first, bisoprolol second, diltiazem third
33005852|NCT05294887|Experimental|placebo first, diltiazem second|Crossover Design: placebo first, diltiazem second, bisoprolol third
33005853|NCT05294874|Active Comparator|classical gait training|physical therapy exercises including classical gait training
33005854|NCT05294874|Active Comparator|classical gait training using ankle weight|physical therapy exercises including classical gait training while using ankle weight
33005855|NCT05294874|Experimental|gait training using ankle weight after botulinum toxin injection|physical therapy exercises including classical gait training while using ankle weight and with BOTOX injection
33005856|NCT05294861|Experimental|YesMdiet|After one week baseline, the participants will be assigned to YesMdiet, consuming milk and dairy products for 14 days
33005857|NCT05294861|Active Comparator|NoMdiet|After one week baseline, the participants will be assigned to NoMdiet, consuming another source of protein and without milk or dairy products for 14 days
33005858|NCT05294848|Experimental|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
33005859|NCT05294848|Active Comparator|RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
33005860|NCT05294848|Placebo Comparator|Neutral Control|This condition is also based on the dot-probe task (see Active Comparator) with a fundamental difference. In this task, only neutral faces will be displayed, and therefore, while participants are exposed to the same task parameters, there will be no attention training and there will be no exposure to threat stimuli.
33005861|NCT05294822|Experimental|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|
33005862|NCT05294783||ACL injured patients|All the ACL injured patients recruited underwent ACL reconstruction with the same group of surgeons lead by the same chief surgeon.
33005863|NCT05294744|Active Comparator|Corticosteroids|Corticosteroids following Standard Clinical Practice
33005864|NCT05294744|Experimental|Corticosteroids + N-acetylcysteine|Corticosteroids following Standard Clinical Practice plus N-acetylcisteine
33005865|NCT05294679|Placebo Comparator|Propofol group|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will commence. If subjects' MOAA/S score ≥ 1 point, additional administration of cyclopofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Additional administration of propofol: The additional dose was 0.5mg/kg/ time, and intravenous bolus was administered."
33005866|NCT05294679|Experimental|Ciprofol ground|"The initial dose of ciprofol was 0.4mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will begin; If subjects' MOAA/S score ≥ 1 point, additional administration of ciprofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Ciprofol supplemental administration: the supplemental dose was 0.1mg/kg/ time, and intravenous bolus was administered."
33005867|NCT05294666|Experimental|cyclosporine group|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
33325399|NCT03913338|Other|Control group|LASIK only
33325400|NCT03913494|Experimental|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
33325401|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
33005868|NCT05294666|Experimental|tacrolimus group|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
33005869|NCT05294640|Experimental|Bacteriostatic Saline as Local Anesthesia|Patients receiving bacteriostatic saline as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
33005870|NCT05294640|Active Comparator|Lidocaine with Epinephrine as Local Anesthesia|Patients receiving lidocaine with epinephrine as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
33005871|NCT05294601|Active Comparator|HIIG Group|General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The high intensity children's games program for 12 weeks, . In this group the activities will include 3 weekly sessions. . The games last 6 minutes with a 2 minute break, four games per session; which is the one established for children of these ages according to the cited authors. The session is divided into 5 minutes of warm-up, 36 minutes of intervention and 8 minutes of cool-down. The intensity varies between 85-95% of HR max. According to the equation of Tanka et., Al. HR max = 208-0.7 x age
33005872|NCT05294601|Active Comparator|MIIG Group|: The interventions will be carried out by a graduate in physical education, recreation and / or sports and the main researcher. General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The medium intensity physical activity program for 12 weeks (28). Medium intensity activities are very similar to those taught in physical education class. In this group the activities will include 3 weekly sessions, with six episodes of 10 min at 65% to 85% of maximum heart rate (HRmax) separated by 5 min of recovery.
33005873|NCT05294601|No Intervention|Control Group|In this group, measurements will be made before, during and after the study. Neither medium nor high intensity interventions will be carried out in order to generate comparisons, control biases and confounding and interaction variables. However, the interventions that have been most beneficial in the intervention groups. It could be implemented in this study once the analysis between groups has been completed, according to the recommendations and follow-up by the ethics committee.
33005874|NCT05294575||OHCA in the general population|All Out-of-Hospital Cardiac Arrests
33005875|NCT05294575||Traumatic OHCA|OHCA related to Trauma
33005876|NCT05294536|Experimental|Liraglutide injection (RD12014)+ Victoza|Subjects receive liraglutide injection(RD12014) in the first cycle and Victoza in the second cycle.
33005877|NCT05294536|Experimental|Victoza + Liraglutide injection (RD12014)|Subjects receive Victoza in the first cycle and liraglutide injection(RD12014) in the second cycle.
33005878|NCT05294497|Experimental|Product usage order A B N C E D|Subjects will use each of the 6 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
33005879|NCT05294497|Experimental|Product usage order B C A D N E|Subjects will use each of the 6 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
33005880|NCT05294497|Experimental|Product usage order C D B E A N|Subjects will use each of the 6 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
33005881|NCT05294497|Experimental|Product usage order D E C N B A|Subjects will use each of the 6 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
33005882|NCT05294497|Experimental|Product usage order E N D A C B|Subjects will use each of the 6 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
33005883|NCT05294497|Experimental|Product usage order N A E B D C|Subjects will use each of the 6 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
33005884|NCT05294484|Active Comparator|Fasting group|Following an overnight fast of at least 10 hours, subjects should be administered single dose of indapamide 1.5 mg SR with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.
33325402|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
33325403|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
33325404|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
33325405|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
33325406|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
33325407|NCT03632590|Placebo Comparator|Placebo|
33325408|NCT05667480|Experimental|VR-based script training|
33325409|NCT05667480|Active Comparator|Conventional script training|
33325410|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
33325411|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
33325412|NCT03913416|Experimental|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
33325413|NCT03913416|Other|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
33325414|NCT01242774|Experimental|Panobinostat|
33325415|NCT05630742||Interstitial Cystitis|patients with an existing diagnosis of BPS/IC. BPS/IC was confirmed by reviewing medical record.
33325416|NCT05630742||control group|patients with chronic non-neoplastic pain, suffering from fibromyalgia or other types of chronic pain (chronic arthralgia or lower back pain).
33325417|NCT04716192|Experimental|Positional release technique|Positional release technique, Mayofascial release technique and ultrasound
33325418|NCT04716192|Active Comparator|Mayofascial release technique and ultrasound|Mayofascial release technique and ultrasound
33325419|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
33325420|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
33005885|NCT05294484|Active Comparator|Fed group|"Following an overnight fast of at least 10 hours, subjects should start the recommended meal 30 minutes prior to administration of the drug. Study subjects should eat this meal in 30 minutes or less; however, indapamide 1.5 mg SR should be administered 30 minutes after start of the meal. The drug should be administered with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.~All subjects should abstain from the consumption of fruit juices during the study period. All the subjects are to be under complete medical supervision."
33005886|NCT05294445|Active Comparator|Group1: Cryo-AF-Ablation|Patients randomized in the Cryo-AF-Ablation group should receive the cryo AF ablation within 21 days from baseline.
33325421|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
33325422|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
33325423|NCT04670172||Chronic rhinosinusitis patients|Adult chronic rhinosinusitis patients capable of using a mobile application.
33325424|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
33325425|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
33325426|NCT01246830||3D cephalometric analysis|
33325427|NCT01246830||2D cephalometric analysis|
33325428|NCT01247376|No Intervention|No Cooling and compression|
33325429|NCT01247376|Experimental|Intervention with cooling and compression|
33325430|NCT03908814|Experimental|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
33005887|NCT05294445|No Intervention|Group 2: Usual care|Patients randomized in the usual care group should start or maintain on AAD therapy within 21 days from baseline, based on decision of the investigator according to current ESC Guidelines.
33005888|NCT05294432||Single Group|Patients of Wilderman Medical Clinic diagnosed with symptomatic Osteoarthritis of the Knee who were prescribed with at least one intra-articular corticosteroid injection.
33005889|NCT05294406|Experimental|IPTp-DP|Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets). The first dose is given by directly observed therapy (DOT), and the remaining doses given to the women to take at home.
33005890|NCT05294393|Placebo Comparator|N/S 0.9%|Wound infiltration with 12 ml of N/S 0.9% at the end of surgery before wound closure
33005891|NCT05294393|Active Comparator|Ropivacaine 10%|Wound infiltration with 12 ml solution of 100mg ropivacaine at the end of surgery before wound closure
33005892|NCT05294393|Experimental|Ropivacaine 10% magnesium sulphate 10mg/kg|Wound infiltration with 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery before wound closure
33005893|NCT05294380||oncologic|"Be between the ages of 2-18 years Being under pediatric oncology outpatient/clinical follow-up Being able to stand unaided without using a cane/walker Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
33105594|NCT04207528|Experimental|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
33105595|NCT04207528|Active Comparator|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
33325431|NCT01253382|Active Comparator|ecallantide|
33325432|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
33325433|NCT01147614|Active Comparator|specialty mental health care referral|
33325434|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
33325435|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
33325436|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
33005894|NCT05294380||control|"Be between the ages of 2-18 years Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
33415406|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
33005895|NCT05294315|Active Comparator|Single level block arm - Control|Single level erector spinae block at 4th transverse process
33415407|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
33415408|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
33415409|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
33005896|NCT05294315|Experimental|Bi-level block arm - Intervention|Bi-level erector spinae block at 4th and 6th transverse process
33005897|NCT05294250|Experimental|XC8, fasted|Administration of XC8 20 mg in fasted state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
33005898|NCT05294250|Experimental|XC8, fed|Administration of XC8 20 mg in fed state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
33005899|NCT05294198|Experimental|Beet protocol|Beta vulgaris L. extract (600mg)
33005900|NCT05294198|Placebo Comparator|Placebo protocol|Starch (600mg)
33005901|NCT05294094|Experimental|intervention group|blended learning
33005902|NCT05294094|Active Comparator|control group|Teaching format as usual
33005903|NCT05293990|Other|Contrast-enhanced fluid attenuated inversion recovery|Confirmation of the difference between FLAIR contrast enhancement and T1 contrast enhancement patterns-->PACS monitor shows the maximum dimension of FLAIR and T1 contrast enhancement by two neurology radiologists on FLAIR and T1 contrast enhancement images. In addition, the maximum diameter of the T2 high-signal lesion around the tumor is obtained using FLAIR images before contrast in the same plane. (Dt2)
33005904|NCT05293977|Active Comparator|Control|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
33005905|NCT05293977|Experimental|Intervention|Patient in the intervention group was verbally provided with pharmaceutical education/counseling about his/her prescribed antibiotic.
33005906|NCT05293873|Experimental|Treatment (BM-MNC trasnplatation)|Autologous bone marrow-derived mononuclear cell will transplant at baseline, and the second transplantation will be performed 6 months after the first transplantation and combination with rehabilitation therapy
33005907|NCT05293873|Other|Control group|rehabilitation therapy
33005908|NCT05293808|Experimental|aspirin 100 mg bis in die|aspirin 100 mg twice daily for the first month after acute coronary syndrome
33005909|NCT05293808|Active Comparator|aspirin 200 mg|aspirin 200 mg once daily for the first month after acute coronary syndrome
33005910|NCT05293808|Active Comparator|aspririn 100 mg|aspirin 100 mg once daily
33005911|NCT05293795|Active Comparator|3d printed model|Mother r is given 3D printed model of fetus' face
33005912|NCT05293795|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
33005913|NCT05293795|No Intervention|Control|Standard of Care
33005914|NCT05293756|Experimental|Intervention: OPTIMA-BP Implementation|Participants randomized to OPTIMA-BP intervention for 6 months then observed for a 6 month follow up period
33005915|NCT05293756|No Intervention|Waitlist: OPTIMA-BP implementation|Participants randomized to waitlist for 6 months, then offered the OPTIMA-BP intervention for 6 months.
33005916|NCT05293652|Experimental|Iontophosresis group|
33415410|NCT02052050|No Intervention|control group|usual care
33005917|NCT05293652|Experimental|Phonophoresis group|
33005918|NCT05293652|Experimental|Traditional group|
33005919|NCT05293574|Experimental|norethisterone acetate group|". In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography.~If there is no remission occurred another month of Norethisterone acetate will be given ."
33005920|NCT05293574|No Intervention|expectant managment group|
33005921|NCT05293483||COVID-19|
33005922|NCT05293483||non-COVID-19|
33005923|NCT05293431|Experimental|Active Stimulation Group|This group will receive real tACS non-invasive brain stimulation
33005924|NCT05293431|Sham Comparator|Sham Control Group|This group will receive Sham tACS non-invasive brain stimulation
33005925|NCT05293405|Experimental|Patients Group|
33005926|NCT05293405|Sham Comparator|Healthy Volunteers Group|
33005927|NCT05293301|Experimental|Periodontal Endosccope|One randomly assigned side of the mouth received deep cleaning treatment with the operator using a periodontal endoscope or Perioscopy® for magnification
33005928|NCT05293301|Active Comparator|Traditional Loupes|One randomly assigned side of the mouth received deep cleaning treatment with the operator using traditional loupe magnification
33005929|NCT05293275|Active Comparator|Virtual Reality Group|patients will use the virtual reality device over two days
33005930|NCT05293275|No Intervention|Standard of care|patients will receive standard of care only
33005931|NCT05293262||Patients who underwent endourological surgery for urolithiasis during COVID19|Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
33005932|NCT05293145|Experimental|Building Futures Program Primary Services|Youth enrolled in the AVANCE-Houston Building Futures Program will receive primary services in either a 7 week workshop or one weekend delivery.
33415411|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
33005933|NCT05293132|Experimental|Montelukast group|30 patients will receive montelukast sodium 10 mg/day film coated tablets (Singulair®; Merck & Co Inc) or (Clear air®; Amoun Pharmaceutical Company S.A.E., Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
33415412|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
33415413|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
33415414|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
33005934|NCT05293132|Experimental|Co Enzyme Q10 group|30 patients will receive co enzyme Q10 capsule 210 mg / day (MEPACO Pharmaceutical Company (Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
33005935|NCT05293132|Active Comparator|Control group|30 patients will receive the standard treatment of sepsis from the onset of the diagnosis of sepsis till discharge from ICU, or death.
33005936|NCT05293119|Experimental|Tofacitinib|In this group, study participants will be treated with per oral tofacitinib citrate (5 mg/twice daily)
33005937|NCT05293119|Active Comparator|Topical corticosteroid|In this group, patients will apply topical Mometasone furoate 0.1% once daily
33005938|NCT05293080|Experimental|Early rhythm control therapy|Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. In case of continuation or recurrence of AF, both modalities may be combined.
33005939|NCT05293080|Active Comparator|Usual care|Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.
33005940|NCT05297019|Experimental|Arm 1: Mild pressure HBOT|"Mild pressure HBOT: 100% O2 @ 4.2 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
33005941|NCT05297019|Experimental|Arm 2: High pressure HBOT|"High pressure HBOT: 100% O2 @ 14 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
33005942|NCT05297019|Experimental|Arm 3: Crossover Arm|Patients will have 3 months of no treatment, and then be randomized to receive either high pressure or mild pressure HBOT
33005943|NCT05297006||Breastfeeding group|The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.
33005944|NCT05297006||Formula group containing new compound functional ingredients|Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
33005945|NCT05297006||Formula group without new compound functional ingredients|Only use formula milk powder without oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
33005946|NCT05296967|Experimental|Chewing gum|POI patients are asked to chew 20 minutes x2/ day
33005947|NCT05296967|No Intervention|No chewing|POI patients receive no intervention
33005948|NCT05296954|Experimental|Group 1|Tachycardia
33005949|NCT05296954|Active Comparator|Group 2|Without tachycardia
33005950|NCT05296941|Experimental|Brush biopsy|
33005951|NCT05296941|Active Comparator|Care as usual|
33005952|NCT05296889||Ennovate® Cervical|Alll patients which were treated with the Ennovate® Cervical system in accordance with the indications given in the instructions for use
33005953|NCT05296863|Experimental|Non-concentrated ADSC-CM|2 ml intradermal injection of non-concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
33005954|NCT05296863|Experimental|Concentrated ADSC-CM|2 ml intradermal injection of concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
33005955|NCT05296824||Pulmonary vein isolation (PVI) only|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) only
33005956|NCT05296824||Pulmonary vein isolation (PVI) with posterior wall isolation (PWI)|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) with posterior wall isolation (PWI)
33005957|NCT05296707|Experimental|Inspiratory muscle training group|Thershold IMT was given this group. Applied for 7 days 6 weeks.
33005958|NCT05296707|Active Comparator|Used routine medicine group|Followed 6 weeks
33005959|NCT05296707|Active Comparator|Control Group|Health children
33005960|NCT05296564|Experimental|HBI 0201-ESO TCRT (Anti-NY-ESO-1 TCR-transduced peripheral blood lymphocytes)|"This is a two-part, non-randomized, open label, single-site Phase I/II study. The first Part A is a dose ranging maximum tolerated dose (MTD) study and Part B is an extension phase to evaluate safety at the selected safe dose. A Data Safety Monitoring Board (DSMB) will determine the safe dose for testing in the expansion phase (Part B).~Part A will be according to a 3+3 dose escalation design. A total of up to 20 patients will participate in this Part.~Part B will be an expansion phase. The objective will be to determine if the treatment regimen is associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% Partial Response (PR) + Complete Response (CR) rate (p1=0.20).~A total of up to 43 patients may be enrolled in Part B (41 +2, allowing for up to 2 non-evaluable patients)."
33005961|NCT05296551|Experimental|Dual Task One|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is simple.
33005962|NCT05296551|Experimental|Dual Task Two|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is complex.
33005963|NCT05296551|Active Comparator|Control|Participants perform only a motor-task that is the same for all groups (no simultaneous cognitive task).
33415415|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
33415416|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
33415417|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
33415418|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
33005964|NCT05296499||Venous outflow obstruction extending to inferior vena cava, symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
33415419|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
33415420|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
33005965|NCT05296499||Venous outflow obstruction extending to inferior vena cava, not symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
33005966|NCT05296499||Unilateral iliac venous outflow obstruction|Baseline assessments Post-operative assessments if applicable
33005967|NCT05296499||Age and sex matched controls|Baseline assessments
33005968|NCT05296486|Experimental|phacovitrectomy surgery with silicone oil tamponade|patients who had phacovitrectomy surgery with silicone oil tamponade.The patients diagnosed cataract The patients' ages are over 50.
33005969|NCT05296486|Experimental|phacovitrectomy surgery with gas tamponade|patients who had phacovitrectomy surgery with gas tamponade.The patients diagnosed cataract The patients' ages are over 50.
33005970|NCT05296486|Experimental|phacovitrectomy surgery with balanced saline solution tamponade|patients who had phacovitrectomy surgery with balanced saline solution tamponade.The patients diagnosed cataract The patients' ages are over 50.
33005971|NCT05296486|Experimental|phacoemulsifacation surgery without vitrectomy|patients who had phacoemulsifacation surgery without vitrectomy.The patients diagnosed cataract The patients' ages are over 50.
33005972|NCT05296434||Control Group|Healthy volunteers undergoing MRI exam, ICG test and blood biochemical tests
33005973|NCT05296434||Child-Pugh A Group|Composed of patients with liver function of Child-Pugh A grade undergoing MRI exam, ICG test and blood biochemical tests
33005974|NCT05296434||Child-Pugh B Group|Composed of patients with liver function of Child-Pugh B grade undergoing MRI exam,ICG test and blood biochemical tests
33005975|NCT05296434||Child-Pugh C Group|Composed of patients with liver function of Child-Pugh C grade undergoing MRI exam
33005976|NCT05296369|Experimental|Experimental|Folic acid intervention
33005977|NCT05296369|No Intervention|Routine|Routine treatment intervention
33005978|NCT05296356|Experimental|OSU6162|Coated tablet, flexible dosing
33005979|NCT05296343||Adolescents and young adults|Boys and girls from 15 to 25 years old admitted to an Emergency Department (ED) following a suicidal act or considered as such by the medical team
33005980|NCT05296343||Parents|One or the two parents of the included adolescents and young adults
33005981|NCT05296343||Healthcare professionals|Professionals working in one emergency departments of the inclusion centers and who usually take care of suicidal adolescents and young adults
33005982|NCT05296317|Experimental|Arm 1 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of G-CSF|"2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
33005983|NCT05296317|Experimental|Arm 2 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF|"2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
33005984|NCT05296291|Active Comparator|High-translucent monolithic zirconia,|
33005985|NCT05296291|Active Comparator|Zirconia ceramic with porcelain|
33005986|NCT05296291|Active Comparator|Metal ceramics.|
33005987|NCT05296200||Observacional group|Subjects must remain to the exposure of gravity (1G) after 4h of hyperbuoyancy floatation(spine unloading)
33005988|NCT05296174|Experimental|cognitive-oriented intervention program|"The intervention group received a 40 mins social support intervention program once a week lasting for 6 weeks.~All participants were assessed by questionnaires before and after the intervention."
33005989|NCT05296174|Active Comparator|received health education program|"The control group received health education activities with the same frequency as the intervention group.~All participants were assessed by questionnaires before and after the intervention."
33005990|NCT05296109|Experimental|Imaging group|patients with parotid tumour being imaged
33005991|NCT05296044|Experimental|JT-003|Drug: JT-003
33005992|NCT05296044|Placebo Comparator|JT-003 Placebo|Drug: JT-003 Placebo
33005993|NCT05296031|Active Comparator|Drug Eluting Stent (DES)|Drug Eluting Stent (DES). Zilver PTX.
33005994|NCT05296031|Placebo Comparator|Bare Metal Stent (BMS)|Bare Metal Stent (BMS). Zilver Flex
33005995|NCT05296005|Experimental|Treatment (chemotherapy, chemoradiation, surgery)|"NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise."
33005996|NCT05295966|Experimental|Intervention Group|Subjects in the intervention group will perform 20 sessions of multisensory training
33005997|NCT05295966|Active Comparator|Control Group|Subjects in the Control Group will not perform 20 sessions of multisensory training and they will keep doing the current therapy
33005998|NCT05295836|No Intervention|CONTROL|In this phase of the study, the rectangular test will be performed in conditions of 16°C and 25-30% humidity, intaking 26 mL/kg/body weight of water one and a half hours before the test.
33005999|NCT05295836|Placebo Comparator|PLACEBO (PLA)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 26 mL/kg/body weight of water and placebo one and a half hours before the test.
33006000|NCT05295836|Experimental|GLYCEROL (GLY)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 1.2 g + 26 mL/kg/body weight of water one and a half hours before the test.
33325437|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
33325438|NCT03913260|Experimental|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
33415421|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
33415422|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
33006001|NCT05295745|Experimental|Cognitive remediation therapy and multidisciplinary intervention|The participants (obese adults) in the experimental group will receive treatment with cognitive remediation therapy, nutritional and physical activity instruction through 18 weekly sessions of intervention.
33006002|NCT05295745|No Intervention|Control|The control group participants will not receive the treatment until the experimental group participants complete the intervention and carry out the measurements
33006003|NCT05295719|Placebo Comparator|Placebo & Flexibility Training (Control)|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period.
33006004|NCT05295719|Active Comparator|Placebo & High-Intensity Interval Training|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period.
33006005|NCT05295719|Active Comparator|n-3 PUFA & Flexibility Training (Control)|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
33415423|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
33415424|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
33415425|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
33415426|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
33415427|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
33415428|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
33006006|NCT05295719|Experimental|n-3 PUFA & High-Intensity Interval Training|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
33006007|NCT05295680|Experimental|Hymecromone|Participants will receive Hymecromone for six months + Standard Of Care (SOC), and will be followed for an additional nine months.
33006008|NCT05295680|No Intervention|Standard Of Care (SOC)|Participants will receive Standard Of Care (SOC), and will be followed for 15 months.
33006009|NCT05295667||Fetal Growth Retardation Group|
33006010|NCT05295576||chronic periodontitis|scaling and root planing
33006011|NCT05295576||Periodontally healthy individuals|no treatment
33006012|NCT05295563||Group 1|Children who had been injected once or twice before were included in Group 1.
33006013|NCT05295563||Group 2|Children who received 3 or more injections were included in Group 2.
33006014|NCT05295472|Experimental|Grapholearn group|Children with DLD who attend a special school for children with DLD. This group will play the computer game GL in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
33006015|NCT05295472|Active Comparator|Math game group|Children with DLD who attend a special school for children with DLD. This group will play a computer game focusing on math in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
33006016|NCT05295472|Active Comparator|Usual schooling|Children with DLD who attend a special school for children with DLD. This children will have normal schooling as usual without playing any of the above computer games.
33325439|NCT03913260|Experimental|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
33325440|NCT03913260|Experimental|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
33325441|NCT03913260|Placebo Comparator|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
33325442|NCT03913260|Experimental|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
33325443|NCT03913260|Experimental|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
33415429|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
33415430|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
33415431|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
33006017|NCT05295381|Experimental|abdominal weight training with cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily. Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
33006018|NCT05295381|Experimental|abdominal weight training (AWT) without cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
33415432|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
33415433|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
33006019|NCT05295381|No Intervention|control|no abdominal weight training and no cough machine
33006023|NCT05295329|Experimental|Test group|Take compound salvia miltiorrhiza dropping pills
33006024|NCT05295329|Placebo Comparator|placebo group|Take a placebo
33006025|NCT05295316||Fibromyalgia|FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association.
33006026|NCT05295316||Control|The control group was recruited in the same geographic area as the FM participant. The general practitioner of each individual patient certified the subject's state of good health.
33006027|NCT05295303|Experimental|Interventional group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review the physiological parameters of patients randomized to the Intervention group daily and treatment can be initiated or modified accordingly through instant communication (electronic communication and/or phone).
33006028|NCT05295303|Placebo Comparator|Control group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review individual patient physiological parameters and risk factors only during the clinic visits
33006029|NCT05295277||Standard of care genetic testing group|Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.
33006031|NCT05294900|Experimental|paclitaxel/carboplatin|paclitaxel+carboplatin
33006032|NCT05286398|Placebo Comparator|Control group|
33006033|NCT05286398|Experimental|Bradach group|
33006034|NCT05286398|Experimental|AEP group|
33006035|NCT05282212||Dental Implant Surgery|Subjects scheduled for a revision surgery after developing infection after implant surgery
33325444|NCT03913260|Experimental|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
33325445|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
33325446|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
33325447|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
33325448|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
33325449|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
33325450|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
33325451|NCT03913182|Experimental|apatinib group|apatinib：500mg po Qd
33325452|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
33325453|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
33325454|NCT05625750||Patients diagnosed with NAFLD|All subjects will receive the currently recognized routine test of NAFLD according to their disease and no additional intervention and treatment will be added for subjects
33325455|NCT03908190|No Intervention|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
33325456|NCT03908190|Experimental|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
33415434|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
33415435|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
33006036|NCT05281679|Experimental|Low-intensity resistance exercise with blood flow restriction group (L-BFR).|All the participants in the low-intensity resistance exercise with blood flow restriction group (L-BFR) will receive 3 sessions of low-intensity resistance training with blood flow restriction for a total of 5 weeks.
33415436|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
33415437|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
33006037|NCT05281679|Active Comparator|High-intensity resistance exercise without blood flow restriction group (H-BFR).|All the participants in the high-intensity resistance exercise without blood flow restriction group (H-BFR) will receive 3 sessions of high-intensity resistance training without blood flow restriction for a total of 5 weeks.
33006038|NCT05280405|Experimental|Early-Proactive Therapeutic Drug Monitoring (E-pTDM)|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (>=) 5 mcg/ml (> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.
33006039|NCT05280405|Active Comparator|Standard dosing|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.
33006040|NCT05279053||Male|
33006041|NCT05279053||Female|
33006042|NCT05276154|Active Comparator|thermoviscous bulk fill resin composite|
33006043|NCT05276154|Active Comparator|conventional bulk fill resin composite|
33006044|NCT05275647|Experimental|Treatment group : BoNT-A 100 U in Normal saline|BOTOX 100U in normal saline (BoNT-A/NS) 30ml in single intravesical instillation
33006045|NCT05275647|Placebo Comparator|Placebo group : Normal saline|Normal saline (N/S) 30ml in single intravesical instillation
33006046|NCT05274347|Experimental|Multi-faceted virtual, remote intervention|"The intervention will use the Aetonix - aTouchAwayTM software platform (AETONIX Systems Inc). Each study participant will receive a tablet with Aetonix software. Interventions Components:~Virtual physical rehabilitation: After discharge, patients will have virtual, supervised group exercise sessions twice weekly with a physiotherapist.~Cognitive behavioral therapy (CBT): After discharge, patients will receive weekly group CBT sessions delivered virtually by a psychologist. Throughout the series of CBT sessions, patients will learn strategies for problem-solving, assertive communication, relaxation, behavioural activation, time-based pacing, challenging unhelpful thinking, building motivation, and goal setting.~Remote monitoring of vital signs and symptoms: Messages will be sent to patients asking them to measure their vitals, to report symptoms, and answer questions about medications. Concerning responses will be flagged for review by the patient's healthcare team."
33006047|NCT05274321||Pediatric Participants|Consenting participants will undergo standard pupillary dilation in one eye and pupillary dilation in the second eye using the Nanodropper attachment.
33006048|NCT05274126|Experimental|Patient group (single group)|300 Patients involved in the recovery process.
33006049|NCT05274035||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
33006050|NCT05273242|Experimental|Artesunate|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
33006051|NCT05273242|Experimental|Imatinib|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
33006052|NCT05273242|Experimental|Infliximab|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
33006053|NCT05273242|No Intervention|Local Standard of Care|No other Intervention Given except the local standard of care
33006054|NCT05273086|Experimental|Sleep intervention program|The Sleep Intervention program Group will be subdivided into two groups of 10 participants to receive the sleep quality improvement program. The program consists of 2 sessions of 90 minutes during one week.
33006055|NCT05273086|No Intervention|Control Group|The control group will continue with their usual routine.
33006056|NCT05272800|Experimental|BIS Group|Dry weight is evaluated monthly by clinical examination and biannually BIS-guided.
33006057|NCT05272800|Active Comparator|CE Group|Dry weight is evaluated monthly by clinical examination alone.
33006058|NCT05271825|Experimental|Broadband amplification|broadband amplification: (125 Hz to 10 kHz)
33006059|NCT05271825|Placebo Comparator|Band-limited amplification|band-limited amplification (125 Hz to 3-4 kHz)
33006060|NCT05271097|Experimental|MyLink2Care app|Participants in the MyLink2Care group will be provided with full app access and will be encouraged to use all features of the app.
33415438|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
33415439|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
33006061|NCT05271097|Active Comparator|treatment-as-usual (TAU)|Participants in the TAU group will receive the MyLink2Care app with major intervention features inactivated.
33006062|NCT05270850|Active Comparator|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
33006063|NCT05270850|Experimental|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula.
33006064|NCT05270317|Active Comparator|Early-Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 6 weeks
33006065|NCT05270317|Active Comparator|Medium -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 8 weeks
33006066|NCT05270317|Active Comparator|Late -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 10 weeks
33325457|NCT03913026|Experimental|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
33415440|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
32865914|NCT04369326|No Intervention|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
32865915|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
32865916|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
32865917|NCT04841460|Experimental|Low-fat ground beef|Participants will consume 25 low-fat ground beef patties, 5 patties per week for 5 weeks.
32865918|NCT04841460|Experimental|High-fat ground beef|Participants will consume 25 high-fat ground beef patties, 5 patties per week for 5 weeks.
32865919|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
32865920|NCT01564485|Active Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
32865921|NCT04428996|Experimental|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
32865922|NCT04428996|Experimental|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
32865923|NCT05583851|Experimental|Digi-ACT Intervention group|22 day long interactive mobile app intervention with daily activities. The intervention will include 5 total modules: psychoeducation on depression/anxiety and the cancer journey; acceptance; cognitive fusion; mindfulness; and committed valued living. There will be different games and reward components for the Through out the course of the intervention, participants will also do video journals to reflect on the different modules and activities they do.
32865924|NCT05583851|Active Comparator|Psychoeducational Video Control group|22 day long mobile app where participants will be given a 15 minute long psychoeducational clip from a publicly available online seminar (from the Hong Kong College of Psychiatrists) on a bi-daily basis. Through out the course of the intervention, participants will also do video journals to reflect on the content of the different video clips.
32865925|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
32865926|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
32865927|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
32865928|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
32865929|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
32865930|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
32865931|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
32865932|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
32865933|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
32865934|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
32865935|NCT03039504|Placebo Comparator|Placebo|placebo
32865936|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
32865937|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
33325458|NCT02713386|Active Comparator|Arm I (paclitaxel and carboplatin)|See Detailed Description.
33325459|NCT02713386|Experimental|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
33325460|NCT02671890|Experimental|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
33325461|NCT02671890|Experimental|Cohort II (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
33325462|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
33415441|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
33415442|NCT02053532||Positron emission tomography/magnetic resonance imaging|
33415443|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
33415444|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
33006067|NCT05269797|Experimental|Health-coaching Intervention|A nurse-lead health coaching intervention to support heart failure self-care management is employed by the nurses. This is a pre-post single group design - there is only one arm.
33006068|NCT05269602||L5 Radiculopathy|Patients who have Lumbar 5 root compression with the Magnetic Resonance İmaging
33006069|NCT05269602||S1 Radiculopathy|Patients who have Sacral 1 root compression with the Magnetic Resonance İmaging
33006070|NCT05269576|Experimental|Single arm that receive two different interventions (clinical practice and clinical simulation).|"An analysis is carried out to the entire group prior to intervention. A second analysis is carried out to the entire group after one of the two interventions. Finally, a last analysis is carried out to the entire group after complete both types of interventions.~We apply the study in a group of medicine students of 3rth course of the degree. We examine their competencies at the beginning of the course. Re-examination is done after they do a period of clinical practice or a period of clinical simulation. At the end of the course, all the students done both interventions (clinical practice and clinical simulation), moment when we do the last examination of their competencies."
33006071|NCT05269511|Experimental|Treatment group|Chinese Herbal Medicine
33006072|NCT05269511|No Intervention|Control group|usual care
33006073|NCT05269264||patients with unilateral or bilateral, primary or secundary lower limb lymphedema (LLL)|patients with unilateral or bilateral, primary or secundary LLL who visit the center for lymphedema at UH Leuven
33006074|NCT05269264||healthy controls|age, BMI and gender matched to the patients with LLL
33006075|NCT05269264||subgroup (n=40)|a subgroup of subjects (patients & healthy controls) will be evaluated again 2 weeks later
33006076|NCT05269121|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotics.
33006077|NCT05269095|Experimental|spinal anesthesia only|Patients will receive spinal anesthesia only
33006078|NCT05269095|Experimental|spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive spinal anesthesia and ultrasound-guided Genicular nerves block
33006079|NCT05269095|Experimental|Spinal anesthesia and US guided Adductor canal nerve block plus infiltration of the interspace|Patients will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block plus infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (PACK) block.
33006080|NCT05268783|Experimental|NEN patients|EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
33006081|NCT05268679||Heart transplant recipients|Heart transplant recipients followed at Bichat Hospital and who were offered vaccination against SARS-CoV-2, regardless of whether they agreed to be vaccinated or not.
33006084|NCT05267938|Experimental|Microneedles|Microneedles is with 750μm of height in order to prepare the palatal mucosa to receive the topical anesthetic
33006085|NCT05267938|Sham Comparator|patch flat|The same device as the microneedles but without microneedles
33006086|NCT05267496|Other|Conventional rehabilitation|Patients will receive conventional pulmonary rehabilitation
33006087|NCT05267496|Experimental|AEROBIKA|Patients will receive conventional pulmonary rehabilitation in addition to an oscillating positive expiratory pressure device
33415445|NCT01349725|Experimental|ARRY-502|
33415446|NCT01349725|Placebo Comparator|Placebo|
33006088|NCT05267431||RA patients recieved biological therapy|RA patients recieved different biological therapy
33006089|NCT05267431||RA patients recieved different DMARDS|RA patients recieved different DMARDS
33006090|NCT05266248|Experimental|Fed state|Standardized high fat breakfast before dosing
33006091|NCT05266248|Experimental|Fasted state|Remain fasted for 4 hours post-dose
33006092|NCT05266131||OSA0HT0|without OSA or hypertension (OSA0HT0)
33006093|NCT05266131||OSA1HT0|OSA without hypertension (OSA1HT0)
33006094|NCT05266131||OSA0HT1|hypertension without OSA (OSA0HT1)
33006095|NCT05266131||OSA1HT1|with OSA and hypertension (OSA1HT1)
33006096|NCT05265585||Echocardiography group|
33006097|NCT05264896|Experimental|FLOT|"Patients randomized to the FLOT arm would receive perioperative FLOT~Regimen:~Docetaxel 50mg/m2, d1~5-FU 2600 mg/m², d1~Leucovorin 200 mg/m², d1~Oxaliplatin 85 mg/m², d1~Every two weeks 4 cycles pre-op and 4 cycles post-op~Granulocyte colony stimulating factor (GCSF) at 30 mu s.c. daily from Day 4 to Day 7 is recommended.~Two weeks after completion of the 4 cycles of pre-op chemotherapy, reassessment endoscopy and CT scan would be performed. Surgery would be performed 4 weeks after pre-op chemotherapy if no distant metastasis was found on CT scan.~Post-op adjuvant FLOT (x 4 cycles) will be started within 10 weeks after surgery."
33006098|NCT05264896|Active Comparator|XELOX|"Patients randomized to adjuvant XELOX arm would receive chemotherapy after surgery.~Capecitabine - 1,000 mg/m² twice daily.~Oxaliplatin - IV infusion, 130mg/m²"
33006099|NCT05264584|Other|control arm|This arm is consisted of 60 patients.They will receive IV hydration and N-acetylcysteine (control arm).
33006100|NCT05264584|Experimental|Febuxostat arm|This arm is consisted of 60 patients.They will receive IV hydration, N-acetylcysteine and Febuxostat .
33415447|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
33415448|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
33415449|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
33415450|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
33415451|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
33415452|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
33415453|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
33415454|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
33415455|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
33417466|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
32865938|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
32865939|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
32865940|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
32865941|NCT01444911|Experimental|Vaginal Renewal Program|
32865942|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
32865943|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
32865944|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
32865945|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
32865946|NCT03038022|Experimental|MGL-3196|Study Drug
32865947|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
32865948|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
32865949|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
32865950|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
32865951|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
32865952|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
32865953|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
32865954|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
32865955|NCT04838496|Experimental|Single-arm study|All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.
32865956|NCT04756973|Active Comparator|Standard weight loss|A 12 week small group weight loss intervention delivered via video teleconference technology.
32865957|NCT04756973|Experimental|Standard weight loss plus self-compassion skills training|A 12 week small group weight loss intervention delivered via video teleconference technology.
32865958|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
32865959|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
32865960|NCT04840758|Experimental|SABR+Sintilimab|Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions. Sintilimab was used 2 weeks after the end of SABR. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
32865961|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
32865962|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
32865963|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
33415456|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
33006101|NCT05264155|Placebo Comparator|Control: one-size-fits-all|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the control group, the parameter values of the dynamic tasks were based on national guidelines."
33006102|NCT05264155|Active Comparator|Treatment: personalized|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the treatment group, these parameters were tailored to the users' self-reported capabilities and health goals."
33006103|NCT05263687|Experimental|Exercise Test|maximal and anaerobic threshold cardiopulmonary parameters
33006104|NCT05263167|Experimental|sodium aescinate group|Trial treatment is administered as sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
33006105|NCT05263167|Placebo Comparator|placebo group|Trial treatment is administered as 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
33415457|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
33325463|NCT02287428|Experimental|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
33325464|NCT02287428|Experimental|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts within 2 weeks of start of RT, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
33325465|NCT02287428|Experimental|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
33325466|NCT02287428|Experimental|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks of start of RT; re-starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
33006110|NCT05262959|Experimental|Donafenib|Donafenib: 0.1g po. BID. And it will be taken on the first day of the study. PD-1: 200mg ivgtt. Q3W. It will be used at the same time as Donafenib. TACE: The first treatment will be carried out 2-3 weeks after taking Donafenib.
33006111|NCT05262686|Experimental|belimumab plus low dose IL-2|"10mg/kg belimumab was intravenously injected to patients with systemic lupus erythematosus every month for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL-2 was injected once a week for 12 weeks subcutaneously."
33006112|NCT05262686|Active Comparator|belimumab|10mg/kg belimumab was administrated to patients with systemic lupus erythematosus for at least 24 weeks, intravenously injected every month.
33006113|NCT05262686|Active Comparator|low dose IL-2|The first stage: interleukine-2 was added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh; The second stage: 1 million IU IL-2 was injected once a week for 12 weeks subcutaneously.
33006114|NCT05261334|Active Comparator|socket shield technique|immediate implant placement with socket shield technique
33006115|NCT05261334|Active Comparator|contour augmentation|early implant placement with contour bone augmentation
33006116|NCT05259540|Experimental|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days
33006117|NCT05258968|Experimental|Educational Session on the Injeti Self Esteem Model|The participant will participate in a 1 hour educational session on the Injeti Self Esteem model.
33006118|NCT05255445||Sickle cell disease (SCD)|Patients with SCD who are chronically transfused (in the U.S. and Brazil)
33006119|NCT05255445||Thalassemia|Patients with thalassemia who are chronically transfused in the U.S.
33415458|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
33415459|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
33415460|NCT02038088||A|intravenous inhalational anesthesia
33415461|NCT02038088||B|intravenous anesthesia
33006120|NCT05255445||Pediatric Hematology-Oncology|Patients in U.S. with pediatric oncologic diagnoses with hypo-proliferative bone marrow requiring single unit red blood cell transfusion
33006121|NCT05255445||Blood Donors|Allogenic blood donors in the US (estimated: 10,200) and allogenic blood donors in Brazil (estimated: 2,100) with extended donation genotyping using an investigational hematology array.
33006122|NCT05254041|Other|Mentrual Cup Removal|Menstrual Cup Removal.
33006123|NCT05254028|Active Comparator|Auricular points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.20mm x 13mm are inserted at the auricular acupuncture points shenmen (TF4), thalamus (AT4), and occiput (AT3) bilateral."
33006124|NCT05254028|Active Comparator|Body points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.25mm x 25mm are inserted at the acupuncture points LI4 Hegu, LR3 Taichong, dan GB20 Fengchi bilateral."
33006125|NCT05253534|Experimental|Gamma Rhythm Stimulation Group|"Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG).~In this study, it was planned to investigate the effect of reducing the progression of glaucomatous damage by applying 40 Hz flicker light therapy for 1 hour a day to POAG patients. It is planned to use visual field test, measurements of retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) layer thicknesses in optical coherence tomography to investigate the effectiveness of the treatment."
33006126|NCT05253534|No Intervention|Control Group|"This group will be monitored without using the device.The data will be used only for comparison.~Considering the sample size calculations and losses, a total of 60 patients are planned to be included in the study, with 30 patients in each group."
33006127|NCT05252338|Experimental|Younger Adults group aged 18-55 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
33006128|NCT05252338|Experimental|Adults group aged ≥65 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
33006129|NCT05238870||Clinicians (interviewees) from Ghent University Hospital, Belgium|Semi-structured interviews with clinicians
33006130|NCT05238870||Clinicians (interviewees) from Brussels University Hospital, Belgium|Semi-structured interviews with clinicians
33006131|NCT05238870||Clinicians (interviewees) from Orebro University Hospital, Sweden|Semi-structured interviews with clinicians
33006132|NCT05238714|Experimental|[14C] venglustat|Single dose of [14C] venglustat Oral Solution under fasting conditions
33006133|NCT05238532|Experimental|Single Arm|CT303
33006134|NCT05238506|Experimental|Lidocaine|1% lidocaine intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
33006135|NCT05238506|Placebo Comparator|Control|0.9% NaCl intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by 0.9% NaCl infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
33006136|NCT05236608|Experimental|Nivolumab and ADG106|"Eligible patients will receive nivolumab and ADG106 by IV infusion according to the study phases below.~Phase 1b:~3 evaluable patients will be treated at the starting dose, and assessed for tolerability over the first cycle. Treatment related dose-limiting toxicities (DLT) will determine the next dose level to be studied. Dose escalation will follow the 3 + 3 study dose titration design.~Phase 2:~The dose of ADG106 given together with nivolumab will be the recommended dose in combination with nivolumab determined in phase 1b."
33415462|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
33415463|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
33006139|NCT05231187||Prospective Arm|Subjects has had a diagnostic blood culture ordered per routine standard of care.
33006140|NCT05231187||Contrived Arm|Samples of healthy whole blood spiked with bacterial strains harboring the resistance gene targets on the T2Resistance Panel.
33006141|NCT05231187||Healthy Donor Arm|Healthy donor subjects.
33006142|NCT05225740|Active Comparator|Control|General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
33006143|NCT05225740|Active Comparator|Standard Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect
33006144|NCT05225740|Experimental|Enhanced Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation
33006145|NCT05225402||Septic Shock|Adult patients with septic shock, admitted to ICUs at Hvidovre and Bispebjerg Hospital, respectively. Sedated and mechanically ventilated adult patients (>18 years).
33415464|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
33415465|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
33415466|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
33415467|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
33415468|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
33415469|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
33006146|NCT05224232|Experimental|Access Socket|Patients will be fitted with the access socket
33006147|NCT05224232|Active Comparator|Rigid socket|Patients will be fitted with their usual rigid socket
33006148|NCT05223894|Experimental|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
33006149|NCT05223894|Sham Comparator|Control|Coronary artery bypass grafting surgery only.
33006150|NCT05223608|Other|ImmuCCo Cohort|"Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity.~Urine collection at initiation of immunotherapy."
33006151|NCT05223517|Experimental|Acupucnture|
33006152|NCT05223517|Sham Comparator|Sham Acupuncture|
33415470|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
33006153|NCT05222880|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
33006154|NCT05220826|No Intervention|Surgical drainaje (the standar of care)|Surgery will consist of performing a craniotomy (burr hole or drill) and evacuation of the hematoma. Depending on the operator, the surgical procedure may incorporate the use of subdural space drainage devices (e.g. Jackson Pratt drainage) connected to a soft suction reservoir. If used, these devices should be removed within 48 hours of installation.
33006155|NCT05220826|Experimental|Surgical drainaje plus early embolization of middle meningeal artery|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
33006156|NCT05217251||exposed group|Parturient women will be identified with frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery with alpha asymmetry group in hospital.
33006157|NCT05217251||control group|Parturient women will be identified without frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery without alpha asymmetry group in hospital.
33006158|NCT05216536||Long COVID|Adults who contracted COVID-19 and present at least one physical or cognitive long COVID-19 symptom for more than 12 weeks following the initial diagnosis.
33006159|NCT05216536||Acute COVID|Adults who contracted COVID-19 but did not experience persistent symptoms for more than 4 weeks following the initial diagnosis.
33006160|NCT05216536||Control|Adults who did not contract COVID-19.
33006161|NCT05215548|Experimental|Group I : Surgery group|The surgery group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the surgery group would receive thoracic surgery with maximal regional control intent. Patients continue afatinib 1 to 2 weeks after surgery until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
33006162|NCT05215548|Active Comparator|Group II : Maintenance group|The control group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the control group would receive afatinib until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
33006163|NCT05214313|Experimental|"Music therapy Intervention group (G1)"|"Patients in the Music therapy intervention group will also perform the 1st session of the program during the inclusion visit (V0). The patients will benefit from fourteen 1-hour music therapy sessions (15 min of reception, installation and debriefing at the end of the session and 45 min of program). The 14 individual sessions will be spread over three months at the rate of 2 weekly sessions the first month then a single weekly session the following month and finally 2 monthly sessions the last month. Patients will be assessed at inclusion, then the first month (V1) and at the end of the intervention (V2)."
33006164|NCT05214313|No Intervention|" Control  group (G2)"|The patients in this group will benefit from the usual care corresponding to a quarterly medical examination. The patients will be assessed on the day of inclusion (V0) and then during the routine three-month medical examination (V2). At the end of the study, these patients will be able to benefit from the same music therapy program, offered under the same operating conditions.
33006165|NCT05213871|Experimental|IASTM group|Group (A) will receive IASTM on the right upper trapezius and levator scapulae twice a week for four weeks in addition to a postural correction program.
33006166|NCT05213871|Experimental|myofascial release group|Group (B) will receive a myofascial release on the right upper trapezius and levator scapulae twice a week for four weeks in addition to the postural correction program.
33006167|NCT05210413|Experimental|Pediatric cohort|Multicentre, open-label, non-randomized, phase I clinical study, with dose-finding and expansion phases.
33006168|NCT05210413|Experimental|Adult cohort|Multicenter phase II single-arm open-label clinical trial, with a pre-screening phase to identify patients with mature tertiary lymphoid structure (TLS).
33006169|NCT05208073|Experimental|Intervention group|The experimental group received 6-week cosmetic therapy.
33415471|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
33417467|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
33006170|NCT05208073|No Intervention|Control group|The control group maintains the institution's original daily routine care.
33006171|NCT05208060|Experimental|MV130|Suspension of 6 inactivated whole bacteria concentrates, that contains 90% of Gram positive bacteria (V104 S. pneumoniae 60%, V102 S. aureus 15%, V101 S. epidermidis 15%) and 10% of Gram negative bacteria (V113 K. pneumoniae 4%, V105 M. catarrhalis 3%, V103 H. influenzae 3%), at a concentration of 300 FTU/mL, equivalent to ~ 10^9 bacteria/mL.
33006172|NCT05208060|Placebo Comparator|Placebo|Sodium chloride 9 mg/mL and water for injection s.q. f 1 mL.
33006173|NCT05205850|Experimental|RC118-ADC|Participants will be allocated to one of the following dose groups: 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC118-ADC followed by 14 days of dose limited toxicity (DLT) observation period.
33006174|NCT05205629||Donafenib + TACE|
33006175|NCT05204784|Experimental|Arm 1|2 Rheopheresis treatments per week x 2, followed by 8 weeks without treatment, 8 overall treatments
33006176|NCT05204784|Experimental|Arm 2|2 Rheopheresis treatments in week 1, followed by 1 treatment every 2 weeks, 8 overall treatments
33006177|NCT05204784|Active Comparator|Control Group|Standard of care treatment with intravenous iloprost
33006178|NCT05203705|Experimental|Treatment group 1|SHR2285 tablet; dose 1
33006179|NCT05203705|Experimental|Treatment group 2|SHR2285 tablet; dose 2
33006180|NCT05203705|Experimental|Treatment group 3|SHR2285 tablet; dose 3
33006181|NCT05203705|Experimental|Treatment group 4|SHR2285 tablet; dose 4
33006182|NCT05203705|Active Comparator|Treatment group 5|Enoxaparin
33006183|NCT05203315|Experimental|Treatment Group A|Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.
33006184|NCT05203315|Experimental|Treatment Group B|Subjects whose baseline Itch and/or Burning/Stinging Score is greater than or equal to 2 (moderate), in addition to one tube of Duobrii along with one jar of CeraVe cream, the participant will be given a tube of hydrocortisone 1% cream and instructed to apply to the treatment area twice daily for 5 days, along with CeraVe cream. Starting at day 6 and ongoing, subjects will be instructed to discontinue the hydrocortisone cream and initiate Duobrii application every night, while continuing the CeraVe cream twice daily.
33006185|NCT05202561|Experimental|Arm A|Drug: RNA tumor vaccine Administration: intramuscular injection Dose: 600 ng/ time Dosing cycle: Day 1, day 4, day 7, and day 14.
33006186|NCT05202561|Experimental|Arm B|"Drug: RNA tumor vaccine+Navuliumab Administration: intravenous injection Dose: 3 mg/kg Timing of administration: Administration was initiated 14 days after the first intramuscular injection of the RNA tumor vaccine.~Duration of administration: once every 2 weeks."
33006187|NCT05200546||"group before"|1st period of 6 months during which only the current detection technique will be used.
33006188|NCT05200546||"group after"|- 2nd period of 6 months after implementation of the PCR solution (CPO and VRE) of the BD company in parallel with the usual screening technique
33006189|NCT05196009|Experimental|Mental Health and Substance Use support|Pilot Mental health and substance use peer navigation, ecological momentary assessments and virtual support group
33006190|NCT05193825|Active Comparator|Group A|Patients in Group A (active comparator) will have their internal pulse generator (IPG) adjusted by conventional procedures, i.e. by regular visits at their caregivers hospital.
33006191|NCT05193825|Experimental|Group B|Patients in Group B (experimental) will have their internal pulse generator (IPG) adjusted by using a novel software (Abbot NeurosphereTM Virtual Clinics) that allows for remote IPG programming and with the aid of a visual analogue scale (VAS).
33006192|NCT05192733||Clinical Specialty|"We will compare responses across the following clinical specialties :~Neuroanesthesiologists~Neurosurgeons~Neurocritical care specialists NB: Some participants may have a double clinical specialty."
33006193|NCT05192733||Clinical Setting|"We will compare responses across the following clinical settings:~Cities~Countries~Number of cases per year"
33006194|NCT05192629|Active Comparator|Group Midazolam|"Administration of oral midazolam (0.25 mg/kg) as premedication before propofol-based sedation.~The patient receives an oral premedication containing 0.125mL/kg of midazolam (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/ml, with a maximum of 20 mg). He/she also receives an intranasal spray containing matching placebo of dexmedetomidine (NaCl 0.9%). The volume administered corresponds to 0.02 mL/kg (which corresponds to a dosage of 2 mcg/kg of pure dexmedetomidine 100 mcg/mL in group D)."
33006195|NCT05192629|Experimental|Group Dexmedetomidine|"Administration of intranasal dexmedetomidine as premedication before propofol-based sedation.~The patient receives an intranasal premedication containing 2 mcg/kg of dexmedetomidine. He/she also receives an oral solution containing matching placebo of midazolam (flavored-water prepared by the pharmacy). The volume administered corresponds to 0.125 mL/kg (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/mL, with a maximum of 20 mg or 10mL)."
33006196|NCT05191550|Experimental|Neurosurgeons, fellows, residents and medical students|Neurosurgeons (14), neurosurgical fellows and neurosurgical residents (24) from Montreal Neurological Institute and Hospital along with medical students (12) who are enrolled in first to fourth year of McGill medical school.
33006197|NCT05191121|Active Comparator|FTP Alone|Functional Task Practice Alone - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks followed by 10 minutes of functional training/carryover in a relevant environment without functional electrical stimulation (FES).
33006198|NCT05191121|Active Comparator|FTP+Con-FES|Functional Task Practice + Conventional Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with conventional parameter (200µs; 40Hz) functional electrical stimulation (FES). followed by 10 minutes of functional training/carryover in a relevant environment.
33006199|NCT05191121|Active Comparator|FTP+WPHF-FES|Functional Task Practice + Wide Pulse, High Frequency Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with wide pulse, high frequency (1000µs; 100 Hz) functional electrical stimulation (FES) followed by 10 minutes of functional training/carryover in a relevant environment.
33006200|NCT05189444|Experimental|Vonoprazan group|Vonoprazan + Amoxicillin + Bismuth potassium citrate Drug: Vonoprazan 20mg bid Other Names: no Drug: Amoxicillin 0.75g tid Other Names: no Drug: Bismuth potassium citrate 0.22g bid Other Names: no
33006201|NCT05189444|Active Comparator|control group: quadruple therapy|Drug: Esomeprazole 20mg bid Other Names: no Drug: Amoxicillin 1.0g bid Other Names: no Drug: Clarithromycin 0.5g bid Other Names:no Drug: Bismuth potassium citrate 0.22g bid Other Names:no
33006202|NCT05186662||WeChat group|
33006203|NCT05186662||Control group|
33415472|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
33006204|NCT05185011|Experimental|mild hepatic impairment|Subjects with mild hepatic impairment
33006205|NCT05185011|Experimental|moderate hepatic impairment|Subjects with mild moderate impairment
33006206|NCT05185011|Experimental|healthy volunteers|Subjects with normal hepatic function
33006209|NCT05180981|Experimental|Breath task|Participants will breathe in specific patterns.
33006210|NCT05180981|Experimental|Transcutaneous vagal nerve stimulation|Participants will receive transcutaneous vagal nerve stimulation in specific patterns.
33006211|NCT05177302||Individuals with hip and/ or groin pain|The young to middle-aged physically active individuals with hip and/ or groin pain, which symptoms lasting for 2 to 6 month.
33006212|NCT05176353|Experimental|VAP diagnostic stewardship|
33006213|NCT05175274|Experimental|Intervention Group|colchicine 0.5mg every 24 hours for 3 years
33006214|NCT05175274|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 3 years
33006215|NCT05175170|Experimental|Decision-aid|Participants will spend up to one hour freely navigating the web-based decision aid. They will complete pre- and post-test measures to determine if using the decision-aid website increased knowledge and impacted decision self-efficacy regarding fertility and fertility preservation.
33006216|NCT05169268||MainRexult Group|Subjects with schizophrenia and related disorders receiving Abilify Maintena (aripiprazole 1 monthly depot) together with Rexulti (Brexpiprazole)
33006217|NCT05165199|Experimental|Elobixibat|10mg Elobixibat administration for 4 weeks
33006220|NCT05163015||with oncogeriatric consultation|"with oncogeriatric consultation group: patients aged 75 and more with cancer with oncogeriatric consultation"
33006221|NCT05163015||without oncogeriatric consultation|"without oncogeriatric consultation group: patients aged 75 and more with cancer without oncogeriatric consultation"
33006222|NCT05160194|Other|GROW Intervention|Every participant received the GROW Intervention, chose not to participate in the GROW intervention, or dropped out before completing the GROW Intervention.
33006225|NCT05157555||"with laryngectomy group"|"with laryngectomy group: patients with laryngectomy for any type of cancer"
33006226|NCT05157178|Experimental|4 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.
33006227|NCT05157178|Experimental|8 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.
33006228|NCT05157178|Active Comparator|12 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.
33006229|NCT05154240|Active Comparator|INS018_055|oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.
33006230|NCT05154240|Placebo Comparator|Placebo|No active ingredient. Frequency similar to the 2 arms above.
33006231|NCT05153278||Control group|Patients that received standard treatment (packed red blood cells) for iron deficiency anemia
33006232|NCT05153278||Experimental group|Patients that received intravenous iron instead of standard treatment (packed red blood cells) for iron deficiency anemia
33105596|NCT04319848|Experimental|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of <1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
33105597|NCT05530291||ESA hyporesponsive CKD patients|A cohort of patients who meets ESA hyporesponsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
33105598|NCT05530291||ESA responsive CKD patients|A cohort of patients who meets ESA responsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
33105599|NCT05529979||Intervention with the EPIONE® device|Patients treated by percutaneous CT-guided procedures in the abdomen with the EPIONE® device
33006233|NCT05150548||Entire Cohort|"Patients undergoing elective colectomy with data that has been collected in the NSQIP® Procedure Targeted Colectomy dataset from 2014-2019 with American Society of Anesthesiologists (ASA) Physical Status I-IV.~Patients will not be included in this cohort with urgent or emergency colectomy or indication for colectomy consisting of Acute diverticulitis, Enterocolitis (e.g. C. Difficile), and Volvulus, patients with disseminated cancer, wound infection, systemic sepsis or ventilator-dependence preoperatively."
33006234|NCT05145426|Experimental|Pain Trials|Multi visit - LIFU/Sham application, with quantitative sensory testing (using peltier device).
33006235|NCT05136885|Experimental|SLS-005|SLS-005 is administered via infusion once weekly for 24 weeks.
33006236|NCT05136885|Placebo Comparator|Matching Placebo|Matching placebo is administered via infusion once weekly for 24 weeks.
33006237|NCT05133427|Experimental|Areas with de-novo or recurrent BCC|Areas with non-nodular de-novo or recurrent BCC area will be treated by high intensity focused ultrasound.
33006238|NCT05129137|Experimental|FDC nefopam hydrochloride 30mg / paracetamol 500mg|Single dose: 2 tablets
33006239|NCT05129137|Active Comparator|nefopam hydrochloride 30mg|Single dose: 2 tablets
33006240|NCT05129137|Active Comparator|paracetamol 500mg|Single dose: 2 tablets
33006241|NCT05129137|Active Comparator|nefopam hydrochloride 30mg and paracetamol 500mg|Single dose: 2 tablets
33006242|NCT05126251|Experimental|Tangningtongluo group|"Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (1.6g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~Lifestyle intervention"
33006243|NCT05126251|Placebo Comparator|Placebo group|"Placebo of Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (2.0g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~2） Lifestyle intervention"
33006244|NCT05121740|Experimental|Arm A: Experimental 1|In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).
33006245|NCT05121740|Experimental|Arm B: Experimental 2|In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).
33006246|NCT05121740|Experimental|Arm C: Experimental 3|In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).
33006247|NCT05114473|Experimental|Workshops|This group will attend face-to-face workshops were the educational program will be developed. These workshops will be available in several sites, and specific care providers will be assigned for each of these sites.
33006248|NCT05114473|Experimental|Online-accessed material|This group will be granted online access to a platform were the educational program will be uploaded. They will be given autonomy regarding when to enter the platform and view the content.
33006249|NCT05114473|No Intervention|Control group|This group will initially no recieve an intervention and will serve as a control group.
33006250|NCT05110898|Experimental|Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg|
33006251|NCT05110898|Active Comparator|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|
33006252|NCT05103696|Experimental|Remimazolam group|Patients received remimazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.3ug/kg of remifentanil during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
33006253|NCT05103696|Active Comparator|EP group|Patients received Etomidate combined with propofol to maintain sufficient sedation (sufficient sedation as judged by MOAA/ S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.3 ug/kg of remifentanil during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation
33006254|NCT05103033|Experimental|Systems Analysis and Improvement Approach (SAIA) for mental health|Those receiving SAIA-MH will attend a 1-week in-person training for facility learning collaboratives. Following the 1-week in-person training, SAIA-MH standard operating procedures will be implemented, including: (1) structured internal/external facilitation following tablet-based guides used in pilot study (1x per week first month; 2x per week for next two months; 1x per month for remainder); (2) facilitation in the 5-step SAIA-MH improvement process.
33006255|NCT05103033|Other|Attentional Placebo Control|"Control facilities will mimic activities of the intervention group in time and contacts, but without the active ingredient of the SAIA-MH implementation strategy"
33006256|NCT05101590|Experimental|Monitored with HDA|Participants undergoing elective major surgery and have an arterial line as part of their standard care with HDA included as part of their care
33006258|NCT05098730|Experimental|Stroke survivors with pets|Stroke survivors with pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
33006259|NCT05098730|Active Comparator|Stroke survivors without pets|Stroke survivors without pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
33006260|NCT05098041|Experimental|Soticlestat 300 mg + Rifampin 600 mg|Soticlestat 3*100 mg tablets, orally, administered once on Day 1 in fasted state in Period 1, followed by a washout period of 4 days, further followed by Rifampin 600 mg, administered as 2*300mg capsules, orally, once daily for 13 consecutive days, from Day 1 to Day 13 in fasted state in Period 2. Soticlestat 3*100 mg tablets, will be administered orally along with rifampin 600 mg (2*300mg) capsules, orally in the morning of Day 11 in Period 2.
33006261|NCT05096780|Active Comparator|Beverage 1|Free caffeine 160 mg
33006262|NCT05096780|Experimental|Beverage 2|Encapsulated caffeine 160 mg
33006263|NCT05096780|Active Comparator|Beverage 3|Free caffeine 250 mg
33006264|NCT05096780|Experimental|Beverage 4|Encapsulated caffeine 250 mg
33006265|NCT05096624|Experimental|DD-TENS (Digital Denture-Transcutaneous Electrical Nerve Stimulation)|Patient with Complete Removable Prostheses according to DD-TENS system
33415473|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
33417468|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
33006266|NCT05096624|Active Comparator|Gold standard|Patient with Complete Removable Prostheses according to usual care
33006267|NCT05096624|Active Comparator|Digital denture System|Patient with Complete Removable Prostheses according to Digital Denture system
33006268|NCT05096403|Active Comparator|Pegcetacoplan|1080 mg, subcutaneus injection, twice weekly
33006269|NCT05096403|Placebo Comparator|Placebo|Sodium acetate, subcutaneus injection, twice weekly
33006270|NCT05096325||Study pump|Subjects receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data.
33006271|NCT05096065|Experimental|Treatment A: Leuprolide Oral Tablet, 120 mg QD|Leuprolide Oral Tablet (Ovarest), 120 mg (2 x 60 mg tablets), administered once daily (QD), for up to 35 consecutive days with food-intake restrictions.
33006272|NCT05096065|Experimental|Treatment B: Leuprolide Oral Tablet, 80 mg QD|Leuprolide Oral Tablet (Ovarest), 80 mg (2 x 40 mg tablets), administered once daily (QD) for up to 35 consecutive days with food-intake restrictions.
33006273|NCT05096065|Experimental|Treatment C: Leuprolide Oral Tablet, 60 mg QD|Leuprolide Oral Tablet (Ovarest), 60 mg, administered once daily (QD) for up to 29 consecutive days with food-intake restrictions.
33006274|NCT05096065|Experimental|Treatment D: Leuprolide Oral Tablet, 60 mg BID|Leuprolide Oral Tablet (Ovarest), 60 mg, administered twice daily (BID), 12 hours apart for up to 35 consecutive days with food-intake restrictions.
33006275|NCT05096065|Experimental|Treatment E:Leuprolide Oral Tablet (Ovarest), 40 mg BID|Leuprolide Oral Tablet (Ovarest), 40 mg, administered twice daily (BID), 12 hours apart for up to 29 consecutive days with food-intake restrictions.
33006276|NCT05094817||Access to Computer|Participants completing the BHA should be at least somewhat comfortable or very comfortable with using a computer and mouse and should use a computer at least once a week.
33006277|NCT05094817||No Access to Computer|Since participants in previous studies on cognitive screening are usually more educated individuals with higher income, participants who do not have proficiency/or access to a computer will be asked to complete some questionnaires to determine any sociodemographic or baseline differences between patients who are able to complete BHA vs. those who are not able to complete BHA.
33006278|NCT05094544|Experimental|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
33006279|NCT05092789|Experimental|Kinesio taping group|"Participants in this group will receive treatment through standardized therapeutic Kinesio taping along with conventional therapy.~Tape will be water proof, porous, adhesive,with width of 5cm and thickness of 0.5 mm."
33006280|NCT05092789|Experimental|Cervical thrust manipulation group|"Participants in this group will receive treatment via cervical thrust manipulation along with conventional therapy.~Manipulation will be directed on mid cervical spine."
33006281|NCT05092789|Active Comparator|Conventional therapy group|.Participants of this group will receive only conventional therapy which will include: Hot pack for 10 minutes Stretching Exercises
33006282|NCT05087836||Patient undergoing cardiac surgery|Each patient will has 2 sets of sensors attached at forehead and temporal area.
33006283|NCT05086471|Experimental|NaviCam SB|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
33006284|NCT05086471|Other|PillCam SB3|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
33006287|NCT05083572|Experimental|Group A (Lavage and Vivomixx)|Colonic lavage, followed by Vivomixx treatment
33006288|NCT05083572|Experimental|Group B (Lavage and Placebo)|Colonic lavage, followed by Placebo treatment
33006289|NCT05083572|Experimental|Group C (Vivomixx)|No colonic lavage, only Vivomixx treatment
33006290|NCT05083572|Experimental|Group D (Rifaximin and Vivomixx)|Rifaximin, followed by Vivomixx treatment
33006291|NCT05077657||Single-Arm|This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
33006292|NCT05076435|Experimental|Restrictive fluid administration|"No IV fluids unless one of the extenuating circumstances occur;~In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP < 90 mmHg), 3) Mottling beyond the kneecap (mottling score >2) OR 4) Urinary output<0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs~IV fluids may be given as carrier for medication, but with lowest possible volume"
33006293|NCT05076435|Active Comparator|Usual care (standard care)|"There will be no upper limit for the use of either IV or oral/enteral fluids~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
33006294|NCT05075772|Experimental|BI 765080 - Administration mode 1 (T)|Subcutaneous (SC) injection (Test, T)
33006295|NCT05075772|Experimental|BI 765080 - Administration mode 2 (R)|Intravenous (IV) infusion (Reference, R)
33006296|NCT05074615|Experimental|Cranio-Cervical Flexion Training Group|"Participants of this group will receive conventional training along with cranio-cervical flexion training and home plan.~Cranio-cervical flexion training will be given with the help of pressure biofeedback unit. the cuff will be inflated at a specific pressure level and patient will be asked to maintain that pressure and gradually increase it."
33006297|NCT05074615|Active Comparator|Conventional Therapy Group|Participants of this group will receive only conventional therapy and home plan will be given which includes; hot pack, TENS, neck isometrics and passive stretching of neck musculature. Home plan will include self-stretches and neck isometrics.
33006298|NCT05073120||Piqray Prescriber's/HCP receiving the guide for hyperglycemia|HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
33105600|NCT02897024|Active Comparator|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
33415474|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
33415475|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
33415476|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
33006299|NCT05070312|Experimental|MEDI3506 dose 1|MEDI3506 dose1
33006300|NCT05070312|Experimental|MEDI3506 dose 2|MEDI3506 dose 2
33006301|NCT05070312|Placebo Comparator|Placebo|Placebo 2 mL and 4 mL
33006302|NCT05066672|Experimental|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
33006303|NCT05066672|Placebo Comparator|matched placebo|2 or 4 oral capsules administered once daily
33006304|NCT05065151|Experimental|Stimulation|Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept PC device.
33006305|NCT05065151|Experimental|No Stimulation|Patients will have stimulation turned off through their Medtronic Percept PC device.
33006306|NCT05058794|Experimental|Resistance exercise group|"During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and LOP was calculated in the body position that the blood flow restriction (BFR) stimulus would be applied. BFR pressure was set at 50% occlusion.Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.~Secondly, Rest between sets (1 min) Therapist will help these positions to maintain Knee extension and Wall Squatting.~The study includes interventional protocol of 6 weeks. Total sessions will be 12 and in each week there will 2 sessions with alternative days and follow up."
33006307|NCT05058794|Active Comparator|Conventional Therapy Group|Patients in this group will receive treatment via Knee extension,Wall squatting Each training session includes 3 minutes warm-up.First, participants will perform 2 sets with 15 repetitions in (0 to 90 degree.) Secondly, Rest between sets (1 min) Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. The study includes interventional protocol of 6 weeks. The sessions will be given on 2 alternate days making it a total of 12 sessions and then follow up.
33006308|NCT05058547|Experimental|SWEPPE|Participants will receive the smartphone application SWEPPE.
33006309|NCT05058547|No Intervention|Control|Participants randomized to the control group will not receive any active intervention for return to work after completing an Interdisciplinary Pain Rehabilitation Program .
33006310|NCT05057273|Experimental|omilancor (BT-11) 1,000mg|Participants will be randomized to receive BT-11 1000 mg tablets/Saline SC or Adalimumab SC/Placebo to BT-11 1000 mg tablets. Randomization to oral BT-11 or SC Adalimumab will be in a 3:1 ratio. The first dose of BT-11 1000 mg/ Saline SC, Adalimumab/ BT-11 matching placebo will be administered on site. All participants will take one tablet by the mouth of BT-11 1000 mg or matching placebo daily for 12 weeks, preferably at the same time in the morning.
33006311|NCT05057273|Active Comparator|adalimumab|Each participant will receive Adalimumab/Saline SC injections administered by an unblinded study nurse according to the following schedule: Week 0 (First dose): Adalimumab 160 mg/Saline SC (4 kits). Week 2: Adalimumab 80 mg/Saline SC (2 kits). Weeks 4, 6, 8, 10, and 12 (Last dose): 40 mg/Saline SC(1 kit).
33006312|NCT05056870|Experimental|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
33006313|NCT05056870|Experimental|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
33006316|NCT05051852||Women with low-grade squamous intraepithelial lesion (LSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
33006317|NCT05046158|Active Comparator|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
33105601|NCT02897024|Experimental|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
33105602|NCT04207489||endoscopic submucosal injection of indocyanine green|
33417469|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
33006318|NCT05046158|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
33006319|NCT05039411|Experimental|Human umbilical cord mesenchymal stem cells (UC-MSCs)|All patients to receive allogeneic UC-MSCs via intralesional injection
33006320|NCT05038176|Experimental|Active intervention group (AI)|The active intervention group (AI) receiving the active treatment (MANUP intervention) which include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
33006321|NCT05038176|Active Comparator|Delayed intervention group (DI)|"DI participants will only receive motivational text-messages. They will then flip and receive full intervention after the AI group has completed the program."
33006322|NCT05037955||ILIT from trial NCT00470457|Patients who received ILIT in the original trial in 2005
33006323|NCT05037955||SCIT from trial NCT00470457|Patients who received SCIT in the original trial in 2005
33006324|NCT05037955||SCIT outpatient control|Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years
33006325|NCT05037669|Experimental|Cohort A: Acute Lymphoblastic Leukemia (ALL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Acute Lymphoblastic Leukemia (ALL)
33006326|NCT05037669|Experimental|Cohort B: Chronic Lymphocytic Leukemia (CLL) + Non-Hodgkin's Lymphoma (NHL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL).
33006327|NCT05034068|No Intervention|control|the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. In each weekly visit, oral sites will be examined, and a score was given to each site based on the degree of mucositis.
33006328|NCT05034068|Active Comparator|bezaydamine hydrochloride.|All patients were advised to rinse 15 mL of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. In case of any problem (e.g. burning or stinging), patients will be allowed to dilute the solution with water in the ratio 1:1 or 1:2. Study evaluations will be conducted before cancer treatment and weekly thereafter until 2 weeks after completion of the therapy .In each weekly visit, oral sites were examined and a score was given to each site based on the degree of mucositis.
33006329|NCT05034068|Active Comparator|low-level laser therapy|the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2. The irradiations will be done intra-orally avoiding the tumor site, oral examinations will be recorded at each irradiation session and the degree of mucositis will be recorded.
33006330|NCT05033743|Experimental|Treatment Group|Secnidazole treatment
33006332|NCT05031195||1st tertile|
33006333|NCT05031195||2nd tertile|
33006334|NCT05031195||3rd tertile|
33006335|NCT05030870|Experimental|Capnographic monitoring group|In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.
33006336|NCT05030870|Active Comparator|Standard monitoring group|In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.
33006337|NCT05030025|Experimental|Group 1|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fasting conditions.
33006338|NCT05030025|Experimental|Group 2|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fed conditions.
33006339|NCT05019924|Active Comparator|Intervention arm|Dietary supplement
33006340|NCT05019924|No Intervention|Control arm|No intervention given
33006341|NCT05018026|No Intervention|Arm 1 (Control Arm)|A default NUSMart that mirrors a conventional web-grocery store in Singapore where some healthier products are displayed with Singapore's Healthier Choice Symbol (HCS) logos (Control).
33006342|NCT05018026|Experimental|Arm 2 (Nutri-Grade Arm)|Similar to Arm 1 except that beverages will be displayed with a color-coded and graded Nutri-Grade label.
33006343|NCT05016687|Experimental|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
33006344|NCT05016687|Placebo Comparator|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
33006345|NCT05016687|Experimental|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
33006346|NCT05016687|Placebo Comparator|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
33105603|NCT04925583|Experimental|Level 0|Total dose 50 Gy, (10 x 5 Gy single dose)
33105604|NCT04925583|Experimental|Level 1|Total dose 55 Gy, (10 x 5.5 Gy single dose)
33415477|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
33415478|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
33006347|NCT05016687|Experimental|Experimental Part IIb: CUR-N399|Healthy subjects >/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
33006348|NCT05016687|Placebo Comparator|Experimental Part IIb: Placebo|Healthy subjects >/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
33006349|NCT05013567|Experimental|Ibuprofen gel 5%|
33006350|NCT05013567|Placebo Comparator|Placebo|
33006351|NCT05011409||Newly diagnosed breast cancer patients|Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
33006352|NCT05010408|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort|Full sweetness (sugar) for 6 months
33006353|NCT05010408|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
33006354|NCT05010408|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort|Reduced sweetness (moderate sugar level) for 6 months
33006355|NCT05010408|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
33006356|NCT05010408|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
33006357|NCT05010408|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
33006358|NCT05008926|Experimental|Naloxegol|"Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.~Management of constipation and gastroparesis according to the recommendations."
33006359|NCT05008926|Placebo Comparator|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
33006360|NCT05006014||Patient with non restorable teeth|Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss
33006363|NCT05000541||Armolipid-L/Armolipid Plus-L|Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria
33006364|NCT04998708|Experimental|Intervention|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM). We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
33006365|NCT04998708|No Intervention|Control|
33006366|NCT04989621|Experimental|Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib|"Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity."
33006367|NCT04989049|Active Comparator|intervention group or case group|topical folic acid on oral ulcers will be applied for 7 days and patients will be asked to visit after 7 days for follow up
33006368|NCT04989049|Placebo Comparator|control group|placebo drug for oral ulcers
33006369|NCT04987021|Experimental|Nucleus Smart App with Remote Assist Custom Sound Pro 6.3|Remote Assist Custom Sound Pro 6.3 to enable clinicians to use the App to remotely to program the recipients sound processors.
33006370|NCT04984044|Active Comparator|Experimental|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
33006371|NCT04984044|Placebo Comparator|Control|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
33006372|NCT04984031||Generalized grade C periodontitis|generalized aggressive periodontitis ( generalized Grade C ,as in new classification) patients characterized with Bone loss/age index more than 1 and extent more 30 %
33006373|NCT04984031||Molar-incisor grade C periodontitis|localized aggressive periodontitis ( Molar-incisor pattern Grade C ,as in new classification) patients characterized with limited affection on molars and incisors and their Bone loss/age index more than 1.
33006374|NCT04983979|Experimental|SZC|3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
33006375|NCT04983979|Placebo Comparator|Placebo|3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
33417470|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
33417471|NCT01318187|Experimental|Paracetamol|
32865964|NCT04838184||Dental patients|Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
32865965|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32865966|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
32865967|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
32865968|NCT02205515|Other|Radiotherapy|SBRT or EBRT
32865969|NCT04365660|Experimental|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
32865970|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
32865971|NCT04837950|Experimental|Before pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview before pulling diaphragmatic suture
32865972|NCT04837950|Experimental|After pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview after pulling diaphragmatic suture
32865973|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
32865974|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
32865975|NCT04558541|Experimental|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
32865976|NCT04558541|Experimental|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
32865977|NCT04833036|Active Comparator|c-CetuIRI|Irinotecan combined with cetuximab
32865978|NCT04833036|Experimental|s-IRI-CetuIRI|single irinotecan first, then irinotecan plus cetuximab sequentially after PD
32865979|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
32865980|NCT04832880|Experimental|Control arm (dexamethasone arm)|IV dexamethasone 6 mg for 10 days
32865981|NCT04832880|Experimental|Remdesivir arm|IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10
32865982|NCT04832880|Experimental|Baricitinib arm|IV dexamethasone 6 mg for 10 days + baricitinib 4 mg die for 10 days. For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days.
32865983|NCT04832880|Experimental|Remdesivir + baricitinib arm|"IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10 + baricitinib 4 mg die for 10 days.~For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days."
32865984|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
32865985|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
32865987|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
32865988|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
32865989|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
32865990|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
32865991|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
32865992|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
32865993|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
32865994|NCT02171351|Experimental|effect of voluntary contractions (VC)|
32865995|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
32865996|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
32865997|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
32865998|NCT02170181||RE-IRRADIATION ARM|
32865999|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
32866000|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
32866001|NCT02169089|Experimental|Spironolactone|Spironolactone
32866002|NCT02169089|Placebo Comparator|Placebo|Placebo
32866003|NCT04788186|No Intervention|Continue beta blocker therapy|Participants in this arm will continue their beta blocker therapy as per their usual clinical care
32866004|NCT04788186|Experimental|De-prescribe beta blocker therapy|Beta blocker therapy will be de-prescribed in this arm
32866005|NCT04550117|Experimental|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
33417472|NCT01318187|Active Comparator|Morphine|
33105605|NCT04925583|Experimental|Level 2|Total dose 60 Gy, (10 x 6 Gy single dose)
33105606|NCT04925583|Experimental|Level 3|Total dose 65 Gy, (10 x 6.5 Gy single dose)
33415479|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33415480|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
32866006|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
32866007|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
32866008|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
32866009|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
32866010|NCT05577221|Experimental|Experimental group|installation of the high-flow humidified nasal oxygen therapy device and variation of the inspiratory flow rate (0 L/min, 30 L/min, 50 L/min and 70 L/min) then performance of the weaning test. of the weaning test. During each step of the protocol (= each variation of the inspiratory flow), the intensity of the dyspnea will be collected, the esophageal pressure will be measured, the respiratory control will be measured, the EMG of the respiratory muscles will be measured and the comfort will be measured. Each step lasts about 15 minutes with 5 minutes of wash-out before the next step. Once the 4 conditions are tested, the weaning test is performed (without wash-out), for a duration of one hour. The whole test lasts 2h15.
32866011|NCT04551287||Discovery Comparison of Cytotechnician versus AI-based Cervical Cancer Screening Model|A competition in cervical cancer screening between cytotechnicians and AI was held to preliminary exploration into the field in Guangzhou, China on August 04, 2019. 15 slides were randomly selected from 108 eligible individuals' WSIs from SYSMH for performance evaluation of the AI-based cervical cancer screening model and cytotechnicians.
32866012|NCT04551287||Training dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
32866013|NCT04551287||SYSMH internal validation dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
32866014|NCT04551287||TAHGMU external validation dataset|600 slides from 600 eligible individuals were obtained in the Third Affiliated Hospital of Guangzhou Medical University (TAHGMU, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
32866015|NCT04551287||GWCMC external validation dataset|600 slides from 600 eligible individuals were obtained in Guangzhou Women and Children Medical Center (GWCMC, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
32866016|NCT04551287||Prospective validation dataset|A prospective validation dataset was conducted to distinguish the diagnostic performance of the cytotechnician, CAISS, and CAISS-assisted groups, in which 2,780 eligible slides from 2,780 individuals were obtained and prospectively labeled between August 28, 2020 and October 16, 2020 at SYSMH.
32866017|NCT04551287||Randomized controlled trial|A prospective randomized controlled trial was conducted to compare the performance of the cytotechnician, CAISS, and CAISS-assisted groups in SYSMH. Here, 618 slides were collected between August 13, 2020, and December 14, 2020, to build the SYSMH randomized controlled trial. The remaining 608 slides after quality control were randomly assigned (1:1:1) to the CAISS group (n = 201), the cytotechnician group (n = 203), and the CAISS-assisted combination group (n = 204).
32866018|NCT04825314|Active Comparator|Bactiguard urethral catheter|Group A: Fifty Patients with urethral catheter using noble metal alloy coated catheter (Bactiguard AB, Stockholm ,Sweden).
32866019|NCT04825314|Active Comparator|Silicone Foley urethral catheter|Group B: Fifty Patients with urethral catheter using silicone Foley catheter (Well Lead, Guangzhou, China).
32866020|NCT01567371|Experimental|LiDCO rapid monitor|
32866021|NCT04551599|Experimental|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fed conditions.~Period 2: Danicopan administered under fasted conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
33006377|NCT04977635||600-cohort|"Patients with long-term (> 5 years) type 1 diabetes aged 16 years and older~As this is an observational study there is no intervention."
33006378|NCT04976244|Active Comparator|Brolucizumab|Arm B
33006379|NCT04976244|Active Comparator|Aflibercept|Arm A
33006380|NCT04976166|Active Comparator|Conventional group|Videos and leaflets will be provided. Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
33006381|NCT04976166|Experimental|Extensive Informed Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients in the EIDM group will receive more informed and detailed education than those in the conventional group. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
33006382|NCT04976166|Experimental|Shared Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
33006383|NCT04975802|Placebo Comparator|0 mg coffeeberry beverage|Appearance-matched to the other products
33006384|NCT04975802|Experimental|100 mg coffeeberry beverage|Appearance-matched to the other products
33006385|NCT04975802|Experimental|300 mg coffeeberry beverage|Appearance-matched to the other products
33006386|NCT04975802|Active Comparator|75 mg caffeine beverage|Appearance-matched to the other products
33006387|NCT04974463||Persistent Opioid Use at 3 months|Patients who continue to use opioids about 3 months after their joint replacement surgery
33006388|NCT04974463||No Persistent Opioid Use at 3 months|Patients who do not use opioids after about 3 months following joint replacement surgery
33325467|NCT02287428|Experimental|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.~Followed by:~6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
33325468|NCT01253616|Experimental|VNS plus tones|
33006391|NCT04972747|Experimental|Suggest skin care with sunflower oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and sunflower oil will be applied twice a day for 14 days.~Absorption of sunflower oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of sunflower oil will be applied to the whole body surface except the genital area and scalp..~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
33006392|NCT04972747|Experimental|Suggest skin care with cocunut oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and coconut oil will be applied twice a day for 14 days.~Absorption of coconut oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of coconut oil will be applied to the whole body surface except the genital area and scalp.~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
33006393|NCT04971811|Experimental|Lower-energy-dense Snack|Test snack with lower-energy-dense snack food
33006394|NCT04971811|Experimental|Higher-energy-dense Snack|Test snack with higher-energy-dense snack food
33006395|NCT04971395|Experimental|Single IV infusion of 2 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
33006396|NCT04971395|Experimental|Single IV infusion of 4 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
33006397|NCT04970134||Thyroid carcinoma|"Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:~Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.~Medullary thyroid carcinoma (MTC)."
33006398|NCT04969783|Experimental|Ventilated Cigarette Filter|Filters with approximately 24-32% filter ventilation
33006399|NCT04969783|Experimental|Unventilated Cigarette Filter|Filters with approximately 0-5.0% filter ventilation
33006400|NCT04969562|Experimental|experiment|Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
33325469|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
33325470|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
33325471|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
33325472|NCT05616000|Experimental|Acetyl-L-Carnitine group|Acetyl-L-Carnitine (2gm once a day), folic acid 5mg (once a day) 43 Patients with Primary Infertility will receive Acetyl-L-Carnitine (2gm once a day) orally& folic acid 5mg orally was given to all the participants of this group (once a day).
33325473|NCT05616000|Experimental|Control group|Coenzyme Q10 (400mg once a day) orally was given to all participants& folic acid 5mg (once a day) was also given orally to these participants 43 Patients with Primary Infertility will receive Coenzyme Q10 (400mg once a day), folic acid 5mg (once a day).
33325474|NCT03908112|Active Comparator|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
33417473|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
33006401|NCT04969562|No Intervention|control|They will continue their routine treatment.
33006402|NCT04968782||Patients with acute appendicitis|
33006403|NCT04967352||Developed Persistent Opioid Use after 3 months following surgery|
33006404|NCT04967352||Did not develop persistent opioid use after 3 months following surgery|
33006405|NCT04966858|Experimental|Individualized Caloric Refeeding (ICR)|Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal
33006406|NCT04966858|Active Comparator|Higher Calorie Refeeding (HCR)|Starting 2000 kcal/d, increasing by 200 kcal/d to goal
33006407|NCT04962477||Pregnant|
33006408|NCT04962477||Non-pregnant|
33006409|NCT04961372||Healthcare Workers|All healthcare professionals working at Gümüşhane Şiran Government Hospital
33006410|NCT04961372||Non-Healthcare Workers|Twice the number of health workers included in the study, non-health worker volunteers
33006411|NCT04960683|Experimental|Robotic -assisted gait training group using Lokomat device|"5 sessions of 40 minutes of conventional therapy and~5 sessions of 40 minutes on Lokomat per week"
33006412|NCT04960683|Active Comparator|Traditional therapy group|• 5 sessions of 40 minutes of conventional therapy
33006413|NCT04956172|Active Comparator|Tone A|Tone A uses an 80dB standard tone
33006414|NCT04956172|Experimental|Tone B|Tone B uses a 93dB standard tone
33006415|NCT04950868|Experimental|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
33006416|NCT04950582||UTI-high risk patients|patients who are at high risk for developing a urinary tract infection (UTI).
33006417|NCT04947137|Experimental|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
33006418|NCT04947137|Experimental|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
33006419|NCT04945850||Covid negative|"20 patients undergoing ocular surgery who are COVID negative will be included as control patients and undergo the same procedures.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
33006420|NCT04945850||Covid positive|"60 patients undergoing ocular surgery with previous COVID infection will be stratified into three groups by time since diagnoses: 3, 6, 12 months ~ 20 patients per group.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
33006421|NCT04944667|Other|TAVR standard|TAVR planning evaluated without VR and TAVR planning after VR analysis
33006422|NCT04941989|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
33006423|NCT04941989|Experimental|Part 2 Multiple Ascending Dose|Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
33006424|NCT04940767|Experimental|Treatment Group A|Patients will concomitantly receive once daily treatment of oral isotretinoin and topical AMZEEQ® for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
33006425|NCT04940767|Experimental|Treatment Group B|Patients will receive once daily treatment of oral isotretinoin for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
33006426|NCT04939116|Experimental|200 mg QD|200 mg of ANG-3070 will be taken once daily for 12 weeks.
33006427|NCT04939116|Experimental|400 mg QD|400 mg of ANG-3070 will be taken once daily for 12 weeks
33006428|NCT04939116|Experimental|300 mg BID|300 mg of ANG-3070 will be taken twice a day for 12 weeks.
33006429|NCT04939116|Placebo Comparator|Placebo|Placebo capsules will be taken once or twice daily for 12 weeks.
33006430|NCT04938804|Experimental|Screening group|
33006431|NCT04935593|Experimental|Renew Intervention Group|Participants in the group will receive training to help children strengthen social, emotional and behavioral knowledge and resilience.
33006432|NCT04935593|No Intervention|Parallel Control Group|Participants in the group will receive the usual bible lessons and activities
33006433|NCT04930614||Transgender and non-binary people|Adult transgender and non-binary people in Flanders and Brussels (Belgium)
33006434|NCT04929405|Experimental|Intervention group|This group has access to the intervention (website for bereaved parents)
33006435|NCT04928144|Experimental|0.025% SHJ002|0.025% SHJ002 Sterile Ophthalmic Solution
33006436|NCT04928144|Experimental|0.080% SHJ002|0.080% SHJ002 Sterile Ophthalmic Solution
33006437|NCT04928144|Experimental|0.25% SHJ002|0.25% SHJ002 Sterile Ophthalmic Solution
33006438|NCT04928144|Experimental|SHJ002 - Maximum tolerated concentration|Maximum tolerated concentration of SHJ002
33006439|NCT04928014||Screening Mammogram|Individuals eligible for a screening mammogram.
33006440|NCT04927793|Experimental|Single arm EDP-938|
33006441|NCT04926701|Experimental|Single ascending dose|Single dose of inhaled ETD001/placebo on one occasion
33006442|NCT04926701|Experimental|Multiple ascending dose (7 days)|Daily doses of ETD001/placebo for 7 consecutive days
33006443|NCT04926701|Experimental|Multiple ascending dose (14 days)|Daily doses of ETD001/placebo for 14 consecutive days
33006444|NCT04921527|Experimental|Chiauranib plus weekly paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most,Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
33105607|NCT04320160|No Intervention|Positive control group|Include the thirty patients before any treatment
33417474|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
33006445|NCT04921527|Placebo Comparator|placebo plus weekly paclitaxel|Patients receive the combined treatment of placebo plus paclitaxel, 21 days for a cycle, 6 cycles at most,placebo is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of placebo.
33006446|NCT04919239|Experimental|RUTI® arm|A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
33415481|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
33415482|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
33006447|NCT04919239|Placebo Comparator|Placebo arm|Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
33006448|NCT04917367||Conventional surgery group|Conventional surgery with Preoperative foreign body localization
33006449|NCT04917367||New surgery group|new surgery with Intraoperative localization of foreign body
33006450|NCT04916743|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
33006451|NCT04916743|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
33006452|NCT04916678|No Intervention|Control|The control period is a 5-day period during which no psychologist is available. ER cares will be provided as usual.
33006453|NCT04916678|Experimental|Intervention|The intervention period is a 5-day period during which trained psychologists are available in the ER and will provide a R-TEP EMDR intervention for patients selected with high risk of PCLS and who may provide psychotherapeutic care or reassurance to other patients should they be identified in need of help.
33006454|NCT04914377|Experimental|Active Drug|Capsules containing TQ Formula
33006455|NCT04914377|Placebo Comparator|Placebo|Capsules containing corn oil
33006456|NCT04911439|Active Comparator|Low Arousal|This group will see 25 affective images of the International Affective Picture System with low arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
33006457|NCT04911439|Active Comparator|Medium Arousal|This group will see 25 affective images of the International Affective Picture System with medium arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
33006458|NCT04911439|Active Comparator|High Arousal|This group will see 25 affective images of the International Affective Picture System with high arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
33006459|NCT04911257||Degenerate Disc Disease|Subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems.
33006460|NCT04909203|Experimental|iKinnect2.0|Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
33006461|NCT04909203|Placebo Comparator|Attention-Control Placebo App & Supporting Materials|Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
33006462|NCT04907487||SEP|With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
33006463|NCT04907487||NO SEP|For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
33006464|NCT04904172||Acute ischemic stroke who undergo intravenous thrombolytic and / or endovascular thrombectomy|Patients with acute ischemic stroke who applied to Ege University Emergency Service and decided to undergo intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments by a Neurology Specialist.
33006465|NCT04903821|Experimental|Group A (Child- Pugh A)|Participants with mild impaired hepatic function (Child-Pugh A), including at least 2 female participants.
33006466|NCT04903821|Experimental|Group B (Child-Pugh B)|Participants with moderate impaired hepatic function (Child-Pugh B), including at least 2 female participants
33006467|NCT04903821|Experimental|Control A match controls for group A|Matched control participants for Group A with normal hepatic function.
33006468|NCT04903821|Experimental|Control B match controls for group B|Matched control participants for Group B with normal hepatic function
33006469|NCT04902235|Experimental|CRH administration|Experimental: CRH administration
33006470|NCT04902235|Placebo Comparator|Placebo administration|Control: Placebo administration
33006471|NCT04900480|No Intervention|Public subsidy to physiotherapy continue as usual|This control arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, where the access and public subsidy to physiotherapy continue as usual.
33006472|NCT04900480|Experimental|Direct access to publicly subsidized physiotherapy|This intervention arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, introducing temporary exemption on the legal required general practitioner referral for public subsidy for treatment in general physiotherapy.
33415483|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
33006473|NCT04899843|Active Comparator|Experimental|This arm includes 61 acne vulgaris patients receiving topical retinoids
33006474|NCT04899843|Placebo Comparator|Control|This arm includes 61 acne vulgaris patients receiving topical retinoids
33415484|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
33415485|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
33415486|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
33006475|NCT04899687|Experimental|Group A: fluoxetine then fluoxetine plus dextromethorphan|Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
33006476|NCT04899687|Experimental|Group B: fluoxetine plus dextromethorphan then fluoxetine|Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
33006477|NCT04897802|Experimental|Experimental: GLP1-RA administration|A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns
33006478|NCT04897802|Placebo Comparator|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration
33006479|NCT04892628|Other|Aerobic training group|"The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.~Exercises will include:~Flexion, extension and abduction at the shoulder joint for anterior, middle and posterior fibers of deltoid~Flexion and extension at the elbow for biceps and triceps trachii~Flexion and extension at the knee joint for quadriceps and hamstring muscles~Plantar flexion at the ankle joint for gastrocnemius and soleus~Three sets of ten repetitions of each exercise will be done."
33006480|NCT04892628|Experimental|Resistance training group|"The intervention group will undergo a progressive resistance training program consisting of active muscle stretching and resistance training. Exercise for intervention group will consist of:~Resisted flexion, extension and abduction at the shoulder joint for anterior, middle and posterior deltoid, using dumbbells~Resisted flexion and extension at the elbow for biceps and triceps trachii, using dumbbells~Resisted flexion and extension of knee joint for quadriceps and hamstring muscles, using therabands~Resisted dorsiflexion and plantar flexion of gastrocnemius and soleus, using therabands~Resistance will be increased on basis of progressive overload principle. Three sets of ten repetitions will be performed per muscle group. Initial weight of the dumbbells will be 1kg and will be increased by 0.5kg per week."
33006481|NCT04891523|Other|Placebo-Probiotic|First receive placebo, then active probiotics.
33006482|NCT04891523|Other|Probiotic-Placebo|First receive active probiotics, then placebo.
33006483|NCT04889807||Patients who need fluid perfusion|
33006484|NCT04884100|Other|PPG recording|arrhythmia recording using PPG monitor
33006485|NCT04883749|Experimental|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
33006486|NCT04883086||diabetic group ( Case)|Total of 91 participants diagnosed with diabetes type 2
33006487|NCT04883086||Non diabetic group (control)|Total of 91 participants healthy and not diagnosed with diabetes Mellitus
33006488|NCT04882384|Experimental|Peripheral Nerve Block (PENG)|Patients will receive the Pericapsular Nerve Group Block.
33006489|NCT04882332||metformin usage index and vitamin B12 level|Samples for correlation between metformin usage index and vitamin B1 level will be withdrawn from 108 type 2 diabetes patients
33006490|NCT04882202|Experimental|Acetaminophen group|patients receiving acetaminophen
33006491|NCT04882202|Placebo Comparator|Placebo group|patients receiving equal amount of normal saline
33006492|NCT04882189||Capsulorhexis|Capsulotomies conducted by Capsulorhexis
33006493|NCT04882189||ZEPTO Precision Capsulotomy Device|Capsulotomies conducted by ZEPTO Precision Capsulotomy Device
33006494|NCT04881617|Experimental|Lexical Retrieval Treatment|
33006495|NCT04881617|Experimental|Script Training|
33006496|NCT04880460|Active Comparator|Experimental|45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
33006497|NCT04880460|Placebo Comparator|Control|45 MDD patients were included in this arm who were received SSRIs and placebo tablets
33006498|NCT04878913||C21|Subject treated with C21 in the VP-C21-006 trial
33006499|NCT04878913||Placebo|Subject treated with placebo in the VP-C21-006 trial
33006500|NCT04876924|Experimental|BBP-711 for SAD|A single dose of BBP-711 will be administered orally.
33006501|NCT04876924|Placebo Comparator|Placebo for SAD|A single dose of matching placebo will be administered orally.
33006502|NCT04876924|Experimental|BBP-711 for MAD|A dose of BBP-711 will be administered orally for multiple days.
33006503|NCT04876924|Placebo Comparator|Placebo for MAD|A dose of matching placebo will be administered orally for multiple days.
33006504|NCT04876924|Experimental|BBP-711 for SAD Food Effect|A single dose of BBP-711 will be administered orally.
33006505|NCT04876924|Placebo Comparator|Placebo for SAD Food Effect|A single dose of matching placebo will be administered orally.
33006506|NCT04871425|Experimental|Ketamine|Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
33006507|NCT04871425|Active Comparator|Fentanyl|Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
33006508|NCT04871217|Experimental|Acute ST-elevation myocardial infarction or chronic coronary artery occlusion|68-Ga-NODAGA-RGD PET after acute ST-elevation myocardial infarction or before and after re-opening of a chronic coronary artery occlusion
33006509|NCT04860791||Multiple Sclerosis patients|
33006510|NCT04858750|Other|Cook D-J stent group|"Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent.~Note: USI is an unexpandable acronym."
33006511|NCT04858750|Other|KYB anti-reflux D-J stent group|Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.
33006512|NCT04858750|Other|Urovision trigonal D-J stent group|"Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent.~Note: ST is an unexpandable acronym. Aibling is a German region name."
33006513|NCT04857528||Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)|This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).
33006514|NCT04857528||Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)|This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.
33105608|NCT04320160|Active Comparator|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
33415487|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
33417475|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
33006515|NCT04855045|Experimental|Group 1 - open label|
33006516|NCT04855045|Experimental|Group 2 - open label|
33006517|NCT04855045|Experimental|Group 3: open label|
33006518|NCT04855045|Experimental|Group 4: double-masked, randomized to one of 2 dose cohorts|
33006519|NCT04850807|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting
33006520|NCT04850807|Experimental|Music & Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences at early signs of agitation
33006521|NCT04838977|Experimental|RESET|Children will view 8 educational modules online and participate in 8 sessions with a therapist via telehealth.
33006522|NCT04838977|No Intervention|Control|Children will receive usual post-trauma care.
33006523|NCT04838197||Caregiver|If the caregiver agrees and consents to participating in the study, basic demographic and social data will be collected at baseline. The caregiver will also complete the caregiver burden questionnaire via telephone call at five different time points: pre-operatively, and post-operative 48 hours, 1 week, 2 weeks, and 1 month.
33006524|NCT04837092|Experimental|FR104 Treatment|
33006525|NCT04835844||Mapping with CARTO|CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
33006526|NCT04835844||Mapping with RHYTHMIA|RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.
33006527|NCT04835584|Experimental|Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
33006528|NCT04835584|Experimental|Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
33006529|NCT04835584|Experimental|Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
33006530|NCT04835584|Experimental|Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
33006531|NCT04835168|Experimental|BT-11 500mg|Oral
33006532|NCT04835168|Experimental|BT-11 1000mg|Oral
33006533|NCT04835168|Placebo Comparator|BT-11 Placebo|Oral
33006534|NCT04834128|Experimental|γδ T cells (IMP, TCB008)|Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).
33006535|NCT04831502|Experimental|Sequence 1: TAK 906 50 mg (Treatment A+Treatment B+Treatment A+Treatment B+Treatment C)|Participants will receive TAK-906 50 milligram (mg) as Treatment A (TAK-906 capsule) and Treatment B (TAK-906 tablet) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
33006536|NCT04831502|Experimental|Sequence 2: TAK-906 50 mg (Treatment B+Treatment A+Treatment B+Treatment A+Treatment C)|Participants will receive TAK-906 50 mg as Treatment B (TAK-906 tablet) and Treatment A (TAK-906 capsule) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
33006537|NCT04830514|Experimental|Recommended dietary allowance (RDA) for protein|(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
33006538|NCT04830514|Experimental|Habitual protein intake consistent with population level norms|(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
33006539|NCT04830514|Experimental|Optimal protein intake (OPI)|(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
33415488|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
33415489|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
33415490|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
33415491|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
33415492|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
33415493|NCT01340183|Experimental|AZD5099|IV Dose
33415494|NCT01340183|Placebo Comparator|Placebo|IV Dose
33417476|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
33417477|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
33417478|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
32866022|NCT04551599|Experimental|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fasted conditions.~Period 2: Danicopan administered under fed conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
32866023|NCT04551599|Experimental|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
32866024|NCT04825002|Experimental|Urinary multimarker sensor arm|A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)
32866025|NCT01448421|Experimental|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
32866026|NCT04557449|Experimental|1A Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
32866027|NCT04557449|Experimental|1A Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
32866028|NCT04557449|Experimental|1A Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
32866029|NCT04557449|Experimental|1A Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
32866030|NCT04557449|Experimental|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
32866031|NCT04557449|Experimental|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
32866032|NCT04557449|Experimental|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
32866033|NCT04557449|Experimental|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
32866034|NCT04557449|Experimental|2B Combination Dose Expansion|PF-07220060 with Letrozole Combination Expansion
32866035|NCT04557449|Experimental|2C Combination Dose Expansion|PF-07220060 with fulvestrant Combination Expansion
32866036|NCT04557449|Experimental|1D Monotherapy Food Effect|PF-07220060 Monotherapy Food Effect
32866037|NCT04557449|Experimental|1A Monotherapy Escalation Arm 5|PF-07220060 Monotherapy Escalation
32866038|NCT04824924|Experimental|HVAG regimen|
32866039|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
32866040|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
32866041|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
32866042|NCT04553705|Experimental|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA) (3% thymoquinone) per day for one month.~In addition to the standard care"
32866043|NCT04553705|Experimental|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.~In addition to the standard care"
32866044|NCT04553705|Experimental|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.~In addition to the standard care"
32866045|NCT04553705|Experimental|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.~In addition to the standard care"
32866046|NCT04553705|Experimental|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.~In addition to the standard care"
32866047|NCT04553705|Active Comparator|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
32866048|NCT04831866||Surveillance Cohort|Surveillance Cohort: Schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff.
32866049|NCT04831866||Exposure Cohort|Exposure Cohort: Schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with SARS-CoV-2 infection.
32866050|NCT02140151|No Intervention|Sham|Sham Injection
33417479|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
32866051|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
32866052|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
32866053|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
32866054|NCT04837872|Experimental|Multimodal Physical Therapy (MPT)|The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
32866055|NCT02135315|Experimental|intensive controle group|The end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
32866056|NCT02135315|Active Comparator|standard control group|The end point in these group was to maintain the systolic blood pressure under 140 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
32866057|NCT04837560|Experimental|Temporarily or permanently wheelchair users which suffer from Venous Edema|Temporarily or permanently wheelchair users which suffer from Venous Edema
32866058|NCT01894373|Experimental|CIK, psoriasis|
32866059|NCT04831632||people aged 50-75|men and women aged 50-75 who belong to Hospital El Cruce's coverage area and do not have personal history of colorectal cancer or inflammatory bowel disease, personal or family history of syndromes of predisposition to known cancers, or family history of colorectal cancer in a first-degree relative aged less than 60
32866060|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
32866061|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
32866062|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
32866063|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
32866064|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
32866065|NCT04824690|Experimental|Virtual Reality Group|The virtual reality group watched a 1.5-minute VR video showing the operating theater and explaining the perioperative process. After the surgery, this group watched cartoons during the first standard nursing procedures after the effect of the anesthesia wore off.
32866066|NCT04824690|No Intervention|Control Group|The control group received conventional care and education regarding the perioperative process of surgery.
32866067|NCT02117297|Experimental|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
32866068|NCT04837170|Experimental|S (+)-Ketamine group|"Drug: Conventional therapy + S (+)-Ketamine In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection,but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Bolus intravenous injection before skin incision, the dose is 0.1~0.5 mg/kg;~Bolus intravenous injection (dose 0.1~0.5 mg/kg) before skin incision +continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation;~Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h."
32866069|NCT04837170|Active Comparator|Control group|Drug: Conventional therapy Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
32866070|NCT02117063|Experimental|Go Girls! Fitness Support Group|
32866071|NCT04824612|Sham Comparator|Sham Group|"intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.) - two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.~Sham PBM in the preoperative and postoperative periods of keloid removal surgery: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month."
32901934|NCT05124132|Experimental|Exercise|The exercise protocol in the parent study (Protocol ID #201410093) was optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty. It consisted of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months. For the current study, participants will continue monthly approximately 1.5 hour classes focused on functional training for the duration of the study. Participants will be encouraged to continue between-session engagement in aerobic and resistance training activities at home.
33415495|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
33006540|NCT04828434|Experimental|Virtual Individual Cognitive Stimulation Therapy|"Virtual Cognitive Stimulation Therapy (V-iCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a warm-up activity, which includes an orientation task and discussion of current affairs, followed by a main activity.~V-iCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have experience in dementia care and will have completed the CST training."
33006541|NCT04828434|No Intervention|Treatment as usual|Standard care.
33006542|NCT04819854|Experimental|EP395|EP395 in ascending doses. Orally, once daily.
33006543|NCT04819854|Placebo Comparator|Placebo|Placebo, weight matched in ascending doses. Orally, once daily.
33006544|NCT04819815||Type 1 diabetes mellitus|"Patients~Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue (fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated."
33415496|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
33417480|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
33417481|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
33417482|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
33006545|NCT04819815||Healthy Controls|Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue ( fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated.
33006546|NCT04816747|Experimental|Autologous PRP|Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
33006547|NCT04809012|Experimental|STI-3031|20 mg/kg STI-3031 administered intravenously Q2W
33006548|NCT04807985||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
33006549|NCT04807725||Peri-implant health|Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.
33006550|NCT04807725||Peri-implantitis|Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.
33006551|NCT04804241|Experimental|10 mg daily Senicapoc|10 mg daily Senicapoc for 52 weeks
33006552|NCT04804241|Placebo Comparator|Placebo Group|Placebo daily for 52 weeks
33006553|NCT04803643||Patients|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
33006554|NCT04803643||Healthy controls|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
33006555|NCT04801459|Experimental|Antiperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The isoperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was consistent.
33006556|NCT04801459|Active Comparator|Isoperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The antiperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
33006557|NCT04800107|Experimental|Treatment Group|Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
33006558|NCT04800107|Placebo Comparator|Placebo Group|Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.
33006559|NCT04799405|Experimental|tDCS MDD|"A group of 5 participants with major depressive disorder (MDD).~tDCS, as a relatively simple and portable technology, is particularly well suited for remotely-supervised, home-based treatment, which would facilitate longer periods of treatment as well as offer a suitable therapeutic option at the present time as the investigators aim to deal with the COVID-19 pandemic."
33006560|NCT04798131|Experimental|Active|The visual feedback will correspond to instructions, adapted to the current hallucinatory state and decoded online from the fMRI signal.
33006561|NCT04798131|Sham Comparator|Sham|The visual feedback will correspond to random instructions independently of the fMRI signal.
33006562|NCT04795440|No Intervention|Eya-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the ejaculate (control group).
33006563|NCT04795440|Experimental|Test-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the testicle (study group).
33006564|NCT04794036|Experimental|Experimental Group|Telerehabilitation asynchronous programme at home
33006565|NCT04794036|Active Comparator|Control Group|Rehabilitation programme with an explanatory booklet at home
33006566|NCT04793867||CF and Non-CF Bronchiectasis|In the first arm (Aims 1 & 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.
33006567|NCT04793867||Healthy Subjects|Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.
33006568|NCT04792957||Pyoderma Gangrenosum|Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
33006569|NCT04792957||Hidradenitis Suppurativa|Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
33006570|NCT04792957||Psoriasis|Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
33006571|NCT04792957||Healthy Subjects|Skin biopsies obtained from patients with healthy subjects, will be used to control group.
33006572|NCT04790773|No Intervention|Standard of care|Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
33006573|NCT04790773|Active Comparator|Alexa Education|Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
33417483|NCT01318265|Experimental|Arm1|
33006575|NCT04788329|Experimental|Relaxation Group|This program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel.
33006576|NCT04788329|Experimental|Meditation Group|"This treatment group will be enrolled in Wim Hof Method, a meditation program. Patients in this group will take the online The Fundamentals Course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively"
33006577|NCT04788329|No Intervention|Standard Care Group|The control group will get the standard of care therapy after surgery.
33006578|NCT04787653|Active Comparator|Otoband efficacy on Tinnitus|"Participants will wear the Otoband on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Each participant will select his/her preferred stimulation level. The OtoBand will be programmed to operate at one of three power levels that are thought to be effective. The OtoBand will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
33006579|NCT04787653|Placebo Comparator|Placebo device efficacy on Tinnitus|"The placebo device will use the same case, headband and battery as the OtoBand. The transducer in the OtoBand will be rotated 90 degrees, so that the placebo device will vibrate in a direction ineffectual at providing bone conducted vibrations. The vibrations will be in the horizontal plane, parallel to the skull, and will not have their energy penetrating the skull all the way to the vestibular system. Each participant will select his/her preferred stimulation level. The placebo devices will be made to vibrate at one of three power levels, none of which are thought to be effective. The placebo will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
33006580|NCT04787380|Experimental|LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
33006581|NCT04787380|No Intervention|LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
33006582|NCT04787198|Experimental|hypertonic saline|
33006583|NCT04787198|Placebo Comparator|isotonic saline|
33006584|NCT04785781|Other|no mask|individuals perform cardiopulmonary test via cycle ergometer without mask till voluntary exhaustion
33006585|NCT04785781|Other|surgical mask|individuals perform cardiopulmonary test via cycle ergometer with surgical mask till voluntary exhaustion
33006586|NCT04785781|Other|N95/fpp2|individuals perform cardiopulmonary test via cycle ergometer with N95 mask till voluntary exhaustion
33325475|NCT03908112|Experimental|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
33325476|NCT03908112|Experimental|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
33325477|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
33006587|NCT04785352|No Intervention|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
33006588|NCT04785352|Experimental|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
33006589|NCT04785352|Experimental|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
33325478|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
33006590|NCT04780763|Active Comparator|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
33006591|NCT04780763|Placebo Comparator|Arm 2, Control: Milk-based non-fermented dairy product|
33006592|NCT04777279|Experimental|Individual physical exercise group|a 12-weeks physical exercise program (60 minutes/ three times weekly)
33006593|NCT04777279|Experimental|Individual Branched-Chain Amino Acids supplements group|a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
33006594|NCT04777279|Experimental|Combination of physical exercise and Branched-Chain Amino Acids supplements group|a 12-weeks physical exercise program (60 minutes/ three times weekly) and a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
33006595|NCT04777279|No Intervention|Control group|no intervention
33006596|NCT04776382|Experimental|Study Group|Trainees of this group will watch an EMME (Eye Movement Modeling Examples) pre-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
33006597|NCT04776382|No Intervention|Control Group|Trainees of this group will not watch the pre-recorded video
33006598|NCT04775966||The study population|Patients meeting eligibility criteria (see appropriate section).
33006599|NCT04775537||OssiMend™ Bioactive Moldable|Patients undergoing Lumber Spine Fusion
33006600|NCT04774315|Experimental|Omalizumab|
33006601|NCT04769479|Experimental|acoramidis|
33006602|NCT04768361|Experimental|Behavioral Activation without Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.
33006603|NCT04768361|Experimental|Behavioral Activation with Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and include mindfulness practices.
33006604|NCT04768335|Active Comparator|Patient group with schizophrenia|The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
33006605|NCT04768335|Active Comparator|Healthy control subjects|Healthy control subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
33006606|NCT04767802|Experimental|PTG-300|Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.
33006607|NCT04767503|Active Comparator|Propofol|Maintence of anesthesia during the operation using target control infusion with propofol 1mg/ml with bispetral index(BIS) in the range 40-60.
33006608|NCT04767503|Sham Comparator|Desflurane|Maintence of anesthesia during the operation using inhalational agent desflurane with 0.5 to 1.5 minimal alveolar concentration (MAC) with bispetral index(BIS) in the range 40-60.
33006609|NCT04766073|Experimental|New Closure Technique|This group will have the uterus closed after delivery of the fetus during cesarean section with a new technique.
33006610|NCT04766073|No Intervention|Regular closure technique|The usual method of closing the surgical incision is to suture the entire wall of the uterus with a stratafix suture without locking the suture.
33006611|NCT04763564|Experimental|Liraglutide then Placebo|Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
33006612|NCT04763564|Experimental|Placebo then Liraglutide|Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
33006613|NCT04761263|Active Comparator|Selected Physical Therapy group|will receive a selected physical therapy program for 90 minutes, 3 times/week for 3 successive months.
33105609|NCT04320160|Active Comparator|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
33325479|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
33325480|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
33325481|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
33415497|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
33415498|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
33415499|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
33415500|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
33415501|NCT05184491|Active Comparator|Naïve patients - ACO therapy|One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals).
33006614|NCT04761263|Experimental|Task-oriented circuit training group|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
33006615|NCT04760496|Experimental|Experimental group|The experimental group will receive oxytocin at 4 mIU/mL
33006616|NCT04760496|Active Comparator|Control group|The control group will receive oxytocin at 2 mIU/mL
33006617|NCT04759898|Active Comparator|Stimulation (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and transcranial direct current stimulation.
33006618|NCT04759898|Sham Comparator|Sham (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and sham transcranial direct current stimulation.
33006619|NCT04759898|Experimental|Stimulation (invasive recording)|Patients with Parkinson's disease undergoing surgery for deep brain stimulation will be studied using electrocorticography combined with transcranial direct current stimulation
33006620|NCT04755816|Sham Comparator|Control Group|Standard heart failure educational information.
33006621|NCT04755816|Experimental|Dietary Sodium Intervention|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
33006622|NCT04755816|Experimental|Clinical Worsening Intervention|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
33006623|NCT04755816|Experimental|Dietary Sodium and Clinical Worsening|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
33006624|NCT04754477|Experimental|Active Osseointegrated Steady-State Implant System (OSI)|
33006625|NCT04750967|Experimental|Active|Greater occipital nerve and supraorbital nerve block with 1% lidocaine once a week for first four weeks then once a month for 5 months
33006626|NCT04750967|Active Comparator|Control|Amitriptyline 25 mg daily for 6 months
33006627|NCT04749186|Active Comparator|Structured Didactic Model Group|A standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
33006628|NCT04749186|No Intervention|Standard Training Model|The standard local institutional teaching program
33006629|NCT04748497|Other|Parasportives of various disciplines|
33006630|NCT04748458||Congenital hip pathologies|Conical tapered stem for osteoarthritis due to congenital hip pathologies
33006631|NCT04743908|No Intervention|Social Network Strategy (SNS Condition)|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared."
33006632|NCT04743908|Experimental|Social Network Strategy + Messaging|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walk through and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared. Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language."
33006633|NCT04739956||Patient: point of care (POC) result not shared|Patients in this phase of the study will not be provided with the POC BhCG result. They will await the laboratory result. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
33105610|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
33105611|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
33415502|NCT05184491|Experimental|Naïve patients - LNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
33006634|NCT04739956||Partner: point of care (POC) result not shared|Partners in this phase of the study will not be informed of the POC BhCG result. They will await the laboratory result to be provided to the patient. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
33006635|NCT04739956||Patient: point of care (POC) result shared|Patients in this phase will be informed of the POC test result, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
33006636|NCT04739956||Partner: point of care (POC) result shared|Partners in this phase will be informed of the POC test result with the patient, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
33006637|NCT04736875||Dialysis|Patients with hemodialysis-dependent end-stage renal disease and a newly created native arteriovenous fistula
33006638|NCT04735315||Born preterm|"Inclusion :~Born preterm ≤29 weeks Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
33006639|NCT04735315||Born term|"Inclusion :~Born full-term at 37-41 weeks Birthweight ˃2500g Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
33006640|NCT04734444|Experimental|SonoClear acoustic coupling fluid (ACF) mimicking brain tissue|SonoClear
33006641|NCT04733547||Donor hepatectomy|Live donors undergoing hepatectomy
33006642|NCT04726124|Experimental|treatment group|Microwave Ablation Therapeutic Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous microwave therapy using Microwave Ablation Therapy Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months,12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
33006643|NCT04726124|Experimental|control group|Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months, 12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
33006644|NCT04725539|Experimental|Intermittent hypoxia (IH) pre-conditioning|"The IH pre-conditioning program will be performed in a sitting position by inhaling a gas mixture with reduced O2 content via face masks.The program will include five sessions per week for 3 weeks. Each session consists of three to five hypoxic (14-10% inspired fraction of oxygen) periods, each lasting 3-5 min with 3-min normoxic intervals.~The control setting includes breathing room air via face mask."
33006645|NCT04725539|Experimental|Hypoxia pre-adaptation|The hypoxia pre-adaptation program consists of sleeping 1 night at 1900m. The control setting includes sleeping 1 night close to sea level.
33006646|NCT04722744|Experimental|screwmented metal frameworks based on virtual implant position.|this group will receive a CAD CAM restoration based on virtually planned implant position.
33006647|NCT04722744|Active Comparator|screw-retained metal frameworks based on actual implant position.|this group will receive screw retained CAD CAM restoration based on actual implant position using conventional open tray impression.
33006648|NCT04722679||Patient|Elderly (defined as the ≥75 years old) patients with NVAF that are treated with a NOAC.
33006649|NCT04722679||Physician|Geriatricians (hospital or office-based).
33006650|NCT04721730|Experimental|PLH-YC|"The Parents will receive the optimised version of the Parenting for Lifelong Health for Young Children from 2-9 y. (PLH-YC) identified in Phase 2.~The groups will be conducted with 12 parents per group (with 2 facilitators). If local restrictions due to COVID-19 restrictions do not allow-in person meetings of this size, we will reduce the sample size (6 parents per group, and facilitator) and or conduct the groups online (e.g., using an online video software).~For each session, parents will receive a snack (or food voucher of same amount), childcare, transportation support (if needed), and a certificate at the end. Also, parents participating in at least four out of five PLH sessions will get a small gift. If the groups need be conducted online because of the COVID-19 pandemic, the parents will receive pre-paid data or another voucher of the same amount."
33105612|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
33105613|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
33105614|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
33006651|NCT04721730|Active Comparator|Lecture|"Parents will receive a lecture called Raising Healthy Children.~The lecture will be conducted with 12 parents per group (with one facilitator). If local restrictions due to COVID-19 pandemic will not allow in-person meetings, the groups will be online (e.g., using a video meeting software).~During the lecture, parents will receive a snack (or a food voucher of the same amount), childcare, transportation support (if needed), and a certificate at the end. If the lecture needs be conducted online because of the COVID-19 pandemic and associated restrictions, the parents will receive pre-paid data or another voucher of the same amount (instead of childcare, transport voucher and the snack)."
33006652|NCT04711603|Experimental|MR13A9/MR13A9|Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
33415503|NCT05184491|Experimental|Naïve patients - MNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
33415504|NCT05184491|Experimental|Treatment-experienced patients- LNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
33006653|NCT04711603|Placebo Comparator|Placebo/MR13A9|Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
33006654|NCT04709042|Experimental|Chordal tension measurement and cardiac Magnetic Resonance Imaging|All patient candidates for NeoChord implantation according to the standard of care will be considered for inclusion in this clinical study. Chordal tension measurement will be performed during Neochord implantation. Moreover, all patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
33006655|NCT04707235||Sickle cell disease patients treated with Siklos|
33006656|NCT04706676|Experimental|Integrative neuromuscular training + motivational counseling + usual care|General and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility.
33006657|NCT04706676|Active Comparator|Active control group + motivational counseling + usual care|home-based training program
33006658|NCT04703010|Experimental|All participants|All participants undergo the same measurements (longitudinal design)
33006659|NCT04698096||metabolic syndrome|Patients with metabolic syndrome
33006660|NCT04698096||Healthy volunteers|Healthy volunteers
33006661|NCT04696380|Experimental|High nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.
33006662|NCT04696380|Experimental|High nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.
33006663|NCT04696380|Experimental|Low nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.
33006664|NCT04696380|Experimental|Low nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.
33006665|NCT04695366||Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up|Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.
33006666|NCT04694196|Experimental|Locate occlusal plane|Use anatomical landmark to locate OP in dentulous subjects.
33006667|NCT04688671|Experimental|ETX-018810|
33006668|NCT04688671|Placebo Comparator|Placebo|
33006669|NCT04681859|Active Comparator|High Flow Nasal Oxygen (HFNO) treatment|
33006670|NCT04681859|Experimental|Continuous positive airway pressure (CPAP) therapy using OxyJet|
33006671|NCT04677660|Experimental|TAK-919|TAK-919 0.5 mL, intramuscular injection in the upper arm
33006672|NCT04677660|Placebo Comparator|Placebo|TAK-919 Matching Placebo, intramuscular injection in the upper arm
33006673|NCT04677517|Experimental|Implanted patients|All the participants are patients with post-lingual deafness and fitted with cochlear implants
33006674|NCT04677348|Experimental|PENG group|pericapsular nerve group (PENG) block before surgery
33006675|NCT04677348|Active Comparator|FICB group|suprainguinal fascia iliaca compartment block (FICB) before surgery
33006676|NCT04675320||Mutated BRCA epithelial ovarian cancer|
33006677|NCT04675320||Recurrent epithelial ovarian cancer|
33006678|NCT04672772||Recurrent and/or metastatic SCCHN|Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
33006679|NCT04671485|Active Comparator|ARM A : standard care|standard care : Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
33006680|NCT04671485|Active Comparator|ARM B : standard care + Autohypnosis|"In addition to the standard care, the patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
33006681|NCT04671485|Active Comparator|ARM C : standard care + Musicotherapy|"In addition to the standard care, the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
33006682|NCT04671082|Experimental|Tolperisone 50 mg|Tolperisone 50 mg
33006683|NCT04671082|Experimental|Tolpersione 100 mg|Tolperisone 100 mg
33006684|NCT04671082|Experimental|Tolperisone 200 mg|Tolperisone 200 mg
33006685|NCT04671082|Placebo Comparator|Placebo|Placebo
33105615|NCT04321447|Experimental|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
33105616|NCT04321447|No Intervention|Usual care group|Usual care
33105617|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
33105618|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
33006686|NCT04669587|Experimental|Part A: Dose Escalation of ZB716 monotherapy (with Food Effect Cohort)|Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 ~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
33006687|NCT04669587|Experimental|Part B: Dose Expansion of ZB716 monotherapy|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part B. For Part B, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined monotherapy RD of ZB716 (based on Part A) QD in a 28-day cycle. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
33006688|NCT04669587|Experimental|Part C: Dose Escalation of ZB716 in combination with palbociclib|Cohorts will follow a 3+3 study design. Approx. 6 to 12 subjects will be enrolled in the dose escalation phase of ZB716 in combination with Palbociclib. For Part C, doses will be administered at escalating doses starting with 1 dose level below the monotherapy RD (determined in Part A) and Palbociclib will be dosed at the fixed standard dose of 125 mg QD. ZB716 will be administered on a 28 day cycle and Palbociclib will be administered for 21 days in the cycle with 7 days off treatment. Administration of the higher dose level (at monotherapy RD) of ZB716 (with the standard dose of Palbociclib) to subsequent subjects will be based on the occurrence of DLTs during the DLT observation period (Cycle 1), until MAD of ZB716 with combination of Palbociclib is reached. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison.
33006689|NCT04669587|Experimental|Part D: Dose Expansion of ZB716 in combination with palbociclib|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part D. For Part D, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined RD of ZB716 QD for 28 days from Part C in combination with the standard dose of Palbociclib (125 mg QD for 21 days with 7 days off treatment). Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
33006690|NCT04668170||hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for SARS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management."
33006691|NCT04668170||healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
33006692|NCT04668092|Experimental|Functional dry needling|Functional dry needling for shortened hamstring muscle
33006693|NCT04662359|Other|Ultrasound Assessment of Rheumatoid Arthritis Severity|All patients will receive an ultrasound scan to assess the severity of their arthritis. This scan will then be placed in their medical record to allow their rheumatologist to utilize the scan when making treatment recommendations.
33006694|NCT04661592|Experimental|Control|Neurologically healthy individuals will be recruited for the longitudinal study
33006695|NCT04661410|Experimental|Reward Re-Training|10 weekly sessions of Reward Re-Training Group Therapy.
33006696|NCT04661410|Active Comparator|Supportive Therapy|10 weekly sessions of Supportive Group Therapy.
33006697|NCT04659941|Experimental|BCG vaccine|0.1 ml of the reconstituted vaccine to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
33006698|NCT04659941|Placebo Comparator|0.9% sodium chloride (NaCl) saline solution|0.1 ml of 0.9% NaCl saline solution to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
33006699|NCT04659382|Experimental|Single arm|XELOX + bevacizumab + atezolizumab + SIRT (Therasphere)
33006700|NCT04658953|Experimental|Ultrasound-guided infiltration|The patient is positioned in the prone position with a block under his stomach. After disinfection of the lumbosacral region with alcoholic chlorhexidine 0.5%, the investigators position the convex probe of the ultrasound machine in the transverse plane. Once the spine has been located, the investigators look for the spinous processes of the lower lumbar vertebrae L4 and L5 with the mark on the cranial side and the side opposite the mark on the side of the sacrum. The latter is visualized as a continuous hyperechoic line. Then, the probe is tilted 90 ° to be in a transverse plane. A 22G needle is introduced in a transverse axis starting from the laterality by inserting it in the direction of the median bone contacts of the lower lumbar vertebrae L3, L4 and L5. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels).
33006701|NCT04658953|Experimental|Fluoroscopy-guided infiltration|"The patient is positioned in the prone position with a block under his stomach. The lumbosacral region is disinfected with alcoholic chlorhexidine 0.5%.~The C-shaped arm of a X-ray fluoroscopy is positioned around the patient in an antero-posterior view tilted ¾ in order to free the classic view called scotty dogs . The puncture point is determined by the positioning of the needle in so-called tunnel vision. The needle is thus brought to the bone contact corresponding to the eye of the scotty dog in tunnel vision, an area corresponding to the passage of the lumbar median branch. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels)."
33006702|NCT04658823|Experimental|HOV-12020|Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)
33105619|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
32901935|NCT05124132|Experimental|Mindfulness-Based Stress Reduction + Exercise|This condition will receive both MBSR and exercise as described. Participants in this condition will attend monthly sessions with encouragement to complete at-home mindfulness practice as well as at-home exercise for the duration of the study.
33105620|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
33105621|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
33105622|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
33415505|NCT05184491|Experimental|Treatment-experienced patients- MNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
33415506|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
33415507|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
32901936|NCT05124132|Active Comparator|Health Education|The health education control condition is based on a chronic disease self-management program developed at Stanford University and was used as an attentional control in the parent study (Protocol ID #201410093). This control intervention was designed to be time-equivalent to MBSR, with 8 weeks of 2.5 hour weekly group classes followed by monthly booster sessions for approximately 15 months. For the current study, participants will continue monthly approximately 1.5 hour sessions covering similar content for the duration of the study.
32901937|NCT05621252|Experimental|PLN-74809|160 mg PLN-74809
32901938|NCT05621252|Placebo Comparator|Placebo|Placebo
32901939|NCT05008848|Experimental|Group I (SGR program, text messages)|Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
32901940|NCT05008848|Active Comparator|Group II (booklet)|Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
33105623|NCT04321096|Placebo Comparator|Placebo|2 pills 3 times daily for 5 days
32901941|NCT05617742|Experimental|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All patients will undergo whole-body 68Ga-FAPI-46 PET scan within two weeks before or after 18F-FDG-PET. Injected activity of 68Ga-FAPI-46 is limited to 100-250 MBq per examination.
33415508|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
33415509|NCT03540680|Other|Premature newborns|Blood punction on the cordon
33105624|NCT04321096|Experimental|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
33105625|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
32901944|NCT00515528|Experimental|Vaccine Alone|Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
32901945|NCT00515528|Experimental|Vaccine plus Ontak|Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration
32901946|NCT05007444|Placebo Comparator|Placebo comparator|Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
32902460|NCT05565625|Experimental|Sunscreen|Participants will receive two of six sunscreens (A, B, C, D, E, and F) at Visit 1 (Day 1) to apply to whole lower legs (1 sunscreen per lower leg), between the knee and ankle. Participant will then select one of the two sunscreens randomly assigned to lower legs and apply the selected sunscreen to full face. After lower legs and facial applications are completed, a trained designee will delineate six 4 centimeters (cm)*4 cm test sites on the participants' volar forearms (3 test sites per volar forearm). The six sunscreens will be randomly assigned to the six test sites at a dose of 2.00 +- 0.05 milligrams per centimeter square (mg/cm^2) using a 1cc tuberculin syringe (without a needle) and a clean finger cot for approximately 20 to 50 seconds and applied by a trained designee.
33105626|NCT04321018|Experimental|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
33105627|NCT04321018|Active Comparator|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
33105628|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
33105629|NCT04320784|Experimental|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
33105630|NCT04320784|Active Comparator|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
33105631|NCT04815252|Experimental|CHIME Intervention|Participants will complete an 8-week compassion and mindfulness-based intervention with a group facilitator. The curriculum focuses on providing mindfulness-based stress reduction techniques for use in the early childhood education environment.
33415510|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
33415511|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
33415512|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
33415513|NCT05187299|Experimental|Group with an observation tool|In this group (OT +), each student will complete an observer tool each time another dyad is performing
33105632|NCT04815252|No Intervention|Waitlist control|Participants are placed on a wait-list to receive the intervention.
33105633|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
32866072|NCT04824612|Experimental|Experimental Group|"Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). Frequency: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month.~Intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide: two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies."
32866073|NCT04824300|Active Comparator|erector spinae plane block group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.Group ESPB was applied before general anesthesia by the same anesthesiologist with block experience. In the sitting position, using an ultrasound-guided linear probe (6-13 MHz) on the side to be operated, T3 is marked 3 cm from the lateral of the spinous processes and with the in-plane technique, a 22G block needle (100mm, B-Braun, Germany) in the cranio-caudal direction first After it was observed that the erector spina muscle was separated from the transverse process with -2 ml normal saline, 20 ml 0.5% bupivacaine and 100 mg lidocaine were administered. And the drug was found to spread to the craniocaudal line at the ESP on ultrasound.Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
33105634|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
33105635|NCT04320706|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
33105636|NCT04320706|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
33415514|NCT05187299|No Intervention|Group without observation tool|In this group (OT-), the student will not use the observer tool and will observe other students without any physical support.
33415515|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
32866074|NCT04824300|No Intervention|non block control group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
32866075|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
32866076|NCT04831710|Experimental|Sintilimab+Chidamide|Participants will receive Sintilimab,200mg, ivd, d1; Chidamide,30mg,po,biw,d1-21; repeated every 3 weeks(up to 1 year) until disease progression, intolerable toxicity, death, or termination of the study for any reason.
32866077|NCT02101775|Experimental|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32866078|NCT02101775|Active Comparator|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32866079|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
32866080|NCT03037320|Other|group B|root coverage by coronally advanced flap
32866081|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution or tablets to be taken BID. Each cycle is defined as 28 days.
32866082|NCT04552769|Experimental|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
32866083|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
32866084|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
32902461|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
33105637|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
33105638|NCT03523819|Experimental|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
33006703|NCT04658823|Placebo Comparator|PLACEBO|Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)
33006704|NCT04657380|Active Comparator|Usual case management practices|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network of caring and non-caregiving professionals, working together with a view to the successful recovery of the patient. The patient and his or her family are at the center of care and receive proposals for psychoeducation and support throughout the different phases of the illness. This is concomitant with a regular evaluation of patients in order to update the care offer according to their clinical needs.
33006705|NCT04657380|Experimental|Mobile case-management application|"The intervention tested will be a mobile application used during consultations involving the patient and the case manager to define care objectives. The mobile application to be evaluated will result from the process of a co-design phase based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers. These stakeholders will define the content and form of the smartphone application during co-building workshops.~The main purpose of the final application will be to assist in the definition of patients' goals using an approach rooted in recovery theory, with the monitoring of goal achievement in three phases : 1) defining priorities for the patients, through a recovery oriented discussion with the patient and the case manager 2) Setting the concrete objectives and list concrete actions tho achieve them 3) evaluating the achievements."
33006706|NCT04655885|Experimental|Optimization of cardiac flow by base water-electrolyte supply|Optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
33006707|NCT04655885|Other|Control arm|Increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
33006708|NCT04649515|Experimental|TY027 1,500 mg|1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
33006709|NCT04649515|Experimental|TY027 2,000 mg|2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
33006710|NCT04649515|Placebo Comparator|Placebo|Placebo will be administered via IV infusion over a period of 30 minutes.
33006711|NCT04648787|Experimental|Intervention group: traditional nursing with family-integrated care|traditional nursing with family-integrated care
33006712|NCT04648787|Experimental|Control group: traditional nursing|traditional nursing
33006713|NCT04648371|Active Comparator|Cognitive Remediation and Active Transcranial Direct Current Stimulation|Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
33006714|NCT04648371|Sham Comparator|Cognitive Remediation and Sham Transcranial Direct Current Stimulation|CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
33006715|NCT04648241|Experimental|≥16 Years Old|TBE vaccine 0.5 mL (intramuscular injection).
33006716|NCT04648241|Experimental|1 to <16 Years Old|TBE vaccine 0.25ｍL (intramuscular injection).
33006717|NCT04648124||Patients for whom there is no planned implant surgery|
33006718|NCT04648124||Patients for whom implantation surgery is planned|
33006719|NCT04648124||case|
33006720|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
33006721|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
33006722|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
33006723|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
33006724|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
33006725|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
33006726|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
33325482|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
33105639|NCT04207567|Experimental|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
33105640|NCT04207567|No Intervention|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
33105641|NCT04923477|Experimental|Exercise Group|Therapeutic exercise of resistance and mobility training delivered by a trained health professional x 8 weeks.
33105642|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
33105643|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
33105644|NCT03512158|Experimental|High NCPAP|Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
33105645|NCT03512158|Active Comparator|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
33105646|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
33105647|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
33105648|NCT02896439|Experimental|Neurophysiological monitoring|
33105649|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
33105650|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
33105651|NCT04807842|Other|Active product|
33105652|NCT04807842|Placebo Comparator|Placebo|
33105653|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
33105654|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
33105655|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
33105656|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
33105657|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33105658|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
32866085|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
32866086|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
32866087|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
32866088|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
32866089|NCT02099591|Experimental|Age group: > = 12y to < 18y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
32866090|NCT02099591|Experimental|Age group: > = 12y to < 18y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
32866091|NCT02099591|Experimental|Age group: > = 6y to < 12y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
32866092|NCT02099591|Experimental|Age group: > = 6y to < 12y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
32866093|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
32866094|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
32866095|NCT02098265|Experimental|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
32866096|NCT02098265|Experimental|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
32866097|NCT02098265|Experimental|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
32902462|NCT01562041|Experimental|Ranolazine 500 mg|Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
32902463|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
32902464|NCT01519453|No Intervention|Control|There is no control arm specific intervention
32902465|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
32902466|NCT05565547||Patients with common eye diseases|Patients who have common eye diseases, including common anterior segment eye diseases (conjunctivitis, keratitis, corneal opacity, cataract) and fundus diseases (age-related macular degeneration, diabetic retinopathy) and refractive error (myopia, high myopia, hyperopia, anisometropia and presbyopia).
32902467|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms. These are considered the Topical Antimicrobial/Antifungal Medications
32902468|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1). Intervention is Sulfamylon® For 5 % Topical Solution.
32902469|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
32902470|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
32902471|NCT05559944|Experimental|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community. A general list of the types of stressors and contexts commonly described will be provided to participants, given that meta-analytic research supports that providing examples enhances the efficacy of expressive writing.
32902472|NCT05559944|Experimental|Self-Affirmation|Participants will respond to one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
32902473|NCT05559944|Placebo Comparator|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
32902474|NCT00565370|Experimental|A|XP+sorafenib
32902475|NCT00565370|Placebo Comparator|B|XP
32902476|NCT05559788||Participants With Multiple Myeloma|Participants with MM who are first relapsed and will start treatment with selinexor, daratumumab and dexamethasone in a real-world clinical practice setting will be observed prospectively for approximately up to 1 year.
32902477|NCT05559632|Active Comparator|conventional drilling group|drilling the other contralateral sites of bone using the conventional sequential drilling system according to the manufactural instruction.
32902478|NCT05559632|Experimental|osseodensification drilling group|bone preparation was performed using tapered multifluted burs (Densah Bur; Versah, MI, USA) at 800- 1200 rpm counterclockwise rotation under saline irrigation. Drilling to the desired depth using the tapered densah pilot drill with speed of 800-1200 rpm with copious irrigation without any lateral pressure with clock wise motion.
32902479|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
32902480|NCT03315182|Experimental|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
32902481|NCT03315182|Experimental|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
32902482|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
32902483|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
32902484|NCT00565916|Experimental|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
32902485|NCT00565916|Active Comparator|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
32902486|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
32902487|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
32902488|NCT05565469|Experimental|Neurostimulator group|Adjustment of neurostimulator settings to see whether or not abdominal stimulation can be provoked
32902489|NCT05559554|Experimental|AK104 (after the change)|Drug: AK104 (after the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
32902490|NCT05559554|Active Comparator|AK104 (before the change)|Drug: AK104 (before the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
32902491|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
32902492|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
33006727|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
33006728|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
33006729|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
33006730|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
33006731|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
33006732|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
33006733|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
33006734|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
33006735|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
33006736|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
33006737|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
33006738|NCT04640493|Experimental|SGLT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
33006739|NCT04635449|Active Comparator|Intervention|age-specific information, complemented by a follow-up targeted telephone call
33006740|NCT04635449|No Intervention|Treatment as usual|usual information given at PICU discharge
33006741|NCT04632810|Experimental|Ketogenic diet + weight loss|
33006742|NCT04632810|Active Comparator|non-Ketogenic diet + weight loss|
33006743|NCT04632810|Active Comparator|Ketogenic eucaloric diet|
33006744|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
33006745|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
33006746|NCT04625777|No Intervention|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
33006747|NCT04625777|Experimental|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
33325483|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
33325484|NCT03907722||Genotypic variants|AA, AG and GG genotype
33006751|NCT04624087|Experimental|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
33006752|NCT04624087|Experimental|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
33006753|NCT04624087|Active Comparator|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
33006754|NCT04622332|Experimental|SIR1-365|SIR1-365 dose 1 daily for 14 days
33006755|NCT04622332|Placebo Comparator|Matching placebo|Matching placebo dose 1 daily for 14 days
33006756|NCT04618692|Active Comparator|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
33006757|NCT04618692|Active Comparator|Microscope|In this group , patients will undergo biliary reconstruction using microscope
33006758|NCT04616027|Experimental|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
33006759|NCT04616027|Experimental|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
33006760|NCT04616027|Experimental|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
33006761|NCT04616027|Experimental|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
33006762|NCT04616027|Experimental|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
33006763|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]).
33006764|NCT04611100|No Intervention|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
33006765|NCT04611100|Experimental|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
33105659|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
32866098|NCT02098265|Active Comparator|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
32866099|NCT02098265|Active Comparator|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
32866100|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
32866101|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
32866102|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
32866103|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
32866104|NCT04274933|Experimental|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
32866105|NCT04274933|Experimental|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
32866106|NCT04394975|Experimental|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.
32866107|NCT04394975|Active Comparator|Control group|Sunitinib will be administered 50mg QD orally according to label recommendation (4 consecutive weeks followed by a 2-week off-treatment period,or 2 consecutive weeks followed by a 1-week off-treatment period), until treatment criteria are met.
32866108|NCT04757129||thrombolysis success group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
32866109|NCT04757129||thrombolysis failure group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
32866110|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
32866111|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
32866112|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
32866113|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
32866114|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
32866115|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
32866116|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
32866117|NCT02062463|No Intervention|Stage 1: Empty Spiromax Followed by Empty Turbohaler|Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices.
32866118|NCT02062463|No Intervention|Stage 1: Empty Turbohaler Followed by Empty Spiromax|Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices.
32866119|NCT02062463|Experimental|Stage 2: BF Spiromax|Participants who have currently received 800 to 1000 micrograms (μg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 μg and 18 μg, respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 μg and 36 μg, respectively.
32866120|NCT02062463|Active Comparator|Stage 2: Symbicort Turbohaler|Participants who have currently received 800 to 1000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 μg and 24 μg respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 μg and 48 μg respectively.
32866121|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
32866122|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
32866123|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
32866124|NCT02013479|Placebo Comparator|Placebo|Placebo
32866125|NCT04824456|Experimental|bilateral sagittal split osteotomy using chisels.|The final split is completed with Smith forceps and flag separators
32902493|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
33006766|NCT04609735|Experimental|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
33006767|NCT04609735|Active Comparator|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
33006768|NCT04609709|Experimental|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
33006769|NCT04609709|Active Comparator|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
33006770|NCT04609657|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
33006771|NCT04609657|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
33006772|NCT04609657|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
33006773|NCT04609657|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
33006774|NCT04609657|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
33006775|NCT04609657|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
33006776|NCT04608916|Active Comparator|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
33006777|NCT04608916|Experimental|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
33006778|NCT04607876|Active Comparator|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
33006779|NCT04607876|Other|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.~Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;~Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required~Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.~FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
33006780|NCT04606784|Experimental|Ampion|Ampion
33006781|NCT04606784|Other|Standard of Care|Standard of Care
33006782|NCT04606602|Experimental|30 mg|
33006783|NCT04606602|Placebo Comparator|Placebo|
33006784|NCT04606602|Experimental|100 mg|
33006785|NCT04606602|Experimental|300 mg|
33006786|NCT04606602|Experimental|600 mg|
33006787|NCT04606602|Experimental|900 mg|
33006788|NCT04606602|Experimental|100 mg multi dose|
33006789|NCT04606602|Experimental|200 mg multi dose|
33006790|NCT04606602|Experimental|300 mg multi dose|
33006791|NCT04606602|Experimental|600 mg multi dose|
33006792|NCT04606602|Placebo Comparator|Placebo multi dose|
33006793|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
33006794|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
33006795|NCT04603690|Experimental|Complementary therapy group|This arm will receive a daily supplementation of 168 mg curcumin, 260 mg quercetin and 9 mcg/360 IU of vitamin D3 (cholecalciferol) as add-on to the standard of care for 14-days
33006796|NCT04603690|Active Comparator|Control group|This arm will receive standard care alone
33006797|NCT04602078|Experimental|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
33006798|NCT04598360|Experimental|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
33006799|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
33006800|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
33006801|NCT04595097|Experimental|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
33105660|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
33415516|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
33415517|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
33006802|NCT04595097|Active Comparator|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
33006803|NCT04590651|Experimental|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
33415518|NCT01341509|Active Comparator|FHL tendon not transferred|
33006804|NCT04590651|Experimental|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
33006805|NCT04588857|Experimental|Active drug|dexamethasone 24 mg i.v., single dose
33006806|NCT04588857|Placebo Comparator|Placebo|saline i.v., single dose
33006807|NCT04580212|Experimental|Intervention arm|This arm received the poultry hygiene intervention.
33006808|NCT04580212|No Intervention|Control arm|This arm received no intervention.
33006809|NCT04579692|Experimental|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
33006810|NCT04577001|Experimental|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
33006811|NCT04577001|Placebo Comparator|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
33006812|NCT04575467|Experimental|CBL-514 320 mg|
33006813|NCT04575467|Experimental|CBL-514 480 mg|
33006814|NCT04575467|Experimental|CBL-514 640 mg|
33006815|NCT04575467|Experimental|CBL-514 800 mg|
33006816|NCT04573075|Other|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
33006817|NCT04573075|Active Comparator|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
33006818|NCT04573075|Experimental|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
33006819|NCT04569448|Experimental|Patient|Individuals diagnosed with Bipolar Disorder Type I and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
33006820|NCT04568733|No Intervention|Resting|
33006821|NCT04568733|Experimental|Pilates exercise session|
33006822|NCT04568733|Active Comparator|Treadmill walking at 3.2 kph|
33006823|NCT04568733|Active Comparator|Treadmill walking at 4.8 kph|
33006824|NCT04567264|Experimental|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
33006825|NCT04566887|Experimental|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
33006826|NCT04562831|Experimental|Newly diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)~Placebo"
33006827|NCT04562831|Experimental|Earlier diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Placebo"
33006828|NCT04545242|Active Comparator|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
33006829|NCT04545242|Active Comparator|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
33006830|NCT04544930|Experimental|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
33006831|NCT04543760|Other|[PP sequence 1] - Wash-out - [SP sequence 2]|
33006832|NCT04543760|Other|[SP sequence 1] - Wash-out - [PP sequence 2]|
33006833|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
33006834|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
33006835|NCT04537559||pre-COVID-19 period|Patients hospitalized between 1.3.2019 and 28.02.2020
33006836|NCT04537559||per-COVID-19 period|Patients hospitalized between 1.3.2020 and 28.02.2022
33006837|NCT04537559||post-COVID-19 period|Patients hospitalized between 1.3.2022 and 28.02.2023
33006838|NCT04532619|Experimental|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
33006839|NCT04532619|No Intervention|Control|Links to parenting websites
33006840|NCT04531085|Active Comparator|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
33006841|NCT04531085|Active Comparator|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
33006842|NCT04531085|Other|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
33415519|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
33415520|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
33415521|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
33415522|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
33415523|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
33415524|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
33415525|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
32866126|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32866127|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32866128|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
32866129|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
32866130|NCT04824222|Experimental|A - SOC+IMP|The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
32866131|NCT04824222|Placebo Comparator|B - SOC+placebo|Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).
32866132|NCT02049047|Experimental|Everolimus|oral everolimus
32866133|NCT04824378||label 1|Baseline data measurement of this group of patients: arm circumference（positive） and ICG (positive).
32866134|NCT04824378||label 2|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (positive).
32866135|NCT04824378||label 3|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (negative).
32866136|NCT05573789||Patients with prostate cancer|Patients with recurrent locally advanced, metastatic and/or high-grade operable prostate cancer and available formalin-fixed paraffin-embedded tumor tissue. Patients received treatment at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology. Tumor molecular profiling was performed.
32866137|NCT04778358|Experimental|OOCYTE DONORS|Administration of a higher dose of Rekovelle (follitropin delta) to increase the ovarian response to 17 oocytes (the optimal range being 15 to 25 oocytes) in an oocyte donor population without compromising safety and efficacy.
32866140|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
32866141|NCT01449747|Sham Comparator|control group|sitagliptin response patients
32866142|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
32866143|NCT05540717|Experimental|PQ Grass|6 subcutaneous injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU
32866144|NCT05540717|Placebo Comparator|Placebo|6 subcutaneous injections of placebo
32866145|NCT04837326|Experimental|Heel Lance Blood Sampling in Facilitated Tucking Position|The infants were put in facilitated tucking position by an experienced newborn nurse. They were put in facilitated tucking position so that their arms and legs were in a flexed midline position close to their trunk in a side-lying position. They were positioned so that they could move their extremities freely. They were held in facilitated tucking position for 120 seconds before the procedure. They were kept in facilitated tucking position until the blood sample was taken from the right heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
32866146|NCT04837326|Experimental|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|The mother, whose privacy was protected, embraced the infant for 120 seconds before the procedure. The infant was embraced by the mother during the heel lance blood sampling from the left heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
32866147|NCT04837326|Experimental|Heel Lance Blood Sampling Using White Noise|The 'Don't Let Your Baby Cry, PT.2' track from the 'Colic' album by Orhan Osman using the 'The Happiest Baby' album by Dr. Harvery Karp which was composed only of intrauterine was made listened to the infants via Xperia Ultra Mp3 Player for 120 seconds before and 120 seconds after the heel lance blood sampling procedure. While white noise was made listened to the infants before, during and after the procedure, Digital Sound LeverMeter brand noise measurement device was put at a distance of 50 cm from the infant and the ambient noise level was adjusted as 55 dB. The blood samples were taken by the researcher after inserting the lancet in the first try.
32866148|NCT04837326|No Intervention|Control Group|Suitable environmental conditions (ambient temperature, silent environment, etc.) were ensured in the study room for the infant's comfort. A saturation probe was inserted to the right wrist of the infant to monitor him/her. A video record was taken for 120 seconds without any intervention to the infants before and after the heel lance blood sampling procedure. The blood samples were taken by the researcher after inserting the lancet in the first try. Heel lance was performed in clinical routine for preterm infants in the control group.
32866149|NCT05460221|Active Comparator|Optimized oil group|Each participant will consume 25 mL/day during 6 months of an Optimized extra virgin olive oil obtained by mixing different varieties of oils rich in bioactive compounds (it contains approx. 490 ppm of bioactive compounds).
32866150|NCT05460221|Experimental|Functional oil group|Each participant will consume 25 mL/day during 6 months of a Functional olive oil prepared with the same Optimized oil and enriched with triterpenic acids obtained from the olive tree (approx. 490 ppm of polyphenols and 380 ppm of triterpenic acids).
33006843|NCT04531085|Other|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
33006844|NCT04530435|Experimental|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
33006845|NCT04530435|No Intervention|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
33006846|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
33006847|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
33006848|NCT04529499|Experimental|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
33006849|NCT04529499|Placebo Comparator|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
33006850|NCT04528433|Experimental|Medical-education-community Collaborated Intervention|
33006851|NCT04528433|Active Comparator|routine clinical care|
33006852|NCT04526132|Experimental|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
33006853|NCT04526132|Placebo Comparator|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
33006854|NCT04523428|Experimental|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
33006855|NCT04521920|Experimental|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
33006856|NCT04508504|Experimental|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
33006857|NCT04508504|Placebo Comparator|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
33006858|NCT04507633|Experimental|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
33006859|NCT04507633|No Intervention|control group|usual care
33006860|NCT04503382|Experimental|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
33006861|NCT04503382|Active Comparator|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
33006862|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
33006863|NCT04501094|Experimental|1/Arm 1-Treatment with Bintrafusp alfa (M7824)|Treatment with Bintrafusp alfa (M7824)
33006864|NCT04496284|Experimental|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
33006865|NCT04496284|No Intervention|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
33006866|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
33006867|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
33006868|NCT04490707|Experimental|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.~AZA -Azacitidine, LEN- Lenalidomide"
33006869|NCT04490707|Experimental|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.~AZA -Azacitidine"
33415526|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
33415527|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
33006870|NCT04490707|No Intervention|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
33006871|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
33006872|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
33006873|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
33006874|NCT04489485||Standard care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
33006875|NCT04489485||Enhanced care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
33006876|NCT04488913|Other|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
33006877|NCT04488913|Active Comparator|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
33006878|NCT04486170|No Intervention|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
33006879|NCT04486170|Experimental|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
33006880|NCT04483479|Experimental|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
33006881|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
33006882|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
33415528|NCT05163834|Experimental|Efgartigimod-1|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
33415529|NCT05163834|Experimental|Efgartigimod-2|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
33006885|NCT04476433|No Intervention|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
33105661|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
33105662|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
33105663|NCT04922424|Experimental|atorvastatin|We are testing that the lipid sensitive statin, atorvastatin treatment will reduce low density lipoprotein cholesterone, sympathetic nerve activity, increase endothelium-dependent vasodilation and improve autonomic function in trans men, while having little impact on cis women.
33415530|NCT05163834|Placebo Comparator|Placebo|Weekly placebo infusions and the pneumovax 23 vaccine on day 22
33415531|NCT05182619|Active Comparator|ultrasoung guided stellate block|stellate ganglion will have ultrasound-guided block via bupivacaine for sympathectomy and enhancement of cerebral blood flow
33415532|NCT05182619|Active Comparator|nimodipine infusion|intravenous nimodipine will be given for enhancement of cerebral blood flow
33415533|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
33415534|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
33415535|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
33006886|NCT04476433|Experimental|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
33006887|NCT04472468|Experimental|Treatment (pericardiotomy)|"Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.~Standard pericardiocentesis with prolonged drainage is performed afterwards.~Pericardial drain is removed when output is less than 100cc/day"
33006888|NCT04472468|No Intervention|Control (standard pericardiocentesis)|"Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.~Pericardial drain is removed when output is less than 100cc/day"
33006889|NCT04469517||HHT|patients with HHT
33006890|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
33006891|NCT04464577|Experimental|Arm A: BMS-986235+Fluconazole|
33006892|NCT04464577|Experimental|Arm B: BMS-986235+ Bupropion|
33006893|NCT04464577|Experimental|Arm C: BMS-986235+ Itraconazole|
33006894|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
33006895|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
33006896|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with >500 CD4 T cells/uL
33006897|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with <350 CD4 T cells/uL
33006898|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
33415536|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
33006900|NCT04454957|Experimental|Mastering Diabetes|Adults (hospital employees, their spouses, and community members) who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
33006901|NCT04454957|No Intervention|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
33006902|NCT04453384|Experimental|Treatment arm|"Administrations of XAV-19~Phase 2a: XAV-19 at 0.5 mg/kg at D1 and D5(Group 1) or at 2 mg/kg at D1 and D5 (Group 2), or at 2 mg/kg at D1 (groupe 3)~Phase 2b: Selected dose from Phase 2a : one administration at 2 mg/kg on day1"
33006903|NCT04453384|Placebo Comparator|Placebo arm|"same administration as treatment arm~Phase 2a: two administrations of placebo (day 1 and day 5) for Group 1 and 2, one administration of placebo on day 1 for Group 3~Phase 2b: one administration of placebo on day 1"
33006904|NCT04451213|Experimental|experimental|
33006905|NCT04448938||optic neuritis|
33006906|NCT04448938||control|
33006907|NCT04440774|Experimental|CHIK low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006908|NCT04440774|Experimental|CHIK mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006909|NCT04440774|Experimental|CHIK high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006910|NCT04440774|Experimental|ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006911|NCT04440774|Experimental|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006912|NCT04440774|Experimental|ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006913|NCT04440774|Experimental|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006914|NCT04440774|Experimental|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006915|NCT04440774|Experimental|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006916|NCT04440774|Placebo Comparator|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
33006917|NCT04434768|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
33415537|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
33415538|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
33415539|NCT02038244|Experimental|Integrative Medicine|
33006918|NCT04430517|Experimental|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
33006919|NCT04427397|Experimental|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
33006920|NCT04427397|No Intervention|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
33006921|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
33006922|NCT04418362|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
33006923|NCT04416867|Active Comparator|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
33006924|NCT04416867|Active Comparator|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
33006925|NCT04416867|Active Comparator|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
33006926|NCT04414618|Active Comparator|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
33006927|NCT04414618|Placebo Comparator|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
33006928|NCT04412824|Active Comparator|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
33006929|NCT04412824|Placebo Comparator|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
33006930|NCT04412057|Experimental|CERC-002|
33006931|NCT04412057|Placebo Comparator|Placebo|
33006932|NCT04408807|Experimental|Study Group|ROPEE screening with speculum-free fundoscopy
33006933|NCT04408807|Active Comparator|Control Group|ROPEE screening with speculum fundoscopy
33006934|NCT04408482|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
33006935|NCT04408482|Active Comparator|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
33006936|NCT04405115|No Intervention|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
33006937|NCT04405115|Active Comparator|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
33006938|NCT04402658|Experimental|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of [La-] and [Glucose].
33006939|NCT04402060|Experimental|180 mg APL-9 IV plus SOC|
33006940|NCT04402060|Placebo Comparator|Isotonic saline plus SOC|
33006941|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
33006942|NCT04393766|Experimental|normal saline|
33006943|NCT04393766|Placebo Comparator|non normal saline|
33006944|NCT04391179|Experimental|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
33006945|NCT04391179|Placebo Comparator|Placebo|Placebo given by mouth four times a day
33006946|NCT04388228|Experimental|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~A low cognitive load of the feedback where the results will be presented with the help of graphs.~Action plans to improve the quality of registration~A push system to minimize the effort the GP must make to consult the feedback."
33415540|NCT01315769||non pregnant nulliparous|Group 1
33415541|NCT01315769||primiparous women|Group 2
33415542|NCT05654090|Experimental|cefoperazone sodium and sulbactam sodium (Product name:Burotam)|Single dose Burotam
33415543|NCT05654090|Active Comparator|cefoperazone sodium and sulbactam sodium (Product name:Brosym)|Single dose Brosym
33415544|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
33415545|NCT04845503|Experimental|MR-guided Radiotherapy (5 x 7,5 Gy)|5 x 7,5 Gy prescribed on the PTV
33006947|NCT04388228|Active Comparator|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
33006948|NCT04386304|Experimental|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
33415546|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
33006949|NCT04386096|Experimental|Mehealth for ADHD software with medication continuity tools|
33006950|NCT04386096|Active Comparator|Mehealth for ADHD software with no medication continuity tools|
33006951|NCT04381169|Experimental|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
33006952|NCT04381169|Experimental|Moderate fluid resuscitation|"At recruitment:~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
33006953|NCT04376684|Experimental|Part 1: Participants receiving otilimab|Participants (age >=18 years and <=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
33006954|NCT04376684|Placebo Comparator|Part 1: Participants receiving placebo 1|Participants (age >=18 years and <=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
33006955|NCT04376684|Experimental|Part 2: Participants receiving otilimab|Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
33006956|NCT04376684|Placebo Comparator|Part 2: Participants receiving placebo 2|Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
33006957|NCT04375683|Experimental|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
33006958|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
33006959|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
33006960|NCT04367987||Patients undergoing colorectal surgery|
33006961|NCT04367116|Experimental|spinal cord stimulation|the spinal cord stimulation was performed and operated
33006962|NCT04363905|Placebo Comparator|Placebo|100 mg lactose capsule
33006963|NCT04363905|Experimental|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
33006964|NCT04362891|Experimental|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
33006965|NCT04362891|Experimental|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
33006966|NCT04362891|Experimental|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
33006967|NCT04362891|Experimental|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
33006968|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
33006969|NCT04357821|Experimental|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
33006970|NCT04356742|Experimental|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
33006971|NCT04356742|Placebo Comparator|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
33415547|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
33415548|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
33415549|NCT05183711||Nurse anesthetist|In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. The participant could download the self-evaluating form (google form, no personal identity record) via QR code.
33006975|NCT04353284|Experimental|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
33006976|NCT04353284|Placebo Comparator|Placebo|Placebo taken for 7 days.
33006977|NCT04350892|Active Comparator|Roux-en-Y Gastric Bypass Surgery|
33006978|NCT04350892|Active Comparator|Sleeve Gastrectomy Surgery|
33006979|NCT04350892|Active Comparator|Very Low Calorie Diet|
33006980|NCT04349358|Other|FDG and FCH PET/CT|
33006981|NCT04348864|Experimental|Positive-Antigen swab test for SARS-COV-2|Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Parallel PCR-based testing occurs in an advanced laboratory to obtain Ct values for positive test results.
33325485|NCT03912480|Experimental|Stem cells from human exfoliated teeth|"Basic treatment:~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).~Stem cell therapy:~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
33325486|NCT01248546||Digital mammography|
33325487|NCT03907956|Experimental|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
33006982|NCT04348864|Sham Comparator|Negative-Antigen swab test for SARS-COV-2|Subjects who have tested negative for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular nasal pharyngeal self-swab or a swab administered in a clinical setting by a trained clinician. PCR-based testing occurs in an advanced laboratory.
33325488|NCT03907956|No Intervention|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
33006985|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
33006986|NCT04337619|Experimental|Standard Behavioral Weight Loss Treatment|
33006987|NCT04337619|Experimental|Behavioral + Mindful Acceptance|
33006988|NCT04337619|Experimental|Behavioral + Values|
33006989|NCT04337619|Experimental|Behavioral + Mindful Awareness|
33006990|NCT04337619|Experimental|Behavioral + Acceptance + Values|
33006991|NCT04337619|Experimental|Behavioral + Acceptance + Awareness|
33006992|NCT04337619|Experimental|Behavioral + Values + Awareness|
33006993|NCT04337619|Experimental|Behavioral + Acceptance + Values + Awareness|
33006994|NCT04332783||Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
33006995|NCT04330807|Other|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
33006996|NCT04330807|Other|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
33006997|NCT04328012|Experimental|Losartan|losartan 25 mg po QD X 14 days
33006998|NCT04328012|Placebo Comparator|Placebo|placebo QD X 14 days
33006999|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
33007000|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
33007001|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
33007002|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
33007003|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.~study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise~study among pupils from 5 to 12 and their parents in elementary schools located in Oise~study among choir members"
33007004|NCT04325646||CORSER-2d|Staff of health care institutions
33007005|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
33007006|NCT04325646||CORSER-3|Subjects returning from a humanitarian mission that started before 31/01/2020
33007007|NCT04325646||CORSER-2f|Subjects with two symptomatic episodes of SARS-CoV-2 infection
33007008|NCT04325646||CORSER-4|Subjects being vaccinated against COVID-19
33007009|NCT04325646||CORSER-5|Subjects with acute SARS-CoV-2 infection and uninfected controls
33007010|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
33007011|NCT04310150|Experimental|Treatment arm label- Collastat®|
33007012|NCT04310150|Active Comparator|Control arm label- Floseal®|an marketed product is Floseal
33007013|NCT04307498|Other|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
33325489|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
33007014|NCT04306848|Experimental|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
33007015|NCT04305444|Experimental|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
33007016|NCT04303897||XEN Glaucoma Stent|
33007017|NCT04303663|Active Comparator|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
33007018|NCT04303663|Experimental|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
33007019|NCT04299061|Experimental|Study Group|
33325490|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
33007021|NCT04294914|Active Comparator|Fibromyalgia|Individuals with fibromyalgia.
33007022|NCT04294914|Experimental|Healthy controls|Healthy, pain-free individuals
33007023|NCT04294147|Experimental|Galcanezumab|Participants received a single subcutaneous (SC) dose of 240 milligram (mg) Galcanezumab.
33007024|NCT04294147|Active Comparator|Erenumab|Participants received a single SC dose of 140 mg Erenumab.
33007025|NCT04293276|Experimental|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
33007026|NCT04292873|No Intervention|Control|
33007027|NCT04292873|Experimental|Vitamin D|Enteral supplement of 569,600 IU vitamin D
33007028|NCT04289454|Other|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
33007029|NCT04269707|Other|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
33007030|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
33007031|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
33007032|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
33007033|NCT04264637|Experimental|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
33007034|NCT04264637|Experimental|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
33007035|NCT04264234|Experimental|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
33007036|NCT04263649||All subjects|patients who require a PICC
33007037|NCT04263246|Experimental|PhytoDyNAmic|Six capsules per day b.i.d.
33007038|NCT04263246|Placebo Comparator|Inulin|Six capsules per day b.i.d.
33007039|NCT04262687|Experimental|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
33007040|NCT04250597|Experimental|Part 1 Dose Escalation|Drug: GNX102 Dose Escalation: 21 day dosing interval
33007041|NCT04250597|Experimental|Part 2 Dose Escalation|Drug: GNX102 Dose Escalation: 7 day dosing interval
33007042|NCT04250597|Experimental|Part 3 Dose Expansion|Drug: GNX102 Dose Expansion: Selected dose level(s) and schedule(s) in expanded cohort(s)
33007043|NCT04245306|Experimental|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
33007044|NCT04245306|Active Comparator|Typically Developing children|A larger group of 150 typically developing children (TD)
33007045|NCT04245306|Experimental|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
33007046|NCT04244487|Experimental|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
33007047|NCT04244487|No Intervention|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
33007048|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
33007049|NCT04240197|Sham Comparator|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
33007050|NCT04240197|Active Comparator|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
33007051|NCT04239976|Experimental|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
33007052|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
33007053|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
33007054|NCT04238546|Experimental|Sirolimus-coated group|
33007055|NCT04238546|Active Comparator|Uncoated group|
33007056|NCT04238091|Active Comparator|Antibiotics prior to FMT|Participants will take a standardized regimen of antibiotics for three days prior to fecal transplant.
33007057|NCT04238091|Active Comparator|No Antibiotics prior to FMT|Participants will not take antibiotics before the transplant.
33007058|NCT04237155|Other|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
33007059|NCT04237155|Other|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
33007060|NCT04237155|Other|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
33007061|NCT04237155|Other|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
33007062|NCT04236531|Experimental|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
33007063|NCT04236531|Experimental|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
33007064|NCT04236531|Sham Comparator|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
33007065|NCT04236271|Experimental|patient|interventional group
33007066|NCT04233801|Experimental|Empagliflozin low dose|
33007067|NCT04233801|Experimental|Empagliflozin high dose|
33007068|NCT04233801|Placebo Comparator|Placebo|
33325491|NCT03912714|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
33007070|NCT04231825|Experimental|Verum Stimulation|This group will receive 6-Hz tACS
33007071|NCT04231825|Active Comparator|Frequency Control|This group will receive 1-Hz tACS
33007072|NCT04226976|Experimental|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
33007073|NCT04226976|Placebo Comparator|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
33007074|NCT04223570|Active Comparator|Ameluz (amino-levulinic acid topical gel) Only|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. This arm includes those participants who have not been prescribed photodynamic therapy and thus they will not receive any light treatment during this study.
33007075|NCT04223570|Active Comparator|Ameluz and Light Therapy|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. For patients who have been prescribed photodynamic therapy, the investigators will perform one additional round of measurements of Protoporphyrin IX using our camera device, in addition to the other secondary outcomes including skin temperature.
33007076|NCT04223479|Experimental|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
33007077|NCT04223479|Placebo Comparator|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
33007078|NCT04219878|Active Comparator|Know@Home App or Website and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app or website and will receive mail-out HIV self-testing kits.
33007079|NCT04219878|Active Comparator|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
32866151|NCT05460221|Placebo Comparator|Control Group|Each participant will consume 25 mL/day during 6 months of a Control extra virgin olive oil prepared from the same Optimized oil washed to eliminate bioactive compounds (approx. 125 ppm of polyphenols).
32866152|NCT04830930|Experimental|Sequence 1|Period 1: fasted condition/ Period 2: fed condition
32866153|NCT04830930|Experimental|Sequence 2|Period 1: fed condition/ Period 2: fasted condition
32866154|NCT04830540|No Intervention|Control|Participants assigned to the control group will be asked to continue wearing their typical shoes and to complete every two weeks the footwear and injury log provided
32866155|NCT04830540|Experimental|Intervention|Individuals assigned to the intervention group will be provided with 2 styles of the OOFOS recovery shoes, and will be asked to wear the OOFOS slide, sandal and/or closed toe shoes as their primary footwear outside training and competition for the 6 weeks between study visits. Intervention participants will also be asked to complete a daily shoe wear log and a shoe comfort assessment survey every other week.
32866156|NCT00054847|Active Comparator|Saphenous Vein Graft|Saphenous Vein Graft
32866157|NCT00054847|Active Comparator|Radial Artery Graft|Radial Artery Graft
32866158|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
32866159|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
33325492|NCT03912714|Active Comparator|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
32866160|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
32866161|NCT02024087|Experimental|Dalantercept 0.6 mg/kg plus sorafenib 400 mg|Cohort 1: Participants received dalantercept 0.6 mg/kg by subcutaneous (SC) injection once every 3 weeks plus sorafenib 400 mg orally (PO) once daily
32866162|NCT02024087|Experimental|Dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 2: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
32866163|NCT02024087|Experimental|Expansion cohort - dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 3: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
32866164|NCT04823832|Active Comparator|ERCP group|endoscopic retrograde cholangiopancreaticography with plastic stent insertion
32866165|NCT04823832|Active Comparator|PTD group|ultrasound guided percutaneous transhepatic catheter insertion
32866166|NCT04823520|Active Comparator|Group 15% concentration|30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.
32866167|NCT04823520|Active Comparator|Group 20 % concentration|30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face.
32866168|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
32866169|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
32866170|NCT04836702||Left ventricular function|"Depressed LV function~LV ejection fraction < 50%~LV systolic function; defined as mild / mod / sev decreased~LV diastolic function; defined as mild (g1 ) / mod (g2) / sev ( g3) decreased~Normal LV function"
32866171|NCT04836702||Right ventricular function|"Depressed RV function~a. RV systolic function defined as mild / mod / sev decreased~Normal RV function"
32866172|NCT04836702||Valvular lesions|"Moderate or severe valvular lesions~Aortic stenosis~Aortic regurgitation~Mitral stenosis~Mitral regurgitation~Tricuspid regurgitation~Clinically normal valvular lesions~No valvular lesion~Mild stenosis / regurgitation of above mentioned lesions"
32866173|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
32866174|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
32866175|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
32866176|NCT05618418||Hospital admitted patients with alcoholic hepatitis|"Inclusion criteria:~Age ≥ 18 Bilirubin > 50 micromol/L History of large alcoholic consumption in period prior to hospital admission (in the last six months) No bile-duct obstruction (investigated through US, CT og MRI)~Exclusion criteria:~Hepatocellulary carcinoma Viral hepatitis Autoimmune hepatitis Portal thrombosis Pregnancy Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors)"
32866177|NCT01517711|Experimental|Tramadol ER|Tramadol in an extended release formulation with an initial dosage of 100 mg daily, increased weekly over the next two weeks, as tolerated, to a maximum of 300 mg daily
32866178|NCT01517711|Placebo Comparator|Placebo capsule|Lactose encapsulated to match appearance of experimental drug
32866179|NCT04830384|Experimental|Fully Active|LLLT & Music Therapy
32866180|NCT04830384|Active Comparator|LLLT Only|LLLT Therapy
32866181|NCT04830384|Placebo Comparator|Music Only|Music Therapy
32866182|NCT04830384|Sham Comparator|Placebo|No Therapy
32866183|NCT04836078|Placebo Comparator|Plain chitosan gel group|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement . Randomization will be performed and concealment from the assessors. For root conditioning purpose, Group (I) ; will be injected subgingivally with chitosan 2% gel .
32866184|NCT04836078|Active Comparator|Chitosan gels containing free Simvastatin|Will be injected subgingivally with simvastatin microsponges dispersed into chitosan 2% gel. .
32866185|NCT04836078|Experimental|Chitosan gels containing Simvastatin microsponges|This group will be injected subgingivally with free simvastatin dispersed into chitosan 2% gel containing .
32866186|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
33007082|NCT04217746|Experimental|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
33007083|NCT04217746|No Intervention|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
33007086|NCT04212117|Other|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
33007087|NCT04212117|Other|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
33007088|NCT04206735|Experimental|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of NIV knowledge and skills through the principles of IPE and teamwork. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will promote and hold training sessions for their peers in person (if safety permits, 2-3 times a month for 4 months). At present, we are providing these training sessions as prerecorded content available whenever the clinician is available. Champions will promote the training to their clinicians for the first 4 months and then at 6 and 12 months for new staff.
33007089|NCT04206501|Experimental|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
33007090|NCT04206501|No Intervention|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
33007091|NCT04203433|Experimental|DLX105-DMP Multi-Dose Twice Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
33007092|NCT04203433|Experimental|DLX105-DMP Multi-Dose Once Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
33007094|NCT04186793|Experimental|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
33007095|NCT04186793|Experimental|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of <3% of total calories)."
33007096|NCT04182841|Other|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
33007097|NCT04181619|Experimental|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
33007098|NCT04181619|Placebo Comparator|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
33007099|NCT04180085|Experimental|BELATACEPT|
33007100|NCT04179565|Active Comparator|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
33007101|NCT04179565|Active Comparator|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
33007102|NCT04178772|Experimental|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
33007103|NCT04178187|Active Comparator|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
33007104|NCT04178187|Placebo Comparator|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
33007105|NCT04169490|Experimental|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
33007106|NCT04169490|Experimental|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
33007107|NCT04169451|Experimental|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days.
33007108|NCT04169451|No Intervention|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
33007109|NCT04169438|Placebo Comparator|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
33007110|NCT04169438|Experimental|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
33105664|NCT04922424|Placebo Comparator|Placebo|We are testing that the placebo will have little effect on low density lipoprotein cholesterone, sympathetic nerve activity, endothelium-dependent vasodilation, autonomic function in trans men or cis women.
33105665|NCT00550056|Experimental|1|NET
33105666|NCT00550056|Experimental|2|TC
33105667|NCT00550056|No Intervention|3|Monitoring Group
33105668|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
33325493|NCT03912714|Active Comparator|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
33007111|NCT04161040|Experimental|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
33007112|NCT04161040|Experimental|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
33007113|NCT04161040|No Intervention|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
33007114|NCT04159818|Experimental|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
33007115|NCT04159818|Experimental|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
33007116|NCT04159818|Experimental|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
33007117|NCT04157881|Other|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
33007118|NCT04157881|Other|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
33007119|NCT04155489|Active Comparator|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
33007120|NCT04155489|Experimental|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
33007121|NCT04152343|Experimental|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
33007122|NCT04151563|Experimental|Arm A: cabozantinib + nivolumab + ipilimumab|
33007123|NCT04151563|Experimental|Arm B: cabozantinib + nivolumab|
33007124|NCT04151563|Experimental|Arm C: nivolumab + ramucirumab + docetaxel|
33007125|NCT04151563|Experimental|Arm D: lucitanib + nivolumab|
33007126|NCT04151563|Experimental|Arm E: nivolumab + docetaxel|
33007127|NCT04151563|Active Comparator|Arm F: docetaxel|
33007128|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
33007129|NCT04142736|Experimental|Prone position|Patients with acute hypoxemic respiratory failure from any cause
33007130|NCT04142736|No Intervention|Supine position|Patients with acute hypoxemic respiratory failure from any cause
33007131|NCT04136990|Active Comparator|Isolated ACL reconstruction|Isolated ACL reconstruction only.
33007132|NCT04136990|Experimental|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
33007133|NCT04136262|Experimental|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
33007134|NCT04136262|Placebo Comparator|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
33007135|NCT04135859|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
33007136|NCT04135859|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
33007137|NCT04133922|Active Comparator|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
33007138|NCT04133922|Active Comparator|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
33007139|NCT04133922|Active Comparator|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
33007140|NCT04133077|Other|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
33007141|NCT04132050|Experimental|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
33007142|NCT04132050|Placebo Comparator|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
33007143|NCT04118049|Experimental|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.~RestoreTM gel: moisturizing personal lubricant.~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
33007144|NCT04118049|Other|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
33007145|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
33007146|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
33007147|NCT04117516|Active Comparator|Open surgery|30 patients will be operated with an open carpal tunnel release.
33007148|NCT04117516|Experimental|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
33007149|NCT04115761|Other|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
33007150|NCT04115761|Other|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
33007151|NCT04115059|Experimental|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.~Dasatinib: Oral Study Drug(s):~Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.~This will continue for up to 24 cycles."
33007152|NCT04114890|Experimental|Pregnant woman with second trimester and third trimester|
33007153|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
33007154|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
33007155|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
33007156|NCT04098484|Active Comparator|Normal-weight|Subjects with a BMI of 18-25 kg/m2
33007157|NCT04098484|Experimental|Obese|Subjects with a BMI of > 30 kg/m2
33007158|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
33007159|NCT04096066|Experimental|KRd (Experimental Arm)|"Carfilzomib (K):~20 mg/m2 IV on day 1 of cycle 1;~56 mg/m2 IV on days 8 and 15 in cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 on days 1 and 15 from cycle 13 and onwards.~Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
33007160|NCT04096066|Active Comparator|Rd (Control Arm)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Until PD or intolerance."
33007161|NCT04093388|Experimental|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
33007162|NCT04093388|Experimental|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
33007163|NCT04085042|No Intervention|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
33007164|NCT04085042|Experimental|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
33007165|NCT04082676|Experimental|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
33007166|NCT04082676|Active Comparator|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
33007167|NCT04081233|Experimental|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
33007168|NCT04081233|Active Comparator|Usual care|This arm will be usual care only. Usual care will include pain managment.
33007169|NCT04074824||Necrotizing enterocolitis|Neonates diagnosed with NEC based on the Modified Bell criteria for NEC including clinical, radiological and Laboratory findings.
33007170|NCT04074824||Non-NEC|Neonates diagnosed with other conditions including low birthweight, prematurity, infection, metabolic, cardiovascular, CNS, respiratory or gastrointestinal problems.
33007171|NCT04073667|Experimental|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
33007172|NCT04073667|Experimental|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
33007173|NCT04070131|No Intervention|Control Group|Regular follow ups.
33007174|NCT04070131|Experimental|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
33007175|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
33007176|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
33007177|NCT04053569|Experimental|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
33007178|NCT04053569|No Intervention|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
33007179|NCT04048824|Experimental|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
33007180|NCT04048824|Active Comparator|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
33007181|NCT04048642|Experimental|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
33007182|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
33007183|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
33007184|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
33007185|NCT04041609|Experimental|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
33007186|NCT04041609|Experimental|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
33007187|NCT04041609|Sham Comparator|Sham Procedure|In-office bilateral sham procedure
33007188|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
33007189|NCT04036994|Active Comparator|Experimental: Treatment group|
33007190|NCT04036994|No Intervention|Control group (no intervention)|
33007191|NCT04032782|Experimental|HM15136|
33007192|NCT04032782|Placebo Comparator|Placebo of HM15136|
33007193|NCT04030520|Experimental|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
33007194|NCT04030520|Active Comparator|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
33007195|NCT04012177|No Intervention|Control Arm|Arm-A: Standard antenatal care (ANC) counseling, service provision and nutrition counseling (World Health Organization (WHO) standard)
33007196|NCT04012177|Experimental|Nutrition only Arm|Arm-B:Balanced-energy protein (BEP), ready-to-use utrition supplement for at least 6 months + Standard ANC counseling, service provision and nutrition counseling (WHO standard)
33007197|NCT04012177|Experimental|Nutrition plus Azithromycin Arm|Arm-C:Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + 2000 mg of Azithromycin at week 20 and 28 of pregnancy + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
33007198|NCT04012177|Experimental|Nutrition plus Choline and Nicotinamide Arm|Arm-D: Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + Choline 450 and Nicotinamide 100 mg (1 each once daily orally starting from week 20 until birth outcome) + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
33007199|NCT04011995|Experimental|Intermittent caloric restriction|
33007200|NCT04011995|Active Comparator|Low carbohydrate diet|
33007201|NCT04007289|Active Comparator|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
33007202|NCT04007289|Placebo Comparator|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
33007203|NCT04004910|Experimental|Immunopheresis® - Arm 1|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient assigned to the treatment with LW-02 column-based Immunopheresis® will require central vascular access for the procedure. This part is alrady completed.
33007204|NCT04004910|Experimental|Immunopheresis® combined with low dose chemotherapy - Arm 2|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient will require central vascular access for the procedure. Patients also will receive a low dose chemotherapy regimen administered iv or oraly. Patients treated with combination will be administered their chemotherapy following the first LW-02 column-based Immunopheresis® procedure of each week starting from week 2, assuming first week of study treatment serves as a run-in period confirming good tolerance of Immunopheresis® alone.
33007205|NCT04004910|Active Comparator|Chemotherapy - Arm 3|Patients who are assigned chemotherapy arm of the study will be treated with low dose chemotherapy alone. The chemotherapy will be administered intravenously or oraly depending on the regimen used.
33007206|NCT04002934|Experimental|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
33007207|NCT04002934|Experimental|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
33007208|NCT04002518||3.0mm and 4.0mm|Patients who have surgically been treated with a 3.0mm or 4.0mm screw.
33007209|NCT04002518||5.0mm|Patients who have surgically been treated with a 5.0mm screw.
33007210|NCT04002518||6.5mm and 8.0mm|Patients who have surgically been treated with a 6.5mm or 8.0mm screw.
33007211|NCT04000334|Experimental|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4.
33007212|NCT04000334|Active Comparator|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm > 30 cm/s, Vd > 20 cm/s, PI < 1.4.
33007213|NCT03993249|Other|Chemoradiotherapy|standard of care chemo-radiotherapy
33007214|NCT03993249|Experimental|Combination|standard of care chemo-radiotherapy + Nivolumab
33325494|NCT03912402|Experimental|BCD-100|BCD-100 mg/kg Q3W
33325495|NCT03912246|Experimental|Healthy volunteers|"Human biological samples:~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
33325496|NCT03912246|Experimental|Patients with neuro-meningeal infection|"Human biological samples:~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Extended collection of CSF~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
33415550|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
33007215|NCT03991611|Experimental|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
33007216|NCT03991611|Other|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
33415551|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
33007217|NCT03991611|Active Comparator|Standard care|Standard care
33007218|NCT03991611|Other|PTSD-REA_COVID cohort|ICU admission between March 1, 2020 and April 30, 2020.
33007219|NCT03990883|Other|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
33007220|NCT03990883|Other|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
33007221|NCT03984890|Experimental|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
33007222|NCT03984890|Other|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
33007223|NCT03982459|Experimental|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
33007224|NCT03980834|Active Comparator|Professional Learning, Program Training and Coaching|
33007225|NCT03980834|Active Comparator|Program for Parents of Pre-K Students|
33007226|NCT03980834|Active Comparator|Program for Pre-K Students|
33007227|NCT03978780|Placebo Comparator|Control Group|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
33007228|NCT03978780|Experimental|Erector spinae plane (ESP) block group|Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
33007229|NCT03978104|Experimental|Okara biscuits|Subjects will consume their habitual diet with daily okara biscuit consumption accounting to 20 grams/ day of dry okara powder for 21 days.
33007230|NCT03978104|Experimental|Bio-okara biscuits|Subjects will consume their habitual diet with daily bio-okara biscuit consumption accounting to 20 grams/ day of dry bio-okara powder for 21 days.
33007231|NCT03978104|Experimental|Control biscuits|Subjects will consume their habitual diet with daily control biscuit consumption for 21 days.
33007232|NCT03973528|Experimental|traditional Chinese medicine|The experimental group use traditional Chinese medicine
33007233|NCT03973528|No Intervention|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
33007234|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
33007235|NCT03968081|Experimental|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
33007236|NCT03968081|Active Comparator|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
33007237|NCT03966742|Experimental|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
33007238|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
33007239|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
33007240|NCT03963388|Experimental|Intervention group|Speech therapy, right after T0 (baseline measurement).
33007241|NCT03963388|No Intervention|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
33007242|NCT03956498|Other|Patients with cervix or vaginal cancer|
33007243|NCT03956394|Other|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
33007244|NCT03956394|Other|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
33007245|NCT03952182|Active Comparator|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
33007246|NCT03952182|Experimental|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
33007247|NCT03948893|Experimental|MORE|
33007248|NCT03948893|Active Comparator|CBT|
33007250|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at <10 weeks gestation at a recruiting facility.
33007251|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
33007252|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
33007253|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
33007254|NCT03929588|Experimental|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
33007255|NCT03929588|Active Comparator|Manual Refraction|BCVA with phoropter
33007256|NCT03929588|Active Comparator|Automated Refraction|BCVA with autorefractoer
33007257|NCT03928678|Active Comparator|thefast track (FTS group)|
33007258|NCT03928678|Placebo Comparator|Thecontrolgroup|
33007259|NCT03926091|Experimental|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
33007260|NCT03926091|Active Comparator|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
33007261|NCT03924700|Experimental|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
33007262|NCT03924700|Active Comparator|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
33007263|NCT03924427|Experimental|BMS-986165|Given daily
33007264|NCT03922451||Pediatric patients supported on ECMO|
33007265|NCT03918629|Experimental|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
33007266|NCT03918629|Experimental|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
33007267|NCT03910491|Experimental|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
33007268|NCT03908073|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
33007269|NCT03908073|Placebo Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
33007270|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
33007271|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
33007272|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D&C).
33007273|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
33007274|NCT03907332|Experimental|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:~One visit during the second trimester of the pregnancy~Two visits during the third trimester of pregnancy"
33007275|NCT03907332|No Intervention|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
33007276|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
33007277|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
33007278|NCT03898843|Experimental|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
33007279|NCT03898843|Active Comparator|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
33007280|NCT03895541|Other|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
33007281|NCT03893448|Experimental|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
33007282|NCT03893448|Active Comparator|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
33007283|NCT03893253|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
33007284|NCT03893253|Active Comparator|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
33007285|NCT03893253|No Intervention|Control group|The control group will receive no booster teaching at all.
33007286|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
33007287|NCT03889314|Placebo Comparator|Placebo|
33007288|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
33007289|NCT03884166||stroke|
33007290|NCT03884166||control|
33415552|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
33007291|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
33007292|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
33007293|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
33007294|NCT03884023||AD group|Alzheimer's disease
33007295|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
33007296|NCT03884023||NC group|Normal Control
33007297|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
33007298|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
33007299|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
33007300|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
33007301|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
33007302|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
33007303|NCT03873792|Other|Allergy pregnant women|
33007304|NCT03873792|Other|Health pregnant women|
33007305|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
33007306|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
33007307|NCT03870880|Experimental|Risperidone ISM 75 mg|"Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
33007308|NCT03870880|Experimental|Risperidone ISM 100 mg|"Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
33007309|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
33007310|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
33007311|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
33007312|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
33007313|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
33007314|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
33007315|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
33007316|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
33007317|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
33105669|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
33007318|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
33007319|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
33007320|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
33105670|NCT02896634||group with none|Selection of samples from biobank with groups with none
33105671|NCT02896634||group with both|Selection of samples from biobank with groups with both.
33105672|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
32866187|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
32866188|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
32866189|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
32866190|NCT04830150|Experimental|supportive interventions group|Supportive and educational nursing interventions about reducing maternal stress levels in the experimental group included the following: the NICU was physically described to mothers on the first day they visited their infants, mothers were introduced to team members, and given information about how to obtain information about their baby, visiting hours and conditions.
32866191|NCT04830150|No Intervention|control group|Mothers did not have any other intervention applied by the researchers during routine operation while their infants were in the unit.
32866192|NCT01516619|Experimental|romiplostim|
32866193|NCT04823598|Active Comparator|Reference group|Coached pushing and Finnish manual perineal protection
32866194|NCT04823598|Experimental|Study group|Uncoached pushing and Hands-poised perineal protection
32866195|NCT00055237|Experimental|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
32866196|NCT00055237|Experimental|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
32866197|NCT04389749|Experimental|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
32866198|NCT04389749|No Intervention|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
32866199|NCT04309812|Active Comparator|Short Stimulation|1 minute duration of stimulation per day for 30 days
32866200|NCT04309812|Experimental|Long Stimulation|30 minutes duration of stimulation per day for 30 days
32866201|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
32866202|NCT01895699|Placebo Comparator|Placebo group|
32866203|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
32866204|NCT01451385|Experimental|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
32866205|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
32866206|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
32866207|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
32866208|NCT04363320|Experimental|High-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit (NIATx Training)~11 monthly (one-hour) NIATx coaching calls~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
32866209|NCT04363320|Experimental|Low-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
32866210|NCT04363320|Experimental|High-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit~11 monthly (one-hour) NIATx coaching calls"
32866211|NCT04363320|Experimental|Low-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
32866212|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for triple negative early breast cancer|Patients with triple negative subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
32866213|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for luminal like early breast cancer|Patients with luminal like subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
32866214|NCT04755959||Stroke|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of Ischemic Stroke, between the years 2016-2020 as documented in an institutionally approved data base of stroke, who will consent to provide access to their data from Google Take Out service.
32866215|NCT04755959||Acute myocardial infarction|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of acute myocardial infarction as documented in an institutionally approved data base of myocardial infarction, who will consent to provide access to their data from Google Take Out service.
32866216|NCT04755959||Healthy controls|Unaffected spouses or volunteers who will consent to provide access to their data from Google Take Out service.
32866217|NCT04836234|Experimental|intervention group|Participants will receive Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum. They will be instructed to chew the gum for pain relief after the separator and initial arch wire placement if required. Chew the gums for 10-12 minutes and as much as they want whenever they feel discomfort or pain. They are free to take any medication when necessary and respond to the questionnaires on the amount of chewing gum and analgesics used.
32866218|NCT04836234|No Intervention|Control group|Participants will not receive any prescription after the separators and initial arch wires placement. They will be specifically asked not to chew chewing gum. As in the intervention group, they can take any medication when they feel necessary and respond to the questionnaires on the amount of analgesics used.
32866219|NCT01463423|Experimental|Limited Primary Non-small Cell Lung Cancer (NSCLC)|Participants with limited primary NSCLCs (graded as T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0)
33007321|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
33007322|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
33007323|NCT03854461|Active Comparator|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
33007324|NCT03854461|Experimental|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
33007325|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
33007326|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
33007327|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
33007328|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week~Person with above symptoms that started at least 6 months before and continused for minimum 3 months~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease~Person who do not respond to at least 2 general treatments for FD~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
33007329|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
33007330|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
33007331|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
33007332|NCT03825536|Experimental|Oral methamphetamine|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the experimental treatment arm, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
33007333|NCT03825536|Placebo Comparator|Placebo oral capsule|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the placebo treatment arm, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
33007334|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
33415553|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
33007335|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
33007336|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
33007337|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
33007340|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
33007341|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
33007342|NCT03811574|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
33007343|NCT03811574|Placebo Comparator|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
33007344|NCT03811574|Experimental|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
33007345|NCT03811574|Placebo Comparator|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
33007346|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
33007347|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
33007348|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
33007349|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
33007350|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33007351|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33007352|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33007353|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33007354|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33415554|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
32866220|NCT01463423|Experimental|History of NSCLC|Participants with prior history of NSCLC and new limited primary NSCLC lesion(s)
32866221|NCT01463423|Experimental|Advanced Lung Cancer Including Metastatic Lung Cancer|Participants with more advanced lung cancer or lung metastases from a variety of different cancers.
33007355|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
33007356|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
33007357|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
33007358|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
33007359|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
33007360|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
33007361|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
33007362|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
33007363|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
33007364|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
33007365|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
33007366|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
33007367|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
33007368|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
33007369|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
33007370|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
33007371|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
33007372|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
33007373|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
33007374|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
33007375|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
33007376|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
33007377|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
33007378|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
32866222|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
33007379|NCT03760835|Experimental|Dual-release hydrocortisone|
33007380|NCT03760835|Active Comparator|Conventional glucocorticoids|
33007381|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
33007382|NCT03759184|Experimental|Arm 1 -DOSE ESCALATION|DOSE ESCALATION: Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the maximum tolerated dose (MTD)
33007383|NCT03759184|Experimental|Arm 2 - DOSE EXPANSION|DOSE EXPANSION: 3 to 6 patients to receive interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
33415555|NCT05183555|Experimental|Patients with definite IE will be included and referred for 18F-FDG PET/CT in the study|Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.
33415556|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
33007386|NCT03748784|Experimental|Dose 1|6E11 vg of ADVM-022
33007387|NCT03748784|Experimental|Dose 2|2E11 vg of ADVM-022
33007388|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
33007389|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
33007392|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
33007393|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
33007394|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
33007395|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
33007396|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
33007397|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
33007398|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
33007399|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
33007400|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
33007401|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
33007402|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
33007403|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
33007404|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007405|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007406|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007407|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007408|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007409|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
33007410|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
33007411|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
33007412|NCT03719170|Experimental|De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
33007413|NCT03719170|No Intervention|No De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
33007414|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
33007415|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
33007416|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
33007417|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
33007418|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
33007419|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
33007420|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
33007421|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
33007422|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
33007423|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
33007424|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
33007425|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
33007426|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
33007427|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
33007428|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
33007429|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
33007430|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
33007431|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
33007432|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
33007433|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
33007434|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
33007435|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
33007436|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
33007437|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
33007438|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
33007439|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
33007440|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
33007441|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
33007442|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
33007443|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
33007444|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
33007445|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
33007446|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
33007447|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
33007448|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
33007449|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
33007450|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
33007451|NCT03685422|Experimental|Virtual Reality|"Patients will be given a VR Gear Headset fitted with a smartphone, and will be offered to choose the calming scenario they wish to experience from a set of predefined scenarios before the surgery. They will be given time to experience VR for up to 25 mins. After the VR session, patients will be given questionnaires, satisfaction with VR, and pain scores.~After the surgery is completed, patient will be transferred to recovery room. Patients may resume VR session for up to 25 mins. After the use of VR, they will be asked on their satisfaction towards the VR experience, and also fill in questionnaires.~On the same day of surgery (0-24 hours post-op), patients will be asked to have another two more VR sessions (up to 25 mins per session), with questionnaire filled in after the sessions.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given.~All the headsets will be disinfected following the hospital's infection control guideline."
33007452|NCT03685422|No Intervention|Non Virtual Reality|"Before the surgery, only questionnaires and pain scores will be documented. After the surgery is completed, patient will be transferred to recovery room. Only questionnaires and pain scores will be documented.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given."
33007453|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
33007454|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
33007455|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
33415557|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
33007456|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
33007457|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
33007458|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
33007459|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
33007460|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
33007461|NCT03660839|Experimental|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
33007462|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
33007463|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
33007464|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
33007465|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
33007466|NCT03651102|Experimental|Thalidomide in combination with hydroxyurea|All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.
33007467|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
33007468|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
33007469|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
33007470|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
33007471|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
33007472|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
33007473|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
33007474|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
33007475|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
33007476|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
33007477|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
33007478|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
33007479|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
33007480|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
33007481|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
33415558|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
33415559|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
33415560|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
33007482|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
33007483|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
33007484|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
33007485|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
33007486|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
33007487|NCT03600116||Study Visit|After consent and enrollment, subjects with type 1 diabetes will arrive to the study visit having fasted the night before. Subjects will be given a meal, and will be given an insulin injection for this meal, calculated based on their prescribed meal to carbohydrate ratio as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL based on their prescribed insulin sensitivity factor. Following the insulin injection, subjects will eat breakfast and be observed in the clinic setting. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
33007488|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
33007489|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
33007490|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"240 mg of nivolumab 3 weeks before RT-Cisplatin~360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin~480 mg of nivolumab for maintenance"
33007491|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
33007492|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
33007493|NCT03575104|Experimental|Daridorexant 10 mg|
33007494|NCT03575104|Experimental|Daridorexant 25 mg|
33007495|NCT03575104|Placebo Comparator|Placebo|
33007496|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
33007497|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
33007498|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
33007499|NCT03573115|Experimental|Acne patients|
33007500|NCT03569982|No Intervention|Control|Patients receiving best supportive care
33007501|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
33007502|NCT03569475|Experimental|Levomilnacipran ER 40-80 mg/day|Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.
33007503|NCT03569475|Active Comparator|Fluoxetine 20 mg/day|Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.
33415561|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
33415562|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
33007504|NCT03569475|Placebo Comparator|Placebo|Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.
33007505|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
33007506|NCT03565380|Experimental|Patients without intervention|usual post-operative care
33007507|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
33007508|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~Cohort B: 6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
33007509|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Cohort B: Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
33007510|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
33007511|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
33007512|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
33007513|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
33007514|NCT03545191|Experimental|Daridorexant 25 mg|
33007515|NCT03545191|Experimental|Daridorexant 50 mg|
33007516|NCT03545191|Placebo Comparator|Placebo|
33007517|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
33007518|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
33007519|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
33007520|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
33007521|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
33007522|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
33007523|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
33007524|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
33415563|NCT05654012|Other|Family History of Migraine|This group has a first degree relative diagnosed with migraine.
33415564|NCT05654012|Other|No Family History of Migraine|This group does not have a first or second degree relative diagnosed with migraine.
33415565|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
33415566|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
33007529|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
33007530|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
33007531|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
33415567|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
33415568|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
33415569|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
33007532|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
33007533|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
33007534|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
33007535|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
33007536|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
33007537|NCT03500549|Experimental|Pegcetacoplan|1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.
33415570|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
33007538|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor.
33007539|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
33007540|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
33007541|NCT03495557|Sham Comparator|Control|Simple closure
33007542|NCT03495557|Experimental|Experimental|Simple closure + mesh
33007543|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
33007544|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
33007545|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
33007546|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
33007547|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
33007548|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
33007549|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
33007550|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
33007551|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
33007552|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
33007553|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
33007554|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
33007555|NCT03445559|No Intervention|Control|No intervention
33007556|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
33007557|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
33007558|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
33007559|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
33007560|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
33007561|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
33007562|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
33415571|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
33415572|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
33007563|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
33007564|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
33415573|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
33007566|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
33007567|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
33007568|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
33007569|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
33007570|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
33007571|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
33007572|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
33007573|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
33007574|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
33007575|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
33007576|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
33007577|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
33007578|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
33007579|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
33007580|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
33007581|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
33007582|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
33007583|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
33007584|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
33007585|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
33007586|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~PC visits will be scheduled on the same day as an oncology visit if possible"
33007587|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
33415574|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
33007588|NCT03366792|Experimental|MRI Targeted Biopsy|
33007589|NCT03366337|Experimental|Bardoxolone Methyl - ADPKD|Participants with autosomal polycystic kidney disease (ADPKD) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
33007590|NCT03366337|Experimental|Bardoxolone Methyl - IgAN|Participants with IgA nephropathy (IgAN) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
33415575|NCT05186831|Experimental|Text-based monitoring|Patients will be asked to take their BP two times daily and text their BP to the study phone number twice a day for 14 days.
33007591|NCT03366337|Experimental|Bardoxolone Methyl - T1D|Participants with Type 1 diabetes (T1D) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
33007592|NCT03366337|Experimental|Bardoxolone Methyl - FSGS|Participants with focal segmental glomerulosclerosis (FSGS) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
33007593|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
33007594|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
33007595|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
33007596|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
33007597|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
33007598|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
33007599|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
33007600|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
33007601|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
33007602|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
33007603|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
33007604|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
33007605|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
33007606|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
33007607|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
33007608|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
33007609|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
33007610|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
33007611|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
33007612|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
33007613|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
33415576|NCT05186831|Active Comparator|Online patient portal|Patients will be asked to take their BP two times daily. They will be given instructions on how to upload BP readings to the online patient portal and will be asked to upload all BP readings. This represents enhanced standard of care.
33415577|NCT01337375|Experimental|A/B|
33415578|NCT01337375|Experimental|C/D|
33105673|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
33105674|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
33007614|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
33007615|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
33007616|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
33007617|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
33007618|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
33007619|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
33007620|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
33007621|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
33007622|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
33007623|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
33007624|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
33007625|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
33007626|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
33007627|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
33007628|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
33007629|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
33007630|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
33007631|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
33007632|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
33007633|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
33007634|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
33007635|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
33007636|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
33007637|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
33007638|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
33007639|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
33007640|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
33007641|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
33007642|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
33007643|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
33007644|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
33007645|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
33007646|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
33007647|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
33007648|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
33105675|NCT00553748|Experimental|I|
33007649|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
33007650|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
33007651|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
33007652|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
33105676|NCT00551850|Experimental|1|
33105677|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
33105678|NCT00550095|Experimental|1|valsartan
33007653|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
33415579|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
33415580|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
33007654|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
33007655|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
33007656|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
33007657|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
33007658|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
33007659|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
33007660|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
33007661|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
33007662|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
33007663|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~Food voucher"
33007664|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
33007665|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC~Enrolled participants will receive monthly voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
33007666|NCT03229629|No Intervention|Control|Control group
33007667|NCT03226795|Experimental|interventional arm|
33007668|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
33007669|NCT03223974|Active Comparator|DES in MB|with regular techniques
33007670|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
33007671|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
33007672|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
33007673|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
33007674|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
33007675|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
33007676|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
33007677|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
33007678|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
33007679|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
33007680|NCT05438342|Experimental|synchronized hyperthermia autologous progenitor expansion -T (SHAPE-T)|Besides NCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with autoimmune cell therapy combined and noninvasive electromagnetic wave hyperthermia
33007681|NCT05438342|Active Comparator|systemic anti-cancer treatment plus Hyperthermia|BesidesNCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with noninvasive electromagnetic wave hyperthermia
33007682|NCT05438342|Active Comparator|systemic anti-cancer treatment|Only apply NCCN guideline recommended systemic anti-cancer treatment ( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy)
33007683|NCT05438316|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. /
33105679|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
33415581|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
33007684|NCT05438316|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33007685|NCT05438238|Experimental|investigational group A|during TVOR +PCB addition of Oncomfort, commercially available Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform IEC62366-1:2015, EN 62304:2006/Amd1:2015, EN 82304-1:2015, EN 82304-1:2016, ISO 13485:2016, EN ISO 14971:2019, EN 60601-1-2:2015
33007686|NCT05438238|No Intervention|reference group|standard of care TVOR + PCB
33007687|NCT05438108|Experimental|SBRT sequential chemotherapy, bevacizumab and sitilimab|
33007688|NCT05438082|Experimental|Antibiotic Prophylaxis|one dose of either Trimethoprim (if < 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg.
33007689|NCT05438082|Placebo Comparator|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
33007690|NCT05438004|Experimental|Ambulatory nice birth|Discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
33007691|NCT05437952|Experimental|Taurine and Exercise (Tau+Ex)|Participants who will receive 3g of taurine supplementation associated with physical training in the period of 16 weeks.
33007692|NCT05437952|Experimental|Placebo and Exercise (PL+Ex)|Participants who will receive 3g of placebo supplementation associated with physical training in the period of 16 weeks.
33007693|NCT05437952|Experimental|Taurine (Tau)|Participants who will receive 3g of taurine supplementation in the period of 16 weeks.
33007694|NCT05437952|Placebo Comparator|Placebo (PL)|Participants who will receive 3g of placebo supplementation in the period of 16 weeks.
33007695|NCT05437913|Other|Self compassion intervention|4 weeks group and online format self compassion intervention
33007696|NCT05437874|Placebo Comparator|Natural Water|"355 ml of water should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
33007697|NCT05437874|Active Comparator|Carbonated water|"355 ml of carbonated water should be drunk~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
33007698|NCT05437874|Experimental|Aspartame/acesulfame K|"355 ml of drink of diet coke should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
33007699|NCT05437874|Experimental|Saccharose|"355 ml of drink of regular coke should be drunk~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
33007700|NCT05437861|No Intervention|Treatment as usual|
33007701|NCT05437861|Experimental|Brief Intervention|
33007702|NCT05437783|Active Comparator|Healthy Bangladeshi Bangalee volunteers|Bangladeshi bangalee participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
33007703|NCT05437783|Active Comparator|Healthy Bangladeshi minor ethnics volunteers|Bangladeshi minor ethnics participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
33007704|NCT05437744|Experimental|Study group|
33007705|NCT05437744|Active Comparator|Control group|
33007706|NCT05437731|Experimental|Study group|
33007707|NCT05437731|Active Comparator|Control group|
33007708|NCT05437718|Other|Group NB (thoracic paravertebral block Group)|Thoracic paravertebral block(TPVB) is performed 20 minutes before the ablation surgery began,30 mL of 0.375% ropivacaine was totally injected in T3-4 and T5-6 spinal segment（the block segment can be adjusted according to the tumor site) under the ultrasound guidance.
33007709|NCT05437666|Experimental|Education group|The education program was given both an educational presentation and a booklet related to the pelvic floor health
33007710|NCT05437666|Other|Control group|The control group will be given a booklet related to the pelvic floor health
33007711|NCT05437653|Active Comparator|Control group|Healthy weight group ( same age and sex)
33007712|NCT05437653|Active Comparator|Obese group|Obese group
33007713|NCT05437627||Study Group:|Study Group: This will be consisted of sixty (60) stuttering patients. They will be divided into 2 subgroups; children group 30 patients with age ranges from (10-18y) and adult group 30 patients with age ranges from (19-30y)
33105680|NCT00550212|Experimental|1|240 mg
33415582|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
33415583|NCT04816799|Experimental|START|START (startle adjuvant rehabilitation therapy) will be applied.
33007714|NCT05437627||Control Group|Control Group: This will be consisted of sixty (60) subjects who have normal fluency. They will be selected from the relative of the patients attending to the outpatient clinic and will be matched for age, sex and socioeconomic state with the patients group.
33007715|NCT05437614|Active Comparator|Treatment of refractory glaucoma using Micropulse diode laser cyclophotocoagulation|
33007716|NCT05437614|Active Comparator|Treatment of refractory glaucoma using cyclocryoablation|
33007717|NCT05437549|Other|PVI|
33007718|NCT05437523|Experimental|Study group participants received a constipation action plan (USCAP)|"Received a personalized, pictographic, constipation action plan which detailed the subjects medications to manage functional constipation. The action plan was downloaded from:~https://wrnmmc.libguides.com/pediatrics/USAP~Watched a study group, specific, education video. Followed up in 4 months."
33415584|NCT04816799|No Intervention|Control|Subjects will train but without START
33415585|NCT04875455|Experimental|Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
33007719|NCT05437523|Active Comparator|Control|Received medications to treat functional constipation Did not receive a written action plan. Watched a control group, specific, education video. Followed up in 4 months.
33007720|NCT05437497|Experimental|Remimazolam group|"Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~Sedation induction before EUS-FNA/FNB: the initial dose of remimazolam is 0.15-0.2 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional remimazolam(0.05 mg/kg each time) is allowed. The injection time of additional remimazolam is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add remimazolam 0.05mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
33007721|NCT05437497|Active Comparator|Propofol group|"Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~Sedation induction before EUS-FNA/FNB: the initial dose of propofol is 1.5-2.0 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional propofol(0.5 mg/kg each time) is allowed. The injection time of additional propofol is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add propofol 0.5mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
33007722|NCT05437484|Experimental|Intervention group: peer-led BASICS session|Participants randomized to the intervention group received a peer-led BASICS session.
33007723|NCT05437484|No Intervention|Control group|Participants randomized to the control group did not receive any specific intervention.
33007724|NCT05437471|Active Comparator|Group A (GnRH analogue with Aromatase Inhibitor|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed by Letroloze 10mg OD for 3 months
33007725|NCT05437471|Active Comparator|Group B (GnRH analogue with Progesterone|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed Duphaston 10mg BD by for 3 months
33007726|NCT05437471|Placebo Comparator|Group C (GnRH analogue alone)|This is a control group. The candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) only.
33007727|NCT05437458||Persistent delirium|People with Parkinson's who have experienced persistent delirium (delirium lasting for ≥14 days) and will also be invited to interview.
33007728|NCT05437458||Non-persistent delirium|People with Parkinson's who have experienced non-persistent delirium (delirium lasting <14 days).
33007729|NCT05437458||No delirium (Control group)|People with Parkinson's who have never experienced delirium
33007730|NCT05437458||Carers for Qualitative Interview|Carers of people with Parkinson's who have consented to being interviewed.
33007731|NCT05437432|Experimental|Vita ambria onlay restoration|onlays constructed from zirconia-reinforced lithium disilicate glass ceramic press system
33007732|NCT05437432|Active Comparator|e.max onlay restoration|onlays constructed from lithium disilicate glass ceramic press system
33007733|NCT05437380|Experimental|CEUS|
33007734|NCT05437367|Other|posture correction exercises group 1|Group A (Control group 1): Participants using smartphones more than 4 hours per day will receive posture correction exercises only.
33007735|NCT05437367|Experimental|scapular stabilization and postural correction exercises group 1|Group B (Experimental group 1): Participants using smartphones more than 4 hours per day will receive scapular stabilization and postural correction exercises.
33105681|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
33105682|NCT02895932|Experimental|Control|Healthy adults
33415586|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
33415587|NCT01340963||Class I|Structurally normal heart, no bundle branch block
33415588|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
33007736|NCT05437367|Other|posture correction exercises group 2|Group C (Control group 2): Participants using smartphones less than 4 hours per day will receive posture correction exercises only.
33325497|NCT03908034|No Intervention|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
33007737|NCT05437367|Experimental|scapular stabilization and postural correction exercises group 2|Group D (Experimental group 2): Participants using smartphones less than 4 hours per day will receive scapular stabilization and postural correction exercises.
33007738|NCT05437341|Experimental|bi-4SCAR-PSMA/CD70 T Cell Therapy for CD70 and/or PSMA positive cancer|
33007739|NCT05437328|Experimental|bi-4SCAR-GD2/CD56 T Cell Therapy for GD2 and/or CD56 positive tumor|
33007740|NCT05437315|Experimental|bi-4SCAR-GD2/PSMA T Cell Therapy for GD2 and PSMA positive tumor|
33007741|NCT05437302|Experimental|interventional|prism spectacles prescribed
33007742|NCT05437302|Active Comparator|non interventional|presbyopia glasses prescribed
33007743|NCT05437237|Experimental|Dry electrode cap EEG|All patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
33007744|NCT05437224|Experimental|ambrisentan|Open Label
33007745|NCT05437185|Active Comparator|Active group|The investigators aimed for six sessions of anodal stimulation over the right DLPFC (F4 in 10-20 EEG system) with cathode above the left DLPFC (F3) using HDCstim by Newronika S.r.l., Italy. The therapy was administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 1.5 mA was delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, both 5x5cm (Current Density of 0.6 A/m2), for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system was used to determine the stimulation location, and dedicated EEG caps were used to ensure consistency between applications.
33007746|NCT05437185|Placebo Comparator|Sham group|The sham (placebo) was administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.
33007747|NCT05437172|Experimental|injectable platelet rich fibrin with deminerlized dentin graft|injectable platelet rich fibrin with deminerlized dentin graft for ridge preservation after teeth extraction
33007748|NCT05437172|Active Comparator|deminerlized dentin graft|deminerlized dentin graft for ridge preservation after teeth extraction
33007749|NCT05437146|Experimental|Puppet|pain and fear
33007750|NCT05437146|No Intervention|control|not pain and fear
33007751|NCT05437081|Experimental|EMERGE program|Participants were randomly assigned to one of two conditions: intervention or control. Intervention participants engaged in a 4 session program named the EMERGE program focused on identity development (emerging adults) or support for emerging adults (parents). Control participants received referrals to community agencies for behavioral and mental health support as needed.
33007752|NCT05437081|No Intervention|Referral services as needed|Participants were randomly assigned to one of two conditions: intervention or control. Control participants received services as usual.
33007753|NCT05436990|Experimental|vactosertib in combination with pembrolizumab|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
33007754|NCT05436964|Placebo Comparator|Placebo group|Use 250 ml of saline as placebo group.
33007755|NCT05436964|Experimental|Experimental group|Use dexmedetomidine as experimental group
33007756|NCT05436938|Experimental|Psoriasis patients with mild severity, treatment group|with Jing Si herbal tea liquid packets use
33007757|NCT05436938|Placebo Comparator|Psoriasis patients with mild severity, placebo group|without Jing Si herbal tea liquid packets use
33007758|NCT05436938|Experimental|Psoriasis patients with moderate to severe severity, treatment goup|with Jing Si herbal tea liquid packets use
33007759|NCT05436938|Placebo Comparator|Psoriasis patients with moderate to severe severity, placebo group|without Jing Si herbal tea liquid packets use
33007760|NCT05436912|Experimental|Healthy participants with normal hepatic function|Selpercatinib administered orally to healthy participants.
33007761|NCT05436912|Experimental|Participants with mild hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per Child-Pugh [CP] classification (CP Class A, score of 5 or 6).
33007762|NCT05436912|Experimental|Participants with moderate hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class C, score of 10 to 15).
33007763|NCT05436912|Experimental|Participants with severe hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class B, score of 7 to 9)).
33007764|NCT05436860||presence of hepatic hyperechogenicity on ultrasound evaluation|
33007765|NCT05436860||absence of hepatic hyperechogenicity on ultrasound evaluation|
33007766|NCT05436847|Experimental|Group A|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate) Proprioceptive Input- age appropriate (Pushups Static quadruped, squat sitting, trampoline, hopping etc. With weights and splints for joint to joint approximation)
33007767|NCT05436847|Active Comparator|Group B|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate)
33105683|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
33415589|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
33007768|NCT05436821|Experimental|Vagus nerve stimulation|"Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with waveform biphasic asymmetric, pulse duration 300 microseconds and frequency 25 hertz. AVNS application was made with Vagustim brand device.~The acute effect of the application was evaluated in both groups by isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed before and after the single session AVNS."
33007769|NCT05436821|Sham Comparator|Control group|"Sham Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with no pulse. AVNS application was made with Vagustim brand device.~Before and after sham AVNS isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed."
33007770|NCT05436782|Active Comparator|Group A|• Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises will be pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session will be of 60 minutes 5 times weekly for 6 weeks
33007771|NCT05436782|Experimental|Group B|Group B (experimental group) will receive routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals will be performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure will be measured at and 6th week interval
33007772|NCT05436756|Other|sampling and clinical data collection|"Biological sampling and collection:~whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~urine: 1 bottle of 30ml~Freezing of serum after centrifugation~Storage at Biological Ressources Center~Collection of clinico-biological data on a dedicated eCRF"
33007773|NCT05436743|Experimental|K-Y jelly soaked packs|K-Y jelly soaked packs inserted for pretension of postoperative sore throat
33007774|NCT05436743|Active Comparator|Water soaked packs|Water soaked packs inserted for pretension of postoperative sore throat
33007775|NCT05436730||"Escape Phenomenon of the Antihypertensive Therapy Efficacy"|Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
33007776|NCT05436704||EUS-FNB|
33007777|NCT05436691|Experimental|Information and Coping with Anxiety Training Intervention|The intervention group received information and coping with anxiety training by an instructor.
33007778|NCT05436691|No Intervention|Control|No intervention was applied to the control group.Data were collected from the control group simultaneously with the study group.
33007779|NCT05436574|Other|Before/after study|Before/after study to measure the effects of the implementation of a dance therapy activity on the quality of life of the elderly population
33007780|NCT05436548|Experimental|Brief and frequent Work-life check-ins between clinic supervisors and each staff member|Primary care clinics assigned to the intervention will conduct frequent (every 8 weeks) supervisor-employee brief (30 min) check-ins to identify work stressors. Supervisors at such clinics will complete training on how to use the check-ins to address work stressors.
33007781|NCT05436548|Experimental|Usual practice, waitlist controls|Primary care clinics randomly assigned to the control condition will continue as usual practice. If the check-is are effective in reducing burnout, then supervisor-level training will become available to supervisors at the end of the study
33007782|NCT05436509|Experimental|bi-4SCAR-CD19/79b T Cell Therapy for CD19 and/or CD79b positive B cell malignancies|
33007783|NCT05436496|Experimental|bi-4SCAR-CD19/70 T Cell Therapy for CD19 and/or CD70 positive B cell malignancies|
33007784|NCT05436457||18-24 Year Olds in Emergency Department|Individuals age 18-24 recruited from one of the four study sites in Flint (1 hospital), Seattle (1 hospital), and Philadelphia (2 hospitals)
33007785|NCT05436405|Experimental|transpedal access|Trans-pedal Access for Endovascular Revascularization in patients with failed antegrade access forComplex Infra-popliteal Lesions in Critically Ischemic Limb
33007786|NCT05436613|Experimental|Device: transcranial direct current stimulation|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
33007787|NCT05436184||Cincinnati IMPRINT birth cohort|mother-infant pairs enrolled at or after week 34 in pregnancy and followed over three flu seasons, up to four years of age.
33007788|NCT05431738|Active Comparator|STENT WITH ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent with anti-migration device : Ella®, Leufen, Novatech
33007789|NCT05431738|Active Comparator|STENT WITHOUT ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent without anti-migration device : Hanarostent® ECW, Life Partners Europe
33007790|NCT05429229|Experimental|Q10 coenzyme, vitamin E and cross-linked hyaluronic acid|This arm will administer eye drops with a combination of cross-linked hyaluronic acid, Q10 coenzyme and vitamin E, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
33007791|NCT05429229|Active Comparator|Sodium hyaluronate|This arm will administer eye drops with sodium hyaluronate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
33007792|NCT05429229|Active Comparator|Sodium hyaluronate and chondroitin sulfate|This arm will administer eye drops with a combination of sodium hyaluronate and chondroitin sulfate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
33007793|NCT05429099|Active Comparator|Free-Hand Surgery (FHS)|In FHS, the site surgeon will proceed with the surgery as per their routine practice.
33415590|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
33007794|NCT05429099|Experimental|Virtual Surgical Planning (VSP)|The trial research engineer (RE), located at Vancouver General Hospital (VGH), will segment the CT data to create a 3D model for surgical planning. During the teleconference between site surgeon (SS) and RE, the RE will load the CT data and the segmented 3D model into the virtual planning environment. With the RE navigating the software, which was created in-house at VGH and used in a previous case series, the SS will determine the extent of disease and define the resection planes. After the cutting planes are created, the RE will use the software to create the reconstruction plan with either the patient-specific fibula or scapula. Once the surgeon is satisfied with the plan, the teleconference will end and the RE will create and 3D print the surgical guides for the mandible, for the fibula or scapula, as well as the 3D computed reconstruction.
33007795|NCT05428618|Experimental|e-BariS app Group|"Self-Monitoring Module and Patient Education Module"
33007796|NCT05428618|Sham Comparator|Self-Monitoring Group|"Self-Monitoring Module"
33007797|NCT05427643|Experimental|study group|"patients need dental implants with narrow alveolar ridge of less than 6 mm horizontal width .~they will receive dental implants with I_PRF mixed with synthetic bone graft."
33007798|NCT05427643|Experimental|control group|patients need dental implant with adequate horizontal bone with of more than 6 mm.
33007801|NCT05426811|Experimental|Regorafenib combined with Raltitrexed|"Regorafenib:~120mg/d，Po，qd,d1-d21，Every 4 weeks~Raltitrexed:~3mg/㎡，ivgtt，d1，Every 3 weeks"
33007802|NCT05426369|Experimental|Dose Escalation|For single dose escalation, the dose level will be 2µg/kg -15 µg/kg.
33007803|NCT05426369|Experimental|Dose Expansion - Group A|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly (group A) for a treatment cycle(21 days).
33007804|NCT05426369|Experimental|Dose Expansion - Group B|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly ( group B )for a treatment cycle(21 days).
33007805|NCT05426369|Experimental|Dose Expansion - Group C|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered twice weekly (C group) for a treatment cycle(21 days).
33007806|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 1|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
33007807|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 2|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
33007808|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 3|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
33007809|NCT05424250|Experimental|Exposure + occasional aversive imagination|repeated imaginations of the participants' most feared apprehension during extinction training with seven standardized exposure steps
33007810|NCT05424250|Active Comparator|Exposure|Standard extinction training with seven standardized exposure steps
33007811|NCT05423600|Experimental|BES+TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
33007812|NCT05423600|Experimental|BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
33007813|NCT05422651||patients with fever|All subjects will receive the currently recognized routine test of fever according to their disease and corresponding etiological treatment if needed and no additional intervention and treatment will be added for subjects
33007814|NCT05422352|Experimental|intervention Group|Patients who will receive carnosine supplementation + Vitamin B complex two tablets per day
33007815|NCT05422352|No Intervention|Control group|Patients will receive only Vitamin B Complex two tablets per day
33007816|NCT05419765||non-cirrhotic NAFLD, carriers of the PNPLA3 I148M variant|Italian Caucasians, aged> 18 and <70 years, with non-cirrhotic NAFLD and carriers of the PNPLA3 I148M variant
33007817|NCT05419765||non-cirrhotic NAFLD, carriers of the wild type allele|Italian Caucasian subjects, aged> 18 and <70 years, with non-cirrhotic NAFLD and carriers of the wild type allele
33007818|NCT05404022|Experimental|Intervention arm|12 weeks home based tailored nutrition and physical activity (PA) programme Participants will have an appointment (face-to-face if possible) with the study physiotherapist and dietitian for delivery of the PA (including breathlessness management) and nutrition intervention components. Participants will receive study equipment at these appointments (or by post) including paper-based tracking diary, resistance bands for strength exercises, a Fitbit activity monitor to track steps and aerobic activity during the study period, nutritional supplements (if prescribed), and printed study materials (if preferred over pdf emails; e.g. cooking tips, recipes). A video/telephone follow-up call (10-15 minutes) will be conducted by the research team with the participant at weeks 2,3,4,5 and 6 and then at weeks 8,10 and 12 to review and adjust their programme (with input from the physiotherapist and dietitian if required).
33007819|NCT05404022|No Intervention|Usual care arm|The usual cancer care will include usual patient management and care prior, during and after cancer treatment - medication, symptom control, cancer advice and support from routine medical and nursing input with access to Allied Health Professionals (AHPs) such as physiotherapists and dietitians as clinically indicated. As part of this, it is common for older adults with cancer to be prescribed high protein supplementation. Control participants will receive a general information leaflet regarding activity and nutrition.
33007820|NCT05400304||Training dataset|No interventions
33007821|NCT05400304||External validation1|No interventions
33007822|NCT05400304||External validation2|No interventions
33007823|NCT05397431||Lanadelumab|Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.
33007824|NCT05393089|Experimental|AGN-190584|Participants will receive one drop of AGN-190584 instilled in each eye once daily for 14 days.
33007825|NCT05393089|Placebo Comparator|Vehicle|Participants will receive one drop of vehicle instilled in each eye once daily for 14 days.
33007826|NCT05360524|Active Comparator|Laminectomy alone in patients with traumatic cervical spinal cord injury without instability|laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.
33007827|NCT05360524|Active Comparator|Laminectomy and fusion in patients with traumatic cervical spinal cord injury without instability|Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis.
33007828|NCT05357859|Experimental|Intervention: solubilized vitamin D3 in MCT|The intervention dose and duration aims to correct their vitamin D deficiency to sufficient status (total serum 25(OH)D >/=30 ng/mL or 75 nmol/L). According to an oral cholecalciferol (D3) loading dose guideline for vitamin D-deficient adults (van Groningen et al. 2010), cumulative dose of more than 200,000 IU solubilized vitamin D3 would be applied in current RCT, with make sure the sufficient supplement. Intervention group will receive 144,000 IU in week0 (W0) and then every 2 weeks of 72,000 IU for total 8 weeks (totally 5 times: 144,000 IU wk0/ 72,000 IU wk2/ 72,000 IU wk4/ 72,000 IU wk6/ 72,000 IU wk8), theoretically to achieve sufficient levels of vitamin D.
33007829|NCT05357859|Placebo Comparator|Placebo: MCT with same amount|control group will receive same volume amount of medium chain triglyceride (MCT).
33007830|NCT05304182|Experimental|Pre-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
33007831|NCT05304182|Active Comparator|Post-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
33007832|NCT05286866|Experimental|Low speed drilling without irrigation|The dental implants will be placed using a low-speed drilling technique without irrigation for the experimental group.
33007833|NCT05286866|Active Comparator|High speed drilling with irrigation|The dental implants will be placed using a high-speed drilling technique with irrigation for the control group.
33007834|NCT05265286|Experimental|Arm 1 prophylaxis treatment|"Subjects of high dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~Subjects of low dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~All subjects are being received PK assessment in ED1 and ED4."
33007835|NCT05259904|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 0a/1. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
33007836|NCT05259904|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 0a/. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
33007837|NCT05239169|Experimental|A: Cape+Durva+Treme|Capecitabine + Durvalumab + Tremelimumab
33007838|NCT05239169|Active Comparator|B: Durva+Treme|Durvalumab + Tremelimumab
33007839|NCT05237440|Other|All patients|Metabolic, hormonal and psychometric evaluations will be carried out during or after hospitalization inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out
33007840|NCT05212792||Case with COVID-19 vaccine adverse event|Patients with GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
33007841|NCT05212792||Control without COVID-19 vaccine adverse event|Participants without experiencing GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
33007842|NCT05195099|Active Comparator|control group|
33007843|NCT05195099|Experimental|respiratory treatment|
33007844|NCT05120596|Experimental|T3P-Y058-739 Intravenous (IV)|Intravenous infusion
33007845|NCT05120596|Experimental|T3P-Y058-739 Intratumoural (IT)|Intratumoural injection
33007846|NCT05120596|Experimental|T3P-Y058-739 plus pembrolizumab|Intravenous infusion
33007847|NCT05082519|Experimental|IDEAL2 intervention|"Focused and short-term intervention of diet and exercise during induction. Calorie goal is >=15% daily deficit as determined by each subject's estimated energy requirement. Fat intake will make up <25% of daily calories. Carbohydrate will make up <55% of daily calories consisting of low glycemic load foods (<100/2,000 kcal adjusted for daily calories). Protein will make up >=20% of daily calories. Subjects will also perform moderate exercise 5 days per week for 30 minutes/session (total = 150 minutes per week). Subjects will have a step goal to decrease sedentary behavior, with a starting goal of >=1000 steps/day and increasing by at least 1000 steps/day each week."
33007848|NCT05082519|No Intervention|Control - Standard of Care|One-time education of diet and exercise, which is the standard of care for ALL patients during induction.
33007849|NCT05019482|Experimental|University-based 8-weeks intervention to promote Physical Activity (PA)|Experimental group: 8-weeks program of Physical Activity constructed by users during a design-based innovative workshops before the beginning of the interventions .
33007850|NCT05019482|No Intervention|Control Group|Control group: No intervention, only two measurement times
33007851|NCT05006079|Placebo Comparator|Placebo drug|Lactose, administered both at 9:30 am and 12:00 pm
33007852|NCT05006079|Active Comparator|Morphine alone|15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
33007853|NCT05006079|Active Comparator|Alprazolam alone|0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
33007854|NCT05006079|Active Comparator|Morphine then alprazolam|15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm
33007855|NCT05006079|Active Comparator|Alprazolam then morphine|0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
33415591|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
33415592|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by conference telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
33415593|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
33415594|NCT01341041|Experimental|chlorine dioxide|2 arms
33415595|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
33007856|NCT05006079|Active Comparator|Morphine+alprazolam simultaneously|morphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
33007857|NCT05003518|Experimental|Condition 1: Low Personalisation+Low Frequency|The intervention will have low levels of personalisation and one message a day will be sent to participants.
33007858|NCT05003518|Experimental|Condition 2: High Personalisation+Low Frequency|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname) and one message a day will be sent to participants.
33415596|NCT02053064|Experimental|SAF-301|
33415597|NCT04805021||Patients in the Acquired Hemophilia A group.|
33415598|NCT04805021||patients in the constitutional hemophilia A group.|
33415599|NCT04805021||patients in the control subjects group.|
33415600|NCT04805021||patients in the group of patients with inflammatory pathology.|
33007859|NCT05003518|Experimental|Condition 3: Low Personalisation+High Frequency|The intervention will have low levels of personalisation and three messages a day will be sent to participants.
33007860|NCT05003518|Experimental|Condition 4: High Personalisation+High Frequency|The intervention will have high levels of personalisation and three messages a day will be sent to participants.
33007861|NCT05003518|Experimental|Condition 5: High Personalisation+Low Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
33007862|NCT05003518|Experimental|Condition 6: Low Personalisation+High Frequency+Gamification|The intervention will have low levels of personalisation, contains gamified progress updates, and three messages a day will be sent to participants.
33007863|NCT05003518|Experimental|Condition 7: High Personalisation+High Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and three message a day will be sent to participants.
33007864|NCT05003518|Experimental|Condition 8: Low Personalisation+Low Frequency+Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and one message a day will be sent to participants.
33007865|NCT05003518|Experimental|Condition 9: High Personalisation+Low Frequency+Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and one message a day will be sent to participants.
33007866|NCT05003518|Experimental|Condition 10: Low Personalisation + High Frequency + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and three message a day will be sent to participants.
33007867|NCT05003518|Experimental|Condition 11: High Personalisation + High Frequency + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and three message a day will be sent to participants.
33007868|NCT05003518|Experimental|Condition 12: Low Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
33007869|NCT05003518|Experimental|Condition 13: High Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
33007870|NCT05003518|Experimental|Condition 14: Low Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three message a day.
33007871|NCT05003518|Experimental|Condition 15: High Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three messages a day.
33007872|NCT05003518|Experimental|Condition 16: Low Personalisation+Low Frequency+Gamification|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
33007873|NCT04970381|Experimental|Rivaroxaban|
33007874|NCT04961944||Hypersensitivity pneumonitis|see elegibility criteria
33007875|NCT04950270||Group|Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours
33007876|NCT04932226|Other|All participants|Each participant is his/her own control. Each will have all four interventions in random order.
33007877|NCT04915560|Experimental|ORTEC Employee|ORTEC professional employees performing an industrial cleaning task.
33007878|NCT04897867|Experimental|CoolSculpting® Elite System|Participants received up to two CoolSculpting® Elite treatment sessions for the abdomen and flanks plus optional additional body areas 8 weeks apart. At the investigator's discretion, per treatment session, up to 8 treatment cycles were performed for the midsection, and if applicable, up to 2 treatment cycles for the submental area, up to 4 cycles to upper arms, and up to 4 cycles each to inner and/or outer thighs.
33007879|NCT04895046|Experimental|Investigational Group|"Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1~Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle"
33007880|NCT04885569|Experimental|Motivational Interviewing with CBT (MICBT)|Participants in this arm will receive a total of 12 weekly sessions of CBT based Motivational Interviewing over a period of 12 weeks.
33007881|NCT04885569|Experimental|Mindfulness based Relapse Prevention Group (MBRP)|Participants in this arm will receive a total of 12 weekly sessions of mindfulness intervention over a period of 12 weeks.
33007882|NCT04885569|Experimental|Integrated MICBT and MBRP Group (CAMIAB)|This will be integrated MICBT plus MBRP intervention. Participants will receive a total of 12 weekly sessions of this integrated CAMIAB intervention.
33007883|NCT04885569|No Intervention|Treatment as usual (TAU)|This will be routine care psychological treatment that they will be receiving.
33007884|NCT04861441|Experimental|Continuous Cryotherapy|Subjects will use continuous cryotherapy post operative for pain control
33007885|NCT04861441|Active Comparator|Icepack|Subjects will use standard icepacks post operative for pain control
33007886|NCT04837105|Active Comparator|Control group|"Classic rehab (physio including strength rehab, fitness, motor activity...) + treadmill gait training 3*/week/4weeks:~5 minutes of warm-up with gradual increase in treadmill speed, max 20 minutes of walking at 80% of maximum speed, 5 minutes of active recovery with gradual decrease in treadmill speed.~(protocol from Grecco et al.)"
33007887|NCT04837105|Experimental|Test group|"Classic rehab - same as control group - (physio including strength rehab, fitness, motor activity...) + overground ARROW CP gait training 3*/week/4weeks:~walking sprint session at maximal speed with gradual increase in number of repetitions over the weeks.~(protocol from Verschuren et al.)"
33007888|NCT04805398|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
33007889|NCT04805398|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
33007890|NCT04765514|Active Comparator|Standard Arm: TMZ with concurrent RT (combined modality arm)|"Patients will receive a total of 21 days of Temozolomide (TMZ), with 15 days of TMZ administered daily with concurrent RT. TMZ will be delivered at a dose of 75 mg/m2, given daily with RT for 15 days, one hour before each session of RT.~After a 4-week break, patients will receive six cycles of adjuvant TMZ according to the standard 5-day schedule (days 1-5) every 28 days, up to 6 cycles as tolerated by the patient. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events, intractable nausea or fatigue."
33007891|NCT04765514|Experimental|Biomarker based treatment|"MGMT (+) Temozolomide monotherapy: Patients will receive Temozolomide (TMZ) at a dose of 75 mg/m2 daily for 21 consecutive days. This will be followed by six cycles of TMZ according to the standard 5-day schedule (days 1-5) every 28 days. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events. Dose will be determined using body surface area (BSA) calculation.~MGMT methylation (-) RT monotherapy: Participants will receive radiation treatment with 40Gy / 15 fractions over a period of 21 days (3 weeks)."
33007892|NCT04726150||Mildly of Asymptomatic COVID|Athletes with prior COVID-19 that had a mildly or asymptomatic course
33007893|NCT04726150||Moderate to Severe Symptoms, Cardiac Symptoms|Athletes with prior COVID-19 that had a moderate to severely symptomatic course, or who experience(d) cardiac symptoms
33007894|NCT04726150||Hospitalized for|Athletes that were hospitalized for COVID-19
33007895|NCT04721444||Arm A - Cohort A1|Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)
33007896|NCT04721444||Arms A and B - Cohort B1|Training set B1: IO and RT naive and pneumonia (without COVID-19)
33007897|NCT04721444||Arms A and B - Cohort B2|Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia
33007898|NCT04721444||Arm B - Cohort A2|Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)
33007899|NCT04721444||Arm A - Test Cohort (Cohort C1)|Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis
33007900|NCT04721444||Arm B - Test Cohort (Cohort C2)|Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.
33007901|NCT04721444||Arm C|Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment
33007902|NCT04704011|Experimental|Arm 1: Basic Needs Assessment|-Patients will receive a phone call from a research team member 2-4 weeks before their colposcopy appointment. The team member will remind the patient of the date and time of their appointment and conduct a basic needs assessment. Those who have at least one unmet basic need or are unsure of their current needs will be referred to the 24-hr assistance hotline, 2-1-1 United Healthy Way Missouri. After the date of their appointment, patients will be contacted to ask whether they contacted 2-1-1 and used any recommended services.
33007903|NCT04704011|Active Comparator|Arm 2: Usual Care Cohort|-Patients will receive an automated phone call two weeks before their colposcopy appointment to remind them of the date and time of their visit.
33007904|NCT04677829|Experimental|PNT001 1000mg|PNT001 diluted in 5% dextrose for infusion
33007905|NCT04677829|Experimental|PNT001 4000mg|PNT001 diluted in 5% dextrose for infusion
33007906|NCT04677829|Placebo Comparator|Placebo|5% dextrose for infusion
33007907|NCT04672551|No Intervention|Waitlist control group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
33105684|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
32901987|NCT05578274|Experimental|SBRT+LDRT|In the experimental group, stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, with LDRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
32901988|NCT05578274|Active Comparator|SBRT alone|In the control group, stereotactic body radiotherapy (SBRT) alone is performed. SBRT is administered three times, at intervals of 1-2 days. The scattered dose should not exceed EQD2 2Gy to the non-irradiated lesion.
32901989|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
32901990|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
32901991|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
32901992|NCT05573750|Experimental|Intervention|Singing groups with an instrument
32901993|NCT05573750|Other|Control (delayed intervention)|Delayed comparator
32901994|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
32901995|NCT01542229|Active Comparator|Arm 2: Usual Treatment|Treatment As Usual
32901996|NCT00520910|Experimental|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
32901997|NCT00520910|No Intervention|No intervention|Subject is not given any treatment.
32901998|NCT00521456|Experimental|1|
32901999|NCT00521456|Placebo Comparator|2|
32902000|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
32902001|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
32902002|NCT03813108|Experimental|1: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902003|NCT03813108|Experimental|2: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902004|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
32902005|NCT03813108|Experimental|4: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902006|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902007|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902008|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
32902009|NCT01796366|Experimental|Insulin 338 + placebo|
32902010|NCT01796366|Active Comparator|Insulin glargine + placebo|
32902011|NCT05120544|Active Comparator|EXTEND|EXTEND participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).
32902012|NCT05120544|Experimental|EXTEND Plus|EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
32902013|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
32902014|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.~Administered as a single dose intra-operatively by periarticular infiltration."
32902015|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
32902016|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
33325498|NCT03908034|Experimental|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
33327101|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
33007908|NCT04672551|Experimental|Intervention group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
33007909|NCT04657198|Experimental|Group High Dose_Adjuvanted|Participants in one of the high dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group High Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by intramuscular (IM) injection in the non-dominant arm.
33007910|NCT04657198|Experimental|Group Medium Dose_Adjuvanted|Participants in one of the medium dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Medium Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
33007911|NCT04657198|Experimental|Group Low Dose_Adjuvanted|Participants in one of the low dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Low Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
33007912|NCT04645836|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
33007913|NCT04645836|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
33007914|NCT04617496|Experimental|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
33007915|NCT04617496|Active Comparator|Control group|Health education
33007916|NCT04590586|Experimental|Apremilast + Standard of Care|Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
33007917|NCT04590586|Placebo Comparator|Apremilast Placebo + Standard of Care|Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
33007918|NCT04590586|Experimental|Lanadelumab + Standard of Care|Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
33007919|NCT04590586|Placebo Comparator|Lanadelumab Placebo + Standard of Care|Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
33007920|NCT04590586|Experimental|Zilucoplan + Standard of Care|Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
33007921|NCT04590586|Placebo Comparator|Zilucoplan Placebo + Standard of Care|Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
33007922|NCT04588012|Experimental|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
33007923|NCT04588012|Active Comparator|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive [Take care of your relationship when love is here to stay] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
32902017|NCT05055570||Hypoxemia group|oxygenation index (OI)≤200
32902018|NCT05055570||Non-hypoxemia group|oxygenation index (OI)>200
32902019|NCT05549102||Treatment Group|Participants undergoing a course of Cognitive Behavioural Therapy (CBT)
32902020|NCT05549102||Waiting List Group|Participants on the Waiting List for CBT
32902021|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
32902022|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
32902023|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
32902024|NCT05119920|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
32902025|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
32902026|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
32902027|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
32902028|NCT04226508|No Intervention|Control|
32902029|NCT04226508|Experimental|Physical exercise|
32902030|NCT01542541|Experimental|Rifaximin|
32902031|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
32902032|NCT05054946|Active Comparator|Endometrioma|Participants who will have endometrioma after histopathological evaluation.
32902033|NCT05054946|Active Comparator|Mature cystic teratoma (dermoid cyst)|Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation.
32902034|NCT05054946|Active Comparator|Serous or mucinous cystadenoma|Participants who will have serous or mucinous cystadenoma after histopathological evaluation.
32902035|NCT00524264|Experimental|1|
32902036|NCT00524264|Placebo Comparator|2|
32902037|NCT05119218||Stunted subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 stunting toddlers toddlers in each area.
32902038|NCT05119218||Normal subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 non-stunted toddlers in each area.
32902039|NCT05505110|Active Comparator|Intervention Group|Vaginal Seeding
32902040|NCT05505110|Sham Comparator|Control Group|Sterile Swab
32902041|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
32902042|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
32902043|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
32902044|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
32902045|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
32902046|NCT04999488|Placebo Comparator|Older adults with sarcopenia (placebo)|
32902047|NCT04999488|Active Comparator|Older adults with sarcopenia (drug)|
32902048|NCT05117814|Experimental|Zanubrtuinib|Zanubrutinib 320mg Qd
32902049|NCT01544023||Breast Reconstruction with TilOOP|
32902050|NCT04999254|Experimental|Osteopathic treatment / Usual care|osteopathic treatment will be applied in this intervention group.
32902051|NCT04999254|Active Comparator|Usual care|Classic medical treatment
32902052|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
32902053|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
32902054|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
32902055|NCT05117658|Experimental|HA121-28|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
32902056|NCT05116566||Patients|Three distinct sub-cohorts will be targeted for recruitment to represent perspectives across the advancing illness course: patients ≤3 months from a poor- prognosis diagnosis (cohort 1), patients ≤ 3 months from disease relapse or progression (cohort 2), and patients actively enrolled on a phase I/II trials (cohort 3).For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent patient is eligible for enrollment if the parent consents for the patient's enrollment but declines his/her own enrollment.
32902057|NCT05116566||Parents|Four distinct sub-cohorts of parents will be targeted for recruitment, including cohorts 1-3 and a fourth bereavement cohort. For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent parent is eligible for enrollment if the patient declines enrollment, but the parent wishes to participate.
32902058|NCT05116566||Oncologist|Pediatric oncologists who treat or refer patients for treatment at St. Jude Children's Research Hospital (SJCRH) will be eligible to participate.
33327102|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
33327103|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
33415601|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
33007924|NCT04564209|Experimental|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
33007925|NCT04564209|No Intervention|Control|The control groups will receive standard health education.
33007926|NCT04477707||Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO or FIGARO.
33007927|NCT04477707||Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO or FIGARO.
33007928|NCT04471506|Other|study group will receive interval training and diet advices|exercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program)17.
33007929|NCT04471506|Other|diet recommendations|The control group will receive diet recommendations. The volunteers will follow diet recommendations for 12 weeks
33007930|NCT04427293|Experimental|Open Label|All participants will receive lenvatinib 12mg BID for 7 days and pembrolizumab 200 mg IV on day 1 prior to surgery
33007931|NCT04312009|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
33007932|NCT04312009|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
33007933|NCT04265638|Experimental|Exercise|
33007934|NCT04265638|No Intervention|Usual Care|
33007935|NCT04252573|Experimental|ChEVAS System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
33007936|NCT04239911|Active Comparator|Enhanced usual care|Home health aides in the enhanced usual care arm will receive a virtual heart failure training course.
33007937|NCT04239911|Experimental|Intervention arm|Home health aides in the intervention arm will receive a virtual heart failure training course and a communication-based messaging app.
33007938|NCT04232696|Experimental|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
33007939|NCT04215029|Experimental|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
33007940|NCT04215029|Active Comparator|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
33007941|NCT04215029|Experimental|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
33007942|NCT04100096|Experimental|Brexpiprazole 2-3 Milligrams Per Day|Participants received brexpiprazole, 2-3 milligrams per day (mg/day) tablets, orally, up to Week 12 during the treatment phase.
33007943|NCT04100096|Placebo Comparator|Placebo|Participants received brexpiprazole-matching placebo tablets, orally, up to Week 12 during the treatment phase.
33007944|NCT04073498|Experimental|Part 1a - Cohort 1|A single IV infusion of 0.0003 mg/kg SerpinPC in healthy subjects.
33007945|NCT04073498|Experimental|Part 1a - Cohort 2|A single IV infusion of 0.001 mg/kg SerpinPC in healthy subjects.
33007946|NCT04073498|Experimental|Part 1a - Cohort 3|A single IV infusion of 0.003 mg/kg SerpinPC in healthy subjects.
33007947|NCT04073498|Experimental|Part 1a - Cohort 4|A single IV infusion of 0.01 mg/kg SerpinPC in healthy subjects.
33007948|NCT04073498|Experimental|Part 1a - Cohort 5|A single SC dose of 0.03 mg/kg SerpinPC and a single SC dose of placebo in healthy subjects.
33007949|NCT04073498|Experimental|Part 1b - Cohort 6|A single SC dose of 0.1 mg/kg SerpinPC and a single SC dose of placebo in patients.
33007950|NCT04073498|Experimental|Part 1b - Cohort 7|A single SC dose of 0.3 mg/kg SerpinPC and a single SC dose of placebo in patients.
33007951|NCT04073498|Experimental|Part 1b - Cohort 8|A single SC dose of 0.6 mg/kg SerpinPC and a single SC dose of placebo in patients.
33007952|NCT04073498|Experimental|Part 1b - Cohort 9|Two single SC doses of 0.6 mg/kg SerpinPC in patients.
33007953|NCT04073498|Experimental|Part 2|Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
33007954|NCT04073498|Experimental|Part 3|A single flat SC dose of SerpinPC will be administered every 4 weeks for 48 weeks (13 doses) to up to 25 patients who have completed Week 24 of Part 2. The dose level will be chosen after reviewing Part 2 data and will not exceed maximum dose level in Part 2.
33007955|NCT04073498|Experimental|Part 4|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 24 weeks (13 doses) to up to 22 patients who have completed Week 48 of Part 3.
33007956|NCT04073498|Experimental|Part 5|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 52 weeks (27 doses) for up to 21 patients who have completed Week 24 of Part 4.
33007957|NCT04039386|Experimental|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
33007958|NCT04039386|Placebo Comparator|Placebo|Young adults with hip pain
33007959|NCT03964337|Experimental|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
33007960|NCT03964337|Active Comparator|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
33007961|NCT03957226|Experimental|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
33007962|NCT03937466|Experimental|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
33007963|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
33007964|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
33007965|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
33007966|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
33007967|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
33007968|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
33007969|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
33007970|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
33007971|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
33007972|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
33007973|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
33007974|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.~PROJECT 3: Patients undergo FMT."
33007975|NCT03793842|Experimental|Usual care then PEEP titration by EIT|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan ARDS protocol high-PEEP arm
33007976|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
33007977|NCT03754322|Active Comparator|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
33007978|NCT03754322|Experimental|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
33007979|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
33007980|NCT03723850|Experimental|Older, active tDCS, dlPFC|"Older adults (ages 60-75) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).~2."
33007981|NCT03723850|Sham Comparator|Older, sham tDCS, dlPFC|Older adults (ages 60-75) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
33007982|NCT03723850|Experimental|Younger, active tDCS, dlPFC|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
33007983|NCT03723850|Sham Comparator|Younger, sham tDCS, dlPFC/parietal|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to either the left dorsolateral prefrontal cortex (area F3 using the 10-20 EEG system, n = 25), or the left parietal cortex (area P5 using the 10-20 EEG system, n = 25). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
33007984|NCT03723850|Active Comparator|Younger, active tDCS, parietal cortex|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left parietal cortex (area P5 using the 10-20 EEG system). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
33007985|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
33007986|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
33007987|NCT03612479|Experimental|KIDFIT Healthy|
33007988|NCT03612479|Active Comparator|KIDFIT Safe|
33007989|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
33007990|NCT03537014|Experimental|MDMA-assisted therapy|Administration of 80 or 120 mg MDMA (with a supplemental dose offered 1.5 to 2 hours later of 40 or 60 mg MDMA respectively) in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
33327104|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
33007991|NCT03537014|Placebo Comparator|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
33007992|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
33007993|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
33007994|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
33007995|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
33007996|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
33007997|NCT03473925|Experimental|Navarixin 30 mg + Pembrolizumab 200 mg|Participants received 30 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years
33007998|NCT03473925|Experimental|Navarixin 100 mg + Pembrolizumab 200 mg|Participants received 100 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
33007999|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
33008000|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
33008001|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
33008002|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
33008003|NCT03230097|Experimental|BI 409306|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
33008004|NCT03230097|Placebo Comparator|Placebo|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
33008005|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
33008006|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
33008007|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
33008008|NCT03190525||Multiple Myeloma patients|
33008009|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
33008010|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
33008011|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
33008012|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
33008013|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
33008014|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
33008015|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
33008016|NCT02803593|Active Comparator|Control|Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
33008017|NCT02803593|Experimental|TICAA Intervention|Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
33008018|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
33008019|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
33105685|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
33105686|NCT00552006|Experimental|NET|
33008020|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
33008021|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
33008022|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
33008023|NCT02663908|Experimental|Degarelix|
33008024|NCT02663908|Active Comparator|Leuprolide|
33008025|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
33008026|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
33008027|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
33008028|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
33008029|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
33008030|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
33008031|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
33008032|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
33008033|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
33008034|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
33008035|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
33008036|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
33008037|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
33008038|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
33008039|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
33008040|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
33008041|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
33008042|NCT01734512|Experimental|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
33008043|NCT01555541|Experimental|Single-arm study|
33008044|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
33008045|NCT01398839|Sham Comparator|Sham Control|
33008046|NCT01398839|Experimental|CXL Treatment|
33008047|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
33008048|NCT00501176|Active Comparator|plastic stent|Stent insertion
33008049|NCT00501176|Active Comparator|metalic stent|Stent inserttion
33008050|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
33008051|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
33008052|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
33008053|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
33008054|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
33008055|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
32902059|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
32902060|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
32902061|NCT04950660|Active Comparator|Caffeine arm|Experimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
32902062|NCT04950660|Placebo Comparator|Placebo arm|Control group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
32902063|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
32902064|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
32902065|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
32902066|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
32902067|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
32902068|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
32902069|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
32902070|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
32902071|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
32902072|NCT04950504|Experimental|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
32902073|NCT04950504|Experimental|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
32902074|NCT04950504|Experimental|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
32902075|NCT04950504|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
32902076|NCT05116254|Other|AZD1390|"the experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy. Drug will be taken at same day as radiotherapy for 5 weeks at weekdays.~When starting dose of 10 mg is proven safe the next cohort will be 40 and thereafter 80 mg"
32902077|NCT05116254|Other|AZD7648|"the experimental oral drug AZD7648 (starting dose once daily 10 mg) will be combined with radiotherapy. Drug will be taken at same day as radiotherapy for 5 weeks at weekdays.~When starting dose of 10 mg is proven safe the next cohort will be 20 and thereafter40 mg"
32902078|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
32902079|NCT05115396|Experimental|Mirror therapy|"To perform mirror therapy, the participant shall be seated in a chair with a table in front of him/her. On the table there will be a mirror in the sagittal plane between the two upper limbs. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the intervention, participants will be instructed to concentrate on the hand reflected in the mirror.~During MT, they will perform an exercise protocol based on previous studies and the American College of Sports Medicine guidelines. The duration will be 30 minutes."
32902080|NCT05115396|Active Comparator|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
33008056|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
33105687|NCT00552006|Active Comparator|AC|
33105688|NCT00552006|No Intervention|WL|Waiting list
33325499|NCT03908034|Experimental|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
33325500|NCT03908034|Experimental|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
33325501|NCT01147770|Experimental|stop progesterone|
33325502|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
33325503|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
33325504|NCT01251510||Healthy adults|
33008057|NCT03178786|Experimental|Parkinson's Disease|
33008058|NCT03178786|Sham Comparator|Healthy Control Subjects|
33008059|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
33008060|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.~RECRUITING"
33008061|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
33008062|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
33008063|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
33008064|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
33008065|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
33008066|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
33008067|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
33008068|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
33008069|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
33008070|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
33008071|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
33325505|NCT01251510||Type 2 diabetes|
33325506|NCT03912168|Experimental|Question Prompt List|
33008074|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
33008075|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
33008076|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
33105689|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
33325507|NCT03912168|Active Comparator|3 questions list|
33325508|NCT03916380|No Intervention|Group A|Tacrolimus Extended Release + Midazolam
33008077|NCT03097146|Other|comprehensive multidisciplinary stroke care|
33415602|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
33415603|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
33008078|NCT03096834|Placebo Comparator|Placebo DB|Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
33008079|NCT03096834|Experimental|AMG334 140 mg DB|AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
33008080|NCT03096834|Experimental|AMG334 140 mg DB cont on AMG334 140 mg|AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
33415604|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
33415605|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
33415606|NCT01316549||Inpatient Pediatric Bone Marrow Transplant Recipients|All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.
33008081|NCT03096834|Experimental|Placebo in DB to AMG334 140 mg|Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch
33008082|NCT03089203|Experimental|Cohort 1|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
33008083|NCT03089203|Experimental|Cohort 2|CART-PSMA-TGFβRDN cells 1-3x10^8 Day 0
33008084|NCT03089203|Experimental|Cohort -3|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
33008085|NCT03089203|Experimental|Cohort 4|CART-PSMA-TGFβRDN cells 0.70-1.00 x 10^8 Day 0
33008086|NCT03089203|Experimental|Cohort 3|CART-PSMA-TGFβRDN cells at the MTD (established by Cohorts 1-2) on day 0
33008087|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
33008088|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
33008089|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
33008090|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
33008091|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
33008092|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
33008093|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
33008094|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
33008095|NCT03056014|Placebo Comparator|placebo|
33008096|NCT03056014|Active Comparator|PUFA 1000 mg|
33008097|NCT03056014|Active Comparator|PUFA 2000 mg|
33008098|NCT03056014|Placebo Comparator|Placebo|
33008099|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
33008100|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
33008101|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
33008102|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
33008103|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
33008104|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
33105690|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
33417484|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
33417485|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
33417486|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
33417487|NCT02081066|Other|patients with cardiovascular risk factors|
33008105|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
33008106|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
33008107|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
33008108|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
33008109|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
33008110|NCT03015194|Experimental|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
33008111|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
33008112|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
33008113|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
33008114|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
33008115|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
33008116|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
33008117|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
33008118|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
33008119|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
33008120|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
33008121|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
33008122|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
33008123|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
33008124|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
33008125|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin (Days 1 and 8)|Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square [mg/m^2] and carboplatin area under the curve [AUC] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
33105691|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
33105692|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
33008126|NCT02978716|Experimental|Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8)|Participants received IV infusion of trilaciclib 240 mg/m^2 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
33325509|NCT03916380|Active Comparator|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
33325510|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
33008127|NCT02978716|Experimental|Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)|Participants received IV infusion of trilaciclib 240 mg/m^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.
33008128|NCT02976220|Experimental|Digital Education|1 month digital education program
33008129|NCT02973321|Placebo Comparator|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
33008130|NCT02973321|Experimental|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
33327105|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
33008131|NCT02973321|Experimental|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
33008132|NCT02973321|Experimental|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
33008133|NCT02973321|Active Comparator|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
33008134|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
33008135|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
33008136|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
33008137|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
33008138|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
33008139|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the end of treatment. Dosing must follow the locally approved label.
33008140|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
33008141|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
33008142|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
33008143|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
33008144|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
33008145|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
33008146|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
33008147|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
33008148|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
33008149|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
33008150|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
33008151|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
33008152|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
33008153|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
33008154|NCT02921971|Placebo Comparator|Placebo|Placebo (for SAR156597), single subcutaneous (SC) injection once in a week (QW) up to Week 24.
33008155|NCT02921971|Experimental|SAR156597|SAR156597 200 milligram (mg), single SC injection QW up to Week 24.
33008156|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
33008157|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
33008158|NCT02906397|Experimental|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
33008159|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
33008160|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
33008161|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
33008162|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
33008163|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
33008164|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
33008165|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
33008166|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
33008167|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
33008168|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
33008169|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
33008170|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
33008171|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
33008172|NCT02838927||Hypoparathyroidism|No intervention.
33008173|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
33008174|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
33008175|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
33008176|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
33008177|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
33008178|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~Participant will receive Usual Care assistance when making treatment decisions.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
33325511|NCT03907254|Experimental|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
33008183|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
33008184|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
33008185|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
33008186|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
33008187|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~SF12~Beck~WOMAC"
33008188|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
33008189|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
33008190|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
33008191|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
33008192|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
33008193|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
33008194|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
33008195|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
33008196|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
33008197|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
33008198|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
33008199|NCT02736656|Experimental|Open-Label Treatment|"Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 ER (100 mg capsule).~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 ER (100, 200 mg capsule).~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months."
33008200|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
33008201|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
33008202|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
33008203|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
33008204|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
33008205|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
33008206|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
33008207|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
33008208|NCT02699515|Experimental|MSB0011359C (M7824)|
33008209|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
33008210|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
33008211|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
33008212|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
33008213|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
33008214|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
33008215|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
33008216|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
33008217|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
33008218|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
33008219|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
33008220|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
33008221|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
33008222|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
33008223|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
33417488|NCT01351571||Cohort|
33008224|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
33008225|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
33008226|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
33008227|NCT02675699|Experimental|Optimisation + HENRY|
33008228|NCT02675699|Active Comparator|HENRY as standard|
33008229|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
33008230|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
33008231|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
33008232|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
33008233|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
33008234|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
33008235|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
33008236|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
33008237|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
33008238|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
33008239|NCT02634905|No Intervention|Control|
33008240|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
33008241|NCT02628444|Experimental|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
33008242|NCT02628444|Experimental|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
33008243|NCT02628444|Experimental|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
33008244|NCT02628444|Experimental|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
33008245|NCT02628444|Experimental|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
33008246|NCT02628444|Experimental|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
33008247|NCT02628444|Experimental|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
33008248|NCT02628444|Experimental|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
33008249|NCT02628444|Experimental|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
33008250|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
33008251|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
33008252|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
33325512|NCT03916146|Experimental|Behavioral Parent Training|
33325513|NCT03916146|No Intervention|Control|
33008253|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
33008254|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
33008255|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
33417489|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
33008257|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
33008258|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
33008259|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
33008260|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
33008261|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
33008262|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
33008263|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
33008264|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
33008265|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
33008266|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
33008267|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
33008268|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
33008269|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
33008270|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
33008271|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
33008272|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
33008273|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
33008274|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
33325514|NCT03915990|Other|control group|60 healthy pregnant women will be included
33325515|NCT03915990|Active Comparator|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
33325516|NCT03915990|Active Comparator|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
33008277|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
33008278|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
33008279|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
33008280|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
33008281|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
33008282|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
33008283|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
33008284|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
33008285|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
33008286|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
33008287|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
33008288|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
33008289|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~Blood samples~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5~Fracture patients with reduced kidney function will be treated with anti-RANKL~Anti-osteoporosis drug prescribed by hospital physician~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
33008290|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
33008291|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
33008292|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
33008293|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
33008294|NCT02526901||No treatment|
33008295|NCT02512172|Experimental|Oral CC-486 & MK-3475|Oral CC-486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
33008296|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
33008297|NCT02512172|Experimental|Oral CC-486 & Romidepsin & MK-3475|Oral CC-486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
33008298|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
33008299|NCT02510703|Other|no diabetes|no diabetes
33008300|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
33008301|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
33008302|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
33008303|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
33008304|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
33008305|NCT02499367|Active Comparator|No induction treatment|
33008306|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
33008307|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
33008308|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
33008309|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
33008310|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
33008311|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
33008312|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
33325517|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
33325518|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
33417490|NCT01351649|Experimental|physical activity|
33417491|NCT02079428||Systolic heart failure, Diastolic heart failure|
33008313|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
33008314|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
33008315|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
33008316|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
33008317|NCT02470286|Experimental|Cohort 1 (SA001 60mg or Placebo)|6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo
33008318|NCT02470286|Experimental|Cohort 2 (SA001 120mg or Placebo)|6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo
33008319|NCT02470286|Experimental|Cohort 3 (SA001 180mg or Placebo)|6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo
33008320|NCT02470286|Experimental|Cohort 4 (SA001 240mg or Placebo)|6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo
33008321|NCT02470286|Experimental|Cohort 5 (SA001 300mg or Placebo)|6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo
33008322|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
33008323|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
33008324|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
33008325|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
33008326|NCT02457559|Experimental|Tirabrutinib 40 mg once daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.
33008327|NCT02457559|Experimental|Tirabrutinib 80 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.
33008328|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
33008329|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
33008330|NCT02457559|Experimental|Tirabrutinib 400 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.
33008331|NCT02457559|Experimental|Tirabrutinib 500 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.
33008332|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
33008333|NCT02457559|Experimental|Tirabrutinib 300 mg twice daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.
33008334|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
33008335|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
33008336|NCT02457559|Experimental|Tirabrutinib 480 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.
33008337|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
33008338|NCT02455505||Risk Screening tool & Cognitive Interview|
33008339|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
33008340|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
33008341|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
33008342|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
33008343|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
33008344|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
33008345|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
33008346|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
33008347|NCT02424409|Active Comparator|1: Control|
33008348|NCT02424409|Experimental|2: Intervention|
33008349|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
33325519|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~Magstream: 2 samples (each on a different stool)~OC Sensor: 2 samples (each on a different stool)~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
33008350|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
33008351|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
33008352|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
33008353|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
33008354|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
33008355|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
33008356|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
33008357|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
33008358|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
33008359|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
33008360|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
33008361|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
33008362|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
33008363|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
33008364|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
33008365|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
33008366|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
33008367|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
33008368|NCT02355379|Experimental|GROUP2- ARM C|Observation
33008369|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
33008370|NCT02353832|Other|No Arm|Study did not have Arm(s)
33008371|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
33008372|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
33008373|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
33008374|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
33008375|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
33008376|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
33008377|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
33008378|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
33008379|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
33008380|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
33008381|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
33417492|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
33325520|NCT03912012|Other|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
33325521|NCT03907098|Experimental|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.~Chemotherapy regimens are selected by physicians based on regular clinical decision."
33325522|NCT03915756|Experimental|With drain|Participants who received a drain during surgery
33008382|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
33008383|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
33008384|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
33008385|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
33325523|NCT03915756|No Intervention|Without drain|Participants who did not receive a drain during surgery
33008386|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
33008387|NCT02300493|Experimental|Experimental|weigh themselves daily
33325524|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
33325525|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
33008388|NCT02300493|Active Comparator|Control|Weigh themselves every six months
33325526|NCT03915834||endovascular treatment group|
33008389|NCT02292654|Experimental|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
33008390|NCT02283281|Experimental|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
33008391|NCT02283281|Experimental|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
33008392|NCT02283281|Placebo Comparator|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
33008393|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
33008394|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
33008395|NCT02243033||Visualase|MR-guided laser focal therapy
33008396|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
33008397|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
33008398|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
33008399|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
33008400|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
33325527|NCT03915912|Experimental|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
33325528|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
33325529|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
33325530|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
33325531|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
33325532|NCT03911934|Active Comparator|Usual care|Usual care in the geriatric outpatient clinic.
33417493|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
33008401|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
33008402|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
33008403|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
33008404|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
33008405|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
33008406|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
33008407|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
33008408|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
33008409|NCT02139436|Other|Wait-list time control|Subjects perform 6 months of their standard of care
33008410|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training
33008411|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
33008412|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
33008413|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
33008414|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
33008415|NCT02106195|Experimental|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
33008416|NCT02104180|Active Comparator|TulleGras M.S.|
33008417|NCT02104180|Active Comparator|Urgotul|
33008418|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
33008419|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
33008420|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
33008421|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
33008422|NCT02040857|Experimental|Palbociclib With Adjuvant Endocrine Therapy|"Palbociclib 125 mg PO qd 21 days on, 7 days off~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
33008423|NCT02001142|Experimental|Exercise|
33008424|NCT02001142|No Intervention|Sedentary Control|
33008425|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
33008426|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
33008427|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
33417494|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
33008428|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
33008429|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
33008430|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
33008431|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
33008432|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
33008433|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
33008434|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
33008435|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
33008437|NCT01913730|No Intervention|No prolonged therapy is scheduled|
33008438|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
33008439|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
33008440|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
33008441|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
33008442|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33008443|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
33008444|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
33008445|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
33008446|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
33008447|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
33008448|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
33008449|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
33008450|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
33008451|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
33008452|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
33008453|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
33008454|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
33008455|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Sorafenib 400 mg orally twice a day;~Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;~Sildenafil 50 mg orally twice a day~A cycle consists of 4 weeks.~*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)"
33008456|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
33008457|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
33008458|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
33008459|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
33008460|NCT01741103|Experimental|Sitagliptin|
33008461|NCT01741103|Placebo Comparator|Placebo|
33417495|NCT01358513||Control Patients|Patients with normal aortic valves
33008462|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
33008463|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
33008464|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
33008465|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
33008466|NCT01619085|Experimental|All subjects|patient to receive a capsule containing Nintedanib twice a day
33008467|NCT01612663|Active Comparator|deep needle non-site specific|
33008468|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
33008469|NCT01612663|Active Comparator|Energy of Living Systems Needling|
33008470|NCT01612663|Placebo Comparator|Sham acupuncture|
33008471|NCT01582802||Pregnant women carrying multiples|Healthy pregnant women carrying twins, triplets and quadruplets will be recruited.
33008472|NCT01499095|Experimental|HOE901-U300|
33008473|NCT01499095|Active Comparator|Lantus|
33008474|NCT01499082|Experimental|HOE901-U300|
33008475|NCT01499082|Active Comparator|Lantus|
33008476|NCT01488890|Experimental|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
33008477|NCT01488890|Experimental|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
33008478|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
33008479|NCT01488890|Active Comparator|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
33008480|NCT01436396|Experimental|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month [M] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
33008481|NCT01436396|Experimental|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
33008482|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
33008483|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
33008484|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
33008485|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
33008486|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
33008487|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
33008488|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
33008489|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
33008490|NCT01374516|Placebo Comparator|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
33008491|NCT01373281|Experimental|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
33008492|NCT01373281|Placebo Comparator|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
33008493|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
33008494|NCT01340105|Experimental|Microwave|Hepatocellular carcinoma treated with microwave ablation
33008495|NCT01340105|Active Comparator|Radiofrequency|Hepatocellular carcinoma treated with radiofrequency ablation
33008496|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
33008497|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
33008498|NCT01254422|Experimental|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
33008499|NCT01254422|Placebo Comparator|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
33008500|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
33008501|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
33008502|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
33008503|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
33008504|NCT01166113|Experimental|PCP|
33008505|NCT01160107|Experimental|RP followed MPR|
33008506|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
33008507|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
33008508|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
33008509|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
33008510|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
33008511|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
33008512|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
33008513|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
33008514|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
33008515|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
33008516|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
33008517|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
33008518|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
33008519|NCT01034306|Experimental|CF101 1 mg|piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks
33008520|NCT01034306|Placebo Comparator|Placebo|placebo tablet to match the active, oral dosage, Q12h for 12 weeks
33008521|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
33008522|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
33417496|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
33008524|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
33417497|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
33008525|NCT00993447|Sham Comparator|Control Vaccine Group|
33325533|NCT03911934|Experimental|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
33008527|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
33008528|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
33008529|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
33008530|NCT00942877|Experimental|Cediranib (AZD2171) Treatment|"Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~Pediatric participants (<16 years old) will be treated with 12 mg/m^2/day once a day for 28 days (28-day cycles)."
33008531|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
33008532|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
33008533|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
33008534|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33008535|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
33008536|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
33008537|NCT00880893|Sham Comparator|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants <12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
33008538|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
33008539|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
33008540|NCT00845390||ICD Patients|ICD patients
33008541|NCT00809991|Experimental|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
33008542|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
33008543|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
33325534|NCT03915444|Experimental|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
33325535|NCT03906864|No Intervention|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
33325536|NCT03906864|Experimental|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
33325537|NCT03906942|Experimental|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
33325538|NCT03906942|No Intervention|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
33325539|NCT05629338|Experimental|Cohort 1|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 1 unit (200 mL) of autologous FrontlineODP.
33008544|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
33008545|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
33008546|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
33008549|NCT00579527|Experimental|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
33008550|NCT00579527|Experimental|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
33008551|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
33008552|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
33008553|NCT00576836|Experimental|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
33008554|NCT00576836|Experimental|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue.~."
33008555|NCT00576407|Experimental|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
33008556|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
33008557|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
33008558|NCT00543348|Active Comparator|1|CUTTING BALLOON ANGIOPLASTY
33008559|NCT00543348|Placebo Comparator|2|Balloon angioplasty with a high pressure balloon
33008560|NCT00531232|Experimental|Clofarabine 55 mg/day|Participants received Clofarabine 55 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
33008561|NCT00531232|Experimental|Clofarabine 35 mg/day|Participants received Clofarabine 35 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
33008562|NCT00531232|Experimental|Clofarabine 25 mg/day|Participants received Clofarabine 25 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
33008563|NCT00512122|Experimental|EN only|Withholding PN during the first week of ICU stay
33008564|NCT00512122|Active Comparator|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
33008565|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
33008566|NCT00389844|No Intervention|1|Routine care
33008567|NCT00389844|Active Comparator|2|Exercise only
33008568|NCT00389844|Active Comparator|3|Motivation only
33008569|NCT00389844|Experimental|4|Exercise plus motivation
33008570|NCT00379340|Experimental|Stage IV and rapid complete response (RCR) of lung metastases|Stage IV and rapid complete response (RCR) of lung metastases continuously treated with DD4A after 6 weeks of DD4A
33008571|NCT00379340|Experimental|Stage IV and slow incomplete response (SIR) of lung metastases|Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A
33008572|NCT00379340|Other|Stage III/IV with LOH 1p and 16q treated with Regimen M|Stage III/IV with LOH 1p and 16q treated with Regimen M
33008573|NCT00379340|Other|Stage IV with non-lung disease treated with Regimen M|Stage IV with non-lung disease treated with Regimen M
33008574|NCT00379340|Other|Stage IV with lung metastases|Stage IV with lung metastases treated with DD4A for less than 6 weeks and/or response inevaluable at week 6
33008575|NCT00365326|Experimental|Treatment with autologous bone marrow (BM)-derived CD133+ stem cell therapy|The Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia.
33417498|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
33008576|NCT00304070|Experimental|Stratum I (surgery, observation)|Patients undergo conventional surgery (primary tumor resection and retroperitoneal lymph node sampling) followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
33008577|NCT00304070|Experimental|Stratum II (exploratory surgery, observation)|Patients undergo conventional surgery (primary tumor resection and extended regional lymph node dissection) followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
33008578|NCT00304070|Experimental|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with a total of 8 cycles of chemotherapy with cisplatin, etoposide and doxorubicin hydrochloride, filgrastim (G-CSF). The first 2 to 4 cycles are called the induction phase, followed by mitotane alone for an additional 2 months. Some patients undergo conventional surgery after chemotherapy course 2 or 4. Some patients undergo additional conventional surgery after finishing all chemotherapy.
33008579|NCT00265525|Experimental|Cardio fit|
33008580|NCT00265525|No Intervention|Usual Care|
33008581|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
33008582|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
33008583|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
33008584|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
33008585|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
33008586|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
33008587|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
33008588|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
33008589|NCT01694160|No Intervention|no intervention|
33008590|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
33008591|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
33008592|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
33008593|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
33008594|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
33008595|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
33008596|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
33008597|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
33008598|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
33008599|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
33008600|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
33008601|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
33008602|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
33008603|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
33008604|NCT01694290|No Intervention|no chemical ice packs|
33008605|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
33008606|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
33008607|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
33008608|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
33008609|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
33417499|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
33417500|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
33417501|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
33417502|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
33417503|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
33417504|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
33417505|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
33417506|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
33008610|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
33008611|NCT01694381|Experimental|mutant pro-urokinase (M5) alone|In the first study part subjects in cohorts of 4 will receive ascending doses of either M5 (3 subjects) or M5-placebo (1 subject) without C1-inhibitor.
33008612|NCT01694381|Experimental|Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|"In the second study part subjects in cohorts of 5 will receive ascending doses of either M5 or M5-placebo, preceded by a single intravenous dose of C1-inhibitor or C1-inhibitor-placebo. Each subject will randomly be allocated to one of the following treatment arms within one cohort:~C1-inhibitor followed by M5 (3 subjects);~C1-inhibitor followed by M5-placebo (1 subject);~C1-inhibitor-placebo followed by M5-placebo (1 subject).~Dose levels of both M5 and C1-inhibitor within each cohort will be chosen based on the available safety, pharmacokinetic and pharmacodynamic data of the preceding cohorts."
33008613|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
33008614|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
33008615|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
33008616|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
33008617|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
33008618|NCT01694446|Experimental|Intraduodenal glucose or fructose|
33008619|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
33008620|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
33008621|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
33008622|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
33008623|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
33008624|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
33008625|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
33008626|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
33008627|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
33008628|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
33008629|NCT01694550||Pacemaker mode programming|High grade AV-block
33008630|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
33008631|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
33008632|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
33008633|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
33008634|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
33008635|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
33008636|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
33008637|NCT01694628|No Intervention|Control|Usual Care
33008638|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
33008639|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
33008640|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
33008641|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
33008642|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
33008643|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
33008644|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
33008645|NCT01694758||Patients with diabetes type 2|
33008646|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
33008647|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
33008648|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
33415607|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
33105693|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
33105694|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up~1-month follow up~3-month follow up~6-month follow up~9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
33105695|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up (FU)~1-month FU~3-month FU~6-month FU~9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
33415608|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
33415609|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
33415610|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
33415611|NCT03439657|Experimental|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
33415612|NCT03439657|Active Comparator|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
33415613|NCT02053220|Experimental|Intra-tumoural cohort|
33415614|NCT02053220|Experimental|Intra-venous cohort|
33415615|NCT02056028||Bile leak after hepatic resection|
33415616|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
33415617|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
33415618|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
33008649|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
33008650|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
33415619|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
33008651|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
33008652|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
33008653|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
33008654|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
33008655|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
33008656|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
33008657|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
33008658|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
33008659|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
33008660|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
33008661|NCT01694875||No Treatment|
33008662|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
33008663|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
33415620|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
33415621|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
33415622|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
33415623|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
33415624|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
33008664|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
33008665|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
33008666|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
33008667|NCT01694927|Experimental|Mesenchymal Stem cells|
33008668|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
33008669|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
33008670|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
33008671|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
33008672|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
33008673|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
33008674|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
33008675|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
33008676|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
33008677|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
33008678|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
33008679|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
33008680|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
33008681|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
33008682|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
33008683|NCT01695109|Placebo Comparator|Placebo|
33008684|NCT01695109|Active Comparator|Liraglutide|
33008685|NCT01695122|Experimental|valproic acid|
33008686|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
33008687|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
33008688|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
33008689|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
33008690|NCT01695161||Fabry disease|Fabry disease
33008691|NCT01695161||healthy controls|healthy controls
33008692|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
33008693|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
33008694|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
33008695|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
33008696|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
33008697|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
33008698|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
33008699|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
33008700|NCT01695252|No Intervention|S-Sup|Standard supervision
33008701|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
33008702|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
33008703|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
33008704|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
33325540|NCT05629338|Experimental|Cohort 2|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection, in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 2 units (400 mL) of autologous FrontlineODP.
33327106|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
33008705|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
33008706|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
33008707|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
33008708|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
33008709|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
33008710|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
33327107|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
33008711|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
33008712|NCT01695395||Intellectual disabled adults without a mental disorder|
33008713|NCT01695395||Intellectual disabled adults with a mental disorder|
33008714|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
33325541|NCT05629338|Active Comparator|Cohort 3 Arm 3|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous FrontlineODP and 4 units of autologous control PF24. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 3 will receive 4 units of FrontlineODP during the first infusion visit, and following a 14 day washout period, they would receive 4 units of PF24 during a second visit.
33327108|NCT03872934||classical western music|classical western music (vivaldi)
33008715|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
33008716|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
33008717|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
33008718|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
33008719|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
33008720|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
33008721|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
33008722|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
33008723|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
33008724|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
33008725|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
33008726|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
33008727|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
33008728|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
33008729|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
33008730|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
33008731|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
33008732|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
33008733|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
33008734|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
33008735|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
33008736|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
33008737|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
33008738|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
33008739|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
33008740|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
33008741|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
33008742|NCT01695642||Microkeratome|mechanical microkeratome
33008743|NCT01695642||Intralase|femtosecond laser
33008744|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
33008745|NCT01695681|Other|Dietary instruction|Gluten-free diet
33008746|NCT01695694|Active Comparator|community support group|
33008747|NCT01695694|Experimental|supporting positive and healthy relationships|
33008748|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
33008749|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
33008750|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
33008751|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
33008752|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
33008753|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
33008754|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
33008755|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
33008756|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
33008757|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
33008758|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
32902081|NCT04949490|Experimental|Group A, BNT162b2s01 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
32902082|NCT04949490|Experimental|Group A, BNT162b2 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
33008759|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
33008760|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
33008761|NCT01695811||FLAK|FLAK
33008762|NCT01695811||PKP|Retrospective
33008763|NCT01695824|Active Comparator|LAA occluder|
33008764|NCT01695824|Active Comparator|Warfarin|
33008765|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
33008766|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
33008767|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
33008768|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
33008769|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
33008770|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
33008771|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
33008772|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
33008773|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
33008774|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
33008775|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
33008776|NCT01695915||Healthy|Transabdominal ultrasound
33008777|NCT01695915||Constipated|Transabdominal ultrasound
33008778|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
33008779|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
33008780|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
33008781|NCT01695967|No Intervention|control|no turbinate cauterization
33327109|NCT03872934||soft rock music|soft rock music (elvis)
33327110|NCT03872934||control group (group not listening music)|control
33415625|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
33008782|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
33008783|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
33008784|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
33008785|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
33008786|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
33008787|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
33008788|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
33008789|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
33008790|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
33008791|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
33008792|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
33008793|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
33008794|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
33008795|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
33008796|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
33008797|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
33008798|NCT01696201|No Intervention|Control group|Sedentary pregnant women
33008799|NCT01696201|Experimental|Exercise group|Exercise program
33008800|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
33008801|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
33008802|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
33008803|NCT01696253||Subjects at risk for Alport sydrome|
33008804|NCT01696253||Newly identified subjects with Alport syndrome|
33008805|NCT01696266||Insulin-treated patients with diabetes|
33008806|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
33008807|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
33008808|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
33008809|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
33008810|NCT01696331|Experimental|Text Message Reminder|
33415626|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
33008811|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
33008812|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
33008813|NCT01696370|Active Comparator|Trimetazidine|
33008814|NCT01696370|Placebo Comparator|Placebo capsule|
33008815|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
33008816|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
33008817|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
33008818|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
33008819|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
33008820|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
33008821|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
33008822|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
33008823|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
33008824|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
33008825|NCT01696461|Experimental|Related donors receiving plerixafor|Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.
33008826|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
33008827|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
33008828|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
33008829|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
33008830|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
33008831|NCT01696500|Experimental|NPB-01|
33008832|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
33008833|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
33008834|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
33008835|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
33008836|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
33008837|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
33008838|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
33008839|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
33008840|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
33008841|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
33008842|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
33008843|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
33008844|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
33008845|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
33008846|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
33008847|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
33008848|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
33008849|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
33008850|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
33008851|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
33008852|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
33008853|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
33008854|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
33008855|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
33008856|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
33008857|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
33008858|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
33008859|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
33008860|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
33008861|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
33008862|NCT01696786|Experimental|Oocyte cryopreservation|
33008863|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
33008864|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
33008865|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
33008866|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
33008867|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
33008868|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
33008869|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
33008870|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
33008871|NCT01696838|Experimental|EA group|Electroacupuncture group
33008872|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
33008873|NCT01696851||wheelchair rugby players with tetraplegia|
33008874|NCT01696851||other routine sport participants with tetraplegia|
33008875|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
33008876|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
33008877|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
33008878|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
33008879|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
33008880|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
33008881|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
33008882|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
33008883|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
33008884|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
33008885|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
33008886|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
33008887|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
33008888|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
33008889|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
33008890|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
33008891|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
33008892|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
33008893|NCT01697111|Experimental|Arm 1|
33008894|NCT01697111|Experimental|Arm 2|
33008895|NCT01697111|Active Comparator|Arm 3|
33008896|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
33008897|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
33008898|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
33008899|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
33008900|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
33008901|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
33008902|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
33008903|NCT01697202||no intervention|
33008904|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
33008905|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
33008906|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
33008907|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
33008908|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
33008909|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
33008910|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
33008911|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
33008912|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
33008913|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
33008914|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
33008915|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
33008916|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
33008917|NCT01697410|Experimental|terlipressin|
33008918|NCT01697410|Active Comparator|norepinephrine|
33008919|NCT01697423|Experimental|platelet-rich plasma|
33008920|NCT01697423|Active Comparator|durolane|
33008921|NCT01697436|Experimental|Crossover Period 1|
33415627|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
33415628|NCT02852161|Experimental|MACE|MACE procedure
33008922|NCT01697436|Experimental|Crossover Period 2|
33008923|NCT01697436|Experimental|Crossover Period 3|
33008924|NCT01697436|Experimental|Crossover Period 4|
33008925|NCT01697475|Experimental|Intervention Group|Motivational text messaging
33008926|NCT01697475|No Intervention|Control Group|Step count
33008927|NCT01697488||Cohort|Overall sample
33008928|NCT01697488||Subgroup|Patients aged >/= 70 years
33008929|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
33008930|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
33008931|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
33008932|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
33008933|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
33008934|NCT01697618|Experimental|BIAsp 30|
33008935|NCT01697618|Active Comparator|BHI 30|
33008936|NCT01697631|Experimental|BIAsp|
33008937|NCT01697631|Experimental|Insulin aspart|
33008938|NCT01697644|Experimental|Low dose|
33008939|NCT01697644|Experimental|High dose|
33008940|NCT01697657|Experimental|Detemir|
33008941|NCT01697657|Active Comparator|NPH|
33008942|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
33008943|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
33008944|NCT01697683|Placebo Comparator|Sugar pill|
33008945|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
33008946|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
33008947|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
33008948|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
33008949|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
33008950|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
33415629|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
33415630|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
33415631|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
33008951|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
33008952|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
33008953|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
33008954|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
33008955|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
33008956|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
33008957|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
33008958|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
33008959|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
33008960|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
33008961|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
33008962|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
33008963|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~min 60%-65%~min 65%-70%~min 70%-75%~min 75%-80%~min 80%-85%~10 min 85%-94%"
33008964|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
33008965|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
33415632|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
33008966|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
33008967|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
33008968|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
33008969|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
33008970|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
33008971|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
33008972|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
33008973|NCT01698034|No Intervention|Control|Wait-list control
33008974|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
33008975|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
33008976|NCT01698060|Experimental|Intestinal Delivery|ND1.1
33008977|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
33008978|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
33008979|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
33008980|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
33008981|NCT01698112|Experimental|Flaxseed High Dose|
33008982|NCT01698112|Experimental|Flaxseed Low Dose|
33008983|NCT01698112|No Intervention|Flaxseed control|
33008984|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
33008985|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
33008986|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
33008987|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
33008988|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
33008989|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
33008990|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
33008991|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
33008992|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
33008993|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
33008994|NCT01698203|Experimental|ropivacaine|
33008995|NCT01698203|Placebo Comparator|placebo|
33008996|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
33008997|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
33008998|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
33008999|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
33009000|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
33009001|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
33009002|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
33009003|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
33009004|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
33009005|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
33009006|NCT01698385|Active Comparator|Lifestyle counseling|
33009007|NCT01698385|No Intervention|Control, just measurements|
33009008|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
33009009|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
33009010|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
33009011|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
33009012|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
33009013|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.~--------------------------------------------------------------------------------"
33009014|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
33009015|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
33009016|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
33009017|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
33009018|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
33009019|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
33009020|NCT01698593|Active Comparator|Ring Finger Nerve Block|
33009021|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
33009022|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
33009023|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
33009024|NCT01698632||benign-looking adnexal masses|
33009025|NCT01698645||PecFent®|
33009026|NCT01698671|Other|InterGard Synergy Vascular Graft|
33009027|NCT01698697|Active Comparator|U100|
33009028|NCT01698697|Experimental|U200|
33009029|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
33009030|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
33009031|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
33009032|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
33009033|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
33009034|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
33009035|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
33009036|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
33009037|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
33009038|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
33009039|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
33009040|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
33009041|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
33009042|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
33009043|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
33009044|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
33009045|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
33009046|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
33009047|NCT01698931|Experimental|Treatment period 1|
33009048|NCT01698931|Active Comparator|Treatment period 2|
33009049|NCT01698931|Placebo Comparator|Treatment period 3|
33009050|NCT01698944|Experimental|Somatropin|
33009051|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
33009052|NCT01698970|Experimental|1 = Tested product|
33009053|NCT01698970|Placebo Comparator|2 = Control product|
33009054|NCT01698996|Active Comparator|No Packing|No Packing
33009055|NCT01698996|Experimental|Packing|Packing
33009056|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
33009057|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
33009058|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
33009059|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
33009060|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
33009061|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
33009062|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
33009063|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
33009064|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
33009065|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
33009066|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
33009067|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
33009068|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
33009069|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
33009070|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
33009071|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
33009072|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
33009073|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
33009074|NCT01699139|Active Comparator|positional device|
33009075|NCT01699139|Sham Comparator|lumbar corset|
33009076|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
33009077|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
33009078|NCT01699165|Active Comparator|Nasal Filter|Active treatment
33009079|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
33009080|NCT01699191|Placebo Comparator|Placebo|Placebo
33009081|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
33009082|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
33009083|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
33009084|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
33009085|NCT01699230|No Intervention|Control group|
33009086|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
33009087|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
33009088|NCT01699269|Other|brain tumor|
33009089|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
33009090|NCT01699282|Active Comparator|control group|
33009091|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
33009092|NCT01699295|Active Comparator|CON|Regular sedentary lessons
33009093|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
33009094|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
33009095|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
33009096|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
33009097|NCT01699334|Experimental|Psychoeducational video|
33327111|NCT01284270|Other|All Patients|All patients undergo the same study procedures
33009098|NCT01699334|Active Comparator|Relaxation video|
33009099|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
33009100|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
33009101|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
33009102|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
33009103|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
33009104|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
33009105|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
33009106|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
33009107|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
33009108|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
33009109|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
33009110|NCT01699438|Experimental|Mesalazine|
33009111|NCT01699438|Placebo Comparator|Placebo|
33009112|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
33009113|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
33327112|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
33327113|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
33327114|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
33327115|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
33415633|NCT04720001||Experimental: Florbetaben F18 recipients|Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
33415634|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
33009114|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
33009115|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
33009116|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
33415635|NCT04705883|Other|Prasterone|10 patients will be treated using prasterone during 6 months.
33415636|NCT04677491|Active Comparator|VVA-FSIAD ospemifene group|Women treated with ospemifene 60 mg/day
33009117|NCT01699529|Experimental|Renal Denervation|
33415637|NCT04677491|Placebo Comparator|VVA-FSIAD placebo group|Women treated with placebo
33415638|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
33415639|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
33415640|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
33415641|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
33009118|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
33009119|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
33009120|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
33009121|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
33009122|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
33009123|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
33009124|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
33009125|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
33009126|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
33009127|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
33009128|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
33009129|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
33009130|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
33009131|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
33009132|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
33009133|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
33009134|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
33009135|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
33009136|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
33009137|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
33009138|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
33009139|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
33009140|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
33009141|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
33009142|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
33009143|NCT01699841||HIV+ and HIV- mothers and their infants|
33009144|NCT01699854|Active Comparator|capsaicin patch|
33009145|NCT01699854|Placebo Comparator|placebo patch|
33009146|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
33009147|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
32902494|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
32902495|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
32902496|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
32902497|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
32902498|NCT05559398|Placebo Comparator|Placebo|
32902499|NCT05559398|Experimental|Glenzocimab|
32902500|NCT04388462||locked plating with predicted distribution of loc|
32902501|NCT04388462||unlocked plating with predicted distribution of loc|
32902502|NCT04388462||Interlocking nail +/- blocking screws|
32902503|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
32902504|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
32902505|NCT00566150|Active Comparator|Levetiracetam|
32902506|NCT00566150|Placebo Comparator|Placebo|
32902507|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
32902508|NCT05559242|Experimental|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride capsules, 12mg, 1 time in total
32902509|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
32902510|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
32902511|NCT00566930|No Intervention|1|
32902512|NCT00566930|Active Comparator|2|spinal manipulation
32902513|NCT00566930|Experimental|3|Spinal manipulation + exercises
32902514|NCT00567008|Experimental|1|Varenicline (Chantix)
32902515|NCT00567008|Placebo Comparator|2|Placebo
32902516|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
32902517|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
32902518|NCT00567320|Active Comparator|Varenicline|
32902519|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
32902520|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
32902521|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
32902522|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
32902523|NCT00568022|Experimental|Ixabepilone + Capecitabine|
32902524|NCT05554562||Injured athletes|Athletes suffering a groin injury
32902525|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
32902526|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
32902527|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
32902528|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
32902529|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
32902530|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
32902531|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
32902532|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
32902533|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
33009148|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
33009149|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
33009150|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
33009151|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
33009152|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
33009153|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
33009154|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
33009155|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
33009156|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
33009157|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
33009158|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
33009159|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
33009160|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
33009161|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
33009162|NCT01700062|Experimental|Medium calorie|
33009163|NCT01700062|Experimental|standard calorie|
33009164|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
33009165|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
33009166|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
33009167|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
33009168|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
33009169|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
33009170|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
33009171|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
33009172|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
33009173|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
33009174|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
33009175|NCT01700244|Experimental|Pacemaker|
33009176|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
33009177|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
33009178|NCT01700283|Experimental|exercise education and walking program|
33009179|NCT01700283|No Intervention|maintain their daily activity|
33009180|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
33009181|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
33009182|NCT01700309|No Intervention|Control group|Treatment as usual
33009183|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
33009184|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
33009185|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
33009186|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
33009187|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
33009188|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
33009189|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
33009190|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
33009191|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
33009192|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
33009193|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
33009194|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
33009195|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
33009196|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
33009197|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
33009198|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
33009199|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
33009200|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
33009201|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
33009202|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
33009203|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
33009204|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
33009205|NCT01700634||OA patients with LOW central sensitization|
33009206|NCT01700634||Control subjects|
33009207|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
33009208|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
33009209|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
33009210|NCT01700660||VIO|Patients operated under VIO.
33009211|NCT01700660||Control|Patients operated without VIO.
33009212|NCT01700686||Obese subjects|Meal test and dexa scan
33415642|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
33415643|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
33009213|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
33009214|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
33415644|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
33009215|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
33009216|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
33009217|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
33009218|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
33009219|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
33009220|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
33009221|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
33009222|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
33009223|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
33009224|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
33009225|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
33009226|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
33009227|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
33009228|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
33009229|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
33009230|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
33009231|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
33009232|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
33009233|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
33009234|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
33009235|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
33009236|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
33009237|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
33009238|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
33009239|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
33009240|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
33009241|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
33009242|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
33009243|NCT01700933|Active Comparator|High-dosage-group|
33009244|NCT01700933|Active Comparator|Low-dosage-group|
33009245|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
33009246|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
33009247|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
33009248|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
33009249|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
33009250|NCT01701089|Experimental|RO4602522 Group 1|
33009251|NCT01701089|Experimental|RO4602522 Group 2|
33009252|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
33009253|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
33009254|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
33009255|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
33009256|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
33009257|NCT01701154||Pompe|Adults and children with Pompe disease.
33009258|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
33009259|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
33009260|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
33009261|NCT01701206|No Intervention|Control arm|
33009262|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
33009263|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
33009264|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
33009265|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
33009266|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
33009267|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
33009268|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
33009269|NCT01701310|Experimental|Ferric carboxymaltose|
33009270|NCT01701310|Active Comparator|Ferrous Sulphate|
33009271|NCT01701323|Experimental|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
33009272|NCT01701336|Experimental|Unique Arm|"Ad6NSmut~MVA-NSmut~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
33009273|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
33009274|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
33009275|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
33009276|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
33009277|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
33009278|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
33009279|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
33009280|NCT01701479|Experimental|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
33327116|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
33327117|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
33009281|NCT01701479|Active Comparator|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
33009282|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
33009283|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
33009284|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
33009285|NCT01701531|Experimental|RBCPF|Treatment intervention arm
33009286|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
33009287|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
33009288|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
33009289|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
33009290|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
33009291|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
33009292|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
33009293|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
33009294|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
33009295|NCT01701635|Active Comparator|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
33009296|NCT01701648|Active Comparator|1|
33009297|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
33009298|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
33009299|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
33009300|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
33009301|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
33009302|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
33009303|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
33009304|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
33009305|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~Half way between the tip of the elbow and the axilla~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~2cm superior to fu tu(LI18)"
33009306|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
33009307|NCT01701739|Experimental|aleglitazar / digoxin|
33009308|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
33009309|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
33009310|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
33009311|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
33009312|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
33009313|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
33417560|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
33009314|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
33009315|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
33009316|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
33009317|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
33009318|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
33009319|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
33009320|NCT01701804||integrative treatment|
33009321|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
33009322|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
33009323|NCT01701830||Control group|30 healthy subject
33009324|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
33009325|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
33009326|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
33009327|NCT01701869||NTHi positive|No intervention, this is an observational study
33009328|NCT01701869||NTHi negative|No intervention, this is an observational study
33009329|NCT01701869||Healthy Control|No intervention, this is an observational study
33009330|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
33009331|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
33009332|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
33009333|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
33009334|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
33009335|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
33009336|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
33009337|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
33009338|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
33009339|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
33009340|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
33009341|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
33009342|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
33009343|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
33009344|NCT01702090|Experimental|TMC114/ritonavir|
33009345|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
33009346|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
33009347|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
33009348|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
33009349|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
32866223|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
32866224|NCT04363164|Experimental|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
32866225|NCT04363164|Experimental|Arm B: Sequential Testosterone and Enzalutamide|Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.
32866226|NCT04363164|Experimental|Arm C: Variable Sequential Testosterone and Enzalutamide|Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 injections per cycle. Each cycle is 56 days. Patients with PSA progression will stop T injection and begin Enzalutamide. Patients on T with initial PSA decline will remain on high dose T for additional cycles of 2 injections until PSA progression occurs (≥25% increase in PSA from PSA nadir on current BAT cycle). These patients will then be started on Enzalutamide. Patients with PSA progression will stop Enzalutamide and will restart injections of T with 2 injections/cycle. Patients on enzalutamide with initial PSA decline after one 56-day cycle will continue on Enzalutamide until PSA progression occurs (≥25% increase in PSA from PSA nadir on current Enzalutamide cycle). These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.
32866227|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
32866228|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
32866229|NCT04836000|Placebo Comparator|Placebo Group|In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 12 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
32866230|NCT04836000|Experimental|Experimental Group|In addition to the conservative treatment of the control group, low-level laser therapy will be applied for 12 weeks.
32866231|NCT04836000|Active Comparator|Control Group|For 12 weeks, all three groups will receive five sessions per week of a protocolised treatment based on therapeutic exercises, analgesic electrotherapy and cryotherapy.
32866232|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
32866233|NCT00056563|Active Comparator|1|Deep Brain Stimulation
32866234|NCT00056563|Active Comparator|2|Best Medical Therapy
32866235|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
32866236|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
32866237|NCT04829916|Experimental|RMC-035|Participants will receive RMC-035 intravenously
32866238|NCT04829916|Placebo Comparator|Placebo|Participants will receive matching placebo solution intravenously
32866239|NCT04829838|Experimental|Intravenous levetireacetam|Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
32866240|NCT04829838|Experimental|intravenous phenytoin|Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
32866241|NCT01431755|Other|Restylane SubQ|
32866242|NCT01431755|Other|Restylane SubQ Lidocaine|
32866243|NCT00057577|Experimental|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
32866244|NCT00057577|Experimental|Medications alone|Participants will receive maintenance of antidepressant medication alone
32866245|NCT05618340|Other|Single group target value method|This trial is a prospective, multicenter, single-group target value method study. All subjects are treated uniformly with the pulse ablation system provided in this protocol for paroxysmal AF, and the test results for the main indicators are statistically compared with the target values, a widely accepted standard in professional medicine, and the test results are considered to be attained if the one-sided 95% confidence interval for the test results is not lower than the target values.
32866246|NCT01571427|Placebo Comparator|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
32866247|NCT01571427|Active Comparator|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
32866248|NCT01428557||Heart Failure patients (Breathe I)|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
32866249|NCT01428557||Heart Failure patients (Breathe Extension)|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
32866250|NCT04822974|Experimental|STUDY ARM|blood samples collection
32866251|NCT05605327|Experimental|EUS-guided gastroenterostomy|
32866252|NCT05605327|Active Comparator|Laparoscopic gastroenterostomy|
32866253|NCT01425671||Schizophrenic patients, family members|Schizophrenia Spectrum Disorder Patients
32866254|NCT01425671||Controls|Normal controls
33009350|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
33009351|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
33009352|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
33009353|NCT01702168||CBT Training|
33009354|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
33009355|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
33417561|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
33009356|NCT01702181|Experimental|OPA-15406|
33009357|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
33009358|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
33009359|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
33009360|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
33009361|NCT01702220|Experimental|CBT|
33009362|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
33009363|NCT01702272||Dengue Virus|
33009364|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
33009365|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
33009366|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
33009367|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
33009368|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
33009369|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
33009370|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
33009371|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
33009372|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
33009373|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
33009374|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
33009375|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
33009376|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
33009377|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
33009378|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
33009379|NCT01702402|Other|Comparison|A comparison area received standard government health services.
33009380|NCT01702415|Placebo Comparator|Placebo|Placebo
33009381|NCT01702415|Experimental|Zoledronic acid|Active IMP
33009382|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
33009383|NCT01702467|Placebo Comparator|Placebo|Matching placebo
33009384|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
33009385|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
33009386|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
33009387|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
33009388|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
33009389|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
33009390|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
33009391|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
33009392|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
33009393|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
33009394|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
33009395|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
33009396|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
33009397|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
33417562|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
33009398|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
33009399|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
33009400|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
33009401|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
33009402|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
33009403|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
33009404|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
33009405|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
33009406|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
33009407|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
33009408|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
33009409|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
33009410|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
33009411|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
33009412|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
33009413|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
33009414|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
33009415|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
33009416|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
33009417|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
33009418|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
33009419|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
33009420|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
33009421|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
33009422|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
33009423|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
33009424|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
33009425|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
33009426|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
33009427|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
33009428|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
33009429|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
33009430|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
33009431|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
33009432|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
33009433|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
33009434|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
33009435|NCT01702753|Placebo Comparator|Placebo|
33009436|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
33009437|NCT01702766|Placebo Comparator|Placebo|
33009438|NCT01702779|Other|optiflow|
33009439|NCT01702779|Other|O2|
33009440|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
33009441|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
33009442|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
33009443|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
33009444|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
33009445|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
33009446|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
33417563|NCT02087930||healthy control|healthy infants
33417564|NCT05190835|Other|Hallux surgery|These are patients operated on for hallux without change of strategy compared to current care
33417507|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
32902534|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
32902535|NCT05363306||thin crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2mm below the crestal bone in presence of thin mucosa (< 2.5mm)
32902536|NCT05363306||medium crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2) 1mm below the crestal bone in presence of medium mucosa (2.5-3.5mm);
32902537|NCT05363306||thick crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 1) at crestal level in presence of thick mucosa (> 3.5 mm);
32902538|NCT05363228|Experimental|Therapy by Dance and Movement|Participants assigned to this part take part in Dance Movement Therapy twice a week (90 minutes each) for the duration of three months.
32902539|NCT05363228|No Intervention|Control to Dance Movement Therapy|Participants assigned to this arm take part in no particular activity for the three months.
32902540|NCT05363228|Experimental|Movement Therapy by Tai Chi|Participants assigned to this part take part inTai Chi class twice a week (90 minutes each) for the duration of three months.
32902541|NCT05363228|No Intervention|Control to Tai Chi|Participants assigned to this arm take part in no particular activity for the three months.
32902542|NCT05547620|Experimental|Low Intensity Focused ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = Cerebellum
32902543|NCT05533580|Experimental|Remimazolam group|"Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~Maintenance of anesthesia remimazolam 0.4~1.2 mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
32902544|NCT05533580|Active Comparator|Propofol group|"Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope.~Maintenance of anesthesia propofol 4~10mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
32902545|NCT05529914|Experimental|Myofascial release + Neuromuscular exercises + Cold pack|
32902546|NCT05529914|Active Comparator|Neuromuscular exercises + Cold pack|
32902547|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
32902548|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
32902549|NCT05362682||Case|
32902550|NCT05362682||Test Negative Control|
32902551|NCT05362604||prenatal|patients affected by confirmed fetal esophageal, duodenal or intestinal atresia and followed in our high-risk pregnancy unit, and scheduled for delivery between 38 and 39 weeks in our tertiary center, regardless of the patient's place of residence
32902552|NCT05362604||postnatal|patients with unsuspected fetal atresia who delivered in their local hospitals: their newborns were transferred to our tertiary hospital within 24 hours and the mother had the option to be also transferred in order to follow her baby.
32902553|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Sample stored in Biorepository"
32902554|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Specimen Testing and Analysis~•Referral to Genetic Counselor, if indicated"
32902555|NCT05473286||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
32902556|NCT05362214||Audio (no visual cue)|The condition that a participant has to perform Baduanjin exercise by following the audio guidance/illustration according to the reference of Baduanjin practicing video.
32902557|NCT05362214||Video (2D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the video guidance/illustration according to the reference of Baduanjin practicing video.
32902558|NCT05362214||Drone (3D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the drone guiding system including a guidance from drone and audio illustration regarding the reference of Baduanjin practicing video.
33009447|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
32902559|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
32902560|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
32902561|NCT01523821|Other|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 & 15.
32902562|NCT01523821|Other|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 & 15.
32902563|NCT01523821|Other|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 & 15.
32902564|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
32902565|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
32902566|NCT05361980||Longitudinal Observational Group|Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU.
32902567|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
32902568|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
32902569|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
32902570|NCT05409716|Experimental|Compressive Elastic dressing|Patients who received compressive elastic dressing as a hemostasis technique after coronary angiography using radial approach.
32902571|NCT05409716|Active Comparator|wristband TR Band|Patients who received wristband TR Band as a hemostasis technique after coronary angiography using radial approach.
32902572|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
32902573|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
32902574|NCT05356598|Experimental|Peer-delivered|The arm will receive an intervention in the form of a peer-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a current ROTC cadet.
32902575|NCT05356598|Experimental|Authority-delivered|The arm will receive an intervention in the form of an authority-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a US Army Lieutenant Colonel who is currently a professor of military science for an ROTC battalion.
32902576|NCT05356598|Other|Control|The arm will receive no true intervention. Participants in the control arm will watch a video of a US Army First Lieutenant exercising with no reference to musculoskeletal injuries or help-seeking behavior.
32902577|NCT05395910|Experimental|PIPAC Paclitaxel|"3 patients will be allocated to PIPAC arm at Paclitaxel 15mg/m2. If there is 1 dose limiting toxicity (DLT), an additional 3 patients will be allocated to PIPAC arm at 15mg/m2. If there is 2 - 3 DLT, study had exceeded its Maximum Tolerable Dose (MTD) and we will proceed to stop recruitment.~Should there be no DLT, recruitment at PIPAC 30mg/m2 and ePIPAC 15mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs."
32902578|NCT05395910|Experimental|ePIPAC Paclitaxel|Should there be no DLT under PIPAC arm at Paclitaxel 15mg/m2, recruitment at ePIPAC 15mg/m2 and PIPAC 30mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs.
32902579|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
32902580|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
32902581|NCT05389046|Experimental|Escitalopram|Escitalopram monotherapy (10-20 mg/day）
32902582|NCT05389046|Experimental|Escitalopram + omega-3 PUFAs|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）
32902583|NCT05389046|Experimental|Escitalopram + Aripiprazole|Escitalopram (10-20 mg/day）combined with Aripiprazole （2.5-10 mg/day)
32902584|NCT05389046|Experimental|Escitalopram + omega-3 PUFAs + Aripiprazole|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）and Aripiprazole （2.5-10 mg/day)
32902585|NCT01566409|Active Comparator|Active maintenance treatment|
32902586|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
32902587|NCT04388696|Experimental|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
32902588|NCT04388696|Active Comparator|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
32902589|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:~Sutent (prospective) - Inlyta~Sutent (retrospective) - Inlyta~Sutent - not further active treatment (supportive care)~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
33325542|NCT05629338|Active Comparator|Cohort 3 Arm 4|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous control PF24 and 4 units of autologous FrontlineODP. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 4 will receive 4 units of PF24 during the first infusion visit, and following a 14 day washout period, they would receive 4 units of FrontlineODP during the second visit.
33325543|NCT03906786|Experimental|motivacional interviewing group|
33325544|NCT03906786|No Intervention|control group|
33325545|NCT01250106|Experimental|Probiotic capsule|
33325546|NCT01250106|Placebo Comparator|placebo capsule|
33325547|NCT01252056|No Intervention|Control|
33009448|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
33009449|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
33009450|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
33009451|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
33009452|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
33009453|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
33009454|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
33009455|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
33009456|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
33009457|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
33009458|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
33009459|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
33009460|NCT01703130|Experimental|Local Anesthestic Dose|
33009461|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
33009462|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
33009463|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
33009464|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
33009465|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
33009466|NCT01703234|Experimental|Ramipril|
33009467|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
33009468|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
33009469|NCT01703273|Experimental|low key intervention|
33009470|NCT01703273|Active Comparator|routine care|
33009471|NCT01703299||imipenem-treated patients|imipenem-treated patients
33009472|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
33009473|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
33325548|NCT01252056|Active Comparator|Probucol|Probucol treatment
33325549|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
33327118|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
33417508|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
33417509|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
33009474|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
33009475|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
33009476|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
33009477|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
33009478|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
33009479|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
33009480|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
33009481|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
33009482|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
33009483|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
33009484|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
33009485|NCT01703416||1|
33009486|NCT01703429||Individuals with MS|
33009487|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
33009488|NCT01703455|Experimental|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
33009489|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
33009490|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
33009491|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
33009492|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
33009493|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
33009494|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
33009495|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
33009496|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
33009497|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
33009498|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
33009499|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
33009500|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
33009501|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
33009502|NCT01703559|Placebo Comparator|Placebo|Administered once daily in both eyes for 15 days
33009503|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
33009504|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
33009505|NCT01703572|Experimental|OMP-52M51|
33009506|NCT01703585||metastatic breast cancer|
33009507|NCT01703585||metastatic colorectal cancer|
33009508|NCT01703585||metastatic gynecological cancer|
33009509|NCT01703585||metastatic melanoma|
33009510|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
33009511|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
33009512|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
33009513|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
33009514|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
33009515|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
33009516|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
33009517|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
33009518|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
33009519|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
33009520|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
33009521|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
33009522|NCT01703676||Patients|Klinefelter Patients
33009523|NCT01703676||Parents|Parents of Klinefelter Patients
33009524|NCT01703676||Controls M|Healthy Male Control with normal karyotype
33009525|NCT01703676||Controls F|Healthy female controls
33009526|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
33009527|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
33009528|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
33009529|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
33009530|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
33009531|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
33009532|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
33009533|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
33009534|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
33009535|NCT01703780||healthy control|"Age>50 years old~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)~No major cardiovascular risk factors:~Dyslipidemia~Diabetes~Smoke within one year"
33009536|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
33009537|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
33009538|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
33009539|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
33009540|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
33009541|NCT01703897||Obese patients|
33009542|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
33009543|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
33009544|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
33009545|NCT01703936|No Intervention|Control group|
33009546|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
33009547|NCT01703975|No Intervention|Single training|Students training alone on the simulator
33009548|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
33009549|NCT01704001|Experimental|Renal impairment grade 0|
33009550|NCT01704001|Experimental|Renal impairment grade 1|
33009551|NCT01704001|Experimental|Renal impairment grade 2|
33009552|NCT01704001|Experimental|Renal impairment grade 3|
33009553|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
33009554|NCT01704014||Control Group|Age and sex-matched control subjects
33009555|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
33009556|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
33009557|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
33417510|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
33009558|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
33009559|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
33009560|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
33009561|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
33009562|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
33009563|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
33009564|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
33009565|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
33009566|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
33009567|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
33009568|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
33009569|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
33009570|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
33009571|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
33009572|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
33009573|NCT01704131||children > 6 months|children > 6 months of age
33009574|NCT01704131||children < 6 months|children < 6 months
33009575|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
33009576|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
33009577|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
33009578|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
33009579|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
33009580|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
33009581|NCT01704274|Placebo Comparator|Placebo|Placebo patch
33009582|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
33009583|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
33009584|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
33009585|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
33009586|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
33009587|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
33009588|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
33009589|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
33009590|NCT01704378|Experimental|BIAsp|
33009591|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
33009592|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
33009593|NCT01704417|Experimental|IDeg followed by IGlar|
33009594|NCT01704417|Experimental|IGlar followed by IDeg|
33009595|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
33009596|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
33009597|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
33009598|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
33009599|NCT01704469|Experimental|The local anesthetic injection group|
33415645|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
33415646|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
33415647|NCT04782791|Experimental|Nivo + SOX|Nivolumab plus SOX
33415648|NCT04782791|Active Comparator|Nivo|Nivolumab
33415649|NCT04773197|Experimental|Coach-assisted C-CBT with BtB|Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
33415650|NCT04773197|Active Comparator|Coach-assisted animated C-CBT with EMW|Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
33009600|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
33009601|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
33415651|NCT04773197|Active Comparator|Standard stand-alone C-CBT with BtB|Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.
33415652|NCT01341353|Active Comparator|Antiarrythmic Drugs|
33009602|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
33009603|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
33009604|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
33009605|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
33009606|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
33009607|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
33009608|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
33009609|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
33009610|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
33009611|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
33009612|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
33009613|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
33009614|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
33009615|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
33009616|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
33415653|NCT01341353|Experimental|ablation|
33415654|NCT05170139|Experimental|Caffeine|Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.
33415655|NCT05170139|Placebo Comparator|Control condition|Participants will ingest a drink of carbohydrates without caffeine
33009617|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
33009618|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
33009619|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
33009620|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
33009621|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
33009622|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
33009623|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
33009624|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
33009625|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
33009626|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
33009627|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
33009628|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
33009629|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
33009630|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
33009631|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
33009632|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
33009633|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
33009634|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
33009635|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
33009636|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
33009637|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
33009638|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
33009639|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
33009640|NCT01704742||No treatment|
33009641|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
33415656|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
33325550|NCT03906552|Experimental|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
33325551|NCT03906552|Experimental|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
33325552|NCT03906552|No Intervention|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~No application was made to theneonates in the control group before heel lancing procedure"
33009642|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
33009643|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
33009644|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
33325553|NCT03906630||Shoulder patients|
33009645|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
33009646|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
33009647|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
33009648|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
33009649|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
33009650|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
33009651|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
33009652|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
33009653|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
33009654|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
33009655|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
33009656|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
33009657|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
33009658|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
33009659|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
33009660|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
33009661|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
33009662|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
33009663|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
33009664|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
33009665|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
33009666|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009667|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009668|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009669|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009670|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009671|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009672|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009673|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
33009674|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
33009675|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
33009676|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
33009677|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
33009678|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
33009679|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
33009680|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
33009681|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
33009682|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
33009683|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
33009684|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
33009685|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
33009686|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
33009687|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
33009688|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
33009689|NCT01705210||Diabetes mellitus type 2 (DM2)|
33009690|NCT01705210||metabolic syndrome (MetS)|
33009691|NCT01705210||healthy controls|
33009692|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
33009693|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
33009694|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
33009695|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
33009696|NCT01705249|Experimental|estradiol / norethisterone acetate|
33009697|NCT01705262||u-65 M|Male patients under 65
33009698|NCT01705262||u-65 K|Female patients under 65 years old
33009699|NCT01705262||o-65 -K|Female patients over 65 years
33009700|NCT01705262||O-65 M|Male patients over 65 years
33009701|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
33009702|NCT01705275|Placebo Comparator|Placebo BID|0mg
33009703|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
33009704|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
33009705|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
33009706|NCT01705327||Parkinson's Disease Subjects|
33009707|NCT01705327||Healthy Control Subjects|
33009708|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33415657|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
33009709|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
33009710|NCT01705379||MenACWY-CRM|2 years of age and older
33009711|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
33009712|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
33009713|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
33009714|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
33009715|NCT01705431|Experimental|Support for students with EBD|
33009716|NCT01705431|No Intervention|Control|Participants continue with services as usual
33009717|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
33009718|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
33009719|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
33009720|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
33009721|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
33009722|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
33009723|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
33009724|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
33009725|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
33009726|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
33009727|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
33009728|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
33009729|NCT01705665||Aspirated Coronary Thrombi During AMI|
33009730|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
33009731|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
33009732|NCT01705704||Cohort|
33009733|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
33009734|NCT01705743|Active Comparator|Group 2 Sevoflurane|
33009735|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
33009736|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
33009737|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
33009738|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
33009739|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
33009740|NCT01705782|No Intervention|Saline|Only saline is given.
33009741|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
33009742|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
33009743|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
33009744|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
33009745|NCT01705808|Experimental|Protein C concentrate|
33009746|NCT01705808|Placebo Comparator|Placebo|
33009747|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
33009748|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
33009749|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
33009750|NCT01705860||Assessment|All subjects will receive same assessments.
33009751|NCT01705873||LPV/r|LPV/r based HAART
33009752|NCT01705873||Efavirenz|EFV first line based HAART
33009753|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
33009754|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
33009755|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
33009756|NCT01705912|Active Comparator|Control|Basic intervention.
33009757|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
33009758|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
33009759|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
33415658|NCT05183087||Special Operations Forces (SOF) Personnel|n=30 SOF Personnel
33415659|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
33415660|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
33009760|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
33009761|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
33415661|NCT01341431|Experimental|bee venom|
33415662|NCT01341431|Placebo Comparator|saline|
33009762|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
33009763|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
33415663|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
33415664|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
33415665|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33009764|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
33415666|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33415667|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33415668|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33415669|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33415670|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
33415671|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
33415672|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
33415673|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
33415674|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
33415675|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
33415676|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
33415677|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
33415678|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
33415679|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
33415680|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
33415681|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
33415682|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
33415683|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
33415684|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
33009765|NCT01705951|Experimental|Group 2: Resistance Training only|
33009766|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
33009767|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
33009768|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
33009769|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
33009770|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
33009771|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
33009772|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
33009773|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
33009774|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
33009775|NCT01706055||Group 1|
33009776|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
33009777|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
33415685|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
33009778|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
33009779|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
33009780|NCT01706185||Cancer Group|
33009781|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
33009782|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
33009783|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
33009784|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
33009785|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
33009786|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
33009787|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
33009788|NCT01706289||diabetic mellitus screen|
33009789|NCT01706302||Cohort Group|
33009790|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
33009791|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
33009792|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
33009793|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
33009794|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
33009795|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
33009796|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
33009797|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
33009798|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
33009799|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
33009800|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
33009801|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
33009802|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
33415686|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
33415687|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
33415688|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
33415689|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
33415690|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
33009803|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
33009804|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
33009805|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
33009806|NCT01706367|Experimental|Low dose C diff vaccine|
33009807|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
33009808|NCT01706367|Experimental|Mid dose C diff vaccine|
33009809|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
33009810|NCT01706367|Experimental|High dose C diff vaccine|
33009811|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
33009812|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
33009813|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
33009814|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
33009815|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
33009816|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
33009817|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
33009818|NCT01706419|No Intervention|no school meal|control group receiving no school meal
33009819|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
33009820|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
33009821|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
33009822|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
33009823|NCT01706445|No Intervention|Control|
33009824|NCT01706445|Other|intervention|Exercise training
33009825|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
33009826|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
33009827|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
33009828|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
33009829|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
33009830|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
33009831|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
33009832|NCT01706523|Experimental|STX209|Active treatment with STX209
33009833|NCT01706562||Itraconazole|
33009834|NCT01706601||Hemorrhoids|Patient with hemorrhoids
33009835|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
33009836|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
33415691|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
33415692|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
33415693|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
33009837|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
33009838|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
33009839|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
33009840|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
33009841|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
33009842|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
33009843|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
33009844|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
33009845|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
33009846|NCT01706718|Placebo Comparator|Control white bread|
33415694|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
33415695|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
33415696|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
33009847|NCT01706718|Experimental|Beetroot bread|
33009848|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
33009849|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
33009850|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
33009851|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
33009852|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
33009853|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
33009854|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
33009855|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
33009856|NCT01706783|Active Comparator|Norditropin NordiFlex®|
33009857|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
33009858|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
33009859|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
33009860|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
33009861|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
33009862|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
33009863|NCT01706809||Biomarkeres|
33009864|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
33009865|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
33009866|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
33009867|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
33009868|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
33009869|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
33009870|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
33009871|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
33009872|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
33009873|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
33009874|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
33009875|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
33009876|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
33009877|NCT01707017|Active Comparator|High-load strength training|
33009878|NCT01707017|Active Comparator|Low-load strength training|
33009879|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
33009880|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
33009881|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
33415697|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
33415698|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
33009882|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
33009883|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
33009884|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
33009885|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
33009886|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
33009887|NCT01707082|Experimental|Part A Cohort 1|
33009888|NCT01707082|Experimental|Part A Cohort 2|
33009889|NCT01707082|Experimental|Part A Cohort 3|
33009890|NCT01707082|Experimental|Part A Cohort 4|
33009891|NCT01707082|Experimental|Part A Cohort 5|
33009892|NCT01707082|Experimental|Part B Cohort 1|
33009893|NCT01707082|Experimental|Part B Cohort 2|
33009894|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
33009895|NCT01707134|Experimental|insulin aspart|
33009896|NCT01707134|Active Comparator|human insulin|
33009897|NCT01707160|Experimental|Treatment period 1|
33009898|NCT01707160|Active Comparator|Treatment period 2|
33009899|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
33009900|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
33009901|NCT01707186||Group 1A|Early phase, requiring change in treatment
33009902|NCT01707186||Group 2|Established phase, stable treatment
33009903|NCT01707186||Group 2A|Established phase, requiring a change in treatment
33009904|NCT01707186||Group 1|Early phase, stable treatment
33009905|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
33009906|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
33009907|NCT01707212|Other|No pain management education|Control - general information about immunization only
33009908|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
33009909|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
33009910|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
33009911|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
33009912|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
33009913|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
33009914|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
33009915|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
33009916|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
33009917|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
33009918|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
33009919|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
33009920|NCT01707355|Active Comparator|invention with poster|intervention - poster
33009921|NCT01707355|No Intervention|control|control - no poster
33009922|NCT01707394|Experimental|Group 1: Apixaban (low dose)|
33009923|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|
33009924|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|
33009925|NCT01707394|Experimental|Group 3: Apixaban (low dose)|
33009926|NCT01707394|Experimental|Group 4: Apixaban (low dose)|
33009927|NCT01707394|Experimental|Group 5: Apixaban (low dose)|
33009928|NCT01707394|Experimental|Group 2A (higher dose): Apixaban (low dose)|
33009929|NCT01707407|Experimental|Pomalidomide|
33009930|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
33009931|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
33009932|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
33009933|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
33009934|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
33009935|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
33009936|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
33009937|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
33009938|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
33009939|NCT01707524|No Intervention|Trans-femoral approach|Observational
33009940|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
33009941|NCT01707550||Cohort|
33009942|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
33009943|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
33009944|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
33009945|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
33009946|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
33009947|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
33009948|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
33009949|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
33009950|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
33009951|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
33009952|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
33009953|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
33009954|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
33009955|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
33009956|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
33009957|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
33009958|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
33009959|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
33009960|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
33417511|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
33415699|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
33009961|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
33009962|NCT01707719||Alzheimer's disease|
33415700|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
33415701|NCT04552925|Active Comparator|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
33009963|NCT01707719||Non demented subjects|
33009964|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
33415702|NCT04552925|Experimental|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
33009965|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
33009966|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
33009967|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
33009968|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
33009969|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
33009970|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
33009971|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
33009972|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
33009973|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
33009974|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
33009975|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
33009976|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
33009977|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
33009978|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
33009979|NCT01707875||fetal ventricle brain asymmetry|
33009980|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
33009981|NCT01707901|Experimental|ONO-8539|ONO-8539
33009982|NCT01707901|Placebo Comparator|Placebo|Placebo
33009983|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
33009984|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
33009985|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
33009986|NCT01707927||mosaic Ultra|Need a aortic valve replacement
33009987|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
33009988|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
33009989|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
33009990|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
33009991|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
33009992|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
33009993|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
33009994|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
33009995|NCT01707979||Non diabetic control|Male participants, control group non diabetic
33009996|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
33009997|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
33415703|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
33415704|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
33009998|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
33009999|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
33010000|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
33010001|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
33010002|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
33010003|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
33010004|NCT01708044|Placebo Comparator|Placebo|
33010005|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
33010006|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
33010007|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
33010008|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
33010009|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
33010010|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
33010011|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
33010012|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
33010013|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
33010014|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
33010015|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
33010016|NCT01708148|Placebo Comparator|Placebo|30 Participants
33010017|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
33010018|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
33010019|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
33010020|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
33010021|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
33010022|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
33010023|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
33010024|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
33010025|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
33010026|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
33010027|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
33010028|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
33010029|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
33010030|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
33010031|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
33010032|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
33010033|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
33010034|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
33010035|NCT01708395||Cohort 1|First 50 patients
33010036|NCT01708395||Cohort 2|2nd group of 50 patients
33010037|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
33010038|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
33010039|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
33415705|NCT04535687|Experimental|Treatment group|Fluzoparib alone
33415706|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
33010040|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
33010041|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
33010042|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
33010043|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
33010044|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
33010045|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
33010046|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
33010047|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
33010048|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
33010049|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
33010050|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
33010051|NCT01708616|Placebo Comparator|Placebo + risperidone|
33010052|NCT01708616|Placebo Comparator|Placebo +placebo|
33010053|NCT01708616|Active Comparator|RO5285119 + placebo|
33010054|NCT01708616|Experimental|RO5285119 + risperidone|
33010055|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
33010056|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
33010057|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~4.4 µg Isoproterenol hydrochloride, injection solution~0.93 mg Aminophylline injection solution~8.8 µg Atropine, injection solution"
33010058|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
33010059|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
33010060|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
33010061|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
33010062|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
33010063|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
33010064|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
33010065|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
33010066|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
33010067|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
33010068|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
33010069|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
33010070|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
32866255|NCT04835922|Experimental|Intercostal Nerve Block|• In Group I (ICBN group): Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine at the termination of PCNL under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each).
33010071|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
33010072|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
33010073|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
33010074|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
33010075|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
33010076|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
33010077|NCT01708746||Enrolled subjects|
33010078|NCT01708746||Historic control|
33010079|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
33010080|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
33010081|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
33415707|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
33415708|NCT04490993|Experimental|APL-1202 treatment|
33415709|NCT04490993|Placebo Comparator|Placebo|
33415710|NCT02055482|Experimental|BAY85-3934|
33415711|NCT02055482|Active Comparator|Darbepoetin|
33415712|NCT04465565|Experimental|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
33010082|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
33010083|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
33010084|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
33010085|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
33010086|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
33010087|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
33010088|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
33010089|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
33010090|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
33010091|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
33010092|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
33010093|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
33010094|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
33010095|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
33010096|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
33010097|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
33010098|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
33010099|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
33010100|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
33010101|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
33010102|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
33010103|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
33010104|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
33010105|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
33010106|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
33010107|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
33010108|NCT01708993|Active Comparator|Arm B: Pemetrexed|
33010109|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
33010110|NCT01708993|Active Comparator|Arm D: Docetaxel|
33010111|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
33010112|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
33010113|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
33010114|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
33010115|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
33010116|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
33010117|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
33010118|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
33010119|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
33010120|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010121|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010122|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010123|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010124|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010125|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
33010126|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
33010127|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
33010128|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
33010129|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
33010130|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
33010131|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
33010132|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
33010133|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
33010134|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
33010135|NCT01709240|Experimental|BioWeld1 System|
33010136|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
33010137|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
33010138|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
33010139|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
33010140|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
33010141|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
33010142|NCT01709279|Other|adipose tissue derived stromal cells|
33010143|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
33010144|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
33010145|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
33010146|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
33010147|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
33010148|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
33010149|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
33010150|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
33010151|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
33010152|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
33010153|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
33010154|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
33010155|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
33010156|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33010157|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~Debulking surgery~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
33010158|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
33010159|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
33010160|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
33010161|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
33010162|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
33010163|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
33010164|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
33010165|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
33010166|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
33010167|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
33010168|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
33010169|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
33010170|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
33010171|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
33010172|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
33417512|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
33417513|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
33010173|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
33010174|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
33010175|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
33010176|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
33010177|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
33010178|NCT01709669||Enrolling by invitation|
33010179|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
33010180|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
33010181|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
33010182|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
33010183|NCT01709773|Experimental|Focal treatment arm|
33010184|NCT01709812|Other|1 standard care|standard care
33010185|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
33010186|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
33010187|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
33010188|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
33010189|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
33010190|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
33010191|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
33010192|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
33010193|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
33010194|NCT01709890||Airway catheter during sedation|
33010195|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
33010196|NCT01709929|Experimental|Insulin detemir|
33010197|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
33010198|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
33010199|NCT01709955|Experimental|Gucomannan|
33010200|NCT01709955|Placebo Comparator|Placebo pill|
33010201|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
33010202|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
33010203|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
33010204|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
33010205|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
33010206|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
33010207|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
33010208|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
33010209|NCT01710072|No Intervention|no aspirin|
33010210|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
33010211|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
33010212|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
33010213|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
33010214|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
33010215|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
33010216|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
33010217|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
33010218|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
33010219|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
33010220|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
33010221|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
33010222|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
33010223|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
33010224|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
33010225|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
33010226|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
33010227|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
33010228|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
33010229|NCT01710267||Observation group|This group includes all volunteers of this observation study.
33010230|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
33010231|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
33010232|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
33010233|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
33010234|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
33010235|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
33010236|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
33010237|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
33010238|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
33010239|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
33010240|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
33010241|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
33010242|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
33010243|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
33010244|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
33010245|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
33010246|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
33417565|NCT05190835|Other|Metatarsal paddle surgery|These are patients operated on for metatarsal paddle without change of strategy compared to current care
33010247|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
33010248|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
33415713|NCT04465565|No Intervention|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
33415714|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
33415715|NCT04743947||Patients with kidney failure receiving dialysis|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).
33415716|NCT04743947||Kidney transplant patients|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.
33010249|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
33010250|NCT01710423|No Intervention|Delayed Entry Control|
33010251|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
33415717|NCT04743947||age-matched controls in non-dialysis, non-kidney transplant patients|Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.
33415718|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
33415719|NCT02059460|Placebo Comparator|Control group|
33010252|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
33010253|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
33010254|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
33010255|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
33010256|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
33010257|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
33010258|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
33010259|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
33010260|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
33010261|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
33010262|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
33010263|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
33010264|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
33010265|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
33010266|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
33010267|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
33010268|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
33010269|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
33010270|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~Capecitabine 625mg/m2 (days 1-21) b.d. orally~8 x 3-weekly cycle"
33010271|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours~6 x 4-weekly cycle"
33010272|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
33010273|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
33415720|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
33415721|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
33417514|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
33325554|NCT03906396|Experimental|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
33325555|NCT03906396|No Intervention|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
33325556|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
33010274|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
33010275|NCT01710631|Placebo Comparator|placebo|placebo tablet
33010276|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
33010277|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
33010278|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
33010279|NCT01710683||Control group|Median age 45 years, 18-63.
33010280|NCT01710683||Intervention group|Median age 46 years, 18-62.
33010281|NCT01710696|Experimental|Individual dose|
33010282|NCT01710696|Experimental|Fixed dose|
33010283|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
33010284|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
33010285|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
33010286|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
33010287|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
33010288|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
33010289|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
33010290|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
33010291|NCT01710761|Placebo Comparator|Placebo|
33010292|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
33010293|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
33010294|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
33010295|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
33010296|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
33010297|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
33010298|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
33010299|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
33010300|NCT01710878|Other|Intergard Synergy Graft|
33010301|NCT01710917||Targinact® (oxycodon/naloxon)|
33325557|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
33325558|NCT03911544|Active Comparator|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
33325559|NCT03911544|No Intervention|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
33325560|NCT03911310|Experimental|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer [18F]PSMA-11 PET/CT followed by the [68Ga]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
33325561|NCT03911310|Active Comparator|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer [68Ga]PSMA-11 PET/CT followed by the [18F]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
33325562|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
33325563|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
33325564|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
33325565|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
33325566|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
33417566|NCT05190835|Other|Hallux and metatarsal pallet surgery|These are patients operated on for hallux and metatarsal paddle without change of strategy compared to current care
33010302|NCT01710930|Experimental|Study of predictive factors|
33010303|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
33325567|NCT03915522|Experimental|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
33325568|NCT03915522|Placebo Comparator|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
33010304|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
33010305|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
33010306|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
33010307|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
33010308|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
33325569|NCT03915600|Experimental|Quinoa|Personalized diet added with quinoa
33325570|NCT03915600|Experimental|Flaxseed|Personalized diet added with Flaxseed
33325571|NCT03915600|Experimental|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
33325572|NCT03915600|No Intervention|Normal diet|Personalized diet without dietary supplement
33325573|NCT03915288|Experimental|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
33325574|NCT03915288|Experimental|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
33325575|NCT03915288|Active Comparator|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
33325576|NCT01148472|Experimental|Escitalopram|
33325577|NCT01148472|Active Comparator|Duloxetine|
33325578|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
33010309|NCT01710982|Active Comparator|TZP-101|TZP-101
33325579|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
33325580|NCT03914820|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
33325581|NCT03914820|Active Comparator|Comparator|Standard surgey without HIPEC CO2
33325582|NCT03914898|Experimental|Nurse led intervention group|"The program was four sessions; It took about 1.5-2 hours. The intervention group was divided into two groups. The author who administered the intervention previously led nurse support groups, is also an active educator in psychiatry and mental health nursing, and has training in cognitive behavioral therapy.~The group sessions were based on cognitive restructuring techniques."
33325583|NCT03914898|No Intervention|Control Group|No intervention was applied to the control group during the study.
33010310|NCT01710982|Placebo Comparator|Placebo|Placebo
33325584|NCT03915054|Active Comparator|AREG-TRIGGER|"Per case (6mL) 5940 µL Basal Medium~60 µL IVM MIX Do not need to filtrate media."
33010311|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
33010312|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
33010313|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
33010314|NCT01711008|Placebo Comparator|No Breakfast|Water only
33010315|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
33010316|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
33010317|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
33010318|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
33325585|NCT03915054|Active Comparator|CONTROL-TRIGGER|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
33010319|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
33010320|NCT01711060|Experimental|oxytocin|
33010321|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
33010322|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
33010323|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
33010324|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
33010325|NCT01711099|Experimental|ESMR treated|
33010326|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
33010327|NCT01711125|Experimental|Arm 1|Baclofen low dose
33010328|NCT01711125|Experimental|Arm 2|Baclofen high dose
33010329|NCT01711125|Placebo Comparator|Arm 3|Placebo
33010330|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
33010331|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
33010332|NCT01711151||Sarciodosis|Questionnaire evaluation
33010333|NCT01711151||Healthy Controls|Questionnaire evaluation
33010334|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
33010335|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
33010336|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
33010337|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
33010338|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
33010339|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
33010340|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
33010341|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
33010342|NCT01711281|Experimental|Intracardiac Impedance Measurement|
33010343|NCT01711307|Experimental|non-operative|cast applied within 48 hours
33010344|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
33010345|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
33010346|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
33010347|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
33010348|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
33010349|NCT01711398|Experimental|IPP204106N|
33010350|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
33010351|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
33010352|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
33010353|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
33010354|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
33010355|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
33010356|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
33010357|NCT01711463|Placebo Comparator|Placebo|matching placebo
33010358|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
33010359|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
33010360|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
33010361|NCT01711502||Female patients diagosed with metastatic breast cancer|
33010362|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
33010363|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33010364|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33010365|NCT01711567|Active Comparator|entecavir|standard drugs
33010366|NCT01711567|Active Comparator|tenofovir|study drugs
33010367|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
33010368|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
33010369|NCT01711606||unselected Fragile-X patients|
33010370|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
33010371|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
33010372|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
33010373|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
33010374|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
33010375|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
33010376|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
33010377|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
33010378|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
33010379|NCT01711762|Experimental|GDC-0973 Single Arm|
33010380|NCT01711775|Experimental|Aleglitazar|
33010381|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
33010382|NCT01711801|Placebo Comparator|Part 1: Placebo|
33010383|NCT01711801|Experimental|Part 1: RO5545965|
33010384|NCT01711801|Experimental|Part 2: Food effect|
33010385|NCT01711814|Experimental|ASP015K|Experimental
33010386|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
33010387|NCT01711840||Symbicort|
33010388|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
33010389|NCT01711892|No Intervention|Control group|Usual care
33010390|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
33010391|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
33010392|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
33417515|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
33010393|NCT01711931|Active Comparator|Everolimus-eluting stent|
33010394|NCT01711931|Active Comparator|Biolimus-eluting stent|
33010395|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
33010396|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
33010397|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
33010398|NCT01711970|Experimental|VB-111|
33010399|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
33010400|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
33010401|NCT01711996||Normal|0-3 year old children without hydronephrosis
33010402|NCT01712022||Dry Eye|clinical diagnosis of dry eye
33010403|NCT01712022||Contact Lens|routine wear of contact lens
33010404|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
33010405|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
33010406|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
33010407|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
33010408|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
33010409|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
33010410|NCT01712100|Experimental|irbesartan|300 mg tablet
33010411|NCT01712100|Active Comparator|Avapro|300 mg tablet
33010412|NCT01712113|Experimental|irbesartan|300 mg tablet
33010413|NCT01712113|Active Comparator|Avapro|300 mg tablet
33010414|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
33010415|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
33010416|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
33010417|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
33010418|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
33010419|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
33010420|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
33010421|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
33010422|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
33010423|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
33010424|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
33010425|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
33010426|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
33010427|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
33010428|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
33010429|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
33010430|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
33010431|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
33010432|NCT01712386|Experimental|COPD|
33010433|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
33010434|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
33010435|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
33010436|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
33010437|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
33010438|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
33010439|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
33010440|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
33010441|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
33325586|NCT03915132|Experimental|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
33010442|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
33010443|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
33325587|NCT01250574||Postoperative infections|
33325588|NCT01250574||Bacterial infections in the GI tract|
33010444|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
33010445|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
33010446|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
33010447|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
33010448|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
33010449|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
33010450|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
33010451|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
33010452|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
33010453|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
33010454|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
33010455|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
33010456|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
33010457|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
33010458|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
33010459|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
33010460|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
33010461|NCT01712737|Experimental|Water control|children were given ad libitum access to water
33010462|NCT01712750||VOT on bypass|
33010463|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
33010464|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
33010465|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
33010466|NCT01712828|Experimental|Lenalidomide plus Quinidine|
33010467|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
33010468|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
33010469|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
33010470|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
33010471|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
33010472|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
33010473|NCT01712880|Active Comparator|open debridement with modular exchange|
33010474|NCT01712880|Active Comparator|one stage exchange|
33010475|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
33010476|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
33325589|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
33325590|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
33325591|NCT03911232|Experimental|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
33325592|NCT03911232|No Intervention|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
33325593|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
33325594|NCT01252368||healthy participants|
33010477|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
33010478|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
33325595|NCT03910842|Experimental|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
33325596|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
33010479|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
33010480|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
33010481|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
33010482|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
33010483|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
33010484|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
33010485|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
33010486|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
33010487|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
33010488|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
33010489|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
33010490|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
33010491|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
33010492|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
33010493|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
33010494|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
33010495|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
33010496|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
33010497|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
33010498|NCT01712971||OPD|standard open pancreaticoduodenectomy
33010499|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
33010500|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
33010501|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
33010502|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
33010503|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
33010504|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
33010505|NCT01713075||Symbicort|
33010506|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
33010507|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
33010508|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
33010509|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
33010510|NCT01713114|Experimental|Low carbohydrate|
33010511|NCT01713114|Experimental|Moderate carbohydrate|
33010512|NCT01713114|Experimental|Higher Carbohydrate|
33010513|NCT01713114|Placebo Comparator|Meal Skipping|
33010514|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
33010515|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
33010516|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
33010517|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
33010518|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
33010519|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
33415722|NCT04739735|Experimental|Computer Controlled -Intraligamentary Anaesthesia (CC-ILA)|"CC-ILA will be administered using the Wand-STA system according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted mandibular teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle."
33010520|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
33010521|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
33010522|NCT01713179|No Intervention|control|
33417516|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
33010523|NCT01713192||Cardiac surgery|
33010524|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
33010525|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
33010526|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
33010527|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
33010528|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
33010529|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
33010530|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
33010531|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
33010532|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
33010533|NCT01713296|Experimental|Pazopanib|
33010534|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
33010535|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
33010536|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
33010537|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
33010538|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
33010539|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
33010540|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
33010541|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
33010542|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
33010543|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
33010544|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
33010545|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
33010546|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
33010547|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
33010548|NCT01713426|Experimental|Qutenza|Cutaneous patch
33010549|NCT01713426|Active Comparator|Pregabalin|Oral capsule
33415723|NCT04739735|Active Comparator|Conventional Injection of Inferior Alveolar Nerve Block|"In the control group, a standard technique for the Inferior Alveolar Nerve Block (IANB) will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed between the two primary molars on the opposite side of the arch, entering the tissues at the level of the occlusal plane or slightly lower until bony resistance is met.~Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. Two-thirds the needle length should be inserted. The needle is withdrawn, then 0.5 ml as a long buccal infiltration distal to the second primary molar is administered."
33415724|NCT02059538|Other|Group 1|Metabolic syndrome
33415725|NCT02059538|Other|Group 2|Severly obese patients
33415726|NCT02059538|Other|Group 3|Type-2 diabetics patients
33010550|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
33010551|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
33415727|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
33415728|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
33415729|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
33415730|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
33415731|NCT02059538|Other|Group 8|Healthy volunteers
33415732|NCT01341899|Experimental|stem cell transplantation|
33010552|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
33010553|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
33010554|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~Routine blood samples~Electrocardiogram (12 leads)~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~Comprehensive Echocardiography"
33010555|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
33010556|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
33010557|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
33010558|NCT01713491||Demented|IQCODE score 64 or more
33010559|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
33010560|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
33010561|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
33010562|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
33010563|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
33010564|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
33010565|NCT01713543|No Intervention|Control Group|Usual care by physician.
33010566|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
33010567|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
33010568|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
33010569|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
33010570|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
33010571|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
33010572|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
33010573|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
33415733|NCT04292405||Heart Failure Patients|Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
33415734|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
33415735|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
33415736|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
33010574|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
33010575|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
33415737|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
33415738|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
33415739|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
33415740|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
33415741|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
33010576|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
33415742|NCT04724681|Active Comparator|Monitoring arm|Patients in this arm will have their vital signs monitored with continuous wireless devices and patients in this arm will be monitored with standard Early Warning Score
33415743|NCT04724681|No Intervention|standard Early Warning Score arm|Patients in this arm will be monitored with standard Early Warning Score
33415744|NCT04356209|Experimental|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
33415745|NCT04356209|Other|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
33415746|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
33010577|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
33010578|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
33010579|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
33415747|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
33010580|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
33010581|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
33010582|NCT01713712|No Intervention|Routine Obstetric Care|
33010583|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
33010584|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route~300 mg dose (independent from total IgE, weight or high)"
33010585|NCT01713725|Placebo Comparator|Placebo|"Saline serum~Subcutaneous route~0.6 ml saline serum with same volume as an active treatment"
33010586|NCT01713738|Experimental|rituximab|
33010587|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
33010588|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
33010589|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
33010590|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
33415748|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
33415749|NCT01343849||Suspected Breast cancer subjects|
33415750|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
33415751|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
33010591|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
33415752|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
33415753|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
33415754|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
33415755|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
33415756|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
33415757|NCT04695431||Patients from the BLU-285-2101 and BLU-285-2202 studies|Patients with advanced systemic mastocytosis who received treatment with avapritinib as part of the BLU-285-2101 and BLU-285-2202 studies
33415758|NCT04695431||External Control Group|Patients with advanced systemic mastocytosis that received best available therapy
33415759|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
33010592|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
33010593|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
33415760|NCT05162573|Experimental|EBRT + 3 GBq Lu-PSMA|
33415761|NCT05162573|Experimental|EBRT + 6 GBq Lu-PSMA|
33010594|NCT01713803|Placebo Comparator|Sugar pill|
33415762|NCT05162573|Experimental|EBRT + 9 GBq Lu-PSMA|
33415763|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
33010595|NCT01713803|Experimental|buprenorphine and nalaxone|
33010596|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
33010597|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
33010598|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
33010599|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
33010600|NCT01713881||post-registry|"Registry Group:~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
33010601|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
33010602|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
33010603|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
33010604|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
33010605|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
33010606|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
33010607|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
33010608|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33010609|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
33010610|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
33010611|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
33010612|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
33010613|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
33010614|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
33010615|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
33010616|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
33010617|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
33010618|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
33010619|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
33010620|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
33010621|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
33010622|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
33010623|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
33415764|NCT02055950||Kidney perfused by pulsatile machine|
33415765|NCT02055950||Kidney stored in refrigerated solution|
33415766|NCT04356755|Experimental|autologous cultured ASC|Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
33415767|NCT04356755|Placebo Comparator|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
33010624|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
33010625|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
33415768|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
33010626|NCT01714154|Experimental|A: setrobuvir|
33010627|NCT01714154|Experimental|B: setrobuvir + DNV/r|
33010628|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
33010629|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
33010630|NCT01714180||Obese Patients|
33010631|NCT01714180||Non-obese Patients|
33010632|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
33010633|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
33010634|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
33010635|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
33010636|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
33010637|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
33010638|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
33010639|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
33010640|NCT01714284|Experimental|Diet and Exercise|
33010641|NCT01714284|Sham Comparator|Informative|
33010642|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
33010643|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
33010644|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
33010645|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
33010646|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
33010647|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
33010648|NCT01714401|Active Comparator|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
33010649|NCT01714401|Active Comparator|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
33010650|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
33010651|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
33010652|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
33415769|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
33010653|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
33010654|NCT01714427|Active Comparator|Dexamethasone|
33415770|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
33415771|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
33010655|NCT01714427|Placebo Comparator|Sterile isotonic saline|
33010656|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
33010657|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
33010658|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
33010659|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
33010660|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
33010661|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
33010662|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
33010663|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
33010664|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
33010665|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
33010666|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
33010667|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
33010668|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
33010669|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
33010670|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
33010671|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
33010672|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
33010673|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
33010674|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
33010675|NCT01714557|No Intervention|No prophylaxis|
33010676|NCT01714557|Active Comparator|piperacillin|
33010677|NCT01714557|Experimental|piperacillin/tazobactam|
33010678|NCT01714570|Experimental|piperacillin/tazobactam|
33010679|NCT01714570|Active Comparator|imipenem/cilastatin|
33010680|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
33010681|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
33010682|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
33010683|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
33010684|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
33010685|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
33010686|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
33415772|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
33415773|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
33415774|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
33415775|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
33010687|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
33010688|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
33010689|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
33010690|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
33010691|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
33010692|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
33010693|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
33010694|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
33010695|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
33010696|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
33010697|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
33010698|NCT01714765|Other|Dovitinib and Everolimus|No Arms
33010699|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
33010700|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
33010701|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
33010702|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
33010703|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
33010704|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
33010705|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
33010706|NCT01714843|Experimental|ASP0456 lowest dose group|oral
33010707|NCT01714843|Experimental|ASP0456 low dose group|oral
33010708|NCT01714843|Experimental|ASP0456 middle dose group|oral
33010709|NCT01714843|Experimental|ASP0456 high dose group|oral
33010710|NCT01714843|Placebo Comparator|placebo group|oral
33010711|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
33010712|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
33010713|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
33010714|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
33010715|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
33010716|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
33010717|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
33010718|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
33010719|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
33010720|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
33010721|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
33010722|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
33010723|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
33010724|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
33105696|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~PAP Initial Set-Up (in-person, 1-hr)~1-week follow-up (FU) (in-person, 1-hr)~1-month FU~2-month FU~3-month FU~5-month FU~8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
33415776|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
33105697|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
33105698|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
33105699|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
33415777|NCT02038400|Experimental|group A|KINETUBE medical Device
33415778|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
33415779|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
33415780|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
33415781|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
33415782|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
33415783|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
33105700|NCT00552045||subject|individuals with epilepsy
33105701|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
33415784|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
33415785|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
33105702|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
33105703|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
33105704|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.~The Dosage will be determine by the DLT of Phase 1~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
33105705|NCT04902495|Experimental|Pulp Dressing MTA Angelus|pulp therapy
33105706|NCT04902495|Experimental|Pulp Dressing MTA Pro Root|pulp therapy
33105707|NCT04902495|Experimental|Pulp Dressing Biodentine|pulp therapy
33105708|NCT02895542||Oral Anti-Cancer Agent|No intervention
33415786|NCT04828187||Study group|8 patients aged between 18 to 75 years with Uncorrected Distance Visual Acuity ≥ 5/10
33105709|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
33105710|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
33105711|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
33105712|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
33105713|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
33325597|NCT03910608|Experimental|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
33325598|NCT03910608|Experimental|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
33010725|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
33325599|NCT03910608|Experimental|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
33325600|NCT03910608|Experimental|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
33325601|NCT03910608|Experimental|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
33325602|NCT03910608|Experimental|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
33010726|NCT01714973|Experimental|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
33010727|NCT01714973|Experimental|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
33010728|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
33010729|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
33010730|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
33010731|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
33010732|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
33010733|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
33010734|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
33010735|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
33010736|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
33010737|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
33010738|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
33010739|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
33010740|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
33010741|NCT01715090|No Intervention|Standard care|
33010742|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
33010743|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
33010744|NCT01715116|Experimental|Enhanced ICD programming|
33010745|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
33010746|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
33010747|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
33010748|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
33010749|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
33010750|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
33010751|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~CPAP was used <4h/ night for 2 consecutive night~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
33010752|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
33010753|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
33010754|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
33010755|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
33010756|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
33010757|NCT01715246|No Intervention|Breasfed reference group|
33010758|NCT01715259|Experimental|Abiraterone acetate|
33010759|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
33010760|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
33010761|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
33010762|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
33010763|NCT01715311|Active Comparator|Tiotropium|Tiotropium
33010764|NCT01715337|Other|pulmonary rehabilitation|
33010765|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
33010766|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet~Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
33010767|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet~Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
33010768|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~resection of the colorectal tumor during surgery~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
33010769|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
33010770|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
33010771|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
33010772|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
33010773|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
33010774|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
33010775|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
33010776|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
33010777|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
33010778|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
33010779|NCT01715493|Experimental|Lysozyme 90 mg|
33010780|NCT01715493|Placebo Comparator|Placebo|
33010781|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
33415787|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
33415788|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
33415789|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
33415790|NCT01344083|Experimental|T1210|
33415791|NCT01344083|Active Comparator|Olopatadine hydrochloride|
33415792|NCT04039217|Experimental|Sample collection 2, 48, and 96 hours after first dose of Biktarvy|Participants in this study arm (Arm A) will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
33415793|NCT04039217|Experimental|Sample collection 4, 26, and 120 hours after first dose of Biktarvy|Participants in this study arm (Arm B) will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
33415794|NCT04039217|Experimental|Sample collection 24, 28, and 72 hours after first dose of Biktarvy|Participants in this study arm (Arm C) will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
33415795|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
33415796|NCT04005521|Experimental|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
33415797|NCT04005521|No Intervention|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
33415798|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
33415799|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
33415800|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
33415801|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
33415802|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
33415803|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
33415804|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
33415805|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
33415806|NCT02038478|Experimental|Transplantation Arm|"Transplantation~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
33415807|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
33415808|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
33415809|NCT05615090|Experimental|I (Prepectoral)|Participants received the Self-help app-based CBT-E for eating disorder for 8 weeks
33415810|NCT05615090|Other|II (Subpectoral)|Waiting list Wait-list control(participants will use the smartphone app after the intervention phase) The waitlist group will receive treatment as usual, Patients from the waitlist group will be offered access to App after a 8-weeks period.
33415811|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
33415812|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
33415813|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
33010782|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
33415814|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
33415815|NCT03057951|Experimental|10 mg Empagliflozin|
33415816|NCT03057951|Placebo Comparator|Placebo|
33415817|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
33415818|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
33415819|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
33010783|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
33010784|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
33010785|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
33010786|NCT01715545||day-3 poor quality embryos|
33010787|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
33010788|NCT01715558||RYTHMIQ study group|
33010789|NCT01715558||Historical control from OPTI-MIND|
33010790|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
33010791|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
33010792|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
33010793|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
33010794|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
33010795|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
33010796|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
33010797|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
33010798|NCT01715623||healthy volunteers|healthy volunteers without allergy
33010799|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
33010800|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
33010801|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
33010802|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
33010803|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
33010804|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
33010805|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
33010806|NCT01715675|Active Comparator|plant stanol|
33010807|NCT01715675|Placebo Comparator|control|
33010808|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
33010809|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
33325603|NCT03910608|Experimental|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
33325604|NCT03910608|Experimental|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
33010810|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
33010811|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
33010812|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
33010813|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
33010814|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
33010815|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~Able to understand and provide signed informed consent.~Age range and gender matched with Parkinsonss Disease for follow up."
33010816|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent"
33010817|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent."
33010818|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
33010819|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
33010820|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
33010821|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
33010822|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
33010823|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
33010824|NCT01715818|Experimental|Aleglitazar|
33010825|NCT01715818|Placebo Comparator|Placebo|
33010826|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
33010827|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
33010828|NCT01715870||"Population of the Epidemiological study on AMD."|
33010829|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
33010830|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
33010831|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
33010832|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
33325605|NCT03906474|Experimental|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
33010833|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~albuminemia, transthyretin, orosomucoid, CRP~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~OS and PFS at 18 and 24 months~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
33325606|NCT03906474|Experimental|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
33010834|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
33010835|NCT01715987||Entecavir|Patients who are taking Entecavir.
33010836|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
33010837|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
33010838|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
33010839|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
33010840|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
33325607|NCT03906474|Experimental|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
33325608|NCT03906084|Active Comparator|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
33325609|NCT03906084|Experimental|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
33325610|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
33325611|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
33325612|NCT03910686|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
33325613|NCT03910686|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
33325614|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
33325615|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
33325616|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
33325617|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
33325618|NCT03906006|Experimental|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
33325619|NCT03906006|Experimental|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
33325620|NCT03906006|Experimental|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
33325621|NCT03906006|Experimental|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
33325622|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
33325623|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
33325624|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
33325625|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured dairy|
33325626|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured non-dairy|
33325627|NCT03914430|Experimental|Water|Energy-free control
33325628|NCT03914508|Experimental|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
33325629|NCT03905850|Experimental|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
33325630|NCT03905850|Experimental|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
33325631|NCT03905850|Experimental|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
33325632|NCT03906162|Experimental|Motivational interviewing|Experimental content + base intervention
33325633|NCT03906162|Active Comparator|Control intervention|Base intervention
33325634|NCT03910374|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
33325635|NCT03910374|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
33010841|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
33010842|NCT01716143|Other|catheter ablation|
33415820|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
33415821|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
33010843|NCT01716182||transacral lumbar interbody fusion procedure|
33010844|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
33415822|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
33415823|NCT01318837|Experimental|sofilenacin group|
33415824|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
33415825|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
33010845|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
33010846|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
33415826|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
33415827|NCT03146663|Experimental|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
33415828|NCT03146663|Experimental|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
33415829|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
33415830|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
33010847|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
33010848|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
33010849|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
33010850|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
33010851|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
33010852|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
33010853|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
33010854|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
33010855|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
33010856|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
33010857|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
33415831|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
33415832|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
33415833|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
33415834|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
33415835|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
33415836|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
33415837|NCT05609552||Tuberculosis patients|Patients with confirmed TB [culture confirmed or positive by genotypic testing with GeneXpert, Accuporobe, etc.] by genotype and/or culture testing positive for M. tuberculosis
33415838|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
33010858|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
33010859|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
33010860|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
33010861|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
33010862|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
33010863|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
33010864|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
33010865|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
33415839|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
33010866|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
33010867|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
33010868|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
33010869|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
33010870|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
33010871|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
33010872|NCT01716481|Experimental|Mesenchymal stem cell treatment|
33010873|NCT01716481|No Intervention|Standard treatment|
33010874|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
33010875|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
33010876|NCT01716494||Normal control|Subjects that are healthy normals
33010877|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
33010878|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
33010879|NCT01716546|Experimental|1|Panitumumab plus DCF
33010880|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
33010881|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
33010882|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
33010883|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
33010884|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
33010885|NCT01716624|Active Comparator|Oxybutynin|
33010886|NCT01716624|Experimental|Botulinum Toxin A injection|
33010887|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
33010888|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
33010889|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
33010890|NCT01716676|Active Comparator|Standard CPAP follow-up|
33010891|NCT01716676|Experimental|Telemedicine CPAP follow-up|
33010892|NCT01716689|Experimental|Patients with advanced sarcoma|
33010893|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
33010894|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
33010895|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
33010896|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
33010897|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
33010898|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
33010899|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
33010900|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
33010901|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
33010902|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
33010903|NCT01716832|Experimental|Mindfulness walking|
33010904|NCT01716832|No Intervention|No intervention (waiting list)|
33010905|NCT01716845||Development group 1|
33010906|NCT01716845||Development group 2|
33010907|NCT01716845||Development group 3|
33010908|NCT01716845||Validation group|
33010909|NCT01716858|Experimental|A single-arm study|
33010910|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
33010911|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
33010912|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
33010913|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
33010914|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
33415840|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
33415841|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
33010915|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
33010916|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
33010917|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
33010918|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
33010919|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
33010920|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
33010921|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
33010922|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
33010923|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
33010924|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
33010925|NCT01716988||Micafungin|
33010926|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33010927|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33010928|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33010929|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33010930|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
33010931|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
33010932|NCT01717079|Active Comparator|Effective arm|Effective coil
33010933|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
33010934|NCT01717092||Consecutive patients with acute PE|
33010935|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
33010936|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
33010937|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
33010938|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
33010939|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
33010940|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
33010941|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
33010942|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
33010943|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
33010944|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
33010945|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
33010946|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
33010947|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
33010948|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
33010949|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
33010950|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
33010951|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
33010952|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
33010953|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
33010954|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
33325636|NCT03914352|Experimental|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
33010955|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
33010956|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
33010957|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
33010958|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
33010959|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
33010960|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
33010961|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
33010962|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
33010963|NCT01717300|Experimental|Anacetrapib 100 mg|
33010964|NCT01717300|Experimental|Anacetrapib 25 mg|
33010965|NCT01717300|Placebo Comparator|Placebo|
33010966|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
33010967|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
33010968|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
33010969|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
33010970|NCT01717365||OTs|Occupational therapists
33010971|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
33010972|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
33010973|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
33010974|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
33010975|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
33010976|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
33010977|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
33010978|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
33010979|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
33010980|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
33010981|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
33010982|NCT01717508|No Intervention|Healthy Controls|
33010983|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
33010984|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
33010985|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
33010986|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
33010987|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
33010988|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
33010989|NCT01717599|Experimental|Diclofenac group|
33010990|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
33010991|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
33010992|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
33105714|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
33105715|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
33105716|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
33105717|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
33105718|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
33105719|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
33415842|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
33415843|NCT05637554|Active Comparator|Laparoscopic clipping appendectomy|This group will undergo laparoscopic clipping of the base of the appendix during laparoscopic appendectomy.
33415844|NCT05637554|Active Comparator|Laparoscopic extracorporeal ligation appendectomy|This group will undergo laparoscopic extracorporeal ligation of the base of the appendix during laparoscopic appendectomy.
33415845|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
33415846|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
33415847|NCT04686773|Experimental|AZD1222 5×10^10 vp + rAd26-S (1.0±0.5) х 10^11vp|Subjects will receive 1 intramuscular (IM) injection of 5×10^10 viral particles (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×10^11 viral particles (nominal) on Day 29 of the study.
33415848|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
33415849|NCT05162495|Experimental|Arm A|Requiring a diagnostic or screening RT-PCR test for COVID-19.
33415850|NCT05162495|Experimental|Arm B|Positive to COVID-19 in RT-PCR test performed up to 48 hours before screening.
33415851|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
33415852|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
33415853|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
33415854|NCT02058134|No Intervention|Control group|
33415855|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
33415856|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
33415857|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
33415858|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
33415859|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
33415860|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
33415861|NCT04827719|Experimental|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
33415862|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
33415863|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
33415864|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
33415865|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
33415866|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
33415867|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
33105720|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
33105721|NCT01261000|Experimental|Pegvisomant|
33105722|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
33105723|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
33105724|NCT00550524|Experimental|A|Knee osteoarthritis
33415868|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
33010993|NCT01717625|Experimental|Montelukast|"montelukast sodium~dosage~< 1000g : 0.5 mg/D QD~1000g~1500g : 1.0 mg/D QD~1500g~2000g : 1.5 mg/D QD~> 2000g : 2mg/D QD~medication period : to discharge or GA 36wks"
33010994|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
33010995|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
33010996|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
33010997|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
33010998|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
33010999|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
33011000|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
33011001|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
33011002|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
33011003|NCT01717703|Experimental|Water Control|Water Control
33011004|NCT01717703|Experimental|Fruit drink|Fruit drink
33011005|NCT01717703|Experimental|Cola|Cola
33011006|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
33011007|NCT01717716|Experimental|Calorie-free control|Calorie-free control
33011008|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
33011009|NCT01717716|Experimental|Glucose drink|Glucose drink
33011010|NCT01717716|Experimental|Sucrose drink|Sucrose drink
33011011|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
33011012|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
33011013|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
33011014|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
33011015|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
33011016|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
33011017|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
33325637|NCT03914352|Active Comparator|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
33325638|NCT03914274|No Intervention|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
33325639|NCT03914274|No Intervention|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
33325640|NCT03914274|No Intervention|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
33325641|NCT03914274|No Intervention|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
33415869|NCT04816955|Experimental|Nutrient-based recommendations|Participants in this group will be given nutrient-based recommendations to reduce free sugar intakes.
33415870|NCT04816955|Experimental|Nutrient- and food-based recommendations|Participants in this group will be given nutrient- and food-based recommendations to reduce free sugar intakes.
33415871|NCT04816955|Experimental|Nutrient- and food-based recommendations with food swaps|Participants in this group will be given nutrient- and food-based recommendations and advice on food swaps to reduce free sugar intakes.
33011018|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
33011019|NCT01717807||lung cancer; advanced pancreatic cancer|
33415872|NCT04816955|Placebo Comparator|Control|Participants in this group will not be given any recommendations to reduce free sugar intakes.
33011020|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
33011021|NCT01717833|Experimental|NEMS group|
33011022|NCT01717833|Sham Comparator|Sham group|
33011023|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
33011024|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
33011025|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
33011026|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
33011027|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
33011028|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
33011029|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
33011030|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
33011031|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
33011032|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
33011033|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
33011034|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
33011035|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
33011036|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
33011037|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
33011038|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
33011039|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
33011040|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
33011041|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
33011042|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
33011043|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
33011044|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
33011045|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
33011046|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
33011047|NCT01718015||Patients with diabetic polyneuropathy|
33011048|NCT01718015||Patients with diabetes without peripheral nerve disorder|
33011049|NCT01718015||Patients with polyneuropathies not due to diabetes|
33011050|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
33011051|NCT01718015||Patients with unspecified nerve disease|
33011052|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
33011053|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
33011054|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
33011055|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
33011056|NCT01718080||Group A|Healthy lean children before puberty
33011057|NCT01718080||Group B|Otherwise healthy overweight children before puberty
33415873|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
33415874|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
33415875|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
33415876|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
33011058|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
33011059|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
33011060|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
33011061|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
33011062|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
33011063|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
33011064|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
33011065|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
33011066|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
33011067|NCT01718132||postoperative patients|
33011068|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
33415877|NCT03640260|No Intervention|controlled|
33415878|NCT01354171|No Intervention|TRUS guided biopsy|
33415879|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
33415880|NCT04668443||Prospective participants in D²EFT study|HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
33011069|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
33011070|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
33011071|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to ICS, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past"
33011072|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
33011073|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
33011074|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
33011075|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
33011076|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
33011077|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
33011078|NCT01718249|Other|deep brain stimulation|
33011079|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
33011080|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
33011081|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
33415881|NCT04668443||Researchers obtaining informed consent for D²EFT study|Healthcare givers involved in the participant informed consent process of D²EFT
33415882|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
33011082|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
33011083|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
33011084|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
33415883|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
33011085|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
33011086|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
33011087|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
33011088|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
33011089|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
33011090|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
33011091|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
33011092|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
33011093|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
33011094|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
33011095|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
33011096|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
33011097|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
33011098|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
33011099|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
33011100|NCT01718457|Experimental|Endobarrier device insertion|
33011101|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
33011102|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
33011103|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
33011104|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
33011105|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
33011106|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
33011107|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
33011108|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
33011109|NCT01718574|Experimental|Self-help book|
33011110|NCT01718574|No Intervention|Usual Care Control|
33011111|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
33011112|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
33011113|NCT01718613|Active Comparator|Norepinephrine|
33011114|NCT01718613|Active Comparator|Vasopressin|
33011115|NCT01718626|Active Comparator|S1+Docetaxel|
33011116|NCT01718626|Experimental|S1+Docetaxel followed by S1|
33011117|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
33011118|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
33011119|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
33011120|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
33011121|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
33011122|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
33011123|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
33011124|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
33011125|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
33011126|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
33011127|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
33011128|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
33011129|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
33011130|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
33011131|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
33011132|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
33011133|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
33011134|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
33011135|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
33011136|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
33011137|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
33011138|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
33011139|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
33011140|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
33011141|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
33011142|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
33011143|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
33011144|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
33011145|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
33011146|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
33011147|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
33011148|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
33011149|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
33011150|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
33011151|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
33011152|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
33011153|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
33011154|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
33415884|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
33417517|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
33011155|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
33011156|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
33011157|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
33011158|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
33011159|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
33011160|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
33011161|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
33011162|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
33011163|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
33011164|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
33011165|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
33011166|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
33011167|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
33011168|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
33011169|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
33011170|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
33011171|NCT01719068||Workers exposed to asbestos|
33011172|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
33011173|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
33011174|NCT01719094||Childhood Cancer Surviviors|
33011175|NCT01719094||Adolescent/young adults with no cancer history|
33011176|NCT01719094||Newly diagnosed cancer patients|
33011177|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
33011178|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
33011179|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
33011180|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
33011181|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
33011182|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
33011183|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
33011184|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
33011185|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
33011186|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33011187|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
33011188|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
33011189|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
33105725|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
33105726|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
33105727|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
33105728|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
33105729|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
33105730|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
33105731|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
33105732|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
33105733|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
33105734|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
33105735|NCT02895191|Placebo Comparator|control group|Placebo
33105736|NCT04765800|Active Comparator|Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)|focus on core psychodynamic treatment principles (Leichsenring & Steinert, 2018); no use of imagery-based interventions
33105737|NCT04765800|Experimental|Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)|regular sessions with and focus on work with guided affectice imagery
33105738|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
33105739|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
33105740|NCT04765020|Experimental|Intervention group|12 weeks moderate to high-intensity exercise program
33105741|NCT04765020|No Intervention|Control group|exercise recommendations
33105742|NCT04680845|Experimental|Self-affirmation|"Participants will be asked to complete a standard questionnaire including:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will… …think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…______________________________________________________________________"
33105743|NCT04680845|No Intervention|Control|Participants will be asked to complete a standard questionnaire.
33105744|NCT00550641|Active Comparator|1|
33415885|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
33415886|NCT01342133||Newborns|
33105745|NCT00550641|Experimental|2|
33105746|NCT04680650|Experimental|Group DS|Anesthesia was maintained with sevoflurane and target-controlled infusion of remifentanil in the group DS
33105747|NCT04680650|Active Comparator|Group DP|Anesthesia was maintained with propofol and target-controlled infusion of remifentanil in the group DP
33105748|NCT04680572|Active Comparator|Bipolar hemiarthroplasty group|
33105749|NCT04680572|Active Comparator|Dual mobility cups total hip replacement group|
33105750|NCT00552435|Experimental|1|Micropulse 810nm diode laser
33105751|NCT00552435|Active Comparator|2|Argon laser photocoagulation
33105752|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
33105753|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
33105754|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
33105755|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
33105756|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
33105757|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
33105758|NCT00552552|Experimental|1|
33105759|NCT00552552|Other|2|waiting control group
33105760|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
33105761|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
33105762|NCT00550875|Experimental|1|
33105763|NCT00550875|Experimental|2|10* concentration of arm 1
33105764|NCT00550875|Placebo Comparator|3|
33105765|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
33105766|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
33105767|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
33415887|NCT01342133||Mothers|
33415888|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
33011190|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
33011191|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
33011192|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
33011193|NCT01719302|Experimental|cohort 1|
33011194|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
33011195|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
33011196|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
33011197|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
33011198|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
33011199|NCT01719315||Primary Insomnia|Patients with primary insomnia
33011200|NCT01719315||Narcolepsy|Subjects with narcolepsy
33011201|NCT01719315||Healthy Controls|healthy participants
33011202|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
33011203|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
33011204|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
33011205|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
33011206|NCT01719406|No Intervention|Control|Standard medical care
33011207|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
33011208|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
33011209|NCT01719432||Obese patients|
33011210|NCT01719432||Non-obese patients|
33011211|NCT01719445||RFPM/Paper and Pen Method|
33011212|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
33011213|NCT01719471||Healthy|Medically healthy individuals who do not smoke
33011214|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
33011215|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
33011216|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
33011217|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
33011218|NCT01719549|Experimental|Dovitinib|
33011219|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
33011220|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
33011221|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
33011222|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
33011223|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
33011224|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
33011225|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
33011226|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
33011227|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
33011228|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
33011229|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
33011230|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
33011231|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
33011232|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
33011233|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
33011234|NCT01719718|Active Comparator|Closure|
33011235|NCT01719718|Sham Comparator|Non-Closure|
33011236|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
33011237|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
33011238|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
33011239|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
33011240|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
33415889|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
33011241|NCT01719796|No Intervention|No TAP catheter|
33011242|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
33011243|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
33011244|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
33011245|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
33011246|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
33011247|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
33011248|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
33011249|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
33011250|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
33011251|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
33011252|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
33011253|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
33011254|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
33011255|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months~Clinic assistants, medics or home visitors"
33011256|NCT01719965||Researchers|"Worked in SMRU for at least 6 months~Physician or scientist"
33011257|NCT01719965||CAB members|- Member of the CAB for at least 3 months
33011258|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
33011259|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
33011260|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
33011261|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
33011262|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
33011263|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
33011264|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
33011265|NCT01720199|No Intervention|Control group|
33011266|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
33011267|NCT01720459|Placebo Comparator|Placebo|
33011268|NCT01720537|Experimental|Cohort 1|
33011269|NCT01720537|Experimental|Cohort 2|
33011270|NCT01720537|Experimental|Cohort 3|
33011271|NCT01720537|Experimental|Cohort 4|
33011272|NCT01720537|Experimental|Cohort 5|
33011273|NCT01720537|Experimental|Cohort 6|
33011274|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
33011275|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
33011276|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
33011277|NCT01721187||Low disinhibition|fMRI during fed and fasted states
33011278|NCT01721187||High disinhibition|fMRI during fed and fasted states
33011279|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
33011280|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
33011281|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
33011282|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
33011283|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
33011284|NCT01721577|Experimental|AXL1717|In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
33011285|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
33415890|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
33415891|NCT01354327|Experimental|Limicol|
33415892|NCT01354327|Placebo Comparator|Placebo|
33011286|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
33011287|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
33011288|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
33011289|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
33011290|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
33011291|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
33011292|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
33011293|NCT01722344|Experimental|Individual Placement and Support (IPS)|
33011294|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
33011295|NCT01722344|No Intervention|Standard intervention|
33011296|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
33011297|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
33011298|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
33011299|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
33011300|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
33011301|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
33011302|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
33011303|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
33231790|NCT00773838|Experimental|Vorinostat + Bortezomib|Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.
33415893|NCT05160311|Other|Optimized Medical Treatment (OMT)|The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for Coronary Artery Disease (CAD)
33011304|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
33011305|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
33011306|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
33011307|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
33231791|NCT00787644|Active Comparator|1|
33011308|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
33011309|NCT01723280||80% oxygen group|
33011310|NCT01723280||30% oxygen group|
33011311|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
33011312|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
33011313|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
33011314|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
33011315|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
33011316|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
33011317|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
33011318|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
33033144|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
33033145|NCT01960023|Experimental|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
33033146|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
33033147|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
33033148|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
33033149|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
33033150|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
33033151|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
33033152|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
33033153|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
33033154|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
33033155|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
33033156|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
33033157|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
33033158|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
33033159|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
33033160|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
33033161|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
33033162|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
33033163|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
33033164|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
33033165|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
33033166|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
33033167|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
33033168|NCT01960231||pancreas specific MODY-2|
33033169|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II~Stimulator II activated~Stimulator I not activated~Measure of efficacy on bladder hyperactivity"
33033170|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II~Stimulator I and II activated~Measure of efficacy on bladder hyperactivity"
33033171|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :~Methotrexate + anti-H1"
33325642|NCT03914274|Experimental|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
33011319|NCT01723475|Experimental|BAY2010112 (s.c.)|
33011320|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
33011321|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
33011322|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
33011323|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
33011324|NCT01724450|Active Comparator|Carvedilol|
33011325|NCT01724450|Placebo Comparator|Control|
33011326|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
33011327|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
33011328|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
33011329|NCT01724684|Other|Telehealth program|Telehealth program service
33011330|NCT01724684|Other|Usual care|Usual care service
33011331|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
33011332|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
33011333|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
33011334|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
33011335|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
33011336|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
33011337|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
33011338|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
33011339|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
33011340|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
33011341|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
33011342|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
33011343|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
33011344|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
33011345|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
33011346|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
33033172|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
33325643|NCT03914274|No Intervention|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
33325644|NCT03914040|Experimental|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
33325645|NCT03914040|No Intervention|Traditional course|Participants in the control group will receive the current face-to-face course.
33325646|NCT03914118|Active Comparator|Preoperative modafinil + postoperative placebo|
33325647|NCT03914118|Active Comparator|Preoperative modafinil + postoperative modafinil|
33325648|NCT03914118|Placebo Comparator|Preoperative placebo + postoperative placebo|
33325649|NCT03914118|No Intervention|Control group|
33325650|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
33011347|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
33011348|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
33011349|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
33011350|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
33011351|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
33011352|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
33011353|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
33011354|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
33011355|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
33011356|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
33011357|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
33011358|NCT01726582|Other|Pre surgery targeted chemo|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm A:~Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:~see link to protocol Figures A & C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011359|NCT01726582|Other|Pre surgery cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm B:~Before surgery: Chemoradiotherapy (cRXT); restaging:~see link to protocol Figure C and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011360|NCT01726582|Other|Pre surgery targeted chemo, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C1:~Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging~see link to protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011361|NCT01726582|Other|Pre surgery FOLFIRINOX, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C2:~standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:~see link at protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011362|NCT01726582|Other|After surgery targeted chemo, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D1:~After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011363|NCT01726582|Other|After surgery Gemcitabine, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D2:~Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011364|NCT01726582|Other|After surgery cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm E:~After surgery: chemoradiotherapy (cXRT); restaging:~see lint to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011365|NCT01726582|Other|After surgery targeted chemo|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F1:~Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011366|NCT01726582|Other|After surgery Gemcitabine|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F2:~Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011367|NCT01726582|Other|After surgery no additional treatment|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm G:~No additional therapy after surgery:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
33011368|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
33011369|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
33011370|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
33011371|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
33011372|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
33011373|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
33011374|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
33011375|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
33011376|NCT01727362|Active Comparator|Usual care + acupuncture|
33231792|NCT00787644|Placebo Comparator|2|
33011377|NCT01727362|Active Comparator|Usual care|
33011378|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
33011379|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
33011380|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
33011381|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
33011382|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
33011383|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
33011384|NCT01727999||TPO responder|Patients with therapeutic response to TPO
33011385|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
33011386|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
33011387|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
33011388|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
33011389|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
33011390|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
33011391|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
33011392|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
33011393|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
33011394|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
33011395|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
33011396|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
33011397|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
33011398|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
33011399|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
33011400|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
33011401|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
33011402|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
33011403|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
33011404|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
33011405|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
33011406|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
33011407|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
33011408|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
33011409|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
33011410|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
33011411|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
33011412|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
33011413|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
33231793|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
33011414|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
33011415|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
33011416|NCT01730014|Experimental|Trial part 1|
33011417|NCT01730014|Experimental|Trial part 2, treatment A|
33011418|NCT01730014|Experimental|Trial part 2, treatment B|
33011419|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
33011420|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
33011421|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33011422|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
33011423|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
33011424|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
33011425|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
33011426|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
33011427|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
33011428|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
33011429|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
33011430|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
33011431|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
33011432|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
33011433|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
33011434|NCT01730274||patients|children operated on a cerebellar tumor
33011435|NCT01730274||healthy subjects|healthy volunteers
33011436|NCT01730287|Experimental|Control|No lining applied in group1.
33011437|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
33011438|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
33011439|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
33011440|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
33011441|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
33011442|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
33011443|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
33011444|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
33011445|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
33011446|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
33011447|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
33011448|NCT01730404|Placebo Comparator|placebo|Placebo
33011449|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
33011450|NCT01730430||Collection of CSF|"Those with Alzheimer's disease~Those with non-Alzheimer's disease dementia~Healthy elderly volunteers"
33011451|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
33011452|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
33011453|NCT01730456|Experimental|RoActemra/Actemra|
33011454|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
33011455|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
33011456|NCT01730495|Experimental|Etanercept|
33415894|NCT05160311|Experimental|Angioplasty (PCI) and Optimized Medical Treatment (OMT)|The patient considered non-viable and randomized to Coronary Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)
33011457|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
33011458|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
33011459|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|
33011460|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|
33011461|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
33011462|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
33011463|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
33011464|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
33011465|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
33011466|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
33011467|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
33011468|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
33011469|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
33011470|NCT01730664|Experimental|ertapenem|single dose ertapenem
33011471|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
33011472|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
33011473|NCT01730703||Adults ages 65 and older|
33011474|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
33011475|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
33011476|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
33011477|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
33011478|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
33011479|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
33011480|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
33011481|NCT01730885|Other|BGStar|Comparision
33011482|NCT01730898|Active Comparator|Control capsule|2 capsules
33011483|NCT01730898|Experimental|Experimental capsule|2 capsules
33011484|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
33011485|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
33011486|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
33011487|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
33011488|NCT01730924|Other|Contact force available|
33011489|NCT01730924|Other|Contact force not available|
33011490|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
33011491|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
33011492|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
33011493|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
33011494|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
33011495|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
33011496|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
33011497|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
33415895|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
33415896|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
33011498|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
33415897|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
33415898|NCT02058524|Experimental|fecal microbiota transplantation|
33415899|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
33011499|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
33011500|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
33011501|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
33011502|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~bupropion 25 mg~flurbiprofen 25 mg~omeprazole 5 mg~dextromethorphan 5 mg~midazolam 1 mg~fexofenadine 25mg~Caffeine (a cup of coffee)"
33011503|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
33011504|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
33011505|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
33011506|NCT01731093|Experimental|AT-001|AT-001
33011507|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
33011508|NCT01731132||Group 1|
33011509|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
33011510|NCT01731158|Other|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
33011511|NCT01731158|Other|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
33011512|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
33011513|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
33011514|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
33011515|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
33011516|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
33011517|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
33011518|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
33011519|NCT01731223|No Intervention|No intervention|Treatment as usual
33011520|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
33011521|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
33011522|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
33011523|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
33011524|NCT01731275|Experimental|E6011|
33011525|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
33011526|NCT01731288||vulvodynia|Women with vulvodynia
33011527|NCT01731288||control|Women without vulvar pain
33011528|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
33011529|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
33011530|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
33011531|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day~800 IU Vitamin D3 per day~Low Dietary Calcium (450 mg per day)"
33011532|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day~High Dietary Calcium (1200 mg per day)"
33011533|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day~Unrestricted Dietary Calcium"
33011534|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
33011535|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
33011536|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
33011537|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
33415900|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
33231794|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
33415901|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
33415902|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
33011538|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
33011539|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
33415903|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
33415904|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
33415905|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
33415906|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
33415907|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
33415908|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
33415909|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
33011540|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
33011541|NCT01731405||There is not another group|
33415910|NCT01354405||Lanreotide|
33011542|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
33011543|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
33011544|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
33011545|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
33011546|NCT01731457|Experimental|Etanercept|
33011547|NCT01731457|No Intervention|Control|
33011548|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
33011549|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
33011550|NCT01731496|No Intervention|Control: Telephone|
33011551|NCT01731496|No Intervention|Control: Text Message|
33011552|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
33011553|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
33011554|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
33011555|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
33011556|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
33011557|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
33011558|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
33011559|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
33011560|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
33011561|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
33011562|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
33011563|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
33011564|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
33011565|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
33011566|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
33011567|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
33415911|NCT03363035|Experimental|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
33011568|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
33011569|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
33011570|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
33011571|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
33011572|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
33011573|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
33011574|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
33011575|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
33011576|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
33011577|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
33011578|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
33011579|NCT01731808|Experimental|Nursing counseling|
33011580|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
33011581|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
33011582|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
33011583|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
33011584|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
33011585|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
33011586|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
33011587|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
33011588|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
33011589|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
33011590|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
33011591|NCT01731977|No Intervention|Waiting list|Treatment as usual
33011592|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
33011593|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
33011594|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
33011595|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
33011596|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
33011597|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
33011598|NCT01732068|Experimental|Corifollitropin alfa+hMG|
33011599|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
33011600|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
33011601|NCT01732133|Experimental|Measurement of arterial pressure|
33011602|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
33415912|NCT03363035|Experimental|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
33011603|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
33415913|NCT03363035|Active Comparator|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
33415914|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
33415915|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
33011604|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
33011605|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
33011606|NCT01732172|Experimental|Patient Group|Patient with urethritis
33011607|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
33011608|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
33011609|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
33011610|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
33011611|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
33011612|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
33011613|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
33011614|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
33011615|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
33011616|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
33011617|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
33011618|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
33011619|NCT01732289|Experimental|A|
33011620|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
33011621|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
33011622|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
33011623|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
33011624|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
33011625|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
33011626|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
33011627|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
33011628|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
33011629|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
33011630|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
33011631|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
33011632|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
33011633|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
33011634|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
33011635|NCT01732523||No treatment|No intervention
33011636|NCT01732562|No Intervention|Control|Patient receives the standard of care.
33011637|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
33011638|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
33011639|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
33011640|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
33011641|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
33011642|NCT01732614|Experimental|Topcon Endpoint Management Laser|
33011643|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
33415916|NCT05211843|No Intervention|No drink|Control; Participants will receive no drink
33011644|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
33011645|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
33011646|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
33011647|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
33011648|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
33011649|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
33011650|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
33011651|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
33011652|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
33011653|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
33011654|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
33011655|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
33011656|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
33011657|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
33011658|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
33011659|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
33011660|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
33011661|NCT01732861|Experimental|CC-292 + Lenalidomide|
33011662|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
33011663|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
33011664|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
33011665|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
33011666|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
33011667|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
33011668|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
33011669|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
33011670|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
33011671|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
33011672|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
33011673|NCT01733004|Experimental|Arm A|MM-141 monotherapy
33011674|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
33011675|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
33011676|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
33011677|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
33011678|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
33011679|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
33011680|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
33011681|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
33011682|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
33011683|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
33011684|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
33011685|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
33011686|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
33011687|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
33011688|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
33011689|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
33011690|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
33011691|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
33011692|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
33011693|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
33011694|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
33011695|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
33011696|NCT01733355|Experimental|Tau diagnostic|[F18] T807
33011697|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
33011698|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
33011699|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
33011700|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
33011701|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
33011702|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
33011703|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
33011704|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
33011705|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
33011706|NCT01733485|Active Comparator|Aspirin|
33011707|NCT01733485|Active Comparator|Indomethacin|
33011708|NCT01733485|No Intervention|Control|
33011709|NCT01733511||admitted to emergency department|
33011710|NCT01733511||patients admitted to surgical ward|
33011711|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
33011712|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
33011713|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
33011714|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
33011715|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
33011716|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
33011717|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
33011718|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
33011719|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
33011720|NCT01733576|Sham Comparator|Sham HD-tDCS|
33011721|NCT01733576|Active Comparator|Active HD-tDCS 1|
33011722|NCT01733576|Active Comparator|Active HD-tDCS 2|
33011723|NCT01733576|Active Comparator|Active HD-tDCS 3|
33033173|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
33011724|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
33011725|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
33011726|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
33011727|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
33011728|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
33011729|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
33011730|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
33011731|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
33011732|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
33011733|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
33011734|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
33011735|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
33011736|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
33011737|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
33011738|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
33011739|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
33011740|NCT01733784|Experimental|Viscoelastic properties of the airway|
33011741|NCT01733797|Experimental|Wooden spatula|
33011742|NCT01733797|Experimental|Therabite|
33011743|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
33011744|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
33011745|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
33011746|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
33011747|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
33011748|NCT01733836|Experimental|Metformin|850mg BID
33011749|NCT01733836|Placebo Comparator|Placebo|
33011750|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
33011751|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
33011752|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
33011753|NCT01733875|Experimental|CC-220 0.03 mg|
33011754|NCT01733875|Experimental|CC-220 0.1 mg|
33011755|NCT01733875|Experimental|CC-220 0.3 mg|
33011756|NCT01733875|Experimental|CC-220 1 mg|
33011757|NCT01733875|Experimental|CC-220 2 mg|
33011758|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
33011759|NCT01733875|Experimental|CC-220 4 mg|
33011760|NCT01733875|Experimental|CC-220 6 mg|
33011761|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
33011762|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
33011763|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
33011764|NCT01733914|Experimental|Acupuncture|Experimental group
33011765|NCT01733914|Sham Comparator|Waiting list|Control group
33011766|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
33011767|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
33011768|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
33011769|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
33011770|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
33011771|NCT01733979|Experimental|Heme-Iron Polypeptide|
33011772|NCT01733979|Placebo Comparator|Placebo|
33011773|NCT01733979|Active Comparator|Heme-Iron|
33011774|NCT01733979|Active Comparator|Organic Iron|
33011775|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
33011776|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
33011777|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
33011778|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
33011779|NCT01734005|Experimental|Red Ginseng|
33011780|NCT01734005|Placebo Comparator|Placebo|
33011781|NCT01734018||Cohort|
33011782|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
33011783|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
33011784|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
33011785|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
33011786|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
33011787|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
33011788|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
33011789|NCT01734096|Active Comparator|control group|healthy volunteer
33011790|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
33011791|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
33011792|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
33011793|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
33011794|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
33011795|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
33011796|NCT01734135|No Intervention|Usual Care|Usual care
33011797|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
33011798|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
33011799|NCT01734148|No Intervention|Control group (Usual Care)|
33011800|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
33011801|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
33011802|NCT01734187|Placebo Comparator|Placebo|
33011803|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
33011804|NCT01734200|Placebo Comparator|Placebo|
33011805|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
33011806|NCT01734213|Placebo Comparator|Placebo|
33011807|NCT01734226|Experimental|Prunus Mume Extract|
33011808|NCT01734226|Placebo Comparator|Placebo|
33011809|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
33011810|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
33033174|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
33011811|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
33011812|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
33011813|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
33011814|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
33011815|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
33011816|NCT01734304|Experimental|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
33011817|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
33011818|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
33011819|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
33011820|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
33011821|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
33011822|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
33011823|NCT01734356|Other|controle|8 healthy people for these pathologies
33011824|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
33011825|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
33011826|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
33011827|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
33011828|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
33011829|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
33011830|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
33011831|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
33011832|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
33011833|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
33011834|NCT01734447|Experimental|1.2, continuous treatment|
33011835|NCT01734447|Experimental|1.2, non-continuous treatment|
33011836|NCT01734447|Experimental|2.4, non-continuous treatment|
33011837|NCT01734460||third trimester pregnant women|no intervention
33011838|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
33011839|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
33011840|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
33011841|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
33011842|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
33011843|NCT01734486|Experimental|Low dose|
33011844|NCT01734486|Experimental|High dose|
33011845|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
33011846|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
33011847|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
33011848|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
33011849|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
33011850|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
33011851|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
33011852|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
33011853|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
33011854|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
33011855|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
33011856|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
33011857|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
33011858|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
33011859|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
33011860|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
33011861|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
33011862|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
33011863|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
33011864|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
33011865|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
33011866|NCT01734694|Active Comparator|Vancomycin|
33011867|NCT01734694|Active Comparator|Comparator|
33011868|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
33011869|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
33011870|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
33011871|NCT01734733|Experimental|NTCELL|"NTCELL 40 microcapsules (+/- 20%)~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
33011872|NCT01734759|Experimental|Taste Test|
33011873|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
33011874|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
33011875|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
33011876|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
33011877|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
33011878|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
33011879|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
33011880|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
33011881|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
33011882|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
33011883|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
33011884|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
33011885|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
33011886|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
33011887|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
33011888|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
33011889|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
33011890|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
33011891|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
33011892|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
33011893|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
33011894|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
33011895|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
33011896|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
33011897|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
33011898|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
33011899|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
33011900|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
33011901|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
33011902|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
33011903|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
33011904|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
33011905|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
33011906|NCT01735110|Experimental|radial approach group|PCI through radial approach
33011907|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
33011908|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
33011909|NCT01735136|Experimental|InSan Bamboo Salt|
33011910|NCT01735136|Placebo Comparator|Placebo|
33011911|NCT01735149|Experimental|Kochujang Pills|
33011912|NCT01735149|Placebo Comparator|Placebo|
33011913|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
33011914|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
33011915|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
33011916|NCT01735188||Living|
33011917|NCT01735188||Deceased|
33011918|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
33011919|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
33011920|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
33011921|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
33011922|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
33011923|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
33011924|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
33011925|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
33011926|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
33011927|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
33011928|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
33011929|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
33011930|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
33011931|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
33011932|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
33011933|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
33011934|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
33011935|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
33011936|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
33011937|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
33011938|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
33011939|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
33011940|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
33011941|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
33011942|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
33011943|NCT01735422|Experimental|r-hLH (2750 IU)|
33011944|NCT01735422|Experimental|r-hLH (5500 IU)|
33011945|NCT01735422|Experimental|r-hLH (11000 IU)|
33011946|NCT01735422|Experimental|r-hLH (22000 IU)|
33011947|NCT01735422|Active Comparator|u-hCG (5000 IU)|
33011948|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
33011949|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
33011950|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
33011951|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
33011952|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
33011953|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
33011954|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
33011955|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
33011956|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
33011957|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
33011958|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
33011959|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
33011960|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
33011961|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
33011962|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
33011963|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
33011964|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
33011965|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
33011966|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
33011967|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
33011968|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
33011969|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
33011970|NCT01735500||CAG without PCI|
33011971|NCT01735500||CAG with PCI|
33011972|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
33011973|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
33011974|NCT01735539|Experimental|Old Bolus|15g EAA bolus
33011975|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
33011976|NCT01735539|Experimental|Young Bolus|15g EAA bolus
33011977|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
33011978|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
33011979|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
33011980|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
33011981|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
33011982|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
33011983|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
33033175|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
33011984|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
33011985|NCT01735643|Experimental|interactive videogame intervention|
33011986|NCT01735643|Experimental|waiting group|
33011987|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
33011988|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
33011989|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
33011990|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
33011991|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
33011992|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
33011993|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
33011994|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
33011995|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
33011996|NCT01735734||Capillary malformation|
33325651|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
33325652|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
33325653|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
33325654|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
33325655|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
33325656|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
33325657|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
33325658|NCT05667402|Experimental|TBF group|The subjects receive TBF conditioning regimen.
33325659|NCT05667402|Active Comparator|Modified BuCY2 group|The subjects receive modified BuCY2 conditioning regimen.
33325660|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
33325661|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
33325662|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
33325663|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
33325664|NCT01252758|Placebo Comparator|placebo|
33325665|NCT01252758|Active Comparator|Ventolin HFA dose 1|
33325666|NCT01252758|Active Comparator|Ventolin HFA dose 2|
33325667|NCT03905772|Experimental|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
33325668|NCT03905772|Experimental|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in responder in the acute fase."
33325669|NCT03905772|Experimental|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in non responder in the acute fase."
33325670|NCT03905772|Experimental|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
33325671|NCT03913962|Experimental|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
33325672|NCT03913962|Active Comparator|Control|healthy children sex- and age-matched
33325673|NCT03913884|Experimental|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
33325674|NCT03913884|Experimental|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
33325675|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
33325676|NCT03909984|Other|Intervention|All participants will be monitored for 2 months.
33325677|NCT03905616|Experimental|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
33325678|NCT03910140|Experimental|TILA-TACE group|
33325679|NCT03913650|Active Comparator|Nerve block(+)|patient accept nerve block for post-op pain control
33325680|NCT03913650|Sham Comparator|Morphine|patient received morphine for post-op pain control
33325681|NCT03905304|Experimental|Meditoxin|Meditoxin administered 200U~300U, single-dose administration.
33325682|NCT03905304|Active Comparator|Botox|Botox administered 200-300U, single-dose administration.
33325683|NCT03903510|Experimental|Virtual Reality|Participants will experience Virtual Reality during their cast removal
33325684|NCT03903510|No Intervention|Standard of care|Participants will receive their usual standard of care treatment during cast removal
33325685|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
33011997|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
33011998|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
33415917|NCT05211843|Experimental|Drinking water|Intervention drink; Participants will receive 500 ml drinking water from the San Francisco tap (i.e. fluoridated tap water). 500 ml is the standard bottle size.
33415918|NCT05211843|Active Comparator|Apple juice|Intervention drink; Participants will receive 200 ml box of apple juice. 200 ml is the standard serving usually available to this study population in the school setting
33417518|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
33011999|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
33012000|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
33012001|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
33012002|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
33012003|NCT01735773||Control group|Healthy volunteers
33012004|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
33012005|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
33012006|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
33012007|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
33012008|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
33012009|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
33012010|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
33012011|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
33012012|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
33012013|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
33012014|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
33012015|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
33012016|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
33012017|NCT01736020|Placebo Comparator|Placebo|Placebo
33012018|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
33012019|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
33012020|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
33012021|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
33012022|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
33012023|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
33012024|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
33012025|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
33012026|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
33012027|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
33012028|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
33012029|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
33033176|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
33012030|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~Text messages to prompt participant to reply with self-monitoring entries~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
33012031|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~Usual medical care from the PCP.~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
33012032|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
33012033|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
33012034|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
33012035|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
33012036|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
33012037|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
33012038|NCT01736202|Active Comparator|Palm oil orally|oral fat load
33012039|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
33012040|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
33012041|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
33012042|NCT01736280|Other|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
33012043|NCT01736306||Volunteers|Volunteer milk donors
33012044|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
33012045|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
33012046|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
33012047|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
33012048|NCT01736410|Other|IHC method|
33012049|NCT01736410|Other|FISH method|
33012050|NCT01736423|Experimental|Female Patients with D-IBS|
33012051|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
33012052|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
33012053|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
33012054|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
33012055|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
33012056|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
33012057|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
33012058|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
33012059|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
33012060|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
33012061|NCT01736514|Experimental|febuxostat group|oral
33012062|NCT01736514|Active Comparator|allopurinol group|oral
33012063|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
33012064|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
33012065|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
33012066|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
33012067|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
33012068|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
33012069|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
33012070|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
33033177|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
33105768|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
33105769|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
32866256|NCT04835922|Active Comparator|Peritract infiltration|In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.
33105770|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
33325686|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
33325687|NCT03909906|Active Comparator|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
33325688|NCT03909906|Placebo Comparator|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
33325689|NCT05571540|Experimental|U-CAR-T Cells (LstCAR019)|Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.
32866257|NCT04822896|Experimental|Kinesthetic Motor Imagery|They will be asked to imagine the exercises kinesthetically from a first person perspective (as if they were doing it themselves).
32866258|NCT04822896|Experimental|Visual Motor Imagery|They will be asked to imagine the exercises visually from a third person perspective (as if they were watching from the mirror / from the mirror while doing it themselves).
33325690|NCT03909672|Experimental|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
33325691|NCT03909672|Placebo Comparator|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.~However, the cups will be made with small holes <2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
33325692|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
33325693|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
33325694|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
33325695|NCT03994822|Experimental|pRESET Thrombectomy Device|Mechanical Thrombectomy using the pRESET Thrombectomy Device
33325696|NCT03994822|Active Comparator|Solitaire Revascularization Device|Mechanical Thrombectomy using the Solitaire Revascularization Device
33325697|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
33325698|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
33325699|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
33325700|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
33325701|NCT04353778|No Intervention|PLWH|People living with HIV (HIV)
33325702|NCT04353778|No Intervention|Healthy Controls|Healthy controls who do not have HIV
33325703|NCT04353778|Active Comparator|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
33325704|NCT04353778|Placebo Comparator|Placebo|PLWH on placebo
33325705|NCT04353778|Other|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
33325706|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
33325707|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
33325708|NCT03903432|Other|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
33325709|NCT03903276|No Intervention|Control|assessment of pain scale and functional capacity
33325710|NCT03903276|Experimental|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
33325711|NCT04711408|Experimental|Virtual reality|women allocated to undergo ultrasound for the diagnosis of endometriosis with Virtual reality System
33325712|NCT04711408|No Intervention|Standart care|women allocated to undergo ultrasound for the diagnosis of endometriosis without VR
33012071|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
33012072|NCT01736735|Experimental|CLP|CLP BID
33012073|NCT01736735|Placebo Comparator|Placebo|BID powder
33012074|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
33012075|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
33012076|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
33012077|NCT01736787|Experimental|Cauliflower Mushroom extract|
33012078|NCT01736787|Placebo Comparator|Placebo|
33012079|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
33012080|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
33012081|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
33012082|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
33012083|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
33012084|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 & 2"
33012085|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
33012086|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
33012087|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
33012088|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
33012089|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
33012090|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
33012091|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
33012092|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
33012093|NCT01736969|Experimental|RD047-023|RD-047-023
33012094|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
33012095|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
33012096|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
33012097|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
33012098|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
33012099|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
33012100|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
33012101|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
33033178|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
33033179|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
33325713|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
32866259|NCT04822896|Active Comparator|Real Physical Movements|They will be asked to actually do the exercises shown in the video.
32866260|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
32866261|NCT02318303|Experimental|GSP 301-1 NS (QD)|
32866262|NCT02318303|Experimental|GSP 301-2 NS (BID)|
32866263|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
32866264|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
32866265|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
32866266|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
32866267|NCT04822428|Experimental|study group(A)|Group (A): included Twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks.
32866268|NCT04822428|No Intervention|Control group(B)|Group (B): included twenty patients who received analgesic drugs only.
32866269|NCT04822506|Experimental|Routine perioperative management and PEA|Routine perioperative management and perioperative electroacupuncture (preoperative, intraoperative, postoperative)；
32866270|NCT04822506|Active Comparator|Routine perioperative management and postEA|Routine perioperative management and postoperative electroacupuncture
32866271|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
32866272|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
32866273|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
32866274|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
32866276|NCT04835610||PVI values|PVI values measured at the finger and forehead areas in pediatric patients
32866277|NCT04835610||no control group|no control group
32866278|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
32866279|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
32866280|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
32866282|NCT04304040|Experimental|Single Arm|
32866283|NCT01361477||patient|"Prolonged ICU stay~Unplanned ICU admission~Complication/adversel during ICU admission~Result of intraoperative complications and admission to ICU 5 Result of early postoperative (within 7 days) and ICU admission"
32866284|NCT04299906|Experimental|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
32866285|NCT00156013|Experimental|1|Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
32866286|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
32866287|NCT01358669|Placebo Comparator|Placebo|Placebo
32866288|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
32866289|NCT00156247|Experimental|etanercept with acitretin|open-label
32866290|NCT03036774|Experimental|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
32866291|NCT03036774|Other|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.~Ultrasonic measurement of antral area"
32866292|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
32866293|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
32866294|NCT01453569|Placebo Comparator|Placebo|
32866295|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
32866296|NCT01895933|No Intervention|No intervention|One side has no intervention
32866297|NCT04828980|Active Comparator|Mindfulness Virtual Reality Experience|Patients will be provided with a mindfulness VR experience for use up to 15 minutes at bedside.
32866298|NCT04828980|Active Comparator|Gaming Virtual Reality Experience|Patients will be provided with an active gaming VR experience for use up to 15 minutes at bedside.
32866299|NCT01334021|Experimental|Diagnostic (biopsy, surgery, genetic testing)|Patients undergo biopsy or surgery to obtain tumor sample for genetic testing. Patients are then assigned to 4 treatment cohorts as determined by genetic test results.
32866300|NCT00156715|Experimental|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
32866301|NCT04829370|Active Comparator|PLT|All subjects are treated with fractional carbon dioxide laser, then applied 2 mL PLT solution (dissolved in normal saline) on the right face.
32866302|NCT04829370|Placebo Comparator|Saline|All subjects are treated with fractional carbon dioxide laser, the left face (control group) be applied 2 mL normal saline
33415919|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
33415920|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
33415921|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
33415922|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
33415923|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
33415924|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
33415925|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
33415926|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
33415927|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
33415928|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
33415929|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
33415930|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
33417567|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
32866303|NCT04835454||control group|The control group consisted of healthy men with no cancer and no chronic diseases. They will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination.
32866304|NCT04835454||Prostate cancer group|Patients who are confirmed to have prostate cancer based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue with no other coexisting cancers or prostate cancer treatment
32866305|NCT04835454||benign prostatic hyperplasia group|Patients who are confirmed to have benign prostatic hyperplasia based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue
32866306|NCT01326455|Other|Terumo Control|
32866307|NCT01326455|Active Comparator|Terumo Fast Release|
32866308|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
32866309|NCT01573533|Experimental|Rituximab|
32866310|NCT04752709|Experimental|Active Group A|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
32866311|NCT04752709|Active Comparator|Active Group B|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
32866312|NCT04835532|Experimental|Control group|"Vertical alveolar bone augmentation was performed by GBR technique before implantation.~BIO-OSS+ BIO-GIDE barrier membrane"
32866313|NCT04835532|Experimental|Treatment group 1|"Vertical alveolar bone augmentation was performed by GBR technique and tenting screws before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws"
32866314|NCT04835532|Experimental|Treatment group 2|"Vertical alveolar bone augmentation was performed by GBR technique in combination with tenting screws and A-PRF, I-PRF before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws+A-PRF, I-PRF"
32866315|NCT04828512||normal glucose tolerance (NGT)|In the 75-g OGTT, an FPG level of < 100 mg/dL or a 120-min PG level of < 140 was diagnosed as NGT.
32866316|NCT04828512||impaired glucose intolerance (IGT)|In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.
32866317|NCT04828512||newly diagnosed DM (subclinical DM)|In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).
32866318|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
32866319|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
32866320|NCT04835220|No Intervention|Control Group|Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls
32866321|NCT04835220|Other|Telehealth intervention group|Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).
32866322|NCT04828122||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32866323|NCT04828122||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
32866324|NCT04828122||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32866325|NCT04828122||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
32866326|NCT04822116|No Intervention|standard of care|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol."
32866327|NCT04822116|Active Comparator|goal directed intraoperative haemodynamic optimization|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol. Additional application of a non-invasive haemodynamic optimization protocol in the post anaesthesia care unit."
32866328|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
32866329|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
32866330|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
32866331|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
32866332|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and dietary recommendations|Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
32866333|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and Vitamin D supplementation|Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
32866334|NCT04821882|No Intervention|Control|Healthy participant
32866335|NCT04821882|Experimental|Dextrose treatment|IC/PBS patients had been treated by intravesical instillations of hyaluronic acid and/or botox for more than 6 months
32866336|NCT01576809|Experimental|Upper Respiratory Tract Infection|
32866337|NCT04835142|Experimental|Double blind control period|"experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.~control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks."
32866338|NCT04835142|Experimental|Open single period|All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
32866339|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
32866340|NCT00158197|Experimental|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
32866341|NCT00158197|Experimental|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
32866342|NCT00158197|Experimental|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, & F for 12 wks and complete measures 1x/wk.
32866343|NCT00158197|No Intervention|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
33012102|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
33012103|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
33012104|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
33415931|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
33012105|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
33012106|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
33012107|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
33012108|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
33012109|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
33012110|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
33012111|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
33012112|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
33012113|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
33012114|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
33012115|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
33012116|NCT01737099|Experimental|DHA-O|
33012117|NCT01737099|Active Comparator|Fish oil|
33012118|NCT01737099|Placebo Comparator|Placebo|
33012119|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
33012120|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
33012121|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
33012122|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
33012123|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
33012124|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
33012125|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
33012126|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
33012127|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
33012128|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
33012129|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
33012130|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
33012131|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
33012132|NCT01737216|Active Comparator|First-line chemotherapy|
33012133|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
33012134|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
33105771|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
33105772|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
33105773|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
33105774|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
33105775|NCT02895074|Experimental|conventional phacoemulsification surgery group|
33105776|NCT04701645|Experimental|Cohort 1: Primary cytoreduction|"Patients with a new or suspected diagnosis of ovarian cancer who are deemed surgical candidates for primary cytoreductive surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
33105777|NCT04701645|Experimental|Cohort 2: Surgical assessment for primary surgery|"Patients with newly diagnosed ovarian cancers who are being considered for either primary surgery or neoadjuvant chemotherapy by their surgical gynecologic oncologist, and who require a laparoscopic procedure to determine their candidacy for surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
33105778|NCT04701645|Experimental|Cohort 3: Secondary cytoreduction|"Patients with recurrent ovarian cancer who are candidates for secondary cytoreduction, e.g.to confirm diagnosis of recurrent ovarian cancer and/or remove oligometastatic lesions.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
33105779|NCT04701645|Experimental|Cohort 4: Interval debulking surgery following neoadjuvant chemotherapy|"Patients with newly diagnosed ovarian cancers who have undergone neoadjuvant chemotherapy and are deemed surgical candidates for interval debulking surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
33105780|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
33105781|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
33105782|NCT04688385|Experimental|Multipeptide Vaccine + XS 15|a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes
33105783|NCT00551109|Placebo Comparator|P|Placebo
33415932|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
32866344|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
33105784|NCT00551109|Experimental|A1|SA4503
33105785|NCT00551109|Experimental|A2|SA4503
33105786|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
33105787|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
33105788|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
33105789|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
33105790|NCT02894528|Experimental|Ridge Preservation (Test Group)|
33105791|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
33105792|NCT00551226||1|Patients with tuberculosis
33105793|NCT00551226||2|Healthy controls
33105794|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
33105795|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
33105796|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
33105797|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
33105798|NCT04640337|Experimental|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
33012135|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
33012136|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
33012137|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
33012138|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~Apical Root Resorption"
33012139|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
33012140|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
33012141|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
33012142|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
33012143|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
33012144|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
33012145|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
33012146|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
33012147|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
33012148|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
33012149|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
33012150|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
33012151|NCT01737372||Healthy participants|No immunological or neurological illnesses.
33012152|NCT01737385||Type 1|One segment fracture
33012153|NCT01737385||Type 2|Two segment fracture
33012154|NCT01737385||Type 3|Three segment fracture
33012155|NCT01737385||Type 4|Four segment fracture
33012156|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
33012157|NCT01737411|Experimental|cesa/vasa|repair of USL
33012158|NCT01737424|Placebo Comparator|Placebo|Placebo
33012159|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
33012160|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
33012161|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
33012162|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
33012163|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
33012164|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
33012165|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
33012166|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
33012167|NCT01737476|Sham Comparator|control|control-sham
33012168|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
33012169|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
33012170|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
33012171|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
33012172|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
33012173|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
33012174|NCT01737489|No Intervention|Control|
33012175|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
33012176|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
33012177|NCT01737541|Placebo Comparator|Placebo|per os daily
33012178|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
33012179|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
33012180|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
33012181|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
33012182|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
33012183|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
33012184|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
33012185|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
33012186|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
33012187|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
33012188|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
33012189|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
33012190|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
33012191|NCT01737723||Study population|Stroke patients
33012192|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
33012193|NCT01737749||Patients undergoing cardiac surgery|
33012194|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
33012195|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
33012196|NCT01737775|Experimental|Head and neck surgery (O group)|
33012197|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
33012198|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
33012199|NCT01737801|Experimental|Lung function test|Lung function test
33012200|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
33012201|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
33012202|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
33012203|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
33012204|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
33012205|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
33012206|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
33012207|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
33012208|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
33012209|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
33012210|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
33012211|NCT01737918|Active Comparator|solifenacin|10 mg per day
33012212|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
33012213|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
33012214|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
33012215|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
33012216|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
33012217|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
33012218|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
33012219|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
33012220|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
33012221|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
33012222|NCT01738061|No Intervention|reference group|They continued their daily routine.
33012223|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
33012224|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
33012225|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
33012226|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
33012227|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
33012228|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
33012229|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
33012230|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
33012231|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
33012232|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
33012233|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
33012234|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
33012235|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
33012236|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
33012237|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
33012238|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
33012239|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
33012240|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
33012241|NCT01738217|Experimental|Fluobeam|
33012242|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
33012243|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
33012244|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
33012245|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
33012246|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
33012247|NCT01738256|Experimental|Control|Control group, no intervention.
33012248|NCT01738269||Apparently healthy subjects|
33012249|NCT01738269||Non-malignant conditions subjects|
33012250|NCT01738269||Malignant conditions subjects|
33012251|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
33012252|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
33012253|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
33012254|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
33012255|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
33012256|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
33012257|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
33012258|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
33012259|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
33012260|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
33012261|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
33012262|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
33012263|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
33012264|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
33012265|NCT01738412||Study population|Stroke patients
33012266|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
33012267|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
33012268|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
33012269|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
33012270|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
33012271|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
33012272|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
33012273|NCT01738516|Other|epileptic patients|Electroencephalography
33012274|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
33012275|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
33012276|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
33012277|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
33012278|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
33012279|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
33012280|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
33012281|NCT01738568|Experimental|Exercise|Aerobic exercise
33012282|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
33012283|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
33012284|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
33012285|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
33012286|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
33012287|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
33012288|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
33012289|NCT01738620|No Intervention|standard care|patients will receive standard care
33012290|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
33012291|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
33012292|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
33012293|NCT01738633|No Intervention|standard care|patients will receive standard care
33012294|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
33012295|NCT01738685|Other|Control.|Nutritional Education.
33012296|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
33012297|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
33012298|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
33012299|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
33012300|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
33012301|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
33325714|NCT04663126|Experimental|Treatment group|Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.
33325715|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
33325716|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
33325717|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
33325718|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
33325719|NCT04282720|Other|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
32866345|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
32866346|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
32866347|NCT01458327|Experimental|3,4-methylenedoxymethamphetamine (MDMA)-assisted therapy|125 mg and 62.5 mg MDMA and therapy
32866348|NCT00158743|Active Comparator|Digoxin immune fab|Digibind treatment plus standard of care
32866349|NCT00158743|Placebo Comparator|placebo (sodium chloride)|
32866350|NCT00161473|Active Comparator|prazosin|
32866351|NCT00161473|Placebo Comparator|placebo (inert substance)|
32866352|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
32866353|NCT01319981|Experimental|Hyper-CMAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
32866354|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
32866355|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
32866356|NCT05605249|Experimental|Cue X|"All participants will train with Cue X gamified AR gait-and-balance-exercises in their home environment for 6 weeks. Participants are invited to use Cue X minimally 5 times a week for 30 minutes total, but preferably on a daily basis. The exact exercises, exercise duration and difficulty level will be prescribed by a movement expert and will be evaluated and adjusted every week in telephone calls or during one of the laboratory assessment.~Half of the participants will train with HoloLens 2 and the other half with Magic Leap 2."
32866357|NCT05605171|Experimental|Posterior reconstruction urethrovesical anastomosis.|The intervention comprised of a 2-stitch approximation of the free edge of the Denonvilliers' fascia and posterior bladder wall cranially, to the posterior aspect of the rhabdosphincter and the posterior median raphe caudally, respectively, following prostate extraction. The aim of this approach is to ultimately restore the length of the urethrosphincteric complex, prevent its caudal retraction, and avoid undue tension on the subsequent vesicourethral anastomosis, and provide a posterior support to the urethral sphincter complex to facilitate its effective contraction.
32866358|NCT05605171|Active Comparator|Conventional urethrovesical anastomosis.|The conventional is fashioned with a continuous running technique that uses two sutures. The first suture is passed in a clockwise hemicircumferential manner, starting from outside in on the bladder neck at the 5 o'clock position and inside out on the urethra up toward the 12 o'clock position. The second suture is similarly run in a counter- clockwise hemicircumferential direction. The running sutures are snug down after each apposition to ensure there is no slack, and finally tied together with several knots at the 12 o'clock position.
32866359|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
32866360|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
32866361|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
32866362|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
32866363|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
32866364|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
32866365|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
32866366|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
32866367|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
32866368|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
32866369|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
32866370|NCT00066781|Experimental|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32866371|NCT00066781|Experimental|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32866372|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
33105799|NCT04640337|Placebo Comparator|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
33105800|NCT04640337|Placebo Comparator|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
33105801|NCT04640337|Placebo Comparator|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
33105802|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
33417568|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
32866373|NCT04754087|Other|G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners|Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
32866374|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
32866375|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
32866376|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
32866377|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
32866378|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
32866379|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
32866380|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
32866381|NCT05604157|Active Comparator|Tourniquet|25 participants with tourniquet application
32866382|NCT05604157|No Intervention|No tourniquet|25 participants without tourniquet application
32866383|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
32866384|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
32866385|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
32866386|NCT05602753||Smokers|All patients who participate in the study will complete the smoking history questionnaire and the carbon monoxide breath test. All patients with positive carbon monoxide breath test indicative of active nicotine exposure will be provided a structured smoking cessation program that includes information, counseling from their surgeon, or a trained health care professional and referral to a smoking cessation program.
32866387|NCT05602753||Non-Smokers|Subjects who self-declared as non-smokers
32866388|NCT05602753||Declared non-smokers with elevated Co2|subjects who self-declared as non-smokers but who tested positive for elevated Co2,
32866389|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
32866390|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
32866391|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
32866392|NCT00066937|Experimental|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
32866393|NCT00066937|Experimental|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
32866394|NCT00066937|Experimental|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
32866395|NCT00066937|Active Comparator|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
32866396|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
32866397|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
33012302|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
33012303|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
33012304|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
33012305|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
33012306|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
33012307|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
33012308|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
33012309|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
33012310|NCT01738828||Subjects with CAD|
33012311|NCT01738828||Subjects without CAD|
33012312|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
33012313|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
33012314|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
33012315|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
33012316|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
33012317|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
33012318|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
33012319|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
33012320|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
33012321|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
33012322|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
33012323|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
33012324|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
33012325|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
33012326|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
33012327|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
33012328|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
33012329|NCT01738932||Patients|women with histologically verified endometriosis
33012330|NCT01738932||Controls|Healthy Danish blood donors
33012331|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
33012332|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
33012333|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
33012334|NCT01738997|Experimental|Group A|Dilation 10 sec
33012335|NCT01738997|Active Comparator|Group B|Dilation 2 min
33012336|NCT01739023|Experimental|Autologous Human Schwann Cells|
33012337|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
33012338|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
33012339|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
33012340|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
33012341|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
33012342|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
33012343|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
33105803|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
33012344|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
33012345|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
33012346|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
33012347|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
33012348|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
33012349|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
33012350|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
33012351|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
33012352|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
33012353|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
33012354|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
33012355|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
33012356|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
33012357|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
33012358|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
33012359|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
33012360|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
33012361|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
33012362|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
33012363|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
33012364|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~I Negative Thoughts and Emotions~G Where's the Fat?/Three Ways to Eat Less Fat~G Taking Your Medications/Stress and You Bi weekly~G Move Those Muscles/Being Active: A Way of Life~G Challenging and Changing Negative Thoughts~G Healthy Eating~G Problem Solving Monthly~G Four Keys to Healthy Eating Out~G Social Support/Communication~G Take Charge of What's Around You/Tip the Calorie Balance~G The Slippery Slope of Lifestyle Change~G Jump Start Your Activity Plan~G Assertiveness/Make Social Cues Work for You.~G You Can Manage Stress~G Life Goals~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
33012365|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
33012366|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
33012367|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
33012368|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
33012369|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
33012370|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
33012371|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
33415933|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
33415934|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
33012372|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
33012373|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
33415935|NCT03150485|Experimental|etafilcon A Toric Multifocal|
33012374|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
33012375|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
33012376|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
33012377|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
33012378|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
33012379|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
33012380|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
33012381|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
33012382|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
33012383|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
33012384|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
33012385|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
33012386|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
33012387|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
33012388|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
33012389|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
33012390|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
33012391|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
33012392|NCT01739478|Experimental|Non-packing of abscess cavity|
33012393|NCT01739478|Other|Packing of abscess cavity|Current practice
33012394|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
33012395|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
33012396|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
33012397|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
33012398|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
33012399|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
33012400|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
33012401|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
33012402|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
33012403|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
33012404|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
33012405|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
33012406|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
33012407|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
33012408|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
33012409|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
33012410|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
33012411|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
33012412|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
33012413|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
33012414|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
33012415|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
33012416|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
33012417|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
33012418|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
33012419|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
33012420|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
33012421|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
33012422|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
33012423|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
33012424|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
33012425|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
33012426|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
33012427|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
33012428|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
33012429|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
33012430|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
33012431|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
33012432|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
33012433|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
33012434|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
33012435|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
33012436|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
33012437|NCT01739946||Implanted subject|Subjects with Interstim implanted
33012438|NCT01739946||Controls|Subjects without Interstim implanted
33012439|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
33012440|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
33012441|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
33012442|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
33012443|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
33012444|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
33012445|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
33012446|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
33012447|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
33012448|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
33012449|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
33012450|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
33012451|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
33012452|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
33012453|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
33012454|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
33012455|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
33012456|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
33012457|NCT01740063|Placebo Comparator|Placebo|placebo group
33012458|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
33012459|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
33012460|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
33012461|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
33012462|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
33012463|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
33012464|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
33012465|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
33012466|NCT01740193|Active Comparator|TAP Block|
33012467|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
33012468|NCT01740219|Experimental|Capacity Enhancement|
33012469|NCT01740219|Active Comparator|Standard Dissemination|
33012470|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
33012471|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
33012472|NCT01740245|Active Comparator|Chlorhexidine|
33012473|NCT01740245|Experimental|Polyhexamethylene biguanide|
33012474|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
33415936|NCT03150485|Active Comparator|etafilcon A Multifocal|
33415937|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
33105804|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
33012475|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
33012476|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
33012477|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
33012478|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
33012479|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
33012480|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
33012481|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
33012482|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
33012483|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
33012484|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
33012485|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
33012486|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
33012487|NCT01740466||Ocular diseases|Observational
33012488|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
33012489|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
33012490|NCT01740505|Experimental|Timing and Coordination|
33012491|NCT01740505|Experimental|Aerobic Walking|
33012492|NCT01740505|Active Comparator|Stretching and Relaxation|
33012493|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
33012494|NCT01740518||PEG 4L|Those who taken PEG 4L alone
33012495|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
33012496|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
33012497|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
33012498|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
33012499|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
33012500|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
33105805|NCT00551343|Other|PWS|
33105806|NCT00551343|Other|Controls|
33012501|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
33012502|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
33012503|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
33012504|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
33012505|NCT01740609|Placebo Comparator|1. Placebo|Placebo
33012506|NCT01740609|Experimental|2.0|
33033180|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
33012507|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
33012508|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
33012509|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
33012510|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
33012511|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
33012512|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
33012513|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
33012514|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
33012515|NCT01740700|Experimental|p-Branch®|
33012516|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
33012517|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
33012518|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
33012519|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
33012520|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
33012521|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
33012522|NCT01740778||Study Group 1|Aurora vs. Microlet 2
33012523|NCT01740778||Study Group 2|Aurora vs. SoftClix
33012524|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
33012525|NCT01740778||Study Group 4|Aurora vs. Multiclix
33012526|NCT01740830|Active Comparator|Anodal tDCS|
33012527|NCT01740830|Sham Comparator|Sham tDCS|
33012528|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
33012529|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
33012530|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
33012531|NCT01740856|Experimental|Rest three hours|Rest three hours
33012532|NCT01740856|Experimental|Rest five hours|Rest five hours
33012533|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
33012534|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
33012535|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
33105807|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
33012536|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
33012537|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
33012538|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
33012539|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
33012540|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
33012541|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
33012542|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
33012543|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
33012544|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
33012545|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
33012546|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
33012547|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
33012548|NCT01740986|Experimental|SA09012 Low dose|
33012549|NCT01740986|Experimental|SA09012 High dose|
33012550|NCT01740986|Placebo Comparator|Placebo|
33012551|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
33012552|NCT01740999|Active Comparator|arthrodesis|arthrodesis
33012553|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
33012554|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
33012555|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
33012556|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
33012557|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
33012558|NCT01741051|No Intervention|Control|
33012559|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
33012560|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
33012561|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
33012562|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
33012563|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
33012564|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
33012565|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
33012566|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
33012567|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
33012568|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
33012569|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
33012570|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
33012571|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
33012572|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
33012573|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
33012574|NCT01741168|Experimental|No Orthosis|No Orthosis
33012575|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
33012576|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
33012577|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
33012578|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
33012579|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
33415938|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
33012580|NCT01741233|Experimental|UV-B irraditation|VitDgen
33012581|NCT01741246||Control|Headache-free subjects.
33012582|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
33012583|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
33012584|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
33012585|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
33012586|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
33012587|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
33012588|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
33012589|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
33012590|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
33012591|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
33012592|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
33012593|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
33012594|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
33012595|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
33012596|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
33012597|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
33012598|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
33012599|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
33012600|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
33012601|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
33012602|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
33012603|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
33012604|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
33012605|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
33012606|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
33012607|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
33012608|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
33012609|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
33012610|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
33012611|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
33012612|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
33415939|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
33415940|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
33415941|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
33012613|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
33415942|NCT05384886||Group1: COVID-19 patients in 2020|All patients over the age of 18 diagnosed with COVID-19 in 2020
33415943|NCT05384886||Group: COVID-19 patients in 2022|All patients over the age of 18 diagnosed with COVID-19 in 2022
33012614|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
33012615|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
33012616|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
33012617|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
33012618|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
33012619|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
33012620|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
33012621|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
33012622|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
33012623|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
33012624|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
33012625|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
33012626|NCT01741506|No Intervention|No treatment|No treatment
33012627|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
33012628|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
33012629|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
33012630|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
33012631|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
33012632|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
33415944|NCT01350427|Experimental|Leucine|
33415945|NCT01350427|Experimental|BCAA|
33415946|NCT01350427|Placebo Comparator|Placebo|
33415947|NCT05384574|Experimental|Intervention|Patients with low levels of Vitamin D on admission to ICU randomized to receive vitamin D supplementation
33415948|NCT05384574|No Intervention|Control|Patients with low levels of Vitamin D on admission to ICU not receiving vitamin D supplementation
33415949|NCT04355585|Experimental|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
33415950|NCT04355585|Experimental|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
33415951|NCT05189743|Experimental|Dermis graft|
33415952|NCT05189743|Experimental|STSG|
33012633|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
33012634|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
33012635|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
33012636|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
33012637|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
33012638|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
33012639|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
33012640|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
33012641|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
33012642|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
33012643|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
33012644|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
33012645|NCT01741662|Other|group psychopathological|
33012646|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
33012647|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
33415953|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg~THC containing cigarettes 30mg~Placebo"
33012648|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
33012649|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
33012650|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
33012651|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
33012652|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
33012653|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
33012654|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
33012655|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
33012656|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
33012657|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
33012658|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
33012659|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
33012660|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
33012661|NCT01741818||Group B|CVP less than 8cmH2o
33012662|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
33012663|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
33012664|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
33012665|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
33012666|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
33012667|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
33012668|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
33012669|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
33012670|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
33012671|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
33012672|NCT01741909|Experimental|Before, After|The intervention is educational
33012673|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
33012674|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
33415954|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg~Placebo~THC containing cigarettes 10mg"
33415955|NCT02061020|Experimental|Sequence 3|"Placebo~THC containing cigarettes 10mg~THC containing cigarettes 30mg"
33415956|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
33415957|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
33417519|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
33012675|NCT01741948||First time users of hormonal contraceptive|
33012676|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
33012677|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
33012678|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
33012679|NCT01741987|Active Comparator|optive® eye drop|
33012680|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
33012681|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
33012682|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
33012683|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
33012684|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
33012685|NCT01742039||b-blocker|
33012686|NCT01742039||amiodarone|
33012687|NCT01742039||atrial pacing|
33012688|NCT01742039||amiodarone plus atrial pacing|
33012689|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
33012690|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
33012691|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
33012692|NCT01742052|Placebo Comparator|Placebo|Placebo
33012693|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
33012694|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
33012695|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
33012696|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
33012697|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
33012698|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
33012699|NCT01742182|No Intervention|Control|
33012700|NCT01742182|No Intervention|PD patients without sleep problems|
33012701|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
33012702|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
33012703|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
33012704|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
33012705|NCT01742221|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
33012706|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose
33012707|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
33012708|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
33012709|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
33012710|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
33012711|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
33012712|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
33012713|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
33012714|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
33012715|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
33012716|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
33012717|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
33012718|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
33012719|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
33012720|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
33012721|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
33012722|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
33012723|NCT01742416|Experimental|Ultrasound|
33012724|NCT01742416|Active Comparator|Palpation Method|
33012725|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
33012726|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
33012727|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
33012728|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
33012729|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
33012730|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
33012731|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
33012732|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
33012733|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
33012734|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
33417520|NCT02079506|Experimental|Treatment A|
33417521|NCT02079506|Experimental|Treatment B|
32866398|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
33012735|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
33012736|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
33417522|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
33417523|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
33417569|NCT03136367|No Intervention|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
32866399|NCT04821492||Hyperhomocysteinemia|
32866400|NCT04821492||Normal Hcy levels|
32866401|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
32866402|NCT04828044||Microwave Ablation/ Coagulation Arm|These patients will receive microwave ablation using MedWaves Microwave Ablation/ Coagulation System.
32866403|NCT05619354||Individuals with headache|"Individuals with primary or secondary headache forms.~The Headache Disability Index will be applied:~In the translation phase:~Complete and assess the Dutch translation of the HDI questionnaire. The questionnaire and its evaluation can be completed online. If desired, the questionnaire can also be completed on paper, whereby the questions can be asked orally by a researcher.~OR~In the validation phase:~To complete the Dutch questionnaire, in combination with other questionnaires (RAND-36 questionnaire and HIT-6 questionnaire).The questionnaires can be completed online. If desired, the questionnaires can also be completed on paper. Afterwards participants will be asked to complete the HDI questionnaire again after 1 month."
32866404|NCT01505673|Active Comparator|Liraglutide|
32866405|NCT01505673|Placebo Comparator|Saline injection|
32866406|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
32866407|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
32866408|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
32866409|NCT04828356|Experimental|Foot reflexology group|The first researcher received hands-on training about reflexology application before the study started. The researcher applied foot reflexology on the patients with liver transplantation in the experimental group in one session (30 minutes) after the operation. Patient confidentiality was maintained in all procedures. The patient identity form was implemented before reflexology application. Pain and comfort levels were assessed as the pre-test. Then, venous blood was taken to determine the plasma β-End level. Foot reflexology was first applied on the right foot, which is effective on the sympathetic nervous system, for 15 min and then, on the left foot, which is effective on the parasympathetic nervous system, for 15 min. Same process was performed on the left foot and the reflexology application was completed within 15 min. Venous blood was taken again to assess the β-End level as the post-test after the application, and the NPS and PCQ were implemented again.
32866410|NCT04828356|No Intervention|No treatment group|The patient identity form, NPS and PCQ were applied on the patients in the control group as the pre-test. After the questions were answered, venous blood was taken to determine the plasma β-End level. No intervention other than clinical protocol was applied on the control group, and after taking venous blood after 30 minutes to determine β-End level, the NPS and PCQ were re-applied as the post-test.
32866411|NCT04828200||sarcopenic patints with knee ostheoarthritis|12 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients with sarcopenia.All subjects were evaluated by the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria for the diagnosis of sarcopenia.
32866412|NCT04828200||non sarcopenic patients with knee ostheoarthritis|90 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients.
32866413|NCT04828200||control group|33 patients between the ages of 50-70, who have been followed up not being exposed to be sarcopenia or knee OA
32866414|NCT04460573|Active Comparator|Smart boot irremovable|Smart boot rendered irremovable with cohesive bandage; no feedback on adherence.
32866415|NCT04460573|Active Comparator|Smart boot removable|Smart boot, removable, without feedback on adherence.
32866416|NCT04460573|Experimental|Smart boot removable+reinforcement|Smart boot with, removable, with reinforcement of adherence via smart watch and smart phone as well as remote patient monitoring.
32866417|NCT04834986|Experimental|Tislelizumab combined with Lenvatinib|
32866418|NCT04828278|Placebo Comparator|Treatment 1|1,600 mg of Placebo (maltodextrin)
32866419|NCT04828278|Active Comparator|Treatment 2|1,500 mg of ASI (bonded arginine silicate) + 100 mg of inositol (nooLVL)
32866420|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
32866421|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
33417524|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
33012737|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
33012738|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
33012739|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
33012740|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
33012741|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
33012742|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
33012743|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
33012744|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
33012745|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
33012746|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
33012747|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
33012748|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
33012749|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
33012750|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
33012751|NCT01742585|Experimental|ASP1585 group|
33012752|NCT01742585|Placebo Comparator|placebo group|
33012753|NCT01742598|Experimental|Portico Implant|
33012754|NCT01742611|Experimental|ASP1585 group|
33012755|NCT01742624|Experimental|Advagraf group|
33012756|NCT01742624|Active Comparator|Prograf group|
33012757|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
33012758|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
33012759|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
33012760|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
33012761|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
33012762|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
33012763|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
33012764|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
33012765|NCT01742676|Experimental|ADVAGRAF group|
33012766|NCT01742676|Active Comparator|PROGRAF group|
33012767|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
33012768|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
33417570|NCT04419337|Experimental|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
33012769|NCT01742702||DYNAMIC (ongoing)|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
33012770|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
33012771|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
33012772|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
33012773|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
33012774|NCT01742702||Aortic stenosis (ongoing)|Subjects with aortic stenosis confirmed by echocardiography
33012775|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
33012776|NCT01742702||Participants of Ironman Triathlon|Altogether 80 athletes participating in a full length Ironman competition. Non-invasive recordingds are performed under normal conditions during the training period and after completion of a full-length Ironman competition.
33012777|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
33012778|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
33012779|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
33012780|NCT01742728||Nagasaki|Sample collection
33012781|NCT01742728||Tokushima|Oxidative stress, cytokine
33012782|NCT01742728||Kanagawa|oxidative stress
33012783|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
33012784|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
33012785|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
33012786|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
33012787|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
33012788|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
33012789|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
33012790|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
33417571|NCT04419337|Active Comparator|Control arm|metformin + DPP4 inhibitors
33417572|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
33417573|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
33417574|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
33012791|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
33012792|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~2 10mg D1-7, D15-21 6mg D1, 8, 15~1 10mg D1-7, D15-21 8mg D1, 8, 15~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~The first patient in arm L will be entered into the study at dosing level one."
33012793|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~The first patient in arm M will be entered into the study at dosing level one."
33012794|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
33012795|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
33012796|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
33012797|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
33012798|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
33012799|NCT01742858||Adolescents|15-18 years old
33012800|NCT01742858||Young adults I|19-24 years old
33012801|NCT01742858||Young adults II|25-30 years old
33012802|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
33012803|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
33012804|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
33012805|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
33012806|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
33012807|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
33012808|NCT01742923|Placebo Comparator|Usual care|Usual care
33012809|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~Consultation with a pharmacist using motivational interviewing techniques~Follow-up telephone calls one month and six months after inclusion"
33012810|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
33012811|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
33012812|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
33012813|NCT01742988|Experimental|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
33012814|NCT01742988|Experimental|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
33012815|NCT01742988|Experimental|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
33012816|NCT01742988|Experimental|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
33012817|NCT01742988|Experimental|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
33012818|NCT01742988|Experimental|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
33012819|NCT01742988|Experimental|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
33012820|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
33012821|NCT01742988|Experimental|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
33012822|NCT01742988|Experimental|Fimepinostat - Biocomparability Arm|Biocomparability Arm
33012823|NCT01742988|Experimental|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
33012824|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
33012825|NCT01742988|Experimental|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
33012826|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
33012827|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
33417575|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
33417576|NCT01354769||Non-intubated patients|
33417577|NCT01354769||Intubated patients|
33012828|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
33012829|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
33012830|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
33012831|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
33012832|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
33415958|NCT04653389|Experimental|Preoperative TACE+Sintilimab+/-Radiotherapy of vein tumor thrombus+postoperative Sintilimab|The first TACE and immunotherapy will be performed at the same time on the first day of treatment. Anti-PD-1 Injection will be administered every three weeks ,until the disease progresses according to mRECIST criteria or intolerable toxicity or the patients' request, or surgery.Hypofractionated radiation therapy will be adopted for Type Vp2, Vp3 PVTT or Type Vv2 HVTT about 2 weeks after the first TACE.If the imaging examination 4 weeks after the surgery confirm that there is no recurrence and no contraindications to receive immunotherapy, anti-PD-1 antibody adjuvant therapy can be started.Every 21 days is a course of treatment, and the longest medication duration lasts for 6 months.
33415959|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
33415960|NCT03134911||anticoagulation non controlled patients|Treated with VKA
33415961|NCT04652843|Other|Idiopathic REM sleep behavior disorders|Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
33415962|NCT04652843|Other|Beginning Parkinson's disease|Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
33415963|NCT04652843|Other|Parkinson's disease state Phase|Group of 20 patients with Parkinson's Disease for more than 5 years
33415964|NCT04652843|Other|Control|Group of 20 patients undergoing coloscopy for family screening for digestive polyps
33415965|NCT05182593|Experimental|Diet 1: moderate/high FODMAP diet. Diet 2: low FODMAP diet.|The subjects will follow the moderate/high FODMAP diet as the first intervention, and the low FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
33415966|NCT05182593|Experimental|Diet 1: low FODMAP diet. Diet 2: moderate/high FODMAP diet.|The subjects will follow the low FODMAP diet as the first intervention, and the moderate/high FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
33415967|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
33415968|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
33415969|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
33415970|NCT05181345||Normal sleep first|"The night before the first heat exposure, the participants will have a normal night at home.~The night before the second heat exposure, the participants sleep will be restricted to 3 hours in bed."
33415971|NCT05181345||Reduced sleep first|"The night before the first heat exposure, the participants sleep will be restricted to 3 hours in bed.~The night before the second heat exposure, the participants will have a normal night at home."
33415972|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
33415973|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
33415974|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
33012833|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
33012834|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
33012835|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
33012836|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
33012837|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
33012838|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
33012839|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
33012840|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
33012841|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
33012842|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
33012843|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
33012844|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
33012845|NCT01743196||Obese|Women with BMI > 30 kg/m2
33012846|NCT01743222|Experimental|eASC|"eASC~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
33012847|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
33012848|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
33012849|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
33012850|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
33012851|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
33012852|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
33012853|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
33012854|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
33012855|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
33012856|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
33012857|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
33012858|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
33012859|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
33012860|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
33012861|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
33012862|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
33012863|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
33012864|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
33012865|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
33012866|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
33012867|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
33012868|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
33012869|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
33012870|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
33012871|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
33012872|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
33012873|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
33012874|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
33012875|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
33012876|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
33012877|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
33012878|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
33012879|NCT01743430|No Intervention|conventional|conventional therapy
33012880|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
33012881|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
33012882|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
33012883|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
33012884|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
33012885|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
33012886|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
33012887|NCT01743534||Conservation of praxies and form plates|
33012888|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
33012889|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
33012890|NCT01743573|Experimental|yoga training|Yoga training
33012891|NCT01743573|No Intervention|control|no yoga training
33012892|NCT01743586|No Intervention|Control|
33012893|NCT01743599||Diabetic men|
33012894|NCT01743599||Non-diabetic men|
33012895|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
33012896|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
33012897|NCT01743612|Experimental|Healthy subjects|18 years old or more
33012898|NCT01743638|Experimental|MR-Guided Laser Ablation|
33012899|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
33012900|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
33012901|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
33012902|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
33012903|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
33012904|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
33012905|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
33012906|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
33012907|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
33012908|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
33012909|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
33012910|NCT01743755|Active Comparator|Dexamethasone|
33012911|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
33415975|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
33415976|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
33415977|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
33415978|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
33415979|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
33415980|NCT05754333|Experimental|White Light/near-infrared fluorescence (WL/NIR-F) - Adults|Adult participants will receive a single dose of ASP5354.
33417578|NCT01352273|Experimental|MEK162 + RAF265|
33012912|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
33012913|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
33012914|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
33012915|NCT01743781|No Intervention|control group|No intervention
33012916|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
33012917|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
33012918|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
33012919|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
33012920|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
33012921|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
33012922|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
33012923|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
33012924|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
33012925|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
33012926|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
33012927|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
33012928|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
33012929|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
33012930|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
33012931|NCT01743846||Major Surgery|Patients undergoing major surgery
33012932|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
33012933|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
33012934|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
33012935|NCT01743898||Control Group|Patient not taking any form of anticoagulation
33012936|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
33012937|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
33012938|NCT01743924|Experimental|Raw|Broccoli,200 grams
33012939|NCT01743924|Experimental|cooked|Microwaved, 200 grams
33012940|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
33012941|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
33012942|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
33012943|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
33012944|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
33012945|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
33012946|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
33012947|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
33012948|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
33012949|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
33012950|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
33012951|NCT01744080|Active Comparator|Early Surgery|
33012952|NCT01744080|Experimental|Regular Wait Time|
33012953|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
33012954|NCT01744106|Placebo Comparator|placebo tablets|Placebo
33012955|NCT01744119||Abdominal Aortic Aneurysm|
33012956|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
33012957|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
33415981|NCT05754333|Experimental|White Light - Adults|Adult participants will receive a single dose of ASP5354.
33012958|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
33012959|NCT01744145|Placebo Comparator|Control 40-60|Control group aged 40-60
33012960|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
33012961|NCT01744145|Placebo Comparator|Control 60 and above|Control group aged 60 and above
33012962|NCT01744158||Children with cerebral palsy|No intervention applicable
33012963|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
33012964|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
33012965|NCT01744210||CHF|
33012966|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
33012967|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
33012968|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
33012969|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
33012970|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
33012971|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
33012972|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
33012973|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
33012974|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
33012975|NCT01744262|Active Comparator|Inhalational anesthesia group|
33012976|NCT01744262|Experimental|Total intravenous anesthesia group|
33012977|NCT01744275|Placebo Comparator|Placebo|Placebo
33012978|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
33012979|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
33012980|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
33012981|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
33012982|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
33012983|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
33012984|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
33012985|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
33012986|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
33012987|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
33012988|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
33012989|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
33012990|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
33012991|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
33012992|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
33012993|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
33012994|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
33012995|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
33012996|NCT01744431||No treatment|
33012997|NCT01744444|Experimental|Memantine first|
33012998|NCT01744444|Experimental|Gabapentin first|
33012999|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
33013000|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
33013001|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
33415982|NCT05754333|Experimental|White Light/near-infrared fluorescence (WL/NIR-F) - Pediatrics|Pediatric participants will receive a single dose of ASP5354.
33415983|NCT01350661||Asthma control level assessment|
33013002|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
33415984|NCT02061254|Experimental|3 groups of subjects|"3 groups:~group of 48 healthy volunteers (matched with venous insufficiency patients)~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
33415985|NCT03480594||Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
33415986|NCT03480594||Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
33415987|NCT05189665|Experimental|Extraperitoneal high sacral ligament suspension Group|We will recruit 62 POP patients ,and perform Surgery Extraperitoneal high sacral ligament suspension surgery on them.
33415988|NCT05189665|Active Comparator|Sacrospinous Ligament Suspension Group|We will recruit 62 POP patients ,and perform sacrospinous ligament suspension surgery on them.
33415989|NCT01344395|Experimental|RK-group|
33415990|NCT01344395|Active Comparator|K-group|
33415991|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
33415992|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
33415993|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
33415994|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
33415995|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
33415996|NCT01342289|Experimental|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
33415997|NCT01342289|Experimental|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
33415998|NCT01342289|Experimental|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
33415999|NCT03618342||PCOS|PCOS women
33416000|NCT03618342||Healthy controls|Healthy control women
33416001|NCT03134599|Active Comparator|etafilcon A|
33416002|NCT03134599|Active Comparator|methafilcon A - Interozzo|
33416003|NCT03134599|Active Comparator|methafilcon A - CVI|
33416004|NCT02062190|Active Comparator|resveratrol|
33416005|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day~1 month"
33416006|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
33416007|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
33416008|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
33416009|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
33416010|NCT05128539|Experimental|JS001(Toripalimab)+JS002|
33013003|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
33013004|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
33013005|NCT01744535|Active Comparator|Paper food diary|
33013006|NCT01744535|Active Comparator|Online food diary|
33013007|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
33416011|NCT01319071||Top-level athletes|
33416012|NCT01319071||Control group|
33416013|NCT05601752|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
33416014|NCT05601752|Experimental|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|
33416015|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
33416016|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
33416017|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
33105808|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
33105809|NCT00551382|Experimental|A|
33105810|NCT00551382|Placebo Comparator|B|
33105811|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
33105812|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
33105813|NCT02894645|Other|Standard Risk (SR)|
33105814|NCT02894645|Other|Intermediate Risk (IR)|
33105815|NCT02894645|Other|High risk (HR)|
33105816|NCT04895631|Experimental|Fluorocholine PET Imaging|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
33105817|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
33105818|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
33105819|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
33105820|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
33105821|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
33105822|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
33105823|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
33105824|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
33105825|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
33105826|NCT05427968||Supine group|Spinal anaesthesia was administered in sitting position and then supine position was maintained.
33105827|NCT05427968||Left tilt group|Spinal anesthesia was administered in sitting position was then maintained on supine position until full anesthetic effect (motor and sensory loss) and then table was tilted 15 degrees to the left.
33105828|NCT04588740|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
33105829|NCT04588740|Placebo Comparator|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
33105830|NCT05427851|Experimental|Group I: Platelet rich Fibrin (PRF) and Biodentine|
33105831|NCT05427851|Experimental|Group II: Diode Laser and Biodentine|
33105832|NCT05427851|Experimental|Group III: Diode laser + PRF + Biodentine|
33105833|NCT04584333|Experimental|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
33105834|NCT04584333|No Intervention|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
33105835|NCT05427734|Experimental|Jaspr2.0|Suicide prevention platform that includes evidence-based practices for suicide prevention and alcohol misuse for use in primary care. Jaspr2.0 includes psychoeducation, behavioral skills training, crisis stabilization planning, lethal means management, brief interventions for the treatment of alcohol misuse, and messages of hope, wisdom, and insights from people with lived experience (PLE). Participants in this condition will also have access to the Jaspr2.0 companion mobile app, Jaspr-at-Home.
33105836|NCT05427734|Active Comparator|Active-Control app + electronic wellness resources brochure|Well-regarded suicide prevention self-help app, plus an electronic wellness resources brochure containing links to health and wellness materials, psychoeducation about suicide, depression, self-help recovery-focused resources (e.g., Alcoholics Anonymous, other 12-Step programs, Moderation Management, etc.), and phone/text information for the National Suicide Prevention Lifeline.
33105837|NCT05427695|Active Comparator|Saline Nasal Irrigation (Control)|Patients will perform nasal irrigation with an isotonic saline solution, using a 240ml NeilMed sinus rinse bottle, 2 times/day for 14 days. A blinded vial supplied by IDS containing a premeasured amount of saline to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
33105838|NCT05427695|Experimental|Lactobacillus sakei nasal irrigation|Patients will perform nasal irrigation with 1 gram of product 2 times/day for 14 days. Each gram of product contains 1×10(9) CFU L. Sakei that will be dissolved in 240 ml water using a 240ml NeilMed sinus rinse bottle. A blinded vial provided by IDS containing a premeasured amount of Lactobacillus sakei to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
33105839|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
33416018|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
33416019|NCT04194606|Active Comparator|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
33325720|NCT03909594|Experimental|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
32866422|NCT00941759||Known or suspected Stage IV disease & an intact primary|Pt will be asked to undergo a research core needle biopsy of the primary tumor. If pts are not agreeable to a research biopsy then the original diagnostic biopsy material will be requested. They will also undergo a diagnostic biopsy of a metastatic site, if not already performed, and a blood draw as appropriate for correlative science studies. Additionally, patients will complete a general medical questions form at the time of enrollment.
32866423|NCT00941759||Unsuspected metastatic disease W/I 3 months of primary b|A blood sample will be collected and patients will complete a general medical questions form at the time of enrollment. Paraffin tissue from the prior surgical procedure will be obtained as Tissue sample. Paraffin tissue from the diagnostic biopsy of a metastatic site will also be obtained. In the event that fresh frozen tissue is available for either site this will also be requested.
32866424|NCT04827966|Active Comparator|Fluoride Varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride. 0.2-0.5ml of the varnish is applied onto the tooth surface after through cleaning. One coats of the varnish will be applied and patient will be instructed not to rinse with water or eat for 30 minutes. This is based on the manufacturer's instructions.
32866425|NCT04827966|Active Comparator|Tooth Mousse|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization. One tube of the Tooth Mousse will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
32866426|NCT04827966|Active Comparator|MI Paste|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
32866427|NCT04827966|Active Comparator|Acidulated phosphate fluoride gel|A stable thixotropic gel providing 1.23% fluoride ion. This is only for professional use and applied by the dentist. The teeth is cleaned and polished and the gel is applied onto a tray. It is filled upto one third of the tray according to manufacturer's instructions. The tray is then inserted into the mouth and the patient is asked to gently bite down lightly for 1 to 4 minutes.The tray is then removed and patient is asked to expectorate any material in the mouth. The patient is instructed not to eat, rinse or drink for 30 minutes.
32866428|NCT04827966|Active Comparator|Fluoride Mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts.
32866429|NCT02247141|Experimental|Subgam®|
32866430|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
32866431|NCT04827654|Experimental|Intervention group|Families in the intervention arm will receive a program of 4 weeks of access to fruit and vegetables through direct access (produce box) and a gift card to the grocery store for purchase of preferred produce.
32866432|NCT04827654|No Intervention|Control Group|Families in the control group will not receive any produce boxes or gift cards during the study period. At the end of the study period they will receive gift cards of equivalent amount.
32866433|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
32866434|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
32866435|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
32866436|NCT04821804|Experimental|Experimental|local application of HYADENT BG on both donor and recipient sites
32866437|NCT04821804|Placebo Comparator|control|application of normal saline on both donor and recipient sites
32866438|NCT04756115||CASES|Adults (age<18 years) diagnosed with a first episode of critical limb ischemia revascularized at our center from January 2016 to July 2019.
32866439|NCT04835064|Experimental|Nab-paclitaxel and Gemcitabine|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15;Gemcitabine 1000 mg/m2 was given intravenously for more than 30min on days 1, 8, and 15, and repeated every 4 weeks.
32866440|NCT04835064|Experimental|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
32866441|NCT05618106|Experimental|low FODMAP diet|Cross-over design with 3 variations
32866442|NCT00819221|Experimental|1|
32866443|NCT04827888||underweight|patients who underwent one of the 25 common orthopaedic surgeries and have a body mass index (BMI) of <18.5kg/m2
32866444|NCT04827888||normal-weight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 18.5kg/m2 and 24.9kg/m2
32866445|NCT04827888||overweight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 25kg/m2 and 29.9kg/m2
32866446|NCT04827888||mildly obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 30kg/m2 and 34.9kg/m2
32866447|NCT04827888||moderately-to-severely obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI ≥35kg/m2
32866448|NCT01507779|Experimental|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
32866449|NCT01507779|Placebo Comparator|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
32866450|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
32866451|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
32866452|NCT04827498||Myocardial ischemia without obstructive coronary stenosis|
32866453|NCT00808613|Active Comparator|Optetrak Posterior Stabilized TKR|Subjects in this arm will receive an Optetrak Posterior Stabilized total knee system.
32866454|NCT00808613|Active Comparator|Optetrak Hi-Flex TKR|Subjects in this arm will receive an Optetrak Hi-Flex total knee system.
32866455|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
32866456|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
32866457|NCT04378127|Experimental|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
32866458|NCT04378127|No Intervention|traditional medical care|traditional medical care
32866459|NCT00799877||1|This registry will evaluate the long-term safety and effectiveness of HUMIRA® as used in routine clinical practice.
32866460|NCT00068341|Experimental|Arm I (neoadjuvant therapy)|see intervention description
32866461|NCT00068341|Experimental|Arm II (neoadjuvant therapy)|please see intervention description
32866462|NCT00068341|Experimental|HER2/neu negative patients|please see intervention description
32866463|NCT04827264||Return to Play Testing using Checklist|"Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with the Safe return to play following ACL reconstruction checklist"
32866464|NCT04827264||Return to Play Testing using Clinical Judgment|Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with clinical judgement
32866465|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
32866466|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
32866467|NCT05600257||Screening cohort|Women received mammography screening
32866468|NCT05600257||Diagnostic cohort|Women received clinical breast examination
32866469|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
32866470|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
32866471|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
32866472|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
32866473|NCT04821258|Experimental|MICODIGEST 2.0 supplement|Treatment with MICODIGEST 2.0 will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20mL/day (10mL before breakfast and 10 mL before dinner) for 4-6 weeks.
32866474|NCT04821258|Placebo Comparator|Placebo|Treatment with placebo will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20 mL/day (before breakfast and before dinner) for 4-6 weeks.
32866475|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
32866476|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
32866477|NCT04821180||patients treated by angle stable plate PHILOS|
32866478|NCT04821180||patients treated by reverse total shoulder arthroplasty SMR|
32866479|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
32866480|NCT04821024||mild-moderate disability|Those whose neck disability index value is 5-34
32866481|NCT04821024||high disability|Those whose neck disability index value is 35 and above
32866482|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
32866483|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
32866484|NCT04834830||Patients with pleural effusion|In patients with pleural effusion and indication for diagnostic and/or therapeutic procedures (thoracocentesis, drainage of fluid, indwelling pleural catheter (IPC) management, and/or video-assisted thoracoscopic surgery), pleural fluid will be examined for various cytokines and PD1-lymphoctyes.
32866485|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
32866486|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
32866487|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
32866488|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
33013008|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
33013009|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
33013010|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
33013011|NCT01744561|No Intervention|Control|Keep activity level constant
33013012|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
33013013|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
33013014|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
33013015|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
33013016|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
33013017|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
33013018|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
33013019|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~first, prior to the beginning of the work shift~second, during an operationally feasible 20-min break during the 1st half of the work shift~third, once during an operationally feasible 20-min break during the 2nd half of the work shift~fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
33013020|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
33013021|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
33013022|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
33013023|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
33013024|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
33013025|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
33013026|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
33013027|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
33013028|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
33013029|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
33013030|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
33013031|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
33013032|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
33013033|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
33013034|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
33325721|NCT03909594|Active Comparator|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
33325722|NCT04636762|Experimental|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab（ PD-L1 inhibitor）for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab） will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receive radiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
33416020|NCT04194606|Experimental|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
33013035|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
33013036|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
33013037|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
33013038|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
33416021|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
33013039|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
33013040|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
33013041|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
33013042|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
33013043|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
33013044|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
33013045|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
33013046|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
33013047|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
33013048|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
33013049|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
33013050|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
33013051|NCT01745016|Placebo Comparator|Placebo|placebo
33013052|NCT01745016|Experimental|Beta-Alanine|beta-alanine
33013053|NCT01745029||Ulcerative Colitis|
33013054|NCT01745042||android postmenopausal women|Clinical exams
33013055|NCT01745042||gynoid postmenopausal women|Clinical exams
33013056|NCT01745068|No Intervention|Control group|
33013057|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
33013058|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
33013059|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
33013060|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
33013061|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
33013062|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
33013063|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
33013064|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
33013065|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
33013066|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
33013067|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
33013068|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
33013069|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
33013070|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
33416022|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
33013071|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
33416023|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
33013072|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
33013073|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
33013074|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
33013075|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
33013076|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
33013077|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
33013078|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
33013079|NCT01745276|Experimental|External pins coated by biphosfonate.|External pins coated by biphosfonate.
33013080|NCT01745276|Active Comparator|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
33013081|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
33013082|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
33013083|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
33013084|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
33013085|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
33013086|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
33013087|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
33013088|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
33013089|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
33013090|NCT01745406||Doctor and nurse|
33013091|NCT01745406||Doctor without nurse|
33013092|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
33013093|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
33013094|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
33013095|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
33013096|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
33013097|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
33013098|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
33013099|NCT01745484|Experimental|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
33013100|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
33013101|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
33013102|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
33013103|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
33013104|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
33013105|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
33013106|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
33013107|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
33013108|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33013109|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33013110|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33013111|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33013112|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33013113|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33013114|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
33013115|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
33013116|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
33013117|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
33013118|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
33013119|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
33013120|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
33013121|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
33013122|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
33013123|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
33013124|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
33013125|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
33013126|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
33013127|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
33013128|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
33013129|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
33013130|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
33013131|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
33013132|NCT01745744|No Intervention|Control|Conventional treatment
33013133|NCT01745770|Experimental|A|
33013134|NCT01745770|Active Comparator|B|
33013135|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
33013136|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
33013137|NCT01745835|Active Comparator|2L Coolprep®|
33013138|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
33013139|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
33013140|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
33013141|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
33013142|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
33013143|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
33013144|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
33013145|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
33013146|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
33013147|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
33013148|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
33013149|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
33013150|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
33013151|NCT01746030||Questionnaires|No treatment
33013152|NCT01746069|Placebo Comparator|health advice|clinical practice routine
33013153|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
33013154|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
33013155|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
33013156|NCT01746134||Cohort|
33013157|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
33013158|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
33013159|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
33013160|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
33416024|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
33013161|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
33013162|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
33013163|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
33013164|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
33013165|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
33013166|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
33013167|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
33013168|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
33013169|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
33013170|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
33013171|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
33013172|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
33013173|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
33013174|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
33013175|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
33013176|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
33013177|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
33013178|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
33013179|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
33013180|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
33013181|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
33013182|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
33013183|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
33013184|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
33013185|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
33013186|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
33013187|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
33013188|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
33013189|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
33013190|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
33013191|NCT01746472|Experimental|2 - B-passive|
33013192|NCT01746472|Experimental|3 - B-active|
33013193|NCT01746472|Experimental|4 - B-active, B-passive|
33013194|NCT01746472|Experimental|6 - z, B-passive|
33013195|NCT01746472|Experimental|7 - z, B-active|
33013196|NCT01746472|Experimental|8 - z, B-active, B-passive|
33013197|NCT01746472|Experimental|10 - t, B-passive|
33013198|NCT01746472|Experimental|11 - t, B-active|
33013199|NCT01746472|Experimental|12 - t, B-active, B-passive|
33013200|NCT01746472|Experimental|14 - t, z|
33013201|NCT01746472|Experimental|15 - t, z, B-active|
33013202|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
33013203|NCT01746485|Experimental|UT-15C|
33013204|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
33013205|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
33013206|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
33013207|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
33013208|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
33013209|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
33013210|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
33013211|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
33013212|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
33013213|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
33013214|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
33013215|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
33013216|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
33013217|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
33013218|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
33013219|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
33013220|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
33013221|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
33013222|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
33013223|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
33013224|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
33013225|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
33013226|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
33013227|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
33013228|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
33013229|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
33013230|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
33013231|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
33013232|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
33013233|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
33013234|NCT01746706|Experimental|patients|
33013235|NCT01746706|Experimental|volunteers|
33013236|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
33013237|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
33013238|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
33013239|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
33013240|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
33013241|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
33013242|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
33325723|NCT04529980|Experimental|Lactobacillus rhanmosus GG(LGG®) Group|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
33325724|NCT04529980|Placebo Comparator|Placebo Control Group|Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
33325725|NCT03904992|No Intervention|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
33013243|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
33013244|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
33013245|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
33013246|NCT01746875|No Intervention|Observation|
33013247|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
33013248|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
33013249|NCT01746927||cricoid pressure|
33013250|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
33013251|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
33013252|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
33013253|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
33013254|NCT01747005||Conventional therapy|
33013255|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
33013256|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
33013257|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
33013258|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
33013259|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
33013260|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
33013261|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
33013262|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
33013263|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
33013264|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
33013265|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
33013266|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
33013267|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
33013268|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
33013269|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
33013270|NCT01747122|Experimental|Wound catheter|Wound catheter
33013271|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
33013272|NCT01747135|Experimental|Open label|
33013273|NCT01747161|Experimental|botulin toxin|botulin toxin
33013274|NCT01747161|Placebo Comparator|physiological water|physiological water
33013275|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
33013276|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
33013277|NCT01747174|Active Comparator|Std PCI|Standard PCI only
33013278|NCT01747187||Septic shock|
33013279|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
33013280|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
33013281|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
33013282|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
33013283|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
33013284|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
33013285|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
33013286|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
33013287|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
33013288|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
33013289|NCT01747291||Atypical femur fracture cohort|
33013290|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
33013291|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
33013292|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
33013293|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
33013294|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
33013295|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
33013296|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
33013297|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
33013298|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
33013299|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
33013300|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
33013301|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
33013302|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
33013303|NCT01747538|Placebo Comparator|Placebo|
33013304|NCT01747538|Experimental|Dose 1 gevokizumab|
33013305|NCT01747538|Experimental|Dose 2 gevokizumab|
33013306|NCT01747564|Experimental|mirabegron group|
33013307|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
33013308|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
33013309|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
33013310|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
33013311|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
33013312|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
33013313|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
33013314|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
33013315|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
33013316|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
33013317|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
33013318|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
33013319|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
33013320|NCT01747681||Microfracture|Microfracture of articular chondral defect
33013321|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
33013322|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
33013323|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
33013324|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
33013325|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
33013326|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
33013327|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
33013328|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
33013329|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
33013330|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
33013331|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
33013332|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
33013333|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
33013334|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
33013335|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33013336|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
33013337|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
33013338|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
33013339|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
33013340|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
33013341|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
33013342|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
33013343|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
33013344|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
33013345|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
33013346|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2~Inflation pressure of 30 cm H2O + 10l O2/min~0.5 ml saline 0.9%~10 Manual Hyperinflation~10 vibrocompression~Aspiration Tracheal"
33013347|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2~0.5 ml saline~10 vibrocompression toracica on the right and left~Aspiration Tracheal"
33013348|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
33013349|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
33013350|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
33013351|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
33013352|NCT01748006||Blood and urine samples|
33013353|NCT01748019|Experimental|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks~--------------------------------------------------------------------------------"
33013354|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
33013355|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
33013356|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
33013357|NCT01748058|No Intervention|Routine care|
33013358|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
33013359|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
33013360|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
33013361|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
33013362|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
33013363|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
33013364|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
33013365|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
33013366|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
33013367|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
33013368|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
33013369|NCT01748136||Single Arm|CT Scan Arm
33013370|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
33013371|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
33013372|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
33013373|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
33013374|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
33013375|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
33013376|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
33013377|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
33013378|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
33013379|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
33013380|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
33325726|NCT03904992|Experimental|Exposed|Subjects with access to the progressive web app in their smartphones.
33013381|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
33013382|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
33013383|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
33013384|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
33013385|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
33013386|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
33013387|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
33013388|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
33013389|NCT01748344|Placebo Comparator|Placebo|Placebo
33013390|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
33013391|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
33013392|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
33013393|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
33013394|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
33013395|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
33013396|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
33013397|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
33013398|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
33013399|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
33013400|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
33013401|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
33013402|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
33013403|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
33013404|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
33013405|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
33013406|NCT01748461|No Intervention|Control group|No cycle ergometer program
33013407|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
33013408|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
33013409|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
33013410|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
33013411|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
33013412|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
33013413|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
33013414|NCT01748539|Experimental|KHK4827 70mg SC|
33013415|NCT01748539|Experimental|KHK4827 140mg SC|
33013416|NCT01748539|Experimental|KHK4827 210mg SC|
33013417|NCT01748539|Placebo Comparator|Placebo SC|
33013418|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
33013419|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
33013420|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
33013421|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
33013422|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
33013423|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
33013424|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
33013425|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
33013426|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
33013427|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
33013428|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
33013429|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
33013430|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
33013431|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
33013432|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
33013433|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
33013434|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
33013435|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
33013436|NCT01748708|Experimental|Magnetic seizure therapy|
33325727|NCT04492072|Experimental|Oxytocin with Mechanical Dilation|"If the patient is randomized to Cook Balloon and Oxytocin - The balloon inflated to 60cc will be placed and oxytocin 2 mu/min will be initiated, and increased incrementally by 2mu/min every 30 minutes. If the cook cannot be placed initially, it will be reattempted and placed within 6 hours of oxytocin starting. The Cook catheter will remain in place until spontaneously expelled, or if not, after 12 hours of placement.~If a Cook Balloon is not available, a Foley catheter can be used in its place as alternate and equivalent form of mechanical dilation."
33327119|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
33013437|NCT01748708|Active Comparator|Electroconvulsive therapy|
33013438|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
33013439|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
33327120|NCT01172652|Experimental|ziprasidone|
33327121|NCT01172652|Placebo Comparator|Placebo|
33013440|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
33013441|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
33013442|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
33013443|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
33013444|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
33013445|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
33013446|NCT01748838|Experimental|Part 1: CTX-4430|
33013447|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
33013448|NCT01748838|Experimental|Part 2: CTX-4430|
33013449|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
33013450|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
33013451|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
33013452|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
33013453|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
33013454|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
33013455|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
33013456|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
33013457|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
33013458|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
33013459|NCT01748981|Other|Physical training|Exercise intervention.
33013460|NCT01748981|Other|As usual|Controls
33013461|NCT01749007||Veterans with HIV/AIDS|
33013462|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
33013463|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
33013464|NCT01749046|Experimental|Remegal|Remegal 1500 mg
33013465|NCT01749046|Placebo Comparator|Placebo|Placebo
33013466|NCT01749059||Congenital Heart Defect|
33013467|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
33013468|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
33013469|NCT01749085|Experimental|Sequence 1|
33013470|NCT01749085|Experimental|Sequence 2|
33013471|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
33013472|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
33013473|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
33013474|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
33013475|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
33013476|NCT01749150|Experimental|with cirrhosis|
33013477|NCT01749150|Experimental|without cirrhosis|
33013478|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
33013479|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
33013480|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
33013481|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
33013482|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
33013483|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
33013484|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
33013485|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
33013486|NCT01749202|Placebo Comparator|Negative Control|
33013487|NCT01749202|Active Comparator|Positive Control|
33013488|NCT01749202|Experimental|Active|
33013489|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
33013490|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
33013491|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
33013492|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
33013493|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
33013494|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
33013495|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
33013496|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
33013497|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
33013498|NCT01749306|Other|Control|Control wound treatment
33013499|NCT01749319|Active Comparator|Oral Baclofen|
33013500|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
33013501|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
33013502|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
33013503|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
33013504|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
33013505|NCT01749358|Other|Active Monitoring|This is an observation only group.
33013506|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
33013507|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
33013508|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33013509|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33013510|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
33013511|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
33013512|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
33013513|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
33013514|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
33013515|NCT01749462||Oxis|
33013516|NCT01749475||midazolam|
33013517|NCT01749475||hypnosis|
33013518|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
33327122|NCT01278732||untreated persons with suspected hypertension|
33327123|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
33327124|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
33327125|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
33416025|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
32866489|NCT05619198|Active Comparator|High Intensity Interval Exercise|Plasma and sensor glucose is monitored before, during and after a bout of high intensity interval exercise
32866490|NCT05619198|Active Comparator|Moderate Intensity Continous Exercise|Plasma and sensor glucose is monitored before, during and after a bout of moderate intensity continous exercise
32866491|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
32866492|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
32866493|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
32866494|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
32866495|NCT04827186|Experimental|highly sensitized patients with either a positive FCXM, or positive CDC cross-match|highly sensitized patients that receive a donor offer and have either a positive FCXM (T or B cell positive) or positive CDC cross-match (B cell positive); a positive CDC cross-match (T cell positive) remains a contraindication at this time.
32866496|NCT04827186|No Intervention|historical cohort of highly sensitized patients with a positive FCXM, or positive CDC cross-match|The control group, as comparison, will be an historical cohort of highly sensitized patients with positive flow (B and T) or positive B standard crossmatch, which received kidney transplant alone or simultaneous kidney and pancreas transplant and followed our standard protocol
32866497|NCT00068575|Experimental|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
32866498|NCT04826718||Cohort|All Health Care Worker (HCW) from Hospital in Santiago and S. Vicente islands, Cabo Verde
32866499|NCT04826718||Control|HCW who report no SARS-CoV-2 infection in the period prior to the interview and/or suspected COVID-19 in the period prior to the interview
32866500|NCT04826718||Cases|HCW who report positive SARS-CoV-2 infection confirmed by performing a positive PCR test and/or positive Rapid Antigen Test in the period prior to the interview
32866501|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1 mg/m2|Bortezomib at 1 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
32866502|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1.3 mg/m2|Bortezomib at 1.3 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
32866503|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1.6 mg/m2|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
32866504|NCT00784823|Experimental|Phase II Cohort|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
32866505|NCT04428684|Experimental|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
32866506|NCT04428684|Active Comparator|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
32866507|NCT01509105||Group1|
32866508|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
32866509|NCT00773357|Placebo Comparator|Placebo|placebo control
32866510|NCT05617950|Experimental|salicylic acid|30% salicylic acid
32866511|NCT05617950|Active Comparator|cryotherapy|liquid nitrogen
32866512|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
32866513|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
32866514|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
32866515|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
32866516|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
32866517|NCT04834752||Patients tested for COVID-19|Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)
32866518|NCT04834674|Experimental|DEB-TACE combined with apatinib and PD-1 antibody|The participants will receive the combined treatment of local therapy (DEB-TACE, oxaliplatin and gemcitabine), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
32866519|NCT00647387|Experimental|1|Implantation with the device
32866520|NCT04834596||patients without hepatic metastases|hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed
32866521|NCT04834596||patients with synchronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed
32866522|NCT04834596||patients with metachronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed
32866523|NCT04834050|Experimental|Rheumatoid arthritis patients|
32866524|NCT04834050|Experimental|Knee Osteoarthritis patients|
32866525|NCT04834050|Experimental|Healthy patients|
32866526|NCT00611117|Experimental|1|High intensity exercise and high fat diet
32866527|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
32866528|NCT04820322|Placebo Comparator|control cookie|a sugarsnap cookie baked specifically for this trial
32866529|NCT04820322|Active Comparator|Fibersym cookie|a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
32902590|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
33013519|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
33416026|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
33013520|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
33013521|NCT01749527|Other|24-hour pad test|decreased activity
33013522|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
33013523|NCT01749553|Experimental|sleeper stretch|
33013524|NCT01749553|No Intervention|no intervention|
33013525|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
33013526|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
33013527|NCT01749566|No Intervention|Group C (no drug)|No additional drug
33013528|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
33013529|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
33013530|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
33013531|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
33013532|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
33013533|NCT01749644||CF patients with chronic pseudomonas infection|
33013534|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
33013535|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
33013536|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
33013537|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
33013538|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
33013539|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
33013540|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
33013541|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
33013542|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
33013543|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
33013544|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
33013545|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
33013546|NCT01749774|Experimental|Physical activity counseling|
33013547|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
33013548|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
33013549|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
33013550|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
33013551|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
33013552|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
33013553|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
33013554|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
33013555|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
33013556|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
33013557|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
33013558|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
33013559|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
33013560|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
33013561|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
33013562|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
33013563|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
33013564|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
33013565|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
33013566|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
33013567|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
33013568|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
33416027|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
33013569|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
33013570|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
33013571|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
33013572|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
33013573|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
33013574|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
33013575|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
33013576|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
33013577|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
33013578|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
33013579|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
33013580|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
33013581|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
33013582|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
33013583|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
33013584|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
33013585|NCT01750151|Experimental|Glucose beverage|Glucose beverage
33013586|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
33013587|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
33013588|NCT01750151|Experimental|Control beverage|Control beverage
33013589|NCT01750164||Invasive breast cancer with metastatic disease|
33013590|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
33013591|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
33013592|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
33013593|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
33013594|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
33013595|NCT01750216||Cohort|
33013596|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
33013597|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
33325728|NCT04492072|Active Comparator|Misoprostol with Mechanical Dilation|If the patient is randomized to Misoprostol and Cook balloon - she will be given 25mcg of misoprostol orally or buccal and a Cook Balloon inflated to 60cc will be placed. She will subsequently receive 50mcg oral or buccal misoprostol every 4 hours up to 4 doses. If regular contractions occur (three or more contractions in a 10-minute period), the patient will be switched to Oxytocin 2 mu/min, and increased incrementally by 2mu/min every 30 minutes. If the cook balloon cannot be placed initially, it will be reattempted and placed within 6 hours of induction start. The Cook catheter will remain in place until spontaneously expelled, or at the fourth misoprostol administration. At this point, oxytocin will be started if not already initiated and artificial rupture of membranes will occur
33325729|NCT03909516|No Intervention|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
32902591|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
32902592|NCT05354336|Experimental|SHR6390（100mg）|
32902593|NCT05354336|Experimental|SHR6390（125mg）|
32902594|NCT05354336|Experimental|SHR6390（150mg）|
32902595|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
32902596|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
32902597|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
32902598|NCT01943318||Autoimmune|Autoimmune Cirrhosis
32902599|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
32902600|NCT01943318||Toxic|Medication related cirrhosis
32902601|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
32902602|NCT05564923||group 1|Advanced cancer patients over 65 years of age receiving nivolumab
32902603|NCT05349110||Gastroenterology patients|"Patient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Colonoscopies will be executed using Fujifilm endoscopy systems (Fujifilm® Corporation, Tokyo, Japan), using Pentax endoscopy systems (Pentax Medical®, Hamburg, Germany), and using Olympus endoscopy systems (Olympus®, Tokyo, Japan)."
32902604|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
32902605|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
32902606|NCT05282264||Patient with hybrid closed-loop systems|
32902607|NCT05282264||Patient without hybrid closed-loop systems|
32902608|NCT05245370|Active Comparator|Control group 1: Control video|
32902609|NCT05245370|Active Comparator|Control group 2: Rationale video + control video|
32902610|NCT05245370|Experimental|Rationale video + clinician testimonial|
32902611|NCT05245370|Experimental|Rationale video + patient testimonial|
32902612|NCT05245370|Experimental|Rationale video + clinician testimonial + patient testimonial|
32902613|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
32902614|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
32902615|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
32902616|NCT05322980||Microcephaly|Infants with primary microcephaly.
32902617|NCT05322980||Control|Infants without primary microcephaly.
32902618|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
32902619|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
32902620|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
32902621|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
32902622|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
32902623|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
32902624|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
32902625|NCT05564845||Severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSS, HbSβº
32902626|NCT05564845||Not severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSβ+, and HbSC and more
32902627|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
32902628|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
32902629|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
32902630|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
32908199|NCT05466032||First year TouroCOM osteopathic medical students|As required by the Touro College of Osteopathic Medicine curriculum, all first year osteopathic students are enrolled in Osteopathic Manual Manipulation (OMM). This course meets three hours per week for the duration of the school year and teaches students about different osteopathic dysfunctions, as well as techniques for how to treat them.
33327126|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
33013598|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
33013599|NCT01750333||Lean children|
33013600|NCT01750333||Overweight Children (OW)|
33013601|NCT01750333||Obese children (Ob)|
33013602|NCT01750359|Active Comparator|curcumin|
33013603|NCT01750359|Placebo Comparator|placebo|
33013604|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
33013605|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
33013606|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
33013607|NCT01750411||Asthma|Severe Asthma Not severe Asthma
33013608|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
33013609|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
33013610|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
33013611|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
33013612|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
33013613|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
33013614|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
33013615|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
33013616|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
33013617|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
33013618|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
33013619|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
33013620|NCT01750489|No Intervention|COPD|
33013621|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
33013622|NCT01750489|No Intervention|Healthy control subjects|
33013623|NCT01750515|Experimental|Intervention group - acupuncture treatment|
33013624|NCT01750515|No Intervention|Control group|
33013625|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
33013626|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
33013627|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
33013628|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
33013629|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
33013630|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
33013631|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
33013632|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
33013633|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
33013634|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
33013635|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
33013636|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
33013637|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
33013638|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
33013639|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
33013640|NCT01750645||Intervention Group|
33013641|NCT01750645||Control Group|
33033181|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
33013642|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
33013643|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
33013644|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
33013645|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
33013646|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
33325730|NCT03909516|Active Comparator|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
33325731|NCT04218448|No Intervention|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.~Somatosensory evoked potentials are carried out according to the usual management."
33013647|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
33325732|NCT04218448|Experimental|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
33013648|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
33013649|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
33013650|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
33325733|NCT03909360|Experimental|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
33325734|NCT03909360|No Intervention|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
33325735|NCT04451668|Experimental|FT218|once nightly sodium oxybate extended release oral solution (FT218)
33013651|NCT01750788||Group 1|
33013652|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
33013653|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
33013654|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
33013655|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
33013656|NCT01750827|Experimental|SB-659032|Single dose open label
33013657|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
33013658|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
33013659|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
33013660|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
33013661|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
33013662|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
33013663|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
33013664|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
33013665|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
33013666|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
33013667|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
33325736|NCT03909126|Experimental|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
33013668|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
33013669|NCT01750970|Experimental|Resection under blue light|
33013670|NCT01750970|Active Comparator|Resection under white light|
33013671|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
33013672|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
33013673|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
33013674|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
33013675|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
33013676|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
33013677|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
33013678|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
33013679|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
33013680|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
33013681|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
33013682|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
33013683|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
33013684|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
33013685|NCT01751191||Training set-chronic response to propranolol|
33013686|NCT01751191||Validation set-chronic response to propranolol|
33013687|NCT01751191||Acute response to propranolol|
33013688|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
33013689|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
33013690|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
33013691|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
33013692|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
33013693|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
33013694|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
33013695|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
33325737|NCT03909126|No Intervention|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
33013696|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
33013697|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
33013698|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
33013699|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
33013700|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
33013701|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
33013702|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
33013703|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
33013704|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
33013705|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
33013706|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
33013707|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
33013708|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
33013709|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
33013710|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
33013711|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
33013712|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
33013713|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
33013714|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
33013715|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
33013716|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
33013717|NCT01751425|Experimental|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
33013718|NCT01751464|Experimental|WrapAround Care|
33013719|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
33013720|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
33013721|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
33013722|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
33013723|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
33013724|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
33013725|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
33013726|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
33013727|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
33013728|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
33013729|NCT01751594|Active Comparator|H4L Comparison Intervention|
33013730|NCT01751594|Experimental|MOVE Intervention|
33013731|NCT01751607||genetic variants|AFib patients with or without the genetic variants
33013732|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
33013733|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
33013734|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~Posterior open approach~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
33013735|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
33013736|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
33013737|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
33013738|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~The total duration of Phase 3 will last approximately six to nine months."
33325738|NCT03909126|Experimental|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
33325739|NCT03909126|No Intervention|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
33013741|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
33013742|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
33013743|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
33013744|NCT01751750|Other|Grape|
33013745|NCT01751763||Group 1|
33013746|NCT01751776|Experimental|BI 655064 Part 1|3 different doses plus placebo in healthy volunteers
33013747|NCT01751776|Experimental|BI 655064 Part 2|2 different doses plus placebo in rheumatoid arthritis patients
33013748|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
33013749|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
33013750|NCT01751815|Experimental|Acu-TENS|
33013751|NCT01751815|Sham Comparator|Placebo-TENS|
33013752|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
33013753|NCT01751854|Experimental|SSRI|SSRI alone or with training
33013754|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
33013755|NCT01751880|Experimental|Exercise Group|
33013756|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
33013757|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
33013758|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
33013759|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
33013760|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
33013761|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
33013762|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
33325740|NCT03905382|Other|Qualitaitve|Qualitaitve
33013763|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
33013764|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
33013765|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
33013766|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
33013767|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
33013768|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
33013769|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
33013770|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
33013771|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
33013772|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
33013773|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
33325741|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
33325742|NCT03909048|Experimental|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
33325743|NCT03909048|Placebo Comparator|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
33325744|NCT04181008|Experimental|0.2 mg|
33325745|NCT04181008|Experimental|0.4 mg|
33325746|NCT04181008|Experimental|0.6 mg|
33325747|NCT03902886||cerebral palsy infants|gait analysis
33325748|NCT03902886||typically developed infants|gait analysis
33325749|NCT01254162|Experimental|Placebo Gel|
33327127|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
33013774|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
33013775|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
33013776|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
33013777|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
33013778|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
33013779|NCT01752179|No Intervention|Control group|without using Kinesio tape
33416028|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
33416029|NCT05211453|Active Comparator|Right sided atrioventricular node ablation|Right sided atrioventricular node ablation
33013780|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
33013781|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
33013782|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
33013783|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
33416030|NCT05211453|Active Comparator|Left sided atrioventricular node ablation|Left sided atrioventricular node ablation
33013784|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
33013785|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
33013786|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
33013787|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
33013788|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
33013789|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
33013790|NCT01752270|No Intervention|blank control|
33013791|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
33013792|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
33013793|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
33013794|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
33013795|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
33013796|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
33013797|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
33013798|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
33013799|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
33013800|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
33013801|NCT01752361||Ulcerative Colitis|
33013802|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
33013803|NCT01752374||Granisetron group|
33013804|NCT01752374||Ramosetron group|
33013805|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
33013806|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
33013807|NCT01752439|No Intervention|Control group|
33013808|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
33013809|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
33325750|NCT04421248|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD. Randomized, blinded, single dose, placebo controlled, crossover trial.
33013810|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
33013811|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
33013812|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
33013813|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
33013814|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
33013815|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
33013816|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
33013817|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
33013818|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
33013819|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
33013820|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
33013821|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
33013822|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
33013823|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
33013824|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
33013825|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
33013826|NCT01752621||acromegaly|patients with acromegaly
33013827|NCT01752621||comparison population|matched background population
33013828|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
33013829|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
33013830|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
33013831|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
33013832|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
33013833|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
33013834|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
33013835|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
33013836|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
33013837|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
33013838|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
33013839|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
33013840|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
33013841|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
33013842|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
33325751|NCT04421248|No Intervention|Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
33325752|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
33013843|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
33013844|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
33013845|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
33013846|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
33013847|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
33013848|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
33325753|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
33325754|NCT04396132|Experimental|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
33325755|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
33325756|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
33325757|NCT04160494|Experimental|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
33325758|NCT04160494|Experimental|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
33013849|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
33013850|NCT01752868|Experimental|supplement|
33013851|NCT01752868|No Intervention|control|
33013852|NCT01752881|Experimental|AdimFlu-S|
33013853|NCT01752894|Active Comparator|Angio guided PCI|
33013854|NCT01752894|Experimental|OCT-guided PCI|
33013855|NCT01752894|Active Comparator|BES|
33013856|NCT01752894|Experimental|EES|
33013857|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
33013858|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
33013859|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
33013860|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
33013861|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
33013862|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
33013863|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
33013864|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
33013865|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
33013866|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
33013867|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
33013868|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
33013869|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
33013870|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
33013871|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
33013872|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
33013873|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
33013874|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
33013875|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
33013876|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
33013877|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
33013878|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
33013879|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
33325759|NCT03902730|Other|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
33325760|NCT03902730|Other|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
33325761|NCT03902730|Other|Back Squat Variation Three|In a randomized order, box squat will be completed.
33325762|NCT03902730|Other|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
33013880|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
33013881|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
33013882|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
33013883|NCT01753128|Active Comparator|imipramine|
33013884|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
33013885|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
33013886|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
33013887|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
33013888|NCT01753180|Experimental|collagenase|
33013889|NCT01753180|Placebo Comparator|saline|
33013890|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
33013891|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
33013892|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
33013893|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
33013894|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
33013895|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
33013896|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
33013897|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
33013898|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
33013899|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
33013900|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
33013901|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
33013902|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
33013903|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
33013904|NCT01753388|Experimental|Treatment by the Liberty Stent|
33013905|NCT01753440|Other|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
33013906|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
33013907|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
33013908|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
33013909|NCT01753466|No Intervention|Control|
33013910|NCT01753479|Experimental|Test subject|
33013911|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
33013912|NCT01753505|Experimental|MDCTA|
33013913|NCT01753531||Flu Symptoms|
33013914|NCT01753583|Experimental|10 patients with corneal abrasions|
33013915|NCT01753583|Experimental|10 patients with corneal infiltrates|
33013916|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
33013917|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
33013918|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
33013919|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
33013920|NCT01753622|Experimental|Exercise group|Physical exercise program
33013921|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
33013922|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
33013923|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
33013924|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
33013925|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
33013926|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
33013927|NCT01753687|Other|50 patients with dry eye syndrome|
33013928|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
33013929|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
33013930|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
33013931|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
33013932|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
33013933|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
33013934|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
33013935|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
33013936|NCT01753791|Experimental|Cohort 1|
33013937|NCT01753791|Experimental|Cohort 2|
33013938|NCT01753791|Experimental|Cohort 3|
33013939|NCT01753791|Experimental|Cohort 4|
33013940|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
33013941|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
33013942|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
33013943|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
33013944|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
33013945|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
33013946|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
33013947|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
33013948|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
33013949|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
33013950|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
33013951|NCT01753921||Healthy control|Control subjects without diabetes.
33013952|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
33013953|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
33013954|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
33013955|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
33013956|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
33013957|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
33013958|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
33013959|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
33013960|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
33013961|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
33013962|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
33013963|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
33013964|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
33013965|NCT01754090|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
33013966|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
33013967|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
33327128|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
33013968|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
33013969|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
33013970|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
33013971|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
33013972|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
33013973|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
33013974|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
33417579|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:~Group breastfeeding counseling during monthly microcredit borrower group meetings~Weekly cell phone messages about breastfeeding"
33013975|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
33013976|NCT01754181|No Intervention|usual treatment|
33013977|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
33013978|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
33013979|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
33013980|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
33013981|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
33013982|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
33013983|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
33013984|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
33013985|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
33013986|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
33013987|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
33013988|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
33013989|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
33013990|NCT01754311||control|Blood donors
33013991|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
33013992|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
33013993|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
33013994|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
33013995|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
33013996|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
33013997|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
33013998|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
33013999|NCT01754506|Placebo Comparator|Placebo|mineral oil
33014000|NCT01754532||Schizophrenia patients|
33014001|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
33014002|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
33014003|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
33014004|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
33014005|NCT01754571|Experimental|CBT treatment|
33014006|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
33014007|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
33014008|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
33014009|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
33014010|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
33014011|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
33014012|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
33416031|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
33417580|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
33014013|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
33014014|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
33014015|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
33014016|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
33014017|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
33014018|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
32739244|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
33014019|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
33014020|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
33014021|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
33014022|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
33014023|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
33014024|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
33014025|NCT01754805|Experimental|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
33014026|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
33014027|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
33014028|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
33014029|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
33014030|NCT01754831|Other|Fluoride varnish|Topical fluoride
33014031|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
33014032|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
33325763|NCT04342546|Experimental|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection) and in the case of adjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection).~The test consists of a blood sample of 2x4 mL"
33325764|NCT03629340|Experimental|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
33325765|NCT03629340|Placebo Comparator|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
33325766|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
33327129|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
33327130|NCT03867474|No Intervention|Control - Usual Care|Control
33327131|NCT01172730||Ultrasound scanning|
33014033|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
33416032|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
33416033|NCT03376152|Active Comparator|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
33416034|NCT03376152|No Intervention|Control Arm|450 households in 15 clusters (30 households per cluster)
33416035|NCT05211375|Active Comparator|SG group|Patients undergoing sleeve gastrectomy
33416036|NCT05211375|Experimental|DJB group|Patients undergoing duodenojejunal bypass with sleeve gastrectomy
33416037|NCT02061488|Active Comparator|open-loop night|
33416038|NCT02061488|Experimental|closed-loop night|
33416039|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
33416040|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
33416041|NCT05089617|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
33416042|NCT05089617|Experimental|SAD Cohort 2|25 mg YG1699 or Placebo
33416043|NCT05089617|Experimental|Multiple Doses Cohort 1|20 mg YG1699 or Placebo
33416044|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
33416045|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
33416046|NCT05210829||High Parent Anxiety|Stationary and Trait Anxiety Scale ≥ 44 points
33416047|NCT05210829||Low Parent Anxiety|Stationary and Trait Anxiety Scale < 44 points
33416048|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
33014034|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
33014035|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
33014036|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
33014037|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
33014038|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
33014039|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
33014040|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
33014041|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
33416049|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
33416050|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
33416051|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
33416052|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
33416053|NCT05210751||Women patients with fibromyalgia|women with fibromyalgia beween age 30-75
33416054|NCT05210751||Control group|Healthy female volunteers aged 30-75 years
33416055|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
33416056|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
33416057|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
33416058|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
33416059|NCT03628833|Experimental|Incontinence Management system|
33416060|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
33416061|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
33416062|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
33416063|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
33416064|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
33416065|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
33325767|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
32902670|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
32902671|NCT05085626|Experimental|fluzoparib+chidamide|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Chidamide: It is recommended to take 20 mg (4 tablets) twice a week, with an interval of no less than 3 days between doses (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), for 30 minutes. Until disease progression or intolerable to patient."
32902672|NCT05085626|Experimental|fluzoparib+camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
32902673|NCT05041946|Experimental|Methylphenidate|treatment of attention deficit disorder and narcolepsy (sleep disorder)
32902674|NCT05041946|Experimental|Placebo|Sugar pill
32902675|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
32902676|NCT05115032|Experimental|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
32902677|NCT05115032|Active Comparator|At-home rehabilitation exercises|Daily rehabilitation exercises involving nodding and shaking of the head
32902678|NCT05092412|Experimental|Low-dose radiotherapy combined with durvalumab, etoposide, and cisplatin/carboplatin|
32902679|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
32902680|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
32902681|NCT05010902||Multiple sclerosis|Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
32902682|NCT05004896|Experimental|Ketamine|Four infusions of ketamine will be administered over two weeks. The first two infusions will be dosed at 0.5mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions.
32902683|NCT05004896|Active Comparator|Midazolam|Four infusions of midazolam will be administered over two weeks. The first two infusions will be dosed at 0.02mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions.
32902684|NCT05005754|Experimental|Probiotics|Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
32902685|NCT05005754|Placebo Comparator|Placebo Control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
32902686|NCT01798082|No Intervention|Standard counseling|
32902687|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
32902688|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
32902689|NCT00576680|Experimental|Temozolomide with RAD001|
32902690|NCT04866602|Experimental|Atoguanil|Atovaquone 500 mg + Proguanil 348 mg
32902691|NCT04866602|Active Comparator|Malarone®|Atovaquone 1000 mg + Proguanil HCl 400 mg
32902692|NCT04730648|Experimental|pcsk9 inhibitor group|patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
32902693|NCT04730648|No Intervention|control group|Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.
32902694|NCT05246540||Patients|
32907263|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
33327132|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
33014042|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
33014043|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
33014044|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
33033182|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
33033183|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
33033184|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
33033185|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
33033186|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
33033187|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
33033188|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
33033189|NCT01960452||Primary insomnia|
33033190|NCT01960452||Healthy sleeping controls|
33033191|NCT01960478|Other|bood test|
33033192|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
32907264|NCT04374188|Active Comparator|ciprofloxacin|ciprofloxacin tablets
33033193|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
33033194|NCT01960517|Experimental|Catheter placed|
32907265|NCT04374188|Active Comparator|levofloxacin|levofloxacin tablets
32907266|NCT04374032|Experimental|ENKORTEN|
32907267|NCT04374032|Other|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
32907268|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
32907269|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
32907270|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
32907271|NCT05633459|Experimental|QRL-201 - Arm 1|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907272|NCT05633459|Experimental|QRL-201 - Arm 2|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907273|NCT05633459|Experimental|QRL-201 - Arm 3|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907274|NCT05633459|Experimental|QRL-201 - Arm 4|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907275|NCT05633459|Experimental|QRL-201 - Arm 5|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907276|NCT05633459|Experimental|QRL-201 - Arm 6|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907277|NCT05633459|Experimental|QRL-201 - Arm 7|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907278|NCT05633459|Experimental|QRL-201 - Arm 8|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
32907279|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
32907280|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
32907281|NCT04906421|Experimental|TVB-2640 50 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
32907282|NCT04906421|Placebo Comparator|Placebo|Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
32907283|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
32907284|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
32907285|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.~Observational with imaging."
32907286|NCT05633381|Experimental|Arm 1 (olaparib, temozolomide)|Patients receive temozolomide is administered at PO QD on days 1-7 of each cycle and olaparib PO BID on days 1-7 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity
32907287|NCT05633381|Active Comparator|Arm 2 (trabectedin, pazopanib)|Patients receive trabectedin IV continuously over 24 hours on day 1 of each cycle and pazopanib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33014045|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
33014046|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
33416066|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
33014047|NCT01755039||Patients with invasive out-of-hospital ventilation|
33014048|NCT01755065||Teenager laparoscopic patients|
33014049|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
33014050|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
33014051|NCT01755104|Experimental|Stablor|dietary supplement Stablor
33014052|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
33416067|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
33416068|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
33014053|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
33416069|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
33014054|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
33014055|NCT01755130|Experimental|Diagnostic (LOUISA 3D)|Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
33416070|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
33416071|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
33416072|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
33416073|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
33416074|NCT04977414|No Intervention|Waitlist control group|Hospitals assigned to this group will be placed in on a waitlist to receive the training intervention at a later date
33417581|NCT02576574|Experimental|Avelumab Biweekly|
33417582|NCT02576574|Experimental|Avelumab Weekly|
33417583|NCT02576574|Active Comparator|Chemotherapy|
33417584|NCT01371019||Women with preterm delivery|
33014056|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
33014057|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
33014058|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
33014059|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
33014060|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
33014061|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
33014062|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
33014063|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
33014064|NCT01755286|Experimental|4 mg OTO-201|
33014065|NCT01755286|Experimental|12 mg OTO-201|
33014066|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
33014067|NCT01755286|Sham Comparator|Sham|
33014068|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
33014069|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
33014070|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
33325768|NCT03902496|Experimental|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
33325769|NCT03902496|Sham Comparator|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
33325770|NCT03908658|Active Comparator|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
33014071|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
33014072|NCT01755312|Experimental|medication reminder|medication reminder
33325771|NCT03908658|Active Comparator|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
33327133|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
33014073|NCT01755312|Placebo Comparator|Placebo|Placebo
33417585|NCT01371019||Women without preterm delivery|
33014074|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
33014075|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
33014076|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
33014077|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
33014078|NCT01755364|Experimental|AdimFlu-V|
33014079|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
33014080|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
33014081|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
33014082|NCT01755403|Other|Benznidazole|
33014083|NCT01755442|Active Comparator|AMG 151|
33014084|NCT01755442|Placebo Comparator|Placebo|
33014085|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
33014086|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
33014087|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
33014088|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
33014089|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
33014090|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
33014091|NCT01755507|Experimental|B|norUDCA
33014092|NCT01755507|Experimental|C|norUDCA
33014093|NCT01755507|Placebo Comparator|placebo|Placebo
33014094|NCT01755507|Experimental|A|norUDCA
33014095|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
33014096|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
33014097|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
33014098|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
33014099|NCT01755533|No Intervention|Control|Continue normal prevention activities
33014100|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
33014101|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
33014102|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
33014103|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
33014104|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
33014105|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
33014106|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
33014107|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33014108|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33014109|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
33014110|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
33014111|NCT01755650|Experimental|D-18F FPM|
33014112|NCT01755650|Experimental|L-18F FPM|
33014113|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
33014114|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
33014115|NCT01755676|Experimental|Orlistat 60 mg|
33014116|NCT01755676|Placebo Comparator|Placebo|
33325772|NCT03904836|Experimental|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
33325773|NCT04234984||Conventional radiofrequency (RF) treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
33325774|NCT03908580|Experimental|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
33325775|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
33325776|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
33325777|NCT05340400||Patients diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
33325778|NCT05340400||Patients not diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
33325779|NCT03904680|Active Comparator|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
33325780|NCT03904680|Active Comparator|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
33325781|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
33325782|NCT04415944|Experimental|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
33325783|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
33325784|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
33325785|NCT03991624|Other|Alzheimer's patients (lack of executive functions)|
33325786|NCT03991624|Other|control (lack of executive functions)|
33325787|NCT03991624|Other|Alzheimer's patients (lack of working memory)|
33325788|NCT03991624|Other|control (lack of working memory)|
33325789|NCT03991624|Other|Alzheimer's patients (lack of episodic memory)|
33325790|NCT03991624|Other|control (lack of episodic memory)|
33325791|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
33325792|NCT01149252|Placebo Comparator|Psoralait|
33325793|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
33325794|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
33325795|NCT01148706|Experimental|ActiSight Needle Guidance System|
33325796|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
33325797|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
33325798|NCT03902106|Active Comparator|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
33325799|NCT03902106|Sham Comparator|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
33325800|NCT03902340|Experimental|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
33325801|NCT03902340|Active Comparator|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
33327134|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
33014117|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
33327135|NCT03872622|Other|CD patients|New onset Crohn's disease patients
33014118|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
33014119|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
33014120|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
33014121|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
33014122|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
33014123|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
33014124|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
33014125|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
33014126|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
33014127|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
33014128|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
33014129|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
33014130|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
33014131|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
33014132|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
33014133|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
33014134|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
33014135|NCT01755806||aortic root dimension change|those without aortic valve calcification
33014136|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
33014137|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
33014138|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
33014139|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
33014140|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
33014141|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
33014142|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
33014143|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
33014144|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
33014145|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
33014146|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
33014147|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
33014148|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
33014149|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
33014150|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
33014151|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
33416075|NCT04977414|Experimental|"Making data count intervention group"|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
33014152|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
33014153|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
33014154|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
33014155|NCT01755962|Other|High Glycemic Load|12-week control diet
33014156|NCT01755988|No Intervention|Usual care|
33014157|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
33014158|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
33014159|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
33014160|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
33014161|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
33014162|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
33014163|NCT01756014||Controls|Age matched healthy subjects
33014164|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
33014165|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
33014166|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
33014167|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
33014168|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
33014169|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
33014170|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
33014171|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
33014172|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
33014173|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
33014174|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
33014175|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
33014176|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33014177|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33014178|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33014179|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33014180|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
33014181|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
33014182|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
33014183|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33014184|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
33416076|NCT05384418|Experimental|patients undergoing transcatheter aortic valve implantation|patients undergoing transcatheter aortic valve implantation for aortic stenosis
33014185|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
33014186|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
33014187|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
33014188|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
33014189|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
33014190|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
33014191|NCT01756261||Group 1|
33014192|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
33014193|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
33014194|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
33014195|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
33014196|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
33014197|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
33014198|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
33014199|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
33014200|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
33014201|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
33014202|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
33014203|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
33014204|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
33014205|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
33014206|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
33327136|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
33416077|NCT05654324|Experimental|Pregnant women|Pregnant women aged 18-40, 20-40 weeks of gestation.
33014207|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
33014208|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
33014209|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
33014210|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
33014211|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
33014212|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
33014213|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
33014214|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
33014215|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
33014216|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
33014217|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
33014218|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
33014219|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
33014220|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
33014221|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
33014222|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
33325802|NCT05285566|Experimental|Exparel® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Exparel®
33014223|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
33014224|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
33014225|NCT01756599|Experimental|leukaemia during childhood or adolescence|
33014226|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
33014227|NCT01756625||First line WT KRAS mCRC|
33014228|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
33014229|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
33014230|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
33014231|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
33014232|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
33014233|NCT01756703|Experimental|MT-3995 Low group|
33014234|NCT01756703|Experimental|MT-3995 High group|
33014235|NCT01756703|Placebo Comparator|Placebo group|
33014236|NCT01756716|Experimental|MT-3995 Low group|
33014237|NCT01756716|Experimental|MT-3995 High group|
33014238|NCT01756716|Placebo Comparator|Placebo group|
33014239|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
33014240|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
33014241|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
33014242|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
33014243|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
33014244|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
33014245|NCT01756768|Experimental|Radio-labeled Dose Arm|
33325803|NCT05285566|Active Comparator|Xylocaine® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Xylocaine® as part of standard of care.
33325804|NCT01149330|Experimental|Adapalene-BPO Gel|
33325805|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
33325806|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
33014246|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
33014247|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
33014248|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
33014249|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
33014250|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
33014251|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
33014252|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
33014253|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
33014254|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
33014255|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
33014256|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
33325807|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
33416078|NCT05654324|Active Comparator|Non-Pregnant|Being a non-pregnant woman who is in the same age range as the experimental group.
33416079|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
33014257|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
33014258|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
33014259|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
33014260|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
33014261|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
33014262|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
33014263|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
33014264|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
33014265|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
33014266|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
33014267|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
33014268|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
33014269|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
33014270|NCT01756963||IBD-SL cohort|
33014271|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
33014272|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
33014273|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
33014274|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
33014275|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
33014276|NCT01757054|Experimental|Probiotic group|
33014277|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
33014278|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
33014279|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
33014280|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
33014281|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
33014282|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
33014283|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
33014284|NCT01757119|Experimental|Drug|
33014285|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
33014286|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
33014287|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
33014288|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
33014289|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
33014290|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
33014291|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
33416080|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
33416081|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
33416082|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
33416083|NCT05654558|Experimental|Auxiliary intrusion cantilevers|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
33014292|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
33014293|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
33014294|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
33014295|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
33014296|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
33014297|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
33014298|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
33014299|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
33014300|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
33014301|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
33014302|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
33014303|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
33014304|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
33014305|NCT01757340|Active Comparator|Weight loss with normal protein intake|
33014306|NCT01757340|Experimental|Weight loss with leucine supplementation|
33014307|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
33014308|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
33014309|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
33014310|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
33014311|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
33014312|NCT01757379|Experimental|13C-labeled acetate|
33014313|NCT01757379|Experimental|13C-labeled propionate|
33014314|NCT01757379|Experimental|13C-labeled butyrate|
33014315|NCT01757379|Experimental|Inulin|
33014316|NCT01757431|Other|ECULIZUMAB|
33014317|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
33014318|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
33014319|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
33014320|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
33014321|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
33014322|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
33014323|NCT01757483||Prescribers|
33014324|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
33014325|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
33014326|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
33014327|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
33014328|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
33416084|NCT05654558|Active Comparator|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
33014329|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
33014330|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
33014331|NCT01757587|Active Comparator|Vildagliptin|
33416085|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
33416086|NCT02061566||Non acute kidney injury|Non acute kidney injury
33416087|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
33014332|NCT01757587|Placebo Comparator|Placebo|
33014333|NCT01757600||Macular Hole|
33014334|NCT01757613|Active Comparator|AK 3012 a for topical use|
33014335|NCT01757613|Active Comparator|AK 3012 b for topical use|
33014336|NCT01757613|Active Comparator|AK 3012 c for topical use|
33014337|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33014338|NCT01757743||Interventional closure|Interventional catheterization closure
33014339|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
33416088|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
33416089|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
33014340|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
33014341|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
33014342|NCT01757795|Experimental|SP-8203|Active arm
33014343|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
33014344|NCT01757808|Experimental|Ranolazine|
33014345|NCT01757808|Placebo Comparator|Placebo|
33014346|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
33014347|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
33014348|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
33014349|NCT01757873|Experimental|Z160|375 mg BID
33014350|NCT01757873|Placebo Comparator|Placebo|matching placebo control
33014351|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
33014352|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
33014353|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
33014354|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
33014355|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
33014356|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
33014357|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
33416090|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
33416091|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
33416092|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
33014358|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
33014359|NCT01757951|Experimental|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
33014360|NCT01757951|Active Comparator|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
33014361|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
33014362|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
33014363|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
33014364|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
33014365|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
33014366|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
33014367|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
33014368|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
33014369|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
33014370|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
33014371|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
33014372|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
33014373|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
33014374|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
33014375|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
33014376|NCT01758133||Mothers not exposed to medical clown activity|
33014377|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
33014378|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
33014379|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
33014380|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
33014381|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
33014382|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
33014383|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
33014384|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
33014385|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
33014386|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
33014387|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
33014388|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
33014389|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
33014390|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
33416093|NCT01344473|No Intervention|No intervention|Standard oral care
33416094|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
33014391|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
33014392|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
33014393|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
33014394|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
33014395|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
33014396|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
33014397|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
33014398|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
33014399|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
33014400|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
33014401|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
33014402|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
33014403|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
33014404|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
33014405|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
33014406|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
33014407|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
33014408|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
33014409|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
33014410|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
33014411|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
33014412|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
33014413|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
33014414|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
33014415|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
33014416|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
33014417|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
33014418|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
33014419|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
33014420|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
33014421|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
33327137|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
33416095|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
33014422|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
33014423|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
33014424|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
33014425|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
33014426|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
33014427|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.~3 months"
33014428|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.~3 months."
33014429|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
33014430|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
33014431|NCT01758562|No Intervention|State-of-the-art mouth care|
33014432|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
33014433|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
33014434|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
33014435|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
33014436|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
33014437|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
33014438|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
33014439|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
33014440|NCT01758627|No Intervention|Peritoneal dialysis group|
33014441|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
33014442|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
33014443|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
33014444|NCT01758666|Experimental|Methotrexate and Calcium folinate|
33014445|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
33014446|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
33014447|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
33014448|NCT01758705||Cohort 1|Cohort 1
33014449|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
33014450|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
33014451|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
33416096|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
33014452|NCT01758783|Placebo Comparator|placebo group|
33014453|NCT01758783|Experimental|Glutamine group|
33014454|NCT01758809|Active Comparator|Bupivacaine|
33014455|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
33014456|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
33014457|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
33014458|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
33014459|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
33014460|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
33014461|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
33014462|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
33416097|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
33416098|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
33014463|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
33014464|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~Inject heparin 5000 units to prevent blood clot during phlebotomy~Inject volume expander equivalent to 5% of blood volume~Remove 5% of whole blood~Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
33014465|NCT01758887||Controls|Healthy control
33014466|NCT01758887||patients|clinical high risk subjects for psychosis
33014467|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
33014468|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
33014469|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
33014470|NCT01758939||Hepatitis C virus infected patients|
33014471|NCT01758952||Beijing Chaoyang Hospital|2000 cases
33014472|NCT01758952||Peking University Hospital|2000 cases
33014473|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
33014474|NCT01758952||Tongji Hospital, Wuhan|2000 cases
33014475|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
33014476|NCT01758952||The Prince Welsh Hospital|1000 cases
33014477|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
33014478|NCT01758965|Experimental|Monotherapy of PPI|PPI
33014479|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
33014480|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
33014481|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
33014482|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
33014483|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:~diagnosed with lipedema following the criteria of Wold~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
33014484|NCT01759004|Active Comparator|patients with obesity|"Obesity group:~BMI ≥ 30~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
33014485|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
33014486|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
33014487|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
33014488|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
33014489|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
33014490|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
33014491|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
33014492|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
33014493|NCT01759069|Experimental|treatment with microscope|treatment with microscope
33014494|NCT01759069|Experimental|treatment without microscope|treatment without microscope
33014495|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
33014496|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
33014497|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
33014498|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
33014499|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
33014500|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
33014501|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
33014502|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
33014503|NCT01759173||college athletes|
33014504|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
33014505|NCT01759225||Cardiovascular Disease Patients|
33014506|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
32739245|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
33014507|NCT01759316|Active Comparator|heliox|Heliox is use in this group
33014508|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
33014509|NCT01759329|Experimental|test coffee|test coffee
33014510|NCT01759329|Active Comparator|control coffee|control coffee
33014511|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
33014512|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
33014513|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
33014514|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
33014515|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
33014516|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
33014517|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
33014518|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
33014519|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
33014520|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
33014521|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
33014522|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
33014523|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
33014524|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
33014525|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
33014526|NCT01759563|Other|single arm study|
33416099|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
33014527|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
33014528|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
33014529|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
33014530|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
33327138|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
33327139|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
33327140|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
33327141|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
33327142|NCT03468660|Experimental|Experimental group|Auditory training with feedback
33327143|NCT03468660|No Intervention|Passive control group|Pre-post testing only; no training
33327144|NCT03468660|Active Comparator|Active Control group|Listening task with no feeback
33327145|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
33327146|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
33327147|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
33327148|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
33327149|NCT03866928|Experimental|Stiripentol|
33327150|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
33327151|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
33327152|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
33327153|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
33327154|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
33327155|NCT02526576|Active Comparator|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
33327156|NCT01172496|Experimental|1 mg tablet; 1mg solution|
33327157|NCT01172496|Experimental|1mg solution; 1mg tablet|
33327158|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
33327159|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
33327160|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
33327161|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
33327162|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
33327163|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
33327164|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
33327165|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
33327166|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
33327167|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
33327168|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
33327169|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
33327170|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
33014531|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
33014532|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
33014533|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
33014534|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
33014535|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
33014536|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
33014537|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
33014538|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
33014539|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
33014540|NCT01759654|Experimental|AdimFlu-V|
33014541|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
33014542|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
33014543|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
33014544|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
33014545|NCT01759693||Control|Healthy volunteers
33014546|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
33014547|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
33014548|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
33014549|NCT01759732|Experimental|HAPLO|
33014550|NCT01759745||Blepharospasm|Blepharospasm, patient's group
33014551|NCT01759745||Control|Healthy control subjects
33014552|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
33014553|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
33014554|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
33014555|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
33014556|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
33014557|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
33014558|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33014559|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33014560|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
33014561|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
33014562|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
33014563|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
33416100|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
33416101|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
33014564|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
33014565|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
33416102|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
33014566|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
33014567|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
33014568|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
33014569|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
33014570|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
33014571|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
33014572|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
33014573|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
33014574|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
33014575|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
33014576|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
33014577|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
33014578|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
33014579|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
33014580|NCT01759992|No Intervention|Control group|Usual care
33014581|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
33014582|NCT01760018|Experimental|Desflurane group|
33014583|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
33014584|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
33014585|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
33416103|NCT02031900||Undergoing EGD|
33014586|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
33014587|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
33014588|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
33014589|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
33014590|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
33014591|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
33014592|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
33014593|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
33014594|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
33014595|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
33014596|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
33014597|NCT01760122|Active Comparator|Pegasys|
33014598|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
33014599|NCT01760135|Active Comparator|high calory|25kcal/kg
33014600|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
33014601|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
33014602|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
33014603|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
33014604|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
33014605|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
33014606|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
33014607|NCT01760213|Experimental|Treatment|intervention delivered via internet
33014608|NCT01760213|No Intervention|Control|
33014609|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
33014610|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~Capecitabine 1000mg/m2 p.o. bid on days 1-7~Oxaliplatin 85mg/m2 intravenously (IV) on day 1~Irinotecan 150mg/m2 IV on day 1"
33014611|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
33014612|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
33014613|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
33014614|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
33014615|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
33014616|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
33014617|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
33014618|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
33014619|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
33014620|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
33014621|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
33014622|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
33014623|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
33014624|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
33014625|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
33014626|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
33014627|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
33014628|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
33014629|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
33014630|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
33014631|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
33014632|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
33033195|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%~Doses:~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
33014633|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
33014634|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
33416104|NCT04903704|Other|Sit to Stand testing|"Participants will undergo an ISWT in the hospital setting. This test is a standard of clinical care and it is essential to the patient assessment on their clinical visit. This test will therefore be conducted first in all cases.~They will be allowed a 30 minute rest before undertaking the 1MSTS test.~Clinical observations (heart rate, blood pressure, oxygen saturations) will be taken before and after both tests. Heart rate and oxygen saturations will be monitored during both tests.~Patient reported measures of dyspnoea and perceived exertion will be recorded on completion of both tests.~Adverse events e.g. dizziness, syncope or the participant becoming unwell be recorded.~Descriptive and inferential statistical analysis will be used to determine the safety of 1MSTS in the hospital setting and comparability between 1MSTS and ISWT for participants. We will also examine comparability between 1MSTS outcomes and other available routinely collected clinical data."
33416105|NCT01342601|Active Comparator|Ectoin products|
33416106|NCT01342601|Placebo Comparator|Placebo products|
33416107|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
33014635|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
33014636|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
33014637|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
33014638|NCT01760525|Experimental|CGM097 - Dose escalation|
33014639|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
33416108|NCT04349657|Experimental|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
33416109|NCT04349657|Active Comparator|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
33416110|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
33014640|NCT01760538|Experimental|exercise group|exercise training
33014641|NCT01760538|Active Comparator|Control|usual care
33014642|NCT01760551||Patients assessed with AMA guide fifth edition|
33014643|NCT01760551||Patients assessed with AMA guide sixth edition|
33014644|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
33014645|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
33014646|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
33014647|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
33014648|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
33014649|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
33014650|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
33014651|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
33014652|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
33014653|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
33014654|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
33014655|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
33014656|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
33014657|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
33014658|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
33014659|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
33014660|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
33014661|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
33014662|NCT01760707|Experimental|Exercise Training|aerobic exercise training
33014663|NCT01760707|Active Comparator|Control|
33014664|NCT01760720|No Intervention|control|Standard care
33014665|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
33014666|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
33014667|NCT01760759|No Intervention|Usual care|Patients receive usual care from their medical providers.
33014668|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
33014669|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
33014670|NCT01760772|Placebo Comparator|Saline|0.9% saline
33014671|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
33014672|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
33014673|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
33014674|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
33014675|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
33014676|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
33014677|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
33014678|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
33014679|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
33014680|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
33014681|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
33014682|NCT01760928||Asthma patients|all
33014683|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
33014684|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
33014685|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
33014686|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
33014687|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
33014688|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
33014689|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
33014690|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
33014691|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
33014692|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
33014693|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
33014694|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
33014695|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
33416111|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
33014696|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
33014697|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
33014698|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
33014699|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
33014700|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
33014701|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
33014702|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
33014703|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
33014704|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
33014705|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
33014706|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
33014707|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
33014708|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
33014709|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
33014710|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
33014711|NCT01761240|Experimental|Study Drug|
33014712|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
33014713|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
33014714|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
33014715|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
33014716|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
33014717|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
33014718|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
33014719|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
33014720|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
33014721|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
33014722|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
33014723|NCT01761396|Active Comparator|UC|Usual care
33014724|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
33014725|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
33014726|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
33014727|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
33014728|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
33014729|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
33014730|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
33416112|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
33014731|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
33014732|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
33014733|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
33014734|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
33014735|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
33014736|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
33014737|NCT01761513|Experimental|Sequence 1|
33014738|NCT01761513|Experimental|Sequence 2|
33014739|NCT01761513|Active Comparator|Sequence 3|
33014740|NCT01761513|Active Comparator|Sequence 4|
33014741|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~Transdermal patch over 24 hours"
33014742|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~Transdermal patch over 24 hours"
33014743|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
33014744|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
33014745|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
33014746|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
33014747|NCT01761578|Experimental|ART18Z Bioresorbable stent|
33014748|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
33014749|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
33014750|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
33014751|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
33014752|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
33014753|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
33014754|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
33014755|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
33014756|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
33014757|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
33014758|NCT01761669||healthy voulnters|
33014759|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
33014760|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
33014761|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
33014762|NCT01761695||CML CP|Diagnosed as CML with chronic phase
33014763|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
33014764|NCT01761695||CML BC|Diagnosed as CML with blast crisis
33014765|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
33014766|NCT01761708||umbilical, epigastric and trocar-site hernia|
33014767|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
33014768|NCT01761734|Experimental|text message|receipt of text message
33014769|NCT01761734|No Intervention|usual care|usual care
33014770|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
33014771|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
33014772|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
33014773|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
33014774|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
33014775|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
33014776|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
33014777|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
33014778|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
33014779|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
33014780|NCT01761812|Experimental|Single arm study|
33014781|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
33014782|NCT01761825|Placebo Comparator|placebo|
33014783|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
33014784|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
33014785|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
33014786|NCT01761851||Cases|Liver cirrhosis
33014787|NCT01761864|Experimental|intervention group|academic detailing receiver
33014788|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
33014789|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
33014790|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
33014791|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
33014792|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
33014793|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
33014794|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
33014795|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
33014796|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
33014797|NCT01761968|Experimental|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
33014798|NCT01761994|Active Comparator|M100|heparin free CRRT group
33014799|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
33014800|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
33014801|NCT01762007||6Mo-2Yr old male patients without hypospadias|
33014802|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
33014803|NCT01762007||2Yr-5Yr old male patients without hypospadias|
33014804|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
33014805|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
33014806|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
33014807|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
33014808|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
33014809|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
33416113|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
33416114|NCT03615378|Placebo Comparator|Placebo|
33014810|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
33416115|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
33416116|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
33416117|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
33416118|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
33014811|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
33014812|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
33014813|NCT01762098||Recurrent miscarriages|
33014814|NCT01762098||Repeated embryo implantation failures|
33014815|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
33014816|NCT01762137|Active Comparator|Coiling|Coiling
33014817|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
33014818|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
33014819|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
33014820|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
33014821|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
33014822|NCT01762176|Active Comparator|Usual care group|Usual care
33014823|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
33014824|NCT01762202|Experimental|Study therapy|
33014825|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
33014826|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
33014827|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
33014828|NCT01762241|Experimental|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
33014829|NCT01762241|No Intervention|Control group|No systematically training/standard of care
33014830|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
33014831|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
33014832|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
33014833|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
33014834|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
33014835|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
33014836|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
33014837|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
33014838|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
33014839|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
33014840|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
33014841|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
33014842|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
33014843|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
33416119|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
33416120|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
33014844|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
33014845|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
33416121|NCT04625153|Experimental|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
33416122|NCT04625153|Experimental|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
33416123|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
33416124|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
33416125|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
33416126|NCT02236728||Parkinson's disease patients|
33416127|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
33014846|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
33014847|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
33014848|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
33014849|NCT01762397|Experimental|PMK-S005|
33014850|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
33014851|NCT01762423|Experimental|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
33014852|NCT01762423|Sham Comparator|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
33014853|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
33014854|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
33014855|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
33014856|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
33014857|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
33014858|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
33014859|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
33033196|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:~Doses:~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
33033197|NCT01960556||Simulation|Simulation Training part of education
33033198|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
33416128|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
33416129|NCT04254653|Experimental|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
33033199|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
33416130|NCT04254653|Experimental|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
33416131|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
33416132|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
33014860|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
33014861|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
33014862|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
33014863|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
33014864|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
33014865|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
33014866|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
33014867|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
33014868|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
33014869|NCT01762527|Experimental|ART|Online adaptive radiotherapy
33014870|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
33014871|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
33014872|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
33014873|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
33014874|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
33014875|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
33014876|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
33014877|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
33327171|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 minutes|Blood test
33327172|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 7 minutes|Blood test
33327173|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
33327174|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
33327175|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
33327176|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
33327177|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
33327178|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
33014878|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
33014879|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
33014880|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
33014881|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
33014882|NCT01762657|Placebo Comparator|Placebos|
33014883|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
33014884|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
33014885|NCT01762683|Experimental|pre-conceptional obesity with a scheduled cesarean section|
33014886|NCT01762683|Active Comparator|non-obese women with a scheduled cesarean section|
33014887|NCT01762683|Active Comparator|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
33014888|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
33014889|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
33014890|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
33014891|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
33014892|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
33014893|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
33014894|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
33014895|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
33014896|NCT01762761|Experimental|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
33014897|NCT01762761|Placebo Comparator|Placebo|Placebo
33014898|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
33014899|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
33014900|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
33014901|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
33014902|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
33014903|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
33014904|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
33325808|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
33325809|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
33325810|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
33014905|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
33014906|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
33014907|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
33014908|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
33014909|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
33014910|NCT01762839|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
33014911|NCT01762839|Placebo Comparator|Placebo|IV placebo
33014912|NCT01762839|Active Comparator|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a moxifloxacin tablet and will not receive a placebo infusion.
33014913|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
33014914|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
33014915|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
33014916|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
33014917|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
33014918|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
33014919|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
33014920|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
33014921|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
33014922|NCT01762917||Restriction|Patients suffering from pulmonary restriction
33014923|NCT01762917||Controls|Pulmonary healthy controls
33014924|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
33014925|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
33014926|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
33014927|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
33014928|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
33014929|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
33014930|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
33014931|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
33014932|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
33014933|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
33014934|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
33014935|NCT01763034|Sham Comparator|limb ischemia|
33014936|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
33014937|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
33014938|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
33014939|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
33014940|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
33014941|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
33014942|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
33014943|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
33014944|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
33325811|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
33325812|NCT03898518|No Intervention|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
33325813|NCT03898518|Experimental|Experimental Group|The experimental group performed the jump rope exercise intervention.
33325814|NCT03984214|Active Comparator|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
33014945|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
33014946|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
33014947|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
33014948|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
33014949|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
33014950|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
33014951|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
33014952|NCT01763229|Experimental|transthoracic echocardiography|
33014953|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
33014954|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
33014955|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
33014956|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
33014957|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
33014958|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
33014959|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
33014960|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
33014961|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
33014962|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
33014963|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
33014964|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
33014965|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
33014966|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
33014967|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
33014968|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
33014969|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
33014970|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
33014971|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
33014972|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
33014973|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
33014974|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
33327179|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
33327180|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3.5 hours|Blood test
33327181|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4 hours|Blood test
33327182|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4.5 hours|Blood test
33327183|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 5 hours|Blood test
33416133|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
33014975|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
33014976|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
33014977|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
33014978|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
33014979|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
33014980|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
33014981|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
33014982|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
33014983|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
33014984|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
33014985|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
33014986|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
33014987|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
33014988|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
33014989|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
33014990|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
33014991|NCT01763528|Active Comparator|nutrition intervention|high protein diet
33014992|NCT01763528|No Intervention|control group|control diet
33014993|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
33014994|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
33014995|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
33014996|NCT01763619|Experimental|Freedom Cervical Disc|
33014997|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
33014998|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
33014999|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
33015000|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
33015001|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
33015002|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
33015003|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
33015004|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
33015005|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
33015006|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
33015007|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
33015008|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
33015009|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
33015010|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
33033200|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
33033201|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
33015011|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
33015012|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
33015013|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
33416134|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
33015014|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
33015015|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
33416135|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
33015016|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
33015017|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
33015018|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
33015019|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
33015020|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
33015021|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
33015022|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
33015023|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
33015024|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
33015025|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
33015026|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
33015027|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
33015028|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
33015029|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
33015030|NCT01763957|Active Comparator|Paula Method|
33015031|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
33015032|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
33015033|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
33015034|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
33015035|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
33015036|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
33033202|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
33033203|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
33033204|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
33033205|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
33015037|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
33015038|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
33416136|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
33015039|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
33416137|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
33416138|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
33416139|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
33416140|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
33416141|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
33416142|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
33416143|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
33416144|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
33416145|NCT01342679|Experimental|dasatinib|
33416146|NCT04852926||A prospective cohort of patients|Female patients treated for non-metastatic breast cancer and followed up in the Observatory of fertility at Jeanne de Flandre Hospital
33015040|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
33015041|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
33015042|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
33015043|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
33015044|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
33015045|NCT01764126|Placebo Comparator|Placebo|Placebo
33015046|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
33015047|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
33015048|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
33015049|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
33015050|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
33015051|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
33015052|NCT01764204||Qingkailing Injection|
33015053|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
33015054|NCT01764230|No Intervention|control group|no intervention
33015055|NCT01764243|Experimental|MT-4666 Low Dose|low dose
33015056|NCT01764243|Experimental|MT-4666 High Dose|high dose
33416147|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
33416148|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
33015057|NCT01764243|Placebo Comparator|Placebo|placebo
33015058|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
33015059|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
33015060|NCT01764282|Experimental|Intervention|comprehensive intervention components
33015061|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
33015062|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
33015063|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
33015064|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
33015065|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
33015066|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
33015067|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
33015068|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
33033206|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
33033207|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
33015069|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
33015070|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
33416149|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
33416150|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
33416151|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
33416152|NCT01344863|Experimental|1|
33416153|NCT01344863|Active Comparator|2|
33416154|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
33416155|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
33416156|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
33015071|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
33015072|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
33015073|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
33015074|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
33015075|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
33015076|NCT01764412||Healthy women|Non interventional
33015077|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
33015078|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
33015079|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
33015080|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
33015081|NCT01764451|No Intervention|No Treatment|
33015082|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
33015083|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
33015084|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
33015085|NCT01764516||Zinc level in male (micro gram per deciliter)|
33015086|NCT01764516||Selenium level in male (micro gram per deciliter)|
33015087|NCT01764516||Zinc level in Female (micro gram per decilitre)|
33015088|NCT01764516||Selenium level in Female (micro gram per decilitre)|
33015089|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
33416157|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
33015090|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
33015091|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
33015092|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
33015093|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
33033208|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
33015094|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
33015095|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
33015096|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
33015097|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
33015098|NCT01764594|Placebo Comparator|Placebo|Placebo
33015099|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
33015100|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
33015101|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
33015102|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
33015103|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
33015104|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
33015105|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
33015106|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
33015107|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
33015108|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
33015109|NCT01764737|Experimental|VX15/2503|
33015110|NCT01764737|Experimental|Placebo|
33015111|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
33015112|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
33015113|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
33015114|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
33015115|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
33015116|NCT01764763||epiaortic group|epiaortic group ( n=1273)
33015117|NCT01764776|Experimental|LDE225|LDE225
33015118|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
33015119|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
33015120|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
33015121|NCT01764815|Experimental|Directional lead|
33015122|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
33015123|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
33033209|NCT01960608||low income group|the income 25% below the quartile
33033210|NCT01960608||low mid income group|the income 25% - 50% below the quartile
33033211|NCT01960608||mid income group|the income 50% - 75% below the quartile
33033212|NCT01960608||high income group|the income 75% over the quartile
33033213|NCT01960621|Experimental|2|
33015124|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
33015125|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
33015126|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
33015127|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
33015128|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
33015129|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
33015130|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
33015131|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
33015132|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
33015133|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
33015134|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
33015135|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
33015136|NCT01765010|Placebo Comparator|Placebo control|Placebo control
33015137|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
33015138|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
33015139|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
33015140|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
33015141|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
33015142|NCT01765036|Experimental|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
33015143|NCT01765062||Before Rapid Maxillary Expansion|T0
33015144|NCT01765062||3 months After Rapid Maxillary Expansion|T1
33015145|NCT01765062||One year After Rapid Maxillary Expansion|T2
33015146|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
33015147|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
33015148|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
33015149|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
33015150|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
33015151|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
33015152|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
33015153|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
33015154|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
33015155|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
33033214|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
33015156|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
33015157|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
33015158|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
33015159|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
33015160|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
33015161|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
33015162|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
33015163|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
33015164|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
33015165|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
33015166|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
33015167|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
33015168|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
33015169|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
33015170|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
33015171|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
33015172|NCT01765348|Experimental|Sentence combining|
33015173|NCT01765348|Active Comparator|Narrative based method|
33015174|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
33015175|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
33015176|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
33015177|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
33015178|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
33015179|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
33015180|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
33015181|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
33015182|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
33015183|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
33015184|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
33015185|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
33015186|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
33015187|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
33015188|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
33015189|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
33015190|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
33015191|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
33015192|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
33015193|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
33015194|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
33015195|NCT01765517|Experimental|Probiotics|Probitoics
33015196|NCT01765517|Placebo Comparator|Placebo|Placebo
33015197|NCT01765556|Experimental|Ketoconazole treatment|
33015198|NCT01765556|Experimental|Vemurafenib treatment|
33015199|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
33015200|NCT01765595|No Intervention|Control|Standard care
33015201|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
33033215|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
33015202|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
33015203|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
33015204|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
33015205|NCT01765621|No Intervention|Standard Care|Control
33015206|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
33015207|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
33015208|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
33015209|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
33015210|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
33015211|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
33015212|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
33015213|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
33015214|NCT01765725|Experimental|Patient education program|Patient education program
33015215|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
33015216|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
33015217|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
33015218|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
33015219|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
33015220|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
33015221|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
33015222|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
33015223|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
33015224|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
33015225|NCT01765855|Experimental|Single Arm Oral Betrixaban|
33015226|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
33015227|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
33015228|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
33015229|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
33015230|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
33015231|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
33015232|NCT01765907|Experimental|HIFU|
33015233|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
33015234|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
33015235|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
33015236|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
33325815|NCT03984214|Placebo Comparator|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
33325816|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
33325817|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
33015237|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
33015238|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
33015239|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
33015240|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
33015241|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
33015242|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
33015243|NCT01766063||Group 1|
33015244|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
33015245|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
33015246|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
33015247|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
33015248|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
33015249|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
33015250|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
33015251|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
33015252|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
33015253|NCT01766167|Experimental|MP-424|
33015254|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
33015255|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
33015256|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
33015257|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
33015258|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
33015259|NCT01766193||cesarean section|women whose first child was born by cesarean section
33015260|NCT01766193||forceps|women whose first child was born by forceps extraction
33015261|NCT01766193||vacuum|women whose first child was born by vacuum extraction
33015262|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
33015263|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
33015264|NCT01766245|Experimental|Formulation A followed by Formulation B|
33015265|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
33015266|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
33015267|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
33325818|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
33325819|NCT02865070||10 babies (full term, ages 37-42 weeks)|
33325820|NCT02865070||5 babies (premature, ages 34-37 weeks)|
33325821|NCT02865070||5 babies (premature, ages 31-34 weeks)|
33325822|NCT02865070||5 babies (premature, ages 28-31 weeks)|
33325823|NCT02865070||5 babies (premature, ages 25-28 weeks)|
33325824|NCT02865070||5 babies (premature, ages 23-25 weeks)|
33015268|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
33015269|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
33015270|NCT01766271|Experimental|SRA plus Health Coaching|
33015271|NCT01766271|Experimental|SRA plus Genetic Testing|
33015272|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
33015273|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
33015274|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
33015275|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
33015276|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
33015277|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
33015278|NCT01766362|Experimental|A session|
33015279|NCT01766362|Other|Four sessions|Every session are spaced out of month
33015280|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
33015281|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
33015282|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
33015283|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
33015284|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
33015285|NCT01766427||morning electroacupuncture with pills|
33015286|NCT01766427||afternoon EA with pills|
33015287|NCT01766427||no EA group with pills|
33015288|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
33015289|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
33015290|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
33015291|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
33015292|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
33015293|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
33015294|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
33015295|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
33015296|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
33015297|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
33015298|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
33015299|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
33015300|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
33015301|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
33015302|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
33015303|NCT01766596|Other|3C cohort|
33015304|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
33325825|NCT02865070||30 babies (any gestational age under 6 months)|
33015305|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
33015306|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
33015307|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
33015308|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
33015309|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
33015310|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
33015311|NCT01766687|No Intervention|Control|
33015312|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
33015313|NCT01766700|Active Comparator|Water|2 water beverages per day.
33015314|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
33015315|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
33015316|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
33015317|NCT01766752|No Intervention|no intervention|standard care
33015318|NCT01766765|Experimental|Early jejunostomy nutrition|
33015319|NCT01766765|Active Comparator|Early oral nutrition|
33015320|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
33015321|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
33015322|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
33015323|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
33015324|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
33015325|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
33015326|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
33015327|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
33015328|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
33015329|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
33015330|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
33015331|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
33015332|NCT01766882|Experimental|Treatment|"Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~Lower dialysate sodium at 137 mmol/L.~Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
33015333|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
33015334|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
33015335|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
33015336|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
33015337|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
33015338|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
33015339|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
33015340|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
33015341|NCT01766973||Chronic back pain|Adults, >6months duration
33015342|NCT01766973||Control|Age and sex matched controls
33015343|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
33015344|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
33015345|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
33015346|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
33015347|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
33015348|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
33015349|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
33015350|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
33015351|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
33015352|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
33015353|NCT01767090|Experimental|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
33015354|NCT01767090|Experimental|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
33015355|NCT01767090|Experimental|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
33015356|NCT01767090|Experimental|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
33015357|NCT01767090|Active Comparator|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
33015358|NCT01767181|No Intervention|A|Control group without intervention
33015359|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
33015360|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
33015361|NCT01767181|Experimental|D|Exercise after the end of the night shift
33015362|NCT01767207||screening for mental disorders|screening for mental disorders
33015363|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
33015364|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
33015365|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
33015366|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
33015367|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
33015368|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
33015369|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
33015370|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
33015371|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
33015372|NCT01767272|Other|fexofenadine 60 mg|First dose strength
33015373|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
33015374|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
33015375|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
33015376|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
33325826|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
33015377|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
33015378|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
33015379|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
33015380|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
33015381|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
33015382|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
33015383|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
33015384|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
33015385|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
33416158|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
33015386|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
33015387|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
33015388|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
33015389|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
33015390|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
33015391|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
33015392|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
33015393|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
33015394|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
33015395|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
33015396|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
33015397|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
33015398|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
33015399|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
33015400|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
33015401|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
33015402|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
33015403|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
33015404|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
33015405|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
33015406|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
33015407|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
33015408|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33015409|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
32739246|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
33416159|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
33416160|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
33015410|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
33015411|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
33015412|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
33015413|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33015414|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33015415|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
33015416|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
33015417|NCT01767610|Experimental|micronized fenofibrate|
33015418|NCT01767610|Experimental|pitavastatin Ca|
33015419|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
33015420|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
33015421|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
33015422|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
33015423|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
33015424|NCT01767662|Experimental|manipulation|home program for parents manipulation
33015425|NCT01767662|Placebo Comparator|observe|observation
33015426|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
33015427|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
33015428|NCT01767727|Other|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
33015429|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
33015430|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
33015431|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
33015432|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
33015433|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
33015434|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
33015435|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
33015436|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
33015437|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
33015438|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
33015439|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
33033216|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
33033217|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
33015440|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
33015441|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
33015442|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
33015443|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
33015444|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
33015445|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
33015446|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation"
33015447|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support System~Academic detailing concerning the rationale for the algorithms"
33015448|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
33015449|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
33015450|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
33015451|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
33015452|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
33015453|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
33015454|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
33015455|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
33015456|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
33015457|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
33015458|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
33015459|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
33015460|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
33015461|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
33015462|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
33015463|NCT01768065|Sham Comparator|placebo sham|A sham device
33015464|NCT01768078|Experimental|with corticoids|
33015465|NCT01768078|Other|without corticoids|
33015466|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
33015467|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
33015468|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
33015469|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
33015470|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
33015471|NCT01768143||Nurse Experts|Educated endoscopy Nurses
33015472|NCT01768156|Experimental|Study arm|
33015473|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
33015474|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
33015475|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
33015476|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
33015477|NCT01768208|Experimental|Saxagliptin|
33416161|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
33325827|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
33015478|NCT01768221|Other|Caregiver intervention|
33015479|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
33325828|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
33325829|NCT05125224||Dihydropyridine calcium channel blocker|Exposure group
33325830|NCT05125224||Hydrochlorothiazide|Reference group
33325831|NCT05759884|Experimental|anti-VEGF combined SML therapy group|The patients were treated with intravitreal injection of anti-VEGF drugs and SML therapy.
33325832|NCT05759884|Active Comparator|anti-VEGF single therapy group|Only intravitreal injection of anti-VEGF drugs was given to patients.
33015480|NCT01768234|No Intervention|Control|No supplemental water provided
33325833|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
33325834|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
33015481|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
33325835|NCT05759806|Experimental|ADHF patients|ADHF patients with compromised response to diuretics treated with Nephronyx system
33325836|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
33325837|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
33015482|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
33015483|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
33015484|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
33015485|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
33033218|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
33033219|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
33033220|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
33033221|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
33033222|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
33033223|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
33033224|NCT01960699||CPC < 3|Good neurological outcome
33033225|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
33033226|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
33033227|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
33033228|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
33033229|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
33015486|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
33015487|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
33015488|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
33015489|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
33015490|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
33015491|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
33015492|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
33015493|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
33015494|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
33015495|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
33015496|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
33015497|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
33015498|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
33015499|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
33015500|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
33015501|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
33015502|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
33015503|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
33015504|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
33015505|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
33015506|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
33015507|NCT01768507|Placebo Comparator|Placebo|no medication
33015508|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
33015509|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
33015510|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
33015511|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
33015512|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
33015513|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
33015514|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
33015515|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
33015516|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
33015517|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
33015518|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
33015519|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
33015520|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
33015521|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
33015522|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
33033230|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
33416162|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
33015523|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
33015524|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
33416163|NCT03316950|Sham Comparator|Placebo Arm|"Patients randomized into the Placebo arm will include participants from the DiVa PlaceboGroup and IntraGen Placebo Group combined and will receive treatment based on the DiVA Sham and IntraGen Sham protocols.~DiVa Placebo: patients will undergo a three-part placebo treatment, spaced 1 month apart (+/- 10 days) of the vulvovaginal area. The vaginal HFL handpiece will be inserted into the vaginal canal but sub-therapeutic energy will not be delivered to the tissue.~IntraGen Placebo: patients will undergo a three-part placebo treatment, space 1 month apart (+/- 10 days) of the vulvovaginal area. This will be achieved through application of the probe, but with applying sub-therapeutic energy to the tissue."
33015525|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
33015526|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
33015527|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
33015528|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
33015529|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~adherence-encouraging interventions - Group meetings~adherence-encouraging interventions - Individual meetings~adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
33015530|NCT01768702|Sham Comparator|Control|Sham, no injection
33015531|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
33015532|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
33015533|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
33015534|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
33015535|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
33015536|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
33015537|NCT01768741|Active Comparator|Laparoscopic liver resection group|
33015538|NCT01768741|Active Comparator|Open liver resection|
33015539|NCT01768754||COPD patients|Usual and Fast Walking Speeds
33015540|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
33015541|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
33015542|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
33015543|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
33015544|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
33015545|NCT01768819|Experimental|Intervention Group|Physical Activity
33015546|NCT01768819|No Intervention|Control Group|
32739247|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
33327184|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
32739248|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
33015547|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
33015548|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
33015549|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
33015550|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
33015551|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
33015552|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
33015553|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
33015554|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
33015555|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
33015556|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
33015557|NCT01768936||eliminated infectious abdominal focus|
33015558|NCT01768936||persisting/progressing infectious abdominal focus|
33015559|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
33015560|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
33015561|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
33015562|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
33015563|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
33015564|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
33015565|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
33015566|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
33015567|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
33015568|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
33015569|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
33015570|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
33015571|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
33015572|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
33015573|NCT01769131||Allis|
33015574|NCT01769131||Tenaculum|
33015575|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
33015576|NCT01769144|Experimental|BCT wound dressing|wound dressing
33015577|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
33015578|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
33015579|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
33015580|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
33033231|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
32739249|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
32739250|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
33015581|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
33015582|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
33015583|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
33015584|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
33015585|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
33015586|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
33015587|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
33015588|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
33015589|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
33015590|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
33015591|NCT01769417|Placebo Comparator|Placebo|
33015592|NCT01769417|Active Comparator|MEDI4893|
33015593|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
33015594|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
33015595|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
33015596|NCT01769495|No Intervention|Control|Standard post ED care
33015597|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
33015598|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
33015599|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
33015600|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
33015601|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
33015602|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
33015603|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
33015604|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
33015605|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
33015606|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
33015607|NCT01769638|Experimental|SPO1101|
33015608|NCT01769638|Experimental|SPO1101D|
33015609|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
33015610|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
33015611|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
33015612|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
33015613|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
33015614|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
33015615|NCT01769690|Experimental|DBS stimulator setting alteration|
33015616|NCT01769703|Experimental|Dabigatran|
33015617|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
33015618|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
33015619|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
33015620|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
33015621|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
33015622|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
33015623|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
33015624|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
33015625|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
33015626|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
33015627|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
33015628|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
33015629|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
33015630|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
33015631|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
33015632|NCT01769820|Placebo Comparator|Placebo|Placebo
33015633|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
33015634|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
33015635|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
33015636|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
33015637|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
33015638|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
33015639|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
33015640|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
33015641|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
33015642|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
33015643|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
33015644|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
33015645|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
33015646|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
33015647|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
33015648|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
33015649|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
33015650|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
33015651|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
33015652|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
33015653|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
33015654|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
33416164|NCT03316950|Experimental|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
33416165|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
33416166|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
33015655|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
33015656|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
33015657|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
33015658|NCT01770093||Parents of Pediatric Inpatients|
33015659|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
33015660|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
33015661|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
33015662|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
33015663|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
33015664|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
33015665|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
33015666|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
33015667|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
33015668|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
33015669|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
33015670|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
33015671|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
33015672|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
33015673|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
33015674|NCT01770262||Healthy|
33015675|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
33015676|NCT01770288|Experimental|Anaerobic Performance|
33015677|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
33015678|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
33325838|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
33325839|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
33015679|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
33015680|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
33015681|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
33015682|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
33015683|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
33325840|NCT01255098||Experimental Group|
33325841|NCT01255098||Control Group|
33325842|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
33325843|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|By use of Cardiac computed tomography, the ejection faction of the right ventricle will be visualized and measured in all participants.
33325844|NCT03901716|Experimental|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
33015684|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
33325845|NCT03901716|Experimental|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
33325846|NCT03901716|Experimental|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
33325847|NCT04113538|Active Comparator|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
33325848|NCT04113538|Experimental|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
33325849|NCT03904368|Active Comparator|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
33325850|NCT03904368|Active Comparator|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
33325851|NCT03901638|Experimental|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
33325852|NCT03901638|Experimental|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
33015685|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
33015686|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
33015687|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
33015688|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
33015689|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
33015690|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
33015691|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
33015692|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
33015693|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
33015694|NCT01770548|Other|Major control|DNA collection
33015695|NCT01770548|Other|Minor control|auditory evoked potentials
33015696|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
33015697|NCT01770574|Experimental|ReproBone|calcaneal lengthening
33015698|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
33015699|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
33015700|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
33015701|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
33015702|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
33325853|NCT03898206|Experimental|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
33325854|NCT03898206|Experimental|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
33325855|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
33325856|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
33325857|NCT03922750|Active Comparator|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
33325858|NCT03903978|Experimental|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
33015703|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
33015704|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
33015705|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
33015706|NCT01770665||Mesothelioma|
33015707|NCT01770665||all cancer types|
33015708|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
33327185|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
33327186|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
33015709|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
33015710|NCT01770704||Patients diagnosed with bipolar disorder I or II|
33015711|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
33015712|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
33015713|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
33015714|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
33015715|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
33015716|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
33015717|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
33015718|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
33015719|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
33015720|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
33015721|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
33015722|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
33015723|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
33015724|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
33015725|NCT01770834||Cohort|
33015726|NCT01770847||Healthy controls|Healthy age matched controls
33015727|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
33015728|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
33015729|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
33015730|NCT01770886|Active Comparator|UE2343|Oral capsule
33015731|NCT01770886|Placebo Comparator|Placebo|Oral capsule
33015732|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
33015733|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
33033232|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
33105840|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
33105841|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
33105842|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
33015734|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
33015735|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
33105843|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
33105844|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
33105845|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
33105846|NCT05427617||Control group|Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.
33105847|NCT05427617||Case group|Case group includes patients with druggable ctDNA abnormality.
33105848|NCT04581018|Active Comparator|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
33105849|NCT04581018|No Intervention|Standard care|No intervention
33105850|NCT05427500|Other|Single SGB|This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.
33105851|NCT05427500|Other|Repeated SGB|This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.
33105852|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CRT)|
33105853|NCT04564482|Other|Short-course preoperative radiotherapy (SCPRT)|
33105854|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CROSS protocol)|
33105855|NCT05427383|Experimental|KN026 + Paclitaxel/ Docetaxel/ Irinotecan|IV KN026 at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
33105856|NCT05427383|Experimental|Placebo + Paclitaxel/ Docetaxel/ Irinotecan|IV Placebo at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
33105857|NCT04680221|Active Comparator|Treatment|The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
33105858|NCT04680221|Placebo Comparator|Control|The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).
33105859|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
33105860|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
33325859|NCT03903978|Active Comparator|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
33327187|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
33416167|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
33416168|NCT01358227|Experimental|PR104|
33015736|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
33015737|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
33015738|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
33015739|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
33015740|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
33015741|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
33015742|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
33015743|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
33015744|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
33015745|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
33015746|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
33015747|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
33015748|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
33015749|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
33015750|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
33015751|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
33015752|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
33015753|NCT01771068|No Intervention|Waiting list|
33015754|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
33015755|NCT01771081||Group1|
33015756|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
33015757|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
33015758|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
33015759|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
33015760|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
33015761|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
33015762|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
33015763|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
33033233|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
33033234|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
33105861|NCT05427344|Experimental|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi
33416169|NCT03311958|Experimental|Nivolumab|
33015764|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
33015765|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
33015766|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
33015767|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
33015768|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
33015769|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
33015770|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
33015771|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
33015772|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
33015773|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
33015774|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
33015775|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
33015776|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
33015777|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
33015778|NCT01771289|Experimental|chemoradiation|
33015779|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
33015780|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
33015781|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
33015782|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
33015783|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
33015784|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
33015785|NCT01771341|Placebo Comparator|Pressure support|
33015786|NCT01771341|Experimental|NAVA|
33015787|NCT01771354|Placebo Comparator|Placebo|Placebo
33015788|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
33015789|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
33015790|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
33015791|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
33015792|NCT01771380||Subjects with impaired glucose tolerance|
33015793|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
33015794|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
33015795|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
33015796|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
33015797|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
33015798|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
33015799|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
33015800|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
33015801|NCT01771445|Active Comparator|IL-1Ra|
33015802|NCT01771445|Placebo Comparator|Placebo|
33015803|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
33327188|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
33015804|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
33015805|NCT01771471|Experimental|NuQu treatment|single administration
33015806|NCT01771471|Other|Saline|single administration
33015807|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
33015808|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
33015809|NCT01771497||Women undergoing neoadjuvant therapy|
33015810|NCT01771523|Active Comparator|Group 1|thyroidectomy
33015811|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
33015812|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
33015813|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
33015814|NCT01771575|Experimental|Treatment Arm|PoNS™ device
33015815|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
33015816|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
33015817|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
33015818|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
33015819|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
33015820|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
33015821|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
33015822|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
33015823|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
33015824|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
33015825|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
33015826|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
33015827|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
33015828|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
33015829|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
33015830|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition
33015831|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence combined with urotherapy|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition combined with standard urotherapy in accordance with International Children's Continence Society (ICCS)
33015832|NCT05318352|Experimental|Transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive tDCS over the right and left prefrontal cortex (F3 and F4 areas) with a constant current of 1.5 mA intensity that lasts for 20 minutes, 3 times a week for 2 weeks in daytime.
33015833|NCT05318352|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive sham tDCS over the right and left prefrontal cortex.
33015834|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
33015835|NCT01771744||48 morbidly obese patients|with primary gastric bypass
33015836|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
33015837|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
33015838|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
33015839|NCT01771796|Experimental|Aerobic and muscle resistance training|
33015840|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
33015841|NCT01771822|Experimental|Ibuprofen 5% topical gel|
33015842|NCT01771822|Experimental|Topical gel vehicle|
33416170|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
33015843|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
33015844|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
33015845|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
33015846|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
33015847|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
33015848|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
33015849|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
33015850|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
33015851|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
33015852|NCT01771861||Seriously injured or potentially seriously injured patients|
33015853|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
33015854|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
33015855|NCT01771900|Experimental|Heart Camp Group|
33015856|NCT01771900|Experimental|Attention Control Group|
33015857|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
33015858|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
33015859|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
33015860|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
33015861|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
33015862|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
33015863|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
33015864|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
33015865|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
33015866|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
33015867|NCT01772030|Other|Recurrent Atrial Fibrillation|
33015868|NCT01772043||Duchenne muscular dystrophy|
33015869|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
33015870|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
33015871|NCT01772082|Active Comparator|Pedometer alone|pedometer
33015872|NCT01772082|Experimental|Pedometer plus website|pedometer and website
33015873|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
33015874|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
33015875|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
33015876|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
33015877|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
33015878|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
33015879|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
33015880|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
33015881|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
33015882|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
33015883|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
33015884|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
33015885|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
33015886|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
33015887|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33015888|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33015889|NCT01772251|Experimental|Oshadi Icp & placebo|
33015890|NCT01772264|Experimental|Arm A - active treatment|
33015891|NCT01772264|Placebo Comparator|Arm B - placebo|
33015892|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
33015893|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
33015894|NCT01772290|Active Comparator|A: Vismodegib|
33015895|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
33015896|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
33015897|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
33015898|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
33015899|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight~SHAM with PureNight"
33015900|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
33015901|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
33015902|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
33015903|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
33015904|NCT01772407||1|laparoscopic surgery in right colon cancer operations
33015905|NCT01772407||2|open surgery in right colon cancer operations
33015906|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
33015907|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
33015908|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
33015909|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
33015910|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
33015911|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
33015912|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
33015913|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
33015914|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
33015915|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
33015916|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
33015917|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
33015918|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
33416171|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
33416172|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
33416173|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
33416174|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
33416175|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
33015919|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
33015920|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
33015921|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
33416176|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
33416177|NCT01358305|Active Comparator|Whey Protein Isolate|
33416178|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
33416179|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
33416180|NCT01547117|Experimental|Low Sodium Dietary Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
33416181|NCT04958382|Experimental|Ciprofol|
33416182|NCT04958382|Placebo Comparator|placebo|
33416183|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
33416184|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
33416185|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
33416186|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
33416187|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
33416188|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
33416189|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
33416190|NCT04847388||ART-naive HIV Patients with substance abuse and without substance abuse|Group A Group B
33416191|NCT04847388||Group A and B|Group A: ART-naive HIV seropositive with H/O substance abuse Group B: ART-naive HIV seropositive without H/O substance abuse
33416192|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
33416193|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
33015922|NCT01772563|Experimental|volasertib + itraconazole|administration of volasertib alone and in combination with itraconazole
33015923|NCT01772589|Active Comparator|New saw blade|New saw blade
33015924|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
33015925|NCT01772615|Experimental|ciprofloxacin-EcN|
33015926|NCT01772615|Experimental|ciprofloxacin-placebo|
33325860|NCT03903978|No Intervention|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
33325861|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
33325862|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
33015927|NCT01772615|Experimental|placebo-EcN|
33015928|NCT01772615|Placebo Comparator|placebo-placebo|
33015929|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
33015930|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
33015931|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
33015932|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
33015933|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
33015934|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
33015935|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
33015936|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
33015937|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
33015938|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
33015939|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
33015940|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
33015941|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
33015942|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
33015943|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
33015944|NCT01772784|Placebo Comparator|placebo|Maltodextrine
33015945|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
33015946|NCT01772784|Active Comparator|polyphenol|
33015947|NCT01772797|Experimental|LDK378 and AUY922|
33015948|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
33015949|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
33325863|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
33325864|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
33325865|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
33325866|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
33325867|NCT03897894|Experimental|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
33325868|NCT03897894|Experimental|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
33325869|NCT03897894|No Intervention|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
33325870|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
33327189|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
33327190|NCT01286298|Experimental|Laser gingivectomy|
33327191|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
33327192|NCT03863418|Placebo Comparator|placebo|maltodextrin
33015950|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
33015951|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
33015952|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
33015953|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
33015954|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
33015955|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
33015956|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
33015957|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
33015958|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
33015959|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
33015960|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
33015961|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
33015962|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
33015963|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
33015964|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
33015965|NCT01772927||Very low birth weight infants,|Parenteral nutrition
33015966|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
33015967|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
33015968|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
33015969|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
33015970|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
33015971|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
33015972|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
33015973|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
33015974|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
33015975|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
33327193|NCT01286376|Active Comparator|symbiotic|
33327194|NCT01286376|Placebo Comparator|placebo|
33416194|NCT03615768|Active Comparator|Adapalene Gel|
33325871|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
33015976|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
33015977|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
33015978|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
33015979|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
33015980|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
33015981|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
33015982|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
33015983|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
33015984|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
33015985|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
33015986|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
33015987|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
33015988|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
33015989|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
33015990|NCT01773213|Other|Bladder dysfunction, ice-water-test|
33015991|NCT01773213|Other|Bladder dysfunction, warm water-test|
33015992|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
33015993|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
33015994|NCT01773304|Experimental|Meal rich in dairy protein|
33015995|NCT01773304|Experimental|Meal rich in meat protein|
33015996|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
33015997|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
33015998|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
33015999|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
33016000|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
33016001|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
33325872|NCT01150812|Experimental|1|
33325873|NCT01149408|Experimental|All patients|All participants enrolled.
33325874|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
33325875|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
33325876|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
33325877|NCT05759728|Experimental|CNA3103 Monotherapy|Up to two doses of intravenous CNA3103 at Day 0 and Month 2
33325878|NCT03901482|Experimental|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
33325879|NCT03901482|Experimental|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
33325880|NCT03901482|Placebo Comparator|STS101 Placebo|STS101 Placebo
33325881|NCT01568398|Experimental|TAK-438 20 mg QD|
33325882|NCT03631966|Experimental|BTX-A injection|
33325883|NCT03904212|Active Comparator|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
33016002|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
33016003|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
33016004|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
33016005|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
33016006|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
33016007|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
33016008|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
33016009|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
33016010|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
33016011|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
33016012|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
33016013|NCT01773434|Experimental|MORAb-004|
33016014|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
33016015|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
33016016|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
33016017|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
33016018|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
33016019|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
33016020|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
33016021|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
33016022|NCT01773551||Optical Index of Breast Density|Breast Density
33016023|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
33016024|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
33016025|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
33016026|NCT01773590|Other|Asthmatics|Rhinovirus Infection
33016027|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
33016028|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
33016029|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
33016030|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
33016031|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
33016032|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
33016033|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
33016034|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
33016035|NCT01773642|No Intervention|Standard of Care|
33016036|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
33016037|NCT01773668|Experimental|Integrated sensor and infusion set|
33016038|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
33016039|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
33016040|NCT01773733||BMI ≥ 30|
33016041|NCT01773733||BMI ≥27 kg/m2 associated with DM2|
33325884|NCT03904212|Placebo Comparator|Placebo|Patients will be treated with saline
33416195|NCT03615768|Active Comparator|Clindamycin Gel|
33105862|NCT05427344|Experimental|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land
33105863|NCT05427344|Experimental|Control group|Control group who will not perform additional physical activity or receive any extra treatments
33105864|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
33105865|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
33105866|NCT05427305|Experimental|TAB008|Eligible patients received TAB008 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
33105867|NCT05427305|Active Comparator|Bevacizumab|Eligible patients received bevacizumab-EU 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
33105868|NCT05427188|Experimental|MIST-paradigm|HV assigned in the MIST paradigm will receive psychosocial stress
33105869|NCT05427188|Sham Comparator|Sham-paradigm|HV assigned in the MIST paradigm will receive no psychosocial stress
33105870|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
33105871|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
33105872|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
33105873|NCT05427110||asymptomatic|Runners without iliotibial band syndrome
33105874|NCT05427110||Iliotibial band syndrome|Runners with iliotibial band syndrome
33105875|NCT05427071|Experimental|Study arm|Magnetic seed guided lumpectomy and targeted axillary dissection
33105876|NCT04680104||Cohort A|Infusion of Na-Lev plus 5-FU (unique administration by one 48h-infusional pump)
33105877|NCT04680104||Cohort B|Infusion of Ca-Lev followed by infusion of 5-FU (two separated administrations by using one plastic bag followed by one 48h-infusional pump)
33105878|NCT04471740|Experimental|Normal-pressure hydrocephalus only|Patients suffering from normal-pressure hydrocephalus with NO sleep apnea
33105879|NCT04471740|Active Comparator|Normal-pressure hydrocephalus with sleep apnea|Patients suffering from normal-pressure hydrocephalus with sleep apnea
33105880|NCT04680143|Experimental|Systemic erythropoietin injections|The study included 10 patients diagnosed as post papilledemic optic atrophy
33105881|NCT04467762||Meningoencephalitis (ME-PED)|"pediatric patients between 0 and 17 years of age~admission to hospital with suspected meningoencephalitis~confirmed meningoencephalitis within 24 hours after admission"
33105882|NCT04467762||Sepsis-associated encephalopathy (SAE-PED)|"pediatric patients between 0 and 17 years of age~admission to hospital with suspected sepsis~confirmed sepsis within 24 hours after admission or time of diagnosis"
33105883|NCT04467762||Control group (CON-PED)|"pediatric patients between 0 and 17 years of age~exclusion of neurocognitive impairment~admission to hospital for minor surgery (e.g. herniotomy, adenoidectomy, fractures treated by osteosynthesis) or for hemangioma treated by propranolol"
33105884|NCT05426954|Active Comparator|BFR deflate|BFR cuff will be deflated at the end of each of the 4 BFR exercises, BFR cuff is inflated prior to start next BFR exercise.
33105885|NCT05426954|Active Comparator|BFR do not deflate|BFR cuff will not be deflated at the end of each of the 4 BFR exercises. Cuff remains inflated start exercise 1 thru completion exercise 4.
33105886|NCT00552825||1|all were in a single group
33105887|NCT05426798|Experimental|TQB2618 injection|TQB2618 injection combined with demethylation drugs, 28 days as a treatment cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
33105888|NCT00436254|Experimental|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
33105889|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
33105890|NCT01234402|Experimental|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
33105891|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:~* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
33105892|NCT05464017|No Intervention|Standard mHealth screening tool|This is a tested standard phone screening tool which determines the need for in-person follow-up after a patient has been discharge. Consenting trauma patients will be contacted via mobile phone at 0.5, 1, 3, and 6 months post-discharge by a research assistant to complete the screening which will guide whether or not the patient should seek follow-up care based on the number of flagged responses to ≥1 question on the 7-item screening survey.
33105893|NCT05464017|Experimental|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|This arm will receive an improvement to the mHealth triage tool using a machine learning approach. Patients will be called using the optimized tool at outcome timepoints (3 months, 6months and 12months). At each call, research assistants will complete the GOSE survey and the mHealth triage tool, entering call outcomes and patient responses directly into the mHealth system. If follow-up care is indicated, the research assistant will share that information with the patient and offer to schedule an appointment.
33105894|NCT05426720||patients with pulmonary tuberculosis|male patients aged 25-60 with active pulmonary tuberculosis
33105895|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
33105896|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
33016042|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
33016043|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
33016044|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
33016045|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
33016046|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
33016047|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
33016048|NCT01773798|Experimental|IDegAsp 15|
33016049|NCT01773798|Experimental|IDegAsp|
33016050|NCT01773798|Experimental|IDeg|
33016051|NCT01773798|Active Comparator|IAsp|
33016052|NCT01773798|Experimental|IDeg + IAsp|
33016053|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
33016054|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
33016055|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
33016056|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
33016057|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
33016058|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
33016059|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
33016060|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
33016061|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
33016062|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
33016063|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
33016064|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
33016065|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
33016066|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
33016067|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
33016068|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
33016069|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
33016070|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
33016071|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
33016072|NCT01774006||Group culture|Embryos cultured in groups of 2-10
33016073|NCT01774006||Individual culture|Embryos cultured individually
33016074|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
33033235|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
33033236|NCT01960829|Experimental|Everolimus|
33033237|NCT01960868|Experimental|patients|
33033238|NCT01960868|Other|control group|
33033239|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
33016075|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
33416196|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
33416197|NCT04178135|Experimental|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
33416198|NCT04178135|Active Comparator|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
33416199|NCT01318291|Placebo Comparator|Control|
33416200|NCT01318291|Experimental|CCRI Group|
33016076|NCT01774123||Healthy|Healthy controls
33016077|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
33016078|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
33016079|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
33016080|NCT01774136|No Intervention|Standard of Care|
33016081|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
33016082|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
33016083|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
33016084|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
33016085|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
33016086|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
33016087|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
33016088|NCT01774201|No Intervention|Control|Control group
33016089|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
33016090|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
33016091|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
33016092|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
33016093|NCT01774240|No Intervention|before|no systematic approach
33016094|NCT01774240|Experimental|after|systematic screening and treatment of delirium
33016095|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
33016096|NCT01774279||anaplastic thyroid cancer|
33016097|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
33016098|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
33016099|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
33016100|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
33016101|NCT01774370||Pradaxa group|
33016102|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
33016103|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
33016104|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
33033240|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
33416201|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
33416202|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
33416203|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
33416204|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
33416205|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
33016105|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
33016106|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
33016107|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
33016108|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
33016109|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
33016110|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
33016111|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
33016112|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
33016113|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
33016114|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
33016115|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
33016116|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
33016117|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
33016118|NCT01774513|Experimental|Procore Needle|
33016119|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
33016120|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
33016121|NCT01774565|Active Comparator|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
33016122|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
33033241|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
33033242|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
33105897|NCT05426642|Experimental|Intervention group|Receive the e-health video and brochure as the intervention
33105898|NCT05426642|Other|Control group|Receive brochure as the intervention
33327195|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
33416206|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
33016123|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
33325885|NCT03901326|Experimental|CTA/CT-FFR care group|If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by DeepFFR for three major epicardial arteries. If CT-FFR value of one or more major coronary arteries is less than 0.75, ICA will be performed directly; if CT-FFR is 0.75-0.8 (including 0.8), physicians will decide whether to start intensive drug therapy or ICA; if CT-FFR value is more than 0.8, only drug therapy will be needed. The clinical management plan will be suggested including optimal medical therapy, ICA, PCI, CABG and other intervention according to the result of this non-invasive examination.
33325886|NCT03901326|No Intervention|routine clinically-indicated diagnostic care group|If the subjects are randomized to CID arm, attending physicians will decide next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
33325887|NCT03897972|Active Comparator|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
33325888|NCT03897972|Experimental|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
33325889|NCT01149018|Experimental|Tetrahydrocannabinol|
33325890|NCT01149018|Placebo Comparator|Placebo|
33325891|NCT03903900|Experimental|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
33016124|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
33325892|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
33325893|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
33325894|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
33325895|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
33016125|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
33016126|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
33016127|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
33016128|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~Ambulatory patient able to leave the bed.~Willingness to consent and participate in a 30-night study~Exclusion:~Lack of capacity to consent, without an identifiable surrogate.~Terminal Prognosis~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
33016129|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
33016130|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
33016131|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
33016132|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
33016133|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
33016134|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
33016135|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
33016136|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
33016137|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
33016138|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
33016139|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
33016140|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
33016141|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
33016142|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
33016143|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
33016144|NCT01774864|Placebo Comparator|Placebo|
33016145|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
33325896|NCT03904056|Active Comparator|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
33016146|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
33016147|NCT01774916|Other|patients|
33016148|NCT01774916|Other|volunter|
33016149|NCT01774942|Experimental|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
33016150|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
33016151|NCT01775020|Experimental|L-arginine|L-arginine
33016152|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
33016153|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
33016154|NCT01775059|Experimental|Integrated sensor and infusion set.|
33016155|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
33016156|NCT01775098|Placebo Comparator|placebo|placebo comparator
33016157|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
33016158|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
33016159|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
33016160|NCT01775150|Experimental|health education|health education via text messaging
33016161|NCT01775150|No Intervention|no health education|no health education via text messaging
33016162|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
33016163|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
33016164|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
33016165|NCT01775176||Polycystic Ovary Syndrome|Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)
33016166|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
33016167|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
33016168|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
33016169|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
33016170|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
33016171|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
33016172|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
33016173|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
33016174|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
33016175|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
33016176|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
33016177|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
33016178|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
33016179|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
33016180|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
33016181|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
33016182|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
33016183|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
33016184|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
33016185|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
33016186|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
33016187|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
33016188|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
33016189|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
33016190|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
33016191|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
33016192|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
33016193|NCT01775397|Active Comparator|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
33016194|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
33016195|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
33016196|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
33016197|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
33016198|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
33016199|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
33016200|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
33016201|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
33016202|NCT01775527|Other|blood test|
33016203|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
33016204|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
33016205|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
33016206|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
33016207|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
33016208|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
33016209|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
33016210|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
33016211|NCT01775605|Active Comparator|Synera|Synera Pain Patch
33016212|NCT01775605|No Intervention|No patch control|No intervention group
33016213|NCT01775605|Sham Comparator|Control|Sham
33016214|NCT01775618|Experimental|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
33016215|NCT01775618|Experimental|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
33016216|NCT01775618|Experimental|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
33016217|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
33016218|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
33016219|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
33016220|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
33016221|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
33016222|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
33016223|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
33016224|NCT01775696||controls|40 controls
33016225|NCT01775696||genetic FTD|5 genetic forms of FTD
33016226|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
33016227|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
33016228|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
33016229|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
33016230|NCT01775761|Experimental|Period 3: Placebo|
33016231|NCT01775826|Other|All Purposes|All participants.
33016232|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
33016233|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
33016234|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
33016235|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
33016236|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
33016237|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
33016238|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
33016239|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
33016240|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
33016241|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
33016242|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
33016243|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
33016244|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
33016245|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
33016246|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
33016247|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
33325897|NCT03904056|Experimental|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
33325898|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
33325899|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
33325900|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
33016248|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
33016249|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
33325901|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
33325902|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
33325903|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
33325904|NCT03897660|Active Comparator|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
33325905|NCT03897660|Active Comparator|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
33325906|NCT03897660|Experimental|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
33016250|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
33016251|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
33016252|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
33016253|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
33016254|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
33016255|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
33016256|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
33016257|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
33016258|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
33016259|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
33016260|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
33016261|NCT01776203|Active Comparator|medroxyprogesterone acetate|
33016262|NCT01776203|No Intervention|control|
33016263|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
33325907|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
33325908|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
33325909|NCT03901170|Experimental|letrozole|patients with letrozole
33325910|NCT03901170|No Intervention|control|patients without letrozole
33325911|NCT03900858|Experimental|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
33325912|NCT03900858|No Intervention|No Intervention|No preventive treatment Follow up without intervention. Have already done.
33325913|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
33325914|NCT01149564|Active Comparator|Oral ibuprofen|
33325915|NCT03900702|Active Comparator|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
33016264|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
33016265|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
33016266|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
33016267|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
33016268|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
33016269|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
33016270|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
33016271|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
33016272|NCT01776333|No Intervention|usual care|
33016273|NCT01776333|Experimental|video arm|video decision aid intervention
33016274|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
33016275|NCT01776346||Healthy control|
33016276|NCT01776359|Active Comparator|High Protein|High Protein
33016277|NCT01776359|Placebo Comparator|Low Protein|Low Protein
33016278|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
33016279|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
33016280|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
33016281|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
33016282|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
33016283|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
33016284|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
33016285|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
33016286|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
33016287|NCT01776489||food allergic|positive reaction during DBPCFC
33016288|NCT01776489||Non-food allergic|no reaction during DBPCFC
33016289|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
33325916|NCT03900702|No Intervention|Wait List Control|Wait list then cross over to active intervention.
33325917|NCT03894072|Active Comparator|HFHO-CPAP|This group will have HFHO before CPAP
33325918|NCT03894072|Active Comparator|CPAP-HFHO|This group will have CPAP and then HFHO
33325919|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
33325920|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
33325921|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
33325922|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
33325923|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
33325924|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
33325925|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
33325926|NCT03893994|Experimental|Stretching group|Posterior shoulder stretching exercises
33325927|NCT03893994|No Intervention|Control Group|No exercise will be applied
33325928|NCT03900390|Experimental|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
33325929|NCT03900390|No Intervention|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
33325930|NCT03900780|Experimental|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
33325931|NCT03900780|Active Comparator|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
33325932|NCT03900312|Experimental|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
33325933|NCT03897504|Experimental|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
33325934|NCT01258218||Accent MRI Group|
33016290|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
33016291|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
33016292|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
33016293|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
33016294|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
33016295|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
33016296|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
33016297|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
33016298|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
33016299|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
33016300|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
33016301|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
33016302|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
33016303|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
33016304|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
33016305|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
33016306|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
33016307|NCT01776593||Lower urinary tract symptoms|
33016308|NCT01776619|Experimental|Multiple Dose: Cohort 1|
33016309|NCT01776619|Experimental|Multiple Dose: Cohort 2|
33016310|NCT01776619|Experimental|Multiple Dose: Cohort 3|
33016311|NCT01776619|Experimental|Multiple Dose: Cohort 4|
33016312|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
33016313|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
33016314|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
33016315|NCT01776671|Other|Gralise|Efficacy of Gralise
33016316|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
33016317|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
33016318|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
33016319|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
33016320|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
33325935|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
33325936|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
33325937|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
33325938|NCT03900234||Residents of the single rural settlement|No interventions will be administered
33325939|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
33325940|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
33325941|NCT01257126|Experimental|diclofenac potassium|
33325942|NCT01257126|Active Comparator|nimesulide|
33325943|NCT03897426|No Intervention|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
33325944|NCT03897426|Experimental|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
33325945|NCT03897738|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
33416207|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
33416208|NCT01345097|Experimental|Younger Group|
33016321|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
33016322|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
33016323|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
33416209|NCT01345097|Experimental|Elderly Group|
33416210|NCT04806048||Hospitalized patients and outpatients|There may be different types of patients with differing follow-up plan but all will bie considered one group regarding on whether they receive their recommended follow-up plan
33016324|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
33016325|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
33016326|NCT01776775|No Intervention|No abdominal binder|No intervention
33016327|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
33016328|NCT01776788|Active Comparator|insulin lispro injection|
33016329|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
33016330|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
33016331|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
33016332|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
33016333|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
33016334|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
33016335|NCT01776879||recording speech and voice|no intervention(s) will be administered
33016336|NCT01776879||speech intelligibility|no intervention(s) will be administered
33016337|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
33016338|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
33016339|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
33016340|NCT01776918||Metabolic Disease- Phenylketonuria|
33016341|NCT01776918||Mitochondrial disorder|
33016342|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
33016343|NCT01776944||Obese children|
33016344|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
33016345|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
33016346|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
33416211|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
33016347|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
33016348|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
33016349|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
33416212|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
33416213|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
33016350|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
33016351|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
33016352|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
33016353|NCT01777074||Generalist physicians Cohort|
33016354|NCT01777074||Paediatricians Cohort|
33016355|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
33016356|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
33016357|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
33016358|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
33016359|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
33016360|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
33016361|NCT01777178|Experimental|Low bicarbonate dialysis|
33016362|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
33016363|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
33016364|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
33016365|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
33016366|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
33016367|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
33016368|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
33016369|NCT01777230||All patients|Alle subjects included retain in one cohort.
33016370|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
33016371|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
33016372|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
33016373|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
33016374|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
33016375|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
33016376|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
33016377|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
33016378|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
33016379|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
33016380|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
33016381|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
33016382|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
33016383|NCT01777373||Control|Control
33016384|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
33016385|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
33016386|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
33016387|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
33016388|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
33016389|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
33416214|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
33016390|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
33016391|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
33325946|NCT03897738|Placebo Comparator|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~Placebo capsules are identical to Amberen and Smart B capsules."
33325947|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization < 25 mmHg
33016392|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
33016393|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
33016394|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
33016395|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
33016396|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
33016397|NCT01777607|Experimental|Intervention|
33016398|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
33016399|NCT01777646|Experimental|MSC-NTF|
33016400|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
33016401|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
33016402|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
33016403|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
33016404|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
33016405|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
33016406|NCT01777685|Other|sulpiride 50 mg|
33016407|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
33325948|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) >15 mmHg
33325949|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP >15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) >3 WU, where available.
33325950|NCT03897114|Experimental|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
33325951|NCT03897114|Placebo Comparator|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
33325952|NCT03900078|Active Comparator|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
33325953|NCT03900078|Experimental|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
33325954|NCT03893604|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
33325955|NCT03893604|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
33325956|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
33325957|NCT02528058||Myopic traction maculopathy|
33325958|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
33325959|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
33325960|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
33325961|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
33325962|NCT03893526|Placebo Comparator|Placebo|Participants are subjected to a standardized meal
33325963|NCT03893526|Active Comparator|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
33325964|NCT03893526|Active Comparator|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
33325965|NCT03893526|Active Comparator|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
33325966|NCT03893526|Active Comparator|Valsartan|206mg valsartan as one single dose followed by a standardized meal
33325967|NCT03900000|Other|Short_Physiotherapy|one period of physiotherapy (8 weeks)
33325968|NCT03900000|Other|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
33325969|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
33325970|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
33016408|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
33325971|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
33325972|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
33325973|NCT03896802|Experimental|Low PEEP|PEEP 5 cmH2O
33325974|NCT03896802|Experimental|High PEEP|PEEP 15 cmH2O
33016409|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
33016410|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
33016411|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
33016412|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
33016413|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
33016414|NCT01777750|No Intervention|Standard treatment|Standard treatment
33016415|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
33016416|NCT01777841|Other|Electronic Care plan delivery|
33016417|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
33016418|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
33016419|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
33016420|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
33016421|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
33016422|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
33016423|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
33016424|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
33016425|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
33016426|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
33016427|NCT01777958||Cohort|
33016428|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
33016429|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
33016430|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
33016431|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
33016432|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
33016433|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
33016434|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
33016435|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
33016436|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
33016437|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
33016438|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
33416215|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
33416216|NCT01318447|Experimental|CyberKnife SBRT|
33416217|NCT02063282||Clostridium difficile carriers|
33416218|NCT02063282||Clostridium difficile non carriers|
33416219|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
33416220|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
33416221|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
33416222|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
33016439|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
33016440|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
33016441|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
33016442|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
33016443|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
33016444|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
33016445|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
33016446|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
33016447|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
33016448|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
33016449|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
33016450|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
33016451|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
33016452|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
33016453|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
33016454|NCT01778244|Experimental|metformin|metformin
33016455|NCT01778244|Placebo Comparator|placebo|placebo
33016456|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
33016457|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
33016458|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
33016459|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
33016460|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
33016461|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
33016462|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
33016463|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
33016464|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
33416223|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
33416224|NCT05251103|Experimental|time-restricted feeding trial|The participants were divided into the time-restricted feeding trial for 5 days
33416225|NCT05251103|Experimental|control trial|The participants in the control trial did not practice intermittent fasting methods
33416226|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
33416227|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
33416228|NCT01318525|Experimental|ALF-5755|
33016465|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
33016466|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
33016467|NCT01778361||HIV positive|
33016468|NCT01778361||HIV negative|
33016469|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
33016470|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
33016471|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
33016472|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
33016473|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
33016474|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
33016475|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
33016476|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
33016477|NCT01778439|Experimental|OMP-52M51|
33016478|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
33016479|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
33016480|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
33016481|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
33016482|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
33016483|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
33016484|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
33016485|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
33016486|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
33016487|NCT01778673||Distal radius fractures Sundsvall Hospital|
33016488|NCT01778673||Distal radius fractures Östersund Hospital.|
33016489|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
33016490|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
33016491|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
33016492|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
33016493|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
33016494|NCT01778712|Experimental|Intervention|Multi-level intervention
33016495|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
33016496|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
33016497|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
33016498|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
33325975|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
33325976|NCT02527590|Experimental|healthy volunteers|
33325977|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
33325978|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
33325979|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
33325980|NCT01151202|Active Comparator|Ivy leaf extract syrup|
33325981|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
33325982|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
33105899|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
33105900|NCT04454697|Experimental|Intervention|Patient receive personalized 3D-printed GWR
33105901|NCT04454697|Active Comparator|Control|Patient receive standardized radiation protection tooth splints
33105902|NCT04206748|Experimental|iGlucose Smart Meter|
33105903|NCT04206748|Placebo Comparator|Rx glucose meter|
33105904|NCT05426603|Experimental|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
33105905|NCT05426603|Other|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
33105906|NCT04454073||Bipolar patients|In euthymic state or with mild to moderate symptoms
33105907|NCT01233232|Placebo Comparator|1|Placebo dose
33105908|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
33105909|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
33105910|NCT05426486|Experimental|ARX788 + pyrotinib maleate|ARX788 1.5 mg/kg intravenously (IV) every three weeks plus pyrotinib maleate 320 mg orally once daily for 6 cycles
33105911|NCT05426486|Active Comparator|trastuzumab + pertuzumab + docetaxel + carboplatin|Trastuzumab (8 mg/kg first dose, followed 6 mg/kg) puls pertuzumab (840 mg first dose, followed 420 mg) plus docetaxel (75 mg/m3) plus carboplatin (AUC6) IV every 3 weeks for 6 cycles
33105912|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
33105913|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
33105914|NCT05463276||Patients with breast cancer|
33105915|NCT05460663|Experimental|VTC/In-person SMART training|The two-hour VTC or in-person will be provided SMART synchronously to a maximum of 10 individuals. A study team member will contact participants in the VTC group to provide available dates and times of scheduled classes, and these participants will be scheduled for a class they would like to attend. Participants in the VTC group will be provided a web-link prior to the session, and each session will have a unique password to access the training. Participants in the on-line training group will be provided a code to access the training website. If local conditions permit in-person group meetings (i.e. Health Protection Condition [HPCON] Alpha or Bravo), in-person group SMART training in a classroom will be offered as an alternative to VTC sessions.
33105916|NCT05460663|Experimental|CBT SMART training|SMART will be provided via completion of a self-paced, on-line version completed over a period of four to eight weeks.
33105917|NCT05426135||Lung cancer group|Participants with lung cancer/pulmonary nodules
33105918|NCT05426135||Stomach cancer group|Participants with Stomach cancer/Stomach lesion
33325983|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
33325984|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
33325985|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
33325986|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
33325987|NCT03900156|No Intervention|comparison group|The CG received no extra care.
33325988|NCT03900156|Experimental|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
33325989|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
33105919|NCT05426135||Colorectal cancer group|Participants with Colorectal cancer/Colorectal lesion
33105920|NCT04389879|Experimental|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
33105921|NCT04389879|Active Comparator|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
33325990|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
33416229|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
33105922|NCT05426018|Experimental|SY-009 -1|0.5mg tid
33105923|NCT05426018|Experimental|SY-009-2|1.0mg tid
33105924|NCT05426018|Experimental|SY-009-3|1.5mg tid
33105925|NCT05426018|Placebo Comparator|Placebo|tid
33105926|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
33105927|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
33105928|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
33105929|NCT05425901|Experimental|IBD|active or quiescent
33105930|NCT05425901|Active Comparator|control|polyp screening
33105931|NCT05425706|Experimental|experiment group|Number of participant is 16. In addition to the conventional therapy, SNAGs technique was applied.
33105932|NCT05425706|No Intervention|control group|Number of participant is 16. Only the conventional therapy was applied.
33105933|NCT05425628|Experimental|Treatment with NeoChord Transcatheter Mitral Repair System|Implanting ePTFE sutures as artificial neochordae using NeoChord Transcatheter Mitral Repair System
33231795|NCT05509998|Active Comparator|Screening Method (SM)|In the SM condition all consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
33416230|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
33016499|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
33016500|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
33016501|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
33016502|NCT01778868||Overweight and obese individuals|
33016503|NCT01778868||Normal weight individuals|
33016504|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
33016505|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
33016506|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
33016507|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
33016508|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
33016509|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
33016510|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
33016511|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
33016512|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
33016513|NCT01778959|Active Comparator|standard OVD|
33016514|NCT01778959|Active Comparator|Iris hooks|
33016515|NCT01778959|Active Comparator|Malyugin Ring|
33016516|NCT01778959|Active Comparator|OVD|
33016517|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
33016518|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
33016519|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
33016520|NCT01778998|Active Comparator|MICS-group|
33016521|NCT01778998|Active Comparator|SICS-group|
33016522|NCT01778998|Active Comparator|SICS pre-cut|
33016523|NCT01778998|Active Comparator|SICS stab-incision|
33016524|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
33016525|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
33016526|NCT01779037||Inpatient Rehabilitation Patients|
33016527|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
33016528|NCT01779063|Active Comparator|education booklet|printed educational booklet
33016529|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
33016530|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
33016531|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
33016532|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
33016533|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
33016534|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
33016535|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
33016536|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
33416231|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
33016537|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
33016538|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
33016539|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
33016540|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
33016541|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
33016542|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
33016543|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
33016544|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
33016545|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
33016546|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
33016547|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
33016548|NCT01779271|Experimental|Pelubiprofen|
33016549|NCT01779271|Active Comparator|Loxoprofen|
33016550|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
33016551|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
33016552|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
33016553|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
33016554|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
33016555|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
33016556|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
33016557|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
33016558|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
33016559|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
33016560|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
33016561|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
33016562|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
33016563|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
33016564|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
33016565|NCT01779427|Experimental|AIM Intervention|
33016566|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
33016567|NCT01779466|Experimental|Experimental A|
33016568|NCT01779466|Experimental|Experimental B|
33016569|NCT01779466|Placebo Comparator|Placebo|
33016570|NCT01779479|Experimental|Cabacitaxel|
33016571|NCT01779479|Active Comparator|Paclitaxel|
33016572|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
33016573|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
33016574|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
33016575|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
33016576|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
33416232|NCT04938258|Experimental|Intensive Case Management Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
33325991|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
33325992|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
33416233|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
33416234|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
33016577|NCT01779531||pCR，XT|
33016578|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
33016579|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
33016580|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
33016581|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
33016582|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
33016583|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
33016584|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
33016585|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
33016586|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
33016587|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
33016588|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
33016589|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
33016590|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
33016591|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
33016592|NCT01779661|Active Comparator|Infant Aquatics|
33016593|NCT01779661|Active Comparator|Infant Massage|Infant Massage
33016594|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
33016595|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
33016596|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
33016597|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
33016598|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
33016599|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
33016600|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
33016601|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
33016602|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
33016603|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
33016604|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
33016605|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
33016606|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
33016607|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
33016608|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
33016609|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
33016610|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
33016611|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
33016612|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
33016613|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
33016614|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
33016615|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
33016616|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
33016617|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
33016618|NCT01779895|Placebo Comparator|Placebo|maltodextrin
33016619|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
33016620|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
33016621|NCT01779921||FVII|
33016622|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
33016623|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
33016624|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
33016625|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
33016626|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
33016627|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
33016628|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
33016629|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
33016630|NCT01780051|Experimental|Sequence A|
33016631|NCT01780051|Experimental|Sequence B|
33016632|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
33016633|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
33016634|NCT01780077|Experimental|RXI-109|
33016635|NCT01780077|Placebo Comparator|Placebo|
33016636|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
33016637|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~Engaging patients: assessing needs and concerns in medication adherence;~Reviewing strengths and barriers and developing coping strategies; and~Rationalizing beliefs and concerns and preventing relapse."
33016638|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
33016639|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
33016640|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
33325993|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
33325994|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
33325995|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
33325996|NCT05098626||Individuals Working Remotely|Individuals aged between 18-60 and working remotely, who volunteered to participate in the study, will form the study group.
33325997|NCT03899610|Experimental|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~Interval debulking surgery~Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
33325998|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
33325999|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
33326000|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
33016641|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
33016642|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
33016643|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
33016644|NCT01780194||Lumbar fusion group|
33016645|NCT01780194||Conservative treatment group|
33016646|NCT01780207|No Intervention|OSA without PFO|
33016647|NCT01780207|Other|OSA with PFO|PFO closure
33016648|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
33016649|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
33016650|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
33016651|NCT01780246|Experimental|nusinersen|
33016652|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
33016653|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
33016654|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
33016655|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
33016656|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
33016657|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
33016658|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
33016659|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
33016660|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
33016661|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
33016662|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
33016663|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
33016664|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
33016665|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
33016666|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
33016667|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
33016668|NCT01780311|Experimental|ABLATION|Catheter Ablation
33016669|NCT01780363||controls|frequency of mevalonate kinase gene frequency
33016670|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
33016671|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
33016672|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
33016673|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
33016674|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
33016675|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
33016676|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
33016677|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
33016678|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
33016679|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
33016680|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
33016681|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
33016682|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
33016683|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
33016684|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
33016685|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
33416235|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
33416236|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
33416237|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
33416238|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
33416239|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
33416240|NCT05210595|Experimental|Control group|Clopidogrel 75 mg/day as maintenance dose
33416241|NCT05210595|Experimental|Treatment group 1|De-escalation strategy dose receive ticagrelor 60 mg twice daily
33016686|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
33016687|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
33016688|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
33016689|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
33016690|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
33016691|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
33016692|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
33016693|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
33016694|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
33016695|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
33016696|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
33016697|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
33016698|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
33016699|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
33016700|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
33016701|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
33016702|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
33016703|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
33016704|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
33016705|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
33016706|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
33016707|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
33016708|NCT01780766||Indolent myeloma patient|
33016709|NCT01780766||Symptomatic Myeloma patient|
33016710|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
33416242|NCT05210595|Experimental|Treatment group 2|De-escalation strategy dose receive ticagrelor 45 mg twice daily
33416243|NCT01358539|Experimental|Pain education|Patients receiving pain education
33416244|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
33416245|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
33416246|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
33416247|NCT03560570||Control|Healthy subject
33416248|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
33416249|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
33416250|NCT05210517|No Intervention|No intervention|
33416251|NCT05210517|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for one week
33016711|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
33416252|NCT05210517|Experimental|Benzbromarone|Benzbromarone 100 mg once daily for one week
33016712|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
33016713|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
33416253|NCT05210517|Experimental|Empagliflozin-Benzbromarone|Empagliflozin 25 mg once daily for one week combined with Benzbromarone 100 mg once daily for one week
33016714|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
33016715|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
33016716|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
33016717|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
33016718|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
33016719|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
33016720|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
33016721|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
33016722|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
33016723|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
33016724|NCT01780896||Study Group|
33016725|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
33016726|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
33016727|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
33016728|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
33016729|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
33016730|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
33416254|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
33417525|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
33016731|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
33016732|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
33016733|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
33016734|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
33016735|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
33016736|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
33016737|NCT01781052||Group 1|
33016738|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
33016739|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
33016740|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
33016741|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
33016742|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
33016743|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
33016744|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
33016745|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
33016746|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
33016747|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
33016748|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
33016749|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
33016750|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
33016751|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
33016752|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
33016753|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
33016754|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
33016755|NCT01781312|Experimental|ProTectis|
33016756|NCT01781312|Experimental|Gastrus|
33016757|NCT01781325|Active Comparator|IBEHR|IBEHR
33016758|NCT01781325|No Intervention|Standard therapy|written instructions
33016759|NCT01781351|Experimental|taping the ankle|
33016760|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
33016761|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
33016762|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
33016763|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
33016764|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
33016765|NCT01781416||1|
33016766|NCT01781442||Patient Arm- temsirolimus|
33016767|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
33016768|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
33016769|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
33016770|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
33016771|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
33016772|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
33016773|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
33016774|NCT01781520|Active Comparator|Best supportive care|
33016775|NCT01781533|Experimental|algorithm|
33016776|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
33016777|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
33016778|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
33016779|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
33016780|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
33016781|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
33016782|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
33016783|NCT01781598||Patients treated with Patient specific instruments in TKA|
33016784|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
33016785|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
33016786|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
33016787|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
33016788|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
33016789|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
33016790|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
33016791|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
33016792|NCT01781689|No Intervention|Health|with no motor function impairment
33016793|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
33016794|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
33016795|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
33016796|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
33016797|NCT01781754||Diabetic patients|Un balanced diabetic patients
33016798|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
33016799|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
33326001|NCT03896412|Experimental|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
33326002|NCT03893214|Experimental|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
33326003|NCT03893214|Placebo Comparator|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
33326004|NCT03896646|Experimental|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
33326005|NCT03896490|Experimental|ACT|
33105934|NCT05457426||robotic right hemicolectomy with CME|The robot was set to come and dock from the right shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook/scissors for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R2), and Cadiere's fenestrated forceps in the right lower quadrant port (R3) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transverse mesocolon with the grasp in R3, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R2. All procedures were performed keeping the principle of complete mesocolic excision.
33105935|NCT05457426||laparoscopic right hemicolectomy with CME|In the aparoscopic group, five trocars were used: a periumbilical incision and left upper quadrant for 12-mm trocars, both lower quadrants for 5-mm trocars, and the right quadrant for one more 5-mm trocar. A 30 degrees laparoscope was inserted through the periumbilical trocar site. After insertion of the trocars, the patient was placed in the Trendelenburg position with a 15 degrees rightward tilt. An ultrasonic device was used for dissection. All procedures were performed keeping the principle of complete mesocolic excision.
33105936|NCT04372797|Experimental|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
33105937|NCT04372797|Active Comparator|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
33105938|NCT05425589|Other|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
33105939|NCT05452278|Experimental|Product sequence ABCD|Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
33105940|NCT05452278|Experimental|Product sequence BCDA|Subjects use Product B on Day 1, Product C on Day 2, Product D on Day 3 and Product A on Day 4
33105941|NCT05452278|Experimental|Product sequence CDAB|Subjects use Product C on Day 1, Product D on Day 2, Product A on Day 3 and Product B on Day 4
33105942|NCT05452278|Experimental|Product sequence DABC|Subjects use Product D on Day 1, Product A on Day 2, Product B on Day 3 and Product C on Day 4
33105943|NCT05425394|Experimental|delayed first bath time|Delay first bath to 8 hours after birth
33105944|NCT05425394|No Intervention|regular bath|Birth temperature 36.5°C, regular bath
33105945|NCT05427123||Youth with or at clinical high risk for Bipolar Spectrum Disorder|Youth included in the study will have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar I or II, Cyclothymic Disorder, or Other Specified Bipolar Disorder (per Course and Outcome of Bipolar Youth study definition)
33105946|NCT04369794|Active Comparator|BCG vaccine|BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
33105947|NCT04369794|Placebo Comparator|Placebo|Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
33105948|NCT05425316||Patients with Cirrhosis|This group will be composed of 200 patients with cirrhosis. Patients will be enrolled regardless of compensated vs. decompensated status, prior history of HE, Model for End Stage Liver Disease (MELD), and cirrhosis etiology.
33105949|NCT05425316||Patients without Cirrhosis|This group will be composed of 50 patients without cirrhosis to act as controls. They will have been found on Fibroscan to not have significant fibrosis.
33105950|NCT05422755||Arm 1|Experimental: Test Drug Recombinant Human Erythropoietin Alfa
33105951|NCT05425238|Experimental|Blood flow restriction|Resistance training protocol but with Blood flow restriction technique Standard BFR Application: a standard pressure (used for all patients) for e.g. 180 mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.
33105952|NCT05425238|Active Comparator|Conventional physical therapy|Resistance training to stimulate skeletal muscle hypertrophy and strength adaptations in Duration of 6 weeks
33105953|NCT05419401|Experimental|Capivasertib|film-coated tablet, 200 mg
33105954|NCT05419401|Experimental|[14C]AZD5363 (Capivasertib)|Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) and Oral Solution, 400 mg (NMT 4.8 MBq)
33105955|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
33105956|NCT04330560|Experimental|Ex group|Receive CR telerehabilitation (exercise telemonitoring link to the healthcare platform + teleconsultation)
33105957|NCT04330560|Active Comparator|Com group|Receive CR telerehabilitation (exercise self-monitoring + teleconsultation)
33105958|NCT04330560|Placebo Comparator|C group|Standard care - traditional center-based CR
33105959|NCT04429061|No Intervention|SOC Arm|Standard of care (SOC): the sexual reproductive curriculum which is implemented by the schools as part of mandatory SRH education.
33326006|NCT03896490|Placebo Comparator|Control|
33326007|NCT03896256|Experimental|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
33326008|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
32739251|NCT04997889|Experimental|artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
33416255|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
33416256|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
33416257|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
33416258|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
33416259|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
33416260|NCT01350817|Active Comparator|Docetaxel|
33416261|NCT01350817|Experimental|Erlotinib|
33416262|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
33016800|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
33016801|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
33016802|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
33016803|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
33016804|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
33016805|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
33016806|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
33016807|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
33016808|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
33016809|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
33016810|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
33016811|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
33016812|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
33016813|NCT01781897|Active Comparator|mosapride|mosapride
33016814|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
33016815|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
33016816|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
33016817|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
33416263|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
33416264|NCT01986075|Experimental|Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
33016818|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
33016819|NCT01781923|No Intervention|Control|No intervention
33016820|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
33016821|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
33016822|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
33016823|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
33016824|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
33016825|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
33016826|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
33016827|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
33016828|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
33016829|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
33016830|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
33016831|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
33016832|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
33016833|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
33016834|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
33016835|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
33016836|NCT01782066|Experimental|Menveo, dose escalating|
33016837|NCT01782066|Experimental|Nimenrix, dose escalating|
33016838|NCT01782079|Experimental|L. brevis|
33016839|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
33016840|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
33016841|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
33016842|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
33016843|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
33016844|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
33326009|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
33326010|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
33326011|NCT03899454|Experimental|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
33326012|NCT03899454|Placebo Comparator|Control|Placebo
33326013|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
33326014|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
33326015|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
33016845|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
33016846|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
33016847|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
33016848|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
33016849|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
33016850|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
33016851|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
33016852|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
33016853|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
33016854|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
33016855|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
33016856|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
33016857|NCT01782248|Other|Control|Control group
33016858|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
33016859|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
33016860|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33016861|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33016862|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33016863|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
33016864|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
33016865|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
33016866|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
33016867|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
33016868|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
33416265|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
33016869|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
33416266|NCT04753710|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel
33416267|NCT04753710|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel
33416268|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
33416269|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
33016870|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
33016871|NCT01782404|Experimental|Chlorhexidine|
33016872|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
33016873|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
33016874|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
33016875|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
33016876|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
33016877|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
33016878|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
33016879|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
33016880|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
33016881|NCT01782534||aortic dissection|aortic dissection
33016882|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
33016883|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
33016884|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
33016885|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
33016886|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
33016887|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
33016888|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
33016889|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
33016890|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
33016891|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
33016892|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
33016893|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
33016894|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
33016895|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
33016896|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
33016897|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
33416270|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
33416271|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
33416272|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
33016898|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
33016899|NCT01782716||ASA|
33016900|NCT01782716||ASA+Euroscore|
33016901|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
33016902|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
33016903|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
33016904|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
33016905|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
33016906|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
33016907|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
33016908|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
33016909|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
33016910|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
33016911|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
33016912|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
33016913|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
33016914|NCT01782924|Experimental|KHK4827 140mg SC|
33016915|NCT01782924|Experimental|KHK4827 210mg SC|
33016916|NCT01782937|Experimental|KHK4827|
33016917|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
33016918|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
33016919|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
33016920|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
33016921|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
33016922|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
33016923|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
33016924|NCT01783093||Sickle cell and pulmonary hypertension|
33016925|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
33326016|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
33326017|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
33326018|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
33326019|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
33105960|NCT04429061|Active Comparator|Enhanced Arm|The SKILLZ-Girl Curriculum, plus the graduation event (including HIVST + access to family planning) and home based delivery of commodities with subsequent encouragement to be involved with SKILLZ-Clubs at their school
33105961|NCT05409885||General anesthesia group|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
33105962|NCT05409885||Spinal anesthesia group|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
33105963|NCT04427306|Experimental|Treatment (talimogene laherparepvec)|
33105964|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
33105965|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
33105966|NCT00552864|Active Comparator|R|
33105967|NCT00552864|Active Comparator|L|
33105968|NCT04419584|Experimental|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
33105969|NCT04419584|Placebo Comparator|Identical looking placebo|Placebo granules, twice per day for 12 weeks
33105970|NCT04327284|Experimental|test group|The test group will receive immediate molar implant placement in fresh extraction socket with nonocclusal loading immediate provisionalization (Straumann BLX 6.5mm).
33416273|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
33105971|NCT04327284|Active Comparator|Control group|The control group will receive delayed molar implant placement at least 12 weeks post molar extraction with nonocclusal loading immediate provisionalization (Straumann BLX 5.0mm).
33105972|NCT04416542|No Intervention|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
33105973|NCT04416542|Active Comparator|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
33105974|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
33416274|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
33416275|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
33416276|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
33416277|NCT02797808|Experimental|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
33416278|NCT02797808|Active Comparator|Healthy Control Children|Children without obsessive compulsive disorder
33416279|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
33416280|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
33416281|NCT05251025|Experimental|Passive sustained stretching|Passive sustained stretching along with conventional treatments
33416282|NCT05251025|Experimental|Myofascial Release|Myofascial Release Technique along with conventional treatments
33416283|NCT05751135|Experimental|Focal muscle vibration group 1|Focal muscle vibration with frequency of 80 Hz will be provided 3 days along with stretching, strengthening and positioning for 8 weeks
33416284|NCT05751135|Experimental|Focal muscle vibration group 2|Focal muscle vibration with frequency of 100 Hz will be provided 3 days a week along with stretching, strengthening and positioning for 8 weeks.
33416285|NCT05751135|Active Comparator|Control group|Stretching, strengthening and positioning in 3 sessions a week for 8 weeks
33416286|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
33416287|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
33416288|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
33416289|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
33105975|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
33105976|NCT05408130|Experimental|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to the intervention arm will receive 5 cycles of ischemia/reperfusion in the non-paralyzed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
33416290|NCT05735301|Other|MR/CT perfusion group|MRI group consisted of patients who underwent DWI, FLAIRE, T1, T2, and MRA sequences.After randomization, the attending physician determined surgical treatment based on the imaging results.
33416291|NCT05735301|Other|MRI group|The perfusion sequence was examined by the Control Group, and the F-stroke Stroke software (Brainseal Intelligent Technology) was used for data processing.After randomization, the attending physician determined surgical treatment based on the imaging results.
33416292|NCT05123027|Experimental|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|
33416293|NCT05123027|Active Comparator|Treatment As Usual Peer|
33416294|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
33016926|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
33016927|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
33016928|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
33016929|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
33016930|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
33016931|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
33016932|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33016933|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33016934|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
33016935|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
33016936|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
33016937|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
33016938|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
33016939|NCT01783249|No Intervention|Control|Usual care monitoring
33016940|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
33016941|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
33016942|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
33016943|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
33016944|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
33016945|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~AFC < 6 on both ovary: 375 IU FSH~6<AFC <=15 on both ovary: 225 IU FSH~AFC> 15 on both ovary: 150 IU FSH"
33016946|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
33016947|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
33016948|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
33016949|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
33016950|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
33016951|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
33016952|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
33326020|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
33416295|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
33416296|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
33416297|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
33416298|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
33416299|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
33016953|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
33016954|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
33016955|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
33016956|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
33016957|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
33016958|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
33016959|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
33016960|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
33016961|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
33016962|NCT01783405||Cases|FH heterozygous
33016963|NCT01783405||Controls|Parents of FH heterozygotes with FH
33016964|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
33016965|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
33016966|NCT01783457|Active Comparator|Control|Usual treatment
33016967|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
33016968|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
33016969|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
33016970|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
33016971|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
33016972|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
33016973|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
33016974|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
33016975|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
33016976|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
33016977|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
33417526|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
33016978|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
33016979|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
33016980|NCT01783691|Experimental|NKTT120|
33016981|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
33016982|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
33016983|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
33016984|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
33016985|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
33016986|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
33016987|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
33016988|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
33016989|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
33016990|NCT01783795|Other|Genetic Analysis|Genetic Analysis
33016991|NCT01783834|Active Comparator|pemetrexed|pemetrexed
33016992|NCT01783834|Active Comparator|gefitinib|gefitinib
33016993|NCT01783873|Placebo Comparator|Placebo|
33016994|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
33016995|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
33016996|NCT01783925||Group 1|
33016997|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
33016998|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
33016999|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
33017000|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
33017001|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
33017002|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
33017003|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
33017004|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
33017005|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
33017006|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
33017007|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
33017008|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
33417527|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
33417528|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
33416300|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
33416301|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
33416302|NCT05007405||Osteoarticular infections|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
33416303|NCT01343069|No Intervention|before surgical checklist|
33416304|NCT01343069|Active Comparator|after implementation surgical checklist|
33416305|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
33416306|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
33416307|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
33416308|NCT01343147|Other|Superficial hyperthermia|Hot packs
33416309|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
33416310|NCT05210127|Experimental|After Scarf Osteotomy Group|30 participants after surgery
33105977|NCT05408130|Sham Comparator|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke.
33105978|NCT04401176|Active Comparator|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
33105979|NCT04401176|Active Comparator|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
33416311|NCT05210127|Experimental|Without Scarf Osteotomy Group|30 participants without surgery
33416312|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
33416313|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
33416314|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
33416315|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
33416316|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
33416317|NCT05209971||macular thickness and visual acuity|optical coherence tomography
33416318|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
33416319|NCT03620357|Active Comparator|SMBG Group|
33416320|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
33416321|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
33416322|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
33416323|NCT05089643|Experimental|CA|Anlotinib 10mg Qd D1-14 Capecitabine 1G /m2 Bid D1-14 / Q21D
33416324|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
33416325|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
33416326|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
33416327|NCT05209581||Study Group|Adult refugees/immigrants living in accommodation structures
33416328|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
33416329|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
33416330|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
33416331|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
33416332|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
33416333|NCT04959435||Case|Behcet's disease patients
33416334|NCT04959435||Controls|Controls that matched two to two at case according to sex,social status and diet.
33416335|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
33416336|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
33416337|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
33416338|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
33326021|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
33326022|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
33326023|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
33017009|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
33017010|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
33017011|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
33017012|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
33017013|NCT01784042|Experimental|Lovaza|Lovaza only
33017014|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
33017015|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
33017016|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
33017017|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
33017018|NCT01784107|Experimental|Belotecan and Ifosfamide|
33017019|NCT01784120|Experimental|doxotubicin/Genexol-PM|
33017020|NCT01784146|Placebo Comparator|Oxygen|
33017021|NCT01784146|Experimental|PEEP + Heliox|
33017022|NCT01784146|Experimental|Oxygen + PEEP|
33017023|NCT01784146|Active Comparator|Heliox|
33017024|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
33017025|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
33017026|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
33017027|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
33017028|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
33017029|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
33017030|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
33017031|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
33017032|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
33017033|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
33017034|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
33017035|NCT01784263|Active Comparator|Standard Community Treatment|
33017036|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
33017037|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
33017038|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
33017039|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
33017040|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
33017041|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
33017042|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
33017043|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
33017044|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
33017045|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
33017046|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
33017047|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
33326024|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
33326025|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
33326026|NCT01258686|Experimental|silymarin, treatment|
33017048|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
33017049|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
33017050|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
33017051|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
33017052|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
33017053|NCT01784380||the case group|
33017054|NCT01784380||the control group|
33017055|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
33017056|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
33017057|NCT01784406|No Intervention|Control|Standard of care.
33017058|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
33017059|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
33017060|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
33017061|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
33017062|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
33017063|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
33017064|NCT01784484||patients with abnormal liver enzymnes|
33017065|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
33017066|NCT01784510|Active Comparator|2 cm|
33017067|NCT01784510|Experimental|6 cm|
33017068|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
33017069|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
33017070|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;~Pemetrexed day 1 q 21 days for 3 cycles;~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
33017071|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
33017072|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
33017073|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
33017074|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
33017075|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
33017076|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
33017077|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
33017078|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
33017079|NCT01784679||Natural History Prospective Observational Group|
33017080|NCT01784679||Online Registry Patient Reported Group|
33017081|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
33017082|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
33017083|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
33017084|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
33017085|NCT01784705|Experimental|Transcranial bright light therapy|
33017086|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
33017087|NCT01784731||Patients|
33017088|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
33017089|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
33017090|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
33017091|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
33105980|NCT04393922|Experimental|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.~Visit 1 Measurements:~MVCs~MEP Recruitment Curves~iMEPs~StartReact~Visit 2 Measurements:~Participant Reported Spasticity~MAS~PSAD~KINARM~MRI of brain and spinal cord"
33326027|NCT01258686|Placebo Comparator|placebo|
33326028|NCT03896178||Firefighters|
33326029|NCT03896178||Pilots|
33326030|NCT03896178||Police|
33326031|NCT03896178||Military personnel|
33017092|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
33017093|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
33417529|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
33017094|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
33017095|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
33017096|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
33017097|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
33017098|NCT01784835|Other|control|patients under standard medical care
33017099|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
33017100|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
33017101|NCT01784887|No Intervention|SOC|Standard of Care
33017102|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab~D2 : 40 μg~D4 : 80 μg"
33017103|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab~D2 : 30 μg~D4 : 60 μg"
33017104|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
33017105|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
33017106|NCT01784952|Experimental|Whole grains and lequmes|
33017107|NCT01784952|Placebo Comparator|refined rice|
33017108|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
33017109|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
33017110|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
33017111|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
33017112|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
33017113|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
33017114|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
33017115|NCT01785030|Experimental|50% Nitrous oxide|
33017116|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
33017117|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
33017118|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
33017119|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
33017120|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
33017121|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
33017122|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
33017123|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
33017124|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
33017125|NCT01785108|Placebo Comparator|Placebo|
33017126|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
33017127|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
33017128|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
33017129|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
33017130|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
33017131|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
33017132|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
33017133|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
33017134|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
33017135|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
33017136|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
33017137|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
33017138|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
33017139|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
33017140|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
33017141|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
33017142|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
33017143|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
33017144|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
33017145|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
33017146|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
33017147|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
33017148|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
33017149|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
33017150|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
33017151|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
33017152|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
33017153|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
33017154|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
33017155|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
33017156|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
33017157|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
33017158|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Baseline observation"
33017159|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Implementation of guidelines"
33017160|NCT01785381|No Intervention|usual care|usual care
33017161|NCT01785381|Other|Added value of coordinator|Added value of coordinator
33017162|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
33017163|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
33017164|NCT01785407|Active Comparator|80 mg FeSO4|
33017165|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
33017166|NCT01785407|Active Comparator|160 mg FeSO4|
33017167|NCT01785407|Active Comparator|240 mg FeSO4|
33017168|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
33017169|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
33017170|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
33017171|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
33017172|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
33017173|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
33017174|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
33017175|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
33017176|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
33017177|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
33017178|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
33017179|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
33017180|NCT01785550||Control Group|No intervention to be performed.
33017181|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
33017182|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
33017183|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
33017184|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
33416339|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
33416340|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic colorectal cancer
33416341|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic endometrium cancer
33416342|NCT05591300||Patients|Patients with acute CO poisoning needing a hyperbaric oxygen treatment
33416343|NCT05591300||Healthy controls|Healthy controls i.e., healthy phisicians than will enter the hyperbaric oxygen therapy chamber to assist the patients
33416344|NCT05747157|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
33416345|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
33416346|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
33416347|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
33416348|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
33416349|NCT05209113|Experimental|Study Group|The self-management module, which will be applied only to the study group, includes the clinical pharmacist informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms. The first interview will end after the Patient Health Engagement-PHE-s, Multiple Sclerosis Self-Management Revised-MSSM-R, Patient Assessment of Chronic Illness Care-PACIC scales and self-management module are applied to the study group by the clinical pharmacist. When the patients come to the outpatient clinic examination 4 and 8 months after the first interview, second and third face-to-face interview will be held with the clinical pharmacist and all scales will be applied again. During the second and third interview, no written and/or verbal information will be given to the patient again.
33416350|NCT05209113|No Intervention|Control Group|Patient Health Engagement (PHE-s), Multiple Sclerosis Self-Management Revised (MSSM-R), Patient Assessment of Chronic Illness Care (PACIC) scales will be administered to the control group patients whose medications and demographic information were obtained in the first face-to-face interview. The same scales will be repeated at the 4th month and 8th month, the self-management module will not be applied to the control group, and within this scope, the patients will not be informed by the clinical pharmacist, and the patient's routine outpatient services will continue.
33416351|NCT03143855|Experimental|Lorcaserin|
33416352|NCT03143855|Placebo Comparator|Control Group|
33416353|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
33416354|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
33017185|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
33017186|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
33017187|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
33017188|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
33017189|NCT01785654||reventilation collapse|
33017190|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
33017191|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
33017192|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
33017193|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
33017194|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
33017195|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
33017196|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
33017197|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
33017198|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
33017199|NCT01785784|Experimental|burn patients|
33017200|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
33017201|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
33017202|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
33017203|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
33017204|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
33017205|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
33017206|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
33017207|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
33017208|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
33017209|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
33017210|NCT01785862|Placebo Comparator|Placebo|Placebo
33017211|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
33017212|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
33017213|NCT01785914||1|
33017214|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
33017215|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
33017216|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
33017217|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
33017218|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
33017219|NCT01785953||1|
33017220|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
33017221|NCT01785966|No Intervention|Usual care|Usual care
33017222|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
33017223|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
33017224|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
33017225|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
33017226|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
33017227|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
33017228|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
33017229|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
33017230|NCT01786031|Experimental|experimental|metastasis biopsy
33017231|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
33017232|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
33017233|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
33017234|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
33017235|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
33017236|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
33017237|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
33017238|NCT01786083|No Intervention|No counseling|Usual care by caregiver
33017239|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
33017240|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
33017241|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
33017242|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
33017243|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
33017244|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
33017245|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
33017246|NCT01786213||Colonoscopist A|
33017247|NCT01786213||Colonoscopist B|
33017248|NCT01786213||Colonoscopist C|
33017249|NCT01786213||Colonoscopist D|
33017250|NCT01786213||Colonoscopist E|
33017251|NCT01786213||Colonoscopist F|
33017252|NCT01786213||Colonoscopist G|
33017253|NCT01786213||Colonoscopist H|
33416355|NCT02878603|Experimental|caplacizumab|Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange [PE], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product [IMP], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.
33416356|NCT05209191|Experimental|Student Athlete Wellness Portal|Web-based intervention that illustrates opioid misuse and diversion resistance strategies.
33017254|NCT01786213||Colonoscopist I|
33017255|NCT01786213||Colonoscopist J|
33017256|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
33017257|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
33017258|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
33017259|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
33017260|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
33017261|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
33017262|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
33017263|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
33017264|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
33017265|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
33017266|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
33017267|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
33017268|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
33017269|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
33017270|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
33017271|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
33017272|NCT01786395|Placebo Comparator|- Placebo|
33017273|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
33017274|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
33017275|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
33017276|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
33017277|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
33017278|NCT01786460||Healthy Volunteers|
33017279|NCT01786473|Experimental|Testogel 1% 5g QD|
33017280|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
33017281|NCT01786486||Delivery system entry|
33017282|NCT01786499|Other|Relaxation Response Training|
33017283|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
33017284|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
33017285|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
33017286|NCT01786538|Experimental|Regorafenib/FOLFOX|
33017287|NCT01786538|Active Comparator|Placebo/FOLFOX|
33017288|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
33017289|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
33017290|NCT01786590|Experimental|EBUS-TBNA|
33017291|NCT01786616||Formoterol|12 mcg BID for four weeks
33017292|NCT01786642||conscious|bronchoscopy without sedative drugs
33017293|NCT01786642||conscious sedation|bronchoscopy under midazolam
33017294|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
33017295|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
33017296|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
33017297|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
33416357|NCT05209191|Active Comparator|Student Athlete Nutritional Program|Web-based intervention that teaches about healthy eating habits for athletes.
33017298|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
33017299|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
33017300|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
33017301|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
33416358|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
33416359|NCT01343225|Active Comparator|atripla|comparator
33416360|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
33416361|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
33416362|NCT05208879||Case group.|"Patients with genetically proven familial hypocholesterolemia, who will accept to participate in this study and have been treated for this pathology since 1990 in the Department of Gastroenterology and Paediatric Nutrition (Pr Peretti) and continue their follow-up into adulthood at the GHE (Groupement Hospitalier Est) in Lyon in the endocrinology-nutrition service (Pr Moulin).~They may be girl/woman or boy/man over 6 years of age and over 12 kg at the time of inclusion (age required for cooperation on macular pigment measurement), agreeing to participate in the study with clear and informed consent. These patients are covered by social security."
33416363|NCT05208879||Control group.|The control group consists of children over 6 years old or adult patients, followed routinely in the ophthalmology department of the Edouard Herriot Hospital, Lyon (Pr Kodjikian) not suffering from genetic hypocholesterolemia and requiring a fundus examination as part of the usual follow-up of their ocular pathology, if this pathology does not interfere with the macular pigment density. An additional measurement of the macular pigment density will be made during this examination. The control group is only needed for the macular pigment analysis. No control group is considered for the characterization of plasma lutein and zeaxanthin deficiency and for the analysis of oxidative stress, so there will be no additional blood sampling for control patients.
33017302|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
33017303|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
33017304|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
33017305|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
33017306|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
33017307|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
33017308|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
33017309|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
33017310|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
33017311|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
33017312|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
33017313|NCT01786798|Other|Transvaginal sonography|
33017314|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
33017315|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
33017316|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
33017317|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
33416364|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age and with pre-pregnancy body mass index (BMI) ≥18.5 and ≤ 39.9 kg/m2 enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
33416365|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
33017318|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
33017319|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
33017320|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
33017321|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
33017322|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
33017323|NCT01786863||Neuromuscular blockade|
33017324|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
33017325|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
33017326|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
33017327|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
33017328|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
33017329|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
33017330|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
33017331|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
33017332|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
33017333|NCT01786980||liver cancer, Radical hepatic resection|
33017334|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
33017335|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
33017336|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
33017337|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
33017338|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
33017339|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
33017340|NCT01787071||one group|Patients receiving fluid challebnge
33017341|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
33017342|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
33017343|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
33017344|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
33017345|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
33017346|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
33017347|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
33017348|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
33017349|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
33017350|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
33017351|NCT01787214|Other|Control|Walnut free meals
33017352|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
33017353|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
33017354|NCT01787253||Irritable bowel syndrome (IBS)|
33017355|NCT01787253||Healthy controls|
33017356|NCT01787253||Microscopic Colitis (MC)|
33017357|NCT01787253||Irritable bowel disease (IBD)|
33017358|NCT01787266||1|pregnant women
33017359|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
33416366|NCT01317251|Experimental|Control diet|Diet without dairy products
33416367|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
33416368|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
33416369|NCT04739865|Experimental|Psilocybin|25mg Psilocybin
33416370|NCT05078333|No Intervention|exercise|All patients in all three groups will perform 15 sessions (for 3 weeks, weekdays), cervical area isometric strengthening exercises, active ROM exercises and stretching exercises for 15 minutes a day with the same physiotherapist.
33416371|NCT05078333|Active Comparator|exercise+HILT|In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
33017360|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
33017361|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
33416372|NCT05078333|Active Comparator|exercise+dry needling|In addition to the exercise program, dry needling (on 3 trigger points on the bilateral trapezius muscle) will be applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
33017362|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
33017363|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
33017364|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
33017365|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
33017366|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
33017367|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
33017368|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
33017369|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
33017370|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
33017371|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
33017372|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
33017373|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
33017374|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
33017375|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
33017376|NCT01787448|Experimental|Ibuprofen 5% topical gel|
33017377|NCT01787448|Experimental|Topical gel vehicle|
33017378|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
33017379|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
33017380|NCT01787474|Experimental|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
33017381|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
33017382|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
33017383|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
33017384|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
33105981|NCT04393922|Experimental|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by ~2 weeks.~Visit 1 and Visit 2~Single intervention of:~Startle + exercise training OR sham-Startle + exercise training~Pre and post measurements:~MVCs~MEP recruitment curves~iMEPs~StartReact~Participant reported spasticity~MAS~PSAD~KINARM~Neuromechanical hand and/or leg testing~GRASSP~TRI-HFT~10-meter walk test~Pendulum Test"
32739252|NCT04997889|Active Comparator|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
33017385|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
33017386|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
33017387|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
33017388|NCT01787565||painPREMIER cohort|
33017389|NCT01787565||Control cohort|
33017390|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
33017391|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
33017392|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
33017393|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
33017394|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
33017395|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
33017396|NCT01787695|No Intervention|No treatment (covered)|
33017397|NCT01787695|Active Comparator|UVA1|
33017398|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
33017399|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
33017400|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
33017401|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
33017402|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
33017403|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
33017404|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
33017405|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
33017406|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
33017407|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
33017408|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
33017409|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
33017410|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
33017411|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
32739253|NCT04492085||Primary hospital or clinics|
32739254|NCT04492085||Secondary hospital|
33017412|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
33017413|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
33017414|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
33017415|NCT01787877||Stroke patients reporting to the ER|
33017416|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
33017417|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
33017418|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
33017419|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
33017420|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
33017421|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
33017422|NCT01787955|Experimental|Braun anastomosis group|
33017423|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
33017424|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
33017425|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA < 400 copies/mL are also eligible; however, the HIV-1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV-1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
33017426|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
33017427|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
33017428|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
33017429|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
33017430|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
33017431|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
33017432|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
33017433|NCT01788072|Active Comparator|Intranasal Oxytocin|
33017434|NCT01788072|Placebo Comparator|Placebo|
33017435|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
33017436|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
33017437|NCT01788098||Healthy controls|Healthy control subjects
33017438|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
33017439|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
33017440|NCT01788124||Metal Speculum|exam with metal speculum
33017441|NCT01788124||Plastic Speculum|exam with plastic speculum
33017442|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
33017443|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
33017444|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
33017445|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
32739255|NCT04492085||Tertiary hospital|
32739256|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
33326032|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
33017446|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
33326033|NCT03895944|Experimental|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
33326034|NCT03895944|Experimental|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
33326035|NCT03895944|Experimental|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
33326036|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33326037|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33326038|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33326039|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
32739257|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
33017447|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
33017448|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
33017449|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
33017450|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
33017451|NCT01788280|Experimental|All participants|All enrolled participants
33017452|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
33017453|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
33017454|NCT01788319|Experimental|lasertrabeculoplasty|
33017455|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
33017456|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
33017457|NCT01788345|Experimental|non-invasive ventilation|
33017458|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
33017459|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
33017460|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
33017461|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
33017462|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
33017463|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
33017464|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
33017465|NCT01788397|No Intervention|Control group|No intervention in the control group
33017466|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
33017467|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
33017468|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
33326040|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33017469|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
33017470|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
33017471|NCT01788488|No Intervention|Standard Therapy|
33017472|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
33017473|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
33017474|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
33017475|NCT01788514|Other|Videogame|Subject will play educational videogame
33105982|NCT04389905|Experimental|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
33105983|NCT04389905|No Intervention|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
33105984|NCT04389905|No Intervention|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
33105985|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
33105986|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
33105987|NCT04305834|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33105988|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
33105989|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
33105990|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
33105991|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
33105992|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
33105993|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
33105994|NCT04360460|Experimental|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
33105995|NCT04360460|Active Comparator|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
33105996|NCT05388591|Experimental|Musicotherapy|
33105997|NCT05388591|No Intervention|Standard care|
33105998|NCT04355234|Experimental|all patients|
33105999|NCT04355234|Experimental|patients who presented a SARS-CoV-2 infection confirmed by PCR|
33106000|NCT04297137|Experimental|Mycoprotein|Ingestion of 30 g mycoprotein drink
33106001|NCT04297137|Experimental|Spirulina|Ingestion of 30 g spirulina protein drink
33106002|NCT04297137|Experimental|Chlorella|Ingestion of 30 g chlorella protein drink
33106003|NCT04297137|Experimental|Pea|Ingestion of 30 g pea protein drink
33106004|NCT04297137|Experimental|Lupin|Ingestion of 30 g lupin protein drink
33106005|NCT04297137|Active Comparator|Milk|Ingestion of 30 g milk protein
33106006|NCT04335305|Experimental|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
33106007|NCT04335305|No Intervention|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
33106008|NCT04288089|Experimental|Palbociclib + H3B-6545 (Dose Escalation and Dose Expansion)|Participants will receive Palbociclib 75, 100, 125 milligram (mg) capsules or tablets, orally, once daily from Days 1 to 21 followed by 7 days off treatment in 28-day cycles along with H3B-6545 150, 300, 450 mg capsules or tablets, orally, once daily from Days 1 to 28 in 28-day cycles in dose escalation part. Based on MTD or RP2D determined for H3B-6545 in combination with palbociclib in dose escalation part, participants will continue to receive study treatment in dose expansion part until PD, development of unacceptable toxicity, or withdrawal of consent (up to 24 months).
33106009|NCT04287738|Experimental|Navigated Care|Telephone-based collaborative dementia care navigation
33106010|NCT04287738|No Intervention|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
33106011|NCT04253951|Experimental|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
33416373|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
33416374|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
33017476|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
33017477|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
32739258|NCT05002101|Active Comparator|zinc group|The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
33017478|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
33017479|NCT01788540|No Intervention|Control|No intervention
33017480|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
33017481|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
33017482|NCT01788605|Experimental|ramosetron|
33017483|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
33017484|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
33017485|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
33017486|NCT01788644||No treatment (observational study)|
33017487|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
33017488|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
33017489|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
33017490|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
33017491|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
33017492|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
33017493|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
33017494|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
33017495|NCT01788709|Active Comparator|B|MoviPrep (split dose)
33017496|NCT01788722||Group 1|
33017497|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
33017498|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
33017499|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
33416375|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
33416376|NCT04736511|Other|Healthy volunteers|Handball players
33416377|NCT05250635||Patients underwent thoracic surgery|Patients underwent thoracic surgery and general anesthesia with usage of DLET are included. Those patients with abnormal breath sound, pulmonary disease or history of cardiothoracic surgery are excluded.
33416378|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
33416379|NCT04769388|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
33416380|NCT04769388|Active Comparator|Osimertinib 80mg QD|All patients randomized into this will only receive Osimertinib 80mg.
33017500|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
33017501|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
33017502|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
33017503|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
33017504|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
33017505|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
33017506|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
33017507|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
33017508|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
33017509|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
33017510|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
33017511|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
33017512|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
33017513|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
33017514|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
33017515|NCT01788852||HIV negative adolescents|HIV negative adolescents
33017516|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
33017517|NCT01788878|Experimental|Questionnaires|completion of questionnaires
33017518|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
33017519|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
33017520|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
33017521|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
33017522|NCT01788956||ICU Patients|80 subjects (male and female)
33017523|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
33017524|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
33017525|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
33017526|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
33017527|NCT01788995||Cohort|
33017528|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
33017529|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
33416381|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
33017530|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
33017531|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
33017532|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
33326041|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33326042|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
33326043|NCT03899376|Active Comparator|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
33326044|NCT03899376|Experimental|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
33326045|NCT01258764|Active Comparator|Lisinopril|
33326046|NCT01258764|Active Comparator|Hydrochlorothiazide|
33326047|NCT03895788|Experimental|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
32866530|NCT04820400|Experimental|VR-360 group (VR-group)|Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
32866531|NCT04820400|No Intervention|Control Group (standard treatment)|The patients will receive standard treatment and will be instructed to use the same button to indicate their pain.
32866532|NCT05619042||Presence / absence of CAC|Participants with or without a level/extension of CAC
33326048|NCT01258842|Experimental|B. lactis HN019|
33326049|NCT01258842|Placebo Comparator|Placebo|
33326050|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
33326051|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
33326052|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
33326053|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
33326054|NCT03899142|Experimental|human hepatitis B immunoglobulin|once, i.m.
33326055|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
33326056|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
32866533|NCT00587561|Experimental|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
32866534|NCT00587561|Other|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
32866535|NCT00581633|Experimental|1|saline infusion for sodium loading
32866536|NCT04318938|Active Comparator|Standard Arm with any available ALK TKI|"st line: Any approved 2nd-generation TKI according to investigator's choice~nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
32866537|NCT04318938|Experimental|Experimental Arm with Brigatinib|"st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8~nd line: Any available ALK TKI according to investigator's choice"
32866538|NCT00581321|Experimental|1|water ingestion
32866539|NCT00580385|Experimental|1|
32866540|NCT04826562|Experimental|dolutegravir/lamivudine|dolutegravir/lamivudine
32866544|NCT05618964|Experimental|Group A: Deep Neck Flexors & Extensors exercises|"Group A Patients will receive:~Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine~Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position~Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
32866545|NCT05618964|No Intervention|Group B: Standardized Physical Therapy|"Standardized Physiotherapy treatment will be:~Hot pack for 10 minutes,~SNAG manual therapy at Cervical spine 6 repetitions for 60 seconds.~Superficial neck muscles (upper trapezius, Levator scapulae, Pect.Major) stretching for 3 times with 30 seconds and~Neck isometrics 10 times with 6 seconds hold. Both groups will come thrice per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed"
32866546|NCT04826406|Experimental|Camrelizumab+Apatinib|
32866547|NCT05617872|Placebo Comparator|Saline|20ml saline infused into duodenum and suction for 5 minutes via EUS
32866548|NCT05617872|Experimental|Vinegar 20ml|20ml vinegar infused into duodenum and suction for 5 minutes via EUS
32866549|NCT05617872|Active Comparator|Vinegar 40ml|40ml vinegar infused into duodenum and suction for 5 minutes via EUS
32866550|NCT05617872|Active Comparator|Vinegar 20ml, 0-5min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the first 5 minutes
32866551|NCT05617872|Active Comparator|Vinegar 20ml, 5-10min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the 5-10 minutes
32866552|NCT05617872|Active Comparator|Vinegar 20ml, 10-15min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the 10-15 minutes
32866553|NCT04198727|Experimental|DPD activity|
33416382|NCT03294109|Experimental|study|liposomal bupivacain
33416383|NCT03294109|No Intervention|control|no intervention
33416384|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
33416385|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
33416386|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
33017533|NCT01789086|Experimental|Liraglutide|
33017534|NCT01789086|Placebo Comparator|Placebo|
33017535|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
33017536|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
33017537|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
33017538|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
33017539|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
33017540|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
33017541|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
33017542|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
33017543|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
33017544|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
33017545|NCT01789216|Placebo Comparator|Placebo|"Standard pain management + perioperative intravenous placebo & oral placebo.~Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
33017546|NCT01789216|Active Comparator|NSAID|"Standard pain management + perioperative intravenous ketorolac & oral placebo.~The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
33017547|NCT01789216|Active Comparator|Gabapentinoid|"Standard pain management + perioperative intravenous placebo & oral pregabalin.~The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
33017548|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
33017549|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
33017550|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
33017551|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
33017552|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
33017553|NCT01789307|Experimental|sucrose|sucrose oral ingestion
33017554|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
33017555|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
33017556|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
33017557|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
33017558|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
33017559|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
33017560|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
33017561|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
33017562|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
33326057|NCT03892902|Experimental|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
33017563|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
33017564|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
33017565|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
33017566|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
33017567|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
33017568|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
33017569|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
33017570|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
33017571|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
33017572|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
33017573|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
33017574|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
33017575|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
33017576|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
33017577|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
33017578|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
33017579|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
33017580|NCT01789619||Extended release tacrolimus (Advagraf®)|
33017581|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
33017582|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
33017583|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
33017584|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
33106012|NCT04253951|Sham Comparator|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
33326058|NCT03892902|Experimental|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
33326059|NCT03892902|Experimental|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
33326060|NCT03892902|Experimental|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
33326061|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
33326062|NCT03895866||Group B|High-risk HPV non-infection
33326063|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
33326064|NCT03892668|Experimental|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
33326065|NCT03892668|Active Comparator|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
33326066|NCT03892668|Placebo Comparator|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
33326067|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
33326068|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
33017585|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
33327196|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
33327197|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
33327198|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
33017586|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
33017587|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
33017588|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
33017589|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
33017590|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
33017591|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
33017592|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
33017593|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
33017594|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
33017595|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
33017596|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
33017597|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
33017598|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
33017599|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
33017600|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
33017601|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
33017602|NCT01789788|Placebo Comparator|Placebo|
33017603|NCT01789788|Experimental|RO6811135|
33017604|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
33017605|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
33017606|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
33017607|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
33017608|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
33017609|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
33017610|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
33017611|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
33017612|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
33017613|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
33017614|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
33017615|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
33017616|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
33416387|NCT04727931||Newly diagnosed epileptic patients|Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
33416388|NCT04727931||Normal controls|Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
33416389|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
33017617|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
33017618|NCT01789957|Experimental|Open-label AC2993|
33017619|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
33017620|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
33017621|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
33017622|NCT01790061|Experimental|Traditional treatments|Oral Tubing
33017623|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
33017624|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
33017625|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
33017626|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
33017627|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
33017628|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
33017629|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
33017630|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
33017631|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
33017632|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
33017633|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
33017634|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
33017635|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
33017636|NCT01791855|Experimental|Healthy Volunteers|
33017637|NCT01791855|Experimental|Mild Renal Impairment|
33017638|NCT01791855|Experimental|Moderate renal impairment|
33017639|NCT01791855|Experimental|Severe renal impairment|
33017640|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
33017641|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
33017642|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
33017643|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
33017644|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
33017645|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
33017646|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
33017647|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
33017648|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
33017649|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
33017650|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
33017651|NCT01792414|Active Comparator|Active TES|Active TES
33017652|NCT01792414|Sham Comparator|Sham TES|Sham TES
33017653|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
33017654|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
33017655|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
33017656|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
33017657|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
33017658|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
33327199|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
33017659|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
33017660|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
33017661|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
33017662|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
33017663|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
33017664|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
33017665|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
33017666|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
33017667|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
33017668|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
33017669|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
33017670|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
33017671|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
33017672|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
33017673|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
33017674|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
33017675|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
33017676|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
33017677|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
33017678|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
33017679|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
33017680|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
33017681|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
33017682|NCT01794182|Placebo Comparator|Matching Placebo|Participants received a bolus dose of matching placebo over 2 minutes, followed by a continuous matching placebo infusion for 72 hours.
33017683|NCT01794182|Experimental|Glyburide for Injection|Participants received a 0.13 mg bolus dose of glyburide over 2 minutes, followed by a 0.16 mg/hr continuous infusion for 6 hours and than a 0.11 mg/hr for 66 hours for a total dosing period of 72 hours.
33017684|NCT01794208|Experimental|treatment 1|Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
33017685|NCT01794208|Experimental|treatment 2|Follitropin Epsilon 75 IU QD s.c.
33327200|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
33017686|NCT01794208|Experimental|treatment 3|Follitropin Epsilon 112.5 IU QD s.c.
33017687|NCT01794208|Experimental|treatment 4|Follitropin Epsilon 150 IU QD s.c.
33017688|NCT01794208|Experimental|treatment 5|Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
33416390|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
33416391|NCT03970811|Experimental|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
33416392|NCT03970811|Active Comparator|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
33017689|NCT01794208|Active Comparator|treatment 6|Follitropin alfa 150 IU QD s.c.
33416393|NCT03446040|Experimental|Part A Dose Escalation: BMS-986258|
33416394|NCT03446040|Experimental|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
33416395|NCT03446040|Experimental|Part B Dose Escalation: BMS-986258 + nivolumab|
33416396|NCT03446040|Experimental|Part C Cohort Expansion: BMS-986258 + nivolumab|
33416397|NCT05192421|Active Comparator|Level 1|Wellness Education
33017690|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
33017691|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
33017692|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
33017693|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
33017694|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
33017695|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
33017696|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
33017697|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
33017698|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
33017699|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
33017700|NCT01794754|Other|Control|Care as usual
33017701|NCT01794754|Experimental|Occupational therapy|Occupational therapy
33017702|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
33017703|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
33017704|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
33017705|NCT01795248|No Intervention|Control|Control without previous GDM.
33017706|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
33017707|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
33017708|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
33017709|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
33017710|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
33017711|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
33017712|NCT01795872|Other|Several diagnostic procedures|
33017713|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
33017714|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
33017715|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
33017716|NCT01796223|Active Comparator|control|Psychotherapy as usual
33017717|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
33416398|NCT05192421|Experimental|Level 2|Wellness Education + Pre-recorded Exercise Videos
33416399|NCT05192421|Experimental|Level 3|Wellness Education + Livestream Exercise Classes
33416400|NCT01350895||Experimental Group|
33416401|NCT01350895||Control Group|
33416402|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
33416403|NCT03963869|Experimental|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
33416404|NCT03963869|Active Comparator|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
33017718|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
33017719|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
33017720|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
33017721|NCT01796353|Active Comparator|usual care|usual care
33017722|NCT01796379|Experimental|High Intensity Interval Training|
33017723|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
33017724|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
33017725|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
33017726|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
33017727|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
33017728|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
33017729|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
33017730|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
33017731|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
33017732|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
33017733|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
33017734|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
33017735|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
33017736|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
33017737|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
33017738|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1 week~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month)~Crossover to standard podiatry visits~Study visit 6 (18 months)~Study visit 7 (24 months)"
33017739|NCT01796808|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6months)~Study Visit 2 (12 months)~Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1 week~Post op study visit 2 (1 month post procedure)~Post op study visit 3 (2 month post procedure)~Post op study visit 4 (6 month post procedure)~Post op study visit 5 (12 month post procedure)"
33017740|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
33017741|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
33017742|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
33017743|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
33017744|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
33017745|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
33017746|NCT01797289|Experimental|First episode of loss of consciousness|
33017747|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
33017748|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
33416405|NCT03963869|Active Comparator|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
33416406|NCT05208801|Sham Comparator|Control|a sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle
33017749|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
33017750|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
33416407|NCT05208801|Active Comparator|Morphine|
33017751|NCT01797796|Experimental|PF-06305591|
33017752|NCT01797796|Placebo Comparator|Placebo|
33017753|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
33017754|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
33017755|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
33017756|NCT01798355|Experimental|Cognitive Behavioral Therapy|
33017757|NCT01798355|Active Comparator|Treatment as usual|
33017758|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
33017759|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
33017760|NCT01798680|Placebo Comparator|Placebo|
33017761|NCT01798823||EIB+A+|"children with EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
33017762|NCT01798823||EIB+A-|"children with EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
33017763|NCT01798823||EIB-A+|"children without EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
33017764|NCT01798823||EIB-A-|"children without EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
33017765|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
33017766|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
33017767|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
33017768|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
33017769|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33017770|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
33017771|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
33017772|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
33017773|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
33017774|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
33017775|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
33017776|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
33017777|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
33017778|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
33416408|NCT05208801|Experimental|Morphine+bupivicaine|
33416409|NCT03614598|Active Comparator|LMA-UNIQUE™|
33416410|NCT03614598|Active Comparator|LMA-SUPREME™|
33106013|NCT05388045|Experimental|Recovery PROM|All study participants will complete the Recovery PROM instrument.
33106014|NCT04252859|Experimental|All Participants|"One session of [18F]FES PET/CT Imaging - COMPLETED~Up to three imaging sessions:~[18F] FES-PET/CT exam,~Optional [18F]FDG PET/CT scan and~Optional follow-up [18F] FES-PET/CT exam."
33106015|NCT05371899|Other|Chiauranib|Take 50 mg ChiauranibCioroni capsules orally on an empty stomach once a day, every day; except on the eighth day 8, when you start taking Cioroni capsules liquid, take a single oral dose of ~50 mg/about 100 Ci of [14C]Chiauranib suspensionCioroni solution once on an empty stomach.
33106016|NCT04248530|Experimental|Renal denervation therapy group|The subject treated by renal denervation by using DENEX system.
33106017|NCT04255212|Experimental|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
33106018|NCT04255212|Placebo Comparator|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
33106019|NCT04255212|Other|Control group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
33106020|NCT04255212|Experimental|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
33106021|NCT04207268|Experimental|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
33106022|NCT04207268|Placebo Comparator|Nutrition Advice alone|Participate in only nutrition advice
33106023|NCT05353803|Experimental|People older than 60 years with heart failure and living at home.|People older than 60 years with heart failure and living at home.
33106024|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
33106025|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
33106026|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
33106027|NCT04176029||Children admitted with confirmed severe malaria|
33106028|NCT05353140|Experimental|Percutaneous left atrial appendage occlusion (LAAO)|"Device: The WATCHMAN/WATCHMAN FLX device~Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 45 days, followed by Aspirin 100mg QD + Clopidogrel 75mg QD for 10.5 months after LAAO"
33106029|NCT05353140|Active Comparator|Novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy|Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 12 months
33106030|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
33106031|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
33106032|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
33327201|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
33327202|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
33327203|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
33327204|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
33327205|NCT01284894|Other|Conventional manometry|
33327206|NCT01284894|Experimental|High resolution manometry|
33327207|NCT01288170|Other|Nebcinal Tobi|crossover design
33327208|NCT01288170|Other|Tobi Nebcinal|crossover design
33327209|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
33327210|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
33327211|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
33416411|NCT03614598|Active Comparator|I-GEL®|
33416412|NCT02064140|Experimental|Neuromuscular blocking agent|
33416413|NCT03963011|No Intervention|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
33416414|NCT03963011|Active Comparator|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
33416415|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
33416416|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
33416417|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
33416418|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
33416419|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
33416420|NCT02868216|No Intervention|Without management training|No anger management training
33017779|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
33017780|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
33017781|NCT01800006||Group 1|
33017782|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
33017783|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
33017784|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
33017785|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
33017786|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
33017787|NCT01800032||Optic Glioma|NF1 associated optic glioma
33017788|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
33017789|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
33017790|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
33017791|NCT01800097|Placebo Comparator|placebo|placebo
33017792|NCT01800097|Active Comparator|Modafinil|Modafinil
33017793|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
33017794|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
33017795|NCT01800136|Experimental|rTMS; tDCS|
33017796|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
33017797|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
33017798|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
33017799|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
33017800|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
33017801|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
33017802|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
33416421|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
33416422|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
33416423|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
33416424|NCT05190627|Experimental|Loratadine treatment on rapamycin|Loratadine (oral administration, daily dose 10mg) in LAM patients that are treated with rapamycin
33416425|NCT05190627|Placebo Comparator|Placebo treatment on rapamycin|Placebo (oral administration, daily dose 10 mg) in LAM patients that are treated with rapamycin
33416426|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
33416427|NCT02064218||healthy subjects|healthy subjects
33416428|NCT01345799|Experimental|TRK-170 Low Dose|
33416429|NCT01345799|Experimental|TRK-170 Middle Dose|
33416430|NCT01345799|Experimental|TRK-170 High Dose|
33416431|NCT01345799|Placebo Comparator|Placebo|
33017803|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
33017804|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
33017805|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
33017806|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
33017807|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
33017808|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
33017809|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
33017810|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
33017811|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
33017812|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
33416432|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
33017813|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
33017814|NCT01800357|Experimental|mildronate|infusion of mildronate
33017815|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
33017816|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
33017817|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
33416433|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
33416434|NCT01358851|Experimental|1|Drug Las41005
33416435|NCT01358851|Other|2|Cryotherapy
33416436|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
33416437|NCT03619941|Placebo Comparator|Placebo|
33416438|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
33416439|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
33416440|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
33416441|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
33416442|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
33416443|NCT01351051||No endometriosis|
33416444|NCT01351051||Superficial endometriosis|
33416445|NCT01351051||Endometrioma|
33416446|NCT01351051||Deep infiltrating endometriosis|
33106033|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
33106034|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
33106035|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
33106036|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
33106037|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
33106038|NCT04138940|Experimental|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
33416447|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
33416448|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
33416449|NCT04418115|Experimental|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
33416450|NCT04418115|No Intervention|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
33416451|NCT01343381|Active Comparator|Hepalean Heparin|
33416452|NCT01343381|Active Comparator|PPC Heparin|
33106039|NCT04138940|Experimental|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
33106040|NCT04138940|Experimental|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
33106041|NCT04138940|Experimental|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
33106042|NCT05345613|Experimental|Tranexamic Acid group|standard solution for injection with TXA and without adrenaline
33106043|NCT05345613|Placebo Comparator|Standard therapy group|standard solution for injection including adrenaline
33106044|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
33106045|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
33106046|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
33106047|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
33416453|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
33416454|NCT02064686|No Intervention|TAE|
33416455|NCT04369755|Other|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
33106048|NCT04208802||Non-smokers|Non-smoking volunteers
33106049|NCT04679519|Active Comparator|Control|Control group that was not given a supplement.
33106050|NCT04679519|Experimental|BCAA|Supplement group that was given Branched Chain Amino Acids (BCAA).
33106051|NCT04679519|Experimental|Leucine|Supplement group that was given Leucine.
33106052|NCT04679519|Experimental|HMB|Supplement group that was given β-Hydroxy β-methylbutyric acid (HMB)
33106053|NCT05345067|Experimental|Experimental: Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
33106054|NCT05345067|Experimental|Experimental: Laughter yoga session parts-2|Warm-up exercises (10 minutes)
33106055|NCT05345067|Experimental|Experimental: Laughter yoga session parts-3|Childish games (10 minutes)
33416456|NCT01343537|Experimental|Monitoring|
33416457|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
33416458|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
33416459|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
33416460|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
33416461|NCT05188365|Active Comparator|group A|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
33416462|NCT05188365|Sham Comparator|Group B|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days.
33017818|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
33017819|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
33017820|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
33017821|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
33017822|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
33017823|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
33017824|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
33017825|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
33017826|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
33017827|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
33017828|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
33017829|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
33017830|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
33017831|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
33017832|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
33017833|NCT01800487|Placebo Comparator|placebo|"Placeo~1 tab three times a day for 4 weeks"
33017834|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
33017835|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
33017836|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
33017837|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
33017838|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
33017839|NCT01800578||Bispectral Index Group|
33017840|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
33106056|NCT05345067|Experimental|Experimental: Laughter yoga session parts-4|Laughter exercises (15 minutes)
33416463|NCT05061251|Experimental|BAY 2402234|Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.
33416464|NCT01351129|Experimental|Formulation 1|
33416465|NCT01351129|Experimental|Formulation 2|
33416466|NCT01351129|Experimental|Formulation 3|
33416467|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
33017841|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
33017842|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
33017843|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
33017844|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
33017845|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
33017846|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
33017847|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
33017848|NCT01800617|Experimental|Liothyronine, Sodium|
33017849|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
33017850|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
33017851|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
33017852|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
33017853|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
33017854|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
33017855|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
33017856|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
33017857|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
33017858|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
33017859|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
33017860|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
33017861|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
33017862|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
33017863|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
33106057|NCT04679792||operated|Patients Under 18 years of age who are operated for Chiari Malformation on the basis of routine neurosurgical assessment.
33017864|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
33017865|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
33017866|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
33017867|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
33017869|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
33017870|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
33017871|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
33017872|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
33017873|NCT01800799|No Intervention|Normal control|Normal control
33017874|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
33017875|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
33017876|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
33017877|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
33017878|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
33017879|NCT01800864|Other|Normal|Normal weight subjects
33017880|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
33017881|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
33017882|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
33017883|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
33017884|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
33017885|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
33017886|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
33017887|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
33017888|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
33017889|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
33017890|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
33017891|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
33017892|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
33017893|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
33017894|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
33017895|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
33017896|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
33017897|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
33017898|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
33017899|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
33017900|NCT01801176|Experimental|Initial monitoring group|
33017901|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
33017902|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
33017903|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
33017904|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
33017905|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
33017906|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
33017907|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
33017908|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
33017909|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
33017910|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
33017911|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
33017912|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
33017913|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
33017914|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
33017915|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
33017916|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
33017917|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
33017918|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
33017919|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
33017920|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
33017921|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
33017922|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
33017923|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
33017924|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
33017925|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
33017926|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
33017927|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
33416468|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
33017928|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
33017929|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
33416469|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
33416470|NCT05187195|Experimental|Telerehabilitation-video group|This group will perform their exercises with prepared personalized exercise videos through the telerehabilitation system 3 days a week for 8 weeks.
33416471|NCT05187195|Experimental|Telerehabilitation-brochure group|This group will perform exercises with personalized exercise brochures defined through the telerehabilitation system 3 days a week for 8 weeks.
33017930|NCT01801527|Experimental|Telerehabilitation group|
33017931|NCT01801527|No Intervention|Control group|Information about usual care
33017932|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
33017933|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
33017934|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
33017935|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
33017936|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
33017937|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
33017938|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
33017939|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
33017940|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
33017941|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
33017942|NCT01801605|Active Comparator|on|active session
33017943|NCT01801605|Placebo Comparator|off|fictive session
33017944|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
33017945|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
33017946|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
33017947|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
33017948|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
33017949|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
33017950|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
33017951|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
33017952|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
33017953|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
33017954|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
33017955|NCT01801748|Experimental|oral wheat challenge|
33017956|NCT01801761||develop group|previous COPD study
33017957|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
33416472|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
33416473|NCT04415177|Experimental|VR Program A|Software with active intervention
33416474|NCT04415177|Active Comparator|VR Program B|Software without active intervention
33106058|NCT04679792||non operated|Patients Under 18 years of age who are not operated for Chiari Malformation on the basis of routine neurosurgical assessment.
33416475|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
33416476|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
33017958|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
33017959|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
33017960|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
33017961|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
33017962|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
33017963|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
33017964|NCT01801826||Treatment|Treatment with CryoTouch IV device
33017965|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
33017966|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
33017967|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
33017968|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
33017969|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
33017970|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
33017971|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
33017972|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
33017973|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation~Size of municipality"
33017974|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
33017975|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
33017976|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
33017977|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
33017978|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
33017979|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
33017980|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
33017981|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
33017982|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
33017983|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
33017984|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
33017985|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
33017986|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
33106059|NCT04679363|Experimental|Active release technique group|Active release technique group (ART group) will receive Oscillatory mobilization with active release technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
33416477|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
33416478|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
33416479|NCT01343615|Active Comparator|carotid stenting|
33416480|NCT01343615|Active Comparator|carotid endarterectomy|
33416481|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
33017987|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
33017988|NCT01802177|No Intervention|No treatment (covered)|
33017989|NCT01802190||Deafness patients|Deafness patients
33017990|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
33017991|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
33017992|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
33017993|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
33017994|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
33017995|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
33017996|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
33017997|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
33017998|NCT01802307|Experimental|Focal Therapy|
33017999|NCT01802359||Mirodenafil|
33018000|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
33018001|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
33018002|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
33018003|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
33018004|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
33018005|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
33018006|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
33018007|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
33018008|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
33018009|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
33018010|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
33018011|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
33018012|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
33018013|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
33018014|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
33018015|NCT01802541|Experimental|DAG oil|
33018016|NCT01802541|Placebo Comparator|TAG oil|
33018017|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
33018018|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
33018019|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
33106060|NCT04679363|Experimental|Post isometric relaxation group|Post isometric relaxation group (PIR group) will receive Oscillatory mobilization with post isometric relaxation technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
33416482|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
33416483|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
33416484|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
33416485|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
33416486|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
33416487|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
33416488|NCT01358929|Experimental|1|
33018020|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
33018021|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
33018022|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
33018023|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
33018024|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
33018025|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
33018026|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
33018027|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
33018028|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
33018029|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
33018030|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~Duration : 6 cycles (3 months) Second phase (sequence #2B)~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~Duration : until PD or limiting toxicity Reintroduction (sequence #3)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~Regimen : aflibercept + fluoropyrimidine~Duration : until PD or limiting toxicity"
33018031|NCT01802697|Experimental|IdeS|Intravenous infusion
33018032|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
33018033|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
33018034|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
33018035|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
33018036|NCT01802801||1|
33018037|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
33018038|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
33416489|NCT01358929|Placebo Comparator|2|
33018039|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
33416490|NCT01345877|Other|gender|
33416491|NCT01568229|Experimental|AMG 747 - Dose 1|
33018040|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
33018041|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
33018042|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
33018043|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
33018044|NCT01802853|Experimental|A: RO6811135 s.c.|
33018045|NCT01802853|Active Comparator|B: RO6811135 i.v.|
33018046|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
33018047|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
33018048|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
33018049|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
33018050|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
33018051|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
33018052|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
33018053|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
33018054|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
33018055|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
33018056|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
33018057|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
33018058|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
33018059|NCT01802996|No Intervention|Arm II|Only chemotherapy
33018060|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
33018061|NCT01803022||Low Molecular Weight Heparin|
33018062|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
33018063|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
33018064|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
33018065|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
33018066|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
33018067|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
33018068|NCT01803061|No Intervention|Usual care|
33018069|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
33018070|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
33416492|NCT01568229|Experimental|AMG 747 - Dose 2|
33416493|NCT01568229|Experimental|AMG 747 - Dose 3|
33416494|NCT01568229|Placebo Comparator|Placebo Comparator|
33416495|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
33416496|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
33416497|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
33416498|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
33416499|NCT02066012||group T|group T composed of lean subjects
33416500|NCT05384028|Experimental|Experimental|Patients in the experimental group will receive full-course case management from a multidisciplinary team from admission to 6 months after discharge
33416501|NCT05384028|Active Comparator|Control|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
33416502|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
33416503|NCT03939533|Experimental|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
33416504|NCT03939533|Experimental|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
33416505|NCT03939533|Experimental|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent [mg/kg] weekly dose
33416506|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
33018071|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
33018072|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
33416507|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
33416508|NCT05134857|Experimental|ZON+ST|Zonisamide (ZON) plus standard treatment (ST)
33416509|NCT05134857|Placebo Comparator|PLO+ST|Placebo (PLO) plus standard treatment (ST)
33416510|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
33018073|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
33018074|NCT01803126||atherosclerosis|No treatment.
33018075|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
33018076|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
33018077|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
33018078|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
33018079|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
33018080|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
33018081|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
33018082|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
33018083|NCT01803217|Experimental|mode switch to atrial pacing|
33018084|NCT01803217|Active Comparator|atrioventricular hysteresis function|
33018085|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
33018086|NCT01803230|Experimental|creatine|creatine supplementation
33018087|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
33018088|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
33018089|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
33018090|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
33018091|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
33018092|NCT01803256||Control subjects:|15 adolescent healthy control subjects
33018093|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
33018094|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
33018095|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
33018096|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
33018097|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
33018098|NCT01803321|Experimental|Cohort 1|Dose 1
33018099|NCT01803321|Experimental|Cohort 2|Dose 2
33018100|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
33018101|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
33018102|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
33106061|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
33416511|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
33416512|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
33416513|NCT05250557||Deferral of PCI group|Patients who undergo successful FFR pullback tracing and have a vessel determined to defer revascularization after FFR measurement will be included.
33416514|NCT05250557||PCI group|Patients who undergo successful FFR pullback tracing and have a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) will be included.
33106062|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
33106063|NCT04679246|Experimental|General Intervention|The strategies will be implemented in the three intervention elementary schools. The schools were conveniently chosen for the size of the student population. In addition to having a sufficient population, it was important that the authorities of each school site agreed to participate.
33106064|NCT04679246|Experimental|Subsample intervention|A group will be randomly selected from each school grade from the intervention schools, and within each chosen group 12 children will be randomly selected per group (48 children in total per school).
33106065|NCT04679246|No Intervention|Control|Three primary schools were selected from a close locality (Villa Corona, Jalisco). This was chosen because it is similar in relation to the social, economic, and geographical context to the locality of intervention. The schools were selected for the similarity in the size of the student population of the intervention schools.
33106066|NCT04090775|Other|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
33106067|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
33106068|NCT05309265|Other|Breast cancer patients with work difficulties|Breast cancer patients with work difficulties can receive any of the three types of support, or a combination of these: information, occupational therapy and social support, in order to overcome barriers and return to work/continue to work
33106069|NCT04166136|Active Comparator|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
33106070|NCT04166136|Active Comparator|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
33416515|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
33416516|NCT04519437|Experimental|REGN10933+REGN10987|
33106071|NCT04166136|Active Comparator|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
33416517|NCT04519437|Placebo Comparator|Placebo|
33416518|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
33106072|NCT04089839||CP-CML participants initiating dasatinib|
33106073|NCT04151043|Other|Verbal suggestion|
33106074|NCT04151043|Other|No suggestion|
33416519|NCT04299997||171 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR unit or on a 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
33416520|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
33106075|NCT04045145|Experimental|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
33106076|NCT01232296|Experimental|TKI258|capsule
33106077|NCT01232296|Experimental|Sorafenib|tablet
33106078|NCT04041011|Experimental|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
33106079|NCT04041011|Experimental|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
33106080|NCT04041011|Experimental|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
33106081|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
33106082|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
33106083|NCT04136379||Clinic monitoring|Patients who attend a warfarin clinic for management of their INR
33106084|NCT04136379||Home monitoring|Patients who undertake home monitoring of their INR using a CoaguChek POC device
33106085|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
33106086|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
33106087|NCT04134390|Experimental|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
33106088|NCT04016558|Experimental|StreamLine|Diabetes education, behavioral management
33106089|NCT04016558|Experimental|TunedIn|Diabetes distress reduction, emotion regulation techniques.
33106090|NCT04016558|Experimental|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
33106091|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
33106092|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
33106093|NCT04684095|No Intervention|routine follow-up group|only according to the routine follow-up frequency to the center visit.
33106094|NCT04684095|Experimental|ePRO group|ePRO group : self-evaluation in ePRO mode was accepted, and the patients were visited in the center according to the routine follow-up frequency.
33106095|NCT03998501|Experimental|Active|5-week CBTm
33106096|NCT03998501|No Intervention|Waitlisted|Waitlisted (will receive 5-week CBTm 3 months after).
33106097|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
33106098|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
33106099|NCT05307744|Experimental|PS128|Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.
33106100|NCT05307744|Placebo Comparator|Placebo|Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.
33106101|NCT05307744|No Intervention|Normal control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
33106102|NCT03973697|Experimental|Single dose of PMT|
33106103|NCT03973697|Experimental|Two doses of PMT|Administered within 24 hours
33416521|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
33416522|NCT03907943|Other|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
33416523|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
33416524|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
33416525|NCT01359085|Active Comparator|Pregabalin|
33416526|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
33416527|NCT04280523|Experimental|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
33106104|NCT00552942|Experimental|1|surgery plus omentectomy
33106105|NCT00552942|No Intervention|2|standard gastric bypass
33106106|NCT03969095|Experimental|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
33106107|NCT03969095|Active Comparator|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
33106108|NCT00554138|Placebo Comparator|1|
33106109|NCT00554138|Experimental|2|
33106110|NCT03923387|Experimental|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
33106111|NCT03923387|Active Comparator|Manual compression|Manual compression hemostasis
33106112|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
33106113|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
33106114|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
33106115|NCT04116528|Other|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
33106116|NCT04116528|Active Comparator|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
33416528|NCT04322357|No Intervention|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
33018103|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
33018104|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
33018105|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
33018106|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018107|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018108|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018109|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018110|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018111|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
33018112|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
33018113|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
33018114|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
33018115|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
33018116|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
33018117|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
33018118|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
33018119|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
33018120|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
33018121|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
33018122|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
33018123|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
33018124|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
33018125|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
33018126|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
33018127|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
33018128|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
33018129|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
33018130|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
33018131|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
33018132|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
33106117|NCT05288907||Pruritus ani patients|Adult patients with pruritus ani (rectal itch) treated with lidocaine ointment
33416529|NCT04322357|Active Comparator|Twice weekly glucocorticoid with or without exercise|"Patients will be randomized to one of 2 groups:~Twice weekly prednisone alone for 12 months~Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training."
33416530|NCT04322357|Active Comparator|Daily glucocorticoid with exercise|Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.
33416531|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
33416532|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
33018133|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
33018134|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
33018135|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
33018136|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
33018137|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
33018138|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
33018139|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
33018140|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
33018141|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
33018142|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
33018143|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
33018144|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
33018145|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
33018146|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
33018147|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
33018148|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
33018149|NCT01803776|Experimental|lifestyle counseling|Physical activity and dietary counseling
33018150|NCT01803776|No Intervention|Control|No active intervention
33018151|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
33018152|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
33018153|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
33018154|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
33018155|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
33416533|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
33416534|NCT04443153|Experimental|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAM
33018156|NCT01803828|Active Comparator|Drug Group (Tadalafil)|Tadalafil 20 mg
33018157|NCT01803828|Placebo Comparator|Placebo Group (PLC)|Placebo 20 mg
33018158|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
33018159|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
33018160|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
33018161|NCT01803893||Embryo culture media|measurement using immunoassay
33018162|NCT01803893||maternal serum|measurement by immunoassay
33018163|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
33416535|NCT04443153|Experimental|Escalation|Subjects randomized to this arm will proceed from SAM to PF to DSS
33416536|NCT05189041|Other|Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
33416537|NCT05189041|Other|Non Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Non Ruptured Cerebral Aneurysm
33018164|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
33018165|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
33018166|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
33018167|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
33018168|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
33018169|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
33018170|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
33018171|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
33018172|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
33018173|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
33018174|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
33018175|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
33018176|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
33018177|NCT01804010|Placebo Comparator|Placebo|Placebo administration
33018178|NCT01804023||Healthy women|
33018179|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
33018180|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
33018181|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
33018182|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
33018183|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
33018184|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
33416538|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
33416539|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
33416540|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
33416541|NCT01351363|Experimental|Electrical pain threshold measrement patients|
33416542|NCT04250571|Experimental|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
33018185|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
33018186|NCT01804218|Placebo Comparator|Placebo|Placebo
33018187|NCT01804218|Experimental|Active, nadolol|Active
33018188|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
33018189|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
33018190|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
33018191|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
33018192|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
33018193|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
33018194|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
33018195|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
33018196|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
33018197|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
33018198|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
33018199|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
33018200|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
33018201|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
33018202|NCT01804400|Experimental|QAW039 + Montelukast|
33018203|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
33018204|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
33018205|NCT01804400|Active Comparator|Montelukast|
33018206|NCT01804400|Placebo Comparator|Placebo|
33018207|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
33018208|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
33018209|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
33018210|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
33018211|NCT01804452||Subjects with a diagnosis of PSP or CBD|
33018212|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
33018213|NCT01804491||Control group|Healthy age matched control subjects
33018214|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
33018215|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
33018216|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
33018217|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
33018218|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
33018219|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
33018220|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
33018221|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
33018222|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
33018223|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
33018224|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
33018225|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
33018226|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
33416543|NCT04250571|Experimental|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
33018227|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
33018228|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
33018229|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
33018230|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
33018231|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
33018232|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
33018233|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
33018234|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
33018235|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
33018236|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
33018237|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
33018238|NCT01804647||33 RRMS patients|No study treatments administered
33018239|NCT01804647||9 PPMS patients|No study treatments administered
33018240|NCT01804647||12 SPMS patients|No study treatments administered
33018241|NCT01804647||4 CIS patients|No study treatments administered
33018242|NCT01804660||25 healthy volunteers|No study treatments administered
33018243|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
33018244|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
33018245|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
33018246|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
33018247|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
33018248|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
33018249|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
33018250|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
33018251|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
33018252|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
33018253|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
33018254|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
33018255|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
33018256|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
33018257|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
33018258|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
33018259|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
33018260|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
33018261|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
33018262|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
33018263|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
33018264|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
33018265|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
33018266|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
33018267|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
33018268|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
33018269|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
33018270|NCT01805011||50 healthy mothers|
33018271|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
33018272|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
33018273|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
33018274|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
33018275|NCT01805102||maternal serum|measurement by immunoassay
33018276|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
33018277|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
33018278|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
33018279|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
33018280|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
33018281|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
33018282|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
33018283|NCT01805167|Other|subjects with a cochlear implant|
33018284|NCT01805193||Suspected coronary heart disease|
33018285|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
33018286|NCT01805219||healthy subjects|
33018287|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
33018288|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
33018289|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
33018290|NCT01805245|Active Comparator|Health Education Control|
33018291|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
33018292|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
33018293|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
33018294|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
33018295|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
33018296|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
33018297|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
33018298|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
33018299|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
33018300|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
33018301|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
33416544|NCT04250571|Experimental|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
33416545|NCT05384106|Experimental|Avela™ (R)-1,3-Butanediol|3 servings of Avela™, with consumption of each serving separated by 30 minutes and each serving providing 11.5 g of (R)-1,3-butanediol [total intake of 34.5 g of (R)-1,3-butanediol].
33018302|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
33018303|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
33018304|NCT01805401|Sham Comparator|Sham tDCS|
33018305|NCT01807507||Healthy Volunteers|
33018306|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
33018307|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
33018308|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
33018309|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
33018310|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
33018311|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
33018312|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
33018313|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
33018314|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
33018315|NCT01807715||Study group|Women seeking first trimester surgical abortion
33018316|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
33018317|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
33018318|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
33018319|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
33018320|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
33018321|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
33018322|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
33018323|NCT01807793|No Intervention|Care as usual|Receive care as usual
33018324|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
33018325|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
33018326|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
33018327|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
33018328|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
33018329|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
33018330|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
33018331|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
33018332|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
33018333|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
33018334|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
33018335|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
33018336|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
33018337|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
33018338|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
33018339|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
33416546|NCT05109351|Experimental|Participating to Boost Meal Participation|Intervention group will receive marketing and communication strategies developed by researchers, community organizations, parents, school nutrition directors, and other school stakeholders.
33416547|NCT05109351|No Intervention|Control|Usual care.
33018340|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
33018341|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
33018342|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
33018343|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
33018344|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
33018345|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
33018346|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:~1a 200 mg PO BID TAK700~1b 200mg PO BID TAK + glucocorticoid~1a 300mg PO BID TAK700 starting dose~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
33018347|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
33018348|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
33018349|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
33018350|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
33018351|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
33018352|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
33018353|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
33018354|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
33018355|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
33018356|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
33018357|NCT01808157|Placebo Comparator|vehicle|Placebo
33018358|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
33018359|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
33018360|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
33018361|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
33018362|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
33018363|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
33018364|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
33018365|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
33018366|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
33018367|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
33018368|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
33018369|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
33416548|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
33018370|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
33018371|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
33018372|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
33018373|NCT01808365||Study cohort|
33018374|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
33416549|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
33416550|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
33416551|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
33018375|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
33416552|NCT03132805|No Intervention|Control|Schools which receive no intervention
33416553|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
33416554|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
33416555|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
33018376|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
33018377|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
33018378|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
33018379|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
33018380|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
33018381|NCT01808443|Experimental|laser|laser, at most 4 times
33018382|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
33018383|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
33018384|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
33018385|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
33018386|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
33018387|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
33018388|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
33018389|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
33018390|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
33018391|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
33018392|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
33018393|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
33018394|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
33018395|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
33018396|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
33018397|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
33018398|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
33018399|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
33018400|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
33018401|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
33018402|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
33018403|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
33416556|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
33018404|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
33018405|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
33018406|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
33018407|NCT01808742||Treatment|Treatment with CryoTouch III device
33018408|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
33018409|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
33018410|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
33018411|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
33018412|NCT01808833||Frail patients|
33018413|NCT01808833||Non-frail patients|
33018414|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
33018415|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
33018416|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
33018417|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
33018418|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
33018419|NCT01808872||Heart Failure|
33018420|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
33018421|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
33018422|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
33018423|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
33018424|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
33018425|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
33018426|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
33018427|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
33018428|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
33018429|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
33018430|NCT01809002|Active Comparator|Collagen Nerve Cuff|
33018431|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
33018432|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
33018433|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
33018434|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
33018435|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
33018436|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
33018437|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
33018438|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
33018439|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
33018440|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
33018441|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
33018442|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
33018443|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
33018444|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
33018445|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
33018446|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
33018447|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018448|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018449|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018450|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018451|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018452|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018453|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
33018454|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
33018455|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
33018456|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
33018457|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
33018458|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
33018459|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
33018460|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
33018461|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
33018462|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
33018463|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
33018464|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
33018465|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
33018466|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
33018467|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
33018468|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
33018469|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
33018470|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
33018471|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
33018472|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
33018473|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
33018474|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
33018475|NCT01809392|No Intervention|no decitabine|
33018476|NCT01809418|Experimental|keePAP|
33018477|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
33018478|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
33018479|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
33018480|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
33018481|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
33018482|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
33018483|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
33018484|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
33018485|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
33018486|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
33018487|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
33018488|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
33018489|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
33018490|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
33018491|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
33018492|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
33018493|NCT01809522|No Intervention|Standard radical prostectomy|
33018494|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
33018495|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
33018496|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
33018497|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
33018498|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
33018499|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
33018500|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
33018501|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
33018502|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
33018503|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
33018504|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
33018505|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
33018506|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
33018507|NCT01809717|Experimental|Weight Lifting Exercises|
33018508|NCT01809730||Cardiovascular risk|patients with CV disease
33018509|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
33018510|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
33018511|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
33018512|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
33018513|NCT01809756|Active Comparator|Caphosol|
33018514|NCT01809756|No Intervention|No intervention|
33018515|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
33018516|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
33018517|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
33018518|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
33018519|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
33018520|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
33018521|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
33018522|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
33018523|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
33018524|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
33018525|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
33018526|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
33018527|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
33018528|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
33018529|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
33018530|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
33018531|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
33018532|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
33018533|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
33018534|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
33018535|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
33018536|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
33018537|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
33018538|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
33018539|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
33018540|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
33018541|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
33018542|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
33018543|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
33018544|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
33018545|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
33018546|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
33018547|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
33018548|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
33018549|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
33018550|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
33018551|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
33018552|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
33018553|NCT01810159|Experimental|ICC|Integrated collaborative care
33018554|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
33018555|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
33018556|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
33018557|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
33018558|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
33018559|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
33018560|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
33018561|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
33018562|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
33018563|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
33018564|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
33018565|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
33018566|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
33018567|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
33018568|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
33018569|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
33018570|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
33018571|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
33018572|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
33018573|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
33018574|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
33018575|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
33018576|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
33018577|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
33018578|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
33018579|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
33018580|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
33327212|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
33327213|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
33018581|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
33018582|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
33018583|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
33018584|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
33018585|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
33018586|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
33018587|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
33018588|NCT01810471|Experimental|ankle supports|
33018589|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
33018590|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
33018591|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
33018592|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
33018593|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
33018594|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
33018595|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
33018596|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
33018597|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
33018598|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
33018599|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
33018600|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
33018601|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
33018602|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
33018603|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
33018604|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
33018605|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
33018606|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
33018607|NCT01810653|Experimental|Macrogol (Transipeg)|
33018608|NCT01810653|Active Comparator|Macrogol (Forlax)|
33018609|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
33018610|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
33018611|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
33018612|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
33018613|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
33018614|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
33018615|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
33018616|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
33018617|NCT01810770|Experimental|Radium-223 dichloride|
33018618|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
33018619|NCT01810796|Placebo Comparator|Placebo|Placebo
33018620|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
33018621|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
33018622|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
33018623|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
33018624|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
33018625|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
33018626|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
33018627|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
33018628|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
33018629|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
33018630|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
33018631|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
33018632|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
33018633|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
33018634|NCT01810900|No Intervention|non-treatment|
33018635|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
33018636|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
33106118|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
33018637|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
33018638|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
33018639|NCT01810965|Experimental|Cohort|
33018640|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
33018641|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
33018642|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
33018643|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
33018644|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
33018645|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
33018646|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
33018647|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
33018648|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
33018649|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
33018650|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
33018651|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
33018652|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
33018653|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
33018654|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
33018655|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
33018656|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
33018657|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
33018658|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
33018659|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
33018660|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
33018661|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
33018662|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
33018663|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
33018664|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
33018665|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
33018666|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
33018667|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
33018668|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
33018669|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
33018670|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
33018671|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
33018672|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
33018673|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
33018674|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
33018675|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
33018676|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
33018677|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
33018678|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
33018679|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
33018680|NCT01811446|Experimental|Obese|Subjects with BMI > 30
33018681|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
33018682|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
33018683|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
33018684|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
33018685|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
33018686|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
33018687|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
33018688|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
33018689|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
33018690|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
33018691|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
33018692|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
33018693|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
33018694|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
33018695|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
33018696|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
33018697|NCT01811615|No Intervention|toothbrushing alone|negative control
33018698|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
33018699|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
33018700|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
33018701|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~Structured and regularly occuring assessments for intimate partner violence (IPV);~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
33018702|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
33018703|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
33018704|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
33018705|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
33018706|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
33018707|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
33018708|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
33018709|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
33018710|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
33018711|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
33018712|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
33018713|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
33018714|NCT01811797|Sham Comparator|Control group|
33018715|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
33018716|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
33018717|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
33018718|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
33018719|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
33018720|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
33018721|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
33018722|NCT01811888||Patients with knee osteoarthritis|
33018723|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
33018724|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
33018725|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
33018726|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
33018727|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
33327214|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
33018728|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
33018729|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
33018730|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
33327215|NCT01175538|Experimental|Lactulose|
33327216|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
33018731|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp~B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp~C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp~D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp~E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp~F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation."
33018732|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
33018733|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
33018734|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
33018735|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
33018736|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
33018737|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
33018738|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
33018739|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
33018740|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
33018741|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
33018742|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
33018743|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
33018744|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
33018745|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
33018746|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
33018747|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
33018748|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
33018749|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
33018750|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
33018751|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
33018752|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
33018753|NCT01812265|Experimental|PF-06305591 Dose 1|
33018754|NCT01812265|Experimental|PF-06305591 Dose 2|
33018755|NCT01812265|Placebo Comparator|Placebo|
33018756|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
33018757|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
33018758|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
33018759|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
33018760|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
33018761|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
33018762|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
33018763|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
33018764|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
33018765|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
33018766|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
33327217|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
33327218|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
33327219|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
33327220|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
33327221|NCT01288326||A|
33327222|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
33327223|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
33327224|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
33416557|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~Laparoscopic lavage and drainage~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
33416558|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
33018767|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
33416559|NCT03612882||Western University Students|Online questionnaire
33416560|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
33416561|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
33416562|NCT05102643|Experimental|Test Product|SARS-CoV-2 DNA Vaccine at 1mg and 2mg, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
33416563|NCT05102643|Placebo Comparator|Reference Product|Matching placebo, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
33416564|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
33416565|NCT04725474|Experimental|Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination|Up to 5 dose levels with CTL-002 administered as IV monotherapy and in combination with a CPI
33018768|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
33018769|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
33018770|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
33018771|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
33018772|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
33018773|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
33018774|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
33018775|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
33018776|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
33018777|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
33018778|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
33018779|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
33018780|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
33018781|NCT01812538|Placebo Comparator|Placebo|Placebo
33018782|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
33018783|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
33018784|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
33416566|NCT04725474|Experimental|Phase 2 (Part B; expansion): CTL-002 + Checkpoint Inhibitor Combination|At defined dose level(s) with CTL-002
33416567|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
33416568|NCT02260232|No Intervention|control|
33326069|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
33326070|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
33326071|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
33018785|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
33018786|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
33018787|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
33018788|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
33018789|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
33018790|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
33018791|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
33018792|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
33018793|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
33018794|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
33018795|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
33018796|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
33018797|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33018798|NCT01812746|Experimental|BIND-014|
33018799|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
33018800|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
33018801|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
33018802|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
33018803|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
33018804|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
33018805|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
33018806|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
33018807|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
33018808|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
33018809|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
33018810|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
33018811|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
33018812|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
33018813|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
33018814|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
33018815|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
33018816|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
33018817|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
33018818|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
33018819|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
33018820|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
33018821|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
33018822|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
33018823|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
33018824|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
33018825|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
33018826|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
33018827|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
33018828|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
33018829|NCT01813084|Experimental|Part A: single dose escalation|
33018830|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
33018831|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
33018832|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
33018833|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
33018834|NCT01813123|No Intervention|Control|
33018835|NCT01813123|Experimental|Intervention|RealTeen
33018836|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
33018837|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
33018838|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
33018839|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
33106119|NCT03912272|Placebo Comparator|Usual Care Control|Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.
33326072|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
33018840|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
33018841|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
33018842|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
33018843|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
33018844|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
33018845|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
33018846|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
33018847|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
33018848|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
33018849|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
33018850|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
33018851|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
33018852|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
33018853|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
33018854|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
33018855|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
33018856|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
33018857|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
33018858|NCT01813279|Experimental|patients|
33018859|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
33018860|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
33018861|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
33018862|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
33018863|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
33018864|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
33018865|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
33018866|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
33018867|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
33018868|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
33018869|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
33018870|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
33018871|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
33018872|NCT01813487|Other|HBsAg vaccine with Entecavir|
33018873|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
33018874|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
33018875|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
33018876|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
33018877|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
33018878|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
33018879|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
33018880|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
33018881|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
33018882|NCT01813539|Experimental|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
33326073|NCT03898752|Experimental|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
33018883|NCT01813539|Experimental|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
33018884|NCT01813539|Experimental|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
33018885|NCT01813539|Experimental|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
33018886|NCT01813539|Experimental|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
33018887|NCT01813539|Experimental|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
33018888|NCT01813539|Experimental|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
33018889|NCT01813539|Experimental|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
33018890|NCT01813539|Experimental|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
33018891|NCT01813539|Experimental|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
33018892|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
33018893|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
33018894|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
33018895|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
33018896|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
33018897|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
33018898|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
33018899|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
33018900|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
33018901|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
33018902|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
33018903|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
33018904|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
33018905|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
33018906|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
33018907|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
33018908|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
33018909|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
33018910|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
33018911|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
33018912|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
33018913|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
33018914|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
33326074|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
33326075|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
33018915|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
33018916|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
33018917|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
33018918|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
33018919|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
33018920|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
33018921|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
33018922|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
33018923|NCT01813799|Experimental|DA-9801 300mg|
33018924|NCT01813799|Experimental|DA-9801 600mg|
33018925|NCT01813799|Experimental|DA-9801 900mg|
33018926|NCT01813799|Placebo Comparator|Placebo|
33018927|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
33018928|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
33018929|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
33018930|NCT01813825||Female >=45 years, negative margins, DCIS|
33018931|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
33018932|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
33018933|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
33018934|NCT01813851|No Intervention|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
33018935|NCT01813851|Experimental|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
33326076|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
33018937|NCT01813877|No Intervention|Standard Diagnostics without PET|
33018938|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
33018939|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
33018940|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
33018941|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
33018942|NCT01813916|No Intervention|proteomic analysis|
33018943|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
33018944|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
33018945|NCT01813968|No Intervention|Control|Standard operating technique
33018946|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
33326077|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
33326078|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
33018947|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
33018948|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
33018949|NCT01813994|Placebo Comparator|Control group|Without simvastatin
33018950|NCT01813994|Experimental|Statin group|With simvastatin
33018951|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
33018952|NCT01814033|Active Comparator|Control Group|Other: Control Group
33018953|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
33018954|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
33326079|NCT03898830|Experimental|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
33018955|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
33018956|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
33018957|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
33018958|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
33018959|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
33018960|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
33018961|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
33018962|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
33018963|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
33018964|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
33018965|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
33018966|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
33018967|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
33018968|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
33018969|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
33018970|NCT01814254||Receiving hemodialysis|
33018971|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
33018972|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
33018973|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
33018974|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
33018975|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
33018976|NCT01814306|Active Comparator|Supreme|Supreme LMA
33018977|NCT01814306|Active Comparator|Proseal|Proseal LMA
33326080|NCT01255644|Experimental|Antiviral drug|
33326081|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
33326082|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
33326083|NCT05119374|Experimental|Investigational SenseGuard Device|All subjects use SenseGuard Device for twice daily monitoring of respiratory parameters.
33018978|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
33018979|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
33018980|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
33018981|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
33018982|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
33018983|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
33018984|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
33018985|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
33018986|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
33018987|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
33018988|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
33018989|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
33018990|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
33018991|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
33018992|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
33018993|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
33018994|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
33018995|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
33018996|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
33018997|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
33018998|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
33018999|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
33019000|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
33019001|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
33019002|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
33019003|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
33019004|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
33019005|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
33019006|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
33019007|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
33326084|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
33326085|NCT03898674|Experimental|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
33327225|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
33326086|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
33019008|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
33019009|NCT01814631||Aloka|image quality and resolution
33326087|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
33326088|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
33326089|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
33019010|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
33326090|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
33326091|NCT01152060||prednisone|
33326092|NCT01152060||prednisone and anti-virus|
33326093|NCT01257984|Experimental|Arm 1|
33326094|NCT01257984|Experimental|Arm 2|
33326095|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
33019011|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
33019012|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
33019013|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
33019014|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
33019015|NCT01814709|Experimental|Itraconazole Arm|
33019016|NCT01814709|Experimental|Rifampin Arm|
33019017|NCT01814735|Experimental|Brown rice|Brown Rice
33019018|NCT01814735|Active Comparator|White rice|White rice
33019019|NCT01814826|Experimental|MLN4924 and Azacitidine|
33019020|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
33019021|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
33019022|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
33019023|NCT01814852|Sham Comparator|Control Group|
33019024|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
33019025|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
33019026|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
33019027|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
33019028|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
33019029|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
33019030|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
33019031|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
33019032|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
33019033|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
33019034|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
33019035|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
33019036|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
33019037|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
33019038|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
33019039|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
33019040|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
33019041|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
33019042|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
33019043|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
33326096|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
33326097|NCT03895164|Placebo Comparator|Standard NE|Control Group will receive standard nutrition education package from primary health care.
33326098|NCT03895164|Experimental|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
33326099|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
33326100|NCT01258062|Placebo Comparator|Placebo|
33327226|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
33019044|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
33019045|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
33019046|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
33019047|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
33019048|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
33019049|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33019050|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33019051|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33019052|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
33019053|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
33019054|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
33019055|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
33019056|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
33019057|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
33019058|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
33019059|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
33019060|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
33019061|NCT01815164|Active Comparator|Educational intervention|Educational intervention
33019062|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
33019063|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
33019064|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
33019065|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
33019066|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
33019067|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
33019068|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
33019069|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
33019070|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
33019071|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
33019072|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
33019073|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
33019074|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
33019075|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
33327227|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
33327228|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
33327229|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
33327230|NCT01178190||lung cancer|
33327231|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
33019076|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
33019077|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
33019078|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
33019079|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
33019080|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
33019081|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
33019082|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
33019083|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
33019084|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
33019085|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
33019086|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
33019087|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
33019088|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
33019089|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
33019090|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
33019091|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
33019092|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
33019093|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
33019094|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
33019095|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
33019096|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
33019097|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
33019098|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
33019099|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
33019100|NCT01815567||controlled hypertension|hypertension with medication controlled
33019101|NCT01815567||uncontrolled hypertension|non-controlled hypertension
33019102|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
33019103|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
33019104|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
33019105|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
33019106|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
33019107|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
33019108|NCT01815619|Experimental|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
33019109|NCT01815619|Active Comparator|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
33019110|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
33019111|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
33019112|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
33327232|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
33327233|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
33327234|NCT03435640|Experimental|NKTR-262 + bempegaldesleukin or + bempegaldesleukin with nivolumab|Phase 1: NKTR-262 in escalating doses, combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a recommended Phase 1b dose for NKTR-262 + bempegaldesleukin with nivolumab, followed by a dose-confirmation cohort.
33019113|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
33019114|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
33019115|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
33019116|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
33019117|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
33019118|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
33019119|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
33019120|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
33019121|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
33019122|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
33019123|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
33019124|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
33019125|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
33019126|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
33019127|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~Patient 60 years of age and older,~No previous hearing aid"
33019128|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
33019129|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
33019130|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
33019131|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
33019132|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
33019133|NCT01815827|Experimental|Japanese Healthy volunteers|
33019134|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
33019135|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
33019136|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
33327235|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
33019137|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
33019138|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
33019139|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
33019140|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
33019141|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
33019142|NCT01815931||ED patients|
33019143|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
33019144|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
33019145|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
33019146|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
33019147|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
33019148|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
33326101|NCT03895398|Experimental|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
33019149|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
33019150|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
33019151|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
33019152|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
33019153|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
33019154|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
33019155|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
33019156|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
33019157|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
33019158|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
33019159|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
33019160|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
33019161|NCT01816126||one-operator technique|
33019162|NCT01816126||two-operator technique|
33019163|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
33019164|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
33019165|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
33019166|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
33019167|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
33019168|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
33019169|NCT01816269||Patients with scaling and patients without scaling|No drug
33019170|NCT01816269||Helicobacter eradicated or non-eradicated|
33019171|NCT01816282|Experimental|Evicel|
33019172|NCT01816282|No Intervention|Control|
33019173|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
33019174|NCT01816321|Active Comparator|recombinant FSH|
33019175|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
33019176|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
33019177|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
33019178|NCT01816347||Routine PCI patients|
33019179|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
33019180|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
33019181|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
33019182|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
33019183|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
33019184|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
33019185|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
33019186|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
33019187|NCT01816399||Routine coronary angiography patients|
33019188|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
33326102|NCT03895398|No Intervention|control arm|no intervention is given to this arm
33019189|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
33019190|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
33019191|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
33019192|NCT01816438||dysplasia or colorectal lesion|300 patients
33019193|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
33019194|NCT01816503||Fentanyl matrix|
33019195|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
33019196|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
33019197|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
33019198|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
33019199|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
33019200|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
33019201|NCT01816542|Other|patch tests on healthy skin|
33019202|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
33019203|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
33019204|NCT01816568|Active Comparator|Group 1|SILS appendectomy
33019205|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
33019206|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
33019207|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
33019208|NCT01816607||Rectal cancer|
33019209|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
33019210|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
33019211|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
33019212|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
33019213|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
33019214|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
33019215|NCT01816672|Other|Usual and Customary Care|Standard of care
33019216|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
33019217|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
33019218|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
33019219|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
33019220|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
33019221|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
33019222|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
33019223|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
33326103|NCT01255878|Experimental|stabilization splint|
33326104|NCT01255878|Experimental|Gabapentine|
33326105|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
33326106|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
33326107|NCT01259154||RFITT+UPPP|
33326108|NCT01259154||UPPP|
33019224|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
33019225|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
33231930|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
33326109|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
33019226|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019227|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019228|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019229|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019230|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019231|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
33019232|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
33019233|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
33019234|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
33019235|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
33019236|NCT01816854||Patients with PAD|
33019237|NCT01816867||Patients with a ventral hernia|
33019238|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
33019239|NCT01816919|Experimental|eNose breath samples|
33019240|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
33019241|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
33019242|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
33019243|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
33019244|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
33019245|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
33019246|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
33019247|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
33019248|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
33019249|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
33019250|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
33019251|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
33019252|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
33019253|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
33019254|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
33019255|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
33019256|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
33019257|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
33019258|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
33019259|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
33231927|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~CNI renal toxicity.~Hepatic fibrosis on biopsy.~CNI neurologic toxicity.~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
33231928|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
33231929|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
33019260|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
33019261|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
33019262|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
33019263|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
33019264|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
33019265|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
33019266|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
33019267|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
33019268|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
33019269|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
33019270|NCT01817231||breast cancer cases|breast cancer cases versus controls
33019271|NCT01817244|Experimental|care management type 1|2-month care management
33019272|NCT01817244|Active Comparator|care management type 2|6-month care management
33019273|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
33019274|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
33019275|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33019276|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
33019277|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
33019278|NCT01817296|Experimental|Single arm|
33019279|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
33019280|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
33019281|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
33019282|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
33019283|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
33019284|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
33019285|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
33019286|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
33019287|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
33231931|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
33019288|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
33019289|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
33019290|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
33019291|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
33019292|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
33019293|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
33019294|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
33019295|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
33019296|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
33019297|NCT01817478|Experimental|medical staff|
33019298|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
33019299|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
33019300|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
33019301|NCT01817569||Byetta|
33019302|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
33019303|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
33019304|NCT01817621|Experimental|Experimental Intervention|
33019305|NCT01817621|Active Comparator|TAU Condition|
33019306|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
33019307|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
33019308|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
33019309|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
33019310|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
33019311|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
33019312|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
33019313|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
33019314|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
33019315|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
33019316|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
33019317|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
33019318|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
33019319|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
33019320|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
33019321|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
33019322|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
33019323|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
33019324|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
33019325|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
33019326|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
33019327|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
33019328|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
33019329|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
33019330|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
33019331|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
33019332|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
33019333|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
33019334|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
33019335|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
33019336|NCT01817868||Group 1|
33019337|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
33019338|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
33019339|NCT01817933|Experimental|Physical therapy|
33019340|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
33019341|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
33019342|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
33019343|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
33019344|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
33019345|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
33019346|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
33019347|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
33019348|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
33019349|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
33019350|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
33019351|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
33019352|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
33019353|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
33019354|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
33019355|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
33019356|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
33019357|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
33019358|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
33019359|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
33019360|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
33019361|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
33019362|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
33327236|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
33327237|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
33327238|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
33327239|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
33327240|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
33327241|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
33019363|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
33019364|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
33019365|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
33019366|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
33019367|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
33019368|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
33019369|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
33019370|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
33019371|NCT01818128|Experimental|Bent shape of bronchial tip|
33019372|NCT01818180|Experimental|Urell|
33019373|NCT01818180|Placebo Comparator|Placebo|
33019374|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
33019375|NCT01818219|Experimental|Study|
33019376|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
33019377|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
33019378|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
33019379|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
33019380|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
33019381|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
33019382|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
33019383|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
33019384|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
33019385|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
33019386|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
33019387|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
33019388|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
33019389|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
33019390|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
33019391|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
33019392|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
33019393|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
33019394|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
33019395|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
33019396|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
33019397|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
33019398|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
33106120|NCT03912272|Experimental|High-intensity Interval Training Group|HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.
33019399|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
33019400|NCT01818479|Experimental|All participants|
33019401|NCT01818505||Gouty arthritis|Patient with gouty arthritis
33019402|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
33019403|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
33019404|NCT01818544|Experimental|BAY85-8501|
33019405|NCT01818544|Placebo Comparator|Placebo|
33019406|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
33019407|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
33019408|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
33019409|NCT01818570|Active Comparator|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
33019410|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
33019411|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
33019412|NCT01818609|Experimental|Step Reduction|"Step reduction:~Take less than 1500 steps/d~No disease"
33019413|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
33019414|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
33019415|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
33019416|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
33019417|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
33019418|NCT01818674|Experimental|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
33019419|NCT01818674|Experimental|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
33019420|NCT01818674|No Intervention|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
33019421|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
33019422|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
33019423|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
33019424|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
33019425|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
33019426|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
33019427|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
33019428|NCT01818817||GA group|In this group of patients general anesthesia is performed.
33019429|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
33019430|NCT01818830||sepsis|SIRS+infection
33019431|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
33019432|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
33019433|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
33019434|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
33019435|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
33019436|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
33019437|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
33019438|NCT01818895||Withdrawal of mechanical ventilation|
33019439|NCT01818908|Experimental|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
33019440|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
33019441|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
33019442|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
33019443|NCT01818947||Gefitinib|
33019444|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
33019445|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
33019446|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
33019447|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
33019448|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
33019449|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
33019450|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
33019451|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
33019452|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
33019453|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
33019454|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
33019455|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
33019456|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
33231932|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
33231933|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
33019459|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
33106121|NCT04683861|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
33231934|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
33231935|NCT04101474|Active Comparator|Ketamine group|half of participants will take ketamine
33019460|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
33019461|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
33019462|NCT01819103||Acute myocardial infarction|Drug Adherence
33019463|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
33019464|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
33019465|NCT01819155|Experimental|TIV|Children randomized to receive TIV
33019466|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
33019467|NCT01819207|Experimental|TEG group|
33019468|NCT01819220|Active Comparator|amlodipine/valsartan|
33019469|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
33019470|NCT01819246|Active Comparator|Pheresis Treatment Arm|
33019471|NCT01819246|Sham Comparator|Control Arm|
33019472|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
33019473|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
33019474|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
33019475|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
33019476|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
33019477|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
33019478|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
33019479|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
33019480|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
33019481|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
33019482|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
33019483|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
33019484|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
33019485|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
33019486|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
33019487|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
33019488|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
33019489|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
33019490|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
33019491|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
33019492|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
33019493|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
33019494|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
33019495|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
33019496|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
33019497|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
33019498|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
33019499|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
33019500|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
33019501|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
33019502|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
33019503|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
33019504|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
33019505|NCT01819545||Alzheimer's disease|no intervention
33019506|NCT01819545||Mild cognitive impairment|no intervention
33019507|NCT01819545||Normal aging|no intervention
33019508|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
33019509|NCT01819571|Experimental|Normal diastolic function group|
33019510|NCT01819571|Active Comparator|Diastolic dysfunction group|
33019511|NCT01819584||Patients below 15 years old|
33019512|NCT01819584||Patients above 15 years old|
33019513|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
33019514|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
33019515|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
33019516|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
33019517|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
33019518|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
33019519|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
33019520|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
33019521|NCT01819649|Placebo Comparator|Yeast tablet|
33019522|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
33019523|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
33019524|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
33019525|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
33019526|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
33019527|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
33019528|NCT01819701|Placebo Comparator|Placebo|starch
33019529|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
33019530|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
33019531|NCT01819740||patients with suspected prostate cancer|
33019532|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
33019533|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
33019534|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
33019535|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
33019536|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
33019537|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
33019538|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
33019539|NCT01819818||Paliperidone palmitate|
33019540|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
33019541|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
33019542|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
33019543|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
33019544|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
33019545|NCT01819896||pacemakers and defibrillators|
33019546|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
33019547|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
33019548|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
33019549|NCT01819974|No Intervention|Control|The normal procedure at the ward
33019550|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
33019551|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
33019552|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
33019553|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
33019554|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
33019555|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
33019556|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
33019557|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
33019558|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
33019559|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
33019560|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
33019561|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
33019562|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
33019563|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
33019564|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
33019565|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
33019566|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
33019567|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
33019568|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
33019569|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
33019570|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
33019571|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
33019572|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
33019573|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
33019574|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
33019575|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
33019576|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
33019577|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
33019578|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
33019579|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
33231936|NCT04101474|No Intervention|Placebo group|the other half of participants will not take any drugs
33326110|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
33326111|NCT03892434|Active Comparator|Bevacizumab|
33326112|NCT03892434|Active Comparator|Dexamethasone|
33327242|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
32739259|NCT05002101|Placebo Comparator|placebo group|The placebo was non-nutritious and vitamin-free, designed to be identical to the zinc syrup in colour, odour, consistency and taste. Zinc and placebo syrups were packaged in similar bottles.
33019580|NCT01820169|Experimental|Single arm|
33019581|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
33019582|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
33019583|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
33019584|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
33019585|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
33019586|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
33019587|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
33019588|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
33019589|NCT01820234|Other|In-person dermatology evaluation|Health care modality
33019590|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
33019591|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
33019592|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
33019593|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
33019594|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
33019595|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
33019596|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
33019597|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
33019598|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
33019599|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
33019600|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
33019601|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
33019602|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
33019603|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
33019604|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
33019605|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
33019606|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
33019607|NCT01820403|No Intervention|control|no box lunch provided to participants.
33019608|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
33019609|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
33019610|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
33019611|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
33019612|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
33019613|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
33019614|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
33019615|NCT01820468|No Intervention|Regular inpatient care|
33019616|NCT01820481|Experimental|Treatment 1|
33019617|NCT01820481|Experimental|Treatment 2|
33106122|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
33106123|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
33106124|NCT03911336|Experimental|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
33106125|NCT03911336|Active Comparator|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
33106126|NCT03911336|Active Comparator|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
33106127|NCT04683822|Experimental|Exercise group|Patients who receive telerehabilitaton
33106128|NCT04683822|No Intervention|Control|Patients with routine care
33106129|NCT03911141|No Intervention|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
33106130|NCT03911141|Experimental|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
33106131|NCT03911141|Experimental|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
33106132|NCT03911141|Experimental|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
33106133|NCT04684056||Riva-control group|Routine concentration of Rivaroxaban (Peak)
33106134|NCT04684056||Riva-High group|High concentration of Rivaroxaban (Peak)
33106135|NCT04684056||Riva-Low group|low concentration of Rivaroxaban (Peak)
33106136|NCT04684056||Dabi-control group|Routine concentration of Dabigatran(Peak)
33106137|NCT04684056||Dabi-High group|High concentration of Dabigatran(Peak)
33106138|NCT04684056||Dabi-low group|low concentration of Dabigatran(Peak)
33106139|NCT04684056||Edo-control group|Routine concentration of Edoxaban(Peak)
33106140|NCT04684056||Edo-high group|High concentration of Edoxaban(Peak)
33106141|NCT04684056||Edo-low group|low concentration of Edoxaban(Peak)
33106142|NCT04684134||experimental group|patients with colorectal polyps
33106143|NCT04684134||control group|patients without intestinal diseases
33106144|NCT05288634|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise practice
33106145|NCT05288634|No Intervention|Control|Routine maintenance
33106146|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
33106147|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
33106148|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
33106149|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
33416569|NCT05095857|Active Comparator|S-ketamine|S-ketamine is given as a continuous infusion started at a dose of 2.0 mg/kg/hour. The infusion rate will be re-evaluated after 24 hours, where (1) the infusion will be stopped if 24 hours ensue without SDs, (2) maintained at 2.0 mg/kg/hour if the 24-hour incidence of SDs decreases below the rate of the previous 24 hours but SD is not totally abolished, or (3) increased to 3.0 mg/kg/hour if the incidence of SD is at or above the rate of the previous 24 hours. If the infusion rate has been increased to 3.0 mg/kg/hour, the rate will be returned to 2.0 mg/kg/hour if 24 consecutive hours of ECoG show no SD.
33019618|NCT01820481|Experimental|Treatment 3|
33019619|NCT01820481|Placebo Comparator|Placebo|
33019620|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
33019621|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
33019622|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
33019623|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
33019624|NCT01820533||smokers|
33019625|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
33019626|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
33019627|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
33019628|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
33019629|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33019630|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
33019631|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
33019632|NCT01820676||iUni G2+|iUni G2+ in all patients
33019633|NCT01820689|Experimental|Tympanometry measurement|
33019634|NCT01820702|Active Comparator|defined training programme|
33019635|NCT01820702|No Intervention|Control|
33019636|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
33019637|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
33019638|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
33019639|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
33019640|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
33019641|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
33019642|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
33019643|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
33019644|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
33019645|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
33019646|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
33019647|NCT01820819||Registered or not on the transplantation national waiting list|
33019648|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
33019649|NCT01820832|No Intervention|Control|General treatments.
33019650|NCT01820845||Cohort of children with scoliosis surgery|
33019651|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
33019652|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
33019653|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
33019654|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
33019655|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
33019656|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
33019657|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
33106150|NCT05285436|Experimental|CloudCath detection|Active monitoring of dialysate effluent by the CloudCath System.
33019658|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
33019659|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~real transcranial direct current stimulation (two weeks, five days a week)~a week of wash-out~Sham transcranial direct current stimulation (two weeks, five days a week)~two weeks of wash-out~real repetitive transcranial magnetic stimulation (two weeks, four days a week)~a week of wash-out~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
33019660|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
33019661|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
33019662|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
33019663|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
33019664|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
33019665|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
33019666|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
33019667|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
33019668|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
33019669|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
33019670|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
33019671|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
33019672|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
33019673|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
33019674|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
33019675|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
33019676|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
33019677|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
33019678|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
33019679|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
33019680|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
33019681|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
33019682|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
33019683|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
33019684|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
33019685|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
33019686|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
33019687|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
33019688|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
33019689|NCT01821170|Experimental|Cognitive remediation|
33019690|NCT01821170|Active Comparator|Supportive psychotherapy|
33019691|NCT01821170|Active Comparator|Methylphenidate|
33019692|NCT01821183||hip rotators muscle strength|
33019693|NCT01821183||control group|no intervention
33019694|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
33019695|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
33019696|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
33106151|NCT05263089|Experimental|Intervention|Injectable Universal flowable resin composite
33106152|NCT05263089|Active Comparator|Control|Conventional resin composite
33019697|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
33019698|NCT01821222|No Intervention|Control|The control group received standard care
33019699|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
33019700|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
33019701|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
33019702|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
33019703|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
33019704|NCT01821261|Experimental|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
33019705|NCT01821261|Active Comparator|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
33019706|NCT01821261|Other|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
33019707|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
33019708|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
33019709|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
33019710|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
33019711|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
33019712|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
33019713|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
33019714|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
33019715|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
33019716|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
33019717|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
33019718|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
33019719|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
33019720|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
33019721|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
33019722|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
33019723|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
33019724|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
33019725|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
33019726|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
33019727|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
33019728|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
33019729|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
33019730|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
33019731|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
33019732|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
33019733|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
33416570|NCT05095857|Placebo Comparator|Isotonic saline|Isotonic saline is given as placebo. It will be given as a continuous infusion started at a dose corresponding to a dose of S-ketamine of 2.0 mg/kg/hour, and follow the criteria for increasing/decreasing infusion rates as S-ketamine. The infusion rate is read from a table listing different infusion rates (ml/hour) based on participant weight and if the treatment tier corresponds to a S-ketamine dose of 2 or 3 mg/kg/hour.
33416571|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
33416572|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
33019734|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
33019735|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
33019736|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
33019737|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
33019738|NCT01821638||Older adults with heart failure|Older adults with heart failure
33019739|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
33019740|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
33019741|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
33019742|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
33019743|NCT01821664||Prosthetic vascular graft implantation, follow up|
33019744|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
33019745|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
33019746|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
33019747|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
33019748|NCT01821742||Children requiring fluid bolus on PICU|
33019749|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
33019750|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
33019751|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
33019752|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
33019753|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
33019754|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
33019755|NCT01821846||Liraglutide|
33019756|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
33019757|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
33019758|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
33019759|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
33019760|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
33019761|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
33019762|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
33019763|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
33019764|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
33019765|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
33106153|NCT03850301|Experimental|Etifoxine then XBD173|
33106154|NCT03850301|Experimental|XBD173 then Etifoxine|
33416573|NCT02067962|Other|Juvenile idiopathic arthritis.|Blood sample
33416574|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
33416575|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
33416576|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
33416577|NCT05250479|No Intervention|Control group|44 pregnant women won't receive mindfulness training
33416578|NCT05250479|Experimental|"experimental group mindfulness education"|mindfulness education 44 pregnant women will receive mindfulness training
33416579|NCT01355653|Experimental|Treatment A|thermal therapy
33416580|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
33416581|NCT05033223|Other|Follow-up|
33416582|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
33019766|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
33416583|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
33416584|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
33019767|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
33019768|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
33019769|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
33019770|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
33019771|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
33019772|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
33019773|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
33019774|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
33019775|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
33019776|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
33019777|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
33019778|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
33019779|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
33019780|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
33019781|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
33019782|NCT01822158|Other|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
33019783|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~Discharge medication counseling from a pharmacist~Home medication if needed~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
33019784|NCT01822184||No treatment|Observational non-treatment study
33019785|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
33019786|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
33019787|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
33019788|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
33019789|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
33416585|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
33416586|NCT05013333|Other|AED 3 with Uni-padz|
33416587|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
33416588|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
33019790|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
33019791|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
33019792|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
33019793|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
33019794|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
33019795|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
33019796|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
33019797|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
33019798|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
33019799|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
33019800|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
33019801|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
33019802|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
33019803|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
33019804|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
33019805|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
33019806|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
33019807|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
33019808|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
33019809|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
33019810|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
33019811|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
33019812|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
33019813|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
33019814|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
33019815|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
33019816|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
33019817|NCT01822626|Experimental|motivational counseling|
33019818|NCT01822626|No Intervention|Usual Care|
33019819|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
33019820|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
33019821|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
33019822|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
33019823|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
33019824|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
33019825|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
33019826|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
33019827|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
33106155|NCT04114929|Experimental|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
33106156|NCT04114929|Active Comparator|Standard Care|Patients will be prescribed exercise based on standard guidelines
33326113|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
33326114|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
33326115|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
33019828|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
33019829|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
33019830|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
33019831|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
33019832|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
33019833|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
33019834|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
33019835|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
33019836|NCT01822847||catheterization|patients undergoing elective heart catheterization
33019837|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
33019838|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
33019839|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
33019840|NCT01822873||Normal|
33019841|NCT01822873||Age-related macular degeneration|
33019842|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
33019843|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
33019844|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
33019845|NCT01822938|No Intervention|control group|No intervention
33019846|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
33019847|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
33019848|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
33019849|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
33019850|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
33326116|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
33326117|NCT03895242|Experimental|Group 1:First supine position,then prone position|First group was supine position then prone position.
33326118|NCT03895242|Experimental|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
33326119|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
33326120|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
33326121|NCT03895086|Experimental|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
33019851|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
33019852|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
33019853|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
33019854|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
33019855|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
33019856|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
33019857|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
33019858|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
33019859|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
33019860|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
33019861|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
33019862|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
33019863|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
33019864|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
33019865|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
33019866|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
33019867|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
33019868|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
33019869|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
33019870|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
33019871|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
33019872|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
33019873|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
33019874|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
33019875|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
33019876|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
33019877|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
33019878|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
33019879|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
33019880|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
33019881|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
33019882|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
33019883|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
33019884|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
33019885|NCT01823302|Other|nutritional counseling|nutritional counseling
33019886|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
33106157|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
33106158|NCT03792932|Active Comparator|Open distal pancreatectomy|
33019887|NCT01823315|Experimental|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
33019888|NCT01823315|Experimental|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, >4h).~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
33019889|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
33019890|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
33019891|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
33019892|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
33019893|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
33019894|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
33019895|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
33019896|NCT01823393|Placebo Comparator|NaCl|without heparin
33019897|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
33019898|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
33019899|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
33019900|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
33019901|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
33019902|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
33019903|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
33019904|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
33019905|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
33106159|NCT05263011|Experimental|Avocado snack|1 avocado
33019906|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
33019907|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
33019908|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
33019909|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
33019910|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
33019911|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
33019912|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
33019913|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
33019914|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
33019915|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
33019916|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
33019917|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
33019918|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
33019919|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
33019920|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
33019921|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
33019922|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
33019923|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
33019924|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
33019925|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
33019926|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
33019927|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
33019928|NCT01823666||Control|Normal cognition.
33019929|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
33019930|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
33019931|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
33019932|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
33019933|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
33019934|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
33019935|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
33019936|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
33019937|NCT01823783|Other|DMD infant|Muscle biopsy
33019938|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
33019939|NCT01823796||Healthy women.|35 healthy women. Control group.
33019940|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
33019941|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
33019942|NCT01823822|Experimental|Oral protein supplement (Tested product)|
33019943|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
33019944|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
33019945|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
33106160|NCT05263011|Placebo Comparator|control snack + fiber supplement + vegetable oil|high fat, high fiber control
33019946|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
33019947|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
33019948|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
33019949|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
33019950|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
33019951|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
33019952|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
33019953|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
33019954|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
33019955|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
33019956|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
33019957|NCT01823952||Males|Adult 18-65
33019958|NCT01823965|Experimental|ranibizumab|
33019959|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
33019960|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
33019961|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
33019962|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
33019963|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~percentage area stenosis ≥75 %~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2~percentage area stenosis between 50 and 75% and major plaque ulceration"
33019964|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
33019965|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
32902083|NCT04949490|Experimental|Group B, BNT162b2 30 µg (2 doses)|Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) will be offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.
33019966|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
33019967|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
33019968|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
33019969|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
33019970|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
33019971|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
33019972|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
33019973|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
33019974|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
33019975|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
33019976|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
33019977|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
33326122|NCT03895086|Other|Classic Physical Activity|Classic patient care in common group of multipathological patients.
33326123|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
33326124|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
33019978|NCT01824173|Experimental|Exercise in lean|Exercise in lean
33019979|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
33019980|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
33019981|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
33019982|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
33019983|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
33019984|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
33019985|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
33019986|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
33019987|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
33019988|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
33019989|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
33019990|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
33019991|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
33019992|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
33019993|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
33019994|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
33019995|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
33019996|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
33019997|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
33019998|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
33019999|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
33020000|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
33020001|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
33326125|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
33326126|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
33326127|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
33327243|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
33327244|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
33327245|NCT01536964|Placebo Comparator|Saline|
33020002|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
33020003|NCT01824381|Experimental|Amniotic membrane in large wounds|
33020004|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
33020005|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
33020006|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
33020007|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
33020008|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
33020009|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
33020010|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
33020011|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
33020012|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
33020013|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
33020014|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
33020015|NCT01824524|Experimental|OROS Hydromorphone|
33020016|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
33106161|NCT05263011|Other|control snack|Low-fiber, low-fat
33327246|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
33327247|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
33020017|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
33020018|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
33020019|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
33020020|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
33020021|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
33020022|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
33020023|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
33020024|NCT01824654|Experimental|Rigid and Elastic registration softwares|
33020025|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
33020026|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
33020027|NCT01824680|Experimental|obesity|
33020028|NCT01824706||craniectomy|craniectomy
33020029|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
33020030|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
33020031|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
33020032|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
33020033|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
33020034|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
33020035|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
33020036|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
33020037|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
33020038|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
33020039|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
33020040|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
33020041|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
33020042|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
33020043|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
33020044|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
33020045|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
33020046|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
33020047|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
33020048|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
33020049|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
33020050|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
33020051|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
33020052|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
33020053|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
33020054|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
33327248|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
33020055|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
33020056|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
33020057|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
33020058|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
33020059|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
33020060|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
33020061|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
33020062|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
33020063|NCT01824992|No Intervention|Observation|subject only got observation
33020064|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
33020065|NCT01825005||group 1:surgery|treatment = surgery only
33020066|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
33020067|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
33020068|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
33020069|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
33020070|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
33020071|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
33020072|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
33020073|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
33020074|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
33020075|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
33020076|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
33020077|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
33020078|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
33020079|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
33020080|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
33020081|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
33020082|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
33020083|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
33020084|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
33020085|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
33020086|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
33020087|NCT01825148||Type 1 Diabetes|patients with long standing T1D
33020088|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
33020089|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
33020090|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
33020091|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
33327249|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
33020092|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
33020093|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
33020094|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
33020095|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
33020096|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
33020097|NCT01825226|No Intervention|Control|
33020098|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
33020099|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
33327250|NCT01285206|Experimental|Routine practice|
33020100|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
33020101|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
33020102|NCT01825304|Other|ARDSNet recommendations,peep|
33020103|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
33020104|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
33020105|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
33020106|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
33020107|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
33020108|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
33020109|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
33020110|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
33020111|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
33020112|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
33020113|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
33020114|NCT01825447|Placebo Comparator|Treatment A|
33020115|NCT01825447|Experimental|Treatment B|
33020116|NCT01825447|Active Comparator|Treatment C|
33020117|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
33020118|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
33020119|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
33020120|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
33020121|NCT01825486||accidental falls|
33020122|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
33020123|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
33020124|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
33020125|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
33020126|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
33020127|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
33020128|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
33020129|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
33020130|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
33020131|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
33020132|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
33020133|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
33020134|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
33020135|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
33020136|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
33020137|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
33020138|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
33020139|NCT01825681|Experimental|positive affect intervention|positive affect intervention
33020140|NCT01825681|No Intervention|wait list control|wait list control
33020141|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
33020142|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
33416589|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
33106164|NCT05255367|Experimental|Intake of (poly)phenol rich foods|Daily consumption of 100 ml of a commercial juice of berries and pomegranate, 20 g dark chocolate and 1 green tea, to test if the supplementation of the diet with (poly)phenol rich foods, during 2 months, reduce the cardiometabolic risk in post-post-menopausal women.
33106165|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
33106166|NCT04095156||Prospective cohort|Patients with biopsy-proven idiopathic MN, who are candidate to receive a B-cell depleting treatment as per center clinical practice.
33106167|NCT04095156||Retrospective cohort|Patients with biopsy-proven idiopathic MN, who already received a B-cell depleting treatment as per center clinical practice.
33106168|NCT04095156||Healthy volunteers cohort|Subjects > 18 years not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
33106169|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
33106170|NCT04679129|Experimental|Single Ascending Dose-ASC42|ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
33106171|NCT04679129|Experimental|Multiple Ascending Dose-ASC42|ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days
33106172|NCT04679129|Placebo Comparator|Single Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
33106173|NCT04679129|Placebo Comparator|Multiple Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days
33106174|NCT04084119|Experimental|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
33106175|NCT04084119|Active Comparator|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
33106176|NCT05236452|Experimental|Integrating of the traditional TB care with modern care through screening, and referral linkage|Integrating traditional care with modern care is a collaboration of two systems through referral linkage. A referral linkage model will be used to detect TB cases in both traditional and modern care services. Health care providers, traditional care providers will participate in the integration process.
33106177|NCT05236452|Active Comparator|Patients proceed with the usual care/ control group|The control group will be followed the existing passive case-findings system (self-referral patients to nearby health facilities that use the same national guidelines to treat TB). The usual care will be carried out using nationally standardized guidelines. The findings obtained from the control groups will be compared with the intervention groups. Finally, changes among the two groups will be assessed and concluded.
33106178|NCT04678934||Bicuspid aortic valve subgroup|For analysis in Bicuspid aortic valve population.
33106179|NCT05236023|No Intervention|Control group|Group receiving care as usual before the intervention takes place
33106180|NCT05236023|Experimental|Intervention group|Group receiving a new model of care based on zero separation and couplet care
33106181|NCT04679090|Experimental|Participant|Participants will answer a series of questionnaires, wear a physical activity tracker (pedometer) and do functional tests (six minute walk test, chair stand test, balance, back scratch, sit and reach, leg strength and hand strength) pre and post.
33106182|NCT04017936|Experimental|Anakinra|100 mg/0.67 mL daily subcutaneous injection for 4 weeks
33106183|NCT04017936|No Intervention|Standard of Care|Continue standard of care treatment
33106184|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
33106185|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
33106186|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
33106187|NCT04017039|No Intervention|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
33106188|NCT04017039|Experimental|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
33106189|NCT05228535|No Intervention|Control|Continue current NICU feeding protocol, introducing human milk fortifier at 8 days
33106190|NCT05228535|Experimental|Intervention|Introducing human milk fortifier at 1 day
33106191|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
33106192|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
33106193|NCT05211141||Patient with knee arthroplasty|patient with HLS KneeTec Deep Dish prosthesis
33106194|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
33327251|NCT01307878|Experimental|arm A|Pre-PTR, chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
33020143|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
33020144|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
33020145|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
33020146|NCT01825733|Experimental|ramosetron|
33020147|NCT01825733|Active Comparator|palonosetron|
33020148|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
33020149|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
33020150|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
33020151|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
33020152|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
33020153|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
33020154|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
33020155|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
33020156|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
33020157|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
33020158|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
33020159|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
33020160|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
33020161|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
33020162|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
33020163|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
33020164|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
33020165|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
33020166|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
33020167|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
33020168|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
33020169|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
33020170|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
33020171|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
33020172|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
33020173|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
33020174|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
33020175|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
33020176|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~1 fx: 16 to 24 Gy~2 fx's: 20 to 26 Gy~3 fx's: 21 to 30 Gy~4 fx's: 24 to 36 Gy"
33020177|NCT01826071|No Intervention|Symptomatic Treatment|
33020178|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
33020179|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
33020180|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
33020181|NCT01826110|Experimental|[11C]PIB|[11C]PIB
33106195|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
33106196|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
33106197|NCT04005690|Experimental|Arm I (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
33416590|NCT04970199|Active Comparator|group 1|thirty lupus women received laser acupuncture (active) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was applied for 1 min on every acupiont).
33416591|NCT04970199|Sham Comparator|group 2|thirty lupus women received laser acupuncture (sham) for one month (3 days) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was be applied for 1 min on every acupiont).
33020182|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
33020183|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
33416592|NCT05250401||patients with liver cirrhosis|
33416593|NCT05250401||control group|
33416594|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
33416595|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
33416596|NCT01359163|Active Comparator|Femulen commercial tablets|
33416597|NCT01359163|Experimental|Femulen reformulated tablets|
33416598|NCT04952493|Experimental|anlotinib + RAI|Patients in this arm will receive anlotinib 6 cycles around RAI treatment ( 4 cycles before and 2 cycles after RAI)
33020184|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
33020185|NCT01826136|No Intervention|Control|
33416599|NCT04952493|Other|RAI only|Patients in this arm will receive RAI treatment as scheduled.
33020186|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
33020187|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
33020188|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
33020189|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
33020190|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
33020191|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
33020192|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
33020193|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
33020194|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
33020195|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
33020196|NCT01826253||Hypovolemia|Fluid expansion
33020197|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
33020198|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
33020199|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
33020200|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
33020201|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
33020202|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
33020203|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
33020204|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
33020205|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
33020206|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
33020207|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
33020208|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
33020209|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
33106198|NCT04005690|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
33106199|NCT04005690|Experimental|Arm III (temuterkib)|Patients receive temuterkib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
33327252|NCT01307878|No Intervention|arm B|Upfront PTR, then chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
33327253|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
33327254|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
33327255|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
33020210|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
33020211|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
33020212|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
33020213|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
33020214|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
33020215|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
33020216|NCT01826409|Experimental|Fermented red ginseng|
33020217|NCT01826409|Placebo Comparator|Placebo|
33020218|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
33020219|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
33020220|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
33020221|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
33020222|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
33020223|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
33020224|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
33020225|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
33020226|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
33020227|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
33020228|NCT01826500||Patients|"Patients having any of the following criteria:~Patients with embryo transfer fresh or frozen~Patients from an IVF cycle,~Patients supported surgically for endometriosis"
33020229|NCT01826500||Controls|Controls
33020230|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
33020231|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
33020232|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
33020233|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
33020234|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
33020235|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
33020236|NCT01826565|Experimental|Rotation|Rotational technique applied
33020237|NCT01826578|Experimental|single port arm|
33020238|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
33020239|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
33020240|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
33020241|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
33020242|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
33020243|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
33020244|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
33020245|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
33020246|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
33020247|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
33106200|NCT04005690|Experimental|Arm IV (onvansertib)|Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
33106201|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
33326128|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
33326129|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
33020248|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
33020249|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
33327256|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
33327257|NCT01173744|Experimental|Gamma-3 Nail|
33327258|NCT01173744|Active Comparator|DHS|
33327259|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
33327260|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
33416600|NCT04952493|Experimental|Penpulimab + RAI|Patients in this arm will receive Penpulimab from one week prior to RAI treatment until the disease progressed or intolerable.
33416601|NCT03730337|Experimental|ONO-7475 monotherapy|
33020250|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
33020251|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
33020252|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
33020253|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
33020254|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
33020255|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
33020256|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
33020257|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
33020258|NCT01826747|Experimental|experimental|Luteal Phase support
33020259|NCT01826747|No Intervention|control|No luteal Phase support
33020260|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
33020261|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
33020262|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
33106202|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
33020263|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
33020264|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
33020265|NCT01826786|Placebo Comparator|Placebo|
33020266|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
33020267|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
33020268|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
33020269|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
33020270|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
33020271|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
33020272|NCT01826903||depressed mother/child dyad - intervention|
33020273|NCT01826903||depressed mother/child dyad - no intervention|
33020274|NCT01826903||non-depressed mother/child dyad|
33020275|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
33020276|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
33020277|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
33020278|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
33020279|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
33020280|NCT01826929|No Intervention|Usual care model|
33020281|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
33020282|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
33020283|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
33020284|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
33020285|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
33020286|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
33020287|NCT01826994|Other|patients|heart type fatty acid binding protein testing
33020288|NCT01827007|Experimental|Study arm, elevation of PEEP|
33020289|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
33020290|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
33020291|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
33020292|NCT01827033|Other|meditation training|
33020293|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
33020294|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
33020295|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
33106203|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
33020296|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
33020297|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
33020298|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
33020299|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
33106204|NCT05209893|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
33106205|NCT05209893|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
33416602|NCT03730337|Experimental|ONO-7475 in combination with ONO-4538|
33020300|NCT01827137|Experimental|vaccine|Galinpepimut-S (GPS) inoculations are started 12-22 d following autologous stem cell transplantation (ASCT). GPS (1.0 ml of emulsion) is given s.c. on weeks 0, 2, 4, 6, 8, & 10 (i.e., x 6). Injection sites are pre-stimulated with Sargramostim (GM-CSF; 70 μg) s.c. on d -2 (± 1 d ) & d 0 of each GPS inoculation. N.B.: during each GPS inoculation, the Sargramostim & GPS are administered to the same anatomical site. Subjects are observed for >/= 30 minutes after vaccination. Non-progressing subjects who are clinically stable (no active infection with fevers & no cardiovascular/respiratory compromise) may receive up to 6 more vaccinations q-month. The use of post-ASCT maintenance therapy with either lenalidomide or bortezomib is allowed starting >/= 3 months after ASCT.
33020301|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
33416603|NCT04717674|Experimental|Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)|Participants will undergo two PET/CT scans with the tracer [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as [18F]FPIA, on 2 separate visits.
33020302|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
33020303|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
33020304|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
33020305|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
33020306|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
33020307|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
33020308|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
33020309|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
33020310|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
33020311|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
33020312|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
33020313|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
33020314|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
33020315|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
33020316|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
33020317|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
33020318|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
33020319|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
33020320|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
33416604|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
33416605|NCT04951245|Experimental|UC group|Ultrasound-assisted CNSs guided SLN mapping
33416606|NCT04951245|Active Comparator|GC group|CNSs plus ICG dual-tracer-guided SLN mapping
33020321|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
33020322|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
33020323|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
33020324|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
33020325|NCT01827501|No Intervention|Group Co|Conventional fluid management
33020326|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
33020327|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
33020328|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
33020329|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
33020330|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
33020331|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
33020332|NCT01827618|No Intervention|Control|
33020333|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
33020334|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
33020335|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
33020336|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
33020337|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
33020338|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
33020339|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
33020340|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
33020341|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
33020342|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
33020343|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
33020344|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
33020345|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
33020346|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
33020347|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
33020348|NCT01827696|Experimental|Treatment|American Ginseng ingestion
33020349|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
33020350|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
33020351|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
33020352|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
33020353|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
33020354|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
33020355|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
33020356|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
33020357|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
33020358|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
33020359|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
33020360|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
33020361|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
33020362|NCT01827852||Cohort|
33020363|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
33020364|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
33020365|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
33020366|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
33020367|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
33020368|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
33020369|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
33020370|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
33020371|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
33020372|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
33020373|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
33020374|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
33020375|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
33020376|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
33020377|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
33020378|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
33020379|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
33020380|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
33020381|NCT01827995|Other|Duo test|Self assessment
33020382|NCT01827995|Other|Routine follow up|Follow up in the clinic
33327261|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
33327262|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
33020383|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
33020384|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
33020385|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
33020386|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
33020387|NCT01828086|Placebo Comparator|Placebo|Placebo to match
33020388|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
33020389|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
33020390|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
33020391|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
33020392|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
33020393|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
33020394|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
33020395|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
33020396|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
33020397|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
33020398|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
33020399|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
33020400|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
33020401|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
33020402|NCT01828229|Experimental|inactivity|Inactivity for two weeks
33020403|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
33020404|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
33020405|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
33020406|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
33020407|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
33020408|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
33020409|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
33020410|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
33020411|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
33020412|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
33020413|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
33020414|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
33020415|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
33020416|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
33020417|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
33020418|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
33020419|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
33020420|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
33020421|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
33020422|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
33020423|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
33020424|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
33020425|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
33020426|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
33020427|NCT01828463|No Intervention|no treatment|comparrator
33020428|NCT01828463|Experimental|Nitisinone 1mg|interventional
33020429|NCT01828463|Experimental|Nitisinone 2mg|interventional
33020430|NCT01828463|Experimental|Nitisinone 4mg|interventional
33020431|NCT01828463|Experimental|Nitisinone 8mg|interventional
33020432|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
33020433|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
33020434|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
33020435|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
33020436|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
33020437|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
33020438|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
33020439|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
33020440|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
33020441|NCT01828580|Experimental|AutoLap|
33020442|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
33020443|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
33020444|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
33020445|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
33020446|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
33020447|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
33020448|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
33020449|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
33020450|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
33020451|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
33020452|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
33020453|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
33326130|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
33326131|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
33327263|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
33020454|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
33020455|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
33020456|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
33020457|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
33020458|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
33020459|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
33020460|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
33020461|NCT01828762|Experimental|DC-TC+GM-CSF|
33020462|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
33020463|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
33020464|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
33020465|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
33020466|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
33020467|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020468|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020469|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020470|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33106206|NCT05199870||Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head to repair hip malfunction/disease/injury.
32866554|NCT04820088|Experimental|Intervention Arm|The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
32902084|NCT04949490|Experimental|Group B transplant subjects, BNT162b2 30 µg (2 doses)|Transplant trial participants from Cohort 13 of the trial BNT162-01 will receive one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which will be followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.
32902085|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
32902086|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
32902087|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
32902088|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
32902089|NCT04203810|Experimental|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
32902090|NCT04203810|Active Comparator|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
32902091|NCT05472090|Experimental|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
32902092|NCT05472090|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
32902093|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
32902094|NCT03184454|Experimental|Medtronic Percept Deep Brain Stimulation|"Single open label arm.~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic Percept deep brain stimulation (DBS) system."
32902095|NCT05113446||MCI(Mild Cognitive Impairment) group|"Inclusion criteria : Patients 65 years of age or older who are admitted to a LTC(long-term care) facilities, Patients diagnosed with mild cognitive impairment by doctors, Patients with a score of 18 or more and 23 or less on the Mini-Mental State Examination~Exclusion criteria : Patients unable to measure the delirium assessment tool, The Short Confusion Assessment Methods (S-CAM) (Inouye, 2014) due to severe vision and hearing problems, Patients with serious psychiatric or neurological diagnosis,Patients who died or were transferred on the day of admission, Patients receiving emergency treatment at the time of the delirium assessment or unable to measure or intervene with S-CAM due to hospital circumstances"
32902096|NCT04521140|Experimental|PKP with Dextenza (study)|"Patients undergoing PKP will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902097|NCT04521140|Other|PKP without Dextenza (Controlled)|"Patients undergoing PKP will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902098|NCT04521140|Experimental|DSEK with Dextenza (study)|"Patients undergoing DSEK will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902099|NCT04521140|Other|DSEK without Dextenza (Controlled)|"Patients undergoing DSEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902100|NCT04521140|Experimental|DMEK with Dextenza (study)|"will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902101|NCT04521140|Other|DMEK without Dextenza (Controlled)|"Patients undergoing DMEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
32902102|NCT04420806|Active Comparator|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
32902103|NCT04420806|Sham Comparator|control|no exercise intervention that affect the present study outcomes
32902104|NCT05352230|Active Comparator|Continue Glucose Monitoring (CGM)|External diabetes device glucose sensor that measures interstitial glucose levels every minute
32902105|NCT05352230|Other|Glucometer|Device that measures capillary blood glucose levels
32902106|NCT04211766|Active Comparator|Group I (supplemental fiber and fat followed by placebo)|Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.
32902107|NCT04211766|Active Comparator|Group II (placebo followed by supplemental fiber and fat)|Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.
32902108|NCT05298332|Experimental|ATI-2173 50 mg Japanese|Healthy adult Japanese subjects will receive 50 mg of ATI-2173
32902109|NCT05298332|Experimental|ATI-2173 50 mg Chinese|Healthy adult Chinese subjects will receive 50 mg of ATI-2173
32902110|NCT05298332|Experimental|ATI-2173 50 mg Non-Asian|Healthy adult non-Asian subjects will receive 50 mg of ATI-2173
32902111|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:~Normal serum troponin (below the 99th percentile)~GFR 60ml/min~Proteinuria <1gr/gr creatinine~Blood and urine samples will be collected for troponin and other measures."
32902112|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
32902113|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 3b:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
32902114|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 4b:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
32902115|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
32902116|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.~Blood and urine samples will be collected for troponin and other measures."
32902117|NCT04211220|Experimental|Type 1 diabetes|
32902118|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
32902119|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
32902120|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
32902121|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
32902122|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
32902123|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
32902124|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
32902125|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
32902126|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
32902127|NCT04210362|Experimental|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
32902128|NCT04210362|Experimental|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
32902129|NCT04210362|Experimental|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
32902130|NCT04210362|No Intervention|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
32902131|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
32902132|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
32902133|NCT05113056|Experimental|Non-randomized|All subjects will be ablated using the Acutus Medical Pulsed Field Ablation System (PFA System) in the management of their atrial fibrillation.
32902134|NCT05112666||Cancer patients with VTE|Adults diagnosed with active (primary or metastatic) cancer experiencing a hospitalization or emergency department admission or a primary care visit with an incident venous thromboembolism (VTE), being administered rivaroxaban or other direct-acting oral anticoagulants (DOACs) or a low molecular weight heparin (LMWH) will be included.
32902135|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
32902136|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
32902137|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
32902138|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
32902139|NCT05112276|Active Comparator|Control Diet|Average Swedish diet
33020471|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020472|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020473|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020474|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33020475|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
33020476|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
33020477|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
33020478|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
33020479|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
33020480|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
33020481|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
33326132|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
33326133|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
33020482|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
33020483|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
33020484|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
33020485|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
33020486|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
33020487|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
33020488|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
33020489|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
33020490|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
33020491|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
33020492|NCT01828918|Other|early recurrence|find the postoperative early relapse out
33020493|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
33020494|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
33020495|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
33020496|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
33326134|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
33326135|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
33326136|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
33326137|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
33326138|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
33326139|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
33326140|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
33020497|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
33020498|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
33020499|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
33020500|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
33326141|NCT01259934|No Intervention|Arm A|Observation only - no therapy
33020501|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
33020502|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
33020503|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
33020504|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
33020505|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
33020506|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
33020507|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
33020508|NCT01829061||No Treatment|
33020509|NCT01829087|Experimental|Botox injection|
33020510|NCT01829087|Placebo Comparator|Control|
33020511|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
33020512|NCT01829100|No Intervention|waitlist|15-week waitlist
33020513|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
33020514|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
33020515|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
33020516|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
33020517|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
33020518|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
33020519|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
33020520|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
33020521|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
33020522|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
33020523|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
33020524|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
33020525|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
33020526|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~Provide HIV and STI test results~First Interview~Attend 8 sessions - 1 session per week~Second interview occurs immediately following the 8th session with HIV and STI tests~Third interview occurs 3 months after the 8th session with HIV and STI tests"
33020527|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~Provide HIV and STI test results~First Interview~No sessions for 8 weeks~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~Attend 8 sessions - 1 session per week~Fourth interview occurs immediately after the 8th session with HIV and STI tests~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
33326142|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
33326143|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
33326144|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
33326145|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
33326146|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
33020528|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
33020529|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
33020530|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
33020531|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
33020532|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
33020533|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
33416607|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
33416608|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
33020534|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
33020535|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
33020536|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
33020537|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~Patients at first-line treatment for MM:~Within 15 days before the start of the treatment~Within one month after the end of the first-line treatment~Six (6) months after the end of the first-line treatment~Patients at relapse after disease response (CR or PR) lasting at least 6 months~At relapse~Within 15 days after the end of the treatment of relapse~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
33020538|NCT01829438|No Intervention|Without music|6MWT without music
33020539|NCT01829438|Experimental|With fast music|6MWT with a fast music
33020540|NCT01829438|Experimental|With slow music|6MWT with a slow music
33020541|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
33020542|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
33020543|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
33020544|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
33020545|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
33020546|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
33020547|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
33020548|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
33020549|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
33416609|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
33416610|NCT04400799|Experimental|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
33416611|NCT04400799|No Intervention|Control Group|No study drug
33020550|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
33020551|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
33020552|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
33020553|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
33020554|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
33020555|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
33020556|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
33020557|NCT01829594|Experimental|Case Management|
33020558|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
33020559|NCT01829607|Placebo Comparator|Placebo|
33020560|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
33020561|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
33020562|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
33020563|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
33020564|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
33020565|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
33020566|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
33020567|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
33020568|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
33020569|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
33020570|NCT01829763|Experimental|botox|
33020571|NCT01829776|Experimental|education|Educational intervention
33020572|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
33020573|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
33020574|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
33020575|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
33020576|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
33020577|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
33020578|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
33020579|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
33020580|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
33020581|NCT01829867|Experimental|sNN0031|
33020582|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
33020583|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
33020584|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
33020585|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
33020586|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
33020587|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
33020588|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
33020589|NCT01829971|Experimental|MRX34|Single agent MRX34
33020590|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
33020591|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
33020592|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
33020593|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
33020594|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
33020595|NCT01830075|No Intervention|Control group|The control group receives care as usual.
33020596|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
33020597|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
33020598|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
33020599|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
33020600|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
33020601|NCT01830270|Experimental|PET regimen|
33020602|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
33020603|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
33020604|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
33020605|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
33020606|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
33020607|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
33020608|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
33020609|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
33020610|NCT01830907|Active Comparator|Parenteral|
33020611|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
33020612|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
33020613|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
33020614|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
33020615|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
33020616|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
33020617|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
33020618|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
33020619|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
33020620|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
33020621|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
33020622|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
33020623|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
33020624|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
33020625|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
33020626|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~younger than 18 years old.~where the clinician/General Practitioner (GP) does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate."
33020627|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~younger than 18 years old.~where the clinician/GP does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
33020628|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
33020629|NCT01831648|Experimental|Volonteers|Blood sample
33020630|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
33020631|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
33020632|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
33020633|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
33106207|NCT03688100|Active Comparator|Medication Management group|The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
33106208|NCT03688100|Active Comparator|Behavioral Activation Therapy|BA is an evidence-based psychotherapy with more than 25 randomized trials showing effectiveness in depression. The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
33106209|NCT03678350|Experimental|Treatment (porfimer sodium, IO-PDT)|Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
33106210|NCT04000503|Experimental|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
33106211|NCT04000503|Experimental|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
33106212|NCT03677102|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
33106213|NCT03677102|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
33106214|NCT05196087||NIP IT!|Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
33106215|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
33106216|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
33106217|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
33106218|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
33106219|NCT05194566|Active Comparator|Real tACS|tACS 75Hz intervention combined with language tasks and breathing exercises. The device will operate in tACS research active stimulation mode.
33106220|NCT05194566|Sham Comparator|Sham tACS|tACS sham intervention combined with language tasks and breathing exercises. The device will operate in tACS sham simulation research mode.
33106221|NCT05189223|Other|Open Pilot|In Phase 2, all Veterans will receive the active treatment.
33106222|NCT05189223|Experimental|Active Condition|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to the active treatment.
33106223|NCT05189223|Active Comparator|Treatment as Usual|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to treatment as usual.
33106224|NCT03653117|Experimental|TPLA|TPLA procedure
33106225|NCT05178420|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
33106226|NCT05178420|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
33106227|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
33106228|NCT03963687|Active Comparator|Control Group|Participants will receive the Standard Nursing Education Intervention first
33106229|NCT03963687|Experimental|Intervention Group|Participants will receive the New Nursing Education Intervention first
33106230|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
33106231|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
33106232|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
33106233|NCT05174091||With Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
33106234|NCT05174091||Without Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
33326147|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
33326148|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
33326149|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
33106235|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
32866555|NCT04820088|No Intervention|Contro Arm|Students randomized to the control group will be given an electronic copy of the Guidelines for Psychological Practice with Transgender and Gender Non-Conforming People (APA, 2015) and asked to take notes in the pdf document. The amount of time students spend on the document and note-taking will be recorded and notes will be analyzed for content. As an incentive, the participants in the control group will be given access to TTACS after they complete the post-intervention assessment.
33106236|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
33106237|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
33106238|NCT03950739|Experimental|Tyvaso to TreT|Each subject will receive a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
33106239|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
33106240|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
33106241|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
32902140|NCT05112276|Experimental|Intervention Diet|The intervention diet will be based on food items that have shown a beneficial effect on gut microbiota associated with cardiometabolic risk factors.
33106242|NCT03943641||Population-based|Population-based cohort of participants registered with a SAIL-contributing practice.
33106243|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
33106244|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
33106245|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
33106246|NCT05172531|Experimental|test group|Participants in the test group received Cisatracurium Besilate 0.12mg/kg/hr Continuous infusion During intubation
33106247|NCT05172531|Sham Comparator|control group|Participants in the control group received saline 0.12ml/kg/hr Continuous infusion During intubation
33106248|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
33106249|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
33106250|NCT05170815||ERISMA® LP/LP EVO|120 subjects with ERISMA® LP/LP EVO implant
33326150|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
33326151|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
33326152|NCT03894930|Experimental|Metta meditation|Eight-week, guided metta meditation training that is administered online
33326153|NCT03894930|No Intervention|Wait-list|Eight-week wait-list control with no training
33326154|NCT03894852||AML|cases with denovo AML and t-AML
33326155|NCT03894852||MDS|cases with denovo MDS and t-MDS
33326156|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
33326157|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
33416612|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
33020634|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
33020635|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
33020636|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
33020637|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
33020638|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
33020639|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
33020640|NCT01832389|No Intervention|Group C|control group
33020641|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
33020642|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
33020643|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
33020644|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
33020645|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
33020646|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
33020647|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
33020648|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
33020649|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
33020650|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
33020651|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
33020652|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
33020653|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
33020654|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
33020655|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
33020656|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
33020657|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
33020658|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
33020659|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
33020660|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
33020661|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
33020662|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
33020663|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
33020664|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
33020665|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
33020666|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
33020667|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
33020668|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
33020669|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
33020670|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
33020671|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
33020672|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
33020673|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
33020674|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
33020675|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
33020676|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
33020677|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
33020678|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
33020679|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
33020680|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
33020681|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
33020682|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
33020683|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
33020684|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
33020685|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
33020686|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
33020687|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
33020688|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
33020689|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
33020690|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
33020691|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
33020692|NCT01835678|Active Comparator|Linagliptin|Linagliptin
33020693|NCT01835678|Placebo Comparator|Placebo|Placebo
33020694|NCT01835717||Cognitively normal individuals|
33020695|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
33020696|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
33020697|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
33326158|NCT03894774|Experimental|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
33326159|NCT03894774|Active Comparator|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).~Duration: At least 3 month to a maximum of 6 month."
33416613|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
33020698|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
33020699|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
33020700|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
33020701|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
33020702|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
33020703|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
33020704|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
33020705|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
33020706|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
33020707|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
33020708|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
33020709|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
33020710|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
33020711|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
33020712|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
33020713|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
33020714|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
33020715|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
33020716|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
33020717|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
33020718|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
33020719|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
33020720|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
33020721|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
33020722|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
33020723|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
33020724|NCT01837472|Experimental|Probiotic|
33020725|NCT01837472|Placebo Comparator|Placebo|
33020726|NCT01838057||painPREMIER cohort|
33020727|NCT01838057||Control cohort|
33020728|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
33020729|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
33106251|NCT05170815||ERISMA® Deformity|120 subjects with ERISMA® Deformity implant
33326160|NCT03894774|No Intervention|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.~Mandatory to control for effects of factors such as brain maturation."
33326161|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
33020730|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
33020731|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
33326162|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
33326163|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
33326164|NCT01260090|Sham Comparator|No Stimulation|
33326165|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
33326166|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
33326167|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
33020732|NCT01838525||SIRS, SEPSIS|
33020733|NCT01838525||sepsis, severe sepsis, septic shock|
33020734|NCT01838525||health, SIRS, Sepsis|
33020735|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
33020736|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
33020737|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
33020738|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
33020739|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
33020740|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
33020741|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
33020742|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
33020743|NCT01839227|Experimental|regional cerebral oxygen saturation|
33020744|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
33020745|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
33020746|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
33020747|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
33020748|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
33020749|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
33020750|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
33020751|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
33020752|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
33020753|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
33106252|NCT05170815||ERISMA® MIS|120 subjects with ERISMA® MIS implant
33106253|NCT05170815||Idys® TLIF PEEK|50 subjects with Idys® TLIF PEEK implant
33106254|NCT05170815||Idys® TLIF TiVAC|50 subjects with Idys® TLIF TiVAC implant
33106255|NCT05170815||Idys® TLIF 3DTi|50 subjects with Idys® TLIF 3DTi implant
33106256|NCT05170815||Idys® ALIF PEEK|50 subjects with Idys® ALIF PEEK implant
33106257|NCT05170815||Idys® ALIF TiVAC|50 subjects with Idys® ALIF TiVAC implant
33106258|NCT05170815||Idys® ALIF 3DTi|50 subjects with Idys® ALIF 3DTi implant
33326168|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
33326169|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
33020754|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
33020755|NCT01840020||Gastric bypass|patients recruited from Central Norway
33020756|NCT01840020||Gastric sleeve|patients recruited from Central Norway
33020757|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
33020758|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
33020759|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
33020760|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
33020761|NCT01840085|Experimental|0.03% DSC127 topical gel|
33020762|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
33020763|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
33020764|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
33020765|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
33020766|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
33020767|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
33020768|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
33020769|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
33020770|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
33020771|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
33020772|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
33020773|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
33020774|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
33020775|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
33020776|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
33020777|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
33020778|NCT01840241|Experimental|BIVON group|
33020779|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
33020780|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
33020781|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
33020782|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
33020783|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
33020784|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
33020785|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
33020786|NCT01840332|Experimental|L-thyroxin|this is one arm study
33020787|NCT01840358|Other|Patients starting pump therapy|
33020788|NCT01840371|Experimental|Propofol based group|
33020789|NCT01840371|Active Comparator|Fentanyl based group|
33020790|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
33106259|NCT05170815||Idys® ALIF ZP 3DTi|50 subjects with Idys® ALIF ZP 3DTi implant
33416614|NCT05250323||Case|Patients with genetic confirmation of Huntington's disease, symptomatic (motor manifestations with a score greater than 4 on the Unified HD scale), who can walk with minimal support, without sensory deficits or other systemic diseases an Investigator judgment that may interfere with the execution of the study, coming from the Enroll study.
33416615|NCT05250323||Control|Age, gender-matched non-gene carriers family relatives
33020791|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
33416616|NCT04697238|Experimental|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
33416617|NCT04697238|Placebo Comparator|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
33416618|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
33416619|NCT01347827||off pump|off-pump CABG surgery
33416620|NCT05383794||Control|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
33416621|NCT05383794||Periodontitis|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
33416622|NCT05383794||Cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
33416623|NCT05383794||Periodontitis + cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
33416624|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
33416625|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
33020792|NCT01840397||Spine surgery|Patients undergoing spine surgery
33020793|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
33020794|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
33020795|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
33020796|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
33020797|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
33020798|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
33020799|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
33020800|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
33020801|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
33020802|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
33020803|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
33020804|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
33020805|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
33020806|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
33020807|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
33020808|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
33020809|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
33020810|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
33020811|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
33020812|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
33020813|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
33020814|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
33020815|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
33020816|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
33020817|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
33106260|NCT05170815||Idys® LLIF 3DTi|50 subjects with Idys® LLIF 3DTi implant
33416626|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
33416627|NCT02068196|Experimental|Ipilimumab|Ipilimumab 3mg/kg
33416628|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
33020818|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
33020819|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
33020820|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
33020821|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
33020822|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
33020823|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
33020824|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
33416629|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
33020825|NCT01840527||Group 1|Advanced Melanoma
33020826|NCT01840527||Group 2|Stage II/III Melanoma
33020827|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
33020828|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
33020829|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
33020830|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
33020831|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
33020832|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
33020833|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
33020834|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
33020835|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
33020836|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
33020837|NCT01840644||all participants|Walking on treadmill, different velocities and incline
33020838|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
33020839|NCT01840696|Experimental|Regadenoson|
33020840|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
33020841|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
33020842|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
33020843|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
33020844|NCT01840748||no vasodilator|patients receiving no vasodilator
33020845|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
33020846|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
33020847|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
33020848|NCT01840761|Placebo Comparator|Placebo|
33020849|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
33020850|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
33020851|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
33020852|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
33020853|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
33020854|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
33020855|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
33020856|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
33106261|NCT03540758|Experimental|Non-diabetic (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.
33106262|NCT03540758|Placebo Comparator|Non-diabetic (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.
33416630|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
33326170|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
33020857|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
33326171|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
33326172|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
33326173|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
33020858|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
33020859|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
33020860|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
33020861|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
33020862|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
33020863|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
33020864|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
33020865|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
33020866|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
33020867|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
33020868|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
33020869|NCT01840969||CAOD group|Single arm study group
33020870|NCT01840982|Experimental|Giant embryonic brown rice|
33020871|NCT01840982|Experimental|Giant embryonic rice|
33020872|NCT01840982|Active Comparator|White rice|
33020873|NCT01840982|Active Comparator|Glucose solution|
33020874|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
33020875|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
33020876|NCT01841008|Placebo Comparator|Group Placebo|
33020877|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
33020878|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
33020879|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
33020880|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
33020881|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
33020882|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
33020883|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
33020884|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
33020885|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
33020886|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
33020887|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
33020888|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
33020889|NCT01841125|Experimental|escitalopram|escitalopram 15mg
33020890|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
33020891|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
33020892|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
33020893|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
33020894|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
33020895|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
33020896|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
33020897|NCT01841190||PROCALCITONIN|
33020898|NCT01841190||DELTA SOFA|
33020899|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
33020900|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
33416631|NCT04065789|Experimental|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
33020901|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
33020902|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
33020903|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
33416632|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
33416633|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
33416634|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
33020904|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
33020905|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
33020906|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
33020907|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
33020908|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
33020909|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
33020910|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
33020911|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
33020912|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
33020913|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
33020914|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
33020915|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
33020916|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
33020917|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
33020918|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
33020919|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
33020920|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
33020921|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
33020922|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
33020923|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
33020924|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
33020925|NCT01841437||iStent|
33020926|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
33020927|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
33020928|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
33020929|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
33020930|NCT01841489|Experimental|Sequence 1|
33020931|NCT01841489|Experimental|Sequence 2|
33020932|NCT01841489|Experimental|Sequence 3|
33020933|NCT01841489|Experimental|Sequence 4|
33020934|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
33020935|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
33020936|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
33106263|NCT03540758|Experimental|T2D (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.
33106264|NCT03540758|Placebo Comparator|T2D (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
33416635|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
33020937|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
33020938|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
33020939|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
33020940|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
33020941|NCT01841645|Other|CLA depletion-repletion|
33020942|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
33020943|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
33020944|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
33020945|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
33020946|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
33020947|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
33020948|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
33020949|NCT01841710||Women|
33020950|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
33020951|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
33020952|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
33020953|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
33020954|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
33020955|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
33020956|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
33020957|NCT01841814|Experimental|lymphoma|
33020958|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
33020959|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
33020960|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
33020961|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
33020962|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
33020963|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
33326174|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
33326175|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
33326176|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
33326177|NCT01153542|Experimental|VX-770|
33326178|NCT01153542|Experimental|desipramine|
33326179|NCT01152606||Cohort|
33326180|NCT01259232||schizophrenia patients,untreated|
33326181|NCT01259232||schizophrenia relatives|
33326182|NCT01259232||controls|
33326183|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
33326184|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
33416636|NCT02066558|Placebo Comparator|placebo|Atmospheric air
33416637|NCT05383716|Experimental|chemotherapy plus pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year
33020964|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
33020965|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
33020966|NCT01841866|Placebo Comparator|awake|LMA removal
33020967|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
33020968|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
33020969|NCT01841892|No Intervention|Usual Care Control|
33020970|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
33020971|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
33020972|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
33020973|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
33020974|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
33020975|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
33020976|NCT01841983|Experimental|Intervention|Be Well Work Well
33020977|NCT01841983|No Intervention|Control|No intervention
33020978|NCT01841996|Experimental|ME1111 solution|
33020979|NCT01841996|Placebo Comparator|Vehicle Solution|
33020980|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
33020981|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
33020982|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
33020983|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
33020984|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
33020985|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
33020986|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
33020987|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
33020988|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
33020989|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
33020990|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
33020991|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
33020992|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
33020993|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
33020994|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
33020995|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
33020996|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
33020997|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
33020998|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
33020999|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
33021000|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
33021001|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control"
33106265|NCT03540758|Experimental|T2D (Diazoxide + Nicotinic Acid)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.
33106266|NCT03540758|Experimental|T2D (Nicotinic Acid + placebo for diazoxide)|Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
33106267|NCT05154045|Experimental|Experimental Formula|One 330 ml serving of study product
33106268|NCT05154045|Active Comparator|Test Meal|40 g Instant oatmeal
33106269|NCT03442322|Active Comparator|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
33106270|NCT03442322|Active Comparator|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
33106271|NCT03870360|Experimental|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
33106272|NCT03870360|Active Comparator|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
33106273|NCT05135481|Active Comparator|CONTROL GROUP|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function.
33106274|NCT05135481|Experimental|STUDY GROUP|"Management in group 2 will include increased lactation care both during hospital stay and post discharge.~Increased lactation care will consist of:~individual consultations on how to properly attach the baby to the breast (at least 3 meetings during hospitalization with personnel trained in lactation counselling), regular (at least once a week) contact with a breastfeeding consultant as part of a closed group on social media or by phone, if necessary (expressed by the mother or based on a referral by a member of the lactation team) an outpatient appointment at the breastfeeding clinic."
33106275|NCT03295136|Experimental|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
33106276|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
33106277|NCT04678778|Experimental|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
33106278|NCT03287765||Experimental 18F-AV-1451|
33106279|NCT03230747|Experimental|TMVR|Subjects will undergo transcatheter mitral valve replacement
33106280|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
33106281|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
33106282|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
33106283|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
33106284|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
33106285|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
33106286|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
33106287|NCT05124288||Acute Myeloid Leukemia relapsed patients|Adult patients (< 18 years old), with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood).
33106288|NCT03077360|Experimental|Weight loss only|
33106289|NCT03077360|Experimental|Exercise Only|
33416638|NCT04933773|Experimental|Set averaging times: 2-4 seconds and 8 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 2-4 seconds, the second pulse oximeter is set to an averaging time of 8 seconds.
33106290|NCT03077360|No Intervention|Delayed Intervention Control|
33106291|NCT03722511|Active Comparator|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
33106292|NCT03722511|Active Comparator|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
33326185|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
32902141|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
33021002|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
33021003|NCT01842191|Experimental|Fish oil|
33021004|NCT01842191|Placebo Comparator|Placebo|
33021005|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
33021006|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
33021007|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
33021008|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
33021009|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
33021010|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
33021011|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
33021012|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
33021013|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
33021014|NCT01842256|Active Comparator|Atorvastatin 40mg|
33021015|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
33021016|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
33021017|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
33021018|NCT01842321|Experimental|Abiraterone Acetate|
33021019|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
33021020|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
33021021|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
33021022|NCT01842412||claudication|
33021023|NCT01842412||healthy|
33021024|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
33021025|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
33021026|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
33021027|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
33021028|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
33021029|NCT01842516|Placebo Comparator|Placebo|Placebo
33021030|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
33021031|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
33021032|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
33021033|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
33021034|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
33021035|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
33021036|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
33021037|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
33021038|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
33021039|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
33021040|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
33021041|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
33326186|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
33021042|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
33021043|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
33021044|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
33021045|NCT01842828|Other|Standard care|Standard care for smoking cessation
33021046|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
33021047|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
33021048|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
33021049|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
33021050|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
33021051|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
33021052|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
33021053|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
33021054|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
33021055|NCT01842945|No Intervention|Wait-list control|
33021056|NCT01842945|Experimental|Treatment with therapist contact|
33021057|NCT01842945|Experimental|Treatment without therapist contact|
33021058|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
33021059|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
33021060|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
33021061|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
33021062|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
33021063|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
33021064|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
33021065|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
33021066|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
33021067|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
33021068|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
33021069|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
33021070|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
33021071|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
33021072|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
33021073|NCT01843101|Other|Keratoconus|5 patients with keratoconus
33021074|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
33021075|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
33021076|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
33021077|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
33021078|NCT01843153|Other|intermittent|injection of ropivacaine on demand
33021079|NCT01843153|Other|continuous|continuous ropivacaine infusion
33021080|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
33021081|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
33326187|NCT03894384||Group:1|Gastric cancer patients
33021082|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
33021083|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
33021084|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
33021085|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
33021086|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
33021087|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
33021088|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
33021089|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
33021090|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
33021091|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
33021092|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
33021093|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
33021094|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
33021095|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
33021096|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
33021097|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
33021098|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
33021099|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
33021100|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
33021101|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
33021102|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
33021103|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
33021104|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
33021105|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
33021106|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
33021107|NCT01843400||Group 1|
33021108|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
33021109|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~popularize and educate the asthma action plan~run a emergency call system for acute exacerbation~educate the proper techniques using inhalers~correct the deficiency of magnesium (magnesium 500mg per day)"
33326188|NCT03894384||Group:2|Patients with benign gastric diseases
33021110|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
33021111|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
33021112|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
33021113|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
33021114|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
33021115|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
33021116|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
33021117|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
33021118|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
33021119|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
33021120|NCT01843556|Experimental|E2022 Tape Formulation|
33021121|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
33021122|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
33021123|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
33021124|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
33021125|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
33021126|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
33021127|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
33021128|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
33021129|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
33021130|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
33021131|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
33021132|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
33021133|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
33021134|NCT01843738|Experimental|All participants|
33021135|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
33021136|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
33021137|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
33021138|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
33021139|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
33021140|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
33021141|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*~then surgery.~All drugs will be sourced from local stock"
33021142|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
33021143|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
33106293|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
33106294|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
33106295|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
33106296|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
33106297|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression.~Participants will undergo serial collection of plasma and serum samples."
33106298|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.~Participants will undergo serial collection of plasma and serum samples."
33106299|NCT04683705||patients without shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the asymptomatic shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
33106300|NCT04683705||patients with shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
33106301|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
33106302|NCT04683744||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the study team's affiliated health systems.
33106303|NCT04683744||Patients receiving primary care at the study team's affiliated health systems|Patients who had a least one primary care visit during the past 24 months at the study team's affiliated health care systems.
33106304|NCT05099445|Experimental|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB000928 200 mg on Day 1.
32902142|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
32902143|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
33106305|NCT05099445|Experimental|Group 2: Mild Renal Impairment|Participants with mild levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
33106306|NCT05099445|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
33416639|NCT04933773|Experimental|Set averaging times: 8 seconds and 16 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 8 seconds, the second pulse oximeter is set to an averaging time of 16 seconds.
33416640|NCT01351831|Experimental|Rehabilitation with strength training|
33106307|NCT05099445|Experimental|Group 4: Severe Renal Impairment|Participants with severe levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
33106308|NCT05099445|Experimental|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB000928 on Day 1 of each of 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB000928.
33106309|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
33106310|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
33106311|NCT05098470|Active Comparator|Metformin|
33106312|NCT05098470|Active Comparator|Insulin Glargine|
33106313|NCT05098470|Experimental|Dorzagliatin|
33106314|NCT02710643|No Intervention|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
33106315|NCT02710643|No Intervention|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
33106316|NCT02710643|Experimental|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
33106317|NCT05093205|Experimental|Part A|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of atorvastatin (20 mg tablet) and midazolam (5 mg syrup).
33106318|NCT05093205|Experimental|Part B|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of an Oral Contraceptive (Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg tablet).
33106319|NCT00552981|Active Comparator|1|
33106320|NCT00552981|Sham Comparator|2|
33416641|NCT01351831|Active Comparator|Rehabilitation without strength training|
33416642|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
33106321|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
33106322|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
33416643|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
33416644|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
33416645|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
33021144|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
33021145|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
33021146|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
33021147|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
33021148|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
33021149|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
33021150|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
33021151|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
33021152|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes~Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~Group 3:~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes~Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
33021153|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
33021154|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
33021155|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
33021156|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
33021157|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
33021158|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
33021159|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
33021160|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
33021161|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
33021162|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
33021163|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
33021164|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
33021165|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
33021166|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
33021167|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
33021168|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
32902144|NCT04995666|Experimental|Hearing Aid|Participants will wear Phonak rechargeable Audeo hearing aids
33021169|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
33021170|NCT01844128||overweight women with infertility|
33021171|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
33021172|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
33021173|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
33021174|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~The TENS device used: FDA K071951~TENS is calibrated to allow for maximum range in the specifications.~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
33021175|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
33021176|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
33021177|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
33021178|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
33021179|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
33021180|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
33021181|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
33021182|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
33021183|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
33021184|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
32902145|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
32902146|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
32902147|NCT05111886|Experimental|Primary Care Personnel Training|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition.
32902148|NCT05111886|Active Comparator|Primary Care Personnel Training Control|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition. Control group personnel will receive a written description of the referral process but no training.
32902149|NCT05111886|Experimental|Parents eHealth GenPMTO|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
33021185|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
33021186|NCT01844297|Other|TDF+3TC+EFV|
33021187|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
33021188|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
33021189|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
33021190|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
33021191|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
33021192|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
33021193|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
33021194|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
33021195|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
33021196|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
33021197|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
33021198|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
33021199|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
33021200|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
33021201|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
33021202|NCT01844440|Experimental|HRM|
33021203|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
33021204|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
33021205|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
33021206|NCT01844466|Experimental|stroke patients|
33021207|NCT01844492|Active Comparator|ICU Usual Care Control|described below
33021208|NCT01844492|Experimental|The PARTNER Intervention|described below
33021209|NCT01844544||patients after femur neck fracture|
33021210|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
33021211|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
33021212|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
33021213|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
33021214|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
33021215|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
33021216|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
33021217|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
33021218|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
33021219|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
33021220|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
33021221|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
33021222|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
33021223|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
33021224|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
33021225|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
33021226|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
33021227|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
33021228|NCT01844713|No Intervention|Control|Distribution of general skin care information
33021229|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
33021230|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
33021231|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
33021232|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
33021233|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
33021234|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
33021235|NCT01844804|Experimental|A = PF-06438179|
33021236|NCT01844804|Active Comparator|B = Infliximab-EU|
33021237|NCT01844804|Active Comparator|C = Infliximab-US|
33021238|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
33021239|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
33021240|NCT01844882||Chronic Kidney Disease|
33021241|NCT01844908|Experimental|Electroacupuncture|
33021242|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
33021243|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
33021244|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
33021245|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
33021246|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
33021247|NCT01844973|Placebo Comparator|Vehicle|
33021248|NCT01844973|Active Comparator|M518101|
33021249|NCT01844999|Other|Usual patient education + standard educational websites|
33021250|NCT01844999|Experimental|Usual patient education + P3P decision support website|
33021251|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
33021252|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
33021253|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
33021254|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
33021255|NCT01845051||Migraine group|Patients diagnosed with migraine
33021256|NCT01845051||Healthy group|Healthy subjects with no migraine as control
33021257|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
33021258|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
33021259|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
33021260|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
33021261|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
33021262|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
33021263|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
33021264|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
33021265|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
33021266|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
33106323|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
33021267|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
33021268|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
33326191|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
33326192|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
33326193|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
33326194|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
33326195|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
33021269|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
33021270|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
33021271|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
33021272|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
33021273|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
33021274|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
33021275|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
33021276|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
33021277|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
33021278|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
33021279|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
33021280|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
33021281|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
33021282|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
33021283|NCT01845194|Experimental|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
33021284|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
33021285|NCT01845233||Non invasive ventilation|
33021286|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
33021287|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
33021288|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
33021289|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
33021290|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
33021291|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
33021292|NCT01845285||aortic valve disease|aortic valve replacement
33021293|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
33021295|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
33021296|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
33021297|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
33021298|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
33021299|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
33326196|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
33326197|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
33326198|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
33326199|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
33326200|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
33326201|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
33021300|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
33021301|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
33021302|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
33021303|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
33021304|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
33021305|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
33021306|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
33021307|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
33021308|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
33021309|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
33021310|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
33021311|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
33021312|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
33021313|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
33021314|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
33021315|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
33021316|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
33021317|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
33021318|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
33021319|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
33021320|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
33021321|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
33021322|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
33021323|NCT01845519|Experimental|Tailored Group|
33021324|NCT01845519|Active Comparator|Targeted Group|
33021325|NCT01845532|Experimental|TPI group|
33021326|NCT01845532|Active Comparator|ELMA group|
33021327|NCT01845532|No Intervention|None group|
33326202|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
33021328|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
33021329|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
33021330|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
33021331|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
33021332|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
33021333|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
33021334|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
33021335|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
33021336|NCT01845623|Experimental|Treatment A|
33021337|NCT01845623|Experimental|Treatment B|
33021338|NCT01845623|Placebo Comparator|Treatment C|
33021339|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
33021340|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
33021341|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
33021342|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
33021343|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
33021344|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
33021345|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
33021346|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
33021347|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
33021348|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
33021349|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
33021350|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
33021351|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
33021352|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
33021353|NCT01845753||All colorectal cancer patients|
33021354|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
33021355|NCT01845766|No Intervention|control arm|
33021356|NCT01845779|Experimental|patients in complete response|
33021357|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
33021358|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
33021359|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
33021360|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
33021361|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
33021362|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
33021363|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
33021364|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
33021365|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
33021366|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
33021367|NCT01845909||young adults - Central region of Portugal|
33021368|NCT01845922|Experimental|Low sodium diet|Low sodium diet
33021369|NCT01845922|No Intervention|Control|Standard diet regime
33021370|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
33021371|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
33021372|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
33021373|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
33021374|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
33021375|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
33021376|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
33021377|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
33021378|NCT01846013|Experimental|Stand|
33021379|NCT01846013|Experimental|Move|
33021380|NCT01846013|Experimental|Stand and Move|
33021381|NCT01846013|No Intervention|General Wellness|
33021382|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
33021383|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
33021384|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
33021385|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
33021386|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
33021387|NCT01846130|No Intervention|Control|Control bed rest group
33021388|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
33021389|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
33021390|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
33021391|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
33021392|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
33021393|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
33021394|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
33021395|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
33326203|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
33326204|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
33326205|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
33326206|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
33327264|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
33327265|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
33021396|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
33021397|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
33021398|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
33021399|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
33021400|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
33021401|NCT01846234||MS patients|MS patients
33021402|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
33021403|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
33021404|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
33021405|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
33021406|NCT01846312||All participants|
33021407|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
33021408|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
33021409|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
33021410|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
33021411|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
33021412|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
33021413|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
33021414|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
33021415|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
33021416|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
33021417|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
33021418|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
33021419|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
33021420|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
33021421|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
33021422|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
33021423|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
33021424|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
33021425|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
33021426|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
33021427|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
33021428|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
33021429|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
33021430|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
33021431|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
33021432|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
33021433|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
33021434|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
33021435|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
33021436|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
33416646|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
33021437|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
33021438|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
33021439|NCT01846754||Hemodialysis patients|
33021440|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
33021441|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
33021442|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
33021443|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
33021444|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
33021445|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
33021446|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
33021447|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
33021448|NCT01846858||CO2 Laser|
33021449|NCT01846858||Monopolar energy|
33021450|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
33021451|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
33021452|NCT01846923|Experimental|PCV13|
33021453|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
33021454|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
33021455|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
33021456|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
33021457|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
33021458|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
33021459|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
33021460|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
33021461|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
33021462|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
33021463|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
33021464|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
33021465|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
33021466|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
33021467|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
32902150|NCT05111886|Active Comparator|Parents Control|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
32902151|NCT05111886|Other|Therapists|Community therapists trained to deliver GenPMTO.
33106324|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
33326207|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
33326208|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
33326209|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
32902152|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
32902153|NCT05148260|Experimental|LTP+|"The LTP+ is divided into two components:~First, underpinned by Piaget's theory of cognitive development (Piaget, 1952; Sidik, 2020) and Bowlby's theory of attachment (Bowlby, 1980; Granqvist & Duschinsky, 2021), the central focus here is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and mum-baby attachment.~Second, well-grounded in the standard framework of cognitive-behavioural theory (Bernal et al., 2009) and uses techniques of active listening, changing negative thinking, guided discovery, behavioural tasks, and homework (i.e. trying things out between sessions, putting what has been learnt into practice), while educating participating mums about depression/anxiety, correlates and management, social support, and practical advice on using appropriate healthcare (Bernal et al., 2009)."
32902154|NCT05148260|Active Comparator|Psychoeducation|This is the comparative group with a primary aim of monitoring participating mums to ensure their postnatal depression does not degenerate. However, supportive, and postnatal educational components are provided. These psychoeducation sessions are grounded on the theory and philosophy of group psychosocial support (with basic but relevant topics on postnatal mental healthcare advice and discussions).
32902155|NCT05131880|Experimental|Experimental|"The experimental group will participate in a physiotherapy program with the addition of the Fisior Tapestry Method physiotherapy program, three sessions per week, for 12 weeks.~An initial assessment will be made at the beginning of the study, another one at the end of the intervention, and another one at follow-up."
32902156|NCT05131880|Active Comparator|Control|The control group will participate in a physiotherapy program three sessions per week for 12 weeks.
32902157|NCT04993950|Experimental|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
32902158|NCT04993950|Active Comparator|SNAGS with thoracic postural correction techniques|active as well as therapist-facilitated stretches.thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
32902159|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
32902160|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
32902161|NCT04850612||Healthcare professionals and researchers (HCPR)|All researchers and healthcare professionals involved in the management of patients with CSDH
32902162|NCT04850612||Patients and carers|Patients who have previously had a diagnosis of CSDH, and their carers
32902163|NCT04993716||Cohort|Patient present in the SAU after an extra-hospital cardiac arrest
32902164|NCT04842266||Treatment of Impending and Actual Pathologic Fractures in the Pelvis from Metastatic Bone Disease|The patient will undergo surgery and will be treated with the IlluminOss implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
32902165|NCT04842266||Treatment of Geriatric Pelvic Fractures with IlluminOss Pelvic Implant|Geriatric pelvic fracture patients will be treated with the IlluminOss Pelvic Implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
32902169|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
32902170|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
32902171|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
32902172|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
32902173|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
33106325|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
33106326|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
33106327|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
33106328|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
33106329|NCT05080530|No Intervention|1. Normal Vit D (> 30ng/mL)|Follow-up after 3 months with standard treatment
33106330|NCT05080530|Experimental|2. Insufficient Vit D (20-30ng/mL)|single oral dose capsule 200,000 IU of Cholecalciferol
33106331|NCT05080530|No Intervention|3. Insufficient Vit D (20-30ng/mL)|Follow-up after 3 months with standard treatment
33106332|NCT05080530|Experimental|4. Deficient Vit D|single oral dose capsule 200,000 IU of Cholecalciferol
33106333|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
33106334|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
33106335|NCT00554177|Experimental|1|Medicane (mifepristone)
33106336|NCT00554177|Placebo Comparator|2|Placebo
33106337|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
33106338|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
33106339|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
33106340|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
33106341|NCT05074173|Other|Patient Group|Participants will be enrolled in a bidirectional text messaging system from Tulane University Medical Group where they will receive and send text from their mobile phones to monitor their anti-hypertension medication regimen. Text messages will be sent: daily for medication and refill reminders; weekly for hypertension education messages and asking if a support person helped them with medication reminders. Study personnel will educate participants on proper blood pressure technique to conduct self-measured blood pressure (SMBP) at home. These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure. Participants will receive the Bluetooth blood pressure device to perform SMBP at enrollment.
33106342|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
33106343|NCT02456480|Experimental|CLS001 topical gel 1%|
33106344|NCT02456480|Placebo Comparator|Vehicle gel|
33106345|NCT03425565|Experimental|Pembrolizumab|
33106346|NCT04678700|Experimental|Experimental groupe|"Intervention; 10 sessions telematics. Before starting and at the end of the respiratory physiotherapy program, the patient complete an online form which includes a quality of life questionnaire, an effort dyspnea questionnaire and an anxiety questionnaire.~The intervention of the following study follow the recommendations of chest physiotherapy in the management of the patient post covid-19 (1)(17).~Pre-session; respiratory frequency, dyspnea, oxigenation level are taken. Breathing techniques;~Abdominal-diaphragmatic breathing(1)(16). (10 times).~Costal expansion exercises with flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration(25)(26).~Jacobson's progressive relaxation(27). Post-session, respiratory frequency and the Borg's dyspnea index/ oxigenation level."
33106347|NCT04678700|Other|control groupe|The control group will complete the same questionnaires before and after the intervention, which will give us an idea of whether our intervention has had any improvement. In order for all patients to be able to receive the therapy if they want to. The control group will be on the waiting list to perform the sessions.
33106348|NCT05073627|No Intervention|Baseline|The investigators measure the baseline of dicloxacillin and the probe drug dabigatran etexilate.
33106349|NCT05073627|Experimental|Dicloxacillin treatment|The investigators measure the concentration of dicloxacillin after 9 and 27 days and the concentration of dabigatran after 10 and 28 days of continuously taking dicloxacillin.
33106350|NCT05050695||Subjects with unilateral chronic low back pain|Subjects with low back pain for more than 3 months on one side of the spine
33106351|NCT05050695||Healthy subjects|Subjects without a history of low back pain
32902174|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
33021468|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
33021469|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
33021470|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
33021471|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
33021472|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
33021473|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
33021474|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
33021475|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
33021476|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
33021477|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
33021478|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
33021479|NCT01847170|Experimental|Fecal Microbial Transplantation|
33021480|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
33021481|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
33021482|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
33021483|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
33021484|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
33021485|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
33021486|NCT01847248||Severe sepsis|Patients with severe sepsis
33021487|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
33021488|NCT01847248||Control|Healthy volunteers
33021489|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
33021490|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
33021491|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
33021492|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
33021493|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
33021494|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
33021495|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
33021496|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
33021497|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
33021498|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
33021499|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
33021500|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
33021501|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
33021502|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
33021503|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
33021504|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
33106352|NCT04678739|Experimental|Group A: Remdesivir + Tocilizumab treatment group|"Drug: Remdesivir Injectable solution Tocilizumab Injectable solution A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
33106353|NCT04678739|No Intervention|Group B: Control group|Treatment as given without Remdesivir and Tocilizumab.
33106354|NCT03421353|Experimental|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
33106355|NCT03421353|Experimental|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
33106356|NCT03421353|Experimental|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
33106357|NCT03421353|Experimental|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks).~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
33106358|NCT03421353|Experimental|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
33106359|NCT03421353|Experimental|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
33106360|NCT03421353|Experimental|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
33106361|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
33106362|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
33106363|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
33106364|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
33106365|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
33106366|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
33106367|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
33106368|NCT02433158|Experimental|Cohort 1|Includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
33106369|NCT02433158|Experimental|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
33106370|NCT05029479|Experimental|Yamakin TMR-Aquabond0|Novel Moisture Resistant, M-TEG-P Phosphate Monomer Based Universal Adhesive (YAMAKIN TMR-Aquabond0)
33106371|NCT05029479|Active Comparator|3m ESPE Single Bond Universal Adhesive|Conventional Universal Adhesive
33106372|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
33106373|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
33106374|NCT02428088|Placebo Comparator|Placebo|Placebo
33106375|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
33326210|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
32902175|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
33106376|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
33106377|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
32902176|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
32902177|NCT01397617|Experimental|NobelActive External|NobelActive External implant
32902178|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
32902179|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
32902180|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
32902181|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
32902182|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
32902183|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
32902184|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
32902185|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
32902186|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
32902187|NCT04797650|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
32902188|NCT04797650|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
32902189|NCT04797650|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
32902190|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
32902191|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
32902192|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
32902193|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
32902194|NCT04946370|Experimental|Pembrolizumab + 225Ac-J591 + ARPI|Patients will receive one dose of 225Ac-J591 (single dose, either 65 or 90 Kbq/kg) in combination with pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule, examples of ARPI include enzalutamide and apalutamide).
32902195|NCT04946370|Experimental|Pembrolizumab + ARPI|Patients will receive pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule) without 225Ac-J591.
32902196|NCT04946136|Experimental|Gait modification|In this pilot study, participants modify their gait patterns guided by real-time visual feedback on their medial knee load while walking on an instrumented treadmill.
32902197|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
32902198|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions"
32902199|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions~Random saliva tests"
32902200|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
32902201|NCT01549405|Experimental|nerve block|Group that performing intercostal block
32902202|NCT04945044|Experimental|Computed adenoma detection system (CADe)|Tis system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions
32902203|NCT04945044|Active Comparator|Control group (absence of CADe)|This is the control group. As in the routine colonoscopy the endoscopist is in charge of the detection of the lesions.
32902204|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
32902695|NCT05246462|Experimental|Experimental group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The experimental group received 7 sessions of logotherapy interviews.
33021505|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
33021506|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
33021507|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
33021508|NCT01847482|Experimental|Therapeutic Hypothermia|
33021509|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
33021510|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
33021511|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
33021512|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
33021513|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
33021514|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
33021515|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
33021516|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
33021517|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
33021518|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
33021519|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
33021520|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
33021521|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
33021522|NCT01847651|Active Comparator|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
33021523|NCT01847651|Placebo Comparator|Placebo|
33021524|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
33021525|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
33021526|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
33106378|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
33106379|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
33021527|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Surgery~Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
33021528|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
33021529|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
33021530|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
33021531|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
33021532|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
33021533|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
33021534|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
33106380|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
33106381|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
33106382|NCT02422979|Experimental|PART 3|Up to 30 patients
33106383|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
33021535|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
33021536|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
33021537|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
33021538|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
33021539|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
33021540|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
33021541|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
33021542|NCT01847781|Active Comparator|Healthy controls|Prevenar13
33021543|NCT01847794|Experimental|chemotheropy|
33021544|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
33021545|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
33021546|NCT01847807|No Intervention|MS control|
33021547|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
33021548|NCT01847833||Patients with brain tumors|
33021549|NCT01847846|Experimental|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
33021550|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
33021551|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
33021552|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
33021553|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
33021554|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
33021555|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
33021556|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
33021557|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
33021558|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
33021559|NCT01847898|Experimental|Balloon Kyphoplasty|
33021560|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
33021561|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
33021562|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
33021563|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
33021564|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
33021565|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
33021566|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
33021567|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
33021568|NCT01847937||Hereditary axonal neuropathic|
33021569|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
33021570|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
33021571|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
33021572|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
33021573|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
33021574|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
33021575|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
33021576|NCT01847989|Experimental|rFXIII|
33021577|NCT01847989|Placebo Comparator|Placebo|
33021578|NCT01848002|Experimental|rFXIII|
33021579|NCT01848002|Placebo Comparator|Placebo|
33021580|NCT01848015||CTCs positive|
33021581|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
33106384|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
33326211|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
33021582|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
33021583|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
33021584|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
33021585|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
33021586|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
33021587|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
33021588|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
33021589|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
33021590|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
33021591|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
33021592|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
33021593|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
33021594|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
33021595|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
33021596|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
33021597|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
33021598|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
33021599|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
33021600|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
33021601|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
33021602|NCT01848119|Placebo Comparator|Placebo|lactose capsules
33021603|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Vincristine: intravenous, 1,4 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
33021604|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
33021605|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
33021606|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
33021607|NCT01848223||late menopause|
33021608|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
33021609|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
33021610|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
33021611|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
33021612|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
33021613|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
33021614|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
33021615|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
33021616|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
33021617|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
33021618|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
33021619|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
33021620|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
33021621|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
33021622|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
33021623|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
33021624|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
33021625|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
33021626|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
33021627|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
33021628|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
33021629|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
33021630|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
33021631|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
33021632|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
33021633|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
33021634|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
33021635|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
33021636|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
33021637|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
33021638|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
33021639|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
33021640|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
33021641|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
33021642|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
33021643|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
33021644|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
33021645|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
33021646|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~Radio show~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
33021647|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
33021648|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
33021649|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
33021650|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
33021651|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
33021652|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
33021653|NCT01848652|Experimental|MYOCET|
33021654|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
33021655|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
33021656|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
33021657|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
33106385|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
33021658|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
33021659|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
33021660|NCT01848717|Experimental|Lift thread|
33021661|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
33021662|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
33021663|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
33021664|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
33021665|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
33021666|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
33021667|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
33021668|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
33021669|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
33021670|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
33021671|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
33021672|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
33021673|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
33021674|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
33021675|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
33021676|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
33021677|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
33021678|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
33021679|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
33021680|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
33021681|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
33021682|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
33021683|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
33021684|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
33021685|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
33021686|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
33021687|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
33021688|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
33021689|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
33021690|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
33326212|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
33021691|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~Day 1: 20 mg (loading dose)~Day 2: 40 mg (loading dose)~Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
33021692|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~Day 1: 50 mg (loading dose)~Day 2-3: 10 mg once daily~Days 4-7: 20 mg once daily"
33021693|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
33021694|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
33021695|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
33021696|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
33021697|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
33021698|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
33021699|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
33021700|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
33021701|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
33021702|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
33021703|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
33021704|NCT01849107|Experimental|Plasma citrulline|
33021705|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
33021706|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
33021707|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
33021708|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
33021709|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
33021710|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
33021711|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
33021712|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
33021713|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
33021714|NCT01849211|Other|neuromuscular block|
33021715|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
33021716|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
33021717|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
33021718|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
33021719|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021720|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021721|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021722|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021723|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021724|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021725|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
33021726|NCT01849315|Placebo Comparator|Control|Sedentary intervention
33021727|NCT01849315|Active Comparator|AKIDS II|Physically active group
33021728|NCT01849328||Breast Cancer|
33021729|NCT01849328||Healthy|
33021730|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
33021731|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
33021732|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
33021733|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
33021734|NCT01849367|Experimental|Active tDCS (1)|
33021735|NCT01849367|Active Comparator|Active tDCS (2)|
33021736|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
33021737|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
33021738|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
33021739|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
33021740|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
33021741|NCT01849432||Control|Healthy Controls
33021742|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
33021743|NCT01849432||Panic Disorder|Participants with Panic Disorder
33021744|NCT01849432||Specific Phobia|Participants who have specific phobias
33021745|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
33021746|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
33021747|NCT01849471||patients with prostate cancer|questionnaires
33021748|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
33021749|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
33021750|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
33021751|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
33021752|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
33021753|NCT01849523|No Intervention|Standard care|Standard care
33021754|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
33021755|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
33021756|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
33021757|NCT01849601|Experimental|PTA catheter|
33021758|NCT01849614||Patient group|Women with left-sided breast cancer
33021759|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
33021760|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
33021761|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
33021762|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
33021763|NCT01849666|Active Comparator|A: phenprocoumon single dose|
33021764|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
33021765|NCT01849679||Post-Extubation Subjects|
33021766|NCT01849705||All subjects|No intervention
33021767|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
33021768|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
33021769|NCT01849731|Experimental|Intervention A|Face-to face intervention
33021770|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
33021771|NCT01849731|No Intervention|Control Group|
33021772|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
33021773|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
33021774|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
33021775|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
33416647|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
33021776|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
33021777|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
33021778|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
33021779|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
33021780|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
33021781|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
33021782|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
33021783|NCT01849887|Placebo Comparator|Placebo|Placebo
33021784|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
33021785|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
33021786|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
33021787|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
33021788|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
33021789|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
33021790|NCT01849939|Experimental|Fludarabin|
33021791|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
33021792|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
33021793|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
33021794|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
33021795|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
33021796|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
33021797|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
33021798|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
33021799|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
33021800|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
33021801|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
33021802|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
33021803|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
33021804|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
33021805|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
33021806|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
33021807|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
33021808|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
33021809|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
33021810|NCT01850147|Experimental|Sunitinib|
33021811|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
33021812|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
33021813|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
33326213|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
33326214|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
33326215|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
33326216|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
33021814|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
33021815|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
33021816|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
33021817|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
33021818|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
33021819|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
33021820|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
33021821|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
33021822|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
33021823|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
33021824|NCT01850225|Experimental|Device implantation|Implantation of device
33021825|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
33021826|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
33021827|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
33021828|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
33021829|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
33021830|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
33021831|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
33021832|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
33021833|NCT01850290||Dopamine Imaging|
33021834|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
33021835|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
33021836|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
33021837|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
33021838|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
33021839|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
33021840|NCT01850420|Experimental|IMC-1|Experimental intervention
33021841|NCT01850420|Placebo Comparator|Matching placebo|
33021842|NCT01850433|Experimental|Internet CBT|
33021843|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
33021844|NCT01850459||IQ-Matched Control Subjects|
33021845|NCT01850459||Age-Matched Neurotypical Controls|
33021846|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
33021847|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
33021848|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
33021849|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
33021850|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
33021851|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
33021852|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
33021853|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
33021854|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
33021855|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
33021856|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
33021857|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
33021858|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
33021859|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
33021860|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
33021861|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
33021862|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
33021863|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
33021864|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
33021865|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
33021866|NCT01850719|Active Comparator|Physical Therapy|
33021867|NCT01850732|Other|ultrasound of aorta|
33021868|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
33021869|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
33021870|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
33021871|NCT01850784|Active Comparator|Standard formula|Standard formula
33021872|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
33021873|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
33021874|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
33021875|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
33021876|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
33021877|NCT01850849|Experimental|LEO 39652 cream|Active drug
33021878|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
33021879|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
33021880|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
33021881|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
33021882|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
33021883|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
33021884|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
33021885|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
33021886|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
33021887|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
33021888|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
33021889|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
33021890|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
33021891|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
33021892|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
33021893|NCT01850966||Iguratimod|
33021894|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
33021895|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
33021896|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
33021897|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
33021898|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
33021899|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
33021900|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
33021901|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
33021902|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
33021903|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
33021904|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
33021905|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
33021906|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
33021907|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
33021908|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
33021909|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
33021910|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
33021911|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
33021912|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
33021913|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
33021914|NCT01851109|No Intervention|Control|
33021915|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
33021916|NCT01851122|Placebo Comparator|Placebo|
33021917|NCT01851122|Experimental|l-theanine|
33021918|NCT01851135|Experimental|Patients with NF1|
33021919|NCT01851135|Other|Healthy controls|
33021920|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
33021921|NCT01851148|Other|usual care|triptans treatment only
33021922|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
33021923|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
33021924|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
33021925|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
33021926|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
33021927|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
33021928|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
33021929|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
33021930|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
33021931|NCT01851239||medical ICU inpatients|
33021932|NCT01851239||surgical ICU inpatients|
33021933|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
33021934|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
33021935|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
33021936|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
33021937|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
33021938|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
33021939|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
33021940|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
33021941|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
33021942|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
33021943|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
33021944|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
33021945|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
33021946|NCT01851343|Experimental|1|All patients will receive the same treatment
33021947|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
33021948|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
33021949|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
33021950|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
33021951|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
33021952|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
33021953|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
33021954|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
33021955|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
33021956|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
33021957|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
33021958|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
33021959|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
33021960|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
33021961|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
33021962|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
33021963|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
33021964|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
33021965|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
33021966|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
33021967|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
33021968|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
33021969|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
33021970|NCT01851603|Placebo Comparator|Sugar pill|Placebo
33021971|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
33021972|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
33021973|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
33021974|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
33416648|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
33021975|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
33021976|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
33021977|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
33021978|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
33021979|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
33021980|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
33021981|NCT01851707|Experimental|IPI-145, low dose BID|
33021982|NCT01851707|Experimental|IPI-145, medium dose BID|
33021983|NCT01851707|Experimental|IPI-145, high dose BID|
33021984|NCT01851707|Placebo Comparator|Placebo BID|
33021985|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~Biomarker blood draws will be drawn at different time points.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
33021986|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
33021987|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
33021988|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
33021989|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
33021990|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
33021991|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
33021992|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
33021993|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
33021994|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
33021995|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
33021996|NCT01851850|Experimental|Drug|
33021997|NCT01851889||CF-LVAD pump speed.|
33021998|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
33021999|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
33022000|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
33022001|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
33022002|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
33022003|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
33022004|NCT01851954|Experimental|clarithromycin|Population PK
33022005|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
32866556|NCT04196777|Experimental|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
32866557|NCT04819932|Experimental|group1|subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition
32866558|NCT04819932|Experimental|group2|subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition
33022006|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
33022007|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
33022008|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
33022009|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
33022010|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
33022011|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
33022012|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
33022013|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
33022014|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
33022015|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
33022016|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
33022017|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
33022018|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
33022019|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
33022020|NCT01852149|Experimental|MPAS Implant|MPAS Implant
33022021|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
33022022|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
33022023|NCT01852240||erectile dysfunction|"Inclusion criteria:~male patients with ED defined by an IIEF-5 score of ≤ 21~age between 18-45a~Exclusion criteria:~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~pure psychogenic (non-organic) ED with good spontaneous / nightly erections~periodontal treatment within the last 3 months~antibiotic intake within the last 3 months"
33022024|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
33022025|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
33022026|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
33022027|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
33106386|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
33022028|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
33022029|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
33022030|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
33022031|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
33022032|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
33022033|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
33022034|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
33022035|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
33022036|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
33022037|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
33022038|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
33022039|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
33022040|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
33022041|NCT01852422||Pelvic prolapse|
33022042|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
33022043|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
33022044|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
33022045|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
33022046|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
33022047|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
33022048|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
33022049|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
33022050|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
33022051|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
33022052|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
33022053|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
33022054|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
33022055|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
33022056|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
33022057|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
33022058|NCT01852578|Experimental|1|
33022059|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022060|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022061|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022062|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022063|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022064|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33106387|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
33022065|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
33022066|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
33022067|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
33022068|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
33022069|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
33022070|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
33022071|NCT01852643|Active Comparator|Spreader graft|
33022072|NCT01852643|Active Comparator|Lateral crural overlay|
33022073|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
33022074|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
33022075|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
33022076|NCT01852682|Experimental|PA21|
33022077|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
33022078|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
33022079|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
33022080|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
33022081|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
33022082|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
33022083|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
33022084|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
33022085|NCT01852760||UC in Remission|Patients with UC in remission
33022086|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
33022087|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
33022088|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
33022089|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
33022090|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
33022091|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
33022092|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
33326217|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
33326218|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
33326219|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
33326220|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
33326221|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
33326222|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
33416649|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
33022093|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
33022094|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
33022095|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
33022096|NCT01852903|Experimental|calcium ascorbate|
33022097|NCT01852903|Active Comparator|ascorbic acid|
33022098|NCT01852903|Placebo Comparator|placebo|
33022099|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
33022100|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
33022101|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
33022102|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
33022103|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
33022104|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
33022105|NCT01852981|No Intervention|Control|Control group.
33022106|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
33022107|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
33022108|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
33022109|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
33022110|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
33022111|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
33022112|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
33022113|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
33022114|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
33022115|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
33022116|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
33022117|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
33022118|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
33022119|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
33022120|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
33022121|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
33022122|NCT01853189|Other|OMT + Usual Care|
33022123|NCT01853189|Other|Usual Care|
33022124|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
33022125|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
33022126|NCT01853241||Single balloon|Single Balloon Enteroscopy
33022127|NCT01853241||Spirus|Spirus Enteroscopy
32866559|NCT04317144|Active Comparator|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
32866560|NCT04317144|Active Comparator|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
33022128|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
33022129|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
33022130|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
33022131|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
33022132|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
33022133|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
33022134|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
33022135|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
33022136|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
33022137|NCT01853358|Experimental|NK Cell infusion|"Cell collection~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~NK Cell selection~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~NK Cell ex-vivo activation~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~NK Cell infusion (60 to 90 days after transplantation)"
33022138|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
33022139|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
33022140|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
33022141|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
33022142|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
33022143|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
33022144|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
33022145|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
33022146|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
33022147|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
33022148|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
33022149|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
33022150|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
33022151|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
33022152|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
33022153|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
33022154|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
33022155|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
33022156|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
33022157|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
33022158|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
32866561|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
33416650|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
32866562|NCT04826250|Experimental|Hypertensive patients - nighttime medication|Hypertensive patients will be instructed to take their medication in the evening for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the morning for four weeks.
33022159|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
33022160|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
33022161|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
33022162|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
33022163|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
33022164|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
33022165|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
33022166|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
33022167|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
33022168|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
33022169|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
33022170|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
33022171|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
33022172|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
33022173|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
33022174|NCT01853852|Experimental|50 mg|GR181413A/AT1001
33022175|NCT01853852|Experimental|150 mg|GR181413A/AT1001
33022176|NCT01853852|Experimental|450 mg|GR181413A/AT1001
33022177|NCT01853852|Placebo Comparator|Placebo|placebo
33022178|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
33022179|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
33022180|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
33022181|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
33022182|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
33022183|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
33022184|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
33022185|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
33022186|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
33022187|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
33022188|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
33022189|NCT01853969||Patients who have carpal tunnel release surgery|
33022190|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
33326223|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
33326224|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
33326225|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
33326226|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
33326227|NCT01260480|Experimental|[18F]-ML-10|
33326228|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
33326229|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
33326230|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
33022191|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
33022192|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
33022193|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
33022194|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
33022195|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
33022196|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
33022197|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
33022198|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
33022199|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
33022200|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
33022201|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
33022202|NCT01854112||T-cell lymphoma|
33022203|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
33022204|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
33022205|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
33022206|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
33022207|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
33022208|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
33022209|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
33022210|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
33022211|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
33022212|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
33022213|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
33022214|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
33022215|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
33022216|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
33022217|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
33022218|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
33022219|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
33022220|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
33326231|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
33416651|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
33022221|NCT01854398|Experimental|CPAP group|
33416652|NCT04924881|Experimental|Active Arm|COVID Rehab Formula granules once daily for 8 weeks
32902239|NCT01550731|Experimental|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
32902240|NCT01550731|Active Comparator|CONTROL|The control group will only receive an advance directive.
32902241|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
33416653|NCT04924881|Placebo Comparator|Placebo Arm|Placebo granules once daily for 8 weeks
33416654|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
33416655|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
32902242|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
32902243|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
32902244|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
32902245|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
32902246|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
32902247|NCT03905876|Other|assessment of psychological experience|Questionnaire
32902248|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
32902249|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
32902250|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
32902251|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
32902252|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
32902253|NCT04132388|Active Comparator|Standard-of-Care|Subjects will be instructed to take adalimumab according to the labeled dosing regimen. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
32902254|NCT04132388|Experimental|Electronic Reporting|"Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
32902255|NCT04944030|Experimental|SCLC (small cell lung cancer)|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
32902256|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) without oncogenic addiction:|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
32902257|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) with oncogenic addiction|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
32902258|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
32902259|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
32902260|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
33416656|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
33106388|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
33106389|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
33106390|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
33106391|NCT03177291|Active Comparator|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
33106392|NCT03177291|Active Comparator|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
33106393|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
33106394|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
33106395|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
33106396|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
33106397|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
33106398|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
33106399|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
33416657|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
33416658|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
33416659|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
33416660|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
33416661|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
33416662|NCT03141905|Active Comparator|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
33416663|NCT03141905|Placebo Comparator|Usual Care|Standard clinical care
33416664|NCT05383638|Other|Health promotion|Health education and popularization of science
33416665|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
33416666|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
33416667|NCT04917315|Experimental|JLP-2002|Drug: JLP-2002
33416668|NCT04917315|Placebo Comparator|Placebo|Drug: Placebo
33416669|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
33416670|NCT03612024||request for organ donation approved|
33416671|NCT03612024||request for organ donation rejected|
33106400|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
33106401|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
33106402|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
33106403|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
33106404|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
33106405|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
33106406|NCT05018832|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
33106407|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
33106408|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
33416672|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
33416673|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
33416674|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
33022222|NCT01854398|Sham Comparator|sham-CPAP group|
33022223|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
33022224|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
33022225|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
33022226|NCT01854437||placebo|placebo 1 tab TDS
33022227|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
33022228|NCT01854450|Other|control|usual obstetrical care
33022229|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
33022230|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
33022231|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
33022232|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
33022233|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
33022234|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
33022235|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
33022236|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
33022237|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
33022238|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
33022239|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
33022240|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
33022241|NCT01854541||Radiotherapy|All patients receiving radiotherapy
33022242|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
33106409|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
33022243|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
33022244|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
33022245|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
33022246|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
33022247|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
33022248|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
33022249|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
33022250|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
33022251|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
33022252|NCT01854671|No Intervention|standard care|
33106410|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
33106411|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
33106412|NCT05007132|Experimental|Arm A|Trifluridine/tipiracil, 35 mg/m² body surface area (BSA), twice daily, orally on days 1-5 and 8-12 Panitumumab at 6 mg/kg bodyweight, intravenous infusion on days 1 and 15
33416675|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
33416676|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
33416677|NCT04887597|Experimental|Secukinumab Treatment|all patients receive Secukinumab as well as a biopsy before and after treatment
33416678|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
33022253|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
33022254|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
33022255|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
33022256|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
33022257|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
33022258|NCT01854749|Experimental|S1 combined with cisplatin|
33022259|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
33022260|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
33022261|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
33022262|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
33022263|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
33022264|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
33022265|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
33022266|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
33022267|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
33022268|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
33022269|NCT01854892|Experimental|Manipulation|Spinal manipulation
33022270|NCT01854892|Experimental|Mobilization|Spinal mobilization
33022271|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
33022272|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
33022273|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
33022274|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
33022275|NCT01854970|Experimental|Patient|
33022276|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
33022277|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
33022278|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
33022279|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
33022280|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
33022281|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
33022282|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
33022283|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
33022284|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
33106413|NCT05007132|Active Comparator|Arm B|Trifluridine/tipiracil, 35 mg/m² body surface area, twice daily, orally on days 1-5 and 8-12 Bevacizumab at 5 mg/kg bodyweight, intravenous infusion on days 1 and 15
33106414|NCT04684017|Experimental|Anlotinib plus etoposide and carboplatin|Etoposide and carboplatin plus anlotinib for 4 cycles and anlotinib as maintenance therapy
33106415|NCT00554450|Experimental|Arm 1|50 mg single dose
33106416|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
33106417|NCT05000151||Patients|Hypermobile Ehlers-Danlos patients (n=21)
33106418|NCT05000151||Healthy subjects|Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients
33106419|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
33106420|NCT00554528|Other|B|patient receiving intersomatic cage
33106421|NCT04683198|Experimental|Experimental: camrelizumab +apatinib+ Carboplatin + Etoposide|Induced stage：camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1 ; maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
33106422|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
33106423|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
33106424|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
33106425|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a fixed dose of 240 mg nivolumab every two weeks or 480 mg every four weeks until progression.
33106426|NCT03075423|Active Comparator|Standard of Care therapy|Standard of Care therapy is administered according to the physician´s decision.
33106427|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
33106428|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
33106429|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
33106430|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
33106431|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
33106432|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
33106433|NCT04683276|Active Comparator|small flap medium-sized macular hole (SFMM)|small flap (1-2 disc-diameter) was performed in medium sized macular hole (250-400 um)
33106434|NCT04683276|Active Comparator|large flap medium-sized macular hole (LFMM)|large flap (3-4 disc-diameter) was performed in medium sized macular hole (250-400 um)
33416679|NCT04192266|Experimental|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
33416680|NCT04192266|Placebo Comparator|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
33416681|NCT01370018|Experimental|alpha-1 proteinase inhibitor in HIV|HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor
33106435|NCT04683276|Active Comparator|small flap large-sized macular hole (SFLM)|small flap (1-2 disc-diameter) was performed in Large sized macular hole (>400 um)
33106436|NCT04683276|Active Comparator|large flap Large-sized macular hole (LFLM)|large flap (3-4 disc-diameter) was performed in large sized macular hole (>400 um)
33106437|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
33106438|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
33106439|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
33106440|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
33106441|NCT04678622||Classic Orthrosis|Group of patients who they will wear the usual splint indicated by the servicio physicians
33416682|NCT01359397|Active Comparator|Herceptin -|
33416683|NCT01359397|Experimental|Herceptin +|
33416684|NCT05250245|Active Comparator|CPAP only group|Patients who are going to receive only CPAP treatment for their moderate-to-severe obstructive sleep apnea syndrome (OSAS)
32866563|NCT04826250|Experimental|Hypertensive patients - morning medication|Hypertensive patients will be instructed to take their medication in the morning for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the evening for four weeks.
32866564|NCT00437255|Active Comparator|1|Clobex® Spray
33022285|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
33022286|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~pharmacogenetics~pharmacokinetics of SN-38~carboxylesterase activity in the index lesion~midazolam clearance test (only in Rotterdam patients)"
33022287|NCT01855100||Rivaroxaban|
33022288|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
33022289|NCT01855113||braces|those with braces for orthodontic correction.
33022290|NCT01855139||Rivaroxaban|
33022291|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
33022292|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
33022293|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
33022294|NCT01855165|No Intervention|General advice|
33022295|NCT01855191||Standard|
33022296|NCT01855191||Standard + saliva collection|
33022297|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
33022298|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
33022299|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
33022300|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
33022301|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
33022302|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
33022303|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
33022304|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
33022305|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
33022306|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
33022307|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
33022308|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
33022309|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
33022310|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
33022311|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
33022312|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
33022313|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
33022314|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
33022315|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
33022316|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
33022317|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
33022318|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
33416685|NCT05250245|Active Comparator|Combined use of CPAP and tolterodine|Patients who are going to receive combined use of CPAP and tolterodine 4mg a day treatment for their OSAS
33416686|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
33416687|NCT02068664||Observational|prism adaptation treatment
33416688|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
33106442|NCT04678622||3D Orthrosis|Group of patients who they will wear the personalized splint designed by the company OPTIMUS 3D.
33106443|NCT04986891||subjects before first chemotherapy cycle with no neuropathy|at least 75 consecutive subjects sent for an evaluation before 1st chemotherapy cycle (TNSc score equal to 0 which means no neuropathy);
33106444|NCT04986891||subjects with stable CIPN condition after chemotherapy completion|subjects sent for an evaluation due to stable CIPN condition (CIPN defined as TNSc > or = 1) after chemotherapy completion (at least 2 months off treatment).
33106445|NCT04971798|Experimental|Cell-free Stem cell-derived Extract Formulation (CCM)|Intraarticular administration of CCM
33106446|NCT04678388|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
33106447|NCT04678388|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
33106448|NCT04678388|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
33106449|NCT04678388|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
33106450|NCT04678388|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
33106451|NCT04678388|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
33106452|NCT02884206|Experimental|LCZ696|Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.
33106453|NCT02884206|Active Comparator|Valsartan|Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.
33106454|NCT04678973|Experimental|Intervention|Participants in the intervention group will receive a 4 week program delivered via text message. Week 1 will include psychoeducation delivered via brief readings and video. Weeks 2-4 will include daily guided mindfulness practice focusing on self-compassion and weight and body image concerns.
33106455|NCT04678973|No Intervention|Wait-list control|Participants in the control group will receive no study content during the 4 week intervention period. They will receive access to intervention content (text messages, audio files) after completing end-of-treatment surveys 4 weeks after randomization.
33106456|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
33106457|NCT04961541|Experimental|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
33106458|NCT04961541|Experimental|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
32866565|NCT00437255|Active Comparator|2|Taclonex® Ointment
33106459|NCT04961541|Experimental|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
33326232|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
33326233|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
33106460|NCT04961541|Experimental|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
33106461|NCT04961541|Experimental|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
33106462|NCT04961541|Experimental|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
33106463|NCT04961541|Experimental|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
33106464|NCT04961541|Experimental|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
33106465|NCT04961541|Experimental|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
33106466|NCT04961541|Experimental|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
33106467|NCT04961541|Experimental|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
33106468|NCT04961541|Experimental|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
33106469|NCT04961541|Experimental|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
33106470|NCT04961541|Experimental|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
33106471|NCT04961541|Experimental|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
33326234|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
32866566|NCT04316286|Experimental|Tele-multidisciplinary participants|Patients undergoing televisit
33106472|NCT04961541|Experimental|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
33106473|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
33106474|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
33106475|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
33326235|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
33416689|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
33416690|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
33022319|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
33022320|NCT01855373|Other|Placebo|No active ingredient
33022321|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
33022322|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
33022323|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
33022324|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
33022325|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
33022326|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
33022327|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
33022328|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
33022329|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
33022330|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
33022331|NCT01855503||Metastatic Breast Cancer|
33022332|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
33022333|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
33022334|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
33022335|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
33022336|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
33022337|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
33022338|NCT01855555||sedation group|Children requiring sedation for MRI/CT
33022339|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
33022340|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
33022341|NCT01855581||sedation group|Children requiring sedation for MRI/CT
33022342|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
33022343|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
33022344|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
33022345|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
33022346|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
33022347|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
33022348|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
33022349|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
33022350|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
33022351|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
33022352|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
33022353|NCT01855685|Experimental|Open label|X vivo gene therapy
33022354|NCT01855698||All patients registered|
33022355|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
33022356|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
33022357|NCT01855737||Warfarin Using Group|
33022358|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
33022359|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
33022360|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
33022361|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
33022362|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~$0 SGD for less than 50,000 steps during the week~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
33022363|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
33022364|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
33022365|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
33022366|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
33022367|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
33022368|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
33022369|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
33022370|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
33022371|NCT01855932|Experimental|Technology Supported|
33022372|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Treatment period: 3 months (from month 1 to month 4)~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
33022373|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
33022374|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
33022375|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
33022376|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
33022377|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
33022378|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
33416691|NCT05249933|Placebo Comparator|Control group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 200ml warm water. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
33022379|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
33022380|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
33022381|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
33022382|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
33022383|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
33022384|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~Class 1a/1c antiarrhythmics~Sotalol~Amiodarone"
33022385|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
33022386|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
33022387|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
33022388|NCT01856127|Experimental|Vilazodone|Vilazodone
33022389|NCT01856127|Active Comparator|Sertraline|Sertraline
33022390|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
33022391|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
33022392|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
33022393|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
33022394|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
33022395|NCT01856179|Experimental|Echium oil young|"BMI<25,~age 20-30"
33022396|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
33022397|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
33022398|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
33022399|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
33022400|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
33022401|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
33022402|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
33022403|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
33022404|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
33022405|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
33022406|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
33022407|NCT01856374|Active Comparator|Cypher group|
33022408|NCT01856374|Experimental|Xience group|
33022409|NCT01856374|Active Comparator|Pravastatin group|
33022410|NCT01856374|Experimental|Atorvastatin group|
33022411|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
33022412|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
33022413|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
33022414|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
33022415|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
33022416|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
33022417|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
33022418|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
33022419|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
33022420|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
33022421|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
33022422|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;~Suspected but without known prior history of CAD~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~Glomerular filtration rate >60 ml/min~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
33022423|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
33022424|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
33022425|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
33022426|NCT01856556|Placebo Comparator|Placebo|Saline
33022427|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
33022428|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
33022429|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
33022430|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
33022431|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
33022432|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
33022433|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
33022434|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
33022435|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
33022436|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
33022437|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
33022438|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
33022439|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~Patient's > 10 kg will receive DPF 10 mg BID + OBR~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
33022440|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
33022441|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
33022442|NCT01856647||psoriatic lean|9 psoriatic lean
33022443|NCT01856647||psoriatic obese|9 psoriatic obese
33022444|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
33022445|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
32866567|NCT04316286|Other|In-office standard participants|Patients undergoing in-office visits
33022446|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
33022447|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
33022448|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
33022449|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
33022450|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
33022451|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
33022452|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
33022453|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
33022454|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
33022455|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
33022456|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
33022457|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
33022458|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
33022459|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
33022460|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
33022461|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
33022462|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
33022463|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
33022464|NCT01856881|Active Comparator|AMG 876|
33022465|NCT01856881|Placebo Comparator|Placebo|
33022466|NCT01856920|Experimental|A|GI-6207 for 1 year
33022467|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
33022468|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
33022469|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
33022470|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
33022471|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
33022472|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
33022473|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
33022474|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
33022475|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
33022476|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
33022477|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
33022478|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
33022479|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
33022480|NCT01857037|Other|Single arm|Single arm
33022481|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
33022482|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
33022483|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
33022484|NCT01857089|Experimental|Pressure Measurement|
33022485|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
33022486|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
33022487|NCT01857141|Experimental|dexmedetomidine|
33022488|NCT01857141|Placebo Comparator|normal saline|
33022489|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
33106476|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
33326236|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
33022490|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
33022491|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
33022492|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
33022493|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
33022494|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
33022495|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
33022496|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
33022497|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
33022498|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
33022499|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
33022500|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
33022501|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
33022502|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
33022503|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
33022504|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
33022505|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
33022506|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
33022507|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
33022508|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
33022509|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
33022510|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
33022511|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
33022512|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
33022513|NCT01857401||Observational study|Blood draw only, observational study
33022514|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
33022515|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
33022516|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
33022517|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
33022518|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
33022519|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
33022520|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
33326237|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
33327266|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
33022521|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
33022522|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
33022523|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
33022524|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
33022525|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
33022526|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
33022527|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
33022528|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
33022529|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
33022530|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
33022531|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
33022532|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
33022533|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
33022534|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
33022535|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
33022536|NCT01857648|No Intervention|Control|Control group.
33022537|NCT01857661|Other|control|hearing aid without an integrated sound generator
33022538|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
33022539|NCT01857687||patients with coronary artery stenosis|
33022540|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
33022541|NCT01857700|Placebo Comparator|Standard of Care|
33022542|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
33022543|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
33022544|NCT01857752|Experimental|temozolomide|
33022545|NCT01857765|Active Comparator|Standard of Care|
33022546|NCT01857765|Experimental|Rehabilitation|
33022547|NCT01857778||Lactating Women|
33022548|NCT01857791|Experimental|multidisciplinary, behavior modification|
33022549|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
33022550|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
33022551|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
33022552|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
33022553|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
33022554|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
33022555|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
33022556|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
33022557|NCT01857843|Experimental|ZES group|
33022558|NCT01857843|Active Comparator|EES group|
33022559|NCT01857843|Experimental|Vytorin group|
33022560|NCT01857843|Active Comparator|Mevalotin group|
33022561|NCT01857856|No Intervention|No treatment|no medical treatment
33022562|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
33106477|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
33106478|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
33106479|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
33106480|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
33106481|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
33106482|NCT04941456|Active Comparator|Open Tracheostomy|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
33106483|NCT04941456|Experimental|PMV in place|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
33106484|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
33106485|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
33106486|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
33106487|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
33416692|NCT05249933|Experimental|Pronase group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 20000 IU pronase Granules Combined with 1 g NaHCO3 dissolved in 200ml warm water to maintain the intragastric pH at 6 - 8. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
33416693|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
33106488|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
33106489|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
33106490|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
33106491|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
33106492|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
33106493|NCT04927494|Experimental|Black women cervical cancer screening|Participants in this group with receive the Health is Wealth intervention.
33106494|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
33106495|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
33106496|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
33106497|NCT02791542||Asthma|Participants with a history of asthma
33106498|NCT02791542||Healthy controls|Participants without a history of asthma
33106499|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
33106500|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
33106501|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
33106502|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
33327267|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
33327268|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
33106503|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
33106504|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
33106505|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
33106506|NCT04922697|Experimental|Prevention (educational videos, questionnaires)|Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
33106507|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
33106508|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
33106509|NCT04918095||Moderate-Severe COPD|COPD patients diagnosed GOLD 2- 3, C- D for moderate-severe, poorly controlled
33106510|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
33106511|NCT04917822|Experimental|Emotion regulation arm|The emotion regulation arm aims at improving emotional regulation skills among parents and children.
33106512|NCT04917822|Active Comparator|Information provision arm|The information provision arm aims at providing information about Hong Kong, such as education, community resources, medical care, employment, housing, and job-seeking among parents and children.
33106513|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
33106514|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
33106515|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
33106516|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
33106517|NCT04678076|Experimental|ketoprofen 25mg/5ml oral gel stick pack|Single dose of ketoprofen 25mg/5ml oral gel stick pack will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
33106518|NCT04678076|Active Comparator|OKi 80 mg granules for oral solution (bipartite sachet)|Single dose of half sachet containing 40 mg of ketoprofen lysine salt (corresponding to 25 mg as ketoprofen) will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
33106519|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
33106520|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
33106521|NCT00554645|Experimental|1|Multi-disciplinary group intervention
33106522|NCT00554645|Active Comparator|2|traditional information
33106523|NCT02257619|Experimental|Itacitinib plus docetaxel|
33106524|NCT04683471|Experimental|Neuromodulation|Neuromodulation
33106525|NCT04683471|Sham Comparator|Sham|Sham
33106526|NCT02235272|Experimental|XG-102|
33106527|NCT02235272|Placebo Comparator|Placebo|
33106528|NCT04891302|Experimental|Clevudine|Clevudine 150 mg once a day for 10 days
33106529|NCT04891302|Placebo Comparator|Placebo|Matching Placebo once a day for 10 days
33106530|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
33106531|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
33106532|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
33106533|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
33106534|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
33106535|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
33326238|NCT05095584|Experimental|validity and reliability of 3 meter backward walking test|"This study was conducted as test-retest design and the psychometric properties of 3-m backward walk test were examined in LLA. The Rivermead Mobility Index, 3-m backward walk test, Berg Balance Scale, Timed Up and Go test were applied to the patients. An experienced physiotherapist performed all these tests. In order to measure test-retest reliability, the second evaluations (retest) were carried out by the same physiotherapist two days following the first evaluation (test). A same evaluator collected data in order to avoid the inter-rater variability error rate between the evaluations. The patient was evaluated at one time of the day for test and retest."
33106536|NCT04857645|Experimental|ASTX727 treatment|
33106537|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
33106538|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
33106539|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
33106540|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
33106541|NCT02585622|Placebo Comparator|Cryostor CS10|
33022563|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
33022564|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
33022565|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
33022566|NCT01857921|Active Comparator|Pravastatin group|
33022567|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
32866570|NCT04826172|Experimental|IMB-1018972 200mg|
32866571|NCT04826172|Placebo Comparator|Placebo|
33022568|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
33022569|NCT01857960||Adolescents|Acne survey among Mexican adolescents
33022570|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
33022571|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
33022572|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
33022573|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
33022574|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
33022575|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
33022576|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
33022577|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
33022578|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
33022579|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
33022580|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
33022581|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
33022582|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
33022583|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
33022584|NCT01858116|Experimental|[68Ga]ABY-025|
33022585|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
33022586|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
33022587|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
33022588|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
33022589|NCT01858155|Experimental|Melatonin|
33022590|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
33022591|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
33022592|NCT01858168|Experimental|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
33022593|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
33022594|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
33022595|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
33022596|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
33022597|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
33022598|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
33022599|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
33022600|NCT01858233|No Intervention|Routine care|standard dietary counseling
33022601|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
33022602|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
33022603|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
33022604|NCT01858259||azathioprine|Patients receiving azathioprine
33022605|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
33022606|NCT01858259||methotrexate|Patients receiving methotrexate
33022607|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
33022608|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
33022609|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
33022610|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
33022611|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
33022612|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
33022613|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
33022614|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
33022615|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
33022616|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
33022617|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
33022618|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
33022619|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
33022620|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
33022621|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
33022622|NCT01858350|No Intervention|No intervention|
33022623|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
33022624|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
33022625|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
33022626|NCT01858415|Experimental|Single arm|
33022627|NCT01858441|Other|Abiraterone Acetate|
33022628|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
33022629|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
33022630|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
33022631|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
33022632|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
33022633|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
33022634|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
33022635|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
33022636|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
33022637|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
33022638|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
33022639|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
33326239|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
33326240|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
33326241|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
33326242|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
33326243|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
32866572|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
33022640|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
33022641|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~Capsules of same size and color as used in metronomic therapy Best supportive care~Management of pain as per WHO standard for pain management"
33022642|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
33022643|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
33022644|NCT01858584|No Intervention|control group|
33022645|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
33022646|NCT01858597||control|Those healthy pregnant women
33022647|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
33022648|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
33022649|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
33022650|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
33022651|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
33022652|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
33022653|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
33022654|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
33022655|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
33022656|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
33022657|NCT01858675|Experimental|Biomarkers, total blood volume|
33022658|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
33022659|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
33022660|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
33022661|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
33022662|NCT01858727|No Intervention|control group|do not active heating group
33022663|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
33022664|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
33022665|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
33416694|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
33416695|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
33416696|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
33416697|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
33416698|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
32866573|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
33022666|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
33022667|NCT01858818||healthy 18 year old males|
33022668|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
33022669|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
33022670|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
33022671|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
33022672|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
33022673|NCT01858857||Geriatric psychiatric in patients|
33022674|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
33022675|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
33022676|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
33022677|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
33022678|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
33022679|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
33022680|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
33022681|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
33022682|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
33022683|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
33022684|NCT01858935|Placebo Comparator|Placebo|
33022685|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
33022686|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
33022687|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
33022688|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
33022689|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
33022690|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
33022691|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
33022692|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
33022693|NCT01859052|Other|low-fat diet|Obese Migraineurs
33022694|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
33022695|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
33022696|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
33022697|NCT01859091|Experimental|Fat Reduction|
33022698|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
33022699|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
33022700|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
33022701|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
33022702|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
33022703|NCT01859156||Carbon Monoxide Exposure|
33106542|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.~Each study cycle is 21 days."
33106543|NCT02223182|Experimental|Viaskin Milk 150 mcg|
33106544|NCT02223182|Experimental|Viaskin Milk 300 mcg|
33106545|NCT02223182|Experimental|Viaskin Milk 500 mcg|
33106546|NCT02223182|Placebo Comparator|Viaskin Placebo|
33106547|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
33106548|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
33106549|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
33106550|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
33106551|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
33106552|NCT02525757|Experimental|Group 1: Chemotherapy + Radiation|"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
33106553|NCT02525757|Experimental|Group 2: MPDL3280A + Chemotherapy + Radiation|"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
33106554|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
33106555|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
33106556|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
33106557|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
33106558|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
33106559|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
33106560|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
33106561|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
33106562|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
33106563|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
33106564|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
33106565|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
33106566|NCT02409303|No Intervention|Control|No intervention received.
33106567|NCT00554723|Experimental|A|NeuroAid
33106568|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
33106569|NCT04851288|Experimental|MitoQ, 20 mg/day|Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
33106570|NCT04851288|Placebo Comparator|Placebo|Matched placebo capsules.
33326244|NCT01262196|Experimental|MP4OX|250-mL dose
33326245|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
33106571|NCT04669145|Experimental|Continuous Regional Anesthesia Lower Limb Surgery|Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks A catheter will be placed for the given block for 48 hours. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
33326246|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
33326247|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
33326248|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
33326249|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
33326250|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
33326251|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
33416699|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
33416700|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
33416701|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
33416702|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
33022704|NCT01859169||Control Group|Group that be administrated biliary drainage only
33022705|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
33022706|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33022707|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
33022708|NCT01859260|No Intervention|Control|
33022709|NCT01859260|Experimental|Intervention|CPAP/autopap
33022710|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
33022711|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
33022712|NCT01859286||regular sign out process|
33022713|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
33022714|NCT01859351|Experimental|WX-037|PI3K inhibitor
33022715|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
33022716|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
33022717|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
33022718|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
33022719|NCT01859416|No Intervention|Control|Usual nutritional care
33022720|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
33022721|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
33022722|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
33022723|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
33022724|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
33022725|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
33022726|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
33022727|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
33022728|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
33022729|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
33022730|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
33022731|NCT01859481|Placebo Comparator|Placebo|
33022732|NCT01859481|Experimental|Eletriptan HBr 40 mg|
33022733|NCT01859481|Experimental|Eletriptan HBr 80 mg|
33022734|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
33022735|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
33022736|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
33022737|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
33022738|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
33022739|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
33022740|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
33022741|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
33022742|NCT01859585|Experimental|Parecoxib|Parecoxib
33022743|NCT01859585|Experimental|Ketorolac|Ketorolac
33022744|NCT01859585|No Intervention|No medication|No medication
33022745|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
33022746|NCT01859650||NSCLC patients undergoing RT|
33022747|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
33022748|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
33022749|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
33022750|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
33022751|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
33022752|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
33022753|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
33022754|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
33022755|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
33022756|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
33022757|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
33022758|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
33022759|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
33022760|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
33022761|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
33022762|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
33022763|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
33022764|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
33022765|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
33022766|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
33022767|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
33022768|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
33022769|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
33022770|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
33022771|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
33022772|NCT01860053|Experimental|behavioral intervention|
33022773|NCT01860053|No Intervention|no treatment control|
32902261|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
32902262|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
32902263|NCT04991688|Experimental|BOTOX-A|
32902264|NCT03693014|Experimental|Stereotactic Body Radiotherapy|Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
32902265|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
32902266|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
32902267|NCT04081688|Experimental|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
32902268|NCT01797692|Other|geriatric assessment|geriatric assessment
32902269|NCT04989738|Experimental|THRIVE Condition|Specifically, parents will learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
32902270|NCT04989738|Active Comparator|Care As Usual - Healthy Steps Model|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
32902271|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
32902272|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
32902273|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
32902274|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
32902275|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
32902276|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
32902277|NCT01507987||Patients with SJM leads implanted|Patient has at least one market released Riata, Riata ST, QuickSite/QuickFlex, or Durata lead implanted
32902278|NCT03906578|Active Comparator|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks
32902279|NCT03906578|Placebo Comparator|Placebo|Two sachets placebo in the evening for 8 weeks
32902280|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
32902281|NCT03265808|Placebo Comparator|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
32902282|NCT03195764|Experimental|T-1101 (Tosylate)|
32902283|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
32902284|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
32902285|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
32902286|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
32902287|NCT03095612|Experimental|Selinexor Monotherapy and in Combination with Docetaxel|"For the selinexor monotherapy cohort, 6 patients each will be treated in two dosing cohorts (weekly and biweekly). Selinexor once weekly oral (40mg, 60mg, 80mg) OR Selinexor twice weekly oral (60mg, 40mg, 60mg weekly).~Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks."
32902288|NCT04081922|Experimental|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
32902289|NCT04081922|No Intervention|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
33022774|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
33416703|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
33416704|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
33416705|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
33417530|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
33022775|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
33022776|NCT01860105|Active Comparator|75mg MDCO-157|iv
33022777|NCT01860105|Active Comparator|150mg MDCO-157|iv
33022778|NCT01860105|Active Comparator|300mg MDCO-157|iv
33022779|NCT01860105|Active Comparator|300mg PLAVIX|oral
33022780|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
33022781|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
33022782|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
33022783|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
33022784|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.~This is minimal intervention and considered the control arm."
33022785|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
33022786|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
33022787|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
33022788|NCT01860183|Experimental|MMF 3g daily|
33022789|NCT01860183|Active Comparator|MMF 2 g daily|
33022790|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
33022791|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
33022792|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
33022793|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
33022794|NCT01860222|Active Comparator|SR|
33022795|NCT01860222|Experimental|PLAT|
33022796|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
33022797|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
33022798|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
33022799|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
33022800|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
33022801|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
33022802|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
33022803|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
33022804|NCT01860274|Experimental|External Mesh|
33022805|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
33022806|NCT01860300|Placebo Comparator|Placebo|Placebo
33022807|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
33326252|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
33326253|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
33326254|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
33326255|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
33326256|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
33326257|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
33022808|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
33022809|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
33022810|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
33022811|NCT01860352|Other|Fish Oil|
33022812|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
33022813|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
33022814|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
33022815|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
33022816|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
33022817|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
33022818|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
33022819|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).~Supervision of primary care professionals through an internet site run by a team of specialists.~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
33022820|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
33022821|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
33022822|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
33022823|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
33022824|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
33022825|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
33022826|NCT01860508|Experimental|pemetrexed|
33022827|NCT01860547|Experimental|bilberry|
33022828|NCT01860547|Experimental|sea buckthorn berry|
33022829|NCT01860547|Experimental|sea buckthorn phenolic extract|
33022830|NCT01860547|Experimental|sea buckthorn oil|
33022831|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
33022832|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
33022833|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
33022834|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
33022835|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠~placebo : 3 people, 12.5㎠"
33022836|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠~placebo : 3 people, 25㎠"
33022837|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠~placebo : 3 people, 50㎠"
33022838|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
33326258|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
33326259|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
33326260|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
33326261|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
33326262|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
32902290|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
32902291|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
32902292|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
32902293|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
32902294|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
32902295|NCT04054076|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
32902296|NCT04054076|Experimental|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
32902297|NCT04054076|Experimental|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
32902298|NCT04054076|No Intervention|Control group|No intervention with therapeutic insoles and/or shoes.
32902299|NCT03796754|Active Comparator|YoBEKA Intervention|
32902300|NCT03796754|No Intervention|Control group|
32902301|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
32902304|NCT04019522|Experimental|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
32902305|NCT04989504|Active Comparator|Arm I (standard of care)|Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
32902306|NCT04989504|Experimental|Arm II (Mepitel Film)|Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
32902307|NCT04011800|Active Comparator|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
32902308|NCT04011800|Experimental|Risk factor modification|Patiemt will undergo risk factor intervention and antiarrhythmic drugs
32902309|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
32902310|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
32902311|NCT03971630|No Intervention|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
32902312|NCT03971630|Experimental|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
32902313|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
32902314|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
32902315|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
32902316|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
32902317|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
32902318|NCT03663452|Active Comparator|Prolonged exposure training|
32902319|NCT03663452|Experimental|TACTICS|
32902320|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
32902321|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
33326263|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
33326264|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
33326265|NCT01152840|Experimental|RAD001|RAD001 daily po medication
33326266|NCT01262274|Active Comparator|ANA|
33326267|NCT01262274|Experimental|ANA+UFT|
33326268|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
33326269|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
33326270|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
33022839|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
33022840|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
33022841|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
33022842|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
33022843|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
33022844|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
33022845|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
33022846|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
33022847|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
33022848|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
33022849|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
33022850|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
33022851|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
33022852|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
33022853|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
33022854|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
33022855|NCT01860820|No Intervention|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
33022856|NCT01860820|Active Comparator|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
33022857|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
33022858|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
33022859|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
33022860|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
33022861|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
33022862|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
33022863|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
33326271|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
33326272|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
33326273|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
33022864|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
33022865|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
33022866|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
33022867|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
33022868|NCT01860872||Combined Group|MRI Quality & Image Relatedness
33022869|NCT01860885||Patients requiring naloxone for respiratory depression|
33022870|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
33022871|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
32902322|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
32902323|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
32902324|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
32902325|NCT03925220|Experimental|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the live session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
32902326|NCT03925220|Active Comparator|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating & Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet live with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
32902327|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
32902328|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
32902329|NCT04988022|Experimental|Dupilumab|dupilumab 600mg loading dose at Baseline (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
32902330|NCT04988022|Placebo Comparator|Placebo|matching placebo loading dose at Baseline (given as two injections) followed by one weekly subcutaneous injection through Week 24. Starting at Week 24, dupilumab 600mg loading dose (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
32902331|NCT03916094|Experimental|HLX22 group|HLX22, at four dose levels (3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
32902332|NCT04987476||ATRT|Children affected by an ATRT at time of surgical resection
32902333|NCT04986852|Experimental|Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg|"Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15~Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)"
32902334|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
32902335|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
32902336|NCT02076074|Experimental|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
32902337|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
32902338|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
32902339|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
32902340|NCT05566171|No Intervention|Control Group|This group will be just follow-up for 4 weeks without any intervention
32902341|NCT05566171|Experimental|Interventional Group|This group will consume 125 g plain Activia Probiotic Yogurt without any aroma/fruit during 4 weeks/1 month
32902342|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
32902343|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
32902344|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
32902345|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
32902346|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
32902347|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
32902348|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
32902349|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
32866574|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
33022872|NCT01860924|Active Comparator|health education|health education control
33022873|NCT01860924|Experimental|exercise|vigorous supervised exercise
33022874|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
33022875|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
33022876|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
33022877|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
33022878|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
33022879|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
33022880|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
33022881|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
33022882|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
33022883|NCT01861080||incident hypertensives|"Inclusion Criteria:~age≧30years~primary incident hypertension~signed informed consent"
33022884|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
33022885|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
33022886|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
33022887|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
33022888|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
33022889|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
33022890|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
32866575|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
32866576|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
33022891|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
33022892|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
33326274|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
33022893|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
33022894|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
33022895|NCT01861197|Experimental|Dovitinib monotherapy|
33022896|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
33022897|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
33022898|NCT01861223|Experimental|afatinib + nimotuzumab|
33022899|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
33022900|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
33022901|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
33022902|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
33022903|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
33022904|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
33022905|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
33417531|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
33022906|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
33022907|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
33022908|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
33022909|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
33022910|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
33022911|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
33417532|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
33022912|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
33022913|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
33022914|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
33022915|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
33022916|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
33022917|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
33022918|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
33022919|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
33022920|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
33022921|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
33326275|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
33326276|NCT01154478|Experimental|C group|Diet rich in polyphenols
33326277|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
33326278|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
33326279|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
33416706|NCT02032836|Experimental|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
33417533|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
33417534|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
33417535|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
33022922|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
33022923|NCT01861444||Cohort|
33022924|NCT01861470||Preterm infants|all <32 weeks
33022925|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
33022926|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
33022927|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
33022928|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
33022929|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
33022930|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
33022931|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
33022932|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
33022933|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
33022934|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
33022935|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
33022936|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
33022937|NCT01861626|Other|sequence 1 : Test drug - Reference|
33022938|NCT01861626|Other|Sequence 2 : Reference - Test drug|
33022939|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
33022940|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
33022941|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
33022942|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
33022943|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
33022944|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
33022945|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
33022946|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
33022947|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
33022948|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
33022949|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
33022950|NCT01861691|Active Comparator|Open surgery|Open colectomy
33022951|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
33022952|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
33022953|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
33022954|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
33022955|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
33022956|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
32746753|NCT04331691|Active Comparator|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
33022957|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
33022958|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
33022959|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
33022960|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
33022961|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
33022962|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
33022963|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
33022964|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
33022965|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
33022966|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
33022967|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
33022968|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
33022969|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
33022970|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
33022971|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
33022972|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
33022973|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
33022974|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
33022975|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
33022976|NCT01861938|Experimental|Melanoma vaccine|
33022977|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily~Duration of treatment:~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
33022978|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.~Duration of treatment:~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
33022979|NCT01861964|Placebo Comparator|Sugar Pill|
33022980|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
33022981|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
33022982|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
33326280|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
33326281|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
33326282|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
33106572|NCT04669145|Experimental|Single Shot Regional Anesthesia Lower Limb Surgery|"Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks. These blocks will be given via a single dose or single shot. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia."
33326283|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
33326284|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
33106573|NCT04669145|Experimental|Continuous Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
33106574|NCT04669145|Experimental|Single Shot Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
33106575|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
33106576|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
33106577|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
33326285|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
33326286|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
33106578|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
33106579|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
33106580|NCT01967511||Healthy control subjects|
33106581|NCT04668911||Controls tested PCR (-) for COVID-19|
33106582|NCT04668911||Tested PCR (+) for COVID-19, Mild - not admitted to the hospital|
33106583|NCT04668911||Tested PCR (+) for COVID-19, Severe - admitted to ICU (Intensive Care Unit)|
33106584|NCT01962636|Experimental|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
33326287|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
33106585|NCT04669106||Healthy group|90 research subjects coming from mothers who had healthy children
33106586|NCT04669106||Stunting group|90 research subjects came from mothers who had stunted children or other nutritional disorders
33106587|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
33106588|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
33326288|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
33326289|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
33326290|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
33326291|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
33326292|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
33326293|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
33326294|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
33326295|NCT01262430|Active Comparator|OtisMed|
33326296|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
33326297|NCT01259622|Placebo Comparator|placebo|
33416707|NCT02032836|Experimental|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
33416708|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~Boost 10 Gy in 5 fr: PTV = +1cm.~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
33416709|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~Boost 26 Gy in 13 fr: PTV = +1cm.~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
33416710|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
33022983|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
33022984|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
33022985|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
33022986|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
33022987|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
33022988|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
33022989|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
33022990|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
33022991|NCT01862068||MPA patients|
33022992|NCT01862068||Healthy Blood Donors|
33022993|NCT01862068||Atherosclerotic patients|
33022994|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
33022995|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
33022996|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
33022997|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
33022998|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
33022999|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
33023000|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
33023001|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
33023002|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
33023003|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
33023004|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
33023005|NCT01862120|Placebo Comparator|placebo|placebo
33023006|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
33023007|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
33023008|NCT01862172|Other|additional MRI|
33023009|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
33023010|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
33023011|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
33023012|NCT01862211|Experimental|members of family of children with a DA1AT|
33023013|NCT01862211|Experimental|children with a DA1AT|
33023014|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
33023015|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
33023016|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
33023017|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
33023018|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
33416711|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
33416712|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
33023019|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
33023020|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
33023021|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
33023022|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
33023023|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
33023024|NCT01862367||rFXIII|
33023025|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
33023026|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
33023027|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
33023028|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
33023029|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
33023030|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
33023031|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
33023032|NCT01862432|Experimental|immediate skin-to-skin|
33023033|NCT01862432|No Intervention|control|
33023034|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
33023035|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
33023036|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
33023037|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
33023038|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
33023039|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
33023040|NCT01862523|Placebo Comparator|diluent|diluent
33023041|NCT01862523|Experimental|capsaicin|capsaicin
33023042|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
33023043|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
33023044|NCT01862549|Active Comparator|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
33023045|NCT01862562|Active Comparator|Open surgery|Conventional procedure
33023046|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
33023047|NCT01862601|Experimental|JetTouch injections|
33023048|NCT01862627||Macular retinoschisis and detachment|
33023049|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
33023050|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
33416713|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
33416714|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
33416715|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
33416716|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
33416717|NCT02068898|Experimental|Tasigna|Marketed capsule
33416718|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
33326298|NCT01259622|Experimental|K201|intravenous K201
33023051|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
33023052|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
33023053|NCT01862692|Active Comparator|Developmental Awareness Skils|
33023054|NCT01862692|Experimental|Baby-Net condition|
33023055|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
33023056|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
33023057|NCT01862809||cases|smokers
33023058|NCT01862809||controls|non-smokers
33023059|NCT01862822|Experimental|upright position|Upright position during urine bag collection
33023060|NCT01862822|No Intervention|usual position|
33023061|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
33023062|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
33023063|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
33023064|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
33023065|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
33023066|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
33023067|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
33023068|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
33023069|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
33023070|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
33023071|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
33023072|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
33023073|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
33023074|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
33023075|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
33023076|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
33023077|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
33023078|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
33023079|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
33023080|NCT01862978|Experimental|Heparin|Patient receiving Heparin
33326299|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
33023081|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
33023082|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
33023083|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
33023084|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
33023085|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
33326300|NCT01155804|Other|Exercice|
33326301|NCT01155804|Other|non-exercice|
33326302|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
33326303|NCT01589874||acute ill patients|
33326304|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
33326305|NCT01154556||HIV1 positive, NNRTI exposure and failure|
33326306|NCT01260792||Children|Children between 5 and 18 years old.
33106589|NCT04668755|Active Comparator|Charcot Restraint Orthotic Walker 3d printed sole|the group fit with Charcot Restraint Orthotic Walker 3d printed sole for 12 week. the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
33106590|NCT04668755|Active Comparator|Generic Charcot Restraint orthotic walker|the group fit with Generic Charcot Restraint Orthotic Walker for 12 week.the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
33106591|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
33106592|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
33106593|NCT01722240|Placebo Comparator|Placebo|Daily Injection
33106594|NCT04668482|Experimental|SCS off|SCS is switched off
33106595|NCT04668482|Experimental|SCS on|SCS is switched on
33106596|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
33106597|NCT04668560|Experimental|Intervention|Course intervention, six weeks wellbeing course
33106598|NCT04668560|No Intervention|Control|Follow-up as usual
33106599|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
33106600|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
33106601|NCT04668404||COVID-19 positive patient with ARDS|All patients with COVID-19 diagnosed with RT-PCR.
33106602|NCT01484730||Vascular Occulsion|Multi-Spectral & Laser Speckle Imaging
33106603|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33416719|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
33106604|NCT04668287|Other|Increasing Self-Esteem|All participants will be included in working groups.
33106605|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
33106606|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
33106607|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
33106608|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
33106609|NCT05423470|Experimental|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
33416720|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
33416721|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
33106610|NCT05423470|Sham Comparator|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
33106611|NCT04668053|Active Comparator|Traditional training protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills
33106612|NCT04668053|Experimental|Hip flexor resistance protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills and hip flexors resistance protocol
33106613|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
33106614|NCT04667936||moderate to severe COVID-19 ARDS|patients with an oxygenation index <200 under intubation anesthesia and mechanical ventilation.
33106615|NCT04667975|Experimental|Part 1(Dose escalation)|"Part 1: 3 or 6 subjects are enrolled, per each dose group in a traditional 3+3 design.~Begin with the starting dose determined by the non-clinical study and increase the dose according to the dose levels. If DLT does not occur in the 3 subjects when they have completed the 1st cycle at each dose level, increase the dose to the next level. Dose escalation proceeds until the maximum tolerated dose (MTD) is reached.~Dose-limiting toxicity (DLT) is evaluated following the completion of dosing for the 1st cycle of all subjects enrolled in each dose group in order to determine whether to proceed to the next level. Following completion of the DLT evaluation of the planned dose level in this study, the SRC reviews the outcome of the evaluation and determines whether to set additional dosing or proceed to PART 2 (Dose expansion)."
33106616|NCT04667975|Experimental|Part 2(Dose expansion)|"Part 2: The primary objective of Part 2 is to evaluate the efficacy of CKD-702 by identifying the ORR after administering the RP2D of CKD-702 determined in Part 1. Along with this, to determine the CKD-702 effective patient group, the patient groups were classified into several cohorts based on non-clinical study results.~Therefore, in Part 2, the RP2D determined in Part 1 is administered until the occurrence of an adverse event causing PD occurrence, death or treatment discontinuation, and tumor response is evaluated based on RECIST version 1.1."
33106617|NCT04831593||Group Elective|In our clinic, pediatric patients who will undergo elective surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in elective pediatric patients before general anesthesia.
33023086|NCT01863056|Experimental|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
33023087|NCT01863056|No Intervention|Control|Used normal work desk which only allows working sitting down
33023088|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
33023089|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
33023090|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
33023091|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
33023092|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
33023093|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
33023094|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
33023095|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
33023096|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
33023097|NCT01863173|Active Comparator|metoprolol|patient or intervention group
33023098|NCT01863173|Active Comparator|placebo group|control group
33023099|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
33023100|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
33023101|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
33023102|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
33023103|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
33023104|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
33023105|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
33023106|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
33023107|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
33023108|NCT01863238||Ivacaftor Treated|
33023109|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
33023110|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
33023111|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
33023112|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
33023113|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
33023114|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
33023115|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
33023116|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
33023117|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
33023118|NCT01863342||CSI score < 40|CSI cutoff value<40
33023119|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
33023120|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
33023121|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
33023122|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
33023123|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
33326307|NCT01260792||Adults|Parents of children between 5 and 18 years old
33326308|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
33326309|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
33326310|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
33416722|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
33417536|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
33023124|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.~CHWs will screen children 06-59 months in their village once a month"
33023125|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns~Mothers will be asked to check their child's MUAC and look for pedal oedema~whenever the child does not seem to be in 'good health' to the mother~whenever the mother feels that the child is 'unwell' or 'sick'~whenever it seems to the mother that her child has lost weight~whenever the mother thinks that it is necessary to do so"
33023126|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
33023127|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
33023128|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
33023129|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
33023130|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
33023131|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.~Placebo is taken once per day for 8 weeks"
33023132|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
33023133|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
33023134|NCT01863485|Experimental|CM082|CM082 tablet
33023135|NCT01863511|Active Comparator|usual care|IV loop diuretics
33023136|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
33023137|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
33023138|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
33023139|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
33023140|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
33023141|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
33023142|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
33023143|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
33023144|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33023145|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33023146|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
33023147|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
33023148|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
33416723|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
33023149|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
33023150|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
33023151|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
33023152|NCT01863693||Cohort|
33023153|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
33023154|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
33023155|NCT01863719|Experimental|Cohort 1|9 Subjects
33023156|NCT01863719|Experimental|Cohort 2|9 Subjects
33023157|NCT01863719|Experimental|Cohort 3|9 Subjects
33023158|NCT01863719|Experimental|Cohort 4|12 Subjects
33023159|NCT01863784|Experimental|JNJ-38518168|
33023160|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.~When the participants reached the active phase they were monitored according to the clinical guidelines."
33023161|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
33023162|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
33023163|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
33023164|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
33023165|NCT01863823|Other|Mouth washing|Mouth washing
33023166|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
33023167|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
33023168|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
33023169|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
33023170|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
33023171|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
33023172|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
33023173|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
33023174|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
33023175|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
33023176|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
33023177|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
33023178|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
33023179|NCT01863979||Acute Atrial Fibrillation|
33023180|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
33023181|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
33023182|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
33326311|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
33326312|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
33023183|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
33023184|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
33023185|NCT01864096|Experimental|Metformin|
33023186|NCT01864096|Placebo Comparator|Placebo|
33023187|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
33326313|NCT03884244|Active Comparator|taking chewing gum patients|
33326314|NCT03884244|No Intervention|no chewing gum|
33326315|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
33326316|NCT01261026||Abnormal intrauterine pregnancy|
33326317|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
33326318|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
33023188|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
33023189|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
33023190|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
33023191|NCT01864213|Experimental|Ametop cream|
33023192|NCT01864226|Placebo Comparator|Placebo|
33023193|NCT01864226|Experimental|RO5545965|
33023194|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
33023195|NCT01864239|No Intervention|Control|Usual care
33023196|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
33023197|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
33023198|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
33023199|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
33023200|NCT01864265|Active Comparator|Certolizumab Pegol|
33023201|NCT01864265|Placebo Comparator|Placebo|
33023202|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
33023203|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
33023204|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
33023205|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
33023206|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
33023207|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
33023208|NCT01864317|Other|Healthy subjects|30 healthy control subjects
33023209|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
33023210|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
33023211|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
33023212|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
33023213|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
33023214|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
33023215|NCT01864356|Placebo Comparator|Placebo|Placebo
33023216|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
33023217|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
33023218|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
33023219|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
33023220|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
33023221|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
33023222|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
33023223|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
33326319|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
33326320|NCT01261104||Hearing impaired elderly|
33326321|NCT01261104||Hearing impaired adults|
33326322|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
33326323|NCT01259700|Experimental|High risk management|
33326324|NCT01259700|Experimental|Salt reduction|
33326325|NCT01259700|Experimental|high risk management and salt reduction|
33023224|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
33023225|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
33023226|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
33023227|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
33023228|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
33023229|NCT01864473|Other|Kshar Sutra|
33023230|NCT01864486|Experimental|Intelligent Retinal Implant System|
33023231|NCT01864499|Experimental|Tumor Resection|
33023232|NCT01864499|Active Comparator|Biopsy Brain Tumor|
33023233|NCT01864512||ITP patients receiving eltrombopag therapy|
33023234|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
33023235|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
33023236|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
33023237|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
33023238|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
33023239|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
33023240|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
33023241|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
33023242|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
33023243|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
33023244|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
33023245|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
33023246|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
33023247|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
33326326|NCT01259700|No Intervention|Usual care|
33326327|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
33326328|NCT01262586|Experimental|Vildagliptin|
33326329|NCT01262586|Active Comparator|Glimepiride|
33326330|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
33326331|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
33326332|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
33326333|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
33326334|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
33326335|NCT01261182|Experimental|In School Feeding|
33326336|NCT01261182|Experimental|Take Home Rations|
33326337|NCT01261182|No Intervention|Control|
33326338|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
33326339|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
33326340|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
33326341|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
33326342|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
33326343|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
33326344|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
33326345|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
33326346|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
33326347|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
33326348|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
33327269|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
33327270|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
33327271|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
33023248|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
33023249|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
33023250|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
33023251|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
33023252|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
33023253|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
33023254|NCT01864694|Experimental|Control|Assessment-only control group
33023255|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
33023256|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
33023257|NCT01864707|Active Comparator|usual care|usual care without additional treatment
33023258|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:~Physical rehabilitation including endurance and resistance exercises two to three times a week.~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
33023259|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
33023260|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
33023261|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
33023262|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
33023263|NCT01864798|Experimental|Denosumab|
33023264|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
33023265|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
33023266|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
33023267|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
33023268|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
33023269|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
33023270|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
33023271|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
33023272|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
33023273|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
33023274|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
33023275|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
33023276|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
33327272|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
33023277|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
33023278|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
33023279|NCT01864928||Stroke population|Adults with ischemic stroke.
33023280|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
33023281|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
33023282|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
33023283|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
33023284|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
33023285|NCT01864967||control|did not receive carbon dioxide
33327273|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
33327274|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
33327275|NCT01178346|Experimental|NicVAX|Experimental vaccine
33327276|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
33023286|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
33023287|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
33023288|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
33023289|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
33023290|NCT01865006||Ligasure LF1212|
33023291|NCT01865006||Ultracision|
33023292|NCT01865006||Conventional|
33023293|NCT01865019||volume controlled|volume ontrolled ventilation
33023294|NCT01865019||pressure controlled|pressure controlled ventilation
33023295|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
33023296|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
33023297|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
33023298|NCT01865097|Experimental|Relaxation guided imagery|
33023299|NCT01865097|Active Comparator|Relaxing music|
33023300|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
33023301|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
33023302|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
33023303|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
33023304|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
33023305|NCT01865149||both optic nerve sheath diameter|
33023306|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
33023307|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
33023308|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
33023309|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
33023310|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
33023311|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
33023312|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
33023313|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
33023314|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
33023315|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
33023316|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
33023317|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
33023318|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
33023319|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
33023320|NCT01865227|No Intervention|Standard treatment|
33023321|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
33327277|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
33023322|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
33023323|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
33023324|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
33023325|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
33023326|NCT01865266|Placebo Comparator|CG|"The compare group(CG):~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
33023327|NCT01865279|Experimental|Trial part 1|
33023328|NCT01865279|Active Comparator|Trial part 2|
33023329|NCT01865292|Experimental|Insulin degludec|
33023330|NCT01865292|Active Comparator|Insulin glargine|
33023331|NCT01865305|Experimental|Trial part 1|
33023332|NCT01865305|Experimental|Trial part 2|
33023333|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
33023334|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
33023335|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
33023336|NCT01865331|Experimental|Low dose, insulin degludec|
33023337|NCT01865331|Experimental|Medium dose, insulin degludec|
33023338|NCT01865331|Experimental|High dose, insulin degludec|
33023339|NCT01865331|Experimental|IDegAsp 50|
33023340|NCT01865344||Heart surgery|Pain monitoring at different time periods
33023341|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
33023342|NCT01865357|Experimental|Control|healthy subject
33023343|NCT01865370|Experimental|Kochujang Pills|
33023344|NCT01865370|Placebo Comparator|Placebo|
33023345|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
33023346|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
33023347|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
33023348|NCT01865422|Experimental|chronic cough|
33023349|NCT01865435|Experimental|new borns|
33023350|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
33023351|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
33023352|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
33023353|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
33023354|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
33023355|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
33023356|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
33023357|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at~EC junction requiring total gastrectomy,~Duodenum requiring Whipple operation;~Large GIST requiring multiviceral resection;~Rectum: requiring APR."
33023358|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
33023359|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
33023360|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
33023361|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
33023362|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
33023363|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
33023364|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
33023365|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
33023366|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
33023367|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
33023368|NCT01865656|No Intervention|Control Arm|
33023369|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
33023370|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
33023371|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
33416724|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
33416725|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
33106618|NCT04831593||Group Emergency|In our clinic, pediatric patients who will undergo emergency surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in emergency pediatric patients before general anesthesia.
33416726|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
33416727|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
33416728|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
33416729|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
33416730|NCT05030363|Experimental|Upfront ALDH enzyme supplement|Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
33416731|NCT05030363|Other|Delayed ALDH enzyme supplement|Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1). On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
33023372|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
33023373|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
33023374|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
33023375|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
33023376|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
33023377|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
33023378|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
33023379|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
33023380|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
33023381|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
33416732|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
33023382|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
33327278|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
32866577|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
33023383|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
33023384|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
33023385|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
33023386|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
33023387|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
33023388|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
33023389|NCT01865864||1|Compliant with CPAP
33023390|NCT01865864||2|noncompliant with CPAP
33023391|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
33023392|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
33023393|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
33023394|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
33023395|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
33023396|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
33023397|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
33023398|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
33023399|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
33023400|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
33023401|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
33023402|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
33023403|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
33023404|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
33023405|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
33023406|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
33023407|NCT01865981||Brugada|Patients suffering from Brugada syndrome
33023408|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
33023409|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
33023410|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
33023411|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
33023412|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
33023413|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
33023414|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
33023415|NCT01866059|Experimental|Calcium silicate cement|Biodentine
33023416|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
33023417|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
33023418|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
33023419|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
33023420|NCT01866085|Active Comparator|AdVance|sling procedure
33023421|NCT01866085|Active Comparator|ARGUS|sling procedure
33023422|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
33023423|NCT01866124|No Intervention|Comparison group|
33023424|NCT01866137||no treatment|no treatment
33023425|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
33023426|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
33023427|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
33023428|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
33023429|NCT01866215|No Intervention|study 1c|no exercise
33023430|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
33023431|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
33023432|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
33023433|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
33023434|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
33023435|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
33023436|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
33023437|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
33023438|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
33023439|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
33023440|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
33023441|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
33023442|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
33416733|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
33023443|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
33023444|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
33023445|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
33023446|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
33023447|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
33023448|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
33023449|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
33023450|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
33023451|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
33023452|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
33023453|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
33023454|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
33023455|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
33023456|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
33023457|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
33023458|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
33416734|NCT04034355|Experimental|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
33326349|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
33326350|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
33326351|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
33326352|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
33326353|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
33023459|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
33326354|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
33326355|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
33326356|NCT03881826|Experimental|Haematological patients|
33326357|NCT03881826|Active Comparator|Healthy volunteers|
33023460|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
33023461|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
33023462|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
33023463|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
33023464|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
33023465|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
33023466|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
33023467|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
33023468|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
33023469|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
33023470|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
33023471|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
33023472|NCT01866579||ethambutol optic neuropathy|
33023473|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
33023474|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
33023475|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
33023476|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
33023477|NCT01866631||No treatment|
33023478|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
33023479|NCT01866644|Placebo Comparator|Saline|With usual technique
33023480|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation~Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the experimental group, it will be developed the support spiritual intervention in all three meetings.~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
33023481|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
33023482|NCT01866683|Experimental|Group 1|1 month respiratory training
33023483|NCT01866683|Experimental|Group 2|1 month waiting period
33023484|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
33023485|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
33023486|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
33023487|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
33023488|NCT01866735|No Intervention|Usual Care|
33023489|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
33023490|NCT01866748|Experimental|Part A (single dose)|
33023491|NCT01866748|Experimental|Part B (multiple dose)|
33023492|NCT01866761||Periodontitis, Lifestyle-related disease|
33023493|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
33023494|NCT01866774|No Intervention|Symptom questionnaire|
33023495|NCT01866787||Study cohort|
33023496|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
33023497|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
33023498|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
33023499|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
33023500|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
33023501|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
33023502|NCT01866878|No Intervention|A control group|
33023503|NCT01866891|Experimental|single arm|
33023504|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
33023505|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
33023506|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
33023507|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
33023508|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
33023509|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
33023510|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
33023511|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
33023512|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
33023513|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
33023514|NCT01867073||Advanced solid tumours|
33023515|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
33023516|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
33326358|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
33023517|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
33023518|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
33023519|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
33023520|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
33023521|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
33023522|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
33023523|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
33023524|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
33023525|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
33023526|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
33023527|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
33023528|NCT01867190|Other|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
33023529|NCT01867203||Statin users|
33023530|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
33023531|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
33023532|NCT01867242|Experimental|Complete Substitution|Use snus in place of cigarettes
33023533|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
33023534|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
33023535|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
33023536|NCT01867268|No Intervention|Control|control group without any intervention
33023537|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
33023538|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
33023539|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
33023540|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
33023541|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
33023542|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
33023543|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
33023544|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
33023545|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
33023546|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
33023547|NCT01867476||Healthy Normals|
33023548|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
33326359|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
33326360|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
33326361|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
33326362|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
33326363|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
33326364|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
33326365|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
33326366|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
33326367|NCT05666934|Experimental|Home-based Augmented Reality Storybook Training Module|The children were entirely involved in this intervention program at home, with 20 minutes each time, 4 times a week for 8 weeks. The caregiver was required to perform the interactive picture book specified by the AR home training modules. During the process, the caregivers could directly contact the researcher by telephone and instant messaging for solving problems that occur during the interaction. The researcher and the caregiver consistently met once every two weeks. On the day of the meeting, the caregiver needs to prepare at least ten minutes of interactive video to discuss with the researcher. The researcher not only provides suggestions for caregiver interaction skills based on the video, in order to facilitate the child's interaction. The interaction strategies were also revised according to the interaction ability and special behavior problems of individual children.
33326368|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
33023549|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
33023550|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
33023551|NCT01867528|Experimental|Laparoscopic adhesiolysis|
33023552|NCT01867528|Active Comparator|Open adhesiolysis|
33023553|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
33023554|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
33023555|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
33023556|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
33023557|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
33023558|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
33023559|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
33023560|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
33023561|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
33023562|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
33023563|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
33023564|NCT01867723|No Intervention|Control group|Control group get usual care
33023565|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
33023566|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
33023567|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
33023568|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
33023569|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
33023570|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
33023571|NCT01867788||Parkinson's disease subjects|
33023572|NCT01867788||Healthy Control subjects|
33023573|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
33023574|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
33023575|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
33023576|NCT01867840||arthritis|
33023577|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
33023578|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
33023579|NCT01867866|Experimental|TAS-102|
33023580|NCT01867866|Experimental|FTD (Trifluridine)|
33023581|NCT01867879|Experimental|TAS-102|
33023582|NCT01867879|Placebo Comparator|Placebo|
33023583|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
33023584|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
33023585|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
33023586|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
33023587|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
33023588|NCT01867931||Erosive Esophagitis|
33023589|NCT01867931||Non-erosive Reflux Disease|
33023590|NCT01867931||Heatlhy volunteers|
33416735|NCT04034355|Placebo Comparator|Placebo|0.9% sodium chloride in 20 mL vials
33416736|NCT05210699|Experimental|Product usage order A B N C E D|Subjects will use each of the 5 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
33023591|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
33023592|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
33023593|NCT01867957|Experimental|Low-dose GC1109|
33023594|NCT01867957|Placebo Comparator|Low-dose Placebo|
33023595|NCT01867957|Experimental|High-dose GC1109|
33023596|NCT01867957|Placebo Comparator|High-dose Placebo|
33023597|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
33023598|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
33023599|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
33023600|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
33023601|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
33023602|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
33023603|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
33023604|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
33023605|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
33023606|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
33023607|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
33023608|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
33023609|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
33023610|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
33023611|NCT01868100|No Intervention|self-completion questionnaire|
33023612|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
33023613|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
33023614|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
33023615|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
33023616|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
33023617|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
33023618|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
33023619|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
33023620|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
33023621|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
33023622|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
33023623|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
33023624|NCT01868230|No Intervention|Standard of Care|
33023625|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
33023626|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
33023627|NCT01868282|Experimental|Group 1|Hamstrings block
33023628|NCT01868282|Active Comparator|Group 2|Obturator block
33023629|NCT01868282|Sham Comparator|Group 3|Control group
33023630|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
33023631|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
33023632|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
33023633|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
33023634|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
33023635|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
33023636|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
33023637|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
33023638|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
33023639|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
33023640|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
33023641|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
33023642|NCT01868399||Suspected dengue fever subjects|No any intervention
33023643|NCT01868399||Community Healty Residents|No intervention
33023644|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
33023645|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
33023646|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
33023647|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
33023648|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
33023649|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
33023650|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
33023651|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
33023652|NCT01868490|Experimental|drug|single-group studies
33023653|NCT01868529|Experimental|Low dose|
33023654|NCT01868529|Experimental|Medium dose|
33023655|NCT01868529|Experimental|High dose|
33023656|NCT01868555|Experimental|IDegAsp 30|
33023657|NCT01868555|Experimental|IDegAsp 45|
33023658|NCT01868555|Experimental|insulin degludec (B)|
33023659|NCT01868555|Experimental|insulin degludec (E)|
33023660|NCT01868568|Experimental|IDegAsp 30 + placebo|
33023661|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
33023662|NCT01868568|Experimental|IDegAsp 40 + placebo|
33023663|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
33023664|NCT01868568|Experimental|IDegAsp 45 + placebo|
33023665|NCT01868568|Experimental|Insulin aspart + insulin degludec|
33023666|NCT01868568|Experimental|IDegAsp 55 + placebo|
33023667|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
33023668|NCT01868568|Active Comparator|BIAsp 30 + placebo|
33023669|NCT01868581|Experimental|insulin degludec|
33023670|NCT01868581|Experimental|IDegAsp|
33023671|NCT01868607||Adult lung function|
33023672|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
33023673|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
33023674|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
33023675|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
33023676|NCT01868672|No Intervention|Control|Participant receives usual care.
33023677|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
33023678|NCT01868685|Placebo Comparator|Placebo|
33023679|NCT01868685|Experimental|BYM338|
32866578|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
32866579|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
32866580|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
32866581|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
33023680|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
33023681|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
33023682|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
33023683|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
33023684|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
33023685|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
33023686|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
33023687|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
33023688|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
33023689|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
33023690|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
33023691|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
33023692|NCT01868802|Experimental|Ketamine treated|
33023693|NCT01868802|Placebo Comparator|Control, placebo treated|
33023694|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
33023695|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
33023696|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
33023697|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
33023698|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
33023699|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
33023700|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
33023701|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
33023702|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
32866582|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
33023703|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
33023704|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
33023705|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
33023706|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
33023707|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
33023708|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
33023709|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
33106619|NCT04825509||Successful weaning group|Patients will be in this group according to primary outcome, if they will succeed spontaneous breathing trial for 120 minutes and will be extubated successfully without need for invasive or non-invasive ventilation for 48 hours
33106620|NCT04825509||Weaning failure group|"Patients will be in this group according to primary outcome, if they will fail spontaneous breathing trial or extubation within 48 hours~Weaning failure will be considered if:~Patients will need MV during spontaneous breathing trial within 120 minutes, or~patients will need invasive or non-invasive ventilation within 48 hours"
33106621|NCT04667897|Experimental|601 1.25mg|
33106622|NCT04667897|Experimental|Ranibizuman 0.5 mg|
33106623|NCT04683081||Foley catheter group|pregnant women who were applied Foley catheter for cervical ripening
33106624|NCT04683081||Cook balloon catheter group|pregnant women who were applied Cook balloon catheter for cervical ripening
33106625|NCT04683081||Modified double-balloon Foley catheter group|pregnant women who were applied modified double-balloon Foley catheter for cervical ripening
33106626|NCT01209832|Experimental|Drug Interaction arm|
33106627|NCT04667819|Experimental|sodium hyaluronate|Sodium hyaluronate has become a novel and effective eye drop for the treatment of the dry eye. However, we design a special method of usage of sodium hyaluronate in dry eye patients.
33106628|NCT04683159|No Intervention|Control|No intervention, only routine pre-operative drops
33106629|NCT04683159|Experimental|Brimonidine 0.15%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.15% in the operating eye
33106630|NCT04683159|Experimental|Brimonidine 0.025%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.025% in the operating eye
33106631|NCT01230892|Active Comparator|Nebivolol|
33106632|NCT01230892|Active Comparator|Atenolol|
33106633|NCT04667624|Active Comparator|Reference|TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)
33106634|NCT04667624|Experimental|Test|LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)
33106635|NCT04667351|Active Comparator|5-fu 2400|
33106636|NCT04667351|Experimental|5-fu 1200|
32866583|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
32866584|NCT00212147|Experimental|General anesthesia with nitrous oxide|
33106637|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
33106638|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
33106639|NCT04811235|Experimental|Arm 1|NIRS monitoring of spinal cord oxygenation and hemodynamics
33106640|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
33106641|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
33106642|NCT04810377|Experimental|EUS-guided gastroenterostomy in malignant gastric outlet obstruction|The patients with malignant gastric outlet obstruction will be confirmed as follows: Histopathological report of cancer, thoracoabdominal tomography and impaired tolerance to oral feeding (tolerance to liquids only or null).
33106643|NCT00556595|Experimental|1|primary electrophysiological approach
33106644|NCT00556595|Active Comparator|2|primary anatomical approach
33106645|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
33106646|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
33106647|NCT04809090|Active Comparator|SMT Group|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews
33106648|NCT04809090|Experimental|SMT+CA|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews and subjects will use an APP together a CA (Conversational Agent) an Artificial Intelligence.
33106649|NCT04809090|Experimental|Only CA|This group will receive only an APP together a CA (Conversational Agent) an Artificial Intelligence.
33106650|NCT04809090|No Intervention|Waiting-List|This group will not receive any intervention
33106651|NCT00556634|Active Comparator|B|
33106652|NCT00556634|Experimental|A|
33106653|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
33106654|NCT04805736|Experimental|Microwave Ablation alone|Microwave Ablation+ Breast Surgery
33416737|NCT05210699|Experimental|Product usage order B C A D N E|Subjects will use each of the 5 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
32866585|NCT00212147|Active Comparator|General anesthesia without nitrous oxide|
33106655|NCT04805736|Experimental|Camrelizumab alone|Camrelizumab+ Breast Surgery
33106656|NCT04805736|Experimental|Microwave Ablation & Camrelizumab|Microwave Ablation + Camrelizumab + Breast Surgery
33106657|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
33106658|NCT04667273|Experimental|Exercise Training (ET) + Neuromuscular Electrical Stimulation (NMES) group|volunteer patients with Subacromial Impingement Syndrome
33106659|NCT04667273|Other|Exercise Training (ET) group|volunteer patients with Subacromial Impingement Syndrome
33106660|NCT04798677|Experimental|Influenza vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Influenza vaccine followed by 30 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
33106661|NCT04798677|Placebo Comparator|Influenza vaccine + placebo|Influenza vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
33106662|NCT04798677|Experimental|Covid-19 vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Covid-19 vaccine followed by 35 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
33416738|NCT05210699|Experimental|Product usage order C D B E A N|Subjects will use each of the 5 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
33326369|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
33326370|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
33326371|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
33416739|NCT05210699|Experimental|Product usage order D E C N B A|Subjects will use each of the 5 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
33023710|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
33023711|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
33023712|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
33023713|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
33023714|NCT01868945|Active Comparator|20 µg/day vitamin D3|
33023715|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
33023716|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
33023717|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
33023718|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
33023719|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
33023720|NCT01869010||HIV Tenofovir|
33023721|NCT01869010||HIV No tenofovir|
33023722|NCT01869010||Seronegative controls|
33023723|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
33023724|NCT01869036|Active Comparator|caudal anesthesia|
33023725|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
33023726|NCT01869049||ITP patients accepted splenectomy|
33023727|NCT01869049||Trauma with spleen rupture underwent splenectomy|
33023728|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
33023729|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
33023730|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
33023731|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
33023732|NCT01869127|No Intervention|Control|Standard care
33023733|NCT01869127|Experimental|Shoes|Shoes
33023734|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
33023735|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
33023736|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
33023737|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
33023738|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
33023739|NCT01869179|Experimental|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
33023740|NCT01869179|Experimental|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
33023741|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
33023742|NCT01869231|Experimental|major surgery|colic surgery
33023743|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
33023744|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
33023745|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
33023746|NCT01869244||hand resting splint|Patients with hand resting splint treatment
33023747|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
33023748|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
33106663|NCT04798677|Placebo Comparator|Covid-19 vaccine + placebo|Covid-19 vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
33416740|NCT05210699|Experimental|Product usage order E N D A C B|Subjects will use each of the 5 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
33416741|NCT05210699|Experimental|Product usage order N A E B D C|Subjects will use each of the 5 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
33416742|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
32866586|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
33023749|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
33023750|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
33023751|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
32866587|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
32866588|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
32866589|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
33023752|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
33023753|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
33023754|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
33023755|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
33023756|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
33023757|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
33023758|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
33023759|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
33023760|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
33023761|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
33023762|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
33023763|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
33023764|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
33023765|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
33023766|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
33023767|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
33023768|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
33023769|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
33023770|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
33023771|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
33023772|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
33023773|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
33023774|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
33023775|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
33023776|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
33023777|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
33023778|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
33023779|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
32866590|NCT04428450|Experimental|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
32866591|NCT04428450|Experimental|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
33023780|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
33023781|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
32866592|NCT04428450|No Intervention|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
33023782|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
33023783|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
33023784|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
33023785|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
33023786|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
33023787|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
33023788|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
33023789|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
33023790|NCT01869621|Experimental|Metformin|6 days treatment with metformin
33023791|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
33023792|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
33023793|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
33023794|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
33023795|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
33023796|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
33023797|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
33023798|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
33416743|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
32866593|NCT02216097|Experimental|Treatment|
32866594|NCT02216097|Placebo Comparator|Placebo|
33023799|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
33023800|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
33023801|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
33023802|NCT01869790|Experimental|Meal challenge|Different fat types
33023803|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
33023804|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
33023805|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
33023806|NCT01869842|Active Comparator|DM, angio group|
33023807|NCT01869842|Experimental|DM, OCT group|
33023808|NCT01869842|Active Comparator|non DM, angio group|
33023809|NCT01869842|Experimental|non DM, OCT group|
33023810|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
33023811|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
33023812|NCT01869868||Depression, ECT|
33023813|NCT01869881|Active Comparator|Sarpogrelate|
33023814|NCT01869881|Placebo Comparator|Placebo|
33023815|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
33023816|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
33023817|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
33023818|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
33023819|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
33023820|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
33023821|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
33023822|NCT01869920|Other|Controll group|Usual care
33023823|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
33023824|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
33023825|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
33023826|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
33023827|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
33023828|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
33023829|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
33023830|NCT01869985|Experimental|HCP1104|HCP1104
33023831|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
33023832|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
33023833|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
33023834|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
33023835|NCT01870011|Experimental|Desflurane balanced anesthesia group|
33023836|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
33023837|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
33023838|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
33023839|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
33106664|NCT04667429|Experimental|Food effect|HEC83518 40mg will be administered fasted, or with high-fat meal for once.
33326372|NCT05482776|Active Comparator|classic training group|The classic training group followed their routine of both physical and cognitive exercises that were recorded for their control. Balance exercises, strength and aerobic exercise. They were assessed at the beginning and at the end of the 10 weeks.
33326373|NCT05482776|Experimental|HIFT group|The experimental group performed 10-weeks training program consisted in Warm-up phase and HIFT training. They were assessed at the beginning and at the end of the 10 weeks.
33326374|NCT01261260|Placebo Comparator|Uridine|1g BID
33023840|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
33023841|NCT01870037|Experimental|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
33023842|NCT01870037|Experimental|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
33023843|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
33023844|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
33023845|NCT01870063||open heart surgery|
33023846|NCT01870089|Experimental|Study group|
33023847|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
33023848|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
33023849|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
33023850|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
33023851|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
33023852|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
33023853|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
33023854|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
33023855|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
33023856|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
33023857|NCT01870141|No Intervention|Current standard of care|
33023858|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
33023859|NCT01870154|Active Comparator|Control group|Usual care
33023860|NCT01870167|Placebo Comparator|placebo|Placebo
33023861|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
33023862|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
33023863|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
33023864|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
33023865|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
33023866|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
33326375|NCT01262742|Active Comparator|Carbetocin 80mcg|
33326376|NCT01262742|Active Comparator|Carbetocin 90mcg|
33326377|NCT01262742|Active Comparator|Carbetocin 100mcg|
33326378|NCT01262742|Active Comparator|Carbetocin 110mcg|
33326379|NCT01262742|Active Comparator|Carbetocin 120mcg|
33326380|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
33023867|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
33023868|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
33023869|NCT01870245|Experimental|ACHN-975|
33023870|NCT01870245|Placebo Comparator|Placebo|
33023871|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
33023872|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
33023873|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
33023874|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
33023875|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
33023876|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
33023877|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
33023878|NCT01870310|No Intervention|Standard medical therapy|
33106665|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 20mg|HEC83518 20mg will be administered before sleep for 15 days .
33326381|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
33326382|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
33416744|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
33023879|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
33023880|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
33023881|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
33023882|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
33023883|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
33023884|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
33023885|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
33023886|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
33023887|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
33023888|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
33023889|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
33023890|NCT01870375||MPS II|Hunter syndrome patients
33023891|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
33023892|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
33023893|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
33023894|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
33023895|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
33023896|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
33023897|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
33023898|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
33023899|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
33023900|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
33023901|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
33023902|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
33023903|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
33023904|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
33023905|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
33023906|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
33023907|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
33023908|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
33023909|NCT01870479|No Intervention|Control|Usual care during chemotherapy
33023910|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
33023911|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
33023912|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
33023913|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
33023914|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
33023915|NCT01870557||Diabetes Mellitus type 1|n=100
33023916|NCT01870557||Diabetes Mellitus type 2|n=100
33023917|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
33023918|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
33023919|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
33023920|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
33023921|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
33023922|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
33023923|NCT01870570|Experimental|Food Product F: White Bread|White Bread
33023924|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
33023925|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
33023926|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
33023927|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
33023928|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
33023929|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
33023930|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
33023931|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
33416745|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
33326383|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
33326384|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
33416746|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
33416747|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
33023932|NCT01870674|Experimental|YH12852|"<SAD cohort>~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~Experimental: YH12852 10mg/single dose, qd~<FSD cohort>~Experimental: YH12852 0.5mg/single dose, qd~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 2mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~<MAD cohort>~Experimental: YH12852 0.5mg/repeat dose, qd~Experimental: YH12852 1mg/repeat dose, qd~Experimental: YH12852 2mg/repeat dose, qd~Experimental: YH12852 3mg/repeat dose, qd~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
33023933|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
33023934|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
33023935|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
33023936|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
33023937|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
33023938|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
33023939|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
33023940|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
33023941|NCT01870752|Other|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
33023942|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
33023943|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
33023944|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
33023945|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
33023946|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
33023947|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
33023948|NCT01870817|No Intervention|Control|Standard care
33023949|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
33023950|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
33023951|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
33023952|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
33023953|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
33023954|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
33023955|NCT01870895|Experimental|YM060 group|
33023956|NCT01870895|Placebo Comparator|Placebo group|
33023957|NCT01870908||tacrolimus + biological agents|
33023958|NCT01870934||Telemedicine, Diabetes, foot ulcer|
33023959|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
33023960|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
33023961|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
33023962|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
33023963|NCT01870986|Experimental|A|PF-06410293
33023964|NCT01870986|Active Comparator|B|Adalimumab-EU
33023965|NCT01870986|Active Comparator|C|Adalimumab-US
33023966|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
33023967|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
33106666|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 40mg|HEC83518 40mg will be administered before sleep for 15 days .
33023968|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
33023969|NCT01871025|Other|Usual care|Usual care in COPD
33023970|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
33023971|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
33023972|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
33023973|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
33023974|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
33023975|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
33023976|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
33023977|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
33023978|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
33023979|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
33023980|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
33023981|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
33023982|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
33023983|NCT01871194||Rivaroxaban|This is a non-interventional study
33023984|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
33023985|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
33023986|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
33023987|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
33023988|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
33023989|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
33023990|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
33023991|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
33023992|NCT01871324|Experimental|Lifestyle counseling|
33023993|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
33023994|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
33023995|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
33023996|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
33023997|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15,31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
33023998|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
33023999|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
33024000|NCT01871389||cholecalciferol|
33024001|NCT01871389||usual treatment|
33024002|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
33024003|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
33106667|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 80mg|HEC83518 80mg will be administered before sleep for 15 days .
33106668|NCT04667429|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo will be administered before sleep for 15 days .
33106669|NCT04667546|Other|Patient having urinary tract infection|Patients with a confirmed urinary tract infection in accordance with the GPIP (french Pediatric Infectious Disease Group) definition and inclusion criteria.
33106670|NCT04784754|Placebo Comparator|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
33106671|NCT04784754|Experimental|Melatonin 3 mg|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
33106672|NCT04784754|Experimental|Melatonin 30 mg|Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
33106673|NCT04666883||Splenic flexure cancer patients|Splenic flexure cancer patients
33106674|NCT04775199|No Intervention|Control|Control: In all conditions, the examiners will teach science using the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) a visual Journal/Reflection, and 4) a pre-recorded reading centered around a given theme such as sound. A research speech-language pathologist will provide two 30-minute interactive science lessons per week for six weeks to children with language learning challenges recruited nationwide. Children will participate in groups of three. Families will log on five additional times during each week to view the science book reading. In the control condition, children will receive these science lessons but no language intervention. Therefore, this intervention constitutes a nonintervention.
33106675|NCT04775199|Experimental|Science + Grammar Intervention|"Grammar: In the science + grammar condition, focused stimulation plus explicit instruction will be employed. Focused stimulation an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities.. The active ingredients are models (30) and recasts (5 per child) of the target structure (e.g., You measured how long the ramp is). Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Focused stimulation will be supplemented with explicit instruction using choral production and visual supports (3x per lesson) and a definition of the meaning of the structure (1 per lesson)."
33106676|NCT04775199|Experimental|Science + Vocabulary Intervention|Vocabulary: This arm will provide Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 12 words that pertain to scientific practices applicable to the FOSS lessons. The words are: compare, diagram, evidence, explanation, hypothesis, materials, model, multiple, pattern, problem, scientist, search. Two words will be targets in each session. The examiners will ensure that for each target word per session there will be at least one definition model and 3 other models directed to the triad of participants and at least 2 elicitations per child. The recorded books also include 6 additional exposures to the words, for a cumulative exposure of 12.
33106677|NCT04666805||Drug Group|Endocrine therapy drugs include selective estrogen receptor modulators (Tamoxifen, Toremifene) and aromatase inhibitors (Anastrozole, Letrozole, Exemestane), which have been widely used in the adjuvant treatment of hormone receptor positive breast cancer.
33106678|NCT04766853|Active Comparator|Dexamethasone+Saline|
33106679|NCT04766853|Experimental|Dexamethasone+Hyaluronic Acid|
33106680|NCT04666376|Other|Vitrified ovarian tissue|Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.
33106681|NCT04766424|Experimental|Behavioral sleep extension group|Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.
33106682|NCT04766424|Other|Health education|Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.
33106683|NCT04666337|Active Comparator|Group B (bupivacaine group)|patients received 20 ml bupivacaine 0.5% plus normal saline (2ml)
33106684|NCT04666337|Active Comparator|Group F (fentanyl group)|patients received 20 ml bupivacaine 0.5% plus fentanyl (100µg-2 ml)
33106685|NCT04666337|Active Comparator|Group T (tramadol group)|patients received 20 ml bupivacaine 0.5% plus tramadol (100mg-2 ml)
33106686|NCT04739319||Age-Related Macular Degeneration|Participants with Age-Related Macular Degeneration
33106687|NCT00556790|Other|1|Standard Care
33106688|NCT00556790|Other|2|Fast Track Care
33106689|NCT04738461|Experimental|Telerehabilitation|Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
33106690|NCT04738461|Active Comparator|Standard Physiotherapy|Patients in the standard physiotherapy group will receive one-to-one physiotherapy sessions in the hospital 5 days a week for 3 weeks. In these sessions, active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
33024004|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
33024005|NCT01871480|Active Comparator|Group B|Gefitinib alone
33024006|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
33024007|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
33024008|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
33024009|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
33106691|NCT04738461|Active Comparator|Home exercise group|The home exercise program was explained to the patients in the control group by the physiotherapist and the relevant brochures were delivered to the patients. Home exercise program will consist of telerehabilitation group exercises. However, patients will be not under any supervision and exercise themselves at home.
33106692|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
33106693|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
33106694|NCT00556907|Other|1|Patients will receive IORT
33106695|NCT04721457|Placebo Comparator|Distilled Water|Vigorously rinse with 15 ml of the distilled water for 30 s (Water for Injections BP; Pharmaceutical Solutions Industry, Jeddah, SA)
33106696|NCT04721457|Active Comparator|Povidone Iodine (PVP-I)|Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s
33106697|NCT04721457|Active Comparator|Hydrogen Peroxide (H2O2)|Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s
33106698|NCT04721457|Active Comparator|Cetylpyridinium Chloride (CPC)|Vigorously rinse with 15 ml of the 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK) for 30 s
33106699|NCT04721457|Active Comparator|Sodium Hypochlorite|Vigorously rinse with 15 ml of the 80 ppm sodium hypochlorite (NaOCl) (Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK) for 30 s
33106700|NCT04721457|Placebo Comparator|No rinse group|There is no mouth rinse in this group. Patients will collect the saliva at all 4-time points without gargling with the mouth rinse.
33106701|NCT04666415|Experimental|Osteopathic treatment + as-usual treatment|"Osteopathic treatment: a protocol of 5 sessions of osteopathic treatment that have a 25 minutes duration and are spaced of around one week between two sessions.~As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers."
33106702|NCT04666415|No Intervention|As-usual treatment|As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers.
33106703|NCT00557024|Experimental|1|radiotherapy after RFA
33106704|NCT00557024|Active Comparator|2|RFA alone
33106705|NCT04720989|Experimental|Bathing With Baby Cleanser|Skin cleansing products will be used in the first baths of the participants in this group.
33106706|NCT04720989|Experimental|Bathing With only Water|Only water will be used in the first baths of the participants in this group.
33106707|NCT04666493|Experimental|Facing Your Fears - Open label|All participants in the study will receive 12 weekly sessions of Facing Your Fears intervention, each lasting approximately 1 to 1.5 hour. Each session involves a component with all the parents and children (30-45 minutes) and a separate time with all the parents only (30-45 minutes). Additionally, there will be two check-in calls (30 minutes each) with the families after weeks 7 and 9 of the program.
33106708|NCT04711785|Active Comparator|Intervention|Multicomponent exercise program twice a week (2 hours per week) during six months
33106709|NCT04711785|No Intervention|Control Goup|Usual routine.
33106710|NCT04666220||Renal cell carcinoma (RCC)|"For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.~Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.~VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels."
33106711|NCT04666220||Adrenal carcinoma|see (RCC)
33106712|NCT04666142|Active Comparator|Individual Characteristics of the Individuals in the Experimental and Control Groups|The personal characteristics of the individuals included in the study were examined.
33106713|NCT04666142|Active Comparator|Disease Characteristics of the Individuals in Experimental and Control Groups|The intensive care experience of the individuals included in the study, their status of receiving respiratory support, and the reason for staying in the intensive care unit were explained.
33416748|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
33416749|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
33106714|NCT04666142|Active Comparator|Distribution of Findings Regarding Sleep Activity of the Individuals in Both Groups|The personal characteristics of the individuals in the experimental and control groups regarding sleep were examined.
33106715|NCT04666142|Active Comparator|Comparison of the Individuals in the experimental and control groups after 24 hours of sleep|The effect of light after 24 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
33106716|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 24 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 24 hours after their admission to the ICU.
33106717|NCT04666142|Active Comparator|Comparison of the Sleep Times of the Individuals in Both Groups 48 Hours After Intensive Care|The effect of light after 48 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
33416750|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
33416751|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
33416752|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
33326385|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
33416753|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
33416754|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
33416755|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
33416756|NCT02069054||Control|Healthy subjects
33416757|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
33416758|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
33416759|NCT01359709|Experimental|Contingency Management|
33416760|NCT01359709|Placebo Comparator|Noncontingent control|
33326386|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
33416761|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
33024010|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
33024011|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
33024012|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
33024013|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
33024014|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
33024015|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
33024016|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
33024017|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
33024018|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
33024019|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
33024020|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
33024021|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
33024022|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
33024023|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
33024024|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
33024025|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
33024026|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
33024027|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
33024028|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
33024029|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
33416762|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
33416763|NCT04158336|Experimental|Single Agent Dose Escalation|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
33416764|NCT04158336|Experimental|Single Agent Food Effect Cohort|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
33416765|NCT04158336|Experimental|Single Agent Dose Expansion|Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
33416766|NCT01346735||ICU infections|Infections acquired during the ICU stay
33416767|NCT03940365|Experimental|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
33416768|NCT01317823|Active Comparator|Bishop score|
33416769|NCT01317823|Active Comparator|transvaginal ultrasound|
33416770|NCT05539898|Other|ICD|ICD implanted
33416771|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 three times a week"
33416772|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
33416773|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
33416774|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
33416775|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
33416776|NCT01359787|Placebo Comparator|Vehicle without active|
33024030|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
33024031|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
33024032|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
33024033|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
33024034|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
33024035|NCT01871701|Placebo Comparator|Placebo|Water intake
33024036|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
33024037|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
33024038|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
33024039|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
33024040|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
33024041|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
33024042|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
33024043|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
33024044|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
33024045|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
33024046|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
33024047|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.~120 patients will receive this combined program"
33024048|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
33024049|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
33024050|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
33024051|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
33024052|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
33416777|NCT02067260|Active Comparator|X5 HairLaser|
33416778|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
33416779|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
33416780|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
33416781|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
33416782|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
33416783|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
33024053|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
33024054|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
33024055|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
33024056|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
33024057|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
33024058|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
33024059|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
33024060|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
33024061|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
33024062|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
33024063|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
33024064|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
33024065|NCT01871961|Experimental|Methotrexate|
33024066|NCT01871974|Experimental|low-dose group FK949E|oral
33024067|NCT01871974|Experimental|high-dose group FK949E|oral
33024068|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
33024069|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
33024070|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
33024071|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
33024072|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
33024073|NCT01872013|Experimental|low dose ASP7991|
33024074|NCT01872013|Experimental|middle dose ASP7991|
33024075|NCT01872013|Experimental|high dose ASP7991|
33024076|NCT01872013|Placebo Comparator|Placebo|
33024077|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
33024078|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
33024079|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
33024080|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
33024081|NCT01872052|Experimental|Acutus Medical System|
33024082|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
33024083|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
33024084|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
33024085|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
33024086|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
33024087|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
33024088|NCT01872117|Experimental|Applications of shortwave diathermy|
33024089|NCT01872117|Experimental|Applications of microwave diathermy|
33024090|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
33416784|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
33416785|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
33416786|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
33416787|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
33416788|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
33416789|NCT04870281||CRT-DX System|
33416790|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
33416791|NCT02033070||Non-Dysplastic IM, LGD, HGD|
33024091|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
33024092|NCT01872156|Other|Control Group|The group control will act according to usual management.
33024093|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
33024094|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
33024095|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
33024096|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
33024097|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
33024098|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
33024099|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
33024100|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
33024101|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
33024102|NCT01872299||Control|Healthy control subjects
33024103|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
33024104|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
33024105|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
33024106|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.~ENT consists of:~Daily conditioning exercise: 35-40 minutes~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
33024107|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
33024108|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
33024109|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
33024110|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
33024111|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
33024112|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
33024113|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
33024114|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
33024115|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
33024116|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
33024117|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
33024118|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
33024119|NCT01872468|No Intervention|Control|There is not intervention in this group.
33024120|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
33024121|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
33024122|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
33024123|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
33024124|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
33024125|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
33024126|NCT01872507|No Intervention|control|usual treatment
33024127|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
33024128|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
33024129|NCT01872546|Experimental|Adalimumab|
33024130|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
33024131|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
33024132|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
33024133|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
33024134|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
33024135|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
33024136|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
33024137|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
33024138|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
33024139|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
33024140|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
33024141|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
33024142|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
33024143|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
33024144|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
33024145|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
33024146|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
33024147|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
33024148|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
33416792|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
33024149|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
33024150|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
33024151|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
33416793|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
33416794|NCT04852029|Active Comparator|Control Group|to remain on current dose of low dose hCG
33416795|NCT04852029|Experimental|Intervention Group|increased dose of low dose hCG prescribed
33416796|NCT01352065|Experimental|BOSENTAN|
33416797|NCT01352065|Experimental|AMBRISENTAN|
33416798|NCT01352065|Placebo Comparator|PLACEBO|
33416799|NCT02065310|No Intervention|Diabetes, Non-diabetes|
33024152|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
33024153|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
33024154|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
33024155|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
33024156|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
33024157|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
33024158|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
33024159|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
33024160|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
33024161|NCT01872780|Active Comparator|rosiglitazone|avandia
33024162|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
33024163|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
33024164|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
33024165|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
33024166|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
33024167|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
33024168|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
33024169|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
33024170|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
33024171|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
33024172|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
33416800|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
33416801|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
33416802|NCT03949881|Experimental|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
33024173|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
33024174|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
33416803|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
33416804|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
33024175|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
33024176|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
33024177|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
33024178|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
33024179|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
33024180|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
33024181|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
33024182|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
33024183|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
33024184|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
33024185|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
33024186|NCT01873014|Experimental|high Iodine intake|
33024187|NCT01873014|Active Comparator|low Iodine intake|
33024188|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
33024189|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
33024190|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
33024191|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
33024192|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
33024193|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
33024194|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
33024195|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
33024196|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
33024197|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
33024198|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
33024199|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
33024200|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
33024201|NCT01873105|Experimental|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
33024202|NCT01873105|No Intervention|Control pre-intervention|Usual care control before implementation of the health team communication intervention
33024203|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
33106718|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 48 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 48 hours after their admission to the ICU.
33106719|NCT04666142|Active Comparator|Distribution of Total Sleep Times of the Individuals in the Experimental and Control Groups|The sleep times of the individuals in both groups were compared
33024204|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
33024205|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
33024206|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
33024207|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
33024208|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
33024209|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
33416805|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
33416806|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
33416807|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
33416808|NCT04835415|Active Comparator|group T|Group (T) (n=26): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
33024210|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
33024211|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
33024212|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
33024213|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
33024214|NCT01873196|No Intervention|Control-No repackaged CSB|
33024215|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
33024216|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
33024217|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
33024218|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
33024219|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
33024220|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
33024221|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
33024222|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
33024223|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
33024224|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
33024225|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
33024226|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
33024227|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
33024228|NCT01873378|No Intervention|No pharmacological treatment|
33024229|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
33024230|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
33024231|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
33024232|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
33024233|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
33024234|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
33024235|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
33024236|NCT01873443|Experimental|Rituximab, MTX, folic acid|
33024237|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
33024238|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
33024239|NCT01873508|Experimental|Fast release MR capsule|
33024240|NCT01873508|Experimental|Slow release MR capsule|
33024241|NCT01873508|Experimental|Target release MR capsule|
33024242|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
33024243|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
33024244|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
33024245|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
33024246|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
33024247|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
33024248|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
33024249|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
33024250|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
33024251|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
33024252|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
33024253|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
33024254|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
33024255|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
33024256|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
33024257|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
33024258|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
33024259|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
33024260|NCT01873690|Placebo Comparator|Placebo|Placebo
33024261|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
33024262|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
33024263|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
33024264|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
33024265|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
33024266|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
33024267|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
33024268|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
33024269|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
33106720|NCT04650126|Experimental|ATM001|Escalating dose levels of ATM001 administered as single dose in healthy subjects
33024270|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
33024271|NCT01873807|Active Comparator|Non-IDA Conditioning|
33024272|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
33024273|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
33024274|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33024275|NCT01873872|Active Comparator|Theralac probiotic|
33024276|NCT01873872|Active Comparator|Culturelle probiotic|
33024277|NCT01873872|Placebo Comparator|Placebo|
33024278|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
33106721|NCT04650126|Placebo Comparator|ATM001 Placebo|Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects
33106722|NCT04665869|Experimental|Combined balance and brisk walking training|Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
33106723|NCT04665869|Active Comparator|Flexibility and strengthening exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)"
33106724|NCT04646616|Experimental|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
33106725|NCT04665908|Other|PT-led triage|Patients are assessed by PT
33106726|NCT04665908|Other|Standard care|The patiens are assessed by a orthopedic surgeon
33106727|NCT04644744|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
33106728|NCT04644744|Experimental|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
33106729|NCT04644744|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
33106730|NCT04665986|Experimental|NHP|Navelbine, Herceptin, Pertuzumab
33106731|NCT04665986|Active Comparator|THP|Docetaxel, Herceptin, Pertuzumab
33106732|NCT04638309|Experimental|Cohort 1|Dose level 1
33106733|NCT04638309|Experimental|Cohort 2|Dose level 2
33106734|NCT04638309|Experimental|Cohort 3|Dose level 3
33106735|NCT04666103|Experimental|Thyroid lobectomy with intraoperative thermal ablation|"Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection. After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
33106736|NCT04666103|No Intervention|Thyroid lobectomy|Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection.
33106737|NCT04633473|Experimental|SIBTime|50 primary parents will be assessed at enrollment, then provided the SIBTime technology and exposed to the learning routines for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
33106738|NCT04632927|Experimental|Secukinumab|AIN457
33106739|NCT04632927|Experimental|Ustekinumab|
33106740|NCT04665830|Active Comparator|Group 1|Evolocumab group, patients who are receiving this therapy for 12 months.
33106741|NCT04665830|Placebo Comparator|Group 2|The Statin group includes patients who are maintained on statin therapy.
33106742|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirrmann MRI class)|Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)
33106743|NCT04665791|Experimental|Challenge|Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10^5 colony forming units and will be escalated to a maximum of 10^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.
33106744|NCT04616781|Active Comparator|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
33106745|NCT04616781|Placebo Comparator|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
33106746|NCT04665674||Pulmonary Langerhans cell histiocytosis (PLCH)|All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
33106747|NCT04683237|Other|MA alone|enrolled patients will receive megestrol acetate 160mg po qd
33416809|NCT04835415|Active Comparator|group R|Group (R) (n=26): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
33416810|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
33106748|NCT04683237|Experimental|MA+liraglutide|enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)
33106749|NCT04665518|Experimental|Acupressure group|The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point [LI 4], Large Intestine Meridian 11th Point [LI 11], and Heart Meridian 7th Point [HT 7]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
33106750|NCT04665518|No Intervention|Control group|Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
33106751|NCT04568694|Experimental|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
33106752|NCT04568694|Active Comparator|Conventional Lung Transplantation|Reference Therapy
33106753|NCT04665323||People living with FOP|
33106754|NCT04665323||Parent or legal guardian primary caregivers|
33106755|NCT04665323||Parent or legal guardian|
33106756|NCT04665323||Siblings|
33106757|NCT04549701|Experimental|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
33106758|NCT04549701|Active Comparator|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
33106759|NCT04665362|Experimental|M1-c6v1 combined with SHR-1210 and Apatinib|Single-arm
33106760|NCT04683120|Experimental|Single Arm Study|This is a single arm study, which will involve all patients qualifying for Breast Conservation Therapy as a part of their breast cancer management excluding patients undergoing neoadjuvant therapy for inoperable disease.
33106761|NCT04665401|Active Comparator|Standard MERIT|24 sessions of Metacognition Reflection and Insight Therapy
33106762|NCT04665401|Experimental|Tailored MERIT|24 sessions of personalized Metacognition Reflection and Insight Therapy (sessions personalized using real-world interactions)
33106763|NCT04506255|Experimental|Silicone tape|Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
33106764|NCT04506255|No Intervention|No dressing|Control treatment using the current standard of care at our institution to the other half, which is no dressing after the initial two week post-op period, will be used on the other half of the incision for comparison. Each individual patient will act as their own control.
33106765|NCT04665440|Other|Voice only then distraction|First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
33106766|NCT04665440|Other|Distraction then voice only|First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli
33106767|NCT04503291|Experimental|supra-papillary metal stent group|The distal ends of metal stents are located above the major papilla in the common bile duct.
33106768|NCT04503291|Active Comparator|trans-papillary metal stent group|The distal ends of metal stents are located below the major papilla in the duodenum.
33106769|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.0014%)|Low Dose
33106770|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.003%)|High Dose
33106771|NCT04498182|Placebo Comparator|Vehicle|AR15512 Ophthalmic Solution Vehicle
33326387|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
33326388|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
33106772|NCT04494555|Experimental|Adaptable Prosthetic Socket|Using measurements of limb-socket displacements from sensors embedded within the socket wall, adaptable sockets make small adjustments to socket size so as to maintain consistent displacements while prosthesis users are active. They do not require the user to stop activity or to touch or modify the prosthesis, and they do not distract users from their objectives.
33106773|NCT04665050|Experimental|pPCV|Participants receive a single dose of pPCV on Day 1.
33106774|NCT04665050|Active Comparator|PNEUMOVAX™23|Participants receive a single dose of PNEUMOVAX™23 on Day 1.
33106775|NCT04470726|Experimental|AIV001 Treatment Dose 1|Intradermal/intratumoral, Dose 1
33106776|NCT04470726|Experimental|AIV001 Treatment Dose 2|Intradermal/intratumoral, Dose 2
33326389|NCT01261416||Infants with seizures|
33326390|NCT03617172|Experimental|Study Drug (Misoprostol)|
33326391|NCT03617172|Placebo Comparator|Placebo|
33326392|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
33326393|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
33326394|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
33106777|NCT04470726|Experimental|AIV001 Treatment Dose 3|Intradermal/intratumoral, Dose 3
33106778|NCT04470726|Experimental|AIV001 Treatment Dose 4|Intradermal/intratumoral, Dose 4
33106779|NCT04665167|Active Comparator|Body image exposure|Guided non-judgmental exposure, 40 minutes total
33106780|NCT04665167|Active Comparator|Self-compassion|8 Short self-compassion meditations, 40 minutes total
33106781|NCT04665011||Clinically stable adults, including heart failure patients visiting an outpatient clinic|Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.
33106782|NCT04665284|Experimental|Empagliflozin|
33106783|NCT04665284|Active Comparator|Usual Care Group|
33106784|NCT04432974|Experimental|ACTIVA|ACTIVA closed-loop anesthesia control system
33106785|NCT04424394|Experimental|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
33106786|NCT04424394|Active Comparator|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
33106787|NCT04664660||Patients with previous histologic diagnosis of endometriosis|
33106788|NCT04664660||Patient without endometriosis|
33106789|NCT04421625|Experimental|Diagnostic test for SARS-Cov2 for patients and health staff|"Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)~Nasal swab test (only if the patient has symptoms)~Questionnaires"
33106790|NCT04664699|Other|Plethysmographic Variability Index group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the PVI group
33106791|NCT04664699|Other|Standard monitoring group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the standard monitoring group
33106792|NCT04416204|Experimental|Type 2 diabetes|
33106793|NCT04416204|Experimental|Participants without diabetes|
33106794|NCT04664504|Active Comparator|Group CRT|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
33106795|NCT04664504|Experimental|Group SCRT|Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
33106796|NCT04664504|Experimental|Group es-SCRT|Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
33106797|NCT04415073|Active Comparator|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
33106798|NCT04415073|Placebo Comparator|Placebo|Matching placebo on Days 1 and 15, IV + SOC
33106799|NCT00557102|Other|cetuximab, FOLFIRI|
33106800|NCT04682808|Experimental|Dose Escalation and Expansion|FCN-338 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL , until the maximum tolerated dose or recommended dose is reached. Followed by up to 43 patients enrolled in the expansion cohort at the recommended dose.
33106801|NCT04664543|Active Comparator|3 days of low residue diet|Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy. This is the active comparator arm of this study.
33106802|NCT04664543|Experimental|Free diet|Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
33106803|NCT04682613|Experimental|"Prevention Program young In Favor of Myself, active teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers will also participate by delivering planned activities to do with their pupils in addition to each week's topic, parallel to the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
33106804|NCT04682613|Active Comparator|"Prevention Program young In Favor of Myself, passive teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers won't participate in the program, they will only be present in the classroom during the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
33106805|NCT04664816|Experimental|n-3PUFAs group|These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
33106806|NCT04664816|Placebo Comparator|Control group|These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
33106807|NCT04682691|Sham Comparator|Group (C)|who will receive flavored water in total volume 15 ml at two hours preoperative.
33106808|NCT04682691|Active Comparator|Group (M)|will be receive 10 ml of oral metoclopramide (10mg)
33106809|NCT04682691|Active Comparator|Group (E)|will receive 10 ml of oral Erythromycin (400mg)
33326395|NCT01261494|Experimental|GFT505 80mg|
33326396|NCT01261494|Placebo Comparator|Matching placebo|
33326397|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
33326398|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
33326399|NCT01261572|Experimental|High dose group|ASP3350 high dose
33326400|NCT01261572|Experimental|Low dose group|ASP3350 low dose
33326401|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
33326402|NCT01261650|Sham Comparator|sham treatment|
33326403|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
33326404|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
33326405|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
33024279|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
33024280|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
33024281|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
33024282|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
33024283|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
33024284|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
33024285|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
33024286|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
33024287|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
33024288|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
33024289|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
33024290|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
33024291|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
33024292|NCT01874028|Experimental|Trientine dihydrochloride|
33024293|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
33024294|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
33024295|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
33024296|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
33024297|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
33024298|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
33024299|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
33024300|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
33024301|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
33024302|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
33024303|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
33024304|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
33024305|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
33024306|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
33024307|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
33024308|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
33024309|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
33024310|NCT01874210||Hemodialysis|Hemodialysis patients
33024311|NCT01874210||Control|"Household contacts on the same diet~Healthy unrelated controls"
33024312|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
33024313|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
33024314|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
33024315|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
33024316|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
33024317|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
33024318|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
33024319|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
33024320|NCT01874301|Experimental|High quantity probiotic food product|
33024321|NCT01874301|Experimental|Low quantity probiotic food product|
33024322|NCT01874301|Placebo Comparator|Placebo|
33024323|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
33024324|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
33024325|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
33024326|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
33024327|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
33024328|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
33024329|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
33024330|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
33024331|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
33024332|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
33024333|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
33024334|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
33024335|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
33024336|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
33024337|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
33024338|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
33024339|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
33024340|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
33024341|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
33024342|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
33024343|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
33024344|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
33024345|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
33024346|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
33024347|NCT01874483|Placebo Comparator|Placebo|placebo
33024348|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
33024349|NCT01874496|Experimental|GDS, meal|GDS, meal
33024350|NCT01874496|Experimental|GDS, no meal|GDS, no meal
33024351|NCT01874496|Active Comparator|control, no meal|control, no meal
33024352|NCT01874496|Active Comparator|control, meal|control, meal
33024353|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
33024354|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
33024355|NCT01874522|Experimental|TAS-102 tablets|
33024356|NCT01874522|Experimental|TAS-102 oral solution|
33024357|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
33024358|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
33024359|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:~320 mg of custirsen + 5 mg of dexamethasone on day 1~480 mg of custirsen + 5 mg of dexamethasone on day 3~640 mg of custirsen + 3 mg of dexamethasone on day 5~640 mg of custirsen on day 7 under fasting conditions"
33024360|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~placebo on day 7 under fasting conditions"
33024361|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
33024362|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
33024363|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
33024364|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
33024365|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
33024366|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
33024367|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
33024368|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
33024369|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
33024370|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Test group: hepatectomy with Aquamantys®"
33024371|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
33024372|NCT01874678|Experimental|TS-1/Cisplatin|single arm
33024373|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
33024374|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
33024375|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
33024376|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
33024377|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
33024378|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
33024379|NCT01874769||Blood collection and skin biopsies|
33024380|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
33024381|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
33024382|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
33024383|NCT01874808||Healthy|Healthy
33024384|NCT01874808||ALS with postural instability|ALS with postural instability
33024385|NCT01874808||ALS without postural instability|ALS without postural instability
33024386|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
33024387|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
33024388|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
33024389|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
33024390|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
33024391|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
33024392|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
33024393|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
33024394|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
33024395|NCT01874873|Experimental|Anlotinib|
33024396|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
33024397|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
33024398|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
33024399|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
33106810|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)|
33106811|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)|
33024400|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
33024401|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
33024402|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
33416811|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
32746754|NCT04331691|Experimental|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
33024403|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
33024404|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
33024405|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
33024406|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
33024407|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
33024408|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
33024409|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
33024410|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
33024411|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
33024412|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
33024413|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
33024414|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
33024415|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
33024416|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
33024417|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
33024418|NCT01875081|No Intervention|Control group|Best Supportive care
33024419|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
33326406|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
33024420|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
33024421|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
33024422|NCT01875094|No Intervention|Usual Care|
33024423|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
33024424|NCT01875120||Female patients with increased risk to experience PONV.|
33024425|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
33024426|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
33024427|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
33024428|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
33024429|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
33024430|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
33024431|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
33024432|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
33024433|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
33024434|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
33024435|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
33024436|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
33024437|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
33024438|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
33024439|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
33024440|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
33024441|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
33024442|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
33024443|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
33024444|NCT01875289|Experimental|Ropivacain|Local anaesthesia
33024445|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
33024446|NCT01875328|Experimental|Telemedicine|Telemedicine group
33024447|NCT01875328|Active Comparator|Clinic|Clinic group
33024448|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
33024449|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
33024450|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
33024451|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
33024452|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
33024453|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
33024454|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
33024455|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
33024456|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
33024457|NCT01875484||High miR-126 group|
33024458|NCT01875484||Moderate miR-126 group|
33024459|NCT01875484||Low miR-126 group|
33024460|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
33416812|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
33024461|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
33024462|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
33024463|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
33024464|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
33024465|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
33024466|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
33024467|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
33024468|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
33024469|NCT01875562|Experimental|Qishe Pill|
33024470|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
33024471|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
33024472|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
33024473|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
33024474|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
33024475|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
33024476|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
33024477|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
33024478|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
33024479|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
33024480|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
33024481|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
33024482|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
33024483|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
33024484|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
33024485|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
33024486|NCT01875705|Experimental|Stage I-Dose Escalation|
33024487|NCT01875705|Experimental|Stage II-Cohort-Expansion|
33024488|NCT01875718|Active Comparator|UC1010 low dose|
33024489|NCT01875718|Active Comparator|UC1010 high dose|
33024490|NCT01875718|Placebo Comparator|Vehicle|
33024491|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
33024492|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
33024493|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
33024494|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
33024495|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
33416813|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
33024496|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
33024497|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
33024498|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
33024499|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
33024500|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
33024501|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
33024502|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
33024503|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
33024504|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
33024505|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
33024506|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
33024507|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
33024508|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
33024509|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
33024510|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
33024511|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
33024512|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
33024513|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
33024514|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
33024515|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
33024516|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
33024517|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
33024518|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
33024519|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
33024520|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
33024521|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
33024522|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
33024523|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
33024524|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
33024525|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
33024526|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
33024527|NCT01876121||Celecox group|
33024528|NCT01876134||Elective cardiac surgery|
33024529|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
33024530|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
33106812|NCT04664114|Experimental|Experimental group|Both the evaluation of the fetus and the ultrasound for visual purposes took 15-20 minutes in total. These pregnant women were asked to bring their mobile phones with them during delivery. When the birth of the pregnant woman started, she was hospitalized by the third researcher. The follow-up and deliveries during the labor were carried out by the 3rd and 4th researchers. With an application installed on the pregnant woman's phone, these two-dimensional images were transformed into three-dimensional images and the pregnant women were watched consecutively with the VR Box 3D virtual reality glasses. In cases where the program was not compatible with the phone of the pregnant woman, the researcher was watched by the midwife. The total image viewing time was recorded.
33106813|NCT04664114|No Intervention|Control Group|Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
33106814|NCT04682418|Experimental|xvision Spine|
33106815|NCT04664036||NAFLD + type 1 diabetes|type 1 diabetes patient with NAFLD on screening
33106816|NCT04664036||noNAFLD + type 1 diabetes|type 1 diabetes patient without NAFLD on screening
33106817|NCT04383912|Experimental|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
33106818|NCT04383912|Placebo Comparator|placebo group (brow)|"Product name: normal saline~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
33106819|NCT04664231||Children with JIA|Children with JIA coming to clinic
33106820|NCT04664231||Healthy Children|Healthy Children in the school
33106821|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
33106822|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
33106823|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
33106824|NCT05423080|Experimental|Bolus group|Participants in this group are administered remimazolam via the bolus injection method during anesthesia induction.
33106825|NCT05423080|Active Comparator|Infusion group|Participants in this group are administered remimazolam via the continuous infusion method during anesthesia induction.
33106826|NCT04376736|No Intervention|Control arm|Patients are reminded about their appointments
33106827|NCT04376736|Experimental|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
33106828|NCT04663763|Experimental|Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy|"A total of 40 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.~Interventions:~Shor-course radiotherapy: 25Gy/5Fx;~Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;~Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;"
33106829|NCT04663880|Experimental|Asthmatic subjects allergic to house dust mite|24 subjects were randomized in a doubleblinded manner into six subgroups. All were exposed first to placebo then in cross over to three different Der p1 concentrations, respectively 15, 25, and 46 ng/m3.
33106830|NCT04663880|Active Comparator|Asthmatic subjects not allergic to house dust mite|13 subjects were exposed first to placebo then to Der p1 concentration of 25 ng/m3.
33106831|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
33106832|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
33106833|NCT04663919|Active Comparator|Anorexia Nervosa|Patients diagnosed with Anorexia Nervosa, having a BMI of <18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
33106834|NCT04663919|Active Comparator|Morbidly Obese|Patients with a BMI> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)
33106835|NCT04663919|No Intervention|Healthy Volunteer|Volunteers with normal BMI and without any additional chronic disease
33106836|NCT04353102|Experimental|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
33106837|NCT04351737|Experimental|Pterygium patients|patients with bilateral pterytium
33106838|NCT04347915|Experimental|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
33106839|NCT04347915|Placebo Comparator|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
33106840|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
33326407|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
33326408|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
33326409|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
33024531|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
33024532|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
33024533|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
33326410|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
33326411|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
33326412|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
33326413|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
33326414|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
33326415|NCT01263288|Placebo Comparator|Placebo|
33024534|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
33024535|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
33024536|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
33024537|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
33024538|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
33024539|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
33024540|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
33024541|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
33024542|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
33024543|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
33024544|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
33024545|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
33024546|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
33024547|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
33024548|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
33024549|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
33024550|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
33326416|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
33024551|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
33024552|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
33024553|NCT01876394|Experimental|Coconut oil|
33024554|NCT01876394|Experimental|Canola oil|
33024555|NCT01876394|Experimental|Grapeseed oil|
33024556|NCT01876394|Experimental|Chia oil|
33024557|NCT01876394|Placebo Comparator|Butter|
33024558|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
33024559|NCT01876407|Placebo Comparator|Placebo|
33024560|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
33024561|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
33024562|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
33024563|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
33024564|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
33024565|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
33024566|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
33326417|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
33326418|NCT01154868|Other|Healos|
33024567|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
33024568|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
33024569|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
33024570|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
33024571|NCT01876537|Active Comparator|Usual surgery|
33024572|NCT01876537|Active Comparator|Hardware wound healing|
33024573|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
33024574|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
33024575|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
33024576|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
33024577|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
33024578|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
33024579|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
33024580|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
33024581|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
33024582|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
33024583|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
33024584|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024585|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024586|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024587|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024588|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024589|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
33024590|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
33024591|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
33024592|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
33024593|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
33024594|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
33024595|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
33024596|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
33024597|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
33024598|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
33024599|NCT01876745||NovoSeven® (activated recombinant factor VII)|
33024600|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
33326419|NCT01261884|No Intervention|Routine prenatal care|
33326420|NCT01261884|Experimental|Exercise support|
33326421|NCT01261884|Experimental|Exercise intervention|
33416814|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
33416815|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
33416816|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
33416817|NCT04801173|Experimental|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
33024601|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
33024602|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
33416818|NCT04801173|Active Comparator|Low calorie diet|Control treatment with a low calorie standard diet
32746755|NCT04330833|Active Comparator|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
32746756|NCT04330833|Experimental|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
33024603|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
33024604|NCT01876836|Experimental|i-gel|i-gel placed after induction
33024605|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
33024606|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
33024607|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
33024608|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
33024609|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
33024610|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
33024611|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
33024612|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.~Each cycle will be repeated every 3 weeks."
33024613|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
33024614|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
33024615|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
33024616|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
33024617|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
33024618|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
33024619|NCT01877018|No Intervention|Usual care|Usual care control group
33024620|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
33024621|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
33024622|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
33024623|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
33024624|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
33024625|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
33024626|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
33024627|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
33024628|NCT01877109||Lymphoma|Lymphoma patients
33024629|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
33024630|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
33024631|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
33416819|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
33024632|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
33024633|NCT01877200||Subjects with diabetes (type 2)|
33024634|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
33416820|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
33416821|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
33416822|NCT05188651||dental professionals wearing FFP2/N95 masks|
33416823|NCT05188651||dental professionals wearing type IIR fluid resistant surgical masks|
33024635|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
33024636|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
33024637|NCT01877252||Endovascular treatment|Angioplasty +/- stent
33024638|NCT01877252||Open treatment|Bypass (vein or prosthetic)
33024639|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
33024640|NCT01877252||Conservative treatment|no vascular intervention
33024641|NCT01877291||Nonsmokers|Young healthy nonsmokers
33024642|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
33024643|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
33024644|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
33024645|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
33024646|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
33024647|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
33024648|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
33024649|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
33024650|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
33024651|NCT01877382|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
33024652|NCT01877382|Experimental|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
33024653|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
33024654|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
33024655|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
33024656|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
33024657|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
33024658|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
33416824|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a targeted, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
33024659|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
33024660|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
33024661|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
33024662|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
33024663|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
33024664|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
33024665|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
33024666|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
33024667|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
33024668|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
33326422|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
33024669|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
33024670|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
33024671|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
33024672|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
33024673|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
32746757|NCT05304273|Active Comparator|Mifepristone|"Participants with 1st trimester miscarriage will receive oral 200mg mifepristone .~After 48 hours of mifepristone, 800 micro gm misoprostol will be given vaginally for expulsion of product of conception (standard care)."
33024674|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
33024675|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
33024676|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
33024677|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
33024678|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
33024679|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
33024680|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
33024681|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
33024682|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
33024683|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
33024684|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
33024685|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
33024686|NCT01877785|Experimental|MHAA4549A Arm|
33024687|NCT01877785|Placebo Comparator|Placebo Arm|
33024688|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
33024689|NCT01877798|Experimental|ScvO2|ScvO2 directed group
33024690|NCT01877811|Experimental|RXDX-105|
33024691|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
33024692|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
33024693|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
33024694|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
33024695|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
33024696|NCT01877876||Patient undergoing spine surgery|
33024697|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
33326423|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
33326424|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
33326425|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
33326426|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
33326427|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
33326428|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
33326429|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
33326430|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
33326431|NCT01263366|Experimental|Norepinephrine|
33326432|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
33326433|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
33326434|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
33326435|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
33326436|NCT01586520||Disease negative|No evidence of disease
33326437|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
33326438|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
33326439|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
33326440|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
33024698|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
33024699|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
33024700|NCT01877902||Pemetrexed 500 mg/m 2|
33024701|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
33024702|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
33024703|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
33024704|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
33024705|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
33024706|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
33024707|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
33024708|NCT01878071||Single group cross sectional|
33024709|NCT01878110|Experimental|COMB|
33024710|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
33024711|NCT01878123|Placebo Comparator|Placebo|
33024712|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
33024713|NCT01878136|Placebo Comparator|Placebo|"Placebo~Dose 1 mL sterile saline"
33024714|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
33024715|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
33024716|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
33024717|NCT01878188|Experimental|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
33024718|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
33024719|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
33024720|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
33106841|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
33024721|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
33024722|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
33024723|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
33024724|NCT01878266|Experimental|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
33024725|NCT01878266|Experimental|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
33024726|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
33024727|NCT01878279||HIV negative|
33024728|NCT01878279||HIV positive|HIV positive children in care
33024729|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
33024730|NCT01878318|Experimental|RoActemra/Actemra|
33024731|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
33024732|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
33326441|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
33024733|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
33326442|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
32746758|NCT05304273|Experimental|Letrozole|"Participants with 1st trimester miscarriage will receive 10mg letrozole orally for three consecutive days.~This is to be followed by tablet misoprostol 800 micro gm vaginally for expulsion of product of conception (standard care)."
33024734|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
33024735|NCT01878357|No Intervention|Arm 3|Without MST
33024736|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
33024737|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
33024738|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
33024739|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
33024740|NCT01878409||Healthy Subjects|Healthy Subjects
33024741|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
33024742|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
33024743|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
33024744|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
33024745|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
33024746|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
33024747|NCT01878448|Experimental|Anlotinib|
33024748|NCT01878474|Experimental|Single ascending dose in Caucasian men|
33024749|NCT01878474|Experimental|Age-effect in Caucasian men|
33024750|NCT01878474|Experimental|Gender-effect in Caucasian women|
33024751|NCT01878474|Experimental|Single ascending dose in Japanese men|
33024752|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
33024753|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
33024754|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
33024755|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
33024756|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
33024757|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
33024758|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
33024759|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
33024760|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
33024761|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
33024762|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
33326443|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
33326444|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
33326445|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
33024763|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
33024764|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
33024765|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
33024766|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
32866595|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
32866596|NCT01454102|Experimental|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
33024767|NCT01878591||Women in active second stage of labour|Ultrasound examinations
33024768|NCT01878630|Experimental|Remote Patient Management|intervention group
33024769|NCT01878630|Active Comparator|Usual Care|control group
33024770|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
33024771|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
33024772|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.~600mg n-acetylcysteine orally twice daily except on day of infusion"
33024773|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
33024774|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
33024775|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
33024776|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
33024777|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
33024778|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
32866597|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
33024779|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
33024780|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
33024781|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
33024782|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
33024783|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
33024784|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
33024785|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
33024786|NCT01878851||pulpotomy|
33024787|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
33024788|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
33024789|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
33024790|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
33024791|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
33024792|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
33024793|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
33024794|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
33024795|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
33326446|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
33326447|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
33326448|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
33326449|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
33326450|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
33326451|NCT01264068|No Intervention|Insomnia control|
33326452|NCT01264068|Experimental|Suan Tsao Jen Tang|
33326453|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
33326454|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33326455|NCT01157598|Active Comparator|BIS group|
33326456|NCT01157598|Placebo Comparator|non BIS group|
33416825|NCT03709277|No Intervention|Standard of Care|The Standard of Care Group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
33416826|NCT03911661|Active Comparator|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
33024796|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
33024797|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
33024798|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
33024799|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
33024800|NCT01879020|Experimental|TA-8995 1 mg|
33024801|NCT01879020|Experimental|TA-8995 2.5 mg|
33024802|NCT01879020|Experimental|TA-8995 5 mg|
33024803|NCT01879020|Experimental|TA-8995 10 mg|
33024804|NCT01879020|Experimental|TA-8995 25 mg|
33024805|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
33024806|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
33024807|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
33024808|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
33024809|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
33024810|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
33024811|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
33024812|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
33024813|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
33024814|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
33024815|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
33024816|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
33024817|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
33024818|NCT01879111|No Intervention|state-of-art depression screening|
33024819|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
33024820|NCT01879137||healthy adults|
33024821|NCT01879137||Patients with a polyuria-polydipsia syndrome|
33024822|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.~Subjects will be followed-up for 50 weeks post-procedure."
33024823|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
33024824|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
33024825|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
33024826|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
33024827|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
33326457|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
33326458|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
33326459|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
33326460|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
33024828|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
33024829|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
33024830|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
33024831|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
33024832|NCT01879254||DBS for OCD|
33024833|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
33024834|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
33024835|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
33024836|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
33024837|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
33024838|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
33024839|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
33024840|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
33024841|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
33024842|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
33024843|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
33024844|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
33024845|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
33024846|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.~The measure of outcome is composite and includes several changes:~Changes in:~cell death (% from tested cells)~cell cycle (% cells in G1, G2 and S phases)~cell migration (% closure in Scratch test)~cell invasion (% cells passing through membrane in Transwell assay)~RNA repertoire (Fold change)~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
33024847|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
33024848|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
33024849|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
33024850|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
33024851|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
33024852|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
33024853|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
33024854|NCT01879475|Experimental|032-11|032-11 topical haemostat.
33024855|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
33024856|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
33024857|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
33024858|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
33024859|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
33024860|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
33024861|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
33024862|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
33024863|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
33024864|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
33024865|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
33024866|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
33024867|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
33024868|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
33024869|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
33024870|NCT01879605|No Intervention|Control grup|No intervention
33024871|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
33024872|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
33024873|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
33024874|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
33024875|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
33024877|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
33024878|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
33024879|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
33024880|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
33024881|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
33106842|NCT04663685|Experimental|Single Arm|This is the only arm in the study. All participants will be allocated to this arm, where they will receive an 8-week remotely-delivered exercise and nutrition program.
33024882|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
33024883|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
33024884|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
33024885|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
33106843|NCT04238676|Experimental|PP353|
33106844|NCT04238676|Placebo Comparator|Sham injection|
33106845|NCT04663451||Toxic Nodule|Hyperthyroid patients with underlying toxic nodule
33106846|NCT04663451||Toxic multinodular goiter|Hyperthyroid patients with underlying toxic multinodular goiter
33106847|NCT04185051|Experimental|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
33106848|NCT04185051|Experimental|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
33106849|NCT04663412|Experimental|Patients FIGO IB stage|Vulvar Cancer IB stage
33106850|NCT04175028|Other|ADHD|Patients with ADHD.
33106851|NCT04175028|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
33106852|NCT04663490||simple acute diverticulitis|Ninety-one percent (n=295) were categorized as simple acute diverticulitis
33106853|NCT04663490||complicated acute diverticulitis|9% (n=30) presented were categorized as complicated acute diverticulitis
33106854|NCT04171050|Active Comparator|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
33106855|NCT04171050|Active Comparator|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
33106856|NCT04662983|Experimental|Experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
33106857|NCT04663139|Experimental|normal weight healthy adult volunteers receiving Xla1|one capsule Xla1 given once daily
33106858|NCT04663139|Experimental|overweight and class 1 obese adult patients receiving Xla1|one capsule Xla1 given once daily
33106859|NCT04663139|Placebo Comparator|overweight and class 1 obese adult patients receiving placebo|one capsule placebo given once daily
33106860|NCT04095780|Experimental|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
33106861|NCT04095780|Experimental|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
33106862|NCT04663178|Experimental|Warm Salt Water Foot Bath Group|"In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale (PFS) were applied to the patients. A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to patients.~Each patient received iodine salt and a liquid thermometer to measure the temperature of the water. The patients were asked 1 day after the treatment to apply warm salt water bath of 41-42ºC once a day for 20 minutes for 7 days.~Subsequently, the fatigue level of the patients was evaluated 30 minutes after having a warm saltwater foot bath and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. In the last interview PFS was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
33106863|NCT04663178|No Intervention|Control Group|"A training booklet about chemotherapy-induced fatigue~In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale were applied to the patients.~A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to experimental group.~Subsequently, the fatigue level of the patients was evaluated and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. The patients were evaluated in the evening. In the last interview conducted with the patient on the 7th day, Piper's Fatigue Scale was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
33106864|NCT04662788|Experimental|Administration of NK cells/Combined Monoclonal Antibodies|
33106865|NCT04088994|Experimental|pathological model|The children assigned to the experimental group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a model with a similar manipulation strategy but improved with respect to the child's current abilities.
33106866|NCT04088994|Active Comparator|Healthy model|The children assigned to the control group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
33106867|NCT04662749||concave group|the group whose level of sinus floor is lower than both of the adjacent teeth
33106868|NCT04662749||angle group|the group whose level of sinus floor is lower than one of the adjacent teeth and higher than the other one of the adjacent teeth
33106869|NCT04662749||flat group|the group whose level of sinus floor is similar to both of the adjacent teeth
33106870|NCT04065516|Experimental|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
33106871|NCT04037007|Active Comparator|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
33106872|NCT04037007|Active Comparator|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
33416827|NCT03911661|Experimental|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
33106873|NCT04037007|Active Comparator|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
33416828|NCT03911661|Experimental|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
33416829|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
33416830|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
33416831|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
33024886|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
33024887|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
33024888|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
33024889|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
33024890|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
33024891|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
33024892|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
33024893|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
33024894|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
33024895|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
33024896|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
33024897|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
33024898|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
33024899|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
33024900|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
33024901|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
33024902|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
33024903|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
33024904|NCT01879917|Active Comparator|Liraglutide|1.8 mg
33024905|NCT01879917|Placebo Comparator|Saline|
33024906|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
33024907|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
33024908|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.~Interventions:~Device: PillCam COLON 2 on D0~Procedure: Standard colonoscopy on D1"
33024909|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
33024910|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
33024911|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
33024912|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
33024913|NCT01879982||Wellness Wearable System & Smartphone|
33024914|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
33024915|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
33106874|NCT04037007|Active Comparator|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
33024916|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
33416832|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
33416833|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
33024917|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
33024918|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
33024919|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
33024920|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
33024921|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
33024922|NCT01880138|Experimental|watching animated cartoon|
33024923|NCT01880138|Placebo Comparator|not watching animated cartoon|
33024924|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
33024925|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
33024926|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
33024927|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
33024928|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
33024929|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
33024930|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
33024931|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
33024932|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
33024933|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
33024934|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
33024935|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
33024936|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
33024937|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
33024938|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
33024939|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with~Diabetes (all types)~Small vessels (≤2.75 mm)~Chronic total occlusion (CTO)~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
33024940|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
33024941|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
33024942|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
33106875|NCT04662827|Experimental|Palmithylethanolamid|Probands receive PEA 3xday for 28 days, 8 weeks wash out will follow, then they receive placebo for 28 days
33106876|NCT04662827|Placebo Comparator|placebo|Probands receive placebo 3xday for 28 days, 8 weeks washout will follow, then they receive PEA for 28 days
33106877|NCT04010253|Experimental|SIMEOX|
33106878|NCT04010253|Active Comparator|Autogenic Drainage|
33416834|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
33416835|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
33416836|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
33416837|NCT05188573|Experimental|EpiDetect Arm|"Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a not detected test result."
33416838|NCT05188573|Experimental|"EpiDetect not detected MRI Arm"|"A pre-specified number of cases with test results not detected will be randomly selected, gender ratio and age matched to subjects with test results detected and will undergo MRI imaging at T0 (n=226), at T1 (n=208 ) at T2 (n=208 ) and 24 months (n=208) from diabetes diagnosis."
33024943|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
33416839|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
33024944|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
33024945|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 1g of bicarbonate."
33024946|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
33024947|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
33024948|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
33024949|NCT01880333|Experimental|Children on Modified Atkin Diet|
33024950|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
33024951|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
33024952|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
33024953|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
33024954|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
33024955|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
33024956|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
33416840|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
33024957|NCT01880450|Experimental|Project Prepared|
33024958|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
33024959|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
33024960|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
33024961|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
33024962|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
33024963|NCT01880476|Experimental|Home visits and group program|
33024964|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
33024965|NCT01880489|No Intervention|Wait List Control Condition|
33024966|NCT01880502|Experimental|Belviq 10mg|
33024967|NCT01880502|Experimental|Belviq 20mg|
33024968|NCT01880502|Placebo Comparator|Placebo|
33024969|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
33024970|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
33024971|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
33024972|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
33024973|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
33024974|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
33024975|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
33024976|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
33024977|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
33024978|NCT01880671|Experimental|Migraine Medical Device|
33024979|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
33024980|NCT01880684||Passive Leg Rising|
33024981|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
33024982|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
33024983|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
33024984|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
33024985|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
33024986|NCT01880788||CNV secondary to CSC|
33024987|NCT01880788||CSC without CNV|
33024988|NCT01880788||CNV secondary to advanced AMD|
33024989|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
33024990|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
33024991|NCT01879241|Experimental|Rasagiline|"Rasagiline~1 mg/day; 18 months"
33024992|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
33024993|NCT01880827|Active Comparator|Royx-en-Y surgery|Mixed meal test (MMS) with flow studies before and 2 months after the operation
33024994|NCT01880827|Active Comparator|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
33024995|NCT01880827|Experimental|Sleeve gastrectomy|Mixed meal test (MMS) with flow studies before and 2 months after the operation
33024996|NCT01880853|Experimental|group 1|screening with mammography alone
33024997|NCT01880853|Experimental|group 2|screening with ultrasonography alone
33024998|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
33024999|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
33025000|NCT01880879|Experimental|helios stent|the group with helios stent implanted
33025001|NCT01880905|Experimental|female undergoing gynecological surgery|
33025002|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
33025003|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
33025004|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
33025005|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
33025006|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
33025007|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
33025008|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
33025009|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
33025010|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
33025011|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
33025012|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
33025013|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
33106879|NCT04662866|Active Comparator|Metformin|Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.
33416841|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
33025014|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
33025015|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
33025016|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
33025017|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
33025018|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
33025019|NCT01881152|Experimental|Intervention|Educational campaign
33025020|NCT01881152|Other|Control|Usual care
33025021|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
33025022|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
33025023|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
33025024|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
33025025|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
33025026|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
33025027|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
33025028|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
33025029|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
33025030|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
33025031|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
33025032|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
33025033|NCT01881243||Adult patients resuscitated from cardiac arrest|
33025034|NCT01881269||No treatment|No treatment, prospective observational
33025035|NCT01881282|Experimental|Carraghenates Cream|
33025036|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
33025037|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
33025038|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
33025039|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
33025040|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
33025041|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
33025042|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
33025043|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
33025044|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
33025045|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
33025046|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
33025047|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
33025048|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
33025049|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
33025050|NCT01881360|Experimental|Gluten-free diet|
33025051|NCT01881360|Active Comparator|Hypocaloric diet|
33025052|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
33025053|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
33025054|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
33416842|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
33416843|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
33416844|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
33416845|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
33025055|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
33025056|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images~Conventional IOC (intraoperative cholangiography)"
33025057|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
33025058|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
33025059|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
33025060|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
33025061|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
33025062|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
33025063|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
33025064|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
33025065|NCT01881529||Limited Scleroderma|
33025066|NCT01881529||Diffuse Scleroderma|
33025067|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
33025068|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
33025069|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure.~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~100mL before tourniquet realised~100mL 3 hours after surgery"
33025070|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure~Intravenous administration of two dosis of Tranexamic Acid as follow:~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
33025071|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
33025072|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
33025073|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
33025074|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
33025075|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
33025076|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
33025077|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
33025078|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
33025079|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
33025080|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
33025081|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
33025082|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
33025083|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
33025084|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
33025085|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
33025086|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
33025087|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
33025088|NCT01881672||Coma patients in ICU under mechanical ventilation|
33025089|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
33025090|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
33025091|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
33025092|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
33025093|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
33025094|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
33025095|NCT01881724|No Intervention|Usual Care|
33025096|NCT01881724|Experimental|sleep education program|
33025097|NCT01881802||morphine or heroin dependence patients|
33025098|NCT01881802||normal control group|
33025099|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
33025100|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
33025101|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
33025102|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
33025103|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
33025104|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
33025105|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
33025106|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.~Educational: congenital heart disease information~Behavioral: cognitive behavioral therapy~Behavioral: social interactions and communication skills"
33025107|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
33025108|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
33025109|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
33025110|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
33025111|NCT01881945|Experimental|Physiological measurments|
33025112|NCT01881958|Experimental|DiaPep277®|
33025113|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
33025114|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
33025115|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
33025116|NCT01881997|Experimental|Fentanyl|IM Fentanyl
33025117|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
33025118|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
33025119|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
33025120|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders.
33025121|NCT01882023||Healthy Controls|Age- and gender matched healthy controls.
33025122|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
33025123|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
33025124|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
33025125|NCT01882101|Experimental|Posterior tibial nerve stimulation|
33025126|NCT01882101|Experimental|Biofeedback|
33416846|NCT04983173|Experimental|Experimental: Clomiphene Citrate (CC) + rFSH|Ovarian Stimulation with CC+rFSH
33106880|NCT04662866|Active Comparator|Empagliflozin|Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.
33106881|NCT04662866|Active Comparator|Linagliptin|Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.
33106882|NCT04662866|Active Comparator|Pioglitazone|Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.
33106883|NCT04662476|Active Comparator|Vitamin D supplement|331 children will each received 60,000IU of vitamin D once a month for 3 months.
33106884|NCT04662476|Active Comparator|Intervention|The intervention arm will receive vitamin D3.
33106885|NCT04008927|Other|All patients|All participants recruited during the RDS survey.
33106886|NCT04008927|Other|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL)
33106887|NCT04008927|Other|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
33106888|NCT04662437||Covid-19 Patient Group|10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
33106889|NCT04662437||Healthy Control Group|10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
33106890|NCT03986424|Experimental|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
33106891|NCT03986424|Active Comparator|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
33106892|NCT04662593|Experimental|Intervention Group|"The intervention group participates in a 17-week whole health program including:~Weekly, small group online meetings with a health coach;~Supportive social media including a private Facebook group and selective text messaging;~Exposure to community tree planting and stewardship (through live streaming or in-person if COVID-19 public health guidance at the time, permits."
33106893|NCT04662593|No Intervention|Control Group|The control group participates only in questionnaire data collection at baseline, 4 months, and 6 months as well as daily weighing. Control group participants will be offered 3 web-based seminars (webinars) highlighting the effective lifestyle approaches demonstrated in the study and intervention group health education materials. The webinars and materials will be provided after the 6-month data collection which concludes the study.
33106894|NCT03975075|Experimental|Biofeedback|Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). The biofeedback training session will be conducted using the eSense Pulse smartphone application. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone.
33326461|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
33326462|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
33326463|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
33326464|NCT01263522|Experimental|Endurance training|
33326465|NCT01263522|Experimental|interval training|
33326466|NCT01263522|Experimental|strength endurance training|
33326467|NCT01263522|Placebo Comparator|control|
33326468|NCT01156662|Active Comparator|No aspiration|
33326469|NCT01156662|Active Comparator|Thrombus aspiration|
33326470|NCT01159470||bacterial infection|children with fever due to bacterial infection
33106895|NCT03975075|Active Comparator|Control Group|"Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). Participants will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone."
33326471|NCT01159470||viral infection|children with fever due to viral infection
33326472|NCT01159548|No Intervention|Saline|
33326473|NCT01159548|Other|Promethazine 6.25 mg|
33326474|NCT01159548|Other|Promethazine 3 mg|
33326475|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
33416847|NCT04983173|Active Comparator|rFSH|Ovarian Stimulation with rFSH
33416848|NCT05686317|Experimental|APTURE shunt + medical therapy|
33416849|NCT05686317|Sham Comparator|Sham + medical therapy|
33416850|NCT02069288|Experimental|1|Fludrocortisone
33416851|NCT02069288|Placebo Comparator|2|Placebo
33416852|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
33025127|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
33025128|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
33025129|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
33025130|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
33025131|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
33025132|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
33025133|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
33025134|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
33025135|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
33025136|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
33025137|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
33025138|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
33025139|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
33025140|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
33025141|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
33025142|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
33025143|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
33025144|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
33025145|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
33025146|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
33025147|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
33025148|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
33025149|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
33025150|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
33025151|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
33025152|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
33025153|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
33025154|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
33416853|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
33416854|NCT01356121|No Intervention|No Sedation|No sedation given in this group
33416855|NCT05725161|Experimental|Acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
33416856|NCT05725161|Other|Wait-list control group with psychoeducation materials provided|Care as usual with psychoeducation materials provided during the study period and ACT sessions provided after the study period ends
33416857|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
33025155|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
33025156|NCT01882322|Experimental|Advagraf conversion group|Oral
33025157|NCT01882322|Active Comparator|Prograf maintenance group|Oral
33025158|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
33025159|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
33025160|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
33025161|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
33025162|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
33025163|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
33025164|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
33025165|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
33025166|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
33025167|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
33025168|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
33025169|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
33025170|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
33025171|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
33025172|NCT01882491|Placebo Comparator|Placebo|
33025173|NCT01882491|Experimental|gevokizumab|
33025174|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
33025175|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
33025176|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
33025177|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025178|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025179|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025180|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025181|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025182|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025183|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025184|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
33025185|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
33025186|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
33025187|NCT01882569||Back surgery|
33025188|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
33106896|NCT03974451|Experimental|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
33416858|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
33416859|NCT01336608|Placebo Comparator|placebo|Placebo
33416860|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
33106897|NCT03974451|Active Comparator|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
33025189|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
33025190|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
33025191|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
33025192|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
33025193|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
33025194|NCT01882634|Experimental|Ultrasound arm|
33025195|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
33025196|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
33025197|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
33025198|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
33025199|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
33025200|NCT01882751||ConforMIS|Patients with ConforMIS implants
33025201|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
33025202|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
33025203|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
33025204|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
33025205|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
33025206|NCT01882881|Active Comparator|Healthy American Control Diet|
33025207|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
33025208|NCT01882881|Experimental|Almond Diet|
33025209|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
33025210|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
33025211|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
33025212|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
33025213|NCT01882920|Active Comparator|Control arm|
33025214|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
33025215|NCT01882959||Placebo|
33025216|NCT01882959||Intervention|Radiofrequncy Denervation
33025217|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
33025218|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
33025219|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
33025220|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
33025221|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml~IV Ampoules 3 g piracetam in 15 ml~Oral solution 33 % piracetam (bottle of 125 ml)~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
33416861|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
33025222|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml~IV Ampoules 3 g placebo in 15 ml~Oral solution 33% placebo (bottle of 125 ml)~Oral tablets 1200 mg placebo (blisters of 10 tablets)~All IV forms were identical in presentation, size and color to allow a double blind design.~All oral forms were identical in shape, size, color and taste to allow a double blind design."
33025223|NCT01883024|Other|Type 1 diabetes|
33025224|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
33025225|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
33025226|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
33025227|NCT01883050|No Intervention|No Intervention|No Intervention
33025228|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
33025229|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
33025230|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
33025231|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
33025232|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
33025233|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
33025234|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
33025235|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
33025236|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
33025237|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
33025238|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
33025239|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
33025240|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
33025241|NCT01883154||IVF pregnancies|
33025242|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: RDEA3170 10 mg or placebo qd."
33025243|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: febuxostat 40 mg qd."
33025244|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
33025245|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
33025246|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
33025247|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
33025248|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
33025249|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
33025250|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
33025251|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
33025252|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
33025253|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
33025254|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
33025255|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
33025256|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
33025257|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
33025258|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
33025259|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
33025260|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
33025261|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
33025262|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
33025263|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
33326476|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
33416862|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
33416863|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
33025264|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
33025265|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
33025266|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
33025267|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
33025268|NCT01883349||Control Arm|Subjects without kidney disease
33025269|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
33025270|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
33025271|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
33025272|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
33025273|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
33025274|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
33025275|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
33025276|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
33025277|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
33025278|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
33025279|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
33025280|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
33025281|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
33025282|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
33025283|NCT01883505|Placebo Comparator|Placebo|Saline
33025284|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
33025285|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
33025286|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
33025287|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
33025288|NCT01883544|Placebo Comparator|placebo|Infusion placebo
33025289|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
33025290|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
33025291|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
33025292|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
33025293|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
33025294|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
33025295|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
33106898|NCT03954678|Experimental|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
33416864|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
33416865|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
33416866|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
33416867|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
33416868|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
33025296|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
33025297|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
33025298|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
33025299|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
33025300|NCT01883622||Healthy|Healthy pregnant women
33025301|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
33025302|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
33025303|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
33025304|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
33025305|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
33025306|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
33025307|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
33025308|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
33025309|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
33025310|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
33025311|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
33025312|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
33025313|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
33025314|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
33025315|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
33025316|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
33025317|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
33025318|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
33025319|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
33025320|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
33025321|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
33025322|NCT01883778||Emergency Department Patients|
33025323|NCT01883778||Emergency Medicine Physicians|
33025324|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
33025325|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
33025326|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
33025327|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
33025328|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
33025329|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
33025330|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
33025331|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
33025332|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
33025333|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
33025334|NCT01883921||Immunoglobulin Therapy|
33025335|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
33025336|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
33025337|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
33025338|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
33025339|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
33025340|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
33025341|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
33025342|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
33025343|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
33025344|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
33025345|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
33025346|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
33025347|NCT01884038|Experimental|1|
33025348|NCT01884038|Placebo Comparator|2|
33025349|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
33025350|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
33025351|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
33025352|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
33025353|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
33025354|NCT01884116|Experimental|NSAID patch + heating pad group|
33025355|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
33025356|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
33025357|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
33025358|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
33025359|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
33025360|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
33025361|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.~Able to understand and provide signed informed consent.~Age range and gender matched with Patients with Huntington Disease Group."
33025362|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
33025363|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
33025364|NCT01884207||orbital tumors|
33025365|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
33025366|NCT01884233|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
33416869|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
33025367|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
33025368|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
33025369|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
33025370|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
33025371|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
33025372|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
33025373|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
33025374|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
33025375|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
33025376|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
33025377|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
33025378|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
33025379|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
33025380|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
33025381|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
33025382|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
33025383|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
33025384|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
33025385|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
33025386|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
33025387|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
33025388|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
33025389|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
33025390|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
33025391|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
33025392|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
33025393|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
33025394|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
33025395|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
33025396|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
33025397|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
33025398|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
32866598|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
32866599|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
32866600|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
32866601|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
33025399|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
33025400|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
33025401|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
33025402|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
33025403|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33025404|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33025405|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33025406|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33025407|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
33025408|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
33025409|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
33025410|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
33025411|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
33025412|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
33025413|NCT01884649||Group of Hashimoto thyroiditis patients|
33025414|NCT01884649||Healty control group|
33025415|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
33025416|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
33025417|NCT01884701|Experimental|Intervention|Intervention
33025418|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
33025419|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
33025420|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
33025421|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
33025422|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
33025423|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
33025424|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
33106899|NCT03954678|Active Comparator|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
33106900|NCT04661969||1|Foreign Substance disseminated to both lower extremities and buttocks
33106901|NCT04661969||2|Foreign Substance isolated to buttocks with moderate to severe skin changes
33106902|NCT04661969||3|Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
33326477|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
33326478|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
33326479|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
33326480|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
33326481|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
33326482|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
33025425|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
33326483|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
33025426|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
33025427|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
33025428|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
33025429|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
33025430|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
33025431|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
33025432|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
33025433|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
33025434|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
33025435|NCT01884883|Other|Internal unicompartmental knee brace|
33025436|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
33025437|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
33326484|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
33326485|NCT01265628||Glaucoma|
33326486|NCT01265628||Retinitis pigmentosa (RP)|
33326487|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
33025438|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
33025439|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
33025440|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
33025441|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
33025442|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
33025443|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
33326488|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
33326489|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
33326490|NCT01159626|Experimental|Single dose|
33326491|NCT01159626|Experimental|Multiple dose|
33326492|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
33326493|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
33025444|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
33025445|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
33025446|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
33025447|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
33025448|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
33025449|NCT01885026|Experimental|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
33025450|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
33025451|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
33025452|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
33025453|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
33025454|NCT01885091|Experimental|Kinerase|
33025455|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
33025456|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
33025457|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
33025458|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
33025459|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
33025460|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
33025461|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
33025462|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
33025463|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
33025464|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
33025465|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
33025466|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
33025467|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
33025468|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
33025469|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
33025470|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
33025471|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
33025472|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
33025473|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
33025474|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
33033243|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
33025475|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers"
33025476|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
33025477|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
33025478|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
33025479|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
33025480|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
33025481|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
33025482|NCT01885403|Experimental|Respiratory Parameters Measurements|
33025483|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
33025484|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
33025485|NCT01885416|Experimental|dairy product meal|dairy product meal
33025486|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
33025487|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
33025488|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
33025489|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
33025490|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
33025491|NCT01885442|Experimental|In-bed leg cycle ergometry|
33025492|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
33025493|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
33025494|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
33025495|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
33025496|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
33025497|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
33025498|NCT01885494||Control group|Untreated control group
33025499|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
33025500|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
33025501|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
33025502|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
33025503|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
33025504|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
33025505|NCT01885533||Post-radiodione medication|watchful monitoring
33025506|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
33025507|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
33025508|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
33025509|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
33033244|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
33416870|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.~Myofascial release assisted the paravertebral fascia."
33416871|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
33416872|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
33025510|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
33025511|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
33025512|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
33025513|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
33025514|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
33025515|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
33025516|NCT01885676|Experimental|PRGF-Endoret|
33025517|NCT01885676|Placebo Comparator|Saline Solution|
33025518|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025519|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
33025520|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025521|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025522|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025523|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025524|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025525|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
33025526|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
33025527|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
33025528|NCT01885741|Experimental|IPBS|
33025529|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
33025530|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
33025531|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
33025532|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
33025533|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
33025534|NCT01885780|Experimental|Astigmatic keratotomy|
33025535|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
33025536|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
33416873|NCT01361347|Experimental|milk|cow's milk
33416874|NCT05697003|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|Test
33416875|NCT05697003|Active Comparator|ADVAIR DISKUS® 100/50|Reference
33416876|NCT01356199|Experimental|ARTRONAT|
33416877|NCT01356199|Placebo Comparator|PLACEBO|
33416878|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
33025537|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
33416879|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
33025538|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
33025539|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
33025540|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
33025541|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
33025542|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
33025543|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
33025544|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
33025545|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
33025546|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
33025547|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
33025548|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
33025549|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
33025550|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
33025551|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
33025552|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
33025553|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
33025554|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
33025555|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
33025556|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
33025557|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
33025558|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
33025559|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
33025560|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
33025561|NCT01886040||cases with endometrial cancer|
33025562|NCT01886053|Active Comparator|Ertapenem|
33025563|NCT01886053|Experimental|Faropenem（low-dose group)|
33025564|NCT01886053|Experimental|Faropenem（high dose group）|
33025565|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
33025566|NCT01886079|Experimental|Dexmedetomidine group|
33025567|NCT01886079|Placebo Comparator|Saline group|
33025568|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
33025569|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
33025570|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
33416880|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
33326494|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
33025571|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
33326495|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
33416881|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
33025572|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
33025573|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
33025574|NCT01886131|Experimental|Synchronised video-polysomnography|
33025575|NCT01886144||Knee OA|People with knee OA of one knee
33025576|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
33025577|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
33025578|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
33025579|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
33025580|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
33025581|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
33025582|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
33025583|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
33025584|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
33025585|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
33025586|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
33025587|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
33025588|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
33025589|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
33025590|NCT01886222|Other|Normothermia|Standard management
33025591|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
33025592|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
33025593|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
33025594|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
33025595|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
33025596|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
33025597|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
33025598|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
33025599|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
33025600|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
33025601|NCT01886339||Healthy population|
33025602|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
33025603|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
33025604|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
33033245|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
33106903|NCT04661969||4|Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
33025605|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
33025606|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
33025607|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
33025608|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
33025609|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
33025610|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
33025611|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
33416882|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
33416883|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33025612|NCT01886443|Experimental|Combined drug approach, safety study|
33025613|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
33025614|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
33025615|NCT01886469|Experimental|Adolescents (12-17yrs)|
33025616|NCT01886469|Experimental|Children (6-11 yrs)|
33025617|NCT01886482|Active Comparator|nutrition intervention|high protein diet
33025618|NCT01886482|No Intervention|no intervention|control diet
33025619|NCT01886495|Active Comparator|nutrition intervention|high protein diet
33025620|NCT01886495|No Intervention|control diet|
33025621|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
33025622|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
33025623|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
33025624|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
33025625|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
33025626|NCT01886534|Other|Usual Care with Caregiver|Usual care
33416884|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
33416885|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
33025627|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
33025628|NCT01886534|Other|Usual Care without Caregiver|Usual Care
33025629|NCT01886547||New patient presented with prostate disease|prostate disease identified
33025630|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
33025631|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
33025632|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
33025633|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
33025634|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
33025635|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
33025636|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
33025637|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
33025638|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
33025639|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
33025640|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
33033246|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
33106904|NCT03943368|Experimental|Experimental: Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
33416886|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
33416887|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
33416888|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
33416889|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
33025641|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
33025642|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
33025643|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
33025644|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
33025645|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
33025646|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
33025647|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
33025648|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
33025649|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
33025650|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
33025651|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
33025652|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
33025653|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
33025654|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
33025655|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
33025656|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
33025657|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
33025658|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
33025659|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
33025660|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
33025661|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
33025662|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
33025663|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
33025664|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
33025665|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
33025666|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
33025667|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
33025668|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
33025669|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
33025670|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
33025671|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
33025672|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
33106905|NCT03943368|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
33106906|NCT04662164|Placebo Comparator|placebo|control
33025673|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
33416890|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
33416891|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
33416892|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
33416893|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
33416894|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
33416895|NCT03610542|No Intervention|Control|This is a no intervention control arm
33416896|NCT03634969|Experimental|Normal Renal Function|
33416897|NCT03634969|Experimental|Mild Renal Impairment|
33416898|NCT03634969|Experimental|Moderate Renal Impairment|
33416899|NCT03634969|Experimental|Severe Renal Impairment|
33416900|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
33025674|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
33025675|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
33025676|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
33025677|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
33025678|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Taught how to complete a visual problem-solving task (Tower of Hanoi)~Given a diary to record training at home.~In-home~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
33025679|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
33025680|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
33025681|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
33025682|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
33025683|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
33025684|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
33025685|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
33025686|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
33025687|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
33025688|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
33025689|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
33025690|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
33025691|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
33025692|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
33025693|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
33025694|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
33025695|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
33106907|NCT04662164|Active Comparator|4.2mg hepalatide|low dose
33106908|NCT04662164|Active Comparator|6.3mg hepalatide|middle dose
33106909|NCT04662164|Active Comparator|8.4mg hepalatide|high dose
33416901|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
33416902|NCT01356433|Other|Arm 2 control first|
33025696|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
33025697|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
33025698|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
33025699|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
33025700|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
33025701|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
33025702|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
33025703|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
33025704|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
33025705|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
33025706|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
33025707|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
33025708|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
33025709|NCT01887275|Experimental|medical ozone therapy with humares|
33025710|NCT01887275|Active Comparator|conventional interferon-α|
33025711|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
33025712|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
33025713|NCT01887340|Experimental|Cohort 1|"PET-TDM~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
33025714|NCT01887340|Experimental|Cohort 2|"PET-TDM~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
33025715|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
33025716|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
33025717|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
33025718|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
33025719|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
33025720|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
33025721|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
33025722|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
33025723|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
33025724|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
33025725|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
33025726|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
33025727|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
33025728|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
33025729|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
33025730|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
33416903|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :~In the fifth session we explained the patients to perform :~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.~Five sets of isometric contraction of the neck extensors for 6-8 seconds~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
33025731|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
33025732|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
33025733|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
33025734|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
33025735|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
33025736|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
33025737|NCT01887561|No Intervention|treatment|
33025738|NCT01887574|Experimental|Open|
33025739|NCT01887613||Regnite group|Patients who receive Regnite
33025740|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
33025741|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
33025742|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
33025743|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
33025744|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
33025745|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
33025746|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
33025747|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
33025748|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
33025749|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
33025750|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
33025751|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
33025752|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
33025753|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
33025754|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
33025755|NCT01887769||Lung cancer patient at diagnosis|
33025756|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
33025757|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
33025758|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
33025759|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
33025760|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
33416904|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
33416905|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
33025761|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
33025762|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
33025763|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
33025764|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
33025765|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
33025766|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
33025767|NCT01887899|Experimental|transcranial direct current stimulation|
33025768|NCT01887899|Placebo Comparator|sham stimulation|
33025769|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
33025770|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
33025771|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
33025772|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
33025773|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
33025774|NCT01887977|Experimental|Computational modeling|
33025775|NCT01888016|Experimental|fascial manipulation|
33025776|NCT01888016|Active Comparator|standard treatment|
33025777|NCT01888029|Experimental|transcranial direct current stimulation|
33025778|NCT01888029|Placebo Comparator|sham stimulation|
33025779|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
33025780|NCT01888055|Experimental|transcranial direct current stimulation|
33025781|NCT01888055|Placebo Comparator|sham stimulation|
33025782|NCT01888068||No treatment|
33025783|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
33025784|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
33025785|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
33025786|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
33025787|NCT01888120||Severe Chronic Pain|
33025788|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
33025789|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
33025790|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
33025791|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
33025792|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
33025793|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
33025794|NCT01888172|Experimental|Weight Watchers Online|
33025795|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
33025796|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
33025797|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
33025798|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
33025799|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
33025800|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
33025801|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
33025802|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
33025803|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
33416906|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.~MRI Neurological Exam Vital Signs Questionnaires"
33416907|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
33416908|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
33025804|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
33025805|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
33025806|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
33025807|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
33025808|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
33025809|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
33025810|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
33025811|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
33025812|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
33025813|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
33025814|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
33025815|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33025816|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
33025817|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
33025818|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
33025819|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
33025820|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
33025821|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
33025822|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
33025823|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
33025824|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies~intervention: minimally invasive, virtual autopsy"
33025825|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
33025826|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
33025827|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
33025828|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
33025829|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
33025830|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
33025831|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
33025832|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
33025833|NCT01888445|Experimental|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
33025834|NCT01888445|Experimental|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
33025835|NCT01888445|Experimental|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
33025836|NCT01888445|Active Comparator|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
33025837|NCT01888458|Experimental|Micafungine|
33025838|NCT01888471|Other|Cases Group|"Cases Group will be defined as:~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
33025839|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
33025840|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
33416909|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
33416910|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
33106910|NCT03918252|Experimental|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
33106911|NCT03918252|Experimental|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
33106912|NCT04662125|Active Comparator|group A|Group A (conservative treatment): Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.
33106913|NCT04662125|Active Comparator|group B|Group B (oral prednisolone): Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.
33106914|NCT04662125|Active Comparator|group C|Group C (oral pregabalin): Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.
33106915|NCT03899181|Active Comparator|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
33106916|NCT03899181|Active Comparator|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
33106917|NCT03899181|Sham Comparator|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar & 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
33106918|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
33106919|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
33106920|NCT00557180||BASALT|Participants in the ACRN BASALT study
33106921|NCT00557180||TALC|Participants in the ACRN TALC study
33106922|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
33106923|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
33106924|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
33106925|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
33106926|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
33106927|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
33106928|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
33106929|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
33106930|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
33106931|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
33106932|NCT03796338||Critically ill patients|age > 18 years
33106933|NCT00539916|Experimental|Jus d'orange|
33106934|NCT00539916|Placebo Comparator|Boisson contrôle|
33106935|NCT04661618|Active Comparator|GT|12 weeks of progressive training in the first phase and 12 weeks of maintenance training in the second phase.
33106936|NCT04661618|Other|Control|"No intervention for the first phase and will be active comparator in the second phase.~No intervention for the first 12 weeks (first phase) and 12 weeks of progressive training in the second phase."
33106938|NCT04661501|Active Comparator|AlloDerm group|Device for immediate implant based breast reconstruction.
33106939|NCT04661501|Active Comparator|AlloMax group|Device for immediate implant based breast reconstruction.
33106940|NCT04661501|Active Comparator|DermACELL group|Device for immediate implant based breast reconstruction.
33106941|NCT04661501|Active Comparator|Flex HD group|Device for immediate implant based breast reconstruction.
33106942|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
33106943|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
33106944|NCT04661696|Experimental|single-arm|Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.
33025841|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
33025842|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
33025843|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
32866602|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
32866603|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
32866604|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
32866605|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
32866606|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
32866607|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
32866608|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
32866609|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
32866610|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
33025844|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
33025845|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
33025846|NCT01888549|Experimental|arm1-High dose PPI|
33025847|NCT01888549|Active Comparator|arm2-standard dose PPI|
33025848|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
32866611|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
32866612|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
32866613|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
32866614|NCT04819776|Experimental|Iloperidone|
32866615|NCT04819776|Placebo Comparator|Placebo|
32866616|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
32866617|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
32866618|NCT04192253|Experimental|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
32866619|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
33025849|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
33025850|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
33025851|NCT01888575||Drug|PPI continuous use; No PPI use
33025852|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
33025853|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
33025854|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
33025855|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
33025856|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
33025857|NCT01888666||slow palatal expansion (SPE)|
33025858|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
33025859|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
33025860|NCT01888705||NE|Smokers wiht normal spirometry.
33025861|NCT01888705||LV|Patients with COPD level I, mild.
33025862|NCT01888705||MOD|Patients with COPD level II, moderate.
32866620|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
33025863|NCT01888705||GV|Patients with COPD level III, severe.
33025864|NCT01888705||MGV|Patients with COPD level IV, very severe.
33025865|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
33025866|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
33025867|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
33025868|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
33025869|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
33025870|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
33025871|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
33025872|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
33025873|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
33025874|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
33025875|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
33025876|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
33025877|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
33025878|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
32866621|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
32866622|NCT00102011|Other|Study I- Arm II|Participants receive standard care
33025879|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
33025880|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
33025881|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
33025882|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
33025883|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
33025884|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
33025885|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
33025886|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
33025887|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
33025888|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
33025889|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
33025890|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
33025891|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
33025892|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
33025893|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
33025894|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
33025895|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
33025896|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
33025897|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
33025898|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
33025899|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
33025900|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
33025901|NCT01888991|No Intervention|water with resting condition|
33025902|NCT01888991|Experimental|glucose with resting condition|
33326496|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
33025903|NCT01888991|Experimental|water with exercise condition|
33025904|NCT01888991|Experimental|glucose with exercise condition|
33326497|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
33326498|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
33326499|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
33326500|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
33326501|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
33326502|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
33025905|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
33025906|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
33025907|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
33025908|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
33025909|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
33025910|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
33025911|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
33025912|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
33025913|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
33025914|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
33025915|NCT01889108|No Intervention|Control|Usual care
33025916|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
33025917|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
33025918|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
33025919|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
33025920|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
33025921|NCT01889134|No Intervention|Control group|No intervention
33025922|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
33025923|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
33025924|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
33025925|NCT01889160|Experimental|Part A Active|AZD4721 Solution
33025926|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
33025927|NCT01889160|Experimental|Part B solution|AZD4721 Solution
33025928|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
33025929|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
33025930|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
33025931|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
33025932|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
33025933|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
33025934|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
33025935|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
33025936|NCT01889225||Framingham Heart study|
33025937|NCT01889225||Framingham Offspring cohort|
33025938|NCT01889225||Atherosclerosis Risk In Communities|
33025939|NCT01889225||Charleston Heart study|
33025940|NCT01889225||Cardiovascular Health study|
33025941|NCT01889225||Rancho Bernardo study|
33025942|NCT01889225||Nurses' Health I study|
33025943|NCT01889225||Panel Study Income Dynamics|
33025944|NCT01889225||MRFIT Referred Care|
33106945|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
33106946|NCT04661774|Other|Sham massage before reflexology massage (RP)|Sham massage (MS) comparator will be realised before RP.
33106947|NCT04661774|Other|Reflexology massage (RP) before Sham massage|RP will be realized before Sham massage.
33106948|NCT03766191|Active Comparator|Food Ads and fMRI|Exposure to food ads during an fMRI scan
33106949|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|Exposure to non-food ads during an fMRI scan
33106950|NCT03766191|Active Comparator|Food Ads and TV show|Exposure to food ads embedded in an age-appropriate TV program
33106951|NCT03766191|Sham Comparator|Non-Food Ads and TV show|Exposure to non-food ads embedded in an age-appropriate TV program
33106952|NCT04661189|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
33106953|NCT04661189|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
33106954|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
33106955|NCT04661345||Septic group|The septic group is composed of patients with prosthetic joint infection mediated by coagulase-negative Staphylococci (CoNS)
33106956|NCT04661345||Aseptic group|The aseptic group is composed of patients with implant failure unrelated to infection.
33106957|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
33106958|NCT04661111|Experimental|Hymovis ONE Arm|Hymovis® ONE (32 mg/4 ml) intra-articular mono injection. Patients will be followed during 12 months including 6 visits.
33106959|NCT03689946|Experimental|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
33106960|NCT04660916||isotretinoin|The patients aged 18-45 that were planned to begin treatment with isotretinoin for acne
33106961|NCT04660916||control|Healthy volunteers aged 18-45 without any diseases/drugs affecting the nail
33106962|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
33106963|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
33106964|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
33106965|NCT04660994||Therapeutic education|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
33106966|NCT04660994||Therapeutic education and Yapouni educational game|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
33326503|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
33025945|NCT01889225||HDFP Referral Care|
33025946|NCT01889225||Alameda County Health and Ways of Living Study|
33025947|NCT01889225||Nurses' Health II study|
33025948|NCT01889225||Tecumseh County Health study|
33025949|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
33025950|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
33025951|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
33106967|NCT05102253|Experimental|TEAS+DCEAS group|Subjects assigned to TEAS+DCEAS group will receive TEAS+DCEAS in addition to routine care.
33106968|NCT05102253|Other|Wait-list control: Routine care group|Subjects assigned to this group will continue their current routine care as usual.
33106969|NCT04660604|Experimental|Graston Technique® Group|Participants were asked to warm up at a speed that they felt comfortable for 5 minutes at a gentle tempo with an ergometer. Time was followed by a stopwatch. Participants who completed warm-up were taken to GT® application. Application was implemented by a GT® certified therapist with 13 years of experience in orthopedic rehabilitation. Intervention dosage was determined as 2 times a week, 12 sessions over 6 weeks. GMed muscle was scanned between crista iliaca and trochanter major, and a fascial release was applied. Each session lasted 5 minutes. At the end of sessions, iliotibial band stretching exercises (30 seconds, 3 repetitions) was given to the treated side. Application protocol has been determined with reference to GT® manual
33106970|NCT04660604|No Intervention|Control Group|Control group is followed up for 6 weeks without intervention.
33106971|NCT05099367|Other|Group 1 : healthy subject|15 healthy subject without diabetes
33106972|NCT05099367|Other|Group 2 : diabetes without ulcer|15 patients with diabetes type II and without foot ulcer
33106973|NCT05099367|Other|Group 3 : diabetes with ulcer active or <2 years|15 patients with diabetes type II and with foot ulcer (active or <2years)
33106974|NCT05099367|Other|Group 4 : Patients with type 2 diabetes, neuropathy and DFU undergoing lower limb|Patients with type 2 diabetes and neuropathy and DFU undergoing lower lunb surgery for skin ulcer
33106975|NCT04660253|Experimental|LTP Plus Dads|Participants in this group will receive 10 sessions of LTP plus dads
33326504|NCT03879252|Experimental|Tooth brushing|
33326505|NCT03879252|Active Comparator|Mouthwash|
33416911|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
33025952|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
33025953|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
33416912|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
33416913|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
33416914|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
33416915|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
33416916|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
33416917|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
33416918|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
33416919|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
33416920|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
33416921|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
33025954|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
33025955|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
33025956|NCT01889277|Placebo Comparator|Placebo|Placebo
33025957|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
33025958|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
33025959|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
33025960|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
33025961|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
33025962|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
33025963|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
33025964|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
33025965|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
33025966|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
33025967|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
33025968|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
33025969|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
33025970|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
33025971|NCT01889459||PCI for CTO|
33025972|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
33025973|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
33025974|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
33025975|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
33416922|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
33416923|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
33416924|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
33416925|NCT01361503||Autism Spectrum Disorder (ASD)|
33416926|NCT01361503||Controls|
33025976|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
33025977|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
33025978|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
33025979|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
33025980|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
33025981|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
33025982|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
33025983|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
33025984|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
33025985|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
33025986|NCT01889589||NYC adults|
33025987|NCT01889615||Suspected ovarian cancer|dual time PET/CT
33025988|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
33025989|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
33025990|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
33025991|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
33025992|NCT01889641||healthy volunteers|Subjects controls
33025993|NCT01889654||patient|
33025994|NCT01889654||healthy volunteers|
33025995|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
33025996|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
33025997|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
33025998|NCT01889693||chronic stable angina|patients with chronic stable angina
33025999|NCT01889693||control|control subjects without coronary artery disease
33026000|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
33026001|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
33026002|NCT01889732||ROTEM|
33026003|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
33026004|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
33026005|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
33026006|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
33026007|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
33026008|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
33026009|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
33033247|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
33033248|NCT01961024||Type 2 diabetic men|
33033249|NCT01961024||Age- and weight-matched controls|
33416927|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
33026010|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
33026011|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
33026012|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
33026013|NCT01889810|Placebo Comparator|Placebo|Placebo group
33026014|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
32866623|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
33026015|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
33026016|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
33026017|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
33026018|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
33026019|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
33026020|NCT01889875|No Intervention|Control group|
33026021|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
33026022|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
33026023|NCT01889888|Experimental|ADRC injection|
33026024|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
33026025|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
33026026|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
33026027|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
33026028|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
33026029|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
33026030|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
33026031|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
33026032|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
33026033|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
33026034|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:~Arm 1. Control group no modifications~Electronic Pill Bottle tracking"
33026035|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging"
33026036|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient~Electronic Pill Bottle tracking; Social Influence"
33033250|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
33033251|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
33033252|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
33416928|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
33026037|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
33026038|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
33026039|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
33026040|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
33026041|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
33026042|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
33026043|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
33026044|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
33026045|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
33026046|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:~center and family self-assessment,~center intervention materials delivered several times over the 6-month period, and;~parent handouts~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
33026047|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:~center and family self-assessment;~targeted technical assistance by Baby NAP SACC consultant for providers and parents;~training workshops for child care providers; and~parent outreach and support."
33026048|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
33026049|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
33026050|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
33026051|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
33026052|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
33026053|NCT01891292|No Intervention|Control|
33026054|NCT01891292|Active Comparator|Enalapril|
33026055|NCT01891292|Active Comparator|N-Acetylcysteine|
33026056|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
33026057|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
33026058|NCT01891487|Active Comparator|Track A|Those on active study medication
33026059|NCT01891487|Placebo Comparator|Track B|Those on placebo.
33026060|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
33026061|NCT01891552||DEBIRI|only DEBIRI treatment
33026062|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
33026063|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
33026064|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
33026065|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
33026066|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
33026067|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
33026068|NCT01892319||All patients|
33026069|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
33026070|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
33416929|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
33026071|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
33026072|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
33026073|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
33026074|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
33026075|NCT01893008|No Intervention|Usual care (no IMT)|
33026076|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
33026077|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
33026078|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
33026079|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
33026080|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
33026081|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
33026082|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
33026083|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
33026084|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
33026085|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
33026086|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
33026087|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
33026088|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
33026089|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
33026090|NCT01894347||Colistin inhalative|"Adult ICU patients with~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
33026091|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
33026092|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
33026093|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
33026094|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
33026095|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
33416930|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
33026096|NCT01894893||Breastfeeding mothers|
33026097|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
33026098|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
33026099|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
33026100|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
33026101|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
33026102|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
33026103|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
33026104|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
33026105|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
33026106|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
33026107|NCT01896622|Experimental|A|Ritonavir
33026108|NCT01896622|Experimental|B|Cobicistat
33026109|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
33026110|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
33026111|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
33026112|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
33026113|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
33026114|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
33026115|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
33026116|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
33026117|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
33026118|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
33026119|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
33026120|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
33026121|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
33026122|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
33026123|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
33026124|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
33026125|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
33026126|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
33026127|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
33026128|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
33026129|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
33026130|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
33026131|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
33026132|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
33026133|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
33026134|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
33026135|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
33026136|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
33026137|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
33026138|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
33026139|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
33026140|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
33416931|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
33416932|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
33416933|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
33416934|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
33416935|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
33026141|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
33026142|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
33026143|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
33326506|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach®, establishment of ventilation~Evaluation of glottic view through LMA-Fastrach® using fibrescope~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
33326507|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel®, establishment of ventilation~Evaluation of glottic view through I-gel® using fibrescope~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
33326508|NCT01156818||Children|Age 8-21 years
33326509|NCT01156818||Adult|Age 21-80 years
33326510|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
33326511|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
33026144|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
33026145|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
33026146|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
33026147|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
33026148|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
33026149|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
33026150|NCT01899417||Standard Knee Replacements|knee joint replacement
33026151|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
33026152|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
33026153|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
33026154|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
33026155|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
33026156|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
33026157|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
33026158|NCT01899599|Experimental|PankoMab-GEX|1700mg, i.v., q3w
33026159|NCT01899599|Placebo Comparator|Placebo|matching placebo
33026160|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
33026161|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
33026162|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
33026163|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
33026164|NCT01899716|No Intervention|Control|
33026165|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
33416936|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
33326512|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
33326513|NCT01264224|Experimental|PAC-14028|
33326514|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
33326515|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
33026166|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
33026167|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
33026168|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
33026169|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
32866624|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
33026170|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
33026171|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
33026172|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
33026173|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
33026174|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
33026175|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
33026176|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
33026177|NCT01900158|Experimental|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
33026178|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026179|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026180|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026181|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026182|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026183|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33326516|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
33326517|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
33326518|NCT01265940|Experimental|Pazopanib + Vinflunine|
33326519|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
33326520|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
33326521|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
33326522|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
33326523|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
33326524|NCT03760146|Experimental|60 years and above 20vPnC/Saline|20vPnC and saline
33326525|NCT03760146|Active Comparator|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
33326526|NCT03760146|Experimental|50 through 59 years of age 20vPnC|20vPnC
33326527|NCT03760146|Experimental|18 through 49 years of age 20vPnC|20vPnC
33326528|NCT03760146|Active Comparator|50 through 59 years of age 13vPnC|13vPnC
33326529|NCT03760146|Active Comparator|18 through 49 years of age 13vPnC|13vPnC
33026184|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33416937|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).~Participants will receive motivational reminders to take medications sent via text message to their cell phones.~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
33416938|NCT05076409|Experimental|All participants|
33416939|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
33416940|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
33416941|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
33416942|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
33416943|NCT05033353|Active Comparator|Group I|Mechanical ventilation was adjusted to maintain an EtCO2 of 33-38 mm Hg in group I regional cerebral oxygen monitoring
33416944|NCT05033353|Active Comparator|Group II|Mechanical ventilation was adjusted to maintain an EtCO2 of 39-45 mm Hg in group II regional cerebral oxygen monitoring
33026185|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026186|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
33026187|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
33026188|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
33026189|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
33026190|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
33026191|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
33026192|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
33026193|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
33026194|NCT01900223||Shoulder prosthesis bearer|
33026195|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
33026196|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
33026197|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
33026198|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
33026199|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
33026200|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
33026201|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
33026202|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
33026203|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
33026204|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
33026205|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
33416945|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
33416946|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
33026206|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
33026207|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
33026208|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
33026209|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
33026210|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
33026211|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
33026212|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
33026213|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
33026214|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
33026215|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
33026216|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
33026217|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
33026218|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
33026219|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
33026220|NCT01900405||Dexmedetomidine|All children undergoing
33026221|NCT01900418|Active Comparator|Walking|Walk with Ease
33026222|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
33026223|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
33026224|NCT01900457|Experimental|patients|vestibular defective patients
33026225|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
33026226|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
33026227|NCT01900483||pre bariatric surgery|
33026228|NCT01900483||post bariatric surgery|
33026229|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
33026230|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
33026231|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
33026232|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
33026233|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
33026234|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
33026235|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
33026236|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
33026237|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
33026238|NCT01900600|Placebo Comparator|Placebo|Placebo
33026239|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
33416947|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
33416948|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
33026240|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
33026241|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
32866625|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
33026242|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
33026243|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
33026244|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
33026245|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
33026246|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
33026247|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
32866626|NCT04833972|Experimental|Experimental: V1: Binary Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has binary (yes/no) response options."
32866627|NCT04833972|Experimental|Experimental: V2: Categorical Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has categorical response options: all or almost all; more than half, but fewer than 90%; fewer than half, but more than 10%; very few, or no one"
33026248|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,~FOLFOX 4 simplified,~FOLFIRI modified.~Bevacizumab 5 mg/kg/ 2 weeks"
33026249|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
33026250|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
33026251|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text~In-clinic educational video~Patient report card~Post-clinic phone text~Outpatient stroke registry"
33026252|NCT01900756|No Intervention|Standard care|Routine and customary management.
33026253|NCT01900769|Experimental|Blood Volume Dilution|
33026254|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
33026255|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
33026256|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
33026257|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
33026258|NCT01900795|Experimental|V117957|
33026259|NCT01900795|Active Comparator|Ibuprofen|
33026260|NCT01900795|Placebo Comparator|Placebo|
33026261|NCT01900808||Patients with chronic liver disease|
33026262|NCT01900821||Women|All women having mammograms
33026263|NCT01900834||All participants|
33026264|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
33026265|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
33026266|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
33026267|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
33026268|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
33026269|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
33026270|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
33026271|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
33026272|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
33026273|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
33026274|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
33026275|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
33033253|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
33026276|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
33026277|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
33026278|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
33026279|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
33026280|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
33026281|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
33026282|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
33026283|NCT01901003|Placebo Comparator|placebo group|placebo
33026284|NCT01901003|Active Comparator|no premedication group|no premedication
33026285|NCT01901003|Experimental|Lorazepam group|lorazepam
33026286|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
33026287|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
33026288|NCT01901016|No Intervention|control|The CG continued to receive their standard care. After data collection at the six-month follow-up, the CG participants were invited to attend one of two relaxation interventions.
33026289|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
33026290|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
33026291|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
33026292|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
33026293|NCT01901068||MonoMax|Elective primary laparotomy
33026294|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
33026295|NCT01901107||Kiklin group|
33026296|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
33026297|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
33026298|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
33026299|NCT01901159|Experimental|RO4995819 capsule|
33026300|NCT01901159|Experimental|RO4995819 tablet|
33026301|NCT01901172|Experimental|Extension|
33026302|NCT01901172|Experimental|Part 1: Drug-drug interaction|
33026303|NCT01901172|Experimental|Part 2: Relative bioavailability|
33026304|NCT01901172|Experimental|Part 3: Food effect|
33026305|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
33026306|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
33026307|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
33026308|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
33026309|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
33026310|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
33026311|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
33026312|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
33026313|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
33026314|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
33026315|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
33026316|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
33416949|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
33416950|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
33416951|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
33416952|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
33416953|NCT01361581||ACD (acid-citrate-dextrose)|
33416954|NCT01361581||4% trisodium citrate|
33416955|NCT01361581||unfractionated heparin (UFH)|
33416956|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
33416957|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
33416958|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
33416959|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
33416960|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
33026317|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
33026318|NCT01901406||ERM|idiopathic epiretinal membrane patients
33026319|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
33026320|NCT01901445|Experimental|Educational action group|
33026321|NCT01901445|No Intervention|Control group|
33026322|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
33026323|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
33026324|NCT01901471|Experimental|CsA Group|
33026325|NCT01901471|Placebo Comparator|Placebo group|
33026326|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
33026327|NCT01901484|Active Comparator|Praziquantel|double dose
33026328|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
33026329|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
33026330|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
33026331|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
33026332|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
33026333|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
33026334|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
33026335|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
33026336|NCT01901549|Active Comparator|PCI+Renal denervation|
33026337|NCT01901549|Active Comparator|PCI alone|
33026338|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
33026339|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
33026340|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
33026341|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
33026342|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
33026343|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
33026344|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
33026345|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
33026346|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
33026347|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
33026348|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
33026349|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
33026350|NCT01901744|Experimental|Patients undergoing cataract surgery|
33026351|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
33026352|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
33026353|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
33026354|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
33026355|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
33026356|NCT01901796|No Intervention|Usual care|Usual prenatal care
33026357|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
33026358|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
33026359|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
33026360|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
33026361|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
33026362|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
33026363|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months~Other names: none"
33026364|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months~Other names: none"
33026365|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
33026366|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
33026367|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
33026368|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
33026369|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
33026370|NCT01901952|Active Comparator|Standard of care|
33026371|NCT01901952|Experimental|Intensive education and support|
33026372|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
33026373|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
33026374|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
33026375|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
33026376|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
33026377|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
33026378|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
33026379|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
33026380|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
33026381|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
33026382|NCT01902030||Proven/Probable IA Patients|Case Population
33026383|NCT01902030||possible/No IA Patients|Control population
33026384|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
33026385|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
33026386|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
33026387|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
33026388|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
33026389|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
33416961|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
33416962|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
33416963|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
33026390|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
33026391|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
33026392|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
33026393|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
33026394|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
33026395|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
33026396|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
33026397|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
33026398|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
33026399|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
33026400|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
33026401|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
33026402|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
33026403|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
33026404|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
33026405|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
33026406|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
33026407|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
33026408|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
33026409|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
33026410|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
33026411|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
33026412|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
33026413|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
33026414|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
33026415|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
33026416|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
33026417|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
33026418|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
33026419|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
33026420|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
33026421|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
33026422|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
33026423|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
33026424|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
33026425|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
33026426|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
33026427|NCT01902485|Active Comparator|Quickstart|Immediate start
33026428|NCT01902485|Active Comparator|Afterstart|Delayed start
33026429|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
33026430|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
33026431|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
33026432|NCT01902511|Experimental|G-CSF + Erythropoietin|
33026433|NCT01902511|Active Comparator|G-CSF|
33026434|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
33026435|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
33026436|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
33026437|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
33026438|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
33026439|NCT01902615||Cohort|
33026440|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
33026441|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
33026442|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
33026443|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
33026444|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
33026445|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
33026446|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
33026447|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
33026448|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
33026449|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
33026450|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
33026451|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
33026452|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
33026453|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
33026454|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
33026455|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
33026456|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
33033254|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
33033255|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
33416964|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
33416965|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
33416966|NCT05128643|Experimental|Population Ⅰ|At 0,1,6 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
33026457|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
33026458|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
33026459|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
33026460|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
33026461|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
33026462|NCT01902823|No Intervention|No Nurse Navigator Services|
33026463|NCT01902823|Experimental|Services from a Nurse Navigator|
33026464|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
33026465|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
33026466|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).~intervention:blood sampling for IL measurement"
33026467|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)~intervention:blood sampling for IL measurement"
33026468|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
33026469|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
33026470|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
33026471|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
33026472|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
33026473|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
33026474|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
33026475|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
33026476|NCT01902979|No Intervention|Usual Care|
33033256|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
33033257|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
33033258|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
33033259|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
33416967|NCT05128643|Experimental|Population II|At 0,1,4 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
33416968|NCT02070224|Other|Knee osteoarthritis|
33026477|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
33026478|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
33026479|NCT01903018|Experimental|P276-00|
33026480|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
33026481|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8~Placebo has same appearance and dosing as azithromycin."
33026482|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8~Placebo has same appearance and dosing as azithromycin."
33026483|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
33026484|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
33026485|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
33026486|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
33026487|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
33026488|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
33026489|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
33026490|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
33026491|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
33026492|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
33026493|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
33026494|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
33026495|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
33026496|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
33026497|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
33026498|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
33026499|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
33026500|NCT01903213||Kiklin group|Oral
33026501|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
33026502|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
33026503|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
33026504|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
33026505|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
33026506|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
33026507|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
33416969|NCT03660215|No Intervention|control group|usual charge
33026508|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
33026509|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
33026510|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
33026511|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
33026512|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
33026513|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
33026514|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
33026515|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital & Medical School, Dundee.
33026516|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
33026517|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
33026518|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
33026519|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
33026520|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
33026521|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
33026522|NCT01903499|Active Comparator|Bean patty|Bean Patty
33026523|NCT01903499|Active Comparator|Beef patty|Beef patty
33026524|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
33026525|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
33026526|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
33026527|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
33026528|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
33026529|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
33026530|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
33026531|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
33026532|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
33026533|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
33026534|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
33026535|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
33026536|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
33026537|NCT01903642|Other|Patients with inflammatory syndrome|
33026538|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
33026539|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
33026540|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
33026541|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
33026542|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
33026543|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
33026544|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
33026545|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
33026546|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
33026547|NCT01903746||Patients in septic shock|
33026548|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
33026549|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
33026550|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
33026551|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
33416970|NCT03660215|Experimental|experimental group|"Mediation:~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
33026552|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
33026553|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
33416971|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
33416972|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
33416973|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
33026554|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
33026555|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
33026556|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
33026557|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
33026558|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
33026559|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
33026560|NCT01903915||Patients|Schizophrenia group
33026561|NCT01903915||Control|Healthy control group
33026562|NCT01903928|Experimental|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
33026563|NCT01903941|Experimental|Training|Aerobic
33026564|NCT01903941|Placebo Comparator|Control|Not exercise
33026565|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
33026566|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
33026567|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
33026568|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
33026569|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
33026570|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
33026571|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
33026572|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
33026573|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
33026574|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
33026575|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
33026576|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
33026577|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
33026578|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
33026579|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
33026580|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
33026581|NCT01904214|Experimental|severe renal impairmnt|
33026582|NCT01904214|Experimental|moderate renal impairment|
33026583|NCT01904214|Experimental|mild renal impairment|
33026584|NCT01904214|Experimental|healthy subjects|
33026585|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
33026586|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
33026587|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
33026588|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
33026589|NCT01904253|Experimental|TAS-102|
33026590|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
33026591|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
33026592|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
33026593|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
33026594|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
33026595|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
33026596|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
33026597|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
33026598|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
33026599|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
33026600|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
33026601|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
33026602|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
33026603|NCT01904318|Placebo Comparator|Placebo|
33026604|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
33026605|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
33026606|NCT01904344|Other|Sensor testing and validation|
33026607|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
33026608|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
33026609|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
33026610|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
33026611|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
33026612|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
33026613|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
33026614|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
33033260|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
33033261|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
33026615|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
33026616|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
33026617|NCT01904500|Other|Cefazolin 2 grams|
33026618|NCT01904500|Active Comparator|Cefazolin 3 grams|
33026619|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
33026620|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
33026621|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
33026622|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
33026623|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
33026624|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
33026625|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
33026626|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
33026627|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
33026628|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
33026629|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
33026630|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
33026631|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
33026632|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
33026633|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
33026634|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
33026635|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
33026636|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
33026637|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
33026638|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
33026639|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
33026640|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
33026641|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
33026642|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
33026643|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
33026644|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
33026645|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
33026646|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
33026647|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
33026648|NCT01904799|Other|Cognitive Assessment|
33026649|NCT01904812|Other|Lupus erythematosus|
33026650|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
33026651|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
33033262|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
33026652|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
33026653|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:~Providing enhanced HIV care."
33026654|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
33026655|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
33026656|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
33026657|NCT01904929|Experimental|Reconditioning in the effort|
33026658|NCT01904968||Colon cancers in patients living the Cote D'or area|
33026659|NCT01904981|Experimental|Atenolol|Atenolol group
33026660|NCT01904981|Experimental|Valsartan|Valsartan group
33026661|NCT01904994|No Intervention|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
33026662|NCT01904994|Experimental|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
33026663|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
33026664|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
33026665|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
33026666|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
33026667|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
33026668|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
33026669|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
33026670|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
33026671|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
33026672|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
33026673|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
33026674|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
33026675|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
33026676|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
33026677|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
33026678|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
33026679|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
33026680|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
33026681|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
33026682|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
33026683|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
33026684|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
33026685|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
33026686|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
33416974|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
33416975|NCT03644849|Sham Comparator|Sham laser intervention group|
33026687|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
33026688|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
33026689|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
33026690|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
33026691|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
33026692|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
33026693|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
33026694|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
33026695|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
33026696|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV~Dose Level 10: 180 mg/m2, IV~Dose Level 11: 240 mg/m2, IV~Dose Level 12: 320 mg/m2, IV~Dose Level 13: 400 mg/m2, IV~Dose Level 14: 540 mg/m2, IV~Dose Level 15: 700 mg/m2, IV~Dose Level 16: 920 mg/m2, IV~Dose Level 17: 1200 mg/m2, IV~Dose Level 18: 1600 mg/m2, IV~Dose Level 19: 2100 mg/m2, IV~Dose Level 20: 2700 mg/m2, IV"
33026697|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
33026698|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
33026699|NCT01905293|Experimental|100% portion size|100% portion size condition
33026700|NCT01905293|Experimental|150% portion size|150% portion size condition
33026701|NCT01905293|Experimental|200% portion size|200% portion size condition
33026702|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
33026703|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
33026704|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
33026705|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
33026706|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
33026707|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
33026708|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
33026709|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
33026710|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
33026711|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
33026712|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts~4 hours IV infusion"
33026713|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion"
33026714|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.~high and low dosage~4 hours IV infusion x 2 times/day x 3 days"
33026715|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion x 2 times/day x 3 days"
33026716|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
33026717|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
33026718|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
33026719|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
33026720|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
33026721|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
33026722|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
33026723|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
33416976|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
33026724|NCT01905488||Group S|patients who showed IJVVI in supine position
33026725|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
33026726|NCT01905501|Experimental|Balanced anesthesia|
33026727|NCT01905514|No Intervention|control|using Medication event monitoring system
33026728|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
33026729|NCT01905527||Standard Services of Group A (Group A1)|
33026730|NCT01905527||Customized Services of Group A (Group A2)|
33026731|NCT01905527||Group B|
33026732|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
33026733|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
33026734|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
33026735|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
33026736|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
33026737|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
33026738|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
33026739|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
33026740|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.~Intervention: Perineal ultrasound"
33026741|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
33026742|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
33026743|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
33026744|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
33026745|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
33026746|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
33026747|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
33026748|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
33026749|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
33026750|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
33026751|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
33026752|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
33026753|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
33026754|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
33026755|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
33026756|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
33026757|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
33026758|NCT01905800|Placebo Comparator|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
33026759|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
33033263|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
33033264|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
33026760|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
33026761|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
33026762|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
33026763|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
33026764|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
33026765|NCT01905917|No Intervention|Control|Usual care
33026766|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
33026767|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
33026768|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
33026769|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
33026770|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
33026771|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
33026772|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
33026773|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
33026774|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
33026775|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
33026776|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
33026777|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
33026778|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
33026779|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
33026780|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
33026781|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
33026782|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
33026783|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
33026784|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
33026785|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
33026786|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
33026787|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
33026788|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
33026789|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
33026790|NCT01906164|Experimental|ALS-008176|
33026791|NCT01906164|Placebo Comparator|Placebo|
33026792|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
33026793|NCT01906203|Experimental|ultramarathon|
33026794|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
33026795|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
33026796|NCT01906229||Acute respiratory distress syndrome (ARDS)|
33026797|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
33026798|NCT01906229||ARDS+SIRS|
33026799|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
33026800|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
33026801|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
33026802|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
33026803|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
33026804|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - active"
33026805|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
33026806|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
33026807|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
33026808|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
33026809|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
33026810|NCT01906320|Experimental|Training group|
33026811|NCT01906320|No Intervention|Control Group|
33026812|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
33026813|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
33026814|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
33026815|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
33026816|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
33026817|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
33026818|NCT01906411||subjecst with different BMI|
33026819|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
33026820|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
33026821|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
33026822|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
33026823|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
33026824|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
33026825|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
33026826|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
33026827|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
33326530|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
33326531|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, PCP or research teams).
33326532|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
33326533|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
33326534|NCT01266252|Experimental|Dexmedetomidine|
33026828|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
33026829|NCT01906554|Experimental|Egg Dose|
33026830|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart~• Pulmonary edema or cyanosis~• Oliguria (< 400 mL in 24 h)~• Persistent headaches~• Epigastric pain and/or impaired liver function~• Thrombocytopenia~• Oligohydramnios, decreased fetal growth, or placental abruption"
33026831|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
33026832|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
33026833|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
33026834|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
33026835|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
33026836|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
33026837|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
33026838|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
33026839|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
33026840|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
33026841|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
33026842|NCT01906632|Other|gene expression profile|
33026843|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
33026844|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
33026845|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
33026846|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
33026847|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
33026848|NCT01906697|Active Comparator|group B|middle turbinate resection
33026849|NCT01906697|Active Comparator|group C|middle turbinate medialization
33026850|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
33326535|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
33326536|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
33326537|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
33327279|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
33416977|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
33416978|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
33416979|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
33026851|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
33026852|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of~patient centred medication reconciliation~intermediate medication review~discharge counseling~transfer of information to primary care"
33026853|NCT01906749|Placebo Comparator|Placebo|Placebo
33026854|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
33026855|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
33026856|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
33026857|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
33026858|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
33026859|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
33026860|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
33026861|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
33026862|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
33026863|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
33026864|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
33026865|NCT01906827||pregnant with ICP|pregnant with ICP
33026866|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
33026867|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
33026868|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
33026869|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
33026870|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
33026871|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
33026872|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
33026873|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
33026874|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
33026875|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
33026876|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
33026877|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
33026878|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
33026879|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
33026880|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
33026881|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
33026882|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
33026883|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
33416980|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
33026884|NCT01906931|Experimental|Portable Oxygen Concentrator first|
33026885|NCT01906931|Active Comparator|Portable oxygen cylinder first|
33026886|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
33026887|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
33026888|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
33026889|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
33026890|NCT01906996||four corner fusion|patients were treated with a four corner fusion
33106976|NCT04660292|Experimental|Study Group|The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
33106977|NCT04660292|Active Comparator|Control Group|While placebo treatment with conventional physiotherapy (active exercises-10 repetitions in all direction in pain free range, isometrics 5-10 seconds brief but maximum contraction each held for 5-16 seconds for flexors, extensors, side flexors and rotators)14 without gliding, oscillations and thrust were recommended for the control group.The placebo group was treated with baseline treatment including TENS 10 minutes and moist hot packs in sitting position for 15 minutes on cervical region in with head resting on table with a pillow.
33106978|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
33106979|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
33106980|NCT04660409|Other|Child Pugh A|
33106981|NCT04660409|Other|Child Pugh B|
33106982|NCT04660409|Other|Child Pugh C|
33106983|NCT04660409|Other|HCC|
33106984|NCT04660409|Other|Healthy|
33106985|NCT01208233|Experimental|1 mg PF-03049423|
33106986|NCT01208233|Experimental|3 mg of PF-03049423|
33106987|NCT01208233|Experimental|6 mg of PF-03049423|
33106988|NCT01208233|Placebo Comparator|Placebo|
33106989|NCT04660565|Experimental|Glucocorticoid monotherapy Group|Patients treated with single glucocorticoid
33106990|NCT04660565|Experimental|Combination therapy Group|Patients treated with Belimumab and glucocorticoid
33106991|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
33106992|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
33106993|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
33106994|NCT04660370|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
33106995|NCT04660370|Experimental|Sequence 2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
33106996|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
33106997|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
33106998|NCT04660136|Experimental|CEUS|
33106999|NCT05420935|Other|IgG group|Patient in the IgG group will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a blood sampling of 250 ml
33107000|NCT05420935|Other|IgE group|Patient in the IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a bone marrow sampling (approx 2 ml)
33416981|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
33107001|NCT05420935|Other|IgG group + IgE group|Patient in the IgG + IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test), a blood sampling of 250 ml and a bone marrow sampling (approx 2 ml)
33107002|NCT01208038|Experimental|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
33107003|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
33107004|NCT04659980|Active Comparator|hilotherapy|
33416982|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
33107005|NCT04659980|Active Comparator|frozen gloves|
33107006|NCT04659785|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
33107007|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
33107008|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained in an one-day course
33107009|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
33107010|NCT04659434|Experimental|treatment group|Sintilimab 200mg ivdrip Q3W; Rituximab 375mg/m2 ivdrip; Gemcitabine 1000mg ivdrip; Oxaliplatin 100mg/m2 ivdrip
33107011|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
33107012|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
33107013|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
33107014|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
33107015|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
33107016|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
33107017|NCT04659356||Patients admitted in Intensive Care Units|All patients admitted in our ICU since august were enrolled in our study, after they have been informed and given their consent for their participation in this observational study.
33107018|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
33107019|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
33107020|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
33107021|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
33107022|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
33107023|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
33107024|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
33107025|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
33107026|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
33107027|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
33107028|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
33107029|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
33107030|NCT04659551|Experimental|Arm 1|Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.
33107031|NCT03524352|Experimental|fecal microbiota|
33107032|NCT03524352|Placebo Comparator|placebo|
33107033|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
33107034|NCT04659668|Experimental|MMG-23-04-2019|MMG-23-04-2019 is composed by sodium hyaluronate at concentration of 2% (20 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.
33107035|NCT05411146|Experimental|[14C]-etrumadenant|Participants will receive a single dose of [14C]-etrumadenant.
33107036|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
33107037|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
33107038|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
33107039|NCT00540462|No Intervention|1|Medical Group
33107040|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
33107041|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
33107042|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
33107043|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
33416983|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
33416984|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
33107044|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
33107045|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
33107046|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
33107047|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
33107048|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
33107049|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
33416985|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
33416986|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
33026891|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
33026892|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
33026893|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
33026894|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
33026895|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
33026896|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
33026897|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
33026898|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
33026899|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
33026900|NCT01907074|Experimental|Cholates Compound|
33026901|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
33026902|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
33026903|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
33026904|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
33026905|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
33026906|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
33026907|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
33026908|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
33026909|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
33107050|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
33107051|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
33416987|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
33026910|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
33026911|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
33026912|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
33026913|NCT01907204|Experimental|Metered dose inhaler|
33026914|NCT01907204|Experimental|Nebulized|
33026915|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
33026916|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
33026917|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
33026918|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
33026919|NCT01907256|Active Comparator|group A|stair step incisions
33026920|NCT01907256|Active Comparator|Group B|inverted V incision
33026921|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
33026922|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
33026923|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
33026924|NCT01907347||ICU patients|
33026925|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
33026926|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
33026927|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
33026928|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
33026929|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
33026930|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
33026931|NCT01907425|Other|Pre-natal Patient|
33026932|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
33026933|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
33026934|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
33026935|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
33026936|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
33026937|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
33026938|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
33026939|NCT01907477|Other|neutropenic patients|
33026940|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
33026941|NCT01907503|Other|Healthy volunteer|Healthy volunteer
33026942|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
33026943|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
33026944|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
33026945|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
33026946|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
33026947|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
33026948|NCT01907555||Patients presenting neutropenia|
33026949|NCT01907568||Patients with schizophrenia|With and without hallucinations
33026950|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
33026951|NCT01907568||Patients with hearing impairment|With and without hallucinations
33326538|NCT05015088||Gastrocnemius Stretching Group|The study will enroll 20 healthy subjects between the ages of 18 to 65 years old. Individuals will be recruited from multiple locations. Exclusion criteria include: any boney or tendinous foot/ankle operative procedure, diagnosis of neuromuscular disorder, any previous ankle fracture or degenerative changes that would limit dorsiflexion range of motion. Participants must have no obvious gait asymmetries demonstrated through observation. In addition, participants who are pregnant will be excluded from participation in the study.
33326539|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
33326540|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
33326541|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
33026952|NCT01907568||Patients with visual loss|With and without hallucinations
33026953|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
33026954|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
33326542|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
33026955|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
33026956|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
33026957|NCT01907568||Patients with delirium|With and without hallucinations
33026958|NCT01907568||Healthy participants|With and without hallucinations
33026959|NCT01907568||Patients with mood disorder|With and without hallucinations
33026960|NCT01907581|Other|Patients admitted to an ICU|
33026961|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
33026962|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
33026963|NCT01907620|Other|Normal pregnancy|women pregnant
33026964|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
33026965|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
33026966|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
33026967|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
33026968|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
33026969|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
33026970|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
33026971|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
33026972|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
33026973|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
33026974|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
33026975|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
33026976|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
33026977|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
33026978|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
33026979|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
33026980|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
33026981|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
33026982|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
33326543|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
33326544|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
33326545|NCT01264458||Control group|
33026983|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
33026984|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
33026985|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
33026986|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33026987|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
33026988|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
33026989|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
33026990|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
33026991|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
33026992|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
33026993|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
33026994|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
33026995|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
33026996|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
33026997|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
33026998|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents~Each resident will complete questionaire:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
33026999|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
33027000|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
33027001|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
33027002|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
33027003|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
33027004|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
33027005|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
33027006|NCT01908010|Experimental|Group 1, low dose|ABT-354
33027007|NCT01908010|Experimental|Group 2, high dose|ABT-354
33326546|NCT01266486|Experimental|Metformin|
33326547|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
33027008|NCT01908023|Experimental|exercise|
33027009|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
33027010|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
33027011|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
33027012|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
33027013|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
33027014|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
33027015|NCT01908114|Experimental|Group B|"Expanded intervention with following components~Community support groups for both male and female at village/community level~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
33027016|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
33027017|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
33027018|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
33027019|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
33027020|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
33027021|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
33027022|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
33027023|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
33027024|NCT01908244|No Intervention|Control|No pentatonic music
33027025|NCT01908244|Experimental|Music|
33027026|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)~Day 5: Ranitidine 150 mg twice daily (bid)~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.~Day 7: Ranitidine 150 mg (bid)"
33027027|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad~Day 3: Ranitidine 150 mg (bid)~Day 7: Lesinurad 400 mg (qd)"
33027028|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
33027029|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
33027030|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
33027031|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
33027032|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
33027033|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
33027034|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
33027035|NCT01908322||Group 1|
33027036|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
33027037|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
33027038|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
33027039|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
33027040|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
33027041|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
33027042|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
33027043|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
33027044|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
33027045|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
33027046|NCT01908387|Experimental|Oral azacitidine|
33027047|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
33027048|NCT01908413|Experimental|CUDC-427|
33027049|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
33027050|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
33027051|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
33027052|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
33027053|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
33027054|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
33027055|NCT01908504|Other|PET-CT|
33027056|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
33027057|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet~This is a single arm study. Individuals in this arm will~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods~receive a single tablet of ferrous sulphate 200mg~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months~have a second blood sample later that day (20 mls of blood~Total number of participants in arm = 100"
33027058|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
33027059|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
33027060|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
33027061|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
33027062|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
33027063|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
33027064|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
33027065|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
33027066|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
33027067|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
33027068|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
33027069|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
33027070|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
33027071|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
33027072|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
33027073|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
33027074|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
33033265|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
33326548|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
33326549|NCT01266564||Cohort|
33326550|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
33027075|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
33027076|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
33027077|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
33027078|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
33027079|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
33027080|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
33027081|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
33027082|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
33027083|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
33027084|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
33027085|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
33027086|NCT01908920|Other|CONTROL|No intervention
33027087|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
33027088|NCT01908946|Experimental|SMS Reminders|SMS reminders
33027089|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
33027090|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
33027091|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
33027092|NCT01908998|Active Comparator|Sandal|
33027093|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
33027094|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
33027095|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
33027096|NCT01909050||refractory celiac disease|
33027097|NCT01909050||well-controlled celiac disease|
33027098|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
33027099|NCT01909050||gluten-sensitivity|
33027100|NCT01909050||disorders other than celiac disease.|
33027101|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
33027102|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice~Vitamin D, Vitamin E, and Vitamin A"
33027103|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice~Control, 700 mg Calcium"
33027104|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
33027105|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
33027106|NCT01909115|Active Comparator|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
33027107|NCT01909115|Experimental|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
33027108|NCT01909128|Experimental|fermented milk|
33027109|NCT01909128|Experimental|fermented rice|
33027110|NCT01909128|Placebo Comparator|placebo|
33027111|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
33027112|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
33027113|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
33027114|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
33027115|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
33027116|NCT01909271|Experimental|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
33027117|NCT01909271|Other|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
33027118|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
33027119|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
33027120|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
33027121|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
33027122|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
33027123|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
33027124|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
33027125|NCT01909323|Placebo Comparator|sugary dessert cream|
33027126|NCT01909323|Experimental|maltitol alone|
33027127|NCT01909323|Experimental|maltitol 85% / FOS 15%|
33027128|NCT01909323|Experimental|maltitol 68% / FOS 32%|
33027129|NCT01909323|Experimental|maltitol 50% / FOS 50%|
33027130|NCT01909323|Experimental|FOS alone|
33027131|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
33027132|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
33027133|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
33027134|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
33027135|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
33027136|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
33027137|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
33027138|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
33027139|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
33027140|NCT01909505||Normal Males|Males with normal levels of serum testosterone
33027141|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
33027142|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
33027143|NCT01909544|Experimental|Oxygen|
33027144|NCT01909544|Sham Comparator|Room air|
33027145|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
33027146|NCT01909557|Placebo Comparator|placebo|
33027147|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
33027148|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
33027149|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
33027150|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
33027151|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
33027152|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
33326551|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
33326552|NCT03759366|Experimental|Eculizumab Intravenous (IV) Infusion|"In the Primary Evaluation Treatment Period (26 weeks), eculizumab will be administered weekly during the initial induction phase and every 2 weeks during the maintenance phase.~In the Extension Period (up to 208 weeks), participants will continue to receive eculizumab every 2 weeks.~Eculizumab will be administered at doses of 300, 600, 900, or 1200 milligrams (mg), based on the participant's current body weight."
33326553|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
33326554|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
33326555|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
33326556|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
33326557|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 - 28 of each 28-day treatment cycle up to 6 cycles till data cut-off: 01 July 2019.
33027153|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
33027154|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
33027155|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
33027156|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
33027157|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
33027158|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
33027159|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
33027160|NCT01909726||Interactive media|ScreenPlay
33027161|NCT01909726||Passive media|Silent nature video
33027162|NCT01909726||No media|Standard care
33027163|NCT01909739|Experimental|Statin group|
33027164|NCT01909739|Placebo Comparator|Placebo group|
33027165|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
33027166|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
33027167|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
33027168|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
33027169|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
33027170|NCT01909817||Routine coronary angiogram patients|
33027171|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
33027172|NCT01909843|Experimental|ALX-0171 Oral inhalation|
33027173|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
33027174|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
33027175|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
33027176|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
33027177|NCT01909908|Experimental|ECM in Saline|
33027178|NCT01909908|Active Comparator|Blood Products|
33027179|NCT01909908|Experimental|ECM in Blood Products|
33027180|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
33027181|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
33027182|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
33027183|NCT01909986|Experimental|E1|[14C]-ONO-4053
33027184|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
33027185|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
33326558|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
33326559|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
33326560|NCT01268124|Experimental|Treatment|
33326561|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
33326562|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
33027186|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
33027187|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
33027188|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
33027189|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
33027190|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
33027191|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
33027192|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
33027193|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
33027194|NCT01910155|Active Comparator|Reference|Ciprodex (R)
33027195|NCT01910155|Placebo Comparator|Placebo|Placebo
33027196|NCT01910168||Cohort|
33027197|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
33027198|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
33027199|NCT01910220|Placebo Comparator|Group 1|placebo
33027200|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
33027201|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
33027202|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
33027203|NCT01910233||adult patients with acute dyspnea in ED|
33027204|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
33027205|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
33027206|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
33027207|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
33027208|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
33027209|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
33027210|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
33027211|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
33027212|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
33027213|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
33027214|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
33027215|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
33027216|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
33027217|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
33027218|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
33027219|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
33027220|NCT01910376||Control cohort|Nursing home residents without cancer
33027221|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
33027222|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
33027223|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
33027224|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
33027225|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
33027226|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
33416988|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
33027227|NCT01910454|Active Comparator|Task Specific Training (TST)|
33027228|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
33027229|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
33027230|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
33027231|NCT01910493|Active Comparator|ART no SMS reminders|control group
33027232|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
33027233|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
33027234|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
33027235|NCT01910506|Experimental|RDEA3170|
33027236|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
33027237|NCT01910545|Experimental|OTS167IV|single arm
33027238|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
33027239|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
33027240|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
33027241|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
33027242|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
33027243|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
33027244|NCT01910597|Experimental|SBG|
33027245|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
33027246|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
33027247|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
33027248|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
33027249|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
33027250|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
33027251|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
33027252|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
33027253|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
33416989|NCT03629327|Active Comparator|ASA 325mg|Daily uptake of 325mg ASA
33416990|NCT03629327|Active Comparator|No drug|no drug
33416991|NCT03629327|Active Comparator|ASA 81mg|daily uptake of 81mg ASA
33416992|NCT04984369|Experimental|Never use other BRAF inhibitor therapy|Never use other BRAF inhibitor therapy
33416993|NCT04984369|Experimental|PD after other BRAF inhibitor therapy N=5~40|PD after other BRAF inhibitor therapy
33416994|NCT04984369|Experimental|SD but intolerant after other BRAF inhibitor therapy|SD but intolerant after other BRAF inhibitor therapy
33416995|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
33027254|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
33027255|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
33027256|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
33027257|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
33027258|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
33027259|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
33027260|NCT01910727|Experimental|Together on Diabetes-Hopkins|
33027261|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
33027262|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
33027263|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
33027264|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
33027265|NCT01910766|Active Comparator|CC alone group|"Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
33027266|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
33027267|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
33027268|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
33027269|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
33027270|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
33027271|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
33027272|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
33027273|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
33027274|NCT01910857|No Intervention|Control|Standard care
33027275|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
33027276|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
33027277|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
33027278|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
33027279|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
33027280|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
33027281|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
33027282|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
33027283|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
33027284|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
33027285|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
33027286|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
33416996|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
33326563|NCT03878706||GLP1 and SGLT2i group|40 patients treated with a combination of liraglutide and empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
33027287|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
33027288|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
33416997|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
33027289|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
33027290|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
33027291|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
33027292|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
33027293|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
33027294|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
33027295|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
33027296|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
33027297|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
33027298|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
33027299|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
33027300|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
33027301|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
33027302|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
33027303|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
33027304|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
33027305|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.~Patients undergo cardiac surgery and are over 18 years of age.~Patients need bypass machine for their cardiac surgery and traditional CO measurement.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
33027306|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
33027307|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
33027308|NCT01911182|Experimental|Inhalation of low concentration of CO2|
33027309|NCT01911182|Active Comparator|caffeine only|
33027310|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
33027311|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
33027312|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
33027313|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
33027314|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
33416998|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
33027315|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
33027316|NCT01911247|Experimental|Arm 1|
33027317|NCT01911286||Standard group|Apnea test according to the recommendation
33027318|NCT01911286||CPAP group|Apnea test with CPAP connection
33416999|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
33027319|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
33027320|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
33027321|NCT01911312|Experimental|Intervention|
33027322|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
33027323|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
33027324|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
33027325|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
33027326|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
33027327|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
33027328|NCT01911364|Experimental|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
33027329|NCT01911364|Active Comparator|Tiotropium|Tiotropium bromide 18 mcg
33027330|NCT01911364|Active Comparator|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium"
33027331|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
33027332|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
33027333|NCT01911416|Experimental|All participants|All participants on study
33027334|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
33027335|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
33027336|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
33027337|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
33027338|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
33027339|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
33027340|NCT01911481|No Intervention|control|
33027341|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
33027342|NCT01911494|No Intervention|Control|Current standard of antenatal care
33027343|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33027344|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
33027345|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
33027346|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
33027347|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
33027348|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
33027349|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
33027350|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
33027351|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
33027352|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
32866628|NCT04833972|Experimental|Experimental: V3: Open-Ended Numerical Estimate|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire permits the study participant to provide an open-ended numerical estimate."
32866629|NCT01466985|Experimental|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
33027353|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
33027354|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
33027355|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
33027356|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
33027357|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
33027358|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
33027359|NCT01911611|Placebo Comparator|Placebo|
33027360|NCT01911611|Experimental|RO6870868|
33027361|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
33027362|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
33027363|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
33027364|NCT01911637|Placebo Comparator|Placebo|Placebo
33027365|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
33027366|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
33027367|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
33027368|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
33027369|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
33027370|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
33027371|NCT01911715|Experimental|Single Oral MDV3100 dose|
33027372|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
33027373|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
33027374|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
33027375|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
33027376|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
33027377|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
33027378|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
33027379|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
33027380|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
33027381|NCT01911858|Experimental|Askina Calgitrol Paste|
33027382|NCT01911871||thalassemia|patients affected with thalassemia
33027383|NCT01911871||sickle cell disease|patients affected with sickle cell disease
33027384|NCT01911871||myelodysplasia|patients affected with myelodysplasia
33027385|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
33027386|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
33027387|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
33027388|NCT01911936|Experimental|LJM716|
33027389|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
33027390|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
33027391|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
32866630|NCT01466985|Experimental|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
32866631|NCT01466985|Experimental|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
33027392|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
33027393|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
33027394|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
33027395|NCT01911988||Colon&Rectal Stage II /Stage III|
33027396|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
33027397|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
33027398|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
33027399|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
33027400|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
33027401|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
33027402|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
33027403|NCT01912092|Experimental|Askina Calgitrol Paste|
33027404|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
33027405|NCT01912105|Active Comparator|control|standard closed suctioning systems
33027406|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
33027407|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
33027408|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
33027409|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
33027410|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
33027411|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
33027412|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
33027413|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
33027414|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
33027415|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
33027416|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
33027417|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
33027418|NCT01912144|Other|coffee|Coffee beverage
33027419|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
33027420|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
33027421|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
33027422|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
33027423|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
33027424|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
32866632|NCT04825782||Pregnant Women exposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
33027425|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
33027426|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
33027427|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
33027428|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
33027429|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
33027430|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
33027431|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
33027432|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
33027433|NCT01912248||Heart failure|strength training
33027434|NCT01912248||Heart Transplant recipients|strength training
33027435|NCT01912248||patients with ischemic heart disease|strength training
33027436|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
33027437|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
33027438|NCT01912300|Experimental|Lean adolescents|
33027439|NCT01912300|Experimental|Obese adolescents|
33027440|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
33027441|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
33027442|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
33027443|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
33027444|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
33027445|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
33027446|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
33027447|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
33027448|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
33027449|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
33027450|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
33027451|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
33027452|NCT01912443||Bevacizumab Plus Chemotherapy|
33027453|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
33027454|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
33027455|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
33027456|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
33027457|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
33027458|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
33027459|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
33027460|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
33417000|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
33027461|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
33027462|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
33027463|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
33027464|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
33027465|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
33027466|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
33027467|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
33027468|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
33027469|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
33027470|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
33027471|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
33027472|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
33027473|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
33027474|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
33027475|NCT01912690|Placebo Comparator|standard of care|
33027476|NCT01912690|Active Comparator|aerobic training only|
33027477|NCT01912690|Active Comparator|Aerobic and strength training|
33027478|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
33027479|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
33027480|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
33027481|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
33027482|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
33027483|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
33027484|NCT01912794|Experimental|Sensory Conditions|
33027485|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
33027486|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
33027487|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
33033266|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
33033267|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
33027488|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
33027489|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
33027490|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
33027491|NCT01912885|Placebo Comparator|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
33027492|NCT01912885|Experimental|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
33027493|NCT01912885|Experimental|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
33027494|NCT01912885|Experimental|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
33027495|NCT01912885|Experimental|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
33027496|NCT01912898||1|
33027497|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
33027498|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
33027499|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
33027500|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
33027501|NCT01913002|Experimental|Treatment A|LX4211 800 mg
33027502|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
33027503|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
33027504|NCT01913002|Placebo Comparator|Treatment D|Placebo
33027505|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
33027506|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
33027507|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
33027508|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
33027509|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
33027510|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
33027511|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
33027512|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
33027513|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
33027514|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
33027515|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
33027516|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
33027517|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
33027518|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
33107052|NCT04659200||Covid Disease Patient Group|Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
33107053|NCT04659200||Covid-Free Control Group|Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
33107054|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
33107055|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
33107056|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
33107057|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
33107058|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
33107059|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
33107060|NCT04659239|Experimental|Investigational Vaccine|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) according to the immunization schedule of D0, D14.
33107061|NCT04659239|Placebo Comparator|Placebo|Participants will receive 2 doses of the placebo according to the immunization schedule of D0, D14.
33107062|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
33107063|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
33107064|NCT00540618|Active Comparator|1|MEDI-507
33107065|NCT00540618|Placebo Comparator|2|
33107066|NCT00540618|Active Comparator|3|MEDI-507
33107067|NCT00540618|Active Comparator|4|MEDI-507
33107068|NCT04658459||Results at short term follow up|Functional and Radiological results at short-term follow up (one year at least)
33107069|NCT04658459||Results at middle term follow up|Functional and Radiological results at the last follow up of the patient (2 years at least)
33107070|NCT00557453||A|Antibiotic treatment
33107071|NCT00557453||B|Non antibiotic treatment
33107072|NCT00540657|Experimental|1|
33107073|NCT00540657|Placebo Comparator|2|
33107074|NCT04658732|Experimental|Alprazolam (A group)|patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer.
33107075|NCT04658732|Experimental|Gabapentin (G group)|patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer.
33107076|NCT04658732|Experimental|Dexmedetomidine (D group)|Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial 200mcg/2ml manufactured by Hospira Inc, Highway 301,Rocky Mount,NC 278001 USA)
33107077|NCT00540696|Experimental|darbepoetin alfa|
33107078|NCT04658615|Other|group with rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
33326564|NCT03878706||GLP1 group|40 patients treated with liraglutide.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
33327280|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
33107079|NCT04658615|Other|group without rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
33107080|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
33107081|NCT04658420|Experimental|Ketamine|One group will receive IV ketamine 0.5mg/kg infused over forty minutes
33107082|NCT04658420|Experimental|Ketamine + Music|One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music
33107083|NCT04658420|Experimental|Music|One hour of pre-planned music without ketamine
33107084|NCT04658420|No Intervention|Treatment as usual|No music nor ketamine given
33107085|NCT00540735|Experimental|1|PDT
33107086|NCT00540735|No Intervention|2|
33107087|NCT03440775|Experimental|Experimental|
33107088|NCT03440775|Sham Comparator|Comparator|
33107089|NCT00557531|Experimental|BL-1040|
33027519|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
33027520|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
33027521|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
33027522|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
33027523|NCT01913197|Experimental|Pre-implant MRI images and planning|
33027524|NCT01913223|Experimental|submucosal dissection by dissector water jet|
33027525|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
33027526|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
33027527|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
33027528|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
33027529|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
33027530|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
33027531|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
33027532|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
33027533|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
33027534|NCT01913301|Experimental|Alagebrium|
33027535|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
33417001|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
33417002|NCT01352429||Phase 1 Feasibility|
33417003|NCT01352429||Phase 2 Registration|
33417004|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
33417005|NCT01319461|Placebo Comparator|sterile normal saline injection|
33417006|NCT01319461|Experimental|Hyalgan injection|
33417007|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
33417008|NCT03180749||Patients implanted with vendor B anchor|
33417009|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)~Case group: 43 women developing PE"
33027536|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
33027537|NCT01913379|Experimental|1: MDV3100|
33027538|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
33027539|NCT01913379|Experimental|3: MDV3100 and itraconazole|
33027540|NCT01913392||morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
33027541|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
33027542|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
33027543|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
33027544|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
33027545|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
33417010|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
33417011|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
33027546|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
33027547|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
33033268|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
33417012|NCT01361815|Other|H-Coil Deep TMS Treatment|
33417013|NCT01349075||TheraSphere|
33027548|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
33027549|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
33027550|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
33326565|NCT03878706||SGLT2i group|40 patients treated with empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
33326566|NCT03878706||Control group|40 patients treated with insulin and metformin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
33027551|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
33027552|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
33027553|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
33027554|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
33027555|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
33027556|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:~ECG gel electrodes~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
33027557|NCT01913613|Experimental|Treatment|Treatment with the IASD device
33027558|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
33027559|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
33027560|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
33027561|NCT01913665|Active Comparator|Inulin|children with functional constipation
33326567|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
33326568|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
33326569|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
33326570|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
33326571|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
33326572|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
33027562|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
33027563|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
33027564|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
33027565|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
33027566|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
33027567|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
33326573|NCT01160172|Experimental|Group A|
33326574|NCT01160172|Experimental|Group B|
33417014|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
33027568|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
33027569|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
33027570|NCT01913743||MINDSETS|overweight/obese
33027571|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
33027572|NCT01913756|No Intervention|Low cheese intake|
33027573|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
33027574|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
33027575|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
33027576|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
33027577|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
33027578|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
33027579|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
33027580|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
33027581|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
33027582|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
33027583|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
33027584|NCT01913847|Placebo Comparator|Placebo|Placebo
33027585|NCT01913860|No Intervention|Control|Control group will receive usual care
33027586|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
33027587|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
33027588|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
33027589|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
33027590|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
33027591|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
33027592|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
33027593|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
33027594|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
33027595|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
33027596|NCT01913964|Placebo Comparator|placebo|
33033269|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
33033270|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
33027597|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
33027598|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
33027599|NCT01914016|Other|prolonged walk|
33027600|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
33027601|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
33027602|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
33027603|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
33027604|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
33027605|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
33027606|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
33027607|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
33027608|NCT01914094|No Intervention|Standard care|Received current standard care.
33027609|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
33027610|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
33027611|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
33027612|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
33027613|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
33027614|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
33027615|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
33027616|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
33027617|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
33027618|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
33027619|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
33027620|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
33027621|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
33027622|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
33027623|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
33027624|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
33027625|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
33027626|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
33417015|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
33417016|NCT05077007|Active Comparator|Percutaneous nephrolithotomy|patients suffering of pelvic renal stones underwent Percutaneous nephrolithotomy
33027627|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
33027628|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
33027629|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
33027630|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
33027631|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
33027632|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
33027633|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
33027634|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
33027635|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
33027636|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
33027637|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
33027638|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
33027639|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
33027640|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
33027641|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
33027642|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
33027643|NCT01914341|Experimental|Music|pentatonic live music
33027644|NCT01914341|No Intervention|control|no intervention
33027645|NCT01914380||Group 1|
33027646|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
33027647|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
33027648|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
33027649|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
33027650|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
33027651|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
33027652|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
33027653|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
33027654|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
33027655|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
33027656|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
33027657|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
33027658|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
33027659|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
33027660|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
33027661|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
33027662|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
33027663|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
33027664|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
33326575|NCT01160172|Experimental|Group C|
33326576|NCT01160172|Experimental|Group D|
33326577|NCT01160172|Placebo Comparator|Group E|
33326578|NCT01160172|Placebo Comparator|Group F|
33326579|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
33326580|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigrane infusion (0.4 mg/min) for 10 mins"
33326581|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
33326582|NCT01266720|Experimental|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
33027665|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
33027666|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
33027667|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
33027668|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
33027669|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
33027670|NCT01914575|Experimental|Dipole Density Mapping|
33027671|NCT01914588|Experimental|Telemonitoring + Standard care|
33027672|NCT01914588|Active Comparator|Standard care|
33027673|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
33027674|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
33027675|NCT01914614||Working Poor Survivors|Low Wage workers
33027676|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
33027677|NCT01914627|Experimental|Loion|
33027678|NCT01914627|Active Comparator|SA-Gel|
33027679|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
33027680|NCT01914653|Experimental|Pre-radiated|
33027681|NCT01914653|Experimental|Not radiated|
33027682|NCT01914653|Experimental|Post-radiated|
33027683|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
33027684|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
33027685|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
33027686|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
33027687|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
33027688|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
33027689|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
33027690|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
33027691|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
33027692|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
33027693|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
33027694|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
33027695|NCT01914796|Placebo Comparator|Single ascending doses|
33027696|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
33027697|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
33027698|NCT01914809|Other|group with a normal pregnancy|
33107090|NCT04658264|Experimental|Treatment Arm|The Treatment group shall receive 2 Kg of the composite flour every week, sufficient for 21 chapattis, and shall eat chapattis made from this flour instead of their usual wheat flour chapattis. The participants shall continue to receive the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study.
33107091|NCT04658264|No Intervention|Control Group|This group shall receive only the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study. They will continue to eat their usual diet as before their enrollment. They shall however receive usual counseling on lifestyle modifications including diet
33107092|NCT04657913|Experimental|cold water spray group|application of cold water in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
33107093|NCT04657913|Experimental|cold saline spray group|application of cold 0.9% SF (saline) in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
33107094|NCT04657913|No Intervention|control group|no intervention
33107095|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
33107096|NCT04657874|Active Comparator|Bromelain and Escin|
33107097|NCT04657874|Placebo Comparator|Placebo|
33107098|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
33107099|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
33107100|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
33107101|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
33107102|NCT04658069||One Cohort receiving routine hemodialysis therapy without any specific interventions|all HD patients enrolled in this study
33107103|NCT00540813|Experimental|Drug Eluting Balloon|
33107104|NCT04658030|Experimental|VR 360 video surgery preparation|Preparing pediatric patients for surgery with a newly developed VR 360 degree video. Maximum 30 minutes, one time.
33107105|NCT04658030|Active Comparator|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
33107106|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
33107107|NCT04658225|Active Comparator|Solution 1|0.12% chlorhexidine
33107108|NCT04658225|Placebo Comparator|Solution 2|Saline solution
33107109|NCT05086692|Experimental|MDNA11|"MDNA11 is a long-acting beta-only recombinant interleukin-2 (rIL-2) albumin fusion"
33107110|NCT04657952|Active Comparator|Standard medical Treatment (paracetamol)|Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.
33107111|NCT04657952|Experimental|Sphenopalatine block|Patients will receive sphenopalatine block
33107112|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
33107113|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
33107114|NCT00541047|Experimental|RADICALS-RT: Early RT|
33107115|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
33107116|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
33107117|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
33107118|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
33107119|NCT04657718|Other|All subjects|The KODEX-EPD system will be used in combination with leads to image during all procedures.
33107120|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
33107121|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
33107122|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
33107123|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
33107124|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
33107125|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
33107126|NCT04657484|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 2 weeks, 10 mg/day for 2 weeks
33107127|NCT04657484|Active Comparator|Low dose prednisolone|A dose of 10 mg/day of prednisolone will be administered for 6 weeks
33107128|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
33107129|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
33107130|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
33107131|NCT04657757|Experimental|Intraoral apparatus|intraoral apparatus in which two platelets of each of the 8 materials (Esteticor Lumina PF; Esteticor Lumina PF - after Lactic acid storage; Pagalinor 2; Esteticor Economic; Pekkton ivory - untreated; Pekkton ivory - rough; Oralloy; Machined Titan Zirconia (TiZr) alloy) are to be examined. Examination is a crystal violet OD595 staining (10 minutes). The color absorbed by the bacteria is then dissolved with a 30% acetic acid and measured spectrophotometrically at 595 nm. The plaque formed on the material surface is removed immediately after removal from the oral cavity and analyzed by determination of Colony Forming Unit (CFU) number.
33107132|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
33107133|NCT04657601||Treatment Group|Patients undergo polypectomy facilitated by the study device.
33417017|NCT05077007|Active Comparator|Extracorporeal Shock Wave Lithotripsy|patients suffering of pelvic renal stones underwent Extracorporeal Shock Wave Lithotripsy
33027699|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
33027700|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
33027701|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
33417018|NCT05077007|No Intervention|control group|Healthy volunteers with negative history of renal stones or renal impairment to measure the level of urinary markers in their urine samples
33027702|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
33027703|NCT01914848|Experimental|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.~--------------------------------------------------------------------------------"
33417019|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
33417020|NCT01356745|Placebo Comparator|medical air|
33027704|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
33027705|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
33027706|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
33027707|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
33027708|NCT01914900|Experimental|induction TPF chemotherapy|
33027709|NCT01914913|Other|BMMNCs|BMMNCs
33027710|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
33027711|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
33027712|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
33027713|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
33027714|NCT01914952|Active Comparator|CaHMB Capsule|
33027715|NCT01914952|Active Comparator|HMB free acid gelcap|
33027716|NCT01914952|Active Comparator|HMB free acid in water|
33027717|NCT01914952|Active Comparator|CaHMB powder in water|
33027718|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
33027719|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
33027720|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
33027721|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
33027722|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
33027723|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
33027724|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
33027725|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
33027726|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
33027727|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
33027728|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
33027729|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
33027730|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
33027731|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
33027732|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
33417021|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
33417022|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
33417023|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
33027733|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
33027734|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
33027735|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
33027736|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
33027737|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
33027738|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
33027739|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
33027740|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
33027741|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
33027742|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
33027743|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
33027744|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
33027745|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
33027746|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
33027747|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
33027748|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
33027749|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
33027750|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
33027751|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
33027752|NCT01915264||Group 1|
33027753|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
33027754|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
33027755|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
33027756|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
33027757|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
33027758|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
33027759|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
33027760|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
33027761|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
33027762|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
33027763|NCT01915290||1600 elderly participants|Norwegian elderly population
33027764|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
33027765|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
33027766|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
33027767|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
33027768|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
33027769|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
33417024|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
33417025|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
33417026|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
33417027|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
33417028|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
33417029|NCT01360567|Placebo Comparator|B formula|placebo
33417030|NCT01360567|Experimental|A formula|Green tea extract
33417031|NCT02077244|Experimental|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
33417032|NCT02077244|No Intervention|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
33417033|NCT02077244|No Intervention|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
33027770|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
33027771|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
33027772|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
33027773|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
33027774|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
33027775|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
33027776|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
33027777|NCT01915433|No Intervention|Usual Care|Control - usual care only.
33027778|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
33027779|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
33027780|NCT01915472|Experimental|IMMU 130|
33027781|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
33027782|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)"
33027783|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
33027784|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
33027785|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
33027786|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
33027787|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
33027788|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
33027789|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
33027790|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
33027791|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
33027792|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
33027793|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
33417034|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
33417035|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
33417036|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
33417037|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
33417038|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
33027794|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
33027795|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
33027796|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
33027797|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
33027798|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
33027799|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
33027800|NCT01915680||Glaucoma|
33027801|NCT01915680||Control|
33027802|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
33027803|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
33027804|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
33027805|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
33027806|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
33027807|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
33027808|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
33027809|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
33027810|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
33027811|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
33027812|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
33027813|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
33027814|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
33027815|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
33027816|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
33027817|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
33027818|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
33417039|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
33027819|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
33027820|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
33027821|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
33027822|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
33027823|NCT01915953||anemia|Measuring Hb valuse on anemia patients
33027824|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
33027825|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
33027826|NCT01915979|Experimental|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
33027827|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
33027828|NCT01915992|Other|Volunteer healthy|
33027829|NCT01915992|Active Comparator|leukemia patient's|
33027830|NCT01916005|Experimental|endocarditis|
33027831|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
33027832|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
33027833|NCT01916031|No Intervention|Standard Curriculum|
33027834|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
33027835|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
33027836|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
33027837|NCT01916070||patients with syncope|
33027838|NCT01916070||patients with near syncope|
33027839|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
33027840|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
33027841|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
33027842|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
33027843|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
33027844|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
33027845|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
33027846|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
33027847|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
33027848|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
33027849|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
33027850|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
33027851|NCT01916200|No Intervention|Blank group|IBS regular treatment group
33027852|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
33027853|NCT01916213|Active Comparator|ICSI|
33027854|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
33027855|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
33027856|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
33027857|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
33027858|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
33027859|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
33027860|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
33027861|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
33027862|NCT01916291|Experimental|Propess insertion|
33027863|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
33107134|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
33326583|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
33027864|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
33027865|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
33027866|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
33027867|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
33027868|NCT01916382|No Intervention|No treatment|comparrator
33027869|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
33027870|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
33027871|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
33027872|NCT01916421|Active Comparator|EZ Shot|
33027873|NCT01916421|Active Comparator|Expect™|
33027874|NCT01916421|Active Comparator|EchoTip® Ultra|
33027875|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
33027876|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
33027877|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
33027878|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
33027879|NCT01916460|Experimental|Gastroparetic patient 19G|Endoscopic Ultrasound Fine Needle Aspiration of the gastric wall prior to surgical placement of gastric neurostimulator with 19-gauge fine core needle used for aspiration
33027880|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
33027881|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
33027882|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
33027883|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
33027884|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
33027885|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
33027886|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
33027887|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
33027888|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
33027889|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
33027890|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
33027891|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
33027892|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
33027893|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
33326584|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
33326585|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
33326586|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
33326587|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
33326588|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
33326589|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
33326590|NCT01266798|Experimental|Portal arm|
33326591|NCT01266798|No Intervention|Treatment as usal|
33326592|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
33417040|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
33107135|NCT04656977|Active Comparator|VR+TAU|Participants will participate first to a VR-based intervention and then to the TAU condition. The TAU condition is a homogenous standard program proposed by the Centre d'études et de recherché en intervention familiale (CERIF) at Université du Québec en Outaouais (UQO) based on group counseling offered to women and men who experienced a perinatal loss.
33107136|NCT04656977|Active Comparator|TAU+VR|Participants will be invited first to participate to the TAU condition and then to the VR-based intervention.
33107137|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
33107138|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
33107139|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
33107140|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
33107141|NCT04656860|Experimental|Juice Plus+|Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
33107142|NCT04656860|Placebo Comparator|Placebo|Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
33107143|NCT04657172|Experimental|Pilocarpine 1% Solution|1% pilocarpine ophthalmic solution administered with the Optejet dispenser
33107144|NCT04657172|Experimental|Pilocarpine 2% Solution|2% pilocarpine ophthalmic solution administered with the Optejet dispenser
33107145|NCT04657172|Placebo Comparator|Placebo Solution|Placebo ophthalmic solution administered with the Optejet dispenser
33107146|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
33417041|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
33417042|NCT02070770|Experimental|Very low calorie diet|
33107147|NCT04656821|Active Comparator|Control Group|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
33107148|NCT04656821|Experimental|Erector Spinae Block (ESB) group|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
33107149|NCT04656821|Experimental|Thoracic Paravertebral Block group|Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
33107150|NCT04656509|Experimental|4-s sprint inertial load training|Participants trained three times a week for eight weeks following the training program consisting of 30 bouts of 4s all-out cycling on an inertial-load ergometer with progressively decreasing recovery time (30 to 24 to 15s).
33107151|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
33107152|NCT04656743|Experimental|intra-articular injection group|will receive ultrasound guided intraarticular injection consisting of 20 mL of 0.25% bupivacaine before surgical procedure. The surgical procedure will be started 30 min after intraarticular injection.
33107153|NCT04656743|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% before surgical procedure. The surgical procedure will be started 30 min after genicular nerve block.
33417043|NCT02070770|Active Comparator|Standard weight loss diet|
33417044|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
33417045|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
33417046|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
33417047|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
33417048|NCT02073032||Head -Neck cancer patients, no intervention|
33417049|NCT04943549|Active Comparator|Group (A)|History of addiction.
33417050|NCT04943549|Placebo Comparator|Group (N)|No history of addiction to any drug.
33417051|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
33107154|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
33107155|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
33107156|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
33417052|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
33417053|NCT04790695|Experimental|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
33027894|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
33027895|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
33417054|NCT03578081|Experimental|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33417055|NCT03578081|Active Comparator|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33417056|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
33027896|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
33027897|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
33027898|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
33027899|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
33027900|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
33027901|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
33027902|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
33027903|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
33027904|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
33027905|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
33027906|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
33027907|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
33027908|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
33027909|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
33027910|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
33027911|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
33027912|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
33027913|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
33027914|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
33027915|NCT01916772||cherubism patients|no interventions
33027916|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
33027917|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
33027918|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
33027919|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
33027920|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
33027921|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
33027922|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
33027923|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
33027924|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
33027925|NCT01916863|Experimental|LX4211|400 mg of LX4211
33027926|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
33027927|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
33027928|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
33027929|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.~Integrated Medical Follow-up package"
33027930|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
33027931|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
33027932|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
33027933|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
33027934|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
33027935|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
33027936|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
33027937|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
33027938|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
33027939|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
33027940|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
33027941|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
33027942|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
33327281|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
33027943|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
33027944|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
33027945|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
33027946|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
33027947|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
33027948|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
33027949|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
33027950|NCT01917058|Active Comparator|abatacept|
33027951|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
33027952|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
33027953|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
33027954|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
33027955|NCT01917110|Experimental|omafilcon A|Contact Lens Group
33027956|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
33027957|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
33027958|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
33027959|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
33027960|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
33027961|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
33027962|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
33027963|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
33027964|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
33417057|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
33417058|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
33027965|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
33027966|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
33027967|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
33027968|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
33027969|NCT01917227|Experimental|Video|
33027970|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
33027971|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
33027972|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
33027973|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
33027974|NCT01917266||Concordant|
33027975|NCT01917266||Discordant|
33027976|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
33027977|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
33027978|NCT01917292|Other|Periodontal care|
33027979|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
33027980|NCT01917305|Experimental|platform-switched implant|platform-switched implant
33027981|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
33027982|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
33027983|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
33027984|NCT01917331|Experimental|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
33027985|NCT01917331|Active Comparator|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
33027986|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
33027987|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
33027988|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
33027989|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
33027990|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
33027991|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
33027992|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
33027993|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
33027994|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
33033271|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
33107157|NCT04656782||Expert panelists|Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.
33027995|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
33027996|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
33027997|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
33027998|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
33027999|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
33028000|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
33028001|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
33028002|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
33028003|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
33028004|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
33028005|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
33028006|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
33028007|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1~Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
33028008|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin~Other Names:~Gemcitabine； gemzer Cisplatin； Cispulan~Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
33028009|NCT01917630|Experimental|ALV003|
33028010|NCT01917630|Placebo Comparator|Placebo|
33028011|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
33028012|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
33028013|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
33028014|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
33028015|NCT01917669||Diabetic Patients|These patients will have good glucose control.
33028016|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
33028017|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
33028018|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
33028019|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
33028020|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
33028021|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
33028022|NCT01917721|Active Comparator|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
33028023|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
33028024|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
33028025|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
33028026|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
33028027|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
33033272|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
33417059|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
33417060|NCT01319305||BREATHE I participatants|
33417061|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
33417062|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
33417063|NCT04755361|Experimental|Housing Outreach Project - Collaboration (HOP-C) + Treatment as Usual|The treatment condition is HOP-C plus treatment as usual (TAU).
33028028|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.~Greater quantity and quality of HW assignments rated by therapists and parents.~Greater quality of the Review process as rated by therapists, parents, and independent coders.~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
33028029|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
33028032|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
33028033|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
33028034|NCT01917916|Experimental|BI 655064 dose group 1|subject to receive BI 655064 dose group 1 single dose
33028035|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 1|subject to receive placebo
33028036|NCT01917916|Experimental|BI 655064 dose group 2|subject to receive BI 655064 dose group 2 single dose
33028037|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 2|subject to receive a placebo
33028038|NCT01917916|Experimental|BI 655064 dose group 4|Subject to receive BI 655064 dose group 4 single dose
33028039|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 4|Subject to receive placebo
33028040|NCT01917916|Experimental|BI 655064 dose group 3|Subject to receive BI 655064 dose group 3 single dose
33028041|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 3|Subject to receive placebo
33028042|NCT01917942|Active Comparator|Standard of Care|Standard of Care
33028043|NCT01917942|Experimental|Humidification|Humidification
33028044|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
33028045|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
33028046|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
33028047|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
33028048|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
33028049|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
33028050|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
33028051|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
33028052|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
33028053|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
33028054|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
33028055|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
33028056|NCT01918111|Experimental|RD group|Renal denervation group
33028057|NCT01918111|Active Comparator|Control group|Control group
33028058|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:~Radiotherapy:~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.~Cisplatin:~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
33028059|NCT01918137|Experimental|chocolate bar|
33326593|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.~In this management patient come to hospital one day before this surgical operation and he is operated next day"
33028060|NCT01918137|Experimental|porridge|
33028061|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
33028062|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
33028063|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
33028064|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
33028065|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
33028066|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
33028067|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
33028068|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
33028069|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
33028070|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
33028071|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
33028072|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
33028073|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
33028074|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
33028075|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
33028076|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
33028077|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
33028078|NCT01918267||Cohort|
33028079|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
33028080|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
33028081|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
33028082|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
33028083|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
33028084|NCT01918319|No Intervention|Control|
33028085|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
33028086|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
33028087|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
33028088|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
33326594|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
33326595|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
33327282|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
32866633|NCT04825782||Pregnant Women unexposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
33028089|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
32866634|NCT01467063|Active Comparator|Glutamine|
32866635|NCT01467063|Placebo Comparator|Placebo|
32866636|NCT04825938|Experimental|Toripalimab + Carboplatin + Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
33028090|NCT01918410|Active Comparator|Contact Lens with alginic acid|
33028091|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
33028092|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
33028093|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
33028094|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
33028095|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
33028096|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
33028097|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
33028098|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
33028099|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
33028100|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
33028101|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
33028102|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
33028103|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
33028104|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
33028105|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
33028106|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
33028107|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
33028108|NCT01918553|Experimental|Subject in the study ALIENOR|
33028109|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
33028110|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
33028111|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
33028112|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
33028113|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
33028114|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
33028115|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
33028116|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
33028117|NCT01918592|Experimental|MRI/PET|
33028118|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
32866637|NCT04826016|Experimental|PHASE Ib - ARM A: POL6326 (balixafortide) + eribulin|On day 1 and 8 of each 21-day cycle (+/- 1 day) fixed eribulin dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) combined with increasing doses of POL6326 (balixafortide) starting at a dose of 11 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Eribulin will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 2 to 5 min. Up to 4 additional cohorts may be introduced
33028119|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
33028120|NCT01918618||Levosimendan|study group
33028121|NCT01918618||No Levosimendan|Control group
33028122|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
33028123|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
33028124|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
33028125|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
33028126|NCT01918670||Pasteur|
33028127|NCT01918670||Grenoble|
33028128|NCT01918670||Nantes|
33028129|NCT01918670||Parly|
33028130|NCT01918670||Rennes|
33028131|NCT01918670||Rouen|
33028132|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
33028133|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
33028134|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
33028135|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
33028136|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
33028137|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
33028138|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
33028139|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
33028140|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
33028141|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
33028142|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
33028143|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
33028144|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
33028145|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
33028146|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
33028147|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
33028148|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
33028149|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
33028150|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
33028151|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
33028152|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
33028153|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
33028154|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
33028155|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
33028156|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
33028157|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
33028158|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
33028159|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
33028160|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
33028161|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
33028162|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
33028163|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
33028164|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
33028165|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
33028166|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
33028167|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
33028168|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
33028169|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: Three FK949E low dose tablets~Days 7 to 10: One FK949E high dose tablet"
33028170|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: One FK949E high dose tablet~Days 7 to 10: Three FK949E low dose tablets"
33028171|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
33028172|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
33028173|NCT01919060||lesions in colon|
33028174|NCT01919060||lesions in extra-colon|
33028175|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
33028176|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
33028177|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
33028178|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
33028179|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
33028180|NCT01919138||severe sepsis, septic shock|
33028181|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
33028182|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
33028183|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
33028184|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
33028185|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
33028186|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
33028187|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
33028188|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
33028189|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
33028190|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
33028191|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
33028192|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
33028193|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
33028194|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
33028195|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
33028196|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
33028197|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
33028198|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
33028199|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
33028200|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
33028201|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
33028202|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
33028203|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
33028204|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
33028205|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
33028206|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
33028207|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
33028208|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
33028209|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
33028210|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
33028211|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
33028212|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
33028213|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
33028214|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
33028215|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
33028216|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
33028217|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
33028218|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
33028219|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
33028220|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
33028221|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
33028222|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
33028223|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
33028224|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
33028225|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
33028226|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
33028227|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
33028228|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
33028229|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
33028230|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
33028231|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
33028232|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
33028233|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
33028234|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
33028235|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
33028236|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
33326596|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
33326597|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
33028237|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
33028238|NCT01919684|Active Comparator|Active|LGD-6972
33028239|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
33028240|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
33028241|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
33028242|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
33028243|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).~Acinetobacter baumannii~Staphylococcus aureus~Klebsiella pneumonia~Pseudomonas aeruginosa~Enterococcus faecalis~Enterococcus faecium"
33028244|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
33028245|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
33028246|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
33028247|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
33028248|NCT01919827|Experimental|MSC endobronchial infusion|
33028249|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
33028250|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
33028251|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
33028252|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
33028253|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
33028254|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
33028255|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
33028256|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
33028257|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
33028258|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
33028259|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
33028260|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
33028261|NCT01919931||Candida Infection|Patients infected with Candida albicans
33028262|NCT01919931||No infection|Patients with no Candida albicans infection
33028263|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
33028264|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
33028265|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
33028266|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
33028267|NCT01919957|No Intervention|memory outcome|
33326598|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
33028268|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
33028269|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
33028270|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
33028271|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
33028272|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
33028273|NCT01920074|Experimental|Rectiv|
33028274|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
33028275|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
33028276|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
33028277|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
33028278|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
33028279|NCT01920516||Melphalan|"Day +1:~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).~Day +30: The above procedure is repeated.~Day +90: In case of response, a third administration following the above procedures will be repeated."
33028280|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
33028281|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
33028282|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
33028283|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
33028284|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
33028285|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
33028286|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
33028287|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
33028288|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
33028289|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
33028290|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
33028291|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
33028292|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
33028293|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
33028294|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
33028295|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
33028296|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
33028297|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
33028298|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
33028299|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
33028300|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
33028301|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
33326599|NCT01264692|Experimental|Treatment A|ACT-280778
33028302|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
33028303|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
33028304|NCT01922635|Other|1|
33028305|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
33028306|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
33028307|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
33028308|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
33033273|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
33326600|NCT01264692|Placebo Comparator|Treatment B|Placebo
33326601|NCT01264692|Other|Treatment C|Amlodipine
33028309|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
33028310|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).~The placebo supplementation is identical-looking to the Bio-25 supplement."
33028311|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:~family engagement, personal preparation, disclosure practice using intervention materials~health promotion training and a mother-child visit~play-for-communication and custody care planning"
33028312|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
33028313|NCT01923168|Experimental|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
33028314|NCT01923168|Experimental|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
33028315|NCT01923168|Placebo Comparator|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
33028316|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
33028317|NCT01923519|Experimental|allergic rhinitis|
33028318|NCT01923519|Experimental|allergic rhinitis and asthma|
33028319|NCT01923519|Experimental|witnesses|
33028320|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
33028321|NCT01923688|No Intervention|control-no intervention|
33028322|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
33028323|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
33028324|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
33028325|NCT01923974|Placebo Comparator|Placebo|IV formulation
33028326|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
33028327|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
33028328|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
33028329|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
33028330|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
33028331|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
33028332|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
33028333|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
33028334|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
33028335|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
33028336|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
33028337|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
33028338|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
33028339|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
33028340|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
33028341|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
33028342|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
33028343|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
33028344|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
33028345|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33326602|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
33417064|NCT04755361|No Intervention|Treatment As Usual|TAU for this population reflects the standard array of services accessed by transitional youth populations. Most will have some contact with a youth worker with ranging focus and intensity (none likely to receive case management at HOP-C intensity), and very few will have any routine contact with other professionals or peer support. They may have some sporadic access to skills development programs and primary healthcare providers with mental health and addictions needs addressed primarily through emergency services at times of crisis.
33417065|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
33028346|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33028347|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
33028348|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
33028349|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
33028350|NCT01925066|Experimental|Aerosolized Vancomycin|
33028351|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
33028352|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
33028353|NCT01925222||Control-vaccinated infant|
33028354|NCT01925222||PCV-vaccinated child, catch-up schedule|
33028355|NCT01925222||Control-vaccinated child, catch-up schedule|
33028356|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
33028357|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
33028358|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
33028359|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
33028360|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
33028361|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
33028362|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
33028363|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
33028364|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
33028365|NCT01926262|No Intervention|Reference group|No Specific Strength Training
33028366|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
33028367|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
33028368|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
33028369|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
33028370|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
33028371|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
33028372|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
33028373|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
33028374|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
33028375|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
33028376|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
33326603|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
33028377|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
33028378|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
33028379|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
33028380|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
33028381|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
33028382|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
33028383|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
33028384|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
33028385|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
33028386|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
33028387|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
33028388|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
33028389|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
33028390|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
33028391|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
33028392|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
33028393|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
33028394|NCT01927939||Histological proven breast cancer with bone lesion|
33028395|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
33028396|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
33028397|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
33028398|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
33028399|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
33028400|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
33028401|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
33028402|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
33028403|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
33028404|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
33028405|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
33028406|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
33028407|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
33028408|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
33028409|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
33028410|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
33028411|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
33028412|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
33028413|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
33028414|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
33028415|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
33028416|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
33028417|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
33028418|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
33028419|NCT01930006|Experimental|MGCD265|
33028420|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
33028421|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
33028422|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
33028423|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
33028424|NCT01930032||All subjects|
33028425|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
33028426|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders~Non-cash financial incentives (FI)"
33028427|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders"
33028428|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
33028429|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
33028430|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
33028431|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
33028432|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
33028433|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
33028434|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
33028435|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
33028436|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
33028437|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
33028438|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
33028439|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
33028440|NCT01930227|No Intervention|Control|No stimulation was given
33028441|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
33028442|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
33028443|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
33326604|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
33326605|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
33326606|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
33326607|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
33326608|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
33326609|NCT05068440|Experimental|Zanubrutinib|administered orally
33326610|NCT03878238|Placebo Comparator|Placebo|
33326611|NCT03878238|Experimental|Probiotic|
33028444|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
33028445|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
33028446|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
33028447|NCT01930279||surface markers on T cells as assessed by FACS|
33028448|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
33028449|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
33028450|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
33028451|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
33028452|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
33028453|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
33028454|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
33028455|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
33028456|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
33028457|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
33028458|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
33028459|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
33028460|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
33028461|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
33028462|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
33028463|NCT01930383||Arm C|patients who receive systemic therapy
33028464|NCT01930396|Experimental|Tinzaparin|
33028465|NCT01930396|Active Comparator|Unfractionated Heparin|
33028466|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting~A toolkit with education, exercise and self management instructions for after hip fracture"
33028467|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
33028468|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
33028469|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
33028470|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
33028471|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
33326612|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
33028472|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
33028473|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
33028474|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
33028475|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
33028476|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
33028477|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
33028478|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
33028479|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
33028480|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
33028481|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
33028482|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
33028483|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
33028484|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
33028485|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
33028486|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
33028487|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
33028488|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
33028489|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
33028490|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
33028491|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
33028492|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
33028493|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
33028494|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
33028495|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
33028496|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
33028497|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
33028498|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
33028499|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
33028500|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
33028501|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
33028502|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
33028503|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
33028504|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
33028505|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
33107158|NCT04656782||Facilitators|The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.
33107159|NCT00541398|Experimental|A|
33107160|NCT00541398|No Intervention|B|
33028506|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
33028507|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
33028508|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
33028509|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
33028510|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
33028511|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
33028512|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
33028513|NCT01930760|Experimental|Educational Intervention Group|
33028514|NCT01930760|Experimental|Behavioural Intervention Group|
33028515|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
33028516|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
33028517|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
33028518|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
33028519|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
33028520|NCT01930838||Controls|Matched on age, sex and body mass index
33028521|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
33028522|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
33028523|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
33028524|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
33028525|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
33028526|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
33028527|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
33028528|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
33028529|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
33028530|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
33028531|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
33028532|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
33028533|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
33028534|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
33028535|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
33028536|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
33028537|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
33028538|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
33028539|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
33028540|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
33028541|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
33028542|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
33028543|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
33028544|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
33028545|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
33028546|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
33028547|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
33028548|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
33028549|NCT01931111||Norwegian Elderly Population|
33028550|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
33028551|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
33028552|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
33028553|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
33028554|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
33028555|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
33028556|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
33028557|NCT01931189|Experimental|NI-071|
33028558|NCT01931189|Active Comparator|Infliximab|
33028559|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
33028560|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
33028561|NCT01931228|Experimental|MI-E plus manually assisted coughing|
33028562|NCT01931228|Experimental|Manually assisted coughing only|
33028563|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
33028564|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
33028565|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
33028566|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
33028567|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
33028568|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
33028569|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
33028570|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
33028571|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
33028572|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
33028573|NCT01931319|Experimental|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
33028574|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
33028575|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
33107161|NCT04656626|Experimental|COVID19 Frontline Health Care Providers recieving mindfulness intervention|This arm will receive mindfulness audios (randomized and double blinded)
33028576|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
33028577|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
33028578|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
33028579|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
33028580|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
33028581|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
33028582|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
33028583|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
33028584|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
33028585|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
33028586|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
33028587|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
33028588|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
33028589|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
33028590|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
33028591|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
33028592|NCT01931410|No Intervention|synpitan|
33028593|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
33028594|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
33028595|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
33028596|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
33028597|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
33028598|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
33028599|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
33028600|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
33028601|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion~Pre-rounds huddle~Bedside RN integration~Patient-centered rounding~Real-time order writing"
33028602|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
33028603|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
33028604|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
33028605|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
33028606|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
33028607|NCT01931618|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
33028608|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
33028609|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
33028610|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
33028611|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
33028612|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
33028613|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
33028614|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
33028615|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
33028616|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
33028617|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
33028618|NCT01931748|Experimental|UNCNT|6 times/ 12 days
33028619|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
33028620|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
33028621|NCT01931774||Acne Patients|
33028622|NCT01931774||Control Subjects|From General Population
33028623|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33028624|NCT01931800||Presenting patients a pneumonia pneumococcique|
33028625|NCT01931800||Patients presenting a bacteremia pneumococcique|
33028626|NCT01931800||Patients affected by pneumococcique meningitis|
33028627|NCT01931813||Infants likely to present febrile convulsions|
33028628|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
33028629|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
33028630|NCT01931891||prreclampsia|
33028631|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
33028632|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
33028633|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
33028634|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
33028635|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
33028636|NCT01931969||IJVC intervention|
33028637|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
33028638|NCT01931982|No Intervention|No treatment|
33028639|NCT01932021|Experimental|adipose tissue grafting|
33028640|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
33028641|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
33028642|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
33028643|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
33028644|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
33028645|NCT01932086|Experimental|White rice|
33028646|NCT01932086|Experimental|Brown rice|
33028647|NCT01932086|Experimental|Black rice|
33028648|NCT01932086|Active Comparator|Bread|
33028649|NCT01932086|Active Comparator|Glucose solution|
33028650|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
33028651|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
33028652|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
33028653|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
33028654|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
33028655|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
33028656|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
33028657|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
33028658|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
33028659|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
33107162|NCT04656626|Placebo Comparator|COVID19 Frontline Health Care Providers receiving progressive muscle relaxation|This arm will receive progressive muscle relaxation audios (randomized and double blinded)
33326613|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
33028660|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
33326614|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
33326615|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
33326616|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
33326617|NCT01268358|Experimental|Lamazym 6.25|
33326618|NCT01268358|Experimental|Lamazym 12.5|
33028661|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
33028662|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
33028663|NCT01932229|Experimental|Afatinib treatment|
33028664|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
33028665|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
33028666|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
33028667|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
33028668|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
33028669|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
33028670|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
33028671|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
33028672|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
33028673|NCT01932333|Experimental|Cohort 1|
33028674|NCT01932333|Experimental|Cohort 2|
33028675|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
33028676|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
33028677|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
33028678|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
33028679|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
33028680|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
33028681|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
33028682|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
33028683|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
33028684|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
33028685|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
33028686|NCT01932463|Experimental|ExAb;ate MRgFUS|
33028687|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
33028688|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
33028689|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
33028690|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
33028691|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
33028692|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
33028693|NCT01932515|No Intervention|Screening|
33028694|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
33028695|NCT01932541|Experimental|Latuda (Lurasidone)|
33107163|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
33107164|NCT04656704|Experimental|Hyaluronidase 200mg monthly|Hyaluronidase 200mg monthly (Weeks 0, 4, 8, 12, 16, 20); for six doses; a 6-month treatment course with follow-up 1 month after
33107165|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
33107166|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
33107167|NCT04656548||HydroPICC|Cohort who received the HydroPICC
33107168|NCT04656548||Standard of Care|Cohort who received something different than HydroPICC
33107169|NCT04656665|Experimental|75mg|Take 75mg of aspirin daily in tihis group
33107170|NCT04656665|Active Comparator|100mg|Take 100mg of aspirin daily in this group
33107171|NCT04656665|No Intervention|blank|Not taking aspirin in this group
33107172|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
33107173|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
33107174|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
33107175|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
33107176|NCT04656314||Healthy participants aged 18 to 40|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
33107177|NCT04656314||Healthy participants aged 60 and above|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
33107178|NCT04656119||patients without irAEs or patients with good efficacy|
33107179|NCT04656119||patients with irAEs or patients with poor efficacy|
33107180|NCT04656197||Patients with dry eye disease|
33107181|NCT04656197||Healthy controls|
33107182|NCT04655846|Active Comparator|Control group|Usual manage during prenatal control program
33107183|NCT04655846|Experimental|Intervention group|Educational intervention towards the maintenance of exclusive breastfeeding in the first six months in first pregnant adolescents enrolled in the prenatal control program
33107184|NCT04655534|Experimental|IMW Group|Patients who performed inspiratory muscle warm-up (IMW) before inspiratory muscle training (IMT)
33107185|NCT04655534|Experimental|Standart IMT Group|Patients who performed standard inspiratory muscle training (IMT) without inspiratory muscle warm-up (IMW) protocol
33107186|NCT03013218|Experimental|Evorpacept (ALX148)|The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
33107187|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
33107188|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
33107189|NCT03013218|Experimental|Evorpacept (ALX148) + Rituximab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
33107190|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
33107191|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
33107192|NCT04655807|Experimental|Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.
33107193|NCT04655807|Experimental|Group 2: SOC Biological Therapy: Ustekinumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.
33107194|NCT04655417|Experimental|INTERVENTION GROUP|SINGLE ARM OF PATIENTS WHO WILL RECEIVE SAME TREATMENT
33107195|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
33107196|NCT02937831||All Study Participants|
33107197|NCT04655339|Experimental|Group-1|Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally. Remaining residual is injected into port incision sites.
33107198|NCT04655339|Experimental|Group-2|Bilateral abdominal Lap-TAP liposomal Bupivacaine (Exparel®) injection with 133mg (20ml) Exparel® plus bupivacaine 0.25% (30ml), plus 10ml of normal saline for a total volume of 60ml, injecting 30ml each side.
33107199|NCT04655339|No Intervention|Group-3|
33107200|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
33107201|NCT04655105|Experimental|Truanatomy rotary file|use of tru anatomy rotary files root canal instrumentation followed by post operative pain evaluation
33107202|NCT04655105|Experimental|hyflex EDM rotary file|use of hyflex EDM rotary files root canal instrumentation followed by post operative pain evaluation
33107203|NCT04655105|Experimental|edge endo reciprocating rotary file|use of edge endo reciprocating rotary files root canal instrumentation followed by post operative pain evaluation
33107204|NCT04655105|Active Comparator|protaper gold rotary file|use of protaper gold rotary files root canal instrumentation followed by post operative pain evaluation
33326619|NCT01268358|Experimental|Lamazym 25|
33107205|NCT04655183|Experimental|Part 1A (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight < 77 kilograms (kg) or baseline platelet count < 150, 000 per cubic millimeter will be included in this Part. Dose escalation of M4344 administered along with niraparib.
33107206|NCT04655183|Experimental|Part 1B (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight > =77 kilograms (kg) and baseline platelet count >=150, 000 per cubic millimeter will be included in this Part. M4344 will be administered at a dose and schedule that was determined as the recommended dose for expansion (RDE) in Part 1A. Dose of niraparib will be escalated to the next higher dose level.
33107207|NCT04655183|Experimental|Part 2 (Dose expansion): PARPi resistant, Niraparib plus M4344|Participants with Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant, germline breast cancer 1/2 mutated (gBRCA1/2m) human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer (aBC) will receive the combination of niraparib and M4344 at the RDE which was determined in Part 1.
33107208|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive niraparib as a single agent.
33107209|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib plus M4344|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive the combination of niraparib and M4344 at the RDE as determined in Part 1 of this study.
33107210|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
33107211|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
33107212|NCT04654949|Experimental|Horticultural Therapy|The Horticultural Therapy group receives 30 minutes of horticultural therapy activities using mobile horticulture kits conducted by therapists or therapy assistants to engage participants at their bedside.
33107213|NCT04654949|No Intervention|Existing Care|The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
33107214|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
33107215|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
33107216|NCT04654871|Experimental|Experimental Group|
33107217|NCT04654871|Experimental|Active Comparator Group|
33107218|NCT04654793|Experimental|Intervention group|Robot assisted inclined bed treatment and FES
33107219|NCT04654793|Active Comparator|Control group|conventional inclined bed treatment
33107220|NCT04654520|Experimental|Drug therapy combined with radiotherapy for primary tumor omitted CTV|"IMRT (omitted CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT (omitted CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
33107221|NCT04654520|No Intervention|Drug therapy combined with radiotherapy for primary tumor with CTV|"IMRT (with CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT ((with CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
33107222|NCT00541788|Experimental|1|Administration of Common Sage
33107223|NCT04654598|Other|BPA level|BPA (bisphenol A) in urine, blood and follicle fluid samples
33107224|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
33107225|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
33107226|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
33326620|NCT01268358|Experimental|Lamazym 50|
33326621|NCT01268358|Experimental|Lamazym 100|
33326622|NCT05452668|Experimental|Group I|Seventeen patients will receive treatment using the red wavelength (660 nm) to provide biostimulation. Plus the current protocol (antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
33326623|NCT05452668|Experimental|Group II|Seventeen patients will receive treatment using the infrared wavelength (970 nm) to provide biosstimulation. plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
33326624|NCT05452668|Sham Comparator|Group III|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
33326625|NCT01162824|Other|No endothelial dysfunction|
33417066|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
33417067|NCT04252105|Experimental|Antioxidant rich diet|
33417068|NCT04252105|No Intervention|Regular diet|
33417537|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
33028696|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
33028697|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
33028698|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
33028699|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
33028700|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
33028701|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
33028702|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
33028703|NCT01932593|Placebo Comparator|Placebo|
33028704|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
33028705|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
33028706|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
33028707|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
33028708|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
33028709|NCT01932684|No Intervention|Control Group|
33028710|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
33028711|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
33028712|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
33028713|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
33028714|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
33028715|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
33028716|NCT01932775|Experimental|GlucoTab System|
33028717|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
33028718|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
33028719|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
33028720|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
33417538|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
33028721|NCT01932814||Aminoglycosides|have received aminoglycosides
33028722|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
33028723|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
33028724|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
33028725|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
33028726|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
33028727|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
33028728|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
33028729|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
33028730|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
33028731|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
33028732|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
33028733|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
33028734|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
33028735|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
33028736|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
33028737|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
33028738|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
33028739|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
33028740|NCT01932944||No treatment|
33028741|NCT01932957|Other|Laparotomy arm|Standard treatment
33028742|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
33028743|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
33028744|NCT01933022|Other|Single Arm: Eligard|Single Arm
33028745|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
33028746|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
33028747|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
33028748|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
33028749|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
33028750|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
33028751|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
33028752|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
33028753|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
33028754|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
33028755|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
33028756|NCT01933126|Placebo Comparator|Placebo|G2 Medium
33028757|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
33028758|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
33028759|NCT01933152||Group 1|
33028760|NCT01933165|Other|LipiView|
33028761|NCT01933178|Other|Cirrus AS-OCT|
33028762|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
33028763|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
33417539|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
33417540|NCT01317719||Distal Biceps Ruptures|
33417069|NCT04576819||Sepsis cohort|"Inclusion criteria~Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)~Treatment with an institutional, evidence-based guideline management bundle for sepsis~Within 24 hrs of sepsis recognition~Exclusion criteria:~alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),~uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),~advanced directives limiting resuscitative efforts,~organ transplant recipient on immunosuppressive agents,~known pregnancy,~inability to obtain informed consent,~HIV/AIDS with CD4 count < 200,~absolute neutrophil count < 500"
33417070|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
33417071|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
33417072|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
32902350|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
32902351|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
32902352|NCT01555957|Experimental|low dose intravenous lipids|
32902353|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
32902354|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
32902355|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
32902356|NCT03760406|Experimental|Severe essential tremor treated by DBS|
32902357|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
32902358|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
32902359|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
32902360|NCT00560612|Placebo Comparator|Placebo|
32902361|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
32902362|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
32902363|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
32902364|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
32902365|NCT03725384|Experimental|Ferrous Sulfate and Vitamin C every other day|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
32902366|NCT03725384|Active Comparator|Ferrous Sulfate and Vitamin C daily|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
32902367|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
32902368|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
32902369|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
32902370|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
32902371|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
32902372|NCT01798628|Experimental|Sequence ABC|
32902373|NCT01798628|Experimental|Sequence ACB|
32902374|NCT01798628|Experimental|Sequence BAC|
32902375|NCT01798628|Experimental|Sequence BCA|
32902376|NCT01798628|Experimental|Sequence CAB|
32902377|NCT01798628|Experimental|Sequence CBA|
33417073|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
33417074|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
33417541|NCT05189405||INVOcell IVC|IVF using intravaginal incubation with INVOcell device for embryo development.
33028764|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
33028765|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
33028766|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
33028767|NCT01933256|Placebo Comparator|Placebo|Placebo
33028768|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
33028769|NCT01933269|Experimental|FACBC|
33028770|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
33028771|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
33028772|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
33028773|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
33028774|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
33028775|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
33028776|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
33028777|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
33028778|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
33028779|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
33028780|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
33028781|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
33028782|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
33028783|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
33028784|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
33028785|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
33028786|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
33028787|NCT01933438|Active Comparator|Control|Standard treatment
33028788|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
33028789|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
33028790|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
33028791|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
33028792|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
33028793|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
33028794|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
33028795|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
33028796|NCT01933516|Experimental|GP2013|
33028797|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
33417075|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
33417076|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
33028798|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
33028799|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
33028800|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
33028801|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
33028802|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
33028803|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
33028804|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
33028805|NCT01933607|Other|TOPS System|Post Marketing Study
33028806|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
33028807|NCT01933633|No Intervention|Control|Standard care
33028808|NCT01933646||Cohort 1|
33028809|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
33028810|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
33028811|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
33028812|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
33028813|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
33028814|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
33028815|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
33028816|NCT01933711|No Intervention|Observation|observational arm, no intervention
33028817|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
33028818|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
33028819|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
33028820|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
33028821|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
33028822|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
33028823|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
33028824|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
33028825|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
33028826|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
33028827|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
33028828|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
33028829|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
33028830|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
33028831|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
33028832|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
33417077|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
33417078|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
33028833|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
33417079|NCT02077400|No Intervention|no antibiotic|
33417080|NCT02077400|Active Comparator|Cephazolin|cefazoline
33028834|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
33028835|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.~Maximum treatment duration will not expand 18 months."
33417081|NCT01362283||Hypertension|Subject who meet eligible criteria
33028836|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
33028837|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
33028838|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
33028839|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
33028840|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh."
33028841|NCT01933997|Experimental|MG01CI 1400 mg|
33028842|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
33028843|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
33028844|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
33028845|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
33028846|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
33028847|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
33028848|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
33028849|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
33028850|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
33028851|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
33028852|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
33417082|NCT02077478|Experimental|MCI|manually controlled infusion will be used
33417083|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
33417084|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
33417085|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
33417086|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
33417087|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
33028853|NCT01934101|Experimental|CHR-5154|CHR-5154
33028854|NCT01934101|Placebo Comparator|Placebo|Placebo
33417088|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
33417089|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
33417090|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
33028855|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
33028856|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
33028857|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
33028858|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
33028859|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
33028860|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
33028861|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
33028862|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
33028863|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
33028864|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
33028865|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
33028866|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
33028867|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
33028868|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
33028869|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
33028870|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
33028871|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
33028872|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
33028873|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028874|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028875|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028876|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028877|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028878|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028879|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028880|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
33028881|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
33417091|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
33417092|NCT01365403|Experimental|Single Arm|
32866638|NCT04826016|Experimental|PHASE Ib - ARM B: POL6326 (balixafortide) + nab-paclitaxel|On day 1, 8 and 15 of each 28-day cycle (+/- 1 day) fixed nab-paclitaxel dose of 100 mg/m2 combined with increasing doses of POL6326 (balixafortide) starting at a dose of 5.5 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Nab-paclitaxel will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 30 min. Up to 5 additional cohorts may be introduced
33028882|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
33028883|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
33028884|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
33028885|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
33028886|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
33028887|NCT01934270|Experimental|Anaerobic Test|
33028888|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
33417093|NCT02070926||Perform coronary CT angiography|
33417094|NCT02070926||Do not perform coronary CT angiography|
33028891|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
33028892|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
33028893|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
33028894|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
33028895|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
33028896|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
33028897|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
33028898|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
33028899|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
33028900|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
33028901|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
33028902|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
33028903|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
33028904|NCT01934426||Admission High Risk|Admission High Risk
33028905|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
33028906|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
33028907|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
33028908|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
33028909|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
33033274|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
33417095|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
33028910|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
33028911|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
33417096|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
33028912|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
33028913|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
33028914|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
33028915|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
33028916|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
33028917|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
33028918|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
33028919|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
33028920|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
33028921|NCT01934673||Subjects with diabetes (type 2)|
33028922|NCT01934686||Subjects with diabetes mellitus (type 2)|
33028923|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
33028924|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
33028925|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
33028926|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
33028927|NCT01934738|Experimental|Group 1: Cohort 1|
33028928|NCT01934738|Experimental|Group 1: Cohort 2|
33028929|NCT01934738|Experimental|Group 1: Cohort 3|
33028930|NCT01934738|Experimental|Group 2: Cohort 4|
33028931|NCT01934738|Experimental|Group 1: Cohort 5|
33028932|NCT01934738|Experimental|Group 2: Cohort 6|
33028933|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
33028934|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
33028935|NCT01934764||autoimmune disease|
33028936|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
33028937|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
33028938|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
33028939|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
33028940|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
33028941|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
33028942|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
33028943|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
33417097|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
33417098|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
33028944|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
33417099|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
33417100|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
33028945|NCT01934842|Experimental|TAP20-C|TAP20-C
33028946|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
33028947|NCT01934881|Experimental|group I|Voltage adjustment only
33028948|NCT01934881|Experimental|group II|Combined parameters adjustment
33028949|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
33028950|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
33028951|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
33028952|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
33028953|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
33028954|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
33028955|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
33028956|NCT01934959|Experimental|Probiotics|
33028957|NCT01934998||SCA6 and control|SCA6 and control
33028958|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
33028959|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
33028960|NCT01935024|No Intervention|Normal Activity level|
33028961|NCT01935024|Active Comparator|Personalized Exercise Regimen|
33028962|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
33028963|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
33028964|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
33028965|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
33028966|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
33028967|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
33028968|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
33028969|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
33417542|NCT05189405||Traditional IVF (tIVF)|Traditional IVF using laboratory equipment and incubators for embryo development
33417543|NCT02083640|Other|Treatment A (Reference)|
33028970|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
33028971|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
33028972|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
33028973|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
33028974|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
33028975|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
33028976|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
33028977|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
33028978|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
33028979|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
33028980|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
33028981|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
33028982|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
33028983|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
33028984|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
33417544|NCT02083640|Other|Treatment B (Test)|
33417545|NCT02083640|Other|Treatment C (Test)|
33028985|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
33028986|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
33028987|NCT01935232||Men|140 Men
33028988|NCT01935232||Female|500 Female
33028989|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
33028990|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
33028991|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
33028992|NCT01935258|Other|care as usual|Usual care of the general practitioner
33028993|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
33028994|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
33028995|NCT01935284||Healthy Volunteers|
33028996|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
33028997|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
33028998|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
33028999|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
33029000|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
33029001|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
33029002|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
33029003|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
33029004|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
33029005|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
33029006|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
33029007|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
33029008|NCT01935401||Women with Bulimia Nervosa|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
33029009|NCT01935401||Healthy Controls|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
33029010|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
33029011|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
33029012|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
33029013|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
33029014|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
33029015|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
33029016|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
33029017|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
33029018|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
33029019|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
33029020|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
33029021|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
33029022|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
33029023|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
33029024|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
33029025|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
33029026|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
33417546|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
33029027|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
33029028|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
33029029|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
33029030|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
33029031|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
33029032|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
33029033|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
33029034|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
33029035|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
33029036|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
33029037|NCT01935570|Experimental|Magnesium|
33029038|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
33029039|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
33029040|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
33029041|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
33029042|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
33029043|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
33029044|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
33029045|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
33029046|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
33029047|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
33029048|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
33029049|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
33029050|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
33029051|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
33029052|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
33029053|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
33029054|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
33029055|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
33326626|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
33326627|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
33029056|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
33029057|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
33029058|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
33029059|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
33029060|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
33029061|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
33029062|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
33029063|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
33029064|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
33029065|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
33029066|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
33029067|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
33029068|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
33029069|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)~Efavirenz, oral capsules, 600 mg~Ritonavir, oral capsules, 100 mg"
33029070|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
33029071|NCT01935856|Experimental|KHK7580|
33029072|NCT01935869|Experimental|LEO 90100|
33029073|NCT01935869|Placebo Comparator|Vehicle|
33029074|NCT01935869|Other|Petrolatum ointment|
33029075|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
33029076|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
33029077|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
33029078|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
33029079|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
33029080|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
33029081|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
33029082|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
33029083|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
33029084|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33029085|NCT01935986|Experimental|probiotic|dietary supplement
33029086|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
33029087|NCT01935999|Other|One piece closed pouch|One piece closed pouch
33029088|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
33029089|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
33029090|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
33029091|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
33326628|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
33326629|NCT01264926||rotator cuff tear, pain|
33327283|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
33029092|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
33029093|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
33326630|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
33029094|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
33029095|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
33029096|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
33029097|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
33029098|NCT01936038|Placebo Comparator|Control Group|CPAP
33029099|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
33029100|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
33029101|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
33029102|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
33029103|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
33029104|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
33029105|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
33029106|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
33029107|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
33029108|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
33029109|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
33029110|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
33029111|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
33029112|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
33029113|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
33029114|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
33029115|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
33029116|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
33029117|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
33029118|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
33029119|NCT01936207||One Group|
33029120|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
33029121|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
33029122|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
33029123|NCT01936233|Experimental|Aspirin AND Lamivudine|
33029124|NCT01936233|Active Comparator|Lamivudine|
33029125|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
33029126|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
33029127|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
33029128|NCT01936285|Experimental|Colchicine|Active treatment group
33029129|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
33326631|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
33417547|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
33029130|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
33029131|NCT01936311|No Intervention|Control Group|This group will receive usual care.
33029132|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
33029133|NCT01936337|Active Comparator|DLX105 Hydrogel|
33029134|NCT01936337|Placebo Comparator|Placebo Hydrogel|
33029135|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
33029136|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
33029137|NCT01936376||head & neck cancer patients, cisplatin treatment|
33029138|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
33029139|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
33029140|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
33029141|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
33029142|NCT01936415|Active Comparator|Vanguard|
33029143|NCT01936428|Other|interview|
33029144|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
33029145|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
33029146|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
33029147|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
33029148|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
33029149|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
33326632|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
33326633|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
33326634|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
33033275|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
33326635|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
33326636|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
33033276|NCT01961388||Group 1|Acarbose_BAY G5421
33033277|NCT01961388||Group 2|Metformin
33326637|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
33326638|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
33326639|NCT05666856|Experimental|CRAFT|Participants assigned to CRAFT will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules that are unlocked weekly include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Problem-solving; 6) Withdrawing Reinforcement; 7) Allowing Natural Consequences; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills. Two additional modules (domestic violence and opioid overdose precautions) are available at any time. CRAFT participants also attend weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group or individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations.
33327284|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
33327285|NCT03859518||patients with Vitiligo|
33327286|NCT03859518||control|
33107227|NCT04654481|Active Comparator|Standard Care Plus Monitoring|All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
33107228|NCT04654481|Experimental|Standard Care Plus Monitoring and HCFWO|In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.
33107229|NCT04654637|Experimental|Arm A|fix model of cycle exercise(online supervise) and routine nutrition consult
33107230|NCT04654637|Experimental|Arm B|fix model of cycle exercise(online supervise) and online nutrition consult
33107231|NCT04654637|Experimental|Arm C|individualize cycle exercise(online supervise) and routine nutrition consult
33107232|NCT04654637|Experimental|Arm D|individualize cycle exercise(online supervise) and online nutrition consult
33107233|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
33107234|NCT04654403|Experimental|Camrelizumab|Camrelizumab (200 mg every 2 weeks),Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years)
33107235|NCT04654403|Active Comparator|Camrelizumab plus chemotherapy|Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
33107236|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
33107237|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
33107238|NCT04654559|Other|Unobtrusive data collection|
33107239|NCT00541983|Active Comparator|1|
33107240|NCT00541983|Placebo Comparator|2|
33107241|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
33107242|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
33107243|NCT04654715||Localized prostate cancer treatment induced rectourethral fistula|Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).
33107244|NCT04654442||Cases|30 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19 at Grenoble University Hospital
33107245|NCT04654442||Controls|30 controls will be recruited : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19 at Grenoble University Hospital
33107246|NCT00542061|Experimental|A|Device: monitoring services
33107247|NCT00542061|No Intervention|B|Control group: no monitoring procedures
33107248|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
33107249|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
33107250|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
33107251|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
33327287|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
33107252|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
33107253|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
33107254|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
33107255|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
33107256|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
33107257|NCT00557648|Experimental|1|CBT for children only
33107258|NCT00557648|Experimental|2|CBT for children with parental involvement
33107259|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
33107260|NCT00542100|Experimental|1|
33107261|NCT00542100|Experimental|2|
33107262|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
33107263|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
33107264|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
33107265|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
33107266|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
33107267|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
33107268|NCT04654286|Active Comparator|Control group (Nerve transfer procedure)|Patient will receive nerve transfer procedure without augmentation
33327288|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
33033278|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
33033279|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
33033280|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
33033281|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
33033282|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
33033283|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
33033284|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
33033285|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
33033286|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
33033287|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
33033288|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
33033289|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
33033290|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
33033291|NCT01961466||Diabetic patients|
33033292|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
33033293|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
33033294|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
33033295|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
33033296|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
33033297|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
33033298|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
33033299|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
33033300|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
33033301|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
33033302|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
33033303|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
33033304|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
33033305|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
33033306|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
33033307|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
33033308|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
33033309|NCT01961661|Placebo Comparator|placebo|maltodextrins
33033310|NCT01961674|Experimental|Capsinoid arm|On capsinoids
33033311|NCT01961674|Placebo Comparator|Placebo arm|Placebo
33033312|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
33033313|NCT01961700|No Intervention|Control group|No physiotherapy.
33033314|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
33033315|NCT01961726|Placebo Comparator|Placebo|
33033316|NCT01961726|Experimental|30 mg dose of JVS-100|
33033317|NCT01961726|Experimental|45 mg dose of JVS-100|
33033318|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
33033319|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
33033320|NCT01961752|Placebo Comparator|Control group|
33033321|NCT01961752|Experimental|Bupivacaine only group|
33033322|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
32866639|NCT04826016|Experimental|PHASE 2 - ARM A: POL6326 (balixafortide) + eribulin|MTD/RDP2 POL6326 (balixafortide) (from arm A phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 1.4 mg/m2 eribulin over 5 min Intravenous infusion on days 1 and 8 in 21-day cycles (+/- 1 day).
33029150|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
33029151|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
33029152|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
33029153|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
33029154|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
33029155|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
33029156|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
33029157|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
33029158|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
33029159|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
33029160|NCT01936584||TEP repair|TEP repair for inguinal hernia
33029161|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
33029162|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
33029163|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
33029164|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
33029165|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
33029166|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
33029167|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
33029168|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
33029169|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
33029170|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
33029171|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
33029172|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
33029173|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
33029174|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
33029175|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
33029176|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
33033323|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
33107269|NCT04654286|Experimental|Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)|Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation
33107270|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
33107271|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
33107272|NCT00542139|Experimental|1|
33107273|NCT00542139|Active Comparator|2|
33107274|NCT04653974|Active Comparator|Needle-free injection group|In needle-free injection techniques, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using the Comfort-In system.
33107275|NCT04653974|Active Comparator|Dental injection group|In the conventional dental-injection method, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using a 27G, 40-mm, disposable syringe with a needle.
33107276|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
33107277|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
33107278|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
33107279|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
33107280|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
33107281|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
33107282|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
33107283|NCT04654247|Sham Comparator|Control group|Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
33107284|NCT04654247|Experimental|Feedback group|Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent. In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
33107285|NCT02493114||Patients with lung cancer|No study intervention
33326640|NCT05666856|Active Comparator|PEER|"Participants assigned to the PEER condition will participate in an online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs.~Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully."
33326641|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
33107286|NCT04654091|Experimental|Cryoteraphy with liquid nitrogen|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
33107287|NCT04654091|Experimental|Nitric-zinc complex|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
33107288|NCT04654169|Experimental|The IAI and SSNB group|Ultrasound-guided IAI and SSNB are planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
33107289|NCT04654169|Active Comparator|The only-IAI group|Ultrasound-guided IAI is planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
33107290|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
33326642|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
33326643|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
33326644|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
33326645|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
33326646|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
33326647|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
33326648|NCT05436600|No Intervention|Control|The control group will undergo standard-of-care vascular risk factor modification. Control participants will be contacted via telephone on a weekly basis to discuss the importance of vascular risk factor management and adherence to prescribed medical management.
33326649|NCT05436600|Experimental|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
33326650|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
33326651|NCT01158612|Placebo Comparator|Saline|
33326652|NCT01267110|Experimental|Intervention|
33326653|NCT01267110|Active Comparator|Control|
33326654|NCT02526966|Other|patient with primitive form of IgA nephropathy|
33326655|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
33326656|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
33326657|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
33326658|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
33326659|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
33029177|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
33029178|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
33326660|NCT01158768||Violence, Comorbidity|
33029179|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
33029180|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
33326661|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
33326662|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
33029181|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
33029182|NCT01936792||Controls|Controls with no premorbid health conditions
33327289|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
33327290|NCT01176084|Experimental|low carbohydrate diet|
33327291|NCT01176084|Experimental|diet & exercise|
33029183|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
33029184|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
33029185|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
33029186|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
33029187|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
33029188|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
33029189|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
33029190|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
33029191|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
33029192|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
33029193|NCT01937065||No treatment|
33029194|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
33029195|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
33029196|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
33029197|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Trendelenburg position - 30 degree"
33029198|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Reverse Trendelenburg position - 30 degree"
33029199|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
33029200|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
33029201|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
33029202|NCT01937156|Experimental|SP-01|
33029203|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
33033324|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
33033325|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
33033326|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
33033327|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
33029204|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
33029205|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
33029206|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
33029207|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
33029208|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
33029209|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
33029210|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
33029211|NCT01937221||mild cognitive impairment|
33029212|NCT01937221||mild to moderate cognitive impairment|
33029213|NCT01937221||normal or control group|
33029214|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
33029215|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
33029216|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
33029217|NCT01937325|Placebo Comparator|Placebo|Matching placebo
33029218|NCT01937338|Experimental|AZD7624|
33029219|NCT01937338|Placebo Comparator|Placebo|
33029220|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
33029221|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
33029222|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
33029223|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
33029224|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
33029225|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
33029226|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
33029227|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
33029228|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
33029229|NCT01937481|No Intervention|Control|Control group
33029230|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
33029231|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
33029232|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
33029233|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
33029234|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
33029235|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
33029236|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
33029237|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
33029238|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
33029239|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
33107291|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
33107292|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
33107293|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
33107294|NCT04653935|Experimental|Full app with all app components|Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills.
33107295|NCT04653935|Active Comparator|Control minimal app with information component only|Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components.
33107296|NCT00542295|Experimental|A|
33107297|NCT00542295|Placebo Comparator|B|
33107298|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
33107299|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
33107300|NCT02335944|Experimental|Phase IB part- NSCLC with EGFR activating mutations|NSCLC participants who have previously documented EGFR mutation and progressed on EGFR TKI treatment
33107301|NCT02335944|Experimental|Phase II- Group 1 (EGFRmut, any T790M, any MET, 2/4L antineoplastic, EGFR TKI resistant)|NSCLC participants with previously documented activating EGFR mutation, with any T790M and MET dysregulation status, who received one to three lines of systemic antineoplastic therapy prior to study entry including one line maximum of first or second generation EGFR TKI and who progressed on this EGFR TKI treatment line.
33107302|NCT02335944|Experimental|Phase II- Group 2 (EGFRmut, de novo T790M, any MET, 1/3L antineoplastic, EGFR TKI naïve)|NSCLC participants harboring T790M mutation in de novo setting, irrespective of the activating mutation status who are treatment naïve or received maximum 2 lines of systemic antineoplastic therapy prior to study entry, but no therapy known to inhibit EGFR.
33107303|NCT02335944|Experimental|Phase II- Group 3 (EGFRmut, T790M negative, any MET, 1L antineoplastic)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, and any MET status who never received any prior line of systemic antineoplastic systemic therapy prior to study entry.
33107304|NCT02335944|Experimental|Phase II- Group 4 (EGFRmut, any T790M, any MET, 1L (treatment naïve) 2-3L antineoplastic)|NSCLC participants with previously documented EGFR activating mutations and any T790M and MET status who were treatment naïve or failed maximum 2 prior lines of any systemic antineoplastic therapy for advanced disease.
33107305|NCT02335944|Experimental|Phase II- Group 5 (EGFRmut, T790M-, MET GCN≥5, 2L, EGFR TKI resistant)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, acquired MET amplification who have progressed on one prior line of therapy for advanced/metastatic NSCLC disease.
33107306|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
33107307|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
33107308|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
33326663|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
33327292|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
33327293|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
33327294|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
33107309|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
33107310|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
33107311|NCT02293980|Experimental|Part 1: MK-3475|Participants with advanced ccRCC receive MK-3475 at an initial dose level of 100mg orally, twice daily (BID) up to approximately 3 weeks. Dose levels will be escalated to identify the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for MK-3475. Each escalated dose will be continued for up to approximately 3 weeks before escalating a dose again until a dose limiting toxicity (DLT) is experienced. Thereafter, participants receive RP2D dose of MK-3795 for up to 2 cycles (each cycle length = 28 days) for up to approximately 1 year. Participants may continue to receive MK-3795 beyond 1 year at the discretion of the Sponsor.
33107312|NCT02293980|Experimental|Part 2: MK-3795 + Nivolumab|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 orally in combination with nivolumab 240mg by IV infusion over ~60 minutes every 2 weeks for up to approximately 1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
33107313|NCT02293980|Experimental|Part 3: MK-3795 + Cabozantinib|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 in combination with cabozantinib 20mg up to 60mg orally QD for up to approximately 1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
33107314|NCT04653506|Experimental|Paracetamol group|Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
33327295|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
33029240|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
33029241|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
33029242|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
33029243|NCT01937663|Experimental|KWA-0711 Dose1|
33029244|NCT01937663|Experimental|KWA-0711 Dose2|
33029245|NCT01937663|Experimental|KWA-0711 Dose3|
33029246|NCT01937663|Experimental|KWA-0711 Dose4|
33029247|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
33029248|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
33029249|NCT01937702|Experimental|Anti-diabetes medication|Insulin
33029250|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
33029251|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
33029252|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
33029253|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
33029254|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
33029255|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
33029256|NCT01937754|Active Comparator|Nitric Oxide supplement|
33029257|NCT01937754|Placebo Comparator|Placebo|
33029258|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
33029259|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
33029260|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
33029261|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
33029262|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
33029263|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
33029264|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
33029265|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
33029266|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
33029267|NCT01937832|Active Comparator|Ertapenem|
33029268|NCT01937832|Experimental|Faropenem|
33029269|NCT01937858||Normal renal function|
33029270|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
33029271|NCT01937858||End stage renal disease on hemodialysis|
33029272|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
33029273|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
33029274|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
33029275|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
33029276|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
33029277|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
33029278|NCT01937936|Active Comparator|Education|Health Education
33029279|NCT01937949|Other|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.~Other names:~Endovascular stent Stent-graft"
33029280|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
33029281|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
33029282|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
33029283|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
33029284|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
33029285|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
33029286|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
33029287|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
33029288|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
33029289|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
33029290|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
33029291|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
33029292|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
33029293|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
33029294|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
33029295|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
33029296|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
33029297|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
33029298|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
33029299|NCT01938196|Experimental|KWA-0711 Dose1|
33029300|NCT01938196|Experimental|KWA-0711 Dose2|
33029301|NCT01938196|Experimental|KWA-0711 Dose3|
33029302|NCT01938196|Experimental|KWA-0711 Dose4|
33029303|NCT01938196|Placebo Comparator|Placebo|
33029304|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
33029305|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
33029306|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
33029307|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
33029308|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
33029309|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
33327296|NCT01288482|Experimental|Asthma Subjects|
33327297|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
33029310|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
33029311|NCT01938287|Experimental|SENSIMED Triggerfish|
33029312|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.~Infusion regimen:~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
33029313|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
33029314|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
33029315|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
33029316|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
33029317|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
33029318|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
33029319|NCT01938365||Diabetes|
33029320|NCT01938365||Normal glucose regulation|
33029321|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
33029322|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
33029323|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
33029324|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
33029325|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
33029326|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
33029327|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
33029328|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
33029329|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
33029330|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
33029331|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
33029332|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
33029333|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
33029334|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
33029335|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice~for 10 days"
33029336|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
33029337|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
33029338|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
33029339|NCT01938586||Surgical excision|
33029340|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
33029341|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
33029342|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
33029343|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
33029344|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
33029345|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
33029346|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
33029347|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
33029348|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
33029349|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
33033328|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.~The second visualization then will be performed with the conventional method."
33033329|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.~The second visualization then will be performed with the retromolar method."
33327298|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
33327299|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
33327300|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
33029350|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
33029351|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
33029352|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
33029353|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
33029354|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
33029355|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
33029356|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
33029357|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
33029358|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
33029359|NCT01938807|Active Comparator|Control|The control group receives standard care.
33029360|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:~entecavir, 0.5mg, qd, oral, for 2 years."
33029361|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
33029362|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
33029363|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
33029364|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
33029365|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
33029366|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
33029367|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029368|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029369|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029370|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029371|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029372|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029373|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029374|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
33029375|NCT01938924|No Intervention|No intervention|No intervention
33029376|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
33029377|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
33029378|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
33029379|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
33029380|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
33327301|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
33327302|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
33029381|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
33029382|NCT01938963|No Intervention|Care as usual|
33029383|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
33029384|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
33029385|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
33029386|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
33029387|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
33029388|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
33029389|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
33029390|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
33029391|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
33029392|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
33029393|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).~Escalation of the ventilatory support per protocol and the attending physician."
33029394|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).~Escalation of the ventilatory support per protocol and the attending physician."
33029395|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
33029396|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
33029397|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
33029398|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
33029399|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
33029400|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
33029401|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
33029402|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
33029403|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
33033330|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
33029404|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
33029405|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
33029406|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
33029407|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
33029408|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
33029409|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
33029410|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
33029411|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
33029412|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
33029413|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
33029414|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
33029415|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
33029416|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
33029417|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
33029418|NCT01939431||Advanced|advanced stage podoconiosis
33029419|NCT01939431||Control|non-podoconiosis controls
33029420|NCT01939431||Early|early stage podoconiosis
33029421|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
33029422|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
33029423|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
33029424|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
33029425|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~This arm also includes laboratory biomarker analysis as an intervention."
33029426|NCT01939509|Experimental|Atenolol-Bisoprolol|
33029427|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
33029428|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
33029429|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
33029430|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
33029431|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.~Adjuvant Therapy:~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
33029432|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
33029433|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
33029434|NCT01939587|Placebo Comparator|Placebo|Placebo
33029435|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
33029436|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
33029437|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
33029438|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
33029439|NCT01939626|Other|Control|Embryos cultured in two Culture media for 5 Days.
33029440|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
33417101|NCT04949789|Other|Placebo without Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
33417102|NCT04949789|Other|Placebo with Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
33029441|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
33029442|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
33029443|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
33029444|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
33029445|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
33029446|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
33029447|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
33029448|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
33029449|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
33029450|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
33029451|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
33029452|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
33029453|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
33029454|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
33029455|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
33029456|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
33029457|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
33029458|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
33029459|NCT01939795|No Intervention|Healthy People|Control group
33029460|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
33029461|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
33029462|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
33029463|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
33029464|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
33029465|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
33029466|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
33029467|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
33029468|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
33029469|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
33029470|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
33029471|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
33029472|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
33029473|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
33029474|NCT01939873|No Intervention|Control group|
33029475|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
33029476|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
33029477|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
33029478|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
33029479|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
33029480|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
33029481|NCT01939951|Placebo Comparator|Placebo|sugar pill
33029482|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
33029483|NCT01939964|Placebo Comparator|Placebo|sugar pill
33029484|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
33029485|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
33029486|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
33029487|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
33029488|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
33029489|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
33029490|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
33029491|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
33029492|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
33029493|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
33029494|NCT01940068|Experimental|New Thickened Amino acid based formula|
33029495|NCT01940068|Active Comparator|Amino acid based formula|
33029496|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%) or~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)~who are not admitted for cardiac surgery"
33029497|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%)~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
33029498|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:~Coronary artery bypass graft surgery and who do not have prior myocardial infarction~Aortic valve replacement"
33029499|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
33029500|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
33029501|NCT01940133|Experimental|PQR309|Different dose evaluation
33029502|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
33029503|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
33029504|NCT01940172|Experimental|Birinapant with Conatumumab|
33029505|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
33029506|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
33029507|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
33029508|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
33029509|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated~If the systolic BP decrease rapidly more than 25% over 15 minutes~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
33029510|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
33029511|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
33029512|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
33029513|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
33029514|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
33029515|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
33029516|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
33029517|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
33029518|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
33029519|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
33029520|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
33029521|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
33029522|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
33029523|NCT01940393|Active Comparator|Cetirizine|Cetirizine
33029524|NCT01940393|Active Comparator|Desloratadine|desloratadine
33029525|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
33029526|NCT01940393|Active Comparator|Ebastine|ebastine
33029527|NCT01940393|Active Comparator|Bilastine|bilastine
33029528|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
33029529|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
33029530|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
33029531|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
33029532|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
33029533|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
33029534|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
33029535|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
33029536|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
33029537|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
33029538|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
33029539|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
33029540|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
33029541|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
33029542|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
33029543|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
33029544|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
33029545|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
33029546|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
33029547|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
33029548|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
33029549|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
33029550|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
33033331|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
33107315|NCT04653506|Experimental|Ibuprofen group|Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
33107316|NCT04653701||Patients with hepatocellular carcinoma treated with TAMDEM® 100 micron and SEQURE® microcatheter|Patients included in this study and with chemoembolization indications will be superselective embolized using TAMDEM® 100 micron preloaded particles (Doxorubicin) and SEQURE® microcatheter combination (SYNERGIC EFFECT). Objective tumoral response and 30 days-complications (Safety) are primary outcomes.
33107317|NCT02188095||Excia T®|
33107318|NCT05081895||Respiratory failure|
33107319|NCT04653857||High-level athlete who had a recent COVID 19 infection, symptomatic or not|High-level athlete who had a recent COVID 19 infection, symptomatic or not
33107320|NCT04653623|Experimental|Tranexamic acid before high tibial osteotomy|"Interventions~Procedure/Surgery: High tibial osteotomy~Drugs: Tranexamic acid"
33107321|NCT04653623|Active Comparator|High tibial osteotomy only|"Interventions~- Procedure/Surgery: High tibial osteotomy"
33107322|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
33107323|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
33107324|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
33107325|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
33107326|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
33107327|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
33107328|NCT04653779|Experimental|Group A|Patients receive Evogliptin 5mg/Metformin 1000mg once a day
33107329|NCT04685031|Experimental|nitroglycerin|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
33107330|NCT04685031|Experimental|clobetasol|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
33107331|NCT04685031|No Intervention|routine|routine nursing care
33107332|NCT04653194|Experimental|Biktarvy treatment|First-line HIV treatment of Biktarvy OD for 48 weeks
33107333|NCT04653194|Active Comparator|Symtuza treatment|First-line HIV treatment of Symtuza OD for 48 weeks
33107334|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
33107335|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
33107336|NCT04653311|Experimental|Endomina procedure + lifestyle intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. This group will also receive the medical standard treatment defined as lifestyle intervention.
33107337|NCT04653311|No Intervention|Lifestyle intervention|The group will receive the medical standard treatment defined as lifestyle therapy combining diet (mediterranean diet) with increased physical activity
33107338|NCT04653155|Experimental|Treatment arm|Participants in the treatment group will show significant improvement on insomnia symptoms after intervention compared to those in the waitlist control group.
33107339|NCT04653155|No Intervention|Waitlist control|Participants in the waitlist control group will show little improvement on insomnia symptoms after the treatment period of the treatment group.
33107340|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval = 10 mm; Lateral = 10 mm
33107341|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval = 5 mm; Lateral 5 - 8 mm
33107342|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
33107343|NCT04653077|Experimental|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
33107344|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
33107345|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
33107346|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
33107347|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
33107348|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
33107349|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
33327303|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
33029551|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
33029552|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
33029553|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
33029554|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
33029555|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
33029556|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
33029557|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
33029558|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
33029559|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
33029560|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
33029561|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
33029562|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
33029563|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
33029564|NCT01940731|Experimental|Colistimethate sodium|
33029565|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
33029566|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
33029567|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
33029568|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
33029569|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
33029570|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
33029571|NCT01940861||Traumatic brain injury|
33029572|NCT01940874||Cerebral oximetry|
33029573|NCT01940913|Active Comparator|Probiotics|
33029574|NCT01940913|Placebo Comparator|Placebo|
33029575|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
33029576|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
33029577|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
33029578|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
33029579|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
33029580|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
33029581|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
33029582|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
33029583|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
33029584|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
33029585|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
33029586|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
33029587|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
33029588|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
33029589|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
33029590|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
33029591|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
33029592|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
33029593|NCT01941082|Experimental|Part A: RO6867461|Single doses
33029594|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
33029595|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
33029596|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
33029597|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
33029598|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
33029599|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
33029600|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
33029601|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029602|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029603|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029604|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029605|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029606|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
33029607|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
33029608|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
33029609|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
33029610|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
33029611|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
33029612|NCT01941238||Insulin pump|
33029613|NCT01941238||MDI|
33029614|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
33029615|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
33029616|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
33029617|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
33029618|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
33029619|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
33029620|NCT01941290||Orsiro|
33029621|NCT01941303||Advanced stage non-small cell lung cancer patients|
33029622|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.~Stratification for phase II component:~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
33033332|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
33029623|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
33029624|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
33029625|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
33029626|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
33029627|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
33029628|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
33029629|NCT01941355|Experimental|Exercise training, psycho-educative|
33029630|NCT01941355|Experimental|Psycho-educative component|
33029631|NCT01941355|Experimental|Exercise training component|
33029632|NCT01941355|No Intervention|Usual care|
33029633|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
33029634|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
33029635|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
33029636|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
33029637|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
33029638|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
33029639|NCT01941394|No Intervention|Without MSC|Without MSC infusion
33029640|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
33029641|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
33029642|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
33029643|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
33029644|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
33029645|NCT01941459||1 Custodiol|Custodiol
33029646|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
33029647|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
33029648|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
33029649|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
33029650|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.~For max. 6 times at all."
33029651|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
33029652|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
33029653|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
33029654|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
33029655|NCT01941654|Experimental|preemptive local ablative therapy|
33033333|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
33029656|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
33029657|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
33029658|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
33029659|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~CHOP-21 Day1 = day 21 (3 cycles)~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.~day 2-Day 5 Prednisone~1mg/kg/day PO."
33029660|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
33029661|NCT01941693|Experimental|Integrated care|"Integrated care:~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
33029662|NCT01941693|Active Comparator|Usual care|Usual care
33029663|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
33029664|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
33029665|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
33029666|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
33029667|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
33029668|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
33029669|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
33029670|NCT01941797|Experimental|Peri-implant mucosa|
33029671|NCT01941797|Active Comparator|periodontal mucosa|
33029672|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
33029673|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
33029674|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
33029675|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
33029676|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
33029677|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
33029678|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
33029679|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
33029680|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
33029681|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
33029682|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
33029683|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
33029684|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
33029685|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
33029686|NCT01941953|Experimental|Metformin and Flourouracil|
33029687|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
33029688|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
33029689|NCT01941979|No Intervention|Observation|
33029690|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
33029691|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
33029692|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
33029693|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
33029694|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
33029695|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
33029696|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
33029697|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
33029698|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
33029699|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
33029700|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
33029701|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
33029702|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
33029703|NCT01942083|Experimental|OPB-111077|orally, once daily
33029704|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
33029705|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
33029706|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
33029707|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
33029708|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
33029709|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.~Interventions : biological/vaccine and drug"
33029710|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination~Interventions : biological/vaccine and drug"
33029711|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
33029712|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
33029713|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
33029714|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
33029715|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
33029716|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
33029717|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
33029718|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
33029719|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
33029720|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
33029721|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
33029722|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
33029723|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
33029724|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
33029725|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
33029726|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
33029727|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
33029728|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
33029729|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
33029730|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
33029731|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
33029732|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
33029733|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
33029734|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
33029735|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
33029736|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
33029737|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
33029738|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
33029739|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
33029740|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
33029741|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
33029742|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
33029743|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
33029744|NCT01942447|Experimental|FMT|FMT
33029745|NCT01942447|Active Comparator|Standard|Vancomycin
33029746|NCT01942460|Experimental|Ferumoxytol|
33029747|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
33029748|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
33029749|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
33029750|NCT01942499|No Intervention|Usual Care|
33029751|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
33029752|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
33029753|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
33029754|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
33029755|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
33029756|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
33029757|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
33029758|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
33029759|NCT01942551|Experimental|tadalafil, dutasteride|
33029760|NCT01942551|Experimental|dutasteride, tadalafil|
33029761|NCT01942564||Case Subjects|"Age 18 years or older~Had a head injury that occurred at least 6 months prior to entering study~Have found lights more bothersome since injury"
33029762|NCT01942564||Control Subjects|"Age 18 years or older~Have not had a previous head injury~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
33029763|NCT01942577|No Intervention|No treatment|
33029764|NCT01942577|Active Comparator|NoSting|
33029765|NCT01942603||Observation|
33029766|NCT01942603||Complete Lymfnode Dissection|
33029767|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.~Condition 1 is a Perpetrator Positive scenario.~The content of the Condition 1 group is as follows:~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
33029768|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.~Condition 2 is a Perpetrator Negative scenario.~The content of the Condition 2 group is as follows:~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
33029769|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.~The content of the Condition 3 group is as follows:~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
33029770|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
33029771|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
33029772|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
33029773|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
33029774|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
33029775|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
33029776|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
33029777|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
33029778|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
33029779|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
33029780|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
33029781|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
33029782|NCT01942759||Oestrogen receptor status|Negative Positive
33029783|NCT01942759||Progesterone receptor status|Negative Positive
33029784|NCT01942759||HER-2 neu status|Negative Positive
33029785|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
33029786|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
33029787|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
33029788|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
33029789|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
33029790|NCT01942824|Experimental|Intervention|Text Message
33029791|NCT01942824|No Intervention|Usual Care|
33327304|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
32866640|NCT04826016|Experimental|PHASE 2 - ARM B: POL6326 (balixafortide) + nab-paclitaxel|MTD/RDP2 POL6326 (balixafortide) (from arm B phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 100 mg/m2 nab-paclitaxel over 30 min Intravenous infusion on days 1, 8 and 15 in 28-day cycles (+/- 1 day).
33029792|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
33029793|NCT01942863|Experimental|water exchange single balloon enteroscopy|
33029794|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
33029795|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
33029796|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
33029797|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
33029798|NCT01942889|Placebo Comparator|Placebo|Placebo
33029799|NCT01942902|Experimental|Continuous Glucose Monitoring System|
33029800|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
33029801|NCT01942928|Active Comparator|Usual NHS care|
33029802|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
33029803|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
33029804|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
33029805|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
33029806|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
33029807|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
33029808|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
33029809|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate~Twice daily"
33029810|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance~Twice daily"
33029811|NCT01943019|Experimental|Linagliptin|Linagliptin daily
33029812|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
33029813|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
33029814|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
33029815|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
33029816|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
33029817|NCT01943045|Placebo Comparator|Placebo|Placebo
33029818|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
33029819|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
33029820|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
33029821|NCT01943071|No Intervention|Care as usual|Care as usual
33029822|NCT01943084|Experimental|Norditropin®|
33029823|NCT01943084|Active Comparator|Genotropin®|
33029824|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
33029825|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
33029826|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
33029827|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
33029828|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
33029829|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
33029830|NCT01943175||Genetic High Risk|
33029831|NCT01943175||Healthy Control|
33029832|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
33029833|NCT01943201|Experimental|new bedsheet|new bedsheet
33029834|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
33029835|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
33029836|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
33029837|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
33029838|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
33029839|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
33029840|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
33417103|NCT04949789|Other|IP I|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
33417104|NCT04949789|Other|IP II|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
33029841|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
33029842|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
33029843|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
33029844|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
33029845|NCT01943331||patients admitted to ICU|
33029846|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
33029847|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
33029848|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
33029849|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
33029850|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
33029851|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
33029852|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
33029853|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
33029854|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
33029855|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
33029856|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
33029857|NCT01943487|Experimental|1: verapamil + EC905|
32902378|NCT03143270|Experimental|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
33029858|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
33029859|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
33029860|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
33029861|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
33029862|NCT01943604|Experimental|Experimental|"Nutella Breakfast~Waffle Breakfast"
33029863|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
33029864|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
33029865|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
33029866|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
33029867|NCT01943643|Experimental|CT angiography, coronary bifurcations|
33029868|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
33029869|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
33029870|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
33029871|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
33029872|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
33029873|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
32902379|NCT03143270|Experimental|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
33029874|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
33029875|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
33029876|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
33029877|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
33029878|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
33029879|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
33029880|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
33029881|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
33029882|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
33029883|NCT01943877|Experimental|Propolis|
33029884|NCT01943877|Sham Comparator|scaling and root planing|
33029885|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
33029886|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
33029887|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
33029888|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
33029889|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
33029890|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
33029891|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
33029892|NCT01943981||Optimal/inappropriate exercise response|
33029893|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
33029894|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
33029895|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
33029896|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
33029897|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
33029898|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
33029899|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
33029900|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
33029901|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
33029902|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
33029903|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
33029904|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
33029905|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
33029906|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
33029907|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
33029908|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
33029909|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
33029910|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
33029911|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
33029912|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
33029913|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
33029914|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
33029915|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
33029916|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
33029917|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
33029918|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
33029919|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
33029920|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
33029921|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
33029922|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
33029923|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
33029924|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
33029925|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
33029926|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
33029927|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
33029928|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
33029929|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
33029930|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
33029931|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
33029932|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
33029933|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
33029934|NCT01944280|No Intervention|control|usual care
33029935|NCT01944306||Low birth-weight, obese|
33029936|NCT01944306||Low birth-weight, normal body weight|
33029937|NCT01944306||Normal birth-weight, obese|
33029938|NCT01944306||Normal birth-weight, normal body weight|
33029939|NCT01944358||Taiwan AIDS study group|
33029940|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
33029941|NCT01944384|No Intervention|without aldactone|
33029942|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
33029943|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
33029944|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:~Must be taking a stable parkinsonian medication~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.~Response to cholinesterase inhibitor over a period of six months will be monitored."
33029945|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.~Response to cholinesterase inhibitor over a period of six months will be monitored."
33029946|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
33029947|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
33029948|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
33029949|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
33029950|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
33029951|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
33029952|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
33029953|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
33029954|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
33029955|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
33029956|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
33029957|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
33029958|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
33029959|NCT01944553|Experimental|prospective|Single Arm
33029960|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
33029961|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
33029962|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
33029963|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
33029964|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
33029965|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
33029966|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
33029967|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
33029968|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
33029969|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
33029970|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
33029971|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
33029972|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
33029973|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
33029974|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
33029975|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
33029976|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
33029977|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
33029978|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
33029979|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
33029980|NCT01944826||Tako-Tsubo And Cancer Registry|
33029981|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
33029982|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
33029983|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
33029984|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
33029985|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
33029986|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
33029987|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
33029988|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
33029989|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
33029990|NCT01944995|Experimental|group B|
33029991|NCT01944995|Experimental|group A|
33029992|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
33029993|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
33029994|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
33029995|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
33029996|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) using DiAs Platform|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
33029997|NCT01945060|Placebo Comparator|DiAs Control-to-Range System not informed for heart rate|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
33029998|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
33029999|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
33030000|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
33030001|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
33030002|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
33030003|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
33030004|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
33030005|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
33030006|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
33030007|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
33030008|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
33030009|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
33030010|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
33030011|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years."
33030012|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
33030013|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
33030014|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
33030015|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
33030016|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
33030017|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital~Patients who have received HD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
33030018|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
33030019|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
33030020|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
33030021|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
33030022|NCT01945346|Experimental|PRX167700|
33030023|NCT01945346|Placebo Comparator|Placebo|
33030024|NCT01945359||Relapsing Remitting MS (RRMS)|
33030025|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
33030026|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
33030027|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
33030028|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
33030029|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
33326664|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
33030030|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
33030031|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
33326665|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
33326666|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
33326667|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
33326668|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
33030032|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
33030033|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
33030034|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
33030035|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
33030036|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
33030037|NCT01945450|No Intervention|No treatment|No antibiotics
33030038|NCT01945476|Experimental|midazolam|midazolam group
33030039|NCT01945476|Active Comparator|normal saline|control group
33030040|NCT01945502||nasal packing with dry packs|
33030041|NCT01945502||nasal packing with wet packs|
33030042|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
33030043|NCT01945502||no nasal packing|
33030044|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
33030045|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
33030046|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
33030047|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
33030048|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
33030049|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
33030050|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
33030051|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
33030052|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
33030053|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
33030054|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
33030055|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
33030056|NCT01945632|No Intervention|no treatment|Control group with no treatment.
33030057|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
33030058|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
33030059|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
33030060|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
33030061|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
33030062|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
33030063|NCT01945697||normal oral mucosa|
33030064|NCT01945697||oral precancerous lesion or oral cancer|
33030065|NCT01945723||Healthy volunteers|Healthy volunteers
33030066|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
33030067|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
33030068|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
33030069|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
33030070|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
33030071|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
33030072|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
33030073|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
33030074|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
33030075|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
33030076|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
33030077|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
33030078|NCT05411016|Placebo Comparator|Placebo|
33030079|NCT05411016|Experimental|KK4277|
33030080|NCT05410990||mortality, MACE (+)|patients with all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
33030081|NCT05410990||mortality, MACE (-)|patients without all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
33030082|NCT05410834||Individuals with polycystic ovarian syndrome|Individuals with a documented diagnosis of polycystic ovarian syndrome
33030083|NCT05410834||Individuals without polycystic ovarian syndrome|Individuals without a known diagnosis of polycystic ovarian syndrome but with regular menstrual cycles
33030084|NCT05410782|Experimental|Power Prenatal for Sperm|This is a single arm study. Participants will take supplements for 3 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)
33030085|NCT05410769|Experimental|PD patients|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
33030086|NCT05410769|Experimental|patient's caregivers|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
33030087|NCT05410717|Experimental|CAR-NK cell therapy group|Appropriate patients who could benefit from the claudin6 targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell therapy group.
33030088|NCT05410704|Experimental|Study Group|Pelvic floor muscle exercises and diaphragmatic breathing exercises will be performed 3 times a week for 12 weeks. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
33030089|NCT05410704|No Intervention|Control Group|No intervention. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
33030090|NCT05410691|No Intervention|Conventional|AVF/AVG cannulation by renal nurses in standardised manner
33030091|NCT05410691|Active Comparator|ultrasound guided|AVF/AVG cannulation by renal nurses by handheld US device
33030092|NCT05410678|Experimental|renal stent group|Acute coronary patients treatment with renal stent
33030093|NCT05410678|Active Comparator|BMCS group|Acute coronary patients treatment with bare-metal stent
33030094|NCT05410665||Sepsis group|Adult septic patients admitted into the intensive care unit (ICU) of Nanjing First Hospital. The diagnostic criteria for sepsis were in accordance with the surviving sepsis guidelines.
33030095|NCT05410665||Control group|Baseline data (including age, sex, body-mass index, disease severity scores) matched adult non-septic critical patients in our ICU.
33030096|NCT05410652||Fecal kit group|Collect stool samples from patients who meet the inclusion criteria. DNA was extracted from fecal samples. After that, the extracted DNA was sequenced by first generation sequencing. Finally，the mutation sites of extracted DNA were detected by fecal gene detection kit.
33030097|NCT05410652||13 C-urea breath test|Patients who meet all the admission and discharge criteria will undergo 13 C-urea breath test.
33030098|NCT05410652||Drug sensitivity test group|Gastroscopy was performed on patients who met the inclusion and exclusion criteria to obtain samples of gastric mucosa. Helicobacter pylori culture and drug sensitivity test were performed on gastric mucosa samples in vitro. Finally, the drug sensitivity test results were collected.
33030099|NCT05410639|Experimental|Study group|Parents of premature infants in the experimental group received online education consist of information to support infants motor,social-communication development.and to manage the parents stress.
33030100|NCT05410639|Placebo Comparator|Control group|The parents of premature babies in the control group did not receive any education programs
33030101|NCT05410626|Experimental|original|This study use 18 and 36 mg of original prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
33030102|NCT05410626|Active Comparator|generic|This study use 18 and 36 mg of generic prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
33030103|NCT05410613|Experimental|combined electromagnetic field and a plantar resistance|
33030104|NCT05410613|Experimental|electromagnetic field|
33030105|NCT05410613|Active Comparator|conservative treatment for the ulcer|
33030106|NCT05410535|Experimental|Patients who received UDCA 600mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 600mg
33030107|NCT05410535|Experimental|Patients who received UDCA 300mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 300mg
33030108|NCT05410535|Placebo Comparator|Patients who received Placebo|Patients who participated in PEGASUS-D clinical trial and received Placebo
33030109|NCT05410522|Experimental|Experimental lung transplant|The training time will be 30 minutes in the morning and 30 minutes in the afternoon with a total daily work time of 60 minutes. The frequency of work will be different in each session, seeking in the morning routine a vascularization and improvement of muscle trophism and in the afternoon an aerobic endurance, activation of the working capacity of the tonic muscles to improve the stabilizing muscles and postural fitness.
33030110|NCT05410522|No Intervention|Control lung transplant|Electro stimulation therapy will not be performed.
33030111|NCT05410483|Experimental|Docetaxel dose level|Initial dose of 60mg/m2 and increase the remaining dose gradient by 5 mg/m2
33030112|NCT05410470||MF patients who received ruxolitinib treatment|
33030113|NCT05410457||thrombolysis group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 4.5 hours; D) received intravenous thrombolysis; E) signed informed consent.
33030114|NCT05410457||thrombectomy group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 24 hours; D) vascular assessment by CTA or multimodal MRI; E) received thrombectomy; F) signed informed consent.
33030115|NCT05410457||stent group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) vascular assessment by CTA or multimodal MRI; D) received stent implantation ; E) Signed informed consent.
33030116|NCT05410457||regular treatment group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) received regular medical treatment; D) signed informed consent.
33030117|NCT05410457||young stroke group|Inclusion criteria: a) age between 18 and 50 years of age (45/55Y); B) hospital admission due to ischemic stroke; C) received CT or MRI imaging assessment; D) signed informed consent.
33030118|NCT05410457||unexplained stroke group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) Received CT or MRI imaging assessment; D)TOAST was classified as unknown cause type (including two or more causes and no cause was found by auxiliary examination); E) signed informed consent.
33030119|NCT05410444|Active Comparator|The control group|The control group received routine indwelling catheterization, the catheter was continuously opened, and the indwelling catheter was replaced every 7 days. When the bladder function returned to normal, the catheter was removed.
33030120|NCT05410444|Experimental|The study group|The observation group, namely intermittent catheterization group, was given one-to-one training and education to patients and their families before the implementation of the project. Frequency and timing of intermittent catheterization: it is recommended to catheterize once every 4 hours and no more than 6 times every 24 hours. If the residual urine volume decreases, the number of catheterization can be appropriately reduced; Before each catheterization, urinate by yourself. The derived urine volume is the residual urine volume. The total amount of urine shall not exceed the safe capacity of the bladder.
33030121|NCT05410405|Experimental|8 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
33030122|NCT05410405|Experimental|10 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
33030123|NCT05410340|Active Comparator|Preterm group 1|To analize the brain activation and oxigenation using the Vojta Therapy
33030124|NCT05410340|Active Comparator|Preterm Group 2|To analize the brain activation and oxigenation using massotherapy
33030125|NCT05410340|Placebo Comparator|Term group 1|To analize the brain activation and oxigenation using the Vojta Therapy
33030126|NCT05410340|Placebo Comparator|Term group 2|To analize the brain activation and oxigenation using massotherapy
33030127|NCT05410314||cHL (85%) and DLBCL (15%)|Patients enrolled in this study are cHL (85%) and DLBCL (15%) long-term survivors, treated mainly with ABVD+ radiotherapy (not under diaphragmatic and pelvic irradiation), without relapse (during quinquennial follow-up) who are followed at the clinic dedicated to fertility in oncology of our Department, which is a regional referral center for this purpose. Therefore, the investigators conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with MIC for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months
33030128|NCT05410275|Experimental|Rivaroxaban|"Rivaroxaban 5 mg daily, administered orally, during 3 consecutive days. After a wash-out period of 4 days, Rivaroxaban 10 mg daily, administered orally, during 3 consecutive days.~After a wash-out period of 4 days, Rivaroxaban 15 mg daily, administered orally, during 3 consecutive days."
33030129|NCT05410210|Experimental|Pharmaceutical care|The intervention group will receive the pharmaceutical care from a pharmacist and the existing standard care available in the Parkinson's disease and movement disorders clinic.
33030130|NCT05410210|No Intervention|Usual care|The usual care includes the current existing care provided to patients in the Parkinson's disease and movement disorders clinic except the pharmaceutical care provided by pharmacists.
33030131|NCT05410119|Experimental|Resilience group|
33030132|NCT05410119|Active Comparator|Controlled group|
33030133|NCT05410093|Experimental|Patients who taking Resveratrol|Take RES (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
33030134|NCT05410093|Active Comparator|Patients who taking VitE|Take vitamin E at a dose of 100 mg per day for three months
33030135|NCT05410067|Experimental|Cervicothoracic Junction Mobilization Technique|"It is a part of manual therapy technique. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given.For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7.~Dosage:~Glide would be given according to the nature, intensity and severity of the patient's pain. 30 sec bouts with 3 sets &amp; 2 reps. Total 2-3 min duration. 2 sessions per week for 3 weeks."
33030136|NCT05410067|Experimental|Eccentric Muscle Energy Technique|"Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.~Dosage:~The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. This is applied for generalized cervical movements in each plane like Flexion, Extension, Side Bending~&amp; Rotation. 3-5 repetitions with 2-3 sets were performed. Total duration: 3-5 min 2 sessions per week for 3 weeks."
33030137|NCT05410041|Experimental|CAR-NK-CD19 Cells|After preconditioning with chemotherapy, CAR-NK-CD19 Cells will be evaluated.
33030138|NCT05409950|Active Comparator|Study group: implants were inserted using socket shield technique at the esthetic zone|
33030139|NCT05409950|No Intervention|Control group: implants were inserted using conventional immediate technique|
33030140|NCT05409924|Experimental|Phase A|ATR-258 Single Ascending Dose or placebo
33030141|NCT05409924|Experimental|Phase B|ATR-258 Multiple Ascending Dose or placebo
33030142|NCT05409924|Experimental|Phase C|ATR-258 Repeated dosing or placebo
33030143|NCT05409755|Active Comparator|Fractional microneedling radiofrequency|Device
33030144|NCT05409755|Active Comparator|Fractional microneedling radiofrequency followed by minoxidil application|Device and drug
33030145|NCT05409755|Active Comparator|Minoxidil|Topical drug
33030146|NCT05409742|Active Comparator|Modified Hall technique|
33030147|NCT05409742|Experimental|Hall Technique|
33030148|NCT05409703|Experimental|The Effect of Reiki on Executive Nurses on Psychological Empowerment, Happiness|Reiki application will take 45 minutes.
33030149|NCT05409703|No Intervention|The Effect of Reiki on Executive Nurses on Emotion Management and Work Engagement|No treatment was applied to the patients in the control group other than their routine care.
33030150|NCT05409677||1-month survivors; 1-month non-survivors|Depending on mortality within 1 month, the patients were divided into two groups named 1-month survivors and 1-month non-survivors.There was no intervention other than normal treatment
33030151|NCT05409638|Experimental|CBT intervention for cancer-related fatigue|Participants will receive 4 weekly sessions consisting of psycho-education around fatigue, pacing, journaling fatigue, relaxation training, CBT, and evidence-based tips to increase physical activity.
33030152|NCT05409638|No Intervention|Wait-list control group|Participants assigned to this arm wait about 3-months to receive the intervention.
33030153|NCT05409625|Experimental|Young adults|Participants aged between 18 and 30 years old without chronic diseases but with two caries lesions or more
33030154|NCT05409586||no recurrence|Patients who recovered after IGM treatment and had no signs of relapse
33030155|NCT05409586||recurrence|Patients whose symptoms reappear 3 months after IGM treatment
33030156|NCT05409560||Cold water swimmers|swimmers participating in the 6-hour cold water swim, qualifying for the English Channel Swim
33030157|NCT05409521|Experimental|Tape Group|Kinesio taping will be applied on thoracic region
33030158|NCT05409521|Placebo Comparator|Placebo Group|Placebo taping will be applied on arm region
33030159|NCT05409495|Experimental|The control group treated with open flap debridement (OFD)|The control group periodontal intrabony defects were treated with open flap debridement (OFD) only.
33030160|NCT05409495|Experimental|The test group treated with OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF)|The test group periodontal intrabony defects were treated with open flap debridement (OFD) with autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF) combined.
33030161|NCT05409469||Chinese patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in China.
33030162|NCT05409469||American patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in the United States.
33030163|NCT05409417|Experimental|Tislelizumab Combined With chemotherapy|Tislelizumab Combined With XELOX and Bevacizumab or Tislelizumab Combined With FOLFOX and Cetuximab
33030164|NCT05409352|Experimental|Self-administered acupressure|The entire intervention will last 12 weeks, including a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained traditional Chinese medicine practitioner. Participants will be instructed to perform self-acupressure on the acupoints according to individualized protocol once a day. Participants will be instructed to maintain self-practice after the intervention.
33030165|NCT05409352|Active Comparator|Aerobic exercise|The 12-week aerobic exercise program consists of a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained exercise specialist. Participants will be advised to perform aerobic exercise of moderate intensity 3 times per week for 30 minutes each time. Accumulating 90 min of exercise per week through more frequent short bouts (e.g. 10-20 min daily) are allowed during the first week of each chemotherapy cycle due to increased symptom burden. Participants will be instructed to maintain self-practice after the intervention.
33030166|NCT05409339|Experimental|"Caffeine-Caffeine (Condition Caffeine)"|Through the 9-day pre-ambulatory, 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg caffeine x 3 times daily.
33030167|NCT05409339|Experimental|"Caffeine-Placebo (Condition Withdrawal)"|During the 9-day ambulatory part, participants received 150 mg caffeine x 3 times daily, followed by a switch to placebo (150 mg mannitol) from the 2nd intake of the 9th day onward, through the laboratory and the post-ambulatory parts.
33030168|NCT05409339|Placebo Comparator|"Placebo (Condition Placebo)"|Through the 9-day ambulatory and 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg mannitol x 3 times daily.
33030169|NCT05409326|Experimental|TQH2722 injection|Participants will receive single dose of TQH2722 injection under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of TQH2722 injection once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
33030170|NCT05409326|Placebo Comparator|Placebo to match TQH2722|Participants will receive single dose of matching placebo under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of matching placebo once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
33030171|NCT05409313|Experimental|EBP and SDM training group|A total of 36 nurses will be received EBP and SDM training program.
33030172|NCT05409313|Active Comparator|SDM training group|A total of 36 nurses will be received SDM training alone.
33030173|NCT05409274||Pregnant women|Pregnant women enrolled across 5 country study sites at any point during pregnancy, up to and including the day of delivery.
33030174|NCT05409261|Experimental|Ad26.COV2.S|Single dose (0.5mL) of SARS-CoV-2 vaccine Ad26.COV2.S.
33030175|NCT05409261|Experimental|NVX-CoV2373|Two doses (0.5mL) of SARS-CoV-2 vaccine NVX-CoV2373, the second dose administered 21 (+/-2 days) days after the first dose.
33030176|NCT05409248|Experimental|Experimental Group|Online games designed to target specific cognitive skills such as attention, perception, or inhibition). Activities' difficulty will be automatically adjusted accordingly to each participant's performance, always demanding a maximum cognitive effort.
33030177|NCT05409248|Active Comparator|Control Group|Online painting and artistic games designed not to target the specific cognitive skills at test. Activities' duration will match those of the experimental group, and its difficulty will be constant through the intervention.
33030178|NCT05409222||Cohort 1A: preventive salpingo-oophorectomy with hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and opt to have hormone replacement therapy
33030179|NCT05409222||Cohort 1B: preventive salpingo-oophorectomy without hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and reject hormone replacement therapy
33030180|NCT05409222||Cohort 2: without preventive salpingo-oophorectomy|Healthy carriers who decide not to proceed to preventive surgery
33030181|NCT05409209||Carotid plaque length|Patients underwent carotid ultrasonography and first coronary angiography simultaneously
33030182|NCT05409196|Experimental|ShigETEC vaccine|"In Stage 1 subjects will be allocated randomly to one of four study cohorts to receive a single oral dose of one of four escalating dose levels of ShigETEC vaccine (ShigETEC 1x10^9 CFU, ShigETEC 1x10^10 CFU, ShigETEC 5x10^10 CFU, ShigETEC 2x10^11 CFU). 8 subjects per dose group will be administered.~Subjects in Stage 2 will be enrolled sequentially by group and allocated randomly to one of three study cohorts determined from Stage 1 to receive either two, three or four doses of the 5x10^10 ShigETEC vaccine at 3-day interval. 8 subjects per dose group will be administered."
33030183|NCT05409196|Placebo Comparator|Placebo|"In Stage 1: 4 subjects in each dose group will receive a single oral dose of placebo~In Stage 2: 4 subjects in each cohort will either receive 2, 3 or 4 doses of placebo at 3-day intervals."
33030184|NCT05409170||pre-covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
33030185|NCT05409170||covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
33030186|NCT05409144|Experimental|Thoracic epidural infusion group|Patients will receive thoracic epidural preoperative
33030187|NCT05409144|Experimental|Erector Spinae Plane Block group|Patients will receive Ultrasound-guided Erector Spinae Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25% and insertion of a catheter
33030188|NCT05409144|Experimental|Serratus Anterior Plane Block group|Patients will receive Ultrasound-guided Serratus Anterior Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25%.
33030189|NCT05409092|Experimental|Astaxanthin|The astaxanthin capsules will contain 8 mg of astaxanthin from freshwater algae in starch beadlets. Ingested daily for 4 weeks.
33030190|NCT05409092|Placebo Comparator|Placebo|The placebo capsules will contain just the starch beadlets with natural red coloring from the pitaya fruit. Ingested daily for 4 weeks.
33030191|NCT05409053|Active Comparator|screw fixation|lateral condyle humerus fracture open reduction and internal fixation by canullated screws
33030192|NCT05409053|Active Comparator|k wire fixation|lateral condyle humerus fracture open reduction and internal fixation by K wire
33030193|NCT05409053|Other|Conservative management|Undisplaced fractured treated conservatively by above elbow slab
33030194|NCT05409053|Other|Closed reduction and percutaneous pinning|Undisplaced fractured treated closed reduction and percutaneous pinning
33326669|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
33326670|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
33030198|NCT05407272|Experimental|Shared mode intervention group (experimental group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
33030199|NCT05407272|Active Comparator|home care routine care group (control group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
33030200|NCT05405335|Experimental|Prone Positioned Group|"Intermittent prone positioning for a total of eight hours per day for seven days. Each cycle of prone positioning should not be less than 30 minutes and note more than 3 hours at one time.~Rest of the treatment as per protocols of the institution"
33030201|NCT05405335|No Intervention|Control Group|Treatment as per institutional protocols- the protocols does not involve prone positioning of the patients
33030202|NCT05403879|Experimental|cases undergoing fixation of fractured greater tuberosity|
33030203|NCT05403177||MOHCCN-O|Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.
33030204|NCT05398952||Long-COVID|Patients with previous COVID-19 disease, and having long COVID symptoms 3 months after the active infection.
33030205|NCT05398952||Post-COVID-19 without long-COVID syndrome|Patients with previous COVID-19 disease, without long COVID symptoms
33030206|NCT05398952||IcMP (positive control)|Patients with ischemic heart disease without COVID-19 disease, and vaccinated at least with one injection
33030207|NCT05398952||Healthy (negative control)|Healthy individuals without COVID-19 disease, and vaccinated at least with one injection
33030208|NCT05397054|Experimental|Investigator|Education, Reformulation, Environmental change, Used salt meter
33030209|NCT05397054|Active Comparator|Control|standard treatment with standard education
33030210|NCT05395897||New users|Users without any reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
33417105|NCT04949789|Other|IP III|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
33417106|NCT05191771|Experimental|Investigational product|
33030211|NCT05395897||Actual or former users|Users without at least one reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
33030212|NCT05393973|Experimental|Core stability exercises along with conventional physical therapy|Core stability exercises
33030213|NCT05393973|Experimental|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercises
33030214|NCT05391256|Experimental|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally six drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating referral of bystanders during 112-calls to retrieve drone delivered AEDs in suspected OHCA.
33030215|NCT05387278|Experimental|Experimental/treatment arm|
33030216|NCT05387278|Placebo Comparator|Placebo|
33030217|NCT05387239|Experimental|Experimental/treatment arm|
33030218|NCT05387239|Placebo Comparator|Placebo|
33030219|NCT05357924|Active Comparator|robotic-assisted laparoscopy|The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms.
33030220|NCT05357924|Active Comparator|conventional laparoscopy|Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery.
33030221|NCT05356520|Experimental|The experimental group|Endoscopic ivor-Lewis operation was performed for siwert type II adenoma at the esophagogastric junction
33030222|NCT05356520|Active Comparator|The control group|Laparoscopic transabdominal enlarged gastrectomy for siwert TYPE II adenoma at the esophagogastric junction was performed
33030223|NCT05350566|Experimental|Sprint interval training group (SIT group)|The model of sprint interval training (SIT) consists of six 30 s all-out cycling bouts on a cycle ergometer, with 4 min rests between tests.
33030224|NCT05350566|Experimental|Moderate intensity continuous training (MICT group)|The moderate intensity continuous training (MICT) consists of 1h cycling on a cycle ergometer at 50% of the maximal aerobic power output
33030225|NCT05336500|Experimental|Pilates method exercises associated with education to keep the abdomen relaxed|The group will receive guidance to perform the exercises in a relaxed and smooth way
33030226|NCT05336500|Active Comparator|Pilates method exercises associated with education to keep the abdomen contracted|The group will receive guidance on the specific activation of the center of strength (the powerhouse)
33030227|NCT05334550|Experimental|Intervention group|Allocated to intervention group through randomization process.
33030228|NCT05334550|No Intervention|Control group|Allocated to control group through randomization process.
33030229|NCT05329376|Experimental|Group A|Three months of daily interactions with a voice command virtual interaction system
33030230|NCT05329376|Other|Group B|Three months of maintenance of usual care
33030231|NCT05326919||Acute myeloid Leukemia (AML)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
33030232|NCT05326919||Acute lymphoblastic leukemia (ALL)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
33030233|NCT05326919||High-risk myelodysplastic syndrome (MDS)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
33030234|NCT05326919||Myeloproliferative neoplasm -related myelofibrosis|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
33030235|NCT05307250|Experimental|Treatment Arm 1|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
33030236|NCT05307250|Experimental|Treatment Arm 2|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)
33030237|NCT05307250|Other|Control Arm|Bolstered Standard of Care (BSOC)
33417107|NCT05191771|Active Comparator|Comparator|
33417108|NCT02073734|Experimental|Dexamethasone|Dexamethasone
33417109|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
33417110|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
33417111|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
33417112|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks~Ivabradine is taken orally twice daily~Dosage will be adjusted according to physician determination"
33030238|NCT05286502||Adults 18 years old or older|
33030239|NCT05281302|No Intervention|Control patients|Patient receiving no additional treatment to conventional occupational therapy sessions
33030240|NCT05281302|Experimental|left-NMV|"Patient will be equipped with vibratory stimulators during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
33030241|NCT05281302|Sham Comparator|left-NMV + sham-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes form sham-tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
33030242|NCT05281302|Experimental|left-NMV + anodal-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes for tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
33030243|NCT05273567|Experimental|Guanfacine-ER|Participants will start on guanfacine-ER 1mg nightly for 1-week (week 1) and slowly increase by 1mg/per week to a max dose of 4mg per day or maximum dose as tolerated. Medication taper to discontinuation will begin in week 11 and continue into week 12 until complete by end of study, decreasing the dose by 1mg every 4 days until stopped.
33030244|NCT05273567|Placebo Comparator|Placebo|Placebo will be taken nightly and titrated and tapered similar to the active arm.
33030245|NCT05262010|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
33030246|NCT05262010|Placebo Comparator|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
33030247|NCT05189340|No Intervention|Standard of Care|Patients in the Standard of Care arm will receive pharmacist discharge education via fully in-person education as is currently being done.
33030248|NCT05189340|Experimental|Intervention|Patients in the Intervention arm will have access to pre-recorded educational videos covering key educational points. Patients will also have in-person interaction with pharmacists to address additional questions not covered in the videos.
33030251|NCT05181228|Experimental|Intervention Group (Web-based family-centered empowerment program intervention)|Intervention group participants will receive the web-based family-centered empowerment intervention for 10 weeks.
33030252|NCT05181228|No Intervention|Control Group|No intervention was applied to the control group.
33030253|NCT05165082|Experimental|Timolol plus cryotherapy|Apply topical timolol solution twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen every other week (at the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
33030254|NCT05165082|Placebo Comparator|Placebo plus cryotherapy|Apply placebo (normal saline) twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen every other week (at the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
33030255|NCT05155527|Experimental|Favipiravir plus Ivermectin|Ivermectin 600 mcg/kg once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
33030256|NCT05155527|Placebo Comparator|Favipiravir plus Placebo|Matching placebo once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
33030257|NCT05151146|Experimental|ANJ900 in the fasted state|Single dose (1800 mg) of ANJ900
33030258|NCT05151146|Experimental|ANJ900 in the fed state|Single dose (1800 mg) of ANJ900
33030259|NCT05151146|Active Comparator|Metformin IR in the fasted state|Single dose (1000 mg) of metformin IR
33030260|NCT05094908|Active Comparator|Regime 1 (30 days)|Regimen 1: arnica tincture applied 3 times a day for 30 days (group 1). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
33030261|NCT05094908|Active Comparator|Regime 2 (45 days)|Regimen 2 arnica tincture applied 3 times a day for 45 days (group 2). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
33030262|NCT05083442|Active Comparator|Group 1 - LLLT|Subject receive Laser treatments and Lifestyle Modifications
33030263|NCT05083442|Sham Comparator|Group 2 - SHAM|Subject receives Sham Laser treatments and Lifestyle Modifications
33030264|NCT05068063|Experimental|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
33030265|NCT05068063|Active Comparator|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
33030266|NCT05049707|Placebo Comparator|Control|The control arm will receive an equivalent volume of normal saline as the treatment group
33030267|NCT05049707|Experimental|IV magnesium|We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.
33030268|NCT05047224|Experimental|Tele-assessment + in-person assessment|Participants in this group will receive a tele-assessment using the TAP and will attend a traditional, in-person evaluation for autism spectrum disorder in a clinic setting.
33030269|NCT05047224|Active Comparator|Tele-assessment only|Participants in this group will receive a tele-assessment using the TAP, followed by a second, shorter tele-assessment.
33030270|NCT05046509||COVID_Patients|"Patients have been confirmed diagnosed with Covid-19 disease by PCR~Patients aged 18 years and above"
33030271|NCT05041166|Experimental|Protocol optimization cohort|Following the [13C]pyruvate injection, dynamic imaging and 3D volumetric imaging of volunteers in the first cohort (HP MRI protocol optimization, Aim 1) will be performed on the 3-T MRI scanner, using different [13C] RF excitation/detection coils.
33030272|NCT05041166|Experimental|Tissue reference cohort|The optimal setup will then be used for HP MRI of the second cohort.
33030273|NCT05002452||Locally Advanced HCC Patients|Patients which are diagnosed with locally advanced hepatocellular carcinoma (HCC) will receive standard HAIC treatment.
33030274|NCT04977622||Primary Progressive MS (PPMS)|Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
33030275|NCT04977622||Non-neurological controls (HC)|Age and sex matched to the PPMS patients
33030276|NCT04967378|Experimental|HEPPI program|
33030277|NCT04967378|No Intervention|Waiting-list control group|Receives access to HEPPI program at the end of the study.
33030278|NCT04948996|Experimental|El Buen Consejo Móvil- Group (EBCM-G)|Participants in the group condition will be placed in groups of five participants within the app. Their version of EBCM will have the functionality to connect individuals to one another via a facilitator-guided chat room (EBCM-G), where they can respond to suggested strategies within the app and communicate with each other or their facilitator guide using voice or text.
33030279|NCT04948996|Active Comparator|El Buen Consejo Móvil- Individual (EBCM-I)|Participants randomized to EBCM-I will receive the same program contents without the group functionality.
33030280|NCT04946396|Experimental|dexmedetomidine intravenous infusion|Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
33030281|NCT04946396|Sham Comparator|0.9% saline solution intravenous infusion|Patients who will receive continuous infusion of 0.9% saline solution (sham group).
33030282|NCT04938895|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
33030283|NCT04938895|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson attire.
33030284|NCT04938895|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
33030285|NCT04938895|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
33030286|NCT04938895|Experimental|Black Woman Investigator|Survey respondents are exposed to a Black woman investigator.
33030287|NCT04938895|Experimental|Black Man Investigator|Survey respondents are exposed to a Black man investigator.
33030288|NCT04938895|Experimental|White Woman Investigator|Survey respondents are exposed to a white woman investigator.
33030289|NCT04938895|Experimental|White Man Investigator|Survey respondents are exposed to a white man investigator.
33030290|NCT04935437|Active Comparator|Intervention|The patients in this arm will be enrolled in a 2 months supervised rehabilitation program. Evaluation will take place at recruitment time and at the end of the program (2 months).
33030291|NCT04935437|No Intervention|Control|The patients in this arm will not be enrolled in a supervised rehabilitation program. Evaluation will take place at recruitment and at 2 months.
33030292|NCT04908657|Experimental|Treatment group|treatment group will administrate oral sildenafil 20 mg three times per day for 3 years
33030293|NCT04908657|No Intervention|Control group|the control group will not receive any specific therapy for decreasing the pulmonary vascular resistance
33030294|NCT04896814|Experimental|Transcutaneous tibial nerve stimulation|The participant will receive an intervention session per week that will be held for a period of 12 weeks. The total application time will be 30 minutes. A symmetrical biphasic current will be applied, with a frequency of 20 Hz in continuous mode and a pulsed frequency of 200 µs.
33030295|NCT04896814|Placebo Comparator|Placebo|The participant will receive one intervention session per week will be performed during a 12 weeks period time. The total application time will be 30 minutes. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied in other localization.
33030296|NCT04887389|Experimental|Group of • Nano Silver Fluoride varnish ( NSF)|"Selected children will be divided randomly into three groups:~Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =50)."
33030297|NCT04887389|Experimental|group of Nano hydroxyapatite varnish (n-HAP)|Group 2 Children receiving Nano-hydroxyapatite varnish (n = 50)
33030298|NCT04887389|Experimental|group of Sodium Fluoride Varnish (NaF)|Group 3: Children receiving Sodium Fluoride Varnish (n = 50)
33030299|NCT04837573|Experimental|Group 1 Intervention, Weeks 1-8|During Weeks 1-8, Group 1 receives the Intervention and Group 2 receives no treatment.
33030300|NCT04837573|Active Comparator|Group 2 Intervention, Weeks 9-16|During Weeks 9-16, Group 2 receives the Intervention and Group 1 receives no treatment.
33030301|NCT04836325|Experimental|Experimental: transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
33030302|NCT04836325|Sham Comparator|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
33030303|NCT04831125||Individuals receiving conduction system pacing|
33030304|NCT04818593|Experimental|ZyMot Separation|Treatment
33030305|NCT04818593|Active Comparator|Density Gradient Centrifugation|Control
33030306|NCT04816734|Experimental|Parents|Parents of children in need of home parenteral nutrition and participating in initial therapeutic education program of Necker-Enfants Malades hospital.
33030307|NCT04812028|Experimental|Prospective Experimental Group|Participants in this group will prospectively receive the intervention.
33030308|NCT04812028|No Intervention|Retrospective Review Group|Participants in this group will have their medical records retrospectively reviewed.
33030309|NCT04782752|Experimental|Experimental: Radiation|"Patients will be differentiated into 4 groups:~Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer~Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer~Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.~Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).~For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached."
33030310|NCT04780880||Youth football players|Young footballers aged 10-16 training and playing for a Polish football club.
33326671|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
33326672|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
33326673|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
33030311|NCT04773392|Active Comparator|Twice-daily Regimen|Twice-daily regimen of immediate release tacrolimus, mycophenolate mofetil (MMF)/mycophenolic acid (MPA) plus daily methylprednisolone or prednisone.
33030312|NCT04773392|Active Comparator|Once-daily Regimen|Once-daily regimen of Envarsus, azathioprine plus methylprednisolone or prednisone.
33030313|NCT04767464|Other|Compass Course|Virtual Compass Course
33030314|NCT04747808|Experimental|LL-BMT1|Group 4 extended-wear contact lens printed with bimatoprost
33030315|NCT04724655|Other|control group|gastric lavage with saline and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
33030316|NCT04724655|Active Comparator|paraffin group|gastric lavage with paraffin oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
33030317|NCT04724655|Active Comparator|coconut group|gastric lavage with coconut oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
33030318|NCT04722835||Normal RV/TLC Group:|Plethysmographic RV/TLC equal or less than lower limit of normal.
33030319|NCT04722835||Abnormal RV/TLC Group:|Plethysmographic RV/TLC higher than lower limit of normal.
33030320|NCT04684121|Experimental|Granexin gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied daily over ten days. Granexin® will be applied to one of two selected target burns."
33030321|NCT04684121|Placebo Comparator|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied daily over ten days. Vehicle will be applied to one of two selected target burns."
33030322|NCT04669743|Experimental|Study Population|Subjects will be recruited and consented following screening. Subjects will be characterized into cohorts based on presence of COPD and smoking status. All subjects enrolled will be undergoing the same interventions: 1st Bronchoscopy (3 wks pre-exposure), Ozone Exposure, 2nd Bronchoscopy (1 day post-exposure), 3rd Bronchoscopy (5 days post-exposure). Ozone exposure will take place in an exposure chamber.
33030323|NCT04655625|Experimental|Group A (AG-0302-COVID19)|
33030324|NCT04655625|Placebo Comparator|Group A (Placebo)|
33030325|NCT04655625|Experimental|Group B (AG-0302-COVID19)|
33030326|NCT04655625|Placebo Comparator|Group B (Placebo)|
33030327|NCT04647734|Experimental|High intensity interval training|The experimental group will on top of standard care undergo a 12 weeks supervised exercise high intensity interval exercise training on an ergometer bike three times a week for 38 minutes. The specific intervals will be determined from our ongoing pilot study (NCT04549337)
33030328|NCT04647734|Active Comparator|Control group|This group will be allocated to standard care and therefore no supervised exercise regimen.
33030329|NCT04629833|Experimental|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
33030330|NCT04629833|Active Comparator|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
33030331|NCT04624581|Experimental|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
33030332|NCT04624581|Sham Comparator|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
33030333|NCT04611022|Experimental|Patients Eligible for HPV Vaccine|
33030334|NCT04561115|Active Comparator|Gamunex-C|Participants will receive Gamunex-C by means of an infusion pump at an individualized dose (based on historical IVIG treatment dose) between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. The subject's usual mg/kg dose (given on either a 3 or 4 week repeating schedule) will be the same mg/kg dose and schedule that the subject was receiving prior to entering screening. This mg/kg dose and schedule will be used throughout the study duration. Note that the weight of the subject will be measured at each visit and if the subject's weight changes, the actual weight at each visit will be used to calculate amount of drug (mg) to be administered. Gamunex-C will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
33030335|NCT04561115|Experimental|IVIG-PEG|Following treatment with Gamunex-C, participants will receive IVIG-PEG by means of an infusion pump at an equivalent dose between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. IVIG-PEG will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
33030336|NCT04538053|Active Comparator|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) QID 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) TDS for a total course of 3 weeks
33030337|NCT04538053|Active Comparator|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) or IV flucloxacillin 50 mg/kg/dise (max 2 g) four-times daily (QID) for 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) three-times daily (TDS) for a total course of 3 weeks
33030338|NCT04520516|Experimental|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
33417113|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks~Placebo is taken orally twice daily~Dosage will be adjusted according to physician determination"
33417114|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
33030339|NCT04520516|Sham Comparator|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
33030340|NCT04487990|No Intervention|Control group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l.
33326674|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
33326675|NCT01265082||Patients in remission with pruritus|
33326676|NCT01265082||Patients in remission without pruritus|
33326677|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
33030341|NCT04487990|Experimental|Intervention group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l associated with unfractionated heparin at 10U / Kg / h.
33030342|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E & F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G & H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
33030343|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
33030344|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
33030345|NCT04476979|Active Comparator|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
33030346|NCT04476979|Experimental|Dexamethasone + Tocilizumab|"Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)~+Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3"
33030347|NCT04425616|Experimental|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:~Month 1: Up to three times per week~Months 2-3: Once per week~Months 4 - 6: One session per month for the last 3 months"
33030348|NCT04411953|Active Comparator|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
33030349|NCT04411953|Experimental|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
33030350|NCT04411940|Active Comparator|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
33030351|NCT04411940|Experimental|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
33030352|NCT04309734|Experimental|Part A - 60 mg AT-777 single dose|
33030353|NCT04309734|Experimental|Part A - 120 mg AT-777 single dose|
33030354|NCT04309734|Placebo Comparator|Part A - Placebo single dose|
33030355|NCT04309734|Experimental|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
33030356|NCT04294160|Experimental|Dabrafenib + LTT462 backbone arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
33030357|NCT04294160|Experimental|Dabrafenib + LTT462 + trametinib triplet arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
33030358|NCT04294160|Experimental|Dabrafenib + LTT462 + LXH254 triplet arm 2|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
33030359|NCT04294160|Experimental|Dabrafenib + LTT462 + TNO155 triplet arm 3|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
33030360|NCT04294160|Experimental|Dabrafenib + LTT462 + spartalizumab triplet arm 4|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
33030361|NCT04294160|Experimental|Dabrafenib + trametinib + TNO155 triplet arm 5|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
33033334|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
33326678|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
33326679|NCT01160796|Experimental|Lcr35®|
33030362|NCT04294160|Experimental|Dabrafenib + LTT462 + Tislelizumab triplet arm 6|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
33030363|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
33030364|NCT04290806||GAC|250 patients with gastric adenocarcinoma
33030365|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
33030366|NCT04290806||EAC|150 patients with esophageal adenocarcinoma
33030367|NCT04281992|Experimental|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
33030368|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
33030369|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
33030370|NCT04264182|Experimental|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
33030371|NCT04264182|No Intervention|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
33030372|NCT04257058|Experimental|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
33030373|NCT04255745|No Intervention|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
33030374|NCT04255745|Experimental|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
33030375|NCT04255303|Experimental|iCPR group|Clinic personnel (Providers and Nurses) will receive online training that includes: 1) an overview of the project; 2) iCPR workflows including triage; 3) CPR component review and risk categories; 4) history and physical examination components of the CPRs. The online training will be followed by in-person training to reinforce the online training and teach additional skills. In-person training sessions led by study team will last approximately 60 minutes, and consist of four basic components: 1) a review of the iCPR ARI protocol and tools; 2) on-screen walk-throughs of common scenarios employing the new tools; 3) physical examination technique practice with simulated patients; A 60-minute in-person follow-up nurse training will take place 4-6 weeks after implementation of the intervention.
33030376|NCT04255303|No Intervention|Control no intervention group|standard care will continue as usual.
33030377|NCT04228783|Experimental|Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)|Participants will receive Intramuscular injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U], Lot 1) on Day 57.
33030378|NCT04228783|Experimental|Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 2) on Day 57.
33030379|NCT04228783|Experimental|Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 3) on Day 57.
33030380|NCT04228783|Placebo Comparator|Control Vaccine: Group 4 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent [%] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
33030381|NCT04228783|Experimental|Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5*10^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
33030382|NCT04228783|Placebo Comparator|Booster Cohort: Group 6 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.
33030383|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
33030385|NCT04202185||G1a|infants under 3 years deaf severe to deep
33030386|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
33030387|NCT04202185||G2|patients <25 years old with one or two Otoferlin mutations
33030388|NCT04186377|Active Comparator|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
33030389|NCT04186377|Experimental|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
33030390|NCT04176250|Experimental|TBA-7371 100 mg QD|
33030391|NCT04176250|Experimental|TBA-7371 100 mg BID|
33030392|NCT04176250|Experimental|TBA-7371 200 mg QD|
33030393|NCT04176250|Experimental|TBA-7371 100 mg TID|
33417115|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
33417116|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
33417117|NCT05187559|Experimental|First Group|Neuromuscular exercise program with standard physiotherapy with no visual feedback.
33030394|NCT04176250|Experimental|TBA-7371 400 mg QD|
33030395|NCT04176250|Active Comparator|HRZE|
33030396|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
33030397|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
33030398|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
33030399|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
33030400|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
33030401|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
33030402|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
33030403|NCT04155346|Experimental|Facility-based prehabilitation (FBP)|"Exercise~Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
33030404|NCT04155346|Experimental|Home-based prehabilitation (HBP)|"Exercise~Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
33030405|NCT04155346|No Intervention|Usual Care|- This group will receive no additional intervention from the routine care.
33030406|NCT04150614|Active Comparator|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
33030407|NCT04150614|Active Comparator|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
33030408|NCT04134754|Other|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
33030409|NCT04114955|Active Comparator|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
33030410|NCT04114955|Other|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
33030411|NCT04068792|Other|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV [-] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV [+] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
33030412|NCT04068792|Experimental|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to [>=] 28 days and less than [<] 3 months): 2.5 milligram per kilogram [mg/kg]; for Age Group 2 (>=3 and <6 months): 3 mg/kg and for Age Group 3 (>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
33030413|NCT04065243|Active Comparator|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
33030414|NCT04065243|Experimental|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
33030415|NCT04060134||SimpliDerm HADM|Patients who had SimpliDerm human acellular dermal matrix used in their breast reconstruction procedure.
33030416|NCT04060134||AlloDerm HADM|Patients who had AlloDerm human acellular dermal matrix used in their breast reconstruction procedure.
33030417|NCT04060134||AlloMax HADM|Patients who had AlloMax human acellular dermal matrix used in their breast reconstruction procedure.
33030418|NCT04060134||FlexHD HADM|Patients who had FlexHD human acellular dermal matrix used in their breast reconstruction procedure.
33030419|NCT04060134||DermACELL HADM|Patients who had DermACELL human acellular dermal matrix used in their breast reconstruction procedure.
33417118|NCT05187559|Experimental|Second Group|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
33326680|NCT01160796|Placebo Comparator|placebo|
33326681|NCT01160874|Experimental|TDA/H|
33030420|NCT04045717|Experimental|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
33030421|NCT04035109|Other|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
33030422|NCT04035109|Other|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
33030423|NCT04030429|Experimental|Crizotinib arm|Crizotinib 250 mg bid orally
33030424|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
33030425|NCT03988439|Experimental|IDP-118 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 4 to 11 years 11 months) will apply IDP-118 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
33030426|NCT03982186|Experimental|Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA|Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) up to 48 weeks.
33030427|NCT03982186|Experimental|Arm 2: JNJ-73763989 (high dose) + Placebo + NA|Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
33030428|NCT03982186|Experimental|Arm 3: JNJ-73763989 (medium dose) + Placebo + NA|Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
33030429|NCT03982186|Experimental|Arm 4: JNJ-73763989 (low dose) + Placebo + NA|Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
33030430|NCT03982186|Experimental|Arm 5: Placebo + JNJ-56136379 + NA|Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
33030431|NCT03982186|Placebo Comparator|Arm 6 (Control): Placebo + Placebo + NA|Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
33030432|NCT03970694|Experimental|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX * 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
33030433|NCT03970694|Other|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX * 4）→ Surgery (if possible) → post-surgery chemotherapy.
33030434|NCT03951077|Placebo Comparator|Placebo|Placebo taken orally twice a day (BID)
33030435|NCT03951077|Experimental|Elagolix 25 mg BID|Elagolix 25 mg taken orally BID plus placebo
33030436|NCT03951077|Experimental|Elagolix 50 mg Once Daily (QD)|Elagolix 50 mg taken orally QD plus placebo
33030437|NCT03951077|Experimental|Elagolix 75 mg BID|Elagolix 75 mg taken orally BID plus placebo
33030438|NCT03951077|Experimental|Elagolix 150 mg QD|Elagolix 150 mg taken orally QD plus placebo
33030439|NCT03951077|Experimental|Elagolix 300 mg QD|Elagolix 300 mg taken orally QD plus placebo
33030440|NCT03941132|Experimental|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
33030441|NCT03941132|Placebo Comparator|Saline Solution - Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
33030442|NCT03920007|Experimental|SAR439483|SAR439483 single dose according to an ascending dose design (dose escalation phase) or SAR439483 single dose (dose expansion phase)
33030443|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
33030444|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
33030445|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
33030446|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
33030447|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
33030448|NCT03873246|Active Comparator|OC-01 0.1%, 0.6 mg/ml|OC-01 (varenicline) nasal spray, 0.6 mg/mL
33030449|NCT03873246|Active Comparator|OC-01 0.2%, 1.2 mg/ml|OC-01 (varenicline) nasal spray, 1.2 mg/mL
33030450|NCT03873246|Placebo Comparator|Placebo|vehicle control
33030451|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
33030452|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
33030453|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
33030454|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
33326682|NCT01160874|Other|Sleep apnea patient|
33326683|NCT01160874|Other|Healthy volunteer|
33326684|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
33326685|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
33326686|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
33030455|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
33030456|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
33030457|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
33030458|NCT03847142|Experimental|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
33030459|NCT03847142|Active Comparator|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
33030460|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
33030461|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
33030462|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
33030463|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
33030464|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
33030465|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
33030466|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
33030467|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
33030468|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
33030469|NCT03645941|No Intervention|Quitline/Treatment Referral|Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
33030470|NCT03645941|Experimental|Facebook+Quitline/Treatment Referral|"Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months~Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement~Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
33030471|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
33030472|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
33030473|NCT03619850|Experimental|Ferumoxytol|
33030474|NCT03619850|Active Comparator|Iron sucrose|
33030475|NCT03540433||Study group|Surgical patients aged ≥70 years
33030476|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
33030477|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
33030478|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
33030479|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
33030480|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
33030481|NCT03439774||Adults 18 years old or older|
33030482|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
33030483|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
33030484|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
33030485|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
33030486|NCT03337802|No Intervention|Pregnant women at standard diet|obstetrical and gynecological follow-up
33030487|NCT03337802|Experimental|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
33030488|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
33030489|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
33030490|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
33030491|NCT03330496||Small infants|1-3 month-old infants (n=15)
33030492|NCT03330496||Older infants|3-6 month-old infants (n=15)
33030493|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
33030494|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
33030495|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
33030496|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
33030497|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
33030498|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
33030499|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
33030500|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
33030501|NCT03231995|Experimental|Respiratory microbiome biomarkers|
33030502|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
33030503|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
33030504|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
33030505|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
33030506|NCT03122496|Experimental|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
33030507|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
33030508|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
33030509|NCT03107104||Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
33030510|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
33030511|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
33030512|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
33030513|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
33030514|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
33030515|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
33326687|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
33326688|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
33326689|NCT01265160||the group of Jiangzhuo prescription|
33326690|NCT01265160||the group of fenofibrate|
33030516|NCT03043313|Experimental|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
33030517|NCT03043313|Experimental|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
33030518|NCT03043313|Experimental|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
33030519|NCT02982174||Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
33030520|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
33030521|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
33030522|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
33030523|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
33030524|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
33030525|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
33030526|NCT02862548|Experimental|TAF|TAF 25 mg once daily for 48 weeks
33030527|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
33030528|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.
33030529|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
33030530|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
33030531|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
33030532|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
33030533|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
33030534|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
33030535|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
33030536|NCT02818738|Placebo Comparator|Placebo|matching verum
33030537|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
33030538|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
33030539|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
33030540|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
33030541|NCT02710682|Active Comparator|Mini-open surgery|Surgery
33030542|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
33030543|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
33030544|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
33030545|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
33030546|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
33326691|NCT01265160||the group of placebo|
33030547|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
33030548|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
33030549|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
33030550|NCT02427256||Pathologic Adults age 29-80 yrs|
33030551|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
33030552|NCT02421497||Normal Healthy Volunteer|
33030553|NCT02421497||Non-CKD Control|
33030554|NCT02421497||Chronic Kidney Disease (CKD)|
33030555|NCT02421497||Dialysis Patients|
33030556|NCT02421497||Renal Transplant Recipients|
33030557|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
33030558|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
33030559|NCT02376868||Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
33030560|NCT02376868||Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
33326692|NCT01161030|Experimental|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
33326693|NCT01161030|Placebo Comparator|Control|cheese stick
33030561|NCT02376868||Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
33030562|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
33030563|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
33030564|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
33030565|NCT02330562|Experimental|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part1-Phase1: MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.~Part2-Phase2: MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.~Part3-Phase2: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.~Part4- Phase1: All subjects will receive MRZ enterally by NG tube as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15.~Part5-Phase1: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion at 0.8 mg/m2 on Days 1, 8, and 15 of every 28-day cycle 0.8 mg/m2"
33030566|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
33030567|NCT02236143||MRI|Subjects undergoing MRI
33030568|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
33030569|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
33030570|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
33030571|NCT02138279||Male and female adults 18+ years of age|
33030572|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
33030573|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
33030574|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
33030575|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
33030576|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
33030577|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
33030578|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
33030579|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
33030580|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
33030581|NCT02045823||Retina|clinical exam with results consistent with retina pathology
33030582|NCT02044276|Experimental|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
33030583|NCT02044276|Active Comparator|pegfilgrastim|SC injection of 6 mg pegfilgrastim
33030585|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
33030586|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
33030587|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
33030588|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid S12 cochlear implant."
33033335|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.~Rescue bolus 5 ml and 30 minutes lockout"
33033336|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
33033337|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
33033338|NCT01961947|Experimental|ASP7374 group|
33417119|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
33030589|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
33030590|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
33030591|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
33030592|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
33030593|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
33417120|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
33417121|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
33417122|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
33417123|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
33417124|NCT01362673|Experimental|Single dose|
33417125|NCT01362673|Experimental|Multiple dose|
33030594|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
33030595|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
33030596|NCT01157091|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33030597|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
33030598|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
33417126|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
33417127|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
33030599|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
33030600|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
33417128|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
33417129|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
33417130|NCT04912583|Active Comparator|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
33417131|NCT04912583|Active Comparator|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
33417132|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
33417133|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
33030601|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
33417134|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
33326694|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
33030602|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
33030603|NCT00504712|Experimental|Active|Testosterone 200 mg intramuscular every 2 weeks
33030604|NCT00504712|Placebo Comparator|Placebo|Saline
33030605|NCT05413226|Experimental|Amount of Celastrol Administered|Increasing doses of Celastrol to each of five male subjects
33030606|NCT05413213|Experimental|Experimental Group|Ambulatory rehabilitation program based on mobilization and muscular solicitation
33030607|NCT05413213|Active Comparator|Control Group|Ambulatory rehabilitation program using ultrasound physiotherapy
33030608|NCT05413200||Patients|Patients diagnosed with moderate and severe AV accompanied by atrophic acne scars
33030609|NCT05413187|Active Comparator|Medical Grade Cannabis oil 30% CBD ,1.5% Δ9-THC|during phase 1; subjects will receive cannabis oil. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
33030610|NCT05413187|Placebo Comparator|Olive oil and Chlorophyl|during phase 1; subjects will receive placebo. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
33030611|NCT05413109|Experimental|Coronary-CT|Patients with PAH, asymptomatic for angina, with a PA trunk diameter ≥ 4 cm that undergo a coronary-CT scan examination
33030612|NCT05413096|Placebo Comparator|x labeled tube|neutral material without any biological effects
33030613|NCT05413096|Active Comparator|Y labeled tube|active agents
33030614|NCT05413044||Abatacept Group|Participants with established RA or PsA and receiving abatacept.
33030615|NCT05413044||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted DMARDs and who start treatment with a non-targeted DMARD.
33030616|NCT05413044||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs.
33030617|NCT05412940||Primary total knee replacement patients|
33030618|NCT05412914|Experimental|Remimazolam|remimazolam infusion
33030619|NCT05412914|Active Comparator|Propofol|propofol infusion
33030620|NCT05412901|Other|Visual spatial discrimination task|exp 1.1
33030621|NCT05412901|Other|Visual spatial discrimination task with temporal manipulation|exp 1.2
33030622|NCT05412901|Other|Crossmodal discrimination task|exp 3.1
33030623|NCT05412901|Other|Visual rule-switching discrimination task [gratings]|exp 3.2
33030624|NCT05412901|Other|Visual rule-switching discrimination task [images]|exp 3.3
33030625|NCT05412797|Experimental|Cycling|Used a DeskCycle during the workday/the intervention increased the amount of time spent being physically active.
33030626|NCT05412797|Active Comparator|Control|Regular activities
33030627|NCT05412771|Experimental|Main cohort|This is a single-arm study. Samples are collected from consenting donors undergoing surgery for medical purposes.
33030628|NCT05412732||group A low risk of infection|
33030629|NCT05412732||group B high risk of infection|
33030630|NCT05412719|Experimental|control group|". Before the procedure, the baby's pulse, blood pressure, SpO2, respiratory rate were checked by an observing nurse and recorded on the Baby Monitoring Form.~An observer nurse will assist the doctor at the beginning of the procedure, and then the baby's upper legs are kept stable in order to maintain the stability of the baby and ensure that the doctor can see the urethral opening. The other observer nurse evaluated the respiratory rate of the baby during the procedure and recorded it in the Infant Follow-up Form after the procedure was completed.~During the procedure, the baby was evaluated by both observer nurses according to the FLAAC pain scale.~No pharmacological or non-pharmacological interventions were made for the baby's pain during the procedure."
33030631|NCT05412719|Experimental|intervention group|Before the procedure, the baby's heart rate, blood pressure, spo2, respiratory rate, FLACC were recorded, 5 minutes before the procedure, the finger puppet was started to be played by singing the red fish song, the baby's pulse, spo2, respiratory rate and FLACC scale were recorded during the procedure, 5 minutes after the procedure Playing more finger puppetry Evaluation of the baby's pulse, blood pressure, spo2, respiratory rate and FLAAC immediately after the procedure and five minutes later
33030632|NCT05412680|Active Comparator|TOETVA|Patients submitted to transoral endoscopic thyroidectomy by vestibular approach
33030633|NCT05412680|Active Comparator|CONVENTIONAL THYROIDECTOMY|Patients submitted to conventional open thyroidectomy by cervical approach
33030634|NCT05412641|Other|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management. The study features only one group. Participants will receive the intervention described. There is no control group.
33030635|NCT05412589|Experimental|intravenous mFOLFOX7 combined with Camrelizumab and apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
33030636|NCT05412576|Experimental|IVL0.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
33030637|NCT05412576|Experimental|IVL1.0 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
33030638|NCT05412576|Experimental|IVL1.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
33033339|NCT01961947|Active Comparator|TIV group|
33033340|NCT01961960|Experimental|ASP7374 group|
33326695|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
33326696|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
33326697|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
33326698|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
32902380|NCT03143270|Experimental|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
32902381|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
32902382|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
32902383|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
32902384|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
32902385|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
32902386|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
32902387|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
32902388|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
32902389|NCT01514383|Experimental|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
32902390|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
32902391|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
32902392|NCT05566093|Experimental|Nonfunctional pancreatic neuroendocrine tumors|The patients with NF-pNETs will undergo EUS-guided ethanol or lauromacrogol ablation
32902393|NCT05565859|Experimental|Planetary Health Plate Signage|A Planetary Health Plate intervention phase where signage was posted in the dining hall promoting the planetary health diet
32902394|NCT05565859|No Intervention|Control|Control phase with dining hall signage as usual.
32902395|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
32902396|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
32902397|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
32902398|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
32902399|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
32902400|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
32902401|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
32902402|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes and MRI scan
32902403|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
32902404|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
32902405|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
32902406|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
32902407|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
32902408|NCT01798238|Placebo Comparator|Placebo group|
32902409|NCT01798238|Experimental|MP-513 group|
32902410|NCT02857400|Other|Arm A (standard)|
32902411|NCT02857400|Experimental|Arm B (experimental)|
32902412|NCT05565781|Active Comparator|ECG Smartwatch for up to 1 year|Cardiac monitoring with an ECG Smartwatch over 1 year after the acute phase of cryptogenic stroke. Simultaneously, a continuous cardiac monitoring will be performed using an Insertable Cardiac Monitor (ICM)
32902413|NCT05565781|Active Comparator|Holter monitoring for up to 1 year|Cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke and 15 additional days of extended use every 3 months up to 1 year
32902414|NCT05565781|Other|Control group|Regular cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke
32902415|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
33417135|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
33417136|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
33417137|NCT04894799|Experimental|Vestibular stimulation|all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
33030639|NCT05412576|Placebo Comparator|Placebo group|At the beginning of surgery, in the placebo group, the same dose of normal saline as the experimental groups will be given until the procedure is over.
33030640|NCT05412537|Active Comparator|CAU|"A sickness funds provides a physician or paramedic's consultation with people on work disability 3 to 6 months after the onset of the sickness period. The goal of this conversation is (1) to gather information on the reason of work disability, (2) gather information of the treatment plan and (3) to encourage people to RTW.~CAU stands for consult as usual"
33030641|NCT05412537|Experimental|Motivational Interviewing|Motivational Interviewing involves a conversation about behavioral change in terms of recovery or RTW. The role of the MI practitioner is to evoke change talk. By change talk, the patient expresses a desire, a reason, an ability or a need for change. It is of importance that patients themselves generate the motivation for change, and it is the practitioner's task to assist them in making informed and contemplated choices to act. The core idea is that people have to become motivated themselves to change such that the new behavior is something that they want instead of something that someone else wants. There are 4 processes: engaging, focusing, evoking and planning. Training in MI for health care professionals typically is provided in 1- to 3-day workshops. This is consistent with the 2-day training in the current research. MI was planned 3 to 6 months after the onset of work disability.
33030642|NCT05412524|Experimental|Reading|Mother and, if desired, mother's partner will read to infant for at least 15 minutes per week, but will be encouraged to read to infant as much as possible. Saliva will be collected from infants and parents for OXTRm assay at pre-specified time points, and at these time point parents will also complete standardized questionnaires including PSS-NICU, PROMIS depression, and PROMIS anxiety to assess parental mood and stress. Reading time will be measured with a reading log provided to the parents, as well as with a commercially-available LENA device to measure word count.
33030643|NCT05412485|Experimental|Treatment group|"Lokomat Certified physiotherapists will perform robotic assisted gait trainings. It will be performed 4 times per a week with a duration of 30 minutes on the lokomat with a treatment of 6 weeks phase.~Initially the Physical therapist will adjust the body -weight support at 70 % which will be gradually reduced until obtain flexion of the knees during stance phases. The lokomat certified physiotherapist will monitor the condition of the knees and adjust the body weight support during the training.~The Gait speed will be set at 0.7 km/hour and will gradually increase according to the comfortable speed selected by the child. The gait speed, Body weight support and the guidance force of the Lokomat will be adjusted and modified individually according to the ability of the child.~Virtual reality games will be used to motivate the participants and verbal encouragement will be used to increase their adherence to the intervention."
33030644|NCT05412485|Active Comparator|Control group|The same procedures will be given twice a week frequency.
33030645|NCT05412472|Experimental|1) Healthy subjects with normal renal function|
33030646|NCT05412472|Experimental|2) Mild renal impairment|
33030647|NCT05412472|Experimental|3) Moderate renal impairment|
33030648|NCT05412472|Experimental|4) Severe renal impairment|
33030649|NCT05412446|Experimental|HER2-positive patients|"Maximum 15 evaluable subjects with HER2-positive status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
33030650|NCT05412446|Experimental|HER2-negative patients|"Maximum 15 evaluable subjects with HER2-negative status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
33030651|NCT05412394|Experimental|Experimental|This is a one-arm study and the group of subjects are all experimental and will receive drug.
33030652|NCT05412342||Patients undergoing elective operations|We will follow a prospective cohort of 558 patients, undergoing any elective surgery at Stanford Hospital. Subjects will undergo baseline and longitudinal testing via a (including NIH Patient-Reported Outcomes Measurement Information System- PROMIS measures of emotional distress). After surgery, participants will report weekly changes in opioid use, pain, and adverse events; and monthly changes in opioid misuse for 1 year.
33030653|NCT05412303||With ECMO-VA|postcardiotomy cardiogenic shosck supported by ECMO-VA
33030654|NCT05412303||Without ECMO-VA|Post cardiotomy cardiogenic shock medically treated (inotrope and vasopressor)
33030655|NCT05412251|No Intervention|contrl|provide an irregular nutrition counselling to case by nutritionist
33030656|NCT05412251|Experimental|intervention|Multi-domain intervention included exercise,cognitive training and diet education was conducted for five hours per week in the first month, second month and third month.
33030657|NCT05412238|Experimental|Pregnant women receiving fortification sachets|pregnant women receive daily fortified sachets containing micro-and macronutrients for 6-9 months
33030658|NCT05412238|Experimental|6-24 months old children receiving fortification sachets|6-24 months old children receiv daily fortified sachets containing micro-and macronutrients for 6-9 months
33030659|NCT05412238|Experimental|2-5 years old children receiving fortification sachets|2-5 years old children receive daily fortified sachets containing micro-and macronutrients for 6-9 months
33030660|NCT05412173|Other|RT-sequence|The volunteers will take 1 capsule (200 mg) of Lagevrio (R), 200 mg capsules (Merck Sharp & Dohme (UK) Limited, UK) in Period 1, and 1 capsule (200 mg) of Molnupiravir (T), 200 mg capsules (Valenta Pharm, Russia) in Period 2.
33417548|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
33030661|NCT05412173|Other|TR-sequence|The volunteers will take 1 capsule (200 mg) of the drug Molnupiravir (T), capsules, 200 mg (Valenta Pharm JSC, Russia) in Period 1, and 1 capsule (200 mg) of the drug Lagevrio (R), capsules, 200 mg (Merck Sharp & Dohme (UK) Limited, UK) in Period 2.
33030662|NCT05412147|Active Comparator|Control group|The control group takes the multi-vitamins (Elevit, Bayer S.A.) with the dosage of one tablet per day on the 1st to 5th day of menstruation, then perform ovulation induction on the second menstrual cycle, and continue to take multi-vitamins until the day of oocyte retrieval.
33030663|NCT05412147|Experimental|Treatment group|The treatment group begins to take Reco-18 on the 1st to 5th day of menstruation with a dosage of 4 pills per day for the whole menstrual cycle, then perform ovulation induction on the second menstrual cycle, and continue to take Reco-18 until the day of oocyte retrieval.
33030664|NCT05412043|Experimental|Persons with MS - Dance group|12 pwMS in the Dance Therapy intervention
33030665|NCT05412043|Active Comparator|persons with MS - excercise group|12 pwMS in the exercise (placebo) group
33030666|NCT05412043|Placebo Comparator|Healthy controls|
33030667|NCT05411952|Experimental|education-mother and child dyad|Mother and child dyad have received dietary intervention for 6 months
33030668|NCT05411952|Experimental|education-only child|Children have received dietary intervention for 6 months. But their mothers didn't receive any dietary intervention
33030669|NCT05411952|Experimental|control|Control group did't receive any dietary intervention during the study
33030670|NCT05411926||The group that receiving PD-1 / PD-L1 inhibitor before liver transplantation|
33030671|NCT05411926||The group without receiving PD-1 / PD-L1 inhibitor before liver transplantation|
33030672|NCT05411900|Experimental|Experimental group: BoNT-A arms|Subjects randomized in experimental group will receive intradermal injections of BoNT-A into the wrist and skin area of the hand where the pain is located.
33030673|NCT05411900|Placebo Comparator|Control group: Placebo arms|Subjects randomized in control group will receive intradermal injections of placebo.
33030674|NCT05411887||Experimental/ Olostar Tablet|Eligible Subjects who received Olostar Tablet treatment for 24 weeks. Dosage: 10/5mg, 10/10mg, 20/5mg, 20/10mg, 20/20mg, 40/10mg, 40/20mg
33030675|NCT05411874|Experimental|Chidamide plus HD-DXM|"Chidamide (orally at 5 mg biw for 24 weeks)~HD-DXM (orally at 40 mg daily for 4 days)"
33030676|NCT05411874|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4 days )
33030677|NCT05411848|Experimental|Intervention|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days
33030678|NCT05411822|Experimental|Lighting Intervention Blue|Blue light (λmax = 451 nm) on and off axis
33030679|NCT05411822|Experimental|Lighting Intervention Green|Green light (λmax = 522 nm) on and off axis
33030680|NCT05411809|No Intervention|Arm1|The ctDNA is positive after SBRT and no adjuvant therapy is used after SBRT.
33030681|NCT05411809|Experimental|Arm 2|The ctDNA is positive after SBRT and adjuvant therapy is used after SBRT.
33030682|NCT05411809|No Intervention|Arm 3|The ctDNA is negative after SBRT and no adjuvant therapy is used after SBRT.
33030683|NCT05411796|Experimental|Tampax menstrual cup (regular flow), then Other menstrual cup (size 1)|
33030684|NCT05411796|Experimental|Other menstrual cup (size 1), then Tampax menstrual cup (regular flow)|
33030685|NCT05411783|No Intervention|High tie of IMV|The IMV will be tie under the pancreas as the usual procedure in left hemicolectomy and ARR
33030686|NCT05411783|Experimental|Low tie of IMV|The IMV will be tie under the left colic vein
33030687|NCT05411757|Experimental|IBR900 cell injection|IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab
33030688|NCT05411744|Experimental|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will receive 28 days of self-administered daily doses of RPT, INH, and pyridoxine (vitamin B6)
33326699|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
33326700|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
33030691|NCT05411692|Experimental|Functional electrical stimulations and motor priming exercise|Functional electrical stimulations and motor priming exercise • Palmar Grasp (holding a ball) of Lateral Grasp (holding a tray),Tripod grip (thumb, index, and middle finger: holding a pen), Two finger opposition (thumb and index finger: holding a peg, Lateral Pinch (thumb and index finger: holding a credit card), lateral pinch, two fingers (index and middle finger: smoker's grip
33030692|NCT05411692|Active Comparator|Functional electrical stimulations|Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve
33030693|NCT05411692|Placebo Comparator|Convetional phyusical therapy|The prescription of resistance load for strength training will be performed with fine motor exercise , based on sub maximal repetitions
33030694|NCT05411679|Experimental|Arm 1|patients with ataxia-telangiectasia mutated protein (ATM)-negative relapsed, advanced GC.
33030695|NCT05411679|Experimental|Arm 2|patients with relapsed extensive stage SCLC.
33030696|NCT05411666|Other|Arm 1|Saline solution maintenance of the Central venous catheter (CVC)
33030697|NCT05411666|Experimental|Arm 2|No maintenance of the Central venous catheter (CVC)
33326701|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
33417549|NCT05189327||Patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease|All patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease in the Republic of Kazakhstan.
33417550|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
33030698|NCT05411640|Experimental|Aerobics with Blood flow restriction|This group will perform Aerobic exercises with Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes
33030699|NCT05411640|Active Comparator|Aerobics without Blood flow restriction|This group will perform Aerobic exercises without Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes.
33030700|NCT05411640|Other|Education and Dietary modifications|This group will only receive education and dietary modifications for Pre-diabetes.
33030701|NCT05411614|Experimental|Convergent Hybrid Ablation with Left Atrial Appendage Exclusion|"Staged Convergent Hybrid Ablation Procedure~Stage 1 - Minimally-Invasive Surgical Epicardial Ablation Procedure with concomitant LAA exclusion.~Stage 2 - Endocardial Catheter Ablation"
33030702|NCT05411614|Active Comparator|Standard Endocardial Catheter Ablation|Standard endocardial catheter ablation
33030703|NCT05411601||C1|Subjects with socket-type attachment of their prostheses
33030704|NCT05411601||C2|Subjects with direct skeletal attachment
33030705|NCT05411510|Experimental|Densah bur|According to the protocol for densah burs. The direction was reversed and the cutting speed was raised to 1200 rpm after the initial perforation close to the sinus floor. After that, two densifying burs were used in succession to elevate the sinus membrane by 2 mm and prepare the implant hole to the desired implant size.
33030706|NCT05411510|Active Comparator|Ostetome|Flat end osteotome of appropriate size will be introduced through the osteotomy to infracture the floor of the sinus by light malleting.
33030707|NCT05411341||Study Group|100 patients with diagnosed cataract or presbyopia who will undergo implantation of intraocular lenses surgery
33030708|NCT05411328|Experimental|traditional physical therapy group|received traditional physical therapy protocol
33030709|NCT05411328|Experimental|virtual reality group|received the same traditional physical therapy in addition to virtual reality games
33030710|NCT05411276||Group 1|HER2 rare mutation advanced/metastatic non-small lung cancer (IV)
33030711|NCT05411263|Experimental|Patients with advanced heart failure undergoing clinically indicated right heart catheterisation|Patients with advanced heart failure undergoing right heart catheterisation as clinically indicated, irrespectively of their ejection fraction.
33030712|NCT05411224|Experimental|Morton Nuroma|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.
33030713|NCT05411172|Experimental|Experimental|"The Effect of the Education Based on the Mastery Learning Model on the Practical Skills of Student Nurses in Chemical, Biological, Radiological, and Nuclear Hazards.~The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks."
33030714|NCT05411172|No Intervention|Control|No intervention
33030715|NCT05407259|No Intervention|Control condition|During the control condition, participants will be asked to read a book related to exercise for approximately 40 minutes.
33030716|NCT05407259|Experimental|Low-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 65% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
33030717|NCT05407259|Experimental|Moderate-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 72% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
33030718|NCT05407259|Experimental|High-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 78% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
33030719|NCT05406843||Preoperative cognitive status of participants undergoing open heart surgery|"Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period.~In this study, it was aimed to determine postoperative cognitive impairment by comparing cognitive functions by using Minimental status test in the preoperative period in participants scheduled for open heart surgery for one year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time."
33030720|NCT05406843||Postoperative cognitive status of participants undergoing open heart surgery|Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period. In this study, it was aimed to determine the postoperative cognitive impairment by comparing it with the cognitive functions in the preoperative period using the Minimental status test in the postoperative period in participants scheduled for open heart surgery for a year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time.
33030721|NCT05405699|No Intervention|Control|
33030722|NCT05405699|Experimental|Intervention|
33030723|NCT05398939||Acne cohort|Adults with acne vulgaris who are going to receive the third dose of COVID-19 vaccine.
33030724|NCT05397366|Experimental|Task Specific Training|Using Task Specific Training
33030725|NCT05397366|Experimental|Neurodevelopmental Training|Using Neurodevelopmental Training
33030726|NCT05396781|Experimental|Augmented Reality High Resolution Microendoscope (HRME) imaging|All study subjects will receive White Light Imaging and Lugol's Chromoendoscopy (LCE) which is the current standard of care procedure. The investigators will record any LCE abnormal areas and record the clinician's plan of action. Following LCE, all subjects will receive Mobile, Augmented Reality High Resolution Microendoscope (marHRME) imaging with the study contrast agent (Proflavine) of any LCE-identified abnormal areas as well as LCE normal areas. The investigators will record the subjective clinician read and confidence level in the investigators' diagnosis, and plan of action. Then the investigators will image the same abnormal and normal areas with the marHRME and record the software read, clinician confidence level, and plan of action. Finally, the imaged areas will be biopsied or resected and evaluated by a pathologist. All subjects will receive both standard of care and marHRME imaging.
33030727|NCT05389800|Experimental|Aerobic Exercise (Moderate-Intensity Interval Training)|"Preoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in rate of perceived exertion (RPE), based on ACSM) and 120 seconds of passive rest in a total of 4 cycles. The basic program will last about 14 minutes, plus 6 minutes for warm-up and recovery. The program will be performed twice a day.~Postoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in RPE, based on ACSM) and 120 seconds of passive rest in a total of 8 cycles. The basic program will last about 30 minutes, plus 6 minutes for warm-up and recovery. The program will be performed 3 times a week for a total of 8 weeks."
33030728|NCT05389800|No Intervention|Control|"Preoperatively: mild intensity activities focusing on memory and attention performing with upper limb movements using the interactive platform Kinems. The program will last about 20 minutes. To ensure that the intensity of activities is mild, there will be a simultaneous recording of heart rate, while at the end of each session the RPE scale will be evaluated.~Postoperatively: none"
33030729|NCT05386420|Experimental|Experimental group|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
33030730|NCT05386420|Placebo Comparator|Control group|Conventional treatment combined with placebo.
33030731|NCT05384951|Experimental|HMB + Vitamin D3 Supplement|Supplement delivery will be a tablet containing both HMB & Vitamin D3. HMB will be administered in its calcium salt form. One tablet will contain 750 mg HMB + 250 IU of Vitamin D3. The target dosage is 3 g HMB + 1000 IU of Vitamin D3 per day.
33030732|NCT05381740|Experimental|cHMC rTMS + Upper Limb Training Training|Real Repetitive Transcranial Magnetic Stimulation given to facilitate the Contralesional Higher Motor Cortices+ Upper Limb Training
33030733|NCT05381740|Sham Comparator|Sham rTMS + Upper Limb Training Training|Sham Repetitive Transcranial Magnetic Stimulation over Contralesional Higher Motor Cortices+ Upper Limb Training
33030734|NCT05335512||Patients underwent TURBT|Patients undergoing complete TURBT for evaluation of a newly diagnosed bladder lesion in TMH and found to have NMIBC (either low risk or high risk)
33030735|NCT05320406|Active Comparator|Arm I (radiation therapy alone)|Patients undergo definitive radiation therapy alone (IMRT, SBRT, proton therapy, brachytherapy) in the absence of disease progression or unacceptable toxicity.
33030736|NCT05320406|Experimental|Arm II (radiation therapy plus leuprolide)|Patients undergo radiation therapy as in Arm I and receive leuprolide SC or IM every 3 or 6 months. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
33030737|NCT05320406|Experimental|Arm III (radiation therapy plus relugolix)|Patients undergo radiation therapy as in Arm I and receive relugolix PO QD. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
33030738|NCT05303038|Experimental|cryoablation combined with tirelizumab + Bevacizumab|
33030739|NCT05290818|Active Comparator|Manual Total Knee Arthroplasty|"This group will receive a conventional manual Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert. The surgeon will then make bone cuts using a manual jig and a hand held saw to prepare the bone surfaces for the implant. A measured resection technique will be employed with a three degree tibial slope. The surgeon will use a conventional jig alignment technique for intramedullary referencing for the femur and extra medullary referencing for the tibia. Once the implant is in position the knee is then balanced by the feel though a range of movement and soft tissue releases will be performed as required to balance the knee in flexion and extension."
33030740|NCT05290818|Experimental|Robotic Assisted Unicompartmental Knee Arthroplasty|This group will receive the cemented Restoris MCK (Mako, Stryker) with a highly crossed linked (X3) polyethylene insert through a less invasive to the knee joint. Instead of using a manual jig and a hand held burr will be used to prepare the bone surfaces for the implant, the MAKO robotic arm will be used by the surgeon to cut the bone at the required alignment. The information from the CT scan will be used to create a 3D model of the patient's bony anatomy and will used to plan the positioning of the implant. Once the trackers are in place registration of the knee joint surface is performed. The specified bone cuts are then performed using the robotic arm, aiming to gap balance the knee through a full range of movement.
33030741|NCT05280925|Experimental|Episodic Future Thinking|Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
33030742|NCT05280925|Active Comparator|Healthy Information Thinking|Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
33030743|NCT05275894|Experimental|Non-surgical electrolytic cleaning|"Implant hygiene instructions and removal of the prosthesis~Local anaesthesia~Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA)~Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).~Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).~Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.~Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).~If necessary, modification and polishing of the prosthesis to make it cleanable."
33030744|NCT05275504|Experimental|Dose Escalation for TT-01488|TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.
33030745|NCT05275504|Experimental|Dose Expansion for TT-01488|TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.
33030746|NCT05274581||Course participants|Course participants er general practitioners who have signed-up to participate in an ultrasound course
33030747|NCT05273840|Placebo Comparator|life intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given to the patients until the end of the visit.
33030748|NCT05273840|Experimental|nutritional supplement intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.
33030749|NCT05263960|Experimental|Part A, Dose escalation|There are 10 dose groups in dose escalation part.
33030750|NCT05263960|Experimental|Part B, Dose expansion|Based on the data of part A, one (MTD or the dose of one level less than MTD) or two (MTD and the dose of one level less than MTD) dose levels will be discussed for further evaluation in part B.
33030751|NCT05260398|Experimental|Mightier Now|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration.
33030752|NCT05260398|No Intervention|Mightier Later|8 weeks of wait list. Families in the Mightier Later condition will receive their Mightier shipment and will be encouraged to play Mightier after follow-up questionnaires have been completed 8 weeks after parents and teachers complete baseline questionnaires.
33030753|NCT05227157||1: intensity of perception of metallic taste|"For this study, there is only one arm: swab with iron sulfate solution at a concentration of 10g/l.~Each subject complete visual scale"
33030754|NCT05218291|Experimental|Technology-Supported Yoga Applied Group|"The yoga initiative to be applied to the intervention group; Yoga, which is mind-breath-body work; It includes meditation, pranayama (breath work), and asanas (yoga poses).~The content of the yoga practice consists of the following poses:~-Tadasana (Mountain pose), -Urdhvahastasana, -Uttanasana, -Ardha Uttanasana, -Plank, -Ashtang Pranam, -Bhujangasana (Mini cobra), -Adho Mukha Svanasana (Downward facing dog), -Vrksasana (Tree Pose), - Utthita Trikonasana (Triangle Pose), -Virabhadrasana I (Warrior I), -Virabhadrasana II (Warrior II), -Virabhadrasana I with Anjali Mudra (Hands Reverse Namaste), -Utkatasana (Chair Pose), -Salabhasana, -Paschimottanasana , -Dandasana, -Salamba Sarvangasana (Shoulder pose), -Ardha Urdhva Dhanurasana (Half Wheel Pose), -Reverse Warrior, -Child's pose, -Ananda Balasana (Happy baby), -Wipers, -Corpse Pose"
33030755|NCT05218291|Active Comparator|Control Group|No intervention was made in caregivers.
33030756|NCT05213052|Experimental|Topical cream, 1 - 2 times daily|Application of a pea-sized amount of cream applied to skin over the area with chronic pain
33030757|NCT05197218|Experimental|Healthy subjects|Prebiotic administration
33030758|NCT05195255|Experimental|Healthy subjects|Prebiotic administration
33030759|NCT05191108|Experimental|The Effect of mİNDFULNESS Stress Reduction Program on Premenstrual Symptoms|In order to prevent bias in the study groups, the Introductory Information Form and PMSS scale will be applied via online Google forms. Participants who meet the criteria will be randomly assigned to the mindfulness stress reduction group (Group 1) and control group (Group 2) in the number determined by power analysis and a simple random number generator program (www.random.org). These experimental and control groups will be recorded by the researchers as a list. Participants participating in the study will be informed about the mindfulness stress reduction application, but they will not be informed about what the mindfulness stress reduction application does (single-blind method). These participants will be asked to sign the consent form by expressing that they can withdraw from the study at any time.
33030760|NCT05191108|No Intervention|Control group|not routinely do anything to reduce premenstrual symptoms
33030761|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence A|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 4 gram/day.
33030762|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence B|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 8 gram/day.
33030763|NCT05172973|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
33030764|NCT05167760|Experimental|Treatment Group|Participants will receive the study drug, apraclonidine, per its FDA-approved package labelling
33030765|NCT05161039|Other|Serranator|
33030766|NCT05161039|Other|POBA|
33030767|NCT05099263|Experimental|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will undergo bilateral treatment of the nasal airway in a single study procedure session. Each side of the nose will be treated as follows:~• Two (2) to six (6) nonoverlapping applications of RF energy are performed at the SSB per nostril.~The default treatment settings will be used for the study: temperature 60 C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (36 months)."
33030768|NCT05097157|Experimental|Treatment with Device|Subjects received up to 5 treatments with the device, spaced 4 weeks apart.
33030769|NCT05082103|Active Comparator|Enzyme lozenge 1|The lozenge contains three plaque extracellular matrix degrading enzymes
33030770|NCT05082103|Active Comparator|Enzyme lozenge 2|"The concentration of the three enzymes in the Enzyme lozenge 2 is threefold the enzyme concentration than in the Enzyme lozenge 1"
33030771|NCT05082103|Placebo Comparator|Placebo lozenge|The placebo lozenge contains the same ingredients except for the enzymes and has an identical taste, color and texture
33326702|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
33030772|NCT05081596|Experimental|Problem Adaptation Therapy for Pain (PATH-Pain)|Problem Adaptation Therapy-PAIN (PATH-PAIN) is an emotion regulation intervention aimes to reduce stress and decrease depression and disability.
33030773|NCT05081596|No Intervention|Attention Control Usual Care|Usual Care involves the continued medical attention and treatment provided by the subject's physician and other medical professionals in primary care. This may include medical intervention or referrals to specialists to address issues of depression, pain or memory difficulties. Subjects will also be asked to meet with a study research assistant for structured interviews and educational sessions consisting of general questions regarding health habits and other non-medical topics unrelated to cognitive impairment, pain, and depression. Additionally, subjects will receive an educational booklet on pain and depression.
33030774|NCT05080647|Active Comparator|Mightier Child Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more play each week) for the 8-week duration. Parents in the Child Play condition will be advised specifically to not play Mightier for the 8-week duration of the study.
33030775|NCT05080647|Experimental|Mightier Child and Parent Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration. Additionally, parents in the Child and Parent Play condition will be encouraged to play Mightier games at least once a week (totalling 15 minutes or more of play each week) for the 8-week duration.
33030776|NCT05077800|Experimental|Safety Run-In: FOLFIRINOX + 9-ING-41 + Losartan|"The study will begin with a Safety Run-In phase to establish the side effects from the study treatment to its safety before beginning the main part of the study, six (6) participants will receive 1-2 cycles of:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily of every 14-day cycle."
33030777|NCT05077800|Experimental|FOLFIRNINOX|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~For Maintenance therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX until further disease progression"
33030778|NCT05077800|Experimental|FOLFIRINOX + Losartan|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Losartan daily up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + Losartan until further disease progression"
33030779|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~For Complete Therapy Round 2, repeat of initial complete therapy until further disease progression"
33030780|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41 + Losartan|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + 9-ING-41+ Losartan until further disease progression"
33030781|NCT05062902|Active Comparator|Template Injection|For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared. 1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively. The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e. paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups. The syringe will be withdrawn before each injection to avoid intravascular injection.
33326703|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
33326704|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
33326705|NCT01163682|Active Comparator|Electro-acupuncture|45 minute sessions scheduled once a week for 12 weeks.
33326706|NCT01163682|Sham Comparator|Sham acupuncture|45 minute sessions scheduled once a week for 12 weeks
33030782|NCT05062902|Experimental|Guided Injection|For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings. NMJ mappings will be generated for each participant. The channel locations will provide angle measurements for each NMJ. The device will calculate these parameters based on acquired HD-sEMG. The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites. The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
33030783|NCT05042674|Other|Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily|Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week
33030784|NCT05042401|Experimental|Treatment group A|
33030785|NCT05042401|Placebo Comparator|Treatment group B|
33030786|NCT05042401|Experimental|Treatment group C|
33030787|NCT05042401|Placebo Comparator|Treatment group D|
33326707|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
33326708|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
33326709|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
33326710|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
33326711|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
33326712|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
33030790|NCT05033028|No Intervention|Treatment-as-Usual|Participants will receive the same treatment as if they had not joined the study
33030791|NCT05033028|Experimental|Smartphone with dose changes after using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.
33030792|NCT05033028|Experimental|Smartphone with dose changes before using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.
33030793|NCT05033028|Experimental|Focus group with Study Physicans|Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study
33030794|NCT05033028|Experimental|Focus group with Clinicians|Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
33030795|NCT05015062|Experimental|Mobile-based intervention with standardized incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
33030796|NCT05015062|Experimental|Mobile-based intervention with performance-based incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
33030797|NCT05015062|No Intervention|Control without intervention|Participants will not receive the mobile-based intervention
33030798|NCT05013021|Other|Sedentary participants|"Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).~These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA)."
33030799|NCT05002868|Experimental|RP12146|RP12146 will be administered orally daily (QD or BID)
33030800|NCT05000034|Experimental|Patients|
33030801|NCT04965792||HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients|Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
33030802|NCT04961320|Experimental|Supportive care (OT, questionnaires)|Patients participate in OT sessions weekly for 3 weeks over 30 minutes each. Patients also complete questionnaires to assess anxiety, depression, fatigue and pain at baseline, 5 and 12 weeks.
33030803|NCT04960384|Placebo Comparator|Placebo|
33030804|NCT04960384|Experimental|Human Fibroblast Growth Factor-2 (FGF-2)|
33033341|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
33326713|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
33326714|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
33326715|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
33326716|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
33030805|NCT04957238|Experimental|ARBORea decision-making tool|After a period of presentation and training on the dedicated decision-making tool (face-to-face, video and paper supports), nurses will be asked to use ARBORéa decision tree. This will be in the form of an electronic file and will give a suggestion of whether or not to use physical restraints. This is based on an algorithm based on specific and mandatory elements (neurological state : RASS (Richmond assessment sedation scale) and CAM-ICU (confusion assessment method-ICU) scores, modification of sedation dosage, equipment levels, presence and adhesion of the family) that will be completed online. ARBORea's suggestion will be collected as well as final caregiver's decision in order to evaluate relevance of the tool. Observations will also be made at least every 8 hours. This period will also be of random duration (stepped wedge)
33030806|NCT04957238|No Intervention|Subjective physical restraints use|After study presentation and required data collection description, nurses will complete elements related to ARBORea's tool variables, and inform their actual practices of physical restraints use, at least every 8 hours. ARBORea data concern patient's neurological state (RASS and CAM-ICU scores) and changes in sedation doses. The conditioning will then be filled in to stratify the risk incurred. Pain management will be notified. Finally, the presence and involvement of the families will be collected. Other data, relating to working conditions of the nurses will be collected: nurse to patient ratio, special and time consuming events (new patient admission, in ICU emergencies, need to conduct a patient to CT-scan facility or operative room, change of patient's equipment). Nurse seniority in ICU will be specified. Incidents that have occurred (fall, self-injury, removal of a level C2 equipment). The random duration of this control period will be determined by stepped wedge sequencing.
33030807|NCT04934397|Experimental|Study Infant Formula|Feed ad libitum during study period
33030808|NCT04927585|Experimental|Group 1 (Treatment): DNA Vaccine + Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0, and Months 3, 6, and 12.
33030809|NCT04927585|Placebo Comparator|Group 1 (Control)|"Participants will receive placebo at Day 0, Months 3, 6, and 12.~Interventions:"
33030810|NCT04927585|Experimental|Group 2 (Treatment): Admixture of DNA Vaccine and Protein Vaccine|Participants will receive admixture of 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine (no adjuvant) at Day 0, and Months 1, 3, 6, and 8.
33030811|NCT04927585|Placebo Comparator|Group 2 (Control)|"Participants will receive placebo at Day 0, and Months 1, 3, 6, and 8.~Interventions:"
33030812|NCT04922411|Experimental|Post-Surgical Group|STN DBS: Subjects with PD and DBS STN implanted will be scanned and tested with DBS ON and OFF
33030813|NCT04917055|Active Comparator|Active Treatment|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
33030814|NCT04917055|Placebo Comparator|Placebo|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
33030815|NCT04912557||Patients|Open major abdominal surgery patient (predicted operative time ≥ 2 hours) with Peridural Analgesia accepted
33030816|NCT04911478||Subjects from Adicet Bio allogeneic γδ CAR T cell interventional studies.|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in Adicet Bio allogeneic γδ CAR T cell study.~Patients will be followed for up to 15 years post treatment of Adicet Bio allogeneic γδ CAR T cell investigational products."
33030817|NCT04899869|Other|Group A (active microbiota first)|Patients will first receive two enemas of active study microbiota mixture (deep-frozen stored stool microbiota mixed from eight donors in order to increase its diversity), then after eight weeks they will receive two enemas with placebo.
33030818|NCT04899869|Other|Group B (inactive microbiota first)|Patients will first receive placebo, then the active study microbiota mixture.
33030819|NCT04899869|Other|Group C (inactive microbiota only)|Patients will receive similarly timed enemas with placebos only.
33030820|NCT04898478|Experimental|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|This arm will consist of a behavioral intervention to increase treatment seeking among Pacific Islanders with opioid use disorders.
33030821|NCT04885946|Experimental|Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.
33030822|NCT04885946|Placebo Comparator|Vancomycin 125 x 4 for 10 days + 2 Placebo|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.
33030823|NCT04885946|Other|Open-label for screened, but not randomized patients with fulminant CDI|This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.
33030824|NCT04868539|Experimental|Sleep Restriction with Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction Group with Extended Duration Artificial Light At Night (ALAN) first, the sleep episodes will be shortened to 5 hours, centered at the same time as the baseline sleep (with bedtime 2.5 hours later and wake time 2.5 hours earlier).
33030825|NCT04868539|Experimental|Sleep Restriction without Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction group without Extended Duration ALAN, the sleep episodes will be shortened to 5 hours as in the ALAN Condition (centered at the same time as the baseline sleep with bedtime 2.5 hours later and wake time 2.5 hours earlier), but the participant will remain sitting in bed in near darkness (< 1 lux) for the 2.5 hours before and after the 5-hour sleep episode, such that their exposure to room lighting and activity (14 hours/day) will remain similar to that in the Baseline condition.
33033342|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
33033343|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
33030826|NCT04866264|Active Comparator|Outpatient Group|"After signing the informed consent, outpatients will be invited for a clinical baseline visit at the Center on Aging and Mobility (CAM), where they will complete the dietary assessment with the eNutrition optimizer at the CAM guided by the study physicians, who will also interpret the immediate results and recommendations produced by the tool to the study participant.~For validating the eNutrition-Optimizer tool, participants will be asked to report their dietary intake in the past 24h during a 24-h diet recall phone call conducted by a trained interviewer on random days (weekday and weekend), so the participant cannot prepare or alter their habits. This 24h diet recall phone calls will be performed 4 times during the second half of the follow-up (month 4 to 6). In addition participants will complete the System Usability Scale at baseline and the subjective effectiveness questionnaire at month 6."
33030827|NCT04866264|Active Comparator|Inpatient Group|After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
33030828|NCT04857632|Experimental|Statins group|
33030829|NCT04857632|No Intervention|Control group|
33030830|NCT04857112|Experimental|Low Dose|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
33030831|NCT04857112|Experimental|High Dose|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
33030832|NCT04857112|Placebo Comparator|Placebo|Matching placebo, QD (Day 1-85)
33030833|NCT04805528|Experimental|Experimental: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS) Therapy|Six (6) small electrodes will be placed on specific points of the body using adhesive pads. These electrodes are connected to the ALTENS device, which will send controlled, low-level electrical impulses through the skin and into the tissue underneath.
33030834|NCT04792385|Experimental|E4/DRSP 15/3 mg|Single treatment arm will receive E4/DRSP 15/3 mg
33030835|NCT04787315|Active Comparator|Intensive rehabilitation without workstation|
33030836|NCT04787315|Experimental|Intensive rehabilitation with workstations|
33030837|NCT04777006|Experimental|Cluster 1 (First Cluster of Clinics Randomized to Receive Care)|Arm 1 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 3 of the trial
33030838|NCT04777006|Experimental|Cluster 2 (Second Cluster of Clinics Randomized to Receive Care)|Arm 2 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 6 of the trial
33030839|NCT04777006|Experimental|Cluster 3 (Third Cluster of Clinics Randomized to Receive Care)|Arm 3 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 9 of the trial
33030840|NCT04777006|Experimental|Cluster 4 (Fourth Cluster of Clinics Randomized to Receive Care)|Arm 4 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 12 of the trial
33030841|NCT04777006|Experimental|Cluster 5 (Fifth Cluster of Clinics Randomized to Receive Care)|Arm 5 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 15 of the trial
33030842|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 1|
33030843|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 2|
33030844|NCT04766476|Placebo Comparator|Placebo|
33030845|NCT04755244|Experimental|evorpacept (ALX148) + venetoclax + azacitidine|"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine~Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine"
33030846|NCT04733534|Active Comparator|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
33030847|NCT04733534|Active Comparator|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
33030848|NCT04725864|No Intervention|No progesterone|Patients will have FET in natural cycles with no extra intervention.
33030849|NCT04725864|Experimental|Progesterone for 3 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for three weeks.
33030850|NCT04725864|Experimental|Progesterone for 7 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for seven weeks.
33030851|NCT04721821||Patients with Rheumatoid Arthritis (RA)|
33030852|NCT04721808||Patients with Rheumatoid Arthritis (RA)|Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward
33030853|NCT04721353|Experimental|Open-label prazosin treatment|Open-label administration of prazosin
33030854|NCT04715945||Women|12,583 women recruited when non-pregnant
33030855|NCT04715945||Children|3,158 liveborn singleton offspring of women recruited to the study
33030856|NCT04700800|Experimental|Exercise, Infusion of Amino Acids|Exercise followed by infusion of amino acids, or infusion of amino acids alone.
33030857|NCT04700800|Active Comparator|Exercise|Exercise with no infusion of amino acids
33030858|NCT04700059|Experimental|Intervention|10 perinatal home visits
33030859|NCT04700059|No Intervention|Usual care|Routine medical care for mother and infant. Access to online resources.
33030860|NCT04688333|Experimental|Supportive care (iConquerFear program, questionnaires)|Patients complete 5 sessions of iConquerFear program online over 5 weeks. Patients also complete questionnaires at baseline, after the intervention, and 2 months later.
33030861|NCT04655391|Experimental|Chapter 1 (glasdegib, decitabine, venetoclax)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD on days 1-28,decitabine IV over 1 hour on days 1-5, and venetoclax PO QD on days 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33030862|NCT04655391|Experimental|Chapter 2 (glasdegib, gilteritinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and gilteritinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33030863|NCT04655391|Experimental|Chapter 3 (glasdegib, bosutinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and bosutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33030864|NCT04655391|Experimental|Chapter 4 (glasdegib, ivosidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33030865|NCT04655391|Experimental|Chapter 5 (glasdegib, enasidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and enasidenib PO QD on days 1-28 .Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33030866|NCT04650100|Experimental|PENG group|For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
33030867|NCT04650100|No Intervention|Control group|No additional intervention, only standard care
33030868|NCT04647994||Covid-19 HC patients|Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.
33030869|NCT04647994||Delivery patients|Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.
33030870|NCT04647994||Prenatal patients|Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.
33030871|NCT04647994||Negative serology patients|Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.
33030872|NCT04644861|Other|Elders aged 70|Program of adapted physical activity
33030873|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
33030874|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
33030875|NCT04610697|Experimental|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
33030876|NCT04610697|Active Comparator|Active control|"Participants in the active control condition will also complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
33030877|NCT04609098|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
33030878|NCT04609098|Experimental|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
33030879|NCT04609098|Experimental|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
33030880|NCT04609098|Experimental|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
33030881|NCT04605614|Experimental|Treatment (pembrolizumab, 64Cu-DOTA-pembrolizumab, PET)|Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over > 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
33030882|NCT04560439|Experimental|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
33030883|NCT04549662|Experimental|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
33030884|NCT04549662|Active Comparator|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
33030885|NCT04549662|Placebo Comparator|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
33033344|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy~refractory extravascular fluid overload~azotemia > 40mmol/L or 240 mg/dL~metabolic acidosis (pH<7,2)~hyperkaliemia (k+>6 mmol/L)"
33030886|NCT04494516||Pre-trial|This cohort of participants will be recruited preceding evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with design of the intervention and implementation strategy. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
33030887|NCT04494516||Post-trial|This cohort of participants will be recruited after evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with future scale up and dissemination of the intervention. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
33030888|NCT04493333|Experimental|Vaginal DHEA|Vaginal insert with 6.5 mg vaginal DHEA self-administered once daily at bedtime for 12 weeks
33030889|NCT04493333|Active Comparator|Vaginal Polycarbophil Moisturizer|Prefilled vaginal applicator with 2.5 g of polycarbophil vaginal moisturizing gel, self-administered two times per week at night for 12 weeks
33030890|NCT04475016|Experimental|Neoadjuvant Therapy|TIP (Paclitaxel + Ifosfamide + Cisplatin) & Nimotuzumab & Triprilimab
33030891|NCT04465591||Myocardial infarction|Recruited patients with STEMI or NSTEMI and elevated Troponin T
33030892|NCT04465591||Myocardial injury|Recruited patients with myocardial injury based on elevated Troponin T and associated with renal failure, severe infection, strenouos exercise, atrial fibrillation, myocarditis, takotsubo cardiomyopathy or other similar conditions
33030893|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
33030894|NCT04422639|Experimental|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
33030895|NCT04422639|Active Comparator|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
33030896|NCT04409743|Active Comparator|Immediate Treatment|The sleep treatment is Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants randomized to this arm will begin treatment immediately after randomization.
33030897|NCT04409743|Other|Waitlist|The subjects assigned to the Waitlist condition will receive the same CBT-I treatment 7 months after randomization.
33030898|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
33030899|NCT04372680|Experimental|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
33030900|NCT04372680|No Intervention|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
33030901|NCT04364672|Experimental|Women with stage 1-4 newly diagnosed breast cancer|
33030902|NCT04362644|Experimental|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
33030903|NCT04359056|No Intervention|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
33030904|NCT04359056|Experimental|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
33030907|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
33030908|NCT04331795|Experimental|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
33030909|NCT04331795|Experimental|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
33030910|NCT04321551|Experimental|Provocative Hormonal Testing|TGN subjects will undergo baseline endocrine and menstrual cycle evaluation, followed by intramuscular (i.m.) administration of testosterone cypionate (TC) 50 mg (standard dose) every 7 d for 32 wks (Fig. 8). After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are independent of E2 signaling.
33030911|NCT04305769|Placebo Comparator|Alanyl-glutamine 0g|
33030912|NCT04305769|Experimental|Alanyl-glutamine 4g|
33327305|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
33327306|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
33030913|NCT04305769|Experimental|Alanyl-glutamine 24g|
33030914|NCT04305769|Experimental|Alanyl-glutamine 44g|
33033345|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
33033346|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
33033347|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
33033348|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
33033349|NCT01962051||Delivery system Entry|
33030915|NCT04302324|Experimental|daratumumab/clarithromycin/pomalidomide/dexamethasone|"Induction Phase: 8 cycles (each cycle is 28 days)~Daratumumab:~1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8~Clarithromycin~500mg PO BID until VGPR or 8 cycles, whichever occurs first~Pomalidomide 4mg PO on Days 1-21~Dexamethasone 20mg IV as pre-medication on Day 1, 8, 15, 22 20mg PO on the day after daratumumab for Cycle 1-2 40mg PO pre-daratumumab on Day 1 and 15 for Cycle 3-6 40mg PO on non-daratumumab on Day 8 and 22 for Cycle 3-6 20mg PO pre-daratumumab on Day 1 for Cycle 7-8~Maintenance Phase: up to 24 months (each cycle is 28 days)~Daratumumab 1800 mg SC on Day 1~Pomalidomide 4mg PO on Day 1-21~Dexamethasone 20mg IV pre-daratumumab on Day 1"
33030916|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally mild)."
33030917|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally moderate)."
33030918|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally severe)."
33417551|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
33030919|NCT04295824||Healthy|20 healthy volunteers
33030920|NCT04293679|Experimental|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
33030921|NCT04293679|Experimental|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
33030922|NCT04293679|Experimental|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
33030923|NCT04293679|Experimental|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
33030924|NCT04293679|Experimental|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
33030925|NCT04263597|Experimental|2'-fucosyllactose for ages 0-5 years|"Starting Dose for ages 0-5 years: 2.5 g/day;~Dose escalation for ages 0-5 years: 5 g/day;~Dose de-escalation for ages 0-5 years: 1.25 g/day"
33030926|NCT04263597|Experimental|2'-fucosyllactose for ages 5.1-10 years|"Starting Dose for ages 5.1-10 years: 5 g/day;~Dose escalation for ages 5.1-10 years: 7.5 g/day;~Dose de-escalation for ages 5.1-10 years: 2.5 g/day"
33030927|NCT04263597|Experimental|2'-fucosyllactose for ages >10 years|"Starting dose for ages >10 years: 10 g/day;~Dose escalation for ages >10 years: 15 g/day;~Dose de-escalation for ages >10 years: 5 g/day"
33030928|NCT04252560||Colorectal|30 patients operated for colorectal cancer
33030929|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
33030930|NCT04247269||Enteral formula standard|Children fed an intact protein formula
33030931|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
33030932|NCT04224792|Experimental|Center-based exercise group|Subjects will be enrolled into a center-based exercise program.
33030933|NCT04224792|Experimental|Home-based exercise group|Subjects will be enrolled into a home-based exercise program.
33030934|NCT04175730|Other|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
33030935|NCT04175730|Other|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
33030936|NCT04174781|Experimental|DEB-TACE+Sintilimab|Participants with BCLC Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria
33030937|NCT04156516|Experimental|HEART|sexual health intervention that focuses on communication skills
33030938|NCT04156516|Active Comparator|HealthyMinds|Attention-matched control: Growth mindset intervention
33030939|NCT04131426|Experimental|Remune dosed twice daily|A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist
33030940|NCT04131426|Experimental|Remune dosed twice daily and daily exercise with EXCAP|A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
33030941|NCT04131426|No Intervention|Usual Care|Usual standard care as prescribed by your oncologist
33030942|NCT04109963|Active Comparator|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
33030943|NCT04109963|Active Comparator|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
33030944|NCT04094779|Active Comparator|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
33030945|NCT04094779|Experimental|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
33030946|NCT04083690|Active Comparator|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
33417552|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
33417553|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
33030947|NCT04083690|Experimental|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
33030948|NCT04083508|Experimental|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
33030949|NCT04074460|Active Comparator|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
33030950|NCT04074460|Active Comparator|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
33030951|NCT04070053|Experimental|TheraPPP Pathway|"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation.~All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods.~To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation.~To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway."
33030952|NCT04069000|Active Comparator|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
33030953|NCT04069000|Experimental|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
33030954|NCT04069000|Experimental|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
33030955|NCT04041063|Experimental|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
33030956|NCT04041063|Active Comparator|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
33030957|NCT04033406|Experimental|VIR-2482|VIR-2482
33030958|NCT04033406|Placebo Comparator|Placebo|Placebo
33030959|NCT03993327|Experimental|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
33030960|NCT03972943|Active Comparator|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
33030961|NCT03972943|Experimental|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
33030962|NCT03957928|Active Comparator|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
33030963|NCT03957928|Experimental|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
33030964|NCT03936452|Experimental|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks When patients obtained an CR or PR after the second dose of the combined regimen, they woud undergo radiotherapy after the third dose of the combined regimen. Subsequently, another three cycles of the combined regimen would be administered to these patients.
33030965|NCT03909035|Experimental|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
33030966|NCT03909035|No Intervention|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
33030967|NCT03896776|Experimental|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site."
33030968|NCT03896776|Experimental|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up."
33030969|NCT03884231||Infinity DBS System with MR Conditional labelling (Leads-only configuration)|The Infinity DBS system with MR Conditional labelling includes a primary cell implantable pulse generator designed to deliver low-intensity electrical pulses to targeted structures in the brain. The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
33033350|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
33030970|NCT03884231||Infinity DBS System with MR Conditional labelling (Full system configuration)|The Infinity DBS system with MR Conditional labelling includes a primary cell implantable pulse generator designed to deliver low-intensity electrical pulses to targeted structures in the brain. The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
33030971|NCT03881579|Other|Usual care|one random half of patients will receive usual care
33030972|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
33030973|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
33030974|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
33030975|NCT03817125|Placebo Comparator|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
33030976|NCT03817125|Experimental|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
33030977|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
33030978|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
33030979|NCT03747042|Experimental|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-30~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
33030980|NCT03724032|Active Comparator|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
33030981|NCT03724032|Sham Comparator|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
33030982|NCT03724032|No Intervention|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NIDCR-R56-DE022637 project [IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
33030983|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
33030984|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
33030985|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
33030986|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
33030987|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
33030988|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
33030989|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"After an initial orientation/control period (4 weeks), group A will receive access to the Time for Living & Caring (TLC) intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose."
33030990|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the Time for Living & Caring (TLC) intervention for 8 weeks."
33030991|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
33030992|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
33030993|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
33030994|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
33030995|NCT03637764|Experimental|Phase1|"Isatuximab and atezolizumab combination in patients with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent glioblastoma multiforme (GBM):~Isatuximab dose 1 depending on DLT observed and atezolizumab predefined dose Q3W"
33030996|NCT03637764|Experimental|Phase2-Cohort A: HCC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
33417554|NCT05189249||Case|Patients who have undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
33030997|NCT03637764|Experimental|Phase2-Cohort B: SCCHN|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
33030998|NCT03637764|Experimental|Phase2-Cohort C: EOC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
33030999|NCT03637764|Experimental|Phase2-Cohort D-1:GBM|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
33031000|NCT03637764|Experimental|Phase2-Cohort D-2: GBM, isatuximab monotherapy|Isatuximab dose 2
33031001|NCT03637764|Experimental|Phase2-Cohort E|Isatuximab and atezolizumab combination: Isatuximab dose 3 and atezolizumab predefined dose Q3W in participants with one tumor type (HCC, SCCHN, EOC, or GBM), or isatuximab monotherapy (GBM only) dose 3
33031002|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
33031003|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.~."
33031004|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
33031005|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
33031006|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
33031007|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
33031008|NCT03512132||control|
33031009|NCT03512132||T1D with normal albumin levels|
33031010|NCT03512132||T1D with macroalbuminuria|
33031011|NCT03512132||T1D with microalbuminuria|
33031012|NCT03512132||T1D with microalbuminuria and statins|
33031013|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
33031014|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
33031015|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
33031016|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
33031017|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
33031018|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
33031019|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
33031020|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
33031021|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
33031022|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
33031023|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA </= 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
33031024|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA > 1.5m^2|"Phase I Part B BSA > 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
33031025|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
33031026|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
33031027|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
33031028|NCT03369600|Experimental|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
33031029|NCT03369600|Experimental|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
33031030|NCT03369600|Experimental|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
33031031|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
33031032|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
33031033|NCT03311152|Experimental|HCC-free cirrhotic patients (Controls)|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
33031034|NCT03311152|Experimental|HCC-positive cirrhotic patients (Cases)|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
33031035|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
33031036|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
33031037|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
33031038|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
33031039|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
33031040|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
33031041|NCT03246503|Experimental|Newborns|"Newborns will be enrolled in the study in 2 different ways. At Staged Enrollment sites, newborns will be enrolled when they are < 48 hours old. These newborns will have a study visit when they are 48 - 167 hours old. At the study visit, a BCB will be determined and blood will be drawn for study purposes for a TSB level. At Simultaneous Enrollment sites, newborns will be enrolled and have a study visit at the time of a blood draw (+/- 2 hours) for a TSB level that is being obtained for clinical purposes. Newborns will be 0-191 hours old."
33031042|NCT03228602|Active Comparator|healthy subjects|
33031043|NCT03228602|Experimental|obese|
33031044|NCT03228602|Experimental|obese diabetic|
33031045|NCT03228602|Experimental|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
33031046|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
33031047|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
33031048|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
33031049|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
33031050|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
33031051|NCT03115333|Experimental|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
33031052|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
33031053|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
33031054|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
33031055|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
33031056|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
33031057|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
33031058|NCT03032406|Experimental|HCQ alone (Arm A)|
33031059|NCT03032406|Experimental|EVE alone (Arm B)|
33031060|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
33031061|NCT03032406|Experimental|observation (Arm D)|
33031062|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
33031063|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
33031064|NCT02864368|Experimental|5-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
33031065|NCT02864368|Experimental|21-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
33031066|NCT02864368|Experimental|5-day TMZ: Safety Cohort|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine. Vaccine components A and B were administered separately, with a delay between them, to determine if it was an individual component or a combination of the components that resulted in adverse reactions.
33031067|NCT02864368|Experimental|5-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
33031068|NCT02864368|Experimental|21-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
33031069|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
33031070|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
33031071|NCT02812225||BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
33031072|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
33031073|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
33031074|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
33031075|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
33031076|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
33031077|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
33031078|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
33031079|NCT02625610|Experimental|Chemotherapy + Best Supportive Care (BSC)|In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
33031080|NCT02625610|Experimental|Avelumab|In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
33031081|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
33031082|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
33031083|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
33031084|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
33031085|NCT02514447|Experimental|Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b|"Patients in Parts 2a and 2b were randomized 1:2 to placebo. Patients received placebo administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
33031086|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a|"Patients in Part 2a were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
33031087|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b|"Patients in Part 2b were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
33031088|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.50 mg/m²)."
33031089|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.25 mg/m²)."
33031090|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
33031091|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
33031092|NCT02514447|Experimental|Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 1|"Patients received trilaciclib (280 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
33031093|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.0 mg/m²)."
33031094|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
33031095|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
33031096|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
33031097|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
33326717|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
33326718|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
33326719|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
33326720|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
33417555|NCT05189249||Control|Patients who have not undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
33031098|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
33031099|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
33031100|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
33031101|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
33031102|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33031103|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
33031104|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
33031105|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
33031106|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
33031107|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
33031108|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
33031109|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
33031110|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
33031111|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
33031112|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
33031113|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
33031114|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
33031115|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
33031116|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
33031117|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
33031118|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
33031119|NCT01595802||Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
33031120|NCT01595802||Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
33326721|NCT04997226|Active Comparator|tDCS over the left DLPFC with adaptive memory game|"The stimulation will be carried out using a battery-powered mobile device made by Neurocon with two 5 x 5 cm electrodes The anodal electrode will be positioned above the F3 region of a standard EEG cap that is parallel to the cortical DLPFC region. The return electrode will be placed over the right eyebrow. The electrodes will remain on the subjects head for 50 minutes - the entire duration of the session. 1mA stimulation will be given for 15 minutes, then a 20-minute break and again 15 minutes of 1 mA stimulation. This protocol has been shown to improve the duration of the stimulus effect (Monte-Silva et al., 2013)."
33417556|NCT01363921|Experimental|Dialysis treatment with HCO1100|
33417557|NCT02079818|Experimental|Penumbra Ruby Coil System|
33031121|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
33031122|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
33031123|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
33031124|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
33031125|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
33031126|NCT01442246|No Intervention|Surveillance|Surveillance
33031127|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
33031128|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
33031129|NCT01210313||no treatment|
33031130|NCT00951769||Control,|Control
33031131|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
33031132|NCT00951769||Australian|Australian difficult airway algorithm
33031133|NCT00788502|Experimental|Healing Touch|Healing Touch (HT) is a gentle form of energy balancing work that promotes relaxation. Subjects in this arm will receive three one-hour sessions of Healing Touch during the first two weeks of their IVF cycle.
33031134|NCT00788502|Experimental|Desensitization Therapy|Desensitization Therapy is a quasi-desensitization procedure where subjects meet with a therapist and generate a list of stressful thoughts and a list of neutral thoughts. Subjects in this arm will receive three one-hour sessions of Desensitization Therapy during the first two weeks of their IVF cycle.
33031135|NCT00788502|No Intervention|Standard Care|Subjects in this arm will receive no therapeutic intervention.
33031136|NCT00765791|Active Comparator|Group 1 (Not 2B)|Selective neck dissection is performed on the dominant arm. Level 2B is not dissected.
33031137|NCT00765791|Active Comparator|Group 2 (2B)|Selective neck dissection is performed on the dominant arm. Level 2B is dissected.
33031138|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
33031139|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
33031140|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
33031141|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
33031142|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
33031143|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
33031144|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
33031145|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
33031146|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
33031147|NCT00712322|Experimental|Cohort 1 (Darifenacin 0.030 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.030 milligrams/kilogram/day (mg/kg/day) dispensed per twice a day (BID) dosing, for 14 days.
33031148|NCT00712322|Experimental|Cohort 2 (Darifenacin 0.0625 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.0625 mg/kg/day dispensed per BID dosing, for 14 days.
33031149|NCT00712322|Experimental|Cohort 3 (Darifenacin 0.125 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.125 mg/kg/day dispensed per BID dosing, for 14 days.
33417558|NCT01358903|Experimental|A|
33031150|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
33031151|NCT00370604|Experimental|1|19g needle, 23g catheter
33031152|NCT00370604|Active Comparator|2|traditional =>18g needle
33031153|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
33031154|NCT05415150|Experimental|Measurement of Platelet function|Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.
33031155|NCT05415085|Experimental|Culprit-first PCI|In this arm, primary PCI with stent implantation will be performed prior to the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated first and the PCI will be performed.
33031156|NCT05415085|No Intervention|Culprit-last PCI|In this arm, primary PCI with stent implantation will be performed after the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated after the contralateral side and then PCI will be performed. This is the common approach.
33031157|NCT05415007|Experimental|GOLD Psychosocial Program|Participant will receive a 2-hour interventional session. Its content will consist of two modules: (1) psychoeducation and coping, providing information in content areas such as side effects of cancer treatments, fever protocols, role disruption and (2) stress, triggers, and self care, where caregivers will be briefed on symptoms of and reactions to traumatic stress in order to help parents accurately label thoughts and emotions related to their child's cancer diagnosis.
33031158|NCT05415007|Active Comparator|Treatment-as-Usual (TAU)|
33031159|NCT05414942|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
33031160|NCT05414942|Experimental|Opioid Reduction Program|Participants will engage in a brief, educational intervention pre-surgery and a brief booster session 2 weeks post-surgery.
33031161|NCT05414929|Experimental|HPV self-sampling group|
33031162|NCT05414903||Children with Normal Hearing|typically developing children with normal hearing (thresholds ≤ 20 dB HL from 0.25 to 8 kHz) age-matched to the children with hearing loss
33031163|NCT05414903||Children with hearing loss and normal vestibular function|Children with hearing loss will have a pure-tone average (PTA) > 65 dB and normal vestibular evaluation.
33031164|NCT05414903||children with hearing loss and vestibular loss|Children with hearing loss will have a pure-tone average (PTA) > 65 dB and and varying degree of vestibular loss (i.e., unilateral or bilateral).
33031165|NCT05414890||Cell Based Assay (CBA)|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA by different operators.
33031166|NCT05414890||CBA-TSA Assay|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA-TSA by different operators.
33417559|NCT01358903|Experimental|B|
33031167|NCT05414799|Other|Control Group|in control group,33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds once a day for 4 to 5 days per week for total duration of 4 week.
33031168|NCT05414799|Experimental|Experimental Group|in experimental group, 33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds followed by chin nodding for 20 second and followed by self neck stretching for 20 seconds. All the exercises are performed once a day for 4 to 5 days per week for total duration of 4 week.
33031169|NCT05414721|Active Comparator|Low flow desflurane anesthesia (Group D)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air) in Group D. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
33031170|NCT05414721|No Intervention|Normal flow desflurane anesthesia (Group N)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 2 L/min (40% O2+60% air) in Group N. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
33031171|NCT05414695|Experimental|Real acupuncture|The patient receives five sessions (weekly) of real acupuncture treatment in the acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes.
33031172|NCT05414695|Placebo Comparator|Placebo acupuncture|The patient receives five sessions (weekly) of placebo acupuncture in the same acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes. The placebo and real acupuncture devices have the same visual features but in the placebo device the needle does not even touch the skin.
33031173|NCT05414669|Experimental|Interventional group|Allopurinol 300 mg was administered orally for a total of 3 days, starting from the day before ESWL
33031174|NCT05414669|Placebo Comparator|Control Group|Placebo was administered orally for a total of 3 days, starting from the day before ESWL
33031175|NCT05414656|Experimental|Group A : Saddle contoured metal matrix|The prepared teeth received the Saddle contoured metal matrix. The saddle clip of matrix connect the band and secured around prepared cavity wall. The anatomical wedge placed into the gingival embrasure to maintain the height of gingival floor and ensure the optimal adaptation of the matrix band in the cervical region.
33031176|NCT05414656|Active Comparator|Group B:pre-contoured self-adhesive matrix|Teeth received the Pre-contoured self adhesive matrix with anatomical wedges. The adhesive end of band closed around the prepared cavity.
33031177|NCT05414643||At- risk group (SCAI stages A, B)|Patients who had a SCAI stage A or B at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was compared with the cardiogenic shock group only for preliminary analysis.
33031178|NCT05414643||Cardiogenic shock group (SCAI stages C-E)|Patients who had a SCAI (Society for Cardiovascular Angiography and Interventions) stage C-E at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was used for all subsequent analyses.
33031179|NCT05414630|Experimental|Envafolimab|Envafolimab: subcutaneous injection, 300mg, Q3W
33031180|NCT05414552|Experimental|ECP treatment arm|ECP treatment per prtocol
33031181|NCT05414539|Experimental|Intervention group|"OptiCogs Online is a 6-week telehealth intervention consisting of cognitive, physical activity and educational components. Cognitive component of the intervention: Throughout the six-week intervention period, there will be three individualised one-to-one cognitive sessions (occurring on week one, week three and week five), delivered by an occupational therapist. Physical activity: The physical activity component will be delivered via telehealth by a physiotherapist.~Aerobic: Progressions from Week 1-Week 6 will result in individual achieving 60 mins moderate intensity aerobic activity @ frequency of 3 times per week as tolerated.~Muscular strengthening: Progressions from Week 1-Week 6 will result in the person post-stroke achieving 10 strengthening exercises x 10 reps x 3 sets @ frequency of 3 times per week as tolerated. Cognitive education: The cognitive education component is underpinned by the Bridges stroke self-management package and based on self-efficacy principles."
33031182|NCT05414526|Experimental|InterCARE package|
33031183|NCT05414474|Active Comparator|Reference|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe).
33031184|NCT05414474|Experimental|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 500 mg AA.
33031185|NCT05414474|Experimental|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) and 80 mg AA.
33031186|NCT05414474|Experimental|Coffee|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe) and 150 mL coffee.
33031187|NCT05414474|Experimental|Breakfast|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 1 bread roll (~100 g) with butter and honey, 1 cup of plain yoghurt (180 mL), 1 cup of coffee (150 mL) and 1 glass of orange juice (250 mL).
33031188|NCT05414474|Experimental|Afternoon|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) in the afternoon .
33031189|NCT05414461|Experimental|Combination treatment|PD-1 inhibitor-based combination treatment
33031190|NCT05414396|Experimental|Supportive care (EML program)|Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
33031191|NCT05414292|Experimental|Drug group|Will take 1mg Rapamune (sirolimus) in oral tablet form daily for 16 weeks.
33031192|NCT05414292|Placebo Comparator|Placebo group|Will take a placebo tablet (lactose) daily for 16 weeks
33031193|NCT05414279|Other|Capillary and venous sodium|From each patient a capillary and venous blood sample will be taken in order to determine the sodium level
33031194|NCT05414266|Experimental|4 months Placebo, then 8 months SADBE 5%|
33031195|NCT05414266|Experimental|12 months SADBE 5%|
33031196|NCT05414253|Experimental|Test group 1|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system + hyaluronic acid mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
33031197|NCT05414253|Experimental|Test group 2|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
33031198|NCT05414253|Placebo Comparator|Control Group|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: placebo mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
33031199|NCT05414188|Active Comparator|Pulmonary rehabilitation group|Patients will receive the radiation therapy according to the existing schedule. Additionally, patients in pulmonary rehabilitation group will participate pulmonary rehabilitation program more than two times per week.
33031200|NCT05414188|No Intervention|Control group|Patients will receive the radiation therapy according to the existing schedule. There will be no additional treatment
33031201|NCT05414149|Active Comparator|IVR group|Patients that received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery were assigned to IVR group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
33031202|NCT05414149|Experimental|IVC group|Patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery were assigned to IVC group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
33031203|NCT05414071|Experimental|NMS Assist|NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
33031204|NCT05413993|Active Comparator|intra and extraoral application|The laser was applied for 60 seconds, in 2 intraoral points and 2 extraoral points.
33031205|NCT05413993|Experimental|extraoral application|The laser was applied only extraoral points
33031206|NCT05413967|Experimental|Mills manipulation in addition to myofasical release therapy|mills manipulation
33031207|NCT05413967|Experimental|Nirschl exercises in addition to myofascial release therapy|Nirschel exercises
33031208|NCT05413954|Placebo Comparator|Control|Control snack
33031209|NCT05413954|Experimental|Test|Test snack
33031210|NCT05413928|Experimental|Intervention|Participants will undergo a baseline phase for 20 days, where they will follow their regular dietary intake, physical activity, and sleep. They will be wearing a CGM and an activity monitor and for a couple of nights, they will use a sleep monitor. That will be followed by 4 interventional phases where they will be asked to limit their daily eating to 10 hours or less (Time Restricted Eating, TRE), with the eating window and the caloric distribution will be shifted during each of the next 3 phases, each phase lasting 20 days. The last phase will last 8 days and participants will be asked to consume provided meals with a determined amount of protein, carbohydrates, and fat. Their body temperature will be measured using a continuous temperature device and a heart rate monitor to capture dynamic rage of the sympathetic response during and after the meal consumption (thermotyping).
33326722|NCT04997226|Placebo Comparator|Sham tDCS over the left DLPFC with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 50 minutes, similar to the active tDCS arm.
33031213|NCT05414227||PSD|Depressed as assessed by the Hamilton Depression Scale 3 months after stroke
33031214|NCT05414227||Non PSD|Nondepressed as assessed by the Hamilton Depression Scale 3 months after stroke
33033351|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
33031215|NCT05413902|Experimental|MMA Protocol Group|"Preoperative Medications~Orphenadrine 100mg PO once preop~Gabapentin 800mg PO once preop~Toradol 60mg IV once preop~Acetaminophen 1,000mg PO once preop~Intraoperative Paraspinal Infusion~Bupivacaine 30cc~Epinephrine 1cc~Xylocaine-MPF Intramuscular Inj 0.5% (30cc of Saline Solution)~Postoperative Medications~Orphenadrine 100mg PO BID~Gabapentin 300mg PO Q6~Toradol 30mg IV Q6hrs*~Methylprednisolone 125mg Q8hrs"
33031216|NCT05413902|Active Comparator|Control (opioids) Group|"Postoperative Medication~1-Morphine 4mg Q4hrs"
33031217|NCT05413876||Men with classical Fabry disease|
33031218|NCT05413876||Women with classical Fabry disease|
33031219|NCT05413876||Men with non-classical Fabry disease|
33031220|NCT05413876||Healthy controls|Age-, Sex-, BMI-matched controls
33031221|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031222|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031223|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031224|NCT05413863|Experimental|Sequence: Humulin® R U-500-Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031225|NCT05413863|Experimental|Sequence: Humulin® R U-500 -Biocon's Human Insulin R U-500-Humulin® R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031226|NCT05413863|Experimental|Sequence: Humulin® R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD(Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
33031227|NCT05413746|Experimental|Antioxidant dressing (active product)|"Wound bed debridement, Antioxidant dressing (active product) application in the wound bed, covered with secondary dressing.~Device: Reoxcare®"
33031228|NCT05413720|Other|Patient with leptospirosis|
33031229|NCT05413694|Experimental|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
33031230|NCT05413681|Active Comparator|metabolic myopathy|a supra-maximal exercise test on a cycloergometer.
33031231|NCT05413681|Placebo Comparator|Control : Healthy volonteers|a supra-maximal exercise test on a cycloergometer.
33031232|NCT05413629|No Intervention|Group1 (n=33)|Control 1: Pretest negative and post test positive group
33031233|NCT05413629|No Intervention|Group 2 (n=33)|Control 2: Pretest positive and post test positive
33031234|NCT05413629|Experimental|Group 3 (n=33)|Experimental 1: Pretest negative and post test positive
33031235|NCT05413629|Experimental|Group 4 ( n=33)|Experimental 2: Pretest positive and post test positive
33031236|NCT05413603|Active Comparator|fluoroscopic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the fluoroscope (FS) to fully focus the shock waves on the stone
33031237|NCT05413603|Active Comparator|ultrasonic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the ultrasound (US), to fully focus the shock waves on the stone
33031238|NCT05413590|Active Comparator|Young, Active group|"From 18 to 35 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 Metabolic Equivalent of Task (MET)-minutes per week"
33031239|NCT05413590|Active Comparator|Young, sedentary group|From 18 to 35 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
33033352|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
33033353|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
33033354|NCT01962077|Experimental|MedCem MTA pulpotomies|
33031240|NCT05413590|Active Comparator|Old, Active group|"From 65 to 80 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
33031241|NCT05413590|Active Comparator|Old sedentary group|From 65 to 80 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
33031242|NCT05413590|Active Comparator|Very old, Active group|"From 81 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
33326723|NCT04997226|Active Comparator|tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but stimulation method will be employed at 2mA intensity for 20 minutes at theta-gamma coupling using a laplacian montage (Alekseichuk et al., 2016).
33326724|NCT04997226|Placebo Comparator|Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 20 minutes, similar to the active tACS arm.
33326725|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
33031243|NCT05413590|Active Comparator|Very old sedentary group|From 81 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
33031244|NCT05413512|Experimental|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
33031245|NCT05413382|Active Comparator|Investigational lozenge|Lozenge containing the enzyme polyphenol oxidase and green coffee extract
33031246|NCT05413382|Placebo Comparator|Placebo lozenge|Lozenge equal to active comparator but without active ingredients
33031247|NCT05411042|Experimental|Intervention group|The experimental group intervened a dance somatosensory game (DSG), DANZ BASE developed by International Games System Company, at the Xinzhuang health center, which is a local bureau with outpatient clinic. The participants in experimental group played twice a week, each time requiring at least lasting 30 minutes, for half of a year.
33031248|NCT05411042|No Intervention|Control group|The control group only performed routine data collection; the research assistant asked the subjects about their usual activities by telephone every month to understand their physical activity in this half of the year.
33031249|NCT05410899||Pelvic Floor Health Education|Education will compose presentation about women health, urinary incontinence, teaching anatomy of the pelvic floor and bladder training
33031250|NCT05410899||Pelvic Floor Health Education and Exercise Program|pelvic floor health education and exercise of pelvic floor muscles for 12 weeks
33031251|NCT05410899||Control|This goup will continue routine treatment such as medication usage
33031252|NCT05409287|Experimental|Immediate Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, immediately after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
33031253|NCT05409287|Active Comparator|Early Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, 4 weeks after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
33031254|NCT05406258|Experimental|Patients performing intermittent catheterization|
33326726|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
33326727|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
33326728|NCT01161264|Experimental|18-60 YOA|
33326729|NCT01161264|Experimental|≥ 60 YOA|
33326730|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
33326731|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
33326732|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
33326733|NCT01163838|Placebo Comparator|Placebo|
33031255|NCT05404971|Experimental|Joint integrity exercises|"Tactile stimulation with the various textures will be applied to the patients with three strokes followed by 3 sec rest period.~Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set."
33326734|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
33326735|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
33326736|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
33326737|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
33326738|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
33326739|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
33326740|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
33326741|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
33326742|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
33031256|NCT05404971|Active Comparator|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
33031257|NCT05404074|Experimental|Cobitolimod 500mg|2-3 single doses of rectal cobitolimod (500mg/50ml) over 3-6 weeks
33326743|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
33326744|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
33326745|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
33031258|NCT05397587|Experimental|Experimental Group aged 6~23 months|Up to 146 subjects aged 6~23 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization and at the age of 72 months.
33031259|NCT05397587|Experimental|Experimental Group aged 24~35 months|Up to 128 subjects aged 24~35 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
33031260|NCT05397587|Experimental|Experimental Group aged 36~71 months|100 subjects aged 36~71 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
33031261|NCT05397587|Active Comparator|Control Group aged 36~71 months|100 subjects aged 36~71 months and have received EV71 vaccine developed by Institute of Medical Biology,Chinese Academy of Medical Sciences will be collected blood samples at 36 months after full immunization .
33031262|NCT05387785|Experimental|500 mg QD|500 mg QD of ANG-3070 will be taken once a day for 10 days.
33031263|NCT05387785|Experimental|300 mg BID|300 mg BID of ANG-3070 will be taken twice a day for 10 days.
33031264|NCT05387785|Placebo Comparator|Placebo-to-match 500 mg QD|Placebo-to-match 500 mg QD of ANG-3070 will be taken once a day for 10 days.
33031265|NCT05387785|Placebo Comparator|Placebo-to-match 300 mg BID|Placebo-to-match 300 mg BID of ANG-3070 will be taken twice a day for 10 days.
33031266|NCT05384522||Parkinson's Disease subjects|Subjects with Parkinson Disease aged 65 years or more at Hoehn and Yahr stage ≤3
33031267|NCT05379244|Experimental|CBT-i|Cognitive Behavioral Therapy for insomnia adjusted for patients with mixed psychiatric disorders
33031268|NCT05378880|Experimental|Intervention clusters|Intervention bundle consisting of 3 components introduced over 12 months: one to improve antibiotic use targeting health centres and medicine stores and two targeting the general population: one to increase community health literacy and one to improve water, hygiene and sanitation practices.
33031269|NCT05378880|No Intervention|Control clusters|
33031270|NCT05371795|Active Comparator|Lancets|
33031271|NCT05371795|Experimental|Comfort Marker 2.0|
33031272|NCT05368883|Experimental|One-legged cycling ergometer training|One-legged cycling ergometer training; 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks.
33031273|NCT05368883|Active Comparator|Two-legged cycling ergometer training|Two-legged cycling ergometer training; 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks.
33031274|NCT05356936|Experimental|Vitamin K2(MK-7) and Vitamin D3|Participants randomized to this group will receive Vitamin K2 (MK-7) and Vitamin D3 by mouth.
33031275|NCT05356936|No Intervention|Control|Participants to this group will receive no intervention.
33031276|NCT05352178|Active Comparator|MDT alone|Metastasis-directed therapy alone
33031277|NCT05352178|Experimental|MDT + 1 month of ADT|Metastasis-directed therapy plus one month of androgen deprivation therapy (gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im)
33031278|NCT05352178|Experimental|MDT + 6 months of ADT + anzalutamide|Metastasis-directed therapy plus 6 months of androgen deprivation therapy (gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im) and enzalutamide (4 x 40 mg each day during 6 months )
33031279|NCT05333796|Experimental|Healthy children (5 to 12 years old)|
33031280|NCT05328141|Experimental|Bread and butter|A toast bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
33326746|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
33326747|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
33031281|NCT05328141|Experimental|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
33031282|NCT05328141|Experimental|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
33031283|NCT05310916|Experimental|Test group|(n=30): type 2 diabetes mellitus patients who will receive an oral antidiabetic along with dapagliflozin at a dose of 10 mg daily for 12 weeks.
33031284|NCT05310916|Active Comparator|Control group|(n=30): type 2 diabetes mellitus patients who will receive two oral antidiabetic agents for 12 weeks
33031285|NCT05291169|Experimental|Omeza Combination Therapy + SOC|The Omeza Combination Therapy under investigation includes two Over the Counter (OTC) drugs, Omeza®Lidocaine Lavage for periwound preparation and pain control, and Omeza® Skin Protectant to be applied to the skin from knee to ankle for increased perfusion. Omeza® Collagen Matrix is an FDA cleared 510(K) medical device which is applied directly to the wound bed. The combination treatment is applied on a weekly basis, followed by compression management
33031286|NCT05291169|No Intervention|SOC|Cleaning and debriding the Study ulcers and compression management on a weekly basis.
33031287|NCT05287243|Other|Inspiratory Muscle Training|involves the intervention portion of the study to improve strength of the cardiopulmonary system
33031288|NCT05285215|Experimental|Integrated psychological program (IPP) group|Patients are assigned to have mindfulness training and music listening before and after delivery. Video counselling will be offered if patient is found to have Edinburgh Postnatal Depression Scale (EPDS) equal to or more than 10. Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
33031289|NCT05285215|No Intervention|Non- Integrated psychological program (IPP) group|Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
33031290|NCT05285202|Experimental|Hotspot-focused ACF/TPT|ACF/TPT intervention will be delivered in a community setting, in geographic areas judged likely to have a high burden of undiagnosed TB
33031291|NCT05285202|Experimental|Facility-based ACF/TPT|ACF/TPT intervention will be delivered on the grounds of a health facility (hospital or large public health center)
33031292|NCT05285202|No Intervention|No intervention|
33031293|NCT05278481|Active Comparator|Reward Message with standard introduction|
33031294|NCT05278481|Active Comparator|Reward Message with culturally tailored introduction|
33031295|NCT05278481|Active Comparator|Threat/Self-efficacy with standard introduction|
33031296|NCT05278481|Active Comparator|Threat/Self-efficacy with culturally tailored introduction|
33031297|NCT05278481|Active Comparator|Social norms message with standard introduction|
33031298|NCT05278481|Active Comparator|Social norms message with culturally tailored introduction|
33031299|NCT05272475|Experimental|Chamomile Tea|Subjects will consume a single serving of chamomile tea on the visit day. The tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
33031300|NCT05272475|Experimental|Chamomile Extract Capsule|Subjects will consume a single chamomile capsule on the visit day. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
33031301|NCT05263466|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional PET-MRI examination and biopsies in addition to the standard of care.
33031302|NCT05259137|No Intervention|Intra-lesional triamcinolone acetonide|This arm will will be our control. They will receive current standard of care of a single intra-lesional injection of 1 mL of 10mg/mL triamcinolone acetonide at 0 weeks, 6 weeks, and 12 weeks.
33031303|NCT05259137|Experimental|Intra-lesional triamcinolone acetonide + enalaprilat|This will be our intervention experiment. They will receive a single intra-lesional injection of 0.5 mL of 10 mg/mL of triamcinolone acetonide + 0.5 mL of 1.25 mg/mL of enalaprilat at 0 weeks, 6 weeks, and 12 weeks.
33031304|NCT05251493|Active Comparator|Iron Isomaltoside/ferric derisomaltose|route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
33031305|NCT05251493|Active Comparator|Iron Sucrose|Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
33031306|NCT05241444|Experimental|Cohort A (≥12 years)|"The first participant in Dose Level 1 will be administered 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in the first participant, the following participants in Dose Level 1 will be administered the same dose of 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 1, participants will be enrolled into Dose Level 2 and administered 3 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
33031307|NCT05241444|Experimental|Cohort B (<12 years)|"Participants in Cohort B will always follow treatment of participants in Cohort A for the same dose level.~The first participant in Dose Level 1 will be administered 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in the first participant, the following participants in Dose Level 1 will be administered the same dose of 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 1, participants will be enrolled into Dose Level 2 and administered 3 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
33031308|NCT05238415|No Intervention|Control group receiving no Post-/Long-COVID assessment|Questionnaires at timepoints t1 (screening), t2 (before intervention), t3 (same time with the intervention/0 months after intervention), t4 (3 months after intervention), t5 (6 months after intervention)
33033355|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
33031309|NCT05238415|Experimental|Intervention group receiving a Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (before intervention), t3 (same time with the intervention/0 months after intervention), t4 (3 months after intervention), t5 (6 months after intervention)~Assessment in clinics for post-/long-COVID"
33031310|NCT05235204|Experimental|Foley catheter removal day 2 or 3 post-operative procedure|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
33031311|NCT05233709|Other|OTf + FeSO4|OTf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with apo-Ovotransferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
33031312|NCT05233709|Other|Lf+ FeSO4|Lf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with lactoferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
33031313|NCT05233709|Other|FeSO4|FeSO4 - This is the control arm where Ferrous sulfate will be given in the form of a solution that will be spread on bread with butter and honey, as a breakfast meal
33031314|NCT05230043||Suicide Attempters using Violent Means|A violent suicidal act is any suicidal act conducted with any means except for medication overdose or superficial wrist cutting.
33031315|NCT05230043||Patient Control|
33031316|NCT05230043||Healthy Controls|
33031317|NCT05230043||Suicide Attempters not using Violent Means|
33031318|NCT05216952|Experimental|UPA 90mg|Participants receive ulipristal acetate 90mg PO followed by self-administration of misoprostol 800mcg vaginally 6 to 18 hours following ulipristal acetate administration.
33031319|NCT05206539|Experimental|SAP11-4 group (Gr CR)|The Gr CR will receive treatment with Curodont RepairTM (Credentis; Windisch, Switzerland), according to the manufacturer's instructions.
33031320|NCT05206539|Active Comparator|CPP-ACFP group (Gr V)|The Gr V will receive treatment with MI varnishTM (GC Corporation, Tokyo, Japan), according to the manufacturer's instructions.
33031321|NCT05206539|Active Comparator|Resin infiltration group (Gr I)|The Gr I receive treatment with Icon Vestibular (DMG, Germany), according to the manufacturer's instructions.
33031322|NCT05206539|Placebo Comparator|Control group (Gr NT)|The control group (Gr NT) receive no intervention except brushing twice daily with aminofluoride toothpaste and toothbrush provided by researcher.
33031323|NCT05191355||subjects with familial hypercholesterolemia|blood test
33031324|NCT05191355||healthy subjects|blood test
33031325|NCT05177887|Experimental|Traumacel PULVIS|Traumacel PULVIS will be poured into the bleeding area directly or using an applicator Traumacel ENDO Applicator.
33031326|NCT05173896|Experimental|Tadalafil|Oral tadalafil (20 mg) capsules once daily for three months.
33031327|NCT05173896|Placebo Comparator|Placebo|Oral placebo capsules once daily for three months.
33031328|NCT05173701|Experimental|Probiotics|Administration of a mixture of probiotics once daily for three months
33031329|NCT05173701|Placebo Comparator|Placebo|Administration of a placebo (maltodextrin) once daily for three months
33031330|NCT05165537|Experimental|NIMM_MRS|testing of new MRS methods
33031331|NCT05165524|Active Comparator|Laser|
33031332|NCT05165524|Active Comparator|Cream|
33031333|NCT05165524|No Intervention|Control|
33031334|NCT05150951|Experimental|Experimental group|Novel exploration is used before extinction in an attempt to strengthen the extinction consolidation.
33031335|NCT05150951|Experimental|Control group|Participants perform a control task (visual attention) instead of the novel exploration.
33031336|NCT05150236|Experimental|Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
33031337|NCT05150236|Experimental|177Lu-PSMA-617|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles or until disease progression or unacceptable toxicity.
33031338|NCT05127200|Experimental|Anodal tsDCS (cervical active, lumbar sham)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the cervical level.~sham tsDCS at the lumbar level."
33031339|NCT05127200|Active Comparator|Anodal tsDCS (cervical sham, lumbar active)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the lumbar level.~sham tsDCS at the cervical level."
33031340|NCT05121896|Active Comparator|Patients with facial synkinesis|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
33031341|NCT05121896|Active Comparator|Control participants|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
33031342|NCT05117619|Experimental|HOME for Us|The HOME intervention is the delivery of an in-home, family inclusive, rehabilitation intervention in eight sessions. Six of the sessions will occur in the home, and two will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
33031343|NCT05117619|Active Comparator|Attention Control|The Attention-control condition is the delivery of educational materials over 8 contacts. Three of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
33031344|NCT05111821|Experimental|Deferiprone|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
33031345|NCT05111821|Active Comparator|Treatment As usual|Patients followed during 6 months according to standard care
33031346|NCT05105438|Active Comparator|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
33031347|NCT05105438|Experimental|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
33326748|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
33031348|NCT05105282|Active Comparator|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
33031349|NCT05105282|Active Comparator|Superficial Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
33031350|NCT05086835|Experimental|Working Memory App (Active Intervention)|A visual-spatial app-based working memory intervention.
33031351|NCT05086835|Active Comparator|Visual Search App (Control Condition)|An app-based visual search task to be used as a control condition.
33031352|NCT05067478||Cohort A Vibegron|Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
33031353|NCT05067478||Cohort B Vibegron|Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or mirabegron and anticholinergic therapy experience will receive vibegron as per the U.S. label.
33031354|NCT05067387|Placebo Comparator|Placebo|Oral placebo; sesame and MCT oil
33031355|NCT05067387|Experimental|20 mg THC|THC suspended in sesame oil
33031356|NCT05067387|Experimental|20 mg CBD|CBD suspended in MCT oil
33031357|NCT05067387|Experimental|20 mg THC + 20 mg CBD|THC and CBD in sesame and MCT oil
33031358|NCT05067101|Experimental|Capsule Sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy
33031359|NCT05067101|Placebo Comparator|Conventional Radical Cystoprostatectomy|Patients undergoing conventional radical cystoprostatectomy
33031360|NCT05066815|Experimental|Hybrid superstructure|screw retained hybrid ceramic crowns
33031361|NCT05066815|Active Comparator|Ceramic superstructure|screw retained lithium disilicate based ceramic crowns
33031362|NCT05036772|No Intervention|Standard Practice|The control arm is supported according to the usual practice. The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography
33031363|NCT05036772|Experimental|Interventionnal|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
33031364|NCT05005455|Active Comparator|bevacizumab with old manufacturing process.|
33031365|NCT05005455|Experimental|bevacizumab with new manufacturing process.|
33031366|NCT05003622|Experimental|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
33031367|NCT04989309|Experimental|Experiment 2. Phonetic precision disrupted by TMS|"Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed dog to cat object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens."
33031368|NCT04989309|Experimental|Experiment 3. Phonetic ambiguity in continuous speech|"Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence (BRASS?). Dependent variables are accuracy and reaction time on this probe verification task."
33031369|NCT04989309|Experimental|Experiment 6: Disruption of talker-specific phonetic learning using TMS.|"Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in coal) and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. gain vs. cane). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker."
33031370|NCT04983017|Active Comparator|Dietary supplements|Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
33031371|NCT04983017|Placebo Comparator|Placebo|Placebo-matched formulations
33031372|NCT04969406|Experimental|Imaging by BOSS System|Imaging by the BOSS System
33031373|NCT04963192|Experimental|OSA or COPD patients having an integrated management at home|OSA or COPD patients having an integrated management at home using connected devices, during 6 months
33031374|NCT04959149|Experimental|face-to-face intubation|intubation approach from front of the patient
33031375|NCT04959149|Active Comparator|standard position intubation|intubation approach from behind the head of the patient
33031376|NCT04940598|Experimental|High intensity interval exercise|High intensity interval arm crank exercise
33031377|NCT04940598|Other|No-Exercise Control|No-exercise control group
33031378|NCT04910386|Experimental|Envafolimb|"Envafolimab plus Gemcitabine&Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.~Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
33031379|NCT04910386|Active Comparator|Gemcitabine&Cisplatin|"Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
33031380|NCT04904107|Experimental|Intervention group|"Chest pain patients in the intervention group will be assessed by EMT personnel by performing the modified HEART score (including POC high sensitive troponin-I measurement (POC HS cTnI)) and the referral policy depends on the result.~In case of a low modified HEART score (modified HEART 0-3) patients will not be referred to the cardiac ED.~Patients with a modified HEART score >3 are directly referred to the cardiac ED after evaluation. These patients will receive standard care."
33031381|NCT04904107|Active Comparator|Control group|Chest pain patients in the control group will receive standard triage and standard care according to the local (EMT) protocol.
33031382|NCT04890977|Experimental|Talking Story|Talking Story is a modular behavioral intervention intended to increase mental health treatment-seeking among Pacific Islanders through the use of narrative films and other culturally syntonic approaches.
33031383|NCT04890977|Placebo Comparator|Wait-list control|The wait-list control will be administered as a control arm to the active Talking Story arm.
33031384|NCT04880486|Sham Comparator|Control group|usually care with extra health education on upper limb exercise
33031385|NCT04880486|Experimental|Exercise group|usually care with extra supervision upper limb exercise with VR
33031386|NCT04877730|Experimental|FCL (Fully Closed Loop)|Closed-loop control without meal anticipation module without meal bolus
33031387|NCT04877730|Experimental|FCL+ (Fully Closed Loop with meal anticipation)|Closed-loop control with meal anticipation module without meal bolus
33031388|NCT04877730|Experimental|HCL (Hybrid Closed Loop)|Closed-loop control without meal anticipation module with meal bolus
33031389|NCT04875715|Experimental|Almond oil|Almond Oil Pressed Cold
33031390|NCT04875715|Active Comparator|Hydroquinone|Hydroquinone 2% cream
33031391|NCT04875260||Critically ill patients|Patients received critical care in the intensive care units
33031392|NCT04872309||Asthma Patients|Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
33031393|NCT04872309||COPD Patients|Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
33031394|NCT04872309||ICU COVID-19|Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
33031395|NCT04872309||Moderate/Severe COVID-19|Adults hospitalised with COVID-19
33031396|NCT04872309||Mild- Non-hospitalised COVID-19|Adult with proven COVID-19 infection, not hospitalised for COVID-19
33031397|NCT04872309||Non-hospitalised symptomatic (long-COVID group)|Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
33031398|NCT04871490|Other|Study Group|All eligible participants.
33031399|NCT04870632|Sham Comparator|Control group|Patients in control group received the education booklet with words and pictures.
33031400|NCT04870632|Experimental|Video group|Patients in intervention group watched YOUTUBE videos to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
33031401|NCT04870632|Experimental|Booklet group|Patients in intervention group read education booklet with words and pictures to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
33031402|NCT04858399||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
33031403|NCT04858399||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
33031404|NCT04858399||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour
33031405|NCT04857541||Health adult|
33031406|NCT04800341||Patients ESADA follow-up|Patients included in the ESADA European database and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire.
33031407|NCT04798989|Experimental|CY6463|
33031408|NCT04798989|Placebo Comparator|Placebo|
33031409|NCT04798144|Experimental|Cryotherapy group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at 2.5°C in the refrigerator using EndoVac negative pressure irrigation system.
33031410|NCT04798144|Placebo Comparator|Control group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at room temperature in the refrigerator using EndoVac negative pressure irrigation system.
33031411|NCT04759872|Experimental|Metabolic Study Visit|Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.
33031412|NCT04757662|Experimental|Tadalafil|"Tadalafil will be given orally once daily for a total of 60 days at a weight-normalized dose as follows:~10 mg/day if weight ≤63.5 kg~15 mg/day if weight >63.5 kg and ≤104.3 kg~20 mg/day for weight >104.3 kg~Standard of care fractionated radiation therapy (RT) to 60 Gy in 30 daily fractions will be administered in this study.~Concurrent temozolomide (TMZ) will be administered as per standard of care, i.e., continuously (Monday through Sunday) from Day 1 of RT to the last day of RT at a daily oral dose of 75 mg/m^2 at the discretion of treating medical oncologist.~Adjuvant therapy will administered as per standard of care. Typically, this consists of adjuvant TMZ initiated 4 to 6 weeks after completion of RT for 6 cycles at 150-200 mg/m^2 PO per day on Days 1-5 of every 28-day cycle. Tumor-treating fields or Optune device (Novocure) as per routine clinical care during adjuvant TMZ is permitted at the discretion of the treating physician."
33031413|NCT04751825|Experimental|I-EAET|Internet administrated Emotional and Awareness and Expression Therapy (I-EAET). 10 weeks. Self-help treatment with therapist contact via text messages at least once a week.
33326749|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
33031414|NCT04751825|No Intervention|WL|Wait-list.
33031415|NCT04742322|Placebo Comparator|Placebo|1x capsule/day - maltodextrin, period of 10 to 14 days
33031416|NCT04742322|Experimental|B Lactis|1x capsule/day - 9x10x10 UFC, period of 10 to 14 days
33031417|NCT04742010|Experimental|Zoledronic Acid|Active treatment
33031418|NCT04742010|Placebo Comparator|Placebo|Placebo
33031419|NCT04733911|Experimental|Eccentric 75|Participants in this arm will perform an eccentric exercise protocol consisted of 75 eccentric repetetions on an isokinetic dynamometer.
33031420|NCT04733911|Experimental|Eccentric 150|Participants in this arm will perform an eccentric exercise protocol consisted of 150 eccentric repetetions on an isokinetic dynamometer.
33031421|NCT04733911|Experimental|Eccentric 300|Participants in this arm will perform an eccentric exercise protocol consisted of 300 eccentric repetetions on an isokinetic dynamometer.
33031422|NCT04733911|No Intervention|Control|Participants in this arm will receive no intervention.
33031423|NCT04704401||Patients PWV follow-up|"Patients included in the meta-analysis sleep apnea syndrome and arterial stiffness and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire."
33031424|NCT04697095|Experimental|early / intermediate AMD without neovessels and without macular atrophy|
33031425|NCT04697095|Experimental|Late exsudative AMD with neovessels|
33031426|NCT04697095|Experimental|Late AMD with macular atrophy without neovessels|
33031427|NCT04697095|Sham Comparator|Patientes with No AMD|
33031428|NCT04646681|Experimental|Group 1|
33031429|NCT04646681|No Intervention|Group 2|
33031430|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
33031431|NCT04636034|Experimental|Ropivacaine-Lidocaine|
33031432|NCT04636034|Placebo Comparator|Placebo|
33031433|NCT04636034|Sham Comparator|"Sham-block with Placebo"|
33031434|NCT04594941|Experimental|Group 1|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the HPLC method
33031435|NCT04594941|Experimental|Group 2|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the SPE method
33031436|NCT04594941|Experimental|Group 3|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method
33031437|NCT04594941|Experimental|Group 4|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method
33031438|NCT04582279|Experimental|Receiving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
33031439|NCT04578327|Experimental|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
33031440|NCT04578327|Experimental|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
33031441|NCT04547946||dabrafenib + trametinib|Patients administered dabrafenib and trametinib
33031442|NCT04546295|Experimental|Brushlink|
33031443|NCT04546295|Active Comparator|Water-flosser|
33031444|NCT04546295|Placebo Comparator|Interproximal Brush|
33031445|NCT04542603|Experimental|treatment naivete women with stage 1-4 newly diagnosed ovarian|
33031446|NCT04524663|Experimental|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
33031447|NCT04524663|Placebo Comparator|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
33031448|NCT04523337|Experimental|MISSION-CJ|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services.
33031449|NCT04523337|Experimental|Enhanced Usual Care|Usual care provided by the mental health residential rehabilitation treatment programs, with patients in both groups are enrolled in, in addition to peer support and community outreach case management. Patients receive 2 Peer Support Curriculum sessions per week (24 sessions total). Patients will receive unstructured community outreach and linkage support while enrolled in the mental health residential rehabilitation program. After discharge, patients will continue to receive 1 hour of weekly linkage support per week.
33031450|NCT04507854|Experimental|Operated athletes|
33031451|NCT04482036|Placebo Comparator|Dementia Collaborative Care|"Patient and caregivers assigned to the three in-person assessments and no mobile application group will complete the following:~The caregiver will be asked to complete three in-person assessments that involve answering survey questions and an interview.~Some of the questions asked will be related to Behavioral and/or Psychological Symptoms the patient experiences.~The caregiver will be asked to answer questions about the patient, the patient's experience with the research study and the caregiver's own experience with the research study.~If the patient's symptoms or the caregiver's distress answers reach a high enough level, a member of the research study team and clinical team will contact the caregiver to ask more questions and check in on the patient and caregiver's safety.~The research study team will also notify Dr. Bateman (the person responsible for the research)."
33033356|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
33033357|NCT01962116|Placebo Comparator|Heparin lock|
33033358|NCT01962116|Experimental|Citrate lock|
33326750|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
33326751|NCT01163994|Active Comparator|MEM-ceftriaxone|
33326752|NCT01163994|Active Comparator|MEM-doxycycline|
33326753|NCT01163994|No Intervention|controls|
33326754|NCT01163994|Active Comparator|EM-doxycycline|
33031452|NCT04482036|Active Comparator|Dementia Collaborative Care Plus BrainCare Notes Application|"Patient and caregivers assigned to the three in-person assessments and mobile application group will complete the same tasks that Group 1 (control group) will complete with the addition of the following:~The caregiver will be asked to monitor the patient and complete 5 to 10-minute long surveys (the neuropsychiatric inventory questionnaire) sent to the caregiver through the mobile application or in-person at each follow-up visit.~The caregiver will be asked to monitor and complete these surveys at different times for a period of 6 months."
33031453|NCT04475744|No Intervention|Control arm|POI women radomized to control arm will undergo a 3-month follow up for: AFC, AMH, FSH and E2 determinations.COS will be initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.
33326755|NCT01267578|Experimental|peptide vaccination|
33326756|NCT03874728||Older people at risk of falls|Older people at risk of falls
33031454|NCT04475744|Experimental|4-step ASCOT arm|POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
33031455|NCT04471532|Experimental|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
33031456|NCT04471532|No Intervention|Control|No attention
33031457|NCT04462198|Experimental|PIPE-505|
33031458|NCT04462198|Placebo Comparator|Placebo|
33031459|NCT04458155||Chest pain patients|"Patients are eligible for participation if they are admitted to:~The cardiac emergency department (ED) because of chest pain for ruling out acute coronary syndrome by troponin analysis~The Coronary Care Unit (CCU) with a NSTEMI or post-percutaneous coronary intervention (PCI) STEMI.~Troponin analysis will be performed according to standard protocol. From every included patient two capillary blood samples and an extra venous blood sample will be drawn during regularly ordered blood work to evaluate HS cTnI levels obtained with the POC instrument."
33031460|NCT04453475|Experimental|Partial digital group: depression|"Burg~Online depression session as a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
33031461|NCT04453475|Experimental|Partial digital group: social work (social medicine)|"NOR~Online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
33031462|NCT04453475|Experimental|Partial digital group: depression + social work|"JUL~Online depression session as a flipped classroom and an online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
33031463|NCT04453475|Active Comparator|Control group: only digital training before rehabilitation|"MOE~Online tobacco cessation a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
33031464|NCT04450706|Experimental|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
33031465|NCT04450706|Experimental|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
33326757|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
33326758|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
33326759|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
33326760|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
33326761|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
33326762|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
33326763|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
33326764|NCT01268748|Other|One port transumb. laparoscopic surgery|
33031469|NCT04438668|Active Comparator|Standard Care|Standard care (SC) for screening for FGR is a healthcare provider auscultating the foetal heart rate with a standard stethoscope, palpation of foetal size by hand, and measuring the size of the woman's uterus with a tape measure, and comparing the measurement to the expected measurement for the gestational age of the foetus.
33031470|NCT04438668|Experimental|Standard Care and Centaflow|Centaflow uses sound-derived maternal intra-arterial turbulence as a marker of foetal growth restriction (FGR) and provides information on the foetal heart rate. Indication for use is as a screening device for FGR in women beyond 27 weeks of pregnancy with a singleton pregnancy.
33031471|NCT04435795|Active Comparator|Ciclesonide inhaled and nasal|Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
33031472|NCT04435795|Placebo Comparator|Placebo|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
33031473|NCT04420923|Experimental|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
33031474|NCT04420923|Active Comparator|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
33031475|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
33031476|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
33031477|NCT04362995||Long Term Follow Up (LTFU)|Subset of participants who participated in the original SJTRC study and agree to continue in LTFU
33031478|NCT04356248|Experimental|High-intensity interval training + energy management education|"High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.~Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
33031479|NCT04356248|Active Comparator|Low-intensity training + progressive muscle relaxation|"Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).~Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
33031480|NCT04350593|Active Comparator|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
33031481|NCT04350593|Placebo Comparator|Placebo|Dapagliflozin matching placebo 10 mg daily
33031482|NCT04342754|Experimental|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
33031483|NCT04342754|Sham Comparator|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
33031484|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
33031485|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
33031486|NCT04260698|Experimental|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:~Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
33031487|NCT04257110|Other|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle ( 21 days or 28 days).
33031488|NCT04257110|Experimental|Part 2: Cohort 1|Breast Cancer with HER2 overexpressing or positive
33031489|NCT04257110|Experimental|Part 2: Cohort 2|Breast Cancer with HER2 low expressing
33031490|NCT04257110|Experimental|Part 2 Cohort 3|Gastric Cancer or gastroesophageal junction cancer with HER2 overexpressing or positive
33031491|NCT04257110|Experimental|Part 2 Cohort 4|Solid Tumors other than Breast Cancer and Gastric Cancer with HER2 overexpressing or positive
33031492|NCT04247620|Experimental|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
33031493|NCT04247620|Other|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
33031494|NCT04247620|No Intervention|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
33033359|NCT01962129||Patients affected by a syndrome OFD|
33031495|NCT04247620|No Intervention|Research Supplement|Following completion of 12-month data collection, a subset of participants from the Usual Care group will have the opportunity to complete an optional and additional week (7 days) of follow-up data collection to characterize general and diabetes-specific sleep patterns.
33031496|NCT04233866|Experimental|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33031497|NCT04233866|Experimental|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33031498|NCT04233645|Experimental|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
33031499|NCT04233645|Active Comparator|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
33031500|NCT04222283|Experimental|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
33031501|NCT04208243|Experimental|Oncology Patient|Any Oncology patient in the CCBD who has not previously received more than two sessions of CAT in the outpatient unit and who will be receiving approximately weekly infusions of at least one hour in the infusion center will be identified by a research assistant.
33031502|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded.~*Based on preliminary results we have expanded our trial and will continue to recruit up to 40 patients with minor stroke."
33031503|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls (n=15) without neurologic disease or prior clinical history of stroke.
33031504|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
33031505|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
33031506|NCT04137367|Experimental|Active Affective Bias Modification|Computer based Affective Bias Modification
33031507|NCT04137367|Sham Comparator|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
33031508|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
33031509|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
33031510|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
33031511|NCT04103424|No Intervention|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
33031512|NCT04103424|Experimental|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
33031513|NCT04099524|Experimental|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
33031514|NCT04099524|Sham Comparator|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
33031515|NCT04095923|Experimental|Social media game|Private Facebook group with weekly walking challenges, Fitbit wearable activity monitor, and brief counseling
33031516|NCT04095923|Active Comparator|Standard self-regulation|Fitbit wearable activity monitor and brief counseling
33031517|NCT04074486||Injured and Matched Control Subjects|Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport).
33033360|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
33033361|NCT01962142||Exacerbated asthma patients|
33033362|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
33033363|NCT01962168||Evolution® Biliary Stent - Uncovered|
33031518|NCT04074486||Healthy Volunteer Subjects|Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment.
33031519|NCT04074486||Non-Concussed Head Injured Subjects|A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0
33031520|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
33031521|NCT04065152|Experimental|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10^6 pfu/ml at week 1 then 10^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
33031522|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
33031523|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia with or without fetal growth restriction ; fetal growth restriction without preeclampsia.
33031524|NCT03977259|No Intervention|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
33031525|NCT03977259|Experimental|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
33031526|NCT03962998|Active Comparator|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
33031527|NCT03962998|Experimental|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
33031528|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
33031529|NCT03955250|Experimental|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
33031530|NCT03955250|Active Comparator|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
33031531|NCT03947450|Experimental|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
33031532|NCT03947450|Placebo Comparator|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
33031533|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
33031534|NCT03917667||Geriatric patients|Patients aged 70 years and older who are admitted to the acute care geriatric units.
33031535|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
33031536|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
33031537|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
33031538|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
33031539|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
33031540|NCT03847090|Experimental|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
33031541|NCT03847090|Placebo Comparator|placebo|placebo capsule
33031542|NCT03810482|Experimental|The study population|"The study population as described by eligibility criteria.~Intervention: 6 minute walking test Intervention: pedometer"
33033364|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
33033365|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
33031543|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
33031544|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
33031545|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
33031546|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
33031547|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
33031548|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
33031549|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
33031550|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
33031551|NCT03738423|Experimental|Treatment 1|
33031552|NCT03738423|Experimental|Treatment 2|
33031553|NCT03738423|Experimental|Treatment 3|
33031554|NCT03738423|Experimental|Treatment 4|
33031555|NCT03738423|Experimental|Treatment 5|Matching placebo
33031556|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
33031557|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
33031558|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
33031559|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
33031560|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
33031561|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
33031562|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
33031563|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
33031564|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
33031565|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
33031566|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
33031567|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
33031568|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
33033366|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
33031569|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
33031570|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
33031571|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
33031572|NCT03600818|Placebo Comparator|Placebo+52 Week Taper|Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
33031573|NCT03600818|Experimental|Sarilumab 200mg q2w+14 Week Taper|Participants received sarilumab 200 milligrams (mg) as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 14 weeks and prednisone-matching placebo from Week 14 up to Week 52.
33031574|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
33031575|NCT03578276|Active Comparator|Standard of Care|"Gatifloxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
33031576|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
33031577|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
33031578|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
33031579|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
33031580|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
33031581|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
33031582|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
33031583|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
33031584|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
33031585|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
33031586|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
33031587|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
33031588|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
33031589|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
33031590|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
33031591|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
33031592|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
33031593|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
33031594|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
33031595|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
33031596|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
33031597|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
33031598|NCT03233191|Experimental|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
33326765|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
33326766|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
33031599|NCT03233191|Experimental|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
33031600|NCT03196206|Experimental|Group A|Normal Renal Function
33031601|NCT03196206|Experimental|Group B|Moderate Renal Impairment
33326767|NCT04995588|Other|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
33031602|NCT03196206|Experimental|Group C|Severe Renal Impairment
33031603|NCT03174184|Experimental|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
33031604|NCT03174184|Experimental|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
33031605|NCT03174184|Experimental|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
33031606|NCT03174184|Experimental|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
33031607|NCT03174184|Experimental|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
33031608|NCT03174184|Experimental|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
33031609|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
33031610|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
33031611|NCT03052933|Experimental|Copanlisib/gemcitabine|
33031612|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
33031613|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
33031614|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
33031615|NCT02959697|Experimental|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
33031616|NCT02959697|Sham Comparator|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
33031617|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
33031618|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
33031619|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
33031620|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
33031621|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
33031622|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
33031623|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
33326768|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
33326769|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
33326770|NCT01164306|Experimental|LifeSkills training|
33326771|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
33326772|NCT01269450|Active Comparator|Utrogestan|
33326773|NCT01269450|Placebo Comparator|placebo|
33031624|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
33031625|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
33031626|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
33031627|NCT02775812|Experimental|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
33031628|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
33031629|NCT02669810|Experimental|PROTHERACYTES|The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia) or a catheter introduced via the femoral / radial route up to coronary arteries for epicardiac injections (BullFrog/Mercator).
33031630|NCT02669810|Active Comparator|Standard of Care|Patients will be treated as standard treatment for CHF post - AMI.
33031631|NCT02657265|Experimental|SpineJack® system|Spine fracture management
33031632|NCT02657265|Active Comparator|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
33031633|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
33031634|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
33031635|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
33031636|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
33031637|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
33031638|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
33031639|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
33031640|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
33031641|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
33031642|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
33031643|NCT02317887|Experimental|Group 1|1e9 vg/eye
33031644|NCT02317887|Experimental|Group 2|1e10 vg/eye
33031645|NCT02317887|Experimental|Group 3|1e11 vg/eye
33031646|NCT02317887|Experimental|Group 4|1e11 vg/eye
33031647|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
33031648|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
33031649|NCT02238496|Other|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
33031650|NCT02238496|Other|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
33326774|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
33326775|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
33326776|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
33326777|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
33326778|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
33326779|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
33031651|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
33031652|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
33031653|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
33031654|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
33031655|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
33031656|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
33031657|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
33031658|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
33031659|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
33031660|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
33031661|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
33031662|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
33031663|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
33031664|NCT01809704||Retina|Clinical exam results consistent with retina pathology
33031665|NCT01711333|Experimental|Pletaal SR capsule|
33031666|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
33031667|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
33031668|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
33031669|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
33031670|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
33031671|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
33031672|NCT01498458|Experimental|pazopanib plus capecitabine|
33031673|NCT01427712||LipaCreon|"In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day.~Also, the dose was adjusted appropriately according to the patient's condition."
33326780|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
33031675|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 0.6 x REE for up to 28 days. The dose of parenteral nutrition (PN) will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
33031676|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.0 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
33326781|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
33326782|NCT01268904||Pediatric status epilepticus|
33326783|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
33326784|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
33326785|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
33031677|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.3 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
33031678|NCT01197066|Other|Certolizumab Pegol|Single Arm
33031679|NCT01079780|Active Comparator|Arm A (IC)|Patients receive cetuximab (500 mg/m2) intravenously (IV) over 60-120 minutes and irinotecan hydrochloride (180 mg/m2) over 60-90 minutes on day 1. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
33031680|NCT01079780|Experimental|Arm B (ICR)|Patients receive ramucirumab (8 mg/kg) IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
33031681|NCT01079780|Experimental|Arm C (mICR)|Patients receive reduced dose of ramucirumab (6 mg/kg) IV over 60 minutes on day 1 and cetuximab (150 mg/m2) and irinotecan hydrochloride (400 mg/m2) as in arm B. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
33031682|NCT00075946|Active Comparator|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
33031683|NCT00075946|Experimental|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
33031684|NCT00003641|Other|Observation|Patients undergo observation for 4 weeks.
33031685|NCT00003641|Experimental|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
33031686|NCT01945827||DeltaMaxx treated Patients|
33031687|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
33031688|NCT01945840|Experimental|Gut hormone infusion|"Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:~Combination of GLP-1/OXM/PYY (GOP)~Single GLP-1~Single OXM~Single PYY~Combination of GLP-1 and OXM~Combination of GLP-1 and PYY~Combination of OXM and PYY"
33031689|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously for 4 weeks.
33031690|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks.
33031691|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
33031692|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
33031693|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
33031694|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
33031695|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
33031696|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
33031697|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
33031698|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
33031699|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
33031700|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
33031701|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
33031702|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
33326786|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
33107350|NCT04653233|Experimental|Intervention|After the theoretical lesson, the students in the experimental group were taken to the laboratory room where the 3D Systems Touch Haptic Simulator is located. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option. Since the preparation of the material in the full teaching method in the simulator takes a long time, these steps were removed to show similarity with the control group. The skill practice option for an average of 5-10 minutes where all steps of the Checklist for Teaching Urinary Catheterization Skill can be applied was used. Urinary catheterization with 3D Systems Touch Haptic Simulator was explained by 1 researcher who was responsible for the Fundamentals of Nursing course.
33107351|NCT04653233|No Intervention|Control|"After the theoretical lesson, the control group was taken to Fundamentals of Nursing Skill Laboratory. 1 researcher, who is responsible for the Fundamentals of Nursing, was explained on the Simple Urinary Catheterization Model by applying the steps of Checklist for Teaching Urinary Catheterization Skills. The students were allowed to ask questions and the questions asked were answered. Then all the students in the control group were taken to an empty class. The two researchers prepared the necessary materials for the urinary catheterization skill practice in the same way in separate rooms. The doors were closed to keep the environment calm during the application. One student was taken to each laboratory rooms in order not to be affected by each other. While the student was practicing, both researchers filled in the Checklist for Teaching Urinary Catheterization Skills. Satisfaction Questionnaire was given to the student who completed the application and asked to fill it."
33107352|NCT00542802|Experimental|LEV|Levetiracetam
33107353|NCT00542802|Active Comparator|CAR|Carbamazepina
33107354|NCT04652648|Active Comparator|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID for 10 days
33107355|NCT04652648|No Intervention|Control|No Intervention
33107356|NCT00542841|Experimental|1|
33107357|NCT04652765|No Intervention|Standard of care (SOC)|SARS-CoV-2 positive participants will receive SOC therapy alone.
33107358|NCT04652765|Active Comparator|SOC plus camostat and bicalutamide|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.
33107359|NCT00542958|Experimental|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.~For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.~UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
33107360|NCT04652492|Experimental|Tislelizumab in combination with cTACE|Tislelizumab in combination with on-demanded cTACE
33107361|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
33107362|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
33107363|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
33107364|NCT04652336|Active Comparator|LSG|This group will receive standard laparoscopic sleeve gastrectomy
33107365|NCT04652336|Experimental|LSG with LTC|This group will receive LSG along with the novel LTC procedure
33107366|NCT04652297|Experimental|HS-10356 single dose|Single oral dose of HS-10356 ascending dose
33107367|NCT04652297|Placebo Comparator|placebo single dose|Single oral dose of placebo ascending doses
33107368|NCT04652297|Experimental|HS-10356 multiple doses|Multiple oral doses of HS-10356 ascending doses
33107369|NCT04652297|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo ascending doses
33107370|NCT04652024|No Intervention|CONTROL GROUP|Girls in the control group received pelvic floor muscle exercise (kegel exercise) daily in the outpatient clinic 12 weeks.
33107371|NCT04652024|Experimental|STUDY GROUP|Girls in the study group received the same physical therapy program given to the control group in addition to anorectal biofeedback for six sessions per week. in addition to kegel exercise
33107372|NCT04651907|Experimental|acupuncture group|The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3mm×30mm. The needle placed for the real acupuncture group will be the same needle size as 0.3mm×30mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
33107373|NCT04651907|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
33107374|NCT04651907|No Intervention|waitlist-controlled group|As an waitlist control group, no acupuncture will be performed.
33107375|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
33107376|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
33107377|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
33107378|NCT00543153||Patients diagnosed with cancer|
33107379|NCT04652258|Other|Treatment arm|"The patients will be administered Tocilizmab (Actemra) at the following dosage :~First dose: 8mg/kg, max. 800mg iv. during 60min~If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose"
33031703|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
33031704|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
33031705|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
33031706|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
33031707|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
33031708|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
33031709|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
33031710|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
33031711|NCT01946061|Experimental|Treatment group|
33031712|NCT01946087|Experimental|RIPC group|
33031713|NCT01946087|Placebo Comparator|Control group|
33031714|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
33031715|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
33031716|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
33031717|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
33031718|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
33031719|NCT01946269|Active Comparator|Standard group|
33031720|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
33031721|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
33031722|NCT01946295|Placebo Comparator|Placebo|Placebo control
33031723|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
33031724|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
33031725|NCT01946334|Experimental|patients|
33031726|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
33031727|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
33031728|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
33031729|NCT01946386|Experimental|LEO 90100|
33031730|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
33031731|NCT01946451||Idiophatic ERMs|
33031732|NCT01946451||Secondary ERMs|
33031733|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
33031734|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
33031735|NCT01946490||Radiotherapy in 2001|
33031736|NCT01946490||Radiotherapy in 2004|
33031737|NCT01946490||Radiotherapy in 2006|
33031738|NCT01946490||Radiotherapy in 2010|
33031739|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
33031740|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
33031741|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
33031742|NCT01946568|Experimental|Single dose Dalbavancin|
33031743|NCT01946581||Cataract Surgery|
33031744|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
33031745|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
33031746|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
33031747|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
33031748|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
33031749|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
33031750|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
33031751|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
33031752|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
33031753|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
33031754|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
33031755|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
33031756|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
33031757|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
33031758|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
33031759|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
33031760|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
33031761|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
33031762|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
33031763|NCT01946789|Experimental|ALT-803|
33031764|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
33031765|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
33031766|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
33031767|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
33031768|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
33031769|NCT01946906|No Intervention|No treatment|patient receive no active treatment
33031770|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
33031771|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
33031772|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
33031773|NCT01946945|No Intervention|Control - Standard ART treatment|
33031774|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
33031775|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
33031776|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
33031777|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
33031778|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
33031779|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
33031780|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
33031781|NCT01946997||Group 1: Non Diabetic|Normal retina
33031782|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
33031783|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
33031784|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
33031785|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
33031786|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
33031787|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
33031788|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
33031789|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
33031790|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
33031791|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
33031792|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
33031793|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
33031794|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
33031795|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
33031796|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
33031797|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
33033367|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
33031798|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
33031799|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
33031800|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
33031801|NCT01947114|Active Comparator|Group Propofol|
33031802|NCT01947114|Active Comparator|Group Ketamine|
33031803|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
33031804|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
33031805|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
33031806|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
33031807|NCT01947205|Active Comparator|paracetamol|Duration
33031808|NCT01947205|Active Comparator|without drug|Control group
33031809|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
33031810|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
33031811|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
33031812|NCT01947218|Experimental|smoking COPD|
33031813|NCT01947218|Experimental|smoking without COPD|
33031814|NCT01947218|Other|No Smoking Control|
33031815|NCT01947218|Experimental|severe asthma|
33031816|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
33031817|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
33031818|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
33031819|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
33031820|NCT01947257|Other|ventilated patients|
33031821|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
33031822|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
33031823|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
33031824|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
33031825|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
33031826|NCT01947322|Experimental|Allogenic NK cells infusion|
33031827|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
33031828|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
33031829|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
33031830|NCT01947387||Integra|
33031831|NCT01947387||Integra + NPWT (short-inpatient use only)|
33031832|NCT01947387||Integra + NPWT (long-all other durations)|
33031833|NCT01947387||Integra + STSG|
33031834|NCT01947387||Integra + Dermoinductive Agent|
33031835|NCT01947387||Free Flap|
33031836|NCT01947387||Local Tissue Flap|
33031837|NCT01947387||NPWT|
33031838|NCT01947387||NPWT then Integra (on same admission)|
33031839|NCT01947400||Hospitalists|AIDET Training
33031840|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
33031841|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
33031842|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
33031843|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
33031844|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
33031845|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
33031846|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
33031847|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
33031848|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
33031849|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
33031850|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
33031851|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
33031852|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
33031853|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
33031854|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
33031855|NCT01947504|Experimental|education and support intervention|education and support intervention
33031856|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
33031857|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
33031858|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
33031859|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
33031860|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
33031861|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
33031862|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
33031863|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
33031864|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
33031865|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
33031866|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
33031867|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
33031868|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
33031869|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
33031870|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
33031871|NCT01947660|Experimental|Continuous regional anesthesia|
33031872|NCT01947660|Active Comparator|Systemic analgesia|
33031873|NCT01947673|Experimental|Modified Mindfulness Based Stress Reduction (MBSR) Program|After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
33326787|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
33107380|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
33107381|NCT04652141|Active Comparator|AsthmaTuner field tests|Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 >12% and 200 ml or positive periodic variability PEF/FEV1 >20%. Treatment recommendation is prescribed individually by treating physician.
33107382|NCT04652141|No Intervention|Traditional trial treatment|Treatment recommendation is prescribed individually to patient by treating physician. The treatment plan is transferred to patient on printed paper and/or oral communication.
33107383|NCT04651517|Experimental|Study arm|Subjects undergoing procedures with the XACT ACE Robotic system.
33107384|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
33107385|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
33107386|NCT04651478|Experimental|Action Observation+Motor Imagery through BCI|"Action Observation+Motor Imagery through a Brain-Computer Interface training paradigm in Virtual Reality using the NeuRow platform during 10 sessions of 20 minutes, divided in 4 series of 5 minutes."
33107387|NCT04651478|Placebo Comparator|Action Observation through non-related with movement illustrations|Control Action Observation protocol of non-related with movement illustrations during 10 sessions of 20 minutes, divided in 4 series of 5 minutes.
33107388|NCT00419328|Experimental|Experimental Arm A|Patients were scheduled to receive a 1 hour intravenous (iv) infusion of NGR-hTNF every 3weeks.- The dose of administered NGR-hTNF was: 0.2, 0.4, 0.8, 1.6 μg/m2 (step 1); 3.2, 6.4, 12.8 μg/m2 (step 2); 19.2, 28.8, 43.2 64.8 μg/m2 (step 3); 86.2, 114.6, 152.4 μg/m2 (step 4)
33107389|NCT04651751|No Intervention|Control|No Intervention: Control Participants exercised on their own without receiving any instructions.
33107390|NCT04651751|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
33107391|NCT00543270|Experimental|Endovascular Repair - EVAR (Powerlink System)|EVAR (Powerlink System)
33107392|NCT00543270|Active Comparator|Open Surgical Control|Open Surgical Control
33107393|NCT04651556|Active Comparator|Parenteral Analgesia|receive ordinary analgesics via intravenous route as paracetamol (7.5- 10 mg/kg) and ketorolac (0.5 mg/kg).
33107394|NCT04651556|Active Comparator|Intraperitoneal instillation|receive (Magnesium sulphate 40 mg/kg and bupivacaine 4mg/kg) in 30 ml of isotonic 0.9%N.S intra peritoneal at the end of surgery.
33107395|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
33107396|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
33107397|NCT04651322|Experimental|Training group|
33107398|NCT04651322|Other|Control group|
33107399|NCT04651049||Propranolol treatment group|
33107400|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
33107401|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
33107402|NCT04651205|No Intervention|Untreated|This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
33107403|NCT04651205|Experimental|Mg-B1 early start|Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).
33107404|NCT04651205|Experimental|B1-Mg early start|Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).
33107405|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
33107406|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
33107407|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
33107408|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
33107409|NCT04651283|Experimental|Adaptive seating equipment group|Study group who received the same selected program for hand function on adaptive swiss ball seating
33107410|NCT04651283|Active Comparator|Traditional seat group|Control group who received a specially selected physical therapy program for hand function on a standard chair seating.
33107411|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
33107412|NCT00557921|Experimental|1|
33107413|NCT00557921|Active Comparator|2|
33107414|NCT03456609|Experimental|shenqifuzheng|
33107415|NCT03456609|Placebo Comparator|0.9%sodium chloride|
33107416|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
33107417|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
33107418|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
33107419|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
33326788|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
33031874|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
33031875|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
33031876|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
33031877|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
33031878|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
33031879|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
33031880|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
33031881|NCT01947738|Experimental|VBY-891|VBY-891
33031882|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
33031883|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
33031884|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
33031885|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training~Chart materials to guide and document disclosure counseling and visits~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
33031886|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:~Modified materials to guide disclosure sessions~Videotaped narratives for parental counseling~Dedicated disclosure counselors to initiate and conduct the disclosure process~Post-disclosure support groups for children~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
33031887|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
33031888|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
33031889|NCT01947803|Experimental|Paliperidone Palmitate|
33031890|NCT01947829||Chronic Hemodialysis|
33031891|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
33031892|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
33031893|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
33031894|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
33031895|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
33031896|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
33031897|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
33031898|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
33031899|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
33031900|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
33031901|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
33031902|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
33031903|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
33031904|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
33031905|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
33031906|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
33031907|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
33031908|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
33031909|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
33326789|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
33031910|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
33031911|NCT01948037|Active Comparator|hydrotherapy|
33031912|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
33031913|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
33031914|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
33031915|NCT01948115|Placebo Comparator|Medical air|
33031916|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
33031917|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
33031918|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
33031919|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
33031920|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
33031921|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
33031922|NCT01948167|Experimental|Coping with Stress|Coping with Stress
33031923|NCT01948180|Experimental|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
33031924|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
33031925|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
33031926|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
33031927|NCT01948232|Experimental|Perindopril|
33031928|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
33031929|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
33031930|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
33031931|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
33031932|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
33031933|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
33031934|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
33031935|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
33031936|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
33031937|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
33031938|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
33107420|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
33107421|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
33031939|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
33031940|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
33031941|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
33031942|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
33031943|NCT01948362|Active Comparator|Sulforadex|Active compound
33031944|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
33031945|NCT01948401|Experimental|Controlled asthma|
33031946|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
33031947|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
33031948|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
33031949|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
33031950|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
33031951|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
33031952|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
33031953|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
33031954|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
33031955|NCT01948466|Experimental|Commercials|Schools Administered Commercials
33031956|NCT01948466|No Intervention|Control|Schools not Administered Commercials
33031957|NCT01948479|Experimental|Insole optimised with inshoe analysis|
33031958|NCT01948479|Active Comparator|Routine insole provision|
33031959|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
33031960|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
33031961|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
33031962|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
33031963|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD~COPD is the 4th leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization were associated with higher costs~Oximetry is an important tool for assessing need for Long-term oxygen therapy~LTOT has been proven to improve survival and quality of life~Patients will be provided a lightweight portable oxygen concentrator to:~support increased activity~improve quality of life~increase functional capacity"
33031964|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
33031965|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
33031966|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
33031967|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
33107422|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
33107423|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
33326790|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
33326791|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
33326792|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
33031968|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
33326793|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
33031969|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
33031970|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
33031971|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
33031972|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
33031973|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
33031974|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
33031975|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
33031976|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
33031977|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
33031978|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
33031979|NCT01948674|Experimental|computerized tasks- adaptive|
33031980|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
33031981|NCT01948687||1. the control group|healthy adult volunteers
33031982|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
33031983|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
33031984|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
33031985|NCT01948700|Other|Standard Intervention|Education
33031986|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
33031987|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
33031988|NCT01948726|Experimental|Hypofractionation with SIB|
33031989|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
33031990|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
33031991|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
33031992|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
33031993|NCT01948765|Active Comparator|Xenon and propofol|
33031994|NCT01948765|Placebo Comparator|propofol|
33031995|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
33031996|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
33031997|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
33031998|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
33031999|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
33032000|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
33032001|NCT01948856|Experimental|J022X ST|
33032002|NCT01948856|Placebo Comparator|Placebo|
33032003|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
33032004|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
33032005|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
33032006|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
33032007|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
33326794|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
33326795|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
33326796|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
33326797|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
33032008|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
33032009|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
33032010|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
33032011|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
33032012|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
33032013|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
33032014|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
33032015|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
33032016|NCT01949012|No Intervention|Control|Standard monitoring
33032017|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
33032018|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
33032019|NCT01949025|No Intervention|Control group|
33032020|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
33032021|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
33032022|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
33032023|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
33032024|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
33032025|NCT01949064|Active Comparator|Grindcare|Biofeedback device
33032026|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
33032027|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
33032028|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
33032029|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
33032030|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
33032031|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
33032032|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
33032033|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
33032034|NCT01949129|Experimental|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is for conditioning before HSCT from MSD or MD. ATG Thymo or Grafalon is used for patients who receive stem cells from unrelated donors.~Fludarabine/Thiotepa/Treosulfan with either ATG Thymo or Grafalon is also used for HSCT from MMD with in vitro T-Cell Depletion (TCD) or with CD34+ selection.~Fludarabine/Thiotepa/Treosulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
33032035|NCT01949129|Active Comparator|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used for conditioning for HSCT with MSD or MD graft with patients who are older than 48 months at the time of conditioning.~TBI/VP16 is also used with Post TX-Cyclophosphamide for MMD-graft without in vitro T-Cell Depletion.~TBI/VP16 with either ATG Thymo or Grafalon is used for MMD-HSCT with in vitro T-Cell Depletion or with CD34+ selection."
33032036|NCT01949129|Experimental|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used for conditioning before HSCT from MSD or MD.~Fludarabine/Thiotepa/iBu with either ATG Thymo or Grafalon is also used for HSCT from MMD-HSCT with T-Cell Depletion (TCD) or haplo with CD34+ selection.~Fludarabine/Thiotepa/iV Busulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
33032037|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
33032038|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
33032039|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
33032040|NCT01949181|Experimental|Pulmonary cancer|
33032041|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
33032042|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
33032043|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
33032044|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
33032045|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
33032046|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
33032047|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
33032048|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
33032049|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
33032050|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
33032051|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
33032052|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
33032053|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
33032054|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
33032055|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
33032056|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
33032057|NCT01949350|Active Comparator|Water|Starved as for surgery
33032058|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
33032059|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
33032060|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
33032061|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
33032062|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
33032063|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
33032064|NCT01949376||Controls|healthy, cognitively normal subjects
33032065|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
33032066|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
33032067|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
33032068|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
33032069|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
33032070|NCT01949441|Experimental|ToleroMune HDM|
33032071|NCT01949441|Placebo Comparator|Placebo|
33032072|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
33032073|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
33032074|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
33032075|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
33032076|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
33032077|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
33032078|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
33032079|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
33032080|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
33032081|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
33032082|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
33032083|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
33032084|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
33032085|NCT01949519|Experimental|Docetaxel and Lycopene|
33032086|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
33032087|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
33032088|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
33032089|NCT01949597||Patients with symptomatic endometriosis|
33032090|NCT01949610|Experimental|14C-JNJ26489112|
33032091|NCT01949623||RP patients|Retinitis Pigmentosa patients
33032092|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
33032093|NCT01949636||lean adolescents|
33032094|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
33032095|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
33032096|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
33032097|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
33032098|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
33032099|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
33032100|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
33032101|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
33032102|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
33032103|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
33032104|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
33032105|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
33032106|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
33032107|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
33032108|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
33032109|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
33032110|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
33032111|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
33032112|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
33032113|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
33032114|NCT01949831|No Intervention|Control|Usual care
33032115|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
33032116|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
33032117|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
33032118|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
33107424|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
33107425|NCT02346162|Experimental|Intervention|Weight management intervention
33107426|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
33107427|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
33107428|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
33107429|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
33107430|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
33107431|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin)|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
33107432|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
33107433|NCT00557999|No Intervention|Control group|
33107434|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
33107435|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
33107436|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
33107437|NCT00558116|Experimental|1|Treatment with Dynasplint device
33107438|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
33107439|NCT05077254|Experimental|Pfizer-BioNTech Bivalent COVID-19 Vaccine + SOC IS Regimen|"Participants will receive a study dose (1 dose) of the Pfizer-BioNTech Bivalent COVID-19 vaccine and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
33107440|NCT05077254|Experimental|Pfizer-BioNTech Bivalent COVID-19 Vaccine +SOC IS Reduction|"Participants will receive an additional dose (1 dose) of the Pfizer-BioNTech Bivalent COVID-19 vaccine, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
33107441|NCT05077254|Experimental|Moderna Bivalent COVID-19 Vaccine + SOC IS Regimen|"Participants will receive an additional dose (1 dose) of the Moderna COVID-19 Vaccine and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
33107442|NCT05077254|Experimental|Moderna Bivalent COVID-19 Vaccine +SOC IS Reduction|"Participants will receive a study dose (1 dose) of the Moderna Bivalent COVID-19 vaccine, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
33107443|NCT04650971|Experimental|"Vaccine UniFluVec 6.7 log EID50/dose"|"Cohort 1 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 6.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
33107444|NCT04650971|Experimental|"Vaccine UniFluVec 7.7 log EID50/dose"|"Cohort 2 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 7.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
33107445|NCT04650971|Placebo Comparator|Placebo|Placebo comparator arm consists of 20 subjects (10 subject in each Сohort).
33107446|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
33107447|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
33326798|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
33326799|NCT01280214|Experimental|Triamcinolone|
33326800|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
33326801|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
33326802|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
33326803|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
33326804|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
33326805|NCT01164540|Experimental|1|Oral Treatment
33326806|NCT01164540|Placebo Comparator|2|Oral treatment
33326807|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
33326808|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
33326809|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
33326810|NCT01280370||1|1.patients treated in a laparoscopic manner
33326811|NCT01280370||2.|2. patients treated in open operative manner
33326812|NCT01280448||Case Group|
33326813|NCT01280448||Control Group|
33326814|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
33326815|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
33032119|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
33032120|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points."
33032121|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points."
33032122|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
33032123|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
33032124|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
33032125|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
33032126|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
33032127|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
33032128|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
33032129|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
33032130|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
33032131|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
33032132|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
33032133|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
33032134|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
33032135|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
33032136|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:~To assess and manage pain and other symptoms resulting from disease progression.~To evaluate the information needs that may arise and to address them.~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.~To provide guidance in decision-making while respecting patient autonomy.~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.~To promote continuity of care."
33032137|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
33032138|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
33032139|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
33032140|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
33032141|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
33032142|NCT01950026|Experimental|white|cryotherapy application
33032143|NCT01950026|Experimental|black|cryotherapy application
33032144|NCT01950026|Experimental|Brown|cryotherapy application
33032145|NCT01950026|Experimental|asian|cryotherapy application
33032146|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
33032147|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
33032148|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
33326816|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
33326817|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
33326818|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
33326819|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
33326820|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
33032149|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
33032150|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
33032151|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
33032152|NCT01950091|No Intervention|Usual care control group|No contact; Control group
33032153|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
33032154|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
33032155|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
33032156|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
33032157|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
33032158|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
33032159|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
33032160|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
33032161|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
33032162|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
33032163|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
33032164|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
33032165|NCT01950208||knee pain|patients suffering from knee injury
33032166|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
33032167|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
33032168|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
33032169|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
33032170|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
33032171|NCT01950325|Experimental|Group 1|1mg/kg IV
33032172|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
33032173|NCT01950325|Experimental|Group 4|20 mg/kg IV
33032174|NCT01950325|Experimental|Group 5|40 mg/kg IV
33032175|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
33032176|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
33032177|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
33032178|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
33032179|NCT01950455|Experimental|NAV5001|
33032180|NCT01950468|Experimental|NAV5001|
33326821|NCT01164696||Group 1|
33032181|NCT01950468|Active Comparator|DaTscan|
33032182|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
33032183|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
33032184|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
33032185|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
33032186|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
33032187|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
33032188|NCT01950507|Experimental|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
33032189|NCT01950507|Experimental|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
33032190|NCT01950507|Experimental|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
33032191|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
33032192|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
33032193|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
33032194|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
33032195|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
33032196|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
33032197|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
33032198|NCT01950611|Experimental|Bortezomib in treatment|
33032199|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
33032200|NCT01950637||Healthcare professionals (HCPs)|
33032201|NCT01950650||Patients with diabetes|
33032202|NCT01950650||Physicians|
33032203|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
33032204|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
33032205|NCT01950689|Placebo Comparator|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
33032206|NCT01950689|Experimental|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
33032207|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.~Patient's head were fixed at neutral position during all intubation period."
33032208|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
33032209|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
33032210|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
33032211|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
33032212|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
33032213|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
33032214|NCT01950754|Other|depressive patients|
33032215|NCT01950754|Other|nondepressed controls|
33032216|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
33032217|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
33032218|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
33032219|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
33032220|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
33032221|NCT01950832||Control|60 healthy volunteers
33032222|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
33032223|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
33032224|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
33032225|NCT01950858|Active Comparator|Control|non weight bearing
33032226|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
33032227|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
33032228|NCT01950884|Active Comparator|lifestyle|lifestyle
33032229|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
33032230|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
33032231|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
33032232|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
33032233|NCT01950949|Experimental|change respiratory parameters, volume expanding|
33032234|NCT01950962|Other|slight periodontal disease|
33032235|NCT01950962|Other|moderate periodontal disease|
33032236|NCT01950962|Other|severe periodontal disease|
33032237|NCT01950975|Other|Parents|2 parents of child
33032238|NCT01950975|Other|infant|
33032239|NCT01950988|Other|Children|
33032240|NCT01950988|Other|Adults|
33032241|NCT01950988|Other|Elderly people|
33032242|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
33032243|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
33032244|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose~If patients show PRU < 85, prasugrel dose will be reduced by 5 mg/d.~If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
33032245|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
33032246|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
33032247|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
33032248|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
33032249|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
33032250|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
33032251|NCT01951040||Oxytocin|Oxytocin was administered during labor
33032252|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
33032253|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032254|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032255|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032256|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032257|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032258|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
33032259|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
33032260|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
33032261|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
33032262|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
33032263|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
33032264|NCT01951183|Placebo Comparator|Placebo|
33032265|NCT01951183|Experimental|RO6811135|
33032266|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
33032267|NCT01951196||Healthy subjects|75 healthy subjects.
33032268|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
33032269|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
33032270|NCT01951222|Experimental|V0162 dose1|
33032271|NCT01951222|Experimental|V0162 dose2|
33032272|NCT01951222|Placebo Comparator|placebo|Placebo
33032273|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
33032274|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
33032275|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
33032276|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
33032277|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
33032278|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
33032279|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
33032280|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
33032281|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
33032282|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
33032283|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
33032284|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
33032285|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
33032286|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
33032287|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
33032288|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
33032289|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
33032290|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
33032291|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
33032292|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
33032293|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
33032294|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
33032295|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
33032296|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
33032297|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
33032298|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
33032299|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
33032300|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
33032301|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
33032302|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
33032303|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
33032304|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
33032305|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
33032306|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
33032307|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
33032308|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
33107448|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
33032309|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
33032310|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
33032311|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
33032312|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
33032313|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
33032314|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
33032315|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
33032316|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
33032317|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
33032318|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
33032319|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
33032320|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
33032321|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
33032322|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
33032323|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
33032324|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
33032325|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
33032326|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
33032327|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
33032328|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
33032329|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
33032330|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
33032331|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.~No treatment, observational"
33032332|NCT01951846|Experimental|BIBF 1120|
33032333|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
33032334|NCT01951859|Placebo Comparator|Placebo Cream|
33032335|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
33032336|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
33032337|NCT01951898|Active Comparator|Montelukast|
33032338|NCT01951898|Sham Comparator|Vitamin B6|
33032339|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
33032340|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
33032341|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
33032342|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
33032343|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
33032344|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
33032345|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
33032346|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
33032347|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
33032348|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
33032349|NCT01952093||Term control group|Healthy term infants
33032350|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
33032351|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
33327307|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
33032352|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
33032353|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
33032354|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
33032355|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
33032356|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
33032357|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
33032358|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
33032359|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
33032360|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
33032361|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
33032362|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
33032363|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
33032364|NCT01952327|Other|plueurapump|Implantation of pleurapump system
33032365|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
33032366|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
33032367|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
33032368|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
33032369|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
33032370|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
33032371|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
33032372|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
33032373|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
33032374|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
33032375|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
33032376|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
33032377|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
33032378|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
33032379|NCT01952509||Cohort|
33032380|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032381|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032382|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032383|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032384|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032385|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
33032386|NCT01952548|Experimental|Dose 1 Active|
33032387|NCT01952548|Experimental|Dose 2 Active|
33032388|NCT01952548|Experimental|Dose 3 Active|
33032389|NCT01952548|Experimental|Dose 4 Active|
33032390|NCT01952548|Experimental|Dose 5 Active|
33032391|NCT01952548|Experimental|Dose 6 Active|
33032392|NCT01952548|Experimental|Dose 7 Active|
33032393|NCT01952548|Placebo Comparator|Dose 1 Placebo|
33032394|NCT01952548|Placebo Comparator|Dose 2 Placebo|
33032395|NCT01952548|Placebo Comparator|Dose 3 Placebo|
33032396|NCT01952548|Placebo Comparator|Dose 4 Placebo|
33032397|NCT01952548|Placebo Comparator|Dose 5 Placebo|
33032398|NCT01952548|Placebo Comparator|Dose 6 Placebo|
33032399|NCT01952548|Placebo Comparator|Dose 7 Placebo|
33032400|NCT01952561|Experimental|2 weeks|
33032401|NCT01952561|Experimental|1 week|
33032402|NCT01952561|Experimental|4 weeks|
33032403|NCT01952561|Experimental|8 weeks|
33032404|NCT01952561|Experimental|12 weeks|
33032405|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
33032406|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
33032407|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
33032408|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
33032409|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
33032410|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
33032411|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
33032412|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
33032413|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
33032414|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
33032415|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
33032416|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
33032417|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
33032418|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
33032419|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
33032420|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
33032421|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
33032422|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
33032423|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
33032424|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
33032425|NCT01952795|No Intervention|No intervention|Usual diet and exercise
33032426|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
33032427|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
33032428|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
33032429|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
33032430|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
33032431|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
33032432|NCT01952899||Albert Schweitzer Hospital|
33032433|NCT01952899||Erasmus MC Academic Hospital|
33032434|NCT01952899||Ikazia Hospital|
33032435|NCT01952899||IJsselland Hospital|
32866641|NCT04833660|Experimental|rTMS group|"Each patient will receive five consecutive sessions (Monday to Friday for 1 week).~Patients in the rTMS group will administer rTMS over the optimal scalp site at 10 Hz, with an intensity of 90% of the MT and a duration of 5 seconds, for a total of 20 trains separated by 55-second intertrain pauses (a total of 1,000 pulses). The coil will be placed tangentially to the scalp at an approximate angle of 45° tilted backward and laterally. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods."
32866642|NCT04833660|Sham Comparator|sham group|Patients in the sham group will administer sham stimulation using the same protocol, except that the angle of the coil is 90° (i.e., perpendicular, rather than tangential) to the skull. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods.
32866643|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
32866644|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
32866645|NCT04818996|Experimental|Mediterranean Diet|In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
32902416|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
32902417|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
32902418|NCT05560802|Experimental|Labour care guide|According to WHO guidelines
32902419|NCT05560802|No Intervention|Standard care|Standard delivery care in Sweden
32902420|NCT05560724|Active Comparator|Anodal M1 tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1: 2mA Combined with 45min of structured motor training.
32902421|NCT05560724|Active Comparator|Combined M1 and cerebellar anodal tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1 combined with contralesional cerebellar montage (2cm lateral to Inion): 2mA per anode Combined with 45min of structured motor training.
32902422|NCT05560724|Sham Comparator|Sham tDCS|Sham stimulation. Combined with 45min of structured motor training.
32902423|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
32902424|NCT02490722|No Intervention|Control|Usual care
32902425|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
32902426|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
32902427|NCT02241980||Medicare Part D patients|Survey
32902428|NCT02241980||Physician Providers|Survey
32902429|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
32902430|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
32902431|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
32902432|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
32902433|NCT05560334|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
32902434|NCT05560256|Experimental|Youth Engage with Diary|24 youth will use the Diary for one month
32902435|NCT05560178|Experimental|Experimental: Training group|women in the intervention group will be given sexual health education once a week for 4 weeks
32902436|NCT05560178|No Intervention|No Intervention: control group|Women will be monitored without any intervention
32902437|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
32902438|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
32902439|NCT01516957|Experimental|AMG 827 140|140 mg AMG 827
32902440|NCT01516957|Placebo Comparator|Placebo SC|Placebo
32902441|NCT01516957|Experimental|AMG 827 280|280 mg AMG 827
32902442|NCT01516957|Experimental|AMG 827 210|AMG 827 SC 210 mg
32902443|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
32902444|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
32902445|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
32902446|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
32902447|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine first
33417138|NCT04894799|Active Comparator|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
32902448|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo first
32902449|NCT03397940||Year Round School|Children attending year round school
33032436|NCT01952899||Maasstad Hospital|
33032437|NCT01952899||Sint Franciscus Gasthuis Hospital|
33032438|NCT01952912|Active Comparator|PkEP|
33032439|NCT01952912|Active Comparator|OP|
33032440|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
33032441|NCT01952938||LINK SL|Patients
33032442|NCT01952938||EnduRo|Patients
32902450|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
33032443|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
33032444|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
33032445|NCT01952964|Experimental|JUC spray dressing|
33032446|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
33032447|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
33032448|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
33032449|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
33032450|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
33032451|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
33032452|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
33032453|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
33032454|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
33032455|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
33032456|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
33032457|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
33032458|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
33032459|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
33032460|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
33032461|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
33032462|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
33032463|NCT01953185|Experimental|Manual diaphragm release technique|
33032464|NCT01953185|Sham Comparator|Control group|
33032465|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
33032466|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
33107449|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
32902451|NCT05560100||Patients|Must have participated in >= 1 session of dry needling treatment and not be a healthcare provider.
32902452|NCT05560100||Dry Needling Experts|"(1) Must have >= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria:~Certification in Dry Needling~Completion of a manual therapy fellowship that included dry needling training~>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling"
33032467|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
33107450|NCT04651127|Experimental|Toripalimab + Chidamide Arm|
33107451|NCT01843413|Experimental|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
33032468|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
33032469|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
33032470|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
33032471|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
33032472|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
33032473|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
33032474|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
33032475|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
33032476|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
33032477|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
33032478|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
33032479|NCT01953471||Allergic rhinitis|
33032480|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
33032481|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
33032482|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
33032483|NCT01953497|Placebo Comparator|Placebo|Placebo
33032484|NCT01953497|Active Comparator|URC102|URC102
33032485|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
33032486|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
33032487|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
33032488|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
33032489|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
33032490|NCT01953549|Active Comparator|relaxation|non-aerobic training
33032491|NCT01953562||Intubated infants|
33032492|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
33032493|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
33032494|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
33032495|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
33032496|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
33032497|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
33032498|NCT01953666|Experimental|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
33032499|NCT01953666|Active Comparator|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
33032500|NCT01953666|No Intervention|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
33032501|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
33032502|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
33032503|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
33032504|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
33032505|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
33032506|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
33032507|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
33032508|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
33032509|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
33032510|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
33032511|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
33032512|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
33032513|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
33032514|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
33032515|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
33032516|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
33032517|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
33032518|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
33032519|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
33032520|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
33032521|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
33032522|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
33032523|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
33032524|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
33032525|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
33032526|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
33032527|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
33032528|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
33032529|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
33032530|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
33032531|NCT01953848|Experimental|1: Low dose EC905|
33032532|NCT01953848|Experimental|2: High dose EC905|
33032533|NCT01953861|Experimental|1: fasted|EC905 + fasted
33032534|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
33032535|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
33032536|NCT01953887|Experimental|1 combination tablet EC905|
33032537|NCT01953887|Experimental|2: solifenacin|
33032538|NCT01953887|Experimental|3: tamsulosin|
33032539|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
33032540|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
33032541|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
33107452|NCT04650776|Experimental|High heat strain|participants exercised at 75% of their heart rate maximum (HR max) and wore light athletic clothing (t-shirt and shorts)
33107453|NCT04650776|Experimental|Low heat strain|participants exercised at 50% HR max, wearing protective firefighter clothing (jacket and trousers)
33032542|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
33032543|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
33032544|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
33032545|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
33032546|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
33032547|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
33032548|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
33032549|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
33032550|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
33032551|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
33032552|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
33032553|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
33032554|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
33032555|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
33032556|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
33032557|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
33032558|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
33032559|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
33032560|NCT01954147|Experimental|GLP-1|Liraglutide
33032561|NCT01954147|Active Comparator|Control|Standard Medical Treatment
33032562|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
33032563|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
33032564|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
33032565|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living~Upon trial completion, treatment will be offered."
33032566|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
33032567|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
33032568|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
33032569|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
33032570|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
33032571|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
33107454|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
33107455|NCT04650737|Active Comparator|Group A (single shot,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB
33032572|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
33326822|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
33417139|NCT05191693||patients with CBD stones up to 8-12mm|72 patients (mean age: 67 years, 52.8% males) were included, of whom 22 (30.5%) had multiple CBD stones, 23 (31.9%) had a history of cholecystectomy, 13 (18.1%) had a periampullary diverticulum and 22 (30.5%) had a previous EST
33032573|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
33417140|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
33417141|NCT04926623|Experimental|CGM with Structured Education|CGM with Structured Education
33032574|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
33032575|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
33032576|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
33032577|NCT01954303||Progress of CHD|
33032578|NCT01954329||Patients suspected of TIA by the GP|
33032579|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
33032580|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
33032581|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
33032582|NCT01954381|Other|control|
33032583|NCT01954381|Experimental|patient|
33032584|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
33032585|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
33032586|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
33032587|NCT01954420|Other|Attention Control|"Standard care + cancer education~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
33032588|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
33032589|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
33032590|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
33032591|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
33032592|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
33032593|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
33032594|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
33032595|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
33032596|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
33032597|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
33417142|NCT04926623|Active Comparator|CGM with Standard Education|CGM with Standard Education
33417143|NCT04926623|Active Comparator|SMBG with Standard Education|SMBG with Standard Education
33417144|NCT02073890||traumatic subarachnoid haemorrhage|
33417145|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
33417146|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
33417147|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
33417148|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
33417149|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
33417150|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
33417151|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
33417152|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
33417153|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
33417154|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
33417155|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
33032598|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
33417156|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
33032599|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
33032600|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
33032601|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
33032602|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
33032603|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
33032604|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
33032605|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
33032606|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
33032607|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
33032608|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
33032609|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
33032610|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
33032611|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
33032612|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032613|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032614|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032615|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
33032616|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032617|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032618|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
33032619|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
33032620|NCT01954602|Experimental|No touch group|Guide-wire cannulation
33032621|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
33032622|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
33107456|NCT04650737|Active Comparator|Group B (continous infusion,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB
33326823|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
33032623|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
33032624|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
33032625|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
33032626|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
33032627|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
33032628|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
33032629|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
33032630|NCT01954654|Experimental|Accelerated treatment|
33032631|NCT01954654|Active Comparator|Standard treatment|
33032632|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
33032633|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
33032634|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
33032635|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
33032636|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
33032637|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
33032638|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
33032639|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
33032640|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
33032641|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
33032642|NCT01954719|No Intervention|control group|cervix not dilated after surgery
33032643|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
33032644|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
33032645|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
33032646|NCT01954758|Experimental|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
33107457|NCT04650503||Patients with eosinophilic asthma at baseline|Patients showing ≥3% sputum eosinophils at baseline
33032647|NCT01954758|Active Comparator|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
33032648|NCT01954758|Active Comparator|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
33032649|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33032650|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
33032651|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
33032652|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
33032653|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
33032654|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
33032655|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
33032656|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
33032657|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
33032658|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
33032659|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
33032660|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
33032661|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
33032662|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
33032663|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
33032664|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
33032665|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
33032666|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
33032667|NCT01954901|Experimental|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
33032668|NCT01954901|Placebo Comparator|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
33032669|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
33032670|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
33107458|NCT04650503||Patients with non eosinophilic asthma at baseline|Patients showing <3% sputum eosinophils at baseline
33417157|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
33032671|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
33032672|NCT01954953||no intervention|
33032673|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
33032674|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
33032675|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
33032676|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
33032677|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
33032678|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
33032679|NCT01955057||Smokers with lung cancer|
33032680|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
33032681|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
33032682|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
33032683|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
33032684|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
33032685|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
33032686|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
33032687|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
33032688|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
33032689|NCT01955148||Twin Pregnancy|Current twin pregnancy
33032690|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
33032691|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
33032692|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
33032693|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
33032694|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
33032695|NCT01955200|Experimental|CLOP-150|clopidogrel 150mg once daily
33032696|NCT01955200|Experimental|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
33032697|NCT01955200|Experimental|TICAG|ticagrelor 90mg twice daily
33032698|NCT01955200|Active Comparator|CON(conventional DAPT)|clopidogrel 75mg once daily
33032699|NCT01955200|Active Comparator|Non-HOPR|clopidogrel 75mg once daily
33032700|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
33032701|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
33032702|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
33032703|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
33032704|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
33032705|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
33032706|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
33032707|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
33032708|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
33032709|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
33032710|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
33032711|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
33032712|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
33032713|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
33032714|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
33032715|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
33032716|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
33032717|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
33032718|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
33032719|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
33032720|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
33032721|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
33032722|NCT01955408||Overactive bladder after Synergo|
33032723|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
33032724|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
33032725|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
33032726|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
33032727|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
33032728|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
33032729|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
33032730|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
33032731|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
33032732|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
33032733|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
33032734|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
33032735|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
33032736|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
33032737|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
33032738|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
33032739|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
33032740|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
33032741|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
33032742|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
33032743|NCT01955603|Experimental|Dose level 1|
33032744|NCT01955603|Experimental|Dose level 2|
33032745|NCT01955603|Experimental|Dose level 3|
33032746|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
33032747|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
33032748|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
33032749|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
33032750|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
33032751|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
33032752|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
33032753|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
33032754|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
33032755|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
33032756|NCT01955746||Type 1 DM|
33032757|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
33032758|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
33032759|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
33032760|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
33032761|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
33032762|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
33032763|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
33032764|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
33417158|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
33032765|NCT01955798|Active Comparator|Veress needle|Veress needle
33032766|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
33032767|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
33032768|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
33032769|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
33032770|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
33032771|NCT01955850|No Intervention|Waiting-list|Waiting-list
33032772|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
33032773|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
33032774|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
33032775|NCT01955876||Group 1|
33032776|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
33032777|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
33032778|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
33032779|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
33032780|NCT01955928|No Intervention|Waiting-list|Waiting-list
33032781|NCT01955967|Other|Lidocaine|
33032782|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
33032783|NCT01956006|Experimental|MIlrinone|ER milrinone
33032784|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
33032785|NCT01956045||Decision making|
33032786|NCT01956058|Experimental|brachytherapy remedial|
33032787|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
33032788|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
33032789|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
33032790|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
33032791|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
33032792|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
33032793|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
33032794|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
33032795|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
33032796|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
33032797|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
33032798|NCT01956214|Experimental|FES exercise|Participants will receive FES
33032799|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
33032800|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
33032801|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
33032802|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
33032803|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
33107459|NCT04650620|Experimental|Plenhyage® thin|Plenhyage® thin for the treatment of mild wrinkles;
33107460|NCT04650620|Experimental|Plenhyage® medium|Plenhyage® medium for the treatment of moderate wrinkles;
33107461|NCT04650620|Experimental|Plenhyage® strong|Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks
33107462|NCT04650386|No Intervention|Treatment As Usual (TAU)|Participants assigned to the TAU condition will be scheduled for buprenorphine medication management appointments and will receive OBOT at the FQHC and adjunctive psychosocial treatment as typically provided at the FQHC. The team will continue to meet with the patient during subsequent MAT visits on a decreasing frequency, with some slight site-specific variation. The schedule of MAT visits generally includes 3 clinic visits during the week of induction, 1-2 visits per week until the patient is stabilized, and monthly thereafter. Behavioral health clinicians provide support to the patient, discuss UDS results, assist with strategic problem-solving around recovery and adjustment to sobriety, and monitor the patient's engagement in MAT.
33107463|NCT04650386|Experimental|Adaptive Intervention|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
33107464|NCT00665769|Placebo Comparator|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
33107465|NCT00665769|Active Comparator|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
33107466|NCT04650308|Active Comparator|Healthy group|healthy men and women aged 20-60 years old.
33107467|NCT04650308|Active Comparator|Non-healthy group|pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.
33107468|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
33107469|NCT04650347|Experimental|internal urethrotomy using Holmium laser representing group|In group 1, a three hundred micron laser fiber was used to conduct the laser energy. holmium laser pulse energy of approximately 1 joule was used that was generated from a Holmium laser Quanta device and total power of 15 watts. the laser fiber was aimed directly to the midline at 12 o'clock position to start the procedure and cut the fibrous tissue till access to a wide lumen.
33107470|NCT04650347|Active Comparator|internal urethrotomy with Sachs cold knife|In group B, Sache cold knife internal urethrotomy was used with the same technique as Holmium laser internal urethrotomy at the same site to mechanically cut instead of the laser fiber.
33107471|NCT04650230|Active Comparator|high flow nasal cannula (HFNC)|Participants in the HFNC group received heated and humidified gas flow with the Fisher & Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
33107472|NCT04650230|Active Comparator|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)|Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
33107473|NCT00595491|Experimental|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
33107474|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
33107475|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
33107476|NCT04649762||Control|Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
33107477|NCT04649762||TAC|Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
33107478|NCT04650113|Experimental|group A|placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude ) 9.The pellet will be remove, and the pulp chamber filled with MTA. 10.The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement
33326824|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
32866646|NCT00070135|Experimental|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
32866647|NCT04816500|Experimental|RIC group|Device: Remote ischemic conditioning RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
32866648|NCT04816500|Other|Regular treatment|
32866649|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
33326825|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
33326826|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
33032804|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
33032805|NCT01956292||Intraparenchimal cerebral haemorrhage|
33032806|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
33032807|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
33032808|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
33032809|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
33032810|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
33032811|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
33032812|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
33032813|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
33032814|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
33032815|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
33032816|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
33032817|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
33032818|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
33032819|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
33032820|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
33032821|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
33032822|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
33032823|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
33032824|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
33032825|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
33032826|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
33032827|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
33032828|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
33032829|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
33032830|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
33032831|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
33032832|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
33032833|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
33032834|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
33032835|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
33033368|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
33417159|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
33032836|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
32866650|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
32866651|NCT04816344||Group MP (n=35)|"The patients were separated into four groups according to the anaesthetic agents given.~Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage."
33032837|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
33032838|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
33032839|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
33032840|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
33032841|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
33032842|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
33032843|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
33032844|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
33032845|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
33032846|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
33032847|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
33032848|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
33032849|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
33032850|NCT01956643|Placebo Comparator|Control|Routine care during NPO
33032851|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
33032852|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
33032853|NCT01956669|Experimental|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m^2/dose was not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
33032854|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
33032855|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
33032856|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
33326827|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
33326828|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
33326829|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
33032857|NCT01956708|Active Comparator|Remote ischemic preconditioning|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
33032858|NCT01956708|Placebo Comparator|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: the cuff is left uninflated"
33032859|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
33032860|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
33032861|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
33032862|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
33032863|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
33032864|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
33032865|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
33032866|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
33032867|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
33032868|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
33032869|NCT01956825|Placebo Comparator|water|just water
33032870|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
33032871|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
33032872|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
33032873|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
33032874|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
33032875|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
33032876|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
33032877|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
33032878|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
33032879|NCT01956864|Experimental|Dose VD 1|Vitamin D
33032880|NCT01956864|Experimental|Dose VD 2|Vitamin D
33032881|NCT01956864|Experimental|Dose VD 3|Vitamin D
33032882|NCT01956864|Experimental|Dose VD 4|Vitamin D
33032883|NCT01956864|Experimental|Dose VD 5|Vitamin D
33032884|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
33032885|NCT01956877||Healthy volunteers|
33032886|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
33032887|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
33032888|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
33032889|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
33032890|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
33032891|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
33326830|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
33326831|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
33326832|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
33326833|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
33326834|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
33326835|NCT01280682|Experimental|rituximab|
33326836|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
33326837|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
33326838|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
33326839|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
33326840|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
33326841|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
33326842|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
33326843|NCT01269216|Active Comparator|5-FU with leucovorin|
33326844|NCT01269216|Active Comparator|TS-1 with Irinotecan|
33326845|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
33033369|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
33033370|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
33033371|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
33033372|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
33033373|NCT01962259|No Intervention|Control|Receives no intervention.
33033374|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
33033375|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
33033376|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.~32 channel-EEg and BIS continuous monitoring"
33033377|NCT01962311|Experimental|All patients|lumbar puncture
33033378|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
33033379|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
33033380|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
33033381|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
33033382|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.~placebo:Physiological saline"
33326846|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
33326847|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
33326848|NCT01280916|No Intervention|Treatment as Usual|
33326849|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
33326850|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
33326851|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
33032892|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
33032893|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
33326852|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
33326853|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
33326854|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
33326855|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
33032894|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
33032895|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
33326856|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
33032896|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
33032897|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
33032898|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
33032899|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
33032900|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
33032901|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
33032902|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
33032903|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
33032904|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
33032905|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
33032906|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
33032907|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
33032908|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
33032909|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
33032910|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
33032911|NCT01957046|Other|Oral Laxative|
33326857|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
33326858|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
33326859|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
33326860|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
33326861|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
33326862|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
33326863|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
33326864|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33032912|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
33032913|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
33032914|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
33032915|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
33032916|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
33032917|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
33032918|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
33032919|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
33032920|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
33032921|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
33032922|NCT01957124|Experimental|PRF application|
33032923|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
33032924|NCT01957228|Experimental|bone biopsies|
33032925|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
33032926|NCT01957254||Severe Sepsis|Patient with severe sepsis
33032927|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
33032928|NCT01957293|Experimental|Salbutamol|
33032929|NCT01957293|Placebo Comparator|Sugar Syrup|
33032930|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
33032931|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
33032932|NCT01957319|Placebo Comparator|placebo|sugar pill
33032933|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
33032934|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
33032935|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
33032936|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
33032937|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
33032938|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
33032939|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
33032940|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
33032941|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
33032942|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
33032943|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
33032944|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
33033668|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
33033669|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
33360417|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
33033670|NCT01965340|No Intervention|Patients treated as usual|
33033671|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
33033672|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
33033673|NCT01965379|Placebo Comparator|Control|Standard care.
33033674|NCT01965392|Experimental|healtn education|one group received an educational program
33033675|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
33033676|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
33033677|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
33033678|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
33033679|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
33033680|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
33033681|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
33033682|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
33033683|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
33033684|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
33033685|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
33033686|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
33033687|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
33033688|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
33033689|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
33033690|NCT01965522|Experimental|Melatonin and Vitamin D|
33033691|NCT01965522|Experimental|Placebo and Vitamin D|
33033692|NCT01965522|Experimental|Melatonin and Placebo|
33033693|NCT01965522|Placebo Comparator|Placebo and Placebo|
33033694|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
33033695|NCT01965574|Experimental|Single arm|
33033696|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
33033697|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
33033698|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )"
33033699|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
33033700|NCT01965639|Experimental|High Risk group|Extension of Care
33033701|NCT01965678|Experimental|OMT|
33033702|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
33033703|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
33033704|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
33033705|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
33033706|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
33033707|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
33360418|NCT03927313|Active Comparator|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
33360419|NCT03927313|Experimental|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
33417586|NCT05189093|Experimental|phase I dose escalation part,Phase II efficacy exploratory part and the efficacy confirmation part|"In the phase I dose escalation part,with a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.~5 cohorts will be carried out in parallel in the phase II efficacy exploration part: Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: Relapsed/refractory peripheral T-cell lymphoma; Cohort 3: Relapsed/refractory classic Hodgkin's lymphoma; Cohort 4: Relapsed/refractory mantle cell lymphoma; Cohort 5: Relapsed/refractory follicular lymphoma and marginal zone lymphoma; In the efficacy exploration part, each cohort will enroll 15 subjects, a total of 5 cohorts, and 75 cases are expected to be enrolled.~In the phase II efficacy confirmation part, one or two indications with better safety and efficacy among the 5 cohorts in the efficacy exploration phase will be selected."
33417587|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
33417588|NCT04006717|No Intervention|Control|Routine root canal treatment
33417589|NCT04006717|Placebo Comparator|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
33417590|NCT04006717|Experimental|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
33417591|NCT04006717|Experimental|Intracanal Cryotherapy|Cold saline irrigation before obturation
33417592|NCT04006717|Experimental|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
33417593|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
33417594|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
33417595|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
33033708|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
33417596|NCT01371097|No Intervention|Control Group|
33417597|NCT01371097|Experimental|Treatment group|
33417598|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
33417599|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
33033709|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
33033710|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
33033711|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
33033712|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
33033713|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
33033714|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
33033715|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
33033716|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
33033717|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
33417600|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
33417601|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
33327464|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
33327465|NCT05666700|Experimental|Cilta-cel|
33327466|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
33327467|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
33033718|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
33033719|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
33033720|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
33033721|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
33033722|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
33033723|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
33033724|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
33033725|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
33033726|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
33033727|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
33033728|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
33033729|NCT01966055|Experimental|Solithromycin|
33033730|NCT01966081|Other|Cases|
33033731|NCT01966081|Other|controls|
33033732|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
33033733|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
33033734|NCT01966133|No Intervention|Control|no interventions were assigned
33033735|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
33033736|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
33033737|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
33033738|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
33033739|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
33033740|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
33033741|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
33033742|NCT01966198|Experimental|all patients|tilt
33033743|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
33033744|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
33033745|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
33033746|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
33033747|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
33327468|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
33417602|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
33417603|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
33417604|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
33033748|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
33033749|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
33033750|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
33033751|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
33033752|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
33033753|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
33033754|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
33033755|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
33033756|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
33033757|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
33033758|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
33033759|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
33033760|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
33033761|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
33033762|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
33033763|NCT01966367|Experimental|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
33033764|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
33033765|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
33033766|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
33033767|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
33033768|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
33107479|NCT04650113|Active Comparator|group B|"Pre-operative radiograph showing all roots and their apices.~Local anesthesia will be administered and a rubber dam will take place ,that ensure good isolation of the treated teeth.~Removal of caries~Pulp chambers will access using a no.330 bur in a high-speed hand piece with water coolant.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece~Pulp amputation will perform using a spoon excavator.~Hemorrhage control will obtain within 5 minutes using sterile cotton pellets placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude )~The pellet will be remove, and the pulp chamber will be filled with MTA.~The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement.~The periapical radiographic will be taken at this baseline visit ."
33107480|NCT04649996||Pandemic period|patients admitted in hospital for acute appendicitis
33107481|NCT04649996||control period|patients admitted in hospital for acute appendicitis
33107482|NCT04649801|No Intervention|conventional|
33107483|NCT04649801|Active Comparator|interventional|
33107484|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
33107485|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
33107486|NCT04649723|Experimental|Rifampicin 600 mg + SHR1459 Tablets 200 mg|
33107487|NCT04649723|Active Comparator|SHR1459 tablets 200 mg|
33107488|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
33107489|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
33107490|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
33107491|NCT04649684|Experimental|Conventional robot-assisted gait training group|they got conventional robot-assisted gait training, guidance force given equally to both limbs
33107492|NCT04649684|Experimental|Lower CIMT robot-assisted gait training group|they got robot-assisted gait training based on CIMT concept
33107493|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
33107494|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
33107495|NCT04649528|Experimental|Supervised HIIT|Exercise intervention, 20 supervised by healthcare professional
33107496|NCT04649528|Experimental|APP HIIT|Exercise intervention, 20 self-monitored assisted by a mobilephone application
33107497|NCT04649645|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
33107498|NCT04649645|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS.
33107499|NCT04649645|Active Comparator|Control Arm (Arm C)|Participant continues to not smoking or using of any nicotine/tobacco products.
33107500|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
33107501|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
33107502|NCT04649606||Experimental|Eligible subjects will undergo repeated observations to evaluate the Meibomian gland appearance
33107503|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
33107504|NCT00544206|Active Comparator|#2|Standard enteral feeding product
33107505|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
33107506|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
33107507|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
33107508|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
33107509|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
33327469|NCT01179594|Placebo Comparator|A|
33327470|NCT01179594|Experimental|B|
33327471|NCT01179594|Placebo Comparator|C|
33327472|NCT01179594|Experimental|D|
33327473|NCT05597254|Experimental|Probiotic with niacin and berry extract|
33327474|NCT05597254|Active Comparator|Probiotic without niacin and berry extract|
33327475|NCT05597254|Placebo Comparator|Placebo|
33327476|NCT03751098|Other|1-TR/PE, 2-Placebo, 3-Placebo|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
33327477|NCT03751098|Other|1-Placebo, 2-Placebo, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
33327478|NCT05595226|Experimental|RT3D-TEE-guided mitral valve repair|Two experienced surgeons and two experienced echocardiography technicians jointly formulated the plan for the TEE-guided mitral valve repair.
33033769|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
33033770|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
33327479|NCT05595226|No Intervention|Control|
33033771|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
33033772|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
33033773|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
33033774|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
33033775|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
33033776|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
33033777|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
33033778|NCT01966562|No Intervention|CG|Control group
33033779|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
33033780|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
33033781|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
33033782|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
33033783|NCT01966614|Experimental|PRX302|PRX302 injection
33033784|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
33033785|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
33033786|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
33033787|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
33033788|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
33033789|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
33033790|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
33033791|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
33033792|NCT01966666|Placebo Comparator|Placebo|
33033793|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
33033794|NCT01966679|Placebo Comparator|Placebo|
33033795|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
33033796|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
33033797|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
33033798|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
33033799|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
33417605|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
33417606|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
33417607|NCT04208815|Experimental|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
33417608|NCT04208815|Placebo Comparator|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
33417609|NCT01371253|Experimental|Nintendo Wii traning|Balance training
33033800|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
33033801|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
33033802|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
33417610|NCT01371253|Placebo Comparator|EVA-soles|
33033803|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
33033804|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
33033805|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
33033806|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
33033807|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
33033808|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
33033809|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
33033810|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
33033811|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
33033812|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
33033813|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
33033814|NCT01966835|No Intervention|control group|no exercise intervention
33033815|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
33033816|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
33033817|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
33033818|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
33033819|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
33033820|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
33033821|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
33033822|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.~The ICE chemotherapy regimen:~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,~Ifosfamide, 2400 mg/m²/d,~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
33033823|NCT01966939||Surgery|Craniotomy or Craniectomy
33033824|NCT01966939||Control|age, gender and teeth condition matched
33033825|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
33033826|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
33033827|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
33033828|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
33033829|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
33033830|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
33033831|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
33033832|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
33417611|NCT01371331|Experimental|Tacrolimus granules|oral
33417612|NCT03972865|Experimental|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
33033833|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
33033834|NCT01967082|Experimental|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
33033835|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
33033836|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
33033837|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
33033838|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
32871541|NCT00295061|Active Comparator|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
32871542|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
32871543|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
32871544|NCT02101411||clopidogrel|treated with cloopidogrel
32871545|NCT02101411||ticagrelor|treated with ticagrelor
32871546|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
33033839|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
33033840|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
33033841|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
33033842|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
33033843|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
33033844|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
33033845|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
33033846|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
33033847|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
33033848|NCT01967212|Active Comparator|Swallow training without biofeedback|
33033849|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
33033850|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
33033851|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
33033852|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
33033853|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
33033854|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
33033855|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
33033856|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
33033857|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
33033858|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
33033859|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
33327483|NCT05576428|Active Comparator|DIET& EXERCISE|diet plan & daily 20 minutes brisk walking.
33327484|NCT05576428|Experimental|N Acetylcysteine WITH DIET & EXERCISE|NAC 200mg BD along with diet plan & exercise.
33033860|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
33033861|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik"
33033862|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
33033863|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
33033864|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
33033865|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
33033866|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
33033867|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
33033868|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
33033869|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
33033870|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
33033871|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
33033872|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
33033873|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
33033874|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
33033875|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
33033876|NCT01967394|Placebo Comparator|Control County|No use of social media
33033877|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
33033878|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
33033879|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
33033880|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
33033881|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
33033882|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
33033883|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
33033884|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
33033885|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
33033886|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
33033887|NCT01967498|Placebo Comparator|placebo|
33033888|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
33033889|NCT01967524|Active Comparator|Ropivacaïne|
33033890|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
33327485|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
33417613|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
33107510|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
33107511|NCT00558155|Experimental|SEN|standard enteral nutrition
33107512|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
33107513|NCT00558155|Experimental|SPN|standard parenteral nutrition
33107514|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
33107515|NCT05476432|Experimental|HAIC 1d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 23 hours in the HAIC 1d group
33327486|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
33327487|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
33107516|NCT05476432|Active Comparator|HAIC 2d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 46 hours in the HAIC 2d group
33107517|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
33107518|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
33107519|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
33327488|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
33327489|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
33107520|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
33327490|NCT01176708|Experimental|Healthy controls|10 healthy controls
33327491|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
33107521|NCT01239745||1|
33107522|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
33327492|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
33107523|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
33327493|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
33327494|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
33107524|NCT04649450|Experimental|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
33107525|NCT04649450|No Intervention|Standard of clinical care|Standard of clinical care.
33107526|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
33107527|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
33107528|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
33107529|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
33327495|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
33327496|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
33327497|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
33327498|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
33327499|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
33327500|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
33107530|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
33327501|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
33327502|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
33327503|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
33327504|NCT03858660||Elderly|Healthy elderly No intervention.
33327505|NCT01176942|Experimental|Probiotic|
33327506|NCT01176942|Placebo Comparator|Placebo|
33327507|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
33327508|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
33327509|NCT03864432|Experimental|25mg SAD|
33327510|NCT03864432|Experimental|50mg SAD|
32871547|NCT00296231|Experimental|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
32871548|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
32871549|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
33033891|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
33033892|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
33033893|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
33033894|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
33033895|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
33033896|NCT01967667|Experimental|Liposomal glutathione|dose steps
33033897|NCT01967667|Placebo Comparator|Placebo|dose steps
33033898|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
33067572|NCT04710849||Treatment Success Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. The treatment success group was defined as not meeting any of the following conditions for failure of systemic hormone therapy during hospitalization (reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
33067573|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
33327511|NCT03864432|Experimental|100mg SAD|
33327512|NCT03864432|Experimental|50mg Multiple dosing|
33327513|NCT01288950|Experimental|Vitamin D3|
33327514|NCT01288950|No Intervention|Placebo|
33327515|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
33327516|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
33327517|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
33327518|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
33327519|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
33327520|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
33327521|NCT01177020||Placentas after delivery or abortion|
33327522|NCT05548426|Experimental|Linezolid 5 Day|Oral Linezolid 600mg, taken twice a day for 5 days
33327523|NCT05548426|Experimental|Linezolid 10 Day|Oral linezolid 600mg, taken twice a day for 10 days
33327524|NCT05548426|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
33327525|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
33327526|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
33327527|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
33327528|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
33033899|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
33033900|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
33033901|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
33033902|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
33033903|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
33033904|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
33033905|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
33033906|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
33033907|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
33033908|NCT01967823|Experimental|1/Cyclophosphamide & Fludarabine + Anti-ESO murine TCR transduced PBL + HD Aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine T-cell receptor (TCR) transduced PBL + high-dose (HD) aldesleukin
33033909|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
33033910|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
33033911|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
33033912|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
33033913|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
33033914|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
33033915|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
33033916|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
33033917|NCT01967927|Experimental|GRID 18F-MISO|
33107531|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
33327529|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
33327530|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
33417614|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
33033918|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.~Events: lung procurement, cold storage on ice, transplantation."
33327531|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
33327532|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
33327533|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
33327534|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
33033919|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
33033920|NCT01967966|Experimental|Bioavailability|
33033921|NCT01967966|Experimental|Elimination & PK|
33033922|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
33033923|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
33033924|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
33033925|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
33033926|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
33033927|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
33033928|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
33033929|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
33033930|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
33033931|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
33033932|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
33033933|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
33033934|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
33033935|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
33033936|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
33033937|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
33033938|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
33033939|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
33033940|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
33033941|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
33033942|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
33033943|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
33033944|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
33327535|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
33327536|NCT01174992|Experimental|Evicel|
33327537|NCT01174992|Other|Sutures only|
33327538|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
33327539|NCT01287780|No Intervention|No intervention|
33327540|NCT05546632||Critically ill patients|Patients included in this study will have blood sampling using EDTA tube and nex generation Cyto-Chex BCT tubes in order to compare compare the expression of mHLA-DR with these two types of tubes
33033945|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
33033946|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
33327541|NCT05509738|Experimental|Group 1: Diaries - SMS|"Group 1 will be asked to complete a 2-day bladder diary + food diary during the first two weeks of the study, then will receive SMS Text reminders during the last 2 weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
33327542|NCT05509738|Experimental|Group 2: SMS - Diaries|"Group 2 will receive SMS Text reminders during the first 2 weeks of the study, and then will be asked to complete a 2-day bladder diary + food diary during the last two weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
33327543|NCT01179828|Active Comparator|1|Oxycodone 15mg
33033947|NCT01968265|Placebo Comparator|Placebo|
33033948|NCT01968265|Active Comparator|ISIS-GCCRRx|
33033949|NCT01968278|Experimental|Baked milk group|BM (baked milk)
33033950|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
33033951|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
33033952|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
33033953|NCT01968304|No Intervention|Iron status follow up|
33033954|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
33033955|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
33033956|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
33033957|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
33033958|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
33033959|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
33033960|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
33033961|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)~ARM I: Rotavirus vaccinated patients~ARM II: Non-rotavirus vaccinated patients"
33033962|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded~for the duration of hospitalization"
33033963|NCT01968460|Experimental|P2B001 Treatment A|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
33033964|NCT01968460|Experimental|P2B001 Treatment B|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
33033965|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
33033966|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
33033967|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
33033968|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
33033969|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
33033970|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
33033971|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
33033972|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
33033973|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
33033974|NCT01968525|Experimental|Group B|Hb 9-12g/L
33033975|NCT01968525|Experimental|Group C|Hb<9g/L
33033976|NCT01968564|Experimental|High-dose curcumin pill|
33033977|NCT01968564|Experimental|Low-dose curcumin pill|
33327544|NCT01179828|Active Comparator|2|Clobazam 20mg
33327545|NCT01179828|Active Comparator|3|Imipramine 75mg
33327546|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
33327547|NCT05479474|Experimental|Platelet rich plasma treatment arm|After consent in obtained, the patient will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.
33417615|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
33327548|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
33327549|NCT05437588|Other|MDD Participant|Participants with MDD will return at six weeks for a second blood draw and assessments
33033978|NCT01968564|Placebo Comparator|Placebo pill|
33033979|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
33327550|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
33327551|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
33417616|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
33033980|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
33033981|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
33033982|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
33033983|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
33033984|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
33033985|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
33033986|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
33033987|NCT01968668|Experimental|BAY94-8862 (5 mg )|
33033988|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
33033989|NCT01968668|Experimental|BAY94-8862 (10 mg)|
33033990|NCT01968668|Placebo Comparator|Placebo|
33033991|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
33033992|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
33033993|NCT01968681|Experimental|Alexandrite laser treatment|
33033994|NCT01968746||ED patients with suspected infection|
33033995|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
33033996|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
33033997|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
33033998|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
33033999|NCT01968798|Placebo Comparator|Placebo|Placebo
33034000|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
33034001|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
33034002|NCT01968837|No Intervention|Cervical cancer screening|
33034003|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
33034004|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
33034005|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
33034006|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
33034007|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
33034008|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
33034009|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
33034010|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
33034011|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
33327552|NCT05421988|Experimental|Individual EFT Therapy|Personal EFT instruction and practice group
33327553|NCT05421988|Experimental|Group EFT Therapy|Group EFT instruction and practice group
33327554|NCT05421988|No Intervention|Wait List|Wait list control group
33327555|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
33327556|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
33327557|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
33327558|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
33327559|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
33417617|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
33327560|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
33327561|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
33327562|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
33327563|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
33327564|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
33034012|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
33034013|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
33034014|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
33034015|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
33034016|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
33034017|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
33034018|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
33034019|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
33034020|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
33034021|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
33034022|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
33034023|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
33034024|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
33034025|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
33034026|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
33034027|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
33034028|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
33034029|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
33034030|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
33034031|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
33034032|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
33034033|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
33034034|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
33034035|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
33034036|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
33034037|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
33034038|NCT01969175|Experimental|Intervention Diet|
33034039|NCT01969175|Placebo Comparator|Control|
33034040|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
33327565|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
33327566|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
33034041|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
33327567|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
33327568|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
33327569|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
33327570|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
33327571|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
33327572|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
33327573|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
33327574|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
33327575|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
33034042|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
33327576|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
33327577|NCT01287858|Placebo Comparator|Placebo|Placebo
33327578|NCT01287858|Active Comparator|AC430|AC430
33327579|NCT01180140|No Intervention|1|without seamguard
33034043|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
33034044|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
33034045|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
33034046|NCT01969318|Placebo Comparator|Placebo/Metformin|
33034047|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
33034048|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
33034049|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
33034050|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
33034051|NCT01969357|Placebo Comparator|Placebo|
33034052|NCT01969357|Experimental|50 mg SP2086|
33034053|NCT01969357|Experimental|100 mg SP2086|
33034054|NCT01969357|Experimental|200 mg SP2086|
33034055|NCT01969357|Active Comparator|100 mg Sitagliptin|
33034056|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
33034057|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
33034058|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
33034059|NCT01969396|Experimental|SonoBiopsy Catheter|
33034060|NCT01969396|Active Comparator|Endometrial biopsy catheter|
33034061|NCT01969422||observation group|observation
33034062|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
33034063|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
33034064|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
33034065|NCT01969474|Placebo Comparator|Placebo|Placebo
33034066|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
33034067|NCT01969487|No Intervention|No preoperative warm-up|
33034068|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
33327580|NCT01180140|Experimental|2|with seamguard
33034069|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
33034070|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
32871550|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
33034071|NCT01969526|No Intervention|No intervention|Usual care
33034072|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
33034073|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
33034074|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
33034075|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
33034076|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
33034077|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
33034078|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
33034079|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
33034080|NCT01969630|Experimental|PES|Systematic PES angioplasty
33034081|NCT01969656|Placebo Comparator|Placebo|
33034082|NCT01969656|Active Comparator|Calcitriol|
33034083|NCT01969656|Experimental|50 ng 2MD|
33034084|NCT01969656|Experimental|110 ng 2MD|
33034085|NCT01969656|Experimental|170 ng 2MD|
33034086|NCT01969656|Experimental|220 ng 2MD|
33034087|NCT01969656|Experimental|440 ng 2MD|
33034088|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
33034089|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
33034090|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
33034091|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
33034092|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
33034093|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
33034094|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
33034095|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
33034096|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
33034097|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
33034098|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
33034099|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
33034100|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
33034101|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
33034102|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
33034103|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
33034104|NCT01969890|No Intervention|standard therapy|Standard therapy
33034105|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
33034106|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
33034107|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
33034108|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
33034109|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
33034110|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
33327581|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
33327582|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
33327583|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
33327584|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
33327585|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
33327586|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg IV on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
33327587|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
33327588|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
33327589|NCT03739866|Experimental|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
33327590|NCT03739866|Experimental|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33034111|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
33034112|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
33034113|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
33034114|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
33034115|NCT01969968|Other|non obese|non obese patients
33034116|NCT01969981||PICC placement|
33034117|NCT01969994|Experimental|Controlled dietary background & (-)-[2-14C]epicatechin intake|
33034118|NCT01970020|Experimental|JNJ-38518168|
33034119|NCT01970033|Placebo Comparator|Placebo|
33034120|NCT01970033|Experimental|SP2086 50 mg b.i.d|
33034121|NCT01970033|Experimental|SP2086 100 mg q.d.|
33034122|NCT01970046|Placebo Comparator|Placebo/Metformin|
33034123|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
33034124|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
33034125|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
33034126|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
33034127|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
33034128|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
33034129|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
33034130|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
33034131|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
33034132|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
33034133|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
33034134|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
33034135|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
33034136|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
33034137|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
33034138|NCT01970098|Experimental|KPS-0373|
33034139|NCT01970098|Placebo Comparator|Placebo|
33034140|NCT01970111|Experimental|KPS-0373|
33034141|NCT01970124|Experimental|KPS-0373|
33034142|NCT01970137|Experimental|KPS-0373|
33034143|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
33034144|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
33034145|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
33034146|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
33034147|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
33034148|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
33034149|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
33034150|NCT01970202|Other|Control|no treatment
33034151|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
33034152|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
33034153|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
33034154|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
33034155|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
33034156|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
33034157|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
33327591|NCT03739866|Experimental|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33034158|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
33034159|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
33327592|NCT03739866|Experimental|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33327593|NCT03739866|Experimental|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33327594|NCT03739866|Placebo Comparator|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33327595|NCT03739866|Experimental|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33034160|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
33034161|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
33034162|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
33034163|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
33034164|NCT01970267|Sham Comparator|Not Treated|
33034165|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
33034166|NCT01970280|No Intervention|Observation|
33034167|NCT01970293|Other|Introduction to AA volunteer|
33034168|NCT01970293|No Intervention|AA materials offered|
33034169|NCT01970319||Diabetic with nephropathy|
33034170|NCT01970319||Diabetics without nephropathy|
33034171|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
33034172|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
33034173|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
33034174|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
33034175|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
33034176|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
33034177|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
33034178|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
33034179|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
33034180|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
33034181|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
33034182|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
33034183|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
33034184|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
33034185|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
33034186|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
33327596|NCT03739866|Experimental|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
33327597|NCT03857724|Experimental|prolapse surgery|
33327598|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
33327599|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
33327600|NCT01181232|Experimental|MR low-dose group|
33327601|NCT01181232|Experimental|MR high-dose group|
33327602|NCT01181232|Active Comparator|IR group|
33327603|NCT01177644|Experimental|Active|
33327604|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
33034187|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
33034188|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,~immediately followed by:~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
33327605|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
33327606|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
33034189|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
33034190|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
33034191|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
33034192|NCT01970579|Experimental|Paclitaxel coated balloon|
33034193|NCT01970579|Active Comparator|uncoated PTA catheter|
33034194|NCT01970605||Patients with PAOD or aneurysms|"Patients~in Fontaine class > IIa,~in need of aneurysm repair,~with defined cardiovascular risk factors or~graft infections.~Surgical reconstruction with defined Silver Graft vascular prosthesis."
33034195|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
33034196|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
33034197|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
33034198|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
33034199|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
33034200|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
33034201|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
33034202|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
33034203|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
33327607|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
33327608|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
33327609|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
33327610|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
33327611|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
33327612|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
33327613|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
33327614|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
33034204|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
33034205|NCT01970683|Experimental|VSL #3|probiotics given orally BID
33034206|NCT01970683|Other|placebo|Near-identically appearing placebo
33034207|NCT01970696||Ovarian Stromal Tumors|
33034208|NCT01970696||Testicular Stromal Tumors|
33034209|NCT01970696||Ovarian Small Cell Carcinoma|
33034210|NCT01970735|Experimental|FSHD patient|
33034211|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
33034212|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
33034213|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
33034214|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
33034215|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
33034216|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
33034217|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
33034218|NCT01970813|No Intervention|Waiting group|no additional intervention
33067574|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
33327615|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
33034219|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
33034220|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
33327616|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
33327617|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
33327618|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
33327619|NCT01289184||control|
33327620|NCT01289184||exposure 2-3 years|
33034221|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
33034222|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
33034223|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
33034224|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
33034225|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
33034226|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
33034227|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
33034228|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
33034229|NCT01970891|Experimental|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
33034230|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
33327621|NCT01289184||exposure 3-5 years|
33327622|NCT01289184||exposure 5-10 years|
33327623|NCT01289184||exposure >15 years|
33327624|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
33327625|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
33327626|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
33327627|NCT01288092|Experimental|BEZ235|
33327628|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
32871551|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
32871552|NCT00299741|Experimental|1|Sunitinib
33327629|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
33327630|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids~Exclusion criteria:~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
33327631|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
33327632|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
33327633|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
32871553|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
32871554|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.~Patients in treatment with biologicals: retrospective routine treatment algorithm"
32899446|NCT01099631|Experimental|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
32899447|NCT01099631|Experimental|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
32899448|NCT01099631|Experimental|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
32899449|NCT01099631|Experimental|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
32899450|NCT01099631|Experimental|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
32899451|NCT05307029||Group A edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 4 implants
32899452|NCT05307029||Group B edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 6 implants
32899453|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
32899454|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
32899455|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
32899456|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
32899457|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
32899458|NCT05306561|Experimental|Arm 1|Single arm trial
32899459|NCT01101971|Experimental|first year medical students|
32899460|NCT05306405|Active Comparator|vaginal misoprostol|only vaginal misoprostol 25 μg tablets will be applied for induction of laour
32899461|NCT05306405|Active Comparator|combined vaginal misoprostol and estradiol|vaginal misoprostol 25 μg (Vagiprost) tablets with vaginal estradiol 150 ml cream will be applied for induction of laour
32899462|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
32899463|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
32899464|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
32899465|NCT04352621|Experimental|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
32899466|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
32899467|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
32899468|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
32899469|NCT05272397|Active Comparator|Drug Session|"In this arm of the study participants receive the drug (Methylphenidate - 20mg), administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
33034231|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
33327634|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
33034232|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
33034233|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
33327635|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
33327636|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
33327637|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
33327638|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
33327639|NCT05666622|Other|Kahramanmaraş Sütçü İmam University|Only routine non-surgical periodontal treatment was applied to the patients.
33327640|NCT01180452|Other|Single group open label|Prospective Cohort
33327641|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
33327642|NCT03857568|Experimental|Placebo|Placebo will be dosed
33034234|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
33034235|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
33034236|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
33034237|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
33034238|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
33034239|NCT01971034|Experimental|Paclitaxel and Metformin|
33034240|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
33034241|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
33034242|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
33034243|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.~Intervention: Device: transcranial direct current stimulation"
33034244|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
33034245|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
33034246|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
33034247|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
33034248|NCT01971112|Placebo Comparator|Placebo|
33034249|NCT01971125||No treatment|"Patients with:~diabetes mellitus type 2~absence of heart disease previously reported~age >45 years~Informed Consent~Patients without:~presence of heart disease previously reported~diabetes type 1~serious systemic disease, with an expected lifetime lower than 2 years~no willingness to participate to the screening~inadequate compliance to study procedure~participation to other study"
33034250|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
33034251|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
33034252|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
33034253|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
33034254|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
33034255|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
33034256|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
33034257|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
33034258|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
33034259|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
33034260|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
33034261|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
33034262|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
33034263|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
33327643|NCT01181544|Experimental|Heparin dose titration|
33327644|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
33327645|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
33327646|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
32740740|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
33107532|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
33107533|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
33107534|NCT04649216|Experimental|Mass Balance|Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.
33107535|NCT04649216|Experimental|Absolute Bioavailability and Mass Balance|Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.
33107536|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
33327647|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
33327648|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
33107537|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
33107538|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
33107539|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
33107540|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
33107541|NCT04648865|Experimental|LY3537031|LY3537031 administered subcutaneously (SC).
33107542|NCT04648865|Placebo Comparator|Placebo|Placebo administered SC.
33107543|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
33107544|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
33107545|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
33327649|NCT01181700|Experimental|Treatment A|
33107546|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
33107547|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
33107548|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
33107549|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
33107550|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
33107551|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
33107552|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
33107553|NCT02888509||healthy control|Well mathed with patients in age, gender, education
33107554|NCT02888509||major depression disorder|patients with major depression disorder
33107555|NCT02888509||anxiety disorder|patients with anxiety disorder
33107556|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
33107557|NCT01238575|Experimental|Extended-release guanfacine|
33107558|NCT01238575|Placebo Comparator|Inactive placebo|
33107559|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.~Intervention: Pelvic Trainer"
33107560|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.~Intervention: Robotic assistance~Intervention: Pelvic Trainer"
33327650|NCT01181700|Experimental|Treatment B|
33327651|NCT01181700|Experimental|Treatment C|
33327652|NCT01181700|Active Comparator|Treatment D|
33327653|NCT01181700|Active Comparator|Treatment E|
33327654|NCT01181700|Active Comparator|Treatment F|
33327655|NCT01181700|Active Comparator|Treatment G|
33327656|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
33327657|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
33327658|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
33327659|NCT05668494|Other|immediate loading|Immediate loading of implants by means of one definitive abutment on one side and temporary abutment on the other side of the posterior mandible restored by provisional crown-split mouth design
33327660|NCT01184820|Experimental|Arm 1|
33327661|NCT01184820|Experimental|Arm 2|
33327662|NCT01289652||HCV + HIV|
33327663|NCT01289652||HCV|
33327664|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
33327665|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
33327666|NCT01180530||A|
33327667|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
33327668|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
33034264|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
33034265|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
33034266|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
33034267|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
33034268|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
33034269|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
33034270|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
33034271|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
33034272|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
33034273|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
33034274|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
33034275|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks"
33034276|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
33034277|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:~pulse pressure variation~stroke volume variation~plethysmographic variation index"
33034278|NCT01971359||Retrospective|
33034279|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
33034280|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
33034281|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
33034282|NCT01971411||Community dwelling elderly black females|
33034283|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
33034284|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
33034285|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
33034286|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
33034287|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
33034288|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33034289|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
33034290|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
33327669|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
33327670|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
33327671|NCT05666544|Active Comparator|Written health education leaflets|Using written health education leaflets to conduct education.
33327672|NCT05666544|Experimental|Web-based patient decision aid|Using web-based patient decision aid of renal replacement therapy.
33327673|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
33327674|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
33327675|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
33327676|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
33327677|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
33327678|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
33327679|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
33327680|NCT01180608|Active Comparator|Pregabalin|
33327681|NCT01180608|Placebo Comparator|placebo + pregabalin|
33327682|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
33417618|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
33034291|NCT01971515|Experimental|MSC2363318A|
33034292|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
33034293|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
33034294|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
33034295|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
33034296|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
33034297|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
33034298|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
33034299|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
33034300|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
33034301|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
33034302|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
33034303|NCT01971606|Placebo Comparator|Placebo group|Placebo group
33034304|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
33034305|NCT01971632|Active Comparator|Oxycodone/Naloxone|
33034306|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
33034307|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
33034308|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:~Induction therapy : 4 cycles of VCD (21 days)~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15~Velcade® and Dexamethasone identical treatment to Arm A~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
33034309|NCT01971671||Chinese lactating mother|no intervention.
33034310|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
33034311|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
33034312|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
33034313|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
33034314|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
33034315|NCT01971749||Unprotected left main coronary artery stenosis patients|
33034316|NCT01971762||Patients diagnosed bacteremia by S. aureus|
33034317|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
33034318|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
33034319|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
33034320|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
33034321|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
33034322|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
33034323|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
33034324|NCT01971827|No Intervention|Control|No intervention
33034325|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
33034326|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
33034327|NCT01971840|No Intervention|Control|No intervention
33034328|NCT01971879|Sham Comparator|Control|
33034329|NCT01971879|Active Comparator|Remote preconditioning|
33034330|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
33034331|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
33034332|NCT01971905||Oben label|There is no intervention on this descriptive study
33034333|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
33034334|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
33034335|NCT01971931||Patients undergoing TKR.|
33327683|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
33034336|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
33034337|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
33034338|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
33034339|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
33034340|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
33034341|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
33034342|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
33034343|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
33034344|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
33034345|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
33034346|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
33034347|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
33034348|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
33034349|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
33034350|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
33034351|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
33034352|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
33034353|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
33034354|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
33034355|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
33034356|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
33034357|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
33034358|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
33034359|NCT01972191||Group 1|Group 1 : Bare eye marking group
33034360|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
33034361|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
33034362|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
33034363|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
33034364|NCT01972243||venous thromboembolism|
33034365|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
33034366|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
33034367|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034368|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034369|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034370|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034371|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034372|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33327684|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
33327685|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
33327686|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
33327687|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
33327688|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
33327689|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
33327690|NCT01181856|Experimental|Group A|Intramuscular immunisation
33327691|NCT01181856|Experimental|Group B|Intradermal immunisation
33034373|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33327692|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
33034374|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034375|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034376|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034377|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034378|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
33034379|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
33034380|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
33034381|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
33034382|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
33034383|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
33034384|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
33034385|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
33034386|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
33034387|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
33034388|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
33034389|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
33034390|NCT01972386||Spectrum Image Analysis|
33034391|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
33034392|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
33034393|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
33034394|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
33034395|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
33034396|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
33034397|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
33034398|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
33034399|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
33034400|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
33034401|NCT01972490|Experimental|ARM A|patients received avastin in combination with mFOLFOX6
33034402|NCT01972490|Active Comparator|ARM B|Patients received mFOLFOX6 alone
33034403|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
33034404|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
33034405|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
33034406|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
33034407|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test~No impaired fasting glucose and impaired glucose tolerance"
33067575|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
33327693|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
33327694|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
33327695|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
33327696|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
33034408|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
33327697|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
33034409|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
33034410|NCT01972581|Experimental|Reaction Time Training|
33034411|NCT01972581|No Intervention|Control|
33034412|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
33034413|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
33034414|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
33034415|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
33034416|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
33034417|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
33034418|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
33034419|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
33034420|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
33034421|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
33034422|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
33034423|NCT01972698|Experimental|Self-directed and simulation-assisted training|
33034424|NCT01972698|Active Comparator|Traditional apprenticeship training|
33034425|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
33034426|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
33034427|NCT01972711|Placebo Comparator|Placebo|Matched placebo
33034428|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
33034429|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
33034430|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
33034431|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
33034432|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
33034433|NCT01972828|Active Comparator|CONTROL|
33034434|NCT01972880|Experimental|tablet-1|
33034435|NCT01972880|Active Comparator|tablet-2|
33034436|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
33034437|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
33034438|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
33034439|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
33034440|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
33327698|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
33327699|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
33327700|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
33327701|NCT01180764|Placebo Comparator|Placebo|Matching placebo
33327702|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
33327703|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
33327704|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
33327705|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
33034441|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
33034442|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
33327706|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
33327707|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
33327708|NCT04986618|Experimental|One-way Nordic Exercise Group|
33034443|NCT01972958|No Intervention|usual care|control group with usual care
33034444|NCT01972971|Other|pharmacist care|
33034445|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
33034446|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
33034447|NCT01973010|Experimental|Massage|To treat low back pain with massage
33034448|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
33034449|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
33034450|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
33034451|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
33034452|NCT01973088||non-urate calculus|
33034453|NCT01973088||non-calculus|
33327709|NCT04986618|Experimental|Two-way Nordic Exercise Group|
33327710|NCT04986618|No Intervention|Control Group|
33327711|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
33327712|NCT01187862|Other|Basel cocktail|
33327713|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
33327714|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
33034454|NCT01973088||urate calculus|
33034455|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
33034456|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
33034457|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
33034458|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
33034459|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
33034460|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
33034461|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
33327715|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
33327716|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
33327717|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
33327718|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
33327719|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
33327720|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
33327721|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
33327722|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
33327723|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
33327724|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
33327725|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
33327726|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
33034462|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
33417619|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
33417620|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
33417621|NCT05190601||Group 1|Enuresis nocturna with children
33034463|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
33034464|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|
33034465|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|
33034466|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|
33034467|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
33034468|NCT01973244|Active Comparator|Norditropin®|
33034469|NCT01973257|Experimental|select from the option menu|select from the option menu
33034470|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
33034471|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
33034472|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
33034473|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
33034474|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
33034475|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
33034476|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
33034477|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
33034478|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
33034479|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
33034480|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
33034481|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
33034482|NCT01973374|No Intervention|Routine Care|
33034483|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
33034484|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
33034485|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
33034486|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
33034487|NCT01973465|Experimental|Fecal Microbiota Therapy|
33034488|NCT01973478|Experimental|DBS|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
33034489|NCT01973478|Sham Comparator|SHAM|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
33034490|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
33034491|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
33034492|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
33417622|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
33417623|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
33417624|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
33417625|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
33417626|NCT05383404||mild dehydration|(3-5)% according to change in body weight.
33417627|NCT05383404||moderate dehydration|(6-9)% according to change in body weight.
33417628|NCT05383404||severe dehydration|(6-9)% according to change in body weight.
33417629|NCT01318421|Experimental|ELND002|ELND002 sc injection
33417630|NCT05190367||No trauma|Patients suffering from chronic pain without traumatic life events
33417631|NCT05190367||Accidental trauma|Patients suffering from chronic pain who have experienced at least one accidental trauma
33417632|NCT05190367||Interpersonal trauma|Patients suffering from chronic pain who have experienced at least one interpersonal trauma
33417633|NCT05190367||PTSD|Patients suffering from chronic pain and diagnosed with PTSD
33417634|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
33417635|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
33034493|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
33034494|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
33034495|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
33034496|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
33034497|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
33034498|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
33034499|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
33034500|NCT01973556|No Intervention|Usual Care|
33034501|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
33034502|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
33034503|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
33034504|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
33034505|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
33034506|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
33034507|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
33034508|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
33034509|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
33034510|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
33034511|NCT01973686|No Intervention|Control|Receives no intervention
33034512|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
33034513|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
33034514|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
33034515|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
33034516|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
33034517|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
33034518|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
33034519|NCT01973764|Other|Ultrasound guided arm|
33034520|NCT01973764|Other|Landmark-based arm|
33034521|NCT01973790|Experimental|Z-338|100mg TID
33034522|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
33034523|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
33034524|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
33034525|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
33034526|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
33034527|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
33034528|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
33034529|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
33034530|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
33034531|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.~Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine.~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
33034532|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
33034533|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
33034534|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
33034535|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
33034536|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
33034537|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
33034538|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
33034539|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
33034540|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
33034541|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
33034542|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
33034543|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
33034544|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
33034545|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
33034546|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
33034547|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
33034548|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
33327727|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
33034549|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
33034550|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
33327728|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
33327729|NCT01188018|Active Comparator|Brief Advice|
33327730|NCT01188018|Experimental|Motivational Interviewing|
33327731|NCT01188018|Active Comparator|Health Education|
33327732|NCT03857334|Experimental|Arm A|
33327733|NCT03857334|Active Comparator|Arm B|
33327734|NCT01588392|Experimental|Short bouts of structured activity|
33327735|NCT01588392|Active Comparator|Unstructured physical activity|
33327736|NCT01587690||Healthy subjects|Self-explanatory
33327737|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
33327738|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
33327739|NCT01185678||Group1|
33034551|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
33034552|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
33034553|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
33327740|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
33327741|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
33327742|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
33034554|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
33034555|NCT01974076|Active Comparator|Active tDCS|
33034556|NCT01974076|Sham Comparator|Sham tDCS|
33034557|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
33034558|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
33034559|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
33034560|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
33034561|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
33034562|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
33034563|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
33034564|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
33034565|NCT01974219||Healthy smokers|Healthy smokers
33034566|NCT01974219||COPD smokers|COPD smokers
33034567|NCT01974232||Romiplostim group|
33034568|NCT01974232||Eltrombopag group|
33034569|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
33034570|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
33034571|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
33034572|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
33034573|NCT01974271||Cohort|
33034574|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
33327743|NCT01188174|Experimental|Clofarabine|
33327744|NCT01588002|Active Comparator|A danoprevir+ritonavir|
33034575|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
33327745|NCT01588002|Active Comparator|B efavirenz|
33034576|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
33034577|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
33034578|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
33034579|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
33034580|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
33034581|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
33034582|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
33034583|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
33034584|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
33034585|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
33034586|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
33034587|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
33034588|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
33034589|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
33034590|NCT01974453||Right transradial|Procedures performed through right transradial approach
33034591|NCT01974453||Left transradial|Procedures performed through left transradial approach
33034592|NCT01974453||Femoral|Procedures performed through transfemoral approach
33034593|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:~heart rate <120 beats/min,~mean arterial blood pressure 65-85 mm Hg,~urine output ≥1 ml/kg /h~Hematocrit ≤35%."
33034594|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
33034595|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
33034596|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
33034597|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
33034598|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
33034599|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
33034600|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
33034601|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
33034602|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
33034603|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
33034604|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
33034605|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
33034606|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
33034607|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
33034608|NCT01974583||the control group C|Group C were covered with paraffin gauze
33327746|NCT01588002|Experimental|C combination|
33327747|NCT01291212|Active Comparator|Testosterone and FSHr|
33327748|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
33327749|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
33327750|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
33327751|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
33327752|NCT01182246|Experimental|AXP107-11|
33327753|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
33327754|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
33327755|NCT04915014|Experimental|laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)|One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
33034609|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
33327756|NCT04915014|Sham Comparator|laparoscopic Roux-en-Y gastric bypass (RYGB)|One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
33327757|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
33327758|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
33034610|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
33034611|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
33034612|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
33034613|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
33034614|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
33034615|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
33034616|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
33034617|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
33034618|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
33034619|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
33034620|NCT01974739|Placebo Comparator|placebo|once a day placebo
33034621|NCT01974778|Experimental|Active|Meal
33034622|NCT01974778|Placebo Comparator|Control|Water
33034623|NCT01974791|Experimental|GET Living Treatment|
33034624|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
33034625|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
33034626|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
33034627|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
33034628|NCT01974869||Inflammatory bowel diseases-2|Controls
33034629|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
33034630|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
33034631|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
33034632|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
33034633|NCT01974934|Experimental|Desvenlafaxine Succinate|
33034634|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
33034635|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
33034636|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
33034637|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
33034638|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
33034639|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
33034640|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
33034641|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
33034642|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
33034643|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
33034644|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
33034645|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
33034646|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
33034647|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
33034648|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
33034649|NCT01975129|Experimental|Vagitocin (Oxytocin)|
33034650|NCT01975142|Experimental|TDM-1|
33034651|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
33034652|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
33034653|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
33417636|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
33034654|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
33034655|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
33034656|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
33034657|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
33034658|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
33034659|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
33034660|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
33034661|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
33034662|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
33034663|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
33034664|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
33034665|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
33034666|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
33034667|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
33034668|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
33034669|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
33034670|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
33034671|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
33034672|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
33034673|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
33107561|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
33107562|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
33417637|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
33417638|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
33327759|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
33327760|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
33107563|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
33107564|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
33107565|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
33107566|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
33107567|NCT04648943|Active Comparator|Patients undergoing Ex-Press mini shunt insertion|Patients in this arm had the Ex-Press mini shunt inserted in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
33107568|NCT04648943|Active Comparator|Patients undergoing trabeculectomy|Patients in this arm had standard trabeculectomy in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
33107569|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
33107570|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
33107571|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
33107572|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
33107573|NCT04648670|Experimental|Group intervention|"The experimental group consists of 101 participants have been subdivided into two groups of 25/26 that perform the same intervention but on a different day of the week.~The two subgroups have received 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~."
33107574|NCT04648670|No Intervention|Group Control|The control group consists of 100 participants. The no intervention group did not receive any type of intervention
33107575|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
33107576|NCT00553293|Placebo Comparator|A,2|rFSH alone
33107577|NCT04648514|Active Comparator|Using of bone osteotomes for closed sinus lifting|Using of summers' osteotome technique by bone osteotomes for closed sinus lifting then evaluation the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement in posterior edentulous maxilla .
33107578|NCT04648514|Active Comparator|Patient satisfaction evaluation after using bone osteotomes|Evaluation of patient satisfaction numerically will be done after using summers' osteotome technique by bone osteotomes for closed sinus lifting in posterior edentulous maxilla
33107579|NCT00544401|Experimental|1|Hypnopuncture Treatment
33107580|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
33107581|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
33107582|NCT04648358|Active Comparator|Control group|The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000
33327761|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
33327762|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
33327763|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
33327764|NCT01188252|Experimental|Roniciclib|
33327765|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback~- intervention:~All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together"
33034674|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
33327766|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation~- intervention:~All cases will undergo one surgery under general anesthesia~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
33327767|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
33327768|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
33327769|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
33327770|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
33327771|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
33327772|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
33327773|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
33327774|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
33327775|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
33327776|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
33327777|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
33327778|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
33034675|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
33034676|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
33034677|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
33034678|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
33034679|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
33034680|NCT01975493||Amoxicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
33034681|NCT01975493||Ampicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
33034682|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
33034683|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
33034684|NCT01975493||Flucloxacillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
33034685|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
33034686|NCT01975506||head start practitioners|
33034687|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
33034688|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
33034689|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
33034690|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
33034691|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
33034692|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
33034693|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
33034694|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
33034695|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
33034696|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
33067576|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
33067577|NCT00132353||Healthy volunteers|For normative data
33327779|NCT03852654|Experimental|treatment|
33327780|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
33327781|NCT01185990||Healthy control subjects|
33327782|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
33327783|NCT01588080|Placebo Comparator|SiPAP|
33327784|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
33327785|NCT03857100|Active Comparator|Intervention|Receives letter and report
33034697|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
33327786|NCT03857100|No Intervention|Control|Does not receive letter and report
32871555|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
33034698|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
33034699|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
33034700|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
33034701|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
33034702|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
33034703|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
33034704|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
33034705|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
33034706|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
33034707|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
33034708|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
33034709|NCT01975740|Experimental|Manual diaphragm release technique|
33034710|NCT01975740|Other|Sham manual diaphragm release technique|
33034711|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
33034712|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
33034713|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
33034714|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
33034715|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
33034716|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
33034717|NCT01975779|Experimental|Cohort B1: Lu AE58054|
33034718|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
33034719|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
33034720|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
33034721|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
33034722|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
33034723|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
33034724|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
33327787|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
33327788|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
33034725|NCT01975870|No Intervention|control group|no use of application on smartphone
33327789|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
33327790|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
33034726|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
33034727|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
33034728|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
33034729|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
33034730|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
33034731|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
33034732|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
33034733|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
33034734|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
33034735|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
33034736|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:~Conservative management when no surgical or endovascular treatment is considered possible or reasonable~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques~Parent vessel occlusion, with or without bypass~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
33034737|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
33067578|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
33034738|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
33327791|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
33327792|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
33327793|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
33327794|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
33327795|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
33327796|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
33034739|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
33034740|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
33327797|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
33327798|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
33034741|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
33034742|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
33327800|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
33327801|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
33327802|NCT01182636|Placebo Comparator|Placebo|Gel base only
33327803|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
33327804|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
33327805|NCT01182714|Other|removal of catheter|
33034743|NCT01976117|Experimental|enose|
33034744|NCT01976130|Experimental|bronchoscopy|Procedure
33034745|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
33034746|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
33034747|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
33034748|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
33034749|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
33034750|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
33034751|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
33034752|NCT01976221||Prioritization|Team-based multifaceted interactive training
33034753|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
33034754|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
33034755|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
33034756|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
33034757|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
33034758|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
33034759|NCT01976403|Experimental|Pain booklet|
33034760|NCT01976403|No Intervention|standard care|
33034761|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
33327806|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
33327807|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
33327808|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
33327809|NCT01182792|Experimental|Antioxidant|
33107583|NCT04648358|Experimental|DEX4mg group|DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.
33107584|NCT04648397|Experimental|Short chewing|Subjects consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a short chewing protocol.
33107585|NCT04648397|Experimental|Long chewing|Subjects will consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a long chewing protocol.
33107586|NCT00544518|Experimental|2|
33107587|NCT00544518|Active Comparator|1|
33107588|NCT04648592|Experimental|Intervention|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.
33107589|NCT04648592|Placebo Comparator|Control|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.
33107590|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
33107591|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
33107592|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
33107593|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
33107594|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
33107595|NCT00544635|Experimental|A|scars will be treated with light
33107596|NCT00544635|Placebo Comparator|B|no intervention
33107597|NCT00558233|Experimental|Intervention group|
33107598|NCT00558233|Placebo Comparator|Placebo group|
33107599|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
33107600|NCT04648475|Experimental|Arm 1|CD19 and CD22 targeted CAR-T cells treat
33107601|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
33107602|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
33107603|NCT04648280|Experimental|Fostemsavir|Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
33107604|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
33107605|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
33107606|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
33107607|NCT04648007||Control|10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
33107608|NCT04648007||Moderate Gamblers|10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
33107609|NCT04648007||Severe Gamblers|10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
33327810|NCT01182792|Placebo Comparator|Control|
33327811|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
33107610|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
33107611|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
33107612|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
33327812|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
33327813|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
33107613|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
33107614|NCT00544791|Placebo Comparator|B|
33107615|NCT04647812|Experimental|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology
33107616|NCT04647812|Experimental|Conventional rehabilitation|Traditional multidisciplinary rehabilitation
33107617|NCT04684797|Experimental|Intervention group|Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
33107618|NCT04647929|Experimental|PRESERFLO MicroShunt|Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
33327814|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
33327815|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
33034762|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
33034763|NCT01976468||SCC metastasis|organ transplant recipients
33034764|NCT01976481|Experimental|Sunbed|sunbed exposure
33034765|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
33034766|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
33034767|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
33034768|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
33034769|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
33034770|NCT01976546||airway|Patients with one or more predictors of diffucult airway
33034771|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
33034772|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
33034773|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
33034774|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
33034775|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
33034776|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
33034777|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
33034778|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
33034779|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
33034780|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
33034781|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
33034782|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
33034783|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
33034784|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
33034785|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
33034786|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
33034787|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
33034788|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
33034789|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
33034790|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
33034791|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
33034792|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
33327816|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
33327817|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
33327818|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
33327819|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
33327820|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
33327821|NCT03852108|No Intervention|Group control|Conventional care
33034793|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
33034794|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
33107619|NCT04647929|Active Comparator|Trabeculectomy|Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
33327822|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
33327823|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
33327824|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
33034795|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
33034796|NCT01976884||Severe sepsis|Patients with severe sepsis
33034797|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
33034798|NCT01976884||Tumor|Patients with pancreatic cancer
33034799|NCT01976884||Volunteer|
33034800|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.~Intervention: Knee flexion measurement 1~Intervention: Knee flexion measurement 2~Intervention: Heel - interface pressure measurements"
33327825|NCT05254314|Experimental|Study Drug (Semaglutide)|Semaglutide 2.4mg once weekly
33327826|NCT05254314|Placebo Comparator|Placebo|Placebo 2.4mg once weekly
33327827|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
33327828|NCT04979286|Experimental|Kinesiotaping Group|Y strip kinesiotaping will be applied to both the gastrocnemius muscles with approximately 20% tension.
33327829|NCT04979286|Placebo Comparator|Placebo Group|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
33327830|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
33327831|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
33034801|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
33034802|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
33034803|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
33034804|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
33034805|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
33034806|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
33034807|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
33034808|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
33034809|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
33034810|NCT01977014||Patient with LenusPro pump|
33034811|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
33067579|NCT04696783|Experimental|Drug Group|Esomeprazole Magnesium Enteric-coated Tablets and lifestyle adjustment
33067580|NCT04696783|Placebo Comparator|non-Drug Group|Only lifestyle adjustment
33327832|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
33327833|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
33327834|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
33327835|NCT05202678|Other|AGN1 LOEP|Subjects treated with AGN1 LOEP in proximal femur
33327836|NCT01188720|No Intervention|Baseline|Assessment only baseline
33327837|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
33327838|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
33327839|NCT05148468|Experimental|Active stimulation|During active stimulation phase, patients will receive through the spinal cord stimulator active tonic stimulation with amplitude set to 90% of paresthesia inducing threshold, therefore allowing blinding. Patients will be evaluated after a two week wash out period with no stimulation and after two weeks of continuous active stimulation.
33107620|NCT04647773|Experimental|HSK16149 20mg BID|
33034812|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
33327840|NCT05148468|Sham Comparator|Sham stimulation|"During sham stimulation phase, patients will receive through the spinal cord stimulator a zero amplitude stimulation, therefore having no electrical current passing through epidural leads but with the program status still displayed as on if checked with patient's personal controller. Patients will be evaluated after a two week wash out period with no stimulation and after two weeks of continuous sham stimulation."
33327841|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
33327842|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
33327843|NCT05238558|Experimental|FMPV-1 vaccination|"GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections.~Total of 8 administrations intradermally; GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment."
33327844|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
33327845|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
33034813|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
33034814|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
33034815|NCT01977066|Experimental|Six months supervised exercise training|
33034816|NCT01977066|Experimental|Six months home-based exercise training|
33034817|NCT01977066|No Intervention|Control group|
33034818|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
33034819|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
33034820|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
33034821|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
33034822|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
33034823|NCT01977131|Experimental|stromal cells modified HGF|
33034824|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
33107621|NCT04647773|Experimental|HSK16149 40mg BID|
33034825|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:~PRP-T 10ug NaCl 0.85%~Frequency: 1 injection"
33034826|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
33034827|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
33034828|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
33327846|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
33327847|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
33327848|NCT02524548|No Intervention|Standard care|Routine care
33327849|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
33327850|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
33327851|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
33034829|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
33034830|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
33327852|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
33327853|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
33034831|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
33327854|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
33327855|NCT03856008|No Intervention|Control.|No intervention will be applied.
33034832|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
33034833|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
33034834|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
33034835|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
33034836|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
33034837|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
33034838|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
33034839|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
33034840|NCT01977313||All study participants|All study participants
33034841|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
33034842|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
33034843|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
33034844|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
33034845|NCT01977365|Experimental|Growth promotion based on child centered approach|
33034846|NCT01977365|No Intervention|Control|
33034847|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
33034848|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
33034849|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
33034850|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
33034851|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
33034852|NCT01977430|No Intervention|Control Arm|
33034853|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
33034854|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
33034855|NCT01977469|Experimental|Low intensity resistance training|Low intensity resistance training + aerobic training
33034856|NCT01977469|Experimental|High intensity resistance training|High intensity resistance training + aerobic training
33034857|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
33034858|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
33034859|NCT01977508||haemodialysis vascular access using ePTFE grafts|
33034860|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
33034861|NCT01977521|Sham Comparator|Sham|Sham stimulation
33034862|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
33034863|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
33034864|NCT01977664||oocyte maturation failure|no intervention
33034865|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
33034866|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
33034867|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
33034868|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
33034869|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.~The cardiac vagal index will be measured at every 8 weeks."
33034870|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
33034871|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
33034872|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
33034873|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
33034874|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
33034875|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
33034876|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
33034877|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
33034878|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
33034879|NCT01977859|Placebo Comparator|Saline|Saline infusion
33034880|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
33034881|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
33034882|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
33034883|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
33034884|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
33034885|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
33034886|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
33034887|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
33034888|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
33034889|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
33034890|NCT01977963||Agranulocytosis|
33034891|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
33034892|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
33034893|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
33034894|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
33034895|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
33034896|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
33034897|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
33034898|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
33034899|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
33034900|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
33034901|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
33107622|NCT04647773|Experimental|HSK16149 60mg BID|
33327856|NCT05137158|Experimental|iTBS stimulation|The patients in iTBS stimulation group will receive iTBS stimulation on the target of the left dorsolateral prefrontal cortex for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
33327857|NCT05137158|Sham Comparator|Sham stimulation|The participants in sham stimulation will receive sham stimulation, as the coil vertical to the brain surface, for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
33327858|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.~All patients will go through functional MRI study"
33034902|NCT01978028|Placebo Comparator|placebo|placebo
33034903|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
33034904|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
33034905|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
33034906|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
33034907|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
33034908|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
33034909|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
33034910|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
33034911|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
33034912|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
33034913|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
33034914|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
33034915|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
33034916|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
33034917|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
33034918|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
33034919|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
33034920|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
33034921|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
33034922|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
33034923|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
33034924|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
33034925|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
33034926|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
33034927|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
33034928|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
33034929|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
33034930|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
33034931|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
33034932|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
33034933|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
33034934|NCT01978327|Placebo Comparator|Placebo|Matching placebo
33034935|NCT01978327|Experimental|simvastatin|for drug-drug interaction
33327859|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
33327860|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
33034936|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
33034937|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
33034938|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
33034939|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
33034940|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
33034941|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
33034942|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
33034943|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
33034944|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
33034945|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
33034946|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
33034947|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
33034948|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
33034949|NCT01978457|Experimental|propranolol|propranolol
33034950|NCT01978457|Placebo Comparator|placebo|placebo
33034951|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
33034952|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
33034953|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
33034954|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
33034955|NCT01978496|Placebo Comparator|Placebo|
33034956|NCT01978496|Experimental|Eletriptan 20 mg|
33034957|NCT01978496|Experimental|Eletriptan 40 mg|
33034958|NCT01978496|Experimental|Eletriptan 80 mg|
33034959|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
33034960|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
33034961|NCT01978548|Experimental|JNJ-54861911 50 mg|
33034962|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
33034963|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
33034964|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
33034965|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
33034966|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
33034967|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
33034968|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
33034969|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
33034970|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
33034971|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
33034972|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
33034973|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
33034974|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
33034975|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
33034976|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary~2nd year: no social persuasion is given beyond sessions~3rd year: Tai-chi teaching by Digital Video Disc only"
33034977|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
33107623|NCT04647773|Experimental|HSK16149 80mg BID|
33034978|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
32871556|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
33034979|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
33327861|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
33327862|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
33034980|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
33034981|NCT01978665|Other|placebo|measurement of fitness
33034982|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
33034983|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
33034984|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
33034985|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
32871557|NCT00248807|Placebo Comparator|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
32871558|NCT00248807|Placebo Comparator|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
33034986|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
33034987|NCT01978704|Experimental|Glycaemic load|
33034988|NCT01978704|Active Comparator|Carbohydrates content|
33034989|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
33034990|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
33034991|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
33034992|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
33034993|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
33034994|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
33034995|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
33034996|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
33034997|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
33034998|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
33034999|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
33035000|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
33035001|NCT01978795|Active Comparator|Control|
33035002|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
33035003|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
33035004|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
33035005|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
33035006|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
33327863|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
33327864|NCT01186926|Experimental|HGNS Treatment|
33327865|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
33327866|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
33327867|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
33035007|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
33035008|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
33327868|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
33327869|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
33035009|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
33035010|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
33035011|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
33035012|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
33035013|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
33035014|NCT01978964|Experimental|ONT-10 Vaccine|
33035015|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
33035016|NCT01978990||Diabetes Management System , blood glucose|
33035017|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
33035018|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
33035019|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
33035020|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
33035021|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
33035022|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
33035023|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
33035024|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
33035025|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
33035026|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
33035027|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
33035028|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
33035029|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
33035030|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
33035031|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
33035032|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
33107624|NCT04647773|Active Comparator|Pregabalin 150mg BID|
33327870|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
33035033|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
33035034|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
33035035|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
33035036|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
33035037|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
33035038|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
33035039|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
33035040|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
33035041|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
33035042|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
33035043|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
33035044|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
33035045|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
33035046|NCT01979354|No Intervention|Control|No spinal morphine
33035047|NCT01979380|Experimental|KD101|
33035048|NCT01979380|Placebo Comparator|placebo|
33035049|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
33035050|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
33035051|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Days 1, 15 and 29"
33035052|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
33035053|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
33035054|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
33035055|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4-PA-GPI at Days 1, 15 and 29"
33035056|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
33035057|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
33035058|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
33035059|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
33035060|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
33035061|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
33035062|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
33035063|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
33035064|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:~Usual pharmacy care with no specific interventions for 3 months~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
33035065|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
33035066|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
33035067|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
33035068|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
33035069|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
33035070|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
33035071|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
33035072|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
33035073|NCT01979562||100 runners|Male runners between 18-60 years.
33035074|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
33035075|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
33035076|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
33035077|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
33035078|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
33327871|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
33327872|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
33327873|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
33327874|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
33327875|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
33327876|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
33327877|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
33035079|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
33035080|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
33035081|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
33035082|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
33035083|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
33035084|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
33035085|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
33035086|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
33035087|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
33035088|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
33035089|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
33035090|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
33035091|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
33035092|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
33035093|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
33035094|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
33035095|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
33327878|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
33327879|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
33327880|NCT01183962|Other|No medicine|Subject does not receive medication
33327881|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
33035096|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
33035097|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
33035098|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
33035099|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
33035100|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
33035101|NCT01979718|Experimental|Full term intervention|"random selection~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
33035102|NCT01979718|Active Comparator|Half term intervention|"random selection~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
33035103|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
33035104|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
33035105|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
33035106|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
33035107|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
33107625|NCT04647773|Placebo Comparator|Placebo BID|
33327882|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
33035108|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
33035109|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
33327883|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
33035110|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
33035111|NCT01979783||LBP|group of subjects with low back pain
33035112|NCT01979783||nonLBP|group without low back pain
33035113|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
33035114|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
33035115|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
33035116|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:~Patient aged ≥ 18 years;~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1~Patient is in stable clinical condition and~the previous specific PH medication has been retained unchanged during the past 3 weeks"
33035117|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
33035118|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
33035119|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
33035120|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
33035121|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
33035122|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
33035123|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
33035124|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
33035125|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
33035126|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
33035127|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
33035128|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
33035129|NCT01979926|Placebo Comparator|Placebo|Sugar pill
33035130|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
33035131|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
33035132|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
33035133|NCT01979978|No Intervention|Control|This group received standard school curriculum.
33035134|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
33035135|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
33035136|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
33035137|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
33035138|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
33035139|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
33035140|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
33035141|NCT01980082|Active Comparator|Cefazolin|"Cefazolin~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
33035142|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
33035143|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
33035144|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
33035145|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
33035146|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
33035147|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
33035148|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
33035149|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
33035150|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
33035151|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
33327884|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
33327885|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
33327886|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
33035152|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon"
33035153|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care"
33035154|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
33035155|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
33035156|NCT01980199|Experimental|Fexinidazole|"600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
33035157|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
33035158|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
33035159|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
33035160|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
33035161|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
33035162|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
33035163|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week~A dose reduction could be explored:~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
33035164|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
33035165|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
33035166|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
33035167|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
33035168|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
33035169|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
33035170|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
33035171|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
33035172|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
33035173|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
33035174|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
33035175|NCT01980394|Other|prospective cohort study|
33035176|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
33035177|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
33035178|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
33035179|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
33035180|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
33035181|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
33035182|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
33327887|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
33035183|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
33035184|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
33035185|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
33035186|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
33035187|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
33035188|NCT01980563|Active Comparator|ultrasound|
33035189|NCT01980563|Active Comparator|combined monitoring|
33035190|NCT01980576||Pre-operative pain measurement|Patients with low back pain
33327888|NCT01588314|Active Comparator|gabapentin|
33327889|NCT01588314|Placebo Comparator|placebo|
33327890|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
33327891|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
33035191|NCT01980602|Experimental|Supervised Exercise Program|
33035192|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
33035193|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
33035194|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
33035195|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
33035196|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
33035197|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
33035198|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
33035199|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
33035200|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
33035201|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
33035202|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
33035203|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
33035204|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
33035205|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
33035206|NCT01980719||Healthy, Age-Matched|
33035207|NCT01980719||Fatigued|
33035208|NCT01980719||Not Fatigued|
33035209|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
33035210|NCT01980745|Placebo Comparator|sugar pill|sugar pill
33035211|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
33035212|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
33035213|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
33035214|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
33035215|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
33035216|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
33035217|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
33035218|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
33035219|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
33327892|NCT01290510|Experimental|hyaluronic acid sodium salt|
33327893|NCT05234424|Active Comparator|THRIVE 40 L/min|40 L/min with 100% oxygen for 10 minutes.
33327894|NCT05234424|Experimental|THRIVE 100 L/min|100 L/min with 100% oxygen for 10 minutes.
33327895|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
33327896|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
33327897|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
33327898|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
33327899|NCT01292460|Active Comparator|Preservative-free timolol|
33327900|NCT01292460|Experimental|Preservative-free FDC and placebo|
33327901|NCT01292460|Active Comparator|Preservative-free tafluprost|
33327902|NCT01292460|Experimental|Preservative-free FDC|
33107626|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
33327903|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
33327904|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
32871559|NCT00248807|Active Comparator|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
33107627|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
33107628|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
33107629|NCT04647461|Experimental|BRIDIN-T Eye drops 0.15%(Non preservative)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
33107630|NCT04647461|Active Comparator|ALPHAGAN-P Eye drops 0.15%(Preservatives)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
33107631|NCT04684992|Experimental|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
33327905|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
33327906|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
33107632|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
33107633|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
33107634|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
33327907|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
33107635|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
33107636|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
33107637|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
33107638|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
33107639|NCT04647422|Experimental|AUD patients|Alcohol Use Disorder patients
33107640|NCT04647422|Experimental|AUD controls|Healthy control participants matched to group 1
33107641|NCT04647422|Experimental|First-degree relatives|Healthy first-degree relatives of AUD patients
33107642|NCT04647422|Experimental|First-degree controls|Healthy control participants matched to group 3
33107643|NCT02908152|Active Comparator|curcumin|curcumin
33107644|NCT02908152|Placebo Comparator|placebo|
33107645|NCT01237327|Active Comparator|1|
33107646|NCT01237327|Experimental|2|
33327908|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.~Propensity matching according to the:~CHA2DS2-VASc parameters~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)~Presence of diastolic dysfunction~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)~Smoking (>5 cigarettes per day)"
33327909|NCT01184274|Experimental|SB939|
33327910|NCT01184352||PCI patients treated with Glider Device|
33327911|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
33327912|NCT01187316|Experimental|TENS|
33327913|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
33327914|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
33327915|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
33327916|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
33327917|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
33327918|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
33327919|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
33327920|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.~Exercise intensity is 50-65%of maximal heart rate (MHR)"
33327921|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
33327922|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
33327923|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
33327924|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
33327925|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
32871560|NCT00248807|Active Comparator|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
32871561|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
33035220|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
33035221|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
33035222|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
33035223|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
33035224|NCT01980966|Experimental|MHAA4549A|
33035225|NCT01980966|Placebo Comparator|Placebo|
33035226|NCT01980966|Active Comparator|Tamiflu|
33035227|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
33035228|NCT01981005|Experimental|RO5424802|
33035229|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
33035230|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
33035231|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
33035232|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
33035233|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
33035234|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
33035235|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
33035236|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
33035237|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
33035238|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
33035239|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
33035240|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
33035241|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
33360420|NCT03927313|Experimental|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
33035242|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
33035243|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
33035244|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
33035245|NCT01981265||Hand osteoarthritis|
33035246|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
33035247|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
33035248|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
33035249|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
33035250|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
33035251|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
33035252|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
33035253|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
33035254|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
33035255|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
33035256|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
33035257|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
33035258|NCT01981382||Incident cases|Persistent nonspecific low back pain
33035259|NCT01981382||Controls|Acute low back pain that resolves in <6 months
33035260|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
33035261|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
33035262|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
33035263|NCT01981421||Liver fibrosis|patients who had chronic liver disease
33035264|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
33035265|NCT01981434|No Intervention|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
33035266|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
33035267|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
33035268|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
33035269|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
33035270|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
33035271|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
33035272|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
33035273|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
33035274|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
33035275|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
33035276|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
33035277|NCT01981499|Experimental|Arm B4|Placebo control
33327926|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
33360421|NCT03523234|Experimental|surgery group|
33360422|NCT03523234|Placebo Comparator|control group|
33035278|NCT01981525|Experimental|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
33035279|NCT01981577||Patients with Parkinson's Disease|
33360423|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
33035280|NCT01981577||Healthy volunteers|
32871562|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
33035281|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
33035282|NCT01981603|No Intervention|usual care|usual care
33035283|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
33035284|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
33035285|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
33035286|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
33035287|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
33035288|NCT01981681|Experimental|Cohort 1 Experimental Arm|
33035289|NCT01981681|Experimental|Cohort 2 Experimental Arm|
33035290|NCT01981681|Experimental|Cohort 3 Experimental Arm|
33035291|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
33035292|NCT01981681|Experimental|Cohort 4 Experimental Arm|
33035293|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
33035294|NCT01981694|Experimental|Single ascending doses|
33035295|NCT01981694|Experimental|Measurement of eye blink rate|
33035296|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
33035297|NCT01981733|Experimental|Device|
33035298|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
33035299|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
33035300|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
33035301|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
33035302|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
33035303|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
33035304|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
33035305|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
33035306|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
33035307|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
33035308|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
33035309|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
33035310|NCT01981941|Experimental|Treatment group|Oral
33035311|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
33035312|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
33035313|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
33035314|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
33035315|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
33035316|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
33035317|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
33035318|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
33035319|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
33035320|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
33035321|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
33035322|NCT01982071|Experimental|Treatment group|Intravenous (IV)
33035323|NCT01982097||Group 1|
33035324|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
33035325|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
33035326|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
33035327|NCT01982149||Group 1|Non-smokers (n=20)
33035328|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
33035329|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
33035330|NCT01982162||Cohort A|severe school aged asthma cohort
33035331|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
33035332|NCT01982162||Cohort C|Severe pre school wheeze cohort
33035333|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
33035334|NCT01982188||Single incision sling|
33035335|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
33035336|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
33035337|NCT01982214|Sham Comparator|sedentary|No intervention
33035338|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
33035339|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
32871563|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
33035340|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
33035341|NCT01982305|Experimental|Simulator|One training session with the simulator.
33035342|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
33035343|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
33035344|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
33035345|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
33035346|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
33035347|NCT01982396|Active Comparator|Twice daily|
33035348|NCT01982396|Experimental|Once daily|
33035349|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
33035350|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
33035351|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
33035352|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
33035353|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
33035354|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
33035355|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
33035356|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
33035357|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
33035358|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
33035359|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
33035360|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
33035361|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
33035362|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.~These patients will be examined in 4 positions with the ultrasound."
33035363|NCT01982526||Endmetrioma surgery|
33035364|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
33035365|NCT01982565|Active Comparator|Control Arm|Standard of Care
33035366|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
33035367|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
33035368|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
33327927|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
33327928|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
33327929|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
33327930|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
33327931|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
33035369|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:~TI-Inhalation Powder A TI-Inhalation Powder B~*30 units (10 units + 20 units)"
33035370|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:~TI-Inhalation Powder B TI-Inhalation Powder A~*30 units (10 units + 20 units)"
33035371|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
33035372|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
33035373|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
33327932|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
33327933|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
33035374|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
33035375|NCT01982669||Different degree of spicy food intake|
33035376|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
33035377|NCT01982721|No Intervention|Healthy volunteers|
33035378|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
33035379|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
33035380|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
33035381|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
33035382|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
33035383|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
33035384|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
33035385|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
33035386|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
33035387|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
33035388|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
33035389|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
33035390|NCT01982838|Active Comparator|Group E|Epidural de novo technique
33035391|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
33035392|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
33035393|NCT01982851|Active Comparator|Group E|Epidural de novo technique
33035394|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
33327934|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
33327935|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
33327936|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
33327937|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
33327938|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
33360424|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
33035395|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
33035396|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
33035397|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
33035398|NCT01982877|Experimental|Educational Control|ICU educational component
33035399|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
33035400|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
33035401|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
33035402|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
33035403|NCT01982929|Sham Comparator|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
33035404|NCT01982929|Experimental|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
33035405|NCT01982981|No Intervention|control|The control group only be assessed
33035406|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
33035407|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
33035408|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
33035409|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
33035410|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
33035411|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
33035412|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
33035413|NCT01983046|Placebo Comparator|placebo|placebo
33035414|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
33035415|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
33035416|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
33035417|NCT01983059||Patients with Liver Venous Thrombosis|
33035418|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
33035419|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
33035420|NCT01983072|Other|Breastfeeding group|reference group
33035421|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
33035422|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
33035423|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
33035424|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
33035425|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
33035426|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
33035427|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
33035428|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
33035429|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
33035430|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
33327939|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
33327940|NCT03851640|Experimental|HC-1119|80mg;
33327941|NCT03851640|Placebo Comparator|placebo|80mg;
33327942|NCT01187628|Experimental|Arm 1|
33327943|NCT01293708||Hospital Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed until hospital d/c
33327944|NCT01293708||Longitudinal Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed for 12 months
33327945|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
33035431|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
33035432|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
33035433|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
33035434|NCT01983280|Experimental|Healing Touch|
33035435|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
33035436|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
33035437|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
33035438|NCT01983332||occupational therapists|Occupational Therapists
33035439|NCT01983345|No Intervention|Control|No prenatal surgical repair of myelomeningocele
33035440|NCT01983345|Experimental|Case - open surgical repair|Prenatal surgical repair of fetal myelomeningocele
33035441|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
33035442|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
33035443|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
33035444|NCT01983384|Placebo Comparator|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
33035445|NCT01983384|Experimental|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
33035446|NCT01983397|Experimental|Resistance training|Resistance training
33035447|NCT01983397|Experimental|Multicomponent training|Multicomponent training
33035448|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
33035449|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
33035450|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
33035451|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.~4 more sessions (one every two days)."
33035452|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
33035453|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
33035454|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
33035455|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
33035456|NCT01983462|Placebo Comparator|Placebo|Placebo
33035457|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
33035458|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
33035459|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
33035460|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|
33035461|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
33327946|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
33327947|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
33327948|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
33327949|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
33327950|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
33327951|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
33327952|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
33035462|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
32871564|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
33035463|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
33035464|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
33035465|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
33035466|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
33035467|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
33035468|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
33035469|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
33035470|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
33035471|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
33035472|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
33035473|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
33035474|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
33035475|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
33035476|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
33035477|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
33035478|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
33035479|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
33035480|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
33035481|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
33035482|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
33035483|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
33035484|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
33035485|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
33107647|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
33327953|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
33327954|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
33327955|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
33327956|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
33327957|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
33327958|NCT01293786||Kidney transplant recipients|
33327959|NCT01293786||Chronic kidney disease|
33327960|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
33360425|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
33035486|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
33035487|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
33035488|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level <1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
33035489|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
33035490|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
33035491|NCT01983670|No Intervention|health group 2|health subjects controlled group
33035492|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
33035493|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
33035494|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
33035495|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
33035496|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
33035497|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
33035498|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg~Day6 Rest~Day7 Rest~Day8 Cord blood infusions"
33035499|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment~Day0 Admit, hydration~Day1 Fludarabine 40 mg/m2 IV~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV~Day5 Rest Day6 Cord blood infusions"
33035500|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
33035501|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
33035502|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
33035503|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
33035504|NCT01983852||1|Children during End of Life Care
33035505|NCT01983865|Other|Exposure to birch pollen|
33035506|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
33035507|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
33035508|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
33035509|NCT01983917|Other|Use of the Diabetes Application|
33035510|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
33035511|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
33327961|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
33327962|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
33327963|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
33327964|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
33327965|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
33035512|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
33035513|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
33035514|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
33035515|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
33035516|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
33035517|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
33035518|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
33035519|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
33035520|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
33035521|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
33035522|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
33035523|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
33035524|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
33035525|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
33035526|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
33035527|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
33067581|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
33067582|NCT00132509|Experimental|DFIL|
33327966|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
33327967|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
33327968|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
33327969|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
33035528|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
33035529|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
33035530|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
33035531|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
33035532|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
33035533|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
33035534|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
33035535|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
33035536|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
33035537|NCT01984112|Experimental|Intramedullary Locked Nail|
33035538|NCT01984112|Active Comparator|Locked Plate|
33035539|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
33035540|NCT01984125|No Intervention|Control|
33035541|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
33035542|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
33035543|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
33035544|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
33035545|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
33327970|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
33327971|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
33327972|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
33035546|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
33327973|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
33035547|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
33035548|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
33035549|NCT01984255|Experimental|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
33035550|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
33035551|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
33035552|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
33035553|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
33035554|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
33035555|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
33035556|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
33035557|NCT01984359|Other|Single arm|Biosamples will be obtained at multiple time-points for all participants
33035558|NCT01984372||Tresiba® users|
33035559|NCT01984385||Patients with a hip fracture|
33035560|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
33035561|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
33035562|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
33035563|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
33035564|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
33035565|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
33035566|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
33035567|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
33327974|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
33327975|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
33327976|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
33327977|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
33436461|NCT05135962|Experimental|Leaf self-expander 450g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
33067583|NCT00132509|Active Comparator|NINDS|
33067584|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
33067585|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
33067586|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
33067587|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
33067588|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
33067589|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
33067590|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
33067591|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
33067592|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
33067593|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
33067594|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
33067595|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
33067596|NCT02266329|Active Comparator|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
33067597|NCT02266329|Placebo Comparator|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
33067598|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
33067599|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
33067600|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
33067601|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
33067602|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
33067603|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
33067604|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
33067605|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
33067606|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
33067607|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
33067608|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
33067609|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
33067610|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
33327978|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
33327979|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
33107648|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
33107649|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
33107650|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
33107651|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
33107652|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
33107653|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
33327980|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
33107654|NCT04319536||Healthy individuals|
33107655|NCT04647695|Experimental|IFN-beta 1b and remdesivir|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
33107656|NCT04647695|Active Comparator|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
33107657|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
33107658|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
33107659|NCT04647305|Experimental|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
33107660|NCT04647305|Active Comparator|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
33107661|NCT04647344|Experimental|Nonsquamous NSCLC|
33327981|NCT01581138|Experimental|12 week treatment|
33327982|NCT01581138|Experimental|16 week treatment|
33107662|NCT04647344|Experimental|Squamous NSCLC|
33107663|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
33107664|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
33107665|NCT04647149|Experimental|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
33107666|NCT04647149|Experimental|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
33107667|NCT04647149|Experimental|Control|12-hour eating window between 08:00 and 20:00
33107668|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
33107669|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
33107670|NCT04646954|Experimental|Study group|All eligible participants are included in the study group
33107671|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
33107672|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
33107673|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
33107674|NCT04647188||Thoracic group|Includes patients undergoing lobectomy (n=100)
33107675|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
33107676|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
33107677|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing tongue base mucosectomy (n=50)
33107678|NCT02908074|Experimental|Experimental: Regimen 1|Drug: BGS649 Dose 1 weekly
33107679|NCT02908074|Experimental|Experimental: Regimen 2|Drug: BGS649 Dose 2 weekly
33107680|NCT02908074|Experimental|Experimental: Regimen 3|Drug: BGS649 Dose 3 weekly
33107681|NCT04646876|Active Comparator|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate~Administration regimen of Mgso4 was as following:~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
33107682|NCT04646876|Placebo Comparator|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
33107683|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
33107684|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
33107685|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
33107686|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
33327983|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
33327984|NCT05671302|Experimental|Walk Together|Walk Together involves four sessions delivered in patients' primary care clinic over approximately two months. Sessions are dyadic (i.e., all sessions include the patient and a family support person), last 30-90 minutes, and are delivered by a trained family therapist. The intervention is a culturally-response, family-based intervention that is strengths-based and includes components of integrative behavioral couples therapy and motivational interviewing. The goals of the intervention are to (a) optimize family support and communication, (b) improve hypertension knowledge, (c) enhance self-management goal-setting, and (d) increase shared problem-solving to address self-management adherence barriers. Environmental barriers to adherence are also addressed consistent with standard care.
33035568|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
33035569|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
32740741|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
32740742|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
32740743|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
32740744|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
32740745|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
32740746|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
32871565|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
33035570|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
33035571|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
33035572|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
33035573|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
33035574|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
33035575|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
33035576|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
33035577|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
33035578|NCT01984567|Experimental|Vitamin E|
33035579|NCT01984567|Experimental|Lipoic acid|
33035580|NCT01984567|Placebo Comparator|Control|
33035581|NCT01984580|Experimental|Zinc|
33035582|NCT01984580|Placebo Comparator|sodium|
33035583|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
33035584|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
33035585|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
33035586|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
33035587|NCT01984619||Blunt Tip Cannula|
33035588|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
33035589|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
33035590|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
33035591|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
33067611|NCT00132743|Active Comparator|1|Optimal Medical Care
33067612|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
33067613|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
33067614|NCT02087592|No Intervention|Control|Usual standard of care
33067615|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
33327985|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
33327986|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
33327987|NCT05671614||Critically ill patients|Critically ill patients with sudden onset of disease receiving mechanical ventilation, to be enrolled within 72 hours of admission, who are likely to need 7 days or more of ICU stay.
33327988|NCT05671614||Volunteers with a very good to excellent performance status|Elective hip surgery patients with a very good to excellent performance status, only limited to joint pain (ECOG 0)
33035592|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
33035593|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
33035594|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
33035595|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
33035596|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
33035597|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
33327989|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
33035598|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
33327990|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
33327991|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
33327992|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
33327993|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
33327994|NCT01191372|Placebo Comparator|saline for injection|
33035599|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
33035600|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
33327995|NCT01191372|Experimental|ARC19499 Low Dose|
33327996|NCT01191372|Experimental|ARC19499 Mid Dose|
33327997|NCT01191372|Experimental|ARC19499 High Dose|
33327998|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
33327999|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
33328000|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
33328001|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
33328002|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
33035601|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
33328003|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
33328004|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
33360426|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
33360427|NCT01128205||Diagnosed for 6 months or more|
33035602|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
33035603|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
33035604|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
33328005|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
33328006|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
33328007|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
33035605|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
33035606|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
33035607|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
33035608|NCT01984814|No Intervention|Control|No cell transplantation was done
33035609|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
33035610|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
33035611|NCT01984827|Placebo Comparator|Placebo|Placebo
33035612|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
33035613|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
33035614|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
33035615|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
33035616|NCT01984918|Active Comparator|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
33035617|NCT01984918|No Intervention|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
33035618|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
33035619|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
33035620|NCT01984944|Other|Autistic Patient|"50 adults~25 childs"
33035621|NCT01984944|Other|Controls|"50 adults~25 childs"
33035622|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
33035623|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
33035624|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
33035625|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
33035626|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
33035627|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
33035628|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
33035629|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
33035630|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
33035631|NCT01985022|Experimental|PII with IES|The treatment condition that this group receives is PII with IES for 9 months.
33035632|NCT01985022|Experimental|IES|The treatment condition that this group receives is IES for 9 months.
33035633|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
33035634|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
33328008|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
33328009|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
33328010|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
33328011|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
33328012|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
33328013|NCT01294410|Other|Open Label|
33328014|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
33328015|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
33328016|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
33328017|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
33328018|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
33328019|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
33328020|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
33328021|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
33328022|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
33328023|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
33035635|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
33035636|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
33035637|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
33035638|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
33035639|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
33035640|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
33035641|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
33035642|NCT01985087|Experimental|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
33035643|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
33360428|NCT01354184|Experimental|CRD007 10 mg tablet|
33035644|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
33035645|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
33035646|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
33035647|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
33035648|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
33035649|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
33035650|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
33035651|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
33035652|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
33035653|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
33035654|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
33035655|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
33035656|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
33035657|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
33035658|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
33035659|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
33035660|NCT01985204|Experimental|Intervention|Iodine tablet
33035661|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
33035662|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
33035663|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
33035664|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
33035665|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
33035666|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
33328024|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
33328025|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
33328026|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
33328027|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
33328028|NCT01194336||Huperzine A: 100 ug|
33328029|NCT01194336||Huperzine A: 200 ug|
33035667|NCT01985269|No Intervention|Control|Normal standard of care
33035668|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
33035669|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --~(starting) 400 mg 3~600 mg 3~(maximum) 800 mg 3"
33035670|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
33035671|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
33035672|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
33035673|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
33035674|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
33035675|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
33035676|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
33035677|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
33035678|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
33035679|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
33035680|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
33035681|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
33035682|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
33035683|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
33035684|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
33035685|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
33035686|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
33035687|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
33035688|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
33035689|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
33035690|NCT01985490|Experimental|epiretinal membrane|
33035691|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
33328030|NCT01194336||Donepezil: 2.5 mg|
33328031|NCT01194336||Donepezil: 5 mg|
33328032|NCT01194336||Galantamine: 4 mg|
33328033|NCT01194336||Galantamine: 8 mg|
33328034|NCT01194336||Placebo|
33328035|NCT01194492|Other|Albumin kinetics|
33035692|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
33035693|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
33328036|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
33328037|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
33328038|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
33328039|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
33360429|NCT01354184|Experimental|CRD007 25 mg tablet|
33035694|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
33035695|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
33035696|NCT01985529|No Intervention|Control|
33035697|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
33035698|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
33035699|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
33035700|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
33035701|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
33035702|NCT01985607|Experimental|Thickened|
33035703|NCT01985607|Active Comparator|Control|
33035704|NCT01985620|Active Comparator|study group|Educational intervention with the parents
33035705|NCT01985620|No Intervention|control group|
33035706|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
33035707|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
33035708|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
33035709|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
33035710|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
33035711|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
33035712|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
33035713|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
33035714|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
33035715|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
33035716|NCT01985698|Active Comparator|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
33035717|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
33035718|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
33035719|NCT01985724|Active Comparator|A|FEC -> TXT
33035720|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
33035721|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
33328040|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
33328041|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
33360430|NCT01354184|Experimental|CRD007 40 mg tablet|
33360431|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
32899470|NCT05272397|Placebo Comparator|Placebo Session|"In this arm of the study participants receive the a placebo, administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
32899471|NCT05272397|Other|Intake Session|In this arm of the study participants are screened for suitability to participate in the experiment based on specified inclusion and exclusion criteria. They also complete some baseline tasks to assess working memory capacity, impulsiveness, and subjective mood.
32899472|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
32899473|NCT01125605||Children 6-12 years|children between 6 and 12 years
32899474|NCT01125605||Children 1-6 years|children between 1 and 6 years
32899475|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
32899476|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
32899477|NCT00271154|Placebo Comparator|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
32899478|NCT00271154|Active Comparator|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
32899479|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
32899480|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
32899481|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
32899482|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
32899483|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
32899484|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
32899485|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
32899486|NCT00272168|Experimental|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
32899487|NCT00272168|Active Comparator|Arm 2: Control|Supportive Treatment for SMI (control)
32899488|NCT00185900|Active Comparator|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
32899489|NCT00185900|Active Comparator|Nifedipine|Preterm labor treatment with Nifedipine.
32899490|NCT00186056|Experimental|Mifepristone|Patients received mifepristone for 6 days
32899491|NCT00186056|Placebo Comparator|placebo|Patients received placebo for 6 days
32899492|NCT00186446|Experimental|Bupropion|
32899493|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
32899494|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
32899495|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
32899496|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
32899497|NCT01899638|Experimental|VI 25 mcg|LABA mono
32899498|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
32899499|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
32899500|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
32899501|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
32899502|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
32899503|NCT00136760|Experimental|1|Contingent reinforcement plus bupropion
32899504|NCT00136760|Experimental|2|Contingent reinforcement plus placebo
32899505|NCT00136760|Experimental|3|Non-contingent reinforcement plus bupropion
32899506|NCT00136760|Placebo Comparator|4|Non-contingent reinforcement plus placebo
32899507|NCT00136838|Experimental|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
32899508|NCT00136838|Experimental|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
32899509|NCT00189098|Placebo Comparator|placebo|
32899510|NCT00189098|Active Comparator|Sulfamethoxazole-trimethoprim|
33328042|NCT01190202|Experimental|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
33360432|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
33360433|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
33360434|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
33035722|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
33035723|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
33035724|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo~Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
33035725|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
33035726|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
33035727|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
33035728|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
33035729|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
33035730|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
33035731|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
33035732|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
33035733|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
33035734|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
33035735|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
33035736|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy~OR~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
33035737|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
33035738|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
33035739|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
33035740|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
33035741|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
33035742|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
33035743|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
33035744|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
33035745|NCT01985880||Control|Control
33035746|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
33035747|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
33035748|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
33035749|NCT01985945|Other|Yoga|
33035750|NCT01985945|No Intervention|Without Yoga|
33035751|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent~Any tumor site~Stage I-IV, M0~Treated with radiotherapy alone or in combination with systemic therapy~Definitive radiotherapy or postoperative radiotherapy~Interventions:~Radiation alone~Radiation in combination with systemic therapy"
33035752|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
33035753|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
32866676|NCT04819230|Experimental|Bias Modification|Attention (ATT) and interpretation (ITT) bias training. Participants complete the ATT and ITT tasks twice per week for four weeks. The ATT trains attention toward neutral stimuli and away from negative stimuli. On trials with one neutral and one threat word, the probe will always follow the location of the neutral word. Therefore, there is a contingency between the valence of the word and the location of the probe. Participants will be asked to indicate which type of probe had appeared in each trial by pressing a corresponding button as rapidly and accurately as possible. The ITT trains participants to make benign (vs. threatening) interpretations of socially-ambiguous scenarios. For each trial, a word suggesting a socially threatening or benign interpretation is presented then replaced by a sentence describing a socially-ambiguous scenario. Participants indicate if they thought the word and sentence were related. Participants will receive corrective feedback after each trial.
33035754|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
33035755|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
33035756|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
33035757|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
33035758|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupivacaine 0.5%
33035759|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupivacaine 0.25%
33035760|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
33035761|NCT01986088|Placebo Comparator|Placebo|
33035762|NCT01986088|Experimental|Eletriptan 40 mg|
33035763|NCT01986088|Experimental|Eletriptan 80 mg|
33035764|NCT01986088|Experimental|Sumatriptan 50 mg|
33035765|NCT01986088|Experimental|Sumatriptan 100 mg|
33035766|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
33035767|NCT01986127|Placebo Comparator|saline|5 ml of saline
33035768|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
33035769|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
33035770|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
33035771|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
33035772|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
33035773|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
33035774|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
33035775|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
33035776|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
33035777|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
33035778|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
33035779|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
33035780|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
33035781|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
33035782|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
33035783|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
33035784|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
33035785|NCT01986270|Placebo Comparator|Placebo|
33035786|NCT01986270|Experimental|Eletriptan 40 mg|
33035787|NCT01986270|Experimental|Eletriptan 80 mg|
33035788|NCT01986270|Experimental|Sumatriptan 25 mg|
33035789|NCT01986270|Experimental|Sumatriptan 50 mg|
33035790|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
33035791|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
33035792|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
33035793|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
33035794|NCT01986296|Experimental|ExAblate Treatment|
33035795|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
33035796|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
33035797|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.~DTP/HB/Hib component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
33360435|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
33360436|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
33360437|NCT01318148|Experimental|Caspofungin|
33360438|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
33360439|NCT03521128|Experimental|the radiological tubal blockage group|
33360440|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
33328043|NCT01190202|Experimental|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
33328044|NCT01190202|Experimental|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
33328045|NCT01190202|Experimental|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
33328046|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
33035798|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age~DTP/HB component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal~Hib component:~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
33328047|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
32740747|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
32740748|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
33035799|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
33035800|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
33035801|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
33035802|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
33035803|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
33035804|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
33035805|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
33035806|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
33035807|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
33035808|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
33035809|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
33035810|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:~Once daily on 2 consecutive days week 1-3."
33035811|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
33035812|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
33035813|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
33035814|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
33328048|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
33107687|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
33107688|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
33107689|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
33107690|NCT04646759|Experimental|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
33107691|NCT04646759|Active Comparator|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m^2, twice daily; Pyrotinib, 400mg, orally administered daily.
33107692|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
33107693|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
33107694|NCT04646798|Active Comparator|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
33107695|NCT04646798|Active Comparator|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
32899511|NCT00145418|Experimental|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
33328049|NCT01989624||Pancreatic Adenocarcinoma|
33328050|NCT02833792|Experimental|Stem Cells|Stem cells
33107696|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
33107697|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
33107698|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
33107699|NCT04646486|Experimental|Intervention - Video debriefing|Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
32899512|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
33107700|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
33107701|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR <60 mL/min/1.73m2, and/or albumin/creatinine ratio >30 mg/mmol or protein/creatinine ratio >50 mg/mmol Anticipated n=75
33107702|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c >48 mmol/mol.~Anticipated n=75"
33107703|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
33107704|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.~Anticipated n=200"
33107705|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
33107706|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
33107707|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
33107708|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
33107709|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
33107710|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
33107711|NCT04646018|Experimental|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
33328051|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
33360441|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
33035815|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
33035816|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
33328052|NCT02660710|Experimental|R-CHOP|We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks
33328053|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
33035817|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
33035818|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
33035819|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
33035820|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
33035821|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
33035822|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
33035823|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
33035824|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
33035825|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
33035826|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
33035827|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
33035828|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
33035829|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
33035830|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
33035831|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
33035832|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
33035833|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
33035834|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
33035835|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
33035836|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
33035837|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
33035838|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
33035839|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
33035840|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
33328054|NCT01296438|Experimental|Treatment sequence 1|
33328055|NCT01296438|Active Comparator|Treatment sequence 2|
33328056|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
33328057|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
33328058|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
33035841|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
33035842|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
33035843|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
33035844|NCT01986621||Patients undergoing elective PCI|
33035845|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
33035846|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
33035847|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
33035848|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
33035849|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
33035850|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
33035851|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
33035852|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
33035853|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
33035854|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
33035855|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
33035856|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
33035857|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
33035858|NCT01986764|Placebo Comparator|Placebo|
33035859|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
33035860|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
33035861|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
33035862|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
33035863|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
33035864|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
33035865|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
33035866|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
33035867|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
33035868|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
33035869|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
33035870|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
33035871|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
33035872|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
33035873|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
33035874|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
33035875|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
33328059|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
33328060|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
33328061|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
33328062|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
33328063|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
33107712|NCT04646018|Sham Comparator|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
33107713|NCT02906436|Experimental|ExVivo lung reconditioning|
33328064|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
33328065|NCT03847272|Experimental|Patients|
33107714|NCT04646135|Experimental|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
33107715|NCT04646135|Experimental|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
33328066|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
33328067|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
33035876|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
33035877|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
33035878|NCT01987024|Active Comparator|group A-usual procedure|
33035879|NCT01987024|Experimental|groupB- actim partus|
33035880|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
33035881|NCT01987063||pregnant woman with twins|pregnant woman with twins
33035882|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
33035883|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
33035884|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
33035885|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
33035886|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
33035887|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
33035888|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
33035889|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
33035890|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
33035891|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
33035892|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
33035893|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
33035894|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
33035895|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
33107716|NCT04646135|Experimental|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
33107717|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
33107718|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
33328068|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
33328069|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
33328070|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
33360442|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
33328071|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
33328072|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
33328073|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
33328074|NCT01190358|Placebo Comparator|Placebo|Sugar pill
33328075|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
33035896|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
33035897|NCT01987258|No Intervention|Control|No exercise (control experiment)
33035898|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
33035899|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
33035900|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
33035901|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
33035902|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
33035903|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
33035904|NCT01987297|Experimental|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
33035905|NCT01987297|Active Comparator|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
33035906|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
33035907|NCT01987310|No Intervention|usual care|follow up group with no intervention
33035908|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
33035909|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
33035910|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
33035911|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
33035912|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
33035913|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
33035914|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
33035915|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
33035916|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
33035917|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
33035918|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
33328076|NCT01296594|Active Comparator|Usual Care|
33328077|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
33328078|NCT01293162||placebo|
33328079|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
33328080|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
33328081|NCT01296828||MOUTH BREATHING CHILDREN|
33328082|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
33328083|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
33328084|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
33328085|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
33328086|NCT05671536|Experimental|Motivational interview|Patients on intervention group will receive 4 sessions of motivational interview at least 20 minutes and once a month. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
33328087|NCT05671536|No Intervention|Control|Patients on control group will receive standard care. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
33328088|NCT01190592|Experimental|Milk|
33328089|NCT01190592|Experimental|Juice|
33328090|NCT01190592|Placebo Comparator|Water|
33328091|NCT01211418|Experimental|Integrative Meditation|
33328092|NCT01211418|Active Comparator|Nondirective Therapy|
33328093|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~A self-care component to promote caregiver health and well-being"
32740057|NCT03652961|Experimental|Abatacept plus DMARD|"Abatacept will be used concomitantly with standard of care disease-modifying anti-rheumatic drugs (DMARDs), other than tumor necrosis factor (TNF) antagonists or Janus kinase (JAK) inhibitors.~Intravenous (IV) Abatacept will be administered as a 30-minute IV infusion utilizing weight range-based dosing:~Less than 60 kg: 500 mg~60 to 100 kg: 750 mg~More than 100 kg: 1000 mg~Following the initial IV Abatacept administration, an IV infusion will be given at Weeks 2 and 4 after the first infusion and every 4 weeks thereafter for a total of 7 Abatacept doses.~Abatacept will be discontinued after 6 months in all patients. Patients who have flared or failed to achieve low disease activity at 6 months will exit the trial except for one post-study visit for lab work at 9 months. In patients who have achieved low disease activity, Abatacept will be held for 6 months or until a flare results while DMARD use is continued."
32740058|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
32740059|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
32740060|NCT03948347|Active Comparator|active|Active patients will receive liraglutide injections
32740061|NCT03948347|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
32740062|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
32740063|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
32899513|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
32899514|NCT04751474|Experimental|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
32899515|NCT04751474|No Intervention|Control group|The control group did not receive any intervention.
32899516|NCT04751318|Experimental|Duloxetine Test Produc|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
32899517|NCT04751318|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
33328094|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
33328095|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
33328096|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
33328097|NCT01293318||Acute pancreatitis|
32899518|NCT01105247|Experimental|PCI-32765|
32899519|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
32899520|NCT05272007||Acute cholecystitis|
32899521|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
32899522|NCT03012659|No Intervention|Control Arm|Usual care
32899523|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
32899524|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
32899525|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
33035919|NCT01987466||Post cardiac arrest patient|
33035920|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
33035921|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
33035922|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
33035923|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
33035924|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
33035925|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
33035926|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
33035927|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
33035928|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
33035929|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
33035930|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
33035931|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
33035932|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
33035933|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
33035934|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
33035935|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
33035936|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
33035937|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
33035938|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
33035939|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
33035940|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
33035941|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
33035942|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
33035943|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
33035944|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33067616|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
33328098|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
33328099|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
33328100|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
33328101|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
33328102|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
33328103|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
33328104|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
33328105|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
33328106|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
33328107|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
32899526|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
33107719|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
33328108|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
33328109|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
33360443|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
32899527|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
33360444|NCT03932617||fluid responders|
33360445|NCT03932617||fluid non responders|
32899528|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
32899529|NCT00277394|Experimental|innohep®|innohep® 175 anti-Xa IU/kg once daily
32899530|NCT00277394|Active Comparator|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
32899531|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
32899532|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
32899533|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
32899534|NCT00278876|Experimental|imatinib mesylate|patients receiving adjuvant imatinib mesylate
32899535|NCT00279500|Experimental|single arm study|Argus 16 Retinal Stimulation System-single arm study.
32899536|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
32899537|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
32899538|NCT04752410|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
32899539|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
32899540|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
32899541|NCT00147212|Experimental|1|ET-743
32899542|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
32899543|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
32899544|NCT00280826|Experimental|Efalizumab|
32899545|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
32899546|NCT01899794|Active Comparator|Oxytrol|medication
32899547|NCT00147446|Experimental|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
32899548|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
33328110|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
33328111|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
33328112|NCT01295268|Active Comparator|Emu Oil|
33328113|NCT01295268|Placebo Comparator|inert oil|
33360446|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
33035945|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33035946|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33035947|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33035948|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33035949|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
33035950|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
33035951|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
33035952|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
33035953|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
33035954|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
33035955|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
33035956|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
33035957|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
33035958|NCT01987843|Placebo Comparator|Placebo|Placebo
33035959|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
33035960|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
33035961|NCT01987882||"A. Natural History or Watchful Waiting"|
33035962|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
33035963|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
33035964|NCT01987882||D. Hip Reconstructive Surgery|
33035965|NCT01987882||E. Salvage Hip Surgery|
33035966|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
33035967|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
33035968|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
33035969|NCT01987947|Placebo Comparator|Placebo|
33035970|NCT01987947|Active Comparator|Quilizumab|
33035971|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
33035972|NCT01988038||No treatment|
33035973|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
33107720|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
33107721|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
33107722|NCT02907684|Experimental|Almonds|Almond snacks
33107723|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
33107724|NCT04646096|Experimental|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
33107725|NCT04681989|Experimental|MOVE-ABC intervention arm|"MOVE-ABC interventional group participants receive usual care plus the MOVE-ABC education instruction and materials. After the participant completes the baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~instructions on the education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment. The follow-up phone calls are expected to take 20 - 30 minutes each time. During these follow-ups research staff will review material, and answer any questions the participant may have. All documentation of phone calls and questions asked by participants during these reviews will be captured in REDCap."
33107726|NCT04681989|No Intervention|Control/Usual Care arm|Control group participants will be measured at baseline and at 1 month follow-up. They receive usual care. Usual care does not include specialized, physical therapy-based education on recovery from breast cancer.
33107727|NCT04646447|Experimental|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
33107728|NCT04682184|Experimental|Wearable Biosensor Patch Device + Propranolol|Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.
33107729|NCT04682184|Experimental|Wearable Biosensor Patch Device + Pseudoephedrine|Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.
33107730|NCT04682184|Experimental|Wearable Biosensor Patch Device (Alone)|Participants will wear biosensor patch device (alone) during one of three study periods.
33107731|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
33107732|NCT04645901|Experimental|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
33107733|NCT04645901|Placebo Comparator|Placebo|Subjects will receive the matching placebo tablets.
33107734|NCT04645940|Experimental|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
33107735|NCT04645940|Experimental|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
33107736|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
33107737|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
33107738|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
33107739|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
33107740|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
33107741|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
33107742|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
33107743|NCT00558506|Experimental|A|Abatacept
33107744|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
33107745|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
33107746|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
33107747|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
33328114|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
33328115|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
33360447|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
33360448|NCT01343498|Experimental|BEZ235|
33360449|NCT01221259|Experimental|Drug E2212|
33360450|NCT01221259|Placebo Comparator|Placebo|
33360451|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
33035974|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
33035975|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
33035976|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
33035977|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
33035978|NCT01988142|Experimental|SCI|
33035979|NCT01988155|Active Comparator|Eccentric Exericse|
33035980|NCT01988155|Experimental|Astym|
33035981|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
33035982|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
33035983|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
33035984|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
33035985|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
33035986|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
33035987|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
33035988|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
33035989|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
33035990|NCT01988220|Active Comparator|repeated exposure to sensory input|
33035991|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
33035992|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
33035993|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
33035994|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
33035995|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
33035996|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
33035997|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
33035998|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
33035999|NCT01988311|No Intervention|Imaging Only|
33036000|NCT01988324|Experimental|FES/FDHT-PET|
33036001|NCT01988350||Non-smokers|
33036002|NCT01988350||Smokers|
33036003|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
33036004|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
33036005|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
33036006|NCT01988428|No Intervention|standard care|"standard care~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
33036007|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
33036008|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
33036009|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
33036010|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
33036011|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
33036012|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
33036013|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
33360452|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
33036014|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
33036015|NCT01988532||Adult PWH|
33036016|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
33036017|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
33036018|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
33036019|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
33036020|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
33036021|NCT01988558|Placebo Comparator|Placebo Group|
33036022|NCT01988597||Dry Eyes|
33036023|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
33036024|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
33036025|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
33036026|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
33036027|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
33036028|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
33036029|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
33036030|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
33036031|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
33036032|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
33036033|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
33036034|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
33036035|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
33036036|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
33036037|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.~Biomarker Analysis~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
33036038|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
33036039|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
33036040|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
33036041|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
33036042|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
33036043|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
33036044|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
33036045|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
33036046|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.~One long acting pill a day until an evidence of disease progression or the end of the study."
33036047|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
33036048|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
33107748|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
33328116|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
33328117|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
33328118|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
33328119|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
32899549|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
32899550|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
32899551|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
32899552|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
32899553|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
32899554|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
32899555|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
32899556|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
32899557|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
32899558|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
32899559|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
32899560|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
32899561|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
32899562|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
32899563|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
32899564|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
32899565|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
32899566|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
32899567|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899568|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899569|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899570|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899571|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899572|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
32899573|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
32899574|NCT01391611|Experimental|Pazopanib arm|
32899575|NCT00281918|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
32899576|NCT00281918|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
32899577|NCT00201734|Experimental|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32899578|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
32899579|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
32899580|NCT04752956|Active Comparator|Grup1|Nasal steroid spray only (NS) (Each dose contains 27.5 micrograms of fluticasone furoate; administered single dose per day as 1 puff through both nostrils)
32899581|NCT04752956|Active Comparator|Grup 2|NS + administered ambient temperature normal saline (NSS) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (NSS; 0,09% NaCl, pH:4-5)
32899582|NCT04752956|Active Comparator|Grup 3|NS + administered ambient temperature hyaluronic acid (HA) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (Nasorinse plus pediatric® Ingredients: water, sodium chlorine, sodium bicarbonate, and HA; pH balanced)
32899583|NCT00203216|Experimental|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
32899584|NCT05156060|Experimental|Gabapentin plus Ketamine|Gabapentin and Ketamine will be taken 3 times per day.
33328120|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
33328121|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
33328122|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
33328123|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
33328124|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
33328125|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
33328126|NCT01191918|Experimental|donepezil|donepezil plus Lithium
33328127|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
33328128|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
33328129|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
32899585|NCT00204932|Active Comparator|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
32899586|NCT00204932|Placebo Comparator|Placebo|The group randomized to control received 4 g/d of safflower oil.
33036049|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
33036050|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
33036051|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
33036052|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
33036053|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
33036054|NCT01988948|Other|student cohort|"Various biological sampling~blood sampling,~oral, vulvar, vaginal and anal sampling for women,~oral and genital sampling for men"
33036055|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
33036056|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
33036057|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
33036058|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
33036059|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
33036060|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
33036061|NCT01989013|Other|biweekly intervention|biweekly intervention
33036062|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
33036063|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
33036064|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
33036065|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
33036066|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
33036067|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
33036068|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
33036069|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
33036070|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
33036071|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
33036072|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
33036073|NCT01989117||Osteopathy|
33036074|NCT01989117||No osteopathy|
33036075|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
33036076|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
33036077|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
33036078|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
33036079|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
33036080|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
33036081|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
33036082|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
33036083|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
33036084|NCT01989247|No Intervention|Control group|
33036085|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
33036086|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
33036087|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
33036088|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
33036089|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
33036090|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
33036091|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
33036092|NCT01989351||VAS<4|
33036093|NCT01989351||VAS>4|
33036094|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
33036095|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
33036096|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
33036097|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
33036098|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
33036099|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
33036100|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
33036101|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
33036102|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
33036103|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
33036104|NCT01989520|Experimental|Treatment A|Phase IIb formulation
33036105|NCT01989520|Experimental|Treatment B|Putative phase III formulation
33036106|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
33036107|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
33036108|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
33036109|NCT01989533|Placebo Comparator|A|Placebo controlled (blinded)
33036110|NCT01989533|Active Comparator|B|Intranasal Randomized
33036111|NCT01989533|Experimental|C|Oral Open label
33036112|NCT01989533|Experimental|D|Intranasal Open Label
33036113|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
33036114|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
33036115|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
33036116|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
33328130|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
33328131|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
33328132|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
33360453|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
33107749|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
33107750|NCT00558623|Placebo Comparator|1|Placebo
33107751|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
33107752|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
32899587|NCT00206336|Experimental|topiramate|Topiramate open label
33107753|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
33107754|NCT00558662|Active Comparator|2|Short-Stretch Bandage
33107755|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
33107756|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
33107757|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
33107758|NCT00558740||healthy volunteers|
33107759|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
33107760|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
33107761|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
33107762|NCT04645472||CT-Ultrasound group|
33107763|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
33107764|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
33107765|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
33107766|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
33107767|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
33107768|NCT04645745|Experimental|myo-inositol plus alpha-lactalbumin|Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)
32899588|NCT00210470|Experimental|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin, zinc supplementation, and omeprazole.
32899589|NCT00212264|Experimental|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
32899590|NCT00212264|Experimental|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
32899591|NCT00212264|Placebo Comparator|Placebo Comparator|No treatment control
32899592|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
32899593|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
32899594|NCT01607892|Experimental|selinexor|
32899595|NCT01108757|Experimental|Drug|
32899596|NCT01108757|Placebo Comparator|Placebo|
32899597|NCT05444712|Active Comparator|Chemotherapy|"The chemotherapy is one of the following regimen administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices and European Medical Agency (EMA) approval :~Cyclophosphamide, doxorubicin, Vincristine and prednisone: (CHOP)~Cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone: (CHOEP)~Brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone: (BV-CHP) for ALCL lymphoma only (based on EMA approval)"
32899598|NCT05444712|Active Comparator|Chemotherapy + ASCT|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices:~Patients with ASCT strategy in Complete Response after 6 cycles will receive a High Dose Therapy (HDT) composed of BCNU, etoposide, cytarabine and melphalan (BEAM) as conditioning regimen before transplantation. That consolidation phase will lasts between 2 to 3 months"
32899599|NCT04352153|Experimental|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
32899600|NCT04352153|Experimental|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
32899601|NCT05215067|Experimental|AK104 plus Docetaxel|AK104 RP2D + Docetaxel 75mg/m^2 every 3 weeks until progressive disease or unacceptable toxicity.
32899602|NCT05214833|Experimental|Real neurofeedback|The first arm will receive real neurofeedback.
32899603|NCT05214833|Sham Comparator|Sham neurofeedback|The second arm will receive sham neurofeedback.
32899604|NCT01915212|Experimental|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
32899605|NCT01915212|Placebo Comparator|Placebo|Sodium Chloride 0.9%
32899606|NCT05184569|Experimental|Verdiperstat|Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.
32899607|NCT05184569|Placebo Comparator|Placebo|Placebo 2 tablets twice daily by mouth for 24 weeks.
32899608|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
32899609|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
32899610|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
32899611|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
32899612|NCT05444010|Experimental|mental health|The effect of mandala painting on mental health. Mental health-related anxiety, depression, well-being, distress and death anxiety and depression will be measured.
32899613|NCT05410860|Experimental|Etripamil NS 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of Etripamil NS 70 mg
33328133|NCT01097746|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab)|Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33328134|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
33328135|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
33328136|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
33328137|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
33328138|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
33328139|NCT01383460|Active Comparator|G-CSF+EPO|
32740064|NCT03899987|Experimental|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..
33036117|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
33036118|NCT01989650|No Intervention|No break|No break will be provided
33036119|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
33036120|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
33036121|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
33036122|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
33036123|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
33036124|NCT01989676|Experimental|PF-05280014|
33036125|NCT01989676|Active Comparator|Herceptin®|
33036126|NCT01989702|Active Comparator|Fermented blueberry product|
33036127|NCT01989702|Placebo Comparator|Placebo|
33036128|NCT01989702|Active Comparator|Probiotic bacteria|
33036129|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
33036130|NCT01989728|Active Comparator|care as usual|
33036131|NCT01989728|Experimental|psychiatric examination and feedback|
33036132|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
33036133|NCT01989767|Active Comparator|control|Rehabilitation as usual
33036134|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
33036135|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
33036136|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
33036137|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
33036138|NCT01989819||control group|A skin biopsy will be performed in control group
33036139|NCT01989819||non auto-immune small fiber neuropathies|
33036140|NCT01989832||Biological and clinical Data collected|
33036141|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
33036142|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
33328140|NCT01383460|Placebo Comparator|Placebo|
33036143|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
33036144|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
33036145|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
33036146|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
33036147|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
33036148|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
33036149|NCT01989897|Experimental|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
33036150|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
33067617|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
33067618|NCT00132821|Active Comparator|A|Bupropion
33328141|NCT05671224|No Intervention|Standard counseling|Standard induction of labor counseling
33328142|NCT05671224|Experimental|Visual aid counseling|Counseling on induction of labor with either a video or a handout
33036151|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
33036152|NCT01989936|Placebo Comparator|Placebo|
33328143|NCT05420116|Experimental|Intervention group|"Physical Activity: Prescription in physical activity include to perform 1 session a week of exercice led by a sports professional, and 2 sessions of authonomus exercice at 60-80% of participants maximum heart rate.~Nutritional: Visits and checks every 2 months with a nutritionist with the aim of improving healthy eating habits.~Positive Mental Health: There are 4 group psycho-emotional sessions based on improving self-esteem, self-control, proactive social attitude and conflict resolution"
33328144|NCT05420116|No Intervention|Control group|Participants follow the habitual controls in nursing consultation. Recomendations of physical activity and diet.
33328145|NCT05419492|Experimental|Part 1|Part 1 will follow an open-label, rule-based, dose-escalation design and will initially evaluate 2 dose levels of ETX101 in participants.
33328146|NCT05419492|Sham Comparator|Part 2|"Part 2 is a dose-selection study, which will follow a double-blind (up through Week 16), randomized, sham delayed-treatment control design~There will be up to 3 cohorts in Part 2. Participants will be randomized 1:1:1 to study treatment (ie, Dose Level 1 or Dose Level 2) or sham procedure with delayed treatment. At the conclusion of Part 1, if the recommendation is made to proceed with a single dose level of ETX101 in Part 2, participants will be randomized 1:1 to study treatment or sham procedure with delayed treatment."
33328147|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
33036153|NCT01989936|Experimental|Eletriptan 40 mg|
33036154|NCT01989936|Experimental|Eletriptan 80 mg|
33036155|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
33036156|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
33036157|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
33036158|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
33036159|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
33036160|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
33036161|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
33036162|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
33036163|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.~No intervention will be undertaken."
33036164|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.~No intervention will be undertaken."
33036165|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
33036166|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
33036167|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
33036168|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
33036169|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
33036170|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
33036171|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
33036172|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
33036173|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
33036174|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
33036175|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
33067619|NCT00132821|Active Comparator|B|Transdermal nicotine patch
33067620|NCT00132821|Placebo Comparator|C|
33067621|NCT00132821|Placebo Comparator|D|
33067622|NCT01244815|Experimental|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
33107769|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
33107770|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
33107771|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
33328148|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
33328149|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
33107772|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
33107773|NCT04645277||Patients with MRI using two dimensional reconstruction|
33107774|NCT04645277||Patients with MRI using three dimensional reconstruction|
33107775|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
33107776|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:~Continue current dose~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
33328150|NCT05419414|Active Comparator|Adenomyosis|Patients who were diagnosed with adenomyosis according to pelvic MRI were examined with transvaginal ultrasound. Certain ultrasonographic features of adenomyosis ( asymmetrical uterine wall thickening, myometrial cysts, fan shaped lines and shadows, presence of irregular junctional zone, presence of clue sign, global enlargement) were recorded. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
33360454|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
33107777|NCT04645043|Experimental|US_Eso|US application on the participant
33107778|NCT02905695|Experimental|Group A|Chirocaine
33107779|NCT02905695|Placebo Comparator|Group B|Placebo
33107780|NCT04645238|Active Comparator|Static Hamstring Stretching|Static Hamstring Stretching
33107781|NCT04645238|Active Comparator|PNF Stretching|PNF Hamstring Stretching (Hold-Relax)
33107782|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
33107783|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
33107784|NCT00558779|Experimental|1|
33107785|NCT00558779|Active Comparator|2|
33107786|NCT02905617||Primary Augmentation|
33107787|NCT02905617||Revision Augmentation|
33107788|NCT02905773|Other|postoperative pain|postoperative pain
33107789|NCT02905773|Other|intensity|intensity
33107790|NCT04644848|Experimental|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
32899614|NCT05410860|Experimental|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo
33107791|NCT02907294|Experimental|PBF-999|
33107792|NCT02907294|Placebo Comparator|Placebo|
33107793|NCT04644887|Experimental|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
33107794|NCT04644887|Active Comparator|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
33107795|NCT04644887|Experimental|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
33107796|NCT04644887|Active Comparator|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
33107797|NCT04644926|Experimental|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
33107798|NCT04682262|Experimental|Cervical dilatation|Patients receive cervical dilatation up to 10 millimeter Hegar dilator under general anaesthesia. Patient undergo standard hysteroscopy operation.
33107799|NCT04682262|No Intervention|Expectant|Patients are scheduled for follow-up.
33107800|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
33107801|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
33107802|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
33107803|NCT04681911|Experimental|Inetetamab Combined With Pyrotinib and Chemotherapy|"Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.~Pyrotinib: 400mg, oral, every day.~Chemotherapy: the choice of physicians，as the following regimens:~Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle Carboplatin, AUC = 6, 3-week cycle Albumin paclitaxel, 100 mg/m2, weekly Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle"
33107804|NCT04644263||Validity and reliability|
33417639|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
33417640|NCT05190289||Compared Group|Patients without inferior clinical outcomes
33417641|NCT05190289||Case Group|Patients with inferior clinical outcomes
33417642|NCT05124509||Three doses of BNT162b2 vaccine|Solid organ transplant patients who received three doses of BNT162b2
33417643|NCT05124509||Two doses of Coronavac and one of BNT162b2 vaccine|Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2
33417644|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
33417645|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
33417646|NCT03941509|No Intervention|Control|All facilities will receive usual care during the control phase of the trial.
33417647|NCT03941509|Experimental|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
32740065|NCT03899987|Experimental|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.
32740066|NCT03899987|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
32740067|NCT03478865|Experimental|Participants|Participants with age-related macular degeneration
32899615|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
32899616|NCT00214526|Experimental|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
32899617|NCT00214526|Active Comparator|Control Group|Conventional therapy with ICS+LABA.
32899618|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
32899619|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
32899620|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
32899621|NCT05098925|Experimental|Intervention|Study of Thermoregulatory Processes in Ultra-endurance Runners in a Hot and Humid Environment
32899622|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
32899623|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
32899624|NCT05443698|Other|Ultrasound Device|All women who choose to enroll in the trial will undergo an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
32899625|NCT05088863|Other|Implementation of health claim|Participants will have 2 weeks to incorporate 40g of flaxseed per day into their diet
32899626|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
32899627|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
32899628|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
32899629|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
32899630|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
32899631|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
32899632|NCT00284180|Experimental|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
32899633|NCT00284180|Experimental|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
32899634|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
32899635|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
32899636|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
32899637|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
32899638|NCT04087460|Experimental|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
32899639|NCT04087460|Placebo Comparator|Low-dose Group B|Subjects received three doses of placebo
32899640|NCT04087460|Experimental|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
33328151|NCT05419414|Active Comparator|Uterine Fibroid|Patients who were diagnosed with myoma uteri according to pelvic MRI were examined with transvaginal ultrasound. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
33328152|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
33107805|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
33328153|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
33328154|NCT05419258|Experimental|use of the device during hemodialysis sessions|use of the device during one month during hemodialysis sessions
33328155|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
33328156|NCT05416840|Experimental|Clonidine|Patients will receive clonidine controlled-release patch (2.5 mg), once a week
33328157|NCT05416840|Active Comparator|Amlodipine|Patients will receive amlodipine (5 mg), once daily
33328158|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
33328159|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
32899641|NCT04087460|Placebo Comparator|Middle-dose Group B|Subjects received three doses of placebo
32899642|NCT04087460|Experimental|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
32899643|NCT04087460|Placebo Comparator|High-dose Group B|Subjects received three doses of placebo
32899644|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
32899645|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
32899646|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
32899647|NCT05031806|Experimental|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
32899648|NCT05031806|Experimental|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
32899649|NCT05031806|Experimental|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
32899650|NCT05031806|Placebo Comparator|Vehicle (eye drop formulation without aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
32899651|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
32899652|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
32899653|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
32899654|NCT04805216||Immunocompromised patients (study group)|People who are likely to have a suppressed immunity due to their haematological disorder or its treatment
32899655|NCT04805216||Immunocompetent volunteers (control group)|People without suppressed immunity
32899656|NCT04389008||Postoperative death|
32899657|NCT04389008||Postoperative non-death|
32899658|NCT00216320|Experimental|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
32899659|NCT00216320|Active Comparator|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
32899660|NCT00216320|Other|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
32899661|NCT00217490|Experimental|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
32899662|NCT00217490|Experimental|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
32899663|NCT00217490|Experimental|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
32899664|NCT00217490|Active Comparator|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
32899665|NCT00217724|Experimental|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
32899666|NCT00217724|Placebo Comparator|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
33328160|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
33328161|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
33036176|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
33036177|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
33328162|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
33328163|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
33328164|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
32740749|NCT05246735|Other|MR-guided NIR|"Women with breast abnormalities will undergo an optical exam (NIR) in combination with MRI where the NIR light imaging system illuminates the breast from multiple positions covering the area of interest.~A total of 60 women will be evaluated: 20 with breast abnormalities receiving gadolinium (Gd) contrast enhancement, 20 with breast abnormalities receiving both Gd-contrast enhancement and indocyanine green (ICG) contrast enhancement, and 20 healthy volunteers not receiving any contrast agents."
33036178|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
33036179|NCT01990183|Experimental|CareToy|CareToy intervention
33036180|NCT01990183|Other|Standard Care|Standard Care
33036181|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
33036182|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
33036183|NCT01990248||Cohort|
33036184|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
33036185|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
33036186|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
33328165|NCT00176436|Active Comparator|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
33036187|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
33036188|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
33036189|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
33036190|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
33036191|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
33036192|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
33036193|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
33328166|NCT00176436|Placebo Comparator|Placebo|Placebo medication, diet support group, group counseling and exercise
33328167|NCT04713982|Experimental|Deutetrabenazine|The mode of administration is oral. Subjects will be started on deutetrabenazine at a dose of 6mg/day. Dosing will be up-titrated in increments of 6mg/day per week to achieve optimal chorea control.
33328168|NCT05282784|Experimental|Hyperthermia group|Hyperthermia Radiotherapy
33328169|NCT05282784|Active Comparator|Control|Radiotherapy
33328170|NCT04170556|Experimental|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
33328171|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
33328172|NCT05410756||FIBROMYALGIA GROUP|Patients diagnosed with Fibromyalgia Syndrome (n=25) who volunteered to be undergone voice analysis.
33036194|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
33036195|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
33036196|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
33036197|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
33036198|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
33036199|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
33036200|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
33036201|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
33036202|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
33036203|NCT01990482|Experimental|coffee|coffee
33036204|NCT01990482|Placebo Comparator|water group|water
33036205|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
33036206|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
33036207|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
33036208|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
33036209|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
33036210|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
33036211|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
33036212|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
33036213|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
33036214|NCT01990638||DM group|
33036215|NCT01990638||non-DM group|
33036216|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
33036217|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.~Group 2 was given a placebo once daily for two weeks."
33036218|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
33036219|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
33036220|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
33107806|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
33328173|NCT05410756||HEALTHY CONTROL GROUP|Healthy volunteers (n=25) without any chronic disease not under any medication volunteered to be undergone voice analysis.
33107807|NCT02907255|Experimental|Oximetry monitor|"Standard care plus~Wireless respiratory monitoring~Covidien~Alarm triggers:~SpO2 ≤89% (heart rate) HR < 50 or > 120"
33107808|NCT02907255|No Intervention|Standard of Care|"• Standard care:~1:4 patient to nurse ratio~Vital signs every 4 hours~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
33107809|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
33107810|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
33328174|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
33328175|NCT01293474||control group|age matched healthy controls
33107811|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
33107812|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
33107813|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
33107814|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
33107815|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
33107816|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
33107817|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
33328176|NCT05409508|Experimental|Patients with mindfulness meditation care|
33328177|NCT05409508|Active Comparator|Patients without mindfulness meditation care|
33328178|NCT05370664||Female COPD|
33328179|NCT05370664||Male COPD|
33107818|NCT04644380|Experimental|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
33328180|NCT05601024|Experimental|Experimental Group|"After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~Participants in this group will receive a 4 week of laughter therapy. Laughter therapy will be conducted on whatsapp.~After laughter therapy (after 1 month): Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale, sociodemographic characteristics, and City of Hope Quality of Life Ostomy.~After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale, sociodemographic characteristics, and City of Hope Quality of Life Ostomy."
33328181|NCT05601024|No Intervention|Control Group|"After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~After 2 weeks: Patients will be called by phone and asked if they have any complaints about their disease.~After 1 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale, sociodemographic characteristics, and City of Hope Quality of Life Ostomy.~After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale, sociodemographic characteristics, and City of Hope Quality of Life Ostomy."
33107819|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
33107820|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
33328182|NCT04167748|Experimental|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
33328183|NCT04167748|No Intervention|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
33328184|NCT05598996|Experimental|COT-Based Intervention|The COT-based intervention will include the following to improve both steps/day (move more), and improving minutes/week of MVPA (exercise): adaptive daily steps/day goal-setting plus feedback; positive reinforcement (i.e., points, which translate to gift cards), self-monitoring of both steps/day and min/week MVPA; education about MVPA sent via text message in both conditions; planning support for scheduling bouts of MVPA via SMS in both conditions; and motivational messages sent via SMS in both conditions, and the use of a self-experimentation tool (REFLECT), developed based on prior successful pilot efforts, focused on fostering effective self-regulatory capacities of individuals.
33107821|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
33107822|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
33107823|NCT04644185|Experimental|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
33107824|NCT04644185|Experimental|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
33107825|NCT04644185|Active Comparator|Placebo+BSC|SCTA01 excipients+best supportive care
33107826|NCT04643795|Experimental|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
33107827|NCT04643795|Experimental|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
32740751|NCT05244473|Experimental|Brentuximab vedotin + ART|Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
33328185|NCT05598996|No Intervention|Control|The non-COT approach was designed to be an equivalent to emerging standard of care options for digital health worksite wellness programs to increase PA (control) for a 12-month study period. Participants assigned to the non-COT-based (control) group will receive the latest Fitbit Versa smartwatch and will download the Fitbit smartphone app. Unlike the intervention group, the daily step goal and the accompanying number of points will be static (10,000 steps/day; 150 points/day, respectively). The goal will be delivered to participants via the standard Fitbit app features and points will be communicated via email. Participants will also receive a weekly PA goal (150 minutes of MVPA/per week) and the same accompanying motivational and informative texts that the intervention group receives. Control participants will not complete the physical activity and exercise reflection and planning exercise (Reflect).
33328186|NCT05344690||cases|diabetic patients suffering from clinically confirmed diabetic retinopathy
33107828|NCT04643795|Experimental|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
33107829|NCT04643795|Experimental|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
33107830|NCT02899494|Other|Group A|Antenatal classes
33107831|NCT02899494|Experimental|Group B|Physical and psychic preparation
33107832|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
33107833|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
33107834|NCT04643756|Active Comparator|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
33328187|NCT05344690||controls|matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.
33328188|NCT01196754|Other|sevoflurane|
33107835|NCT04643756|Active Comparator|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
33107836|NCT02905461|Experimental|Intervention|Contraceptive text messages
33107837|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
33107838|NCT04643873|Experimental|Experimental group 1|physical activity counseiling +pilates exercise group
33107839|NCT04643873|Experimental|Experimental group 2|only physical activity counseiling group
33328189|NCT05208580|Experimental|On-line education|Virtual educational activities
33107840|NCT04643873|No Intervention|Control Group|only followed by family physician
33107841|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
33107842|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
33107843|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
33107844|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
33328190|NCT05208580|Experimental|Contact education|Live educational classes
33328191|NCT05208580|No Intervention|Control group|Regular perioperative care without additional educational activities
33328192|NCT01295424||Single group study|
33328193|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
33360455|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
33360456|NCT01354340|Experimental|Limicol simple dose|
32740752|NCT05244473|Placebo Comparator|Placebo + ART|Placebo given on Day 1 and Day 15. ART will be given throughout the study.
33107845|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
33107846|NCT04643717||intensive care patients|
33107847|NCT02905344||1|Control, no anatomical model used for description
33107848|NCT02905344||2|Anatomical model used for description
33107849|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
33107850|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
33107851|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
33107852|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
33036221|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
33036222|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
33328194|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33328195|NCT05207644|Other|Letrozole followed by misoprostol|There is only one arm in this study.
33036223|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
33328196|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
33328197|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
33328198|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.~Ideal Body Weight : Total volume (ml)~[<64 kg : 40 ml]~[65-74 kg : 45 ml]~[≥ 75 kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
33328199|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
33328200|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
33328201|NCT05671068||DYT-SGCE|Patients with myoclonus dystonia (DYT-SGCE)
33036224|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
33036225|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
33036226|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
33036227|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
33036228|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
33036229|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
33036230|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
33036231|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
33036232|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
33036233|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
33036234|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
33036235|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
33036236|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
33036237|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
33036238|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
33036239|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
33036240|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
33036241|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
33036242|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
33036243|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
33036244|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
33036245|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
33036246|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
33036247|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
33036248|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
33328202|NCT05671068||Healthy volunteers|Control group
33328203|NCT05131828|Experimental|Research arm: metformin and clemastine|
33036249|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
33036250|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
33328204|NCT05131828|Placebo Comparator|Control arm: placebos for both metformin + clemastine|
33328205|NCT05594628|Experimental|Neuromuscular Training+Basketball training|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking neuromuscular training+usual basketball training
33328206|NCT05594628|No Intervention|Control group(Basketball training)|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking just the usual basketball training and not any extra interventions.
33328207|NCT05123716|Experimental|Experimental: Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 100 mg MDMA.
33328208|NCT05123716|Experimental|Experimental: MDMA Then Placebo|Participants first receive 100 mg MDMA at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
33328209|NCT03845868||Egang hospital physical examination center|
33036251|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
33036252|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
33328210|NCT03845868||Ezhou CDC physical examination center|
33328211|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
33328212|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
33328213|NCT01195350||stroke|
33328214|NCT01382992||Early Stage|
33036253|NCT01991041||Rufinamide|
33328215|NCT01382992||Late Stage|
33328216|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
33328217|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
33328218|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
33328219|NCT04945174|Active Comparator|Exercise|12 weeks of supervised cardiorespiratory exercise twice a week (6 weeks at the hospital and 6 weeks in the local municipality) combined with patient education and individual follow-up sessions
33328220|NCT04945174|No Intervention|Usual care|The usual care group is encouraged to perform home-based aerobic exercise on their own
33036254|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
33328221|NCT01192854|Experimental|1|
33328222|NCT01192854|Active Comparator|2|
33328223|NCT01382914|Experimental|chlorhexidine 0.12 %|
33360457|NCT01354340|Experimental|Limicol double doses|
33360458|NCT01354340|Placebo Comparator|Placebo|
33036255|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
33036256|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
33036257|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
33036258|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
33036259|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
33036260|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
33036261|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
33036262|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
33036263|NCT01991119|Active Comparator|Propafenone|Propafenone group
33036264|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
33036265|NCT01991132|Other|MediView 2.0 software|
33036266|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
33036267|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
33036268|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
33036269|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
33036270|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
33036271|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
33036272|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
33036273|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
33036274|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
33328224|NCT05557890|Experimental|System Constellation VR-Seminar (exp. group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars.
33036275|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
33328225|NCT05557890|Experimental|System Constellation VR-Seminar (control group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars. Study participants randomized to this group receive the intervention (system constellations VR-seminar) 4 months after the experimental group.
33328226|NCT01382836||Black inner city children with persistent asthma|
33328227|NCT01382836||Black inner city non-atopic healthy children|
33328228|NCT04905810|Experimental|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33036276|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
33036277|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
33036278|NCT01991249|Experimental|blood sample|
33036279|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
33036280|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
33036281|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
33036282|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
33036283|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
33036284|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
33036285|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
33036286|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
33036287|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
33036288|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
33036289|NCT01991327|Active Comparator|Placebo Androxal|
33036290|NCT01991340||Cohort|
33036291|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
33328229|NCT03912064|Experimental|CD25/Treg-depleted DLI + Ipilimumab|"Ipilimumab is administered intravenously every 12 weeks~Patients will receive a defined dose of CD25hi Treg depleted DLI intravenoudsly"
33328230|NCT03997318|Experimental|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
33328231|NCT03997318|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
33328232|NCT05386914|Experimental|Carrier APOE4|
33328233|NCT05386914|Other|Non-Carrier APOE4|
33328234|NCT03992092|Experimental|C-Mac VS|Intubation using the C-MAC Video Stylet
33328235|NCT03992092|Active Comparator|FB|Intubation using the Flexible Bronchoscope
33328236|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
33328237|NCT01195428|Placebo Comparator|Placebo|Placebo
33036292|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
33036293|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
33036294|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
33036295|NCT01991366||No Eptifibatide|Receive no eptifibatide
33036296|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
33036297|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
33036298|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
33036299|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
33036300|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
33067623|NCT01244815|Experimental|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
33107853|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
33107854|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
33107855|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
33107856|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
33107857|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
33328238|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
33328239|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
33328240|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
33107858|NCT04643600|Active Comparator|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
33107859|NCT04643600|Active Comparator|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
33107860|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
33107861|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
33107862|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
33107863|NCT04643561|Experimental|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
33107864|NCT02898909|Experimental|16 pieces fragmentation|
33107865|NCT02898909|Active Comparator|8 pieces fragmentation|
33107866|NCT04643483|Experimental|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
33107867|NCT04643483|Experimental|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
33328241|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
33328242|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
33328243|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
33360459|NCT03523546|Experimental|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
33036301|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
33036302|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
33036303|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
33036304|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
33036305|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
33036306|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
33036307|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
33036308|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
33036309|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
33036310|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
33036311|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
33036312|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
33036313|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
33036314|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
33036315|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
33036316|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
33036317|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
33036318|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
33036319|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
33036320|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
33036321|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
33036322|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
33036323|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
33036324|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
33036325|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
33036326|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
33036327|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
33036328|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
33036329|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
33036330|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
33036331|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
33036332|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
33036333|NCT01991626|Other|FePP control|Maize meal containing FePP
33036334|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
33036335|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
33036336|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
33036337|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).~One group of patients."
33360460|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
33360461|NCT01130233|Experimental|robotic|robotic assisted rectal resection
33360462|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
33360463|NCT03496012|Experimental|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
33328244|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
33328245|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
33036338|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
33036339|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
33360464|NCT03496012|Experimental|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
33360465|NCT03496012|No Intervention|Untreated Control Group|Participants will receive no sham surgery or study medication.
33360466|NCT01348646|Other|Lifestyle counseling|
33036340|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
33036341|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
32740753|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
33036342|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
33036343|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
33036344|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
33036345|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
33036346|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
33036347|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
33036348|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
33036349|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
33036350|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
33036351|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
33036352|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
33036353|NCT01991847|Experimental|Physical activity|Physical activity
33036354|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
33036355|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
33036356|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
33036357|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
33036358|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
33036359|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
33036360|NCT01991925||quality of life, quality of care|
33036361|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
33036362|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
33036363|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
33036364|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
33360467|NCT01128283||Sepsis|Patients with severe sepsis
33107868|NCT04643483|Active Comparator|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to <40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
33328246|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
33328247|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
33107869|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
33107870|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
33107871|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
33107872|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
33107873|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
33107874|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
33107875|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
33107876|NCT04643132|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
33107877|NCT04643132|Active Comparator|S-ketamine at low dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
33107878|NCT04643132|Active Comparator|S-ketamine at high dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
33328248|NCT03496168|Experimental|mavacamten (MYK-461)|
33328249|NCT04903392|Experimental|Backward Walking Group|Conventional therapy + Backward Walking Training
33328250|NCT04903392|Other|Forward Walking Group|Conventional therapy + Forward Walking Training
33328251|NCT03439462|Experimental|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|Single arm, open-label, multi-institutional study to identify the RP2D and determine the efficacy and safety profile of ABI-009 administered as first-line therapy in combination with mFOLFOX6 and bevacizumab in patients with advanced or mCRC.
33107879|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
33107880|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
33107881|NCT04643171|Experimental|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
33107882|NCT04643171|Active Comparator|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
33107883|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
33107884|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
33107885|NCT04643288|Experimental|OFD control group|open flap debridement for periodontal intrabony defects
33107886|NCT04643288|Experimental|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
33107887|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
33107888|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
33107889|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
33107890|NCT04643054|Experimental|Ovotransferrin|Dietary Supplement: Ovotransferrin
33107891|NCT04643054|No Intervention|Standard of care|Standard of care
33107892|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
33360468|NCT01128283||Non-infected|ICU patients without evidence of infection
33107893|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
33107894|NCT04643210|Experimental|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom & Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
33328252|NCT03941860|Experimental|Arm A (lenalidomide, ixazomib citrate)|Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
33328253|NCT03941860|Placebo Comparator|Arm B (lenalidomide, placebo)|Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
33328254|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
33328255|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
33328256|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
33328257|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
33036365|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
33036366|NCT01992003||Patients undergoing spine surgery|
33036367|NCT01992029||ALS Patients|
33036368|NCT01992029||Control patients suffering from neuropathy|
33036369|NCT01992029||Control patients suffering from myopathy|
33036370|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
33036371|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
33036372|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
33036373|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
33036374|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
33036375|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
33036376|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
33036377|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)~Subjects will take a written test focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
33036378|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
33036379|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
33036380|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
33036381|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
33036382|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
33036383|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
33036384|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
33328258|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
33328259|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
33328260|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
33328261|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
33328262|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
33328263|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
33328264|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
33328265|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
33036385|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
33036386|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
33036387|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
33036388|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
33036389|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
33036390|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
33036391|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
33036392|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
33036393|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
33036394|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
33036395|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
33036396|NCT01992263|Experimental|Vitamin D (600 IU)|
33036397|NCT01992263|Experimental|Vitamin D (2000 IU)|
33036398|NCT01992263|Experimental|Vitamin D (4000 IU)|
33036399|NCT01992263|Placebo Comparator|Placebo|
33036400|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
33036401|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
33036402|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
33036403|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
33036404|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
33036405|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
33036406|NCT01992315|Experimental|Adipose-Derived ECM|
33036407|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
33036408|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
33036409|NCT01992367|Placebo Comparator|Placebo|placebo arm
33036410|NCT01992367|Other|ASLAN003|Active drug
33036411|NCT01992406||Transrectal hybrid-NOTES anterior resection|
33036412|NCT01992445||Suicidal|
33036413|NCT01992445||Other mental health|
33036414|NCT01992445||Control (non suicidal, non mental health)|
33036415|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
33036416|NCT01992497|Placebo Comparator|Formula + placebo|
33036417|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
33036418|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
33036419|NCT01992497|Placebo Comparator|Breastfed + placebo|
33036420|NCT01992510||silicone oil fiiled eye|those with a condition
33036421|NCT01992510||fellow eye|the contralateral eye in the same patient
33360469|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
33036422|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
33036423|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
33328266|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~Fulfilling ACR criteria for fibromyalgia.~Severe ischemic heart disease.~Concurrent treatment for depression/anxiety with antidepressant drugs.~Concurrent neurological disease.~Other reason as evaluated by the P.I."
33328267|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
33328268|NCT03904888|Other|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
33328269|NCT03904888|Other|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
33036424|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
33036425|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
33328270|NCT03904888|Other|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
33036426|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
33036427|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
33036428|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
33036429|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
33036430|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
33036431|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
33036432|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
33036433|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
33036434|NCT01992666|Experimental|Blood sampling|
33036435|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
33036436|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
33036437|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
33036438|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
33036439|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.~Stereotactic Body Radiotherapy (SBRT):~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
33036440|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
33036441|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
33328271|NCT03904888|Other|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
33036442|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).~vs."
33036443|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
33036444|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
33036445|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
33036446|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
33036447|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
33036448|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
33067624|NCT01244815|Experimental|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
33328272|NCT05670834||control group (GroupA)|normal healthy non-cataractous volunteers aged ≥21 years
33328273|NCT05670834||Group B (experimental group 1)|cataractous patients aged >50 years and diagnosed with senile cataract.
33328274|NCT05670834||Group C (experimental group 2)|cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract
33328275|NCT03815578|Experimental|Rheumatoid Arthritis (RA) patients|RA according to the ACR/EULAR 2010 classification criteria
33036449|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.~Route of administration : oral by nasogastric tube.~Medication permitted and not permitted during the trial:~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
33036450|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
33328276|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
33036451|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
33036452|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
33036453|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
33036454|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
33036455|NCT01992835|Experimental|Grass pollen allergen extract|
33036456|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
33036457|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
33036458|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
33036459|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
33036460|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
33036461|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
33036462|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
33036463|NCT01992913|Other|UC|usual care
33036464|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
33036465|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
33036466|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
33036467|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
33036468|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
33036469|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
33067625|NCT01244815|Placebo Comparator|Placebo|Participants receive placebo BID for 21 days.
33067626|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
33328277|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
33328278|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
33036470|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
33036471|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
33417648|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
33417649|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
32740754|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
33036472|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
33036473|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
33036474|NCT01993004||Healthy subjects|Self-explanatory
33036475|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
33036476|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
33036477|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
33036478|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
33036479|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
33036480|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
33036481|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
33036482|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
33036483|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
33036484|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
33036485|NCT01993147|Other|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
33036486|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
33036487|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
33036488|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
33036489|NCT01993199|Active Comparator|deep biopsy|
33036490|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
33036491|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
33036492|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
33036493|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
33036494|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
33036495|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
33036496|NCT01993251|Active Comparator|melatonin 0.5mg|
33036497|NCT01993251|Active Comparator|melatonin 2mg|
33036498|NCT01993251|Active Comparator|melatonin 6mg|
33036499|NCT01993251|Placebo Comparator|placebo|
33036500|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
33036501|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
33036502|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
33036503|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
33036504|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
33036505|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
33036506|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
33036507|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
33036508|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
33067627|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
33067628|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
33067629|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
33107895|NCT04643210|Active Comparator|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
33107896|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
33107897|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
33107898|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
33107899|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
33328279|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
33328280|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
33107900|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
33107901|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
33107902|NCT04642664|Experimental|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
33107903|NCT04642742||Plant sterol chewable|
33107904|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
33328281|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
33107905|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
33107906|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
33107907|NCT04642547|Experimental|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight > 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight > 60Kg). Route of administration: Oral.
33107908|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
33107909|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
33107910|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
33107911|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol <9mcg/dL.
33107912|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol >= 9mcg/dL.
33328282|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
32740755|NCT05239403||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10-15 minutes up to 4 weeks prior to day of vaccination and undergo collection of blood samples up to 4 weeks before or on the day of vaccination and within 3 weeks post vaccination. Patients may also undergo collection of stool samples up to 4 weeks prior to day of vaccination.
33107913|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
33107914|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
33107915|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
33328283|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
33328284|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
33328285|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
32899667|NCT04752644|Experimental|Group1: MVA-BN-RSV|"Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
32899668|NCT04752644|Placebo Comparator|Group 2: Placebo|"Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
33036509|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
33036510|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
32899669|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
32899670|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
32899671|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
32899672|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
32899673|NCT04062656|Experimental|B - Nivolumab|"Responders~6 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 postoperative cycles nivolumab (i.v., 240mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
32899674|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
32899675|NCT00287222|Experimental|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
32899676|NCT04751240|Experimental|SIT and Resistance|Participants will complete 10 weeks of a SIT and resistance training paradigm.
32899677|NCT00218426|Active Comparator|ONP + DNI|Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
32899678|NCT00218426|Active Comparator|ON + DNIP|Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
33036511|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
33328286|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
33328287|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
33328288|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
33328289|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
32899679|NCT00218426|Placebo Comparator|ONP + DNIP|Oral placebo naltrexone + placebo naltrexone implant
32899680|NCT01134575|Experimental|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
32899681|NCT01134575|Experimental|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
32899682|NCT01134575|Experimental|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
32899683|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
32899684|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
32899685|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
32899686|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
33328290|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
33328291|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
33328292|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
33328293|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
33328294|NCT02930590|Active Comparator|Standard mattress|basic foam
33328295|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
33328296|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
33328297|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
33328298|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
33036512|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
33036513|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
33036514|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
33036515|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
33036516|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
33036517|NCT01993394|Experimental|ventilation|hypergravity gas mixture
33036518|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
33036519|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
33036520|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
33036521|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
33036522|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
33036523|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
33036524|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
33036525|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
33036526|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
33036527|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
33036528|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
33036529|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
33036530|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
33036531|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
33036532|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
33036533|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
33036534|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
33036535|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
33036536|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
33036537|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
33036538|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
33036539|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
33036540|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
33036541|NCT01993563|Experimental|Graded Motor Imagery|
33036542|NCT01993563|Active Comparator|Standard treatment|
33036543|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
33036544|NCT01993589|No Intervention|Control group|Control group
33036545|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
33328299|NCT01195740|Experimental|Attachment Based Family Therapy|
33036546|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
33036547|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
33036548|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
33328300|NCT01195740|Active Comparator|Enhanced Usual Care|
33328301|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
33328302|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
33328303|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
33328304|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
33328305|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
33328306|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
33328307|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
33036549|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
33036550|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
33036551|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
33036552|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
33036553|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
33036554|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
33036555|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
33036556|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
33036557|NCT01993654||Nevus|
33036558|NCT01993654||Racial Melanosis|
33036559|NCT01993654||Primary Acquired Melanosis|
33036560|NCT01993654||Malignant Melanoma|
33036561|NCT01993654||Normal|
33036562|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
33036563|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
33036564|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
33036565|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
33036566|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
33036567|NCT01993745||Study group|ECMO Patients survived
33036568|NCT01993745||Control|ECMO Patient died
33036569|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
33036570|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
33036571|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
33036572|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
33036573|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
33036574|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
33328308|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
33328309|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
33328310|NCT05351710|Experimental|Exposure-Based Treatment for Perfectionism|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 2 days at home (8 treatment sessions total).
33360470|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
33036575|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
33036576|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
33067630|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
33067631|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
33328311|NCT05351710|Active Comparator|Stress Management Condition|This arm consists of a 2-week, computerized, stress-management condition in which participants watch videos of health habits (e.g., nutrition, exercise, sleep) and relaxation videos. These sessions are completed every 2 days at home (8 sessions total).
33328312|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
33328313|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
33328314|NCT01195974|Other|Run In Period|YASMIN
33328315|NCT05324098|Experimental|Health services research (STAND-T, text messages)|Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.
33328316|NCT03268356|Other|AGN1 Treatment|Subjects who have suffered a fragility hip fracture in one hip, sign the consent form and meet the inclusion and none of the exclusion of the study will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) in the non-fractured hip.
33328317|NCT04731376|Experimental|Arm I (testosterone cypionate)|Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.
33328318|NCT04731376|Active Comparator|Arm II (best practice)|Patients with normal testosterone levels receive standard peri-operative care.
33328319|NCT05670756||Medication allergy|Patients who have a medication allergy listed in their electronic medical record.
33328320|NCT05281354|No Intervention|standard care|Follow-up according to standard practice
32866677|NCT04819230|Placebo Comparator|Control Condition|"A combination of attention (ATT-C) and interpretation (ITT-C) control tasks~These tasks are identical to the experimental tasks (ATT and ITT) with the exceptions that:~ATT-C: It is designed to train attention toward neither neutral nor the threat stimuli. This will be achieved by having an equal number of probes follow the location of the threatening word and the neutral word.~ITT-C: It is not designed to train benign interpretations of ambiguous social scenarios. Thus, no feedback will be given during the inter-trial interval, rather participants will see a blank screen between trials.~Participants will complete both the ATT-C and ITT-C tasks twice per week for four weeks, totaling to eight experimental sessions."
33036577|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
33036578|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
33036579|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
33036580|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
33036581|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
33036582|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
33036583|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
33036584|NCT01993966||non-tumoral|specimens come from non-tumoral patients
33036585|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
33036586|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
33036587|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
33036588|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
33036589|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
33036590|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
33036591|NCT01994018||Retrospective Chart Review|RR-MS patients treated with a FDA approved immuno-modulatory drug for MS.
33036592|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
33036593|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
33036594|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
33036595|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
33036596|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
33328321|NCT05281354|Experimental|multimodal intervention|Addition of a treatment to normalise resting energy expenditure according to the observed abnormalities
33328322|NCT05274178|Experimental|Study Group|All participants will be wearing the Audeo P hearing devices for this study.
33328323|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
33328324|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
33328325|NCT05257720||Remission|Patient with schizophrenia in remission
33328326|NCT05257720||treatment resistant|patient with treatment resistant schizophrenia
33036597|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
33328327|NCT05257720||controls|healthy controls
33328328|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
33036598|NCT01994044|Active Comparator|Multimodal rehabilitation|
33036599|NCT01994044|Active Comparator|Cervical fusion|
33036600|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
33036601|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
33036602|NCT01994083|Placebo Comparator|Placebo|Placebo
33036603|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
33036604|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
33036605|NCT01994122||People who have dropped out of school|
33036606|NCT01994122||College students (control group)|
33036607|NCT01994135|Active Comparator|Reference food|The reference food is white bread
33036608|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
33036609|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
33036610|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
33036611|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
33036612|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
33036613|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
33036614|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
33036615|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
33036616|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
33036617|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
33036618|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
33036619|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
33036620|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
33036621|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
33036622|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
33036623|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
33036624|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
33036625|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
33036626|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
33036627|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
33107916|NCT04642313|Placebo Comparator|PLACEBO group|Placebo treatment: starch tablets (250 mg)
33328329|NCT05255224||Retrospective|Patients admitted to Mass Brigham Hospitals for cardiac surgery from 1st January 1998 to 31st December 2020
33328330|NCT05255224||Prospective|Patients admitted to Barts Health, Liverpool Heart and Chest Hospital, or Oxford University Hospitals NHS Foundation Trust for cardiac surgery between 1st October 2021 to 31st July 2023
33328331|NCT01295970|Active Comparator|Radiosurgery (SRS)|
33036628|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
33036629|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
33036630|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
33036631|NCT01994421|Sham Comparator|Kinesiotape|
33328332|NCT01295970|Active Comparator|Surgery|
33328333|NCT05195008|Experimental|Part A [Single Ascending Dose (SAD)]: BIIB113 Cohort 1|Participants aged 18 to 64 years will receive Dose 1 of BIIB113, orally, once daily (QD), on Day 1 of Part A of the study.
33036632|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
33328334|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 2|Participants aged 18 to 64 years will receive Dose 2 of BIIB113, orally, QD, on Day 1 of Part A of the study
33328335|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 3|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, on Day 1 of Part A of the study.
33328336|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 4|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Day 1 of Part A of the study.
33328337|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 5|Participants aged 18 to 64 years will receive Dose 5 of BIIB113, orally, QD, on Day 1 of Part A of the study
33328338|NCT05195008|Placebo Comparator|Part A (SAD): BIIB113-Matching Placebo (Cohorts 1-5)|Participants aged 18 to 64 years will receive BIIB113-matching placebo, orally, QD, on Day 1 of Part A of the study.
33036633|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
33036634|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
33036635|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
33036636|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
33036637|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
33036638|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
33036639|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
33036640|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
33036641|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
33036642|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
33036643|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
33036644|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
33036645|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.~Challenge occurs 3 weeks after final immunization."
33036646|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.~Challenge occurs 3 weeks after final immunization."
33036647|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
33036648|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
33036649|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
33036650|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
33036651|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
33036652|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
33036653|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
33036654|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
33036655|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
33328339|NCT05195008|Experimental|Part B [Multiple Ascending Dose (MAD)]: BIIB113 Cohort 6|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, up to Day 14 of Part B of the study.
33036656|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
33328340|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 7|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
33328341|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 8|Participants aged 18 to 64 years will receive Dose 6 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
33328342|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113 Cohort 9|Participants aged 65 to 75 years will receive BIIB113, orally, QD, on Days 1 to 14 of Part B of the study. The calculated dose level will be adaptive by design based on review of the safety, tolerability, and PK data from Cohorts 1 to 7.
33328343|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113-Matching Placebo (Cohorts 6 to 9)|Participants aged 18 to 75 will receive BIIB113-matching placebo, orally, QD, on Days 1 to 14 of Part B of the study.
33328344|NCT05195008|Experimental|Part C (OGA-PET SAD): BIIB113|Participants aged 20 to 64 will receive single dose of BIIB113, orally, QD, on Day 1 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578), on Days 1 to 4 of Part C of the study.
33328345|NCT05195008|Experimental|Part C (OGA-PET MAD): BIIB113|Participants aged 20 to 64 years will receive multiple doses of BIIB113, orally, QD, on Days 1 to 14 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578) on Day 1 and either of Day 15, Day 16 or Day 17 of Part C of the study.
33328346|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
33328347|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
33328348|NCT05138848|Experimental|Time in Bed Restriction|Time in Bed (TIB) restriction of 85% of habitual TIB.
33328349|NCT05138848|Active Comparator|Control|Participants will follow their typical sleep schedule consistent with measured average sleep and wake times.
33360471|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
33417650|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
33036657|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
33036658|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
33036659|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
33036660|NCT01994668|Experimental|Lorazepam|
33036661|NCT01994668|Placebo Comparator|Placebo|
33036662|NCT01994681||Pancreatic Cancer|
33036663|NCT01994681||Healthy|
33036664|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
33036665|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
33036666|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
33036667|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
33036668|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
33036669|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
33036670|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
33036671|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
33036672|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
33036673|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
33036674|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
33036675|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
33036676|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
33036677|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
33036678|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
33036679|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
33036680|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
33036681|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
33036682|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
33328350|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
33328351|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
33328352|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
33328353|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
33328354|NCT01296048||Body Analysis|
33328355|NCT05136118|Active Comparator|Group MS|The modified surgeon assisted approach for TAPB Before the closure of the peritoneum, TAPB will be performed; at the level of the umbilicus 8 to 10cms from the midline bilaterally. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin slightly directed towards the ipsilateral anterior superior iliac spine. After feeling the 2 pops of the external and the internal oblique aponeurosis by the anesthesiologist, the surgeon will confirm proper needle placement by his hand inside the abdominal cavity. The LA will be injected after negative aspiration and a bleb will be palpated by the surgeon as the injection continues. The same procedure will be repeated on the other side.
33328356|NCT05136118|Active Comparator|Group US|The ultra-sound guided approach for TAPB. After abdominal wall closure, the linear probe of the ultra- sound will be placed perpendicular to the skin at the mid-axillary line between the iliac crest and the costal margin; the TAP will be located between the internal oblique and the transversus abdominis muscle. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin and the 2 pops of the external and the internal oblique aponeurosis will be also felt. The LA will be injected after negative aspiration and its spread in the plane will be observed. The same procedure will be repeated on the other side.
33417651|NCT01364077|Active Comparator|Ivabradine|
33417652|NCT01364077|Placebo Comparator|Control|
33417653|NCT01361399|Experimental|Arm 1|
33036683|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
33036684|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
33036685|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
33417654|NCT01361399|Active Comparator|Arm 2|
33036686|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
33036687|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
33036688|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
33036689|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
33036690|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
33036691|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
33328357|NCT05104762|Active Comparator|Arm 1 plasmapheresis|Arm 1 (plasmapheresis): This study will be conducted at Assiut University at Neurology and psychiatry department as Group 1 of patients presented with Guillian Barrie syndrome (40 patients) will be subjected to plasmapheresis after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months)
33328358|NCT05104762|Active Comparator|Arm 2: Intravenous injection of immunoglobulin|This study will be conducted at Assiut University at Neurology and psychiatry department as Group 2 of patients presented with Guillian Barrie syndrome (20 patients) will be subjected to intravenous injection of immunoglobulin after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score, and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months).
32740068|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
32740756|NCT05634759|Experimental|Routine Community-wide MDA followed by Two Additional Rounds of Treatment for Children|The enhanced MDA Strategy 1 consists of a routine community-wide MDA followed by two additional rounds targeted to children age 6 months to 9 years. The additional rounds of treatment will occur 2 weeks apart and will begin 1 week after the community-wide MDA.
33036692|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
33036693|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
33036694|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
33328359|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
33328360|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
33036695|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
33036696|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
33036697|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
33036698|NCT01995110|Experimental|normal weight subjects|
33036699|NCT01995110|Experimental|obese subjects|
33036700|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
33036701|NCT01995162|Experimental|Free-living conditions|
33036702|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
33036703|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
33036704|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
33036705|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
33036706|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
33036707|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
33036708|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
33036709|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
33036710|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
33036711|NCT01995253|Experimental|Controlled conditions|
33328361|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
33328362|NCT01196364|Experimental|Sedentary activity, glucose beverage|
33328363|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
33328364|NCT01196364|Experimental|Exercise activity, glucose beverage|
33417655|NCT01361399|Active Comparator|Arm 3|
33417656|NCT01361399|Placebo Comparator|Arm 4|
33328365|NCT05084716|Experimental|Intervention|At the intervention site during healthcare facility outreach events, PrEP initiators will be offered guidance on selecting an adherence supporter during PrEP initiation. All outreach event attendees at the events will be offered the opportunity to attend the intervention workshops. Check-in reminder calls will be conducted systematically with PrEP users.
33328366|NCT05084716|No Intervention|Control|At the control site, healthcare facility staff will continue to provide PrEP according to the standard of care.
33328367|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
33328368|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
33328369|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
33328370|NCT05058664|No Intervention|Control (standard care)|
33417657|NCT05190133|Experimental|Treatment A|
33417658|NCT05190133|Experimental|Treatment B|
33036712|NCT01995253|Experimental|Free-living conditions|
33036713|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
33036714|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
33036715|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
33036716|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
33036717|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
33036718|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
33036719|NCT01995331|Other|moderate-dose cyclophosphomide|
33036720|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
33036721|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
33036722|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
33036723|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
33036724|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
33036725|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
33036726|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
33036727|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
33036728|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
33036729|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
33036730|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
33036731|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
33036732|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
33036733|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
33036734|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
33036735|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
33036736|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
33036737|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:~Endeavor Resolute Stent - a premounted cobalt alloy based stent~Delivery system - Rapid Exchange (RX) Coronary System~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
33036738|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
33036739|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
33036740|NCT01995617|Experimental|Low Dose (Cohort 1)|
33036741|NCT01995617|Experimental|Mid Dose (Cohort 2)|
33036742|NCT01995617|Experimental|High Dose (Cohort 3)|
33036743|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
33036744|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
33036745|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
33036746|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
33107917|NCT04642313|Experimental|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
33107918|NCT04642313|Experimental|Potassium group|Potassium group: Potassium chloride (250 mg)
33107919|NCT04642313|Experimental|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
33328371|NCT05058664|Experimental|A-F texting component|The A-F texting component will include content consistent with best-practice recommendations for parents to buffer youth against suicide risk.
33328372|NCT05058664|Experimental|A-F texting plus P-F texting component|A-F texting plus P-F texting component arm includes the A-F component, as above, and P-F component. The P-F component includes an embedded micro-randomized trial (MRT) involving two daily randomizations to P-F message vs. no message conditions for the duration of the 6-week intervention. Participants who are randomized to this arm will be randomized twice each day (morning and evening) to either receive or not receive the P-F message at each randomization.
33107920|NCT04642157|Experimental|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
33107921|NCT04642157|Other|control group|Participants of the control arm will receive generic professional help contacts.
33328373|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
33328374|NCT05033002|No Intervention|Treatment as Usual Group|This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.
33328375|NCT05033002|Experimental|Stigma Intervention Group|This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.
33328376|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
33328377|NCT03255252|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
33107922|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
33328378|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
33328379|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328380|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328381|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328382|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328383|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328384|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
33328385|NCT01296204|Experimental|BB4 antibody-Iodine 131|
33328386|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
33328387|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
33328388|NCT05505552|Experimental|Vitamin K|Participants receive 1 mg/d phylloquinone orally for 24 weeks
33328389|NCT05505552|Placebo Comparator|Placebo|Participants receive daily placebo matching phylloquinone for 24 weeks
33328390|NCT04964206||Neuraxial analgesia exposure|For mothers who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided according to routine practice of each study center.
33107923|NCT04642118|Experimental|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
33328391|NCT04964206||No neuraxial analgesia exposure|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
33328392|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
33107924|NCT04642118|Active Comparator|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
33107925|NCT04642118|No Intervention|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist."
33107926|NCT04641923|Experimental|Seprafilm|Antiadhesion barrier applied
33328393|NCT01197846|Placebo Comparator|Placebo|
33328394|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
33328395|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
33328396|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
33328397|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
33107927|NCT04641923|No Intervention|No seprafilm|No barrier applied
33036747|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
33036748|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
33328398|NCT01586754||With Metabolic Syndrome|
33328399|NCT01586754||Without Metabolic Syndrome|
33328400|NCT05499858|Other|Vegetables|Vegetables will be provided to volunteers as part of a heat and serve meal kit.
33328401|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
33328402|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
33328403|NCT01193790|Experimental|Coblation|
33036749|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
33036750|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
33036751|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
33036752|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
33036753|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
33036754|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
33036755|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
33036756|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
33036757|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
33036758|NCT01995773||Healthy Controls|Healthy control women
33036759|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
33036760|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
33036761|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
33036762|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
33036763|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
33036764|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
33036765|NCT01995812|No Intervention|Control group|
33036766|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
33036767|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
33036768|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
33036769|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
33107928|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
33328404|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 to < 18 years
33328405|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 to < 12 years
33328406|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 to < 6 years
33328407|NCT01296282||Heart failure patients|
33328408|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
33328409|NCT01196520||HCII Controls|Matched controls from the local health clinics
33328410|NCT01196520||Population Controls|Matched controls from the geographic region
33328411|NCT05670678||a2 growing up stage 3 formula puls lactoferrin supplement|"per 100g serving~Lactoferrin 30 mg~Galactooligosaccharides (GOS) at 3 g~DHA 0.37~Lactoferrin supplement plus: 2.68 ml per serving, 20 mg per 2 ml, 600 mg per bottle"
33328412|NCT05670678||Enfinitas growing up stage 3 formula|"per 100g serving~Lactoferrin 330 mg~Galactooligosaccharides (GOS) at 1.58 mg~β-Glucan 22 mg~DHA 0.4"
33328413|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
33328414|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
33328415|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
32740069|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
33328416|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
33036770|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
33036771|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
33036772|NCT01995890|No Intervention|control|No intervention in the control arm
33036773|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
33036774|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
33036775|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
33036776|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
33036777|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
33036778|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
33036779|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
33036780|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
33036781|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
33036782|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
33036783|NCT01995994||RT-CGM|
33036784|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
33036785|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
33036786|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
33036787|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
33036788|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
33036789|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
33036790|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
33036791|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
33036792|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
33036793|NCT01996098|No Intervention|Chemotherapy alone|No intervention
33036794|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
33036795|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
33036796|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
33036797|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
33036798|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
33036799|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
33036800|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
33036801|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
33036802|NCT01996163||Male|
33036803|NCT01996163||Female|
33036804|NCT01996176|Experimental|Intervention group|Intervention group
33328417|NCT04679896|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
33328418|NCT04679896|Other|Local autograft|
33036805|NCT01996176|Placebo Comparator|Intervention control|Control group
33328419|NCT05487690|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries.
33328420|NCT05487690|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
33328421|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
33328422|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
33036806|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
33036807|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
33328423|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle
33328424|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.~Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle."
33328425|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle."
33328426|NCT02773030|Experimental|Cohort G1: CC-220 in combination with CFZ and DEX - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg
33360472|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
33036808|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
33036809|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
33036810|NCT01996215||AMD controls|
33036811|NCT01996215||AMD cases|
33036812|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
33036813|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
33036814|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
33036815|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
33036816|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
33036817|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
33036818|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
33328427|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg
33036819|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
33036820|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
33360473|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
33036821|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
33036822|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
33036823|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
33036824|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
33036825|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
33036826|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
33036827|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
33036828|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
33036829|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
33036830|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
33036831|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
33036832|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
33036833|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
33036834|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
33036835|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
33036836|NCT01996540|Experimental|Interventional arm|Interventional arm
33036837|NCT01996540|No Intervention|Standard arm|Standard arm
33036838|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
33036839|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
33036840|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
33036841|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
33036842|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
33036843|NCT01996670||<2h group|
33036844|NCT01996670||2-4h group|
33036845|NCT01996670||>4h group|
33036846|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
33036847|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
33036848|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
33036849|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
33036850|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
33036851|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
33036852|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
33036853|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
33036854|NCT01996774||Child, peanut/ nut allergy, no treatment|
33036855|NCT01996774||Child, peanut/nut allergy, tolerance|
33036856|NCT01996774||Non allergic child, without atopia|
33036857|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
33036858|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
33036859|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
33036860|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
33036861|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
33036862|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
33036863|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
33036864|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
33036865|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
33036866|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
33036867|NCT01996956|Other|Volume loading|
33036868|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
33036869|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
33036870|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
33036871|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:~EMA:~Ecological Momentary Assessment (EMA) of Emotion throughout the day.~Intervention:~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.~Gratitude: Participants identify one more more things that make them feel grateful.~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
33036872|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.~EMA detail:~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
33036873|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
33036874|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
33036875|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
33036876|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
33036877|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
33328428|NCT02773030|Experimental|Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2|Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
33360474|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
33360475|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
33360476|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
33036878|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
33036879|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
33036880|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
33036881|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
33036882|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
33036883|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
33036884|NCT01997099||Library Creation|Individuals responsible for creating the drug library
33036885|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
33036886|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
33036887|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
33036888|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
33036889|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
33036890|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
33036891|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
33036892|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
33036893|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
33036894|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
33036895|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
33036896|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
33036897|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
33036898|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
33036899|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
33036900|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week"
33036901|NCT01997203|No Intervention|HCV without Vit D|
33036902|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
33036903|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
33036904|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
33036905|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
33036906|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
33036907|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
33036908|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
33036909|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
33036910|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
33036911|NCT01997307||Age >=65 to 74|
33036912|NCT01997307||Age >=75 to 84|
33036913|NCT01997307||Age >=85|
33036914|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
33328429|NCT02773030|Experimental|Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
33328430|NCT02773030|Experimental|Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle. Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
33328431|NCT02773030|Experimental|Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible|Part 2
33328432|NCT02773030|Experimental|Cohort C: CC-220 Monotherapy in RRMM|Part 2
33036915|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
33036916|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
33036917|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
33036918|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
33036919|NCT01997372|Experimental|high dose ATG,low dose ATG|
33036920|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
33036921|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
33036922|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
33036923|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
33036924|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
33036925|NCT01997541||plain tube|
33036926|NCT01997541||reinforced tube|
33036927|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
33036928|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
33036929|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
33036930|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
33036931|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
33036932|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
33036933|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
33036934|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
33036935|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
33036936|NCT01997632|Experimental|investigational vaccine|
33036937|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
33036938|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
33036939|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
33036940|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
33067632|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
33328433|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
33036941|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
33036942|NCT01997671|No Intervention|Control group|Routine clinical practice
33328434|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
33328435|NCT01197924||healthy volonteer children|paired for the sex and the age
33328436|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
33328437|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
33328438|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
32740757|NCT05634759|Experimental|Routine Community-wide MDA followed by a Second Community-wide MDA|The enhanced MDA Strategy 2 consist of a routine community-wide MDA followed by a second community-wide MDA approximately 6-8 months later. The timing of the second MDA will depend on local conditions and logistical concerns.
33036943|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
33036944|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
33036945|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
33036946|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
33036947|NCT01997736|Experimental|Ablation|
33036948|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
33036949|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
33036950|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
33036951|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
33036952|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
33036953|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
33036954|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
33036955|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
33036956|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
33036957|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
33036958|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
33036959|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
33036960|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
33036961|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
33036962|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
33036963|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model~Polysomnogram Sleep Study"
33036964|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
33036965|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
33036966|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
33036967|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
33036968|NCT01997957|No Intervention|TACE+HAIC-OXA|
33328439|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
33328440|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
33328441|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
33328442|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
33328443|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
33328444|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
33360477|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
33417659|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
33036969|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
33036970|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
33036971|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
33036972|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
33036973|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
33036974|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
33036975|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
33036976|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
33036977|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
33036978|NCT01998074|Experimental|Study formula|
33036979|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
33036980|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
33036981|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
33036982|NCT01998100|Experimental|Prolonged Exposure + Exercise|
33036983|NCT01998100|Active Comparator|Prolonged Exposure Alone|
33036984|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
33036985|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
33036986|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
33036987|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
33036988|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
33036989|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
33036990|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
33036991|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
33036992|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
33036993|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
33036994|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
33036995|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
33036996|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
33036997|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
33036998|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
33036999|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
33037000|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
33037001|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
33037002|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
33037003|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
33037004|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
33067633|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
33067634|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
33067635|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
33417660|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
33417661|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
33107929|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
33107930|NCT04642040|Experimental|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
33107931|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
33328445|NCT05668260|Experimental|Biodegradable Stent|An internal biodegradable pancreatic stent (ArchimedesTM) will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
33328446|NCT05668260|No Intervention|Non Stent|No stent will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
33107932|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
33107933|NCT04642001|Other|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
33107934|NCT04642001|Experimental|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
33107935|NCT04642001|Experimental|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
33107936|NCT04642001|Experimental|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
33328447|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
33107937|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
33107938|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
33107939|NCT04641845|Experimental|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
33107940|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
33107941|NCT04641689|Active Comparator|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
33107942|NCT04641689|Active Comparator|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
33107943|NCT04641689|Experimental|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
33107944|NCT04641689|No Intervention|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
33107945|NCT02898753|Experimental|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
33107946|NCT02898753|Experimental|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
33107947|NCT02898753|Experimental|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
33107948|NCT02898753|Active Comparator|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
33107949|NCT04641572|No Intervention|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
33107950|NCT04641572|Experimental|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
33107951|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
33107952|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
33107953|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
33107954|NCT04641533|Experimental|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
33107955|NCT04641533|Active Comparator|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
33107956|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
33107957|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
33328448|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
33328449|NCT01196676|Experimental|1|AZD4451
33328450|NCT01196676|Placebo Comparator|2|Placebo
33037005|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
33037006|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
33328451|NCT04903236||Non-patient healthy volunteer|Undertake MR Imaging to enable development of sequences.
33328452|NCT04903236||Patient|Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.
33328453|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
33328454|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
33328455|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
33328456|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
33328457|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
33328458|NCT02567422|Experimental|Treatment (berzosertib, cisplatin, radiation therapy)|Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity.
33328459|NCT05467410|Experimental|COG-AM|30-minute morning session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 09:00 AM - 11:00 AM, in addition to UC
33328460|NCT05467410|Experimental|COG-PM|30-minute afternoon/evening session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 16:00 PM - 18:00 PM, in addition to UC
33328461|NCT05467410|No Intervention|UC|Standard post-ICU inpatient care/usual care
33037007|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
33037008|NCT01998282||Control|Traditional water management practices and cooking stoves
33037009|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days~Dosage:~tablet for body weight between 5-14.9 Kilograms.~tablets for body weight between 15-24.9 Kilograms.~tablets for body weight between 25-34.9 Kilograms."
33037010|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
33037011|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
33037012|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
33037013|NCT01998308||Group 4|50 knees will have single injection of Monovisc
33037014|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
33037015|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
33037016|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
33037017|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
33037018|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
33037019|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
33037020|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
33037021|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
33037022|NCT01998373|No Intervention|control without education|this group did not receive an education
33037023|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
33328462|NCT05289648|Experimental|Preoperative Niraparib|Single arm. Following the initial assessment and endometrial biopsy the participants will receive niraparib for 28 days. After the treatment period the patients will be surgically staged. All participants will receive the standard of care.
33328463|NCT05457270|Experimental|Sequence 1 (Formulation A + Formulation B)|Participants will receive a single oral dose of Treatment 1: Formulation A followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 2: AZD4831 Formulation B.
33037024|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
33037025|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
33328464|NCT05457270|Experimental|Sequence 2 (Formulation B + Formulation A)|Participants will receive a single oral dose of Treatment 2: Formulation B followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 1 Formulation A.
33328465|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
33037026|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
33328466|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
33328467|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
33037027|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
33037028|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
33037029|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
33037030|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
33037031|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
33037032|NCT01998490|No Intervention|Control|Control group with treatment as usual
33037033|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
33037034|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
33037035|NCT01998516||Schizophrenia Patients|
33037036|NCT01998516||Bipolar I Patients|
33037037|NCT01998516||Siblings of Schizophrenia Patients|
33037038|NCT01998516||Siblings of Bipolar I Patients|
33037039|NCT01998516||Healthy Controls|
33037040|NCT01998542|Experimental|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
33037041|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
33037042|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
33037043|NCT01998568||Corneal edema|Intraocular pressure measurement
33037044|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
33037045|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
33037046|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
33037047|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
33037048|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
33037049|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
33037050|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
33037051|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
33328468|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
33328469|NCT05289258|Active Comparator|Neuropsychological treatment|Combination of different neuropsychological rehabilitation programs
33328470|NCT05289258|Experimental|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).
33328471|NCT05289258|Other|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
33328472|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
33328473|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
33037052|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
33037053|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
33037054|NCT01998646|Placebo Comparator|Placebo|
33037055|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
33037056|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
33037057|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
33037058|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
33037059|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
33037060|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
33037061|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
33037062|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
33037063|NCT01998711|Experimental|Memory group|Memory training
33037064|NCT01998711|No Intervention|Control|Standard care
33037065|NCT01998724|No Intervention|Standard Care|No intervention
33037066|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
33037067|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
33037068|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
33037069|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
33037070|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
33037071|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
33037072|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
33037073|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
33037074|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
33037075|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
33037076|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
33037077|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
33037078|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
33037079|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
33037080|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
33037081|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
33037082|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
33037083|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
33328474|NCT04889976|Experimental|Double-active|Active portable transcranial electrical stimulation (ptES) and active internet-based behavioral therapy (iBT).
33328475|NCT04889976|Active Comparator|ptES-only|Active portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
33328476|NCT04889976|Sham Comparator|Double-sham|Sham portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
33328477|NCT04861818|Experimental|Morning group|Participant are assigned to the morning group (7-9am) for 30-min exercise/rest interventions.
33328478|NCT04861818|Experimental|Afternoon group|Participant are assigned to the afternoon group (3-5pm) for 30-min exercise/rest interventions.
33037084|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
33328479|NCT01199640|Experimental|MLN1202|
33328480|NCT04831398|Placebo Comparator|Placebo|Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.
33328481|NCT04831398|Experimental|Melatonin|5mg commercially available melatonin (MEL) spray will be given sublingually.
33037085|NCT01999023|No Intervention|Observational group|No intervention
33037086|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
33328482|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
33328483|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
33328484|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
33328485|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
33037087|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
33037088|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
33037089|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
33037090|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
33037091|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
33037092|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
33037093|NCT01999140||Primary prevention|
33037094|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
33037095|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
33037096|NCT01999166||Osteoarthritis|
33037097|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
33037098|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
33037099|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
33037100|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
33037101|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
33037102|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
33037103|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
33037104|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
33037105|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
33037106|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
33037107|NCT01999296||Patients undergoing laparoscopic surgery|
33037108|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
33037109|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
33037110|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
33067636|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
33328486|NCT03844932|Experimental|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
33328487|NCT03844932|Experimental|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
33328488|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
33328489|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
33328490|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
33037111|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~Cytarabine 200 mg/m²/day D1 to D7~OMEGAVEN® 2 ml/kg D1 to D9,~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours~Induction cycle :~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~- Cytarabine 200 mg/m²/day IV D1 to D7~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :~Daunorubicin 35 mg/m²/day IV D17 and D18~OMEGAVEN® 2 ml/kg~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).~Consolidation will be administered at investigator's discretion"
33328491|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
33328492|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
33037112|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
33037113|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
33037114|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
33037115|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
33037116|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
33037117|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
33037118|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
33037119|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
33037120|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
33037121|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
33037122|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
33037123|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
33037124|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
33037125|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
33037126|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
33037127|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
33037128|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
33037129|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
33037130|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
33037131|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
33037132|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
33037133|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
33037134|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
33037135|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
33037136|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
33037137|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
33037138|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
33037139|NCT01999699|Experimental|HEPLISAV|
33037140|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
33037141|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
33037142|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
33037143|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).~Intervention: EC1456 and EC20"
33037144|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).~Intervention: EC1456 and EC20"
33037145|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).~Intervention: EC1456 and EC20"
33328493|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
33328494|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
33328495|NCT04136418|Active Comparator|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
33328496|NCT04136418|Experimental|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
33328497|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
33037146|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).~Intervention: EC1456 and EC20"
33037147|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.~Intervention: EC1456 and EC20"
33328498|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
33328499|NCT05670054|Active Comparator|palbociclib + fulvestrant|Arm A includes patients who receive palbociclib 125 mg tab/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
33037148|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.~Intervention: EC1456 and EC20"
33037149|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).~Intervention: EC1456 and EC20"
33037150|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
33037151|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
33037152|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
33037153|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
33037154|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
33037155|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
33037156|NCT01999816|No Intervention|Control|Usual care
33037157|NCT01999829|Experimental|citrate of caffeine|
33037158|NCT01999829|Placebo Comparator|placebo|
33037159|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
33037160|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
33037161|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
33037162|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
33037163|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
33037164|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
33037165|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
33037166|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
33037167|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
33037168|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
33037169|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
33037170|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
33037171|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
33037172|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
33037173|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
33037174|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
33037175|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
33037176|NCT01999998|Experimental|Pilot|
33037177|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
33328500|NCT05670054|Active Comparator|Ribociclib + fulvestrant|Arm B includes patients who receive ribociclib 200 mg 3 tabs/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
33328501|NCT04777656|Experimental|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
33328502|NCT04777656|Active Comparator|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
33037178|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
33037179|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles~Surgery~Adjuvant therapy: FOLFOX4 8 cycles~TME (Total Mesorectal Excision)"
32740758|NCT05634759|Active Comparator|Standard-of-Care Annual MDA|Programmatic Control Comparator data for the standard-of-care annual MDA will come from the MDA conducted in 2022 in a random selection of 15 non-study villages.
33037180|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
33037181|NCT02000076|Experimental|Full sleep|Sleep with no restriction
33037182|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
33037183|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
33037184|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
33037185|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
33037186|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
33037187|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
33037188|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.~The treatment will continue until disease progression or intolerable adverse event"
33037189|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
33037190|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
33037191|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
33037192|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
33037193|NCT02000245|No Intervention|control|control
33037194|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
33328503|NCT04777656|Other|Not randomized|Patient not in remission at M2 or refusing randomisation
33328504|NCT05670600|Experimental|intervention group|The intervention group received training by sending foot and ankle exercise videos to their mobile phones via WhatsApp.
33037195|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
33037196|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
33037197|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
33037198|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
33037199|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
33037200|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
33037201|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
33037202|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
33037203|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
33037204|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
33328505|NCT04776564||Intensive courses|Participants on courses delivered within four days
33328506|NCT04776564||Long courses|Participants on courses delivered over minimum four weeks
33328507|NCT04776564||Clinical|Participants attending G7P courses delivered within the specialist health care setting
33328508|NCT04776564||Internett|Participants attending G7P courses delivered as an online course
33328509|NCT04776564||Professional|Participants attending G7P courses wihere professional health care personell are delivering the teaching
33328510|NCT04776564||Non-professional|Participants attending G7P courses wihere no professional health care personell are delivering the teaching
33328511|NCT04776564||Control group|A sample of couples from the public that do not at the moment participate in couple therapy or any couple enhancement programs
33328512|NCT05226078|Experimental|Four Sessions of CBT-I|
33328513|NCT05226078|Experimental|Eight Sessions of CBT-I|
33328514|NCT05226078|Experimental|Ten Sessions of CBT-I|
33328515|NCT05226078|Experimental|Twelve Sessions of CBT-I|
32740070|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
32740071|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
33037205|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
33037206|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
33037207|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration~cohort 2. 1.0 x 10^8 stem cells after registration"
33037208|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
33037209|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
33037210|NCT02000388|Other|Standard of care|The intervention used will be standard of care
33037211|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
33037212|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
33037213|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
33037214|NCT02000466||Exposed cohort|
33037215|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
33037216|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
33037217|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
33037218|NCT02000492|No Intervention|Control|
33037219|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
33037220|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
33037221|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
33037222|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
33037223|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
33037224|NCT02000544|Other|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
33037225|NCT02000557||Class II Malocclusion|
33037226|NCT02000570|Experimental|sitting position|
33037227|NCT02000609|Active Comparator|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
33037228|NCT02000609|Placebo Comparator|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
33037229|NCT02000609|Active Comparator|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
33037230|NCT02000609|Active Comparator|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
33037231|NCT02000609|Active Comparator|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
33037232|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
33037233|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
33037234|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
33037235|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
33037236|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
33328516|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
33328517|NCT03844854|No Intervention|Control Group|Without intervention.
33328518|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
33328519|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
33328520|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
33328521|NCT04738734|Experimental|CellFX Procedure|CellFX device using pre-defined energy protocols
33328522|NCT04738734|Active Comparator|Cryosurgical Procedure|Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.
33328523|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
33328524|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
33328525|NCT04716036|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
33328526|NCT04716036|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
33037237|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
33328527|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
33037238|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
33328528|NCT01202214|Experimental|Active drug|
33328529|NCT01202214|Placebo Comparator|Placebo|
32740072|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
33328530|NCT03841734|Experimental|Treatment bosentan|
33328531|NCT01202292|Experimental|Lifestyle counseling|
33037239|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
33037240|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
33037241|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
33037242|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
33037243|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
33037244|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
33328532|NCT05212740|Experimental|Corticosteroid|The participants will receive prednisolone for four weeks.
33328533|NCT05212740|Active Comparator|Exercise|The participants will receive joint mobilization techniques, stretching and home exercise.
33037245|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
33037246|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
33037247|NCT02000804|Experimental|darapladib 160mg|drug
33037248|NCT02000830||Placebo|Participants received placebo during the earlier study
33037249|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
33037250|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
33037251|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
33037252|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
33037253|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
33037254|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
33037255|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
33037256|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
33037257|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
33037258|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
33037259|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
33328534|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
33328535|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
33328536|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
33328537|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
33417662|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
33328538|NCT04091490|Experimental|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
33037260|NCT02000999||Patients with bile duct strictures|
33037261|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
33037262|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
33037263|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
33037264|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
33037265|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
33037266|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
33037267|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
33037268|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
33037269|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
33037270|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
33037271|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
33037272|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
33037273|NCT02001116|Experimental|Pilot Hospitals|
33037274|NCT02001116|No Intervention|Control Hospitals|
33037275|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
33037276|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
33037277|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
33037278|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
33037279|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
33037280|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
33037281|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
33037282|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
33037283|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
33037284|NCT02001207||MICU patients|
33037285|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
33037286|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
33037287|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
33067637|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
33328539|NCT04707300|Experimental|Human T Lymphoid Progenitor (HTLP) injection|HTLP cellular product obtained after 7 days of culture of immune-selected CB
33328540|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
33328541|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
33328542|NCT05184816|Experimental|Deferoxamine (DFO)|This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from non-small cell lung cancer (NSCLC). Study objectives will include safety (1a/1b), pharmacokinetics (PK) and pharmacodynamics (PD) of IT-DFO (1a/1b), and preliminary anti-tumoral efficacy in patients with LM from NSCLC (1b).
33328543|NCT03843918|Experimental|Group A (Phase II only)|LAE001+ADT
33328544|NCT03843918|Placebo Comparator|Group B (Phase II only)|Placebo+ADT
33328545|NCT04084392|Active Comparator|Usual Care|Participants randomized to this arm will receive care as usual.
33328546|NCT04084392|Active Comparator|Bridge Clinic|Participants randomized to this arm will be referred to the Bridge Clinic to facilitate identification and referral to an outpatient provider for addiction treatment.
33328547|NCT05174754|Experimental|Inflammatory Bowel Disease Exercise Group|The exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
33328548|NCT05174754|Other|Inflammatory Bowel Disease Control Group|The IBD control group will be randomized to best medical therapy alone.
32740759|NCT05501795||WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
33037288|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
33328549|NCT05174754|No Intervention|Healthy Control Group|A group of healthy controls without inflammatory bowel disease will be included in the study for comparison of inflammatory markers including cytokine analysis and body composition.
33328550|NCT05667870||Newborns with CHD and their mothers|Consecutive newborns with CHD (n=100), who are diagnosed and born in the University Hospitals of Leuven and Ghent, are eligible for inclusion. Mothers (n=100) will be asked for participation in the study before delivery and written informed consent will be obtained. Umbilical cord blood of the ENVIRONAGE study (Hasselt University) will be used as a control group.
33328551|NCT05667870||(Young) adults with CHD - study 2|An age-stratified random sample of (young) adults with CHD, followed-up at the University Hospital of Leuven and the Ghent University Hospital will be included. Age strata for this study are: 18-24y; 25-34y; 35-44y; 45-54y; 55+. In total 500 patients will be included, 100 in each age stratum.
33328552|NCT05667870||(Young) adults with CHD - study 3|At the University Hospital of Leuven and Ghent University Hospital, patients with selected complex (Fontan operation; Systemic right ventricle), moderate (Tetralogy of Fallot; Coarctation of the aorta), and mild heart defects (isolated atrial septal defect; isolated ventricular septal defect) are eligible. For each type of heart defect 20 patients are enrolled. The overall sample will comprise 120 patients, who will be part of study 2 as well.
33037289|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
33328553|NCT05667870||Healthy controls|Data on healthy controls (n=500) will be retrieved from blood donors at the blood donation service of the Belgian Red Cross-Flanders. The healthy controls will be matched to the included adult patients (in study 2) based on sex and age.
33328554|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
33037290|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
33328555|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
33328556|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
33037291|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
33037292|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
33037293|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
33037294|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
33037295|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
33037296|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
33037297|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
33328557|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
33328558|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
33328559|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
33328560|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
33328561|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
33328562|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
33328563|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
33328564|NCT05670444|Active Comparator|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
33328565|NCT05670444|Placebo Comparator|placebo|Patients from the placebo group received three similar pills
33328566|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
33328567|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
33328568|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
33328569|NCT01200108|No Intervention|Placebo via AKITA|
33037298|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
33037299|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
33037300|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
33037301|NCT02001350||Resistant hypertension|
33037302|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
33037303|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
33037304|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
33037305|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
33037306|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
33037307|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
33037308|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
33037309|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
33037310|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
33037311|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
33037312|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
33037313|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
33037314|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
33037315|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
33037316|NCT02001441||No treatment|
33037317|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
33037318|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
33037319|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
33037320|NCT02001467|No Intervention|Control|No training is provided the control group participants.
33037321|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days~CGM = continuous Glucose Monitoring"
33037322|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
33037323|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
33037324|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
33037325|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
33037326|NCT02001532||Healthy controls|Sex and age-matched healthy controls
33037327|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
33037328|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
33328570|NCT01200186||Group 1|
33328571|NCT01200186||Group 2|
33328572|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
33328573|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
33328574|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
33328575|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
33328576|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
33328577|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
33328578|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
33328579|NCT05111808|Experimental|Methyl Blue|This group will receive intraoperative IV methyl blue
33037329|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
33037330|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
33037331|NCT02001584|Experimental|Healthy Volunteers|
33037332|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
33037333|NCT02001597||Surgery patients|
33037334|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
33037335|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
33037336|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
33037337|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
33037338|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.~Individuals will be genotyped at a total of 96 SNPs"
33037339|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
33037340|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
33037341|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
33037342|NCT02001675|Experimental|Volunteer healthy|
33037343|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
33037344|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
33037345|NCT02001727|Other|Control group|primarily unscreened group
33037346|NCT02001740|Placebo Comparator|lidocaine|frequency = once
33037347|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
33037348|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
33037349|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
33037350|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
33037351|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
33037352|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
33037353|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
33037354|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
33037355|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
33037356|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
33037357|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
33037358|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
33037359|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
33037360|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
33037361|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):~Carbohydrate 28.5 g~Protein 8 g as Whey Protein Isolate~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg~Vitamin D3 10 μg~Resveratrol 150 mg"
33328580|NCT01566786|Experimental|activated recombinant human factor VII|
33328581|NCT01566786|Placebo Comparator|Placebo|
33328582|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
33328583|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
33417663|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
33328584|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
33328585|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
33328586|NCT03843684|Experimental|Knee osteoarthritis patients|
33328587|NCT05759650|Experimental|Analyses of Kinematic and Kinetic parameters of movement|
33037362|NCT02001831|Placebo Comparator|Control|"Placebo control~Liquid nutrient support~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
33328588|NCT01200264|Experimental|apremilast for all subjects|
33328589|NCT04818970|Experimental|Phototherapy of narrow band ultraviolet Light B-Band NB-UVB|Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
33328590|NCT04818970|Placebo Comparator|Placebo - Light|Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
33328591|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
32740760|NCT05634681|Experimental|Intervention arm|
32740761|NCT05634681|Active Comparator|Control arm|
33037363|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
33037364|NCT02001844|Experimental|Trial Group|"Trial Group:~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
33037365|NCT02001857|Experimental|TachoSil|TachoSil
33037366|NCT02001857|No Intervention|No TachoSil|No TachoSil
33037367|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
33037368|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
33037369|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
33037370|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
33037371|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
33037372|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
33037373|NCT02001909|Experimental|Regorafenib|
33037374|NCT02001909|Experimental|Neomycin|
33037375|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
33037376|NCT02001922|No Intervention|Usual care|Usual COPD care
33037377|NCT02001935|Other|theophylline|
33037378|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
33037379|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
33037380|NCT02001974|Experimental|Group 1|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
33037381|NCT02001974|Experimental|Group 2|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
33037382|NCT02001974|Experimental|Group 3|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).
33037383|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
33037384|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
33037385|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
33037386|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
33037387|NCT02002026|Placebo Comparator|Control group|Conventional CS
33037388|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
33037389|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
33328592|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH initiating PAH therapy for the first time"
33328593|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
33328594|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients with PAH who are NOT undergoing changes in their treatment regime"
33328595|NCT04811872|Experimental|Intact umbilical cord milking (I-UCM)|
33328596|NCT04811872|Experimental|Cut-umbilical cord milking(C-UCM)|
33328597|NCT04811872|Experimental|Delayed Cord Clamping (DCC )|
33328598|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
33328599|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
33328600|NCT04801498||Healthy controls|Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
33328601|NCT04801498||Chronic pain patients not taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
33328602|NCT04801498||Chronic pain patients taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
33328603|NCT04040166|Other|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
33328604|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
33328605|NCT05669820|Active Comparator|Salovum|Salovum, an egg yolk powder will be orally at dose of 11 g 3 times daily.
33328606|NCT05669820|Placebo Comparator|Placebo|Placebo, an egg yolk powder will be orally at dose of 11 g 3 times daily.
33328607|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.~Tumours of any size will be eligible~Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist~Micro metastases (<=0.2mm) will be eligibile~Isolated tumour cells only (node negative i+/i-) are excluded"
33328608|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.~Min tumour size 2.1mm (T2)~Histological proof of involvement of at 1 lymph node, including micrometastases (<=0.2mm)"
33328609|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
33328610|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
33328611|NCT04799236|Active Comparator|Group 1: Oral Miltefosine|Miltefosine will be administered per os at 150 mg/day [50 mg tid] for 28 days. This is the standard regimen of miltefosine for persons >45 kg.
33417664|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
32740073|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
33037390|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
33037391|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
33037392|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
33037393|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
33037394|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
33037395|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
33037396|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
33037397|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
33037398|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
33037399|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
33037400|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
33037401|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
33037402|NCT02002156|Experimental|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
33037403|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
33037404|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
33328612|NCT04799236|Active Comparator|Group 2: Intravenous pentavalent antimony|IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days. Antimony will be diluted in 10 times its volume in 5%Dextrose in destilled water and injected IV in 20 minutes
33328613|NCT04799236|Experimental|Group 3: Intravenous liposomal amphotericin B|LAMB will be administered IV at 3 ampules [150 mg] on each of days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Three ampules is the individual dose suggested by Aronson et al [2016] and equals 2.5 mg/kg/dose for a 60 kg person. 15 doses of 3 ampules (total of 2250 mg) equals 37.5 mg/kg for a 60 kg person.
33037405|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
33037406|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
33037407|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
33037408|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
33037409|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
33037410|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
33037411|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
33037412|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
33037413|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
33037414|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
33037415|NCT02002286|Other|cART control|Continue current cART regimen
33037416|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
33037417|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
33037418|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
33037419|NCT02002338||Pterygium|Patients who were operated of pterygium
33037420|NCT02002351||Pulmonary disease|
33037421|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
33037422|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
33037423|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
33037424|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
33037425|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
33037426|NCT02002403|Placebo Comparator|Placebo|
33328614|NCT03985098|Experimental|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
33328615|NCT03985098|No Intervention|Control|usual care
33328616|NCT03796156|Experimental|Aspirin|75mg of non enteric coated or dispersible aspirin once daily added to usual medications
33328617|NCT03796156|No Intervention|Usual care|Usual medications only
33328618|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
33037427|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
33328619|NCT05759572|Experimental|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Apatinib and endocrine therapy.
33328620|NCT05759572|Active Comparator|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
33328621|NCT01202370|Experimental|AR-67|Phase 1 study
33328622|NCT01200576||1|healthy volunteers
33328623|NCT04720378|Experimental|Cohort 1|0.1 ml/kg IV ST266 once a day for 5 days
33037428|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
33037429|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
33037430|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
33037431|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
33037432|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
33037433|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
33037434|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
33037435|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
33037436|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
33037437|NCT02002442|Placebo Comparator|Saline|
33037438|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
33037439|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
33037440|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
33037441|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
33037442|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
33037443|NCT02002520||case group|patients undergo third molar surgery
33037444|NCT02002520||control group|subjects do not require surgery
33037445|NCT02002546||ED chest pain presenting patients|
33037446|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
33037447|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
33037448|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
33037449|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
33037450|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
33037451|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
33037452|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
33037453|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
33037454|NCT02002624|Experimental|PSI|Patient specific instrumentation
33037455|NCT02002637|Experimental|Latella Knee Implant System|
33037456|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
33037457|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
33037458|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
33037459|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
33037460|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
33037461|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
33328624|NCT04720378|Experimental|Cohort 2|0.25 ml/kg IV ST266 once a day for 5 days
33328625|NCT04720378|Experimental|Cohort 3|0.5 ml/kg IV ST266 once a day for 5 days
33107958|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
33107959|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .~Affiliated with a social security, consenting to the study"
33417665|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
33417666|NCT01359215||Control|Children who have never been anesthetized
33107960|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
33107961|NCT04641494|Placebo Comparator|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
33107962|NCT04641494|Active Comparator|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
33107963|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
33107964|NCT04641377|Experimental|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
33107965|NCT04641377|Active Comparator|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
33107966|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
33107967|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
33417667|NCT05189899|Active Comparator|With virtual reality|One hemodialysis session with virtual reality
33417668|NCT05189899|No Intervention|without virtual reality|One hemodialysis session without virtual reality
33107968|NCT04641455|Experimental|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
33107969|NCT04641455|Active Comparator|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
33107970|NCT04641455|Placebo Comparator|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
33107971|NCT04641455|No Intervention|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
33107972|NCT02898480|Experimental|Remote ischemic conditioning|
33417669|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
33107973|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
33107974|NCT04641182||No prone position|The control group will not be in prone position
33107975|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
33107976|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
33107977|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
33107978|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
33107979|NCT02898285|Active Comparator|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
33107980|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
33107981|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
33107982|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
33107983|NCT04640831|Experimental|GH001 dose A|
33107984|NCT04640831|Experimental|GH001 dose B|
33107985|NCT04640831|Experimental|GH001 dose C|
33107986|NCT04640831|Experimental|GH001 dose D|
33107987|NCT04640831|Experimental|GH001 Individualized Dosing|
33328626|NCT04720378|Experimental|Cohort 4|1.0 ml/kg IV ST266 once a day for 5 days
33328627|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
33037462|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
33037463|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
33037464|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
33037465|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
33037466|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
33037467|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
33037468|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
33328628|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
33328629|NCT04703140|Experimental|nasopharyngeal swabs|One patient will have 2 nasopharyngeal for PCR and COVIDISC
33328630|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
33328631|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
33328632|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
33328633|NCT03630952|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
33328634|NCT03630952|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
33328635|NCT03630952|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
33328636|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
33328637|NCT03952962|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
33360478|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
33037469|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
33037470|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
33037471|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
33037472|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
33037473|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
33037474|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
33037475|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
33037476|NCT02002923|Active Comparator|PVI only|
33037477|NCT02002923|Active Comparator|PVI+BT injection|
33037478|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
33037479|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
33037480|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
33067638|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
33067639|NCT00133055|Experimental|Treatment booklet and telephone coaching|
33037481|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
33037482|NCT02002988|Experimental|BT injection|
33037483|NCT02003001|Experimental|BT injection|
33037484|NCT02003027|Experimental|BT injection|
33037485|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
33037486|NCT02003066|Experimental|Standard|
33037487|NCT02003066|Active Comparator|Conservative|
33037488|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
33037489|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
33037490|NCT02003118|Experimental|AKR 202|
33037491|NCT02003118|Placebo Comparator|Placebo|
33037492|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
33037493|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
33037494|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
33037495|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
33037496|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
33037497|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
33037498|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
33037499|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
33037500|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
33037501|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
33037502|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
33037503|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
33037504|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
33037505|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
33037506|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
33037507|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
33037508|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
33037509|NCT02003339|Experimental|RMIs|
33037510|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
33037511|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
33037512|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
33037513|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
33328638|NCT03952962|Experimental|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
33360479|NCT02289118||Diagnostic Imaging|[18F]T807 imaging tracer.
33360480|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
33107988|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
33107989|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
33107990|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
33107991|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
33107992|NCT02898168|Experimental|WA|
33107993|NCT02898168|Active Comparator|Control|
33107994|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
33107995|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
33107996|NCT02897973||Controls|Able-bodied individuals without amputation
33107997|NCT04640207|Experimental|Facial skin treatment|Facial skin treatment using the Alma Hybrid system.
33107998|NCT04640129|Active Comparator|TDF group|tenofovir 300mg taken orally per day.
33328639|NCT05282160|No Intervention|Control Group|The control group (G1) will be composed of puerperal women over 18 years of age attended by Lucila Balalai Municipal Maternity in Londrina. Recruitment will be done through a chart review, which will include single-fetus primiparous that delivered on full term without intercurrence (between 37 and 42 weeks).
33328640|NCT05282160|Experimental|Epino Group|The study group (G2) will be composed of women over 18 years of age, primigravidae, between 30 and 32 weeks of gestation attended by the Basic Health Units of the central region of Londrina. Only those who agree to participate in the study and sign the free and informed consent form will be included.
33328641|NCT05032638|Experimental|Experimental Group|Subjects with motor impairment will work closely with an occupational therapist to identify a goal and select activities that they will work on at home to improve the function of their affected arm.
33328642|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
33328643|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
33328644|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
33328645|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
33037514|NCT02003430||<65 years old|20 patients less than 65 years of age
33037515|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
33037516|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
33037517|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
33037518|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
33037519|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
33037520|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
33037521|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
33328646|NCT03752866|Experimental|Portico™ Valve, Delivery System(s) and Loading Systems(s)|Implantation of the Portico ™ Valve using the Portico Delivery and Loading Systems
33328647|NCT03752866|Experimental|Portico™ Valve, FlexNav Delivery and Loading System(s)|Implantation of the Portico ™ Valve using the FlexNav Delivery and Loading Systems
33328648|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
33328649|NCT05759494||A|50 patients before use rapid diagnostic test (multiplex PCR filmArray)
33037522|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
33037523|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
33037524|NCT02003521||Intervension|Lung Flute
33037525|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
33037526|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
33037527|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
33037528|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
33037529|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
33037530|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
33037531|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
33037532|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .~Both arm will use institutional skin care protocol."
33037533|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.~Both arm will use institutional skin care protocol."
33037534|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
33037535|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
33037536|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
33037537|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
33037538|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
33037539|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
33037540|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
33037541|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
33037542|NCT02003716||No treatment|
33037543|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
33037544|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
33037545|NCT02003755|Experimental|Spastic CP|continuous passive motion training
33037546|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
33037547|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
33037548|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
33037549|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
33037550|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
33037551|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
33037552|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
33067640|NCT00133055|Other|Usual Care|
33067641|NCT00133094|Other|Arm 1|
33067642|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
33328650|NCT05759494||B|50 patients after use rapid diagnostic test (multiplex PCR filmArray)
33328651|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
33328652|NCT03730480|Experimental|Subjects with and without Diabetes test Contour Next and Contour TV3|All subjects test CONTOUR NEXT BGMS and CONTOUR TV3 BGMS
33328653|NCT05282628|Experimental|Building Better Brains and Behavior program (B4 Preterm)|Online learning modules completed sequentially and in conjunction with live coaching sessions led by a trained therapist.
33328654|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
33328655|NCT04571814|Experimental|Parent and child intervention|Both parent and child will receive a computerized intervention to reduce error sensitivity.
33328656|NCT04571814|Experimental|Parent intervention and child control|Parent will receive a computerized intervention to reduce error sensitivity and child will receive an active control (a computerized program targeting health behaviors).
33037553|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
33037554|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
33328657|NCT04571814|Experimental|Parent control and child intervention|Child will receive a computerized intervention to reduce error sensitivity and parent will receive an active control (a computerized program targeting health behaviors).
33328658|NCT04571814|Active Comparator|Parent and child control|Both parent and child will receive an active control (a computerized program targeting health behaviors).
33328659|NCT05008380|Experimental|Standard of care + prone positioning|Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
33328660|NCT05008380|No Intervention|Standard of care|Standard of care
33328661|NCT01200732|Active Comparator|Tadalafil|
33328662|NCT01200732|Placebo Comparator|placebo|
33037555|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
33328663|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
33328664|NCT01198938|Active Comparator|Melatonin|
32740074|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
33037556|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
33037557|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
33328665|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
33328666|NCT01566708|Experimental|treatment group|
33328667|NCT01566708|Active Comparator|waiting list group|
33328668|NCT01566708|Active Comparator|control group|
33328671|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
33037558|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
33037559|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
33037560|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
33037561|NCT02003950|Other|Chocolate pre-restriction|
33037562|NCT02003950|Other|Chocolate Baseline|
33037563|NCT02003950|Other|Chocolate post-restriction|
33037564|NCT02003950|Other|Salty Snacks|
33037565|NCT02003950|Other|Sweet Non-Chocolate Snacks|
33037566|NCT02003950|Other|Dried Fruit|
33037567|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
33037568|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
33037569|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
33037570|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
33328672|NCT05003778|Active Comparator|Traditional equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using traditional equipment (i.e., power racks, barbells, dumbbells, etc.)
33328673|NCT05003778|Experimental|Minimal equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.)
33037571|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
33037572|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
33037573|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
33037574|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
33037575|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
33037576|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
33037577|NCT02004054||optic neurotis|measure of pupil diameter
33037578|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
33037579|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
33328674|NCT05003778|Experimental|Minimal equipment resistance and endurance training with blood flow restriction|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.) while wearing upper- and lower-body blood-flow restriction cuffs
33328675|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
33360481|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
33037580|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
33037581|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
33037582|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
33037583|NCT02004119|Placebo Comparator|Placebo|
33037584|NCT02004119|Experimental|KHK4577|
33037585|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events~Gratitude letter~Performing acts of kindness~Using personal strengths~Enjoyable and meaningful activities:~Repeating one of the previous exercises."
33037586|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Daily Events~Health Events~Morning and Evening Events~Interactions with Others~Leisure Time Activities~Repeating one of the previous exercises."
33037587|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
33037588|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
33037589|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
33037590|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
33037591|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
33037592|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
33037593|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
33037594|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
33037595|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
33037596|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
33037597|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
33037598|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
33037599|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once~2nd administration - DW1029M600mg PO Once~3rd administration - DW1029M1200mg PO Once"
33037600|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once~2nd administration - DW1029M1200mg PO Once~3rd administration - DW1029M300mg PO Once"
33037601|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once~2nd administration - DW1029M300mg PO Once~3rd administration - DW1029M600mg PO Once"
33037602|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
33037603|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
33037604|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
33037605|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
33037606|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
33037607|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
33037608|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
33037609|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
33037610|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
33037611|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
33037612|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
33037613|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
33037614|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
33037615|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
33328676|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
33328677|NCT04525872|Experimental|Premature infants|Premature infants who are expected to receive TPN for a minimum of 5 days and infants with gastrointestinal surgical problems (e.g., ileal atresia, gastroschisis), expected to receive TPN for a minimum of 5 days
33328678|NCT05282082||Patients at the moment of their admission to the hospital in one of the three cities|Swabs will be taken from patients who are willing to participate.
33328679|NCT05282082||"Healthy volunteers living in high-risk areas in one of the three cities."|Swabs will be taken from healthy volunteers who are willing to participate.
33328680|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
33328681|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
33328682|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
33328683|NCT04988490||Daily cannabis users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report daily cannabis use
33328684|NCT04988490||Cannabis non-users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report no cannabis use
33328685|NCT04979676|Experimental|Cognitive Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
33360482|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
33360483|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:~MSC+prednisone+cyclosporine;~MSC+prednisone+tacrolimus;~MSC+prednisone+mycophenolate mofetil."
33360484|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:~Placebo+prednisone+cyclosporine;~Placebo+prednisone+tacrolimus;~Placebo+prednisone+mycophenolate mofetil."
33037616|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
33037617|NCT02004444||Untreated|10 untreated patients
33037618|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
33037619|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
33037620|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
33037621|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
33037622|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
33037623|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
33037624|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
33037625|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
33037626|NCT02004509|Active Comparator|anticoagulant|Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
33037627|NCT02004509|No Intervention|Control|Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
33037628|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
33037629|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
33037630|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
33037631|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
33037632|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
33037633|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
33037634|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
33037635|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
33037636|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
33417670|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
33417671|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
33417672|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
33417673|NCT01359527||Hip Resurfacing|
33037637|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :~Collagenase ...0.6 U~Vehicle qs ... 1 g~Presentation:~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
32740075|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
32740076|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
33037638|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :~Collagenase ... 0.6 U~Vehicle qs ... 1 g~Presentation~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
33037639|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
33037640|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
33037641|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
33037642|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
33037643|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
33037644|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
33037645|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
33037646|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
33037647|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
33037648|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
33037649|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
33037650|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
33037651|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
33037652|NCT02004743|Other|Control|Treatment as Usual
33037653|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
33037654|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
33037655|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
33037656|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
33037657|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
33067643|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
33067644|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
33067645|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
33417674|NCT01359527||Total Hip Arthroplasty|
33417675|NCT03913195|Experimental|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
33037658|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
33037659|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
33037660|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
33037661|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
33037662|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
33037663|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
33037664|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
33037665|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
33037666|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
33037667|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
33037668|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
33037669|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
33037670|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
33037671|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
33037672|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
33037673|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
33037674|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
33037675|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
33037676|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
33037677|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
33037678|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
33037679|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
33037680|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
33037681|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
33037682|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
33037683|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
33037684|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
33037685|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
33037686|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
33037687|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
33037688|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
33037689|NCT02005120|Experimental|Arm A|Bevacizumab
33037690|NCT02005120|Experimental|Arm B|recombinant human endostatin
33037691|NCT02005133||VEGF inhibitor naïve|
33037692|NCT02005133||VEGF inhibitor prior treated|
33037693|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
33037694|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
33037695|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
33328686|NCT04979676|Experimental|Compassion-focused Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
33328687|NCT04979676|Experimental|Acceptance and Commitment Therapy|Experimental group subjected to active individual psychotherapy based on developing skills for acceptance, defusing, and focusing on the present moments, which in turn sustain acting in social events in line with ones valued actions instead of prioritizing the avoidance of negative internal experiences). Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
33328688|NCT04979676|Placebo Comparator|Waiting-list control|Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
33328689|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
33328690|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
33037696|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
33328691|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
33328692|NCT04497012|Active Comparator|Low Iron Sulfate Supplementation|Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
33360485|NCT03927235|Sham Comparator|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
33037697|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
33037698|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
33037699|NCT02005198||Survey|
33037700|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
33037701|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
33037702|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
33037703|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
33037704|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
33037705|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
33037706|NCT02005302|Experimental|Vitamin D2 Treatment|
33037707|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
33037708|NCT02005302|Experimental|low protein diet|
33037709|NCT02005302|Active Comparator|normal protein diet|
33037710|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
33037711|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
33037712|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
33037713|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
33037714|NCT02005341|Active Comparator|Autograft bone|
33037715|NCT02005341|Experimental|nanOss with bone marrow aspirate|
33037716|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
33067646|NCT00133172|Active Comparator|2|Standard steroid maintenance
33067647|NCT00842283||dermatologic diseases|skin tissue sample
33067648|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
33360486|NCT03927235|Experimental|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
33360487|NCT03927235|Experimental|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
33328693|NCT04497012|Active Comparator|High Iron Sulfate Supplementation|Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
33328694|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
33328695|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
33037717|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
33037718|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
33037719|NCT02005380||Text-based Task|This group is required to do the text-based task
33037720|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
33328696|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
33328697|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
33328698|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
33328699|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
33360488|NCT03927235|Experimental|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
33037721|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
33037722|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
33037723|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
33037724|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
33037725|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
33037726|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
33037727|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
33037728|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
33037729|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
33037730|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
33037731|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
33037732|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
33037733|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
33037734|NCT02005523|Experimental|RNS60|
33037735|NCT02005523|Placebo Comparator|Saline|
33037736|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
33037737|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
33037738|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
33067649|NCT00133211|Experimental|2|
33067650|NCT00133250|Experimental|A|Abciximab
33067651|NCT00133250|Placebo Comparator|B|Heparin Sodium
33067652|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
33037739|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
33328700|NCT03792516|Experimental|Artesunate ointment 40%, 1 cycle|Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
33328701|NCT03792516|Experimental|Artesunate ointment 40%, 2 cycles|Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
33328702|NCT03792516|Experimental|Artesunate ointment 40%, 3 cycles|Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
33328703|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
33328704|NCT03744156|Experimental|Cognitive Behavioral Treatment-Insomnia|Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
33328705|NCT03744156|Experimental|Sleep Hygiene Education|Sleep Hygiene Education. 8 Session treatment focusing on sleep hygiene education.
33328706|NCT01202838||Composite Implant|Subject receiving composite implant
33328707|NCT03840798||Pretest/Baseline period|
33037740|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
33037741|NCT02005640||MSCT-based prothesis sizing|
33328708|NCT03840798||Posttest/go-live period|
33037742|NCT02005640||Echocardiographic-based prothesis sizing|
33037743|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
33037744|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
33037745|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
33037746|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
33037747|NCT02005679|Experimental|deaf persons with potential dementia|
33037748|NCT02005705|Active Comparator|Outpatient|
33037749|NCT02005705|Active Comparator|Inpatient|
33037750|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
33037751|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
33037752|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
33037753|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
33037754|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
33037755|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
33037756|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
33037757|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
33037758|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
33037759|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
33037760|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
33037761|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
33037762|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
33037763|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
33037764|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
33037765|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
33037766|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
33037767|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
33037768|NCT02005822|No Intervention|Control|"Refusal control group:~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.~Historical control group:~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
33037769|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support at facility~Weekly support groups provided in clinic~Phone call, SMS, or home visit for each missed appointment"
33067653|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
33067654|NCT00144534|Experimental|1|
33067655|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
33328709|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
33328710|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
33328711|NCT01202916||Congenital Heart Disease|
33037770|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support in community prior to each visit~Monthly support groups in community~Home visits for each missed appointment"
33037771|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
33328712|NCT01202916||Healthy children|
33328713|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
33328714|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
33037772|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
33037773|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
33037774|NCT02005848|Placebo Comparator|Placebo|Placebo
33037775|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.~After that platelet gel will be loaded on the top of implant"
33037776|NCT02005874||Dry eye|
33037777|NCT02005874||Non-dry eye|
33328715|NCT03674112|Experimental|A: P+H IV Followed by PH FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
33360489|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
33037778|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
33037779|NCT02005900|Placebo Comparator|PLACEBO|
33037780|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
33037781|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
33037782|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
33037783|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
33037784|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
33037785|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
33037786|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
33037787|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
33037788|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
33037789|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
33037790|NCT02005991|Experimental|PF-05212377 70 mg|
33037791|NCT02005991|Experimental|PF-05212377 20 mg|
33037792|NCT02005991|Experimental|PF-05212377 10 mg|
33037793|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
33037794|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
33037795|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
33037796|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
33037797|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
33037798|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
33067656|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
33067657|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
33360490|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
33360491|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
33037799|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
33037800|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
33360492|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
33360493|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
33037801|NCT02006134||ADULT VASCULITIS/ COHORT 1|Adult patients in this cohort are those at or near the time of diagnosis of GPA, MPA, EGPA or unclassified vasculitis that are participants in DCVAS. Clinical data and blood (RNA, DNA) will be collected at the time-of-diagnosis only.
33037802|NCT02006134||ADULT VASCULITIS / COHORT 2|Adult patients in this cohort are those individuals that are participants in DCVAS and have any form of vasculitis. Clinical data and blood (DNA) collected at the time-of-diagnosis will be used for study.
33037803|NCT02006134||HEALTHY CHILDREN / PEDIATRIC CONTROL|Participants in this cohort are otherwise healthy children with no history of inflammatory disease. Children will provide a one time donation of blood (RNA, serum) and urine.
33037804|NCT02006134||HEALTHY ADULTS / ADULT CONTROL|Participants in this cohort are otherwise healthy adults with no history of inflammatory disease. Adults will provide a one time donation urine and will provide blood (RNA, serum) as many as 4 times.
33037805|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
33037806|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
33037807|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
33037808|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
33037809|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
33037810|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
33037811|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
33037812|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
33037813|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
33037814|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
33037815|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
33037816|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
33037817|NCT02006290|Experimental|1|
33037818|NCT02006290|Placebo Comparator|2|
33037819|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
33037820|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
33037821|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
33037822|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
33037823|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
33037824|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
33037825|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
33037826|NCT02006368|Experimental|Storage Age|
33037827|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
33037828|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
33037829|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
33037830|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
33037831|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
33037832|NCT02006433|Experimental|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
33037833|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
33037834|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
33037835|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
33037836|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
33037837|NCT02006498|Experimental|Sillymarin|Active component study medication
33037838|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
33037839|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
33037840|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
33037841|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
33037842|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
33037843|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
33037844|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
33037845|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
33037846|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
33037847|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
33037848|NCT02006615|Experimental|High frequency rTMS plus fNIRS|rTMS with neuroimage assessment of functional near infrared spectroscopy
33037849|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
33037850|NCT02006615|Experimental|High frequency rTMS|High frequency rTMS to modulate brain areas
33037851|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
33037852|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
33037853|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
33037854|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
33037855|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
33037856|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
33037857|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
33037858|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
33037859|NCT02006797|No Intervention|control|usual care
33037860|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
33037861|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
33037862|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
33037863|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
33037864|NCT02006862||olanzapine, schizophrenia|
33037865|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
33037866|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
33037867|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
33037868|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
33037869|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
33037870|NCT02006914||Placebo|HIV+ and insulin resistant
33037871|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
33037872|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
33037873|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
33037874|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
33037875|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
33037876|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
33037877|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
33037878|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
33037879|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
33037880|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
33037881|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
33037882|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
33037883|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
33067658|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
33067659|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
33067660|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
33067661|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
33067662|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
33067663|NCT00144612|Experimental|1|
33067664|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
33067665|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
33067666|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
33067667|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
33067668|NCT00144651|Experimental|1|
33067669|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
33067670|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
33067671|NCT00404391|Placebo Comparator|placebo|
33067672|NCT04726904|Other|Conventional lead placement|The cadaver is placed in the prone position. The exact location for insertion of the needle is defined with the conventional technique.
33067673|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
33067674|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
33067675|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
33067676|NCT00133601|Experimental|1|CBT-1
33067677|NCT00133601|No Intervention|2|Control Group
33107999|NCT04640129|Experimental|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
33108000|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
33108001|NCT04640324|No Intervention|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
33108002|NCT04640324|Active Comparator|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
33108003|NCT04640324|Experimental|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
33108004|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
33108005|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
33108006|NCT04640285|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
33108007|NCT04640285|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
33108008|NCT04640285|Experimental|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
33108009|NCT04640285|Experimental|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
33108010|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
33108011|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
33108012|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
33108013|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
33108014|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
33108015|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
33328716|NCT03674112|Experimental|B: PH FDC SC Followed by P+H IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
33328717|NCT04427202|Other|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
33108016|NCT02897739||Health Volunteers|Participants who have normal hearts.
33108017|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
33108018|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
33108019|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
33108020|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
33328718|NCT05670366|Other|Physically active participants|There is only one study arm, namely all participants are subjected to the same interventions.
33108021|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
33328719|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
33108022|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
33108023|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
33108024|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
33108025|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
33108026|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
33108027|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
33108028|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
33360494|NCT01221493|Experimental|Cryo biospy|
33108029|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
33108030|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
33108031|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
33108032|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
33108033|NCT00559559|Other|Control Group|Patient Notifier turned OFF
33108034|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
33108035|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
33108036|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
33108037|NCT02897661|Experimental|Early WMT and EEN|WMT (day1), EEN (day1-15)
33328720|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
33328721|NCT05281926|Experimental|Poly-ICLC|Hiltonol is a poly-ICLC developed by the Oncovir, Inc. A phase I study of hiltonol monotherapy in solid tumors was completed (NCT01984892). Clinical trials of hiltonol plus ICIs are undergone in various type cancers (NCT03721679, NCT02834052).
33108038|NCT02897661|Experimental|Late WMT and EEN|WMT (day8), EEN (day1-15)
33108039|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
33108040|NCT03454685||Healthy subjects|healthy subjects
33108041|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
33108042|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
33108043|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
33328722|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
33328723|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
33108044|NCT04640090|Experimental|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
33108045|NCT02897622|Other|Case management|Case management
33108046|NCT04639739|Experimental|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
33108047|NCT04639700|Experimental|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
33108048|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
33108049|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
33108050|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
33328724|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
33328725|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
33328726|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
33328727|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
33108051|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
33328728|NCT01199172|No Intervention|Control|
33328729|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
33328730|NCT01199172|Experimental|VH + VP|
33328731|NCT05282472|Experimental|with surgical mask|all participants who were applied CPET with surgical mask
33108052|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
33108053|NCT04206631|Placebo Comparator|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
33328732|NCT05282472|Active Comparator|without surgical mask|all participants who were applied CPET without surgical mask
33108054|NCT04206631|Active Comparator|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
33328733|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
33328734|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
33037884|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
33328735|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
33328736|NCT04408170||Work Stream A|Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.
33328737|NCT04408170||Work Stream B|Known COVID-positive and/or COVID-negative community testing
33328738|NCT04408170||Work Stream C|Undifferentiated community testing
33328739|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
33037885|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
33037886|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
33037887|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
33037888|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
33037889|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
33037890|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State~Diclofenac potassium 50 mg"
33037891|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg~Diclofenac potassium 50 mg"
33037892|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
33037893|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
33037894|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
33037895|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
33037896|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
33037897|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
33037898|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
33037899|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
33037900|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
33037901|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
33037902|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
33067678|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
33067679|NCT04726917||Patients with COPD|Patients qualified for 3-week in-hospital pulmonary rehabilitation
33328740|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
33037903|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);~were admitted to the hospital during (part of) the infection episode.~Date of entry into cohort: date of index culture of infection episode"
33328741|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
33328742|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
33328743|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
33328744|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
33328745|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
33328746|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
33328747|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
33328748|NCT04934436|Experimental|Intervention Group|According to their chronotype, the intervention group will then be given sleeping glasses and earplugs at night for those who are in the morning type, and till afternoon during the day for those who are in the evening type. Moreover, patients in the intervention group will be given 5000 Lux daylight during the time they are awake depending on their circadian rhythms. An Android smartwatch will be used to determine patients' sleeping and waking up times, sleep quality and sleep depth. Nursing care will also be provided when patients are awake per their chronotype. Before the study, intensive care nurses will be trained to provide appropriate care according to the circadian rhythm and chronotype to have consistency in the care. Patients will be observed for three days and during this time cortisone and melatonin levels will be checked in both control and intervention groups. At the end of the third day, surveys will be conducted once again with both groups.
33328749|NCT04934436|No Intervention|Control Group|All surveys that will be used in the study will be applied to both groups during the first and last interviews. The control group will not have any interventions, only the standard ICU care to be provided.
33328750|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
33328751|NCT03840564||control group|the analyzes will be done at the central laboratory
33328752|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
33328753|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
33328754|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
33328755|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
33328756|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
33037904|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.~Date of cohort entry: date of index culture of matched infected patient"
33037905|NCT02007395||colonoscopy population|
33037906|NCT02007408|Placebo Comparator|Placebo group|
33037907|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
33037908|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
33037909|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
33037910|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
33037911|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
33108055|NCT05510128|Experimental|Management with the protocol|"Patients who participate in the study in the experimental arm benefit from an adapted management, which falls under the application of the national cooperation protocol.~This management may lead to the dispensing of an antibiotic by the pharmacist himself."
33328757|NCT04353258|Experimental|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
33108056|NCT05510128|No Intervention|Standard care|"Patients participating in the study in the control arm will benefit from a management comparable to the current one. In addition to a reminder of the hygienic and dietary rules by the pharmacist, the patient may be offered a drug indicated for improving urinary comfort.~The pharmacist should also remind the patient that she can consult a doctor, especially in case of non relief or aggravation of symptoms."
33108057|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
33108058|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
33108059|NCT05496634|Experimental|Exercise Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process. Individuals in the exercise group also participated in pilates sessions that lasted 50 minutes, 2 days a week for 8 weeks.
33108060|NCT05496634|Experimental|Control Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process.
33108061|NCT05472961|Experimental|Within Subjects Experimental Design|All participants are tested in all conditions.
33108062|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
33108063|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
33108064|NCT04639856|Active Comparator|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
33328758|NCT04353258|Active Comparator|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
33328759|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
33108065|NCT04639856|Active Comparator|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
33108066|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
33108067|NCT04639349|Experimental|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
33108068|NCT04639349|Other|control group|The control group will not be trained
33108069|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
33328760|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~Early so called NEWS-monitoring (measuring of standard physiological parameters);~Early start of antibiotics;~Rapid (within 6 hours) start of operation;~Goal-directed fluid therapy;~Intensified post-operative monitoring;~The presence of both surgical and anesthesiological specialists in the early care of the patients."
33108070|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
33108071|NCT04639544|Placebo Comparator|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
33108072|NCT04639544|Experimental|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
33108073|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
33108074|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
33108075|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
33108076|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
33108077|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
33108078|NCT04639232|Placebo Comparator|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
33108079|NCT04639232|Experimental|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
33108080|NCT04639232|Experimental|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
33328761|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
33328762|NCT01201512||Temporomandibular disorders|
33328763|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
33037912|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
33037913|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
33037914|NCT02007460|Experimental|Exercise leg|
33037915|NCT02007460|No Intervention|Control leg|
33037916|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
33037917|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
33037918|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
33037919|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
33037920|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
33037921|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
33037922|NCT02007525|Experimental|Yoga intervention|
33037923|NCT02007525|No Intervention|Wait list control|
33037924|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
33037925|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
33037926|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
33037927|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
33037928|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
33037929|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
33037930|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
33037931|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
33037932|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
33037933|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
33037934|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
33037935|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
33037936|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
33037937|NCT02007642||No study treatment|
33037938|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
33037939|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
33037940|NCT02007668|No Intervention|Control|This participants will not receive intervention
33037941|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
33037942|NCT02007681|No Intervention|Control|Regular free week with no changes performed
33037943|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
33037944|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
33037945|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
33037946|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
33328764|NCT01199328|Active Comparator|1|Aspirin 81 mg
33037947|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
33037948|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
33328765|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
33328766|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
33328767|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
33328768|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
33328769|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
33360495|NCT02289274|Experimental|NVP-1203|NVP-1203
33360496|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
32740077|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
33037949|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
33037950|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
33037951|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
33037952|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
33037953|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
33037954|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
33037955|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
33037956|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
33037957|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
33037958|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
33037959|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
33037960|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
33037961|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
33037962|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
33037963|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
33037964|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
33037965|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
33067680|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
33067681|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
33067682|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
33037966|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
33037967|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
33037968|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
33037969|NCT02007902||Very preterm babies|Observational model: cohort
33037970|NCT02007915|Experimental|Pamidronate Disodium|
33037971|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
33037972|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
33037973|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
33037974|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
33037975|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
33037976|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
33037977|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
33037978|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
33037979|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
33037980|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine~Etoposide~Cytarabine~Melphalan~HDT will be followed by an Autologous Stem Cell Transplantation"
33037981|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
33037982|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
33037983|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
33037984|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
33037985|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
33037986|NCT02008071|Experimental|Daily step goal financial incentive|
33037987|NCT02008071|Active Comparator|Control, Standard of Care|
33037988|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
33037989|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
33037990|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
33037991|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
33037992|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
33037993|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
33037994|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
33037995|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
33067683|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
33067684|NCT00144846|Other|Arm 1|
33067685|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
33067686|NCT00144885|No Intervention|1|
33067687|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
33067688|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
33067689|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
33328770|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
33328771|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
33328772|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
33328773|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
33328774|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
33328775|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
33328776|NCT05281848|Active Comparator|Smoker-Periodontitis; Non-surgical periodontal treatment|
33328777|NCT05281848|Active Comparator|Nonsmoker-Periodontitis;Non-surgical periodontal treatment|
33328778|NCT05281848|No Intervention|Healthy|
33328779|NCT05669430|Experimental|Part A - Dose Escalation|Part A involves a 3 + 3 dose escalation scheme to evaluate safety and dose limiting toxicities (DLTs) and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 (RP2D) of GV20-0251.
33328780|NCT05669430|Experimental|Part B - Cohort Expansion|Part B is a cohort expansion in which eligible patients will be treated at the MTD of GV20-0251 to further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of GV20-0251 as well as to evaluate anti-tumor activity in patients with selected malignancies.
33328781|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
33037996|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
33037997|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
33037998|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
33328782|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
33328783|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
33037999|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
33328784|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
33328785|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
33328786|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
33328787|NCT03840408|Active Comparator|Surgery|
33038000|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
33328788|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
33328789|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
33328790|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
33328791|NCT01203228|Active Comparator|A|Myeloablative conditioning
33328792|NCT01203228|Experimental|B|Reduced Intensity Conditioning
33328793|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
33328794|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
33328795|NCT01204008|Experimental|CS|conservative discectomy
33328796|NCT01204008|Active Comparator|AS|
33328797|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
33328798|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
33328799|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
33328800|NCT04253106|Experimental|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
33328801|NCT04253106|Active Comparator|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
33328802|NCT04222998|Experimental|Intervention group|Household receives the home-based growth chart
33328803|NCT04222998|Active Comparator|Control group|Household does not receive the home-based growth chart
33328804|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
33328805|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
33328806|NCT01201668||Persistent Tooth Pain|
33328807|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
33328808|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
33038001|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
33328809|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
33328810|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
33328811|NCT04208256|Sham Comparator|Energy Neutral|Bottled water (300 ml) with added fruit punch-flavored non-nutritive sweetener (aspartame) will be used as the energy neutral stimulus.
33328812|NCT04208256|Active Comparator|Energy Surplus|300ml fruit punch-flavored Glucola (75-gram[g], Azer Scientific) will be used as the energy surplus stimulus.
33328813|NCT05669508|Experimental|Treatment Arm|Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing functional task practice in occupational therapy sessions.
33038002|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
33328814|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
33328815|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
33038003|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
33038004|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
33038005|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
33038006|NCT02008201|No Intervention|observational|No dose
33038007|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
33038008|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
33038009|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
33038010|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
33038011|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
33038012|NCT02008266||Patients with Rheumatoid Arthritis|
33038013|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
33038014|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
33038015|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
33038016|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
33038017|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
33038018|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
33038019|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
33038020|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
33038021|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
33038022|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
33038023|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
33038024|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
33038025|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
33328816|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
33328817|NCT05121324|Experimental|Intervention|This arm will be exposed to the study intervention: a standardized seizure protocol.
33038026|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
33038027|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
33038028|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
33328818|NCT05121324|Active Comparator|Control|This arm will be exposed to the emergency medical services (EMS) agency's existing seizure protocol; this is the control arm
33328819|NCT01204086|Experimental|venlafaxine|
33328820|NCT01204086|Experimental|fluoxetine|
33328821|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
33038029|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
33038030|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
33038031|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
33038032|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
33038033|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
33038034|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
33038035|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
33038036|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
33038037|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
33038038|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
33038039|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
33038040|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
33038041|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
33038042|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
33038043|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
33038044|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
33038045|NCT02008539|Experimental|treatment arm|
33038046|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
33038047|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
33038048|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
33038049|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
33038050|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
33038051|NCT02008604||Stroke patients|
33038052|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
33038053|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
33038054|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
33038055|NCT02008630|No Intervention|Control|Control group with treatment as usual
33038056|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
33038057|NCT02008643|Active Comparator|children with chronic diseases|
33038058|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
33038059|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions~Gustatory sensitivity test using Taste strips~Blood sampling~Questionnaires"
33038060|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
33038061|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
33038062|NCT02008695|Active Comparator|adult microfinance|adults receive loan
33038063|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
33038064|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
33038065|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
33038066|NCT02008721|Placebo Comparator|Placebo|Placebo
33328822|NCT03840096|No Intervention|Control|
33328823|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
33328824|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
33360497|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
33360498|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
33038067|NCT02008734|No Intervention|Control|
33038068|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
33038069|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
33038070|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
33038071|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
33038072|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
33038073|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
33038074|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
33038075|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
33038076|NCT02008812|Experimental|Ad sensor|virus detection
33038077|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
33038078|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
33038079|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
33038080|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
33038081|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
33038082|NCT02008864|Placebo Comparator|Placebo|Wheat
33038083|NCT02008864|Active Comparator|Senna|Senna
33038084|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
33038085|NCT02008955|Experimental|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
33038086|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
33038087|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
33038088|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
33038089|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
33038090|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
33038091|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
33038092|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.~Immunohistochemistry will look for specific markers of disease in your DNA.~RNA sequencing will be used to help doctors and scientists understand how your genes are working.~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
33038093|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
33038094|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
33038095|NCT02009033|Experimental|Ringer's lactate|Fluid therapy during operation
33038096|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
33038097|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
33038098|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
33038099|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
33038100|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
33038101|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
33038102|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
33038103|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
33038104|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
33038105|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
33038106|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
33038107|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
33038108|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
33038109|NCT02009189|Placebo Comparator|Control|Saline flush
33038110|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
33038111|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
33038112|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
33038113|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
33038114|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
33038115|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
33038116|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
33038117|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
33038118|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
33038119|NCT02009241|No Intervention|Control|
33038120|NCT02009254|Experimental|Mashed Potatoes (as produced)|
33038121|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
33038122|NCT02009254|Experimental|glucose control (50 g)|
33038123|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
33038124|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
33038125|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
33038126|NCT05778903|Active Comparator|Ultrasound guided Suprazygomatic Maxillary Nerve Block|An ultasound guided SMNB is admitted on one half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
33038127|NCT05778903|Active Comparator|Landmark guided Suprazygomatic Maxillary Nerve Block landmark|A langmark guided SMNB is admitted on the other half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
33038128|NCT05778890|Experimental|Intervention group|The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Intervention group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form. These exercises were not given to the control group.
33038129|NCT05778890|Active Comparator|control group|Control group is physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. This group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
33038130|NCT05778877|Experimental|Cohort 1 - Adolescents|IV infusion of MMA-101 in the first patient on Day 1 IV infusion of SEL-302 in the second and third patient on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Adolescents ages ≥12 and <18
33038131|NCT05778877|Experimental|Cohort 2 - Children|IV infusion of SEL-302 in all patients on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Children ages ≥3 and <12
33038132|NCT05778864|Experimental|LY3473329 (Control)|LY3473329 administered orally to participants with normal renal function
33038133|NCT05778864|Experimental|LY3473329 (Mild Renal Impairment)|LY3473329 administered orally to participants with mild renal impairment
33038134|NCT05778864|Experimental|LY3473329 (Moderate Renal Impairment)|LY3473329 administered orally to participants with moderate renal impairment
33038135|NCT05778864|Experimental|LY3473329 (Severe Renal Impairment)|LY3473329 administered orally to participants with severe renal impairment
33038136|NCT05778864|Experimental|LY3473329 (End-Stage Renal Disease)|LY3473329 administered orally to participants with end-stage renal disease
33038137|NCT05778838|Placebo Comparator|Control|Will receive IV vasopressor infusion only
33038138|NCT05778838|Active Comparator|Midodrine|Will receive oral midodrine 10 mg/ 8 hours in addition to IV vasopressor infusion till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours).
33328825|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
33328826|NCT01567176|Other|Single Arm|
33038139|NCT05778825|Experimental|Oral Minoxidil|Patients receive oral minoxidil at a dose of 0.01 (<40kg) and 0.02 (≥40kg) mg/kg/day for 8 months
33328827|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
33328828|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
33038140|NCT05778825|Active Comparator|Placebo followed by oral Minoxidil|Patient receive placebo for 4 months followed by oral minoxidil for 4 months
33038141|NCT05778812|Experimental|Full Sleep|"With Full Sleep, the app provides daily lessons about sleep and skills that can help with sleep. In the app, participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they additionally complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach. The intent of coach access is for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST (Radar Enabled Sensing Technology) device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
33038142|NCT05778812|Active Comparator|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
33038143|NCT05778786|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (test then control) with a washout period of 7+/-2 days duration between wear periods.
33038144|NCT05778786|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (control then test) with a washout period of 7+/-2 days duration between wear periods.
33038145|NCT05778773||TAVR|"Patients undergoing aortic valve replacement through the Transcatheter Aortic Valve Replacement procedure.~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
33038146|NCT05778773||AVR|"Patients undergoing aortic valve replacement through conventional open-heart surgery (sternotomy and biological valve implantation).~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
33038147|NCT05778760|Active Comparator|Retinol|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
33038148|NCT05778760|Experimental|Adapinoid|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
33038149|NCT05778747|Experimental|Intervention|A total of 20 patients with HF and 20 caregivers (n= 40) who have at least mild depressive symptoms (Patient Health Questionnaire 9 [PHQ-9] score = 5) will be randomly assigned to the intervention or usual care group stratified by patient and caregiver groups (Figure 1). Only participants in the intervention will be asked to attend the 12-week sessions (two sessions per week; a total of 24 sessions in 12 weeks) via video conferencing (i.e., ZOOM). The short-term intervention efficacy will be assessed at the following week of the completion of 12-weeks sessions. Primary psychological outcomes include depressive symptoms, anxiety, stress, and quality of life. Primary physical outcomes include physical activity level, sleep quality, and perceived symptoms.
33038150|NCT05778747|No Intervention|Usual Care|Participants in the usual care group will also receive the printed information and links to the AHA's Life's Simple 7 program without explicit skills and training, including education and stress management. We will encourage stress management by watching and practicing yoga programs by providing a yoga mat.
33038151|NCT05778734|Other|Treatment group|"For the R00 phase: CM-PST treatment group will receive CM-PST intervention, which will consist of 8 sessions total, delivered remotely via Zoom videoconferences in individual sessions over 12 weeks. The first 4 sessions will be delivered weekly, and the remaining 4 sessions every other week. CM-PST will teach participants problem-solving skills using a structured 5-step method. In addition, participants will receive incentives for alcohol abstinence and submission of urine samples twice/wk.~K99 phase participants will also receive CM-PST intervention."
33067690|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
33328829|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
33328830|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
33328831|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
33328832|NCT01201824|Other|1|
33328833|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
33328834|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
33328835|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
33038152|NCT05778734|Other|Control group|For the R00 phase: Participants in CM-only control will receive incentives for alcohol abstinence and submission of urine samples twice/wk. Participant incentives will start at a $10 gift card, with a $5 increase each subsequent measurement point on which alcohol is not detected or reported, to a maximum of $25, but no gift card on days when alcohol use is detected or reported, and the gift card reinforcer value will be re-set to $10.
33038153|NCT05778721||adult patients with a diagnosis of idiopathic hypersomnia|adult patients with a diagnosis of idiopathic hypersomnia according to the International Classification of Sleep Disorders (ICSD 3) criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.
33038154|NCT05778708|Experimental|Tai-Chi intervention group|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted.
33038155|NCT05778708|Experimental|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises.
33038156|NCT05778708|No Intervention|Self-management control group|Patients in this group will receive written information regarding the recommended levels of exercise (i.e., at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic exercise every week) that they can perform at home (self-management) while continuing to receive their standard treatment. They will also be provided with a daily exercise log to record their exercise type, frequency, and intensity.
33038157|NCT05778695|Experimental|Parkinson Disease|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) three times daily (TID) as tolerated. KE dose will be titrated down to a tolerated level if necessary.
33038158|NCT05778695|Experimental|Parkinson Disease Dementia/Lewy Body Dementia|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
33038159|NCT05778695|Experimental|Healthy Controls|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
33038160|NCT05778682|Experimental|Suction based protocol|Weaning protocol based on suctioning frequency. Once the weaning of mechanical ventilation, the patients in this arm will be on high-flow nasal canula. The canula will be remove if the decannulation conditions are met (if the patient require less than 2 aspirations in 8 hours for 24 consecutive hours)
33038161|NCT05778682|Other|Usual care|Usual care will mainly base on the capping trial.
33038162|NCT05778669||Cohort Group: Longitudinal follow-up intervention|Monitoring of medical, health and psychosocial conditions through questionnaires, on-site assessments and medical record checking.
33038163|NCT05778656|Experimental|Mediterranean diet without red and/or processed meat|They will receive motivation and behavioral support through a study specific website which will be accessed after randomization. The research team will give participants further information on the use of this website. One of the features of the website will allow participants to collect and self-monitor their dietary intakes using 24h dietary recalls. Participants will be instructed to fill in as many recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. Other features of the website include specific indications to eliminate red and processed meat in the context of a healthy Mediterranean dietary pattern, considering the key elements proposed in the dietary guidelines to improve cardiovascular health. The website will also provide them general information about the Mediterranean diet, as well as recipes, tips, and alternatives to replace meat when cooking at home or eating out. The rest of the clinical care will be as usual.
33038164|NCT05778656|No Intervention|General advice based on the Mediterranean diet|The control group will be guided to use the same website although they will only have access to a restricted version of it, with the dietary recall feature plus general information about the Mediterranean diet. They will not receive specific recommendations to reduce red and processed meat or any other support or advice. Participants will be instructed to fill in as many 24h dietary recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. The rest of the clinical care will be as usual.
33038165|NCT05778630|Other|Group A. Focus group|Individuals will participate in one or several, semi-structured focus group meetings.
33038166|NCT05778630|Other|Group B. Individual|Individuals will participate in a semi-structured qualitative interview.
33038167|NCT05778617|Active Comparator|Ambroxol hydrochloride|"Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
33328836|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
33328837|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
33328838|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
33328839|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
33328840|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
33328841|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
33328842|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
33328843|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
33360499|NCT03932695|Active Comparator|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
33360500|NCT03932695|Active Comparator|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
33038168|NCT05778617|Placebo Comparator|Placebo|"Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
33038169|NCT05778604|Experimental|Physio-fEedback Exercise pRogram (PEER) Group|In week 1 participants will receive the first technology-based physio-feedback, cognitive reframing based on the fall risk appraisal matrix and develop a personal goal setting and action plan. From week 1 to week 8, participants will receive tailored exercise training. Participants will perform peer-led exercises (60 mins/week) and individual exercise at home for at least 30 minutes twice per week. Exercise training consists of four sets of exercise: a) warm-up (seated); b) strength upper and lower body (seated and standing); c) balance (standing and moving); and d) stretch lower and upper body. Participants will receive an exercise booklet (English or Spanish version) with illustrations that highlight steps for each set of exercise and provide a wide variety of exercises to integrate into daily activity such as cooking. Finally, in week 8, participants will receive the second physio-feedback and printed BTracks Balance System (BBS) results.
33038170|NCT05778604|Experimental|Attention Control (AC) Group|Participants in the AC group will receive an information pamphlet about falls, Simple Exercises for Improving Balance and Preventing Falls in Older Adults, (English or Spanish version) that was developed by the CDC Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention. The topics contain information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise included what you can do to prevent falls, check for safety, postural hypotension, and chair rise exercise. The control group will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will be offered the PEER intervention when the study concludes.
33038171|NCT05778591|Experimental|Placebo, buprenorphine|One group will receive placebo first, then buprenorphine (0.15mg).
33038172|NCT05778591|Experimental|Buprenorphine, placebo|One group will receive buprenorphine (0.15mg) first, then placebo.
33038173|NCT05778578|No Intervention|Control|All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
33038174|NCT05778578|Active Comparator|Intervention|Participants in Arm 2 will receive a monthly UBI stipend of $500 for 6 months. Study staff will explain that UBI payments will continue for 6 months and that the UBI payments will be suspended if an individual is reincarcerated (e.g. the participant will not receive UBI payments to their ClinCard during months of incarceration and will not receive additional months post-release from incarceration). Participants will receive their monthly UBI payment, along with all study-related compensation for completing baseline and follow-up assessments, through a ClinCard, which is a loadable debit card with an ID number unique to the participant. The UBI will be loaded to the participant's ClinCard on the first day of each month.
33038175|NCT05778565|Experimental|Extraocular muscle stretching arm|
33038176|NCT05778552||Home-based pelvic muscle training devices group|Patients underwent pelvic muscle training by home-based device and at home.
33038177|NCT05778552||Traditional pelvic muscle training devices group|Patients underwent traditional pelvic muscle training at hospital
33038178|NCT05778539|Experimental|Lateral retinacular release group|During the implantation of a total knee arthroplasty a lateral retinacular release is performed
33038179|NCT05778539|No Intervention|Non-release group|No aditional gesture in the lateral retinaculum is performed during the implantation of a total knee arthroplasty
33038180|NCT05778526|Experimental|Social VR Intervention|Social VR intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display for the Social VR intervention. Each session of the Social VR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect. The duration will be adjusted depending on the emotion of the participants during the intervention. The Social VR intervention will mainly help the participant to enhance their social interaction skills and executive function. The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) supermarket and restaurant. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants.
33038181|NCT05778526|Active Comparator|Traditional social skills training|An experienced SEN teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell & Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the Social VR training. The training lasts 20 minutes which depends on the emotion of the participants.
33038182|NCT05778526|No Intervention|Waitlist control group|The participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 3-week intervention period.
33038183|NCT05778513||Cases|Male subjects with obesity
33360501|NCT03932695|Placebo Comparator|Placebo|maltodextrin
33038184|NCT05778513||Controls|Male subjects without obesity
33038185|NCT05778487|No Intervention|Control Group|"Standard of care for dietary instructions only.~The control group will consist of retrospectively recruited participants who have recently undergone a successful elective spine surgery, and followed the preoperative nutrition standards for their surgery, as outlined by the research institution's fasting dietary guidelines. Recruitment will include the most recent spine surgeries that meet the inclusion criteria and match prospective patient demographics."
33038186|NCT05778487|Experimental|Carbohydrate Group|"Standard of care for dietary instructions + carbohydrate loading.~The carbohydrate (CHO) group will consist of prospectively recruited patients scheduled to undergo an elective spine surgery. These participants will also follow the preoperative nutrition standards, however, in addition, they will be instructed to consume 710ml of a simple, commercial carbohydrate sports drink on the day of their procedure up to 2 hours prior to surgery."
33038187|NCT05778474|Experimental|Healthy participants|At least 10 healthy participants aged from 18 to 60 years old with symmetric walking at visual analysis. Participants will be excluded if pregnant, if they present with pharmacologic therapies which could affect balance and walking, and if they suffered from (or presently present with) orthopedic or neurologic conditions potentially impairing walking.
33038188|NCT05778474|Experimental|Pathologic group|At least 15 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled. Participants will present a unilateral motor impairment, not preventing passive oscillation of the upper limbs.
33038189|NCT05778461|Experimental|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
33038190|NCT05778461|Placebo Comparator|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
33360502|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
33038191|NCT05778448|Experimental|BCI-FES-VR|Participants look at an external screen displaying the VR avatar participant's arms while performing wrist dorsiflexion MI in random order (left or right). The BCI system detects the ERD of the motor area corresponding to correct MI. Then, visual feedback with the VR and motor-tactile feedback with the discharge of the FES is delivered. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
33038192|NCT05778448|Active Comparator|BCI-FES|Same procedure as arm 1 (BCI-FES-VR), but the difference is that the participant's hands replace the VR system. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
33038193|NCT05778448|Active Comparator|BCI-VR|Same procedure as arm 1 (BCI-FES-VR), but the FES is removed. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
33038194|NCT05778435|Experimental|wireless fetal monitoring group|wireless fetal monitoring system was applied to the experimental group
33038195|NCT05778435|No Intervention|Control group|Standard wired fetal monitoring system was applied to the control group.
33038196|NCT05778409|Experimental|Cordyceps Cicadae extract group|500 mg/ day for 1 month
33038197|NCT05778396|Active Comparator|Active spinal manual therapy protocol|(1) Side-lying lumbar spine manipulation, (2) prone lumbar spine mobilization, and (3) prone thoracic spine manipulation.
33038198|NCT05778396|Sham Comparator|Control spinal manual therapy protocol|(1) Control side-lying lumbar spine manipulation, (2) control prone lumbar spine mobilization, and (3) control prone thoracic spine manipulation.
33038199|NCT05778383|No Intervention|Standars of Care|Standard of Care of treatment for SARS-coV-2 infection
33038200|NCT05778383|Experimental|Zinc Supplementation +Standard of Care|Standard of care + ( 240mg zinc acetate Zinc (75mg Zn element) +NM QD) during 14 days
33038201|NCT05778370||Group 1|will include 15 patients (30 eyes) of age matched non-diabetic candidates (control group)
33038202|NCT05778370||Group 2|will include 15 patients (30 eyes) of diabetic patients with good glycemic control (HbA1c ≤7%),
33038203|NCT05778370||Group 3|will include 15 patients (30 eyes) of diabetic patients with poor glycemic control (HbA1c <7% (
33038204|NCT05778357||Evaluation of neuromotor development of healthy infants|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
33038205|NCT05778344|Experimental|Home-based pulmonary rehabilitation group|The home-based pulmonary rehabilitation group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will receive a home-based exercise plan, which comprises aerobic exercise and resistance exercise with instruction sheets. The participants will also be given a smart watch (to record heart rate, step count and distance in daily life) and a portable pulse oximeter (to monitor heart pulse and oxygen saturation during exercise) for 12 weeks. Teletechnology will be incorporated into home-based pulmonary rehabilitation via videotelephony (or telephone calls if indicated). Time points for these teletechnology-assisted consultations will be at day 7, day 14 after randomization and every 2 weeks after that until the completion of the study (week 12).
33038206|NCT05778344|Active Comparator|Usual care group|The usual care group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will also receive general exercise education and exercise safety principles but not any consultation about their physical activity/exercise during the study period.
33038207|NCT05778331||Group A : POSEIDON group 3|"Age : < 35~AFC: < 5~AMH : < 1.2~Planning for IVF"
33038208|NCT05778331||Group B: POSEIDON group 4|"Age : ≥ 35 years old~AFC : < 5~AMH : < 1.2~Planning for IVF"
33038209|NCT05778318||Control group|Patients without Lianhua Qingwen treatment.
33038210|NCT05778318||Observation Group|Patients with Lianhua Qingwen treatment.
33108081|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
33108082|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
33108083|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
33328844|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
33108084|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
33108085|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
33108086|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
33108087|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
33108088|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
33108089|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
33108090|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
33108091|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
33108092|NCT04639271|Experimental|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
33108093|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
33108094|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
33108095|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
33108096|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
33108097|NCT04639076|Active Comparator|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
33108098|NCT04639076|Experimental|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
33108099|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
33108100|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
33108101|NCT04639154|Placebo Comparator|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
33108102|NCT04639154|Active Comparator|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
33108103|NCT04639154|Active Comparator|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
33108104|NCT04681053|Active Comparator|Group (A) received both oral and inhaled ivermectin in addition to the standard of care.|use oral and inhaled ivermectin
33108105|NCT04681053|Active Comparator|B) received oral ivermectin in addition to the standard of care|receive oral ivermectin
33108106|NCT04681053|Active Comparator|c) received inhaled ivermectin in addition to the standard of care|received inhaled ivermectin
33108107|NCT04681053|No Intervention|Group (d) received the current standard of care only|received standard of care only
33108108|NCT04639193|Experimental|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
33328845|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
33328846|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
33328847|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
33328848|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
33038211|NCT05778305|Active Comparator|Dexmedetomidine group|patients will have loading Dexmedetomidine( 1ug/kg) over 10 minutes followed by continuous infusion of (0.5ug/kg/hr) from the initiation of anaesthesia up to extubation in the ICU. Patients will not be extubated until completely awake and have no sign of arrhythmias and bleeding
33038212|NCT05778305|Placebo Comparator|control group|patients will receive the same volume of 0.9% saline infusion as loading and maintenance infusion.
33328849|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
33328850|NCT01206192||Abused Chinese women|
33328851|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
33328852|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
33328853|NCT01298154|Experimental|Intact Pea Protein (20 g)|
33328854|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
33328855|NCT01298154|Experimental|Intact Whey Protein|
33328856|NCT01298154|Experimental|Hydrolyzed Whey Protein|
33328857|NCT01298154|Experimental|Water|
33328858|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
33328859|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
33328860|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
33328861|NCT01203540|Experimental|Naaga in ABAK system|
33038213|NCT05778253||Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy|
33038214|NCT05778240|Experimental|Status quo bias and implementation intention bias|Participants' families in this arm were informed about prophylaxis program and provided a schedule additionally called two days before appointments (status quo bias) and were asked to plan the appointment day (implementation intention).
33038215|NCT05778240|Experimental|Availability bias and social norm|Participants' families in this arm were informed about prophylaxis program and provided a schedule and were received messages biweekly informing about benefits of program and adherence rate (availability bias and social norm).
33038216|NCT05778240|Experimental|Control|Participants' families in this arm were informed about prophylaxis program and provided a schedule
33038217|NCT05778227|Active Comparator|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
33038218|NCT05778227|Experimental|smearOFF|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
33038219|NCT05778227|Experimental|Etidronic acid/ Sodium Hypochlorite (HEBP/NaOCl)|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
33038220|NCT05778227|Experimental|Maleic acid (MA)|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
33038221|NCT05778227|No Intervention|Control group|Final irrigation of root canal treatment will be done with 0.9% saline.
33038222|NCT05778214|Experimental|Interventional Robotic System Assisted Surgery|Experimental group underwent cerebral angiography using the vascular interventional surgical control system
33038223|NCT05778214|No Intervention|Traditional Manual Surgery|The control group process the traditional manual operation for cerebral angiography
33038224|NCT05778201|Experimental|Baby Drink group|1 package/ day for 1 month
33038225|NCT05778188|Experimental|RLS-0071|Doses of RLS-0071 to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
33038226|NCT05778188|Placebo Comparator|Placebo|Doses of sterile saline (sodium chloride, 0.9%) to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
33038227|NCT05778149|Experimental|Treatment|single arm,Treatment plan: Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
33038228|NCT05778136|No Intervention|Usual Care|Participants receive usual care
33038229|NCT05778136|Experimental|Usual Care + exercise|Participants receive usual care and one-leg resistance exercise training
33038230|NCT05778123||TBI|Patients with traumatic brain injury.
33038231|NCT05778123||Control|Patients with hydrocephalus.
33038232|NCT05778110||TBI|Patients with traumatic brain injury.
33038233|NCT05778110||ICH|Patients with hypertensive intracranial hemorrhage.
33038234|NCT05778097|Experimental|Apalutamide+ADT|Apalutamide (240 mg once daily) in combination with ADT for 12 cycles (28 days of each cycle)
33328862|NCT01203540|Placebo Comparator|Saline solution|
33328863|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
33328864|NCT05622786|Experimental|High-Intensity Treadmill Gait Training (HIGT)|High-intensity walking physical therapy with some low intensity therapy.
33328865|NCT05622786|Active Comparator|Low Intensity Physical Therapy|Low-intensity gait activities, exercises (such as lower extremity strength training with or without weights or electrical stimulation, sit to stands from a chair, mat exercises for upper/lower extremities and core strength, etc.), stretches, balance training activities, and other therapeutic activities (such as transfers, bed mobility training, etc.).
33328866|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
33328867|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
33328868|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
33038235|NCT05778084|Other|Heart failure patients with reduced and mildly reduced ejection fraction|"One paired test group described as Heart Failure patients with reduced and mildly reduced ejection fraction are indicated for Empagliflozin.~Blood samples will be collected as a baseline before Empagliflozin administration to test for N-terminal Pro-B-type Natriuretic Peptide,~Followed by administration of empagliflozin for 6 months.~Then retest the N-terminal Pro-B-type Natriuretic Peptide after 6 months."
33038236|NCT05778071|Experimental|eneboparatide|Starting dose of 20 mcg; Administered once daily by subcutaneous injection
33328869|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
33328870|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
33328871|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
33328872|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
33038237|NCT05778071|Placebo Comparator|Placebo|Administered once daily by subcutaneous injection
33038238|NCT05778058|Experimental|Unilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 30 minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
33038239|NCT05778058|Experimental|Bilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 20minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in bilateral ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
33038240|NCT05778058|Sham Comparator|Bilateral Sham Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load. Bisiklet egzersiz uygulaması sonrasında tekrar değerlendirilecektir.~It will be re-evaluated after the cycling exercise. After the assessment is complete, sham stimulation with Vagustim for 20 minutes will be given non-invasively. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated."
33038241|NCT05778019||Case Scenarios|No personal patient information is shared. The circulated case scenarios within the network will be constructed cases from the clinical practice, to serve representatively
33038242|NCT05777993|Experimental|Mitapivat|Participants will receive mitapivat of 5, 20 or 50 milligrams (mg), orally, twice daily (BID), based on the last dose received by the participants in the antecedent study. Mitapivat will be administered from Day 1 up to end of treatment period of this study.
33038243|NCT05777967|Experimental|Single Arm|
33038244|NCT05777954||Systemic Sclerosis patients|
33038245|NCT05777954||Healthy subjects|
33038246|NCT05777941|Experimental|Eccentric Training|This Group will train on the KREHA for 20 Trainings
33038247|NCT05777928|Experimental|Sleeve gastrectomy group|Subjects with obesity candidates for sleeve gastrectomy
33038248|NCT05777928|Experimental|OverStitch™ Endoscopic Suturing System group|Subjects candidates for a revision bariatric surgery with Overstitch endoscopic
33038249|NCT05777902|Experimental|Patient|
33038250|NCT05777889||Study CRPS Group|"Enrolled patients with complex regional pain syndrome undergoing a surgical procedure that requires spinal cord stimulation.~All participants in the group will have an image of their feet taken perpendicularly with a 1-inch space from all four sides using a FLIR T420 or T62101 camera with 320*240 resolution.~All participants will also answer questionnaires about: their average pain score, CRPS severity, quality of life, and neuropathic pain."
33038251|NCT05777876|No Intervention|non-TRD|Patients with first episode or relapse of untreated depression group are treated with escitalopram for 8 weeks, and if effective, they are included in the n-TRD group. If ineffective, Venlafaxine is used for full treatment for 8 weeks; if effective, the patients are included in the non-TRD group. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
33038252|NCT05777876|Experimental|TRD Target stimulation A|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target A (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
33038253|NCT05777876|Experimental|TRD Target stimulation B|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target B (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
33038254|NCT05777876|Experimental|TRD Target stimulation C|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target C (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
33328873|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
33328874|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
33038255|NCT05777876|Sham Comparator|TRD sham stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: sham stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 seconds, total wearing the instrument for 30 minutes)
33038256|NCT05777876|Experimental|TRD closed-loop stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Patients receive closed-loop stimulation guided by EEG phase, and the stimulation target is the effective deep brain region target verified in this study. Regimen: stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit)
33038257|NCT05777876|Experimental|HC experimental stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. HC will receive TIS intervention in the exercise area for one time, the stimulation scheme adopted 20 Hz and 2mA total current intensity, and each stimulation lasted for 30 minutes (15 seconds respectively for lead-in and withdrawal)
33038258|NCT05777876|Sham Comparator|HC sham stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Electrode placement, current intensity and intervention times are consistent with those of TIS regimen. 20 Hz, 2mA total current intensityis used, but only lasted for 30 seconds, and then the current is 0 for a total of 30 minutes.
33038259|NCT05777876|No Intervention|HC observation|Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
33038262|NCT05777850|Active Comparator|Conventional ablation|CTI ablation with electroanatomic navigation system using individual 25-40 W applications of unlimited duration until achieving in each application the minimum value of one of the currently accepted and used lesion markers: Ablation Index >500 at the anterior half of the CTI and >400 at the posterior half with de CARTO 3 system. Minimum contact force required is 5 grams. Maximum distance between applications must be 6 mm.
33038263|NCT05777850|Experimental|High-power short-duration ablation|CTI ablation with electroanatomic navigation system using individual high power (90W) short duration (4 seconds) applications in a catheters' stable position with a minimum contact force of 15-30 g at the anterior half and 10-25 g at the posterior one. Maximum distance between applications is settled at 4 mm.
33038264|NCT05777837|Active Comparator|Laparoscopic Excision of Large Cesarean Scar Niche|
33038265|NCT05777837|Active Comparator|Combined Hysteroscopic and Laparoscopic Repair without Excision of Large Cesarean Scar Niche|
33038266|NCT05777824|No Intervention|low-risk and PCR|Observation
33038267|NCT05777824|Experimental|low-risk and MPR|immunotherapy maintenance
33038268|NCT05777824|Experimental|low-risk and IPR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
33038269|NCT05777824|Experimental|high-risk and PCR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
33038270|NCT05777824|Experimental|high-risk and MPR|postoperative radiotherapy (60 Gy) and immunotherapy maintenance
33038271|NCT05777824|Experimental|high-risk and IPR|postoperative concurrent chemoradiotherapy (60 Gy) and immunotherapy maintenance
33038272|NCT05777785|Experimental|Active|VIZO Glasses- personalized
33038273|NCT05777772|Experimental|Educational Intervention|Educational Intervention
33038274|NCT05777746|Experimental|An online 12 week plant-based dietary program|
33038275|NCT05777746|Other|Usual Diet|
33038276|NCT05777733|Experimental|N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major|N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
33038277|NCT05777720|No Intervention|Control|No intervention will be administered in this arm. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will provide a link to the basic CDC isolation guidelines which would be part of standard of care. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
33038278|NCT05777720|Experimental|Intervention|Families are provided with one filtration fan unit per room in their home (and one for the index case; if the family lives in a studio, they would receive 2 units). Investigators will advise families on ventilation improvements in their home. Investigators will provide an instructional pamphlet that describes how the fans work and the importance of ventilation. Investigators will follow-up on day 3-4 to check in and run through a checklist to ensure the fans are working and ventilation improvements are being attempted. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
33038279|NCT05777707|Experimental|Neoadjuvant PD-1 Blockade Plus Chemotherapy|PD-1 blockade, 200 mg, IV., every 3 weeks, 2-3 cycles； Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles； Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
33038280|NCT05777694|Active Comparator|Group 1: 25 gauge spinal needle|Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
33328875|NCT01298622||controls|
33328876|NCT01298622||OCD patients|
33328877|NCT01298622||OCD parents|
33328878|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
33328879|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
33038281|NCT05777694|Active Comparator|Group 2: 26 gauge spinal needle|Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
33038282|NCT05777694|Active Comparator|Group 3: 27 gauge spina needle|Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
33328880|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
33328881|NCT03818958||fibromyalgia|subjects with fibromyalgia
33038283|NCT05777668||Head and neck cancer patients undergoing radiotherapy|
33038284|NCT05777655|Experimental|Medication management app|Standard of care (statin prescription, targeted monitoring of individual LDL-C values by primary care physician) + medication management app and follow-up visits at our institution at 6 and 18 months
33038285|NCT05777655|No Intervention|Standard of care|Statin prescription, targeted monitoring of individual LDL-C values by primary care physician and follow-up visits at our institution at 6 and 18 months
33038286|NCT05777642|Experimental|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles drink will be provided as the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The placebo will be provided as the second drink, 2-4 days after the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
33038287|NCT05777642|Placebo Comparator|Placebo First|"In this arm, the placebo drink will be provided as the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The oxygen nanobubbles will be provided as the second drink, 2-4 days after the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
33038288|NCT05777577|Experimental|Rheumatoid Arthritis Probiotic (RAP)|patients with RA 30-50 yers old, who have 4 or more swollen and painful joints, who did not take probiotic and other drugs that affect the microbiome
33038289|NCT05777577|Active Comparator|Rheumatoid Arthritis Probiotic1 (RAP1)|closest relatives (brothers and sister, children, parents) living in the same living area and corresponding to the age group, without RA, who did not take probiotic and other drugs that affect the microbiome
33038290|NCT05777564|Other|HIIT for knee OA|high intensity exercise
33038291|NCT05777538|Experimental|Foot exercise with hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days
33038292|NCT05777538|Active Comparator|Foot exercise|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each
33038293|NCT05777525|No Intervention|Echography|Ultrasound skin measurements will be taken before and after the enriched cream treatment.
33038294|NCT05777525|No Intervention|"Visiopor PP-34 camera"|"Measurements of the skin will be taken by Visiopor PP-34 camera before and after the treatment with enriched cream."
33038295|NCT05777525|No Intervention|Mycological culture|Skin samples will be taken and analyzed by mycological culture before and after treatment with enriched cream
33038296|NCT05777525|Experimental|treatment application|The essential oil enriched cream will be applied to study participants.
33038297|NCT05777512|Experimental|Group A: Gastric Followed by Jejunal Feeds|Participants randomized into this group will begin with one ten-day block of nasogastric (NG) feeds followed by one ten-day block of nasojejunal (NJ, postpyloric) feeds.
33038298|NCT05777512|Experimental|Group B: Jejunal Followed by Gastric Feeds|Participants randomized into this group will begin with one ten-day block of nasojejunal (NJ, postpyloric) feeds followed by one ten-day block of nasogastric (NG) feeds.
33038299|NCT05777499|Experimental|Music Therapy|See Intervention section
33038300|NCT05777499|Active Comparator|Control Therapy|See Intervention section
33038301|NCT05777486|Experimental|TikTok Influencer Ads with Food|Participants randomized to view TikTok influencers' posts with food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
33038302|NCT05777486|Experimental|TikTok Influencer Ads without Food|Participants randomized to view TikTok influencers' posts without food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
33038303|NCT05777434|Active Comparator|Group A (Conventional Physical Therapy)|"Patients in this group will recieve conventional physical therapy including hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises (cervical bracing with deep neck flexor activation followed by extremity ROM) along with general flexibility exercises.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
33328882|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
33328883|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
33328884|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
33328885|NCT05622708|Experimental|Treatment Period 1|Open-label Secukinumab PFS (prefilled syringe) labeled as AIN457 150mg/1mL
33328886|NCT05622708|Experimental|Treatment Period 2|Double-blind Secukinumab and Placebo PFS labeled as AIN457 150mg/1mL/Placebo
33328887|NCT05622240|Experimental|99mTc-MIRC213 Dosimetry study|about 6 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan at 5min、20min、40min、60min、90min、120min、180min、240min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
33328888|NCT05622240|Experimental|99mTc-MIRC213 wholebody and SPECT/CT scan|About 30 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan 1 \2\3h later and underwent SPECT/CT scan at 2h.
33328889|NCT01300806||myHERO SBIRT|
33038304|NCT05777434|Experimental|Group B (Scapulothoracic Stabilization Exercises)|"Patients will recieve scapulothoracic stabilization exercises in addition to the convential physical therapy including hot pack, TENS, axial elongation, cervical isometrics and cervical stabilization exercises. SSE would include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
33038305|NCT05777421|Active Comparator|Conventional Physical Therapy Regime for Knee Osteoarthrithis|"Pt will receive conventional therapy targeting stretching and stretching of knee musculature in combination with electrotherapy for pain modulation.~Frequency : 2-3 times for a duration of 6 weeks Pt will be guided home plan based exercises."
33038306|NCT05777421|Experimental|Virtual reality Based Therapeutic Exercise Regimes|"VR-based therapeutic exercise regimes utilizing Xbox, that focus on different activities like Partial squatting, lunges, side lunge, calf raises, and hamstring curls.~Gaming exercises begin will an easy warm up round and get challenging with different rounds of each game as the patient progresses to week 6.~Frequency: 2-3 times for a duration for 6 weeks Pt will be guided home plan based exercises"
33038307|NCT05777408|Active Comparator|Control Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides 3 sets of 10 repetitions.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3 depending on the patients pain status and compliance."
33038308|NCT05777408|Experimental|Experimental Group|"Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides and cranial base release.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Cranial base release would be given for around 1-4minutes until the tissues relax and would be given once daily"
33038309|NCT05777395|Experimental|Maitland + Conventional PT Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Maitland oscillatory mobilizations. 3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given in 2 seconds.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are postero-anterior unilateral vertebral pressure and Maitland rotation."
33038310|NCT05777395|Experimental|Kaltenborn + Conventional PT Group|"Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~Kaltenborn technique used will be atlas-axis rotation."
33038311|NCT05777369|Experimental|R-CMOP|R-CMOP：Rituximab, Cyclophosphamide, Mitoxantrone hydrochloride liposomes, Vincristine or Vindesine, Prednisone
33038312|NCT05777356||Omivorous|Healthy volunteers without dietary restrictions
33038313|NCT05777356||Vegetarians|Healthy volunteers who do not consume meat products
33038314|NCT05777356||Vegans|Healthy volunteers who do not consume any animal product
33038315|NCT05777343|Experimental|Intervention 1|Participants will receive exercise, PNE and online cognitive training sessions.
33038316|NCT05777343|Active Comparator|Intervention 2|Participants will receive exercise and pain neuroscience education (PNE).
33038317|NCT05777343|Active Comparator|Intervention 3|Participants will receive online cognitive training sessions.
33038318|NCT05777330|Other|Autoantibody-positive first-degree relatives of type 1 diabetes patients|
33038319|NCT05777317|Experimental|10 kHz SCS plus CMM|Treatment with high frequency, 10 kHz spinal cord stimulation (SCS) in addition to conventional medical management (CMM)
33038320|NCT05777317|Active Comparator|CMM alone|Treatment with conventional medical management (CMM) alone
33038321|NCT05777291|Experimental|Experimental arm|Patients will be given physical activity recommendations ABD will be using the study devices: activity watch (Fitbit Sense) and a sleep monitoring mattress (Withings, Sleep Analyzer)
33038322|NCT05777291|Active Comparator|Control arm|Patients will be given physical activity recommendations only
33038323|NCT05777278|Experimental|Savolitinib Plus Docetaxel|Single Arm
33038324|NCT05777265|Experimental|Training Group|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks
33328890|NCT01300806||clinician administered SBIRT|
33328891|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
33328892|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
33328893|NCT05669352|Experimental|CA-4948 and Pembrolizumab|
33038325|NCT05777252|Experimental|Training Group|Circuit training will be applied to the participants for a total of 16 weeks, with an average of 40 minutes a day, 3 days a week, taking into account the recommendations of the American College of Sports Medicine (ACSM).
33038326|NCT05777239|Experimental|Dental Implant Approach for Crestal Sinus Elevation|
33038327|NCT05777213|Experimental|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs)|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) made as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks.
33038328|NCT05777187|Experimental|Clinical Decision Support|Clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment.
33038329|NCT05777187|No Intervention|Standard of Care|No clinical decision support will appear, and standard of care procedures will take place.
33038330|NCT05777148|Experimental|postdilution online hemodiafiltration|hemodialysis by using post dilution online HDF technique
33038331|NCT05777148|Experimental|super high-flux hemodialysis|hemodialysis by using super high-flux dialyzer
33038332|NCT05777122|Experimental|group A|lignocaine gel every 8 hours
33038333|NCT05777122|Experimental|group B|chewing gum every 8 hours 5-10 mins chew
33038334|NCT05777109|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
33038335|NCT05777109|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
33038336|NCT05777096||registered|"Paragliding pilots over the age of 18. Registered at the Fédération Française de Vol Libre (FFVL) in the year 2022 and/or 2023 Paragliding in the year 2022 and/or 2023"
33038337|NCT05777083|Experimental|Inferior STEMI group|Patients who undergo emergent coronary angiography for ST-elevation myocardial infarction.
33038338|NCT05777083|Active Comparator|Control group|Patients who undergo elective coronary angiography to differentiate angina symptom. ST-elevation myocardial infarction will be excluded.
33038339|NCT05776641|Active Comparator|Active GENUS light and sound|The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.
33038340|NCT05776641|Sham Comparator|Sham GENUS light and sound|The device is the same as the active device but it delivers light and sound at different frequencies.
33038341|NCT05776329|Experimental|Low-inflammatory and environmentally friendly dietary strategy (AIA-D)|The environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and includes nutrients related to anti-inflammatory responses
33038342|NCT05776329|Active Comparator|General healthy diet recommendations (CONV-D).|The active comparator CONV-D is based on the general healthy diet recommendations
33038343|NCT05776069|Placebo Comparator|Part 1|Cohorts 1-8 IV or SC VGA039 or Placebo dose to be determined
33038344|NCT05776069|Experimental|Part 2|Cohorts 9-12 SC VGA039 dose to be determined
33038345|NCT05775718|Experimental|1-<2 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
33038346|NCT05775718|Experimental|2-<3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
33038347|NCT05775718|Experimental|≥ 3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
33038348|NCT05775367|Experimental|Study Group|This group of children with single-sided deafness will receive a cochlear implant.
33038349|NCT05775367|No Intervention|Typical Hearing Control Group (THCG)|This group of five-year-old children will have typical hearing in both ears.
33038350|NCT05775367|No Intervention|Single-Sided Deafness Control Group (SSDCG)|This group of five-year-old children will have single-sided deafness and no cochlear implant.
33038351|NCT05775250|Experimental|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
33328894|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
33328895|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33328896|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33038352|NCT05775250|Active Comparator|fluoride varnish|5% NaF fluoride varnish, it will be administrated once.
33038353|NCT05774730||Emphysema quantitative analysis softwarebased on chest image AI technology|
33038354|NCT05774730||artificial analysis|
33038355|NCT05774730||imported Chartis detection system|
33038356|NCT05774483|Active Comparator|Sentinel node biopsy|
33038357|NCT05774483|Experimental|Limited elective neck dissection|
33038358|NCT05774301|Experimental|Nurses|A simulation-based training will be done for all nurses
33038359|NCT05773248||Standard care|
33038360|NCT05773248||ERAS|
33038361|NCT05773209|Experimental|RLRL of 100% intensity|Participants will be treated with RLRL treatment (100% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
33038362|NCT05773209|Sham Comparator|RLRL of 5% intensity|Participants will be treated with the sham device (5% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
33038363|NCT05770440||Group 1|Patient with COPD and at least 1 SARS-Cov2 Infection
33038364|NCT05770440||Group 2|Patient with COPD and no SARS-COV2 Infection
33038365|NCT05770271|Experimental|The mild senile groin eczema, neurodermatitis and psoriasis and one treatment|Participants with itching of mild senile groin eczema, neurodermatitis and psoriasis will receive one treatment with the device and complete the questionnaire.
33038366|NCT05764551|Experimental|DNA methylation|The enrolled individuals with HCC would receive serum DNA methylation test before their treatment (including all kinds of recommened HCC treatment). Then regularly serum DNA methylation test would be done at 4th~8th weeks, 16th week, 32th week and 48th week. If the enrolled patients did not have HCC recurrence during at 48th week. The regular check of serum DNA methylation would be canceled. The enrolled patients would be observed till 96th week. If there is any recurrence during 48~96th week, one time of serum DNA methylation would be checked at the time of recurrence. The observation and intervention would be completed at 96th week.
33038367|NCT05758766|No Intervention|Regular diet|Participants will continue their regular diet.
33038368|NCT05758766|Experimental|Plant based omega 3 Fatty Acid|Participants ingest their regular diet supplemented with a plant-based omega-3-FA
33038369|NCT05755672||Synchronous mCRC patients|Patients diagnosed with synchronous metastatic colorectal cancer with planned treatment with curative intent at Skåne University Hospital (Malmö and Lund), who have accepted the study invitation (agreeing to participation - informed consent)
33038370|NCT05755399|Experimental|Experimental group|Participants scheduled for brain surgery
33038371|NCT05753306|Experimental|Treatment (gastrectomy, HIPEC)|Patients undergo collection of stool and blood sample before and after surgery. Patients also undergo robotic gastrectomy and HIPEC with docetaxel and cisplatin on study. Patients undergo CT, MRI, or PET/CT scans throughout the trial.
33038372|NCT05751837|Experimental|Treatment Arm|Injection of Lipopolysaccharide into one abdominal tumor
33038373|NCT05751655||Drowning patients|Process of experiencing respiratory impairment from submersion/immersion in liquid
33038374|NCT05750745|Experimental|Test Dentifrice|Participants will be instructed to brush the two test teeth first, then the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Sensitivity & Gum. After brushing, participants will be instructed to rinse once with 10 milliliters (mL) of water using the measuring cup provided.
33038375|NCT05750745|Active Comparator|Negative Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Crest Cavity Protection Fresh Lime. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
33038376|NCT05750745|Active Comparator|Positive Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Repair and Protect. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
33038377|NCT05743998||Hemodialysis patients|They will fill 2 questionnaires and ill do some functional tests.
33038378|NCT05743998||Peritoneal dialysis patients|They will fill 2 questionnaires and ill do some functional tests.
33038379|NCT05742685|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
33038380|NCT05742685|No Intervention|Control Arm|Up to daily, untailored text messages.
33038381|NCT05741892|Experimental|3D fracture reposition guide group|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
33038382|NCT05741086|Experimental|Evolocumab added to statin therapy|Evolocumab (140 mg every 2 weeks for 1 year) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management in both arms.
33038383|NCT05741086|Active Comparator|Statin therapy|Atorvastatin 20-40mg. Anti-platelet aggregation and risk factor management in both arms.
33038384|NCT05741047|Active Comparator|a2 Group|The group consuming a2Milk skim milk powder (1L) containing A2 β-casein only
33038385|NCT05741047|Placebo Comparator|Control Group|The group consuming Yili skim milk powder (1L) containing A1 and A2 β-caseins
33038386|NCT05740995||Neoadjuvant Anti-PD-1 Plus Chemotherapy Group|Patients with locally advanced resectable ESCC (cT3-4aN0-1M0) who receive neoadjuvant anti-PD-1 plus chemotherapy and donate biological samples
33328897|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33328898|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33328899|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33328900|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
33328901|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
33328902|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
33328903|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
33038389|NCT05734417|Experimental|Probiotic|Intervention consists of daily administration of excipient plus Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day administered daily for 4-weeks
33038390|NCT05734417|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
33038391|NCT05728866|Experimental|Virtual reality (VR) therapy|
33038392|NCT05728489|Experimental|BI 765250 very low dose group|
33038393|NCT05728489|Placebo Comparator|Placebo group|
33038394|NCT05728489|Experimental|BI 765250 low dose group|
33038395|NCT05728489|Experimental|BI 765250 medium dose group|
33038396|NCT05728489|Experimental|BI 765250 high dose group|
33038397|NCT05726396|Experimental|RMT group|16 patients will be randomized to Oral restorative microbiota therapy (RMT). Consenting eligible participants receive a loading dose of RMT capsules.
33038398|NCT05726396|Placebo Comparator|active placebo|participants in the placebo arm will receive an identical looking placebo capsules
33038399|NCT05726214|Other|Control Group|The control group will receive general recommendations for maintaining physically active and reducing sedentary behaviors. This will be done verbally and through written material.
33038400|NCT05726214|Experimental|Intervention Group|"The intervention group will receive the same recommendations as the control group. In addition, they will participate in a 6-month multicomponent physical exercise program consisting of a) 1 face-to-face weekly multicomponent session (Rodriguez-Larrad et al. BMC Geriatrics (2017) 17:60), and b) 2 autonomous sessions at home following the Vivifrail program (https://vivifrail.com/es/inicio/).~Face-to-face supervised sessions will last 1 hour and include strength, balance, and flexibility exercises (50%-75% of the 1 repetition maximum for strength exercises). The volume, intensity and difficulty of the exercises will be individualized based on the initial performance of each participant, and will progress as the participants' physical capacity evolves.~At-home training will follow the Vivifrail program."
33038401|NCT05722743|Experimental|Harmony at HOME|Participants in this group will receive the Harmony at HOME intervention.
33038402|NCT05722743|Active Comparator|National Institute on Aging Program|Participants in this group will receive the National Institute on Aging education.
33038403|NCT05721937||Exposed to CIBINQO during pregnancy|Received at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy (within 1 day prior to the date of conception).
33038404|NCT05721937||Unexposed to CIBINQO during pregnancy|Diagnosed with moderate-to-severe atopic dermatitis, but not exposed to CIBINQO during pregnancy.
33038405|NCT05718843|Experimental|Group 1: Participants with severe renal impairment|
33038406|NCT05718843|Experimental|Group 2: Participants with normal renal function individually matched to participants of Group 1|
33038407|NCT05718843|Experimental|Group 3: Participants with moderate renal impairment|
33038408|NCT05718843|Experimental|Group 4: Participants with normal renal function matching Group 3|
33038409|NCT05718843|Experimental|Group 5: Participants with mild renal impairment|
33038410|NCT05718843|Experimental|Group 6: Participants with normal renal function matching Group 5|
33038411|NCT05717140|Experimental|Treatment (aerosolized sargramostim, nivolumab)|Patients receive aerosolized sargramostim via inhalation using the Aerogen Solo nebulization device and receive nivolumab IV on study. Patients also undergo collection of blood samples on study and undergo CT or MRI at screening and on study.
33038412|NCT05715177|Experimental|Cura kinesio-taping|consisted of 66 subjects who will receive kinesio-taping from origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
33038413|NCT05715177|Placebo Comparator|Placebo kinesio-taping|consisted of 66 subjects who will receive placebo kinesio-taping across quadriceps.
33038414|NCT05712096||EVUSHELD Arm|Individuals given EVUSHELD for pre-exposure prophylaxis
33038415|NCT05712096||Concurrent Control Arm|Individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
33038416|NCT05708950|Experimental|KVA12123 Monotherapy Dose Escalation|Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.
33038417|NCT05708950|Experimental|KVA12123 Plus Pembrolizumab Dose Escalation|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.
33360503|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
32740078|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
33038418|NCT05708950|Experimental|KVA12123 Monotherapy Dose Expansion|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.
33038419|NCT05708950|Experimental|KVA12123 Plus Pembrolizumab Dose Expansion|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.
33038420|NCT05707273|Experimental|Treatment (CD19-CAR T cells)|Patients undergo T cell leukapheresis, receive fludarabine and cyclophosphamide IV, and then receive CD19-CAR T cell infusion IV on study.
33038421|NCT05706259|Active Comparator|Soft gelatin vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU soft gelatin capsule of vitamin D3 for 4-weeks
33038422|NCT05706259|Experimental|Orodispersible vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU orodispersible (sachet) vitamin D3 for 4-weeks
33038423|NCT05703880||Finerenone (Kerendia, BAY948862)|Adults with CKD and T2D from the USA who initiate finerenone.
33038424|NCT05701917|Active Comparator|Interventional|Interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm).
33038425|NCT05701917|Active Comparator|Conservative Medical Management|Conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm).
33038426|NCT05699200|Other|Spontaneous coronary artery dissection (SCAD) group|Subject with a history of SCAD will undergo a series of diagnostic studies to assess neurovascular function.
33038427|NCT05699200|Other|Healthy Control Group|Healthy subjects will undergo a series of diagnostic studies to assess neurovascular function.
33038428|NCT05692882|Experimental|Percutaneous transluminal angioplasty and stenting|All patients will be implanted with Drug-Eluting Stents (NOVA DES).
33038429|NCT05680129|Experimental|B1: XW003+MET|High dosage of XW003 once weekly
33038430|NCT05680129|Experimental|B2: XW003+MET|Low dosage of XW003 once weekly
33038431|NCT05680129|Active Comparator|B3: Dulaglutide+MET|1.5mg Dulaglutide once weekly
33038432|NCT05677971|Experimental|Fazirsiran|Participants will receive fazirsiran 200 milligram per milliliter (mg/ml) subcutaneous (SC) injection on Day 1, at Week 4, and then every 12 weeks (Q12 W) thereafter up to Week 196.
33038433|NCT05677971|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
33038434|NCT05674799|Experimental|Healthy Lifestyle|"Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a pre-session designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers."
33038435|NCT05674799|No Intervention|Healthy Women|Women in the Healthy Women group get a packet of information standardly given in OB clinics about how to be healthy before, during and after pregnancy.
33038436|NCT05670587|Experimental|All participants|
33038437|NCT05669677||Standard|Chronic liver disease
33038438|NCT05668858|Experimental|Study treatment|Participants will receive treatment during the first cycle. Participants with clinical benefits received more cycles of additional therapy. Administration will be discontinued due to disease progression or occurrence of intolerable toxicity or other reasons.
33038439|NCT05657990|Experimental|Pre-operative Tamsulosin administration|Subjects will be provided with a prescription for Tamsulosin (generic) to be taken 7 days prior to scheduled surgery for thoracic cancer. Tamsulosin dose is set at 0.4mg/day and should be taken daily for seven days prior to their planned surgery date. Study subjects will also be given a diary to record their daily usage. Study subjects should take Tamsulosin on the day of the surgery with a sip of water.
33038440|NCT05654870|Experimental|Valbenazine|Valbenazine once daily
33038441|NCT05654870|Placebo Comparator|Placebo|Placebo once daily
33038442|NCT05644834|Experimental|Mobile Medical Unit|Participants utilizing the mobile medical unit will be offered an appointment with a university system healthcare provider to receive blood pressure check, blood glucose check, HIV testing and/or Pre-exposure Prophylaxis (PrEP) consultation.
33038443|NCT05640687||aPAP|
33038444|NCT05640687||healthy control|
33038445|NCT05639374|Experimental|BASICS_HealthyClassroom|"Students assigned to the IG will receive the peer-led preventive program. The preventive program consists of a single face-to-face session, lasting about 45-50 minutes. First, the participant will receive, from the Research Staff in Training, the individualized feedback sheet prepared from the baseline information obtained through the BASICS_HealthyClassroom Questionnaire. Subsequently, they will have a motivational interview with the counsellor. The content of the intervention will be adapted to the interests and level of motivation of each participant."
33038446|NCT05639374|No Intervention|Control Group|Students assigned to the CG will not receive any type of intervention, they will only receive the usual information and messages that students receive in their daily environments and at the University.
33038447|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty with the use of bone plugs|
33038448|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty without the use of bone plugs|
33038449|NCT05635487|Experimental|SHR-A1811+Pyrotinib|
33038450|NCT05632133|Experimental|lacosamide arm|We assessed CGRP before and after receiving 50 mo lacosamide Bid for 3 months in 50 migraine patients
33328904|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
33328905|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
33328906|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
33328907|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
33038451|NCT05630053|Active Comparator|Cementless Persona Keel Knee System|Persona PPS CoCr Cementless Femur and Persona OsseoTi Keel Cementless Tibia
33038452|NCT05630053|Active Comparator|Cemented Persona Keel Knee System|Persona Keel Cemented Tibia
33038453|NCT05627856|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33038454|NCT05624151|Active Comparator|general anesthesia+ infraorbital nerve block by dexmedetomidine plus bupivacaine|
33038455|NCT05624151|Active Comparator|general anesthesia+ infraorbital nerve block by magnesium sulphate plus bupivacaine|
33038456|NCT05624151|Active Comparator|general anesthesia+infraorbital nerve block by bupivacaine only|
33038457|NCT05623982|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33038458|NCT05620355|Experimental|BG2109 100mg group|One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
33038459|NCT05620355|Experimental|BG2109 200mg+ABT group|Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.
33038460|NCT05620355|Placebo Comparator|Placebo group|Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
33038461|NCT05616390|Experimental|experimental group|Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy
33038462|NCT05616299|Experimental|BrightPoint Epidural|102 subjects will receive an epidural using the BrightPoint device concurrent with usual LOR technique using the same epidural needle, sterile saline, syringe, etc.
33038463|NCT05616299|No Intervention|Normal Epidural|102 subjects will have an epidural placed in usual manner with LOR technique using the same epidural needle, sterile saline, syringe etc. but without use of the BrightPoint device.
33038464|NCT05614817|Experimental|[Treatment Period 1]Group 1-Dose1|CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.
33038465|NCT05614817|Placebo Comparator|[Treatment Period 1]Goup 2-Placebo1|Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14
33038466|NCT05614817|Experimental|[Treatment Period 2] Group 1-Dose2|CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)
33038467|NCT05614817|Experimental|[Treatment Period 2] Group 1-Dose3|CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50
33038468|NCT05614817|Placebo Comparator|[Treatment Period 2] Group 1-Placebo2|Placebo Q2W SC starting at Week 16 with the last dose at Week 50
33038469|NCT05614817|Placebo Comparator|[Treatment Period 2] Group 2-Placebo|PBO 1 pts responders that continue PBO 1
33038470|NCT05614817|Experimental|[Treatment Period 2] Group 3-Dose|Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)
33038471|NCT05613413|Experimental|Single|All subjects will receive carbozantinib 40mg PO once daily Days 1-21 Q3W and pembrolizumab 200mg IV infusion Q3W as maintenance therapy following 4 cycles of induction therapy with disease control
33038472|NCT05612412|Experimental|Morning Exercise|Morning exercise session
33038473|NCT05612412|Experimental|Evening Exercise|Evening exercise session
33038474|NCT05605054|Experimental|Coach-guided|In person or phone call with an assigned Health Coach for about 1 hour per week for 12 weeks to complete the Health Literacy course, and with an assigned Service Navigator for 30 minutes per week for 12 weeks to address health and social service needs.
33038475|NCT05605054|Active Comparator|Self study|Self-guided printed or online version of the Health Literacy course (approximately 1 hour per week for 12 weeks) and comprehensive Service Navigation report with recommended referrals to services, providers, and contact information for service providers so that the participant can access these resources independently (i.e., without Navigator assistance).
33038476|NCT05603897|Experimental|Mann Assessment of Swallowing Ability (MASA) Group|Participants in this group will receive the MASA dysphagia screening once upon admission to inpatient rehabilitation for approximately 20 minutes.
33038477|NCT05603897|Other|Non-standardized clinical swallow evaluation Group|Participants in this group will receive standard of care treatment (dysphagia screening once upon admission to inpatient rehabilitation using a non-standardized clinical swallow evaluation for approximately 15 minutes).
33038478|NCT05602688|Experimental|Supplement Group|This arm will receive oral 200 mg Lemon Balm supplement tablet two times a day for three-weeks.
33038479|NCT05602688|Active Comparator|Control group|This arm will receive an oral matched placebo tablet two times a day for three-weeks.
33038480|NCT05597150|Experimental|Experimental Group|
33038481|NCT05595460|Experimental|RYZ101 + SoC|RYZ101 (Actinium 225 radiolabeled somatostatin analog (SSA)) 6.5 MBq/175 μCi in combination with standard of care (SoC) carboplatin + etoposide + atezolizumab
33108109|NCT04639193|Experimental|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
33108110|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
33108111|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
33108112|NCT04680819||Compared with given anatolian propolis group and do not use anatolian propolis group|According to the spectrophotometic analysis report of this anatolian group, there should be a minimum phenolic 106.0 mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te / ml.
33108113|NCT04638764|Active Comparator|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
33108114|NCT04638764|Active Comparator|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
33108115|NCT04638764|Active Comparator|Aerobic interval training|"Patient to be randomised into aerobic training training group."
33108116|NCT04680858|No Intervention|Standard Communication|Endoscopic procedures performed by skilled endoscopic team with standard communication (no headset)
33108117|NCT04680858|Experimental|DECT enhanced Communication|Endoscopic procedures performed by skilled endoscopic team with enhanced communication tools ( DECT headset)
33108118|NCT04638959||GC|patients diagnosed with GC
33108119|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
33108120|NCT04680429|Experimental|RP7214, Single and multiple doses|"In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD.~In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID."
33108121|NCT04680429|Placebo Comparator|Placebo, Single and multiple doses|In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
33328908|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
33328909|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
33108122|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
33108123|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
33108124|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
33328910|NCT04630210|Experimental|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
33108125|NCT04638530|Other|Residents|All residents will participate in the activity
33108126|NCT00559715|Experimental|A|
33108127|NCT00559715|Active Comparator|B|
33108128|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
33108129|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
33328911|NCT04630210|Experimental|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
33108130|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
33328912|NCT04630210|Experimental|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
33328913|NCT04630210|No Intervention|D: Observation|Observation until surgery
33328914|NCT04613752|Experimental|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
33328915|NCT04202926|Experimental|10hz group|a high frequency stimulation
33328916|NCT04202926|Sham Comparator|sham group|a sham coil which frequency is 10hz but do not induce stimulation
33328917|NCT05759338|Experimental|Intervention|Using the Revian Red All LED cap 10 minutes each day for 6 months
32740079|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
33328918|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
33328919|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
33328920|NCT02051218|Active Comparator|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
33328921|NCT02051218|Experimental|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]
33038482|NCT05593471|Experimental|High intensity exercises|The first group (HG) received a High-intensity exercise program consisting of progressive resistance training for 30 min using dumbbells, sandbags, and TheraBand with different colors. The exercised muscles were (knee extensors, elbow flexors, chest muscles, hip adductors, abductors, abdominal muscles, back muscles, and hand grip muscles) (references). The intensity of exercise was determined by the load which was kept at 65% of the 10-repetition maximum throughout the program duration. The repetitions of each exercise were kept at a fixed value of 2 sets of 10 - 12 repetitions per session (exercises stopped if the patient reached fatigue level). For progression, the 10-repetition maximum test was performed on a weekly schedule and the amount of load was adjusted accordingly. Exercises were done in a cyclic manner where half of the selected muscles were exercised per session and the other half were exercised in the next session.
33038483|NCT05593471|Experimental|low intensity aerobic exercises|The second group (LG) received a low-intensity aerobic exercise program consisting of an arm ergometer, and a bicycle ergometer to train both upper and lower body muscles. Additionally, 5 minutes of regular treadmill walking was added at the beginning and the end of the exercises session as warming up and cooling down respectively. Exercises were performed in a cyclic manner where the arm and bicycle ergometers were used alternatively. The rate of perceived exertion (RPE) scale was used to monitor the intensity of the exercises to be at 3 -4 level. The actual working out time was 20 minutes plus 10 minutes for the warming up and cooling down. Sessions were performed 3 times per week for six weeks.
33038484|NCT05592418|Experimental|Ampligen / rintatolimod|Subjects will receive rintatolimod (intravenous [IV]), up to 400 mg twice weekly for 12 weeks.
33038485|NCT05592418|Placebo Comparator|Placebo / Saline|Subjects will receive placebo / normal saline (intravenous [IV]), up to 160 mL twice weekly for 12 weeks.
33038486|NCT05592236|Experimental|Study group|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
33038487|NCT05592236|Active Comparator|Control Group|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
33038488|NCT05590468|Experimental|Nicotinamide Riboside treatment group|Subjects will receive vitamin B3 derivative Nicotinamide Riboside (NR) daily for 12 months
33038489|NCT05590468|Placebo Comparator|Placebo Group|Subjects will receive a placebo daily for 12 months
33038490|NCT05587894|Experimental|Nirmatrelvir/r 5 days alone|
33038491|NCT05587894|Experimental|Nirmatrelvir/r 10 days alone|
33038492|NCT05587894|Experimental|Nirmatrelvir/r 5 days + remdesivir s.d|
33038493|NCT05587894|Experimental|Nirmatrelvir/r 10 days + remdesivir s.d|
33038494|NCT05587751|Experimental|Pulmonary Function in Transgender and Gender Diverse Patients|Transgender and gender diverse (TGD) patients undergoing masculinizing or feminizing hormone therapies will have breathing tests to evaluate their lung function
33038495|NCT05587712|Experimental|Children ≥1 to <18 years old|Participants will receive a subcutaneous (SC) injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
33038496|NCT05584111|Experimental|Dose Level 1|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038497|NCT05584111|Experimental|Dose Level 2|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038498|NCT05584111|Experimental|Dose Level 3|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038499|NCT05584111|Experimental|Dose Level 4|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038500|NCT05584111|Experimental|Dose Level 5|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038501|NCT05584111|Experimental|Dose Level 6|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038502|NCT05584111|Experimental|Dose Level 7|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038503|NCT05584111|Experimental|Dose Level 8|30mg and 100mg capsules, daily administration for 3 week (21 day) cycles
33038504|NCT05582798|Active Comparator|Alpha1-Proteinase Inhibitor 180mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
33038505|NCT05582798|Active Comparator|Alpha1-Proteinase Inhibitor 120mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
33038506|NCT05582798|Placebo Comparator|Placebo 1|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion.
33038507|NCT05582798|Placebo Comparator|Placebo 2|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 120mg/kg, intravenous infusion.
33328922|NCT01382368|Experimental|Sildenafil|
33038510|NCT05564754|Active Comparator|Sedation, temperature device and high MAP|Continuous deep sedation for 36 hours Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >85mmHg.
33038511|NCT05564754|Active Comparator|Sedation, no temperature device and high MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of >85mmHg.
33038512|NCT05564754|Active Comparator|Sedation, temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >65mmHg.
33038513|NCT05564754|Active Comparator|Sedation, no temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
33108131|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
33108132|NCT02896803|Experimental|Experimental|mFLOX
33328923|NCT04568824|Experimental|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
33360504|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
33038514|NCT05564754|Active Comparator|Minimal sedation, temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >85mmHg.
33038515|NCT05564754|Active Comparator|Minimal sedation, no temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
33038516|NCT05564754|Active Comparator|Minimal sedation, temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >65mmHg.
33038517|NCT05564754|Active Comparator|Minimal sedation, no temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
33038518|NCT05563051|Other|Interventional treatment|Open label
33038519|NCT05559580|Experimental|BI 685509|BI 685509
33038520|NCT05559580|Placebo Comparator|Placebo|Placebo
33038521|NCT05555953||Phase-1|The draft CORONATE questionnaire will be administered to participants to create the final version of the questionnaire.
33038522|NCT05555953||Phase-2|The questionnaire created in Phase 1 will be administered to a new group of participants for validation. All partners who are in a relationship with the participants since at least 3 years will be asked to participate in the study for the comparison between participants' and partners' perspectives on the impact of long-term psoriasis on participants' life.
33038523|NCT05554601|No Intervention|attention control|participants receive a FitBit and set goals but do no other intervention
33038524|NCT05554601|Experimental|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration with each other
33038525|NCT05554601|Experimental|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
33038527|NCT05548270|Experimental|DPI-386|Each 0.12 gram of the gel contains0.2 mg of scopolamine HBr
33038528|NCT05548270|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
33038529|NCT05547464|Experimental|BNT164a1|Escalating dose levels
33038530|NCT05547464|Experimental|BNT164b1|Escalating dose levels
33038531|NCT05547464|Placebo Comparator|Placebo|Isotonic NaCl solution (0.9%)
33038532|NCT05546814|Experimental|Sodium algorithm|Starting at 2 weeks of age, the sodium algorithm group will be started based on their sodium levels. This will be adjusted weekly based on weight gain and sodium levels.
33038533|NCT05546814|No Intervention|Control|Subjects will be cared for by current protocols
33038534|NCT05546450|No Intervention|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
33038535|NCT05546450|Experimental|Cornus mas L. and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 30 g/day lyophilized Cornus mas L. fruit powder for their one portion of fruit a day.
33038536|NCT05546450|Experimental|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
33038537|NCT05546450|Experimental|Cornus mas L. Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 30 g/day lyophilized Cornus mas L. fruit powder
33038538|NCT05546450|No Intervention|Healthy Control Group|This group included healthy individuals who were not diagnosed with Metabolic Associated Fatty Liver.
33038539|NCT05545111|Experimental|Dose Level A|Participant administered Dose Level A (6 weeks)
33038540|NCT05545111|Experimental|Dose Level B|Participant administered Dose Level B (6 weeks)
33038541|NCT05545111|Experimental|Dose Level C|Participant administered Dose Level C (6 weeks)
33038542|NCT05545111|Experimental|Dose Level D|Participant administered Dose Level D (6 weeks)
33038543|NCT05545111|Placebo Comparator|Placebo Schedule|Participant administered placebo (6 weeks)
33038544|NCT05543629|Experimental|Part A: BMS-986442 + Nivolumab|
33038545|NCT05543629|Experimental|Part B1: BMS-986442 + Nivolumab|Second line (2L) + Post-immuno-oncology (IO)/Platinum-Doublet Non-small cell lung cancer (NSCLC)
33038546|NCT05543629|Experimental|Part B2: BMS-986442 + Nivolumab|Post IO Gastric Cancer/Gastroesophageal Junction and Post-IO squamous cell carcinoma of the head and neck (SCCHN)
33038547|NCT05543629|Experimental|Part C: BMS-986442 + Nivolumab + Docetaxel|
33038548|NCT05543629|Experimental|Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed|
33038549|NCT05543629|Experimental|Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel|
33038550|NCT05536076|Active Comparator|Intervention hypercapnia arm|Intermittent hypercapnia treatment five days per week for two weeks.
33038551|NCT05536076|Placebo Comparator|Control room air arm|Intermittent pressurized air five days per week for two weeks.
33038552|NCT05534620|Experimental|Treosulfan and Fludarabine|Participants will receive treosulfan 10 gram per square meter (g/m^2), intravenous (IV) infusion, given over 2 hours once daily on three consecutive days (day -4 to day -2), followed by fludarabine, 30 milligram per square meter (mg/m^2) IV infusion once daily on 5 consecutive days (days -6 to -2), preceding allogeneic haematopoietic stem cell transplantation (alloHSCT) on Day 0.
33108133|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
33108134|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
33108135|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
33108136|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
33108137|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
33108138|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
33108139|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
33108140|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
33108141|NCT00559910|Placebo Comparator|Placebo|Placebo
33108142|NCT04680624|Other|Single Group|
33108143|NCT04638608|Other|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
33108144|NCT04638608|Other|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
33108145|NCT00553683|Experimental|poly ICLC|
33108146|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
33108147|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
33360505|NCT03930433|Active Comparator|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
33108148|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
33108149|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
33108150|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
33360506|NCT03930433|Placebo Comparator|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
33108151|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
33108152|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
33108153|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
33108154|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
33108155|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
33108156|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
33360507|NCT03930433|Placebo Comparator|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
33108157|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.~The skin will be closed using a subcutaneous purse-string closure"
33108158|NCT04638101|Experimental|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
33108159|NCT04638101|Experimental|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
33108160|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
33108161|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
33108162|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
33108163|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
33108164|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
33108165|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
33108166|NCT04638491|Experimental|single-arm|PM01183-Dose Escalation
33108167|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
33108168|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
33108169|NCT04638140||Healthy hip population|
33108170|NCT04638140||Hip defect population|
33108171|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
33108172|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
33108173|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
33108174|NCT01235338|Experimental|Venlafaxine XR + LDX|
33108175|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
33108176|NCT04638296||Nurses|OR Nurses
33108177|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
33108178|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:~exposure with TETRA (6W/kg)"
33108179|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
33108180|NCT01234675|Experimental|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
33108181|NCT01234675|Placebo Comparator|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
33108182|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
33108183|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
33108184|NCT04638452|Other|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
33108185|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
33108186|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
33108187|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
33108188|NCT04637789|Other|controlled group|
33108189|NCT04637789|Experimental|experimental group|
33328924|NCT04568824|Active Comparator|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
33328925|NCT04563442||covid 19|complications and comorbidities
33108190|NCT04638218|Experimental|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
33328926|NCT04546828|Experimental|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
33328927|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
33328928|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
33108191|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
33108192|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
33108193|NCT04638257|Experimental|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
33108194|NCT04638257|Placebo Comparator|Placebo|Receives placebo
33328929|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
33328930|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
33328931|NCT05759260||Cases|Athletes with QT interval prolongation
33328932|NCT05759260||Controls|Athletes without QT interval prolongation
33328933|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
33328934|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
33328935|NCT04084444|Experimental|T8 tablet 0.5mg|Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
33328936|NCT04084444|Experimental|T8 tablet 1mg|Oral T8 tablet with HARRT, 1mg, once daily for 48 week
33328937|NCT04084444|Placebo Comparator|Placebo|Oral Placebo with HARRT, once daily for 48 week
33328938|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
33108195|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
33108196|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
33108197|NCT04637906|Experimental|L-arginine|Bioarginina®, 2 orally administered vials per day
33108198|NCT04637906|Placebo Comparator|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
33328939|NCT02563002|Active Comparator|Standard of Care (SOC)|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
33328940|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
33328941|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
32740080|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
32740081|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
32740082|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
33038553|NCT05534347||Juvenile Idiopathic Arthritis|Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
33038554|NCT05526391|Experimental|Early PK Cohort: TAK-341 Dose 1|Participants will be randomized to receive TAK-341 at a starting Dose 1 at 4 week intervals for up to 52 weeks.
33038555|NCT05526391|Placebo Comparator|Early PK Cohort: Placebo|Participants will be randomized to receive TAK-341 placebo, up to 52 weeks.
33038556|NCT05526391|Experimental|Main Cohort: TAK-341 Dose 2|Participants will be randomized to receive TAK-341 at a starting Dose 2 at 4 week intervals for up to 52 weeks.
33038557|NCT05526391|Placebo Comparator|Main Cohort: Placebo|Participants will be randomized to receive TAK-341 placebo, up to 52 weeks.
33038558|NCT05524597|Experimental|Writing about Experiences|Participants will be asked to write about experiences with familiar individuals in their lives.
33038559|NCT05524597|Placebo Comparator|Writing about Places|Participants will be asked to write about experiences with familiar places in their lives.
33038560|NCT05521516|Active Comparator|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular Neuromodulation with NSS-2 Bridge device
33038561|NCT05521516|Sham Comparator|Sham Treatment|Application of 5 days of a nonfunctional sham device
33038562|NCT05518123|Experimental|Rimegepant 75 mg|
33038563|NCT05518123|Placebo Comparator|Placebo|
33038564|NCT05517850|Active Comparator|Therapist-guided|12 weeks of therapist-guided, exposure-based intervention via tha internet, with comprehensive material
33038565|NCT05517850|Experimental|Self-guided|12 weeks of self-guided, exposure-based intervention via the internet, with shortened and improved material
33038566|NCT05517226|Experimental|Cohort 1|Participants in each cohort will receive Dose A cotadutide subcutaneously.
33038567|NCT05517226|Experimental|Cohort 2|Participants in each cohort will receive Dose A cotadutide subcutaneously.
33038568|NCT05517226|Experimental|Cohort 3|Participants in each cohort will receive Dose A cotadutide subcutaneously.
33038569|NCT05517226|Experimental|Cohort 4|Participants in each cohort will receive Dose A cotadutide subcutaneously.
33038570|NCT05514548|Experimental|INV 202 10 mg|INV-202 10 mg Arm
33038571|NCT05514548|Experimental|INV-202 25 mg|INV-202 25 mg Arm
33038572|NCT05514548|Placebo Comparator|Placebo|Placebo Arm
33038573|NCT05514197|Experimental|Vitamin C arm|Intravenous loading of 5g ascorbic acid before incision of wound
33038574|NCT05514197|Placebo Comparator|Control arm|Intravenous loading of the same volume Normal saline as experimental arm
33038575|NCT05512377|Experimental|BI 907828 treatment arm|
33038576|NCT05510193|Experimental|Aktio|Use of the prosthesis for 2 weeks, after a 3-session training
33038577|NCT05510193|No Intervention|Control|Non-use of the prosthesis
33038579|NCT05507749|Experimental|a group of participants receive implantable loop recorder before cryoballoon ablation|Following enrollment, an implantable loop recorder is implanted in all participants for the purpose of arrhythmia (any atrial fibrillation or atrial tachycardia) detection (Reveal LINQ, Medtronic, Minneapolis, MN).
33038580|NCT05502094||Group 1|Participants who experienced Post-Covid 19 syndrome were involved in this group.
33038581|NCT05502094||Group 2|Participants who fully recovered after Covid-19 were involved in this group.
33038582|NCT05502094||Group 3|Participants who had never had Covid-19 were involved in this group.
33038583|NCT05499052||REKOVELLE®|
33038584|NCT05496738|Experimental|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously
33038585|NCT05496738|Experimental|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously
33038586|NCT05496738|Placebo Comparator|Intravenous placebo|Placebo will be administered intravenously
33038587|NCT05496738|Placebo Comparator|Subcutaneous Placebo|Placebo will be administered subcutaneously
33038588|NCT05493735|Placebo Comparator|Control|Lubricating jelly (placebo) will be placed in the vagina to the level of the pessary, five minutes prior to pessary removal.
33038589|NCT05493735|Experimental|Experimental|Lidocaine jelly will be placed in the vagina to the level of the pessary, five minutes prior to the pessary removal.
33038590|NCT05493293|Experimental|NBI-921352 Treatment|Treatment for up to 107 weeks.
33038591|NCT05491213|Experimental|TELESCOPE intervention|If a participant is a current smoker then they are offered and navigated to evidence - based smoking cessation. If the participant is interested in screening the the LDCT is ordered, support for screening, diagnostic testing and oncology care as needed from Nurse Navigator.
33038592|NCT05491213|No Intervention|Enhanced usual care (EUC)|Participants will be surveyed one week after the scheduled office visit (EUC patients) ) to collect primary and secondary outcome data related to the coaching and office visit.
33328942|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
33328943|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
33328944|NCT05077488|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Intradermal injection (deep dermis) in marionettes lines and/or forehead by a specialist injector
33328945|NCT05668728|Active Comparator|Group 1|Dry needling + standard exercise program with 4 sessions of stick and pull out method at 1 week intervals
33328946|NCT05668728|Active Comparator|Group 2|Dry needling + standard exercise program with 4 sessions of turn-and-wait method at 1-week intervals
33328947|NCT05668728|Active Comparator|Group 3|Dry needling + standard exercise program with 4 sessions of stick and turn and wait method 1-week intervals
33328948|NCT05668572|Experimental|The Group of Investigational Vaccine|
33038593|NCT05489575|Experimental|Active CPAP (Daytime Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 2 hours while supine and awake.
33038594|NCT05489575|Sham Comparator|Sham CPAP (Daytime Study)|Sham CPAP is applied for up to 2 hours while supine and awake.
33038595|NCT05489575|Experimental|Active CPAP (Overnight Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 9 hours during the night.
33328949|NCT05668572|Active Comparator|The Group of Active Control Vaccine|
33328950|NCT03828240|Other|Enhanced rehabilitation|
33328951|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
33328952|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
33328953|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
33328954|NCT05281458|Experimental|Early endoscopic interventions for AP|Participants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
33328955|NCT05281458|No Intervention|Standard endoscopic interventions for AP|Participants in the control group will have postponed drainage, preferably until AP progress to the walled-off necrosis stage.
33328956|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
33328957|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
33038596|NCT05489575|Sham Comparator|Sham CPAP (Overnight Study)|Sham CPAP is applied for up to 9 hours during the night.
33038597|NCT05489575|Active Comparator|Sleeping in a head-up tilt position (Overnight Study)|Sleeping with the bed tilted head-up by 10 degrees for up to 9 hours during the night.
33038598|NCT05485753|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33038599|NCT05483907|Experimental|BBT-877|200 mg twice daily (BID)of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
33038600|NCT05483907|Placebo Comparator|Placebo|200 mg twice daily (BID)of Placebo in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
33038601|NCT05477524|Experimental|VLA15 Lot 1 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
33038602|NCT05477524|Experimental|VLA15 Lot 2 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
33038603|NCT05477524|Experimental|VLA15 Lot 3 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
33038604|NCT05477524|Placebo Comparator|Placebo (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
33038605|NCT05472441|Active Comparator|Mid Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
33038606|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
33038607|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
33038608|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
33038609|NCT05470504|Other|1|open label pegvisomant
33038610|NCT05466240|Active Comparator|AT-752 750-mg TID for 5 days|Tablet; 750-mg, Three (3) times a day for 5-days
33038611|NCT05466240|Active Comparator|AT-752 Dose A for 5 days|Tablet; Dose A, for 5-days
33038612|NCT05466240|Active Comparator|AT-752 Dose B for 5 days|Tablet; Dose B, for 5-days
33038613|NCT05464784|Experimental|MN-001|
33108199|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
33108200|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
33108201|NCT04637750|Experimental|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
33108202|NCT04637750|No Intervention|Control group|GPs not receiving any informative intervention
33108203|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
33108204|NCT04637633|Experimental|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
33108205|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
33328958|NCT02374476|Active Comparator|Registry|Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful
33108206|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
33108207|NCT04637867|Other|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
33108208|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
33108209|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
33108210|NCT01234480|Experimental|Participants with Cervical Disease|Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
33108211|NCT01234480|Experimental|Participants without Cervical Disease|Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
33108212|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
33108213|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
33108214|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
33108215|NCT04637828|Experimental|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
33108216|NCT04637828|No Intervention|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
33108217|NCT04206475|Experimental|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
33108218|NCT04206475|Active Comparator|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
33108219|NCT05512624|Experimental|Intervention Arm|The course of Common Elements Treatment Approach (CETA - the intervention under study) is built to be flexible depending on need. Mild symptoms could result in fewer sessions (e.g., 5), while greater severity may require 8-12 sessions.
33108220|NCT05512624|No Intervention|Waitlisted Arm|The waitlisted arm will be offered the CETA approach upon conclusion of the endline data collection.
33108221|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
33108222|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
33108223|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
33108224|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
33108225|NCT04637711|Experimental|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
33108226|NCT04637711|No Intervention|Extensive lesion excision|
33108227|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
33108228|NCT04637516|Active Comparator|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
33108229|NCT04637516|Placebo Comparator|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
33108230|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
33108231|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
33108232|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
33328959|NCT01300884||healthy volunteers|
33328960|NCT01300884||patients with fecal incontinence|
33328961|NCT01300884||patients with constipation|
33328962|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
33328963|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
33038614|NCT05464784|Placebo Comparator|MN-001 Placebo|The placebo comparator is a tablet identical in appearance to MN-001.
33328964|NCT03818022|No Intervention|Control|
33328965|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
33328966|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
33328967|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
33328968|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
33038615|NCT05463237||Pregnant women with gestational diabetes(n:87)|Visceral adipokine level will be examined in pregnant women with gestational diabetes.
33038616|NCT05463237||Control group pregnant (n:87)|Visceral adipokine level will be examined in pregnant women with normal pregnant .
33038617|NCT05459571|Experimental|Axicabtagene Ciloleucel|"Participant will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m^2 and fludarabine 30 mg/m^2 ) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2.~Participant will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10^6 cells/kg."
33038618|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then continue as early responder|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage (for 8 weeks).
33038619|NCT05457985|Experimental|Clinician Supported (CS) PTSD Coach App then continue as early responder|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first). Early responders will be encouraged to continue app use but will discontinue clinician support sessions for 8 weeks.
33038620|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then full PE|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
33038621|NCT05457985|Experimental|Clinician Supported PTSD Coach App then full PE|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
33038622|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then continued PE-PC|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to continue with PE-PC (medium intensity) will continue weekly sessions for 8 weeks.
33038623|NCT05457985|Experimental|Clinician Supported PTSD Coach App then continued CS PTSD Coach App|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to continue this treatment will have the frequency reduced to twice monthly.
33038624|NCT05455424|Experimental|Niraparib + ASC|"Patients will receive 200/300 mg of niraparib daily for study period of up to 24 weeks. Patients will be treated until disease progression, withdrawal, death or development of significant treatment limiting toxicity. Niraparib will be supplied in oral formulation as 100 mg capsules. The starting dose of Niraparib will be based upon the patient's baseline body weight and/or platelet count:~Participants with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 109/L will be administered niraparib 300 mg daily.~Participants with a baseline body weight <77 kg or baseline platelet count <150 x 109/L will be administered niraparib 200 mg daily.~The dose of Niraparib can be reduced in 100 mg increments, to a minimum of 100 mg, per protocol. Dose escalations are not permitted."
33038625|NCT05455424|Active Comparator|Active Symptom Control|Patients in this arm will be managed symptomatically and will be treated as per the standard of care at each participating site. ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
33038626|NCT05453006|Experimental|Intervention|At the three intervention clinics, clinic providers or staff will offer women the option to perform HPV self-sampling as an alternative to cervical cancer screening by a clinician.
33038627|NCT05453006|No Intervention|Control|Control clinics will have passive participation and their only involvement will be that data will be pulled from these clinics. Women in the control clinics will be offered usual care cervical cancer screening by a clinician. The research team will not have any contact with women in the control clinics.
33328969|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
33328970|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
33038630|NCT05447286|Placebo Comparator|Placebo + Oxycodone|Participants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
33038631|NCT05447286|Active Comparator|NYX-783: 50 mg dose + Oxycodone|Participants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
33328971|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
33328972|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
33328973|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
33038632|NCT05447286|Active Comparator|NYX-783: 150 mg dose + Oxycodone|Participants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
33328974|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
33328975|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
33328976|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
33328977|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
33328978|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
33328979|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
33328980|NCT01206972|Experimental|Arm 1|
33038633|NCT05440799|Experimental|BI 1819479|
33038634|NCT05440799|Placebo Comparator|Placebo|
33328981|NCT01206972|Experimental|Arm 2|
33328982|NCT01206972|Experimental|Arm 3|
33328983|NCT01206972|Active Comparator|Arm 4|
33328984|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
33328985|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
33328986|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
33328987|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
33328988|NCT01299246|Experimental|improving self-care|
33328989|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
33328990|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
33038635|NCT05439616|Experimental|Cariprazine|Participants will receive age-and weight dependent flexible doses of cariprazine once daily for 8-weeks.
33038636|NCT05439616|Placebo Comparator|Placebo|Participants will receive placebo once daily for 8-weeks.
33038637|NCT05437991|Other|Morphological quantification of low-grade carotid stenosis|Morphological quantification using ECST method and implying two independent observers
33038638|NCT05437978|Experimental|"Adapted Physical Activity (APA) program called Cap Sport Santé 83"|
33038639|NCT05436262|Other|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
33038640|NCT05436262|Other|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where the participants will then perform respective motor and/or imagery tasks at home for 3 weeks.
33038641|NCT05431166|Experimental|Immediate Treatment Group|8 weeks of Yoga Classes during first 8 weeks of study
33038642|NCT05431166|Active Comparator|Waitlist Control|8 weeks of Yoga Classes during second 8 weeks of study
33038643|NCT05423522|Experimental|NanoLithium® NP03|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: Approximately one year (12 weeks for the double-blind period and 36 weeks for the subsequent open-label period)."
33038644|NCT05423522|Placebo Comparator|Placebo|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: 12 weeks during the double-blind period."
33038645|NCT05423158|Experimental|d-Coaching|Will receive home-based cardiac rehabilitation (HBCR) with digital coaching (d-Coaching) intervention
33038646|NCT05423158|No Intervention|Usual Care|Will receive home-based cardiac rehabilitation (HBCR) alone
33038647|NCT05421143||Quantitative study with medication reconciliation|The data collection will continue consecutively until the goal of 150 patients is reached. If it is feasible, we will try to reach 200 patients. We think 150-200 patients will give good insight into different types of medication discrepancies, since studies have shown that up to 90% of patients have at least one medication discrepancy in primary care.
33038648|NCT05421143||Qualitative semi-structured interviews with patients and next of kin|A selection of patients from the quantitative study described above will be chosen purposively and step by step along the way to ensure the informational strength in the selection. When possible, we will include next of kin in the interviews together with the patient. We aim to include around 20-30 patients, without counting in next of kin. The part will be accomplished together with the quantitative part. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; women and men, different ethnicities, education type, spread in age, number of medications and help from next of kin/homecare nurses or not. It is also important to ensure variability in number and type of medications and diagnoses.
33038649|NCT05421143||Qualitative semi-structured interviews with HCP|HCP will be recruited purposively along the quantitative study to ensure the informational strength in the selection. We aim to include around 15-20 HCP. The HCP recruited are involved in the patients medication regime or management, this to ensure that they have knowledge about patients with multiple long term conditions. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; woman and men, physicians and homecare nurses, spread in age, years of working experience, different ethnicities and number of medications the patients they care for use.
33108233|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
33108234|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
33038650|NCT05416060|Experimental|Dulce Digital|Patients will participate in a text-based diabetes self-management educational and support (DSME/S) program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
33038651|NCT05416060|Experimental|Project Dulce Telehealth DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
33038652|NCT05416060|Experimental|Project Dulce Live DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
33038653|NCT05413317||Adult patients hospitalized for suspicion of pulmonary embolism recurrence|Patients with at least one of the following symptoms: acute dyspnea or aggravation of chronic dyspnea, chest pain, hemoptysis or syncope
33038654|NCT05410158|Other|Pecs block group|"The Pecs block will be performed while the patient in the supine position with the ipsilateral upper limb abducted 90 degree with an 80 mm 21 G needle (Pajunk®SonoPlex Stim cannula U.S.A) using linear array ultrasound probe of high frequency (Sonosite®, Inc. U.S.A) starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line .~Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg) (Ketamine® Sigma-Tec, Egypt) injected between the pectoralis minor and the serratus anterior muscles , and skin incision will be performed 15 minutes after the block was given."
33038655|NCT05410158|Other|Topical instillation group:|After surgical hemostasis before wound closure Patients will receive 1 mg/kg ketamine hydrochloride plus 30 mL of 0.25% bupivacaine hydrochloride which will be put in asterile syringe and irrigated onto the surgical field at the end of surgery .
33038656|NCT05407311|Experimental|64Cu-SAR-BBN|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-BBN.
33038657|NCT05401487||Adult patient with a severe trauma requiring SMUR activation|Trauma defined by appearance of lesions following a fall, a road accident, a burn or the penetration of a foreign body and regulated by one of the SAMU PACA region centres (84, 83, 13, 04)
33038658|NCT05399355|Active Comparator|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
33038659|NCT05399355|Sham Comparator|Sham Treatment|Application of 7-30 days of a nonfunctional sham device.
33038660|NCT05399004||Observational (survey)|Patients complete surveys over 15-20 minutes at baseline and at 3, 6, and 12 months.
33038661|NCT05397470|Experimental|Treatment|Losmapimod 15 mg twice daily by mouth with food for 48 weeks.
33038662|NCT05397470|Placebo Comparator|Placebo|Placebo twice daily by mouth with food for 48 weeks.
33038663|NCT05392803|Experimental|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy, 7 day washout, 30 days of sham."
33038664|NCT05392803|Experimental|Sham then Active Treatment|"Application of 30 days of a nonfunctional sham device, 7 day washout, then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy"
33038665|NCT05389696|Experimental|Part1. Group1. MIT-001 SC 10mg|Single subcutaneous administration of 10mg MIT-001 or placebo
33038666|NCT05389696|Experimental|Part1. Group2. MIT-001 SC 20mg|Single subcutaneous administration of 20mg MIT-001 or placebo
33328991|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
33038667|NCT05389696|Experimental|Part1. Group3. MIT-001 SC 40mg and IV 40mg|Single subcutaneous administration of 40mg MIT-001 or placebo and then signle intravenous administration of 40mg MIT-001 or placebo
32866678|NCT05618652|Active Comparator|Clinician Coaching Immediate Intervention Arm-- Caregivers|"Clinicians who receive the intervention will participate for up to 12 months, which includes completion of didactics, 8 audio-recorded clinical encounters, 4 feedback sessions, and completion of a post-intervention brief interview and survey. After completing didactic training elements, clinicians will receive coaching and professional feedback on their communication with caregivers of children in the hospital. The investigators will provide clinicians with illustrative examples from their encounters to prompt discussion and self-reflection.~Caregivers of hospitalized children will not know if their clinician has received the communication intervention. The investigators will recruit 40 caregivers in this arm."
33038668|NCT05389696|Experimental|Part2. Group1: MIT-001 SC 20mg|Multiple subcutaneous administration of 20mg MIT-001/day or placebo for 7days
33038669|NCT05389696|Experimental|Part2. Group2: MIT-001 SC 40mg|Multiple subcutaneous administration of 40mg MIT-001/day or placebo for 7days
33038670|NCT05383885||Observational cohort|"The study is an observational study on a single cohort of consecutive out-of-hospital cardiac arrest patients.~All patients in the cohort will be monitored with a non-invasive pletismograph. No intervention will be administered to any patient and no decision on treatment will be based on the collected informations. Treating physicians will be blinded to collected values of perfusion index during the study"
33038671|NCT05381454|Experimental|MitoQ|Treatment group
33038672|NCT05381454|No Intervention|Control group|Control group
33038673|NCT05378347|Experimental|Medtronic Endurant II/IIs|Subjects will be randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
33038674|NCT05378347|Experimental|Gore Excluder / Excluder Conformable|Subjects will be randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
33038675|NCT05373823|Experimental|Enhance MSS using multi-level stakeholder collaboration (Mo.1-15)|Enhancements of MSS to increase intervention effects - theory - based strategies (PHM), (BCT)
33038676|NCT05373823|Experimental|Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60)|RCT of enhanced MSS testing effectiveness (through SSE, sun protection behavior Involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
33328992|NCT03817476|Experimental|T1-T2-R|
33328993|NCT03817476|Experimental|T1-R-T2|
33328994|NCT03817476|Experimental|T2-T1-R|
33328995|NCT03817476|Experimental|T2-R-T1|
33328996|NCT03817476|Experimental|R-T1-T2|
32866679|NCT05618652|Other|Clinician Coaching Wait-List Control Arm-- Caregivers|"Clinicians in the wait-list control arm will initially serve as the control arm then receive the intervention to provide feasibility and acceptability data. The clinicians randomized the control arm will undergo didactics and feedback once their pre-intervention audio-recordings are complete.~Caregivers of hospitalized children will not know if their clinician has yet received the communication intervention. The investigators will recruit 40 caregivers in this arm prior to clinicians receiving the intervention."
33038677|NCT05373823|Active Comparator|Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)|Assessment of implementation outcomes and key contextual factors from the perspective of multi - level stakeholders
32866680|NCT04427670|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
32866681|NCT04427670|Other|Group intervention|Group intervention will be provided to the experimental group.
32866682|NCT04783649||High risk group|Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy
32866683|NCT04783649||Population sample|A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening
32866684|NCT04783805||Spontaneous HSIL regression|Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).
32866685|NCT04783805||Conization|Women who have cervical conization for any reason during follow-up. Patients in this group will be further classified according to indication criteria: failure to meet criteria for conservative management or persistence of HSIL after 24 months of follow-up.
32866686|NCT01470651|Experimental|Armodafinil|Active medication
32866687|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
32866688|NCT04783493|Active Comparator|ACTIVE|In the active group, non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold, this determined by abdominal muscle contractions, found from single pulses, applied gradually every 10 seconds until the contractions appear. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds.
32866689|NCT04783493|Placebo Comparator|PLACEBO|In the placebo group, a coil will be allocated in the T2-T3 thoracic region, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated. To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS).
32866690|NCT04066049|Active Comparator|Treatment|Participants in the Treatment group will receive a hybrid therapist-implemented and caregiver-implemented intervention be compared to a BAU control group. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
32866691|NCT04066049|No Intervention|Control|Participants in the BAU group will be offered 10 caregiver support sessions after completing the 12-month follow-up. These home-based sessions will emphasize shared book reading, modeling vocabulary for school readiness in play and routines, and include general information for families about options for public school language related services. Each session will last about 30 minutes and be conducted by a trained staff member. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
32866692|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
32866693|NCT04783337|Experimental|HR-pQCT (high resolution computertomograph)|"This arm is the inverventional group for all collected cases. No other arms are available as comparator or control. All patients are treated the same.~Description of the intervention in the section Intervention."
32866694|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
32866695|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
32866696|NCT04783025|Experimental|Intervention Group (IG)|The participants in the IG will receive BGCTS, a blended training programme
32866697|NCT04783025|Active Comparator|Control Group (CG)|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staff.
32866698|NCT04782557|Experimental|EUS-guided PVA and HVA|Patient will undergo EUS-guided PVA and HVA
33038678|NCT05373784|Experimental|FMT cohort|This will be a single-arm pilot study of patients with uncomplicated diverticulitis. All subjects enrolled as recipients will undergo FMT via colonoscopy.
33328997|NCT03817476|Experimental|R-T2-T1|
33328998|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
33328999|NCT01299324|No Intervention|Control|Standard of care only. No infusion
33329000|NCT01299402|Experimental|Soulera Herbal Blend|
33329001|NCT01299402|Placebo Comparator|Placebo Blend|
33360508|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
33360509|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
32866699|NCT01472445|Experimental|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
32866700|NCT01472445|Experimental|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
32866701|NCT04782635|Experimental|AI group|"Care givers will be selected through permuted block.~They will be explained the procedure of intervention and written consent will be asked.~Mobile application will be installed in their mobile.~They will be explained the working of mobile application~Application will make a standard diet plan for the child according to the requirements of the child~Then the child will use the application for one month.~After one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application.~Nutritional status of the patient will be monitored including weight, height, clinical signs, dietary history and will be updated in application.~Then patient will follow the application for one month~After another one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application and nutritional status will be measured"
32866702|NCT04782635|Other|usual care group|"Caregivers (Mothers/fathers/guardians) will be selected through permuted block.~Patient weight, height, clinical signs will be noted.~Caregivers will be handed over pamphlet regarding dietary instructions on discharge.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted including weight, height, clinical signs and dietary history.~Patient will leave hospital with no added dietary instruction.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted weight, height, clinical sign, and dietary history."
32866703|NCT04782479||in the air|the position of the practitioner's hand holding the tube was placed in the air while the assistant pulling back the stylet.
32866704|NCT04782479||on the cheek of a manikin|the position of the practitioner's hand holding the tube was placed on the cheek of a manikin while the assistant pulling back the stylet.
32866705|NCT04782089|Experimental|Camrelizumab+Fluzoparib|
32866706|NCT04782167|Experimental|BRACE protocol|Researcher give Brace protocol to one group
32866707|NCT04782167|Experimental|Proprioception training|Researcher give proprioception protocol to one group
32866708|NCT04782011|Experimental|ATC/DDD arm|The intervention is the introduction of the ATC/DDD including the training of healthcare workers on its importance and usage in monitoring antibiotic use. The unit of intervention will be a health facility. Antibiotic prescriptions and antibiotic utilization records for adult patients (in-patients and ambulatory) from the selected facilities will be enrolled in the study.
32866709|NCT04782011|No Intervention|Control arm|The health care workers will continue with standard practice. However, the research team will collect data on antibiotic prescriptions and antibiotic utilization for adult patients (in-patients and ambulatory) from the selected facilities. The data will be compared with that of the intervention arm.
32866710|NCT01584609|Experimental|Penumbra System with Separator 3D|
32866711|NCT01584609|Active Comparator|Penumbra System alone|
32866712|NCT04755023|Experimental|Treatment Arm|Administration of 6 cycles of chemotherapy
32866713|NCT04781933|Active Comparator|Treatment with Combo|3 dietary supplements will be given
32866714|NCT04781933|Placebo Comparator|Treatment with Placebo|3 placebos will be given
32866715|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
32866716|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
32866717|NCT04781621|Experimental|Robotic Gait Training|Patients in the Robotic Gait Training (RGT) group will receive 90 minutes per week of RGT once patients are deemed clinically appropriate as defined by being able to tolerate standing for 15 minutes without orthostatic intolerance. The duration of treatment will span the patient's length of stay in inpatient rehabilitation. The Ekso Bionics Ekso GT™ robotic exoskeleton will be used for RGT.
32866718|NCT04781621|Active Comparator|Usual Care Gait Training|Usual Care (UC) gait training including body weight-supported treadmill training (BWSTT) and conventional overground walking.
32866719|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
32866720|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
32866721|NCT04781777|No Intervention|Control group|Dexmehtasone and local anesthetics in carpal tunnel syndrome
32866722|NCT04781777|Active Comparator|Insulin group|insulin added to dexamehtasone and local anesthetics
32866723|NCT04781075|Experimental|TAP Block with Exparel|TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline
32866724|NCT04781075|Active Comparator|TAP Block with bupivicaine|TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline
32866725|NCT04780997|Experimental|Virtual Realty|Microsoft Xbox Kinect® was used for virtual reality exercises
32866726|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
32866727|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
32866728|NCT04825392|Experimental|HX008|
32866729|NCT04780919|Experimental|Treatment Group (A)|Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
33038679|NCT05371613|Experimental|Cohort A: Participants with nMPS II|
33038680|NCT05371613|Experimental|Cohort B: Participants with nnMPS II|
33038681|NCT05371613|Experimental|Open-label Treatment Phase|Participants who meet pre-specified criteria may receive DNL310 or idursulfase
33038682|NCT05370352|Experimental|Mobile chat messaging|Standard smoking cessation treatment + Personalised chat messaging
33038683|NCT05370352|Active Comparator|SMS messaging|Standard smoking cessation treatment + Regular SMS text messaging generic information about the harms of smoking and the benefits of quitting
33329002|NCT02918292|Experimental|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
33329003|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
33329004|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
33329005|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
33038684|NCT05366413|Experimental|Pain management strategies|"Participants will receive early referral to an anesthesia-trained interventional pain management specialist evaluated for pain management strategies.~Participants will complete surveys every 2 months and will have the option of tracking their pain at home using a secure smartphone application.~Participants will be followed on the study for 4 months."
33038685|NCT05358613|Experimental|Immediate treatment|"The My Choices program will be offered immediately (maximum 10 working days from their first research interview) to the participants of this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
33038686|NCT05358613|Active Comparator|Waiting list|"The My Choices program will be offered 3 months after the first research interview to the participants in this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
33329006|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
33329007|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
33329008|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
33038687|NCT05357677|Experimental|SR419-Placebo sequence|30 mg of SR419 administered TID for 4 weeks followed by placebo administered TID for 4 weeks
33038688|NCT05357677|Experimental|Placebo-SR419 sequence|placebo administered TID for 4 weeks followed by 30 mg of SR419 administered TID for 4 weeks
33038689|NCT05352347|Active Comparator|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
33038690|NCT05352347|Active Comparator|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
33038691|NCT05352347|Placebo Comparator|Placebo|Normal saline (NS) 100mL bid
33038692|NCT05337293|Experimental|COPE-HF Partnership Intervention|Working with a trained registered nurse interventionist, participants in this arm were trained to use a 4-step problem-solving process to manage identified problems related to heart failure. Heart failure self-care education and materials were provided as indicated based on specific identified problems.
33038693|NCT05337293|Sham Comparator|Attention|Participants in this arm received telephone calls from a trained research assistant on the same schedule as the intervention group. During these calls basic data were collected on several key areas of heart failure self-care. No intervention or patient education took place during these calls.
33038694|NCT05337293|No Intervention|Usual Care|Participants in this arm received usual care from their healthcare providers and facility designated heart failure discharge education only.
33038695|NCT05333211|Experimental|Investigational Arm with Ortho-R/PRP|Using a double row, Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) with Ortho-R/PRP combination
33038696|NCT05333211|No Intervention|Control Arm Standard of Care without Ortho-R/PRP|Using the Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) without Ortho-R/PRP combination
33038697|NCT05331222|Experimental|Jantar-1 (JT-1), 7% (w/w) aqueous solution|Dosing regimen: ad libitum between at least 2 doses, in the morning and in the evening, and at most 10 doses per day. A dose corresponds to two strokes of 100ul each per nostril.
33038698|NCT05329584|Experimental|Group I|InSpace device + accelerated rehabilitation in a formalized program (FP)
33038699|NCT05329584|Experimental|Group II|InSpace device + accelerated rehabilitation in an at-home program (AHP)
33038700|NCT05329441||Study Participants|All depressed participants will undergo the same study procedures
33038701|NCT05321082|Experimental|BI 1015550 low dose|
33038702|NCT05321082|Experimental|BI 1015550 high dose|
33038703|NCT05321082|Placebo Comparator|Placebo|
33038704|NCT05321069|Experimental|BI 1015550 low dose|
33038705|NCT05321069|Experimental|BI 1015550 high dose|
33038706|NCT05321069|Placebo Comparator|Placebo|
33038707|NCT05317442|Experimental|Pressure Injury in Sacrum Wound|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply once a day~Duration: up to 16 weeks"
33329009|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
33329010|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
32866730|NCT04780919|Sham Comparator|Sham Group (B)|Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
32866731|NCT04816110|Experimental|mineralized plasmatic matrix with collagen membrane|
32866732|NCT04816110|Active Comparator|mineralized plasmatic matrix without collagen membrane|
32866733|NCT05565963|Experimental|Intervention group.|12-week intervention, with a 12-week follow-up. Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state.
32866734|NCT05565963|No Intervention|Control group.|No intervention with a 12 week follow-up.
32866735|NCT03991169|Experimental|Oral Iron therapy|Participant will receive oral iron therapy.
32866736|NCT03991169|No Intervention|No oral iron therapy|Participant will not receive oral iron therapy for 3 months.
32866737|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
32866738|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
32866739|NCT04780529|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
32866740|NCT04411992|Experimental|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
32866741|NCT04411992|No Intervention|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
32866742|NCT04411992|Experimental|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
32866743|NCT04411992|No Intervention|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
32866744|NCT04780373||Development cohort|
32866745|NCT04780373||Validation cohort|
32866746|NCT01512849|Experimental|TA-7284 Low|
32866747|NCT01512849|Experimental|TA-7284 High|
32866748|NCT04816032|Experimental|Pennebaker's expressive writing|Three consecutive days for 20 minutes daily of expressive writing. The topic of the traumatic traveling experience, focalizing the attention on the deeper emotions, thoughts, and feelings.
32866749|NCT04816032|Active Comparator|Writing about different aspects of their knowledge|Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
32866750|NCT04816032|No Intervention|Control|No intervention
32866751|NCT03945383|Experimental|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
32866752|NCT04780451|Experimental|Omega|
32866753|NCT04780451|Placebo Comparator|Placebo|
32866754|NCT01586091|Placebo Comparator|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
32866755|NCT01586091|Active Comparator|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
32866756|NCT01586091|Active Comparator|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
32866757|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
32866758|NCT04818684||Physician|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
32866759|NCT04818684||Psychologists|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
32866760|NCT04818684||Caregivers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
32866761|NCT04818684||Nurses|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
32866762|NCT04818684||Social and Educational Assistants|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
32866763|NCT04818684||Volunteers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit. The representative participating in the study will preferably be the volunteer coordinator.
32866764|NCT04818684||Relatives|"Relative of a patient who died in the palliative care unit at least 6 months ago Person to trust or to prevent if not designated Relative understanding and speaking sufficient French Relative not a health professional~Relative who visited the palliative care unit during the last 3 days of the patient's life and who met the care team:~Traceability of the arrival of the loved one in the last 2/3 days of the patient's hospitalization~Traceability of a meeting of the loved one with a member of the team over the last 3 days of his hospitalization or verification during telephone contact with the loved one after drawing lots Relative with an email address (to be verified during telephone contact with the loved one after drawing lots)"
32866765|NCT04779749||COVID positive <20 weeks|Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
32866766|NCT04779749||COVID positive >20 weeks|Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
33038708|NCT05312970|Active Comparator|Varithena®|Varithena® (polidocanol injectable foam) 1%
33038709|NCT05312970|Active Comparator|FDA-approved ETA systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
33038710|NCT05305391|Experimental|A2 milk + placebo|A2 whole milk, 3.5% fat, heat-treated; placebo capsule without enzyme
33038711|NCT05305391|Experimental|A2 milk+ lactase enzyme|A2 whole milk, 3.5% fat, heat-treated; lactase capsule
33038712|NCT05305391|Experimental|Protein-hydrolyzed A1 milk + placebo|Protein-hydrolyzed lactose-free milk, 3% fat, heat-treated; placebo capsule without enzyme
33329011|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
33329012|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
33329013|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
33329014|NCT05654532|Experimental|AC699 Dose Escalation|Participants will receive an assigned dose of AC699 monotherapy during dose escalation. One cycle is defined as 28 days.
33329015|NCT01301352|No Intervention|Nasojejunal feeding (control)|
33329016|NCT01301352|Experimental|Nasogastric feeding (intervention)|
33329017|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
33329018|NCT01207284|No Intervention|Control|
33329019|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
32866767|NCT04779749||Control|Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020
33329020|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
33329021|NCT01299636|Experimental|PM060184|
33329022|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
33329023|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
33329024|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
33329025|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
33329026|NCT05608746|Experimental|Intervention Group|
33329027|NCT05608746|Other|Control Group|
33038713|NCT05301439|Experimental|Restoration Group|Participants in this group will receive the universal adhesive restorative procedure combined with condensable bulk fill resin, for the restoration of the cavited teeth.
33038714|NCT05301439|Experimental|Hall Technique Group|Participants in this group will receive the Hall Technique with steel crowns for the restoration of the cavited teeth.
33038715|NCT05301439|Experimental|Steel Crown with Conventional Technique Group|Participants in this group will receive steel crowns with conventional technique for the restoration of the cavited teeth.
33038716|NCT05300139||Patients included in the ULTREC study who had a recurrence of deep vein thrombosis|Patients who have a baseline CDUS diagnosis of recurrent DVT as identified in the ULTREC study.
33329028|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
33329029|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
33038717|NCT05297695|Experimental|Study group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will receive H. pylori eradication therapy.
33038718|NCT05297695|No Intervention|Control group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will not receive H. pylori eradication therapy.
33329030|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
33329031|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
33329032|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
33038719|NCT05291403|Experimental|Experimental group (medical thoracoscopic cryotherapy)|
33038720|NCT05291403|Active Comparator|Cisplatin/erythromycin control group (sequential intrathoracic injection of cisplatin/erythromycin)|
33038721|NCT05291403|Other|Blank control group|Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.
33108235|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
33329033|NCT05604144|Other|Active Treatment|As a Proof of Concept Study, 5 subjects will follow the same protocol, with one cryoanalgesic treatment (iovera°®) with a 6 month clinical follow-up.
33329034|NCT03720210|Experimental|RFA group|RFA
33329035|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
33329036|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
33329037|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
33329038|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
33329039|NCT05624034||Healthy group|Subjects with no previous medical history (healthy volunteers) will be assessed for eligibility criteria.
33329040|NCT05624034||Idiopathic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and not having a known cause of gastroparesis like endocrine, neurological, rheumatological disorder.
33360510|NCT01585519|Experimental|(Group 2) 2 High Apples|
33360511|NCT01585519|Experimental|(Group 3) 2 Low Apples|
33360512|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
33360513|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
33360514|NCT03275740|Experimental|PF-06755347 intravenous healthy participant|intravenous administration
33108236|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
33108237|NCT00560144|Experimental|1|
33108238|NCT00560144|Experimental|2|
33108239|NCT00560144|Experimental|3|
33108240|NCT02895477|Experimental|Intervention group|Hearing aid
33108241|NCT02895477|Experimental|Test group|Hearing aid
33108242|NCT04317391|Experimental|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
33108243|NCT04637477|Experimental|Virtual ELM|
33108244|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
33108245|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
33108246|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
33108247|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
33108248|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
33108249|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
33329041|NCT05624034||Diabetic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and Diabetes mellitus of any duration.
33108250|NCT01227928|Experimental|pazopanib|experimental medication
33108251|NCT01227928|Placebo Comparator|placebo|placebo comparator
33108252|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
33108253|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
33329042|NCT00898638||Healthy Volunteers|Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.
33329043|NCT00898638||Head and Neck Tumor patients|Eligible patients will be identified at the Vanderbilt Head & Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).
33329044|NCT05602818|Experimental|Soticlestat 300 mg|Participants will receive a single oral dose of soticlestat 300 milligrams (mg).
33329045|NCT05602818|Experimental|Soticlestat 600 mg|Participants will receive a single oral dose of soticlestat 600 mg.
33329046|NCT05602818|Experimental|Soticlestat 900 mg|Participants will receive a single oral dose of soticlestat 900 mg.
33329047|NCT05602818|Active Comparator|Alprazolam 2 mg|Participants will receive a single oral dose of over encapsulated alprazolam 2 mg.
33329048|NCT05602818|Placebo Comparator|Placebo|Participants will receive a single oral dose of matching placebo.
33329049|NCT05668104|Experimental|Jing Si Herbal Tea Liquid Packet|Participants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally twice daily for 28 days.
33329050|NCT05668104|Placebo Comparator|Jing Si Herbal Tea Liquid Packet Placebo|Participants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally twice daily for 28 days.
33329051|NCT00843882|Active Comparator|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
33329052|NCT00843882|Experimental|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
33108254|NCT04637360|Experimental|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
33108255|NCT04637360|Experimental|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
33108256|NCT05656924|Experimental|digital prosthetic interface technology group|Study participants randomized to this group will use the digital prosthetic interface technology developed by Bionic Skins.
33108257|NCT05656924|No Intervention|traditional socket and liner technology group|Study participants randomized to this group will use a traditional socket-liner technology (i.e., study participants will use their own liner and socket system).
33108258|NCT05656885|Active Comparator|Soft Spherical Hydrogel Contact Lens A|Subjects will wear Soft Spherical Hydrogel Contact Lens A for the first period of 15 minutes and Soft Spherical Silicone Hydrogel Contact Lens B for the second period of 15 minutes.
33329053|NCT01297140|Experimental|questionary|
33329054|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
33108259|NCT05656885|Experimental|Soft Spherical Silicone Hydrogel Contact Lens B|Subjects will wear Soft Spherical Silicone Hydrogel Contact Lens B for the second period of 15 minutes.
33108260|NCT04317703|Experimental|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
33108261|NCT04317703|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
33108262|NCT05656846|Experimental|Experimental: PulseNmore ES™|"Experimental: PulseNmore ES™:~The study population will be recruited between 12 and 14 weeks of gestation. These patients will be followed using a twice weekly virtual visit by a member of the study team. This visit will include a short survey of obstetrical complaints such as contractions leakage of fluid and decreased fetal movements, as well as a brief sonographic survey using the portable ultrasound device."
33329055|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
33329056|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
32866768|NCT04818606|Experimental|Intervention (MORE) Group|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings. Pre-recorded guided meditations created by study personnel using scripts from the MORE manual will be provided to participants to facilitate their daily practice.
32866769|NCT04818606|No Intervention|Control Group|This group will undergo treatment as usual (TAU) over the course of the eight-week time period of parallel group comparison. This may or may not involve regularly scheduled, standard visits with other medical personnel, including primary care, specialized medical services, or complementary and integrative health practitioners (e.g., acupuncture). Participants will be asked to refrain from altering therapeutic approaches to pain management during this time unless medically necessary and will be asked to report any changes made to their treatment plan on a daily basis.
33329057|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
33329058|NCT05623644||TD-PD patients undergoing MRgFUS thalamotomy|The imaging data from patients with tremor dominant PD underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
33329059|NCT05623644||MR-ET patients undergoing MRgFUS thalamotomy|The imaging data from patients with medication-resistant ET underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
32866770|NCT04779671|Experimental|VR group|
32866771|NCT04779671|Active Comparator|control group|
32866772|NCT05565573|Experimental|Medroxyprogesterone acetate|Administered MPA at a dosage of 500 mg/d concurrently
32866773|NCT05565573|Experimental|LNG-IUS|Go through LNG-IUS insertion
32866774|NCT04807686|Active Comparator|traditional algorithm|
32866775|NCT04807686|Experimental|notched-type algorithm|
32866776|NCT04389359|Experimental|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.~Maximum treatment duration will be 26 weeks (6 months)."
32866777|NCT04389359|No Intervention|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
32866778|NCT04807452|Active Comparator|Strength and balance training|Exercises like ROMS, stretching, static balance and dynamic balance
32866779|NCT04807452|Experimental|Aerobics training|Control Group received aerobic training.
32866780|NCT04779515|Experimental|Low-pressure|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
32866781|NCT04779515|Active Comparator|Standard-pressure|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
32866782|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
32866783|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
32866784|NCT04815954|Experimental|Early group|Early urinary catheter removal: 24±6 hours after completion of surgery.
32866785|NCT04815954|Active Comparator|Delayed group|Delayed urinary catheter removal: 72±6 hours after completion of surgery.
32866786|NCT04779281|Experimental|Oral Rehydration Salts supplemented with L. Rhamnosus GG|a supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
32866787|NCT04779281|Experimental|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
32866788|NCT01587105|No Intervention|Control|Usual Care Group
32866789|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
32866790|NCT03913325|Experimental|PREVSAM model|
32866791|NCT03913325|Active Comparator|Treatment as usual|
32866792|NCT04807140|Experimental|Toripalimab|Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days
33329060|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
33329061|NCT03825276|Experimental|Mango consumption|
33329062|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
33329063|NCT05281380|Other|Intervention with vitamin supplement|Intervention with vitamin supplement Multi-E and Multi-G
33329064|NCT01297218|Experimental|NEUROSTEM®-AD|
33329065|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
33329066|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
33329067|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
33360515|NCT03275740|Placebo Comparator|Placebo intravenous healthy participant|intravenous administration
33360516|NCT03275740|Experimental|PF-06755347 subcutaneous healthy participant|subcutaneous administration
33360517|NCT03275740|Placebo Comparator|Placebo subcutaneous healthy participant|subcutaneous administration
33360518|NCT03275740|Experimental|PF-06755347 subcutaneous ITP|subcutaneous
33108263|NCT05656846|Active Comparator|Control Standard Ultrasound|A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
33108264|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
33108265|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
33108266|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
33108267|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
33108268|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
33108269|NCT04636892|Experimental|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
33329068|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
33329069|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
33329070|NCT05623566|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
33329071|NCT05583396|Other|Acute exercise|Pulmonary diffusing capacity using the DLCO/NO technique is assessed at rest and during exercise (60% of maximal workload on a bicycle ergometer)
33108270|NCT04636892|Experimental|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:~Central jet MR >40% LA or holosystolic eccentric jet MR~Vena contracta ≥0.7 cm~Regurgitant volume ≥60 mL~Regurgitant fraction ≥50%~ERO ≥0.40 cm2~Angiographic grade 3 to 4+"
33329072|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
33329073|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
33329074|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
33329075|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
33329076|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
33329077|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
33329078|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
33329079|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
33108271|NCT04636892|Experimental|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of < or = to 35%
33329080|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
33329081|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
33329082|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
33329083|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
33329084|NCT01299870|Active Comparator|AED treatment plus placebo|
33329085|NCT01299870|Experimental|Keishibukuryogan|
33329086|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
33329087|NCT01567254|Active Comparator|music|6 children receiving music disk
33329088|NCT03816306||Single group study|
33329089|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
33329090|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
33329091|NCT05560698|Other|Control|Standard reporting method
33329092|NCT05560698|Other|Intervention|Web based motivation-enhancing app
33329093|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
33329094|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
33329095|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
33329096|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
33329097|NCT01300104|Experimental|Exercise and whole grain rye|
33329098|NCT01300104|Active Comparator|No prescriptions|
33038726|NCT05282121|Experimental|BI 685509 HBV treatment group|Hepatitis B Virus (HBV)
33038727|NCT05282121|Experimental|BI 685509 HCV treatment group|Hepatitis C Virus (HCV)
33038728|NCT05282121|Experimental|BI 685509 NASH treatment group|Non-Alcoholic Steatohepatitis (NASH)
33038729|NCT05282121|Experimental|BI 685509 + empagliflozin NASH treatment group|
33038730|NCT05280665||The non-specialized group|"Patients who were operated by a non-specialized surgeon. Non-specialized surgeons were defined as general surgeon who does not have the characteristics of a specialized gastric cancer surgeon.~The non-specialized group will be divided into two subgroups (high-volume vs low-volume) for further analysis."
33038731|NCT05280665||The specialized group|"Patients who were operated by a specialized gastric cancer surgeon. Specialized gastric cancer surgeons were defined as surgeons who meet all of the criteria for a specialized gastric cancer surgeon.~Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~Who identified themselves as primarily gastric surgeons during the study period~Whose annual gastric cancer surgery volume is more than 21"
33038732|NCT05279690|Experimental|Cohort 1 low-dose colchicine|Participants with advanced/recurrent solid tumors who will receive low-dose colchicine (0.6 mg oral BID)
33038733|NCT05279690|Experimental|Cohort 1 high-dose colchicine|Participants with metastatic solid tumors who will receive high-dose colchicine (0.6 mg oral TID)
33038734|NCT05279690|Experimental|Cohort 2 Participants with post-radical surgery|Participants with post-radical surgery for high-risk clinically localized urothelial cancer will receive colchicine 0.6 mg oral BID.
33038735|NCT05275088|Experimental|Treatment|Transcatheter atrioventricular valve replacement with the Prizvalve® system
33038736|NCT05271682|Experimental|Part 1: 0.4 mg|FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038737|NCT05271682|Experimental|Part 1: 0.8 mg|FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038738|NCT05271682|Experimental|Part 1: 1.4 mg|FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038739|NCT05271682|Experimental|Part 1: 2.0 mg|FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038740|NCT05271682|Experimental|Part 1: 2.8 mg|FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038741|NCT05271682|Experimental|Part 1: 3.6 mg|FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038742|NCT05271682|Experimental|Part 2: lower dose expansion|FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038743|NCT05271682|Experimental|Part 2: MTD pr MTD-1 dose expansion|FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
33038744|NCT05261139|Experimental|Cohort 1 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir will be given as tablets by mouth twice a day for 5 days (10 doses total).~Weight ≥40 kg~≥12 to <18 years~≥6 to <12 years"
33038745|NCT05261139|Experimental|Cohort 2 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given as tablets by mouth twice a day for 5 days (10 doses total) Weight ≥20 to <40 kg, ≥6 to <18 years
33038746|NCT05261139|Experimental|Cohort 3 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥2 to <6 years"
33038747|NCT05261139|Experimental|Cohort 4 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥1 month to <2 years"
33038748|NCT05261139|Experimental|Cohort 5 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir <1 month old
33329099|NCT01297374|Experimental|dietetic counseling|
33329100|NCT01297374|Experimental|physical activities|
33329101|NCT01297374|Experimental|Lifestyle counseling|
33329102|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
33329103|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
33329104|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
33038749|NCT05255302|Active Comparator|Arm A : control Arm|6 months treatment by chemotherapy + pembrolizumab followed by pembrolizumab ± pemetrexed for patients with non-squamous cell carcinoma (SCC) until 2 years max
33038750|NCT05255302|Experimental|Arm B : experimental arm|6 months treatment by chemotherapy + pembrolizumab followed by pemetrexed for patients with non-SCC or observation for patients with SCC
33038751|NCT05254379|Experimental|Transcranial Direct-Current Stimulation (tDCS)|Participants will be assigned to tDCS intervention. Starting Day 1 of EHVP-IOP, remote-based tDCS will be administered with a constant current intensity for 20 min per session for up to 10 sessions over 2 weeks (one session per day) using a Soterix 1x1 tDCS mini-CT Stimulator with headgear and saline-soaked surface sponge electrodes. Therapy sessions will be performed over Zoom. With the exception of day one when the session will occur on its own, the sessions will occur within one hour of the start of the daily therapy session.
33038752|NCT05238675|Experimental|BI 1291583: Low dose group|
33038753|NCT05238675|Experimental|BI 1291583: Medium dose group|
33038754|NCT05238675|Experimental|BI 1291583: High dose group|
33038755|NCT05238675|Placebo Comparator|Placebo|
33038756|NCT05237050|Experimental|Sound therapy associated with relaxation|
33038757|NCT05237050|Active Comparator|Relaxation alone|
33038758|NCT05234125|Active Comparator|Intervention arm|Sleep hygiene practices and cognitive-behavioral principles
33038759|NCT05234125|Placebo Comparator|Attention control|Training about pregnancy issues
33038760|NCT05233475|Active Comparator|Control group (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
33038761|NCT05233475|Experimental|Intervention Group (EUC + GAIN Lite)|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
33038762|NCT05232682|Experimental|Probiotic Arm|Probiotic arm
33038763|NCT05231512|Experimental|Individuals living with post-Covid-19 respiratory symptoms|Live virtual music therapy interventions for people experiencing difficulties breathing after having had COVID-19 (diagnosed or presumed).
33038764|NCT05227209|Experimental|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
33038765|NCT05223192|Experimental|Intervention group|Participants in this group will receive the ocean disc music therapy entrainment intervention
33038766|NCT05223192|No Intervention|Control group|Participants in this group will not receive any intervention
33038767|NCT05215340|Experimental|Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd)|Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd.
33038768|NCT05215340|Active Comparator|Pembrolizumb|Participants will be randomized to receive 200 mg pembrolizumab.
33038769|NCT05213624|Experimental|BI 764198 - low dose|BI 764198 - low dose
33038770|NCT05213624|Experimental|BI 764198 - medium dose|BI 764198 - medium dose
33038771|NCT05213624|Experimental|BI 764198 - high dose|BI 764198 - high dose
33038772|NCT05213624|Placebo Comparator|Placebo|Placebo
33038773|NCT05201014||1 year follow-up|patients who were treated in the year before and are now returning for their 1-year follow-up.
33038774|NCT05201014||Prior to anthracycline-based therapy|patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
33038775|NCT05200247|Experimental|Patients with Generalized Pustular Psoriasis (GPP) presenting with a flare|
33038776|NCT05199636|Experimental|Dragon fruit product|A dragon fruit beverage
32740083|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
33038777|NCT05199636|No Intervention|General health advice|Based on Eatwell guide and guidelines for type 2 diabetes prevention from the National Institute for Health and Care Excellence (NICE)
33038778|NCT05198830|Experimental|Arm I (methoxyamine, usual care)|Patients receive methoxyamine PO on day 1 of each cycle, pemetrexed IV over 10 minutes on day 1 of each cycle, and cisplatin IV over 60 minutes on day 3 of each cycle. Beginning day 3, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
33038779|NCT05198830|Active Comparator|Arm II (usual care)|Patients receive pemetrexed IV over 10 minutes and cisplatin IV over 60 minutes on day 1 of each cycle. Beginning day 1 of each cycle, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
33038780|NCT05192863||Participants with CD|Participants diagnosed with moderately to severely active CD who are initiating vedolizumab intravenous (IV) induction treatment with the option to switch to vedolizumab subcutaneous (SC) treatment, as maintenance therapy in accordance with the current SmPC will be observed prospectively for 18 months.
33038781|NCT05192486|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33038782|NCT05191966|Active Comparator|Group S-QLB3|S-QLB3 block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
33038783|NCT05191966|Active Comparator|Group TPVB|TPVB block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
32740084|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
33417676|NCT03913195|Experimental|Core Group|HIV-infected Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds. Healthy Volunteer Core Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
33108272|NCT04636892|Experimental|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) >20mmHg
32866793|NCT04807140|Experimental|Toripalimab + Carboplatin+ Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
32866794|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
32866795|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
32866796|NCT04779125|Experimental|Gluteus plasty enhanced with Progrip self gripping mesh|All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
32866797|NCT04818528|Experimental|Constraint Induced Movement Therapy and Routine Physical Therapy|Patients received constrained induced movement therapy and routine physical therapy for up to 6 hrs/day, 5 days/week for 4 weeks.
32866798|NCT04818528|Active Comparator|Routine Physical Therapy|Patients received routine physical therapy for 5 days/week for 4 weeks.
32866799|NCT04754789|Active Comparator|group for loading with statin before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive two 80-mg loading doses of atorvastatin, the first loading dose will be administered in the Emergency Room before transfer to Cath Lab, the second dose of 80-mg atorvastatin will be administered 24 hours afterthe first dose."
32866800|NCT04754789|Placebo Comparator|group receive the routine guidelines management before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive only the routine management."
32866801|NCT04817904|Experimental|Statin-Treated|"This arm will be receiving:~Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)~Rosuvastatin 10 mg/day"
32866802|NCT04817904|No Intervention|Statin-Free|"This arm will be receiving:~-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)"
32866803|NCT04754867|Experimental|"discontinued-smoker age-progressed"|"Participants in the discontinued smoker age-progressed virtual reality condition will see two rendering of themselves in optimal health twenty years into the future, a frontal and profile view."
32866804|NCT04754867|Experimental|"discontinued-smoker + continued smoking age-progressed"|"Participants in the discontinued smoker + continued smoking age-progressed virtual reality condition will see two frontal renderings of themselves twenty years in the future, one in optimal health and one incorporating appearance-related medical consequences of moderate-heavy smoking over twenty years (e.g., skin that is dry and discolored, increased wrinkles, etc.)."
32866805|NCT04754867|Experimental|Current self virtual reality images|Participants in the current self virtual reality condition will see their present age self in a virtual reality rendering.
32866806|NCT04807062|Experimental|DTPFs treated with structural bicortical autologous ICBG combined with TBTM|
32866807|NCT04754555||subacute phase|between 7 days and 6 months post-stroke;
32866808|NCT04754555||chronic phase|minimum 6 months post-stroke
32866809|NCT04815486|Experimental|Bilateral rTMS combined with MI through a BCI training platform in VR with NeuRow|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks, and Motor Imagery (MI) treatment through the BCI training paradigm in VR (NeuRow) for 12 non-consecutive sessions (Monday, Wednesday and Friday) in four weeks.
32866810|NCT04815486|Active Comparator|Repetitive TMS in bilateral cortical primary motor area|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks.
32866811|NCT04778891|Experimental|Intervention group|In addition to usual care provided by general practitioner (GP) and other health care providers, a pharmacist-practitioner in collaboration with GPs from the study setting provided CMM services to patients in the intervention group. Based on the pre-defined inclusion criteria, GPs were selecting patients and referring them to the pharmacist. The individual consultation with the patient was held at the private counselling area where pharmacist and patient were able to talk face-to-face apart from the other patients. The initial assessment lasted 60-90 minutes and the follow-up evaluations 30-60 minutes. Alternatively, patients were followed-up by telephone. Communication with GPs took place in a written (electronic consultation system Health net. PRO; e-mail) and, if needed by face-to-face conversation. Each patient in the intervention group needed to agree to participate in the study by signing an Informed consent form.
32866812|NCT04778891|No Intervention|Control group|Patients in the control group received the usual care which includes GP and other health care provider visits. Data for the patients pertaining to the control group were provided by the 'control' GP and collected parallel with the intervention group. 'Control' GP profile corresponded to the profile of GPs included in the intervention group - the number of years of professional experience in the primary health care less than ten.
32866813|NCT04815408|Experimental|NIC|"Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
32740085|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
33038784|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K: 1e6 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K, and safety of dose will be determined.
33038785|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+1:1e7 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+1, and safety of dose will be determined.
33038786|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+2: 1-5e8 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+2, and safety of dose will be determined.
33038787|NCT05185947|Experimental|1/ IP Catheter Placement and Bidirectional Chemotherapy|IP and IV paclitaxel administration with oral nilotinib
33038788|NCT05183217|Active Comparator|Online continence promotion program without tailoring|Participants will be allocated to the online continence promotion program without tailoring.
33038789|NCT05183217|Experimental|Online continence promotion program with tailoring|Participants will be allocated to the online continence promotion program with tailoring.
33038790|NCT05182840|Experimental|Treatment period: Empagliflozin + BI 690517|
33038791|NCT05182840|Experimental|Treatment period: Empagliflozin + Placebo to BI 690517|
33038792|NCT05182840|Experimental|Treatment period: Placebo to Empagliflozin + BI 690517|
33038793|NCT05182840|Placebo Comparator|Treatment period: Placebo to Empagliflozin + Placebo to BI 690517|
33038794|NCT05176106|Experimental|Intervention-Randomized Parishes|Parishes will be randomized in Masindi District to receive the intervention (i.e., an incentives package). VHTs who are active in that parish will thereby receive the incentives intervention.
33038795|NCT05176106|No Intervention|Control-Randomized Parishes|Non-intervention randomized parishes will be the control parishes. Active VHTs in the control parishes will not receive the incentives intervention.
33038796|NCT05175105|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
33038797|NCT05175105|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
33038798|NCT05175105|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the open-label extension period will receive both mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment.
33038799|NCT05169710|Experimental|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg/day
33038800|NCT05169710|Experimental|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg/day
33038801|NCT05169710|Placebo Comparator|Placebo|Placebo
33038802|NCT05163353|Experimental|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
33038803|NCT05163353|Other|Delayed treatment with diluted Radiesse|Delayed injection of Décolleté Wrinkles with diluted Radiesse
33038804|NCT05161481|Experimental|BI 685509, dose group 1|
33038805|NCT05161481|Experimental|BI 685509, dose group 2|
33038806|NCT05161481|Placebo Comparator|Placebo|Placebo
33329105|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
33329106|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
33329107|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
33329108|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
33329109|NCT01301586|Active Comparator|Oral antibiotic|
33329110|NCT01297530|Experimental|Arm 1|
33329111|NCT01297608|Experimental|treatment|
33329112|NCT01297608|Placebo Comparator|placebo|
33329113|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
33329114|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
33329115|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
33329116|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
33329117|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
33329118|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
33329119|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
33329120|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
33329121|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
33360519|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
32866814|NCT04815408|Active Comparator|NC|"Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
32866815|NCT01588821|Experimental|Treatment Arm|Cabozantinib
32866816|NCT04778735|Other|Pediatric Patients with Liver Transplantation|
32866817|NCT04806906|Experimental|CC-486|subjects will receive 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
32866818|NCT05565261||Group 1: Complete Dentures|The group consists of patients using conventional complete dentures applied to edentulous patients.
32866819|NCT05565261||Group 2: Implant Supported Overdentures|The group consists of patients who use implant-supported overdentures after 2 dental implants have been surgically placed in edentulous patients and osseointegration has occurred.
32866820|NCT04778813|Experimental|Artemether-lumefantrin (AL)|"The tablets will be given orally according to patients' age and under supervision of study team as follows:~Day 0: H0 and H8~Day 1: H24 and H36~Day 2: H48 and H60"
32866821|NCT04778813|Experimental|Dihydro-artemisinin-piperaquin (DHA-PPQ)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
32866822|NCT04778813|Experimental|Artesunate-Pyronaridin (As-Pyr)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
32866823|NCT05565183|Experimental|Patients with diagnosed Atrial fibrillation and an indication of catheter ablation|
32866824|NCT04817982|Experimental|Perineural dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group.
32866825|NCT04817982|Active Comparator|Systemic dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically.
32866826|NCT04817982|Placebo Comparator|Placebo|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group.
32866827|NCT04817982|Active Comparator|Perineural lidocaine|Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group.
32866828|NCT04779047|Active Comparator|group 1|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
32866829|NCT04779047|Active Comparator|group 2|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.
32866830|NCT05565027|Active Comparator|Pneumotachograph|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by pneumotachograph.
32866831|NCT05565027|Experimental|Dynamic digital radiography|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by dynamic digital radiography analysis.
32866832|NCT04817748||Acute ST segment elevation myocardial infarction（STEMI）|the patients' coronary and venous blood were drawn for metabolomics study
32866833|NCT04817748||Acute non ST segment elevation myocardial infarction（NSTEMI）|the patients' coronary and venous blood were drawn for metabolomics study
32866834|NCT04817748||Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）|the patients' coronary and venous blood were drawn for metabolomics study
32866835|NCT04817748||Patients with normal coronary artery（NCA)|the patients' coronary and venous blood were drawn for metabolomics study
32866836|NCT04779203||Osseodensification|Osseodensification is a novel, biomechanical osteotomy preparation technique that preserves bone through a non-excavating drilling process utilizing specially designed burs with a tapered geometry and specially designed flutes progressively expand the osteotomy whilst compacting bone into its walls and apex.
32866837|NCT04779203||Standard Drilling|Utilizing conventional drilling technique with standard bone drilling techniques.
32866838|NCT05564949|Experimental|Classic Ketogenic Diet|Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.
32866839|NCT04817592||Age1(20-25)|The groups are divided as per age
32866840|NCT04817592||Age2(25-30)|
32866841|NCT04817592||Age3(30-35)|
32866842|NCT04817592||Age4(35-40)|
32866843|NCT04817592||Age5(40-45)|
32866844|NCT04778033||Vaccinated Men|Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine
32866845|NCT05564871|Experimental|Occupation-based teleintervention|20 children and their parents will be participate in Occupation-based teleintervention.
33360520|NCT01224769||bendamustine +/- rituximab|
33360521|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
33360522|NCT02289430|Active Comparator|Ezetrol|ezetimibe
33360523|NCT02289430|Active Comparator|Crestor|rosuvastatin
33360524|NCT03930511|No Intervention|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
33329122|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
32866846|NCT05564871|Experimental|Occupation-based in person intervention|20 children and their parents will be participate in Occupation-based in person intervention.
32866847|NCT04817436|Active Comparator|Without adapted physical activity program (APA)|
32866848|NCT04817436|Experimental|With adapted physical activity program (APA)|
32866849|NCT04778345|Experimental|18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT|After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
33038807|NCT05153915|Experimental|Tacrolimus granules (Modigraf)|"The first dose of Modigraf should be administered within 24 hours after reperfusion. Participants will be treated with a Modigraf-based immunosuppressive regimen.~The initial daily dose of Modigraf is given in two divided doses (recommended interval 12 hours) postoperatively. Subsequent oral Modigraf doses will be adjusted by the investigator based on clinical evidence of efficacy, occurrence of AEs, and tacrolimus whole blood trough level."
33038808|NCT05144256|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
33038809|NCT05144256|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
33038810|NCT05144256|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will receive both mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment.
33038811|NCT05143866|Experimental|Self-help CBT|Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide
33038812|NCT05139238|Active Comparator|Oral Nifedipine|Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of <160 systolic and <105 diastolic is achieved. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
33038813|NCT05139238|Active Comparator|Intravenous labetalol|Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
33038814|NCT05138068|Experimental|MDMA-assisted psychotherapy|Two sessions of manualized MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose 1.5 to 2 hours later. MDMA sessions are preceded by 3 non-drug preparatory psychotherapy sessions and followed by 3 integrative non-drug psychotherapy sessions.
32866850|NCT04427826|Experimental|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
32866851|NCT05564793|Active Comparator|Control|"The CRT device is implanted according to clinical practice, without pre-implantation planning. The outcome of the procedure is assessed via echography as per clinical practice.~In addition to clinical practice, the subjects are required to fill in a quality-of-life questionnaire and are subject to an ECG mapping procedure with the Amycard 01C device, including non-contrast CT, to assess the distance between left ventricular lead placement and the latest electrical activation site in the absence of planning information."
33038815|NCT05138068|Other|Delayed treatment|Participants randomly assigned to the delayed treatment control condition will wait 16 weeks and then receive MDMA-assisted therapy protocol described in the experimental arm of the study.
33038816|NCT05135091|Experimental|NRTX-1001 (Stage 1)|Up to 10 subjects.
33038817|NCT05135091|Experimental|NRTX-1001 (Stage 2)|Up to 20 subjects.
33038818|NCT05135091|Sham Comparator|Sham Comparator (Stage 2)|Up to 10 subjects.
33038819|NCT05121168|Experimental|Active Treatment|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
33038820|NCT05121168|Placebo Comparator|Placebo|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
33038821|NCT05116332||Obstetrics and Gynaecology (O&G)|"Trainees from ST3/ST4/ST5 grades (n=11) and ST6/ST7 grades (n=12). As O&G training covers both Obstetrics & Gynaecology curriculums, we will recruit trainees in their final two years of training (i.e. ST6 and ST7) with gynaecology special interest; undertaking at least one gynaecology Advanced Training Skills Modules (ATSM). These include advanced laparoscopic training, open and laparoscopic benign abdomen, urogynaecology, gynaecology-oncology and reproductive medicine.~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=5) and ST6/7 (n=5)."
33038822|NCT05116332||General Surgery (GS)|"Trainees from ST3/ST4/ST5 (n=11) and senior trainees from ST7/ST8 (n=11).~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=6) and ST7/8 (n=4)"
33038823|NCT05103657|Experimental|BI 1358894|
33038824|NCT05103657|Placebo Comparator|Placebo|
33038825|NCT05103332|Experimental|Zilebesiran (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
33038826|NCT05103332|Experimental|Placebo (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
33038827|NCT05103332|Experimental|Zilebesiran (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
32740086|NCT03847649|Active Comparator|Cohort 1: High Risk|
32740087|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
32740088|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
33038828|NCT05103332|Placebo Comparator|Placebo (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
33038829|NCT05103332|Placebo Comparator|Zilebesiran (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
33038830|NCT05103332|Placebo Comparator|Placebo (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
33329123|NCT03815526|Experimental|Dynamic tape|
33329124|NCT03815526|Experimental|Kinesio tape|
33329125|NCT03815526|Experimental|Sport tape|
33329126|NCT01205724|Experimental|A|
33329127|NCT01205724|Experimental|B|
33329128|NCT01205724|Experimental|C|
33329129|NCT05534100||Healthy Control|
33329130|NCT05534100||PTSD|
33329131|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
33329132|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
33038831|NCT05091905|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout).
33038832|NCT05091905|Experimental|Titratable Automated Boluses|Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
33038833|NCT05087992|Experimental|Phase 1a: BI 905711 + FOLFIRI + Bevacizumab|Phase 1a: Dose escalation in colorectal adenocarcinoma (CRC)
33038834|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI|Phase 1b: Dose Expansion: Single arm cohort in 2nd line Pancreatic Ductal Adenocarcinoma (PDAC)
33038835|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm A.
33038836|NCT05087992|Experimental|Phase 1b: FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm B.
33038837|NCT05085873|Experimental|Sodium oxybate|
33038838|NCT05085873|Active Comparator|Midazolam|
33038839|NCT05083169|Experimental|Arm A: Teclistamab-daratumumab (Tec-Dara)|Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
33038840|NCT05083169|Experimental|Arm B: DPd or DVd|Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously.
33038841|NCT05078242|Experimental|Experimental: EaseVRx sessions|This is a study of patients with chronic pain to assess usability of a VR device at home. The main goals are 1) to collect data on feasibility of recruitment, 2) to collect data on daily adherence to therapy, and 3) to collect preliminary effectiveness data on pain and mood outcomes. There will be 7 sessions over one week, with each session lasting about 2-16 minutes. All patients recruited will be in the active arm; this is not a randomized pilot study.
33329133|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
33329134|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
33329135|NCT05623332||Maraciclatide imaging group|Women referred to the endometriosis clinic for suspected endometriosis undergoing a maraciclatide imaging scan
33329136|NCT05623332||Control|Control group (samples but no scan) - Women undergoing surgery for any other condition than endometriosis
33329137|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
33329138|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
33329139|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
33329140|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
33329141|NCT01560000|Other|fiber|
33329142|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
33329143|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
33329144|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
33329145|NCT05517018||single layer uterotomy|53 women with a single-layer uterotomy while closing the uterus during Ceserian
33329146|NCT05517018||double layer uterotomy|53 women with a double layer uterotomy while closing the uterus during Ceserian
33329147|NCT05517018||purse string uterotomy|53 women with a purse string uterotomy tecnique had used while closing the uterus during Ceserian
33329148|NCT05652114|Experimental|Child play of Mightier|Ad lib child biofeedback video game play in home
33329149|NCT03819738|Experimental|fMRI intervention|
33329150|NCT01205958|Active Comparator|medication(Zaltoprofen)|
33329151|NCT01205958|Active Comparator|Acupuncture|
33038842|NCT05077605|Experimental|Functional residual capacity|Functional residual capacity measure during and after extubation
32740089|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
33038843|NCT05070624|Experimental|Intervention|"After informed consent, we will assign participants in a 1:1 ratio to the intervention or control group using Randomize.net.~Participants randomized to intervention group will get access to the Virtual Peer Support Program."
33038844|NCT05070624|No Intervention|Control|Control group: Those randomized to the waitlist control will be given access to the peer support intervention on completion of the first 12-week program. A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions 21. will have access to informational resources via the aTouchAway™ App and will also receive the intervention at the end of the trial.
33038845|NCT05057013|Experimental|Part A Arm 1 Dose Escalation (single agent)|Groups of patients will receive increasing doses of HMBD-001 as a single agent to find a safe dose that best targets cancer cells. Approximately 26 patients with tumours known to express HER3 will be entered into this arm.
33038846|NCT05057013|Experimental|Part B Arm 1 Dose Expansion (single agent)|An expansion cohort of up to 25 patients with a confirmed HER3 positive or confirmed NRG1 fusion rearrangement RAS wild type colorectal cancer, castration resistant prostate cancer, triple negative breast cancer or squamous cell head and neck cancer will receive the HMBD-001 single agent RP2D as determined in Part A Arm 1.
33038847|NCT05049291|Experimental|Intervention|One time receipt and review of an information sheet
33108273|NCT04636892|Experimental|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
33329152|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
33329153|NCT05623098||Dietary fiber was not added to enteral nutrition preparation|Dietary fiber was not added to enteral nutrition preparation
33329154|NCT05623098||Dietary fiber was added to enteral nutrition preparation|Dietary fiber was added to enteral nutrition preparation
33329155|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
33038848|NCT05049291|No Intervention|Non-Intervention|Usual care will be delivered per standards of care.
33038849|NCT05048082|Experimental|Fluorescence imaging with pegsitacianine|Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
33038850|NCT05047263|Experimental|Finerenone (BAY94-8862)|Participants will receive finerenone.
33038851|NCT05047263|Placebo Comparator|Placebo|Participants will receive placebo.
33038852|NCT05041309|Experimental|Axicabtagene Ciloleucel (KTE-C19 )|All participants who previously received axicabtagene ciloleucel (KTE-C19 ) in the parent study will be enrolled in this arm for long-term follow-up.
33038853|NCT05041309|Experimental|Brexucabtagene Autoleucel (KTE-X19)|All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.
33038854|NCT05041309|Experimental|KITE-585|All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.
33038855|NCT05041309|Experimental|KITE-718|All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.
33038856|NCT05041309|Experimental|KITE-439|All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.
33038857|NCT05041309|Experimental|KITE-222|All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.
33038858|NCT05041309|Experimental|KITE-363|All participants who previously received KITE-363 in the parent study will be enrolled in this arm for long-term follow-up.
33038859|NCT05041114|Other|Single|Implantation of motor neuroprosthesis medical device.
33038860|NCT05036707|Active Comparator|1|Healthy Volunteer
33038861|NCT05035823|Other|Single|Implantation of the motor neuroprosthesis medical device.
33038862|NCT05031507||1|Subjects with rare skeletal disorders
33038863|NCT05028647|Active Comparator|VR treatment|5 subjects per country aged 13-16 treated with VR supported (Oculos) program, one hour a day for 5 days
33038864|NCT05028647|Active Comparator|AR treatment|5 subjects per country aged 10-13 treated with AR supported (tablet) program, one hour a day for 5 days
33038865|NCT05028647|No Intervention|control age 13-16|dyslexic subjects aged 13-16 not randomized to active treatment
33038866|NCT05028647|No Intervention|Control age 10-12|dyslexic subjects aged 10-12 not randomized to active treatment
33038867|NCT05026138||Biological relatives without HPV|Biological relatives without current HPV disease serving as controls to be compared with those from affected participants for evaluation of the differences between people with HPV and without.
33038868|NCT05026138||Participants with HPV|Patients with recurrent HPV related diseases refractory to standard-of-care medical or surgical interventions.
33038869|NCT05025943|Experimental|Standard lifestyle intervention + omega-3 fatty acid enriched diet|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods
33038870|NCT05025943|Active Comparator|Standard lifestyle intervention|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)
33038871|NCT05014672|Experimental|Setanaxib 1200 mg/day|"Participants will be administered setanaxib at a dose of 1200 mg/day for the 52-week double-blind treatment period and the 52-week extension period.~The interim analysis outcome will determine if the setanaxib dose level for participants receiving 1200 mg/day will be escalated to 1600 mg/day for the continued extension period."
33038872|NCT05014672|Experimental|Setanaxib 1600 mg/day|"Participants will be administered setanaxib at a dose of 1600 mg/day for the 52-week double-blind treatment period and the 52-week extension period.~The interim analysis outcome will determine if the setanaxib dose level for participants receiving 1600 mg/day will be reduced to 1200 mg/day for the continued extension period."
33038873|NCT05014672|Placebo Comparator|Placebo|"Participants will be administered a placebo for the 52-week double-blind treatment period.~During the 52-week extension period, participants will switch from placebo to setanaxib at a dose of either 1200 or 1600 mg/day depending on interim analysis outcome."
33038874|NCT05012098|Experimental|1/Arm 1|Treatment with Bintrafusp alfa
33038875|NCT05010005|Experimental|Ruxolitinib and Duvelisib|Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown.
33038876|NCT04997655||Upper Transabdominal Plain Block|All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
33038877|NCT04997655||Opioid analgesia|All patients in this group are routinely administered general anesthesia. Apart from this, in the other group, which does not have peripheral nerve block and only routine opioid analgesia is considered sufficient, only routine peroperative USG diaphragm measurements will be recorded observationally.
33038878|NCT04995549|Experimental|Measures using Cutiscan® CS 100|
33038879|NCT04987983|Experimental|Experimental SLP-R|Infant placed in a SLP-R on the researcher's lap. Infant body positioned on side-lying position on the right side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
33038880|NCT04987983|Experimental|Experimental SLP-L|Infant placed in a SLP-L on the researcher's lap. Infant body positioned on side-lying position on the left side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands).
33038881|NCT04987645|Other|Water-Assisted Colonoscopy|If this intervention is chosen randomly, the trainee will use water only technique for insertion.
33038882|NCT04987645|Other|Water and Air Insufflation|If this intervention is chosen randomly, the trainee will use water and air insufflation technique for insertion.
33038883|NCT04983589|Placebo Comparator|Vehicle|Participants received vehicle, one drop bilaterally (in each eye), twice daily (BID), with a gap of 6 hours between both doses, for up to 14 days.
33038884|NCT04983589|Experimental|AGN-190584|AGN-190584 ophthalmic solution, one drop bilaterally (in each eye), BID, with a gap of 6 hours between both doses, for up to 14 days.
33038885|NCT04982393||Patients with PH1|Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
33038886|NCT04978493|Experimental|BI 706321 + ustekinumab|
33038887|NCT04978493|Placebo Comparator|Placebo + ustekinumab|
33038888|NCT04976153|Experimental|aSMDC|Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
33038889|NCT04976153|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product
33038890|NCT04976127|Experimental|Talineuren dose escalation|14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), and 8 months (Amendment 3).
33038891|NCT04976127|Experimental|Talineuren repeated dose|8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), and 8 months (Amendment 3).
33038892|NCT04976127|Experimental|Talineuren dose consolidation with intrapatient dosing|8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).
33038893|NCT04975334|Experimental|kisspeptin, GnRH, naloxone|IV administration of kisspeptin 112-121; six boluses in a 35-hour period. IV administration of GnRH; two boluses in a 35-hour period. IV administration of naloxone; one bolus and an infusion over a 13-hour period.
33038894|NCT04961580||Ceftazidime avitbatan sodiumt group|Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.
33038895|NCT04958252|Experimental|Single dose part: BI 1569912 low dose|
33038896|NCT04958252|Experimental|Single dose part: BI 1569912 lower medium dose|
33038897|NCT04958252|Experimental|Single dose part: BI 1569912 higher medium dose|
33038898|NCT04958252|Experimental|Single dose part: BI 1569912 high dose|
33038899|NCT04958252|Experimental|Multiple dose part: BI 1569912|Additional dose group for multiple dose part may be added based on experience gained during the single dose part
33038900|NCT04958252|Placebo Comparator|Placebo|
33038901|NCT04948450|Experimental|Intervention group|"Physical activity intervention:~Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home.~Cognitive stimulation intervention:~The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts.~Social intervention:~The social intervention will be combined with physical and cognitive interventions by doing in a group.~Metabolic and vascular risk factors:~Metabolic and vascular risk factors of the intervention group will be evaluated by cardiologists and endocrinologists in the study."
33038902|NCT04948450|No Intervention|Control group|The control group will receive general health advice every 3 months based on their physical examination and blood results. They will be provided information on the vascular risk factors for dementia and will receive instruction and handouts on diet and exercise.
33038903|NCT04945759|Experimental|Isokinetic Exercise (İE) Group:|"Isokinetic Exercise (IE) Group:~(Knee Joint Flexion / Extension, Hip Joint Internal / External Rotation and Abduction / Adduction Strengthening Program)~Patients will be seated on the isokinetic Cybex-Humac Norm device in a 90° upright sitting position. It will be fixed to the seat with torso, pelvis and thigh straps. During this training, patients will be told that the dynamometer arm will bring the knee from extension to flexion. During this exercise, the patient will be advised to resist the dynamometer as much as possible while moving the knee in flexion/extension, internal/external rotation, and abduction/adduction with the dynamometer."
33067691|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
33067692|NCT00141531|Active Comparator|Apaziquone|
33067693|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
33067694|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
33329156|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
33329157|NCT01300416||With Gastro-Intestinal (GI) symptoms|
33329158|NCT01300416||Without GI symptoms|
33329159|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
33329160|NCT03830190|No Intervention|Control group|No intervention
33329161|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
33329162|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
33329163|NCT01297998|Experimental|gemcitabine , cisplatin|
33329164|NCT05622942|Experimental|Recombinant Pneumococcal Protein Vaccine（PBPV）|Subjects received 1 dose of PBPV
33329165|NCT05622942|Active Comparator|Pneumococcal Polysaccharide Vaccine-23-valent (PPV23)|Subjects received 1 dose of PPV23
33329166|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
33360525|NCT03930511|Experimental|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
33067695|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
33067696|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
33067697|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
33067698|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
33067699|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
33067700|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
33067701|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
33067702|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
33067703|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
33067704|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
33067705|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
33067706|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
33067707|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
33067708|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
33067709|NCT00405678|Experimental|2|Subjects receiving chemo only
33067710|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
33067711|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
33067712|NCT04710810|Experimental|Experimental|Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
33067713|NCT04710810|No Intervention|Control|Patients receives standard therapy (applied behavioral analysis, speech therapy).
33108274|NCT05656690||Healthy older Adults|Healthy older Adults: older adults without disability indicators
33108275|NCT05656690||Disability Older Adults|Disability Older Adults: older adults with disability indicators
33108276|NCT05656612|Experimental|The Group Given Training 1-2 Weeks Before The Procedure|Participants received breast biopsy procedure training once. 1-2 weeks before the breast biopsy procedure.
33108277|NCT05656612|Experimental|The group trained on the day of the procedure|Participants received one time breast biopsy procedure training. The day of the breast biopsy procedure.
33108278|NCT05656612|Experimental|Repetitive training group|Participants received twice breast biopsy procedure training. The first training is 1-2 weeks before the breast biopsy procedure. The second training is the day of the breast biopsy procedure.
33108279|NCT04636580|Experimental|anxious parent|Parents were divided into two groups anxious and non-anxious.
33108280|NCT04636580|Experimental|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
33108281|NCT02895048||Chronic heart failure|
33108282|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
33108283|NCT05656573|Experimental|autologous CART-PSMA cells|
33108284|NCT05656534|Placebo Comparator|Control|Individuals will take a placebo pill during the Acute Drug Challenge and daily for 28 days.
33108285|NCT05656534|Experimental|Suvorexant Treatment|Individuals will take 10mg of suvorexant (Merck & Co Inc.) during the Acute Drug Challenge and daily for 28 days.
33108286|NCT05656456||OCD patients|Patients with obsessive-compulsive disorder
33108287|NCT05656456||live-in family members|Live-in family members of OCD patients
33108288|NCT05656339|Sham Comparator|12 hours Fast - Fast Group|Participants will proceed in 12 hours fast condition for blood collection for laboratory assays
33108289|NCT05656339|Active Comparator|Carbohydrate plus whey protein supplement - CHO+WP group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates plus whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
33108290|NCT05656339|Placebo Comparator|Carbohydrate supplement - CHO group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates alone without whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
33108291|NCT04636541|Experimental|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
33108292|NCT04636541|Active Comparator|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
33108293|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
33329167|NCT05458206|Experimental|diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins for 5 to 7 minute conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
33329168|NCT05458206|Experimental|mulligan SNAG mobilization, and conventional|"mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds. (3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
33329169|NCT05458206|Experimental|mulligan SNAG mobilization, diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins. (5 to 7 minutes) mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds(3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
33329170|NCT05458206|Active Comparator|the conventional therapy|the patient will receive chin-in, inter-scapular exercises, and pectoralis stretch (3 sets,10 repetitions)
33329171|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
33329172|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
33038904|NCT04945759|Active Comparator|Isokinetic Exercise + Aussie Current (IE+AC)Group:|Aussie Current and Isokinetic Exercise program will be applied to the patients. The distal electrode is placed on the anterior part of the thigh and superior to the patella. The proximal electrode will be placed on the thigh. One electrode will be placed between the anterior superior and posterior superior iliac spine of the PFPS(Patellofemoral Pain Syndrome) side and the other electrode will be placed in a triangle on the greater trochanter of the femur in the gluteus medius muscle. By contacting the Turkish authorities of the BTL 4825SPREMIUM device, the current was adjusted in the Aussie Current 1 kHz frequency, 400 ms phase time, 50 hz burst frequency, 4 ms duration device. This new burst modality medium frequency alternating current will be applied to the patient for 20 minutes.
33038905|NCT04945759|Active Comparator|Isokinetic Exercise + Russian Current (IE+RC) Group:|"Isokinetic Exercise program will be applied to the patients. Similarly, as with the Aussie Current, the Russian current will be applied to the vastus lateralis-medialis and gluteus medius muscles.~Russian current will be set as 2500 Hz sinusoidal current, 200 ms phase time, 50 hz burst frequency, 50% duty cycle, 10 ms duration.~The patient will be treated for 20 minutes."
33038906|NCT04945759|Placebo Comparator|Isokinetic Exercise + placebo Electrical Stimulation (IE+PES) Group:|Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
33038907|NCT04941560||Algorithm training and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to training and validate the algorithm for CAD detection based on facial photos.
33038908|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 1|Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.
33038909|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 2|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
33038910|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 3|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
33329173|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
33329174|NCT05451108|Experimental|Insertion of PCL Pectus scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone (PCL) Pectus scaffold with autologous fat graft for pectus excavatum defect correction.
33038911|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 4|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
33329175|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
33329176|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
33329177|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
33329178|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
33329179|NCT05622864|Experimental|PartA|
33329180|NCT05622864|Experimental|PartB|
33329181|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
33038912|NCT04936035|Placebo Comparator|Placebo + ALN-AGT01|Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.
33038913|NCT04929951|Experimental|MFAT (Micro Fragmented Adipose Tissue)|Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
33038914|NCT04929951|Active Comparator|Conventional Therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
33038915|NCT04929041|Experimental|Arm A (immunotherapy, +/- chemotherapy)|See Detailed Description
33038916|NCT04929041|Experimental|Arm B ( immunotherapy, +/- chemotherapy, SBRT)|Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of SBRT every other day.
33038917|NCT04920799|Active Comparator|Nitrate rich beetroot juice|
33038918|NCT04920799|Placebo Comparator|Nitrate depleted beetroot juice|
33038919|NCT04919408|Experimental|Patients scheduled for cesarean section under spinal anesthesia|Patients scheduled for cesarean section under spinal anesthesia ASA I and II according to The ASA Physical Status Classification System
33038920|NCT04914663|Experimental|All-extremity exercise|
33038921|NCT04914663|Active Comparator|Treadmill exercise|
33038922|NCT04914663|No Intervention|Usual Care|
33038923|NCT04903522|Experimental|Depressive patients|Patients suffering from major depressive disorder with anxiety symptoms
33038924|NCT04888936||NCI RASopathies Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
33038925|NCT04888936||NCI RASopathies Field Cohort|includes Proband, Other carriers in family, Family Controls
33038926|NCT04887259|Experimental|LAVA-051|"In part 1 (dose escalation) LAVA-051 will be administered via intravenous infusion with dose escalation~In part 2 (dose expansion) patients will receive LAVA-051 at the dose established in part 1 of the study"
33038927|NCT04886154|Experimental|ABCWY low dose Group|Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.
33038928|NCT04886154|Placebo Comparator|Placebo low dose Group|Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.
33038929|NCT04886154|Experimental|ABCWY high dose Group|Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.
33329182|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
33038930|NCT04886154|Placebo Comparator|Placebo high dose Group|Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.
33038931|NCT04886154|Experimental|ABCWY low dose_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
33329183|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
33329184|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
33038932|NCT04886154|Experimental|ABCWY low dose_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
33038933|NCT04886154|Experimental|ABCWY high dose_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
33038934|NCT04886154|Experimental|ABCWY high dose_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
33038935|NCT04886154|Active Comparator|Control Group|Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
33038936|NCT04886154|Experimental|ABCWY low dose_01 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
33038937|NCT04886154|Experimental|ABCWY high dose_01 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
33038938|NCT04886154|Experimental|ABCWY low doseS_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
33038939|NCT04886154|Experimental|ABCWY high doseS_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
33038940|NCT04886154|Experimental|ABCWY low doseS_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
33038941|NCT04886154|Experimental|ABCWY high doseS_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
33038942|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
33038943|NCT04879628|Experimental|IV SAR441344|SAR441344 IV
33038944|NCT04879628|Placebo Comparator|IV Placebo|Placebo IV
33038945|NCT04879628|Experimental|SC SAR441344|SAR441344 SC
33038946|NCT04879628|Placebo Comparator|SC Placebo|Placebo SC
33038947|NCT04878263|Active Comparator|Control group|
33038948|NCT04878263|Experimental|FIL-EAS ic group|
33038949|NCT04868851|Active Comparator|Here for Health only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
33038950|NCT04868851|Experimental|mHealth technology assisted exercise counselling (mHealth)|Patients will complete the Here for Health Healthy Lifestyle intervention before completing a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
33038951|NCT04861922|Experimental|Unfractionated Heparin|A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.
33038952|NCT04861922|Placebo Comparator|Normal saline|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.
33038953|NCT04855630|Experimental|Sleep Only Group|Participants in this group will wear the DREEM 2 headband for 12 weeks.
33038954|NCT04855630|Active Comparator|Exercise Only Group|Participants in this group will workout twice a week for 12 weeks.
33038955|NCT04855630|Active Comparator|Exercise and Sleep Group|Participants in this group will take part in a guided exercise program in additional to wearing the DREEM 2 headband for 12 weeks.
33038956|NCT04854824||'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
33038957|NCT04854824||'Historic control' cohort|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and treated at home by family physicians with drug regimens that are not necessarily guided by those proposed in the recommendations
33038958|NCT04851249||Adult participants operated for Hallux Valgus deformity|All adult participants accepted for hallux valgus corrective surgery at ostfold hospital trust (ØHT) is asked to participate in the study. The goal is to include 200-250 participants.
33038959|NCT04850794|Experimental|Case A then Case B|Participant will first review and answer questions about Case A without using the tool. Then, they will use the tool to answer questions about case B.
33038960|NCT04850794|Experimental|Case B then Case A|Participant will first review and answer questions about Case B without using the tool. Then, they will use the tool to answer questions about case A.
33038961|NCT04846881|Experimental|Iclepertin|
33038962|NCT04846881|Placebo Comparator|Placebo|
33038963|NCT04846868|Experimental|Iclepertin|
33038964|NCT04846868|Placebo Comparator|Placebo|
33038965|NCT04844437||Digital examination of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by digital examination and fetal head station evaluated by two clinicians.
33108294|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
33108295|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
32866852|NCT05564793|Experimental|Active|A pre-implantation ECG mapping with the Amycard 01C device, including CT, is performed prior to the CRT device implantation. The resulting target area for the left ventricular lead placement is communicated to the implanting physician, who will attempt to reach a point close to the target, using the available venous access. At six-month follow-up, response to the therapy is assessed using echocardiography, and a second ECG mapping with Amycard 01C is performed, to assess the distance between actual implantation site and target in the presence of pre-implantation planning information.
33108296|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
32866853|NCT03699995|Experimental|Screening (imaging, biopsy)|Participants undergo imaging of suspicious moles via smartphone app MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
32866854|NCT04817280||Ice Swimmers Group.|No intervention. Data obtained from Polish ice swimmers reported by them retrospectively in the questionnaire.
33108297|NCT00624637|No Intervention|C|no intervention, standard postoperative care
33108298|NCT05656144|Experimental|Cadonilimab|Cadonilimab monotherapy
32866855|NCT04806828||HF|Preoperative classification of inguinal hernia
33108299|NCT05656105|Experimental|Healty Volunteers|
33108300|NCT05656105|Experimental|PASC|Patients meeting the case definition criteria for PASC
33329185|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
33329186|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
33329187|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
33360526|NCT03930511|No Intervention|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
32866856|NCT04777487|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and GCF obtained.
32866857|NCT04777487|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
32866858|NCT04777487|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
32866859|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
32866860|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
32866861|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
32866862|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
32866863|NCT04777097||healthy pregnant women|Healthy patients who receive a cesarean operation
32866864|NCT04777097||Pre-eclampsia|Patients with pre-eclampsia who receive a caesarean operation
32866865|NCT04815018||Patients with New Cases of SARS-CoV-2|Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
32866866|NCT04815018||Patients without SARS-CoV-2|This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.
32866867|NCT00168337|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
32866868|NCT00168337|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
32866869|NCT00168337|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
32866870|NCT04748198|Experimental|Study group|Intracorneal ring segments are implanted for treatment of keratoconus, and posterior corneal surface is assessed preoperatively and postoperatively.
32866871|NCT04776863||Smokeless tobacco|Individuals using smokeless tobacco
32866872|NCT04776863||No smokeless tobacco|Individuals who do not use smokeless tobacco
32866873|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
32866874|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
32866875|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
32866876|NCT04776785|Experimental|Group 1|"In Group 1, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications, Profluorid® Varnish application will be repeated for test 1 and control lesions."
33038966|NCT04844437||Transperineal assessment of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by transperineal ultrasound and fetal head station evaluated by two experienced clinicians.
33038967|NCT04840472|Experimental|111-In panitumumab|The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.
33038968|NCT04832477|Other|Stigma Counseling for PrEP Access|Behavioral counseling
33038969|NCT04827615|Other|High Risk|"Group 2: Of all adults in (1), those at high risk of diabetes and hypertension, defined as having a score >4 based on the following criteria:~Age 40-49 years (+1), age ≥50 years (+2)~Used to smoke or use smokeless tobacco products or sometimes currently use (+1), currently use daily (+2)~Currently consume alcohol daily (+1)~Waist circumference 81-90 cm (women)/91-100 cm (men) (+1), >90 cm (women)/>100cm (men) (+2)~Physical activity <150 minutes per week (+1)~Parent and/or sibling with high blood pressure, diabetes, or heart disease (+2)"
33038970|NCT04827615|Other|Eligible adults|Group 1: All adults ≥30 years old living in the 12 target villages who meet eligibility criteria and provide informed consent
33038971|NCT04813627||Participants with R0 resected Stage II (high risk) or Stage III CRC|The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
33038972|NCT04805450|Active Comparator|ES before SEMS placement|ERCP with ES before biliary fully covered SEMS placement.
33038973|NCT04805450|Active Comparator|no ES before SEMS placement|ERCP without ES before biliary fully covered SEMS placement.
33038974|NCT04804137||Group|adult patients with adenocarcinoma type non-small cell lung cancer
33038975|NCT04794517|Experimental|IMP|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
33038976|NCT04794517|Placebo Comparator|Placebo|Placebo, one tablet/die will be administered orally for six-weeks.
33038977|NCT04791371|Experimental|Type 2 Diabetes|Participants aged 30-55 with type 2 diabetes
33038978|NCT04791371|Experimental|Healthy overweight control|Participants aged 30-55 with BMI 25-40 without type 2 diabetes
33038979|NCT04790370|Active Comparator|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
33038980|NCT04790370|Active Comparator|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
33038981|NCT04790253|Active Comparator|PCI followed by brain MR surveillance|"Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain.~Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months.~Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician."
33038982|NCT04790253|No Intervention|MRI Active Surveillance|Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.
33038983|NCT04789408|Experimental|KITE-222|"Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.~Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222."
33038984|NCT04783389|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
33038985|NCT04783389|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
33038986|NCT04783389|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
33038987|NCT04782830|Experimental|placebo|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
33038988|NCT04782830|Active Comparator|Standard treatment|Either midodrine or atomoxetine at their regular dose.
33038989|NCT04777357|Placebo Comparator|Placebo|Participants will receive Placebo over a 6 week treatment period.
33038990|NCT04777357|Experimental|Cariprazine|Participants will receive flexible dose Cariprazine over a 6 week treatment period.
33038991|NCT04771000|Experimental|Ambrisentan|Ambrisentan, 125µg twice a day for up to 28 days
33038992|NCT04771000|Placebo Comparator|Placebo|Placebo
33038993|NCT04766944||Critically ill trauma patients of 50 years old and above|Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma
33038994|NCT04763590|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) had 3 principal components: (1) psychoeducation, (2) cognitive restructuring, and (3) exposure. In this treatment, derived from an empirically-supported treatment for panic disorder, psychoeducation consisted of teaching about the interrelationship between thoughts, feelings, and physical sensations during weaning. The cognitive component taught patients how to challenge their thoughts, with a particular focus on identifying thoughts that over-estimated the probability of negative medical events. The behavioral component consisted of reducing the need for mechanical ventilation in a step-wise, graduated, manner.
33038995|NCT04760288|Experimental|Arm A (Pralsetinib)|Participants will receive pralsetinib at a dose of 400 milligrams (mg) orally once daily (PO QD) in 28-day cycles.
33038996|NCT04760288|Active Comparator|Arm B (SOC: Cabozantinib/Vandetanib)|Adult participants will receive investigator's choice of SOC MKI therapy with either 140 mg cabozantinib PO QD or 300 mg vandetanib PO QD in 28-day cycles. Adolescents participants (≥ 12 and < 18 years of age) will receive vandetanib, PO QD or every other day, in 28-day cycles depending on the body surface area (BSA), at a dose determined according to the dosing nomogram available in the E.U. Vandetanib SmPC.
33038997|NCT04753307||Patients at least 45 years at-risk for cardiovascular complications|
33329188|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
33329189|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
33329190|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
33436462|NCT05135962|Experimental|Leaf expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf Leaf Expander appliance anchored on second deciduous molars.~Activation: The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 15 quarter-turns of the screw per month until expansion has been completed. After active expansion the Leaf Expander was kept on teeth as a passive retainer and removed after one year from its application."
33038998|NCT04720157|Experimental|177Lu-PSMA-617|Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
33038999|NCT04720157|Active Comparator|Standard of Care|For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
33039000|NCT04712565|Experimental|Astra Tech Implant System Profile EV|Implants with sloped marginal configuration without bone augmentation are used.
33039001|NCT04712565|Active Comparator|Astra Tech Implant System EV|Implants with regular neck design and GBR procedure fixed with two membrane pins will be used.
33039002|NCT04711109|Experimental|Arm A (denosumab)|Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.
33039003|NCT04711109|Placebo Comparator|Arm B (placebo)|Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.
33039004|NCT04710043|Experimental|Part 1 group A BNT153|Monotherapy dose escalation.
33039005|NCT04710043|Experimental|Part 1 group B BNT152|Monotherapy dose escalation.
33039006|NCT04704934|Experimental|Trastuzumab deruxtecan|Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
33039007|NCT04704934|Active Comparator|Ramucirumab + paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
33039008|NCT04699123|Experimental|Arm 1a - NC318 only|At the discretion of the treating physician, advanced NSCLC patients on arm 1a will receive NC318 alone.
33039009|NCT04699123|Experimental|Arm 1b - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
33039010|NCT04699123|Experimental|Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2 will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive combination therapy with NC318 and pembrolizumab.
33039011|NCT04696562|Experimental|Intervention group|The intervention group is the group in which the investigors applied deep breathing exercises with triflo.
33039012|NCT04696562|No Intervention|Control group|The control group is the group that receives standard clinical care.
33039013|NCT04696055|Experimental|Regorafenib+Pembrolizumab|Participants with advanced hepatocellular carcinoma (HCC) progressed on 1L anti-PD-1/PD-L1 therapy.
33039014|NCT04693780|Experimental|Structured guide with pre-appraisal content|Once logged into the website, participants in the intervention group will navigate health information through an annotated structured guide to health evidence which is designed to inform participants where to find specific health information but it will also provide information to understand why such content is more valuable than other content. This structured annotated guide to evidence will also outline the value of pre-appraisal and will help them navigate to products produced for them. These products have been produced by the research team and include a collection of web resource ratings, evidence summaries and blog posts modelled after those developed and presented on the McMaster Optimal Aging Portal. The topics of this citizen content match the scope of the IMAGINE Network.
33039015|NCT04693780|Placebo Comparator|Listing without pre-appraisal content|Once logged into the website, participants in the control group will navigate health information through a structured one-page guide (see Appendix 1) that does not include pre-appraisal information. Instead it will list the main organizations in the field that produce citizen content with descriptions of the type of content they produce with links to their individual websites. This will be presented to participants when they login to the platform. None of the citizen content produced specifically for the study will be provided to them prior to crossing-over.
33039016|NCT04690946|Active Comparator|Cognitive Behavioral Therapy|14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
33039017|NCT04690946|Active Comparator|Emotion-Focused Therapy|14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
33039018|NCT04686786|Experimental|CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.
33039019|NCT04649242|Active Comparator|BHV3000 (active drug)|BHV3000 (rimegepant) 75 mg or 50 mg ODT
33039020|NCT04649242|Placebo Comparator|Placebo|Matching 75 mg or 50 mg ODT placebo
33329191|NCT03819192||neonates with signs of EONS|
32740090|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
32740091|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
33417677|NCT03913195|Experimental|Intramuscular Injection Group|HIV-infected Intramuscular Injection Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via Intramuscular Injection. Healthy Volunteer Intramuscular Injection Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via intramuscular injection.
33417678|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
33039024|NCT04620382|Active Comparator|Midodrine|Single oral dose of midodrine (5-10mg) combined with sham abdominal compression
33039025|NCT04620382|Experimental|Abdominal Compression|Abdominal compression (up to 40 mmHg) combined with a placebo pill
33039026|NCT04607564|Experimental|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
33039027|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
33039028|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
33039029|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
33329192|NCT03819192||neonates without signs of EONS|
33329193|NCT03819192||pregnant women with PPROM|
33329194|NCT01560312|Experimental|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
33329195|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
33039034|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
33039035|NCT04575935|Experimental|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
33039036|NCT04575935|Active Comparator|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
33039037|NCT04575207|Experimental|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR > 0.80.
33039038|NCT04575207|Active Comparator|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR > 0.80.
33039039|NCT04573387|Active Comparator|Fixed-time drainage|Drainage will be removed after 48 hours.
33039040|NCT04573387|Experimental|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
33039041|NCT04567420|Experimental|Arm A|Palbociclib/Fulvestrant Combination
33039042|NCT04567420|Active Comparator|Arm B|Adjuvant Therapy
33039043|NCT04565483|Experimental|BENRALIZUMAB|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
33039044|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
33039045|NCT04558281|Experimental|Active Treatment|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
33039046|NCT04558281|Placebo Comparator|Placebo|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline
33039048|NCT04556591|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
33329196|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
33329197|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
33417679|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
33417680|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
33039049|NCT04556591|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
33039050|NCT04553081|Active Comparator|Dovato|We aim to include 134 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
33039051|NCT04553081|Active Comparator|Biktarvy|We aim to include 134 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
33039052|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
33417681|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
33417682|NCT02864082|Experimental|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
33329198|NCT05400798|Experimental|Adipose Derived Regenerative Cells|a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
33329199|NCT05400798|Active Comparator|Corticosteroid|a single corticosteroid injection into the subacromial space of the index arm
33329200|NCT01301898|Experimental|GC1111_0.5mg/kg|
33329201|NCT01301898|Experimental|GC1111_1.0mg/kg|
33329202|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
33329203|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
33417683|NCT02864082|Experimental|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
33417684|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
33329204|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
33417685|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
33417686|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
33039058|NCT04523714|Active Comparator|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
33039059|NCT04523714|Active Comparator|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
33329205|NCT05385588|Experimental|Single arm|290 PLHIV, aged 55 to 76 years old
33417687|NCT05091281|Active Comparator|Group I|After induction of anesthesia intubation was done by Macintosh laryngoscope
33417688|NCT05091281|Active Comparator|Group II|After induction of anesthesia intubation was done by GlideScope®videolaryngoscope
33417689|NCT05091281|Active Comparator|Group III|After induction of anesthesia intubation was done byC-MAC®(D) videolaryngoscope
33039060|NCT04523714|No Intervention|Usual Care plus information|Receipt of a bound copy of the 2020 edition of the American Chronic Pain Association Resource Guide to Chronic Pain Management and any pharmacologic and nonpharmacologic treatments available to them without restriction
33039061|NCT04522973|Other|Within group four condition comparison|On four separate occasions, participants will come to the research center and complete one of the four conditions. All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
33039062|NCT04521478|Experimental|Treatment group 1|BI 1358894
33039063|NCT04521478|Placebo Comparator|Placebo group|Placebo
33039064|NCT04521478|Experimental|Treatment group 2|Quetiapine
33329206|NCT05383092|Experimental|Adapted physical activity Strong|
33329207|NCT05383092|Active Comparator|Adapted physical activity Soft|
33329208|NCT05344560|Experimental|test/control/control|Eligible subjects that are habitual contact lens wearers will be randomized into the (test/control/control) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
33329209|NCT05344560|Experimental|control/test/test|Eligible subjects that are habitual contact lens wearers will be randomized into the (control/test/test) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
33329210|NCT05369130||Develop Persistent Postsurgical Pain|Pain present 3 months post-op related to the surgical operation
33329211|NCT05369130||Absence of Persistent Postsurgical Pain|Resolution of post-operative pain within the first three months of the operation
33329212|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
33329213|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
33039065|NCT04502225|Experimental|Elevation of the whole bed (tilt)|Tilt of the whole bed so that the participant's head is raised by 9 and/or 12 inches.
33039066|NCT04502225|Experimental|Elevation of the trunk|Elevation of the trunk by tilting just the head of the bed so that the participant's head is raised by 9 and/or 12 inches.
33039067|NCT04502225|Experimental|Elevation of the whole bed (tilt) - In home|Tilt of the whole bed so that the participant's head is raised by 8 inches.
33039068|NCT04502225|Experimental|Elevation of the trunk - In home|Elevation of the trunk by raising the head 8 inches on a wedge pillow.
33039069|NCT04501081||1|DFNA patients and their family members (affected)
33039070|NCT04501081||2|DFNA patients and their family members (unaffected)
33039071|NCT04495855||Visanne treatment|Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne
33039072|NCT04493424|Experimental|Treatment group|Up to 260 weeks
33039073|NCT04478747|Active Comparator|Transvaginal mesh|BSC mesh (A.M.I., Feldkirch, Austria) is attached to the sacrospinosus ligaments and to the apical part of the vagina.
33039074|NCT04478747|Active Comparator|Colposacropexy with the apical fixation only|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina.
33039075|NCT04478747|Active Comparator|Colposacropexy with the apical and the levator fixation|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina with fixation reaching to the level of the levator planes.
33039076|NCT04468984|Experimental|Arm A: Navitoclax + Ruxolitinib|Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
33329214|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
33329215|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
33329216|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
33329217|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
33329218|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
33329219|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
33329220|NCT05647434|No Intervention|group C|conventional ventilation
33329221|NCT05647434|Active Comparator|group SI|Sustained inflations done after ultrasound during capnoperitoneum every 20 min.
33329222|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
33329223|NCT03806946||group1|ADHD with normal EEG
33039077|NCT04468984|Active Comparator|Arm B: Best Available Therapy (BAT)|Participants will receive one of the BAT options, per the investigator's discretion.
33039078|NCT04468321|Experimental|Apple Watch|Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.
33039079|NCT04468321|Placebo Comparator|Withings Move|Patients will be provided with the Withings Move with activity tracking.
33039080|NCT04461587|Experimental|Pirfenidone [Esbriet]|"Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:~Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)~Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)~Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment."
33039081|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28-day cycles.
33039082|NCT04446052|Placebo Comparator|Placebo|
33039083|NCT04446052|Active Comparator|GM-CSF priming|
33039084|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IV-VI, Female
33039085|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IV-VI, Male
33039086|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
33039087|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
33039088|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IV-VI, Female
33039089|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IV-VI, Male
33039090|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type I-III, Female
33039091|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type I-III, Male
33039092|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IV-VI, Female
33039093|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IV-VI, Male
33039094|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type I-III, Female
33039095|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type I-III, Male
33329224|NCT03806946||group 2|ADHD with abnormal EEG
33329225|NCT03806946||group 3|Epilepsy
33329226|NCT03806946||group 4|Healthy control group
33329227|NCT03806946||group 5|ADHD and epilepsy
33329228|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
33417690|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
33039096|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IV-VI, Female
33417691|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
33417692|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
33417693|NCT01359605|Experimental|varespladib methyl|
33417694|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
33417695|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
33417696|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
33417697|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
33039097|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IV-VI, Male
33039098|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type I-III, Female
33039099|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type I-III, Male
33039100|NCT04429087|Experimental|BI 764532|
33039101|NCT04428034|Experimental|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
33039102|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
33039103|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
33039104|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
33039105|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
33039106|NCT04371107|Experimental|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
33039107|NCT04371107|Active Comparator|symptomatic treatment|continuation of symptomatic treatment
33039108|NCT04368494|No Intervention|Control|Continue with normal activity.
33039109|NCT04368494|Experimental|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
33039110|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
33039111|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
33039112|NCT04364984||DRi group|Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
33039113|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
33039114|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
33039115|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
33039116|NCT04311086|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
33039118|NCT04298905|No Intervention|Standard of Care|Individuals randomized to standard of care will receive a standardized adherence education session and provided with a paper-based diary to track appointments and adherence. Instructions will be provided on the importance of daily adherence in the primary health care facility closest to patients' residence, as per standard of care. Directly observed therapy (DOT) is recommended for all patients at patients' nearest clinic. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
33039119|NCT04298905|Active Comparator|mHealth intervention|Individuals randomized to the intervention arm will receive the same standardized adherence education, followed by an orientation session to the study intervention. This orientation will include education on basic smartphone operations and use. The CHW will set up appointment reminders for clinic visits as well as daily adherence reminders for submission of the video DOT sessions and symptom reports. A smartphone capable of downloading apps, receiving short message service (SMS) and access wifi and cellular connectivity will be provided to intervention patients. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
33039120|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
33067714|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
33067715|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
33417698|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
33417699|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
33417700|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
33417701|NCT05188859|Experimental|Treatment|"Regimen:~Sintilimab, 200mg, ivgtt d1, q3w, 21 days per cycle~Anlotinib, 12mg, po, qd, d1-14, q3w, 21 days per cycle~Pemetrexed, 500mg/m², ivgtt , d1, q3w, 21 days per cycle, 4-6 cycles.~Cisplatin, 75mg/m2 , ivgtt, d1, q3w/Carboplatin, AUC 5.0, ivgtt, d1, q3w, 21 days per cycle, 4-6 cycles."
33039121|NCT04294095|Experimental|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
33039122|NCT04294095|Active Comparator|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
33417702|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
33417703|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
32740092|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
32740093|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
33039123|NCT04281446|Experimental|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
33039124|NCT04281446|Sham Comparator|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
32740094|NCT03750227|Active Comparator|Arm A (Post-operative SRS)|Patients undergo surgery on day 1. Within 2 weeks, patients undergo stereotactic radiosurgery.
33039125|NCT04278833|Other|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
33039126|NCT04278833|Other|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
32740095|NCT03750227|Experimental|Arm B (Pre-operative SRS)|Patients undergo stereotactic radiosurgery on day 1. Within 4 weeks, patients undergo surgery.
32740096|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
33039127|NCT04270838|Experimental|Group AC1 (Adult low dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 2.5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33039128|NCT04270838|Experimental|Group AC2 (Adult high dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33039129|NCT04270838|Experimental|Group AC3 (Adult preferred dose)|Volunteers aged 18-45 years. Volunteers will receive a preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33039130|NCT04270838|Experimental|Group AV1 (Adult single-visit Verobab)|Volunteers aged 18-45 years. Volunteers will receive Rabies IRV on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33067716|NCT00152256|Experimental|1|
33067717|NCT00152256|Experimental|2|
33417704|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
33417705|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
32740097|NCT03725345|Active Comparator|Alcohol Group|Participants who have recently consumed alcohol.
32740098|NCT03725345|Sham Comparator|No Alcohol Group|Participants who have not recently consumed alcohol.
33108301|NCT05656066|Experimental|The Vibration Intervention Group (VI)|After the injection area was determined in the VI group, the vibration device was held for 30 seconds in the area to be injected, then the injection was applied by pulling up 3 cm while the device was operating.
33329229|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
33329230|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
33108302|NCT05656066|Experimental|The Pressure Intervention Group|After the injection area was determined in the PI group, 30 seconds light pressure was applied with the thumb and then the injection was given
33108303|NCT05656066|No Intervention|The Control Group|The routine IM injection was applied to the children in the control group.
33108304|NCT04680663||Non-severe complications group|where the non-complicated patients is the patients running the normal postoperative course of surgery and without any need for intervention
33108305|NCT04680663||severe complications group|any deviation from the normal post-operative course
33108306|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
33108307|NCT00560222|Placebo Comparator|B|placebo
33108308|NCT04316299||AKI|COVID-19 patients with acute kidney injury
33108309|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
33108310|NCT04317508|Active Comparator|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
33108311|NCT04317508|Placebo Comparator|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
33108312|NCT05655988|Active Comparator|mesh migration after TEPP / fixation free mesh|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
33108313|NCT05655988|Active Comparator|mesh migration after TEPP / mesh with fixation|TEPP surgeries performed with mesh fixation
33108314|NCT04636658|Active Comparator|Incentive spirometer training|Incentive spirometer training
33108315|NCT04636658|Experimental|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
33108316|NCT05655910|Experimental|Group 1 (Not malnourished) - 3 products per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
33108317|NCT05655910|Experimental|Group 1 (Not malnourished) - 1 product per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 1 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
33108318|NCT05655910|Experimental|Group 2 (at risk/malnourished)|Patients assessed as at risk for malnourishment or malnourished based on AND-ASPEN criteria automatically assigned to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
33108319|NCT04317274|Experimental|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
33108320|NCT04317274|Experimental|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
33108321|NCT04317274|Experimental|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
33108322|NCT04317274|Experimental|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
33108323|NCT04636463|Experimental|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
33329231|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
33329232|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
33108324|NCT04636463|No Intervention|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
33108325|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
33108326|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
33108327|NCT04680702|Experimental|Metabolic Syndrome and Sims Score|
33108328|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
33108329|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
33108330|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
33108331|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
33108332|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
33108333|NCT00560300|Experimental|4|Calcitriol + Sevelamer
33108334|NCT02895243|Experimental|Prehabilitation|
33108335|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
33108336|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
33108337|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
33108338|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
33108339|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
33108340|NCT00560456|Experimental|1|snorers
33108341|NCT00560456|Other|2|healthy volonters (control)
33108342|NCT00560456|Experimental|3|young subjects
33108343|NCT00560456|Experimental|4|mature subjects
33108344|NCT04636814|Experimental|CHF6001 1600µg|
33039131|NCT04270838|Experimental|PC1a (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 1×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33039132|NCT04270838|Experimental|PC1b (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a half adult preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33329233|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
33329234|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
33329235|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
33329236|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
33329237|NCT04368858|Experimental|Cohort 1 : experimental group|Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
33039133|NCT04270838|Experimental|PC2 (Paediatric high dose)|Volunteers aged 2-6 years. Volunteers will receive a full adult preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33039134|NCT04270838|Experimental|PC3 (Paediatric preferred dose)|Volunteers aged 2-6 years. Volunteers will receive a paediatric preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The paediatric preferred dose will be 50-100% of the adult preferred dose. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33329238|NCT03813810||Normal|People without any chronic pulmonary diseases.
33329239|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
33329240|NCT03813810||Asthma|Patients with asthma
33329241|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
33329242|NCT04359888||MCET Group|Multi-Component Exercise Training (MCET) Group
33329243|NCT04359888||BRT Group|Balanced Reach Training Group
33329244|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
33329245|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
33039135|NCT04270838|Experimental|PV1 (Paediatric single-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
33329246|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
33039136|NCT04270838|Experimental|PV2 (Paediatric two-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0 followed by another dose on D7. All participants will also receive Verorab as a 4 site ID on D365 (SPEP+0) and Verorab as a 2 site ID on D379 (SPEP+14).
33039137|NCT04266028|Experimental|DM-101 Single Dose|Participants received a single subcutaneous (SC) dose of DM-101 30 ng on Day 1
33039138|NCT04266028|Placebo Comparator|Placebo Single Dose|Participants received a single SC injection of placebo on Day 1
33039139|NCT04266028|Experimental|DM-101 Low Multiple Ascending Doses (MAD)|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 42, and 56.
33039140|NCT04266028|Placebo Comparator|Placebo Low MAD|Participants received 5 biweekly administered SC injections of placebo on Day 1,14, 28, 42, and 56.
33039141|NCT04266028|Experimental|DM-101 High MAD|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 200 ng (dose divided into two SC injections) on Day 42, and 300 ng (dose divided into three SC injections) on Day 56.
33039142|NCT04266028|Placebo Comparator|Placebo High MAD|Participants received 5 biweekly administered SC injections of placebo as follows: single injection on Day 1, 14 and 28; two injections on Day 42; three injections on Day 56.
33039143|NCT04266028|Experimental|DM-101 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC doses of DM-101 as follows: 100, 250, 500, 1000, 2500, 5000, 10000 and 25000 ng during Day 1 and Day 2.
33039144|NCT04266028|Placebo Comparator|Placebo 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC injections of placebo during Day 1 and Day 2.
33039145|NCT04264702||Prospective arm|Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
33039146|NCT04264702||Control Arm|The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
33067718|NCT00152256|Placebo Comparator|3|
33329247|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
32866877|NCT04776785|Experimental|Group 2|"In Group 2, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2).~At the 6th and 12th months after the clinical applications; Profluorid® Varnish application will be repeated for test 1 lesions, and MI Varnish™ application will be repeated for test 2 lesions."
32866878|NCT04776785|Active Comparator|Group 3|"In Group 3, one lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications; MI Varnish™ application will be repeated for test 2 lesions, and Profluorid® Varnish application will be repeated for control lesions."
32866879|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
32866880|NCT00073957|Experimental|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
32866881|NCT04354428|Placebo Comparator|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
32866882|NCT04354428|Experimental|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])
32866883|NCT04354428|Experimental|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
32866884|NCT04354428|Experimental|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
32866885|NCT04354428|Placebo Comparator|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
32866886|NCT04754009|Active Comparator|Treatment as Usual (TAU)|Participants assigned to treatment as usual group are required to see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
32866887|NCT04754009|Experimental|Trauma-Sensitive Yoga + TAU|Participants assigned to the Trauma-Sensitive Yoga group will attend a 1-hour long session of yoga once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
32866888|NCT04754009|Experimental|Chen Style Tai Chi + TAU|Participants assigned to the Chen Style Tai Chi group will attend a 1-hour long session of tai chi once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
32866889|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
32866890|NCT05596513|Active Comparator|control group|received intensive motor-learning approaches that focuses on training of the affected hand (motor-learning approaches such as - constraint-induced movement therapy (CIMT) and hand-arm bimanual intensive training (HABIT) provide an alternative).
32866891|NCT05596513|Experimental|study group|received the intensive motor-learning approaches of the control group but from a vertical surface
32866892|NCT04753775|Experimental|22 patients were assigned to Group-A|22 patients were assigned to Group-A
32866893|NCT04753775|Placebo Comparator|22 patients were assigned to Group-B|22 patients were assigned to Group-B
32866894|NCT04775849|Experimental|Intraoperative Berger Space Imaging|Intraoperative OCT imaging of the space between the posterior capsule and the anterior hyaloid
32866895|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
32866896|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
32866897|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
32866898|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
32866899|NCT04775615|Experimental|Treatment group A|
32866900|NCT04775615|Experimental|Treatment group B|
32866901|NCT04775615|Experimental|Treatment group C|
32866902|NCT04775693|Experimental|RE|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as both an inpatient (2 days a week RE) and an outpatient (3 days a week RE).
32866903|NCT04775693|Active Comparator|SOC|Participants receive standard of care gait training only as both an inpatient (at least 2 days a week) and an outpatient (at least 3 days a week).
32866904|NCT04775693|Experimental|RE/SOC|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as an inpatient (2 days a week RE) and standard of care only as an outpatient (at least 3 days a week).
32866905|NCT04817202|Experimental|Group A1 (hzVSF-v13 50mg, intravenous, single dose)|Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.
32866906|NCT04817202|Experimental|Group A2 (hzVSF-v13 100mg, intravenous, single dose)|Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.
33108345|NCT04636814|Experimental|CHF6001 3200µg|
33108346|NCT04636814|Placebo Comparator|Placebo|
33108347|NCT04636814|Active Comparator|Roflumilast|
33108348|NCT04636424|Experimental|spastic diplegic group|assessment of the speed and weight distribution during gait
33108349|NCT04636424|Experimental|hemiplegic group|assessment of the speed and weight distribution during gait
33329248|NCT05271006|Experimental|Exercise group|"Weeks 1 - 12:~For the duration of the study, participant will be completing any of the physical activities customizable within the Down Dog apps. He/she will be asked to complete a minimum of four 20-minute workouts per week.~Every two weeks, participant will receive a survey to complete.~Week 24:~At week 24 (12 weeks after their initial 12-week participation in the study), participant will receive a check-in email with the final survey to complete.~Investigators will also record the use of the apps at week 24."
33108350|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
33108351|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
33108352|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with > 50% narrowing of luminal diameter.
33108353|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
33108354|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
33329249|NCT05271006|No Intervention|Waitlist control group|"Weeks 1 - 12:~For the 12 weeks of the study, participant will be asked to continue their typical, pre-study daily and weekly routine, maintaining the physical activity he/she was completing before the start of the study.~Every two weeks, the participant will receive a survey to complete.~Week 24:~• At the end of the first 12 weeks that he/she have access to the suite of apps (i.e., 24 weeks following their randomization to the waitlist control group), participant will receive a check-in email with the final survey to complete."
33329250|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
33108355|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
33108356|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
33108357|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
33108358|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
33108359|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
33108360|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
33108361|NCT04635722|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
33108362|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
33108363|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
33108364|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
33108365|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
33108366|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
33108367|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
33108368|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
33108369|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
33329251|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
33329252|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
33329253|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
33329254|NCT01304472|Active Comparator|Clopidogrel|
33329255|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
33039147|NCT04264442|Experimental|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor.
33039148|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
33039149|NCT04248244|Experimental|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
33329256|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
33329257|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
33329258|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
33039150|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
33039151|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
33039152|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
33039153|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
33329259|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
33329260|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
33329261|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
33329262|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
33329263|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
33329264|NCT05227404|Experimental|COVID19 Assays|All participants enrolled will receive 2 point of care assays, and 1 central lab assay
33329265|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
33329266|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
33329267|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
33329268|NCT03347838|Experimental|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
33039154|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
33039155|NCT04229004|Active Comparator|Gemcitabine combined with nab-paclitaxel|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.
33039156|NCT04229004|Active Comparator|mFOLFIRINOX|Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion
33039157|NCT04229004|Experimental|pamrevlumab (FibroGen)|"Arm is closed to recruitment.~Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.~Subjects enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.~Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines."
33067719|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
33067720|NCT00134537|Active Comparator|2|Conservative Care
33067721|NCT00152295|Experimental|1|
33329269|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
33329270|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
33039158|NCT04229004|Experimental|Canakinumab and Spartalizumab|"Arm is closed to recruitment.~Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine.~Subjects enrolled to this treatment arm will receive treatment with Canakinumab and Spartalizumab in combination with nab-paclitaxel and gemcitabine."
33039159|NCT04229004|Experimental|Experimental: SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
33039160|NCT04227132|Experimental|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
33039161|NCT04227132|Experimental|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
33039162|NCT04226690|Experimental|Active Dose 1|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
33039163|NCT04226690|Placebo Comparator|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
33039164|NCT04226690|Experimental|Active Dose 2|Participants will receive the second most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions
33039165|NCT04225065|Active Comparator|Chlorhexidine prep|Chlorhexidine prep prior to their operation
33039166|NCT04225065|Active Comparator|Betadine prep|Betadine prep prior to their operation
33329271|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
33329272|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
33329273|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
33329274|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
33329275|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
33329276|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
33039167|NCT04221087|Placebo Comparator|Placebo Arm|Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
33039168|NCT04221087|Experimental|Dexamethasone Arm|Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
33039169|NCT04219605||Symptomatic vaginitis patients|Symptomatic patients evaluated in the clinic for vulvovaginal symptoms.
33039170|NCT04200911|Experimental|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
33039171|NCT04181762|Experimental|secukinumab|secukinumab 300 mg s.c.
33039172|NCT04181762|Placebo Comparator|placebo|secukinumab placebo s.c.
33039173|NCT04181710|Experimental|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
33039174|NCT04181710|Other|Control|Organ preserved in preservation solution routinely used according to the local practice
33039175|NCT04174092|Experimental|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
33039176|NCT04174092|Experimental|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
33039177|NCT04174092|Experimental|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
33039178|NCT04174001||Neuro group|"Patients who meet the following criteria:~18 years of age or younger~diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke~planned for any surgical procedures that require general anesthesia~planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
32866907|NCT04817202|Experimental|Group A3 (hzVSF-v13 200mg, intravenous, single dose)|Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.
32866908|NCT04817202|Experimental|Group A4 (hzVSF-v13 400mg, intravenous, single dose)|Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.
32866909|NCT04817202|Experimental|Group A5 (hzVSF-v13 800mg, intravenous, single dose)|Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.
32866910|NCT04817202|Experimental|Group A6 (hzVSF-v13 1200mg, intravenous, single dose)|Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.
32866911|NCT04817202|Experimental|Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)|Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.
32866912|NCT04817202|Experimental|Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)|Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
32866913|NCT04817202|Experimental|Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)|Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
32866914|NCT04817202|Placebo Comparator|Placebo (intravenous, single dose)|Single administration (intravenous) of placebo on Day 1.
32866915|NCT04817202|Placebo Comparator|Placebo (subcutaneous, single dose)|Single administration (subcutaneous) of placebo on Day 1.
32866916|NCT04817202|Placebo Comparator|Placebo (intravenous, multiple dose)|Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.
32866917|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
32866918|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
32866919|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
32866920|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
32866921|NCT04775303|Experimental|experimental group|Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily
32866922|NCT04817514|Experimental|specific shoulder rehabilitation protocol group (SRG);|
32866923|NCT04817514|Experimental|specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG)|
32866924|NCT04817358||Demirjian method|According to the Demirjian method, the development of the seven left mandibular permanent teeth (except the third molar) were rated on the eight-stage scale from A to H. Each stage of mineralization was given a score, total dental maturity score was evaluated according to standard tables for boys and girls
32866925|NCT04817358||Willems method|Willems' method was determined using the Demirjian calcification stages but scores were evaluated according to Willems' specific tables
32866926|NCT04817358||Nolla method|In the Nolla method, the development of seven left mandibular and maxillar teeth were defined on 10 stages. If the tooth was between stages an appropriate fraction (0.2, 0.5 or 0.7) was added. The total score was determined according to the tables prepared for girls and boys as recommended by Nolla
32866927|NCT04816968|Experimental|Arm A - Cefepime|Continuous infusion of Cefepime at home.
32866928|NCT04816968|Experimental|Arm B - Piperacillin/tazobactam|Continuous infusion of Piperacillin/tazobactam at home.
32866929|NCT04816968|Experimental|Arm C - Meropenem|Continuous infusion of meropenem at home.
32866930|NCT04816968|Experimental|Arm D - Vancomycin|Continuous infusion of vancomycin at home.
32866931|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
32866932|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
32866933|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
32866934|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
32866935|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
32866936|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
32866937|NCT04775459||Surfactant administration without using score LUS|"It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration.~The surfactant was administrated only if the fraction of inspired oxygen (FiO2) >30% among the Guidelines of 2019"
32866938|NCT04775459||Surfactant administration using score LUS|"It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration.~The surfactant is administrated if FiO2 >30% OR if score LUS >8/18 among the literature"
32866939|NCT05563077|Experimental|Moderate-intensity interval training (MIIT)|24 participants with resistant hypertension will perform moderate-intensity interval training.
32866940|NCT05563077|Experimental|Moderate-intensity continuous training (MICT)|24 participants with resistant hypertension will perform moderate-intensity continuous training.
32866941|NCT05563077|No Intervention|Usual care|24 participants with resistant hypertension will maintain usual care for 4 months.
32866942|NCT04774835|Active Comparator|Standard aPS|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor.
32866943|NCT04774835|Experimental|aPS + HIVST|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor as well as the option to do HIV self-testing (HIVST) instead of testing at the local HTS location.
33067722|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
33067723|NCT00134654|Active Comparator|Group A|Premarin once a day
33039179|NCT04174001||Control group|"Patients who meet the following criteria:~18 years of age or younger-planned for any surgical procedures that require general anesthesia~planned postoperative invasive blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
33039180|NCT04170348|Experimental|Daily oral vitamin D3|Oral vitamin D3, 3,333 IU
33329277|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
33329278|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
33329279|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
33329280|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
33329281|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
33329282|NCT03813498|Experimental|intervention group|
33329283|NCT03813498|Other|control group|
33039181|NCT04170348|Active Comparator|Monthly bolus oral vitamin D3|Bolus oral vitamin D3, 100,000 IU
33039182|NCT04166409|Active Comparator|Arm I (vincristine sulfate, carboplatin)|"INDUCTION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and magnetic resonance imaging (MRI) at baseline and end of induction.~MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up."
33039183|NCT04166409|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up.
33329284|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
33039184|NCT04154683|Experimental|group using Cellvizio® optical biopsy|
33039185|NCT04153357|Active Comparator|intubation time airtraq|intubation time of Airtraq
33039186|NCT04153357|Active Comparator|intubation time of c-mac|intubation time of c-mac
33039187|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
33039188|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
33039189|NCT04153344||Controls|Patients with no neurofibromatosis type 1
33039190|NCT04153149|Experimental|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
33039191|NCT04153149|Placebo Comparator|Placebo|Participants will receive placebo during the double-blind period.
33039192|NCT04130997|Experimental|Ublituximab Infusions|"RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study"
33039193|NCT04124315||PAD Patients Completing SET|This single-group study includes patients with peripheral artery disease (PAD) who are completing a physician-prescribed supervised exercise training (SET) program.
33039194|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
33039195|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
33039196|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
33039197|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
33039198|NCT04102007|Other|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
33039199|NCT04100161|Experimental|Protein supplementation|20g protein supplementation twice daily for 3 months
33039200|NCT04100161|Active Comparator|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
33039201|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
33039202|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
33067724|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
33329285|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
33329286|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
33329287|NCT05216172|Experimental|AZD1656|AZD1656 100mg BD for 3 months
33329288|NCT05216172|Placebo Comparator|placebo|placebo 100mg BD for 3 months
33360527|NCT03930511|No Intervention|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
33417706|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
32866944|NCT04806204|Experimental|music therapy before the angiography|Patients in the Intervention 1 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes before the CAG procedure. Since individuals are in the CAG unit collectively before the procedure, headphones will be used in order not to disturb other individuals. After the interviews, musical types will be arranged as instrumental, non-verbal, at 70 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice. Instrumental works will be uploaded to the portable MP3 player provided by the researchers.
32866945|NCT04806204|Experimental|music therapy during the angiography|Patients in the Intervention 2 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the CAG hall during the CAG procedure. After the interviews, musical types will be arranged as instrumental, non-verbal, 75 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice.
33108370|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
33108371|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
32866946|NCT04806204|No Intervention|control group|After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
32866947|NCT04774757|Experimental|Systemic therapy sequenced PALND|All received systemtic therapy (at most two lines).
32866948|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
32866949|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
32866950|NCT04806438|Active Comparator|Group A (nebulized lignocaine group)|Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
32866951|NCT04806438|Active Comparator|Group B (nerve block group)|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.
32866952|NCT04774679|Experimental|Biopsy Arm|All patients who underwent EUS Guided biopsy
32866953|NCT04806126||Virtual Mentoring Program Participants|Physicians credentialed at Satellite Healthcare will be eligible to participate along with nephrology fellows from training programs affiliated with credentialed physicians.
32866954|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
32866955|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
32866956|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
32866957|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
32866958|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
32866959|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
32866960|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
32866961|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
32866962|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
32866963|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
32866964|NCT02211495|Active Comparator|No device|Treated with best medical therapy
32866965|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
32866966|NCT00074035|Experimental|Pentostatin|treatment of pts with refractory graft vs host disease
32866967|NCT04817124|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
32866968|NCT04817124|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
32866969|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
32866970|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
32866971|NCT04798326|Experimental|MW032|MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
32866972|NCT04798326|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
32866973|NCT05617248|Experimental|Experimental: Self-efficacy training (App)|This group will receive a digital one week self-efficacy training with three training sessions per day and EMA (10 per day).
32866974|NCT05617248|No Intervention|Control|This group will receive EMA questionnaires for one week (10 per day).
32866975|NCT04773977|Experimental|IBI362 liquid formulation|Participants received single subcutaneous injection of IBI362 liquid formulation
32866976|NCT04773977|Experimental|IBI362 lyophilized powder|Participants received single subcutaneous injection of IBI362 lyophilized powder
32866977|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
33108372|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
33108373|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
33108374|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
33108375|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
33108376|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
33108377|NCT04635956|Experimental|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
33108378|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
33108379|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
33108380|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
33108381|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
33108382|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
33108383|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
33108384|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
33108385|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
33108386|NCT04635176|Placebo Comparator|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
33108387|NCT04635176|Active Comparator|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
33108388|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
33108389|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
33108390|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
33108391|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
33108392|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
33108393|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
33108394|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
33108395|NCT04635566|Active Comparator|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
33108396|NCT04635566|Placebo Comparator|Placebo|Placebo one time/day at the evening.
33108397|NCT04635293|Active Comparator|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
33108398|NCT04635293|Placebo Comparator|patients who were not administered levosimendan prior to surgery|
33108399|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
33108400|NCT04635215||Participants|There are not multiple groups in this study
33329289|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
33329290|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
33329291|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention~This product is a biofortified cultivar apple with anthocyanins."
33329292|NCT03795324|Experimental|Green Apple|"Green Apple intervention~This product is a common cultivar apple without anthocyanins."
33329293|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention~This product is an infusion of aronia fruit extract rich in anthocyanin."
33329294|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
33329295|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
32866978|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
32866979|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
32866980|NCT00074269|Experimental|treatment|
32866981|NCT04773743|Experimental|chronic nonspecific low back pain|Remotely delivered yoga intervention
32866982|NCT04773509|Active Comparator|PVB group|Patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides
32866983|NCT04773509|No Intervention|Control group|PVB are not performed in the control group.
32866984|NCT00074815|Experimental|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
32866985|NCT00074815|Experimental|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
32866986|NCT00074815|Active Comparator|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
32866987|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
32866988|NCT04773431|Experimental|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
32866989|NCT04774367|Other|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|
32866990|NCT04774367|Other|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|
32866991|NCT00756769||1|Patients with SLE
32866992|NCT00756769||2|Related unaffected controls
32866993|NCT00756769||3|Unrelated unaffected controls
32866994|NCT04772729|Active Comparator|Insulin Aspart|Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.
32866995|NCT04772729|Experimental|Insulin Fiasp|Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.
32866996|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
32866997|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
32866998|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
32866999|NCT04772105|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route of administration: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: once every 4 weeks, 6 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
32867000|NCT04772105|Experimental|4mg of BAT5906|Specification: 16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4mg/eye/time, 50μl; medication duration: once every 4 weeks, 3 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
32867001|NCT05562375|Experimental|Patients|73 patients are to be recruited from the ones that go to the oral medicine service at the university clinic of Rey Juan Carlos in Madrid that present a compatible clinic diagnostic compatible with oral potentially malignant disorders. Each patient will receive first an intraoral exploration, taking note of location and size of the injury. After that, an exploration with the GOCCLES® device will be made, also taking note of the location and size data. Thereafter, the blue toluidine stain will be used, taking note of the size and location of the marked areas. Pictures will be taken through all the steps. Finally, a biopsy will be made of the area or areas the clinic considers and/or marked by the device or the toluidine blue.
32867002|NCT04772495||Study group|with Multiple sclerosis
32867003|NCT04772495||Control group|not Multiple sclerosis
32867004|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
32867005|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
32867006|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
32867007|NCT04772339||Healthy Adults|Healthy adults aged between 18-30
32867008|NCT04771949||All patients coming to the University Clinic of Dentistry|All patients coming to the dental University Clinic will be screened for the inclusion in the study.
32867009|NCT00075829|Active Comparator|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
32867010|NCT00075829|Active Comparator|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
33329296|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
33329297|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
33329298|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
33329299|NCT01304628|Placebo Comparator|Placebo|
33329300|NCT03293784|Other|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
33329301|NCT03293784|Other|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
33329302|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
33039203|NCT04095663|Active Comparator|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
33039204|NCT04095663|Active Comparator|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
33039205|NCT04086485|Experimental|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
33039206|NCT04086485|Experimental|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
33039207|NCT04072354|Experimental|SEP-363856 50mg|SEP-363856 50mg dosed once daily
33039208|NCT04072354|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
33039209|NCT04072354|Placebo Comparator|Placebo|Placebo dosed once daily
33039210|NCT04064827|Experimental|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
33039211|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
33329303|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
33329304|NCT03353350|Experimental|Efpeglenatide 2mg|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
33329305|NCT03353350|Experimental|Efpeglenatide 4 mg|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
33329306|NCT03353350|Experimental|Efpeglenatide 6 mg|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
33329307|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
33039212|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
33039213|NCT04060680|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
33039214|NCT04059770|Experimental|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
33039215|NCT04059770|Experimental|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
33039216|NCT04059770|Active Comparator|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
33039217|NCT04057898|Experimental|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.
33039218|NCT04057898|Placebo Comparator|placebo|Subjects will take up to 5 matching placebo capsules twice a day for 12 months.
33039219|NCT04051892|Experimental|Implantation of FixNip™ NRI|Female Patients Seeking Reconstructive Surgery of the Nipple
33039220|NCT04050280|Experimental|CLAG-GO|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
33039221|NCT04040205|Experimental|Abemaciclib|Subjects will be treated with abemaciclib 200 mg twice daily by mouth.
33039224|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 1)|
33039225|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 2)|
33039226|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 1)|
33039227|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 2)|
33039228|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
33329308|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.~Parents of all participants will provide proxy report. Children with CP > 8 years of age and cognitively able (approx. 50%) will provide self-report."
33329309|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
33329310|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
33329311|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
33329312|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
32867011|NCT00075829|Active Comparator|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
32867012|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
32867013|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
32867014|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
32867015|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
32867016|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
32867017|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
32867018|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
32867019|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
32867020|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
32867021|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
32867022|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
32867023|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
32867024|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
32867025|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
32867026|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
32867027|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
32867028|NCT04771559|Other|Cancer patients|Covid-19 antibody levels of patients will be measured
32867029|NCT04771559|Other|Healthy control|Covid-19 antibody levels of healthy controls will be measured
32867030|NCT05558709|Experimental|Patients|Patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL) or fronto-temporal lobar degeneration (FTD))
32867031|NCT05558709|Other|Relatives|Caregivers or relatives of included patients, having regular contact with the patient (≥ 2 times per month).
32867032|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
32867033|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
32867034|NCT00585559|Placebo Comparator|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
32867035|NCT00585559|Active Comparator|Acetaminophen and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
32867036|NCT00585559|Active Comparator|N-acetylcysteine and acetaminophen|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
32867037|NCT00585559|Active Comparator|Acetaminophen 1 Gram and N-acetylcysteine|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
32867038|NCT00585559|Active Comparator|Acetaminophen 1.5 Gram and N-acetylcysteine|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
32867039|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
32867040|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
32867041|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
32867042|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
32867043|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
32867044|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
32867045|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
32867046|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
32867047|NCT04797936|Active Comparator|Treatment group BNO 1030|BNO 1030
32867048|NCT04797936|Other|Control group|Standard care
32867049|NCT04771247|Experimental|CLEAR|Patients with GERD post LSG will undergo CLEAR (cardia band ligation).
32867050|NCT00176839|Experimental|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
32867051|NCT04797624||Baseline group|The baseline group included the patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
32867052|NCT04797624||Pandemic group|The pandemic group included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
33039229|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
33039230|NCT04018755|Experimental|treatment|anakinra 100 mg subcutaneous once daily
33108401|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
33108402|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
33108403|NCT02894775||included in a clinical trial|
33108404|NCT02894775||not included in a clinical trial|
33108405|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
33108406|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
33108407|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
33108408|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
33108409|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
33108410|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
33108411|NCT04635332|Experimental|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
33108412|NCT04635332|Active Comparator|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
33108413|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
33108414|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
33108415|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
33108416|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
33108417|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
33108418|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
33108419|NCT04635020|Experimental|Stable glaucoma iStent|Cataract surgery combined with iStent inject
33108420|NCT04635020|Experimental|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
33108421|NCT04635020|Active Comparator|Stable glaucoma|Cataract surgery
33329313|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
33329314|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
33329315|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
33329316|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
33329317|NCT05209230|Experimental|Continuous renal replacement therapy arm|Echocardiographic evaluation (with 2D speckle tracking analysis of left ventricular segmental function) 1 hour before and 3 hours after the initiation of continuous renal replacement therapy (continuous veno venous hemofiltration) initiation
33329318|NCT05209230|Other|Control arm|Two echocardiographic evaluations (with 2D speckle tracking analysis of left ventricular segmental function) at an interval of 4 hours, before the continuous renal replacement therapy initiation.
33329319|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
33329320|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,~Administration: Day 1 of each 3-week cycle"
33329321|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33108422|NCT04635020|Experimental|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
33108423|NCT04635020|Experimental|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
33108424|NCT05655871|Experimental|Enterprise Group|"Elderly individuals were divided into 5 groups according to the stages of change in the TTM scale. According to the change phase, those in the non-thinking phase are at 10:00 on Mondays, Wednesdays and Fridays, those in the thinking phase are at 13:00 on Mondays, Wednesdays and Fridays, and those in the preparatory phase are at 15:00 on Mondays, Wednesdays and Fridays of the week. They were asked to come to the seminar hall at 00:00. It was explained that a training video about physical activity would be watched. Those in the preparation phase were asked to come to the activity hall at 10:00 on Tuesdays, Thursdays and Saturdays of the week, and at 14:00 on Tuesdays, Thursdays and Saturdays of the week, while wearing their comfortable clothes. It was said that a training and motivational video about physical activity would be watched and the exercises would be done under the supervision of the researcher with the show-and-make technique."
33329322|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33329323|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
33329324|NCT05759182|Experimental|Cerebral Palsy gait training using a pediatric exoskeleton|"ExoAtlet Bambini Outcome, Safety, and Efficacy 8 participants with cerebral palsy will participate in gait training using ExoAtlet Bambini powered exoskeleton.~Intervention: Device: Gait training using ExoAtlet exoskeleton"
33329325|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
33039231|NCT04004000|Experimental|Treatment|FSHD1 subjects with genetic confirmation with receive 15 mg of losmapimod twice daily given by mouth; for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or study termination.
33039232|NCT03994731|Experimental|Pegloticase + MTX|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral MTX 15 mg weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + Immunomodulator (IMM) Period, in addition to oral 15 mg MTX, participants receive intravenous (IV) pegloticase 8 mg administered every 2 weeks (Q2W) for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for infusion reaction (IR) prophylaxis."
33039233|NCT03994731|Placebo Comparator|Pegloticase + Placebo|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral placebo for MTX weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + IMM Period, in addition to oral placebo for MTX, all participants receive IV pegloticase 8 mg administered Q2W for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for IR prophylaxis."
33329326|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
33329327|NCT03633214|No Intervention|No training module (Control)|
33039234|NCT03984357|Experimental|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
33039235|NCT03964233|Experimental|Dose Escalation - BI 907828 + ezabenlimab|All neoplasms
33039236|NCT03964233|Experimental|Dose Expansion - Cohort 1 BI 907828 + ezabenlimab|
33039237|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + ezabenlimab|
33039238|NCT03964233|Experimental|Dose Escalation - BI 907828 + ezabenlimab + BI 754111|All neoplasms
33329328|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
33039240|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
33039241|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
33039242|NCT03935750|Experimental|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
33039243|NCT03935750|Active Comparator|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
33039244|NCT03935750|Experimental|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
33039245|NCT03935750|Active Comparator|QT alone|Patients will undergo ACLR using a QT autograft without LET.
33039246|NCT03933215||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
33329329|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
33329330|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
33329331|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
33329332|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
33329333|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
33329334|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
33039247|NCT03921489||Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
33039248|NCT03886246|Experimental|Spesolimab (every 6 weeks)|
33039249|NCT03886246|Experimental|Spesolimab (every 12 weeks)|
33039250|NCT03886246|Experimental|Spesolimab (every 4 weeks)|
33039251|NCT03868943|Experimental|Solriamfetol|Given orally daily
33039252|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33039253|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33039254|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33039255|NCT03841448|Experimental|Cemdisiran|Participants will receive cemdisiran during the Treatment and optional Open-Label Extension (OLE) Periods in combination with standard of care.
33039256|NCT03841448|Placebo Comparator|Placebo|Participants will receive matching placebo during the Treatment Period in combination with standard of care. During the optional OLE Period participants will receive cemdisiran in combination with standard of care.
33039257|NCT03829683|Active Comparator|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
33039258|NCT03829683|Placebo Comparator|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
33039259|NCT03824522||All Study Participants|Participants who are newly prescribed with Adynovate and participants previously treated with Adynovate will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician.
33039260|NCT03815825|Experimental|IONIS-FB-LRx|Stage 1 participants will receive IONIS-FB-LRx randomized to 1 of 3 dose levels, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 will expand 2 of the dosing cohorts in a new randomized group of participants based on the Stage 1 interim analysis. Participants will be randomized to 1 of 2 of the expanded cohorts, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
33039261|NCT03815825|Experimental|Placebo|Stage 1 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
33039262|NCT03812991|No Intervention|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
33039263|NCT03812991|Experimental|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
33039264|NCT03812653|Experimental|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
33039265|NCT03812653|No Intervention|Control Arm: Usual Care.|6 months of usual medical therapy alone.
33039266|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
33039267|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
33039268|NCT03801915|Experimental|Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1)|Pre-operative escalation doses of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
33039269|NCT03801915|Experimental|Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1)|Pre-operative RD of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
33039270|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
33039271|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
33039272|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
33039273|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
33039274|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
33039275|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
33039276|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
33329335|NCT04403464|Experimental|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
33329336|NCT04403464|Active Comparator|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
33329337|NCT03970096|Experimental|Arm A1 (TBI, TnD)|Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33329338|NCT03970096|Experimental|Arm A2 (busulfan, TnD)|Patients receive fludarabine IV over 30 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33329339|NCT03970096|Experimental|Arm C1 (TBI, PTCy, tacrolimus)|Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33329340|NCT03970096|Experimental|Arm C2 (busulfan, PTCy, tacrolimus)|Patients receive fludarabine IV over 30 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33360528|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
33360529|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
33360530|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
33039277|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
33039278|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
33039280|NCT03730701|Experimental|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
33039281|NCT03730701|No Intervention|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
33039282|NCT03725202|Experimental|Arm A|Upadacitinib dose A administered daily + 26-week CS taper regimen
33039283|NCT03725202|Experimental|Arm B|Upadacitinib dose B administered daily + 26-week CS taper regimen
33039284|NCT03725202|Placebo Comparator|Arm C|Placebo administered daily + 52-week CS taper regimen
33039287|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
33039288|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
33329341|NCT03970096|Experimental|Arm D1 (TBI, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33360531|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
32867053|NCT04771325|Other|Arm 1|Women are normally escorted to the health facilities by one or more family members and or friends. Women usually labor in an open first stage room where more than one woman is admitted sometimes with curtains to separate the beds with one person allowed besides her to provide support. The support persons do not have designated roles to play during this process. Routine analgesia is not given neither is continuous fetal monitoring. Midwives,
32867054|NCT04771325|Experimental|Arm 2|One session of training on admission in labor. The training will focus on emotional and physical support; emotional support including being Present, demonstrating a caring and positive attitude, saying calming verbal expressions, using humor, praise, encouraging and acknowledging efforts during the process of pushing the baby. Physical support including supporting her to change position favoring upright positions, walking with her, giving her drinks and food, massage, reminding her to go and pass urine, helping her find a comfortable position for pushing, wipe her face with cool cloth and help her breast feed
32867055|NCT04771091|Experimental|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist.
32867056|NCT00176917|Experimental|Treatment Arm|All patients treated with chemotherapy and transplantation.
32867057|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
32867058|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
32867059|NCT04770701|Experimental|Ahah drug|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+)~Ahah composition contains the following ingredients (concentrated extracts of plants):~Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg"
32867060|NCT04770701|Experimental|Ahah Placebo|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV)(+), Hepatitis B virus (HBV)(+), Tuberculosis (+)~Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)"
32867061|NCT04770077||Group S|Spray before intubation
32867062|NCT04770077||Group C|Intubation directly
32867063|NCT04770389|Placebo Comparator|Placebo|placebo obicetrapib + placebo ezetimibe; once daily
32867064|NCT04770389|Experimental|Combination therapy|5 mg obicetrapib + 10 mg ezetimibe; once daily
32867065|NCT04770389|Experimental|Obicetrapib monotherapy|5 mg obicetrapib + placebo ezetimibe; once daily
32867066|NCT04770389|Experimental|Ezetimibe monotherapy|placebo obicetrapib + 10 mg ezetimibe; once daily
32867067|NCT04753619|Experimental|Niclosamide group: NCS group|NCL + standard therapy
32867068|NCT04753619|No Intervention|Control group|Control group
32867069|NCT04753463||Residents of Ophthalmology working on COVID-19 departments|Residents of ophthalmology working on COVID-19 departments and dealing with SARS-CoV-2 positive patients
32867070|NCT04753463||Residents of Ophthalmology working on general ophthalmic departments|Residents of Ophthalmology working on general ophthalmic departments and not dealing with SARS-CoV-2 positive patients
32867071|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
32867072|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
32867073|NCT04753151|Experimental|Tranexamic acid|Patients scheduled for liver transplantation and allocated for treatment with tranexamic acid (Group 1).
32867074|NCT04753151|Placebo Comparator|Placebo|Patients scheduled for liver transplantation and allocated for treatment with placebo (Group 2).
32867075|NCT04769609||Concentrated growth factor (CGF) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CGF
32867076|NCT04769609||Collagen membrane (CM) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CM
32867077|NCT05606549|Experimental|marital self disclosure|
32867078|NCT05606549|No Intervention|Routine care|
32867079|NCT05606471|Active Comparator|VLCD only|Participants in this group will be placed on a very-low calorie diet with a daily energy intake limit of 800 kilocalories. 600 kilocalories will be made up of total meal replacement products supplied by Lighterlife UK. The remaining 200 kilocalories will be flexible for participants to add additional vegetables to supplement the total meal replacement products, allowing some variety to the diet.
33039289|NCT03683186|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
33329342|NCT03970096|Experimental|Arm D2 (busulfan, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
33329343|NCT05759026|Experimental|control condition - with VR - with Tablet|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329344|NCT05759026|Experimental|with VR - control condition - with tablet|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329345|NCT05759026|Experimental|with tablet - control condition - with VR|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329346|NCT05759026|Experimental|Control condition - with tablet - with VR|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329347|NCT05759026|Experimental|with VR - with tablet - control condition|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329348|NCT05759026|Experimental|with tablet - with VR - control condition|The patient will be randomized so that the order of the 3 interventions, during step 1, will be determined in a random way.
33329349|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
33329350|NCT01384240|Experimental|Proflavine Hemisulfate|
33329351|NCT04357600|Experimental|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
33329352|NCT04332640|Experimental|Next Generation Phaco System|VERITAS Vision System
33039293|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
33039294|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
33039295|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
33039296|NCT03648541|Experimental|All Patients|1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
33039297|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
33039298|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
33039299|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
33039300|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
33039301|NCT03639311|Experimental|Participants receiving Injection CAB LA plus RPV LA|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
33039302|NCT03639311|Experimental|Participants receiving Oral DTG plus RPV|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available.
33329353|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
33329354|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
33329355|NCT04293796|Experimental|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
33360532|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
33039303|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
33039304|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
33039305|NCT03626688|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
33039306|NCT03626688|Placebo Comparator|Placebo|Matching placebo tablets (oral)
33039307|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
33039308|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
33360533|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
33360534|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
33039309|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
33039310|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
33417707|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
33417708|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
33436463|NCT05135962|Experimental|Leaf self-expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
33436464|NCT05221333|Other|Healthy participants|Up to 25ml of saline administered through OBI
33108425|NCT05655871|Experimental|Control Group|"Data collection forms were applied to the control group in the pre-test. These forms are; Personal Information Form, Tinetti Balance and Gait Test, Exercise Change Stages Scale, Exercise Change Process Scale, Exercise Decision-Making Scale, Exercise Self-Efficacy Scale. In order to avoid an ethical dilemma between the individuals in the control and intervention groups, the videos will be watched by the individuals in the control group at the end of the study."
33108426|NCT04681716|Active Comparator|ELDOA GROUP|ELDOA position was instructed to this group
32867080|NCT05606471|Active Comparator|Semaglutide only|Participants will be asked to self-administer the GLP-1 agonist Semaglutide weekly, as per clinical practice. They will be asked to start at 0.25mg and increase every two weeks (if tolerated) to the maintenance dose of 1mg, which they will continue until the end of the study.
32867081|NCT05606471|Experimental|Combined VLCD plus Semaglutide|Participants in this group will both partake in the VLCD, and take the weekly dose of Semaglutide (as described above).
32867082|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
32867083|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
32867084|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
32867085|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
32867086|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
32867087|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
32867088|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
32867089|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
32867090|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
32867091|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
32867092|NCT05606393|Experimental|traditional speech therapy and additional virtual reality training group|Each participant received 1-hour traditional speech therapy(ST) and additional 30-minute VR training immediately after each session of traditional ST. All participants received 3 sessions of treatment every week for 3 weeks.
32867093|NCT05606393|Active Comparator|traditional speech therapy group|Each participant received 1-hour traditional speech therapy(ST) only for each session. All participants received 3 sessions of treatment every week for 3 weeks.
32867094|NCT05606315|Experimental|Remimazolam besylate|
32867095|NCT05606315|Active Comparator|propofol|
32867096|NCT05606315|Active Comparator|midazolam|
32867097|NCT05606237|Experimental|Low Level Red Light Treatment Arm|On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
32867098|NCT05606237|No Intervention|Control Treatment Arm|Subjects in the control group will wear single vision spectacles.
32867099|NCT05606081|Experimental|Use of risk prediction scores|The prediction model is being used to identify patients who are at highest risk for colorectal cancer based on their risk scores.
32867100|NCT05606003|Experimental|Multi-level Multi-Component Intervention (MLI)|Individuals receive COVID-19 CHW-delivered education and navigation, 2-1-1 helpline referrals, and social marketing messaging.
32867101|NCT05606003|Experimental|Community Just-in-Time-Adaptive Intervention (JITAI)|Individuals receive MLI intervention components that are informed by real-time data and community stakeholder feedback.
32867102|NCT05606003|No Intervention|Comparison Condition|Individuals receive standard exposure to ongoing city and county COVID-19 communication and testing.
32867103|NCT02516501|Active Comparator|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
32867104|NCT02516501|Experimental|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
33108427|NCT04681716|Experimental|CONVENTIONAL PHYSIOTHERAPY|Hot pack,TENS and mobalization was given in this group
33108428|NCT04681521|Experimental|HOT THERAPY:GROUP A|Hot Compress Group
32867105|NCT02516501|Experimental|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
32867106|NCT05605925|Active Comparator|Control arm|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
32867107|NCT05605925|Experimental|Intervention arm|IVN 600 mcg/kg/day for 3 days + 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
32867108|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
32867109|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
32867110|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
32867111|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
32867112|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
32867113|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
32867114|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
32867115|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
32867116|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
32867117|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
32867118|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
32867119|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
32867120|NCT01855607|Experimental|topical menthol|Patients with neuropathic pain will receive topical menthol following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
32867121|NCT01855607|Active Comparator|placebo lotion|Patients with neuropathic pain will receive placebo lotion following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
32867122|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
32867123|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
32867124|NCT01596699|Experimental|Patients with Myeloid Malignancies|
32867125|NCT01596699|Experimental|Patients with Non-Malignancies|
32867126|NCT01148849|Experimental|Cohort 1: 0.1 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867127|NCT01148849|Experimental|Cohort 2: 0.3 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867128|NCT01148849|Experimental|Cohort 3: 1.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867129|NCT01148849|Experimental|Cohort 4: 3.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867130|NCT01148849|Experimental|Cohort 5: 6.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867131|NCT01148849|Experimental|Cohort 6: 10 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867132|NCT01148849|Experimental|Cohort 7: 15 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867133|NCT01148849|Experimental|Cohort 8: 18 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
32867134|NCT05605457|Experimental|PRG barrier coat|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
32867135|NCT05605457|Active Comparator|Resin modified glass ionomer|Resin modified glass ionomer (Fuji II LC, GC, Japan). RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction.
32867136|NCT05605379||Responders (with CCR at 1 year)|
32867137|NCT05605379||No responders (without CCR at 1 year)|
33108429|NCT04681521|Experimental|COLD THERAPY:GROUP B|Cold Compress Group
32867138|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
32867139|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
32867140|NCT05605301|Experimental|Sequential ascending dose cohort|Cohort 1 will receive single 40 mg dose once. Cohort 2 will receive single 60 mg dose once. Cohort 3 will receive (2) 60 mg dose on one occasion.
32867141|NCT03007797||vaccination rate- pregnant- influenca|
32867142|NCT05566743|Experimental|the maintenance arm|in this arm patients will receive 4 months of induction FOLFRINOX then maintenance capecitabine
32867143|NCT05566743|Other|the control arm|in this arm patients will receive 4 months of FOLFRINOX then kept under follow-up
32867144|NCT00076219|Experimental|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
32867145|NCT00076219|Active Comparator|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
32867146|NCT05605145||Immunocompromised patients|"Patients with immunocompromised conditions, including but not limited to HIV infection, long-term systemic use of corticosteroids, use of immunosuppressive agents, hematologic malignancies, solid tumors, hematopoietic stem cell transplantation, solid organ transplantation, radiotherapy and/or chemotherapy for malignancies,primary immunodeficiency disease.~Typical clinical manifestations of PJP such as fever,nonproductive cough, shortness of breath, and progressive hypoxemia.~Radiological abnormalities suggestive to PJP in bilateral lungs revealed by chest computed tomography (CT).~Respiratory tract samples were collected for qPCR and/or mNGS detection."
32867147|NCT05604521|Active Comparator|Group 1a: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10^6 PfSPZ Vaccine.~Group 1a: Approximately half (22/23) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
33039311|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
33039312|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
33039313|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
33039314|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
33039315|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
32867148|NCT05604521|Active Comparator|Group 1b: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10^6 PfSPZ Vaccine.~Group 1b: Approximately half (22/23) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
33039320|NCT03602391|Experimental|SCP Plus|
33039321|NCT03602391|No Intervention|Services as usual|
33039322|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
33039323|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
33039324|NCT03581305|Active Comparator|Dopaminergic arm|"25 eligible HIV-infected individuals and 50 eligible HIV-negative (HIV-) individuals for the dopaminergic arm.~Dopaminergic arm:~Group A: HIV-positive subjects with or without co- morbidities; Group B: HIV-negative subjects with co-morbidities; Group C: HIV-negative subjects without co-morbidities"
33039325|NCT03581305|Active Comparator|Serotonergic arm|"20 HIV-infected individuals and 20 HIV-negative individuals for the serotonergic arm~Serotonergic arm:~Group D: HIV-positive subjects with or without co-morbidities; Group E: HIV-negative subjects with or without co-morbidities"
33039326|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
33039327|NCT03575364||Registry|Patients with proximal lower extremity DVT.
33039328|NCT03556202|Experimental|125 Milligram (mg) Mirikizumab Q8W|Participants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).
33039329|NCT03556202|Experimental|250 mg Mirikizumab Q8W Excluding Secukinumab|Participants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)
33039330|NCT03556202|Experimental|Secukinumab/250 mg Mirikizumab Q8W|Participants from previous originating study [who received secukinumab (AMAJ)] received 250 mg mirikizumab administered SC Q8W.
33039331|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
33039332|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
33039333|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
33039334|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
33039335|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
33039336|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
33039337|NCT03541174|Experimental|Aprocitentan 25 mg in Part 1 (double-blind)|Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.
33039338|NCT03541174|Experimental|Aprocitentan 12.5 mg in Part 1 (double-blind)|Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.
33039339|NCT03541174|Placebo Comparator|Placebo in Part 1 (double-blind)|Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.
33039340|NCT03541174|Experimental|Aprocitentan 25 mg in Part 2 (single-blind, single arm)|After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.
33108430|NCT04681521|Placebo Comparator|PLACEBO: GROUP C|Inoperative compress Group
33108431|NCT04634942|Experimental|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
33108432|NCT04634942|Experimental|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
32867149|NCT05604521|Placebo Comparator|Group 2a: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2a: Approximately half (7/8) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
32867150|NCT05604521|Placebo Comparator|Group 2b: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2b: Approximately half (7/8) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
32867151|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
32867152|NCT05601323|Experimental|HIFU (High-Intensity Focused Ultrasound) + Chemotherapy|"HIFU treatment with Suizenji: up to 2 times per week (1 course) for pancreatic primary lesions; the second course should be at least 60 days apart, up to a maximum of 5 courses.~Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX"
32867153|NCT05601323|Active Comparator|Chemotherapy|Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX
33108433|NCT04634942|No Intervention|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
33108434|NCT04634942|Placebo Comparator|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
33108435|NCT04634942|Placebo Comparator|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
33108436|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
33108437|NCT04681599|No Intervention|Nebulization without filter or scavenger|Subject will use a standard nebulizer
33360535|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
33360536|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
33360537|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
33360538|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
33360539|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
33360540|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
33360541|NCT01329211||Gastroparesis Patients|
33360542|NCT01329211||Gastroparesis Patients' Caregivers|
33360543|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
33360544|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
33360545|NCT03874897|Experimental|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
33360546|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
33360547|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
33360548|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
33360549|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
33360550|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
33108438|NCT04681599|Experimental|Nebulization with a filter or scavenger|Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask
33108439|NCT04681599|No Intervention|High-flow nasal cannula|Subject will use high-flow nasal cannula at 40 L/min
33108440|NCT04681599|Experimental|High-flow nasal cannula with a scavenger face tent|Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent
33108441|NCT04681599|Active Comparator|High-flow nasal cannula with a surgical mask|Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula
33108442|NCT04635137|Experimental|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
33108443|NCT05655832|Experimental|COPD cohort|
33108444|NCT05655832|Experimental|Calibration participants cohort|
33108445|NCT05655793||With Neurodegeneration|Includes patients with mild cognitive impairment and dementia
33108446|NCT05655793||Without Neurodegeneration|Includes healthy controls and patients with subjective cognitive decline
33108447|NCT00624676|Experimental|A|LHA formulation
33108448|NCT00624676|Active Comparator|B|5% benzoyl peroxide
33108449|NCT04634903|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
33360551|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
33360552|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
33360553|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
33360554|NCT01127113|Active Comparator|SPIO alone|
33360555|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
33360556|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
33360557|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
33360558|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
33360559|NCT01227733||Breast Tumor|Breast Tumor Blocks
33360560|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
33360561|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
33360562|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
33360563|NCT03926767|Experimental|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
33360564|NCT03926767|Active Comparator|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
33360565|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
33360566|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
33360567|NCT03926455|Experimental|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
33360568|NCT03926455|Experimental|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
33360569|NCT03926455|Experimental|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
33360570|NCT03926455|Active Comparator|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
33360571|NCT03926455|Placebo Comparator|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
33360572|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
33360573|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
33360574|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
33360575|NCT01127191||Military|
33360576|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
33417709|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
33108450|NCT04634903|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
33108451|NCT04634903|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
33417710|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
33417711|NCT01319591||CNS lymphoma patients|
33108452|NCT05655754|Active Comparator|Methohexital|"Initial dose: methohexital 1 mg/kg (≙ 80 mg methohexital in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 10 mg methohexital will be administered until sufficient depth of anesthesia according to defined criteria is achieved. Criteria for sufficient depth of anesthesia will be comprised by a) the abolition of the eye-lash reflex b) absence of motor reaction upon inflation of the tourniquet.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session."
33108453|NCT05655754|Active Comparator|Ketofol|"Esketamine and propofol will be prepared shortly before injection by the nurse anesthetist as follows: 4 ml esketamine 25mg/ml, 6ml NaCl (0,9%), 10ml propofol (10mg/ml). The stability of ketamine-propofol mixtures (undiluted, 50:50 ratio) in one syringe has been documented for up to 3 hours.~Initial dose: esketamine 0,5 mg/kg + propofol 0,5 mg/kg (≙ 40 mg esketamine + 40 mg propofol in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 5mg esketamine and 5 mg propofol will be administered until a sufficient depth of anesthesia is achieved.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session"
33108454|NCT02894385|Experimental|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
33417712|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
33417713|NCT05187949||Patients|"Quantitative study: Surveys: 1,067 out of a total of 1,389,725 people of residents of the Valencian Community, Spain. Three groups with quota control: proportional to age (40-50; 50-70; > 70 years) of men aged 40 and over who have not had prostate cancer from each stratum (geographical area and population habitat).~Qualitative study: general population focus groups: 3"
33417714|NCT05187949||General Practitioners|"Quantitative study: 369 General Practitioners working in two Health Departments in the Valencian Community, Spain (Dept of Health Alicante, General Hospital 19, 255,439 habitants) and (Dept of Health Alicante, S Juan Alicante 17, 233,115 habitants).~Qualitative study: general practitioners focus groups: 2."
33417715|NCT05187949||Urologists|Quantitative study: 345 Urologists working in Valencian Community, Spain Qualitative study: urologists focus groups: 1.
33417716|NCT03609996||PDR treated with Laser|
33417717|NCT03609996||PDR treated with Lucentis|
33417718|NCT05178199|Experimental|Remote Psychological Support Group|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
33417719|NCT05178199|Active Comparator|Mindfulness through audio and video|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
33417720|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
33417721|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
33417722|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
33329356|NCT04293796|Experimental|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
33329357|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
33329358|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
33039341|NCT03541174|Experimental|Aprocitentan 25 mg in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.
33039342|NCT03541174|Placebo Comparator|Placebo in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.
33329359|NCT04258072|Experimental|open label,single arm|Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
33329360|NCT03923452|Experimental|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator. Due to COVID-19, the program will be held virtually.
32867154|NCT05597267|Experimental|Treatment with the MIRIA Laser|3-4 experimental treatments at 4-6 week intervals
32867155|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
32867156|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
33039343|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
33039344|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
33039345|NCT03534245||1|Healthy children aged 2 - 9 years
33039346|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
33039347|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
33039348|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
33039349|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
33039350|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
33039351|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
33039352|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
33039353|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
33039354|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
33039355|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
33039356|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
33039357|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
33039358|NCT03480633||Control|Defined as patients without a history of heart failure
33039359|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.
33039360|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.
33039361|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
33039362|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
33329361|NCT03923452|No Intervention|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
33360577|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
33039363|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
33039364|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
33039365|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
33108455|NCT02894385|Experimental|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
33417723|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
33108456|NCT02894385|Experimental|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
33108457|NCT05655715|Experimental|A SBRT + ipi/nivo|Stereotactic body radiotherapy of 8 Gray (Gy) x 3 on one soft tissue or bone metastasis + Nivolumab 3mg/kg IV every 3 weeks (Q3W) + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks treatment in total
33108458|NCT05655715|Experimental|B ipi/nivo|Nivolumab 3mg/kg IV Q3W + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV Q4W for up to 52 weeks treatment in total
33108459|NCT05655676|Experimental|89Zr-NY008|
33329362|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
33108460|NCT04634864|Active Comparator|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
33108461|NCT04634864|Sham Comparator|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
33108462|NCT02887417||patients|glioblastoma patients
33108463|NCT02887417||controls|healthy controls
33108464|NCT04317235|Active Comparator|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
33329363|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
33329364|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
33108465|NCT04317235|Active Comparator|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
33108466|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
33108467|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
33108468|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
33108469|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
33108470|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
33329365|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
33329366|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
33329367|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
33329368|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
33329369|NCT04210414|Experimental|Day 3 transfer|Transfer on day 3 when only one embryo is available
33329370|NCT04210414|Experimental|Day 5 transfer|Transfer on day 5 when only one embryo is available
33329371|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
33329372|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fasted|Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
33329373|NCT04188730|Active Comparator|LUCEMYRA (lofexidine) tablets, fasted|Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
33329374|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fed|Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
33329375|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
33329376|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
33329377|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
33329378|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
33329379|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
33329380|NCT03852472|Placebo Comparator|Group A|Placebo b.i.d
33329381|NCT03852472|Active Comparator|Group B|Avacopan 10 mg b.i.d
33329382|NCT03852472|Active Comparator|Group C|Avacopan 30 mg b.i.d
33329383|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
33329384|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
33329385|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
33039366|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
33417724|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
33417725|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
33417726|NCT05168761||laparoscopic partial nephrectomy|The investigators included all hospitalisations for LPN using CCAM(Classification Commune des actes médicaux) code (JAFC005) after removing the 83 hospitals using RAPN in 2017. LPN complications were from hospitals using exclusively LPN.
33417727|NCT05168761||open partial nephrectomy|OPN has its own CCAM codes; they group laparotomy (JAFA019 / JAFA030) and lumbotomy (JAFA008 / JAFA024)
33417728|NCT05168761||robot assisted partial nephrectomy|At the time of this study, RAPN did not have a specific coding. The investigators had contacted the hospitals with Vinci robotic surgical procedures in 2013 and the investigators included here PN from hospitalisations from the 25 centres using exclusively RAPN for more than five years. Thus, in this study, RAPN was performed by experts in robotic surgery.
33417729|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
33039367|NCT03459846|Experimental|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
33417730|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
33039368|NCT03459846|Experimental|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
33039369|NCT03452137|Active Comparator|Atezolizumab|Participants will receive Atezolizumab for 16 cycles, or up to 1 year (whichever occurs first)
33039370|NCT03452137|Experimental|Placebo|Participants will receive Placebo for 16 cycles, or up to 1 year (whichever occurs first).
33039371|NCT03449381|Experimental|Dose Escalation|
33039372|NCT03449381|Experimental|Dose Expansion|
33039375|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
33039376|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
33039377|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
33039378|NCT03433781|Experimental|Absorbic Acid|All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment.
33039379|NCT03429543|Experimental|Linagliptin|Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks
33039380|NCT03429543|Experimental|Empagliflozin|Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ≥ 7% at week 12
33108471|NCT05655559|Experimental|Treadmill Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during treadmill exercises.
33417731|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|
33417732|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|
33417733|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|
33417734|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
33417735|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
33417736|NCT02083874|Experimental|CBD|Open label CBD
33039381|NCT03429543|Placebo Comparator|Placebo|Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks
33039382|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
33039383|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
33039384|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
33039385|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
33039386|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
33039387|NCT03394066|Experimental|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
33039388|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2weeks and cross-over to the palmitoleate-rich oil
33039389|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
33039390|NCT03364153|Experimental|Cohort 1|Zimura dose group
33039391|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
33039392|NCT03361852|Experimental|Neo Vax|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
32867157|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
32867158|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
32867159|NCT05566665||ECMO requiring ARDS patients|"The study population for the Aim 1 study will comprise adult patients admitted to the participating ICUs suffering from ARDS (as defined by the Berlin criteria) and treated with ECMO.~The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol."
32867160|NCT05566665||Antibiotic treated ECMO requiring ARDS patients.|The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol.
33039393|NCT03361852|Experimental|NeoVax and pembrolizumab|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Patients will receive pembrolizumab every 3 weeks starting on day 78~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
33039394|NCT03350516|Experimental|Daily 500 mg Calcium|
33039395|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
33039396|NCT03350451|Experimental|Lumasiran (ALN-GO1)|
33039397|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
33039398|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
33039399|NCT03329508|Experimental|P2B001 0.6/0.75 mg|Fixed dose combination once daily capsule of pramipexole 0.6mg and rasagiline 0.75mg, + matching placebo tablet
33039400|NCT03329508|Experimental|rasagiline 0.75mg|Rasagiline 0.75mg Once daily capsule, component of P2B001, + matching placebo tablet
33039401|NCT03329508|Experimental|Pramipexole 0.6mg|Pramipexole 0.6mg once daily capsule, component of P2B001 + matching placebo tablet
33039402|NCT03329508|Active Comparator|Pramipexole Extended Release|Marketed pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg + matching placebo capsule
33039403|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
33417737|NCT01367197|No Intervention|No intervention|Observation only
33417738|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
33417739|NCT05188781||Pembrolizumab combined with Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
33039404|NCT03325972|Placebo Comparator|Placebo|saline placebo
33039405|NCT03319745|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
33039406|NCT03312556|Placebo Comparator|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
33039407|NCT03312556|Active Comparator|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
33039408|NCT03289039|Experimental|Neratinib|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)"
33039409|NCT03289039|Experimental|Neratinib + Fulvestrant|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)~Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.~Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
33417740|NCT02083952|Experimental|swaddle blanket|
33417741|NCT01367353|Experimental|ovarian cancer|
33417742|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
32867161|NCT05597189|Experimental|Botanical extracts high dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
32867162|NCT05597189|Experimental|Botanical extracts low dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
32867163|NCT05597189|Placebo Comparator|Control group|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
32867164|NCT05566509||Breast Conservative Surgery|The patients who had minimally invasive surgery.
32867165|NCT05566509||Mastectomy|The patients who had invasive and destructive surgery.
32867166|NCT05596721|Experimental|Azithromycin + ICS/LABA|Azithromycin: 500mg, po, 3 times per week for 12w ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
32867167|NCT05596721|Placebo Comparator|ICS/LABA|ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
32867168|NCT00076687|Experimental|1|
32867169|NCT00076687|Experimental|2|
32867170|NCT00076687|Placebo Comparator|3|
32867171|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
32867172|NCT00952445|Experimental|T0903131 Besylate (higher dose)|10.0 mg
32867173|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
32867174|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
33039410|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
33039411|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
33039412|NCT03237858|Active Comparator|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
33039413|NCT03237858|Placebo Comparator|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
33039414|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
33039415|NCT03233711|Other|Arm B (clinical observation)|Patients undergo observation while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
33039416|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
33039417|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
33039418|NCT03206086|Experimental|Group|Eltrombopag
33039419|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
33039420|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
33039421|NCT03200717|Experimental|Pazopanib- 2nd line treatment|Participants received pazopanib as 2nd line treatment
33039422|NCT03200717|Experimental|Pazopanib- 3rd line treatment|Participants received pazopanib as 3rd line treatment
33039423|NCT03191578|Experimental|RUTI® injection|
33039424|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
33417743|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
33039426|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
33039427|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
33039428|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
33039429|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
33039430|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
33039431|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
33329386|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
33329387|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
33329388|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
33329389|NCT01569334|Other|untransplanted|
33329390|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
33329391|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
33329392|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
33329393|NCT05758870||Research Group|surgical stabilization of low rib fracures by internal fixation
33329394|NCT05758870||Controls Group|conservative treatment of low rib fractures
33329395|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
33329396|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
33039432|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
33039433|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
33039434|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
33039435|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~Diabetes patients who consent to participate the study.~Age 65+;~Diagnosis code for diabetes in the last 2 years;~Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
33039436|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
32867175|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
33039437|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
33039438|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
33067725|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
32867176|NCT04752995|Other|high tibial osteotomy|Under general anesthesia, a one-cm vertical skin incision was done at the medial subcutaneous border of the tibia, one fingerbreadth below the tibial tuberosity. This was confirmed by intra-operative C-arm images. Longitudinal periosteal incision was done with minimal dissection. Incomplete medial transverse osteotomy including both anterior and posterior cortex was performed using drill bit or small thin osteotome.Osteotomy was completed manually by osteoclasis of the lateral cortex to provide postoperative stability by the preserved lateral periosteum. No fibular osteotomy was needed in the present study.
32867177|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
32867178|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
32867179|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
32867180|NCT05469269|Experimental|Education and Passive Navigation|This arm receives barber-led education and access to a resource website. Barbers will encourage clients to access the screening website. Other study materials will also be located within the shop. The resource website will be accessible via QR code that will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire.
32867181|NCT05469269|Experimental|Education and Active Navigation|This arm includes all interventions of the first arm plus the addition of a community navigator. The community navigator will be onsite to assist in information delivery and navigation to resources and encourage the completion of the Screener through the QR code. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
32867182|NCT05469269|Experimental|Education and Active Navigation with Community Based Outreach|This arm adds the community navigator and a community outreach screening event. Case Comprehensive Cancer Center Community Outreach and Engagement will offer barber shops an onsite PSA screening event.
32867183|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
32867184|NCT05442593|Experimental|Pre-adolescents|Acute plyometric training
32867185|NCT05442593|Experimental|Adolescents|Acute plyometric training
32867186|NCT05566431|Active Comparator|ICP monitoring based Protocol|Arm one will use a consensus-developed management protocol for paediatric severe traumatic brain injury based on recommendations from the Brain Trauma Foundation Guidelines, which uses invasive intracranial pressure monitoring
32867187|NCT05566431|Active Comparator|No ICP Monitoring Protocol CREVICE|Arm two will use the Consensus-Revised Imaging and Clinical Examination (CREVICE) management protocol for paediatric severe traumatic brain injury based on imaging and clinical examination in the absence of invasive intracranial pressure monitoring
32867188|NCT05417087|Experimental|SF001 administered without water|test product administered without water
32867189|NCT05417087|Experimental|SF001 administered with water|test product administered with water
32867190|NCT05417087|Experimental|Trintellix|Reference product administered with water
32867191|NCT05346887|Experimental|Home-based Therapy|
32867192|NCT01526343|Experimental|Reveal XT|
32867193|NCT05566197|Experimental|Intervention|This group will receive dietary adjustment and nutrition counseling.
32867194|NCT05566197|Active Comparator|Control|This group will receive standard diet and nutrition counseling.
32867195|NCT05331131|Experimental|Ketamine Mouthwash|"Enrolled patients with histologically confirmed squamous cell carcinoma of the head and neck undergoing definitive radiation therapy to 70Gy with concurrent cisplatin chemotherapy who develop grade 3+ toxicity will be prescribed ketamine mouthwash at a strength of 20mg/5mL in NovaFilm suspension with OraSweet flavoring agent via swish and spit route of administration. They will take the investigational drug four times daily."
32867196|NCT05326529|Active Comparator|Traditional Cardiac Rehabilitation (Hospital based programme)|Traditional Cardiac Rehabilitation will involve 8 hospital-based exercise sessions, and one virtual education day over 8 weeks, supervised by CR health care professionals.
33067726|NCT00134966|Experimental|1|
33067727|NCT00134966|Active Comparator|2|
33108472|NCT05655559|Experimental|Cycle Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during cycling exercises.
33108473|NCT00560729|No Intervention|I|
33108474|NCT00560729|Active Comparator|II|oral nutrition
33108475|NCT00560729|Experimental|III|oral nutrition
33108476|NCT00560729|Experimental|IV|oral nutrition
33108477|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
33108478|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
33108479|NCT00560768|Experimental|1|
33108480|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
33108481|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
33108482|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
33108483|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
33108484|NCT00560807|No Intervention|A|Zero treatment/3 weeks
33108485|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
33108486|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
33108487|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
33108488|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
33108489|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
33108490|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
33108491|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
33329397|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
33108492|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
33108493|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
33108494|NCT00560807|No Intervention|E|Zero treatment/6 weeks
33329398|NCT01380964||DMD patients|DMD Patients
33329399|NCT01380964||Control patients|Control patients
33329400|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
33329401|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
33329402|NCT01384162|Experimental|sNN0029, ICV infusion|
33067728|NCT00152568|Experimental|Child Passenger Safety Technician services|
33067729|NCT00135005|Experimental|AMN107 + STI571|
33067730|NCT00142233|Experimental|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
33108495|NCT00560807|No Intervention|I|Zero treatment/12 weeks
33108496|NCT05351554|Experimental|Treatment Arm 1|Namilumab with prednisone, or equivalent
33108497|NCT05351554|Placebo Comparator|Treatment Arm 2|Placebo with prednisone, or equivalent
33108498|NCT05351554|Experimental|Treatment Arm 3|Namilumab with current dose of prednisone, or equivalent
33108499|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
33329403|NCT05757778|Experimental|Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will be neurotized by connecting the lateral intercostal nerve to the nipple with interposing standard nerve grafting techniques. The neurotized breast will serve as the experimental breast. The other breast will not receive any breast neurotizing procedure."
33329404|NCT05757778|No Intervention|Non-Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will not receive any breast neurotizing procedure. The non-neurotized breast will serve as the control breast."
33329405|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
33329406|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
33329407|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
33329408|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
32867197|NCT05326529|Experimental|Traditional combined with Web-based Cardiac Rehabilitation|Traditional combined with Web-based Cardiac Rehabilitation. Patients will attend 8 hospital-based exercise sessions and one virtual education day over 8-weeks with access to additional web-based (MyHeart app) exercise and educational information.
32867198|NCT05326529|Experimental|Web-based Cardiac Rehabilitation|Web-based Cardiac Rehabilitation, using MyHeart app introduced during a pre-CR assessment, will follow an 8-week individualised self-managed platform, allowing contact with the CR health professionals via app messages only (no direct contact for web-based CR).
33108500|NCT05655403|Experimental|Step training group|The participants assigned to the ST condition will receive a 40-minute ST session twice a week for 12 weeks. The sessions will be delivered at community centers for older adults by an instructor with at least 5 years of experience in dementia care. Each session will consist of a 5-minute flexibility exercise warm-up, a 30-minute stepping exercise, and a 5-minute cool-down. A non-slip plastic mat marked with two standing panels and a number of removable stepping panels that can be secured to the plastic mat using hook-and-loop fasteners will be used as the exercise device. While standing on the standing panels, the participants will receive verbal instructions to (1) use one of their feet to step on a specific stepping panel and (2) return the stepping foot to the standing panel multiple times throughout every session.
33108501|NCT05655403|Active Comparator|Wait-list control group|The participants assigned to the WC condition will then receive usual care for 12 weeks. After completing the 12-week assessment, they will complete the ST program.
33108502|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
33108503|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
33108504|NCT05655286|Experimental|Group A- immediately rinse mouth|Children are instructed to rinse their teeth with a cup of water containing about 50 ml immediately after SDF treatment. Afterwards, no post-treatment protocol is given to children.
33108505|NCT05655286|Experimental|Group B- not to rinse for at least 30 minutes|Children are instructed not to eat and drink for at least 30 minutes.
33108506|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
33329409|NCT03794544|Experimental|Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
33329410|NCT03794544|Experimental|Durvalumab 1500 mg + Oleclumab 3000 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
33329411|NCT03794544|Experimental|Durvalumab 1500 mg + Monalizumab 750 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
33329412|NCT03794544|Experimental|Durvalumab 1500 mg + Danvatirsen 200 mg|Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
33329413|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
33329414|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
33329415|NCT01380652|Experimental|rehabilitation with vibration training|
33329416|NCT01380652|No Intervention|rehabilitation without vibration training|
33329417|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
33329418|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
33329419|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
33329420|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
33329421|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT~Details:~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
32867199|NCT01526577|Experimental|LC23-1306|experimental drug
32867200|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
32867201|NCT01526577|Active Comparator|Ticagrelor|active comparator
33329422|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
33329423|NCT03737734|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
33329424|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
33329425|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
33329426|NCT01384006||Control|standard pancreas allograft recipients
33329427|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
33329428|NCT05182320||OrthoPath|
33039439|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
33039440|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
33329429|NCT05182320||Control|
33329430|NCT05756842|Experimental|Honey-based gel consumption|A honey-based gel will be administered to participants in this arm.
33039441|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Rectal surgery is planned during week 15"
33039442|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
33039443|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
33039444|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
33039445|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
33039446|NCT03113201|Experimental|Collabri Flex|Collaborative care
33039447|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
33039448|NCT03113175|Experimental|Collabri Flex|Collaborative care
33039449|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
33329431|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
33329432|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
33329433|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
33329434|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
33329435|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
33039450|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.~Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
33039451|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
33039452|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
33039454|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
33039455|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
33039456|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
33039457|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
33039458|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
33039459|NCT03048201|Other|Physica CR with LMC Liner|Subjects that receive the Physica Cruciate Retaining Knee System with LMC Liner
33039460|NCT03047993|Experimental|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
33039461|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
33039462|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
33039466|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
33039467|NCT02974582|Experimental|1/Part 1|60 Participants of high and low SES
33039468|NCT02974582|Experimental|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
33039469|NCT02974582|Experimental|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
33039470|NCT02974582|Experimental|4/Part 2 - Control|Randomized to view direct mail marketing
33039471|NCT02953431|Placebo Comparator|Sham CPAP|Participants will be randomized to Sham CPAP
33039472|NCT02953431|Active Comparator|CPAP 10|Participants will be randomized to CPAP 10
33039473|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with atrophic AMD.
33039474|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
33039475|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
33039476|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
33039482|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin
33039483|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I + aldesleukin
33039486|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
33039487|NCT02807506|Experimental|Aim 1 (Survey): Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
33039488|NCT02807506|Experimental|Aim 1 (Survey): Clinicians|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
32867202|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
33039489|NCT02807506|Experimental|Aim 1 (Survey): Caregivers|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
33039490|NCT02807506|Experimental|Aim 2: Deployment 1 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
32867203|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
33039491|NCT02807506|Experimental|Aim 2: Deployment 2 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
33329436|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
33329437|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
33329438|NCT01383850|Active Comparator|NCPAP + standard air|
33039492|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
33039493|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
33039494|NCT02769975||Case Only|Children ages 3 months to 100 with known or suspected endocrine or metabolism disorders. Family members ages 3 months to 100. They may participate in the DNA part of the study
33039495|NCT02768701|Experimental|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
33039496|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
33039497|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
33039498|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
33039499|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care with palliative care."
33039500|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care"
33039501|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
33039502|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
33039503|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:~Posture study with blood samples for autoantibody testing~24-hour heart rhythm and blood pressure monitoring~autonomic function tests~Quantitative Axonal Sudomotor Reflex Testing~Total blood volume assessment~Pharmacologic testing with phenylephrine~Pharmacologic testing with isoproterenol~Cardiac output with rebreathing~Assessment of splanchnic capacitance~Microneurography"
33039504|NCT02719899||1|Healthy Volunteers
33039505|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
33039506|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
33039507|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
33039508|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
33039509|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
33039510|NCT02684201|Experimental|Boston Scientific cord stimulator lead|"A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance."
33039511|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
33039512|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
33039513|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
33329439|NCT01383850|Experimental|NCPAP + Heliox|
33329440|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
33329441|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
33329442|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
32867204|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
32867205|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
32867206|NCT05322629|Experimental|Intervention (enhanced PrEP HIV biofeedback)|"Women in the intervention arm (n=325) will receive enhanced PrEP bio-feedback adherence counseling:~Real-time novel immunoassay using urine that measures tenofovir and enhanced bio-feedback counseling. The novel urine assay shows tenofovir concentrations if PrEP is taken in the past 48 hours thereby enabling counselors to provide feedback on adherence levels, immediately.~Enhanced counseling on recent adherence levels~Rapid PrEP collection~In second randomization at 6m, women on PrEP with poor adherence or continuation, will be offered differentiated PrEP delivery in the community or in the clinic. The study will follow these participants for 15m to assess longer term PrEP continuation and adherence."
32867207|NCT05322629|Active Comparator|Standard of care|Women in the standard of care arm (n=325) will receive facility-based PrEP and monthly HIV testing in pregnancy and quarterly in postpartum. PrEP prescriptions and HIV testing will be provided according to the national PrEP guidelines. The women will be followed through 6m postpartum for the first randomization and through 15m with the standard of care for the second randomization.
32867208|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
32867209|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
32867210|NCT05282381||Cohort of renal transplant recipients|
32867211|NCT00078403|Experimental|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
32867212|NCT00078403|Experimental|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
32867213|NCT00078403|Experimental|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA <600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly & RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA >=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
32867214|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
32867215|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
32867216|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
32867217|NCT01897519|Experimental|Arm 3 high dose ABT-719|
32867218|NCT01897519|Placebo Comparator|Arm 4 Placebo|
32867219|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
32867220|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
32867221|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
32867222|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
32867223|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
32867224|NCT05211713|Experimental|Intervention group receiving Opp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
32867225|NCT05211713|No Intervention|Control group|The waiting list control group will receive the intervention after study completion.
32867226|NCT00178711|Active Comparator|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
32867227|NCT00178711|No Intervention|control|treated at normothermia
32867228|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
32867229|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
33039514|NCT02595944|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood samples collection during screening and follow-up.
33329443|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
33329444|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
33329445|NCT03812640|Experimental|Vicryl|Vicryl suture
33329446|NCT03812640|Active Comparator|Nylon|Nylon suture
33329447|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
33039515|NCT02595944|Active Comparator|Arm II (observation)|Patients are followed serially with CT and/or PET/CT imaging for up to 1 year. Patients also undergo blood sample collection during screening and follow-up.
32867230|NCT05590273|Experimental|Proof-of-concept trial|Inform CALM adaptations for caregivers of patients with brain cancer.
32867231|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
33329448|NCT01302210||control|Usual standard of care
33329449|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
33329450|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
33329451|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
33329452|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
33039521|NCT02562235|Experimental|Riociguat|Participants with age ≥6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time.
33039522|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
33039524|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
33039525|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
33039526|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
33039527|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
33039528|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
33039529|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
33039530|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
33039531|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
33039532|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
33039533|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
33039534|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
33039535|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
33039536|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
33039537|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
33039538|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
33039539|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
33039540|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
33039541|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
33039542|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.~The dose has to be calculated as follows:~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
33329453|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
33360578|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
33039543|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
33329454|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
33329455|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
33360579|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
33039544|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33039545|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33039546|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
33039547|NCT02322840|Experimental|TMVR Implant|Twelve TMVR Implant
33039549|NCT02268253|Experimental|Tagraxofusp (SL-401)|
33039550|NCT02242968||Healthy Volunteers|Male and Female healthy volunteers between aged 18 and 65 years.
33039551|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
33039552|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
33039553|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
33039554|NCT02204072|Experimental|BI 836845 & Enzalutamide|
33039555|NCT02204072|Active Comparator|Enzalutamide|
33039556|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
33039557|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
33039558|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
33039559|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
33039560|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33039561|NCT02107976|Experimental|Stage 1|Upon admission, diabetic subjects maywill discontinue their oral hypoglycemic medications and/or insulin regimen per investigators discretion. Oral hypoglycemic agents and/or insulin doses will be adjusted and may be supplemented with a correction scale and/or and transitioned to a basal-bolus insulin regimen. In order to achieve optimal glycemic monitoring and for safety reasons, subjects may be fitted with a Dexcom continuous glucose monitor (CGM) upon inpatient admission. CGM will be used to supplement, rather than replace, fingerstick glucose measurements. CGM monitoring will include a sensor fitted subcutaneously, a wireless transmitter that allows for remote glucose monitoring by the research team.
33039562|NCT02107976|Experimental|Stage 2|Subjects may be considered for arm stage 2 inpatient study no less than 8 weeks duration from arm stage 1 study. Once the RBC vitamin C concentrations are optimal (>30 uM), subjects may be re-admitted to Clinical Center metabolic unit and undergo the same protocol as described above in arm stage 1. Oral vitamin C and E supplementation may be discontinued on admission. The inpatient diet, glucose monitoring and sampling scheme will be the same as described for the first inpatient study.
33329456|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~Followed by Trastuzumab 2 mg/kg weekly thereafter~Lapatinib 1000 mg by mouth (PO) daily~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
33329457|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
33329458|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
33360580|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
33360581|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
33039563|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
33039564|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
33039565|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:~Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
33039566|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
33039567|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
33039568|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning cycle 2, patients also receive rituximab IV over 4 hours on days 1 and 2 of cycle 2, and day 1 of cycles 3-7. Treatment repeats every 28 days for 7 cycles in the absence of unacceptable toxicity. In the absence of disease progression, patients may continue ibrutinib PO QD.
33039569|NCT02048813|Active Comparator|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab IV over 4 hours on days 1 and 2 of cycle 1, and day 1 of cycles 2-6. Patients also receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 cycles in the absence of unacceptable toxicity.
33039570|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
33039571|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
33039572|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
33039573|NCT02019693|Experimental|Capmatinib (INC280)|INC280 400 mg twice every day by mouth, continuously
33039574|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
33039575|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
33039576|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
33039577|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
33039578|NCT01898494|Experimental|Arm S (Surgery) then Arm A (Low risk, observation)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.
33039579|NCT01898494|Experimental|Arm S (Surgery) then Arm B (Intermediate risk, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.
33039580|NCT01898494|Experimental|Arm S (Surgery) then Arm C (Intermediate risk, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.
33039581|NCT01898494|Experimental|Arm S (Surgery) then Arm D (High risk, IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
33360582|NCT03926377|Other|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
33360583|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
32867232|NCT01527513|Placebo Comparator|Placebo|
33039582|NCT01888913||Adult Women|Adult Women aged 18-50
33039583|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
33039585|NCT01778504||Probands|Children, adolescents, and adults
33039586|NCT01778504||Relatives of Probands|1st, 2nd, and 3rd degree relatives
33039587|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
33039588|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
33039589|NCT01730131||Control Patients at Risk for PML|Participants with impaired immune function from any cause and considered at risk for PML
33039590|NCT01730131||Healthy Volunteers|Healthy volunteers without impaired immune function
33039591|NCT01730131||PML Patients|Participants with PML
33039592|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
33039593|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
33039594|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
33039596|NCT01621594|Experimental|1|Subjects with Clinical indication for a coronary CT angiography exam
33039597|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
33039598|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
33039599|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
33039600|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
33039601|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
33039602|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
33039603|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
33039604|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
33039605|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
33039606|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
33039607|NCT01386424||Healthy Volunteers|Healthy Volunteers
33039608|NCT01375530||1|Healthy adults 18 years old or older
33039609|NCT01332097|Experimental|Treatment A|Single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
33039610|NCT01332097|Placebo Comparator|Treatment B/G/E/I|Matching placebo comparator arm
33039611|NCT01332097|Active Comparator|Treatment C|Single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
33039612|NCT01332097|Experimental|Treatment D|Single oral dose of 20mg dose of BCT197 capsules
33039613|NCT01332097|Experimental|Treatment F|Single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
33039614|NCT01332097|Experimental|Treatment H|Single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
33039617|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
33039618|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
33039619|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
33039620|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
33039621|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
33039622|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
33039623|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
33360584|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
33360585|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
33039624|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
33039625|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
33039626|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
33039627|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
33039628|NCT01175993|Active Comparator|Eliptical training|Home base exercise
33039629|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
33039630|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
33039631|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
33039632|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
33039633|NCT01148381||smokers|healthy individuals with nicotine use disorder
33039634|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
33039635|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
33039636|NCT01143519||FLT1 C-677T|SNP
33039637|NCT01143519||MDM2 rs2279744|SNP
33039638|NCT01143519||p53 rs1042522|SNP
33039639|NCT01143519||RMM1 rs1465952|SNP
33039640|NCT01143519||TLR8 rs3761624|SNP
33039641|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
33039642|NCT01105858||Volunteers|Adult volunteers &amp; family members recruited from the Phoenix metropolitan area
33039643|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
33039644|NCT01036685||379-bench-control|healthy control who will only do behavioral tasks
33039645|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only do behavioral tasks
33039646|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who will only do behavioral tasks
33039647|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
33039648|NCT01036685||379-control|healthy control who can do MRI and tDCS
33039649|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI and tDCS
33039650|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who can do MRI and tDCS
33039651|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI and tDCS
33039652|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
33039653|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
33039654|NCT01019343|Placebo Comparator|Healthy Volunteers|Healthy Volunteers
33039655|NCT01019343|Active Comparator|Movement Disorder|Subjects diagnosed with movement disorder
33039656|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
33039657|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
33039659|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
33039660|NCT00976963|Active Comparator|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediatley
33039661|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
33039662|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
33039663|NCT00967005|Placebo Comparator|Sugar Pill|
33039664|NCT00873288|Active Comparator|Usual Care mailing intervention|routine colposcopy reminder letter mailed
33039665|NCT00873288|Experimental|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
33039666|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
33039667|NCT00862433|Experimental|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
33039668|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
33039669|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
33039670|NCT00862433|Experimental|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
32867233|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
32867234|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
32867235|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
33360586|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
32867236|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
32867237|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
32867238|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
32867239|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
32867240|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
32867241|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
32867242|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
32867243|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
32867244|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
32867245|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
32867246|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
32867247|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
32867248|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
32867249|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
32867250|NCT04351425|Experimental|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
32867251|NCT04351425|Active Comparator|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
32867252|NCT02592798|Experimental|Abatacept|"Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
32867253|NCT02592798|Placebo Comparator|Placebo|"Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
32867254|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
32867255|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
32867256|NCT01530243|Placebo Comparator|Placebo|
32867257|NCT01530243|Active Comparator|Terazosin|
32867258|NCT01530243|Active Comparator|Tolterodine|
32867259|NCT01530243|Active Comparator|Tolterodine + Terazosin|
32867260|NCT04797546|Experimental|Adductor Canal Block|With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
32867261|NCT04797546|Active Comparator|Patient Controlled Morphine Analgesia|Patients are placed under General Anesthesia, and after surgery, a Morphine patient controlled analgesia delivery system is installed. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
32867262|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
32867263|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
32867264|NCT00078559|Experimental|Alemtuzumab|
32867265|NCT04797702|Experimental|Experimental group|Glumetinib combined with Toripalimab
32867266|NCT04805814|Active Comparator|Intervention Group|All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.
32867267|NCT04805814|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.
32867268|NCT00081653|Experimental|1|
32867269|NCT00081653|Active Comparator|2|
32867270|NCT00078715|Experimental|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
32867271|NCT00078715|Experimental|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
32867272|NCT04805580|Active Comparator|intrathecal block|patients (25) will receive unilateral intrathecal block using 1.5 ml of hyperbaric bupivacaine
32867273|NCT04805580|Active Comparator|Quadratus lumborum block|patients (25) will receive quadratus lumborum block by an anterior approach using 30 ml of bupivacaine 0.25%
32867274|NCT04398745|Experimental|Part 1: Participants with normal/mild impaired renal function|Participants with normal or mildly impaired renal function (Normal: individual glomerular filtration rate [iGFR]: >=90 milliliter per minute; Mild impairment: iGFR: 60-89 mL/min will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
32867275|NCT04398745|Experimental|Part 1: Participants with severe renal impairment|Participants with severely impaired renal function (iGFR: 15-29 mL/min) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
32867276|NCT04398745|Experimental|Part 2: Participants with ESRD (not on dialysis)|Participants with ESRD (iGFR: <15 mL/min) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
32867277|NCT04398745|Experimental|Part 2: Participants with ESRD (on hemodialysis)|Participants with ESRD (iGFR: <15 mL/min) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
32867278|NCT04805034||HBeAg positive/HBsAg positive|
32867279|NCT04805034||HBeAg seroconversion /HBsAg loss|
32867280|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
32867281|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
32867282|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
32867283|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
32867284|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
32867285|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
32867286|NCT05192915|Other|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
32867287|NCT04804956||Early-rectal cancer|The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
32867288|NCT04804956||Advanced-rectal cancer|The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
32867289|NCT04804956||Synchronous metastasis -rectal cancer|The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.
32867290|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
32867291|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
33039671|NCT00794352||Healthy Volunteer|Healthy patients with NO inflammatory and/or demyelinating/dysmyelinating diseases of the CN
33039672|NCT00794352||Patient Cohort|Patients who present with CNS white matter injury (including inflammatory and/or demyelinating/dysmyelinating diseases of the CNS)
33039673|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
33039674|NCT00600496|Experimental|1|AZD6244 + docetaxel
33039675|NCT00600496|Experimental|2|AZD6244 + Dacarbazine
33039676|NCT00600496|Experimental|3|AZD6244 + Erlotinib
33039677|NCT00600496|Experimental|4|AZD6244 + Temsirolimus
33039678|NCT00542230||Healthy Volunteers|Healthy Volunteers
33039679|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
33039680|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
32867292|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
32867293|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
33039681|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33039683|NCT00477958|Experimental|Geriatric Assessment Tool|
33039684|NCT00453505|Experimental|1|Healthy Volunteers
33039685|NCT00453505|Sham Comparator|1a|Healthy Volunteers
33039686|NCT00453505|Experimental|2|Healthy Volunteers
33039687|NCT00453505|Sham Comparator|2a|Healthy Volunteers
33039688|NCT00453505|Experimental|3|Healthy Volunteers
33039689|NCT00453505|Sham Comparator|3a|Healthy Volunteers
33039690|NCT00453505|Experimental|4|Healthy Volunteers
33039691|NCT00453505|Sham Comparator|4a|Healthy Volunteers
33039693|NCT00359580||AGDB|Those individuals who are listed in the Fisher Family History and other genealogy books ordatabases will be included in the AGDB.
33360587|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
33039695|NCT00342654||1|Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.
33039696|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person-to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
33039697|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
33039698|NCT00341523||1|Chinese adults at high risk for esophageal cancer
33039699|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
33039700|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
33039701|NCT00339911||1/ single cohort|Healthy NCI Frederick Cancer Research and Development Center employees
33039702|NCT00326482||Prior Liver Biopsy|HIV+ historical liver biopsy history
33039703|NCT00326482||Prospective Liver Biopsy with ARV|HIV+ taking c/ARV medications
33039704|NCT00326482||Prospective Liver Biopsy without ARV|HIV+ not taking c/ARV medications
33039705|NCT00271622||healthy volunteers|healthy volunteers
33039706|NCT00271622||individuals at risk|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
33039707|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
33039708|NCT00203996|No Intervention|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
33039709|NCT00203996|Experimental|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
33039710|NCT00203996|Experimental|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
33039711|NCT00203996|Experimental|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
33039712|NCT00203996|Experimental|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
33039713|NCT00203996|Experimental|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
33108507|NCT04318990|Experimental|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
33108508|NCT04318990|Active Comparator|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
33108509|NCT05655247|Experimental|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|
33108510|NCT05655247|Active Comparator|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|Modified Coronally Advanced Tunnel (MCAT)
33108511|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
33108512|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
33108513|NCT04634708||Pediatric patients on EXCOR VAD support|
33108514|NCT04319263|Experimental|intermediate and high risk non muscle invasive bladder cancer|
33108515|NCT05655169|Experimental|Piezosurgery and low-level laser therapy|Piezocision will be applied in this group of patients using a piezosurgery knife and after six weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.
33108516|NCT05655169|Experimental|Piezosurgery only|Piezocision will be applied in this group of patients using a piezosurgery knife
33329459|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
33329460|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
33329461|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
33329462|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
32867294|NCT04804878||Biospeciman Repository and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
32867295|NCT05587543|Experimental|CAR-T|Target A positivity was assigned to CAR-T cell therapy.
33329463|NCT05574972|Experimental|Timing Carotid Stent|
32867296|NCT05587543|Experimental|TCR-T|Target A negative, Target B positive and Target C positive were assigned to TCR-T cell treatment group.
33108517|NCT05655169|Active Comparator|Traditional treatment without acceleration|In this group of patients, the en masse retraction will be conventional without any acceleration intervention.
33108518|NCT05655130|Experimental|Test Group|Test Group will receive 10mg intravenous dexamethasone at the time of incision, administered by the assigned anesthesiologist. Post-surgery, Test Group patients will be prescribed a 6-day oral methylprednisolone taper course.
33108519|NCT05655130|Other|Control Group|Standard of care with no placebo
33108520|NCT05658484|Experimental|Dimethyl fumarate (DMF)|Participants will receive DMF 120 mg capsules, orally, twice daily (BID) for the first 7 days, followed by 240 mg BID (maintenance dose) after 7 days for up to Week 48.
33108521|NCT05658406|Active Comparator|Group A|intraoperative infusion of 15 mL/kg/hour Ringer's lactate.
33108522|NCT05658406|Active Comparator|Group B|intraoperative infusion of 10 mL/kg/hour Ringer's lactate
33108523|NCT05658406|Active Comparator|Group C|intraoperative infusion of 6 mL/kg/hour Ringer's lactate.
33108524|NCT05658406|Placebo Comparator|Group D|standard fluid management alone
33108525|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
33108526|NCT05658367|Active Comparator|Group 1|- Group I: The group applied arm massage with sesame oil
33108527|NCT05658367|Experimental|Group 2|- Group II: The group applied arm massage with a mixture of sesame-lavender oil
33108528|NCT05658367|Placebo Comparator|Group 3|- Group III (Control): The group applied arm massage with paraffin oil
33108529|NCT04319146|Other|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
33108530|NCT04206592|Active Comparator|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
33108531|NCT04206592|Active Comparator|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
33108532|NCT02894697|Active Comparator|Angiography-guidance|
33108533|NCT02894697|Experimental|OCT-guidance|
33108534|NCT05471206|Experimental|Milk intolerant volunteers|
33108535|NCT05471206|Active Comparator|Milk tolerant volunteers|
33329464|NCT05574972|Active Comparator|Carotid Wallstent|
33360588|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
33039714|NCT00203996|Experimental|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
33039715|NCT00203996|Experimental|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
33329465|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.~Inclusion Criteria:~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).~Exclusion criteria:~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
33329466|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
33329467|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
33329468|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
33329469|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
33329470|NCT01308034|Experimental|association sunitinib radiotherapy|
33329471|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
32740099|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
32740100|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
32740101|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
32867297|NCT04814160|Active Comparator|autogenous bone graft|autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
33039716|NCT00203996|Experimental|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
33039717|NCT00203996|Experimental|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
33039725|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
33039726|NCT00114647||1|Healthy Volunteers
33039727|NCT00114647||2|HIV
33039728|NCT00099437|Experimental|1|Fulvestrant 500 mg
33039729|NCT00099437|Experimental|2|Fulvestrant 250 mg
33417744|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
33039730|NCT00092222|Active Comparator|Active Treament 3|Patients not responding to high- dose zidovudine and valganciclovir alone may be treated with botezomib plus high- dose zidovudine and valganciclovir
33039731|NCT00092222|Active Comparator|Active Treatment 1|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
33039732|NCT00092222|Active Comparator|Active Treatment 2|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing suchpatients
33329472|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
33329473|NCT04182360|Active Comparator|Carbetocin 10mcg|Patient is given 10mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33039733|NCT00092222|Active Comparator|Active Treatment 4|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or lmaintenancel therapy with dose escalating interferon-alpha
33039734|NCT00092222|Active Comparator|Active Treatment 5|High dose zidovudin and valganciclovir
33039735|NCT00092222|Active Comparator|Natural History|Observation Only
33039736|NCT00085930|Experimental|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
33039740|NCT00073060||NIH Platelepheresis Donors|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
33329474|NCT04182360|Active Comparator|Carbetocin 20mcg|Patient is given 20mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33329475|NCT04182360|Active Comparator|Carbetocin 40mcg|Patient is given 40mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33329476|NCT04182360|Active Comparator|Carbetocin 60mcg|Patient is given 60mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33329477|NCT04182360|Active Comparator|Carbetocin 80mcg|Patient is given 80mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33039741|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
33039742|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
33329478|NCT04182360|Active Comparator|Carbetocin 100mcg|Patient is given 100mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
33329479|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
33329480|NCT01303770|Active Comparator|Control group|
33329481|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
33329482|NCT05105100||Participants with Melanoma|Participants will undergo a pre-treatment tumor core biopsy and Peripheral blood mononuclear cell (PBMC) collection. Then, patients will be started on pembrolizumab per standard of care and PBMCs will be collected every 3 weeks (1 cycle)
33329483|NCT05569278|Experimental|GEH200486 Cohort 1|Participants will receive 0.05 mmol/kg of GE200486 0.5 M injection
33329484|NCT05569278|Experimental|GEH200486 Cohort 2|Participants will receive 0.1 mmol/kg of GE200486 0.5 M injection
33329485|NCT05569278|Experimental|GEH200486 Cohort 3|Participants will receive 0.2 mmol/kg of GE200486 0.5 M injection
33329486|NCT05569278|Experimental|GEH200486 Cohort 4|Participants will receive 0.3 mmol/kg of GE200486 0.5 M injection
33329487|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
33329488|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
33329489|NCT00005044|Experimental|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
33039747|NCT00071045||1|patients undergoing allogeneic stem cell transplantation
33039748|NCT00071045||2|HLA compatible donors
33039749|NCT00068159||1|Untreated-NYHA Class I HH subjects without conventional therapy for HH
33039750|NCT00068159||2|Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelation therapy
33039751|NCT00068159||3|Age-gender matched healthy HH control volunteers
33039752|NCT00060775||Non-Targets|Characterized by temperament - no behavioral inhibition
33039753|NCT00060775||Targets|Characterized by temperament - high/low behavioral inhibition
33039754|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
33039755|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
33039756|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
33039757|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
33039758|NCT00034216||Participants|Participants with cancer 18 years of age and older
33039759|NCT00027274||1|All families with a member who has one of the relevant syndromes.
33039760|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
33039761|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
33039762|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
33329490|NCT00005044|Experimental|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
33329491|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
33329492|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
33329493|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
33329494|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
33329495|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
33329496|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
33329497|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
33039763|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
33039764|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
33329498|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
33039767|NCT00001727||1|Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.
33039768|NCT00001645||Diarrhea GI parasite|Subjects infected with a GI parasite
33039769|NCT00001645||Echinococcus|Subjects infected with echinococcus
33039770|NCT00001645||Intestinal worm|Subjects infected with parasitic intestinal worm
33039771|NCT00001645||Malaria|Subjects infected with malaria
33039772|NCT00001645||Parasitic infection|Subjects infected with a parasitic infection that is not included in the other cohorts
33039773|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
33039776|NCT00001465||LAM|Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
33039777|NCT00001393||African descent controls|Controls; adult healthy volunteers of African descent without kidney disease
33039778|NCT00001393||African-Americans with FSGS|African-American patients with idiopathic or HIV-associated collapsing glomerulopathy
33039779|NCT00001393||African-Americans with HIV|Hyper-normal controls; adult African-Americans with HIV and without kidney disease
33039780|NCT00001393||European and Asian descent controls|Controls; healthy volunteers of European or Asian descent without kidney disease
33039781|NCT00001393||Kidney donors|People donating kidneys at NIH
33039782|NCT00001393||Other patients with idiopathic FSGS|Patients of other areas of descent with idiopathic FSGS
33039783|NCT00001393||Relatives of patients with familial FSGS|Relatives of patients with familial FSGS
33329499|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
33329500|NCT05090202||"HFrEF  Heart failure with reduced ejection fraction"|"chronic heart failure with echocardiographic finding of LVEF Left ventricular ejection fraction equal or less than 40%"
33039784|NCT00001393||Tamils|Adults with Tamilian descent
33039787|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
33039788|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
33039789|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
33039793|NCT00001337|Experimental|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
33039794|NCT00001281||HIV Infected Individuals|HIV infected Individuals
33039795|NCT00001281||HIV Uninfected Individuals|HIV uninfected Individuals
33039796|NCT00001281||Individuals with/without Immunodeficiencies|Individuals with/without immunodeficiencies
33039797|NCT00001281||Individuals with/without infectious diseases|Individuals with/without infectious diseases of interest
33039798|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
33039800|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
33329501|NCT05090202||"HFmrEF Heart failure with mildly reduced ejection fraction"|chronic heart failure with echocardiographic finding of LVEF between 41% and 49%
33329502|NCT05090202||"HFpEF  Heart failure with preserved ejection fraction"|chronic heart failure with echocardiographic finding of LVEF equal or more than 50%
33329503|NCT01305018|Experimental|Exercise and BCAA|
33329504|NCT01305018|Experimental|Exercise and Leucine|
33329505|NCT01305018|Placebo Comparator|Exercise and Placebo|
33039801|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
33039802|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
33039803|NCT00001223||CF Patients|cystic fibrosis patients
33039804|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
33039805|NCT00001215||Control|healthy volunteers
33039806|NCT00001215||Family Member|a family member of a documented proband
33039807|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
33039808|NCT00001208||Patients|Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
33039809|NCT00001163||1|primary clinical; volunteers come from all U.S.
33039810|NCT02009280|Experimental|Propofol group|Propofol group
33039811|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
33039812|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
33039813|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
33039814|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
33417745|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
32867298|NCT04814160|Experimental|mix of bioactive glass and autogenous bone graft|1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
32867299|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
32867300|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
32867301|NCT04804410|Experimental|Dielectric Properties of Tissue Samples from Thoracic Malignancies and Corresponding Normal Tissues|Our plan is to analyze 3-5 tissue probes acquired from 30 patients with a variety of thoracic malignancies. The investigators will plan to acquire tissue from each type of malignancy including: lung cancer, esophageal cancer and pleural based tumors. Tissue will be acquired in the operating room. Impedance measurements will be collected on multiple sections of excised tissue and will be translated into dielectric properties. After acquisition of data, the investigators will assess the data and continue to acquire patients to obtain significant estimates of overall tissue properties in each type of tumor. After undergoing an informed consent process in accordance with IRB approval, patients with be formally enrolled. All tumor electric property data will be stored securely and remain anonymous of patient identifying data.
33039815|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:~Epistatus administered PRN by family / carer for symptoms"
33039816|NCT02009358|Experimental|Mental health promotion group|
33039817|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
33039818|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
33039819|NCT02009410|Experimental|Creon|
33039820|NCT02009410|Placebo Comparator|Placebo|
33039821|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
33039822|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
33039823|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
33039824|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
33039825|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
33039826|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
33039827|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
33039828|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
33039829|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
33039830|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
33417746|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
33417747|NCT03634657|Active Comparator|Plain X-ray protection shield|
32867302|NCT01531803|Experimental|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation."
32867303|NCT01531803|Placebo Comparator|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
32867304|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
32867305|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
32867306|NCT00180271|Experimental|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
32867307|NCT00180271|Active Comparator|ICD|ICD: Implantable cardioverter defibrillator
32867308|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
32867309|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
32867310|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
32867311|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
32867312|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
32867313|NCT01531959|Active Comparator|Midodrine|
32867314|NCT01531959|Placebo Comparator|Placebo|
32867315|NCT00181207|Experimental|Active|Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
32867316|NCT00181207|Placebo Comparator|Sham|Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
32867317|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
32867318|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
32867319|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
32867320|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
32867321|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
32867322|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
32867323|NCT00181285|Sham Comparator|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
32867324|NCT00181285|Active Comparator|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
32867325|NCT03001245|Experimental|IPC|Interpersonal Counseling
32867326|NCT03001245|Active Comparator|ST|Standard treatment
32867327|NCT00181363|Experimental|Mamma board|use of the mamma board during radiotherapy
32867328|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32867329|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
32867330|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
32867331|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
32867332|NCT03006549|Experimental|Emergency Manual|emergency manual present
32867333|NCT03006549|No Intervention|No Emergency|NO emergency manual present
32867334|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
33039831|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
33039832|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
33039833|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
33039834|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
33039835|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
33039836|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
33039837|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
33039838|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
32867335|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
32867336|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
32867337|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
32867338|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
32867339|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
33039839|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
33039840|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
33039841|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
33039842|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
33039843|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
33039844|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
33039845|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
33039846|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
33039847|NCT02009735|Experimental|virosensor|virus detection
33039848|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
33039849|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
33039850|NCT02009761|Experimental|BI 655064 subcutaneous|Escalating single dose as subcutaneous injection
33039851|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
33039852|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
33039853|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
33039854|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
33039855|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
33039856|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
33039857|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
33039858|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
33039859|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
33039860|NCT02009891||Control|Control couples who will not use predictive model
33039861|NCT02009891||Predictive model|Couples who will use predictive model
33039862|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
33039863|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
33039864|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:~TSAT < 25%~Serum iron concentration < 150 ug/mL~Serum ferritin concentration < 1,500 ng/mL"
33039865|NCT02009943|No Intervention|Control|No iron supplementation
32867340|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
33039866|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
33039867|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
33039868|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
33039869|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
33039870|NCT02010008|No Intervention|Comparison|Usual care
33039871|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
33039872|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
33039873|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
33329506|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
33329507|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
33329508|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
33329509|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
33329510|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
33329511|NCT02722668|Experimental|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
33329512|NCT02722668|Experimental|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
33329513|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
33329514|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
33329515|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
33039874|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
33039875|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
33039876|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
33039877|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
33039878|NCT02010086|Active Comparator|Standard Community Treatment|
33039879|NCT02010099|Experimental|PP110 Gel|PP110 Gel
33039880|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
33039881|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
33039882|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
33039883|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
33039884|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
33039885|NCT02010164|Experimental|Old-CoQ10|
33039886|NCT02010164|No Intervention|Old|
33039887|NCT02010164|No Intervention|Young|Young less than 33 years old participants
33039888|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
33039889|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
33329516|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
33329517|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
33039890|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
33039891|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
33039892|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
33039893|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
33039894|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
33039895|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
33039896|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
33039897|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
33039898|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
33039899|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
33329518|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
33039900|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
33039901|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
33329519|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
33329520|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
33329521|NCT04072458|Experimental|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m^2.
33329522|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
33329523|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
33329524|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
33329525|NCT03991728||Alloplastic total TMJ replacement|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
33329526|NCT01304004|Experimental|Experimental drinking yogurt|
33329527|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
33039902|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
33039903|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
33039904|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
33039905|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
33039906|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
33039907|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
33039908|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
33039909|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
33039910|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
33039911|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
33039912|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
33039913|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
33039914|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
33039915|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
33329528|NCT03953976|Experimental|PET-CT at 3 months and ENT evaluation|Treatment to the gross primary and nodal disease (70 Gy), with suspicious nodes treated to 66.5 Gy, all in 35 fractions. CT and PET-CT are required for nodal assessment. Restaging PET-CT must be performed between 11-14 weeks from the completion of treatment. The patient must see an otolaryngologist after the PET-CT to decide on post-treatment neck dissection per the surgeon's judgement. Patients will then be seen every 3 months (+/- 2 weeks) for the first year, and then at least every 6 months (+/-2 weeks) until the 36 month. Subsequent and intervening follow-up visits will be made per physician preference
33329529|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
33329530|NCT01305096|No Intervention|Control group|Matched control
33329531|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
33417748|NCT03634657|Experimental|Protection shield & X-ray protective strips|
33417749|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
33039916|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
33039917|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
33039918|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
33039919|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
33039920|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
33329532|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
33329533|NCT05069844|Experimental|Gum chewing for 2 minutes|Patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
33329534|NCT05069844|Experimental|Gum chewing for 4 minutes|Patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
33329535|NCT05069844|No Intervention|Control group|Patients will be asked to swallow 2 times only.
32867341|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
33329536|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
33329537|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
33329538|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
33329539|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
33039921|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
32867342|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
33039922|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
33039923|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
33039924|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
33039925|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
33039926|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
33039927|NCT02010515||Sinus rhythm, first ICD implantation|
33039928|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
33039929|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
33039930|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
33039931|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
33039932|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
33039933|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
33329540|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
33329541|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
33329542|NCT05629026|Experimental|primary lymphoedema|patients with primary lymphoedema
33329543|NCT05629026|Experimental|secondary lymphoedema|patients with secondary lymphoedema
33329544|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
33329545|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
33329546|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
33108536|NCT04634474|Experimental|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
33108537|NCT05658289|Active Comparator|Latarjet|The Latarjet involves the use of a auto-graft to be fixated to the anterior portion of the glenoid to recreate the size of the glenoid.
33108538|NCT05658289|Experimental|Anatomic Glenoid Reconstruction|An allograft will be used for the patients in this group, inserted through a new portal and fixed to the anterior rim of the glenoid to recreate the size of the glenoid.
33108539|NCT05469997|Experimental|MeDi(KD-MCT)|The participants in this arm will first undergo the MeDi-KD intervention followed by the MeDi-MCT intervention, after an 8-week washout period.
33108540|NCT05469997|Experimental|MeDi(MCT-KD)|The participants in this arm will first undergo the MeDi-MCT intervention followed by the MeDi-KD intervention, after an 8-week washout period.
33329547|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
33417750|NCT04563195|Other|open label|open label study; all subjects will receive the same drug at the same dose
33108542|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
33108543|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
33108544|NCT04634006|Active Comparator|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
33329548|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
33329549|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
33329550|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
33329551|NCT02571036|Experimental|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]
33329552|NCT02571036|Experimental|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
33329553|NCT02571036|Experimental|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
33329554|NCT02571036|Experimental|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
33329555|NCT02571036|Experimental|Extension Cohort|150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
33329556|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
33329557|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose [TDD] of CHF 5259 12.5 μg)
33329558|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
33329559|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
33329560|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
33329561|NCT03084796|Placebo Comparator|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
33329562|NCT03084796|Active Comparator|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
33329563|NCT03717012|Active Comparator|Nintedanib treatment alone|
33329564|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
33329565|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
33329566|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
33329567|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
33329568|NCT01305486||XenMatrix|
33329569|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
33329570|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
33329571|NCT01848912||Bone Marrow Transplant Patients|
33329572|NCT04893252|Experimental|vactosertib in combination with durvalumab|single arm study
33329573|NCT04863300|Experimental|Intervention group|Participants in the intervention group will receive a collaborative stepped care programme provided by registered social workers and trained Peer Supporters from aged care service units - the Districts Elderly Community Centres (DECC), and mental health service units - the Integrated Community Centre on Mental Wellness (ICCMW), all are local NGOs. In the collaborative stepped care model (see attachment Table 1), older persons are matched to the intervention module that most suits their current needs. The person does not have to start at the lowest level of intervention to progress to the next level of intervention. Rather, they enter the service with the intervention level aligned to their needs, e.g., level of risks, symptom severity (measured by the Patient Health Questionnaire, PHQ-9), and intervention response. Home visits or other format of contact will be delivered by trained Peer Supporters employed by the NGOs to detect and engage hidden cases.
33329574|NCT03797742||NC|Patients without heart failure.
33329575|NCT03797742||DCM|Dilated cardiomyopathy patients.
33329576|NCT03797742||ICM|Ischemic cardiomyopathy patients.
33329577|NCT03887988||Orbital Fracture|Patients with dislocated fracture of the inferior and/or medial orbital wall
33329578|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
33329579|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
33329580|NCT03811314|Experimental|Strength training|Muscle strength training programs
33329581|NCT03811314|Experimental|Aerobic training|Aerobic training programs
33329582|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
33329583|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
33329584|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
33329585|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
32867343|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
33039934|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
33039935|NCT02010619|Experimental|Cognitive behavior therapy|
33329586|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
33329587|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
33329588|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
33329589|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
33039936|NCT02010619|Active Comparator|Supportive therapy|
33039937|NCT02010658|No Intervention|Memory|
33039938|NCT02010658|Experimental|Cognitive Aid|
33039939|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
33039940|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
33039941|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
33039942|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
33039943|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
33039944|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
33039945|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
33039946|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
33039947|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
33039948|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
33039949|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
33039950|NCT02010801|Experimental|IRE for tumor before tumor resection|
33039951|NCT02010827||Patients|Patients
33039952|NCT02010827||healthy controls|healthy controls
33039953|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
33039954|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
33039955|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
33039956|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
33039957|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
33039958|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
33039959|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
33039960|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
33039961|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
33039962|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
33039963|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
33329590|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
33329591|NCT03811626|No Intervention|Comparator|Patient with no specific management
33329592|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
33329593|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
33329594|NCT01380496|Experimental|A|Subjects received the Par formulated product
33329595|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
33360589|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
33360590|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
33108545|NCT04634006|Active Comparator|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
33108546|NCT04634006|Sham Comparator|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
33108547|NCT05428098|Experimental|experiment group|In addition to standard care, patients will be given discharge training, planned within the framework of the Life model, one day before discharge. It is planned that the discharge training will be given by the researcher in the patient's room and by providing an accompanying person. Written training material will be delivered to the patients for their re-use after the training.
33108548|NCT05428098|No Intervention|control group|standard care will be applied
33108549|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
33108550|NCT04633850||After implementation|Perineural bupivacaine with intravenous dexamethasone.
33108551|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
33108552|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
33108553|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
33108554|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
33108555|NCT04633382|Experimental|Conducting research of enhanced recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.~Refusal of cleansing enemas.~Refusal of premedication. NSAIDs 30 minutes before surgery~Prevention of thromboembolic complications~Multimodal analgesia: epidural catheter, paracetamol.~Minimally invasive access.~Prevention of hypothermia~Targeted infusion therapy.~Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.~Early activation of the patient.~Early enteral nutrition.~Prevention of nausea and vomiting."
33108556|NCT04633382|Placebo Comparator|Conducting research of traditional recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Fasting for 2 days~Use of cleansing enemas. Bowel preparation~Premedication~Prevention of thromboembolic complications~Without multimodal analgesia~Traditional access.~Prevention of hypothermia~Targeted infusion therapy.~Use of drains: gastric, intra-abdominal, bile duct drainage.~Activation of patients within 2 days.~Enteral nutrition after 2 days after surgery.~Without the use of metoclopramide"
33108557|NCT02903628|Experimental|eye health education|
33108558|NCT04633733|Experimental|Single arm|"This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
33108559|NCT04633343|Experimental|Small Volume Breath Group|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
33108560|NCT04633343|Experimental|Large Volume Breath Group|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
33108561|NCT05428059|Experimental|application group|In addition to standard care, training and consultancy will be provided with a mobile application.
33108562|NCT05428059|No Intervention|control group|Standard care will be given
33108563|NCT04633265|Experimental|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
33108564|NCT05427942||Switch from adalimumab originator|
33108565|NCT05427942||Switch from adalimumab biosimilar 40 mg/0,8 mL|
33108566|NCT04632875|Experimental|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
33108567|NCT04632875|Experimental|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
33108568|NCT05427903|Experimental|Cryotherapy|
33108569|NCT05427903|Experimental|IANB plus buccal infiltration local anesthesia|
33108570|NCT05427903|Active Comparator|IANB|
33108571|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
33108572|NCT04633109||obese|Subjects with obesity as defined by BMI >= 30; men and women; age range 18-69 years; written informed consent
33108573|NCT05427747|Experimental|cefotaxime|ceotaxime 2g iv /8hr
33108574|NCT05427747|Experimental|meropenem|meropenem 1g iv /8hr
33108575|NCT04633031||Group 1|Cheneau brace
33108576|NCT04633031||Group 2|Boston brace
33108577|NCT04632914|Experimental|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
33108578|NCT04632914|Active Comparator|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
33108579|NCT05427591|Experimental|Group (1A)|"30 children with 60 primary molars underwent caries removal by the CMCR method BRIX3000® (the experimental group) on one molar (n = 30)."
33108580|NCT05427591|Active Comparator|Group (1C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
33360591|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
33417751|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
33417752|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
33417753|NCT01371409|Experimental|active cTBS|
33417754|NCT01371409|Sham Comparator|Sham cTBS|
33417755|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
33417756|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
33417757|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
33417758|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
33436465|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
33039964|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
32740102|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
33039965|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
33039966|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
33039967|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
33039968|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
33039969|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
33039970|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
33039971|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
33039972|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
33039973|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
33039974|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
33039975|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
33039976|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
33039977|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
33039978|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
33039979|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
33039980|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
33039981|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
33039982|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
33039983|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
33039984|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
33039985|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
33436466|NCT05565703|Experimental|Intervention Group|This group is randomly selected from the Acute care for elders unit and receives a one hour intervention with the PARO robotic seal two days in a row during their hospital stay.
33108581|NCT05427591|Experimental|Group (2B)|"30 children with 60 primary molars underwent caries removal by the CMCR method Carie-CareTM  (the experimental group) on one molar (n = 30)."
33108582|NCT05427591|Active Comparator|Group (2C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
33108583|NCT04632602|Other|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
33108584|NCT04632602|Other|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
33108585|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
33108586|NCT00445367||Case|
33108587|NCT00445367||Control|
33108588|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
33108589|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
33108590|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
33108591|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
33108592|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
33108593|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
33108594|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
33108595|NCT05427435|Experimental|Marshall ethanolisation with specific catheter|Patients will undergo the destruction of Marshall bundles by ethanol infusion with the specific catheter
33108596|NCT00445523|Experimental|1|TroVax® alone
33108597|NCT00445523|Experimental|2|TroVax® plus IFN-α
33108598|NCT05427357|Experimental|Diseased side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in diseased side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
33108599|NCT05427357|Experimental|Healthy side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in healthy side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
33108600|NCT05427357|Other|Both side of the healthy control group (80 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in side of the both side of the healthy control group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
33108601|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
33108602|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
33108603|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
33108604|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
33360592|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
33360593|NCT02529319|Active Comparator|Conventional Ablation|"Surgery~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
33360594|NCT02298244|Active Comparator|PV isolation + GP Ablation|
33360595|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
33360596|NCT03932149|Experimental|Experimental Group|Real stimulation
33360597|NCT03932149|Sham Comparator|Control Group|Sham stimulation
33329596|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
33039986|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
33039987|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
33039988|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
33329597|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
33329598|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
33329599|NCT01380418||Study group|Obese BMI>30 18-85 years old
33329600|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
33329601|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
33329602|NCT05422768||Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
33039989|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
33039990|NCT02011191|Placebo Comparator|Sugar pill|
33039991|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)~Intervention: Electrical Impedance Myography (EIM)."
33329603|NCT05422768||Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
33039992|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
33039993|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
33039994|NCT02011217|Experimental|Rye crisp bread A|
33039995|NCT02011217|Experimental|Rye crisp bread B|
33039996|NCT02011217|Experimental|Wheat crisp bread C|
33039997|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
33039998|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
33039999|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
33040000|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
33040001|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
33040002|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
33040003|NCT02011256|Experimental|Implantable loop-recorder|
33040004|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
33040005|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
33040006|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
33040007|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
33040008|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
33040009|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
33040010|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
33040011|NCT02011308|Active Comparator|Green Light Laser|
33040012|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
33040013|NCT02011334|Experimental|RoActemra/Actemra|
33040014|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
33040015|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
33040016|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
33040017|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
33040018|NCT02011373|Experimental|IFABOND|
33040019|NCT02011412||Intermountain Risk Score known|
33040020|NCT02011412||Intermountain Risk Score Unknown|
33040021|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
33108605|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
33108606|NCT05427318|Active Comparator|PATH Active Intervention Arm|Participants assigned to this group will receive care as usual if they are assigned to this group. In addition, participants in this arm will receive HIV care support from a trained peer navigator and have access to a mHealth web application designed to support their health and HIV care.
33108607|NCT05427318|No Intervention|Usual Care|Participants assigned to this group are in the control arm and will receive standard of care following the Ryan White model of care.
33108608|NCT04699175|Experimental|Treatment group A|
33108609|NCT04699175|Experimental|Treatment group B|
33108610|NCT04699175|Placebo Comparator|Treatment group C|
33108611|NCT05427084|Active Comparator|Active|Canagliflozin 300mg PO daily
33108612|NCT05427084|Placebo Comparator|Placebo|Placebo PO daily
33108613|NCT03277781||Current smokers|
33108614|NCT03277781||Ex-smokers|
33108615|NCT03277781||Coronary heart disease|
33108616|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
33108617|NCT02902887|No Intervention|Observation|No intervention, just observation
33108618|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
33108619|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
33329604|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
33329605|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
33329606|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
33329607|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
33329608|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
33329609|NCT01304394|Other|parenteral nutrition solution|
33329610|NCT01379326|Experimental|Mebendazole|
33329611|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
33329612|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
33329613|NCT00791466|Experimental|1|
33329614|NCT00791466|Placebo Comparator|2|
33329615|NCT05748574|Experimental|"Sleep Well Sachet Treatment"|"Sachet of Sleep Well direct granulate (2.0 g)~1 sachet contains: 190 mg standardized dry extract of Melissa officinalis leaf , 75 mg dried pressed juice of fresh Lactuca sativa herb, 0.41 g Magnesiumdicitrate, 0.12 g L-Tryptophan, excipients and natural flavors."
33329616|NCT01560546|Active Comparator|Testim|
33329617|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
33329618|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
33329619|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
33329620|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
33329621|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
33329624|NCT04921254|Experimental|BSG005|Active antifungal drug
33329625|NCT04921254|Placebo Comparator|Placebo|Will be a 5% glucose infusion
33329626|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
33329627|NCT03630874|Experimental|Experimental arm|
33329628|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
33329629|NCT03792984|Placebo Comparator|Metformin + Placebo|
33329630|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
33329631|NCT05422456||Chronic pain group|children are diagnosed with chronic headache by pediatric neurologist
33329632|NCT05422456||Health group|children without chronic pain
33329633|NCT04914546|Experimental|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
33040022|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
33417759|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
33040023|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
33040024|NCT02011438|No Intervention|Control|Education/Support Condition
33040025|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
33417760|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.~Normal saline (NS) 100ml IV for 20min, before incision."
33040026|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
33040027|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
33040028|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
33040029|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
33417761|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
33417762|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
33417763|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
33417764|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
33417765|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
33040030|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
33040031|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
33040032|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
33040033|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
33040034|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
33040035|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
33040036|NCT02011594|Experimental|Arm A|Nimotuzumab
33040037|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
33040038|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
33040039|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
33040040|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33040041|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33040042|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33040043|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33040044|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
33040045|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
33040046|NCT02011659|Active Comparator|Ramosetron|
33040047|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
32867344|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
33329634|NCT04914546|Experimental|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
33329635|NCT04914546|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
33329636|NCT04914546|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
33329637|NCT05200234|Experimental|Intervention group|Nattokinase + standard medical treatment
33329638|NCT05200234|Placebo Comparator|Control group|Placebo + Standard medical treatment
33329639|NCT05669196||standard thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with standard thoracotomy
33329640|NCT05669196||muscle sparing thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with muscle sparing thoracotomy
33329641|NCT05669196||VATS group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with video-assisted thoracic surgery
33329642|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
33040048|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
33040049|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
33040050|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
33040051|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
33040052|NCT02011711||Mirena|Women interested in beginning use of Mirena
33040053|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
33040054|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
33040055|NCT02011724|Experimental|Apligraf|
33040056|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
33040057|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
33040058|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
33040059|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
33040060|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
33040061|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
33040062|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
33040063|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
33040064|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
33040065|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
33040066|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
33040067|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
33040068|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
33040069|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
33040070|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
33040071|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
33040072|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
33040073|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
33040074|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
33329643|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
33040075|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
33329644|NCT05736874|Experimental|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
32867345|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
33040076|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
33040077|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
33040078|NCT02011919|Other|Echopulse|Echopulse HIFU
33040079|NCT02011932||Healthy volunteers|
33040080|NCT02011932||Chronic hepatitis C|
33040081|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~1 x 50 mg capsule per day if patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg"
33040082|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
33040083|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
33040084|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
33040085|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
33040086|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
33040087|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
33040088|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
33040089|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
33040090|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
33040091|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
33040092|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
33040093|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
33040094|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
33040095|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
33040096|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
33040097|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
33040098|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
33040099|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
33040100|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
33040101|NCT02012127||Acromegalic patients|
33040102|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
33040103|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33040104|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33040105|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33067731|NCT00142233|Experimental|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
32867346|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
32867347|NCT03000621||Patients with liver injury|
32867348|NCT03000621||Healthy subjects|
32867349|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
32867350|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
32867351|NCT00182767|Experimental|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
32867352|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
32867353|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
32867354|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
32867355|NCT01533597|Active Comparator|Solifenacin|
32867356|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
32867357|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
33417766|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
32867358|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
32867359|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
32867360|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
32867361|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
32867362|NCT04804176|Active Comparator|5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation|The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
32867363|NCT04804176|Active Comparator|GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation|The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
32867364|NCT04804176|Sham Comparator|the control group|The instrument is not working, only in exhaust mode.
32867365|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
32867366|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
33040106|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33040107|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33108620|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
33417767|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
33417768|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
32867367|NCT04796688|Experimental|Fludarabine + Cyclophosphamide + AT19 cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10^7, 1.0×10^7, and 2.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
32867368|NCT04796532|No Intervention|Control|No intervention. The control group will maintain their normal physical and dietary activity.
32867369|NCT04796532|Experimental|Homebased HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Homebased HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. This group will have 16 week follow-up.
32867370|NCT04796532|Experimental|Traditional HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional-HIIT group participants will attend presential HIIT workout sessions supervised. This group will have 16 week follow-up.
33417769|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
33417770|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
33417771|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
32740103|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
32740104|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
32740105|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
32740106|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
32740107|NCT02702687|Experimental|PEF Feedback|This group will have 9 visits across 15 months.
32740108|NCT02702687|Active Comparator|Control Feedback|This group will have 9 visits across 15 months.
32740109|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
32740110|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
32740111|NCT03311009|Experimental|GLPG1972|
32740112|NCT03311009|Placebo Comparator|Placebo|
32740113|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
32740114|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
32740115|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
32740116|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
32740117|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
32740118|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
32740119|NCT05333315|Experimental|Investigation Product 1 (IP1) in softchews form|0,5 g of glucomannan per softchew
32740120|NCT05333315|Experimental|Investigation Product 2 (IP2) in powder form|Fiber of light Indian plantain, 7 g; glucomannan, 4,3 g; Inulin 2,5 g; Apple fiber, 1g; Choline, bitartrate 90 mg; Apple pectin,50 mg; Inositol, 40 mg
32740121|NCT05333315|Experimental|Investigation Product 3 (IP3) in powder form and capsules form|POWDER: Plantain fibre 10 g; Inulin, 2 g; Apple fibre, 1,5 g; Root of pellitory, 500 mg; Apple pectin, 450 mg CAPSULE: Pumpkin seed extract, 300 mg; Garlic extract odourless, 300 mg; Artichoke leaf extract, 150 mg; Cumin seed extract, 150 mg; Peppermint leaf extract, 150 mg; Anise seed extract, 150 mg; Curcuma rhizome extract, 150 mg; Vitamin C, 42 mg; Zinc (in gluconate),10 mg; Vitamin B6, 1,5 mg
32740122|NCT05333315|Experimental|Investigation Product 4 (IP4) in liquid form|LIQUID: Arabinogalactan, 700 mg; Inulin, 700 mg; Beta-glucans, 30 mg
32740123|NCT05333315|Experimental|Investigation Product 5 (IP5) in two capsules form|CAPSULE 1:L-arginine, 100 mg; Choline bitartrate, 100 mg; L-carnosine, 100 mg; L-taurine, 100 mg; Soy lecithin, 50 mg; R-alfa lipoic acid,10 mg; Vitamin B6,2 mg; Folic acid, 200 µg; Vitamin D3, 5 µg; Vitamin B12, 2 µg CAPSULE 2: Schisandra fruit extract, 400 mg; Milk thistle fruit extract associated with phospholipids, 200 mg; Grape seed extract associated with phospholipids, 50 mg; Grape seed extract (Vitis vinifera),50 mg
32740124|NCT05309993|Active Comparator|Posterior Tibial Nerve Stimulation (PTNS)|Women randomized to the PTNS will be scheduled for sessions once weekly for 30 minutes, for 12 weeks total. The patient sits reclined with their legs elevated on a foot rest. After alcohol swab, a 34 gauge needle is inserted percutaneously 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice) at a 60 degree angle. A surface electrode is placed on the medial ipsilateral heel. The needle and electrode are connected to a low voltage (9V) electrical stimulator. Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 μsec is increased until flexion of the big toe or fanning of all toes visualized, or until the woman reports a tingling sensation across the heel or sole of the foot. The current is then set to the highest level of tolerable to the patient (0-10 mA) and then she undergoes therapy for 30 minutes.
32740125|NCT05309993|Experimental|Home transcutaneous electrical nerve stimulation (TENS)|"Women randomized to the TENS group will be asked to purchase a TENS 7000 device (estimated cost $30) and will administer self-treatment at home, daily for 20 minutes, for 12 weeks total.~TENS treatment will be performed as follows (adapted from the most common setting from a s systematic review of TENS for OAB):~- Surface electrodes, 2 x 2 in diameter, will be placed 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice). The second surface electrode is placed on the medial aspect of the ipsilateral calcaneus. The electrodes are connected to the TENS device with pre-set settings.~Women will complete 20-minute daily TENS treatment for 12 weeks total."
33329645|NCT05736874|Placebo Comparator|Arm C - Placebo|Placebo is a self-administered inhaled agent. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
33329646|NCT05483166|Experimental|ImPACT program|The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
33329647|NCT04884126||One stage dental implants placement|
33040108|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33040109|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
33329648|NCT04884126||Second stage dental implants placement|
33040110|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
33329649|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
33040111|NCT02012205|No Intervention|control|not cupping
33329650|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
33329651|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
33040112|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
33040113|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
33040114|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
33040115|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
33040116|NCT02012257|Experimental|Common Site|AMSA nerve block injection
33040117|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
33040118|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
33040119|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
33040120|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
33040121|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
33329652|NCT03792594||Historical control group|The patients receive arthroscopic repair only
33329653|NCT05200078||Radiotherapy at free-breathing|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at free-breathing
33329654|NCT05200078||Radiotherapy at deep inspiration breath-hold|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at deep inspiration breath-hold
33329655|NCT03810846|Experimental|Exercise|Walking football exercise program
33329656|NCT05625048|Experimental|Intervention group|The intervention group receives same treatment as the control groups and in addition transperinal ultrasound guided instruction in pelvic floor muscle training at 2nd and 3rd session.
33329657|NCT05625048|No Intervention|Control group 1|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
33329658|NCT05625048|No Intervention|Control group 2|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
33329659|NCT04152382|Experimental|LY3462817 - Intravenous (IV)|LY3462817 administered as IV infusions.
33329660|NCT04152382|Placebo Comparator|Placebo - IV|Placebo administered as IV infusions.
33329661|NCT04152382|Experimental|LY3462817 - Subcutaneous (SC)|LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
33329662|NCT04152382|Placebo Comparator|Placebo - SC|Placebo administered as SC injections. (SC administration is discretionary/optional.)
33329663|NCT04152382|Experimental|LY3509754|LY3509754 administered orally.
33329664|NCT04152382|Placebo Comparator|Placebo|Placebo administered orally.
33329665|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
33329666|NCT05421442||Abatacept Group|Participants with established rheumatoid arthritis (RA) or psoriatic arthritis (PsA) and receiving abatacept
33040122|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
33040123|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
33040124|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
33040125|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
33329667|NCT05421442||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted disease modifying anti-rheumatic drugs (DMARDs) and who start treatment with a non-targeted DMARD
33329668|NCT05421442||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs
33040126|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
33329669|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
33329670|NCT01379248|No Intervention|no thrombus aspiration|
33329671|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
33329672|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
33040127|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
33040128|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
33329673|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
33329674|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
33329675|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
33040129|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
33040130|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
33040131|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
33040132|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
33040133|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
33040134|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
33040135|NCT02012400|Experimental|Intervention group|
33040136|NCT02012400|No Intervention|Control group|
33040137|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
33040138|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
33040139|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
33040140|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
33040141|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
33040142|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
33040143|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
33040144|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
33040145|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
33040146|NCT02012504||Western medicine|venlafaxine or escitalopram
33040147|NCT02012504||Chinese medcine|Shuganjieyu capsule
33040148|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
33040149|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
33040150|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
33040151|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
33040152|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
33040153|NCT02012556|Experimental|Tesamorelin|
33329676|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
33329677|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
33329678|NCT03949894|Experimental|tolvaptan|
33329679|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
33329680|NCT03901456|Experimental|Treatment|Participants in the treatment arm will receive the Care to Plan (CtP) intervention.
32740126|NCT02215265|No Intervention|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
33040154|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
33329681|NCT03901456|Active Comparator|Control|"Usual care control group.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
33329682|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
33329683|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
33329684|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
33040155|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
33040156|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
33329685|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
33329686|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
33329687|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
33329688|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
33329689|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
33329690|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
33329691|NCT01306188||Breast cancer|Metastatic breast cancer
33329692|NCT01306188||Lung cancer|Metastatic lung cancer
33329693|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
33329694|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
33329695|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
33329696|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
33329697|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
33329698|NCT05669118||Autotransplantation|Patients who receive one tooth autotransplanted.
33329699|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
33329700|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
33329701|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
33329702|NCT05421286||PLWH ≥50 years old|
33329703|NCT01302990|Experimental|5 micrograms H1 VLP|
33329704|NCT01302990|Experimental|13 micrograms H1 VLP|
33329705|NCT01302990|Experimental|28 micrograms H1 VLP|
33329706|NCT01302990|Active Comparator|45 micrograms Fluzone|
33329707|NCT01302990|Placebo Comparator|Placebo|
33329708|NCT05624970|Experimental|group (A)|"Group (A):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), aerobic training, tobacco cessation program and nutritional advices for 12 weeks."
33329709|NCT05624970|Experimental|group (B)|"Group (B):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), tobacco cessation program and nutritional advices for 12 weeks."
33329710|NCT05624892|Experimental|Experimental Group|Application of mirror therapy to the experimental group with virtual reality application
33329711|NCT05624892|No Intervention|Control Group|Application of classical mirror therapy to the control group
33329712|NCT01379950||periodontitis|patients diagnosed with periodontal disease
33329713|NCT05421208|Other|PNS Activity Measurement in relation to the Inflammation in post- COVID 19 POTS|PNS activity Measurement Biochemical endpoints: Blood sample for Inflammatory markers. Autonomic symptoms assessment questionnaire (COMPASS-31),32 quality of life EQ-5D and neuropsychological tests
33329714|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
33329715|NCT05421130|Other|SP-GRIPFLOW|This is a single-arm clinical investigation. Enrolled subjects will have cerebral perfusion with the investigational device during surgical repair of the aortic arch. A total of 1-3 investigational devices will be used per subject.
33040157|NCT02012595||Healthy Controls|Healthy participants
33329716|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
33329717|NCT05405244|Other|Bromocriptine, then Placebo|During the first intervention visit, participants receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Following a 2-week washout period, participants return for the second intervention visit, where they receive 2 capsules of placebo (sugar free calcium supplement) matched in shape (circle) and color (white) to bromocriptine. Both bromocriptine and placebo are administered orally.
33417772|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
33417773|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
33108621|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
33108622|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
33108623|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
33108624|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
33108625|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
33108626|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
33108627|NCT05427045|Experimental|Intervention group|Adult patients < 50 years old who have multiple sclerosis and back pain who are undergoing home exercise
33108628|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
33108629|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.~Intervention Anakinra in add on Therapy."
33329718|NCT05405244|Other|Placebo, then Bromocriptine|During the first intervention visit, participants receive 2 capsules of placebo (sugar free calcium supplement). Following a 2-week washout period, participants return for the second intervention visit, where they receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Both bromocriptine and placebo are administered orally.
33417774|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
33108630|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
33417775|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
32867371|NCT04796376|Other|Cutting seton|A piece of surgical thread that's left in the fistula for several weeks to keep it open. This allow it to drain and help its heal.
33108631|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
33108632|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
33108633|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
33108634|NCT01225549|Experimental|1|AZD5423 75ug
33108635|NCT01225549|Experimental|2|AZD5423 300ug
33108636|NCT01225549|Active Comparator|3|Budesonide 200 microgram
33108637|NCT01225549|Placebo Comparator|4|Placebo
33108638|NCT05469685|Experimental|10-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
33108639|NCT05469685|Active Comparator|14-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
33108640|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
33108641|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
33108642|NCT05658133|Other|Survey for student athletes|15 to 20 minute online questionnaire completed using Qualtrics
33108643|NCT05658133|Other|Survey for influencers of student athletes|15 to 20 minute online questionnaire completed using Qualtrics
33108644|NCT04680234|Active Comparator|Cryotherapy group|Patients underwent superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C very 2 weeks for maximum six sessions
33329719|NCT05420974|Experimental|NIR fluorescence|The included patients will be subdivided in four equal subgroups in order to evaluate alteration of NIR fluorescence signal during arthroscopy in combination with a (temporary) tourniquet and irrigation pump system.
33329720|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants~Prospective Participants (NOT participating in TROG 08.03 (RAVES))~Retrospective TROG 08.03 (RAVES) Participants~Participating in dosimetric evaluation and toxicity/QoL study~Participating in dosimetric evaluation only"
33329721|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
33329722|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
33417776|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
33417777|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
33417778|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
33417779|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
33417780|NCT02088164||Healthy men|Healthy men who received PSA screening
33417781|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
32867372|NCT04796064|Experimental|low-intensity aerobic training group|
32867373|NCT04796064|Experimental|high-intensity aerobic training group|
32867374|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
32867375|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
32867376|NCT04814238||mini-David|
32867377|NCT04814238||mini-Yacoub|
32867378|NCT04814238||mini-Bentall|
32867379|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
32867380|NCT03000777|Placebo Comparator|Placebo|Isomaltose
32867381|NCT04796298|Experimental|Ballistic Hamstring Stretching Group|Ballistic Hamstring Stretching
32867382|NCT04796298|Experimental|Hamstring Extender Exercise Group|Hamstring Extender Exercise
32867383|NCT04796298|Experimental|Kinesiotape Group|Kinesiotape
32867384|NCT04796142|Experimental|Reconciliation|Interventional trial without drugs
32867385|NCT02212587|Experimental|TOBI Podhaler|
32867386|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
32867387|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
32867388|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
32867389|NCT04803864|Experimental|Roxadustat|Early and short-term Roxadustat treatment
32867390|NCT04803864|No Intervention|Control|Patients only receive conventional therapies as recommended by guidelines.
32867391|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
32867392|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
32867393|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
32867394|NCT04814004|Experimental|hCD19.IL15.CAR-iNKT cells|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
32867395|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
32867396|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
32867397|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
32867398|NCT04813770|Experimental|Theory-based messages|Theory-based health messages about COVID-19 and COVID-19 vaccination, the necessity of COVID-19 vaccination to oneself and others, and COVID-19 vaccine regulatory approval processes. These messages are based on publicly available information and are hypothesised to increase perceived necessity and reduce concerns about vaccination, and target known barriers to vaccine uptake.
32867399|NCT04813770|Active Comparator|General messages|General messages about the COVID-19 virus and the vaccination programme. These messages do not target necessity and concerns, but are anticipated to promote understanding of the pandemic.
32867400|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
32867401|NCT04426734|Experimental|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
32867402|NCT04426734|Active Comparator|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
32867403|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
32867404|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
32867405|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
32867406|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
32867407|NCT04795518||Cross sectional study by questionnaire among group of pediatric dentistry|"An interviewed questionnaire is divided into two parts. The first part of the questionnaire will investigate the socio-demographic characteristics of the respondents. The second part of the questionnaire is divided into five sections to cover the following items:~Use of antibiotics pattern~Knowledge about antibiotics~Sources of information"
32867408|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
32867409|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
32867410|NCT04813848|Experimental|Varnish fluoride|Varnish fluoride to be applied on the surface of exposed dentin
32867411|NCT04813848|Active Comparator|Bonding agent|Bonding agent to be applied on the surface of exposed dentin
32867412|NCT04813536||nurses in Assiut university hospitals|currently working nurses exposed to shift work
32867413|NCT04813536||control group|currently working nurses not exposed to shift work
32867414|NCT02999841|Experimental|Group A|Acarbose
32867415|NCT02999841|Active Comparator|Group B|Vildagliptin
32867416|NCT04795050|Experimental|Intervention|
32867417|NCT04795050|No Intervention|Control|
32867418|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
32867419|NCT04795206||Cohort 1: Main Cohort|All eligible participants with CHM in IRIS Registry will be included.
32867420|NCT04795206||Cohort 2: Trial-Matched Cohort|Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
32867421|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
33108645|NCT04680234|Active Comparator|Microneedling group|Patients underwent microneedling 2 weeks for maximum six sessions
33329723|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
33329724|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
33329725|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
33329726|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
33040158|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
33040159|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
33329727|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
33329728|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
33329729|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
33040160|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
33329730|NCT03762460|Experimental|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
33329731|NCT03762460|Placebo Comparator|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
33040161|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
33040162|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
33329732|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
33329733|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
33329734|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
33329735|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
33329736|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
33329737|NCT03516214|Experimental|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
33329738|NCT05624814||Experimental group|Patients with chronic pain which failed standard therapies and with an implanted Spinal Cord Stimulator
33329739|NCT05624814||Comparison group|Patients with chronic pain following traditional therapies, i.e. pharmacological, psychological, physical and occupational therapies or surgery.
33040163|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
33040164|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
33040165|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
33040166|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
33040167|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
33040168|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
33329740|NCT05624814||Control group|Healthy volunteers matched for age and schooling to those included in the experimental group
33329741|NCT05416684||PEEK Group|
33040169|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
33040170|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
33040171|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
33040172|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
33040173|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
33040174|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
33329742|NCT05416684||Titanium Mesh Group|
33329743|NCT05624736||Glioblastoma Group|Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
33329744|NCT05624736||Astrocytoma Group|Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
33329745|NCT05624736||Oligodendroglioma Group|Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
33360598|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
32867422|NCT01667562|No Intervention|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
32867423|NCT04281108|Experimental|APT-1011|APT-1011 3 mg HS
32867424|NCT04281108|Placebo Comparator|Placebo|HS
32867425|NCT04803318|Experimental|Combination treatment of 3 inhibitors|Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
32867426|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
32867427|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
32867428|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
32867429|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
32867430|NCT04803162||patients with eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group. EoE patients were then treated for 8 weeks with PPs - omeprazole in the dose of 20 mg twice daily. After 8 weeks, each patient in the EoE group again passed all the tests (the protocols were identical to those used for qualifying patients to the project).
32867431|NCT04803162||patients without eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group.
32867432|NCT04813068||Interview arm|Group of patients who have agreed to have a qualitative interview on the topic of recurrence of lung cancer
32867433|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
32867434|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
32867435|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
32867436|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
32867437|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
33040175|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
33040176|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
33329746|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
33360599|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
33417782|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
33040177|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
33329747|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
33329748|NCT04782102|Experimental|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
33329749|NCT04782102|No Intervention|Care-as-usual|Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
33329750|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
33329751|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
33329752|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
33040178|NCT02012803|Experimental|Operative treatment|
33040179|NCT02012803|Active Comparator|conservative treatment|
33040180|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
33040181|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
33040182|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
33040183|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
33040184|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
33040185|NCT02012855|Experimental|Exercise only|90 minutes of exercise
33040186|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
33040187|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
33040188|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
33040189|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
33040190|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
33040191|NCT02012881|Active Comparator|Control|Usual practice
33040192|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
33040193|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
33040194|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
33040195|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
33040196|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
33040197|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
33040198|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
33040199|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
33040200|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
33040201|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
33040202|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
33040203|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
33040204|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
33040205|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
32867438|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
32867439|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
32867440|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
32867441|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
32867442|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
32867443|NCT02247375|Experimental|Low dose of BIIL 284 BS|
32867444|NCT02247375|Experimental|High dose of BIIL 284 BS|
32867445|NCT02247375|Placebo Comparator|Placebo|
32867446|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
32867447|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
32867448|NCT04803396|Placebo Comparator|Placebo|Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
32867449|NCT04803396|Experimental|50 mg DF2755A|"The experimental drug was administered once a day (oad) as one oral capsule of 50 mg.~The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions."
32867450|NCT04803396|Experimental|150 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
32867451|NCT04803396|Experimental|300 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
32867452|NCT04803396|Experimental|600 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
32867453|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
32867454|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
32867455|NCT04803474||Klinefelter|Patients with Klinefelter syndrome
32867456|NCT04803474||Turner|Patient with Turner syndrome
32867457|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
32867458|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
32867459|NCT04426578|Experimental|Perhexiline|
33108646|NCT05658094|Experimental|Exosome|Exosome (100e10 particle) injections with an interval of 14 days during two months.
33360600|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
32867460|NCT04426578|Placebo Comparator|Placebo|
32867461|NCT04802694|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
32867462|NCT04802694|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube.
32867463|NCT04802694|Active Comparator|Adhesive product|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube.
32867464|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
32867465|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
32867466|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
32867467|NCT04802928|Placebo Comparator|A|Placebo tablets.
32867468|NCT04802928|Experimental|B|
32867469|NCT05365425|Experimental|Tgfenon|Choline fenofibrate (135mg as fenofibric acid) 1 tablet once daily oral administration regardless of diet
32867470|NCT05365425|Active Comparator|Policosanol 10|Policosanol 10mg 1 tablet once daily oral administration
32867471|NCT03005457|Experimental|Stroke|
32867472|NCT03005457|Experimental|Hemiparesis other|
32867473|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
32867474|NCT05616234|Experimental|Exercise trial|Participants will perform a bout of exercise. In addition, a baseline and post-exercise blood sample will be drawn.
32867475|NCT05350371|Experimental|Placebo|
32867476|NCT05350371|Experimental|Pirfenidone Treatment|
32867477|NCT04802850|Experimental|Real MWM|Real mobilization with movement
32867478|NCT04802850|Sham Comparator|Sham MWM|sham or placebo mobilization with movement
32867479|NCT05616078|Experimental|laser treatment|LP-Nd:YAG laser treatment
32867480|NCT05616078|Active Comparator|cryotherapy|cryotherapy with liquid nitrogen
32867481|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
32867482|NCT04794738|Experimental|Treatment group A|
32867483|NCT04794738|Experimental|Treatment group B|
32867484|NCT04794738|Placebo Comparator|Treatment group C|
32867485|NCT04794738|Active Comparator|Treatment group D|
32867486|NCT04794426|Active Comparator|control group|The group that have caries in primary molars and treat them with Hall Technique
32867487|NCT04794426|Experimental|experimental group|The group that have caries in primary molars and treat them with Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC.
33040206|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
33360601|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
33360602|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
32867488|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
32867489|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
32867490|NCT04794348|Active Comparator|Fresh Frozen Plasma (FFP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL of fresh frozen plasma. After completion of warfarin dosing, approximately 810 mL of fresh frozen plasma will be intravenously administered to the subject.
32867491|NCT04794348|Experimental|Freeze Dried Plasma (FDP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
32867492|NCT05270655|Experimental|Cognitive-behavioural intervention|Five sessions of cognitive-behavioural intervention will be delivered on a weekly basis.
32867493|NCT05270655|No Intervention|Usual care|Participants in the control group will receive the usual psychosocial care provided by the staff nurses. To offer them attention, a research assistant in each hospital will meet them every week for 30 minutes to ask them about treatment adherence and any other concerns. The parents will be invited to attend it if they want to do so. Each participant will be given an appointment slip and reminded with a phone call two days before the next appointment. For participants whose medical appointment is more than a week, the research will contact them via phone.
32867494|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
32867495|NCT05672979|Experimental|Brolucizumab treated|"Intravitreal brolucizumab 6mg injection.~Initial treatment consists of a loading dose of three intravitreal injections of brolucizumab at monthly intervals. After 3 loading doses, patients are followed by monthly observation visits until the month 6 and bimonthly afterwards until disease-recurrence interval is determined (It can be monthly as per the investigator's judgement.). Following loading phase, the first treatment interval is determined by patients' disease recurrent interval, 1 month shorter than first recurrence interval (maximum first injection interval is 16 weeks). The injection interval is shortened if there is any fluid change or decreased visual acuity. If the criteria for treatment adjustment were not met and residual fluid was decreased from the previous visit, the injection interval is maintained. And the interval is extended if there was no fluid on OCT. The minimum and maximum injection intervals are 8 and 16 weeks, respectively."
32867496|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
32867497|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
32867498|NCT04794504|Experimental|Botox Injection Group|Two weeks pre-operatively, patients in the Botox injection group will receive intramuscular injections of Botox totaling 100U bilaterally (50U/side). 10 U will be injected into the temporalis (over 5 sites) and 40 U will be injected into the masseter muscle (over 4 sites). Botox will be reconstituted from a powdered form in 2cc of 0.9% sterile saline, and appropriate volumes will be administered.
32867499|NCT04794504|Placebo Comparator|Saline Injection Group|Two weeks pre-operatively, patients in the saline injection group will receive intramuscular injections of Botox totaling the same volumes administered for Botox patients above, across the same number of sites in the temporalis and masseter muscles bilaterally.
32867500|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
32867501|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
32867502|NCT05073315|Active Comparator|Continued-use Group (Adalimumab)|Randomized participants will receive continuous injection of adalimumab Q2W until last dose at Week 28.
33040207|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
33040208|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
33040209|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
33040210|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
33040211|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
33040212|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
33329753|NCT05624658|Active Comparator|PCSK9 inhibitors in combination Atorvastatin at a dose of 80 mg /Rosuvastatin 40 mg/ day|Patients who showed high compliance and did not reach the target LDL-C values 1 month after the development of ACS on the 2nd visit will be randomized into two groups of 60 patients each. Group 1 - taking PCSK9 inhibitors (Alirocumab 150 mg by subcutaneous injection once every 2 weeks or Evolocumab 140 mg by subcutaneous injection once every 2 weeks - open-label prescription of drugs) while taking Atorvastatin at a dose of 80 mg./ Rosuvastatin 40 mg / day.
33329754|NCT05624658|Active Comparator|Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/ day.|Group 2 - receiving Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/day.
33329755|NCT05347186|Experimental|Systematic corrective exercises and non-biomechanical functional exercises|
33329756|NCT05347186|Other|Non biomechanical functional exercises.|
33329757|NCT05388162|Other|coposcopy|patients undergoing colposcopy will have images taken of the cervix with a standard colposcope and the Mobile colposcope. de-identified images from both devices will then be entered into a custom colposcopic image evaluation program. Images will then be randomly evaluated by expert colposcopists as normal, abnormal or cannot evaluate. On abnormal images, the most abnormal point on the images will be marked as teh recommended biopsy site. Scoring for images from the standard colposcope will be compared with that for the Mobile Colposcope.
33329758|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
33329759|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
33040213|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
33040214|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
33040215|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
33040216|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
33040217|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
33040218|NCT02013154|Experimental|Part A: DKN-01 (Dose Escalation)|Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22
33040219|NCT02013154|Experimental|Part B: DKN-01 (Dose Confirmation)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
33040220|NCT02013154|Experimental|Part C: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
33329760|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
33329761|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
33329762|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
33329763|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
33329764|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
33329765|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
33329766|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
33040221|NCT02013154|Experimental|Part D: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
33040222|NCT02013154|Experimental|DKN-01 Monotherapy Substudy|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15
33040223|NCT02013154|Experimental|Part E: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
33040224|NCT02013154|Experimental|Part F DKN-01 (Dose Escalation+Expansion)|Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle
33040225|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
33040226|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
33040227|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
33040228|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
33040229|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
33040230|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
33040231|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
33040232|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
33040233|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
33040234|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
33040235|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
33040236|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
33329767|NCT03810300|Experimental|Control|No transfer, no behavior change communication
33329768|NCT05202964||Tolerance and adherence to oral antibiotics in patients managed for BJI|Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
33040237|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
33040238|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
33040239|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
33040240|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
33040241|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
33040242|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
33040243|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
33040244|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
33067732|NCT00142233|Placebo Comparator|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
33329769|NCT01567332|Experimental|rTMS active|
33329770|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
33329771|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
33329772|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
33360603|NCT03932227|Other|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
33360604|NCT03932227|Other|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
33360605|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
32867503|NCT05073315|Experimental|Switching Group (Adalimumab - ABP 501)|Participants will initially receive adalimumab until Week 10 during the lead-in period. Thereafter, starting from Week 12, participants will switch between ABP 501 and adalimumab Q2W with last dose of ABP 501 at Week 28.
32867504|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
32867505|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
32867506|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
32867507|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
32867508|NCT04794114|Experimental|orthosis in hemiplegia|
32867509|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
32867510|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
32867511|NCT04813302|Experimental|Gingival recession treatment|Gingival recession treatment by means of a coronally advanced flap and a connective tissue graft
32867512|NCT04813146|Experimental|Synchronized Lifestyle Modification Program (SLP)|Synchronized Lifestyle Modification Program ( Synchronization of dietary intake with the natural circadian rhythm of the body)
32867513|NCT04813146|Experimental|Synchronized Lifestyle Modification Program along with Physiotherapy|Synchronized Lifestyle Modification Program along with Physiotherapy (Synchronization of dietary intake and Physiotherapy including aerobic, resistance, flexibility and balance exercises)
32867514|NCT04813146|Experimental|Physiotherapy|Physiotherapy (aerobics, resistance, flexibility and balance exercises)
32867515|NCT04813146|No Intervention|Control Group|No Intervention will be given to this group ( conventional medicine will be given to these patient )
32867516|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
32867517|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
32867518|NCT04802460|Experimental|virtual reality|Patients assigned to the VR group will be engaged with the VR using a publicly available VR set. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
32867519|NCT04802460|No Intervention|control arm|Patients in the control arm will undergo standard of care office hysteroscopy. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
32867520|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
32867521|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
32867522|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
32867523|NCT04427436||Control|Healthy Elderly
32867524|NCT03004989||Programme 1|RTW group in day clinics
32867525|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
32867526|NCT03004989||Programme 3|My work and I
32867527|NCT04347018|Experimental|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
32867528|NCT04347018|Active Comparator|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
32867529|NCT05672745|Experimental|WB-LIFE|
32867530|NCT04427514|Experimental|CAPD group|Standard CAPD therapy wtih telemedicine system
32867531|NCT05672511|Experimental|İntervention group|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory.
32867532|NCT05672511|No Intervention|Control group|. The control group will not receive any simulation training
32867533|NCT04793256|Experimental|intervention|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
32867534|NCT04793256|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
32867535|NCT04997811|Experimental|VBaP|Combination of sodium valproate, bezafibrate, medroxyprogesterone
32867536|NCT04997811|Experimental|Danzol|Single agent
32867537|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
32867538|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
32867539|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
32867540|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
32867541|NCT04813224|Experimental|TRAUMA CENTERED EMDR-BASED TREATMENT|"Phase 1) Client history before session 1 Phase 2) Preparation for the treatment of the traumatic event, with psycho education and regulation strategies.~Phases 3 to 6) Gives the sense of Safety (safe place, past resource, desired future-PC, timeline) control structure, order, differentiation of past & present (move concretely between past danger to present safety) EMD strategy gives containment boundaries to current T-Episode.~Phase 7) Session closure A group debriefing of the experience will take place, and some of the stabilization exercises Phase 8) Re-Evaluation This phase will take place immediately after the group intervention. It assesses which participants may need individual attention and which may need further evaluation to identify the nature and extent of their symptoms."
32904908|NCT04000880|Experimental|Project 2: Exercise-Diet|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
33040245|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
33040246|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
33040247|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
33040248|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
33040249|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
33040250|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
33040251|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
33040252|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
33040253|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
33040254|NCT02013596|No Intervention|Control|Patients were given no TEAS
33040255|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
33040256|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
33040257|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
33040258|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
33040259|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
33329773|NCT04703166||Participants with Atrial Fibrillation or have Moderate-high risk factors for Atrial Fibrillation|"Participants who have atrial fibrillation or have moderate to high-risk factors for the development of atrial fibrillation as verified by the Atherosclerotic CardioVascular Disease (ASCVD) risk calculation tool.~Participants will be provided with a Samsung Galaxy Watch Active2 to wear daily and will also be asked to wear an ECG patch for 30-days at baseline, 6, 9 and 12 months.~A Cardiac MRI (CMR) will be taken at baseline and at 12 months."
33329774|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
33329775|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
33040260|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
33040261|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
33040262|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
33040263|NCT02013713||Family Hypercholesterolemia in cardiology|
33040264|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
33040265|NCT02013739||Patients with chronic heart failure|other
33040266|NCT02013739||Healthy volontiers|other
33040267|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
33040268|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
33040269|NCT02013804|Experimental|Dose arms|Dose Escalation
33040270|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
33040271|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
33040272|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
33040273|NCT02013856|Experimental|High Procyanidin|High procyanidin only
33040274|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
33040275|NCT02013869|Experimental|Flow-I|Wash in of desflurane in an anaesthesia machine without below
33040276|NCT02013869|Active Comparator|Asys|Wash in of desflurane in conventional anaesthesia machine Asys
33040277|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
33067733|NCT00135083|Experimental|1|"Once daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
33329776|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
33329777|NCT05375136||All Participants|Participants who are prescribed with lenvatinib/pembrolizumab combination per approved prescribing information of lenvatinib and pembrolizumab in the post marketing setting will be enrolled and observed for up to 48 weeks or until clinical benefit or unacceptable toxicity occurs or discontinuation of therapy due to any reason, whichever occurs first.
32867542|NCT04813224|Active Comparator|TRAUMA-FOCUSED CBT-BASED TREATMENT|TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
32867543|NCT04945161|Experimental|Arm A: N = 6 ON101 plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
32867544|NCT04945161|Placebo Comparator|Arm B: N = 6 Placebo plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
32867545|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
32867546|NCT04793178|Active Comparator|Oxygen Reserve Index Blinded Group|Aneshesist will be blinded for oxygen reserve index monitoring (ORI, Masimo Corporation), but he will be allowed to use pulse oxymetry and end-tidal carbon dioxide monitoring to manage the respiratory conditions and depth of sedation.
32867547|NCT04793178|Experimental|Oxygen Reserve Index Group|Aneshesist will be allowed to use pulse oxymetry, end-tidal carbon dioxide and oxygen reserve index (ORI) monitoring. He will manage the depth of sedation, respiaratory conditions.
32867548|NCT05672433|Active Comparator|Cafestol|Participants in this arm ingest 6 mg cafestol capsules twice daily with breakfast and dinner.
32867549|NCT05672433|Placebo Comparator|Placebo|Participants in this arm ingest placebo capsules twice daily with breakfast and dinner.
32867550|NCT04801836|Experimental|Treatment Arm|Subjects will receive 15 mg E4 orally once daily for 21 consecutive days
32867551|NCT04801836|Placebo Comparator|Placebo Arm|Subjects will receive matching placebo orally once daily for 21 consecutive days.
32867552|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
32867553|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
32867554|NCT04812990||hepatitis c patients|50 patients will be recruited for study group from consecutive patients previously diagnosed by hepatitis C regardless of the etiology of the condition and regularly attending at Soad Kafay hospital. Participants with history of smoking and alcoholism that could affect their oral health status were excluded.
32867555|NCT04812990||clinically healthy patients|populations will be randomly recruited from the out-patient of dental diagnosis clinic in Misr University For science & technology university to include total 50 clinically healthy participants, with no history of liver disease, or any other chronic debilitating illness, or habit of smoking or drinking, , as well as history of an intervention or condition that could affect the oral mucosa (e.g., history of radiotherapy and/or not receiving any medication that could affect oral health.
32867556|NCT05672355|Experimental|Arm I (GEO-CM04S1)|Patients receive GEO-CM04S1 vaccine IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
32867557|NCT05672355|Active Comparator|Arm II (mRNA Covid-19 Vaccine)|Patients receive mRNA vaccine injection IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
32867558|NCT05672277|Experimental|Group 1|Group 1 will be applied TENS three days per week
32867559|NCT05672277|Active Comparator|Group 2|Group 2 will be applied TENS one day per week
32867560|NCT04801914||Matrix Metalloproteinases|Value of serum matrix metalloproteinase activity before and one month after PTBD
32867561|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
32867562|NCT04812756|Experimental|Texting intervention|This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
32867563|NCT04801992||MINI WELL Ready (SIFI SpA, Italy)|Extended depth of focus intraocular lens implantation
32867564|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
32867565|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
33067734|NCT00135083|Experimental|2|"Twice daily:~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
33067735|NCT00135083|Experimental|3|"Twice daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
32867566|NCT04812600||Cardiac Rehabilitation|Individuals assigned to phase II (outpatient) cardiac rehabilitation program will undergo their normal exercise routines while the investigators make the measurements pre and post exercise at 0 week, and following 1 and 4 weeks of exercise.
32867567|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
32867568|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
32867569|NCT04801446|Active Comparator|Transcranial Direct Current Stimulation|
33329778|NCT05368428|Experimental|Supportive Care (TENS)|Patients undergo TENS therapy daily over 1 hour for 14 days in the absence of disease progression or unacceptable toxicity.
33329779|NCT01096966|Experimental|Bupivacaine TTS|
32867570|NCT04801446|Sham Comparator|Sham Stimulation|
32867571|NCT05672121|Experimental|KH631 Dose 1|dose1:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
33040278|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
33040279|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
33040280|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
33040281|NCT02013934|Active Comparator|Probiotics|Dietary supplement
33040282|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
33040283|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
33040284|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
33040285|NCT02013960|Experimental|Laminaria|cytotec and laminaria
33329780|NCT01096966|Placebo Comparator|Placebo patch|
33329781|NCT05348538|Experimental|Medication review with follow up or MaJ? for the acronym in french|All the pharmacists accepting to participate in the study will perform the intervention.
33329782|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
33329783|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
33329784|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
33329785|NCT05319054|No Intervention|Cohort|Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.
33329786|NCT05319054|Active Comparator|Optimised Conservative Management|Cohort participants who are identified as having 'major LARS' at any point are treated with Optimised Conservative Managements, consisting of medication, dietary advice, lifestyle advice and physiotherapy.
33329787|NCT05319054|Active Comparator|Trans-Anal Irrigation|Cohort participants who are identified as having 'major LARS' at any point are treated with Trans-anal irrigation, in additional to receiving optimised conservative management. Transanal irrigation system will be decided upon with the participant and procured locally.
33329788|NCT05319054|Active Comparator|Sacral NeuroModulation|Cohort participants who are identified as having 'major LARS' at any point are treated with Sacral Neuromodulation system, in addition to receiving optimised conservative management. Medtronic Interstim system will be used.
33329789|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
33040286|NCT02013960|Active Comparator|Cytotec|Cytotec only
33040287|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
33040288|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
33040289|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
33040290|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
33040291|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
33040292|NCT02013999|Active Comparator|Control|standard occupuational therapy
33040293|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
33040294|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
33040295|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
33040296|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
33040297|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
33040298|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
33329790|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
33417783|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
33417784|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
33040299|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
33040300|NCT02014090|Active Comparator|ECP|90 minutes of ECP
33040301|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
33040302|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
33417785|NCT01367587|Experimental|Arm 1|
33417786|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
33417787|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
33040303|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
33040304|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
33040305|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
33040306|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
33040307|NCT02014155|Experimental|COPD group not rehabilitation|
33040308|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
33040309|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
33040310|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
33040311|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
33040312|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
33040313|NCT02014207|Experimental|golden crinkle|
33040314|NCT02014207|Experimental|high blanch|
33040315|NCT02014207|Experimental|low blanche|
33040316|NCT02014207|Experimental|high chill|
33040317|NCT02014207|Experimental|low chill|
33040318|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
33040319|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
33040320|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
33040321|NCT02014220|Experimental|white bread with margarine|energy control
33040322|NCT02014220|Experimental|white bread|control
33040323|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
33040324|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
33040325|NCT02014259|Experimental|Subjects with renal impairment|
33040326|NCT02014259|Active Comparator|Subjects with normal renal function|
33040327|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
33040328|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
33040329|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
33040330|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
33040331|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
33040332|NCT02014350||DePuy Delta Xtend RTSA|
33040333|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
33040334|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
33040335|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
33040336|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
33417788|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
33329791|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
33040337|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
33040338|NCT02014506|Experimental|HAPLO|
33040339|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
33040340|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
33040341|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
33040342|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
33040343|NCT02014558|Experimental|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040344|NCT02014558|Experimental|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040345|NCT02014558|Experimental|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33329792|NCT05462002||plantar fasciitis group|Distance runners with plantar fasciitis
32867572|NCT05672121|Experimental|KH631 Dose 2|dose2:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
32867573|NCT05672121|Experimental|KH631 Dose 3|dose3:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
32867574|NCT05672121|Experimental|KH631 Dose 4|dose4:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
32867575|NCT05672121|Experimental|KH631 Dose 5|dose5:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
33040346|NCT02014558|Experimental|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040347|NCT02014558|Experimental|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040348|NCT02014558|Experimental|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040349|NCT02014558|Experimental|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
33040350|NCT02014558|Experimental|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
33040351|NCT02014558|Experimental|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
33040352|NCT02014558|Experimental|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
33040353|NCT02014558|Experimental|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
33040354|NCT02014558|Experimental|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
33067736|NCT04725357|Experimental|Arthroscopic Labral Repair + postoperative Meloxicam|After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam
33067737|NCT04725357|Active Comparator|Arthroscopic Labral Repair without Meloxicam|After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)
33067738|NCT00135122|Placebo Comparator|2|Placebo in six days
33067739|NCT00135278|Other|CSF Drainage|
33067740|NCT00135278|Other|No CSF Drainage|
32867576|NCT04792944||No treatment|Those are the patients that do not receive any treatment for the aneurysm, neither endovascular nor surgical
32867577|NCT04792944||External ventricular drain only with neither embolization nor clipping|These patients will be treated with an external ventricular drain only with neither embolization nor clipping
32867578|NCT04792944||Embolization|These patients will be treated endovascularly
32867579|NCT04792944||Programmed surgical clipping|These patients will be treated no on an emergency basis with surgical clipping of an aneurysm that has bled
32867580|NCT04792944||Emergency surgical clipping with cisternal urokinase administration|These patients with undergo emergency surgical clipping with cisternal urokinase administration
32867581|NCT04792944||Patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping|This group will include patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping
33040355|NCT02014558|Experimental|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
33040356|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
33040357|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
33040358|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
33040359|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
33040360|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
33040361|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
33040362|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
33329793|NCT05462002||asymptomatic control group|Distance runners without plantar fasciitis
33329794|NCT05624424|Experimental|Remimazolam Besylate|Induction of anesthesia Slowly inject Remimazolam Besylate 0.3~0.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional Remimazolam Besylate (0.05 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
33360606|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
33360607|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
32867582|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
32867583|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
33040363|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
33040364|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
33040365|NCT02014688||American Indian or Alaskan Native Descent|
33040366|NCT02014688||Black or African American Descent|
33040367|NCT02014688||Asian Descent|
33040368|NCT02014688||Hispanic Descent|
33040369|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
33040370|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
33040371|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
33040372|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
33040373|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
33040374|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
33040375|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26"
33040376|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
33040377|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
32867584|NCT05671965|Active Comparator|Xylitol|20 volunteers receive 33.5g xylitol dissolved in 300mL tap water as an oral pre-load.
32867585|NCT05671965|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
32867586|NCT05671965|Active Comparator|Acesulfame Potassium|20 volunteers receive 0.1675g Ace-K dissolved in 300mL tap water as an oral pre-load.
32867587|NCT05671965|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
32867588|NCT05616936|Experimental|Group I|Intervention side: application of i-PRF with distalization of maxillary first molar that will be performed on intervention sides according to a standardized protocol.
32867589|NCT05616936|No Intervention|Group II|Control side: distalization of maxillary first molar that will be performed without any intervention
32867590|NCT05616936|Experimental|Group A|levelling and alignment assisted with Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
32867591|NCT05616936|No Intervention|Group B|leveling and alignment will be commenced without Injection of Injectable platelet-rich fibrin (i-PRF)
32867592|NCT05616936|Experimental|Group a|Will includes 9 patients who will receive intrusive arch after leveling and alignment assisted Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
32867593|NCT05616936|No Intervention|Group b|Will includes 9 patients who will receive intrusive utility arches after leveling and alignment without Injection of Injectable platelet-rich fibrin (i-PRF)
32867594|NCT05671809||NCRT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCRT with surgery.
32867595|NCT05671809||NCT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCT with surgery.
32867596|NCT05671809||surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is surgery.
32867597|NCT04792710|Experimental|Intervention arm|This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
32867598|NCT04792710|Placebo Comparator|Control arm|This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
32867599|NCT04792632||Intervention|Intervention is the use of Veye Lung Nodules during the reading of the CT scans
32867600|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
32867601|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
32867602|NCT04792398|Experimental|Sleep Bruxism Subjects|"Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.~One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments."
32867603|NCT05671731|Experimental|Intervention|"The intervention group received Beneo Synergy 1 - 4gm twice/school day in 4 ounces orange juice with calcium for 12 weeks. We started with 1gm then increased the next day by a gram to reach the 4gm dose.~Intervention group participants completed Project FUN (8 module online nutrition and physical activity program) individually (password protected) in the school computer lab along with a workbook also used to check intervention completion."
32867604|NCT05671731|No Intervention|Control|The control group participated in usual school activities only completing pre and post measures.
32867605|NCT04792242|Active Comparator|goal directed therapy|svo2,haematocrite value,urine output,mean arterial pressure and central venous pressure
32867606|NCT04792242|Active Comparator|PCO2 gap algorithm|PCO2 gap,haematocrite value,Spo2,cardiac index
32867607|NCT04814433|Experimental|Topical lidocaine and bupivacaine alone|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
32867608|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
32867609|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and tranexamic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
32867610|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
32867611|NCT04792476|Active Comparator|Active Comparator: Experimental group|The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
32867612|NCT04792476|No Intervention|No Intervention: Control group|"The control group will only receive the conventional treatment offered in the clinical program. For 12 weeks, parients will attend 8 visits with mental health specialist nurse, where they will receive information, oral and written, to comply with the recommendations for physical exercise: 150-300 min/week of moderate physical activity or 75-150 min/week of vigorous physical activity.~In both groups (experimental and control), patients will be informed of the risk of weight gain, and they will be advised, regardless of the group assigned, to watch their diet and increase physical exercise until they meet the weekly recommendations."
32867613|NCT05615922|Experimental|Remotely Supervised tDCS and Word-Naming Practice|At each session, the tDCS device will deliver 2.0 mA electric current for 30 minutes over the left frontotemporal lobe with focus on the inferior frontal gyrus (IFG). Participants will receive 20 intervention sessions over the course of the interventional period (4 weeks) on weekdays (Monday-Friday). During the stimulation period, participants will engage in a picture-naming exercise as guided by the study tDCS clinicians.
32867614|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
32867615|NCT04801134|Other|Food insecurity|Food insecure families will be assigned education and community resources needed.
32867616|NCT05668065|Experimental|CoronaVac/CoronaVac|Biological: Coronavac Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
33329795|NCT05624424|Active Comparator|Propofol|Induction of anesthesia Slowly inject Propofol 2~2.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional Propofol (0.5 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
33329796|NCT05624424|Active Comparator|Sevoflurane|Induction of anesthesia Slowly inject Etomidate 0.03 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional etomidate (0.03 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
33329797|NCT05461846|Experimental|Group (A)|The integrated neuromuscular inhibition technique (INIT) is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
33329798|NCT05461846|No Intervention|Group (B)|control group
33329799|NCT05461690|Experimental|Niraparib group|200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
33329800|NCT04689048|Other|PET/CT, MRI|In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
33329801|NCT05461612|Experimental|SRT Pacing|SRT sensing and pacing of the left atrium to detect AF and restore sinus rhythm.
33329802|NCT05624346|Experimental|Experimental Group|After the operation, breathing exercises will be applied to the patients.
33329803|NCT05624346|No Intervention|Control Group|There will be no intervention other than routine nursing care practices in the hospital.
33329804|NCT05461534|Experimental|Intervention group: mindfulness yoga|an 8-week structured mindfulness yoga program
33329805|NCT05461534|No Intervention|Waiting-list control group|provided the 8-week structured mindfulness yoga upon their completion of the study
33329806|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
33329807|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
33329808|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
33329809|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
33329810|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
33329811|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
33329812|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
33329813|NCT01305642|Experimental|Individualized fortification of breast milk|
33329814|NCT04101916|Experimental|Paired Associative Stimulation|
33040378|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
33040379|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
33040380|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
33040381|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
33040382|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
33040383|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
33040384|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
33040385|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
33040386|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
33040387|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
33040388|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
33040389|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
33040390|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
33040391|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
33040392|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
33040393|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
33040394|NCT02014883|Experimental|GLUT1 DS|
33329815|NCT04101916|Sham Comparator|Sham|
32867617|NCT05668065|Active Comparator|CoronaVac/BNT162b2|"Biological: CoronaVac/BNT162b2 First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2."
32867618|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
32867619|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
32867620|NCT04800978|Experimental|BVAC-C+Durvalumab|"• Part A: The primary objective of the part A is to assess the maximum tolerable dose of BVAC-C combined with durvalumab 1500 mg as defined by dose-limiting toxicities (DLTs), and to find the maximum tolerated dose (MTD) that can be safely used for Part B (single arm phase II).~• Part B: The primary objective of the part B is to evaluate the safety and clinical efficacy, as measured by 6-month PFS rate, of the combination therapy of durvalumab and BVAC-C in patients with HPV 16 or 18 positive cervical cancer recurrent after or refractory to first-line platinum-based chemotherapy +/-bevacizumab."
32867621|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
32867622|NCT04731363|Experimental|Xylitol|oral xylitol, a potent artificial sweetener
32867623|NCT04731363|Experimental|Erythritol|oral erythritol, a potent artificial sweetener
32867624|NCT05615766|Experimental|Device Intervention|The intervention group who will be undergoing rehabilitation using the robotic exoskeleton in addition to the assigned traditional rehabilitation programme on their dominant arm only.
32867625|NCT05615766|No Intervention|Control|the matched control group will be the same subjects undergoing traditional rehabilitation only on their non-dominant arm.
32867626|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
32867627|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
32867628|NCT02092987|Experimental|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
33108647|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
33108648|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
33108649|NCT00446069|Experimental|Egalet® morphine|
33329816|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
33329817|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
33329818|NCT05764252|Other|BioEP|The EEG will be analysed using the BioEP algorithm
33329819|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
33329820|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
33329821|NCT05456230||Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
32867629|NCT02092987|Active Comparator|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
32867630|NCT04791774|Active Comparator|Protein group|Patients receive 20 grams of Intrinsically labelled milk protein.
32867631|NCT04791774|Experimental|Free amino acid group|Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
32867632|NCT05660187|Experimental|Telehealth care|Telehealth visits will be performed using institutionally-approved, secure, web-based teleconferencing. The standard neurology visits will occur every 6 months with their established neurology clinician via telehealth. The comprehensive care will be offered via telehealth or within the patient's local community. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
32867633|NCT05660187|Active Comparator|In-Clinic care|Standard neurology visits will be conducted in-clinic visits every 6 months with their established neurology clinician. The comprehensive MS care visits will be conducted in-clinic. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
32867634|NCT00183469|Active Comparator|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
32867635|NCT00183469|Placebo Comparator|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
32867636|NCT04714905||Pregnant Cohort|Pregnant (up to and including 15 weeks), 18+ years of age.
33108650|NCT00446069|Active Comparator|MST Continus®|
33329822|NCT05456230||Non-Midazolam|Midazolam was not given during the operation.
33329823|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
33329824|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
33329825|NCT05764174|Active Comparator|Factual messages|Participants in the arm with factual messages will listen to actual data on vaccination.
33360608|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
33040395|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
33329826|NCT05764174|Active Comparator|Narrative message|Participants the narrative messages will listen to messages appealing to emotions that were explored in a qualitative study conducted earlier.
33040396|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
33040397|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.~Biomarker blood draw"
33040398|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
33040399|NCT02014909|Experimental|KTN3379|KTN3379
33040400|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
33040401|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
33040402|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
33040403|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
33040404|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
33040405|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
33040406|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.~The phases comprise:~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
33040407|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
33040408|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
33040409|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
33040410|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
33040411|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
33040412|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
33040413|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.~The amount of running will be increased with 10 % per week."
33040414|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
33040415|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
33040416|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
33040417|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
33040418|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
33040419|NCT02015130|Experimental|individual treatment|Individualized treatment
33040420|NCT02015130|No Intervention|control group|treatment according to current national guidelines
33040421|NCT02015143||Bipolar Disorder|
33040422|NCT02015143||Unipolar Disorder|
33040423|NCT02015156|Experimental|PF-05280014|
33040424|NCT02015156|Active Comparator|Trastuzumab-US|
33040425|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs~D1-D14 Capecitabine 850mg/m2 p.o bid~D1 ~ Lapatinib 1250 mg qd dailiy"
33040426|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
33040427|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
33040428|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
33040429|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
33040430|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
33329827|NCT05764174|Active Comparator|Mixed messages|The mixed arm will combine both factual and narrative messages.
33329828|NCT05764174|No Intervention|Control arm|Participants in the control arm will not be provided with a message and will only be asked for whether they participant got vaccinated in the last two weeks.
33040431|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
33040432|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
33040433|NCT02015273||Growth Disorders|
33040434|NCT02015286||Growth Disorders|
33040435|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
33040436|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
33040437|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
33040438|NCT02015312|Placebo Comparator|Placebo|"capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
33040439|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
33040440|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
33040441|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
33040442|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
33040443|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
33040444|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
33040445|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
33040446|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
33329829|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
33329830|NCT05426122|Experimental|Barley rice protein|Barley rice protein powder presented as a shake
33329831|NCT05426122|Experimental|Pea protein|Pea protein powder presented as a shake
33329832|NCT05426122|Experimental|Whey protein|Whey protein powder presented as a shake
33329833|NCT03792126|No Intervention|Standard Care|
33329834|NCT03792126|Experimental|Implicit Learning Approach|
33329835|NCT05404048|Experimental|PD-L1 PET-imaging|The main intervention of this study is 89Zr-atezolizumab PET-scan combined with a low-dose CT-scan. The PET/CT scan will be performed before infusion of CAR T-cell therapy. In patients with an end-of-treatment F-FDG positive PET-signal a second 89Zr-atezolizumab PET/CT-scan will be performed.
33329836|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
33329837|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
32867637|NCT04714905||Pre-pregnancy Cohort|Anticipating to be pregnant, 18-40 years of age.
33040447|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
33040448|NCT02015403|Active Comparator|Standard Care|
33040449|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
33040450|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
33040451|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
33040452|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
33040453|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
33040454|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
33040455|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
33040456|NCT02015468|Experimental|Early mobilization|
33040457|NCT02015468|Experimental|Late mobilization|
33040458|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
33040459|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
33040460|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
33040461|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
33040462|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
33040463|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
33040464|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
33040465|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
33040466|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
33040467|NCT02015533|Experimental|CR8020|
33040468|NCT02015533|Placebo Comparator|Placebo|
33040469|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
33040470|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
33329838|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
33329839|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
33329840|NCT05273034|Experimental|1-h sepsis bundle|
33329841|NCT05273034|No Intervention|Current practice|
33329842|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
33329843|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
33329844|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
33329845|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
33329846|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
33329847|NCT05364814||Obese Group|A single sample group . Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks.Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks. At the end of each week, food consumption records and scales were applied. During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet was started and the same procedures were repeated.During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet (with the addition of probiotic yogurt) was changed and the same procedures were repeated.
33040471|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
33040472|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
33040473|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
33040474|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
33040475|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
33040476|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
33040477|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
33040478|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
33040479|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
33040480|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
33040481|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
33040482|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
33040483|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
33040484|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
33040485|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
33040486|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
33040487|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
33040488|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
33040489|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
33040490|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
33108651|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
33108652|NCT05658016|Experimental|TK112690|TK112690 treatment
33108653|NCT05658016|Placebo Comparator|Placebo|TK112690 formulation
33329848|NCT05265000|Experimental|tSpinalStim|Individuals in this arm will receive spinal cord stimulation
33108654|NCT05464459|Experimental|HAPY interposition elbow replacement|HAPY is a pyrocarbon sphere for use as an interposition joint replacement. In this study, the implant is being used as a novel procedure in the Elbow (outside approved label usage)
33108655|NCT01224925|Active Comparator|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
33108656|NCT01224925|Experimental|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
33108657|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
33108658|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
33108659|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
33108660|NCT05657938||DMD Patients|Ambulatory males aged 4 to <13 years with Duchenne Muscular Dystrophy
33108661|NCT05657938||Age Matched Controls|Normal male age-matched controls
33108662|NCT04680351|Experimental|phrenic stimulation|
33108663|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
33108664|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
33108665|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
33108666|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
33108667|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
33108668|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
33108669|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
33108670|NCT05657821|Experimental|pumpkin seed extract capsules|. In the intervention group, pregnant women received pumpkin seed extract capsules for 12 weeks
33108671|NCT05657821|Placebo Comparator|Iron tablets|the control group received iron tablets for 12 weeks
33108672|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
33108673|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
33108674|NCT04680273|Experimental|Part 1: [14C]-GDC-9545|Participants will be enrolled to receive a single dose of Carbon-14 labelled [14C]-GDC-9545.
33108675|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BCD|Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
33108676|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BDC|Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
33108677|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
33108678|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
33108679|NCT04679922|Active Comparator|Peri Implant mucosal thickness connective tissue graft|
33108680|NCT04679922|Experimental|Peri Implant mucosal thickness fascia lata graft|
33108681|NCT05426889|Other|Surgical|undergo surgery
33108682|NCT05426889|Other|non-surgical groups|no surgery
33108683|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
33329849|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
33040491|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
33329850|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
33329851|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
33329852|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
33040492|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
33040493|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
33040494|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
33040495|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
33040496|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
33040497|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
33040498|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
33040499|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
33040500|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
33040501|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
33040502|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
33040503|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
33040504|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
33040505|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
33040506|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
33040507|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
33108684|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
33108685|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
33329853|NCT05693844|Experimental|CD40 ligand expressing MSLN-CAR T cells|Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel and cyclophosphamide before the infusion of CD40 ligand expressing MSLN-CAR T cells.
33329854|NCT05343754|Active Comparator|Hyperbaric Oxygen Therapy|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80 minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
33329855|NCT05343754|Active Comparator|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
33360609|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
32867638|NCT04791618|Active Comparator|Health360x only (High tech)|"Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone.~The Health360x application will send messages to participants in this arm reminding them to perform study related activities."
32867639|NCT04791618|Experimental|Health360x plus Coach (High tech High touch)|"Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions.~The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors"
32867640|NCT04661163|Experimental|Virtual reality avatar therapy|Patients will be offered seven individual sessions of virtual reality therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 50 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.
32867641|NCT04661163|No Intervention|Supportive counselling (comparison group)|The control group is offered seven session with health professionals providing supportive counselling. This can (but does not necessarily) involve psychotherapy targeting auditory hallucinations.
32867642|NCT02248155||RLS patients|
32867643|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
32867644|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
32867645|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
32867646|NCT05655585|Experimental|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
32867647|NCT05655585|Experimental|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
32867648|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
32867649|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
32867650|NCT04812132|Active Comparator|Women|
32867651|NCT04812132|Active Comparator|Men|
33417789|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
32867652|NCT04800432|Experimental|Feasibility and acceptability of ADAPT+|ADAPT+ is a family-based obesity intervention for high-risk Latino youth and their parents living in rural communities that incorporates culture-specific components and mindfulness-based approaches to promote adaptive health behaviors in a high-risk and underserved population.
32867653|NCT04800432|Active Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) provides publicly available material in both English and Spanish on the role of diet and exercise in pediatric obesity in a one-time information session.
32867654|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).~If the vein then is isolated after a single application, the operator can move on to the next vein."
33040508|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
33417790|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
33417791|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
33417792|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
33417793|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
33417794|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
33329856|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O.~Pressure support (PS): 12-20 cmH2O.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
33417795|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
33108686|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
33108687|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
33108688|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
33329857|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C~Flow rate 30: 50 L/min.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
33329858|NCT05342584|Experimental|Venetoclax plus 7+3|see detailed description
33108689|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
33108690|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
33108691|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
33108692|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
33108693|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
33329859|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
33329860|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
33108694|NCT02957318|Experimental|FiberBind|
33108695|NCT02957318|Experimental|RG-I fiber|
33108696|NCT02957318|Placebo Comparator|Placebo|
33329861|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
33329862|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
33329863|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
33329864|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
33329865|NCT03297190|No Intervention|Usual Care|
33329866|NCT05320120|Experimental|first 56mg esketamine (2x Spravato® 28 mg nasal spray), then placebo|
33329867|NCT05320120|Experimental|first placebo (0.9% saline solution nasal spray), then ketamine|
33329868|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
33329869|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
33329870|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
33329871|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
33329872|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
32867655|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
32867656|NCT05645835|Experimental|intervention|Participants will engage with the app delivering the intervention five days a week for 8 weeks.
33040509|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
33040510|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
33040511|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
33040512|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
33040513|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
33040514|NCT02015871|Experimental|Degarelix|
33040515|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
33040516|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
33040517|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
33040518|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
33329873|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
33329874|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
33329875|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
33329876|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
33417796|NCT03131453|Experimental|CNP520 50 mg|50 mg capsule taken orally once daily
32867657|NCT05645835|Active Comparator|active placebo|Participants will engage with a placebo control app five days a week for 8 weeks.
32867658|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
33040519|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
33040520|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
33040521|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
33040522|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
33040523|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
33040524|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
33040525|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
33040526|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
33040527|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
33040528|NCT02016027|Experimental|Carica folia Arm|
33040529|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
33040530|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
33040531|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
33040532|NCT02016066|Experimental|CR6261|
33040533|NCT02016066|Placebo Comparator|Placebo|
33040534|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
33040535|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
33040536|NCT02016092||Patients with Parkinson's disease|
33040537|NCT02016092||Healthy Controls|
33040538|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
33040539|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
33417797|NCT03131453|Experimental|CNP520 15 mg|15 mg capsule taken orally once daily
33417798|NCT03131453|Placebo Comparator|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
33040540|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
33040541|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
33040542|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
33040543|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
33040544|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
33040545|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
33040546|NCT02016222|Experimental|Tears sampling|
33417799|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
33417800|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
33040547|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
33040548|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
33040549|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
33329877|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
33329878|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
33417801|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
33040550|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
33040551|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
33040552|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
33040553|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
33040554|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
33040555|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
33040556|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
33040557|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
33040558|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
33040559|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
33040560|NCT02016391|Experimental|Dexmedetomidine|
33040561|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
33040562|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
33040563|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
33040564|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
33040565|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
33040566|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
33040567|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
33040568|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
32867659|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
32867660|NCT04349280|Experimental|Participants receiving bintrafusp alfa|Participants will receive bintrafusp alfa.
32867661|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
32867662|NCT05631171|Experimental|Solution group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms. In addition, the experimental group will be given a smartwatch to each person which will collect real-time data on activity, training and sleep in a completely anonymous way. Also, through a mobile application, the patient of the experimental group will answer questionnaires about health status perception. The application has also been trained to provide educational content and motivational messages to support the patient's self-management. The data provided by patients in both groups of the study will be coded, in order to maintain the confidentiality of the individual.
32867663|NCT05631171|No Intervention|Control group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms.
32867664|NCT04812054|Experimental|Hypothermic oxygenated machine perfusion|Allografts will be subject to end-ischemic hypothermic oxygenated perfusion at 12 degrees Celsius through both hepatic artery and portal vein after a period of simple cold storage at 4 degrees Celsius and immediately prior to implantation. The perfusion will last at least 2 hours and the period will be prolonged in case of ongoing hepatectomy, in order to perform graft implantation immediately after perfusion.
32867665|NCT04812054|Active Comparator|Simple cold storage|Allografts will be stored in perfusate at 4 degrees Celsius from the procurement until implantation.
32867666|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
32867667|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
32867668|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
32867669|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
32867670|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
32867671|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
32867672|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
32867673|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
32867674|NCT04811742|Experimental|immersion bathing group|Immersion bathing was started by placing the baby's whole body, except for the head and neck, into a bathtub of warm water with a depth of 13-14 cm. The baby was shampooed and cleaned in the tub. Then, the baby was taken out of the water and rinsed over the tub. Finally, the baby was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
32867675|NCT04811742|Experimental|showering group|Shower was started by keeping the baby's face down and firmly gripping the baby from his/her armpit and head by one of the nurse's hands. The baby was washed under running water with the other hand. The second nurse assisted to ensure the flow of water. After the baby was rinsed, he/she was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
32867676|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
32867677|NCT03003897||Placebo Treatment|Participants receiving placebo.
32867678|NCT04800042|Other|Patients with scheduled major surgery|Patients with scheduled major surgery
32867679|NCT04563039|Experimental|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer
32867680|NCT04563039|Active Comparator|Standard Ureteroscopic Laser Lithotripsy|Standard Ureteroscopic Laser Lithotripsy
32867681|NCT04800120|Active Comparator|Study Group|Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
32867682|NCT04800120|No Intervention|Control Group|Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy
32867683|NCT04799730||SLE cases in remission|according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI <5
32867684|NCT04799730||SLE cases in activity|according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5
32867685|NCT04799730||Control group|Healthy age and sex matched subjects.
32867686|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
32867687|NCT05614869|Experimental|Treatment Group|Subjects undergoing 1 of 4 types of surgery will be enrolled and treated with the PREVENA Plus Incision Management System
33040569|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
33417802|NCT01367743|Active Comparator|epinephrine|
33417803|NCT01367743|Active Comparator|norepinephrine|
33417804|NCT02084732|Experimental|Sorafenib|drug
32867688|NCT04790838||Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
32867689|NCT04790838||Reference Product|ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
32867690|NCT04791072|Experimental|Telecoaching group|They will be given breathing exercise training and will be asked to do it every day for 8 weeks. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. They will be called by phone once a week and encouraging speeches will be made.
32867691|NCT04791072|Active Comparator|Control Group|They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
32867692|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
32867693|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
32867694|NCT04791150|Experimental|Patient with cancer immunotherapy treatment|All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.
33417805|NCT02084810|Active Comparator|NovoSeven®|
32867695|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
32867696|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
32867697|NCT04811586|Experimental|one-step Hybrid Coronary Revascularization (HCR)|One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.
32867698|NCT04811586|Active Comparator|Percutaneous Coronary Intervention (PCI)|PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.
32867699|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
32867700|NCT04790760|Experimental|Continuous Glucose Monitoring|Participants will wear a CGM device on the back of both their left and right arm for 6 weeks.
33040570|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
33040571|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
33040572|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
33040573|NCT02016495|Placebo Comparator|Placebo|
33329879|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
33329880|NCT05621772|Experimental|Experimental group (Meridian Activation Remedy System for Parkinson's Disease)|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD) treatment (16 times/8 weeks total, 2 times/week)
33329881|NCT05621772|No Intervention|Control group (Usual Care)|Usual care (all participants will be allowed to continue their prescribed medication and treatment (except Korean Medicine therapy), and they will not receive any additional treatment or therapy in the research institute), and lifestyle advice (all participants will receive a smart band and application-based guidance about their lifestyle)
33329882|NCT05621070|Experimental|JS002 150mg Q2W|JS002 150mg Q2W SC for 52 weeks
33329883|NCT05621070|Placebo Comparator|JS002 450mg Q4W|JS002 450mg Q4W SC for 52 weeks
32867701|NCT05571345|Experimental|PF614 50 mg|PF614 50 mg capsule (1 x 50 mg capsule over-encapsulated and 1 x placebo to match PF614 capsule)
32867702|NCT05571345|Experimental|PF614 100 mg|PF614 100 mg capsule (1 x 100 mg capsule and 1 x placebo to match PF614 capsule)
33040574|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
33040575|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
33040576|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
33040577|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
33040578|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
33040579|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
33040580|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
33040581|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
33040582|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
33329884|NCT05621070|Placebo Comparator|Placebo Q2W|Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks
33329885|NCT05621070|Placebo Comparator|Placebo Q4W|Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks
33329886|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
33108697|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
33108698|NCT05426850||ctDNA(+) Cohort|ctDNA(+) Cohort in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples.
33108699|NCT05426850||ctDNA(-) Cohort|ctDNA(-) Cohort in pretreatment and posttreatment plasma samples was defined by the absence of one or more mutations identified in match tumor samples.
33108700|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
33108701|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
33108702|NCT04319419|Experimental|Supplement with micronutrients|Nutrition education with a supplement
33329887|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
33329888|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
33108703|NCT04319419|Experimental|Nutrition education|Group received only nutrition education
33108704|NCT05657782|Experimental|Fixed Dose-Ranging|"The first, fixed dose-ranging module utilizes a classical 3+3 design. The name is derived from the typical cohort size at a given dose [3], and the typical expansion size at that dose [3] if 1 dose-limiting side effect is observed. This module will address the uncertainty regarding the relationship between dose and adverse events (AEs). A set of pre-specified doses (log10 values 6, 7, 8, 9, and 10) will be employed, based on animal experiments and other live OCV trials. Three participants will be administered each dose (15 participants total)."
32867703|NCT05571345|Experimental|PF614 200 mg|PF614 200 mg capsule (2 x 100 mg capsules)
32867704|NCT05571345|Active Comparator|Oxycodone IR 40 mg|Oxycodone HCl 40 mg (2 x 20 mg capsules over-encapsulated to match PF614 capsules).
32867705|NCT05571345|Placebo Comparator|Placebo|Placebo capsules to match PF614 (2 x placebo capsules)
32867706|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
32867707|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
33108705|NCT05657782|Experimental|Adaptive Dose-finding/Optimization|A modified continual reassessment method (CRM) adaptive design will guide the dose optimization module. CRM cohorts comprise 3 participants treated concurrently at each dose. All three subjects in each cohort will receive a single dose based on the CRM model fit to all the available dose-response data.
33108706|NCT05657782|Active Comparator|Expansion module - active product|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
33329889|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
33329890|NCT01378936|Experimental|MI plus IOC group intervention|
33329891|NCT01378936|Experimental|Motivational Interview only|
32867708|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
32867709|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
33108707|NCT05657782|Placebo Comparator|Expansion module - placebo|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
33108708|NCT05426694|Experimental|Group A|The interventional group received stretching and strengthening exercises along with scapular clock exercises. For the first two weeks, only scapular clock exercises were performed by the patient actively. After 2 weeks, the subjects performed scapular clock exercises by using the thera-band.
32867710|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
32867711|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
32867712|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
33108709|NCT05426694|Active Comparator|Group B|The active control group received stretching and strengthening exercises only. The stretching and strengthening exercises include corner stretch, wall-washes and pectoralis minor muscle stretch.
32867713|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
33108710|NCT05657743|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
33108711|NCT00446693|Experimental|I|Use of EndoFast Reliant System
33108712|NCT04319029|No Intervention|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
33108713|NCT04319029|Active Comparator|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
33329892|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
33329893|NCT05764096||COVID-19 patients|35 patients admitted to the intensive care unit due to COVID-19 contagion
33329894|NCT05764096||Healthy control participants|an age- and education-matched group of 35 healthy individuals who did not report a previous COVID-19 contagion
32867714|NCT02248311||Patients/Control Group|Observational
32867715|NCT02248311||Patients/Group Control|Observational
33040583|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:~Obstetrics ward, AIIMS hospital"
33108714|NCT05657704|No Intervention|Tramadol|Patients treated with Tramadol, 100 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
33329895|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
33329896|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
33329897|NCT05059366|Experimental|Expert participants randomized to MVG followed by 2VE|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the Manual ventilation grip device (MVG) first followed by the standard 2VE technique alone.
33329898|NCT05059366|Experimental|Expert participants randomized to 2VE followed by MVG|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG).
33417806|NCT02084810|Experimental|Eptacog alfa A 6 mg|
33436467|NCT05565703|Active Comparator|Attention Control Group|This group is randomly selected from the Acute Care for Elders unit and receives a one hour visit from the Researcher or research assistant two days in a row.
33436468|NCT04346914|Experimental|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
33040584|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
33040585|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
33040586|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.~Days 8-14:~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
33040587|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
33040588|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
33040589|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
33040590|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
33040591|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
33040592|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
33040593|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
33040594|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
33040595|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
33040596|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
33040597|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
33040598|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
33040599|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
33040600|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
33040601|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
33040602|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
33040603|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
33040604|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
33040605|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
33040606|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
33040607|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
33329899|NCT05059366|Experimental|Novice participants randomized to MVG followed by 2VE|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) first followed by the standard technique (2VE) alone
33329900|NCT05059366|Experimental|Novice participants randomized to 2VE followed by MVG|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG)
33329901|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
32740762|NCT05493605|Other|Cases|The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).
33040608|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
33040609|NCT02016846|Placebo Comparator|Placebo|
33040610|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
33040611|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
33040612|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
33040613|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
33040614|NCT02016911|Experimental|Subjects with hepatic impairment|
33040615|NCT02016911|Active Comparator|Subjects with normal hepatic function|
33040616|NCT02016937||group g|general anesthesia, n: 21
33040617|NCT02016937||group S|spinal anesthesia, n: 21
33040618|NCT02016937||group E|epidural anesthesia, n: 21
33040619|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
33040620|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
33040621|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
33040622|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
33040623|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
33040624|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
33040625|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
33040626|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
33040627|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
33040628|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
33040629|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
33040630|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
33040631|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
33040632|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
33040633|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
33040634|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
33040635|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
33040636|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
33040637|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
33040638|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
33040639|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
33040640|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
33040641|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
33040642|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
33040643|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
33040644|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
33040645|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
33040646|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
33040647|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
33329902|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
33329903|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
32867716|NCT04508907|Experimental|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
33329904|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
33329905|NCT05693766|Active Comparator|Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes|
33329906|NCT05693766|Experimental|Capecitabine_Non-Luminal A subtypes|
33329907|NCT04882930|Experimental|Functional Near-Infrared Spectroscopy (fNIRS) acquisitions|The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
33329908|NCT05693610|Experimental|Portable OSP|Outcomes will be assessed with the portable version of the OSP.
33329909|NCT05693610|Experimental|Cloud-based OSP|Outcomes will be assessed with the cloud-based version of the OSP.
33329910|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:~Age~Sex~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).~GINA step (Global Initiative for Asthma).~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The Asthma Control Test (ACT)"
33329911|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:~Age~Sex~Pack Years~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The COPD Assessment Test (CAT)"
33040648|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
33040649|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
33040650|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
33040651|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
33040652|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
33040653|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
33040654|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
33040655|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
33040656|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
33040657|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
33040658|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
33040659|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
33040660|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
33040661|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
33040662|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
33040663|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
33040664|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
33040665|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
33040666|NCT02017314|Active Comparator|Group I|Patients with BMI <30
33040667|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
33040668|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
33040669|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
33040670|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
33040671|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
33329912|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
33329913|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
33329914|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
33329915|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
33436469|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
33436470|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
33436471|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
33040672|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
33040673|NCT02017392|No Intervention|blank control|No intervention.
33040674|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
33040675|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
33040676|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
33040677|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
33040678|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
33040679|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
33040680|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
33040681|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
33040682|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
33040683|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
33040684|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
33040685|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
33040686|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
33040687|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
33040688|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
33040689|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
33040690|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
33040691|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
33040692|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
33040693|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
32867717|NCT04799574|Experimental|music therapy activity|The music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle.
32867718|NCT04799574|Placebo Comparator|Health education lecture|routine activities of community
33040694|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
32867719|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
32867720|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
32867721|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
32867722|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
32867723|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
32867724|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
32867725|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
32867726|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
32867727|NCT04811274||Patients|Minor patients with alveolar proteinosis by mutations of the MARS gene.
32867728|NCT04811274||Controls|Minors patients without alveolar proteinosis.
32867729|NCT04799184|Experimental|Group I Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml."
32867730|NCT04799184|Active Comparator|Group II no Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml."
32867731|NCT02221557|Experimental|New alloplastic bone graft material|
32867732|NCT05562297|Experimental|sintilimab + nab-paclitaxel + gemcitabine|Experimental: sintilimab + nab-paclitaxel + gemcitabine nab-paclitaxel at 125 mg/m^2 on days 1, and 8; gemcitabine at 1000 mg/m^2 on days 1, and 8; sintilimab at 200mg on day 1;
32867733|NCT04790292|Active Comparator|group M|group M 10mg morphine +0.25% bupivacaine
32867734|NCT04790292|Active Comparator|group MD|group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine
32867735|NCT03003195|Experimental|Vaccination: P10s-PADRE/MONTANIDE ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
32867736|NCT04811430||Randomized Traditional|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
32867737|NCT04811430||Radomized Cue Needle Tracking technology|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
32867738|NCT02248467||eugonadal|50 eugonadal subjects
32867739|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
32867740|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
32867741|NCT04790136|Experimental|GLA-015|GLA-015 (Glatt Pharmaceutical Services GmbH & Co. KG, Germany); 5.051 g granules containing 1500 mg cannabidiol to be dispersed in water; oral multiple dose administration twice daily over 7 consecutive days after a light meal
32867742|NCT04790136|Active Comparator|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|"DAC C-052 Cannabidiol / NRF 22.10 Ölige Cannabidiol-Lösung 100 mg/ml (Oily cannabidiol solution 100 mg/ml) (Glatt Pharmaceutical Services GmbH & Co. KG, Germany; according to DAC/NRF specifications); 15 ml solution containing 1500 mg cannabidiol; oral multiple dose administration twice daily over 7 consecutive days after a light meal"
32867743|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
32867744|NCT04812444|Experimental|Zylox Peripheral Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
32867745|NCT04812444|Active Comparator|Zilver Vena Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
33040695|NCT02017613|Experimental|Single arm|RP6530 administered orally
33040696|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
33040697|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
33040698|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
33040699|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
32740763|NCT05728983|Experimental|Treatment group|Participants randomly assigned to the treatment group arm experience both a well-rested and sleep-restricted week during the study
33040700|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
33040701|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
33040702|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
33040703|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
33040704|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
33040705|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
33040706|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
33040707|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
33040708|NCT02017769||Healthy controls|Healthy, gender and age matched controls
33040709|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
33040710|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
33040711|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
33040712|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
33040713|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
33040714|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
33040715|NCT02017808||OCT|Healthy controls
33040716|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
33040717|NCT02017821|No Intervention|care as usual|
33040718|NCT02017834|Experimental|harmonic scalpel|
33040719|NCT02017834|Active Comparator|standard technique|
33040720|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
33040721|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
33040722|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
33040723|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
33040724|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
33040725|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
33040726|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
33040727|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
33040728|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
33040729|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
33040730|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
33040731|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
33040732|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
33040733|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
33040734|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
33040735|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
33040736|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
33040737|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
33040738|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
33040739|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
33040740|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
33040741|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
33040742|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
33040743|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
33040744|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
33040745|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
33040746|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
33040747|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
33040748|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
33040749|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
33040750|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
33040751|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
33040752|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
33040753|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
33040754|NCT02018029||cardiac resynchronisation therapy|
33040755|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
33040756|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
33040757|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
33040758|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
33040759|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
33040760|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
33040761|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
33040762|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
33040763|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
33040764|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
33040765|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
33040766|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
33040767|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
33040768|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
33040769|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
33040770|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
33040771|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
33040772|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
33040773|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
33040774|NCT02018224|Experimental|End-to-end suturation without augmentation|
33040775|NCT02018224|Experimental|End-to-end suturation with augmentation|
33040776|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
33040777|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
33040778|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
33040779|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
33040780|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
33040781|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
32867746|NCT05472597||nuMoM2b Heart Health Study Cohort|A large and diverse (both geographically and demographically) group of adult women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospective collected thereafter.
33040782|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
33040783|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
33040784|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
33040785|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
32867747|NCT04789980||Patients|Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy
32867748|NCT04394637||PROSe-ICD|PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.
33040786|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
33040787|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
32867749|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
33329916|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
32867750|NCT04790214|Experimental|Stable CHF patients|Stable CHF patients on stage II/III based on the New York Heart Failure classification
33040788|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
32867751|NCT04339101|Experimental|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
32867752|NCT04789824|Experimental|Investigation group|Eye Hygiene (warm compress, eyelid massage, and eyelid cleaning)
33040789|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
33040790|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
33329917|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
32867753|NCT04789824|No Intervention|Control Group|No intervention
32867754|NCT04798404||Exercise Intervention in 20 collective sessions|104 elders recruited among the community (mean age: 82.1 ± 5.7, 72 women and 32 men), diagnosed in initial consultation with mobility disability risk (sedentary or/and pre-frail/frail or/and sarcopenia at least probable) who participated in 20 collective sessions twice a week and two hours per week, and have been seen for reassessment in final consultation.
33040791|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
33040792|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
33040793|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
33040794|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
33329918|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
32867755|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
32867756|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
33040795|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
33040796|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
32867757|NCT04798560||Patients undergoing Whipple operation|After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF
32867758|NCT05446233|Experimental|[14C] Antaitavir Hasophate|Eligible healthy male subjects received a single oral 100 mg (radioactivity of 200µCi) dose of [14C] Antaitavir Hasophate
32867759|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
32867760|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
32867761|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
32867762|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
32867763|NCT05615688|Experimental|Orthodontic Separators Placed|Elastomeric separators will be placed on the mesial and distal of the lower first permanent molars for a total of four separators per subject.
32867764|NCT04810650|Experimental|PREP/PEP at Outpatient Clinics Dynamic Prevention Intervention|
32867765|NCT04810650|Active Comparator|PREP/PEP at Outpatient Clinics Control|
32867766|NCT04810650|Experimental|PREP/PEP at Antenatal Clinics Dynamic Prevention Intervention|
32867767|NCT04810650|Active Comparator|PREP/PEP at Antenatal Clinics Control|
32867768|NCT04810650|Experimental|PREP/PEP at Community Households Dynamic Prevention Intervention|
32867769|NCT04810650|Active Comparator|PREP/PEP at Community Households Control|
32867770|NCT04810650|Experimental|Mobility Dynamic Treatment Intervention|
32867771|NCT04810650|Active Comparator|Mobility Control|
32867772|NCT04810650|Experimental|Healthy Living for Heavy Alcohol Users Intervention|
32867773|NCT04810650|Active Comparator|Heavy Alcohol Users Control|
32867774|NCT04810650|Experimental|Hypertension Linkage Intervention|
32867775|NCT04810650|Active Comparator|Hypertension Linkage Control|
32867776|NCT04810650|Experimental|Hypertension Community Intervention|
32867777|NCT04810650|Active Comparator|Hypertension Community Control|
33329919|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
33329920|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
32867780|NCT04288245|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
32867781|NCT04288245|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
32867782|NCT04789512||Covid-19 players|Female volleyball players with Covid-19
32867783|NCT04789512||non-Covid-19 players|Female volleyball players with non Covid-19
33329921|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
33329922|NCT04913194|Experimental|Immediate Treatment|Participants in this arm will receive the intervention within 2 weeks of completing the intake session.
33329923|NCT04913194|Other|Waitlist Control|Participants in this arm will not receive any intervention for two weeks. Participants will complete the treatment after 4-6 weeks of being on the waitlist after their intake session.
33329924|NCT05540340|Experimental|Pharmacokinetic directed melphalan|This is a feasibility study of pharmacokinetic (PK)-directed Captisol Enabled (CE) melphalan dosing to target an AUC of 8.5 (+/- 1.5) using a population PK model in lymphoma patients receiving BEAM [carmustine (BCNU) (B), etoposide (E), cytarabine (Ara-C) (A), and melphalan (M)], followed by autologous hematopoietic cell transplantation (AHCT). This study will enroll 20 patients with lymphoma planned for BEAM-AHCT. Carmustine IV will be given on day -6, followed by etoposide IV and cytarabine IV from day -5 to -2 as per the MSK inpatient or outpatient standard of care. The calculated melphalan dose based on population PK model to achieve the proposed melphalan target exposure [8.5 (+/- 1.5) mg*h/L], will be administered on day -1, and six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing to determine if the goal AUC was achieved.
33329925|NCT04120480|Experimental|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
33329926|NCT04120480|No Intervention|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
33040797|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
33040798|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
33040799|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
33040800|NCT02018406|Experimental|Intervention|Intervention Group
33040801|NCT02018406|Placebo Comparator|Control|Control Group
33040802|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~the activation step with an IV infusion of AlloStim on Day 28;~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
33040803|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
33040804|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
33040805|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
33040806|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
33040807|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
33040808|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
33040809|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
33040810|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
33329927|NCT04755426||Patients with severe aortic stenosis|Adults with severe aortic stenosis who either have faced or are facing a decision about valve replacement (depending on the phase of the research)
33329928|NCT04755426||Health care providers|HCPs who guide decisions about managing AS, including interventional cardiologists, cardiac surgeons and advanced practice providers (APPs), including nurse practitioners and physician assistants.
33329929|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
33436472|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
33436473|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
33040811|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
33040812|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
33040813|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
33040814|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
33040815|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
33040816|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
33040817|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
33040818|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
33040819|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
33040820|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
33040821|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
33040822|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
33040823|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
33040824|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
33040825|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
33040826|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
33040827|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
33417807|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
33417808|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
33417809|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
33417810|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
33417811|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
33417812|NCT01371799|Placebo Comparator|Placebo|Placebo
33417813|NCT02732509||Lean|Body mass index less than 25 kg/m2
33417814|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
33417815|NCT02686814|Experimental|MDT-2215|17mm MDT-2215 aortic valve bioprosthesis
33417816|NCT02673151|Experimental|68Ga-PSMA-11 PET/CT|Patients receive 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11). Participant will be injected IV with 3 to 7 millicurie (mCi) of 68Ga-PSMA-11. Beginning 50 to 100 minutes later, a low-dose computed tomography (CT) scan will be obtained from vertex to mid thighs; followed by a static positron emission tomography (PET) scan over the same .
33417817|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
33417818|NCT01367821||Healthy volunteers|Healthy volunteers
33417819|NCT02082002||MS-Group|MS-Group
33417820|NCT02082002||Healthy control|Healthy control
33417821|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
32740764|NCT05728983|Placebo Comparator|Control group|Participants randomly assigned to the treatment group arm experience two well-rested weeks during the study (and they still have an ad lib sleep week in between the two well-rested weeks)
33040828|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
33040829|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
33040830|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
33040831|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
33040832|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
33040833|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
33040834|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
33040835|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
33040836|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
33040837|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
33040838|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
33040839|NCT02018666|Experimental|spontaneous NAVA mode|
33040840|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
33040841|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
33040842|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
33040843|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
33417822|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
33417823|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
33417824|NCT02082080|No Intervention|Obese and overweight children|
33108715|NCT05657704|No Intervention|Dexketoprofen|Patients treated with Dexketoprofen 25 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
33417825|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
32867784|NCT04810728|Experimental|Extract Psidii guava|2 Capsule of extract Psidii guava, three times daily
32867785|NCT04810728|Active Comparator|Standard therapy|Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
33417826|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
32867786|NCT05425485|Active Comparator|EducAR strategy|"Healthcare personnel involved in the care of patients with RA in the selected centres will be provided with access to a website and instructed in its use in a videoconference. The website includes a training section for healthcare professionals and another for patients. The former includes explanatory videos on how to manage doctor-patient communication and to facilitate adherence and what not to do, tools to explain treatment options (shared decision aids) and links to key documents. The patient section includes information for patients (downloadable in leaflet format), medication calendars and disease diaries, videos explaining medication administration in RA and links to patient associations, among other tools.~Both access to the website and its materials and to the instruction session will be open to all those involved in the corresponding service, but will not be mandatory."
32867787|NCT05425485|No Intervention|Standard of care|Physicians in the control group will not be instructed and will have no access to the materials included in the physician section of the webpage.
32867788|NCT05401227|Experimental|High Ketamine, TS-134|Two administrations of ketamine 0.23 mg/kg pre post 4 days of TS-134 20 mg
32867789|NCT05401227|Placebo Comparator|High ketamine, placebo|Two administrations of ketamine 0.23 mg/kg pre post 4 days of placebo
32867790|NCT05401227|Experimental|Medium Ketamine, TS-134|Two administrations of ketamine 0.125 mg/kg pre post 4 days of TS-134 20 mg
32867791|NCT05401227|Placebo Comparator|Medium Ketamine, placebo|Two administrations of ketamine 0.125 mg/kg pre post 4 days of placebo
32867792|NCT05401227|Experimental|Low Ketamine, TS-134|Two administrations of ketamine 0.06 mg/kg pre post 4 days of TS-134 20 mg
32867793|NCT05401227|Placebo Comparator|Low Ketamine, placebo|Two administrations of ketamine 0.06 mg/kg pre post 4 days of placebo
32867794|NCT04786938|Experimental|Saccharomyces boulardii|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34) plus S. boulardii CNCM I-745 (approximately 22.5 x109 CFU
32867795|NCT04786938|No Intervention|No intervention|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34)
32867796|NCT04809870||LC (liver cirrhotic patients)|Patients with concomitant liver cirrhosis
32867797|NCT04809870||Non-LC (non liver cirrhotic patients)|Patients without concomitant liver cirrhosis
32867798|NCT04214691|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
32867799|NCT04214691|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
32867800|NCT04786392|Active Comparator|Lutein supplement|"Supplement containing 5 mg powdered lutein, capsule filler microcrystalline cellulose.~To be administered once."
32867801|NCT04786392|Experimental|Blended food beverage|Blended food beverage containing 5 mg lutein from baby spinach. To be administered/consumed once.
32867802|NCT04786392|Experimental|Whole food|Consumption of 5 mg of lutein from baby spinach. To be administered/consumed once.
32867803|NCT05367687|Experimental|Treatment group|Camrelizumab Plus Rivoceranib (Apatinib)
32867804|NCT05367687|Active Comparator|Control group|Camrelizumab
32867805|NCT04786314|Experimental|Hot Water Application Group|Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
32867806|NCT04786314|Experimental|Cold Water Application Group|Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
32867807|NCT04786314|No Intervention|Control Group|There will be no intervention other than routine follow-up and maintenance.
32867808|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
32867809|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
32867810|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
32867811|NCT04789356|Active Comparator|High-risk individuals (with comorbidities)|Public safety and security (police officers and law enforcement, fire department), and high school and college/university professionals of the state government public education network who present at least one of the comorbidities included in the National Plan for the Operationalization of Vaccination Against COVID-19 will be invited to receive the CoronaVac vaccine
32867812|NCT04789356|No Intervention|Low-risk individuals (without comorbidities)|Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project.
32867813|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
32867814|NCT04788810|Experimental|Oral route|Volunteers receiving d12-Cl2BPA via oral route
33417827|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
33417828|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
33417829|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
33417830|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
33417831|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
33417832|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
32867815|NCT04788810|Experimental|Dermal route|Volunteers receiving d12-Cl2BPA via oral route
32740765|NCT05634603|Active Comparator|Intervention|Lactose-free milk formula (Frisolac LF ®)
32740766|NCT05634603|Placebo Comparator|Placebo|Regular infant milk formula
32740767|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
32740768|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
32740769|NCT05728905|Experimental|Therapeutic exercise|The patients assigned to this group performed a self-treatment program that included three coordination exercises, two post-isometric relaxation (contraction-relaxation) and one self-traction. All exercises were performed in front of a mirror. It was performed every 3 hours, 5 times a day, for 4 weeks. The patient was instructed and supervised by a physiotherapist until they were executed correctly. All participants were provided with a video where the procedure and dosage of each exercise was described in detail.
32740770|NCT05728905|Experimental|Therapeutic exercise + orthopedic manual therapy|The patients assigned to this group performed the exercise program and also received a manual therapy treatment applied by a physiotherapist. Two sessions were held per week for 4 weeks (8 sessions). Treatment consisted of traction, mobilization, and friction massage of the muscles of mastication.
32740771|NCT05728905|No Intervention|Control|The patients assigned to this group did not receive any type of intervention during the 4 weeks. They were asked not to change their habits or receive any other type of treatment.
32740772|NCT02310269||Pasireotide|
32740773|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
32740774|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
32740775|NCT05728827|Experimental|Anti-gravity treadmill + Blood Flow Restriction training|
32740776|NCT05728827|Active Comparator|Anti-gravity treadmill|
32740777|NCT05634525|Experimental|MRTX849 (Adagrasib)|Helps to control pancreatic cancer that has a KRAS G12 mutation.
32740778|NCT05728749||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
32740779|NCT04489745|Experimental|SBRT and ADT|Patients undergo SBRT to a dose of 40 Gy in 5 fractions to prostate, and optional 25 Gy in 5 fractions to SVs and Pelvic LNs, with 9 months of Androgen Deprivation Therapy
32740780|NCT05634447|Experimental|Sequence 1|"Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 2: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 4: CKD-391 - A single oral dose of 1 tablet under fasting condition"
32740781|NCT05634447|Experimental|Sequence 2|"Period 1: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 3: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition"
32740782|NCT05728671|Experimental|IP2015_PO release form 1|Test formulation 1
32740783|NCT05728671|Experimental|IP2015_PO release form 2|Test formulation 2
32740784|NCT05728671|Experimental|IP2015_PO release form 3|Test formulation 3
32740785|NCT04419519|Experimental|Venetoclax monotherapy|
32740786|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
32740787|NCT05183867|Experimental|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
32740788|NCT05183867|Active Comparator|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
32740789|NCT05183867|No Intervention|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
32740790|NCT05183165|Other|Patients with Wilson's disease declaring pregnancy,|Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.
32740791|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
32740792|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
32740793|NCT04392765|Other|Therapy arm|Six week use of eXciteOSA device. Once daily for 20 minutes.
32740794|NCT05180123|Other|Patients after ACL reconstruction in adolescence|
32740795|NCT05179811||Cohort|Patients with functional dysphonia using the Voice Handicap Index score.
33417833|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
33040844|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
33417834|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
33417835|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
33040845|NCT02018718|Other|Marathoners|
33040846|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
33040847|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
33040848|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
33040849|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
33040850|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
33040851|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
33040852|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
33040853|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
33040854|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
33040855|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
33040856|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
33040857|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
33040858|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
33040859|NCT02018874|Experimental|LY2780301|
33040860|NCT02018900|Placebo Comparator|Placebo|Placebo
33040861|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
33040862|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
33040863|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
33040864|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
33040865|NCT02018952|Other|Ultrasonography assessment|
33040866|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
33040867|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
33067741|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
33067742|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
33067743|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
33067744|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
33067745|NCT00135590|Experimental|1|Protein pulse-feeding
33067746|NCT00135590|Active Comparator|2|Spread diet
33067747|NCT00135668|Active Comparator|1|Nitroprusside infusion 0.3 mcg/kg/min
33067748|NCT00135668|Active Comparator|2|nitroprusside infusion 1 mcg/kg/min
33067749|NCT00135668|Active Comparator|3|nitroprusside infusion 2 mcg/kg/min
33067750|NCT00135668|Active Comparator|4|nitroprusside 3 mcg/kg/min
33067751|NCT00135785|Active Comparator|1|Bupropion
33067752|NCT00135785|Placebo Comparator|2|Placebo
33067753|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
33067754|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
33067755|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
33067756|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
33067757|NCT04724616|No Intervention|Control Group|Participants received no specific educational program
33067758|NCT04724616|Experimental|Intervention Group|Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
33417836|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
33417837|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
33360610|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
33417838|NCT05042947|Experimental|DLCT|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences, and the experimental group used double-loop coil clamp technology to treat the wound.
33417839|NCT05042947|Active Comparator|Traditional technology|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences.The control group used the traditional hemostatic clip technique to treat the wound
33417840|NCT05505578|Experimental|GamerFit Condition|Includes use of a Fitbit and exergaming devices, the GamerFit app, and weekly telehealth coaching sessions.
33417841|NCT05505578|Active Comparator|Comparator Condition|Youth assigned to the comparator condition (n=30) will receive a Fitbit device (same as the intervention condition) and the Fitbit account activated on their device (e.g. phone/tablet/computer). They will receive instructions on using the PA and sleep tracking features, as well as a booklet of healthy habit tips. They will receive reminders to charge, sync and review their Fitbit data for the duration of the intervention.
33417842|NCT01365013|Experimental|Lifestyle counseling|
33417843|NCT01365013|Active Comparator|control group|
33417844|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
33417845|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
33417846|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
33417847|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
33040868|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
33040869|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
33417848|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
33417849|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
33417850|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
33417851|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
33040870|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
33040871|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
32740127|NCT02215265|Active Comparator|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
32740798|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
33040872|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
33040873|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
33040874|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
33040875|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
33040876|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
33040877|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
33040878|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
33040879|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
33040880|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
32867816|NCT04197687|Experimental|Arm I - No pCR (trastuzumab emtansine, TPIV100, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of TPIV100 ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
32867817|NCT04197687|Placebo Comparator|Arm II - No pCR (trastuzumab emtansine, placebo, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive placebo ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of placebo ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
32867818|NCT04197687|Experimental|Treatment (pCR)|Patients receive standard of care maintenance therapy with trastuzumab and pertuzumab for 1 year in the absence of disease progression or unacceptable toxicity.
32867819|NCT04809792|Experimental|Head and neck cancer|In this arm patients with head and neck cancers treated with SBRT are recruited.
32867820|NCT04810182||Glioblastoma Patients treated with Regorafenib|Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).
32867821|NCT05340387|Experimental|Balance Resistance Aerobic Cognitive Exercises (BRACE)|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
32867822|NCT05340387|Active Comparator|Otago's Exercises|Otago's protocol is combination of warm up, strengthening, balance and flexibility exercises.
32867823|NCT04786470|Active Comparator|Local Anaesthetic Infusion|
32867824|NCT04786470|Sham Comparator|Saline Infusion|
32867825|NCT04785846||Single Group|Adult patients with coronary artery disease undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm.
32867826|NCT04788654|Active Comparator|Pharmacological group|Pharmacological analgesia will be performed
32867827|NCT04788654|Experimental|Pharmacologican and surgical group|Pharmacological and surgical analgesia will be performed.
32867828|NCT04788732||1-Inhalation Anesthesia|patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
32867829|NCT04788732||2-Total Intravenous Anesthesia|the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
32867830|NCT04788732||3-Balanced anesthesia|the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
32867831|NCT04809480||Non-COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from January 2017 up to February 2020
32867832|NCT04809480||COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from February 2020 up to December 2020 with positive COVID19 PCR test
32867833|NCT04788264|Experimental|Arm I (exercise training, behavior modification)|Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11.
32867834|NCT04788264|Active Comparator|Arm II (Fitbit, consultation)|Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12.
32867835|NCT04788030||Digital nerve reconstruction with muscle-in-vein conduits|
32867836|NCT04787952||Group 1= healthy subjects|"Inclusion criteria to the group 1 (healthy males) N=20:~BMI <25 kg/m2;~RR<140/90mmHg;~age 21-43 years~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~no chronic disease"
32867837|NCT04787952||Group 2 = overweight/obese subjects|"Inclusion criteria to the group 2 ( overweight/obese males ) N=20:~Blood pressure < 140/90 mmHg (well controlled by inh ACE; no beta-blockers)~No chronic disease~BMI > 25 <35kg/m²~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~age 21-43 years"
32867838|NCT04785768|Experimental|PCA with continuous + bolus dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
32867839|NCT04785768|Experimental|PCA with bolus-only dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
32867840|NCT04785768|Active Comparator|Oral opioid|（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.
33040881|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
33040882|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
33417852|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
32740128|NCT02215265|Experimental|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
32740129|NCT02215265|Active Comparator|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
33040883|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
33040884|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
33040885|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
33040886|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
32740799|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
32740800|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
33040887|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
33040888|NCT02019147||Healthy Term Neonates|Controls
33040889|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
33040890|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
33040891|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
33040892|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
33040893|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
33040894|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
33040895|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
33040896|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
33040897|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
33040898|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
33040899|NCT02019290|Experimental|bitopertin-Midazolam|
33040900|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
33040901|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
33040902|NCT02019329|Placebo Comparator|Placebo + risperidone|
33040903|NCT02019329|Experimental|RO5545965 + risperidone|
33040904|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
33040905|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
33040906|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
33040907|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
33040908|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
33040909|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
33040910|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
33040911|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
33040912|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
33040913|NCT02019394|Experimental|Lu AE58054|
33040914|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
33040915|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
33040916|NCT02019433||Structan®|
33108716|NCT05657704|Experimental|Experimental Group|"The patients in this group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype.~Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours"
33417853|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
33417854|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
33417855|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
32867841|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
32867842|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
32867843|NCT05615298||Cancer|"Negative image data: Has been interpreted as negative in screening mammograms~Benign image data: Has a suspicious lesion for breast cancer in screening mammograms but confirmed as a benign through the follow-up biopsy or has been interpreted as a benign in screening mammograms and confirmed as a benign in the further diagnostic images taken after at least two years from the screening mammograms."
32867844|NCT05615298||Non-cancer|Has a suspicious lesion for breast cancer in screening mammograms and confirmed as a cancer (malignant) through the follow-up biopsy.
32867845|NCT04768296|Experimental|Berzosertib + Topotecan|In Japan, a Safety Run-in Part will be conducted. In case safety and tolerability is confirmed in the Safety Run-in part, Japanese participants will enroll in the Main Part of the Phase 2. Both in the Safety Run-in and Main Part of the Phase 2, participants will receive berzosertib and topotecan until disease progression or other criteria for study intervention discontinuation are met.
32867846|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
32867847|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
32867848|NCT04785612|Experimental|RSVPreF|A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume
32867849|NCT04785612|Placebo Comparator|Placebo|A single intramuscular injection of Placebo to match active vaccine
32867850|NCT04788498|Experimental|Laparoendoscpoic single site surgery LESS|35 patients undergoing laparoscopic ovarian cystectomy A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
32867851|NCT04788498|Active Comparator|Conventional multiport laparoscopy|35 patients undergoing laparoscopic ovarian cystectomy It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
32867852|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
32867853|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
32867854|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
32867855|NCT04787796|Experimental|The Self-built-in M-ECG recorders have passed the electrical.|We shall conduct this prospective clinical study to define the specific patterns of multichannel ECG change in adults with suspected CAD or ACS. For multichannel ECG (M-ECG) examination, the signal will be recorded with a Self-built-in ECG recorder.
32867856|NCT05316285|Experimental|Yoga Group|It will consist of students who choose the Yoga for a Healthy Life lesson. For 14 weeks, one day a week and 60 minutes a day, theoretical and practical yoga training will be applied.
32867857|NCT05316285|No Intervention|Control Group|The control group will consist of students who chose the Fashion and Beauty lesson.
32867858|NCT05295771|Experimental|Test arm|Geistlich Fibro-Gide ®.
32867859|NCT05295771|Active Comparator|Control|Autogenous Connective Tissue Graft.
32867860|NCT04341558|No Intervention|Baseline|During this baseline period, postoperative monitoring will be continued as normal by nursing and medical staff without intervention. No training of family members will take place
32867861|NCT04341558|Active Comparator|Intervention|Family carers will be trained to perform and document basic vital signs whilst they provide personal care to their relatives after surgery in order to supplement patient monitoring conducted by nursing staff.
32867862|NCT04808700|Other|Focal cartilage lesion|Patients with focal cartilage lesions who underwent a knee surgery using the Episealer implant
32867863|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
32867864|NCT04787718|Experimental|Almond|Participants will consume 2.0 oz of raw, shelled, unsalted almonds.
32867865|NCT04787718|Active Comparator|Control group|an isocaloric (2.0 oz raw almonds) amount of unsalted pretzels daily.
32867866|NCT05280561|Experimental|DHM group|This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in ~100 ml water for oral administration, once daily for 20 days.
32867867|NCT05280561|Placebo Comparator|Control group|The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
32867868|NCT04785222|Experimental|DB|Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
32867869|NCT04785222|Active Comparator|BP|Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side
32867870|NCT04785222|Placebo Comparator|NS|Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side
33108717|NCT04319185|Experimental|Intervention|All patients who qualify for the study will receive the intervention
33417856|NCT02085122|Experimental|noninvasive ventilation|
33417857|NCT02085122|No Intervention|Control Group|
33417858|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
33417859|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
32740801|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
32740802|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
32740803|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
32740804|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
32740805|NCT05728593|Active Comparator|study group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
32740806|NCT05728593|Active Comparator|control group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
32740807|NCT05173337|No Intervention|control group|Nefopam will not be administered in this group.
32740808|NCT05173337|Experimental|nefopam group|Intravenous nefopam 20 mg will be administered twice, immediately after induction of anesthesia and at the end of surgery.
32740809|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
32740810|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
32740811|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
32740812|NCT05728515|Experimental|PET scan|Patients will receive an intravenous injection of 68Ga-NY104
32740813|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
32740814|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
32740815|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
32740816|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
32740817|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
32740818|NCT04880577|Experimental|TAF|25 mg of daily TAF
32740819|NCT04880577|Placebo Comparator|Placebo|Placebo pill
32740820|NCT04353921||Single-Dose of Psilocybin|
32740821|NCT04353921||Niacin-Control|
32740822|NCT04290897|Experimental|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
32740823|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
32740824|NCT04280211||Control Group|Healthy adults over 40 years old
32740825|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
32740826|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|"Participants received a peer recovery specialist-delivered behavioral activation (BA) intervention (Peer Activate) to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention."
32740827|NCT04680689||Fuse-Heart -SG 01|Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
32740828|NCT04680689||Fuse-Heart -SG 02|Study subjects surviving an acute myocardial infarction, revascularized or not.
32740829|NCT04489901|Experimental|Extra Virgin Olivei oil group|The women in the experimental (olive oil) group were asked to apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
32740830|NCT04489901|No Intervention|Control group|The women in the control group did not undergo any intervention.
32740831|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
32740832|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
33040917|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
33108718|NCT00446732|Active Comparator|1|
33040918|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
33040919|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
33040920|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
33040921|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
33040922|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
33040923|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
33040924|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
33040925|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
33040926|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
33040927|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
33040928|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
33040929|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
33040930|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
33040931|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
33040932|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
33040933|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
33040934|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
33040935|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
33040936|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
33417860|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
33417861|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
32867871|NCT05277207|Experimental|MESH|Participants assigned to this group will receive a treatment that includes personalized smoking cessation facilitation meetings with cognitive-behavioral therapy, personalized smoking cessation pharmacotherapy, and personalized text messaging.
32867872|NCT05277207|Active Comparator|Best Practice Telehealth Group|Participants assigned to this group will be referred to Quit Vet (VA's quitline for stopping tobacco) and SmokefreeVET (a free text messaging program to help you quit), and will receive information about getting quit medications.
32867873|NCT04808856|Experimental|ACTH|Adrenocorticotropic Hormone
32867874|NCT04808856|Active Comparator|Methylprednisolone|Methylprednisolone
32867875|NCT04787406|Active Comparator|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
32867876|NCT04787406|Active Comparator|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
32867877|NCT04787406|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
32867878|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
32867879|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
32867880|NCT04808622|Experimental|TSC 0.5 mg/kg|TSC 0.5 mg/kg given as a one-time IV bolus injection
32867881|NCT04808622|Experimental|TSC 1.0 mg/kg|TSC 1.0 mg/kg given as a one-time IV bolus injection
32867882|NCT04808622|Experimental|TSC 1.5 mg/kg|TSC 1.5 mg/kg given as a one-time IV bolus injection
32867883|NCT04808622|Experimental|TSC 2.0 mg/kg|TSC 2.0 mg/kg given as a one-time IV bolus injection
32867884|NCT04808622|Experimental|TSC 2.5 mg/kg|TSC 2.5 mg/kg given as a one-time IV bolus injection
32867885|NCT04808622|Placebo Comparator|Placebo|7 mL normal saline given as a one-time IV bolus injection
32867886|NCT04787016|Experimental|Pilate training|The participants of this group perform pilate training along with conventional cricket training.
32867887|NCT04787016|No Intervention|Conventional training|The participants perform only conventional cricket training.
32867888|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
32867889|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
32867890|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
32867891|NCT04784832|Placebo Comparator|Sequence 1 - Control|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation No mental training
32867892|NCT04784832|Experimental|Sequence 1 - Training (same Task)|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
32867893|NCT04784832|Experimental|Sequence 1 - Training (similar task)|Motor task (Pretest and Posttests with a similar task in immediate post test) Transcranial magnetic stimulation Mental training
32867894|NCT04784832|Experimental|Sequence 1 - Training (different task)|Motor task (Pretest and Posttests with a different task in immediate post test) Transcranial magnetic stimulation Mental training
32867895|NCT04784832|Experimental|Sequence 2 - Mental|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
32867896|NCT04784832|Experimental|Sequence 2 - Physical|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
32867897|NCT04784832|Sham Comparator|Sequence 3 - Control 1|Mental Training Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
32867898|NCT04784832|Active Comparator|Sequence 3 - Control 2|Paired Associative Stimulation Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
32867899|NCT04784832|Experimental|Sequence 3 - Training (same task)|Paired Associative Stimulation Mental training (one task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
32867900|NCT04784832|Experimental|Sequence 3 - Training (different task)|Paired Associative Stimulation Mental training (two tasks) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
32867901|NCT04784832|Sham Comparator|Sequence 4 - Control|Transcranial magnetic stimulation Motor task Mental training
32867902|NCT04784832|Experimental|Sequence 4 - Cathodal|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
32867903|NCT04784832|Experimental|Sequence 4 - Anodal|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
32867904|NCT04784832|Experimental|Sequence 4 - Immobilization|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
32867905|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
33108719|NCT00446732|No Intervention|2|
33108720|NCT05426616|Active Comparator|Control group: Collagen membrane|(Xenoprotect, Nobel Biocare, Göteborg, Sweden)
32867906|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
32867907|NCT04784988|Experimental|PROPEL-like arm|Adynovate prophylaxis targeting a 12% FVIII through level based on PK assessment with my-PK-fit
33329930|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
33108721|NCT05426616|Experimental|Test group: titanium reinforced d-PTFE membrane|(Creos Syntoprotect,Nobel Biocare AB, Göteborg, Sweden)
33108722|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
33108723|NCT01222078|Experimental|otelixizumab|otelixizumab
33108724|NCT03277586|Experimental|Probio'Stick|
33108725|NCT03277586|Placebo Comparator|Placebo|
32867908|NCT04784988|Active Comparator|Control arm|standard treatment with plasma derived or recombinant products containing FVIII according to current guidelines
32867909|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
32867910|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
32867911|NCT04784676|Experimental|nanohybrid composite blocks|nanohybrid composite CAD/CAM blocks
32867912|NCT04784676|Active Comparator|ceramic blocks|ceramic CAD/CAM blocks emax
33108726|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
33108727|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
33108728|NCT02902536||Normal Controls|Patients without myasthenia
33108729|NCT04317157|Experimental|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
33108730|NCT04317157|Placebo Comparator|Placebo Clinical Trial|Participants will ingest placebo ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
33108731|NCT04317157|Experimental|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
33108732|NCT04317157|Placebo Comparator|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo ~45 minutes before the trial.
33108733|NCT04317157|Active Comparator|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
33108734|NCT04317157|No Intervention|Control|Participants will perform a baseline trial with no intervention.
33108735|NCT04318873|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
33108736|NCT04318873|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
33108737|NCT04317079|Active Comparator|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
33108738|NCT04317079|Active Comparator|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
33108739|NCT04317079|Placebo Comparator|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
33108740|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
33108741|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
33108742|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
33360611|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
33360612|NCT03929965|Experimental|advanced solid tumors with FGFR alteration|
33360613|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
33360614|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
32867913|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
32867914|NCT03002181|Experimental|Red Flag group|Red Flags education group.
32867915|NCT04869267|Experimental|ACT group|Participants in the intervention group will receive ACT intervention, consisting of four individual sessions (First session by face to face, the last three sessions by Wechat) of 60-90 min each (once/week), in addition to usual care.
32867916|NCT04869267|Other|Usual care group|Participants randomized to the control group will receive usual care, including treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge.
32867917|NCT04808154|Experimental|test drug|Powder for oral solution of SNP-630.
32867918|NCT04784910|Experimental|DWP14012 20mg|orally, once daily
32867919|NCT04784910|Active Comparator|Lansoprazole 15mg|orally, once daily
32867920|NCT01625013|Experimental|Synvisc-One|
32867921|NCT04808310|Active Comparator|Angiography|The indication to further coronary intervention will be based on angiographic diameter stenosis.
32867922|NCT04808310|Experimental|Quantitative flow ratio (QFR)|The indication to further coronary intervention will be based on QFR.
32867923|NCT00083551|Active Comparator|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
32867924|NCT00083551|Active Comparator|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
32867925|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
32867926|NCT05614206|Experimental|Toddlers at elevated likelihood of developing autism with autistic signs, with early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who receive an early intervention from 18 to 24 months
32867927|NCT05614206|No Intervention|Toddlers at elevated likelihood of developing autism with autistic signs, without early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who do not receive an early intervention
32867928|NCT05614206|No Intervention|Toddlers at elevated likelihood of developing autism without autistic signs who received monitoring|Toddlers at elevated likelihood of developing autism without clinical autistic signs who only received assessment and monitoring
32867929|NCT05614206|No Intervention|Typically developing toddlers who received monitoring|Typically developing toddlers who only received assessment and monitoring
32867930|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
32867931|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
32867932|NCT05473416|Experimental|1- McKenzie (Group A)|Back extension exercise. Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
32867933|NCT05473416|Experimental|2- Pilates (Group B)|Pelvic tilt exercise Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
32867934|NCT03933813|Experimental|IV Iron Sucrose|Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
32867935|NCT04833699|No Intervention|Control|Group A served as the control group who did not receive any intervention except our clinical standard postoperative care
32867936|NCT04833699|Experimental|Study|Group B served as the hot pack group that warm water (80 C) was put in a hot pack (Fig 1) and then placed on the patients umbilicus at 6, 12, and 18 h after the operation for 45 minutes in addition to clinical standard postoperative care.
32867937|NCT04765761|Active Comparator|PLMA with Introducer'|PLMA placed in position with the help of the introducer-tool and then the introducer-tool retained in place throughout the institution and duration of positive pressure ventilation.
32867938|NCT04765761|Active Comparator|PLMA without Introducer|PLMA placed in position with the help of the introducer-tool and then the introducer-tool removed before institution of positive pressure ventilation.
32867939|NCT01628523||All ED patients requiring mechanical ventilation|
32867940|NCT04808232|Experimental|health education and progressive muscle relaxation exercise|Health education and progressive muscle relaxation exercise training was given to women in this group.
32867941|NCT04808232|Experimental|progressive muscle relaxation exercise|Progressive muscle relaxation exercise training was given to women in this group.
32867942|NCT04808232|No Intervention|Control group|women in this group were not intervened.
32867943|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
32867944|NCT05473104|Experimental|experimental group|Teens and parents participate in the training once a week for 14 consecutive weeks in parallel groups.
32867945|NCT05473104|No Intervention|waiting-list group|Teens and parents participate in the training in a second moment, immediately after the experimental group concluded the program, once a week for 14 consecutive weeks in parallel groups.
32867946|NCT04259424|Experimental|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
32867947|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
32867948|NCT05177328|Experimental|ShA9 dominant and placebo non-dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of ShA9 applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of placebo applied to their contralateral arm (i.e. left arm for a right handed participant).
33040937|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
33040938|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
33040939|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
33329931|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
33329932|NCT04804306||Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients
33040940|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
33040941|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
33040942|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
33040943|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
33040944|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
33040945|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
33040946|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
33040947|NCT02019862||TRJ®|
33040948|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
33040949|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
33040950|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
33040951|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
33040952|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
33040953|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
33040954|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
33040955|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
33040956|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
33040957|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
33040958|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
33040959|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
33040960|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
33040961|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
33040962|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
33040963|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
33040964|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
33040965|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
33040966|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
33040967|NCT02020005|Experimental|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33040968|NCT02020005|Experimental|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33329933|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
33329934|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
33040969|NCT02020005|Experimental|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33040970|NCT02020005|Experimental|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33329935|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
33329936|NCT02434354|Experimental|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
33329937|NCT05553210|Experimental|Intervention group|The intervention group will get a 6-week therapist-guided online stress recovery intervention with an intervention plan.
33040971|NCT02020005|Experimental|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33040972|NCT02020005|Experimental|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
33040973|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
33040974|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
33040975|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
33040976|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
33040977|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
33040978|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
33040979|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
33040980|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
33040981|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
33040982|NCT02020161|Experimental|ATRA-Idarubicin|
33040983|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
33040984|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
33040985|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
33040986|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
33040987|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
33040988|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
33040989|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
33040990|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
32867949|NCT05177328|Experimental|ShA9 non-dominant and placebo dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of placebo applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of ShA9 applied to their contralateral arm (i.e. left arm for a right handed participant).
33329938|NCT05553210|Experimental|Control group|The control group will get a 6-week therapist-guided online stress recovery intervention without an intervention plan. The control group will participate in the program at the same time as the intervention group.
33329939|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
33329940|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
33329941|NCT05693454|Placebo Comparator|Control|local wound infiltration at the end of spine surgery with NaCl
33329942|NCT05693454|Active Comparator|Arm I|local wound infiltration at the end of spine surgery with Ropivacain
33329943|NCT05693454|Active Comparator|Arm II|local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
33329944|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
33329945|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
33040991|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
33040992|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
33040993|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
33040994|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
33040995|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
33040996|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
33040997|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
33040998|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
33040999|NCT02020343||Healthy|Not insulin resistant
33041000|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
33041001|NCT02020343||Type 2 diabetics|Type 2 diabetics
33041002|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
33041003|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
33041004|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041005|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041006|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041007|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041008|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041009|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
33041010|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
33041011|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
33041012|NCT02020421|Experimental|rTMS|Participants will receive real rTMS and sham tDCS
33041013|NCT02020421|Experimental|tDCS|Participants will receive real tDCS and sham rTMS
33041014|NCT02020421|Sham Comparator|Sham|Participants will receive both sham rTMS and sham tDCS
33041015|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
33041016|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
33041017|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
33041018|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
33041019|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
33041020|NCT02020486|Experimental|Group A|Experimental
33041021|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
33041022|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
33041023|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
33041024|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
33041025|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
33041026|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
33041027|NCT02020551|Placebo Comparator|saline spray application|Placebo group
33041028|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
33329946|NCT05549700|Experimental|Common fibular nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the common fibular nerve
33329947|NCT05549700|Experimental|Tibial nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the tibial nerve
33329948|NCT04796818|Experimental|Diagnostic (IVIM DWI)|Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.
33329949|NCT04783480|Active Comparator|Birthly plus standard of care|Women will receive a code to sign up for childbirth education classes through the Birthly platform. They will also participate in childbirth education at their own discretion.
33329950|NCT04783480|Placebo Comparator|Standard of Care|Women will not receive a code for the 3 Birthly courses. They will participate in childbirth education at their own discretion.
33329951|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
33329952|NCT05764018|Placebo Comparator|Normoxia-Placebo|Participants will be breathing room air, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
33329953|NCT05764018|Experimental|Normoxia-Caffeine|Participants will be breathing room air, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
33041029|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
33041030|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
33041031|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
33041032|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
33041033|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
33041034|NCT02020655||10 healthy volunteers|Shear- force model
33041035|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
33041036|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
33041037|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
33041038|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
33041039|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.~Hypocaloric diet"
33041040|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.~Hypocaloric diet"
33041041|NCT02020733|Other|balloon catheter|
33041042|NCT02020733|Other|metal cannula|
33041043|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
33041044|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
33041045|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
33041046|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
33041047|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
33041048|NCT02020772|Experimental|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
33041049|NCT02020772|Active Comparator|usual primary health care 1|usual care of musculoskeletal pain in general practice
33041050|NCT02020772|Experimental|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
33041051|NCT02020772|Active Comparator|usual primary health care 2|usual care of musculoskeletal pain in general practice
33041052|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
33041053|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
33041054|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
33041055|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
33041056|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
33041057|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.~Imagery with functional MRI initial. Imagery with PET-scanner initial."
33041058|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
33041059|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
33041060|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
33041061|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
32867950|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
32867951|NCT04177914|Active Comparator|ETV+CPC|Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus
32867952|NCT04177914|Active Comparator|Ventriculoperitoneal Shunt|Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus
32867953|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
32867954|NCT04122378|Experimental|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
32867955|NCT04122378|No Intervention|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
32867956|NCT05472636||Patients|Patients under the age of 18 who were admitted to the dermatology outpatient clinic between 2008-2021 and diagnosed with granuloma annulare
32867957|NCT05080608||Nerve injury|This is an interview study of patients with injury to the median, ulnar or digital nerve or brachial plexus injury.
32740833|NCT05097989|Experimental|LN Cohort: ALXN2050 180 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
32740834|NCT05097989|Experimental|LN Cohort: ALXN2050 120 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
32867958|NCT01629615|Experimental|BKM120|
32867959|NCT05472480||Chronic Venous Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
32867960|NCT05472480||Carotid Stenosis Patients|Consecutive patients admitted to Vascular Surgery Units.
32867961|NCT05472480||Abdominal Aortic Aneurysm Patients|Consecutive patients admitted to Vascular Surgery Units.
32867962|NCT05472480||Peripheral Artery Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
32867963|NCT05472402|Other|LADIES online planning focus groups|Participants will including up to 40 women who will participate in a single focus group to answer questions related to planning for modification of an existing in-person intervention for online delivery. Data from the focus groups will be used to modify the curriculum. Separately, a 12-person advisory board will be identified to provide input on the revised curriculum to assist with planning a future pilot study.
32867964|NCT04677777|Other|Standard of Care|Patients randomized to receive this treatment will receive standard of care appropriate for the condition.
32867965|NCT04677777|Experimental|PP-007|Patients randomized to receive this treatment will receive a single infusion of PP-007
32867966|NCT05472246|Experimental|VR group|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure.
32867967|NCT05472246|No Intervention|Control group|Control group will undergo the routine anesthesia procedure.
32867968|NCT01629771||Lymphatic Filariasis|
32867969|NCT01629771||Patients without Lymphatic Filariasis|
32867970|NCT05472168|Other|Obese|Age 18-55 years Obesity (BMI ≥30 kg/m2) Written informed consent Normosmia (defined by sniffin Sticks test)
32867971|NCT05472168|Other|Lean|Age 18-55 years Lean (BMI 18-25 kg/m2) Written informed consent Normosmia (defined by sniffin Sticks test)
32867972|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms once per day and topical DFMO to bilateral forearms once per day.
32867973|NCT04091022|Placebo Comparator|Placebo + Placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms once per day and placebo for topical DFMO to bilateral forearms once per day.
32867974|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
32867975|NCT01490918|Experimental|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
32867976|NCT01490918|Other|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
32867977|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
32867978|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
32867979|NCT04053504|Experimental|Intervention|Behavioral intervention delivered by parent peer leaders.
32867980|NCT04053504|No Intervention|Standard Care|Standard diabetes care
32867981|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
32867982|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
32867983|NCT04026048|Experimental|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
32867984|NCT04026048|Experimental|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
32867985|NCT05072184|Active Comparator|ESP block|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
32867986|NCT05072184|Sham Comparator|Control|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of saline on each side
32740835|NCT05097989|Placebo Comparator|LN Cohort: Placebo|Participants diagnosed with LN with an active flare will receive matched placebo in addition to standard-of-care background therapy.
32740836|NCT05097989|Experimental|IgAN Cohort: ALXN2050 180 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
33041062|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
33041063|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
33041064|NCT02020980||Post-stroke lower limb spasticity patients|
33041065|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
33041066|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
33329954|NCT05764018|Placebo Comparator|Hypoxia-Placebo|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
33329955|NCT05764018|Experimental|Hypoxia-Caffeine|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
33329956|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
33329957|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
33329958|NCT04839328|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
33041067|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
33329959|NCT04839328|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
33329960|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
33329961|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
33329962|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
33360615|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
33041068|NCT02021019|No Intervention|Usual Care|Usual care
33041069|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
33041070|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
33041071|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
33041072|NCT02021058|Experimental|Experimental Formula|Experimental Formula
33041073|NCT02021058|Other|Standard Formula|Standard Control formula
33041074|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
33041075|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
33041076|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
33041077|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
33041078|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
33041079|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
33041080|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
33041081|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
33041082|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
33041083|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
33041084|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
33041085|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
33041086|NCT02021162||Gilenya|MS patients taking Gilenya
33041087|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
33041088|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
33041089|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
33417862|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
33417863|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
33417864|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
33417865|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
33417866|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
33417867|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
33041090|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
32740837|NCT05097989|Experimental|IgAN Cohort: ALXN2050 120 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
33041091|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
32740838|NCT05097989|Placebo Comparator|IgAN Cohort: Placebo|Participants diagnosed with IgAN will receive matched placebo in addition to standard-of-care background therapy.
32740839|NCT04656587|Other|Standard Therapy (Control)|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
33041092|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
33041093|NCT02021201|Experimental|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
33041094|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
33041095|NCT02021227|No Intervention|Standard group|
33041096|NCT02021227|Other|Chair sitting group|
33041097|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
33041098|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
33041099|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
33041100|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:~459 mg of corn starch~6 mg of magnesium stearate~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.~Methods of administration: Oral.~Duration of treatment: 14 days"
33041101|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule~Composition: One capsule of 560 mg contains Lactibiane tolerance:~345 mg of corn starch~114 mg premix lactic~6 mg of magnesium stearate Excipients: magnesium stearate~Method of administration: Oral~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
33041102|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
33041103|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
33041104|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
33041105|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
33041106|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
33041107|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
33041108|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
33041109|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
33041110|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
33041111|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
33041112|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
33067759|NCT00135902|Active Comparator|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
33041113|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
33041114|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
33417868|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
33417869|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
33417870|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
33417871|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
33417872|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
33417873|NCT03131219|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing < 20 kg, for a total of 26 weeks of study treatment in the initial Evaluation Period.~After the Initial Evaluation Period, participants rolled over into an Extension Period in which all participant continued their weight-based maintenance dose until the product was registered or approved (in accordance with country specific regulation) or for up to 4.5 years, whichever occurred first."
33417874|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
33417875|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
33041115|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
33041116|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
33041117|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
33041118|NCT02021435|Experimental|Salt Substitute|salt substitute
33041119|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
33041120|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
33041121|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
33041122|NCT02021513|Placebo Comparator|Placebo|Olive Oil
33041123|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
33041124|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
33041125|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
33041126|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
33041127|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
33041128|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
33041129|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
33041130|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
33329963|NCT03785496|Experimental|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
33329964|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
33329965|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
33329966|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
33329967|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
33329968|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
33329969|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
33329970|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
33329971|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
33041131|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
33329972|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
33329973|NCT01376986|No Intervention|control|no access to the activation platform
33329974|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
33329975|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
33329977|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
33329978|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
33329979|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
33041132|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
33041133|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
33041134|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
33041135|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
33041136|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
33041137|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
33041138|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
33041139|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
33041140|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
33041141|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
33041142|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
33329980|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
33329981|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
33329982|NCT05693376||Intervention group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age > 65 years for male and >70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg and at least 1 major or ≥ 2 minor criteria. Major criteria: a) Carpal tunnel syndrom; b) Non-traumatic rupture of the biceps tendon; c) NT-proBNP > 1000 pg/ml; d) hs Troponin value above the 99th percentile without dynamic changes (≤ 20%). Minor criteria: a) Diastolic dysfunction (at least grade 2, E' < 10 cm/s); b) Sinus bradycardia/AV block/pacemaker; c) Atrial fibrillation.
33329983|NCT05693376||Control group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age > 65 years for male and >70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg.
33329984|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
33329985|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
33329986|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
33329987|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
33041143|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
33041144|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.~Otheriwize normal primary PCI."
33067760|NCT00135902|Placebo Comparator|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
33329988|NCT04294576|Experimental|Arm 1; BJ-001|Phase 1a Part 1, Part 2, and Part 4: dose escalation for BJ-001 as single agent
33329989|NCT04294576|Experimental|Arm 2; BJ-001 and pembrolizumab|"Phase 1a Part 3 and Part 5: dose escalation for BJ-001 in combination with Pembrolizumab~Phase 1b: expansion cohorts for the combination of BJ-001 and pembrolizumab"
33329990|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
33329991|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
33329992|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
33329993|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
33329994|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
33329995|NCT04637386|Active Comparator|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
33329996|NCT04637386|Active Comparator|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
33329997|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
33329998|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
33329999|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
33330000|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
33330001|NCT01308684|Experimental|1|
33330002|NCT01308684|Experimental|2|
33330003|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures.~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
33330004|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from chin to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
33330005|NCT05613114|Experimental|Medication|Dalfampridine plus physiotherapy
33330006|NCT05613114|Placebo Comparator|No Medication|Placebo plus physiotherapy
33330007|NCT04596514|Experimental|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
33330008|NCT04596514|Active Comparator|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
33330009|NCT05691348|Experimental|Ambulatory pathway|
33330010|NCT05691348|Active Comparator|Conventional hospitalisation|
33330011|NCT01378624|Experimental|Bronchoscopy|
33330012|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
33330013|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
33330014|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
33330015|NCT05763940|Experimental|OmegaBoost (QD)|Participants assigned the study supplement OmegaBoost, taken once daily (QD).
33330016|NCT05763940|Experimental|OmegaBoost (BID)|Participants assigned the study supplement OmegaBoost, taken twice daily (BID).
33330017|NCT05763940|Active Comparator|Nature Made (soft gel)|Participants assigned the Nature Made (soft gel), taken twice daily.
33330018|NCT05763940|Active Comparator|Nature Made (gummy)|Participants assigned the Nature Made (gummy), taken twice daily.
33330019|NCT05694780|Experimental|Experimental|Women in the intervention group will receive standard obstetric care plus the STEP intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
33330020|NCT05694780|No Intervention|Control|Women in the control group will receive standard obstetric care.
33330021|NCT04436224|Experimental|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
33330022|NCT04436224|Active Comparator|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
33330023|NCT04436224|Active Comparator|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
33330024|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
33067761|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
33330025|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
33330026|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
33330027|NCT04541446|Experimental|Residents to receive Dynamic Haptic Robotic Training|
33067762|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
33330028|NCT04541446|Experimental|Residents to receive Advanced Dynamic Haptic Robotic Training|
33067763|NCT04726670||A Comparison of Pain Levels|A Comparison of Pain Levels at different time intervals according to the Irrigation Activation Protocols
33330029|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
33330030|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
33067764|NCT04726670||The evaluation of postoperative pain (Mean Rank) within the group according to time periods|The evaluation of postoperative pain (Mean Rank) within the group according to time periods
33330031|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
33067765|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
33067766|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
33067767|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
33067768|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
33067769|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
33067770|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
33067771|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
33067772|NCT00159510|Active Comparator|MB alone|Single methylene blue used
33067773|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
33067774|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
33067775|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
33067776|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
33067777|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
33067778|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
33067779|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
33067780|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
33041145|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
33330032|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
33330033|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
33330034|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
33330035|NCT04524598|Experimental|Limbix Spark|A 5 week CBT-based intervention
33330036|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
33330037|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
33330038|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
33041146|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
33041147|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
33041148|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
33041149|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
33041150|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
33041151|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
33041152|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
33041153|NCT02021838||California|Lethality Assessment Program
33041154|NCT02021838||North Carolina|Lethality Assessment Program
33041155|NCT02021838||Ohio|Domestic Violence High Risk Team
33041156|NCT02021838||Illinois|Lethality Assessment Program
33041157|NCT02021838||Michigan|Lethality Assessment Program
33041158|NCT02021838||Tennessee|Lethality Assessment Program
33041159|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
33041160|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
33041161|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
33041162|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
33041163|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
33041164|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
33041165|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
33041166|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
33041167|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
33041168|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
33041169|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
33041170|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
33041171|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041172|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33330039|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
32867987|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
32867988|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
32867989|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
32867990|NCT04981626||Control|"Females~Age : matched for the AN group~No present or past eating disorders~No past or current psychotic disorders~No current substance abuse or dependence.~No current psychiatric medication"
32867991|NCT04981626||AN group|"Females~16 years ≤ Age ≤ 25 years~Diagnostic of AN according to DSM-5 criteria~No past or current psychotic disorders~No current substance abuse or dependence (excluding tobacco).~No current psychiatric medication"
32867992|NCT05613972|Experimental|Brief Suicide and Trauma Therapy (BSTT)|This novel suicide intervention integrates Brief Skills for Safer Learning (B-SfSL) with trauma therapy. BSTT incorporates the guiding principles of taking a non-pathologizing approach to treatment, emphasizing safety, attending to the therapeutic relationship, empowering clients, and incorporating solution-focused concepts.
32867993|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
32867994|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
32867995|NCT03827460|Experimental|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
32867996|NCT03827460|Experimental|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
32867997|NCT03827460|Experimental|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
32867998|NCT03794388|Experimental|Arm CAPSAICINE topical|"Application of capsaicin patches at 8% on the painful area~1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later."
32867999|NCT03794388|Active Comparator|Arm PREGABALINE|"Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.~An interval of 3 to 7 days must be observed between each dose increase."
32868000|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
32868001|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
32868002|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
32868003|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
32868004|NCT03753360|Other|Active Control Group|relaxing music
32868005|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
32868006|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
32868007|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
32868008|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
32868009|NCT04426422|Experimental|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
32868010|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
33330040|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
33360616|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
33330041|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
33330042|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
33330043|NCT05074446|Experimental|intensivist in the experimental group|Stereotype threat manipulation will be performed on the intensivist in the experimental group just before they are taken into the testing room.
33330044|NCT05074446|No Intervention|intensivist in the control group|The intensivist in the control group will not be given any prior information.
33330045|NCT05074446|Experimental|non-intensivist in the experimental group|Stereotype threat manipulation will be performed on the non-intensivist in the experimental group just before they are taken into the testing room.
33041173|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041174|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041175|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041176|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041177|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041178|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041179|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041180|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
33041181|NCT02021994||Arm Automatic Electronic BPM|
33330046|NCT05074446|No Intervention|non-intensivist in the control group|The non-intensivist in the control group will not be given any prior information.
33330047|NCT04254562|Experimental|Experimental Group: HYPE Services|The experimental arm will receive the HYPE intervention for 12 months.
33330048|NCT04254562|Active Comparator|Control Group: Enhanced Academic Services as Usual|"The control arm will receive a special personalized packet of resources available on campus and off-campus within a 10-mile radius, as enhanced academic services as usual."
33330049|NCT05694624||Sepsis patients|Patients admitted to the intensive care unit with sepsis diagnosed or suspected
33330050|NCT05694624||Surgical patients|Previously healthy patients who are operated for colon cancer with laparoscopic technique.
33041182|NCT02021994||mercury sphygmomanometer|
33041183|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
33041184|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
33041185|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
33041186|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
33041187|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
33041188|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
33041189|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
33041190|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
33041191|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
33041192|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
33041193|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
33041194|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
33041195|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
33041196|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
33041197|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
33041198|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
33041199|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
33041200|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
33041201|NCT02022215|Experimental|ME1111 Solution, Low strength|
33041202|NCT02022215|Experimental|ME1111 Solution, High strength|
33041203|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
33041204|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
33041205|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
33041206|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
32868011|NCT05471778|Experimental|comedy movie group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the comedy group on the first evening after surgery. 25-minute comedy film was watched. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
33041207|NCT02022254|Experimental|Semaglutide administrations|
32868012|NCT05471778|Experimental|Music group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the music group on the first evening after surgery. 25 minutes of music (nature sound) was played. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
32868013|NCT05471778|No Intervention|Control group|In the follow-up of the patient, no application was made other than clinical protocols. Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the control group on the first evening after surgery. No intervention was made. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
33041208|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
33041209|NCT02022267||control group|healthy children of employees of our hospital
33330051|NCT04247308|Experimental|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
33330052|NCT04247308|Active Comparator|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
33330053|NCT05688384|No Intervention|Control arm (LA)|Patients in this arm will undergo SVP insertion in local anesthesia (LA)
33330054|NCT05688384|Active Comparator|Study arm (LA+PCS)|Patients in this arm will undergo SVP insertion in local anesthesia and PCS (LA+PCS)
33041210|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
33041211|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
33041212|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
33041213|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
33041214|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
33041215|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
33041216|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
33041217|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
33041218|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
33041219|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
33041220|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
33330055|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
33108743|NCT05657431|Experimental|group 1 (Ylang ylang oil)|A square cotton ball impregnated with a drop of ylang-ylang oil was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
33108744|NCT05657431|Experimental|group 2 (Lemon oil)|A square cotton ball impregnated with a drop of lemon oil was placed in the participants randomized to group 2 (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
33108745|NCT05657431|Placebo Comparator|group 3 (Control)|A square cotton ball impregnated with a drop of salin was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
32868014|NCT04573101|No Intervention|Before intervention|Participants answer questionnaire before any stimulus is given.
32868015|NCT04573101|No Intervention|After intervention|Participants answer questionnaire after the series of stimulus is given.
33108746|NCT04699214|Experimental|Endostar combined with chemotherapy AI|"Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.~AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W."
33108747|NCT04699214|Active Comparator|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
33330056|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
32868016|NCT04573101|Experimental|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
32868017|NCT04573101|Experimental|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
33360617|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
32868018|NCT04573101|Experimental|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
32868019|NCT04573101|Experimental|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
32868020|NCT04573101|Experimental|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
32868021|NCT04573101|Experimental|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
32868022|NCT04573101|Experimental|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
32868023|NCT04573101|Experimental|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
32868024|NCT04573101|Experimental|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
32868025|NCT04573101|Experimental|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
32868026|NCT04573101|Experimental|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
32868027|NCT04573101|Experimental|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
32868028|NCT04573101|Experimental|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
32868029|NCT04573101|Experimental|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
32868030|NCT04573101|Experimental|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
32868031|NCT04573101|Experimental|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
32868032|NCT04573101|Experimental|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
32868033|NCT04573101|Experimental|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
32868034|NCT04573101|Experimental|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
32868035|NCT04573101|Experimental|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
32868036|NCT04573101|Experimental|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
32868037|NCT04573101|Experimental|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
32868038|NCT04573101|Experimental|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
32868039|NCT04573101|Experimental|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
32905021|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
33417876|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
33417877|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
33417878|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
32740840|NCT04656587|Experimental|Standard Therapy plus BPAP|Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
32740841|NCT05085977|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
32740842|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
32740843|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
32740844|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
32740845|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
32740846|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD > 20) at the time of listing (n=500)
32740847|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
32740848|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
32740849|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
32740850|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
32740851|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
32740852|NCT04490213||hydrofibre, Aquacel|Study participants were previously treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
32740853|NCT04490213||polyurethane foam, Allevyn|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
32740854|NCT04490213||porcine xenograft, Mediskin|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
32740855|NCT05728437|Experimental|Study group|This group includes 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment.
32740856|NCT05728437|No Intervention|Control group|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
32740857|NCT05728359||Cardiogenic shock and MI|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically (ie. inotropes +/- intra aortic balloon pump only). N=50
32740858|NCT05728359||Cardiogenic shock and MI wtih ECMO|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with ECMO (+/- LV unloading device). N=50
32740859|NCT05728359||Cardiogenic shock and MI wtih Impella|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with Impella. N=50
32740860|NCT05728359||MI without cardiogenic shock|Patients presenting with acute myocardial infarction and cardiogenic shock as a control comparator
32740861|NCT05728359||Non ischemic Cardiogenic Shock ie myocarditis|Patients presenting with myocarditis and cardiogenic shock as a control comparator
32740862|NCT04562597|Placebo Comparator|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
32740863|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
32740864|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
32740865|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
32868040|NCT05471700|Experimental|Azacitidine combined with Venetoclax|"Each course is 28 days long. Subjects with newly diagnosed AML receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. If concomitantly receiving azoles, the dose of Venetoclax will be adjusted according to the instructions. At the same time patients will receive Azacitidine 75mg/m2 subcutaneous on Days 1-7.The induction therapy includes 1-2 cycle until subjects get remission.~Once complete remission, subjects will receive consolidation. Azacitidine combined with Venetoclax or middle to high dose of arabinoside based chemotherapy would be given at the discretion of the physician."
32868041|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
32868042|NCT01490450|Experimental|BMS-945429 (25mg)|
32868043|NCT01490450|Experimental|BMS-945429 (100mg)|
32868044|NCT01490450|Experimental|BMS-945429 (200mg)|
32868045|NCT04350255|Active Comparator|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
32868046|NCT04350255|Active Comparator|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
32868047|NCT04976868||Pimecrolimus Cream 1% - Elidel®|Elidel® as prescribed within routine clinical practice
32868048|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
32868049|NCT05611944|Experimental|I&S arm|The 150 participants of the experimental arm will be assigned to the I&S group and they will be inserted bilateral Nelton drains of 24 sizes in the subcutaneous space after the closure of the rectus sheath. Their wound will be irrigated with 500cc Normal saline at running speed followed by suction for a full day. The procedure will be repeated for three consecutive days. The drains will be removed on the fourth postoperative day.
32868050|NCT05611944|No Intervention|control|The 150 participants of the non-intervention group will be assigned to the control arm, The wound will be closed by interrupted mattress stitches without the insertion of subcutaneous drains.
32868051|NCT04076150|Experimental|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
32868052|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
32868053|NCT05466318|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
32868054|NCT05466318|Active Comparator|BEAM|Treated with BCNU, etoposide, cytarabine and melphalan (BEAM) therapy followed by autologous hematopoietic stem cell transplantation.
32868055|NCT05464914|No Intervention|Conventional upper immediate denture|Conventional upper immediate denture without any surgical lining
32868056|NCT05464914|Active Comparator|Upper immediate denture lined by surgical dressing|Upper immediate denture lined by surgical dressing using CEO Pack dressing
32868057|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
32868058|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
32868059|NCT05611866|Experimental|Fecal Microbiota Transplantation|Recruited patients will receive Fecal Microbiota Transplantation
32868060|NCT04928664|Active Comparator|Liposoaml Bupivacaine (LB) Group|Intervention group
32868061|NCT04928664|Experimental|Standard Bupivacaine (SB) Group|Control group
32868062|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
32868063|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
32868064|NCT04340154|Experimental|chimeric antigen receptor T cell treatment|
32868065|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
32868066|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
32868067|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
32868068|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
33041221|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
33041222|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
33041223|NCT02022449|No Intervention|Control|participants only complete assessments
33360618|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
33360619|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
33360620|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
33360621|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
33360622|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
33360623|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
33360624|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33041224|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
33041225|NCT02022462|Experimental|Health Navigation|Up to 151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
33041226|NCT02022462|Other|Waitlist Control|Up to 146 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (n = 73, 6 month waitlist with treatment as usual then they will receive the intervention) or immediate intervention with the Bridge (n = 73). Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
33041227|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
33041228|NCT02022475|Placebo Comparator|Placebo|similar appearance
33041229|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
33041230|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
33041231|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
33041232|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
33041233|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
33041234|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
33330057|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
33041235|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
33041236|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
33041237|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
33041238|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
33041239|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
33041240|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
33041241|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
33041242|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
33041243|NCT02022553|Experimental|rectal cancer, surgery|
33041244|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
33041245|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
33041246|NCT02022605|Experimental|Hands-on EMS training group|
33041247|NCT02022605|Active Comparator|Standard training group|
33041248|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
33041249|NCT02022683|No Intervention|Standard of Care|Patients are given Standard Medical Care
33041250|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
33041251|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
33041252|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
33041253|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
33041254|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
33041255|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
33041256|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
33041257|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
33330058|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.~Inspiratory muscle training~The training program contains strengthening exercises on the diaphragm muscle."
33360625|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33360626|NCT01225237|Experimental|ramosetron group|
33360627|NCT01225237|Placebo Comparator|Placebo group|
33360628|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
33360629|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
33330059|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
33330060|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
33041258|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
33330061|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
33330062|NCT01378468||Patients with first ischemic stroke|
33330063|NCT05687292||CDSS Ventilator Weaning Group|This group will be exposed to the CDSS to inform weaning and discontinuation of mechanical ventilation.
33330064|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
33330065|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
33330066|NCT05687058|Experimental|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|All participants undergoing thrice-weekly hemodialysis (HD) on the Monday-Wednesday-Friday (MWF) schedule will be assigned to the empagliflozin 25 mg thrice-weekly post-hemodialysis dosing arm (Group I).
33330067|NCT05687058|Experimental|Empagliflozin 10 mg daily dosing|Patients undergoing thrice-weekly hemodialysis (HD) on the Tuesday-Thursday-Saturday (TTS) schedule, patients on twice-weekly HD, or patients on peritoneal dialysis will receive empagliflozin 10 mg daily (Group II).
33330068|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
33041259|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
33041260|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
33041261|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
33041262|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
33041263|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
33041264|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
33041265|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
33330069|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
33330070|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
33330071|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
33041266|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
33041267|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab 21 day cycles of carboplatin, paclitaxel, and bevacizumab
33041268|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
33041269|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
33041270|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
33041271|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
33041272|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
33041273|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
33041274|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
33041275|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
33330072|NCT05694546|Experimental|Community Health Worker Post-Discharge Intervention|This group will be offered a community-based visit from a community health worker following hospital discharge.
33041276|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
33041277|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
33041278|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
33041279|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
33041280|NCT02023086||FABRY group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~OSOME (oxygen flow at the optic nerve head measurement)~Tropicamide"
33330073|NCT05763784|Experimental|Pelvic Tightrope fixation|Theses patients will be treated with Tightrope for their traumatic pubic symphysis diastasis
33330074|NCT01308996|Experimental|INFUSE® Bone Graft|
33330075|NCT01308996|Active Comparator|Autogenous bone graft|
33330076|NCT01378312|Placebo Comparator|Placebo Arm|
33330077|NCT01378312|Active Comparator|AERAS 402 Arm|
33041281|NCT02023086||CONTROL group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~oxygen flow at the optic nerve head measurement (OSOME)~Under tropicamide"
33041282|NCT02023138|Active Comparator|Focus group|
33041283|NCT02023138|Experimental|Wiki|
33330078|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
33041284|NCT02023164|Experimental|Test Drug|10 mg/mL, 1 mL
33041285|NCT02023164|Active Comparator|Control|50 mg/mL, 1 mL
33041286|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
33041287|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
33041288|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
33041289|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
33041290|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
33041291|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
33041292|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
33041293|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
33041294|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
33041295|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
33041296|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
33041297|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
33041298|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
33041299|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
33041300|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
33041301|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
33041302|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
33041303|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
33041304|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
33041305|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
33041306|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
33041307|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
33041308|NCT02023359||Treatment|Everolimus and exemestane
33041309|NCT02023372|Other|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
33041310|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
33041311|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
33041312|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
33330079|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
33436474|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
33041313|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
33041314|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
33041315|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
33041316|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
33041317|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
33041318|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
33041319|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
33041320|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
33041321|NCT02023489|Other|Type 2 Diabetes Mellitus|
33041322|NCT02023489|Other|Insulin sensitive volunteers|
33041323|NCT02023489|Other|prediabetic subjects|
33041324|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
33041325|NCT02023489|Other|Type 1 diabetes mellitus|
33041326|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
33041327|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
33041328|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
33041329|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
33041330|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
33041331|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
33041332|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
33041333|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
33041334|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
33041335|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
33041336|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
33041337|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
33041338|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
33041339|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
33041340|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
33041341|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
33041342|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
33041343|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
33041344|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
33041345|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
33041346|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
33041347|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
33041348|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
33041349|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
33041350|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
33041351|NCT02023723|Experimental|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
33041352|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
33330080|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
33330081|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
33041353|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
33041354|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
33041355|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
33041356|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
33041357|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
33041358|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg~Intervention: Biological: Pneumostem®"
33041359|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
33041360|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
33041361|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
33041362|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
33041363|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
33041364|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
33041365|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
33041366|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
33041367|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
33041368|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
33041369|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
33041370|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
33041371|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
33041372|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
33041373|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
33041374|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
33041375|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
33041376|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
33041377|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
33041378|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:~4L split polyethylene glycol solution~split magnesium citrate/sodium picosulphate preparation regimen"
33041379|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
33041380|NCT02024035||Tomotherapy|
33041381|NCT02024035||Arc'therapy Vmat|
33041382|NCT02024035||Arctherapy Rapid'Arc|
33041383|NCT02024048||Pregnant|OCT
33041384|NCT02024048||Control|OCT
33330082|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.~Oral surgery procedures Suturing End of procedure"
33330083|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
33330084|NCT00706420|Experimental|1|Islet cell transplantation alone
33330085|NCT05678790|Experimental|Balance and Coordination|Since it is a case study, there will be only one group in the study.
33330086|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
33330087|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
33330088|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
33330089|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
33330090|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
33041385|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
33041386|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
33041387|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
33041388|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.~Intervention: a fasted venous blood sample is taken before PET-scan"
33041389|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.~Intervention: fasted venous blood sample"
33041390|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
33041391|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
33041392|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
33041393|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
33041394|NCT02024152|Experimental|JDP-205 IV high dose|
33041395|NCT02024152|Experimental|JDP-205 IV low dose|
33041396|NCT02024152|Experimental|JDP-205 IM high dose|
33041397|NCT02024152|Active Comparator|Control|
33041398|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
33041399|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
33330091|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
33330092|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
33330093|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
33330094|NCT04083274|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
33417879|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
33417880|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
33417881|NCT02296801|Other|Combined Groups B+D+C|Combined data
33041400|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
33041401|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
33417882|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
33417883|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
33417884|NCT02085434|Experimental|FITLINE practice-based referral program|
33417885|NCT02085434|No Intervention|Contemporaneous control|
33417886|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
33041402|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
33041403|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
33041404|NCT02024269|Experimental|Adipose Stem Cells|
33041405|NCT02024282|Other|usual care|
33041406|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
33041407|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
33041408|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
33041409|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
33041410|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
33041411|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
33041412|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
33041413|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
33041414|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
33041415|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
33041416|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
33041417|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
33041418|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
33041419|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
33041420|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
33041421|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
33041422|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
33041423|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
33041424|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
33041425|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
33041426|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
33041427|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
33436475|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
33041428|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
33041429|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
33041430|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
33041431|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
33041432|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
33041433|NCT02024503||Control group|Healthy Volunteers.
33041434|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
33041435|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
33330095|NCT04083274|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
33041436|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen."
33041437|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to 50mg doses is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
33041438|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
33041439|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
33041440|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
33041441|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
33041442|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
33041443|NCT02024594|No Intervention|control|No intervention
33041444|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
33041445|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
33041446|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
33041447|NCT02024659|Experimental|budesonide|
33041448|NCT02024659|Placebo Comparator|placebo|
33041449|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
33041450|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
33041451|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
33041452|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
33041453|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
33041454|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
33108748|NCT04699214|Placebo Comparator|Observation group|"The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.~Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end."
33108749|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
33108750|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
33108751|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
33108752|NCT03277235|No Intervention|Control|Usual care
33108753|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
33108754|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
33108755|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
33330096|NCT03787056|Other|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
33330099|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
33330100|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
33330101|NCT04244656|Experimental|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
33330102|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
33330103|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
33330104|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
33330105|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
33330106|NCT04130854|Experimental|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
33360630|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
33436476|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
33108756|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
33108757|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
33108758|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
33108759|NCT05342701|Experimental|CHAMP-ASP|"CHAMP, is a mastery climate motor skills intervention, that provides children the opportunity to establish behaviors that reinforce decision-making while participating in a motor activity tasks. Children will participate in CHAMP for 35 minutes/day 3-4 days per week for 19 weeks.~Each 35-min session consists of three parts:~3-5 min of motor skill introductory activity that includes a group motor activity, the teaching of the lesson that includes a demonstration and understanding of developmentally appropriate learning clues;~25 min of motor skill instruction and practice (i.e., 'active motor engagement'), participants will be encouraged to move through 3-4 motor activity stations that align with the TARGET structure; and~3 -5 min motor skill closure activity that involves a review of the lesson and critical elements."
33108760|NCT05342701|No Intervention|Control - Standard of Practice|The Control (standard of practice) condition will be the school typical ASP and will be implemented according to the existing procedures.
33108761|NCT05657392|Experimental|Inhibitory repetitive Transcranial Magnetic Stimulation|All patients will receive inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency. The contralesional primary motor cortex region will be stimulated with a Neurosoft-Neuro MS/D device. There will be a total of 10 treatment sessions over a 2-week period. Before each intervention, the resting motor threshold (rMT) value will be determined. rMT will be detected by obtaining a motor-evoked potential of >50 μV amplitude on EMG recording of the contralateral first dorsal interosseous muscle in at least 5 out of 10 stimulations to the primary motor cortex. 90% of the motor threshold will be set in the stimulation. Each stimulation is planned for a total of 20 minutes and a total of 1200 pulses in the form of 1 Hz stimulation.
33108762|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
33108763|NCT01221181|Experimental|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
33108764|NCT05657314|Active Comparator|Comparator|15 grams of pea protein dissolved in 12 ounces of water.
33108765|NCT05657314|Experimental|Active|15 grams of pea protein + probiotic blend (1 billion CFU/capsule - blend of Lactobacillus rhamnosus, Lactobacillus acidophilus, Saccharomyces boulardii, and Bifidobacterium breve) dissolved in 12 ounces of water.
33108766|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
33108767|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
33108768|NCT05657236|Other|control group|
33108769|NCT05657236|Experimental|Experimental group|
33108770|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
33108771|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
33108772|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
33108773|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
33108774|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
33108775|NCT04317001|Active Comparator|Active treatment with modafinil|active intervention
33108776|NCT04317001|Placebo Comparator|Placebo|placebo intervention
33108777|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
33108778|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
33108779|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
33108780|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
33108781|NCT05426499||Patients requiring cefotaxime treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
33108782|NCT05426499||Patients requiring meropenem treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
33108783|NCT05426499||Patients requiring fluconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
33330107|NCT04130854|Active Comparator|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
33330108|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
33330109|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
33330110|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
33330111|NCT03784560||study group|anesthesia residents with 24 hours working shift
33330112|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
33436477|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
33108784|NCT05426499||Patients requiring isavuconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
33108785|NCT05426499||Patients requiring anidulafungin treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
33108786|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
33108787|NCT00446810|Active Comparator|A1|Benfotiamine
32868069|NCT04875390|Other|group E|Intraoperative Erector spina plane block ( 0.3 ml/kg bupivacaine 0.25% at thoracic level 7 and 0.3 ml/kg bupivacaine 0.25% bupivacaine at thoracic level 11, totaling 0.6 ml/kg of 0.25% bupivacaine) will be performed after the surgery is completed.
33108788|NCT00446810|Active Comparator|A2|
33108789|NCT05657197|Experimental|Intervention (exercise) group|The patients in the intervention group will follow a personalised and intensive exercise program.
33108790|NCT05657197|Other|Control group|The patients in the control group will receive usual care.
33108791|NCT05464420|Experimental|V116 Lot 1|Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
33108792|NCT05464420|Experimental|V116 Lot 2|Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
33108793|NCT05464420|Experimental|V116 Lot 3|Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
33108794|NCT05464420|Active Comparator|PPSV23|Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
33108795|NCT05426187||Group 1|Women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso
33108796|NCT05426187||Group 2|Women of the same age and nulligravid who did not participate in the phase 1b trial
33108797|NCT05426187||Group 3|Women of the same age and primigravid who did not participate in the phase 1b trial
33108798|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
33108799|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
33108800|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
33108801|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
33108802|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
33330113|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
33330114|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
33330115|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
33330116|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
33330117|NCT04749108|Experimental|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
33108803|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
33108804|NCT05657158||Brolucizumab|brolucizumab in routine clinical practice
33108805|NCT01220167|Experimental|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
33108806|NCT01220167|Experimental|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
33108807|NCT01220167|Experimental|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
33108808|NCT02901912||Active|Women who perform at least 3h of physical activity per week
33108809|NCT02901912||Sedentary|Women who did not perform any kind of exercise
33108810|NCT05657119|Experimental|FSN Intervention|"Participate in a short 20-30-minute motivational interviewing (MI) session that discusses the person's goals and strengths related to keeping loved ones safe through safe firearm storage (e.g. making one's home safer to protect the youth or other family living there) and supporting wellness (i.e. mental health promotion), about the benefits of safer firearm storage practices (e.g. enhancing youth safety or avoiding youth harm), and then picking out safe storage devices and wellness resources to take home as 'cues for action'.~Receive 4-weeks of text messages tailored by their survey responses (1x to 4x weekly depending on baseline survey and baseline structured interview responses). They may opt out at any time."
33041455|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
33041456|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
33041457|NCT02024789|Placebo Comparator|Placebo|
33041458|NCT02024789|Experimental|RG1662 120 mg bid|
33041459|NCT02024789|Experimental|RG1662 240 mg bid|
33041460|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
33041461|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
33041462|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
33041463|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
33041464|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
33041465|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
33041466|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
33041467|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
33041468|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
33041469|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
33041470|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
33041471|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
33330118|NCT04749108|Active Comparator|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
33330119|NCT04116970|Experimental|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
33041472|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
33330120|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
33330121|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
33330122|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
33330123|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
33330124|NCT05694390|Experimental|Experimental group: The group applied sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed.
33436478|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
33041473|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
33041474|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
33041475|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
33041476|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
33041477|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
33041478|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
33041479|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
33041480|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
33041481|NCT02025010|Experimental|abiraterone acetate|"Participants will be treated with four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) orally on 28-day cycles. For participants who experience persistent or severe mineralocorticoid excess or have PSA progression, prednisone 5 mg by mouth twice daily will be added.~Patients will be treated until radiographic disease progression and unacceptable AE or taken off study for other reason."
33041482|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
33041483|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
33041484|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
33041485|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
33041486|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
33041487|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
33041488|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
33041489|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
33330125|NCT05694390|No Intervention|Control group: The group applied fixed with a tape (blaster)|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the control group, the catheter was fixed with a tape (blaster), routinely used in the clinic, and was monitored hourly until the catheter was removed.
33330126|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
33330127|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
33330128|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
33330129|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
33330130|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
33041490|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
33041491|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
33041492|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
33041493|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
33041494|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
33041495|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
33041496|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
33041497|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
33041498|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
33041499|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
33041500|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
33041501|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
33041502|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
33041503|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
33041504|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
33041505|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
33330131|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
32868070|NCT04875390|Other|group L|Intraoperative local infiltration (0.6 ml/kg of 0.25% bupivacaine will be given to the wound lips at the end of the surgery.
32868071|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
32868072|NCT05613894|Experimental|Dose Escalation (Part 1)|Part 1 will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and/or recommended dose and schedule
32868073|NCT05613894|Experimental|Dose Expansion Cohort (Part 2)|Expansion Phase to assess identified MTD and schedule from Part 1.
32868074|NCT00081497|Experimental|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
32868075|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
32868076|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
32868077|NCT05611788|Experimental|Structure Learning Training|The intervention group will receive structure learning training that tap on their ability to extract patterns from prior stimuli presentations to make predictions. Participants will be presented with visual sequences of symbols determined by frequency statistics and upon mastery, more complex context-based statistics. No feedback will be provided and participants are trained in an adaptive manner
32868078|NCT05611788|No Intervention|Passive Control|The passive control group will not receive any intervention but will receive the same pre-post cognitive-behavioural and neuroimaging intervention assessments.
33330132|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
33330133|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
32868081|NCT05613816||Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
32868082|NCT04839822|Experimental|Intervention Arm: Psychoeducation with elements of CBT & mood chart.|Patients will receive full access to edupression.com® immediately after inclusion. This intervention includes all medical mechanisms of action of edupression.com®: Psychoeducation with elements of CBT (learning content and exercises) and a mood chart (depression symptom monitoring).
32868083|NCT04839822|Active Comparator|Active control arm: (occupational) interventions and progress monitoring.|These patients will also receive an edupression.com® account with different content. This content will be limited to medically useful tips, that have have not been shown to be effective in improving depressive symptoms in RCTs. Patients of both arms will be instructed to use chat functions to contact study personnel and to fill out questionnaires and tests to collect outcome and additional measures.
32868084|NCT05613738|Experimental|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
32868085|NCT05613738|Experimental|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
32868086|NCT05613738|Experimental|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
32868087|NCT05433246|No Intervention|Control Group|The patients received routine care.
32868088|NCT05433246|Experimental|Massage therapy group|The patients in the massage group were given classical massage for 2 consecutive days in each chemotherapy cycle (with an interval of two weeks). Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
32868089|NCT04159467|Active Comparator|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
32868090|NCT04159467|Experimental|Grupo 2 - low calorie diet + PFMT (experimental)|"The experimental group will receive supervised pelvic floor muscle training in addition to a hypocaloric diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary contractions of the pelvic floor muscles. The 4 sets will be performed in 2 different positions (sitting and standing). Once a month, they will receive a supervised in-person session using the same protocol described above, in the other weeks of the month will receive a session supervised by telephysiotherapy once a week. In addition to supervised sessions, women will be encouraged to perform the protocol three more days a week. In addition, they will be instructed to perform the knack maneuver."
32868091|NCT00081263|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
33330134|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
33330135|NCT03784092|No Intervention|control|
33330136|NCT03784092|Experimental|feedback|
33330137|NCT05694312|Experimental|Ibrutinib|Patients will receive ibrutinib 420 mg/day orally for up to 12 cycles of 28 days.
33330138|NCT04108234|Experimental|Treatment group A|HR071603,nasal spray,dose escalation.
33330139|NCT04108234|Placebo Comparator|Treatment group B|Placebo, nasal spray
33108811|NCT05657119|Active Comparator|Comparison|Participate in a home safety discussion and take home a carbon monoxide detector, a carbon monoxide info sheet, a gun storage pamphlet, and a mental health resource magnet.
33108812|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
33108813|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
33108814|NCT00447044|Experimental|3|Resistance exercise.
33108815|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
33330140|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
33330141|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
33330142|NCT01378000||UFH,once a day|
33330143|NCT01378000||heparin Calcium,every 12 hours|
33330144|NCT01378000||dextran,Salviae,once a day|
33330145|NCT01378000||UFH,continuous intravenous infusion,|
33330146|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
33330147|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
33330148|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
33330149|NCT01310634|Other|Conventional treatment|Usual educational program
33330150|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
33330151|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
33330152|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
33330153|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
33330154|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.~Once a week , for 4 weeks"
33330155|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.~Once a week , for 4 weeks"
33330156|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
33108816|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
33108817|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
33108818|NCT00447161|Placebo Comparator|2|Placebo
33108819|NCT05425992||Patients treated in CCBD|Patients who are currently receiving therapy at the Center for Cancer and Blood Disorders
33108820|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
33108821|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
33108822|NCT00447317|Experimental|A|Intervention
33108823|NCT00447317|Other|B|Attention control, standard dietary education
33330157|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
33330158|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
33330159|NCT05763550|Experimental|HSK16149 20mg BID|
33330160|NCT05763550|Experimental|HSK16149 40mg BID|
33330161|NCT05763550|Active Comparator|Pregabalin 150mg BID|
33330162|NCT03784248||asymptomatic carrier|
33330163|NCT03784248||uninfected subjects|
33330164|NCT05764642|Experimental|Chronic Kidney Disease Group|Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Lumason ultrasound contrast agent.
33330165|NCT05764642|Active Comparator|Healthy Control Group|Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Lumason ultrasound contrast agent.
33330166|NCT05694234||sugammadex group|patients who administered sugammadex
33330167|NCT05694234||AChEI group|patients who administered pyridostigmine-glycopyrrolate or neostigmine-glycopyrrolate
33330168|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
33330169|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
33330170|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
33360631|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
33330171|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
33330172|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
33330173|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
33330174|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
33330175|NCT05763472||Patients with germline BRCA1/2 patitents|Women with germline BRCA-1/2 mutations, previously treated or undergoing treatment with platinum-based chemotherapy and/or PARP inhibitors for ovarian cancer, who have developed breast cancer, subjected to genomic profiling of breast and ovarian tumor samples.
33330176|NCT05763394|Experimental|Polarized workout|
33041506|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
33041507|NCT02025218|Experimental|Re-administration gefitinib|
33041508|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
33041509|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
33041510|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
33041511|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
33041512|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
33041513|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
33041514|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
33041515|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
33041516|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
33330177|NCT05763394|Experimental|High intensity workout|
32868092|NCT00081263|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
33041517|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
33330178|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days~mFOLFOX6~oxaliplatin 85 mg/m2 IV Day 1 and~leucovorin 400 mg/m2 IV Day 1 and~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and~Avelumab 800 mg IV Day 1~Cycles 10 and subsequent; Maintenance; Cycle = 14 days~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
33330179|NCT01569724|Experimental|bexarotene|
33330180|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
33330181|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
32740866|NCT04562597|Active Comparator|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
33041518|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
33041519|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
33041520|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
33041521|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
33041522|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
33041523|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
33041524|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
33041525|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
33041526|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
33041527|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
33041528|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
33041529|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
33041530|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
33041531|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
33041532|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
33330182|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
33041533|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
33041534|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
33041535|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
33041536|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
33041537|NCT02025452|Experimental|Delayed diagnostics and probiotic|
33041538|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
33041539|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))~If rate inadequate the physician has option of:~Further doses of metoprolol IV or PO~Intravenous amiodarone~IV diltiazem~Observation"
33041540|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).~If after 15 minutes~The first dose is tolerated, and~Ventricular rate is over 100 beats a minute AND~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.~If rate inadequate the physician has an option of:~Metoprolol PO (by mouth) or IV (intravenous)~Digoxin PO or IV~Intravenous amiodarone~Observation"
33041541|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
33041542|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
33041543|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
33041544|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
33041545|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
33360632|NCT03932383|Experimental|Modified CPAP|Single arm cohort study of modified mask
33436479|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
33041546|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
33041547|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
33041548|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
33041549|NCT02025582|Experimental|Kinesio tape|
33041550|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
33041551|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
33417887|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
33417888|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
33417889|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
33041552|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
33041553|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
33041554|NCT02025660|Experimental|Mw|
33041555|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
33041556|NCT02025673||Healthy Controls|Healthy subjects as control group.
33041557|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
33041558|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
33041559|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
32868093|NCT05423418|Active Comparator|A244/B.63521 + 200 μg of ALFQ adjuvant|Arm 1: An injection containing 300 μg A244 plus 300 μg B.63521 with 200 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
32868094|NCT05423418|Active Comparator|A244/B.63521 + 100 μg of ALFQ adjuvant|Arm 2: An injection containing 300 μg A244 plus 300 μg B.63521 with 100 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
33417890|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
33417891|NCT01365247|Active Comparator|Active Monitoring Control Group|
33417892|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
33417893|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
33417894|NCT02143063|Active Comparator|standard care|standard care
33436480|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
33041560|NCT02025699||LRTI|
33041561|NCT02025699||Sepsis|
33041562|NCT02025699||Non-Infectious disease group|
33041563|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
33041564|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
33041565|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
33041566|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
33041567|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
33041568|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
33041569|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
33041570|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
33041571|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
33041572|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
33041573|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
33041574|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
33041575|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
33041576|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
33041577|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
33041578|NCT02025920|Experimental|Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
33041579|NCT02025920|Experimental|Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
33041580|NCT02025920|Active Comparator|Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
33041581|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
33041582|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
33041583|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
33041584|NCT02025946||Total Ankle Arthroplasty|
33041585|NCT02025946||Tibiotalar Arthrodesis|
33041586|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
33330183|NCT05764486|Other|treatment plan|Treatment plan performed by Hitachi's Heavy Ion Beam Therapy System HyBEAT will be designed to suit the particular needs of each subject and the course of treatment will differ for each subject depending on the type of tumor, varying from 1 day to 4 weeks. All subjects will be monitored for 12 weeks after receiving the last treatment.
33330184|NCT05694078|Experimental|Lumbrical Injured Climbers|6-weeks relative motion splinting protocol, while pain-free sport activities are permitted
33330185|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
33330186|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
33330187|NCT03427528|Experimental|FAB Pilot Study (Father/Male Participants)|"Fathers (male partners) received Fathers and Babies (FAB). FAB is a 12-session intervention with content that mirrors content found in MB, but was father-centric.~The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session."
33360633|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
33436481|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
33041587|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
33041588|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
33041589|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
33041590|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
33041591|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
33041592|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
33041593|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
33041594|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
33041595|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
33041596|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
33041597|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
33041598|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
33041599|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
33041600|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
33041601|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
33041602|NCT02026167|No Intervention|Usual Care|No intervention, usual care
33041603|NCT02026167|Experimental|Intervention|Collaborative care with Health Care Assistant
33041604|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
33041605|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
33041606|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
33041607|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
33041608|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.~Intervention: Data gloves to perform movements"
33041609|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements~Intervention: Data gloves to perform movements"
33041610|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
33041611|NCT02026284||Gravid women|A questionnaire was performed to gravid women
33108824|NCT05425914|Active Comparator|Conventional Treatment|Receiving conventional dry eye treatment in the form of artificial tears four times per days for 90 days.
33041612|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
33041613|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
33041614|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
33041615|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
33041616|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
33041617|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
33041618|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
33041619|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
33041620|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
33041621|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
33041622|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
33041623|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
33330188|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Mother/Female Participants)|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT) while her partner received Fathers and Babies in parallel. MB 1-on-1 is 12-sessions and is a postpartum depression preventive intervention. MB includes an introductory module followed by three cognitive-behavioral therapy modules: (1) pleasant activities, (2) thoughts, and (3) contact with others. After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
33330189|NCT05694000|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on."
33330190|NCT05694000|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off."
33330191|NCT05622396|Experimental|MBSR program adapted|8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews
33330192|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
33041624|NCT02026479|Experimental|regular treatment comparator|Ginaton
33041625|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
33041626|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
33041627|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
33041628|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
33041629|NCT02026505||Multiple Myeloma, Bortezomib|
33041630|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
33041631|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
33041632|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
33041633|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
33041634|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
33041635|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
33041636|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
33041637|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
33041638|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
33041639|NCT02026583|Experimental|Simvastatin|
33041640|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
33330193|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
33330194|NCT04074148|Experimental|Diabetes Prevention Education Program|Diabetes Prevention Education Program
33330195|NCT04074148|Experimental|control|Diabetes Prevention Education brochure
33041641|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
33041642|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
33041643|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
33041644|NCT02026648||cases with cervical cancer|
33041645|NCT02026661||those that did not receive ICSI or LAH|
33041646|NCT02026661||those that received ICSI only|
33041647|NCT02026661||those that received LAH only|
33041648|NCT02026661||those that received both ICSI and LAH|
33041649|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
33041650|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
33041651|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
33041652|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
33041653|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
33041654|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
33041655|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
33041656|NCT02026752||Study Population|
33041657|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
33041658|NCT02026765|Other|traditional lens|traditional Aspheric lens
33041659|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
33041660|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
33041661|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
33041662|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
33041663|NCT02026804||Prenatal mental disorders|
33041664|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33041665|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
33041666|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
33041667|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
33041668|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
33041669|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
33041670|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
33041671|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
33041672|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
33041673|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
33041674|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
33041675|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
33041676|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
33041677|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
33330196|NCT05763238|Experimental|Interventional Group|Preoperative Exercise therapy Patient Education, and post-operative conventional protocol.
33330197|NCT05763238|Active Comparator|Control group|Patient Education, and post-operative conventional protocol.
33330198|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
33041678|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
33041679|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
33330199|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
33330200|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
33330201|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
33330202|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
33330203|NCT03166930|Experimental|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
33330204|NCT03166930|Active Comparator|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management.
33041680|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
33041681|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
33041682|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
33041683|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
33041684|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
33041685|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
33041686|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
33041687|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
33041688|NCT02027012|Experimental|Renal denervation with Vessix system|
33041689|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
33041690|NCT02027038|Active Comparator|Controls|healthy controls
33041691|NCT02027064|Experimental|interferon|
33041692|NCT02027077|Active Comparator|Control group|Control group
33041693|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
33041694|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
33041695|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
33041696|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
33041697|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
33041698|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
33041699|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
33041700|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
33041701|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
33041702|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
33041703|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
33041704|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
33041705|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
33041706|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
33041707|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
33041708|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
33041709|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
33330205|NCT03786120||1|First 25 subjects
33330206|NCT03786120||2|Second cohort of 25 subjects
33330207|NCT03783858|Other|Single|
33330208|NCT01308138|Experimental|ExerciseTr|
33330209|NCT01308138|Experimental|Remote ischemic preconditioning group|
33330210|NCT01308138|No Intervention|Control patient group|
33041710|NCT02027207|Experimental|Shanchol|
33041711|NCT02027207|Placebo Comparator|Placebo|
33041712|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
33041713|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
33041714|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
33041715|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
33041716|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
33041717|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
33041718|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
33041719|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
33041720|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
33041721|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
33041722|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
33041723|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
33041724|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
33041725|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
33041726|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
33041727|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
33041728|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
33041729|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
32740867|NCT04562597|Placebo Comparator|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
32740868|NCT04433637|Experimental|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
32740869|NCT04433637|Experimental|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
33041730|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
33041731|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
33041732|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
33041733|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
33041734|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
33041735|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
33041736|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33041737|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33436482|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
32740870|NCT04433637|No Intervention|Control Group|No intervention was applied to the pregnant women in the control group.
32740871|NCT05728281|Other|Resumption of sexual intercourse recommended 4 weeks after hysterectomy|
33041738|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33041739|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33330211|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
33330212|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
33330213|NCT05437848|Experimental|Cotadutide|Those subjects who were randomized to cotadutide once daily SC will begin at 50 μg once daily, then up-titrated to 100 μg once daily a week later, after that up-titration will be done at 100 μg increment weekly, till to a maximum of 600 μg once daily.
33330214|NCT05437848|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
33330215|NCT05517642|Experimental|Ad5-nCoV-IH|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose, will receive a second booster dose of IH Convidecia vaccine.
33330216|NCT05517642|Active Comparator|mRNA vaccine BNT162b2 (Pfizer)|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose,will receive a second booster dose of mRNA vaccine BNT162b2 (Pfizer).
33360634|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
33360635|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
33360636|NCT01130467||Normal control|
33360637|NCT01130467||pure ADHD|
33360638|NCT01130467||ADHD with comorbidity|
32740872|NCT05728281|Other|Resumption of sexual intercourse recommended 8 weeks after hysterectomy|
33041740|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33041741|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
33041742|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
33041743|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
33041744|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
33041745|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
33041746|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
33041747|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
33041748|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
33041749|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
33041750|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
33041751|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
33041752|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
33041753|NCT02027584||preterm infant|gestational age at birth < 37 weeks
33041754|NCT02027584||term infant|gestational age at birth >36 weeks
33041755|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
33041756|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
33330217|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
33330218|NCT01561092|Active Comparator|Escitalopram|
33330219|NCT01561092|Placebo Comparator|Non active drug|
33330220|NCT05494866|Experimental|Arm 1|CYP3A Inhibitor Cobicistat and the cytostatics Gemcitabine and nab-Paclitaxel
32868095|NCT05423418|Active Comparator|A244/B.63521 + 50 μg of ALFQ adjuvant|Arm 3: An injection containing 300 μg of A244 plus 300 μg B.63521 with 50 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
32868096|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
33330221|NCT05492526|Other|Usual Cardiac Rehabilitation|Patients receive usual care and wear Ki monitor - doesn't receive any feedback during the cardiac rehabilitation period.
32868097|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
32868098|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
32868099|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
32868100|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
32868101|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
32868102|NCT05414370|Active Comparator|Liquid medical oxygen|Liquid medical oxygen will be administered using high-flow nasal cannula delivery system.
32868103|NCT05414370|Placebo Comparator|Synthetic medical air|Synthetic medical air will be administered using high-flow nasal cannula delivery system.
32868104|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
32868105|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
32868106|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
32868107|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
32868108|NCT04426344|Experimental|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
32868109|NCT04426344|No Intervention|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature < 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
32868110|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
32868111|NCT03388944|Experimental|PCT group|PCT group
32868112|NCT03388944|No Intervention|Standard practice group|No intervention
32868113|NCT05118269|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
32868114|NCT05118269|Active Comparator|Optimal Medical Therapy (Control)|Patients will be treated according to Optimal Medical Therapy
32868115|NCT05613582|Experimental|Primary Motor Cortex (M1)|Subjects were randomly assigned to receive tDCS stimulation at the primary motor cortex (M1)
33041757|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
33330222|NCT05492526|Experimental|Intervention Arm - Usual Cardiac Rehabilitation plus contextualised Data feedback|Patient receives usual care and also wears Ki monitor and receives contextualised data feedback
33330223|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
33330224|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
33041758|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
33041759|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
33041760|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
33041761|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
33041762|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
33330225|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
33330226|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
33330227|NCT01309542|Experimental|DVS|
33330228|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
33330229|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
33041763|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
33041764|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
33330230|NCT01309620|Placebo Comparator|Placebo|
33330231|NCT01309620|Experimental|Zinc supplement|
32868116|NCT05613582|Experimental|Primary Sensory Cortex (S1)|Subjects were randomly assigned to receive tDCS stimulation at the primary sensory cortex (S1)
32868117|NCT05613582|Experimental|Dorsolateral Prefrontal Cortex (DLPFC)|Subjects were randomly assigned to receive tDCS stimulation at the dorsolateral prefrontal cortex (DLPFC)
32868118|NCT05613582|Sham Comparator|Sham|The sham intervention procedure was carried out similarly to the experimental group, but in the following group, the device would only conduct electric current in the first and last 30 seconds of the intervention.
32868119|NCT05103449|No Intervention|Control Group (No Video Coaching)|Control Group (No Video Coaching)
32868120|NCT05103449|Experimental|Experimental Group (Video Coaching)|Video-based coaching group
32868121|NCT05613504|Active Comparator|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
33041765|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
33041766|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
33041767|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
33041768|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
33041769|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
33041770|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
33041771|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
33041772|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
33041773|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
33041774|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day~Adjust insulin glargine dose according to Fasting blood glucose~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
33330232|NCT05585034|Experimental|Dose Escalation and Expansion XmAb808 administered in combination with pembrolizumab|XmAb®808 in combination with pembrolizumab
33436483|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
33041775|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
33041776|NCT02027766|No Intervention|Control|
33041777|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
33041778|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
33041779|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
33041780|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
33041781|NCT02027792|No Intervention|Usual care|no specific intervention
33041782|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
33041783|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
33041784|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
33041785|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
32868122|NCT05613504|Sham Comparator|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
32868123|NCT05613504|No Intervention|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
32868124|NCT05087381|Experimental|Fluvoxamine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.
33417895|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
32868125|NCT05087381|Experimental|Fluvoxamine in Combination with Bromhexine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
33041786|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
33041787|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
33041788|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
33041789|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
33041790|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
33041791|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
33041792|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
33041793|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
33041794|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
33041795|NCT02027961|Experimental|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
33108825|NCT05425914|Experimental|Vitamin D3 Supplementation|Receiving vitamin d3 supplementation 6000IU per day along with artificial tears for 90 days.
33417896|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
33041796|NCT02027961|Experimental|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
33041797|NCT02027961|Experimental|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
32868126|NCT05087381|Experimental|Fluvoxamine in Combination with Cyproheptadine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.
32868127|NCT05087381|Experimental|Niclosamide Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.
32868128|NCT05087381|Experimental|Niclosamide in Combination with Bromhexine Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
32868129|NCT05087381|No Intervention|Usual Care Arm|The control group received treatment according to the latest usual care medical guidelines provide by ministry of Thailand at that time.
33041798|NCT02027961|Experimental|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
33041799|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
33041800|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
33041801|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
33041802|NCT02027987|Placebo Comparator|placebo|
33041803|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
33041804|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
33041805|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
33041806|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
33041807|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
33041808|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
33041809|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
33041810|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
33041811|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
33041812|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
33041813|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
33041814|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
33041815|NCT02028117|Experimental|Enadenotucirev|
33041816|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
33041817|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
33041818|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
32868130|NCT05613348|Experimental|humanized CAR19T2 T cell to B-cell acute lymphoblastic leukemia/lymphoma|Patients received fludarabine and cyclophosphamide (Flu/Cy) for lymphodepletion (Cy at 300-500 mg/m2/dose for four days and Flu at 20-30 mg/m2/dose for two days) before CAR19T2 T cells administration. This CAR19T2 T cell will be infused over 30 minutes on days Day 0.
32868131|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
32868132|NCT05611710|Placebo Comparator|Placebo|The control group will be formed of 80 dengue patients with warning signs or severe dengue receiving placebo.
32868133|NCT05611710|Experimental|Anakinra|The intervention group will include 80 dengue patients with warning signs or severe dengue receiving anakinra.
33417897|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
33417898|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
33417899|NCT02088944||exposed to IFX|
33417900|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D013 on Day22~Day28"
33417901|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
32868134|NCT04958291|Experimental|Administration of Dose A of CC-99677 or Placebo|Administration of Dose A of CC-99677 or Placebo
32868135|NCT04958291|Experimental|Administration of Dose B of CC-99677 or Placebo|Administration of Dose B of CC-99677 or Placebo
32868136|NCT04958291|Experimental|Administration of Dose C of CC-99677 or Placebo|Administration of Dose C of CC-99677 or Placebo
32868137|NCT05611632|Experimental|Interventional|Blood collection and multi-cancer early detection testing with return of positive test results.
32868138|NCT05611632|No Intervention|Control|Blood collection only.
32868139|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
32868140|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
32868141|NCT05611398||Lactate Level Under 2 mmol/L|Patients with a lactate level below 2
32868142|NCT05611398||Lactate Level Over 2 mmol/L|Patients with a lactate level above 2
32868143|NCT00080483|Experimental|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
32868144|NCT00080483|Active Comparator|2|AndroGel transdermally 5 g a day for two years
32868145|NCT05248620|Active Comparator|Active|Amoxicillin/clavulanic acid 500/125mg, tablets, will be administered before each hemodialysis for 6 months
32868146|NCT05248620|Placebo Comparator|Placebo|Placebo tablets, similar to the active drug, will be administered before each hemodialysis for 6 months
32868147|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
32868148|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
32868149|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
32868150|NCT00089141|Active Comparator|Mycophenolate mofetil|Patients receive oral mycophenolate mofetil twice daily.
32868151|NCT00089141|Placebo Comparator|Placebo|Patients receive oral placebo twice daily
32868152|NCT05611320|Experimental|Awareness Campaign|Raise awareness among parents about how and why to use local produce in their kid's meals.
32868153|NCT05611320|Experimental|Online Shopping|Provide information about an online shopping platform where the parents can shop for local produce online, and have it delivered, to disrupt their current ingredient-selection habits.
32868154|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
32868155|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
32868156|NCT05611242|Experimental|BMM+/-IAT+CAT with Stenting|Best Medical Management (BMM) +/- Intra-arterial Therapy (IAT) with added carotid thrombectomy (CAT) using stenting approach.
32868157|NCT05611242|Experimental|BMM+/-IAT+CAT without stenting|Best Medical Management (BMM)+/-intra-arterial treatment (IAT) with mechanical thrombectomy (for IVO) added to proximal extra-cranial carotid occlusion none stenting thrombectomy treatment (CAT) none stenting: angioplasty, aspiration or atherectomy)
32868158|NCT04753073|Experimental|NIPP|Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
32868159|NCT04753073|No Intervention|Controll|LEEP-Exzision
32868160|NCT05615142|Experimental|LDRT+SBRT Combined with PD-1 Inhibitors|"Part A-Dose escalation cohort. DOSE LEVEL: Low Dose Radiotherapy (LDRT) dose from 2 Gy to 6Gy (2 Gy/f) + partial stereotactic body radiation therapy (SBRT) dose at 10 Gy to 30 Gy (10 Gy/f) + PD-1 inhibitor (dose as recommended in the instruction manual).~Part-B - Expansion cohort. LDRT and partial SBRT doses at MTD determined in Part A + PD-1 inhibitor (dose as recommended in the instruction manual)."
32868161|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
32868162|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
32868163|NCT00184717|Experimental|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
32868164|NCT00184717|Experimental|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
33417902|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D326 and D337 on Day22~Day28"
33417903|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
33436484|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
33436485|NCT05135884||Cohort|
33436486|NCT05704465|Other|Reiki Therapy|Reiki is a biofield therapy technique based on energy healing.
33041819|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
33041820|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
33041821|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
33041822|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
33041823|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
33041824|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
33041825|NCT02028260|Placebo Comparator|Placebo|normal saline
33041826|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
33041827|NCT02028273||Actively using patients|Participants actively using cocaine.
33041828|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
33041829|NCT02028286|Experimental|CLS001|CLS001
33041830|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
33041831|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
33041832|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
33041833|NCT02028351||Normal|No Intervention
33041834|NCT02028351||Cataract|No intervention
32868165|NCT00184717|No Intervention|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
32868166|NCT00184717|Experimental|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
33041835|NCT02028351||Maculopathy|No Intervention
33041836|NCT02028377|Experimental|Imaging|PET/MRI
33041837|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
33041838|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
33041839|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
33041840|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
33041841|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
33041842|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
32868167|NCT00184717|Experimental|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
32868168|NCT04806893|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
32868169|NCT04806893|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
33041843|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
33041844|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
33041845|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
33041846|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
33041847|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
33041848|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
33041849|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
33041850|NCT02028442|Experimental|Enadenotucirev|
33041851|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
33041852|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
33108826|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
32868170|NCT05614986||Patients with Mild Cognitive Impairment Undergoing TAVR|Patients will be treated with standard of care. In addition, patients will complete the mini MoCA at 3 time points
32868171|NCT04751747|Experimental|Supportive care (CT simulation, contrast agent)|Patients undergo CT stimulation with or without IV contrast over 1.5 hours on days -15 to -1, then undergo SOC chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29.
32868172|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
32868173|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
32868174|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
32868175|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
32868176|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
32868177|NCT05346497||Bentall|Patients who underwent Bentall procedure for ATAAD
32868178|NCT05346497||David|Patients who underwent David procedure for ATAAD
32868179|NCT05346497||ARR|Patients who underwent aortic root reconstruction procedure except Bentall and David procedure for ATAAD
32868180|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
32868181|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
32868182|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
32868183|NCT03849534|Active Comparator|Counseling|Just information at the first visit
32868184|NCT05346419|Experimental|Postmenopausal Osteopenia-osteoporosis patients|All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
32868185|NCT00084409|Experimental|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
32868186|NCT00084409|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
32868187|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
32868188|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
32868189|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
32868190|NCT02914899|Active Comparator|Pilot RCT Control Group|Eligible NYC Chinese livery drivers will receive written materials only
32868191|NCT02914899|Experimental|Pilot RCT CHW Intervention Group|Eligible NYC Chinese livery drivers will receive written materials and navigation for shared decision making (SDM) and lung cancer screening (LCS).
32868192|NCT02914899|Experimental|Focus Group|The investigators conducted a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke.
32868193|NCT02914899|Experimental|In-Depth Interview Group|12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community.
32868194|NCT02914899|Experimental|Pre-pilot Group|Approximately 10 Chinese livery drivers who smoke or who quit smoking with the past 15 years and have a 30 pack-year history of smoking
32868195|NCT04743791|Active Comparator|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
32868196|NCT04743791|Placebo Comparator|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
32868197|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|Group I - melatonin 3mg + Acyclovir 400mg
32868198|NCT03831165|Active Comparator|Acyclovir 400mg|Group II - Acyclovir 400mg twice a day
32868199|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|Group III - placebo + melatonin 3mg
32868200|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
32868201|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
32868202|NCT00088621|Experimental|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
32868203|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.~Cells for infusion are prepared using the CliniMACS system."
33067781|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
33067782|NCT04724538|Experimental|Healthy volunteers|CT-scans for exclusion of pneumonia. Accumulated absorbed dose calculation of volunteers' lungs after inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 833 MBq of 99mTc-pertechnetate.
33330233|NCT05129670|Experimental|Calcite chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised calcite chewing gum. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
33330234|NCT05129670|Placebo Comparator|Unmatched Placebo chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised unmatched placebo gum product. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
33330235|NCT05351658|Experimental|Temporary Cardiac Pacing with Active-Fixation Leads|
33330236|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
33330237|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
33330238|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
33330239|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
33330240|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
33330241|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
33041853|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
33041854|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with~Cohort 1: Exemestane 25 mg orally once daily.~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
33041855|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
33330242|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
33330243|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:~Patients intake simethicone solution 20-30 min before the procedure."
33330244|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:~Patients intake simethicone solution 31-60 min before the procedure."
33330245|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
33330246|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
33330247|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
33041856|NCT02028533|Active Comparator|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
33041857|NCT02028533|Placebo Comparator|Patients 2|Participants will receive 40 International Units of intranasal placebo.
33041858|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
33041859|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
33041860|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
33041861|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
33041862|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
33041863|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
33041864|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
33041865|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
33041866|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
33041867|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
33041868|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
33041869|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
33041870|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
33041871|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
33041872|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
33041873|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
32868204|NCT05574985|Experimental|Research Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated one dose of the study vaccine
32868205|NCT05574985|Active Comparator|Control Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated with one dose of control vaccine
33041874|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
33041875|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
33041876|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
33041877|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
33041878|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
33041879|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
33041880|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
33041881|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
33041882|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
33041883|NCT02028728||Orsiro|
33041884|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
33041885|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
33041886|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
33041887|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
33041888|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
33041889|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
32868206|NCT05574985|Experimental|Observation group ①|People 6 to 9 months after the completion of the inactivated COVID-19 vaccine booster immunization were vaccinated one dose of the study vaccine
32868207|NCT05574985|Experimental|Observation group ②|People 6 to 15 months after the completion of basic immunization with COVID-19 recombinant vaccine were vaccinated one dose of the study vaccine
32868208|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
32868209|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
32868210|NCT00187369|Other|Caesarean Section|delivery by CS
33041890|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
33041891|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
33041892|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
32868211|NCT00187369|Other|Vaginal Birth|delivery by VB
32868212|NCT04773366|Experimental|Group 1|"Multisystem patients (≥2 organs/systems) with involvement of one or more Risk organs, i.e. hematopoietic system, liver or spleen.~All patients in this group receive an initial therapy (Week 1~6) followed by a consolidation continuation therapy (Week 7~22) and maintenance continuation therapy (Week 25~52)."
32868213|NCT04773366|Experimental|Group 2|"Multisystem patients, but without involvement of Risk organs.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
33041893|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
33041894|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
33041895|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
33041896|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
33041897|NCT02028936|Experimental|Grape juice rich in polyphenols|
33041898|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
33041899|NCT02028949|Experimental|Chemo-lipiodol|
33041900|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
33041901|NCT02028962|No Intervention|Control|
33041902|NCT02028975|Other|Patients with type 2 diabetes|
33041903|NCT02028975|Other|Obese patients without diabetes|
33041904|NCT02028975|Other|Healthy volunteers|
32868214|NCT04773366|Experimental|Group 3|"Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
32868215|NCT04773366|Experimental|Group 4|"Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion).~All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation."
32868216|NCT04731857||Genetic diseases|For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
32868217|NCT04714541|Experimental|Ketogenic Diet Adoption Followed by Ketamine Infusion|All 5 Participants Will Be Educated to Adopt a Ketogenic Diet, As Outpatient. After at Least 4 Weeks on the Diet, They Will Have A Series of Titrated Intravenous Ketamine Infusions Over A 2 Week Period
32868218|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32868219|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
32868220|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
32868221|NCT00187681|Experimental|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
32868222|NCT00187681|Experimental|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
32868223|NCT03739437|Experimental|Mobile Contingency Management|
32868224|NCT03739437|Active Comparator|Standard Care|
32868225|NCT00083759|Active Comparator|natalizumab|
32868226|NCT00083759|Placebo Comparator|placebo|
32868227|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
32868228|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
32868229|NCT03693807|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
32868230|NCT05613270|Experimental|18F-FES PET/CT|Inject 18F-FES and then perform PET/CT scan.
32868231|NCT05147610|Experimental|patients requiring an IOP (intra-Ocular Pression) measurement|group representing adults patients in ophthalmologic consultation requiring an IOP measurement
32868232|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
32868233|NCT04692168||Entire group|The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.
32868234|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
32868235|NCT05614830|Experimental|Intervention group|
32868236|NCT05614830|Active Comparator|Control group|Usual physical therapy protocol 4 sessions, two sessions per week each session will include a group of therapeutic exercises
32868237|NCT03692403|Experimental|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
32868238|NCT03692403|Experimental|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
32868239|NCT03692403|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
32868240|NCT03692403|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
32868241|NCT05614674||Healthy group|People who don't suffer from low back pain
32868242|NCT05614674||People with low back pain|People who are suffering from low back pain. The pain level has to be at least 3 out of 10 according to Visual Analog Scale (VAS) to be in this group.
32868243|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
32868244|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
32868245|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
32868246|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
32868247|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
32868248|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
32868249|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
33330248|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
33330249|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
33330250|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
33041905|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingest enzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (24 weeks).
33041906|NCT02029014|Experimental|LAmbre closure system|
33041907|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
33041908|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
33330251|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
33041909|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
33041910|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
33330252|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
33041911|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
33041912|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
33041913|NCT02029092||Orsiro|
33330253|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
33330254|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
33330255|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
33041914|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
33041915|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
33041916|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
33041917|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
33041918|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
33041919|NCT02029131|Experimental|Exercise|
33041920|NCT02029131|No Intervention|Controls|
33041921|NCT02029157|Experimental|ARQ 197|Daily oral dose
33041922|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
33041923|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
33041924|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
33041925|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
33041926|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33041927|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
33041928|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
33041929|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
33041930|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
33041931|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
33041932|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
33041933|NCT02029287|Experimental|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
33041934|NCT02029287|Active Comparator|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
33041935|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
33041936|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
33041937|NCT02029313|Experimental|MKT-N2|Montelukast
33041938|NCT02029313|Active Comparator|Singulair|Montelukast sodium
33041939|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
33041940|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
33041941|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
33041942|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
33041943|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
33041944|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
33041945|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
33041946|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
33041947|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
33041948|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
33041949|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
33041950|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
33041951|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
33041952|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
33041953|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
33041954|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
33041955|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
32868250|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
32868251|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
32868252|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
32868253|NCT00088699|Experimental|Ketamine, Then Placebo|Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
32868254|NCT00088699|Experimental|Placebo, Then Ketamine|Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg
32868255|NCT05138094|Active Comparator|Minimally invasive two-stage resection|Minimally invasive resection of the primary colorectal carcinoma and liver metastases in two stages. The liver metastases or the colorectal carcinoma can be resected during the first surgical procedure.
32868256|NCT05138094|Experimental|Minimally invasive simultaneous resection|Minimally invasive resection of both the primary colorectal carcinoma and the liver metastases in one procedure.
33041956|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
33041957|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
33041958|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
33041959|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
33041960|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
33041961|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
33041962|NCT02029586|Experimental|MB12066|
33041963|NCT02029586|Placebo Comparator|Placebo|
33041964|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
33041965|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
33041966|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
33041967|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
32868257|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
32868258|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
32868259|NCT00089011|Experimental|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
32868260|NCT00089011|Experimental|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
32868261|NCT05614596|Active Comparator|CT guided for patient with chronic low back pain|CT guided treatment in patients with low back pain
32868262|NCT05614596|Active Comparator|Flouroscopic guided for patient wit chronic low back pain|Flouroscopic guided treatment in patients with low back pain
32868263|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
32868264|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
32868265|NCT00347412|Experimental|Group A: NOV-002 plus Chemotherapy|NOV-002 in combination with Paclitaxel and Carboplatin
32868266|NCT00347412|Active Comparator|Group B: Chemotherapy Alone|Paclitaxel and Carboplatin
32868267|NCT00189475|Active Comparator|Montelukast|Treated for 4 months with montelukast 4 mg per day
32868268|NCT00189475|Placebo Comparator|Placebo|Treated for 4 months with placebo
32868269|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
32868270|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
32868271|NCT04625634|Experimental|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
32868272|NCT03839784||Neurocognitive Assessment Arm|
32868273|NCT00193375|Experimental|Intervention|Patients received carboplatin [area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
32868274|NCT05475210|Experimental|Peptide Receptor Radionucleotide Therapy (PRRT)|The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.
32868275|NCT04603950|Experimental|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
32868276|NCT04603950|Sham Comparator|control group|The second 20 patients received Continue Adductor Canal Block alone
32868277|NCT05014152|Experimental|Single group|"This study is specially designed according to its age range and customized/non-customized range, and meets the requirements of ISO 80601-2-56 test population (table). Comply with the age range and population requirements of ISO 80601-2-56, as well as clinical and subject trials, including news to the population over five years old, and hopefuls must account for at least 30% of the total and less than 50% of the total.~Each subject uses Q-temp-w1 to measure axillary temperature and obtains 3 temperature values, and at the same time uses a reference body temperature patch (Omron thermometer MC-171W) to measure the other side axillary temperature, and 1 is measured Temperature value data. Perform clinical efficacy analysis based on the measurement results. The main evaluation indicators of the trial include clinical bias, limits of agreement, and clinical repeatability."
32868278|NCT04589208|Experimental|Ketamine|ketamine
32868279|NCT00193453|Experimental|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
32868280|NCT05614518|Experimental|18F-NaF-PET/CT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Sodium Fluoride F-18 injection Dosage Form: Injection Dosage: Administer 5-10 mCi as an intravenous injection Frequency and Duration: Single dose"
32868281|NCT05614518|Active Comparator|99mTc-MDP-BS±SPECT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Technetium[99mTc] Methylenediphosphonate Injection Dosage Form: Injection Dosage: Administer 10-25 mCi as an intravenous injection Frequency and Duration: Single dose"
32868282|NCT04757922||Intervention: bilateral salpingectomy|Premenopausal women between 30 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
32868283|NCT04757922||Control: tubal ligation or no sterilization|The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
32868284|NCT00091507|Experimental|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
32868285|NCT00091507|Placebo Comparator|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
33330256|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
32868286|NCT05611164|No Intervention|Sperm selected by embryologist without software assistance|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the no intervention arm, the individual spermatozoa for injection are selected subjectively by the embryologist."
33041968|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
33041969|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
33041970|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
33041971|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
33041972|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
33041973|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
33041974|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
33041975|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
33041976|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
33041977|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
33041978|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
33041979|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
33041980|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
33041981|NCT02029768||Women with burn injury|
33041982|NCT02029768||Men with burn injury|
33041983|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
32868287|NCT05611164|Experimental|Sperm selected with AI assistant SiD|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the experimental arm, the spermatozoa selection for injection is performed based on the recommendation of the AI assistant SiD."
33041984|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
33041985|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
33041986|NCT02029807||Blood donors|Healthy adult volunteers donating blood
33041987|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
32868288|NCT04757688|Experimental|Cardiac radioablation (CRA)|CRA delivered via linear accelerator (stereotactic body radiotherapy) to the suspected arrhythmogenic substrate to a dose of 25 Gy in 1 fraction.
32868289|NCT04439760|No Intervention|control study.|No intervention
32868290|NCT04439760|Active Comparator|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
32868291|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
32868292|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
32868293|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
32868294|NCT05611086|Experimental|NAC Group|Participants of this group was given capsules containing 600mg N-acetylcysteine
32868295|NCT05611086|Placebo Comparator|Placebo|Participants of this group was given capsules containing lactose
33041988|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
33041989|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .~Polygraphic examination between 30 and 36 weeks of amenorhea"
33041990|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
33041991|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
33041992|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
33041993|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
33041994|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
33041995|NCT02029924|Active Comparator|Humalog®|Humalog®
33041996|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
32868296|NCT00093379|Experimental|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
33417904|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):~Rituximab IV over at least 90 minutes on day 2~Carfilzomib IV over 30 minutes on days 1, and 2~Cyclophosphamide IV over 30-60 minutes on day 3~Doxorubicin hydrochloride IV over 3-5 minutes on day 3~Vincristine sulfate IV over 1 minute on day 3~Prednisone PO on days 3-7 any time~Pegfilgrastim day 4~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
33417905|NCT02082548|Experimental|Intervention|educational intervention arm
32868297|NCT04338750|Experimental|Telephone Acceptance and Commitment Therapy Intervention for Caregivers (TACTICs)|Participants in the ACT arm will learn new and more adaptive ways to respond to challenges, including anxiety and the irreversibility of dementia and its behavioral manifestations.
32868298|NCT04338750|Active Comparator|minimally-Enhanced Usual Care (mEUC)|Participants randomized to mEUC will receive educational, science-based reading and resources, including a listing of Alzheimer's Association sponsored support groups closest to their home address.
32868299|NCT04928742|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
32868300|NCT04928742|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
32868301|NCT05614440|Active Comparator|Only local anesthetic group|
32868302|NCT05614440|Experimental|Tramadol group|
32868303|NCT05613192|Active Comparator|Placebo|Group 1: patients receive the standard conventional therapy in addition to placebo for 4 months.
32868304|NCT05613192|Experimental|Cholecalciferol|Group 2: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
32868305|NCT05474820|Other|Saliva and serum collection of patients and samples molecules analysis|After periodontal examination, samples were collected from all patients via informing them about procedures. Then all samples were stored at -80 C unto analyses.
32868306|NCT05474820|Other|Periodontal examination|All periodontal indices were measured in six sites in each tooth present in the arch by one calibrated periodontist
32868307|NCT00194779|Experimental|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
33417906|NCT02082548|No Intervention|control|Standard of care
33417907|NCT04523298|Experimental|Laser|
33417908|NCT04523298|Active Comparator|PFE|
32868311|NCT05474742|Experimental|Intervention group|Use of the Nori Health app during the study period, standard care
32868312|NCT05474742|No Intervention|Control group|No use of the Nori Health app during the study period, standard care
32868313|NCT05611008|Experimental|Intervention condition|
32868314|NCT05611008|No Intervention|Control condition|
32868315|NCT05474664|Experimental|protein-losing enteropathy after Fontan operation|single-arm with protein-losing enteropathy after Fontan operation
32868316|NCT00093847|Experimental|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
32868317|NCT00093847|Placebo Comparator|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
32868318|NCT04860492|Active Comparator|Renalof|Patients will be given and, advised to take Renalof tablets 325mg three times a day for 90 days
32868319|NCT04860492|Placebo Comparator|Placebo|Patients will be given and, advised to take Placebo three times a day for 90 days
32868320|NCT05610930|No Intervention|Control arm|"Participants received a questionnaire including 3 sets of images of food packaging, (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, but without front-of-pack nutritional label (in case the original Nutri-Score was displayed on the product, it was hidden by the investigators). They had the possibility to check the back-of-pack nutrition facts and ingredient information. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed."
33041997|NCT02029937|No Intervention|Standard of care|No invention
33041998|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
33417909|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
33041999|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
33042000|NCT02030158||Usual resuscitation|Usual resuscitation
33417910|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
33417911|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
33417912|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
33417913|NCT04435470||Control|Healthy children 1-16 years old
32868321|NCT05610930|Experimental|Experimental arm|"Participants received a questionnaire including 3 sets of images of real food product packaging (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, with the Nutri-Score 2.0 displayed on the front-of-pack of each product. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed. Last, a series of questions evaluated how participants of this arm perceived the Nutri-Score 2.0 and whether they found it helpful."
32868322|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
32868323|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
32868324|NCT05614362|Experimental|Channa striatus extract|Channa striatus group was given 3x1 500mg dose of Channa striatus for 21 days
32868325|NCT05614362|Placebo Comparator|Placebo|Placebo group was given 3x1 dose of maltodextrin for 21 days
32868326|NCT05610852|Active Comparator|Transvesical Single Port Robotic Partial Prostatectomy|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to Prostatectomy. Prostatectomy consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
32868327|NCT05610852|Active Comparator|High-intensity focused ultrasound (HIFU)|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to HIFU. HIFU consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
32868328|NCT04338984|Active Comparator|General anesthesia alone (AG)|"Opioid based analgesia:~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
32868329|NCT04338984|Experimental|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
32868330|NCT05614284|Experimental|Virtuous|Virtuous +/- Local Bone
32868331|NCT05614284|Active Comparator|Autograft|Autograft +/- Allograft Chips
32868332|NCT04754100|Experimental|Allogeneic iNKT Cells|3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days [2 weeks]).
32868333|NCT04208724|Experimental|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
32868334|NCT04181424|Active Comparator|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
32868335|NCT04181424|Experimental|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
32868336|NCT04181424|Experimental|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
32868337|NCT04181424|Experimental|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
32868338|NCT04148508|Experimental|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
32868339|NCT04148508|Active Comparator|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
32868340|NCT04148508|Placebo Comparator|Self-monitoring|Self-help self-monitoring delivered via mobile app
32868341|NCT00095563|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
32868342|NCT05473806|Experimental|Pioglitazone 15mg|pioglitazone hydrochloride. PO. 2 tablets once a day.
32868343|NCT05473806|Experimental|Evogliptin 5mg|Evogliptin tartrate. PO. 1 tablets once a day.
32868344|NCT00089609|Experimental|Main cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
33042001|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
33042002|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
33042003|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
33042004|NCT02030236|Experimental|Cooling|
33330257|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
33330258|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
33330259|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
33330260|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
33330261|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
33330262|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
33330263|NCT05542836||Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
33330264|NCT05542836||Standard postoperative activity restrictions|Standard conservative postoperative activity and return to work recommendations
33330265|NCT03781284|Experimental|PET/MRI with bowel purgation|
33330266|NCT03781284|Experimental|PET/MRI without bowel purgation|
33330267|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
33330268|NCT01561170||Chronically venous ulcer|A group of 36 patients
33330269|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
33330270|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
33330271|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
33330272|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
33330273|NCT01317654||Survivors of TBM trial 2001-2005|
33330274|NCT02865850|Experimental|Vadadustat|
33330275|NCT02865850|Active Comparator|Darbepoetin alfa|
33417914|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
33417915|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
33042005|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
33042006|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
33042007|NCT02030470|Other|fotosan|
33042008|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
33042009|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
33042010|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
33042011|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
33042012|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
32868345|NCT00089609|Experimental|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
32868346|NCT00195013|Experimental|Glutamine|10 grams three times a day (orally) for four days and then stop
33417916|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
33417917|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
33417918|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
33417919|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
33042013|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
33042014|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
33042015|NCT02031367|Active Comparator|Corticosteroid|
33042016|NCT02031367|Experimental|Platelet Rich Plasma|
33042017|NCT02031497|Experimental|Drink with sweeteners|
33042018|NCT02031497|Active Comparator|Drink without sweeteners|
33042019|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
33042020|NCT02031692|No Intervention|Control|
33042021|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
33042022|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
33042023|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
33042024|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
33042025|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
33042026|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
33042027|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
33042028|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
33417920|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
33417921|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
33417922|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
32868347|NCT00195013|Placebo Comparator|Placebo|10 grams three times a day (orally) for four days and then stop
32868348|NCT04661514|Experimental|Safety, Tolerability, and Treatment|On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
32868349|NCT04123938|Experimental|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
33042029|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
33042030|NCT02032537|Active Comparator|Callmax cream|
33042031|NCT02032537|Placebo Comparator|Placebo|
33042032|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
33042033|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
33042034|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
33042035|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
33417923|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
33417924|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
33330276|NCT03711162|Experimental|GLPG1690 600 mg|Participants received GLPG1690 (ziritaxestat) 600 mg, film-coated tablets orally once daily (mean GLPG1690 exposure was up to 325.3 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
32868350|NCT04123938|Active Comparator|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
32868351|NCT04123938|Placebo Comparator|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
32868352|NCT04095702|Experimental|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
32868353|NCT04095702|Placebo Comparator|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
32868354|NCT04678505|Experimental|Panel A: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of 100 mg MK-3402 via intravenous (IV) infusion on Day 1.
32868355|NCT04678505|Experimental|Panel B: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
32868356|NCT04678505|Experimental|Panel C: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
32868357|NCT04678505|Experimental|Panel D: Healthy Participants|Healthy matched control participants will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
32868358|NCT04678505|Experimental|Panel E: End-Stage Renal Disease (ESRD) Undergoing Hemodialysis|Participants with ESRD undergoing HD will receive a single dose of 100 mg MK-3402 via IV infusion after HD on Day 1 of Period 1 and before HD on Day 1 of Period 2. There will be at least a 6-day washout period before dosing in Period 2.
32868359|NCT00195403||1|
32868360|NCT05612958|Experimental|DKM-410|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
32868361|NCT05612958|Active Comparator|Juvederm ULTRA PLUS XC 1.0ml|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
32868362|NCT04678349|Experimental|PHGG|Patient who met inclusion criteria and consented during intervention period will be assigned as PHGG group. Surgical medical officer will obtain consent from eligible subject. After consented, subjects will be assessed weight and PG-SGA during admission. They will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar once allowed orally. Staff nurse in charged will monitor compliance of subject on the PHGG. Daily stoma output & consistency will be recorded and daily energy protein intake will be assessed by dietitian in charged. Renal profile will be taken daily as routine procedure for patients with ileostomy.
32868363|NCT04678349|Other|CG|Historical records of patients with ileostomy under conventional care from January 2016 to June 2019 (before started on PHGG) will be assessed and traced retrospectively from the medical system. Data will be recorded in data collection sheet.
32868364|NCT00197119|Active Comparator|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
32868365|NCT00197119|Active Comparator|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
32868366|NCT04592874|Experimental|AL002 Dose 1|AL002 every 4 weeks
32868367|NCT04592874|Experimental|AL002 Dose 2|AL002 every 4 weeks
32868368|NCT04592874|Experimental|AL002 Dose 3|AL002 every 4 weeks
32868369|NCT04592874|Placebo Comparator|Placebo|Placebo every 4 weeks
32868370|NCT04643327|Experimental|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
32868371|NCT04643327|Placebo Comparator|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
33042036|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
32868372|NCT05404789|Other|Diabetic Subjects|Individuals with history of diabetes mellitus
32868373|NCT05404789|Other|Subjects with history of arrhythmia|Individuals with history of cardiac arrhythmia
32868374|NCT05404789|Other|Control Subjects|Individuals without history of either Diabetes or cardiac arrhythmia
32868375|NCT04761575||FFQ validation|All participants to complete all aspects of the study.
32868376|NCT03088241|Experimental|Intervention|switch to second-line ART
32868377|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
32868378|NCT00095875|Experimental|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
32868379|NCT00095875|Experimental|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
32868380|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
32868381|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
32868382|NCT04549896|Experimental|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
32868383|NCT04549896|Active Comparator|Control|No CT scan before CTO PCI
32868384|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
33042037|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
33042038|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
33042039|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
33042040|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
33042041|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
33042042|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
33042043|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042044|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042045|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042046|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042047|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042048|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
33042049|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
33042050|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
33042051|NCT02033720||Asystole|Initial arrest rhythm is asystole.
33042052|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
33042053|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
33042054|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
33042055|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
33042056|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
33042057|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
33330277|NCT03711162|Experimental|GLPG1690 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet for oral use once daily (mean GLPG1690 exposure was up to 356.0 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
33330278|NCT03711162|Placebo Comparator|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets for oral use once daily (mean GLPG1690 exposure was up to 353.4 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
33330279|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
33042058|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
33042059|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
33330280|NCT05763082|Experimental|Padagis active product|
33330281|NCT05763082|Active Comparator|Reference product|
33042060|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
33108827|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
33042061|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
33042062|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
33330282|NCT05763082|Placebo Comparator|Padagis placebo product|
33330283|NCT05492370|Experimental|EpiCor|500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
33330284|NCT05492370|Placebo Comparator|Placebo|Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
32868385|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
33042063|NCT02034279|No Intervention|No albumin|Only antibiotics
33330285|NCT05762926|Experimental|Experimental|Diffuse unguided holocranial application focused sound wave pulses, using the Storz Duolith SD1 ULTRA equipment.
33330286|NCT05762926|Active Comparator|Active Comparator|Diffuse unguided holocranial application without sound waves pulses, using the Storz Duolith SD1 ULTRA equipment, prepared to block the sound waves.
33330287|NCT01309698|Experimental|Treatment Sequence 1|
33042064|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
33042065|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:~Practicing, board-certified radiation oncologists~Perform consultations on at least 80 patients with prostate cancer annually~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
33042066|NCT02034825||Practicing urologic surgeons|"US board-certified~Practicing urologic surgeons~Performing at least 40 radical prostate surgeries annually~Urologists will be excluded from participating in the study if:~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;~They have spent less than 3 years in practice or perform less than 40 RP's per year~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
33042067|NCT02034851||Dexamethasone|Intervention group
33042068|NCT02034851||Control|Placebo group (physiological saline)
33042069|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
33042070|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
33042071|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
33042072|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:~Open the eyes to verbal commands.~Follow the examiner's instructions with the eyes.~Squeeze hands on request.~Stick out the tongue on request.~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
33042073|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
33042074|NCT02035046|Other|study's population|
33042075|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
33042076|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
33042077|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
33042078|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
33042079|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
33042080|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
33330288|NCT01309698|Experimental|Treatment Sequence 2|
33330289|NCT01309698|Experimental|Treatment Sequence 3|
33330290|NCT01309698|Experimental|Treatment Sequence 4|
33330291|NCT01309698|Experimental|Treatment Sequence 5|
33330292|NCT01309698|Experimental|Treatment Sequence 6|
33330293|NCT01142284|Placebo Comparator|Placebo|Placebo
33330294|NCT01142284|Experimental|Cilostazol|cilostazol
33330295|NCT01142284|Experimental|Probucol|probucol
33330296|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
33330297|NCT03783156|Other|hot snare|polypectomy with hot snare
33330298|NCT03783156|Other|cold snare|polypectomy with cold snare
33330299|NCT05762848||Researcher|Patients will have their Head circumference measured with a tape and with the mobile phone app.
33330300|NCT05762848||Parent|Patients will have their Head circumference measured with a tape and with the mobile phone app.
33330301|NCT01309776|Experimental|Tianeptine|
33330302|NCT01309776|Active Comparator|Escitalopram|
33417925|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
33042081|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
33042082|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
33042083|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
33042084|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
33042085|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
33042086|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
33042087|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
33042088|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
33042089|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
33042090|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
33042091|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
33042092|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
33417926|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
32868386|NCT04089072|Experimental|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP >65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
32868387|NCT04089072|Experimental|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
32868388|NCT00006227|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
32868389|NCT04087980|Experimental|Poseidon System Treatment|
32868390|NCT00096109|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
32868391|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
32868392|NCT00097669|Active Comparator|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug)|Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
32868393|NCT00097669|Placebo Comparator|Placebo Tablet|Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.
32868394|NCT05612880||Non-intervention controls|Men with advanced prostate cancer initiating androgen receptor signaling inhibitor treatment.
32868395|NCT03995628|Experimental|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
32868396|NCT03995628|No Intervention|No Steroid Group|Participants will not receive dexamethasone
33042093|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
33042094|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
33042095|NCT02036450|Experimental|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
33042096|NCT02036450|No Intervention|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
33042097|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
33042098|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
33042099|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
33042100|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
33042101|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
33417927|NCT04989829|Experimental|Treatment group|
32868397|NCT00010439|Experimental|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
32868398|NCT05473494|Experimental|training group|
33042102|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
33042103|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
33417928|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
33042104|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
33042105|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
33042106|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
33042107|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
33042108|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
33042109|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
33042110|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
33042111|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
33042112|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
32868399|NCT05473494|Active Comparator|control group|
32868400|NCT04463940||Umbilical cord arterial blood|participant's umbilical cord arterial blood will be obtained
32868401|NCT04463940||Umbilical cord venus blood|participant's umbilical cord Venus blood will be obtained
33042113|NCT02039492|Experimental|A|Denervation
33108828|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
32868402|NCT04463940||Maternal blood|participant's blood will be obtained
32868403|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
32868404|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher & Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
32868405|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
32868406|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
32868407|NCT03908736|Other|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
32868408|NCT04392336|Experimental|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
32868409|NCT04392336|No Intervention|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
33042114|NCT02039492|Active Comparator|B|Treatment with aldactone
33042115|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
33042116|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
33042117|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
33042118|NCT02039596|Experimental|English breakfast|Diet: English food items
33042119|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
33042120|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
33042121|NCT02039609||Omnivores|No intervention, habitual diet
33042122|NCT02039609||Vegetarians|No intervention, habitual diet
33042123|NCT02039609||Vegans|No intervention, habitual diet
33042124|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
33042125|NCT02039622||Patient under study condition|Patient under study condition
33108829|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
33108830|NCT00447395||GROUP 4|•Healthy young sperm donors
33108831|NCT05425875|Experimental|Manual suction|A 50-mL syringe will be used to apply the suction.
33330303|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
33330304|NCT05308290|Experimental|Blood pressure managed by cerebral autoregulation|In this arm cerebral autoregulation monitoring will be used to determine the lower and upper limits of cerebral autoregulation. Monitoring will continue throughout the surgery. Blood pressure management will be maintained to be within the limits of cerebral autoregulation.
33330305|NCT05308290|Active Comparator|Standard of care blood pressure management|In this arm cerebral autoregulation monitoring will be used for observation. The anesthesia provider will use usual care guidelines for blood pressure management.
33330306|NCT00497926|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
33042126|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
33042127|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
33042128|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
33042129|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
33042130|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
33042131|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
33042132|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Sound isolation~INTERVENTION: Third hour. Music therapy~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
33042133|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Music therapy~INTERVENTION: Third hour. Sound isolation~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
33042134|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
33042135|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
33042136|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
33042137|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
33042138|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
33042139|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
33042140|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
33042141|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
33042142|NCT02040194|Experimental|AM-101 injection|AM-101
33042143|NCT02040194|Placebo Comparator|Placebo injection|Placebo
33042144|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
33042145|NCT02040220||Group 1|Eylea treatment goup
33042146|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
33042147|NCT02040233|Active Comparator|BAY1067197|
33042148|NCT02040233|Placebo Comparator|Placebo (10 mg)|
33330307|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
33330308|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
33330309|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
33042149|NCT02040233|Placebo Comparator|Placebo|
33042150|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
33042151|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
33042152|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
33042153|NCT02040272|No Intervention|no surgery|no surgery
33042154|NCT02040285|Active Comparator|Free laxative CTC|
33042155|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
33042156|NCT02040311|Experimental|Topiramate 96 mg daily|
33108832|NCT05425875|Experimental|Manual suction with tubing|A 50-mL syringe with a 15-cm rubber tubing.
33108833|NCT05425875|Active Comparator|Wall mount suction|A negative pressure of <100 mmHg will be applied using continuous wall suction.
33108834|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
33108835|NCT05425602|Experimental|MAX40279-01+KN046|"This is an open-label Phase I/II clinical study.~Drug: Stage1: Dose1:MAX40279-01 (35mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose2:MAX40279-01( 50mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose3:MAX40279-01( 70mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage2: Dose3:MAX40279-01( RP2D BID)+KN046 ( 5mg/kg Q3Week)"
33108836|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
33330310|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
33330311|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
33330312|NCT05487768|Experimental|Anterior cruciate ligament reconstruction group|Patients that underwent an anterior cruciate ligament reconstruction
32868410|NCT05468892|Active Comparator|Arm A|Trifluridine-Tipiracil
32868411|NCT05468892|Experimental|Arm B|Panitumumab + Trifluridine-Tipiracil
33330313|NCT05487768|Active Comparator|Control group|Healthy matched controls
33330314|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
33330315|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
33417929|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
33436487|NCT05704465|Other|Qi-gong Therapy|Qigong technique is a type of mind-body meditative exercise developed in traditional Chinese medicine more than 5000 years ago.
32868412|NCT00200161|Active Comparator|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
32868413|NCT00200161|Experimental|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
32905022|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
32905023|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
32905024|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~24 additional weeks of CBT"
32905025|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
32905026|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
32905027|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
32905028|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
32905029|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
32905030|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
32905031|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
32905032|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
32905033|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
32905034|NCT01361633|Experimental|Medication|250 mg d-cycloserine
32905035|NCT01361633|Placebo Comparator|Sugar Pill|
32905036|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
32905037|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
32905038|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
32905039|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
32905040|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
32905041|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
33108837|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
33108838|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
33108839|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
33108840|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
33108841|NCT00447551|Experimental|single group|
33108842|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
33108843|NCT00447668|Experimental|1|
33108844|NCT00447668|Active Comparator|2|Exercise
32868414|NCT05459454|Experimental|Digital intervention group|"Participants will be instructed to download a lifestyle-changing mobile application, and they will receive an access code to activate the breast cancer program to which they will have access for 12 months.The 14-week intervention program aims to support lifestyle changes by remote symptom monitoring, patient reported outcomes (PROs) and having participants enter data and answer questionnaires via the SidekickHealth platform, and to empower positive lifestyle changes. The program's objective is to empower self-assessment of symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content.~Beyond this, all patients in the interventional arm will also receive standard of care as defined for the control arm."
33108845|NCT00447668|Active Comparator|3|Self-care book recommendations
33108846|NCT05425407|Placebo Comparator|Placebo|Only whey protein will be provided
33108847|NCT05425407|Experimental|Collagen|A mix of whey protein and collagen peptides will be provided
33108848|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
33108849|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
33108850|NCT05425368|Experimental|silver diamine fluoride group|partial caries removal will be carried out then Silver Diamine Fluoride will be applied as indirect pulp capping agent and rubbed for 1 minute followed by Glass ionomer filling
33108851|NCT05425368|Active Comparator|mineral trioxide aggregate group|partial caries removal will be carried out then mineral trioxide aggregate will be placed as indirect pulp capping agent followed by glass ionomer filling
33108852|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
33108853|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
33108854|NCT04681326|Experimental|Biological prosthesis|The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
33108855|NCT04681326|No Intervention|Standard of care|Normal abdominal wall closure
33108856|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
33108857|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
33108858|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
33108859|NCT05425329|Experimental|Probiotic treatment|P. acidilatici, CECT 7483, L. plantarum CECT 7484, L. plantarum CECT7485 in a ration of 1:1:1 at a dose of 3b cfu/day.
33108860|NCT05425329|Placebo Comparator|Placebo treatment|Capsules indistinguishable from intervention containing maltodextrin.
33108861|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
33108862|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
33108863|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
33108864|NCT00448214|Experimental|1|Low dose
33108865|NCT00448214|Experimental|2|Middle dose
33108866|NCT00448214|Experimental|3|High dose
33108867|NCT00448214|Active Comparator|4|
33108868|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
33108869|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
33108870|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
33108871|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
33108872|NCT05425212|Experimental|Functional activation with kinesio tapping|given 5 cm wide kinesio tape at tibialis anterior and gastrocnemius to facilitate dorsiflexion of the ankle and inhibit planter flexion simultaneously along with conventional treatment.
33108873|NCT05425212|Active Comparator|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; Heel walk; Pebble picking; Single leg standing; and Ankle range of motions
33108874|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
33108875|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
33108876|NCT05425017||Low back pain group|Participants currently experiencing low back pain will have small accelerometers taped along spine and do a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
33108877|NCT05425017||Healthy group|Participants will have small accelerometers taped along spine and do a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
33108878|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
33108879|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
33330316|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
33330317|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
33330318|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
33417930|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
32868415|NCT05459454|No Intervention|Standard of Care|The control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
33108880|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
33108881|NCT00448409|Experimental|1|TroVax alone
33108882|NCT00448409|Experimental|2|TroVax plus GM-CSF
33108883|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
33108884|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
33108885|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
33108886|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
33108887|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
33108888|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
33330319|NCT02344420|Other|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
33330320|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
33330321|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
33330322|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
33330323|NCT04456920|Experimental|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
33330324|NCT04456920|Experimental|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
33330325|NCT04456920|No Intervention|Control group|group without e-PROs (standard care)
33330326|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
33330327|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
33330328|NCT02171884||Group T1|Singletons conceived naturally
33330329|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
33330330|NCT01309854|Experimental|pioglitazone|
33330331|NCT01309854|Experimental|pioglitazone and fostamatinib|
33330332|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
33330333|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
33330334|NCT05097534|Active Comparator|iDSMES|"Eligible study subjects randomized to the intervention arm will receive:~A. Intensive Diabetes Self-Management, Education, and Support (iDSMES). Participants will be enrolled in groups in a virtual or in-person setting with their lifestyle coach, in this one-year educational program B. Services addressing Social Determinants of Health All study subjects will have their data collected at time points around baseline, 6 months and 12 months from consenting including glycemic control, hypertension management, dyslipidemia management, prevention or management of complications, healthcare outcomes, lifestyle change outcomes, patient-centeredness outcomes, Secondary diabetes self-management behaviors, self-efficacy in managing diabetes, diabetes distress, and Morisky Green Levine Medication Adherence Scale."
33330335|NCT05097534|Placebo Comparator|Standard of Care|Eligible study subjects randomized to the intervention arm will receive standard of care offered to patients with diabetes.
33330336|NCT05074212|Experimental|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
33330337|NCT05074212|Experimental|Second Intention Healing|The study participant will not have any sutures placed.
33330338|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate~Vaccinations on Day 0, Day 28, and Day 140"
33042157|NCT02040311|Experimental|Topiramate 192 mg daily|
33042158|NCT02040311|Placebo Comparator|placebo|
33330339|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
33330340|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
33330341|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
33042159|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
33042160|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
33330342|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
33330343|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
33330344|NCT05073510||BlueDop Vascular Expert (BVE)|PAD assessment with BVE
33330345|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
33330346|NCT05305560|Experimental|Active IMP|
33330347|NCT05305560|Placebo Comparator|Placebo|
32868417|NCT00200785|Active Comparator|Garlic powder in ambient water|high allicin
32868418|NCT00200785|Experimental|garlic powder in boiling water|no allicin
33042161|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
33042162|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
33042163|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
33042164|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
33042165|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
33042166|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
33042167|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
33042168|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
33042169|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
33042170|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
33042171|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
33042172|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
33042173|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
33042174|NCT02040441|Other|Observational|Low-risk pattern: Standard care
33042175|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent~Paclitaxel - single intravascular dose up to 20 mg"
33042176|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
33042177|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
33042178|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
33042179|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
33042180|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
33042181|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
33042182|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
33042183|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
33042184|NCT02040506|Experimental|IGN523|IGN523
33042185|NCT02040519|Experimental|Evaluation by voiding diaries|
33330348|NCT05301894|Experimental|NBI-827104|NBI-827104 administered orally
33330349|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
33330350|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
33330351|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
33330352|NCT03782922|Experimental|Exercise Training Program|
33330353|NCT03782922|No Intervention|Control|
33330354|NCT03782844|Experimental|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
33330355|NCT03782844|Experimental|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
32868419|NCT00016913|Experimental|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
32868420|NCT05558046||Low Ovarian Reserve|Patients diagnosed as low ovarian reserve were recruited to the study who have Antimüllerian Hormone level of 1 ng/ml or lower. Patients with low ovarian reserve were diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. Male infertility is an exclusion.
33042186|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
33330356|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
33330357|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
33330358|NCT05285904||Ofatumumab|Population under routine medical care prescribed Ofatumumab in an early Relapsing Multiple Sclerosis
33330359|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
33330360|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
33108889|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
33330361|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
32905042|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
32905043|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
32905044|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
32905045|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
32905046|NCT01277783|Experimental|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
32905047|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
32905048|NCT01362959|Experimental|Nicotine patch|
32905049|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
32905050|NCT01278953|Experimental|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
32905051|NCT01278953|Active Comparator|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
32905052|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
32905053|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
32905054|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
32905055|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
32905056|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
32905057|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
32905058|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
32905059|NCT00848510|Experimental|EMD 525797|
32905060|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
32905061|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
32905062|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
33417931|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
32740130|NCT02215265|Experimental|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
32740131|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
32740132|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
32740133|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
32740134|NCT03310307|Active Comparator|vitamin D3|50,000 IU
32740135|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
32740136|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
33067783|NCT04724538|Experimental|Patient with COVID-19 pneumonia|Inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 4165 MBq of 99mTc-pertechnetate. CT scans a day before, 7 and 14 days after inhalation procedure. Blood tests a day before, 1, 3 and 7 days after inhalation procedure.
33067784|NCT04724538|No Intervention|Patient with COVID-19 pneumonia without intervention|Blood tests at 1, 3 and 7 days.
33067785|NCT00137189|Experimental|Music therapy|See published study protocol
33067786|NCT00137189|Other|Standard care|See published study protocol
33067787|NCT00159939|Active Comparator|prone position|prone positioning
33067788|NCT00159939|No Intervention|supine position|
33067789|NCT00137306|Other|Arm 1|
33067790|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
33067791|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
33067792|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
33067793|NCT00153504|Active Comparator|Standard local practice housing assistance|
33067794|NCT00137501|Other|A|High dose Nifedpine arm
33067795|NCT00137501|Other|B|Low dose Nifedipine arm
33067796|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
33067797|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
33067798|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
33067799|NCT05441111|Experimental|COMET + guided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
33067800|NCT05441111|Active Comparator|COMET + unguided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Participants are left to read the book on their own (i.e., without an eCoach)"
33067801|NCT00160290|Experimental|A|Lactulose Group
33067802|NCT00160290|Active Comparator|B|Plantago Group
33067803|NCT00137735|Active Comparator|1|Gabapentin
33067804|NCT00137735|Placebo Comparator|2|Placebo
33067805|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
33067806|NCT00153894|Active Comparator|Group A|Immediate Exercise
33067807|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
33067808|NCT00138008|Active Comparator|1|Drug: endocrine therapy
33067809|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
33067810|NCT00160446|Experimental|1|
33067811|NCT00160446|Experimental|2|
33067812|NCT00160446|Experimental|3|
33067813|NCT00160446|Placebo Comparator|4|
33067814|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
33067815|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
33067816|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
33067817|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
33067818|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
33067819|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
33067820|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
33067821|NCT00404183|Placebo Comparator|Placebo|
33067822|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
33067823|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
33067824|NCT00404222|Placebo Comparator|Placebo|
33067825|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
33067826|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
33330362|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
33330363|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
33330364|NCT05526144|Placebo Comparator|Placebo group|Placebo group will receive placebo tablets
33330365|NCT05526144|Active Comparator|Study group|Study group will receive Synthroid (Levothyroxine) 25, 50, or 75 mcg daily
33042187|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
33042188|NCT02040571|Experimental|Closed Loop|
33042189|NCT02040571|Active Comparator|Open Loop|
33042190|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
33042191|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
33042192|NCT02040597|Experimental|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
33042193|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
33042194|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
33042195|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
33042196|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
33042197|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
33042198|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
33042199|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
33042200|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
33042201|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
33042202|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
33042203|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
33042204|NCT02040701||SDB group|
33042205|NCT02040701||Control group|
33042206|NCT02040714||Nonoperative management between ages 6-8 in early stage|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33042207|NCT02040714||Operative management between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process
33042208|NCT02040714||Nonoperative management between age 8-11 in early stage|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
33042209|NCT02040714||Operative containment with short-term non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
33042210|NCT02040714||Operative containment with prolonged non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
33042211|NCT02040714||Operative containment for over 11 age group|Patients presenting over age 11 may receive multiple drilling and be non weight bearing for up to 6 months according to the treating physician's preference. Patients with application of fixator (arthrodiastasis) will be studied in this cohort arm as well, which typically involved 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal. Other surgical techniques may be included, however these are the most common for this age group.
33042212|NCT02040714||Nonoperative management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
33042213|NCT02040714||Nonoperative management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33417932|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
33417933|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
32740137|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
33067827|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
33067828|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
33108890|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
33108891|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
33108892|NCT05424666|Experimental|Patient going Oncoplastic Breast surgeries|Lipofilling After Oncoplastic Breast surgeries : Evaluation of Outcomes and Patient Satisfaction
33108893|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
33108894|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
33108895|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
33108896|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
33108897|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
33108898|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
33108899|NCT04699370|Experimental|cognition-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to cognition-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For Cognition- targeted exercise , all standardized physical therapy exercises will be performed in a time-contingent rather than in a symptom-contingent way ."
33330366|NCT05002608|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
33330367|NCT05002608|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
33330368|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.~=> Group: Fluoride Varnish"
33330369|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.~=> Group: Curodont Repair + Fluoride Varnish"
33330370|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).~=> Group: Curodont Repair + Curodont Protect"
33330371|NCT05669040|Active Comparator|Patient experience|
33330372|NCT05669040|Active Comparator|Adherence to drug treatment|
33330373|NCT05669040|Active Comparator|Positive mental health|
33330374|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
33330375|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
33330376|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
33067829|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
33067830|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
33330377|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
33330378|NCT04531254|Experimental|Masking at all times|Children in this group will be asked to wear a face mask/covering in the classroom and common areas during the simulation
33330379|NCT04531254|No Intervention|No mask/masking when physical distancing is not maintained|Children in this group will not be asked to wear a mask (JK-Grade 4) or only asked to wear a mask when physical distancing in the classroom cannot be maintained (Grade 5-Grade 12) during the simulation
33330380|NCT03072160|Experimental|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 1: cancer vaccine"
33330381|NCT03072160|Experimental|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 2: had no previous vaccine"
33330382|NCT04955730|Experimental|NPWT - Negative Pressure Wound Therapy|Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.
33330383|NCT04955730|No Intervention|Standard of Care Wound Therapy|Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.
33330384|NCT05517486|Experimental|50 mg GTX-101|
33330385|NCT05517486|Experimental|100 mg GTX-101|
33330386|NCT05517486|Experimental|200 mg GTX-101|
33330387|NCT05517486|Active Comparator|Bupivacaine subcutaneous injection|
33330388|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
33330389|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
33330390|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
32868421|NCT05558046||Unexplained Infertile (Control group)|Patients diagnosed as unexplained infertility (UI) were recruited to the study who have Antimüllerian Hormone level of 1.5 ng/ml or higher as a control group. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy.
33042214|NCT02040714||Operative management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33042215|NCT02040714||Late Stage Bracing group|Patients presenting with <= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33330391|NCT05480904||On campus|SJLIFE Study Campus Visit
33042216|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33042217|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
33042218|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
33042219|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
33042220|NCT02040740||Observation|Healthy early pubertal boys
33042221|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
33042222|NCT02040818|Experimental|Antibiotic Lock Solution|
33042223|NCT02040818|Active Comparator|Guide-wire Exchange|
33042224|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
33042225|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
33042226|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
33330392|NCT05480904||Remote|SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors
33330393|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
33330394|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
33330395|NCT04952532|Other|Cognitive Remediation+Bridging Intervention|This is a pilot study to collect feasibility data on this novel cognitive remediation intervention for Veterans at high risk for suicide. All patients will receive the active intervention.
33330396|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
33330397|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
33330398|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
33330399|NCT00407602|Other|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
33330400|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
33330401|NCT05202652|Placebo Comparator|Control Group|The control group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing 455mg of the carrier substance (magnesium stearate)
33330402|NCT05202652|Active Comparator|HealthSpan(HS) Group|The HS group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing the 455mg of the mixture of the active compounds along with the carrier.
33330403|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
33108900|NCT04699370|Active Comparator|symptom-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to symptom-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For symptom- targeted exercise, All Standardized physical therapy exercises will be performed in a symptom-contingent way (Stop or adjust the exercise when it hurts)."
33108901|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
33108902|NCT04699448|Active Comparator|High-protein hypocaloric diet|Composition of hypocaloric diet: protein:40%,carbohydrates:30% and fat:30%.
33108903|NCT04699448|Active Comparator|High-carbohydrate hypocaloric diet|Composition of hypocaloric diet: carbohydrate 60%, protein:18% and fat:22%
33108904|NCT01220128|Experimental|Cohort A-GSK2302024A Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
33108905|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
33108906|NCT01220128|Experimental|Cohort B-GSK2302024A Group|This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
33108907|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
33108908|NCT01220128|Experimental|Cohort C-GSK2302024A Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
33108909|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
33108910|NCT01220128|Experimental|Cohort D-GSK2302024A-D14 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
33108911|NCT04699409|Experimental|FAST|stroke education: FAST
33108912|NCT04699409|Experimental|STROKE 112|stroke education: STROKE 112
33108913|NCT05424588||Healthy male amateur Caucasian cyclists|Healthy male amateur Caucasian cyclists who attended the NC4000 4th edition underwent clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection.
33108914|NCT04698941|Experimental|Simvastatin + Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
33108915|NCT04698941|Active Comparator|Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles)
33108916|NCT04206202|Experimental|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
32868422|NCT05612646|Active Comparator|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
33108917|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
33108918|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
33108919|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).~."
33108920|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
33108921|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
33108922|NCT05424471|Experimental|Family Spirit Nurture (FSN)|Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
33042227|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
33042228|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
33042229|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
33417934|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
33042230|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
33042231|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
33042232|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)~Radical 7 (Pleth Variability Index)~CardioQ (stroke volume)"
33042233|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
33042234|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
33042235|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
33042236|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
33042237|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
32740138|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
33042238|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
33042239|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
33042240|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
33042241|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
33042242|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
33042243|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
33042244|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
33042245|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
33042246|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
33417935|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
33417936|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
33417937|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
33417938|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
33417939|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
33417940|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
33417941|NCT01368367|Active Comparator|Intensive exercise group|
33417942|NCT01368367|Placebo Comparator|Stretch exercise only|
33417943|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
33417944|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
33417945|NCT04635631|Experimental|talazoparib|1 mg QD
33417946|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
33042247|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
33042248|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
33042249|NCT02041117|Other|Rosuvastatin|
32868423|NCT05612646|Experimental|acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
33042250|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
33042251|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
33042252|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
33042253|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
33042254|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
33042255|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
33042256|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
33042257|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
33042258|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
33042259|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
33042260|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
33042261|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
33042262|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
33042263|NCT02041260|Experimental|Open Label Cabozantimib|
32740139|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
32740140|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
33042264|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
33042265|NCT02041312||Gastric cancer|No intervention
33330404|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
33330405|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
33330406|NCT05762614||patient on invasive mechanical ventilation able to perform a SBT|
32740141|NCT01534481|Active Comparator|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
32740142|NCT01534481|Placebo Comparator|Preterm Formula|Preterm formula determined by center practice
32740143|NCT01517945||Breast cancer survivors and Rare cancer survivors|This is a Cycle for Survival and Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS) and rare cancer survivors (RCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States. About 50 percent of people with cancer have a rare cancer. Even though they account for about half of all cancer diagnoses when combined, research aimed at supporting RCS is sparse, leaving RCS with limited support after treatment.
33042266|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
33042267|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
33042268|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
33042269|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
33042270|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
33330407|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
33330408|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
33330409|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
33330410|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
33330411|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
32868424|NCT04612907|Active Comparator|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
32868425|NCT04612907|Experimental|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
32868426|NCT00201409|Experimental|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
33108923|NCT05424471|Other|Control Vehicle Safety|Control group participants receive 1 lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
32868427|NCT00201409|Placebo Comparator|2|Participants will be randomized to receive placebo.
33108924|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
33108925|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
33108926|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
33108927|NCT05424393||RA Patients receiving routine treatment|During the induction phase, the dose of YISAIPU is 50mg/wk. Patients who achieved clinical remission or low activity after 24 weeks of induction treatment can enter the maintenance phase. Those who fail to succeed in induction treatment will not be followed up. During the maintenance phase, the dose of YISAIPU could be either 50mg/wk or 25mg/wk. Patients will be followed up regularly for 2.5 years.
33108928|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
33108929|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
33108930|NCT05424354|Experimental|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing (TPD) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. TPD will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
33108931|NCT05424354|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to Standard of Care (SOC) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. The standard of care burn dressing will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
33108932|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
33108933|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
33108934|NCT01219933|Experimental|1|
33108935|NCT05373901|Experimental|Dinutuximab beta cohort|Patients who received dinutuximab beta as maintenance therapy
33108936|NCT05424120|Active Comparator|Manual aspiration|pleural fluid is drained using a standard thoracentesis kit and via a syringe and three-way stopcock
33108937|NCT05424120|Active Comparator|Wall suction|pleural fluid is drained using a standard thoracentesis kit and by attaching tubing to wall suctioning set at -50 mmHg continuously
33108938|NCT05424120|Active Comparator|Vacuum bottle drainage|pleural fluid is drained using a standard thoracentesis kit and tubing that attaches to a glass vacuum container
33108939|NCT05368441|Experimental|Midazolam-Group M|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room.
33108940|NCT05368441|Placebo Comparator|Control- Group S|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room.
33108941|NCT05468359|Other|Treatment|All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.
33108942|NCT05657080||Cases|"This will include patients with:~existing diagnosis of proximal GIM undergoing endoscopic surveillance~a new diagnosis of proximal GIM requiring repeat endoscopy~a historical diagnosis of GIM retrieved from the pathology records through retrospective analysis and lost in follow up~gastric adenocarcinoma from upper GI multidisciplinary meeting."
33108943|NCT05657080||Controls|Controls will be patients with no known premalignant conditions of the upper GI tract and fit to undergo an upper endoscopy. They will be recruited via standard referral routes for upper GI endoscopy due to upper GI symptoms via standard referral routes. Individuals must be able to provide informed consent.
33108944|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
33108945|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
33108946|NCT05466877|Experimental|MG-K10 Regimen 1|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
33108947|NCT05466877|Experimental|MG-K10 Regimen 2|subcutaneous injection every 2 weeks
33108948|NCT05466877|Experimental|MG-K10 Regimen 3|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
33108949|NCT05466877|Placebo Comparator|Placebo|subcutaneous injection every 2 weeks
33108950|NCT04316845|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
33108951|NCT05456932|Experimental|Intravenous iron|Intravenous iron therapy
33108952|NCT05456932|Experimental|Ferric maltol|Treatment with oral ferric maltol
33108953|NCT05456932|Experimental|Ferrous fumarate|Treatment with oral ferrous fumarate
33108954|NCT05423886|Experimental|Intervention arm|Participants receive a personalized screening invitation interval (1,2 or 3 years) based on their fecal Hemoglobin concentration of the negative fecal immunochemical test in previous round.
33108955|NCT05423886|No Intervention|Control arm|Participants receive a standard screening invitation interval (2 years).
33108956|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
33042271|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
33042272|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
33042273|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
33042274|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
33042275|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
33042276|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
33042277|NCT02041403||Renal resistive Index|
33042278|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
33042279|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
33417947|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
33042280|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
33042281|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
33042282|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
33417948|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
33042283|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
33042284|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33042285|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33042286|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
33042287|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
33042288|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
33042289|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
33042290|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
33042291|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
33042292|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
33042293|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
33042294|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
33042295|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
33042296|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
33042297|NCT02041650|Other|Patients with ACS treated medically|
33042298|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
33042299|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
33042300|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
33042301|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
33042302|NCT02041715|Experimental|TKM-100802 for Injection|
33042303|NCT02041715|Placebo Comparator|Placebo|
33417949|NCT04463667|Experimental|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
33417950|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
33417951|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
32868428|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
33042304|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
33042305|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
33042306|NCT02041741|No Intervention|Wait-List Control|No intervention
33042307|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
33042308|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
33042309|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
33042310|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
33042311|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
33042312|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
33042313|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
33042314|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22.~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
33042315|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
33042316|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
33042317|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
33042318|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
33042319|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
33042320|NCT02041871|Placebo Comparator|Placebo|Placebo
33042321|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
33042322|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
33042323|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
33042324|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
33042325|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
33042326|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
33042327|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
33042328|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
33042329|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
33042330|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
33042331|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
33042332|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
33042333|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
33042334|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
33042335|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
33042336|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
33042337|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
33042338|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
33042339|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
33042340|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
33042341|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
33042342|NCT02042144||Group 1|
33042343|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
33042344|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
33067831|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
33042345|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
33108957|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
33417952|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
33042346|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
33042347|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
33042348|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
33042349|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
33042350|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
33042351|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
33042352|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~No hormone modification."
33042353|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
33042354|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
33042355|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
33042356|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
33042357|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
33042358|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
33042359|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
33042360|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
33042361|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
33042362|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
33042363|NCT02042352||pH test|VpH test gloves
33330412|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
33330413|NCT05762536|Active Comparator|Docetaxel or cabazitaxel (SOC)|
32868429|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
32868430|NCT03889080||Control|Age- and gender-matched healthy controls
33042364|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
33042365|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
33042366|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
33042367|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
33042368|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
33042369|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
33042370|NCT02042508|Experimental|Paraplegic patients|
33042371|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
33042372|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
33042373|NCT02042547||Patients about to undergo heart surgery|
33042374|NCT02042560||Patients with ITP|
33042375|NCT02042560||Controls|
33042376|NCT02042573|Other|Depressive patients treated with rTMS|
33042377|NCT02042573|Other|Depressive patients treated with SSRI|
33042378|NCT02042573|Other|Controls|
33042379|NCT02042586||Patients|
33042380|NCT02042586||Controls|
33042381|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
33042382|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
33042383|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
33042384|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
33042385|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
33042386|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
33042387|NCT02042664|Experimental|treatment BYETTA|
33042388|NCT02042664|Active Comparator|metformine|
33042389|NCT02042690|Active Comparator|chemotherapy|"Drugs:~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
33042390|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
33042391|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
33042392|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
33042393|NCT02042703||cataracts|patients with cataracts
33042394|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
33042395|NCT02042729|Experimental|E2022- Tape Formulation|
33042396|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
33042397|NCT02042729|Active Comparator|E2022- New Formulation|
33042398|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
33042399|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
33042400|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
33042401|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
33042402|NCT02042807|Placebo Comparator|Placebo|placebo arm
33042403|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
33042404|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
32868431|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
32868432|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
32868433|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
32868434|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
32868435|NCT00023309|Experimental|Lamivudine and adefovir|
32868436|NCT00023309|Active Comparator|Adefovir|
32868437|NCT05456178||Adult subjects with chronic obstructive pulmonary disease|In adult patients with chronic obstructive pulmonary disease, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks, to be analyzed by the mycology laboratory of the Croix-Rousse hospital, Lyon.
32868438|NCT00098059|Experimental|Famciclovir, pediatric oral formulation|single-arm
32868439|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
32868440|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
32868441|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
32868442|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
32868443|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
32868444|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
32868445|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.~Blood specimen at each visits"
32868446|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.~Blood specimen at each visits"
32868447|NCT00098371|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
32868448|NCT04745988|Experimental|Lenvatinib Plus Pembrolizumab|One cycle is 21 days, with Lenvatinib plus Pembrolizumab repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
32868449|NCT04745988|Experimental|Lenvatinib, Pembrolizumab Plus FLOT|One cycle is 21 days, with Lenvatinib, Pembrolizumab plus FLOT repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
32868450|NCT01647945|Placebo Comparator|Placebo|
32868451|NCT01647945|Experimental|FK506 level < 2|
32868452|NCT01647945|Experimental|FK506 level 2-3|
32868453|NCT01647945|Experimental|FK506 level 3-5|
32868454|NCT05557734|Active Comparator|caudal epidural group|"the patient will be positioned in lateral position, sterilized from the iliac crest margin to the lower buttock by betadine and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound. Short axis (transverse) will be used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) will be used for direct puncture of sacrococcygeal membrane out of plane then the probe will be rotated to long axis (longitudinal) and the needle will be seen in plane in the epidural space. Injection of 40 ml 0.125% bupivacaine will expand the epidural space. The patient will be repositioned to lithotomy position and surgery will start after 5 min. of preparing the patient and sterilization to the surgery"
32868455|NCT05557734|Active Comparator|perianal block group|, the patient will be in the lithotomy position, paint and drape the area of the block under strict aseptic precaution, draw a circle with a radius of 2.5cm around anal opening, mark a point at 2,4,8,10 clock position, prepare 40 ml 0.125% bupivacaine, use 1.5-inch 23/24 gauge needle connected to 10 ml syringe, insert full length of the needle into the ischiorectal fat immediately peripheral to the external sphinchter. This injection scheme target the terminal nerve branches of the anus rather than blocking the trunk of major nerves. At 2 clock position, inject 2-3 ml of LA with tilting in lateral direction,withdraw needle 1cm and after every 1cm inject 2-3ml of LA, repeat procedure at 4,8,10 clock position, remaining around 10 ml of LA is used to infiltrate in subcutaneous tissue in circumference of anal opening.
32868456|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
32868457|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
32868458|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.
33108958|NCT05657041|Experimental|Group 1: body weight <60kg|Treatment with clopidogrel 50mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with clopidogrel 25mg once daily (max 14 days).
33042405|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~Tear Break Up Time (TBUT)~Ocular Surface Disease Index (OSDI)~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
32740144|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
32740145|NCT03310151|No Intervention|control|Follows usual care
32740146|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
33042406|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~TBUT~OSDI~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
33042407|NCT02042833||Cohort|
33042408|NCT02042846|Experimental|SportWelding Fiji Anchor|
33042409|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
33330414|NCT05762536|Experimental|Docetaxel or cabazitaxel with darolutamide|
33330415|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
33042410|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
33042411|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
33042412|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
33042413|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
33330416|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
33330417|NCT05202574|Active Comparator|dexamethasone|
33330418|NCT05202574|Active Comparator|ondanestrone|
33330419|NCT05202574|Placebo Comparator|control group|
33330420|NCT05202496|Experimental|Experimental: oral vitamin D supplementation during orthodontic treatment|"The biological methods include using various chemicals like parathyroid hormone, thyroid hormone, prostaglandins, corticosteroids, relaxin and vitamin D.~Due to its important role in bone remodeling, vitamin D is hypothesized to play an important role in accelerating orthodontic tooth movement.~experimental group subjects with serum vitamin D levels in the range of 30-40 ng/ml are enrolled"
33330421|NCT05202496|Active Comparator|control : Orthodontic treatment with no intervention|control group subjects with serum vitamin D levels in the range of (30-40 ng/ml) are enrolled
33330422|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
33330423|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
33330424|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
33330425|NCT05201560|Experimental|Butorphanol tartrate|Butorphanol tartrate on the patients with mechanical ventilation
33330426|NCT05201560|Active Comparator|fentanyl|fentanyl on the patients with mechanical ventilation
33330427|NCT05201326|Experimental|Treatment arm|irinotecan + bevacizumab + Re-radiotherapy
32740147|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
32740148|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
32740149|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
32740150|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
33042414|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
33042415|NCT02042937|No Intervention|Control|No intervention
33042416|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
33042417|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
33042418|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
33042419|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
33042420|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
33042421|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
33042422|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
33042423|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
33042424|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
33042425|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
33108959|NCT05657041|No Intervention|Group 2: body weight 60-100kg|Treatment with clopidogrel 75mg once daily
33108960|NCT05657041|Experimental|Group 3: body weight >100kg|Treatment with clopidogrel 150mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with prasugrel 10mg once daily (max 14 days).
33108961|NCT00449267|Experimental|1|
33108962|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108963|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108964|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108965|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108966|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108967|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
33108968|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
33108969|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
33108970|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
33108971|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
33108972|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
33108973|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
33108974|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
33108975|NCT05656963||Idiopathic membranous nephropathy|Patients with idiopathic membranous nephropathy proved by renal biopsy
33108976|NCT05656963||Non-Idiopathic membranous nephropathy|Other primary glomerular diseases except membranous nephropathy
33108977|NCT05656963||Diabetic kidney disease|Patients with clinical diagnosis of diabetes and kidney disease
33108978|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
33108979|NCT05423847||Benin1|Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
33108980|NCT05423847||Mali1|Mali urban recruitment site University Hospital Bamako, outpatient emergency department
33108981|NCT05423847||South-Africa1|South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
33108982|NCT05423847||South-Africa2|South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
33108983|NCT05423808|Experimental|Intervention group|Patients in the intervention group will be part of a renewed care pathway supported by digital tools.
33108984|NCT05423808|No Intervention|Control group|Patients in the control group will receive standard of care, specific to the hospital where the patient is being treated.
33108985|NCT03276299|Active Comparator|test 1|six minute walking test
33108986|NCT03276299|Experimental|test 2|six minute walking test
33108987|NCT03276299|Experimental|test with encouragement|six minute walking test
33108988|NCT03276299|Active Comparator|test without encouragement|six minute walking test
33108989|NCT04680078|Active Comparator|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
33108990|NCT04680078|Active Comparator|Conventional Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop.
33108991|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
33108992|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
33108993|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
32868459|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine)75 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.
32868460|NCT00100165|Placebo Comparator|placebo|Patient receives placebo twice per day in a blinded capsule.
32868461|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
32868462|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
32868463|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
32868464|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
32868465|NCT04351191|Active Comparator|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
32868466|NCT04351191|Experimental|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
32868467|NCT04351191|Active Comparator|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
32868468|NCT04351191|Placebo Comparator|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
32868469|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
32868470|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
32868471|NCT05557578|Experimental|Experimental arm|Tislelizumab combined with GEMOX (GOT) regimen
32868472|NCT02995317||Fall accidents|
32868473|NCT00201877|Experimental|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
32868474|NCT05557500|Experimental|Fibromyalgia patients with use of rtms sessions for treatment|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
32868475|NCT05557500|Experimental|Fibromyalgia pt with use of sphenopalatine ganglion block as treatment|Pain killing intervention for pain control of myofacial pain in fibromyalgia patients
32868476|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
32868477|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
32868478|NCT05358691|Experimental|AN0025: Dose level one: 250 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
32868479|NCT05358691|Experimental|AN0025: Dose level two: 375 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
32868480|NCT05400720|Experimental|Mentee|Participants will be approached by a mentor, exchange experiences and invite the prospective mentee to the program. Those interested to continue will undergo matching based on their desired criteria.
32868481|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
32868482|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
32868483|NCT05399628|Experimental|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with a marked tip
33067832|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
32868484|NCT05399628|Active Comparator|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with an unmarked tip
32868485|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
32868486|NCT05335291||Group I|
32868487|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
32868488|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
32868489|NCT05391672|Other|Repair group|Repair of partial torn ACL by suturing stump and fixation to femoral footprint by anchors
32868490|NCT05391672|Other|Augmentation group|We will use hamstring graft in which fixation of graft will be by adjustable loop devices for femoral part fixation & Bioscrews +/- staples for tibial part fixation
33108994|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
33108995|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
33108996|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
33108997|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
33108998|NCT04679883|Experimental|GLH8NDE 5% and GLH8NDE Placebo|Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo
33108999|NCT04679883|Experimental|GLH8NDE 5%|Total 6 times 1 drop of GLH8NDE 5%
33109000|NCT04679883|Placebo Comparator|GLH8NDE Placebo|Total 6 times 1 drop of GLH8NDE Placebo
33109001|NCT01188655||Treatment Group Enbrel|
33109002|NCT02900703||PATIENT|
33109003|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
33109004|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
33109005|NCT00449618|Placebo Comparator|3|Placebo on awakening
33109006|NCT00449618|Placebo Comparator|4|Placebo at bedtime
33109007|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
33109008|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
33109009|NCT04316767|Experimental|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
33109010|NCT04316767|No Intervention|Control|Participants will receive usual supportive care provided to family members of ICU patients.
33109011|NCT04318444|Experimental|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
33109012|NCT04318444|Placebo Comparator|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
33109013|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
33109014|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
33330428|NCT05274906|Experimental|Controlled HEI-2015 diet with red and processed meat|
33330429|NCT05274906|Experimental|Controlled HEI-2015 diet without red and processed meat|
33330430|NCT05762458|Experimental|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
33330431|NCT05762458|Experimental|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
33330432|NCT05762458|Placebo Comparator|Placebo group|The eligible subjects will receive placebo to Ammoxetine.
33109015|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
33109016|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
33109017|NCT05423613|Experimental|Microneedling treated scar|Microneedling
33109018|NCT05423613|No Intervention|Control scar|No intervention, standard of care
33109019|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
33109020|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
33109021|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
33109022|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
33330433|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
33330434|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
33330435|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
33330436|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
33330437|NCT05762380|Active Comparator|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
33042426|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
33042427|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
33042428|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
33042429|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
33042430|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
33042431|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
33042432|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
33042433|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
33042434|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
33042435|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
33042436|NCT02043119|No Intervention|Standard of Care|
33042437|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
33042438|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
33042439|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
33042440|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
33042441|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
33042442|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
33042443|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
33042444|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
33042445|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
33042446|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
33042447|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
33042448|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
33042449|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
33042450|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
33042451|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
33042452|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
33042453|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
33042454|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
33042455|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
33042456|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
33042457|NCT02043275|Experimental|Leg training|Lower body resistance training only
33042458|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
33042459|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
33042460|NCT02043288|Active Comparator|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
33330438|NCT05762380|Experimental|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
33330439|NCT04928430|Experimental|XAV-19|XAV-19
33330440|NCT04928430|Placebo Comparator|Placebo|
33330441|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
33042461|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
33042462|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
33042463|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
33330442|NCT05762302|Experimental|Adults with suspected Lower Respiratory Track Infection (LRTI)- The MeMed BV arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will receive the BV result, this will include a recommendation regarding antibiotic treatment. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
32740151|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
32740152|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
33330443|NCT05762302|No Intervention|Adults with suspected Lower Respiratory Track Infection (LRTI)- The control arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will not receive the BV result, and will treat according to standard of care. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
33330444|NCT03775902|Experimental|Healthy subjects|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
33330445|NCT03775902|Experimental|Pre and/or type 2 diabetics|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
33330446|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
33330447|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
33417953|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
33417954|NCT02085902|No Intervention|standard anesthesia|
33042464|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
33042465|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
33042466|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
33042467|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
33042468|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
33042469|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
33042470|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
33042471|NCT02043418||children VIH+|children infected with HIV
33042472|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
33042473|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
33042474|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
33042475|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
33042476|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
33042477|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
33042478|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
33042479|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
33042480|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
33042481|NCT02043535|Other|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
33042482|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
33417955|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
33417956|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
33042483|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
32868491|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
33042484|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
33042485|NCT02043600|Experimental|Yoga|
33042486|NCT02043600|Active Comparator|Self-care|
33042487|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
33042488|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
33042489|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
33042490|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
33042491|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
33042492|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
33042493|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
33042494|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
33042495|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
33042496|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
33042497|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
33042498|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.~Stem Cell Dose:~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
33042499|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
33042500|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
33042501|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:~review routinely collected information;~conduct questionnaires with caregiver and child;~conduct additional assessments of child;~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
33042502|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
33042503|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
33042504|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
33042505|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
33042506|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
33042507|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
33042508|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
33042509|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
33042510|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
33042511|NCT02043912||patients treated with haloperidol|
33042512|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
33042513|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
33042514|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
33042515|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
33042516|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
33042517|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
33042518|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
33109023|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
33109024|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
33109025|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
33109026|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
33109027|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
33109028|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
33109029|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
33109030|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
33109031|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
33109032|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
33109033|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
33109034|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
33109035|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
33109036|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
33109037|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
33109038|NCT05423067|Other|BUAO|"The study done in two phases:~Phase one from October 2011to May 2012 pilot study including twenty nine (29) premenopausal patients followed up for six months~Phase two from October 2012 till May 2014. Including Eighty nine (89) premenopausal patients"
33109039|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
33109040|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
33109041|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
33109042|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
33109043|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
33109044|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
33109045|NCT02900196|Experimental|1 - Test|
33109046|NCT02900196|Placebo Comparator|2 - Placebo|
33109047|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
32868492|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
33109048|NCT00449852|Experimental|Interactive Voice Response Group|
33109049|NCT00449852|No Intervention|Usual Care Group|
33109050|NCT04681209|Experimental|DRT-Condition|This is the experimental group that engaged in the DRT-based intervention activity.
33109051|NCT04681209|Active Comparator|Empathy-Condition|This is the experimental group that engaged in the empathy-based intervention activity.
33109052|NCT05423028|Active Comparator|Dextrose|
33109053|NCT05423028|Experimental|Vitamin B12|
32868493|NCT03557892|Experimental|CSII+CGM|
33109054|NCT05423028|Experimental|Dextrose + Vitamin B12|
33109055|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
33109056|NCT00449969|Experimental|1. Extended feedback|
33109057|NCT00449969|Active Comparator|2. Limited feedback|
33109058|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
33109059|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection~Surgery: 2-4 weeks after denosumab"
33109060|NCT00450086|Experimental|A|
33109061|NCT00450086|Experimental|B|
33109062|NCT00450086|Placebo Comparator|C|
33109063|NCT05422911|Active Comparator|Abiraterone Acetate|
33109064|NCT05422911|Active Comparator|Standard of Care|
33109065|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
33109066|NCT02900157|Experimental|MEDI9090|
33109067|NCT05422872||Croatia|Twenty to twenty-five professionals assigned to Croatian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33330448|NCT05181280|Experimental|Intervention|"Treatment: Standardized body image messaging targeting mothers. Following a similar model that has been used in previous studies testing the effect of traditional media exposure on body image and disordered eating behaviour, participants randomized to the treatment condition will have 1 exposure session per day over 5 days. Each exposure session will consist of 15 social media body message posts. Body image messaging targeting mothers will consist of mothers with ideal postpartum bodies and captions trending over the past 24 months."
33330449|NCT05181280|Placebo Comparator|Control|Control: Standardized infant feeding tips messaging. Participants randomized to the control will have 1 exposure session/day over 5 days. Each exposure will consist of 15 social media posts on infant feeding tips.
33330450|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
33330451|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
33330452|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
33042519|NCT02044029||Age- and gender-matched controls|
33042520|NCT02044029||Patients with spinal muscular atrophy|
33330453|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, Future, and Risk"
33330454|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Future"
33417957|NCT02654223|Experimental|MG56 Mannosylated 1000 subcutaneous|1000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
32868494|NCT03557892|Active Comparator|MDI with degludec|
33330455|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Risk"
33042521|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
33042522|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:~HDV antibodies~if positive, HDV RNA"
33330456|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Scenarios"
33330457|NCT04661566|Experimental|Education+Narratives+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Future, and Risk"
33330458|NCT04661566|Experimental|Education+Narratives+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Future"
33330459|NCT04661566|Experimental|Education+Narratives+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Risk"
33042523|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
33042524|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
33042525|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
33042526|NCT02044120|Experimental|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
33042527|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
33042528|NCT02044120|Experimental|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
33042529|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
33042530|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
33042531|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
33042532|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
33042533|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
33042534|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
33042535|NCT02044185||control group|normal population with health screening
33042536|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.~Blood-stage controlled human malaria infection (CHMI) at day 70."
33042537|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.~Blood-stage controlled human malaria infection (CHMI) at day 70."
33330460|NCT04661566|Experimental|Education+Narratives+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Skills"
33417958|NCT02654223|Experimental|MG56 Mannosylated 3000 subcutaneous|3000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
33042538|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Counseling for depression~Drug:~Pharmacotherapy for heart failure Pharmacotherapy for depression"
33042539|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Usual care for depression~Drug:~Pharmacotherapy for heart failure~Usual Care for depression"
33042540|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
33042541|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
33042542|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
33042543|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
33042544|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
33042545|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
33042546|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
33042547|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
33042548|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
33042549|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
33042550|NCT02044315|Experimental|High-zone|High-zone ICD programming
33042551|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
33042552|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
33042553|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
33042554|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
33042555|NCT02044432|Experimental|Ginger compress|
33042556|NCT02044432|No Intervention|Wait list|
33042557|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
33042558|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
33042559|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
33042560|NCT02044471|No Intervention|Control|standard care
33042561|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.~Behavioral screening of patients at HIV primary care visits.~Dissemination of palm cards with empowering messages at HIV primary care visits."
33042562|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
33042563|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:~Transient Elastography (Fibroscan)~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
33042564|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
33042565|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
33042566|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
33042567|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
33042568|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
33042569|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
33042570|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
33042571|NCT02044588||HBsAg negative kidney allograft donor|
33042572|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
33042573|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
33042574|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
33042575|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
33330461|NCT04661566|Experimental|Education+Narratives+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives. Scenarios, Future, and Risk"
33330462|NCT04661566|Experimental|Education+Narratives+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Future"
33330463|NCT04661566|Experimental|Education+Narratives+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Risk"
33330464|NCT04661566|Experimental|Education+Narratives+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Scenarios"
33330465|NCT04661566|Experimental|Education+Narratives+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Future, and Risk"
33330466|NCT04661566|Experimental|Education+Narratives+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Future"
33330467|NCT04661566|Experimental|Education+Narratives+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Risk"
33330468|NCT04661566|Experimental|Education+Narratives|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives"
33330469|NCT04661566|Experimental|Education+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, Future, and Risk"
33330470|NCT04661566|Experimental|Education+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Future"
33417959|NCT02654223|Experimental|MG56 Mannosylated 5000 subcutaneous|5000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
33417960|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
33417961|NCT02654223|Experimental|MG56 Mannosylated 1000 sublingual|1000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
33417962|NCT02654223|Experimental|MG56 Mannosylated 3000 sublingual|3000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
33042576|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
33042577|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
33042578|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
33042579|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
33042580|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
33042581|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
33042582|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
33042583|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
33042584|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
33042585|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
33042586|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
33042587|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
33042588|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
33042589|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
33042590|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
33042591|NCT02044666|Experimental|Treatment|
33042592|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
33042593|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
33042594|NCT02044679|Other|C = no change|No change
33042595|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
33330471|NCT04661566|Experimental|Education+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Risk"
33330472|NCT04661566|Experimental|Education+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Scenarios"
33417963|NCT02654223|Experimental|MG56 Mannosylated 5000 sublingual|5000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
33417964|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
33417965|NCT01368523|Experimental|nilotinib|
33330473|NCT04661566|Experimental|Education+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Future, and Risk"
33417966|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
33330474|NCT04661566|Experimental|Education+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills Future"
33417967|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
33330475|NCT04661566|Experimental|Education+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Risk"
33417968|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
33417969|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
33417970|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
33417971|NCT01368601|No Intervention|Control without CPAP|
33417972|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
33042596|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
33042597|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
33042598|NCT02044744|Experimental|Referral|Physical activity referral
33042599|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
33042600|NCT02044757|Experimental|SSB withdrawal|
33042601|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
33042602|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
33042603|NCT02044809|Placebo Comparator|Placebo|
33042604|NCT02044809|Experimental|Cannabidiol 200mg Oral|
33042605|NCT02044809|Experimental|Cannabidiol 400mg Oral|
33042606|NCT02044809|Experimental|Cannabidiol 800mg Oral|
33042607|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
33042608|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
33042609|NCT02044861|Experimental|ACT-PFK-158|dose escalation
33042610|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
33042611|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
33042612|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
33042613|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
33042614|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
33042615|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
33042616|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
33042617|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
33042618|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
33042619|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
33042620|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
33042621|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
33042622|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
33042623|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
33042624|NCT02045043||Cardiomyopathy patients with ICDs|
33042625|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
33042626|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
33042627|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
33042628|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
33042629|NCT02045069|Placebo Comparator|Placebo|Placebo
33042630|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
33042631|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
33042632|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
33330476|NCT04661566|Experimental|Education+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills"
33042633|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
33330477|NCT04661566|Experimental|Education+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios, Future, and Risk"
33330478|NCT04661566|Experimental|Education+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Future"
33330479|NCT04661566|Experimental|Education+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Risk"
33330480|NCT04661566|Experimental|Education+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios"
33330481|NCT04661566|Experimental|Education+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future and Risk"
33042634|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
33042635|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
33042636|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
33042637|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
33042638|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
33042639|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
33042640|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
33042641|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
33042642|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
33042643|NCT02045199|Experimental|V0111|
33042644|NCT02045199|Placebo Comparator|Placebo|
33042645|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
33042646|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
33042647|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
33042648|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
33042649|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
33042650|NCT02045316||Normal pregnants|pregnants without obstetric complications
33042651|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
33042652|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
33042653|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
33042654|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
33042655|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
33042656|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
33042657|NCT02045394||Patients presenting with haemoptysis|
33042658|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
33042659|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
33042660|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
33042661|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
33042662|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
33330482|NCT04661566|Experimental|Education+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future"
33042663|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
33042664|NCT02045498|No Intervention|conventional cpr|conventional cpr
33042665|NCT02045524|Experimental|Injection location1|Single dose IM injection
33330483|NCT04661566|Experimental|Education+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Risk"
33330484|NCT04661566|Experimental|Education|Participants will receive a version of the Mission Wellness app (intervention) that only includes the static educational component.
33330485|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
33330486|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
33330487|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
33330488|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
33042666|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
33042667|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
33330489|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
33042668|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
33042669|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
33042670|NCT02045563||Patients with type-1 diabetes|
33042671|NCT02045563||Patients with type-2 diabetes|
33042672|NCT02045563||Volontaires sains|
33042673|NCT02045576|Experimental|Sleep position trainer|Nightbalance
33042674|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
33042675|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
33042676|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
33042677|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
33042678|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
33042679|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
33042680|NCT02045615||New|Proposed technique for Wichita nail extraction
33042681|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
33042682|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
33042683|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
33042684|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
33042685|NCT02045654||MDS patients|MDS patients who were treated with decitabine
33042686|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
33042687|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
33042688|NCT02045680||deep block|deep block
33042689|NCT02045680||non deep block (historical control)|non deep block (historical control)
33042690|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
33042691|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
33042692|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
33042693|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
33042694|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
33330490|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
33330491|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
32868495|NCT04090736|Experimental|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off [weekend]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
32868496|NCT04090736|Active Comparator|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
32868497|NCT05557344|Active Comparator|Oral acetaminophen arm|they will receive oral acetaminophen, placebo (saline) IV
32868498|NCT05557344|Active Comparator|IV acetaminophen arm|they will receive IV acetaminophen, placebo oral
32868499|NCT01653405|Experimental|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
32868500|NCT01653405|No Intervention|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
32868501|NCT00101413|Experimental|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
32868502|NCT04089332|Experimental|Enrolled, eligible|Single arm for eligible subjects
32868503|NCT03515226|Active Comparator|Traditional Training|20 hours of didactic education and training in CBT principles, depression assessment and cultural competency and 25 hours in dyad role playing of CBT manualized treatment sessions with supervision.
32868504|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
32868505|NCT01246869|Experimental|All Participants|All enrolled participants will complete three imaging sessions on separate days, beginning with a research MRI, then a PET scan with FDG and [15O]water, and a PET scan with FMISO. The two PET scans will be in any order on different days within one week of each other, and preferably on consecutive days. The research MRI will be within 14 days of the first PET scan.
32868506|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
32868507|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
32868508|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
32868509|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
32868510|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
32868511|NCT05557188|Placebo Comparator|Placebo|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
32868512|NCT05557188|Active Comparator|Experimental|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
32868513|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
32868514|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
32868515|NCT04075994|Experimental|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
32868516|NCT04075994|Active Comparator|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
32868517|NCT05557110|Experimental|reduced-intensity chemotherapy followed by berintuzumab|"Induction therapy was performed with reduced intensity chemotherapy (including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vindesine 3 mg/m2, and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. Bone marrow evaluation was performed on day 22±2, and consolidation therapy was performed after achieving bone marrow remission (CR/CRh/CRi). If CR/CRh/CRi was not achieved in the first course of induction therapy, Blinatumomab (28ug/d×14d) should be continued and bone marrow evaluation should be evaluated again.~The regimen of consolidation therapy is recommended as multidrug combination chemotherapy (including high-dose Methotrexate or Cytarabine combined with Asparaginase) or alternating with Blinatumomab (28 ug/d×28d). If Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is not performed, consolidation therapy needs at least 4 courses before 2 years maintenance therapy."
32905063|NCT03698708|Experimental|CARES Intervention- 12 sessions|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
33360639|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
33417973|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
33417974|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
33417975|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
33109068|NCT05422872||Estonia|Twenty to twenty-five professionals assigned to Estonian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
32868518|NCT05612334|Experimental|Experimental|The data collection forms used in the research were applied in the treatment group at the first polyclinic visit (0. month) via face-to-face interviews. First, they were informed about the benefits of exercise and walking. They were also informed about the duration and type of exercise and what should be considered before, during, and after exercises. Then, an informative training booklet prepared by the researcher containing the same information was given to them. An exercise program (5 minutes warm-up-30 minutes walking-5 minutes cooling down) was demonstrated to the patient by the researcher, and then the patient performed the first exercise under the supervision of the researcher. Beginning with the second exercise, the patient performed a 40-minute exercise program, 3 days a week, for 3 months. During this period, the researcher regularly made phone calls once a week to motivate the patient and check whether the patient performed the exercise program.
32868519|NCT05612334|Placebo Comparator|Placebo|The breathing exercise group, which constitutes the placebo-control group, was first informed about correct breathing techniques by the researcher, and an informative training brochure prepared by the researcher, containing correct breathing exercise information, was given to them. The exercise was performed by the researcher and shown to the patient. The first exercise was performed by the patient under the supervision of the researcher. They were informed about the continuation of the breathing exercise program for 3 months, once a day for 10 minutes, starting from the 2nd exercise. Regular phone calls were made once a week.
32868520|NCT05612334|No Intervention|No intervention|The control group was contacted by regular phone calls once a week to monitor their compliance with the treatment, to encourage them to express their problems, if any, and to motivate them for the treatment process.
32868521|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
32868522|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
32868523|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
32868524|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
32868525|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
32868526|NCT03253926|Experimental|Lorcaserin + Marijuana|
32868527|NCT03253926|Placebo Comparator|Placebo + Marijuana|
32868528|NCT05379504|Experimental|Self Management|"The 5A's Behavior Change Mode [39] is the framework for the self-management intervention. The five As will be addressed through the integration of the self-management intervention and the sensor system. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN, and SW) for 12 visits per participant."
32868529|NCT05379504|Active Comparator|Health Education|Participant's randomized to the standard health education arm will receive the intervention at Month 1 and then months 3, 6, 9 and 12.
32868530|NCT05364450|Active Comparator|Enhanced Usual Care (EUC)|The EUC group will meet for a single 90-minute coaching session via Zoom Health.
32868531|NCT05364450|Active Comparator|Acceptance Commitment Therapy (ACT)|The ACT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
32868532|NCT05364450|Active Comparator|Cognitive Behavioral Therapy (CBT)|The CBT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
32868533|NCT05356182|Active Comparator|Control Diet Arm|control diet arm (~20% protein content)
32868534|NCT05356182|Active Comparator|Low-Protein Diet Arm|intervention low-protein diet arm (10% protein content)
32868535|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
32868536|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
32868537|NCT04334538|Active Comparator|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
32868538|NCT04334538|Experimental|oat-RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
32868539|NCT01468844|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
32868540|NCT01468844|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
33109069|NCT05422872||Finland|Twenty to twenty-five professionals assigned to Finnish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109070|NCT05422872||Germany|Twenty to twenty-five professionals assigned to German healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
32868541|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
33109071|NCT05422872||Israel|Twenty to twenty-five professionals assigned to Israeli healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109072|NCT05422872||Lithuania|Twenty to twenty-five professionals assigned to Lithuanian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109073|NCT05422872||Malta|Twenty to twenty-five professionals assigned to Maltese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
32868542|NCT00203203|Experimental|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
32868543|NCT00203203|Other|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.~At 6 months, subject is offered stem cell therapy."
33109074|NCT05422872||Portugal|Twenty to twenty-five professionals assigned to Portuguese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109075|NCT05422872||Slovakia|Twenty to twenty-five professionals assigned to Slovakian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109076|NCT05422872||Spain|Twenty to twenty-five professionals assigned to Spanish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109077|NCT05422872||Serbia|Twenty to twenty-five professionals assigned to Serbian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
33109078|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
33109079|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
33109080|NCT05422833||Before|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 1996 and 2006 - before certification of our center."
32868544|NCT05349318|Active Comparator|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive HBOT twice a week.
33109081|NCT05422833||After|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 2007 and 2019 - after certification of our center."
32868545|NCT05349318|Sham Comparator|Sham active arm|The protocol comprises of 60 consecutive Sham sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive Shan sessions twice a week.
33109082|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
33109083|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
33109084|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
33109085|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
33109086|NCT05422677||single arm, single group(No interventional)|Observational
33109087|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
33109088|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
33109089|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
33109090|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
33109091|NCT05422248|Active Comparator|Series|Standard wound care for 4 weeks followed by intervention device wound care for up to 12 weeks.
33109092|NCT05422248|Active Comparator|Paired|Intervention device wound care to a portion of wound and standard wound care to the remaining portion of the wound, for up to 12 weeks.
33109093|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
33109094|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
33109095|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
33109096|NCT05421390|No Intervention|≤1 dairy serving/day|Limited dairy intake
32868546|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
33109097|NCT05421390|Experimental|2-3 servings/day reduced-fat|2-3 servings/day of skim milk, fat-free yogurt, and low-fat cheese
33109098|NCT05421390|Experimental|2-3 servings/day regular-fat|2-3 servings/day of regular-fat milk, yogurt, and cheese
33417976|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
33109099|NCT04699097||azytromycin|children who recieved azithromycin due to COVID 19 infection
33109100|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
33417977|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
33417978|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
33417979|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
33417980|NCT04502121|Experimental|Intervention group (IG)|
33109101|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
33109102|NCT04698746|Active Comparator|Ultrasound guided pericapsular nerve group block|Injection of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline mixture between iliopubic eminentia and psoas tendon under ultrasound guidance
33417981|NCT04502121|No Intervention|Standard of Care (SOC)|
33417982|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
33417983|NCT04893187|Experimental|Part 1: Single Dose Escalation SSS17|Escalating doses of SSS17, single dose administration
33417984|NCT04893187|Placebo Comparator|Part 1: Single Dose Escalation matching Placebo|Escalating doses of matching placebo, single dose administration
33109103|NCT04698746|Active Comparator|Intra-articular local anesthetic injection|At the end of the surgical case, a total of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline injection intra-articularly.
33109104|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
33109105|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
33109106|NCT05421234|Active Comparator|infertile men with post-COVID-19 (vaccinated or without vaccination)|15 infertile men with post-COVID-19 (vaccinated or without vaccination)
33109107|NCT05421234|Active Comparator|infertile men without post-COVID-19 (vaccinated or without vaccination)|15 infertile men without post-COVID-19 (vaccinated or without vaccination)
33109108|NCT05421234|Active Comparator|Control: 15 healthy men volunteers (no COVID-19, no other pathologies)|15 healthy men volunteers (no COVID-19, no other pathologies) as control group
33109109|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
33109110|NCT00450398|Placebo Comparator|2|
33109111|NCT05421195|Experimental|Glucocorticoid therapy with olfactory training|olfactory training plus oral Glucocorticoid
33109112|NCT05421195|Other|Olfactory training|Olfactory training only
33109113|NCT05420805|Active Comparator|Pre- and post-biotic (ALAC, inulin, FOS, and sodium butyrate)|The product (ALAC+butyrate+inulin+fructo oligosaccharides FOS) is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <50 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥50 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.
33109114|NCT05420805|Active Comparator|Post-biotic (sodium butyrate and zinc oxide)|The product (sodium butyrate+ zinc oxide) is in the form of tablets. Dosage is dependent on weight. For participants weighing <25 kg, one 380 mg tablet is intended to be administered orally twice a day . For participants weighing 25 to 40 kg, three 380 mg tablet dose is intended to be administered orally according to the 2+1 tablets per day schedule (12h interval). For participants weighing ≥40 kg, four 380 mg tablet dose is intended to be administered orally according to the 2+2 tablets per day schedule (12h interval).
33417985|NCT04893187|Experimental|Part 2: Multiple Dose Escalation SSS17|Escalating doses of SSS17, multiple dose administration
33417986|NCT04893187|Placebo Comparator|Part 2: Multiple Dose Escalation matching Placebo|Escalating doses of matching placebo, multiple dose administration
33417987|NCT04893187|Experimental|Part 3: Treatment Sequence 1 (A to B)|The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
33417988|NCT04893187|Experimental|Part 3: Treatment Sequence 2 (B to A)|The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
33417989|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
33417990|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
33417991|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
33417992|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
33330492|NCT05174182|Experimental|A novel treatment approach|"The experimental intervention were first comprised and tested in a large cohort of 10-14-year-old adolescents with a similar condition (patellofemoral pain) and was associated with a successful outcome after 12 weeks.~Afterwards, the intervention was changed slightly to target adolescents with Osgood Schlatter and then pilot-tested in a cohort of 51 participants. In this cohort, most participants needed more time to progress through exercises and sport, and the investigators have therefore piloted extending the intervention further in the clinic, with more success on these aspects.~The experimental intervention will contain an active approach with self-management of load and progressive exercise therapy throughout the treatment course, delivered through 4 one-on-one visits lasting approximately 20 minutes (at months 0, 1, 2, 3) with a physiotherapist and an accompanying leaflet with written and illustrated exercise description, and advice and information."
33360640|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
33360641|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
33360642|NCT01128439||1|
33360643|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
33042695|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
33042696|NCT02045758|Experimental|TAP20-C|TAP20-C
33042697|NCT02045758|Active Comparator|Fingerstick|Fingerstick
33042698|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
33042699|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
33042700|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
33042701|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
33042702|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
33042703|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
33042704|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
33042705|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
33042706|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
33042707|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
33042708|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
33042709|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
33042710|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
33042711|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
33042712|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
33042713|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
33042714|NCT02045888|Placebo Comparator|Placebo|Placebo
33042715|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
33042716|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
33042717|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
33360644|NCT03517696|No Intervention|Control|Routine vaginal exam
33360645|NCT03930043||Health Control|
32868547|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
32868548|NCT05556720|Experimental|People living with Human Immunodeficiency Virus (HIV)|"Eligible participants living with HIV will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, Spikevax (elasomeran/imelasomeran [SPIKEVAX Bivalent Original/Omicron]); 25 micrograms of imelasomeran that targets the Omicron variant BA.1, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, Comirnaty (Tozinameran/riltozinameran [Comirnaty Original/Omicron BA.1); 15 µg of tozinameran and 15 µg of riltozinameran.~TBC"
32868549|NCT05556720|Experimental|Solid Organ Transplant recipients|"Eligible participants who have previously received at least one solid organ transplant, including kidney, pancreas, liver, heart, lung, or any combination of these organs at least 6 weeks prior and without episodes of severe rejection requiring T- or B-cell depleting agents in the prior 3 months, will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, Spikevax (elasomeran/imelasomeran [SPIKEVAX Bivalent Original/Omicron]); 25 micrograms of imelasomeran that targets the Omicron variant BA.1, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, Comirnaty (Tozinameran/riltozinameran [Comirnaty Original/Omicron BA.1); 15 µg of tozinameran and 15 µg of riltozinameran.~TBC"
32868550|NCT05556720|Experimental|People with Haematological Neoplasms (CLL, NHL, MM)|"Undergoing chemotherapy, immunotherapy and/or targeted therapy, or completed in the last 2 years for chronic lymphocytic leukemia, multiple myeloma or non-Hodgkin lymphoma will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, Spikevax (elasomeran/imelasomeran [SPIKEVAX Bivalent Original/Omicron]); 25 micrograms of imelasomeran that targets the Omicron variant BA.1, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, Comirnaty (Tozinameran/riltozinameran [Comirnaty Original/Omicron BA.1); 15 µg of tozinameran and 15 µg of riltozinameran.~TBC"
32868551|NCT00204373|Experimental|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
32868552|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
32868553|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
32868554|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
32868555|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
32868556|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
32868557|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
32868558|NCT04748432||Multi-drug resistant group (MDR)|Patients with resistant NFGNB isolate as MDR group
32868559|NCT04748432||Non-Multi-drug resistant group (Non-MDR)|Patients with sensitive NFGNB isolate as Non-MDR group
32868560|NCT04748432||Control group (Control)|Patients without suspicion of VAP and other signs of nosocomial infection as the control group
32868561|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
32868562|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
32868563|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
32868564|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
33360646|NCT03930043||Non-gastrointestinal Lymphoma|
33360647|NCT03930043||Gastric Lymphoma|
33360648|NCT03930043||Intestinal Lymphoma|
33360649|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
33360650|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
33417993|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
32868565|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
32868566|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
32868567|NCT01005615|Sham Comparator|No FES Cycling|
32868568|NCT01005615|Active Comparator|FES Cycling|
32868569|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
32868570|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
32868571|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
32868572|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
32868573|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
32868574|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
32868575|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
32868576|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
32868577|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
32868578|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
32868579|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
32868580|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
32868581|NCT02249247|Experimental|Low dose of BIIL 284 BS|
32868582|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
32868583|NCT02249247|Experimental|High dose of BIIL 284 BS|
32868584|NCT02249247|Placebo Comparator|Placebo|
32868585|NCT00473343|Experimental|Metvix® PDT|Participants with basal cell carcinoma (BCC) lesions were administered to photodynamic therapy (PDT) with Metvix® cream 160 milligrams per gram (mg/g) applied for three hours, followed by illumination using non-coherent light with a fluency of 75 Joule per centimeter square (J/cm*2) and fluency rate of 70-200 milliwatt per centimeter square (mW/cm*2) up to 13 weeks.
32868586|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
32868587|NCT00032591|Active Comparator|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
32868588|NCT00032591|Other|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
32868589|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
32868590|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
32868591|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
32868592|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
32868593|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
32868594|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
32868595|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
32868596|NCT05346341|Experimental|Minimally invasive techniques|
32868597|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
32868598|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
32868599|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
32868600|NCT00033917|Active Comparator|1|indomethacin
32868601|NCT00033917|Placebo Comparator|2|placebo
32868602|NCT02341287|Active Comparator|Warming hydrogel glove, then non-thermal glove|In the first two-week period, subjects will wear a warming hydrogel glove. In the second two-week period, subjects will wear a non-thermal glove. Also a actigraph to monitor sleep latency.
33042718|NCT02045927|Other|Control Group|sedation monitoring with RASS score
33109115|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
32868603|NCT02341287|Placebo Comparator|Non-thermal glove, then warming hydrogel glove|In the first two-week period, subjects will wear a non-thermal glove. In the second two-week period, subjects will wear a warming hydrogel glove. Also an actigraph to monitor sleep latency.
32868604|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
32868605|NCT00036569|Experimental|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
32868606|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
32868607|NCT01968941|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
32868608|NCT01968941|Active Comparator|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
32868609|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
32868610|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
32868611|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
32868612|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
32868613|NCT05050929|Active Comparator|20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases|Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
32868614|NCT05050929|Experimental|8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases|A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
32868615|NCT05046093|Experimental|Single intervention arm - transbronchial cryobiopsy|Patients enrolled in this single arm will have lung nodules biopsied by transbronchial cryobiopsy.
32868616|NCT05042661|Experimental|acupuncture-like transcutaneous electrical nerve stimulation|"The experimental group received acupuncture-like transcutaneous electrical nerve stimulation three times a week for 4 weeks.~Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment"
32868617|NCT05042661|No Intervention|Control group:conventional therapy|The control group will receive routine care.
32868618|NCT02323581|Experimental|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the TAAA device or the Physician-Specified TAAA Device will be implanted.~The TAAA Device is a standard configuration branched stent graft with a combination of two branches for the mesenteric arteries and two fenestrations for the renal arteries.~The Physician-Specified TAAA Devices are designed on a per patient basis and may include a combination of up to 4 fenestrations and branches for mesenteric and renal arteries. An additional 5th branch or fenestration may be included if there is a large accessory renal artery. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
32868619|NCT02323581|Experimental|Aortic Arch Study Arm|Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
32868620|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
32868621|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
32868622|NCT04980417|Experimental|concomitant cholecystectomy|concomitant cholecystectomy with bariatric procedure
32868623|NCT04980417|Active Comparator|delayed cholecystectomy|delayed cholecystectomy
32868624|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
32868625|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
32868626|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
32868627|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
32868628|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
32868629|NCT00040937|Experimental|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
33042719|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
33042720|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
33042721|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
33417994|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
33417995|NCT04431375|Experimental|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
33042722|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
33042723|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
33042724|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
33042725|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
33042726|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
33042727|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
33042728|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
33042729|NCT02045992|Experimental|Caffeine|Caffeine 500mg
33042730|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
33042731|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
33042732|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
33042733|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
33042734|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
33042735|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
33042736|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
33042737|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
33042738|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
33067833|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
33067834|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
33417996|NCT04431375|Active Comparator|Tenofovir|TabletTenofovir [antiviral] 300mg per oral once a day
33417997|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
32740153|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~MAP set at 80-85 mmHg for 5 min.~MAP set at 70-75 mmHg for 5 min.~MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
32740154|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
32740155|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
32740156|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
32740157|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
32740158|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
32740159|NCT03309761||Patients aged 55-60|
32740160|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
32740161|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
33042739|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
33042740|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
33330493|NCT05174182|Active Comparator|Usual care|The investigators have performed a step-wise mixed-methods sub-study to investigate current standard of care in the most common settings in Denmark (Sports Physiotherapists mainly from private primary practice, and Orthopedic Surgeons caring for these patients, invited from all public secondary care orthopedic departments in Denmark). Results were then combined with reports from patients seen in the clinic (n=34) who were questioned in detail on what modalities and advice they had previously received. The results were mostly compatible with the recent international survey of clinicians treating Osgood-Schlatter. With the findings from this process the investigators have developed a patient-aimed leaflet, which will contain vignettes and elaborations of the multimodal approaches included in the standardized usual care package, which will be implemented through four visits (at months 0, 1, 2, 3) with a physiotherapist (mirroring the plan of care of the experimental group).
33330494|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
33330495|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
33330496|NCT05171218|Experimental|Music & Auditory Beat Stimulation|Participants listened to calm music with theta auditory beat stimulation for 24 minutes
33330497|NCT05171218|Active Comparator|Music Alone|Participants listened to calm music for 24 minutes
33330498|NCT05171218|Active Comparator|Auditory Beat Stimulation|Participants listened to theta auditory beat stimulation for 24 minutes
33330499|NCT05171218|Sham Comparator|Pink Noise|Participants listened to pink noise for 24 minutes
33330500|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
33330501|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
33042741|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
33042742|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
33042743|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
33042744|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
33042745|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
33042746|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
33042747|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
33042748|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
33042749|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
33042750|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
33067835|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
33067836|NCT00138632|Experimental|1|
33330502|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
33330503|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
33330504|NCT05091892|Experimental|Water Group|Neurodevelopmental treatment
32740164|NCT03313973|Experimental|with self stretching same muscle|
33042751|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
33042752|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
33042753|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
33042754|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
33042755|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
33042756|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33042757|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
33042758|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
33042759|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
33042760|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
33042761|NCT02046460|Active Comparator|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
33042762|NCT02046460|Experimental|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
33042763|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
33042764|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
33042765|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
33042766|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
33042767|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
33042768|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
33042769|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
33042770|NCT02046551|Placebo Comparator|Placebo|placebo
33067837|NCT00138632|Experimental|2|
33042771|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
33042772|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
33042773|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
33042774|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
33042775|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
33042776|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
33042777|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
33042778|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
33042779|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
33042780|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
33042781|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
33042782|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
33042783|NCT02046707|Experimental|Patients with chronic heart failure|
33042784|NCT02046707|Other|Controls|
33042785|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
33042786|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
33042787|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
33042788|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
33042789|NCT02046759|Experimental|Pharmacist-Intervention|
33042790|NCT02046759|Active Comparator|Routine Care|
33042791|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
33042792|NCT02046798|Experimental|14C labeled ASP3652|
33042793|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
32740165|NCT03313973|Sham Comparator|with self stretching forearm muscle|
32740166|NCT05160077|Other|Fasting|All examinations are in a fasting state.
33042794|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
33042795|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
33042796|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
33042797|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
33042798|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
33042799|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
33042800|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
33067838|NCT00138632|Placebo Comparator|3|
33067839|NCT00160875|Experimental|Cisplatin, Irinotecan|
32740167|NCT05160077|Other|Standardised Breakfast|"Preprandial examination is in fasting state, all postprandial examinations will be conducted with standardized dietary.~30 minutes after the beginning of the preprandial examination participants receive an standardized breakfast. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal."
33109116|NCT05420259|Experimental|Combined Exercise and Dietary Intervention|Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Fortimel Compact®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.
32868630|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
32868631|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
32868632|NCT04756895|Experimental|Bayesian method|Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application
32868633|NCT04756895|Active Comparator|Standard method|Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.
32868634|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
32868635|NCT04757285||control group|25 healthcare personnel volunteers not working in quarantine hospitals of matched age
32868636|NCT04757285||healthcare providers worked in Intensive Care Units|"35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.~Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function."
32868637|NCT02234427|Experimental|Aspirin|
32868638|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
32868639|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
32868640|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
32868641|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
32868642|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
32868643|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
32868644|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
32868645|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
32868646|NCT00041717|Active Comparator|fampridine-SR 50mg/day|
32868647|NCT00041717|Placebo Comparator|Placebo|
33042801|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
33109117|NCT05420259|Other|Control|Standard Care
33109118|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
33109119|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
33109120|NCT03276104|Active Comparator|IOL repositioning group|
33109121|NCT03276104|Active Comparator|IOL exchange group|
32868648|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
32868649|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
32868650|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
33330505|NCT05091892|Experimental|Land Group|Lonqitudinal, transversal and compined rotation in a hydrotherapy programm
33042802|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
33042803|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
33042804|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
33042805|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
33042806|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
33042807|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
33042808|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
33042809|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
33042810|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
33042811|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
33042812|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
33042813|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
33042814|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
33042815|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.~Effect of dialysis on levels of rivaroxaban:~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
33042816|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
33042817|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
33042818|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
33042819|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
33330506|NCT05084326||Mohamedabosena|
33330507|NCT05070286||Young people with MS and NMOSD|"Young people aged 10-25 years, who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-structured interviews."
33330508|NCT05070286||Parents of young people with MS and NMOSD|"Parents of young people aged 10-25 who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-Structured Interviews"
33330509|NCT05070286||Clinicians|Health care practitioners from medical, nursing and AHP backgrounds with at least two years' experience in NMOSD and MS.
33330510|NCT05762224|Experimental|Effect of kinesio taping on upper limb lymphedema|Kinesio taping was applied 2 times a week for 3 weeks to the KT group. KT improves fluid movement by widening the distance between connective tissues like skin and fascia,fascia and muscles and skin and muscles.
33330511|NCT05762224|Active Comparator|Effect of pressure garments on upper limb lymphedema|PG group received pressure garments ( 20-60 mmHg)for at least 15 to 18 hours per day for 3 weeks.
33330512|NCT04976452|Experimental|Group 1|Group 1 will include first year Physical Therapy students who will be trained for Blood Pressure (BP) measurement using a brief powerpoint lecture, completion of an interactive BP measurement module from the American Medical Association which includes a quiz assessment and certificate of completion, and a competency examination during the lab portion of class.
33330513|NCT04976452|No Intervention|Group 2|Group 2 consists of second year PT students who only had a powerpoint lecture on Blood Pressure measurement that was done virtually with no lab component or American Medical Association interactive module training.
33330514|NCT04889508|Experimental|Socio-emotional mental training|The socio-emotional intervention will consist of 10 weeks of daily Affect Dyad practice with a partner.
33330515|NCT04889508|Experimental|Mindfulness-based mental training|The intervention will consist of 10 weeks of daily individual Breathing Meditation practice.
33360651|NCT03926221|Experimental|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
33360652|NCT03517618|Experimental|S-1 + leucovorin|Single arm
33417998|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
33417999|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
33418000|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
33418001|NCT05721573|Active Comparator|0.5 mg/kg ABC008|Part A - ABC008 N=12 Part B - ABC008 N= 67
33418002|NCT05721573|Active Comparator|2.0 mg/kg ABC008|Part A - ABC008 N=12 Part B - ABC008 N= 67
33042820|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
33042821|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
33042822|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
33418003|NCT05721573|Placebo Comparator|Placebo|Part A - Placebo N= 6 Part B - Placebo N= 67
33042823|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
33042824|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
33042825|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
33042826|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
33042827|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
33042828|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
33042829|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
33042830|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
33042831|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
33042832|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
33042833|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(MICS CABG group, n=50)"
33042834|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(OPCABG group, n=50)"
33042835|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
33042836|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
33042837|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
33042838|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
33042839|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
33042840|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
33042841|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
33042842|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
32868651|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
32868652|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
33418004|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
33418005|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
33418006|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
33042843|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
33042844|NCT02047357|No Intervention|Control|This arm will receive no intervention
33042845|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
33042846|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
33042847|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
33042848|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
33042849|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
33042850|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
33042851|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
33042852|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
33042853|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
33042854|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
33042855|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
33042856|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
33042857|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
33042858|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
33042859|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
33042860|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
33042861|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
33042862|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
33042863|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
33042864|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
33109122|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
33418007|NCT05721105||ECMO|50 Patients admitted to pediatric intensive care at the University Hospital of Nantes between January 2014 and December 2022 and supported by ECMO during their hospitalization.
33418008|NCT05721105||Control|50 patients hospitalized at the same age, during the same time period, and sharing the same diagnostic categories as the ECMO group, but the control group never had ECMO.
33418009|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
33418010|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
33418011|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
33418012|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
33418013|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
33109123|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
33109124|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
33109125|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
33109126|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
33109127|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
33109128|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of QW dosing as dose modification.
33109129|NCT05419830|Active Comparator|AM antihypertensive dosing arm|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
33109130|NCT05419830|Experimental|BBTI arm|participants will receive the behavioral treatment for insomnia BBTI by the study RN. Participants will also be asked to take their antihypertensive medication within an hour of awakening
33109131|NCT05419830|Experimental|PM antihypertensive dosing or Chronotherapy arm|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
33109132|NCT04699019||Active Runners|All participants will be required to run unshod for a combination of four prescribed speeds (walking and up to 9 mph) and three different foot strike patterns (rearfoot, midfoot, and forefoot) on level ground.
33109133|NCT04698863||high flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 4 L/min for Group High flow rate.
33109134|NCT04698863||low flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 1 L/min for Group Low flow rate.
33109135|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
33109136|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
33109137|NCT04679844|Experimental|MagnetOs Putty|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device; MagnetOs Putty"
33109138|NCT04679844|Active Comparator|Autograft Bone|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device: Autologous bone graft"
33109139|NCT05419713|Experimental|Visual scences|Lit target locations in visual environment will be varied and subjects' perceived locations will be measured.
33109140|NCT05419167|Experimental|STEP-COVID|Participants will participate online to the 6 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities.
33109141|NCT05419167|No Intervention|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
33109142|NCT04451226|Experimental|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
33109143|NCT04447989|Active Comparator|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
33109144|NCT04447989|Placebo Comparator|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
33109145|NCT04447989|Active Comparator|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
33109146|NCT04447989|Placebo Comparator|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
33109147|NCT04447989|Active Comparator|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
33109148|NCT04447989|Placebo Comparator|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
33109149|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
33109150|NCT05418894|No Intervention|EMU|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
33109151|NCT05418894|Experimental|TRD|
33109152|NCT04436835|Experimental|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
33109153|NCT00450944|Experimental|Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22|
33109154|NCT05417607|Other|A+ Treatment/Feasibility participants|Total participation is expected to require a maximum of 20 weeks (plus optional remote follow-up at 16 week). Diagnostic/screening visits occur between 1 and 6 weeks prior to baseline and start of coaching. ESDM-informed parent coaching (~1 hour sessions) is delivered remotely (through telehealth) with a study clinician for 8 weeks and strategies are implemented within the child's typical daily routines by the caregiver. No medication is provided by the study team. Data is collected weekly and final assessment will be obtained at 16 weeks after baseline.
33109155|NCT05386719|Other|Early stage breast cancer survivors|Patients with history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins
32868653|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
33042865|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
33042866|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
33042867|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
33042868|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
33042869|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
33042870|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
33042871|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
33042872|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33042873|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
33042874|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
33042875|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
33042876|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33042877|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~Bone marrow will be infused intravenously~Cyclophosphamide will be administered IV once daily~Total Body Irradiation (TBI) will be delivered per institutional practice~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
33042878|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
33042879|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
33067840|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
33042880|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
33042881|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
33042882|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
33042883|NCT05681013|Experimental|Laughter Therapy Group|A pre-test was administered to all students. In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index and Perceived Stress Scale were applied. Experimental and control groups were formed randomly among the students who filled all the scales. Communication groups were established for the students in both groups without being told which group they belonged to. Considering the hours suitable for the experimental group, 8 sessions of laughter therapy were applied for an average of 45 minutes. At the end of the therapy in the last session, a post-test was administered to all of the students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
33042884|NCT05681013|No Intervention|Control Group|In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied. At the end of the therapy in the last session, a post-test was administered to all students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
33042885|NCT05680935|Experimental|atherosclerosis of the brachiocephalic arteries|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries.
33042886|NCT05680935|Experimental|No brachiocephalic atherosclerosis|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Up to 30 people - the control group without brachiocephalic atherosclerosis.
33042887|NCT05680857|Placebo Comparator|Placebo|The placebo group will receive a product in sachet form that doesn't have marine collagen peptide and Coenzyme Q10.
33042888|NCT05680857|Experimental|Product containing marine collagen peptide and Coenzyme Q10.|This group will receive the product containing marine collagen peptide from the fish origin and Coenzyme Q10 in sachet form.
33042889|NCT05680740|Experimental|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
33042890|NCT05680701|Active Comparator|real tACS|The investigators will administer the transcranial alternating current stimulation (tACS) intervention at 10 Hz to the participants. This intervention will utilize 6 electrodes; electrode placement and current parameters for each electrode have been optimized using a standard brain to generate an average electric field of 0.25 V/m. To ensure adherence to current safety recommendations for tACS, optimizations will be constrained to a maximum of total injected current 4.0 mA and a max. current per electrode of 2.0 mA. Stimulation will start and end with a 60 s ramp up/down to maximize comfort. This standard approach is both well-tolerated and safe in older adults. In a separate visit, we will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
33042891|NCT05680701|Sham Comparator|sham tACS|The investigators will administer the sham tACS intervention to the participants. They will use an active sham in which very low-level alternating currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
33042892|NCT05680662|Experimental|adjuvant quadruple thearpy of quercetin , zinc, EGCG, metformin for 100 breast cancer cases|experimental study of adjuvant quadruple therapy of quercetin, zinc, EGCG, and metformin for 100 cases of different types of breast cancer women daily dose as follows daily 500 mg orally quercetin OD daily 50 mg zinc sulfate orally OD daily 300 mg EGCG orally OD daily metformin 850 mg orally OD during chemotherapy courses and until last stage of treatment
33042893|NCT05680662|Experimental|no adjuvant thearpy for 100 cases of breast cancer breast for this group ( controlled group )|this arm ( 100 cases controlled group not taken adjuvant therapy only was taken the regular chemotherapy as prescription
33042894|NCT05680545|Experimental|Sevoflurane vaporized in ECMO machines|Patients' sedation will be managed with sevoflurane-based anesthesia directly vaporized into the ECMO machine.
33042895|NCT05680506|Experimental|Pain neuroscience education group|Pain neuroscience education 10- 15min Hot pack(10 min) TENS Kaltenborn Moilization technique at L4-L5 segment stretchings and stabilization exercises. (5 reps/1 set) Total duration:40 min/session
33042896|NCT05680506|Active Comparator|Standard therapy group|Hot pack(10 min) TENS Kaltenborn Mobilization technique at L4-L5 segment stretchings and stabilization exercises (5 reps /1 set) Total duration:30 min/session
33042897|NCT05680389|Experimental|Minocycline|100 mg twice daily for 3 months
33042898|NCT05680389|Placebo Comparator|Placebo|twice daily for 3 months
33042899|NCT05680350|Active Comparator|Study group|"Study group Patients with unexplained infertility had estimated their Plasma Expression level for GeneMicro RNA 203 & 210 by qRT-PCR followed by laparoscopic exploration"
33042900|NCT05680350|Active Comparator|Control Group|Control group Patients with unexplained infertility underwent laparoscopy only
33042901|NCT05680272|Experimental|extrimental group|The experimental group will be given training on empathetic communication and the positive birth perception awareness scale will be applied to the experimental group.
33042902|NCT05680272|No Intervention|control group|No intervention will be made in the control group.
33042903|NCT05680077||Positive group|Esophageal carcinoma and high-grade intraepithelial neoplasia patients.
33330516|NCT04889508|Other|Retest Control Group (Waitlist control)|"The retest control group, which is also a waitlist control group, will first not undergo an intervention, but will be tested prior to and after the 10-week period at Pre- and Post-test wherein other groups undergo the interventions.~In a second step, the waitlist control group will then also undergo a 10-week period of socio-emotional intervention.~During the first 10-week intervention period, this group will only be tested serving as a re-test control group. After Post-test, however, they will be given the chance to also enroll in a 10-week socio-emotional mental training with the exact same protocol as the socio-emotional intervention experimental group above.~Both the experimental intervention arm groups will be given the possibility to continue their daily assigned practices (respective socio-emotional and mindfulness-based training exercises) after post-test for the duration of the 10-weeks during which the waitlist control group undergoes the socio-emotional intervention."
33330517|NCT05214508|Active Comparator|COPD patient|COPD patients diagnosed based on spirometry, PFT and history
32868654|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
33042904|NCT05680077||Negative group|Patients with other digestive malignancies (including gastric cancer, colorectal cancer, liver cancer, pancreatic cancer,Cholangiocarcinoma, etc.) and patients with non-digestive malignant tumors (including thyroid cancer, lung squamous cell carcinoma, cervix Cancer, endometrial cancer, breast cancer, prostate cancer, etc.), Patients with benign digestive disorders (including esophagitis, gastritis, enteritis, appendicitis, gastric polyps, colorectal polyps, etc.).
33042905|NCT05679921|Experimental|PP1|pembrolizumab in combination with pazopanib
33042906|NCT05679921|Experimental|PP2|pembrolizumab for patients progressing on pazopanib.
33042907|NCT05679726|Experimental|Intervention group (reflexology group)|The group in which reflexology massage (foot massage) was applied once a week for 20 minutes (10 minutes on each foot) for a total of 4 weeks, and the pain scale and fatigue and stress level were measured once a week at the beginning of the study and at the end of the study 4 weeks later.
33042908|NCT05679726|No Intervention|Control group|Pain scale once a week for 4 weeks without any application, and fatigue and stress level at the beginning of the study and at the end of the study after 4 weeks were measured in the group.
33042909|NCT05679687|Experimental|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
33042910|NCT05679648||Rheumatoid arthritis patients|
33042911|NCT05679648||control|
33042912|NCT05679609|Experimental|group 1|participants would use incentive spirometry for 2 months together with ordinary medical treatment
33042913|NCT05679609|No Intervention|group 2|participants would receive only ordinary medical treatment for 2 months
33042914|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
33042915|NCT00386841|Placebo Comparator|Placebo|Placebo
33042916|NCT05679453|Active Comparator|Etodolac|Etodolac, 400 mg tid per a day for four days
33042917|NCT05679453|Active Comparator|Lornoxicam|Lornoxicam, 8 mg twice per day for four days
33042918|NCT05679414||Study group|Covid 19 patients in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.Follow up patient for 28 days as regard development of vascular thrombotic manifestation
33042919|NCT05679414||Control group|Healthy subjects in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.
33042920|NCT05679375|Active Comparator|Intrathecal Ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine.
33042921|NCT05679375|Active Comparator|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine.
33042922|NCT05679336|Experimental|Rituximab, Cyclophosphamide, and Corticosteroids group|The experimental treatment group: 40 participants will receive combined immunosuppressive therapy with Rituximab, Cyclophosphamide, and Corticosteroids.
33042923|NCT05678595|Active Comparator|A hot laser derived from a Nd: YAG laser|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
33042924|NCT05678595|Sham Comparator|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
33042925|NCT05677191|Experimental|proximal femoral nail|20 patient with trochanteric fractures , unstable type will use proximal femoral nail
33042926|NCT05677191|Active Comparator|Dual Mobility Arthroplasty|20 patient with trochanteric fractures , unstable type will use dual mobility arthroplasty
33042927|NCT05677152|Active Comparator|Zoledronic Acid|zoledronic acid 5 mg (Aclasta®) administered as single intravenous infusion (100 ml): Verum
33042928|NCT05677152|Placebo Comparator|physiological saline solution 0.9%|Sodium chloride (physiological saline solution 0.9%) administered as single intravenous infusion (100 ml): Placebo
33042929|NCT05677035|Experimental|Pharmacokinetic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
33042930|NCT05677035|Experimental|Pharmacodynamic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
33042931|NCT05676957|Experimental|Study group|The subjects will be considered to be enrolled in the study group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the study group of the trial to allow endovascular therapy with the Thermogard XP3 Intravascular Temperature Management (IVTM) System after recanalization.
33042932|NCT05676957|No Intervention|Control group|The subjects will be considered to be enrolled in the control group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the control group of the trial.
33330518|NCT05214508|No Intervention|Control|Healthy volunteers
33042933|NCT05676567||Hip Arthroplasty|Patients undergoing total hip replacement, hip resurfacing or revision hip replacement
33330519|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
33330520|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
33330521|NCT05214430|Experimental|3 months exclusive enteral nutrition after surgery|3 months exclusive enteral nutrition after surgery
33330522|NCT05214430|Experimental|less than 1 months exclusive enteral nutrition after surgery|less than 1 months exclusive enteral nutrition after surgery
33042934|NCT05676567||Knee Arthroplasty|Patients undergoing total knee replacement, partial knee replacement or revision knee replacement
33042935|NCT05676567||Shoulder Arthroplasty|Patients undergoing total shoulder replacement, reverse shoulder replacement or partial shoulder replacement (hemiarthroplasty).
33042936|NCT05675943|Experimental|Anti-COVID-19 Antibody SA55 for Injection|Anti-COVID-19 Antibody SA55 for Injection
33042937|NCT05675943|Placebo Comparator|Placebo|Anti-COVID-19 Antibody SA55 for Injection administered intramuscular
33330523|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
33330524|NCT01320930|Placebo Comparator|Control|Conventional care
33330525|NCT05214352||young population with cerebral palsy-Families-Therapist and researchers|The principal group is designed by all people who composed the research and who will work together in the intervention manual elaboration on the participation in the community.
33330526|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
33330527|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
33330528|NCT05237934||Cohort 1|Participants with confirmed/suspected NENs including ACC
33330529|NCT05213884|Experimental|Camrelizumab plus chemoradiotherapy|Induction camrelizumab therapy at least one cycle (every 3 weeks) followed by definitive concurrent chemoradiotherapy. After 4~6 weeks of the completion of radiotherapy, adjuvant camrelizumab therapy will begin every 3 weeks for 16 cycles (1 year) or continue until progression or unacceptable toxicity.
33330530|NCT05224440|Experimental|Sponsorship Initiative|TSMV receives a VA certified and volunteer sponsor (1-on-1) approximately 6 months prior to military discharge. Sponsorship continues for approximately 6 months after military discharge.
33330531|NCT05224440|No Intervention|Transition as Usual|TSMVs transition to civilian life as usual.
33042938|NCT05675280||Iron deficiency at diagnosis|
33042939|NCT05675280||No iron deficiency at diagnosis|
33042940|NCT05675163|Placebo Comparator|Placebo|matched dose of sunflower oil
33042941|NCT05675163|Experimental|Vitamin K2 low dose|333 μg/d Vitamin K2 (MK-7)
33330532|NCT05213494|Active Comparator|Low-dose inulin|3-5 years old: 3g of fiber/day from inulin mixed in a beverage 6-9 years old: 5g of fiber/day from inulin mixed in a beverage
33042942|NCT05675163|Experimental|Vitamin K2 high dose|666 μg/d Vitamin K2 (MK-7)
33042943|NCT05670522|Experimental|Transcranial direct current stimulation group|Children assigned to the transcranial direct current stimulation group received active transcranial direct current at their primary motor cortex (Active dose 11, ser. No 13070350, Active Tek Inc., USA). Stimulation was conducted at an intensity of 1 mA for 20 min per session, 5 times/week for 2 successive weeks (total of 10 sessions). 1 mA was shown to be appropriate in children's investigations. The anode (+) was positioned on the midline sagittal plane of the skull, corresponding to the motor area of lower limbs, and the cathode (-) was positioned over the inion. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
33042944|NCT05670522|Experimental|Virtual reality group|Children assigned to the virtual reality group received virtual balance training using Nintendo Wii and Wii Balance Board, with a custom training program developed from activities on the Wii Fit Plus game. Training was conducted for 30 minutes, 5 sessions/week for 2 successive weeks (total of 10 sessions). Two sessions with Wii Fit Plus were conducted before the treatment protocol to help the children familiarize with the VR setup. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
33042945|NCT05666115|Experimental|Probiotic group|Participants in the probiotics group will receive probiotic supplementation for 12 weeks.
33042946|NCT05666115|Active Comparator|Exercise group|The control group will undergo a 12-week online-delivered Tabata program, as a form of high-intensity interval training.
33042947|NCT04005456|Other|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
33330533|NCT05213494|Experimental|Low-dose soluble corn fiber|3-5 years old: 3g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 5g of fiber/day from soluble corn fiber mixed in a beverage
33330534|NCT05213494|Active Comparator|High-dose inulin|3-5 years old: 6g of fiber/day from inulin mixed in a beverage 6-9 years old: 8g of fiber/day from inulin mixed in a beverage
33330535|NCT05213494|Experimental|High-dose soluble corn fiber|3-5 years old: 6g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 8g of fiber/day from soluble corn fiber mixed in a beverage
33330536|NCT05213494|No Intervention|Baseline|3-9 years old: pre-intervention.
33330537|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
33330538|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
33042948|NCT04005456|Other|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
33042949|NCT04005456|Other|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
33330539|NCT01321086|No Intervention|Control|
33042950|NCT04005456|Other|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
33330540|NCT03778866|Experimental|Bicarbonate-buffered Medium|
33330541|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
32868655|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
33042951|NCT04005456|Other|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
33042952|NCT04005456|Other|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
33042953|NCT04005456|Other|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
33042954|NCT04005456|Other|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
33042955|NCT04005456|Other|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
33042956|NCT04005456|Other|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
33042957|NCT04005456|Other|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
33042958|NCT04005456|Other|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
33042959|NCT04005456|Other|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
33042960|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
33042961|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
33042962|NCT04005456|Other|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
33042963|NCT04005456|Other|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
33042964|NCT04005456|Other|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
33042965|NCT04005456|Other|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
33042966|NCT04005456|Other|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
33067841|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
33330542|NCT05711212|Experimental|Xanthohumol|single dose of 172 mg of micellar solubilized Xanthohumol
33330543|NCT05711212|Placebo Comparator|Placebo|
33330544|NCT05182476|Placebo Comparator|Placebo|Placebo daily
33330545|NCT05182476|Experimental|Luvadaxistat treatment schedule 1|Luvadaxistat daily
33330546|NCT05182476|Experimental|Luvadaxistat treatment schedule 2|Luvadaxistat daily
33330547|NCT05212714|Experimental|taVNS Treatment|n = 20
33418014|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
33418015|NCT02638298|Experimental|NPWT dressing|
33418016|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
33042967|NCT04005456|Other|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
33042968|NCT05655156|Experimental|Multiple Knee Ligament Injuries|"Sub-groups of n=7 incurring ligament reconstruction using OrthoPureXT in the following anatomical locations:~Posterior cruciate ligament (PCL)~Anterior cruciate ligament (ACL)~Posteromedial corner including the medial collateral ligament (MCL)~Posterolateral corner including the lateral collateral ligament (LCL)"
33042969|NCT05653986||Ubrogepant + Atogepant|Participants will receive ubrogepant in combination with atogepant as prescribed by their physician in routine clinical practice.
33042970|NCT05632770|Experimental|Stepped Collaborative Care (Intervention)|Patients in the intervention condition will receive a stepped collaborative care intervention that includes posttraumatic concern elicitation, proactive care management, medication, and psychotherapy elements targeting posttraumatic stress disorder (PTSD) and related comorbidity.
33042971|NCT05632770|Active Comparator|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|Patients in the control condition will receive usual trauma center care with American College of Surgeons (ACS) required psychosocial screening and referral.
33042972|NCT05626725||Observationnal cohort|Patients with type 1 diabetes and using an AID system.
33042973|NCT05611203|Experimental|Oropharyngeal swab only including the posterior oropharyngeal wall|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall only
33042974|NCT05611203|Experimental|Oropharyngeal swab including the posterior oropharyngeal wall and both palatine tonsils|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall and both palatine tonsils
33042975|NCT05605509|Active Comparator|RP-6306 + Gemcitabine|
33042976|NCT05605509|Active Comparator|RP-6306 + FOLFIRI|
33042977|NCT05605509|Active Comparator|RP-6306 + Trastuzumab|
33042978|NCT05597163|Experimental|0.01% atropine|0.01% atropine eye drop
33042979|NCT05597163|Experimental|0.025% atropine|0.025% atropine eye drop
33042980|NCT05597163|Experimental|0.05% atropine|0.05% atropine eye drop
33042981|NCT05597163|Other|cross-over|first year: placebo second year: 0.05% atropine eye drop
33042982|NCT05595837||COVID-19 positive donors|
33042983|NCT05595837||COVID-19 negative donors|
33042984|NCT03983772|Experimental|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
33042985|NCT03983772|Experimental|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
33042986|NCT03983772|Experimental|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
33042987|NCT03983772|Placebo Comparator|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
33042988|NCT05576532|Experimental|bcl-2 inhibitor plus IM2 regimen|bcl-2 inhibitor plus IM2 regimen
33042989|NCT05567055|Experimental|Capmatinib|400 mg orally, twice daily
33042990|NCT03981471|Other|Elderly without fall history|Elderly people in the community who have no fall history
33042991|NCT03981471|Other|Elderly with fall history|Elderly people in the community who have fall history
33042992|NCT05565885||patients with vascularitis|Two additional 7ml EDTA tubes of blood are taken from the same blood puncture as during routine follow-up at several points in the follow-up
33042994|NCT05550129|Experimental|AMG 510 + Metformin|
33042995|NCT05523726|Experimental|Preventative Cognitive Behavioral Therapy for Insomnia|Participants in this group will complete daily sleep diary entries for one week, and then have a telehealth pCBT-I session with a nurse coach, where they will receive personalized sleep recommendations to improve sleep quality.
33042996|NCT05523726|No Intervention|Digital Sleep Education Control|Participants in this group will receive digital sleep education, including tips on how to improve your sleep via interactive email. These materials are selected to help prevent chronic insomnia.
33042997|NCT05508204|Experimental|Cohort A|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level A
33042998|NCT05508204|Experimental|Cohort B|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level B
33042999|NCT05508204|Experimental|Cohort C|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level C
33043000|NCT05500716|Experimental|Auricular Non-Invasive Vagus Nerve Stimulation+Traditional Rehabilitation Program|"Auricular Non-Invasive Vagus Nerve Stimulation~Deep Friction Massage~Myofascial Trigger Point Compression Therapy~Temporomandibular Joint Mobilization~Rocabado Exercises~Muscle-Energy Techniques"
33043001|NCT05500716|Active Comparator|Traditional Rehabilitation Program|"Deep Friction Massage~Myofascial Trigger Point Compression Therapy~Temporomandibular Joint Mobilization~Rocabado Exercises~Muscle-Energy Techniques"
33043002|NCT05489835||Employees|Employees in Austrian companies affected by digitalization
33043003|NCT05482698|Experimental|MC2-25 cream|MC2-25 cream Twice daily applications for 12 weeks
33043004|NCT05482698|Placebo Comparator|MC2-25 vehicle|MC2-25 vehicle Twice daily applications for 12 weeks
33043005|NCT05470101|Experimental|Cohort A1: ITI-333 2.25 mg|
33043006|NCT05470101|Experimental|Cohort A2: ITI-333 dose to be determined based on Cohort A1|
33043007|NCT05470101|Experimental|Cohort A3: ITI-333 dose to be determined based on Cohort A1 and A2|
33043008|NCT05470101|Experimental|Cohort A4: ITI-333 dose to be determined based on Cohort A1, A2 and A3|
33043009|NCT05458284|Active Comparator|real acupuncture (RA)|Real Acupuncture weekly till taxane completion
33043010|NCT05458284|Placebo Comparator|sham acupuncture (SA)|Sham Acupuncture weekly till taxane completion
33043011|NCT05423535|Active Comparator|Control group: Collagen Matrix|collagen matrix: Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland
33043012|NCT05423535|Experimental|Test group: Hemostatic Gelatin Sponge|Hemostatic gelatin spons: Spongostan Dental® 1x1x1 cm, Ethicon, Johnson & Johnson, New Brunswick, VS
33043013|NCT05419479|Experimental|LEAD-IN: DOSE DE-ESCALATION|The lead-in dose de-escalation cohort (Phase 1b) will enroll 6 patients (up to 12 patients in 2 dose levels if needed; 6 patients per DL) to receive zimberelimab, domvanalimab, and APX005M
33043014|NCT05419479|Experimental|ARM A: ZIMBERELIMAB + DOMVANALIMAB + APX005M|"Participants will be randomly assigned to one of two groups~Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion."
33418017|NCT04180995|Experimental|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
32868656|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
32868657|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
33043015|NCT05419479|Active Comparator|ARM B: FOLFIRI|Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion
33043016|NCT05419479|Experimental|CROSSOVER: ZIMBERELIMAB + DOMVANALIMAB + APX005M|Participants in Arm B (control arm) who experience disease progression (as defined by RECIST v1.1) will be given the option to crossover and receive domvanalimab + zimberelimab, + APX005M in the second-line setting, provided they meet eligibility criteria
33043017|NCT05320770|Experimental|TMD patients with joint hyper mobility|
33043018|NCT03940131|Experimental|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
33043019|NCT05309187|Experimental|IO-202 Monotherapy (dose escalation)|
32868658|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
32868659|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
32868660|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
32868661|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
32868662|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
32868663|NCT04761497|Experimental|active music therapy|Each session consisted of: song of welcome (patients had to greet and introduce themselves), rhythmic exercise (three songs were used; therapist and patients kept rhythm by clapping their hands), dance exercises (three songs were used; patients should make free body movements in response to music), game of recognition of songs and interpreters (four songs were used) and song of goodbye.
32868664|NCT04761497|Experimental|passive music therapy|The therapist and the patients were seat listening to the music recorded in a CD. The therapist told patients which the name and the interpreter of each song of the list.
33043020|NCT05309187|Experimental|IO-202 dose escalation + pembrolizumab|Increasing dose levels of IO-202 with fixed dose of pembrolizumab
33043021|NCT05309187|Experimental|IO-202 + pembrolizumab combination therapy (dose expansion)|RP2D + pembrolizumab combination therapy in solid tumor cohorts
33043022|NCT05257044|Experimental|CBG|Participants will ingest 20 mg of CBG tincture in this arm
33043023|NCT05257044|Placebo Comparator|Placebo|Participants will ingest 20 mg of placebo tincture in this arm
33043024|NCT03939390|No Intervention|follicular phase stimulation|
33043025|NCT03939390|Experimental|luteal phase stimulation|
32868665|NCT04761497|Placebo Comparator|control|Patients were watching nature videos for the same duration than the interventions. A therapist was with them facilitating the activity.
32868666|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
33043026|NCT05230173|Other|Switching Targeted Immunomodulators Treatment|"Participants randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the participants' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~For participants randomized to switch to an alternative TIM, selection of alternative agent will be determined at the discretion of the local site physician in accordance with clinical guidelines on the management of moderate to severe ulcerative colitis, and management of moderate to severe CD from the AGA and ACG.9, 34, 35 These guidelines include recommendations on positioning of TIMs for first line use (TIM-naïve patients) and second-line use (in patients with prior exposure to TIMs)."
33043027|NCT05230173|Other|Continuing Index Targeted Immunomodulators Treatment|Participants randomized to a strategy of continuing TIM will continue on their concomitant therapy.
33043028|NCT05214963|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
33043029|NCT05214963|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation
33043030|NCT05196828|Active Comparator|Arm 1 - Direct Roll-Over Extension|24-wks of Active neurostimulation - Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation; followed by 8-wks of No Intervention
33043031|NCT05196828|No Intervention|Arm 2 - Control Group|24-wks of No Intervention
33043032|NCT05178810|Experimental|FAB122|
33043033|NCT05178810|Placebo Comparator|Placebo|
33109156|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
33109157|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
33109158|NCT02931812||Healthy subjects|30 healthy subjects to compare
33109159|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
33109160|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
33109161|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
33109162|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
33109163|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
33109164|NCT04359108|Experimental|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
33109165|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
33109166|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
33109167|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
33109168|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
33109169|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
33109170|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
33109171|NCT02931461|Experimental|needle Procore ®|
33109172|NCT02931461|Active Comparator|needle Cook®|
33109173|NCT04593641|Experimental|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
33109174|NCT04593641|Experimental|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
33109175|NCT04593641|Experimental|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
33109176|NCT04356027||Standard of Care: Angiography, OCT, FFR, and VFR|Patients will have Pre-OCT Angiography, OCT pullbacks, a FFR measurement and a VFR analysis
33109177|NCT04584632|Experimental|EVSS|Efemoral Vascular Scaffold System (EVSS)
33330548|NCT05212714|Sham Comparator|Sham Comparator|n = 10
33330549|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
33330550|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
33330551|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
33330552|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
33330553|NCT05212636|Experimental|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a 17-Item Hamilton Rating Scale for Depression (HRSD) score of at least 18
33330554|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
33330555|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
33330556|NCT05212558|Placebo Comparator|Placebo group|This group received a conventional respiratory retraining program plus unloaded (placebo) respiratory muscle training
33330557|NCT05212558|Active Comparator|Inspiratory muscle training group|This group received a conventional respiratory retraining program plus inspiratory muscle training only
33330558|NCT05212558|Experimental|Combined training group|This group received a conventional respiratory retraining program plus inspiratory and expiratory muscle training in the same respiratory cycle.
33418018|NCT02627690||Islet transplanted|patients who underwent islet transplantation
33043034|NCT05173935|Active Comparator|PEG Group|Subjects will gastrostomy tube placement via percutaneous endoscopic gastrostomy (PEG) method.
33043035|NCT05173935|Active Comparator|RIG Group|Subjects will have the placement of a gastrostomy tube via radiologically-inserted gastrostomy (RIG) method.
33043036|NCT05173116||prospective study|API-VIGIE program adult participant who agreed to participate in the study
33043037|NCT05173116||retrospective study|Any stay for adults patients in the emergency room of the ARRAS hospital for API during the period covered (from 1 year before to 1 year after the installation of the APIVIGIE program) (main diagnosis or associated with an API (F10.0 according to the ICD-10 classification used by Department of Medical Information)
33043038|NCT05160597|Experimental|Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)|"SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.~IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS."
33043039|NCT05160519|Experimental|Experimental|30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the effectiveness of Class IV laser.
33043040|NCT05160519|Sham Comparator|Sham Controlled|30 participants will subject to irradiation but the equipment will be kept off.
33043041|NCT05146167|Experimental|Bodhi AIM|Participants randomized to the intervention group will receive the Bodhi AIM app
33043042|NCT05146167|Active Comparator|HIB|Participants randomized to the health promotion control group will receive the HIB app
33043043|NCT05145816|Experimental|Cohort (DL 0) for Part 1|Cohort (DL 0) for Starting Dose : Belantamab mafodotin 2.5 mg/kg on Day 1 every 6 weeks
33043044|NCT05145816|Experimental|Cohort (DL +1) for Part 1|Cohort (DL +1) for Dose Escalation: Belantamab mafodotin 2.5 mg/kg on Day 1 every 4 weeks
33418019|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
33418020|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
33043045|NCT05145816|Experimental|Cohort (DL -1) for Part 1|Cohort (DL -1) for Dose De-escalation : Belantamab mafodotin 2.5 mg/kg on Day 1 every 8 weeks
33043046|NCT05145816|Experimental|Cohort (DL -2) for Part 1|Cohort (DL -2) for Dose De-escalation: Belantamab mafodotin 1.9 mg/kg on Day 1 every 8 weeks
33043047|NCT05145816|Experimental|Cohort Dose Expansion for Part 2|Cohort Dose expansion for Part 2: Belantamab mafodotin Dose 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosage calculations.
33043048|NCT05142540||blood and saliva sampling|blood and saliva samples will be taken
33043049|NCT05129709|Experimental|"My Health Priorities Identification Program"|"The intervention, the My Health Priorities Identification Program consists of four self-directed, web-based modules intended to guide patients with MCCs in identifying their own health priorities. These priorities can then be used to guide discussions with family caregivers and clinicians regarding specific goals and preferences that they wish to guide future treatment decisions. Most models of palliative care have been developed based on white middle-class populations and may not apply to African Americans (AA) who have a very different cultural value set."
33043050|NCT05120037|Experimental|Active|
33418021|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
33043051|NCT05120037|Sham Comparator|Sham|
33043052|NCT05090397|Experimental|Active|
33043053|NCT05090397|Sham Comparator|Sham|
33043054|NCT05053620||Single arm|All patients.
33418022|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
33418023|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
33043055|NCT05031468||Group 1: Individuals vaccinated during pregnancy|Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
33043056|NCT05031468||Group 2: Individuals vaccinated postpartum|Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
33043057|NCT05031468||Group 3: Infants of individuals vaccinated during pregnancy|Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)
33043058|NCT05031468||Group 4: Infants of individuals vaccinated postpartum|Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)
33043059|NCT05031468||Group 5: Individuals receiving additional vaccines during pregnancy|Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 200 individuals).
33043060|NCT05031468||Group 6: Infants of individuals receiving additional vaccines during pregnancy|Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 200 infants).
33043061|NCT05004012|Other|Control|No diagnosis of gastroparesis, functional dyspepsia, or prior G-POEM
33043062|NCT05004012|Other|Gastroparesis|Patients with a diagnosis of gastroparesis meeting the inclusion criteria
33043063|NCT05004012|Other|Functional Dyspepsia|Patients with a diagnosis of functional dyspepsia meeting the inclusion criteria
33043064|NCT05004012|Other|G-POEM|Patients who received a G-POEM procedure meeting the inclusion criteria
33043065|NCT05000307|Experimental|Volunteers, infected with COVID-19|
32868667|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
33043066|NCT00387270|Experimental|A|Dimebon
33043067|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
33067842|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
33418024|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
33418025|NCT04165161|Other|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
33418026|NCT04165161|Other|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
33418027|NCT04165161|Other|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
33418028|NCT04165161|Other|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
33043068|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
33043069|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
33043070|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
33043071|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
33043072|NCT04965636|Experimental|Participants receiving mepolizumab|
33043073|NCT04921722|Experimental|Topical use of sirolimus|Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
33043074|NCT04921722|Active Comparator|Oral use of sirolimus|Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
33043075|NCT04920825|Active Comparator|Sacha Inchi Oil softgel|Oral Sacha Inchi oil softgel supplement
33043076|NCT04920825|Placebo Comparator|Corn oil softgel|Oral corn oil softgel
33043077|NCT04910568|Experimental|Single-Agent Cevostamab (Arm A)|"Cohort A1S is a safety run-in arm evaluating cevostamab administered in 28-day cycles on a modified weekly schedule.~Upon completion, Cohort A1E, an expansion cohort may be opened. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule."
33043078|NCT04910568|Experimental|Cevostamab plus Pomalidomide and Dexamethasone (Pd) (Arm B)|"Participants will be treated with cevostamab monotherapy during a 15-day period prior to the start of pomalidomide treatment (cevostamab pre-phase).~Cohort B1S is a safety run-in arm evaluating cevostamab and Pd administered in 28-day cycles every 2 weeks (Q2W) followed by every 4 weeks (Q4W) schedule.~Upon completion, 2 expansion cohorts will be opened at dose level 1 (Cohort B1E) and at dose level 2 (Cohort B2E). They will follow the same Q2W/Q4W dosing schedule as Cohort B1S."
33043079|NCT04910568|Experimental|Cevostamab plus Daratumumab and Dexamethasone (Dd) (Arm C)|"Cohort C1S is a safety run-in arm evaluating cevostamab and Dd administered in 21 day cycles from Cycle(C)1 - C8 every 3 weeks (Q3W) and 28-day cycles from C9 onwards Q4W.~Upon completion, 2 expansion cohorts will be opened at dose level 1 (Cohort C1E) and at dose level 2 (Cohort C2E). They will follow the same Q3W/Q4W dosing schedule as Cohort C1S."
33043080|NCT04907643|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
33043081|NCT04907643|Experimental|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
33043082|NCT04907643|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
33043083|NCT04880070|Experimental|Shockwave Device|The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.
33043084|NCT04860336||Pregnant women less than or equal to 14w0d gestation|
33043085|NCT04833387|Experimental|PD-1 antibody + capecitabine + radiation|
33043086|NCT04831008|Active Comparator|Figure-of-eight|Using the figure-of-eight closure technique when closing access for structural heart therapies.
33043087|NCT04831008|Active Comparator|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
33043088|NCT04804293|Experimental|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
33043089|NCT04804293|Experimental|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
33043090|NCT04803084||Advanced Pathology|Breast magnetic resonance imaging (MRI) as a preliminary predictive biomarker for breast cancer treatment response.
33043091|NCT04793685|Experimental|Active Drug|Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.
33043092|NCT04793685|Placebo Comparator|Placebo Drug|Placebo for 12 weeks.
33043093|NCT04787991|Experimental|Cohort A: Nivolumab + Ipilimumab + nP/gem|
33043094|NCT04787991|Experimental|Cohort B: Hydroxychloroquine + Ipilimumab + nP/gem|
33043095|NCT04787991|Experimental|Cohort C: NG-350A + Ipilimumab + nP/gem|
33418029|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
33418030|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
33418031|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
33043096|NCT04762602|Experimental|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
33043097|NCT04762602|Experimental|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
33043098|NCT04745676||Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
33043099|NCT04726410|Experimental|Cold-stored Platelet (CSP)|early infusion of up to 2 units of urgent release cold stored platelets (CSP)
33043100|NCT04726410|Active Comparator|Standard care|standard care therapy
33043101|NCT04677738|Placebo Comparator|Placebo|Placebo delivered in capsule format. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
33043102|NCT04677738|Experimental|B. breve|Capsule containing B breve. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
33043103|NCT04552080|Active Comparator|Test: Amoxicillin|
33043104|NCT04552080|Placebo Comparator|Comparator: Placebo|
33043105|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
33043106|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
33043107|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
33043108|NCT04380480|Experimental|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
33043109|NCT04360473|Active Comparator|Control group|The patients in this group will receive general balanced anesthesia
33043110|NCT04360473|Experimental|Ketamine group|The patients in this group will receive 0.3 mg / kg of ketamine in saline (total volume of 100 ml) 15 min before general balanced anesthetic induction
33043111|NCT04360473|Experimental|Magnesium sulfate group|The patients in this group will receive 40 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
33043112|NCT04360473|Experimental|Magnesium / ketamine group|The patients in this group will receive 0.15 mg / kg of ketamine + 20 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
33043113|NCT04330989|Experimental|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
33043114|NCT04330989|No Intervention|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will antiretroviral educational material about HIV prevention and treatment (as appropriate to this arm).
33043115|NCT04330989|Experimental|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
33043116|NCT04330989|No Intervention|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
33043117|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
33043118|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
33043119|NCT04329975||Participants with Nocturia|Participants with nocturia due to nocturnal polyuria treated with MINIRINMELT OD Tablet 25μg or 50μg as per daily clinical practice.
33043120|NCT04305795|Other|Cohort 1L- HNSCC|Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma
33043121|NCT04305795|Other|Cohort 2- 1LcuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
33043122|NCT04305795|Other|Cohort 3- 2L CuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
33043123|NCT04203303||Observational|Observational
33043124|NCT00423384|Experimental|1|Ibandronate
33043125|NCT00423384|Placebo Comparator|2|
33043126|NCT04175613|Experimental|Patients treated with Apremilast|Subjects with a weight between 20 kg to < 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
33043127|NCT04062552|Experimental|Group I (ENABLE palliative care program, phone calls, VLC)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.
33418032|NCT04566510|Experimental|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
33418033|NCT04566510|Active Comparator|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
33418034|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
32868668|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
32868669|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
32868670|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
32868671|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
32868672|NCT01601691|Experimental|Spacer|Subjects with spacer injection
32868673|NCT00048737|Experimental|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
32868674|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
32868675|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
32868676|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
32868677|NCT01951937|Placebo Comparator|Placebo|Habitual diet
32868678|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
32868679|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
32868680|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
32868681|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
32868682|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
32868683|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
32868684|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
32868685|NCT01666197|Placebo Comparator|placebo|
32868686|NCT01697709|Placebo Comparator|Placebo|Placebo medication
32868687|NCT01697709|Experimental|quetiapine|Quetiapine treatment
32868688|NCT00048815|Active Comparator|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
32868689|NCT00048815|Experimental|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
32868690|NCT00048815|Placebo Comparator|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
32868691|NCT01605435|Experimental|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
32868692|NCT01605435|Experimental|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
32868693|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
32868694|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
32868695|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
32868696|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
32868697|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
32868698|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
32868699|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
32868700|NCT01698333|Experimental|122-0551|
32868701|NCT01607853|Experimental|Daivobet® gel|
32868702|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (> 18 years old) from 22 different countries.
32868703|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
32868704|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
32868705|NCT01610427|Experimental|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
32868706|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
32868707|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
32868708|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
32868709|NCT00101647|Experimental|1|
32868710|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
32868711|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
32868712|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
32868713|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
32868714|NCT00053495|Experimental|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
32868715|NCT00053495|Experimental|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
32868716|NCT00053495|Experimental|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
32868717|NCT00053495|Experimental|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
32868718|NCT00053495|Active Comparator|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
32868719|NCT05327491|Experimental|Treatment Sequence ABC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 1 tablet (test 1) Period 2 - as 2 tablets (reference) Period 3 - as 1 tablet (test 2)"
32868720|NCT05327491|Experimental|Treatment Sequence BAC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 2 tablets (reference) Period 2 - as 1 tablet (test 1) Period 3 - as 1 tablet (test 2)"
32868721|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
32868722|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
32868723|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
32868724|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
32868725|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
32868726|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
32868727|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
32868728|NCT02229513|No Intervention|Control|Normal cesarean technique.
32868729|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
32868730|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
32868731|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
32868732|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
32868733|NCT05556642||Group 1|Patients with relapsed/ refractory Hepatoblastoma
32868734|NCT05556564||No group|
32868735|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
32868736|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
33067843|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
33418035|NCT04099329|Experimental|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
33418036|NCT04099329|No Intervention|Control|No intervention will be delivered by athletes and coaches will be surveyed.
33418037|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
33418038|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
33043128|NCT04062552|Experimental|Group II (ENABLE palliative care program, phone calls, TA)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for 15 months.
33043129|NCT04027647|Experimental|Treatment|Daily administration of oral Dacomitinib
33043130|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
33043131|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
33043132|NCT03988257|Experimental|Experimental group|Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day.
33043133|NCT03988257|Placebo Comparator|Control group|A vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight.
33043134|NCT03957954|Experimental|Cultivated Limbal Stem-Cells (cLSC)|One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
33043135|NCT03957954|Active Comparator|Scleral Contact Lens Device (SCL)|Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
33043136|NCT03945357|Active Comparator|Saline Irrigation|Normal saline is to be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional saline irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure.
33043137|NCT03945357|Active Comparator|Antibiotic Irrigation|Antibiotic solution is prepared consisting of 240 mg gentamicin and 600 mg clindamycin in 500 ml saline to ensure proper concentration. This solution should be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional antibiotic irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure. This second irrigation is not timed.
33043138|NCT03945318|Experimental|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
33043139|NCT03945318|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of placebo administered by IV infusion.
33043140|NCT03945318|Experimental|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
33043141|NCT03945318|Placebo Comparator|Part 2: Placebo|Subjects will receive placebo by IV infusion.
33043142|NCT03945318|Experimental|Part 3: BION-1301|Two cohorts of subjects will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at a dose and schedule to be determined.
33043143|NCT03937128|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
33043144|NCT03937128|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
33043145|NCT03913221|Active Comparator|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
33043146|NCT03913221|Active Comparator|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
33043147|NCT03903549|Experimental|Brain uptake and kinetics in Parkinson patients|
33043148|NCT03903549|Experimental|Brain uptake and kinetics in healthy volunteers|
33043149|NCT03903549|Experimental|Dosimetry in healthy volunteers|
33043150|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
33043151|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
33043152|NCT03786081|Experimental|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
33043153|NCT03786081|Experimental|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
33043154|NCT03786081|Experimental|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
33043155|NCT03786081|Experimental|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
33043156|NCT03786081|Experimental|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
33043157|NCT03786081|Experimental|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
32868737|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
33043158|NCT03786081|Experimental|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
33109178|NCT04341441|Active Comparator|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
33043159|NCT03786081|Experimental|H: Tisotumab vedotin + pembrolizumab + carboplatin +/- bevacizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab and carboplatin with or without bevacizumab once every three weeks in previously untreated patients
33043160|NCT03782259|Placebo Comparator|Placebo|10mg tabs placebo matching dapagliflozin.
33043161|NCT03782259|Active Comparator|Active|10mg tabs of dapagliflozin
33043162|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
33043163|NCT03672318|Experimental|CAR138 T cells|The first 3 subjects enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 subjects provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each subject to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another subject is allowed to enroll in the cohort.
33043164|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
33043165|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
33043166|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
33043167|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
33043168|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
33043169|NCT03568656|Experimental|CCS1477 dose escalation - mCRPC|CCS1477 monotherapy in patients with mCRPC
33043170|NCT03568656|Experimental|CCS1477 expansion phase - mCRPC|CCS1477 monotherapy in patients with mCRPC
33043171|NCT03568656|Experimental|CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC|CCS1477 plus abiraterone acetate in patients with mCRPC
33043172|NCT03568656|Experimental|CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC|CCS1477 plus enzalutamide in patients with mCRPC
33043173|NCT03568656|Experimental|CCS1477 Monotherapy - Solid tumours|CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition
33043174|NCT03568656|Experimental|CCS1477 and darolutamide, combination dose finding and expansion - mCRPC|CCS1477 plus darolutamide in patients with mCRPC
33043175|NCT03568656|Experimental|CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer|CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.
33043176|NCT03568656|Experimental|CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer|CCS1477 plus atezolizumab in patients with non-small cell lung cancer
33043177|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from time of vaccination to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
33043178|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
33043179|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
33043180|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A, B, C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
33043181|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
33043182|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
32868738|NCT05313516|Experimental|OKKO Health app|Use of OKKO Health app for home monitoring.
32868739|NCT01672827|Experimental|[18F]Flutemetamol|
33330559|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
33330560|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
33330561|NCT05212324||widening|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
33043183|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
33043184|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
33043185|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
33043186|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
33330562|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
33330563|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
33043187|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
32868740|NCT01906853|No Intervention|No BCG|No BCG
32868741|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
32868742|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
33043188|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
33043189|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
33043190|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
33043191|NCT03020160|Experimental|Emicizumab: PK Run-in Cohort|Participants received emicizumab subcutaneously (SC) at a dose of 6 mg/kg once every 4 weeks, with no loading dose, for at least 24 weeks.
33043192|NCT03020160|Experimental|Emicizumab: Expansion Cohort|Participants received emicizumab subcutaneously (SC) at a loading dose of 3 mg/kg once every week for the first 4 weeks followed by a maintenance dose of 6 mg/kg emicizumab SC once every 4 weeks for at least 24 weeks.
33043193|NCT03002259|No Intervention|Control|No placebo required
33043194|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
32868743|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
33043195|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
33043196|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
32868744|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
32868745|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
32868746|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
33043197|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
33043198|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
33043199|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
33043200|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
33043201|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
33043202|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
32868747|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
33043203|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
33043204|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
33043205|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
33043206|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
33043207|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
33043208|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
33043209|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
33043210|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
33043211|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)~Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
33043212|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
33043213|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
33043214|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
33043215|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
33043216|NCT02373813|Experimental|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
33043217|NCT02373813|Experimental|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
33043218|NCT02373813|Experimental|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
33043219|NCT02373813|Experimental|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
33043220|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
33043221|NCT02305641||Cohort|Method of continuous surveillance per standard of care
33043222|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
33043223|NCT01853748|Active Comparator|Trastuzumab emtansine (T-DM1)|T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
33043224|NCT01853748|Active Comparator|Paclitaxel + Trastuzumab|paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
33043225|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
33043226|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
33043227|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
33043228|NCT04712331|Experimental|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
33043229|NCT04712331|Experimental|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
33043230|NCT04712331|Experimental|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
33043231|NCT04712331|No Intervention|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
33043232|NCT01756248||Group 1|
33043233|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
33043234|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
33043235|NCT00006081|Experimental|Bryostatin-1 + Taxol|
33043236|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
33043237|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
33043238|NCT00006111|Experimental|resectable disease|
33043239|NCT00006111|Experimental|unresectable disease|
33043240|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
32868748|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
33043241|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
33043242|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
33043243|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
33043244|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
33043245|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
33043246|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
33043247|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
33043248|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
33043249|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
33043250|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
32868749|NCT03431987||Marijuana Users|
32868750|NCT05299320||Patients with Post-Covid|Being between the ages of 18-30, - Being a volunteer - Having had Covid-19 in the last 3 month Exclusion Criteria - Presence of neurologic and oncologic disease - Presence of orthopedic surgery - Presence of active Covid-19 disease - Any cardiopulmonary disease
32868751|NCT05299320||Healthy Person|Being between the ages of 18-30, Being a volunteer, not having Covid-19 before
32868752|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
32868753|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
32868754|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
32868755|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
32868756|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
32868757|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
32868758|NCT00105001|Active Comparator|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
32868759|NCT00105001|Experimental|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
33043251|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
33043252|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
33043253|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
33043254|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
33043255|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
32868760|NCT00105001|Experimental|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
32868761|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
32868762|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
32868763|NCT05275842|Experimental|Cognitive Processing Therapy-Lifesteps (CPT-L) [Group A]|
32868764|NCT05275842|Active Comparator|Lifesteps [Group B]|
32868765|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
32868766|NCT05556408|Other|High-Resolution Solid-State Manometry|Before catheterization, the patients were monitored by pulse oximetry, electrocardiogram, automatic noninvasive arterial blood pressure and bispectral index (BIS). Before the insertion of the manometric catheter an intravenous cannula was inserted. The manometric catheter was placed through the nose until the pressure from the lower esophageal sphincter to the stomach could be recorded. After confirming the position of the catheter, the catheter was taped to the nose.
32868767|NCT00054353|Experimental|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
32868768|NCT00054353|Experimental|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
32868769|NCT05556330|Experimental|horizontal ridge augmentation by computer guided autogenous cortical shell technique|
32868770|NCT05556330|Active Comparator|horizontal ridge augmentation by free hand autogenous cortical shell technique|
32868771|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
32868772|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
32868773|NCT05556252|Experimental|Intervention Group|
32868774|NCT05556252|Placebo Comparator|Control Group|
32868775|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
32868776|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
32868777|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
32868778|NCT05700786|No Intervention|Control Group|"The control group is made up of participants who are eligible but not assigned to the treatment. For ethical reasons they will be able to access the intervention once the experimental group has concluded the study. During the waiting-list phase, participants can access a mental health intervention, but in this case they are excluded from the study. Participants are told that there is only one possible active group and therefore a waiting-list is created. This explanation is given to reduce a worsening symptom bias for feeling excluded from treatment."
33043256|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
33043257|NCT03750981|Other|A 12-week pilot intervention study introducing a high-intensi|
33043258|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
33043259|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
33043260|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
33043261|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
33043262|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:~venepuncture~spirometry."
33043263|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
33043264|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
33043265|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
33043266|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
33043267|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
33043268|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
32868779|NCT05700786|Active Comparator|Experimental Group|The experimental intervention is an integrative mindful compassion group therapy as manualized by Cheli, Cavalletti, Flett & Hewitt (2020). The structure was outlined on the base of standard mindfulness-based interventions, comprising eight 2-hour online group sessions and one day of silence lasting 4 hours in presence. The contents and the phases of the intervention were rooted in two different frameworks. On the one hand, the sequence of and the types of practices were defined in accordance with the mindful compassion protocol (Gilbert & Choden, 2014). On the other hand, the shared conceptualization of perfectionism and its role in triggering, maintaining, and inducing relapses in personality disoders was proposed through the relational model by Hewitt and colleagues (2017). The hybrid format (online weekly sessions plus an in presence half-day of silence) has been developed in accordance with existing COViD-19 emergency and rules.
33418039|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
33418040|NCT03987009|Experimental|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
32868780|NCT01701999|Experimental|Vaccine|
32868781|NCT00208507|Active Comparator|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
32868782|NCT00208507|Active Comparator|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
32868783|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
32868784|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
32868785|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
32868786|NCT05556018|Experimental|Tailor-made CRT delivery|Cardiac resynchronization therapy given according to Electrical Activation Mapping result
32868787|NCT00208975|Active Comparator|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
32868788|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
32868789|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
32868790|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
32868791|NCT04389151|Other|The experimental group|
32868792|NCT05231928|Experimental|Argon Laser Iridoplasty|Argon Laser is applied to the anterior iris surface after pharmacological miosis and instillation of ocular surface anesthetic using YAG capsulotomy lens or Abraham Iridotomy lens as auxiliary lenses. Laser is applied at sites and with parameters that are tailored for each case according to exact iris configuration, iris colour and pupil diameter.
32868793|NCT05223972|Experimental|Scoliosis Treatment Group|For the scoliosis group treatment include schroth theraphy
32868794|NCT05223972|Experimental|Lyon Treatment|For the scoliosis group treatment include Lyon theraphy..
32868795|NCT00214045|Active Comparator|Flexible Cystoscopy|Flexible Cystoscopy
32868796|NCT00214045|Active Comparator|Rigid Cystoscopy|Rigid Cystoscopy
32868797|NCT01880892|Experimental|Post cricopharyngeal myotomy|Subjects scheduled to undergo an endoscopic criocopharyngeal myotomy, which is the standard treatment for a Zenker's diverticulum, will have levels of laryngopharyngeal reflux measured after the procedure.
32868798|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
32868799|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
32868800|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
32868801|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
33067844|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
33067845|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
33418041|NCT03987009|Experimental|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
33418042|NCT03987009|Experimental|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
32868802|NCT05700942|Experimental|High Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. For the high dose group, a standard dosage of 30 continuous minutes of 2.5 mA stimulus will be used.
32868803|NCT05700942|Active Comparator|Low Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. The low dose condition will use an identical montage and stimulation arrangement, except the stimulation will be delivered briefly at the beginning and end of the stimulation period (30 seconds) with a three-second ramp.
33418043|NCT03987009|Experimental|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
32868804|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
32868805|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
32868806|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
32868807|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
32868808|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
32868809|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
32868810|NCT00107575|Active Comparator|Standard treatment (ST)|Standard smoking cessation treatment (ST)
32868811|NCT00107575|Experimental|ST-BI|Standard treatment plus a brief alcohol intervention
32868812|NCT05700240||Orthokeratology treatment|
32868813|NCT05700240||single-vision spectacle correction|
32868814|NCT05549856|Experimental|Dry suction group|22G Franseen needle biopsy with dry suction technique(The puncture needle be filled with air)
32868815|NCT05549856|Active Comparator|Wet suction group|22G Franseen needle biopsy with wet suction(The puncture needle be filled with saline before sugry)
32868816|NCT05555628|Experimental|Mandibular Exercise|At the beginning of the treatment, the therapist will perform a soft tissue massage to the patient's muscles. Then, an exercise protocol for specific muscles (masseter, temporal muscles, mandibular region muscles) will be administered. This group, the exercise will focus only on the chin area, not general like posture.
32868817|NCT05555628|Experimental|Mandibular and Postural Exercise|The patients will perform posture exercises, including stabilization of the upper body and cervical region, accompanied by a physiotherapist. A theraband suitable for the patient's muscular strength will be used for posture exercises,. The appropriate therabant selection will be decided by a maximum repetition method.
32868818|NCT05555628|Active Comparator|Occlusal Splint|"The patients assigned to this group will be treated by the occlusal splint administered by the dentist and the recommendations that they should pay attention to in daily life.~Occlusal splints will be prepared according to previously published criteria by Okeson and other researchers. Occlusal splint measurement and production will be done by technicians with 5 years of experience. Using the models obtained from the maxillary measurements of the patients, 0.5 mm thick thermoplastic rigid splints will be prepared and adjusted according to the patient's occlusion. Occlusal splints will be prepared for night use only. Patients will use splints every night for 6 weeks. Splint use of the patients and possible side effects or plaque-related disorders will be followed up with phone calls to be made every 2 weeks."
32871566|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
33418044|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
33418045|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
33418046|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE < 5.8kPa; rule out cut-off value)
33418047|NCT04400604||2: Patients with intermediate risk of fibrosis|
33043269|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
33043270|NCT00005866|Experimental|treatment|
33043271|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
33043274|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
33043275|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
33043276|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
33043277|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
33043278|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
33043279|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
33043280|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
33043281|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33043282|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
33043283|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
33043284|NCT00387738|Placebo Comparator|3|
33043285|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
33043286|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
33043287|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
33043288|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
33043289|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
33043290|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
33043291|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
33043292|NCT00387855|Experimental|1|receive SOS program
33043293|NCT00005983|Active Comparator|surgery|surgery followed by observation
33043294|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
33043295|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
33043296|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
33043297|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
33418048|NCT04400604||Patients with high risk of extensive fibrosis|
33043298|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
33418049|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
33418050|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
33418051|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
33418052|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
33418053|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
33043299|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
33418054|NCT02090972||Patients with fracture|"fracture within the last 14 days~no other fractures within the last 6 month~patients >60 years"
33043300|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
33418055|NCT02090972||Control Patients|"patients hospitalized for an internal reason~no other fractures within the last 6 month~patients >60 years"
33418056|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
33418057|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
33418058|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
33418059|NCT01307787|Other|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
33418060|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
33043301|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
33043302|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
33043303|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
33418061|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
33418062|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
33418063|NCT05664711|Experimental|Stellate Ganglion Block|The stellate ganglion and nearby cervical sympathetic ganglia will be blocked with 10 mL 0.5 percent bupivacaine under ultrasound guidance.
33418064|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
33418065|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
33043304|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
33043305|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
33043306|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
33067846|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
33418066|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
33418067|NCT02091128||Females with classic galactosemia and POI|
33418068|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
33418069|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
33418070|NCT02089568|Placebo Comparator|Control|comparator
33418071|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
33418072|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
33043307|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
32868819|NCT05555472|Active Comparator|Care-as-usual Halt-condition|Participants in this arm will follow the regular Halt-intervention. Halt professionals, not trained in YIM-approach, will be instructed to follow their regular working procedure. On average, the intervention consists of 3 meetings: an initial meeting, an intervention meeting, and a closing meeting. The aim is to complete the intervention within 100 days (min.-max.: 1-6 meetings, 1-20 hours). During the initial meeting, compulsory activities are screening and risk assessment, reflection on the committed offense/crime, and parental involvement. Based on these activities, the duration and the content of the intervention are determined. Professionals can select activities from 5 different modules: (1) reflection on behaviour, (2) parental involvement, (3) social skills training, (4) victim-offender reconciliation, and (5) future. A form of victim-offender reconciliation, however, is compulsory. Professionals are required to register relevant information regarding the Halt-process.
32868820|NCT05555472|Experimental|Halt-plus-YIM-condition|Participants in this arm will follow the Halt-plus-YIM-intervention. YIM trained Halt professionals implement the YIM approach in their regular working procedure in 7 steps: (1) during risk assessment, they support youth in identifying a YIM; (2) during the course of the study, professionals will be instructed to motivate and explain the YIM approach in cases with 3 or more meetings; (3) if a YIM is nominated, a meeting between the professional and the YIM takes place; (4) to 'position' the YIM, a joint meeting is arranged to discuss expectations/goals of all involved parties; (5) interim contact between professional and YIM takes place; (6) a joint evaluative meeting takes place; (7) if agreed upon, closure of Halt's engagement takes place. Note, the YIM often remains involved after this completion. Professionals register on the Halt- and YIM-process and whether the approach was deployed: 'NO' (i.e., only step 1), 'PARTLY' (i.e., steps 1 and 2) or 'YES' (i.e., at least step 3 or 4).
33043308|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
33043309|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
33043310|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
33043311|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
33043312|NCT05681065|No Intervention|Control group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient.
33043313|NCT05681065|Experimental|Intervention Group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient. In addition, these participants will be provided with the TeNDER technological tool. The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of the biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of health professionals.
33043314|NCT05681026||Yoga Sessions|Participants will take part in Yoga of gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
33043315|NCT05680987|Other|Retrograde Femoral Nail-Advanced|
33043316|NCT05680909||SaCo VLM evaluation|"Prospective group of morbidly obese patients scheduled for elective bariatric procedure with the use of SaCo VLM for airway management.~The following features related to SoCo VLM use will be recorded: insertion of SaCo VLM, evaluation of ventilation parameters, attempt of endotracheal intubation via SaCo VLM's lumen under continuouis visualisation of entrance to larynx using videoscope intergatred system"
33418073|NCT02091596|Placebo Comparator|PluroGel|PluroGel
33418074|NCT02091596|Experimental|PluroGel N|PluroGel N
33418075|NCT03126019|Experimental|Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW|Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
33418076|NCT03126019|Experimental|Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD|Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.
33418077|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
33418078|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
33043317|NCT05680870|No Intervention|Control group|Control grp will not receive omeprazole . They will receive chemotherapy protocols only
33043318|NCT05680870|Experimental|Intervention group|Intervention group will receive omeprazole plus chemotherapy protocols
33043319|NCT05680831|Experimental|0.070 ppm ozone concentration|Exposure to 0.070 ppm ozone for 6.6 hours while performing moderate intermittent exercise.
33043320|NCT05680831|Experimental|Clean air (0.0 ppm ozone)|Exposure to clean air (0.0 ppm ozone) for 6.6 hours while performing moderate intermittent exercise.
33043321|NCT05680792|Other|Administration of nitazoxanide alone|Participants in this arm will receive 1000 mg of nitazoxanide tablets alone
33043322|NCT05680792|Other|"Administration of nitazoxanide and atazanavir/ritonavir separately"|Participants in this arm will receive 1000 mg of nitazoxanide tablets twice daily together with one tablet of atazanavir/ritonavir (300 mg/100 mg) once daily in the morning.
32868821|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
32868822|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
32868823|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
32868824|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
32868825|NCT04743024||Household|Household carer-child pairs will be included according to age and consent criteria
33418079|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
33418080|NCT02087384|Experimental|Gardasil|Gardasil
32868826|NCT04742868|Experimental|Arm 1 QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with bone will be used as graft for the surgery.
32868827|NCT04742868|Experimental|Arm 2 HAMSTRING TENDON GRAFT|Hamstring tendon with bone will be used as graft for the surgery
32868828|NCT04742868|Experimental|Arm 3. QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without bone will be used as graft for the surgery.
32868829|NCT00217399|Experimental|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
32868830|NCT04742556|Experimental|BI 3011441|
32868831|NCT04739670|Experimental|Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin|Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV
32868832|NCT00108277|Experimental|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
32868833|NCT00108277|Active Comparator|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
32868834|NCT00108277|No Intervention|Waitlist|Waitlist - treatment as usual
32868835|NCT05549778|Experimental|polaprezinc experimental group|Abiraterone and 2 bags (75 mg per bag) polaprezinc per day for 6 months
32868836|NCT05549778|Placebo Comparator|placebo comparison group|Abiraterone without polaprezinc
32868837|NCT05286619|Experimental|Pembrolizumab plus Platinum and Gemcitabine|Pembrolizumab 200 mg will be administered as 30-minute IV infusion Day 1 of every 3 weeks. Pembrolizumab will be administered first followed by the platinum and gemcitabine infusions. Cisplatin will be administered on Day 1 and 8 of each 3-weeks treatment cycle with a dose of 35 mg/m2 for 60 minutes. Carboplatin will be administered on Day 1 of each 3-weeks treatment cycle given as a dose of AUC 5 for 60 minutes. Gemcitabine will be administered on Day 1 and 8 of each 3-weeks treatment given as a dose of 1250 mg/m2 for 30 minutes. AEs associated with pembrolizumab exposure, including coadministration with additional compounds, may represent an immunologic aetiology. If one or all of the chemotherapy components is discontinued, subjects can continue with pembrolizumab up to the full 35 cycles.
32868838|NCT05549622|Other|Low-soluble fiber diet|
32868839|NCT05549622|Active Comparator|High-soluble fiber diet|
32868840|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
32868841|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
32868842|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
32868843|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
32868844|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
32868845|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
32868846|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
32868847|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
32868848|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
32868849|NCT04329624|Active Comparator|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
32868850|NCT04329624|Placebo Comparator|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
32868851|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
32868852|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
32868853|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
32868854|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
32868855|NCT05549310|Active Comparator|CPAP group|"CPAP group : The first stage:receiving CPAP treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. CPAP group continued to receive corresponding treatment for 6 months."
32868856|NCT05549310|Experimental|HFNC group|"HFNC group : The first stage:receiving HFNC treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. HFNC group continued to receive corresponding treatment for 6 months."
33330564|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
33418081|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
32868857|NCT00218023|Experimental|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
33043323|NCT05680753|Experimental|Stratified Blended Approach arm|First, physiotherapists will use two stratification tools to decide the most suitable content and intensity as well as mode of care delivery of primary care physiotherapy. The content and intensity of physiotherapy will be matched to the patient's risk of persistent disabling pain as assessed with the Keele STarT MSK tool. The mode of care delivery of physiotherapy will be matched to the patient's suitability for blended care as assessed using the Dutch Blended Physiotherapy Checklist (i.e. yes or no). Second, physiotherapists will receive two practical tools to provide the matched treatment of the mode of care delivery. If considered suitable for blended care, the patient will receive a blended physiotherapy treatment (e-Exercise), in which a smartphone app with personalized information, exercises and physical activity modules is an integral part of physiotherapy treatment. If patients are considered not to be suitable for blended care, a paper-based workbook will be integrated.
33043324|NCT05680753|Active Comparator|Usual physiotherapy arm|Patients in the usual physiotherapy arm will be offered usual care (face-to-face or video consults) based upon the recommendations of the guidelines of the Royal Dutch Association for Physiotherapy (KNGF). The clinical guideline for neck pain, recommends categorization in treatment profiles based on: the severity of neck pain, the course of symptoms (normal vs. deviant) and the presence of psychosocial factors that may hinder recovery (yes vs. no). The clinical guideline for complaints of the arm, neck and shoulder recommends categorization in treatment profiles based on the region of complaints indicated as most problematic and the relationship between complaints, disabilities, and limitations in participation. No stratification tools to identify patient subgroups and subsequently match them to a treatment are recommended by the guidelines.
33043325|NCT05680714||FALLERS IN THE INTERVENTION BOROUGHS|"Fallers 65+ years from the borough of Nordstrand from January 1. 2015 Fallers 65+ years from the borough of Østensjø from September 1. 2016~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
33043326|NCT05680714||FALLERS IN THE CONTROL BOROUGHS|"Fallers 65+ years from all the 13 other boroughs of Oslo.~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
33043327|NCT05680714||NON-FALLERS|All non-fallers 65+ years from all Oslo boroughs.
33043328|NCT05680675|Experimental|Arm 1|Single-Tracer FDG (F18 Fluorodeoxyglucose) PET/CT exam + Single-Tracer Cu64-DOTATATE PET/CT
33043329|NCT05680675|Experimental|Arm 2|Single-Tracer FDG PET/CT exam + Single-Tracer Ga68-DOTATATE PET/CT exam
33043330|NCT05680675|Experimental|Arm 3|Single-Tracer FDG PET/CT exam + Single-Tracer PSMA (prostate-specific membrane antigen) PET/CT exam
33043331|NCT05680597|Experimental|Supervised Tele-Rehabilitation Home Exercise|40 subjects will have tele-rehabilitation virtually with a physical therapist for 60 minutes, three times per week for four weeks of intervention. Subjects will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
33043332|NCT05680597|Active Comparator|Unsupervised Rehabilitation Home Exercise|40 subjects will complete their home exercise Agility Boot Camp (ABC) program for 60 minutes, three times per week for four weeks of intervention. Subjects will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
33043333|NCT05680558|Experimental|UVA Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis System|TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.
33043334|NCT05680402|Experimental|Group 1|Soft tissue mobilization
33043335|NCT05680402|Active Comparator|Group 2|Piriformis Stretching
33043336|NCT05680363|Active Comparator|Standard Sperm Preparation|Sperm samples in the control group will undergo traditional processing in the lab prior to insemination.
33043337|NCT05680363|Experimental|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing in the lab prior to insemination.
33043338|NCT05680324|Active Comparator|Abdominoplasty with Monsplasty|
33043339|NCT05680324|Active Comparator|Abdominoplasty without monsplasty|
33043340|NCT05680285|Experimental|diode laser pulpotomy|"Diode laser (Solase-976 Dental Diode Laser)~With a wavelength of 980 nm and a frequency of 110 Hz~In pulse mode, working for 1 ms and stopping for 8 ms~With a power output of 1 W during each laser pulse from the 400 µm fiber optic tip~By touching the fiber optic tip to the remaining pulp tissue~for 3 seconds~With 3 J energy to each root pulp during the process"
32868858|NCT00218023|Experimental|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
32871567|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
33043341|NCT05680285|Experimental|low level diode laser pulpotomy|"Diode laser (Solase-976 Dental Diode Laser)~It has a wavelength of 980 nm and a frequency of 165 Hz.~In pulse mode by setting it to run for 2 ms and stop for 4 ms~At a power of 0.2 W during each laser pulse from a 400 µm fiber optic tip~Without the fiber optic tip touching the remaining pulp tissue~for 10 seconds~With 2 J Energy to each root pulp"
33418082|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
33418083|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
33418084|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
33418085|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
33418086|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
33418087|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
32868859|NCT00218023|Experimental|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
32868860|NCT00218023|Placebo Comparator|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
32868861|NCT05549232||Hematologic Malignancies|Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.
32868862|NCT05549232||Acute Burn|Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.
32868863|NCT00054665|Experimental|Part A: PS-341 Alone|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
32868864|NCT00054665|Experimental|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4.~EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days."
32868865|NCT05700708||Cirrhosis with Refractory Ascites|
32868866|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
32868867|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
32868868|NCT00218335|Experimental|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
32868869|NCT00218335|Active Comparator|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
32868870|NCT00057551|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
32868871|NCT00057551|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
32868872|NCT00057551|Active Comparator|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
32868873|NCT05555316|Experimental|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg).
32868874|NCT00218491|Experimental|1200mg N-Acetylcysteine|1200mg N-Acetylcysteine
32868875|NCT00218491|Experimental|2400mg N-Acetylcysteine|2400mg N-Acetylcysteine
32868876|NCT00218491|Placebo Comparator|Matching Placebo|Matching Placebo
32868877|NCT05700864|Experimental|Oxervate® (cenegermin)|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj
32868878|NCT05555160|Experimental|Single-chamber valve tip conductive PICC catheter|
32868879|NCT05555160|Experimental|Single - chamber valve non - tip conductive PICC catheter|
32868880|NCT00221299|Active Comparator|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
32868881|NCT00221299|Active Comparator|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
33043342|NCT05680207|Active Comparator|Intervention group|Type 2 Diabetes Mellitus patients who received a empowerment training program for 6 weeks, 2 hours a week
33418088|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
33418089|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
33043343|NCT05680207|No Intervention|Control group|Type 2 Diabetes Mellitus patients who did not receive a empowerment training program
33043344|NCT05680090||Eligible participants for AI-based ophthalmic emergency triage and primary diagnosis|
32868882|NCT00221299|Active Comparator|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
32868883|NCT00221299|Active Comparator|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
32868884|NCT05555004|Experimental|TEST1|
33043345|NCT05680012|Experimental|Gluten challenge group|Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months
33043346|NCT05680012|No Intervention|Gluten de-challenge group|Suspected celiac disease either showing typical symptoms or positive celiac disease serology
33043347|NCT05680012|No Intervention|Control group|No history or symptoms of celiac disease
33043348|NCT05679973|Experimental|Polybutester|Polybutester suture is a copolymer of polyglycol terephthalate and polybutylene terephthalate. It is a synthetic, non-resorbable, monofilament suture material. Polybutester is stronger than other monofilaments. Suture memory is poor and packaging does not retain its shape. Therefore, this suture is easier to work with and the knot security is higher. Polybutester suture adapts better to tensile strength than other synthetic sutures. This suture adapts to the increasing wound edema and returns to its original shape when the edema subsides. Also, this suture reduces the risk of hypertrophic scar formation due to its ability to adapt to the edema and changing configuration of a healing wound. It produces better cosmetic results.
33043349|NCT05679973|Active Comparator|Polypropylene|Polypropylene, used as suture material, is formed by bringing isotactic stereoisomers of a linear hydrocarbon crystalline polymer into sterile monofilament form. Polymer polypropylene is a non-resorbable, synthetic, monofilament suture. It has high compressive strength and low tissue reactivity. It is resistant to infection formation. In general, the ability to close and protect the wound is good. The suture memory is high, therefore it is difficult to use and the knot security is less than other sutures. Allergic reaction due to polypropylene sutures is very rare.
33043350|NCT05679934|Experimental|Home-Based Exercise|Patients who perform home-based exercise program
33418090|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
33418091|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
33418092|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
33043351|NCT05679934|Experimental|Telerehabilitation|Patients who perform telerehabilitation exercise program
33043352|NCT05679934|No Intervention|Control Group|No intervention
33043353|NCT05679856|Experimental|Single vocal cord hypofractionated radiotherapy|Hypofractionated radiotherapy 58.08Gy/16 fractions to affected vocal cord plus margins to account for motion and setup errors using IMRT/VMAT technique
33418093|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
33418094|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
33418095|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
33418096|NCT03952923|Experimental|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
33418097|NCT01368913||Patients treated with orally disintegrating tablet|
33418098|NCT01368913||Patients treated with tablets|
33418099|NCT05494970||Patients with ORL cancer for which radiotherapy treatment is required.|
33418100|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
33418101|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
33418102|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
33418103|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
33418104|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
33418105|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
33418106|NCT04610827|Active Comparator|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
33418107|NCT04610827|Active Comparator|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
33418108|NCT04610827|Active Comparator|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
32868885|NCT05555004|Experimental|TEST2|
33043354|NCT05679856|Active Comparator|Whole laryngeal radiotherapy|Radiotherapy 63Gy/28 fractions to whole larynx from lower border of hyoid bone to lower border of cricoid cartilage using IMRT/VMAT technique
33418109|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
33418110|NCT04503733|Experimental|Q4W GMA301 IV injections (300 mg)|"Drug: Q4W GMA301 IV injections (300 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
33418111|NCT04503733|Experimental|Q4W GMA301 IV injections (600 mg)|"Drug: Q4W GMA301 IV injections (600 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
32868886|NCT05554848|No Intervention|control group|patients will receive normal saline instead of dexmedetomidine and MgSo4 .
33330565|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
33330566|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
32868887|NCT05554848|Active Comparator|dexmedetomidine group|patients will receive the same of dexmedetomidine as MD group in addition to normal saline instead of Magnesium Sulfate .
33330567|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
33330568|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
33330569|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
33330570|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
33330571|NCT05211934||The group with delirium|
33330572|NCT05211934||The group without delirium|
33330573|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
33330574|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
32868888|NCT05554848|Active Comparator|Dexmedetomidine Mgso4 group|patients will receive dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period (Precedex ; Hospira Worldwide ,Lake Forest, IL).(20) and receiving Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
32868889|NCT05554692|Experimental|Enrolled Participants - Older adults with cochlear implants|Individuals who already use at least one cochlear implant.
32868890|NCT05554692|Other|Enrolled Participants - Adults with typical hearing|Control group to provide baseline or comparison data
32868891|NCT05554536|Other|Single arm intervention|All patients will undergo a PEEP titration trial in each surgery step (before pneumoperitoneum, during pneumoperitoneum, after pneumoperitoneum). The PEEP titration trial will be done in steps of 2 cmH2O, starting from clinical PEEP 16 cmH2O and ending to PEEP 6 cmH2O. Each PEEP level will be kept for 2 minutes. The PEEP titration trial will be stopped in case of haemodynamic instability or severe desaturation (Spo2 < 92%). Each PEEP titration trial will be recorded using Electrical impedance tomography (EIT).
32868892|NCT05554458|Experimental|Control Group|Paired allocation into intervention group IG (N = 33) and control group CG (N = 33) is based on the number of risk factors identified in the family. IG and CG complete questionnaires at the baseline assessment (T0), at the post-test assessment (T1), and at the follow-up assessments after 6 months (T2) and 12 months (T3).
32868893|NCT05554458|Active Comparator|Intervention Group|IG receive the ChildTalks+ intervention within 2 months after T0 and CG after the T3 assessment.
32868894|NCT00057785|Experimental|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
32868895|NCT05554224||Severe obesity without liver disease|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 0-2).
32868896|NCT05554224||Severe obesity with liver disease without criteria for steatohepatitis|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis, but their biopsies presented some liver severity (scores 3 and 4).
32868897|NCT05554224||Severe obesity with well-defined steatohepatitis and/or cirrhosis|Patients with severe obesity who met the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 5-8).
32868898|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
32868899|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
32868900|NCT04323306|Active Comparator|Cohort 1 SAD|5 mg MMV533 with single ascending dose
32868901|NCT04323306|Active Comparator|Cohort 2 SAD|Single ascending dose to be determined after SRC review of previous cohort.
32868902|NCT04323306|Active Comparator|Cohort 3 SAD|Single ascending dose to be determined after SRC review of previous cohort.
32868903|NCT04323306|Active Comparator|Cohort 4 SAD|Single ascending dose to be determined after SRC review of previous cohort.
32868904|NCT04323306|Active Comparator|Cohort 5 SAD|Single ascending dose to be determined after SRC review of previous cohort.
32868905|NCT04323306|Active Comparator|Cohort 6 SAD|Single ascending dose to be determined after SRC review of previous cohort.
32868906|NCT04323306|Active Comparator|Cohort 7 SAD|Single ascending dose to be determined determine after SRT review of previous cohort. Dose will not exceed 400 mg.
32868907|NCT04323306|Active Comparator|Part 2: Food Effect|Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533 determined to be safe in Part 1.
32868908|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
32868909|NCT05548998||High flow cohort (HFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow ≥ 1L/min, were included in this cohort.
33418112|NCT04503733|Experimental|Q4W GMA301 IV injections (1000 mg)|"Drug: Q4W GMA301 IV injections (1000 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
33418113|NCT04503733|Experimental|Q4W GMA301 IV injections (1800 mg)|"Drug: Q4W GMA301 IV injections (1800 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
33418114|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
33418115|NCT02089724||vemurafenib/other BRAF inhibitors|
33418116|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
32868910|NCT05548998||Low flow cohort (LFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow < 1L/min, were included in this cohort.
32868911|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
32868912|NCT01666782|Experimental|High-Dose Influenza Vaccine|
32868913|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
32868914|NCT05548842|Experimental|Combined group|This group takes the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill for 12 weeks.
32868915|NCT05548842|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
32868916|NCT00058019|Experimental|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
32868917|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
32868918|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
32868919|NCT05548686|Experimental|Adapted Physical Activity|Patients benefiting from adapted physical activity
32868920|NCT05548608||Group I (Healthy control)|Group I consists of patient relatives and patients who applied to the outpatient clinic for another ailment.
32868921|NCT05548608||Group II (chronic low back pain due to LSS )|Group II consisted of patients diagnosed with LSS and confirmed by MRI findings.
32868922|NCT05548608||Group III (undergoing surgery due to LSS )|Participants who had surgery for LSS at least 3 months ago were included in Group III.
32868923|NCT04752839||Exposed Workers|Workers who have been exposed during COVID 19 pandemic.
32868924|NCT00110461|Active Comparator|1|Aripiprazole 10 mg tablet
32868925|NCT00110461|Active Comparator|2|Aripiprazole 30 mg tablet
32868926|NCT00110461|Placebo Comparator|3|Placebo
32868927|NCT05700162|Experimental|Photograph|As soon as the mother starts to express her milk, she will be asked to look at the photo of her baby sent to her on whatsapp for 5 minutes.
32868928|NCT05700162|Experimental|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on whatsapp.
32868929|NCT05700162|Experimental|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp.
32868930|NCT05700162|Experimental|Control Group|The mother will be asked to express both breasts for 15 minutes every 3 hours. No additional application will be made.
32868931|NCT05548530||Stereotactic intracranial hematoma puncture treatment group|Check the CT slice of the patient's brain, find out the patient's largest hematoma level, measure the coordinates of the puncture center, locate and mark the skull surface according to the measured coordinates, select the puncture point under the stereotaxic instrument, Mainly avoid important blood vessels, nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
32868932|NCT05548530||drug treatment group|General treatment: Based on high-level nursing care and close and continuous attention to the patient's vital signs, the patient is instructed to stay in bed continuously, give oxygen, and instruct the patient to avoid emotional agitation, etc. ②Special treatment: use hemostatic drugs, control blood pressure to prevent rebleeding, control blood sugar, control body temperature, anti-epilepsy, prevent infection, dehydration and lower intracranial pressure, etc. Multisystem complications such as tract hemorrhage should be actively managed.
32868933|NCT05558670||coma|
32868934|NCT05558670||VS/UWS|
32868935|NCT05558670||MCS|
32868936|NCT05558670||EMCS|
32868937|NCT04068896|Experimental|NGM120 Dose 1|NGM120 Subcutaneous Injection
32868938|NCT04068896|Experimental|NGM120 Dose 2|NGM120 Subcutaneous Injection
32868939|NCT04068896|Experimental|NGM120 Dose 3|NGM120 Subcutaneous Injection
32868940|NCT04068896|Experimental|NGM120 Dose 4|NGM120 Subcutaneous Injection
32868941|NCT04068896|Experimental|NGM120 Dose 5|NGM120 Subcutaneous Injection
32868942|NCT04068896|Experimental|NGM120 Dose 6|NGM120 Subcutaneous Injection
32868943|NCT04068896|Placebo Comparator|Placebo|Placebo
32868944|NCT05558514|Experimental|Place-based map|CIs will be mapped according to each participant's unique place-based map using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map than the one they were assigned for 1 additional month. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
33043355|NCT05679817|Experimental|D-GAE group|This group received a 12-week aerobic training in addition to the traditional physical rehabilitation.
33418117|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
33418118|NCT02091830||Non-surgical treatment|
32740168|NCT05160077|Other|Standardised Breakfast and ICG|"Preprandial examination are in a fasting state, all postprandial examinations will be conducted with standardized dietary including indocyanine green (ICG) dye.~30 minutes after the beginning of the preprandial examination participants receive an standardised breakfast containing ICG. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal without ICG."
33043356|NCT05679817|Active Comparator|Control group|This group received the traditional physical rehabilitation only
33043357|NCT05679739|Experimental|Individualized blood pressure strategy|Hemodynamic optimization performed to an individualized target mean arterial pressure in the first 72 hours post ROSC based on cerebral perfusion assessed serially.
32740169|NCT03313739|Experimental|Intervention group|An Educational Program
32740170|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
32740171|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
32740172|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
32740173|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
32740174|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
32740175|NCT03313661|No Intervention|Placebo|Placebo
32740176|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
32740177|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
32740178|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
32740179|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
32740180|NCT03313505||Patients who had been tested for S100B protein|
32740181|NCT03313505||Patients who have benefited from another strategy|
32740182|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
32740183|NCT03313427|Other|Control|Usual care
32740184|NCT03309293|Other|controls|biological samples bank
32740185|NCT03309293|Experimental|cases|
32740186|NCT03313349|Other|Usual Provision (UP)|"Usual Provision~Psychotherapy: 1. cognitive therapy 2.family intervention"
32740187|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision~Psychotherapy: 1.cognitive therapy 2.family intervention"
32740188|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
32740189|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
32740190|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
32740191|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
32740192|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
32740193|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
32740194|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
32740195|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
32740196|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
32740197|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
32740198|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
32740199|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
32740200|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
32740201|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
32740202|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
32740203|NCT02469467|Experimental|VS-505|750 mg capsule
32740204|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
32740205|NCT03313193|No Intervention|Arm B|Usual care alone
33109179|NCT04341441|Active Comparator|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
33109180|NCT04341441|Active Comparator|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
33109181|NCT04341441|Active Comparator|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
33109182|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
33330575|NCT05211778|No Intervention|Control Group|This group will continue to receive the routine standard of care during their treatment journey.
33330576|NCT05211778|Experimental|Digital Education Group|In addition to the standard of care, this group will complete an audiovisual digital education module during their postoperative stay in hospital.
33330577|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
33330578|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
33330579|NCT05211622|Experimental|Group I, OZOCLO|"• Group I, OZOCLO~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks~chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks"
33330580|NCT05211622|Placebo Comparator|Group II, OBC|• Group II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 3 weeks
33330581|NCT05211622|Active Comparator|Group III, CHX|• Group III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks
33330582|NCT05211622|Active Comparator|Group IV, AAL-OZ|"• Group IV, AAL-OZ~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks"
33330583|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
33330584|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
33330585|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
33330586|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
33330587|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
33330588|NCT05211544|Active Comparator|intervention group 1|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
33330589|NCT05211544|Active Comparator|intervention group 2|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
33330590|NCT05211544|Active Comparator|control group|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
33330591|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
33330592|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
33330593|NCT05210686|Experimental|subgingival re-instrumentation + gel containing PDRN and HA|subgingival re-instrumentation + gel containing PDRN and HA
33330594|NCT05210686|Active Comparator|subgingival re-instrumentation|subgingival re-instrumentation
33330595|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
33330596|NCT05210452|Experimental|Patients with alopecia receiving standard treatment and follicular stem cells|Patients with alopecia receiving standard treatment and autologous follicular stem cells
33330597|NCT05210452|Active Comparator|Patients with alopecia receiving standard treatment|Patients with alopecia receiving standard treatment
33418119|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
33043358|NCT05679739|No Intervention|Standard-of-care group|Hemodynamic optimization to a target mean arterial pressure of ≥65mmHg throughout the first 72 hours post-ROSC.
32868945|NCT05558514|Active Comparator|Default map|CIs will be mapped according to the clinical default program using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map for 1 additional month from the one they were randomly assigned. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
32868946|NCT05548218|No Intervention|New diagnosis of diabetes control group|
32868947|NCT05548218|Experimental|New diagnosis of diabetes intervention group|
32868948|NCT05548218|No Intervention|Uncontrolled diabetes control group|
33330598|NCT05210218|Experimental|mildly hypocaloric diet + CC 300 mg +WS 150 mg tid|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK) to be taken three times a day. All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
32868949|NCT05548218|Experimental|Uncontrolled diabetes intervention group|
32868950|NCT00061373|Experimental|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
32868951|NCT00061373|Experimental|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide.~--------------------------------------------------------------------------------"
32868952|NCT05700084|Experimental|Utidelone Capsule (Part 1)|Utidelone Capsule, available as 10 mg/capsule and 15 mg /capsule. Doses between 50 mg/m2/d and 120 mg/m2/d administered orally will be explored. Patients will be dosed for 5/7 consecutive days in a 21 day cycle.
32868953|NCT05700084|Experimental|Utidelone Capsule/Utidelone Injection (Group A-B, Part 2)|At cycle 0, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 1, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At Cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
32868954|NCT05700084|Experimental|Utidelone Injection/Utidelone Capsule (Group B-A, Part 2)|At cycle 0, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At cycle 1, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
32868955|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
32868956|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
33418120|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
32868959|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
32868960|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
32868961|NCT05558436||Cancer group|Patients with colorectal cancer.
32868962|NCT05558436||Control group|Patients with benign colorectal disease.
32868963|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
32868964|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
32868965|NCT05553990||Acute ischemic stroke with active tumor|Acute ischemic stroke with active tumor
32868966|NCT05553990||Acute ischemic stroke without active tumor|Acute ischemic stroke without active tumor
32868967|NCT00112723|Experimental|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I."
32868968|NCT04327206|Experimental|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
32868969|NCT04327206|Placebo Comparator|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
32868970|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
32871568|NCT04350645|Active Comparator|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
33043359|NCT05679700|Experimental|Chronic stroke patients with knee hyperextension|
33418121|NCT05191927||female group|all are female
32868972|NCT00113425|Experimental|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
32868973|NCT00113425|No Intervention|Control|Untreated
32868974|NCT05543226|Experimental|PHGG|
32868975|NCT05543226|Placebo Comparator|without PHGG|
32868976|NCT05700552|Experimental|Intervention Group|In the intervention group, after cesarean delivery in the operating room, maternal vital signs and the newborn's 1st and 5th minute Apgar Score will be evaluated. After the newborn baby is aspirated if necessary, dried with a green cover under the radiant warmer, tied the diaper, and put on a hat, the newborn with an Apgar Score ≥7 and vital signs stable will be wrapped in pre-warmed operating room covers. After providing a suitable environment, the newborn whose body temperature is stabilized will be placed in the prone position without any covering and clothing on the chest area of the mother, and the ALPS value will be applied for about 3 minutes due to the application of hospital procedures, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
32868977|NCT05700552|No Intervention|Control group|The routine procedure of the institution where the study will be performed will be applied to the newborn baby after cesarean section in the control group. Within the scope of this procedure, after the baby is born, the umbilical cord is cut, mouth and nose aspiration is performed under the radiant heater in the operating room, they are dried, and the Apgar Score is evaluated at the 1st and 5th minutes by the midwife. The newborn is wrapped in pre-heated operating room covers, and after being shown to the mother, anthropometric measurements (height, body weight, head circumference) are taken and taken to the delivery room for the administration of vitamin K, hepatitis B vaccine, and the first examination of the baby. The first ALPS value will be recorded in the delivery room in the baby care area, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
32868978|NCT05700006||Age 65+, AI therapy|Postmenopausal women age 65 and older who are starting treatment with standard of care aromatase inhibitor therapy
32868979|NCT05700006||Age 65+, no endocrine therapy|Postmenopausal women age 65 and older who are not starting treatment with any endocrine therapy
32868980|NCT05700006||Age under 65, AI therapy|Postmenopausal women age less than 65 who are starting treatment with standard of care aromatase inhibitor therapy
32868981|NCT02096731||LABA + tiotropium|
32868982|NCT02096731||LABA mono|
32868983|NCT02096731||neither tiotropium nor LABA|
32868984|NCT02096731||tiotropium + LABA|
32868985|NCT02096731||tiotropium mono|
32868986|NCT05211115|Experimental|Split thickness flap + Volume stable collagen matrix|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 6mm thick volume stable collagen matrix will be stabilised at the inner aspect of the flap.
32868987|NCT05211115|Active Comparator|Full thickness flap + Volume stable collagen matrix|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide by 6-8mm high volume stable collagen matrix will be stabilised at the inner aspect of the flap.
32868988|NCT05211115|Active Comparator|Split thickness flap + Autogenous connective tissue|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
32868989|NCT05211115|Active Comparator|Full thickness flap + Autogenous connective tissue|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
32868990|NCT05543148||normal hearing with subjective hearing difficulty|
32868991|NCT05543148||mild hearing loss (unaided)|
32868992|NCT05543148||moderate hearing loss (unaided)|
32868993|NCT05543148||moderate hearing loss (aided)|
32868994|NCT05553756|No Intervention|preoperative clear liquid|Patients will drink 200 ml of clear liquid two hours before Cesarean section
32868995|NCT05553756|Active Comparator|preoperative maltodextrin|Patients will drink 200 ml of maltodexin two hours before Cesarean section
32868996|NCT00115297|Experimental|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
32868997|NCT00115297|Placebo Comparator|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
32868998|NCT05543070|Experimental|Low-dose Radiotherapy|Involved-site radiotherapy (3 Gy*4f) in one week
32868999|NCT00116857|Active Comparator|Sertraline/omega-3 supplement|
33043360|NCT05679583|Experimental|Preoperative SBRT arm|Patients with resectable pancreatic cancer will receive preoperative SBRT 2 to 4 weeks before surgery. And 4 weeks after surgery, adjuvant CTx will be administered for 6 months.
32869000|NCT00116857|Placebo Comparator|Sertraline/corn oil|
32869001|NCT05547828|Other|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
32869002|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
32869003|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
32869004|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
33418122|NCT05191927||male group|all are male
33418123|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
33418124|NCT04497415|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
33418125|NCT04497415|No Intervention|Assessment only|Control
33418126|NCT05462834|Experimental|Compressed Air then Supplemental Oxygen|
32740206|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
32869005|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
33109183|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
33418127|NCT05462834|Experimental|Supplemental Oxygen then Compressed Air|
33418128|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
33418129|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
32740207|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
32740208|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
32740209|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
32740210|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
32740211|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
32740212|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
32740213|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
32740214|NCT03308279||Asinthomatic|The only group evaluated
32740215|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
32740216|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
32740217|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
32740218|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
32740219|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
32740220|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
32740221|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
32740222|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
32740223|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
32740224|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
32740225|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
32740226|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
32740227|NCT03308201|Experimental|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
32740228|NCT03308201|Experimental|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
32740229|NCT03308123||Health Care Professionals|Health care professionals
32740230|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
32740231|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
33109184|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
33109185|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
33109186|NCT05381259|Other|hortitherapy intervention versus control|"Horticultural therapy refers to physical and psychic therapy by nature by focusing on the action of gardening on the body, intellect, psych and mind.~Horticultural in the form of therapeutic gardening serves as a support to help and treat various pathologies in the brain.~It is a form of curative treatment exploiting the planting and maintenance of garden. The term is a contraction of  horticultural  and  therapy."
33109187|NCT05456620|Experimental|Low Tendon Compression Rehabilitation (LTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is limited (12 weeks).
33109188|NCT05456620|Active Comparator|High Tendon Compression Rehabilitation (HTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is not limited (12 weeks).
33109189|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
33109190|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
33109191|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
33109192|NCT05347719|Experimental|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions led by a trained healthcare provider. Post-intervention, the experimental group will receive treatment as usual.
33109193|NCT05347719|No Intervention|Wait List Control|Participants will engage in treatment as usual during the baseline period. After the experimental group completes the MBCT intervention, the wait list control group will complete the MBCT intervention.
33109194|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
33109195|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
33109196|NCT04262817|Experimental|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
33109197|NCT04262817|Experimental|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
33109198|NCT04679259|Experimental|Cardiac surgical patients|
33109199|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
33109200|NCT04679766|Experimental|Patients with non-restorable tooth in maxillary bi-cuspid region with labial/buccal plate dehiscence|
33109201|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
33109202|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
33109203|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
33109204|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
33109205|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
33109206|NCT04238013|Active Comparator|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
33109207|NCT04238013|Active Comparator|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
33109208|NCT04689737|Experimental|Experimental group|Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days
33109209|NCT05342220|Active Comparator|Remote Ischemic Preconditioning|Remote ischemic preconditioining
33109210|NCT05342220|Sham Comparator|Control|Sham preconditioning
33109211|NCT04689815|Experimental|Oral arsenic trioxide-Azacitidine|12 monthly cycles of oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle).
33109212|NCT05341557|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).
33109213|NCT05341557|Experimental|Dose Expansion|"Oral capsules administered at recommended doses. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).~Cohort 1: Advanced NSCLC Cohort 2: Relapsed/refractory lymphoma Cohort 3: Advanced HCC Cohort 4: Other Advanced Solid Tumors"
33109214|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
33109215|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
32869006|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
33109216|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV~Dose Level 2: 180mg/m2, IV~Dose Level 3: 240mg/m2, IV~Dose Level 4: 320mg/m2, IV~Dose Level 5: 400mg/m2, IV~Dose Level 6: 540mg/m2, IV~Dose Level 7: 650mg/m2, IV~Dose Level 8: 780mg/m2, IV~Dose Level 9: 950mg/m2, IV~Dose Level 10: 1150mg/m2, IV~Dose Level 11: 1400mg/m2, IV~Dose Level 12: 1700mg/m2, IV~Dose Level 13: 2000mg/m2, IV~Dose Level 14: 2400mg/m2, IV~Dose Level 15: 2900mg/m2, IV~Dose Level 16: 3500mg/m2, IV"
33418130|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
33418131|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
33109221|NCT05330052|Experimental|Agilik|The participant will be provided custom knee orthoses (the Agilik) to trial in this study
33109222|NCT04224285|Experimental|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
33109223|NCT04224285|No Intervention|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
33109224|NCT04207437|Experimental|Vibration Therapy|Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.
33109225|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
33109226|NCT02931227|Experimental|Brain-injured group|
33109227|NCT02931227|Experimental|Hypothermia group|
33109228|NCT02931227|Experimental|Hyperthermia group|
33109229|NCT02931227|Experimental|PICCO group|
32869007|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
33109230|NCT04191798|Experimental|KinexConnect|Rehab at Home Patients
33109231|NCT04191798|Active Comparator|Outpatient PT|In-person PT patients
33109232|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
33109233|NCT04180488|Experimental|Study A Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
33109234|NCT04180488|Placebo Comparator|Study A Matched Placebo|placebo, on top of non-sedating H1-antihistamine
33109235|NCT04180488|Experimental|Study B Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
33109236|NCT04180488|Placebo Comparator|Study B Matched Placebo|placebo, on top of non-sedating H1-antihistamine
33109237|NCT04180488|Experimental|Study C Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
33109238|NCT04180488|Placebo Comparator|Study C Matched Placebo|placebo, on top of non-sedating H1-antihistamine
33109239|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
33109240|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
33109241|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
33109242|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
33109243|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
33330599|NCT05210218|Placebo Comparator|mildly hypocaloric diet + placebo tid|Each patient took the placebo (i.e., the same amount of cellulose). All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
32869008|NCT00117559|Experimental|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
32869009|NCT00117559|No Intervention|Treatment as Ususal|Control group, no treatment provided
32869010|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
32869011|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
32869012|NCT04752319|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
32869013|NCT04752319|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
32869014|NCT04752241|Experimental|IMAP|Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
33109244|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
33109245|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
33109246|NCT05310058|Active Comparator|12.5 g/d of C6 ketone di-ester|Low dose of ketone di-ester.
33109247|NCT05310058|Active Comparator|25 g/d of C6 ketone di-ester|Middle dose of ketone di-ester.
33109248|NCT05310058|Active Comparator|50 g/d of C6 ketone di-ester|Highest dose of ketone di-ester.
33109249|NCT05308576|Experimental|SCTV01E|one dose of SCTV01E on D0
32869015|NCT04752241|Active Comparator|IMAS|Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
32869016|NCT00119041|Experimental|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
32869017|NCT00119041|No Intervention|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
32869018|NCT00119041|No Intervention|Provider Interviews|Qualitative interviews with providers
33109250|NCT05308576|Placebo Comparator|Placebo|one dose of Placebo on D0
33109251|NCT05452642|Active Comparator|DASH diet|12-month DASH diet intervention with psychological support
33330600|NCT05499312|Experimental|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
33330601|NCT05499312|Placebo Comparator|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
33330602|NCT05205538|Experimental|Females|Female participant group
33330603|NCT05205538|Experimental|Males|Male participant group
33330604|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
33330605|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
33330606|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
33330607|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
33330608|NCT05705518|Experimental|Systane Complete PF (Treatment)|Masked subjects assigned to Arm 1 will use Systane Complete PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
33330609|NCT05705518|Placebo Comparator|Refresh Relieva PF (Control)|Masked subjects assigned to Arm 2 will use Refresh Relieva PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
33330610|NCT05705518|Active Comparator|Refresh Optive Mega-3 PF (Active Comparator 1)|Masked subjects assigned to Arm 3 will use Refresh Optive Mega-3 PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
32869019|NCT00227617|Experimental|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
32869020|NCT00228943|Experimental|Acute tryptophan depletion|Full-strength tryptophan depletion
32869021|NCT00228943|Active Comparator|Control|Half-strength tryptophan depletion drink used as a control
32869022|NCT00229957|Experimental|Intervention|Intervention
32869023|NCT00229957|No Intervention|Control|Control group received usual care in primary care.
32869024|NCT05183971||(1) Degenerative Cervical Myelopathy|Chinese subjects aged 40 or above who have radiological evidences of Degenerative Cervical Myelopathy, both symptomatic and asymptomatic with Nurick Grade less than 3 will be included.
32869025|NCT05183971||(2) Healthy Controls|Chinese healthy controls aged 40 or above who have no myelopathic sign of Degenerative Cervical Myelopathy with Nurick Grade less than 3 will be included.
33109252|NCT05452642|Experimental|Very low-carbohydrate diet|12-month very low-carbohydrate diet intervention with psychological support
33109253|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
33109254|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
33109255|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
33109256|NCT05329311||ERATS protocol applied|Inflammatory parameters of the operated patients by applying the ERATS protocol will be investigated.
33109257|NCT05329311||ERATS protocol not applied|Inflammatory parameters of patients who were operated without the ERATS protocol will be investigated.
33109258|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
33043361|NCT05679505|Experimental|Left ear transcutaneous vagus nerve stimulation|"Left ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
32869026|NCT05183893|Experimental|Experimental: L-Citrulline|5 g of L-citruline + 5 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the product, which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
32869027|NCT05183893|Experimental|Experimental: Citrulline-malate|8g of citrulline-malate + 2 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the products which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
33043362|NCT05679505|Experimental|Bilateral double ear transcutaneous vagus nerve stimulation|"Bilateral double ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
33043363|NCT05679466|Active Comparator|ReCOV|
33043364|NCT05679466|Placebo Comparator|ReCOV placebo|
33043365|NCT05442619|Experimental|Portable therapeutic baby nest group|Blood will be drawn from newborns using the portable therapeutic baby nest.
33043366|NCT05442619|Active Comparator|Control group|Blood collection from newborns will be done according to the clinical routine.
33043367|NCT05679427|Active Comparator|Arm A|Single fraction radiosurgery on bone metastases (21-24Gy x 1 fraction)
33043368|NCT05679427|Active Comparator|Arm B|Multi-fractioned stereotactic ablative radiotherapy (5 fractions delivered in 5 consecutive working days) with SIB on bone metastases (5Gy x 5 fractions + SIB up to 40-50Gy)
33330611|NCT05705518|Active Comparator|CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2)|Masked subjects assigned to Arm 4 will use CVS Health Lubricant Eye Drop (PG 0.6%) artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
33330612|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
33330613|NCT05705440|Other|RSVPreF3 Group|Participants received the RSVPreF3 vaccine during the RSV MAT primary studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
32869028|NCT05183893|Placebo Comparator|Placebo|10g of maltodextrin plus additives (Lifepro®).
32869029|NCT05170867|Experimental|Probiotic group|Two capsules of Hafnia alvei HA4597™ probiotic/day (5 x 107 CFU/day) for 60 days
32869030|NCT05170867|Placebo Comparator|Placebo group|Two identical capsules of placebo/day for 60 days
33043369|NCT05679388|Experimental|Study Group 1|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 1 will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7"
33067847|NCT04696705|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
33330614|NCT05705440|Other|Control Group|Participants received any control (placebo, Tdap or influenza vaccine) during the RSV MAT primary studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
33330615|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
33330616|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
33330617|NCT03778320|Experimental|CTP-692|
33330618|NCT03778320|Active Comparator|D-Serine|
33330619|NCT05191264||percutaneous osteosynthesis and cementoplasty procedure|"Patient with percutaneous osteosynthesis and cementoplasty procedure will be included.~Patients have assessed for pain and quality of life during consultations as part of an interventional radiology procedure (pre-procedure consultation, and follow-up consultations at 1, 3, 6 and 12 months after the procedure."
33330620|NCT04872348||Eyes receiving OMNI intervention after medication washout|
33330621|NCT04872348||Eyes receiving OMNI intervention without medication washout|
33330622|NCT05190406|Experimental|Pulpotomy|complete pulpotomy will be done till the level of root canal orifice.
33330623|NCT05190406|Active Comparator|Root canal treatment|Single visit root canal treatment will be done according to standard protocol.
33330624|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
33330625|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
33330626|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
33330627|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
33330628|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
33330629|NCT05100706|Experimental|Continuous adductor canal block (CACB)|Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.
33330630|NCT05100706|Placebo Comparator|Sham continuous adductor canal block (ShACB).|Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.
33418132|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
33043370|NCT05679388|Experimental|Study Group 2a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2a will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7~Itraconazole (200 mg) on Days 1-14"
33043371|NCT05679388|Experimental|Study Group 2b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2b will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7~Ritonavir (100 mg tablets taken by mouth) on Days 1-14"
33043372|NCT05679388|Experimental|Study Group 3a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3a will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-4~Itraconazole (200 mg tablets taken by mouth) on Days 1-14"
33043373|NCT05679388|Experimental|Study Group 3b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3b will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-4~Ritonavir (100 mg) on Days 1-14"
33043374|NCT05678296||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
33043375|NCT05678296||group 1|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
33043376|NCT05678296||group 2|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
33043377|NCT05675293|Experimental|EXPERIMENTAL ARM|
33043378|NCT05675293|Active Comparator|CONTROL ARM|
33043379|NCT05675176||Group 1|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of self lubricated silicon tiemann 10 fr urinary catheter.
33043380|NCT05675176||Group 2|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of straight tipped latex foley 14 fr urinary catheter
33043381|NCT05673304|Experimental|Interventional group|Patients will be treated on the primary tumour with a total dose of 24 Gy (8 Gy x 3 fractions QD) within 2 weeks from the start of neoadjuvant chemotherapy
33043382|NCT05673304|No Intervention|observational cohort|This cohort will include patients fulfilling inclusion criteria who refuse enrollment in the interventional cohort and patients where SBRT boost appears not feasible after enrollment for technical issues
33043383|NCT05669404|No Intervention|Control Group (CG)|Patients continued to consume their usual diet for 3 months
33043384|NCT05669404|Experimental|Salt Restriction Group (SRG)|Patients continued to consume their usual diet, but they restricted sodium intake to 2,000 mg/ day for 3 months.
33043385|NCT05669404|Experimental|DASH Diet combined with salt restriction Group (DDG)|Patients consumed the DASH diet for 3 months.
33043386|NCT05669404|Experimental|Mediterranean Diet combined with salt restriction Group (MDG)|Patients consumed the MedDiet diet for 3 months.
33043387|NCT03996148|Active Comparator|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
33043388|NCT03996148|Active Comparator|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
33043389|NCT03996148|Active Comparator|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
33043390|NCT05660200|Experimental|IBSA Iron ODF|A single dose of IBSA Iron ODF containing 30mg Iron and 400ug folic acid will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
33418133|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
33043391|NCT05660200|Active Comparator|SiderAL® FORTE|A single dose of SiderAL® FORTE containing 30mg Iron and 70mg vitamin C will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
33043392|NCT05656183|Experimental|Single Arm|To investigate the diagnostic efficacy of WGS and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
33043393|NCT05656027|Experimental|Aceclidine + Brimonidine (LNZ101) dosed bilaterally|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
33043394|NCT05656027|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100 (Aceclidine) ophthalmic solution
33418134|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
33418135|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
33109259|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
33109260|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
33109261|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
33109262|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
33109263|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
33109264|NCT04506905|Experimental|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
33109265|NCT04506905|Experimental|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
33109266|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
33109267|NCT04506905|Placebo Comparator|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
33330631|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
33330632|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
33109268|NCT05326230|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)
33109269|NCT05326230|Sham Comparator|Sham Control|Renal Angiogram
33109270|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
33109271|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
33109272|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
33109273|NCT04480502|Experimental|Cohort A|Patients treated with 300 mg of single agent envafolimab every three weeks
33109274|NCT04480502|Experimental|Cohort B|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
33109275|NCT04480502|Experimental|Cohort C|Patients treated with 600 mg of single agent envafolimab every three weeks
33109276|NCT04480502|Experimental|Cohort D|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 600 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
33109277|NCT04316338|Experimental|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
33109278|NCT00554112|Active Comparator|1|Exercise
33109279|NCT00554112|Active Comparator|2|Exercise
33109280|NCT00554112|No Intervention|3|Control
33109281|NCT05463172|Experimental|pelvic floor muscles strengthening exercises|pelvic floor muscles strengthening exercises
33109282|NCT05463172|Experimental|abdominal strengthening exercises|abdominal strengthening exercises
33109283|NCT05461105|Experimental|Cohort A: rencofilstat 75 mg|1 rencofilstat 75 mg softgel capsule, 75 mg daily dose, QD 120 days
33109284|NCT05461105|Experimental|Cohort B: rencofilstat 150 mg|2 rencofilstat 75 mg softgel capsules, 150 mg daily dose, QD 120 days
33330633|NCT05087524|Experimental|BinaxNOW Surveillance|Participants will agree to the performance of nasal swabs samples to be used for diagnosis or screening. Samples will be obtained by research staff in the school setting. Madison Metropolitan School District (MMSD) has obtained a Clinical Laboratory Improvement Amendments (CLIA) waiver for collection of samples. When there is a positive test, a saliva sample will be collected for testing with a standard polymerase chain reaction (PCR) method. The standard PCR samples will be processed at University of Wisconsin (UW) Clinical Laboratory.
33109285|NCT05461105|Experimental|Cohort C: rencofilstat 225 mg|3 rencofilstat 75 mg softgel capsules, 225 mg daily dose, QD 120 days
33109286|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
33109287|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
33109288|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
33109289|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
33109290|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
33109291|NCT04447040|Placebo Comparator|Placebo|Placebo tablets administered as a single two-tablet dose.
33109292|NCT05321043|Other|Vitamin B2 labeled group|A liquid of vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the patients' hands outside the endoscopy center.
33109293|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
33109294|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
32869031|NCT05135377||Children with Anaphylaxis|Patients under 18 years of age presenting to the Emergency Department (ED) with an allergic reaction that matches diagnostic criteria for anaphylaxis.
33109295|NCT05305677|Experimental|NMN intervention|8 weeks of NMN
33109296|NCT05305677|Placebo Comparator|Placebo|8 weeks of NMN-free placebo
33109297|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
33109298|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
33109299|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
33109300|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
33109301|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
33109302|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
33109303|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
33109304|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
33109305|NCT05290467|No Intervention|control group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the control group. Participants will be scheduled for 12 routine ANC visits.
33109306|NCT05290467|Experimental|experimental group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the experimental group. Participants will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Message, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
33109307|NCT04151433|Active Comparator|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
33109308|NCT04151433|Active Comparator|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
33109309|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33109310|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
33109311|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
33109312|NCT04141917|No Intervention|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
33109313|NCT04141917|Active Comparator|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A & B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
33109314|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
33109315|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
32869032|NCT01439282|Experimental|Eribulin + Capecitabine|
33330634|NCT04868682|Experimental|Behavioral Education Intervention I|Manual-based education program provided in individual sessions
33330635|NCT04868682|Active Comparator|Behavioral Education Intervention II|Manual-based education program provided in individual sessions
33330636|NCT05032144|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33109316|NCT04117659|Experimental|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
33109317|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
33109318|NCT05289492|Experimental|A: Participants will receive EOS884448|EOS884448 will be administered
33109319|NCT05289492|Experimental|B: Participants will receive EOS884448 and iberdomide|EOS884448 and iberdomide will be administered
33109320|NCT05289492|Experimental|C: Participants will receive EOS884448, iberdomide and dexamethasone|EOS884448, iberdomide and dexamethasone will be administered
33109321|NCT04116606|Active Comparator|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
33109322|NCT04116606|Placebo Comparator|Matching placebo|
33109323|NCT02930603||Control|Control: Healthy child
33109324|NCT02930603||Experimental|Patients with Developmental Disabilities
33109325|NCT05288751|No Intervention|Treatment as usual (TAU)|These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
33109326|NCT05288751|Experimental|Attendance-only CM|Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
33109327|NCT05288751|Experimental|Attendance + abstinence CM|Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.
33109328|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
33109329|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
33109330|NCT04679571|Experimental|Targeted Albumin with Standard Medical Treatment|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks
33109331|NCT04679571|Active Comparator|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year"
33109332|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
33109333|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
33109334|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
33109335|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
33109336|NCT04679415|Experimental|Standard of care + hzVSF-v13 200 mg at D1, hzVSF-v13 100mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
33109337|NCT04679415|Experimental|Standard of care + hzVSF-v13 400 mg at D1, hzVSF-v13 200mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
33109338|NCT04679415|Placebo Comparator|Standard of care + 3 doses of the placebo (normal saline) IV|Drug: Placebo (Normal saline solution) Dosage form: 0.9% NaCl Solution Frequency Frequency: Dose at Day 1, 3, 7 Other names: 0.9% Normal saline
33109339|NCT02930330|Experimental|Interval|"2x / week INT~2x / week CONT"
33109340|NCT02930330|Active Comparator|Continuous|4x / week CONT
33109341|NCT05280600||NMDAR-antibody encephalitis|Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
33330637|NCT05032144|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33330638|NCT05032144|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33330639|NCT05032144|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33330640|NCT05032144|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30mg/kg of STSA-1002 as a single dose or dose-matched placebo.
33330641|NCT04647708|Experimental|Part A (Cohort 1): M5049 Dose A|
33330642|NCT04647708|Experimental|Part A (Cohort 2): M5049 Dose B|
33330643|NCT04647708|Experimental|Part A (Cohort 3): M5049 Dose C|
33330644|NCT04647708|Experimental|Part A (Cohort 4): M5049 Dose D|
33330645|NCT04647708|Placebo Comparator|Part A: Placebo|
33330646|NCT04647708|Experimental|Part B (Cohort 5): M5049 Dose E|
33330647|NCT04647708|Placebo Comparator|Part B: Placebo|
33330648|NCT04908436|Experimental|Normal renal function|Healthy participants with creatinine clearance (CLCR) >80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
33330649|NCT04908436|Experimental|Mild renal impairment|Participants with CLCR 50-80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
33043395|NCT05656027|Experimental|Brimonidine ophthalmic solution dosed bilaterally|Brimonidine ophthalmic solution
33043396|NCT05643781||Co-TB Group|Follow up all participants from hospital discharge until 12 months post-Covid-19 infection. Conduct investigations assessing cardiopulmonary, socioeconomic, quality of life outcomes. No interventions.
33043397|NCT05634070|Experimental|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold in the thorax region with autologous fat graft to camouflage pectus excavatum defect.
33043398|NCT03986203|Experimental|Active|Subjects in this group will receive the active treatment for each daily treatment session.
32869033|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
32869034|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
32869035|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
33043399|NCT03986203|Sham Comparator|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
33043400|NCT05586958|Experimental|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 6 months
33418136|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
33418137|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
33043401|NCT05586958|Experimental|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 6 months
33043402|NCT05586958|Experimental|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 6 months
33043403|NCT05586958|Placebo Comparator|Placebo|Placebo, Once a day (QD) for up to 6 months
33043404|NCT05580718|Experimental|Online CBT targeting cardiac anxiety|CBT for MI primarily targets two processes of MI-related disability: fear of cardiac-related symptoms avoidance behavior and physical inactivity. The CBT is therapist-guided and lasts for 8 weeks.
33043405|NCT05580718|No Intervention|Waitlist control|Participants randomised to waitlist can have no other concurrent psychological treatment but are free to use any medical treatment as usual. Participants on the waitlist also complete pre- and post-treatment, the follow-up measurement as well as weekly instruments (with exception of the treatment process measures Credibility scale and WAI). After the 3-month follow-up assessments, participants will receive internet-CBT for MI over 8 weeks
33043406|NCT05552404|Other|Conservative therapy|will receive conservative therapy such as bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
33043407|NCT05552404|Active Comparator|Aminophylline|will receive conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
33043408|NCT05552404|Active Comparator|transnasal spheno-palatine ganglion block|will receive the conservative therapy plus transnasal spheno-palatine ganglion block under strict protective and safety measures against COVID-19, using a hollow cotton swab soaked in lidocaine 2% for 5 minutes in each nostril then 0.5ml of lidocaine 2% will be injected slowly through the hollow swab and repeated once after another 5 minutes where the patient will stay in the supine position for 10 minutes.
33418138|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
32869036|NCT04068818||Eyes with normal anterior segment|
32869037|NCT04068818||Eyes with anterior segment abnormalities|
32869038|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
32869039|NCT00063635|Active Comparator|1|Metformin, 500 mg, twice daily
32869040|NCT00063635|Active Comparator|2|Vitamin E, 400 IU, twice daily
32869041|NCT00063635|Placebo Comparator|3|Matching placebo
32869042|NCT04068662|Experimental|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
32869043|NCT04068662|Active Comparator|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
32869044|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
32869045|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
32871569|NCT04350645|Placebo Comparator|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
33043409|NCT05546320|Active Comparator|Migraine Medication Group|Patients randomized into migraine medication group will be given Metoprolol 25mg twice a day as the control group.
33043410|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 1|Patients randomized into anticoagulation or anti-platelet medication group will be given aspirin.
33043411|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 2|Patients randomized into anticoagulation or anti-platelet medication group will be given clopidogrel.
33043412|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 3|Patients randomized into anticoagulation or anti-platelet medication group will be given Rivaroxaban.
33043413|NCT05535595|Experimental|Experimental|This group will perform genetic study for predicting adverse reaction to ACEI. Based on the result of genetic study, participants will receive ACEI or ARB.
33043414|NCT05535595|Active Comparator|Control|Participants will receive ACEI without genetic study.
33043415|NCT05524402|Experimental|TOR-C 1|TOR-C 1 is an active intervention adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program delivered over live video with weekly sessions and home practice.
33043416|NCT05524402|Active Comparator|TOR-C 2|TOR-C 2 is an active intervention that will be dose, attention and time matched to the TOR-C 1 program. TOR-C 2 is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with mTBI and anxiety. The TOR-C 2 sessions provide educational information on the relationship between anxiety and mTBI, return to activity, the role of nutrition and sleep, and healthcare self-management. The format is a 4-week program delivered over live-video.
33043417|NCT05504707|Experimental|Dendritic Cell Vaccine dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of HER2- and HER3- primed DC1 study vaccines. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
33043418|NCT05470816|Active Comparator|Tranexamic Acid|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
33043419|NCT05470816|Placebo Comparator|Placebo|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
33330650|NCT04908436|Experimental|Moderate renal impairment|Participants with CLCR 30-<50 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
33330651|NCT04908436|Experimental|Severe renal impairment|Participants with CLCR <30 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
32871570|NCT01790399|Experimental|Identification of sentinel node(s)|
33043420|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
33043421|NCT00386971|Active Comparator|1|L-carnitine
33043422|NCT00386971|Placebo Comparator|2|Placebo
33043423|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
33043424|NCT00387049|Active Comparator|Standard smoking cessation care|
33043425|NCT00387166||1|Mexican-American women, aged 40-65
33043426|NCT05435950|Experimental|Adult participants with Carpal Tunnel syndrome or with Trigger Finger/Thumb|
33043427|NCT05431543|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|LENZ 101: Aceclidine/Brimonidine combination ophthalmic solution
33043428|NCT05431543|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LENZ 100: Aceclidine ophthalmic solution
33043429|NCT05431543|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary vehicle ophthalmic solution
33043430|NCT05413018|Experimental|CC-486 Administration|
33043431|NCT05413018|Placebo Comparator|Placebo Administration|
33043432|NCT05403736|Experimental|CARMA|Cardiac Aggressive Risk MitigAtion plan with biosensor monitoring
33043433|NCT05401786|Experimental|Anti-CTLA-4, SBRT and PD1|"Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions.~Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg intravenously every 3 weeks) until disease progression, unacceptable toxicity, patient request for discontinuation, or up to 2 years of treatment"
33043434|NCT05397028|Experimental|Intervention Group|Replace meals with a plant-based meal replacement and self-prepared Meditteranean meals for a max 1200 calorie per day. Enroll in a 12 week intensive lifestyle intervention program.
33043435|NCT05397028|No Intervention|Standard of Care Group|
33043436|NCT00006420||Observational, no interventions|
33043437|NCT05391763|Other|Right: removal of fascia pectoralis, left: preservation of fascia pectoralis|
33043438|NCT05391763|Other|Left: removal of fascia pectoralis, right: preservation of fascia pectoralis|
33043439|NCT03957733|Experimental|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
33043440|NCT03957733|No Intervention|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
33043441|NCT05350150|Experimental|Auricular Vagal Nerve Stimulation|Patients will undergo a standard EPS with 4 catheters. Following the standard EPS, patients will be hooked up a Parasym device to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve, EPS will be repeated.
33043442|NCT05314309||mtFIT|Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings.
33043443|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
33043444|NCT05293561||COVID-19 cases|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
33043445|NCT05293561||control|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
33043446|NCT05285683|Active Comparator|Methylphenidate|0.5mg/kg
33043447|NCT05285683|Active Comparator|Carbidopa/levodopa,|25mg/100mg
33043448|NCT05285683|Placebo Comparator|Placebo|Oral Pill
33043449|NCT05247970|Experimental|Part 1: S-309309|Participants will receive S-309309 at specific timepoints in a fasted state.
33043450|NCT05247970|Experimental|Part 2: S-309309 and Midazolam|Participants will receive S-309309 and Midazolam at specific timepoints fed state.
33043451|NCT05247970|Placebo Comparator|Part 1 and 2: Placebo|Participants will receive a matching placebo to S-309309 at specific timepoints in either a fed or fasted state.
33043452|NCT05180656|Experimental|Yoga Intervention Group|All participants will be assigned to the yoga intervention group (single arm).
33043453|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
33043454|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
33043455|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
33043456|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
33043457|NCT05159791|Experimental|Anomalous coronary blood flow|Subjects suspected to have AAOCA will be submitted to angiographic coronary CT imaging to confirm the diagnosis. If the diagnosis of AAOCA will be confirmed, subjects will undergo to invasive coronary blood flow evaluation (intervention).
33043458|NCT05147233|Experimental|Active Treatment Arm|OCS-01 (Ophthalmic Suspension) - topical use
33043459|NCT05147233|Placebo Comparator|Vehicle Placebo Arm|Vehicle
33043460|NCT05126758|Active Comparator|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
33043461|NCT05126758|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
33043462|NCT05122975|Experimental|S48168 (ARM210) once daily for 28 days|Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
33043463|NCT05122975|Placebo Comparator|Matching Placebo once daily for 28 days|Oral dose of placebo once daily on top of standard of care regimen for 28 days.
33043464|NCT05088109||SI|adult patients with septic shock will be enrolled,At the time of admission (before the start of vasopressors), age of patients, source of sepsis, baseline systolic (SBP), diastolic (DBP), mean blood pressure (MAP), heart rate (HR), shock index (SI), adjusted shock index (ASI), modified shock index (MSI), diastolic shock index (DSI), baseline lactate, ABG, capillary refill time and body temperature will be recorded. Subsequent recordings will be at 0 (before starting vasopressors), 1, 2, 4, 8, and 12, 24, 48, 72 hours for all parameters except for lactate and ABG will be every 12 hours. SOFA scores, APACHE II, GCS, Charlson Comorbidity Index, will be recorded at admission; and mean total vasopressor dose, urine output will be recorded daily. Cause of death will be documented. All readings will continue for 72 after admission.
33043465|NCT05079139|Other|surgical technique of Musset|
33043466|NCT05064241|Experimental|Virtual Advisory Board|Participants have access to a genetic counselor to answer their questions on accessing genetic medicine.
33043467|NCT05064241|No Intervention|Virtual Peer-to-Peer Discussion Board|Participants answer each others' questions on the topic of accessing genetic medicine.
33043468|NCT05058274||Single arm|All participants
33043469|NCT05054647||family caregivers of palliative patients|psychometric questionnaires
33043470|NCT03926845|Active Comparator|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
33043471|NCT03926845|Placebo Comparator|Vehicle|The cream contains no active ingredients.
33043472|NCT05048836|Experimental|Food subsidy, no lifestyle support, 6 months|Participant will receive $40 healthy food subsidy for 6 months.
33043473|NCT05048836|Experimental|Food delivery, no lifestyle support, 6 months|Participant will receive twice monthly healthy food delivery for 6 months.
33043474|NCT05048836|Experimental|Food subsidy, with lifestyle support, 6 months|Participants will receive food subsidy and healthy lifestyle support for 6 months.
33043475|NCT05048836|Experimental|Food delivery, with lifestyle support, 6 months|Participants will receive twice monthly food box deliveries and lifestyle support for 6 months.
33043476|NCT05048836|Experimental|Food subsidy, no lifestyle support, 12 months|Participants will receive food subsidy for 12 months.
33043477|NCT05048836|Experimental|Food delivery, no lifestyle support, 12 months|Participants will receive twice monthly food box deliveries for 12 months.
33043478|NCT05048836|Experimental|Food subsidy, with lifestyle support, 12 months|Participant will receive food subsidy and lifestyle support for 12 months.
33043479|NCT05048836|Experimental|Food delivery, with lifestyle support, 12 months|Participants will receive twice monthly food box deliveries and lifestyle support for 12 months.
33043480|NCT05042908|Experimental|A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors|Drug: LBL-003Injection The test drugLBL-003will be preset with 6 escalation dose levels: dose A, dose B, dose C, dose D and dose E, dose F , administered twice a week.
33043481|NCT05025241|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
33043482|NCT05018728|Experimental|Voxelotor|Children with sickle cell anemia taking voxelotor for 12 weeks.
33043483|NCT05000515|Experimental|High-resistance inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
33043484|NCT05000515|Active Comparator|Aerobic exercise|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
33043485|NCT04986202|Experimental|Part A 2.5 mg|AZD4831 2.5 mg
33043486|NCT04986202|Experimental|Part A 5 mg|AZD4831 5 mg
33043487|NCT04986202|Placebo Comparator|Part A Placebo|Placebo
33043488|NCT04986202|Experimental|Part B Dose based on Part A|AZD4831 Dose based on Part A
33043489|NCT04986202|Placebo Comparator|Part B Placebo|Placebo
33043490|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
33067848|NCT04696588|Experimental|Kinesiotherapy group|This is the group (n=59) receives treatment i.e complex set of neck exercises and massage
32869046|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
33330652|NCT04906330||PPHM-0000-21|50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
33330653|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
33330654|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
32869047|NCT04748666|Experimental|3 PST sessions and no boosters|
32869048|NCT04748666|Experimental|3 PST sessions with monthly boosters for 6 months|
32869049|NCT04748666|Experimental|6 PST sessions, no boosters|
32869050|NCT04748666|Experimental|6 PST sessions with monthly boosters for 6 months|
32869051|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
32869052|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
32869053|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
32869054|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
32869055|NCT04402775|No Intervention|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
32869056|NCT04402775|Experimental|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
32869057|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
32869058|NCT01865045||no treatment|no treatment
32869059|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
32869060|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
32869061|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
32869062|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
32869063|NCT00066677|Experimental|rhuMAB-VEGF|bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.
32869064|NCT00066677|Experimental|rhuMAB-VEGF and Docetaxel|rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.
32869065|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
32869066|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
32869067|NCT04752683||Organisation 1|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
32869068|NCT04752683||Organisation 2|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
32869069|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
32869070|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
32869071|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
32869072|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
32869073|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
32869074|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
32869075|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
32869076|NCT01673919|Experimental|RoActemra/Actemra|
32869077|NCT01665144|Experimental|Siponimod (BAF312)|Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
32869078|NCT01665144|Placebo Comparator|Placebo|Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.
33418139|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
33418140|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
32869079|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
32869080|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
32869081|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
32869082|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
32869083|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
32869084|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
32869085|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
32869086|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
32869087|NCT05547594|Experimental|Prehabilitation|Arm undergoing multimodal prehabilitation (physical activity, nutritional education and anxiety management) during the weeks leading up to surgery
32869088|NCT05547594|No Intervention|Standard of care|Arm receiving standard of care (no prehabilitation)
32869089|NCT05547516|Active Comparator|Standard infusion chemotherapy (including gemcitabine, mitomycin, Epirubicin, etc.)|Standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.) was dissolved in 50mL normal saline or glucose and perfused into the bladder for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery.
32869090|NCT05547516|Active Comparator|BL-5ALA-PDT|Bl-5ala-pdt protocol: 1.5g 5ALA, dissolved in 50mL normal saline, was infused into the bladder for 2h before surgery and before each cystoscopy, and blue laser irradiation was performed under flexible cystoscopy at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
32869091|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
32869092|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
32869093|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
32869094|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
32869095|NCT01618227|Experimental|Rehabilitation without splinting|
32869096|NCT05552898|Placebo Comparator|Placebo Control 1|Sleep Product Form 1 - control
32869097|NCT05552898|Experimental|Active Product 1.1|Sleep Product Form 1 - active product 1
32869098|NCT05552898|Experimental|Active Product 1.2|Sleep Product Form 1 - active product 2
32869099|NCT05552898|Experimental|Active Product 1.3|Sleep Product Form 1 - active product 3
32869100|NCT05552898|Experimental|Active Product 1.4|Sleep Product Form 1 - active product 4
32869101|NCT05552898|Experimental|Active Product 1.5|Sleep Product Form 1 - active product 5
32869102|NCT01620567|Placebo Comparator|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
32869103|NCT01620567|Active Comparator|avocados|1 avocados/day
32869104|NCT05542680|Experimental|Group 1|In the intervention group, the special cushion for semi recumbent position was used
32869105|NCT05542680|No Intervention|Group 2|Routine nursing intervention
32869106|NCT05552820|Experimental|Verum Electroacupuncture|Verum electroacupuncture treatment will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
32869107|NCT05552820|Sham Comparator|Sham Electroacupuncture|Sham electroacupuncture on non-acupoints plus non-penetrating plus no electrical stimulation will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
32869108|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
32869109|NCT05547438|Experimental|Treatment Arm 1|0.8, 4, 8, or 16 mg/mL NTS-104 solution for IV infusion
32869110|NCT05547438|Placebo Comparator|Treatment Arm 2|Single administration of placebo at the same volume and duration
32869111|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
32871571|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
33418141|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
33418142|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
32869112|NCT05547282|Other|Low-dose radiotherapy combined with conventional radiotherapy after immunotherapy failure|"The chest, abdomen and pelvis were located by enhanced CT, and the target area was delineated. The lesions were visible lymph nodes with short diameter ≥1cm, and there were metastases confirmed by two associate chief physicians by enhanced MR and PET/CT examination results.~The primary lesion, the largest metastatic lesion or the lesion causing symptoms were selected and divided into 1.8-2Gy/F,40Gy-60Gy. For the remaining lesions, at least one easily evaluated and measurable lesion was selected as the observation lesion, and the unselected lesions (≤10 lesions) were given 1.6Gy/f, 1f/w, 4-6 times.~Immunotherapy regimens are administered according to the specific dose and interval of the original immunization regimen, such as concurrent chemotherapy or antiangiogenic drug therapy regimens. He used Nivolumab, Pembrolizumab, Troripalimab and Camrelizumanb.~Immunotherapy was performed at a frequency of 3 weeks in combination with radiotherapy until progression."
32869113|NCT05547126|Active Comparator|Group 1 - anodal tDCS + dual-task training|"The anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session"
32869114|NCT05547126|Active Comparator|Group 2 - tDCS dualsite + dual-task training|"Two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
32869115|NCT05547126|Placebo Comparator|Group 3 - tDCS sham + dual-task training|"The positioning of the electrodes will be the same as for group 1, however the device will be configured in sham mode in which the current will cease 30 seconds after the start of stimulation.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session"
32869116|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
32869117|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
32869118|NCT05552742|Active Comparator|Conservative Rehabilitation|Only conservative rehabilitation treatment was applied to the patients in group 1.
32869119|NCT05552742|Experimental|Conservative Rehabilitation + Virtual Balance Training|Conservative rehabilitation treatment and virtual balance study were applied to the patients in group 2.
32869120|NCT05552586|Active Comparator|Melatonin group|Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
32869121|NCT05552586|Placebo Comparator|Control group|Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
32869122|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
32869123|NCT00069329|Experimental|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
33330655|NCT04877392|No Intervention|Control (usual measures to control pain)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure.
32869125|NCT05542368||Patients with IBD|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~c)-Imaging:~Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity.~d ) Endoscopic findings regarding diagnosis of IBD confirmed by histopathological examination"
32869126|NCT05542368||Healty individuals as a control group|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~c)-Imaging:~Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity."
32869127|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
32869128|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
32869129|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
32869130|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
32869131|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
32869132|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
33418143|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
33418144|NCT00792831|Experimental|ITF2357|ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.
32869135|NCT05552274|Placebo Comparator|SAD Cohorts 1 to 2: Participants receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo
33330656|NCT04877392|Experimental|Case (usual measures to control pain plus inhaled lavender essential oil)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
33330657|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
33330658|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
33330659|NCT03778242|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1 gm tranexamic acid ( 2 ampoules) in 100 ml saline by slow infusion
33330660|NCT03778242|Active Comparator|oxytocin plus placebo to TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus2 placebo ampoules to tranexamic acid(TA) in 100 ml saline by slow infusion
32869136|NCT05552274|Experimental|SAD Cohorts 1 to 2: Participants receiving ECC4703|Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
33043491|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
33043492|NCT00387361|Experimental|1|
33043493|NCT00387361|No Intervention|2|
33043494|NCT03923296||HCPs|Health care professional interviews (market research)
33043495|NCT03923296||Patients or caregivers|Patients or caregivers interviews
33043496|NCT03918343|Other|All patients|
33043497|NCT03906604|Other|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
33043498|NCT03906604|Other|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
33043499|NCT03896464|Active Comparator|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
33043500|NCT03896464|Active Comparator|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
33043501|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
33043502|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
33043503|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
33043504|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
33043505|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
33043506|NCT00388011|Experimental|3|Intranasal morphine 15 mg
33043507|NCT00388011|Experimental|4|Intranasal morphine 30 mg
33043508|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
33043509|NCT00388011|Placebo Comparator|6|Intranasal placebo
33043510|NCT04918381|Experimental|CellFX Procedure|Treatment of the BCC with CellFX System
33043511|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
33043512|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
33043513|NCT04852978|Experimental|Wave 1 Dose 1|
33043514|NCT04852978|Experimental|Wave 1 Dose 2|
33043515|NCT04852978|Experimental|Wave 1 Dose 3|
33043516|NCT04852978|Experimental|Wave 1 Vaccine only|
33043517|NCT04852978|Experimental|Wave 2 Dose 1|
33043518|NCT04852978|Experimental|Wave 2 Dose 2|
33043519|NCT04852978|Experimental|Wave 2 Vaccine only|
33043520|NCT04852978|Experimental|Wave 3 Dose 1|
33043521|NCT04852978|Experimental|Wave 3 Dose 2|
33043522|NCT04852978|Experimental|Wave 3 Vaccine only|
33043523|NCT04852978|Experimental|Wave 4 Dose 1|
33043524|NCT04852978|Experimental|Wave 4 Vaccine only|
33043525|NCT04849975|Experimental|Pelvimetry group|The participants oh this group will successively perform MRI pelvimetry and EOS imaging.
33043526|NCT04817137|Other|All Enrolled Patients|Patients will wear the Caretaker Pulse Decomposition Analysis (PDA) Device, which will record the patient's blood pressure.
33043527|NCT04775485|Experimental|Arm #1|Pediatric patients with low-grade glioma treated with DAY101 (Registrational Arm)
33043528|NCT04775485|Experimental|Arm #2|Expanded access arm of pediatric patients with low-grade glioma treated with DAY101
33043529|NCT04775485|Experimental|Arm #3|Pediatric patients with advanced solid tumors treated with DAY101
33043530|NCT04759456|Experimental|Intervention group|Participants will undergo 12-week comprehensive remotely-supervised rehabilitation program along with individually titrated CPAP therapy.
33043531|NCT04759456|No Intervention|Control group|Participants will undergo individually titrated CPAP therapy.
33043532|NCT04742023|Experimental|Intervention Arm|
33330661|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
33330662|NCT04801576|Placebo Comparator|Placebo mouthrinse|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse without flouride for 28 days; toothpaste with 1050 ppm F and mouthrinse without flouride for 28 days; toothpaste with 1450 ppm F and mouthrinse without flouride for 28 days.
33330663|NCT04801576|Experimental|Fluoride in mouthrinses|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse with 450 ppm F for 28 days; toothpaste with 1050 ppm F and mouthrinse with 450 ppm F for 28 days; toothpaste with 1450 ppm F and mouthrinse with 450 ppm F for 28 days.
33330664|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
32869137|NCT05552274|Placebo Comparator|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
33043533|NCT04742023|Placebo Comparator|Control Arm|
33330665|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
33043534|NCT00388128|Placebo Comparator|A|
33043535|NCT04740775|Experimental|LiquiBand Exceed|Surgical wound closure using the LiquiBand Exceed Topical Skin Adhesive
33043536|NCT04740775|Experimental|Liquiband Rapid|Surgical wound closure using the LiquiBand Rapid Topical Skin Adhesive
33043537|NCT04689646|Experimental|Mind-Body Intervention 1|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 1.
33043538|NCT04689646|Active Comparator|Mind-Body Intervention 2|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 2.
33043539|NCT04689646|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
33043540|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
33043541|NCT04640545|Experimental|LBL-007+Toripalimab+Axitinib Tablets|"Study Part A： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv；~Study Part B： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv+Axitinib Tablets 5mg + Axitinib Tablets 1mg"
33043542|NCT04607005|Experimental|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
33043543|NCT04607005|Placebo Comparator|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
33043544|NCT04604197|Experimental|Angiography and Clinical Follow up|After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
33043545|NCT04604197|Active Comparator|Clinical Follow up|After PCI. The patient is randomized to a Clinical Follow to 36 months
33043546|NCT04593121|Experimental|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
33043547|NCT04593121|Experimental|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
33043548|NCT04593121|Experimental|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
33043549|NCT04593121|Experimental|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
33043550|NCT04593121|Experimental|Cohort 7A|Participants will receive Dose 5 of BIIB107 or placebo SC on Day 1.
33043551|NCT04593121|Experimental|Cohort 5A|Participants will receive Dose 5 of BIIB107 or placebo intravenous (IV) on Day 1.
33043552|NCT04593121|Experimental|Cohort 8A|Participants will receive Dose 6 of BIIB107 or placebo SC on Day 1.
33043553|NCT04593121|Experimental|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
33330666|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
33330667|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
33330668|NCT05697328|Experimental|Pseudoephedrine|over the counter pseudoephedrine
33330669|NCT05697328|Placebo Comparator|Placebo|pharmacy created placebo capsule
33330670|NCT05691634|Experimental|Patient with tatoo|
33330671|NCT05159778|Experimental|Experimental|
33330672|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
33330673|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
33330674|NCT04476576|Experimental|Aerobic|3 months program, 3 times/week aerobic ambulatory program.
33330675|NCT04476576|Active Comparator|Flexibility|3 months program, 3 times/week flexibility ambulatory program
33043554|NCT04593121|Experimental|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
33043555|NCT04590547|Experimental|GLS-1027 120 mg|One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily
33043556|NCT04590547|Experimental|GLS-1027 360 mg|Three 120 mg pills of GLS-1027 given by mouth once daily
33043557|NCT04590547|Placebo Comparator|Placebo|Three Placebo pills given by mouth once daily
33043558|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
33043559|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
33043560|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
33043561|NCT04575181|Experimental|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
33043562|NCT04575181|Active Comparator|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
33043563|NCT00387439|Experimental|standard medical treatment|standard medical treatment
33330676|NCT04668586|Experimental|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
33330677|NCT04668586|Experimental|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
33330678|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
33330679|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
33043564|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
33043565|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
33330680|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
33330681|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
33330682|NCT04651192||Soldiers|50 Israeli Defense Forces (IDF) infantry soldiers, all male, aged 18 years, with Hebrew as the dominant language and no condition excluding an MRI scan.
33330683|NCT04651192||Students|50 Reserve Officer Training Corps (ROTC) undergraduate students at Tel-Aviv University, all male, aged 18-19, with Hebrew as the dominant language and no condition excluding an MRI scan.
33330684|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
33330685|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
33330686|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
33360653|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)~Participants enrolled in KORNERSTONE with a biopsy proven GN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
33043566|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
33043567|NCT04513522|Experimental|Nivolumab + ipilimumab|
33043568|NCT00006471|Experimental|Fenretinide|
33043569|NCT04428619|Active Comparator|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
33043570|NCT04428619|Sham Comparator|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
33043571|NCT04371172||Patients with TAVI|cognitive research battery, MRI, laboratory values
33043572|NCT04370119||(1) Healthcare workers|All healthcare workers at University Medicine Greifswald who were enrolled in the study between 04/2020-08/2020
33043573|NCT04370119||(2) Healthcare workers in high-risk areas of the hospital (intensive care, emergency medicine)|Healthcare workers at University Medicine Greifswald who were enrolled in the study between 01/2021-03/2021
33043574|NCT04370119||(3) Healthcare workers after SARS-CoV-2 vaccination|Healthcare workers at University Medicine Greifswald who received a SARS-CoV-2 vaccination within the last 7-21 days
33043575|NCT04369573|Active Comparator|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
33043576|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
33043577|NCT04359121||Physicians|Questionnaires
33043578|NCT04359121||Medical staff|Questionnaires
33043579|NCT04359121||General public|Questionnaires
33043580|NCT04359121||Patients with psychiatric disorders|Questionnaires
33043581|NCT04355572|Experimental|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
33043582|NCT04355572|Placebo Comparator|Placebo|Patients will take placebo for 6 months
33043583|NCT03815851|Other|Drain group|Place prophylactic drainage after surgery.
33043584|NCT03815851|Other|No-drain group|Not place prophylactic drainage after surgery.
33043585|NCT04271488|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 35 milligram (mg) tablet of tasurgratinib in the morning with 150 milliliters (mL) of water following an overnight fast of at least 10 hours.
32869138|NCT05552274|Experimental|MAD Cohorts 1 to 4: Participants receiving ECC4703|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
32869139|NCT05698602|Experimental|NivolisMonitor and NivolisAnton Arm|"For each patient enrolled in the study, a NivolisMonitor device is added to the usual ventilatory device for 3 days. NivolisMonitor is connected to the patient circuit, between the ventilatory device and the patient interface, ideally at the patient end of the circuit or possibly at the end of the breathing support device of the circuit (NIV or HDN).~NivolisMonitor continuously measures pressure (P in cm H20) and flow (F in L.min-1) as well as temperature (T in degree Celsisus), relative humidity (RH in percent RH) and, optionally, the Fi02 (in percent).~In addition, an overnight transcutaneous capnia recording will be performed using a Sentec SDM monitor to which a NivolisAnton device will be connected and will be able to collect data and transmit it via remote monitoring."
32869140|NCT05552040|Experimental|START NOW Group|START NOW is an evidence-informed psychotherapy composed of a total of 32-skills-based-sessions, originally designed for inmates in correctional systems. A previous study of incarcerated individuals found that for each additional session of START NOW completed, a 5% reduction in the incident rate of disciplinary reports was noted.10 In fact, individuals with a higher overall security risk score also had a greater reduction in the number of disciplinary reports with more sessions attended, suggesting that START NOW is an effective behavioral intervention for those who need it most. A follow-up study on these same participants concluded that START NOW appears to have a beneficial clinical effect with each session completed being associated with a 5% decrease in subsequent psychiatric hospital days.
32869141|NCT05552040|Active Comparator|Treatment-as-Usual (TAU) Group|TAU groups are weekly sessions required in an OBOT clinic and focus primarily on supportive therapeutic techniques.
32869142|NCT00072449|Experimental|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
32869143|NCT05551962|Active Comparator|First group|The patients undergo implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the maxilla or palate.
32869144|NCT05551962|Experimental|Second group|"The patients undergo implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibro-Gide"
32869145|NCT05546736|Experimental|iCanWork Intervention|iCanWork includes 6 1-hour sessions with a VRC and 1 to 4 1-hour sessions with an OT. In the positive event that a participant has returned to work during the study, three of the six VRC sessions are reserved to support the participants in their transition to the workplace.
32869146|NCT05546736|No Intervention|Control|Participants randomized to the control group will receive their usual care and will be referred to the Cancer Work website for educational resources related to RTW. If they contact the team with RTW-related questions, they will be referred to their care teams.
32869147|NCT04756661|Experimental|Carbetocin|Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
32869148|NCT04756661|Active Comparator|Oxytocin plus misoprostol|Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
32869149|NCT05699694|Experimental|Experimental Stemregen|Experimental product encapsulated will be consumed orally with a glass of water. Six capsules per day will be consumed daily for 6 months.
32869150|NCT05542212|Experimental|TMS treatment group|
32869151|NCT05542212|Sham Comparator|TMS Sham Control Group|
32869152|NCT05542212|No Intervention|Normal Control|
32869153|NCT00072761|Active Comparator|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
32869154|NCT00072761|No Intervention|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
32869155|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
32869156|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
32869157|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
32869158|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
32869159|NCT05551884||Training cohort|Training cohort was set to develop the novel non-invasive model based on metabolomics technology for HVPG.
32869160|NCT05551884||Validation cohort|Validation cohort was set to validate the novel non-invasive model based on metabolomics technology for HVPG.
32869161|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
32869162|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
32869163|NCT05551806|Experimental|CBT-I group|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment 4 weeks after the post-intervention assessment. They will be invited to participate in an interview after completing the post-intervention assessment.
33330687|NCT04630054|Experimental|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
33330688|NCT04630054|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
33330689|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
33330690|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
33330691|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
33109342|NCT05280600||Antibody-negative autoimmune encephalitis|Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
33109343|NCT05280600||Healthy control|Healthy children and young people (ages 8-24 years).
33109344|NCT02929940||PiZZ|Observational
33109345|NCT02929940||PiMZ|Observational
33109346|NCT02929940||Other AATD variants|Observational
33109347|NCT02929940||PiMM (Control)|Observational
33109348|NCT05278260|Placebo Comparator|Control|
33418145|NCT00496431|Experimental|ITF2357|Patients were provided with the appropriate number of 50 mg hard gelatine capsules for oral administration for 7 days treatment, i.e. at the daily dose of 100 mg, 14 capsules 50 mg each, plus 2 spare capsules suitable in case of accidental loss.
33109349|NCT05278260|Experimental|Active|
33109350|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
33109351|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
33109352|NCT05274282|Experimental|Animation Therapy Group|10 sessions of Animation Therapy (1 session/week)
33109353|NCT05274282|No Intervention|Control Group|No intervention
33109354|NCT04444895|Experimental|Lanadelumab|Rollover participants from SHP643-303 (NCT04206605) will receive 300 milligram (mg) of lanadelumab solution in prefilled syringe subcutaneously (SC) for 26 weeks once every 2 weeks (Q2W) or once every 4 weeks (Q4W) if well controlled during SHP643-303 (NCT04206605) with up to 13 doses.
33109355|NCT05238363|Experimental|HLX07|HLX07 1500mg ivgtt Q3W
33109356|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
33109357|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
33109358|NCT04080492||Hypertrophic Cardiomyopathy|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy.
33109359|NCT04080492||Thoracic Aortic Dilatation|Patients being seen for the first time at the Cleveland Clinic for Thoracic Aortic Dilatation.
33109360|NCT04080492||Radiation Induced Heart Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
33109361|NCT02930096||pulsatility index mesured with doppler ultrasound|
33109362|NCT04049721|Active Comparator|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
33109363|NCT04049721|Experimental|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
33109364|NCT04038294|Experimental|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
33109365|NCT04038294|Placebo Comparator|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
33109366|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
33109367|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
33109368|NCT04024761|Experimental|CIML NK|"CIML NK will be administered intravenously on day 0~Fludarabine will be administered as IV infusion once daily for 3 doses beginning on day -5.~Cyclophosphamide will be administered as IV infusion on days -5 and -4."
33330692|NCT04627714|Experimental|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
33418146|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
33418147|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
33418148|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
33418149|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
33043586|NCT04271488|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive 10 mg dose of tasurgratinib as capsule (2 capsules each of 5 mg) in the morning with 150 mL of water following an overnight fast of at least 10 hours.
33043587|NCT04271488|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, race, gender and body weight) will receive a single 35 mg tablet of tasurgratinib in the morning with 150 mL of water following an overnight fast of at least 10 hours.
33043588|NCT04232293|Experimental|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
33043589|NCT04205149||Pre-ERAS implementation arm|
33043590|NCT04205149||Post-ERAS implementation arm|
33043591|NCT04201834|Experimental|Risperidone|Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
33043592|NCT04199221|No Intervention|Lecture|an initial brief lecture with no further training
33043593|NCT04199221|Experimental|Stress management|an initial brief lecture with stress management lecture
33043594|NCT04199221|Active Comparator|Hands-on training|an initial brief lecture with addition hands-on training for the task
33043595|NCT04199221|Experimental|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
33043596|NCT04192435|Active Comparator|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
33043597|NCT04192435|Placebo Comparator|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
33043598|NCT04191187|Experimental|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
33043599|NCT04185454|Experimental|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
33043600|NCT04185454|Experimental|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
33043601|NCT04185454|Experimental|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
33043602|NCT04164199|Experimental|Tislelizumab monotherapy|
33043603|NCT04164199|Experimental|Pamiparib Monotherapy|
33043604|NCT04164199|Experimental|Tislelizumab and Pamiparib Combination Therapy|
33043605|NCT04164199|Experimental|Tislelizumab and Pemetrexed Combination Therapy|
33043606|NCT04164199|Experimental|Tislelizumab and Capecitabine Combination Therapy|
33043607|NCT04164199|Experimental|Experimental: Pamiparib and temozolomide|
33043608|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
33043609|NCT04128670|Experimental|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
33043610|NCT04128670|Placebo Comparator|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
33043611|NCT04128670|No Intervention|No Tape|This group will not receive any intervention.
33043612|NCT04121728|Other|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
33043613|NCT04121728|Other|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
33043614|NCT03940066|Other|Monitoring group|
33043615|NCT03940066|Other|Standard Care|
33109369|NCT04017000|Active Comparator|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.~The participants Urodynamic clinic will run according to routine care."
33330693|NCT04627714|Experimental|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
33043616|NCT03924778|Experimental|DASH diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber
33043617|NCT03924778|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber
33043618|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
33043619|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
33043620|NCT03771157|Experimental|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
33109370|NCT04017000|Other|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
32869164|NCT05551806|No Intervention|Waitlist control group|Participants in the waitlist control group will wait for 6 weeks without the CBT-I intervention and then complete the post-intervention assessment; while waiting for 4 more weeks and then completing the follow-up assessment. The waitlist control participants will start CBT-I (equivalent to that of the CBT-I group) immediately after completing the follow-up assessment.
32869165|NCT05542134||V-A ECMO without P2Y12 inhibitors|control group
32869166|NCT05542134||V-A ECMO with P2Y12 inhibitor at the time of ECMO|observational group 1
33109371|NCT02929745|Experimental|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
33109372|NCT02929745|Experimental|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
32869167|NCT05542134||V-A ECMO already recieving P2Y12 inhibitors|observational group 2
33109373|NCT02929745|Experimental|Healthy Skin|Healthy patients will donate blood and skin samples
33330694|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
33330695|NCT04611880|Other|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
33330696|NCT03769740||CPR Group|
33330697|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
33330698|NCT04581148||M6|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M6) with residual blood samples.
33330699|NCT04581148||M12|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M12) with residual blood samples.
33330700|NCT04581148||M15|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M15) with residual blood samples.
33330701|NCT04581148||M19|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M19) with residual blood samples.
33330702|NCT04581148||M21|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M21) with residual blood samples.
33330703|NCT04581148||M22|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M22) with residual blood samples.
33330704|NCT04581148||M23|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M23) with residual blood samples.
33330705|NCT04581148||M24|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M24) with residual blood samples.
33330706|NCT04581148||M25|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M25) with residual blood samples.
33330707|NCT04581148||M26|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M26) with residual blood samples.
33330708|NCT03942094|Experimental|Nilotinib|
33330709|NCT04554316|Active Comparator|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
32869168|NCT00073073|Experimental|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
32869169|NCT05551572||septic samples|patients undergoing revision surgery for prosthetic joint infection
32869170|NCT05551572||aseptic samples|patients undergoing revision surgery for prosthetic replacement without infection
32869171|NCT05546424||control|"Non-specific cognitive exercises included general advice from MS neuropsychologist specialists on how to manage cognitive difficulties and general cognitives exercises to improve cognitive performance elaborated at our MS Unit, using exercises like sudokus, crosswords and labyrinths.~This control group will require the completion of at least 30 minutes of cognitive exercises daily from Monday to Friday for 5 months. As a complement, patients will be instructed to read newspapers or magazines at least 15 minutes daily."
32871572|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
33109374|NCT04007406|Experimental|DP13 low|DP13 for 8 weeks
33109375|NCT04007406|Experimental|DP13 middle|DP13 for 8 weeks
33109376|NCT04007406|Experimental|DP13 high|DP13 for 8 weeks
33109377|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
33109378|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
33109379|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
33330710|NCT04554316|Active Comparator|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
33330711|NCT04478812|Experimental|Single Group Assignment|
33330712|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
33330713|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
33043621|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
33043622|NCT03746587|Experimental|Arimoclomol I|Arimoclomol, oral capsule
33043623|NCT03746587|Experimental|Arimoclomol II|Arimoclomol, oral capsule
33330714|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
33330715|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
33330716|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
33043624|NCT03746587|Experimental|Arimoclomol III|Arimoclomol, oral capsule
33043625|NCT03746587|Placebo Comparator|Placebo|Placebo oral capsule matching experimental arm
33043626|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
33043627|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
33043628|NCT03624517|Experimental|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
33043629|NCT03624517|Active Comparator|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
33043630|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
33043631|NCT03600883|Experimental|Phase 1 Dose Exploration Part 1 monotherapy|"Cohorts with food effect and alternative dosing regimens~Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort"
33330717|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
33330718|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
33043632|NCT03600883|Experimental|Phase 1 Dose Expansion Part 2 monotherapy|Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
33043633|NCT03600883|Experimental|Phase 2 monotherapy|Additional subjects will be enrolled in the dose expansion to confirm the recommended phase 2 dose. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose
33330719|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
33043634|NCT03600883|Experimental|Phase 1 combination arm with sotorasib and anti PD-1/L1|Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
33043635|NCT03600883|Experimental|Phase 1 monotherapy treatment naive advanced NSCLC|Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
33043636|NCT03600883|Experimental|Phase 2 monotherapy dose comparison|Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
33043637|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
33043638|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
33043639|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
33043640|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
33043641|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
33043642|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
33043643|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
33330720|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
33330721|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
33043644|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
33330722|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
33330723|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
33330724|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
33330725|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
33418150|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
33418151|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
33418152|NCT03627897|Other|Control group|
33418153|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
33418154|NCT02248532|Active Comparator|Group B|Single stem cell administration
33109380|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
33418155|NCT05191849|Other|Small Cell Lung Cancer receiving chemotherapy|
33418156|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
33418157|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
33418158|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
33109381|NCT05237661|Experimental|Dietary supplement|Dietary supplement: Moon Balance
33418159|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
33418160|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
33418161|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~Fall prevention tips~Fall prevention exercise videos noting technique and safety~Guest expert videos and communication with expert~Tools to set exercise goals, reminders and track progress~Fall prevention specialist for feedback and group activities~Discussion and messaging (1:1, small and large group)~Fall prevention resources."
33418162|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
33418163|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
33418164|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
33418165|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
33418166|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
33418167|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
33418168|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
33109382|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
33109383|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
33109384|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
33109385|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
33109386|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
33109387|NCT03993132||Patients with type 2 diabetes|
33109388|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
33109389|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
33109390|NCT00553878|Placebo Comparator|dutasteride|
33109391|NCT04407689|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
33418169|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
33418170|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
33418171|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33109392|NCT04407689|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
33109393|NCT05225064|No Intervention|Control|No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
33109394|NCT05225064|Experimental|Village-level vaccine clinics with monetary, non-monetary, or no incentive|Village-level vaccine clinics with monetary, non-monetary, or no incentive. Villages are cross-randomized to grocery coupon, food ration, no incentive, or grocery coupon to both community member and community health worker after the community member has received a vaccination.
33109395|NCT05225064|Experimental|Household-level vaccination with monetary or no incentive|Household-level vaccination with monetary incentive or no incentive. Villages are cross-randomized to grocery coupon or no incentive upon receiving vaccination
33418172|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
33418173|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
32869172|NCT05546424||Intervention EMRESERVA|"Specific cognitive rehabilitation program EM-Reserva will be provided by two specialized MS~Neuropsychologists in groups of 6 participants who will meet approximately an hour weekly, for 5 months.EM reserva cognitive program includes the following activities:~Cognitive leisure tasks~Physical exercises (workout exercises)~Activities that promote social relationships (social exercises)"
32869173|NCT00074165|Experimental|All subjects|
32869174|NCT01466660|Experimental|afatinib|afatinib once daily.
32869175|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
32869176|NCT05711043|Experimental|Intervention group|Endoscopic sutured gastroplasty with endomina device
32869177|NCT05711043|No Intervention|Control group|Standard diabetes care
32869178|NCT05542056||Patients with newly prescribed thiazide or thiazide-like diuretic|As the study population of this observational study shall be as representative as possible all patients with a new thiazide or thiazide-like diuretic regardless of the indication, co-morbidities and co-medication can be included.
32869179|NCT05710887|Active Comparator|Treatment; Nitrous Oxide 50%|A single 45-minute session of inhaled 50% nitrous oxide.
32869180|NCT05710887|Placebo Comparator|Control; Oxygen-air mixture|A single 45-minute session of inhaled Oxygen-air mixture
32869181|NCT00075335|Experimental|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
32869182|NCT05551494||Endometriosis group|Cases will include women aged 18-45 with a surgical diagnosis of endometriosis in the previous 24 months or with a current nonsurgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
32869183|NCT05551494||Control group|Control group are women aged 18-45 attending our outpatient clinic for periodical gynaecological care, contraception, or cervical cancer screening programme, and without a previous clinical or surgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
32869184|NCT03088787||Patients for TAVR|Patients for TAVR
32869185|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
32869186|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
32869187|NCT05541900|Active Comparator|TEC-Sacredness|Active condition of the intervention. For the active intervention group, the three match types are as follows: (1) a self-related word paired with a life-related stimulus; (2) a sacredness of life-related stimulus paired with a pleasant stimulus; and (3) a neutral stimulus paired with a neutral stimulus.
32869188|NCT05541900|Placebo Comparator|TEC-Control|Control condition of the intervention. The control paradigm maintains the same parameters, however, all three match pairings will be neutral.
32869189|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
32869190|NCT01466348|Active Comparator|Paracetamol|Paracetamol
32869191|NCT05551416||EPIGASTRIC|Patients with GC.
32869192|NCT05551416||EDGAR 1|Symptomatic patients subjected to a diagnostic gastroscopy to study the prevalence of premalignant gastric lesions.
32869193|NCT05551416||EDGAR 2|Patients with premalignant gastric lesions and early gastric neoplasias treated by endoscopy resection.
32869194|NCT05551416||Negative control|"Patients from EDGAR 1 without gastric pathology or familial history of this neoplasia."
32869195|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
32869196|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
32869197|NCT05551338|Experimental|Intervention|Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in their home setting in addition to their conventional care
32869198|NCT05551338|No Intervention|Control|Patients will undergo only their conventional care
32869199|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
32869200|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
32869201|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
32869202|NCT05699382|Active Comparator|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
32869203|NCT05699382|No Intervention|control group|Waiting for the intervention
32869204|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
32869205|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
32869206|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
32869207|NCT05546112|Experimental|Experimental group|Transcutaneous trigeminal nerve stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
32869208|NCT05546112|Sham Comparator|Control group|Sham stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
32869209|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
32869210|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
32869211|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
32869212|NCT01466192|Experimental|MP-424|
32869213|NCT05541666||The Emotional Freedom Technique Group|"After the patients in the case group are determined, the scales will be introduced. The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. After that, the emotional freedom technique will be explained.~On the postoperative 1st and 2nd days, firstly pain and anxiety levels will be measured with the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales. And then one session of emotional freedom technique that is approximately 30 minutes, will be applied. And after all, the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied again."
32869214|NCT05541666||Control Group|The patient in the control group will be interviewed on the preoperative 1sy day and the scales will be introduced, The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. On the postoperative 1st and 2nd days, no application will be made other than the clinical protocols and the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied to the patient.
32869215|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
32869216|NCT04616066|Experimental|Dates Arm|Consumption of Khalas dates (3 dates =30g undried dates) twice daily (phytoestrogen content 329ug/100g)
32869217|NCT04616066|Experimental|Raisins Arm|Consumption of Raisins (30g twice daily, phytoestrogen content of 9.6ug/100g)
32869218|NCT05541588|Active Comparator|ESPB|Erector Spinae Plane Block group
32869219|NCT05541588|Active Comparator|QLB|Quadratus Lumborum Block group
32869220|NCT00120523|Experimental|1|Pimecrolimus
32869221|NCT00120523|Active Comparator|2|Topical corticosteroids
32869222|NCT05541510|Placebo Comparator|Placebo Comparator|Participants will receive placebo (formulation buffer) on treatment days 1, 3 and 5.
32869223|NCT05541510|Experimental|Low dose treatment group|Participants will receive 20 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
32869224|NCT05541510|Experimental|High dose treatment group|Participants will receive 40 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
32869225|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
32869226|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
32869227|NCT04425876|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
32869228|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
32869229|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
32869230|NCT05550870|Experimental|Group 1|Group 1 will be given Raw Fenugreek seed powder. The dose will be 7.5grams two times a day i.e, before breakfast and before dinner for the period of three months.
32869231|NCT05550870|Experimental|Group 2|Group 2 will be given Roasted Fenugreek seed powder, 7.5 grams twice a day before breakfast and dinner for the period of three months.Total number of arms will be 2.
32869232|NCT05541432|Active Comparator|Home exercise|Home exercise program, with biweekly group virtual education and exercise classes.
32869233|NCT05541432|Experimental|Supervised strength training (group 1)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
32869234|NCT05541432|Experimental|Supervised strength training (group 2)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
32869235|NCT00121225|Experimental|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
32869236|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
33067849|NCT04696588|No Intervention|Waiting List group|Individuals registered in the waiting list for receiving the treatment specified for kinesiotherapy group (n=59).These patients receive no treatment for tinnitus.
33067850|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
33067851|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
33067852|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
33067853|NCT00138944|Placebo Comparator|1|Placebo
33067854|NCT00138944|Active Comparator|2|Eplerenone
33067855|NCT01243177|Experimental|Lacosamide|
33067856|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
33067857|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
33067858|NCT04705584|Active Comparator|Topical steroids|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
32869237|NCT05134987|Experimental|NNC0363-0845 followed by insulin detemir|Participants will get subcutaneous (under the skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of insulin detemir up to 6 times daily for 3 days.
32869238|NCT05134987|Experimental|Insulin detemir followed by NNC0363-0845|Participants will get subcutaneous (under the skin) injections of insulin detemir up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of NNC0363-0845 (study medicine) up to 6 times daily for 3 days.
32869239|NCT04426188|Sham Comparator|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
32869240|NCT04426188|Experimental|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
32869241|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
32869242|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
32869243|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
33330726|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
32869244|NCT04239235|Experimental|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
32869245|NCT04239235|No Intervention|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
32869246|NCT05545800|Experimental|metformin+empagliflozin+insulin glargine|metformin+empagliflozin+insulin glargine
32869247|NCT05545800|Experimental|IDegLira|IDegLira
32869248|NCT05545800|Active Comparator|premixed insulin analogues|premixed insulin analogues
33330727|NCT03438526|Experimental|Melatonin (Circadin ®)|
33330728|NCT03438526|Placebo Comparator|Placebo|
32869251|NCT00230737|Experimental|A|Melatonin 0.4 mg
32869252|NCT00230737|Experimental|B|Melatonin 4.0 mg
32869253|NCT00230737|Placebo Comparator|C|
32869254|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
32869255|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
32869256|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
32869257|NCT05545722|Experimental|life coaching group with diabetes|Individuals with diabetes in the intervention 1 group will be interviewed for 'life coaching with diabetes'. Coaching is a set of systems that make people think deeply and reveal their own awareness and potential. A coach is a person who deliberately applies all these systems with awareness. Life coaching sessions with diabetes are based on the philosophy of coaching. Sessions are continued with questions that will enable the individual to realize the deficiencies in diabetes self-management. It helps the person with diabetes to discover solutions.This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
32869258|NCT05545722|Experimental|Standard diabetes education|Standard diabetes education will be given to individuals with diabetes in this group. This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
32869259|NCT05545722|No Intervention|control group|only pre-test and post-test were applied to this group. The patients in this group are the patient group who received training from the diabetes nurse of the hospital.
32869260|NCT05545644|Experimental|Brief Family-Involved Treatment for Alcohol Use Disorder (B-FIT_|Up to 3 sessions of family-involved treatment for patients with alcohol use disorder (AUD) and a family member: Session 1; psychoeducation; increasing supportive behaviors, enhancing positive activities. Session 2: Improving communication; recovery contracts. Session 3: Review of session1 & 2 interventions; continue with communication skills.
32869261|NCT05545644|Active Comparator|Treatment as Usual (TAU|Treatment as usual in inpatient AUD rehabilitation program, including daily therapy groups, individual counseling, and health and recreational activities.
32869262|NCT00231283|Experimental|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
32869263|NCT05433051|Active Comparator|Buccal miniscrews with TPA|active comparator double center
32869264|NCT05433051|Active Comparator|vertical holding appliance|active comparator double center
32869265|NCT04425564|Active Comparator|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
32869266|NCT04425564|Experimental|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
32871573|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
33330729|NCT03769506|Active Comparator|ASP-1929 Photoimmunotherapy|Use of ASP1929 PIT therapy
33330730|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
33330731|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
33418174|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
33043645|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts. Patients who are deemed inevaluable will be replaced for the primary objective. Patients will be considered inevaluable if they don't receive one dose of conditioning regimen and are removed from the study.
33418175|NCT03125629|Experimental|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
33418176|NCT03125629|Experimental|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
33418177|NCT03125629|Experimental|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
33418178|NCT03125629|Experimental|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
33418179|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
32871574|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
33043646|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
33043647|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
33043648|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
33043649|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
33043650|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
33043651|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
33043652|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
33043653|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
33043654|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
33043655|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer >=160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
33043656|NCT03116347|Experimental|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was >= 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
33043657|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
33043658|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
33043659|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
33043660|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
33043661|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
33043662|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
32871575|NCT00330733|Placebo Comparator|Placebo|Matching placebo
33043663|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
33043664|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
33043665|NCT03003325|Active Comparator|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
33043666|NCT03003325|Experimental|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
33043667|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
33043668|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
33043669|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
33043670|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
33043671|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
33043672|NCT02890069|Experimental|CRC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
33043673|NCT02890069|Experimental|NSCLC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
33043674|NCT02890069|Experimental|TNBC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
33043675|NCT02890069|Experimental|CRC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
33043676|NCT02890069|Experimental|NSCLC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
33043677|NCT02890069|Experimental|TNBC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
33043678|NCT02890069|Experimental|CRC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
33043679|NCT02890069|Experimental|NSCLC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
33043680|NCT02890069|Experimental|TNBC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
33043681|NCT02890069|Experimental|CRC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
33043682|NCT02890069|Experimental|TNBC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
33043683|NCT02890069|Experimental|NSCLC- PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
33043684|NCT02890069|Experimental|CRC - PDR001 + HDM201|Dose escalation completed, expansion arm.
33043685|NCT02890069|Experimental|RCC - PDR001 + HDM201|Dose escalation completed, expansion arm.
33043686|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
33067859|NCT04705584|Experimental|Topical Cyclosporine A|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
33330732|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
33330733|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
33330734|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
33330735|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
33330736|NCT03773718||Russkoe pole|400 patients
33330737|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
33330738|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
33330739|NCT03772470|Experimental|1X Incentive|1X airtime incentive
33330740|NCT03772470|Experimental|2X incentive|2X airtime incentive
33330741|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
33043687|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
33330742|NCT05468034|Experimental|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
33330743|NCT05468034|No Intervention|Usual Care|Participants randomized to usual care (UC) will receive care per their treatment team. UC participants are encouraged to exercise but will not be provided components of the intervention. Participants in the UC arm will be given usual care handouts at baseline from the American College of Sports Medicine.
33043688|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
33043689|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
33043690|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
33043691|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
33043692|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
33043693|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
33043694|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
33043695|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
33043696|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
33043697|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
33043698|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
33043699|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
33043700|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
33043701|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
33043702|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
33043703|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
33043704|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
33330744|NCT02977624|Experimental|Tele-CO-OP|The intervention included weekly videoconferencing sessions using the Cognitive Orientation to Daily Occupational Performance approach (tele-CO-OP) over a period of three months. Participant identified five functional goals, of which three were directly addressed.
33330745|NCT02977624|No Intervention|Waitlist control|The waitlist control group did not receive the intervention during the same time period
33330746|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
33330747|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
33043705|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
33043706|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
33043707|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
33043708|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
33043709|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
33043710|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
33043711|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
33043712|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
33043713|NCT01955356|Experimental|Scratching|induced endometrial injury
33043714|NCT01955356|No Intervention|No scratching|None intervention
33043715|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
33043716|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
33043717|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
33043718|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
33043719|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
33043720|NCT04712227||difficult intubation|patients with a difficult intubation score of 5 or more
33043721|NCT04712227||easy intubation|patients with difficult intubation score less than 5
33043722|NCT04712227||difficult mask ventilation|group 3 and 4 by han mask ventilation grouping
33043723|NCT04712227||easy mask ventilation|group 1 and 2 according to han mask ventilation grouping
33043724|NCT01742143||ICCAN|For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.
33043725|NCT01742143||Usual and Customary Group (U&C)|Participants in this group will receive the same written materials on social and economic resources as ICCAN group.
33043726|NCT00388167||1|Caspofungin
33043727|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
33043728|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
33043729|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
33043730|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
33043731|NCT00388323|Experimental|1|
33043732|NCT00786760||1. Men ages 18 - 44 years|
33043733|NCT00786760||2. Men ages 45 - 70 years|
33043734|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
33043735|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
33043736|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
33043737|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
33043738|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
32871576|NCT00330733|Active Comparator|Salsalate Therapy|Salsalate
33109396|NCT05225064|Experimental|Village-level vaccination without incentive, plus mask promotion|Individuals are encourage to attend village-level vaccine clinics but not given any incentive. Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
33109397|NCT05225064|Experimental|Village-level vaccination without incentive|Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
33109398|NCT04389593||Single arm|This is a single arm study in which all participants have one MRI
33109399|NCT05222919|Active Comparator|Bare performance supplement|Dietary supplement
33109400|NCT05222919|Placebo Comparator|Placebo|Placebo
33109401|NCT02929862|Experimental|Single Agent 55716|
33109402|NCT05219409|Active Comparator|Treatment group|Sitagliptin
33109403|NCT05219409|Placebo Comparator|Control group|Placebo
33330748|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
33109404|NCT04381052|Experimental|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
33109405|NCT04381052|Placebo Comparator|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
33109406|NCT03956940|Experimental|Intplex test|In vitro diagnostic device
33109407|NCT05204823|Experimental|Experimental Product 1|Consumption of 221.24 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
33109408|NCT05204823|Experimental|Experimental Product 2|Consumption of 282.81 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
33109409|NCT05204823|Experimental|Experimental Product 3|Consumption of 589,62 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
33109410|NCT05204823|Experimental|Experimental Product 4|Consumption of 573,39 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
33109411|NCT05204823|Active Comparator|Control product|Consumption of 25g of glucose. Subjects will take this amount only on the day of the visit that they are to consume this product.
33330749|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
33109412|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
33109413|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
33109414|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
33109415|NCT05200572|Experimental|Cancer Patients|Dyadic Life Review will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes.
33109416|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
33109417|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
33109418|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
33109419|NCT03934281|Active Comparator|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
33330750|NCT03769272||Echocardiographic targeting|
33330751|NCT03769272||Electrogram targeting|
33330752|NCT04140162|Experimental|Dara-Rd followed by Dara-RVd|"Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24~Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36~Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88~Maintenance regimen with lenalidomide (R) until progression or intolerance"
33043739|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
33043740|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
33330753|NCT04092114|Other|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
33330754|NCT04092114|Experimental|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:~Module A: General Partner Communication and Relationship Skills~Module B: Partner Disclosure and Communication around PrEP Use~Module C: Responding to Intimate Partner Violence and Safety Planning"
33330755|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
33043741|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
33330756|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
33043742|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
33043743|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
33043744|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
33330757|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
33330758|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
33330759|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
33330760|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
33330761|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
33330762|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
33043745|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
33043746|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
33043747|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
33043748|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
33043749|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
33043750|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
33043751|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
33043752|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
33043753|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
33043754|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
33043755|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
33043756|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
33043757|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
33043758|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
33043759|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
33043760|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
33043761|NCT00006229|Experimental|BMS-275291|
33043762|NCT00006229|Placebo Comparator|Placebo|
33043763|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
33043764|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
33043765|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
33043766|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
33043767|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
33043768|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
33043769|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
33043770|NCT00007605|Active Comparator|2|Sotalol
33043771|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
33330763|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
33330764|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
33330765|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
33330766|NCT04068480||Capsule endoscopy|Patient refered for small bowel capsule endoscopy in conventional indication.
33330767|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (Baseline),~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,~a post-treatment cognitive assessment (Week 7), and~a follow up cognitive assessment (Week 11)"
33330768|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (baseline),~seven weeks of no intervention,~a post-treatment cognitive assessment (week 7), and~a follow up cognitive assessment (week 11)"
33043772|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
33043773|NCT00006295||Pedigree 1|
33043774|NCT00006295||Pedigree 2|
33043775|NCT00006295||Pedigree 3|
33043776|NCT00006295||Pedigree 4|
33043777|NCT00006295||Pedigree 5|
33043778|NCT00006295||Pedigree 6|
33043779|NCT00006295||Pedigree 7|
33043780|NCT00006295||Pedigree 8|
33043781|NCT00006295||Pedigree 9|
33043782|NCT00006295||Pedigree 10|
33043783|NCT00006295||Pedigree 11|
33043784|NCT00006295||Pedigree 12|
33043785|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
33043786|NCT00007683|Active Comparator|2|Aspirin 182 mg
33043787|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
33043788|NCT00007722||1|
33043789|NCT00007761|Experimental|1|Bipolar Disorder Program
33043790|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
33043791|NCT03677011|Other|category 1|Low responder
33043792|NCT03677011|Other|category 2|Medium Responder and High Responder
33043793|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
33043794|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
33043795|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
33043796|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
33043797|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
33043798|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
33043799|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
33043800|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
33043801|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
33067860|NCT04705584|Experimental|Topical Tacrolimus|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.
33418180|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
33418181|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
33418182|NCT02090192|Experimental|WBV+ PRT training|
33418183|NCT02090192|Active Comparator|PRT training|
33418184|NCT02090192|Placebo Comparator|Control group|
33043802|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
33043803|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33043804|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
33043805|NCT00006388|Experimental|Radiation plus Tamoxifen|
33043806|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
33043807|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
33043808|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
33043809|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
33043810|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
33043811|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
33043812|NCT00006469|Other|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
33043813|NCT00006472|Other|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
33043814|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
33043815|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
33043816|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
33043817|NCT05448261|Experimental|Emotion-centered problem-solving intervention (EPi)|The EPi comprises four weekly 60 minutes individual face-to-face session (45 minutes of emotion-centered problem-solving intervention and 15 minutes of stroke education), followed by two bi-weekly telephone follow-ups (30 minutes) and one face-to-face round up session (60 minutes). The content of the stroke education will be based on a developed booklet for local family caregivers (please refer to control group).
33043818|NCT05448261|Sham Comparator|Stroke education|The CG will receive basic education on stroke caregiving, as research indicates that basic education is not effective in improving problem-solving coping abilities and depressive symptoms. Four weekly individual stroke education (60 minutes/session) will be conducted by a trained research nurse. It will be based on a developed information booklet for local stroke caregivers. The participants will received three biweekly phone calls for general greetings. Questions relating to stroke caregiving raised by the caregivers will be answered according to the educative content. Any extra information provided will be documented.
33043819|NCT00006505|Experimental|Transplant|Islet cell transplantation
33043820|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
33043821|NCT00008502||18 years of age or older|without keloids
33043822|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
33043823|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
33043824|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
33043825|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
33043826|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
33043827|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
33043828|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
32871577|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
33418185|NCT05452928|Active Comparator|Active arm|Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).
33418186|NCT05452928|Placebo Comparator|Placebo|Randomisation to 7 days of IV and/or oral placebo.
33418187|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
33418188|NCT00264602|Experimental|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
33418189|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
33418190|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
33418191|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
33109420|NCT03934281|Experimental|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
33418192|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
33418193|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
33418194|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
33418195|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
33418196|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
33418197|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
33418198|NCT02095964||Cardiac Syndrome X|
33418199|NCT02095964||Control Group|
33418200|NCT02096120||All patients|
33109421|NCT04689893|Experimental|68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT scan|Patients of Tumor-induced osteomalacia PET/CT imaging: The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20~40min after the injection in two consecutive days.
33109422|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
33418201|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
33418202|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
33418203|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
33418204|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
33418205|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
33418206|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
33418207|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
33418208|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
33418209|NCT05451914|Experimental|My Diabetes Care|Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.
33418210|NCT05451914|No Intervention|Usual Care|Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)
33418211|NCT00390741|Active Comparator|1|Home-based exercise program
33418212|NCT00390741|No Intervention|2|Usual care
33418213|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
32871578|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
33418214|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
33418215|NCT00261807|Other|Single ARM Study|It was a single arm study with higher dose of daptomycin used for patients with severe skin and soft tissue infections.
33418216|NCT05216523||Cases|Admitted Covid-19 cases who developed Barotrauma
33418217|NCT05216523||Controls|Admitted Covid-19 cases who did not develop Barotrauma, matched with Cases with respect to age and sex.
33418218|NCT02093078||CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
33418219|NCT02093078||Control Arm|
33418220|NCT05672901|Experimental|StrataMGT|Participants will apply StrataMGT (silicone gel) 2-5 times daily (no limit in application times) to treat GSM for 3 months.
33418221|NCT05672901|Active Comparator|Estrace|Participants will receive Estrace vaginal cream (estrogen) to treat GSM for 3 months. Application will be 1 g daily for the first two weeks. Afterwards, a maintenance dosage of 1 g three times a week is applied.
33418222|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
33418223|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
33418224|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
33418225|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
33418226|NCT02090582|Other|Structured Palliative Care|
33418227|NCT02090582|Other|Usual Care|
33418228|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33418229|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33418230|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33418231|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33418232|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33418233|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
33043829|NCT00006565|Experimental|1|HEPA Air Cleaners
33043830|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
33043831|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
33043832|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
33043833|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
33043834|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
33043835|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
33043836|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
33043837|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
32871579|NCT05192369|Experimental|Treatment A: Therapeutic Dose|Single oral dose of 12mg CTP-543
32871580|NCT05192369|Experimental|Treatment B: Supratherapeutic Dose|Single oral dose of 48mg CTP-543
33043838|NCT05636046||transseptal catheterization performed without auxiliary tools|patients in whom transseptal catheterization have been performed without auxiliary tools
33043839|NCT05636046||transseptal catheterization performed with auxiliary tools|patients in who transseptal catheterization have been performed with the use of auxiliary tools
33043840|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
33043841|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
33330769|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
33330770|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
33330771|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
33043842|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
33330772|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
33330773|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
33330774|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
33330775|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
33330776|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
33330777|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
33043843|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
33043844|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
33330778|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
33043845|NCT00007579||1|
33043846|NCT00007618||1|
33043847|NCT05636202||Survival group|Patients who survived sepsis
33043848|NCT05636202||Death group|Patients who died of sepsis
33043849|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
33043850|NCT00007657|Active Comparator|2|Intensive medical therapy
33043851|NCT00007696||1|
33043852|NCT00007774|Experimental|1|Olanzapine
33043853|NCT00007774|Active Comparator|2|Haloperidol
33043854|NCT00007813|Experimental|Arm 1|
33043855|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
33043856|NCT05636280|Experimental|schroth exercise group|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
33043857|NCT05636280|Active Comparator|traditional scoliosis exercise group|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
33043858|NCT05636397|Experimental|BPD±PH|"Arm 1: BPD±PH~Total of 12-24 infants; 6-12 at each dose level of oral dosage form of L-Citrulline. (300 or 500 mg/kg/day divided q6 hours).~Dose Level 1 = 300 mg/kg/day Dose Level 2 = 500 mg/kg/day"
33043859|NCT05636397|Experimental|Surgical NEC|"Arm 2: sNEC~A total of 18-36 infants with Stage III NEC; 6-12 at each dose level of oral dosage form of L-Citrulline. (75, 150 or 225 mg/kg/day divided q6 hours)~Dose Level 1 = 75 mg/kg/day Dose Level 2 = 150 mg/kg/day Dose Level 3 = 225 mg/kg/day"
33043860|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
33043861|NCT05636137||High School Students|The sample of the study consists of high school students who do not have mental disabilities that will prevent them from understanding and answering the questions, aged 15-18 and volunteer to participate in the study, have internet at home and have an individual device that provides internet access.
33043862|NCT05636254||Chronic Meningitis|"Chronic meningitis : Case definition~Headache with or without fever, nuchal stiffness and systemic symptoms AND~CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND~Deemed by the treating physician that the syndrome is consistent with chronic meningitis~Patients who are positive for antibodies to HIV and pregnant females will also be included."
33043863|NCT05636332|Other|New electrodes|New package of electrodes
33043864|NCT05636332|Other|24-hour opened electrodes|Electrodes opened 24 hours
33043865|NCT05636332|Other|30 day opened electrodes|Electrodes opened 30 days
33043866|NCT05636449|Active Comparator|Group Suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block after the surgery
33043867|NCT05636449|Active Comparator|Group Periarticular Infiltration Group|A local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
33043868|NCT05636527||Thoracic Aortic Disease|"The NEXUS™ Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic diseases involving the aortic arch with proximal landing zone in ascending aorta and the Brachiocephalic artery. This includes:~Aneurysm Dissecting aneurysm / dissection and intramural hematoma {IMH) False / Pseudo aneurysm if not infected Residual aneurysm/dissection following ascending aorta open repair Penetrating ulcer, if not infected"
33043869|NCT05636553|Experimental|Massage|Women will receive four 60 minute massage consultations within a four-month period at intervals of their choosing.
33043870|NCT05636566|Active Comparator|Group (S)|sevoflurane inhalational anaesthesia for induction, then sevoflurane and fentanyl infusion for maintenance ,
33330779|NCT03772002|Experimental|HCV screening|
33043871|NCT05636566|Active Comparator|Group P|propofol infusion for induction afterward propofol and fentanyl infusions for maintenance of anaesthesia
33043872|NCT05636566|Active Comparator|Group D|dexmedetomedine infusion for induction after that dexmedetomedine and fentanyl infusions for maintenance
33043873|NCT05636644||Group A|anthracyclines+cyclophosphamide+other paclitaxel drugs
33043874|NCT05636644||Group B|anthracyclines+cyclophosphamide+nab paclitaxel
33043875|NCT05636722|Experimental|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire before and after (6 weeks after baseline) using the online self-help intervention (unguided web-based intervention).
33043876|NCT05447143|Other|Control Group (CG)|The control group will be queued to be included in the exercise program and participants' routine treatment will continue.
33043877|NCT05447143|Experimental|Video Group (VG)|The exercise will be given as a video and participants will be asked to continue the exercises for 8 weeks, 3 days a week. Patients will be contacted by phone every week to ask if participants have any problems with the exercise program and their compliance.
33043878|NCT05447143|Experimental|Brochure Group (BG)|Exercise will be given as a brochure and participants will be asked to continue the exercises given for 8 weeks, 3 days a week. Visual feedback will be provided by asking participants to mark the exercise tracking chart on the exercise brochures.
33043879|NCT05636631||Patients with Pneumonia (1)|Patients presented with symptoms suggestive of pneumonia as fever, tachypnea, cough with sputum. These patients will receive IV fluids & antibiotics with follow up of sepsis parameters
33043880|NCT05636631||Patients with decongestive heart failure (2)|Patients presented with symptoms suggestive of acute congestive heart failure as dyspnea, orthopnea, bilateral lower limb edema. These patients will receive anti-failure treatment as diuretics, ACE inhibitors & Beta blockers with follow up of resolving signs of decompensated heart failure
33043881|NCT05636761||group EliteHRV|the group (Elite) that started the assessment with the EliteHRV mobile application
33043882|NCT05636761||group Polar|the (Polar) group that started the evaluation with the Polar V800 watch
33043883|NCT05636839|Experimental|UVB treatment|"UVB treatment 3 times per week for 10 weeks~Before treatment starts, researchers will collect 20 ml of blood from participants. After 10-week treatment, researchers will collect 20 ml of blood from participants again."
33043884|NCT05636917||radiculopathy|Patients with suspected radiculopathy who are prescribed the nerve conduction test at the Lozano-Blesa University Hospital and who have undergone or are awaiting an MRI scan.
33043885|NCT05636670||SLE group|"The researcher signed the informed consent voluntarily;~Male or female patients aged 14-55 years;~Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~Patients who need to undergo head imaging examination according to the judgment of treating doctors, and the results of head imaging examination are not consistent with changes in cerebrovascular disease.~no antibiotics have been taken in the past 2 weeks;"
33043886|NCT05636670||NPSLE epilepsy group|"The researcher signed the informed consent voluntarily;~Male or female patients aged 14-55 years~Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~Patients who need MRI according to the judgment of the treating doctor, and reveal that the MRI suggests cerebrovascular disease;~no antibiotics have been taken in the past 2 weeks;"
33043887|NCT05636670||Healthy control group|"Male or female patient volunteers aged 14-55 from the Health Examination Center of Nanfang Hospital,~Voluntary signing of informed consent;~no systemic disease;~According to the judgment of the researchers, healthy volunteers matching SLE group in age, gender and education level were selected as the control group;"
33043888|NCT05636956|Experimental|Patients who receive education and counseling program|Patients with CIEDs and low health literacy received education and counseling program by researchers.
33043889|NCT05636956|No Intervention|Patients who receive clinical routine care|Patients with CIEDs and low health literacy received only clinical routine care.
33043890|NCT05636995||Primary Hyperaldosteronism Diagnosed Women|Post-partum women who had a hypertensive disorder of pregnancy and a screened primary hyperaldosteronism (positive aldosterone/renin ratio).
33043891|NCT05636995||Control Women|Post-partum women who had a hypertensive disorder of pregnancy without underlying primary hyperaldosteronism (negative aldosterone/renin ratio)
33043892|NCT05637034|Experimental|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
33043893|NCT05637268|Experimental|treatment group|"Treatment with camrelizumab combined with chemotherapy was planned for 4 to 6 cycles, after which carrilizumab monotherapy was maintained until disease progression, unacceptable toxicity, or patient withdrawal.~A total of 4 to 6 cycles, after carrilizumab maintenance treatment for one year."
32871581|NCT05192369|Placebo Comparator|Treatment D: Placebo|Single oral dose of 1 Placebo tablet
32871582|NCT05192369|Active Comparator|Treatment C: Positive Control|Single oral dose of 400mg Moxifloxacin
33043894|NCT05637307|Experimental|sentinel node procedure|Participants will indergo the standard treatment for their disease ( i.e. brachytherapy) but a sentinel node procedure will be added to their treatment
33043895|NCT05637346|Experimental|Patients scheduled for laparotomy|This is a single-center observational feasibility study to develop an automatic segmentation and registration algorithm based on ultrasound imaging of the pelvic arteries. The duration of this study will be approximately 1 year. Patients scheduled for a laparotomy at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. The ultrasound acquisitions for this study will be performed intra-operatively with CE marked equipment for intra-operative ultrasound. There is no impact on the standard surgical procedure or decision making of the surgery. After surgery, no further participation or cooperation of the patient is required.
33043896|NCT05637385|Experimental|central vision loss|will receive behavioral intervention
33043897|NCT05637385|Active Comparator|normal vision|using simulated central scotomas, will receive behavioral intervention
33067861|NCT00139256|Experimental|Betamethasone|Betamethasone injection
32871583|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
33043898|NCT05637580||combined well responder|Both primary tumor and nodal response achieve major pathological response (MPR).
33043899|NCT05637580||poor responder|Primary tumor or/and nodal response can not achieve MPR.
33043900|NCT05637736|Experimental|Mindfulness-based Stress Reduction by Therapeutic VR|
33043901|NCT05637736|Active Comparator|mindfulness-based therapy|
33043902|NCT05637775|Experimental|EXP - BCI|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
33043903|NCT05637775|Active Comparator|CTRL - MI|MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
33043904|NCT05637853||HFrEF patients (diagnosed within 3 months or hospitalized for worsening of HFrEF)|"Standardized sequencing of all for main HFrEF drugs: Betablockers, RAASi, SGLT2i, MRA.~All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion. In the second week, RAASi will be introduced with either angiotensin converting enzyme inhibitor (ACEi)(Ramipril or Enalapril) or angiotensin receptor neprilisyn inhibitor (ARNI)(Sacubitril/Valsartan). If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced. During the following weeks, both BB and ACEi/ARNI/ARB will be up titrated every second week according to the sequencing algoritm. MRA (Spironolactone, Eplerenone) will be introduced and up titrated in week 3 and 7 respectively. If the patient is already on either BB or ACEi/ARNI/ARB/MRA they will continue with the previous prescription and dose until the titration scheme indicates uptitration."
33043905|NCT05637216|Experimental|Breast Conservation Surgery with Losartan|The study drug losartan 12.5 milligram capsule will be taken by mouth twice daily starting the day of radiation therapy until the follow up 1 year after finishing radiation therapy for participants who had breast conservation surgery.
33043906|NCT05637216|Placebo Comparator|Breast Conservation Surgery with Placebo|The study drug placebo 12.5 milligram capsule will be taken by mouth twice daily starting the day of radiation therapy until the follow up 1 year after finishing radiation therapy for participants who had breast conservation surgery.
33043907|NCT05637216|Experimental|Mastectomy with Losartan|The study drug losartan 12.5 milligram capsule will be taken by mouth twice daily starting the day of radiation therapy until the follow up 1 year after finishing radiation therapy for participants who had a mastectomy.
33043908|NCT05637216|Placebo Comparator|Mastectomy with Placebo|The study drug placebo 12.5 milligram capsule will be taken by mouth twice daily starting the day of radiation therapy until the follow up 1 year after finishing radiation therapy for participants who had a mastectomy.
33043909|NCT05637931||adult polymyositis and dermatomyositis|
33043910|NCT05637931||juvenile dermatomyositis|
33043911|NCT05637931||healthy controls|
33043912|NCT05638048|Active Comparator|The control group|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
33043913|NCT05638048|Experimental|Experiment 1 set|Patients were routinely implanted with PICC, and the optimal duration-relaxation time of grip strength training was adopted on the basis of health education in the control group.
33043914|NCT05638048|Experimental|Experiment 2 set|"On the basis of control group~Determine the best grip strength On the basis of the control group, color Doppler ultrasound and electronic grip force were used to record the optimal grip strength of patients to achieve effective blood flow velocity before and 24 hours after PICC insertion.~Design precise grip strength training guidance program On the basis of the control group, the patients were instructed to perform grip strength training according to the determined best grip strength and the best duration of clenching and relaxation time."
33043915|NCT05638087|Experimental|Dexamethasone Treatment|Oral Dexamethasone treatment
33043916|NCT05638087|Placebo Comparator|Placebo Treatment|Placebo control
33043917|NCT05638126|Experimental|Part 1|HRS-1780 table or placebo single dose
33043918|NCT05638126|Experimental|Part 2|HRS-1780 table or placebo single dose with food effect
33330780|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
33330781|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
33330782|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
33330783|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
33330784|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
33330785|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
33330786|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
33330787|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
33330788|NCT04393350|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33330789|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
33330790|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
33330791|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
33360654|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
33043919|NCT05638126|Experimental|Part 3|HRS-1780 table or placebo multiple dose
33043920|NCT05638243||High-risk residents|
33043921|NCT05637372||Study group|Patients without any disorders and diseases in age range ensuring full temporomandibular joint development.
33043922|NCT05638282|Experimental|Cendakimab|
33043923|NCT05638282|Placebo Comparator|Placebo|
33043924|NCT05638321|Experimental|Treatment Arm 1|Eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications
33043925|NCT05638321|Experimental|Treatment Arm 2|Eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications [Treatment Arm 2 and Treatment Arm 3].
33043926|NCT05638321|Experimental|Treatment Arm 3|Two (2) inferonasal sclerostomies will be performed by the MIMS® system in the eyes of subjects who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications (i.e., refractory glaucoma).
33043927|NCT05638477|Experimental|Parkinson's disease|Eye tracking using Eyelink 1000 during free-viewing of videos
33043928|NCT05638477|Experimental|Progressive Supranuclear Palsy|Eye tracking using Eyelink 1000 during free-viewing of videos
33043929|NCT05638477|Experimental|Multiple System Atrophy|Eye tracking using Eyelink 1000 during free-viewing of videos
33043930|NCT05638477|Experimental|Corticobasal Syndrome|Eye tracking using Eyelink 1000 during free-viewing of videos
33043931|NCT05637411||Retrospective cohort|The clinical data, socioeconomical data and environmental exposure data from 800.000 asthmatic patients attended in our region from 2007 to 2021 will be analysed to train and validate a risk predictive model for exacerbation (defined as emergency visits)
33043932|NCT05637411||Prospective cohort|The same inclusion/exclusion criteria were applied prospectively. This is an external validation cohort.
33043935|NCT05638633|Active Comparator|1st arm (prednisolone and placebo)|Day 1-5: prednisolone 20mg 1x1 and placebo 1x1 Day 6-28: prednisolone 5mg 1x1 and placebo 1x1
33043936|NCT05638633|Active Comparator|2nd arm (placebo and Vitamin B compound)|Day 1-5: Placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µ B12) 1x1 Day 6-28: placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500 µg B12) 1x1
33043937|NCT05638633|Active Comparator|3rd arm (prednisolone and Vitamin B compound)|Day 1-5: prednisolone 20mg 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µg B12) 1x1 Day 6-28: prednisolone 5mg 1x1 and Vitamin B compound (100 mg B1, 50mg B6, 500µg B12) 1x1
33043938|NCT05638633|Placebo Comparator|4rd arm (placebo and placebo)|Day 1-5: Placebo 1x1 and placebo 1x1 Day 6-28: placebo 1x1 and placebo 1x1
33043939|NCT05637450|Experimental|Fish protein supplement|Blue Whiting Protein Hydrolysate
33043940|NCT05637450|Placebo Comparator|Placebo|Isocalorific Maltodextrin Citrus Flavoured Powder
33043941|NCT05638711||Before group|"Patient: ICU patients received CVVH between 2019/01/01 - 2020/10/01 (before utilization of built-in calculator)~received regular protocol of ICU patient care (same in two groups)"
33043942|NCT05638711||After group|"Patient: ICU patients received CVVH between 2020/10/01 - 2021/12/31 (after utilization of built-in calculator)~received regular protocol of ICU patient care (same in two groups)"
33043943|NCT05638789|Active Comparator|EST alone|
33043944|NCT05638789|Active Comparator|EST + EPLBD|
33043945|NCT05637489|Experimental|Treatment|Patients receive PING administered by RN
33043946|NCT05637489|No Intervention|Control|Usual care
33043947|NCT05638828|Experimental|Cell injection|
33043948|NCT05638867|Experimental|Experimental Group|Triple Antithrombotic Therapy: Aspirin (12 months) + Clopidogrel (12 months) + Rivaroxaban (3 months)
33043949|NCT05638867|Other|Control Group|Dual Antiplatelet Therapy: Aspirin (12 months) + Clopidogrel (12 months)
33043950|NCT05638906|Experimental|single-arm study with intra-subject comparisons|Study eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications.
33043951|NCT05638984|Experimental|low-dose decitabine combined with tirelizumab|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion.
33043952|NCT05638984|Active Comparator|tirelizumab|Tirelizumab injection, 10ml: 100mg/1 bottle, 200mg, Q3W, D1 IV infusion.
33043953|NCT05637528||MagTrace patients|Patients who underwent sentinel lymph node biopsy with MagTrace one year ago.
33043954|NCT05639023|Experimental|Manipulation Techniques Group|Subjects will be received orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
33043955|NCT05639023|Experimental|Control Group|Subjects will be received sham orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
33043956|NCT05639062|Active Comparator|Narrative-based card game|
33043957|NCT05639062|No Intervention|PUKE card game|
33043958|NCT05639101|Other|Intervention group|Clinicians will use a Clinical decision support system to better manage their patients. Asthmatic patients will use a smartphone app for their self management.
33043959|NCT05639101|No Intervention|Control|Asthmatic patients that will not be subject to any intervention
33043960|NCT05639140||Color discrimination deficit|
33043961|NCT05639140||Without Color discrimination deficit|
33043962|NCT05637684|Experimental|low intensity pulsed ultrasound group|low intensity pulsed ultrasound application The following parameters will be used: intensity of 0.3 W/cm2 at a 1megahertz frequency for 20 minutes and pulsed (20%) ultrasound waves and conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
33043963|NCT05637684|Sham Comparator|control group|conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
33043964|NCT05639257|Active Comparator|Lamotrigine|"An escalation phase of 28 days:~- tablet Lamotrigine 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Lamotrigine 100 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
33043965|NCT05639257|Active Comparator|Namuscla|"A placebo phase of 28 days:~- tablet placebo 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Namuscla 167 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
33043966|NCT05639296||MSUS experts|Physicians with extensive experience with MSUS (performed more than 1000 examinations).
33043967|NCT05637723|Experimental|schroth exercise group|Included participants will be included in the Schroth exercise program by a Schroth-trained physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
33043968|NCT05637723|Active Comparator|traditional scoliosis exercise group|Included participants will be included in the traditional scoliosis exercise program by a physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
33043969|NCT05637723|No Intervention|control group|Any exercise program for scoliosis will not be applied to this group.
33043970|NCT05639608|Experimental|systemically healthy females with gingivitis|scaling will be done at baseline
33043971|NCT05639608|No Intervention|systemically and periodontally healthy females|data will be recorded at baseline and no intervention will be done
33043972|NCT05639725|Experimental|EXTRACTION OF MAXILLARY IST PREMOLARS|Experimental: EXTRACTION treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
33043973|NCT05639725|Experimental|DISTALIZATION|Experimental: DISTALIZATION treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
33043974|NCT05639764|Experimental|specific Immersive virtual reality (VRi) software|"Intervention group will perform active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The intervention will last 3 sessions / week of 15 minutes, therefore carrying a total duration of two weeks of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
33043975|NCT05639764|Active Comparator|non specific Immersive virtual reality (VRi) software|"The control group will perform a VRi intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces. This intervention will attempt to assess the influence of the immersive context and the playful component compared to the intervention group. This treatment will last 3 sessions / week of 15 minutes, therefore taking a total duration of two weeks of treatment with a total of 6 sessions."
33043976|NCT05639803|Experimental|PEGIFNα1b 1.5 μg/kg|8 randomized participants receive one dose PEGIFNα1b 1.5 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
33043977|NCT05639803|Experimental|PEGIFNα1b 3.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 3.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
33043978|NCT05639803|Experimental|PEGIFNα1b 5.0μg/kg|8 randomized participants receive one dose PEGIFNα1b 5.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
33043979|NCT05639803|Experimental|PEGIFNα1b 6.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 6.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
33043980|NCT05639803|Experimental|PEGIFNα1b 7.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 7.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
33043981|NCT05639881|Experimental|Experimental: Intervention|Subjects receive a brief intervention to improve their immune health literacy and self-management skills.
33043982|NCT05639881|Active Comparator|Services as Usual|Subjects receive routine mental health care.
33043983|NCT00000136|Experimental|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
33043984|NCT00000136|Experimental|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
33043985|NCT00000142|Experimental|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
33043986|NCT00000142|Experimental|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
33043987|NCT00000142|Experimental|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
33043988|NCT00000145|Experimental|1|Antioxidants
33043989|NCT00000145|Experimental|2|Zinc
33043990|NCT00000145|Experimental|3|Antioxidants and zinc
33043991|NCT00000145|No Intervention|4|
33043992|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
33043993|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
33067862|NCT00139256|Placebo Comparator|Placebo|Placebo injection
33067863|NCT00161265||1|women with breast cancer
33067864|NCT00161304|Active Comparator|Testosterone Enanthate|Testosterone
33067865|NCT00161304|Placebo Comparator|Placebo|Placebo
33043994|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
33043995|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
33043996|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
33043997|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
33043998|NCT03577327||Adults with vitiligo|
33418234|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
33418235|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
33043999|NCT03577327||Healthy adults|
33044000|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
33044001|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
33044002|NCT05637957|Experimental|Physiotherapy + Active tDCS|20 minutes of active anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
33044003|NCT05637957|Active Comparator|Physiotherapy + Sham tDCS|20 minutes of sham anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
33044004|NCT03562156|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
33044005|NCT03562156|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
33044006|NCT03545386|Experimental|FMT|
33044007|NCT03545386|Placebo Comparator|Placebo|
33044008|NCT05638035||non-obese women|After obtaining demographic information for women with a BMI of 18-27.9 kg/m2 for at least 6 months, Body Mass Index (BMI) will be calculated and the relationship between rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated and will be compared with obese group.
33044009|NCT05638035||obese women|After obtaining demographic information in women with a BMI of 30-39.9 kg/m2, Body Mass Index (BMI) will be calculated and the relationship between obesity and rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated.
33044010|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
33044011|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
33418236|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
33418237|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
33418238|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
33418239|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
33418240|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
33418241|NCT02090660|Experimental|VATS wedge lung resection|
33418242|NCT00073671|Experimental|1= Cognitive behavioral prevention of depression program|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
33044012|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
33044013|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
33044014|NCT05638074||With cervical facet tropism|
33044015|NCT05638074||Without cervical facet tropism|
33044016|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
33044017|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
33044018|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
33044019|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
33044020|NCT00000460||Low intensity exercise|
33044021|NCT00000460||High intensity exercise|
33044022|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
33044023|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
33044024|NCT05638191||Experiemental: Surgical Arm|Individuals in this group will receive nerve transfer surgery 6 - 9 months post cervical spine injury and be observed for two years post-operatively.
33067866|NCT04705389|Other|Case group|Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
33418243|NCT00073671|Active Comparator|2 = Usual care|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
33418244|NCT02090738|Experimental|Arm1|Treatment group
33044025|NCT05638191||Control: Non-surgical|Individuals in this group will not have undergone nerve transfer surgery. They will be observed for two years post injury while receiving standard of care including medical and rehabilitation. We want to reinforce that individuals are not being randomized to surgery versus non-surgery. Rather individuals this group will either have made the decision not to undergo surgery, independent their participation in this study.
33044026|NCT00388999|Other|0 mg/kg|
33044027|NCT00388999|Other|0.5 mg/kg|
33044028|NCT00388999|Other|1.0 mg/kg|
33044029|NCT05638230||HIgh HFA-PEFF points (≥5)|
33044030|NCT05638230||Low to intermediate HFA-PEFF points (<5)|
33044031|NCT05638308|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
33044032|NCT05638425||Group 1|
33044033|NCT05638464|Experimental|Multisite HD-tDCS group|Constant current will be applied for 20min and the electrodes will be placed over the target area
33044034|NCT05638464|Active Comparator|Conventional tDCS Group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
33044035|NCT05638464|Sham Comparator|Sham HD-tDCS group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered.
33044036|NCT05638464|Experimental|multisite HD-tDCS with EMG-driven robot hand group|The stimulation electrodes are fixed on the ipsilesional sensorimotor cortex according to the brain activation map detected by task based fMRI.
33044037|NCT05638464|Sham Comparator|Sham HD-tDCS EMG-driven robot hand group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered.
33044038|NCT05638503||Hypertension with left ventricular hypertrophy group|"2015 ASE/EACVI guideline standard: Eccentric hypertrophy, EH: LVMI>115g/ m2（male）or LVMI>95g/ m2（female）and RWT≤0.42 Concentric hypertrophy, CH: LVMI>115g/ m2（male）or LVMI>95g/ m2（female）and RWT>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Eccentric hypertrophy, EH: LVMI>108g/ m2（male）and RWT≤0.51or LVMI>99g/ m2（female）and RWT≤0.49 Concentric hypertrophy, CH: LVMI>108g/ m2（male）and RWT>0.51 or LVMI>99g/ m2（female）and RWT>0.49"
33044039|NCT05638503||Hypertension with left ventricular non-hypertrophy group|"2015 ASE/EACVI guideline standard: Normal left ventricular geometry, NG: LVMI≤115g/m2（male）or LVMI≤95g/m2（female）and RWT≤0.42 Concentric remodeling, CR: LVMI≤115g/m2（male）or LVMI≤95g/ m2（female）and RWT>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Normal left ventricular geometry, NG: LVMI≤108g/ m2（male）and RWT≤0.51 or LVMI≤99g/ m2（female）and RWT>0.49 Concentric remodeling, CR: LVMI≤108g/ m2（male）and RWT>0.51 or LVMI≤99g/ m2（female）and RWT>0.49"
33044040|NCT05638542||Control group|Patients who are not diagnosed with colorectal adenoma or colorectal cancer
33044041|NCT05638542||Colorectal adenoma group|Patients who are diagnosed with colorectal adenoma
33044042|NCT05638542||Colorectal cancer group|Patients who are diagnosed with colorectal cancer
33044043|NCT05638659|Experimental|Experimental group|Twice a week for 8 weeks, total of 16 sessions course of computerized dual-task balance and home program.
33044044|NCT05638659|Active Comparator|Control group|Medical consultation and traditional balance training, and assessed after 8 weeks.
33044045|NCT05638815||Parkinson's Disease (PD)|
33044046|NCT05638815||Multiple System Atrophy (MSA)|
33044047|NCT05638815||Health volunteers|
33044048|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
33044049|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
33044050|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
33044051|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
33044052|NCT00389116|Experimental|1|
33044053|NCT00389116|Placebo Comparator|2|
33044054|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
33044055|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
33044056|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
33044057|NCT00389233|Experimental|1|2L gut cleansing solution
33044058|NCT00389233|Active Comparator|2|4L preparation
33044059|NCT05638971|Experimental|Sensor Group|The first half sample size Peripheral intravenous canula will be enrolled in a non-alarming group. ivWatch will monitor the Peripheral intravenous canula insertion site collecting data without notifications. The goals of the study on the nonalarming group are: a) to evaluate ivWatch sensitivity to detect infiltration in comparison with nurse standard of care; b) to estimate the difference in terms of time to detection of ivWatch in comparison with nurse standard of care
33044060|NCT05639049|Experimental|Enova GF3|Patient will receive the monofocal IOL in one eye during cataract surgery
33044061|NCT05639049|Experimental|Tecnis 1-piece ZCB00|Patient will receive the monofocal IOL in one eye during cataract surgery
33044062|NCT05639088|Experimental|Group A: SHIFT2|"Adolescents and young adults will engage in routine medical visits and attend 6 sessions (1x/month) focused on transition preparation and diabetes management with a transition coach and will receive bi-weekly messages during these 6-months that encourage self-management behaviors.~Parents will attend 2 sessions (month 1 and 6) with a transition coach and will receive materials, complementing their child's lesson, 1x/month for months 2-5 that focus on transition their role and supporting their child's diabetes management."
33044063|NCT05639088|Placebo Comparator|Group B: TAU+/Control|Participants will engage in routine medical visits and will receive education materials monthly (1x/month) regarding healthcare transition and diabetes management.
33330792|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
33330793|NCT04379700|Experimental|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
33044064|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
33044065|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
33330794|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
33330795|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
33330796|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
33044066|NCT05639127|Experimental|Low dose, wash out, high dose|
33044067|NCT05639244|Other|First TRE, then regular diet|This group will start with 2 weeks TRE and will switch to the 2 week period of consuming their regular diet after a wash-out period.
33044068|NCT05639244|Other|First regular diet, then TRE|This group will start with the 2 week period of consuming their regular diet and will switch to 2 weeks TRE after a wash-out period.
33044069|NCT05639322|Active Comparator|Ketamine only|
33044070|NCT05639322|Active Comparator|Psychotherapy only|
33044071|NCT05639322|Experimental|Ketamine + Psychotherapy|
33044072|NCT05639361||Standard Condensed|"Will complete a traditional schedule of 10 exposures over a 2-week period followed by a one-month break period before the final assessment. Because this schedule of exposure has been used most frequently in repeated exposure studies, this group will serve as the reference group."
33044073|NCT05639361||Periodic|Will complete a schedule of 5 exposures over a 2-week period, followed by a 2-week break, and then another 5 exposures over an additional 2-week period.
33044074|NCT05639361||Extended|Will complete a schedule of 10 exposures over a continuous 6-week period of time (approximately one exposure every 3-5 days).
33044075|NCT05639439|Active Comparator|Group A- Fastrach|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the intubating laryngeal mask airway Fastrach, while the laryngeal view through Fastrach will be evaluated using a flexible fiberoptic bronchoscope"
33044076|NCT05639439|Active Comparator|Group B- Proseal|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the Proseal laryngeal mask airway, while the laryngeal view through Proseal will be evaluated using a flexible fiberoptic bronchoscope"
33044077|NCT05639439|Active Comparator|Group C- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the I-gel supraglottic airway device, while the laryngeal view through I-gel will be evaluated using a flexible fiberoptic bronchoscope"
33044078|NCT05639439|Active Comparator|Group D- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the Protector laryngeal mask airway, while the laryngeal view through Protector will be evaluated using a flexible fiberoptic bronchoscope"
33044079|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
33044080|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
33044081|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
33044082|NCT00001183||Group 1|Pulmonary Patients
33044083|NCT05639751|Experimental|PRT3789|PRT3789 will be administered by intravenous infusion
33044084|NCT00001213|Experimental|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
33044085|NCT05639829|Experimental|Weekday time-restricted eating|The intervention consisted of 8 weeks of ad libitum TRE with a 12-8 pm 8-hour eating window on weekdays. Participants received instructions to only consume water, black coffee, or black tea from 8 pm to 12 pm on weekdays and during the weekend, where there were no restrictions on eating timing. No other dietary or physical activity instructions were given.
33044086|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
33044087|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
33044088|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
33044089|NCT00000135|Experimental|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
33044090|NCT00000135|Placebo Comparator|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
33044091|NCT00388557|Experimental|1|
33044092|NCT00001651|Experimental|HIV-infected subjects|HIV-infected adults
33044093|NCT00001651|Experimental|HIV-negative subjects|HIV-negative adults
33044094|NCT00001723|Placebo Comparator|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
33044095|NCT00001723|Experimental|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
33044096|NCT00001756||Healthy Volunteers|Healthy Volunteers
33044097|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
33044098|NCT05641636||childhood cancer survivors - the main group|childhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group
33330797|NCT03762642||Mastectomy|
33330798|NCT03762642||Breast-Conserving Surgery|
33418245|NCT02090738|Active Comparator|Arm2|Control group
33418246|NCT05218863||Confirmed AMI|Patients in whom diagnosis of acute mesenteric ischaemia (AMI) was confirmed. For these patients full data collection is required, including 1-year outcome. Maximum 500 patients in this group.
33418247|NCT05218863||AMI suspected but not confirmed|"Patients in whom acute mesenteric ischaemia (AMI) was suspected but not confirmed. For these patients minimal data will be collected, only hospital survival as outcome.~Maximum 2000 patients in this group."
33418248|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
32869267|NCT05550792|Active Comparator|Optimizer device|"100 patients were enrolled sequentially, 100 patients were implanted with an optimizer smart against the background of optimal drug therapy for heart failure~100 patients were implanted with a CCM Optimizer device without an atrial lead, per the protocol specifications recived optimal drug therapy CHF The following studies were performed in the 100 patients with CHF and AF before implantation of the MCC device and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ)."
32869268|NCT05550792|No Intervention|Without Optimizer device|100 patients were enrolled sequentially,100 patients received only optimal drug therapy for chronic heart failure 100 patients ( Without Optimizer device ) with CHF and AF before study and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ).
32869269|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
33418249|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
33418250|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
33418251|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
33418252|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
33418253|NCT05218317||MS-Relapse|"Twenty-seven patients (MS-Relapse) for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse.~The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings These subjects underwent Corneal Confocal Microscopy (IVCM)."
32869270|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
32869271|NCT00123409|Experimental|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
32869272|NCT00123409|Placebo Comparator|Usual Care|Usual Care
32869273|NCT05541198|No Intervention|Control Group|"Routine clinical care continued to be provided to the patients in the control group.~Routine maintenance applications include the following parameters;~Risk assessment using Braden Risk Scale~Positioning~Elevate the heels."
32869274|NCT05541198|Experimental|Intervention Group|"A pressure injury care bundle was developed in line with the relevant literature. After the development of the bundle, a 30-minute training program was applied to the nurses on general information about pressure injuries, the pressure injury care bundle, and how to use the bundle. The training program was carried out in four separate sessions arranged according to the working schedules of 40 nurses providing services in ICU.~Care Bundle include this parameters;~Risk Assessment~Skin Assessment~Skin Care~Positioning~Regulation of Nutrition and Liquid Management"
32869275|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
32869276|NCT05550558|Experimental|Anlotinib + Camrelizumab|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week plus Camrelizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
32869277|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
32869278|NCT05106595||Traditional Occupational Therapy|participants receiving traditional occupational therapy treatments and interventions provided in the inpatient rehabilitation setting. This includes, but is not limited to , therapeutic activity, therapeutic exercise, neuromuscular re-education. This group is retrospectively collected, and will not include participants who had access to the BAT.
32869279|NCT05106595||Bimanual Arm Trainer|Participants who are prospectively enrolled, who are appropriate for BAT use. Participants will receive additional traditional occupational therapy interventions, as deemed appropriate by treating therapists.
32869280|NCT05550480|Experimental|Continuous glucose monitoring|"Participants will monitor their glucose levels using CGM with access to interstitial glucose levels continuously throughout the day.~Each study period is preceded by 20 days of masked CGM assessment."
33044099|NCT05641636||the control group|healthy people formed the control group
33067867|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
33044100|NCT05641558|Experimental|611 dose 1 plus placebo|One subcutaneous injections of 611 150 mg on Day 1, followed by a 4-week observation period. Two subcutaneous injections of 611 150 mg (for a total of 300 mg) as a loading dose on Week 0 Day 29, followed by one 150 mg injection quaque week (QW) from Week 1 to Week 15 (15 cycles).
33044101|NCT05641558|Experimental|611 dose 2 plus placebo|Two subcutaneous injections of 611 150 mg (for a total of 300 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection quaque 2 week (Q2W) from Week 1 to Week 15 (8 cycles).
32869281|NCT05550480|No Intervention|Self-monitoring of blood glucose|"Participants will monitor their blood glucose levels using a glucometer and a capillary blood sample from finger-pricking. Participants will in addition use masked CGM for the last 20 days of the study period to monitor glucose levels for comparison.~Each study period is preceded by 20 days of masked CGM assessment."
32869282|NCT05419323||Traditional clinical pathway for OSA|"After referral, patients will have an initial encounter with a sleep care provider which might include in-person visits, telephone clinics, or video conferencing.~Intervention/Treatment: Patients in Arm 1 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
33044102|NCT05641558|Experimental|611 dose 3 plus placebo|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection QW from Week 1 to Week 15 (15 cycles).
33044103|NCT05641441||Stereotactic radiosurgery group|Patients with unilateral Vestibular Schwannoma treated with stereotactic radiosurgery, as proposed by the institution's skull base tumor board independently of the study.
33044104|NCT05641441||Wait and scan group|Patients with unilateral Vestibular Schwannoma followed with an MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study.
33044105|NCT05641402|Other|Experienced acceptability study|The final study in this research will involve people with type 2 diabetes receiving the text messages
33044106|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
33044107|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
33044108|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
33044109|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
33044110|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
33044111|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
33044112|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
33418254|NCT05218317||MS-Control|"Thirty-one patients (MS-Control) who were followed up with the diagnosis of RRMS The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings.~These subjects underwent Corneal Confocal Microscopy (IVCM)."
33418255|NCT05218317||Healthy Controls|Thirty healthy age and gender similar population These subjects underwent Corneal Confocal Microscopy (IVCM).
33418256|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
33418257|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
33418258|NCT05656911|Experimental|Zabedosertib|Participants will receive zabedosertib for up to 12 weeks (84 days).
32869283|NCT05419323||DREAM clinical pathway for OSA|"After referral, patients will not have an initial encounter with a care provider. After a clinician conducts a chart review of medical records, patients in the DREAM pathway will be referred for sleep testing.~Intervention/Treatment: Patients in Arm 2 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
32869284|NCT05419323||Negative predictive value of HSAT|"Results of sleep tests will be compared for patients who undergo both HSAT and polysomnographic (PSG) procedures.~Intervention/Treatment: Patients in Arm 3 will undergo~a) HSAT sleep testing followed by PSG testing, or b) simultaneous administration of PSG and HSAT sleep testing."
32869285|NCT00123643|Experimental|Rosiglitazone|
33044113|NCT05641363|Active Comparator|Standard dose group A|IV ketorolac 0.5 mg/kg/dose up to a maximum dose of 30 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg
33044114|NCT05641363|Experimental|Low dose group B1|IV ketorolac 0.5 mg/kg to a maximum of 10 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg
33044115|NCT05641363|Experimental|Low dose group B2|IV ketorolac 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 30 mg
33044116|NCT05641168|Experimental|Ostomy Adhesive material|Newly designed ostomy adhesive material
33044117|NCT05641168|Other|comparator adhesive material|Adhesive material already on the market e.g adhesive material from SenSura Mio ostomy product
33044118|NCT05641090|Experimental|Nordic walking in water|The groups trained Nordic walking in water
33044119|NCT05641090|No Intervention|No exercise intervention|The groups did not receive exercise
33044120|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
33044121|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
33044122|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
33044123|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
33044124|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
33044125|NCT05641051|Experimental|Metoclopramide group|Patients will receive 10 mg intravenous metoclopramide / 6 hours.
33044126|NCT05641051|Placebo Comparator|Control group|Patients will receive the same volume of intravenous placebo / 6 hours.
33044127|NCT05641012||metastatic melanoma group|adult with metastatic melanoma treated by immunotherapy
33044128|NCT05640856||Group D|STOP BANG Score <3
33044129|NCT05640856||Group Y|STOP BANG Score ≥ 3
33044130|NCT05640817|Active Comparator|Group 1 as control group|cisplatin with standard hydration with normal saline
33109423|NCT05184426||Exposed: Positive anti-HLA antibodies|Heart transplant patients who have developed antiHLA antibodies after transplant
33109424|NCT05184426||Non-exposed: Negative anti-HLA antibodies|Heart transplant patients without antiHLA antibodies with similar transplant date to its correspondent case.
33109425|NCT04689425|Experimental|MNC+PRP|The combination of PRP and MNC
33109426|NCT04689425|Active Comparator|PRP|PRP alone.
33109427|NCT05184192|Experimental|Gabapentin|"This arm will be given the active treatment, oral Letco (gabapentin) gelatin capsules of 300mg each.~Up to the first four weeks will be a titration period (week 1 300mg TID, week 2 600mg TID, week 3 900mg TID, week 4 1,200mg TID) as tolerated. If intolerable adverse reactions occur, the dosage will be decreased to prior tolerable dose (e.g., if 900mg TID is intolerable, dose will be decreased to 600mg TID).~The following eight weeks will be fixed dose, the highest tolerable dose from the titration period.~Up to two weeks will be a taper down tailored to the maximum dose the participant reached during the titration and fixed periods.~A maximum 14 weeks will mark the end of active treatment. Follow-up assessments will be conducted 4 weeks after completion of the taper-down period."
33109428|NCT05184192|Placebo Comparator|Placebo|"Placebo gelatin capsules that look, smell, and taste like gabapentin capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule TID the first week, the second week two capsules TID, the third week three capsules TID, and fourth week four capsules TID as tolerated. If intolerable, the dose will be decreased to prior tolerable dose.~The next eight weeks will be a fixed amount of placebo based on the highest tolerable amount from the titration period.~Subjects will then taper-down placebo to imitate the gabapentin arm for maximum two weeks based on highest dose achieved during study.~4 weeks after completion of taper-down, follow-up assessments will be conducted."
33109429|NCT04689581|Experimental|Bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
33109430|NCT04689581|Experimental|Modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
33109431|NCT03887676|Active Comparator|Arbaclofen|
33109432|NCT03887676|Placebo Comparator|Placebo|
33109433|NCT04689620|Experimental|HELIUM NEON LASER plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
33109434|NCT04689620|Experimental|GALLIUM ARSENIDE plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
33109435|NCT04689620|Active Comparator|regular ulcer care|dressing for the ulcer
33109436|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
33109437|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
33109438|NCT05167032|Experimental|Cognitive Multisensory Rehabilitation (CMR) Group|"After the baseline testing, participants in the CMR group will receive 8 weeks of one-on-one, in-person therapy, 3 times a week, for 45 min. The CMR sessions will be recorded on video.~The participants will undergo clinical assessments and MRI scans at 3 time points: at baseline; a post-intervention after the first 8 weeks of CMR and a clinical assessment (no MRI) at 3 months."
33109439|NCT05167032|Active Comparator|Adaptive Fitness Group|"After the baseline testing, participants in the adapted fitness group will start with a fitness assessment and then complete a fitness program under supervision for 8 weeks, 3x/week, for 45 min. Staff at the Courage Kenny Rehabilitation Institute will monitor training adherence through a log sheet.~The participants will undergo clinical assessments and MRI scans at 3 times points: at baseline; a post-intervention after the first 8 weeks of adaptive fitness and a clinical assessment (no MRI) at 3 months."
33109440|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
33109441|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
33109442|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
33109443|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
33109444|NCT04291469|Placebo Comparator|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
33109445|NCT04291469|Experimental|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks
33109446|NCT04291469|Experimental|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
33109447|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
33330799|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
33330800|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
33330801|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
33330802|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
33330803|NCT03771222|No Intervention|No prophylactic DLI|
32869286|NCT00123643|Active Comparator|Glyburide|
32869287|NCT05698524|Experimental|Single arm|"Patients will receive a combination of PCI-24781 and temozolomide. Patients will receive a loading dose of PCI-24781 prior to the start of Cycle 1; patients will take PCI-24781 by mouth twice a day starting 7 days prior to Cycle 1, Day 1 and ending 4 days prior to Cycle 1, Day 1.~Patients will continue taking PCI-24781 on days 1-4, 8-11, 15-18, and 22-25 of each 28 day cycle, starting with Cycle 1, Day 1. The initial dose level is 60 mg of PCI-24781 by mouth twice daily. The dose level may be escalated based on results of interim data analysis.~Patients will additionally initiate metronomic temozolomide on Cycle 1, Day 1 at a dose of 50 mg/m2, taken by mouth twice daily. Patients will continue the PCI-24781 and metronomic temozolomide regimen until disease progression or intolerance."
33044131|NCT05640817|Active Comparator|Group two as Pentoxifylline|receive cisplatin with standard hydration with normal saline and Pentoxifylline 400 mg SR tablets twice daily for three cycles.
33044132|NCT00000255|Placebo Comparator|0% Nitrous oxide|
33044133|NCT00000255|Active Comparator|10% nitrous oxide|
33044134|NCT00000255|Active Comparator|20% nitrous oxide|
33044135|NCT00000255|Active Comparator|30% nitrous oxide|
33044136|NCT00000255|Active Comparator|40% nitrous oxide|
33044137|NCT05640739|No Intervention|Control group patients|Data will be collected from the patients in the control group without any application and their ability to use MDI will be evaluated.
33044138|NCT05640739|Experimental|Demonstration group patients|Patients in the demonstration group will be given inhaler training (practically) by the researcher. The training will include steps compatible with the video. After the training, the patients will be asked to use inhaler drugs again, and their skill scores will be re-evaluated and the mistakes made by the patients will be shown by the researcher in the demonstration group. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
32869288|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
33044139|NCT05640739|Experimental|Video group patients|The patients in the video group will be shown the video of using MDI prepared by the researchers. The training will be completed by watching the MDI usage video prepared by the researchers in the patients in the video group. After the training, the patients will be asked to use the inhaler again and their skill scores will be re-evaluated. Their mistakes will be shown by making them watch it again from the video. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
33044140|NCT05640583|Experimental|IBD|10 patients diagnosed with colonic IBD (5 diagnosed with Ulcerative Colitis and 5 diagnosed with Crohn's Disease) scheduled for a surveillance colonoscopy
33044141|NCT05640583|Active Comparator|Control|10 patients scheduled for a routine screening colonoscopy who do not have a history of IBD symptoms or IBD diagnosis
33044142|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
32869289|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
33044143|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
33044144|NCT05640544|Experimental|Sound and light stimulation in Gamma band|
33044145|NCT05640505|Experimental|Experimental|This group received 03 gratitude interventions for 4 weeks
33044146|NCT05640505|No Intervention|Control Group|This group did not receive any intervention during active phase. Only the scores on dependent variables were measured. After completion of study, the same interventions were repeated with this group.
33044147|NCT05640466|Other|Adult patient with displaced metatarsal head fractures|"A Kirschner wire with its distal end is placed showing a small bend into the medullar cavity through the lateral margin of the proximal metaphysis of the affected metatarsal using a 5mm skin incision at that level. The skin incision was made over the interosseus space, so as to use one incision for the two neighbouring metatarsal bones. The diameter of the Kirschner wires to be used should be related to the size of the fractured metatarsal medullar cavity. Kirschner wire will be driven anterograde, with the help of an X-ray image intensifier.~Subsequently, the wire will be rotated 180 to direct its end to the dorsum of the foot so as to provoke a translation effect on the metatarsal head in order to obtain the head reduction, and maintained this reduction with the Kirschner wire."
33044148|NCT05640427|Placebo Comparator|Group C|Group C received general anesthesia with intravenous normal saline. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
33044149|NCT05640427|Experimental|Group D1|groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
32869290|NCT00235573|Experimental|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
32869291|NCT05545488|Experimental|Experimental group|Before preparing for pelvic training, information was given about virtual training applications, 1-2 minutes of practical information about both virtual glasses and pelvic training. Afterwards, the woman was taken to the gynecological examination table and, as the doctor began the examination, virtual glasses were put on the woman and a virtual reality application containing both sound and image was performed for 5-15 minutes. In the meantime, the pelvic examination was performed by the physician, the researcher accompanied the woman at all stages of the pelvic examination process and provided care based on ethical principles, which cared for the woman, respected, protected privacy.
33044150|NCT05640427|Experimental|Group D2|groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
33418259|NCT05656911|Placebo Comparator|Matching placebo to zabedosertib|Participants will receive placebo to zabedosertib for up to 12 weeks (84 days).
33418260|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
33418261|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
33418262|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
33418263|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
33418264|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
33418265|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
33418266|NCT03507855|Active Comparator|Control|Normal operating room environment.
33418267|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
33418268|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
33418269|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
33418270|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
33418271|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
33418272|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
33418273|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
33418274|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
33044151|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
33044152|NCT05640388||RV3278A arm : Treated group|This group will receive the RV3278A - ET0943 product
33044153|NCT05640388||RV4632A arm : Control group|This group will receive the RV4632A - RY1845 product
33044154|NCT05640349||Case|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice during the Covid-19 Pandemic lockdown (between 23/03/2020 and 24/05/2020).
33044155|NCT05640349||Control|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice between 23/03/2019 and 24/05/2019.
33044156|NCT05640271|Experimental|Early Tocilizumab|This arm will receive tocilizumab 80 mg at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive 50 mL of normal saline.
33044157|NCT05640271|Active Comparator|Delayed Tocilizumab|This arm will receive 50 mL of normal saline at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive tocilizumab 80 mg. Thus, this delayed arm will serve as a placebo comparator for the first 48 hours and then as an active comparator for the remaining duration on study.
33044158|NCT05640154|Experimental|Educational program|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. they will receive the nursing educational program which will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).also they will receive health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management).
33044159|NCT05640154|No Intervention|control group|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. the will not receive educational program and life style promotion.
33044160|NCT05640115|Experimental|Group A (Ureteral Stenting)|Group A: Participants in this group will receive a standard of care ureteral stenting performed by a urologist.
33044161|NCT05640115|Experimental|Group B (Percutaneous Nephrostomy)|Participants in this group will receive a standard of care percutaneous nephrostomy tube placement performed by an interventional radiologist.
33044162|NCT05640076||Pre-implementation|Patients took over from the Metropolitan Palliative Care Service from 1/1/2018 to 31/8/2018 and from 1/1/2019 to 31/12/2019
33044163|NCT05640076||Post-implementation|Patients took over from the Metropolitan Palliative Care Service from 1/1/2021 to 31/8/2022
33044164|NCT03295747|Experimental|180 mg|180 mg of peppermint oil
33044165|NCT03295747|Experimental|360 mg|360 mg of peppermint oil
33044166|NCT03295747|Experimental|540 mg|540 mg of peppermint oil
33044167|NCT05639998|Experimental|Group 1(COVAXIN® + COVAXIN®)|"Group 1 (COVAXIN® + COVAXIN®):~In this group, 152 participants will be recruited who will receive COVAXIN® on day 0 and on day 28 via the intramuscular route"
33044168|NCT05639998|Experimental|Group 2(COVAXIN® + BBV154)|"Group 2 (COVAXIN® + BBV154):~In this group, 152 participants will be recruited who will receive COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28.~*Post 56 days of vaccination, participants with seroconversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
33067868|NCT01242748|Active Comparator|Goserelin acetate|
33067869|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
33067870|NCT00139451|Active Comparator|Observation and Growth Hormone|
33044169|NCT05639998|Experimental|Group 3(BBV154 + COVAXIN®)|"Group 3 (BBV154 + COVAXIN®):~In this group, 152 participants will be recruited who will receive BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28.~*Post 56 days of vaccination, participants with sero-conversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
33044170|NCT05639998|Experimental|Group 4(BBV154 + BBV154)|"Group 4 (BBV154 + BBV154):~In this group, 152 participants will be recruited who will receive BBV154 on day 0 and on day 28 via the intranasal route."
33044171|NCT05639959||Commercial product group|group who are taking commercial nasal spray products
33044172|NCT05639959||New formulation product group|who are taking new formulation nasal spray product with same strength
33044173|NCT05639920||Group A|
33044174|NCT03575208|Experimental|HBIG followed by Peginterferon alfa-2a|HBIg x 12 weeks followed by peginterferon alfa-2a 180mcg x 24 weeks
33044175|NCT03575208|Active Comparator|Peginterferon alfa-2a|Peginterferon alfa-2a 180mcg x 24 weeks
33330804|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
33330805|NCT04018248|Experimental|Treatment (BR101801): Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
33330806|NCT04018248|Experimental|Treatment (BR101801):Phase Ib (dose expansion)|• Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL
33330807|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
33330808|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
33330809|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
33044176|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
33044177|NCT05637541|Experimental|Low-dose group|Drug 1 is a vial of 130 tablets of the experimental drug, and drug 2 is a vial of 130 tablets of the placebo
33044178|NCT05637541|Experimental|High-dose group|Drug 1 and 2 are each a vial of 130 tablets of the experimental drug
33330810|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
33330811|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
33044179|NCT05637541|Placebo Comparator|Placebo group|Drug 1 and drug 2 are each a vial of 130 tablets of the placebo
33044180|NCT05635591|Experimental|KSD-101|
33044181|NCT05634187||Patients suffering from symptoms suggestive for gastroesophageal reflux disease|Patients suffering from dysphasia, heartburn, laryngitis or pharyngitis suggestive for gastroesophageal reflux disease
33044182|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
33044183|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
33044184|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
33044185|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
33044186|NCT05632744|Experimental|CG-100 Intraluminal Bypass Device|Subjects will be treated with CG-100 Intraluminal Bypass Device
33044187|NCT05631925|Active Comparator|Group bolus|Propofol will be administered in bolus doses of 0.5mg/kg. Doses will be determined according to the clinical condition of the patient.
33044188|NCT05631925|Active Comparator|Group infusion|Propofol will be administered as 10mg/kg/hour infusion. The infusion dose will be adjusted so that the Bispectral index (BIS) is in the range of 40-60.
33044189|NCT03562221|Experimental|Gluten free diet|Gluten free diet
33044190|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
33044191|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
33044192|NCT05631379||All patients meeting inclusion criteria|All patients meeting inclusion criteria
33044193|NCT05631379||Subgroup of patients with available preoperative CT/MRI scans|Subgroup of patients with available preoperative CT/MRI scans will be detected and body composition measurements will be assessed min order to detect nutrition-related syndromes
33044194|NCT05629468|Active Comparator|Azithromycin and Topical|group A (n=25) received tab. azithromycin 250mg oral on alternate days and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
33044195|NCT05629468|Experimental|Probiotics and Topical|group B (n=25) received Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
33044196|NCT05629468|Other|Azithromycin and Probiotics and Topical|combination group C (n=25) received tab. azithromycin 250mg oral on alternate days, Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
33044197|NCT00000378|Active Comparator|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
33044198|NCT00000378|Active Comparator|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
33044199|NCT05626621|Active Comparator|Azelastine and Mometasone Nasal Spray|The study intervention will be saline irrigation (240 mL) followed by azelastine spray (137 mcg/spray) and mometasone spray (50 mcg/spray). Participants will have to dissolve the salt packet in a 240 mL sinus rinse bottle to create the saline solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the saline solution for each side followed by 2 sprays per nostril of both of the nasal sprays.
33044200|NCT05626621|Experimental|Mometasone Nasal Irrigation|The study intervention will be mometasone (1 mg/capsule). Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
33109448|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
33109449|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
32869292|NCT05545488|No Intervention|Control group|The control group was accompanied by the woman at all stages of the pelvic examination process, and the care service that cared for the woman, was respectful, privacy was protected and based on ethical principles was given in the same way, but the virtual glasses initiative was not applied.
32869293|NCT05710809|Experimental|Intervention group|Patients in the intervention groups will receive adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions
33330812|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
33330813|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td) (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
33330814|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccines #1 and #2 with Td pre-conditioning (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine.
33330815|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
33330816|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
33330817|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
33330818|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
33330819|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
33330820|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
33330821|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
33330822|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
33330823|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
33330824|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
33330825|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
33330826|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
33330827|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
33330828|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
32869294|NCT05710809|No Intervention|Usual care group|Patients in the usual care groups will receive standard treatment with adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner
32869295|NCT05541042||patients with glioblastoma|
32869296|NCT05545410|Other|healthy volunteers|
32869297|NCT01687179|Experimental|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
32869298|NCT05540886|No Intervention|Control|Standard practices are expected at hospitals before the education intervention is deployed
32869299|NCT05540886|Experimental|Intervention|"The main intervention - the training of trainers/champions (ToT) will be delivered to selected facility cleaning champions from three or four hospitals within a certain month. Four sets of ToT are expected to happen during the study period."
32869300|NCT05344677|Experimental|trendlenburg position group|in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period
33109450|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
33109451|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
33109452|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
33109453|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
33109454|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
33109455|NCT02929277|Other|single arm study|
33109456|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
33330829|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
33330830|NCT03627676|Experimental|Intervention|
33330831|NCT04478838|Experimental|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
32869301|NCT05344677|Experimental|warm pad application group|in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
32869302|NCT05344677|Experimental|deep breathing group|the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers
32869303|NCT05710731|Experimental|low-reality simulation Group|In this group, urinary catheterization will be performed through a plastic half-hip model.
32869304|NCT05710731|Experimental|Computer Based Simulation Group|In this group, urinary catheterization will be performed through a computer-based full-body model.
32869305|NCT05710731|Experimental|Virtual Reality Simulation Group|In this group, urinary catheterization will be performed through a software based on virtual reality technology.
32869306|NCT00124579|Experimental|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
32869307|NCT05550324||Affected Subjects|The subjects must have the diagnosis of cardiovascular disease
32869308|NCT05550324||Syndromes associated with Cardiovascular Disease|The subject must have a syndrome associated with cardiovascular disease
32869309|NCT05550324||Family Members|The subject must be related to an individual in cohort 1 or 2
32869310|NCT05550324||Controls|The subject is considered a control and does not fall into any of the other cohorts
32869311|NCT05550246|Experimental|AtoOxy Predicted Responders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
32869312|NCT05550246|Experimental|AtoOxy Predicted Nonresponders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
32869313|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
32869314|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
32869315|NCT05540730||Obstetric brachial plexus paralysis|
32869316|NCT05540730||Control|
32869317|NCT05550168|Experimental|Intervention (Laser group)|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
32869318|NCT05550168|No Intervention|Contralateral (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
32869319|NCT05550168|No Intervention|Control (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
32869320|NCT05710653|Experimental|HTNex|The participants will adhere to 12 weeks of exercise training, three times a week.
32869321|NCT05710653|No Intervention|HTNcg|These participants will maintain their normal lifestyle without intervention.
32869322|NCT05710653|Experimental|ELEex|The participants will adhere to 12 weeks of exercise training, three times a week.
32869323|NCT05710653|No Intervention|ELEcg|These participants will maintain their normal lifestyle without intervention.
32869324|NCT05710653|Experimental|NTex (Control Group-exercise)|The participants will adhere to 12 weeks of exercise training, three times a week.
32869325|NCT05710653|No Intervention|NTcg (Control Group-no exercise)|These participants will maintain their normal lifestyle without intervention.
32869326|NCT05550090||Patients with liver metastasis from breast cancer requiring antitumor therapy|Patients with liver metastasis from breast cancer requiring antitumor therapy
32869327|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
32869328|NCT00124735|Experimental|Rocuronium bolus maintenance|Rocuronium bolus maintenance
32869329|NCT00124735|Experimental|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
32869330|NCT05545254||Breast cancer patients and their family members who have undertaken genetic testing|In this study, 259 participants were recruited from November 2019 to March 2022. All participants originated from a genetic counseling clinic of a cancer center in Shanghai, China. 259 participants were contact, and among them, 158 participants finally agreed to participate and completed the survey.
32869331|NCT05340309|Experimental|Treatment (atezolizumab and recombinant human hyaluronidase)|Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.
32869332|NCT05339841|No Intervention|Control group|Subjects monitored following usual-care.
32869333|NCT05339841|Experimental|Intervention group|Subjects in the intervention group, in addition to usual-care, will download a mHealth App that contains educational information promoting healthy lifestyle behaviours. The participant will be also able to self-monitor his/her clinical status regarding hypertension, diabetes or hypercholesterolemia.
32869334|NCT00125515|Placebo Comparator|Placebo|Placebo plus oral naltrexone
32869335|NCT00125515|Active Comparator|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
32869336|NCT00125515|Active Comparator|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
32869337|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
32871584|NCT05185973|Experimental|"For-Baby powder supplement"|For-baby supplements provided as powder containing dry yeast powder, biovita mixed probiotics, synergy probiotics and other nutrients such as glucose, xylitol, chocolate powder, chocolate flavor powder, organic galactose oligosaccharide, chicory extract powder, vegetable Cream substitute, silicon dioxide, milk flavor powder, whole milk powder, zinc oxide, vitamin B12, vitamin B6, enzyme mixed preparation, vitamin C, organic alpha rice powder, folate 0.4mg, thiamine, leucin, isoleucin, valine, glutamine, and magnesium chloride.
33067871|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
33330832|NCT04478838|No Intervention|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
33330833|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
33330834|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
33044201|NCT05626621|Experimental|Azelastine and Mometasone Nasal Irrigation|The study intervention will be azelastine (1mg) and mometasone (1 mg). The azelastine and mometasone will be provided in one capsule identical to the mometasone capsule. Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
33044202|NCT05625256||Accuracy of Continuous Noninvasive Blood Pressure at Various Stages of Anesthesia|To compare noninvasive continuous arterial pressures obtained from the SentiCor-300 with direct intra-arterial blood pressure measurements at various stages of anesthesia (such as induction, laryngoscopy, maintenance, emergence, and recovery) and after emergence in various positions.
33044203|NCT05621941|Experimental|Game-Supported Goal Management Training|Seven treatment sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist and cognitive trainer or occupational therapist.
33044204|NCT05621941|Active Comparator|Information Group|Seven information sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist.
33330835|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
33330836|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
33330837|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33044205|NCT05619172|Experimental|SOT101 and Cetuximab|Participants will be first treated with 9 µg/kg of SOT101 and then proceed to be treated with either 12 µg/kg or 6 µg/kg of SOT101 in combination with cetuximab (depending on the safety evaluation of the first safety cohort). SOT101 treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 2 (±1 day), day 8 (±1 day), and day 9 (±1 day) of each 21-day cycle, Cetuximab treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 8 (±1 day), and day 15 (±1 day) of each 21-day cycle; on day 1 and day 8, cetuximab infusion will start within 30 minutes after SOT101 administration.
33044206|NCT05618041|Experimental|CAR-T Autologous T cell injection|Patients will be treated with CAR-T cells
33044207|NCT05611606||DanFunD baseline|"Data from the DanFunD baseline cohort will be included (11). It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen.~Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) (2) and diagnostic research interviews (n=1,590) (12).~Participants with FSD will be defined as follows:~FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires (14) and diagnostic interviews (3)~Three functional somatic syndromes, i.e. irritable bowel (15), chronic widespread pain (16), and chronic fatigue (17) will be defined with questionnaires.~Severe physical disease will be defined as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease."
33044208|NCT05606926|Other|Group I|15 Children with spastic diplegia in this group will a designed physical therapy program for 60 minutes per session in addition to WBV for 10 minutes, three times a week, for three consecutive months.
33044209|NCT05606926|Experimental|Experimental group|15 Children with spastic diplegia in this group will receive the same designed physical therapy program while WBV will be conducted while wearing a weighted vest.
33044210|NCT05601778|Experimental|HSK31858 20mg|multiple oral doses: 20mg/d for 24w
33044211|NCT05601778|Experimental|HSK31858 40mg|multiple oral doses: 20mg/d for 24w
33044212|NCT05601778|Placebo Comparator|placebo|multiple oral doses for 24w
33044213|NCT00000408|Experimental|email discussion group|
33044214|NCT00000408|No Intervention|rancomized control group|usual care
33044215|NCT05597683|Experimental|QL block group|Bilateral transmuscular QL block will be performed under ultrasound-guidance. Twenty mililiter of 0.375% ropivacaine will be injected to each side.
33044216|NCT05597683|No Intervention|Control group|QL block will be not performed.
33044217|NCT05593900|Experimental|Intervention|Parents have the option to use telehealth to virtually connect with the nurse before transfer
33044218|NCT05593900|No Intervention|Control|Standard of care
33044219|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
33044220|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
33044221|NCT05582746|Other|COVID-19 mHealth Intervention|We are using a pre-post study design, given the low risk of the educational intervention and expected benefit.
33044222|NCT05573113|Active Comparator|AXR Arm 1|Abdomen Radiograph
33044223|NCT05573113|Active Comparator|AXR + BUS Arm 2|Abdomen Radiograph + Bowel Ultrasound
33044224|NCT05568706|Experimental|EDP-938|EDP-938 800 mg, once daily
33044225|NCT05568706|Placebo Comparator|Placebo|Matching placebo, once daily
33044226|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
33044227|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
33067872|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
33067873|NCT04705740||September 2013 to August 2015|5 endoscopists
33067874|NCT04705740||September 2015 to December 2017|4 endoscopists
33330838|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33330839|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33330840|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33330841|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33044228|NCT05563792|Experimental|OPTIONS Intervention Coaching|Intervention participants will participate in a series of four coaching sessions focused on helping patients clarify their values and treatment goals, aligning these values and goals and their lifestyle with nonpharmacological treatment options, working on overcoming barriers to use and adherence of nonpharmacological treatment options (using motivational interviewing), and preparing patients to discuss these options with their primary care providers. A decision aid will be used during these coaching sessions.
33044229|NCT05563792|No Intervention|OPTIONS Waitlist Control|Participants randomized into waitlist control group will receive the intervention decision aid after completing the last survey at 9 months. Participants will also be offered the opportunity to have a brief 20-minute session with a member of the OPTIONS study staff to help walk them through this decision aid.
33044230|NCT05557513|Active Comparator|Ag-RDT (arm 1)|Symptomatic /suspected COVID-19 participant or close contact/family members of COVID-19 patient will be tested with Ag RDT and also involve in awareness-raising campaign with mask distribution.
33044231|NCT05557513|No Intervention|No Ag-RDT (arm 2)|No community based Ag RDT testing but there has routine ATK or RT-PCR test by Thai health authorities if local health volunteer finds symptomatic or suspected COVID-19 or close contact with positive cases in their villages. The participant also involves in awareness-raising campaign with mask distribution.
33044232|NCT05555758|Experimental|Part A: Caucasian Cohort|Three ascending dose levels(Cohort A1、Cohort A2 and Cohort A3) of either MAD Aom0319 (n=8) or placebo (n=2)
33044233|NCT05555758|Experimental|Part B: Chinese Cohort|One dose level of MAD Aom0319 (n=8) or placebo (n=2) based on the data of Cohort A2 collected in Part A.
33044234|NCT05551858|Placebo Comparator|Placebo|"Arm 1. Placebo for first 12 weeks. Placebo is a fiber filler called Avicel and is given by mouth three times daily.~Note: After 12 weeks on placebo, these subjects will receive proglumide 400 mg orally three times daily open labeled for 12 additional weeks."
33044235|NCT05551858|Experimental|Proglumide|Proglumide therapy 400 mg by mouth three times daily for 12 weeks in a blinded fashion followed by continued proglumide 400 mg by mouth three times daily for 12 additional weeks in an open labeled fashion. Hence this arm receives proglumide for a total of 24 weeks.
33044236|NCT05539534|Experimental|Training|This is a one-arm trial. The intervention group receives a training on suicide prevention.
33044237|NCT05530174|Experimental|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
33044238|NCT05530174|Active Comparator|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
33044239|NCT05529628||Control|Healthy volunteers with no known chronic or cancer disease
33044240|NCT05529628||Fournier's gangrene|Fournier's gangrene patients
33044241|NCT05529628||Perianal abscess|Perianal abscess patients
33044242|NCT05529043|Active Comparator|MINISTOP app|Receives the MINISTOP app for 12-months.
33044243|NCT05529043|Experimental|MINISTOP Plus Program|Receives the MINISTOP app for 12-months and receives Community Group Mini.
33044244|NCT05519683|Experimental|TEA at location A|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
33044245|NCT05519683|Sham Comparator|TEA at location B|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
33044246|NCT05519683|Experimental|TEA at location C|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
33044247|NCT05519683|Experimental|Escitalopram treatment|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
33044248|NCT05516563|Active Comparator|EDucation and eXercise intervention (EDX)|EDX-Ireland will involve 6 face-to-face education and exercise sessions on a individualised basis with a physiotherapist, delivered over eight weeks. This will be supplemented by a home based exercise programme.
33330842|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33330843|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
33330844|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
32905064|NCT03698708|Experimental|CARES Intervention- 8 sessions|Participants in the intervention will participate in 8 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
33109457|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
33109458|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
33109459|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
33109460|NCT05159037|Experimental|Active GC-MRT Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will have been trained with prior to a stressful speech task.
33109461|NCT05159037|Placebo Comparator|Control Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will not have been trained with but ranked as highly liked prior to a stressful speech task.
33109462|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
33109463|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
33330845|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
33330846|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
33330847|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
33109464|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
33109465|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
33109466|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
33109467|NCT05152836|Experimental|Vibrotactile stimulation atdifferent settings|All participants receive vibrotactile stimulation at three different stimulation settings as well as one sham condition. Specifically, stimulation is applied at (1) brief bursts of 80Hz that occur at the individual tremor frequency, (2) 80Hz bursts at tremor frequency*1.5, and (3) continuous stimulation at 80Hz. The sham condition does not involve any stimulation. All of the stimulations will be applied under three different contextual manipulations: during rest, posture and cognitive coactivation (serial subtraction task). Within each context, stimulation/sham conditions are applied in random order.
33109468|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
33109469|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
33109470|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33109471|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33109472|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33330848|NCT05444634|Experimental|distraction card|Immediately before the procedure, the child will be asked questions about the distraction cards. Questions about the cards will continue to be asked immediately after the intramuscular injection is finished.
33330849|NCT05444634|Experimental|Stress Ball|The child will be informed about the stress ball and asked to play continuously
33330850|NCT05444634|No Intervention|Control|
33109473|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33109474|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33109475|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
33109476|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
33109477|NCT05151315|Active Comparator|Evolution Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the Evolution Total Knee System
33109478|NCT05151315|Experimental|Evolution with NitrX Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the NitrX Evolution Total Knee System which has the specialized protective coating
33109479|NCT02929043||Dentine hypersensitivity subjects|
33109480|NCT05134974|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
33418275|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
33418276|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
33418277|NCT05216289|Active Comparator|probiac + topical fixed combination|
33418278|NCT05216289|Placebo Comparator|placebo + topical fixed combination|
32869338|NCT05338827|Experimental|Polyvinyl Chloride Tube group|The PVC tube used is a stiff tube with an anterior curvature of approximately 130°, which retains the additional curvature imposed by its passage through the ventilation conduit of the ILMA. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
32869339|NCT05338827|Experimental|Wire-Reinforced Tube group|In contrast to the PVC tube, the WR tube is flexible with a slightly anterior curvature. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
32869340|NCT00125593|Placebo Comparator|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
32869341|NCT00125593|Active Comparator|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
32869342|NCT00125593|Other|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
32869343|NCT05332275|Experimental|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
32869344|NCT05332275|Active Comparator|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and follow up to address potential contamination effects across study arms.
32869345|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
32869346|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
32869347|NCT01898845|Experimental|LEE011|LEE011
32869348|NCT02249715|Experimental|rDTMS|
32869349|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
32869350|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
32869351|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
32869352|NCT00236977|Experimental|Venofer|iron sucrose injection
32869353|NCT00236977|Active Comparator|Ferrous Sulfate|oral iron
32869354|NCT04753021|Experimental|Exercise|Progressive exercise training
32869355|NCT04753177|Experimental|Neoadjuvant combined hormone therapy|Ribocyclib, fulvestrant, triptorelin
33418279|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
33330851|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
33330852|NCT03761862||Control|The control group with bilateral tubal ligation
33330853|NCT03761862||Neural Therapy|The treatment group
33330854|NCT04230486|Experimental|Experimental Group Virtual Reality (VR) Treatment|Visual Auditory Virtual Reality rehabilitation for visual hemianopia
33330855|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
33330856|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
33067875|NCT04705740||January 2018 to June 2020|3 endoscopists
33330857|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
33330858|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
32869356|NCT04753177|Active Comparator|Chemotherapy (the control)|doxorubicin, cyclophosphamide, paclitaxel
32905065|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
33330859|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
33330860|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
33330861|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
33330862|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
33330863|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
33330864|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
33330865|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
32905066|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
32905067|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
32905068|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
32905069|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
32905070|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
32905071|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
32905072|NCT01280201|Experimental|Pazopanib|
32905073|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
32905074|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
32905075|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
32905076|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
32905077|NCT04382690||India|People residing in India
32905078|NCT04382690||United Kingdom|People residing in the United Kingdom
32905079|NCT04382690||China|People residing in China
32905080|NCT04382690||Australia|People residing in Australia
32905081|NCT04382690||South Africa|People residing in South Africa
32905082|NCT04382690||Indonesia|People residing in Indonesia
32905083|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
32905084|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
32869357|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
32869358|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
32869359|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
32869360|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
32869361|NCT04753099|Experimental|Intervention|Receives occupation-based coaching via telehealth
32869362|NCT04753099|No Intervention|Control|No intervention Will receive the occupation-based coaching via telehealth after the 12-weeks
32869363|NCT00127231|Experimental|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
32869364|NCT00127231|Active Comparator|2 Standard Care Arm|
32869365|NCT00079001|Experimental|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
32869366|NCT00079001|Active Comparator|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
32869367|NCT05234307|Experimental|Treatment (PBF-1129, nivolumab)|Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32869368|NCT04937881|Experimental|TAF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
32869369|NCT04937881|Active Comparator|TDF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
32869370|NCT00238615|Experimental|Chemotherapy+Radiation+Surgery|"Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
32869371|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
32869372|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
32869373|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
32869374|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
32869375|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
32869376|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
32869377|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
32869378|NCT02249403|Placebo Comparator|Placebo|
32869379|NCT03088631|Active Comparator|Metformin group|
32869380|NCT03088631|Placebo Comparator|Placebo group|
32869381|NCT00131677|Active Comparator|active immediate|participants in this arm start study product immediately upon enrollment
32869382|NCT00131677|Placebo Comparator|placebo immediate|participants in this arm start study product immediately upon enrollment
32869383|NCT00131677|Active Comparator|active delayed|persons in this arm start study product 9 months after enrollment
32869384|NCT00131677|Placebo Comparator|placebo delayed|participants in this arm start study product nine months after enrollment
33330866|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
33330867|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
32869387|NCT02245815|Experimental|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
32869388|NCT02245815|Experimental|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
32869389|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
32869390|NCT00240487|Active Comparator|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
32869391|NCT00240487|Active Comparator|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
32869392|NCT05203731|Experimental|Exercise Group|Participants who will be randomized to moderate intensity exercise after extinction (Day 1)
32869393|NCT05203731|Sham Comparator|Seated group|Participants who will be randomized to sitting after extinction (Day 1)
32869394|NCT05392517|Experimental|Group A|self-mobilization technique
32869395|NCT05392517|Other|Group B|: conventional treatment
32869396|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
32869397|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
32869398|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
32869399|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
33044249|NCT05516563|No Intervention|Usual Care|"Participants will continue to follow what they have done so far for their hip pain, or what their doctor has suggested/prescribed. If a participant is referred to physiotherapy as part of the usual care treatment, waiting time will be recorded.~Participants will receive a written information leaflet on the pathology of gluteal tendinopathy and general advice on symptom management."
33044250|NCT05510635|Experimental|interactive bibliotherapy|All adolescents enrolled in the experimental group will receive two times of interactive bibliotherapy with an interval of 7 to 14 days. The researcher will read the story to the participant and then discuss it with him/her.
33044251|NCT05510635|Active Comparator|reading bibliotherapy|All adolescents enrolled in the comparison group will receive two times of reading bibliotherapy with an interval of 7 to 14 days. The participant will read the story alone.
33044252|NCT05507944||Healthcare workers at Oslo University Hospital|"Occupational control.~Environmental exposure during commuting."
33044253|NCT05507944||Hairdressers|"Occupational exposure for airway irritants during hairdressing.~Environmental exposure during commuting."
33044254|NCT05486611|Experimental|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
33044255|NCT05486611|Sham Comparator|Digital Education Application Group|Participants assigned to the Digital Education mobile app group will be given instructions on how to download and access the application that will provide general health information. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date. We expect a target dosage of roughly 30 minutes per week (120 min), which would make it comparable to Woebot (about 5 min per day X 28 days = 140 min).
33044256|NCT05486455|Experimental|CT scan|
33044257|NCT05481658|Experimental|Diphencyprone (DPCP)|0.4% and 0.04% ointment
33044258|NCT05477758||CASPER|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
33044259|NCT05477758||CASPER+|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Major depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
33044260|NCT05477758||SHARD|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive the self-help booklet based on the principles of behavioural activation or usual GP care
33044261|NCT05455060|Experimental|Chinese herbal formula (CHF)|The patients in CHF group will take CHF capsules, 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW<40kg; 1.5gm BID for BW<20kg)
33044262|NCT05455060|Placebo Comparator|Control|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group, in which 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW<40kg; 1.5gm BID for BW<20kg)
33044263|NCT05442268|Experimental|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively.
33044264|NCT05442268|Experimental|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen (every 6 hours postoperatively)
33044265|NCT05451355|Active Comparator|Control Group|Participants receive a link to review an educational webpage (e.g., the AAP Firearm Storage Web Page)
33044266|NCT05451355|Experimental|Intervention Group|Participants receive the newly developed prototype (e.g., the Family Safety Check In)
33044267|NCT05448820|Experimental|P1 Cohort 1A: Dose 1 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
33044268|NCT05448820|Experimental|P1 Cohort 2A: Dose 2 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
33044269|NCT05448820|Experimental|P1 Cohort 1B: Dose 1 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
33044270|NCT05448820|Experimental|P1 Cohort 2B: Dose 2 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
33044271|NCT05448820|Experimental|P2: Sarcoma Subtype 1 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
33044272|NCT05448820|Experimental|P2: Sarcoma Subtype 2 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
33044273|NCT05448820|Experimental|P2: Sarcoma Subtype 3 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
33044274|NCT05448820|Experimental|P2: Sarcoma Subtype 4 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
33044275|NCT05446012||women diagnosed with ectopic pregnancy (n: 40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in women diagnosed with ectopic pregnancy
33044276|NCT05446012||Control group pregnants (n:40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in pregnant women in early pregnancy week.
33044277|NCT05444023|Experimental|Transverse separated suturing technique|During pubocervical fascia reconstruction, the surgeon will perform suturing at the transverse plane with an intermittent stitching technique.
33044278|NCT05444023|Active Comparator|circular continue suturing technique|During pubocervical fascia reconstruction, the surgeon will perform a continuous stitching technique which includes the lateral parts of the anterior compartment defect.
33044279|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
33044280|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
33044281|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
33044282|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
33044283|NCT05418868|Experimental|Part A: Participants receiving CAB 200 mg/mL with rHuPH20|
33044284|NCT05418868|Experimental|Part C: Participants receiving CAB 400 mg/mL|
33044285|NCT05418868|Experimental|Part D: Participants receiving CAB 400 mg/mL with rHuPH20|
33044286|NCT05409079|Experimental|Abilitech Assist|The Abilitech™ Assist device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
33044287|NCT05398003|Experimental|Study population|12 patients with neck and upper limb pain who have failed multidisciplinary treatment and are candidates for cervical medullary stimulation will be included.
33044288|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
33044289|NCT05387317|Experimental|Pfizer-BioNTech Standard dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044290|NCT05387317|Experimental|Pfizer-BioNTech Fractional dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044291|NCT05387317|Experimental|AstraZeneca Standard dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044292|NCT05387317|Experimental|AstraZeneca Fractional dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044293|NCT05387317|Experimental|Moderna Standard Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044294|NCT05387317|Experimental|Moderna Fractional Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
33044295|NCT05387317|Experimental|Pfizer-BioNTech Standard dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044296|NCT05387317|Experimental|Pfizer-BioNTech Fractional dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044297|NCT05387317|Experimental|AstraZeneca Standard dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044298|NCT05387317|Experimental|AstraZeneca Fractional dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044299|NCT05387317|Experimental|Moderna Standard Dose after AstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044300|NCT05387317|Experimental|Moderna Fractional Dose afterAstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
33044301|NCT05383417|Experimental|EndoClip|Clip applied to endotracheal tube.
33044302|NCT05383417|No Intervention|No Clip|No clip applied to endotracheal tube.
33044303|NCT05374915|Experimental|REM-001 photodynamic therapy (PDT)|Single arm study. All enrolled patients receive REM-001 therapy
33418280|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
33418281|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
33044304|NCT05349838|Experimental|DTG/RPV FDC Regimen|One combined Dolutegravir 50mg /Rilpivirine 25mg FDC tablet taken orally once daily
33044305|NCT05349838|Active Comparator|Continued ART Regimen|Patients will continue the current boosted PI regimen (or other antiretroviral combination) for 48 weeks. Patients will then be switched to one combined Dolutegravir/Rilpivirine FDC tablet taken orally once daily for 48 weeks.
33044306|NCT05346289||Women|
33044307|NCT05346289||Men|
33044308|NCT05314816|Experimental|Blood culture identification panel|BioFire BCID2 (Blood culture identification panel) will be performed on positive blood culture specimens.
33044309|NCT05314816|No Intervention|Concurrent control|Standard blood culture process will be performed concurrently on select positive blood culture specimens during the study period. BCID2 will NOT be performed on these specimens.
33044310|NCT05314816|No Intervention|Retrospective control|Standard blood culture process was performed prior to the study period.
33044311|NCT05313763|Experimental|Conventional physical therapy group|Conventional physical therapy is the first line of treatment in cervical spondylosis.
33044312|NCT05313763|Active Comparator|Kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Kinesio-tape applications will be applied in 6 sessions during conventional physical therapy, twice a week at four-day intervals.
33044313|NCT05313763|Sham Comparator|Sham kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Sham kinesio-tape applications will be applied twice a week at four-day intervals, 6 sessions during conventional physical therapy.
33044314|NCT05312008|Experimental|Clamp|Clamped alcohol exposure, repeated tests of subjective and cognitive effects of alcohol, 2 sessions (intranasal oxytocin or placebo), double blind
33044315|NCT05312008|Experimental|Progressive work for alcohol|Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind
33044316|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
33044317|NCT03164980|Experimental|Arm B|"Carboplatin/PLD~Carboplatin/Gemcitabine~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
33044318|NCT05305456|Experimental|Tanreqing capsule|3 capsules per time, 3 times a day，7 days of treatment
33044319|NCT05305456|Placebo Comparator|Tanreqing capsule simulator|3 capsules per time, 3 times a day，7 days of treatment
33044320|NCT05278234|Experimental|Intervention arm|Participants will engage in a 7-week multicomponent chronic pain self-management program.
33044321|NCT05278234|No Intervention|Usual care control arm|After completing the 12 month telephone survey, control group participants will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a workshop that provides key intervention content and individualized goal-setting guidance.
33044322|NCT05260918|Active Comparator|Flotation-REST|Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event the participant needs assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks.
33044323|NCT05260918|Placebo Comparator|Nappod|Participants in this arm will be asked to lie comfortably in a special recliner called a Metro Nappod for the duration of a 60 minute session twice a week for 3 weeks. The chair is located in a quiet and dimly lit room to minimize interruptions. The pod is equipped with a privacy visor, built-in speaker, and a timer with an alarm.
33044324|NCT05254795|No Intervention|Usual care recipients|
33044325|NCT05254795|Experimental|Molecular tumor board intervention|
33044326|NCT05247658|Active Comparator|Therapeutic lens alone|
33044327|NCT05247658|Experimental|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|
32740873|NCT04562129|Experimental|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg during week one of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on during week one of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
32740874|NCT04447911|Experimental|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
32740875|NCT04447911|Placebo Comparator|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
33044328|NCT05241379|Experimental|Amber UI Therapy|Participants will undergo surgical implantation of the Amber UI System incorporating 2 electrode leads connected to a single IPG
33044329|NCT00388986|Experimental|1|
33044330|NCT00388986|Experimental|2|
33044331|NCT00388986|Experimental|3|
33044332|NCT05234203|Experimental|HTB Rejuvenate|4 capsules of study interventional supplement delivered as 2 capsules two times a day for 90 days.
33044333|NCT05233696|Experimental|RT followed by nab-paclitaxel/paclitaxel plus pembrolizumab|Nab-paclitaxel/paclitaxel plus pembrolizumab will be started within 7 days of completion of RT.
33044334|NCT05223673|Experimental|Futuximab/modotuximab combined with trifluridine/tipiracil (Safety Lead-In and Phase III parts)|
33044335|NCT05223673|Active Comparator|Trifluridine/tipiracil (Phase III part)|
33044336|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in left ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the left ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
33044337|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in right ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the right ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
33044338|NCT05212363|Experimental|Calf Compression|Subjects will wear calf compression garments while video gaming for 2 hours. All subjects will undergo blood flow assessments before and after wearing lower leg graduated compression gear during their gaming session (i.e. compression during uninterrupted sitting).
33044339|NCT05212363|Experimental|6- minute Walk|Subjects will game for 2 hours sitting and take a 6 minute walking break at the one hour period before resuming game play. All subjects will undergo blood flow assessments before and after taking an active break (i.e. 6-minute walk) during their gaming session.
33044340|NCT05212363|No Intervention|Continuous video game play|Subjects will game for 2 hours sitting with no break. All subjects will undergo blood flow assessments without wearing lower leg graduated compression gear or taking an active break during their gaming session (i.e. during uninterrupted sitting).
32869400|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
33330868|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
32869401|NCT05168475|Active Comparator|Rituximab|
32869402|NCT05168475|Active Comparator|Infliximab|
33044341|NCT05199805|Experimental|Mindfulness-based pain management|The program consists of sessions of 150 minutes once a week over the course of 8 weeks. Treatment as usual is allowed.
33044342|NCT05199805|No Intervention|Waiting-List|The control group will receive no active intervention in addition to treatment as usual during the study period.
33044343|NCT05198713|Experimental|Experimental|All participants will be fit with the study hearing aid and under go the same testing conditions.
33044344|NCT05192590|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the CDMT test results.
33044345|NCT05192590|Experimental|Educational Materials and CDMT Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
33044346|NCT05192590|Experimental|Educational Materials and CDMT Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
33044347|NCT05185492||Cardiogenic shock cohort|Primary diagnosis of Cardiogenic Shock at the time of index evaluation. The clinical and hemodynamic criteria used to diagnose Cardiogenic Shock will be those as defined in the Society for Cardiovascular Angiography and Interventions clinical expert consensus statement on the classification of cardiogenic shock.
33044348|NCT05183152|Experimental|NMES-BCI|Sensory-threshold electrical stimulation is delivered to the flexors/extensors of the forearm contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
33044349|NCT05183152|Active Comparator|Visual-BCI|Bar-based visual feedback is provided on a screen contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
33044350|NCT05174299|Experimental|double active magnetic stimulation|the multi-target magnetic stimulation on motor cortex combined with spinal cord
33044351|NCT05174299|Active Comparator|single active magnetic stimulation|the active magnetic stimulation on motor cortex and sham stimulation on spinal cord
33044352|NCT05174299|Sham Comparator|double sham magnetic stimulation|the sham magnetic stimulation on motor cortex and sham stimulation on spinal cord
33044353|NCT05168020|Experimental|Safety Behavior Fading|"Participants will be asked to identify their five most common SBs from the SAFE. Participants will then be shown a sample checklist with instructions to fill it out. For the next 14 days, participants will receive the following text message Please remember to avoid using SBs you selected. As you drop them, you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each SB over the past 24 hours"
33044354|NCT05168020|Active Comparator|Unhealthy Behavior Fading|"Participants will be asked to pick five unhealthy behaviors they engage in most often to decrease. Participants will then be shown the same sample checklist as the Safety Behavior Fading Group. For the next 14 days participants will receive the following text message Please try to remember to decrease your unhealthy behaviors. As you decrease them you will feel better, and you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each Unhealthy Behavior over the past 24 hours."
33044355|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
33044356|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
33044357|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
33044358|NCT05162170||Primary Mediastinal large B-Cell Lymphoma (PMBCL)|The present study consists of a retrospective multicenter collection of series of consecutive patients diagnosed with PMBCL over the relevant time period (13 years, from 2007 to 2019 included).
33044359|NCT05158894||Ubrelvy-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
33044360|NCT05158894||Unexposed Women With Migraine|Pregnant women with migraine (treated and untreated) who have never taken Ubrelvy (i.e., before or during the enrolled pregnancy) or who have discontinued Ubrelvy at least 3 months prior to the first day of last menstrual period (LMP).
33044361|NCT05157607|Experimental|Family Connections Protocol for Relatives of Patients with SBD.|"The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:~Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).~Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.~Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.~Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management."
33330869|NCT03767556|No Intervention|Control|This group will not receive intervention
32869403|NCT05168475|Active Comparator|Tocilizumab|
33044362|NCT05157607|Active Comparator|Treatment as Usual Optimized Protocol (TAU-O).|"Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:~Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity."
33044363|NCT05148013|Experimental|Pilates exercise group|Pilates exercise group will receive a total of 20 sessions of 30 minute Pilates exercises 5 days a week which will be performed under the supervision of a physiotherapist.
33044364|NCT05148013|Experimental|PNF exercise group|A total of 20 sessions of PNF exercises for 30 minutes, 5 days a week, will be performed individually with a physiotherapist.
33044365|NCT05146219|Experimental|TY-9591 Tablets|TY-9591 Tablets 160mg/d
33044366|NCT00389935|Experimental|Treatment|
33044367|NCT05129527|Experimental|InspirerMundi app plus usual care|Patients, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management.
33044368|NCT05129527|Active Comparator|Usual care|Patients in the control group will maintain usual care during the study.
33044369|NCT05119777|Experimental|HArmonyCa Injectable Gel|HArmonyCa injected at the discretion of the Treating Investigator (TI) to the midface for initial treatment and an optional touch-up treatment 14 days later
33044370|NCT05116930|Experimental|Postpartum dural puncture headache following dural puncture from Tuohy needle|Subjects identified as experienced a post dural puncture headache after a confirmed dural puncture from a Tuohy needle will receive an IV administration of the study medications neostigmine and atropine
33044371|NCT05112484||Gilenya|Gilenya (fingolimod) - first registration 17 March 2011, last renewal 16 November 2020, selective immunosuppressant (ATC code L04AA27), sphingosine-1-phosphate receptor modulator
33044372|NCT05112484||Tecfidera|Tecfidera (dimethyl fumarate) - first registration 30 January 2014, last renewal 20 September 2018, cytostatic and immunomodulatory drug (ATC code L04AX07), an activator of the transcription pathway of nuclear factor Nrf2
33044373|NCT05112484||Mavenclad|Mavenclad (cladribine) - first registration 22/08/2017, selective immunosuppressant (ATC code L04AA40), nucleoside analogue of deoxyadenosine
33044374|NCT05112484||Aubagio|Aubagio (teriflunomide) - first registration on 26 August 2013, last renewal on 28 May 2018, selective immunosuppressant (ATC code L04AA31), an inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase
33044375|NCT05104450|Experimental|lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention in addition to usual care.
33044376|NCT05104450|No Intervention|usual care control|Participants in this arm will continue with usual care without the lifestyle intervention.
33044377|NCT05100316|Other|Participants with solid tumors and hematological malignancies|Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.
33044378|NCT05094388||Critically ill patients|Patients admitted to intensive care units
33044379|NCT05090800|Experimental|Definity contrast agent|
33044380|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
33044381|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
33044382|NCT05054608||COVID-19 ICU cohort|All patients, 18 to 63 years old, admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
33044383|NCT05054608||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
33044384|NCT05054608||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
33044385|NCT05049616|Experimental|Hctz/Lisinopril|Hctz/Lisinopril for postpartum management of hypertension. either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)
33044386|NCT05049616|Active Comparator|Extended release nifedipine|calcium channel blocker (Nifedipine
33044387|NCT05041699|Experimental|IPM Ring-105|Ring-105 (xx mg dapivirine + xxx mg levonorgestrel)
33044388|NCT05041699|Active Comparator|IPM Ring-106.|Ring-106 (xx mg dapivirine + xxx mg levonorgestrel)
33044389|NCT05039359|Active Comparator|FlecIH-103 (flecainide acetate inhalation solution)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
33044390|NCT05039359|Placebo Comparator|Vehicle-matched inhalation solution (placebo)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.
33044391|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
33044392|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
33044393|NCT05020483|Experimental|FEIBA Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive activated prothrombin complex concentrate (aPCC) FEIBA to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
33044394|NCT05020483|Placebo Comparator|Placebo Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive a placebo to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
33044395|NCT05019430|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
33330870|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
33330871|NCT03767478|Sham Comparator|Control group|Best Medical Therapy + Sham Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
33109481|NCT05134974|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
33109482|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
33109483|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
33109484|NCT05099211|Experimental|Patients muscle strengthening|
33109485|NCT05099211|Experimental|Aerobic Training Patients|
33109486|NCT05099211|Active Comparator|Healthy patients|
33109487|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
33109488|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
33109489|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
33330872|NCT03767478|Active Comparator|Intervention group|Best Medical Therapy + Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
33330873|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
33109490|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
33109491|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
33109492|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
32869404|NCT05168475|Placebo Comparator|Placebo|Placebo may be to one of the active biologics (ie placebo to Rituximab, Placebo to Infliximab, placebo to Tocilizumab). Only 1 placebo is in a randomised sequence of interventions.
32869405|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
33109493|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
33109494|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
33109495|NCT05097027|Experimental|Blood flow restriction recovery (Experimental I)|Active recovery program with blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
32869406|NCT00241969|Experimental|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
33109496|NCT05097027|Experimental|Non-Blood flow restriction recovery (Experimental II)|Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
33109497|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
33109498|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
33109499|NCT04679220|Active Comparator|Non-heated Resin Composite group|Patients received Non-heated nanofilled resin composite on one side of the mouth
33109500|NCT04679220|Placebo Comparator|Preheated Resin Composite group|Patients received preheated nanofilled resin composite on the other side of the mouth
33109501|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
33109502|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
33109503|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
33109504|NCT04679142||Adult patients starting a treatment with Baclocur®|Baclofen(Baclocur®) 10mg, 20mg, 30mg, 40mg.
33109505|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
33109506|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
33418282|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
33418283|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
33418284|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
33418285|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
33418286|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
32869407|NCT00241969|Active Comparator|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
33109507|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
33109508|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
33109509|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
33109510|NCT05064813|Experimental|Mindfulness Based Stress Reduction Group|8 weeks of Mindfulness Based Stress Reduction Group (MBSR).
33109511|NCT05064813|Active Comparator|Stress Education Group|8 weeks of Stress Education Group (SE).
33109512|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
33109513|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
33109514|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
33109515|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
33109516|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
33109517|NCT02928458|Active Comparator|Omnipaque|Arm 1
33109518|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
33109519|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
33109520|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
33109521|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
32869408|NCT05709951|Active Comparator|Functional exercises|Piriformis stretching Cobra pose Sit up Bridging exercise
33109522|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
33109523|NCT05052918|Active Comparator|Exercise|"Patients with prediabetes undergoing a 12-week exercise program~(1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks)"
33109524|NCT05052918|No Intervention|Control|Patients with prediabetes with no intervention
33109525|NCT05052918|No Intervention|Metformin|Patients with prediabetes using metformin
33109526|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
33109527|NCT02928302|No Intervention|no screening|no TVU CL screening
33109528|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
33109529|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
33109530|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
33109531|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
33044396|NCT05019430|Experimental|Zolmitriptan Dose 1|Subjects will be maintained on oral zolmitriptan dose 1. Cocaine will be administered acutely during zolmitriptan dose 1 maintenance. Placebo will be administered acutely during zolmitriptan dose 1 maintenance.
33044397|NCT05019430|Experimental|Zolmitriptan Dose 2|Subjects will be maintained on oral zolmitriptan dose 2. Cocaine will be administered acutely during zolmitriptan dose 2 maintenance. Placebo will be administered acutely during zolmitriptan dose 2 maintenance.
33330874|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
33330875|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
33330876|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
33330877|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
33330878|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
32869409|NCT05709951|Active Comparator|Core Stability Exercises|Pelvic bridging Plank Cat and camel Curl up
33044398|NCT05019430|Experimental|Zolmitriptan Dose 3|Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.
33044399|NCT05018143|Experimental|STARS|The investigators will deliver an online intervention focused on safety planning (STARS). The intervention content includes life skills interactive modules across 14 domains, a goal tracker, referral to community resources, and scheduling of peer mentoring sessions.
33044400|NCT05018143|Active Comparator|Control Condition|The investigators will deliver an in-person therapeutic session where participants can develop an individualized safety plan for use during a suicidal crisis, focusing on adaptive coping, addressing barriers or ambivalence, and strengthening their self-efficacy.
33044401|NCT05011552|Experimental|The intervention group|
33044402|NCT05011552|Placebo Comparator|The control group|
33044403|NCT05000203|Experimental|Specific intervention for fear of childbirth|"Online education intervention Participants randomly assigned to the experimental group will be informed by telephone call of their inclusion in the first phase of the trial.~Participants in the intervention group will be encouraged to attend routine consultations with their midwife and obstetrician, as well as to take advantage of the group maternal education that participants usually develop in their health center.~Specific intranatal support~An experimental group will be carried out with a specific support intervention in the obstetric-gynecological emergency area that will supplement the one usually provided to all pregnant women.~At the end of the participant's stay within the emergency area due to hospital discharge, admission to the ward, or the end of the pregnancy, the collaborating midwife will fill out an online form designed to monitor the care offered. Said form will also be completed at the end of the work shift if the participant's care continues."
33044404|NCT05000203|Active Comparator|Routine intervention for fear of childbirth|"Usual care~Participants randomly assigned to the control group will be informed by telephone call of their inclusion in the first phase of the trial. The process under study will be explained in detail, resolving any doubts at that time.~Regular intranatal support~The participants in the control group will not be identified as pregnant women with fear of childbirth, and will receive the usual care in the obstetric-gynecological emergency area."
33044405|NCT04997434|Experimental|Intervention|After 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. The patient will have 15 to 20 minutes to carry out an artistic activity, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session.
33044406|NCT04997434|No Intervention|Control|The questionnaires and VAS will be offered to the control group at the beginning of the wait, then after 30 minutes of waiting under usual conditions.
33044407|NCT04997044|Other|control group|control group
33044408|NCT04997044|Experimental|Experimental group|selective dorsal rhizotomy group
33044409|NCT04992247|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
33044410|NCT04992247|Placebo Comparator|Placebo|Excipient
33044411|NCT04991506|Experimental|Part 1 ES102 Escalation in combination with JS001|ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
33044412|NCT04991506|Experimental|Part 2 ES102 Expansion in combination with JS001|Subjects will be treated with ES102 at the RP2D in combination with JS001.
33044413|NCT04976257|Experimental|Ga-PSMA-11, PET/CT, Angiogram, and Prostatic Arterial Catheterization|Patients receive 68Ga-PSMA-11 IV over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after on day 1. One to 14 days later, patients undergo pelvic angiogram and prostatic arterial catheterization. Patients then receive 68Ga-PSMA-11 IA over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after.
33044414|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
33044415|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
33044416|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
33330879|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
33330880|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
33418287|NCT02820753|No Intervention|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
33418288|NCT02820753|Active Comparator|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
33418289|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
33418290|NCT02093858||olanzapine|15-25mg/day for 24 weeks
33418291|NCT05218161|Active Comparator|DA|Group DA: will be assigned to patients in whom dexmedetomidine alone will be used.
33044417|NCT04935814|Experimental|Continuous vasopressin infusion|After general anesthesia, patients will receive a continuous infusion of vasopressin in order to improve mean arterial pressure by 20 mmHg.
33044418|NCT04931758||Patients with low back pain|
33044419|NCT04931758||Controls|
33044420|NCT04921969|Experimental|Ruxolitinib (1.5% Cream)|Study drug will be administered twice daiily.
33044421|NCT04921969|Experimental|Ruxolitinib (0.75% cream)|Study drug will be administered twice daily.
33044422|NCT04921969|Placebo Comparator|Vehicle Cream|Vehicle cream will be administered twice daily.
33044423|NCT04914403|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
33044424|NCT04910074|Experimental|Low-level therapy intervention|Patients will receive low-level laser therapy on the skin overlying the mandible for 40 seconds per side. All other post-operative care will be as per clinic routine.
33044425|NCT04910074|Placebo Comparator|dummy intervention|Patients will receive no dose of laser, but the handpiece will be used against their skin top mimic the LLLT. All other post-operative care will be as per clinic routine.
33044426|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
33044427|NCT04888858|Experimental|Epidural Analgesia|All subjects will be given epidural analgesia to treat their labor pain. As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
33044428|NCT04870957|Experimental|MBSR (mindfulness-based stress reduction)|Run-in treatment then MBSR.
33044429|NCT04870957|Experimental|PT and exercise|Run-in treatment then PT and exercise
33044430|NCT04870957|Experimental|Acupressure|Run-in treatment then Acupressure
33044431|NCT04870957|Experimental|Duloxetine|Run-in treatment then Duloxetine
33044432|NCT04870957|Experimental|MBSR then PT and exercise|Run-in treatment then 8 weeks of MBSR, and then 8 weeks of PT and exercise.
33044433|NCT04870957|Experimental|MBSR then Acupressure|Run-in treatment, then 8 weeks of MBSR, and then 8 weeks Acupressure.
33044434|NCT04870957|Experimental|MBSR then Duloxetine|Run-in treatment, then 8 weeks of MBSR, and then approximately 8 weeks of Duloxetine
33044435|NCT04870957|Experimental|PT and exercise then MBSR|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of MBSR.
33044436|NCT04870957|Experimental|PT and exercise then Acupressure|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of Acupressure
33044437|NCT04870957|Experimental|PT and exercise then Duloxetine|Run-in treatment, then 8 weeks of PT and exercise, and then approximately 8 weeks of Duloxetine
33044438|NCT04870957|Experimental|Acupressure then MBSR|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of MBSR
33044439|NCT04870957|Experimental|Acupressure then PT and exercise|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of PT and exercise.
33044440|NCT04870957|Experimental|Acupressure then Duloxetine|Run-in treatment, then 8 weeks of Acupressure, and then approximately 8 weeks of Duloxetine
33044441|NCT04870957|Experimental|Duloxetine then MBSR|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of MBSR.
33044442|NCT04870957|Experimental|Duloxetine then PT and exercise|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of PT and exercise
33044443|NCT04870957|Experimental|Duloxetine then Acupressure|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks Acupressure.
33044444|NCT04870957|Experimental|PainGuide|Run-in treatment only with no additional treatments.
33044445|NCT04862221|Experimental|High-dose methylprednisolone|Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
33044446|NCT04862221|Experimental|Equine anti-thymocyte globulin|Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
33044447|NCT04862221|Placebo Comparator|Supportive care|Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
33044448|NCT04846504|Active Comparator|MMBFM program with clinician coach support|Telephonic coaching provided by licensed mental health professionals to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
33044449|NCT04846504|Active Comparator|MMBFM program with peer coach support|Telephonic coaching provided by trained peers with lived experience of perinatal depression to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
33109532|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
33109533|NCT05048433|Experimental|implementation strategy for active learning to promote physical activity|
33330881|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
33044450|NCT04846504|Active Comparator|Patient facing strategy intervention arm|Centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text, without direct involvement of OB providers.
33044451|NCT04846504|Active Comparator|Patient facing plus clinic facing strategy intervention arm|OB clinic providers' use of printed recruitment materials and/or electronic medical records prompts to recommend/refer women receiving prenatal care to access the MMBFM program. These clinic facing implementation strategies will be added to the patient facing strategies of centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text
33330882|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
33330883|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
33330884|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
33330885|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
33330886|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
33330887|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
33330888|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
33330889|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
33044452|NCT04842253|Experimental|High flow nasal cannula|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
33044453|NCT04842253|No Intervention|Low flow nasal cannula|Participants in the current standard of care will receive low flow nasal cannula during deep sedation.
33044454|NCT04841629|Experimental|PreBioGyn Gel|Topical administration to forearm
33044455|NCT04841629|Active Comparator|Trimosan Gel|Topical administration to forearm
33044456|NCT04841629|Active Comparator|RepHresh Gel|Topical administration to forearm
33044457|NCT04833283|Experimental|the intervention group intermittent hypoxic-hyperoxic training|"the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)~Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s)."
33044458|NCT04833283|Placebo Comparator|the control group|intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask
33044459|NCT04826068|Experimental|Emotional Processing|The intervention looks at emotional processing of face interpretation.
33044460|NCT04826068|Placebo Comparator|Control intervention|The control group is seeing the same faces and are asked questions regarding them.
33044461|NCT04820335|Experimental|Immediate Treatment Group|Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
33044462|NCT04820335|No Intervention|Delayed Treatment Control|Participants will not receive the intervention immediately. After 8 weeks, participants in this arm will complete the SEMAT. This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
33044463|NCT04806685|Experimental|Intervention|Diet therapy plus sleep education
33044464|NCT04806685|Other|Control|Diet therapy
33044465|NCT04802746|Experimental|Sequence ABC in Part A|Study participants randomized to this arm will receive Staccato Placebo (A) and two fixed doses of Staccato alprazolam Dose 1 (B) and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
33044466|NCT04802746|Experimental|Sequence BCA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato alprazolam Dose 2 (C), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
33044467|NCT04802746|Experimental|Sequence CAB in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato Placebo (A), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
33044468|NCT04802746|Experimental|Sequence ACB in Part A|Study participants randomized to this arm will receive Staccato Placebo (A), Staccato alprazolam Dose 2 (C), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
33044469|NCT04802746|Experimental|Sequence BAC in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato Placebo (A), and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
33418292|NCT05218161|Experimental|KD|Group KD: will be assigned to patients receiving ketamine plus dexmedetomidine.
33109534|NCT05048433|Active Comparator|Usual Implementation support|
33109535|NCT04276415|Experimental|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
33109536|NCT04276415|Experimental|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
33109537|NCT04276415|Experimental|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
33109538|NCT05046249||Chiropractic clinicians|Swiss chiropractic clinicians
33109539|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
33109540|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
33330890|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
33330891|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
33109541|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
33109542|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
33109543|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
33109544|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
33109545|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
33109546|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
33109547|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
33109548|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
33109549|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
33109550|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
33109551|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
33109552|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
33109553|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
33109554|NCT03358797|Experimental|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
33109555|NCT03358797|Experimental|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
33109556|NCT03358797|Experimental|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
33109557|NCT03358797|Experimental|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
33109558|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
33109559|NCT05046132|Experimental|Group 1: Setmelanotide 7 mg|SC setmelanotide 7 mg; oral placebo on Days 10 and 16
33109560|NCT05046132|Active Comparator|Group 2: Active placebo (Day 10)|SC placebo; oral moxifloxacin (positive control) on Day 10 and oral placebo on Day 16
33360655|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
33360656|NCT03925051|Experimental|CMAB807|60mg by subcutaneous injection once on the first day.
33360657|NCT03925051|Active Comparator|Prolia®|60mg by subcutaneous injection once on the first day.
32869410|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
33418293|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
33418294|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
32869411|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
32869412|NCT03139305|Active Comparator|Glucagon Low Dose|
32869413|NCT03139305|Active Comparator|Glucagon High Dose|
32869414|NCT03139305|Placebo Comparator|Placebo|
32869415|NCT04878367|Experimental|COPD_E|COPD patients with intervention
32869416|NCT04878367|No Intervention|COPD_C|COPD patients without intervention
33418295|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
32869417|NCT05388617|Experimental|Group A|Subjects in Group A will receive up to 8 treatments with the Brera/Med 400 device on their abdomen or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects will return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments.
32869418|NCT05388617|Experimental|Group B|Subjects in Group B may receive up to 8 treatments with the Brera/Med 400 device on their abdomen and/or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects may be asked return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments. Outcome measures will not be taken for subjects enrolled in this group.
32869419|NCT05163327||Healthy Volunteer|10 Volunteers (Male or Female), aged18 or over, with no known history of Coronary Artery Disease
32869420|NCT05163327||Known Coronary Artery Disease|10 Volunteers (Male orFemale), aged 18 or over,with a known significant (defined as => 70% stenosis) single or 2 vessel Coronary Artery Disease
32869421|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
32869422|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
32869423|NCT01897909||HIV negative|HIV negative blood donors
32869424|NCT00084149|Experimental|Cyclosporin|Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
32869425|NCT00084149|Experimental|No Cyclosporin|The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
32869426|NCT04797247|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
32869427|NCT04797247|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
32869428|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
32869429|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
32869430|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
32869431|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
32869432|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
32869433|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
32869434|NCT02959905|Experimental|medium-dose lymphodepletion regimen|Patients will receive medium-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
32869435|NCT02959905|Experimental|low-dose lymphodepletion regimen|Patients will receive low-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
32869436|NCT02959905|Experimental|No lymphodepletion regimen|Patients will only receive TSA-CTL.
32869437|NCT00134017|Experimental|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
32869438|NCT04783051|Active Comparator|IPTp-SP|The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
32869439|NCT04783051|Experimental|ISTp-US-Py|The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive
33109561|NCT05046132|Active Comparator|Group 3: Active placebo (Day 16)|SC placebo; oral placebo on Day 10 and oral moxifloxacin on Day 16
33330892|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
33109562|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
33109563|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
33109564|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
33109565|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
33109566|NCT05045547||Patients with febrile illness|Febrile patients attending village malaria workers (VMWs)
33109567|NCT05045547||Health centre staffs|Health centre staffs from 12 rural health centres
33109568|NCT05045547||Key stakeholders|"Key stakeholders , for example health managers and health professionals:~the director, deputy-directors, and technical officers at the National Malaria Control Program;~the directors and deputy-directors of the Provincial Health Departments in Battambang and Pailin province;~health officers actively involved in community-based (malaria) programmes at the district levels in Battambang and Pailin provinces;~health workers (i.e., nurses or doctors) actively involved in community-based (malaria) programmes in Battambang and Pailin provinces;~community representatives and village malaria workers from villages in both Battambang Pailin province."
33330893|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
33330894|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
33109569|NCT05036616||Separation technique|
33109570|NCT05036616||Integration technique|
33109571|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
33109572|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
33109573|NCT05005299|Experimental|Dose Level A|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
33109574|NCT05005299|Experimental|Dose Level B|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
33360658|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
33360659|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
33109575|NCT05005299|Experimental|Dose Level C|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
33109576|NCT05005299|Experimental|Dose Level B'|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
33109577|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
33109578|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
33109579|NCT04973436|Experimental|Dialectical Behavioral Therapy Skills Training|The DBT-MLC intervention will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. The DBT-MLC intervention will consist of 8-10 weekly sessions that will last approximately 60 minutes each.
33109580|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
33109581|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
33109582|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
33109583|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
33109584|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
33044470|NCT04802746|Experimental|Sequence CBA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato alprazolam Dose 1 (B), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
33044471|NCT04802746|Experimental|Staccato alprazolam in Part B|Study participants randomized to this arm will receive Staccato alprazolam at pre-specified time points in Part B.
33044472|NCT04802746|Placebo Comparator|Staccato placebo in Part B|Study participants randomized to this arm will receive Staccato placebo at pre-specified time points in Part B.
33044473|NCT04798378|Experimental|Treatment Arm|Participants will received a customized NuroSleeve and undergo 8 weeks of occupational therapy using the NuroSleeve (135 minutes per week for 8 weeks: this can be done as 45 minutes three times per week, 68 minute sessions twice per week, or one 135 minute once per week).
33044476|NCT04782505|Experimental|Cohort 1 (Part 1)|DWJ1248 100mg (100mg 1tab) PO
33044477|NCT04782505|Experimental|Cohort 2 (Part 1)|DWJ1248 200mg (100mg 2tab) PO
33044478|NCT04782505|Experimental|Cohort 3 (Part 1)|DWJ1248 300mg (100mg 3tab) PO
33044479|NCT04782505|Experimental|Group A (Part 2)|DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO
33044480|NCT04782505|Experimental|Group B (Part 2)|DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO
33044481|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
33044482|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
33044483|NCT04770142|Experimental|TIRA|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
33044484|NCT04762225|Experimental|RPTR-168|Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors and melanoma.
33044485|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
33044486|NCT04758988|Other|Group A|This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
33044487|NCT04758988|No Intervention|Group B|"This group is withheld their access to the AI augmented digital online educational system for 2 months.~After the 2 months delay, the subjects in the group are given the same access as the participants in Group A."
33044488|NCT00000588|Experimental|Chronic therapy of PIH according to medical condition|"Half of overall participants will get one of the following doses according to their medical condition:~Reducing the body iron burden to near-normal levels in non- transfusion-dependent patients with iron-loading anemias (requires chelate- induced iron excretion of at least 0.10 to 0.20 mg Fe/kg/day);~Maintaining near-normal body iron stores in transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine (requires chelate-induced iron excretion of at least 0.25 to 0.40 mg Fe/kg/day);~Reducing the body iron burden to near-normal levels in iron-loaded, transfusion-dependent patients (requires chelate-induced iron excretion greater than 0.40 mg Fe/kg/day)."
33044489|NCT00000588|Placebo Comparator|Placebo|"Half of the participants will receive a Placebo:~Non-transfusion-dependent patients~Transfusion-dependent patients~Iron-loaded, transfusion-dependent patients"
33044490|NCT04749238|Experimental|Treatment with NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
33044491|NCT04742881|Experimental|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
33044492|NCT04742881|Active Comparator|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
33044493|NCT04732663||Persistently Symptomatic Covid-19 (PS-CoV)|PS-CoV will be defined as individuals with a history of molecular testing confirmed COVID-19 infection, recovered from acute infection but with ongoing symptoms (self-reported, pulmonary, cardiac, musculoskeletal or other symptoms) of at least 4 weeks' duration. Recovery from acute infection will be defined according to provincial health guidelines: at least 10 days' (14 in those hospitalized; 21 in those with immunocompromise) from onset of symptoms with at least 24 hours without a fever, without taking anti-pyretic medications and improvement of other symptoms.
33044494|NCT04732663||Recovered Covid-19|Recovered Covid-19 Survivors will be defined as individuals without complaint of a persisting covid-19 symptom. Recovered Covid-19 survivors will be matched to PS-CoV for age, sex, body mass index and time post corona virus infection.
33044495|NCT04732663||Control|Covid Naïve Controls will be defined as individuals who have no known history of covid-19. Control participants will be matched to PS-CoV for age, sex and body mass index.
33044496|NCT04713514|No Intervention|Arm A : Best Supportive Care|Observational arm (Standard of care)
33044497|NCT04713514|Experimental|Arm B : OSE2101|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.~OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion."
33044498|NCT04713514|Experimental|Arm C : OSE2101 + Pembrolizumab|OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
33067876|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
33044499|NCT04709419|Experimental|Celliant Sock|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction. Celliant® fibers are comprised of a proprietary blend of infrared (IR) emitting ceramic materials mixed with polyethylene terephthalate (PET). The proprietary blend consists of the following components: alumina oxide; silicon dioxide; and titanium dioxide. The Celliant fibers are woven or knitted into yarn and used to manufacture the Celliant Sock. The Celliant Sock content will be 82% Celliant polyester, 13% Nylon and 5% Spandex. Celliant fibers absorb energy (heat) generated by the wearer's body by radiation, convection and conduction, and also from the environment, and re emit the energy as infrared radiation back into the wearer's body."
33044500|NCT04709419|Sham Comparator|Control Sock|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
33044501|NCT04709224|Experimental|Cohort 1: LAI Lumateperone 50 mg SC in the abdomen|
33044502|NCT04709224|Experimental|Cohort 2: LAI Lumateperone 100 mg SC in the abdomen|
33044503|NCT04709224|Experimental|Cohort 3: LAI Lumateperone 200 mg SC in the abdomen|
33044504|NCT04709224|Experimental|Cohort 4: LAI Lumateperone 100 or 200 mg SC in the outer area of the upper arm|
33044505|NCT04688242|Experimental|Treatment Arm|Anal dilatation plus probiotics per anus Q3D, starting from 2 weeks after proctectomy until reduction of ileostomy.
33044506|NCT04688242|No Intervention|Control Arm|No anal dilatation or probiotics per anus was allowed, from 2 weeks after proctectomy until reduction of ileostomy.
33044507|NCT04677400|Experimental|Experimental Group|Participants in the Experimental group start the MBA intervention immediately (Time 0; T0).
33044508|NCT04677400|Active Comparator|Waiting-list group|Participants in the waiting-list group start the MBA intervention at Time 1 (T1; 15 days after the Experimental group).
33330895|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
33330896|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
33330897|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
33360660|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies
33044509|NCT04663828|Other|Structured counseling|Patients will receive a structured counseling therapy
33044510|NCT04663828|Other|Hearing Aids|Patients will receive hearing aids support
33044511|NCT04663828|Other|Cognitive behavioral therapy|Patients will receive cognitive behavioral therapy
33044512|NCT04663828|Other|Sound therapy|Patients will follow a sound therapy program
33044513|NCT04663828|Other|Combination of sound therapy and cognitive behavioral therapy|Patients will receive a combination of sound therapy and cognitive behavioral therapy
33044514|NCT04663828|Other|Combination of hearing aids and cognitive behavioral therapy|Patients will receive a combination of hearing aids and cognitive behavioral therapy
33044515|NCT04663828|Other|Combination of hearing aids and structured counseling|Patients will receive a combination of hearing aids and structured counseling
33044516|NCT04663828|Other|Combination of structured counseling and sound therapy|Patients will receive a combination of structured counseling and sound therapy
33044517|NCT04663828|Other|Combination of hearing aids and sound therapy|Patients will receive a combination of hearing and sound therapy
33044518|NCT04663828|Other|Combination of cognitive behavioral therapy and sound therapy|Patients will receive a combination of cognitive behavioral therapy and sound therapy
33044519|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
33044520|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
33044521|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
33044522|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
33044523|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
33044524|NCT04650880|Active Comparator|Vitamin D|Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
33044525|NCT04650880|Placebo Comparator|Placebo|Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
33044526|NCT04601077|Active Comparator|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
33044527|NCT04601077|Placebo Comparator|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
33044528|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
33044529|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
33330898|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
33330899|NCT03766932||Blood culture candida positive group|
33330900|NCT03766932||Tracheal aspiration candida culture positive group|
33044530|NCT04557124|Experimental|USS|social cognitive training
33044531|NCT04557124|Active Comparator|MovingForward|problem solving training
33044532|NCT04547530|Active Comparator|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
33044533|NCT04547530|Placebo Comparator|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
33044534|NCT04544683|Other|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
33044535|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
33044536|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
33044537|NCT04535986|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
33044538|NCT04535986|Placebo Comparator|Arm 2|Placebo Nebulized BID
33044539|NCT04535011|No Intervention|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
33044540|NCT04535011|Experimental|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
33044541|NCT04535011|Experimental|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
33044542|NCT04535011|Experimental|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of… [being a better husband].)"
33044543|NCT04531696|Other|Standard|"UPTIDER consists of 8 substudies:~Pilot phase~Invasive Lobular Carcinoma (ILC) substudy~Inflammatory Breast Cancer (IBC) substudy~Molecular heterogeneity and treatment response substudy~Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy~Metabolomics substudy~Liquid biopsy substudy~Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
33044544|NCT04517500|Experimental|Home-base pulmonary rehabilitation with mindful breathing modu|Subjects will complete in a home-based pulmonary rehabilitation program and in addition will complete a mindful breathing practice using a module on a computer tablet.
33044545|NCT04517500|Active Comparator|Home-base pulmonary rehabilitation|Subjects will complete 12 week home-based pulmonary rehabilitation with health coaching
33044546|NCT04511494|Active Comparator|OIT peanut|"Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.~n=50 patients"
33044547|NCT04511494|No Intervention|Peanut avoidance|"Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.~n=25 patients"
33044548|NCT04511494|No Intervention|Healthy controls|"Control Group with non-allergic, age-matched children. No challenges are performed in this group.~n=30 patients"
33044549|NCT04511494|No Intervention|Children not reacting at the baseline peanut challenge|"Peanut-allergic children not reacting at the baseline peanut challenge, will not be eligible for randomisation. They will have a clinical visit after 1+3 years. No more challenges in this group.~n=X patients"
33044550|NCT04509700|Experimental|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
33044551|NCT04509700|Experimental|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
33044552|NCT04509700|Experimental|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
33044553|NCT04509700|Experimental|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
33044554|NCT04495504|Experimental|Ropivacaine group|Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.
33044555|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
32869440|NCT00084383|Experimental|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
32869441|NCT04765813|Experimental|CBT and active smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
32869442|NCT04765813|Active Comparator|CBT and control smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with a control App
32869443|NCT00243061|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32869444|NCT00139399|Active Comparator|Saphenous vein|Saphenous vein aortocoronary bypass graft
32869445|NCT00139399|Experimental|Radial artery|Radial artery aortocoronary bypass graft
32869446|NCT00245557|No Intervention|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
32869447|NCT00245557|Experimental|Depressed|Depressed subjects receive experimental drug
32869448|NCT00245635|Experimental|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
32869449|NCT00245635|Placebo Comparator|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
32869450|NCT00141115|Experimental|Levetiracetam|Levetiracetam 1500 mg BID
32869451|NCT00249379|Experimental|Acamprosate|Subjects randomized to receive acamprosate
32869452|NCT00249379|No Intervention|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
32869453|NCT00141739|Experimental|GVHD prophylaxis|GVHD prophylaxis with etanercept
32869454|NCT00142597|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
32869455|NCT00142597|Sham Comparator|Sham Treatment|Sham acupuncture is used.
32869456|NCT00143845|Experimental|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
32869457|NCT00086957|Experimental|ZD1839, Trastuzumab and Docetaxel|
32869458|NCT00144391|Experimental|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
32869459|NCT00144391|Placebo Comparator|Placebo|Placebo 2 pumps per day for 6 months
33330901|NCT03766932||Urine candida culture positive group|
33330902|NCT03766932||Other aseptic humoral candida positive group|
33330903|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
33330904|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
33330905|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
33330906|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
33330907|NCT03766776|Experimental|Anlotinib Arm|
33330908|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
33330909|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
33330910|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
33330911|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
33330912|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
33330913|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
33330914|NCT01561794|Experimental|Ciprofloxacin|
32869460|NCT00145249|Active Comparator|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
33044556|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
33044557|NCT04466956|Active Comparator|Virtual reality for reduction of pain and anxiety during MVA|25 participants randomised to use VR headset during MVA and complete questionnaire and short interview regarding experience
33044558|NCT04466956|No Intervention|Control group- no VR|25 participants randomised to not use VR headset during MVA and complete questionnaire and short interview regarding experience
33044559|NCT00389103|Placebo Comparator|placebo|
33044560|NCT04438447|Experimental|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
33044561|NCT04438447|Active Comparator|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
33044562|NCT04437667|Experimental|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
33044563|NCT04437667|Active Comparator|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
33044564|NCT04396288|Experimental|Healthy volunteers|
33044565|NCT04384003|Active Comparator|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
33044566|NCT04384003|Active Comparator|The 3-D Motion Analysis|An optoelectronic-based 3D motion analysis system, including cameras, force plates, and an EMG system will be used in this study. A lower limb model (pelvis included) will be established through commercial motion analysis software (VICON Corp, UK). We will use this model to measure joint kinematics, joint kinetics, and ground reaction forces during functional activities, such as level walking.
33044567|NCT04384003|Active Comparator|EMG acquisition system|Electromyographic signals measures will be focused on the Abductor Hallucis (AbdH), Peroneus Longus (PL) and Previous Brevis (PB), Gluteus Medius (Glut Med), and Gluteus Maximus (Glut Max). In order to reduce the cross-talk of other muscles in the foot, a miniature wireless surface EMG sensor (TrignoTM Mini Sensor, Delsys Inc. USA) will be used after confirmation of our previous research results.
33044568|NCT04384003|Active Comparator|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor & server, 2 optical rulers, 2 rail scale, and 7 load cells.~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
33044569|NCT04382677|Experimental|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
33044570|NCT04382677|Other|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
33044571|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
33044572|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
33044573|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
33044574|NCT04350073||COVID-19 ICU Patients|COVID-10 patients with respiratory failure admitted to the ICU
33044575|NCT04350073||ICU Patients (Control)|Non-COVID-19 respiratory failure patients requiring mechanical ventilation > 48 h receiving similar ICU standards of care at Duke
33044576|NCT04331353|Active Comparator|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
33044577|NCT04331353|Active Comparator|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
33044578|NCT04321954|Experimental|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits~Lenvatinib will be administered orally daily at a predetermined dose for 2, 4, or 6 cycles, dependent on response. 1 cycle is 28 days.~Surgery per standard of care will follow lenvatinib treatment."
33330915|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
33330916|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
33330917|NCT01321398||Critically Ill patients receiving HFO|
33360661|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
33360662|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
33360663|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
33044581|NCT04312672||Follow up cohort|no intervention follow up study
33044582|NCT00390481|Other|Intervention|EC-IC Bypass
33044583|NCT00390481|No Intervention|Control|Best Medical Therapy
33044584|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
33044585|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
33044586|NCT04286269|Experimental|Intervention|Participants in this group will be randomized to receive the intervention.
33044587|NCT04286269|Sham Comparator|Placebo|Participants in this group will be randomized to receive a sham treatment.
33044588|NCT04286191|Experimental|Up-conditioning (UC) Group|
33330918|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
33330919|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
33330920|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
33360664|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
33044589|NCT04286191|Sham Comparator|Control (NC) Group|
33044590|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
33044591|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
33044592|NCT04227106|Experimental|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
33044593|NCT04206007|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
33044594|NCT04205812|Experimental|INCMGA00012 + chemotherapy (nonsquamous NSCLC)|INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.
33044595|NCT04205812|Active Comparator|Placebo + chemotherapy (nonsquamous NSCLC)|Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
33044596|NCT04205812|Experimental|INCMGA00012 + chemotherapy (squamous NSCLC)|INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.
33044597|NCT04205812|Active Comparator|Placebo + chemotherapy (squamous NSCLC)|Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
33044598|NCT04199689|Experimental|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
33044599|NCT04199689|Placebo Comparator|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
33044600|NCT04185415|Experimental|bepranemab|Subjects will be randomized to receive bepranemab.
33044601|NCT04185415|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo.
33044602|NCT04172974|Experimental|Treatment for depression and anxiety|Treatment
33044603|NCT04172974|Other|Usual care|Usual Care
33044604|NCT04169347|Other|Active|This is an open label study single arm
33044605|NCT04154488|Experimental|Mavorixafor|"Part 1: Adult participants and adolescent participants who weigh more than 50 kilograms (kg) will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each), orally once on Day 1. Adolescents weighing less than or equal to 50 kg will receive mavorixafor 200 mg (2 capsules of 100 mg each), orally once on Day 1.~Part 2: Eligible participants from Part 1 will receive once daily dosing of mavorixafor for 6 months."
33044606|NCT04142983|Experimental|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
33044607|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
33044608|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
33044609|NCT04112914|No Intervention|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
33044610|NCT04112914|Experimental|New education|Participants receive the newly developed educational toolkit
33044611|NCT04104139|Experimental|Treatment (TAS-102, IMRT, 3D-CRT)|Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX or CAPOX.
33044612|NCT04084795|Active Comparator|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
33044613|NCT04084795|Placebo Comparator|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
33044614|NCT04084795|No Intervention|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
33330921|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
33044615|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
33044616|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
33044617|NCT04069897|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
33044618|NCT04069897|Placebo Comparator|Controls|Placebo injections
33044619|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
33044620|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
33044621|NCT04038346|Experimental|NSAID|Naproxen at weight based standard dose given bid daily until symptoms resolve
33044622|NCT04038346|Active Comparator|Acetaminophen|Acetaminophen at weight based standard dose given qid until symptoms resolve
33044623|NCT04038346|Experimental|NSAID first, then Acetaminophen|Naproxen at weight based standard dose given bid for one week, then acetaminophen at weight based standard dose given qid until symptoms resolve
33044624|NCT04038346|No Intervention|Standard Care|Symptom observation only
33044625|NCT04020172|Experimental|Dobutamine + Goal-Directed Fluid Therapy|All patients will receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250 ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume index of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4 hours postoperatively. The infusion rate will be halved and/or discontinued if the patient develops tachycardia (heart rate ≥ 100 bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
33044626|NCT04020172|No Intervention|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
33044627|NCT04016896|Experimental|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
33044628|NCT04016896|Active Comparator|Enhanced Usual Care|enhanced usual care
33044629|NCT04011202|Experimental|VR Group|Receives the VR protocol
33044630|NCT04011202|No Intervention|Control Group|Receives regular care
33044631|NCT04009681|Experimental|Cohort A-THOR-707 Q2W Monotherapy (Dose Escalation)|THOR-707 Q2W will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent
33044632|NCT04009681|Experimental|Cohort B-THOR-707 Q3W Monotherapy (Dose Escalation)|THOR-707 Q3W will be administered in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
33044633|NCT04009681|Experimental|Cohort C-THOR-707 Q3W with checkpoint inhibitor (Dose Escalation)|THOR-707 Q3W will be administered in sequential ascending doses in combination with a checkpoint inhibitor Q3W or every 6 weeks (Q6W) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
33044634|NCT04009681|Experimental|Cohort D-THOR-707 Q3W with anti-EGFR antibody (Dose Escalation)|THOR-707 Q3W will be administered in sequential ascending doses in combination with an anti-EGFR antibody weekly dosing (QW) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
33044635|NCT04009681|Experimental|Cohort E-THOR-707 Q2W with checkpoint inhibitor (Dose Expansion)|THOR-707 Q2W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 8-week cycle of THOR-707 monotherapy on Cycle 1 Day 1 followed by THOR-707 Q2W + checkpoint inhibitor Q6W starting at Cycle 1 Day 15. Subsequently treatment will consist of repeated 6-week cycles with combination therapy.
33044636|NCT04009681|Experimental|Cohort F-THOR-707 Q3W with checkpoint inhibitor (Dose Expansion)|THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.
33044637|NCT04004416|Placebo Comparator|Healthy Controls|
33044638|NCT04004416|Experimental|Early Psychosis patients|
33044639|NCT04004416|Experimental|Schizophrenia or Schizoaffective disorder patients|
33044640|NCT04004416|Experimental|Bipolar disorder patients|
33044641|NCT03991741|Experimental|melanoma|
33044642|NCT03991741|Experimental|head and neck cancer|
33044643|NCT03978793||MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.
33044644|NCT03967522|Experimental|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
33044645|NCT03962374|Experimental|Frova|Frova will be used to facilitate the endotracheal intubation.
33044646|NCT03962374|Active Comparator|Stylet|Stylet will be used to facilitate the endotracheal intubation.
33044647|NCT03937609|Other|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
33044648|NCT03937609|Experimental|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
33044649|NCT03906175|Experimental|Whole-body hyperthermia|Whole-body hyperthermia will be applied 2 times during 4 weeks. At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
33330922|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
33330923|NCT00112840|Experimental|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
33330924|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
33330925|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
33330926|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
33330927|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
33330928|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
33044650|NCT03906175|No Intervention|Wait list|Participants will wait for 6 weeks (primary outcome assessment point). They will then receive the same treatment procedure as the experimental group. They will also be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
33044651|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
33044652|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
33044653|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
33044654|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
33044655|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
33044656|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
33044657|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
33044658|NCT03872479|Experimental|Adults Low Dose|Single dose of EDIT-101 administered by subretinal injection surgery
33044659|NCT03872479|Experimental|Adults Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
33044660|NCT03872479|Experimental|Adults High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
33044661|NCT03872479|Experimental|Pediatric Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
33044662|NCT03872479|Experimental|Pediatric High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
33044663|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
33044664|NCT03842137|Active Comparator|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
33044665|NCT03842137|Sham Comparator|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
33044666|NCT03836053|Experimental|AMG 420|Single Arm Design
33044667|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
33044668|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
33044669|NCT03797560|Experimental|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
33044670|NCT03797560|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
33044671|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
33044672|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010) and CSBD according to ICD-11.
33044673|NCT03730948|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
33044674|NCT03729271|Experimental|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
33044675|NCT00390637|Experimental|1|Low Protein, Low GI Diet
33044676|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
33044677|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
33044678|NCT00390637|Experimental|4|High Protein, High glycemic index diet
33044679|NCT00390637|Experimental|5|Control diet (current recommendations)
33044680|NCT03646123|Experimental|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
33330929|NCT05223244|Active Comparator|dimethyl sulfoxide (DMSO)|Six weekly bladder instillations with 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
33330930|NCT05223244|Experimental|bupivacaine, triamcinolone, and heparin (BTH)|Six weekly bladder instillations with 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
33330931|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
33330932|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
33330933|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
33330934|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
33044681|NCT03646123|Experimental|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
33044682|NCT03646123|Experimental|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
33330935|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors.
33330936|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors.
33044683|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
33044684|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
33044685|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
33044686|NCT02311582|Experimental|Phase II (after amendment #12): MK-3475 + MLA|"After amendment 12, all patients will be enrolled in this arm~MK-3475 will be given every 3 weeks no more than 1 week after MLA~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
33044687|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
33044688|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
33044689|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
33044690|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33044691|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33044692|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33044693|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33109585|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
32869461|NCT00145249|Experimental|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
32869462|NCT00145249|Experimental|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
32869463|NCT00153803|Experimental|1|Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
32869464|NCT00153803|Placebo Comparator|2|Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
32869465|NCT00252967|Placebo Comparator|Placebo|Placebo taken daily
32869466|NCT00252967|Experimental|Atorvastatin|Atorvastatin at a dose of 80 mg daily
32869467|NCT01796171|Experimental|Part A, Arm 1: with lilotomab pre-dosing|"Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.~COMPLETED enrolment into this arm"
32869468|NCT01796171|Experimental|Part A, Arm 2: without pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.~COMPLETED enrolment into this arm"
32869469|NCT01796171|Experimental|Part A, Arm 3: with rituximab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.~COMPLETED enrolment into this arm"
32869470|NCT01796171|Experimental|Part A, Arm 4: with higher dose lilotomab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
32869471|NCT01796171|Experimental|Part A, Arm 5: with intermediate dose lilotomab pre-dosing|"Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
32869472|NCT01796171|Experimental|Part B and Part C|"Available dosing arm - '40/15'~Completed enrolment"
32869473|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
32869474|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
32869475|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
32869476|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
32869477|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
32869478|NCT00088985|Experimental|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
32869479|NCT00156923|Experimental|Medisorb naltrexone 380 mg|
32869480|NCT00156923|Experimental|Medisorb naltrexone 190 mg|
32869481|NCT00093041|Experimental|Zalutumumab 0.15 mg/kg|
32869482|NCT00093041|Experimental|Zalutumumab 0.5 mg/kg|
32869483|NCT00093041|Experimental|Zalutumumab 1 mg/kg|
32869484|NCT00093041|Experimental|Zalutumumab 2 mg/kg|
32869485|NCT00093041|Experimental|Zalutumumab 4 mg/kg|
32869486|NCT00093041|Experimental|Zalutumumab 8 mg/kg|
32869487|NCT00158249|Placebo Comparator|placebo|matched capsules
32869488|NCT00158249|Experimental|citicoline|2 gm/day
32869489|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
32869490|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
32869491|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
32869492|NCT04745663|Experimental|Povidone-Iodine 0.3 %|A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
32869493|NCT04745663|Active Comparator|Povidone-Iodine 5 %|Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.
32869494|NCT01760915||Severe asthma|Subjects with severe asthma (SARP protocol definition)
32869495|NCT01760915||Well controlled asthma|Subjects with well controlled asthma
32869496|NCT01760915||Normal control|Subjects that are healthy normals
32869497|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
32869498|NCT01747577|Experimental|Solifenacin group|
32869499|NCT01747577|Placebo Comparator|Placebo group|
32869500|NCT00094211||Low Walkability/Low Income|Participants reside in a low walkability, low income neighborhood
32869501|NCT00094211||Low Walkability/High Income|Participants reside in a low walkability, high income neighborhood
32869502|NCT00094211||High Walkability/Low Income|Participants reside in a high walkability, low income neighborhood
32869503|NCT00094211||High Walkability/High Income|Participants reside in a high walkability, high income neighborhood
32869504|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
32869505|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
32869506|NCT00159263|Placebo Comparator|Placebo|placebo
32869507|NCT00159263|Experimental|Formoterol|Oxis(®) 12 μg
32869508|NCT00159263|Experimental|Budesonide low dose|Pulmicort(®) 200 μg
32869509|NCT00159263|Experimental|Budesonide high dose|Pulmicort(®) 800 μg
33044694|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33044695|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33044696|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.~This arm was divided into three groups:~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
33044697|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33044698|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33044699|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.~This arm was divided into two groups:~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
33044700|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33044701|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
33044702|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33330937|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Expansion|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
33330938|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion GC/GEJ|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 28 additional patients with 2 anti-PD-(L) 1 naive HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
33330939|NCT04336098|Experimental|SRF617 + Pembrolizumab + Gemcitabine + Albumin-bound Paclitaxel Quadruplet Dose Expansion|Enrollment at the recommended phase 2 combination dose established in the combination dose escalation arms (if recommended phase 2 combination doses differ, the lower of the starting 2 doses will be used) may be expanded to include up to approximately 30 additional patients with advanced 1L PDAC.
33330940|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion anti-PD-L1 GC/GEJ, PD-L1+ NSCLC|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 29 additional patients with anti-PD-(L) 1 relapsed/refractory PD-L1+ HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma or advanced PD-L1+ NSCLC to further evaluate safety with SRF617 and pembrolizumab combination therapy.
33330941|NCT05223010|Active Comparator|1|39 participant will receive melatonin 0.05 mg/kg
33330942|NCT05223010|Active Comparator|2|39 participant will receive melatonin 0.2 mg/kg
33044703|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33330943|NCT05223010|Active Comparator|3|39 participant will receive melatonin 0.4 mg/kg
33330944|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
33330945|NCT05222698|Active Comparator|Group A|Segmental free latissimus muscle trasfer to the face.
33330946|NCT05222698|Active Comparator|Group B|Free gracillis muscle trasfer to the face.
33330947|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
33330948|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
33330949|NCT05222074||CVP ≥ 12|central venous pressure ≥12 mmHg
33330950|NCT05222074||CVP ≥ 16|central venous pressure ≥16 mmHg
33330951|NCT05222074||CVP ≥ 20|central venous pressure ≥20 mmHg
33330952|NCT05222074||MAP ≤ 55 mmHg|mean arterial pressure ≤55 mmHg
33330953|NCT05222074||MAP ≤ 65 mmHg|mean arterial pressure ≤65 mmHg
33330954|NCT05222074||MAP ≤ 75 mmHg|mean arterial pressure ≤75 mmHg
33330955|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
33360665|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
33330956|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
33330957|NCT05653336|Experimental|Subjects implanted with PerQseal Vascular Closure Device|Subjects implanted with bioabsorbable implant to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
33330958|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
33360666|NCT03929419|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
32869510|NCT00159263|Experimental|Budesonide/formoterol combination single|single 100/6 μg SYM100
32869511|NCT00159263|Experimental|Budesonide/formoterol combination double|double 200/12 μg SYM200
32869512|NCT00159419|Active Comparator|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
32869513|NCT00159419|Active Comparator|Pamidronate|3 mg/kg IV q4 months
32869514|NCT00159965|Active Comparator|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
32869515|NCT00159965|Placebo Comparator|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
32869516|NCT02926833|Experimental|KTE-C19 + ATZ|Participants will receive conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days. Treatment with ATZ will begin 21 days following KTE-C19 (Phase 1 Cohort 1), 14 days following KTE-C19 (Phase 1 Cohort 2), and 1 day following KTE-C19 (Phase 1, Cohort 3 & Phase 2).
32869517|NCT00096161|Experimental|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
32869518|NCT00097253|Experimental|Lavender|
32869519|NCT00097253|Experimental|Citrus|
32869520|NCT00097253|Placebo Comparator|Water|
32869521|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
32869522|NCT00099047|Experimental|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
32869523|NCT00099047|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
32869524|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily
32869525|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily
32869526|NCT05709873|Experimental|Imagery rehearsal therapy (IRT)|Participants randomized to this group will receive 5 sessions of IRT.
32869527|NCT05709873|Experimental|Imagery rehearsal therapy and targeted dream control (IRT+TDC)|Participants randomized to this group will receive 5 sessions of IRT followed by 2 sessions of TDC.
32869528|NCT05709795|Experimental|Confluent areas|Ablation first of confluent areas of low wave speed and high voltage in the CTI
32869529|NCT05709795|Experimental|Wave Speed|Ablation first of areas of low wave speed in the CTI
32869530|NCT05709795|Active Comparator|Voltage|Ablation first of areas of high voltage in the CTI
32869531|NCT05709795|Active Comparator|CTI line|Direct CTI line performance (gold standard)
32869532|NCT00166205|Experimental|Gastric Band|Single-arm study, all subjects banded.
32869533|NCT05709639|Experimental|Responder|Increased carbohydrate intake (top 50%) vs moderate to regression in carbohydrate intake (lower 50%)
32869534|NCT05709561|Active Comparator|Acupressure Group|Acupressure was applied to the acupressure group twice a week in the first week by the researcher. Then, in the second week, it was observed that the students themselves applied this application twice this week under the supervision of the researcher.Then the acupressure group was asked to apply acupressure two days a week for 12 weeks, a total of 24 times.
32869535|NCT05709561|Active Comparator|Mindfulness Group|The researcher and students practiced mindfulness once a week for 8 weeks. Then the students were asked to do 3 cycles of application alone every day. mid-test was applied.
32869536|NCT05709561|Placebo Comparator|Plasebo Group|Acupressure and mindfulness practices were not applied to the control group and they continued their routine care.
32869537|NCT00253435|Experimental|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:~On Day -21, patients receive 131I-MIBG infusion.~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.~On Day -4, patients receive Carboplatin, Etoposide.~On Day -3, Day -2, Day -1, patients rest.~On Day 0, patients receive peripheral blood stem cell infusion.~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
32869538|NCT05034081|Experimental|group A|to know the effect of post-bariatric body contouring surgery on weight loss and metabolism
33044704|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33044705|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
33360667|NCT03929419|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
33044706|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.
33044707|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
33044708|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
33044709|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
33044710|NCT03471247|Experimental|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
33044711|NCT03471247|Active Comparator|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
33044712|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
33044713|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
33044714|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
33044715|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
33044716|NCT03423160||Autism|Right-handed children, ages 8.0-12.9, diagnosed with high-functioning ASD (and no co-morbid conditions, excluding anxiety disorders)
33044717|NCT03423160||Control|Right-handed children, ages 8.0-12.9, with no neurological or psychiatric diagnoses, currently or by history
33044718|NCT03404986|Other|Standardized ureteroscopy group|
33044719|NCT03404986|Other|Ultrasonography ureteroscopy group|
33044720|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
33044721|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
33044722|NCT03366844|Experimental|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
33044723|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
33044724|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
33044725|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
33044726|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
33044727|NCT03317392|Experimental|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33044728|NCT03317392|Experimental|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib.
33044729|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
33044730|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
33044731|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
33044732|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
33360668|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
33044733|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
33044734|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
33044735|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
33044736|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
33044737|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
33044738|NCT00390871|Active Comparator|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
33044739|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
33044740|NCT03211741|Other|open label|
33044741|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33044742|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
33044743|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
33044744|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
33044745|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
33044746|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
33044747|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
33044748|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
33044749|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
33044750|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
33044751|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
33044752|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
33044753|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
33044754|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
33044755|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
33044756|NCT03055858|Experimental|PDA closure|
33044757|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
33044758|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
33044759|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
33044760|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
33044761|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
33044762|NCT03054298|Active Comparator|Cohort 6|Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.
33044763|NCT03054298|Active Comparator|Cohort 7|a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.
33044764|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
33044765|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
33044766|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
33044767|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=13 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
33044768|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=15 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
33044769|NCT02987335||Lean Nondiabetic Subjects|N=16 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
33044770|NCT02987335||Obese Nondiabetic Subjects|N=9 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the Type 2 diabetes Mellitus group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
33044771|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
33044772|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
33044773|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
33067877|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
33067878|NCT00139490|Placebo Comparator|C|Usual Care group
33067879|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
32869539|NCT05034081|No Intervention|group B|compare this group of patients with group A to detect weight changes and metabolic changes without any post-bariatric intervention
33109586|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
33109587|NCT04960917|Experimental|eHealth literacy workshop|Community members from pre-existing municipality groups will participate in a workshop aimed to raise their ehealth literacy level.
33109588|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
33109589|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
33109590|NCT04679649|Experimental|Trial A - Intervention Group (manual mobilisation)|Participants will continue to receive routine care and 13 sessions of manual spinal mobilisation will be administered over a 6 months period to compare routine care vs routine care plus manual spine mobilisation physiotherapy.
33109591|NCT04679649|No Intervention|Trial A - Control Group (routine care)|Participants in control group will continue to receive routine care, and routine care measurements for axial spondyloarthritis will be taken at baseline, 3 months and 6 months plus follow up.
33330959|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
33109592|NCT02927522|Placebo Comparator|Control|Placebo was administrated
33109593|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
33109594|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
33109595|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
33109596|NCT04679493|Experimental|XC7 100 mg single|Cohort 1 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 100 mg (3 subjects) or placebo (1 subject, see placebo single arm)
33109597|NCT04679493|Experimental|XC7 200 mg single|Cohort 2 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 200 mg (3 subjects) or placebo (1 subject, see placebo single arm)
33109598|NCT04679493|Placebo Comparator|Placebo single|Placebo comparator arm will consist of 2 subjects (1 subject from Сohorts 1 and 2)
33330960|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
33330961|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
33109599|NCT04679493|Experimental|XC7 200 mg multiple|Cohort 3 - 6 subjects will be randomized in a 6:2 ratio to be treated either XC7 200 mg (6 subjects) or placebo (1 subject, see placebo multiple arm)
33330962|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
33330963|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
33330964|NCT03766074|Placebo Comparator|control|Placebo every other week
33109600|NCT04679493|Placebo Comparator|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 3
33109601|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
33109602|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
33109603|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
33109604|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
33330965|NCT05221216||patients in Intensive Care unit|patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record.
33330966|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
33330967|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
33330968|NCT05221138|Experimental|VV116 after High-fat meal intake|a single oral after High-fat meal intake
33330969|NCT05221138|Experimental|VV116 after Fasting+Standard diet|a single oral after Fasting
33330970|NCT05221138|Experimental|VV116 after Standard meal intake|a single oral after Standard meal intake
33330971|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
33330972|NCT03758820|No Intervention|Control group|Usual local practice
33330973|NCT05220982|Experimental|Conversation Training Therapy|
33330974|NCT05220982|Experimental|Global Voice Prevention and Therapy Model|
33330975|NCT05220982|Experimental|Modified Conversation Training Therapy|
33330976|NCT05220982|Experimental|Modified Global Voice Prevention and Therapy Model|
33330977|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
33044774|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
33044775|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
33044776|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
33044777|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
33044778|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
33044779|NCT02773849|Experimental|ADSTILADRIN|Intravesical administration of ADSTILADRIN into the bladder
33044780|NCT02764918||Children|
33044781|NCT02764918||Mothers|
33418296|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
32869540|NCT02230839|Experimental|Exercise training protocol|
33044782|NCT02735083|Experimental|UCART19 follow-up|
33044783|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
33044784|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
33044785|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
33044786|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
33044787|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
33044788|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
33044789|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
33044790|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33044791|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
33044792|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
33044793|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
33044794|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
33044795|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
33044796|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
33044797|NCT02419495|Experimental|Arm A (selinexor, carboplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
33044798|NCT02419495|Experimental|Arm B (selinexor, paclitaxel)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) on days 1-14. Patients then receive selinexor PO on days 1, 3, 8 and 10 and paclitaxel IV over 3 hours on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After 8 cycles of combination treatment, patients can continue single agent selinexor until disease progression.
33044799|NCT02419495|Experimental|Arm C (selinexor, eribulin)|Patients receive selinexor PO on days 1, 8, and 15 and eribulin IV over 1 hour on days 1 and 8. Combination treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
33330978|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
33330979|NCT05220592|Experimental|Internet-based recovery training program (n=35)|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week.
33330980|NCT05220592|No Intervention|Wait-list control group (n=34)|Wait-list control group received equal and parallell assessment and eligibility procedure as the experimental conditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
33330981|NCT03759990|Active Comparator|insertion time|
32869541|NCT02230839|Experimental|Energy restriction-induced weight loss|
33044800|NCT02419495|Experimental|Arm D (selinexor, doxorubicin, cyclophosphamide) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15, doxorubicin IV over 90 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
33044801|NCT02419495|Experimental|Arm E (selinexor, carboplatin, paclitaxel) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for up to 8 cycles depending con cancer type (6 cycles for non-small cell lung cancer, up to 8 cycles for ovarian cancer and other histological malignancies) in the absence of disease progression or unacceptable toxicity. After 6 to 8 cycles, patients can continue single agent selinexor until disease progression.
33044802|NCT02419495|Experimental|Arm F (selinexor, carboplatin, pemetrexed) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
33044803|NCT02419495|Experimental|Arm G (selinexor, topotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
33044804|NCT02419495|Experimental|Arm H (selinexor, FOLFIRI) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15 and 22, irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 48 hours and leucovorin calcium IV over 2 hours on days 1 and 15. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
33044805|NCT02419495|Experimental|Arm I (selinexor, irinotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
33044806|NCT02419495|Experimental|Arm J (selinexor, capecitabine, oxaliplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15, capecitabine PO twice daily (BID) on days 1-14 and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
33044807|NCT02419495|Experimental|Arm K (selinexor, olaparib) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15, and 22 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33044808|NCT02419495|Experimental|Arm L (selinexor, pembrolizumab)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33044809|NCT02419495|Experimental|Arm M (selinexor, nivolumab|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33044810|NCT02419495|Experimental|Arm P (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, 15, 22, 29, and 36, nivolumab IV over 30 minutes on days 1, 15, and 29, and ipilimumab PO QD on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33044811|NCT02419495|Experimental|Arms N and O (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1, and ipilimumab PO QD on day 1. Cycles repeat every 3 weeks for 4 cycles. Starting cycle 5, patients receive selinexor PO on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33044812|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
33044813|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
33044814|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
33044815|NCT02304913|Experimental|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
33044816|NCT02304913|Sham Comparator|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
33067880|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
33330982|NCT03759990|Active Comparator|intubation time|
33360669|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
33330983|NCT05220436|Experimental|DISCOVER workshop programme|"As this is a case series study, all participants will receive the intervention (i.e. no other arms to the study design).~The DISCOVER workshop programme includes: 1:1 mental health and emotional well-being assessment session with a Clinical Psychologist, a group workshop day, follow-up supportive phone calls and a closing follow-up 1:1 mental health and emotional well-being session with a Clinical Psychologist."
33330984|NCT05220124|Experimental|Immunotherapy with Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 3-4 treatment cycles,21 days per cycle.
33330985|NCT05220124|No Intervention|Immunotherapy without Probiotics|control group, Immunotherapy without Probiotics
33044817|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
33330986|NCT05197660||- cataract surgery|
33330987|NCT05197660||- hip arthoplasty|
33330988|NCT05197660||- knee arthoplasty|
33330989|NCT05197660||- coronary angioplasty|
33330990|NCT05197660||- definitive cardiac stimulation (pacemaker)|
33330991|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
33330992|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
33330993|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
33360670|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
32869542|NCT02230839|No Intervention|Health Education|
33044818|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
33044819|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
33044820|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
33044821|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
33044822|NCT00391183|No Intervention|Best supportive care|
33044823|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
33044824|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.~Sirolimus dosage is based on blood levels."
33044825|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
33044826|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
33044827|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
33044828|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus~Sirolimus dosage is based on blood levels.~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
33044829|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
33044830|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
33044831|NCT01804816|Experimental|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
33330994|NCT05173636|Experimental|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
33330995|NCT05173636|Experimental|thoracic mobilization|A posteroanterior unilateral pressure will be applied over the transverse processes at T2-T5 on the ipsilateral side of pain in prone position.
33360671|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
33044832|NCT01804816|Placebo Comparator|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
33044833|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
33044834|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
33044835|NCT01776190|Experimental|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
33044836|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
33044837|NCT01764529||The BVMC FCCM cohort|"Aim 1: To investigate the relationship between lesion burden and outcomes in familial CCM.~Aim 2: To investigate the role of the gut microbiome in familial CCM disease severity.~Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM."
33044838|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
33044839|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
33044840|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
33044841|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
33044842|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
33044843|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33044844|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
33044845|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
33044846|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
33044847|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
33044848|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
33044849|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
33044850|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
33044851|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
33044852|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
33044853|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
33044854|NCT00584233|Experimental|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
33044855|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
33044856|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
33044857|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
33044858|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
33109605|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
33109606|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
33109607|NCT04941300|Other|Mailed FIT Outreach|Primer, FIT Kit, Reminders, Abnormal FIT Follow-up
33109608|NCT04941300|No Intervention|Usual Care|
33109609|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
33109610|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
33109611|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
33109612|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
33330996|NCT05168644|Experimental|Drug: Niclosamide Inhalation Powder|"PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg.~PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID."
33330997|NCT05168644|Placebo Comparator|Drug: Placebo|"PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects (Part A) will receive a single dose of Placebo.~PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses."
33109613|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
33109614|NCT04938648|Experimental|Intervention|"The intervention consists of the following:~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
33109615|NCT04938648|Active Comparator|Delayed Intervention (wait list control)|"The delayed intervention consists of the following:~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~three months after mailing the deprescribing educational materials, dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences.~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
33109616|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
33109617|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
33109618|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
33109619|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
33109620|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
33109621|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
33109622|NCT04917393|Experimental|Multi-organ denervation|Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
33109623|NCT04917393|Sham Comparator|Control Arm|Subjects will recieved the sham procedure
33109624|NCT03455166|Other|Psoriasis|
33109625|NCT03455166|Other|Psoriatic arthropathy|
33109626|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
33109627|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
33109628|NCT02927015|Experimental|White potato chips|White potato chips
33109629|NCT02927015|Experimental|Crackers|Crackers
33044859|NCT00009646|Placebo Comparator|Placebo|Saline solution
33044860|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
33044861|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
33044862|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
33044863|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
33044864|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
33044865|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
33044866|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
33044867|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
33044868|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
33044869|NCT00011362|Placebo Comparator|Placebo|Saline
33044870|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
33044871|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
33044872|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
33044873|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
33044874|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
33044875|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
33044876|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33044877|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
33044878|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
33044879|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
33044880|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
33044881|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
33044882|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
33044883|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
33044884|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
33044885|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
33044886|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
33044887|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
33330998|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
33330999|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
33044888|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
33044889|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
33044890|NCT00012259|Experimental|troxacitabine|
33044891|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
33044892|NCT00012610|Other|Arm 1|
33044893|NCT00012649||Group 1|
33044894|NCT00012688|Other|Arm 1|
33044895|NCT00012727|Other|Arm 1|
33044896|NCT00012766|Other|Arm 1|
33044897|NCT00012805|Other|Arm 1|
33044898|NCT00012844|Other|Arm 1|
33044899|NCT00012883|Other|Arm 1|Homewalking Exercise Program
33044900|NCT00012922|Other|Arm 1|
33044901|NCT00012961||Group 1|
33044902|NCT00013000|Other|Arm 1|
33044903|NCT00013039|Other|Arm 1|
33044904|NCT00013078|Other|Arm 1|
33044905|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
33044906|NCT00013117|Other|Arm 1|
33044907|NCT00013156|Other|Arm 1|
33044908|NCT00013195|Other|Arm 1|
33044909|NCT00013234|Other|Arm 1|
33044910|NCT00013390|Active Comparator|1|Tinnitus Masking
33044911|NCT00013390|Other|2|Tinnitus Retraining Therapy
33044912|NCT00001305|Experimental|Growth Hormone|Treatment of children with types III and IV osteogenesis imperfecta with Humatrope
33044913|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
33044914|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
33044915|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
33044916|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33044917|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
33044918|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
33044919|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
33044920|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
33044921|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
33044922|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
33044923|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
33044924|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
33044925|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
33044926|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
33331000|NCT05645536|Experimental|TOL2506|TOL2506 in combination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)
33331001|NCT05139862|Experimental|Active iTBS|Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)
33331002|NCT05119738||Three doses of BNT162b2.|Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.
33331003|NCT05119738||Two doses of Coronavac and one of BNT162b2.|Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.
33331004|NCT05088694|Experimental|Intervention|Classrooms assigned to the intervention group will receive the Peaceful Coexistence (middle school) or Anti-extremism (high school) curricula.
33044927|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
33044928|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
33044929|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
33044930|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
33044931|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
33044932|NCT05442450|Experimental|Diet+excercise+oral semaglutide|Participants will receive individual counselling sessions for reduced-calorie diet and physical activity (with 150 minutes per week of physical activity, such as walking). Participants in this group will receive oral Semaglutide drug along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on your symptoms (nausea, vomiting, constipation etc)
33044933|NCT05442450|No Intervention|Diet+excercise|Participants in this group will receive individual counselling sessions for reduced-calorie diet and increased physical activity (with 150 minutes per week of physical activity, such as walking).
33044934|NCT00391729|Placebo Comparator|1|
33044935|NCT00391729|Experimental|2|
33044936|NCT00015340|Experimental|Buprenorphine/Naloxone|
33044937|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
33044938|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
33044939|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
33044940|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
33044941|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
33044942|NCT00015964|Experimental|Daily administration of ZD1839|
33044943|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
33044944|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
33044945|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
33044946|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
33044947|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
33044948|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
33044949|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
33109630|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
33331005|NCT05088694|No Intervention|No intervention|Classrooms assigned to the No intervention group will receive general information during their sessions.
33331006|NCT02174406||women scheduled for breast screening|"Each patient will have the following:~Screening whole breast ultrasound~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
33331007|NCT05077384|Experimental|Surufatinib|Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
33418297|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
33044950|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
33044951|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
33044952|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
33044953|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
33044954|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
33044955|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
33044956|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
33044957|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
33044958|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
33044959|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
33044960|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
33044961|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
33044962|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
33044963|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
33044964|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
33044965|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
33044966|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
33044967|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
33044968|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
33044969|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
33044970|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
33044971|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
33044972|NCT00016432|Experimental|Group 1|Exemestane
33044973|NCT00016432|Placebo Comparator|Group 2|Placebo
33044974|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
33044975|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
33044976|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
33044977|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
33044978|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
33044979|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
33044980|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
33044981|NCT00001464||Group 1|Smokers exposed to oxygen
33044982|NCT00977860|Other|SBRT|
33044983|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
33044984|NCT00016744|Placebo Comparator|2|
33044985|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
33044986|NCT00386633|Active Comparator|2|10E8_TCID50
33044987|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
33044988|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
33044989|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
33044990|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
33044991|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
33044992|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
33044993|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
33044994|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
33044995|NCT04734418|Experimental|Remifentanil group|
33044996|NCT04734418|Active Comparator|Dexmedetomidine|
33331008|NCT03211416|Experimental|Treatment (sorafenib tosylate, pembrolizumab)|Patients receive sorafenib tosylate PO BID on days -28 to -1 and 1-21. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33044997|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
33044998|NCT04734223||Group 1|The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
33044999|NCT04734223||Group 2|The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
33045000|NCT04734223||Group 3|The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
33045001|NCT04734223||Group 4|The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
33045002|NCT04734340|Experimental|EIT-guided group|Treatment based on EIT
33045003|NCT04734340|Placebo Comparator|Control group|Treatment based on ARDS-net Peep setting
33045004|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
33045005|NCT00017368|Experimental|All Patients|
33045006|NCT05681000|Experimental|Utidelone Capsule at 25 mg/m2/d for 5 days|Cohort 1: 2 subjects are planned to take Utidelone Capsule at 25 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
33045007|NCT05681000|Experimental|Utidelone Capsule at 50 mg/m2/d for 5 days|Cohort 2: 2 subjects are planned to take Utidelone Capsule at 50 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
33045008|NCT05681000|Experimental|Utidelone Capsule at 75 mg/m2/d for 5 days|Cohort 3: 3-6 subjects are planned to take Utidelone Capsule at 75 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
33045009|NCT05681000|Experimental|Utidelone Capsule at 100 mg/m2/d for 5 days|Cohort 4: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
33045010|NCT05681000|Experimental|Utidelone Capsule at 100 mg/m2/d for 7 days|Cohort 5: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
33045011|NCT05681000|Experimental|Utidelone Capsule at 120 mg/m2/d for 7 days|Cohort 6: 3-6 subjects are planned to take Utidelone Capsule at 120 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
33045012|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
33045013|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
33045014|NCT05680961||Parkinson's patients|Cohort of patients with clinical diagnosis of Parkinson's diseases with varied symptoms and severity.
33045015|NCT05680922|Experimental|Experimental LB2102|DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)
33045016|NCT04734067||observational group|Patients receiving ICIs for the first time
33045017|NCT05680805|Active Comparator|With mutation|Participants with single nucleotide polymorphisms of SLC22A1 gene (with mutation)
33045018|NCT05680805|Active Comparator|Without mutation|Participants without single nucleotide polymorphisms of SLC22A1 gene
33045019|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
33045020|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
33045021|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
33045022|NCT05680766|Experimental|Intervention arm|IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).
33045023|NCT00001566|Experimental|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
33045024|NCT05680727|Other|real individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with individualized resting state functional connectivity.
33045025|NCT05680727|Other|sham individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with head measurements (i.e., Beam F3)
33045026|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
33045027|NCT04381468|Experimental|pepinemab 40mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
33045028|NCT04381468|Placebo Comparator|Placebo|.A placebo control will be administered via monthly intravenous infusions.
33045029|NCT00001575|Experimental|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
33045030|NCT05680649|Experimental|Intervention|Breathing exercise
33045031|NCT05680649|No Intervention|Control|Standard practice
33045032|NCT04255147|Experimental|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
33045033|NCT04247191|Experimental|P-Chat|The P-Chat is a brief individually delivered intervention
33045034|NCT04247191|Experimental|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
33045035|NCT04247191|Experimental|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
33331009|NCT05059990|Experimental|Low Intensity Aerobic Exercises Group|stationary cycle for aerobic exercise
33331010|NCT05059990|Active Comparator|Active Exercises Group|Upper and lower limb range of Motion (ROM) & stretching exercises uses in active exercise group
33331011|NCT05412888|Placebo Comparator|Supplemented population 300mg|Supplemented population 300mg/24h CoQ10 - 25 participants
33331012|NCT05412888|Experimental|Training and IPC preconditioning|Group subjected to training and preconditioning by ischemia (IPC training) - 25 participants,
33331013|NCT05412888|Placebo Comparator|Control group (placebo)|Control group to CoQ10 supplementation (placebo)- 25 participants
33331014|NCT05412888|Sham Comparator|IPC control group|IPC control group - 25 participants
33331015|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
33331016|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
33331017|NCT03805464|Experimental|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
33045036|NCT04247191|No Intervention|Control|This group will only complete assessments and will not receive any intervention.
33331018|NCT02105766|Experimental|male donor - female recipient|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody)
33331019|NCT02105766|Experimental|patients with preexisting antibodies|patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
33331020|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
33331021|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
33331022|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
33331023|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
33331024|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
33045037|NCT04217317|Experimental|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
33045039|NCT00001596|Active Comparator|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
33045040|NCT00001596|Placebo Comparator|Placebo|Subjects received placebo (3 pills), three times daily.
33045041|NCT05680571||Parkinson|Patients suffering from PD of both genders above 18 years of age and Gender- and age-matched HC without any eye- or neurological disorder.
33045042|NCT05680571||Ataxia|Patients suffering from AT of both genders above 18 years of ageand Gender- and age-matched HC without any eye- or neurological disorder.
33045043|NCT03366103|Experimental|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33045044|NCT03346135|Experimental|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
33045045|NCT05680532|Experimental|BR group|Experimental group AZ subjects were requested to take 50 g of BR powder dissolved in 240 ml of water for 4 weeks.
33045046|NCT05680532|Placebo Comparator|Placebo group|Placebo group AZ subjects were requested to take 50 g of dextrin powder dissolved in 240 ml of water for 4 weeks.
33045047|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
33045048|NCT04733872|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
33045049|NCT04733872|Experimental|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
33045050|NCT05576545|Experimental|general routine care and the Breast Cancer Self-Care App|
33045051|NCT05576545|No Intervention|general routine care|
33045052|NCT05680493|Experimental|Dry needling|Total 12 sessions of trigger point dry needling at lumbar muscles with Hot pack,with 3 sessions per week
33045053|NCT05680493|Active Comparator|manual pressure release|Hot pack for 15 min then manual pressure release
33045054|NCT05576194||TauroPace irrigation group|every consecutive CIED placement, revision, extraction conducted with TauroPace
33045055|NCT05576194||antiseptic irrigation group|every procedure conducted with adjunct antiseptic irrigation, which could be Taurolidine, TauroPace or Hydrogen Peroxide 3%
33045056|NCT05680376||Recurrent Pregnancy loss|patients with a diagnosis of recurrent miscarriage
33045057|NCT05680376||Healthy Controls|healthy women at same age and similar demographics
33045058|NCT00392080|Placebo Comparator|3|
33045059|NCT00392080|Experimental|1|75 mg BID
33045060|NCT00392080|Experimental|2|
33045061|NCT05680259|Experimental|Maela connected follow-up|patient will benefit of the Maela connected follow-up
33045062|NCT05680259|Active Comparator|control group|control group with a traditional follow-up
33109631|NCT04910412|Experimental|Anodal tDCS with gait training|Anodal tDCS will be applied over the primary motor cortex (M1) (anodal or active electrode on M1 area, cathodal or reference electrode on supraorbital area) for 20 mins with 2 mA intensity before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
33109632|NCT04910412|Active Comparator|Sham tDCS with gait training|Sham tDCS will be applied over the primary motor cortex for 20mins before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
33109633|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
33109634|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
33109635|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
33109636|NCT00553956|No Intervention|2|Waiting list control
33109637|NCT04887246||UNISALUD population|Refers to all affiliated members or beneficiaries of the UNISALUD entity, who got any of tthe COVID-19 vaccines available in Colombia
33109638|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
33109639|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
33109640|NCT04878549||Febrile Adults|1200 adult participants (15 to 45 years old) with a febrile illness without localising features and reported duration of 3-14 days.
33109641|NCT04878549||Controls|400 afebrile, healthy adult participants (15 to 45 years old).
33109642|NCT04878549||Febrile Children|400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days. This is an exploratory arm of the study.
33109643|NCT04679298||Apixaban|N=20
33109644|NCT04679298||Edoxaban|N=20
33109645|NCT04679298||Dabigatran|N=20
33109646|NCT04679298||Rivaroxaban|N=20
33109647|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
33109648|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
33109649|NCT04871607|Experimental|Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)|Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours QD and cytarabine IV over 2 hours BID or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC > 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
33109650|NCT02926547||CCIS|
33109651|NCT02926547||invasive breast cancer|
33109652|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
33109653|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
33109654|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
33109655|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
33109656|NCT04680195|Experimental|Thalidomide treatment Group|"Induction period:~Thalidomide tablets: 50-100 mg/d, qn, po.~Maintenance period:~Thalidomide tablets: 50-75 mg/d qn, po."
33109657|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
33109658|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
33109659|NCT04867434|Active Comparator|RZL-012 50mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses 270 mg for the high doses. Each injection point will be dosed with 7.5 mg for the high dose in a volume of 0.15 mL/injection site.
33109660|NCT04867434|Active Comparator|RZL-012 34mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg for the low dose. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose in a volume of 0.15 mL/injection site.
33109661|NCT04867434|Placebo Comparator|Placebo|Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL.
33109662|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
33109663|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
33109664|NCT04864431|Active Comparator|Vitamin D group|Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU
33109665|NCT04864431|Placebo Comparator|Control group|Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo
33109666|NCT02926118|Experimental|Low glycemic load|Low glycemic load
33109667|NCT02926118|Experimental|High glycemic load|High glycemic load
33418298|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
33418299|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
33418300|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
33418301|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
33418302|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
33045064|NCT05574595|Experimental|The Mean of the Hemodialysis Comfort Scale scores of the experimental and group patients|To the Experimental Group; The information form and the short form of the comfort scale will be applied to the patient who is taken to the dialysis unit to start HD treatment.
33045065|NCT05574595|No Intervention|The mean of the Hemodialysis Comfort Scale scores of the control group patients|No procedure was performed on the patients in the control group.
33045066|NCT05574556||myoelectric activity of the quadriceps muscle|electromyography myoelectric activity of the quadriceps muscle
33109668|NCT00553995|Experimental|Salsalate|Salsalate
33418303|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
33109669|NCT00553995|Placebo Comparator|Placebo|Placebo
33418304|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
33418305|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
33045067|NCT05574478||Patients and Caregivers|Participants will include patients diagnosed with metastatic breast cancer and caregivers for patients diagnosed with metastatic breast cancer. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
33045068|NCT05680220|Experimental|Active Neurostimulation System (NSS)|Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day
33045069|NCT05680220|Placebo Comparator|Sham Neurostimulation System (NSS)|Exposure to the NSS device set to continuous color-matched white light for 1 hour a day
33045070|NCT05574283|Experimental|ESPB group|ESPB group: 30 patients will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
33045071|NCT05574283|Experimental|TQLB group|TQLB group: 30 patient will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
33045072|NCT05574205|Experimental|High Quality Protein|Participants will consume four high-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 75:25 animal:plant protein with most of the animal protein from supplemental high-quality protein powder.
33045073|NCT05574205|Experimental|Low Quality Protein|Participants will consume four low-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 25:75 animal:plant protein with most of the plant protein from supplemental low-quality protein powder.
33045074|NCT05574166|Experimental|SP-8356 powder|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
33045075|NCT05574166|Placebo Comparator|Placebo|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
33045076|NCT02971774||questionnary|self administered questionnary
33045079|NCT05680142|Active Comparator|Control Group|the control group, Group C
33045080|NCT05680142|Active Comparator|Cervical ESP|the block-applied patients, Group E.
33045081|NCT05574049|Active Comparator|Single Dose|Once daily mouth strip containing 8mg of THCV and 10mg of CBD
33045082|NCT05574049|Active Comparator|Double Dose|Once daily mouth strip containing 16mg of THCV and 20mg of CBD
33045083|NCT05574049|Placebo Comparator|Placebo|Once daily mouth strip containing nothing
33045084|NCT05573971|Experimental|with verbal encouragement|
33045085|NCT05573971|No Intervention|without verbal encouragement|
33045086|NCT05573893||Cohort 1|Cohort 1 containing patients with documentation of a CANKADO PRO-React Onco questionnaire on at least 30 days during the first 90 days after activating/ first usage of the DiGA within the study.
33045087|NCT05573893||Cohort 2|Cohort 2 containing patients with documentation of a CANKADO PRO-React Onco questionnaire on less than 30 days during the first 90 days after activating/ first usage of the DiGA within the study or having stated at baseline to decline CANKADO PRO-React Onco usage.
33045088|NCT05573854|Sham Comparator|Overnight Fast|After an overnight fast period of eight hours, the 6 participants will attend the Radiology Service of the Hospital de Câncer, Cuiaba, Brazil to perform MRI images of the upper abdomen with the objective of measuring the fasting GRV. GRV will be evaluated by tracking the region of interest (ROI) in each slice, forming a volume by the sum of all ROIs (phase 1).
33331025|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
33331026|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
33331027|NCT05558410|Experimental|VX-548|Participants will receive VX-548.
33045089|NCT05573854|Active Comparator|Oral Supplement|Each of the 6 participants while still inside the MRI exam room just after the MRI in fast condition, will ingest 200mL of the study oral supplement (OS). The individual will be immediately positioned in the supine position and another MRI scan will be carried out. In this second phase, GRV will be evaluated again as in phase 1 (phase 2).
33045090|NCT05573854|Active Comparator|3h after ingestion|Finally, phase 3 will be performed after a 3-hour pause. All volunteers, while still in the Radiology Service and fasted after the ingestion of the OS described in phase 2, will be submitted to a third MRI scan of the upper abdomen to measure again the GRV as previously described.
33045091|NCT05680064|No Intervention|Control|Patients who are routinely followed up will be included in the control group. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days.
33045092|NCT05680064|Experimental|Gum-Chewing Group|In the gum-chewing group, routine follow-up and additional gum-chewing training will be given (at least 10 minutes 4 times a day, preferably before meals and with sugar-free gum). Patients in the Gum Chewing Group will chew gum as recommended for 15 days. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days. In the study, the chewing gum group will chew Vivident Xylit Full Fresh Mint Flavored Liquid Filled Sugar-Free Sweetener Gum. The contents of the gum; Sweeteners (Xylitol, Sorbitols, Mannitol, Maltitols, Aspartame, Acesulfame-K), Gum Yeast, Stabilizer (Glycerol), Flavorings, Natural Mint Flavoring, Maltodextrin, Starch, Emulsifiers (E473, Soy Lecithin), Green Tea Extract, Consistency Enhancers (Cellulose Gum, Xanthan Gum), Coconut Oil, Antioxidant (E321), Brightener (Carnauba Wax), Colorant (E133). There is no allergen warning.
33045093|NCT05680064|Experimental|Tongue, lip, chin exercise group|In the tongue, lip and chin exercise group, patients who are routinely followed up and who will be given additional tongue, lip and jaw exercises training (at least 10 minutes 4 times a day and preferably before meals) will take place. Patients in Tongue, Lip, Chin Exercise Group will do the tongue, lip and chin exercises as recommended for 15 days. At the end of 15 days, all patients will come the second interview. The same data collection methods are repeated after 15 days. content of the training to be given to the tongue, lip and chin exercise group and the exercise brochure to be given to the patients T.C. Oral-Motor Exercises Brochure published by the Ministry of Health Istanbul Provincial Health Directorate, Basic Evaluation Principles in Treatment Movements book and Specialist. It was determined and prepared in line with the recommendations of physiotherapist İbrahim ÖZDEMİR.
33045094|NCT05573815|Experimental|Positive group|A patient diagnosed with brain metastasis after a brain MR
33045095|NCT05573815|Experimental|Negative group|A normal person or a patient not diagnosed with brain metastasis after a brain MR
33045096|NCT05573776|Experimental|Exercise Therapy, High Protein supplement|
33331028|NCT05558410|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
33331029|NCT05558410|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
33045099|NCT05573659|Experimental|video-assisted capillary refill time.|
33045100|NCT05573659|Active Comparator|visual capillary refill time.|
33045101|NCT05679947|Experimental|Mobilization Protocol|The study group patients were mobilized according to the developed mobilization protocol.The protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the discharged day. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 h after surgery. Implement mobilization protocol 3 times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every 2 h. Level 2: ROM should occur at least 3 times a day. Level 3: The head of bed (HOB) >30 degrees. Duration goal: 5-15 min. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 min. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 min. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 min. Progress to level 6. Level 6: Patient is able to ambulate at least 3 times a day.
33045102|NCT05679947|No Intervention|Control|No intervention was made to the control group, only data were collected at the same time as the study group.The patients in the control group was mobilized by the researchers according to the routine clinical mobilization practice.
33045103|NCT05573386||Filgrastim to Pegfilgrastim|Participants in this group will receive filgrastim treatment, followed by pegfilgrastim treatment at the 8-week mark.
33045104|NCT05573386||Pegfilgrastim to filgrastim|Participants in this group will receive pegfilgrastim treatment, followed by filgrastim treatment at the 8-week mark
33045105|NCT00001656|Active Comparator|Olanzapine|
33045106|NCT00001656|Active Comparator|Clozapine|
33045107|NCT05573347||Bone marrow harvest from side-lying patient|This group will have bone marrow harvested from the PSIS extraction site while lying in the lateral decubitus position.
33045108|NCT05573347||Bone marrow harvest from patient lying prone|This group will have bone marrow harvested from the PSIS extraction site while lying in the prone position.
33045109|NCT05573308|Experimental|Clear Aligners with Dental Monitoring|"Experiment group: DM (Remote Dental Monitoring approach). Remote Dental Monitoring by DMTM will be implemented in the patient's orthodontic treatment. Pretreatment, 3D digital intra-oral scans will be uploaded to the DMTM dashboard, so they serve as the baseline for 3D tracking of tooth movement. Patients will be trained on how to use the DMTM application and do DM remote scans using their smartphones DM scan box and rector.~They will be instructed to do the DM scan after the initial tray insertion. Replacement of the aligners trays will be based on DM GO tracking function, which is specifically targeted at clear aligner treatment."
33331030|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
33360672|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
33331031|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
33331032|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
33331033|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
33331034|NCT05557162|Experimental|Notification of the AI ECG algorithm and the A3E scores|Provider-facing recommendation report that alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
33331035|NCT05557162|No Intervention|Usual Care|No alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
33331036|NCT01322334|Experimental|Singing exercises|
33418306|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
33045110|NCT05573308|Active Comparator|Clear Aligners replaced every 7 days|Group 2:Control group. All subjects will have conventional aligner treatment with aligners replaced every 7 days, and standard in-office visits every 8 weeks.
33045111|NCT05573308|Active Comparator|Clear Aligners replaced every 14 days|Group 3: (n=40) Control group. All subjects will have conventional aligner treatment with aligners replaced every 14 days, and standard in-office visits every 8 weeks.
33045112|NCT05679869|Active Comparator|VR Simulated Outdoor Environment|Exposure to recorded outdoor environmental sounds
33045113|NCT05679869|Experimental|VR Simulated Outdoor Environment with Masking Sounds|Exposure to recorded outdoor environmental sounds augmented with masking sounds
33045114|NCT05573269|Experimental|FOPE group|"Dietary supplement, Polyphenolic extract from pine bark (Oligopin® 100mg) and fish oil capsule contained EPA 350mg + DHA 250mg. This group will receive a nutritional supplement for a period of 6 months.~The participants will have a capsule of polyphenolic extract and a capsule of fish oil a day."
33045115|NCT05573269|Active Comparator|FO group|This group will have placebo capsule and fish oil capsule. Placebo capsule contained maltodextrin and magnesium stearate, while fish oil contained EPA 350mg + DHA 250mg. The participants will receive the supplements for a period of 6 months and have a capsule of placebo and a capsule of fish oil a day.
33045116|NCT05573191|Experimental|LP group|The experimental group received 1.5 mg/kg lidocaine intravenously,after 90s, the corresponding dose of propofol was injected intravenously at 30mg/kg/h, and to observe Whether consciousness disappears or not，recording NTI values, heart rate, oxygen saturation, mean arterial pressure and drug side effects in the baseline state, 90s after lidocaine administration, 60s and 120s after propofol administration
33045117|NCT05573191|Placebo Comparator|P group|Replace lidocaine with equal volume normal saline,Others are the same as the experimental group.
33045118|NCT05573152|Experimental|Nursing|Nursing Group (Nurse): the nursing team will use of the warming device air flow device from the moment the patients enter the operating room until anesthesia induction. The warming device will be set up connected to the patient and to the motor with the activation of the system at 43°C by the nursing team. The monitoring of the times since the entrance of the patient in the operating room until the induction of the anesthesia will be controlled by a member of the anesthesia team (regardless of the room process);
33045119|NCT05679830|Experimental|160mg Cannabidiol Isolate|320mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
33045120|NCT05679830|Experimental|320mg Cannabidiol Isolate|160mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
33045121|NCT05572957|Active Comparator|GDMT group|"With the current guidelines of recommended therapies for HF, each patient who meets the inclusion criteria should begin being on all 4 drug classes after enrollment, including a beta-blocker (BB), a RAS inhibitor (ACEI, ARB) or ARNI (preferred), an MRA, and an SGLT2i.~The appeal drugs should be gradually uptitrated to the maximum tolerated dose within the first 3-6 months.~Ivabradine will be added to the patients whose resting heart rates remain above 70 beats per minute (bpm) after adequate medical treatment, including a BB at maximum tolerated dose."
33045122|NCT05572957|Experimental|LBBP+GDMT group|"In this arm, medications are the same as the GDMT group. The LBBP lead is introduced into the right ventricle (RV) and is placed on the right side of the interventricular septum (IVS). The lead is advanced deeply into the IVS until reaching the LV septal subendocardium and right bundle branch block (RBBB) morphology of the paced QRS complex is observed in electrocardiogram (ECG) lead V1.~If LBBP fails, his bundle pacing (HBP) should be considered when HBP could correct LBBB.~If both of LBBP and HBP fail, conventional BiVP-CRT could be the last option."
33045123|NCT05679791||Group 1|
33045124|NCT05679791||Group 2|
33045125|NCT05572801|No Intervention|ARM A: HPV positive standard of care follow-up|The national follow-up program + collection of blood samples for retrospective translational research
33045126|NCT05572801|Experimental|ARM B: HPV positive ctDNA guided imaging in follow-up|The national follow-up program + ctDNA guided additional imaging + collection of blood samples for retrospective translational research
33045127|NCT05572801|No Intervention|ARM O: HPV negative observational arm|"Patients with HPV negative disease will be included in an observational arm (ARM O)~ARM O: The national follow-up program + collection of blood samples for retrospective translational research"
33045128|NCT05572762|Experimental|Atraumatic Peribulbar Technique|a cannula is used to apply ophthalmic block
33045129|NCT05572762|Active Comparator|Conventional peribulbar block|a 24 or 25 gauge needle is used to provide regional o anesthesia to the study group
33045130|NCT05572723|Active Comparator|Group Remifentanil|Remifentanil group was initially to receive remifentanil (group R), 0.01-0.2 g/kg/min without intraoperative loading.
33331037|NCT05087212|Experimental|plerixafor|Participants will receive the first dose of plerixafor by subcutaneous (SC) injection on the evening of Day 4 (10 to 11 hours (± 1 hour) prior to the start of next day's apheresis). For a maximum of 4 days, patients will continue to receive daily plerixafor in the evening, followed by a morning dose of G-CSF and apheresis for up to a maximum of 4 apheresis or until ≥ 6×106 Cluster of differentiation 34 (CD34) + cells/kg were collected.
33045131|NCT05572723|Active Comparator|Group Dexmedetomidine|Dexmedetomidine group, dexmedetomidine (group D) was initiated with a bolus of 1 mg/kg and received 0.2-0.7 g/kg per hour as an infusion during surgery.
33418307|NCT05217771|Experimental|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
33331038|NCT05086510|Active Comparator|Sinus Rhythm|This group will undergo mapping during sinus rhythm to identify and ablate late potentials that may be incriminated in the tachycardia circuit.
33331039|NCT05086510|Active Comparator|Right ventricular extrastimulus pacing group|This group will undergo mapping during right ventricular single extrastimulus pacing to identify and thus ablate potentials that might have been masked during sinus rhythm.
33331040|NCT01617642||Control group|Healthy control group, matched for age and gender
33331041|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
33418308|NCT05217771|Experimental|control group|Patients in control group will receive high tone sham therapy 3 times per week and self-stretch for hand and shoulder.
33045134|NCT05570071|Experimental|vaginal radiofrequency|vaginal radiofrequency therapy 4 times
33045135|NCT05570071|Active Comparator|electromyography biofeedback|electromyography combined with biofeedback therapy 15 times
33045136|NCT04733716|Active Comparator|Total Knee Arthroplasty with using Tourniquet|A pneumatic tourniquet was used before surgery at the proximal thigh and inflated before the skin incision until skin closure in this group. The tourniquet was inflated to either 275 or 325 mmHg, depending on the patient's systolic blood pressure.
33045137|NCT04733716|Active Comparator|Total Knee Arthroplasty without using Tourniquet|A pneumatic tourniquet was not used in this group during the total knee arthroplasty.
33045138|NCT05563753||ABT in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation with antibiotic treatment in the first week of life
33045139|NCT05563753||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation without antibiotic treatment in the first week of life
33045140|NCT05560984|Experimental|study population|Women with previous one or more cesarean sections with placenta previa and focal accrete
33045141|NCT05558137||Elderly|patients aged 80 years or older
33045142|NCT05558137||Young|patients aged 18-40 years
33045143|NCT05557786||Real CB-tACS (10 days cerebellar tACS)|Real cerebellar tACS, 70Hz,2mA (peak to peak), 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
33045144|NCT05557786||Sham CB-tACS (10 days sham cerebellar tACS)|Sham cerebellar tACS,10Hz, 2mA (peak to peak) for 40s, and then no current 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
33045145|NCT05530759||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood and buccal samples before or after SOC biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.
33045146|NCT05525104|No Intervention|Control|In patients randomised to the control group, sevoflurane will be titrated according to a Minimal Alveolar Concentration (MAC) of 0.9 respectively an end tidal sevoflurane concentration of 2.3% based on standard practice in our paediatric anaesthesia department.
33045147|NCT05525104|Experimental|Treatment|In patients randomised to the intervention group of the trial, the anaesthetic agent sevoflurane will be titrated according to the typical DSA pattern for general anaesthesia with sevoflurane, provided by the Narcotrend
33045148|NCT05520775|Experimental|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (.25mg to 1.0mg) over 9 weeks.
33045149|NCT05520775|Sham Comparator|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
33045150|NCT05517304|Experimental|tcVNS|Stimulation twice daily with transcutaneous Vagal Nerve Stimulation (tcVNS)
33045151|NCT05517304|Active Comparator|sham|stimulation with sham
33045152|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
33045153|NCT05506345|Experimental|intervention group|The intervention group carried out a series of creative drama workshops based on social interaction theory on the basis of routine nursing teaching.
33045154|NCT05506345|No Intervention|control group|The control group adopted conventional nursing teaching methods (conventional nursing teaching methods included safety education, healthy lifestyle, role positioning of nursing students, nursing etiquette, communication skills, nursing professional theory and skill training, nursing career planning, and clinical one-on-one teaching, according to plan to complete the teaching task).
33045155|NCT05485558|Placebo Comparator|Control group|30 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
33045156|NCT05485558|Experimental|N-acetyl cysteine group|30 patients will receive 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
33045157|NCT05679635|Other|Study participants|"In intubated patients during CPAP ventilation, a conventional tube adapter (CTA, Ventinova Medical B.V., Eindhoven, The Netherlands) will be connected to the tracheal tube for tracheal pressure measurement. Tracheal pressure measurements will be recorded directly from the respirator Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) three times, as well as the corresponding airway pressure values from the Evita Infinity V500 respirator (Dräger Medical, Lübeck, Germany).~Study related time points:~T1: 10 minutes after insertion of the conventional tube adapter during CPAP without ventilator support T2: 10 minutes after T1 during CPAP with activated automatic tube compensation (ATC) T3: 10 minutes after T2 during CPAP with assisted spontaneous breathing (ASB) of 4 cmH2O"
33045158|NCT05465317||Patients with Type 2 Diabetes Mellitus (T2DM)|
33045159|NCT05455099||obese group|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Based on the inclusion criteria, 1200 overweight Han people（body mass index 24.0-27.9 kg/m²）and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
33045160|NCT05455099||overweight group|Participants will be assigned to overweight group (body mass index ≥ 28.0 kg/m²). Based on the inclusion criteria, 1200 obese Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
33045161|NCT05446207|Active Comparator|Group A|This group will receive routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 4th week and at 8th week.
33045162|NCT05446207|Experimental|Group B|This group will receive passive music therapy and routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 4th week and at 8th week.
33045163|NCT04733794|Experimental|Surgery for Stoma Reversal|All study participants will receive stoma reversal, complete baseline questionnaire, pelvic floor training and follow up questionnaires
33045164|NCT04733755|Experimental|Beauty Image|
33045165|NCT04733755|Placebo Comparator|Placebo Control|
33045166|NCT05367271|Experimental|Botulinum Toxin A (BTX-A)|20 units of Onabotulinum A in 200 µL of saline
33045167|NCT05367271|Active Comparator|Corticosteroid|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline
33045168|NCT05365672|Experimental|MIC with low immunosuppression|"Patients in MIC Arm A receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction."
33045169|NCT05365672|Experimental|MIC with minimal immunosuppression|"Patients in MIC Arm B receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction.~The mycophenolic acid derivative will be stopped between Days 141 and 182."
33045170|NCT05365672|Other|Standard of care immunosuppression for transplantation|Patients of the Control Arm receive standard of care immunosuppression for kidney transplantations according to the Efficacy Limiting Toxicity Elimination (ELITE) symphony scheme (interleukin [IL]-2 receptor antibody induction therapy, tacrolimus, mycophenolic acid derivative and corticosteroids) without the investigational medicinal product MIC.
33045171|NCT05679401|Experimental|Imlifidase and Standard-of-Care (SoC)|"Imlifidase is administered IV as one dose of 0.25 mg/kg over 15 minutes.~SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids."
33045172|NCT05679401|Active Comparator|Standard-of-Care (SoC)|SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids.
33045175|NCT05331820|No Intervention|standard care group|this group of participants will be used to compare to the intervention group. normal and professional instructions and motivation will be given to them but they will not receive weekly reminders about the importance of adherence to instructions
33045176|NCT05331820|Experimental|weekly reminder group|this group of participants will receive a weekly reminder about the importance of oral hygiene, appliance care, and adherence to recommendations from the dentist.
33045177|NCT05326438|Experimental|CIRCLE mHealth app|"The investigators will trial a modified version of the mHealth app called Connections with Alaska Native/American Indian people who want to change the way they use alcohol."
33045178|NCT05319496|Experimental|isCGM with education and feedback|Intervention subjects will receive three isCGM sensors (FreeStyle Libre 2, Abbott Laboratories) for use over weeks 1-6. They will have encounters with a diabetes educator for individualized education and coaching during weeks 1-2 and 5-6.
33045179|NCT05319496|Active Comparator|Enhanced usual care with education and feedback only|Enhanced usual care subjects will receive two encounters with a diabetes educator for individualized education and coaching, during weeks 1-2 and 5-6. They will not be provided with isCGM sensors.
33045180|NCT05676983|Experimental|Spiky balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the rough (spiky) surface of the extra balance disc.
33045181|NCT05676983|Experimental|Smooth balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the smooth (flat) surface of the extra balance disc.
33045182|NCT05314933|Active Comparator|Study drug|"Each subject receives either a single dose (SAD) or a multiple dose (MAD) of a 3.5% 2-Deoxyglucose as nasal spray solution.~The starting dose for the first cohort is 3.5 mg/day up to a maximum of 84 mg/day at cohort 6."
33045183|NCT05314933|Placebo Comparator|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of placebo. The dose for each cohort is corresponding the amount of solution needed in the verum group.
33045184|NCT05311618|Experimental|NGM438 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
33045185|NCT05311618|Experimental|NGM438 Combination Dose Finding with Pembrolizumab|Part 1b NGM438 plus pembrolizumab
33045186|NCT05311618|Experimental|Biopsy Cohort with NGM438 Monotherapy Lead-in Followed by Combination Therapy with Pembrolizumab|Part 1C NGM438 followed by NGM438 plus pembrolizumab
33045187|NCT05675657|Placebo Comparator|Control group|Patients will be operated under general anesthesia.
33045188|NCT05675657|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
33045189|NCT05675657|Active Comparator|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
33109670|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
33109671|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
33109672|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
33109673|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
33418309|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
33418310|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
33109674|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
33109675|NCT04798287||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
33109676|NCT04798287||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
33109677|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
33109678|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
33109679|NCT04798209|Experimental|Part A (single ascending dose) Dose A1|Single dose A1 of ACT-777991.
33109680|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A2|Single dose A2 of ACT-777991.
33109681|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A3|Single dose A3 of ACT-777991.
33109682|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A4|Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
33418311|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
33109683|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A5|Single dose A5 of ACT-777991.
33109684|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A6|Single dose A6 of ACT-777991.
33109685|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A7|Single dose A7 of ACT-777991.
33109686|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A8|Single dose A8 of ACT-777991.
33109687|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B1|Multiple doses B1 of ACT-777991.
33109688|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B2|Multiple doses B2 of ACT-777991.
33109689|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B3|Multiple doses B3 of ACT-777991.
33109690|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B4|Multiple doses B4 of ACT-777991.
33109691|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B5|Multiple doses B5 of ACT-777991.
33109692|NCT04798209|Experimental|Part A (single ascending dose) Absolute Bioavailability|Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
33109693|NCT04798209|Experimental|Part B (multiple ascending dose) ADME|Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
33109694|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
33109695|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
33109696|NCT04794543||e-cigarettes and/or e-liquid vaping smokers|actively use e-cigarettes or e-liquid vaping
33109697|NCT04794543||cigarette smokers|actively use burning leaf tobacco cigarettes or inhaled burning leaf marijuana (cannabis)
33109698|NCT04794543||Non-smokers|no use of e-cigarettes or vape or active smoking in the past 5 years (and less than a total of 10 pack-years lifetime use)
33109699|NCT04784013|Active Comparator|Conventional group|
33109700|NCT04784013|Active Comparator|90W-group|
33109701|NCT04783350|Experimental|Transcranial alternating current stimulation (tACS)|Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.
33109702|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
33109703|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
33109704|NCT04764708|Active Comparator|Control Group|Cognitive behavioral therapy plus standard psychopharmacological treatment.
33109705|NCT04764708|Experimental|Experimental Group|A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.
33045190|NCT05307952|Other|Better-performing|"Those of the participants who show a speech recognition percentage above 70% will undergo testing in order to provide a ceiling error profile for comparison during statistical analysis."
33045191|NCT05307952|Experimental|Poorer-performing|Those of the participants who show a speech recognition percentage below 70% will undergo two interventions: the first adjusting the fitting of their cochlear implant, and the second providing them with a personalized, self-administered training program.
33045192|NCT05290207||Newly diagnosed male obese patients with type 2 diabetes|
33045193|NCT05290207||Newly diagnosed male non-obese patients with type 2 diabetes|
33045194|NCT05290207||Newly diagnosed male patients with type 1 diabetes|
33045195|NCT05290207||Healthy, non-obese men|
33045196|NCT05282485|Experimental|Synbiotic Group|A synbiotic combining 2'-Fucosyllactose (2'-FL) human milk oligosaccharides (HMO) with B.infantis (probiotic) will be administered to infants from 4 to 24 weeks of age.
33045197|NCT05282485|Placebo Comparator|Placebo Group|Maltodextrin will be administered to infants from 4 to 24 weeks of age.
33045198|NCT05266183|Experimental|Simultaneous Variety, Small Portion|3 different foods served in a small portion.
33045199|NCT05266183|Experimental|Simultaneous Variety, Large Portion|3 different foods served in a large portion.
33045200|NCT05266183|Experimental|Single-Food, Small Portion|1 food served in a small portion.
33045201|NCT05266183|Experimental|Single-Food, Large Portion|1 food served in a large portion.
33418312|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
33418313|NCT02384421|Experimental|Activa PC+S Neurostimulator|"Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool~PC+S: Primary Cell+Sensing"
33045202|NCT05673629|Experimental|The treatment group-Utidelone in combination with AC|"Utidelone Injection at 30 mg/m2/d administered on days 1-5 of each cycle. Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2 administered once daily on day 1 of each cycle.~One treatment cycle has 21 days, and there are 6 cycles in total."
33045203|NCT05673629|Active Comparator|The control group-Docetaxel in combination with AC|"Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered on day 1 of each cycle.~One cycle has 21 days, and there are 6 cycles in total."
33045204|NCT04007276|Experimental|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
33045205|NCT04007276|Sham Comparator|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
33045206|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
33045207|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
33045208|NCT05258071|Experimental|Pirepemat dose 1|Pirepemat tablets, dose 1 (mg), 2 tablets t.i.d. for 84 days.
33045209|NCT05258071|Experimental|Pirepemat dose 2|Pirepemat tablets, dose 2 (mg), 2 tablets t.i.d. for 84 days.
33045210|NCT05258071|Placebo Comparator|Placebo|Placebo tablets, 2 tablets t.i.d. for 84 days.
33045211|NCT05673356|Experimental|Main arm of the study|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients.
33045212|NCT05236348|Experimental|Patients 21-60yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
33045213|NCT05236348|Experimental|Patients 60-85yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
33045214|NCT05234437|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at 3.6mg/m2 given at a minimum of 28-day intervals.
33045215|NCT05233384||Patients with hereditary dysfibrinogenemia|Patient, male or female, aged over 18, with confirmed hereditary dysfibrinogenemia
33045219|NCT05671484|Active Comparator|Transversalis Fascial Plane Block Group|Patients will receive ultrasound-guided transversalis fascial plane block
33045220|NCT05671484|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block
33045221|NCT05171179|Other|Intravenous lidocaine|Intravenous (IV) lidocaine infusion without Pecs block (standard of care per ERAS protocol)
33045222|NCT05171179|Active Comparator|Blocks+Bupivacaine|Use of Pecs block types I and II with bupivacaine as local anesthetic
33418314|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
33109706|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.~CDSS overview:~The study MDs order CKD triple marker tests~Patients will go to the lab as per usual clinical care~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines~Results will also be sent to the Study MD's for monitoring~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
33418315|NCT05215977|Experimental|MW031|MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
33418316|NCT05215977|Placebo Comparator|placebo|Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
33109707|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.~CDSS Plus overview:~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
33109708|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
33109709|NCT04748445||All participants|
33109710|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
33418317|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
33418318|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
33109711|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
33109712|NCT04679454|Experimental|Preoperative Radiation Treatment|
33109713|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
33109714|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
33109715|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
33109716|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
33109717|NCT04744974|Experimental|Mediterranean diet|Participants will be given dietician counseling on a Mediterranean diet
33109718|NCT04744974|Experimental|DASH diet|Participants will be given dietician counseling on a DASH diet
33109719|NCT04242251|No Intervention|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
33109720|NCT04242251|Experimental|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
33109721|NCT04173650|Experimental|AGLE 102|Treatment arm
32869543|NCT05033847|Experimental|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
32869544|NCT05033847|Experimental|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
33109722|NCT04725786|Experimental|Case group|The intervention of the research corresponds to the realization of a thoracic echography.
33109723|NCT04723524|Experimental|Treatment group|150 Cases, treated with Jinhua Qinggan (JHQG) Granules
33109724|NCT04723524|Placebo Comparator|Control group|150 Cases, Placebo treated
33109725|NCT04152551|Experimental|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
33109726|NCT04152551|No Intervention|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
32869545|NCT05033847|Experimental|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
33109727|NCT04152551|No Intervention|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
33109728|NCT04152551|No Intervention|Adult Control Arm|Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.
33109729|NCT04719897|Experimental|FIRST: Repairing Thoughts|
33109730|NCT02925806||ER/LA opioids included in the class REMS|
33109731|NCT02925806||IR Opioids|
33045223|NCT05171179|Experimental|Blocks+Bupivacaine+Exparel|Use of Pecs block types I and II with mixture of bupivacaine and Exparel* (*Must include bupivacaine at lower dose to decrease intra-operative variability in pain control due to delayed onset of Exparel and in ability to use lidocaine infusion with injection of Exparel)
33045224|NCT05668364|Experimental|Exposition group|Outdoor cold air exposure (<10°C or <50°F) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
33045225|NCT05668364|No Intervention|Control group|Indoor ambient air exposure (24-25°C or 75-77°C). Participants remained under observation at indoor ambient until 60 minutes from triage.
33045226|NCT05156905|Experimental|Cirmtuzumab + Docetaxel|There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
33045227|NCT05144269|Experimental|Multimodal exercises group|Multimodal exercise-based telerehabilitation will be implemented with video conference method. For telerehabilitation, a program including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises was created. Sessions consist of 45 minutes. Telerehabilitation will take place 2 days a week for 8 weeks.
33045228|NCT05144269|No Intervention|Education group|30 minutes of training will be given about postpartum and exercises. As exercise, only aerobic walking exercise, which can be started for 15 minutes a day and 3 days a week according to the guide, gradually increasing, up to 30 minutes and up to 4 days a week will be applied. There will also be a warm-up and a cool-down period before the walking exercise. *Exercise intensity is determined in the 12-14 score range according to the Borg Scale, and how to apply it will be explained.
33331042|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
33418319|NCT05215899|Experimental|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION
33418320|NCT05215899|Experimental|Comparison group|Patients in the comparison group will not be subjected to any intervention other than the tests specified in the method. Comparison group patients will continue their standard treatment and care. Questionnaires and scales will be applied to this group again before the application starts and after the application is finished.
33045229|NCT05139979|Experimental|Webinar-Based Intervention|Breathing and Wellness Webinar: two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
33045230|NCT05139979|Placebo Comparator|Control|This group will be asked to wait for 3 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
33045231|NCT05663762||Pre-pandemic births|Live hospital births that occurred May 1 - December 1 2019
33045232|NCT05663762||Early- pandemic births|Live hospital births that occurred May 1 - December 1 2020
33045233|NCT05663762||Late- pandemic births|Live hospital births that occurred May 1 - December 1 2021
33045234|NCT05095441|Experimental|Part 1: Dose Escalation|C5252 single agent dose escalation in participants with glioblastoma
33045235|NCT05095441|Experimental|Part 2: Dose Expansion|Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma
33045236|NCT05080738|Experimental|Intervention group|The patients in the intervention group will be asked to practice upper extremity home exercises including stretching, mobility and strengthening, as home exercises, 5 days a week for 8 weeks, which will be taught by the physiotherapist.
33045237|NCT05080738|No Intervention|Control|Education group:Patients will be informed about joint protection principles by a physiotherapist for once.
33045238|NCT05066776||Patients with Pulmonary Nodule|Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.
33045239|NCT05055661|No Intervention|The control group|Patients randomized to the control group will receive health education, audiovisual educational meterial regarding the use of inhalers and inhalators spacers and be contacted throughout the six months to collect the study variables, by telephone contact.
33045240|NCT05055661|Experimental|The intervention group|Patients randomized to the intervention grop will receive the same health education as the control group at the reference Basic Health Unit and also will be carried, once a month, the pharmaceutical teleconsultation during six months, by video call. The study variables will be collected in the same periods as the control group patients, by telephone contact.
33045241|NCT05037799||Group 1|body-weight < 50kg
33045242|NCT05037799||Group 2|50 kg ≤ body-weight < 100 kg
33045243|NCT05037799||Group 3|100 kg ≤ body-weight < 150 kg
33045244|NCT05037799||Group 4|150 kg ≤ body-weight < 200 kg
33045245|NCT05650853|Experimental|Study intervention|Transrectal ultrasound and Urethroscopy
33045246|NCT05026333|Experimental|High Stress Group|Group of high stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
33045247|NCT05026333|Experimental|Low Stress Group|Group of low stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
33045248|NCT05023252|Experimental|mobile application|Participants use a mobile application on their smartphone
33045250|NCT04993807|Experimental|Shared decision-making tool|Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
33109732|NCT02925806||Celecoxib|
33045251|NCT04983901|Experimental|Group I (imipenem, cilastatin, relebactam)|Patients receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes q6h for 2 days for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h. Patients may continue to receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes for up to 14 days if clinically indicated by the assessment of the treating physician.
33045252|NCT04983901|Active Comparator|Group II (cefepime, meropenem, piperacillin/tazobactam)|Patients receive cefepime IV q8h for a minimum of 6 doses, meropenem IV q8h for a minimum of 6 doses, or piperacillin/tazobactam IV q6h for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h.
33045253|NCT04981639|Active Comparator|I (IVPCA)|Intravenous patient controlled analgesia will be performed.
33045254|NCT04981639|Active Comparator|II (IVPCA+TAP)|Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
33045255|NCT04981639|Active Comparator|III (IVPCA, IMS, and TAP)|Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
33045256|NCT05634200||Patients with haemoptysis and negative/non-diagnostic CT scan|Patients with haemoptysis and negative/non-diagnostic CT scan (i.e. with focal peripheral lung fibrosis, calcified parenchymal nodules with a maximum diameter <5 mm, linear subsegmental atelectasis, hilar-mediastinal lymph nodes with a short axis <1 cm, pleural thickening/pleural calcification and focal area of emphysema with a diameter <1 cm) for whom bronchoscopy is deemed necessary to obtain an aetiological diagnosis.
33045257|NCT04978675|Experimental|Diagnostic (F-18 rhPSMA-7.3, PET/MRI)|Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.
33045258|NCT04971343||Unselected blood donors|
33045259|NCT04971343||Hospitalized patients|
33045260|NCT04971343||Known HIV-1 Ab positive|
33045261|NCT04971343||Known HIV-2 Ab positive|
33045262|NCT04971343||Known Acute HIV-1 p24 Ag positive|
33045263|NCT00001788||1|patients with primary immunodeficiency disorders
33045264|NCT04962256||Study group|Patients with degenerative CSM or OPLL undergoing C3-7 open-door laminoplasty
33045265|NCT05631470||Enrolled|Participants with ICAS will be scheduled for both MR screening and pressure-wire-based FFR measurement.
33045266|NCT04954573|Other|Morphea|
33045267|NCT04954573|Other|Sclerotic graft-versus-host disease (GVHD)|
33045268|NCT04951804|Active Comparator|EUS-CPN with bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL preceded by injection of 10 ml of bupivacaine 0.5%.
33045269|NCT04951804|Experimental|EUS-CPN without bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL only.
33045270|NCT04949620|Experimental|REThink game, then responder monitoring|Participants in this group will have access to the REThink game for four weeks; based on their response to the intervention, they will be monitored for an additional period of four weeks.
33045271|NCT04949620|Experimental|REThink game, then online parent intervention for non-responders|Participants who are allocated to the REThink game and do not respond to the four-week intervention will be allocated to the online
33045272|NCT04949620|No Intervention|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks) and the online parenting program (after an additional four weeks).
33045273|NCT05620628|Experimental|Savoritinib and Durvalumab|A fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 mg/kg Q4W) is used in the present study for patients >30 kg (dosing by bodyweight only required for patients ≤30 kg).And Savolitinib will be administered orally 600mg once a day for 28 days as one cycle.
33331043|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
33331044|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
33331045|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
33331046|NCT05070910|Experimental|NDT|Therapy will be provided 2 days to 4 days per week for one-hour sessions
33331047|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
33331048|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
33331049|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
33331050|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
33045274|NCT04940650|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
33045275|NCT04935307|Experimental|Patients with multiple chemical sensitivity (MCS)|MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
33109733|NCT02925806||Benzodiazepines|
33045276|NCT04935307|Experimental|Patients with multi-systemic functional somatic disorders (FSD)|Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
33045277|NCT04935307|Experimental|Healthy controls|Healthy participants
33045278|NCT00001806|Experimental|Group|Group education and counseling
33045279|NCT00001806|Active Comparator|Individual|Individual education and counseling
33045280|NCT04922710|Experimental|Home-based aerobic exercise|Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home
33045281|NCT05591651|Experimental|Preparation with hyaluronic acid|Treatment of damaged nipple skin: Preparation with hyaluronic acid. The hyaluronic acid preparation will contain white vaseline and 0.2% sodium hyaluronate in a 30 g container.
33045282|NCT05591651|Experimental|Neutral Preparation without hyaluronic acid|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid. The neutral preparation will contain white vaseline only, in a 30 g container, and wiil have the same appearance and fragrance as the active preparation.
33045283|NCT04905121|Experimental|Psilocybin|
33045284|NCT04893811|Experimental|Single Arm|Bivalent recombinant lipoprotein 2086 vaccine
33045285|NCT04887805|Experimental|Treatment (pembrolizumab, lenvatinib mesylate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib mesylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33045286|NCT05583812|Experimental|SAD Dose 1|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
33045287|NCT05583812|Experimental|SAD Dose 2|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
33045288|NCT05583812|Experimental|MAD Dose 1|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
33045289|NCT05583812|Experimental|MAD Dose 2|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
33045290|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
33045291|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
33045292|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
33045293|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
33045294|NCT04878757|Experimental|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
33045295|NCT04878757|No Intervention|Control - Business-As-Usual|Involves participation in the schools' typical math program
33045296|NCT04872127|Experimental|CAS with proximal protection|using proximal embolism protection device during CAS
33045297|NCT04872127|Active Comparator|CAS with distal protection|using distal protection device during CAS
33418321|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
33045298|NCT04837027|Experimental|Aerobic training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
33045299|NCT04837027|Active Comparator|Balance training|Balance Training A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance
33045300|NCT05641623|Active Comparator|OSU6162|White, circular, coated tablets. Flexible dosage: the starting dose will be 15 mg TID and the maximal dose 45 mg TID.
33045301|NCT05641623|Placebo Comparator|Placebo|Coated tablets, flexible dosage, TID
33045302|NCT05573672|Experimental|Immediate Start|Dietary Counselling (7 bi-weekly sessions) plus omega-3 supplementation
33045303|NCT05573672|No Intervention|Waitlist Control|Participants will wait 12 weeks and then complete the same intervention as the Immediate Start arm.
33045304|NCT04828018||Key Staff|Key Staff will take part in one interview lasting up to 60 minutes
33045305|NCT04828018||In-Pensioners|Royal Hospital Chelsea In-Pensioners will take part in one interview lasting up to 90 minutes and complete n=2 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF) at the start of their qualitative interview.
33045306|NCT04828018||New In-Pensioner|New In-Pensioners wil be asked to complete a total of n=4 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF), n=2 on admission to Royal Hospital Chelsea and n=2 six months after admission.
33045307|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 1|TAK-994 dose 1, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
33045308|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 2|TAK-994 dose 2, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
33045309|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 3|TAK-994 dose 3, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
33045310|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 1|Following the Active Drug Extension Period, participants randomized to active treatment Dose 1 will continue to receive same dose (TAK-994, dose 1, tablets, orally) from Day 57 to Day 84.
33045311|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 2|Following the Active Drug Extension Period, participants randomized to active treatment Dose 2 will continue to receive same dose (TAK-994, dose 2, tablets, orally) from Day 57 to Day 84.
33045312|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 3|Following the Active Drug Extension Period, participants randomized to active treatment Dose 3 will continue to receive same dose (TAK-994, dose 3, tablets, orally) from Day 57 to Day 84.
33045313|NCT04820842|Placebo Comparator|Double-blind Randomized Withdrawal Period: Placebo|Following the Active Drug Extension Period participants will receive placebo-matching tablets for 4 weeks (from Day 57 to Day 84).
33045314|NCT05641545|Experimental|IVAC-RCC-001|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
33045315|NCT05573360|Other|Sequence 1|NGF5-A/NGF4-B/NGF6-B/NGF6-E/Systane, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
33045316|NCT05573360|Other|Sequence 2|NGF4-B/NGF6-B/NGF6-E/Systane/NGF5-A, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
33045317|NCT05573360|Other|Sequence 3|NGF6-B/NGF6-E/Systane/NGF5-A/NGF4-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
33045318|NCT05573360|Other|Sequence 4|NGF6-E/Systane/NGF5-A/NGF4-B/NGF6-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
33418322|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
33418323|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
33418324|NCT02033928||Arm I: Transplant patients|
33418325|NCT02033928||Arm II: Plasma cell dyscrasia patients|
33418326|NCT05383248|Experimental|High Reward - High Variance|
33418327|NCT05383248|Active Comparator|High Reward - Low Variance|
33418328|NCT05215821||group1|subjects with evidence of insulin resistance estimated by high HOMA level
33045319|NCT05573360|Other|Sequence 5|Systane/NGF5-A/NGF4-B/NGF6-B/NGF6-E, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
33045320|NCT04805437|Experimental|3D TLSO|A 3-dimensional Boston brace will be designed to the patient's individual type of scoliosis. In-brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
33045321|NCT04805437|Active Comparator|Standard TLSO|A standard Boston brace will be designed to the patient's individual type of scoliosis. In brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
33045322|NCT04796779|Experimental|CLC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the intervention group will use the Tandem t:slim X2 with Control-IQ Technology v1.0 during the first 13 weeks of the study (RCT phase, weeks 1-13) and then use Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 for the remaining 13 weeks of the study (extension phase, weeks 14-26).
33045323|NCT04796779|Active Comparator|SC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the SC group will use their existing insulin therapy in conjunction with study Dexcom G6 CGM during the first 13 weeks of the study (RCT phase, weeks 1-13). The SC group will then transition to using the Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 and study Dexcom G6 CGM for the remaining 13 weeks of the study (weeks 14-26).
33045324|NCT05641506|Experimental|Arm|Participants received Niraparib 200mg or 300mg QD PO continually combined with Yangzheng Xiaoji capsule， 0.36g*4 tid，28 days as one cycle，up to 3 cycles.
33067881|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
33067882|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
33418329|NCT05215821||group 2|subjects without insulin resistance estimated by normal HOMA level
33418330|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
33418331|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
33418332|NCT05215743|Experimental|Combined antioxidant therapy (CAT)|Intravenous administration of deferoxamine, n-acetylcysteine, and ascorbate over 90 minutes.
33418333|NCT05215743|Placebo Comparator|Placebo|Intravenous administration of dextrose 5% over 90 minutes
33418334|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
33418335|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
33418336|NCT05215665|Experimental|group 1|Lenvatinib+Toripalimab
33418337|NCT05215665|Experimental|group 2|GEMOX+Lenvatinib+Toripalimab
33418338|NCT05215665|Experimental|group 3|Lenvatinib+Toripalimab (failure of GEMOX treatment)
33418339|NCT05215665|Experimental|group 4|GEMOX+Toripalimab
33418340|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
33045325|NCT04766710|Experimental|Community-based ART delivery (CAD)|The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
33045326|NCT04766710|Active Comparator|ART multi-month dispensing (MMD)|A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
33045327|NCT05572658||mRNA-1345: Exposed|Eligible US participants from the mRNA-1345-P301 (P301) study who received the mRNA-1345 vaccine.
33045328|NCT05572658||Placebo/Control: Referent|Eligible US participants from the P301 study who received placebo and eligible US-based, matched, unvaccinated RWD participants.
33045329|NCT04752475|Experimental|Lasix (furosemide)|Furosemide 20 mg, oral, once daily for 5 days
33045330|NCT04752475|Placebo Comparator|Placebo|Identical-appearing placebo, oral, once daily for 5 days
33045331|NCT05641467|Experimental|Video will be watched with virtual reality glasses during episiotomy repair|Views of nature with virtual reality glasses during episiotomy repair.
33045332|NCT05641467|No Intervention|Control|It will be perform routine practice who the women in the control group.
33045333|NCT04747600||serous cystic neoplasms|
33045334|NCT04747600||mucinous cystic neoplasms|
33045335|NCT04747600||intra-papillary mucinous neoplasms|
33045336|NCT04747600||solid pseudo-papillary neoplasms|
33045337|NCT04734730|Experimental|Treatment (talazoparib, androgen deprivation therapy)|Patients receive talazoparib PO QD, abiraterone acetate PO QD, and prednisone PO QD on days 1-28. Patients also receive androgen deprivation therapy consisting of degarelix SC on day 1; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of subsequent cycles; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of cycles 2, 5, 8, and 11; or goserelin acetate SC monthly or every 3 months. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33045338|NCT04727710|Experimental|Part 2: Couples-based mindfulness intervention|Mindfulness-based intervention + Usual care
33045339|NCT04727710|Active Comparator|Part 2: Usual care|Usual care
33045340|NCT05641428|Experimental|Arm A (ARI-0001)|Infusion with Point of Care CAR T-cells
33045341|NCT05641428|Active Comparator|Arm B (Axi-cel)|Infusion with Standard of Care CAR T-cells
33067883|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
33418341|NCT02094092|Placebo Comparator|Placebo drops|Arm B
33418342|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
33418343|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
33418344|NCT05217303|Experimental|HL-085|12 mg BID HL-085
33418345|NCT05667753|Active Comparator|Basic|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the basic group will receive the basic implementation strategy package.
33045342|NCT05562713|No Intervention|Control (Arm #1)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. They will not have a follow-up appointment scheduled. Research team will call them to check if the patient is able to perform CIC independently. If they can, a visit will be scheduled for them to demonstrate this in clinic.
33045343|NCT05562713|Experimental|Present Bias without Loss Aversion (Arm #2)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. Child will receive a prize (~$5-20 in value) for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. If they can demonstrate this ability, they will receive a large prize (~$30-50 in value)
33045344|NCT05562713|Experimental|Present Bias with Loss Aversion (dependent on accrual) (Arm #3)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. Child will pick a prize for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. All of the prizes that the child picked will be given only if fully-independent CIC is demonstrated.
33045345|NCT04723108|Experimental|Virtual reality arm|Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
33045346|NCT04699747|Experimental|Multiple sclerosis|F-18 3F4AP PET Scan
33045347|NCT04699747|Active Comparator|Healthy controls|F-18 3F4AP PET Scan
33045348|NCT04651816|Active Comparator|Control PSH DPP only|This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.
33045349|NCT04651816|Experimental|Treatment 1 Financial Incentives A|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
33045350|NCT04651816|Experimental|Treatment 2 Financial Incentives B|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
33045351|NCT04651816|Experimental|Treatment 3 Motivational Text Messaging|This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.
33045352|NCT05641389||Monitoring Group|Participants will be monitored via a transdermal monitor for four weeks. They will give four breath samples a day for these weeks as well as 5 Blood spot samples.
33045353|NCT05555888|Experimental|Treatment Arm|A total of 34 patients will receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TEM or TME surgery.
33045354|NCT04619680|Experimental|Nintedanib|150 mg PO twice a day, taken with food, (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
33045355|NCT04619680|Placebo Comparator|Placebo|placebo equivalent 150mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
33045356|NCT04604782|Experimental|adolescents aged 12 to <18 years|
33045357|NCT04604782|Experimental|children aged 2 to <12 years|
33045358|NCT04604782|Experimental|infants aged 1 to <24 months and who weigh at least 3 kg|
33045359|NCT04591834||Observational|No Intervention
33045360|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
33045361|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)|Standard of Care
33045362|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
33045363|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
33418346|NCT05667753|Experimental|Enhanced|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the enhanced group will receive the enhanced implementation strategy package.
33418347|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
33418348|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
33418349|NCT05217147||Patient group|60 patients with laryngeal carcinoma
33418350|NCT05217147||Control group|20 healthy age- and sex- matched controls
33418351|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
33418352|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
33045364|NCT04733365|Experimental|Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
33045365|NCT04733365|No Intervention|Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
33045366|NCT04560712|Experimental|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
33045367|NCT04560712|Active Comparator|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
33045368|NCT03354585|Experimental|Meditation Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
33067884|NCT04726943|Experimental|RF Energy|RF delivery targeting the atrial side of a significant residual leak in patients with acute and chronic evidence of incomplete percutaneous LAA occlusion
33331051|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
33331052|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
33331053|NCT05065450|Experimental|Brain Stimulation|Neurosurgical epilepsy patients that undergo placement of medial temporal electrode for seizure localizations will be recruited. All participants will view a series of images of emotionally-neutral objects on a computer screen. After each item presentation, they will randomly undergo either active-BLAES or sham-stimulation. Over subsequent days, free recall and recognition memory for these items, relative to new distractor items will be tested. Memory for items presented with and without stimulation will be compared. Brain activity recorded in the medial temporal lobe during item presentations will be used to predict subsequent memory. Such good and bad memory states (biomarkers) will be used to perform closed-loop stimulation when bad memory states are detected in order to enhance subsequent memory.
33331054|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
33331055|NCT01321788||CONTROL|The group that will receive placebo for 14 days
33045369|NCT03354585|Active Comparator|Meditatin Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
33045370|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
33331056|NCT05053828||Non-diabetic controls on clopidogrel|Non-diabetic patients prescribed clopidogrel
33331057|NCT05053828||Diabetic patients on clopidogrel|Diabetic patients on clopidogrel
33045371|NCT05547425|Experimental|Blur obfuscation|Blurring is applied to objects and people in the background of images.
33331058|NCT05053828||Diabetic patients on antiplatelet drugs other than clopidogrel|Diabetic patients on antiplatelet drugs other than clopidogrel
33045372|NCT05547425|Experimental|Edge obfuscation|Objects and people in the background of images are replaced with an outline of the object.
33045373|NCT05547425|Experimental|Cartoon obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
33045374|NCT05547425|Experimental|Raw images|No editing is performed on images.
33045375|NCT04551664|Experimental|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
33045376|NCT04551664|Active Comparator|Best medical management group|Patients in this group will receive best medical management alone.
33045377|NCT04545424|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
33045378|NCT04545424|Active Comparator|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
33045379|NCT05536310||Trilogy TAVI|Patients receiving JenaValve Trilogy Heart Valve System for management of symptomatic, severe aortic stenosis (AS)/ aortic regurgitation (AR) who are at high risk for surgical aortic valve replacement (SAVR)
33045380|NCT04526119|Experimental|Z-338|
33045381|NCT04526119|Placebo Comparator|Placebo|
33045382|NCT04495894|Experimental|Preoperative Ketorolac|Participants randomized to receive ketorolac prior to surgery for stage I/II NSCLC and stage III RCC. Participants will receive standard-of-care surgery. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered.
33045383|NCT04495894|No Intervention|Control Group|Participants randomized to the control group receiving the standard of care during surgery for stage I/II NSCLC and stage III RCC. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints.
33045384|NCT04487236|Experimental|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
33045385|NCT04487236|Experimental|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
33045386|NCT04487236|Experimental|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
33045387|NCT04487236|Experimental|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
33045388|NCT04487236|Experimental|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
33045389|NCT04487236|Experimental|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
33045390|NCT04487236|Experimental|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
33045391|NCT04487236|Experimental|ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
33067885|NCT00161577|Other|A|Group A = Ketorolac
33067886|NCT00161577|Placebo Comparator|B|
33067887|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
33067888|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
33331059|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
33331060|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
33331061|NCT05038306|Active Comparator|Chinese Medicine|
32869546|NCT04963725||Participants Initiating Therapy with Ustekinumab|Data will be collected for participants in Japan who have had an inadequate response, or been intolerant to, conventional or biologic therapies. The treating physician has made the decision to initiate ustekinumab induction therapy in the routine clinical practice - either as a first or subsequent biologic therapy initiating for their moderate to severe ulcerative colitis.
33045392|NCT04487236|Experimental|ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
33045393|NCT04487236|Experimental|ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
33067889|NCT00139841|Experimental|1|bendamustine
33331062|NCT05038306|Placebo Comparator|Placebo|
33331063|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
33331064|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
33067890|NCT04724187|Experimental|intrauterine misoprostol and oxytocin|there will be added effect of misoprostol to stimulate uterine contraction along with oxytocin
33067891|NCT04724187|Active Comparator|oxytocin|only oxytocin will stimulate uterine contraction
33067892|NCT04727021|Experimental|Treatment A: Single oral dose of a 20 mg tablet rivaroxaban|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
33067893|NCT04727021|Experimental|Treatment B: Single oral dose of 20 mg rivaroxaban, granules|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
33067894|NCT04724226|Experimental|C-couple|Camrelizumab and Apatinib after Cryoablation
33067895|NCT00139958||1|
33067896|NCT00139958||2|
33067897|NCT04724343|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33067898|NCT04724343|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33067899|NCT00140075|Experimental|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
33067900|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
33067901|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
33067902|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
33067903|NCT04724382|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
33067904|NCT04724382|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
33067905|NCT01242514|Experimental|A|Oral treatment
33067906|NCT01242514|Experimental|B|Oral treatment
33067907|NCT01242514|Experimental|C|Oral treatment
33067908|NCT04710966|Experimental|debridement group|For the debridement group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic debridement will be performed.
33067909|NCT04710966|Experimental|repair group|For the repair group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic repair will be performed.
33067910|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
33067911|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
33067912|NCT01241461|Experimental|LY2584702|
33067913|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
33331065|NCT05026606|Experimental|Treatment (etigilimab, nivolumab)|Patients receive etigilimab IV over 30-90 minutes on days 1 and 15 and nivolumab IV over 30 minutes on days 2 and 15 of cycle 1 and days 1 and 15 of subsequent cycles. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
33331066|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
33331067|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
33331068|NCT05233488|Experimental|Low US dose|Pulsed US, 1 W/cm2, 10% duty cycle.
33045394|NCT04487236|Experimental|ZN-A-1041+Capecitabine+Trastuzumab|"Phase 1c:~The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion"
33045395|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
33045396|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
33045397|NCT04463641|Experimental|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
33045398|NCT05641311|Experimental|Cohort 1: Japanese Participants|All Japanese participants will receive a single dose of ALXN1840 15 milligrams (mg) in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
33045399|NCT05641311|Experimental|Cohort 2: Non-Japanese Participants|All non-Japanese participants will receive a single dose of ALXN1840 15 mg in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
33045400|NCT04452331|Experimental|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
33045401|NCT04452331|Sham Comparator|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
33331069|NCT05233488|Experimental|Intermediate US dose|Pulsed US, 1 W/cm2, 50% duty cycle.
33045402|NCT04452331|Placebo Comparator|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
33045403|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
33045404|NCT04212169|Experimental|MEDI3506 at dose level 1|Participant will receive multiple doses of MEDI3506 at dose level 1.
33045405|NCT04212169|Experimental|MEDI3506 at dose level 2|Participant will receive multiple doses of MEDI3506 at dose level 2.
33045406|NCT04212169|Experimental|MEDI3506 at dose level 3|Participant will receive multiple doses of MEDI3506 at dose level 3.
33045407|NCT04212169|Placebo Comparator|Placebo|Participant will receive multiple doses of Placebo
33045408|NCT05641272|Experimental|Group I: sublingual allergoid-mannan conjugates (MM09 at 3.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
33045409|NCT05641272|Experimental|Group II: sublingual allergoid-mannan conjugates (MM09 at 9.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
33045410|NCT05641272|Placebo Comparator|Group III: sublingual placebo|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
33045411|NCT05529992|Experimental|Velaglucerase Alfa (VPRIV)|Participants will receive VPRIV intravenous infusion once every other week (EOW) for 60 (+10) minutes as per physician treatment plan for up to 51 weeks.
33045412|NCT04172506|Experimental|AK105|AK105 200 mg, every 2 weeks
33045413|NCT04144036|Experimental|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
33045414|NCT04144036|Experimental|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
33067914|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
33067915|NCT01245634|Experimental|A|
33067916|NCT01245634|Placebo Comparator|B|
33331070|NCT05233488|Experimental|High US dose|Pulsed US, 3 W/cm2, 10% duty cycle.
33331071|NCT05233488|Experimental|Higher US dose|Pulsed US, 3 W/cm2, 50% duty cycle.
33331072|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes"
33331073|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes (30s ON)"
33331074|NCT05019040|Experimental|PA1010 5 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 5 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
33331075|NCT05019040|Experimental|PA1010 10 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 10 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
33331076|NCT05019040|Experimental|PA1010 20 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 20 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
33331077|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
33331078|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
33331079|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
33331080|NCT05552482||Patients with ESRD with early AVF failure|Patients with ESRD who underwent AVF access creation surgery with early AVF failure
33331081|NCT05552482||patients with ESRD without early AVF failure|Patients with ESRD who underwent AVF access creation surgery without early AVF failure
33331082|NCT03764358|Active Comparator|Arteriovenous fistula|
33331083|NCT03764358|Experimental|Tunneled Cuffed Catheter|
33331084|NCT04926376|Experimental|EYE90 Microspheres Treament|Radioembolization with Eye90 Microspheres
33045415|NCT04144036|Experimental|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
33045416|NCT04144036|Experimental|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
33045417|NCT04141891|Experimental|Driving Decision Aid|Web-based Driving Decision Aid
33045418|NCT04141891|Active Comparator|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
33045419|NCT04134169||Rheumatoid arthritis|
33045420|NCT05495204||IBA+OBR (trials)|Participants in TMB-202 or TMB-301/311 trials who received 800 mg ibalizumab every 2 weeks, with or without a loading dose
33045421|NCT05495204||Non-IBA+OBR (OPERA)|Heavily treatment experienced adults living with HIV in care in OPERA, with documented resistance to ≥1 ARV from each of three ARV classes switching to a new regimen that does not include ibalizumab
33045422|NCT04118374|Experimental|Standard Carb Diet then Low Carb Diet|
33045423|NCT04118374|Experimental|Low Carb Diet then Standard Carb Diet|
33045424|NCT05641233|Experimental|Intervention arm|
33045425|NCT04114942|Experimental|Constant Coach|Randomized to have coach during didactic training and internship.
33045426|NCT04114942|Experimental|Internship Only Coach|Randomized to have coach during internship only.
33045427|NCT04114942|Experimental|Never Coach|Randomized to never have coach.
33045428|NCT05481593|Experimental|Scheduled Coaching Calls & Gamified Rewards|
33045429|NCT05481593|Experimental|No Scheduled Coaching Call & Gamified Rewards|
33045430|NCT05481593|Experimental|Scheduled Coaching Calls & Independent rewards (No Gamification)|
33045431|NCT05481593|Experimental|No Scheduled Coaching Calls & Independent Rewards (No Gamification)|
33045432|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
33045433|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
33045434|NCT04067713||PARADIGM-A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Androgen Receptor Signalling Inhibitor (ARSI) drugs with androgen deprivation therapy (ADT).
33045435|NCT04067713||PARADIGM-E|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Enzalutamide with androgen deprivation therapy (ADT).
33045436|NCT04045210|No Intervention|No Intervention|
33045437|NCT04045210|Experimental|Doula|
33045438|NCT05478512|Experimental|VenObi+Ven or VenObi+VenZan|Patients will receive VenObi combination followed by Venetoclax single agent or Venetoclax+zanubrutinib, according to MRD.
33045439|NCT05641038|Active Comparator|Group 1 Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
33045440|NCT05641038|Active Comparator|Group 2 Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
33067917|NCT01240876|Experimental|CEP-37247|
33331085|NCT05177094|Experimental|LY3526318|Participants will be administered LY3526318 orally.
33331086|NCT05177094|Placebo Comparator|Placebo|Participants will be administered placebo orally.
33331087|NCT04920838|Active Comparator|Paracetamol|Patients in this arm will receive paracetamol during 14 days
33331088|NCT04920838|Experimental|Nitazoxanide and Ciclésonide|Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days
33109734|NCT04706754||Prospective|Confirmed ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF cancer patients from across participating sites/cancer centers across Canada.
33109735|NCT04689308|Experimental|Part A: Dose Escalation and Determination of RP2D|Part A: Dose Escalation and determination of RP2D, multiple dose levels of MH048 to be evaluated
33331089|NCT04920838|Experimental|Telmisartan|Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days
33067918|NCT01240876|Placebo Comparator|Matching placebo|
33067919|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
33331090|NCT04920838|Experimental|Fluoxétine and Budésonide|Patients in this arm will receive the combination of Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2*400 mcg) during 7 days
33331091|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
33331092|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
33067920|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
32905085|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
32905086|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
32905087|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
32905088|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
33067921|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
33067922|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
33067923|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
33067924|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
32905089|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
32905090|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
32905091|NCT04311710|Experimental|Part 1 Arm A: mM, mUC, HCC|metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
32905092|NCT04311710|Experimental|Part 1: Arm B: mM|metastatic Melanoma (mM)
32905093|NCT04311710|Experimental|Part 2: Arm A: NSCLC|metastatic non small cell lung cancer (NSCLC)
32905094|NCT04311710|Experimental|Part 2: Arm B: RCC|advanced or metastatic renal cell carcinoma (RCC)
32905095|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
32905096|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
32905097|NCT01402427|Active Comparator|Verapamil|
32905098|NCT01402427|Placebo Comparator|Placebo|
32905099|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
32905100|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
32905101|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
32905102|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
32905103|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
32905104|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
32905105|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
33331093|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
33331094|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
33331095|NCT05416632|Experimental|Arthrometer|
33331096|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
33045441|NCT04029883|No Intervention|Control Group|The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them. The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions. Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved. These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
33045442|NCT04029883|Active Comparator|Message Group|The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months. A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time. To keep the importance of routinizing pill- taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform. These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy. Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
33331097|NCT04887922|No Intervention|Pre-Surgery: No Incentive Spirometry (IS)|-Will not receive a incentive spirometer prior to surgery
33331098|NCT04887922|Experimental|Pre-Surgery: Standard Incentive Spirometry (IS)|"Will receive a conventional spirometer prior to surgery~Will be asked to perform spirometry 30 times per day."
33045443|NCT04029883|Experimental|Incentive Group|The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy. In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits. When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied. MEMS software can be easily customized to display this information. If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag. The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
33045444|NCT04028674|Experimental|Early Activation of Laryngeal Pacing device|Early Activation of the laryngeal pacing device (n=9) at one month post-implantation.
33045445|NCT04028674|Sham Comparator|Delayed Activation of Laryngeal Pacing device|Delayed activation of the laryngeal pacing device (n=3) at two months post-implantation.
33045446|NCT04027777|Experimental|Aktiia.product-P0|Main study arm including 85 subjects
33045447|NCT04027777|Experimental|Aktiia.product-P0 Diabetics|Second study arm including 40 diabetic patients
33045448|NCT04027777|Experimental|Aktiia.product-P0 Aged|Thirs study arm including 40 patients aged 65+
33045449|NCT05470517|Active Comparator|Standard of Care (Arm A)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
33045450|NCT05470517|Experimental|Standard of Care and Antibiotic instillation (Arm B)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy and subsequent instillation of 10ml of intra-peritoneal ceftriaxone (2g)
33045451|NCT03967834|Other|Patient with Soft Tissue Sarcoma (Prospective cohort)|
33045452|NCT05466929|Experimental|TeACH System Resources|Patients who screen positive for anxiety will receive stakeholder-informed feedback and resources (i.e., psychoeducation and mental health recommendations).
33045453|NCT05466929|No Intervention|Evidence-based Resources|Patients who screen positive for anxiety will receive a link to a webpage providing psychoeducation about anxiety and possible treatment options.
33045454|NCT03960190|Experimental|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
33045455|NCT03960190|Experimental|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
33045456|NCT03960151|Experimental|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
33045457|NCT04733326|Experimental|Cryothrapy|5 ml Saline at low temperature (2.5°C) will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
33045458|NCT04733326|Experimental|Ketroloc tromethamine|2ml 30 mg Ketroloc tromethamine will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
33045459|NCT04733326|Placebo Comparator|Saline at room temperature|30 ml Saline at room temperature will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
33045460|NCT05464355||Biomarker monitoring|
33045461|NCT05640921|Experimental|Group-integrated Cognitive Behavioural Therapy (Gi-CBT)|The Gi-CBT sessions will cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience through post-traumatic situations and adversities.
33045462|NCT05640921|Active Comparator|Media Intervention|The second group will receive Media Orientation (MO). The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
33331099|NCT04887922|Experimental|Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message|"Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS."
33045463|NCT03960112|Experimental|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
33045464|NCT03959995|Experimental|exercise|Exercise group
33045465|NCT03959995|Sham Comparator|control|active control group
33045466|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
33045467|NCT03959839|Experimental|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
33045468|NCT03959839|Experimental|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
33331100|NCT04887922|Active Comparator|Post-Surgery: Standard Incentive Spirometry (IS)|"After surgery, the participants will receive a conventional spirometer.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)"
33331101|NCT04887922|Experimental|Post-Surgery: Digital Incentive Spirometry (IS) + Text Message|"After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period."
33045469|NCT03959761|Experimental|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
33045470|NCT03959722|Experimental|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
33045471|NCT03959722|Placebo Comparator|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
33045472|NCT03959683|Active Comparator|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
33045473|NCT03959683|Active Comparator|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
33331102|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
33331103|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
33331104|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
33331105|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
33331106|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
33331107|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
33331108|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
33331109|NCT05551156|Experimental|Animal-assisted interaction|A dog-handler team will visit participants in their hospital room
33045474|NCT03959566|Active Comparator|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily"
33045475|NCT03959566|Experimental|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally once daily"
33045476|NCT03959566|Experimental|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~1200 mg Sutezolid orally once daily"
33045477|NCT03959566|Experimental|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally twice daily"
33045478|NCT03959566|Experimental|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~800 mg Sutezolid orally twice daily~2 mg Midazolam orally once per day on day-1 and day 14"
33045479|NCT03959488|Experimental|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
33045480|NCT03959488|Active Comparator|Palivizumab|anti-RSV monoclonal antibody
33045481|NCT05640882|Experimental|VRET|VRET - 10 week protocol using VR
33045482|NCT05640882|Active Comparator|VRET Olfaction|VRET olfaction - 10 week protocol using VR with olfaction
33045483|NCT03959449|Experimental|Action Observation and Motor imagery|
33045484|NCT03959449|Active Comparator|Motor Imagery|
33045485|NCT03959449|Experimental|Exercise plus motor imagery and action observation|
33045486|NCT03959410||HPV-positive patients|Patients who are positive for HPV DNA test
33045487|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
33045488|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
33045489|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
33045490|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
33045491|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
33045492|NCT03959293|Experimental|FOLFIRI plus durvalumab|"Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
33045493|NCT03959293|Experimental|FOLFIRI plus durvalumab plus tremelimumab|"Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.~Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion~5-FU bolus: 400 mg/m² by 10-minutes IV bolus~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
33045494|NCT05640765|Active Comparator|Arm 1: (Standard of care + Educational material)|CGs receive the standard of care services assigned by the care team for their patient. Participants also receive additional educational and supportive material for health and wellness.
33045495|NCT05640765|Experimental|Arm 2: (Standard of care + BeWell360-CG)|CGs receive the standard of care services assigned by the care team for their patient and participate in the BeWell360-CG coaching sessions on study.
33045496|NCT05441072||Diabetic Retinopathy (DR)|Patients suffering from DR of both genders above 18 years of age with different disease degree. Each patient will be measured with BulbiCam device 6 times within three days
33045497|NCT05441072||Healthy controls DR|Gender- and age-matched healthy controls without any eye disease to the DR patients
33045498|NCT05441072||Age related macular degeneration (AMD)|Patients suffering from AMD of both genders above 18 years of age with different disease degree.
33045499|NCT05441072||Healthy controls AMD|Gender- and age-matched healthy controls without any eye disease to the AMD patients
33045500|NCT03959254|Experimental|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
33045501|NCT03959254|Active Comparator|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
33045502|NCT04733521|Experimental|NSCLC|
33045503|NCT04733521|Experimental|BTC|
33045504|NCT03959215|Experimental|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
33045505|NCT03959215|Active Comparator|Usual care|Usual post-operative physiotherapy rehabilitation
33045506|NCT05640726|Experimental|(SCRT) followed by PD-1+ standard therapy|
33045507|NCT03959176|Experimental|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
33045508|NCT03959176|Experimental|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
33045509|NCT05437757|Experimental|Implantation of PCL Breast scaffold|Insertion of a 3D printed medical-grade polycaprolactone-PCL Breast scaffold with autologous fat graft for unilateral or bilateral breast implant revision and congenital defect correction surgery.
33045510|NCT03959059|Experimental|PKP of traditional procedure|traditional method of PKP
33045511|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
33045512|NCT03958981|Experimental|castor oil group|60 mL of castor oil in 140 mL of orange juice
33045513|NCT03958981|Placebo Comparator|placebo group|Patients will receive sunflower oil as a placebo
33045514|NCT03958942|Active Comparator|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
33045515|NCT03958942|Active Comparator|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
33045516|NCT03958864|Experimental|CC-90001 100 mg|100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
33045517|NCT03958864|Experimental|CC-90001 200 mg|200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
33045518|NCT03958864|Experimental|CC-90001 400 mg|400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
33045519|NCT05640648|Active Comparator|Standard Implementation Strategy Period|During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
33109736|NCT04689308|Experimental|Part B: Dose Expansion in Selected Relapsed/Refractory B-cell Malignancies|Part B: Selected relapsed/refractory B-NHL subjects with at least 1 prior systemic OR standard-of-care therapy.
33109737|NCT04674189|Experimental|CVnCoV: Group 1, Lot 1|Participants in Group 1 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33331110|NCT05551156|Experimental|Conversational interaction|Conversational interaction with the participants and the dog-handler
33331111|NCT05551156|No Intervention|Treatment as usual|Participants will received the regular services currently being received in the hospital
33331112|NCT05165940|Active Comparator|TAU|Treatment As Usual with a VA mental health treatment coordinator
33418353|NCT05217069|Other|RAS wild-type Avelumab|"Induction therapy:~FOLFIRI 5-FU: 400 mg/m2 (i.v. bolus) Folinic acid: 400mg/m2 Irinotecan: 180 mg/m2 5-FU: 2.400 mg/m2 (i.v. 46h)~Cetuximab 400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w~Maintenance therapy:~Avelumab 10mg/kg IV (day 1 q2w)"
33045520|NCT05640648|Experimental|Enhanced Contact Investigation Intervention Period|"The enhanced contact investigation strategy includes 4 implementation facilitation tools and 3 continuous quality improvement techniques and will be delivered as a branded package named for an inspirational Luganda phrase that is translated as We are together with you. Implementation facilitation tools include 1) a TB education pamphlet, 2) a contact identification algorithm, 3) an instructional video on sputum collection, and 4) community health riders who transport clients, community health workers, and sputum samples by motorcycle. The continuous quality improvement techniques delivered as the community of practice package include 1) community of practice meetings, 2) audit and feedback reports and 3) a group chat application."
33045521|NCT03958825|Active Comparator|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
33045522|NCT03958825|Experimental|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
33045523|NCT03958786|Experimental|single arm|500 HIV-1 infected patients, aged 70 years and older
33045524|NCT03958708|Experimental|Treatment Arm|
33045525|NCT05640609|Experimental|Capeox regimen combined with Sintilimab and Bevacizumab|Capeox regimen combined with Sintilimab and Bevacizumab
33045526|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
33045527|NCT03958591|Experimental|Intensive-de-escalation group with intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Wearable devices and smart apps will be used to manage and follow-up patients.
33045528|NCT03958591|Experimental|Intensive-de-escalation group without intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Traditional ways such as telephone contact will be used to follow-up patients.
33045529|NCT03958591|Active Comparator|Traditionally upgrading group|The combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks and thereafter the oral hypoglycemic therapies will be applied. Traditional ways will be used to follow-up patients.
33045530|NCT05411861|Experimental|CPL-01|Low dose of CPL-01
33045531|NCT05411861|Active Comparator|Ropivacaine HCl|Low dose of Ropivacaine HCl
33045532|NCT05411861|Placebo Comparator|Placebo|Low volume of placebo
33045533|NCT03958513|Placebo Comparator|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
33045534|NCT03958513|Experimental|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
33045535|NCT05640570|Experimental|The individualized Jade Wind-Barrier Herbal Tea Bag (JWBT) arm|
33045536|NCT05640570|No Intervention|Control arm|
33045537|NCT03958396|Active Comparator|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
33045538|NCT03958396|Active Comparator|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
33045539|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
33045540|NCT03958318|Experimental|Exercise|Multi-modal exercise program
33045541|NCT03958318|Experimental|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
33045542|NCT03958318|No Intervention|Control|No interventions
33045543|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.~Exclusion criteria:~a) Unwilling to participate~b) Minors (under 18 years old)~c) Foetus mortus or perinatal death of the newborn~d) Admission of the newborn to the ICU~e) Unfamiliar with slovak language~f) Multiple pregnancy"
33045544|NCT05640531|Experimental|WCK 771|WCK 771 600mg, 800mg, and 1000mg WCK 771 BID. Dosage form : IV Infusion
33045545|NCT05640531|Placebo Comparator|Placebo infusion|Matching Placebo administered as IV infusion
33045546|NCT05389982|Placebo Comparator|Standard Care|
33045547|NCT05389982|Active Comparator|standard care + mHealth (GetWell)|
33045548|NCT05389982|Active Comparator|mHealth (GetWell)|
33045549|NCT03958240|Other|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
33045550|NCT03958162|Experimental|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
33045551|NCT03958162|Experimental|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
33067925|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
33331113|NCT05165940|Experimental|New Health Services Intervention|Novel health services intervention with a VA mental health treatment coordinator
33418354|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
33418355|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
33045552|NCT03958123|Experimental|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
33045553|NCT03958123|Experimental|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
33045554|NCT03958123|Experimental|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
33045555|NCT03958123|Experimental|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
33045556|NCT05640492|Experimental|MCT Group|Older adults (more than 59 years old) with depressive symptoms
33045557|NCT05640492|No Intervention|Control Group|
33045558|NCT03933865|Other|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
33045559|NCT03921385||Single cohort - navigated cranial and spine surgery|
33045560|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
33045561|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
33045562|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
33045563|NCT05640453|Active Comparator|Pregabalin group|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
33045564|NCT05640453|Active Comparator|Dexmedetomidine group|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.
33045565|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
33045566|NCT05292326|Experimental|PacePress|the patients will be dressed with PacePress medical device instead of a standard compression device
33045567|NCT05292326|Active Comparator|standard compression band/tourniquet|standard treatment with respect to preventing hemorrhagic complications and implantation site inflammation, the patients will be dressed with a standard compression device/sand bag
33045568|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
33045569|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
33418356|NCT05209737|Experimental|Trendelenburg position|Position: 10-degree Head-down position
33418357|NCT05209737|Active Comparator|Semirecumbent position|Position: 30-degree Head-up position
33045572|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
33045573|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
33418358|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
33109738|NCT04674189|Experimental|CVnCoV: Group 2, Lot 2|Participants in Group 2 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33331114|NCT05133804|Experimental|Treatment with Reboxetine and Methylphenidate|"During the first 3 weeks of the study, subjects in the active treatment group will take reboxetine at a dose of 4mgper day, with the instructions to start at 2mg per day for 3 days and then increase the dosage to 4mg per day for 26 days, i.e. until completion of the study.~On day 22 of the study, the patients will take the first dosage of10mg Ritalin or a placebo, and remain in the clinic for 2 hours to guard safety and guidance during possible occurrence of side effects such as anxiety, palpitations, etc. During the observation time in the clinic, 6 Ritalin IR 10mg and 3 Reboxetine 4mg pills will be handed out to the participants. These pills will be taken at the responsibility of the subject at8:00 AM (Ritalin and Reboxetine) and at noon (Ritalin only) at the following three days."
33331115|NCT05133804|Placebo Comparator|Treatment with Placebo|The patients will take placebos according to the medication schedule of the treatment group.
33109739|NCT04674189|Placebo Comparator|Placebo|Participants will receive a placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33109740|NCT04672122|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity will be at 2 mA (sham mode). The scope of intervention is to investigate effect of sham tDCS on muscle strength.
33109741|NCT04672122|Experimental|Cathodal-tDCS 1 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
33109742|NCT04672122|Experimental|Cathodal-tDCS 1.5 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1.5 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
33109743|NCT04672122|Experimental|Cathodal-tDCS 2 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
33109744|NCT04689191|Experimental|Experimental Vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
33109745|NCT04689191|Active Comparator|Active Comparator Vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
33109746|NCT04671498||Ancillary-correlative (biospecimen collection) (Breast Cancer patients)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
33109747|NCT04671498||Ancillary-correlative (biospecimen collection) (Volunteer)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
33109748|NCT04689113|Experimental|Intervention Group|ıntervention group After determining the women according to the research criteria, they were randomized into intervention and control groups.Firstly, Pre-tests were applied to the women in the experimental group. The Incontinence Health Belief Development Program was applied to the women in the experimental group as 5 sessions.This program includes the following topics; urinary system anatomy and physiology, urinary incontinence and risk factors, definition of kegel exercise and its place in urinary incontinence treatment, kegel exercise applied expression, health motivation. A WhatsApp group was established to remind women in the intervention group about the kegel exercise 3 times a day for 3 months to increase their self-efficacy. In addition, a facebook group was opened and posts about urinary incontinence and kegel exercises were made. Posttests were made 3 months after the training ended
33109749|NCT04689113|No Intervention|Control Group|Firstly, Pre-tests were applied to the women in the control group. No intervention was applied to this group.Posttests were made 3 months after pre-test.
33109750|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
33109751|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
33331116|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
33331117|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
33331118|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
33109752|NCT04664673|Experimental|HABIT-ILE|HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks adapted for adults stroke survivors
33109753|NCT04664673|Active Comparator|Regular care|Usual customary treatment for adults stroke survivors during two weeks
33109754|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
33109755|NCT02925377|Active Comparator|Control|Standard warm-up
33109756|NCT04654299||standard PD (ST-PD)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and standard hepaticojejunostomy
33331119|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
33331120|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia~Postoperative analgesia was performed with epidural analgesia~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
33109757|NCT04654299||PD with external biliary stent(PD-BS)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and hepaticojejunostomy with external biliary stent for externalization of bile fluid
33331121|NCT05410938||Intraperitoneal group|The intraperitoneal regimen was given as 135 mg/m2 intravenous paclitaxel over a 3 or 24 hours period on day 1, followed by 75-100 mg/m2 intraperitoneal cisplatin on day 2 and 60 mg/m2 intraperitoneal paclitaxel on day 8. For women with significantly impaired renal function (i.e., estimated glomerular filtration rate<50 mL/min/1.73 m2), carboplatin (area under the curve [AUC]=6) was used instead of cisplatin.
33418359|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
33331122|NCT05410938||Triweekly group|The triweekly intravenous chemotherapy regimen was given as 175 mg/m2 paclitaxel and carboplatin at a dose calculated to produce an AUC of 6 mg/mL/min on day 1. Bevacizumab was given at a dose of 7.5mg/kg intravenously on day 2 since cycle 2. The treatments were repeated every 3 weeks for 6 cycles. Those women without achievement of complete response after 6 cycles of chemotherapy might be treated with an additional 1-2 cycles of chemotherapy. Bevacizumab was continued for 12 additional cycles or until disease progression, death, unacceptable toxic effects, or patient voluntary withdrawal [5].
33331123|NCT04764448|Experimental|Belcesiran Cohort 1|
33045576|NCT03806491|Experimental|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
33045577|NCT03806491|Active Comparator|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
33045578|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
33045579|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
33045580|NCT05640141||Control|Control group composed of 80 healthy aged volunteers.
33045581|NCT05640141||Motoric Cognitive Syndrom|MCR group composed of 80 MCR participants.
33045582|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
33045583|NCT03641287|Experimental|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
33045584|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
33045585|NCT03618784|Experimental|FURESTEM-RA Inj.|
33045586|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
33045587|NCT05243810|Experimental|Intervention|A prospective, single-arm, repeated measures feasibility study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.
33045588|NCT05640102||Cohort 1: MYD88 L265P mutation|Arm A: Treatment-naïve (TN); Arm B: Relapsed/refractory (R/R)
33045589|NCT05640102||Cohort 2: Non-L265P MYD88 mutation(s) and MYD88 wildtype|Arm C: TN and R/R
33045590|NCT03592888|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
33045591|NCT05640063|Experimental|Intervention Arm|Provision of Enhanced Delivery and Newborn Kits (CMWs and LHW program will continue to function as usual)
33331124|NCT04764448|Placebo Comparator|Placebo Cohort 1|
33331125|NCT04764448|Experimental|Belcesiran Cohort 2|
33331126|NCT04764448|Placebo Comparator|Placebo Cohort 2|
33331127|NCT04764448|Experimental|Belcesiran Cohort 3|
33331128|NCT04764448|Placebo Comparator|Placebo Cohort 3|
33331129|NCT02627196|Experimental|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
33331130|NCT02627196|Active Comparator|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
33331131|NCT04756648|Experimental|CT0180 cells|CT0180 Cells infusion after lymphocyte-depleting with fludarabine and cyclophosphamide.
33331132|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
33045592|NCT05640063|No Intervention|Control Arm|Standard Delivery Kits alone (CMWs and LHW program will continue to function as usual)
33045593|NCT05238389|Experimental|Robotic group|In the robotic group, patients will undergo a 30-session upper limb robotic rehabilitation using the device MOTORE.
33045594|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
33045595|NCT03564340|Experimental|Monotherapy|REGN4018 administration
33045596|NCT03564340|Experimental|Combination Therapy|REGN4018 and cemiplimab administration
33045597|NCT05639907|Experimental|K21 Cavity cleanser-coated TAD|A TAD to be placed is coated with K21 solution. The solution is allowed to evaporate to dryness, leaving a K21-rich film. The TAD is placed following the University TAD placement protocol.
33331133|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
33331134|NCT05123196|Experimental|MT-8554|MT-8554 will be started from a low dose, and gradually increase the dose in order.
33331135|NCT05123196|Placebo Comparator|Placebo|
33331136|NCT04680910|Experimental|Propofol infusion - moderate dose|Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression.
33331137|NCT04680910|Active Comparator|Propofol infusion - low dose|Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.
33331138|NCT05115630|Experimental|Cyclophosphamide|On Days 3 and 4, you will receive cyclophosphamide by vein over about 3 hours to help lower the risk of graft-versus-host disease
33331139|NCT05115630|Experimental|Mesna|On Days 3 and 4, You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses.
33045598|NCT05639907|Placebo Comparator|Ethanol Control|A TAD to be placed is coated with ethanol solution. The solution is allowed to evaporate to dryness (no residue is expected). The TAD is placed following the University TAD placement protocol.
33045599|NCT05206175|Experimental|Primary Arm|Components of the Affect Therapeutic Program for MUD Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine-based addiction counseling with clinical personnel, twice-weekly group therapy, and monthly psychiatrist appointments for evaluation and management and medication support, as needed.
33045600|NCT00392743||pet/spect scan|
33045601|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
33045602|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
33045603|NCT05639166|Experimental|Active|IBIO123 10 mg
33045604|NCT05639166|Placebo Comparator|Placebo|Matching Placebo
33045605|NCT05190419|Experimental|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening
33045606|NCT05190419|Experimental|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening
33045607|NCT05190419|Experimental|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening
33045608|NCT05190419|Placebo Comparator|Placebo tablets BID|Oral, twice daily morning and evening
33045609|NCT05638893|Experimental|Placebo group|Placebo tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
33045610|NCT05638893|Experimental|Metformin group|Metformin 500mg tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
33045611|NCT05190302||Phase I - Patients undergoing regional anesthesia with a block allowing a neurostimulation.|The investigators propose to conduct a single-blind, prospective observational study on all eligible patients undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.
33045612|NCT05637567|Experimental|Treatment Arm|100 mg acetylsalicylic acid per os once daily, starting 1-4 weeks before surgery until 6 months after surgery
33045613|NCT05637567|Placebo Comparator|Control Arm|Identically looking placebo pill, starting 1-4 weeks before surgery until 6 months after surgery
33045614|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
33045615|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
33045616|NCT05162651|Active Comparator|Contingency management group|Randomized to receive individual motivational interviewing therapy and contingency management
33418360|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
33418361|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
33045617|NCT05162651|Other|Control group|Randomized to receive individual motivational interviewing therapy alone
33045618|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.~Average treatment period 4 years."
33045619|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
33045620|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
33045621|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
33045622|NCT05636943|Experimental|Adapted Intimacy Enhancement|Participants receive intimacy enhancement sessions and read a booklet about intimacy and metastatic breast cancer
33045623|NCT05636943|Active Comparator|Intimacy Facts & Resources|Participants read a booklet about intimacy and metastatic breast cancer.
33045624|NCT03508726|Experimental|Phase I dose escalation/Phase II portion|"Phase 1 dose escalation:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.~Phase II portion:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation."
33045625|NCT03435484|Active Comparator|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
33045626|NCT03435484|Active Comparator|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
33045627|NCT05636787|Experimental|Arm B - TreoMel|Chemotherapy regime consisting of treosulfan on three days at 14 g/m2 followed by 200 mg/m2 melphalan given on two days at 100 mg/m2.
33045628|NCT05636787|Active Comparator|Arm A - Mel|Chemotherapy regime consisting of 200 mg/m2 melphalan, split into two days à 100 mg/m2.
33045629|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
33045630|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
33418362|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
32905106|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
32905107|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
32905108|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
32905109|NCT01365611|Experimental|Ketorolac tromethamine|
32905110|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
32905111|NCT01404611|Active Comparator|DF289|Ear drops
32905112|NCT01404611|Active Comparator|DF277|Ear drops
32905113|NCT01404611|Experimental|DF289 plus DF277|Ear drops
32905114|NCT01365845|Active Comparator|1|Conventional photon plan
32905115|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
32905116|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
32905117|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
32905118|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
32905119|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905120|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905121|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905122|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905123|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905124|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
32905125|NCT01404923|Experimental|meteospasmyl|
32905126|NCT01404923|Active Comparator|standard of care|
32905127|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
32905128|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
32905129|NCT04287218|Experimental|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
32905130|NCT04287218|Active Comparator|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
32905131|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
32905132|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
33045633|NCT05636475|Experimental|Manuel hand massage group|According to the hand massage training received, the patient coming out of the surgery is in diamond shape for ten minutes for each hand.
33045634|NCT05636475|Experimental|machine-based hand massage|The pressure setting of the machine is made according to the manual massage application method. In manual massage and machine massage, machine adjustments are made to keep the temperature and pressure difference as low as possible. A hand massage is done for ten minutes for each hand.
33045635|NCT05636475|No Intervention|Control group|The control group will be treated only according to the clinical analgesia protocol.
33045636|NCT05155163|No Intervention|Treatment as Usual|Treatment as usual for opioid use disorder
33045637|NCT05155163|Experimental|SC-POWR|Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction
33045638|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
33045639|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
33045640|NCT05636085||Eligible subjects|Subjects ≥45 years of age and at average risk of colorectal cancer.
33045641|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
33045642|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
33045643|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
33045644|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
33045645|NCT05154578|Experimental|Group 1: 4 week dose interval; 2 doses|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
33045646|NCT05154578|Experimental|Group 2: early intervention; 4 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
33045647|NCT05154578|Experimental|Group 3: early intervention; 8 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
33045648|NCT05154578|Experimental|Group 4: single dose|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA, and one injection of placebo at 30 (±1) weeks GA.
33045649|NCT05154578|Placebo Comparator|Group 5: placebo|Participants will receive one injection of placebo at 22, 26 and 30 weeks (±1) GA
33045650|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
33045651|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
33045652|NCT05635188||Open Surgery|
33331140|NCT05115630|Experimental|Filgrastim|Starting on Day 7, you will begin to receive filgrastim as an injection under the skin 1 time a day.
33045653|NCT05635188||Laparoscopic Surgery|
33045654|NCT05635188||Trephine Surgery|
33045655|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
33045656|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
33045657|NCT05012930|Experimental|Study Provided Diet - Meat|A group of complementary foods provided to participants by researchers.
33045658|NCT05012930|Experimental|Study Provided Diet - Plant|A group of complementary foods provided to participants by researchers.
33045659|NCT05012930|Experimental|Study Provided Diet - Dairy|A group of complementary foods provided to participants by researchers.
33045660|NCT05012930|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
33045661|NCT05634564|Experimental|Concurrent radiochemotherapy combined with immunotherapy|Participants will receive tislelizumab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
33045662|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
33045663|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
33045664|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
33331141|NCT05115630|Experimental|Melphalan|On Day -7, you will receive melphalan by vein over about 30 minutes.
33331142|NCT05115630|Experimental|Fludarabine phosphate|On Days -7, -6, -5, and -4, you will receive fludarabine by vein about 1 hour.
33331143|NCT05115630|Experimental|Tacrolimus|Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.
33331144|NCT05115630|Experimental|Mycophenolate mofetil|by mouth 3 times a day for 90 days or longer.
33331145|NCT05115630|Experimental|Total Body Irradiation One Dose|on Day -2, you may receive 1 dose of total body irradiation (TBI).
33331146|NCT04678492|Experimental|High-dose esomeprazole and amoxicillin dual therapy|Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
33331147|NCT04678492|Active Comparator|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
33045665|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
33331148|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
33045666|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
33045667|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
33045668|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
33045669|NCT05634252|Experimental|Education + Action Plan + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
33045670|NCT05634252|Experimental|Education + Action Plan + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
33045671|NCT05634252|Experimental|Education + Action Plan + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
33045672|NCT05634252|Experimental|Education + Action Plan|Students in this intervention will receive education on skin cancer and prevention strategies and complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure.
33045673|NCT05634252|Experimental|Education + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
33045674|NCT05634252|Experimental|Education + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
33045675|NCT05634252|Experimental|Education + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
33045676|NCT05634252|Experimental|Education|Students in this intervention will receive education on skin cancer and prevention strategies.
33045677|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
33045678|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
33045679|NCT04999826||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
33045680|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
33045681|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
33045682|NCT03151993|Active Comparator|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
33045683|NCT05633472|Experimental|Experimental: Treatment group|Vitamin D (2000IU/day) for 6 months
33045684|NCT05633472|Placebo Comparator|Placebo Comparator: Control group|placebo
33045685|NCT04996238|Other|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid will be collected just before the first vaccination (T1: pre-vaccination), between 14 and 30 days after the second vaccination (T2: post-vaccination), 6 months after the second vaccination (T3: 6 months post-vaccination), between 14 and 30 days after the third/booster vaccination (T4: post-booster-vaccination) and 6 months after the third/booster vaccination (T5: 6 months post-booster-vaccination)
33045686|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~Explore the regulation of hippo-YAP pathway in NESCs."
33067926|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
33331149|NCT04266366|Active Comparator|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
33045687|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
33331150|NCT04266366|Experimental|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
33331151|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
33331152|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
33331153|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
33331154|NCT05091528|Experimental|SBT6050 + T-DXd (5.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
33331155|NCT05091528|Experimental|SBT6050 + T-DXd (6.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
33331156|NCT05091528|Experimental|SBT6050 + Tucatinib + Trastuzumab + Capecitabine|SBT6050 plus tucatinib, trastuzumab, and capecitabine
33331157|NCT05091528|Experimental|SBT6050 + Tucatinib + Trastuzumab|SBT6050 plus tucatinib and trastuzumab
33331158|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
33331159|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
33331160|NCT04236258|Active Comparator|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
33045688|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
33045689|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
33045690|NCT05633160|Experimental|67Cu-SAR-BBN|"In the dose escalation phase:~64Cu-SAR-BBN: Patients will receive up to 2 administrations of 200MBq~67Cu-SAR-BBN: Cohorts 1 - 3: Single administration (dose will be determined based on cohort allocation).~Cohort 4: 2 administrations at the recommended dose (determined by cohorts 1-3).~In the cohort expansion phase:~Patients will receive up to 3 administrations of 200MBq of 64Cu-SAR-BBN and 2 administrations at the recommended dose level of 67Cu-SAR-BBN, determined through the dose escalation.~Additional administrations: (up to a maximum total of 4) may be offered to those participants with radiological non-progression."
33045691|NCT04984655|Other|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|
33045692|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
33045693|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
33045694|NCT03151798|Experimental|Phase I: Observational studies|Patients are eligible who are undergoing either bariatric surgery or a liver biopsy for the diagnosis of nonalcoholic fatty liver disease
33045695|NCT03151798|Experimental|Phase II: Lifestyle treatment|Subjects will undergo lifestyle modification to cause weight loss and improved fitness
33045696|NCT03151798|Placebo Comparator|Phase II: Control treatment|Subjects will be given dietary advice and a stretching program.
33045697|NCT03151759||No radiotherapy|Surgery only
33045698|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
33045699|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
33045700|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
33045701|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
33045702|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
33045703|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
33067927|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
33067928|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
33067929|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
33067930|NCT01245517|Experimental|Dietary Phosphorus Education Program|
33331161|NCT04236258|Active Comparator|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
33331162|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
33331163|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
33331164|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
33331165|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
33331166|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
33418363|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
33418364|NCT02099552||XLHED|Those with the condition of XLHED
33045704|NCT05632809|Experimental|NKTR-255 combination (Durvalumab)|"Participants will receive vein over about 30 minutes. Participants receive the first dose within 72 hours (3 days) after you complete CRT and the second dose at 3 weeks after you complete CRT. Then, you will receive NKTR-255 one (1) time every 4 weeks after that for up to 1 year.~Durvalumab Participants will receive durvalumab by vein over about 30 minutes. You will receive the first dose at 3 weeks after you complete CRT therapy. Then, you will receive durvalumab one (1) time every 4 weeks after that for up to 1 year"
33045705|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
33045706|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
33045707|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
33045708|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
33045709|NCT03151564|Experimental|Deep Learning Image Reconstruction (DLIR)|DLIR is available in both single (SE) and dual/multi energy (DE) CT scanning modes. DLIR SECT and DLIR DECT reconstructions have yet to be compared.
33045710|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
33045711|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
33045712|NCT05630937|Experimental|NMS-01940153E|"Phase 1: Patients will be allocated to sequential cohorts of progressively higher dose levels of NMS-01940153E based on the presence of Dose Limiting Toxicities (DLT).~Phase 2: Patients will be treated at the recommended phase 2 dose (RP2D) defined in the Phase I portion, as starting dose. Intra-patients dose escalation will be applied for patients who tolerate well the drug during the first cycle and experience only mild or no neutropenia."
33045713|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
33045714|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
33045715|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
33045716|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
33045717|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
33045718|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
33045719|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
33045720|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
33045721|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
33045722|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
33045723|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
33045724|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
33045725|NCT04733443|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 /45mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
33045726|NCT04733443|Active Comparator|SeQuent® Please Neo|paclitaxel released coronary balloon catheters Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
33045727|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
33045728|NCT05628675|Experimental|Intervention|"Single-session 90-minute psychoeducational group (Baby CHAT) delivered antenatally."
33045729|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
33045730|NCT03151330|Other|Screened arm|This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control.
33045731|NCT03922646|Experimental|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
33045732|NCT03922646|Active Comparator|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
33045733|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
33045734|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
33045735|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
33045736|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
33045737|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
33045738|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
33045739|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
33045740|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
33045741|NCT04712266|Active Comparator|Insulin IV|calculated insulin rate
33045742|NCT04712266|Experimental|Insulin and Glucagon IV|calculated molar ratio insulin:glucagon
33045743|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
33045744|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
33045745|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
33045746|NCT03912818|Experimental|Cohort II (durvalumab, cis-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Cisplatin 70 mg/m2 on Cycle Day 2, and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
33045747|NCT03912818|Experimental|Cohort III (Durvalumab, carbo-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Carboplatin: AUC 5 on Cycle Day 1 and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
33045748|NCT03912818|Experimental|Cohort I (durvalumab, DD MVAC)|Durvalumab (MEDI4736), at1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Dose Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD MVAC), in 14 day cycles (2 weeks), Methotrexate 30 mg/m2 on Cycle Day 1, Vinblastine 3 mg/m2 on Cycle Day 2, Doxorubicin 30 mg/m2 on Cycle Day 2 and Cisplatin 70 mg/m2 on Cycle Day 2. Patients undergo cystectomy within 6 weeks.
33045749|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
33045750|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
33045751|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
33045752|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
33045753|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
33331167|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
33331168|NCT04558138|Experimental|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
33045754|NCT05616312|Experimental|Postoperative teach-back educational program|Patients will receive teach-back education while they fill out questionnaires.
33045755|NCT05616312|No Intervention|Control|Patients will not receive any teach-back education while filling out questionnaires.
33045756|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
33045757|NCT00393172|No Intervention|no exercise|
33045758|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
33045759|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
33045760|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
33045761|NCT03906539|Placebo Comparator|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
33045762|NCT03906539|Experimental|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
33045763|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
33045764|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
33045765|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
33045766|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~ECG: 12 lead electrocardiogram that visualizes cardiac activity~history and physical: background information about athlete's and their family history~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
33045767|NCT05608512||hospice care nurses|nurses who have worked in a palliative care or hospice unit
33045768|NCT03899090|Experimental|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
33045769|NCT03899090|Active Comparator|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
33045770|NCT03899090|Experimental|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
33045771|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~Expression of insulin-like growth factor 1 receptor (IGF-1R)~Adiponectin~Leptin~Resistin~Osteocalcin~Osteoprotegerin~Insulin, c-peptid~HOMA-IR"
33045772|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
33045773|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
33045774|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
33045775|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
33045776|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
33045777|NCT05605665|Active Comparator|Low-dose interleukin-2|One million IU of IL-2 was injected subcutaneously once every other day for 4 weeks.
33045778|NCT05605665|Active Comparator|Rapamycin|Rapamycin 0.5ml once per day for 4 weeks.
33045779|NCT05605665|Experimental|Low-dose interleukin-2 and rapamycin|One million IU of IL-2 was injected subcutaneously once every other day and rapamycin 0.5ml once per day for 4 weeks.
33045780|NCT03150745|Other|Colposcopic group|
33045781|NCT03150745|Other|office hysteroscopic group|
33045782|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)~Involving prepubertal (seventh grade or roughly age 12 years) children.~AND~Activity Tracker Criteria:~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking~- Meets these criteria within either one or both years of follow-up"
33067931|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
33418365|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
33045783|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:~Participation in more than 1 sport at any physical activity level OR~Participation in none or low training and/or competition in organized sports for any period of time.~Involving prepubertal children.~AND~Activity Tracker Criteria:~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking~- Meets these criteria during both years of follow-up"
33045784|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
33045785|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
33045786|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
33045787|NCT04903262|Experimental|ECCO2R|"Patients will be initially treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~ECCO2R initiated during standardized ventilation with blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5-2.0x baseline. Target: maintain PaCO2 at baseline ± 20%.~VT initially reduced to 5 mL/kg. Sweep gas initiated and VT decreased to 4.5 then 4 mL/kg; PEEP adjusted to maintain same mean airway pressure as during standardized ventilation, provided that Pplat ≤ 25 cmH2O.~Respiratory rate decreased to 8 bpm. If PaCO2 > 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
33045788|NCT04903262|Active Comparator|Standard of care|"Patients will be treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
33045789|NCT03150628|Experimental|Study population|
33045790|NCT00393250|Experimental|1|Hypnosis
33045791|NCT00393250|Active Comparator|2|Control
33045792|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
33045793|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
33045794|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
33045795|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
33045796|NCT05600829|Experimental|Intervention|Patients participate in a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
33045797|NCT05600829|Other|Control|Patients participate in a traditional 12-week outpatient CR program.
33045798|NCT04895852|Experimental|TEAS group|30 minutes TEAS therapy on DU20, EX-HN3, LI4, LR3 once per day for three days before surgery.
33045799|NCT04895852|Sham Comparator|Control group|The control group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA.
33045800|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
33045801|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
33045802|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
33045803|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
33045804|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
33045805|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
33045806|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
33418366|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
33418367|NCT05425784|Experimental|Lumoral Treatment (Study group)|"Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse -tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol five to seven (5-7) times a week. Regular use shall be defined as frequency of a minimum of twice a week.~Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects."
33045807|NCT05600283|Experimental|Self-collected vaginal swab samples|Subjects will self-collect a vaginal swab using the Evalyn brush and complete a scheduled standard of care clinician-collected cervical swab
33045808|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
33045809|NCT04893317|Experimental|Ablation in the ventricle with the Adagio VT cryoablation system|all study subjects will receive an ablation procedure using the Adagio Medical VT Cryoablation System
33045810|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
33045811|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
33045812|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
33045813|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
33045814|NCT05597553|Experimental|Premixed MTA|The premixed bioceramics putty are ready to use materials, fast setting, with superior handling properties and hydrophilic in nature that necessitate moisture from the adjacent tissues to set. They have advantage of insensitive to moisture and blood contamination with less technique sensitive.
33045815|NCT05597553|Active Comparator|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a bioactive, biocompatible, antibacterial material with good stability, and excellent sealing ability that has been used as a dressing material in pulp capping procedures in permanent teeth, although it has good properties, it has many limitations, including long setting time, handling property and tooth discoloration making the use of this material challenging for many clinicians.
33045816|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
33045817|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant."
33045818|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
33045819|NCT04887935|Experimental|Dapagliflozin|"Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy~Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy."
33045820|NCT03083665|Placebo Comparator|Placebo|"12 weeks Treatment Period: Subjects will receive Placebo~4 weeks Down-Titration Period: Subjects will receive Placebo"
33045821|NCT03083665|Experimental|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period"
33045822|NCT03083665|Experimental|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
33045823|NCT05588973|Experimental|Intervention group|"50 patients will be randomized to the MEDISKIN group and 50 to the panthenol group. Everyone will start using their cream from the start of the treatment and will continue for 2 weeks after the end of the radiation therapy (twice a day). If there are cases of patients using panthenol and it is deemed necessary based on symptoms to use MEDISKIN then they will automatically change group. Before starting to use the skin cosmetic products, patients will be asked to test the product for any allergic reactions. The mini-patch test which is standard of practice is carried out by using the substance on the inner elbow or wrist for 24 hours and observing for any reactions."
33045824|NCT05588973|Placebo Comparator|Control group|The group will be using panthenol istead of the MEDISKIN product
33045825|NCT04864886||Healthy volunteers|Control group
33045826|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
33045827|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
33045828|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
33045829|NCT04712344|Experimental|COVID-19 convalescent plasma|A total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 and standard treatment.
33045830|NCT04712344|No Intervention|Standard treatment|Standard treatment.
33045831|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
33067932|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
33067933|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
33045832|NCT05585853|Experimental|Virtual Reality application group|Virtual reality glasses (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) compatible with the mobile phone (Lenovo P2a42) with the Android operating system will be worn and the patient will be watched (underwater world, open-air museum tours, beach trips and nature scenes) by patients for an average of 10 minutes during chest tube removal.
33045833|NCT05585853|No Intervention|Standard of care|Only standard care will be given and no application will be made.
33045834|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
33331169|NCT04558138|No Intervention|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
33331170|NCT03049618|Experimental|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
33045835|NCT04853576|Experimental|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
33045836|NCT02866006|Experimental|BVAC-C mono(High dose)|BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)
33045837|NCT02866006|Experimental|BVAC-C mono(Intermediate dose)|BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)
33045838|NCT02866006|Experimental|BVAC-C + Topo Combi|BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks
33045839|NCT02825836|Experimental|TL-895 80/160 mg QD in R/R Participants|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045840|NCT02825836|Experimental|TL-895 300 mg QD in R/R Participants|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045841|NCT02825836|Experimental|TL-895 600 mg QD in R/R Participants|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045842|NCT02825836|Experimental|TL-895 300 mg BID in R/R Participants|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045843|NCT02825836|Experimental|TL-895 900 mg QD in R/R Participants|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045844|NCT02825836|Experimental|TL-895 100 mg BID in R/R Participants|Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045845|NCT02825836|Experimental|TL-895 150 mg BID in R/R Participants|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045846|NCT02825836|Experimental|TL-895 150 mg BID in Treatment Naïve Participants|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045847|NCT02825836|Experimental|TL-895 100 mg BID in Treatment Naïve Participants|Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
33045848|NCT05575752|Experimental|high temperature (32℃) group|Subjects in exposure group will be exposed to high temperature (32℃) for about 2 hours in a chamber.
33045849|NCT05575752|Sham Comparator|moderate temperature (22℃) group|Subjects in exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
33045850|NCT04826159|Experimental|IMB-1018972 200 mg|
33045851|NCT02766166||Predictive Monitoring|
33045852|NCT02766166||No Predictive Monitoring|
33045853|NCT05573919|Experimental|VivAer Patients|These patients will undergo the VivAer procedure, which involves the use of a stylus to deliver radiofrequency heating to the nasal sidewall to reshape the tissue. This will be done to resolve the patients' nasal obstruction. They will have PNIF measurements taken and will complete symptom assessment questionnaires before and after the VivAer procedure.
33045854|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
33045855|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
33045856|NCT04804046|Experimental|Synbiotic|Bifidobacterium longum spp. longum R0175, Bifidobacterium animalis spp. Lafti B94, Bifidobacterium bifidum R0071 at 3x10^9 CFU/d plus resistant starch type 2, arabinoxylan, and galactooligosaccharide at 24 g/d will serve as the treatment.
33045857|NCT04804046|Placebo Comparator|Digestible Maltodextrin|Digestible maltodextrin will serve as the placebo.
33045858|NCT02743468||Healthy Volunteers|Healthy Volunteers
33045859|NCT05570721|Experimental|Women with perimenopausal depression|Participants will undergo a social stress task (TSST)
33045860|NCT05570721|Experimental|Women without perimenopausal depression|Participants will undergo a social stress task (TSST)
33045861|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
33045862|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
33045863|NCT02633098|Experimental|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
33045864|NCT02633098|Placebo Comparator|Matching placebo|Matching placebo oral tablets once daily for 14 days.
33045865|NCT04798196|Placebo Comparator|Control group|Participants will receive treatment as usual (TAU).
33045866|NCT04798196|Experimental|ElderTree on laptop (ET- LT)|Participants will receive ElderTree on a laptop.
33045867|NCT04798196|Experimental|ElderTree on smart system (ET- SS)|Participants will receive ElderTree on a smart system.
33045868|NCT05565144||cerebral amyloid angiopathy (CAA)|Patients with CAA treated with intravenous thrombolysis
33418368|NCT05425784|Active Comparator|Standard of care (Control group)|Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects.
33045871|NCT04796831|Experimental|All Participants|Participants who will receive a single, oral dose of 60 mg quizartinib and a single, IV administration of 50 μg 14C-quizartinib solution for infusion at 4 hours post-oral dosing.
33045872|NCT05543538|Placebo Comparator|multimedia audio-visual program|
33045873|NCT05543538|Experimental|multimedia audio-visual and experiential learning programmes|
33045874|NCT05543538|Experimental|multimedia audio-visual and teachers' personal demonstration and experiential learning|
33045875|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
33045876|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
33045877|NCT04744220|Experimental|Yoga Training Group|"Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.~During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.~Yoga Session~1-8 weeks and duration~Breathing Exercises 5 min~Instant Relaxation Technique 2 min~Warm-up Exercises 10 min~Quick Relaxation Technique 3 min~Asanas (Posture Exercises) 15 min~Alternative Breathing Exercises 10 min~Deep Relaxation Technique 3 min"
33331171|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33331172|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
33331173|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
33331174|NCT05536102|Experimental|Experiment group|Pegylated Liposomal Doxorubicin + Oxaliplatin + Capecitabine + Tislelizumab; reapt every 21 days.
33331175|NCT04495348||Open-label arm|Participants are switched to doravirine and then switched back to INSTI-based therapy.
33331176|NCT04493320|Experimental|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1 week taper period.~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.~Participants will then enter a 1-week taper period."
33045878|NCT04744220|No Intervention|Control group|"Training: The exercise program will include respiration exercises that they can do at home.~Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.~Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions)"
33045879|NCT02250937|Experimental|Arm I (busulfan days -13 and -12 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
33045880|NCT02250937|Experimental|Arm II (busulfan days -20 and -13 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
33045881|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
33045882|NCT04710173||ARDS children|children with severe ARDS
33045883|NCT05537298||Survivor|Patients (n = 206) surviving critical illness will be enrolled to longitudinal, observational study examining muscle strength, power, and fatigue as well as physical function at hospital discharge and repeated at 3-, 6-, and 12-month following. A subset of individuals (n =40) will undergo muscle biopsies and blood will be collected.
33045884|NCT05537298||Control|A group of health controls will be recruited to serve as comparator to measures of strength, power, physical function, and muscle tissue analyses. Control will participate in a one-time assessment
33045885|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
33045886|NCT04708886|Experimental|Females with Chronic SCI|12-month treatment with monthly subcutaneous romosozumab injections (210 mg), followed by 12-month treatment with weekly oral alendronate tablets (70 mg)
33045887|NCT00393328|Active Comparator|A|
33045888|NCT00393328|Active Comparator|B|
33045889|NCT05530551|Experimental|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
33045890|NCT05530551|Active Comparator|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
33045891|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
33045892|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
33045893|NCT01807468|Experimental|HaploSC+NK|
33045894|NCT04667468|Experimental|Cold-stored Platelet (CSP)|early infusion of one apheresis unit urgent release cold stored platelets (CSP)
33045895|NCT04667468|Active Comparator|Standard Care|resuscitation, blood and blood component transfusion per site standard care
33045896|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
33045897|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
33045898|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
33045899|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
33045900|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
33045901|NCT01807195||the medical records of those in whom a contrast medium|
33045902|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
33045903|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
33045904|NCT05530473||CTR Group|Eyes had a capsular tension ring (CTR) implanted into the capsular bag during the cataract surgery.
33045905|NCT05530473||NCTR Group|Eyes underwent cataract surgery without implanting a CTR.
33045906|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
33045907|NCT04650581|Experimental|Ipatasertib + Fulvestrant|
33045908|NCT04650581|Placebo Comparator|Placebo|
33045909|NCT05526885|Experimental|Approach 1 - CAD4TB screening|Participants with a CAD4TB version 7 (Delft Imaging, NL) score above the overall threshold (as defined for study approach 1) are eligible for Xpert MTB/RIF Ultra testing.
33045910|NCT05526885|Experimental|Approach 2 - CAD4TB screening with POC-CRP triage testing|Participants with a CAD4TB version 7 (Delft Imaging, NL) score within the threshold window (between lower and upper limit threshold as defined for study approach 2), a POC-CRP LumiraDx (LumiraDx Limited, UK) test will follow as a triage test. If CRP is above the determined threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed. If the CAD4TB score is above the upper limit threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed (without further CRP testing).
33045911|NCT01349803|Experimental|PT005 MDI|PT005 MDI
33045912|NCT01349803|Experimental|PT001 MDI|PT001 MDI
33045913|NCT01349803|Experimental|PT003 MDI|PT003 MDI
33045914|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
33045915|NCT01807000|Experimental|Radiolabeled Prucalopride Succinate|
33418369|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
33418370|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
33418371|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
33418372|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
33418373|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
33418374|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
33418375|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
33045923|NCT04636853|Experimental|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
33045924|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
33045925|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
33045926|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
33045927|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
33045928|NCT04604873|No Intervention|No hospital one day care|No hospital one day care
33045929|NCT04604873|Other|Hospital one day care|Hospital one day care
33067934|NCT01247701|Experimental|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
33418376|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
33418377|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
33418378|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
33418379|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
33045930|NCT05520060|Experimental|experimental|The experimental group will be placed in continuous midwifery care. The continuous and supportive care stages to be presented at birth are planned within the framework of Kolcaba's comfort theory. According to this theory, interventions will be applied according to the physical, psychospiritual, environmental and sociocultural comfort needs of women.
33045931|NCT05520060|Placebo Comparator|Control|The experimental group will be placed in routine midwifery care.
33045932|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
33045933|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
33045934|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
33045935|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
33045936|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
33045937|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
33045938|NCT05519397||No response|The breast cancer patients with no response to neoadjuvant therapy
33045939|NCT05519397||Moderate response|The breast cancer patients with moderate response to neoadjuvant therapy
33045940|NCT05519397||Good response|The breast cancer patients with good response to neoadjuvant therapy
33045941|NCT01806688|Experimental|Experimental Snack #1|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
33045942|NCT01806688|Experimental|Experimental Snack #2|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of a buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
33045943|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
33045944|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
33045945|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
33045946|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
33045947|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
33045948|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
33045949|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
33045950|NCT05517291|Experimental|DCB|participants in this group will be received drug-coated balloon angioplasty
33045951|NCT05517291|Active Comparator|stenting|participants in this group will be received primary selective stenting
33331177|NCT04493320|Experimental|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1-week taper period."
33045952|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
33045953|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
33067935|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
33360673|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
33067936|NCT00140582|No Intervention|B : no maintenance|No further treatment
33067937|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
33067938|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
33067939|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
33067940|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
33067941|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
33067942|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
33067943|NCT00162201|Experimental|1|
33067944|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
33067945|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
33067946|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
33067947|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
33067948|NCT04518241|Experimental|Condition 1|Core, fixed compensation, TMQQ, MI sessions
33067949|NCT04518241|Experimental|Condition 2|Core, lottery prize, TMQQ, MI sessions
33067950|NCT04518241|Experimental|Condition 3|Core, fixed compensation, MI sessions
33067951|NCT04518241|Experimental|Condition 4|Core, lottery prize, MI sessions
33067952|NCT04518241|Experimental|Condition 5|Core, fixed compensation, TMQQ
33067953|NCT04518241|Experimental|Condition 6|Core, lottery prize, TMQQ
33067954|NCT04518241|Experimental|Condition 7|Core, fixed compensation
33067955|NCT04518241|Experimental|Condition 8|Core, lottery prize
33067956|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
33067957|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
33067958|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
33067959|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
33067960|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
33067961|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
33067962|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
33067963|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
33067964|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
33067965|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
33067966|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
33067967|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
33067968|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
33067969|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
33067970|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
33067971|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
33067972|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
33067973|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
33067974|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
33067975|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
33067976|NCT04515628|Experimental|Period A: Rosuvastatin|
33067977|NCT04515628|Experimental|Period B: Branebrutinib|
33067978|NCT04515628|Experimental|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
33067979|NCT04515628|Experimental|Period D: Branebrutinib|
33067980|NCT04511845|Experimental|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
33045954|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
33045955|NCT05492955|Active Comparator|Standard of Care (SOC)|Participants will receive clinic-based standard of care
33045956|NCT05492955|Experimental|Community Health Worker Care Model (CHW)|Participants will be given a standard blood pressure cuff (Omron) for at-home BP monitoring, and will be assigned to a CHW for follow-up visits and medication delivery.
33045957|NCT05492955|Experimental|Enhanced Community Health Worker + Mobile Health Monitoring (eCHW+)|Participants will be given a blood pressure cuff with cellular capability (Blipcare) for at-home BP monitoring which automatically transmit BP data to our server for nurse review. These participants will also be assigned to a CHW for follow-up visits and medication delivery.
33045958|NCT01806571|Experimental|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
33045959|NCT04590248|Experimental|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
33045960|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
33045961|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
33045962|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
33418380|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
33045963|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
33418381|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
33045964|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
33045965|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
33045966|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
33418382|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
33418383|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
33045967|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
33045968|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
33109758|NCT04622670|Experimental|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over and receive a yoga manual and DVD during and after CRT.
33418384|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
33418385|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
33418386|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
33418387|NCT01619553||affected|individuals with keloids
33418388|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
33418389|NCT02094404||Children at the ED<18yr|
33045969|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
33045970|NCT05489445||Patients undergoing EP|Patients already clinically indicated for undergoing catheter-based eletrophysiological intervention, in which the FDA approved medical device KODEX-EPD system will be used.
33418390|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
33418391|NCT01377753|Experimental|Arm 1/Magnetic Resonance (MR) Thermal Image Guided Laser Ablation|Eligible subjects will undergo MR thermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
33418392|NCT03556670|Experimental|Total Worker Health Intervention|
33418393|NCT03556670|Active Comparator|Control|
33418394|NCT02250560|Experimental|Replenine®-VF|
33418395|NCT05197647||Patients with mild COVID-19|Patients with symptomatic COVID-19 disease not requiring hospitalization.
33418396|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
33045971|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
33045972|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
33067981|NCT04511845|Experimental|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
33109759|NCT04622670|Active Comparator|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
33109760|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
33109761|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
33109762|NCT02925416|Experimental|Two doses oritavancin|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL D5W will be administered.
33109763|NCT02925416|Other|One dose oritavancin, one dose placebo|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, a placebo (D5W) will be administered.
33109764|NCT04614246|Experimental|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
33109765|NCT04614246|Experimental|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
33109766|NCT04614246|Experimental|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
33109767|NCT04614246|Active Comparator|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
33109768|NCT04614246|Placebo Comparator|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
33109769|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously~Pembrolizumab will be administered every 3 weeks intravenously"
33109770|NCT04578912|Active Comparator|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
33109771|NCT04578912|Active Comparator|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
33109772|NCT04578912|Sham Comparator|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
33109773|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria~Ileal pouch reservoir in situ~Greater than three years since closure of ileostomy~Normal pouch function as defined by Orësland score of <4~Never had a diagnosis of pouchitis~Never had treatment for pouchitis~No evidence of pouchitis on rigid pouchoscopy~CRP <10"
33109774|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
33109775|NCT02917889|Experimental|Placebo protocol|300 mg in pills
33109776|NCT02917811||ICU patients|
33109777|NCT04564092|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
33109778|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
33109779|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
33109780|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
33109781|NCT04688840||study results and satisfaction with telemedicine|the investigators designed a group on WhatsApp for all patients included in the study. The questionnaires were sent on the group to be filled by the patients in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of patients' informations, every patient was asked to resend the file and x- ray pictures to the surgeon private account. the investigators collected data received by all patients and reviewed all x-rays. If there was any serious complain or major radiological finding the investigators asked the patient for immediate clinical visit.
33109782|NCT04688840||study results and satisfaction with routine follow up|the investigators asked the patients to come for routine follow up visit (RV) and reevaluate them clinically and radiologically. the investigators asked patients to calculate total time needed for completion of the questionnaires, time needed for x-ray and the investigators added time needed for reviewing these files. The same was done at the RV including time of transportation
33109783|NCT04688879||According to the degree of occlusion, 13 patients were divided into complete and incomplete groups.|Seven patients were complete occlusion and 6 patients were incomplete occlusion and all underwent thrombolysis with intra-arterial urokinase and the outcome was analysed..
33109784|NCT04526418|Experimental|24/7 EEG™ SubQ System|To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.
33331178|NCT04493164|Experimental|Treatment (CPX-351, ivosidenib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and ivosidenib PO QD on days 1-28. Patients who do not achieve complete remission may receive a second cycle of induction therapy in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission proceed to consolidation.~CONSOLIDATION: Patients receive CPX-351 IV over 90 minutes on days 1 and 3, and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who are experiencing clinical benefit and who have not experienced excessive toxicity after completion of 2 years of maintenance may be eligible to continue therapy after discussion with the principal investigator."
33331179|NCT04452916|Active Comparator|Fasting|Starts immediately with 5 days of Buchinger fasting
33109785|NCT04688957|Active Comparator|osteotome sinus lifting|
33109786|NCT04688957|Experimental|oseodensification sinus lifting|
33109787|NCT04517721|Experimental|Treatment group|"The 4C's-TBuRP for adult burn survivors comprises of two phases:~Phase 1: Discharge planning/ preparation and day of discharge (Comprehensive assessment and evaluation, Education, guidance, and counselling, Treatment and procedures, Case management (referral for nursing follow-up), multi-disciplinary follow-up and Surveillance)~Phase 2: Follow-up Phase (2 WeChat Telehealth, 6 structured telephone follow-ups and daytime patient/ family-initiated telephone service; home visit based on meeting criteria) over an 8-week follow-up with delivery of rehabilitation care across the spectrum by trained nurse case managers ongoing assessment, intervention using the Omaha System and delivery of evidence-based care."
33109788|NCT04517721|Active Comparator|Control group|Participants in the control group will receive the care at the discharge planning phase and thereafter continue to utilise the exiting service available at the hospital, that is, medical review in the hospital.
33109789|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
33109790|NCT04486989|Experimental|Cardiovascular Conditioning Protocol|Participants will complete a sub maximal cardiovascular training program twice per week for a period of 4 weeks.
33109791|NCT04486989|Active Comparator|Voice Production Exercises|Participants will complete voice production exercises twice per week for a period of 4 weeks.
33109792|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
33109793|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
33109794|NCT04486638||Pregnant women and their offspring(s)|Women and their offspring(s) exposed to Dengvaxia during pregnancy
33109795|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
33109796|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
33109797|NCT04485273|Active Comparator|Dexmedetomedine Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected, in addition to dexmedetomedine.
33109798|NCT04485273|Placebo Comparator|Control Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected.
33109799|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
33109800|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
33109801|NCT02205840|Experimental|SI-614|
33109802|NCT02205840|Placebo Comparator|Placebo Vehicle|
33109803|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
33109804|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
33109805|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
33109806|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
33109807|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
33109808|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
33109809|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
33109810|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
33109811|NCT02205099|Placebo Comparator|Placebo|Placebo
33109812|NCT02200380|Experimental|CDX-301|
33109813|NCT02200380|Experimental|CDX-301 and plerixafor|
33109814|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
33109815|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
33109816|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
33109817|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
33109818|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
33109819|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
33109820|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
33109821|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
33109822|NCT02187003|Experimental|Rivipansel Treatment Arm|
33109823|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
33109824|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
33109825|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
33331180|NCT04452916|Placebo Comparator|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
33331181|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
33331182|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
33331183|NCT04362826|Experimental|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
33331184|NCT04362826|Placebo Comparator|Placebo|Placebo plus normal standard of care for breast cancer.
33331185|NCT05524714|Experimental|solubilized Xanthohumol low dose|single dose of 86 mg micellar solubilized Xanthohumol
33045973|NCT04581317|Experimental|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
33045974|NCT04581317|Experimental|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
33045975|NCT04581317|Experimental|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
33045976|NCT01806259|Experimental|ketorolac 30 mg|Active drug to be compared with placebo
33045977|NCT01806259|Placebo Comparator|NaCl 0.9% 3mL|Placebo looking like the Active drug
33045978|NCT05482542|Other|Cyclophosphamide/ATG Conditioning Regimen|Cyclophosphamide (200 mg /kg) / rabbit antithymocyte globulin (6.0 mg/kg)
33045979|NCT05482542|Other|Cyclophosphamide/Rituximab Conditioning Regimen|Cyclophosphamide (200 mg/kg) / rituximab (1000 mg).
33045980|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
33045981|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
33045982|NCT04579757|Experimental|Surufatinib and tislelizumab (dose escalation_Part 1)|In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).
33045983|NCT04579757|Experimental|Surufatinib and tislelizumab (indication specific_Part 2)|In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W
33045984|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
33045985|NCT05482425|Other|Autologous facial fat graft injection- washed fat|Washed fat injected into both the left and right sides of the face.
33045986|NCT05482425|Other|Autologous facial fat graft injection-unwashed fat|Unwashed fat injected into both the left and right sides of the face.
33045987|NCT01806181|Other|Cancer Treatment|
33045988|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
33045989|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
33045990|NCT00387452|Active Comparator|1|
33045991|NCT00387452|Active Comparator|2|
33045992|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
33045993|NCT05457075||Case|Stage II-III rectal cancer patients who have neoadjuvant therapy
33045994|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
33045995|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
33045996|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
33045997|NCT01805986||MS patient|
33045998|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
33045999|NCT04551131|Experimental|Frontline Arm|"Safety Phase:~Patients with newly diagnosed HLH will receive ruxolitinib PO or NGT, dexamethasone, PO or IV and etoposide IV.~Expansion Phase:~Patients with newly diagnosed HLH treatment will begin with ruxolitinib PO or NGT at the MTD dose. Dexamethasone will be administered PO or IV. Etoposide IV will be added based on disease response."
33046000|NCT04551131|Experimental|Salvage Arm|Patients with relapsed/refractory HLH will receive ruxolitinib PO or NGT and dexamethasone PO or IV. Etoposide IV will be added based on disease response.
33046001|NCT05451693||Outreach-ER|Outreach-ER is a psychosocial intervention designed by dementia experts in the field of care partner interventions. The care plan will be personalized to the needs of the care partner/PLWD.
33046002|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
33046003|NCT01805830|Experimental|MP513 group|
33046004|NCT01805830|Placebo Comparator|Placebo group|
33331186|NCT05524714|Experimental|solubilized Xanthohumol high dose|single dose of 172 mg micellar solubilized Xanthohumol
33331187|NCT05524714|Active Comparator|native Xanthohumol low dose|single dose of 86 mg native Xanthohumol
33331188|NCT05524714|Active Comparator|native Xanthohumol high dose|single dose of 172 mg native Xanthohumol
33331189|NCT05692804||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
33046005|NCT04527107|Experimental|THR-149 dose level 1|
33046006|NCT04527107|Experimental|THR-149 dose level 2|
33046007|NCT04527107|Experimental|THR-149 dose level 3|
33046008|NCT04527107|Experimental|THR-149 + sham|
33046009|NCT04527107|Experimental|THR-149 + aflibercept flip-over|
33046010|NCT04527107|Active Comparator|Aflibercept + THR-149 flip-over|
33046011|NCT04527107|Active Comparator|Aflibercept + sham|
33046012|NCT01805791|Placebo Comparator|Placebo|Placebo, oral tablets, three times a day
33046013|NCT01805791|Experimental|HMPL-004 1800 mg/day|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
33046014|NCT01805791|Experimental|HMPL-004 2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
33046015|NCT05444244|Active Comparator|Brain Health Community Registry Recruitment|
33046016|NCT05444244|No Intervention|Standard Recruitment|
33046017|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
33046018|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
33046019|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
33046020|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
33046021|NCT04493645|Active Comparator|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
33046022|NCT04493645|Experimental|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
33046023|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
33046024|NCT05437887|Experimental|Fucoidan|All patients are in the experimental group.
33046025|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
33046026|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
33046027|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
33046028|NCT01805557|Active Comparator|R-DHAP|R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
33046029|NCT01805557|Experimental|BR-DHAP|Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
33046030|NCT04477343|Experimental|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
33046031|NCT00389727|Experimental|Group 1 Patients|Radiotherapy Patients
33046032|NCT00389727|No Intervention|Group 2|
33046033|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
33046034|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
33046035|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
33046036|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
33046037|NCT04474223|Experimental|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
33046038|NCT05430477||Cohort 1|Subjects recruited to Cohort I will include patients who are scheduled to undergo oral lesion biopsy as well as patients who are determined to need a biopsy at the time of visual examination, which often occurs in-clinic. Cohort I will consist of 200 oral lesion biopsy patients total. Prior to the start of enrollment in this Cohort, up to 5 additional subjects will be enrolled to optimize the data acquisition process.
33046039|NCT05430477||Cohort 2|Potential study participants will be identified through Dartmouth-Hitchcock Medical Center (DHMC)'s Head and Neck Tumor Clinic, and will be patients with diagnosed or suspected cancer of the oral cavity, oropharynx, hypopharynx, or larynx who require biopsy or resection for either diagnostic or therapeutic purposes. Cohort II will be comprised of 50 patients undergoing oral cavity cancer resections. Initially, up to 5 subjects will be enrolled in addition to the 50 patients in this Cohort in order to optimize the data acquisition process.
33046040|NCT01805440|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
33046041|NCT01805440|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
33046042|NCT01805440|No Intervention|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
33046043|NCT01688011||Newly diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
33046044|NCT01688011||Newly diagnosed Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
33046045|NCT01688011||Newly diagnosed Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
33109826|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
33046046|NCT01688011||Treated Myelofibrosis (MF)|Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
33331190|NCT05692804||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
33331191|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
33046047|NCT01688011||Newly diagnosed Idiopathic cytopenia of undetermined significance (ICUS)|Newly diagnosed ICUS patients.
33046048|NCT01688011||Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Treated LR-MDS patients receiving first active treatment regimen containing at least one non-ESA therapy
33046049|NCT05428488|Experimental|Experimental|"All included patients will receive TNF inhibitors subcutaneous for 3 months. In the experimental arm, a therapeutic sequential strategy will be proposed from M3 visit.~At 3 months (M3), patients who have at least a moderate EULAR response (delta DAS28-CRP between M0 and M3>0.6 and DAS28-CRP≤5.1 at M3) will be randomized with a 1:1 ratio in the sequential strategy arm or the control arm.~In the sequential strategy (experimental) arm, the 88 randomized RA patients will be switched to abatacept subcutaneous for 9 months."
33331192|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
33331193|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
33331194|NCT05692648|Experimental|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
33331195|NCT05692648|Experimental|Hourly position change group:|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
33331196|NCT05692648|Other|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation.
33331197|NCT05692570|Experimental|Single-sequence, 3-period|Period 1: single dose of PBI-200; Period 2: daily dosing of ritonavir with a single dose of PBI-200 co-administered once ritonavir steady state reached; Period 3: daily dosing of cobicistat with a single dose of PBI-200 co-administered once cobicistat steady state reached.
33331198|NCT05692492|Experimental|ZSP1601 50mg BID|
33331199|NCT05692492|Experimental|ZSP1601 100 mg BID|
33046050|NCT05428488|Active Comparator|Control|"All included patients will receive TNF inhibitors subcutaneous for 3 months. In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for another 9 months (from M3 visit).~In case of insufficient response to a first TNF inhibitor at 6 or 9 months, a second TNF inhibitor will be proposed."
33046051|NCT05427708|Experimental|Interoceptive Exposure (IE)|Participants assigned to the interoceptive exposure condition will receive twice-weekly 90-minute in-person treatment sessions for four weeks. This treatment will include education about anxiety and factors that maintain anxiety symptoms. In addition, participants will be asked to perform exercises designed to activate potentially distressing - but harmless - bodily sensations that are commonly associated with stress and anxiety. Participants will also be encouraged to practice these exercises daily at home.
33331200|NCT05692492|Placebo Comparator|Placebo|
33046052|NCT05427708|Experimental|Capnometry-Guided Respiratory Intervention (CGRI)|If assigned to this condition, participants will be expected to complete twice-daily 17-minute tablet-assisted breathing exercises at home for four weeks. They will also receive brief phone check-ins with their study therapist weekly to review progress and troubleshoot any problems they may be experiencing. Last, these participants will have access to a paced-breathing app that provides audio recordings to maintain specified breathing rates for up to 10 minutes.
33046053|NCT05427708|Active Comparator|Psycho-Education (PsyEd)|If assigned to this condition, participants will undergo one 90-minute video conferencing session with a therapist. During this session, they will be provided information about the nature and causes of anxiety-related disorders and learn tips for coping with anxiety symptoms when they arise. At the end of this session, participants will receive handouts that will help reinforce what they've learned.
33046054|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.~Intervention: Fecal microbiota transplantation"
33046055|NCT01515124|No Intervention|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:~2 custom fitted compression garments (baseline and 6 months)~evaluations for flare-ups at request (and at each measurement time point)~lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
33046056|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
33046057|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
33109827|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
33331201|NCT05692414|Experimental|Preoperative carbohydrate loaded patients|
33331202|NCT05692414|No Intervention|Conventional fasting protocol|
33046058|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
33046059|NCT05426928||HIPEC|"Adults undergoing cytoreductive surgery and who are deemed eligible for HIPEC after surgical exploration in the operating theatre.~The patients will receive HIPEC according to routine practice, as defined by the surgical oncologist."
33046060|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
33109828|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
33046061|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
33046062|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
33109829|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
33331203|NCT05692336|Experimental|vestibular training|balance training that focus on vestibular system stimulation like when the eyes are folded while standing on a balance board or walking on swinging boards
33331204|NCT05692336|Experimental|dual task training|The children received special balance training in the form of dual-task training performing balance activities as a basic task in conjunction with second task that includes upper limb activity using basketball and long rings shaft or cognitive task like telling a story during balance training .
33331205|NCT05692258|Experimental|Acupuncture therapy + basic therapy|"Acupuncture treatment-Selected acupoints: Dazhui (GV14) , Feishu(BL13), Dingchuan(EX-B1), Tiantu(CV22), Danzhong(RN17), Quchi(LI11), Kongzui(LU6), Neiguan(PC6), Yinlingquan(SP9), Fenglong(ST40), Qihai(cv6). Once a day for 10 consecutive times.~Western medicine treatment (basic treatment) : According to the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial 10th Edition) issued by the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine, patients are arranged to be quarantined in hospitals for treatment. Conventional Western medicine treatment includes supportive treatment, antiviral therapy, immunotherapy, anticoagulant therapy, antibiotic therapy, etc."
33331206|NCT05692258|Sham Comparator|sham acupuncture + basic therapy|sham acupuncture. Acupoint selection, body position, intervention time and course of treatment are the same as those in acupuncture treatment group. After acupoint disinfection, fixed pad is pasted on the acupoint, and 1.5 blunt needle will be used to Pierce directly through the sham instrument to fix pad to the skin surface without piercing the skin, and do not require Deqi. Western medicine treatment (basic treatment) is the same as the acupuncture group.
33046063|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
33046064|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
33046065|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
33046066|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
33046067|NCT05426460|Experimental|AAT + tDCS|Approach Avoidance Task + Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
33046068|NCT05426460|Sham Comparator|AAT + sham tDCS|Approach Avoidance Task with Sham Transcranial Direct Current Stimulation.
33046069|NCT05426460|Active Comparator|AC + tDCS|Active Control Task with Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
33046070|NCT05426460|Sham Comparator|AC + sham tDCS|Active Control Task with sham Transcranial Direct Current Stimulation
33046071|NCT01466452|Active Comparator|Aspirin 100|
33046072|NCT01466452|Active Comparator|Aspirin 200|
33046073|NCT01466452|Active Comparator|Aspirin 100 x 2|
33046074|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
33046075|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
33046076|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
33046077|NCT01466374|Experimental|Cohort 1: Induction|Placebo
33046078|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
33046079|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
33046080|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
33046081|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
33046082|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
33046083|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
33046084|NCT05426109|Experimental|Peanut snacks|Participants will be provided and consume an extra 500 kcal/day of peanut-containing snacks for 10 weeks.
33046085|NCT05426109|Active Comparator|No peanut-containing snacks|Participants will be provided and consume an extra 500 kcal/day of snacks without peanuts or peanut-containing foods for 10 weeks.
33046086|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
33046087|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
33046088|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
33046089|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
33046090|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
33046091|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
33046092|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
33046093|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
33046094|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
33331207|NCT05692180|Experimental|Benralizumab|Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.
33046095|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.~-Intervention - Magnetic Levator Prosthesis (MLP)"
33418397|NCT05194761|Active Comparator|using nebulization|extubated neonates will be divided in two group , one will receive saline nebulization for 3 days postextubation ,
33046096|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.~-Intervention - Magnetic Levator Prosthesis (MLP)"
33046097|NCT05424198|Active Comparator|Trident Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge insulated cannula with a 5 mm active tip will be placed perpendicularly at targeted medial branches (the nerves carrying pain signals from the facet joints).
33331208|NCT05692180|Placebo Comparator|Placebo|Patients will receive a matching solution of the placebo via SC injection.
33331209|NCT05692024|Active Comparator|Coffee|Participants in the active arm will take 10 capsules of coffee, each of which will contain 600 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend (equivalent daily dose: three cups of coffee). Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
33046098|NCT05424198|Active Comparator|Conventional Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge conventional cannula with a straight 4 mm active tip will be placed parallel and oblique to the targeted medial branch branches (the nerves carrying pain signals from the facet joints). At each location, one lesion will be made to accommodate anatomic variation.
33046099|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
33046100|NCT04390763|Experimental|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
33046101|NCT04390763|Experimental|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
33046102|NCT04390763|Experimental|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
33046103|NCT04390763|Active Comparator|Randomized Arm 3|gemcitabine + nab-paclitaxel
33046104|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
33046105|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
33046106|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
33046107|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
33046108|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
33046109|NCT00393640|No Intervention|B|
33046110|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
33046111|NCT00393640|No Intervention|D|
33046112|NCT05420025|Experimental|CHILDREN APPLIED WITH VIRTUAL REALITY GLASSES|Before the first dressing (5 minutes before the dressing) of the children who were accepted to the Organ Transplantation A Service from the intensive care unit after the transplantation, the introductory characteristics form and scales will be applied and the physiological parameters of the child (heart rate, respiratory rate, blood pressure) will be applied by the researcher. , oxygen saturation) will be taken. Then the children will be put on SGG and the glasses will be synchronized. During the dressing, children will be shown a video with SGG, which received expert opinion beforehand. After the dressing, the physiological parameters of the children will be measured again and the scales will be applied again.
33046113|NCT01465984|Experimental|IV Paracetamol|
33046114|NCT01465984|Active Comparator|IV Morphine Sulfate|
33046115|NCT04328246|Experimental|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
33046116|NCT04328246|Active Comparator|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
33046117|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
33046118|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
33046119|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
33046120|NCT01465906|Active Comparator|Tiotropium bromide|
33046121|NCT05408832|Experimental|Personalized Trial ABCCBA|Participants in Arm 1 will receive a Personalized Trial of the 3 stress management interventions in an ABCCBA treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of study-provided stress management content each week.
33109830|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
33109831|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
33331210|NCT05692024|Placebo Comparator|Placebo|Participants in the placebo arm will take 10 capsules of placebo.Each placebo capsule will contain 600 mg of microcrystalline cellulose with flavor and food-coloring substances. Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
33331211|NCT05691946|Experimental|Kinesiology Taping Group|Kinesiology Taping Group
33331212|NCT05691946|Placebo Comparator|Placebo Control Group|Placebo Taping Group
33331213|NCT05691790|Active Comparator|Control Group|Participants who are allocated to the control group will receive a pamphlet about recommendation for influenza vaccines, pneumococcal vaccines, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. This group will receive six control telephone care visits over six weeks. We will purposively balance the characteristics of the student helpers who do the control telephone visits and the patient activation interviews. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health. In the last telephone care visit, the interviewer will give a summary for how to live a healthy lifestyle and a reminder of taking the recommended vaccinations for older people shown in the pamphlet.
33331214|NCT05691790|Experimental|Intervention Group|"Intervention development and delivery The interventions will involve deliver a booklet designed based on MMA and six telephone interviews for patient activation.~Design of booklet for older people's preventive care: The booklet will be framed as one series of Positive aging via preventive care-vaccination. According to MMA, the booklet will be aimed to translate expert knowledge into information that can fit to older people's mental models (e.g., misperceptions and knowledge deficits revealed in our previous qualitative studies) regarding vaccinations to facilitate cognitive process of the information.~Patient activation sections: We will design six telephone-based patient activation sections with accommodation for older people's mental models and decision-making preference. The motivation interviewing (MI) techniques will be incorporated into the design of patient activation sections."
33331215|NCT05691556||Children CP|Children with cerebral palsy with motor impairment of the upper limb(s), seen in consultation and included in a HABIT-ILE therapeutic program and/or botulinum toxin injections
33331216|NCT05422612|Experimental|Intervention A: Fluoxetine HCl|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all subjects will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a subject's dose is decreased due to tolerability, the dose will not be increased.
33046122|NCT05408832|Experimental|Personalized Trial CBAABC|Participants in Arm 2 will receive a Personalized Trial of the 3 stress management interventions in a CBAABC treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of the study-provided stress management content each week.
33046123|NCT05408832|Active Comparator|Standard Care|Participants in Arm 3 will receive Standard Care of the 3 stress management techniques (mindfulness meditation, yoga, and brisk walking). Participants will receive access to the same number of views of the mindfulness meditation, yoga, and brisk walking content given to participants randomized in Arm 1 and Arm 2. However, they will not be prompted to complete any session according to a randomization sequence. A link to the stress management video will be delivered via text 1 time per week to the participant. Participants will be limited to 36 total views of study-provided stress management content (12 total views per stress management technique).
33046124|NCT01465867|Experimental|Selenium|
33046125|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
33046126|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
33046127|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
33046128|NCT04244864|Active Comparator|Treatment as usual (TAU)|8-12 months of treatment
33046129|NCT04244864|Experimental|Cross-sectoral social intervention|8-12 months of treatment
33046130|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
33046131|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
33046132|NCT05408052|Active Comparator|Standard Epidural|Standard epidural technic will be applied before the anesthesia induction for perioperative analgesia
33046133|NCT05408052|Active Comparator|Dural Puncture Epidural (DPE)|Dural Puncture Epidural technic will be applied before the anesthesia induction for perioperative analgesia
33046134|NCT01465750||Ovarian Cancer|
33046135|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
33046136|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
33046137|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
33046138|NCT01465633|Active Comparator|with iodine|
33046139|NCT01465633|Experimental|without iodine|
33046140|NCT05395026|Experimental|Investigational Stimulation Parameters|
33046141|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
33046142|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
33331217|NCT05422612|Placebo Comparator|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
33331218|NCT05422612|Experimental|Intervention B Vilazodone|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. A televisit will be conducted by site personnel 1 week after each increase in dose to determine tolerability. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
33331219|NCT05422612|Placebo Comparator|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
33331220|NCT05422612|Experimental|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily within 30 minutes of going to bed at least 2 hours after the last meal.
33331221|NCT05422612|Placebo Comparator|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
33418398|NCT05194761|No Intervention|No nebulization|the other group will only receive the standard only
33046145|NCT04208321|Experimental|Cohort 1|40 mg (1 tablet of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
33046146|NCT04208321|Experimental|Cohort 2|80 mg (2 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
33046147|NCT04208321|Experimental|Cohort 3|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
33046148|NCT04208321|Experimental|Cohort 4|320 mg (4 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
33046149|NCT04208321|Experimental|Cohort 5|640 mg (8 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
33418399|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
33046150|NCT04208321|Experimental|Cohort 6|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6, or matching placebo, n=2, after high-calorie, high-fat meal on Day 1 in a double-blind manner.
33046151|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
33046152|NCT05394636||cerebral amyloid angiopathy (CAA)|Clinical and 1.5T MRI T2*-weighted imaging characteristics analyses from sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS,
33046153|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
33046154|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
33046155|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
33046156|NCT01465399|Experimental|PRGF-Endoret|
33046157|NCT01465399|Active Comparator|Conventional treatment|
33046158|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
33046159|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
33046160|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
33046161|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
33046162|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
33046163|NCT05393505|Experimental|Fast-tRack Absolute Neutrophil Count (FRANC) Protocol|"Patient's blood sample will be expedited for complete blood count with differentials. Intravenous antibiotic is given depending on absolute neutrophil count. If neutropenia is present, broad-spectrum antibiotic (meropenem 1 g or levofloxacin 500 mg) will be given after septic workup within 1 hour of registration in emergency department before transfer to wards. If absent, antibiotic according to Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) with reference to previous bacterial sensitivity pattern, or amoxiclav 1.2 g if not specified, will be given. Other interventions are given according to clinical needs. The regimen is continued until clinicians recommend an alternative antimicrobial based on clinical grounds, or detection of other pathogens which indicate another antimicrobial."
33046164|NCT05393505|Active Comparator|Standard of Care|"The control group refers to the existing clinical pathway which guides management of adult patients with suspected NF in ED. Without information of absolute neutrophil count, Meropenem 1 g IV bolus (or Levofloxacin 500 mg IV infusion over 1 hour if Penicillin-allergic) will be given within 1 hour of ED registration after septic workup. Other interventions are given according to clinical needs.~Subsequent treatment in wards will be determined by doctor's clinical judgement, on a personalised basis. Each patient will be assessed by a parent team member. There is no standardised antibiotic de-escalation protocol in place, but it is a usual practice to continue Meropenem or Levofloxacin injections until clinical improvement, rising ANC, and negative culture results. After that it will be replaced with an antibiotic with a narrower spectrum, such as oral Amoxiclav, before discharge."
33046165|NCT01465243|Experimental|Icotinib|This is a single arm study.
33046166|NCT04201457|Experimental|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
33046167|NCT04201457|Experimental|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
33046168|NCT04201457|Experimental|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
33046169|NCT04201457|Experimental|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
33046170|NCT04201457|Experimental|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
33046171|NCT04201457|Experimental|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
33046172|NCT01465204|No Intervention|Control|
33046173|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
33046174|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
33046175|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
33046176|NCT04712188||Arcing|"10 patients with traumatic spinal cord injury using the arcing stroke pattern to propel manual wheelchair"
33046177|NCT04712188||Semicirculer|"10 patients with traumatic spinal cord injury using the semicirculer stroke pattern to propel manual wheelchair"
33046178|NCT04712188||Single loop|"10 patients with traumatic spinal cord injury using the single loop stroke pattern to propel manual wheelchair"
33046179|NCT04712188||Double loop|"10 patients with traumatic spinal cord injury using the double loop stroke pattern to propel manual wheelchair"
33046180|NCT04712149|Experimental|intervention arm|In the intervention arm, 15 patients will receive a weekly questionnaire. Alerts will be sent to the multidisciplinary care team, who will undertake follow-up actions. In the control arm, 15 patients will receive the standard care pathway without weekly questionnaire and without automatic alerts to the care team. The standard care pathways and the care team are the same in both groups. In this pilot study, the weekly follow-up will be evaluated by a validation questionnaire, semi-structured interviews with patients and the care team, and workload registration of the care team during a six-month period.
33046181|NCT04712149|No Intervention|Control arm|
33046182|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
33046183|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
33046184|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
33046185|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
33046186|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
33046187|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
33046188|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
33046189|NCT01465009|Experimental|Arm 1|
33046190|NCT01465009|Active Comparator|Arm 2|
33046191|NCT01465009|Placebo Comparator|Arm 3|
33418400|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
33418401|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
33046192|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
33046193|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
33046194|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
33046195|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
33046196|NCT04169477|Experimental|cTENS-mTENS|Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form
33046197|NCT04169477|Experimental|mTENS-cTENS|Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode
33046198|NCT01464892|Experimental|Imagery Rescripting|
33046199|NCT01464892|Active Comparator|STAIR plus Imagery Rescripting|
33046200|NCT01464892|No Intervention|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
33046201|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
33046202|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
33046203|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
33046204|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
33046205|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
33046206|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
33046207|NCT04140734|Experimental|Hard Palate|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use hard palate
33046208|NCT04140734|Active Comparator|Autologous Ear Cartilage|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use autologous ear cartilage
33046209|NCT04140734|Active Comparator|Porcine Acellular Dermal Matrix|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use porcine acellular dermal matrix
33046210|NCT01464775|Experimental|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
33046211|NCT01464775|Active Comparator|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
33046212|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
33046213|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
33046214|NCT05363709|Experimental|Balstilimab|Participants will receive Balstilimab by vein over about 30 minutes on Days 1 and 15 of each cycle (every 2 weeks)
33046215|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
33046216|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
33046217|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
33046218|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
33046219|NCT05361720|Experimental|Arm I (ipilimumab, nivolumab)|"INDUCTION: Patients receive ipilimumab and nivolumab IV on day 1. Cycles repeat every 21 days for 4 cycles.~MAINTENANCE: Patients receive nivolumab IV on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
33046220|NCT05361720|Experimental|Arm II (nivolumab, cabozantinib)|Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33046221|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
33046222|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
33046223|NCT01464658|Other|panniculectomy|surgical intervention
33046224|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
33046225|NCT01464502|Active Comparator|Standard CRT Implant|
33046226|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
33046227|NCT05358366|Experimental|Infeccion de Amor (Love Infection)|"33 Latinas will view four IA intervention episodes, one per week immediately after the baseline survey and orientation.~Participants will receive an email to their preferred email address with a password to access to the episode on the IA's website: https://www.infecciondeamor.com. Each 10-minute episode can be watched more than once during the week and presents a situation with notable HIV risk and ways the characters avoided risk (e.g., condom use) or confronted consequences of poor practices (e.g., HIV infection). The one-week time frame for each episode is needed to provide time to review and reflect about IA's content and modify HIV prevention behaviors. It will also allow Latinas to obtain information and support from the team and referral if needed. This time frame was effective to improve behaviors in previous studies."
33046228|NCT05358366|Other|Wait-listed|"A wait-listed control group of 33 Latinas will receive IA in the same manner as the intervention group.~Latinas will start watching the telenovela episodes 4 months after their baseline survey (after T3 survey).~Latinas will be informed at recruitment of this group condition and the study randomization. During the waiting time, participants will be called on a monthly basis to encourage participation and refer to services if needed."
33046229|NCT04083950|Experimental|Single group|All participants will receive the vaccine and aspirin.
33046230|NCT00393679|Experimental|1|AS-AQ
33046231|NCT00393679|Experimental|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
33046232|NCT00393679|Experimental|3|AL
33046233|NCT00393679|Experimental|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
33046234|NCT04712032|Experimental|Image Guided Bowel Anastomosis group|ICG-guided perfusion assessment
33046235|NCT04712032|No Intervention|Conventional Bowel Anastomosis group|conventional perfusion assessment
33046236|NCT05352867|Experimental|50μg group|
33046237|NCT05352867|Experimental|100μg group|
33046238|NCT05352867|Placebo Comparator|Placebo|
33046239|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
33046240|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
33331222|NCT05691400|Experimental|CYP3A4*1/*1|"This arm will include subjects with CYP3A4*1/*1 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
33331223|NCT05691400|Experimental|CYP3A4*1/*22|"This arm will include subjects with CYP3A4*1/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
33331224|NCT05691400|Experimental|CYP3A4*22/*22|"This arm will include subjects with CYP3A4*22/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
33331225|NCT05421364|Experimental|Endometrial cell composition|The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.
33331226|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
33331227|NCT05688826|Experimental|Sugar load|Sugar dissolved in water will be ingested during 5 minutes
33331228|NCT03619720|Experimental|Participants|
33331229|NCT05679076||Fabry patients|Fabry patients
33331230|NCT05663554|Experimental|WW Intervention|Participants in the intervention arm will be contacted by a WW Coach and will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics specific to diabetes.
33331231|NCT05663554|Active Comparator|Usual Care|Patients in the Usual Care Arm will continue to receive routine medical care by their healthcare provider. In addition, at the baseline visit, participants in the Usual Care Arm will receive one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments, based on current recommendations of the American Diabetes Association
33331232|NCT05417308|Active Comparator|Arm I (topical minoxidil)|Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
33331233|NCT05417308|Experimental|Arm II (orally minoxidil)|Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
32905133|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
32905134|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
32905135|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
32905136|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
32905137|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
32905138|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
32905139|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
32905140|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~macular laser per treatment criteria"
32905141|NCT00855842|Experimental|osmotic dilator|osmotic dilator
32905142|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
32905143|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
32905144|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
32905145|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
32905146|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
32905147|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
32905148|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
32905149|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
32905150|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
32905151|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
33046241|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
33046242|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
33046243|NCT04078568|Active Comparator|the standard group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
33046244|NCT04078568|Experimental|the standard+prednisolone group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
33046245|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
33046246|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
33046247|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
33046248|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
33046249|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
33046250|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
33046251|NCT00911560|Experimental|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
33046252|NCT00911560|Experimental|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
33046253|NCT00911560|Experimental|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
33046254|NCT04060316|Experimental|GLS-1200|3 ml of GLS-1200 (1 mg/ml in 0.9% saline)
33046255|NCT04060316|Placebo Comparator|Sterile Saline|3 ml of 0.9% saline
33046256|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
33046257|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
33046258|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
33046259|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
33046260|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
33046261|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
33046262|NCT04059146|Experimental|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.~All participants will receive the same progressive Achilles tendon loading exercise program."
33046263|NCT04059146|Active Comparator|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.~All participants will receive the same progressive Achilles tendon loading exercise program."
33046264|NCT05341011|Experimental|Treatment (TX) Group|The TX group received 14 weeks of the PEERS® intervention immediately following a baseline assessment,
33046265|NCT05341011|Experimental|Delayed Treatment Control (DTC) Group|The DTC group received the same intervention after a 14-week waiting period. Parents and teens attended concurrent sessions held in separate rooms.
33046266|NCT00847795|Experimental|1|5ng Avotermin
33046267|NCT00847795|Experimental|2|50ng Avotermin
33046268|NCT00847795|Experimental|3|100ng Avotermin
33046269|NCT00847795|Placebo Comparator|4|Placebo
33046270|NCT00847795|No Intervention|5|Standard Care
33109832|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
33046271|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
33046272|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
33046273|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
33046274|NCT00847717|Experimental|1|IIb preserving neck dissection
33046275|NCT00847717|Other|2|Conventional neck dissection
33046276|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
33046277|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
33046278|NCT00847678|Experimental|3|Mycograb + Amphotericin B
33046279|NCT05337852|Experimental|Experimental group|"To the pregnant women in the experimental group;~Emotional freedom technique will be applied online with the researcher, 3 sessions every other day for 1 week,~PUQE, PRAQ-2 tests will be applied before the intervention,~SUE and PUQE will be applied before and after each session,~After 3 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
33046280|NCT05337852|No Intervention|Control group|"After each intervention applied to the experimental group, SUE and PUQE will be applied to the control group over the phone, simultaneously.~After 1 week, post-test data will be obtained with PUQE, SUE, PRAQ-2."
33046281|NCT04042259|Active Comparator|Negative Pressure Wound Therapy|Standardized wound closure with negative pressure therapy.
33046282|NCT04042259|Other|Historic Cohort|Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.
33046283|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
33046284|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
33046285|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
33046286|NCT00847522|Experimental|All patients|All participants enrolled.
33046287|NCT05327127|Experimental|K-001|K-877-ER and CSG452 Once daily (QD)
33046288|NCT05327127|Experimental|K-877-ER|K-877-ER and CSG452 Placebo QD
33046289|NCT05327127|Experimental|CSG452|CSG452 and K-877-ER Placebo QD
33046290|NCT05327127|Placebo Comparator|Placebo|
33046291|NCT04039139|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
33046292|NCT04039139|Experimental|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1. Further details are not provided for blinding purposes.
33046293|NCT04039139|Active Comparator|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2. Further details are not provided for blinding purposes.
33046294|NCT00847483|Active Comparator|Latanoprost|
33046295|NCT00847483|Active Comparator|Travoprost|
33046296|NCT00847483|Active Comparator|Bimatoprost|
33046297|NCT00847444|Active Comparator|AA|Drug intervention
33046298|NCT00847444|Active Comparator|BA|Lifestyle intervention
33046299|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
33046300|NCT04034927|Active Comparator|Arm I (olaparib)|Patients receive olaparib PO BID in the absence of disease progression or unacceptable toxicity.
33046301|NCT04034927|Experimental|Arm II (olaparib, tremelimumab)|Patients receive olaparib as in Arm I. Patients also receive tremelimumab IV over 60 minutes on day 1. Cycles of tremelimumab repeat every 4 weeks for 4 doses and then every 12 weeks for up to 2 years total in the absence of disease progression or unacceptable toxicity.
33046302|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
33046303|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
33046304|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
33046305|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
33046306|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
32905152|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
33046307|NCT05321160|Experimental|Group E|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
33046308|NCT05321160|Active Comparator|Group S|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained.
33046309|NCT00847327|Experimental|Parental Support|
33046310|NCT00847327|Active Comparator|Diabetes Education|
33046311|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
33046312|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
33046313|NCT04009343|Active Comparator|Artemether-lumefantrine|Standard 6-dose regimen
33046314|NCT04009343|Experimental|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
33046315|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
33046316|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
33046317|NCT03969641|Experimental|RIV4|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
32905153|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
33046318|NCT03969641|Active Comparator|IIV4|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
33046319|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
33046320|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
33046321|NCT00847171|Experimental|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
33046322|NCT05314608||Subjects with subchondral bone pathology|Subjects with subchondral bone pathology
33046323|NCT03940586|Experimental|Letermovir|Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
33046324|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
33046325|NCT04733482|No Intervention|Control group|Participants in the control group received usual care during adjuvant chemotherapy. The usual care consisted of written information and verbal guidance on the adverse effects of chemotherapy and related psychological reactions.
33046326|NCT04733482|Experimental|Cosmetic care group|Participants in the intervention group received cosmetic care in combination with usual care. The cosmetic care was a 3-hour, free-of-charge beauty activity, including face moisturizing steps, make-up, wigs, and breast prostheses wearing. It was provided by professional cosmeticians at a cosmetic training base before the patients finished half of their chemotherapy cycle.
33046327|NCT05313633|Experimental|Wii group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a Wii training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
33046328|NCT05313633|Experimental|plyometric group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a plyometric training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
33046329|NCT04733248|Active Comparator|Kinesiotaping group|Hot pack, Tens, stretching exercises, Kinesiotaping (I-O) and Home plan
33046330|NCT04733248|Experimental|stretching group|Hot pack, Tens, stretching exercises and Home plan
33046331|NCT00847054|Experimental|MORAb-004|
33046332|NCT03887741|Experimental|Plasmapheresis|3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months
33046333|NCT03887741|Experimental|Plasma infusion|3 patients will have biweekly plasma infusion for 6 months and followed for 12 months
33331234|NCT05606848|Active Comparator|Control product|Nutrition Emulsion (TPF-T) is a tumor-specific enteral nutrition therapy
33331235|NCT05606848|Experimental|Study prodcut|Foods for special medical purposes [FSMP] for patients with tumors
33331236|NCT05601856||Alzheimer's Patient|"patients with AD whose clinical dementia rating (CDR) is > 1 Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
33046334|NCT03887741|No Intervention|Control group|3 patients will be followed for 12 months
33046335|NCT00846976|Experimental|200 mg Casodex|
33046336|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
33046337|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
33046338|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
33046339|NCT00846859|Experimental|varenicline|
33046340|NCT00846859|Placebo Comparator|placebo|
33046341|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
33046342|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
33046343|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
33046344|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
33046345|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
33046346|NCT00846703|Active Comparator|Protocol A (MM)|
33046347|NCT00846703|Experimental|Protocol B (MM/VD)|
33046348|NCT05303376|Experimental|Active|
33046349|NCT05303376|Placebo Comparator|Placebo|
33046350|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
33046351|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
33046352|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
33046353|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
33046354|NCT03772964|Placebo Comparator|Placebo|Subjects will be exposed to placebo for up to 90 days.
33046355|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
33046356|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
33046357|NCT05298813|Experimental|Active|
33046358|NCT05298813|Placebo Comparator|Placebo|
33046359|NCT00846547|Experimental|Arbaclofen|
33046360|NCT00846508|Experimental|ciaplantin,cancer,survival|
33046361|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
33046362|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
33046363|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
33046364|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
33046365|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
33046366|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
33046367|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
33046368|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
33046369|NCT03721172|Experimental|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
33046370|NCT03721172|Experimental|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
33046371|NCT03721172|Experimental|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
33046372|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
33046373|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
33046374|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
33046375|NCT05288985|Experimental|Erector spinae plane catheter group in addition to Systemic Analgesia|
33046376|NCT05288985|Active Comparator|Systemic Analgesia Only Group|
33046377|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
33046378|NCT00846313|No Intervention|Control|
33046379|NCT00846274|Active Comparator|Antithrombin III|
33046380|NCT00846274|Experimental|SK Antithrombin III|
33046381|NCT00846235|Experimental|Moisturising cream|
33046382|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
33046383|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
33046384|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
33046385|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
33046386|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
33046387|NCT00846118|No Intervention|optimal standard care|
33046388|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
33046389|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
33046390|NCT03651401||rotator cuff related shoulder pain|Participants were assessed for SME, pain (rest, activity, night, measurement), and upper extremity function (FIT-HaNSA).
33046391|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, and upper extremity function (FIT-HaNSA).
33046392|NCT00845962|Active Comparator|Chloroprocaine|
33046393|NCT00845962|Active Comparator|Bupivacaine|
33046394|NCT05253807|Experimental|Cohort A: Squamous NSCLC|Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
33046395|NCT05253807|Experimental|Cohort B: Non-squamous NSCLC|Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
33046396|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
33046397|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
33046398|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
33046399|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
33046400|NCT04711798||Patients receiving cardiac surgery|Patients receiving cardiac surgery will be included. All patients received a passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system, a lung recruitment maneuver (LRM) and an echographic evaluation of the right cardiac function.
33046401|NCT05247255|Active Comparator|Intervention Group|Quadratus lumborum nerve block with 0.25% ropivacaine
33046402|NCT05247255|Placebo Comparator|Control Group|Quadratus lumborum nerve block with saline
33046403|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
33046404|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
33046405|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
33046406|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
33046407|NCT05231811|Experimental|experimental group|During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated.
33046408|NCT05231811|No Intervention|control group|no intervention will be made in the control group
33046409|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
33046410|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
33046411|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
33046412|NCT00276835|Experimental|Genistein and Interleukin-2|
33046413|NCT05231070|Experimental|TeleSPC|"Patients will be offered regular multidisciplinary video consultations with the SPC team and these patients and their informal caregiver will also be offered a dyadic psychological intervention.~Regular multidisciplinary video consultations with multidisciplinary team, involvering cooperation between the section og Palliative medicine and the Department of Oncology, District nurse and the general practitioner.~Operationel definition of informal caregiver: Patients will designated the closest person involved in their care (e.g., spouse, son/daughter, other relatives, and friends)."
33046414|NCT05231070|No Intervention|Control|Patients will follow the current practice in the healthcare system (standard care). Control patients will be offered information to clarify the options available in case of unmet palliative needs. Patients' informal caregiver will be invited to participate in the study, but no intervention will be offered.
33046415|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
33046416|NCT05212818|Experimental|Low Dose of Active Drug|80 patients will be randomly assigned to low dose, take active drug BID.
33046417|NCT05212818|Experimental|Low Dose Placebo Control|80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
33046418|NCT05212818|Experimental|High Dose of Active Drug|160 patients will be randomly assigned to high dose, take the active drug BID.
33046419|NCT05212818|Experimental|High Dose Placebo Control|80 will be randomly assigned to high dose placebo, take the placebo BID.
33046420|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
33046421|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
33046422|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
33046423|NCT00276640|Active Comparator|radiation|radiation therapy group
33046424|NCT00276640|No Intervention|Control|Control group: wait and see strategy
33046425|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
33046426|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
33046427|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
33046428|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
33046429|NCT05198778|Experimental|Test group 1: Renal impairment patient|Administer URC102, single-dose
33046430|NCT05198778|Experimental|Test group 2: Renal impairment patient|Administer URC102, single-dose
33046431|NCT05198778|Experimental|Control group: Healthy adult people|Administer URC102, 2 doses
33046432|NCT00276406|Experimental|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
33046433|NCT00276406|Placebo Comparator|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
33046434|NCT00389883|Active Comparator|1|propofol et remifentanil
33046435|NCT00389883|Experimental|2|sevoflurane et sufentanil
33046436|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
33046437|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
33046438|NCT03261089||Unresponsive patients post-cardiac arrest|As early as possible post-resuscitation, patients should undergo a detailed neurologic examination, comprised of a thorough assessment for consciousness and detailed cranial nerve function and motor response assessments. Neurologic assessment scores such as the Full Outline of Unresponsiveness, Glasgow Coma Scale (GCS), and Pittsburgh Cardiac Arrest Category Score will be also be used. On the first assessment (day of cardiac arrest), the PCAC score should be assigned only on the basis of the best neurologic exam in the first 6 hours after ROSC. Patients that are sedated or intubated will have the verbal score of GCS be estimated by a derivation of motor and eye scores. The presence of potential confounders, including core body temperature, medications, and/or intoxicants, as well as metabolic derangements should be noted.
33046439|NCT00276250|Experimental|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
33046440|NCT00276250|Experimental|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
33046441|NCT00276250|Experimental|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
33046442|NCT05161767||Recovered group|This will group will consists of people who have a remission of their symptoms at 6-months follow-up after whiplash injury.
33046443|NCT05161767||non-recovered group|This will group will consists of people who develop persistent symptoms at 6-months follow-up after whiplash injury.
33046444|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
33046445|NCT05158413|Experimental|High dose|Experimental: high dose of sesame 20 patients
33046446|NCT05158413|Active Comparator|Low dose|Active Comparator: low dose of sesame 20 patients
33046447|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
33046448|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
33046449|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
33046450|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
33331237|NCT05601856||Spousal Caregiver to Alzheimer's Patient|"Spousal Caregiver to Alzheimer's Patient group, Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
33046451|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
33046452|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
33046453|NCT05156853|Experimental|Insect-based menu|Replacement of meat proteins with insect-based alternatives at main meals 3 times weekly.
33046454|NCT05156853|Active Comparator|Plant-based menu|Replacement of meat proteins with plant-based alternatives at main meals 3 times weekly.
33046455|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
33046456|NCT03194789|Active Comparator|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
33046457|NCT03194789|Experimental|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
33046458|NCT05149599|Experimental|Treated patients|
33360674|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
33046459|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
33046460|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
33046461|NCT05567107|Experimental|experimental group: applied foot massage|Scales were applied preoperative to the patients. After being discharged from the intensive care unit in the postoperative period, the scales were applied without any intervention on the first day of hospitalization (day 0). Pain intensity was evaluated according to the Visual Comparison Pain Scale and classical foot massage was applied to patients who stated that they had 4 or more pain. After leaving the intensive care unit in the postoperative period, the scales were applied on the 2nd day (day 1) when the patient came to the service. After the scales, foot massage was applied again. After leaving the intensive care unit in the postoperative period, the scales were applied on the third day (day 2) when the patient came to the service. After the scales, foot massage was applied again. After the patient was discharged from the intensive care unit in the postoperative period, the scales were applied on the fourth day (3rd day) when they came to the service.
33046462|NCT05567107|No Intervention|control group: unapplied foot massage|Each data collection tool was collected without applying foot massage, as in the experimental group patients. While the patients in the control group received only analgesic treatment postoperatively, the patients in the experimental group received foot massage in addition to the analgesic treatment. Only routine nursing care was given to the patients in the control group postoperatively.
33046463|NCT05142384|Experimental|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 3 (10-15 min calls occurring post-randomization, and 3- and 6-weeks later."
33046464|NCT05142384|Active Comparator|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies.
33046465|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
33109833|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
33046466|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Cyclophosphamide one intravenous injection 2 days prior to procedure.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
33046467|NCT03152318|Experimental|Arm C- Multiple Dose rQNestin|"Arm C includes up to 6 intratumoral repeated doses of rQNestin34.5v.2, first in a cohort receiving 10^8 pfus per time point, followed by a cohort receiving 10^9 or 10^7 pfus per time point.~Arm C adds 2 cohorts of 12 subjects in an open-label clinical trial of rQNestin34.5v.2 administered at two dose levels~The injections are planned for days 0, 15, 30, 60, 90, and 120~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent."
33046468|NCT05566990|Experimental|LIV-GAMMA SN Inj.10%|
33046469|NCT05566951|Experimental|Experimental group|-The experimental group that applied the technology-based psychosocial program
33046470|NCT05566951|Other|Control group|Control group receiving standard care
33046471|NCT05566054|Experimental|VAC group|Chidamide 10mg orally daily for 7 days (d1-d7), AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is PR/NR, the patient needs to withdraw from the trial, If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients were fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients needs to withdraw from the trial if progression or recurrence of the disease.
33046472|NCT05566054|Active Comparator|VA group|AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is still PR/NR, the patient needs to enter VEN+AZA+Chidamide group. If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patient needs to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patient needs to withdraw from the trial if progression or recurrence of the disease.
33046473|NCT05565430||Healthy Control|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
33046474|NCT05565430||Mild Asthmatics|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
33046475|NCT05565430||Severe Asthmatics|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
33046476|NCT03089606|Other|Single Arm|This is a single arm study. All participants completed the study interventions which are pembrolizumab treatment, FDG PET, C11-AMT PET and CT scans.
33046477|NCT05559970|Active Comparator|Conventional sedation|Conventional sedation receiving analgosedation with fentanyl
33046478|NCT05559970|Experimental|Inhalational sedation|Inhalational sedation receiving isoflurane for sedation for 12 hours
33046479|NCT05140746|Experimental|PET/CT for prediction of NAC efficacy|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT will be scanned before, during or after NAC.
33046480|NCT05495971|Experimental|Presbyopia|Subject's baseline vision will be compared with vision wearing treatment product
33046481|NCT05492227||Fresh left-over specimens of SARS-CoV-2 positive subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
33046482|NCT05492227||Fresh left-over specimens of SARS-CoV-2 negative subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
33046483|NCT05132205|Experimental|Radiofrequency Ablation|Patients will receive RFA as a one-time intervention, with a possible second treatment after 6 months if adequate resolution is not noted on ultrasound.
33046484|NCT05464732|Experimental|Monovision|"The target refraction is plano (0.00 D) for the dominant eye and between -0.50 D and -0.75 D for the non-dominant eye. The Vivity IOL will be implanted bilaterally.~Corrected vision will involve correcting the dominant eye for emmetropia and the non-dominant eye for -0.50 D."
33046485|NCT05464732|Active Comparator|Emmetropia|Subject's vision will be tested with both eyes corrected for emmetropia.
33046486|NCT02979977|Experimental|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.
33046487|NCT05428657|Experimental|Eye-tracking Training Group|EC Brain After-school Program- computerised eye-tracking training program
33046488|NCT05428657|Active Comparator|Conventional Training Group|Conventional intervention program for special educational needs
33331238|NCT05601856||Healthy adult control|"Age-matched to Spousal Caregiver to Alzheimer's Patient group Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
33046489|NCT05131035|Experimental|Single Arm intervention|All participants will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the level of training needed to impact processing speed.
33046490|NCT05424757||Children who are taking PEG 3350|"Children less than 17 years old who have taken PEG 3350 daily for at least 30 days.~Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day.~Preference will be given to children taking at least 17 grams/day.~Notes:~Only children who are already taking PEG 3350 as part of their current medical regimen will be included. Changes to medical therapy are not recommended as part of this study.~Children in three subgroups will be enrolled:~Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~Children with bowel problems that might increase intestinal permeability.~Children with neurologic disease or with neuropsychiatric disorders or symptoms."
33046491|NCT05424757||Children who are not taking PEG 3350|"Children less than 17 years old who have NOT taken PEG 3350 for at least 30 days.~Children in three subgroups will be included:~Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~Children with bowel problems that might increase intestinal permeability.~Children with neurologic disease or with neuropsychiatric disorders or symptoms."
33046492|NCT05415163|Experimental|vascular photobiomodulation|Laser will be applied with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
33046493|NCT05415163|Sham Comparator|photbiomodulation-sham|The device will be placed with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet no laser apllied.
33046494|NCT05128227|Active Comparator|Pharm-SAVES|This an approximately 30-minute self-guided online module that covers basic information about suicide prevention gatekeeper skills training that is relevant to community pharmacists.
33046495|NCT05128227|Experimental|Interactive video case|An approximately 30-minute self-guided online suicide prevention gatekeeper skills training module, plus two approximately 5-minute interactive video cases in which participants are asked to respond to patients who exhibit suicidal warning signs.
33046496|NCT05351359|Active Comparator|Active control|The patients from the active control group will receive brief physical activity advice from their general practitioners at baseline, and they will also receive the Fitbit tracker to self-monitor their daily steps.
33046497|NCT05351359|Experimental|Intervention|The patients in the intervention group will be exposed to the same procedures as those from the active control group, but will also receive a mHealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months.
33046498|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
33046499|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
33046500|NCT05327530|Experimental|Group A: Avelumab|
33046501|NCT05327530|Experimental|Group B: Avelumab + Sacituzumab Govitecan|
33331239|NCT05578846|Experimental|Treatment sequence ABC|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33360675|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
33046502|NCT05327530|Experimental|Group C: Avelumab + M6223|
33046503|NCT05327530|Experimental|Group D: Avelumab + NKTR-255|
33046504|NCT05120427|No Intervention|Control|Access to standard care.
33046505|NCT05120427|Experimental|LNS only|Children in this arm will receive lipid-based nutrient supplements (LNS) for 12-18 months. LNS are 20 g/~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet. The LNS used in this study will be Nutributter plus.
33046506|NCT05120427|Experimental|Growth Charts Only|Children in this arm will receive a growth chart that can be installed at children's homes. Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding. After the home installation of growth charts, caregivers will be given a short introduction on how to use them and on how to interpret the measurements by study staff.
33046507|NCT05120427|Experimental|LNS and Growth Charts|Children in the combined arm will receive both growth charts and LNS.
33046508|NCT05317663|Experimental|Waterpipe with Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe with HWL for up to 45 minutes.
33046509|NCT05317663|Experimental|Absence of Waterpipe without Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe without HWL for up to 45 minutes.
33046510|NCT05282446|Experimental|INV-202|INV-202 25mg by mouth once daily
33046511|NCT05282446|Placebo Comparator|Placebo|Matching placebo by mouth once daily
33046512|NCT05262556|Experimental|NP-101 (TQ Formula) + Nivolumab + Ipilimumab|
33046513|NCT05070585|Experimental|Isothiocyanate Rich Juice|The juices will contain 37,5g isothiocyanate rich sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
33046514|NCT05070585|Placebo Comparator|Placebo Juice|The juices will contain 37,5g alfalfa sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
33046515|NCT05223049||Psoriatic Arthritis patients with neuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≥4 or PainDETECT score of ≥13.
33046516|NCT05223049||Psoriatic Arthritis patients with nonneuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≤4 or PainDETECT score of ≤13.
33046517|NCT05205928|Active Comparator|Placebo + closed-loop insulin system|
33046518|NCT05205928|Experimental|Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system|Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection.
33046519|NCT05197855|Experimental|Technological innovations and CPAP|Patients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.
33046520|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
33046521|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
33046522|NCT05190757||Laryngeal Mask Airway|
33046523|NCT05190757||Face Mask|
33109834|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
33418402|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
33046524|NCT05186077||Healthy Controls|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
33046525|NCT05186077||Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
33046526|NCT05186077||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed or manic with their current episode lasting at least 6months and not responding to 2 or more adequate evidence-based treatments for BDI or BDII.
33046527|NCT05065476||Study Group|"Participants signed up for the webinar will be learning and practicing the Isha Kriya practice (meditation for beginners) taught by the Isha Foundation."
33046528|NCT05184439||Study group after surgery|33 children and adolescents (39 knees) with recurrent patellar dislocation were treated with MPFL reconstruction using the adductor magnus tendon between 2010 and 2012. The group is under clinical observation with evaluation being made.
33046529|NCT00387530|Other|Single Arm Study of Biopsy|
33046530|NCT04729660|Active Comparator|Study group|Evaluate of the Kinesio tex gold tape that applied to anterior neck localised.
33046531|NCT04729660|Sham Comparator|Sham group|Evaluate of the Kinesio tex gold tape that applied to different neck localised as no-stretched.
33046532|NCT05134480|Active Comparator|Cornea from donor with diabetes|Participant will be assigned a cornea recovered from a donor with diabetes.
33046533|NCT05134480|Active Comparator|Cornea from donor without diabetes|Participant will be assigned a cornea recovered from a donor without diabetes.
33046534|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours~Cohort 1 (n=8): 12 to < 18 years of age (40 mg/kg)~Cohort 2 (n=8): 6 to < 12 years of age (40 mg/kg)~Cohort 2b (n=4): 6 to < 12 years of age (60 mg/kg)~Cohort 3 (n=8): 2 to < 6 years of age (60 mg/kg)~Cohort 4 (n=8): 3 months to < 2 years of age (60 mg/kg)~Cohort 5 (n=24): Birth to < 3 months of age (dose TBD)~Group A: Gestational Age (GA) < 32 weeks, Postnatal Age (PNA) < 2 weeks (n=6)~Group B: GA < 32 weeks, PNA > 2 weeks (n=6)~Group C: GA > 32 weeks, PNA < 2 weeks (n=6)~Group D: GA > 32 weeks, PNA > 2 weeks (n=6)~Cohort 6 (n=7): 2 to < 12 years of age and ≤ 35 kg of weight (80 mg/kg)"
33046535|NCT05071144||Pediatric Spine Deformity Patients|Standard of care surgery using robotics coupled with navigation
33046536|NCT05061693|Experimental|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
33046537|NCT05061693|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
33046538|NCT05061693|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
33046539|NCT05061693|Placebo Comparator|Placebo followed by INCB054707 Dose B or C|Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
33046540|NCT05048758||Individuals with AUD + moderate to severe ACE|Individuals with alcohol use disorder (AUD) and moderate to severe adverse childhood experiences (ACE)
33046541|NCT05048758||Individuals with AUD + no or mild ACE|Individuals with alcohol use disorder (AUD) and no or mild adverse childhood experiences (ACE)
33046542|NCT05048407|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
33046543|NCT04996069|Experimental|All Participants|This is a single arm study. All subjects enrolled will be apart of the experimental group. Subjects in this group will use Crest Whitening Emulsions on their teeth up to 4 times a day for 7 days in order for the study team to evaluate if the study intervention product increases saliva production in this Xerostomic population.
33046544|NCT04978636|Active Comparator|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB.
33046545|NCT04978636|Active Comparator|Continuous low tidal volume ventilation with using FiO2 of 1.0|The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB.
33046546|NCT04978636|Active Comparator|Apnea|The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB.
33046547|NCT02680184|Experimental|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram [mg], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
33046548|NCT02680184|Experimental|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
33046549|NCT02680184|Experimental|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses <10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
33046550|NCT00390000|Experimental|Arm I|See Detailed Description
33046551|NCT04955275|Experimental|Parkinson's Disease Patients receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will undergo 10 weeks of Brain HQ training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.
33046552|NCT04955275|No Intervention|Parkinson's Disease Patients not receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.
33046553|NCT04941781|Experimental|PIPE-307|Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of [11C] PIPE- 307.
33046554|NCT04899622|Experimental|Combined MBSR and exercise|Group A will take part in live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme, in addition to supervised exercise classes.
33046555|NCT04899622|Active Comparator|Online Self-Management Guide|Group B will be invited to interact with an online self-management guide accessible in the members area of the study website.
33046556|NCT04856176|Experimental|GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed|All patients will receive GM-CSF plus maintenance pembrolizumab with or without pemetrexed, following completion of 4 cycles of chemo-immunotherapy
33046557|NCT05054790|Experimental|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
33046558|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
33046559|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
33046560|NCT04824859|Experimental|Experimental|The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
33046561|NCT04817449||Suspected Ovarian Cancer|Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.
33046562|NCT05047965|Experimental|Diagnostic (standard MRI, Dixon MRI)|Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
33046563|NCT04805983|Experimental|10 mg BMS-984923|
33046564|NCT04805983|Experimental|40 mg BMS-984923|
33046565|NCT04805983|Experimental|70 mg BMS-984923|
33046566|NCT04805983|Experimental|100 mg BMS-984923|
33046567|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
33046568|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
33046569|NCT04802434|Experimental|Strengthening Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member, or friend) will attend weekly 3 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach cognitive compensation and mindfulness-based emotion regulation skills. Strategies from the PEERS Social Skills Program will also be taught. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
33046570|NCT04802434|Active Comparator|PEERS Social Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member or friend) will attend weekly 1.5 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach skills for improving social relationships and handling social rejection. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
33331240|NCT05578846|Experimental|Treatment sequence ACB|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33109835|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
33109836|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
33109837|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
33109838|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
33109839|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
33109840|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
33109841|NCT02917226|Experimental|Clinical decision support and monitoring system|
33109842|NCT02917226|No Intervention|Control Group|
33109843|NCT02153502|Experimental|AVP-786|
33109844|NCT02153502|Placebo Comparator|Placebo|
33331241|NCT05578846|Experimental|Treatment sequence BAC|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33418403|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
33109845|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
33109846|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
33109847|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
33109848|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
33109849|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
33109850|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
33360676|NCT03925987|Experimental|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
33109851|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
33109852|NCT02917070||Patients|Patients who have chronic kidney diseases
33109853|NCT02917070||Healthy controls|Healthy subjects
33109854|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
33109855|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
33109856|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
33109857|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
33109858|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
33109859|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
33109860|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
33109861|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
33109862|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
33109863|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
33109864|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
33109865|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
33109866|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
33109867|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
33109868|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
33109869|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
33109870|NCT01228656|Active Comparator|-mometasone furoate|
33109871|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
33331242|NCT05578846|Experimental|Treatment sequence BCA|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33046571|NCT04802434|No Intervention|Delayed Treatment Control Group|Participants in the delayed treatment control group will participate in a 10-month wait period, during which they will complete data collection procedures at three time points (Baseline, Post, and 6-month follow-up).
33046572|NCT04732507|Active Comparator|One to two needle passes|Receive 1-2 needle passes for needling at each trigger point
33046573|NCT04732507|Active Comparator|Ten needle passes|Receive 10 needle passes for needling at each trigger point
33046574|NCT04732507|Active Comparator|Twenty needle passes|Receive 20 needle passes for needling at each trigger point
33046575|NCT05047770|Active Comparator|HZ/suSeq Group|Participants randomized to HZ/suSeq Group receive one mRNA-1273 booster dose administered at Day 1, followed by the first dose of HZ/su vaccine administered at Week 2 and the second dose of HZ/su vaccine administered at Week 10.
33046576|NCT05047770|Experimental|HZ/suCoAd Group|Participants randomized to HZ/suCoAd Group receive one mRNA-1273 booster dose co-administered with the first dose of HZ/su vaccine at Day 1, followed by the second dose of HZ/su vaccine administered at Week 8.
33046577|NCT05047770|Active Comparator|FluD-QIVSeq Group|Participants randomized to FluD-QIVSeq Group receive one mRNA-1273 booster dose at Day 1, followed by one dose of Flu D-QIV vaccine at Week 2.
33046578|NCT05047770|Experimental|FluD-QIVCoAd Group|Participants randomized to FluD-QIVCoAd Group receive one mRNA-1273 booster dose co-administered with one dose of Flu D-QIV vaccine at Day 1.
33046579|NCT04649359|Experimental|Elranatamab (cohort A)|BCMA-CD3 bispecific antibody
33331243|NCT05578846|Experimental|Treatment sequence CAB|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33331244|NCT05578846|Experimental|Treatment sequence CBA|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
33046580|NCT04649359|Experimental|Elranatamab (cohort B)|BCMA-CD3 bispecific antibody
33046581|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
33331245|NCT05574322|Experimental|Training group (PRP)|Participants benefiting from an 8-week muscle strengthening program (PRP)
33331246|NCT05574322|Sham Comparator|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
33331247|NCT05544136|Experimental|Participants with Squamous Cell Carcinoma Head and Neck Cancer|Participants will be hypoxia-negative T0-3N1-2B small cell carcinoma head and neck cancer/SCC HNC patients (HPV-OPC, HPV- UPC with nodal metastasis(es), HPC, or LXC) who are eligible for definitive CRT with de-escalated radiation concurrent with 2 cycles of SOC chemotherapy. Hypoxia status will be determined by the absence of hypoxia radiotracer uptake on 18F-FMISO PET/CT imaging
33331248|NCT05536336|Experimental|Okamoto Lubricated Synthetic Polyurethane Male Condom|The test device name is Okamoto 001 Lubricated Polyurethane Male Condom. The condom is made in Japan and conforms to ASTM D6324-11 (2017) Standard Test Methods for Male Condoms Made from Polyurethane.
33331249|NCT05536336|Active Comparator|Latex condom|Commercially available latex lubricated condom.
33331250|NCT05535712|Experimental|Da Vinci SP intervnetion group|for patients who received Da Vinci SP robotic surgery
33331251|NCT05407324|Experimental|CORT113176 (Dazucorilant) 300 mg|300 mg of dazucorilant will be administered once daily.
33046582|NCT04608292|Active Comparator|Single-voxel MRS|MRS
33046583|NCT04608292|Active Comparator|Multi-voxel MRSI|MRSI
33046584|NCT04608292|Active Comparator|Magnetization Transfer Imaging|MTI
33046585|NCT04608292|Active Comparator|Single-voxel MRS + ClearMate(TM)|MRS+CM
33046586|NCT04608292|Active Comparator|Multi-voxel MRSI + ClearMate(TM)|MRSI+CM
33046587|NCT04608292|Active Comparator|Magnetization Transfer Imaging + ClearMate(TM)|MTI+CM
33046588|NCT04608292|Active Comparator|Single-voxel MRS + CM + Blood Sampling|MRS+CM+B
33046589|NCT04608292|Active Comparator|Multi-voxel MRSI + CM + Blood Sampling|MRSI+CM+B
33046590|NCT04608292|Active Comparator|Magnetization Transfer Imaging + CM + Blood Sampling|MTI+CM+B
33046591|NCT05029362|Other|Beta testing group|
33046592|NCT04599478|Experimental|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
33046593|NCT04599478|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
33046594|NCT04599478|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
33046595|NCT04599478|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
33046596|NCT04574245||Resectable group|
33046597|NCT04574245||Potentially resectable group|
33046598|NCT04574245||Unresectable group|
33046599|NCT04556617|Experimental|PLX2853 + Abiraterone Acetate + Prednisone|"Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.~Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled."
33331252|NCT05407324|Experimental|CORT113176 (Dazucorilant) 150 mg|150 mg of dazucorilant will be administered once daily.
33331253|NCT05407324|Placebo Comparator|Placebo (matched to study drug)|Placebo will be administered once daily.
33046600|NCT04556617|Experimental|PLX2853 + Olaparib|"Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.~Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled."
33046601|NCT05029284|Experimental|teleABLE|Participants will complete 12 teleABLE sessions via videoconferencing, guided by an intervention therapist and participant workbook.
33331254|NCT05407012|Experimental|Intervention of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
33046602|NCT04554862|Active Comparator|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
33046603|NCT04554862|Active Comparator|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
33046604|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
33046605|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
33046606|NCT05027490|Experimental|patients receiving CANUT support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~CANUT support : patients will receive the CANUT guide (food guide) to help them deal with eating disorders encountered during their chemotherapy treatment ; the CANUT support includes calls from a dietician between chemotherapy cycles for support and advice.~anthropometric measures~Prehension strength measurement~food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~Quality of Life Questionnaire Core 30 (QLQ C30)~Scratch & Snif Test~Taste Strip Test~Nutrition interview~24 H feed back questionnaire~condiment questionnaire~tobacco questionnaire"
33046607|NCT05027490|Active Comparator|patients not receiving canut support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~anthropometric measures~Prehension strength measurement~food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~Quality of Life Questionnaire Core 30 (QLQ C30)~Scratch & Snif Test~Taste Strip Test~Nutrition interview~24 H feed back questionnaire~condiment questionnaire~tobacco questionnaire"
33046608|NCT04550728|Experimental|FES+robot|Participants in this group will have FES during ankle robot training
33046609|NCT04550728|Active Comparator|Robot|Participants in this group will have ankle robot training only
33046610|NCT04543357||All participants|Household contacts of a DMD patient in an interventional study of fordadistrogene movaparvovec.
33046611|NCT04532749|Experimental|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
33046612|NCT04532749|Placebo Comparator|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
33046613|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
33046614|NCT05022615||Mild Non-Proliferative Diabetic Retinopathy (NPDR)|Presence of at least one retinal microaneurysm or hemorrhage as determined by clinician.
33046615|NCT05022615||Moderate NPDR|Increasing hemorrhages and microaneurysms as well as cotton wool spots, venous beading (VB) or Intraretinal microvascular abnormalities (IRMA) to a mild degree as determined by clinician
33046616|NCT05022615||Severe NPDR|"4-2-1 rule-that is, one has severe NPDR if hemorrhages or microaneurysms, or both, appear in all four retinal quadrants; venous beading appears in two or more retinal quadrants; or prominent IRMAs are present in at least one retinal quadrant as determined by clinician."
33046617|NCT05022615||Proliferative Diabetic Retinopathy (PDR)|Neovascularization, either on or within one disc diameter (DD) of the optic disc (NVD) or elsewhere in the retina (NVE); a preretinal hemorrhage (PRH); or vitreous hemorrhage (VH) as determined by the clinician.
33046618|NCT04526782|Experimental|Cohort 1 (1st line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
33046619|NCT04526782|Experimental|Cohort 2 (2nd line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
33046620|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
33046621|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
33046622|NCT04420702|Experimental|Early Detection Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~Standard of care prostate biopsy will be performed within 12 weeks of MRI~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
33046623|NCT04420702|Experimental|Active Surveillance Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~Standard of care prostate biopsy will be performed within 12 weeks of MRI~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
33046624|NCT05014074|Experimental|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
33046625|NCT04379713|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33331255|NCT05407012|No Intervention|Absence of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
33331256|NCT05502562||Participants with type 2 diabetes|Adult participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
33331257|NCT05501548|Experimental|Olaparib and Vitamin C|Olaparib will be administered at 300 mg by mouth, twice daily; ascorbate will be administered at 1 g/kg IV twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.
33331258|NCT05455840|Experimental|Intervention|Patients with qualified criteria will be enrolled in this study
33046626|NCT04379713|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
33046627|NCT03802097|Experimental|A group (treatment group)|No use of antimicrobial prophylaxis
33331259|NCT05425732|Experimental|Cohort 1 V116|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.
33331260|NCT05425732|Active Comparator|Cohort 1 PCV20|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.
33046628|NCT03802097|Experimental|B group (control group)|Use of antimicrobial prophylaxis
33331261|NCT05425732|Experimental|Cohort 2 V116|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.
33331262|NCT05425732|Active Comparator|Cohort 2 PCV20|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.
33331263|NCT05413252|No Intervention|Current Practice|Practices will deliver care as usual and patients at these sites receive standard HTN care delivered.
33331264|NCT05413252|Active Comparator|Practice Facilitation|
33046629|NCT04276558|Experimental|Dose 1 - 0.5 µg/day|Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID
33046630|NCT04276558|Experimental|Dose 2 - 2.5 µg/day|Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID
33046631|NCT04276558|Experimental|Dose 3 - 5 µg/day|Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID
33046632|NCT04276558|Placebo Comparator|Vehicle|Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID
33046633|NCT05001516|Experimental|LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;"
33046634|NCT05001516|Experimental|LM302 Dose Escalation Level 2, 0.4 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;"
33046635|NCT05001516|Experimental|LM302 Dose Escalation Level 3, 0.8 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
33046636|NCT05001516|Experimental|LM302 Dose Escalation Level 4, 1.6mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
33046637|NCT05001516|Experimental|LM302 Dose Escalation Level 5, 2.4mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;"
33046638|NCT05001516|Experimental|LM302 Dose Escalation Level 6, 2.8mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;"
33046639|NCT03791216||Psoriasis patients to be treated only topically|
33046640|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
33046641|NCT03791216||Age-, sex- and BMI percentile-matched controls|
33046642|NCT03791216||Patients being treated with isotretinoin for acne|
33046643|NCT04230499|Experimental|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
33046644|NCT04230499|Experimental|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
33046645|NCT04230499|Experimental|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
33046646|NCT04188964|Experimental|Treatment|Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
33046647|NCT04996680|Experimental|Blood flow restriction group|patients in this group will undergo a standard strength training program combined with an occlusion cuff. The cuff will reduce the amount of blood flow and therefore increase the metabolic stimulus. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
33109872|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
33109873|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
33331265|NCT05412160|Experimental|ARM A - BioArginine receivers|Patients will be randomized to receive BioArginine C™ twice daily on top of usual chronic inhaled therapy
33331266|NCT05412160|Placebo Comparator|ARM B - placebo receivers|Patients will be randomized to receive placebo twice daily on top of usual chronic inhaled therapy
33331267|NCT05389462|Experimental|Part 1: Dose Escalation, ADCT-601 Combination Therapy|In Part 1 (dose escalation), participants with selected sarcoma indications will receive escalating doses of ADCT-601 in combination with gemcitabine.
33331268|NCT05389462|Experimental|Part 1: Dose Escalation, ADCT-601 Monotherapy|In Part 1 (dose escalation), participants with sarcomas indications (regardless of AXL gene amplification status), non-small-cell lung cancer (NSCLC) (regardless of AXL gene amplification status), and solid tumors with AXL gene amplification, will receive ADCT-601 monotherapy.
33109874|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
33418404|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
33418405|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
33046648|NCT04996680|Sham Comparator|Sham group|patients in this group will undergo the same standard strength training program as the BFR-group, combined with an occlusion cuff but pressurized so there is no significant effect on the lower limb blood flow. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
33046649|NCT04996680|Active Comparator|Control group|patients in this group will undergo the same standard strength training program as the BFR-group and placebo-group, but without a tourniquet.
33046650|NCT04712435|Experimental|Experimental: N-acetylcysteine|Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
33046651|NCT04712435|Placebo Comparator|Placebo Comparator: Placebo|200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
33046652|NCT04121962|Experimental|Peer Mentor|Peer Mentor Training is 5 groups with a 30 day reunion session. This condition is focused on training participants with communication skills to promote HIV and STI home-based testing and treatment and pre-exposure prophylaxis (PrEP) to individuals in their social networks. Participants will also learn how to use the Star website to request home-based testing kits. Peer Mentor training is conducted by a two health educators. The sessions are held once a week and will last approximately 90 minutes.
33046653|NCT04121962|Active Comparator|Control|Participants will receive information on how to use the website to request at-home test kits
33046654|NCT04104022|No Intervention|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
33046655|NCT04104022|Active Comparator|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
33046656|NCT04104022|Experimental|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
33046657|NCT04993482||type 2 diabetes mellitus group|124 adults with type 2 diabetes mellitus will be included
33046658|NCT04993482||control group|124 control adults will be included
33046659|NCT04102579|Experimental|Valbenazine|Capsule, administered orally once daily for 12 weeks.
33046660|NCT04102579|Placebo Comparator|Placebo|Capsule, administered orally once daily for 12 weeks.
33046661|NCT04712513||Patients with coronary artery disease and hemodynamically stable|
33046662|NCT03999853|Experimental|Conventional Therapy / Butyrate|Subjects will be receiving usual therapy for the first study period (approx 1 month) then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) for approx 2 months
33046663|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
33046664|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
33046665|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
33046666|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
33046667|NCT04991376||Vancomycin|Critically ill patients who suffered from sepsis, treated with vancomycin.
33046668|NCT04991376||Gentamicin|Critically ill patients who suffered from sepsis, treated with gentamicin.
33046669|NCT04991376||Other antibiotic groups|Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).
33046670|NCT04712084|No Intervention|Control group|Extubation procedure following standard of care
33046671|NCT04712084|Experimental|Pressure support group|Extubation procedure is performed with 100% of O2 but with application of positive pressure before and after extubation
33046672|NCT03977194|Active Comparator|Arm A : standard treatment|Carboplatine + paclitaxel (4 cycles of 28 days)
33046673|NCT03977194|Experimental|Arm B : standard treatment + immunotherapy|Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity
33046674|NCT04729465|Active Comparator|Active Comparator|"Active Comparator: Control Patients with cardiac disaese receive general anesthesia with Propofol~Interventions:~Drug: Propofol"
33046675|NCT04729465|Experimental|Experimental|"Experimental: Bispectral Index Monitor Patients with cardiac disease receive a general anesthesia with Propofol where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Interventions:~Drug: Propofol Device: Bispectral Index Monitor"
33046676|NCT04989387|Experimental|Treatment Group A Dose Escalation and Expansion|INCA00186 will be administered as monotherapy every 2 or every 4 weeks.
33046677|NCT04989387|Experimental|Treatment Group B1 Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
33046678|NCT04989387|Experimental|Treatment Group B2 Dose Escalation and Expansion|INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.
33046679|NCT04989387|Experimental|Treatment Group C Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.
33046680|NCT04712162|Other|D: maintain anesthesia with desflurane|D: maintain anesthesia with Suprane® (Desflurane) at 6%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
33046681|NCT04712162|Other|S: maintain anesthesia with sevoflurane.|S: maintain anesthesia with Sevorane® (Sevoflurane) at 2%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
33046682|NCT02965183|Experimental|Temperature measurements|
33046683|NCT04729309|Experimental|Mass Balance (MB) Cohort|Participants will receive oral [14C] RO7049389 under fasted conditions, followed by intravenous IV [13C] after a two-hour period.
33046684|NCT04729309|Experimental|Absolute Bioavailability (BA) Cohort|In Periods 1 and 2, participants will receive oral [12C] RO7049389 under fasted conditions, followed by IV [13C] RO7049389. There is a minimum 7-day washout between periods.
33046685|NCT04712357|Placebo Comparator|Placebo (Vitamin C)|Control placebo (Vitamin C - 500mg / day, for 10 days)
33046686|NCT04712357|Active Comparator|Tenofovir disoproxyl fumarate (TDF)|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
33046687|NCT04712357|Active Comparator|TDF + FTC|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
33046688|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
33046689|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
33046690|NCT03933670|Experimental|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
33046691|NCT03794908|Experimental|Light therapy A (Bright) via the Re-Timer®|"60 minutes/day~For the first hour after waking"
33046692|NCT03794908|Active Comparator|Light therapy B (Dim) via the Re-Timer®|"60 minutes/day~For the first hour after waking"
33046693|NCT04712201|Experimental|En bloc|En bloc transurethral resection of the bladder
33046694|NCT04712201|Active Comparator|Conventional|Conventional transurethral resection of the bladder
33046695|NCT03713632|Active Comparator|Secukinumab 1|Secukinumab 300mg every 2 weeks
33046696|NCT03713632|Active Comparator|Secukinumab 2|Secukinumab 300mg every 4 weeks
33046697|NCT03713632|Placebo Comparator|Placebo 1|Placebo group to secukinumab 300mg every 2 weeks
33046698|NCT03713632|Placebo Comparator|Placebo 2|Placebo group to secukinumab 300mg every 4 weeks
33046699|NCT00390039|Experimental|A|MNS075 7.5mg
33046700|NCT00390039|Placebo Comparator|B|Placebo
33046701|NCT00390039|Active Comparator|C|IV Morphine
33418406|NCT05194605||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
33046702|NCT00390039|Experimental|E|MNS075 15mg
33046703|NCT00390039|Placebo Comparator|D|Placebo
33046704|NCT00390039|Placebo Comparator|F|Placebo
33418407|NCT05194605||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
33046705|NCT01838369|Experimental|BI-505|
33046706|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
33046707|NCT04954326|Experimental|S95014 lyophilizate|Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
33046708|NCT04954326|Active Comparator|S95014 liquid|Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
33046709|NCT00399919|Experimental|PLC|Investigational drug
33046710|NCT00399919|Placebo Comparator|Placebo|
33046711|NCT04935801|Sham Comparator|LD Vehicle_GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (14.8ug) without peptides
33046712|NCT04935801|Experimental|LD PepGNP-Dengue|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (14.8ug) plus peptides
33418408|NCT05189145|Active Comparator|Group I (control)|All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.
33046713|NCT04935801|Sham Comparator|HD vehicle-GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (44.5ug) without peptides
33046714|NCT04935801|Experimental|HD PepGNP-Dengue|High dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (44.5ug) plus peptides
33046715|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.
33046716|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
33046717|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
33046718|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
33046719|NCT01269593|Experimental|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
33046720|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
33046721|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
33046722|NCT04933266|Active Comparator|Low dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
33046723|NCT04933266|Active Comparator|High dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 10ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 10ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 20ml will be given).
33046724|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
33046725|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
33046726|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
33046727|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
33046728|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
33046729|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
33109875|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
33109876|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
33331269|NCT05389462|Experimental|Part 2: Dose Expansion, ADCT-601 Combination Therapy|"In Part 2 (dose expansion), participants with selected sarcoma indications will receive ADCT-601 in combination with gemcitabine.~Participants will be split into 2 groups:~Group 1: Participants without gemcitabine in prior lines of therapy~Group 2: Participants with gemcitabine containing regimen in prior lines of therapy"
33331270|NCT05389462|Experimental|Part 2: Dose Expansion, ADCT-601 Monotherapy|In Part 2 (dose expansion), participants with AXL gene amplification and selected indications will receive ADCT-601 monotherapy.
33331271|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
33331272|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
33331273|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
33331274|NCT05395858||Hemophilia A patients|Patients will be identified via standard medical charts or electronic medical records (EMRs).
33331275|NCT05393362|Experimental|Cardiac Rehabilitation Program (CR)|The CR program will consist of aerobic exercise sessions and strength exercise sessions. The exercises will be individualized after assessing short effort capacities (strength exercise) and long efforts (aerobic exercise). It will be done four days a week, with a minimum of 48 hours between sessions of the same type of exercise. To make progress will be taking a clinical criterion into account, determined by the absence of symptoms derived from HF at the current intensity, and a temporary criterion where provided that the clinical criterion is met, the intensity will be increased every two-three weeks.
33331276|NCT05393362|Active Comparator|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
33331277|NCT05391022|Experimental|Run-In Food Effect Period|Unblinded, open label drug will be administered once in a fasted state and twice in a fed state with a minimum of 5 days between each dose prior to entering the continuous treatment phase.
33046730|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
33046731|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
33046732|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046733|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046734|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046735|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046736|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046737|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046738|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
33046739|NCT04927143|Active Comparator|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
33046740|NCT04927143|Experimental|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive incentives worth $2-$8."
33046741|NCT04927143|Experimental|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive incentives worth $4-$16."
33046742|NCT04927143|Experimental|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive incentives worth $6-12."
33046743|NCT04927143|Experimental|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive incentives worth $10-$20."
33046744|NCT04927143|Experimental|Constant High|"In the Constant groups, incentive amounts will remain unchanged across time. The High group will receive incentives worth $16."
33046745|NCT04927143|Experimental|Constant Low|"In the Constant groups, incentive amounts will remain unchanged across time. The Low group will receive incentives worth $8 every test."
33046746|NCT00379652|Active Comparator|A|Patient-based intervention
33046747|NCT00379652|Active Comparator|B|Health center-based intervention
33046748|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
33046749|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
33046750|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
33046751|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
33046752|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
33046753|NCT02395705|No Intervention|Surgery alone group|"Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
33331278|NCT05391022|Experimental|Continuous Treatment Period|Unblinded, open label drug will be administered once daily for 14 consecutive days followed by a 7 day break, which is considered 1 cycle of treatment (1 cycle = 21 days).
33331279|NCT05387590|Other|Preventiometer Device|The Preventiometer is a physical wellness tool that assesses multiple physical wellness measures in a 60 ± 15 minutes period of time. It is intended to promote population wellness by empowering individuals to act upon the information they receive about their overall health.
33331280|NCT05386342|Other|LeMaitre TufTex Over-the-Wire Embolectomy Catheter|The LeMaitre Over the Wire Embolectomy Catherer is indicated for use in the removal of emboli and thrombi during embolectomy and/or thrombectomy. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
32869547|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
33331281|NCT04315298|Experimental|Sarilumab 200mg IV (P2)|Phase 2
33331282|NCT04315298|Experimental|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
33331283|NCT04315298|Experimental|Sarilumab 400mg IV (P2)|Phase 2
33331284|NCT04315298|Experimental|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
33331285|NCT04315298|Experimental|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
33331286|NCT04315298|Experimental|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
33046754|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
33046755|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
33046756|NCT04895943||Group with adjustable IGB|
33046757|NCT04895943||Group with non-adjustable IGB|
33046758|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
33046759|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
33046760|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
33046761|NCT00083863||Framingham Heart Study Offspring|
33046762|NCT00083863||FHS Gen 3|
33046763|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
33046764|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
33046765|NCT00083980|Experimental|Herbal treatment kava|Kava
33046766|NCT04893174|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.
33046767|NCT04889352|Experimental|Access to colonoscopy web app|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.
33046768|NCT04889352|No Intervention|Control|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).
33046769|NCT04870047|Experimental|p64 MW HPC Flow Diverter + SAPT|
33046770|NCT04870047|Experimental|p64 MW Flow Diverter + DAPT|
33046771|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
33046772|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
33046773|NCT04865718||neurovascular surgery group|Subjects undergoing neurovascular surgery including aneurysm clipping
33046774|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33331287|NCT04650542|Experimental|HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2)|"HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2~Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"
33331288|NCT03747224|Experimental|ARO-ANG3|
33331289|NCT03747224|Placebo Comparator|Placebo|
33360677|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
33046775|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
33046776|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
33046777|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
33046778|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
33046779|NCT03038373||Group III|Lean Diabetics, No surgery
33046780|NCT03038373||Group IV|Lean Non Diabetics, No surgery
33046781|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33046782|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
33046783|NCT04843800|Experimental|Acupuncture|The acupuncture treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. The acupuncture treatment protocol will be semi standardized according to usual practice. All patients will be treated with a selection of local and distant points, comprising 10 minutes of insertion time, 30 minutes of needle retention and manipulation to achieve de qi (an irradiating feeling) if possible.
33046784|NCT04843800|Experimental|Chiropractic|The chiropractic treatments will consist of one 20-minute session weekly, for 3 consecutive weeks. The Diversified technique is one of the most commonly practiced techniques by chiropractors. In the treatment of low back pain, this technique involves the application of a quick (high-velocity), short (low-amplitude) thrust (adjustment) to the lombo-pelvic area.
33046785|NCT04843800|Experimental|Waiting list and Therapeutic Massage|The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
33046786|NCT00400114|Experimental|sunitinib|
33046787|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
33046788|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
33046789|NCT04838457|Experimental|ACME-TM|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
33046790|NCT00085306|Experimental|Recombinant interferon beta|
33046791|NCT04729348|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits.~PEMBROLIZUMAB daily, every 3 weeks~LENVATINIB daily every 3 weeks"
33046792|NCT04838028||Standard polypropylene mesh|Density > 50 g/square meter
33046793|NCT04838028||Lightweight mesh|"A mesh based on either polypropylene or polyester. Some variants contain purely 1 polymer. Others are composite, ie, contain also an absorbable material.~The density < 50 g/square meter (when applicable, after partial absorption)"
33046794|NCT04838028||Fixation with metal tacks|Non-absorbable metal staples or tacks
33046795|NCT04838028||Fixation with absorbable tacks|Absorbable synthetic staples or tacks
33046796|NCT04838028||Fibrin glue fixation|Biologic glue/sealant produced from human donor blood
33046797|NCT04838028||Non-fixation|Mesh is deployed without fixation
33331290|NCT04621058|Experimental|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:~If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
33046798|NCT04838028||3D mesh|"A polypropylene mesh with a preformed anatomic shape corresponding to the inner preperitoneal curvature of the groin.~The category does not differentiate between standard and lightweight variants."
33046799|NCT04838028||Progrip fixation|Absorbable (Velcro type of) microhooks. The particular meshes come with prefabricated Progrip microhooks. Progrip = Registered trademark.
33046800|NCT04838028||Polyester mesh|Polyester-based mesh. This category does not differentiate between standard and lightweight variants
33046801|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
33046802|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
33046803|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
33046804|NCT00085501|Active Comparator|1|
33046805|NCT00085501|Active Comparator|2|
33046806|NCT04836975||SCLC|Patient Diagnosed with Small Cell Lung Cancer- (extensive or limited)
33046807|NCT04836975||NSCLC|Patient diagnosed with primary stage III Non-Small cell lung Cancer
33046808|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
33046809|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
33046810|NCT04811664|Experimental|Immediate Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 1 and Day 29.
33046811|NCT04811664|Experimental|Delayed Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 113 and Day 141.
33046812|NCT04811664|No Intervention|Vaccine Declined|Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study
33046813|NCT04729426|Experimental|Position Group|Position group
33046814|NCT04729426|No Intervention|Control group|No Position group
33046815|NCT04798638|Experimental|Arm1: TY-9591 + Osimertinib + TY-9591|Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
33046816|NCT04798638|Experimental|Arm2: Osimertinib + TY-9591 + TY-9591|Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
33046817|NCT00085852|Experimental|Single|Treatment with BLVR
33046818|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33046819|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
33046820|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
33046821|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
33046822|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
33046823|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
33046824|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
33046825|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
33046826|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
33046827|NCT04796415|Experimental|DEMA-Pro|The DEMA-Pro intervention will be administrated. Subjects will attend six weekly, 1-hour telephone sessions.
33046828|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
33046829|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
33046830|NCT00086242|Experimental|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
33046831|NCT00086242|No Intervention|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
33046832|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
33046833|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
33046834|NCT04788771|Sham Comparator|Tracheal intubation in laparoscopic extraperitoneal hernia repair|Tracheal intubation in laparoscopic extraperitoneal hernia repair
33046835|NCT04788771|Active Comparator|laryngeal mask airway in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
33046836|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
33046837|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
33418409|NCT05189145|Experimental|group II (experimental)|"All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.~progesterone (P4) and estradiol assessed and Progesterone supplement adjustments based on serum level of P4 on day of embryo transfer dividing Group II (Cases) into 3 groups:~Group II A: If P4 levels < 5ng/dl, one progesterone supplement in form of 100 mg intramuscular injection daily added~Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added~Group II C: If P4 levels >10ng, continue on 400 mg prontogest suppositories twice daily"
33418410|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
33046838|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
33046839|NCT04784637|Experimental|Group 1|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) for 6 weeks
33046840|NCT04784637|Experimental|Group 2|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) +Behavioral Adaptation Module (BAM) for 6 weeks
33046841|NCT00086749||Tamoxifen group|
33046842|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
33046843|NCT04784130|Experimental|DHSMP core|Dietary Modification and Physical Activity
33046844|NCT04784130|Experimental|DHSMP core plus|Dietary Modification, physical activity and medication adherence
33046845|NCT04784130|Active Comparator|DHSMP control|enhanced usual care-3 hours of education plus materials.
33046846|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
33046847|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)~Radiation Therapy (5 days/week for 6-7 weeks)~Surgery (if required) 14 -12 weeks after radiotherapy~Follow-up"
33046848|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
33046849|NCT04783155|Experimental|12-weeks pulmonary rehabilitation training plus inspiratory muscle training|To assess maximum inspiratory pressure, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home.
33046850|NCT04783155|Placebo Comparator|12-weeks pulmonary rehabilitation plus placebo (inactive) inspiratory muscle|To assess maximum inspiratory pressure with placebo, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home. The resistance will be set to about 5% throughout the study.
33046851|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33046852|NCT04764357|Experimental|Cooling Cap Therapy|Participants receiving cooling cap therapy
33046853|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
33046854|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
33046855|NCT00087295|Experimental|Treatment|Depsipeptide
33046856|NCT04762953|Experimental|SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis|Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
33046857|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
33046858|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33046859|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
33418411|NCT00473031|Experimental|1|High Protein
33046860|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
33046861|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
33046862|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
33418412|NCT00473031|Active Comparator|2|Normal Protein
33046863|NCT04760613|Active Comparator|Cannabidiol (CBD)|
33046864|NCT04760613|Placebo Comparator|Placebo (PCB)|
33046865|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
33046866|NCT04747470|Experimental|GS-3583 Dose Escalation|Participants will receive an escalating dose of GS-3583 for up to 52 weeks or until the participant meets study treatment discontinuation criteria.
33046867|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
33046868|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
33046869|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
33046870|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
33046871|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
33046872|NCT04727619|Experimental|Experimental|Participants who participated in the SLEEP program.
33046873|NCT04727619|No Intervention|Control|Participants who did not participate in the SLEEP program.
33046874|NCT04709796|Experimental|Intervention group: EmbryoGlue|Embryo transfer with EmbryoGlue®
33046875|NCT04709796|Active Comparator|Control group|Conventional embryo transfer
33046876|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
33046877|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
33046878|NCT04704336|No Intervention|Self-directed without Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and provided standard of care.
33046879|NCT04704336|Experimental|With Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
33046880|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
33046881|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
33046882|NCT00088426||HPE|Patients with HPE
33046883|NCT04700865|Other|Examination|Continuous ECG monitoring for minimum 3 days
33046884|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
33046885|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
33046886|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
33046887|NCT00088582|Experimental|Pasireotide (SOM230)|
33046888|NCT04695444|Active Comparator|conventional PVC tube|When performing nasotracheal intubation, clinicians use the conventional PVC tube.
33046889|NCT04695444|Experimental|PVC tube with rubber suction catheter|When performing nasotracheal intubation, clinicians use the conventional PVC tube + rubber suction catheter.
33046890|NCT04695444|Experimental|velvet soft PVC tube|When performing nasotracheal intubation, clinicians use the velvet soft PVC tube.
33046891|NCT00088777|Experimental|MET|
33046892|NCT00088777|Experimental|CSE|
33046893|NCT04688736|Experimental|Placebo|Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.
33046894|NCT04688736|Active Comparator|Chlorpheniramine|Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.
33046895|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33046896|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
33046897|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
33331291|NCT04621058|Placebo Comparator|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
33046898|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
33046899|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
33331292|NCT04314284|Other|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
33331293|NCT04314284|Experimental|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
33331294|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
33331295|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
33331296|NCT01562600||Nexium|
33331297|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
33331298|NCT04451330|Experimental|Trifarotene Cream + Doxycycline|Participants were applied with Trifarotene (CD5789) 50 micrograms per gram (mcg/g) cream topically on the face once daily in the evening for 12 weeks and received doxycycline 120 milligrams (mg) tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
33331299|NCT04451330|Placebo Comparator|Trifarotene Vehicle + Doxycycline Placebo|Participants were applied with vehicle CD5789 topically on the face once daily in the evening for 12 weeks and received doxycycline matching placebo tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
33331300|NCT04609514|Experimental|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
33331301|NCT04609514|Active Comparator|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
33046900|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
33046901|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
33046902|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
33046903|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
33046904|NCT04664205|Experimental|High intensity interval training, then Moderate Intensity Continuous Training|Participants randomly assigned to this arm will first receive high intensity interval training followed by moderate intensity continuous training.
33046905|NCT04664205|Experimental|Moderate Intensity Continous Training, then High Intensity Training|Participants randomly assigned to this arm will first receive moderate intensity continuous training followed by high intensity interval training.
33046906|NCT04664205|No Intervention|Control: No exercise|Participants will complete the same pre- post measurements, with no exercise in between.
33046907|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
33046908|NCT00400231|Active Comparator|1|Metformin
33046909|NCT00400231|Active Comparator|2|Fenofibrate
33046910|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
33046911|NCT00400231|Placebo Comparator|4|
33046912|NCT04657146||Patients with suspected newly-diagnosed Glioblastoma (GBM)|Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as >90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.
33109877|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
33109878|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
33109879|NCT02916368||with surgery|
33109880|NCT02916368||with chemotherapy or radiotherapy|
33109881|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
33109882|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
33046913|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
33418413|NCT03555812|Experimental|Healthy volunteers|"a medical examination~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
33046915|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
33046916|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
33046917|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
33046918|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
33046919|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
33046920|NCT00089323|Other|1: Bone Marrow Aspiration|
33046921|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
33046922|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
33046923|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
33046924|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
33046925|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
33046926|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
33046927|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
33046928|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
33046929|NCT04656990|Experimental|Gross motor and social-emotional integrated intervention group|Participants will receive a nine-month intervention which focuses on gross motor skills, physical activity, and social-emotional skills.
33046930|NCT04656990|No Intervention|Control|Participants will receive the center's everyday business as usual curriculum.
33046931|NCT00090025|Experimental|becatecarin|becatecarin
33046932|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
33046933|NCT04642053|Experimental|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
33046934|NCT04642053|Experimental|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
33046935|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
33046936|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
33046937|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
33046938|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
33046939|NCT04633902|Experimental|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
33046940|NCT04729153||Chronic HCV patients previously treated by DAADs.|
33046941|NCT04729153||Chronic HCV patients not treated by DAADs yet.|
33331302|NCT02493426|Placebo Comparator|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
33046942|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
33046943|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
33046944|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33331303|NCT02493426|Experimental|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
33331304|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
33331305|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
33331306|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
33046945|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33046946|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33046947|NCT00091351|Experimental|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
33046948|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
33046949|NCT04619706|Experimental|Arm A: FSD201 600 mg|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
33046950|NCT04619706|Experimental|Arm B: FSD201 1200 mg|Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
33046951|NCT04619706|Placebo Comparator|Arm C: Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
33046952|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
33046953|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
33046954|NCT04612140|Experimental|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
33331307|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
33331308|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
33331309|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
33046955|NCT04612140|Active Comparator|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
33046956|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
33046957|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
33046958|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
33046959|NCT04596423||A|Extended fetal heart examination
33046960|NCT04596423||B|Modified extended heart examination
33046961|NCT04596423||C|Sief_Twist sign only examination
33046962|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
33046963|NCT00091858|Placebo Comparator|Placebo Q4W|
33046964|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
33046965|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
33046966|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
33046967|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
33046968|NCT02972346|No Intervention|ACTH(-)|routine treatment
33046969|NCT04586244|Experimental|Treatment Group A|epacadostat will be administered in combination with retifanlimab.
33046970|NCT04586244|Experimental|Treatment Group B|retifanlimab will be administered as monotherapy.
33046971|NCT04586244|Experimental|Treatment Group C|epacadostat will be administered as monotherapy.
33046972|NCT04586244|Experimental|Treatment Group D|retifanlimab will be administered in combination with INCAGN02385.
33046973|NCT04586244|Experimental|Treatment Group E|retifanlimab will be administered in combination with INCAGN02385 and INCAGN02390.
33046974|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
33046975|NCT04576416|Experimental|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
33046976|NCT04576416|No Intervention|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
33046977|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
33046978|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
33331310|NCT05063994|Experimental|Chronocort|Hydrocortisone modified-release capsule - Chronocort®. 63 subjects will be randomised to this group using an interactive response technology (IRT).
33331311|NCT05063994|Active Comparator|Cortef|Immediate-release hydrocortisone capsule (IRHC) - Cortef. 63 subjects will be randomised to this group using an interactive response technology (IRT).
32740876|NCT04554719|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
33046979|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
32740877|NCT04452981|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
33331312|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
33331313|NCT04664400|Experimental|N-of-few Study of Pain|
33331314|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
33331315|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
33046980|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
33046981|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
33046982|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
33046983|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
33046984|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
33046985|NCT04551066|Experimental|Group A : parsaclisib + ruxolitinib|Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
33046986|NCT04551066|Placebo Comparator|Group B : placebo + ruxolitinib|Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
33109883|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
33109884|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
33331316|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
33331317|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
33331318|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
33331319|NCT04448756|Experimental|M5049 50 mg|
33331320|NCT04448756|Experimental|M5049 100 mg|
33331321|NCT04448756|Placebo Comparator|Placebo|
33331322|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
33331323|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
33331324|NCT05063136|Experimental|Capecitabine+endocrine therapy|capecitabine (500mg, tid) (for 1 year)+standard endocrine therapy (at least 5 years)
33331325|NCT05063136|Placebo Comparator|Placebo+endocrine therapy|oral placebo (tid) (for 1 year) + standard endocrine therapy (at least 5 years)
33331326|NCT05053932||Patients included in Drepagreffe 1 study (NCT01340404)|biological collection
33331327|NCT04276220|Other|Tenosynovial Biopsy|
33331328|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:~Extended written information and education of patients with atrial fibrillation."
33331329|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
33331330|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
32740878|NCT04452981|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
33331331|NCT05036538|Experimental|Relaxation intervention with natural sounds|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
33331332|NCT05036538|Experimental|Relaxation intervention with natural sounds and binaural beats|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
33046987|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
33046988|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
33331333|NCT05036538|Experimental|Relaxation intervention with natural sounds and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
32740879|NCT04539041|Experimental|Cohort A NIO752|4 injections of NIO752 at dose A
32740880|NCT04539041|Experimental|Cohort B NIO752|4 injections of NIO752 at dose B
32740881|NCT04539041|Placebo Comparator|Placebo|4 injections of placebo
33046989|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
33046990|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
33046991|NCT00093730|Experimental|BMS-59926|
33046992|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
33046993|NCT04544709|Other|Discogenic Low Back Pain|Patient with Refractory Discogenic Low back pain who will be scheduled for platelet rich plasma injection as standard of care.
33046994|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
33046995|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
33046996|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
33046997|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
33046998|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
33046999|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
33109885|NCT02916524|No Intervention|Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline|This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
33109886|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
33109887|NCT02116998|Placebo Comparator|Placebo|
32740882|NCT04539041|Experimental|Cohort C NIO752|4 injections of NIO752 at dose C
33047000|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
33331334|NCT05036538|Experimental|Relaxation intervention with natural sounds, binaural beats and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
33047001|NCT04538430|Other|Axial Low Back Pain|Patient diagnosed with axial low back pain not responding to conservative measures and no symptoms of radiculopathy, that is scheduled to have a SPRINT percutaneous peripheral nerve stimulator placed as standard of care.
33047002|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
33047003|NCT00094276|Active Comparator|2|FACI intervention
33047004|NCT00094276|Active Comparator|3|Breathmobile intervention
33331335|NCT05036538|No Intervention|Control without Intervention|
33331336|NCT04274192|Experimental|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with synchronized)|Subjects will first receive HFNC synchronized to his/her own efforts via NAVA at 6 LPM followed by continuous HFNC at 6 LPM and then HFNC synchronized to his/her own efforts via NAVA at 8 LPM followed by continuous HFNC at 8 LPM
33331337|NCT04274192|Active Comparator|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with continuous)|Subjects will first receive continuous HFNC at 6 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 6 LPM. Next, subjects will receive continuous HFNC at 8 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 8 LPM.
33047005|NCT00094276|No Intervention|4|Control group
33047006|NCT00094354||1|HIV-infected FPDs
33047007|NCT00094354||2|Family members of HIV-infected FPDs
33047008|NCT00094354||3|Local healthcare workers
33047009|NCT00094354||4|Villagers not related to an HIV-infected individual
33047010|NCT00094432|Active Comparator|A1|
33047011|NCT00094432|Placebo Comparator|A2|
33047012|NCT04519827|Experimental|New Rice-based hydrolysate|The TEST formula is a new Rice-based hydrolysate with new ingredient.
33047013|NCT04519827|Placebo Comparator|Amino-acid based formula|The PLACEBO is an Amino-acid based formula.
33047014|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
33047015|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
33047016|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
33047017|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
33047018|NCT04515030||Primary glaucoma|"Primary glaucoma patients were diagnosed based on guidelines [1-2]. Patients with a confirmed diagnosis of primary glaucoma were enrolled and classified into the acute angle-closure crisis (AACC), primary angle-closure glaucoma (PACG), and primary open-angle glaucoma (POAG) subgroups.~Prum BE, Herndon LW, Moroi SE, et al. Primary Angle Closure Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P1-40. doi:10.1016/j.ophtha.2015.10.049~Prum BE, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P41-111. doi:10.1016/j.ophtha.2015.10.053"
33047019|NCT04515030||Senile cataract|"Senile cataract patients were diagnosed based on guideline [3]. Patients with a confirmed diagnosis of senile cataract were enrolled and considered as controls for aqueous humor-related analysis.~[3] Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the Adult Eye Preferred Practice Pattern®. Ophthalmology 2017;124:P1-119. doi:10.1016/j.ophtha.2016.09.027"
33047020|NCT04515030||Normal control|Normal people without ocular diseases were enrolled as normal control.
33047021|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
33047022|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
33047023|NCT00094822||Pegfilgrastim|
33047024|NCT00094822||PLACEBO|
33047025|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
33047026|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
33109888|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
33109889|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
33109890|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
33331338|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
33331339|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
33331340|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
33331341|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.~Education, basic medical order."
33047027|NCT04506879|Other|Popliteal Sciatic Nerve block|Patients will lie on their chest on the examination couch with both feet rested on the pillow to relax their lower extremity. Ultrasound scan of the nerves in popliteal fossa will be identified and then local anesthetic agents [1.5% lidocaine with 1:200,000 adrenaline and 0.5ml of 8.4% sodium bicarbonate (total 30ml)] will be injected close to the nerves (Common peroneal nerve and tibial nerve). The injections below the bifurcation near the two nerves are expected to produce quicker block than the injections above the bifurcation.
33047028|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
33047029|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
33047030|NCT00095329|Experimental|sirolimus|
33047031|NCT04504149|Experimental|PRIMED|Shared decision making session
33047032|NCT04504149|No Intervention|Usual Care|The investigators will characterize usual care using chart review and administrative data to identify medications (prescribed, filled), number of mental health sessions received, types of providers seen, and the content of treatment sessions as captured in chart notes.
33047033|NCT04492566|Experimental|AID Evaluation|"After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
33047034|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
33047035|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
33047036|NCT04476030|Experimental|Experimental: SAGE-217 + Assigned ADT|Participants will receive SAGE-217 capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
33047037|NCT04476030|Active Comparator|Active Comparator: Placebo + Assigned ADT|Participants will receive SAGE-217-matching placebo capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
33047038|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
33047039|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
33047040|NCT00095719|Active Comparator|A1|
33047041|NCT00095719|Placebo Comparator|B1|
33047042|NCT00095758|Placebo Comparator|A1|
33047043|NCT00095758|Active Comparator|A2|
33047044|NCT02964637||Progressive supranuclear palsy|Observational Study
33047045|NCT02964637||Corticobasal syndrome|Observational Study
33047046|NCT02964637||Behavoral variant FTD|Observational Study
33047047|NCT02964637||Semantic variant PPA|Observational Study
33047048|NCT02964637||Non-fluent variant PPA|Observational Study
33047049|NCT02964637||FTD-motor neuron disease|Observational Study
33047050|NCT02964637||Healthy controls|Observational Study
33047051|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
33047052|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
33047053|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33047054|NCT04432428|Experimental|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
33331342|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
33109891|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
33331343|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
33109892|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
32869548|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
32869549|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
33331344|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
33331345|NCT04660032|Experimental|Nudge|Obstetric care providers will receive electronic prompts (nudge) for participants in this arm
33331346|NCT04660032|No Intervention|Usual care|Usual postpartum follow-up with visit at 4-12 weeks postpartum
33109893|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
33109894|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
33109895|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
33109896|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
33109897|NCT01709214|Experimental|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
33109898|NCT01709214|Experimental|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
33109899|NCT01709214|Placebo Comparator|Placebo|Twice daily Placebo, oral administration for 15 weeks
33109900|NCT01709214|Active Comparator|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
33109901|NCT02916602|Experimental|Treatment|HCP1401
33109902|NCT02916602|Active Comparator|Reference|HCP0605
33109903|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
33109904|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
33109905|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
33109906|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
33109907|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
33109908|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
33109909|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
33109910|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
33109911|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
33109912|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
33109913|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
33109914|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
33109915|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
33109916|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
33109917|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
33331347|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
33331348|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
33331349|NCT04387136|Experimental|Sublingual Sufentanil|Participants in this arm will receive the intervention.
33331350|NCT04387136|No Intervention|Control|Participants in this arm will not receive an intervention.
32869550|NCT01775085|Active Comparator|Discussion Group (DG)|
32869551|NCT00147043|Experimental|Autologous Stem Cells|
33331351|NCT04658784|Experimental|Intervention|Receives posterior colporrhaphy closure using standardized technique with 2-0 V-Loc 90TM, Medtronic
33047055|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33047056|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
33047057|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
33047058|NCT04431960|Active Comparator|low-BC Group|consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
33047059|NCT04431960|Active Comparator|high-BC Group|consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
33047060|NCT04431960|Placebo Comparator|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
33047061|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33047062|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33047063|NCT04398459|Experimental|iBRIAN|
33047064|NCT04381182|Other|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
33047065|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
33047066|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
33047067|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
33047068|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
33047069|NCT04353648||Duke ICU/Trauma Center Patients|Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.
33047070|NCT04340076|Experimental|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
33047071|NCT04340076|Active Comparator|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
33047072|NCT04310709|Experimental|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks~Regorafenib~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
33047073|NCT00390312|Active Comparator|4|Intravenous morphine
33047074|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
33047075|NCT00390312|Experimental|2|Intranasal morphine 15 mg
33047076|NCT00390312|Active Comparator|3|Oral morphine 60 mg
33047077|NCT00390312|Placebo Comparator|5|Intranasal placebo
33047078|NCT00390312|Placebo Comparator|6|Oral placebo
33047079|NCT00390312|Placebo Comparator|7|Intravenous placebo
33331352|NCT04658784|Active Comparator|Control|Receives posterior colporrhaphy closure using standardized technique with conventional 2-0 PDS® Ethicon
33331353|NCT05018130|Experimental|Bio-integrative|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
33331354|NCT05018130|Active Comparator|Metallic|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.
33331355|NCT04252586|Experimental|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
33331356|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
33331357|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
33331358|NCT04985370|Experimental|Pain neuroscience education plus exercise|Three sessions of pain neuroscience education plus exercise.
33331359|NCT04985370|Active Comparator|Exercise alone|Exercise alone without pain neuroscience education.
33047080|NCT00400387|Other|Multivitamin supplement|
33047081|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
33047082|NCT00400465|Active Comparator|Control group|Pressure dressing
33047083|NCT00400465|Experimental|Experimental group|Normal dressing
33047084|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
33047085|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
33047086|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
33047087|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
33047088|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
33047089|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
33047090|NCT04294836|Experimental|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
33047091|NCT04294836|Placebo Comparator|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
33047092|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
33047093|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
33047094|NCT04294680|Experimental|Opiate Sparing|Cryotherapy one hour daily four times per day for two weeks postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeproazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative Oxycodone 5 milligrams every six hours by mouth as needed for uncontrolled pain for fourteen days postoperative
33047095|NCT04294680|No Intervention|Opiate Based|Oxycodone 5 to 10 milligrams every four to six hours by mouth as needed for pain for fourteen days postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeprazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative
33047096|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
33047097|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
33047098|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33047099|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33047100|NCT04290546|Experimental|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)~CIML NK cell infusion (Dose 0 or -1) infused on Day 0.~Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
33047101|NCT04290546|Experimental|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.~Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~Interleukin-15 Superagonist (N-803) Administration~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
33047102|NCT04284345|Experimental|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
33360678|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
33360679|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
33360680|NCT03929497|Experimental|Lu AF11167|
33360681|NCT03514030||positive|serum AQP4-antibody is positive
33360682|NCT03514030||negtive|serum AQP4-antibody is negtive
33331360|NCT05359536|Experimental|E-learning Intervention|Early career educators in the intervention condition will be asked to complete a 5-hour e-learning course over a two week timeframe. The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
33331361|NCT05359536|No Intervention|Usual Practice Control|Early career educators in the control condition will be asked to continue with their usual practices. They will be invited to complete the e-learning course after the study period.
33331362|NCT04247828|Experimental|Experimental and Generic Communication Interfaces for AAC|Receives both Experimental and Generic AAC systems to communicate. Each participant will receive both devices, with Experimental AAC presented first (Day 1) and Generic AAC presented second (Day 2; reference).
33047103|NCT04273464|Experimental|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.31 participants.
33047104|NCT04273464|Active Comparator|DIEP-group|26 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
33047105|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
33047106|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
33047107|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
33047108|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
33047109|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
33047110|NCT03633305|No Intervention|No additional treatment|
33047111|NCT02907372|Other|cognitive tests|
33047112|NCT04728763||Cases|"Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :~Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or~Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)"
33047113|NCT04728763||Control Group|Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
33047114|NCT04728724|Experimental|Group A|Anti-PD-1 monotherapy
33047115|NCT04728724|Experimental|Group B|Anti-PD-1 plus chemotherapy
33047116|NCT04728568|Experimental|Sintilimab|Sintilimab will be administered every 3 weeks Sintilimab will be administered through IV infusion
33047117|NCT04728529|Experimental|USSM protocol|patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
33047118|NCT04728529|Experimental|ACCM protocol|patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
33047119|NCT04253730|No Intervention|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
33047120|NCT04253730|Experimental|Cold Condition|Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
33047121|NCT04231851|Experimental|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
33047122|NCT00099502|Experimental|Arm 1|
33047123|NCT00099502|Experimental|Arm 2|
33047124|NCT00099502|Active Comparator|Arm 3|
33047125|NCT04210596|Active Comparator|Control group|Connective tissue graft harvested from the palate
33047126|NCT04210596|Experimental|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
33047127|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
33047128|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
33047129|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
33331363|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
33047130|NCT04199091|Experimental|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
33047131|NCT04199091|Active Comparator|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
33047132|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
33047133|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
33047134|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
33047135|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
33047136|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
33047137|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
33047138|NCT00400699|Other|REview|
33047139|NCT00400738|Experimental|1|different dose per arm
33047140|NCT00400738|Experimental|2|different dose per arm
33047141|NCT00400738|Experimental|3|different dose per arm
33047142|NCT00400738|Experimental|4|different dose per arm
33047143|NCT04197765|Sham Comparator|Sham|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
33047144|NCT04197765|Active Comparator|Active acTBS|"For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays."
33047145|NCT00099580|Experimental|1|
33047146|NCT00099580|Placebo Comparator|2|
33047147|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
33047148|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
33047149|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
33331364|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
33047150|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
33047151|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
33047152|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
33047153|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
33047154|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
33047155|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
33047156|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
33047157|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
33047158|NCT04143711|Experimental|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
33047159|NCT04143711|Experimental|Monotherapy DF1001 Safety/PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
33047160|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047161|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 Low)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047162|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Cancers with Erbb2 Amplification|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047163|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab|Combination dose escalation of DF1001 in combination with nivolumab in patients with select solid tumors.
33331365|NCT04357262|No Intervention|Control|No other non-standard of care activities will be performed
33331366|NCT04357262|Experimental|Intervention|Will be signed up for the automated text messaging program (StreaMD)
33331367|NCT04232540|Experimental|Patient participants|Patient and provider will view and discuss results of the MedViewer test.
33331368|NCT04232540|Experimental|Provider participants|Patient and provider will view and discuss results of the MedViewer test.
33331369|NCT04504032|Experimental|Rivaroxaban|
33331370|NCT04504032|Placebo Comparator|Placebo|
33331371|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
33331372|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
33331373|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
33331374|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
33331375|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
33047164|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab-paclitaxel|Combination dose escalation of DF1001 in combination with nab-paclitaxel in patients with select solid tumors.
33047165|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nivolumab after evaluation for safety in the Combination Therapy with DF1001 and nivolumab Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
33047166|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab-paclitaxel Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
33047167|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Urothelial Bladder Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
33047168|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 High)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047169|NCT04143711|Experimental|Monotherapy DF1001 Expansion in NSCLC|Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047170|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in NSCLC|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
33047171|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Gastric Cancer|Monotherapy expansion cohort enrolling up to 20 patients with gastric cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047172|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Gastric Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with gastric cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
33047173|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Esophageal Cancer|Monotherapy expansion cohort enrolling up to 20 patients with esophageal cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
33047174|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Esophageal Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with esophageal cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
33047175|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
33047176|NCT04126395||Controls|"This groups consists of children now aged 6-12y:~Without a medical diagnosis possibly influencing motor development~Without motor problems (M-ABC-2 and DCD-Q)~Without social reponsiveness problems (SRS-2)"
33047177|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)~Without social responsiveness problems (SRS-2)"
33047178|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)~With social responsiveness problems (SRS-2)"
33047179|NCT04097652|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
33047180|NCT04071756|Experimental|Topical Tazarotene 0.1% Gel Plus BPS|"Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
33047181|NCT04071756|Placebo Comparator|Placebo Gel Plus BPS|"A substance that has no therapeutic effect, used as a control in testing new drugs~Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
33047182|NCT00100477|Other|Arm 1|
33047183|NCT04063878|Experimental|Single tooth restorations using Acuris conometric concept|
33047184|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
33109918|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
33109919|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
33331376|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33360683|NCT03925909|Experimental|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
33109920|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
33109921|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
33109922|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
33109923|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
33109924|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
33109925|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
33360684|NCT03925909|Experimental|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
33360685|NCT03925909|Experimental|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
33109926|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
33109927|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
33109928|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
33109929|NCT04688606||Two groups|"Initial diagnosis of suspected hepatocellular carcinoma;~patients undergoing liver transplantation, radical resection or ablation of liver cancer"
33109930|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
33109931|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
33109932|NCT04688489|Active Comparator|Intervention|The intervention consists of a supplement of maltodextrin at training episodes combined with added dietary carbohydrates at all meals
33109933|NCT04688489|No Intervention|Control|The control receives no intervention. Standard treatment will be administered.
33109934|NCT04688567|Experimental|Patient-driven iCBT|Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment program
33109935|NCT04688567|Active Comparator|Standardized iCBT (TAU)|Patients who are randomized to the control condition undergo the usual iCBT program available for anxiety disorders for a standardized time period of 8 weeks
33109936|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
33109937|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
33109938|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
33109939|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
33109940|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
33109941|NCT04688723|Active Comparator|Dabigatran/Clopidogrel|Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.
33109942|NCT04688723|Experimental|Dabigatran/Ticagrelor|Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.
33109943|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
33109944|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
33109945|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
33109946|NCT04688645|Experimental|Balanced crystalloid solution|Balanced crystalloid solution - Plasmalyte.
33109947|NCT04688645|Active Comparator|Normal saline|0.9% sodium chloride solution.
33109948|NCT00555282|Experimental|1|coated central venous catheter
33109949|NCT00555282|Active Comparator|2|standard central venous catheter
33109950|NCT04688372||Inpatient encounters with COVID-19 present-on-admission|See Study description above
33109951|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
33109952|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
33109953|NCT02915861||EXPa|Scrub typhus patients: Group A
33109954|NCT02915861||EXPb|Scrub typhus patients: Group B
33109955|NCT02915861||EXPc|Scrub typhus patients: Group C
33331377|NCT05460858|Experimental|N-acetyl cystein|Seventy participants who randomly assigned in the intervention group, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction, will be received 1200 (2×600) mg of effervescent tablets of NAC daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles. Also, we will measure severity of dysmenorea by visual analogue scale (VAS) technique.
33331378|NCT05460858|Placebo Comparator|effervescent placebo|Seventy participants who randomly assigned to the control group, during 6 weeks simultaneous to start the standard long agonist protocol, or antagonist induction, will be received 1200 (2×600) mg of effervescent placebo tablets daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval, in addition to, follicular fluid will be obtained from the mature follicles. Also, we measure severity of dysmenorrhea by visual analogue scale (VAS) technique.
33331379|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
33360686|NCT03925909|No Intervention|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
33047185|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
33047186|NCT04728685|Active Comparator|Group A|One-fifth of body weight traction force will be given
33047187|NCT04728685|Active Comparator|Group B|One-third of body weight traction force will be given
33047188|NCT04728685|Active Comparator|Group C|One-half of body weight traction force will be given
33047189|NCT04728607|Experimental|Participants|Individuals requiring ring removal.
33047190|NCT04062708|Experimental|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
33047191|NCT04728490|Experimental|Allogenic transplantation using treosulfan in conditioning regimen|"Haplo-identical transplantation using treosulfan in conditioning regimen Treosuflan, in the conditioning regimen will be administrated as followed 10 gr/m2 per day -4, -3 and -2 IV route~In combination with:~Thiotepa 5 mg/kg on day -6 Fludarabine 30 mg/m2 per day from day -5 to day -1"
33047192|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
33047193|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33047194|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
33047195|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
33047196|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
33047197|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
33047198|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
33047199|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
33047200|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
33047201|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
33047202|NCT04059549|Active Comparator|A-CHESS Drinker|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
33047203|NCT04059549|Experimental|PartnerCHESS Drinker|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
33109956|NCT02915861||EXC|Control group
33331380|NCT05359224|Active Comparator|Clopidogrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
33331381|NCT05359224|Active Comparator|prasugrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
32869552|NCT01774071|Experimental|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
33331382|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
33331383|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
33331384|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
33331385|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
33331386|NCT03756168|Experimental|Treatment subjects|Single group of subjects with will have the treatment of a 1060 nm diode laser administered to them
33360687|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
33360688|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
33360689|NCT03925129|Experimental|TENS|
33360690|NCT03925129|Sham Comparator|Sham TENS|
33047204|NCT04059549|Active Comparator|A-CHESS Partner|Patient's partner randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
33047205|NCT04059549|Experimental|PartnerCHESS Partner|Patient's partner randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
33047206|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
33047207|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
33047208|NCT04041570|Experimental|Group 1: cAd3-EBO S vaccine (1x10^10 PU)|cAd3-EBO S vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
33047209|NCT04041570|Experimental|Group 2: cAd3-EBO S vaccine (1x10^11 PU)|cAd3-EBO S vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
33047210|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
33047211|NCT00400855|Experimental|Arm 1|study drug
33047212|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
33047213|NCT04034511|Experimental|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
33047214|NCT04034511|No Intervention|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
33047215|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
33047216|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
33047217|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
33047218|NCT04033146|Experimental|Economical muscle dynamics|The investigators are trying to figure out how to optimize muscle contractile conditions for mobility. To do this, the investigators are systematically altering muscle contraction conditions for all participants.
33047219|NCT00101491|Experimental|1|
33047220|NCT00101491|Other|2|Attention Control Comparator
33047221|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
33047222|NCT00006401|Placebo Comparator|Placebo|
33047223|NCT00101569|Experimental|A1|
33047224|NCT00101569|Experimental|A2|
33047225|NCT03991884|Experimental|Dose -1 (0.3 mg/m^2)|Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33360691|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
33360692|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
33047226|NCT03991884|Experimental|Dose 1 (0.3 mg/m^2)|Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33360693|NCT03929575|Placebo Comparator|Placebo of calcium|Participants will consume 250 mg of calcium
33360694|NCT03929575|Experimental|Rhodiola|Participants will consume 250 mg of Rhodiola
32740883|NCT04539041|Experimental|Cohort D NIO752|4 injections of NIO752 at dose D
33047227|NCT03991884|Experimental|Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33047228|NCT03991884|Experimental|Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33047229|NCT00101725|Experimental|125 mg crofelemer|
33047230|NCT00101725|Experimental|250 mg crofelemer|
33047231|NCT00101725|Experimental|500 mg crofelemer|
33047232|NCT00101725|Placebo Comparator|placebo|
33047233|NCT04729036||mandibular fracture group|
33047234|NCT03972930|Experimental|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
33047235|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
33047236|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
33047237|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
33047238|NCT03967470|Placebo Comparator|Placebo arm|Placebo spray used during one month
33047239|NCT03967470|Active Comparator|Treatment arm|Bacteria spray used during one month
33047240|NCT03960177|Experimental|Treatment (glucarpidase)|Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
33047241|NCT03955029|Experimental|Conventional Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow conventional Interval Training
33047242|NCT03955029|Experimental|Progressive Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow progressive Interval Training
33047243|NCT00102388|Experimental|vildagliptin|
33047244|NCT00102388|Active Comparator|Gliclazide|
33047245|NCT00006425||1|25 women undergoing ductal lavage
33047246|NCT03947307|Experimental|Experimental Intervention (treatment / medical device)|Patients in the experimental group will receive lymphtaping using Easytape® according to common practice on day 1 after surgery by specifically trained physiotherapists. The tape has an elasticity of 150%. The material is moisture- and air-permeable with a hypoallergenic adhesive coating that is activated by body temperature to increase durability of contact. If possible the taping will be left for 7 days, in case of insufficient adhesion taping will be repeated.
33047247|NCT03947307|Active Comparator|Control Intervention (compression treatment )|Patients in the control group will be treated with manual lymphatic drainage followed by compression treatment using compressive stockings if accepted or compressive bandaging in cases with pronounced swelling depending on medical necessity.
33047248|NCT03947307|Sham Comparator|Control Intervention (sham taping)|Patients in the control group will be treated by sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
33047249|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
33047250|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
33047251|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
33047252|NCT03923049|Other|PET/MRI|Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis
33047253|NCT03900429|Placebo Comparator|Matching Placebo|Placebo Daily
33047254|NCT03900429|Active Comparator|80 mg MGL-3196|80 mg daily
33047255|NCT03900429|Active Comparator|100 mg MGL-3196|100 mg daily
33047256|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
33047257|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
33047258|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
33047259|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
33360695|NCT03929575|Experimental|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
33360696|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
33047260|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
33331387|NCT04919928|Experimental|Bimodal solution with cochlear implant and hearing aid (CI+HA)|"This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization.~Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting."
33047261|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
33047262|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
33331388|NCT04919928|Experimental|Bilateral new replacement Hearing Aids (HA+HA)|This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.
33331389|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
33047263|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
33047264|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
33331390|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
33331391|NCT03753126|Other|Cardiac CT imaging|
33331392|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
33331393|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
33331394|NCT04913766|Active Comparator|Services as usual|Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.
33047265|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
33047266|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
33047267|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
33047268|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
33047269|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
33047270|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
33047271|NCT00103168|No Intervention|Control|
33047272|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
33047273|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
33047274|NCT00103246|Experimental|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
33047275|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33047276|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
33047277|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
33047278|NCT00103519|Placebo Comparator|Placebo|Placebo BID
33047279|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
33047280|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
33047281|NCT00103792|Active Comparator|2|cyclophosphamide
33047282|NCT03891966|Active Comparator|Splint|
33047283|NCT03891966|Active Comparator|Soft Dressing|
33047284|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
33047285|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
33047286|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
33047287|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
33047288|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
33047289|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
33047290|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
33047291|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
33047292|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
33047293|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
33047294|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
33331395|NCT04913766|Experimental|Problem Management Plus|Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.
33047295|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
33047296|NCT00104494|Experimental|1|CF, Zinc acetate
33047297|NCT00104494|Experimental|2|CF, Placebo
33047298|NCT00104494|No Intervention|3|Controls
33047299|NCT00388115|Experimental|RFA prior to surgery|
33331396|NCT04605588|Active Comparator|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin & Hydroxychloroquine sulfate
33331397|NCT04605588|Placebo Comparator|Placebo|5 day dosing of placebo
33331398|NCT04885296|Experimental|Test/Control|Eligible subjects will be randomized into one of two possible lens wear sequences, Test/Control.
33331399|NCT04885296|Experimental|Control/Test|Eligible subjects will be randomized into one of two possible lens wear sequences, Control/Test.
32740884|NCT04539041|Experimental|Cohort E NIO752|4 injections of NIO752 at dose E
32740885|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
32740886|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
33047300|NCT00390585|Experimental|A|Iodixanol 320
33047301|NCT00390585|Active Comparator|B|Iomeprol 350
33047302|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
33047303|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
33047304|NCT00104689|Experimental|Capecitabine + Oxaliplatin|Patients receive oral capecitabine once daily on days 1-14 and oxaliplatin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
33047305|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
33047306|NCT00104767|Experimental|celecoxib|
33047307|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
33047308|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
33047309|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
33047310|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
33047311|NCT03869892|Experimental|S95005 + Bevacizumab|
33047312|NCT03869892|Active Comparator|Capecitabine + Bevacizumab|
33047313|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33047314|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
33047315|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
33047316|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
33047317|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
33047318|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
33047319|NCT00105547|Experimental|1|800 mg BID
33047320|NCT00105547|Placebo Comparator|2|BID dosing
33047321|NCT00105625||Group 1|
33047322|NCT00105664|Other|Arm 1|
33047323|NCT00105703|Other|Arm 1|
33331400|NCT04602000|Experimental|CT-P59 40 mg/kg group (Part 1)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
33331401|NCT04602000|Experimental|CT-P59 80 mg/kg group (Part 1)|CT-P59 (regdanvimab), 80 mg/kg by IV infusion once
33331402|NCT04602000|Placebo Comparator|Placebo group (Part 1)|Placebo, matching in volume of CT-P59 80 mg/kg by IV infusion once
33331403|NCT04602000|Experimental|CT-P59 40 mg/kg group (Part 2)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
33047324|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
33331404|NCT04602000|Placebo Comparator|Placebo group (Part 2)|Placebo, matching in volume of CT-P59 40 mg/kg by IV infusion once
33331405|NCT05053230|Experimental|IM@Home|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
33331406|NCT05053230|Placebo Comparator|Enhanced usual care|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
33331407|NCT05361018|Experimental|Whole Body Vibration exercise - WBV|The vibration exercises take place on a tri-planar vibration platform (Power Plate) according to the initially determined setting for each individual (highest, though feasible neuromuscular response). . Each session lasts for about 15-30 min in total, leaving sufficient time for regeneration. Training consists of at least four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions and adherence are documented by the exercise supervisor. Adverse events are documented, and patients asked to give feedback regarding the feasibility and subjective impression of each individual setting. All training sessions will be supervised. The participants rating of perceived exertion (RPE) will be assessed immediately after each set of exercise.
33360697|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
33360698|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
33360699|NCT03924739|Experimental|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
33047325|NCT00105742|Other|Arm 1|
33047326|NCT00105781|Other|Arm 1|
33047327|NCT00105820|Other|Arm 1|
33047328|NCT00105859|Other|1|
33047329|NCT00105898|Experimental|Arm 1|Intervention group
33047330|NCT00105898|Active Comparator|Arm 2|Comparator
33047331|NCT00105898|Sham Comparator|Arm 3|Comparator
33047332|NCT00106171|Experimental|1|Participants will receive HAART for 1 year
33047333|NCT00106171|No Intervention|2|Participants will receive no treatment
33047334|NCT03815682|Experimental|RPTR-147:1|Arm A: Escalating doses of RPTR-147:1 as a monotherapy in solid tumors and lymphomas
33047335|NCT03815682|Experimental|RPTR-147:1 and Pembrolizumab|Arm B: Escalating doses of RPTR-147:1 in combination with Pembrolizumab in patients with solid tumors and lymphomas
33047336|NCT03815682|Experimental|RPTR-147:2|Arm C: Escalating doses of RPTR-147:2 in patients with HPV-16 positive tumors
33047337|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
33047338|NCT00106210|Active Comparator|2|Behavioral Intervention 2
33047339|NCT00106288|Experimental|1|
33047340|NCT00106288|Active Comparator|2|
33047341|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
33047342|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
33047343|NCT00106327|Active Comparator|3|Diet/nutrition control group
33047344|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
33047345|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
33047346|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
33047347|NCT04728256|Experimental|İntervention group|A six-session antenatal care program included both music listening and laughter therapy, and was designed for those in the study group as a session every week. The program was carried out by arranging a session of music listening for one week and a laughter therapy session over the following week. Also, the notes uttered by pregnants women were discussed at the week laughter listening sessions were performed. Data from the intervention group was collected four times as pretest (after providing informed contest), first-interval measurement (fourth week of the intervention), second-interval measurement (the first month following the birth) and post-test (the third month following the birth).The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
33047348|NCT04728256|No Intervention|Control group|Mothers receiving standard antenatal care in the prenatal period, giving birth, and having a three-month-old baby constituted the control group. The Control group was created after the procedures were completed for those in the intervention group. Only the post test was applied to the control group.The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
33047349|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
33109957|NCT02102802||Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
33109958|NCT01694277|Experimental|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
33109959|NCT01694277|Active Comparator|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
33047350|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
33047351|NCT00106522|Experimental|1|
33047352|NCT00106522|Experimental|2|
33047353|NCT00106522|Placebo Comparator|3|
33047354|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
33047355|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
33047356|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
33047357|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
33047358|NCT00401362|Experimental|Arm 1|
33047359|NCT00401362|Placebo Comparator|Arm 3|
33047360|NCT00401362|Experimental|Arm 2|
33047361|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
33047362|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
33331408|NCT05361018|Active Comparator|Conventional Aerobic and Resistance exercise - CAR|exercise sessions commence with 20 min of moderate intensity continuous aerobic exercise at a rating of perceived exertion (RPE) of 13-15 on the Borg scale. Participants complete both resistance exercises and high intensity intermittent aerobic exercises during each session. The resistance training regimen consists of 8 exercises (leg press, biceps curls, triceps extensions, bench press, shoulder press, standing row, sit ups/Russian weighted abdominal twist, and prone lying back extensions. Participants complete 2 sets of 8-12 repetitions at an initial intensity of 70 % of their estimated 1 repetition maximum (1-RM) strength and increase to 80 % of estimated 1-RM when more than 12 repetitions can be correctly performed by the participant
33047363|NCT00106678||Infected through risk behaviors|
33047364|NCT00106678||Infected perinatally or through blood/blood products.|
33047365|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
33047366|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
33047367|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
33047368|NCT03745287|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
33047369|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
33047370|NCT00107185|Experimental|Vaccine|
33047371|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
33331409|NCT03757962|Experimental|Dietary intervention|
33331410|NCT05039892|Experimental|All eligible subjects|
33047372|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
33047373|NCT03694158|Experimental|Treatment group|Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.
33047374|NCT03694158|Placebo Comparator|Placebo group|Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
33047375|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
33047376|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
33047377|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
33047378|NCT03690843||Control Group|Typically developing children
33047379|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
33047380|NCT00107419|Experimental|pemetrexed|pemetrexed
33331411|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
33047381|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
33047382|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
33331412|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
33047383|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
33047384|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
33047385|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
33047386|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
33047387|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
33047388|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
33047389|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
33047390|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
33047391|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
33047392|NCT00107497|Active Comparator|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
33047393|NCT00107497|Active Comparator|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
33047394|NCT00107497|Active Comparator|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
33047395|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
33331413|NCT03041116|Experimental|Fosmetpantotenate|Administered as powder for reconstitution.
33331414|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
33047396|NCT03672825|Experimental|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
33047397|NCT04712396|Experimental|Capivasertib + Itraconazole|Subjects will receive a single oral dose of capivasertib on Day 1 during treatment period 1, itraconazole on Days 3, 4, and 5 during treatment period 2, and single oral dose of capivasertib plus a dose of itraconazole on Day 6, followed by itraconazole alone on Day 7 during treatment period 3.
33047398|NCT03672747|Active Comparator|Anodal|Participants will receive occipital anodal stimulation using high-definition tDCS
33047399|NCT03672747|Active Comparator|Cathodal|Participants will receive occipital cathodal stimulation using high-definition tDCS
33047400|NCT03672747|Placebo Comparator|Sham|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
33047401|NCT00107770|Other|1|ALS patient
33047402|NCT03667482|Experimental|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
33047403|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
33047404|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
33047405|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
33047406|NCT00107926|Experimental|licarbazepine|
33047407|NCT00107926|Placebo Comparator|Placebo|
33047408|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
33047409|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
33047410|NCT00107965|Experimental|1|
33047411|NCT00107965|Experimental|2|
33047412|NCT00107965|Experimental|3|
33047413|NCT00107965|Placebo Comparator|4|
33047414|NCT00107965|Experimental|5|
33047415|NCT00107965|Experimental|6|
33047416|NCT00107965|Experimental|7|
33047417|NCT00107965|Placebo Comparator|8|
33047418|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
33047419|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
33047420|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
33109960|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
33109961|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
33331415|NCT04860258|Experimental|CVnCoV Vaccine|Participants will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29.
33331416|NCT05374798|Experimental|Heart Rate Variability-Biofeedback via Smartwatch Device Intervention|Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed.
33047421|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
33047422|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
33331417|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
33331418|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
33331419|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
33047423|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
33047424|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
33047425|NCT00108316|Other|Arm 1|
33047426|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
33047427|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
33047428|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
33047429|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33047430|NCT03619551|Experimental|Low Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg*h/L .~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
33047431|NCT03619551|Experimental|Medium Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg*h/L.~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
33047432|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
33047433|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
33047434|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
33047435|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
33047436|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
33047437|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
33047438|NCT03608397|Placebo Comparator|Placebo|Placebo Group
33047439|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33047440|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
33047441|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
33047442|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
33047443|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
33047444|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
33047445|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
33047446|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
33047447|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
33109962|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
33109963|NCT03103490|Other|18F-FSPG PET/MRI|Patients undergoing 18F-FSPG PET/MRI scan
33109964|NCT03103490|Other|18F-FSPG PET/CT|Patients undergoing 18F-FSPG PET/CT scan
33109965|NCT01669980|Experimental|Ceftaroline fosamil|
33047448|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
33047449|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
33047450|NCT03595917|Experimental|ABL001, Dasatinib, Prednisone|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)~Dasatinib-Fixed doses oral once a day per cycle~ABL001 is administered orally daily per cycle~Prednisone-Fixed doses oral once a day per cycle. --- Prednisone will be tapered and stop during cycle 2."
33047451|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
33047452|NCT00109369|No Intervention|Control|Usual Care
33047453|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
33047454|NCT00109408|Experimental|1|
33047455|NCT00109408|Active Comparator|2|
33047456|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
33047457|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
33047458|NCT00109486|Experimental|Arm 1|
33047459|NCT03513042||Cohort|"Intervention:~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.~Baseline measurements:~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.~Interim measurements conventional):~FDG PET-CT will be repeated at the end of the second week of IMPT.~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.~A subcohort will also undergo activation PET imaging three times during IMPT."
33047460|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
33047461|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
33047462|NCT00109759|Experimental|RagweedMATAMPL|
33047463|NCT00109759|Placebo Comparator|Placebo|
33047464|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
33047465|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
33047466|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
33047467|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
33331420|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
33331421|NCT05460546|Experimental|Jincaopian Tablets high-dose group|Patients receive high dose Jincaopian Tablets 0.6g/day for 12 weeks.
33331422|NCT05460546|Experimental|Jincaopian Tablets low-dose group|Patients receive low dose Jincaopian Tablets 0.3g/day for 12 weeks.
33331423|NCT05460546|Placebo Comparator|Placebo group|Patients receive a matching placebo for 12 weeks.
33047468|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
33360700|NCT03924739|No Intervention|Control group|The control group will receive the conventional care provided by the study hospital.
33360701|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
33047469|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
33047470|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
33047471|NCT00110227|Experimental|Tai Chi|12-week tai chi program
33047472|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
33047473|NCT00110344|Experimental|Arm 1|
33047474|NCT00110344|Placebo Comparator|Arm 2|
33047475|NCT00110383|Experimental|1|Supervised therapy
33047476|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
33047477|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
33047478|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
33109966|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
33109967|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
32869553|NCT01774071|Experimental|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
33047479|NCT03434262|Experimental|A: ribociclib + gemcitabine|"Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.~Stratum A has completed all the necessary accrual"
33047480|NCT03434262|Experimental|B: ribociclib + trametinib|"Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.~Stratum B has completed all the necessary accrual"
33047481|NCT03434262|Experimental|C: ribociclib + sonidegib|"Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.~Stratum C is being closed due to low accrual"
33047482|NCT00388193|Experimental|1|
33047483|NCT00110695|Experimental|A|
33047484|NCT00110773|Experimental|S-Caine Peel|
33047485|NCT00110773|Placebo Comparator|Placebo Peel|
33047486|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
33047487|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
33047488|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
33047489|NCT00388271|Active Comparator|1|xatral
33047490|NCT00388271|Placebo Comparator|2|standard treatment
33047491|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
33047492|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
33047493|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
33047494|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
33047495|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
33047496|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
33047497|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
33047498|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
33047499|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
33047500|NCT00388310|Placebo Comparator|Placebo|
33047501|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
33047502|NCT03419052|Active Comparator|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
33047503|NCT03419052|Active Comparator|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
33047504|NCT03419052|Sham Comparator|Double Control|Consumption of low polyphenol foods AND online (inert) games
33047505|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
33047506|NCT00111358|Placebo Comparator|Control|
33047507|NCT00111436|Experimental|50 mg|50 mg once weekly
33047508|NCT00111436|Experimental|100 mg|50 mg twice weekly
33047509|NCT00111592|Active Comparator|1|current usual care
33047510|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
33047511|NCT00111631|Experimental|1|
33047512|NCT00111631|Experimental|2|
33047513|NCT00111631|Experimental|3|
33047514|NCT00111631|Placebo Comparator|4|
33047515|NCT00111670|Experimental|1|
33047516|NCT00111670|Experimental|2|
33047517|NCT00111670|Experimental|3|
33047518|NCT00111670|Experimental|4|
33047519|NCT00111670|Placebo Comparator|5|
33047520|NCT00111748|Active Comparator|1|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
33109968|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
33331424|NCT05288062|Experimental|Cohort A (lenalidomide, dexamethasone)|Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
33331425|NCT05288062|Experimental|Cohort B (lenalidomide, dexamethasone)|Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.
33331426|NCT05288062|Experimental|Cohort C (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
33331427|NCT05288062|Experimental|Cohort D (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.
33331428|NCT04582266||Arm 1|Pregnant women hospitalized and receiving RDV for treatment of COVID-19.
33331429|NCT04582266||Arm 2|Non-pregnant women of childbearing potential hospitalized and receiving RDV for treatment of COVID-19.
33047521|NCT00111748|Active Comparator|2|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
33047522|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
33047523|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
33331430|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
33331431|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
33331432|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
33331433|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
33331434|NCT05280418|Active Comparator|Tezepelumab|"Tezepelumab 210 mg subcutaneous injections every 4 weeks as an investigational drug.~Sterile tezepelumab will be provided 110 mg/mL pre-filled vial, with a dose of 210 mg delivered by pre-filled syringe."
33331435|NCT05280418|Placebo Comparator|Matched placebo|Sterile placebo for tezepelumab will be provided in identically matched pre-filled syringes.
33331436|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
33331437|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
33418414|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~a medical examination~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
33047524|NCT00111865|No Intervention|Usual Care|
33047525|NCT03409809|Experimental|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
33047526|NCT03409809|Experimental|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
33047527|NCT03409809|Experimental|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
33047528|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
33047529|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
33047530|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
33047531|NCT00401674|Experimental|SINGLE ARM|
33047532|NCT00112021|Experimental|Pramlintide Acetate|
33047533|NCT00112021|Placebo Comparator|Placebo|
33047534|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
33109969|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
33109970|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
33109971|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
33109972|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
33109973|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
33109974|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
33418415|NCT05423366|Active Comparator|Large-Focused Extracorporeal Shock Wave Therapy|
33109975|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
33109976|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
33109977|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
33109978|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
33109979|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
33109980|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
33109981|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
33109982|NCT04677894||Group Direct Laringoscopy|Group DL: Group of patients intubated using a Macintoch blade laryngoscope.
33109983|NCT04677894||Group Videolaringoscopy|Group VL: Group of patients intubated using a McGrath video laryngoscope.
33109984|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
33109985|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
33109986|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
33109987|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
33109988|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
33109989|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
33109990|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
33109991|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
33109992|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
33109993|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
33109994|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
33109995|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
33109996|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
33109997|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
33109998|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
33109999|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
33418416|NCT05423366|Active Comparator|Controlled-Unfocused (Radial) Extracorporeal Shock Wave Therapy|
33110000|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
33110001|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
33110002|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
33110003|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
33110004|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
33110005|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
33110006|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
33110007|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
33110008|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
33110009|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
33110010|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
33418417|NCT05423366|Sham Comparator|Sham Extracorporeal Shock Wave Therapy|
33110011|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
33110012|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
33110013|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
33110014|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
33331438|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
33331439|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
33331440|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
33110015|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
33110016|NCT01661166|Experimental|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
33110017|NCT01661166|Placebo Comparator|Placebo|Placebo Oral once daily for three months
33110018|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
33110019|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
33110020|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
33110021|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
33110022|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
33110023|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
33110024|NCT01658826|Experimental|AIC316|100 mg once daily for 28 days
33110025|NCT01658826|Active Comparator|Valacyclovir|500 mg once daily for 28 days
33110026|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
33110027|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
33110028|NCT04677582|Experimental|Intervention Group|The intervention group will receive weekly education sessions about nutrition, exercise, and behavioral health.
33110029|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
33110030|NCT02092077|Experimental|TV-1106 0.554 mg|
33110031|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
33110032|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
33110033|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
33110034|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
33110035|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
33110036|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
33110037|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
33110038|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
33110039|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
33110040|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
33110041|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
33110042|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
33110043|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
33331441|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
33331442|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
33331443|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
33331444|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
33331445|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
33331446|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
33331447|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
33331448|NCT05266378|Experimental|Block group|The group undergoing PECs block
33047535|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
33047536|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
33047537|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
33047538|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
33047539|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
33047540|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
33047541|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
33047542|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
33047543|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
33047544|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
33047545|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
33047546|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
33047547|NCT03288090||Treated|
33047548|NCT03288090||Non-treated|
33047549|NCT00007631|Active Comparator|1|Topical Tretinoin
33047550|NCT00007631|Placebo Comparator|2|Placebo
33047551|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33047552|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
33047553|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
33047554|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
33047555|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
33047556|NCT00113035||Patients with late onset Pompe Disease|
33047557|NCT00007709||1|
33047558|NCT00113074|Active Comparator|1|Weight management and BP control program
33047559|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
33047560|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
33047561|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
33047562|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
33047563|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
33047564|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
33047565|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
33047566|NCT00113503|Active Comparator|Azathioprine weight-based dose|
33047567|NCT00113503|Experimental|Azathioprine individualised dose|
33047568|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
33047569|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
33047570|NCT00113698|Placebo Comparator|1|
33047571|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
33047572|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
33047573|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
33047574|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
33047575|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
33047576|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
33047577|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
33047578|NCT00113815|Experimental|004|placebo placebo
33110044|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
33047579|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
33047580|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
33047581|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
33047582|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33047583|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
33047584|NCT00114361|Active Comparator|2|Peg IFN + Placebo
33047585|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
33047586|NCT04728178|Active Comparator|study group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.
33047587|NCT04728178|Placebo Comparator|control group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. They were given 250 ml of crystalloid in the first stage if the MAP was below 65 mmHg, and 250 ml of colloid bolus if the hypotensive episode continued. If hypotension persisted despite these fluid boluses, a vasoconstrictor agent was used. In addition, when the diuresis of the patients was detected at 0.5mg/kg/hr or less, 250 ml of colloid bolus was administered.
33047588|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
33047589|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
33047590|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
33047591|NCT00114868|Placebo Comparator|Placebo|placebo
33047592|NCT03034200|Experimental|ONC201 phase 2 d1d2 weekly cohort|625 mg ONC201 by mouth daily for 2 consecutive days weekly
33047593|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
33047594|NCT03007407|Experimental|durvalumab and tremelimumab|
33047595|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
33047596|NCT00115180||White|White patients with long bone fractures no intervention
33047597|NCT00115180||African-American|African-American patients with long bone fracture no intervention
33047598|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
33047599|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
33047600|NCT00115258|No Intervention|standard of care|
33047601|NCT00390936|No Intervention|1|4 dosages
33418418|NCT02097914|No Intervention|Control|Participant receives usual care.
33047602|NCT00115453|Experimental|A|Active treatment arm.
33047603|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
33047604|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
33047605|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
33047606|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
33047607|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
33047608|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
33047609|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
33047610|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
33047611|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
33047612|NCT00115687|Placebo Comparator|A|placebo
33047613|NCT00115687|Experimental|B|2 mg nicotine gum
33047614|NCT00115726|Experimental|1|furosemide
33047615|NCT00115726|Placebo Comparator|2|placebo
33110045|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
33047616|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
33331449|NCT05266378|Placebo Comparator|Control group|The group not receiving PECs block
33047617|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
33047618|NCT00115882|No Intervention|2|no-intervention control
33047619|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
33047620|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
33047621|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
33047622|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
33047623|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
33047624|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
33047625|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
33047626|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
33047627|NCT04727671|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33047628|NCT04727671|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33047629|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
33047630|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
33047631|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
33047632|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
33047633|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
33047634|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
33047635|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
33047636|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
33047637|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
33047638|NCT00116818|Experimental|Arm 1|
33047639|NCT04727905|Experimental|energy drink|Intake after exercise
33047640|NCT04727905|Placebo Comparator|Seasoned water|Intake after exercise
33047641|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
33047642|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
33331450|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
33331451|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
33331452|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
33331453|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
33331454|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
33047643|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
33047644|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
33047645|NCT00388388|Experimental|1|Losartan treatment
33047646|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
33047647|NCT00116974|Experimental|1|
33047648|NCT00116974|Placebo Comparator|2|
33047649|NCT02743455|Active Comparator|Group 1|Subjects will receive 1.0x10^8 TCID50 of MVA-BN as two doses subcutaneously on Day 1 and Day 29. N=15
33047650|NCT02743455|Experimental|Group 2|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
33047651|NCT02743455|Experimental|Group 3|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as two doses intramuscularly on Day 1 and Day 29. N=15
33047652|NCT02743455|Experimental|Group 4|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as a single dose intramuscularly on Day 1 and matching placebo on Day 29. N=15
33047653|NCT02743455|Active Comparator|Group 5|Subjects will receive = / > 4.74 log10 PFU of YF-Vax as a single dose subcutaneously on Day 1 and matching placebo on Day 29. N=15
33047654|NCT02743455|Experimental|Group 6|Subjects with prior receipt of MVA-BN will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
33047655|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
33047656|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
33047657|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
33047658|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
33047659|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
33047660|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
33047661|NCT00117208|Experimental|1|
33047662|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
33047663|NCT00117208|Other|3|combination
33418419|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
33047664|NCT00388427|Other|Advanced Solid Malignancies|
33047665|NCT05442463||women|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Angiotensin II is administered via IV: 3 ng/kg/min for 30 minutes then 6 ng/kg/min for 30 minutes.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
33047666|NCT05442463||men|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Angiotensin II is administered via IV: 3 ng/kg/min for 30 minutes then 6 ng/kg/min for 30 minutes.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
33047667|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
33047668|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
33047669|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
33047670|NCT00423410|Experimental|EPC2407 (crinobulin)|
33047671|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
33047672|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
33047673|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
33047674|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
33047675|NCT04728022|Experimental|Students|Education program
33047676|NCT05441371|Experimental|Test; Parodontax toothpaste|1.st quadrant of subject
33047677|NCT05441371|Placebo Comparator|Control; Regular toothpaste|2.nd quadrant of subject
33047678|NCT00117481|Experimental|1|
33047679|NCT00117481|Experimental|2|
33047680|NCT00117481|Placebo Comparator|3|
33047681|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
33047682|NCT00000113|Active Comparator|Single Vision Lenses|
33047683|NCT04727515|Experimental|General anesthesia|Patients will receive general anesthesia
33047684|NCT04727515|Experimental|Axillary Block|Patients will receive axillary nerve block
33047685|NCT05636111|Experimental|Dose Escalation and Dose Expansion|Pariticipants will be assigned to a dose level of combined paclitaxel, bevacizumab, and lurbinectedin
33047686|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
33047687|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
33331455|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
33331456|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
33331457|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
33331458|NCT05198674|Experimental|Main Cohort: Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
33331459|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
33047688|NCT05636150|Experimental|Fruquintinib plus S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w."
33047689|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
33047690|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
33047691|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
33047692|NCT05636306|Experimental|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
33047693|NCT05636306|Placebo Comparator|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
33047694|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
33047695|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
33047696|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
33047697|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
33047698|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
33047699|NCT05636384|Experimental|Intervention|Patients enrolled in the intervention cluster (institution) are given specialized home-based medical care based on a specialized home-based medical team approach.
33047700|NCT05636384|No Intervention|Control|"Patients enrolled in the control cluster (institution) are only given the educational materials.~Except for the home-based care intervention, usual care for advanced cancer patients was not restricted for these patients."
33047701|NCT00118456|Experimental|1|Continuous daily dosing
33047702|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
33047703|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
33047704|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
33047705|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
33047706|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
33047707|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
33331460|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
33331461|NCT05280990|Experimental|Future Liver Remnant Function (FLRF)|Preoperative FLRF risk assessment via 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS)
33331462|NCT05280990|Active Comparator|Future Liver Remnant Volume (FLRV)|Preoperative FLRV assessment by CT/MRI volumetry
33331463|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
33331464|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
33331465|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
33331466|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
33047708|NCT05636423||Italian physiotherapists|The survey will take place through the administration of a questionnaire accessible via the website of the Italian Physiotherapy Association (AIFI), the Scientific Association of reference for the physiotherapists, registered since 2020 in the list of Scientific Societies recognized by the Italian Health Ministry.
33047709|NCT00118573|Experimental|EVAR|AAA repair with endografting
33047710|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
33047711|NCT00118612|Experimental|Therapeutic Regimen|
33047712|NCT00118612|Experimental|Intermediate dose|
33047713|NCT00118612|Experimental|Low dose|
33047714|NCT00118612|Placebo Comparator|Placebo|
33047715|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
33047716|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
33047717|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
33047718|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
33047719|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
33047720|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
33047721|NCT05636462|Experimental|Global postural re-education|It consists of 27 patients who will receive conventional exercises and global postural re-education which will be divided in three components First in lying posture to stretch anterior muscles of neck for 15 min, second component in supine position and stretching posterior muscles for 15 min and final component is in standing position under a load of gravity for 5 min for 3 days a week .
33047722|NCT05636462|Active Comparator|Conventional Physical therapy|It consists of 27 patients who will receive conventional therapy including stretching and strengthening exercises of neck for 3 days a week.
33047723|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
33047724|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
33047725|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
33047726|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
33047727|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
33047728|NCT00118729|Experimental|Arm 1|
33047729|NCT02706873|Active Comparator|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
33047730|NCT02706873|Experimental|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
33047731|NCT02706873|Experimental|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
33047732|NCT02706873|Experimental|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
33047733|NCT05636579|Experimental|EO2002 with Ripasudil|EO2002 + topical Ripasudil daily, then reinjection at week 6 + topical Ripasudil daily
33047734|NCT05636579|Experimental|EO2002 without Ripasudil|EO2002 injection at Day 0 and re-injection at Week 6
33047735|NCT00118846|Experimental|1|25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
33047736|NCT00118846|Placebo Comparator|2|Matching placebo
33047737|NCT05636618|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation to determine MTD/MFD in 32 patients receiving up to 4 administrations of [212Pb]VMT-α-NET approximately 8 weeks apart.~The second part of the study is a dose expansion based on the identified MTD/MFD for the selection of [212Pb]VMT-α-NET dose(s) in up to 20 additional subjects for further clinical development.~A dosimetry sub-study utilizing [203Pb]VMT-α-NET has been incorporated into the study."
33047738|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
33047739|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
33047740|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
33047741|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
33047742|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
33331467|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
33331468|NCT05190718||Dysphagia rehabilitation|All interventions are part of routine treatment of dysphagia.
33331469|NCT04432376|Active Comparator|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
33331470|NCT04432376|Placebo Comparator|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
33331471|NCT04432376|Other|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
33331472|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
33331473|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
33047743|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
33331474|NCT05187910|Active Comparator|Patients with Voice Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
33331475|NCT05187910|Active Comparator|Patients with Swallowing Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
33331476|NCT05187910|Active Comparator|Patients with Upper Airway Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
33047744|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
33047745|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
33047746|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
33047747|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
33047748|NCT05636696|Experimental|couple eMBCT|The couple eMBCT has nine sessions, takes 15-20 weeks, can be followed from home and will be supervised remotely by a trained psychotherapist. Consistent with the original (patient-only) eMBCT, the couple eMBCT aims to change the patient's behavioral and cognitive reactions to fatigue and other cancer-related stressors. Couple eMBCT includes information for partners each session, the possibility for partners to perform exercises and one session specifically dedicated to the couple's mutual relationship and mindful communication about CCRF. Couples can determine themselves to which degree the partner is involved in the therapy.
33047749|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
33047750|NCT05636735||midwife students group|midwife students in France
33047751|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
33047752|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
33047753|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
33047754|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
33047755|NCT05636813|Experimental|Training|Program of training of use of assistive technology
33047756|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
33047757|NCT00119782|Experimental|1|Comprehensive worksite intervention
33047758|NCT00119782|Experimental|2|Delayed intervention control group
33047759|NCT05636891|Experimental|Stimus|Treatment: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
33047760|NCT05636891|Active Comparator|Aranesp|Control: Amgen's Aranesp® 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
33047761|NCT02598219|Experimental|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
33047762|NCT02598219|Other|B : Current initial staging protocols|Current initial staging protocols
33047763|NCT00119821|Experimental|I|Behavioral Weight Reduction
33047764|NCT00119821|Other|II|Exercise
33047765|NCT00119821|Other|III|Smoking Cessation
33047766|NCT00119977|Active Comparator|1|
33047767|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
33047768|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
33047769|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
33047770|NCT00120016|Experimental|1|Mediterranean diet
33047771|NCT00120016|No Intervention|2|non-intervention diet
33047772|NCT05636930||smart bracelet|Type and specification:FRA-B39
33047773|NCT05636969||Prehabilitation|Patients in this cohort will undergo baseline and post-NAT pulmonary function test (spirometry, diffusion capacity of carbon monoxide) and cardiorespiratory fitness assessment (CPET). In addition, they will attend a multimodal prehabilitation programme consisted of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12 weeks; 2) nutritional consultation and optimization if needed; 3) individual or group-based psychological support.
33047774|NCT05636969||Control|Patients in the control cohort would undergo baseline and post-NAT pulmonary function test and cardiorespiratory fitness assessment (CPET).
33331477|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
33331478|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
33331479|NCT05180968|Experimental|Nabilone 0.5mg|Subjects will receive nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
33331480|NCT05180968|Placebo Comparator|Oral placebo|Subjects will receive placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
33047775|NCT02470728|No Intervention|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
33047776|NCT02470728|Experimental|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
33047777|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
33047778|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
33047779|NCT04727437|Active Comparator|Control|Full dose anticoagulation treatment as standard care for at least 3 months.
33047780|NCT04727437|Experimental|Intervention|Withholding anticoagulation for Isolated Sub-Segmental Pulmonary Embolism (ISSPE) for at least 3 months.
33047781|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
33047782|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
33047783|NCT02454933|Experimental|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion & once daily tablet 80 mg
33047784|NCT02454933|Experimental|AZD9291 Monotherapy|Once daily tablet 80 mg
33047785|NCT04727320|Experimental|patient+TUDCA|
33047786|NCT04727320|Placebo Comparator|patient+placebo|
33047787|NCT05637125|Active Comparator|Group A|Group A received aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks.
33047788|NCT05637125|Active Comparator|Group B|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks.
33047789|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
33047790|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
33047791|NCT05637164|Experimental|Norepinephrine|
33047792|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
33047793|NCT05637203|Experimental|THRIVE + Discharge / Safety Planning|"Participants assigned to the intervention condition will receive THRIVE Crisis Recovery and Care Transition Program, which consists of group-based reflections on giving and belonging and a plan for community connection and treatment, followed by 3-4 coaching calls to reinforce and troubleshoot the plans."
33047794|NCT05637203|Active Comparator|Discharge / Safety Planning Alone|Participants assigned to the control condition will receive Discharge/Safety Planning as it is practiced by Connections Health Solutions per industry best practices.
33331481|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
33331482|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
33110046|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
33110047|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
33110048|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
33110049|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
33110050|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
33110051|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
33110052|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
33110053|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
33110054|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
33110055|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
33331483|NCT03746678||C-Care Mobile Application|
33331484|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
33110056|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
33110057|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
33110058|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
33110059|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
33110060|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
33110061|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
33331485|NCT03696108|Experimental|Gefapixant 45 mg BID|Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).
33331486|NCT04526938|Experimental|Endovascular repair|Endovascular repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms including those secondary to aortic dissection using a physician-modified endovascular graft.
33331487|NCT04219358|Active Comparator|Placebo & Standard Treatment|
33331488|NCT04219358|Experimental|Imiquimod 5% & Standard Treatment|
33331489|NCT04219358|Experimental|Imiquimod 0.05% & Standard Treatment|
33331490|NCT04219358|Experimental|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
33331491|NCT05159206|Other|CT group|CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Per-operative navigation based on the CT scan.
33331492|NCT05156164|Experimental|Kinesio-taping Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each) plus a bi-weekly treatment focused on the joint complex of the shoulder plus Kinesio-taping (KT) treatment.~The Kinesio-taping treatment consists in 4 applications of KT on the affected shoulder to be held for 5 days a week, followed by 2 days of rest to safeguard skin integrity before a further application.~5 KT strips with graded tensions will be placed on the following muscles:~supraspinatus with a tension of 70%.~infraspinatus with a tension of 70%. 3,4,5) deltoid (3 strips, 50% of tension) A sixth application with a tension of 90% originates at the level of the anterior face of the humeral head and it ends to the lower corner of the scapula."
33110062|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
33110063|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
33110064|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
33110065|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
33047795|NCT00120796|Active Comparator|1|Lamivudine alone
33047796|NCT00120796|Experimental|2|Lamivudine + Vaccine
33047797|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
33047798|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
33047799|NCT04727164|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors
33047800|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
33047801|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
33047802|NCT05637320|Experimental|Intervention Arm|Treatment will be administered to participants in this arm.
33047803|NCT05637320|No Intervention|Control Arm|No treatment will be administered to participants in this arm until post-test assessment has been completed.
32869554|NCT00166361|Experimental|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
32869555|NCT00166361|Active Comparator|JJ Stent|Subjects assigned to this arm received a JJ stent.
32869556|NCT05709405|Experimental|Reading Intervention|"The reading material is made based on the research of Professor Janice Light and Professor David McNaughton at Penn State University. The reading material Lesing for alle (Reading for all) contains all the principles, strategies, and methods that form the basis of Accessible Literacy Learning (ALL). The intervention is conducted by trained teachers, in a place known to the students. The material contains: tasks in sound blending, letter-sound correspondence, phoneme- segmentation, sight words, single-word decoding, and shared reading.~Due to the multiple single baseline design, each participant will be regarded as being in the control condition, and then will be randonly assigned to four different baselines starting the intervention individually after the 2nd, 3rd, 4th, and 5th month."
33047804|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33047805|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
33047806|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
33047807|NCT00121303|No Intervention|Arm 1 no further treatment|
33047808|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
33047809|NCT02362464|Experimental|Long Term T-cell Receptor Alternate Reading Frame Protein (TARP) Peptide Vaccinations|Intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
33047810|NCT05637359||Patients scheduled for navigated abdominal cancer surgery|Patients are 18 years old or older. Patients are scheduled for tumor surgery in the abdominal/pelvic area and navigation surgery with a scheduled Cone Beam CT-scan in the operating room. Patients provide written 'informed consent'. The to be administered intervention is a percutaneous tracked ultrasound measurement of the patient's pelvic bone on the operating room after anesthesia.
33047811|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
33047812|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
33047813|NCT00391131|Experimental|Ig NextGen 16%|
33047814|NCT05637398|Active Comparator|Colchicine 0.5 bid|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
33047815|NCT05637398|No Intervention|Usual Care|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
33047816|NCT05637437|Active Comparator|Control Group|Participants in the control group will receive the usual care of the hospital.
33047817|NCT05637437|Experimental|Intervention Group|Participants in the intervention group will receive a peer supported diabetes self-care intervention through digital media
33047818|NCT04727398|Other|Cataract patients who was scheduled for phacoemulsification|Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.
33047819|NCT04711096||Group A|TAB group formed of 65 patients
33047820|NCT04711096||Group B|"Group B : The Infiltration Group formed of 65 patients.~• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin."
33047821|NCT04711096||Group C|"Group C : Narcotics only group formed of 20 patients~• routine analgesic was taken only without any intervention"
33047822|NCT04705948|Experimental|ketamine group|ketamine gargle (0.5 mg/kg up to 30 ml dextrose water) 15 minutes before the operation
33047823|NCT04705948|Experimental|magnesium sulfate group|magnesium sulfate gargle (20 mg/kg up to 30 mL G5%) 15 minutes before the operation.
33047824|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
33110066|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
33110067|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
33110068|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
33110069|NCT02914379|Experimental|[¹⁴C]-LY3337641|Oral dose of LY3337641 containing 120 microcuries of radioactivity.
33110070|NCT04677699||Birth Cohort|Newborns less than 8 months old and born in the state of Washington.
33110071|NCT04677699||Kids Cohort|Children ages 4-7 years and born in the state of Washington.
33110072|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
33110073|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
33110074|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
33110075|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
33110076|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
33110077|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
33110078|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:~Two subjects per cohort will receive single oral doses of placebo"
33110079|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
32869557|NCT04930107|Active Comparator|Recurrent Infection Cohort - symptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic
33110080|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
33110081|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
33110082|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
33110083|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
33110084|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
33110085|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
33110086|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
33110087|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
33110088|NCT01628094|Experimental|Part II|
33110089|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
33110090|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
33110091|NCT01627314|Experimental|ProHema-CB with MAC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with myeloablative conditioning regimen (MAC)
33110092|NCT01627314|Experimental|ProHema-CB with RIC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with reduced intensity conditioning regimen (RIC)
33110093|NCT01627314|Placebo Comparator|Control Arm with MAC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with myeloablative conditioning regimen
33110094|NCT01627314|Placebo Comparator|Control Arm with RIC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with reduced intensity conditioning regimen
33110095|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
33110096|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
32869558|NCT04930107|Active Comparator|Assumed First-Time Infection Cohort|Participants with their suspected first vulvovaginal candidiasis infection
32869559|NCT04930107|No Intervention|Asymptomatic Cohort|Participants with no history of vulvovaginal candidiasis
33047825|NCT00121654|Active Comparator|1|paresthesic SCS
33047826|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
33047827|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
33047828|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
33047829|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
33047830|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
33047831|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
33047832|NCT00121732|Experimental|A|
33047833|NCT00121732|Experimental|B|
33047834|NCT05637749|Experimental|Control|Serious game intervention to be played as is, without facilitation.
33047835|NCT05637749|Active Comparator|Intervention|Serious game intervention to be played with facilitator present in game environment.
33047836|NCT05637788||HCC Patients Submitted Surgery|"For the retrospective data collection, the planned number of subjects that will be enrolled will be almost 150/year. Considering the study-period (2010-2020), it is estimated a total of 1500 patients.~For the prospective observational data collection, the estimation of patients'enrolment is based on the number of patients treated per year in the participating centers (globally 150/year). Since the observational nature, patients will be evaluated for their enrolment consecutively. The prospective data collection will be prosecuted for 2 years, leading to a prospective cohort of 300 patients. The whole study is planned to be ended in December 2023. Inclusion and exclusion criteria will be the same among the retrospective and the prospective parts of the study."
33047837|NCT05637827||children with hyperopia|The refractive error and axial length of eye were observed
33047838|NCT05637827||children with emmetropia|The refractive error and axial length of eye were observed
33047839|NCT05637827||children with myopia|The refractive error and axial length of eye were observed
33047840|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
33047841|NCT00122122|Other|Arm 1|
33047842|NCT00122161|Other|Arm 1|
33047843|NCT05637905||psoriatic arthritis patients group|
33047844|NCT05637905||health control group|
33047845|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
33047846|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
33047847|NCT05637944||intubated within day 7th|patients needing oro-tracheal intubation within day 7th from admission.
33047848|NCT05637944||non intubated within day 7th|patients not requiring intubation within day 7th from admission
33047849|NCT01720407|Experimental|Imiquimod|
33047850|NCT01720407|Placebo Comparator|Placebo|
33047851|NCT05637983|Experimental|US-guided femoral puncture|US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
33047852|NCT05637983|Active Comparator|Fluoroscopy-guided puncture|Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
33047853|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
33047854|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
33047855|NCT00402220|Active Comparator|1|active TMS
33047856|NCT00402220|Placebo Comparator|2|Sham TMS
33047857|NCT05638022||Newborns|Newborns matching inclusion criteria
33047858|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
33047859|NCT00129493|Other|Arm 1|
33047860|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
33047861|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
33047862|NCT00129454|No Intervention|Assessment only|No intervention
33047863|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
33047864|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
33047865|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
33047866|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
33331493|NCT05156164|Sham Comparator|Control Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each), plus a bi-weekly treatment focused on the joint complex of the shoulder, plus shame KT treatment.~- The CG will undergo a KT application on the deltoid but without support function with the same frequency and duration as the experimental group (shame-application)."
32740887|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
33047867|NCT00129337|Experimental|1|0.1 mg/kg
33047868|NCT00129337|Experimental|2|0.3 mg/kg
33047869|NCT00129337|Experimental|3|1 mg/kg
33047870|NCT00129337|Experimental|4|3 mg/kg
33047871|NCT00129298|Experimental|1|Tiagabine
33047872|NCT00129298|Placebo Comparator|2|Matching placebo
33047873|NCT00936078||Non-donors/controls|Healthy normotensive people who have not donated a kidney including relatives or friends of the donor, or candidates who were ineligible to donate due to blood group or cross-match incompatibility. These non-donor/controls must meet all screening criteria (same as standard criteria donors).
33047874|NCT00936078||Living Kidney Donors|"Living kidney donors who went on to donate their kidney. All donors were recruited and are divided into 2 groups:~Standard criteria donors (meet all screening criteria)~Expanded-criteria donors (did not meet one or more of the screening criteria)~Expanded criteria donors will be examined in a separate protocol and analysis."
33047875|NCT05638100||Rivaroxaban-H|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(20mg/15mg)
33047876|NCT05638100||Rivaroxaban-M|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(10mg)
33047877|NCT05638100||Rivaroxaban-L|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(7.5mg)
33047878|NCT05638139|Experimental|SygeLIX-F + SygeLIX-G|Combination of SygeLIX-F, a plug made of an assembly of umbilical cord lining and Wharton's jelly in the form of a cylinder of porous structure, and SygeLIX-G, a Wharton's jelly gel reconstituted in a syringe.
33047879|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
33047880|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
33047881|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
33047882|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
33047883|NCT05638178||Adult|18+
33047884|NCT05638178||Pediatric|Under 18
33047885|NCT05638256|Experimental|68Ga-NY104|
33047886|NCT05638295|Experimental|Cohort I Arm A (sotorasib, panitumumab)|Patients receive sotorasib PO and panitumumab IV on study. Patients also undergo collection of blood samples and a tumor biopsy before treatment and CT or MRI at follow up.
33047887|NCT05638295|Active Comparator|Cohort I Arm B (sotorasib)|Patients receive sotorasib PO on study. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples and a tumor biopsy before treatment and CT or MRI at follow up.
33047888|NCT05638295|Experimental|Cohort II (sotorasib, panitumumab)|Patients receive combination therapy as in Arm A.
33047889|NCT05638451|Experimental|Sintilimab and Bevacizumab and Temozolomide|single arm study
33047890|NCT05638685||Dutch-speaking people living or working in Belgium|Every participant was asked to complete a questionnaire about the impact of a COVID-19 infection and/or the impact of lockdown measures as a result of the COVID-19 pandemic on fatigue and musculoskeletal complaints.
33047891|NCT00128713|Active Comparator|1|Lower Dose Prophylactic Platelets
33047892|NCT00128713|Active Comparator|2|Medium Dose Prophylactic Platelets
33047893|NCT00128713|Active Comparator|3|Higher Dose Prophylactic Platelets
33047894|NCT05638763|Experimental|Dasatinib and ketoconazole|Patients will receive dasatinib at a dose of 25mg orally daily for one year and ketoconazole 200mg orally two times per day for one year.
33047895|NCT05638841||atrial fibrillation|After radiofrequency ablation of patients with atrial fibrillation
33047896|NCT00128557|Placebo Comparator|Placebo|Supplement containing soybean oil with a small amount of vitamin E as an antioxidant
33047897|NCT00128557|Active Comparator|Vitamin A|15,000 ug retinol equivalents (50,000 International Units)
33047898|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
33047899|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
33047900|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
33047901|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
33047902|NCT00394459|Active Comparator|A|Perifix Standard
33047903|NCT00394459|Experimental|B|Perifix New
33047904|NCT05638919||Oral Antiviral Group|Study participant initiated with oral antiviral (nirmatrelvir plus ritonavir or molnupiravir) for the treatment of COVID-19
33047905|NCT05638919||Non Oral Antiviral Group|Study participant not initiated with oral antiviral for the treatment of COVID-19
33047906|NCT00128479|Experimental|mifepristone 300 mg|
33047907|NCT00128479|Placebo Comparator|placebo|
33047908|NCT00128479|Experimental|mifepristone 600 mg|
33047909|NCT00128479|Experimental|mifepristone 1200 mg|
33047910|NCT05638958|Experimental|Test group|A customized PEEK abutment mimicking the subgingival emergence of the extraction site will be screw-retained on the implant to seal the extraction site and to support healing of buccal soft tissues.
33047911|NCT05638958|Active Comparator|Control group|A commercially available healing abutment will be screwed on top of the implant and a collagen sponge will be used to protect the graft.
33047912|NCT05638997|Experimental|Instrument Assisted Manipulation Group|Instrument Assisted Manipulation + Core exercises
33047913|NCT05638997|Experimental|Mulligan Mobilization with Movement Group|Mulligan Mobilization with Movement + Core exercises
33047914|NCT05638997|Active Comparator|Control group|Core exercises
33047915|NCT00128401|Active Comparator|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
33047916|NCT00128401|Placebo Comparator|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
33047917|NCT05639036|Active Comparator|Control-Free Hand External Ventricular Drain Placement|This group will receive an external ventricular drain placed using the standard free-hand technique
33361251|NCT03920917|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
33361252|NCT03510676|Experimental|NiTiDES|Single arm
33047918|NCT05639036|Experimental|Intervention - Image Guided External Ventricular Drain Placement Using the NAV3 System|This group will receive an external ventricular drain placed using the assistance of the Stryker NAV3 image guidance system
33047919|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
33047920|NCT00394576|Experimental|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
33047921|NCT00394576|Active Comparator|usual care|usual care
33047922|NCT05639075|Experimental|Gait analysis|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
33047923|NCT00018616|Other|1|
33047924|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
33047925|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
33047926|NCT00018694|Other|Arm 1|
33047927|NCT05639114|Experimental|Ianalumab s.c. monthly|Ianalumab s.c. monthly
33047928|NCT05639114|Experimental|Ianalumab s.c. quarterly|Ianalumab s.c. quarterly
33047929|NCT05639114|Placebo Comparator|Placebo s.c. monthly|placebo s.c. monthly
33047930|NCT05639153|Experimental|DR30303|DR30303 injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
33047931|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
33047932|NCT05639387|Experimental|Group of healthy volunteers (part I)|Participants will undergo active tVNS.
33047933|NCT05639387|Sham Comparator|Group of healthy volunteers (part II)|Participants will undergo sham tVNS.
33047934|NCT05639465|Experimental|JoH-C19|After initial randomization, some participants will be assigned to receive JoH-C19
33047935|NCT05639465|Active Comparator|Switch off Get Active|After initial randomization, some participants will be assigned to receive Switch Off Get Active
33047936|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
33047937|NCT05639504||NEWS2 score of 2-4|Bio-sample collection
33047938|NCT05639504||NEWS2 score of 5-6|Bio-sample collection
33047939|NCT05639504||NEWS2 score of ≥7|Bio-sample collection
33047940|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
33047941|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
33047942|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
33047943|NCT05639621|Experimental|Meaningful accompaniment|Patient who is going to undergo an endoscopic procedure and who will have a significant accompaniment by a person freely chosen by the patient and who will escort him in a visual and tactile way during the pre-procedure, intra-procedure, and post-procedure endoscopic stage.
33047944|NCT05639621|No Intervention|Usual care|Patient who is going to undergo an endoscopic procedure and who receives regular care provided by the service during the pre-procedure, intra-procedure and post-procedure stage.
33047945|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
33047946|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
33047947|NCT05639660||Aflibercept group|Single arm, Aflibercept 2.0mg/0.05ml, intravitreal injection
33110097|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
33110098|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
33331494|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
33361253|NCT03918733|Experimental|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
33361254|NCT03918733|Experimental|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
33047948|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
33047949|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
33047950|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
33047951|NCT05639699|Experimental|Experimental group|Motivational interview will be done to the experimental group
33047952|NCT05639699|No Intervention|I Control group|No intervention will be applied to the control group
33047953|NCT05639699|No Intervention|II Control group|No intervention will be applied to the control group
33047954|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
33047955|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
33047956|NCT05639738|Other|All subject|Clinical and instrumental measurements
33047957|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
33047958|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
33047959|NCT05639816|Experimental|saline irrigation group|The patients received saline irrigation of common bile duct after complete ERCP stone removal confirmed by occluded cholangiogram
33047960|NCT05639816|No Intervention|control|The patients whom complete ERCP stone removal confirmed by occluded cholangiogram were follow up according to standard treatment
33047961|NCT00020878|Experimental|Study|See intervention description.
33047962|NCT05639855|Experimental|Third year students of the Bachelor's Degree in Occupational Therapy|Third-year students of the Bachelor's Degree in Occupational Therapy will receive training on a specific module on mental health and stigma in the university curriculum.
33047963|NCT05639855|No Intervention|Students of University of A Coruña|The students of the University of A Coruña will take part in an online survey to find out the attitudes and beliefs of future professionals from different areas of knowledge regarding mental health.
33047964|NCT05639855|No Intervention|People with mental health disorder|Users of a Psychosocial and Labor Rehabilitation Centers in the A Coruña Health Care Area will take part in interviews to find out their experiences regarding the attributions made towards them by citizens and health professionals.
33047965|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
33047966|NCT00021151|Experimental|Alemtuzumab|
33047967|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
33047968|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
33047969|NCT00000134|Experimental|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
33110099|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
33047970|NCT00000134|Active Comparator|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
33047971|NCT00000134|Active Comparator|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
33110100|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
33110101|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
33110102|NCT00554892|Active Comparator|1|Bowel preparation
33047972|NCT00394810|Experimental|1|
33110103|NCT00554892|Experimental|2|without bowel preparation
33110104|NCT01626573|Experimental|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
33110105|NCT01626573|Placebo Comparator|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
33331495|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
33331496|NCT04218110|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
33110106|NCT01626573|Experimental|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
33110107|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
33331497|NCT04218110|Experimental|Project X 10.5ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
33331498|NCT04218110|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
33047973|NCT00388544|Experimental|1|
33047974|NCT00388544|Experimental|2|
33047975|NCT00388544|Experimental|3|
33047976|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
33047977|NCT00021814|Placebo Comparator|Placebo|Doxazosin and Finasteride placebos
33047978|NCT00021814|Experimental|Doxazosin|Doxazosin and Finasteride placebo
33047979|NCT00021814|Experimental|Finasteride|Doxazosin placebo and Finasteride
33047980|NCT00021814|Experimental|Combination|Doxazosin and Finasteride
33047981|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
33047982|NCT00388661|Placebo Comparator|Placebo|
33047983|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
33047984|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
33047985|NCT00388700|Experimental|GM-CT-01|
33047986|NCT00022126|Experimental|Modified Augmented BFM Therapy|
33047987|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
33047988|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
33047989|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
33047990|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
33047991|NCT00388739|Active Comparator|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
33110108|NCT01626573|Experimental|Itacitinib 100mg once a day|Itacitinib 100mg once a day
33110109|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
33110110|NCT01626573|Experimental|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
33110111|NCT01626573|Placebo Comparator|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
33110112|NCT01626573|Experimental|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
33110113|NCT01626573|Placebo Comparator|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
33110114|NCT01626573|Experimental|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
33110115|NCT01626573|Placebo Comparator|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
33110116|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
33331499|NCT04218110|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.
33110117|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
33110118|NCT02914028|Active Comparator|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
33110119|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
33110120|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
33110121|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
33110122|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
33110123|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
33110124|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
33110125|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
33110126|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
33110127|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
33110128|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
33110129|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
33110130|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
33110131|NCT02064426|Experimental|Molidustat (BAY85-3934)|
33110132|NCT02064426|Active Comparator|Epoetin alfa/beta|
33110133|NCT00899301||Patients with Breast Cancer|
33110134|NCT00899301||Patients without breast cancer|
33110135|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
33110136|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
33110137|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
33110138|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
33110139|NCT02063997|Experimental|Arhalofenate 600 mg|
33110140|NCT02063997|Experimental|Arhalofenate 800 mg|
33110141|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
33110142|NCT02063997|Active Comparator|Allopurinol 300 mg|
33110143|NCT02063997|Placebo Comparator|Placebo|
33110144|NCT02913443|Experimental|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
33110145|NCT02913443|Experimental|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
33110146|NCT02913443|Experimental|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
33110147|NCT02913443|Experimental|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
33110148|NCT00585507|Experimental|single|fulvestrant 500mg
33110149|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
33110150|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
33110151|NCT02063685|Other|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
33110152|NCT02063685|Experimental|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
33110153|NCT02063685|Experimental|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
33110154|NCT02063685|Experimental|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
33110155|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
33110156|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
33110157|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
33110158|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
33047992|NCT00388739|Experimental|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
33047993|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
33047994|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
33047995|NCT00022399|Experimental|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
33047996|NCT00022399|Placebo Comparator|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
33047997|NCT00000143|Experimental|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
33047998|NCT00000143|Experimental|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
33047999|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
33048000|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
33048001|NCT04733287|Experimental|Effect of High Intensity Interval Training|"Young and older subjects will participate in single-leg, high-intensity interval training of the right knee extensors (4 intervals of 4 minutes at 80% of max aerobic power with 4 minute rest intervals between, 3x per week for 6 weeks).~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
33048002|NCT04733287|Experimental|Effect of Muscle Heat Therapy|"Young and older subjects will participate in single-leg,heat therapy training of a single leg ( quadriceps femoris, 120 minutes of shortwave diathermy to raise the muscle temperature to ~39C) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
33048003|NCT04733287|Sham Comparator|Effect of Sham Muscle Heat Therapy|"Young and older subjects will participate in a sham treatment of single-leg,heat therapy training of the right knee extensors (120 minutes with shortwave diathermy unit positioned on leg, but not turned on) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
33048004|NCT04733287|Sham Comparator|Effect of Immobilization with Daily Sham Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of a sham heat therapy treatment each day. For the sham treatment, the heating device will be applied to the limb, but, unbeknownst to the participant, it will not be turned on.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
33048005|NCT04733287|Experimental|Effect of Immobilization with Daily Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of heat therapy treatment each day. Heat therapy will consist of 120 minutes of shortwave diathermy to raise the quadriceps femoris muscle temperature to ~39C.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
33048006|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
33048007|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
33048008|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
33048009|NCT00394966|Experimental|SCH 619734 Dose 1|
33048010|NCT00394966|Experimental|SCH 619734 Dose 2|
33048011|NCT00394966|Experimental|SCH 619734 Dose 3|
33048012|NCT00394966|Experimental|SCH 619734 Dose 4|
33048013|NCT00394966|Placebo Comparator|Placebo|
33048014|NCT00000170|Active Comparator|Patching|
33048015|NCT00000170|Active Comparator|Atropine|Atropine
33048016|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
33048017|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
33048018|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
33048019|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
33048020|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
33048021|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
33048022|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
33048023|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
33048024|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
33048025|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
33048026|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
33048027|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
33048028|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
33048029|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
33048030|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
33048031|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
33048032|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
33048033|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
33418420|NCT05150847|Other|Prone Positioning|Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements of oxygenation and respiratory mechanics were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supine positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation( PV tool) (9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
33418421|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
33048034|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
33048035|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
33048036|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
33048037|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
33048038|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
33048039|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
33048040|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
33048041|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
33048042|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
33048043|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
33048044|NCT00000257|Active Comparator|Light drinkers|
33048045|NCT00000257|Active Comparator|Moderate drinkers|
33048046|NCT00024466|Experimental|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
33048047|NCT04733131||converted to a belatacept based immunosuppression|Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
33048048|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
33048049|NCT00000359|Experimental|Modified Epley maneuver|
33048050|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
33048051|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
33048052|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
33048053|NCT00011349||Group 1|
33048054|NCT00395200|Experimental|MSC Treatment|
33048055|NCT00395239|Experimental|1|
33048056|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
33048057|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
33048058|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
33048059|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
33048060|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
33048061|NCT00000380|Placebo Comparator|Placebo|Placebo
33048062|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33048063|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
33048064|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
33048065|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
33048066|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
33048067|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
33048068|NCT00000392|Active Comparator|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
33048069|NCT00000392|Placebo Comparator|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
33048070|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
33048071|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
33048072|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
33048073|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
33048074|NCT00000410|Active Comparator|Surgery|Diskectomy
33048075|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
33048076|NCT00025675|Active Comparator|p450|p450 inhibitor
33048077|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
33048078|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
33048079|NCT00000416|Active Comparator|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
33048080|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
33048081|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
33048082|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
33048083|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
33048084|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
33048085|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
33048086|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
33331500|NCT05154994|Experimental|Treatment (durvalumab, tremelimumab, belinostat)|Patients receive durvalumab IV over 60 minutes on day 1. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycle 1. Beginning cycle 2, patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33331501|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
33048087|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
33048088|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
33048089|NCT00026338|Active Comparator|Placebo plus gemcitabine|
33048090|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
33048091|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
33048092|NCT04733209|Experimental|Mobilization with movement|"Mobilization with movement technique and traditional physiotherapy were applied to the intervention group. For mobilization with movement technique, the patient was asked to actively flex and extend the wrist with the forearm in neutral in a sitting position on a treatment table, and the pain was asked. The painful side was determined according to the patient's statement.~In a patient whose painful side was flexion, the wrist joint was shifted manually (with the help of the web space of both hands of the therapist) to the lateral and medial at the same time while the patient actively flexed the wrist. The treatment was done 3 times a week for 4 weeks."
33048093|NCT04733209|Active Comparator|Conventional|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the transverse carpal ligament in the wrist with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; tendon-nerve gliding exercises, night splint, stretching and strengthening exercises applied. The treatment was done 3 times a week for 4 weeks.
33048094|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
33048095|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
33048096|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
33048097|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
33048098|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
33048099|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
33048100|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
33048101|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
33048102|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
33048103|NCT00000479|Experimental|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
33048104|NCT00000479|Experimental|2|Vitamin E (600 IU every other day) and placebo
33048105|NCT00000479|Experimental|3|Aspirin (100 mg every other day) and placebo
33048106|NCT00000479|Placebo Comparator|4|Placebo and placebo
33048107|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
33048108|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
33331502|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
33048109|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
33331503|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
33331504|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
33331505|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
32740888|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
32869560|NCT04930107|No Intervention|Recurrent Infection Cohort - asymptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic
33048110|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
33048111|NCT04732741||Oral Cancer|patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.
33048112|NCT04732741||Premalignant lesions|patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.
33048113|NCT04732741||Control Group|healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history
33048114|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
33048115|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
33048116|NCT00028795|Experimental|Chemoradiotherapy|
33048117|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
33331506|NCT05409612|Active Comparator|Supemtek® arm|"Patients recieving a quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
33048118|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33048119|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
33048120|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
33048121|NCT01803555|Experimental|BF Spiromax|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
33048122|NCT01803555|Active Comparator|Symbicort Turbohaler|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
33048123|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
33048124|NCT00028990|Active Comparator|Paclitaxel|
33048125|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
33048126|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
33048127|NCT00012597|Other|Arm 1|
33048128|NCT00012636|Other|Arm 1|
33048129|NCT00012675||Group 1|
33048130|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
33048131|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
33048132|NCT00012714|Other|Arm 1|
33048133|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
33048134|NCT00395941|Active Comparator|Control|Acitretin
33048135|NCT00395941|Experimental|Experimental|Pioglitazone
33048136|NCT00012753|Other|Arm 1|
33048137|NCT00012792|Other|Arm 1|
33048138|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
33048139|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
33048140|NCT00012831||Group 1|
33048141|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33048142|NCT00012870|Other|Arm 1|
33048143|NCT04711759|Experimental|Sequence A: High flow nasal cannula - Standard oxygen therapy|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of standard oxygen therapy.
33048144|NCT04711759|Experimental|Sequence B: Standard oxygen therapy - High flow nasal cannula|Once participants are extubated they will receive one hour of standard oxygen therapy followed by one hour of high flow nasal cannula.
33048145|NCT04711720|Experimental|Navigation|
33048146|NCT04711720|No Intervention|Control|
33048147|NCT00012909|Other|Arm 1|
33048148|NCT00031096|Experimental|Arm 1|
33048149|NCT00031096|Placebo Comparator|Arm 2|
33048150|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
33048151|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
33048152|NCT00012948|Other|Arm 1|
33048153|NCT00012987|Other|Arm 1|
33048154|NCT00396214|Experimental|1|
33048155|NCT00396214|Experimental|2|
33048156|NCT00396214|Active Comparator|3|
33048157|NCT00013026|Other|Arm 1|
33048158|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
33048159|NCT00013065||Group 1|
33048160|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
33048161|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
33048162|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
33048163|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
33048164|NCT00000569|Placebo Comparator|Placebo|Placebo
33048165|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
33048166|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
33048167|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
33048168|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
33048169|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
33048170|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
33048171|NCT00013104||Group 1|
33048172|NCT00013143|Other|Arm 1|
33048173|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33048174|NCT00000575|Active Comparator|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
33048175|NCT00000575|Active Comparator|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
33048176|NCT00000575|Placebo Comparator|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
33048177|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
33048178|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
33048179|NCT00013182|Other|Arm 1|
33418422|NCT04967079|Experimental|Anlotinib + Trametinib|Anlotinib given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus trametinib 2 milligrams (mg) given orally, once daily.
33418423|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
33048180|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
33418424|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
33418425|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
33418426|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
33418427|NCT03120949|Experimental|Treatment Arm 1: OKZ 64 mg q4w + MTX|Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
33048181|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
33048182|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
33048183|NCT00032227|Experimental|1|Surgical release of CTS
33048184|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
33048185|NCT00013221|Other|Arm 1|
33048186|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
33048187|NCT00013260|Other|Arm 1|
33048188|NCT00032539||1|
33048189|NCT00032617|Active Comparator|1|Prolonged Exposure
33048190|NCT00032617|Active Comparator|2|Present Centered Therapy
33048191|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
33048192|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
33048193|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
33048194|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
33048195|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
33048196|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
33048197|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
33048198|NCT00000620|Experimental|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
33048199|NCT00000620|Active Comparator|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
33048200|NCT00000620|Experimental|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
33048201|NCT00000620|Active Comparator|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
33048202|NCT00000620|Experimental|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
33048203|NCT00000620|Placebo Comparator|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
33048204|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
33048205|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
33048206|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
33048207|NCT00013533|Experimental|1|Transplant with Induction Therapy
33048208|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
33048209|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
33331507|NCT05409612|Active Comparator|Vaxigriptetra® arm|Patients receiving a quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
33331508|NCT05406570|Active Comparator|Standardized tidal volume|Ventilation with tidal volume 6 ml/kg
33110159|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
33110160|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
33110161|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
33110162|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
33110163|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
33110164|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
33331509|NCT05406570|Experimental|Personalized tidal volume|Ventilation with tidal volume aiming to minimize cardiopulmonary interactions as assessed by pulse pressure variation
32740889|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
33331510|NCT04210310|Experimental|high-dose intranasal oxytocin|Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
33331511|NCT04210310|Placebo Comparator|Nasal spray|Subjects swill be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). The spray can be taken with or without food. Subjects will take 4 sprays daily of the placebo for the entire study.
32740890|NCT04504175|Experimental|Acute infusion|Acute phase: ketamine infusions twice a week for 4 weeks
33048210|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
33048211|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
33048212|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
33048213|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
32740891|NCT05724225||First group with atrial fibrillation disease|10 Atrial fibrillation(AF), predominant right atrial dilatation with at least moderate IT
32740892|NCT05724225||Second group with atrial fibrillation disease and tricuspid insufficiency|10 AF, predominantly right atrial dilatation without TI (or TI no more than mild)
32740893|NCT05724225||Third group with AF and mitral insufficiency|10 AF, predominantly left atrial dilatation with at least moderate MI
32740894|NCT05724225||Fourth group with atrial fibrillation and IM|10 AF, predominantly left atrial dilatation without MI (or no more than mild MI)
33048214|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
33048215|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
33048216|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
33048217|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
33048218|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
33048219|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
32740895|NCT05724225||Fifth group with tricuspid insufficiency|10 IT at least moderate to right ventricular remodeling in patients with pulmonary hypertension
33048220|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
33110165|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
33048221|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
33048222|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048223|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048224|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048225|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048226|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048227|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
33048228|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
33048229|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
33048230|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
33048231|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
33048232|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
33048233|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
33048234|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
33048235|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
33048236|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
33048237|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
33048238|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
33048239|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
33048240|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
33048241|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
33048242|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
33048243|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
33110166|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
33110167|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
33048244|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
33048245|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
33048246|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
33048247|NCT00033865|No Intervention|2|Sleep hygiene instructions only
33331512|NCT04805190|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
33331513|NCT04805190|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
33331514|NCT03755466|Active Comparator|BARI|
33331515|NCT03755466|Active Comparator|Bio|
33331516|NCT03755466|Active Comparator|Tofa|
33048248|NCT00389090|Experimental|Temozolomide + O6BG|
32869561|NCT00100841|Experimental|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
33048249|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
33048250|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
33048251|NCT02972567|Experimental|Probiotic|Lactobacillus strain
33048252|NCT02972567|Placebo Comparator|Control|Maltodextrin
33048253|NCT04711876||Test group with enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +
33048254|NCT04711876||Control group with no enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -
33048255|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
33048256|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
33048257|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
33048258|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
33048259|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
33048260|NCT04711681|Experimental|PBS1|"This group will recieve an enhanced PBS intervention."
33048261|NCT04711681|Active Comparator|PBS 2|"This group will receive standard PBS with fewer training and coaching sessions than PBS 1."
33048262|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
33048263|NCT04711642|No Intervention|No intervention|Control group.
33048264|NCT04711642|Experimental|Treatment 1|Sodium hyaluronate 0.1% eyedrops (Systane ultra plus), q.i.d from day 7 to day 30 after cataract surgery.
33048265|NCT04711642|Experimental|Treatment 2|Sodium hyaluronate 0.1% eyedrops (Hylo-comod), q.i.d from day 7 to day 30 after cataract surgery.
33048266|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
33048267|NCT04732819|No Intervention|Usual care|Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media.
33110168|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
33331517|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
32740896|NCT05724225||Sixth group with mitral insufficiency|10 MI at least average from left ventricular remodeling from left ventricular dysfunction
32740897|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
32740898|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
32869562|NCT04911543|Experimental|Part A: [18F]-JNJ-70099731|Participants will receive an intravenous (IV) bolus injection of [18F]-JNJ-70099731 on Day 1 of Part A to investigate the total body bio-distribution and measure the radiation dosimetry of [18F]-JNJ-70099731.
33048268|NCT04732819|Experimental|High touch|Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.
33048269|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
33048270|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
33048271|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
33048272|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
33048273|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.~（3 months after the start of the trial and 1 months after the end of the trial.）"
33048274|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
33048275|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
33048276|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
33048277|NCT00035425|Experimental|B.|
33048278|NCT00035464|Placebo Comparator|1|Placebo tablets
33331518|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
33048279|NCT00035464|Experimental|2|125 mg azimilide tablets
33048280|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
33048281|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
33048282|NCT00035620|Active Comparator|Filgrastim|Filgrastim
33048283|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
33048284|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
33331519|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
33048285|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
33048286|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
33048287|NCT04732390|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
33048288|NCT04732390|Active Comparator|Group (M)|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .
33331520|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
33331521|NCT04208750|Experimental|R-Refraction|
33331522|NCT04208750|Active Comparator|S-Refraction|
33331523|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
33331524|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
33331525|NCT03746522|Experimental|Setmelanotide|Dosage form: Subcutaneous injection Dosage: 3 mg Frequency: daily
33331526|NCT03746522|Placebo Comparator|Placebo|Dosage form: Subcutaneous injection Dosage: 3 mg equivalent volume Frequency: daily
33331527|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
33331528|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
33331529|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
33331530|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
33331531|NCT05145010|Experimental|Arm 1: Rollover subjects|Children who have completed QED-sponsored interventional study with infigratinib
33331532|NCT05145010|Experimental|Arm 2: Treatment naïve subjects|Children naïve to infigratinib
33331533|NCT04381988|Experimental|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
33048289|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
33048290|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
33048291|NCT00000785||A|All eligible CPCRA subjects
33048292|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
33048293|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
33048294|NCT00391521|Active Comparator|1|Regimen 1
33048295|NCT00391521|Active Comparator|2|Regimen 2
33048296|NCT00391521|Active Comparator|3|Regimen 3
33048297|NCT04732585|Experimental|Patient with PFPS or ACL injury|Physiotherapy intervention Surgical intervention
33048298|NCT04732585|No Intervention|Healthy control group|The healthy control group will not do any intervention
33048299|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
33048300|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
33048301|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
33048302|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
33048303|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
33048304|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
33048305|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
33418428|NCT03120949|Experimental|Treatment Arm 2: OKZ 64 mg q2w + MTX|Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
33048306|NCT00036868|Experimental|CMF + Herceptin|
33048307|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
33048308|NCT00037648|Placebo Comparator|placebo|
33048309|NCT00037648|Experimental|anakinra|
33048310|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
33048311|NCT00037921|Other|1|
33048312|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
33048313|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
33048314|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
33048315|NCT00038155|Other|1|
33048316|NCT00038194|Experimental|Imatinib + Docetaxel|
33048317|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
33048318|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
33048319|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
33048320|NCT05434273|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
33048321|NCT05434273|Sham Comparator|Control|Receive usual care
33048322|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
33048323|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
33048324|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
33048325|NCT05434195|No Intervention|Normotensive|A sub-cohort of 32 normotensive women will be recruited to establish normal pregnancy values for the measures performed as well as validation of outcome measures.
33048326|NCT05434195|Placebo Comparator|Preeclampsia - Placebo|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo.
33048327|NCT05434195|Active Comparator|Preeclampsia - low dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo low dose of 5-MTHF.
33048328|NCT05434195|Active Comparator|Preeclampsia - high dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo high dose of 5-MTHF.
33048329|NCT05434000|Other|Children with sickle cell anaemia and abnormal TCD values (200cm/s)|The children identified with abnormal TCD values will be given hydroxyurea and followed for one year
33048330|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
33048331|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
33048332|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
33110169|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
33048333|NCT05433922|Experimental|CSA + Avatrombopag|cyclosporine 3 mg/kg orally in two doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: two dosing groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks.If the 40 mg dose group trial meets the desired trial objectives, the 60 mg dose group trial will not be conducted.
33048334|NCT05433883|Experimental|treatment group|30 severe OSA patients (apnea/hypopnea >30)
33048335|NCT05433883|No Intervention|control group|15 simple snoring patients (apnea/hypopnea <5 )
33048336|NCT05433883|No Intervention|comparative group|15 mild cognitive impairment patients.
33048337|NCT05433844|Other|Group 1|Test Drug for Period I Reference Drug for Period II
33048338|NCT05433844|Other|Group 2|Reference Drug for Period I Test Drug for Period II
33048339|NCT05433805|Experimental|FMD first|"Patients receive nutritional counselling on the principles of the FMD diet and individual recommendations for optimising the micronutrient balance (vitamins, trace elements) based on their corresponding baseline values. A food diary is given to the patients to assess treatment adherence on FMD days.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. Patients will be instructed about ambulatory exercises during a physiotherapeutic counselling, scheduled in week 13. Physiotherapy exercises should only be carried out on FMD-free days. Patients also receive a diary in which they document daily physical activity."
33048340|NCT05433805|Experimental|Physiotherapy first|"Patients receive physiotherapy counselling, with structured ambulatory exercises shown and explained. The patients receive a diary where they have to document their physical activity every day.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. For this purposphe, nutritional counselling on the principles of the FMD diet is planned for week 13. In addition, individual recommendations for optimising the micronutrient balance (vitamins, trace elements) are given based on the respective baseline values. The physiotherapeutic exercises are to be carried out only on FMD-free days. Patients will also be given a food diary to assess treatment adherence on FMD days."
33048341|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
33048342|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
33048343|NCT05433376|Experimental|IVL group|
33048344|NCT05433298|Experimental|Treatment|Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)
33048345|NCT05433298|Placebo Comparator|Placebo|Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution
33048346|NCT05433025|Experimental|Intervention|Cervigard Neck Collar, which is a device used to treat neck pain caused by forward head posture.
33048347|NCT05433025|No Intervention|Waitlist Control|This group will receive no intervention for 6 weeks after enrollment. They will receive the device after 6 weeks.
33048348|NCT00396643|Experimental|A|
33048349|NCT00396643|Placebo Comparator|B|Coconut oil
33048350|NCT04732468|Experimental|Cohort 1- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 1, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Suspension for injection) again on day 22 (boost).
33048351|NCT04732468|Experimental|Cohort 2- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 2, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Oral capsule) on day 22 (boost).
33048352|NCT04732468|Experimental|Cohort 3 - hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 3, hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on days 1 (prime) and on day 22 (boost).
33048353|NCT04732468|Experimental|Cohort 4 - hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 4, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on days 15 (boost) and 22 (boost).
33048354|NCT00396721|Active Comparator|A|
33048355|NCT00396721|Experimental|B|
33048356|NCT05432908|Experimental|Orofacial exercises and oropharyngeal functions|Orofacial exercises and oropharyngeal functions.
33048357|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
33048358|NCT05432869|Experimental|Electrical stimulation (ES) group|ES group will be given additional external electrical stimulation to the lifestyle advices.
33048359|NCT05432869|Experimental|Control group|Control group will be given only lifestyle advices .
33048360|NCT05432440|Experimental|Intervention group (the digital asthma education program)|"The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.~The time schedule will be described as:~Explain study purposes, program, procedures, and instructions (10 minutes).~Accompany children and parents to download and install the MIRACLE program on Google Play Store for free on their personal computers, tablets, or smartphones (5 minutes).~Asthma education will take place over one session lasting approximately 45 minutes."
33110170|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
33110171|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
33331534|NCT04381988|Placebo Comparator|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
33048361|NCT05432440|Active Comparator|Control group (the booklet asthma education program)|"For the control group, a pharmacist (same personnel) will provide an asthma education using a booklet for 45-60 minutes to children and parents. Patients will be asked to read the booklet at home for 15 minutes in 7 days. It mainly covered the same content as the MIRACLE program. The time schedule will be described as:~Explain study purposes, booklet, procedures, and instructions (10 minutes).~Asthma education will take place over one session lasting approximately 45 minutes."
33048362|NCT05432401|Experimental|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10^8, 2.0 × 10^8 and 4.0 × 10^8 CAR-T groups in order of sequence. And the subjects will be administered once.
33048363|NCT05432362|Experimental|Verum Normal Weight|Normal weight participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
33048364|NCT05432362|Experimental|Verum Obesity|Adipose participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
33048365|NCT05432362|Experimental|Verum Depression|Depressive participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
33048366|NCT05432362|Placebo Comparator|Placebo Normal Weight|"Normal weight participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free."
33048367|NCT05432362|Placebo Comparator|Placebo Obesity|"Obese participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
33048368|NCT05432362|Placebo Comparator|Placebo Depression|"Depressive participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
33048369|NCT05432128||Low-risk group|Combined with AI calculation of malignant probability and ctDNA methylation results, patients were divided into three groups. The high probability of malignancy calculated by AI was defined as positive, and vice versa. The methylation markers detected in specific peripheral blood of lung cancer were defined as positive, and vice versa. Negative for both items was considered as low risk group. Follow-up was conducted according to The Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules (2018 edition). 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study.
33048370|NCT05432128||medium-risk group|As above, one positive patient was considered to be in the medium-risk group and was reexamined every 6 months, with a total of 3 reexaminations expected
33048371|NCT05432128||High-risk group|Same as above, both positive are considered high-risk group.Part of high-risk nodules (5-10mm) will be reviewed every 3 months for the above two examinations, which is expected to be reviewed 6 times in total. Biopsy or surgical resection of high-risk nodules over 10mm will be performed after evaluation by the expert group and the patient's knowledge, and histopathological diagnosis will be made and compared with ctDNA methylation results. To analyze the sensitivity and specificity of ctDNA methylation markers in lung cancer.
33048372|NCT05422300|Experimental|Mid-Follicular Phase|7-10 days after the onset of menses, determined by self-reports and confirmed with ovulation test kits.
33048373|NCT05422300|Experimental|Mid-Luteal Phase|5-7 days after ovulation, determined by self-reports and confirmed with ovulation test kits.
33048374|NCT05422261||Experimental Group|Children with Autism Spectrum Disorder and their parents
33048375|NCT05422261||Control Group|Health children and their parents
33048376|NCT05403112|Active Comparator|Group I: autogenous bone rings|sinus lifting was augmented by bone rings were harvested from chin
33048377|NCT05403112|Active Comparator|GroupII : autogenous sticky bone|sinus lifting was augmented by autogenous sticky bone was harvested from chin and immediate implant placement
33048378|NCT05363254|Experimental|Cohort 1: Marlboro Gold Box|Subjects will self-assign to a Cohort 1 based on their self-reported use of Marlboro Gold as their usual brand of combustible cigarettes.
33048379|NCT05363254|Experimental|Cohort 2: Newport Box|Subjects will self-assign to a Cohort 2 based on their self-reported use of Newport as their usual brand of combustible cigarettes.
33048380|NCT05363254|Experimental|Cohort 3: HTP device with mode A (20023145) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33048381|NCT05363254|Experimental|Cohort 4: HTP device with mode B (20022187) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33048382|NCT05363254|Experimental|Cohort 5: HTP device with mode A (20023145) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33331535|NCT04333498|Experimental|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
33048383|NCT05363254|Experimental|Cohort 6: HTP device with mode B (20022187) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33331536|NCT05144386|Experimental|EBT-101 Dose-Level 1|Cohort A: Participants will be administered dose-level 1 of EBT-101
33331537|NCT05144386|Experimental|EBT-101 Dose-Level 2|Cohort B: Participants will be administered dose-level 2 of EBT-101
33048384|NCT05363254|Experimental|Cohort 7: HTP device with mode A (20023145) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33418429|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
33418430|NCT05070117|Experimental|Resistance/strength training|
33048385|NCT05363254|Experimental|Cohort 8: HTP device with mode B (20022187) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
33048386|NCT05363254|Experimental|Cohort 9: HTP device with mode A (20023145) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
33048387|NCT05363254|Experimental|Cohort 10: HTP device with mode B (20022187) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
33048388|NCT05319652|Experimental|Pain self-management program|Participants log in to the online program and develop practical strategies to manage CNCP.
33048389|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
33048390|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
33048391|NCT05280691|Other|Family Support Intervention|Families in the intervention group receive the Family Support Intervention in addition to usual care
33048392|NCT05280691|No Intervention|Usual Care|Families in the control group will receive usual care.
33048393|NCT05238766|No Intervention|Treatment as Usual|This arm does not receive any intervention. It will serve as a comparison for the experimental arm.
33048394|NCT05238766|Experimental|Treatment + DEAL|Parents in the Treatment plus Defuse Experience Accept Live (T+DEAL) arm will attend five 45-min DEAL sessions with a therapist. Across the five sessions, the therapist will 1) introduce caregivers to behavior change strategies that maximize contact with positive-maintaining contingencies related to adherence, while undermining the contingencies that maintain accommodation, and 2) provide caregivers with new treatment-related committed actions that are sensitive to positive changes in parent-child interactions.
33048395|NCT05216809|Active Comparator|Young Adults|Equal sex distribution (10M/10F); ages 18-35 years old.
33048396|NCT05216809|Active Comparator|Older Adults|Equal sex distribution (6M/6F); ages 60-80 years old.
33048397|NCT05195242|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
33048398|NCT05195242|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
33048399|NCT05147077|Experimental|Integrated rehabilitation group|This group will include 94 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation.
33048400|NCT05147077|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of escitalopram oxalate (10 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
33048401|NCT05146882|Experimental|belcesiran|Participants who completed the DCR-A1AT-201 treatment period will receive open-label belcesiran administered subcutaneously
33048402|NCT05146882|No Intervention|Observational|Participants who completed the DCR-A1AT-201 Conditional Follow-up period will enter DCR-A1AT-202 for continued follow-up (will not receive open-label belcesiran)
33048403|NCT05118139|Experimental|1.5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 1.5% ENDS products based on their preferred flavor.
33048404|NCT05118139|Experimental|2.4% nicotine cartridges|Subjects will self-assign to one of 2 flavor variants of 2.4% ENDS products based on their preferred flavor.
33048405|NCT05118139|Experimental|5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 5% ENDS products based on their preferred flavor.
33048406|NCT05114863|Experimental|Non-menthol smokers|Subjects will be randomized to one of ten product use sequences, such that one of the five IPs (A1,B,C,D,N) will be used in each of the five Test Sessions.
33048407|NCT05114863|Experimental|Menthol smokers|Subjects will be randomized to one of six product use sequences, such that one of the six IPs (A2,E,F,G,H,N) will be used in each of the six Test Sessions.
33048408|NCT05101915|Experimental|Interventional|Single arm trial involving all patients receiving IMP
33048409|NCT05089903|Experimental|No Order|
33048410|NCT05089903|Experimental|No Order + Text (NO+T)|
33048411|NCT05089903|Experimental|Bulk Order (BO)|
33048412|NCT05089903|Experimental|Bulk Order + Text (BO+T)|
33048413|NCT05089903|Experimental|Clinician Endorsement (CE)|
33048414|NCT05089903|Experimental|Clinician Endorsement + Text (CE+T)|
33048415|NCT05089903|Experimental|Standard Messaging (SM)|
33048416|NCT05089903|Experimental|Standard Messaging (SM+T)|
33418431|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
33418432|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
33331538|NCT05144386|Experimental|EBT-101 Dose-Level 3|Cohort C: Participants will be administered dose-level 3 of EBT-101
33418433|NCT04964193|Experimental|Elzsa film-coated tablet|Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
32740899|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
33048417|NCT05083975|Experimental|Buzzy System|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after activating the buzzy device extra orally proximal to the site of injection for 30-60 seconds.
33048418|NCT05083975|Active Comparator|Control|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after application of 20% Benzocaine topical anesthestic gel.
33048419|NCT05078437|Experimental|Treatment optimization|Participants will undergo an evaluation of all the medications taken and changes will be proposed for treatment optimization.
33048420|NCT05078047|Experimental|Experimental arm|"Reduced dose intensity of IO:~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
33048421|NCT05078047|No Intervention|Control arm|"Standard IO:~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
33048422|NCT05076877|Experimental|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
33048423|NCT04996654|Experimental|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
33048424|NCT04996654|Active Comparator|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
33048425|NCT04976023|Active Comparator|Active Arm|14.55g of Yupingfeng Powder granules twice daily for 8 weeks
33048426|NCT04976023|Placebo Comparator|Placebo Arm|14.55g of placebo granules twice daily for 8 weeks
33048427|NCT04970836|Experimental|Low titer with two doses of HB Vaccines|anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
33048428|NCT04970836|Active Comparator|Low titer with one dose of HB Vaccine|anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
33048429|NCT04970836|Active Comparator|Extremely low titer with two doses of HB Vaccines|anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
33048430|NCT04970836|Active Comparator|Extremely low titer with one dose of HB Vaccine|anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
33048431|NCT04896541|Experimental|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
33048432|NCT04896541|Experimental|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
33048433|NCT04892407|Experimental|Algeness DF 3.5%|This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.
33048434|NCT04892407|Active Comparator|Juvéderm Voluma|This arm is with a Control product that is already CE Marked and sold for this indication.
33048435|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
33048436|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
33048437|NCT04815382|Experimental|Dynamic Upper Limb Orthosis group|"The dynamic upper limb orthosis group will receive a treatment based on the use of a dynamic upper limb orthosis.~Participants of this group will continue to receive their regular therapy"
33048438|NCT04815382|No Intervention|Control group|The control group will not receive any type of intervention Participants of this group will continue to receive their regular therapy
33048439|NCT04796155||labour arrest|Pregnant women whose labour progress is delayed and suspected or diagnosed as labour arrest according to the NICE guidelines. Intrapartum ultrasound will be performed at the suspicion of labour arrest in the active phase of the first and second stage of labour. Amniotomy will be performed as routine obstetric care according to the local clinical protocols in accordance with the NICE guideline. Later, diagnosis of labour arrest will be made in slow progress following amniotomy (<1cm cervical dilatation in 2 hours) where a sonographic examination will be repeated.
33048440|NCT04759807|Placebo Comparator|Placebo|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
33048441|NCT04759807|Active Comparator|PUR1800 250 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
33048442|NCT04759807|Active Comparator|PUR1800 500 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
33361255|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
33361256|NCT03511924|No Intervention|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
33048443|NCT04693585|Experimental|Arm 1: live support|Real-time live voice call plus standard of postnatal care.
33048444|NCT04693585|Experimental|Arm 2: asynchronous support|Text-based, asynchronous, on-demand social support plus standard of postnatal care
33048445|NCT04693585|Experimental|Arm 3: both live and asynchronous support|Real-time live voice call plus standard of postnatal care; text-based, asynchronous, on-demand social support plus standard of postnatal care
33048446|NCT04693585|No Intervention|Arm 4: control|Standard of postnatal care.
33048447|NCT04680442|Active Comparator|Control Group|Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.
33048448|NCT04680442|Experimental|Intervention Group|The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.
33048449|NCT04529551|Experimental|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
33048450|NCT04529551|Experimental|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
33048451|NCT04511065|Experimental|Intervention Group|The intervention group will be provided with a survey to determine areas of interest to guide the 7-week literacy intervention plan of completing a newsletter. Students will complete the newsletter virtually using secure Zoom meetings 2x per week for 30 minutes per session. The results of the GORT 5 and TOC will be used to determine the baseline reading skills of the students and each researcher will use the results of the assessments to guide the intervention with the newsletter topic that is chosen by the student. For example, if the GORT 5 notes deficiency with reading accuracy, the focus of the intervention will be ensuring that reading accuracy is a focus of the summary that is crafted by the student for the newsletter.
33048452|NCT04511065|No Intervention|Control Group|The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
33048453|NCT04414813|Experimental|hAESCs treatment|50 millions hAESCs are transplanted to participants with PD.
33048454|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
33048455|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
33048456|NCT04390867|Experimental|TOPS1 DBS|Participants receive TOPS1 for one week if it meets screening criteria, followed by one week each of TOPS2, TOPS3, and Standard in random order.
33048457|NCT04390867|Experimental|TOPS2 DBS|Participants receive TOPS2 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS3, and Standard in random order.
33048458|NCT04390867|Experimental|TOPS3 DBS|Participants receive TOPS3 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS2, and Standard in random order.
33048459|NCT04390867|Active Comparator|Standard DBS|Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order.
33048460|NCT04219618|Experimental|Off-Pump|
33048461|NCT04219618|Active Comparator|On-Pump|
33048462|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
33048463|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
33048464|NCT04185922|Experimental|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
33048465|NCT04185922|No Intervention|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
33048466|NCT04171999|Experimental|Usual Care + Intervention (Case)|Cases will receive the CommunityRx Intervention.
33048467|NCT04171999|No Intervention|Usual Care (Control)|Controls will receive the usual standard care, which consists of information about hospital food resources and access to Feed1st hospital food pantries prior to discharge.
33048468|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
33048469|NCT04141423|Active Comparator|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
33048470|NCT04141423|Active Comparator|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
33048471|NCT04141423|Active Comparator|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
33048472|NCT04141423|Active Comparator|Derived Dose level|Derived Dose level cohort with a sentinel dosing design (60 mg fixed preprandial dose plus an additional 30 mg postprandial rescue dose, if required)
33048473|NCT04081246|Experimental|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
33048474|NCT04042402|Experimental|Open Label|Open label, monthly subcutaneous injection
33048475|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
33048476|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
33048477|NCT03955510|Other|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
33048478|NCT03955510|Other|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
33048479|NCT03955510|Other|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
33048480|NCT03955510|Other|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
33048481|NCT03872128|Active Comparator|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
33048482|NCT03872128|Active Comparator|patients receiving 500mg PREG|Patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
33048483|NCT03872128|Placebo Comparator|placebo|Patients randomly assigned to receive a placebo daily.
33048484|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
33048485|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
33048486|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
33048487|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
33048488|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
33048489|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
33048490|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
33048491|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
33048492|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.~After the screening procedures confirm participation in the research study:~Dabrafenib will be taken twice a day for 28 consecutive days~Trametinib will be taken once a day for 28 consecutive days~PDR001 will be administered IV every 28 days."
33048493|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
33048494|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
33048495|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
33048496|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
33048497|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
33048498|NCT03531853|Experimental|Imaging patients|Get uveitis patients and ER patients to image their eyes
33048499|NCT03509896||Participants newly diagnosed with CML-CP|
33048500|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
33048501|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
33048502|NCT03206476|Active Comparator|Control group|Nutritional information
33048503|NCT02970916|Experimental|FOLFIRI+aflibercept|
33048504|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33048505|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
33048506|NCT00001151|Experimental|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
33048507|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
33048508|NCT00016302|Experimental|Regimen A|See detailed description.
33048509|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
33048510|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
33048511|NCT00016302|Experimental|Regimen D|See detailed description.
33048512|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
33048513|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
33048514|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
33048515|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
33048518|NCT03031873|Other|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
33048519|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
33048520|NCT02892955|Experimental|HeartMate 3 LVAS (HM3 LVAS)|The study was a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
33048521|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
33048522|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
33048523|NCT02754544|Experimental|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
33048524|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
33048525|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
33048526|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
33048527|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
33048528|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
33048529|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
33048530|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
33048531|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
33048532|NCT04732039|Experimental|LVAD recipients|Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
33048533|NCT04732039|Experimental|Healthy controls|Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.
33048534|NCT02179489|No Intervention|Control|surgery alone
33048535|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
33048536|NCT00001262|Experimental|Copper histidine|
33361257|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
33048537|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
33048538|NCT00001277|No Intervention|Primary hyperparathyroidism|Patients with confirmed or suspected primary hyperparathyroidism or complications
33048539|NCT00001277|Experimental|DOTATATE and F-DOPA|Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA
33048540|NCT02088190||Age group 1|Age > 60 years old
33048541|NCT02088190||Age group 2|Age < 60 years old
33048542|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
33048543|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
33048544|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
33048545|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
33048546|NCT00038389|Experimental|Vioxx MTD|
33048547|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
33048548|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
33048549|NCT00038779|Experimental|Megadose T cell depleted|
33048550|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
33048551|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
33048552|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
33048553|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
33048554|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
33048555|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
33048556|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
33048557|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
33048558|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
33048559|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
33048560|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
33048561|NCT00001304|Experimental|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
33048562|NCT00001304|Experimental|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
33048563|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
33048564|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
33048565|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
33048566|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
33048567|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
33048568|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
33048569|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
33110172|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
33361258|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
33361259|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
33361260|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
33048570|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
33048571|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33048572|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
33048573|NCT00544830|Experimental|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
33048574|NCT00001322|Experimental|Phase 1 - Lupron|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
33048575|NCT00001322|Experimental|Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
33048576|NCT00001322|Experimental|Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
33048577|NCT00039559|Other|Early detection|
33048578|NCT04731961|Active Comparator|Controls|Subjects in this arm will be administered the standard injection site protocol (15 sites).
33048579|NCT04731961|Experimental|Experimental|Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
33048580|NCT00039832|Experimental|1|CT
33048581|NCT00039832|Experimental|2|MRI
33048582|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
33048583|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
33048584|NCT00040105|Experimental|Zarnestra + Gleevec|
33048585|NCT04734249|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combined With Chemotherapy
33048586|NCT04734171|Placebo Comparator|Informational sheet (IS)|participant receives an informational sheet about COVID-19
33048587|NCT04734171|Active Comparator|IS + Video Solo|participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
33048588|NCT04734171|Active Comparator|IS + Video Friends|participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
33048589|NCT04734171|No Intervention|Control|No intervention
33048590|NCT04734093||Sohag university recruited patients|
33048591|NCT04734093||Minia university recruited patients|
33048592|NCT04734093||Assuit university recruited patients|
33048593|NCT04734093||Kasr Elini recruited patients|
33048594|NCT04734093||Tanta university recruited patients|
33048595|NCT04734093||Monofia university recruited patients|
33048596|NCT04734093||Aswan university recruited patients|
33048597|NCT04734093||Ain shams university recruited patients|
33048598|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
33048599|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
33048600|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
33048601|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
33048602|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
33048603|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
33048604|NCT04734132|Experimental|Moringa|Six Moringa oleifera capsules (400 mg dry leaf powder /capsule) consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
33048605|NCT04734132|Placebo Comparator|Placebo|Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
33048606|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
33048607|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
33048608|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
33048609|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
33048610|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33048611|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
33048612|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
33048613|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
33048614|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
33048615|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
33048616|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
33048617|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
33048618|NCT00041509|Experimental|SB424323, 500 mg BID|
33048619|NCT00041509|Experimental|SB424323, 125 mg BID|
33048620|NCT00041509|Placebo Comparator|Placebo|
33048621|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
33048622|NCT00041548|Placebo Comparator|2|oxygen
33048623|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
33048624|NCT00041782|Experimental|Dalteparin|
33048625|NCT00042211|Experimental|1|Problem Solving Treatment
33048626|NCT00042211|Active Comparator|2|Control
33048627|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
33048628|NCT00042406|Placebo Comparator|Placebo|
33048629|NCT00042406|Experimental|HuMax-CD4 80 mg|80 mg
33048630|NCT00042406|Experimental|HuMax-CD4 160 mg|160 mg
33048631|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
33048632|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
33048633|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
33361261|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
33331539|NCT04304872|Experimental|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
33331540|NCT04304872|Experimental|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
33331541|NCT04304872|Experimental|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
33331542|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
33331543|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
33048634|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
33048635|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
33048636|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
33048637|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
33048638|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
33048639|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
33048640|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
33048641|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
33048642|NCT04732234|Active Comparator|( Group A)|ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.
33048643|NCT04732234|Placebo Comparator|(Group B)|ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.
33048644|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
33048645|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
33048646|NCT02970604|No Intervention|No treatment|No treatment for 7 days
33048647|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
33048648|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
33048649|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
33331544|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
33331545|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
33331546|NCT03668392|Experimental|Patients on Oncospar|
33331547|NCT04216576|Active Comparator|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
33418434|NCT04964193|Active Comparator|Diane-35 Sugar-coated tablet|Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
33418435|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
33418436|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
33048650|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
33048651|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
33418437|NCT02095262|Active Comparator|STAR2|Reactive auditory training
33418438|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
33418439|NCT02095262|Experimental|Submarine|Interactive auditory training
33418440|NCT04814199||Patients using epidural management algorithm|Patients will be educated and given an algorithm to follow while in labour and after having an epidural catheter placed.
33418441|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
33048652|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
33048653|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
33048654|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
33418442|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
33048655|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
33048656|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
33048657|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
33048658|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
33048659|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
33048660|NCT04734327|Experimental|Orthokine periradicular injection|Ultrasound guided injections
33048661|NCT04734327|Active Comparator|Orthokine epidural injection|Ultrasound guided injections
33048662|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
33048663|NCT00001586|Experimental|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
33048664|NCT00001586|Experimental|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
33048665|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
33048666|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
33048667|NCT04731727|Experimental|Cross linking treatment for corneal thinning|Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
33048668|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
33048669|NCT00391794|Active Comparator|ES|one 4-hour educational program
33048670|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
33048671|NCT00044551|Experimental|Arm 1|
33048672|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33048673|NCT00397423|Active Comparator|1|1,G-CSF,intervention
33048674|NCT00397423|Placebo Comparator|2|2,NS,intervention
33048675|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
33048676|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
33048677|NCT00018174|Experimental|1|
33048678|NCT00018174|Placebo Comparator|2|
33048679|NCT00044590||Cases|Patients with Parkinson's Disease
33048680|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
33048681|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
33048682|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
33048683|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
33048684|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
33048685|NCT04734054|Experimental|Rapid maxillary expansion|The rapid maxillary expansion will be conducted using bonded modified Hyrax palatal expander. The expander will be activated twice daily (0.4 mm) until an overcorrection of 2-3 mm will be gained.
33418443|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
33418444|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
33048686|NCT04734054|Active Comparator|Slow maxillary expansion|The slow maxillary expansion using a removable plate with a midline screw will be accomplished. The expander will be activated twice weekly until an overcorrection of 2-3 mm will be gained.
33048687|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
33048688|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
33048689|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
33048690|NCT04731805|Experimental|Moving On After Breast Cancer - Intervention Arm|Participants are randomized to the intervention arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Participants are given the patient education materials (booklet, therapeutic exercise DVD, small ball, range of motion wand). The research assistant orients the participant to the education materials and summarizes each section of the booklet. The research assistant also teaches the participant how to do the therapeutic exercises in the booklet. All participants in the intervention also receive usual care.
33048691|NCT04731805|No Intervention|Usual Care|Participants are randomized to the usual care arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Usual care consists of pre-operative testing, pre-operative nursing education on care of the surgical incision and pain management followed by breast cancer surgery.
33048692|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
33048693|NCT00045175|Experimental|UCN-01 in combination with topotecan|
33048694|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
33048695|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
33048696|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
33048697|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33048698|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
33048699|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
33048700|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33048701|NCT04731766|Active Comparator|Citrine 5% Sodium Fluoride|It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
33048702|NCT04731766|Experimental|concocuted Nano-silver fluoride|Nano-silver fluoride (NSF) is a laboratory synthesized solution
33048703|NCT00001703|Experimental|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
33048704|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
33048705|NCT00045799|Active Comparator|Cimetidine IV|
33048706|NCT04394130|Experimental|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
33048707|NCT04394130|No Intervention|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~After the injection, the catheter will be removed.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
33048708|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
33048709|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
33048710|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
33048711|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
33048712|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
33048713|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
33048714|NCT04380207|Experimental|QPX7728|antibiotic
33048715|NCT04380207|Placebo Comparator|Placebo|Matched placebo
33048716|NCT04380207|Experimental|QPX2014|antibiotic
33048717|NCT04369560|Experimental|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
33048718|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
33048719|NCT04731493||therapeutic Education Program|"individual and group sessions will be set up with educational workshops specialized by age group (child / adolescent / transition / adult / entourage / parents), socio-administrative workshops, etc.~The objectives will be adapted to each age group and to each patient individually."
33048720|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
33048721|NCT04364880|Experimental|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
33048722|NCT04364880|Sham Comparator|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
33048723|NCT04318041|Experimental|diacerein (Artrodar)|
33048724|NCT04318041|Placebo Comparator|placebo|
33048725|NCT00397657|Active Comparator|Extended release niacin|
33048726|NCT00397657|Active Comparator|Ezetimibe|
33048727|NCT04305405|Experimental|Dose 1|Below 35 kilos
33048728|NCT04305405|Experimental|Dose 2|Greater than/equal to 35 kilos
33048729|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
33048730|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
33048731|NCT04258410|Placebo Comparator|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
33048732|NCT04258410|Experimental|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
33048733|NCT04222959|Experimental|Girls Invest Intervention|Girls Invest intervention participants will have been randomized to receive the intervention immediately upon completion of the baseline survey. Intervention participants will also complete the 6 month follow-up survey. (n=50 dyads; 100 total participants)
33048734|NCT04222959|No Intervention|Wait-List Control Condition Participants|Control condition participants will be randomized upon completion of the baseline survey and put on a wait-list to receive Girls Invest behavioral intervention after the 6 month follow-up survey. (n=50 dyads; 100 total participants)
33048735|NCT00046735|Experimental|1|
33048736|NCT04213053|Other|Concomitant strabismus patients|Horizontal strabismus surgery
33048737|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.~Continued (see detailed description)"
33048738|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
33048739|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
33048740|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and self-injection of 125ml by a volunteer (Arm I):|A volunteer layperson (research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. Then the subject will self-inject a second 125ml of TLE into his/her right anterior thigh.
33331548|NCT04216576|Experimental|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
33361262|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
33331549|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
33048741|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and 125ml by another volunteer (Arm II):|A volunteer layperson (primary research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. The primary research subject will then receive a second 125ml of TLE injected into his/her right anterior thigh by a second adult volunteer who is at least 16 years old and not a medical professional.
33048742|NCT04733781|Active Comparator|Subcutaneous injection of 250ml by a physician into a volunteer (Arm III)|A volunteer layperson (research subject), at least 16 years old, will receive 250ml of TLE injected subcutaneously into the one anterior thigh by a physician.
33048743|NCT04198311|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks
33048744|NCT05641571|Experimental|Exercise group|The 3~6 months home-based extremity exercise program will be intervened between newly diagnosed with breast cancer to the completion of chemotherapy. Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time.
33048745|NCT05641571|No Intervention|Observational group|The observational group will need to record the extra exercise performed and the exercise prescription will be distributed after the study.
33048746|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
33048747|NCT04163874|Experimental|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
33048748|NCT04163874|Placebo Comparator|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
33048749|NCT04163874|Active Comparator|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
33048750|NCT00047437|Active Comparator|2|
33331550|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
33048751|NCT00047437|No Intervention|1|
33048752|NCT05641493|Experimental|HLX208 combined HLX10|"For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.~For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks."
33048753|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
33048754|NCT05641376|Active Comparator|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia.
33048755|NCT05641376|Active Comparator|Intravenous Dexmedetomidine|Children will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
33048756|NCT04153890|Experimental|FamPALcare|Standard Care plus FamPALcare
33048757|NCT04153890|No Intervention|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
33048758|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
33048759|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
33048760|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
33048761|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
33048762|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
33048763|NCT00047827|Experimental|1|
33048764|NCT00393783|Experimental|1|HER2 ECD DNA.
33048765|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
33048766|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
33048767|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
33048768|NCT00389480|Experimental|I|Dose escalating
33048769|NCT00291447|Experimental|Cohort 1|Patients received a single infusion of 5 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
33048770|NCT00291447|Experimental|Cohort 2|Patients received a single infusion of 10 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
33048771|NCT00291447|Experimental|Cohort 3|Patients received a single infusion of 20 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
33048772|NCT00291447|Experimental|Cohort 4|Patients received a single infusion of 40 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
33048773|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
33048774|NCT00048139|Experimental|1|
33048775|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
33361263|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
33361264|NCT05401669|Experimental|Trans-radial artery access|
33361265|NCT05401669|Active Comparator|Trans-femoral Artery access|
33048776|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
33048777|NCT05641337|Experimental|group with new combination therapy|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day.
33048778|NCT05641337|Active Comparator|group with intensive insulin therapy|group was treated with intensive insulin therapy.The initial total amount of insulin is 0.5U/kg, of which 40% is basal insulin and 20% is aspart insulin before three meals
33048779|NCT04712370|Active Comparator|Conventional caudal block|Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block
33048780|NCT04712370|Experimental|Ultrasound-guided caudal block|Patients of this group will receive caudal block using ultrasound.
33048781|NCT04712370|Experimental|Ultrasound guided erector spinae plane Block|Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .
33048782|NCT02970526||colorectal cancer survivors|
33048783|NCT05641220||Biopsy|Newly diagnosed elderly (>70 years of age) glioblastoma patients who undergo biopsy
33048784|NCT05641220||Resection|Newly diagnosed elderly (>70 years of age) glioblastoma patients who undergo resection
33048785|NCT00048646|Placebo Comparator|placebo|placebo
33048786|NCT00048646|Experimental|IV progesterone|IV progesterone
33331551|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
33331552|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
33331553|NCT04176016|Experimental|Single Study Arm, no competitor|
32869563|NCT04911543|Experimental|Part B: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of Part B to measure the uptake, distribution, and clearance of [18F]-JNJ-70099731 and to model the tissue specific kinetics of [18F]-JNJ-70099731 in the human brain with the appropriate arterial input function.
33331554|NCT05668832|Experimental|oral intake of UVB-exposed mushrooms|Daily intake of 500 g of UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
33048787|NCT05641181|Experimental|CRB4101 100mg dose group|Participants will receive a single oral dose of 100mg of CRB4101
33048788|NCT05641181|Experimental|CRB4101 200mg dose group|Participants will receive a single oral dose of 200mg of CRB4101
33048789|NCT05641181|Experimental|CRB4101 400mg dose group|Participants will receive a single oral dose of400mg of CRB4101
33048790|NCT05641181|Experimental|CRB4101 800mg dose group|Participants will receive a single oral dose of 800mg of CRB4101
33048791|NCT05641181|Experimental|CRB4101 1200mg dose group|Participants will receive a single oral dose of 1200mg of CRB4101
33048792|NCT05641181|Experimental|CRB4101 1600mg dose group|Participants will receive a single oral dose of 1600mg of CRB4101
33048793|NCT05641181|Placebo Comparator|placebo group|Subjects will receive a placebo
33048794|NCT05576298|Experimental|TR sequence|Experimental:Insulin degludec injection (RD15003)+Tresiba Subjects receive Insulin degludec injection(RD15003) in the first cycle and Tresiba in the second cycle.
33048795|NCT05576298|Experimental|RT sequence|Experimental:Tresiba+Insulin degludec injection (RD15003) Subjects receive Insulin Tresiba in the first cycle and degludec injection(RD15003) in the second cycle.
33048796|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
33048797|NCT05576259|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
33048798|NCT05576259|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
33048799|NCT05641064|Placebo Comparator|Saline|Continuous infusion of saline starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
33048800|NCT05641064|Experimental|Dexmedetomidine 0.5|Continuous infusion of dexmedetomidine in dose 0.5 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
33048801|NCT05641064|Experimental|Dexmedetomidine 1|Continuous infusion of dexmedetomidine in dose 1 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
33048802|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
33048803|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
33048804|NCT05576181|Experimental|ThisCART19A cells infusion and HSCT|"In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.~After patients achieve MRD- remissions through ThisCART19A, they will subsequently receive hematological stem cell transplantations."
33048805|NCT05640947|Experimental|LAMS gastro-gastrostomy|
33048806|NCT00049309|No Intervention|Control|Usual diet
33048807|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
33331555|NCT05668832|Placebo Comparator|oral intake of non-UVB-exposed mushrooms|Daily intake of 500 g of non-UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
33331556|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
33418445|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
33048808|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
33048809|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
33048810|NCT05640908||Prospective|Participants who have scheduled spinal fusion with pelvic fixation/fusion using iFuse Bedrock Granite. These participants will be followed for 2 years.
33048811|NCT05576142||Case Group|Patients from this group were diagnosed from allergic rhinitis and/or asthma.
33048812|NCT05576142||Control Group|Healthy children.
33048813|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
33048814|NCT05640791|Experimental|Gemcitabine, cisplatin, nab-paclitaxel, durvalumab|Participants receive nab-paclitaxel over 30 minutes, cisplatin over 60 minutes, and gemcitabine over 30 minutes on days 1 and 8; durvalumab over 60 minutes on days 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
33048815|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
33048816|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
33048817|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
33048818|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
33048819|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
33048820|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
33048821|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
33048822|NCT05640713|Experimental|ThisCART19A cells infusion|In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.
33048823|NCT05640635|Active Comparator|Ventilator weaning first|
33048824|NCT05640635|Active Comparator|ECMO weaning first|
33048825|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
33048826|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
33048827|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
33048828|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
33048829|NCT00397774|Other|No exercise|Best supportive care, no exercise
33048830|NCT00389558|Active Comparator|2|Biseptine
33048831|NCT00389558|Active Comparator|1|Amukin
33048832|NCT05576103||Primary brain tumour patients receiving RT|Primary brain tumor patients are screened at time of consultation for this observational study, and the study population is diverse across sex/gender, and racial/ethnic groups.
33418446|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
33418447|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
33418448|NCT05655819|Active Comparator|Glutamine Group|Subjects will receive glutamine for 28 days.
33418449|NCT05655819|Placebo Comparator|Placebo Group|Subjects will receive placebo for 28 days.
33418450|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
33048833|NCT00389636|Active Comparator|1|TheraGauze alone
33418451|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
33418452|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
32869564|NCT04911543|Experimental|Part C: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of each period of Part C to determine the test-retest variability in the regional brain kinetics and binding properties of [18F]-JNJ-70099731.
33048834|NCT00389636|Active Comparator|2|Theragauze + Regranex
33048835|NCT04731337|Active Comparator|Patient's normal canine occlusal relationship|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
33048836|NCT04731337|Sham Comparator|Canine occlusal relationship after full mouth rehabilitation|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
33048837|NCT05640440||children who stutter|assessment executive function and stuttering severity in 30 child with stuttering
33048838|NCT05640440||children who don't stutter|assessment executive function in 30 child with stuttering
33048839|NCT05574660|Experimental|High-Fat/High-Sugar (HF/HS) Diet|Participants randomized to consume an HF/HS yoghurt (40.8 % kcal from fat, 45.6 % kcal from carbohydrates, 13 % kcal from protein of 79.5 total kcal) two times a day for eight weeks in addition to their normal diet.
33048840|NCT05574660|Experimental|Low-Fat/Low-Sugar (LF/LS) Diet|Participants randomized to consume an LF/LS yoghurt (17.1 % kcal from fat, 29.1 % kcal from carbohydrates, 51.9 % kcal from protein of 78 total kcal) two times a day for eight weeks in addition to their normal diet.
33048841|NCT05640362|Placebo Comparator|Benzydamine mouthwash|
33048842|NCT05640362|Experimental|Natural enzymes mouthwash|
33048843|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
33048844|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
33048845|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
33048846|NCT05640167|Other|EMPOWER PD Clinic Participation|All participants will be assigned to the same interdisciplinary clinic and educational intervention
33048847|NCT05574543|Experimental|0.25 mg AGA111|0.25 mg AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
33048848|NCT05574543|Experimental|0.5 mg AGA111|0.5 mg AGA111 in ABC is locally delivered to the participants at the intervertebral space.
33048849|NCT05574543|Placebo Comparator|Placebo|Placebo in ABC is locally delivered at the intervertebral space.
33048850|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
33048851|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
33048852|NCT05574465|Other|Manometry Device|At 10 minutes prior to anticipated removal of the endotracheal tube, pass the routine manometry catheter per naris to 30 cms.
33048853|NCT05640128|Other|Aldosterone in HPLC-MS/MS,|Aldosterone in HPLC-MS/MS measurement
33048854|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
33048855|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
33048856|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
33048857|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
33048858|NCT05574426|Experimental|Cardiovascular Movement Breaks|Participants will perform 3-4 exercise snacks (30-60s bursts of exercise) on at least 3 days of the week. The exercises prescribed in this arm will be designed to increase heart rate.
33048859|NCT05574426|Active Comparator|Mobility Movement Breaks|Participants will perform 3-4 mobility snacks (30-60s of mobility exercises or stretching) on at least 3 days of the week. The exercises prescribed in this arm are not designed to increase heart rate.
33048860|NCT05640050|Experimental|Audit Implementation with Community Engagement|This feasibility and implementation research implementing in secondary level care hospitals (Tehsil Head Quarters THQ) at Matiari district of Sindh Province, Pakistan. The audit committees will be established in three THQs including management, specialist, medical officer, and community representatives from catchment area.The implementation phases follow the standard World Health Organization (WHO) audit system. The initial step includes identifying death cases for review and subsequently collecting the detailed information on the near miss and adverse event history. A mixed methods data analysis will include both quantitative components, such as identification of trends in rates and causes of death and geographic location, and qualitative components, such as analysis of modifiable factors. A monthly monitoring cycle will be set up within the implementing facilities to ensure effective implementation of the audit systems.
33048861|NCT05574348|Experimental|PO2 - Control|"This arm will start with PO2, followed by Control. The PO2 consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2 but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
33418453|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
33048862|NCT05574348|Experimental|Control - PO2|"This arm will start with Control, followed by PO2. The PO2 consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2 but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
33048863|NCT05639777|Experimental|Intranasal|That will receive intranasal dexmedetomidine (1.5mcg/kg)
33048864|NCT05639777|Placebo Comparator|control group|That will receive the same volume of 2 ml of intranasal normal saline
33048865|NCT05574192|Other|Social Engagement Intervention|The social engagement intervention includes in-person visits by peer-workers to undertake accompanied social activities with enrolled participants. Each visit will last one hour, occur two times per month over a 12 month period. Activity categories will be self-selected by participants based on physical abilities and interests. Categories include: a) arts based activity; b) physical activity.
33048866|NCT05636774|Experimental|Heart failure medication arm|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin
33048867|NCT05636774|Placebo Comparator|Placebo arm|Placebo tables / infusion
33331557|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
33048868|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
33048869|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
33048870|NCT05636189|Active Comparator|warming group|warming of the patient with whole body warming blanket in the OR during induction of anesthesia, prewarmed intravenous fluid during the operation.
33048871|NCT05636189|No Intervention|no warming group|There will be no whole body warming during induction.
33048872|NCT05574075||group of preterm and term children|group 1: preterm children group 2: term children
33048873|NCT05574075||group of different ages of preschool children|group 1: children with age of 25 months-36 months group 2: children with age of 37 months-48 months group 3: children with age of 49 months-60 months
33048874|NCT04731532|Active Comparator|Classical respiratory physiotherapy application|Patient positions, postural drainage application tapping and trifled
33048875|NCT04731532|Active Comparator|classical respiratory physiotherapy with thoracic vibration|Thoracic Vibration: The physiotherapist places his hands open with his / her fingers on the front and side walls of the patient's chest when the elbow is at 5-10 degrees of flexion. The elbow expands the patient's chest with vibrations. Exercise can be repeated 5-10 times a day+Patient positions, postural drainage application tapping and trifled
33048876|NCT05636072|Experimental|Treatment Immediately|Participants will engage in well-being tools immediately for 1-week.
33048877|NCT05636072|No Intervention|Waitlist Control|Participants will wait 1 week to begin the well-being tools.
33048878|NCT04731415|Other|Healthy pregnant women|Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.
33048879|NCT05573958|Experimental|Arm A: Rivaroxaban, Clopidogrel, and Aspirin|Rivaroxaban 2.5 mg tablet twice daily orally, Clopidogrel 75 mg tablet once daily orally, and Aspirin 81 mg tablet once daily
33048880|NCT05573958|Active Comparator|Arm B: Clopidogrel and Aspirin|Clopidogrel 75 mg tablet once daily, and Aspirin 81 mg tablet once daily
33048881|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
33048882|NCT05635136||The DIVAT cohort|"patient > 18 years of age who received renal transplant are registered in the DIVAT cohort (standing for computerized and validated data in transplantation, Données Informatisées VAlidées Transplantation). It comprises more than 300 clinical and biological parameters collected at the time of transplant, at 3 months, 6 months and at each anniversary of the transplant. The DIVAT cohort and network is accredited by the CNIL (standing for Commission Nationale de l'Informatique et des Libertés)"
33048883|NCT05573880|Experimental|generalized joint hypermobility|
33048884|NCT05573880|Experimental|without generalized joint hypermobility|
33048885|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
33048886|NCT05635058|Experimental|Reminisence Therapy|The participants in the intervention group received reminiscence therapy which was implemented by the researcher as one session per week for eight weeks. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher.
33331558|NCT04101526|No Intervention|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
33331559|NCT04101526|Experimental|Videoconference Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Behavioral: New Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
33331560|NCT04101526|No Intervention|Waitlist control group|No intervention until 6 weeks after the baseline assessment, at which point participants complete a follow-up assessment and then are offered the new CBT-I intervention.
33331561|NCT04497948|Other|Single Arm|Single Arm
33331562|NCT05126992||AZD1222|at least one dose of AZD1222
33331563|NCT05126992||comparator 1|concurrent unvaccinated
33331564|NCT05126992||comparator 2|historical controls
33331565|NCT05126992||comparator 3|"active comparators*~*Feasibility of the active comparator analysis will be assessed prior to conducting the analysis to ensure comparability between groups"
33048887|NCT05635058|No Intervention|Control Group|"Interviews were conducted with the individuals in the control group on a designated day of the week, at a designated place in the nursing home. The researcher interviewed the individuals in the control group once a week for eight weeks. During these meetings, daily issues and events such as health, sports, and weather were discussed. Each of the mentioned interviews lasted 45-60 minutes. At the end of eight weeks, SMMT and the Multidimensional Observation Scale for Elderly Individuals were implemented again to the participants in the intervention and control groups."
33331566|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
33331567|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
33048890|NCT00052195|Placebo Comparator|B|
33048891|NCT00052195|Experimental|A|
33048892|NCT05634551||Questionnaires (All Participants)|If participants are found to be eligible and agree to take part in the study, information about you (such as age, gender, race, ethnicity, marital status, education, employment status, religious beliefs, and information about your cancer diagnosis and history, current therapy and goal of cancer therapy) will be collected.
33048893|NCT05634551||Interview (Some Participants)|Not every participant will be asked to have an interview. It is expected that about 20-30 participants will take part in the interview part of the study.
33048894|NCT04731454|Experimental|Healthy Nordic Diet (ND)|A healthy diet meeting and exceeding the Nordic Nutrition Recommendations and with more than 80% foods from the Nordic region.
33048895|NCT04731454|Experimental|Control Diet (CD)|A control diet approximating the average depressed person's diet, i.e. of somewhat lower quality than the average Swedish diet.
33048896|NCT05634122|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
33048897|NCT05634122|Active Comparator|Treatment as Usual (TAU)|Standard care. The standard treatment would generally be pharmacological to address chronic pain, adjusted to the symptomatic profile of each patient.
33048898|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
33048899|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
33048900|NCT05573412||All Particpants|Group contains all participants as this is a systemic review of stem cell cryopreservation techniques
33048901|NCT05633927||Non-immunological responder|Patients who start ART with <350 CD4+ T cells, maintaining undetectable viral load, and increasing <200 CD4+ T cell count after 18 months of follow-up.
33048902|NCT05633927||Immunological responder|Patients with >350 CD4+ T cells
33048903|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33048904|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
33048905|NCT05633888|Experimental|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
33048906|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
33048907|NCT00052936|Experimental|S6|6x CHOP-14
33048908|NCT00052936|Experimental|R6|6x CHOP-14 + 8x Rituximab
33048909|NCT00052936|Experimental|S8|8x CHOP-14
33048910|NCT00052936|Experimental|R8|8x CHOP-14 + 8x Rituximab
33048911|NCT05573178|Experimental|Ablation of left atrial ganglion plexus|In this arm, ablation of GPs will only performed in the left atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP) and right interior ganglion plexus（RIGP).
33048912|NCT05573178|Experimental|combined ablation of left and right atrial ganglion plexus|In the arm the, ablation of GPs will perform in both atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP), right interior ganglion plexus (RIGP), and superior vena cava ganglion plexus (SVCGP). SVCGP were ablated in the right atrium，the left GPs were ablated through the left atrium
33331568|NCT04805008|Experimental|Intervention|Lactation cookies
33331569|NCT04805008|Placebo Comparator|Control|Control cookies
33331570|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
33331571|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
33331572|NCT04650646|Experimental|Hypoglycaemic clamp i combination with exercise|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
33048913|NCT05633849|Placebo Comparator|Placebo group|In placebo group, participants were instructed to take two 500 mg olive oil placebo (placebo group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
33048914|NCT05633849|Experimental|Specialized pro-resolving mediators (SMP) group|In SPM group, Participants were instructed to take two 500 mg softgels of LIPINOVA after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
33048915|NCT02970253|Active Comparator|Capsular resection|Capsular resection
33418454|NCT04865497|Experimental|High dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
33418455|NCT04865497|Experimental|Low dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
33418456|NCT04865497|Other|Adjuvant-free Group|Adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
33048916|NCT02970253|Active Comparator|Capsular retention|Capsular retention
33048917|NCT05573139|Experimental|muscle strength assessment|
33048918|NCT05633498|Experimental|Self-help book|A self-help book for coping with shift work
33048919|NCT05633498|Active Comparator|Sleep hygiene advice|A sheet of paper with basic and standard sleep hygiene advice
33048920|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
33048921|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
33048922|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
33048923|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
33048924|NCT05572983|Experimental|Chidamide in Combination With CHOP|Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.
33048925|NCT05633225||Patient-group|Ninety adolescents, 13-17 years of age Diagnosed with Hypermobility Spectrum Disorder or hypermobile Ehlers Danlos Syndrome.
33048926|NCT05633225||Control-group|Ninety adolescents, 13-17 years of age. Participants have to be pain free at time of investigation (NRS score <3/10)
33048927|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
33048928|NCT05572905|Experimental|Young lean men and women|25 to 40 y.o. participants with body mass index in range of 18.5 to 25
33048929|NCT05572905|Experimental|Young obese men and women|25 to 40 y.o. participants with body mass index in range of 30 to 45.
33048930|NCT05572905|Experimental|Elderly men and women|65 to 80 y.o. participants with body mass index in range of 18.5 to 30.
33048931|NCT05633069||Patients requiring orotracheal intubation or tracheostomy|"Patients hospitalized in the surgical Intensive Care Unit (ICU) of the University Hospital of Saint-Etienne between September 2015 and August 2016 for medical-surgical pathologies, requiring orotracheal intubation or tracheostomy, and presenting on the day of recording a Riker sedation score of 3 or 4 will be included.~Datas analysed by medical records."
33048932|NCT05572866||2019|No intervention will be carried out. The sum total of surgeries carried out during 2019 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
33048933|NCT05572866||2020|No intervention will be carried out. The sum total of surgeries carried out during 2020 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
33048934|NCT05572866||2021|No intervention will be carried out. The sum total of surgeries carried out during 2021 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
33048935|NCT05572866||2022|No intervention will be carried out. The sum total of surgeries carried out during 2022 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
33048936|NCT05632055||Pregnancy with GDM|Pregnant women who positive test for 100gm OGTT (abnormal 2 or more blood glucose level according NDDG (National Diabetes Data Group) criteria)
33048937|NCT05632055||Pregnancy without GDM|Pregnant women who negative test for 100gm OGTT
33048938|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
33048939|NCT04731220||Study group|Newly diagnosed as bile duct cancer
33048940|NCT04731220||Control group|No history of cancer in previous 5 years
33048941|NCT05572788|Active Comparator|Rectal Indomethacin|Patients assigned to the Indomethacin group will receive100 mg of indomethacin administered per rectal route (two tablets of 50 mg indomethacin suppositories)
33048942|NCT05572788|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive two glycerin suppositories.
33048943|NCT05631860||DanFunD baseline|The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
33048944|NCT05631860||DanFunD 5-years follow-up investigation|The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
33048945|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
33048946|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
33418457|NCT04865497|Other|Control Group|Haemophilus b Conjugate Vaccine,10μg/dose
33418458|NCT02100878||Lean adolescents|
33418459|NCT02100878||Obese adolescents|
33048947|NCT05629520||Participants with Major Depressive Disorder including TRD|Treatment resistant depression (TRD) participants are defined as participants with Major Depressive Disorder (MDD) who fail to respond to at least two lines of antidepressant medication treatment interventions.
33048948|NCT05572671|Experimental|fMRI smoking lapse task|
33048949|NCT02970019|Experimental|K0706|K0706 will be administered once a day
33418460|NCT05665725|Experimental|Treatment (siltuximab, biospecimen)|Patients receive siltuximab IV prior to CE19.CAR-T cell therapy and as clinically indicated on study. Patients undergo CT scan or PET scan throughout the trial. Patients also undergo blood sample collection during screening and on study.
33048950|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
33048951|NCT05626790|Experimental|PNF Stretching|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. In addition to the exercises, three different types of PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.
33048952|NCT05626790|Active Comparator|Prolonged Stretching|"All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.~In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week."
33048953|NCT05572554|Experimental|Foot Bath Group|"This group of elderly people were taught the foot bath practically by a researcher at the pre-study meeting and were given the Foot Bath Information Brochure and a personalized water thermometer. The other researcher administered the Elderly Information Form and PSQI to all elderly people before the study using individual interviews lasting approximately 15 minutes and pen and paper method. The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks. In addition, the PSQI, which provides information about sleep quality, type, and severity of sleep disturbance, was applied to the elderly before the study (pretest), 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times during 8 weeks."
33048954|NCT05572554|No Intervention|Control Group|No application was made to the elderly in this group. Only the PSQI, which gives information about sleep quality, type, and severity of sleep disturbance, was administered to the elderly before the study (pretest), at the 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times for 8 weeks.
33048955|NCT05626595|Experimental|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the early learning and childcare centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
33048956|NCT05626595|Sham Comparator|Project|"The PRO-ECO project to increase the quality of outdoor play involves four primary components:~Modifying ELCC's outdoor play policies: the ELCC policy on outdoor play requirements and procedures will be modified in conjunction with ELCC management.~ECE training and mentorship:~ECEs will undergo the Learning Outside Together (LOT) program, which incorporates traditional wisdom into training on Indigenous ways of knowing, learning and experiencing the land as teacher.~ELCC outdoor space modification:~This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~Parent engagement:~ELCCs will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
33048957|NCT04731259|Experimental|ATR-04|The intervention is an ointment that will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
33048958|NCT04731259|Placebo Comparator|Placebo|Placebo ointment will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
33048959|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
33048960|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
33048961|NCT05626478|Active Comparator|Arm 1 - Cataract surgery gtt regimen per SOC|Following cataract surgery patients will receive: Prednisolone Acetate 1% QID X 2 Weeks, then BID x 2 weeks and stop / Moxifloxacin 0.5% QID X 1 Week and stop /Prolensa 0.07% QD X 4 Weeks and stop.
33048962|NCT05626478|Experimental|Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen|Following cataract surgery with DEXTENZA, patients will receive: Moxifloxacin 0.5% QID X 1 Week and stop /Prolensa 0.07% QD X 4 Weeks and stop
33048963|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
33048964|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
33048965|NCT00053833|Experimental|irinotecan|irinotecan
33048966|NCT05570682|Active Comparator|Manual induction|General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol 2 mg/kg, Rocuronium 0.6 mg/kg General Anesthesia mainteneance: Propofol 4-6 mg/kg/h to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)
33418461|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
33418462|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
33418463|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
33418464|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
33331573|NCT04650646|Experimental|Hypoglycaemic clamp in combination with bed rest|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with bed rest. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
33048967|NCT05570682|Experimental|Target Controlled Induction|"General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol TCI with Schneider site effect model starting from 2 mcg/ml and increasing the dose untile loss of consciousness, Rocuronium 0.6 mg/kg.~General Anesthesia mainteneance: Propofol TCI with Schneider site effect model in order to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)"
33048968|NCT05624918|Experimental|Investigational Group|"Nab-paclitaxel + gemcitabine + NovoTTF-200T for 3 cycles (28 day cycles)~Participants who have stable disease or better after the first 3 cycles of treatment will undergo pancreatectomy within 8 weeks of receiving treatment. If the surgery yields R0 or R1 then patient will receive another 3 cycles of treatment regimen (within 8 weeks of surgery).~Those who do not undergo surgery will still be included in the evaluable patients for the objectives"
33048969|NCT05569902|Experimental|Active tACS|Participants in this group received 20 minutes of active 6 Hz stimulation over the medial prefrontal cortex.
33048970|NCT05569902|Sham Comparator|Sham tACS|Participants in this group received 20 minutes of sham stimulation over the medial prefrontal cortex.
33048971|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
33048972|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
33048973|NCT05568069|Experimental|Intervention|ICD or CRTD fitted
33048974|NCT05568069|No Intervention|Control|No ICD fitted (with Implantable Loop Recorder) or Cardiac Resynchronisation Therapy Pacemaker (CRTP)
33048975|NCT05568069|No Intervention|Registry|Usual medical care
33048976|NCT00054184|Experimental|Study drug|
33048977|NCT05621525|Experimental|Part A Dose Escalation and Part B Dose Expansion|"Part A: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).~Part B: Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)"
33048978|NCT05619458|Experimental|Mindfulness intervention|The intervention will consist of 6 one-hour sessions delivered once per week in a classroom at an alternative high school during normal school hours.
33048979|NCT05567250|Experimental|Experimental Intervention + Usual Care|Intervention group families will receive usual care and they will be connected via telephone to 211LA.
33048980|NCT05567250|No Intervention|No Intervention: Usual Care|This group will receive usual care
33048981|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
33048982|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
33048983|NCT05560230|Experimental|Clonidine|A 100 ml isotonic saline will be mixed with 1 ml clonidine (150 μg). The blinded 100 ml bag including isotonic saline and clonidine 150 μg will be infused over 5-10 min., immediately after intubation.
33048984|NCT05560230|Placebo Comparator|Isotonic saline|A 100 ml isotonic saline will be mixed with 1 ml isotonic saline. The blinded 100 ml bag including isotonic saline will be infused over 5-10 min., immediately after intubation.
33048985|NCT05616338|Experimental|Eligible patients|
33048986|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
33048987|NCT05615519||Eligible participants for smartphone-based strabismus measurement and diagnosis|Facial videos dataset Facial videos were collected using smartphone and following the programmatic cover tests.
33048988|NCT05556993||LGBTQIA+ Persons living with Parkinson's Disease|125 LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45-minute phone survey.
33048989|NCT05556993||Non- LGBTQIA+ Persons living with Parkinson's Disease|125 Non- LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45- minute phone survey.
33048990|NCT05556993||LGBTQIA+ caregivers of people living with Parkinson's Disease|125 LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
33048991|NCT05556993||Non- LGBTQIA+ caregivers of people living with Parkinson's Disease|125 non- LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
33048992|NCT05556993||Health care providers of people living with Parkinson's Disease|100 health care providers of people living with Parkinson's Disease will complete a 45-minute online survey.
33048993|NCT05612243|Experimental|Yogurt enriched with probiotics and polyphenols|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g)
33331574|NCT04800666|Experimental|Facial Nerve Block Group|Facial Nerve Block and oral Mecobalamin Tablets
33331575|NCT04800666|Experimental|Stellate Ganglion Block Group|Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
33331576|NCT04800666|Experimental|D Group|Facial Nerve Block
33331577|NCT04800666|Other|C Group|control
33331578|NCT04794270|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
33331579|NCT04794270|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
33331580|NCT04567186|Experimental|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control).
33331581|NCT04567186|Experimental|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test).
32869565|NCT04908579|Active Comparator|- GROUP (I): 30 patients|
32869566|NCT04908579|Active Comparator|- GROUP (II): 30 patients|
33048994|NCT05612243|Active Comparator|Yogurt enriched with probiotics|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
33048995|NCT05612243|Placebo Comparator|Plain yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
33048996|NCT05609591|Experimental|Liquid diet group|From 8:00 on the day before colonoscopy, oral fluids including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were taken to ensure energy intake and blood glucose stability. The fasting starts at 9:00 AM on the day of colonoscopy.
33048997|NCT05609591|Experimental|Enteral nutrition group|Oral administration of 100% short peptide enteral nutrition preparation from 8:00 on the day before colonoscopy. The fasting starts at 9:00 AM on the day of colonoscopy.
33048998|NCT05609591|Experimental|Low residual diet group|From 8:00 on the day before colonoscopy, the patients were given oral administration of less residue food included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. The fasting starts at 9:00 AM on the day of colonoscopy.
33048999|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
33049000|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
33049001|NCT05545878|Experimental|Intervention: Super enhanced single vision lens 01 for spectacles|Participants in the intervention group will wear the newly designed SESL01 lens with anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
33049002|NCT05545878|No Intervention|Control: Standard single vision lenses with an anti-reflection coating|Participants in the control group will be corrected with standard single vision lenses with an anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
33049003|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
33049004|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
33049005|NCT05609435|Experimental|REASSURE Follow Up care|
33049006|NCT05609435|No Intervention|Usual Follow Up Care|
33049007|NCT05539287|Placebo Comparator|Control group|25 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
33049008|NCT05539287|Experimental|Probiotic Group|25 patients will receive Lactobacillus species 5 billion colony forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
33049009|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
33049010|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
33049011|NCT05607056|Experimental|Probiotic|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
33049012|NCT05607056|Placebo Comparator|Placebo|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
33049013|NCT00398359|Experimental|1|
33049014|NCT05531643|Experimental|Active TENS|TENS delivered for 20 minutes to the forehead via the active Cefaly (R) device; at least 3 times per week in-home; for 6 months.
33049015|NCT05531643|Sham Comparator|Sham TENS|Sham TENS delivered for 20 minutes to the forehead via the sham Cefaly (R) device; at least 3 times per week in-home; for 6 months.
33049016|NCT05606159|Experimental|Bacillus velezensis DSM 33864|"This arm will receive a single strain probiotic capsule containing Bacillus velezensis DSM 33864 (DifProtecTM).~The probiotic will be taken orally, once a day, for 8 weeks."
33049017|NCT05606159|Placebo Comparator|Placebo control group|A placebo capsule containing microcrystalline cellulose will be taken orally, once a day, for 8 weeks.
33049018|NCT05527704|Active Comparator|CPAP+Salbutamol|All patients will receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulised salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
33049019|NCT05527704|Placebo Comparator|CPAP+Placebo|Patients in the placebo group will also receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. In addition, patients will receive 3 mL nebulised 0.9% NaCl administered for 30 min. as a placebo
33331582|NCT05460156|Experimental|NM Bridges|Receive NM Bridges supportive care from trained personnel
33331583|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
33049020|NCT05604482|Experimental|CXCR4-PET experimental group|In addition to the current standard of imaging in GCA, using FDG-PET/CT, participants receive CXCR4-PET.
33049021|NCT05525325|Active Comparator|General Anesthesia Group|Patients randomized to the GA arm are intubated after anesthetic induction.
33049022|NCT05525325|Experimental|Procedural Sedation Group|After randomization into the PS arm, the need for analgesics or sedatives are evaluated clinically.
33049023|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
33049024|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
33049025|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
33049026|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
33049031|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
33049032|NCT05596292|Experimental|early mobilization protocol and immersive virtual reality|Three days of an early mobilization protocol using immersive virtual reality glasses. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation. The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
33049033|NCT05596292|Active Comparator|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
33049034|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
33049035|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
33049036|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
33049037|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
33049038|NCT05590754||Experimental Group|8 participants (4 males, 25.5±4.4 years, 63.5±10.6 kg, 163.2±5.6 cm)
33049039|NCT05590754||Observational Group|8 participants (3 males, 27.0±2.0 years, 68.4±11.8 kg, 176.5±10.9 cm
33049040|NCT00056056|Experimental|Bexarotene and PUVA|
33049041|NCT00056056|Active Comparator|PUVA|
33049042|NCT00056095|Experimental|Allograft (compatible family member)|
33049043|NCT00056095|Other|Allograft (compatible non-family member)|
33049044|NCT05587127|Experimental|Cognitive Behavioral Therapy|Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.
33049045|NCT05587127|No Intervention|Usual Care|In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.
33049046|NCT05499000|Experimental|Experimental group|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS pre-tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the second session, post-test data will be obtained with SUE, PMSS."
33049047|NCT05499000|No Intervention|Control group|KBF, SUE and PMSS pre-tests will be applied to the participants, SUE, PMSS and post-test data will be obtained simultaneously with the experimental group.
33049048|NCT05556824|Active Comparator|Proton Pump Inhibitor (PPI) Partial Responders - Drug Product|Panosyl-isomaltooligosaccharide (PIMO) liquid 1 g (1.5 ml) per day for 8 weeks
33049049|NCT05556824|Placebo Comparator|Proton Pump Inhibitor (PPI) Partial Responders - Placebo|Placebo liquid (1.5 ml) per day for 8 weeks
33418465|NCT05222607||Facial treatment with incobotulinumtoxinA in treatment naïve participants|
32869567|NCT04908579|Active Comparator|- GROUP (III) (Control): 30 patients|
33049050|NCT05556824|Active Comparator|Proton Pump Inhibitor (PPI) Responders - Drug Product|Panosyl-isomaltooligosaccharide (PIMO) liquid 1 g (1.5 ml) per day for 8 weeks
32869568|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
33049051|NCT05556824|Placebo Comparator|Proton Pump Inhibitor (PPI) Responders - Placebo|Placebo liquid (1.5 ml) per day for 8 weeks
33049052|NCT00056290|Active Comparator|1|VEGF
33049053|NCT00056290|Placebo Comparator|2|Placebo
33331584|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
33331585|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
33331586|NCT04471168|Experimental|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
33049054|NCT05467917||Index Case|a) minor testing positive for SARS-CoV-2; b) symptomatic health workers or any individual with a history of exposure to SARS-CoV-2 confirmed positive patients; c) health workers or any individual who tests positive regardless of symptoms. Index case must be living in a multi-person household that includes at least one child with a history of exposure to SARS-CoV-2 positive patients
33049055|NCT05467917||Household Contact|Anyone residing in the house for at least 24 hours at the time of the index case diagnosis or study enrollment.
33331587|NCT04471168|Sham Comparator|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
33049056|NCT00056329|Experimental|1|vitamin E plus multivitamin
33049057|NCT00056329|Placebo Comparator|2|placebo with multivitamin
33049058|NCT05540678|Placebo Comparator|Placebo|Chewing gum containing maltitol powder
33049059|NCT05540678|Experimental|Investigational|chewing gums containing fibers
33049060|NCT05540678|No Intervention|No-treatment control|No study chewing gum
33049061|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
33049062|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
33049063|NCT05463081|Experimental|Genitourinary disorder|"Participants with:~stress urinary incontinence,~mixed urinary incontinence with a predominance of the stress component,~genitourinary menopausal syndrome,~dystrophic and atrophic processes in the genital area,~scleroatrophic changes in the urogenital region.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
33049064|NCT05463081|Experimental|Relaxation of vagina|"Participants with:~prolapse of the genitals I-II degree,~vaginal relaxation syndrome,~postpartum recovery,~sexual dysfunctions,~restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes),~preoperative preparation for genital prolapse surgery and postoperative rehabilitation.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
33049065|NCT05539469|Experimental|Trial group|Patients from this group will be assisted by Orthodontika application during orthopedic treatment. Reminders will be sent for the activation of Rapid Maxillary Expander and for oral hygiene maneuvers. Written information about orthopedic treatment and oral hygiene tips can be read.
33049066|NCT05539469|Other|Control group|Patients from this group will not have access to Orthodontika application during orthopedic treatment. Patients will receive only verbal instruction about the activation of Rapid Maxillary Expander and for oral hygiene maneuvers.
33049067|NCT05437692|Experimental|zimberelimab plus concurrent radiotherapy and chemotherapy|19 patients will treated with zimberelimab plus concurrent radiotherapy and chemotherapy
33049068|NCT05525975|No Intervention|Control/Standard of Care|This arm will follow the standard of care practices of the Shoulder Surgery Department at UIHC, and will work as a control group.
33049069|NCT05525975|Experimental|Education Arm|"Participants in this arm will receive at their preoperative work-up visit a brochure and will watch an educational video. Both educational materials (brochure and video) will address information about opioid medications, pain management techniques and properly disposal of any excess opioid medication. In addition, participants receive an envelope in which they will be able to dispose their unused opioid pills. These envelopes will be the same ones used in our pilot study (IRB# 202012142). The disposal method consists of secured, labeled envelopes to dispose of the excess of Opioid medication. These envelopes will be provided by Sharps Compliance, Inc., a company that manages pharmaceutical waste disposal programs for healthcare facilities. Through their TakeAway Medication Recovery System Envelope (USPS) they allow the collection and disposal of controlled substances (Schedules II-IV) and non-controlled medications."
33049070|NCT05509283|No Intervention|Passive control|Patients in the passive control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
33049071|NCT05509283|Experimental|Active control|Patients in the active control arm will receive messages reminding them to get a flu shot without being advised of their risk status.
33049072|NCT05509283|Experimental|High risk only|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
33049073|NCT05509283|Experimental|Risk based on medical records|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records.
33049074|NCT05509283|Experimental|High risk based on algorithm|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm.
33049075|NCT05433714||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform the figure of 8 walk test.
33049076|NCT05503862|Experimental|Arm A|At home semen testing via the YoSperm device
33049077|NCT05503862|No Intervention|Arm B|Standard of Care
33331588|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
33331589|NCT04391920||COVID-19 ICU Patients|
33331590|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
33331591|NCT03751878|Other|Control arm|Standard peer review process.
33331592|NCT04324606|Experimental|Group 1a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
33049078|NCT05433675|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as dispersible final market image (FMI) in fasted conditions (test) (Treatment A) in Intervention Period 1 followed by a single oral dose of film-coated opsumit tablet in fasted conditions (reference) (Treatment B) in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
33049079|NCT05433675|Experimental|Treatment Sequence BA|Participants will receive Treatment B in Intervention Period 1 followed Treatment A in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
33049080|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
33049081|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
33049082|NCT05499143||Parents of children with DCD or related movement difficulties|
33049083|NCT05433636|Experimental|Body Scan Practice|
33049084|NCT05433636|Experimental|Mindful Breathing Practice|
33049085|NCT05433636|Experimental|Mindfulness of Discomfort Practice|
33049086|NCT05433636|Experimental|Mindful Savoring Practice|
33049087|NCT05433636|Active Comparator|Integrative Health Recording|
33418466|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
33049088|NCT04730869|Experimental|Standard treatment in conjunction with MTP|"Standard:~Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks or, in adults unfit for this [eg >65 years and/or poor performance status] 40-Gy in 15 fractions over 3 weeks) with daily oral temozolomide.~Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended).~MTP:~If 6 weeks of chemoradiation - Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts.~If 3 weeks of chemoradiation - One 5-day fast during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet between fasts."
33049089|NCT05495321|Experimental|low-dose IL-2|"The first stage (double-blind treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
33049090|NCT05495321|Placebo Comparator|Placebo|"The first stage (double-blind treatment period): Placebo was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
33049091|NCT05413785|Experimental|Participants with Hepatitis C|Participants will be clients at the Lexington Probation and Parole office who are Hepatitic C positive.
33049092|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
33049093|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
33049094|NCT05410197|Experimental|Envofolimab + Lenvatinib + Gemcitabine + Cisplatin|Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
33049095|NCT03262454|Experimental|Interventions|Atezolizumab
33049096|NCT00057070|Other|Arm 1|
33049097|NCT00057109||Group 1|
33049098|NCT00057148|Other|Arm 1|
33049099|NCT05487170|Experimental|RNK05047|Dose-escalation of RNK05047 IV infusion
33049100|NCT05407038|Experimental|Supportive care (remote monitoring with health coaching)|Patients undergo routine exercise using a remote monitoring system (Garmin Vívofit activity monitor, Nonin 3150 WristOx2 pulse oximeter, and an Android tablet) over 30 minutes at least 6 days per week and complete daily questionnaires over 20 minutes for 12 weeks. Patients also receive health coaching telephone calls over 5-20 minutes once a week for 12 weeks. At the end of the 12 weeks, patients complete an audio taped telephone interview.
33049101|NCT00057187|Other|Arm 1|
33049102|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
33049103|NCT05486897||cerebral amyloid angiopathy|Patient with cerebral amyloid angiopathy
33049104|NCT05486897||Hypertensive arteriopathy|Patients with hypertensive arteriopathy
33049105|NCT05388864|Experimental|Three-Tier Model|130 children with ACEs who received well-child care by a trained provider will be enrolled in this group.
33049106|NCT05388864|No Intervention|Comparison Group|80 children without ACEs who received usual well-child care will be enrolled in this group.
33049107|NCT05388864|No Intervention|Control Group|130 children with ACEs who received usual well-child care will be enrolled in this group.
33049108|NCT05452811||Open Burch Colposuspension|The retropubic space was entered through a laparotomy Pfannenstiel incision, and two permanent sutures were placed on each side lateral to the urethra, one set at the level of the mid urethra and the other set at the level of the bladder neck.
33049109|NCT05452811||Laparoscopic Burch Colposuspension|After a pneumo peritoneum was established entrance to the retropubic space began with a transverse incision of the anterior peritoneum using sharp dissection and electrocautery. The space was developed using blunt and sharp dissection to identify clearly the retropubic anatomy, including the pubic symphysis, bladder neck, and Cooper's ligaments. The bladder neck was identified and the paraurethral tissue was exposed. A no. 0 permanent suture then was introduced through the 10-mm port and was grasped with a laparoscopic needle driver. With the surgeon's hand in the vagina to elevate the paraurethral tissue, two figure-of-eight sutures incorporating full-thickness vagina excluding epithelium were placed on each side, one set lateral to the mid urethra and the other set lateral to the bladder neck. Each of these sutures then was passed through the ipsilateral Cooper's ligament and was secured with a series of extracorporeal knots using an endoscopic knot pusher.
33331593|NCT04324606|Active Comparator|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine
33331594|NCT04324606|Experimental|Group 1c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 5x10^10vp ChAdOx1 nCoV-19 9 months later
33418467|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
33049110|NCT05388435|Experimental|Part 1: Dose Escalation Phase|Part 1 is a dose escalation phase of SKL27969 to evaluate the safety, tolerability, and define the MTD and RP2D. Part 1 will have an accelerated titration design with a 3+3 design.
33049111|NCT05388435|Experimental|Part 2: Dose Expansion Phase|Part 2 includes tumor-specific expansion cohorts utilizing the MTD/RP2D doses (determined from Part 1) to further explore safety and anti-tumor activity of SKL27969, in addition to the PK and PD from the patients with the selected tumor types.
33049112|NCT05447741||Patients with fibromyalgia|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
33049113|NCT05447741||Patients with psoriasis arthritis|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
33049114|NCT05447741||Asymptomatic controls|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
33049115|NCT04733859|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
33049116|NCT04733859|Experimental|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
33049117|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
33049118|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
33049119|NCT05349864|Experimental|PF-07284890 Sequence 1|"PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
33049120|NCT05349864|Experimental|PF-07284890 Sequence 2|"PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
33049121|NCT05446766|Experimental|Self-guided Exposure-based Digital Intervention for Health Anxiety|Eight weeks of self-guided exposure-based intervention delivered digitally, via the Internet.
33049122|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
33049123|NCT02969746|No Intervention|control|Standard practice
33049124|NCT05310747|Experimental|Artwork present + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with artwork for 10 minutes
33049125|NCT05310747|Experimental|Artwork present + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with artwork for 10 minutes
33049126|NCT05310747|Experimental|Artwork absent + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
33049127|NCT05310747|Active Comparator|Artwork absent + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
33049128|NCT05310747|No Intervention|Hanging control group|Individuals will receive no exposure to any independent variables (i.e. artwork: present or absent; social connection prime: high or low) for 10 minutes before completing their final survey.
33049129|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
33049130|NCT05436314|Experimental|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
33049131|NCT05436314|Sham Comparator|Sham Group|Sham Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
33049132|NCT05309304|Experimental|3 g cefazolin|Healthy adult subjects weighing ≥120 kg. (g=grams)
33049133|NCT05309304|Active Comparator|2 g cefazolin|Healthy adult subjects weighing <120 kg. (g=grams)
33049134|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
33331595|NCT04324606|Experimental|Group 1d|Volunteers will receive a standard single dose of MenACWY vaccine. 9 moths later they will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 4-12 weeks apart
33331596|NCT04324606|Experimental|Group 2a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
33331597|NCT04324606|Active Comparator|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine
33331598|NCT04324606|Experimental|Group 2c|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and week 8
33331599|NCT04324606|Experimental|Group 2d|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10^10vp ChAdOx1 nCoV-19 at week 8
33331600|NCT04324606|Active Comparator|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine at week 0 and week 8
33418468|NCT05170321||patients undergoing knee arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent knee arthroplasty and was recorded in HQMS were included in this group
33049135|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
33049136|NCT05436041|Experimental|Nutri|PCPs will receive an alert to use Nutri personalized diet goal setting software with enrolled patients
32869569|NCT00147199|Experimental|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
33049137|NCT05436041|No Intervention|Control|Usual care
33049138|NCT00057967|Experimental|Treatment arm|alemtuzumab
33049139|NCT05433155|Active Comparator|Videolaryngoscopy|Nasotracheal intubation performed with the Storz C-Mac Video Laryngoscope
33049140|NCT05433155|Active Comparator|Direct Laryngoscopy|Nasotracheal Intubation performed with the standard clinical direct blades
33049141|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
33049142|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33049143|NCT05273892|Experimental|Diet + Activity + Sleep|
33049144|NCT05273892|Active Comparator|Diet + Activity|
33049145|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
33049146|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
33049147|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
33049148|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
33049149|NCT00058201|No Intervention|Arm III|Patients undergo observation.
33049150|NCT05432765|Active Comparator|Physician Dosing|Subjects will continue per SOC, where the management of their immunosuppression regimen will be determined by their physician per center practices, including dd-cfDNA data.
33049151|NCT05432765|Experimental|PPM Dosing|Subjects will have dd-cfDNA data analyzed by PPM. Data, such as drug levels and regimens, will be used to fit a 2nd order polynomial for each patient to build patient-specific dose-response profiles with covariates that include the administered drugs tacrolimus, steroids, and MMF/MPA. PPM will be used to derive an optimal combination of tacrolimus, MMF/MPA, and prednisone to achieve minimal renal allograft injury, while staying within the therapeutic range of the medications. All else being equal, the most efficacious combination with the lowest dose of tacrolimus will be utilized.
33049152|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
33049153|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
33049154|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
33049155|NCT00392145|Active Comparator|1|
33049156|NCT00392145|Experimental|2|
33049157|NCT05413460|Experimental|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
33049158|NCT05413460|No Intervention|Control|Electrodes are placed at acupoints and connected to the stimulator. But no stimulation is given during surgery.
33049159|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
33049160|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
33049161|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
33049162|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
33049163|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
33049164|NCT00058591|Experimental|Treatment|Treatment dose levels 1, 2 and 3
33049165|NCT05409443|Active Comparator|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2, and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm (3,6).~The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of 1mL 2% lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation the tines are retracted for all electrodes prior to removal."
33049166|NCT05409443|Active Comparator|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"To target the L5 dorsal ramus, an electrode will be placed in parallel between the junction of the sacral ala and S1 superior articular process.~A periforaminal electrode position will be used to target the lateral branches from S1 to S3, as suggested by Roberts et al. and previously performed by Cohen et al. (6,18). An 22-G cannula with a 5-mm exposed tip was directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~The appropriate locations are confirmed in both AP and lateral views. Following injection of 1mL 2% lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
33049167|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
33049168|NCT05393141|Experimental|diet group|weight loss diet intervention for 12 weeks
33331601|NCT04324606|Experimental|Group 2f|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
33331602|NCT04324606|Active Comparator|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
33331603|NCT04324606|Experimental|Group 3a|Volunteers will receive one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 4
33331604|NCT04324606|Experimental|Group 3b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0, a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
33331605|NCT04324606|Experimental|Group 4a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
33331606|NCT04324606|Active Comparator|Group 4b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
33331607|NCT04324606|Experimental|Group 4c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
33331608|NCT04324606|Active Comparator|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
33331609|NCT04324606|Experimental|Group 5a|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 ≤ 16 weeks apart, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
33331610|NCT04324606|Experimental|Group 5b|Volunteers will receive two standard single doses of MenACWY vaccine ≤ 16 weeks apart, a dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months then a second dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) 4-12 weeks later
32740232|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
33331611|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
33331612|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
32869570|NCT00147199|Placebo Comparator|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
33049169|NCT05393141|Experimental|diet+bety group|weight loss diet intervention for 12 weeks and exercise-based biopsychosocial approach (Cognitive Exercise Therapy Approach-BETY) intervention for 12 weeks
33331613|NCT05460078|Experimental|Virtual program|Seen at a location where the virtual program is being offered
33331614|NCT05460078|No Intervention|Standard care|Seen at a location where standard care is offered
33049170|NCT05393141|No Intervention|control group|no intervention, control
33331615|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
33331616|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
33049174|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
33049175|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
33049176|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
33049177|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
33049178|NCT00059254|Experimental|Oleic acid (OA)|
33049179|NCT00059254|Experimental|Palmitic acid (PA)|
33049180|NCT00059371|Active Comparator|Circumcised immediately|
33049181|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
33331617|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
33331618|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
33331619|NCT04031014|Experimental|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
33331620|NCT04031014|Sham Comparator|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
33331621|NCT05762068||Airway management experts|The Steering Committee selected Experts from across the globe based on pre-defined criteria and will conduct iterative Delphi rounds to generate consensus among the experts.
33418469|NCT05170321||patients undergoing hip arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent hip arthroplasty and was recorded in HQMS were included in this group
33049182|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
33049183|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
32740233|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
33049184|NCT05368025||Newly diagnosed Oropharyngeal cancer patients|Newly diagnosed oropharyngeal cancer patients will be enrolled into the study. Patients will receive both mobile health systems and be asked to complete swallowing exercises and report symptoms daily for a period of 6 months. Following completion of the study, this group will be interviewed individually to gain insight into the user experience of using both systems
33049185|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
33049186|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:~T > 4 cm;~multicentric tumors (mono or bilateral);~primary lesion completely excised during prior diagnostic surgery~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
33049187|NCT05364476|Experimental|16 weeks digital intervention with online and offline support|This study is a single-arm, non-randomized clinical trial, which will collect participant's baseline data, apply relevant assessment scales, collect data using a comprehensive digital intervention in 16 weeks to evaluate the improvement of relevant markers post intervention.
33049188|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
33049189|NCT05228262|Other|Cohort follow-up|Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management.
33049190|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
32740234|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
33049191|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
33049192|NCT05364047|Other|Low-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049193|NCT05364047|Other|Middle-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049194|NCT05364047|Other|High-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049195|NCT05364047|Other|Low-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049196|NCT05364047|Other|Middle-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049197|NCT05364047|Other|High-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
33049198|NCT05223582|Experimental|Fluzoparib and abiraterone treatment group|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 150mg fluzoparib bid. Patients would be treated with 5mg prednisone bid. Patients would get medical castration.
33049199|NCT05359133|Active Comparator|Tetrodotoxin for injection|30 µg, 1 ml SC injection in the thigh or abdomen, twice daily for 4 Days
33049200|NCT05359133|Placebo Comparator|Placebo|1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days
33049201|NCT05174559|Active Comparator|Active LNAA|Active LNAA tablets are given to each participant in 3 multiple crossovers for a total exposure to the Active Comparator 3 times. The allocation is randomized within each cycle of two treatments (active/inactive). There are 3 total cycles for each participant. The intervention is PreKUnil® tablets.
32740235|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
32740236|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
32740237|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
33418470|NCT05170321||patients undergoing shoulder arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent shoulder arthroplasty and was recorded in HQMS were included in this group
33418471|NCT05170321||patients undergoing ankle arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent ankle arthroplasty and was recorded in HQMS were included in this group
32740238|NCT04442633|Active Comparator|conventional therapy|topical corticosteroid plus antifungal
33049202|NCT05174559|Placebo Comparator|Inactive LNAA|Inactive LNAA tablets (placebos) are given to each participant in 3 multiple crossovers for a total exposure to the Inactive Comparator 3 times. The allocation is randomized within each cycle of two treatments (inactive/active). There are 3 total cycles for each participant. The placebo intervention is PreKUnil® placebo tablets.
33049203|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
33049204|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
33049205|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
33049206|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
33049207|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
33049208|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
33049209|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
33049210|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
33049211|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
33049212|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
33049213|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
33049214|NCT05166135||Acute Myeloid Leukemia|Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
32740239|NCT04442633|Experimental|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
33049215|NCT05166135||Relapsed/Refractory Acute Lymphoid Leukemia|Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
33049216|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
33049217|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
33049218|NCT04730752||Right Low Quadrant Pain|AIR and AAS scores will be calculated for the patients with right low quadrant pain in emergency service.
33049219|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
33049220|NCT05158257|Active Comparator|Intervention: balloon and Stents|plain balloon and Stents group
33049221|NCT05158257|Experimental|Intervention: debulking and drug coated balloon|debulking and drug coated balloon group
33049222|NCT02968966|Experimental|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
33049223|NCT05353244|Active Comparator|Active PrTMS|Participants will receive PrTMS five days a week for six weeks.
33049224|NCT05353244|Sham Comparator|Sham|Participants will receive sham treatment five days a week for six weeks.
33049225|NCT05155020|Experimental|AK120 regimen 1|
33049226|NCT05155020|Experimental|AK120 regimen 2|
33049227|NCT05155020|Experimental|AK120 regimen 3|
33049228|NCT05155020|Placebo Comparator|Placebo|
33049229|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
33049230|NCT05344157|Experimental|XSTEM-OA|Single intra-articular injection of XSTEM-OA
33049231|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33049232|NCT05134662|Experimental|ALT-801 Dose Level 1|
33049233|NCT05134662|Experimental|ALT-801 Dose Level 2|
33049234|NCT05134662|Experimental|ALT-801 Dose Level 3|
33049235|NCT05134662|Placebo Comparator|Placebo|
33049236|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
33049237|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
33049238|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
33049239|NCT02968927|Experimental|Vitamin D|Vitamin D3
33049240|NCT02968927|Experimental|CC-11050|CC-11050
33049241|NCT05344040|Experimental|Remotely Delivered and Supported Aerobic Walking Exercise Training|
33049242|NCT05344040|Active Comparator|Remotely Delivered and Supported Stretching and Toning|
33049243|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
33049244|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
33049245|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
33049246|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
33049247|NCT05105685|Placebo Comparator|Group A|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
33049248|NCT05105685|Experimental|Group B|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
33049249|NCT05325164|Experimental|Methadone|"DESCRIPTION:~Blinded methadone 1mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 0.5mg Q4H x 4 doses + 1.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.0 mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Second increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Third increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Fourth increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 1.0mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Second increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Third increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.5mg Q2H PRN (max 4 doses)~Fourth increase: 3.0mg Q4H x 4 doses + 6.0mg QHS + 1.5mg Q2H PRN (max 4 doses)"
32740240|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
32740241|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
32740242|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
33049250|NCT05325164|Active Comparator|Morphine|"DESCRIPTION:~Blinded morphine 5mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 2.5mg Q4H x 4 doses + 5.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 5.0 mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Second increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Third increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Fourth increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 5.0mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Second increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Third increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 12.5mg Q2H PRN (max 4 doses)~Fourth increase: 15.0mg Q4H x 4 doses + 30.0mg QHS + 12.5mg Q2H PRN (max 4 doses)"
33049251|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
33049252|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
33049253|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
33049254|NCT05055921|Experimental|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
33049255|NCT04730908|Placebo Comparator|G0 - placebo|Dental gel without fluoride in the composition
33049256|NCT04730908|Sham Comparator|G1: Daily Regenerator Dentalclean Neutro (RDCN)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). NEUTRAL pH
33049257|NCT04730908|Active Comparator|G2: Sensodyne Repair & Protect (SRP)|1426 ppm of sodium fluoride and calcium sodium phosphosilicate 5% (NOVAMIN technology).
33049258|NCT04730908|Experimental|G3: Daily Regenerator Dentalclean Acid (RDCA)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). ACIDIC FORMULA
33049259|NCT04730908|Active Comparator|G4: Colgate Total Daily Repair (CTDR)|1450 ppm F- of as sodium fluoride, 0.30% triclosan, arginine, tetrasodium pyrophosphate.
33049260|NCT05319197||SLD Group|
32740243|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
32740244|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
32740245|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
33049261|NCT05319197||Healthy Control Group|
33049262|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
33049263|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
33049264|NCT04731181|Experimental|mobile application (little lovely dentist).|intervention mobile application simulating the dental procedure that will be done to the child
33049265|NCT04731181|No Intervention|Tell-Show-Do technique.|control behavior technique where ''tell'' is to tell the child about the procedure in non-threatening words, ''show'' is to demonstrate the procedure to the child, and ''do'' is the execution of the procedure
33049266|NCT05055336|Experimental|Gastroparesis|Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
33049267|NCT05055336|Experimental|Dyspepsia|Participants in this group are children diagnosed with functional dyspepsia per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
33049268|NCT05055336|Experimental|Healthy Controls|Participants in this group are children that do not have gastroparesis, functional dyspepsia, or any other gastroenterology condition. Participants will be getting an ultrasound once.
33049269|NCT05312372|Experimental|S095033 in combination with paclitaxel|"Dose escalation - phase 1: S095033 will be administrated at dose of 100 mg,150 mg or 200 mg everyday during a 28-day cycle. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.~Dose expansion - phase 2: Participants with MTAP-deletion and those with MTAP-wild type tumors will be evaluated in separate and independent dose expansion subpopulations.S095033 will be administrated every day during a 28-day cycle at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
33049270|NCT04730713||Admitted to the center ICU due to neurosurgery, brain dysfunction and other neurological reasons|Aneurysmal subarachnoid hemorrhage (aSAH), traumatic brain injury (TBI), acute deficiency Blood stroke (AIS), acute cerebral hemorrhage (ICH), hypoxic ischemic encephalopathy (HIE), Sepsis-associated encephalopathy (SAE), intracranial tumor surgery; older than 18 years old, <85 Years old; patients who need lumbar puncture.
33049271|NCT05038410|Active Comparator|Wobenzym®|Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
33049272|NCT05038410|Placebo Comparator|PLACEBO|No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
33049273|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
33049274|NCT05037513|Active Comparator|CDC-PrEP|1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
33049275|NCT05037513|Experimental|SBCM-PrEP|Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
33049276|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
33049277|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
33049278|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
33049279|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
33049280|NCT05300945|No Intervention|Control|
33049281|NCT05300945|Experimental|HIPEC|
33049282|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
33049283|NCT05030493||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
33049284|NCT05030493||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg mFOLFOX6 + bevacizumab combination therapy, once every two weeks
33049285|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
33049286|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
33049287|NCT05292794|Experimental|PD Patients treated with CereGate Software|This singular arm contains participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. Participants will use the CereGate software for 60(+/-8) days on demand.
33331622|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
33418472|NCT05170321||patients undergoing elbow arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent elbow arthroplasty and was recorded in HQMS were included in this group
33049288|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
33049289|NCT00061087|Active Comparator|BUPROPION|Bupropion
33049290|NCT00061087|Placebo Comparator|PLACEBO|Placebo
33049291|NCT05282225|Experimental|MI-SP +supportive Texts + monitoring (Sequence A)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group A: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge.
33049292|NCT05282225|Experimental|MI-SP + monitoring (Sequence D)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group D: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge.
33049293|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + portal follow-up for non-responders (Sequence B).|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group B: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the portal follow-up for non-responders.
33049294|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + booster call for non-responders (Sequence C)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group C: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the booster call for non-responders.
33049295|NCT05282225|Experimental|MI-SP + monitoring + portal follow-up for non-responders (Sequence E)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group E: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the portal follow-up for non-responders.
33049296|NCT05282225|Experimental|MI-SP + monitoring + booster call for non-responders (Sequence F)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group F: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the booster call for non-responders.
33049297|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~2 month intervention~Eye-tracking post-testing"
33331623|NCT05761990|Experimental|POST ISOMTERIC RELAXATION TECHNIQUES|"Participants in Group A will instruct to perform the PIR techniques~These steps are taken when using the PIR approach:~Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~Starting with this new barrier, the procedure is carried out two or three more times."
33049298|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~Eye-tracking post-testing"
33049299|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
33049300|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
33049301|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
33049302|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
33049303|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
33049304|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
33049305|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
33049306|NCT04711564||Provision of olive oil emulsions in PN|Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition
33049307|NCT04711564||Provision of soybean emulsions in PN|Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)
33049308|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
33049309|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
33049310|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
33418473|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
32740246|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
32740247|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
32740248|NCT03312101|Experimental|Experimental|exercise program
33418474|NCT04889469||Breast hypertrophy operated|Women who have had a breast reduction in the public health care system
32740249|NCT03312101|No Intervention|Control|observation
32740250|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
33049311|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
33049312|NCT05259410|Experimental|Time restricted eating|Participants will eat all food within the hours of 10am-6pm daily.
33049313|NCT05259410|No Intervention|Standard care|Current standard care is to eat enough calories and protein to maintain weight and lean mass.
33049314|NCT05001009|Active Comparator|No then high patient engagement|First stage: No patient engagement Second stage: High patient engagement
33049315|NCT05001009|Active Comparator|No then low patient engagement|First stage: No patient engagement Second stage: Low patient engagement
33049316|NCT05001009|Active Comparator|No then no patient engagement|First stage: No patient engagement Second stage: No patient engagement
33049317|NCT05001009|Active Comparator|Low then high patient engagement|First stage: Low patient engagement Second stage: High patient engagement
33049318|NCT05001009|Active Comparator|Low then low patient engagement|First stage: Low patient engagement Second stage: Low patient engagement
33049319|NCT05001009|Active Comparator|Low then no patient engagement|First stage: Low patient engagement Second stage: No patient engagement
33049320|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
33049321|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
33418475|NCT04889469||Breast hypertrophy controls|Women with symptoms of breast hypertrophy, who do not fulfill the requirements to have a breast reduction in the public health care system
33049322|NCT05243732|Experimental|Mindful Music Listening|"Participants in the mindful music listening group, will receive personalised music playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to.~In addition to listening to their preferred music daily, they will be emailed a brief mindful music exercise to complete prior to listening to their preferred music playlist (weeks 1-4). The mindful music exercise will have spoken instructions, and focus on key element of mindfulness of paying attention to the present moment. For example, If participants were to notice any thoughts or sensations arising either during the brief exercise or during subsequent music listening, they are to allow them to pass and to gently bring their attention back to the exercise/music."
33049323|NCT05243732|Active Comparator|Music Listening|Participants in the music listening group will receive personalised playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to. In contrast to the mindful-music condition, no specific listening instructions will be given to the music listening only condition.
33049324|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
33049325|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
33049326|NCT04997304|Experimental|AirDuo and ProAir|This trial includes using the inhaler (AirDuo®) Digihaler™ and rescue inhalers (ProAir®) Digihaler™.
33049327|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
33049328|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
33049329|NCT04977180|Experimental|Treatment arm (beta blocker and ACE inhibitor)|Participants will receive a beta blocker (either metoprolol or carvedilol) and an ACE inhibitor (lisinopril) at standard doses based on tolerance starting from when they start induction therapy for AML through 90 days after the first day of the last cycle of therapy that includes an anthracycline (whether that is in the induction, re-induction, or consolidation phase of treatment). They will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
33049330|NCT04977180|No Intervention|Standard Clinical Care|Participants will receive standard clinical care, but will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
33049331|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
33049332|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
33049333|NCT00389792|No Intervention|ATI-2042 200 mg|
33418476|NCT04889469||Augmented controls|Patients who have breast hypertrophy due to cosmetic breast augmentation
33418477|NCT04889469||The general public|Random sample of the general public
33049334|NCT00389792|No Intervention|ATI-2042 400 mg|
33049335|NCT00389792|No Intervention|ATI-2042 600 mg|
33049336|NCT00389792|No Intervention|ATI-2042 Placebo|
33049337|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
33049338|NCT04954365||Cohort 1|Patients that received rescue treatment according to the standard of care (SOC).
33049339|NCT04954365||Cohort 2|Patients that received rescue treatment with IV amisulpride.
33049340|NCT00061750|Experimental|ICL670|
33049341|NCT00061750|Active Comparator|Deferoxamine|
33049342|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
33049343|NCT04939584|Experimental|Intervention|"The study will be conducted using the venous cannulations that are standard of care for the indicated procedure. Additional access points may be necessary if access to coronary sinus is difficult from existing femoral venous cannulations. Sterile study leads or EP catheters will be temporarily placed into the RA, CS, and RV (for R-wave sensing using intracardiac electrograms - optional) which will be connected to the investigational device (CESS).~Up to two MPTs will be delivered and subject responses following each MPT regarding perception and acceptability of MPT to treat AF will be obtained. MPT voltages will not exceed 100V."
33049344|NCT05221346|Experimental|Plant food supplement|"Dietary supplements in capsule form~1 capsule per day at breakfast"
33049345|NCT05221346|Placebo Comparator|Maltodextrin|"Dietary supplements in capsule form~1 capsule per day at breakfast"
32740251|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
33049346|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
33049347|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
33049348|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
33049349|NCT04936776||Text message 1|Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
33418478|NCT05168527|Experimental|experimental group|This is an opened single-arm phase 2 study， the study drug includes Fruquintinib combine with Paclitaxel Injection and Gemcitabine.
33418479|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
33418480|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
33418481|NCT01372657||cataract patients|cataract patients
33418482|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
33418483|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
33418484|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
33049350|NCT04936776||Text message 2|Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
33418485|NCT05166031|Active Comparator|bOPV dose|Naïve infants to receive two doses of bOPV at 2 and 3 months of age.
33049351|NCT04936776||No text message|No text sent.
33049352|NCT05219825|Experimental|Breathwork group|Treatment-seeking individuals with cannabis use disorder who will participate in the 1-week breathwork workshop.
33049353|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
33049354|NCT04917900|Experimental|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
33049355|NCT05219435|Experimental|Nivolumab plus Ipilimumab|Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
33049356|NCT04730323|Experimental|Tocilizumab Group|Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
33049357|NCT04730323|Active Comparator|Methylprednisolone (corticosteroid) group|Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.
33049358|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
33049359|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
33049360|NCT04900272|Experimental|VIPA device and companion booklet|For Aim 2, we will recruit a total of 20-40 older adult homebound patients who are likely to be socially isolated, through the Geriatric and General Internal Medicine clinics at Northwestern (over 2,300 homebound older adults) to use the VIPA and accompanying instructional booklet focused on social-isolation. Either the study PI or Research Study Coordinator (RSC) will visit the participant's home, or assist the patient virtually, once consented, to set up the Google Home or Amazon Alexa device for them and review the companion VIPA booklet with them.
33049361|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
33049362|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
33049363|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
33049364|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
33049365|NCT05215808|Experimental|RBN-3143|RBN-3143 in single ascending dose followed by multiple ascending dose cohorts, randomized 3:1 ratio
33049366|NCT05215808|Active Comparator|Placebo|Placebo randomized in 1:3 ratio with ascending RBN-3143 single and multiple dosing
33049367|NCT05215808|Other|Pantoprazole|Open Label PPI cohort to evaluate concurrent administration of pantoprazole on RBN-3143 pharmacokinetics
33049368|NCT05215808|Other|Midazolam|Open Label DDI Cohort (12 subjects) to evaluate the effect of RBN-3143 on the exposure of midazolam, a sensitive CYP3A4 substrate
33049369|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
33049370|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
33049371|NCT05195684|Other|single arm|entirely within-subject outcome variables
33049372|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
33049373|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
33049374|NCT04870476|Experimental|"Internet-delivered treatment: One step at the time"|"Internet-delivered treatment: One step at the time. All participants receive the internet-delivered therapist-assisted 11-modules treatment program One step at the time."
33049375|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
33049376|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
33049377|NCT04865874|Experimental|PPV-GDT|Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)
33049378|NCT04865874|Active Comparator|Zero balance|Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output
33049379|NCT05183984|Experimental|ARM A: carboplatin/paclitaxel + niraparib|carboplatin AUC 5-6 + paclitaxel 175 mg/m² q3w, 5 cycles, followed by niraparib 200* or 300 mg/d for 2 years.
33049380|NCT05183984|Experimental|ARM B: carboplatin/paclitaxel/bevaziumab + niraparib/bevacizumab|carboplatin AUC 5-6 + paclitaxel 175 mg/m² + bevacizumab 15 mg/kg q3w, 5 cycles, followed by bevacizumab 15 mg/kg q3w for 15 months + niraparib 200*or 300 mg/d for 2 years.
33418486|NCT05166031|Active Comparator|nOPV2 dose|Naïve infants to receive two doses of nOPV2 at 2 and 3 months of age.
33418487|NCT05166031|Experimental|bOPV + nOPV2 dose|Naïve infants to receive two doses of nOPV2 and bOPV at 2 and 3 months of age.
33418488|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
33049381|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
33049382|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
33049383|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
33049384|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
33049385|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
33049386|NCT00062491|Experimental|1|Karenitecin (BNP1350)
33049387|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
33049388|NCT04733625|Active Comparator|Intervention(Vitamin D therapy|40 patients with diabetes and vitamin D deficinecy that are Covid-19 positive. a single dose of Cholecaciferol will be administered
33049389|NCT04733625|Placebo Comparator|Placebo|16 diabetic patients with vitamin D deficiancy and COVID-19 POSITIVE
33049390|NCT02967718||Control group|the healthy patients
33049391|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
33049392|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
33049393|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
33049394|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
33049395|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
33049396|NCT05181293|Experimental|Experimental|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
33049397|NCT05181293|No Intervention|No Intervention|In addition to routine health services, teenage mothers will receive the BabyThrive app after the intervention is completed. Participants will learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive also will demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of baby to facilitate growth monitoring.
33049398|NCT00062569|Experimental|1|
33049399|NCT00062569|Experimental|2|
33360702|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
33360703|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
33360704|NCT01131247|Experimental|ofatumumab + bendamustine|
33360705|NCT03513874|Experimental|Metformin + Insulin|
33049404|NCT05178914|Experimental|The interventional group|"Patients are defined by the disclosure of the IMR value. The pre-PCI IMR is used to guide therapy.~For patients with pre-PCI IMR ≥ 25 will benefit from intensified coronary artery disease treatment to manage the microcirculatory damage according to the recommendations and consensus of European experts.~For patients with a pre-PCI IMR < 25 will benefit from de-escalade therapeutic adaptation."
32869571|NCT04836273|Experimental|120 µg dasiglucagon|Subcutaneous 120 µg dasiglucagon self-administration
32869572|NCT04836273|Placebo Comparator|Placebo|Subcutaneous placebo self-administration
33049405|NCT05178914|Sham Comparator|The control group|The control group is defined as follows: the pre-PCI IMR has been performed but its result is not undisclosed (sham procedure) ; patients will receive standard medical treatment according to the physician's preference.
33049406|NCT00062842|Experimental|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
33360706|NCT03513874|Active Comparator|Insulin alone|
33360707|NCT05170516|Experimental|Experimental Group A|In experimental group A, 4°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
33360708|NCT05170516|Experimental|Experimental Group B|In experimental group B, 10°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
33360709|NCT05170516|Active Comparator|Control Group A|In control group A, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 4 °C saline irrigation on one side.
33360710|NCT05170516|Active Comparator|Control Group B|In control group B, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 10 °C saline irrigation on one side.
33360711|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
33360712|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
33360713|NCT03517306||Beijing|No interventions
33049407|NCT05178563|Experimental|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
33049408|NCT05178563|Sham Comparator|; IPT+Placebo|This experimental arm consist of performing IPT in randomly assigning patients to receive sham use of photodynamic therapy(PDT).
33049409|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
33049410|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
33049411|NCT00389909|Active Comparator|1|Treatment based on patient weight;
33049412|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
33049413|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
33049414|NCT00063076|No Intervention|Control|Half head untreated as control
33049415|NCT04744662|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection
33049416|NCT04744662|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection
33049417|NCT04744662|Sham Comparator|Treatment Group C|sham injection without penetrating the eye
33049418|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
33049419|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
33049420|NCT05167019|Active Comparator|Usual care|Usual care
33049421|NCT05167019|Experimental|The CODE intervention|The CODE intervention consists of 4 items, of which individual coaching sessions of 1 hour. In total each doctor taking care of hospitalized patients will be able to receive maximum 16 individual coaching sessions during the 4 months intervention period (one weekly). Every doctor will be invited to participate to at least 8 coaching sessions, to be extended on request, during the intervention period.
33049422|NCT04736823|Experimental|Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
33049423|NCT04736823|Experimental|Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)|Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
33049424|NCT04736823|Experimental|Part1 Cohort3(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
33049425|NCT04736823|Experimental|Part2 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
33049426|NCT04736823|Experimental|Part2 Cohort2(Penpulimab(AK105) + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) until progression."
33049427|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
33049428|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
33049429|NCT02967601||Elective Cesarean Section|
33049430|NCT05165576|Experimental|Child-centered communication|The child's preparation for the MRI scanning is conducted using a child-centered communication type of interaction
33049431|NCT05165576|Active Comparator|Magnetic Resonance Imaging (MRI) Simulation Toy|The child's preparation for the MRI scanning is conducted through provision of general information about the MRI exam simulated with an MRI toy
33049432|NCT05165576|No Intervention|General information about the Magnetic Resonance Imaging (MRI) exam|The child's preparation for the MRI scanning is based on the provision of routine information about the MRI exam
33049433|NCT04707690|Active Comparator|Intraurethral laser therapy|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2."
33360714|NCT03517306||Ningxia|No interventions
33360715|NCT03517306||Wenzhou|No interventions
33360716|NCT03517306||Changzhou|No interventions
33360717|NCT01228123|Active Comparator|CVVH arm|
33360718|NCT01228123|Active Comparator|IHD arm|
33360719|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
33360720|NCT03929263|Experimental|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
33360721|NCT03929107|Experimental|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
33360722|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
33360723|NCT01329523||Family Members|Younger biological family members of the patients with dementia
33049434|NCT04707690|Placebo Comparator|Intraurethral SHAM laser therapy|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
33049435|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
33331624|NCT05761990|Experimental|NOVEL STRETCHING|"The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
33049436|NCT00063583|Placebo Comparator|Placebo|Placebo
33049437|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
33049438|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
33049439|NCT05157191||mRNA COVID-19 vaccine|Children and adolescents (ages ≥ 5 to < 16) who receive mRNA COVID-19 vaccine per standard of care
33049440|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
33049441|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
33049442|NCT00063778|Placebo Comparator|Placebo|
33049443|NCT04655118|Experimental|Cohort 1a, Relapsed/Refractory Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
33049444|NCT04655118|Experimental|Cohort 1b, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
33049445|NCT04655118|Experimental|Cohort 1c, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
33049446|NCT04655118|Experimental|Cohort 1d, Relapsed/Refractory Myelofibrosis|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
33049447|NCT04655118|Experimental|Cohort 2a, JAKi Intolerant Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
33049448|NCT04655118|Experimental|Cohort 2b, JAKi Intolerant Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
33049449|NCT04655118|Experimental|Cohort 3a, JAKi Ineligible Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
33049450|NCT04655118|Experimental|Cohort 3b, JAKi Ineligible Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
33049451|NCT04655118|Experimental|Cohort 1 Expansion, Relapsed/Refractory Myelofibrosis|TL-895 administered orally at RP2D and schedule
33049452|NCT04655118|Experimental|Cohort 3 Expansion, JAKi Ineligible Myelofibrosis|TL-895 administered orally at RP2D and schedule
33049453|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
33049454|NCT05153876||Participants|Participants filling in the questionnaires
33049455|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33049456|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
33049457|NCT04648683|Experimental|Individual telehealth mindfulness|Telehealth mindfulness sessions delivered one-on-one with mindfulness therapist
33049458|NCT04648683|Experimental|Group Telehealth Mindfulness|Telehealth mindfulness sessions delivered in a small-group format with mindfulness therapist
33049459|NCT00064012|Active Comparator|Velcade Alone|Velcade
33049460|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
33049461|NCT05146700|Experimental|Restrictive oxygen|"- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants)~and~- Only trial participants receiving an FiO2 = 0.21 can saturate >94%~Pre-oxygenation as usual prior to intubation is permitted"
33331625|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
33360724|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
33331626|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
33331627|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
33331628|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
32740252|NCT05280431|Experimental|Experimental Group (AGREE)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the AGREE exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
32869573|NCT05709249|Active Comparator|intervention group|Subjects in the intervention group will be treated with XLJDOD compound granule.
33049462|NCT05146700|Active Comparator|Liberal oxygen|"- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98%~or~- FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%"
33049463|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
33049464|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:~20 mL injected into the peri-incisional soft tissues in a circumferential fashion~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.~Interventions:~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
33049465|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
33049466|NCT05141357|Experimental|HBI-8000 in combination with pembrolizumab|
33049467|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
33049468|NCT05138822|Experimental|GSK3882347 + Placebo|Participants will be administered GSK3882347 plus placebo.
33049469|NCT05138822|Active Comparator|Nitrofurantoin+ Placebo|Participants will be administered nitrofurantoin plus placebo.
33331629|NCT05761912||Ultrasound fusion targeted biopsy|Prostate ultrasound had abnormal echo and radiomics analysis showed high scores
33331630|NCT05761912||mpMRI cognitive fusion targeted biopsy|PI-RADS score ≥ 3
33331631|NCT04168190|Experimental|Phase 1: V116 0.5 mL|Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
33331632|NCT04168190|Experimental|Phase 1: V116 1.0 mL|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
33331633|NCT04168190|Active Comparator|Phase 1: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
33331634|NCT04168190|Experimental|Phase 2: V116|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
33331635|NCT04168190|Active Comparator|Phase 2: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2
33331636|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
33049470|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
33049471|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33049472|NCT05126147|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg twice daily for 6 months.
33049473|NCT05126147|No Intervention|Control|Observation and active surveillance.
33049474|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
33049475|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
33049476|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
33049477|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
33331637|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
33331638|NCT03939520|Experimental|Combined therapy|
32740253|NCT05280431|Experimental|Experimental Group (FEXO)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the FEXO exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
32740254|NCT05280431|Other|Control Group (Conventional therapy)|15 sessions, 3 sessions per week. Each session consists of 45 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke.
33331639|NCT03939520|Active Comparator|Switch monotherapy|
33331640|NCT03939520|Other|Control group|
33049478|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
33049479|NCT04604847|Other|Total knee arthroplasty|patient operated for a total knee arthroplasty
33049480|NCT05125211|Experimental|Single dose-escalation of GB001 recombinant peptide spray|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
33049481|NCT05125211|Experimental|Oral retention time test for a single dose|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of the group is 0.108mg.
33331641|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
32740255|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
33049482|NCT05125211|Experimental|Multiple Ascending Dose of GB001 recombinant peptide spray|Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.
33049483|NCT04578873|Experimental|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
33049484|NCT04578873|Experimental|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
33049485|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
33049486|NCT05122091|Experimental|Fruquintinib group|"Two-four preoperative cycles of Fruquintinib plus SOX. One cycle consists of Day 1-14 Fruquintinib 5mg oral (daily), Day 1 Oxaliplatin 130mg/M2 intravenous, Day 1-14 Tegafur gimeracil oteracil potassium capsule 40-60mg bid（dosage according to body surface area）.~Repeated every 21st day"
33049487|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
33049488|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
33049489|NCT04573452||Normal pregnancy group|
33049490|NCT04573452||Placenta accreta at 24-32 weeks group|
33049491|NCT05115656|Experimental|Online group intervention 1|Participants in group 1 meet weekly online for a 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
33049492|NCT05115656|Active Comparator|Online group intervention 2|Similar to group 1, participants will meet weekly online or in person for 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
33049493|NCT04570722|Other|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
33049494|NCT05113394|Experimental|Experimental arm|HDM sublingual Immunotherapy (HDM-SLIT) with Odactra® for 3 years to high-risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.
33049495|NCT05113394|Placebo Comparator|Placebo arm|Placebo administered sublingually for 3 years to high-risk infants aged between 6 to 12 months with outcome of asthma development assessed 1.5 years after discontinuation of treatment.
33049496|NCT04560699|Active Comparator|Physiotherapeutic group|medical care and physiotherapeutic treatment
33049497|NCT04560699|Active Comparator|medical care group|Medical care
33049498|NCT04527861|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
33331642|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
33331643|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
33331644|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
33331645|NCT04476108|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
33331646|NCT04476108|Placebo Comparator|Placebo|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg IV infusion for a total of 4 doses.
33049499|NCT04527861|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3~5 ports）.
33331647|NCT05460000|Experimental|Arm A (3 cycles of chemotherapy + maintenance therapy with niraparib)|3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
32740256|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
33331648|NCT05460000|Active Comparator|Arm B (6 cycles of chemotherapy + maintenance therapy with niraparib)|6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
33331649|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
33331650|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
33049500|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
33049501|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
33049502|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
33049503|NCT00398827|Placebo Comparator|Placebo|
33049504|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
33049505|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
33049506|NCT05105048|Experimental|mRNA-1647|CMV-seronegative or CMV-seropositive participants will receive mRNA-1647 vaccine by intramuscular (IM) injection in a 0-, 2-, and 6-month schedule.
33049507|NCT05105048|Placebo Comparator|Placebo|CMV-seronegative or CMV-seropositive participants will receive placebo matching to mRNA-1647 vaccine by IM injection in a 0-, 2-, and 6-month schedule.
33049508|NCT04518111||Unicompartmental Knee Arthroplasty (UKA)|Patients who underwent primary UKA with Oxford Partial Knee with the Microplasty® instrumentation for AMOA.
33049509|NCT04518111||High Tibial Osteotomy (HTO)|Patients who underwent Open Wedge HTO for AMOA.
33049510|NCT05089760||Infants with bacteria sepsis|Infants diagnosed with culture-proven sepsis
33049511|NCT04488081|Active Comparator|Control/Backbone (Remdesivir and Dexamethasone)|"Participants randomized to the backbone control will be given standard of care (supportive care for ARDS, including remdesivir and, if needed, lung protective ventilation). Because dexamethasone was shown to have benefit in at least one large randomized clinical trial, patients in the backbone control arm should receive dexamethasone for a total of 10 days during the hospitalization or until or hospital discharge.~Remdesivir (intravenous): 200-mg loading dose on day 1, followed by a daily maintenance dose of 100-mg on days 2 through 10.~Dexamethasone (intravenous): 6 mg intravenous or oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable."
33049512|NCT04488081|Experimental|Imatinib + Standard of Care|Subjects will be administered standard of care + 800 mg imatinib on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
33049513|NCT04488081|Experimental|Cenicriviroc + Standard of Care (CLOSED)|Subjects administered standard of care + cenicriviroc orally , loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
33049514|NCT04488081|Experimental|Icatibant + Standard of Care (CLOSED)|Subjects administered standard of care + icatibant subcutaneously, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
33049515|NCT04488081|Experimental|Apremilast + Standard of Care (CLOSED)|Subjects administered standard of care + apremilast orally , 30 mg bid × 14 days.
33049516|NCT04488081|Experimental|Dornase + Standard of Care (CLOSED)|"For Non-intubated subjects: Subjects administered standard of care + dornase, 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: Subjects administered standard of care + dornase, 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
33049517|NCT04488081|Experimental|Celecoxib/famotidine + Standard of Care (CLOSED)|"Subjects administered standard of care + celecoxib/famotidine orally .~Celecoxib, oral: 400 mg BID for 7 days.~Famotidine, oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days."
33049518|NCT04488081|Experimental|IC14 + Standard of Care (CLOSED)|Subjects administered standard of care + IC14 intravenously , 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
33049519|NCT04488081|Experimental|Narsoplimab + Standard of Care (CLOSED)|Subjects administered standard of care + narsoplimab dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
33049520|NCT04488081|Experimental|Aviptadil + Standard of Care (CLOSED)|Subjects administered standard of care + aviptadil (inhalation via nebulizer), 100 µg three times (TID) daily for a maximum of 14 days
33049521|NCT04488081|Experimental|Cyproheptadine + Standard of Care (CLOSED)|Subjects administered standard of care + cyproheptadine via 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days.
33331651|NCT05668962|Experimental|SELPERCATINIB + I-131|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Participants will be treated with Selpercatinib for 4 weeks.~In the fourth week of treatment, participants will receive a therapeutic dose of I-131.~Those participants in whom radioiodine uptake has been restored may be offered a second 4-week course of selpercatinib plus I-131 treatment"
33360725|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
33331652|NCT04014322|Experimental|E-cigarette|All participants will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 8weeks. They will be assessed at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
33049522|NCT04488081|Experimental|Cyclosporine + Standard of Care (CLOSED)|Subjects administered standard of care + modified cyclosporine at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
33049523|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
33049524|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
33049525|NCT05085821|Experimental|Experimental 1: HEART - Placebo - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: HEART, Placebo (after >24hour washout)"
33049526|NCT05085821|Experimental|Experimental 2: HEART - Placebo - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
33049527|NCT05085821|Experimental|Experimental 3: Placebo - HEART - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: Placebo, HEART (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
33049528|NCT05085821|Experimental|Experimental 4: Placebo - HEART - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
33049529|NCT04438044|Experimental|ICP-022|150mg,QD
33049530|NCT05083754|Experimental|Arm A- Retifanlimab and Radiation Therapy|Participants will receive Retifanlimab and Radiation Therapy.
33049531|NCT05083754|Experimental|Arm B- Retifanlimab, Radiation Therapy and Temozolomide|Participants will receive Retifanlimab, Radiation Therapy and Temozolomide.
33049532|NCT05083754|Other|Arm C- Radiation Therapy and Temozolomide|Participants will receive Radiation Therapy and Temozolomide which is the Standard of Care.
33049533|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
33049534|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~Follow up end at 1 month post delivery."
33049535|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~No follow up after delivery."
33049536|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.~Follow up end at 3 years of age."
33049537|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.~Follow up end at 3 years of age."
33049538|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
33049539|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
33049540|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
33049541|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
33049542|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS) plus antihistamines (AH1)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) plus antihistamines (AH1) for 4 weeks
33049543|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) for 4 weeks
33049544|NCT05080322|Active Comparator|maintenance intranasal corticosteroid (INS)|the patients will be treated with intra-nasal corticosteroid(INS) maintenance therapy for 4 weeks
33049545|NCT00066196|Other|2|Integrin + Dacarbazine
33049546|NCT00066196|Active Comparator|1|MEDI-522
33049547|NCT04401150|Experimental|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
33049548|NCT04401150|Placebo Comparator|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
33049549|NCT05077280|Experimental|one arm|see below
33049550|NCT04388475|Experimental|All patients|All patients enrolled in this study
33049551|NCT00066430|Experimental|Infrared coagulator|
33049552|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
33049553|NCT00066586|Active Comparator|Exemestane|
33049554|NCT00066586|Placebo Comparator|Placebo|
33049555|NCT04258488|Experimental|Oral Factor Xa inhibitor|
33049556|NCT04258488|Active Comparator|Vitamin K antagonist|
33360726|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
33360727|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
33360728|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
33360729|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
33360730|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
33360731|NCT02292550|Experimental|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
33360732|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
33418489|NCT04860375|Experimental|Multidisciplinary, holistic and patient-centered care|Based on the outcome from the assessment and disease phenotype, personalized care plans will be prepared and given to the patients, including dietary program, adjusted exercise program, psychological counselling, treatment of comorbidities etc. Patients will come for planned follow-up visits, according to the protocol (total 5 visits).
33331653|NCT04732338|Experimental|Study arm - Osteopathic Manipulative Therapy|"Standard of care including physical therapy, occupational therapy and over the counter medication AND OMT as described below:~Musculoskeletal examination of the cervical spine. Testing will be comprised of :~Range of motion testing involving cervical rotation, lateral side bending, flexion and extension.~Muscular palpation of the cervical paraspinals for hypertonicity of the muscles and/or tenderness.~Patient placed supine on the examination table.~Treatment sessions lasting 5-10 minutes each. OMT techniques: cervical muscle energy, myofascial release of the cervical paraspinals and a suboccipital release.~Assessment with Headache Impact Test (HIT-6) at baseline and follow-up visit and change in pain scores between baseline and post treatment."
33049557|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33049558|NCT05061134|Experimental|Main study: Ceralasertib + Durvalumab|Participants will receive ceralasertib on Days 1 to 7 plus durvalumab Day 8, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
33418490|NCT04860375|Active Comparator|Standard care|The control group will be recruited from the Swedish Airway Register at the end of the study. Selection will be based on propensity score matching to the intervention group.
33418491|NCT04230265|Experimental|UniCAR02-T-CD123|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the recombinant antibody derivative TM123.
33418492|NCT04856319|Active Comparator|Prophylaxis|2 g amoxicillin+clavulanic acid 1 hour prior to dental implant surgery
33049559|NCT05061134|Experimental|Main study: Ceralasertib|Participants will receive ceralasertib on Days 1 to 7, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
33049560|NCT05061134|Experimental|Biopsy Sub-study: Ceralasertib + Durvalumab|From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 1 to 7 plus durvalumab Day 8, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
33049561|NCT05061134|Experimental|Biopsy study: Ceralasertib|During Cycle 0, participants will receive ceralasertib on Days 1 to 7, followed by an off-treatment period between Days 8 to 28.
33049562|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
33049563|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
33049564|NCT04248543|Experimental|quantitative MRI at 4 weeks|
33049565|NCT05045963||Observational (medical record review)|Patients' medical charts are reviewed retrospectively.
33049566|NCT04235673|Experimental|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
33049567|NCT04235673|Placebo Comparator|placebo|oral drops manufactured to mimic melatonin
33049568|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
33049569|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
33049570|NCT04220307|Experimental|AK104 6 mg/kg|AK104 IV every 2 weeks (q2w)
33049571|NCT04220307|Experimental|AK104 15 mg/kg|AK104 IV every 3 weeks (q3w)
33049572|NCT05041127|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
33049573|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
33049574|NCT00398905|Experimental|Arm 1|
33049575|NCT00398905|Experimental|Arm 2|
33049576|NCT00398905|Experimental|Arm 3|
33049577|NCT00398905|Experimental|Arm 4|
33049578|NCT00398905|Experimental|Arm 5|
33049579|NCT00398905|Active Comparator|Arm 6|
33049580|NCT05036642|Experimental|Stroke Survivors|Stroke survivors with upper extremity motor impairments
33049581|NCT04172571|Experimental|AK105 and anlotinib|
33049582|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
33049583|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
33049584|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
33049585|NCT05027633|Other|pembrolizumab, docetaxel, and cisplatin or carboplatin|IV
33049586|NCT04103268||Sepsis|
33049587|NCT04103268||Control|
32740257|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
33049588|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
33049589|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
33049590|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
33049591|NCT05021939|No Intervention|Control Group|No treatment will be given to the control group. Evaluation will be done at the at the baseline and 8th week.
33049592|NCT05021939|Experimental|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
33049593|NCT05021939|Experimental|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
33049594|NCT04096833|Experimental|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
33049595|NCT04096833|No Intervention|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
33049596|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
33049597|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
33049598|NCT04096560|Placebo Comparator|Part A, Cohorts A1a and Cohorts A1b and A2 (Optional), NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT1.
33049599|NCT04096560|Experimental|Part A, Cohort A1a, NT1 Participants: TAK-994 TBD|TAK-994, tablets, dose level 1 for 28 days, in participants with NT1.
33049600|NCT04096560|Experimental|Part A, Cohort A1b, NT1 Participants: TAK-994|TAK-994 tablets, dose to be determined (TBD) based on safety, tolerability and/or efficacy in Cohort A1a participants with NT1.
33049601|NCT04096560|Experimental|Part A, Cohort A2 (Optional), NT1 Participants: TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort A1, for 28 days.
33049602|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 1|TAK-994 dose 1, tablets, for 56 days in participants with NT1.
33049603|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 2|TAK-994 dose 2, tablets, for 56 days in participants with NT1.
33049604|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 3|TAK-994 dose 3, tablets, 56 days in participants with NT1.
33049605|NCT04096560|Placebo Comparator|Part B, NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 56 days in participants with NT1.
33049606|NCT04096560|Placebo Comparator|Part C, NT1 Participants in China: Placebo|TAK-994 placebo-matching tablets for 56 days, in participants with NT1 in China.
33049607|NCT04096560|Experimental|Part C, NT1 Participants in China: TAK-994|TAK-994 tablets, dose TBD based on safety and tolerability in Part B, for 56 days in participants with NT1 in China.
33049608|NCT04096560|Placebo Comparator|Part D, Cohort D1a, D1b and D2, NT2 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT2.
33049609|NCT04096560|Experimental|Part D, Cohort D1a, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety, tolerability and/or efficacy in Part A , for 28 days in participants with NT2.
33049610|NCT04096560|Experimental|Part D, Cohort D1b, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety and/or tolerability efficacy in Cohort D1a participants with NT2.
33049611|NCT04096560|Experimental|Part D, Cohort D2, NT2 Participants (Optional) : TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort D1, for 28 days.
33049612|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
33049613|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
33049614|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
33049615|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
33049616|NCT05010707|Active Comparator|Transdermal estradiol plus spironolactone|"Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose."
33049617|NCT05010707|Active Comparator|Daily sublingual estradiol plus spironolactone|"Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
33331654|NCT04732338|No Intervention|Control - Standard of care|Standard of care including physical therapy, occupational therapy and over the counter medication.
33331655|NCT03754842|Placebo Comparator|Placebo|
33331656|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
33049618|NCT05010707|Active Comparator|Twice daily sublingual estradiol plus spironolactone|"Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
33049619|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
33049620|NCT04091880|Experimental|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
33049621|NCT04091880|Active Comparator|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
33049622|NCT04091880|Active Comparator|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
33049623|NCT00067873|Active Comparator|Diet only|
33049624|NCT00067873|Experimental|Diet plus aerobic exercise|
33049625|NCT00067873|Experimental|Diet plus resistance exercise|
33049626|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
33049627|NCT04999241|Experimental|EEN combined therapy group|in the induction of remission phase, EEN will be used combine with corticosteroids or infliximab
33049628|NCT04999241|Active Comparator|Non EEN combination group|in the induction of remission phase, corticosteroids or infliximab will be used without EEN
33049629|NCT04074096|Experimental|Encorafenib + binimetinib + pembrolizumab|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID) + pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W).
33049630|NCT04074096|Experimental|SRS followed by encorafenib + binimetinib + pembrolizumab|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID + pembrolizumab 200 mg IV Q3W. The treatment should be started more than 24 hours and less than 8 days (excluded) after the SRS
33049631|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
33049632|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
33049633|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
33049634|NCT04991870|Experimental|Group 1 (CB-NK-TGF-betaR2-/NR3C1- )|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity.
33049635|NCT04991870|Experimental|Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity.
33049636|NCT04987346|Experimental|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
33049637|NCT00392535|Active Comparator|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
33049638|NCT00392535|Experimental|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
33049639|NCT00392535|Experimental|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
33049640|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
33049641|NCT04975295|Experimental|LY3361237|LY3361237 administered subcutaneously (SC).
33049642|NCT04975295|Placebo Comparator|Placebo|Placebo administered SC.
33049643|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
33049644|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
33049645|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
33049646|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
33331657|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
33360733|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
33049649|NCT02966821|Experimental|Surufatinib|Surufatinib 300mg once-daily
33049650|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
33049651|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
33049652|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
33049653|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
33049654|NCT00399061|Active Comparator|1|Systane
33049655|NCT00399061|Active Comparator|2|Optive
33049656|NCT00399061|Placebo Comparator|3|Restasis
33049657|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
33049658|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
33049659|NCT04966637||Individuals with COPD|"This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.~This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort"
33049660|NCT04963712|Experimental|Zadaxin-HIV(n=20)|Study participants will be given Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the successive 22 weeks.
33418493|NCT04856319|Placebo Comparator|Placebo|placebo 1 hour prior to dental implant surgery
33418494|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
33049661|NCT04002219|Experimental|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
33049662|NCT04002219|Placebo Comparator|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
33049663|NCT04960280|Experimental|Computerized Auscultation|Patients presenting to the echocardiogram laboratory for routine clinically indicated echocardiography or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures will undergo a computerized auscultation using the ©VoqX stethoscope and will have their heart sounds auscultated and recorded.
33049664|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
33049665|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
33049666|NCT04958720||Cohort 1|Resectable non-advanced cancer
33049667|NCT04958720||Cohort 2|Unresectable advanced cancer
32740258|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
33049668|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
33049669|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
33049670|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
33049671|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
33049672|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
33049673|NCT03960099|Active Comparator|Pictograph in Banner and Verification Alert|Patient Pictograph displayed in the banner (at the top of the screen) AND Pictograph displayed in a verification alert when placing electronic orders.
33049674|NCT03960099|No Intervention|No Pictograph|No patient Pictographs displayed in the electronic health record.
33049675|NCT03960060|Experimental|CCT301-59|The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1x10^6, 3x10^6, 1x10^7 CCT301-59 CAR positive T cells/kg weight, intravenous infusion.
33049676|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
33049677|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
33049678|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
33360734|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
33360735|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
33360736|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
33360737|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
33360738|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
33360739|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
33360740|NCT03925363|Active Comparator|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
33360741|NCT03925363|Sham Comparator|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
33049679|NCT04953728|Experimental|Subjects with IBS-C|All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
33049680|NCT03960021|Experimental|Single arm|Each patient is treated with 2 RFA interventions.
33049681|NCT00070213|Active Comparator|MdG (modified de Gramont)|2 weekly 5FU/FA schedule
33049682|NCT00070213|Experimental|OxMdG (80%) for 12 weeks|MdG + oxaliplatin
33049683|NCT00070213|Experimental|Capcitabine|
33049684|NCT00070213|Experimental|OxCap|
33049685|NCT04949204||Migraine patients|Wearable wrist sensor + headache application on smartphone
33049686|NCT04949204||Cluster Headache Patients|Wearable wrist sensor + headache application on smartphone
33049687|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
33049688|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
33331658|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
33331659|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
33331660|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
33331661|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
33331662|NCT01569802||screening|
33331663|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
33331664|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
33331665|NCT04191590|Other|Patient with Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of Chronic Rhinosinusitis (CRS)
33418495|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
33418496|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
33418497|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
33418498|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
33418499|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
32740259|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
33418500|NCT04781283|Experimental|specular microscopy|The density measurement is a painless and very brief examination (less than a minute) during which the patient places his head on a chin rest while maintaining his forehead on a bar provided for this purpose while looking straight ahead. The measurements are then taken without contact with the patient's eye.
33418501|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
32740260|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
33049689|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
33049692|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
33049693|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
33049694|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
33049695|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
33049696|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
33049697|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
33049698|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
33049699|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
33049700|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
33049701|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33049702|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
32740261|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
33331666|NCT04191590|Other|Patient without Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of endonasal surgery for nasal obstruction or patients requiring an endonasal surgical approach such as pituitary adenomas for example.
33049703|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
33049704|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
33049705|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
33049706|NCT00070954|Placebo Comparator|2|look-alike placebo
33331667|NCT05761834||Partecipants with Fabry Desease (FD)|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin [IL]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor [TNF], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease [MMP]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1).~Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
33360742|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
33360743|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
33360744|NCT03925285|Experimental|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
33418502|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
33049707|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
33049708|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
33049709|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
33049710|NCT04730440||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
33049711|NCT04730440||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
33049712|NCT00071071|Experimental|280 mg and 560 mg|
33049713|NCT04910750|Active Comparator|Intervention Arm 1 - Pulse oximetry and Clinical Decision Support Algorithm|Facilities in intervention arm 1 will be provided with handheld pulse oximeters and tablet-based clinical decision support algorithms, with pulse oximetry, CDSA and IMCI refresher training
33049714|NCT04910750|Active Comparator|Intervention Arm 2 - Pulse oximetry alone|Facilities in intervention arm 2 will be provided with handheld pulse oximeters and paper-based guidance (pulse oximetry job aid and IMCI chart booklet integrating pulse oximetry), with pulse oximetry and IMCI refresher training
33049715|NCT04910750|No Intervention|Control Arm - Routine Primary Health Care|Facilities in the control arm will be provided with IMCI refresher training
33049716|NCT03959826|Active Comparator|Job activity contracting|Standard services plus job activity contracting
33049717|NCT03959826|Experimental|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
33049718|NCT03959787|Experimental|Educational pamphlet and standard care|patients randomized to the educational pamphlet arm will receive the educational pamphlet
33049719|NCT03959787|No Intervention|control group - standard care|Patients randomized to control arm, will receive the standard care.
33049720|NCT04908371|Active Comparator|Selective Trunk Block (SeTB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. After identifying the three trunks of the brachial plexus, ultrasound guided selective trunk block will be done using local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 20ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
33049721|NCT04908371|Active Comparator|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC-BPB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
33049722|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
33049723|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
33049724|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
33049725|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
33049726|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
33049727|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
33049728|NCT04895696|Experimental|Afimetoran: Dose 1|
33049729|NCT04895696|Experimental|Afimetoran: Dose 2|
33049730|NCT04895696|Experimental|Afimetoran: Dose 3|
33049731|NCT04895696|Placebo Comparator|Placebo|
33360745|NCT03924505|Experimental|Implementation Manual and External Facilitation|This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
33360746|NCT03924505|Active Comparator|Implementation Manual - only|This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
33049732|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
33049733|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
33049734|NCT00071500|No Intervention|3|Participants will not use any device
33049735|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
33049736|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
33049737|NCT00071539|Experimental|TP38 50 ng/mL|
33049738|NCT00071539|Experimental|TP38 100 ng/mL|
33049739|NCT03959709|Experimental|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
33049740|NCT03959709|Active Comparator|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
33049741|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
33049742|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
33049743|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
33049744|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
33049745|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
33049746|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
33049747|NCT04876040|Experimental|PCI+Impella plus SSO2|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated post-procedure with an infusion of SSO2 Therapy for a duration of 60 minutes.
33049748|NCT04876040|Active Comparator|PCI+Impella|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated with Standard of Care.
33049749|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
33049750|NCT03959670||Crawford extent III TAAA|
33049751|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
33049752|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
33049753|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
33049754|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
33049755|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
33049756|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
33049757|NCT03959631|Experimental|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
33049758|NCT03959631|No Intervention|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
33049759|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
33049760|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
33049761|NCT03959553|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
33049762|NCT03959553|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
33049763|NCT03959553|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
33049764|NCT04847141|Experimental|C19-IG 20% 1 g|Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 milliliters (mL) C19-IG 20% plus one syringe of 5 mL sterile 0.9% sodium chloride (NaCl) on Day 1.
33049765|NCT04847141|Experimental|C19-IG 20% 2 g|Participants will receive 2 g of C19-IG 20% SC infusion containing two syringes 5 mL each of C19-IG 20% on Day 1.
33049766|NCT04847141|Placebo Comparator|Placebo|Participants will receive C19-IG 20% matching placebo as SC infusion containing two syringes of 5 mL each sterile 0.9% NaCl injection on Day 1.
33049767|NCT03959514|Experimental|AT247|Single subcutaneous injection 0.3 U/Kg
33049768|NCT03959514|Active Comparator|NovoRapid|Single subcutaneous injection 0.3 U/Kg
33049769|NCT03959514|Active Comparator|Fiasp|Single subcutaneous injection 0.3 U/Kg
33049770|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049771|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049772|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049773|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33110173|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
33110174|NCT02053116|Experimental|PF-05175157|
33110175|NCT02053116|Placebo Comparator|Placebo|
33110176|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
33110177|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
33110178|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
33110179|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
33331668|NCT05761834||Partecipants with hypertrophic cardiomyopathy (HCM) systemic inflammation|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin [IL]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor [TNF], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease [MMP]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1). Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
33110180|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
33110181|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
33110182|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
33110183|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
33110184|NCT02913053|Active Comparator|Aerobic exercise|
33110185|NCT02913053|Active Comparator|Stretching and Toning|
33110186|NCT02913053|No Intervention|Usual care: Control Group|
33110187|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
33110188|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
33110189|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
33110190|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
33110191|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
32740262|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
32740263|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
33110192|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
33110193|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
33110194|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
33110195|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
32740264|NCT03307499|Experimental|Treatment|NeoPatch
33110196|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
33110197|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
33110198|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
33110199|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
33110200|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
33110201|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
33110202|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
33110203|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
33110204|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
33110205|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
33110206|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
33110207|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
33110208|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
33110209|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
33110210|NCT02026401|Placebo Comparator|Placebo|Placebo
33110211|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
33110212|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
33110213|NCT05355298|Experimental|AMP945|Part A: AMP945 administered in dose escalating cohorts Part B: AMP945 recommended phase 2 dose
32740265|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
33110214|NCT04318522|Experimental|Stimulation Group|
33110215|NCT04318522|Sham Comparator|Control Group|
33110216|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.~It was inserted only first time entry in the study."
33110217|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
32740266|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
33331669|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
33110218|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
33110219|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
33110220|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
33110221|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
33110222|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
33110223|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
33110224|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
33110225|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
33110226|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
33110227|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
33110228|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
33110229|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
33110230|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
33110231|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
33110232|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
33110233|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
32740267|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
33110234|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
33110235|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
33110236|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
33110237|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
33110238|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
33110239|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
33110240|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
33110241|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
33110242|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
33110243|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
33110244|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
33110245|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
33110246|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
33049774|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049775|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049776|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
33049777|NCT04730596|Placebo Comparator|Group I (Control group)|- The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
33049778|NCT04730596|Experimental|Group II (Ketamine group)|- The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
33049779|NCT04730596|Experimental|Group III (Dexmedetomidine group)|- The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
33049780|NCT04846088|Experimental|Product usage order ABICHDGEF|Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session
33049781|NCT04846088|Experimental|Product usage order BCADIEHFG|Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session
33331670|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
33331671|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
33331672|NCT03757104|No Intervention|control|standard of care
33049782|NCT04846088|Experimental|Product usage order CDBEAFIGH|Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session
33049783|NCT04846088|Experimental|Product usage order DECFBGAHI|Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session
33049784|NCT04846088|Experimental|Product usage order EFDGCHBIA|Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session
33049785|NCT04846088|Experimental|Product usage order FGEHDICAB|Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session
33049786|NCT04846088|Experimental|Product usage order GHFIEADBC|Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session
33049787|NCT04846088|Experimental|Product usage order HIGAFBECD|Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session
33049788|NCT04846088|Experimental|Product usage order IAHBGCFDE|Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session
33049789|NCT04846088|Experimental|Product usage order FEGDHCIBA|Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session
33049790|NCT04846088|Experimental|Product usage order GFHEIDACB|Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session
33049791|NCT04846088|Experimental|Product usage order HGIFAEBDC|Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session
33049792|NCT04846088|Experimental|Product usage order IHAGBFCED|Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session
33049793|NCT04846088|Experimental|Product usage order AIBHCGDFE|Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session
33049794|NCT04846088|Experimental|Product usage order BACIDHEGF|Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session
33049795|NCT04846088|Experimental|Product usage order CBDAEIFHG|Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session
33049796|NCT04846088|Experimental|Product usage order DCEBFAGIH|Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session
33049797|NCT04846088|Experimental|Product usage order EDFCGBHAI|Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session
33049798|NCT04730674|Experimental|post-mastectomty seroma group|female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. Then after 5 days the patient were examined again for seroma re-collection or the presence of complications. The amount of seroma aspirated in each session.
33049799|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
33049800|NCT03959397|Experimental|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
33049801|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
33331673|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
33331674|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 10^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10^6 CART22 cells/kg~Day 2, 30% fraction: 0.6-3x10^6 CART22 cells/kg~Day 3, 60% fraction: 1.2-6x10^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10^7~Day 2, 30% fraction: 0.3-1.5x10^8~Day 3, 60% fraction: 0.6-3x10^8"
33331675|NCT02341534|Other|BioMonitor arm|BioMonitor group (implantation with investigational device + transfer of information via Home Monitoring)
33331676|NCT02341534|No Intervention|Control arm|Control group (standard of care)
33049802|NCT04843904|Experimental|Venetoclax|"Participants will be separated into two cohorts: Cohort A: Patients at low risk for TLS. Cohort B: Patients with both median and high risk for TLS.~Five (5) participants from cohort A will be initially enrolled, if these first 5 participants tolerate the accelerated ramp-up, cohorts A and B will enroll simultaneously.~All participants will be hospitalized and receive venetoclax daily with accelerated dose increases over 5 days to reach full dose. After reaching full dose, participants will be discharged and continue daily venetoclax at home.~Per doctor assessment, some participants may also receive rituximab or obinutuzumab as part of the treatment regimen with venetoclax.~Rituximab: Given every 28 days starting on the second study cycle and continuing for up to 6 cycles as per standard of care.~Obinutuzumab: Days 1, 2, 8, and 15 of cycle 1 and once every 28 days there after for up to 6 cycles as per standard of care."
33049803|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.~The AIT exercise protocol includes the following components:~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
33049804|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
33049805|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
33049806|NCT04733586|Active Comparator|fascia iliaca group|
33049807|NCT04733586|Active Comparator|quadratus lumborum|
33049808|NCT04840589|Experimental|Doublet treatment (ZEN003694, nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening .
33049809|NCT04840589|Experimental|Triplet treatment (nivolumab, ZEN003694, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1, ipilimumab IV over 90 minutes on day 1, and ZEN003694 PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 5, patients are no longer treated with ipilimumab, but receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening and on study.
33049810|NCT00072631|Experimental|1 erlotinib|
33049811|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
33049812|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
33049813|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
33049814|NCT03959358|Experimental|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
33049815|NCT03959358|Experimental|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
33049816|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
33049817|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
33049818|NCT04839848||Permanent suture|Mesh fixation with permanent suture
33049819|NCT04839848||Long-term absorbable|Mesh fixation with long-term absorbable suture
33331677|NCT04189952|Experimental|Acalabrutinib + R-ICE|Acalabrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide (R-ICE). All participants will receive combination treatment for 3 cycles. Each cycle lasts 21 consecutive days. Combination treatment includes twice daily dose of Acalabrutinib, Rituximab on Day 1 of each cycle, Ifosfamide and Carboplatin on Day 2 of each cycle, and Etoposide on Days 1-3 of each cycle.
33331678|NCT04716426|Experimental|Tetracycline hydrochloride 3%|4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
33331679|NCT04716426|Placebo Comparator|Placebo|4 drops of placebo applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
33049820|NCT04839848||Short-term absorbable|Mesh fixation with short-term absorbable suture
33331680|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
33331681|NCT03694548|Other|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
33331682|NCT03694548|Other|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
32740268|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
32869574|NCT05709249|Placebo Comparator|control group|Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
33049821|NCT04839848||Fibrin glue|Biologic glue/sealant produced from human donor blood
33049822|NCT04839848||Progrip|Pre-fabricated absorbable fixation hooks, integrated in mesh. Progrip is a registered trademark owned by Medtronic
32869575|NCT05709171|Experimental|Experimental|Each patient will undergo one standard of care 18FDG PET/CT and one 64Cu-DOTATATE PET/CT within 4 weeks.
33049823|NCT03959280|Experimental|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
33049824|NCT03959280|Active Comparator|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
33331683|NCT03694548|Experimental|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
33331684|NCT01747096|Experimental|68-Ga-DOTANOC|
33331685|NCT04166630|Experimental|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
33331686|NCT04166630|Experimental|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
33049825|NCT04837118|Experimental|Supportive care (resistance training)|SEE DETAILED DESCRIPTION.
33049826|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
33049827|NCT03959163|Other|DMSA/Quick MRI|All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.
33049828|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
33049829|NCT02966197|No Intervention|Control group|no intervention
33049830|NCT04834349|Experimental|Cohort I (NBTXR3, SBRT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo SBRT QOD on days 15-29. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33049831|NCT04834349|Experimental|Cohort II (NBTXR3, IMRT/IMPT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
33049832|NCT00072982|Active Comparator|1|Fish Oil
33049833|NCT00072982|Active Comparator|2|Borage Oil
33049834|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
33049835|NCT03959124|Experimental|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
33049836|NCT03959124|Active Comparator|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
33049837|NCT03959124|No Intervention|Normal control|Matched aged and demographics subjects
33049838|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
33049839|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
33049840|NCT03959046|Experimental|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
33049841|NCT03959046|No Intervention|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
33049842|NCT04827953|Experimental|Investigational treatment|Conventional Chemotherapy (Gemcitabine + nab-paclitaxel) plus NLM-001 plus Zalifrelimab
33049843|NCT04711291|No Intervention|Remain on IR-Tac prescribed doses every 12 hours|Patient will remain in Tacrolimus IR-Tac Arm and will complete medication adherence questionnaire monthly. They will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus Trough levels and change in tacrolimus dose levels during their routine follow up.
33049844|NCT04711291|Active Comparator|Convert to Envarsus XR once daily|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR and will complete medication adherence questionnaire. However, patients in this group will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
32869576|NCT00101933|Experimental|1|Active Stimulation
33331687|NCT05761756|Active Comparator|Sleep Deprivation|Effect of sleep deprivation on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be tested before and after 24 hours of sleep deprivation. The order of sleep deprivation vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
33331688|NCT05761756|Experimental|Caffeine|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally [59]. Pre-dive methylphenidate will be administered as a single dose of 5 mg [60]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
33331689|NCT05761756|Experimental|Methylphenidate|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally [59]. Pre-dive methylphenidate will be administered as a single dose of 5 mg [60]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
33331690|NCT05761756|Experimental|Carbon Dioxide Exposure|Effect of simulated chronic CO2 exposure on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be studied before and after induction of metabolic alkalosis as described above with daily oral administration of sodium bicarbonate. Oral bicarbonate to simulate hypercapnia exposure will seek to increase serum bicarbonate to 30 mM/L via daily oral intake of 6 teaspoons of NaHCO3 for five days. Subsequently, blood will be drawn and intake adjusted as necessary [61]. The order of alkalization vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
32869577|NCT00101933|Sham Comparator|2|No Stimulation
33049845|NCT04711291|Experimental|Convert to Envarsus XR once daily combined with TransMedAx app use|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR, will receive notification by scanning a QR code through TransMedAx application and will complete medication adherence questionnaire. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
33049846|NCT04821830||Parkinson's disease patients who take levo-dopa as standard of care|Participants will undergo evaluation of the relationship between the LDR and movement vigor. All participants will undergo standard evaluation with standard clinical rating scales and three outcome measures: Tapping Speed Task - Measurement of Bradykinesia; Grip Strength Task - Measurement of Incentive-Outcome Coupling - Movement Vigor; Joystick Movement Task - Measurement of Incentive-Outcome Coupling - Movement Vigor. Some participants may opt in to an additional training and evaluation: Value Driven Attentional Oculomotor Capture.
33049847|NCT03958929|Experimental|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
33049848|NCT03958929|No Intervention|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
33049849|NCT04820855|Experimental|Treatment|This is an individual treatment program devised by a pelvic floor physical therapist including a daily yoga series and mindfulness via a Smartphone app.
33049850|NCT04820855|Active Comparator|Control|These are participants undergoing regular treatment for interstitial cystitis with their providers
33049851|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
33049852|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
33049853|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
33049854|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
33049855|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
33049856|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
33049857|NCT03958890|Experimental|HLX10|
33049858|NCT03958890|Placebo Comparator|placebo|
33049859|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
33049860|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
33049861|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
33049862|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
33049863|NCT00073840|Placebo Comparator|III|Placebo QID
33049864|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
33049865|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
33049866|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
33331691|NCT05234736|Experimental|CBL-514|All 10 participants enrolled in the study will receive a single course of treatment with CBL-514 800 mg (unit dose: 2.0 mg/cm^2) on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.
33331692|NCT04544046|Active Comparator|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
33331693|NCT04544046|Experimental|Supportive Oncology Care at Home|"The research study procedures include:~Remote monitoring of symptoms, vitals, and body weight~Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)~Data collection from medical record"
33331694|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
33331695|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
33049870|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
33331696|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
33331697|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
33331698|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
33331699|NCT05200884|Active Comparator|: A (Lidocaine 2%)|"20 children will be injected with 1 ml of lidocaine 2% with epinephrine. each one received lidocaine2% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e. 20 injections will be distributed randomly to the two drugs using the randomization table"
33049871|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
33049872|NCT04781387|Experimental|CRS3123 200 milligram|"CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
33049873|NCT04781387|Experimental|CRS3123 400 milligram|"CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
33049874|NCT04781387|Active Comparator|Vancomycin 125 milligram|Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
33049875|NCT02965885|Experimental|TAS-116|
33049876|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
33049877|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
33049878|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
33049879|NCT04767776|Experimental|Arm A|"Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)"
33049880|NCT04767776|Experimental|Arm B|"Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)"
33049881|NCT04767776|Experimental|Arm C|"Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)"
33049882|NCT04767776|Experimental|Arm D|"Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)"
33049883|NCT04730284|Experimental|Health supplements|One arm only
33049884|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
33049885|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
33049886|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
33049887|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
33049888|NCT03958812||Normal|healthy volunteers
33049889|NCT04754321|Experimental|Arm A (pembrolizumab, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
33049890|NCT04754321|Experimental|Arm B (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
33049891|NCT04754321|Experimental|Arm C (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
33049892|NCT04730245|Experimental|Microbiota modification|
32740269|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
33110247|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
33110248|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
33110249|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
33110250|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
33110251|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
33110252|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
33110253|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
33110254|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
33110255|NCT02912234|Experimental|Apixaban and Clarithromycin|
33110256|NCT04676139|Experimental|Fluoxetine|patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks
33110257|NCT04676139|Placebo Comparator|Placebo|patients will undergo maintenance therapy Placebo for 12 weeks
33110258|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
33110259|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
33110260|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
33331700|NCT05200884|Experimental|B (Articaine 4%)|"20 children will be injected with 1 ml of Articaine 4% with epinephrine. each one received articaine 4% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e.20 injections will be distributed randomly to the two drugs using the randomization table"
33331701|NCT04178720|Experimental|LID018869|Lehfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
33331702|NCT04178720|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
33331703|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
33331704|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
33331705|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
33360747|NCT03929341|Experimental|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
33049893|NCT03958773|Experimental|Cardiovalve treatment|Patients that implanted with the Cardiovalve device
33049894|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
32740270|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
33049895|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
33049896|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
33049897|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
33049898|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
33049899|NCT03958734|Other|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
33049900|NCT03958734|Other|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
33049901|NCT00074776|Experimental|1 Lithium|
33049902|NCT00074776|Experimental|2 Lamotrigine|
33049903|NCT00074932|Other|1|
33049904|NCT03958695|Active Comparator|Tunable-tension transobturator tape (TTT)|
33049905|NCT03958695|Active Comparator|Transobturator mid-urethral tape (TOT)|
33049906|NCT04741256|Experimental|Tracheostomy discharge protocol|"All head and neck cancer patients regardless of participation in the study will receive the standard of care: A copy of a tracheostomy education booklet and standardized discharge training for patients and their caregivers by nursing staff during their inpatient stay.~Research personnel will provide protocol training to the inpatient nurses who are to provide training to caregivers.~Pre-implementation phase: Eligible patient participants identified & healthcare utilization recorded. Nursing staff participants complete nursing survey to capture volume of tracheostomy-related questions received.~Protocol-phase: Caregiver participants will complete a survey prior to patient tracheostomy, on day of patient discharge, and one week following discharge~Post-implementation phase: Nursing staff participants will complete an additional survey similar to the one in the pre-implementation phase. EMR will be reviewed for implementation fidelity."
33049907|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
33049908|NCT04729595|Active Comparator|Active Treatment|Tempol (MMB-02) 800 mg per Day (n=124)
33049909|NCT04729595|Placebo Comparator|Placebo|Placebo (n=124)
33049910|NCT01349829|Experimental|HAVpur|
33049911|NCT01349829|Active Comparator|Havrix|
33049912|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
33049913|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
33049914|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
33049915|NCT04716101|Experimental|Patients with nonspecific low back pain|Patients will be randomized to receive either a massage technique or a sham massage technique.
33049916|NCT04716101|Active Comparator|Asymptomatic volunteers|Similarly, the volunteers will be randomized to receive either a massage technique or a sham massage technique.
33049917|NCT03958617|Active Comparator|On condition|Ongoing thalamic deep brain stimulation
33049918|NCT03958617|Sham Comparator|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
33049919|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33049920|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
33049921|NCT04707443|Experimental|donor human milk|For patients who can be fed orally or through tubes after surgery, donor milk will be used to feeding for 4 weeks.
33049922|NCT04707443|Active Comparator|extensively hydrolyzed formula|For patients who can be fed orally or through tubes after surgery, extensively hydrolyzed formula will be used to feeding for 4 weeks.
33049923|NCT03958539|Active Comparator|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
33049924|NCT03958539|No Intervention|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
33049925|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
33049926|NCT04703855|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
33049927|NCT03958500|Experimental|Comprehensive anastomotic testing|"All patients undergo:~Indocyanine green fluorescent angiography intraluminally and intraperitoneally~Air leak test~Methylene blue test"
33049928|NCT04690907|Experimental|Intervention group|Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
33049929|NCT04690907|No Intervention|Control group|Written material on healthy diet during pregnancy, otherwise basic care and counseling at maternity care clinics.
33049930|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
33360748|NCT03929341|Experimental|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
33049931|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
33049932|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
33049933|NCT00392730||1|Preterm infants in NICU and age-matched controls
33049934|NCT00392730||2|Term infants in NICU and age-matched controls
33049935|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
33049936|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
33049937|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
33049938|NCT04650425|Experimental|Intervention group|Each participant will undergo one or two sessions, consisting of cognitive tasks, video-EEG recording and administering of questionnaires.
33049939|NCT03958422|Experimental|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
33049940|NCT03958422|No Intervention|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
33049941|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
33049942|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
33049943|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
33049944|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
33049945|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
33049946|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
33049947|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
33049948|NCT03958383|Experimental|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
33049949|NCT04608188|Experimental|Summer Program|Children in the intervention will attend a summer day camp operated at their school.
33049950|NCT04608188|No Intervention|No Program|The control children will not receive an intervention of any kind and will be asked to go about their summer as they typically would.
33049951|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
33049952|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
33049953|NCT00399334||001|
33049954|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
33049955|NCT00399373||Control group|No additional improvement modalities
33049956|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
33049957|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
33049958|NCT04607993|Experimental|Prone position ventilation technique|Prone position ventilation for children with congenital heart disease after surgery
33049959|NCT04607993|No Intervention|Control group|conventional postoperative position, no prone position ventilation
33049960|NCT03958227|Experimental|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
33049961|NCT03958227|Experimental|''Exercise group''|This treatment group will be received only exercise interventions.
33049962|NCT04591808|Experimental|S05167|
33049963|NCT04591808|Active Comparator|Lipitor®|
33331706|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
33331707|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
33331708|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
32740271|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
32740272|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
33049964|NCT04591808|Active Comparator|Coversyl®|
33049965|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).~Clinical data collected for each patients:~Age~Sex~Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)~Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)~Carcinoid valvulopathy"
32740273|NCT03307265|Experimental|Imbalance correction|
32740274|NCT03307265|Active Comparator|Control|
33049966|NCT04576949|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
33049967|NCT04576949|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
33049968|NCT04576949|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
33049969|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
33049970|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
33049971|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
33049972|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
33049973|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
33049974|NCT04572074|Active Comparator|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
33049975|NCT04572074|Experimental|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
33049976|NCT03951207|Experimental|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
33049977|NCT03951207|Experimental|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
33049978|NCT03951207|Active Comparator|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
33049979|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
33049980|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
33049981|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
33049982|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
33049983|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
33049984|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
33049985|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
33049986|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
33049987|NCT03939429|Experimental|QPX2015|QPX2015, antibiotic
33049988|NCT03939429|Placebo Comparator|Placebo|Matched placebo
33049989|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
33049990|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
33049991|NCT04729894|Experimental|Safe Medication Storage Device + Education|
33049992|NCT04729894|Active Comparator|Education|
33049993|NCT03927222|Experimental|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed GBM patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
33049994|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
33049995|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
33049996|NCT04561388|Other|Cochlear implant candidates with measurable residual hearing|"Electrocochleography responses to acoustic will be recorded during the cochlear implantation and the 6 first months of use of the cochlear implant.~A pure tone audiometry will be done prior and after the implantation. Speech audiometry will be done twice after the cochlear implantation."
33049997|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33049998|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
33049999|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33050000|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
33050001|NCT04551482|Experimental|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
33050002|NCT04551482|Placebo Comparator|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
33050003|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
33050004|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
33050005|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33050006|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
33050007|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
33050008|NCT03780972|Active Comparator|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
33050009|NCT03780972|Active Comparator|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
33050010|NCT03780972|Active Comparator|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
33050011|NCT03780972|Active Comparator|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
33050012|NCT04551053|Experimental|Group A : ruxolitinib +parsaclisib|Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
33050013|NCT04551053|Placebo Comparator|Group B : ruxolitinib + placebo|Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
33050014|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
33050015|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
33110261|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
33331709|NCT03749096|Placebo Comparator|Placebo|
33331710|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
33331711|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
33331712|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
33331713|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
33331714|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
33331715|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
33331716|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
33331717|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
33331718|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
33331719|NCT04173572|Experimental|Walking Group|Participants will be walking two times a week in supervised virtual walking groups on a secure online platform (Zoom) and will also participate in independent walks done at a location of their own choosing outside group participation.
33050016|NCT04549571|Experimental|Arm I: (iCanDecide - ESE)|Patients utilize the iCanDecide - ESE website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
33050017|NCT04549571|Active Comparator|Arm II: (iCanDecide - S)|Patients utilize the iCanDecide - S website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
33050018|NCT04549571|Experimental|Clinics 1-5: (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 1-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33418503|NCT04769739|Active Comparator|CO2 insufflation|Colonoscopy will be performed in the traditional fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal.
33050019|NCT04549571|Experimental|Clinics 6-8 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 10-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050020|NCT04549571|Experimental|Clinics 9-11 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 20-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050021|NCT04549571|Experimental|Clinics 12-14 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 30-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050022|NCT04549571|Experimental|Clinics 15-17 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 40-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050023|NCT04549571|Experimental|Clinics 18-20 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 50-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050024|NCT04549571|Active Comparator|Clinics 21-25 (usual care)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and continue to provide breast cancer surgical care per their usual care. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
33050025|NCT03766581|Placebo Comparator|BMS-986177 Placebo|Specified Dose on Specified Days
33050026|NCT03766581|Experimental|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050027|NCT03766581|Experimental|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050028|NCT03766581|Experimental|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050029|NCT03766581|Experimental|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050030|NCT03766581|Experimental|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050031|NCT03766581|Experimental|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050032|NCT03766581|Experimental|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
33050033|NCT00399412||LQTS|Long QT syndrome
33050034|NCT00399412||HF|Heart Failure
33050035|NCT00399412||CRT|Cardiac Resynchronization Therapy
33050036|NCT00399412||Wide QRS|QRS > 120 milliseconds
33050037|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
33050038|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
33050039|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
33050040|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
33050041|NCT04711447|Other|no-tape, experimental KT, sham KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition.
33050042|NCT04711447|Other|no-tape, sham KT, experimental KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both a sham-KT (S-KT) condition and experimental-KT (E-KT).
33050043|NCT04538417|Other|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
33050044|NCT04711213|Active Comparator|Dexamethasone Dose 1|
33050045|NCT04711213|Active Comparator|Dexamethasone Dose 2|
33050046|NCT04711213|Placebo Comparator|Placebo Dose 1|
33050047|NCT04711213|Placebo Comparator|Placebo Dose 2|
33050048|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
33050049|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
33050050|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
33418504|NCT04769739|Active Comparator|WE with water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual decal debris, predominantly during insertion.
33331720|NCT04173572|Active Comparator|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
33331721|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
33331722|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
32740275|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
32740276|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
32740277|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
32740278|NCT03311243|Active Comparator|Systemically healthy controls|
32740900|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
33050051|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
33050052|NCT04534751|Experimental|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
33050053|NCT04534751|Active Comparator|Control Group: Standard FP transfusion|Frozen Plasma (FP)
33050054|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
33050055|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
33050056|NCT04510454|Experimental|RT-PCR and ddPCR sampling analyses|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
33050057|NCT00078520|Experimental|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
33050058|NCT00078520|Experimental|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
33050059|NCT00078520|Experimental|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
33331723|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
33331724|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
33050060|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
33331725|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
33050061|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
33050062|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
33050063|NCT00078832|Experimental|anastrozole|anastrozole 1mg
33050064|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
33110262|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
33331726|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
33360749|NCT03929341|Active Comparator|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
33331727|NCT04676412|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
33331728|NCT04676412|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
33050065|NCT03659916|Experimental|A4250|"Capsules for oral administration (40 or 120 µg/kg) once daily for 72 weeks, or 40 µg/kg/day for the first 12 weeks followed by 120 µg/kg/day for the remaining 60 weeks"
33050066|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
33050067|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
33050068|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
33050069|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
33050070|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
33050071|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
33050072|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
33050073|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
33050074|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
33050075|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
33050076|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
33050077|NCT04478708|Experimental|Part A: AMG 133|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
33050078|NCT04478708|Placebo Comparator|Part A: Placebo|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
33050079|NCT04478708|Experimental|Part B: AMG 133|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
33050080|NCT04478708|Placebo Comparator|Part B: Placebo|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
33050081|NCT04478708|Experimental|Part C: AMG 133|Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
33050082|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
33050083|NCT00079105|No Intervention|Registration|Registration, without treatment
33050084|NCT04472429|Placebo Comparator|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
33050085|NCT04472429|Experimental|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
33050086|NCT03647124||Lenalidomide treated Relapsed or refractory mantle cell lymphoma (R/R-MCL) participants in Europe|
33050087|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
33050088|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
33050089|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
33050090|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
33050091|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
33050092|NCT04467827||Group A1 male|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
33050093|NCT04467827||Group A2 female|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
33050094|NCT04467827||Group B1 male|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
33050095|NCT04467827||Group B2 female|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
33050096|NCT04467827||Group C1 male|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
33050097|NCT04467827||Group C2 female|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
33067982|NCT04510051|Experimental|Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)|Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
33067983|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
33050098|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
33050099|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33050100|NCT04467086|No Intervention|Control Arm - Usual Care|"Participants in the control group will receive usual intravenous sedation according to practices already in place at each participating site. The choice of agent, route of delivery, method of monitoring, and target levels of sedation will be determined by the treating team; however, we will recommend best practice clinical guidelines be followed. Current guidelines recommend analgesia first sedation titrated to relief of pain and dyspnea and sedative infusions if need for anxiety or agitation titrated to a prescribed level of sedation using a validated sedation scale. Patients may receive adjunct sedative/analgesic medications (e.g., enteral benzodiazepines) but propranolol use in the control group will be considered a protocol violation."
33050101|NCT04467086|Experimental|Intervention Arm - Propranolol hydrochloride|"Participants in the control arm will received sedation as described for the control arm, but with the addition of propranolol hydrochloride (titrated up as described under Intervention Description) and a corresponding reduction in sedatives as appropriate and described under Intervention Description."
33050102|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
33050103|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
33050104|NCT03528681|Placebo Comparator|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
33050105|NCT04466228|Experimental|Stim1 high dose|This group will receive high dose non-invasive transcranial electrical stimulation
33050106|NCT04466228|Experimental|Stim2 low dose|This group will receive low dose non-invasive transcranial electrical stimulation
33050107|NCT04466228|Sham Comparator|Sham control|This group will receive sham control non-invasive transcranial electrical stimulation
33050108|NCT00079612|Experimental|Arm 1|
33050109|NCT00079612|Placebo Comparator|Arm 2|
33050110|NCT03526107|Active Comparator|CF Control|CF Control: 587 mg of cocoa flavanols (101 mg epicatechin), <1 mg caffeine and <1 mg theobromine
33050111|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols (102 mg epicatechin), 11 mg caffeine and 93 mg theobromine
33050112|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols (101 mg epicatechin), 112 mg caffeine and <1 mg theobromine(Experimental)
33050113|NCT04451720|Experimental|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
33050114|NCT04451720|Experimental|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
33050115|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
33050116|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
33050117|NCT00079963|Experimental|X|Vitamin C
33050118|NCT00079963|Experimental|Y|Vitamin E
33331729|NCT05134740|Experimental|Experimental Arm|Patients receiving autologous TAA-specific cytotoxic CTLs
33050119|NCT00079963|Placebo Comparator|Z|Placebo
33050120|NCT04450901|Experimental|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
33050121|NCT04450901|Experimental|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
33331730|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
33331731|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
33331732|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
33331733|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
33331734|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
33050122|NCT04450901|Experimental|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
33050123|NCT04450901|Experimental|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
33050124|NCT04450901|Experimental|Cohort B1|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
33050125|NCT04450901|Experimental|Cohort B2|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 3 weeks (Q3W). Dose: 300 mg"
33067984|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
33067985|NCT04517734||Pregnant Adolescents|
33331735|NCT05334264|Experimental|Group A|cervical cerclage between 14 and 20 weeks will be done by one of the three authors. McDonald cervical cerclage.
33331736|NCT05334264|No Intervention|Group B|Routine antenatal care without cerclage
33331737|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
33050126|NCT04450901|Experimental|Cohort B2 reserve|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 300 mg"
33331738|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
33331739|NCT05070702|Experimental|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
33331740|NCT05070702|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
33331741|NCT05070702|Experimental|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
33050127|NCT04450901|Experimental|Cohort B3|"Tumor type: Metastatic NSCLC (Non-small-cell lung carcinoma), unresectable or metastatic, MSI-H (microsatellite instability-high) or dMMR (Deficient MisMatch Repair), recurrent or metastatic HNSCC (Head and neck squamous cell carcinoma), non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer.~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
33050128|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
33050129|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
33050130|NCT04437368|Experimental|GT005 Low Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
33050131|NCT04437368|Experimental|GT005 High Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
33050132|NCT04437368|No Intervention|Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
33050133|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
33050134|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
33050135|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
33050136|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
33050137|NCT04436666|Experimental|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
33050138|NCT04436666|Experimental|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
33331742|NCT05070702|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
33360750|NCT03929341|Active Comparator|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
33050139|NCT04436666|No Intervention|control|No Intervention
33050140|NCT00080314|Active Comparator|A1|
33050141|NCT00080314|Placebo Comparator|A2|
33050142|NCT04435496|Other|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
33050143|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
33050144|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
33050145|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
33050146|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
33050147|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
33050148|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
33360751|NCT04464694|Experimental|Ranibizumab|Single intravitreal injection of ranibizumab (0.5 mg) 3~7 days before vitrectomy
33050149|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
33331743|NCT04150250|Experimental|iOWH032|On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
33050150|NCT04423367|Experimental|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
33050151|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
33050152|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
33050153|NCT03444948|Experimental|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
33050154|NCT03444948|Active Comparator|standard medical care|Subject will receive standard medical care, including pain relief drugs
33050155|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
33050156|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
33050157|NCT04343027|No Intervention|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
33050158|NCT04343027|Experimental|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
33050159|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
33050160|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
33050161|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
33050162|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
33050163|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
33050164|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
33050165|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
33050166|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
33050167|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
33050168|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
33050169|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
33050170|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
33050171|NCT04319510|Experimental|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
33050172|NCT04319510|Experimental|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
33050173|NCT04319510|Other|Treatment as usual / wait list control|Waiting period of six months.
33050174|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
33050175|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
33050176|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
33050177|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
33050178|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
33050179|NCT00081484|Experimental|1|
33050180|NCT00081484|Active Comparator|2|
33050181|NCT04317716|Experimental|Intervention|Fall prevention program and brochure about falls and fall risk factors
33050182|NCT04317716|Other|Control|Bbrochure about falls and fall risk factors
33050183|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
33050184|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
33050185|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~1 session of exercise counseling~3 weekly 25-minute sessions of vigorous intensity aerobic exercise~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
33050186|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
33050187|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
33067986|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
33331744|NCT04150250|Placebo Comparator|Placebo|On Day 1, participants were challenged with 10^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
33331745|NCT04537806|Placebo Comparator|Placebo|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous intravenous (IV) infusion of brexanolone-matching placebo.
33331746|NCT04537806|Experimental|Brexanolone|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous IV infusion of brexanolone at 70 micrograms per kilogram per hour (mcg/kg/h) for 58 hours followed by a 2-hour taper of brexanolone at 35 mcg/kg/h.
33331747|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
33360752|NCT04464694|Sham Comparator|Sham injection|Sham injection 3~7 days before vitrectomy
33067987|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
33067988|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
33067989|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
33067990|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
33067991|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
33067992|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
33067993|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
33067994|NCT00504946|Active Comparator|I|
33067995|NCT00504946|Active Comparator|II|
33067996|NCT00504946|Placebo Comparator|III|
33067997|NCT00504946|Active Comparator|A|
33067998|NCT00504946|Placebo Comparator|B|
33067999|NCT00505024|Experimental|IVRS Only|
33068000|NCT00505024|Experimental|IVRS + Symptoms Report|
33068001|NCT04511416|Active Comparator|Intervention|Metformin
33068002|NCT04511416|Placebo Comparator|Placebo|Placebo
33068003|NCT04517695||COVID-19 ICU Patients|Patients who are admitted to the ICU with a confirmed SARS-CoV-2 infection
33068004|NCT04517695||ICU Patients with bacterial infection|"Patients who are admitted to the ICU with a confirmed bacterial infection.~Bacterial infection is defined as the clinical suspicion of a bacterial infection with the presence of two or more clinical markers of infection:~abnormal body temperature (>38C or <36C)~increased heart rate (>90 b/min),~increased respiratory rate > 20/min or a decreased arterial CO2: PaCO2 < 32 mmHg~Abnormal white blood cell count: < 4000 mm3 or > 12,000 /mm3 or > 10% immature cells~OR~The presence of a positive (blood) culture with bacterial growth."
33068005|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
33068006|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
33068007|NCT00407082|No Intervention|No intervention|Fellow eye
33068008|NCT04517617||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
33068009|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)] ,tacrolimus, mycophenolate mofetil and prednisone~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
33068010|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
33068011|NCT04512040|Experimental|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
33068012|NCT04510363||cardiac arrest survivors|cardiac arrest survivors
33068013|NCT04510363||age- and sex-matched controls|age- and sex-matched controls
33068014|NCT00155259|Experimental|A|
33068015|NCT04517383|Experimental|POS group|Patients in the POS group will undergo ET under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6hrs, during which period the patients will be sedated with sedatives to maintain a BIS value of 50~70 and Ramsay sedation score of 5 ~ 6. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs. After 6hs, the patients will be recovered and extubated.
33068016|NCT04517383|Active Comparator|Con group|Patients in the Con group will undergo ET under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs for at least 7hrs after the surgery.
33068017|NCT04519216|Active Comparator|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
33068018|NCT04519216|Experimental|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
33068019|NCT04518124|Experimental|Propranolol|
33068020|NCT04517344|Experimental|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If oxygen saturation (SpO2) is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
33050188|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
33050189|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
33050190|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
33050191|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
33050192|NCT00399685|Active Comparator|A|
33050193|NCT00399685|Active Comparator|B|
33050194|NCT00399685|Active Comparator|C|
33050195|NCT00399685|Active Comparator|D|
33050196|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
33050197|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
33050198|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
33050199|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
33050200|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
33050201|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
33050202|NCT00082147|Experimental|Biopsy|Biopsy
33050203|NCT00082186|Experimental|1|Oral bosentan tablets
33050204|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
33050205|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
33050206|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
33050207|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
33331748|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
33331749|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
33331750|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
33331751|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
33331752|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
33331753|NCT04533204|Experimental|Mnemonic strategy training|Training using mnemonic strategies
33050208|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
33050209|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
33331754|NCT04533204|Active Comparator|Spaced retrieval training|Training using spaced retrieval
33331755|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
33331756|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
33331757|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
33331758|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
33331759|NCT04465422|Experimental|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
33360753|NCT03924349|Experimental|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
33050210|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
33050211|NCT03151980|Other|Untreated skin and sun exposure|
33050212|NCT04269239|Other|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
33050213|NCT04269239|Other|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
33050214|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
33050215|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
32871585|NCT05185973|Placebo Comparator|Micronutrient powder|Micronutrient powder containing containing glucose 236.3mg, xylitol 150mg, chocolate powder 600mg, chocolate flavor powder 45mg, organic galactose oligosaccharide 60mg, chicory extract powder 60mg, vegetable Cream substitute 135mg, silicon dioxide 45mg, milk flavor powder 30mg, whole milk powder 75mg, zinc oxide 11.2mg, vitamin B12 2.6mg, vitamin B6 2mg, enzyme mixed preparation 2mg, vitamin C 1mg, organic alpha rice powder 1mg, folate 0.4mg, thiamine 0.5mg, and maltodextrin 1,541mg.
33050216|NCT04259450|Experimental|AFM24|"Phase 1: Treatment of escalating doses of AFM24.~Phase 2a: Treatment of AFM24 at maximum tolerated dose/recommended phase 2 dose, stratified into cohorts by tumor type."
33050217|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
33050218|NCT04245956|Experimental|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
33050219|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
33050220|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
33050221|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
33331760|NCT04465422|Active Comparator|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
33331761|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
33050222|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
33050223|NCT04240691||Time-and-Attention Control Session|60 Minute diet & nutrition control session
33050224|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
33050225|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
33050226|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
33050227|NCT04729699|Experimental|Intervention group|Intervention group (n=10) received 12 physiotherapy sessions and exercises for TMJ 30-45 minutes 2 days per week.
33050228|NCT04729699|Active Comparator|Control group|Control group (n=9) was introduced with physiotherapy program in order to perform it independently at home.
33050229|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
33050230|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
33050231|NCT03151707|Experimental|Nicotinamide riboside 2g/day|Participants will receive NR at a dose of 2g/day
33050232|NCT05568589||Preoperative Interpectoral - Pectoserratus Plane Block|The block will be done by the Anesthesiologist.
33050233|NCT05568589||Intraoperative Interpectoral - Pectoserratus Plane Block|The block will be made by the surgeon.
33050234|NCT05568589||Non Block|will not be blocked.
33050235|NCT05568316|Experimental|Experimental: Preoperative Immunonutrition (Group 1)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for only 5 days before surgery, in addition to their standard isocaloric diet.~Duration: 5 days (preoperative) Dietary therapy: Standard oral nutrition and IMN product for 5 days before operation.~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
33050236|NCT05568316|Experimental|Experimental: Perioperative Immunonutrition (Group 2)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~Duration: 5 days preoperative and 5 days postoperative Dietary therapy: Standard oral nutrition and IMN product for 5 days before and after operation (perioperative).~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
33050237|NCT05568277|Experimental|Education|A minimum of 12-week training program and follow-up based on Pender's Health Promotion Model is planned until the 24th gestational week.
33050238|NCT05568277|No Intervention|Control|No intervention will be made by the researcher and they will receive routine antenatal care. After the post-test data are collected, the education booklet prepared by the researcher will be given to the pregnant women and sent to their e-mail addresses.
33050239|NCT05568238|Other|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction|Incisional hernia incidence for patients treated with Vacuum Assisted Wound Closure and Permanent On-lay Mesh mediated fascial traction
33050240|NCT03151668|Experimental|Dexmedetomidin|
33050241|NCT03151668|No Intervention|Midazolam|
33110263|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
33110264|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
33110265|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
33110266|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
33110267|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
33110268|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
33110269|NCT04676061|Placebo Comparator|Control Group|Placebo to Norethindrone acetate (NTA)
33110270|NCT04676061|Active Comparator|Treatment Group|Norethindrone acetate (NTA)
33110271|NCT02946905||SCD participant|No intervention
33110272|NCT02946905||Non-SCD participant|No intervention
33110273|NCT04675944|Experimental|BIA 5-1058 / treprostinil|Three treatment periods separated by a washout period of at least 10 days
33110274|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
33110275|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
33110276|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
33110277|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
33110278|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~Group 1 will receive EW02 for 15 consecutive days during the second cycle~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
33110279|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~Group 2 will receive 15 consecutive days of Placebo~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
33110280|NCT01991184|Experimental|Dose-escalation|
33110281|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
33110282|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
33110283|NCT02911883||Normal|Not having glaucoma or retinal pathology
33110284|NCT02911883||Glaucoma|Having glaucoma.
33110285|NCT02911883||Retina|Having retinal pathology
33110286|NCT04675905||PACORUS-D Main cohort|Eligibility, Endpoints as described above
33110287|NCT04675905||PACORUS-D Delirium-Subcohort|Eligibility: patients aged >= 65 years undergoing noncardiac nonneurosurgical procedures (definition see above); Endpoints as described above; additional explanatory variable: postoperative Delirium detected by CAM on postoperative day 1 and 2
33110288|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
33110289|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
33331762|NCT04676256|Experimental|Early Vitrectomy|Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
33331763|NCT04676256|Active Comparator|Comparator|"Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.~Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up"
33331764|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
33331765|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
33331766|NCT03744806||treated with intravitreal bevacizumab.|
33110290|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
33110291|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
33110292|NCT01989429|Active Comparator|Daivonex|topical application
33110293|NCT01989429|Placebo Comparator|vehicle|topical application
33110294|NCT01989429|Experimental|M518101|topical application
33110295|NCT02911532|Experimental|Optical Coherence tomography|
33110296|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
33110297|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
33110298|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
33110299|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
33110300|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
33050242|NCT05568082|Experimental|AMG 510 + Itraconazole|
33331767|NCT03744806||control group|
33331768|NCT01562366|Experimental|Group 1|
33331769|NCT01562366|Active Comparator|Group 2|
33331770|NCT04531098|Experimental|Sci-B-Vac-SciGen|The 3-antigen HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
33331771|NCT04531098|Active Comparator|Engerix-B|The single antigen HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
33331772|NCT04531098|Experimental|Sci-B-Vac-BTG|The 3-antigen HepB vaccine, Sci-B-Vac-BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-BTG was supplied in a final volume of 1.2 ml vials
33331773|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
33050243|NCT04218071|Experimental|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
33050244|NCT04218071|Experimental|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
33050245|NCT05568043|Experimental|In-person intervention delivery with virtual mentoring|The implemented interventions will be in-person and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
33050246|NCT05568043|Experimental|In-person intervention delivery with virtual mentoring and co-design|The implemented interventions will be in-person and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
33050247|NCT05568043|Experimental|Virtual intervention delivery with virtual mentoring|The implemented interventions will be virtual and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
33050248|NCT05568043|Experimental|Virtual intervention delivery with virtual mentoring with co-design|The implemented interventions will be virtual and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
33050249|NCT05567965|Experimental|Intensified home care intervention + Training|Users will receive an intensification in their home care intervention for dependence, receiving an intervention of a minimum of 1 hour per day and a maximum of 3.5 hours, to support their activities of daily living. The intensification will be personalised according to the specific needs of the user that the professionals consider necessary to attend. The weekly distribution of the intervention will be flexible in terms of timetables, as agreed between professional and informal caregivers. In addition, each informal caregiver will receive multimodal online training with the aim of providing knowledge, skills and attitudes that empower them to face the challenge of caring, guaranteeing quality care, preventing situations that may negatively affect both the person and the family dynamics and enabling an optimal evolution in caregiving.
33050250|NCT05567965|Active Comparator|Conventional home care intervention|Participants will continue with their conventional home care intervention for dependence, comprising activities that are mainly carried out at the users' home and are oriented towards supporting their activities of daily living. This intervention is of personalised attention and its average intensity is about 20 minutes per day.
33050251|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
33050252|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
33331774|NCT04142450|Experimental|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
33331775|NCT04529850|Experimental|Open Label Active Arm|90mg GC4419 by IV
33331776|NCT05039346||Brain Tumor|Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
32871586|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
33331777|NCT05039346||Care Giver|"Should a patient be unable to answer, the care giver will step in and provide surrogate answers.~Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire."
33331778|NCT04225676|Experimental|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients > 50 kg body weight."
33331779|NCT00070564|Active Comparator|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
33331780|NCT00070564|Experimental|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
33331781|NCT00070564|Active Comparator|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
33331782|NCT00070564|Experimental|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
33331783|NCT00070564|Experimental|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
33331784|NCT00070564|Experimental|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
33331785|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
33050256|NCT04196972|Experimental|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
33331786|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
33360754|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
33360755|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
33050257|NCT04196972|Experimental|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
33050258|NCT05567653|Experimental|Probiotic treatment group|ca. 30 participants
33050259|NCT05567653|Placebo Comparator|Placebo group|ca. 30 participants
33050260|NCT05567614||75|patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis
33050261|NCT04172714|Experimental|Second mapping with low-dose Y90|Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
33050262|NCT05567575|Experimental|TechCare|"Participants in this arm will receive a mobile app based cognitive behavior therapy informed TechCare intervention for a period of 12 weeks."
33050263|NCT05567575|Active Comparator|Wait-List control group:|Participants in this arm will be offered the intervention once the intervention arm have completed their 3rd month outcome assessment.
33050264|NCT04733508|Experimental|111In-exendin-DTPA|Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography
33050265|NCT04733508|Experimental|exendin-IRDye800CW|Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy
33050266|NCT05567536||Clopidogrel group|This group are those who received clopidogrel 75mg qd as a single antiplatelet agent therapy after PCI.
33050267|NCT05567536||Aspirin group|This group are those who received aspirin 100mg qd as a single antiplatelet agent therapy after PCI.
33050268|NCT05567341|Experimental|RIC|On the right upper extremity a blood pressure cuff is inflated to 200mmHg for 4x5min at the beginning of the surgery
33050269|NCT05567341|Sham Comparator|Control|On the right upper extremity a blood pressure cuff is inflated to 0mmHg for 4x5min at the beginning of the surgery
33050270|NCT05567146|Experimental|Experimental group|"Adolescents going to high school, Gamification technique is applied to the Intervention group for seven weeks.~Intervention:gamification technique with tele-nursing"
33360756|NCT03924271|Experimental|ONCOLOGY|Patient with a cancer
33360757|NCT01130779|Experimental|tarceva|continuation of tarceva
33050271|NCT05567146|No Intervention|Control group|Adolescents going to high school
33050272|NCT04114370|Experimental|Participants with Glioma|[F18]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
33050273|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
33050274|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
33050275|NCT04103606|Experimental|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
33050276|NCT04103606|Active Comparator|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
33050277|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
33050278|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
33050279|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
33050280|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
33050281|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
33050282|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
33050283|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
33050284|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
33050285|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
33050286|NCT04091048||Primary Cohort|
33050287|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
33050288|NCT00135733|Active Comparator|A|Amevive
33050289|NCT00135733|Placebo Comparator|B|Placebo
33050290|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
33050291|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
33050292|NCT04061798|Experimental|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
33050293|NCT04061798|Active Comparator|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
33050294|NCT00135811|Active Comparator|1|Cyclosporin
33050295|NCT00135811|Active Comparator|2|MMF and Dexamethasone
33331787|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
33050296|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
33050297|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
33050298|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
33050299|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
33050300|NCT00136201|Experimental|1|armDesc1
33050301|NCT03151239|Placebo Comparator|Placebo|
33050302|NCT03151239|Experimental|NMN supplementation|
33050303|NCT04042025|Other|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene.
33050304|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
33050305|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
33331788|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
33331789|NCT03700320|Active Comparator|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
33050306|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
33050307|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
33050308|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
33050309|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
33050310|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
33050311|NCT04026386|Experimental|Center Based or In-Home Early Intervention Program|
33050312|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
33050313|NCT00136591|Experimental|B|
33050314|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
33050315|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
33050316|NCT03998579|Experimental|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
33050317|NCT03998579|Active Comparator|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
33050318|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
33050319|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
33050320|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
33050321|NCT00136708|Other|Control|
33050322|NCT03991130|Experimental|High Dose IL-2 and Nivolumab|
33050323|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
33050324|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
33050325|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
33050326|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.~Placebo~Bupropion~Memantine"
33050327|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion~Memantine~Placebo"
33050328|NCT00136786|Placebo Comparator|Intervention 3|"Memantine~Placebo~Bupropion"
33050329|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
33050330|NCT00136825|Experimental|1|N-Acetylcysteine
33331790|NCT03700320|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
33331791|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
33331792|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
33331793|NCT03744338||Group 1|
33331794|NCT04223258|Experimental|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
33331795|NCT04223258|Active Comparator|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
33331796|NCT01561950|Experimental|Factor VII|
33331797|NCT01561950|Placebo Comparator|Placebo|
33331798|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
33331799|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
33331800|NCT03748628|Experimental|Single arm EDP-305|
33050331|NCT00393198|Experimental|Arm 1|
33050332|NCT00393198|Placebo Comparator|Arm 2|
33050333|NCT00393198|Active Comparator|Arm 3|
33050334|NCT03968822|Experimental|Intralipid 20% IV Bolus|
33050335|NCT03968822|Placebo Comparator|Saline|
33050336|NCT00136864|Experimental|1|PET Imaging
33050337|NCT00136864|No Intervention|2|Standard Imaging
33050338|NCT03947606|Experimental|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
33050339|NCT03947606|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
33050340|NCT03947606|Experimental|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
33331801|NCT04456686|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
33050341|NCT03947606|Experimental|Basic social support only|1 in-person/telephone weekly session on providing decision social support
33050342|NCT03947606|Experimental|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
33050343|NCT03947606|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
33050344|NCT03947606|Experimental|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
33050345|NCT03947606|Experimental|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
33050346|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
33050347|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
33050348|NCT03940157|Experimental|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
33050349|NCT03151083|Active Comparator|Phase 1: Implementation As Usual (Implementation Through Rese|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
33050350|NCT03151083|Experimental|Phase 2: Primary Care Coached Digital CBTi Implementation (Im|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
33050351|NCT03151083|Experimental|Phase 3: Primary Care Mental Health Collaborative Care Implem|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
33050352|NCT00137176|Experimental|Rebif + Lipitor|
33050353|NCT00137215|Active Comparator|A|
33050354|NCT00137254|Active Comparator|A|
33331802|NCT04456686|Placebo Comparator|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
33331803|NCT05206318|Experimental|20 participants with topical cysteamine cream|Participants with post-inflammatory hyperpigmentation will apply topical cysteamine cream for a 16 weeks period.
33331804|NCT05206318|Sham Comparator|20 participants with topical vehicle control cream|Participants with post-inflammatory hyperpigmentation will apply topical vehicle-control cream for a 16 weeks period.
33331805|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
33331806|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
33331807|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
33050355|NCT03906149|Experimental|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
33418505|NCT04769739|Experimental|WE with 50% saline|Residual air in the colon will be removed, 50% salline (1:1 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
33418506|NCT04769739|Experimental|WE with 25% saline|Residual air in the colon will be removed, 25% saline (1:3 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
33050356|NCT03906149|Active Comparator|Standard medical care|Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
33050357|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
33050358|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
33050359|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
33050360|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
33050361|NCT03894215|Experimental|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
33050362|NCT03894215|Experimental|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
33050363|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
33050364|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
33050365|NCT00137605|Experimental|Pneumovax/immediate|
33050366|NCT00137605|Experimental|Pneumovax/delayed|
33050367|NCT00137605|Experimental|Prevnar/immediate|
33050368|NCT00137605|Experimental|Prevnar/delayed|
33050369|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
33050370|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
33050371|NCT00137800|Experimental|Tarceva|Chemotherapy Single Agent Systemic
33050372|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
33050373|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
33050374|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
33050375|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
33050376|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
33050377|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
33050378|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
33050379|NCT03150888||Hospital based hypertension cohort|
33050380|NCT03150888||Community based hypertension cohort|
33050381|NCT02834780|Experimental|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma
33050382|NCT03150849||patient group|patient with chronic lymphocytic leukemia
33050383|NCT03150849||control group|healthy control group
33050384|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
33050385|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
33050386|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
33050387|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
33050388|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
33050389|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
33050390|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
33050391|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
33050392|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
33050393|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
33050394|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
33050395|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
33050396|NCT03893825|Experimental|TV-46000 q1m|Participants will receive a subcutaneous (SC) injection of TV-46000 at baseline and every 4 weeks (q4w) thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
33050397|NCT03893825|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
33050398|NCT03890666|Experimental|Digital System (DS)|Participants will be trained on the use of the albuterol eMDPI DS (including instructions on how to use both the eMDPI and the App) and, upon demonstrating competency, will receive 2 albuterol eMDPI devices for use as reliever bronchodilators to replace their reliever treatment during the study. The eMDPI Digital System consists of 4 devices: Device 1: albuterol eMDPI (the test investigational medicinal product [IMP]); Device 2: Patient-facing App; Device 3: Digital health platform (DHP) (Cloud solution); and Device 4: Provider-facing Dashboard. Participants will receive 90 micrograms (mcg) albuterol, 1 to 2 oral inhalations every 4 to 6 hours, as needed for 12 weeks.
33050399|NCT03890666|Active Comparator|Concurrent Control (CC)|Participants will be treated with their standard of care albuterol-administering reliever inhalers and will use the digital system during the treatment period. Participants will be reimbursed or given a voucher to use to purchase their existing reliever medications.
33050400|NCT03861767|Experimental|SPRY: Metformin LD-SC|"LD-SC (low-dose, short course)~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050401|NCT03861767|Experimental|SPRY: Metformin LD-IC|"LD-IC (low-dose, intermediate course)~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050402|NCT03861767|Experimental|SPRY: Metformin LD-LC|"LD-LC (low-dose, long course)~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050403|NCT03861767|Experimental|SPRY: Metformin ID-SC|"ID-SC (intermediate-dose, short course)~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050404|NCT03861767|Experimental|SPRY: Metformin ID-IC|"ID-IC (intermediate-dose, intermediate course)~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050405|NCT03861767|Experimental|SPRY: Metformin ID-LC|"ID-LC (intermediate-dose, long course)~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050406|NCT03861767|Experimental|SPRY: Metformin HD-SC|"HD-SC (high-dose, short course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050407|NCT03861767|Experimental|SPRY: Metformin HD-IC|"HD-IC (high-dose, intermediate course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050408|NCT03861767|Experimental|SPRY: Metformin HD-LC|"HD-LC (high-dose, long course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
33050409|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
33050410|NCT00139360|Experimental|1|Active drug
33050411|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
33050412|NCT03844412|Active Comparator|peripheral treatment|5% lidocaine/5 mg/ml 0.02% estradiol compound cream
33050413|NCT03844412|Active Comparator|central treatment|tricyclic antidepressant nortriptyline pill
33050414|NCT03844412|Active Comparator|combined peripheral and central treatments|5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
33050415|NCT03844412|Placebo Comparator|placebo|placebo cream and placebo pill
33050416|NCT00139594|Experimental|licarbazepine|
33050417|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
33050418|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
33050419|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
33050420|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
33050421|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
33050422|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
33050423|NCT00404287|Placebo Comparator|placebo|
33050424|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
33050425|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
33050426|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
33050427|NCT03803228|Experimental|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
33050428|NCT03803228|Active Comparator|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
33050429|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
33050430|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
33050431|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
33050432|NCT03150498|Experimental|BTD-001 (fed)|
33050433|NCT03150498|Experimental|BTD-001 (fasted)|
33050434|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
33050435|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
33050436|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
33050437|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
33050438|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
33050439|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
33050440|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
33050441|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
33050442|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
33050443|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
33050444|NCT03748121|Experimental|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
33050445|NCT03748121|Active Comparator|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
33050446|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
33050447|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
33050448|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
33050449|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
33050450|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
33050451|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
33050452|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
33050453|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
33050454|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
33050455|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
33050456|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
33050457|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
33050458|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
33050459|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
33050460|NCT03735992|No Intervention|Wait list|Treatment as usual.
33050461|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
33050462|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
33050463|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
33050464|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
33050465|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
33050466|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive starch capsules to be taken daily."
33050467|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
33050468|NCT02964598|Experimental|Control|Minimal information on sleep timing
33050469|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
33050470|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
33050471|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
33050472|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
33050473|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
33050474|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
33050475|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
33050476|NCT03709706|Experimental|Arm A: lete-cel monotherapy|In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
33050477|NCT03709706|Experimental|Arm B: lete-cel plus pembrolizumab|In Arm B, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
33050478|NCT03709706|Experimental|Arm C: lete-cel plus pembrolizumab|In Arm C, participants with NSCLC (with actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
33050479|NCT00141193|Placebo Comparator|A|
33050480|NCT03110523|Experimental|Group A|High Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
33050481|NCT03110523|Experimental|Group B|Low Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
33050482|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
33050483|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
33331808|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
33331809|NCT05206006|Other|Control Group|As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
33331810|NCT05206006|Experimental|computerized decision support app (CDSA) Group|
33050484|NCT03093051|Experimental|UPT Treatment|Investigational therapy (UPT)
33050485|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
33050486|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
33050487|NCT00404443|Sham Comparator|1|arm 1: placebo needle
33050488|NCT00404521|Experimental|Arm 1|
33050489|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
33050490|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
33050491|NCT04726696|No Intervention|Control group|None intervention to be administered, they continue their normal routine.
33050492|NCT04726696|Experimental|Intervention group|ROLE-AP is a multifaceted program offered over a month period to participating primary care nurses and includes three interactive workshops. Each workshop will be 4 hours long.
33050493|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
33050494|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
33050495|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:~core stabilization exercise~movement system impairment approach~neuromuscular activation using suspension~kinematic linkage imbalance"
33050496|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
33418507|NCT05138731||Stable angina (SA)|Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
33418508|NCT05138731||Unstable angina (UA）|Including resting angina (attack at rest, the duration is usually >20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
33050499|NCT00141544|Experimental|1|
33050500|NCT00141544|Active Comparator|2|
33050501|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
33050502|NCT00141661|Experimental|Low Dose Arm|
33050503|NCT00141661|Experimental|High Dose Arm|
33050504|NCT00141661|Placebo Comparator|Placebo Control|
33050505|NCT04712214|Experimental|Patients with brain tumours candidate for neurosurgery|Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
33050506|NCT00141856|Other|1|
33050507|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
33050508|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
33050509|NCT03555149|Experimental|Atezolizumab + Isatuximab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
33050510|NCT03555149|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
33050511|NCT03555149|Experimental|Atezolizumab + Idasanutlin|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
33050512|NCT03555149|Experimental|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
33050513|NCT03555149|Experimental|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
33050514|NCT03555149|Experimental|Atezolizumab + LOAd703|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
33331811|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
33331812|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
32740279|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
33050515|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
33331813|NCT05027048|Experimental|Calcium chloride|"1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
32740280|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
33050516|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
33331814|NCT05027048|Placebo Comparator|Saline placebo|"60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
33331815|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
33050517|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
33050518|NCT00142051|Experimental|1|inhaled NO
33331816|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
33331817|NCT05761678||Transgender people|Whether they have transitioned or not, with or without reassignment surgery.
33050519|NCT00142051|Placebo Comparator|2|room air inhalation
33331818|NCT05205694||Late COVID-19 and PERIO|Participants in the late convalescent stage of COVID-19 with diagnosed periodontitis
33331819|NCT05205694||PERIO non COVID-19|Participants with diagnosed periodontitis and no history of COVID-19
33050520|NCT03546413||LEAP Participants|LEAP participants are followed during an extended period of ad-libitum peanut consumption and then assessed for peanut allergy and other allergic outcomes. Target accrual is 630.
33050521|NCT03546413||LEAP Siblings|LEAP participant siblings will be randomly assigned to the intervention or control group based on the allocation of their LEAP participants sibling.Target accrual is 746.
33050522|NCT03546413||LEAP Parents|Any parent of a child who enrolled in the LEAP study. Target accrual is 945.
33050523|NCT00142090|Experimental|2|3% Hypertonic saline
33331820|NCT05205694||Late COVID-19 non PERIO|Participants in the late convalescent stage of COVID-19 without periodontitis
33331821|NCT05205694||Non PERIO non COVID-19|Participants with no history of COVID-19 and without periodontitis
33050524|NCT00142090|Placebo Comparator|1|Normal saline
33050525|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
33050526|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
33050527|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
33050528|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
33050529|NCT00142207|Active Comparator|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
33050530|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
33050531|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
33050532|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
33050533|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
33050534|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
33050535|NCT00142246|Placebo Comparator|2|Dual placebo comparator
33050536|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
33050537|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
33331822|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
33331823|NCT05205616|Placebo Comparator|Reciprocating saw|The traditional surgical instrument used for cutting bilateral sagittal split osteotomies
33331824|NCT05205616|Active Comparator|Sonopet ultrasonic saw|This instrument is being compared to the reciprocating saw
33331825|NCT05761600||Art Therapist|Professionally qualified and HCPC registered Arts Therapists delivering group arts therapy in the community settings in the UK
33050538|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
33050539|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
33331826|NCT05761600||People with a Learning Disability|Adults (18 years+) currently attending an art therapy group who have a learning disability and can consent and communicate in a way that supports meaningful engagement in the study.
32740281|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
32740282|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
33331827|NCT05761600||Identified Support Person|Person who is well-known to the person with a learning disability (e.g. NHS staff, paid support staff or family members who are carers) who provides practical and/or emotional support to the person with a learning disability attending the art therapy group
33331828|NCT05761522||Patients with septic shock for 24 hours or more|Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
32740283|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
32740284|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
33050540|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
33050541|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
33050542|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
33331829|NCT04425252|Other|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
33331830|NCT04425252|Experimental|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
33050543|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
33050544|NCT00142753|Experimental|B1: ATN 025 Recombivax|
33050545|NCT00142753|Experimental|B2: ATN 025 Twinrix|
33050546|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
33050547|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
33050548|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
33050549|NCT00142831|Placebo Comparator|2|Identical Placebo
33050550|NCT00142870|Placebo Comparator|A|
33050551|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
33050552|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
33050553|NCT02780427|Active Comparator|1-6 months (Group 1)|
33050554|NCT02780427|Active Comparator|7-12 months (Group 2)|
33050555|NCT02780427|Active Comparator|13-18 months (Group 3)|
33050556|NCT02780427|Active Comparator|19-24 months (Group 4)|
33050557|NCT03487913|Experimental|High dose lixivaptan / CKD1 or CKD2|Oral high dose lixivaptan in participants with CKD1 or CKD2
33050558|NCT03487913|Experimental|Low dose lixivaptan / CKD1 or CKD2|Oral low dose lixivaptan in participants with CKD1 or CKD2
33050559|NCT03487913|Experimental|High dose lixivaptan / CKD3|Oral high dose lixivaptan in participants with CKD3
33050560|NCT03487913|Experimental|Low dose lixivaptan / CKD3|Oral low dose lixivaptan in participants with CKD3
33050561|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
33050562|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
33050563|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
33050564|NCT02554383|Active Comparator|Treatment A|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
33050565|NCT02554383|Placebo Comparator|Treatment B|Placebo made to match the study antibiotic will be taken bid orally for 10 days
33050566|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
33331831|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
33110301|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
33110302|NCT04675671||Pregabalin group (Group P)|Group pregabalin patients will be received 75 mg of pregabalin twice daily for 2 days before surgery
33110303|NCT04675671||Control group (Group C)|The Control group will be received plasebo capsule mg at the same point in time
33110304|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
33110305|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
33110306|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
33110307|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
33331832|NCT01569958|Active Comparator|tDCS|
33331833|NCT01569958|Sham Comparator|sham|
33331834|NCT04998162|Experimental|SVF injection|All patients with ankle osteoarthritis will be treated with a single injection of SVF, obtained from the patient's abdominal adipose tissue. All patients will be examined with a baseline clinical visit and will be followed-up with clinical evaluation at 1, 3, 6, 12 and 24 months.
32740285|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
32740286|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
32740287|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
32740288|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
33331835|NCT05204914|Other|Supra glottic airway devices|
33331836|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
33331837|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
33331838|NCT05459610||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
33331839|NCT05459610||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
33331840|NCT04003610|Experimental|Pemigatinib + Pembrolizumab|Combination of pemigatinib (13.5 milligrams [mg] once a day orally) plus pembrolizumab (200 mg every 3 weeks [Q3W] intravenously [IV])
33331841|NCT04003610|Experimental|Pemigatinib|Pemigatinib (13.5 mg once a day orally) alone
33331842|NCT04003610|Active Comparator|Standard of Care|Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve [AUC] of 5 mg/milliliters [mL]/minute [min] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.
33331843|NCT03754296||CATCHVIEW stent retriever|
33331844|NCT03744182|Experimental|HM15211|
33110308|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
33331845|NCT03744182|Placebo Comparator|Placebo|
33110309|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
33110310|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
33110311|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
33110312|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
33110313|NCT02911220|Other|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
33110314|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
33110315|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
33110316|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
33110317|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
33110318|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
33331846|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
33331847|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
33331848|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
33331849|NCT03999554|Experimental|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
33331850|NCT03999554|Experimental|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
33331851|NCT03999554|Experimental|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
33050567|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
33050568|NCT02479698|Experimental|Treatment (BK-specific cytotoxic T lymphocytes)|Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.
33331852|NCT03999554|Active Comparator|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
33331853|NCT03999554|Placebo Comparator|Placebo|Saline will be administered intranasally on days 1 and 29
33331854|NCT04129346|Experimental|Fit2ThriveMB|Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
33331855|NCT04129346|Active Comparator|Healthy Living Control|Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net. They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
33331856|NCT05280626|Experimental|A: PD-1+R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group A uses Sindilizumab + R-CHOP, with Sindilizumab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles, CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
33331857|NCT05280626|Active Comparator|B: R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP and plans for 5 cycles. CR patients in group B are followed up for observation.
33331858|NCT04526574|Active Comparator|Coadministration Group|Participants receive injections of pneumococcal vaccine (20vPnC) and influenza vaccine at the same visit, and then receive an injection of saline 1 month later.
33331859|NCT04526574|Active Comparator|Separate Administration Group|Participants receive injections of saline and influenza vaccine at the same visit, and then receive an injection of 20vPnC 1 month later.
32740289|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
33050569|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
33050570|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
33050571|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
33050572|NCT02431923||Non Contact Controls|Selected Controls
33050573|NCT04726267|Other|Glaucoma patients who was scheduled for trabeculectomy|Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.
33050574|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
33050575|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
33050576|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
33050577|NCT04726345|Experimental|Fexofenadine|Participants in this arm will receive fexofenadine 180mg once daily, in addition to standard of care pain medications (NSAIDs).
33050578|NCT04726345|Placebo Comparator|Placebo|Participants in this arm will receive placebo once daily, in addition to standard of care pain medications (NSAIDs).
33050579|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
33050580|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
33050581|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
33050582|NCT00143533|Other|1|
33050583|NCT00143572|Other|1|
33050584|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
33050585|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
33050586|NCT00143611|Placebo Comparator|Placebo|
33050587|NCT02247752|Other|Inactive carriers|
33050588|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~Combivir and lopinavir/ritonavir twice a day."
33050589|NCT00144001||Group 1|
33050590|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
33050591|NCT00144040|Other|Arm 1|
33050592|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
33050593|NCT02231775|Experimental|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
33110319|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
33110320|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
33110321|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
33110322|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
33110323|NCT04676919|Experimental|pulsed mode phonophoresis group|Phonophoresis therapy with pulsed mode ultrasound.
33110324|NCT04676919|Experimental|continuous mode phonophoresis group|Phonophoresis therapy with continuous mode ultrasound.
33110325|NCT04676919|Sham Comparator|sham group|Sham ultrasound
33110326|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
33110327|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
33110328|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
33110329|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
33110330|NCT02910947|Experimental|quadratus lumborum|
33110331|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
33110332|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
33110333|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
33110334|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
33110335|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
33110336|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
33110337|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
33110338|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
33110339|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
33110340|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
33110341|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
33110342|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
33110343|NCT01217476|Active Comparator|Trafermin 0.01% spray|
33110344|NCT01217476|Placebo Comparator|Matching placebo spray|
33110345|NCT04677075||mastectomy group|patients with breast cancer and eligible for mastectomy
33110346|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
33110347|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
33418509|NCT05138731||Acute non-ST-segment elevation myocardial infarction （NSTEMI）|Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
33418510|NCT05138731||Acute ST-segment elevation myocardial infarction （STEMI）|Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
33418511|NCT05138731||normal coronary artery （NCA）|symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
33418512|NCT05138731||nonobstructive coronary atherosclerosis （NOCA）|stenosis < 50% in coronary arteries
33418513|NCT05138731||healthy volunteers|Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
33418514|NCT05406284||double kissing nano culotte stenting|
33050594|NCT02143128|Experimental|Efficacy Safety Score|Patients assessed using the ESS
33050595|NCT02143128|Active Comparator|Verbal Numeric Rating Scale|Patients assessed using VNRS
33050596|NCT02143128|No Intervention|Control|Regular follow up
33050597|NCT05595343||Early adopting surgeons|Surgeons who started performing LDP during phase 3 of the IDEAL framework; the Assessment phase. They received training in the form of fellowships, proctoring, and courses
33050598|NCT05595343||Pioneering surgeons|Surgeons who started performing LDP during phase 2 of the IDEAL framework; the Development and Exploration phase. They did not receive any specific form of training and were therefore considered self-taught.
33050599|NCT05595304|Experimental|Oral Functionalization|Prosthesis repairment: prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts and follow up with conventional prosthesis treatment
33050600|NCT05595304|Active Comparator|control|conventional prosthetic treatment (new prosthesis)
33050601|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
33050602|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
33050603|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
33050604|NCT01965912|Experimental|Kuvan®|
33050605|NCT04726540||Group I|
33050606|NCT04726540||Group II|
33050607|NCT05595187|Experimental|Tricuspid repair|Tricuspid repair techniques included suture placement and the type of prosthetic annuloplasty with specified the use of an approved rigid, incomplete, nonplanar, and undersized (ranging 26, 28, or 30, 32, 34 mm) ring.
33050608|NCT05595187|No Intervention|Blank control|
33050609|NCT03191786|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
33050610|NCT03191786|Active Comparator|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
33050611|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
33050612|NCT05595109|Placebo Comparator|Group one: (Placebo group)|"which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day)~followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily."
33050613|NCT05595109|Active Comparator|Group two: (Silymarin group)|which will receive the same regimen plus silymarin 140mg once daily.
33050614|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
33050615|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
33050616|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
33050617|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
33050618|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
33050619|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
33050620|NCT05594992|Experimental|JR-141 2.0 mg/kg/week|
33050621|NCT05594914|Experimental|AK104 plus concurrent chemoradiation therapy|AK104 10mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 10 mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5) is combined with radiotherapy(50Gy/25F) for 2 cycles.
33050622|NCT01919619|Experimental|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
33050623|NCT05594836|Experimental|Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
33050624|NCT05594836|No Intervention|control|not Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
33050625|NCT05594719|Experimental|Light group 1|Sun-like spectrum, color temperature of 5000K, shorter-wavelength dominant;
33050626|NCT05594719|Placebo Comparator|Light group 2|Sun-like spectrum, color temperature of 5000K, wavelength proportion similar to the sunlight
33050627|NCT05594719|Experimental|Light group 3|Sun-like spectrum, color temperature of 5000K, longer-wavelength dominant.
33050628|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
33050629|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
33050630|NCT05594602|Experimental|EDP-235 and Itraconazole interaction (Part 1)|Subjects will receive EDP-235 and Itraconazole on respective dosing days
33050631|NCT05594602|Experimental|EDP-235 and Carbamazepine interaction (Part 2)|Subjects will receive EDP-235 and Carbamazepine on respective dosing days
33050632|NCT05594602|Experimental|EDP and Quinidine interaction (Part 3)|Subjects will receive EDP-235 and Quinidine on respective dosing days
33050633|NCT03098576||Matched|Matched targeted drug treatment
33050634|NCT03098576||Control|Unmatched standard of care
33050635|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
33050638|NCT05594368|Experimental|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|
33050639|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
33050640|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
33050641|NCT05594329|Experimental|Experimental meal 1|Instant noodle soup containing 2 servings of dried Pleurotus oyster mushroom.
33050642|NCT05594329|Experimental|Experimental meal 2|Instant noodle soup containing 1 serving of dried Pleurotus oyster mushroom.
33050643|NCT05594329|Experimental|Experimental meal 3|Instant noodle soup containing 0.5 serving of dried Pleurotus oyster mushroom.
33050644|NCT05594329|Placebo Comparator|Control meal|Instant noodle soup containing cornflour and maltodextrin in a 2.5:1 ratio.
33050645|NCT05594212|Experimental|The effectiveness of receiving abdominal breathing training|The effectiveness of receiving abdominal breathing training Training for 8 weeks (1 time a week, 15 minutes each time). Performed one-on-one by a trainer in a sleep center. At home, you can use the abdominal breathing training video to train yourself (10 minutes a day, can be divided into 10 minutes), and you need to fill in the abdominal breathing training log.
33050646|NCT05594212|No Intervention|The effectiveness of not receiving abdominal breathing training|The effectiveness of not receiving abdominal breathing training The trainer does not provide abdominal breathing training, does not perform abdominal breathing exercises at home, and does not need to fill in abdominal breathing training logs.
33050647|NCT03096782|Experimental|Group I (chemotherapy, TBI, cord blood)|"Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
33050648|NCT03096782|Experimental|Group II (chemotherapy, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
33050649|NCT03096782|Experimental|Group III (chemotherapy, TBI, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
33050650|NCT05594134|Experimental|Automatic toothbrush with nylon bristles|
33050651|NCT05594134|Active Comparator|Automatic toothbrush with silicone bristles|
33050652|NCT05594134|Active Comparator|Manual toothbrush used for 2 minutes|
33050653|NCT05594134|Active Comparator|Manual toothbrush used for 45 seconds|
33050654|NCT05594134|No Intervention|No brushing|
33050655|NCT01807455|Experimental|Restylane Vital Lidocaine|
33050656|NCT05594056|Experimental|Preeclampsia|Patients with severe preeclampsia and gestational age between 34-40 weeks.
33050657|NCT05594056|Active Comparator|Control|Patients with normal gestations between 34-40 weeks.
33050658|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
33050659|NCT02964169|No Intervention|No Family Planning Support|Routine care
33331860|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
33331861|NCT04145258|Other|WHO TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
33050660|NCT05594017|Experimental|Scopolamine (5ug/kg)|"Subjects will receive a dose of scopolamine (5ug/kg) on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the sham session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
33050661|NCT05594017|Placebo Comparator|Placebo|"Subjects will receive saline (5ug/kg) via IV on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the scopolamine session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
33050662|NCT05593939|Experimental|Exercise arm|12 week aerobic exercise will be performed in agreement with current guidelines for exercise in older adults from the American College of Sports Medicine. A frequency of 5 days/week, totaling 150-300 min/week, performed at both moderate and vigorous intensities is chosen. This dose has a high level of evidence supporting positive effects on health- and life-span.
33050663|NCT05593939|Experimental|Time restricted feeding|A 12 week fasting/feeding regiment of 16 hours fasting /8 hours feeding each day is chosen. This ratio has been shown to be tolerable in older individuals.
33050664|NCT05593939|Experimental|Nicotinamide riboside|Previous clinical trials have shown that an nicotinamide riboside dose up to 2 g/day is well tolerated with no treatment-emergent adverse events reported so far and with efficacy on our primary outcome measurement. A dose of 2 g/day NR is therefore chosen and will be split in two: 1 g in the morning and 1 g in the evening.
33050665|NCT05593939|No Intervention|Control|A control group with no intervention.
33050666|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
33050667|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
33050668|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
33331862|NCT04145258|Other|WHO TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
33050669|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
33050670|NCT05586724|Active Comparator|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
33050671|NCT05586724|Active Comparator|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan.
33050672|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
33050673|NCT05572489||patients with cervicogenic headache|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
33050674|NCT05572489||healthy controls|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
33050675|NCT04726384||Observed group|The group was monitored for physical activity levels using the SenseWear Armband device. The group was informed of the purpose of the study and asked to wear the device 24 hours a day for the next 4 days (Friday-Monday) excluding bath time, no more than 30 minutes. Patients received the device on Thursday afternoon and returned it on Tuesday. However, the days Friday-Monday were analyzed to have a record of the entire days
33050676|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
33050677|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
33050678|NCT05552911||De novo coronary lesions: cutting balloon group|De novo coronary lesions were pretreated with a cutting balloon and then treated with a drug-coated balloon.
33050679|NCT05552911||De novo coronary lesions: non-cutting balloon group|De novo coronary lesions were pretreated with a non-cutting (Compliance balloon or/and non-compliant balloon) balloon and then treated with a drug-coated balloon.
33050680|NCT05552911||In-stent restenosis: Type-I|Body stenosis: restenosis of the stent body, not beyond the edge of the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
33331863|NCT04145258|Other|Intensified TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
33331864|NCT04145258|Other|Intensified TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
33331865|NCT04422990|Experimental|LID018869|Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
33050681|NCT05552911||In-stent restenosis: Type-II|Marginal stenosis type: restenosis at the edge of the stent, stenosis ≥50% within 5mm of the stent edge, which can continue into the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
33050682|NCT05552911||In-stent restenosis:Type-III|Diffuse proliferative type: the lesion extends to the whole scaffold body and beyond the edge of both ends.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
33050683|NCT05552911||In-stent restenosis:Type-IV|Complete occlusion type: complete occlusion in the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
33050684|NCT05551663|Experimental|Isometric exercise training|
33050685|NCT05551663|No Intervention|Control group|
33050686|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
33050687|NCT05550103|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
33050688|NCT05550103|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
33050689|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
33050690|NCT05545657||Type 2 Diabetes|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition.
33050691|NCT05545657||Healthy Control|These participants have normal glucose tolerance and normal cognition.
33050692|NCT05519800|Active Comparator|High Glycaemic Index|A diet comprising of High Glycaemic Carbohydrate. Supplemented with a maltodextrin containing beverage.
33050693|NCT05519800|Experimental|Low Glycaemic Index|A diet comprising of Low Glycaemic Carbohydrate. Supplemented with an Isomaltulose containing beverage.
33050694|NCT05504941|Experimental|Study Intervention: DSA|additional diagnostic cerebral DSA
33050695|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
33050696|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
33050697|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
33050698|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
33050699|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
33050700|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
33050701|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
33110348|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
33110349|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
33110351|NCT04675437|Experimental|Frail patients (CABG, HF or mini-AVR)|12-weeks cardiac exercise program (3 sessions per week) consisting of aerobic exercises (ergometer, treadmill and arm ergometer).
33110352|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
33110353|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
33110354|NCT04677192|Experimental|Microwave Ablation Combined with Chemotherapy|All patients will receive microwave ablation of oligohepatic metastasis and chemotherapy according to NCCN guidelines,and the efficacy was evaluated every 8 weeks until the disease progressed or the patient could not tolerate it.
33110355|NCT02550470||Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
33110356|NCT02550470||Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
33110357|NCT02550470||Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
33110358|NCT04688216||MDRO|
33110359|NCT04688216||Non-MDRO|
33110360|NCT04675359|Active Comparator|Enzymatic digestion group|A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue
33110361|NCT04675359|Active Comparator|Mechanical fragmentation group|A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint
33110362|NCT04675203||Normal tooth eruption|
33110363|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
33110364|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
33110365|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
33110366|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
33110367|NCT04675281||Critically-ill adult patients who died in the Intensive Care Unit from a documented COVID-19|
33110368|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
33331866|NCT04422990|Active Comparator|Biofinity|Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
33331867|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
33331868|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
33331869|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
33331870|NCT04377308|No Intervention|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
33050702|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
33050703|NCT05488015|Experimental|Intervention|1 week of familiarisation through videos, audios and information documents, followed by 8 weeks of self-treatment with two GPR postures.
33331871|NCT04377308|Active Comparator|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
33331872|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
33331873|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
33331874|NCT04447404|Experimental|DUR-928|
33331875|NCT04447404|Placebo Comparator|Placebo|
33331876|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
32740290|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
33050704|NCT05488015|Active Comparator|Control|No change in lifestyle habits during the 8-week trial.
33331877|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
33050705|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
33050706|NCT05482165|Experimental|Intervention group|The students of this group will receive multi-faceted intervention activities toward weight management.
33050707|NCT05482165|No Intervention|Usual practice group|The students of this group will receive regular health education.
33050708|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
33050709|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
33050710|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
33050711|NCT05468671|Experimental|Remazolam general anesthesia group (R group)|Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction.Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance.
33050712|NCT05468671|Active Comparator|Propofol general anesthesia control group (P group)|Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia.Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance.
33050713|NCT05465044|Experimental|Twice-Weekly Hemodialysis|Twice-weekly hemodialysis with incremental crossover to thrice-weekly hemodialysis as indicated
33050714|NCT05465044|Placebo Comparator|Thrice-Weekly Hemodialysis|Outright thrice-weekly hemodialysis without option to switch to less frequent dialysis schedule
33050715|NCT05463991|Experimental|Bioengineered collagen implant|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the bioengineered collagen implant is sutured to the healty urethral area after incision of the urethra at the stricture location.
33050716|NCT01807104|Active Comparator|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
33331878|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
33331879|NCT03988166|Other|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
33331880|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
33331881|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
33331882|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
33331883|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
33331884|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
33331885|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
33050717|NCT01807104|Active Comparator|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
33331886|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
33050718|NCT05462236|Experimental|Module 1: Arm A: Multiple dose finding cohorts|Monotherapy with AUM 001 administered orally QOD
33050719|NCT05462236|Experimental|Module1: Arm B/C: Multiple cohorts of AUM001 with fixed dose of pembrolizumab or irinotecan|Combination doses with AUM 001 administered orally QOD with intravenous pembrolizumab at 200mg Q3W or Irinotecan at 350mg/m2 Q3W
33050720|NCT05462236|Experimental|Module 2: Arm B' and C': Dose Expansion|Combination therapy with AUM001 administered orally QOD at RP2D (as determined in Module 1) and either pembrolizumab at 200mg IV Q3W (arm B') or irinotecan 350mg/m2 IV Q3W (arm C')
33050721|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
33050722|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33050723|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
33050724|NCT05461885|Experimental|Vega Exercise Community|Participants will be offered one hour of tailored supervised, gym-based exercise training three times per week for a period of four months. In addition, participants are offered free-of-charge membership to the gym for six months and are invited to take part in training classes and use fitness equipment provided by the gym to regular members. The supervised program is tailored to meet the needs and requirements of this particular group of young adults and will include three weekly sessions of moderate-to-high intensity and mobility exercises.
33050725|NCT05461885|No Intervention|Usual care|Participants will receive treatment as usual and be informed of the official physical activity guidelines as part of the information on group allocation. Moreover, they will be advised to continue their daily living, as they normally would do, not guiding them to other interventions neither preventing them to do so. In addition, participants in the usual care group will be given a subsidized membership including access to the exercise classes for four months after the 12 months follow up.
33050726|NCT05461807||Cancer patients with venous thromboembolism (VTE)|Adults diagnosed with active (primary or metastatic) cancer excluding oesophageal, gastric, unresected colorectal, bladder, central nervous system cancers (except brain) and leukaemia (a cohort of CAT (Cancer-associated thrombosis) patients at a low risk for bleeding, which is defined as per the ISTH (International Society on Thrombosis and Haemostasis) guidelines), admitted to the hospital, emergency department or observation unit for acute DVT (Deep vein thrombosis) and/or PE (Pulmonary embolism) on or after January 1, 2013 (to correspond with the US availability of rivaroxaban for VTE treatment), being treated with a therapeutic VTE dose of rivaroxaban or apixaban on day 7 post-acute VTE diagnosis (index date).
33050727|NCT05437900|Experimental|Pressure Microcatheter guided strategy - PIOS-MC|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
33050728|NCT05437900|Active Comparator|Pressure Wire guided strategy - PIOS-PW|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
33050729|NCT05437900|Experimental|Pressure Microcatheter guided strategy - Standard of care|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
33050730|NCT05437900|Active Comparator|Pressure Wire guided strategy - Standard of care|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
33050731|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
33050732|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
33050733|NCT05433649|Experimental|Experimental group|Participants performing 16 sessions of therapeutic exercise for 8 weeks with a frequency of two sessions per week. All sessions had a practical focus (strength and stretching exercises) with the help of elastic bands.
33050734|NCT05433649|No Intervention|Control group|They do not change their lifestyle and do not receive the therapeutic exercise sessions.
33050735|NCT01807026|Experimental|Cohort A: 70 mg LY2886721|Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.
33050736|NCT01807026|Placebo Comparator|Cohort A: Placebo|Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).
33050737|NCT01807026|Experimental|Cohort B: 70 mg LY2886721|Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.
33050738|NCT01807026|Placebo Comparator|Cohort B: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).
33050739|NCT01807026|Experimental|Cohort C: 280 mg LY2886721|Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.
33050740|NCT01807026|Placebo Comparator|Cohort C: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).
33050741|NCT05428540|Experimental|Intervention group|Polyphenol-rich dietary supplement (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
33050742|NCT05428540|Placebo Comparator|Control group|Placebo (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
33331887|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
33331888|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
33418515|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
33418516|NCT01369459|No Intervention|Historical Control|
33050743|NCT05427370|Experimental|Revascularization by PCI|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.
33050744|NCT05427370|Experimental|Revascularization by CABG|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >1.5 mm for CABG. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon
33050745|NCT05419687|Experimental|Arm 1 De-escalating violence training|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. A refreshment training will be introduced at month 11.
33050746|NCT05419687|Experimental|Arm 2 De-escalating violence training|The de-escalating violence training intervention will be introduced before the second observation period at month 11. A refreshment training will be introduced at month 18.
33050747|NCT05419687|Experimental|Arm 3 De-escalating violence training|The de-escalating violence training intervention will be introduced before the third observation period at month 18.
33050748|NCT05419687|Experimental|Arm 4 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. The code of conduct via a warning board will be introduced at month 11. A refreshment training will be introduced at month 18.
33050749|NCT05419687|Experimental|Arm 5 De-escalating violence training + Code of conduct|The de-escalating violence training intervention and the code of conduct via a warning board will be simultaneously introduced at month 11. A refreshment training will be introduced at month 18.
33050750|NCT05419687|Experimental|Arm 6 Code of conduct + De-escalating violence training|The code of conduct via a warning board will be introduced at month 11. The de-escalating violence training intervention will be introduced at month 18.
33050751|NCT05419687|Experimental|Arm 7 De-escalating violence training + Code of conduct|The de-escalating violence training intervention is introduced after a pre-interventional period of 3 months. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
33418517|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
33418518|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
33418519|NCT05222295|Experimental|Supervised Pulmonary Telerehabilitation Group|Three times a week for 8 weeks, a supervised and standardized pulmonary rehabilitation program will be applied in the form of telerehabilitation with simultaneous video conference method, accompanied by a specialist physiotherapist, while the patients are at home.
33418520|NCT05222295|Experimental|Cognitive Telerehabilitation Group|Motor imagery + action observation methods will be applied. In therapy, a video recording of each exercise in the supervised telerehabilitation group will be sent to the patients by the physiotherapist in accordance with the number of repetitions. At the end of the session, the cognitive telerehabilitation group will be asked to actively do the breathing exercises and active breathing techniques cycle in the supervised telerehabilitation group as well as to imagine with the instructions in the video recording, and commands will be given accordingly.
33418521|NCT05442710|Experimental|ARTICE Treatment Group|Subjects with septic shock treated with immune cell extracorporeal therapy on top of standard of care
33418522|NCT05442710|No Intervention|Control Group|Subjects with septic shock receiving standard of care
33050752|NCT05419687|Experimental|Arm 8 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced before the second observation period at month 11. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
33050753|NCT05419687|Experimental|Arm 9 De-escalating violence training + Code of conduct|The code of conduct via a warning board and the violence de-escalating training will be simultaneously introduced at month 18.
33050754|NCT05419687|Experimental|Arm 10 Code of conduct|The code of conduct via a warning board will be introduced at month 11.
33050755|NCT05419687|Experimental|Arm 11 Code of conduct|The code of conduct via a warning board will be introduced at month 18.
33050756|NCT00390923|Experimental|1|
33050757|NCT00390923|Placebo Comparator|2|
33050758|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
33050759|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
33050760|NCT05397847|Experimental|Experiment|Education, rational drug use guide and consultancy services will be provided to elderly individuals through home visits.
33050761|NCT05397847|No Intervention|Control|No intervention will be made to the control group, and after the post-test, the rational drug use guide and the medicine box will also be given to the control group.
33068021|NCT04517344|Experimental|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
33418523|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
33110369|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
33110370|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
33110371|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
33110372|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
33110373|NCT04316377|Active Comparator|Treatment|Chloroquine therapy in addition to standard of care
33110374|NCT04316377|No Intervention|No Treatment|Standard of care
33110375|NCT04677036||TUH Staff|Staff within Tallaght University Hospital - anonymised
33110376|NCT04677036||ASIT Members|Members of the Association of Surgeons in Training - anonymised
33110377|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
33110378|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
33110379|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:~SenSura test product~SenSura"
33110380|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:~SenSura~SunSura test product"
33110381|NCT02910440|Experimental|DCL-101|
33110382|NCT02910440|Active Comparator|GoLytely|
33110383|NCT04676997|Experimental|Camrelizumab+Chemotherapy|Participants receive Camrelizumab d1,15 (Q2W) + nab-paclitaxel d1,8,15(QW 3/4) x 4 cycles, followed by Camrelizumab Q2W + epirubicin + cyclophosphamide Q2W x 4 cycles as neoadjuvant therapy prior to surgery
33110384|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the ICSCI one (1) time per week during which you will perform FES cycling for 1 hour each.
33110385|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
33110386|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
33110387|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
33110388|NCT00624403|Active Comparator|1|LMA ProSeal
33110389|NCT00624403|Experimental|2|I-Gel
33110390|NCT02910128|Experimental|School intervention|chiquichefs education innovation
33110391|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
33110392|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
33110393|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
33110394|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
33331889|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
33331890|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
33331891|NCT05204758|Experimental|Study arm|Patients receive afatinib and TCM. TCM recipe was chosen from three essential TCM formulas, including Bai He Gu Jin Tang (yin nourishing), Wen Dan Tang (phlegm reducing), and Qing Shang Fang Fen Tang (heat clearing). The packages contained 1.6 g TCM preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of TCM preparations with each meal three times a day, for a total of nine packages per day. Administration of TCM was initiated at the same time as afatinib and continued for a total of three months.
33418524|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
33050762|NCT05394610|Active Comparator|Active Treatment|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies. The device is externally communicating only. The Sana Device will be administered at least twice daily, with one treatment session being just prior to bedtime. Additional PRN sessions with the Sana device will be allowed at the subject's discretion.
33418525|NCT05222061|Active Comparator|provisional-stenting group|Provisional stenting will be performed according to european bifurcation club consensus. MB and SB predilatation will be at the operator's discretion. A stent is delivered in the main vessel and positioned across the bifurcation. POT is mandatotary. In case of dissection impeding the flow in the SB or acute coronary closure after MB atenting a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus.
33050763|NCT05394610|Sham Comparator|Sham Arm|The sham treatment device was designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and ound but should offer no therapeutic effect to the level of the Sana Device. The sham device will run on the same headset, use a matched intensity of light/audio and used on the same schedule as the Sana treatment.
33050764|NCT05387629|Experimental|Experimental|Social media increases the academic success of nursing students.
33050765|NCT05387629|No Intervention|Control|Social media does not affect the academic success of nursing students.
33050766|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
33050767|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
33050768|NCT05378776|Experimental|Sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm.
33050769|NCT05378776|Placebo Comparator|Control|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
33050770|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
33050771|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
33050772|NCT05374525|Experimental|Routine Implementation (RI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI) . PSPs and SSPs will have access to standard toolkits for APRETUDE to use as needed.
33050773|NCT05374525|Experimental|Dynamic Implementation (DI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI). PSPs and SSPs will have access to enhanced toolkits, a digital health end to end implementation strategy and implementation facilitation for APRETUDE to use.
33050774|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
33050775|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
33050776|NCT05360329|Experimental|Mild to moderate knee osteoarthritis (Kellgren Lawrence Score 1-3)|Geniculate artery embolization will be performed in all eligible participants.
33050777|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
33050778|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
33050779|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
33050780|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
33050781|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
33050782|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
33050783|NCT05336032|Active Comparator|Oral glucose tolerance test|The volunteer will be performing the standardized oral glucose tolerance test with 75 gm of glucose. After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
32740291|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
33050784|NCT05336032|Experimental|Post prandial response to Rice|The participants will be served cooked basmati rice (70-gram available glucose). After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
33050785|NCT05329831|Experimental|Experimental|"Patients will be asked to fill out the Introductory Information Form, the Numerical Rating Scale, the Oxford Happiness Scale Short Form, and the Life Activities Scale scales. Then, the educational needs of the patients in the experimental group will be determined. Trainings will be planned individually for each patient according to the needs of the patients.~After the patients go to their homes, telehealth will be implemented. Patients included in the experimental group will continue their routine physician appointments and prescriptions. In addition, telehealth education initiative will be made for the patients. Structured training will be applied to the patients once a week for 12 weeks, each training will be 20-40 minutes. The researcher will develop a trusting relationship with the patient and evaluate the patient's compliance with treatment, obstacles to happiness, information needs related to pain management, and difficulties in life activities."
33050786|NCT05329831|No Intervention|Control|No application will be made by the researcher to the patients in the control group. Patients will continue with their prescriptions and physician visit routines. The scales will be administered to the patients in this group at the beginning of the study and at the 4th, 8th, and 12th weeks.
33050787|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
33050788|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
33050789|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
33050790|NCT05310955|Experimental|Control group|daily rehabilitation interventions
33050791|NCT05310955|Experimental|Interventional group|daily rehabilitation interventions and shen-based Qigong exercise
33050792|NCT05300152|Experimental|ACTIVA BioACTIVE Base/Liner|is a BioACTIVE glass-incorporated light-curable pulp capping material also known as light-cured resin-modified calcium silicate
33050793|NCT05300152|Active Comparator|Mineral trioxide aggregate (MTA)|is a bioactive materials containing calcium silicate
33050794|NCT05275933|Placebo Comparator|PC+SC|Placebo Control Capsules (PC) are provided in addition to Standard Care medications
33050795|NCT05275933|Active Comparator|LH+SC|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications.
33050796|NCT05259163|Experimental|LFR-260|The LFR-260 is a portable digital refractor which allows for determination of refractive error as well as for fully remote refractions during eye exams.
33050797|NCT05259163|Active Comparator|Traditional phoropter|The traditional phoropter is intended to be used for distance vision testing in any environment. The traditional phoropter is an application-controlled instrument providing the same subjective refraction capabilities for distance vision testing as the standard of care eye examination including sphere, cylinder, and axis.
33050798|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
33050799|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
33050800|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
33050801|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
33050802|NCT05228431|Experimental|Sandwich Regimen|All rectal patients in this group will receive standard surgical resection.
33050803|NCT05227456|Experimental|Etonogestrel implant|The participants will receive an etonogestrel 68mg implant
33050804|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
33050805|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
33050806|NCT05216146|Experimental|Experimental|Specially designed program for physical fitness enhancement
33050807|NCT05216146|Active Comparator|Control|A regular program of physical exercise
33050808|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
33050809|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
33050810|NCT05214898||Immediate Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
33068022|NCT04517344|Experimental|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
33068023|NCT00505102|Active Comparator|A|
33050811|NCT05214898||Delayed-Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
33050812|NCT05211661||Invasively ventilated patients (n=15)|"First measurement (comprehensive protocol) within 48 hours from initiation of MV.~Serial measurements every third day including 2 measurements after extubation."
33050813|NCT02776787||Patients|Patients with diverticulitis
33050814|NCT02776787||Surgeons|Surgeons who perform elective colon resections
33050815|NCT05208424||Normal glycemia|100 patients without evidence of dysglycemia.
33050816|NCT05208424||Prediabetes|100 patients with evidence of pre-diabetes defined as hemoglobin A1C (HbA1c) 5.7-6.4% with or without fasting plasma glucose (FPG) of 100 mg/dL to 125 mg/dL.
33050817|NCT05208424||Diabetes|100 patients without evidence diabetes defined as hemoglobin HbA1c > 6.4% with or without FPG >125 mg/dL.
33050818|NCT05197075|Experimental|Darunavir/Cobicistat (DRV/COBI) Fixed Dose Combination (FDC)|Participants will receive the DRV/COBI FDC tablet for oral use, dispersed in water on Day 1.
33050819|NCT05175430|Active Comparator|Pretreatment with paroxetine|Pretreatment with paroxetine (10 mg daily for 1 week followed by 20 mg daily for 5 weeks, per os), followed by administration of LSD (0.1 mg, per os) on the study day
33050820|NCT05175430|Placebo Comparator|Pretreatment with placebo|Pretreatment with placebo for 6 weeks (mannitol, per os), followed by administration of LSD (0.1 mg, per os) on the study day
33050821|NCT01806675|Experimental|Glioblastoma Multiforme (GBM)|Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)
33050822|NCT01806675|Experimental|Gynecological Cancers|Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
33050823|NCT01806675|Experimental|Renal Cell Cancer (RCC)|Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
33050824|NCT05173519|Active Comparator|Omnibond topical skin adhesive|
33050825|NCT05173519|Active Comparator|Dermabond topical skin adhesive|
33050826|NCT02762981|Experimental|Relacorilant with nab-paclitaxel|Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.
33331892|NCT05204758|Placebo Comparator|Control arm|Patients receive afatinib and placebo. Placebo without the medical ingredients was prepared to be similar to the weight, color, smell, taste, and packaging of the TCM formulas. The packages contained 1.6 g placebo preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of placebo preparations with each meal three times a day, for a total of nine packages per day. Administration of placebo was initiated at the same time as afatinib and continued for a total of three months.
33050827|NCT01806636||Treatment|Patients treated with PneumRx Coil System
33050828|NCT05148052|Experimental|Conventional therapy first|Group receiving conventional occupational therapy first and then virtual reality exergames.
33050829|NCT05148052|Experimental|Virtual reality first|Group receiving virtual reality exergames with virtual reality first and then conventional occupational therapy.
33050835|NCT05065567|Active Comparator|haloperidol|these patients will receive 5mg IM haloperidol
33050836|NCT05065567|Active Comparator|droperidol|these patients will receive 2.5mg IV droperidol
33050837|NCT05065567|Active Comparator|ondansetron|these patients will receive 8mg IV ondansetron
33050838|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
33050839|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
33050840|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
33068024|NCT04696237||orthodontists|
33068025|NCT04696237||general dentists|
33068026|NCT04696237||oral and maxillofacial surgeons|
33331893|NCT05204524|Experimental|Subjected arm|"temozolomide for injection (once a day, with a fixed dose of 200 mg (body surface area ≤1.7m2) or 300 mg (body surface area > 1.7 m2), for 5 days, with 21 days as a cycle) combined with epirubicin (60 mg/m2 21-day scheme).~Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months."
33331894|NCT05204056|Experimental|Group A|Twenty patients who were given intraoperative joint cavity infusion therapy using 20ml tranexamic and 40ml iced normal saline.
33331895|NCT05204056|Experimental|Group B|Twenty patients who were given 20ml of iced normal saline, 20ml of iced cocktail and 20ml of tranexamic
33331896|NCT05204056|Active Comparator|Control group|Twenty patients were given joint cavity infusion therapy with 20ml tranexamic only as the control group
32740292|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
33331897|NCT05761444|Experimental|Eze/Ato: Ezetimibe/Atorvastatin|Participants will receive ezetimibe/atorvastatin 10/40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C < 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target level is not reached at Visit 3, dose is increased to ezetimibe/atorvastatin 10/80 mg QD from Visit 3 to Visit 4.
33331898|NCT05761444|Active Comparator|Ato: Atorvastatin|Participants will receive atorvastatin 40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C < 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target is not reached at Visit 3, dose is increased to atorvastatin 80 mg QD from Visit 3 to Visit 4.
32740293|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
32740294|NCT03306719||Control Group|Pregnant women without IAI
32740295|NCT04442321|Active Comparator|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
33418526|NCT05222061|Experimental|DCB group|"Coronary guidewires should be passed to the MB and SB, respectively. Lesion preparation of the main branch should be undertaken as considered necessary. Lesion preparation of the side branch is mandatorary. If the angiographic result will be good after predilatation (residual stenosis < 30%), drug-eluting stent will implanted in the main branch of the bifurcation site (the stent diameter should be choosen based on the diameter of the distal MB). A kissing with conventional balloons should be performed in the MB and SB. Reapet kissing with drug-coated balloonin the SB and conventional balloon in MB (30 seconds at low pressure (8-10 bar) should be performed. The DCB diameter was again 0.8-1.0 of the vessel diameter.~In case of dissection impeding the flow in the SB or acute coronary closure after DCB application a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus."
33418527|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
33050843|NCT05026372|Experimental|Mindfulness + Compassion (MC)|For participants randomized to the MC condition will focus on compassion and creating positive emotions. This session will include techniques such as guided visualizations and a loving kindness meditation that are intended to facilitate connection with their partners. During this session, couples will also learn the ground rules of mindful and compassionate listening and sharing, as they will be asked to engage in an emotional disclosure task. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
33050844|NCT05026372|Experimental|Mindfulness + Gratitude (MG)|Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
33050845|NCT05026372|Experimental|Mindfulness + Value-Based Living (MV)|Session 2 for participants randomized to group MV will focus on learning strategies to live life according to their values. They will first engage in a reflection exercise to help identify their values, and then complete a worksheet. Couples will brain storm together strategies to ensure that their lives reflect their self-identified values. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
33050846|NCT05026372|No Intervention|Attention Control (AC)|For participants randomized to the AC condition, both sessions will focus on discussing issues and themes that emerge for couples, such as communication and perceived supportiveness. Utilizing a reflective listening approach, the interventionist will focus on encouraging participants to share concerns related to their daily experiences. Unlike in the MC, MG, and MV groups, the interventionist will not offer advice, support (other than reflective listening) or any other tools to participants. Additionally, the interventionist will not probe for deep emotional disclosure. Please see the appendix for the session outline. We believe a control group that discusses daily relationship-related concerns serves as an excellent comparison condition in this study since it is viewed as credible by participants and equates for time and attention as well as nonspecific treatment effects such as those provided through social interactions.
33068027|NCT04696237||plastic surgeons|
33068028|NCT04696237||cleft nurses|
33068029|NCT04696237||cleft lip and palate patients|
33068030|NCT04696237||speech therapists|
33068031|NCT04696237||ENT specialists|
33068032|NCT04696237||psychiatrists|
33331899|NCT05203744|Experimental|Standard Dose (200 mg)|Participants will receive the standard 200 mg tafenoquine dose (200 mg daily for 3 days) followed by 200 mg weekly for two weeks to check for tolerability and adverse effects.
33331900|NCT05203744|Experimental|Low Monthly Dose (600 mg)|"The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose."
33331901|NCT05203744|Experimental|High Monthly Dose (800 mg)|The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose
33331902|NCT04413552|Experimental|Part I: INDV-2000|Participants will receive a single dose of INDV-2000. The starting dose is 1 mg with dose escalation dependent upon observed clinical safety, tolerability and pharmacokinetics.
33331903|NCT04413552|Placebo Comparator|Part I: Placebo|Participants will receive a single dose of matching placebo.
33331904|NCT04413552|Experimental|Part II: INDV-2000 Fasted/Fed|Participants will receive a single dose of INDV-2000 orally on Day 1 under fasted conditions and a single dose of INDV-2000 after a high-fat breakfast on Day 8. Dose to be determined based on a well-tolerated dose studied in Part I.
33331905|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
33331906|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
32740296|NCT04442321|Sham Comparator|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
32740297|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
32740298|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
32740299|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
33050847|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
33050848|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
33050849|NCT05015920|Experimental|Mobilization,harvest,transduction,conditioning,treatment,engraftment|Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
33050850|NCT05005975|Experimental|Dersimelagon 100mg|
33050851|NCT04997473|Experimental|App Group|Participants will be receiving an addiction model based mobile health (mHealth) weight loss intervention with coaching for a total of 4 months duration
33050852|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
33050853|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
33050854|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:~Last Immune Tolerance Network (ITN) T1DM week 104 study visit,~Last AbATE (NCT00129259) follow-up visit, or~Last ITN066AI T1DES visit~Detectable C-peptide is defined as a value above the lower limit of detection."
33050855|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:~Last ITN T1DM week 104 study visit,~Last AbATE follow-up visit, or last~ITN066AI T1DES visit~Undetectable C-peptide is defined as a value below the lower limit of detection."
33050856|NCT02964130|Other|Follow-up patient|Medical follow-up visit
33050857|NCT04958044|Experimental|Calcium electroporation|Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection
33050858|NCT04953754|Experimental|Melatonin Group|This group will get melatonin 5mg nightly
33050859|NCT04953754|Active Comparator|Control Group|This group will not get any treatment (melatonin)
33050860|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
33050861|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
33050862|NCT04951453||Aneurysmal subarachnoid haemorrhage|Patients with SAH (see eligibility criteria below). Planned enrollment: 50 patients.
33418528|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
33050863|NCT04951453||Intracerebral haemorrhage|Patients with ICH (see eligibility criteria below). Planned enrollment: 50 patients.
33050864|NCT04951453||Traumatic Brain Injury|Patients with TBI (see eligibility criteria below). Planned enrollment: 50 patients.
33050865|NCT04923412|Experimental|Pulmonary branch of vagus nerve preserved|Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
33050866|NCT04923412|Experimental|Pulmonary branch of vagus nerve not-preserved|Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
33050867|NCT04912336||VV-ECMO|Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.
33050868|NCT04912336||VA-ECMO|Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.
33050869|NCT01806402||Retina|Having clinical diagnosis of retina pathology
33050870|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
33050871|NCT04726462|Experimental|Functional exercise group|
33050872|NCT04726462|Experimental|Posture exercises group|
33050873|NCT04871308|Placebo Comparator|Control|Placebo group using normal saline infusion
33050874|NCT04871308|Active Comparator|Dexmedetomidine|From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
33050875|NCT04861051|Other|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
33050876|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
33050877|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
33050878|NCT04846855|Experimental|Ropivacaine 35%|Local Anesthesia with Ropivacaine
33050879|NCT04829227|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
33050880|NCT04829227|Experimental|"off the face areas"|"off the face areas: abdomen, or arms or thighs or Décolleté."
33050881|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
33050882|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
33050883|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
33050884|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
33050885|NCT04828096|Active Comparator|Penta-one retainer|Penta-one retainer is one wire that is been in use for many years. Penta-one retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retainers are going to be bonded with sandblasted enamel and half without.
33050886|NCT04828096|Experimental|Ortho-FlexTech retainer|Ortho-Flextech chain wire is relatively new in the market and needs to be evaluated. Ortho-Flextech retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
33050887|NCT04828096|Experimental|Memotain retainer|Memotain wire is relatively new in the market. It requires digital scanning and the technique is said to be very exact. Memotain retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
33050888|NCT04816201|Experimental|Electroacupuncture|Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
33050889|NCT04816201|Sham Comparator|Sham electroacupuncture|Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
33050890|NCT01806285||Patients with Respiratory Symptoms|
33050891|NCT04803331|Experimental|cT1-2N0M0 oral cancer patients|Patients undergo routine sentinel lymph node procedure (99mTc injection, planar imaging, SPECT-CT and surgery) for clinical purposes. After 99mTc injections and imaging has been executed peritumoral SPIO injections are performed by a medical doctor. A T2*-weighted iron sensitive MRI scan is made 1 hour later.
33068033|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
33068034|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
33050892|NCT04799860|Experimental|health promotive work-way|Six primary care units that voluntarily enrolls as experimental units. The units will receive implementation support based on previous research and tailored to the specific prerequisits and context for each unit. Strategies includes involvement of target groups; informationa and interactive education;use of external and internal facilitators tarined for the purpose; systematic feedback and learning dialogs during the project. The implementation support will take approximately 12 months.
33050893|NCT04799860|No Intervention|Control|Six primary care centers of similar size and socioeconomic background in the population listed to each center.
33331907|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
33050894|NCT04794907||DR|Patients with diabetes
33050895|NCT04794907||AMD|Patients age 55 and older
33050896|NCT04787029|Experimental|prophylactic medical compression therapy group|"This study provides medical compression stockings from the start date of Docetaxel administration for patients who have undergone mastectomy and axillary lymphectomy for breast cancer, and who are planning to receive Docetaxel adjuvant chemotherapy. The intervention group wears medical compression stockings for upper limbs with a pressure level of 1 (15-21mmHg) during the day from the start of docetaxel administration to 3 months after the end of administration.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
33050897|NCT04787029|No Intervention|control group|"The control group proceeds as an observation, but interventions such as providing stockings in the event of lymphedema are performed.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
33050898|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
33050899|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
33050900|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
33050901|NCT04774198||Occurrence of persistent postoperative hypotension|Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
33050902|NCT04774198||No occurrence of persistent postoperative hypotension|Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
33050903|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
33050904|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
33050905|NCT04749043|Active Comparator|Virtual Reality then Nitrous Oxide|30 minute exposure to virtual reality, 5 minute washout period, then 30 minute exposure to nitrous oxide
33050906|NCT04749043|Active Comparator|Nitrous Oxide then Virtual Reality|30 minute exposure to nitrous oxide, 5 minute washout period, then 30 minute exposure to virtual reality
33050907|NCT02687360|Active Comparator|Active rTMS stimulation|This arm will receive high-frequency rTMS pulses directed at the medial prefrontal and anterior cingulate cortices.
33050908|NCT02687360|Sham Comparator|Sham rTMS stimulation|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil and to produce activation of facial muscles similar to the effect of active rTMS without stimulating the brain itself.
33050909|NCT00405262|Active Comparator|1|
33050910|NCT00405262|Experimental|2|
33050911|NCT00405262|Experimental|3|
33050912|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
33050913|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
33050914|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
33050915|NCT00405340|Experimental|Drug|Rituximab
33331908|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
33331909|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
33331910|NCT05761366|Experimental|Al18F-PSMA-BCH PET/CT|Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors.（including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.）
33331911|NCT05203666||degenerative lumbar spinal stenosis|All patients treated in 2019 with a percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
33331912|NCT05302466|Active Comparator|gymnastic (control group)|"usual care home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily."
33331913|NCT05302466|Experimental|gymnastic plus dental bite pads (intervention group)|Identical home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily plus dental bite pads during exercise. The dental bite pads are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise.
33331914|NCT05203588|Experimental|Experimental group|Patients in this group are received denosumab (60 mg) subcutaneously at one week and 26 weeks after the lumbar fusion surgery, combined with receiving daily calcium (≥1·0 g) and vitamin D (≥400 IU).
32740300|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
33050916|NCT00391001|Experimental|1|
33050917|NCT00391001|Placebo Comparator|2|
33050918|NCT04740541|Experimental|Threonine Requirement in CD Patients|Males aged 18 - 49 with stable Crohn's disease will be seen for pre-study They will be studied up to 5 times for different levels of threonine intakes.
33050919|NCT04713826|Experimental|BAY2586116_Placebo|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive BAY2586116 in treatment period 1, and placebo in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG (polysomnography).~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
33050920|NCT04713826|Experimental|Placebo_BAY2586116|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive placebo in treatment period 1, and BAY2586116 in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG.~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
33050921|NCT04713319|Placebo Comparator|Placebo|"Ten participants were randomly selected to the placebo group.~Calcium chloride (E509) dissolved into water. Extremely small equimolar calcium dose with the test item."
33050922|NCT04713319|Active Comparator|RH013001 (DGA)|D-glyceric acid (DGA) calcium salt dehydrate (RH013001) dissolved into 1.8 dl of water. Effective dose of DGA was 3.33 mg / kg body weigh for the first 4 days. Thereafter the dose was reduced to half for the 14 days follow up period. Frequency: 2 times a day.
33050923|NCT04669093|Experimental|Placebo|All participants will participate in two sessions, one with a placebo suggestion that matches the participant's motivational style, and one with placebo suggestion that does not match their motivational style, in a pseudo-random order.
33050924|NCT04669093|Experimental|Control|Each session will also include a control phase, in which the same cream will be applied, and participants will be instructed that the cream has no analgesic effects.
33050925|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
33050926|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
33050927|NCT04635904|Experimental|Imaginal exposure|A behavioral intervention in imagery
33050928|NCT04635904|Experimental|Imagery rescripting|A different behavioral intervention in imagery
33050929|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
33050930|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
33331915|NCT05203588|Sham Comparator|Control group|Patients in this group are only received daily calcium (≥1·0 g) and vitamin D (≥400 IU) after the lumbar fusion surgery.
33331916|NCT05761288|Experimental|Surgery days with intraoperative microbreaks and exercises|Surgery days randomized to intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. The exercises will be performed just before surgical time-out, at a surgically safe and convenient time 45-75 mins after the start of the case and at the end of the case. A surgically safe and convenient time means the surgeon feels that it is safe to take an approximately 1.5-2 minute break during the procedure at that time. Surgeons will skip the microbreak if there is no surgically convenient or safe time during the case. Surgeons will stop the microbreak at any point if needed to ensure patient safety.
33331917|NCT05761288|No Intervention|Surgery days without intraoperative microbreaks and exercises|Surgery days without intraoperative microbreaks and exercises will include no intervention. Surgeons will perform the surgeries as they are normally performed and surgeons will not take microbreaks or perform exercises.
33331918|NCT05203354|Active Comparator|NB-UVB group|Patients who receive Narrowband ultraviolet B phototherapy
33050931|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
33050932|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
33050933|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
33050934|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
33068035|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
33331919|NCT05203354|Active Comparator|Acitretin group|Patients who receive acitretin
33331920|NCT05203354|No Intervention|Control group|It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level
33418529|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
33050935|NCT02646683|Other|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
33050936|NCT02646683|Other|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
33050937|NCT04585087|Experimental|Healthy adult men|"Participants will initially be seen for a pre-study assessment (2 hours). They will then be studied for up to 6 times (6 different levels of threonine intake). Each set of experiments will be 9-days in length. During the first 2 days, a pre-adaptation (milkshake) diet will be consumed. For the remaining 7 days, a protein liquid drink and protein-free cookies will be consumed. All of the diets will be provided by the investigators.~During each 9-day experiment, participants are expected to come to the Clinical Research Centre at the Hospital for Sick Children for breath and urine collection (5 hours total for each visit)"
33050938|NCT04575220|Experimental|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
33050939|NCT04541914|Experimental|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
33050940|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
33050941|NCT04528810||Child injuries|pediatric patients under the age of 18 years newly diagnosed with injuries in the emergency department
33050942|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
33050943|NCT00393627|Placebo Comparator|2|Routine medical care
33050944|NCT04516408|Experimental|Recombinant zoster vaccine|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.
33050945|NCT04516408|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.
33050946|NCT04476901|Placebo Comparator|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.
33050947|NCT04476901|Experimental|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.
33050948|NCT04476901|Placebo Comparator|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.
33050949|NCT04476901|Experimental|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.
33050950|NCT04476901|Placebo Comparator|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.
33050951|NCT04476901|Experimental|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.
33050952|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
33050953|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
33050954|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
33331921|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33331922|NCT05203042||prediabetes|
33331923|NCT05203042||diabetes|
33331924|NCT05761210||cases; subjects with steatosis|
33331925|NCT05761210||controls; subjects without steatosis|
33331926|NCT03754062|Placebo Comparator|Placebo|Placebo control
33331927|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
33331928|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
33331929|NCT05202886|Experimental|Liver from deceased donors|This study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
33331930|NCT05185960|Experimental|ALLSWEET®|ALLSWEET® will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
33331931|NCT05185960|Experimental|ALLSWEET® consumed with sucrose|ALLSWEET® and sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
33331932|NCT05185960|Active Comparator|Sucrose|Sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
33418530|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
33418531|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
33050955|NCT04453969||Breastfeeding mothers positive for COVID-19|
33050956|NCT04437355|Active Comparator|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
33050957|NCT04437355|Active Comparator|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
33050958|NCT04437355|Active Comparator|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
33050959|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
33050960|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
33050961|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
33050962|NCT04427956|Active Comparator|Isotonic riboflavin|CXL (UVA 9mW/cm2) treatment using isotonic riboflavin
33050963|NCT04427956|Active Comparator|Hypotonic riboflavin|CXL (UVA 9mW/cm2) using hypotonic riboflavin
33050964|NCT04427956|Active Comparator|Iontophoresis|Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
33050965|NCT04414150|Experimental|SHR-1802|
33050966|NCT04396444|Experimental|Lavender Aromastick Group|The aromastick is a plastic tube, similar in size to a lipstick. A study team member will prepare the aromastick by infusing ten drops of lavender essential oil onto a blank cotton wick inside the tube and sealing the cap.
33050967|NCT04396444|Placebo Comparator|Blank Aromastick Group|A study team member will prepare the blank aromastick by placing a blank cotton wick inside the aromastick tube and sealing the cap.
33050968|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
33050969|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
33418532|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
33418533|NCT05108077|Experimental|Cytokine-induced killer cells|Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
33418534|NCT05108077|Active Comparator|Control|Patients with metastatic tumors of the urogenital area receiving standard treatment
33418535|NCT04952805|Experimental|Interventional Arm _400 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.
33050970|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
33050971|NCT02496416|Active Comparator|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
33050972|NCT04380454|Experimental|Fast treadmill walking with functional electrical stimulation (FastFES)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of FastFES. FastFES is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
33050973|NCT04380454|Active Comparator|Fast treadmill walking (Fast)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of Fast. Fast is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
33050974|NCT04380064|Experimental|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
33050975|NCT04380064|Active Comparator|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
33050976|NCT04341181|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
33050977|NCT04341181|Experimental|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
33050978|NCT04341181|Experimental|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
33050979|NCT04341181|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
33050980|NCT04341181|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
33050981|NCT04341181|Experimental|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
33418536|NCT04952805|Experimental|Interventional Arm _100 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.
33418537|NCT04952805|Placebo Comparator|Placebo Arm|To all the patients enrolled is admistrated with single dose of placebo
33418538|NCT01372267|Experimental|CBT for pain|
33418539|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
33110395|NCT04675086|Experimental|Aralast NP + Antiviral Treatment + Standard of Care|"The investigational product is alpha1-proteinase inhibitor, administered as a loading dose of 120mg/kg/body weight intravenous infusion on the first day, and then 60mg/kg/BW intravenous infusion on Days 3, 5, 7 and 9. Booster infusion of 120 mg/kg/BWon Day 17.~The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
33110396|NCT04675086|Active Comparator|Antiviral Treatment + Standard of Care|"The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
33110397|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
33110398|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
33110399|NCT04688138||ischemic stroke|Patients with ischemic stroke within 7 days of onset
33110400|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
33110401|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
33110402|NCT04687943||PELOID therapy|A total of 15 sessions of peloid therapy for 3 weeks, 5 days a week for 42 patients in the first group
33110403|NCT04687943||Kinesio tape|42 patients in group 2 will be given 2 sessions of muscle and fascia correction techniques per week, with kinesio tape application and cold application
33110404|NCT04687943||Exercise|42 patients in the third group will be given 3 sets of 10 repetitions home exercise programs for 3 weeks
33110405|NCT04674657||caspofungin|Adult critically ill patients on ECMO receiving caspofungin therapy
33110406|NCT04674657||posaconazole|Adult critically ill patients on ECMO receiving posaconazole therapy
33110407|NCT04688060||fallers|stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure Patients who have fallen 1 or more times since stroke
33110408|NCT04688060||non-fallers|"stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure.~Patients who have not fallen 1 or more times since stroke"
33110409|NCT04674735|Experimental|APSLXR|
33110410|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
33110411|NCT04674930|No Intervention|Control group|Pharmacological management
33110412|NCT04674930|Experimental|Exercise group|"Aerobic training: The target training zone was set at 40-60% of the peak heart rate, as determined in the baseline 6min walk test (6MWT), with a rating of 11-13 on the Borg rating of perceived Exertion scale.~Resistance Training: This training was prescribed at 70% of one repetition maximum (RM). Patients were instructed to train a variety of upper and lower body muscle groups (e.g., latissimus, deltoid, biceps, quadriceps, and gastrocnemius muscles), using Thera-band"
33110413|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
33110414|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
33110415|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
33110416|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
33110417|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
33110418|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
33110419|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
33110420|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
33418540|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
33418541|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
33418542|NCT04134013|Experimental|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
33418543|NCT04134013|Active Comparator|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
33418544|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
33050982|NCT04341181|Experimental|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
33050983|NCT04341181|Experimental|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
33050984|NCT04341181|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
33050985|NCT04341181|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
33050986|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
33050987|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
33050988|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
33050989|NCT04314583|Active Comparator|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
33418545|NCT04714047|Experimental|Group 1:|PRT
33418546|NCT04714047|Experimental|Group 2:|PRT + Booster sessions
33418547|NCT04714047|Active Comparator|Group 3:|NEMEX
33050990|NCT04314583|Experimental|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
33050991|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
33050992|NCT02423876|Experimental|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
33050993|NCT02423876|Active Comparator|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
33050994|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
33050995|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
33050996|NCT04302259|Experimental|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
33050997|NCT04298242|Experimental|MRgFUS Treatment|The pancreatic tumor will be ablated with magnetic resonance guided focused ultrasound (MRgFUS).
33050998|NCT04288258|Experimental|Treatment|Health and Wellness Program
33050999|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
33051000|NCT01805895|Experimental|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
33051001|NCT01805895|No Intervention|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
33051002|NCT04278274||patients will be evaluated by artificial intelligence system and expert radiologist|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment, and not yet receive total mesorectum excision (TME) surgery will be enrolled. The post-neoadjuvant treatment MRI images features of each enrolled patients will be captured by the artificial intelligence system, and evaluated by experienced radiologists as well. Blind to the pathologic report of TME specimen, both approaches further respectively yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient, shown as pCR or non-pCR.
33051003|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
33418548|NCT04714047|Experimental|Group 4:|NEMEX + Booster sessions
33418549|NCT04952467|Experimental|Drug: (14C)-XEN1101|Subjects will receive oral 14C-XEN1101 under fed conditions.
33418550|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
33051004|NCT04255030|Experimental|First stage: Self-directed Coping Together|
33051005|NCT04255030|Experimental|First stage: Minimally guided telephone support (lay coaching)|
33418551|NCT01369693|Active Comparator|General Portion 1 g pouch|
33418552|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
33418553|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
33418554|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
33418555|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
33418556|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
33418557|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
33051006|NCT04255030|Experimental|Second stage: High intensity Motivational Interviewing (MI)|
33051007|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
33051008|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
33051009|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
33051010|NCT04253080|No Intervention|patients with primary thin melanoma < or = 1mm|patients with primary thin melanoma (Breslow thickness less than or equal 1 mm)
33051011|NCT04253080|No Intervention|patients with primary thick melanoma > or = 3 mm|patients with primary thick melanoma (Breslow greater than or equal 3 mm)
33418558|NCT04663503|Experimental|Intervention arm -Exercise Program|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. It consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization (Appendix 3). This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
33051012|NCT04253080|Other|patient with melanoma who received treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
33051013|NCT04234048|Experimental|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b~Accelerated Phase 1a~Up to 8 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m^2/day X 5 days every 21 days):~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient)~Standard Phase 1a~Up to 18 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):~Dose Level 9 320 (3-6 patients) Dose Level 10 448 (3-6 patients) Dose Level 11 627 (3-6 patients)~Phase 1b~20 patients for phase 1b at the maximum tolerated dose (MTD)"
33051014|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
33051015|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
33051016|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
33051017|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
33051018|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
33051019|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
33051020|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg administered orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
33051021|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg administered orally once daily for 12 weeks
33051022|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 20 mg|Omaveloxolone (RTA 408) Capsules, 20 mg administered orally once daily for 12 weeks
33051023|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 40 mg|Omaveloxolone (RTA 408) Capsules, 40 mg administered orally once daily for 12 weeks
33418559|NCT04663503|No Intervention|Control arm- No intervention|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
33418560|NCT02102594|Experimental|Bortezomib (Velcade)|
33418561|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
33051024|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 80 mg|Omaveloxolone (RTA 408) Capsules, 80 mg administered orally once daily for 12 weeks
33051025|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 160 mg|Omaveloxolone (RTA 408) Capsules, 160 mg administered orally once daily for 12 weeks
33051026|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 300 mg|Omaveloxolone (RTA 408) Capsules, 300 mg administered orally once daily for 12 weeks
33051027|NCT02255435|Placebo Comparator|Part 1 Placebo Capsules|Placebo capsules administered orally once daily for 12 weeks
33051028|NCT02255435|Placebo Comparator|Part 2 Placebo Capsules|Placebo capsules administered orally once daily for 48 weeks
33051029|NCT02255435|Experimental|Part 2 Omaveloxolone Capsules 150 mg|Omaveloxolone (RTA 408) Capsules, 150 mg administered orally once daily for 48 weeks
33051030|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
33051031|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
33051032|NCT04206046|Active Comparator|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
33051033|NCT04206046|Active Comparator|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
33051034|NCT00405418|Experimental|1|Insulin Glargine
33051035|NCT00405418|Active Comparator|2|Insulin Detemir
33051036|NCT04102852|Experimental|LGG regular dose|Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
33051037|NCT04102852|Experimental|LGG double dose|Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
33051038|NCT04083001|Experimental|OTR4132MD|"one medical device (10mL) of one of the 5 available concentrations (20 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) will be administrated as a one shot-dose to the patient.~The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg and 2 mg."
33051039|NCT04078321|Experimental|Single case design|Single case studies
33051040|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
33051041|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
33051042|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
33051043|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
33051044|NCT04057378|Active Comparator|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
33051045|NCT04057378|Active Comparator|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
33051046|NCT04038580|Sham Comparator|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
33051047|NCT04038580|Experimental|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
33051048|NCT04033276|Active Comparator|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
33051049|NCT04033276|Active Comparator|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
33051050|NCT04014790|Experimental|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
33051051|NCT03969823|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
33051052|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
33051053|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
33051054|NCT03948256|Active Comparator|Control intervention|Prompt closure, based on best available scientific data
33051055|NCT03948256|Experimental|Experimental intervention|Gradual weaning, based on best available scientific data
33051056|NCT04725799||MESS with and without stressful stimuli|The subjects participate in meal, exercise, sleep activities alone or in combination with stressful stimuli.
33051057|NCT04726072|Experimental|Kundalini Yoga|The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises and meditation. Participants were also asked to do at-home practice for half an hour daily.
33051058|NCT04726072|Active Comparator|Psychoeducation|The psychoeducation group consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily
33051059|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
33051060|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
33051061|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
33051062|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
33051063|NCT04725487|Experimental|Standard integration program with social and health promoting intervention|Participants follow the standard integration program offered by Naestved Municipality and participate in various social and health promoting activities in addition
33051064|NCT04725487|Active Comparator|Standard integration program|Participants follow the standard integration program offered by Naestved Municipality
33051065|NCT00391235||BPD|Children with bipolar disorder
33051066|NCT00391235||HC|Healthy comparison children
33051067|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
33051068|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
33051069|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
33051070|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
33051071|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
33051072|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
33051073|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
33051074|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
33051075|NCT01981148||Healthy patients|Healthy patients
33051076|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
33051077|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
33051078|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
33418562|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
33051079|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
33051080|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
33418563|NCT04946877||case group|100 ADHD patients; will be taken from outpatient clinic of child and adolescence psychiatry of Assiut university hospitals.
33418564|NCT04946877||control group|100 normal children; they will be selected from neurology clinic complaining from minor neurological complaint e.g : headache, will match with the case group for age, sex and educational level.
33051081|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
33418565|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
33418566|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
33051082|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
33051083|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
33051084|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
33051085|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
33051086|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
33051087|NCT03748888|No Intervention|Control Group|Sedentary participants.
33051088|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
33051089|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
33418567|NCT05361590|Experimental|Study group|Subjects in the study group will use the Lumoral device once a day according to the verbal and written instructions provided to them. In addition, they will brush their teeth twice daily in their customary manner while using the provided sonic toothbrush and regular toothpaste.
33418568|NCT05361590|Active Comparator|Control group|Subjects in the control group will brush their teeth in their customary manner twice daily while using the provided sonic toothbrush and regular toothpaste. They will not receive any additional intervention.
33418569|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
33051090|NCT03744286|Experimental|Balance Slip|"Perform standard clinical balance assessments~Determine the optimal slip distance by 10 passes each with plank movement of 2, 4, 6 and 8 on visit 1"
33051091|NCT03734731|Other|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
33418570|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
33051093|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
33051094|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
33051095|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
33051096|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
33051097|NCT01902173|Experimental|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib (Phase I): Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial.~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib (Phase I and Phase II): Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial."
33051098|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.~Onset of PD symptoms of <5 years~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
33051099|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects~Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
33051100|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;~Age-and sex-matched with PD subjects~Chinese aged 40 or above;~Absence of dream enactment behaviors;~Not cohabiting with proband"
33051101|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of RSWA as measured by v-PSG."
33051102|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
33051103|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 40 or above ;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
33051104|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
33418571|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
33051105|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
33051106|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
33051107|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
33051108|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
33051109|NCT03626857|Experimental|NMES+ECC|Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC). Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks. For NMES, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions.
33051110|NCT03626857|Placebo Comparator|NMES placebo + ECC placebo|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC)placebo arm. Patients randomized to the NMES placebo + ECC placebo group will first receive NMES placebo for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES placebo, patients will have NMES placebo delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session.~For the eccentric exercise placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions."
33418572|NCT02106260|Experimental|CLS003|
33418573|NCT05365087||TS Cohort|Patients who chose the Transoral Fundoplication (TF) prior to the Laparoscopic Sleeve Gastrectomy (LSG) procedure.
33418574|NCT05365087||RNY Cohort|Patients who chose the Laparoscopic Roux-enY Gastric Bypass procedure.
33051111|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
33051112|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
33051113|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
33051114|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
33051115|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
33051116|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
33051117|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
33051118|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
33051119|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
33418575|NCT05221905|Active Comparator|Acute High-Intensity Exercise|Subjects will exercise at an intensity of 75% of the difference between the lactate threshold and VO2peak until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
33418576|NCT05221905|Active Comparator|Acute Moderate-Intensity Exercise|Subjects will exercise at an intensity at the lactate threshold until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
33418577|NCT05221905|Placebo Comparator|Non-Exercise Control|Measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, without exercise taking place during time points 0-60 min.
33051120|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
33051121|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
33051122|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
33418578|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
33418579|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
33418580|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
33418581|NCT04806217|Experimental|¨Patients with multiple sclerosis|"Patients :~With multiple sclerosis~Aged of 18 and over~Recruited during their consultation in the adult outpatient unit or neurological unit or during a hospitalization."
33418582|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
33051125|NCT03341143|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
33051126|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33068036|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
33068037|NCT04511728|Experimental|HSK3486|
33068038|NCT04511728|Active Comparator|Propofol|
33418583|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.~Saturated fat Triolein 13C"
33418584|NCT04728139|Active Comparator|patients with colorecta cancer|
33418585|NCT04728139|No Intervention|healthy individuals|
33418586|NCT05221671|No Intervention|not received information leaflet|"During the preoperative anesthesia clinic examination, demographic data will be recorded and routine information about anesthesia will be provided. However, the information leaflet will not be handed to the patient and parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
33418587|NCT05221671|Active Comparator|received information leaflet|"During the preoperative anesthesia evaluation, the children and their parents, who are included in the group who will receive information leaflets according to randomization, will be given information leaflets and both the child and their parents will be asked to read them before the procedure day. Age-appropriate brochures will be provided for children, and parent information leaflets will be provided for parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
33418588|NCT02101424||Overdose|
33418589|NCT05221515|Experimental|Intervention condition|Participants received both parent training and child-focussed treatment
33418590|NCT05221515|Active Comparator|Control condition|Participants received only parent training
33418591|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
33418592|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
32871587|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
33418593|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
33418594|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
32740301|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
32740302|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
32740303|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
32740304|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
32740305|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
32740306|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
32740307|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
32740308|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
32740309|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
32740310|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
32740311|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
32740312|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
32740313|NCT02467985|No Intervention|Control|
32740314|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
32740315|NCT03306329|Experimental|DNS-7801 (low-dose)|
32740316|NCT03306329|Experimental|DNS-7801 (high-dose)|
32740317|NCT03306329|Placebo Comparator|Placebo|
32740318|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
32740319|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
32740320|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
32740321|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
32740322|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
32740323|NCT03304301|No Intervention|control group|Participants will receive routine care.
32740324|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
32740325|NCT04490759||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System
32740326|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
32740327|NCT03304067|Experimental|Intervention|
32740328|NCT03304067|No Intervention|Control|
32740329|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
33418595|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
33418596|NCT02101580|Experimental|ADI-PEG 20|
33418597|NCT05648019|Experimental|Single Arm|CD19-directed CAR T-cell therapy for relapsed/refractory B-lineage leukaemia/lymphoma.
32869578|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
32869579|NCT00149227|Active Comparator|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
32869580|NCT00149227|Experimental|Valsartan|Valsartan add-on treatment
32869581|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
33418598|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
33418599|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
33418600|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
33418601|NCT04249323|Experimental|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
33418602|NCT04249323|Placebo Comparator|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
33418603|NCT04249323|Experimental|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
33418604|NCT04249323|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
33418605|NCT04249323|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
33418606|NCT02102750|Experimental|tafluprost|
33418607|NCT04227327|Experimental|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
33418608|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy
32869582|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
32869583|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
32869584|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
32869585|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
32869586|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
32869587|NCT04789083|Experimental|Group 1 (Propolis)|Medical therapy and propolis
32869588|NCT04789083|Experimental|Group 2 (Nurse Coaching/ Nursing education)|Medical treatment and nurse coaching
32869589|NCT04789083|Placebo Comparator|Group 3 (Plassebo)|Medical treatment and plassebo will be applied.
32869590|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
32869591|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
32869592|NCT05708235|No Intervention|Arm A: Control Arm|Patients must continue the same standard ET,prescribed as per standard practice, used in the surveillance phase. Changes in ET are not allowed.
33418609|NCT02102828|Experimental|extended compression|aspirin and extended compression therapy in combination
33051127|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33051128|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33051129|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
32871588|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
33051130|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
33051131|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33051132|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33051133|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
33051134|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
33051135|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
33051136|NCT04710823|Experimental|Thoracic paravertebral block|Patients will receive ultrasound-guided continuous thoracic paravertebral blockusing bupivacaine 0.25% for 4 days.
33051137|NCT04710823|Experimental|Serratus anterior plane block|Patients will receive ultrasound-guided continuous SAP block using bupivacaine 0.25% for 4 days.
33051138|NCT00405535|Experimental|A|glycine powder
33051139|NCT00405535|Placebo Comparator|B|placebo powder
33051140|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
33051141|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
33051142|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
33051143|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
33051144|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
33051145|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
33051146|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
33051147|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
33051148|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
33051149|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
33051150|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
33051151|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
33051152|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
33110421|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
32869593|NCT05708235|Experimental|Arm B: Experimental Arm with giredestrant|Giredestrant: 30 mg will be taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).
33051153|NCT02825641|Active Comparator|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
33051154|NCT02825641|Active Comparator|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
33051155|NCT02825641|Experimental|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
33051156|NCT02825641|Experimental|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
33051157|NCT02777047|Experimental|Intervention|The interdisciplinary multimodal intervention is led by a clinical pharmacologist and includes: a detailed discharge medication reconciliation and management plan focused on oral anticoagulants at hospital discharge; a circle of care handover and coordination with patient, hospital team and community providers; and early post-discharge follow-up virtual medication check-up visits at 24 hours, 1 week, and 1 month.
33331933|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
33051158|NCT02777047|No Intervention|Control|Patients allocated to the control group will receive usual care, plus the URL to Thrombosis Canada website. Usual care in the participating sites includes OAC management by family doctors except for new thromboembolic events which will be followed short term by thromboembolism or hematology specialists, complicated atrial fibrillation which will have cardiology involved temporarily, and a small proportion of warfarin management which is provided in an anticoagulation clinic. This choice of control group is the most relevant for generalizability to both academic and community practices.
33331934|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
33331935|NCT05184244||Participants with CP|Children with CP
33331936|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
33331937|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
33331938|NCT05180032|Experimental|Romosozumab group|Romosozumab (evenity) administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
33331939|NCT05180032|Placebo Comparator|Control group|Placebo administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
33331940|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
33331941|NCT05761132|Experimental|Neoadjuvant pembrolizumab|"Patients receive pembrolizumab, 200 mg IV Q3W for a total of 2 administrations per patient over a period of 6 weeks prior to surgery.~Responders have the option to fall into an extension cohort and, after consultation with the multidisciplinary team, will be treated with adjuvant pembrolizumab from week 16 until week 58 (400 mg IV, Q6W, 7 times)."
33360758|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
33051159|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
33051160|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
33360759|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
33110422|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
33360760|NCT03519724|Experimental|SUG|
33360761|NCT03519724|Active Comparator|NEO|
33360762|NCT02292862||MG Main Group|lymph node and blood sampling
33360763|NCT01130935||1|
33110423|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
33110424|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
33110425|NCT04674891|Active Comparator|baseline physical therapy treatment|baseline physical therapy treatment ,Control group- Group A
33110426|NCT04674891|Experimental|Cervical Stabilization exercises|baseline physical therapy treatment along with Cervical Stabilization exercises- Experimental Group- Group B
33110427|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
33110428|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
33110429|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
33110430|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
33110431|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
33110432|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
33110433|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
33110434|NCT01216189||Preoperative radiotherapy|Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
33110435|NCT01216189||No preoperative radiotherapy|Women with rectal cancer treated with surgery alone (no RT).
33110436|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
33110437|NCT04674696|Experimental|Experimental|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
33110438|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
33110439|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
33110440|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
33110441|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
33360764|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
33360765|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
33360766|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
33360767|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
33360768|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
33331942|NCT04656496|Experimental|NOURISH-T+|NOURISH-T+ targets parents as agents of change by providing intensive parent skills training emphasizing role modeling of positive health behaviors to foster the development of healthy eating and physical activity in pediatric cancer survivors. The NOURISH-T+ group will have 6 weekly, 1-1.5 hour, manualized sessions delivered using video-conferencing. There will be 2 additional brief sessions where the child will participate along with their parent to promote child engagement. Additionally, there will be one session with a pediatric oncology dietician based out of Nicklaus Children's Hospital who will discuss personalized nutritional strategies. Brief booster sessions at 2-, 4-, 8-, and 10- months will maximize retention and follow-up participation. NOURISH-T+ content is theory-based, manualized, and builds upon strengths of our prior work with NOURISH-T (our pilot) and NOURISH (our work with otherwise healthy overweight and obese children).
33360769|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
33360770|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
33418610|NCT05228119|Experimental|Oncolytic Virus Injection(RT-01)|"RT-01 will be administered either intravenously or with a combination of intravenously and intratumorally on day 1.~Nivolumab will be administered intravenously every 3 weeks starting on day 5."
33418611|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
33418612|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
33051161|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
33051162|NCT04711057|Experimental|Pulmonary Rehabilitation + Community-based PA program|After PR, the experimental group will integrate a community-based PA program.
33051163|NCT04711057|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
33051164|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.~At each consultation with the overweight child and his/her biological parents there are two therapists present."
33051165|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
33051166|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
33051167|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
33051168|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
33051169|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
33051170|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
33051171|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
33051172|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
33051173|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
33051174|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
33051175|NCT01496313|Active Comparator|300mg vandetanib|
33051176|NCT01496313|Active Comparator|150mg vandetanib|
33418613|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
33418614|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
33051179|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
33360771|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
33360772|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
33360773|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
33360774|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
33360775|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
33360776|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
32869594|NCT05708235|Experimental|Arm C: Experimental Arm with giredestrant + abemaciclib|"Giredestrant: 30 mg will be taken PO QD on Days 1to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~Abemaciclib 150mg will be taken PO twice daily (BID) (two intakes for a total daily dose of 300 mg) during each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
32869595|NCT05708235|Experimental|Arm D: Experimental Arm with giredestrant + inavolisib|"Giredestrant: 30 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~Inavolisib: 9 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
32869596|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
32869597|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
32869598|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
32869599|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
32869600|NCT05695911|Experimental|Limb Load Biofeedback Training Intervention|The limb-load biofeedback training focuses on altering habitual movement patterns to promote proper prosthetic limb loading with an emphasis on between-limb loading symmetry. Participants randomized to the EXP group will receive 12 biofeedback training sessions (1 in-person, 11 telehealth) tapered over 40 weeks.
32869601|NCT05695911|Placebo Comparator|Attention Control Intervention|The CTL group intervention will include the same standard of care rehabilitation sessions as the EXP group and receive the same computer tablets for telehealth sessions as the EXP group. The CTL group will also have attention control educational sessions at the same frequency, timing, and duration as the EXP group limb-load biofeedback sessions (12 total sessions) with the first session being an in-person session at the Week 24. There will be no biofeedback training intervention in the CTL group. As such, there will be no behavioral intervention or wearable sensors provided to the CTL group. The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group.
32869602|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
32869603|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
32869604|NCT04663945|Experimental|Intervention|"This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions.~Other: remote controlled exercise plus home exercise~Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise"
32869605|NCT04663945|No Intervention|Control|"This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training.~Other: basic education"
32869606|NCT01790347|Experimental|Exercise group|
32869607|NCT01790347|No Intervention|Control group|Sedentary pregnant women
32869608|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
32869609|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
32869610|NCT01742299|Experimental|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
32869611|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
32869612|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
32869613|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
32869614|NCT04693533|Other|treatment effect|No 2 arms and only 1 intervention
32869615|NCT05690763|Experimental|XP-endo Finisher|use of XP-endo Finisher
32869616|NCT05690763|Experimental|EndoActivator|use of EndoActivator
32869617|NCT00258349|Experimental|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
32869618|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
32869619|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
32869620|NCT01899157||Survey|"Thai naive HIV-infected patients~Thai HIV-infected patient reciering highly active antiretroviral therapy"
32869621|NCT05165485|Experimental|Revefenacin|Revefenacin DoseA administered with tiotropium placebo
32869622|NCT05165485|Active Comparator|Tiotropium|Tiotropium DoseB administered with revefenacin placebo
32869623|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
32871589|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
33051180|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
33051181|NCT01466556||Obese children|
32871590|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
33051182|NCT01466517|Active Comparator|Reference Drug|
33051183|NCT01466517|Active Comparator|Test Drug|
33051184|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
33051185|NCT01466439|Other|high frequency rTMS|
33051186|NCT01466439|Other|low frequency rTMS|
33051187|NCT01466400||infants two to six months of age|
33051188|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
33051189|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
33051190|NCT01466361|Placebo Comparator|Placebo|Placebo
33051191|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
33051192|NCT00001832|Experimental|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.~They didn't receive any drugs."
33051193|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051194|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051195|NCT00001832|Experimental|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051196|NCT00001832|Experimental|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051197|NCT00001832|Experimental|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33331943|NCT04656496|Active Comparator|EUC - Brief NOURISH-T+|The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
33331944|NCT05761054|Experimental|A|
33331945|NCT04411680|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
33331946|NCT04411680|Active Comparator|Control Arm|Standard of care for COVID-19
33051198|NCT00001832|Experimental|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
33051199|NCT00001832|Experimental|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
33051200|NCT00001832|Experimental|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
33051201|NCT00001832|Experimental|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33068039|NCT04510987|Experimental|Experimental: Treatment 1|Participants in Groups 1-4 and Group 6 will receive a single dose of BAY2433334 on one occasion. Participants in Group 5 will receive a single dose of BAY2433334 on a dialysis-free day.
33068040|NCT04510987|Experimental|Experimental: Treatment 2|Participants in Group 5 will receive a single dose of BAY2433334 on a day with dialysis treatment.
33331947|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
33331948|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
33331949|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
33331950|NCT05098756|Experimental|Art therapy group|Experimental group received 8-week art therapy. Art therapy uses different themes and materials to art-making.
33331951|NCT05098756|No Intervention|No intervention group|No intervention group maintain the institution's original daily routine and participation in activities.
33051202|NCT00001832|Experimental|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
33051203|NCT00001832|Experimental|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
33051204|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051205|NCT00001832|Experimental|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33331952|NCT05083780|Experimental|mFORFIRINOX, Chlorphenesin Carbamate, Hydroxychloroquine|
32869624|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
32869625|NCT00258817|Experimental|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
32869626|NCT00258817|Experimental|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
32869627|NCT05686863|Active Comparator|P group|induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
32869628|NCT05686863|Experimental|R group|induction: Remimazolam 0.2 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
32869629|NCT05683899||Group A|141 days with AI scores displayed
32869630|NCT05683899||Group B|141 days with AI scores not displayed
32869631|NCT04605783|Experimental|Travelan®|Product will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
32869632|NCT04605783|Placebo Comparator|Placebo|Placebo will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
32869633|NCT00259285|Experimental|A|
32869634|NCT05682339|Active Comparator|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-isoleucine.
32869635|NCT05682339|Active Comparator|L-isoleucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
32869636|NCT05682339|Active Comparator|Quinine + L-isoleucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
32869637|NCT05682339|Placebo Comparator|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
32869638|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
32869639|NCT04576923|Experimental|Liver Incytes|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Liver Incytes.
32869640|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
32869641|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
32869642|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
32869643|NCT01716195|Experimental|Response Adapted Chemoradiation|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 followed by response adapted Radiation Therapy (5 - 6 weeks) + Paclitaxel
32869644|NCT05670639|Other|Pilot|
32869645|NCT05663931|Experimental|DM Discharge Toolkit|Up to 60 participants will be recruited for the intervention group. Participants will receive the current standard of care DM education for insulin at Northwestern Memorial Hospital and the adjunctive education with the DM Discharge Toolkit.
32869646|NCT05663931|No Intervention|Current Standard of Care Discharge DM Training|Up to 60 participants will be recruited for the control group. Participants will receive the current standard of care DM education for insulin use during current discharge care processes at Northwestern Memorial Hospital.
32869647|NCT04505007|No Intervention|Usual clinical care|In this arm, patients with devices and heart failure will undergo usual clinical care. This consists of follow-up as deemed necessary by their primary care providers.
33051206|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
33051207|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
33051208|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
33051209|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
33051210|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
33051211|NCT01466088|Experimental|AZD3480|
33051212|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
33051213|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
33051214|NCT00009620|Experimental|Phenobarbital|
33051215|NCT00009620|Placebo Comparator|Placebo|
33051216|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
33051217|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
33051218|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
33418615|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
33418616|NCT04218357|Experimental|Probenecid|2g probenecid, one pill by mouth once, for one day
33051219|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
33051220|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
33051221|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
33051222|NCT01465893|Sham Comparator|control|follow up
33051223|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
33051224|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
33418617|NCT04218357|Placebo Comparator|matching placebo|Placebo, one pill by mouth once, for one day
33051225|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
33051226|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
33418618|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
33051227|NCT01465776|Experimental|Treatment (chemoprevention)|
33051228|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
33051229|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
33418619|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
33051230|NCT01465698|Experimental|Exercise|
33418620|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
33051231|NCT01465698|Experimental|Counseling|
33051232|NCT01465698|Experimental|Exercise and counseling|
32871591|NCT05748015|Active Comparator|relapsing-remitting multiple sclerosis|Patients with relapsing-remitting multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
33051233|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
33051234|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
33051235|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
33051236|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
33051237|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
33051238|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
33051239|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
33051240|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
33331953|NCT05760976|Experimental|Age range of 18 to 44 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
33331954|NCT05760976|Experimental|Age range of 45 to 59 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
33051241|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
33360777|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
33360778|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
33360779|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
33360780|NCT01131091|Other|Group B|Subjects with severe renal impairment
33051242|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
33051243|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
33051244|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
33051245|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
33051246|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
33051247|NCT00391352||MS|MS patient is matched to healthy volunteer
33051248|NCT00391352||Control|
33051249|NCT01465269|Experimental|GIST Intervention|
33051250|NCT01465269|Active Comparator|Alternative Intervention|
33051251|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
33051252|NCT01465152|Experimental|Met|
33051253|NCT01465152|Active Comparator|Rep|
33051254|NCT01465152|Active Comparator|Met+Rep|
33051255|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
33051256|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
33051257|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
33051258|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
33051259|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
33051260|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
33360781|NCT01131091|Other|Group C|Subjects with moderate renal impairment
33051261|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
33051262|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
33051263|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
33051264|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
33051265|NCT01464957|No Intervention|Usual care|No newsletter intervention
33051266|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
33051267|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
33051268|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
33051269|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
33051270|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
33051271|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
33051272|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
33051273|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
33051274|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
33051275|NCT01464645||Primary|Post Market Study
33051276|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
33051277|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
33051278|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
33051279|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
33051280|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
33051281|NCT01464528|No Intervention|control|
33051282|NCT00393744|Experimental|1|
33331955|NCT05760976|Experimental|Age range of 60 to 80 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
33331956|NCT04974346|Experimental|study arm|"External beam radiotherapy:~Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least."
33331957|NCT04974346|Active Comparator|control arm|"External beam radiotherapy:~Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least."
33331958|NCT04956796||Group A|At the beginning of Phase 1, participants from Group A will be exposed to the video airway library in addition to the conventional airway training. At the beginning of Phase 2, participants will continue with conventional airway training only. Each phase will last for 1 month.
33360782|NCT01131091|Other|Group D|Subjects with mild renal impairment
33051283|NCT00393744|Active Comparator|2|
33051284|NCT04711980|Experimental|Mudan granule|"Based on the standard medical care, experimental group were treated with Mudan Granule 7g , 3 times/d.~Intervention: Drug: Mudan granule"
33051285|NCT04711980|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 7g , 3 times/d Intervention: Drug: Placebo
33051286|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
33051287|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
33051288|NCT00393900||1|Children with tympanostomy tubes for chronic OME
33051289|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
33110442|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
33051290|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
33418621|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
33051292|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
33051293|NCT00847977|Experimental|2|Isofundine - Tetraspan
33051294|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
33051295|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
33051296|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
33051297|NCT00847938|No Intervention|4|no injection of neostigmine
33051298|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
33051299|NCT00847899|Active Comparator|1|AR9281
33051300|NCT00847899|Active Comparator|2|AR9281
33051301|NCT00847899|Placebo Comparator|3|Placebo
33051302|NCT00847899|Placebo Comparator|4|Placebo
33051303|NCT00847860|Experimental|1|Cilostazol
33051304|NCT00847860|Active Comparator|2|Asprin
33051305|NCT00011492||1/All Patients|All eligible patients
33051306|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
33051307|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
33051308|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
33051309|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
33051310|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
33051311|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
33051312|NCT00847821||Raloxifene 60 mg|
33051313|NCT00847821||Placebo|
33051314|NCT00011531|Other|1|
33051315|NCT00011570|Other|1|
33051316|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
33051317|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
33051318|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
33051319|NCT00847587|Experimental|1|Early postpartum insertion
33051320|NCT00847587|Active Comparator|2|Standard postpartum insertion
33051321|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
33051322|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
33051323|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
33051324|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
33051325|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
33051326|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
33051327|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
33051328|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
33051329|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
33051330|NCT00847314||Group 1|
33051331|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
33051332|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
33051333|NCT00847275|Experimental|2|"Geriatric follow-up arm"
33051334|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
33051335|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
33051336|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
33051337|NCT00847158|Active Comparator|1|phacoemulsification alone
33051338|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
33051339|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
33051340|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
33051341|NCT00847080|Experimental|Sitagliptin|
33051342|NCT00847080|Placebo Comparator|Placebo|
33051343|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33051344|NCT04733469|Experimental|Multimedia Psychoeducational Intervention + Enhanced Usual Care|Intervention participants receive the Multimedia Psychoeducational Intervention in addition to Enhanced Usual Care
33051345|NCT04733469|Other|Enhanced Usual Care|Control participants receive Enhanced Usual Care
33110443|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
33418622|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
33331959|NCT04956796||Group B|At the beginning of Phase 1, participants from Group B will be exposed to the conventional airway training only. At the beginning of Phase 2, the participants in Group B will be exposed to the video airway library. Each phase will last for 1 month.
33051346|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
33051347|NCT00847002|Active Comparator|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
33051348|NCT00847002|Active Comparator|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
33051349|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
33331960|NCT04410198|Experimental|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant requires roxadustat <60 milligrams (mg)/week to maintain Hb levels, the dose frequency will be reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from CERA, the initial roxadustat dose will be based on the average prescribed CERA dose in the last 8 weeks prior to conversion. For participants with <6 weeks of prior CERA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
33331961|NCT04947202||Safil Mesh|
33331962|NCT04887766|Active Comparator|Active|GS300: Three (3) GS300 capsules [approximately 0.65 grams (g)] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day
33331963|NCT04887766|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)
33331964|NCT05457114||Pulmonary artery catheter group|Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters
33051350|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
33051351|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
33051352|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
33051353|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
33051354|NCT00846885|Experimental|1|
33051355|NCT00846885|Active Comparator|2|
33051356|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
33051357|NCT00846690|Experimental|TAC|serves as comparator
33051358|NCT00012623||Group 1|
33051359|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
33051360|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
33051361|NCT00012662|Other|Arm 1|
33051362|NCT00846612|Experimental|Avastin-Doxil|
33051363|NCT00012701||Group 1|
33051364|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
33051365|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
33051366|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
33051367|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
33051368|NCT00012740|Other|Arm 1|
33051369|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
33051370|NCT00012779|Other|Arm 1|
33051371|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
33051372|NCT00394017|No Intervention|Control group|usual implementations
33331965|NCT05457114||Non-pulmonary artery catheter group|Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo
33331966|NCT05760898|Experimental|Blood pressure intervention arm|The investigators will recruit 25 Black RA patients with HTN for the study. Participants will be provided with a home blood pressure monitor, teaching from nursing staff regarding the correct use of the monitor, and a guide to help interpret normal and elevated blood pressure values. Participants will be instructed to obtain and record blood pressure values at least three times per week over the course of 3 months. Every 2 weeks, these results will be sent to the study team, and participants will complete a brief survey regarding other factors that may influence blood pressure control, including RA disease activity (RAPID3 score), pain, current use of acute RA therapies, anti-hypertensive medication use, anti-hypertensive medication adherence, and current perceived barriers to HTN self-management.
33051373|NCT00012818|Other|Arm 1|
33331967|NCT05280678|Experimental|SH2018-10 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
33051374|NCT00012857|Other|Arm 1|
33051375|NCT00394056|Other|Period 1|
33360783|NCT01131091|Other|Group E|Healthy subjects
33360784|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
33360785|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
33360786|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
33051376|NCT00394056|Other|Period 2|
33051377|NCT00394056|Other|Period 3|
33051378|NCT00012896|Other|Arm 1|
33051379|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
33051380|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
33051381|NCT00012935|Other|Arm 1|
33051382|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
33051383|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
33051384|NCT00012974|Other|Arm 1|
33051385|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
33051386|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
33051387|NCT00013013|Other|Arm 1|
33051388|NCT00013052|Other|Arm 1|
33051389|NCT00846261|Experimental|Ilzarov|
33051390|NCT00013091|Other|Arm 1|
33051391|NCT04733352|Experimental|proximal acupoints of knees|GB34, SP9, and EX-LE2
33051392|NCT04733352|Experimental|distal acupoints of knees|LI11, HT3, and TE10
33051393|NCT00013130|Other|Arm 1|
33051394|NCT00846222|Experimental|Mild theraputic hypothermia|
33051395|NCT00013169|Other|Arm 1|
33051396|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
33051397|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
33051398|NCT00013208|Other|Arm 1|
33051399|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
33051400|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
33051401|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
33051402|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
33051403|NCT00013247|Other|Arm 1|
33051404|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
33051405|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
33051406|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
33051407|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
33051408|NCT00845910|Experimental|1|
33051409|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
33051410|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
33051411|NCT00013481|Other|1|
33051412|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
33051413|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
33051414|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
33051415|NCT04711746|Experimental|Previous proximal unprovoked pulmonary embolism|
33051416|NCT04711746|Active Comparator|Previous proximal provoked pulmonary embolism|
33051417|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
33051418|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
33051419|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
33051420|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
33051421|NCT00276939|Active Comparator|2|ADA diet
33051422|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
33051423|NCT00276627|Active Comparator|communication lecture|
33051424|NCT00276627|Experimental|lecture plus CD-ROM|
33360787|NCT01228201|Experimental|Aerboic interval training|
33360788|NCT01228201|Active Comparator|Moderate continuous training|
33051425|NCT00014144|Experimental|ZD 1839|
33051426|NCT00276549|Experimental|Gemcitabine and Docetaxel i|
33051427|NCT00276510|Experimental|1|
33051428|NCT00276510|Placebo Comparator|2|
33051429|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
33051430|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
33051431|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
33051432|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
33051433|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
33051434|NCT00394173|Experimental|1|
33051435|NCT00394173|Placebo Comparator|2|
33051436|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
33051437|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
33051438|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
33360789|NCT03920449|Active Comparator|Botulinum toxin injection|
33051439|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
33051440|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
33051441|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
33051442|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
33051443|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
33051444|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
33051445|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
33051446|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
33051447|NCT00275496|Active Comparator|WEX only|
33051448|NCT00275496|Active Comparator|WEX + SLND|
33051449|NCT00275496|Active Comparator|WEX+SLND+CLND|
33051450|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
33051451|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
33051452|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
33051453|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
33051454|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
33051455|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
33051456|NCT00275145|Experimental|Control|Control/sedentary intervention
33051457|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10^6 cells/Kg"
33051458|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
33051459|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
33051460|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
33051461|NCT00274989|Experimental|Bendamustine plus Rituximab|
33051462|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
33360790|NCT03920449|Active Comparator|Posterolateral internal sphincterotomy|
33360791|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
33360792|NCT03920059|Placebo Comparator|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
33110444|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
33110445|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
33110446|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
33110447|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
33110448|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
33110449|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
33110450|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
33110451|NCT02909894|Experimental|Prolonged Sitting|
33110452|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
33110453|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
33110454|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
33110455|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
33110456|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
33110457|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
33110458|NCT04675008|Experimental|Study arm|Dacomitinib
33110459|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
33110460|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
33110461|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
33110462|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
33110463|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
33418623|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
33418624|NCT01376011|Experimental|healthy young|
33418625|NCT01376011|Experimental|healthy old|
33418626|NCT04033107|Experimental|Treatment arm|Vitamin C combined with metformin
33110464|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
33418627|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
33110465|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
33110466|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
33110467|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
33110468|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
33110469|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
33110470|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
33110471|NCT02909192|Active Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
33110472|NCT04674423|Experimental|TAF Treatment|TAF treatment for 144 weeks and followed for 48 weeks after 144-week TAF treatment
33110473|NCT04674423|No Intervention|Observation arm|Observation for 144 weeks
33110474|NCT02909387|Experimental|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
33110475|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
33110476|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
33110477|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
33110478|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
33110479|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
33110480|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
33418628|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
33418629|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
33051463|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
33418630|NCT02106806|Other|Placebo Control|Volunteers received placebo
33418631|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
33051464|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
33051465|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
33418632|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
33051466|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
33051467|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
33051468|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
33051469|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
33051470|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
33051471|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
33051472|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
33051473|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
33051474|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
33051475|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
33051476|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
33051477|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
33051478|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
33051479|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
33051480|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
33051481|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
33051482|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
33051483|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
33051484|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
33051485|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
33051486|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33051487|NCT00130026|Placebo Comparator|I|Saline placebo
33051488|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
33051489|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
33051490|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
33051491|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
33051492|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
33051493|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
33051494|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
33051495|NCT00129753|Experimental|Alemtuzumab|
33051496|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
33051497|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
33051498|NCT00129714|No Intervention|wait and see|
33051499|NCT00129714|Experimental|collar|
33051500|NCT00129714|Experimental|physiotherapy|
33051501|NCT00129675|Experimental|[123I]ß CIT|To assess [123I]ß CIT and SPECT imaging
33051502|NCT01119365|Experimental|Light|Sequence of bright light flashes of varying durations, interflash intervals, flash lengths, flash brightness, and flash color.
33051503|NCT00129636|Other|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
33051504|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
33051505|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
33051506|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
33051507|NCT00129480|Experimental|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
33051508|NCT00129480|No Intervention|Treatment as usual|Treatment as usual
33051509|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
33051510|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
33051511|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
33051512|NCT00129441|Experimental|Merck L-830982|
33051513|NCT00129441|Placebo Comparator|Sugar pill|
33051514|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
33051515|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
33051516|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
33051517|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
33051518|NCT00129285|Experimental|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
33051519|NCT00129285|Experimental|High Dose Modafinil|High dose modafinil 400 mg daily
33051520|NCT00129285|Placebo Comparator|Placebo|Placebo
33051521|NCT00129246|Active Comparator|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
33051522|NCT00129246|Experimental|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
33051523|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
33051524|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
33051525|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
33051526|NCT04734236|Active Comparator|New technique group|
33051527|NCT04734236|Sham Comparator|Xpert group|
33051528|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
33110481|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
33331968|NCT05280678|Experimental|SH1514-08 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
33051529|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
33051530|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
33051531|NCT00128817|Experimental|1|Concurrent Chemoradiation
33051532|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
33051533|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
33051534|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
33051535|NCT00017537|Experimental|Dose #1|dose #1 administered
33051536|NCT00017537|Experimental|Dose #2|dose #2 administered
33051537|NCT00017537|Experimental|Dose #3|Dose #3 administered
33051538|NCT00017537|Experimental|Dose #4|Dose #4 administered
33051539|NCT00017537|Experimental|Dose #5|Administered dose #5
33051540|NCT00128505|Experimental|mifepristone|
33051541|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
33051542|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
33051543|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
33051544|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
33051545|NCT00017810|Experimental|Condition 1: Dietary Intervention|Patients will receive behavioral dietary intervention using normal foods.
33051546|NCT00017810|Active Comparator|Condition 2 (Control): HIV Self-Care|Patients will receive HIV self-care information, and be given the dietary intervention at the completion of the last study session (post study).
33051547|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
33051548|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
33051549|NCT00128310|Active Comparator|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
33051550|NCT00128310|Experimental|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
33051551|NCT00006099|Experimental|Intraperitoneal (IP) Infusion of 111In-hu3S193|"Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline."
33331969|NCT04876300||Menotropin Cohort|
33331970|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
33331971|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
33331972|NCT05760040|Experimental|Virtual Reality (VR)|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
33331973|NCT05760040|Experimental|Control group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
33331974|NCT05324358|Experimental|NTM-001 Treatment Arm|"NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.~Subjects will also receive placebo to IV Morphine (injections)."
33331975|NCT05324358|Active Comparator|Morphine Treatment Arm|"A single IV morphine bolus (4 mg) every 4h for up to 24h.~Subjects will also receive placebo to NTM-001."
33418633|NCT05707299|Experimental|Observation group|This group will include 20 patients with MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
33418634|NCT05707299|Other|Control group|This group will include 20 healthy control participants without MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
33418635|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
33418636|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
33418637|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
33418638|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
33051552|NCT00006099|Experimental|Intravenous Infusion of 111In-hu3S193|Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.
33051553|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
33051554|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
33051555|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
33051556|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
33051557|NCT04734353|Experimental|E5 group|Escalation in CHIP
33051558|NCT04734353|Active Comparator|T60 group|Escalation in CHIP
33051559|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
33051560|NCT00018798||Annual review only|23 participants received annual reviews only
33051561|NCT04734314|Experimental|conventional treatment of back pain|Group A: received conventional treatment of back pain which included; TENS 20 min and hot packs 10 min .The total treatment session is 30 min three session per week for four weeks
33051562|NCT04734314|Experimental|vojta therapy|received conventional treatment of back pain in addition to Vojta therapy . The total treatment session is 40 min.
33051563|NCT04734119||Group A- same anesthesiologist|In Group A patients were evaluated preoperatively and anesthetized by the same anesthesiologist.
33051564|NCT04734119||Group B- different anesthesiologist|In Group B the preoperative assessment and actual anesthesia was performed by two different anesthesiologists
33051565|NCT00018356|Other|1|
33051566|NCT04734041|Other|Integrative Medicine|Anti-inflammatory (Mediterranean) diet, as well as general behavioral and psychosocial support.
33051567|NCT00018434||Group 1|
33051568|NCT04312919|Experimental|Intervention Group|3 in-person visit group
33051569|NCT04312919|Active Comparator|Control/Crossover Group|5 in-person visit group
33051570|NCT04312802||Observational|Single arm observational study
33051571|NCT04280783|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
33051572|NCT04280783|Other|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
33051573|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
33051574|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
33051575|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
33051576|NCT04205513|No Intervention|Control Group|Standard titration management strategy, consisting of regular in-office visits.
33051577|NCT04205513|Experimental|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
33051578|NCT04146935|Experimental|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
33051579|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
33051580|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
33051581|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
33051582|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
33051583|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
33051584|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
33051585|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
33331976|NCT05324358|Placebo Comparator|Placebo Treatment Arm|"Subjects randomized will receive placebos of both active treatments concomitantly.~Placebo to NTM-001: Placebo loading dose applied over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mL/h for 24h by a pre-programmed infusion pump.~Placebo to IV morphine injections: A single IV placebo bolus every 4h for up to 24h."
33360793|NCT03920059|Active Comparator|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
33110482|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
33110483|NCT00555867||1|Standard routine care for breast cancer
33110484|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
33110485|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
33110486|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
33110487|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
33110488|NCT00555945|Active Comparator|2|Sliding hip screw
33110489|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
33110490|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
33110491|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
33110492|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
33110493|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
33110494|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
33110495|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
33110496|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
33110497|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
33110498|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
33110499|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
33110500|NCT05312489||Upper extremity arterial trauma|Vascular traumatic injuries of the arterial system of the upper limbs.
33110501|NCT05312489||Lower extremity arterial trauma|Vascular traumatic injuries of the arterial system of the lower limbs.
33110502|NCT01911897|Experimental|MobiusHD|MobiusHD
33110503|NCT05312333||critically-ill childern|
33110504|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
33110505|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
33110506|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
33110507|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive resting breathing pattern evaluation, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
33110508|NCT04674540||Sedation and Analgesia Implementation Status Group|To investigate the implementation status of sedation and analgesia in ICU critical patients.
33110509|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
33110510|NCT04674501||Thoracic irradiation|A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.
33110511|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
33110512|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
33110513|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
33110514|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
33110515|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
33418639|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
33418640|NCT02101892|Placebo Comparator|placebo|sugar pills
33418641|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
33418642|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
33418643|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
33051586|NCT03174314|Experimental|Visually impaired|Visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
33051587|NCT03174314|Active Comparator|Healthy controls|Healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
33051588|NCT03174314|Experimental|Thailand Site - Group A|During the first 15 days, group A will go through an assistive mode and then a passive mode for the next 15 days
33051589|NCT03174314|Active Comparator|Thailand Site - Group B|Group B will go through a passive mode for the first 15 days and then an assistive mode for the second half of the month
33051590|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
33051591|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
33051592|NCT02079662|Experimental|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
33051593|NCT02079662|Active Comparator|Arm II (standard of care)|Patients undergo standard of care.
33418644|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
33051595|NCT00142454|Experimental|Imiquimod + NY-ESO-1|Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
33051596|NCT05576675|Experimental|SN group|sufentanil 100 μ g + nalbuphine 40 mg
33418645|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
33418646|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
33051597|NCT05576675|Experimental|HN group|hydromorphone 10 mg+ nalbuphine 40 mg
33051598|NCT05576675|Experimental|S group|sufentanil 200 μ g,
33051599|NCT05576636|Experimental|Intervention group|After the pre-tests (the COVID-19 Disease Perception Scale, and the Fear of COVID-19 Scale) , the students were given simulation education for one months.
33418647|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
32871592|NCT05748015|Active Comparator|primary progressive multiple sclerosis|Patients with primary progressive multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
33051600|NCT05576636|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
33418648|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
33051601|NCT05576480|Experimental|SCRT sequential Penpulimab in combination with CAPEOX|"Short-course radiotherapy (SCRT) + one dose of immunotherapy in week 1：Radiotherapy once daily at 5Gy, D1-D5 (5×5Gy); Penpulimab, 200mg, intravenous for 60±5min, D6 or D7.~Rest at week 2, 4 cycles of chemotherapy (CAPEOX) + immunotherapy from week 3 in cycles of 3 weeks: Capecitabine, 1000 mg/m2 orally, administered twice daily, D1-D14 per cycle; Oxaliplatin, 135 mg/m2, intravenous >2h, administered every cycle D1; Penpulimab, 200 mg, administered intravenously for 60 ± 5 min every cycle D1.~Clinical re-staging assessment at the end of neoadjuvant therapy allows for a watch-and-wait strategy if cCR is achieved. If any residual lesions remained, radical rectal cancer surgery would be performed at least 2 weeks after the last dose of capecitabine. Whether post-operative adjuvant treatment is performed and the option of post-operative adjuvant treatment is decided by the investigator."
33051602|NCT05576363||Maternal|Second trimester
33051603|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
33051604|NCT05576324||longitudinal|Inclusion of patients with diagnosed CF prior ETI therapy, follow-up visit after 6 months
33418649|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
33418650|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
33418651|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
33418652|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
33418653|NCT01374061|Active Comparator|1: Classical intubation|
33418654|NCT01374061|Experimental|2: Glidescope intubation|
33110516|NCT05311280|Experimental|high intensity interval training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition. Between each session, subjects were allowed to rest at least 1 minutes.~Exercise training would be implemented in the form of high-intensity interval training and resistance exercise. High-intensity interval training intensity of the target heart rate (THR) was calculated as follows: THR = (HRmax - HRrest) × 80-90%Intensity + HRrest[26]. The HIIT program included four 3-min bouts at high-intensity (80-90%HRR), separated by 3-min of active recovery and total for 4 cycles of 24-min HIIT intervention. The HIIT exercise options were running on a treadmill."
33110517|NCT05311280|Active Comparator|home exercise training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition.~Home exercise is composed of ambulation training outside or inside. Three phase including warm up, training phase, and cool down. The intensity of training phase is decided by rating of perceived exertion (RPE) range from 11~15. 2~5 training times a week will involved according to patients' preference."
33110518|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
33110519|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
33110520|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
33110521|NCT05305352|No Intervention|No intervention|The no intervention arm will not receive counselling but will follow their routine diet suggested during their routine antenatal visits.
33110522|NCT05305352|Experimental|Intervention|The intervention arm will be counselled about very low carbohydrate diet (<10%carbohydrate)
33331977|NCT04720456|Experimental|SHAPE with Sonazoid|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at The Children's Hospital of Philadelphia (CHOP) will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent Sonazoid® (perfluorobutane microbubbles) will be performed during a single visit. A dose of three vials with 16 μL each of microbubbles will be prepared. An infusion of the ultrasound contrast agent at the rate of 0.18 mL/kg/hour will be co-infused with an infusion of saline at the rate of 120 mL/hour resulting in an effective dosage of 1.44 μL microbubbles/kg/hour as per the FDA approved IND through an IV line in a peripheral vein. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
33360794|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
33110523|NCT04673838|Experimental|Lower Extremity Sensory Training + Bobath Therapy|Intervention Group will have Lower extremity sensory training and Bobath Therapy.
33110524|NCT04673838|Active Comparator|Bobath Therapy|Control Group will have only Bobath Therapy. Bobath approach will be applied for 4 weeks, 3 days a week and 12 sessions in total.
32871593|NCT05747937|Experimental|Amyotrophic Lateral Sclerosis patients|Amyotrophic Lateral Sclerosis (ALS) patients within 18 months from symptoms onset will be recruited
33110525|NCT05298293|Experimental|ONCOLAXY follow-up|patients will make a regular assessment of symptoms via an electronic questionnaire
33110526|NCT05298293|No Intervention|Standard follow-up|patients will have the standard follow-up
33110527|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
33110528|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
33110529|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
33110530|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
33110531|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
33110532|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
33110533|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
33110534|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33110535|NCT05296538|Experimental|Broad-Minded Affective Coping Intervention + Risk assessment and signposting|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. They will then be offered six sessions of the Broad-Minded Affective Coping (BMAC) Intervention. Sessions will take place weekly where possible and the intervention window will be eight weeks. A booster session will be offered in the 8 weeks following the end of therapy.
33110536|NCT05296538|Other|Risk assessment and signposting + Treatment As Usual|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. In addition they will be able to access usual care from their University counselling service or other health services.
33331978|NCT04720456|Active Comparator|SHAPE with Lumason|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at CHOP will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent LUMASON® (sulfur hexafluoride lipid-type A microspheres) will be performed during a single visit. Two doses of 0.03 mL/kg (or 2.4 mL maximum) as per package labeling will be prepared and mixed with saline at a 1:10 dilution in a 50 ml bag of saline. The diluted preparation of Lumason will be through an IV line in a peripheral vein up to 4 mL/min using an infusion setup. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
33331979|NCT04720456|Experimental|Longitudinal SHAPE|SHAPE will be used to monitor subjects identified in the initial examination as having portal hypertension for up to 18 months. These subjects will undergo laboratory testing every 6 months as a part of their clinical standard of care. During these times the SHAPE examination will also be repeated using the same ultrasound contrast agent and infusion methodologies (including dosages) as during the initial study.
33418655|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
33051605|NCT05576324||under ETI|Patients with diagnosed CF already receiving ETI therapy for 6 months
33051606|NCT05576324||no ETI|Patients with diagnosed CF that have refused an ETI treatment or are not eligible for ETI therapy
33051607|NCT05576324||Healthy Individuals|Healthy, age- and gender-matched probands
33051608|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
33051609|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
33051610|NCT04733690||Healthy Volunteers (Glycemic Index)|The glycemic index (GI) of the common bean product will be assessed in this cohort among 10 study participants. The GI of the product will be assessed on 3 test days over a 120 min period on each study day.
33051611|NCT04733690||Healthy Volunteers(Food Insulin Index)|The food insulin index (FII) of the common bean product will be assessed in this cohort among 10 study participants. This study will recruit 10 participants. The FII of the product will be assessed on 3 test days over a 120 min period on each study day.
33051612|NCT04733690||Type-2 diabetes (T2DM) patients|Glycemic, insulinemic and satiety responses associated with the consumption of the common bean product will be assessed in this cohort among 10 T2DM patients. Participants will attend one study visit lasting approximately 120 min.
33051613|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
33051614|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
33051615|NCT00020787|Experimental|Treatment|See intervention description.
33051616|NCT05576168|Experimental|T2DM group|patients with T2DM
33051617|NCT05576168|Active Comparator|control group|patients without T2DM
33051618|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
33051619|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
33051620|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
33051621|NCT05576051||All TNFi initiations|
33051622|NCT05576051||TNFi initiations after 11/6/2012 for comparisons with Tofacitinib initiators|
33051623|NCT05576051||RA patient in Corrona with initiation Tofacitinib during follow-up in Corron|
33051624|NCT05574647|No Intervention|Standard: mpMRI|Participants will undergo mpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
33331980|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
33331981|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
33360795|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
33110537|NCT04673916|Active Comparator|Clobetasol treatment|The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied [11]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
33110538|NCT04673916|Active Comparator|Anti-inflammatory mouthwash|In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
33110539|NCT01887366|Experimental|TV-1380 150 mg|
33110540|NCT01887366|Experimental|TV-1380 300 mg|
33110541|NCT01887366|Placebo Comparator|Placebo|
33110542|NCT04674072|Experimental|Intervention group|The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).
33110543|NCT04674072|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions
33110544|NCT05289089|Experimental|Positive Psychology Intervention Group|Participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
33110545|NCT05289089|Active Comparator|Wait list Control Group|After waiting for 9 weeks, participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
33110546|NCT04674150|Sham Comparator|Non-AR Group|Patients allocated to the control group will be able to interact with the iPad and visualize objects and decals in the walls but not able to initiate the AR technology. In other terms, patients in this group will be provided with the same iPad to the AR group patients with the only exception that the AR technology will be off and will only see objects through the device camera in normal reality.
33110547|NCT04674150|Active Comparator|AR Group|Patients randomized to the AR group will be able to use the iPad and SpellBound app to initiate the AR experiences in the game.
33110548|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
33110549|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
33110550|NCT01885260|Placebo Comparator|Placebo|Placebo
33110551|NCT05287568|Experimental|Cohort 1 CC-486 200 mg|CC-486 200 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
33110552|NCT05287568|Experimental|Cohort 2 CC-486 300 mg|CC-486 300 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
33110553|NCT05287568|Experimental|Dose Expansion Cohort|CC-486 MTD will be determine following the completion of Cohort 1 and Cohort 2 with venetoclax at 400 mg/day PI regimen for 28 days.
33110554|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
33110555|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
33110556|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
33110557|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
33110558|NCT05285540|Experimental|Single Dose: DT-216|DT-216 will be administered once
33110559|NCT05285540|Experimental|Single Dose: DT-216 matching placebo|Placebo will be administered once
33110560|NCT04673799|Experimental|MV088|MV088 injection (60mg) by subcutaneous injection once on the first day
33110561|NCT04673799|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day
33418656|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
33110564|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
33110565|NCT01873677|Experimental|M518101|Proper quantity twice a day
33110566|NCT05236400|Experimental|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|After participating in a clinical trial and receiving unmanned electric airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
33110567|NCT05236400|Active Comparator|Manual phlegm suction system|After participating in a clinical trial and applying manual airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
33110568|NCT04673526|Experimental|Intersphincteric resection|After a laparoscopic TME (total mesorectal excision) is carried out down to the elevator ani plane and the anorectal junction, the intersphincteric plane is dissected, opening the space between puborectalis muscle and interior sphincter. Margin of resection is at least 1 cm below the lower margin of the tumor. Rectal excision is completed with transanal circumferential dissection and after specimen extraction through the anus, a colo-anal hand sewn anastomosis is fashioned.
33110569|NCT04673526|Active Comparator|Abdomen-perineal procedures|After identification of the elevator ani plane, the descendent colon is transected with a linear stapler and a terminal stoma is fashioned. Then, a circumferential incision is made around anal orifice and perineal dissection is performed circumferentially to the pelvic cavity. Perineal defect is repaired performing mono-lateral or bilateral inferior gluteal flap.
33110570|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
33051625|NCT05574647|Active Comparator|Intervention 1: bpMRI|Participants will undergo bpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
33051626|NCT05574647|No Intervention|Standard: Visual estimation targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo a visual estimation targeted biopsy
33418657|NCT05658783|Experimental|Intervention Group|Participants in this study group will be asked to keep their feet in 42oC (42 Degrees Celsius) hot water for 20 minutes on the night of the day of surgery.
33418658|NCT05658783|No Intervention|Control Group|Participants in this study group will take the standard service clinical procedure and hot water foot bath will not be applied.
33418659|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
33418660|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
33051627|NCT05574647|Active Comparator|Intervention 2: Image-fusion targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo an image fusion targeted biopsy.
33051628|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
32871594|NCT05747937|Active Comparator|Healthy controls|A population of healthy controls matched for sex and age will be enrolled
33051629|NCT05574608|Experimental|Experimental: Experimental: CD123-CAR-NK.|The relapsed/refractory AML patients will receive allogenic CD123-Targeted CAR-NK cells infusion up to 3 dose levels (1x10^6/kg, 5x10^6/kg, 2x10^7/kg) after FC chemotherapy.
33051630|NCT05574569|Experimental|Group 1: Play Therapy|Play therapy will be given to the participants.
33051631|NCT05574569|Experimental|Group 2: Mindful Parenting|Mindful parenting worksheets will be given to the parents.
33051632|NCT05574569|Experimental|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
33051633|NCT05574569|No Intervention|Group 4: Treatment as usual|No intervention will be given to the participants
33051634|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33051635|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
33051636|NCT05574413|Placebo Comparator|Resting (no exercise) control|Resting (no exercise) control condition
33051637|NCT05574413|Experimental|Moderate intensity continuous exercise (MICE)|Experimental session involving an acute bout of moderate intensity continuous exercise (MICE; continous cycling expending 350 kcal at 70% of lactate threshold)
33051638|NCT05574413|Experimental|High intensity continuous exercise (HICE)|Experimental session involving an acute bout of high intensity continuous exercise (HICE; continuous cycling expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
33051639|NCT05574413|Experimental|High intensity interval exercise (HIIT)|Experimental session involving an acute bout of high intensity interval exercise (HIIT; cycling intervals expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
33051640|NCT05574374|Experimental|Cohort 1|"Treatment A: DWC202202 1 tablet qd for 7days~Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days"
33051641|NCT05574374|Experimental|Cohort 2|"Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~Treatment A: DWC202202 1 tablet qd for 7days~Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days"
33051642|NCT05574374|Experimental|Cohort 3|"Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~Treatment A: DWC202202 1 tablet qd for 7days"
33051643|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33051644|NCT05574257|Active Comparator|Group P|The group received propofol injection at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery).
33051645|NCT05574257|Experimental|Group R|The group received remimazolam injection at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery).
33051646|NCT05574218|Experimental|Glycine - Test|Polishing treatment with glycine powder air-polishing after ultrasonic plaque debridement.
33051647|NCT05574218|Active Comparator|Rubber cup - Control|Polishing treatment with a rubber cup and polishing paste after ultrasonic debridement
33051648|NCT05574179|Experimental|midazola.|Inj.midazolam
33051649|NCT05574179|Experimental|Dexnedetomidine|inj.dexmedetomidine
33051650|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33051651|NCT05574023|Experimental|Predictive Alarm (PA)|Patients use the CGM sensor with Predictive Alarm on set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.
33051652|NCT05574023|Active Comparator|Alarm on Threshold (AoT)|Patients use the CGM sensor with alarms on a threshold of 70 mg/dl for hypoglycemia and 250 mg/dl for hyperglycemia.
33418661|NCT03967587|Experimental|Neosense Umbilical Catheter|
33418662|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
33418663|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
33110571|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
33110572|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
33110573|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
33110574|NCT05212220|Experimental|Intervention|The intervention group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. The intervention group will receive 15-30 minutes of a nurse-led phone call, and 10-week instant messaging after completing the one-week EMA documentation.
33110575|NCT05212220|No Intervention|Control|The control group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. No intervention will be provided to the control group after completing the one-week EMA documentation.
33360796|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
33360797|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
33051653|NCT05573945|Experimental|Family Education Only|"Family Education Only. Parents will be asked to participate in an evidence based program s that includes 6-8 visits with a a trained healthcare provider.~This program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~Active listening Visits includes a cycle of 5-6 consecutive meetings lasting about an hour. The meetings will take place in a defined and dedicated space (private room) or if possible (if no other parents are present) at the baby's cradle. The meeting will take place between a single parent and a trained direct operator. This is not a psychotherapeutic intervention but a support that is provided to the parent. The support is mainly based on active listening, on the problems posed by the parent and on the subject's empowerment."
33051654|NCT05573945|Active Comparator|Family Education and Active Listening|"Family Education and Active Listening. Parents of infants will be asked to participate in an evidence based program for parents of NICU infants that includes 6-8 visits with a a trained healthcare provider operator.~This evidence-based program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The program takes its conceptual basis from the Mother Infant Transaction Program (MITP).~It involves about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalisation in the NICU directly at the child's bed between the operator and one or both parents."
33051655|NCT05573906|Experimental|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
33051656|NCT05573906|Active Comparator|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
33051657|NCT05573867|Experimental|Intervention group|"Individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
33051658|NCT05573867|No Intervention|Control group|Control group receive routine written and verbal information about PSF and information about recommended level of physical activity.
33051659|NCT05573633|Experimental|smartwatches group|
33051660|NCT05573633|Active Comparator|no smartwatche group|
33051661|NCT05573594|Experimental|MET Group|"the participants in the study group were under 8 sessions of MET, 2 times a week, in addition to the conventional physiotherapy program.~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes."
33051662|NCT05573594|Experimental|Control Group|"In this study, the participants in the control group were under conventional physiotherapy program for 5 times a week, a total of 10 sessions~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes"
33051663|NCT05573516|Experimental|Fixation with 4mm lag screws|
33051664|NCT05573516|Active Comparator|Fixation with 4mm fully-threaded positional screws|
33051665|NCT05573438|Experimental|Fructose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose).
33051666|NCT05573438|Experimental|Sucrose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose).
33360798|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
33360799|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
33360800|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
33360801|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
33418664|NCT05707221|Active Comparator|mechanical cleaning method by denture brush and Chlorhexidine toothpaste|patients will be instructed to brush both sides of the removable appliance once a day for 1 minute before bedtime using the toothbrush and the CHX toothpaste provided and water
33418665|NCT05707221|Active Comparator|chemical cleaning method with cleaning tablet|patients will be instructed to immerse the appliance in 150 ml cup with tap water and dissolve one cleansing tablet for 20 minutes according to the manufacture instructions.
33418666|NCT05707221|Active Comparator|combination of mechanical and chemical cleaning|first submitted to the mechanical method, followed by the chemical method.
33051667|NCT05573438|Placebo Comparator|Glucose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose).
33051668|NCT05573204|Active Comparator|Group 1 obeticholic acid group|28 non alcoholic steatohepatitis patients receiving obeticholic acid 10 mg once daily for 6 months duration
33051669|NCT05573204|Active Comparator|Group 2 vitamin E group|31 non alcoholic steatohepatitis patients receiving vitamin E 400 mg twice daily for 6 months duration
33051670|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
33051671|NCT05573126|Experimental|Module B - EP0062 Dose level 1|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
33418667|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
33418668|NCT05220969||Elite male youth footballers|Elite male youth footballers at an English championship / premier league football club
33418669|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
33418670|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
33418671|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
33051672|NCT05573126|Experimental|Module B - EP0062 Dose level 2|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
33418672|NCT05707143|Active Comparator|home based stabilization exercises|knee rolls, the cat, spine curl, bridging, single knee to chest, pelvic tilt
33418673|NCT05707143|Experimental|kegel exercises|kegel exercises
33418674|NCT02102282||Subject study|Patients with breast cancer during pregnancy
33051673|NCT05573087|Active Comparator|Aquatic Based Exercise|maximal jump squats in a pool
33051674|NCT05573087|Active Comparator|Land Based Exercise|cycle ergometer
33068041|NCT04519996|Experimental|US Internal Jugular Vein Collapsibility Index|The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility.
33068042|NCT04519996|Experimental|US Inferior Vena Cava Collapsibility Index|The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration.
33068043|NCT00162318|Experimental|A|
33418675|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)~Low body weight ≤ 60 kg~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
33418676|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
33418677|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
33418678|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
33068044|NCT00404417|Experimental|1|Botox/Placebo
33068045|NCT00404417|Experimental|2|Botox/Botox
33068046|NCT00404417|Experimental|3|Placebo/Botox
33068047|NCT00404417|Placebo Comparator|4|Placebo/Placebo
33068048|NCT04519918|No Intervention|Standard ICSI procedure|a single spermatozoon was injected into the ooplasm.
33068049|NCT04519918|Experimental|Chemical oocyte activation|After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
33068050|NCT04519918|Experimental|Mechanical oocyte activation|Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
33068051|NCT04519606||One-lung ventilation|During one-lung ventilation, the dependent lung (non-operation lung) will be mechanically ventilated with a fixed positive end-expiratory pressure (PEEP) of 4 cmH2O and the peak pressure below 30 cmH2O. Tidal volumes will be titrated from the initial 4 ml/kg predicted body weight (PBW) to 7 ml/kg PBW. Optimal lung compliance is determined by the levels of upper reflection point of the pressure-volume loop closed to 30 cmH2O. Chest tomography will be undertaken with the optimal tidal volume during OLV phase and when the independent lung is completely recruited using the stepwise PEEP increase method.
33068052|NCT04519762|Sham Comparator|Control group|Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.
33068053|NCT04519762|Active Comparator|Study group|Management of sepsis/ septic shock in addition to management of hypophosphatemia.
33110576|NCT04677270|Experimental|Traditional interface|Digital problem solving tool with a simple textbased graphical interface
33331982|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.~Local treatments for metastatic lesions will be added in this group.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
33051675|NCT02972021|Other|control|Pure oxygen by nasal cannula group
33051676|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
33051677|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33051678|NCT05572931|Sham Comparator|Sham comparator|In addition to the routine analgesic (Acetaminophen 500mg, TID), the patients were treated with sham FSN at the 1st, 24th, and 48th hours after surgery. The sham FSN was used a fine acupuncture needle without swaying movement and reperfusion approach.
33051679|NCT05572931|Experimental|Experimental|In addition to postoperative routine analgesic (Acetaminophen 500mg, TID), patients were received FSN treatment. The FSN insertion point and time are the same as control group. And then we performed swaying movement and reperfusion approach.
33051680|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
33051681|NCT05572814|No Intervention|Usual Care|Teaching - CardioSmart Resources + Clinician Education
33051682|NCT05572814|Active Comparator|Decision Support|Technology - Facilitated Solution (Existing Team)
33051683|NCT05572814|Active Comparator|Referral|Teams - Protocol-Supported Team, (Virtual GDMT Team)
33051684|NCT05571956|Experimental|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs u
33051685|NCT05571137||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV treatment|Participants who had a HSCT after January 1, 2016, and developed post-transplant CMV infection were subsequently characterized as RRI to currently available anti-CMV treatment for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
33051686|NCT05571137||Cohort 2: Pre-emptive CMV Treatment|Participants who had a HSCT after January 1, 2019, were preemptively treated for CMV for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
33051687|NCT05571020|Experimental|Mat Pilates Group|"Two days a week, approximately one hour a day, for a total of eight weeks, in groups of 5-6 people, they were included in the mat pilates exercise program.~Before starting the exercise program, the study group participants were informed about the principles of the pilates working system (I am not sure if this statement is correct terminologically), the training program and the 5 key elements of the pilates approach, neutral spine (head-neck-shoulder-waist-abdominal placement), lumbopelvic stabilization, Informative training on scapular stabilization, focusing and breathing was given."
33051688|NCT05571020|No Intervention|Control Group|Control group participants did not participate in any exercise program.
33051689|NCT05570903||Awake prone position Group|Patients in awake prone position will be included.
33051690|NCT05570903||Non awake prone position Group|Patients in non awake prone position will be included.
33051691|NCT05569928|Active Comparator|Homozygous FHBL2 subjects|
33051692|NCT05569928|Active Comparator|Heterozygous FHBL2 carriers|
33051693|NCT05569928|Active Comparator|ANGPTL3 wild-type Campodimele residents|
33051694|NCT05569889||control group|The medical staff was using the traditional surgical draping kit and single-packed sterile instruments (SPSI) that have to be opened separately
33051695|NCT05569889||experimental group|The medical staff was using only the single packed CST, and containing all the necessary single-use items like surgical blades, sutures, dressing, surgical drapes, syringes, compresses, surgical gloves, jerseys.
33051696|NCT05569265|Experimental|Hemodynamic prediction index based goal directed hemodynamic therapy|Hemodynamic handling will be based hemodynamic prediction index (HPI)
33051697|NCT05569265|No Intervention|No HPI|Patients in the control group will be treated according to standard practice.
33051698|NCT04733885|Experimental|Electrical Stimulation group|ES and lifestyle advice have been applied ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
33051699|NCT04733885|Sham Comparator|Sham Electric Stimulation group|Sham ES and lifestyle advice have been applied Sham ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
33051700|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
33051701|NCT05557643|Active Comparator|Mindfulness-Based Stress Reduction (MBSR)|Participants in the MBSR arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual) as well as a 8 hour group mindfulness retreat in week 6-7 of the curriculum.
33051702|NCT05557643|Experimental|Mindfulness-Based Stress Reduction (MBSR) + Psilocybin-Assisted Psychotherapy (PAP)|Participants in the MBSR + PAP arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual). They will additionally complete a psilocybin-assisted psychotherapy (PAP) intervention that involves three 2-hour group preparatory sessions, a single 8-hour group psilocybin administration session (done in place of the mindfulness retreat), and three 2-hour group integration sessions. All PAP intervention sessions will utilize a 1:1 therapist to participant ratio with an additional lead therapist present.
33110577|NCT04677270|Experimental|Advanced interface|Digital problem solving tool with an advanced graphical interface and automatic functions
33331983|NCT04670848|Experimental|Patients suspected of suffering from sleep apnea|
33051703|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
33051704|NCT05554445||Adult CD patients who are prescribed the Crohn disease exclusion diet|Clinically stable CD patients with active disease by CD symptoms score 4 <Harvey-Bradshaw index (HBI) at baseline and Calprotectin>50g/l / endoscopy / imaging proven active disease from the previous 4 months
33331984|NCT04670848|Experimental|Healthy volunteers|
33051705|NCT04733313|Active Comparator|quadratus lumborum-2|
33051706|NCT04733313|Active Comparator|quadratus lumborum-3|
33051707|NCT05553275|Active Comparator|Group 1:Usual Care|
33051708|NCT05553275|Experimental|Group 2: Permissive Care|
33051709|NCT05551871|Active Comparator|Simvastatin|the patient will receive simvastatin 40mg
33051710|NCT05551871|Placebo Comparator|Placebo|the patient will receive placebo drug
33051711|NCT05550857|Active Comparator|Myofascial release|"Group A:~This group will receive routine physiotherapy with myofascial release. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
33051712|NCT05550857|Experimental|eccentric resistance exercise|"Group B:~This group will receive routine physiotherapy and myofascial release with eccentric resistance exercise . This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
33051713|NCT00022737|Experimental|Arm I|See Design Details.
33051714|NCT05550779|Experimental|Mental Exercise A|Participants follow instructions on a 10-minute audio clip
33051715|NCT05550779|Active Comparator|Mental Exercise B|Participants follow instructions on a 10-minute audio clip
33051716|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
33051717|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
33051718|NCT05530694|No Intervention|Control|Usual care
33051719|NCT05530694|Experimental|Intervention|Intervention phase
33051720|NCT05521646|Experimental|Intervention|QiC implemented
33051721|NCT05521646|No Intervention|Control|
33051722|NCT00022854|Placebo Comparator|1|
33051723|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
33051724|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
33051725|NCT05521412|Experimental|Experimental: Treatment Arm|In this single-arm study, patients will receive doses of [161 Tb]Tb PSMA I&T on Day 1 of every 6 week Cycle. The dose of [161 Tb]Tb PSMA I&T will vary in dose-escalation. Up to 6 Cycles will be given.
33051726|NCT05514860|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
33051727|NCT05514860|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
33051728|NCT05513066||Ephedrine/phenylephrine mixture|10 mL of 0.75 mg/ml ephedrine and 10 mL of 37.5 μg/ml phenylephrine are mixed in a 20 mL syringe. The speed is generally started at 20 ml/h and then adapted according to blood pressure.
33051729|NCT05513066||baby noradrenaline|20 mL of baby norepinephrine 10µg/mL is prepared in a 50 mL syringe. The speed is generally started at 30 ml/h and then adapted according to blood pressure.
33051730|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
33051731|NCT05512754|Experimental|Ibuprofen|Participants receive Ibuprofen 400 mg tablet orally every 8 hours for 10 days
33051732|NCT05512754|No Intervention|Control|Participants receive no NSAIDs
33051733|NCT05507840|Experimental|Intervention|Near or infra red light provided by the Valeda machine will be applied in the intervention eye
33051734|NCT05507840|Sham Comparator|Control|Light with very low intensity provided by the same Valeda machine will be applied in the control eye
33051735|NCT05505422|Experimental|On demand ECMO (study group)|
33051736|NCT05505422|Active Comparator|Routine ECMO (control group)|
33051737|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
33051738|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
33051739|NCT05502575|Experimental|Self-monitoring and individualized stress management|Self-monitoring and individualized stress management materials available on a smartphone.
33051740|NCT05502575|Active Comparator|Self-monitoring and general stress management|Self-monitoring and general stress management materials available on a smartphone.
33051741|NCT05486312|Experimental|Single arm|Single arm acceptability and feasibility of CT-155.
33331985|NCT04660864|Experimental|Rhinochill|Treatment with nasal cavity cooling 10 minutes during three consecutive migraine attacks.
33331986|NCT05384496|Experimental|Axitinib and Nivolumab for the Treatment of Mucosal Melanoma|This is a single center trial enrolling up to 20 total patients with unresectable primary or advanced mucosal melanomas arising from the head and neck, gastrointestinal, or genitourinary tract to receive frontline therapy with nivolumab IV 480mg q4 weeks plus axitinib 5mg PO twice daily. A Simon 2-stage design will be utilized. Upon progression with good tolerance, addition of stereotactive body radiation therapy (SBRT) or CTLA-4 blockade to continued nivolumab plus axitinib will be offered to patients depending on the type of progression. For patients with local or oligometastatic progression, stereotactic body radiotherapy (SBRT) will be added; for patients with progression in a site of prior radiotherapy or with multifocal or distant progression not amenable to SBRT, ipilimumab 1mg/kg IV q3 weeks for up to 4 doses will be added.
33331987|NCT04653610||HIV-infected individuals|
33331988|NCT04653610||HIV-seronegative healthy volunteers|
33110578|NCT02887105||Patients with cerebrovascular accident|
33110579|NCT05194592|Active Comparator|Dapagliflozin group|Dapagliflozin 10mg for 6 months.
33110580|NCT05194592|Placebo Comparator|Gemigliptin group|Gemigliptin 50mg for 6 months.
33110581|NCT01871415|Experimental|Aleglitazar + metformin|
33110582|NCT01871415|Active Comparator|Placebo + metformin|
33110583|NCT05189717|Experimental|Single Group|Firstly Dose Escalation and Dose Expansion of HRS-8080 monotherapy should be conducted. After RP2D and MTD of the HRS-8080 monotherapy were confirmed, Dose Escalation and Dose Extension of HRS-8080 in combination with other anti-cancer treatment would be completed, including SHR 6390, or Abemaciclib, or Everolimus.
33110584|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
33110585|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
33110586|NCT05182463|Experimental|Sequential Combination Group|Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks, followed by combination therapy with peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
33331989|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
33331990|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
33110587|NCT05182463|Experimental|Initial Combination Group|NAs combined with peginterferon are used for 12-24 weeks, followed by peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
33110588|NCT05182463|Experimental|Whole-course Combination Group|NAs combined with peginterferon are used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
33110589|NCT05182463|Experimental|Peginterferon Monotherapy Group|Peginterferon is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
33110590|NCT05182463|Experimental|NAs Monotherapy Group|NAs is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
33110591|NCT04673643|Experimental|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
33110592|NCT05133128|Other|PATIENTS with cancer and HEALTHY VOLUNTEERS|"Cohort 1: Patients with Non-Small Cell Lung cancer (25 patients)~Cohort 2: Patients with Colorectal cancer (25 patients)~Cohort 3: Patients with Pancreatic cancer (25 patients)~Cohort 4: Patients with Liver cancer (25 patients)~Cohort 5: Patients with Gastric cancer/cholangiocarcinoma (25 patients)~Cohort 6: Healthy volunteers (25 subjects)"
33110593|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
33110594|NCT05125484|Experimental|Experimental Intervention group 1|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
33110595|NCT05125484|Experimental|Experimental interventional group II|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
33110596|NCT04673097|Experimental|Group 1|
33110597|NCT04673097|Active Comparator|Group 2|
33110598|NCT04673097|Active Comparator|Group 3|
33110599|NCT05108129|Active Comparator|Group M-TAPA|In the operating room, all of the patients will receive standard monitoring. An anesthesiologist will perform anesthesia inductions. After tracheal intubation, a linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
33331991|NCT04639024|Experimental|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
33331992|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
33331993|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
33331994|NCT04603846|Experimental|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
33331995|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
33331996|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
33360802|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
33331997|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
33331998|NCT04579900|Experimental|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
33051742|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
33051743|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
33051744|NCT05481671||Questionnaires assessed patients with traumatic fractures|"①Age 18 and above.~②Patients who were diagnosed as fractures due to accidental trauma and were diagnosed by X-rays and clinicians and required surgical treatment.~③Have the normal cognitive ability, expression ability and social participation ability."
33051745|NCT05478980|Experimental|Active Tea - Good Sleepers|
33051746|NCT05478980|Active Comparator|Control Tea - Good Sleepers|
33051747|NCT05478980|Experimental|Active Tea - Poor Sleepers|
33051748|NCT05478980|Active Comparator|Control Tea - Poor Sleepers|
33051749|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
33051750|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
33051751|NCT00395031|Other|Ziprasidone|Open label
33051752|NCT05471375||Stroke|For this cohort, individuals who have experienced a stroke will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
33051753|NCT05471375||Parkinsons Disease|For this cohort, individuals who have been diagnosed with Parkinsons Disease will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
33051754|NCT05471375||Lower Limb Amputation|For this cohort, individuals who have experienced a lower limb amputation will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
33051755|NCT05471375||Healthy Control|For this cohort, individuals who have no significant neurologic or orthopedic injuries will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
33051756|NCT05460806|Experimental|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
33051757|NCT05460806|No Intervention|Control|
33051758|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
33051759|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
33051760|NCT05447624|Active Comparator|Patients undergoing ablation of two of the genicular nerve branches|
33051761|NCT05447624|Active Comparator|Patients undergoing ablation of three of the genicular nerve branches|
33331999|NCT04579900|Active Comparator|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
33332000|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
33332001|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
33332002|NCT04578106|Experimental|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
33360803|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
33360804|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
33360805|NCT03919591|Other|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
33360806|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
33360807|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
33360808|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
33360809|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
33360810|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
33360811|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
33360812|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
33360813|NCT03923881|Experimental|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
33051762|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
33051763|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
33051764|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
33051765|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
33332003|NCT04578106|No Intervention|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
33332004|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
32740330|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
32740331|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
32740332|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
33051766|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
33051767|NCT05418335||stroke group|stroke history at least 3 months ago
33051768|NCT05418335||Control group|Healthy control
33051769|NCT05408117|Experimental|A= left/superior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
33051770|NCT05408117|Experimental|B= right/inferior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
33051771|NCT05367323||Group A|22 women who underwent cesarean delivery using spinal anesthesia
33051772|NCT05367323||Group B|22 women who were in the control group (they never experience pregnancy, or anaesthesia)
33051773|NCT05359172||Tranexamic acid|They will receive preoperative intravenous tranexamic acid infusions.
33051774|NCT05359172||Controls|They will not receive intravenous tranexamic acid infusions.
33051775|NCT05351879|Experimental|GAD-Alum (DIamyd) 40 μg/mL and Vitamin D|"Patients with a Vitamin D level <100 nmol/L (40 ng/mL) at screening will receive oral Vitamin D supplementation (2000 IU daily) for 60 days, starting 30 days prior to the injection.~On Visit 2 (Day 0), patients eligible for the study will receive one intralymphatic injection of 4µg Diamyd."
33051776|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
33051777|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
33051778|NCT05345951|Experimental|e-PBI+|The e-PBI+ is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens, with additional content on cannabis use.
33051779|NCT05345951|Experimental|e-PBI|the e-PBI is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens.
33051780|NCT05345951|No Intervention|e-AC|The e-AC is the attention matched control. They will receive general university-related materials to read, sections on parent and family resources (e.g., message from administrators, getting involved, academic calendar), advising, money matters, financial aid, campus life (arts, entertainment, housing, etc.), health and safety (health, counseling services, alcohol and drug laws). It is equivalent to the e-PBI+ and e-PBI on length of content and time to read. This group will not receive an intervention.
33051781|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
33051782|NCT05338424||Sprint Interval Training (SIT)|"The 1-session SIT protocol will include Work bouts performed at maximal intensity targets. Three Work bouts will be performed at 20-second intervals separated by 2 recovery bouts consisting of 2 minutes of low-intensity cycling. The SIT session will employ a standardized warm up and cool down of 3 minutes at a self-selected light intensity, per current guidelines. SIT sessions will take 15 minutes to complete."
33418679|NCT05220891||Crystalloid group|"Group( 1)Patients will be randomly assigned to be treated with crystalloid (n=30). They will receive an intravenous infusion of saline at a constant rate utilizing a pump infusion device (170 mL of 3.5% saline solution per liter of ascites removed at 999 mL/h). The amount of liquid infused and rate of infusion was selected based on previous studies (Sola-vera et al.,2003) Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
33051783|NCT05338424||Stretching|Stretching will include a low-intensity range of motion and stretching exercises with session duration (15 minutes) being matched to SIT.
33051784|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
33051785|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
33051786|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
33051787|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
33051788|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
33051789|NCT05326880|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
33051790|NCT05326880|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
33051791|NCT05304221||Intervention group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was assisted by the Shamir Resistance Calculator.
33051792|NCT05304221||Control group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was not assisted by the Shamir Resistance Calculator.
33051793|NCT05292911|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
33051794|NCT05292911|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
33051795|NCT05292911|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
33051796|NCT05292911|Placebo Comparator|Placebo|Administered once a week for 12 weeks
33051797|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
33051798|NCT05268185|Active Comparator|Moderna Booster Recommendation|Participants assigned to this arm will be recommended to receive the Moderna vaccine for their Covid-19 booster shot.
33051799|NCT05268185|Active Comparator|Pfizer Booster Recommendation|Participants assigned to this arm will be recommended to receive the Pfizer vaccine for their Covid-19 booster shot.
33051800|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
33051801|NCT05258864|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
33051802|NCT05258864|No Intervention|Control|No Intervention Control
33051803|NCT05249465|Experimental|Condition 1|Core Only
33051804|NCT05249465|Experimental|Condition 2|Core + Track Weight
33051805|NCT05249465|Experimental|Condition 3|Core + Track Steps
33051806|NCT05249465|Experimental|Condition 4|Core + Track Diet
33051807|NCT05249465|Experimental|Condition 5|Core + Track Weight + Track Steps
33051808|NCT05249465|Experimental|Condition 6|Core + Track Weight + Track Diet
33051809|NCT05249465|Experimental|Condition 7|Core + Track Steps + Track Diet
33051810|NCT05249465|Experimental|Condition 8|Core + Track Weight + Track Steps + Track Diet
33051811|NCT05240924|Experimental|Exposure and Response Prevention (ERP)|ERP will be based upon the Treatments That Work series, which contains both a provider manual and client workbook. Sessions will last 90 minutes and occur weekly for 16 sessions. All ERP treatment will be delivered via VTH. Participants will receive instructions on accessing the VTH platform and take part in a brief practice run connecting to the VTH appointment with guidance from an RA. ERP treatment content includes psychoeducation about OCD, assessment of OCD symptoms, the rationale for treatment, construction of a hierarchy or a list of feared or avoided situations, and in-session in-vivo and imaginal exposures. Weekly homework assignments will include self-monitoring, reading chapters about the treatment, and practicing exposures daily. All therapy sessions will be audio-recorded. Although sessions are expected to occur weekly, accounting for delays due to scheduling, holidays, and missed appointments, the investigators will allow up to 6 months to complete the treatment.
33051812|NCT05240924|Other|Control Condition|Participants randomized to the control condition will receive 16 weekly sessions of stress management training via video telehealth. This control condition was chosen because it is expected to provide the therapeutic alliance and common factors associated with therapy generally and some specific effects in anxiety reduction.
33051813|NCT02971995|Experimental|Prostate cancer/TEP scan|
33051814|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
33051815|NCT05239286|Active Comparator|Group conventional|
33051816|NCT05239286|Experimental|Group PVI|
33051817|NCT05217134|Experimental|Dural Puncture Epidural Analgesia (DPEA)|A 27-Whitacre spinal needle puncture will be performed with confirmation of LCR return, before the introduction of epidural catheter.
33051818|NCT05217134|No Intervention|Epidural Analgesia (EA)|Standard epidural anesthesia wil be performed.
33051819|NCT05158283|Experimental|Intervention: Chocolate balloon|Chocolate balloon group
33051820|NCT05158283|Experimental|Intervention: plain balloon|plain balloon group
32871595|NCT00301873|Experimental|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
33332005|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
33332006|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
33332007|NCT04472182|Experimental|Fluoride varnish with xylitol coated calcium and phosphate|
33332008|NCT04472182|Active Comparator|Conventional Fluoride varnish|
33332009|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
33332010|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
33332011|NCT04423744|Experimental|Intervention ABCD|"Intervention A:~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once~Intervention B:~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once~Intervention C:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once~Intervention D:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
33332012|NCT04423744|Experimental|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
33332013|NCT04423744|Experimental|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
32871596|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33051821|NCT05142449|Experimental|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day.
33051822|NCT05142449|Placebo Comparator|Placebo|Patients receive 8 capsules Placebo perioperatively and for the next 3 days 6 capsules per day.
33051823|NCT05142332|Experimental|Intervention Arm|Covid vaccine educational intervention consisting of vaccine messaging platforms (flyers, videos, scripted face-to-face messaging)
33051824|NCT05142332|No Intervention|Non-interventional Arm|Usual care
33051825|NCT05138003|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
33051826|NCT05135195|Experimental|First Set of Experiments|The anticipated number of participants is 336. All participants have healthy vision.
33051827|NCT05135195|Experimental|Second Set of Experiments|The anticipated number of participants is 100. Of these, 80 participants have healthy vision, and 20 have glaucoma.
33051828|NCT05121545|Other|Pro-GRID treatment Arm|Patients enrolled in this study will receive spatially-fractionated radiotherapy or GRID-therapy, which involves delivering a one-time treatment of high dose radiation to small amounts of tumor in a manner that creates alternating regions of high and low dose radiation within the tumor. Patients will receive 2 (lowest dose) to 18 Gy (highest dose) in a single fraction.
33051829|NCT05093894|Active Comparator|Group 1: Microlyte will be cut into strips and placed on the surgical incision|Microlyte will be cut into strips and placed on the surgical incision
33051830|NCT05093894|No Intervention|Group 2: Nothing will be placed on the surgical incision|Nothing will be placed on the surgical incision
33051831|NCT05080049|Experimental|erythropoietin|Erythropoietin alpha or theta 40,000 UI (1 ml) sc each week if Hb <12 g/dL (for maximum 5 weeks)
33051832|NCT05080049|Placebo Comparator|Placebo|saline sc injection (1 ml) each weeks if Hb <12 g/dL, for a maximum of 5 weeks,
33051833|NCT05079581|Other|Intervention group|Pelvic floor exercises
33051834|NCT05079581|No Intervention|Control group|Education session
33051835|NCT05073419|Active Comparator|Control|Post-AMI patients in this arm will receive standard of care
33051836|NCT05073419|Experimental|ICM|Post-AMI patients in this arm will receive standard of care and an ICM
33051837|NCT05073185||High Obesity Risk|Half of the children (25 boys and 25 girls) will be healthy weight, but at high-risk for obesity (defined as having a biological mother with a body mass index ≥ 30 kg/m2)
33051838|NCT05073185||Low Obesity Risk|Half (25 boys and 25 girls) will be healthy weight, but at low-risk for obesity (defined as having a biological mother with a body mass index < 25 kg/m2).
33051839|NCT05072444|Experimental|QPX7728|Drug: QPX7728 beta lactamase inhibitor Other names: IV
33051840|NCT05072444|Experimental|QPX2014|Drug: QPX2014 antibiotic Other names: IV
33051841|NCT05068739|Experimental|PA-EMR (Partial ampullary endoscopic mucosal resection)|Partial ampullary endoscopic mucosal resection
33051842|NCT05068739|Active Comparator|NKF(Needle knife fistulotomy)|Needle knife fistulotomy
33051843|NCT05056688|Experimental|Application of training set to experimental group|Testicular Model BSE/TSE Training Set
33051844|NCT05056688|No Intervention|Control Group|
33051845|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051846|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051847|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051848|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051849|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051850|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33332014|NCT04423744|Experimental|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
33051851|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051852|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
33051853|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
33332015|NCT01562652|Experimental|Research|
33332016|NCT04421170|Experimental|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
33332017|NCT04421170|No Intervention|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
33332018|NCT04884204|Experimental|Symptom management with Lee Symptom Scale|Participants will receive disease specific questionnaires electronically, cGVHD-PRO (Lee Symtpom Scale), one week prior to their scheduled visit in the outpatient clinic. The participants will be asked to answer the questionnaire from home without any involvement from clinicians. Afterwards the PRO data will be used during the scheduled clinical consultations as an instrument to discover symptoms on chronic GVHD and systematically to monitoring symptoms developing over time.
33332019|NCT05759416|Active Comparator|Gp I(Melatonin gp)|Group I: included 20 chronic periodontitis patients, treated by conventional periodontal therapy SRP combined with intra- pocket application of Melatonin gel once weekly for 1 month begin application at the second week after initial therapy.
33332020|NCT05759416|Placebo Comparator|Gp II(placebo gp)|Group II: included 20 chronic periodontitis patients, treated by SRP combined with the injection of placebo, weekly for one month
33332021|NCT04386538|Experimental|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
33332022|NCT04386538|Active Comparator|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
33332023|NCT04364152|Experimental|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
33332024|NCT04364152|Experimental|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
33051854|NCT05055830||Children (<21 years of age) who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care and are admitted to the pediatric cardiac intensive care unit
33051855|NCT05051891|Experimental|the experimental group|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
33051856|NCT05051891|Experimental|The control group|R-CHOP
33051857|NCT05042414|Experimental|Breastmilk|Randomized intervention order.
33051858|NCT05025956|Experimental|Fisetin group (investigational group)|"20mg/kg of Fisetin per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
33051859|NCT05025956|Placebo Comparator|Placebo group (control group)|"20mg/kg of Placebo per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
33051860|NCT05023382||Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
33051861|NCT05019131|Experimental|Intervention arm|"Training: The investigators will develop a training for providers that addresses the following topics: Stress & positive coping mechanisms; Unconscious bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication;~Peer support and mentorship: The investigators will identify what works best for these groups in terms of group composition, size, and how the groups want to interact.~Leadership engagement: To ensure leadership buy in, support and sustainability of the intervention, the investigators will engage leadership of the County.~Embedded champions: To facilitate ongoing engagement, the investigators will identify local leaders, and invite them to training where they will be taught how to facilitate peer support groups and serve as champions."
33051862|NCT05019131|No Intervention|Control arm|Will not receive any training during the intervention period
33051863|NCT05006300|Experimental|Group 1|One application of Topialyse Baume Barrière per day
33051864|NCT05006300|Experimental|Group 2|Two applications of Topialyse Baume Barrière per day
33418680|NCT05220891||Colloid group|"Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
33418681|NCT05219305|Experimental|Freeze-Dried Bone Allograft|edentulous site grafted with FDBA in previous study.
33051865|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
33051866|NCT04994366||Intervention Group|The cohort receiving Thank you cards during their stay.
33051867|NCT04994366||Control Group|The cohort not receiving thank you cards during their stay.
33051868|NCT04975178|Experimental|MTBVAC|"Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results.~MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vials should be stored in the site pharmacy between -20°C and -40ºC. A single vaccine vial will be used for each participant."
33051869|NCT04975178|Active Comparator|BCG|"BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.~One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial.~BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC."
33051870|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33051871|NCT04964414|Active Comparator|Smell Retraining Only|Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
33418682|NCT05219305|Experimental|Partially-demineralized tooth graft|edentulous site grafted with partially-demineralized tooth graft in the previous study.
33418683|NCT05219305|Experimental|mineralized tooth graft|edentulous site grafted with mineralized tooth graft in the previous study.
33418684|NCT05707065|Experimental|core strengthening exercises|"Participants will be positioned in supine.~first stage participants will be taught to activate abdominal wall musculature. They will be initially trained to perform abdominal bracing.~Then positioned in quadruped position and asked to lift alternate arms, gradually progressing to alternate leg lifts and alternate arm/leg raises to activate multifidus.~Then side bridges (side plank) exercise for activation of quadratus lumborum and obliques.~Then asked to perform trunk curls in crook lying, asking them to lift their upper trunk slightly (15°) from the plinth, hold the position for 5 sec.~Perform 30 repetitions of each exercise with 8-sec hold.~Maintain normal diaphragmatic breathing throughout the intervention"
33418685|NCT05707065|Experimental|Proprioceptive Neuromuscular Facilitation|"Rhythmic initiation (RI) Patients progressively performed voluntary relaxation, passive movements, active assisted, active resisted movements and than active movements.~Dynamic reversals (slow reversals) Isotonic contractions of first agonists and then antagonists performed against resistance was performed initially.~Stabilizing reversals Isotonic contractions of first agonists, then antagonists against resistance was performed in an alternate way.~Mixture of isotonic (agonist reversals, AR) resisted concentric, contraction of agonist muscles moving with the range was performed progressively following eccentric, lengthening contraction, moving slowing to the start position. .~Total 30 min for 3 days a week for a total duration of 4 weeks was set as a optimal time frame duration. Each technique was given for 10 min."
33418686|NCT01372891||Patients underging PCI|
33051872|NCT04964414|Experimental|Smell Retraining + Budesonide|Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
33051873|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33051874|NCT04960397|Experimental|Cohort 1|A cohort of influenza non-naïve 45 healthy children, 9-17 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1. N=45.
33051875|NCT04960397|Experimental|Cohort 2|A cohort of influenza non-naïve 45 healthy children, 2-8 years old, will receive a single dose of 10^8 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1 intranasally. N= 45
33051876|NCT04960397|Experimental|Cohort 3|Once, there is sufficient evidence of safety and tolerability in Cohorts 1 and 2,and enrollment has completed of all 45 in each of these cohorts. Cohort 3 will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or placebo (N=10) at Day 1. N=25.
33051877|NCT04960397|Experimental|Cohort 4|Once, there is sufficient evidence of safety and tolerability in Cohort 3 and enrollment has been completed for this cohort, and fifth cohorts (Cohorts 4 and 5) will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive two doses of the 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or two doses of placebo (N=10) at Day 1 and Day 29. N=25
33051878|NCT04960397|Experimental|Cohort 5|Participants in Cohort 4, will enroll concurrently. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomized to receive two doses of 10^7 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=8.
33068054|NCT04519723|Other|Alma Harmony Laser System|There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
33332025|NCT04364152|Experimental|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
33332026|NCT04364152|Experimental|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
33051879|NCT04960397|Experimental|Cohort 6|Once, there is sufficient evidence of safety in Cohort 5, Cohort 6 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, where a lead-in group (N=20) will be randomly assigned to receive either two doses of 10^8 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=20. Once lead-in group completes Day 8, the SRC will review the safety and determine if Cohort 7 may begin enrollment. Additional group of children may continue to enroll during the SRC review, which will be assigned randomly to receive two doses of 10^8 TCID50 of intranasal Sing2016 M2SR (N=12) or two doses of placebo (N=6) at Day 1 and Day 29. N= 26
33051880|NCT04960397|Experimental|Cohort 7|Once, there is sufficient evidence of safety in Cohort 6, Cohort 7 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomly assigned to receive two doses of 10^9 TCID50 dose of intranasal Sing2016 M2SR vaccine (N=18) or two doses of placebo (N=8) at Day 1 and Day 29. N=26
32871597|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33051881|NCT04955678|Experimental|ZG-801|
33051882|NCT04955678|Placebo Comparator|Placebo|
33051883|NCT04946318|Placebo Comparator|24-week Placebo|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 24 weeks
33051884|NCT04946318|Placebo Comparator|12-week wash out + 12-week Placebo|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and Placebo inhaled once daily for 12 weeks"
33051885|NCT04946318|Placebo Comparator|12-week Placebo|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with Placebo inhaled once daily for 12 weeks
33051886|NCT04946318|Experimental|24-week CSJ117|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated once daily for 24 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
33051887|NCT04946318|Experimental|12-week wash out + 12-week CSJ117|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and then they will be treated once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 12 weeks."
33051888|NCT04946318|Experimental|12-week CSJ117|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
33051889|NCT04922255|Active Comparator|disposable urethral support device|disposable urethral support device
33051890|NCT04922255|Active Comparator|Reusable Underwear|Reusable Underwear
33051891|NCT04922255|Active Comparator|pelvic floor muscle therapy (PFMT)|Pelvic floor muscle therapy
33051892|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
33051893|NCT04898153|Experimental|aXess|Patients will be implanted with the Xeltis hemodialysis access graft (aXess)
33051896|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose < 4.0 mmol/L|16g of carbohydrates will be given when glucose levels are below 4.0 mmol/L (management per guidelines)
33051897|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 4.5 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 4.5 mmol/L.
33051898|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 5.0 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 5.0 mmol/L.
33051899|NCT04733820|Experimental|Adjuvant chemotherapy group|"Participant will receive at least 2 cycles of adjuvant chemotherapy. If having any of the following factors, participant will receive additional 2 cycles of adjuvant chemotherapy per risk factor. All patients received maximum 6 cycles of postoperative chemotherapy.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 4cm before surgery."
33051900|NCT04733820|No Intervention|Control group|The participants receive no intervention.
33051901|NCT04857827|Experimental|QLS-101 ophthalmic solution 1.0%|Ophthalmic solution once daily (QD) dosing in both eyes (OU) for 14 days followed by 14 days of twice daily (BID) dosing.
33051902|NCT04857827|Active Comparator|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
33051903|NCT04857827|Experimental|QLS-101 ophthalmic solution 2.0%|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
33051904|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33051905|NCT04733651|Active Comparator|Control arm|In this arm subjects will receive the hospital COVID-19 standard care
33051906|NCT04733651|Experimental|Isoquercetin arm|In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
33051907|NCT04733001|Experimental|HSG4112 Treatment Arm: Fasted|Single oral dosing of HSG4112 480 mg under fasted conditions
33051908|NCT04733001|Experimental|HSG4112 Treatment Arm: Low-Calorie Diet|Single oral dosing of HSG4112 480 mg under low-calorie (400-500 kcal with 100-125 kcal fat) diet conditions
33051909|NCT04733001|Experimental|HSG4112 Treatment Arm: High-Calorie Diet|Single oral dosing of HSG4112 480 mg under high-calorie (800-1000 kcal with 500-600 kcal fat) diet conditions
33051910|NCT04846517|Other|TMS Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
33051911|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
33051912|NCT04815902|Experimental|Active Fisetin and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
33051913|NCT04815902|Active Comparator|Active Fisetin and Losartan Placebo|Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
33051914|NCT04815902|Active Comparator|Fisetin Placebo and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
33051915|NCT04815902|Placebo Comparator|Control|Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
33332027|NCT04364152|Experimental|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
33332028|NCT04364152|Experimental|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
33332029|NCT04165824|Experimental|MT-1186|
33332030|NCT04360330|Experimental|Preoperative SABER|"Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.~Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
33332031|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
33332032|NCT05758714|No Intervention|Peak Traffic Commute|"Rush hour is defined as between 6:30 and 8:30 am. This is when most Hartford residents commute to work."
33332033|NCT05758714|Experimental|Non-rush hour Commute|
33332034|NCT04873206||Functional/ Cyclical Endometrial group.|cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.
33332035|NCT04873206||Hyperplastic Endometrial group.|cases of endometrial hyperplasia obtained by D&C or hystrectomy will be stained by H&E stain and categorized into typical or atypical hyperplasia.
33332036|NCT04873206||Primary Endometrial Adenocarcinoma group.|cases of primary endometrial adenocarcinoma obtained by D&C or hystrectomy operations
33332037|NCT05758480|Experimental|Patients with Long COVID|
33332038|NCT05758480|Active Comparator|COVID-19 recovered patients (Control)|
33332039|NCT04222816|Active Comparator|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
33332040|NCT04222816|Experimental|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
33332041|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
33332042|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
33332043|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
33332044|NCT04823364|Active Comparator|Medically healthy adults diagnosed with ADHD|Medically healthy adults diagnosed with ADHD (men and women) ages 18-40 years (N= 35), treated with Amphetamines (Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin)
33332045|NCT04823364|No Intervention|Control|HCS (N= 25) volunteers ages 18-40 years, who did not report ADHD or any other illness or medical conditions, and who do not take chronically medications, will be enrolled from the general population.
33332046|NCT03984812|Experimental|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
33332047|NCT03984812|Experimental|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
33332048|NCT03984812|Experimental|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
33418687|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
33110600|NCT05108129|Experimental|Group OSTAP|In the second group, the patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
33110601|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
33110602|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
33110603|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
33110604|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
33110605|NCT05102474||Moderate to Severe Psoriasis|Moderate to severe psoriasis will be defined as affected body surface area (BSA) ≥3%.
33110606|NCT05102474||Healthy Controls|Healthy controls will be age and sex matched subjects with no prior or current history of psoriasis.
33110607|NCT04673253|Active Comparator|Passive leg raise|group for passive leg raise
33110608|NCT04673253|Placebo Comparator|Control|
33110609|NCT05096897||IBD patients|
33110610|NCT05096897||Non-IBD patients (irritable bowel syndrome)|
33110611|NCT04673214|Experimental|Triple therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days
33110612|NCT04673214|Active Comparator|Double therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.
33110613|NCT05092490|Experimental|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
33110614|NCT05092490|Active Comparator|Stand local anesthetic infiltration|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
33110615|NCT04672473|Experimental|Treatment|DAC combined with Ag-CTL
33418688|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
33418689|NCT05706909||Genex with ABMC|Injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the Core decompression procedure
33110616|NCT05040113|Experimental|CBP-307|Take CBP-307orally at 30 min ± 2 min after the start of high-fat breakfast intake
33110617|NCT01845987|Placebo Comparator|Placebo|
33418690|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
33110618|NCT01845987|Experimental|CNTO 1959|
33110619|NCT00556023|Experimental|CP-675,206 and gemcitabine|
33110620|NCT05011214|Active Comparator|group S|patients were anesthetized by face mask with 5 vol% sevoflurane with total 5 L/min-1 fresh gas flow. Anaesthesia was maintained by continuously using 3-4% sevoflurane.
33110621|NCT05011214|Experimental|group E|patients received 0.5mg/kg IV esketamine at first, after surgical field disinfection, another 0.25mg/kg IV esketamine was administered. Then 1mg/kg propofol was administered every 5 minutes after intubation.
33110622|NCT00556062|Experimental|1: Lot 1|
33110623|NCT00556062|Experimental|2: Lot 2|
33110624|NCT00556062|Experimental|3: Lot 3|
33110625|NCT00556062|Active Comparator|4: control vaccine|
33110626|NCT04965155|Experimental|Isatuximab-Dexamethasone|Isatuximab-Dexamethasone pre and post transplant in relapsed multiple myeloma patients.
33110627|NCT04676841||Hemiarthroplasty|Hip fracture patients operated with hemiarthroplasty
33110628|NCT04949438|Experimental|Cohort 1: Participants with severe renal impairment|Participants with severe renal impairment will receive a single oral dose of AZD4831 on Day 1.
33110629|NCT04949438|Experimental|Cohort 2 :Healthy participants|Healthy participants will receive a single oral dose of AZD4831 on Day 1.
33110630|NCT04676763|Experimental|Substance P challenge in Part 1|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 1 will include a single challenge visit.
33110631|NCT04676763|Experimental|Substance P challenge in Part 2|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 2 will include two challenge visits.
33110632|NCT04944563|Experimental|Segmentectomy|Patients receive segmentectomy
33110633|NCT04944563|Active Comparator|Lobectomy|Patients receive lobectomy
33110634|NCT04672707|Experimental|Group A|Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
33110635|NCT04672707|Experimental|Group B|Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
33110636|NCT04672707|Experimental|Group C|Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
33110637|NCT04672707|Experimental|Group D|Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
33110638|NCT04932083|Placebo Comparator|Bupivacaine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml sterile water.
33110639|NCT04932083|Experimental|Fentanyl|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml fentanyl (25µg).
33110640|NCT04932083|Experimental|Nalbuphine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water.
33110641|NCT04932083|Experimental|Midazolam|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 2mg of midazolam in 0.5 ml sterile water.
33110642|NCT04923035||Case|"Children aged 5 years and below with clinically diagnosed pneumonia and attending the outpatient's department or admitted as a hospital inpatient at three sentinel sites. Pneumonia. Suspected pneumonia cases will be identified by a family physician or paediatrician based on medical history and clinical symptoms.~Pneumonia is defined as (WHO Fact Sheet 2019) patient with history of:~cough and/or~difficulty/rapid breathing and/or~intercostal recession,~with or without fever. and supported by chest x-ray findings."
33110643|NCT04923035||Control|Healthy children aged 5 years and below without any intercurrent respiratory illness and who is in good health as determined by a brief medical history and/or clinical judgement of the investigator whose parent/LAR is willing and able to give informed consent.
33110644|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
33110645|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
33110646|NCT04920071||Control|150 healthy control participants
33110647|NCT04920071||AMD Cohort high-contrast VA group i|Better than 0.4 logMAR
33110648|NCT04920071||AMD Cohort high-contrast VA group ii|0.4-0.6 logMAR
33110649|NCT04920071||AMD Cohort high-contrast VA group iii|0.6-0.8 logMAR
33110650|NCT04920071||AMD Cohort high-contrast VA group iv|0.8-1.0 logMAR
33110651|NCT04672785||Patients who underwent a posterior fossa craniectomy for a cerebellar hematoma|
33110652|NCT01825980|Experimental|BZF961|
33110653|NCT01825980|Placebo Comparator|Placebo|
33110654|NCT04858490|Experimental|Symptom-triggered diazepam treatment|Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
33110655|NCT04672200|Experimental|Intervention arm|This group will receive the weekly group exercise which will be delivered online initially, and in the community clubs once they are allowed to reconvene according to government guidance. The duration of the intervention is 12 weeks.
33110656|NCT04676685|Experimental|Part A, Cohort 1: E2730 20 Milligram (mg) or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 20 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
33110657|NCT04676685|Experimental|Part A, Cohort 2: E2730 40 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 40 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
33110658|NCT04676685|Experimental|Part A, Cohort 3: E2730 60 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 60 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
33110659|NCT04676685|Experimental|Part A, Cohort 4: E2730 80 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 80 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
33110660|NCT04676685|Experimental|Part B, E2730 80 mg: Fasted + Fed|Participants will receive a single treatment of E2730 (80 mg capsule) in fasted condition on Day 1 treatment period 1 followed by E2730 80 mg capsule in fed condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
33110661|NCT04676685|Experimental|Part B, E2730 80 mg: Fed + Fasted|Participants will receive a single treatment of E2730 80 mg capsule in fed condition on Day 1 of treatment period 1 followed by E2730 80 mg capsule in fasted condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
33332049|NCT03984812|Experimental|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
33110662|NCT04672317|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
33110663|NCT04791878|Experimental|Mesenchymal stem cells|allogeneic bone marrow derived mesenchymal stem cells
33332050|NCT03984812|Experimental|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
33110664|NCT04672278|Experimental|Group A|
33110665|NCT04672278|Experimental|Group B|
33110666|NCT04790045|Other|Venetoclax-based treatment|Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care
33332051|NCT03984812|Experimental|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
33332052|NCT03984812|Experimental|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
33110667|NCT04676568|Active Comparator|extravesical VVF repair|
33110668|NCT04676568|Active Comparator|Transvesical VVF repair|
33110669|NCT04676295|Experimental|PE intervention|A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.
33110670|NCT04676295|No Intervention|PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
33110671|NCT04676295|No Intervention|Non-PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
33110672|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
33110673|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
33110674|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
33110675|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
33110676|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
33110677|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
33110678|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
33110679|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
33110680|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
33110681|NCT00555165|Experimental|I|
33110682|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
33110683|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
33110684|NCT04671732||Fenestrated endovascular aortic aneurysm repair (FEVAR)|
33110685|NCT04671732||Open repair (OR)|
33110686|NCT04759625|Experimental|Biscuit enriched with mushroom powder|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
33110687|NCT04759625|Placebo Comparator|Placebo biscuit|Daily consumption of a placebo biscuit
33110688|NCT01823016|Placebo Comparator|Placebo|
33332053|NCT03984812|Experimental|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
33332054|NCT03984812|Experimental|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
33110689|NCT01823016|Experimental|JNJ-38518168|
33110690|NCT04754282|Active Comparator|Traditional sitting position|Expecting women are positioned in a traditional sitting position for epidural analgesia catheter placement during labour.
33110691|NCT04754282|Experimental|Cross-legged sitting position|Expecting women are positioned in a crosse-legged sitting position for epidural analgesia catheter placement during labour.
33110692|NCT04671888|Experimental|COPD patients|
33110693|NCT04722653|Experimental|NN0194-0499|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo, Asian participants will only receive NNC0194-0499. There will be 3 cohorts with escalating dose levels. There should be at least 4 days between dose administration of the last participant in a dose level cohort and dose administration of the first participant in the following dose level cohort.
33110694|NCT04722653|Placebo Comparator|Placebo|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo.
33110695|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
33110696|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
33110697|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
32871598|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33110698|NCT04700345|Experimental|Embolization|Middle meningeal artery(MMA) embolization
33110699|NCT04700345|Active Comparator|No embolization|Traditional treatment group
33110700|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
33110701|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
33110702|NCT01815450|Placebo Comparator|Placebo|Topical cream
33110703|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
33110704|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
33110705|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
33110706|NCT04671524|Experimental|pediatric patients diagnosed with rheumatic diseases.|"Exercise group; a combination of stretching, range of motion, and strengthening exercise.~The exercise program will take 8 weeks, 3 days per week, and 45 minutes."
33110707|NCT04671524|No Intervention|healthy controls|The healthy control group will be examined and the outcomes will be compared with the experimental group.
33110708|NCT04671849|Experimental|adult patients_Dose 1|
33110709|NCT04671849|Experimental|adult patients_Dose 2|
33110710|NCT04671849|Experimental|adult patients_Dose 3|
33110711|NCT04671849|Experimental|adult patients_Dose 4|
33110712|NCT04671849|Experimental|adult patients_Dose 5|
33110713|NCT04671849|Experimental|adult patients_Dose 6|
33110714|NCT04671849|Experimental|adult patients_Dose 7|
33110715|NCT04671849|Experimental|adult patients_Dose 8|
33110716|NCT04664777||Group1|"Living liver donors who operated between 1 August and 15 november:~After anesthesia induction and surgical field sterilization, before surgical incision; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded.~After the surgical procedure is over and before the patient is awakened from anesthesia; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded."
33110717|NCT01785771|Experimental|ITCA 650|
33110718|NCT04664582|Experimental|Sentinel Lymph Node Biopsy|Lymphoscintigraphy will be ordered alongside usual pre-operative investigations. Intra-operatively, the excision of the primary tumor will be done with the aim of histologically clear margins and appropriate closure as per routine practice at the operating surgeon's discretion. The patients are injected with technicium 99 pre-operatively and a sentinel lymph node biopsy will be performed with a handheld gamma probe.
33110719|NCT04664582|No Intervention|Standard of Care|These patients will be treated with standard of care, which is wide local excision of the primary tumor without performance of sentinel lymph node biopsy, if not indicated.
33110720|NCT04671537|Experimental|Study group (preloading with crystalloid fluid - isotonic solution)|Preloading with crystalloid fluid (isotonic solution) at 10 ml/kg of ideal body weight
33110721|NCT04671537|No Intervention|Control group (not preloading)|no preloading
33110722|NCT04660760|Experimental|Arm A (TAS-102, ramucirumab)|Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
33110723|NCT04660760|Active Comparator|Arm B (paclitaxel, ramucirumab)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
33110724|NCT04627415|Experimental|Face to Face Treatment|The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
33332055|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
33110725|NCT04627415|Experimental|Online Treatment|For the online version of the program, in addition to content regarding an overview of ADHD, the initial session consists of brief video clips demonstrating how to access PEAK sessions on the Internet, and an orientation to online content (e.g., handouts, interactive chat sessions, research team contact links). Prior to the session, parents are provided with password-protected individual access codes. Similar to the F2F program, check-ins are provided weekly via each parent's preferred mode of communication (i.e., text, internet, phone) to query strategies implemented, praise success, and troubleshoot alternative strategies. Parents in the online condition will also receive supplemental optimistic training to improve pessimistic thinking patterns about their child and parenting.
33110726|NCT04627415|Other|Waitlist Control|The comparison condition is a waitlist control group that will receive no intervention throughout the intervention timeframe. Instead, participants will receive wellness information about typical child development and constructs unrelated to the intervention content. Subsequent to the 12-month follow-up assessment, they will be provided access to the online version of the program. To encourage ongoing participation in the absence of services, parents will be informed that, at the end of the intervention timeframe, they will receive support (i.e., weekly contact to answer questions) while they complete the online program.
33110727|NCT04671459|Experimental|TTFields and SRS based on MRI or FET-PET|All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.
33110728|NCT04620356|Experimental|DryNites arm|"Participants in this arm use DryNites every night for 4 weeks (run-in period), an additional 4 weeks (intervention core trial period), and an optional additional 4 weeks (extension period). All participants in this arm also receive absorbent bad mats to use every night."
33110729|NCT04620356|No Intervention|No Pants arm|"Participants in this arm use DryNites every night for 4 weeks only during the initial run-in period. Thereafter, participants in this arm do not use DryNites during the 4 week intervention core trial period or the optional additional 4 weeks extension period. All participants in this arm also receive absorbent bad mats to use every night."
33110730|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
33110731|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
33110732|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
33110733|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
33110734|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
33110735|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
33110736|NCT04607252|Experimental|Metformin plus megestrol acetate|Metformin 1500mg per day plus megestrol acetate 160mg per day.
33110737|NCT04607252|Active Comparator|Megestrol acetate|Megestrol acetate 160mg per day.
33110738|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
33110739|NCT04601285|Experimental|Dose Escalation|
33332056|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
33332057|NCT03743714|Experimental|males|healthy, sedentary males
33332058|NCT03743714|Experimental|females|healthy, sedentary females
33332059|NCT04764630|Experimental|A. Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min)
33332060|NCT04764630|Experimental|B. Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
33332061|NCT04764630|Active Comparator|C. Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
33332062|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
33332063|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
33332064|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
33332065|NCT03814850|Experimental|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
33332066|NCT03814850|Sham Comparator|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
33332067|NCT04153188|Experimental|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
33332068|NCT04153188|Active Comparator|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
33332069|NCT04113746|Experimental|Asthma and Exercise Lifestyle Change|Participants receive asthma and lifestyle change education related to exercise
33332070|NCT04113746|Placebo Comparator|Asthma Education|No lifestyle change education
33332071|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
33332072|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
33418691|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~Three evaluation and preparation sessions,~Eight EMDR sessions weekly with variable length of 60 minutes and~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
33110740|NCT04671264|Experimental|VC group|"Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight.~Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application."
33110741|NCT04671264|Placebo Comparator|Control group|The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.
33110742|NCT04583774|Other|Anorexia Nervosa Group|Participants with anorexia nervosa
33110743|NCT04583774|Other|Healthy Control Group|Participants who are considered to be healthy controls
33110744|NCT04671303|Experimental|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
33110745|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
33110746|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
33110747|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
33418692|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
33418693|NCT05082337|Experimental|Guidewire|The SAVVY guidewire will be used in all TAVR procedures of patients included in the study
33110748|NCT04578392|Active Comparator|high ligation of ileocolic artery|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
33110749|NCT04578392|Active Comparator|mesenteric sparing for a primary ileocolic resection|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
33110750|NCT04671420|Experimental|HLX01|
33110751|NCT04671420|Active Comparator|EU-sourced rituximab (Mabthera®)|
33110752|NCT04573556||Lemborexant|Participants with insomnia will initiate treatment with lemborexant 5 milligram (mg), tablet, orally as per the clinical judgment of the treating physician as part of routine clinical care. Dosage and administration of lemborexant tablet will be according to package insert and actual dosing and frequency will be decided by physician including dose escalation from initial dose of 5 mg up to 10 mg once daily. All participants will be observed prospectively for up to 24 weeks.
33418694|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
33418695|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
33418696|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
33110753|NCT04671108|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
33418697|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
33418698|NCT05081089|Active Comparator|Artemether-lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
33110754|NCT04671108|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
33110755|NCT04573166|Experimental|CURB procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation (CURB)
33418699|NCT05081089|Experimental|AL with 0.25mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of AL treatment.
33418700|NCT05081089|Active Comparator|Sulphadoxine-pyrimethamine with amodiaquine (SPAQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days.
33418701|NCT05081089|Experimental|SPAQ with 1.66mg/kg tafenoquine (TQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days and a single dose of 1.66mg/kg tafenoquine (TQ) on the first day of SPAQ treatment.
33418702|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
33418703|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of bacteremia and/or urinary tract infection and/or respiratory tract infection (including tracheobronchitis) or sepsis
33418704|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
33418705|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
32740333|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
33051916|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33051917|NCT00026247|Experimental|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
33051918|NCT04808414|Experimental|QPX9003 for IV infusion|IV novel polymyxin antibiotic Single and Multiple IV doses x 7 days via IV infusion q6hrs
33051919|NCT04808414|Placebo Comparator|Placebo for Infusion|IV saline Single and Multiple IV doses x 7 days via IV infusion q6hrs
33051920|NCT04792190|Active Comparator|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
33051921|NCT04792190|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
33051922|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
33051923|NCT04746833|Experimental|SUMMIT|Participants randomized to the experimental intervention will participate in a Motivational Interviewing (MI) session lasting between 30 and 60 minutes with study psychologist. All MI sessions will be audiotaped using a VA-approved digital recorder and transcribed verbatim. Participants will subsequently be shown how to access SUMMIT via a set of unique anonymized login credentials and to navigate the components of SUMMIT on one or more devices, depending on their preference. They will then be trained on how to complete the outcome surveys.
33051924|NCT04746833|Placebo Comparator|control|Participants randomized to the control intervention will use an eHealth comparator: My Pain Diary: Chronic Pain Management (iPhone, Android). This app includes a pain monitoring functioning only, and thus will only minimally overlap, if at all, with SUMMIT's components. Control participants will not participate in a MI session. Participants will download the app and be shown how to use the My Pain Diary app and trained how to complete the outcome surveys
33051925|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
33051926|NCT04730882||Healthy Control|Healthy subjects 18-35 years of age
33051927|NCT04730882||Type 1 Diabetes|People with type 1 diabetes (18-35 yrs) who have type 1 diabetes based on WHO diagnostic criteria for > 1 year
33051928|NCT04726280|Experimental|10 ml single-shot injection|"In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
33051929|NCT04726280|Active Comparator|20 ml single-shot injection group|"In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
33051930|NCT04707716|Experimental|conometric concept (Acuris system)|single implant crown retention using friction only
33051931|NCT04707716|Active Comparator|screw retention|screw retained implant Crown fixation
33051932|NCT04707716|Active Comparator|cementation|cement retained implant Crown fixation
33051933|NCT04704791|Experimental|Procedure arm|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
33051934|NCT04699487|Experimental|Patient receiving Photobiomodulation|
33051935|NCT00026637|Active Comparator|Sertraline|
33051936|NCT00026637|Active Comparator|CBT|
33051937|NCT04678115|Experimental|MLP first, KTFS second|Participants in this arm will receive the MLP in the first period of the crossover and the KTFS in the second period.
33051938|NCT04678115|Experimental|KTFS first, MLP second|Participants in this arm will receive the KTFS in the first period of the crossover and the MLP in the second period.
33051939|NCT04669067|Experimental|Phase 1b - Dose Level 1|KRT-232 240mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
33110756|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
33110757|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
33051940|NCT04669067|Experimental|Phase 1b - Dose Level 2|KRT-232 300mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
33110758|NCT04687982|Experimental|mDLI infusion|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
33110759|NCT04671147||Skull tong femoral traction|
33110760|NCT04671147||Cotrell longitudinal traction|
33110761|NCT04571723|Active Comparator|Established Diabetes Prevention Program|This arm will receive the established diabetes prevention program curriculum.
33110762|NCT04571723|Active Comparator|Health Mindset modified Diabetes Prevention Program|This arm will receive the modified curriculum with the added health mindset information.
33110763|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
33110764|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
33110765|NCT04567160|Active Comparator|Propofol group|Induction and maintenance of general anesthesia using propofol
33110766|NCT04567160|Active Comparator|Sevoflurane group|Induction and maintenance of general anesthesia using sevoflurane
33110767|NCT04670952|Experimental|Low Pressure Laparoscopic Cholecystectomy|"LPLC refers to Low Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 10mmHg."
33110768|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|"This is taken as the control group. SPLC refers to Standard Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 14 mmHg."
33110769|NCT04545866|Experimental|budesonide with surfactant|Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.
33110770|NCT04545866|Active Comparator|surfactant alone|Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).
33110771|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
33110772|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
33110773|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
33110774|NCT04545593|Experimental|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
33110775|NCT04545593|Active Comparator|Enhanced Usual Care|The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
33110776|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
33110777|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
33110778|NCT04543994|Experimental|Remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)."
33110779|NCT04543994|Experimental|Remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
33110780|NCT04543994|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall.~If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
33110781|NCT04671225|Experimental|Intervention - Psychoeducation at the referral hospital|Intervention: Manual-structured group psychoeducation.
33110782|NCT04671225|Other|Waiting list - at the referral hospital|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
33110783|NCT04519697|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
33332073|NCT03611010|Experimental|Cohort 1|Cohort 1 = Baseline daily dose of 10 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
33051941|NCT04669067|Experimental|Phase 1b - Dose Level 3|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 150 mg BID continuously for the first 28-day cycle~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 150 mg BID continuously for each 28-day cycle."
33051942|NCT04669067|Experimental|Phase 1b - Dose Level 4|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 300 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 300 mg BID continuously for each 28-day cycle."
33332074|NCT03611010|Experimental|Cohort 2|Cohort 2 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
33332075|NCT03611010|Experimental|Cohort 3|Cohort 3 = Baseline daily dose of 40 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
33332076|NCT03611010|Experimental|Cohort 4|Cohort 4 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then SC study drug for up to 15 days
33332077|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide~Single arm study"
33332078|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
33332079|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
33332080|NCT05296746|Experimental|Responder (ROR-low)|Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years
33332081|NCT05296746|Other|Non-responder (ROR-medium/high)|"Adjuvant chemotherapy. 3 regimens are permitted.~Regimen 1:~- Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 90 mg/m2) and Cyclophosphamide 600 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks.~Regimen 2:~- Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600 mg/m2 day 1 every 21 days for 4-6 cycles.~Regimen 3:~- Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 90 mg/m2) and Cyclophosphamide 600 mg/m2 day 1 every 14/21 days for 4 cycles.~Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years"
33332082|NCT04357782|Active Comparator|Mild hypoxemia|S/F ratio >250 prior to Vitamin C infusion
33332083|NCT04357782|Active Comparator|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
33332084|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
33360814|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
33418706|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
33418707|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
33051943|NCT04669067|Experimental|Phase 1b - Dose Level 5|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 450 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 450 mg BID continuously for each 28-day cycle."
33051944|NCT04669067|Experimental|Phase 2 - Dose Expansion|Dose expansion of the recommended phase 2 dose of TL-895 in combination with KRT-232 as determined in Phase 1b.
33051945|NCT04657094|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with acalabrutinib may be continued beyond 12 cycles for a maximum of 36 cycles if, in the opinion of the treating physician, the patient might benefit from ongoing therapy.
33051946|NCT04628780|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
33051947|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
33051948|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
33051949|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
33051950|NCT04628039||COVID Positive|Veterans aged 18 years or older who have a positive SARS-CoV-2 diagnosis (confirmed or presumptive) or who have been discharged home within 2 weeks to 1 year of diagnosis
33051951|NCT04611230||Adult Volunteers (Low Risk Group)|Volunteers with jobs that do not require close contact with (i.e., within 6 feet of) the general public or co-workers.
33051952|NCT04611230||Adult Volunteers (Medium - Low Risk Group)|Volunteers with jobs that require in-frequent contact with (i.e., within 6 feet of) the general public or co-workers.
33051953|NCT04611230||Adult Volunteers (Medium - High Risk Group)|Volunteers with jobs that require frequent contact with (i.e., within 6 feet of) the general public or co-workers.
33051954|NCT04611230||Adult Volunteers (High Risk Group)|Volunteers with jobs that require frequent and/or close contact with (i.e., within 6 feet of) individuals with high potential for exposure to known or suspected sources of COVID-19.
33051955|NCT04610684|Experimental|Study Treatment Arm|4 cycles of induction treatment with Atezolizumab (1200 mg on Day 1) combined with carboplatin (5-6 AUC on Day 1) and etoposide (80-100 mg/m2 on Days 1-3). After 4 cycles of induction treatment, subjects will receive atezolizumab maintenance 1200 mg on Day 1 of each 3-week cycle.
33051957|NCT04590365|Experimental|Coldamaris plus|verum Coldamaris plus i.e. 0.12% Iota-Carrageenan plus 0.04% Kappa-Carrageenan in 0.5% saline
33051958|NCT04590365|Placebo Comparator|Coldamaris sine|Coldamaris sine i.e. 0.5% saline
33051959|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
33332085|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
33332086|NCT03980522|Experimental|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
33332087|NCT03980522|Experimental|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
33332088|NCT03980522|Experimental|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
33332089|NCT03980522|Experimental|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
33332090|NCT03980522|Experimental|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
33332091|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
33332092|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
33332093|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
33332094|NCT04402866|Experimental|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
33332095|NCT04402866|Experimental|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
33332096|NCT04402866|Experimental|Part 2: Placebo|99 subjects will be randomized to receive Placebo
33332097|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
33051960|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
33332098|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
33051961|NCT04733261|Active Comparator|Diaphragmatic mobility|The patient will be in supine, supported on one/two pillows under her head, and a bolster under her knees.
33051962|NCT04733261|Experimental|Chest Physiotherapy|Give passive ROM exercise to all joints of the upper and lower extremities.
33051963|NCT04567940|Experimental|Intervention group|Behavioural multicomponent intervention
33051964|NCT04567940|No Intervention|Control group|Usual care
33051965|NCT04473950|Experimental|Pain Group|Patients with chronic pain who are maintained on methadone for opioid use disorder
33051966|NCT04473950|Placebo Comparator|No Pain Group|Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
33051967|NCT04473482|Experimental|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
33051968|NCT04473482|No Intervention|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
33051969|NCT04464434|Experimental|Upfront autologous HSCT|
33332099|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). Participants who stop pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stop after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, are eligible for up to an additional 1 year of treatment after progressive disease if they meet the criteria for retreatment.
33332100|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
33332101|NCT04348656|Experimental|Convalescent plasma|~500 mL ABO compatible convalescent apheresis plasma
33332102|NCT04348656|No Intervention|Standard of care|Treated as per institutional standard of care.
33332103|NCT05296668|Experimental|Cuffed ETT group|(group C) to receive a cuffed ETT for airway management.
33332104|NCT05296668|Active Comparator|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
33332105|NCT04136548|Experimental|Fentanyl|Fentanyl will be administered intravenously during one visit.
33332106|NCT04136548|Placebo Comparator|Placebo|Placebo (saline) will be administered intravenously during one visit.
33332107|NCT04348500|Active Comparator|Clazakizumab|25 mg in 50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
33332108|NCT04348500|Placebo Comparator|Placebo|50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
33332109|NCT05758168|No Intervention|Layered Closure|A cutaneous layer of sutures will be placed on one side of wound, as is standard of care.
33332110|NCT05758168|Experimental|Layered Closure with Tie-Over Bolster Dressing|The other side of wound will have a cutaneous layer of sutures with the addition of a bolster dressing.
33418708|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
33332111|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
33332112|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
33110784|NCT04519697|Placebo Comparator|Placebo|Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.
33110785|NCT04670601|Experimental|Flurbiprofen 8.75 mg|Flurbiprofen 8.75 mg lemon and honey flavour lozenge
33110786|NCT04670601|Active Comparator|Strepfen 8.75 mg|Strepfen 8.75 mg lemon and honey lozenge
33332113|NCT04062058|Experimental|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
33332114|NCT04347954|Experimental|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
33332115|NCT04347954|Experimental|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5"
33332116|NCT04347954|Placebo Comparator|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
33110787|NCT04444583||HFpEF|HF patients with preserved ejection fraction (HFpEF)
33110788|NCT04444583||HFrEF|HF patients with reduced ejection fraction (HFrEF)
33110789|NCT04670913|Experimental|Camrelizumab plus Apatinib|Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po
33110790|NCT04419896||Retrospective|"Inclusion criteria for Retrospective Subjects:~Men and women 18 years or older;~Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and~For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result."
33110791|NCT04419896||Prospective|"Inclusion criteria for Prospective Subjects:~Men and women aged 18 years or older;~Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);~Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and~Consents to be a part of the Registry."
33110792|NCT04671069|Experimental|MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet|
33110793|NCT04382807||Subjective, chronic tinnitus|Tinnitus patients who received internet-based psycho-educational counseling
33110794|NCT04670835||Case Group (unic)|"Group/Cohort Label :~Users of Emergency Call Centers Users of French territory 'Region Pays de la Loire'~Group/Cohort Description:~All Users calling through the five Emergency Medical Centers of the French Pays de la Loire region (5 areas of the region are : Loire-Atlantique, Maine-et-Loire, Mayenne, Sarthe, Vendée).~In each Emergency Medical Center, an advanced telephone system automatically keeps track of all inbound calls.~Average annual number of incoming calls for the 5 Emergency Medical Center of Pays de la Loire region is 1,6 million."
33110795|NCT04374539|Experimental|Plasma exchange|Plasma exchange with human serum albumin + Polyclonal immunoglobulin + standard medical treatment
33110796|NCT04374539|Active Comparator|Standar medical treatment|Standar medical treatment
33332117|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
33332118|NCT03878134|Active Comparator|Patients|750 male or female, 18 and older patients
33332119|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
33110797|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
33110798|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
33110799|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
33110800|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
33110801|NCT04363346|Experimental|Dose Strategy 1|"Dose Strategy 1:~Day 1 - FT516 is given at 9x107 cells/dose (low)"
33110802|NCT04363346|Experimental|Dose Strategy 2|"Dose Strategy 2:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid)"
33110803|NCT04363346|Experimental|Dose Strategy 3|"Dose Strategy 3:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid) + Day 7 - FT516 is given at 9x108 cells/dose (high)"
33110804|NCT04335188||In-patients with SARS-CoV-2 infection|"In-patients fulfilling the following criteria:~SARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study No explicit medical exclusion criteria are stated to avoid selection bias."
33051970|NCT04464434|Active Comparator|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage) or mycophenolic acid (up to 2.160 grams daily).~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
33051971|NCT04440059|Experimental|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
33051972|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
33051973|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
33418709|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
33418710|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
33418711|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
33418712|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
33051974|NCT00395382|Active Comparator|1|Alendronate
33051975|NCT00395382|Placebo Comparator|2|Placebo
33051976|NCT04227353|Experimental|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
33051977|NCT04227353|No Intervention|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
33051978|NCT04206488|Experimental|JNJ-70033093 + Digoxin|Participants will receive JNJ-70033093 as oral capsules (Treatment A) in Period 1, followed by digoxin tablets as loading dose and maintenance doses (Treatment B) in Period 2, and then digoxin tablets along with JNJ-70033093 (Treatment C) in Period 3. There will be a washout period of minimum 5 days (and maximum 7 days) between the last dosing day of Period 1 and the first dosing day of Period 2. There is no washout between Periods 2 and 3 (that is, the last day of Treatment B is to be followed by the first day of Treatment C).
33051979|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
33418713|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
33051980|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
33051981|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
33051982|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
33051983|NCT04166864|Experimental|SCC-Determined TMS|
33051984|NCT04163003|Experimental|TAPAS|Participants will participate in the TAPAS intervention, which will consist of one in-person engagement session with a therapist and 8 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week.
33051985|NCT04163003|Experimental|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention in this arm.
33051986|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
33051987|NCT04154930|Experimental|Treatment|"Restylane-L® injected with optional touch at 1 month and optional retreatment at 12 months~,"
33051988|NCT04154930|No Intervention|No Treatment Control|No treatment control with optional treatment at 12 months
33051989|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
33051990|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
33051991|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
33051992|NCT04137887|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
33051993|NCT04137887|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
33418714|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
33418715|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
33418716|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
33418717|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
33418718|NCT05138263||Young normal controls|"age : 20 ~ 54~without dementia, MCI, or other major neurological/psychiatric illness"
33418719|NCT05138263||Elderly normal controls|"age : 55 ~ 90~without dementia, MCI, or other major neurological/psychiatric illness"
33051994|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32871599|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33051995|NCT04137536|Experimental|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
33051996|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
33051997|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
33051998|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
33051999|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
33052000|NCT04022876|Experimental|Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed|
33052001|NCT04022876|Experimental|Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed|
33052002|NCT04022876|Experimental|Part 1 SCLC: ALRN-6924+Topotecan|
33052003|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
33052004|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
33052005|NCT04001114|Other|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
33052006|NCT04001114|Other|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
33052007|NCT03999476|Experimental|ambu scope|intubation of cancer tongue patients with ambu scope device
33052008|NCT03999476|Active Comparator|fiberoptic|intubation of cancer tongue patients with fiberoptic device
33052009|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
33052010|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
33052011|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
33052012|NCT03962933||Flexcystoscopy/Uromonitor|Control cystoscopy every 4 - 8 and 12 months as a standard procedure, And Urine test (Uromonitor) every 4 months
33052013|NCT03960164|Experimental|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
33052014|NCT03960125|Experimental|4% Imipramine Cream on Upper Forearm Site|Base cream will be applied to the lower forearm site.
33052015|NCT03960125|Experimental|4% Imipramine Cream on Lower Forearm Site|Base cream will be applied to the upper forearm site.
33052016|NCT00392561|Experimental|1|Selenium
33052017|NCT00392561|Experimental|2|Vitamin E
33052018|NCT00392561|Experimental|3|Vitamin E + Selenium
33052019|NCT00392561|No Intervention|Arm 4|
33052020|NCT03960086|Experimental|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
33110805|NCT04670718|Experimental|OCT probe|The examination of gastrointestinal tract resected specimen with the use of the OCT probe
33110806|NCT04332458|Other|Patients with stroke without exercise experience|Patients who are discharged from the hospital within one month after a minor stroke or TIA and are not offered physical rehabilitation afterwards
32740334|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
33418720|NCT05138263||MCI (Mild cognitive impairment)|"age : 55 ~ 90~without major neurological/psychiatric illness~concern regarding a change in cognition, lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
33418721|NCT05138263||AD (Alzheimer's diseases)|"age: 55 ~ 90~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia(Alzheimer's diseases)"
33418722|NCT05220579|Experimental|"Exposure to TOR device"|"Patients undergo standard therapy + exposure to the TOR device~Modes of patients' treatment with the TOR device:~The exposure is carried out for at least 5 (five) days in a row for at least 4 hours daily in the 15 + 15 mode (15 minutes exposure + 15 minutes break).~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
33418723|NCT05220579|No Intervention|Control|"Patients received standard therapy~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
33418724|NCT05220579|Placebo Comparator|"Placebo (exposure to switched off TOR device)"|"Patients undergo standard therapy + a switched off TOR device was installed in the wards~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
33052021|NCT03960086|Active Comparator|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
33418725|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
33418726|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
33052022|NCT03960047|Experimental|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
33418727|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
33418728|NCT05123989|Experimental|Personalized move goals|Participants will be sent daily messages in the Welltory mobile app with personalized move goals that are based on each participant's historical physical activity data and their daily wellbeing
33418729|NCT05123989|Active Comparator|Constant move goals|Participants will be sent daily messages in the Welltory mobile app with a static move goal of 10,000 steps per day
33418730|NCT05123989|No Intervention|No intervention|Participants will not be sent any messages with move goals in the Welltory mobile app
33418731|NCT02107352||Naltrexone|50mg/day
33418732|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
33418733|NCT02107352||Baclofen|30 mg/day
33418734|NCT02107352||Placebo|
33418735|NCT05677581||pregnancy and lactation period women|
33052023|NCT03960047|Experimental|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
33052024|NCT03960047|No Intervention|Control|Receives no intervention
33052025|NCT03959969|Experimental|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
33052026|NCT03959969|Active Comparator|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
33052027|NCT03959930|Experimental|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
33052028|NCT03959852|Active Comparator|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
33052029|NCT03959852|Active Comparator|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
33052030|NCT03959852|Experimental|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
33052031|NCT03959774|Experimental|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
33052032|NCT00028548|Experimental|XK469|
33052033|NCT03959735|Experimental|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
33110807|NCT04332458|Other|Patients with stroke with exercise experience|Patients with a minor stroke who have participated in an exercise study (HITPALS)
33052034|NCT03959735|No Intervention|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
33052035|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
33052036|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
33052037|NCT03959696|Active Comparator|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
33052038|NCT03959696|Experimental|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
33052039|NCT04733196|Experimental|Essential oils|Mouthwash based on essential oils - menthol, eucalypts oil, thymol, alcohol
33052040|NCT04733196|Experimental|Essential oils in combination with clorhexidine 0,12%|Mouthwash based on essential oils - mentol, eucalypt oil, thymol, alcohol, and 0,12% chlorhexidine
33052041|NCT04733196|Placebo Comparator|Placebo mouthwash|Water, colorant, sweetener
33052042|NCT04733196|Experimental|Clorhexidine 0,20% in combination with aroma oils|Mouthwash based on 0,20% chorhexidine without alcohol in combination with aroma oils of rose and lavender
33052043|NCT04733196|Experimental|Prebiotic|Mouthwash based on prebiotic
33052044|NCT04733196|Experimental|Hydrogen peroxide|Mouthwash based on 0,8% hydrogen peroxide in combination with menthol and eucalypts oil
33052045|NCT03959618||dietary supplements group|dietary supplements questionary
33052046|NCT00028665|Experimental|Arm I: with rituximab IV|
33052047|NCT00028665|Active Comparator|Arm II: without rituximab IV|
33052048|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
33052049|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
33332120|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
33332121|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
33332122|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
33332123|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
33332124|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
32871600|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33052050|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
33332125|NCT05757544|Experimental|Dose optimization phase (Open Label): IV Ganaxolone followed by bolus|
33332126|NCT05757544|Experimental|Double-blind phase: IV Ganaxolone + SOC|
33332127|NCT05757544|Placebo Comparator|Double-blind phase: IV Placebo + SOC|
33332128|NCT03797404||Mepolizumab|Patients receiving mepolizumab
33052051|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
33052052|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
33052053|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
33052054|NCT03959501|Experimental|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
33052055|NCT03959501|Active Comparator|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
33052056|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
33052057|NCT03959462|Experimental|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
33052058|NCT03959462|Sham Comparator|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
33052059|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33332129|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
33332130|NCT03745612|Experimental|TRF|Time restricted feeding
33052060|NCT03959384|Experimental|Surfactant replacement (Curosurf)|"Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
33332131|NCT03745612|Active Comparator|CER|continuous energy restriction
33332132|NCT03979820|Experimental|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
33332133|NCT03979820|Experimental|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
33052061|NCT03959384|Placebo Comparator|Ambient Air|"Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
32740335|NCT04490837||COVID-19 positive|Patients with clinical, radiological and/or PCR positive for COVID-19 infection
32740336|NCT04490837||Normal|Normal human serum from blood donnors before COVID-19 pandemia
32740337|NCT04490837||Pathological controls|Patients with other positive virological serologies
32740338|NCT04491149|Experimental|women using virtual glass during amniocentesis/foeticide|
33052062|NCT03959345|Experimental|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
33052063|NCT03959345|Active Comparator|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
33052064|NCT03959306|Experimental|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
33052065|NCT03959306|Active Comparator|Group II|this group of patients will receive their standard anti-diabetic treatment only
33052066|NCT03959267|No Intervention|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
33052067|NCT03959267|Other|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
33052068|NCT04733612|Experimental|SMS Group|In addition to traditional treatment received three to four informative SMS messages per week during the 6-month period
33052069|NCT04733612|No Intervention|Control Group|Followed in accordance with the traditional treatment schedule
33052070|NCT03959228|No Intervention|referencial diet|0.8 g/kg/day of protein
33052071|NCT03959228|Experimental|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
33052072|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
33052073|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
33052074|NCT03959150|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
33052075|NCT03959150|No Intervention|Observation|Observation
33052076|NCT03958877|Experimental|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
33052077|NCT03958877|Active Comparator|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
33052078|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
33052079|NCT03958838|Experimental|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
33052080|NCT03958838|No Intervention|Control Group|Subjects in the control group will receive usual care from community health center staff.
33052081|NCT03958799|Experimental|Group 1: Investigational Product (IP) Formulation A|IP Formulation A administration, participation in Stage 1 and Stage 2
33052082|NCT03958799|Experimental|Group 2: IP Formulation A|IP Formulation A administration, participation in Stage 1
33052083|NCT03958799|Experimental|Group 3: IP Formulation B|IP Formulation B administration, participation in Stage 1 and Stage 2
33052084|NCT03958799|Experimental|Group 4: IP Formulation B|IP Formulation B administration, participation in Stage 1
33052085|NCT03958799|Experimental|Group 5: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
33052086|NCT03958799|Experimental|Group 6: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
33332134|NCT03979820|Active Comparator|Phenelzine/Phenelzine + Tyramine|
33332135|NCT03979820|Placebo Comparator|Placebo/Placebo + Tyramine|
33052087|NCT03958799|Experimental|Group 7: IP Formulation D|IP Formulation D administration, participation in Stage 1 and Stage 2
33052088|NCT03958799|Active Comparator|Group 8: Tdap|TdaP administration, participation in Stage 1 and Stage 2
33052089|NCT03958799|Active Comparator|Group 9: Tdap|TdaP administration, participation in Stage 1
33052090|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
33052091|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
33332136|NCT03647488|Experimental|Run-in part: capmatinib + spartalizumab|Participants (enrolled in the run-in part) were treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
33332137|NCT03647488|Experimental|Randomized part: capmatinib+spartalizumab|Participants (enrolled in the randomized part) treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
33332138|NCT03647488|Active Comparator|Randomized part: docetaxel|Participants (enrolled in the randomized part) treated with docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
33332139|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
33332140|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
33332141|NCT04110314|Active Comparator|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
33332142|NCT04110314|Active Comparator|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
33332143|NCT04110314|Active Comparator|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
33332144|NCT04110314|Active Comparator|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
32740339|NCT04491149|No Intervention|women undergoing amniocentesis/foeticide|
32740340|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
32740341|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
32740342|NCT03303833||Persons with Lynch syndrome|
32740343|NCT02468141|Experimental|SJDBT group|Herbal medicine
32740344|NCT02468141|Placebo Comparator|Placebo|Placebo control
32740345|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
32740346|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
32740347|NCT04491071||Volunteers|volunteers over 18 years of age
33052092|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
33052093|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
33052094|NCT03958721|Experimental|Concurrent Adjuvant Capecitabine and Radiotherapy|
33052095|NCT03958682|Experimental|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
33052096|NCT03958604|Experimental|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
33052097|NCT00395772|Active Comparator|Arm 4|
33052098|NCT00395772|Experimental|Arm 1|
33052099|NCT00395772|Experimental|Arm 2|
33052100|NCT00395772|Experimental|Arm 3|
33332145|NCT04110314|Active Comparator|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
33052103|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
33052104|NCT00395889|Active Comparator|Lifestyle Counseling|
33052105|NCT03958526|Active Comparator|Active|Active stimulation over M1
33052106|NCT03958526|Placebo Comparator|Sham|Sham stimulation over M1
33052107|NCT03958448|Experimental|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
33052108|NCT03958448|Experimental|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
33052109|NCT03958370||Fitbit|
33052110|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
33110808|NCT04670211||Tooth-borne distractor|Maxillary distraction with the use of a tooth-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
33052111|NCT03958292|Experimental|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
33052112|NCT03958253|Experimental|Lung Cancer Screening Toolbox|"WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.~During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
33332146|NCT04110314|No Intervention|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
33332147|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
33332148|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
33332149|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
33052113|NCT03958214|Experimental|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
33052114|NCT03958214|Active Comparator|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
33332150|NCT03483220||cases|patients with cannabis use disorder
33052115|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
33052116|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
33332151|NCT04109456|Experimental|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
33332152|NCT04109456|Experimental|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.~A modified 3+3 design will be used."
33332153|NCT04109456|Experimental|Part 3, Combination Arm|The safety and tolerability of IN10018 in combination with Cobimetinib and Atezolizumab will be assessed.
33052117|NCT03958136|Experimental|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
33052118|NCT03958136|Experimental|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
33332154|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
33332155|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
33332156|NCT04109222|Experimental|Group 1: Fluzone Quadrivalent Influenza vaccine: 6 to < 36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
33332157|NCT04109222|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to < 9 years|Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
33332158|NCT04109222|Experimental|Group 3: Fluzone High-Dose Influenza Vaccine: >= 65 years|Participants aged >=65 years received a of 0.5-mL dose of Fluzone high-dose vaccine, intramuscularly, at Day 0.
33052119|NCT03958136|Experimental|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
33052120|NCT03958097|Experimental|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10^9 .~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
33052121|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
33052122|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
33052123|NCT03934229|Experimental|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day
33052124|NCT03934229|Placebo Comparator|Group Placebo|Placebo
33052125|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
33052126|NCT03933059|Active Comparator|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
33052127|NCT03933059|Active Comparator|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
33052128|NCT03933059|Active Comparator|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
33052129|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
33052130|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
33052131|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
33052132|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
33052133|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
33052134|NCT01349816|Experimental|PT001|PT001 MDI
33052135|NCT01349816|Experimental|PT005|PT005 MDI
33052136|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
33052137|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
33052138|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
33052139|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
33052140|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
33052141|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
33052142|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
33052143|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
33052144|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
33052145|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
33052146|NCT03857945|Active Comparator|Mobility Device Training Group|Patients receiving preoperative mobility device(s) training before surgery
33052147|NCT03857945|No Intervention|No Mobility Device Training Group|Patients not receiving preoperative mobility device(s) training before surgery
33052148|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33052149|NCT03857087||Diagnostic 68Ga PSMA PET/MRI|Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
33052150|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
33052151|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
33052152|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
33052153|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
33052154|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
33052155|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
33052156|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
33052157|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
33332159|NCT04098458|Experimental|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
33052158|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
33052159|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
32740348|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
33052160|NCT03797456|Experimental|ICP-022|
33052161|NCT03779789|Experimental|vortioxetine|
33332160|NCT04128696|Experimental|Participants receiving feladilimab and pembrolizumab|Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 [IgG4] monoclonal antibody [mAb]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
33052162|NCT03779789|Active Comparator|SSRIs|
33052163|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 1|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
33332161|NCT04128696|Active Comparator|Participants receiving placebo and pembrolizumab|Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
33052164|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 2|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
33052165|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
33052166|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
33052167|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
33052168|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
33052169|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
33052170|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
33052171|NCT03698006|Experimental|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
33052172|NCT03698006|Active Comparator|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
33052173|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
33052174|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
33052175|NCT04711707|Experimental|Community navigator|This group is guided through the resources and provided bi-monthly support with a community navigator
33052176|NCT04711707|Other|Self-Navigation|This group receives the social needs resources to self-navigation
33052177|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
33052178|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
33052179|NCT04712448||Healthy subjects|Donors of the Transfusion Center of Venice Healthy volunteers afferent to BioBIM
33332162|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
33332163|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
33052180|NCT04712448||Patients|Patients with chronic diseases afferent to BioBIM
33052181|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
33052182|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
33052183|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
33052184|NCT04711863|Experimental|Fluvoxamine|Start fluvoxamine 50 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
33052185|NCT04711863|Placebo Comparator|Placebo|Start ursodeoxycholate (UDCA) 100 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
33052186|NCT04712058|Experimental|Same-day initiation with BIC/F/TAF|
33052187|NCT04711668|Experimental|Group Ketamin|0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively
33052188|NCT04711668|Experimental|Group Lidokain|1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively
33052189|NCT04711668|Placebo Comparator|Group Placebo|i.v. saline (in the same volume and duration like group ketamine/lidokain)
33052190|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 541 mg cocoa flavanols (75 mg epicatechin) and 315 g of milk (1% fat)
33052191|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
33332164|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
33052192|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
33052193|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
33052194|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
33052195|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin) and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
33052196|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin)
33052197|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
33052198|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
33052199|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 638 mg cocoa flavanols (88 mg epicatechin) Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
33052200|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
33052201|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
33052202|NCT03509909|Active Comparator|Supportive exercise|12-week group-based stretching and strengthening class
33052203|NCT03465449|Active Comparator|usual care|
33052204|NCT03465449|Experimental|CKD-EDU arm|
33052205|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
33052206|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
33052207|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
33052208|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
33052209|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=40) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) 12-pack of beer on passenger seat, or (2) 12-pack of sparkling water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
33052210|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
33052211|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
33052212|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
33052213|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
33052214|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
33052215|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
33052216|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
33052217|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
33052218|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
33052219|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
33052220|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
33052221|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
33052222|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
33052223|NCT03152240||Women patients|Women patients
33052224|NCT03152240||Men patients|Men patients
33052225|NCT00031395|Active Comparator|1|
33052226|NCT00031395|Active Comparator|2|
33332165|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
33332166|NCT03447262|Experimental|VX-659/TEZ/IVA TC|Participants from parent studies VX17-659-102 (NCT03447249) or VX17-659-103 (NCT03460990) were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study VX17-659-105.
33332167|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
33332168|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
33332169|NCT04092530|Experimental|Intervention - Aim 2|During the intervention period, staff will capture women during the first well-baby visit (WBV) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
33332170|NCT04092530|No Intervention|Control - Aim 2|Clinics will schedule postpartum contraception using normal clinic procedures.
33418736|NCT05677581||healthy women of childbearing age|
33418737|NCT01372969|Experimental|Cx601|
33052227|NCT00031395|Active Comparator|3|
33052228|NCT00031395|Placebo Comparator|4|
33052229|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
33052230|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
33052231|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
33052232|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
33052233|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
33052234|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33052235|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
33052236|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
33052237|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
33052238|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
33052239|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
33052240|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
33052241|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
33052242|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
33052243|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
33052244|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~Vaginal smear for evaluation with Gram's stain and Nuget's criteria~Vaginal swab for yeast culture~Vaginal swab for Trichomonas vaginalis NAAT~Vaginal swab for discrepant analysis testing"
33052245|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
33052246|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
33052247|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
33052248|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
33052249|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
33052250|NCT00031746|Active Comparator|soy protein + isoflavones|
33052251|NCT00031746|Active Comparator|casein proteins|
33052252|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
33052253|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
33052254|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
33052255|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
33052256|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
33052257|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
33332171|NCT04399356|Active Comparator|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally on day 1 and daily for 6 more days (total 7 days of treatment)
33052258|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
33052259|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
33052260|NCT03151655|Experimental|MATTeRS Video|
33052261|NCT03151655|Active Comparator|Didactic Video|
33052262|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
33052263|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
33052264|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
33052265|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
33052266|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
33052267|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
33332172|NCT04399356|Placebo Comparator|Control|Participants in the control group will receive identical-appearing placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment)
33332173|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
33332174|NCT03691428|Experimental|Intervention|
33332175|NCT03691428|Other|Wait-list|Participants will get the WOOP training after the last outcome assessment.
33332176|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
33110809|NCT04670211||Bone-borne distractor|Maxillary distraction with the use of a bone-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
33110810|NCT04670211||Hybrid distractor|Maxillary distraction with the use of a hybrid distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
33110811|NCT04322123|Experimental|Hydroxychloroquine|Hydroxychloroquine after randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 07 days.
33110812|NCT04322123|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 07 days.
33110813|NCT04322123|No Intervention|Control|standard treatment protocol for 2019-nCoV infection.
33110814|NCT04670328||Covid-19 disease severity|Mild, moderate, severe and critical disease
33110815|NCT04670367|Placebo Comparator|Arm A: usual care|routine usual care
33110816|NCT04670367|Experimental|Arm B: walk|walk 30mins per day, 5 days per week.
33110817|NCT04670367|Experimental|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
33110818|NCT04670367|Experimental|Arm D: Baduanjin plus walk|walk 30mins then Baduanjin 12 mins per day, 5 days per week.
33110819|NCT04313348|Active Comparator|Control Arm|Study participants in this arm will receive no SMS reminders nor social supporter notifications.
33110820|NCT04313348|Experimental|Intervention Arm 1|"Participants will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery at their preferred time and day of the week will be sent to study participants. The content of the SMS reminders will be customized and determined by each individual at enrollment. If the participant has no preference, we will suggest This is your ANC visit reminder, encouraging you to attend. This technology is already integrated and running in Uganda via the Yo! Uganda Gateway."
33110821|NCT04313348|Experimental|Intervention Arm 2|"Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of scheduled SMS arm above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the social support engagement arm). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do."
33110822|NCT04670289|Experimental|Treatment|TenoMiR intralesional injection
33110823|NCT04670289|Placebo Comparator|Placebo|0.9% saline intralesional injection
33110824|NCT04259138|Other|Symptomatic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission.
33110825|NCT04259138|Other|Symptomatic and endoscopic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.
33110826|NCT04259138|Other|Symptomatic, endoscopic and histological remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
33110827|NCT01741155|Experimental|Single Arm Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.
33110828|NCT01741155|Experimental|Randomized Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m^2 IV administered in 3-week cycles until progression or intolerable toxicity.
33110829|NCT01741155|Active Comparator|Randomized Part: Docetaxel|Patients will receive 75 mg/m^2 docetaxel in 3-week cycles until progression or intolerable toxicity.
33110830|NCT04244630|Other|Antioxidants|Eligible patients will receive over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses.
33110831|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
33110832|NCT04670406|Experimental|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
33110833|NCT04239053||ESPB block group|Patients receiving ESPB will be enrolled to this group.
33110834|NCT04670250||newly diagnosed patients with ulcerative colitis|patients who are newly diagnosed to have ulcerative colitis who are above 18 years old,not pregnant and not known to have cancer colon
33110835|NCT04119284|Experimental|Anterior Vertebral Tethering|Anterior Vertebral Tether Vertebral body tethering done through anterior spine surgery under anesthesia.
33110836|NCT00556179|Experimental|1|
33110837|NCT04116515|Active Comparator|Care Only|A third of the participants will have standard clinical care only.
33110838|NCT04116515|Experimental|Care + AVG|A third of the participants will have the same standard clinical care plus an Xbox and active games.
33110839|NCT04116515|Experimental|Care + AVG + Narratives|A third of the participants will have the same standard clinical care, an Xbox and active games, plus the stories delivered to their Xbox consoles.
33110840|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
33418738|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
33418739|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
33110841|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
33110842|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
33418740|NCT05706831|Experimental|Group 1|Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks.
33332177|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
33332178|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
33332179|NCT04091360|Experimental|RPL554 100 mcg|"Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler.~Part B: not applicable"
33332180|NCT04091360|Experimental|RPL554 300 mcg|Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
33332181|NCT04091360|Experimental|RPL554 1000 mcg|Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
33052268|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
33052269|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
33052270|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
33052271|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
33052272|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
33052273|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
33052274|NCT03151382|Experimental|Experimental group|
33052275|NCT03151382|Other|Control group|
33052276|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
33052277|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
33052278|NCT04712279|Active Comparator|Ivermectin 0.6mg/kg/day|
33052279|NCT04712279|Active Comparator|Ivermectin 1.0mg/kg/day|
33052280|NCT04712279|Placebo Comparator|Placebo|
33052281|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
33052282|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
33052283|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
33052284|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
33052285|NCT00032370|Other|1|Elective vascular surgery
33052286|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
33052287|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
33052288|NCT00393224||cohort|hospital based family cohort
33052289|NCT00032565||1|No intervention. Telephone interview.
33052290|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~San Rafael Petzal~San Sebastian Huehuetenango~San Gaspar Ixchil~Santa Bárbara~Colotenango~Aguacatán"
33052291|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~Tamahú~San Miguel Tucurú~Panzós~Senahú~Telemán"
33052292|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~San Idelfonso Ixtahuacán~La Democracia~San Juan Atitán~Tectitán~Santiago Chimaltenango"
33052293|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~Lanquín~Santa María Cahabón~Chisec~Chahal~Raxruhá~Campur"
33052294|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~Nenton~Jacaltenango~Todos Santos Cuchumatán~Santa Eulalia~San Mateo Ixtatán~San Juan Ixcoy"
33052295|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~Santa Cruz Verapaz~Tactic~San Pedro Carchá~San Juan Chamelco"
33052296|NCT04711941|Experimental|ToM training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
33052297|NCT04711941|Active Comparator|Non mentalistic training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
33052298|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
33052299|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
33052300|NCT00032643|Other|Arm 1|
33110843|NCT04687748|Experimental|EMG BF Group|Pelvic floor muscle contraction will be performed via an S-EMGBF device; patients in the s-EMGBF group will receive visual and auditory feedback.
33332182|NCT04091360|Experimental|RPL554 3000 mcg|"Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler.~Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion."
33332183|NCT04091360|Experimental|RPL554 6000 mcg|"Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler.~Part B: not applicable"
33332184|NCT04091360|Placebo Comparator|RPL554 Placebo|Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.
33332185|NCT04118166|Experimental|Ipilimumab/nivolumab + cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
33332186|NCT04346628|Experimental|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
33332187|NCT04346628|Active Comparator|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
33332188|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
33332189|NCT02450708||For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
33332190|NCT02450708||For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
33332191|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients."
33332192|NCT04343976|Experimental|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
33332193|NCT04343976|Placebo Comparator|Saline Placebo|Subcutaneous injection of saline placebo
33052301|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
33052302|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
33052303|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
33332194|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
33332195|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
33332196|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
33052304|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
33052305|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
33332197|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
33332198|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
33332199|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
33332200|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
33052306|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
33052307|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33110844|NCT04687748|Active Comparator|Control Group|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds.
33332201|NCT05755906|Experimental|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), BDI (320/19.2μg/day)
33332202|NCT05755906|Active Comparator|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
33332203|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
33332204|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
33332205|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
33110845|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
33110846|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
33418741|NCT05706831|Experimental|Group 2|Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks.
32871601|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33110847|NCT04687787|Experimental|Group I|This group will receive Core Stability Exercises with Application of TENS
33110848|NCT04687787|Active Comparator|Group II|This group will receive Routinely prescribed Exercises with application of TENS
33110849|NCT01712451|Experimental|LIPO-102, Low|
33110850|NCT01712451|Experimental|LIPO-102, Mid|
33110851|NCT01712451|Experimental|LIPO-102, High|
33110852|NCT01712451|Experimental|LIPO-102; Placebo|
33110853|NCT01712451|Experimental|salmeterol xinafoate|
33110854|NCT00541268|Experimental|A - ICD implantation|Heart Failure nonischemic etiology treated by optimal medical treatment and receiving a prophylactic ICD
33110855|NCT00541268|Active Comparator|B - control|Heart Failure nonischemic etiology treated by optimal medical treatment
33110856|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
33110857|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
33110858|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
33110859|NCT04046237|No Intervention|Usual treatment - Control group|"The patient is referred to his treating dentist with a diagnosis report of his oral state including his periodontal status.~The usual care usually includes the extraction of non-preservable teeth, the dental prosthesis to replace them and at least one descaling session."
33110860|NCT04046237|Experimental|Periodontal treatment - Intervention group|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit at M9.~Briefly, the intervention group includes initial therapy with information on oral hygiene techniques, scaling and surfacing of dental roots. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
33110861|NCT00555243|Experimental|1|Laparoscopic Simulation Education
33110862|NCT00555243|Placebo Comparator|2|
33110863|NCT04014764||Single group|"Documented hematologic malignancy in need of starting an active anti-cancer therapy.~This is a non-interventional study."
33110864|NCT04669158|Experimental|Idebenone|Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
33110865|NCT04669158|Placebo Comparator|Placebo|Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
33110866|NCT04669821|Experimental|HSK3486|
33110867|NCT04669821|Active Comparator|Propofol|
33110868|NCT04670055|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
33110869|NCT00532025|Experimental|1|Sorafenib treatment
33332206|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
33332207|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
33332208|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
33418742|NCT05706831|Experimental|Group 3|Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks.
33418743|NCT05063929|Experimental|Fruits|Participants will receive 2 cup eq fruits per day
33418744|NCT05063929|Other|Fruit restriction|Participants will receive 1/2 cup eq fruits per day
33110872|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins
33332209|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
33332210|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
33332211|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
33332212|NCT05753644|Experimental|SGB group|The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.
33052308|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33052309|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33332213|NCT05753644|Placebo Comparator|control group|The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.
33332214|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
33332215|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
33332216|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
33052310|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33052311|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33052312|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
33052313|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
33052314|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
33332217|NCT04334460|Active Comparator|Active (BLD-2660) Group|
33332218|NCT04334460|Placebo Comparator|Placebo Group|
33052315|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
33052316|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
33052317|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
33052318|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
33052319|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
33052320|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
33332219|NCT01935466||Pioglitazone|Ever users of Pioglitazone
33332220|NCT01935466||Other drugs|Never users of pioglitazone
33332221|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 to 2 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include ~10 to 15 patients, and friends and family members are encouraged to attend. Intervention sessions consist of 30-min to 60-min of behavior change activities and 60-min focused on healthy behaviors."
33332222|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
33332223|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
33332224|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
33332225|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
33332226|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
33332227|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
33332228|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
33332229|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
33332230|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
33332231|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
32871602|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33332232|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
33418745|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
32871603|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33052321|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
33052322|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
33052323|NCT00396435|Experimental|Group A|High Hb target
33052324|NCT00396435|Active Comparator|Group B|Low Hb Target
33052325|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
33052326|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
33052327|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
33052328|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
33052329|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
33052330|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
33052331|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
33052332|NCT03150368|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
33052333|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
33052334|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
33052335|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
33052336|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
33052337|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
33052338|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
33052339|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
33052340|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
33052341|NCT03150212|Placebo Comparator|Placebo|
33052342|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
33052343|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
33052344|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
33052345|NCT03110978|Experimental|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
33052346|NCT03110978|Experimental|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
33052347|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
33052348|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
33052349|NCT00033306|Experimental|BMS-247550|
33052350|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
33052351|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
33332233|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
33418746|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
33418747|NCT05220501|Active Comparator|Micro-US Only|Subjects will undergo biopsy using micro-ultrasound only.
33418748|NCT05220501|Active Comparator|mpMRI + Micro-US|Subjects will undergo fusion biopsy using mpMRI and micro-ultrasound
33418749|NCT05220501|Active Comparator|mpMRI Only|Subjects will undergo biopsy using mpMRI fused with regular ultrasound
33052352|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:~necrotizing enterocolitis (stage ≥2)~spontaneous intestinal perforation~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
33052353|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
33418750|NCT05011201|Experimental|Experimental Group|Participants will undergo a single testing session of gait retraining using two variants of the dual joint visual feedback system (DJVF). The DJVF system uses IMU sensors to measure knee and hip joint motions and calculates the users foot position, relative to their pelvis. The relative foot position is represented in real time on a screen in front of the user with feedback designed to elicit increases in anteriorly located foot positions.
33418751|NCT02110316|Other|Bioavailability|1 arm, different dosage form
33418752|NCT05625087|Experimental|ALPELISIB ARM|Oral alpelisib (300 mg daily, in 28-day cycle) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice
33418753|NCT05625087|Active Comparator|RIBOCICLIB ARM|Oral ribociclib (600 mg daily, 3 weeks on, then 1 week off treatment in 28-day cycles) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice.
33418754|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
33418755|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
33418756|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
33052356|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
33052357|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
33052358|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
33052359|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
33052360|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
33052361|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
33052362|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
33052363|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
33052364|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
33052365|NCT02804087|Experimental|MobiusHD Implantation|
33052366|NCT02804087|Sham Comparator|Sham Implantation|Sham
33052367|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
33052368|NCT00393263|Experimental|1|pimecrolimus
33052369|NCT00393263|Active Comparator|2|clobetasol
33052370|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33052371|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33052372|NCT02723708|Experimental|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
33418757|NCT05220267|Other|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle) .Sintilimab was administered intravenously (200mg once every 3weeks).
33418758|NCT02110394||bendamustine and rituximab|
33418759|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
33418760|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
33418761|NCT03052959|Experimental|Immediate Intervention|
33418762|NCT03052959|Other|Wait List Intervention|
33418763|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years~none of the following contraindications for Methylprednisolone:~Allergy against Methylprednisolone.~Currently in systemic treatment with glucocorticoid~Current gastric ulcer~Insulin dependent diabetes mellitus~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
33418764|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment~age >17 years, Danish social security number~and none of the following at time of surgery:~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
33418765|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
33052373|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
33052374|NCT02548559|Experimental|Full-Spectrum Cannabidiol|1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
33332234|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
33332235|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
33332236|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
33332237|NCT03064438|Experimental|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
33332238|NCT03064438|Placebo Comparator|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
33052375|NCT02548559|Experimental|Single-Compound Cannabidiol|1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
33052376|NCT02548559|Placebo Comparator|Placebo|1 ml of placebo solution administered three times per day (TID) for four weeks.
33332239|NCT04327986|Experimental|Cohort 1 Phase 1A/Arm 1A|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824)
33332240|NCT04327986|Experimental|Cohort 2 Phase 1B/Arm 1B|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824) and stereotactic body radiotherapy (SBRT)
33332241|NCT04327986|Experimental|Phase II Cohort 3/Arm 2|Recommended phase 2 dose (RP2D) of bintrafusp alfa (M7824) and NHS-IL12 (M9241) in combination with stereotactic body radiotherapy (SBRT)
33418766|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
33418767|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
33052377|NCT00033735|Experimental|fluorouracil|
33052378|NCT00033735|Experimental|Irofulven|
33052381|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates~Prospective cohort group: HIV testing rates"
33052382|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
33052383|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
33052384|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
33052385|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
33052386|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
33052387|NCT02149823|Active Comparator|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
33052388|NCT02149823|Active Comparator|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
33052389|NCT02149823|Active Comparator|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
33332242|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 1|PD patients treated by Dopamine replacement therapy, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
33332243|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 2|PD patients treated by Deep Brain Stimulation, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
33332244|NCT05209516|Active Comparator|Healthy individuals|Healthy participants, aged between 18 and 85, will be recruited as control subjects by means of ads posting.
33332245|NCT05209204||40 pateint glucoma suspect|ASOCT
33332246|NCT05209048||VTE of Derivation group|VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and developed VTE within 30 days after operation
33332247|NCT05209048||No-VTE of Derivation group|No-VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and did not develop VTE within 30 days after surgery or after 30 days
33332248|NCT05209048||VTE of Validation group|VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and developed VTE within 30 days after operation
33110873|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and placebo|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo
33110874|NCT04669119|Placebo Comparator|Placebo|Patients treated post-operatively for 30 days with placebo
33110875|NCT04669080|Other|Cost navigation training intervention|
33110876|NCT03954080|Experimental|ISS|
33110877|NCT04669353|Active Comparator|Platelet Rich Plasma|In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
33110878|NCT04669353|No Intervention|control group|In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure
33110879|NCT04669275|Experimental|telephone counseling|People receiving telephone counselling.
33110880|NCT04669275|Experimental|telephone counselin|People receiving telephone counselling.
33110881|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
33110882|NCT04669977|Experimental|Auxiliary|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. They are expected to finish the mulberry juice in 10 to 11 days. Measurements of clinical symptoms and blood sampling are conducted on day 1 of every other week for 5 weeks. If clinical measurements or blood extractions fail or miss, a substitute assessment or blood sample will be obtained on day 2 or day 3. The research period for these participants is 29 days (4 weeks). The checkpoints are arranged because patients with oxaliplatin treatment visit the clinic every two weeks, and patients with paclitaxel treatment visit the clinic every week. For patients having docetaxel therapy, the research period is 43 days (6 weeks) because docetaxel is administered every three weeks.
33110883|NCT04669977|No Intervention|Non-auxiliary|For the non-auxiliary group (control group), patients are informed of their allocation results and they will not consume mulberry juice during the research period but will receive the mulberry juice after the research period.
33110884|NCT04668807|Experimental|Connected Medical Device|"SMART ANGEL Intra-hospital System 's Connected Medical Device (DMC) measuring physiological parameters in the operating room"
33110885|NCT04668807|Active Comparator|Traditional system|Traditional wired transmission system between the sensor and the data processing device in the operating room
33110886|NCT03849248|Experimental|Intervention|This group of babies will have a maternal scented cloth placed under their heads
33110887|NCT03849248|No Intervention|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
33110888|NCT04669392|Experimental|70% Ethanol|Using 70% Ethanol Alcohol as a root canal irrigating solution before obturating the lower primary second molar with Metapex
33110889|NCT04669392|No Intervention|Normal Saline|Irrigating the canals with Normal Saline before obturating the lower primary second molar with Metapex
33110890|NCT04668963|Experimental|INTENSIVE MIRROR THERAPY|The intensive therapy group participants received 5 Mirror Therapy (+physiotherapy) sessions /week for 6 weeks, which makes a total of 30 sessions.
33110891|NCT04668963|Active Comparator|SPACED OVER TIME MIRROR THERAPY|The conventional therapy group received the same number of sessions but more spaced in time, consisting in 3 Mirror Therapy (+physiotherapy) sessions/week for 10 weeks.
33110892|NCT04865627||independent walking with walking aid|the participant is able to walk with a walking aid and does not need further assistance.
33332249|NCT05209048||No-VTE of Validation group|No-VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and did not develop VTE within 30 days after surgery or after 30 days
32871604|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33110893|NCT04865627||dependent walking with walking aid|the participant is able to walk with assistance and a walking aid
33418768|NCT05603169|Active Comparator|High Intensity Resistance Training|This group will perform high intensity resistance training under supervised physiotherapist in a gym setting. The training load for the first 2 weeks will be 60%-75% of 1RM and increased to 75%-90% of 1RM the following weeks. Load would be increased if the participants will be able to perform 3 sets of 12 repetitions with that load.
33110894|NCT04775264|Experimental|Pulsed Electric Field Energy Ablation|ablation of ganglionated plexi structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery to eliminate atrial fibrillation
33110895|NCT04669509||Group 1|Patients with normal ALT, AST and total bilirubin values
33110896|NCT04669509||Group 2|Patients whose ALT, AST or total bilirubin levels are up to 3 times upper limit of normal
33110897|NCT04669509||Group 3|Patients whose ALT, AST or total bilirubin levels are increased more than 3 times upper limit of normal
33110898|NCT04757753|Experimental|ready-to-use root canal sealer: PA1704|PA1704 is used in combination with gutta percha points for the permanent obturation of root canals.
33110899|NCT04757753|Other|root canal sealer: BioRoot™ RCS|BioRoot™ RCS is used in combination with gutta percha points for the permanent obturation of root canals.
33110900|NCT04669626|Other|Group 2|Wound cleansing with NaCl (natrium chlorid) solution 0.9%
33110901|NCT04669626|Experimental|Group 1|Wound cleansing with Octenilin®
33110902|NCT04749641|Experimental|Open surgical biopsy|A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.
33110903|NCT04749641|Experimental|Stereotactic biopsy|A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.
33110904|NCT04669470|Active Comparator|Group with adjustable IGB|
33110905|NCT04669470|Active Comparator|Group with nin-adjustable IGB|
32740349|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
33052390|NCT02149823|Active Comparator|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
33052391|NCT02149823|Active Comparator|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
33052392|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
33052393|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
33052394|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
33052395|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
33052396|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
33052397|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
33052398|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
33052399|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
33052400|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
33052401|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
33052402|NCT01807364||controls|control patients
33052403|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
33052404|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
33052405|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
33052406|NCT00034281|Experimental|TAK-165 QD|
33052407|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
33052408|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
33052409|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
33052410|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
33052411|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
33052412|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
33052413|NCT04712045|Experimental|New PPE|Use of Short sleeve gown and single pair of gloves
33052414|NCT04712045|Active Comparator|Old PPE|Use of Long sleeve gown and double pairs of gloves
33052415|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
33052416|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
33052417|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
33052418|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
33052419|NCT01807091|Experimental|Treatment (chemotherapy)|Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.
33052420|NCT00034554|Experimental|1|0.1mg
33052421|NCT00034554|Experimental|2|0.5mg
33052422|NCT00034554|Experimental|3|2.0mg
33052423|NCT00034554|Experimental|4|4.0mg
33052424|NCT00034554|Experimental|5|8.0mg
33052425|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
33052426|NCT00393341||Case|Women with breast cancer
33052427|NCT00393341||Control|Women without breast cancer
33052428|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
33052429|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
33110906|NCT04738760||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with standard dose vitamin D in addition to standard COVID-19 management.
32740350|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
32740351|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
32740352|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
33052430|NCT01806935|Experimental|DC086|cream
33052431|NCT01806935|Placebo Comparator|placebo|
33052432|NCT01806857|Other|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
33052433|NCT01806857|Other|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
33052434|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
33052435|NCT01806818|Experimental|Epirisone 50mg TID|
33052436|NCT01806818|Placebo Comparator|Placebo comparator|
33052437|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
33052438|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
33052439|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
33052440|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
33052441|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
33052442|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
33052443|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
33052444|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
33052445|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
33052446|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
33052447|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
33052448|NCT01806233|Experimental|Acupuncture|acupuncture
33052449|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
33052450|NCT00035100|Experimental|EPO906|
33052451|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
33052452|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
33052453|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
33052454|NCT01806155||Craniotomy|Patient undergoing major craniotomy
33052455|NCT01806116|Experimental|decitabine + transplantation|
33052456|NCT01806077|Experimental|PZ-128|
33052457|NCT00035451|Placebo Comparator|1|placebo tablets
33052458|NCT00035451|Active Comparator|2|Sotalol
33052459|NCT00035451|Experimental|3|azimilide
33110907|NCT04738760||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with high dose vitamin Din addition to standard COVID-19 management.
33110908|NCT04669431|Experimental|Xbox kinect Training|X Box Games include Tennis Playing, Joy riding, Rally ball.
33110909|NCT04669431|Active Comparator|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living
33110910|NCT04668612|Active Comparator|Standard-bolus|Standard boluses for all meal
33110911|NCT04668612|Experimental|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m
33110912|NCT04668924|Experimental|Epi-on PiXL in high oxygen|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
33110913|NCT04732676|Experimental|Experimental group|participants will receive and use during 4 weeks the full interventional version of the smartphone application (combining EMA + EMI) targeting craving and personal situations at risk for use
33418769|NCT05603169|Active Comparator|High Intensity Aerobic Training|This group will perform aerobic training under supervision of a physical therapist in gym setting. To calculate exercise intensity, the HR will be maintained at 75-90% of the maximum (HRmax). The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
33418770|NCT05059639|Experimental|Almond (2 ounces)|Consume 2 ounces almond daily for 8 weeks
33418771|NCT05059639|Active Comparator|Pretzel|Consume comparative amount of pretzel for 8 weeks
33110914|NCT04732676|Placebo Comparator|control group|: participants will receive and use a restricted version of the smartphone application (only EMA: 4 electronic questionnaires per day to assess main problematic substance use / addictive behavior) during 4 weeks
33110915|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
33110916|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
33110917|NCT00556296|Experimental|1|
33110918|NCT00556296|Experimental|2|
33110919|NCT00556296|Experimental|3|
33110920|NCT00556296|Placebo Comparator|4|
33110921|NCT04709003||vaccinated|participants who received the Covid-19 vaccine
33110922|NCT04709003||unvaccinated|participants who didn't received the Covid-19 vaccine
33110923|NCT00556335|Experimental|manual aspiration|manual aspiration
33110924|NCT00556335|Active Comparator|conventional drainage|conventional drainage
33110925|NCT04668456|Placebo Comparator|Group C (control group)|Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
33110926|NCT04668456|Active Comparator|Group SD (subtenon dexmedetomiine)|Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
33110927|NCT04668456|Active Comparator|Group ID (iv dexmedetomidine)|Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.
33110928|NCT04693169|Experimental|[Al18F]PSMA137 PET/CT imaging|All study participants will be allocated to this arm (single-arm study).Study participants will undergo [Al18F]PSMA137 PET/CT scans.
33110929|NCT04668417|Active Comparator|Reminders with direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with a link enabling direct scheduling
33110930|NCT04668417|Active Comparator|Reminders with no direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with no direct scheduling link
33110931|NCT04686968|Experimental|Greenhouse group|Patients underwent greenhouse technique：The high-strength suture was passed through the tendon using Mason-Allen method, and then Crimson duvet procedure was performed on the foot print area from the articular surface of the humeral head to the apex of the greater tubercle. Immediately after this procedure, a lateral row anchor was used.
33418772|NCT05706675|Experimental|Experimental|Periodontitis patients that will be treatyed with Non surgical Periodontal Therapy
33418773|NCT05706675|No Intervention|Control|Periodontally healthy patients
33418774|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
33418775|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
33418776|NCT05656131|Experimental|fluzoparib|Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.
33110932|NCT04686968|Active Comparator|Vent group|The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
33110933|NCT00556413|Experimental|ERBIRINOX|5FU + Irinotecan + Oxaliplatine + Cetuximab
33110934|NCT04687085|Placebo Comparator|Neutral Content|Participants will listen to a 10 minute neutral content recording just prior to epidural catheter placement.
33110935|NCT04687085|Experimental|Mindful Meditation|Participants will listen to a 10 minute mindful meditation recording just prior to epidural catheter placement.
33110936|NCT04668573|Experimental|Trunk exercise group|Participants received trunk exercise for 30 minutes per session, twice a week for 12 weeks.
33110937|NCT04668573|No Intervention|Control group|Participants remained their regular activities.
33110938|NCT04686695|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation|
33110939|NCT04668651||diabetic|diabetic patients
33110940|NCT04668651||non diabetic|non-diabetic patients
33418777|NCT05656131|Experimental|fluzoparib+Camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
33110942|NCT04668690|Experimental|Experimental: Mitoxantrone Hydrochloride Liposome Injection|Patients with relapsed/refractory PTCL will receive Mitoxantrone Hydrochloride Liposome Injection every 28 days (a cycle) for a maximum of 8 cycles. The dose of Mitoxantrone Hydrochloride Liposome Injection is 20 mg/m2.
33418778|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
33418779|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
33418780|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
33418781|NCT05220189||Hematuria patients aged ≥40|Device: EarlyTect Bladder Cancer test, PENK methylation assay by LTE (Linear Target Enrichment)-qMSP (quantitative methylation-specific real time PCR)
33052460|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
33052461|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
33052462|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
33052463|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
33052464|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
33052465|NCT00035490|Placebo Comparator|1|Placebo tablets
33052466|NCT00035490|Experimental|2|75 mg azimilide
33052467|NCT00035490|Experimental|3|125 mg azimilide
33418782|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
33052468|NCT00035607|Active Comparator|Darbepoetin alfa SC|
33052469|NCT00035607|Experimental|Darbepoetin alfa IV|
33052470|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
33052471|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
33052472|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
33052473|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
33052474|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
33052475|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
33052476|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
33052477|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
33052478|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
33052479|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
33052480|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
33052481|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
33052482|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
33052483|NCT01805882|Experimental|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
33110943|NCT04668690|Active Comparator|Active Comparator: Chidamide|Patients with relapsed/refractory PTCL will receive Chidamide 30 mg p.o., twice per week until disease progression.
33332250|NCT05208658|Experimental|Classical Vision Therapy Treatment: vision therapy exercises for fusional vergence abilities|"The Experimental Group (EG) it consist in a Classical Vision Therapy Treatment. This group will do weekly office-based therapy of 45 minutes of visual exercises during 12 weeks. The office-based done by the EG consists of a vergence therapy and its protocol will follow Scheiman's Protocol and Indications.~The exercises do not tough the eye or use drugs. They are just visual training exercises that improve fusional convergence and divergence response."
33052484|NCT01805882|Experimental|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
33361266|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
33361267|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
33361268|NCT05401591|Active Comparator|Milk protein|
33361269|NCT05401591|Experimental|Whole cell chlorella|
33418783|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
33361270|NCT05401591|Experimental|Cracked cell chlorella|
33361271|NCT05401591|Experimental|Spirulina|
33110944|NCT04645628|Experimental|All subjects will have an MRI examination|
33052485|NCT01805882|Experimental|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
33110945|NCT04668534|Experimental|Treatment group 1|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
33110946|NCT04668534|Experimental|Treatment group 2|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
33110947|NCT04668534|Active Comparator|Control group|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
33110948|NCT04629326|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
33110949|NCT04668495||Cangrelor Group|This is the study cohort that the blood sample will be obtained from. There are no interventions
33110950|NCT04622813|Placebo Comparator|Placebo group|
33110951|NCT04622813|Experimental|Multimodal group|
33418784|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
33418785|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
33110952|NCT04658979|Experimental|Intervention group|
33110953|NCT04593992|Experimental|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
33418786|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
33418787|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
33110954|NCT04593992|Placebo Comparator|Placebo|Placebo stimulation 5 times within a week for 12 weeks
33418788|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
33418789|NCT02110550|No Intervention|IPS.emmax crown|
33418790|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
33418791|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
33110956|NCT04668729|No Intervention|Control group|20 people will be included in the control group. 3 measurements will be taken one week apart in total. Measurements will consist of maximum isometric muscle strength, lumbar range of motion, balance performance, and pain intensity. And it will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD) and Modified Schober test, flamingo balance test, and visual analog scale.
33110957|NCT04668729|Experimental|Chiropractic group|20 people will be included in the experimental group. Lumbal chiropractic HVLA (High Velocity, Low amplitude: HVLA) spinal manipulation and sacroiliac joint chiropractic HVLA manipulation will be applied 3 times in total with a weekly interval. The maximum isometric muscle strength before and immediately after the application, lumbar joint range of motion, balance performance, and pain intensity will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD), and Modified Schober test, flamingo balance test, and visual analog scale.
33418792|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
33418793|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
33418794|NCT01845649|Active Comparator|Vehicle (3 Times/Week)|Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.
33418795|NCT01845649|Experimental|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.
33418796|NCT03554252|Experimental|Frequencies|
33418797|NCT03554252|Experimental|Percentages|
33418798|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
33418799|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
33418800|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
33052486|NCT01805882|Experimental|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
33052487|NCT01805882|Experimental|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
33418801|NCT01825291||sleep apnea|
33110958|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
33110959|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
33332251|NCT05208658|Placebo Comparator|Eye Movement Therapy Treatment: vision therapy placebo exercises not improve fusional vergence|"The Control Group or Placebo Group consist in a Control: Eye Movement Therapy Treatment. This group will do weekly office-based placebo therapy of 15 minutes during 12 weeks of visual exercises. This placebo therapy will consist of smooth-pursuit and discrimination exercises that do not influence vergence response.~The exercises do not tough the eye nor use drugs. They are just visual training exercises that do not improve fusional vergence response as they improve smooth-pursuit eye movements."
33110960|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
32740353|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
33110961|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
33110962|NCT04585100|Experimental|Phase 2a|
33110963|NCT04668378|Experimental|Time restricted eating (TRE) - two month|partecipants underwent 2 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
33110964|NCT04668378|Active Comparator|Normal Diet (ND) - two month|partecipants underwent 2 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
33110965|NCT04668378|Experimental|Time restricted eating (TRE) - twelve month|partecipants underwent 12 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
33110966|NCT04668378|Active Comparator|Normal Diet (ND) - twelve month|partecipants underwent 12 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
33110967|NCT04562441|Experimental|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
33110968|NCT04668222|Experimental|Deficiency of Qi and Yang (QYang-group)|Participants will receive Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
33110969|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yang (PQYang-group)|The placebo is made of 5% Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
33110970|NCT04668222|Experimental|Deficiency of Qi and Yin (QYin-group)|Participants will receive Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
33110971|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yin (PQYin-group)|The placebo is made of 5% Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
33110972|NCT04560140|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
33110973|NCT04560140|No Intervention|Usual care group|Participants will receive usual stroke care.
33110974|NCT04547309|Experimental|68Ga/18F-HER2 Affibody PET/CT scan|
32740354|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
33110975|NCT04659057|Active Comparator|Group L|Lidocaine group; 45 randomly assigned patients.
33110976|NCT04659057|Active Comparator|Group D|Demedetomidine group; 45 randomly assigned patients.
33110977|NCT04659057|Active Comparator|Group DL|Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.
33110978|NCT04659057|Placebo Comparator|Group C|Control group; 45 randomly assigned patients.
33110979|NCT04547153|Experimental|LD-FUD|5-Fu 200mg/m2/day continuously days 1-21 ; Docetaxel 25mg/m2, days 1, 8 and 15; Repeated every four weeks.
33110980|NCT04668261||Neurosurgical patients|"• Neurosurgical diseases with the potential to alter blood flow to the brain:~Cerebrovascular disease~Brain tumors~Normal Pressure Hydrocephalus"
33332252|NCT05208502||BIS|All inclusions will receive the general anesthesia with BIS monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the EEG monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
33110981|NCT04668261||Healthy subjects|"Male and Female subjects >18 years of age~Written Informed Consent by the participant after information about the project. Foreign speaking healthy subjects should be accompanied by a person with sufficient German language proficiency to act as a translator"
33110982|NCT04658745|Experimental|iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
33332253|NCT05208502||DSA|All inclusions will receive the general anesthesia with SedLine monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the DSA monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
33332254|NCT04322682|Active Comparator|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
33332255|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
33052488|NCT01805882|Experimental|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
33052489|NCT01805882|Experimental|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
33052490|NCT01805882|Experimental|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
33052491|NCT01805882|Experimental|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
33052492|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
33052493|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
33052494|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
33052495|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
33052496|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
33052497|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
33052498|NCT04732377|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
33052499|NCT04732377|Active Comparator|Group (D)|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
33052500|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
33052501|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
33052502|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
33052503|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
33052504|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
33052505|NCT01805687|Other|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
33052506|NCT01805648|Experimental|rhTPO|Active investigational product
33052507|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
33052508|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
33052509|NCT01805531||Rivaroxaban|
33052510|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
33052511|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
33052512|NCT04732611|Experimental|Pilates|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
33052513|NCT04732611|Active Comparator|Walking|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks
33052514|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
33052515|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
33052516|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
33052517|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
33052518|NCT01788917|Experimental|Vegetarians|Dietary supplement: 10 mL linseed oil per day
33052519|NCT01788917|Placebo Comparator|Omnivores|Dietary supplement: 10 mL linseed oil per day
33332256|NCT05743582||COPD patients|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
33332257|NCT05743582||Healthy controls - smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
33332258|NCT05743582||Healthy controls - non-smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
33332259|NCT05207878|Experimental|Movement task|"All participants perform the STEGA-MRI (standardized tracing evaluation & grapheme assessment - MRI) precision drawing task during fMRI scanning.~Motor assessments outside the MRI do not qualify as interventions."
33332260|NCT04000672|Active Comparator|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
33332261|NCT04000672|Experimental|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
33332262|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
33052520|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
33052521|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
33052522|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
33332263|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
33332264|NCT05207800||healthy pregnant woman|healthy pregnant woman
33332265|NCT05207800||pregnant women with TPROM|pregnant women with term premature rupture of membranes
33052523|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
33052524|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
33052525|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
33052526|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
33052527|NCT01466543|Placebo Comparator|Placebo|placebo medication
33052528|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
33052529|NCT01466465|Experimental|Vigantol|
33052530|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
33052531|NCT01466426||DVT confirmed|
33052532|NCT01466426||DVT ruled out|
33052533|NCT01466426||PE confirmed|
33052534|NCT01466426||PE ruled out|
33052535|NCT01466309|Experimental|treatment|patients treated with Somnoguard
33052536|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
33052537|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
33052538|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
33052539|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33052540|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
33052541|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
33052542|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
33052543|NCT01466036|Experimental|Metastatic or Unresectable PNET|35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
33052544|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
33052545|NCT01465919|Experimental|mirtazapine|mirtazapine
33052546|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
33052547|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
33052548|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
33052549|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
33052550|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
33052551|NCT01465841|Experimental|Embolization with the PC 400 coils|
33052552|NCT01465724|Experimental|Renal denervation|
33332266|NCT05207800||pregnant women with PPROM|pregnant women with preterm premature rupture of membranes
33332267|NCT05743036|Experimental|Dose Escalation|Participants will receive different doses of ZN-c3 in combination with different doses of Encorafenib and a fixed dose of Cetuximab
33332268|NCT05743036|Experimental|Dose Expansion|Participants will receive recommended dose of ZN-c3 and encorafenib as determined in dose escalation phase in combination with cetuximab
33332269|NCT04115358|Experimental|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
33332270|NCT04115358|Active Comparator|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
33332271|NCT04115358|Active Comparator|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
33332272|NCT05741788|Experimental|Experimental group|Prospective cohort of patients clinically scheduled to undergo spinal cord stimulation for the treatment of chronic back pain or radiculopathy.
33332273|NCT05207332|Experimental|Vegan product|
33332274|NCT05207332|Active Comparator|Control|
33332275|NCT05741710|Experimental|Methylone|
33332276|NCT05741710|Placebo Comparator|Placebo|
33332277|NCT05207176|Experimental|DWP16001|Total number of subjects: 24 (8 Korean, 8 Caucasian, and 8 Hispanic)
33332278|NCT03628690|Experimental|BandGrip|Topical skin closure device
33332279|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
33052553|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
33052554|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
33332280|NCT05668884|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
33052555|NCT01465646|Active Comparator|with idodine|
33052556|NCT01465646|Experimental|without iodine|
33052557|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
33052558|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
33052559|NCT01465568|Active Comparator|Denosumab|denosumab
33052560|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
33052561|NCT01465529|Experimental|Active|
33052562|NCT01465529|Placebo Comparator|Placebo|
33052563|NCT01465490|Experimental|Monitoring and Feedback Intervention|
33052564|NCT01465490|No Intervention|Treatment as usual|
33052565|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
33052566|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
33052567|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
33052568|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
33052569|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
33052570|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
33052571|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
33052572|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
33052573|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
33052574|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
33052575|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
33052576|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
33052577|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
33052578|NCT01465217|Experimental|text message medication reminders|
33052579|NCT01465217|No Intervention|control|
33332281|NCT05187208|Experimental|Experimental|BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients (high-grade serous or high-grade endoemtrioid)
33332282|NCT04109118|Other|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
33332283|NCT03619954|Experimental|NK cells infusion|
33332284|NCT05081206|Experimental|Manually controlled|
33332285|NCT05081206|Experimental|Target controlled|
33332286|NCT05063032|Experimental|High-density mapping guided ablation|High-density map and return-cycles map in order to localize the protected isthmus with precision for focal/minimal ablation.
33332287|NCT05063032|Active Comparator|Empirical linear ablation|Empirical predefined set of linear ablation.
33332288|NCT04105998|Experimental|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
33332289|NCT04105998|Experimental|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
33052580|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
33052581|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
33052582|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
33052583|NCT00396552|Experimental|1|
33052584|NCT00396552|Sham Comparator|2|
33052585|NCT01465061||Online support user|
33052586|NCT01464983|Active Comparator|Arm 1|
33052587|NCT01464983|Experimental|Arm 2|
33052588|NCT01464983|Active Comparator|Arm 3|
33052589|NCT01464983|Active Comparator|Arm 4|
33052590|NCT01464983|Placebo Comparator|Arm 5|
33052591|NCT01464944|Experimental|Arm 2|
33052592|NCT01464944|Active Comparator|Arm 3|
33052593|NCT01464944|Active Comparator|Arm 4|
33052594|NCT01464944|Placebo Comparator|Arm 5|
33052595|NCT01464944|Experimental|Arm 1|
33052596|NCT01464905|Experimental|NU100|
33052597|NCT01464905|Placebo Comparator|Placebo|
33332290|NCT05008822|Experimental|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
33052598|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
33052599|NCT00037635|Experimental|AMG 073|
33052600|NCT00037635|Placebo Comparator|placebo|
33052601|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
33052602|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
33332291|NCT05008822|Active Comparator|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
33052603|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
33332292|NCT05734690|Experimental|Medication & Education-First|Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
33332293|NCT05734690|Active Comparator|Education-First|Patient will first receive curated patient education, an alert to providers, and provider education, and then after 3 months begin participation in the remote heart failure clinic.
33052604|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
33052605|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
33052606|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~intolerable toxicity precluding further treatment progression of disease~patient refusal~occurrence of pregnancy"
33052607|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
33052608|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
33052609|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
33052610|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
33052611|NCT01464632||Primary|Post Market Study
33052612|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
33052613|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
33052614|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
33052615|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
33052616|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
33052617|NCT00037986|Other|1|
33052618|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
33052619|NCT00393770|Experimental|L-acetylcarnitine|
33052620|NCT00038064|Active Comparator|rHuEPO|
33052621|NCT00038064|Experimental|Darbepoetin alfa|
33332294|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
33332295|NCT04913116||SARS-Cov-2 positives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
33332296|NCT04913116||SARS-CoV-2 negatives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
33332297|NCT04902898|Other|Circumcision|Adult patients treated with circumcision
33332298|NCT04902898|Active Comparator|Circumcision with device|Adult patients treated with sterile single-use circular stapling device CIRCCURERII (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
33332299|NCT04900714|Experimental|Decremental PEEP|Every participant will be exposed to a stepwise decremental PEEP.
33052622|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
33052623|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
33332300|NCT04690192|Experimental|CNCT19 following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10^6/kg) will be infused in a single-dose on day +2, +3 or +4.
33052624|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
33052625|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
33052626|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
33052627|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
33052628|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
33052629|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
33052630|NCT05434260|Active Comparator|Surgiphor: sterile povidone iodine irrigation solution|Surgiphor Wound Irrigation Solution, bottle consisting of sterile 0.5% PVP-I formulation with 0.9% saline, Potassium Iodide, Phosphate Buffer, Vitamin E TPGS
33052631|NCT05434260|Placebo Comparator|Sterile saline|
33052632|NCT00847925|Other|A|50ng Avotermin/100ul
33052633|NCT00847925|Other|B|20ng Avotermin/100ul
33052634|NCT00847925|Other|C|5ng Avotermin/100ul
33052635|NCT00847925|Other|D|100ng Avotermin/100ul
33052636|NCT00847925|Other|E|500ng Avotermin/100ul
33052637|NCT00847925|Other|F|0.25ng Avotermin/100ul
33052638|NCT00847925|Other|G|1ng Avotermin/100ul
33052639|NCT00847925|Other|H|20ng Avotermin/100ul
33052640|NCT00847925|Other|I|50ng Avotermin/100ul
33052641|NCT05434221|Experimental|Experiment group|interns in the experiment group receive COPE during their internship.
33052642|NCT05434221|No Intervention|Control group|interns in the control group do not receive any specific communication training during their internship.
33052643|NCT00847847|Other|2|control subjects with muscle biopsy
33052644|NCT00847847|Other|1|ALS patients with muscle biopsy
33052645|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
33052646|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
33052647|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
33052648|NCT05433909|Experimental|Endometriosis group|The endometriosis group will include women who will undergo surgery for endometriosis.
33052649|NCT05433909|Experimental|Control Group|The control group include women who will undergo surgery for other gynecological diseases in which the presence of endometriosis will be excluded during the operation.
33052650|NCT04711772||DOR group|Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.
33052651|NCT04711772||Control group|Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.
33052652|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
33052653|NCT04732299||Acute thrombus group|Within 14 days after onset
33052654|NCT04732299||Subacute thrombus group|During 15-30 days after onset
33052655|NCT04732299||Chronic thrombosis group|More than 15-30 days after onset
33052656|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
33052657|NCT00847574|Experimental|Lower-fat|20% of calories from fat
33052658|NCT00847496|Experimental|1|AWBAT
33332301|NCT04397718|Placebo Comparator|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
33332302|NCT04397718|Experimental|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
33332303|NCT04679038|Experimental|combinational therapy part|SHR-1701 + famitinib
33332304|NCT04679038|Experimental|monotherapy part|famitinib
33332305|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
33332306|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
33332307|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
33361272|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
33052659|NCT00847496|Active Comparator|2|BIOBRANE(R)
33052660|NCT04733339||'Traditional' group|10 stroke patients
33052661|NCT04733339||'Technology-supported' group|10 stroke patients
33052662|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
33418802|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
33418803|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
33418804|NCT01374139|Experimental|Cohort 1|
33418805|NCT01374139|Experimental|Cohort 2|
33418806|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
33418807|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
33052663|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
33052664|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
33052665|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
33418808|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
33418809|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
33418810|NCT04988425|Experimental|TNFα monoclonal antibody group|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
33418811|NCT04988425|Active Comparator|Methylprednisolone group|Injection of 500mg of methylprednisolone immediately after admission before surgery.
32871605|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33052666|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
33052667|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
33052668|NCT00847418|Experimental|Esketamine|
33052669|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
33052670|NCT05433597|Placebo Comparator|Control group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Placebo: Normal saline 1-2ml, intramuscular injection, QD, 30 days in the first and third months, once a day."
33052671|NCT05433597|Active Comparator|Experimental group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Tianenfu (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intrascularization, QD, 30 days in the first and third months, once a day."
33052672|NCT05433480|Experimental|experimental group|Intervention Drug: BPI-16350, Fulvestrant
33052673|NCT05433480|Placebo Comparator|control group|Intervention Drug: Placebo, Fulvestrant
33052674|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
33052675|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
33052676|NCT05433363||normal control|normal, cognitive test normal, PET(-)
33052677|NCT05433363||cognitive disorder due to AD|PET Aβ（+），MCI-AD and AD dementia
33052678|NCT05433363||cognitive disorder NOT due to AD|PET Aβ（-），MCI or dementia not due to AD
33052679|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
33052680|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
33052681|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
33052682|NCT05433129|Other|Block Testing|Perturbations to the system will be investigated through a series of testing (block design separated by baseline rest): A. transient hyperemic response testing via carotid compression methods, B. orthostatic challenge responses (lying-to-sit, sit-to-stand),8 C. vascular chemo-reactivity via fast and slow breathing exercises and D. impact of neurovascular coupling through cognitive/Stroop testing. Work here will establish areas for improvement in real time.
33052683|NCT05432973|Experimental|PENS|
33052684|NCT05432973|Active Comparator|Neurodynamics and manual therapy|
33052685|NCT04733456||IBD Patients (UC and CD)|"Participants will complete a Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, *EQ5D-5L, *GAD-774, *PHQ-975, *PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, *Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy (*questionnaires available through the CIHR IMAGINE grant).~Stool will be collected at baseline and after 16 weeks for assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome (through the International Microbiome Center [IMC], U of C). Blood will be drawn and urine collected at baseline and after 16 weeks for inflammatory markers and metabolomic [IMC] analysis"
33418812|NCT04988425|Placebo Comparator|Control group|Injection of the same volume of saline immediately after admission before surgery.
33052686|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
33052687|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
33052688|NCT00847067|Active Comparator|Block|
33052689|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
33332308|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
33332309|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
33052690|NCT00396669|Experimental|Dopamine release|
33052691|NCT00847028|Experimental|1|glucose 10%
33052692|NCT00847028|Experimental|2|glucose 20%
33052693|NCT00847028|Experimental|3|glucose 30%
33052694|NCT00847028|Placebo Comparator|4|placebo: sterile water
33052695|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
33052696|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
33052697|NCT00846989|Experimental|1|
33052698|NCT00846989|Experimental|2|
33052699|NCT00846989|Active Comparator|3|
33052700|NCT00396747|Active Comparator|A|Methotrexate
33052701|NCT00396747|Active Comparator|B|MTX + MP
33052702|NCT00396747|Active Comparator|C|MTX + IFX
33052703|NCT00846950|Experimental|healthy volunteers|
33332310|NCT05730712|Experimental|Treatment (HP, enzalutamide)|Patients receive pertuzumab, trastuzumab, and hyaluronidase-zzxf SC and enzalutamide PO on study. Patients undergo ECHO, biopsy, CT, and MRI scans. Patients also undergo collection of blood and tissue samples.
33052704|NCT05432934|Experimental|Dexamethasone|Dexamethasone 16mg will be added to local anesthetic solution for TAP blocks. 4mg will be injected at 4 anterior abdominal wall sites in a laparoscopically-administered TAP block. This is a single intraoperative dose.
33052705|NCT05432934|No Intervention|Local anesthetic only|Local anesthetic (bupivacaine 0.25) 1mL/kg will be used for TAP blocks.
33052706|NCT00846911||Group 1|
33052707|NCT05432895|Active Comparator|Control( static splinting)|conventional static splint
33052708|NCT05432895|Experimental|Experiment( dynamic splinting)|Device treats plantar fasciitis and replacing boot immobilization
33052709|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
33110983|NCT04658745|Sham Comparator|Sham iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere, but with a sham coil (i.e., sham iTBS). After the sham stimulation, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
33332311|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
33332312|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
33332313|NCT05730556|Experimental|Electrical Neuromodulation, Then Sham|Subjects will first have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
33418813|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
33332314|NCT05730556|Experimental|Sham, Then Electrical Neuromodulation|Subjects will first have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
33332315|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
33332316|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
33052710|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
33052711|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
33052712|NCT05432778|Experimental|Study Group|All patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available).
33052713|NCT05432778|No Intervention|Control Group|Patients in Controls will receive standard-of-care virostatic prophylaxis with valgancyclovir 450 mg bid.
33052714|NCT05432661||1 nasal kanul|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. The data of the nasal cannula group will be obtained from retrospective file and archive scanning. After providing standard monitoring, preoxygenation was performed for 3 minutes. After preoxygenation, 2-4 L/min oxygen was given to the patients who would receive oxygen support by nasal cannula. Patients were followed for at least 15 minutes after the procedure or until the patient recovered. Our aim is the early recovery of patients without complications.
33052715|NCT05432661||2 HİGH-FLOW NASAL OXYGEN|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. After the standard monitoring is established, preoxygenation will be performed for 3 minutes. . After preoxygenation, 40 L/min oxygen will be administered through a HFNO system to patients who will receive oxygen support with HFNO ( Inspired O2 FLO High Flow Oxygen Therapy ). Patients will be followed for a minimum of 15 minutes after the procedure or until the patient recovers.
33052716|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
33052717|NCT05432622||Nivolumab Monotherapy|Participants who started adjuvant nivolumab
33052718|NCT05432622||Pembrolizumab Monotherapy|Participants who started adjuvant pembrolizumab
33052719|NCT05432622||Dabrafenib + Trametinib Combination Therapy|Participants who started adjuvant dabrafenib + trametinib combination therapy
33052720|NCT05432622||No Treatment of a Systemic Therapy|Participants with no systemic treatment during the study observation period until record of recurrence
33052721|NCT00846794||1 Asymptomatic|students with conditions being studied
33052722|NCT00846794||2 Symptomatic|students without conditions being studied
33052723|NCT05432544|Experimental|SAD, SHR-1918|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 injection
33052724|NCT05432544|Placebo Comparator|SAD, SHR-1918 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 placebo injection
33052725|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
33052726|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
33052727|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
33052728|NCT00846716|Active Comparator|SU or Biguanide|
33052729|NCT05432427|Experimental|Group A, B, C, D, E, F, G|Scans
33052730|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
33052731|NCT00846677|Active Comparator|2|Vitamin D syrup
33052732|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
33052733|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
33052734|NCT00846599||1|High omega-3
33052735|NCT00846599||2|High saturated fat
33052736|NCT00846560||1 ALS patients|
33052737|NCT00846560||2 Healthy subjects|
33052738|NCT05431647|Active Comparator|İntervention group: Physiotherapy and Sensory Integration Therapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy~Sensory integration therapy program~8 weeks 2 days in a week 45 minutes per session Sensory integration therapy"
33052739|NCT05431647|Active Comparator|Control group only Physiotherapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy"
33418814|NCT03553784|No Intervention|Control Group|No intervention.
33418815|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
33052740|NCT00846482|Experimental|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
32740355|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
32740356|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
32740901|NCT05720403|Experimental|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. The individuals in pilates exercise groups will be divided into six small groups to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes cool-down and stretching exercises. The exercises will be performed in ten repetitions.
33052741|NCT05429346||Genital herpes treated before third trimester|Pregnant women with genital herpes infection receiving treatment before the 3rd trimester.
33052742|NCT05429346||Genital herpes treated during third trimester|Pregnant women with genital herpes infection receiving treatment during the 3rd trimester.
33332317|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
33332318|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
33052743|NCT05429346||Genital herpes untreated|Pregnant women with untreated genital herpes infection.
33052744|NCT05429346||Control Group|Pregnant women (controls) with neither genital herpes infection nor treatment.
33052745|NCT05428683|Other|prophylactic measures against post-operative inflammations|Usage of triamcinolone and moxifloxacin combination to be injected intravitreally by using 30 G needle.
33052746|NCT05425953||Klinefelter syndrome|Patients with 47, XXY n=60
33052747|NCT05425953||Turner syndrom|Patients with 45, X n=60
33052748|NCT05425953||47, XXX|Patients with 47, XXX n=20
33052749|NCT05425953||47, XYY|Patients with 47, XYY n=20
33052750|NCT05425953||Male controls|Male controls n=80
33052751|NCT05425953||Female controls|Female controls n=80
33052752|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
33052753|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
33052754|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
33052755|NCT05424549|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
33052756|NCT05424549|Placebo Comparator|Vehicle Ophthalmic Solution|
33052757|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
33052758|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
33052759|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
33052760|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
33052761|NCT05424432|Experimental|short course neoadjuvant chemoradiotherapy plus toripalimab|"Paclitaxel, carboplatin and toripalimab every 3 weeks for two cycles. Concurrent short course neoadjuvant radiotherapy (30 Gy in 12 fractions, 5 days per week, D3-D18).~Surgery will be performed within 8-10 weeks after the completion of preoperative therapy described above."
33052762|NCT00846404||Case|Patients with Diastolic Dysfunction
33052763|NCT00846404||Control|Patients without Diastolic Dysfunction
33052764|NCT05417646|Active Comparator|HNF1A-MODY - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
33052765|NCT05417646|Placebo Comparator|HNF1A-MODY - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
33052766|NCT05417646|Active Comparator|Type 2 Diabetes - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
33052767|NCT05417646|Placebo Comparator|Type 2 Diabetes - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
33052768|NCT05382546|Experimental|NTM-001 Treatment Arm|NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.
33052769|NCT05364255|Experimental|[14C]AZD9833 (D8532C00005)|Oral Solution, 75 mg (NMT 0.67 MBq)
33052770|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
33052771|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
33052772|NCT05330013|Other|Control|Healthy volunteers who are age and sex matched
33052773|NCT05330013|Experimental|Subjects with HFpEF|Subjects are defined as patients with a diagnosis of HFpEF clinically confirmed by a licensed physician or advanced practitioner who meet the inclusion and exclusion criteria and are able to provide informed consent.
33052774|NCT05325567|Active Comparator|1 incision technique|a mini-open incision that allows adequate exposure of the transverse carpal ligament (TCL), while staying distal to the distal wrist crease.
33052775|NCT05325567|Active Comparator|Two incision technique|A two-incision open carpal tunnel release techniques to ensure complete release both proximally and distally
33110984|NCT04658745|Sham Comparator|iTBS to the ipsilesional primary motor cortex plus sham mirror therapy|"iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time, but with a covered mirror (e.g., sham mirror therapy).~In the sham mirror therapy condition, the mirror is covered by a cloth and the participant is instructed to move both arms while looking at a cross mark on the covered mirror and imaging the analogous movements of the affected arm. The movement practice will involve 5 table-top tasks (same as mirror therapy) and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes."
33110985|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
33110986|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
32740902|NCT05720403|No Intervention|control group|The group received breathing and relaxation exercises with a home program.
32740903|NCT04433169|Experimental|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
33110987|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
33110988|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
33110989|NCT04658511|Experimental|Participants|Patients diagnosed with cubital tunnel syndrome who are being scheduled for a primary endoscopic cubital tunnel release by the principle investigator will be recruited
33110990|NCT04668027|Experimental|chronic airway disease group|Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
33110991|NCT00533819|Experimental|1|
33110992|NCT00533819|No Intervention|2|would have routine physical activity
33110993|NCT04658589|Experimental|Laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
33332319|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
33332321|NCT04543968|Experimental|hydroxytyrosol (HT) intake|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
33332322|NCT04543968|Experimental|hydroxytyrosol (HT) intake and withdraw|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
33110994|NCT04658589|Active Comparator|Open distal gastrectomy|Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
33110995|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
33110996|NCT04658394|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
33110997|NCT04658394|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
33418816|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
33110999|NCT04667988|Experimental|RA patients|newly diagnosed RA will started therapy with conventional synthetic DMARDs (including methotrexate)
33111000|NCT04667988|Experimental|control|JAK2 mutation assesment by PCR
33111001|NCT04536116|Experimental|MRI simulation|MRI simulation with a Virtual Reality headset
33111002|NCT04536116|No Intervention|Standard medical care|Standard medical care
33111003|NCT04668183||Pudendal Nerve Block|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
33332323|NCT04503148|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
33332324|NCT04503148|Active Comparator|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
33332325|NCT04097106||Lean BMI (19-25)|
33332326|NCT04097106||Obese BMI (30-35)|
33332327|NCT04368910|Experimental|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
33418817|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
33052776|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
33052777|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
33052778|NCT05284188|Active Comparator|Open Modified Broström operation group|Patients who accept an open modified Broström operation
33418818|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
33052779|NCT05284188|Active Comparator|Arthroscopic Modified Broström operation group|Patients who accept an arthroscopic modified Broström operation
33052780|NCT00846248|Active Comparator|1|Chromium picolinate
33418819|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
33418820|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.~Subjects will be instructed to practice everyday, each action repeat for 10 times."
33418821|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
33418822|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
33418823|NCT02111018|Active Comparator|CVVH|
33418824|NCT02111018|Experimental|CytoSorb Device|
33052781|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
33052782|NCT05227170|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 8 weeks.
33052783|NCT05227170|Placebo Comparator|Heat-killed placebo control|Subjects will consume potato starch (2 capsules) once daily for 8 weeks.
33052784|NCT05217537|Experimental|Cohort 1 (adolescents)|12 to < 18 years of age
33052785|NCT05217537|Experimental|Cohort 2 (children)|8 to < 12 years of age
33052786|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
33052787|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
33052788|NCT05185050||AIS with MPS|the participants who has Cobb angle above 10 degrees and diagnosed with myofascial pain syndrome
33052789|NCT05185050||AIS with no pain|the participants who has Cobb angle above 10 degrees and without pain
33052790|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
33052791|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
33052792|NCT00846092|Experimental|Device|"The study will require 20 subjects.~Each subject will have one study eye that will be designated for treatment.~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
33052793|NCT05081154|Experimental|Product usage order A B G C F D E|Subjects will use each of the 7 products (A B G C F D E) during an evaluation period, followed by a 4 hour Test Session
33052794|NCT05081154|Experimental|Product usage order B C A D G E F|Subjects will use each of the 7 products (B C A D G E F) during an evaluation period, followed by a 4 hour Test Session
33052795|NCT05081154|Experimental|Product usage order C D B E A F G|Subjects will use each of the 7 products (C D B E A F G) during an evaluation period, followed by a 4 hour Test Session
33052796|NCT05081154|Experimental|Product usage order D E C F B G A|Subjects will use each of the 7 products (D E C F B G A) during an evaluation period, followed by a 4 hour Test Session
33052797|NCT05081154|Experimental|Product usage order E F D G C A B|Subjects will use each of the 7 products (E F D G C A B) during an evaluation period, followed by a 4 hour Test Session
33052798|NCT05081154|Experimental|Product usage order F G E A D B C|Subjects will use each of the 7 products (F G E A D B C) during an evaluation period, followed by a 4 hour Test Session
33052799|NCT05081154|Experimental|Product usage order G A F B E C D|Subjects will use each of the 7 products (G A F B E C D) during an evaluation period, followed by a 4 hour Test Session
33418825|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
33418826|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
33418827|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
33052800|NCT05081154|Experimental|Product usage order E D F C G B A|Subjects will use each of the 7 products (E D F C G B A) during an evaluation period, followed by a 4 hour Test Session
33052801|NCT05081154|Experimental|Product usage order F E G D A C B|Subjects will use each of the 7 products (F E G D A C B) during an evaluation period, followed by a 4 hour Test Session
33052802|NCT05081154|Experimental|Product usage order G F A E B D C|Subjects will use each of the 7 products (G F A E B D C) during an evaluation period, followed by a 4 hour Test Session
33052803|NCT05081154|Experimental|Product usage order A G B F C E D|Subjects will use each of the 7 products (A G B F C E D) during an evaluation period, followed by a 4 hour Test Session
33052804|NCT05081154|Experimental|Product usage order B A C G D F E|Subjects will use each of the 7 products (B A C G D F E) during an evaluation period, followed by a 4 hour Test Session
33052805|NCT05081154|Experimental|Product usage order C B D A E G F|Subjects will use each of the 7 products (C B D A E G F) during an evaluation period, followed by a 4 hour Test Session
33052806|NCT05081154|Experimental|Product usage order D C E B F A G|Subjects will use each of the 7 products (D C E B F A G) during an evaluation period, followed by a 4 hour Test Session
33052807|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
33052808|NCT05051553|Experimental|Treatment 1A|
33052809|NCT05051553|Experimental|Treatment 1B|
33052810|NCT05051553|Experimental|Treatment 2A|
33052811|NCT05051553|Experimental|Treatment 2B|
33052812|NCT05051553|Experimental|Treatment 2C|
33052813|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
33052814|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
33052815|NCT00845936|Experimental|1|850 mg of Metformin bid
33052816|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
33052817|NCT04941378|Experimental|OTL 38|The study drug in question is an Investigational New Drug (IND), folate analog ligand conjugated with an indole cyanine green-like dye called OTL38. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, completed at least 1 hour prior to intraoperative imaging
33052818|NCT04888377||Antenatal exposure to low dose aspirin|Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.
33052819|NCT04888377||Antenatal exposure to Placebo|Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.
33052820|NCT00277043|Experimental|1 Test Dose|
33052821|NCT00277043|Active Comparator|2) Non test dose arm|
33052822|NCT04858035|Experimental|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
33052823|NCT04732572|Experimental|Adenotonsillectomy|Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care.
33052824|NCT04732572|Active Comparator|Watchful waiting with supportive care|Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made.
33052825|NCT00276965|Experimental|A|Participants will take lithium only.
33052826|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
33052827|NCT00276965|Experimental|C|Participants will take sertraline only.
33052828|NCT04854057|Active Comparator|Intermittent Hypoxia (AIH) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes~TESS + Functional Task Practice Duration: 45 minutes"
33052829|NCT04854057|Sham Comparator|Intermittent Room Air (SHAM) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes~TESS + Functional Task Practice Duration: 45 minutes"
33052830|NCT00396786|Experimental|Arm 1|
33052831|NCT00396786|Experimental|Arm 2|
33052832|NCT00396786|Experimental|Arm 3|
33052833|NCT00396786|Experimental|Arm 4|
33052834|NCT00396786|Experimental|Arm 5|
33052835|NCT00396786|Active Comparator|Arm 6|
33052836|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
33418828|NCT05706441||ultrasound|Pulmonary and diaphragm ultrasound was evaluated within one hour before withdrawal
33111004|NCT04668183||Dorsal Penile Nerve Block|Ultrasound (US) guided dorsal penile nerve block with in plane technique was done. Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
33111005|NCT04522271|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5 g/m2 of an individually optimized resistant starch for approximately 5 months
33111006|NCT04522271|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 5 months
33111007|NCT04667793|Experimental|Thymoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Carboplatin AUC 5, Amycin 50mg/m2, Cyclophosphamide 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
33111008|NCT04667793|Experimental|Thymic carcinoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Cisplatin 50mg/m2, Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
33111009|NCT04521998|Experimental|electroacupuncture|The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
33111010|NCT04521998|Experimental|Transcutaneous electrical nerve stimulation|The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
33111011|NCT04658706|Sham Comparator|Control|a physical activity prescription to be performed autonomously
33111012|NCT04658706|Experimental|Prehabilitation|They will receive a supervised exercise programat least 2 weeks before starting the conventional chemoradiotherapy treatment and concomitant
33111013|NCT04658706|Experimental|Rehabilitation|They will receive a supervised exercise programat 12 weeks after the first radiotherapy session, once standard treatment has finished
33111014|NCT04520594|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5g/m2 of an individually optimized resistant starch for approximately 6 months
33111015|NCT04520594|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 6 months
33111016|NCT04520555|Experimental|Laryngeal mask airway group|Flexible laryngeal mask airway is inserted for general anesthesia
33111017|NCT04520555|Active Comparator|intubation group|Endotracheal intubation was performed for general anesthesia
33111018|NCT04658550||Remote Weight Loss Behaviour Modification Program with Meal Replacements|This is the prospective study group who will receive 26-weeks of weight loss and maintenance counselling in a remote setting and a low-calorie meal replacement as part of their usual care.
33111019|NCT04658550||In Person Weight Bahaviour Modification Program with Meal Replacements|This is the retrospective study group who received 26-weeks of weight loss and maintenance counselling in person and a low-calorie meal replacement as part of their usual care.
33111020|NCT04658355|Active Comparator|Povidone-Iodine|Povidone-iodine to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
33111021|NCT04658355|Experimental|Chlorhexidine Gluconate|Chlorhexidine gluconate to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
33111022|NCT04498442|No Intervention|Yoga Practitioners|Yoga practitioners arm is the observational arm of the study, wherein participants who follow Isha school of yoga and have completed either of the three courses : Inner Engineering Online (IEO), Inner Engineering Completion (Shambhavi Mahamudra kriya) or Shakthi Chalana Kriya can be included in this group. The participant are advised to continue with their routine yoga practice with no change in the duration of practice or frequency of their practices. Participants of this group have expertise in yoga practice and have been practicing yoga for more than 6 weeks before study enrollment.
33111023|NCT04498442|Active Comparator|Control Yoga|"Control Yoga is the active comparator arm of the study. Participants who are randomly allocated to this group, practice Simha Kriya, a deep breathing exercise taught by the Isha School of yoga."
33111024|NCT04498442|Placebo Comparator|Control Idle|Control Idle is the active comparator arm of the study. Participants who are randomly allocated to this group, are advised to either read a book for 15 minutes each day or sit idle for 15 minutes. This is the true control group for the study
33111025|NCT04667598|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
33111026|NCT04667598|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
33111027|NCT04497974|Active Comparator|Regular dietary sweetness exposure - Control|Regular dietary sweetness exposure (RSE) - The RSE group consumes a diet with 25 - 30 % energy from sweet tasting foods, for 6 months.
33111028|NCT04497974|Experimental|Low dietary sweetness exposure - Experimental|Low dietary sweetness exposure (LSE) - The LSE group consumes a diet with 10 - 15 % energy from sweet tasting foods, for 6 months.
33418829|NCT05617521|Experimental|Abdominal Binder Intervention Group|Patients randomized to the Abdominal Binder Intervention Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy.
33052837|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
33052838|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
33052839|NCT00276848|Active Comparator|Fludarabine|
33052840|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
33052841|NCT04845165||Patients with FPL2 genetically confirmed|patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.
33052842|NCT04810689|Experimental|XFBD Arm|XFBD (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
33052843|NCT04810689|Placebo Comparator|Placebo Arm|Placebo (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
33052844|NCT04805346|Experimental|Therapeutic Group|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
33332328|NCT04368910|Active Comparator|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
33052845|NCT04805346|No Intervention|Control Group|A control group will undergo a similar procedure, but the cuff will not be inflated.
33052846|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
33052847|NCT04434222|Active Comparator|Compressive stockings group|Group receives postoperatively compressive stockings for a period of 6 weeks.
33052848|NCT04434222|No Intervention|Control group|The control group is treated without compressive stockings.
33052849|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~10 5 ---~10 10 ---~10* 10* 75~10* 10* 150"
33052850|NCT04433949|Active Comparator|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
33052851|NCT04433949|Experimental|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
33052852|NCT00276536|Experimental|Treatment|IFN weekly
33052853|NCT04430790|Experimental|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
33052854|NCT04430790|Placebo Comparator|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
32740357|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
33052855|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
33052856|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
33052857|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
33052858|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
33052859|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
33052860|NCT00276263|Experimental|1|
33052861|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
33052862|NCT04266873|Experimental|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
33052863|NCT04201665|Experimental|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
33332329|NCT04249258|Experimental|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
33332330|NCT04235608|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
33332331|NCT04235608|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs
33052864|NCT04201665|Active Comparator|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
33332332|NCT03938584|Experimental|Vitamin C|
33332333|NCT03938584|Placebo Comparator|Placebo|
33052865|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
33332334|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
33332335|NCT03721276|Experimental|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
33332336|NCT03721276|Other|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
33332337|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
33332338|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
33332339|NCT05724472|Experimental|Study Group 1|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^6 pfu intramuscularly Day 1
33332340|NCT05724472|Experimental|Study Group 2|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^7 pfu intramuscularly Day 1
33332341|NCT05724472|Experimental|Study Group 3|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^8 pfu intramuscularly Day 1
33332342|NCT03311854|Experimental|Emapalumab|
33052866|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
33052867|NCT04149210|Experimental|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
33052868|NCT04149210|Placebo Comparator|Artificial Tears|one drop two times daily for four weeks
33052869|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
33052870|NCT00397137|Experimental|Stapled Anopexy|Circular stapled anopexy
33052871|NCT00397137|Active Comparator|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
33052872|NCT00275834|Experimental|A|Zonisamide 400 mg
33052873|NCT00275834|Experimental|B|Zonisamide 200 mg
33052874|NCT00275834|Placebo Comparator|C|matching placebo
33052875|NCT04061421|Experimental|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
33052876|NCT00275756|Experimental|1|
33052877|NCT00275756|Experimental|2|
33052878|NCT00275756|Experimental|3|
33052879|NCT03969888|Experimental|Part 1: ABBV-3067 + Placebo|Participants will receive various dosing regimens for ABBV-3067 plus placebo ABBV-2222 taken orally depending on arm assignment.
33052880|NCT03969888|Experimental|Part 1: ABBV-3067 + ABBV-2222|Participants will receive fixed dose of ABBV-3067 plus various dosing regimens for ABBV-2222 taken orally depending on arm assignment.
33052881|NCT03969888|Placebo Comparator|Part 1 and Part 2: Placebo|Participants in Part 1 and Part 2 will receive placebo ABBV-3067 plus placebo ABBV-2222 taken orally.
33052882|NCT03969888|Experimental|Part 2: ABBV-3067 + ABBV-2222|Participants will receive various dosing regimens for ABBV-3067 plus a fixed dose of ABBV-2222 taken orally depending on arm assignment.
33052883|NCT03957057|Experimental|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
33052884|NCT03957057|Experimental|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
33052885|NCT03957057|Active Comparator|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
33052886|NCT03953157|Experimental|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
33052887|NCT03953157|Experimental|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
33052888|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
33052889|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
33332343|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
33332344|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
33332345|NCT04389840|Experimental|Cohort 1 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.25 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
33332346|NCT04389840|Placebo Comparator|Cohort 1 placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours])
33332347|NCT04389840|Experimental|Cohort 2 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
33052890|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
32740358|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
32740359|NCT02468063|Active Comparator|Noradrenaline|
32740360|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
32740361|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
32740362|NCT03305315||Cases|Diseases of the temporomandibular joint
33052891|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
33052892|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
33052893|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
33052894|NCT03762447|Experimental|INCB086550|
33052895|NCT00275366|Other|1|
33052896|NCT00041457||Physicians' Health Study I|
33052897|NCT00041457||Physicians' Health Study II|
33111029|NCT04497974|Experimental|High dietary sweetness exposure - Experimental|High dietary sweetness exposure (HSE) - The HSE group consumes a diet with 40 - 45 % energy from sweet tasting foods, for 6 months.
33332348|NCT04389840|Placebo Comparator|Cohort 2 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
32740363|NCT03305315||Controls|Asymptomatic subjects
33052898|NCT00041457||Women's Health Study|
33332349|NCT04389840|Experimental|Cohort 3 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
33332350|NCT04389840|Placebo Comparator|Cohort 3 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
33332351|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
33052899|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
33052900|NCT00275288||Healthy Normal|
33332352|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
33332353|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
33332354|NCT02940106|Active Comparator|open device|New cryopreservation system.
33332355|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
33332356|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
33052901|NCT00275288||Active Disease|
33052902|NCT03533946|Experimental|Rucaparib, all patients|Single Arm study, all patients will get rucaparib
33052903|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
33052904|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
33052905|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
33052906|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
33052907|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
33052908|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
33052909|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
33052910|NCT03502200|Experimental|E-cigarette|5% nicotine JUUL e-cigarette (Tobacco or Menthol flavor). Will also receive counseling.
33052911|NCT03502200|Active Comparator|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard assessments. Will also receive counseling.
33052912|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
33052913|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
33052914|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
33111030|NCT04667676|Experimental|TENS Therapy Group|patients received acupoint TENS
32740364|NCT03303443||Younger|20-40 years old patients
32740365|NCT03303443||Elderly|over 60 years old patients
33332357|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
33332358|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
33052915|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
33052916|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
32740366|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
32740367|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
32740368|NCT04490681|Experimental|Ertugliflozin|Ertugliflozin 5mg
32740369|NCT04490681|Placebo Comparator|placebo|Placebo
32740370|NCT04491305||Women with pathohistological confirmation|Women aged between 18 and 50 with surgically proven endometriosis.
33052917|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
33052918|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
33052919|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
33052920|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
33052921|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~Myeloablation:~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
33052922|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
33052923|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
33052924|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
33052925|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
33052926|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
33052927|NCT03062826||Patients with STEMI treated medically|Drug: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) for at least 12 months.
33052928|NCT00130364|Experimental|1|Pimecrolimus
33052929|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
33052930|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
33052931|NCT00130325|Active Comparator|A|Isoniazid arm
33052932|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
33052933|NCT00130169|Experimental|1|
33052934|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
33052935|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
33052936|NCT00130091|Experimental|Clonidine|administer with local anesthetic
33052937|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
33052938|NCT00129740|Experimental|Nilotinib|400 mg orally twice daily
33052939|NCT00129662|Experimental|Intervention arm|Pictorial action plan
33052940|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
33111031|NCT04667676|Sham Comparator|Control group|patients received shame acupoint TENS
33111032|NCT04686539|Experimental|Recipients of CBD oil|Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
33111033|NCT04686539|Placebo Comparator|Recipients of Placebo|Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.
33332359|NCT04495530||Patient|Patients will be considering commencing or discontinuing parenteral nutrition, or will be receiving home parenteral nutrition
33332360|NCT04495530||Carer|Carers will be those caring for a patient with advanced cancer who is considering commencing or discontinuing parenteral nutrition, or already receiving parenteral nutrition. Carers will also be recruited if they previously cared for a person with advanced cancer receiving parenteral nutrition in the last 12 months
33332361|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
33052941|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
33052942|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
33052943|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
33052944|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
33052945|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
33052946|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
33052947|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
33052948|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
33052949|NCT00712881|Experimental|Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)|Participants will receive MCH (liposomal doxorubicin hydrochloride [60 milligrams {mg}/square meter {m^2}], cyclophosphamide (600 mg/m^2), and trastuzumab (8 or 6 mg/kilogram {kg}), administered as intravenous (IV) infusion on Day 1 of each of 4 consecutive 21-day cycles. For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles. After 4 cycles of MCH, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel [100 mg/m^2] and trastuzumab [6 mg/kg]).
33052950|NCT00712881|Active Comparator|Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)|Participants will receive AC (free doxorubicin hydrochloride [60 mg/m^2] and cyclophosphamide [600 mg/m^2]), administered as IV infusion on Day 1 of each of 4 consecutive 21-day cycles. After 4 cycles of AC, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel [100 mg/m^2] and trastuzumab [8 or 6 mg/kg]). For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles.
33052951|NCT00470223|Experimental|Chemotherapy + zoledronic acid|
33052952|NCT00470223|Active Comparator|chemotherapy|
33052953|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
33052954|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
33052955|NCT00128921|Experimental|Velcade, Cohort A|Treatment: 1.3 mg/m^2
33052956|NCT00128921|Experimental|Velcade, Cohort B|Treatment: 1.0 mg/m^2
33052957|NCT00128921|Experimental|Velcade, Cohort C|Treatment: 0.7 mg/m^2
33052958|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
33052959|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
33052960|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
33052961|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
33332362|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
33332363|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
33332364|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
33332365|NCT03232164|Experimental|18F-DCFPyL PET|Four separate substudies evaluating 18F-DCFPyL PET imaging of prostate cancer in four prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, (3) androgen-resistant metastatic disease and (4) detection of clinically significant prostate cancer in low to intermediate risk primary prostate cancer
33332366|NCT05720104|Experimental|Study group|Use of Lumoral Treatment device. Standard oral hygiene instructions.
33332367|NCT05720104|Other|Control group|Standard oral hygiene instructions.
33332368|NCT02547298||All participants|All participants will be filling out questionnaires and undergoing cystoscopy with hydrodistension for evaluative reasons
33332369|NCT05717920|Experimental|ADX-629|
33332370|NCT02054104|Experimental|1/Vaccine Plus Chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
33332371|NCT02054104|Experimental|2/Vaccine Alone|H1299 cell lysates with iscomatrix adjuvant vaccine
33332372|NCT04397614|Experimental|No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
33332373|NCT04397614|Experimental|Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
33332374|NCT04480710|Experimental|CRV431 75mg|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
33332375|NCT04480710|Placebo Comparator|Placebo, 75mg|Placebo, softgel capsule, QD, 28 days, fasted conditions
33052962|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
33052963|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
33332376|NCT04480710|Experimental|CRV431 225mg|CRV431, softgel capsule, 225mg, QD, 28 days, fasted conditions
33332377|NCT04480710|Placebo Comparator|Placebo, 225mg|CRV431, 3 softgel capsules, 225mg, QD, 28 days, fasted conditions
33052964|NCT00038415|Experimental|Vaccine|
33052965|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
33052966|NCT00394511|No Intervention|Arm II|No further treatment.
33052967|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
33052968|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
33052969|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
33052970|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
33052971|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
33052972|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
33052973|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
33052974|NCT00128336|Active Comparator|Nurse support|
33052975|NCT00128336|Experimental|Intensive support|
33052976|NCT00128336|Active Comparator|High carbohydrate diet|
33052977|NCT00128336|Experimental|High mono-unsaturated fat diet|
33052978|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
33052979|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
33332378|NCT04377334|Experimental|MSC Treatment|
33332379|NCT04377334|No Intervention|control|
33052982|NCT05770817||6-20-year-old youth|6-20-year-old youth
33052983|NCT05770804|Experimental|Intervention group|Face to face group
33052984|NCT05770804|No Intervention|Control Group|Control Group
33052985|NCT05770791|Active Comparator|Group A|Group A Obese Grade I
33052986|NCT05770791|Active Comparator|Group B|Group B Obese Grade I
33052987|NCT05770778|Active Comparator|Inclined Backward Intervention Group|Hemiplegic Cerebral Palsy Children
33052988|NCT05770778|Active Comparator|Kneel Walk Intervention Group|Hemiplegic Cerebral Palsy Children
33052989|NCT05770739|Other|ERAS group|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
33052990|NCT05770739|Other|placebo group|In this gruop,Children with cholangiectasia were given traditional perioperative treatment
33052991|NCT05770726|Active Comparator|probiotics-spray (PS) group|In the PS group, the colonoscopic prescription of 10 grams of probiotics powder is performed once on one of the first three days (D0-D3).
33052992|NCT05770726|Active Comparator|probiotics-oral (PO) group|In the PO group, we will prescribe oral probiotics 2 capsules once per day for 5 days (a total of 10 grams) as adjunctive treatment during the first five days (D0-D4).
33332380|NCT04333732|Experimental|M-M-R II ®|Education and surveillance plus M-M-R II ®
33332381|NCT04333732|Placebo Comparator|Placebo|Education and surveillance plus placebo
33332382|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
33332383|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
33332384|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
33332385|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
33332386|NCT04331704|Experimental|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
33111034|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
33332387|NCT04331704|Active Comparator|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
33332388|NCT04323124|Experimental|Treatment|PF-07059013 assignment
33332389|NCT04323124|Placebo Comparator|Placebo|Placebo assignment
33332390|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
33332391|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
32740371|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
33332392|NCT04311034|Experimental|RC48|
33332393|NCT04229290|Experimental|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
33332394|NCT04229290|Active Comparator|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
33332395|NCT04181476|Other|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
32740372|NCT03303287|No Intervention|control|usual
33052993|NCT05770713||Female patients with HR+/HER2- ABC/MBC who received a CDK4/6i based therapy for their ABC/MBC.|Female patients who received an oral treatment of CDK4/6i based therapy for their ABC/MBC.
33052994|NCT05770687||SGLT-2 inhibitor|Patients with naive use of SGLT-2 inhibitors after PCI
33052995|NCT05770674|Active Comparator|1 Month DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 1 month following PCI. Following 1 month, clopidogrel 75 mg once daily will be given for 11 months.
33052996|NCT05770674|Active Comparator|12 Months DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 12 months following PCI.
33052997|NCT05770661||Myopes|To collect the ocular data among myopic children.
33052998|NCT05770661||Non-myopes|To collect the ocular data among non-myopic children.
33052999|NCT05770648|Experimental|K-clipTM transcatheter annuloplasty system+Guideline Directed Medical Therapy GDMT|
33053000|NCT05770648|Other|Guideline Directed Medical Therapy, GDMT|
33053001|NCT05770635|Experimental|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|The experimental group received chemotherapy drug + polyvinyl alcohol embolized microspheres (Huihe Medical) for target lesion TACE (Trans-Arterial Chemoembolization)treatment.Experimental group and control group were selected to use iodide oil according to the condition of subjects.
33053002|NCT05770635|Other|Embosphere and chemotherapy drug|
33053003|NCT05770622|Experimental|Vancomycin first-dose trough dose adjustment calculation|Participants will have individualised model-based intermittent vancomycin dosing using the Vanc App dosing calculator (as used in VANC APP Part 1, see clinicaltrials.gov ID: NCT04044703). A first-dose trough concentration will be measured for each participant and the clinician will then enter that concentration into the web application ('First-dose trough dose adjustment calculator'). A dose adjustment will be generated by the calculator if the predicted steady-state level is outside of target range. If the predicted steady-state level is within target range (10-20mg/L) the calculator will recommend continuing with the same dose. The vancomycin concentration is then measured at steady state to determine if the target concentration has been achieved.
33053004|NCT05770596|Experimental|Vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
33053005|NCT05770596|Placebo Comparator|Placebo group|patients in this group will receive placebo tablets with the same manner.1 hour before surgery and for 50 days starting from the 2nd postoperative day.
33053007|NCT05770531|Active Comparator|Arm A (biospecimen banking)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for banking on study. Patients undergo CT or MRI during screening and on study.
33053008|NCT05770531|Experimental|Arm B (biospecimen evaluation, possible treatment change)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for ctDNA evaluation on study. Patients may receive sacituzumab govitecan IV based on ctDNA results on study. Patients undergo CT or MRI during screening and on study.
33053009|NCT05770518|Experimental|Biofeedback|In office video biofeedback performed at the time of the diagnosis.
33053010|NCT05770518|Active Comparator|Laryngeal control therapy|A specific type of behavioral therapy performed by speech and language pathologists
33053011|NCT05770505|Experimental|Supervised exercise|
33053012|NCT05770505|No Intervention|Control group|
33053013|NCT05770492||Epithelial Basement Membrane Dystrophy|Patients with epithelial basement membrane dystrophy
33053014|NCT05770492||Healthy|Patients/Subjects without corneal pathologies
33053015|NCT05770479|Experimental|ME-CCT Booster Training|3-4 Sessions of ME-CCT Booster Training
33053016|NCT05770479|Other|Treatment as Usual|Treatment as Usual
33053017|NCT05770466|Experimental|Experimental group|Treated with P1101 (Ropeginterferon alfa-2b) plus standard of care (SOC)
33053018|NCT05770466|Active Comparator|Control group|Treated with SOC alone
33053019|NCT05770427|Experimental|Intervention group|
33053020|NCT05770414|Experimental|Intervention group|Participants assigned to this group will receive the MTC online program after completing the pre-intervention questionnaire.
33053021|NCT05770414|No Intervention|Waitlist control group|Participants assigned to this group will not receive the MTC online program during the study period. At the end of the 8 weeks and after the post-questionnaire is completed, they will have the option to receive the MTC online program if they wish.
33111035|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
33332396|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
33332397|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
32740373|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
33053022|NCT05770401|Experimental|Internet-Behavioral Cough Suppression Therapy|Participants will watch treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
33053023|NCT05770401|Sham Comparator|Sham Treatment|Participants will watch sham treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
33053024|NCT05770388|Active Comparator|Control Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their general mental health status and level of suicidal risk, and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app.
33053025|NCT05770388|Experimental|Intervention Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their mental health status and level of suicidal risk and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app. Additionally, participants will also receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary. After two months, this group will receive a new contact with a clinical psychologist via phone call or chat. In this contact, mood and level of suicidal risk will be assessed, and participants will be encouraged to seek mental health help if they have not already done so.
33053026|NCT05770375|Experimental|MDMA|Each subject will receive 3 doses of MDMA in ascending order: 40mg, 80mg, 120mg.
33053027|NCT05770336||Patient with previous hospitalization for Covid-19 infection|
33053028|NCT05770323||Patients with normal uric acid levels|Patient with uric acid level (2.5_6)for femal and (3_7)for males
33053029|NCT05770323||Patients with elevated uric acid level (hyperurecemia)|Uric acid level more than 7 for males and more than 6 for female
33053030|NCT05770310|Experimental|JS015|
33332398|NCT04156438|Active Comparator|Low tidal volume ventilation|Conventional low tidal volume ventilation
33332399|NCT04156438|Experimental|Airway pressure release ventilation|Early use of airway pressure release ventilation
33068055|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
33332400|NCT04086654|Other|International Trauma Interview (ITI)|
33332401|NCT04099108|Experimental|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
33332402|NCT04099108|No Intervention|Control|Standard of care only
33332403|NCT04068142|No Intervention|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
33332404|NCT04068142|Experimental|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
33332405|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
33332406|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
33332407|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
33332408|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
32740904|NCT04433169|Active Comparator|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
33111036|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
33111037|NCT04474808|Experimental|L-arginine-containing foot cream|The participants apply one foot (randomized assignment) with the L-arginine-containing foot cream twice a day (morning and evening) over a period of six weeks.
33111038|NCT04474808|Active Comparator|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the Urea-containing foot cream twice a day (morning and evening) over a period of six weeks.
33111039|NCT04667871||Eyes for cataract surgery|Eyes for cataract surgery
33111040|NCT04667871||Eyes without cataract surgery|Eyes without cataract surgery
33111041|NCT04686578||Fibromyalgia group|Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.
33111042|NCT04686578||Control Group|The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.
33111043|NCT04667832||abnormal ABI|those patients with ankle brachial index ( ABI) less than 0.9
33111044|NCT04667832||normal ABI|Those patients with ankle brachial index more than 0.9
33111045|NCT04667910|Experimental|601 1.25mg|
33111046|NCT04667910|Experimental|Ranibizuman 0.5 mg|
33111047|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
33111048|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
33111049|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
33332409|NCT03988192|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
33111050|NCT04668105|Experimental|High volume nordic hamstring exercise|High volume Nordic hamstring exercise
33111051|NCT04668105|Experimental|Low volume Nordic Hamstring exercise|Low volume Nordic Hamstring exercise
33332410|NCT03945760|Experimental|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
33332411|NCT03945760|Placebo Comparator|Subjects Taking Placebo|Subjects will be taking placebo
33332412|NCT03935698|Experimental|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
33332413|NCT03900754|Experimental|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
33111052|NCT04333043||Hearing Aids|Hearing Aids use
33332414|NCT03900754|Placebo Comparator|Placebo|Saline
33332415|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
33332416|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
33332417|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 of a 28 day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
33332418|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
33332419|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
33111053|NCT04667286|Experimental|Oxygen and Prone Position (PP)|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96% plus PP for a minimum of 10 hrs a day
33111054|NCT04667286|Active Comparator|Oxygen|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96%
33111055|NCT04330001|Experimental|FAIOL|Implantation of FAIOL in the capsular bag in the posterior chamber of the eye. The IOL is intended to be used over the lifetime of the subject.
33111056|NCT04658238||Dry eye disease|Patients with dry eye disease
33111057|NCT04658238||Healthy controls|Healthy controls without dry eye disease
33111058|NCT04657965|Experimental|Administration of LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
33111059|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
33111060|NCT00534014|Active Comparator|B|250 mg Vitamin C
33111061|NCT00534014|Active Comparator|C|500 mg Vitamin C
33111062|NCT00534014|Active Comparator|D|1000 mg Vitamin C
33111063|NCT04658004|Experimental|Administration of NKG2D CAR T-cells|
33111064|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
33111065|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
33111066|NCT04658043|Experimental|ASD Intervention Group|Participants in the ASD intervention group will receive training to help children improve socioemotional functioning.
33111067|NCT04658043|No Intervention|Wait List Control Group|Participants in this group will be placed on the wait list and receive the ASD intervention training 2 months after the other groups
33111068|NCT04304066|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
33111069|NCT04657848|Experimental|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
33111070|NCT04658121||Senior Living Facilities|Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
33332420|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
33332421|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
32869648|NCT04505007|Experimental|Specialized clinic|"In this arm, patients with devices and heart failure will be enrolled in a specialized clinic with the following aims:~Referral to a heart failure nurse practitioner to undergo optimization of medical therapy.~Optimization of device programming with reduction of ventricular pacing where possible, rate responsiveness when indicated.~For those patients with CRT - ECG optimization using a previously tested protocol will be performed. This will consist of attempts to achieve the shortest QRS duration with the following guidelines:~Two BV fusion patterns in leads V1 and V2: QRS normalization or a new or an increased R wave.~QRS difference ≤-25 ms. Remodelling probability increases as QRS difference takes on larger negative values (QRS difference = BV paced QRS - LBBB QRS duration, in ms)."
32869649|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
32869650|NCT04492059|Experimental|Blood flow restriction augmented physical therapy|The group will undergo traditional physical therapy with the augment of blood flow restriction therapy under the supervision of trained physical therapists.
32869651|NCT04492059|Active Comparator|Traditional physical therapy|The group will undergo traditional physical therapy without the augment of blood flow restriction therapy under the supervision of trained physical therapists.
33111071|NCT04658121||Outpatient Healthcare Facilities|Adults attending outpatient healthcare in neighborhoods of selected research sites
33111072|NCT04658121||General Communities|Adults and children (>2 months of age) in neighborhoods of selected research sites
33111073|NCT04296110|Active Comparator|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
33111074|NCT04296110|Experimental|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
33111075|NCT04657614|Experimental|Neutral Alignment Group|A straight pylon with the ankle at neutral.
33111076|NCT04657614|Experimental|Anterior Alignment Group|An anteriorly displaced pylon with ankle dorsiflexion at 5 degrees.
33111077|NCT04657614|Experimental|Posterior Alignment Group|A posteriorly displaced pylon with 5 degrees of plantarflexion at the ankle.
33111078|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
33111079|NCT04244513|Experimental|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
33111080|NCT04244513|Sham Comparator|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
33111081|NCT04657536|Experimental|TRF group|the group who treated with temperature controlled radiofrequency
33111082|NCT04657536|Active Comparator|Estriol group|the group who treated with promestriene vaginal soft capsules
33111083|NCT04236206|Experimental|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
33111084|NCT04236206|No Intervention|Non-SMS Recipients|Control group with no intervention.
33111085|NCT04686617|No Intervention|No-force group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction on one side and the other side was used as the premolar tooth control group. Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks. At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
33332422|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
33332423|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
33332424|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
33332425|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
33332426|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
33332427|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
33332428|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
33332429|NCT04292730|Active Comparator|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
33332430|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
33332431|NCT04330248|Experimental|Erdafitinib and Carbamazepine|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 30 minutes after the start of a standardized breakfast in Period 1 followed by repeated doses of carbamazepine orally every 12 hours from Days 15 to 35 (carbamazepine Dose 1 from Days 15 to 17, Dose 2 from Days 18 to 20, and then Dose 3 from Days 21 to 35) 30 minutes after the start of standardized meal (breakfast and dinner) in Period 2. After 8 Days of Dose 3 carbamazepine treatment, on Day 28, participants will receive a single oral dose of erdafitinib dose 1 with that day's carbamazepine dose.
33332432|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
33332433|NCT04382586|Experimental|Zanubrutinib + Supportive Care|Participants received zanubrutinib plus supportive care
33053033|NCT05770284|Experimental|Subject will receive 12 weeks of exercise with standard medical management (SMT)|"Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc~Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)~Aerobic exercises consist of Brisk walking~Resistance Exercises consist of movements targeting the major muscle groups with weight lifting~Intensity:~Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.~Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength~End point: 12 weeks~Stopping rule:~Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.~Progression to exclusion criteria i.e. decompensation etc~Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day"
33053034|NCT05770284|Active Comparator|standard medical management (SMT)|standard medical management (SMT)
33332434|NCT04382586|Active Comparator|Placebo + Supportive Care|Participants received placebo plus supportive care alone
33332435|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
33332436|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
33332437|NCT04275336|Experimental|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
32871606|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33053035|NCT05770206|Experimental|experimental Group|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
33053036|NCT05770206|Active Comparator|Control Group|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
33053037|NCT05770193|Experimental|pursed lip breathing and CBT in addition to kinesio tape.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to kinesio tape.
33053038|NCT05770193|Experimental|pursed lip breathing and CBT in addition to diaphragmatic breathing exercise.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to diaphragmatic breathing exercise
33053039|NCT05770193|Active Comparator|pursed lip breathing and CBT.|patients will receive pursed lip breathing and cognitive-behavioral therapy.
33053044|NCT05770141|Other|LHP GROUP|patients received Laser Hemorrhoidoplasty procedure
33053045|NCT05770141|Other|MM GROUP|patients received conventional open surgical hemorrhoidectomy
33053046|NCT05770115|Experimental|Group A|vicryl 2/0
33053047|NCT05770115|Active Comparator|Group B|vicryl 1
33053048|NCT05770102|Experimental|Treatment Arm 2: Atezolizumab|This atezolizumab treatment arm is for adult, TYA and paediatric participants with cancers with high TMB or high MSI or proven (previously diagnosed) CMMRD.
33053049|NCT05770089|Experimental|AM-APA|The group following the Adapted Physical Activity program via videoconferencing in addition to the outpatient care.
33053050|NCT05770089|No Intervention|AM-T|The group without additional intervention other than the outpatient care.
33418830|NCT05617521|Sham Comparator|Sham Group|Sham Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure.
33053053|NCT05770063|Experimental|intervention group|compound amino acid supplement
33053054|NCT05770063|Placebo Comparator|control group|placebo
33053056|NCT05770011|Active Comparator|Conventional impression|Impression will be taken conventionally using rubber base open tray
33053057|NCT05770011|Experimental|digital impression without splinting the scan bodies|Impression will be taken by intraoral scaner
33053058|NCT05770011|Experimental|digital impression with splinting the scan bodies|Impression will be taken by intraoral scaner
33053059|NCT05769998|Experimental|Acceptance and Commitment-based treatment|Acceptance and Commitment-based (ACT) treatment including a face-to-face component administered during the patient stay in the rehabilitation unit and an online component including 4 ACT modules with an estimated duration of one month. The treatment is added to the Treatment as Usual provided in the rehabilitation unit.
33053060|NCT05769998|Other|Treatment as usual|Usual care including pharmacological therapy and exercise therapy, administered in the rehabilitation unit independently from the project.
33053061|NCT05769972|Experimental|Immersive Virtual Reality (Parkinson's disease)|
33053062|NCT05769972|Active Comparator|Computer-based cognitive rehabilitation (Parkinson's disease)|
33053063|NCT05769972|Experimental|Computer-based cognitive rehabilitation (Huntington's disease)|
33053064|NCT05769972|Active Comparator|Music-therapy (Huntington's disease)|
33068056|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
32740905|NCT05711121|Active Comparator|S1 transforaminal|The group receiving S1 transforaminal epidural steroid injection
33111086|NCT04686617|Active Comparator|Force Group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
33111087|NCT04657419||Participant|Patient or health professional coming to the Bordeaux University Hospital screening center for COVID-19 screening
33111088|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
33111089|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
33111090|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
33111091|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
33111092|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
33332438|NCT04275336|Experimental|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
33111093|NCT04184804|Experimental|Behavioral Intervention|School-based intervention
33332439|NCT04275336|Experimental|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
33332440|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
33332441|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
33111094|NCT04184804|No Intervention|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
33111095|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
33111096|NCT00556608|Active Comparator|Sinvisc|
33332442|NCT03912454|Experimental|BMAC Injection|
33332443|NCT03749304|Experimental|ANI monitor|
33332444|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
33332445|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
32740906|NCT05711121|Active Comparator|Caudal|The group receiving caudal epidural steroid injection
33111097|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
33111098|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
33111099|NCT00556647||A|Fast-track diagnosis
33111100|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
33111101|NCT00556686||1|Individuals with a history of canker sores.
33111102|NCT00556686||2|Individuals with no history of canker sores.
33111103|NCT04176458|Other|MBT in liver disease|Methacetin Breath test (MBT) intervention
33111104|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
33111105|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
33111106|NCT04686656|Active Comparator|nasal oxygen supplementation group|supplemental oxygen will be administered with nasal cannula
33111107|NCT04686656|Active Comparator|buccal oxygen supplementation group|supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube
33111108|NCT04168502|Experimental|Experimental arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
33111109|NCT04168502|Active Comparator|Standard arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~clinical observation"
33111110|NCT04667169|Experimental|Laser Haemorrhoidoplasty|A stab incision was made at the ano-cutaneous junction and the anodermis was tunneled with artery forceps to the pedicle of the haemorrhoids. The laser catheter was introduced submucosally towards the pedicle guided by a visible beam to ascertain the exact location of the laser fibre. This was then followed by about six pulsed laser energy delivered at five mm interval, while gradually withdrawing the laser catheter.
33111111|NCT04667169|Experimental|Haemorrhoidal Artery Ligation|In addition to the delivery of laser energy as per the procedure described above, each identified pedicle was ligated with a suture, without Doppler guidance.
33111112|NCT04666896|Experimental|Evidence-based tailored care (group A)|Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
33111113|NCT04666896|Active Comparator|Evidence-based standard care (group B)|This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
33111114|NCT04166396|Experimental|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
33111115|NCT04166396|Experimental|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
33111116|NCT04166396|Experimental|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
33111117|NCT04166396|Experimental|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
33111118|NCT04666935|Experimental|Intervention group|The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).
33111119|NCT04666935|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
33332446|NCT04273776|Active Comparator|Suvorexant Arm|10 mg of Suvorexant
33332447|NCT04273776|Active Comparator|Zolpidem Arm|5 mg of Zolpidem
33332448|NCT04273776|Placebo Comparator|Placebo|10mg of Avicel
33332449|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
33332450|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
33332451|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
33332452|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
33332453|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
33332454|NCT05676112||Nintedanib new users|
33332455|NCT05676112||Pirfenidone new users|
33332456|NCT05676112||no drug-treated users|subjects who did not receive nintedanib, pirfenidone
33332457|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
33332458|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
33332459|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
33332460|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
33332461|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
33332462|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
33332463|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
33332465|NCT05216458|Experimental|Control|Households in the control group did not receive any messages during the intervention period from June 2021 to August 2021
33332466|NCT05216458|Experimental|Generic Outreach|"Households in the generic outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees, which explain that nearly all Covered California members get subsidies to pay for health insurance and encourage them to explore their plan options using an online Shop & Compare tool.~For the generic arm, the outreach materials described new financial assistance under the American Rescue Plan and noted the availability of plans as low as $1/month."
33332467|NCT05216458|Experimental|Personalized Outreach|"Households in the personalized outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees.~For the personalized arm, the outreach explicitly informed the household that they were eligible for a $1/month CSR Silver 94 plan and described the benefits this plan confers. The outreach materials for the personalized group were not only designed to increase enrollment, but also to simplify the search process by providing households with a clear recommendation to pick a CSR Silver plan; this included highlighting the low out-of-pocket costs these plans provide when accessing care, a screenshot of what the plan would look like when they entered the shopping portal and peer comparison language that noted 9 out of 10 consumers like them choose CSR Silver plans"
33332468|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
33332469|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
33111120|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
33053065|NCT05769959|Experimental|Part I Single Participant Cohort RO7515629 Dose Escalation|Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
33332470|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
33053066|NCT05769959|Experimental|Part II Multiple Participant Cohort RO7515629 Dose Escalation|Participants will receive RO7515629 intravenously, as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity, step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
33053067|NCT05769959|Experimental|Part III Multiple Participant Cohort RO7515629 Dose Expansion|Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
33053068|NCT05769933||Healthy participants|Healthy volunteers with no history of neurological problems or mental disorders; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
33053069|NCT05769933||Essential tremor patients|Non-hospitalized volunteers who have been diagnosed with essential tremor and are indicated for thalamic surgery. Interventions: MRI.
33053070|NCT05769933||Psychosis patients|Non-hospitalized volunteers who have been diagnosed with early psychosis, and clinically assessed; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
33053071|NCT05769933||Healthy controls|Healthy volunteers who have been clinically assessed and determined to be suitable matched controls with respect to the psychosis group; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
33053072|NCT05769933||Epilepsy patients|Non-hospitalized volunteers who have been diagnosed with epilepsy.
33053073|NCT05769920|Experimental|TTHX1114 Dose Level 1|TTHX1114(NM141) Ophthalmic Solution (DL1): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
33053074|NCT05769920|Experimental|TTHX1114 Dose Level 2|TTHX1114(NM141) Ophthalmic Solution (DL2): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
33053075|NCT05769920|Experimental|TTHX1114 Dose Level 3|TTHX1114(NM141) Ophthalmic Solution (DL3): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
33053076|NCT05769920|Experimental|TTHX1114 Dose Level 4|TTHX1114(NM141) Ophthalmic Solution (DL4): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
33053077|NCT05769907|Experimental|single arm|The single-arm pilot study will be a feasibility study of the Motivation to Lose Weight version 1 (MLW v.1). The study includes presential and online sessions. Participants will be recruited through advertisements on social media and selected according to the inclusion criteria. Participants will receive 8 sessions of approximately 30-45 minutes of motivational interviewing (MI) according to the processes of change in weight loss, as measured by the S-Weight scale.
33053078|NCT05769881|Active Comparator|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
33053079|NCT05769881|Active Comparator|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access.
33053080|NCT05769855|Experimental|HR18034|
33053081|NCT05769855|Active Comparator|ropivacaine HCl|
33053082|NCT05769855|Placebo Comparator|Sodium Chloride Physiological Solution|
33053083|NCT05769829||Cohort 1: Pre-diagnosis/+Gastrointestinal Symptoms|"Up to 450 participants with gastrointestinal symptoms, undergoing endoscopy with biopsy will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.~In addition to the 450 participants enrolled, 50 more participants that meet inclusion/exclusion for cohort 1 will be enrolled to complete only the initial visit and endoscopy visit. Participants will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis."
33053084|NCT05769829||Cohort 2: Diagnosed Inflammatory Bowel Disease, Pre-treatment|Up to 400 participants recently diagnosed with inflammatory bowel disease but not yet started on a medication regimen to address their symptoms will have blood drawn with metadata attached. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.
33053085|NCT05769829||Cohort 3: Potential Cross-Reactive Diseases|Patients will be eligible for this cohort if they fail to be diagnosed with inflammatory bowel disease but have a confirmed diagnosis of potential cross reactive disease states including Irritable Bowel Syndrome, Functional Diarrhea, Celiac Disease.
33418831|NCT04862858|Active Comparator|Intervention|The educational outreach intervention will entail a multi-faced strategy to provide patients resources to learn more about reducing their risk for heart disease and supporting providers in the care of their patients by sharing recent guideline-recommended treatments for these high-risk individuals.
33418832|NCT04862858|No Intervention|Control|Patients and primary care providers randomly selected and assigned to the control arm will not receive any of the educational outreach communications.
33053086|NCT05769829||Cohort 4: Healthy Controls|Up to 228 participants free from GI symptoms for the last 90 days and no previous medical history or clinical diagnosis of GI illness.
33053087|NCT05769816|Experimental|Group 1|NAs combined with anti-PD-1 antibody, followed by NAs monotherapy
33053088|NCT05769816|Active Comparator|Group 2|NAs
33053089|NCT05769777|Experimental|Amlitelimab|Subcutaneous injection as per protocol
33053090|NCT05769738|Experimental|Furosemide group|Inhaled furosemide
33418833|NCT02104622|Experimental|ReWalk training|
33418834|NCT05219643|Experimental|NAVA|Received NAVA.
33418835|NCT05219643|Active Comparator|PSV|Received PSV.
33418836|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
33053091|NCT05769738|Placebo Comparator|Placebo group|Inhaled saline
33053092|NCT05769725|Experimental|Serplulimab in Combination With Docetaxel +S-1|
33418837|NCT05706363|Active Comparator|MPFL reconstruction with gracillis graft|MPFL reconstructrion with gracillis graft and screw fixation in femur
32869652|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
33053093|NCT05769725|Placebo Comparator|Docetaxel +S-1|
33053094|NCT05769712||healthy people|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; ③ No medical history of shoulder and neck pain; ④ Ultrasound examination (-).~Exclusion criteria: ① pregnant women or postpartum 1 year; ② Shoulder pain with active or passive cervical motion; ③ History of upper extremity trauma; (4) Shoulder surgery or treatment history, intra-articular injection history, use history of glucocorticoids, estrogens, quinolones and cholesterol drugs; (5) Shoulder joint fear test (shoulder joint abduction 90°, slowly increasing external rotation, the subject had a positive expression of fear); (6) Evidence of adhesive shoulder joint bursitis, such as the passive range of motion of the 2 motion planes of the shoulder joint is obviously limited; ⑦ Systemic autoimmune diseases, metabolic diseases, endocrine diseases, psoriasis; ⑧ unable to complete the relevant movements and positions; ⑨ Those who are reluctant to continue the experiment and ask to quit."
33053095|NCT05769712||diabetic|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; (3) Patients who meet the clinical guidelines for diabetes diagnosis and treatment and are diagnosed with diabetes (ADA guidelines 2020: patients with typical diabetes symptoms and random blood glucose ≥11.1 mmol/L or fasting blood glucose ≥7.0 mmol/L or 2h blood glucose ≥11.1 mmol/L after glucose loading without typical diabetes symptoms); ④ Medical history ≥2 years.~Exclusion criteria: as above."
33053096|NCT05769699|Experimental|Biomarkers|
33053097|NCT05769673|Experimental|Customized Healing Abutments|Placement of a customized CAD/CAM healing abutment after implant placement.
33053098|NCT05769673|Active Comparator|Stock Healing Abutments|Placement of a stock healing abutment after implant placement.
33053099|NCT05769660|Experimental|BEY1107 + Temozolomide|Administer BEY1107 in combination with Temozolomide, 4-weeks as 1 cycle.
33053100|NCT05769647|Experimental|Virtual Reality Glasses Group|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~The video containing the nature walk will be watched by virtual reality. 3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
33053101|NCT05769647|Experimental|Ball Squeezing Group|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The IV catheter insertion attempt will be made while the patient continues to squeeze the ball.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
33053102|NCT05769647|No Intervention|Control Group:|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~An intravenous catheter will be placed.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
33053103|NCT05769634|Experimental|Interoceptive Challenge Battery|During simultaneous stereoelectroencephalography recording (n=30) patients will complete a series of three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation.
33418838|NCT05706363|Experimental|MPFL reconstruction with quadriceps graft|MPFL reconstructrion with quadriceps graft and suture anchor fixation in femur
33418839|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
33332471|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
33332472|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
33332473|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
33332474|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
33332475|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
33332476|NCT04259346|Experimental|Ixekizumab (Reference)|Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
33332477|NCT04259346|Experimental|Ixekizumab (Test)|Test formulation of 80 mg ixekizumab administered as a SC injection via AI.
33332478|NCT04324944|Experimental|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
33053104|NCT05769621||PA Participants|Participants with PA who meet all eligibility criteria for medical record abstraction.
33053110|NCT05769582|Experimental|Anti-BK polyomavirus (AntiBKV)|1,000mg Anti-BK polyomavirus (AntiBKV) intravenous infusion every 4 weeks (4 doses)
33053111|NCT05769582|Placebo Comparator|Placebo|Placebo intravenous infusion every 4 weeks (4 doses)
33053112|NCT05769569|Experimental|Antiretroviral therapy + Investigational Products|Active Group (ART with the addition of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120 and ALFQ vaccination)
33053113|NCT05769569|Active Comparator|Antiretroviral therapy only|Control Group (continue only with ART without further interventions)
33053114|NCT05769530|Experimental|Drug intervention group|"In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.~The main result of this study was the occurrence of agitation within 30 minutes after general anesthesia. The occurrence of agitation was determined by the Riker sedation-excitement score (5-7)."
33053115|NCT05769530|Placebo Comparator|placebo group|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation.
33053116|NCT05769478|Experimental|Amifampridine will be orally administered to study participants|Amifampridine will be orally administered to study participants following completion of the baseline SFEMG. Post-dose SFEMG will commence at 30 minutes following dosing and will be completed within 30 minutes. The participant will remain under observation in the Diagnostic Neurology suite for 2 hours after dosing so it is estimated that the entire protocol including monitoring will be completed within 2-3 hours.
33053117|NCT05769452|Experimental|BD Nexiva™|The intervention group was given a closed IV catheter system called BD Nexiva™.
33053118|NCT05769452|Experimental|BD Insyte™ Autoguard™|The control group received an open IV catheter called BD Insyte™ Autoguard™.
33053119|NCT05769439||NTS iT2D-dTwin case-co-twin-control cohort|The twin pairs discordant for incident type 2 diabetes (iT2D) [17 monozygotic (MZ) and 20 dizygotic twin pairs (DZ)] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iT2D while his co-twin did not or develop iT2D at least one year later.
33053120|NCT05769439||NTS iOB-dTwin case-co-twin-control cohort|The twin pairs discordant for incident obesity (iOB) [11 monozygotic (MZ) and 15 dizygotic twin pairs (DZ)] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iOB while his co-twin did not or develop iOB at least one year later.
33053121|NCT05769413||Patients with human immunodeficiency virus infection|Patients with human immunodeficiency virus infection
33053122|NCT05769400||Patients wiht Hepatitis C Virus Infection|Patients with hepatitis c virus infection.
33053123|NCT05769387||Patients with no hormonal deficit|
33053124|NCT05769387||Patients with hormonal deficiencies|
33332479|NCT04324944|Active Comparator|Money Management|Money Management is the active control arm.
33332480|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
33332481|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
33332482|NCT04320966||Acquired Anemia|Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32
33332483|NCT04320966||Control|Age and sex matched individuals with hemoglobin in the upper quartile of normal
33332484|NCT05028816|Other|Group 1|"Side 1: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)~Side 2: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)"
33332485|NCT05028816|Other|Group 2|"Side 1: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)~Side 2: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)"
33332486|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
33332487|NCT03748836|Placebo Comparator|Single Dose Placebo|
33332488|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
33332489|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
33332490|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
33332491|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
32740374|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
32740375|NCT03305003|Active Comparator|Communication modality: spiral notebook|
33053125|NCT05769374|Experimental|Two player mode(parental involvement) in AVG play|the parent involvement group requires one parent to accompany the child to complete the experimental task
33053126|NCT05769374|Experimental|Single player mode in AVG play|the single-person model and the child need to complete the experimental task under the parent's supervision.
33053127|NCT05769374|Active Comparator|children did not engage in any AVGs play|children did not engage in any AVGs play nor any other structured school-based PA programs beyond physical education.
33053128|NCT05769361|Experimental|UNST|Training protocol with unstable devices
33053129|NCT05769361|Experimental|ST|Training protocol with stable devices
33053130|NCT05769361|No Intervention|CTRL|
33053131|NCT05769348|Active Comparator|Active Unilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive UNILATERAL high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
33053132|NCT05769348|Active Comparator|Active Bilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive BILATERAL high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
33053133|NCT05769348|Sham Comparator|Sham Treatment|Chronic migraine patients will be randomized (Taves method) to receive SHAM high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 20 days (M-F for 4 weeks).
33053134|NCT05769348|No Intervention|No Treatment|Episodic Migraine Patients will not receive study treatment. These patients will complete observational study components (Screening visit, baseline visit, MRI and PET scan only).
33053135|NCT05769335|Experimental|early calorie restriction (eCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g. 8:00 - 16:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
33053136|NCT05769335|Experimental|delayed calorie restriction (dCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g 12:00 - 20:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
33053137|NCT05769335|Active Comparator|Calorie restriction (CR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements every day for 8 weeks. The menus will encourage breakfast and after-dinner consumption of the snack to eat over at least a 12 hour time frame per day (e.g. 8:00 - 20:00), except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
33053138|NCT05769309|Active Comparator|Erector spinae block group|the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
33053139|NCT05769309|Other|control group|no block will be done but only IV analgesia.
33053140|NCT05769283|Active Comparator|Platelet Rich Plasma|Platelet Rich Plasma Injection
33053141|NCT05769283|Placebo Comparator|Saline|Placebo injection of saline
33053142|NCT05769231|Experimental|Intervention group|
33053143|NCT05769231|No Intervention|Control group|Waitlist control
33053144|NCT05769218|Experimental|CHORUS+|The baseline questionnaire for participants in this arm will be followed by a 30-minute motivational interviewing (MI) session with the peer recovery coach (PRC), and will assess readiness for change and provide information about PrEP. The PRC will also assess readiness for MOUD, and this will be further explored during subsequent visits.
33053145|NCT05769218|Active Comparator|Usual care- control|Participants in this arm will receive passive referral for care. there will be no PRC MI session and they will not be offered PrEP or MOUD.
33053146|NCT05769205|Experimental|female with ovarian masses|MRI with contrast according to the kidney function test of the patients
33053147|NCT05769192|Experimental|Group 1|Group 1 will be applied classical physiotherapy and classical massage
33053148|NCT05769192|Placebo Comparator|Group 2|Group 2 will be applied classical physiotherapy and placebo massage
33053149|NCT05769179|Experimental|Massage group|Massage group will be applied classic massage+cervical stabilisation exercises
33053150|NCT05769179|Experimental|Connective tissue massage group|Connective tissue group will be applied connective tissue massage+cervical stabilisation exercises
33053151|NCT05769179|Experimental|Mobilization group|Mobilization group will be applied cervical mobilization techniques+cervical stabilisation exercises
33053152|NCT05769166||School children|school children aged from five to seven years
33332492|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
33332493|NCT04239924|Experimental|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
33332494|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
33332495|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
33332496|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
33332497|NCT01562262||CTR|Control group
33332498|NCT01562262||ASS|Apnea without complaints group
33332499|NCT01562262||ACS|SAOS Group
33332500|NCT01562340|Active Comparator|Pomegranate fruit extract|
32740376|NCT03305003|Experimental|Communication modality: mobile application|
33053153|NCT05769153|Experimental|Cohort 1 (Stage 1)|One intravitreal (IVT) injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR lower dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 16 and 36 according to protocol-specified disease activity criteria.
33053154|NCT05769153|Experimental|Cohort 2 (Stage 1)|One IVT injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR higher dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 16 and 36 according to protocol-specified disease activity criteria.
33053155|NCT05769153|Experimental|AR-14034 SR lower dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR lower dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
33053156|NCT05769153|Experimental|AR-14034 SR higher dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR higher dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
33053157|NCT05769153|Active Comparator|Aflibercept (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48. Sham procedures will be performed between Weeks 16 and 52.
33053158|NCT05769127|Experimental|Intervention|All subjects participating in the diabetes prevention program will be offered body composition analysis and liver fat analysis, before, during, and after the lifestyle intervention
33053159|NCT05769114|Active Comparator|Surgical treatment|The surgeon will perform a minimally invasive (percutaneous) posterior stabilization of the injured spinal segments. Transpedicular screws will be inserted into the vertebral body superior and inferior to the fractured vertebra under fluoroscopic control. In a second stage procedure a lumbo- or thoracotomy (depending on the fracture level below or above the diaphragm) is performed to remove the fractured part of the vertebral body (hemicorporectomy) including the intervertebral disc segments. The resulting void is replaced by an (expandable) spacer/cage.
33053160|NCT05769114|No Intervention|Non-surgical treatment|The patients will receive an external bracing (3-point hyperextension brace) for six weeks, which must be always worn except when lying flat in bed. The brace is adjusted by an experienced orthopedist. A physiotherapist will instruct the patient to accomplish daily activities with the restriction he or she will have by wearing the brace.
33053161|NCT05769114|Other|Observational arm|Patients who do not agree to randomization will be given the option to participate in the observational arm of the study. Their treatment will be surgical fixation with an anterior-posterior stabilization (as per our current internal hospital standard).
33053162|NCT05769101|Experimental|Multi-Ingredient Post-Workout Supplement|A 60 g dose of a commercially available Recovery supplement providing ~205 kcal including Proteins (+EAA), Carbohydrates, Creatine, and Vitamin D. Diluted in 350 ml of water.
33053163|NCT05769101|Placebo Comparator|Maltodextrin Supplement|An isoenergetic Maltodextrin supplement will be administered as placebo. Dissolved in 350 ml of water.
33053164|NCT05769088|Experimental|Multi-Ingredient Pre-Workout Supplement|"A 60 g dose of a commercially available preworkout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine~1 g, yerba mate 0.3 g and caffeine 0.4 g. With 350 ml of water."
33332501|NCT01562340|Active Comparator|Pomegranate juice|
33332502|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
33332503|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
33332504|NCT01562418|No Intervention|general instructions|general instructions with no intervention
33332505|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
33332506|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
33332507|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
33332508|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
33332509|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
33053165|NCT05769088|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 350 ml of water.
33053166|NCT05769075|Experimental|Escalation stage|Escalation stage: Multiple doses of TY-2136b for oral administration to find the maximum tolerated dose
33053167|NCT05769075|Experimental|Expansion stage|Expansion stage: 4 distinct expansion cohorts
33053168|NCT05769049|Experimental|REC610|
33053169|NCT05769049|Active Comparator|Shingrix|
33053170|NCT05769036|Active Comparator|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the biventricular pacing
33332510|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
33332511|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
33332512|NCT03676634|Experimental|Vaccine|rBV A/B
33332513|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
33332514|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
33332515|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
33332516|NCT05105360|Active Comparator|Petersen's closure group|Petersen's space closure method
33332517|NCT05105360|Experimental|Mefix group|Mesentery fixation method
33332518|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
33053171|NCT05769036|Experimental|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the left bundle branch pacing
33053172|NCT05769023|Experimental|Experimental|behavioral intervention
33053173|NCT05769010|Experimental|Arm 1|SHR-A1811
33053174|NCT05769010|Experimental|Arm 2|SHR-A1811 and pyrotinib
33053175|NCT05769010|Experimental|Arm 3|SHR-A1811 and bevacizumab
33053176|NCT05768997|Experimental|High dose IV iron plus ESA combination arm|
33053177|NCT05768997|Active Comparator|ESA monotherapy arm|
33053178|NCT05768984|Experimental|Experimental group|Empowerment program will be implemented.
33053179|NCT05768984|No Intervention|Control group|No program will be implemented.
33053180|NCT05768971||Active Crohn´s disease|Ultrasound in patients with proven active Crohn´s disease scheduled for therapy with anti tumor necrosis factor alpha antibodies
33053181|NCT05768971||Patients with Food allergy|Patients with proven food allergy
33053182|NCT05768971||Healthy controls|Healthy, food-tolerant volunteers without any abdominal complaint
33053183|NCT05768958|Experimental|Morning exercise|Study visit performed in the morning with 45 min exercise.
33053184|NCT05768958|Experimental|Morning control|Study visit performed in the morning with 45 min rest period.
33053185|NCT05768958|Experimental|Evening exercise|Study visit performed in the evening with 45 min exercise.
33053186|NCT05768958|Experimental|Evening control|Study visit performed in the evening with 45 min rest period.
33053187|NCT05768945||Semaglutide|Exposure group
33053188|NCT05768945||DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin)|Reference group
33053189|NCT05768919|Experimental|Tolerability, Safety, and Efficacy of LC in Combination with RT and TMZ|Define the MTD/recommended Phase 2 dose (RP2D) of LC, administered IV weekly in combination with standard CRT (60 Gy in 30-33 fractions M-F, and daily oral TMZ 75 mg/m2), in patients with high grade malignant gliomas. This study seeks the MTD/RP2D of LC when added to TMZ during concurrent RT and adjuvant TMZ after RT. The study will evaluate escalating doses of LC delivered by IV infusion weekly as a gravity infusion (without infusion pump). Within each cohort, the dose will remain the same. In the first cohort, dosing will begin at Level 1 (300 mg/m2). The infusion of LC will begin at the start of CRT. Patients will be evaluable for the cohort if they have completed 80% of the planned doses of LC, 80% of RT and 60% of TMZ within the first 10 weeks of treatment. Patients who experience a dose-limiting toxicity (DLT) will be evaluable for the cohort if they have received at least 1 dose of LC.
33111121|NCT04667091|Experimental|Experimental|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Positional Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
33332519|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
33332520|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
33332521|NCT04369742|Experimental|Hydroxychloroquine|
33332522|NCT04369742|Placebo Comparator|Placebo|
33332523|NCT04369430|Experimental|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
33332524|NCT04369430|Placebo Comparator|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
33332525|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
33332526|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
33332527|NCT04362176|Experimental|pathogen reduced SARS-CoV-2 convalescent plasma|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.
33332528|NCT04362176|Placebo Comparator|Placebo|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.
32740377|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
33332529|NCT04080752|Experimental|JNJ-61393215 135 milligram (mg)|Participants will receive JNJ-61393215 135 mg (3*45 mg capsules) orally once daily for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
33332530|NCT04080752|Placebo Comparator|Placebo|Participants will receive matching placebo for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
33332531|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
33332532|NCT03748238|No Intervention|Control group|No hysteroscopy
33332533|NCT03745586|Experimental|All study participants|
33332534|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
33332535|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
33332536|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
33332537|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
33053191|NCT05768880|Experimental|Arm A - DIPG|
33053192|NCT05768880|Experimental|Arm B - DMG & recurrent/refractory tumors|
33053193|NCT05767645|Experimental|Mistral device|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
33053194|NCT05767606|Active Comparator|NVX arm|NVX plus placebo
33053195|NCT05767606|Active Comparator|PCV20 arm|PCV20 (Apexxnar®) plus placebo
33053196|NCT05767606|Experimental|Combination arm|NVX plus PCV20
33053197|NCT05767606|Placebo Comparator|Placebo arm|Placebo (normal saline) plus placebo
33332538|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
33332539|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
33332540|NCT04079816|Experimental|INVSENSOR00025|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor.
33332541|NCT03055936|Experimental|A1|levodopa 50 mg, carbidopa 12.5 mg
33053198|NCT05766956|Experimental|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
33053199|NCT05766956|Active Comparator|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
33053200|NCT05766046|Experimental|Standard arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an annual interval (according to guidelines)
33053201|NCT05766046|Experimental|Risk-based arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an interval of two years.
33053202|NCT05765305||Letrozole|Letrozole versus letrozole with chromium
33053203|NCT05765227|Other|LID#224381, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
33053204|NCT05765227|Other|AOHG MF, then LID#224381|Lotrafilcon B multifocal contact lenses worn first, with lehfilcon A multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
33053205|NCT05765058|Placebo Comparator|SDF solution|Subjects will receive one of the available non-operative treatment methods for root caries, namely silver diamine fluoride solution (SDF [38% F-, 38,000 ppm F]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) twice daily.
33111122|NCT04667091|Active Comparator|Comparator|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Myofascial Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
33332542|NCT03055936|Experimental|B1|levodopa 50 mg, carbidopa 65 mg
33332543|NCT03055936|Experimental|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
33332544|NCT03055936|Experimental|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
33332545|NCT03055936|Experimental|A2|levodopa 100 mg, carbidopa 25 mg
33332546|NCT03055936|Experimental|B2|levodopa 100 mg, carbidopa 65 mg
33332547|NCT03055936|Experimental|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
33332548|NCT03055936|Experimental|D2|levodopa 100 mg, carbidopa 37,5 mg
33332549|NCT03055936|Experimental|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
33332550|NCT03055936|Experimental|B3|levodopa 150 mg, carbidopa 65 mg
33332551|NCT03055936|Experimental|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
33332552|NCT03055936|Experimental|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
33332553|NCT03055936|Experimental|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
33332554|NCT03055936|Experimental|B4|levodopa 100 mg, carbidopa 65 mg
33332555|NCT03055936|Experimental|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
33332556|NCT03055936|Experimental|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
32740378|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
33053206|NCT05765058|Placebo Comparator|NaF Varnish|Subjects will receive one of the available non-operative treatment methods for root caries, namely sodium fluoride varnish (NaF, [5% F-, 22,600 ppm F]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
32740379|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
33053207|NCT05765058|Experimental|Tooth mousse|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Biosmalto Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
33053208|NCT05765058|Sham Comparator|Placebo varnish|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Placebo tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
33053209|NCT05765006|Experimental|Relma-cel be administrated in four dose level|
33332557|NCT05216068|Other|donated abandonment embryos|Embryos biopsies for PGT-A (by use of NGS platforms from our institute) will be used for the validation of our Lab QC.
33332558|NCT05215444||survivors|
33332559|NCT05215444||non survivors|
33332560|NCT05215366||children with febrile seizures|
33332561|NCT05215366||febrile children without seizures|
33332562|NCT05215366||healthy control children|
33332563|NCT05201170|Experimental|PL9643 Opthalmic Solution|PL9643 ophthalmic solution bilaterally three times a day.
33053210|NCT05764408|Experimental|Retractor|Research team members will apply a pannus retractor adhesive according to manufacturer's directions. The sonographer will be asked to attempt all views of the detailed anatomic survey before the adhesive is removed. If the sonographer thinks that additional views could be obtained with the adhesive removed using transabdominal or transvaginal imaging, this is acceptable based on the pragmatic design of this study.
33053211|NCT05764408|No Intervention|No retractor|The detailed anatomic survey will proceed per normal protocol. Approaches may include transabdominal and transvaginal imaging.
33332564|NCT05201170|Active Comparator|Vehicle Opthalmic Solution|Vehicle opthalmic solution bilaterally three times a day.
33332565|NCT05194696||Caffeine questionnaire|A questionnaire concerning caffeine habits will be handed out to the patients
33332566|NCT05667142|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
33332567|NCT05667142|Placebo Comparator|Placebo|Placebo
33332568|NCT05045872|Experimental|EMRA|Patients will receive contrast-enhanced renal artery magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography.
33332569|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
33332570|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
33053212|NCT05764135|Experimental|Intervention Group|25 individuals will be randomized into the intervention group and download SCI-Lynx Mobile Application.
33053213|NCT05764135|No Intervention|Control Group|25 individuals will be randomized into the control group or usual care. They will then have an opportunity at the end of the 1-month to download the SCI-Lynx Mobile Application.
33053214|NCT05764083||Inpatient Cohort|COVID-19-positive or -suspected inpatients: Eligible inpatient cohort participants include Veterans who receive inpatient care at VHA facilities and are tested for SARS-CoV-2. Members of this inpatient cohort include those with and without SARS-CoV-2 infection.
33053215|NCT05764083||Outpatient Cohort|COVID-19-positive or -suspected outpatients: Eligible outpatient cohort participants include Veterans who seek care in (1) VA medical center emergency departments, (2) VA medical center urgent care clinics, or (3) VA medical center COVID-19-specific testing sites, and who are tested for SARS-CoV-2 but do not require hospital admission at the time of evaluation. Members of this outpatient cohort include those with and without SARS-CoV-2 infection.
33332571|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
33332572|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
33332573|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
33332574|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
33332575|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
33111123|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
33111124|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
33332576|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
33332577|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
33332578|NCT04920916|Experimental|Dupilimab|Active Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
33332579|NCT04920916|Placebo Comparator|Placebo|Dupilimab Placebo: placebo (normal saline) will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28.
32869653|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
33053216|NCT05764083||Community Living Center Cohort|Community Living Center residents: Eligible Community Living Center cohort participants include all residents who reside in VA medical center-operated Community Living Centers. Members of this Community Living Center cohort include those with and without SARS-CoV-2 infection.
33053217|NCT05763316||Study participants|Neonates admitted to NICU and fulfilling eligibility criteria
33053218|NCT05763160|Experimental|RZL-012 50mg/ml|
33053219|NCT05762159||erector spinae block|Patients receiving erector spinae block for pain management of spinal osteosynthesis. Pupillometer will be realized during analgesia (usual practice).
33053220|NCT05762146|Experimental|Riociguat +Propylthiouracil +Perphenazine|"Triple combination therapy group:~○ each patient in this group will receive two doses (8 +/- 2 hours between doses) of orally administered combination therapy of riociguat, propylthiouracil, and perphenazine, in addition to standard of care."
33053221|NCT05762146|No Intervention|standard of care|Control group: each patient in this group will receive only standard of care
33053222|NCT05762133|Experimental|ASSET-PPD intervention group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is receiving the ASSET-PPD training
33053223|NCT05762133|No Intervention|No additional treatment group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is not receiving the ASSET-PPD training
33053224|NCT05762120|No Intervention|Control|Usual Care
33053225|NCT05762120|Other|Intervention|Weight Management Programme
33053226|NCT05762094||CAR-R|Patients with impaired renal function (eGFR < 60ml/min/1.73m2) treated by carbapenem
33053227|NCT05762094||CAR-L|Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by carbapenem
33053228|NCT05762094||CAR-LR|Patients with co-morbidity of both liver cirrhosis or impaired liver function (Child-Pugh grade B or C) and impaired renal function (eGFR < 60ml/min/1.73m2) treated by carbapenem
33053229|NCT05762094||CAR-N|Patients with normal liver function or renal function treated by carbapenem
33053230|NCT05760612|Active Comparator|Trastuzumab combined with Parstuzumab|Trastuzumab（6mg/KG） and Parstuzumab（420mg/ONCE），once every three weeks，18 times in total with preoperative treatment
33053231|NCT05760612|Experimental|Trastuzumab combined with nelatinib|Trastuzumab（6mg/KG), once every three weeks, 18 times in total with preoperative treatment, during Trastuzumab treatment, take nelatinib（240mg） per day during treatment.
33053232|NCT05760469|Other|Screening Rash|This is an exploratory study to assess the usefulness and reliability of the ITD-IAD-M for diagnosing, tracking, and treating IAD and ITD in hospitals.Participants for the study will be identified by nursing staff from admitted patients. After informed consent, the primary care nurse will collect qualitative information from the patient based on the history of their skin condition, whether the rash is new or recurring for them, and their pain, irritation, and discomfort measures. All patients participating in the study will receive the standard of care for patients presenting with MASD as prescribed by their primary care physician. The nurse will complete the ITD-IAD-M tool daily along with routine patient care. Each day the nurse documents the rash status and whether the treatment can be stopped based on the nursing assessment. The nurse/research assistant will also take a standardized digital live picture of the rash (without any identifying features) daily for a maximum of 7 days.
33053233|NCT05760144|Active Comparator|DMPA|
33053234|NCT05760144|Active Comparator|Etonogestrel implant|
33053235|NCT05756023|Active Comparator|PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs
33053236|NCT05756023|Active Comparator|Non PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs
33053237|NCT05755087|Experimental|Treatment (Tegavivint)|Patients receive tegavivint IV on study. Patients also undergo CT and/or PET and undergo blood sample collection throughout the trial.
33053238|NCT05754918|Active Comparator|TnoFS then TFS|Cochlear Implant with TnoFS first during 6 weeks then with TFS during 6 weeks
33053239|NCT05754918|Active Comparator|TFS then TnoFS|Cochlear Implant with TFS first during 6 weeks then with TnoFS during 6 weeks
33053240|NCT05752682||Syncope and fall|Consecutive patients aged ≥40 years referred to the Faint & Fall Clinics for assessment of an episode of faint or fall.
33053241|NCT05751928|Experimental|Subjects with pCR and pnCR (Group 1A)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with pathological complete (pCR) and near complete response (pnCR) (Group 1A): excision of the primary lesion (if not previously performed) without regional lymphadenectomy, followed by up to 12 months of anti-PD1 agent in the adjuvant setting."
33053242|NCT05751928|Experimental|Subjects with a pPR or pNR to neoadjuvant therapy (Group 1B)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with a pathological partial response (pPR) or non-responders (pNR) to neoadjuvant therapy (Group 1B): excision of the primary lesion (if not performed earlier), regional lymphadenectomy, then up to 12 months of adjuvant therapy with anti-PD1 agent."
33053243|NCT05751928|Active Comparator|Control Group (Group 2)|Subjects start treatment with excision of the primary lesion (if not previously performed), regional lymphadenectomy followed by adjuvant therapy with anti-PD1 agent (up to 12 months). This approach is considered the standard therapy for patients in the target population.
33053244|NCT05746195|Experimental|Text message intervention|Adaptive 12-week text message intervention using reinforcement learning to increase whole grain and reduce refined grain intake. Participants will also complete semi-structured follow-up interviews and study related questionnaires.
33053245|NCT05744674|Experimental|HR18034|
33053246|NCT05744674|Active Comparator|Ropivacaine Hydrochloride Injection|
33111125|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
33332580|NCT04695652|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33332581|NCT04695652|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
32740380|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
33111126|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
33111127|NCT04667052|Experimental|JNJ 64304500: Reference|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 reference formulation.
33111128|NCT04667052|Experimental|JNJ 64304500: Test|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 test formulation.
33111129|NCT04136522|Active Comparator|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
33111130|NCT04136522|Experimental|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
33111131|NCT04667130|Experimental|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
33111132|NCT01215916|Experimental|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
33111133|NCT01215916|Experimental|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
33111134|NCT01215916|Experimental|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
33111135|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
33111136|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
33111137|NCT04666818||Self Monitoring Blood Glucose (SMBG)|Women used self-monitoring of blood glucose= Control group (CG)
33111138|NCT04666818||Flash Glucose Monitoring (FGM)|Women used flash glucose monitoring= FGM group (FG)
33111139|NCT00534560|Experimental|1|
33111140|NCT00534560|Experimental|2|
33111141|NCT00534560|Placebo Comparator|3|
33111142|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
33111143|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
33111144|NCT04666779||No access|Group not accessing chiropractic care
33111145|NCT04666779||Access to care|Group with access to care in a 6 months period. Differences in the degree of access, measured in ranges of numbers of visits, will be used as independent variable within this group.
33111146|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
33111147|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
33111148|NCT04117295|Experimental|Treatment|Subjects implanted with the Carmat TAH
33111149|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
33111150|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
33332582|NCT04637698|Experimental|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
33332583|NCT04636060|Experimental|Iron-treatment group|
33332584|NCT04576078|Experimental|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
33332585|NCT04576078|Placebo Comparator|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
33332586|NCT04489108|Experimental|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
33332587|NCT04489108|Active Comparator|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
33111151|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
33111152|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
33111153|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
33111154|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
33111155|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
33111156|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
33111157|NCT04666506||VR as distraction during a medical procedure|Paediatric outpatients undergoing a medical procedure, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a distraction method during a potentially painful or scary procedure (e.g., vaccination, wound care, venipuncture,...).
33111158|NCT04666506||VR as relaxation method during a hospital stay|Paediatric inpatients, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a relaxation method during a potentially stressful hospital stay (e.g., patients with psychosomatic complaints, patients with eating disorders,...).
33111159|NCT04083365|Experimental|CAPECITABINE + concomitant RT + Durvalumab|After careful staging, patients will be initiated to a standard concomitant chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks and 5040 cGy radiotherapy for 5 days per week for 5 weeks. At the end of treatment patients will undergo a lesion biopsy. One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations. From week 9 to 10 after neoadjuvant therapy will be performed re-staging with CT and MRI scan. Surgery will be performed at week 10-12 from the end of CT/RT and the surgical piece will be analyzed
33111160|NCT04666623|Active Comparator|intranasal esketamine (56mg)|
33111161|NCT04666623|Placebo Comparator|placebo|
33111162|NCT04072211|Other|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
33111163|NCT00534677|Active Comparator|A|
33111164|NCT00534677|Active Comparator|B|
33111165|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
33332588|NCT04265794|Experimental|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
33332589|NCT04265794|No Intervention|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
33332590|NCT03972124|Active Comparator|CBD 100 mg OD|The lower dose CBD group will start with CBD capsules 10 mg OD, then increase the dose every 4 days until on the target dose of 100 mg OD.
33332591|NCT03972124|Experimental|CBD 200 mg OD|The higher dose CBD group will start with CBD capsules 10 mg OD and will increase every 4 days until on a target dose of 200 mg OD.
33332592|NCT03972124|Placebo Comparator|Placebo|
33332593|NCT03931252|Experimental|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
33332594|NCT03931252|Experimental|High protein|Ensure High Protein 8 ounce can
33332595|NCT03771586|Experimental|SAGE-718|
33332596|NCT03771586|Placebo Comparator|Placebo|
33332597|NCT03263416|Experimental|Arm A|
33332598|NCT03263416|Other|Arm B|Standard
33111166|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
33111167|NCT00556803|Active Comparator|2|RFA alone
33111168|NCT04018235||localized disease or locally advanced disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy"
33111169|NCT04018235||metastatic disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
33111170|NCT04018235||follow up disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
33111171|NCT00556959|Experimental|1|CLONICEL High Dose
33111172|NCT00556959|Experimental|2|CLONICEL Low Dose
33111173|NCT00556959|Placebo Comparator|3|Placebo
33111174|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
33111175|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
33111176|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
33111177|NCT01184326|Experimental|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
33332599|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
33332600|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
33332601|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
33332602|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
33332603|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
33418840|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
33418841|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
33418842|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
33418843|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
33053247|NCT05744336|Experimental|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) will wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure.
33053248|NCT05744336|Placebo Comparator|Group 2 control group|Group 2 control group has no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
33053249|NCT05742594|Experimental|Intervention Sequence: ADBC|Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention Period 1, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention C (lazertinib test formulation) on Day 1 of Intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
33053250|NCT05742594|Experimental|Intervention Sequence: BACD|Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 2, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
33053251|NCT05742594|Experimental|Intervention Sequence: CBDA|Participants will receive intervention C (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
33053252|NCT05742594|Experimental|Intervention Sequence: DCAB|Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 3 followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
33418844|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
33418845|NCT05706285||Erector Spina Plane Block and Intravenous Patient Controlled Analgesia|
33418846|NCT05706285||Intrathecal Morphine and Intravenous Patient Controlled Analgesia|
33053256|NCT05736978|Experimental|Treatment regimen based on C1D14 MRD|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy will be given azacitidine 75mg/m2, d1-7 and venetoclax 100mg on day 1 and 200mg on day 2, 400mg on day 3-28. Based on MRD results on C1D14, MRD negative patients will go on azacitidine and venetoclax regimen and for patients with MRD positive, selinexor 60mg on D15 and D22 will be added. Patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive treatment until disease progression or unacceptable toxic effects.
33053257|NCT05736965|Experimental|SAV arm|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy or who refuse to receive intensive chemotherapy will receive selinexor in combination with azacitidine and venetoclax, 28 days per cycle, patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive SAV regimen until disease progression or unacceptable toxic effects.
33053260|NCT05731947|Experimental|Phase 1a: Dose Escalation|Participants will receive SNDX-5613 three times a day (TID) from Day 1 of each 28-day cycle.
33053261|NCT05731947|Experimental|Phase 1b: Signal-Seeking|Participants will receive SNDX-5613 TID from Day 1 of each 28-day cycle.
33053262|NCT05731947|Experimental|Phase 2: SNDX-5613|Participants will receive SNDX-5613 from Day 1 of each 28-day cycle.
33053263|NCT05731947|Active Comparator|Phase 2: Chemotherapy|Participants will receive chemotherapy from Day 1 of each 28-day cycle.
33053264|NCT05728086|Experimental|Group art therapy|Participants randomised to the intervention group receive the group art therapy intervention shortly after baseline assessment. Adherence to the intervention will be checked via an adherence questionnaire completed by therapist delivering the intervention after each session. In addition, 20% of sessions will be observed by an independent researcher for adherence checking.
33053265|NCT05728086|No Intervention|waitlist control group|Participants randomised to the waitlist control group will complete outcomes measures at baseline and at the end of a 6 week waiting period. They will then begin the intervention (1-2 weeks after the intervention group has finished).
33418847|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
33111178|NCT01184326|Experimental|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
33111179|NCT01184326|Experimental|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
33111180|NCT01184326|Experimental|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
33111181|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
33111182|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
33111183|NCT03898115|Experimental|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
33111184|NCT03898115|No Intervention|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
33111185|NCT04666233|Experimental|Resuscitation with PPE for prevention of SARS-Cov-2 infection|
33111186|NCT04666233|Active Comparator|Resuscitation without PPE for prevention of SARS-Cov-2 infection|
33111187|NCT04666155|Experimental|Intermittent Colon Exoperistalsis|ICE Treatment with Mowoot device. 20min dayly for 12 weeks
33111188|NCT04666155|Active Comparator|Standard-of-Care|Standard-of-care for chronic constipation for 12 weeks.
33111189|NCT03896867|Experimental|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
33111190|NCT03896867|Active Comparator|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
33111191|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
33111192|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:~Mother diagnosed with HIV in labor and delivery?~Mother start ART after 32 weeks' gestation?~Maternal viral load above 1000 copies/ml in the 3rd trimester?~Mother seroconvert during pregnancy?~Was the mother not adhering to ART during pregnancy?"
33111193|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
33111194|NCT03895814|Experimental|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
33111195|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
33111196|NCT04666194|Active Comparator|Cold forceps|4-6mm polyps were removed with cold forceps
33111197|NCT04666194|Active Comparator|Cold snare|4-6mm polyps were removed with cold snare
33111198|NCT04666194|Active Comparator|Hot snare|4-6mm polyps were removed with hot snare
33111199|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
33111200|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
33111201|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
33111202|NCT04666077|Experimental|Home-based MT through Supervised, Supported Singing (H3S)|Treatment arm 1
33111203|NCT04666077|Experimental|H3S and IMT|Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
33332604|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
33332605|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
33111204|NCT04666077|Placebo Comparator|Attention Control (AtCon)|Comparison condition with comparable attention
33111205|NCT04666116|No Intervention|COVID-19 patients no dietary administration|Only medication agreed by the hospital committee
33111206|NCT04666116|Experimental|COVID-19 patients with dietary administration|Medication agreed by the hospital committee and nutritional supplement.
33332606|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
33332607|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
33332608|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
33332609|NCT02335060|Placebo Comparator|Placebo and Placebo|
33332610|NCT00284986|Experimental|Prochymal®|
33418848|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
33053266|NCT05726864|Experimental|Phase 1A: ELI-002 7P (Low Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
33053267|NCT05726864|Experimental|Phase 1A: ELI-002 7P (High Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
33053268|NCT05726864|Experimental|Phase 1B: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
33332611|NCT05219188||Heart failure with preserved ejection fraction and BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
33332612|NCT05219188||Heart failure with preserved ejection fraction and BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
33332613|NCT05219188||Healthy controls with BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
33332614|NCT05219188||Healthy controls with BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
33332615|NCT05219032|Experimental|Interpreter|Professional Spanish interpreter
33332616|NCT05219032|No Intervention|Usual Care|Usual care provided to patients
32740381|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
33332617|NCT05218954||patients with heterotopic ossification|patients with heterotopic ossification following THR
33332618|NCT05218954||patients without heterotopic ossification|patients without heterotopic ossification following THR
32740382|NCT05728073||Standard (non-ERCP) Group|Patients who underwent surgery for acute cholecystitis without a previous ERCP history.
32740383|NCT05728073||ERCP group|Patients who underwent surgery for acute cholecystitis with a previous ERCP history.
32740384|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
32740385|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
32740907|NCT05709483|Experimental|Women with prior history of preeclampsia who received aspirin in subsequent gestation|Single-dose of enteric-coated 81 mg aspirin
32740908|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
32740909|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
33053269|NCT05726864|Experimental|Phase 2 randomized: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
33053270|NCT05723575|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
33053271|NCT05721664|Experimental|Evidence-based nursing practices training program|Evidence-based nursing practices training program for nurses caring mechanically ventilated patients
33053272|NCT05721664|Active Comparator|control group taking the traditional education|control group taking the traditional education related to caring of mechanically ventilated patients
33053273|NCT05717075|Other|Group A (Parents Round, then no special round)|Parents of enrolled patient receive the intervention for two weeks after the consent to the study (Period I). For two weeks after the intervention in Period I, the parents do not receive the intervention (Period II).
33053274|NCT05717075|Other|Group B (no special round, then Parents Round)|Parents of enrolled patient receive no intervention for two weeks after the consent to the study (Period I). For two weeks after Period I, the parents receive the intervention (Period II).
33053275|NCT05716282||NMB estimation group|All patients undergoing surgery with a single dose of 0.6 mg/kg rocuronium and quantitative neuromuscular transmission monitoring by TOFScan at the adductor pollicis.
33053276|NCT05714644|Active Comparator|Mailed FIT Kit|A FIT kit mailed to the patient's home
33053277|NCT05714644|Active Comparator|Cologuard|A Cologuard test mailed to the patient's home
33053278|NCT05713929|Active Comparator|Recruitment maneuver (RM) group 1|
33053279|NCT05713929|Active Comparator|Reverse Trend (REV TREND) group 2|
33332619|NCT05218876|Experimental|Low- to moderate intensity strength and endurance training|Participants will perform a combination of strength and endurance training with low-to moderate-intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
33332620|NCT05218876|Experimental|High intensity strength and endurance training|Participants will perform a combination of strength and endurance training with high intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
33361273|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
33361274|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
32869654|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
32869655|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
33053280|NCT05712226|Other|Sleepiz One+ vs. gold standard|Each enrolled participant will undergo a simultaneous recording with the Sleepiz One+, Capnography device and cardiorespiratory polygraphy with reduced number of channels (ECG and REB only) to measure respiration rate at and heart rate at rest, while sitting and lying down on a bed.
32869656|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
32869657|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
33053281|NCT05712109||ACL group|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8 months after the surgery
33053282|NCT05707884|Active Comparator|volatile sedation|Patients receive volatile sedation for the intended 72 hours of deep sedation after complex free flap surgery.
33053283|NCT05707884|No Intervention|intravenous sedation|Patients receive intravenous sedation (e.g. propofol) for the intended 72 hours of deep sedation after complex free flap surgery.
33053284|NCT05706727|Experimental|Mephentermine ( M group)|Group M
33053285|NCT05706727|Experimental|Phenylephrine ( P group )|Group P
33053286|NCT05706493|Other|Non-surgical periodontal treatment|assessment of different periodontal parameters and gingival crevicular fluid sampling will be done then non surgical periodontal treatment will be performed then after 3 months re assessment of the periodontal parameters and gingival crevicular fluid sampling will be done
33053287|NCT05705739|Experimental|Retrolaminar plane block|
33053288|NCT05705739|Experimental|ESPB|
33053289|NCT05705726|Experimental|facia iliaca block|
33053290|NCT05705726|Experimental|Precedex and ketamine|
33053293|NCT05704569||the outcome group|The composite endpoint included the presence of any of the following events: cardiovascular death, MI, stroke, hospitalization and/or application due to CHD, and transient ischemic attack
33053294|NCT05704569||no-outcome group|individuals who did not experience any events during the observation period
33053295|NCT05699291||Patient eligible for the sentinel lymph node technique by lndocyanine Green.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using Indocyanine Green in patients with breast cancer, from the point of view of the health insurance and the hospital.
33053296|NCT05699291||Patient eligible for the sentinel lymph node technique by isotopes.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using isotopes in patients with breast cancer, from the point of view of health insurance and the hospital.
33053297|NCT05698238|Experimental|Treatment arm|
33053298|NCT05697783||Methadone-treated group|
33053299|NCT05697783||Fentanyl-patch treated group|
33053300|NCT05696730|Experimental|Communication intervention about sexuality in people with COPD|Communication intervention. Individual counselling to improve holistic well-being by addressing sexuality and to increase adherence for long-term physical activity given the correlation with sexual activity.
33053301|NCT05696730|No Intervention|30 minutes counselling and intervention material per request after the RCT|Usual care. Participants will have the possibility to receive a brief version of the intervention on request (30 minutes counselling and intervention material) at the end of the 3-months follow-up assessment visit.
33053302|NCT05690724|Experimental|Mitocholine™|Mitocholine™ is a novel formulation of three nutrients choline, succinic acid, and nicotinamide (a vitamin B3)
33053303|NCT05690724|Placebo Comparator|Placebo|The Placebo product will be identical in appearance and taste to the investigational product
33053304|NCT05686486|Experimental|Tai Chi inspired gymnastics practiced in a family caregiver-resident dyad|15 dyads will be recruited: 3 groups of 5 dyads where in each group, 10 participants (5 family caregivers and 5 residents) will benefit together from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
33053305|NCT05686486|Active Comparator|Tai Chi inspired gymnastics practised individually|30 dyads will be recruited: 3 groups of 10 family caregivers and 3 groups of 10 residents. The 30 family caregivers recruited will be the caregivers of the 30 residents recruited. Each group will benefit separately from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
33053306|NCT05686486|No Intervention|Control group|15 dyads will be recruited: 3 groups of 5 dyads. The family caregivers and the residents will not receive the intervention during the study. They will be able to continue their usual activities. At the end of the study, they will be offered the 24 sessions of the Tai Chi inspired gymnastics programme in family caregiver-resident dyad.
33053307|NCT05686408|Experimental|TNX-601 ER, 39.4 mg|1x TNX-601 ER, 39.4 mg, pill taken orally once daily for 6 weeks.
33053308|NCT05686408|Placebo Comparator|Placebo|Placebo pill taken orally once daily for 6 weeks.
33053309|NCT05685511|No Intervention|Usual Care|
33361275|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
33361276|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
33053310|NCT05685511|Experimental|Intervention Bundle (Behavioral Activation + Medication Optimization)|"Behavioral activation (BA) will span across 3 months postoperatively & will begin pre-operatively, with sessions approximately every two weeks. After discharge, the behavioral intervention will continue for 10-12 sessions, or out to approximately 3 months postoperatively.~Medications will be reviewed & optimized by a team of interventionists including a psychiatrist, pharmacologist, & pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house & that no new inappropriate medications are initiated. After discharge, & up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
33053311|NCT05678127|Experimental|Patients with unilateral ACNES|
33332621|NCT05218564|Experimental|Group 1, consisting of participants with COPD and usually using O2|In this group, in addition to the standard care, the participant undergoes the 6 Minute Walking Test (6MWT) using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The same, then, in addition to the standard care, is subjected to the execution of the 6 Minute Walking Test (6MWT), thanks to the use of cylinders of Oxygen (O2), believing that inside the cylinder there is Oxygen (O2). The sequence of this group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen).
32740910|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
33053312|NCT05677997|No Intervention|Control|Receiving monthly resources only
33053313|NCT05677997|Experimental|Intervention Group|Receiving sessions with a resource navigator 2x a month, and monthly resources.
33361277|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
32871607|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
33053314|NCT05676047|Experimental|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
33053315|NCT05676047|Active Comparator|Educational Group|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
32740911|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
33053316|NCT05673486|Experimental|PENG block + multimodal IV analgesia|PENG block + multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
33053317|NCT05673486|Active Comparator|Multimodal analgesia alone|Multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
33053318|NCT05672225|Active Comparator|Control group|Continuous channel: normal saline 100ml, 2ml/h (fixed rate) Selector & Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
33053319|NCT05672225|Experimental|Dexmedetomidine group|Continuous channel: dexmedetomidine 10mcg/kg (Total 100ml with normal saline), 2ml/h (fixed rate) Selector & Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
33361278|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
33053320|NCT05670821||Patients with generalized pustular psoriasis (GPP)|
33053321|NCT05664789|Active Comparator|N-acetylcysteine|12 week administration of active study compound
33053322|NCT05664789|Placebo Comparator|Placebo|12 week administration of matched placebo
33053323|NCT05664555|Active Comparator|Na Fluorescein 3mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 3mL (300mg) before taking fluorescein angiography.
33053324|NCT05664555|Experimental|Na Fluorescein 1mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 1mL (100mg) before taking fluorescein angiography.
33053325|NCT05664295||insomnia patients|Jenkins Sleep Disorders scale skor >1 and Epworth Sleepiness scale skor >9
33053326|NCT05664295||noninsomniacs|Jenkins Sleep Disorders scale skor <2 and Epworth Sleepiness scale skor <10
33053327|NCT05663580||HIV-positive people virologically suppressed without resistance/failure to NNRTI and INI|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
33053328|NCT05663411|Experimental|Treatment group A: SHR6508|
33053329|NCT05663411|Experimental|Treatment group B: SHR6508|
33053330|NCT05663411|Active Comparator|Treatment group C: Cinacalcet|
33053331|NCT05662176|Experimental|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
33053332|NCT05662176|Other|Control: Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
33053333|NCT05657860|Sham Comparator|Placebo|
33053334|NCT05657860|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
33053335|NCT05657808|Placebo Comparator|Placebo Control 1|Rest Product Form 1 - control
33053336|NCT05657808|Placebo Comparator|Placebo Control 2|Rest Product Form 2 - control
33361279|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
33361280|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
32869658|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
33053337|NCT05657808|Experimental|Active Product 1.1|Rest Product Form 1 - active product 1
33053338|NCT05657808|Experimental|Active Product 1.2|Rest Product Form 1 - active product 2
33053339|NCT05657808|Experimental|Active Product 2.1|Rest Product Form 2 - active product 1
33053340|NCT05657808|Experimental|Active Product 2.2|Rest Product Form 2 - active product 2
33053341|NCT05654623|Experimental|ARV-471|
33053342|NCT05654623|Active Comparator|Fulvestrant|
33053343|NCT05653427|Experimental|Amivantamab Monotherapy|Participants will receive amivantamab monotherapy intravenously once weekly on Days 1 and 2 in Cycle 1 and on Days 1 and 15 from Cycle 2 onwards based on body weight. Each cycle is of 28 days.
33053344|NCT05644626|Experimental|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
33053345|NCT05644626|Experimental|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
33418849|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
33053356|NCT05642962|Experimental|Arm 1|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 384 units lipase/kg of body weight per meal or snack
33053357|NCT05642962|Experimental|Arm 2|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 1350 units lipase/kg of body weight per meal or snack
33053358|NCT05640401|Experimental|Endoscopy procedure + mixed reality|This group is comprised by expert gastrointestinal endoscopists designated to perform diagnostic procedures. The procedure will be performed without physical surgical monitors, and through the guidance of Mixed Reality by using the HXtend™ application holographic monitors.
33053359|NCT05633615|Experimental|Step I (lymphodepleting chemotherapy)|Patients receive lymphodepleting chemotherapy consisting of fludarabine IV and cyclophosphamide IV on study. Patients then receive tisagenlecleucel IV, axicabtagene ciloleucel IV, or lisocabtagene maraleucel IV on study.
33053360|NCT05633615|Experimental|Step II Arm I (mosunetuzumab)|Patients receive mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
33053361|NCT05633615|Experimental|Step II Arm II (polatuzumab vedotin)|Patients receive polatuzumab vedotin IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
33053362|NCT05633615|Experimental|Step II Arm III (polatuzumab vedotin, mosunetuzumab)|Patients receive polatuzumab vedotin IV and mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
33053363|NCT05633615|Active Comparator|Step II Arm IV (observation)|Patients undergo observation on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study. Patients with subsequent progression within 12 months of CAR T-cell therapy may crossover to Arm III.
33053364|NCT05631964|Experimental|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053365|NCT05631223|Experimental|Interventional Telemedicine Arm|Single Arm Intervention
33053367|NCT05626907|Experimental|Assigned Diet #1|
33053368|NCT05626907|Experimental|Assigned Diet #2|
33053369|NCT05626907|Other|Assigned Diet #3|
33053370|NCT05621967|Experimental|Silent Breathing / Tonation Breathing Techniques (TBT)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~Next 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually"
33053371|NCT05621967|Experimental|Silent Breathing / Music Driven Vocal Exercises (MDVE)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~Next 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person"
33053372|NCT05621967|Experimental|Tonation Breathing Techniques (TBT) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually~Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
33361281|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
33361282|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
33361283|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
33361284|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
33361285|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
33361286|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
33418850|NCT05205681||Pandemic Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2020 and February 2021
33418851|NCT05205681||Control Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2019 and February 2020
33418852|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
33418853|NCT05606835|Active Comparator|Pronation Group|Participants will be assessed using the foot posture index-6 (FPI-6), and those who exhibit pronation of the subtalar joint will be included in the study. Participants to be included in the study will be divided into two groups according to their values for pronation increase in the subtalar joint. Participants with a value between 6 and 9 according to FPI-6 will be included in pronation group.
33418854|NCT05606835|Active Comparator|Hyper pronation group|Participants with a value between 10 and 12 according to FPI-6 will be included in hyper pronation group.
33053373|NCT05621967|Experimental|Music Driven Vocal Exercises (MDVE) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person~Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
33053374|NCT05619627|Experimental|Dexmedetomidine 12 mcg/kg|Group One: Subjects will receive oral dexmedetomidine 12 mcg/kg 2 hours prior to MRI
33053375|NCT05619627|Experimental|Dexmedetomidine 18 mcg/kg|Group Two: Subjects will receive oral dexmedetomidine 18 mcg/kg 2 hours prior to MRI
33053376|NCT05619627|Experimental|Dexmedetomidine 24 mcg/kg|Group Three: Subjects will receive oral dexmedetomidine 24 mcg/kg 2 hours prior to MRI
33053377|NCT05619627|Active Comparator|General anesthesia control|Control group: Subjects will receive general anesthesia for their MRI
33053378|NCT05615818|Experimental|Experimental|Molecular targeted therapy matched to genetic alteration carried by the tumour
33053379|NCT05615818|Active Comparator|Control|Continued standard of care treatment for first-line biliary tract cancer
33053380|NCT05609864||Intravenous (IV) drugs|Patient's data and data relating to prepared/administrated/discarded IV drugs will be collected during 24 hours in the operating rooms by anesthesia department
33053381|NCT05608291|Experimental|Fianlimab HD + Cemiplimab|Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
33053382|NCT05608291|Experimental|Fianlimab LD + Cemiplimab|Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
33053383|NCT05608291|Active Comparator|Pembrolizumab|Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo
33053384|NCT05605444|Experimental|Isometric exercise-one repetition|Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.
33053385|NCT05605444|Experimental|Isometric exercise-three repetitions|Isometric exercise consisting of 1 session only. The session will last for around 10 minutes which will include asking the patient to perform 3 repetition of wall squat (each time the exercise will be performed for 3 min or to volitional fatigue at 100°degree knee angle); patient will be given 30 sec rest between repetitions.
33053386|NCT05605444|No Intervention|Control (no intervention)|Will not receive any intervention
33053387|NCT05604053|Experimental|Within-subjects motivation manipulation|Low or high motivation
33053390|NCT05602740||MINDRHYTHM HARMONY|Passive Recording of the head pulse
33053391|NCT05602077|Experimental|POCUS and Control Intervention|"POCUS: Point of care ultrasound~Control-Intervention: X-ray examination and Cone Beam Computed Tomography (CBCT)"
33053392|NCT05599672|Experimental|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment
33053393|NCT05599672|Active Comparator|Standard medication counseling|Standard Medication Counseling (SMC) (1) will offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids
33053394|NCT05599503|Experimental|SimpleC Wellness Platform with Social Robot Interaction|Participants in the Social Robot condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion. Participants will also will have access to social and health reminders as well as social and wellness programs facilitated by a virtual robot agent in their own room via the Companion, social and health reminders as well as social and wellness programs facilitated by a physical robot in the community area and a staff member (likely the activity director).
33053395|NCT05599503|Active Comparator|SimpleC Wellness Platform|Participants in the SimpleC Wellness Platform condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion.
33053396|NCT05595603|Experimental|Zoledronic Acid loaded bone cement|4mg zoledronic acid-loaded gentamicin bone cement (PMMA)
33053397|NCT05595603|Active Comparator|conventional gentamicin bone cement|gentamicin bone cement (PMMA)
33053398|NCT05593549|Experimental|Trehalose|10g mixed in 500 mL of water, consumed 1 time per day
33053399|NCT05593549|Placebo Comparator|Placebo|10g microcrystalline cellulose in 500 mL, consumed 1 time per day
33053400|NCT05591040|Experimental|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
33111207|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
33111208|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
33111209|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
33418855|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
33418856|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
33111210|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
33111211|NCT04665882|Experimental|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
33418857|NCT05602233|Experimental|Balance training:|It is planned to apply hop to stabilization exercises developed by Mckeon et al. The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
33418858|NCT05602233|Experimental|STARS|A combination of STARS developed by Mckeon et al. is planned for the STARS group. The training will be given for 6 weeks, 3 times a week for 5 minutes. STARS includes; joint mobilization, plantar massage and triceps surae stretching.
33418859|NCT05602233|Experimental|Combined Training|Each participant in the combined training program will receive 4 weeks of balance training after 2 weeks of STARS treatment. STARS and hop to stabilization treatment protocol will be applied in the same way.
33418860|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
33418861|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
33418862|NCT05706207|Experimental|Arm 1|Treatment with 0.03 mg/kg HB0030 injection administered intravenously
33418863|NCT05706207|Experimental|Arm 2|Treatment with 0.3 mg/kg HB0030 injection administered intravenously
33418864|NCT05706207|Experimental|Arm 3|Treatment with 1 mg/kg HB0030 injection administered intravenously
33418865|NCT05706207|Experimental|Arm 4|Treatment with 3 mg/kg HB0030 injection administered intravenously
33418866|NCT05706207|Experimental|Arm 5|Treatment with 10 mg/kg HB0030 injection administered intravenously
33418867|NCT05706207|Experimental|Arm 6|Treatment with 20 mg/kg HB0030 injection administered intravenously
33418868|NCT05706207|Experimental|Arm 7|Treatment with 30 mg/kg HB0030 injection administered intravenously
33418869|NCT05706207|Experimental|Arm 8|Treatment with 40 mg/kg HB0030 injection administered intravenously
33053401|NCT05591040|Active Comparator|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
33053402|NCT05590156|Experimental|Action Observation Therapy (AOT)|"AOT is a method based on the principle that the patient watches the movements of a healthy individual and then tries to imitate them. AOT consists of a monitoring-imitation cycle. A cycle consists of 3 minutes of observation, and 3 minutes of imitation. The intervention will consist of 10 cycles for simple functions. Complex movements will be applied by separating them into their components. The cycle time for each component is the same. Take for example, the cup-reaching function: The first component is the cup-reaching activity. The second component is the glass grip. One cycle will be completed on the first component (6 minutes), then one cycle will be completed for the second component (6 minutes) and one cycle (6 minutes) will be completed for the entire movement. Cycles will follow each other for 60 minutes.~For the AOT, 31 different videos were prepared for the shoulder, elbow, and wrist. Applications will be made in the hospital under the supervision of a physiotherapist."
33418870|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
33418871|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
33111212|NCT04665882|No Intervention|Standard axillary lymph node dissection|Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.
33111213|NCT04686344|Active Comparator|Hypertonic saline continuous infusion Group|will receive Hypertonic saline continuous infusion
33111214|NCT04686344|Active Comparator|Hypertonic saline intermittent boluses Group|will receive Hypertonic saline intermittent boluses for 48 hours
33111215|NCT05450536|Other|Autism College Students|Single subject design means subjects are their own control.
33111216|NCT05349136|Experimental|Synchronous telerehabilitation group|Synchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
33111217|NCT05349136|Experimental|Asynchronous telerehabilitation group|Asynchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
33111218|NCT05349136|No Intervention|Control group|Conventional physiotherapy
33111219|NCT04316416|Active Comparator|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
33111220|NCT04316416|Active Comparator|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
33111221|NCT04316416|Placebo Comparator|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
33111222|NCT05449522|Experimental|Treatment group|Experimental group will receive 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) theoretically to achieve sufficient level of vitamin D.
33111223|NCT05449522|Placebo Comparator|Control group|
33111224|NCT04665804|Experimental|Experimental Group A (Creatine Supplementation)|
33111225|NCT04665804|Experimental|Experimental Group B (Glucosamine and Chondroitin sulfate Supplementation)|
33111226|NCT05434468|Experimental|Sustained neutral apophyseal glides group|Sustained neutral apophyseal glides will apply on this group.
33111227|NCT05434468|Experimental|Gong mobilization|mobilization technique
33111228|NCT04316455|Experimental|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
33111229|NCT05431192|Experimental|Mindful Training + Enhanced Usual Care|Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks.
33111230|NCT05431192|Other|Enhanced Usual Care alone|Usual care.
33111231|NCT00534755|Other|Breast database|Database
33111232|NCT00534872|Experimental|SB649868|10 mg
33111233|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
33111234|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
33111235|NCT04665609|Experimental|Anlotinib and TQB2450 solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Oral anlotinib (12 mg/d) will be administered and its cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks. The treatment continues until disease progression or treatment intolerance. Anlotinib and TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
33111236|NCT04665609|Active Comparator|TQB2450 Solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks.TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
33111237|NCT03785093||Chinese Family|Chinese parents and their offsprings
33111238|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
33111239|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
33111240|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
33111241|NCT03737981|Active Comparator|Arm I (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Treatment repeats every 28 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 15, patients receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity.
33111242|NCT03737981|Experimental|Arm II (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Beginning cycle 3, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity. All patients will then receive a 15th cycle of ibrutinib. Beginning cycle 16, patients who do not achieve a BM MRD negative CR, receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a BM MRD negative CR undergo observation every 3 cycles for 6 years, then every 6 cycles thereafter.
33111243|NCT04665492||SCI with CNP|People with subacute spinal cord injury and no chronic pain
33111244|NCT04665492||SCI no CNP|People with subacute spinal cord injury with central neuropathic pain
33111245|NCT04665492||Able bodied|Able bodied people with no chronic pain
33111246|NCT04665219|Active Comparator|Control group|Only receive a standard message.
33111247|NCT04665219|Experimental|Test group|Receive HBM-based messages.
33111248|NCT04665102||No pathology|
33111249|NCT04665102||Pathology|
33111250|NCT04665141||Standard of care|Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.
33111251|NCT04665141||Biological therapies|Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.
33111252|NCT04665063|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
33111253|NCT04665180|Experimental|Primary knee arthroplasty|Questionnaires
33111254|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
33111255|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
33111256|NCT04664712|Active Comparator|shock wave|
33111257|NCT04664712|Active Comparator|shock wave and tendon supplement|
33111258|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
33111259|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
33418872|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
33111262|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
33111263|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
33111264|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
33111265|NCT04664439|Experimental|CT-FFR|The CCTA images of the patients in this group will be analyzed and the FFR values of the lesions will be measured using the indicated software. ICA will be determined according to the value of CTFFR.
33111266|NCT04664439|No Intervention|direct ICA|The patients will be submitted to undergoing ICA procedure according to the decision of the investigators.
33111267|NCT04664595|Sham Comparator|Group SP|The Supreme™ group
33111268|NCT04664595|Active Comparator|Group PS|The ProSeal™ group
33111269|NCT04664595|Active Comparator|Group IG|The I-gel™ group
33111270|NCT04664595|Active Comparator|Group LT|The Laryngeal Tube Suction IITM group
33111271|NCT04665024|Active Comparator|Group 1|"G1 included patients undergoing planned surgery who performed chest physiotherapy at home in two weeks period before the surgical operation pre and postoperative chest physiotherapy was performed in G1.~The chest physiotherapy included the following steps~Snipping through the nose several times, then breathe out through the mouth~Taking a deep breath through the nose, hold the air in, push it down in the stomach, than back to the chest, and in the end breath out through the mouth~Put both hands on the shoulders. Lift the elbows to the sides and take a deep breath through the nose, then lower them, breathe out through the mouth. This procedure was done for the other side as well.~Put both hands on your hips. Lift your right arm to the side, turn backwards with it and take a deep breath through the nose, then turn back, put your hand back to the hip and breathe out through the mouth.This procedure was done for the other side as well"
33111272|NCT04665024|Active Comparator|Group 2|"G2 included patients who patients undergoing planned surgery but did not perform preoperative chest physiotherapy at home.only postoperative chest physiotherapy made in G2.~The patient was seen on the first day after surgery in the intensive care unit and was asked if he had performed breathing exercises at home before surgery and then re-evaluation of both groups with respect to respiratory functions and oxygen saturation values from the first day until the seventh after surgery. Also, a daily chest physical therapy program was introduced in accordance with the hospital's policy until the patient's discharge.~Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy mentioned above but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.~The exercises were repeated 10 times and performed 3-4 times per day."
33111273|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
33111274|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
33111275|NCT01215175|Active Comparator|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
33111276|NCT01215175|Experimental|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
33111277|NCT01215175|Experimental|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
33111278|NCT01215175|Active Comparator|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
33111279|NCT01215175|Experimental|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
33111280|NCT04664283|Experimental|DCB group by OCT guided|
33111281|NCT04664283|Active Comparator|DES group by OCT guided|
33111282|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
33111283|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
33111284|NCT04316026|Experimental|interventional group|group receiving shock wave therapy
33111285|NCT04316026|Sham Comparator|control group|sham shock wave therapy
33053403|NCT05590156|Experimental|Robotic Rehabilitation|"The robotic rehabilitation application will be performed with the ExoRehab X (HoustonBionics, Inc.) device. There is no engine to create any repulsive-pulling force in this device. It is a system that works entirely with the patient's active movement.~Active movements of the shoulder, elbow, and wrist in all directions can be performed with the device. Motion is detected with the help of the device's censor, and the avatar moves on the screen. There are 10 different purposeful games embedded in the device. The device also allows resistance exercise thanks to resistance modules.~Which joint will be trained will be determined according to the potential of the patient. For example, if programming will be done for the shoulder, elbow and wrist, the treatment time will be 20 minutes for each joint.~Applications will be made in the hospital under the supervision of a physiotherapist."
33053404|NCT05588479|Placebo Comparator|Control|Capsules with no pomegranate extract One capsule to be administered once a day for 12 weeks.
33053405|NCT05588479|Experimental|Intervention|Capsules with 500 mg of pomegranate extract One capsule to be administered once a day for 12 weeks.
33332622|NCT05218564|Placebo Comparator|Group 2, consisting of participants with COPD and usually not using O2|In this group, in addition to standard care, the participant is given the 6 Minute Walking Test (6MWT) using oxygen (O2) cylinders, believing that there is oxygen (O2) inside the cylinder. Next, the participant undergoes the 6 Minute Walking Test (6MWT), using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The sequence of this group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
33332623|NCT05218174|Experimental|Exercise training program|"Participants in this arm will complete an 8-week exercise training program comprised of an initial functional assessment to create an exercise prescription, followed by 7 in-person weekly sessions. Each session consisting of approximately 50 minutes of individualized exercise training and approximately 10 minutes of cognitive training via the Sports Academy CogPT iPad app. All participants will receive exercise and cognitive training delivered weekly in a group-based setting at Sports Academy within the Star in Frisco, Texas during the intervention period. Additionally, they will have access to daily workouts pushed to their phone via the MOVE exercise app developed by our team."
33053410|NCT05579717|Experimental|Equine Assisted Learning group|Participants in this group will receive 16 sessions of Equine Assisted Learning (EAL), facilitated by a trained clinician at Cartier Farms.
33053411|NCT05579717|No Intervention|Waitlist control group|Participants in the waitlist control group will not receive EAL for the duration of the study.
33053412|NCT05579626|Active Comparator|high-intensity statin arm|(high-intensity statin arm): rosuvastatin 20 mg PO qd, once daily
33053413|NCT05579626|Active Comparator|low-intensity statin plus ezetimibe arm|(low-intensity statin plus ezetimibe arm ): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
33053414|NCT05577715|Experimental|MORAb-202 Dose 1|
33053415|NCT05577715|Experimental|MORAb-202 Dose 2|
33053416|NCT05573464|Experimental|BGF MDI HFO 320/14.4/9.6μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO (HFO-1234ze)
33053417|NCT05573464|Active Comparator|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFA
33053418|NCT05570838|Experimental|FES + conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training using Functional Electrical Stimulation applyed by Fesia Grasp device and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
33053419|NCT05570838|Active Comparator|Conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
33053420|NCT05568940||Pre-menopausal women >18 years old with endometriosis and/or uterine fibroids|GnRH-a depot (11.25mg IM x 1) and daily Tibolone 2.5mg orally once a day for 2-3 months.
33053421|NCT05566769|Experimental|NMOSDCopilot|Performance of digital tests and standard test in clinic at D0 and M6 Use of NMOSDCopilot at-home in between visits during 12 months
33053422|NCT05565248|Experimental|VCTX211 unit|
33053423|NCT05563454|Experimental|Dose step 1|Each participant will receive an single dose (SD) of dose 1 of BAY2395840 or matching placebo.
33053424|NCT05563454|Experimental|Dose step 2|Each participant will receive an single dose (SD) of dose 2 of BAY2395840 or matching placebo.
33053425|NCT05563454|Experimental|Dose step 3|Each participant will receive an single dose (SD) of dose 3 of BAY2395840 or matching placebo.
33053426|NCT05563454|Experimental|Dose step 4|Each participant will receive multiple doses (MDs) of dose 3 of BAY2395840 or matching placebo.
33053427|NCT05562973|Experimental|Dose Sequence 1 (15, 20, 25)|"Psilocybin dose sequence~Session 1: 15 mg Session 2: 20 mg Session 3: 25 mg"
33053428|NCT05562973|Experimental|Dose Sequence 2 (20, 25, 30)|"Psilocybin dose sequence~Session 1: 20 mg Session 2: 25 mg Session 3: 30 mg"
33053429|NCT05562973|Experimental|Dose Sequence 3 (25, 30, 35)|"Psilocybin dose sequence~Session 1: 25 mg Session 2: 30 mg Session 3: 35 mg"
33332624|NCT05218174|Sham Comparator|No training program|Participants in this arm will be wearing the WHOOP band for 8-weeks but will not be exposed to any active intervention.
33332625|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
33332626|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
33332627|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
33332628|NCT04075604|Experimental|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
33332629|NCT04075604|Experimental|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
33332630|NCT04075604|Active Comparator|Arm C: Palbociclib+ANZ|
33332631|NCT05217550|Experimental|Intervention (Veggie Brek)|Nursery staff will present vegetables (raw carrot and cucumber batons) to children alongside their main breakfast food for five consecutive days every weekday morning for three weeks.
33053430|NCT05562973|Experimental|Dose Sequence 4 (30, 35, 40)|"Psilocybin dose sequence~Session 1: 30 mg Session 2: 35 mg Session 3: 40 mg"
33332632|NCT05217550|No Intervention|Control|Children will be served their normal breakfast (with no vegetables) across the three-week intervention period.
33053431|NCT05562973|Experimental|Dose Sequence 5 (35, 40, 45)|"Psilocybin dose sequence~Session 1: 35 mg Session 2: 40 mg Session 3: 45 mg"
32740912|NCT03681483|Experimental|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
33053432|NCT05557838|Experimental|cohort 1|durvalumab in combination with tremelimumab
33053433|NCT05557838|Experimental|cohort 2|durvalumab in combination with tremelimumab
33053434|NCT05556616|Experimental|Group 1 (NDMM Maintenance) Arm 1: Modakafusp alfa + Lenalidomide|Modakafusp alfa, infusion intravenously (IV), once on Day 1, once every 4 weeks (Q4W), in combination with Lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, any other discontinuation criterion is met, or to a maximum of 2 years for MRD-negative participants, whichever occurs first.
33053435|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 2: Modakafusp alfa + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053436|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 3: Modakafusp alfa + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Bortezomib injection subcutaneously on Days 1, 8 and 15 for the first 8 cycles and subsequently on Days 1 and 8 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053437|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 4: Modakafusp alfa + Carfilzomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053438|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm A: Modakafusp alfa + Pomalidomide + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle along with Bortezomib injection subcutaneously on Days 1, 8 and 15 for the first 8 cycles and subsequently on Days 1 and 8 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053439|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm B: Modakafusp alfa + Carfilzomib + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Carfilzomib IV, on Days 1, 8 and 15 of a 28-day (4-week) treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053440|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm C: Modakafusp alfa + Daratumumab + Carfilzomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Daratumumab injection subcutaneously on Days 1, 8, 15 and 22 of Cycles 1 and 2, further followed by on Days 1 and 15 of Cycles 3 to 6, thereafter on Day 1 on a 28-day (4-week) treatment cycle along with Carfilzomib IV on Day 1, 8 and 15 of treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053441|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Daratumumab injection subcutaneously on Days 1, 8, 15 and 22 of Cycles 1 and 2, further followed by on Days 1 and 15 of Cycles 3 to 6, thereafter on Day 1 on a 28-day (4-week) treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
33053442|NCT05554120||Non-smoking adolescents|Non-smoking youth aged 12-17 years old. As the investigators monitor the cohort, it is possible that some of the cohort will become smokers.
33053443|NCT05554120||Smoking adults from disadvantaged neighbourhoods|Smoking adults aged 18 years and older from disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
33053444|NCT05554120||Smoking adults from non-disadvantaged neighbourhoods|Smoking adults aged 18 years and older from non-disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
33053445|NCT05552261||Group Long-term follow-up|All eligible patients, after completing enrollment in the original DEFENDO Study, will be invited to enter the DEFENDO Long-Term Follow-Up Study (all standard of care is permitted), according to inclusion and exclusion criteria.
33053446|NCT05551364|No Intervention|Conventional Treatment|The children will continue with their current rehabilitation program
33053447|NCT05551364|Experimental|Treatment with the ATLAS 2030 Exoskeleton|The children will receive 2 hours of exoskeleton ATLAS 2030 gait training a week for 3 months
33053448|NCT05551299|Experimental|Photodynamic therapy (PDT)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one PDT at baseline according to the clinical routine of the trial site.
33053449|NCT05551299|Experimental|Radiofrequency ablation (RFA)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one RFA at baseline according to the clinical routine of the trial site.
33053450|NCT05549323|Experimental|Treatment Group 1|Oral PF-07054894
33053451|NCT05549323|Placebo Comparator|Treatment Group 2|Matched Placebo
32740386|NCT05727995|Experimental|Experimental group|The dressing is a polyurethane film with acrylic adhesive that adheres the dressing to the skin surrounding the incision and a polyurethane shell that encapsulates the foam bolster and interface layer, providing a closed system. The PICO pump maintains negative pressure wound therapy (NPWT) at 80mmHg (nominal) +/- 20mmHg to the wound surface. Exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film. PICO is intended for use in wound sizes (surface area x depth) up to 400 cm3, which are considered to be low to moderately exuding. The kit is intended to be used for 7 days on low-exuding wounds and 6 days on moderately exuding wounds. The therapy duration of the kit may be less than indicated if a clinical practice or other factors, such as wound type, wound size, rate or volume of exudate, orientation of the dressing or environmental conditions, result in more frequent dressing changes.
32740387|NCT05727995|Sham Comparator|Control group|Patients in the control arm will receive a usual care dressing using absorbent cotton pads placed in contact with the wound. Dressings will be applied directly to the wound surface to protect the wound surface environment and the wound bed. Dressing chances are scheduled every 48h.
32740388|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
33332633|NCT05217472|Experimental|Ravagalimab|Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)
33332634|NCT05217472|Placebo Comparator|Placebo|Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)
33332635|NCT05217394|Experimental|OTHIG|"Occupational Therapy Handwriting Intervention Guideline - this is the experimental guideline to be tested in this study.~Section C: Intervention for Handwriting Readiness Skills~Handwriting development~Pre-writing skills~Gross motor skills activities~Fine motor skills activities~Motor visual skills activities Section D: Intervention for Handwriting Skills~Handwriting tools~Pencil grasp~Posture and position~Hand dominance~Writing capitals, lowercase, and numbers~Handwriting speed Section E: Handwriting Intervention Module~Session 1: Development of Handwriting Skills Activities~Session 2: Pre-writing Skills Activities~Session 3: Gross and Fine Motor Skills Activities~Session 4: Writing Capital Letters~Session 5: Writing Lowercase Letters~Session 6: Writing Numbers"
33418873|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
33053452|NCT05546697|Active Comparator|Yoga-based Intervention|Yoga classes will be gentle and physically accessible for people who are naïve to yoga. Teachers will frequently guide participants to focus on their breathing and coordinate movements with breath. Teachers will offer variations on the postures and encourage participants to choose variations that provide some challenge but do not cause strain or pain. Classes will be 1 hour long and include a brief sitting meditation, warm-ups, standing postures, and a final resting meditation. All participants will be invited to attend a synchronous yoga class via a HIPAA-compliant videoconference option once per week during the first 3 months of the study. Classes will be offered at multiple times throughout the week.
33053453|NCT05546697|Active Comparator|Behavioral Activation|The goal of Behavioral Activation Psychotherapy is to help people identify and (re)engage in meaningful and positive activities through psychoeducation, identification of values and associated activities, goal setting, problem-solving, and monitoring of goal completion. There will be a BA manual for therapists and training provided by study staff on the manual (e.g., asynchronous and synchronous training sessions). BA therapists will be community clinicians. BA will be provided individually via telehealth and will be billed to participant insurance. At the start of BA treatment, participants will be oriented to the time-limited nature of BA, with the expectation that they will attend 8 sessions over the course of 3 months.
32871608|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
33053454|NCT05543785|Placebo Comparator|control|"will receive 50 ml normal saline in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 30 mg ketorolac diluted in 10 ml saline in the peripheral general circulation."
33053455|NCT05543785|Active Comparator|ketorolac|"will receive 15 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 10 ml saline in the peripheral general circulation."
33053456|NCT05532800|Experimental|JS002|Cobort 1:150 mg/1mL Q2W PFS,Cobort 2:150 mg/1mL Q2W AI
33053457|NCT05532800|Placebo Comparator|Placebo|Cobort 1:/1mL Q2W PFS,Cobort 2:1mL Q2W AI
33053458|NCT05528510|Experimental|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) subcutaneous (SC) injection followed by guselkumab (Dose 2) SC injection.
33053459|NCT05528510|Experimental|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) SC injection followed by guselkumab (Dose 3) SC injection.
33053460|NCT05528510|Placebo Comparator|Group 3: Placebo|Participants will receive matching placebo SC injection.
33053461|NCT05527847|Active Comparator|Healthy Living with Diabetes (HLWD)|Participants will have a 6-week self-management program, followed by the option to work with a Community Health Worker for the remaining 4 months.
33053462|NCT05527847|Experimental|Peers EXCEL|Participants will have an 8-week self-management program, and will participate in phone calls with a peer for the remaining 4 months.
33053463|NCT05526742|Experimental|Group 1|"Subjects will receive single-dose of CKD-510 capsule in fasted state (treatment A) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive tablet in a fed state (treatment C) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
33053464|NCT05526742|Experimental|Group 2|"Subjects will receive single-dose of CKD-510 tablet in a fed state (treatment C) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive capsule in fasted state (treatment A) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
33053465|NCT05525845|Other|Food-Print Main Arm|Functional Magnetic Resonance Imaging (pCASL-MRI) after Caloric and Volumetric stimulus in lean patients will be performed on all patients in the study
33418874|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
33053466|NCT05524532|Experimental|Immulina TM 800 mg/day|Immulina Dietary supplementation (200 mg per capsule) 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 8 weeks duration
33053467|NCT05524532|Placebo Comparator|Placebo|inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 8 weeks duration
33053468|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 1|
33053469|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 2|
33053470|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 3|
33053471|NCT05522439|Placebo Comparator|Placebo|
33053472|NCT05516615||Healthy volunteers|"Aged more than 35~No known current or pre-existing problems that would affect the cardiovascular or respiratory system"
33053473|NCT05516615||Patient population|"Aged more than 35~Referral of subjects with known or suspected CAD for adenosine stress first-pass perfusion MRI based on the clinical judgement of their referring physician"
33053474|NCT05514717|Experimental|XMT-2056|XMT-2056 alone (monotherapy)
33053475|NCT05511389|Active Comparator|Anterolateral shock vector|"Patients with electrodes placed on the chest to obtain an anterolateral (front-to-side placement; also known as anteroapical) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
33053476|NCT05511389|Active Comparator|Anteroposterior shock vector|"Patients with electrodes placed on the chest to obtain an anteroposterior (front-to-back placement) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
33053477|NCT05510908||New, primary or recurrent disease|Considering or currently receiving cancer treatment
33053478|NCT05510908||Metastic or locally advanced cancer|This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
33053479|NCT05510908||Prior cancer|Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
33053480|NCT05509439|Experimental|Home Transfusion|"This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed.~Home Transfusion Program Components~Participants will be in the research study for up to six months"
33053481|NCT05505201|Experimental|Active stimulation group|Fifteen sessions of inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. 120% of the resting motor threshold will be used in the stimulation. One session of stimulation will last for a total of 30 minutes and a total of 1800 pulses in the form of 1 Hz stimulation.
33053482|NCT05505201|Sham Comparator|Sham stimulation group|Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held in an upright position and stimulation will be performed at the 10% of the resting motor threshold.
33053483|NCT05503797|Experimental|Group A|Participants with unresectable, locally advanced or metastatic solid tumors or primary CNS tumors harboring BRAF fusions, will receive 900 mg of FORE8394 administered with 150 mg of cobicistat once daily (QD), continuously in 3-weeks cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
33053484|NCT05503797|Experimental|Group B|Participants with recurrent primary CNS tumors harboring BRAF V600E mutations will receive 900 mg of FORE8394 administered with 150 mg of cobicistat QD, continuously in 3-week cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
33053485|NCT05502783|Experimental|Fostamatinib Arm|The subjects will receive oral fostamatinib daily for 12 weeks.
33053486|NCT05500313|Experimental|Hypno-breastfeeding Education|An announcement was made on social media platforms for hypno-breastfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail. An average of 4-5 women were included in each group. this group, the training consisted of 4 sessions and a total of 12 hours. It included information about breastfeeding, hypnosis approaches and different techniques. In line with the demands of the group, the session days and hours were decided with together. The Hypno-Breastfeeding Education Programme was offered to each group in a maximum of 2 weeks.
33053487|NCT05500313|Experimental|Standart Breastfeeding Education|An announcement was made on social media platforms for standart breatfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail.This education was done in one go. In this group, the training consisted of 1 sessions and a total of 3 hours. It included only information about breastfeeding.
33053488|NCT05499416|Experimental|Bimekizumab 320 mg SC injections|Bimekizumab 320 mg solution administered via SC injections every 4 weeks for 16 weeks.
33053489|NCT05496998|Experimental|Medtronic Intrepid™ TMVR TF System|Medtronic Intrepid™ TMVR TF System
33053490|NCT05495334||All participants|Eligible and enrolled subjects with knee OA pain who require treatment on the target knee as a part of pain management.
33053491|NCT05492864|Experimental|open bite with extrusion arch|single arm study, measures will be recorded before and after
33053492|NCT05491109|Experimental|Venous Assistance and Contracture Management System (VACOM)|Venous Assistance and Contracture Management System (VACOM) + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
33053493|NCT05491109|Active Comparator|Intermittent Pneumatic Compression (IPC)|Intermittent Pneumatic Compression (IPC) which is the standard care + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
33418875|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
33418876|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
33418877|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
33418878|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
33418879|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
33418880|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
33418881|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
33418882|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
33418883|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
33053497|NCT05480696|Experimental|Oligofructose Inulin Supplementation|The intervention group will receive a daily fibre supplementation of (fructo-oligosaccharide enriched inulin, 4g twice daily; Orafti®Synergy1, BENEO), a tasteless white powder contained within a tear-able, partitioned 4g sachet, sprinkled and dissolved in 125 mL of water.
33332636|NCT05217394|No Intervention|NOTi|"Natural Occupational Therapy Intervention - this means, the participants in this group are not exposed to the OTHIG. They receive natural OT intervention without exposure to the OTHIG.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia."
33332637|NCT01765400|Active Comparator|Prasugrel|Prasugrel oral 10 mg once daily for 2 weeks
33332638|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel oral 75 mg once daily for 2 weeks
33053498|NCT05480696|Sham Comparator|Maltodextrin Supplementation|The control group will receive a daily supplementation of carbohydrate placebo (isocaloric maltodextrin), identical in colour, packaging, preparation, and dose (4g, twice daily; C*Dry MD™,Cargill).
33053499|NCT05479773|Other|Group A|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask without suction ; 3) Lumena mask with suction."
33053500|NCT05479773|Other|Group B|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask with suction ; 3) Lumena mask without suction."
33053501|NCT05479773|Other|Group C|"Treatment order:~1) Lumena mask without suction ; 2) Lumena mask with suction ; 3) Standard NIV mask."
33053502|NCT05479773|Other|Group D|"Treatment order:~1) Lumena mask with suction ; 2) Lumena mask without suction ; 3) Standard NIV mask."
33053503|NCT05478499|Experimental|Deucravacitinib|
33053504|NCT05478499|Placebo Comparator|Placebo|
33053505|NCT05470920|Experimental|Electronic decision aid arm|Receive decision aid followed by an appointment with their oncologist.
33053506|NCT05470920|Active Comparator|Genetic counselor Arm|Receive pretest counseling with a genetic counselor.
33053507|NCT05470348|Experimental|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053508|NCT05463666||Population controls|Participants between 55 and 85 years of age without a diagnosis of RA, or other inflammatory RMD (osteoarthritis allowed). Controls > 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
33053509|NCT05463666||RA patients|Participants between 55 and 85 years of age with a diagnosis of RA by the treating rheumatologist. Patients > 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
33332639|NCT05217316|No Intervention|Control Group|Control group will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth.
33332640|NCT05217316|Experimental|Intervention Group|Both groups will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth. The intervention lies in which the intervention group will receive a supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child.
33332641|NCT05217238|Experimental|Age range of 18 to 44 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
33332642|NCT05217238|Experimental|Age range of 45 to 59 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
33418884|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
33418885|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
33418886|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
33053510|NCT05461768|Experimental|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053511|NCT05457465|Experimental|Hemp-Derived Cannabidiol Solution|Patients will administer a custom-formulated, hemp-derived, high-CBD solution twice daily for 4 weeks
33053512|NCT05453955|Experimental|Propofol-Remimazolam|General anesthesia was induced and maintained with propofol, then switched to remimazolam after 60 minutes from incision.
33053513|NCT05453955|Experimental|Remimazolam-Propofol|General anesthesia was induced and maintained with remimazolam, then changed to propofol after 60 minutes from incision.
33111286|NCT04664517|Active Comparator|FIN (Flexible intramedullary nail)|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
33111287|NCT04664517|Active Comparator|Long arm cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
33111288|NCT04664517|Other|Patient Choice FIN|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
33111289|NCT04664517|Other|Patient Choice cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
33111290|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (low nicotine dose)|participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111291|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (high nicotine dose)|participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111292|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (low nicotine dose)|participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111293|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (high nicotine dose)|participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111294|NCT05335915|Experimental|Fruit Flavored Pouch (low nicotine dose)|participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111295|NCT05335915|Experimental|Fruit Flavored Pouch (high nicotine dose)|participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
33111296|NCT05335915|Active Comparator|Own brand cigarettes|participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
33111297|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
33111298|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
33111299|NCT01215097|Experimental|Linagliptin|once a day
33111300|NCT01215097|Placebo Comparator|placebo|once a day
33111301|NCT04664322||NIV/HFNC|patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy
33111302|NCT04664322||HFNC/NIV|patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation
33111303|NCT03554174|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
33111304|NCT03554174|Experimental|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
33111305|NCT03554174|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
33111306|NCT03554174|Experimental|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
33418887|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
33111307|NCT04318795|Experimental|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
33111308|NCT04318795|Experimental|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
33111309|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
33111310|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
33418888|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
33418889|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
33418890|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
33418891|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
33111311|NCT04664010|Experimental|moderate COVID-19 group|patients with moderate COVID-19 receiving western medicine treatment
33111312|NCT04664010|Experimental|severe COVID-19 group|patients with severe COVID-19 receiving western medicine treatment
33111313|NCT04664010|Experimental|moderate COVID-19 with traditional Chinese medicine group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
33111314|NCT04664010|Experimental|moderate COVID-19 with combination therapy group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
33111315|NCT04664010|Experimental|severe COVID-19 with traditional Chinese medicine group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
33111316|NCT04664010|Experimental|severe COVID-19 with combination therapy group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
33111317|NCT04664127||Combination therapy (Kagocel + Valacyclovir: n=25)|Therapy according to routine practice (including Kagocel). Groups will be splitted during the final data analysis.
33111318|NCT04664127||Monotherapy by Valacyclovir (n=20)|Therapy according to routine practice. Groups will be splitted during the final data analysis.
33053514|NCT05452772|Active Comparator|Psilocybin|30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 30 mg of psilocybin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 40 mg for the second session.
33053515|NCT05452772|Active Comparator|Niacin|150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 150 mg niacin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 200 mg niacin for the second session.
33053516|NCT05452239|Experimental|Eptinezumab|Participants will receive an intravenous (IV) infusion of eptinezumab at Week 0 and Week 12.
33053517|NCT05452239|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching placebo to eptinezumab at Week 0. Then, all participants will receive a single IV infusion of eptinezumab at Week 12.
33053518|NCT05450692|Experimental|Group A: Ceralasertib plus durvalumab combination therapy|Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
33053519|NCT05450692|Active Comparator|Group B: Docetaxel monotherapy|Participants will be administered docetaxel (standard of care) administered intravenously.
33053520|NCT05448599|Experimental|6MW3211|Phase I, 6MW3811 monotherapy in 2 dose levels of 30mg/kg or 45mg/kg; phase II, 6MW3811 will be given in combination with AZA( cohort1) and AZA plus VEN(cohort 2)
33053521|NCT05447897|Other|Stakeholder Advisory Group|"To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.~Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group four times for 1-2 hours each."
33053522|NCT05447559|Placebo Comparator|Intraoperative only Surgical Antimicrobial Prophylaxis Arm|Placebo administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
33053523|NCT05447559|Other|Intraoperative and 24-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered 8-hourly following the preoperative dose (time=0) for two doses then placebo 8-hourly for three doses (total of 5 postoperative doses of cefazolin/placebo)
33053524|NCT05447559|Active Comparator|Intraoperative and 48-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
33053525|NCT05444933||Sequencing post-cabozantinib|Participants treated by cabozantinib and who received another systemic therapy post-cabozantinib.
33053526|NCT05444933||Long responders|Participants treated by cabozantinib and who had a disease controlled (CR, PR or SDi during > 12 months after cabozantinib initiation with or without additional local treatment).
33053527|NCT05444933||Non-responders|Participants treated by cabozantinib and who had a progressive disease less than 3 months after cabozantinib treatment initiation.
33053528|NCT05444933||Cabozantinib & rechallenge|Participants treated by cabozantinib who received systemic therapy and/or had prolonged treatment-free interval (≥ 12 weeks) between two cabozantinib treatment periods. Participants with at least one cabozantinib rechallenge could be included in this subgroup.
33053529|NCT05444933||Cabozantinib & therapeutic schedules|Participants treated by cabozantinib and who needed 1/ a dose increase following disease progression and/or a prior reduction, Or 2/ had any dose reduction/dose interruption of cabozantinib (schedule adaptation).
33053530|NCT05444933||Cabozantinib & local treatment|Participants treated by cabozantinib and who needed concomitant local treatment (LT) by surgery or radiotherapy
33053531|NCT05444933||Cabozantinib & elderly patients|Participants treated by cabozantinib and aged ≥ 75 years
33053532|NCT05442853|Active Comparator|Continuous Glucose Monitoring|Study subjects in this arm will receive glycemic management based on continuous glucose monitoring with CGM device. CGM readings will be available to patients, nurses, and the treating team. All treatment decisions for this group will be based on CGM readings, confirmatory POC readings (as necessary), and venipuncture.
33053533|NCT05442853|Active Comparator|Point of Care Glucose Monitoring|Study subjects in this arm will receive glycemic management based on point of care blood glucose readings. CGM will be placed in blinded mode and used for study comparison only. Patients, nurses, and other treatment team will be blinded to the CGM readings. All treatment decisions for this group will be based on POC readings and venipuncture
33053534|NCT05441501|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-80038114. The dose levels will be escalated based on the dose limiting toxicities (DLTs) evaluation by the study evaluation team (SET).
33053535|NCT05441501|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-80038114 at the recommended Phase 2 dose (RP2D) determined in Part 1.
33053536|NCT05438043|Experimental|Daratumumab|Participants will receive a single dose of daratumumab 16 milligrams per kilograms (mg/kg) intravenous (IV) or 1800 mg subcutaneous (SC) infusion on Cycle 1 Day 1 (28-day cycle), as monotherapy or in combination with standards of care (that is, pomalidomide and dexamethasone, lenalidomide and dexamethasone, carfilzomib and dexamethasone), depending on the treatment received in the parent study. Participants who received daratumumab IV during the parent study, will have an option to switch to daratumumab SC on Day 1 of any cycle during this long-term extension study.
33053537|NCT05435963|Experimental|COPD undergoing pulmonary rehabilitation|45 individuals with COPD will complete the UCLA-LS scale, CRQ, HADS, and 6 minute walk test before and after pulmonary rehabilitation.
33053538|NCT05427786|Experimental|Pre-PCI IC Nicorandil|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Nicorandil group will be administrated 8cc or more of the prescribed drug (Nicroandil) according to randomization into the coronary artery before starting balloon therapy."
33111319|NCT04664049||NRICM101|Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101
33111320|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
33111321|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
33111322|NCT04664088|Experimental|Acupuncture group|Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).
33111323|NCT04664088|Active Comparator|Medication group|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.
33111324|NCT00535067||Breast Cancer Survivors|
33111325|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
33111326|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
33111327|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
33111328|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
33111329|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
33111330|NCT04663854|Experimental|Trehalose|Trehalose Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks.
33111331|NCT04663854|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks.
33111332|NCT04664244|Experimental|All eligible patients|All eligible patients enrolled
33111333|NCT04663815|Other|AB arm|Animal-assisted activity intervention on 2nd day of hospitalization, control intervention on the 4th day of hospitalization.
33111334|NCT04663815|Other|BA arm|Control intervention on 2nd day of hospitalization, animal-assisted activity intervention on the 4th day of hospitalization.
33111335|NCT04663581|Experimental|Left Sided Colonoscopy|Left Sided starting position in colonoscopy
33111336|NCT04663581|Active Comparator|Right sided Colonoscopy|Right Sided starting position in colonoscopy
33111337|NCT04663698|Experimental|Healthy|Lung-healthy subjects, randomized lung function testing
33111338|NCT04663698|Experimental|Patient 1|COPD patients, randomized lung function testing
33111339|NCT04663698|Experimental|Patient 2|COPD patients, randomized lung function testing
33111340|NCT04663698|Experimental|Patient 3|COPD patients, randomized lung function testing
33111341|NCT04663698|Experimental|Patient 4|COPD patients, randomized lung function testing
33111342|NCT04663425||Sleeve gastrectomy operation|Outcome of patients that underwent sleeve gastrectomy with BMI greater than 60.
33111343|NCT04663425||Gastric bypass operation|Outcome of patients that underwent gastric bypass with BMI greater than 60.
33111344|NCT04663425||Gastric Band operation|Outcome of patients that underwent gastric banding with BMI greater than 60.
33111345|NCT04663659||diabetic group|Patients over the age of 18 with diabetes mellitus in intensive care unit
33111346|NCT04663659||non-diabetic group|Patients over the age of 18 without diabetes mellitus in intensive care unit
33111347|NCT04663971||Crohn's disease|Patients with Crohn's disease.
33111348|NCT04663971||Ulcerative colitis|Patients with Ulcerative colitis
33111349|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
33111350|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
33111351|NCT03504488|Experimental|Monotherapy - CAB-ROR2-ADC (BA3021) alone|BA3021 alone
33111352|NCT03504488|Experimental|Combination Therapy|CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
33111353|NCT04663542|Experimental|0-week immobilization|0-week brace immobilization after the surgery will be conducted.
33111354|NCT04663542|Experimental|2-week immobilization|2-week brace immobilization after the surgery will be conducted.
33111355|NCT04663542|Other|4-week immobilization|4-week brace immobilization after the surgery will be conducted.
33111356|NCT04663542|Other|6-week immobilization|6-week brace immobilization after the surgery will be conducted.
33111357|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
33111358|NCT04663269|Other|Control|Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
33111359|NCT04663269|Experimental|ANES Block|Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.
33111360|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy.
33111361|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
33053539|NCT05427786|No Intervention|Standard PCI|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Standard PCI group will be performed coronary intervention including starting balloon therapy without pre-administrated nicorandil."
33053540|NCT05426525|Experimental|Empagliflozin|Participants will be provided 10-25mg empagliflozin per day for 13 weeks.
33053541|NCT05426525|Placebo Comparator|Multivitamin-Placebo|Participants will be provided 1 multivitamin-placebo per day for 13 weeks.
33053542|NCT05426343|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
33053543|NCT05426343|Active Comparator|AZD1222|n=ChAdOx1 nCoV-19 vaccine
33053544|NCT05423665||Fetal growth restricted|Observation of cardiac remodeling perinatal and postnatal
33053545|NCT05423665||Appropriately grown|Observation of cardiac remodeling perinatal and postnatal
33053546|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Single Ascending Dose [SAD] Cohorts A-F)|Non-Asian healthy participants will receive a SAD of either JNJ-64457744 or matching placebo as an oral formulation under fasted conditions on Day 1. Cohort F will be optional.
33053547|NCT05423106|Experimental|Part 1: JNJ-64457744 (Cohorts G-H)|Non-Asian healthy participants will receive 3 single doses of JNJ-64457744 as an oral formulation in 3 intervention periods (to assess inter-subject PK-PD) matching the doses evaluated in Cohorts A, C and E for Cohort G and Cohorts B, D and F for Cohort H, under fasted conditions on Day 1. Cohort H will be optional for Intervention period 3.
33053548|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Cohort I)|Non-Asian healthy participants who previously received study intervention under fasted conditions will receive either JNJ-64457744 or matching placebo as an oral formulation (depending upon what was administered previously in Cohorts A to F) under fed conditions on Day 1.
33053549|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Cohort J)|Asian healthy participants will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo, as an oral formulation, under fasted conditions on Day 1.
33053550|NCT05423106|Experimental|Part 1: JNJ-64457744 (Cohort K)|Optional Cohort K: Non-Asian healthy participants will receive an oral formulation of JNJ-64457744 in the first intervention period and will cross over to receive the other formulation during the second intervention period, under fasted conditions on Day 1.
33053551|NCT05423106|Experimental|Part 2 JNJ-64457744 or Placebo|Chronic hepatitis B participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate [TDF], tenofovir alafenamide [TAF] and entecavir [ETV]) will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo as an oral formulation, under fasted condition on Day 1.
33053552|NCT05423106|Experimental|Part 3: JNJ-64457744 or Placebo (Multiple Ascending Doses [MADs])|Participants will receive MADs of either JNJ-64457744 or matching placebo once weekly under fasted conditions as an oral formulation.
33053553|NCT05417776|Experimental|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive [68Ga]CBP8 and undergo PET-MRI.
33053554|NCT05417776|Experimental|First degree relatives of a family member with pulmonary fibrosis|First degree relatives of a family member with pulmonary fibrosis will receive [68Ga]CBP8 and undergo PET-MRI.
33053555|NCT05413707|Experimental|Fixation group|"Patients are placed in a prone position on the operating table. Fixation of the posterior malleolus fracture. Posterior, and/or lateral and medial malleolus fractures will be treated with open reduction and internal fixation. ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm. Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus. The posteromedial fragment in Mason and Molloy type 2B will be fixed with one or more screws, or plate, if this fragment is displaced more than 2 mm. A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced >2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suture button."
33053556|NCT05413707|Active Comparator|Non-fixation group|"Patients are placed in a supine position on the operating table. No fixation of the PMF. The PMF is reduced by ligamentotaxis. Lateral and/or medial malleolus fractures will be treated with ORIF if present.~ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm.~Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus.~A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced >2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suturebutton."
33053557|NCT05406505|Experimental|Dapagliflozine 10mg|
33053558|NCT05406505|Placebo Comparator|Placebo|
33053559|NCT05405660|Experimental|barzolvolimab 150 mg in patients with Symptomatic Dermographism|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
33053560|NCT05405660|Experimental|barzolvolimab 300 mg in patients with Symptomatic Dermographism|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
33053561|NCT05405660|Placebo Comparator|Placebo Comparator in patients with Symptomatic Dermographism|Placebo injection subcutaneous every 4 weeks for 20 weeks
33053562|NCT05405660|Experimental|barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
33053563|NCT05405660|Experimental|barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
33053564|NCT05405660|Placebo Comparator|Placebo Comparator in patients with Chronic Inducible Cold Urticaria|Placebo injection subcutaneous every 4 weeks for 20 weeks
33053565|NCT05403593||Participants with Intracranial Stenosis|Patients with Intracranial Stenosis who undergo Mechanical Thrombectomy will be added to the registry given they meet the age inclusion criteria.
33053566|NCT05402553|Active Comparator|Intervention|
33053567|NCT05402553|Placebo Comparator|Control|
33111362|NCT03312738|Experimental|Everolimus + Exemestane|Everolimus 10mg/Day + Exemestane 25mg/Day
33418892|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
33053568|NCT05402072|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
33053569|NCT05402072|Experimental|Autologous matrix-induced chondrogenesis (AMIC)|Those allocated to the AMIC treatment group will also receive microfracture. Once the walls of the debrided lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The dry Chondro-Gide® matrix will be prepared by cutting it to 10% smaller than the focal defect (as it increases in size about 10% after moistening). Once the cartilage lesion is dried manually, the implant will then be secured to the defect in a press-fit fashion to the surrounding cartilage. Manual pressure is then applied to secure the implant into the defect and the hip is released from traction and rotated to facilitate further fixation of the graft. Traction is then applied to arthroscopically confirm position and fixation of the implant.
33053570|NCT05397730||TBP|Patients with definite or probable tuberculous pleuritis
33418893|NCT02111876||AHRF follow-up|
33418894|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
32871609|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
33053571|NCT05397730||Non-TBP|Patients without tuberculous pleuritis
33053572|NCT05395663|Active Comparator|Arm 1: Usual practice|People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides.
33053573|NCT05395663|Experimental|Arm 2: Health navigator|"People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides. In addition, a trained health navigator will meet with the homeowner three times to assist the homeowner's decision-making.~Activities include: i) Interpreting results, ii) Improving health literacy and numeracy through teach-back moments, iii) Assessment of household risk for contaminants from well and septic, iv) Assessment of risk to family members, pets, livestock, etc v) Coaching to resolve ambivalence or lack of motivation and other barriers using elicit-provide-elicit motivational interviewing; vi) Assistance with decision-making and weighing financial options, and vii) Goal-setting and action plans."
33053574|NCT05393934|Placebo Comparator|PNC (Pediatric Nutrition Care)|This first group will be given pediatric nutrition care (PNC) in visit 0. In this group parents will receive nutritional advice about how many calories are needed, the type and form of food that can be given so that the baby can gain weight accordingly.
33053575|NCT05393934|Active Comparator|FSMP (Food for Special Medical Purposes) & PNC (Pediatric Nutrition Care)|In this second group, subject will receive PNC in visit 0 and food for special medically purposes/FSMP that will be given according to daily calorie needs which are determined based on ideal body weight (BB) according to body length. In general, FSMP will be given 3 times a day, according to the needs of each subject. Parents will be taught about preparation of FSMP e.g. dissolving and the correct amount of product (image will be attached in the appendix). FSMP will be given during the research period and will be discontinued when not needed anymore.
33053576|NCT05393427|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053577|NCT05388370||Base Cohort|The Base Cohort includes all enrolled patients aged 3 to < 18 years.
33053578|NCT05388370||Nested Prospective Cohort|The Nested Prospective Cohort will include the subset of Base Cohort patients aged 8 to < 18 years who have not reached Tanner Stage V on the index date
33053579|NCT05386329|Experimental|Therapist-guided smartphone-delivered CBT|Participants will complete app-based cognitive-behavioral therapy (CBT) treatment for major depressive disorder (MDD) through their personal mobile smartphone. They will also be assigned a therapist, who will provide brief virtual treatment sessions (up to 25 minutes via a video platform) over the course of the same treatment period.
33053580|NCT05385692|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053581|NCT05383118|Experimental|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~One multimedia e-learning lesson on promoting brain health and preventing dementia;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to dementia risk factors"
33418895|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
33053582|NCT05383118|Active Comparator|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~One multimedia e-learning lesson on mild cognitive impairment;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to mild cognitive impairment"
33418896|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
33418897|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
33053583|NCT05379595|Experimental|Cohorts A, B, and C: Amivantamab Monotherapy|Participants with left-sided colorectal cancer (CRC) in Cohort A (no prior anti-epidermal growth factor receptor [EGFR] therapy) and in Cohort B (post anti-EGFR therapy), and right-sided CRC in Cohort C (with or without anti-EGFR therapy), will be administered intravenous (IV) infusion of amivantamab 1050 milligrams (mg) if body weight (BW) is less than (<) 80 kilograms (kg) or 1400 mg if BW is greater than or equal to (>=) 80 kg, as monotherapy on Days 1 and 15 of Cycle 2 (28-days cycle).
33053584|NCT05379595|Active Comparator|Cohorts Ph1b-D and D: Amivantamab+5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)|Participants who are anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab 1050 or 700 mg (dose level 0 [DL0]) if BW is <80 kg, or 1400 or 1050 mg (dose de-escalation [DL-1]) if BW is >= 80 kg, on Days -1, -2, 8 and 22 of Cycle 1 and along with mFOLFOX6 SOC chemotherapy on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days) in Phase 1b dose confirmation Cohort (Cohort Ph1b-D). Participant in Phase 2 Cohort (Cohort D) will receive recommended Phase 2 combination dose (RP2CD) of amivantamab along with mFOLFOX6 SOC chemotherapy determined in Cohort Ph1b-D.
33053585|NCT05379595|Active Comparator|Cohorts Ph1b-E and E: Amivantamab+5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)|Participants who are anti-EGFR treatment naïve, have not received irinotecan-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab along with FOLFIRI SOC chemotherapy on Days -1, -2, and 8 of Cycle 1 and Days 1 and 15 of Cycle 2 in Ph1b-E. For Cohort E, RP2CD determined in Ph1b-E will be administered.
33053586|NCT05379322|Experimental|Group A (Anti-TNF)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the diffuse myeloid phenotype will be assigned to receive anti-TNF medication at the discretion of the treating physician.
33053587|NCT05379322|Experimental|Group B (JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the lymphoid- myeloid phenotype will be assigned to receive JAK inhibitor medication at the discretion of the treating physician.
33053588|NCT05379322|Experimental|Group C (Anti-TNF or JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the pauci-cellular phenotype will be randomized to either anti-TNF or JAK inhibitor medication 1:1.
33053589|NCT05378165|Experimental|Music group|The music group listened to Acemasiran-type classical Turkish music with a headset from an MP3 player starting at about 10 min before colonoscopy until completion of the procedure.
33053590|NCT05378165|Experimental|Stress ball group|"The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
33053591|NCT05378165|Experimental|Video group|"The patients in the video group allowed to watch a licensed virtual reality application, A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
33053592|NCT05378165|Other|Control group|Standard colonoscopy was performed on the patients in the control group, without any additional intervention.
33053593|NCT05376696|Experimental|Set for Variability|"Students in the experimental group will receive an average of 10-12 hrs. of small group intervention. All lessons will include (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) teaching common, vocabulary words (iii)shared book reading, and (iv) Set-for-variability component (SfV). This component will focus on teaching students how to find the sound variation of a grapheme-phoneme rule. For example when to use the sound /k/in /ch/ to read words such as stomach"
33053594|NCT05376696|Active Comparator|Current best practices|The control group will receive current-best practices (CBP). The participants will receive a similar approach as in the intervention group without Set-for-Variability. The participants will receive (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) vocabulary, (iii) shared book reading, and (iv) the absence of teaching Set-for-Variability. Instead of Set-for-variability, the participants will receive sight word reading of frequent words. They will learn the most frequent pronunciation of vowels: ee, ea, oo, ou, oa, ai, ay
33053595|NCT05373862|Experimental|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants with cardiac arrhythmias/ablation history who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for atrial and ventricular procedures will be using multi-electrode mapping catheter.
33418898|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
33053598|NCT05368389||Healthdot Patients|This group represents the patient who have undergone a bariatric procedure and had the Healthdot device attached and had data collected from the device for 10 days.
33053599|NCT05368389||Healthdot providers|This group represents the providers or study/hospital staff who were involved in the attachment, recruitment, and enrollment of the Healthdot patients.
33053600|NCT05367570||Normal weight group|The first work package of this study is cross-sectional. The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
33053601|NCT05367570||Overweight/obesity group|The first work package of this study is cross-sectional The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
33053602|NCT05363982|Active Comparator|Transcranial Photobiomodulation (tPBM) Treatment|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light is applied to forebrain.
33053603|NCT05363982|Sham Comparator|Placebo/ Sham Treatment|The sham treatment will mimic the tPBM procedure, while delivering no light.
33053604|NCT05363618|Active Comparator|Product Tolerability Arm|Study Product MHS-1031 1g (1.4 ml) per day
33053605|NCT05363618|Placebo Comparator|Placebo Tolerability Arm|Placebo (Neotame 7.92 mcg/g, phosphoric acid, and sterile water) 1.4 ml per day
33053606|NCT05351801|Active Comparator|THC (Dronabinol)|Target dose of 10mg per day.
33053607|NCT05351801|Active Comparator|CBD (Epidolex)|Target dose of 800 mg per day.
33053608|NCT05351801|Active Comparator|THC + CBD (Nabiximols)|Target dose of 10.8 mg / 10 mg per day.
33053609|NCT05351801|Placebo Comparator|Placebo|Identical in appearance to the three active comparators.
33053610|NCT05349175|Experimental|Cohort A|Receives AIR device feedback beginning immediately after training
33053611|NCT05349175|Experimental|Cohort B|Receives AIR device feedback beginning 2 months after training
33053612|NCT05349175|Experimental|Cohort C|Receives AIR device feedback beginning 4 months after training
33053613|NCT05347485|Experimental|Ciltacabtagene Autoleucel (Cilta-cel)|Eligible participants will receive bridging therapy (that is, anti-plasma cell directed treatment) based on participant's clinical status and timing of availability of cilta-cel (JNJ-68284528) along with lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square [mg/m^2] intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants will receive a single IV infusion of cilta-cel (JNJ-68284528) at a total targeted dose of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg).
33053614|NCT05347095|Experimental|Group 1: Guselkumab|Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
33053615|NCT05347095|Experimental|Group 2: Guselkumab|Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
33053616|NCT05347095|Experimental|Group 3: Placebo|Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
33053617|NCT05346406|Active Comparator|Peripherally Inserted Central Catheter|
33053618|NCT05346406|Experimental|Long Peripheral Catheter|
33053619|NCT05342948||pRPL|Primary RPL patients: no prior birth ≥22 weeks
33053620|NCT05342948||sRPL with a first born boy|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only boy(s)
33053621|NCT05342948||sRPL with a first born girl|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only girl(s)
33053622|NCT05341115|Experimental|Leuprorelin Acetate Depot 3M 11.25 mg|Participants with CPP having body weight ≥20 kg will receive the recommended dose of leuprorelin acetate depot 11.25 mg subcutaneous administration (SC) every 12 weeks based on the standard of 30～180ug/kg/4weeks for the 24-week Treatment Period. It is not recommended to exceed the dose above 180 μg/kg.
33111363|NCT03312738|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
33053623|NCT05339685|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053624|NCT05337605||Hand driven tissue removal system|Endometrial polyp removed by hysteroscopic hand-driven tissue removal system in a previous study.
33053625|NCT05337605||Motor driven tissue removal system|Endometrial polyp removed by hysteroscopic motor-driven tissue removal system in a previous study.
33053626|NCT05337046||Tissue removal system|Endometrial polyp removed by hysteroscopic tissue removal system in a previous study.
33053627|NCT05337046||Bipolar resectoscopy|Endometrial polyp removed by hysteroscopic bipolar resectoscopy in a previous study.
33053628|NCT05329766|Experimental|A1: First Line - Treatment Naïve Participants|Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W)
33053629|NCT05329766|Experimental|A2: First Line - Treatment Naïve Participants|Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W
33111364|NCT03465020||ITP patients|On active treatment
33418899|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
33053630|NCT05329766|Experimental|B1: Second Line or greater Checkpoint Inhibitor Naïve Participants|Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion
33053631|NCT05329766|Experimental|B2: Second Line or greater Checkpoint Inhibitor Naïve Participants|Zimberelimab Q4W and Quemliclustat Q2W administered by IV infusion
33418900|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
33418901|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
33418902|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
33418903|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
33418904|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
33053632|NCT05329766|Experimental|Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants|Domvanalimab and zimberelimab Q3W administered by IV infusion
33053633|NCT05327114|Experimental|Nipocalimab|Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
33053634|NCT05327114|Placebo Comparator|Placebo|Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
33053635|NCT05321368|Experimental|LINKED-HEARTS Program|"Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data.~Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources.~The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control."
33053636|NCT05321368|No Intervention|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
33053637|NCT05319106|Experimental|Stem cell preparation combined with silver ion dressing|
33053638|NCT05319106|Placebo Comparator|silver ion dressing|
33053639|NCT05317299|Active Comparator|Resistance Exercise Group|During 8 week progressive resistance exercises (three times a week)
33053640|NCT05317299|Active Comparator|Plyometric Exercise Group|During 8 week progressive plyometric exercises (three times a week)
33053641|NCT05317299|Active Comparator|High Intensity Interval Training Group|During 8 week progressive Hight Intensity Interval Training (three times a week)
33053642|NCT05314985|Experimental|Prehab Group / Intervention Group|4 to 8 weeks of preoperative physical therapy training and education intervention before total knee replacement surgery.
33053643|NCT05314985|No Intervention|Control Group|Usual care / no treatment before total knee replacement surgery.
33053644|NCT05314413|Experimental|Single Leg Immobilization - Males|Males will be subjected to 7-days of single-leg immobilization.
33053645|NCT05314413|Experimental|Single Leg Immobilization - Females|Females will be subjected to 7-days of single-leg immobilization.
33053646|NCT05313243|Experimental|Brentuximab vedotin (brentuximab) and pembrolizumab|"All subjects are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy.~After receiving 35 total doses of pembrolizumab (i.e. scheduled for 16 doses in the combinatorial setting and 8 doses as monotherapy), a subject's pembrolizumab treatment will be complete."
33053647|NCT05308537|Experimental|Mindful Compassion Care Program|The MCCP comprises six regular 1 hour and 30-minute sessions and 1 all-day class lasting 4 hours and 30 minutes.
33053648|NCT05308537|No Intervention|Waiting List|
33053649|NCT05308264|Experimental|Experimental|Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd
33053650|NCT05305963||Case|250 women diagnosed with BC when they were aged 30-39 years
33053651|NCT05305963||Control|750 controls currently aged 30-39 years
33053652|NCT05303558||Participants With High-risk Localized Prostate Cancer|Adult participants from Japan, South Korea, and Taiwan with high-risk localized prostate cancer (HR LPC) who received radical prostatectomy (RP) and perioperative (neoadjuvant and/ or adjuvant) hormonal therapy will be observed from the date of confirmed HR LPC diagnosis until death, lost to follow-up (last known visit), or end of study period, whichever comes first. This study will utilize data from electronic medical records (EMR) in South Korea and Taiwan, and data from chart reviews in Japan. Data will be analyzed retrospectively from 1 January 2015 to 30 June 2017, with a follow-up till 30 June 2022.
33332643|NCT05217238|Experimental|Age range of 60 to 80 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
33332644|NCT03796208|Experimental|Tobacco Intervention|Participants in this group will be randomized to the Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC) intervention.
33053653|NCT05301114|Experimental|Intervention participants|Among patients who completed the social needs screening as a part of standard of care, all stage I-III Black cancer survivors will be invited to participate in a three or six-month community health worker intervention. The community health worker will assess social needs and provide three or six months of support depending on risk level.
32740389|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
33053654|NCT05301023|Experimental|Individual group|In the individual group, the participants receive individualized antibiotic therapy.
33053655|NCT05301023|Active Comparator|Standard group|In the standard group, the participants receive standard antibiotic therapy as defined by the national guideline.
33053656|NCT05300022|No Intervention|Arm 1: Semi-structured Interviews|Arm 1 will be conducted from months 0-15 and will use interviews to better understand existing challenges in diabetes technology educational practices. It is not a clinical trial, but is a crucial part of what builds to the clinical trial.
33053657|NCT05300022|Experimental|Arm 2: Designing an App Delivered Curriculum|Arm 2 will be conducted from months 10-33 and will use information learned in arm 1 to develop and beta test an educational curriculum. Arm 2 also is not a clinical trial, but is a crucial part of what builds to the clinical trial.
33053658|NCT05300022|Active Comparator|Arm 3: TeKnO T1D: Parents Pilot Study|Arm 3 will be conducted from months 30-60 and involves a pilot and feasibility study of the newly developed educational curriculum. This is the clinical trial.
33053659|NCT05299073|Experimental|MB09 (denosumab biosimilar)|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
33053660|NCT05299073|Active Comparator|US-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
33053661|NCT05299073|Active Comparator|EU-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
33053662|NCT05298696|Active Comparator|Intervention|Cilostazol 100 mg twice daily for treatment period
33053663|NCT05298696|Placebo Comparator|Control|placebo twice daily for treatment period
33053664|NCT05295823|No Intervention|Healthcare provider performed standard PVR measurement using existing ultrasound technology|The Urologic healthcare provider will perform standard point-of-care PVR measurement on the participant (3 consecutive measurements during the same encounter) using existing ultrasound technology
33053665|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and bladder ultrasound images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images
33053666|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and abstract bladder images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images
33053667|NCT05295823|Experimental|Self PVR measurement using Butterfly and bladder ultrasound images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images (prior to catheterization, if needed)
33053668|NCT05295823|Experimental|Self PVR measurement using Butterfly and abstract bladder images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images (prior to catheterization, if needed)
33053669|NCT05293782|Active Comparator|Kinesiotaping on trunk flexor muscles|Kinesiotaping
33053670|NCT05293782|Active Comparator|Kinesiotaping on trunk extensor muscles|Kinesiotaping
33053671|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk flexor muscles|Kinesiotaping
33053672|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk extensor muscles|Kinesiotaping
33053673|NCT05287425|Experimental|Gentamicin eye drops|4 drops daily in both eyes for 7 ± 1 days
33053674|NCT05287425|Experimental|Ciprofloxacin eye drops|4 drops daily in both eyes for 7 ± 1 days
33053675|NCT05287425|Active Comparator|Povidone eye drops unpreserved|4 drops daily in both eyes for 7 ± 1 days
33053676|NCT05287425|Active Comparator|Povidone eye drops preserved|4 drops daily in both eyes for 7 ± 1 days
33053677|NCT05276492|Experimental|Group 1: Dose Regimen 1|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal every other day.~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
33068057|NCT04519450||ICU patients without an with chronic respiratory diseases|The group will consist of >50 patients admitted to the intensive care unit, of which at least 20 with chronic respiratory diseases. Patients of both sexes, patients with and without chronic respiratory diseases, and also patients requiring mechanical ventilation were included and their demographic characteristics and outcomes registered. All patients will sign an informed consent form before inclusion in the prospective observational study.
33068058|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
33068059|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
33332645|NCT03796208|Active Comparator|Treatment As Usual|Participants in this group will be randomized to tobacco treatment as usual.
33111365|NCT04686500|Other|Deep Inspiration Breath-hold (DIBH) Respiratory Motion|DIBH qualified patient will experience one high-resolution CT scan as SOC and additional 3 low resolution/lower dose CT scans to further investigate inter-DIBH patient surface and tumor position stability and repeatability
33111366|NCT03303339|Experimental|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
33111367|NCT03303339|Experimental|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
33111368|NCT03303339|Experimental|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
33111369|NCT04686461|Experimental|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks
33111370|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
33111371|NCT03299946|Experimental|Arm 1|
33111372|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
33111373|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
33111374|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
33111375|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
33111376|NCT00535379|Experimental|1|
33111377|NCT00535418|Experimental|Letrozole|
33111378|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
33111379|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
33111380|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
33111381|NCT03288948|Active Comparator|Standard Contrast Increment|
33111382|NCT03288948|Experimental|Reduced Contrast Increment|
33111383|NCT03288948|Experimental|No Contrast Increment|
33111384|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
33111385|NCT04679064|Active Comparator|Phisician's choice of standard chemotherapy|"Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21~+/- Bevacizumab at defined scehedule"
33111386|NCT04679064|Experimental|Niraparib+Dostarlimab|Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28
33111387|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
33111388|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
33111389|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
33111390|NCT04662957|Experimental|Probiotic preparation|Multi-strain probiotic mixture. The daily dose was five billion (2 capsules/day).
33111391|NCT04662957|Placebo Comparator|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture (2 capsules/day).
33111392|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
33111393|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
33111394|NCT04679103|Experimental|Eculisumab (JSC GENERIUM, Russia)|Eculizumab
33111395|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
33111396|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
33361287|NCT03918265|Experimental|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
33361288|NCT03920839|Experimental|INCMGA00012 + gemcitabine/cisplatin|
33361289|NCT03920839|Experimental|INCMGA00012 + pemetrexed/cisplatin|
33361290|NCT03920839|Experimental|INCMGA00012 + pemetrexed/carboplatin|
32740390|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
33053678|NCT05276492|Experimental|Group 2: Dose Regimen 2|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1, day 3, day 5 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
33053679|NCT05276492|Experimental|Group 3: Dose Regimen 3|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 and day 4 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
33053680|NCT05276492|Experimental|Group 4: Dose Regimen 4|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
33053681|NCT05276466|Other|Single arm|All subject's samples will undergo the same diagnostic test utilizing Polymerase Chain Reaction and Next-Generation DNA Sequencing
33053682|NCT05275023|Experimental|Arm 1: JNJ-73763989 + PD-1 Inhibitor + Nucleos(t)ide analog (NA)|Participants will receive JNJ-73763989 subcutaneous (SC) injections and single dose of programmed cell death protein receptor-1 (PD-1) inhibitor as intravenous (IV) infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide [TAF] or entecavir [ETV]).
33053683|NCT05275023|Experimental|Arm 2: JNJ-73763989 + PD-1 Inhibitor + NA|Participants will receive JNJ-73763989 SC injections and multiple doses of PD-1 inhibitor as IV infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, TAF or ETV).
33332646|NCT05217160|Experimental|KeraStat® Gel with Morphine|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
33361291|NCT03920839|Experimental|INCMGA00012 + paclitaxel/carboplatin|
33361292|NCT01131793|Experimental|RF Guidewire|
33361293|NCT03135548|Experimental|Spesolimab (low dose)|
33053684|NCT05272150|Experimental|Cohort A: Moderate-to-severe Plaque Psoriasis|Participants will receive either guselkumab subcutaneously (SC) or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
33053685|NCT05272150|Experimental|Cohort B: Moderate-to-severe Scalp Psoriasis|Participants will receive either guselkumab SC or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
33053686|NCT05270902|Active Comparator|Adsorber Group|"Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences.~For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1."
33053687|NCT05270902|No Intervention|Control|The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
33053688|NCT05267678||Pregnant women with history of recurrent miscarriage|
33053689|NCT05266898|Experimental|Gardasil-9 recipients|Participants receive 3-dose Gardasil-9 vaccine series.
33053690|NCT05266872||PD patients|Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)
33053691|NCT05266872||Healthy controls|Gender- and age-matched healthy controls
33053692|NCT05265377|Experimental|STELO Exoskeleton|9 treatment sessions will be performed with the Stelo exoskeleton.
33068060|NCT04519060|No Intervention|No eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care.
33361294|NCT03135548|Experimental|Spesolimab (high dose)|
33361295|NCT03135548|Placebo Comparator|Placebo|
33361296|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
33332647|NCT05217160|Active Comparator|KeraStat® Gel|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
33332648|NCT05216848||nulliparas with no existing complications in the third trimester|"The investigators involve every nullipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language"
33332649|NCT05216848||multiparas with no existing complications in the third trimester|"The investigators involve every multipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language, previous caesarean section"
33332650|NCT01495676|Active Comparator|Radiotherapy + cisplatin|
33332651|NCT01495676|Experimental|Radiotherapy + cisplatin + gemcitabine|
33053693|NCT05265273|Experimental|Nipocalimab|Participants aged 2 to less than [<] 18 years of age will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).
33053694|NCT05264740|Experimental|Motivational interviewing|
33332652|NCT03739346|Experimental|Control|Tell, show, do technique
33332653|NCT03739346|Experimental|Intervention|Hypnosis.
32740391|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
32740392|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
33053695|NCT05264740|Active Comparator|no motivational interviewing|
33053696|NCT05262491|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053697|NCT05261399|Active Comparator|Chemotherapy|Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W
33053698|NCT05261399|Experimental|Savolitinib + Osimertinib|300 mg savolitinib BID plus 80 mg osimertinib QD
33053699|NCT05259722|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for up to 24 weeks
33053700|NCT05259722|Active Comparator|Alitretinoin capsules 30 mg per capsule|1 capsule per day for up to 24 weeks
33053701|NCT05259657|Experimental|Lymfit intervention|Participants randomized to the intervention group will be allocated a pre-registered Inspire II model Fitbit. The kinesiologist will design a personalized exercise prescription for the participant. The kinesiologist will follow up with the participants every 2 weeks for 3 months to discuss their progress and to modify or advance their exercise prescriptions as needed.
33053702|NCT05259657|Other|Wait-list control arm|The control group participants will begin receiving the Lymfit intervention 3 months after they sign the consent form.
33053703|NCT05258721|Experimental|Treatment Group|Participants with gingivitis or periodontitis (Stage I or II) brush with ClōSYS® Sensitive Fluoride Toothpaste twice daily and rinse with ClōSYS® Sensitive Rinse twice daily after brushing.
33053704|NCT05257785|Experimental|Lymfit exercise intervention|Participants randomized to the intervention group will be allocated a pre-registered Fitbit, a personalized exercise prescription designed by the kinesiologist, and 12 weeks of supervision by the kinesiologist.
33053705|NCT05257785|Other|Waitlist control|Participants will receive the exact same Lymfit exercise intervention 3 months after they consent to participate in the study.
33053706|NCT05257057||Endometrial hyperplasia|These are patients with a diagnosis of endometrial hyperplasia at WellSpan in the study time frame diagnosed via endometrial biopsy, dilation and curettage, or hysterectomy.
33053707|NCT05255003|Experimental|Modified dose LMWH without platelet transfusion support|"Patients will be given modified dose LMWH as below based on the first platelet count of the day (daily in admitted patients or at least 3 times a week in outpatients), without empiric platelet transfusion:~I. Platelet count 25-50,000/µL: 50% dose LMWH~II. Platelet count < 25,000/µL: hold anticoagulation"
33053708|NCT05255003|Active Comparator|Full dose LMWH with platelet transfusion support|"Patients assigned to full dose LMWH will be empirically transfused will be given for 14 days when the first platelet count of the day falls below 50,000/uL (daily inpatient or at least 3 times a week in outpatients). Post-transfusion counts will not be routinely obtained unless there are clinical indications, such as prior to a procedure or reasonable expectation that a single transfusion will be insufficient to achieve the target (50,000/uL).~After Day 14, patients will be transitioned to modified dose LMWH as the other arm without platelet transfusion.~LMWH will be prescribed as standard of care and can include enoxaparin, dalteparin, or tinzaparin. Full dose LMWH is listed as the following:~Enoxaparin - 1mg/kg subcutaneously twice daily~Dalteparin - 200 IU/kg subcutaneously daily for the first month of an acute VTE then 150 U/kg subcutaneously daily thereafter~Tinzaparin - 175 units/kg subcutaneously daily"
33053709|NCT05254496|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
33332654|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
33332655|NCT01318876||University of British Columbia, Vancouver.|
33332656|NCT01318876||Health care workers in Halifax|
33332657|NCT01318876||Health care workers from CHUQ hospitals|
33332658|NCT01318876||Health care workers from Toronto|
33332659|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
33332660|NCT01318876||The Ottawa General Hospital, Ottawa|
33053710|NCT05254496|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern.
33053711|NCT05254496|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
33053712|NCT05249608|Other|Single arm|A single arm study, only investigational product-the Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity in patients with a BMI ≥ 30 kg/m2. to evaluate the safety and performance of the investigational device for the intended use.
33053713|NCT05246137|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 ug/dose|COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA
33053714|NCT05245812|Experimental|Treatment arm (SPrNSM)|Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm)
33053715|NCT05245474|Experimental|CRT+concurrent PD-1 inhibition (Experiment Arm 1)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
33053716|NCT05245474|Experimental|CRT+sequential PD-1 inhibition (Experiment Arm 2)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 15 after completion of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
33053717|NCT05245474|Active Comparator|CRT without PD-1 inhibition (Control Arm)|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 8~12 weeks after completion of radiation.
33053718|NCT05242484|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053719|NCT05242484|Experimental|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33332661|NCT05122624|Experimental|Score intervention arm|The PredicTB score will be implemented in this arm.
32871610|NCT05747781|Active Comparator|Pilot Phase|12 patients with glaumatous optic neuropathy
33053720|NCT05242484|Experimental|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053721|NCT05242484|Experimental|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053722|NCT05242484|Experimental|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053723|NCT05242484|Experimental|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053724|NCT05242471|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053725|NCT05242471|Experimental|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053726|NCT05242471|Experimental|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053727|NCT05242471|Experimental|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053728|NCT05242471|Experimental|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33111397|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
33332662|NCT05122624|No Intervention|Control arm|The standard of care will be conducted in this arm.
33332663|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
33332664|NCT05663086|Experimental|Low-dose vaccine|30μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
33332665|NCT05663086|Experimental|High-dose vaccine|60μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
33053729|NCT05242471|Experimental|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
33053730|NCT05242445|Experimental|Cohort 1: Cetrelimab or Placebo (Dose 1)|Participants will receive cetrelimab Dose 1 or placebo via subcutaneous (SC) injection on Day 1.
33053731|NCT05242445|Experimental|Cohort 2 (Optional): Cetrelimab or Placebo (Dose 2)|Participants will receive cetrelimab Dose 2 or placebo administered via an Intravenous (IV) infusion on Day 1 based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as pharmacokinetic (PK) and receptor occupancy (RO) data through at least day 4 postdose).
33053732|NCT05242445|Experimental|Cohort 3 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
33332666|NCT05663086|Active Comparator|Positive control|Positive-controlled vaccine is to be used in the clinical trial. The number of each arm is 60.
33332667|NCT05103982|Experimental|Coping with Infertility Program|"The program consists of brief weekly videos, each addressing a particular psychological technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week."
33332668|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
33332669|NCT05065294|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
33332670|NCT05662228|Experimental|Lorazepam|Participants will receive lorazepam as an oral pill three times daily for 12 weeks as well as titration doses for an additional 4 weeks (approximately).
33332671|NCT05662228|Experimental|Intravenous immunoglobulin (IVIG)|Participants will receive 4 doses of IVIG treatment over 12 weeks.
33332672|NCT05662228|Experimental|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
33332673|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
33332674|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
33332675|NCT05661604||Participants at High Risk for Poor Outcomes From a Respiratory Infection|Data will be collected for participants at high risk for poor outcomes from a respiratory infection. The duration of participation per participant will be 12 months.
33332676|NCT05052970|Experimental|12 mg/m ^ 2 dose group (ArmA)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
33332677|NCT05052970|Experimental|16 mg/m ^ 2 dose group (ArmB)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
33053733|NCT05242445|Experimental|Cohort 4 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohorts (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
33053734|NCT05242432|Experimental|Cohort (C)1 Group (G)1: Adults, 60 years and older (Ad26/protein preF RSV Vaccine)|Participants will receive a single intramuscular (IM) injection of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26/protein preF RSV) vaccine on Day 1.
33053735|NCT05242432|Placebo Comparator|C1 G2: Adults, 60 years and older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
33053736|NCT05242432|Experimental|C2 G3: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Ad26/protein preF RSV Vaccine)|Participants will receive a single IM injection of Ad26/protein preF RSV vaccine on Day 1.
33053737|NCT05242432|Placebo Comparator|C2 G4: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
33053738|NCT05234671|Experimental|Exercise group|The exercise group will perform a supervised combined (e.g., aerobic and resistance training) 12-week exercise programme, twice per week adjunct to the patient's standard care.
33053739|NCT05234671|No Intervention|Control group|The control group will not perform the exercise programme and will receive only the standard care.
33053740|NCT05232799|Experimental|Care Anywhere with Community Paramedics program|Subjects will be discharged from a pre-hospital setting, Emergency Department or the hospital with community paramedic services ordered and overseen by the treating clinical team per current standard of care.
33053741|NCT05232799|No Intervention|Standard of Care|Subjects will receive continued usual care
33053742|NCT05232032|Experimental|Participants with MDD or an anxiety disorder receiving the nociceptin receptor antagonist|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered.
33332678|NCT05052970|Experimental|20 mg/m ^ 2 dose group (ArmC)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
33332679|NCT05025514||Patients treated for cancer, vaccinated or eligible for anti-COVID vaccination.|"Patients undergoing treatment with anti-PD immunotherapy, anti-PDL1 or anti-CTLA4 immunotherapy for any tumour (solid, liquid) treated in the medical oncology departments of the Occitanie area.~who have been vaccinated or who are eligible for inoculation with one of the available anti-COVID19 vaccines."
33332680|NCT04903210|Experimental|NMN group|NMN10000 WRIGHT LIFE® + lifestyle modification.
33332681|NCT04903210|Other|Control group|Lifestyle modification only.
32740393|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
33111398|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
33111399|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
33111400|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
33332682|NCT04879810|Active Comparator|Ginger exosomes|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
33332683|NCT04879810|Active Comparator|Curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
33111401|NCT04663191||Full VATS|
33111402|NCT04663191||VATS with conversion|
33111403|NCT04663191||Thoracotomy upfront|
33111404|NCT04678713|Experimental|Fat rich diet|Participants consuming 3 days of fat rich diet
33111405|NCT04678713|Experimental|Carbohydrate rich diet|Participants consuming 3 days of carbohydrate rich diet
33111406|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
33111407|NCT00535574|Active Comparator|placebo|
33111408|NCT04678830|Placebo Comparator|Placebo|
33111409|NCT04678830|Experimental|700mg Leronlimab|
33111410|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
33332684|NCT04879810|Active Comparator|Ginger exosomes plus curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
33332685|NCT04786444|Active Comparator|VLA1553 Lot 1|
33332686|NCT04786444|Active Comparator|VLA1553 Lot 2|
33332687|NCT04786444|Active Comparator|VLA1553 Lot 3|
33332688|NCT04719208|Experimental|Chlorhexidine gluconate (A)|Mouth rinse with 0.2% Chlorhexidine gluconate,
33332689|NCT04719208|Experimental|Hydrogen peroxide (B)|Mouth rinse with 1.5% hydrogen peroxide
33332690|NCT04719208|Experimental|Betadine (C)|Mouth rinse with betadine mouthwash,
33332691|NCT04719208|Experimental|Mouth wash (D)|Mouth rinse with alcohol-based mouthwash
33332692|NCT04719208|Placebo Comparator|Water (E)|Mouth rinse with water
33332693|NCT04701190|Active Comparator|Noradrenaline 0.05/10|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
33332694|NCT04701190|Active Comparator|Noradrenaline 0.075/5|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
33361297|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
33111411|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
33111412|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
33111413|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
33111414|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
33111415|NCT04678791|Experimental|Nimotuzumab+ chemoradiotherapy|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.
32740394|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
33053743|NCT05232032|Placebo Comparator|Participants with MDD or an anxiety disorder receiving the placebo|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
33053744|NCT05232032|Experimental|Healthy controls receiving the nociceptin receptor antagonist|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive a nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the nociceptin receptor antagonist is administered.
33053745|NCT05232032|Placebo Comparator|Healthy controls receiving the placebo|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
33053746|NCT05222516|Experimental|OM-85|Daily administration of OM-85 (Broncho-Vaxom) 3.5 mg capsules
33053747|NCT05222516|Placebo Comparator|Placebo|Daily administration of Placebo capsules
33053748|NCT05219890|Experimental|OBESE PATIENTS|Obese patients will be recruited from the outpatient Clinic of Obesity at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
33332695|NCT04701190|Active Comparator|Noradrenaline 0.1/0|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
33053749|NCT05219890|Active Comparator|CONTROL GROUP|Healthy normal volunteers will be recruited from friends and family of the investigators, and staff at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
33332696|NCT04629664|Active Comparator|FX-322|FX-322, 1 dose (N=24)
33332697|NCT04629664|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
33332698|NCT04496362|Experimental|subcutaneous heparin anticoagulation|Experimental arm
33053750|NCT05219422|Active Comparator|Project ALERT only|Some schools will be randomized to receive Project ALERT only for 3 years starting fall 2022.
33332699|NCT04496362|No Intervention|systemic intravenous anticoagulation|SOC arm
33332700|NCT04429126|Experimental|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
33332701|NCT04429126|Active Comparator|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
33332702|NCT04429126|No Intervention|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
33332703|NCT04423588|Other|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
33053751|NCT05219422|Active Comparator|Project ALERT plus GTO|Some schools will be randomized to receive Project ALERT plus Getting to Outcomes for 3 years starting fall 2022.
33053752|NCT05219422|No Intervention|Status quo|Some schools not receive either Project ALERT or Project ALERT plus GTO until year 3 of the study.
33053753|NCT05217381||Cohort 1|Patients with an initial diagnostic of early breast cancer or locally advanced breast cancer or de novo metastatic breast cancer
33053754|NCT05216978|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~After consent procedures, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
33053755|NCT05216601|Active Comparator|MVC-COV1901|15 mcg of S-2P protein with adjuvant
33053756|NCT05216601|Experimental|MVC-COV1901(Beta)-15|15 mcg of S-2P protein(Beta) with adjuvant
33053757|NCT05216601|Experimental|MVC-COV1901(Beta)-25|25 mcg of S-2P protein(Beta) with adjuvant
33053758|NCT05215730|Active Comparator|Copper oxide dressings (COD)|"MedCu wound dressings with copper oxide (COD) (Copper Arm)."
33053759|NCT05215730|Active Comparator|"Vacuum-assisted closure (VAC) treatment (VAC Arm)"|"Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment (VAC Arm)."
33053760|NCT05211427|Experimental|Patients|Patients with oropharynx cancer
33053761|NCT05211427|Experimental|Healthy subjects|Patients with non malignant pharynx pathology
33053762|NCT05210556||No Antibiotic Bowel Prep|Patients who did not receive a preoperative antibiotic bowel preparation
33332704|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
33332705|NCT04314778|Experimental|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
33332706|NCT04314778|No Intervention|Control|Participants in the control group will have data collected passively via Fitbit.
33332707|NCT04297852|Active Comparator|Vegan drink|Treatment group
33332708|NCT04297852|Placebo Comparator|Control|Placebo group
33053763|NCT05210556||Antibiotic Bowel Prep|Patients who did receive a preoperative antibiotic bowel preparation
33053764|NCT05210179|Active Comparator|TURKOVAC-Koçak|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
33053765|NCT05210179|Active Comparator|TURKOVAC-Dollvet|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
33053766|NCT05209074|Experimental|Ivosidenib+mFOLFIRINOX|
33053767|NCT05208242|Experimental|Hyperoncotic albumin|Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.
33053768|NCT05208242|Active Comparator|Buffered crystalloids|Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.
33053769|NCT05208125|Experimental|CSSMS|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
33053770|NCT05208125|Placebo Comparator|PPPPP|Normal saline solution at weeks 0, 4, 12, 22, and 28 (PPPPP).
33053771|NCT05201937|Experimental|Arm A: Panel 1 (JNJ-64281802 High Dose Regimen)|Participants will receive Loading Dose (LD) 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by maintenance Dose (MD) 1 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
33053772|NCT05201937|Experimental|Arm A: Panel 2 (JNJ-64281802 High Dose Regimen)|Participants will receive LD 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 2 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
33053773|NCT05201937|Experimental|Arm B: Panel 3 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 3 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
33053774|NCT05201937|Experimental|Arm B: Panel 4 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 4 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
33053775|NCT05201937|Experimental|Arm C: Panel 5 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
33053776|NCT05201937|Experimental|Arm C: Panel 6 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
33053777|NCT05201807|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
33053778|NCT05201794|Experimental|High-dose JNJ-64281802 regimen (HDR)|Participants will receive JNJ-64281802 400 milligrams (mg) loading dose (LD) twice daily for 48 hours (2 days), followed by JNJ-64281802 150 mg maintenance dose (MD) once daily for 26 days in fed conditions.
33053779|NCT05201794|Experimental|Low-dose JNJ-64281802 regimen (LDR)|Participants will receive JNJ-64281802 150 mg LD twice daily for 48 hours (2 days), followed by JNJ-64281802 50 mg MD once daily for 26 days in fed conditions.
33053780|NCT05201794|Placebo Comparator|Placebo|Participants will receive JNJ-64281802 matching placebo LD and MD from Day 1 to Day 28.
33053781|NCT05197699||DMT-Treated Participants|MS participants who are receiving DMTs will be enrolled.
33053782|NCT05197699||Untreated Participants|MS participants who are receiving no DMT treatment or receiving only symptomatic treatment will be enrolled.
33053783|NCT05197153|Experimental|Half dose of MVC-COV1901|7.5 mcg of S-2P protein with adjuvant
33053784|NCT05197153|Experimental|Full dose of MVC-COV1901|15 mcg of S-2P protein with adjuvant
33053785|NCT05197153|Experimental|AZD1222|5*10^10 viral particles of AZD1222
33053786|NCT05197153|Active Comparator|Half dose of mRNA-1273|50 mcg mRNA encoding the pre-fusion stabilized S protein
33053787|NCT05197049|Experimental|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
33053788|NCT05197049|Experimental|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
33053789|NCT05197049|Placebo Comparator|Group 3: Placebo|Participants will receive placebo injection subcutaneously.
33053790|NCT05194982|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33053791|NCT05194839|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
33332709|NCT03053518|Active Comparator|Life Style|
33332710|NCT03053518|Experimental|Life Style + Metformin|
33332711|NCT05659576|Active Comparator|One Stage Consent|Patient will sign one consent form.
33332712|NCT05659576|Experimental|Two Stage Consent|Patient will sign two consent forms.
32740395|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
33053792|NCT05194839|Experimental|RIST4721 200 mg|RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
33053793|NCT05194839|Placebo Comparator|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
33053794|NCT05194241|Experimental|One MORE|
33053795|NCT05194241|No Intervention|Waitlist Control|
33053796|NCT05192850||Metformin use|These participants were on metformin for any duration at any point in time in the study period
33053797|NCT05192850||No metformin use|These participants were never on metformin for any duration at any point in time in the study period
33053798|NCT05192642||Larotrectinib clinical trial cohort|
33053799|NCT05192642||RW external comparator cohort|
33053800|NCT05188963|Active Comparator|Women with postvoid residual volume cut-off at 150 ml|
33332713|NCT05659576|Experimental|Sucralfate|During their RT course, patients randomized to the PS arm will receive a prescription for either: 1) sucralfate, 1 gram/10 mL oral suspension or 2) sucralfate 1 gram tablets.
33332714|NCT05659576|Active Comparator|Usual Care|Standard supportive care by using opioids.
33361298|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
33111416|NCT04678791|Active Comparator|Chemoradiotherapy|Patients receive cisplatin and undergo external-beam radiation and brachytherapy
33111417|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
33111418|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
33111419|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
33111420|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
33111421|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
33111422|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
33111423|NCT04663035|Experimental|Ablation Plus Tislelizumab|Patients in this arm will receive ablation followed by tislelizumab, which will be started within 3-7 days after ablation until disease progression or intolerable toxicity, for 12 months.
33111424|NCT04663035|Active Comparator|Ablation Alone|Patients in this group will receive ablation therapy and then enter the follow-up phase.
33111425|NCT04662762|Experimental|nursing intervention group|An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
33111426|NCT04662762|No Intervention|Usual care group|The patient is followed up and regular visits
33111427|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
33111428|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
33111429|NCT04662840|Sham Comparator|Sham procedure|"The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. A script detailing the procedure verbally will be followed by the interventionalists to waste time, but the only actual medical act that will be done is freezing of the skin around the knee (as for nerve ablation procedure) and at the groin (as for embolization procedure). Dressings will be applied at the knee and groin area."
33111430|NCT04662840|Active Comparator|Geniculate artery embolization|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee (as for the ablation procedure) and at the groin and in this group a geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint. Dressings will be applied at the knee and groin area.
33111431|NCT04662840|Active Comparator|Geniculate nerve ablation|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee and at the groin (as for the embolization procedure) and in this group a geniculate nerve ablation will be performed by advancing a radiofrequency ablation (RFA) needle at three locations alongside the tibia and femur where the nerves course and ablation performed. Dressings will be applied at the knee and groin area.
33111432|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
33111433|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
33332715|NCT05659498|Experimental|Intervention|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
33332716|NCT05659498|No Intervention|Control|Participants in the control group will receive educational information on maintaining optimal cardiovascular health. Participants will be encouraged to undergo 30 minutes of moderate-intensity aerobic activity at least 5 days per week. Participants will be given educational materials on recommended diet and exercise.
33332717|NCT04090684|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
33332718|NCT04015336|Experimental|Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T cells|Up to 3x10^10 E7 T-Cell Receptor (TCR) T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
33332719|NCT03970642|Experimental|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
33332720|NCT03970642|No Intervention|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
33111434|NCT03205293|No Intervention|Control Group|Regular school curriculum
33111435|NCT04662606|No Intervention|Fasting-group|
33111436|NCT04662606|Experimental|Fed-group|
33111437|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
32740396|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
33053801|NCT05188963|Experimental|Women with postvoid residual volume cut-off at 250 ml|
33053802|NCT05182034|Experimental|Study Group 1: SMUP-IA-01 (low dose)|Investigational Product - 4.0×10^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33053803|NCT05182034|Experimental|Study Group 2:SMUP-IA-01 (mid dose)|Investigational Product - 1.0×10^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33053804|NCT05182034|Active Comparator|Active Control Group|Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)
33053805|NCT05179655|Experimental|ERITA + TAU (Treatment as usual)|The Emotion Regulation Individual Therapy for Adolescents (ERITA) intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth
33053806|NCT05179655|Other|TAU (Treatment as usual)|Within mental health services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this study the control intervention (TAU) consists of clinical assessment and treatment for patient's current primary psychiatric condition (referral condition and A-diagnosis).
33053807|NCT05176496||Cohort 1|Women with a continuous observation of 365 days after January 1st, 2000 and before December 31, 2020.
33053808|NCT05176496||Cohort 2|Women diagnosed with HMB.
33053809|NCT05174065|Experimental|Apremilast|Apremilast will be administered to participants twice daily (BID)
33053810|NCT05174065|Experimental|Placebo and Apremilast|Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.
33053811|NCT05173714|Placebo Comparator|SLIMM + Standard RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
33053812|NCT05173714|Active Comparator|SLIMM + Guided RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
33053813|NCT05173714|Experimental|SLIMM + Guided RT + Semaglutide|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
33053814|NCT05171881|Experimental|Interventional Arm|All infants will undergo non-invasive NIRS monitoring of cerebral oxygen saturation and will have algorithm-driven clinical interventions to maintain cerebral saturation within target range during the first 72 hours of life.
33053815|NCT05170243|Active Comparator|9MW1911 Injection|Experimental drug administered IV infusion
33053816|NCT05170243|Placebo Comparator|9MW1911 Injection Placebo|Placebo administered IV infusion
33053817|NCT05154760|Active Comparator|one on one video conference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of one on one interviews with video conference method once a week.
33053818|NCT05154760|Active Comparator|group videoconference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of group interviews with video conference method once a week.
33053819|NCT05151640||Nintedanib treatment group|
33053820|NCT05149755|Experimental|Medtronic Evolut PRO+, or Evolut FX,TAVR System, & guideline-directed management & therapy (GDMT)|Medtronic Evolut PRO+ TAVR or Evolut FX TAVR Systems, & guideline-directed management & therapy
33053821|NCT05149755|No Intervention|Clinical site determined guideline-directed management and therapy (GDMT) alone|Clinical site determined guideline-directed management and therapy (GDMT) alone
33053822|NCT05148780|Other|Participants with Acute Respiratory Infections (ARI) in Outpatient Setting|Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus [RSV], Influenza, severe acute respiratory syndrome coronavirus 2 [SARS-COV-2]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.
33053823|NCT05145868|Experimental|Intervention|
33053824|NCT05145868|Sham Comparator|Attention Control|
33053825|NCT05130359|Placebo Comparator|Placebo|consume 2 sachet per day for 4 weeks
33053826|NCT05130359|Experimental|Banana peel extract|consume 2 sachet per day for 4 weeks
33053827|NCT05130034|Experimental|Home-based pulmonary rehab for fibrotic interstitial lung disease|Subjects diagnosed with fibrotic interstitial lung disease will participate in a home-rehab program that promotes more physical activity in daily life.
33053828|NCT05129605||Cohort 1|Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene
33053829|NCT05129605||Cohort 2|Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes
33053830|NCT05127720||patients with severe sleep apnea|defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment
33053831|NCT05127720||patients with autonomic imbalance|defined by PRD ≥ 5.75deg2 assessed within the first 12 months of enrollment
33053832|NCT05127720||patients with a sedentary lifestyle|defined by a pacemaker-derived mean daily physical activity level < 2h in the first 12 months after enrollment
33053833|NCT05127577|Experimental|Abdominal massage group|Abdominal massage will be applied to the experimental group 2 times a day, morning and evening, until defecation, starting in the evening of the first day after the surgical intervention.
33053834|NCT05127577|No Intervention|Control group|The control group will be received routine treatment and care in the unit.
33053835|NCT05125679|Experimental|Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous injection at Weeks 0, 4, 12, 20 and 28.
33053836|NCT05123599|Experimental|JNJ-73763989 plus JNJ-64300535 plus Nucleos(t)ide Analogs (NAs)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (q4w), NA (either Entecavir monohydrate [ETV], Tenofovir disoproxil or Tenofovir alafemide [TAF]) oral tablets once daily (qd) and JNJ-64300535 intramuscular (IM) injection q4w. From day 187, participants will receive treatment with NA oral tablets qd up to Week 36.
33053837|NCT05123118|Experimental|Integrated intervention|Integrated intervention of smoking cessation and breastfeeding
33053838|NCT05123118|Active Comparator|Attention placebo control group|Instructions on general pregnancy and infant care
33053839|NCT05112939|Experimental|Panel A: Rilpivirine (RPV) Long-acting (LA)|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1.
33053840|NCT05112939|Experimental|Panel B: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1.
33053841|NCT05112939|Experimental|Panel C: RPV LA|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A.
33053842|NCT05112939|Experimental|Panel D: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel B.
33053843|NCT05112939|Experimental|Panel E: RPV LA + Cabotegravir (CAB) LA|Participants will receive one dose of RPV LA (formulation 1) with CAB LA (formulation 3) (Treatment I) on Day 1.
33053844|NCT05111717||group 1|Peripheral venous blood samples will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). DNA will be obtained from blood samples , and global DNA methylation analysis will be done.
33053845|NCT05105919|Experimental|Aspirin therapy|All participants will be assigned to aspirin therapy. Participants will receive 80 mg of enteric coated aspirin per day for a 7 day period.
33053846|NCT05104749|Experimental|Homeopathic Treatment Group|Individualized homeopathic medicines on impregnated lactose pellets will be prescribed to each participant based on the totality of their physical, emotional, and mental symptoms. All medicines prescribed are listed in the Homeopathic Pharmacopoeia of the United States (HPUS) as outlined in the Food, Drug, and Cosmetics Act of 1939
33053847|NCT05104749|Placebo Comparator|Placebo Group|Identical lactose pellets in size, odor, and taste without the impregnated homeopathic medicines.
33053848|NCT05104632||Breast conserving surgery only|Patients who receive breast conserving surgery.
33053849|NCT05104632||Mastectomy only|Patients who receive mastectomy surgery.
33053850|NCT05104632||Mastectomy & breast reconstruction|Patients who receive mastectomy and breast reconstruction.
33053851|NCT05102136|Experimental|Intravenous Cohorts|Randomized 6:2 to REGN9933 or placebo
33053852|NCT05102136|Experimental|Subcutaneous Cohorts|Randomized 6:2 to REGN9933 or placebo
33053853|NCT05099549|Experimental|Phase 1, Dose Escalation|"It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.~SNK01 (fixed dose) will be administered weekly by IV infusion."
33053854|NCT05099549|Experimental|Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
33053855|NCT05099549|Experimental|Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)|SNK01 (fixed dose) will be administered weekly by IV infusion.
33053856|NCT05099549|Experimental|Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
33053857|NCT05098938|Experimental|Acyclovir 50mg buccal tablet treatment group|
33053858|NCT05098938|Placebo Comparator|Matching placebo group|
33053859|NCT05096195|Experimental|Intervention|60 mg of denosumab (Prolia) will be administered every 6 months over a 15 - month period. Monitoring of serum calcium and phosphate will occur and bloodwork will be drawn for 4 weeks following each denosumab injection. Correction of vitamin D deficiency (if required), the adjustment of calcium dialysate and the provision of intravenous (IV) or oral (po) calcitriol/calcidiol will be administered as needed following each denosumab injection as described in the Beside Protocol. Once the study monitoring period is over, serum calcium monitoring and management will occur as per routine care in the dialysis centre. All intervention activities will occur during regularly scheduled hemodyalisis sessions.
33068061|NCT04519060|Experimental|Eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care and the application of eye shields. They will be worn until four (4) hours after the last dose of dilating eye drops.
33068062|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
33068063|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
33068064|NCT00505297||A|Subjects with potentiall rapidl progressing OA
33068065|NCT00505297||B|Age-matched healthy subjects with no knee pain
33068066|NCT04519333|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation
33068067|NCT00141440|Experimental|1|COPD patients
33068068|NCT04518904||Group of poor prognosis|In this group,the patients had suffered from systemic infection,pulmonary complications or died.
33053860|NCT05096195|No Intervention|Usual care|Usual care participants will continue to receive the typical standard of care in their dialysis unit which includes their routine dialysis monitoring and bloodwork. They will not receive denosumab, calcium and vitamin prophylaxis. There will be no extra monitoring or bloodwork.
33053861|NCT05095909|Experimental|Cryo-compression|"Fitted with compression sleeve for the NICE Recovery SystemTM applied to the operative shoulder immediately post - operatively Minimum 6 hours treatment per day post-operatively. Utilize cyro-compression unit with a Medium compression level (inflate to 35 mmHg for 2 minutes and then deflate to 5 mmHg for 30 seconds) and Level 3 cooling (50F (10C)) for the first 24 hours. After that time, the compression and cooling levels will be up to the patients' discretion."
33053862|NCT05095909|Active Comparator|Cryo-therapy|Fitted with a standard gel ice pack with wrap immediately post-operatively. Minimum 6 hours treatment per day using gel ice packs.
33053863|NCT05092009||All patiens|There is only one arm in this trial
33053864|NCT05083247|Active Comparator|Arm A|mFOLFIRINOX (oxaliplatin: 85 mg/m2, CPT-11: 165-180 mg/m2, folinic acid: 400mg/m2 and 5FU 2000-2400 mg/m2/46 h) regimen for 8 cycles every 2 weeks; or*Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 for 4 cycles in case of unfit for mFFX).
33053865|NCT05083247|Experimental|Arm B|mFOLFIRINOX for 6 cycles (or for 3 cycles Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 in case of unfit for mFFX) +Isotoxic high-dose SBRT: 5 x 7Gy with Simultaneous Integrated Boost (SIB) up to maximum 55Gy (= 1 week; starting ideally 2 weeks and maximum within 4 weeks after the end of chemotherapy)
33053866|NCT05081453|Experimental|Pavlik harness treatment group|Application of a pavlik harness for 2 months in position seeking 90º of flexion of both knees and 45º of hip flexion with some abduction. An ultrasound control is performed at 2 and 6 months
33053867|NCT05081453|No Intervention|Control group without intervention|Control group without intervention. An ultrasound control is performed at 2 and 6 months
33053868|NCT05077774|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System
33053869|NCT05077527|Experimental|Treatment (conditioning, axicabtagene ciloleucel)|Patients receive fludarabine IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5, -4, and -3. Patients then receive axicabtagene ciloleucel IV over 30 minutes on day 0.
33053870|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib|To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in G12C inhibitor naïve and exposed patients
33053871|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib - G12C inhibitor naïve|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor naïve patients
33053872|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib - G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients
33053873|NCT05071664|Experimental|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
33053874|NCT05071664|Active Comparator|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
33053876|NCT05070364|Experimental|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
33053877|NCT05070364|No Intervention|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
33053878|NCT05070169||Early Surgical Fixation|Prospective cohort of patients with intertrochanteric fractures with DOAC (direct oral anticoagulation) therapy undergoing early surgical fixation (within 24 hours).
33053879|NCT05070169||Delayed Surgical Fixation|Retrospective control group of patients with intertrochanteric fractures with DOAC medication who underwent delayed surgical fixation (≥48 hours) from January 2014 to December 2018.
33053880|NCT05066282||Participants with past PTSD who received IMP in the main study|
33053881|NCT05064436|Experimental|Part A - Healthy Participants|
33053882|NCT05064436|Experimental|Part B - Participants with MS|
33053883|NCT05061238|Other|Vibrating Device|you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.
33053884|NCT05059054|Experimental|Strengthening group|Strengthening exercise
33053885|NCT05059054|Active Comparator|Insole group|Insole application
33053886|NCT05054439|Experimental|SI-B001 combined with paclitaxel|SI-B001 in combination with paclitaxel for the treatment of recurrent metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) with disease progression or intolerance.； The patient had previously received anti-PD-1 mab ± platinum-based chemotherapy； Patients' previous treatment line should be ≤2L.
33053887|NCT05050097|Experimental|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
33053888|NCT05050097|Experimental|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
33053889|NCT05050097|Experimental|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
33053890|NCT05050097|Experimental|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
33053891|NCT05050097|Experimental|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
33053892|NCT05050006|Experimental|Cohort 1|Patients who relapsed after or were refractory to at least 1 prior line of systemic therapy including a PD-1 inhibitor.
33053893|NCT05050006|Experimental|Cohort 2|Patients who were intolerant to a PD-1 inhibitor and have persistent disease after stopping PD-1 therapy.
32869659|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
32869660|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
32869661|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
32869662|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
32869663|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
33053894|NCT05050006|Experimental|Cohort 3|Patients who had a best response of stable disease despite being treated with at least 4 doses of a PD-1 inhibitor in the previous line of therapy.
33053895|NCT05049798||Cohort 1: Guselkumab|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
33053896|NCT05049798||Cohort 2: Interleukin-17 inhibitor (IL-17i)|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
33053897|NCT05049603|Experimental|Atorvastatin|Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks
33053898|NCT05049603|Placebo Comparator|Placebo|Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks
33053899|NCT05048797|Experimental|Arm 1|Trastuzumab Deruxtecan (T-DXd)
33053900|NCT05048797|Active Comparator|Arm 2|Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)
33053901|NCT05037851|Experimental|PC945|14.8 mg PC945 administered twice daily for 12 weeks
33053902|NCT05037851|Active Comparator|Standard of Care (SoC)|Mold-active SoC prophylaxis/pre-emptive therapy
33053903|NCT05037162|Experimental|Arm 1 - CimetrA-1|CimetrA-1, with a total dose containing a combination of Curcumin 40 mg, Boswellia 30 mg and Vitamin C 120 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
33053904|NCT05037162|Experimental|Arm 2 - CimetrA-2|CimetrA-2, with a total dose containing a combination of Curcumin 28 mg, Boswellia 21 mg and Vitamin C 84 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
33053905|NCT05037162|Placebo Comparator|Arm 3 - Placebo|Placebo, composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
33053906|NCT05036122|Experimental|Whole-body exercise in healthy adults (Aim 1)|Subjects will have blood [lactate] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
33053907|NCT05036122|Experimental|ICU patients susceptible to developing sepsis (Aim 2)|Subjects will have blood [lactate] measurement obtained with the LabClasp device as frequently as required for clinical purposes
33053908|NCT05032157|Experimental|Arm 1: LOU064 (blinded)|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
33053909|NCT05032157|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
33053910|NCT05032092|Experimental|Adult patients with locally advanced and/or metastasized carcinoma|"Liquid biopsies of all 200 study patients will be analysed with FoundationOne®Liquid CDx.~Tissue biopsies from all study patients for whom a tissue biopsy is available will be analysed with FoundationOne® CDx and IHC (approximately 50% of the enrolled patients).~Biomarker Monitoring of study patients receiving matched therapy with AVENIO ctDNA Surveillance Kit."
33053911|NCT05029882|Experimental|Part 1 (Monotherapy Dose Escalation)|Participants with advanced solid tumors will receive escalating doses of ABBV-400.
33053912|NCT05029882|Experimental|Part 2a (wtEGFR Non-Small Cell Lung Cancer [NSCLC])|Participants with c-Met intermediate/high advanced non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).
33053913|NCT05029882|Experimental|Part 2b (mutEGFR NSCLC)|Participants with c-Met intermediate/High advanced non-squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.
33053914|NCT05029882|Experimental|Part 2c (wtEGFR NSCLC)|Participants with c-Met low non-squamous wtEGFR NSCLC will receive ABBV-400 at RP2D.
33053915|NCT05029882|Experimental|Part 2d (Squamous NSCLC)|Participants with squamous NSCLC will receive ABBV-400 at RP2D.
33053916|NCT05029882|Experimental|Part 3 (Gastric/Gastroesophageal Junction Adenocarcinoma)|Participants with c-Met overexpressing Gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.
32869664|NCT05545176||out of hospital cardiac arrest patients in Asia countries|
32869665|NCT04735536|Experimental|Active Treatment- CT1812|Active Treatment- CT1812 at a dose of 300mg
32869666|NCT04735536|Placebo Comparator|Control - Placebo|Drug: Placebo Non-active study drug
32869667|NCT05545098||JIA patients|"Assessment of Survivin and Lubricin in the serum and in the Synovial fluid if available in JIA patients~Assessment of activity using Juvenile arthritis disease activity score in 27 joints (JADAS 27) in the studied JIA patients.~Identifying the prevalence of functional disability in JIA children and adolescents using the childhood health assessment questionnaire (CHAQ).~performing MSUS on the involved joints."
32869668|NCT05545098||control group|Assessment of Survivin and Lubricin in the serum
32869669|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
32869670|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
33053917|NCT05029882|Experimental|Part 4 (Colorectal Cancer)|Participants with c-Met unselected Colorectal Cancer; will receive ABBV-400 at the RP2D or Dose A.
33053918|NCT05027932|Experimental|Group A|15 participants receiving IM BPL1357 &amp; IN Placebo
33053919|NCT05027932|Experimental|Group B|15 participants receiving IN BPL1357 &amp; IM Placebo
33053920|NCT05027932|Sham Comparator|Group C|15 participants receiving IM and IN placebo
33053921|NCT05025332|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
33053922|NCT05024318|Active Comparator|SABR plus nephrectomy|Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
33053923|NCT05024318|Experimental|Pembrolizumab followed by SABR after cycle 1 plus nephrectomy|Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
33053924|NCT05022849|Experimental|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents [example, abiraterone, enzalutamide] and radiotherapy, or chemotherapy [example, docetaxel]) if clinically indicated to maintain disease stability.
33053925|NCT05022849|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
33053926|NCT05022654|Experimental|SI-B001 combined with irinotecan|Patients with recurrent metastatic esophageal squamous cell carcinoma who had failed first-line therapy with PD-1(L1) monoclonal antibody plus platinum-based chemotherapy were enrolled.
33053927|NCT05022472|Experimental|Intervention|We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults >18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants). The two major components of the 2VIDA! intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
33053928|NCT05022472|No Intervention|Standard of care|The standard of care for vaccine delivery at the control sites. This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
33053929|NCT05020457|Experimental|SI-B001 combined with AP or TP_A|SI-B001 combined with Platinum-based chemotherapy(AP or TP). Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant after first-line treatment with anti-PD-1 /L1 mab alone.
33053930|NCT05020457|Experimental|SI-B001 combined with Docetaxel_B|Patients with EGFRwt/ALKwt non-small cell lung cancer were included and progressed or were intolerant after first-line treatment with platinum-based two-drug chemotherapy plus anti-PD-1 /L1 mab.
33053931|NCT05020457|Experimental|SI-B001 combined with Docetaxel_C|Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant to treatment with anti-PD-1 /PD-L1 monoclonal antibody after first-line or above chemotherapy.
33053932|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Escalation|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~Leukapheresis: On day -8 white blood cells will be collected.~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using a 3+3 dose escalation design"
33053933|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Expansion|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~Leukapheresis: On day -8 white blood cells will be collected.~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using the respective dose (at or below the Maximum Tolerated Dose-MTD), as determined during the dose escalation part."
33053934|NCT05020314|Experimental|Clinically Based: Healthy Weight Clinic|
33053935|NCT05020002||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
33053936|NCT05020002||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
33053937|NCT05020002||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
32740397|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
32740398|NCT02466893|Other|ADAPT Technique/Standard SR Group|
32740399|NCT05727917|Experimental|hetrombopag group (Experimental group)|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response (CR, platelet count ≥50×109/L for 3 consecutive days without platelet transfusions for 7 consecutive days). The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
32740400|NCT05727917|Placebo Comparator|Control group|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days.
32740401|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
32869671|NCT05550012|No Intervention|standard-dose CT|those patients undergo standard-dose liver CT in portal vein and delayed phase
33053938|NCT05019625||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
33053939|NCT05019625||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
33111438|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
33111439|NCT04662528|Placebo Comparator|Placebo|
33332721|NCT05044078|Experimental|Group 1 (Autogenic Inhibition)|Autogenic Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the Conventional therapy including neck Isometric strengthening exercise (Neck Flexion, Extension, Both sides Rotation, and Neck Bending with each 5 rep, 10-sec hold, 1 set, in all sessions), Maitland Central posterio-anterior glide (Grade 1 and 2, 30 rep, 3 sets, in all sessions) and hot pack (10 minutes in all sessions on the back of the neck)
33332722|NCT05044078|Active Comparator|Group 2 (Reciprocal Inhibition)|Reciprocal Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the with same Conventional therapy as in group 1 .
33332723|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
33332724|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
33332725|NCT04963816|Active Comparator|Group A Quadratus Lumborum Block with dexamethasone IV|QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
33332726|NCT04963816|Active Comparator|Group B Quadratus Lumborum Block with dexamethasone locally|QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
33332727|NCT04963816|Placebo Comparator|Group C Quadratus Lumborum Block with bupivacaine alone|Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.
33332728|NCT04957732|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, Standard of Care (SoC), which was normal saline, was used.
33332729|NCT04957732|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
33332730|NCT05641324|Experimental|ANV419 single agent, dose 1, Q2W|
33053940|NCT05019625||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
33053941|NCT05019625||Ultrasound and myography testing|We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
33053942|NCT05017662|Other|Data collection|
33053943|NCT05016908||Biofluid collection|Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.
33053944|NCT05015426|Experimental|Dose Level -1|"Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1~Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion"
33332731|NCT05641324|Experimental|ANV419 single agent, dose 2, Q2W|
33053945|NCT05015426|Experimental|Dose Level 1|Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
33053946|NCT05015426|Experimental|Dose Level 2|Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
33111440|NCT04662528|Experimental|MAT9001 (omega-3-pentaenoic acid)|
33332732|NCT05641324|Experimental|ANV419 Q2W + Lenalidomide plus low-dose dexamethasone|
33332733|NCT05641324|Experimental|ANV419 Q2W + Daratumumab|
33332734|NCT05639530|Experimental|:treated with different doses of single intravitreal injections of IBI333|"Biological: IBI333 Dose 1 IBI333 of single IVT injections，~Biological: IBI333 Dose 2 IBI333 of single IVT injections"
33332735|NCT05639530|Experimental|treated with different doses of multiple intravitreal injections of IBI333|"Biological: IBI333 Dose 3 IBI333 of multiple IVT injections，~Biological: IBI333 Dose 4 IBI333 of multiple IVT injections"
33332736|NCT04933240|Active Comparator|Tamoxifen|tamoxifen 10mg daily for 7 days
33332737|NCT04933240|Active Comparator|Estradiol|estradiol 1mg daily for 7 days
33332738|NCT04933240|Placebo Comparator|placebo|placebo daily for 7 days
33053947|NCT05015426|Experimental|Dose Level 3|Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
33053948|NCT05015426|Experimental|Treatment at Maximum Tolerated Dose|Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion
33332739|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
33332740|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
33332741|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
33332742|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
33332743|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
33332744|NCT05637112||Prospective Cohort|All patients aged ≥18 years diagnosed with SLE who initiate anifrolumab as prescribed by their healthcare provider (HCP) per the approved country-specific label and are treated at the study sites will be eligible for inclusion.
33332745|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
33332746|NCT01317940|No Intervention|Standard of Care Group A|
33332747|NCT01317940|Experimental|Group B (Early Survivors)|
33332748|NCT01317940|No Intervention|Observation Only - Group B|
33332749|NCT01317940|No Intervention|Group C (Siblings of Group A)|
33332750|NCT05707312||POLEmut (POLE mutant endometrial cancer patients)|POLE mutant endometrial cancer patients
32869672|NCT05550012|Experimental|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase
33053949|NCT05014360|Experimental|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
33053950|NCT05012982|Experimental|AirBand followed by uninflated AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
33053951|NCT05012982|Experimental|Uninflated Airbnd followed by AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
33053952|NCT05012189|Active Comparator|Oseltamivir|Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.
33053953|NCT05012189|Experimental|Baloxavir|Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.
33053954|NCT05007080|Experimental|Group 1: Ad26.COV2.S Dose Level 1 (Lower Volume): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
33053955|NCT05007080|Experimental|Group 2: Ad26.COV2.S Dose Level 2: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
33053956|NCT05007080|Experimental|Group 3: Ad26.COV2.S Dose Level 3: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
33053957|NCT05007080|Experimental|Group 4: Ad26.COV2.S Dose Level 1: 2-Dose Regimen|Participants will receive 2-dose of Ad26.COV2.S at dose level 1 on Day 1 and 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
33053958|NCT05007080|Experimental|Group 5: Ad26.COV2.S Dose Level 2: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
33053959|NCT05007080|Experimental|Group 6: Ad26.COV2.S Dose Level 3: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
33053960|NCT05006573|Experimental|Benralizumab|Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
33053961|NCT05006573|Placebo Comparator|Placebo|Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
33053962|NCT04995900|Experimental|Intervention|Intervention period with active Heart Matters education delivered
33053963|NCT04995900|No Intervention|Control|Control period with no Heart Matters education delivered.
33053964|NCT04995068||Included patients|See inclusion and exclusion criteria
33053965|NCT04987671|Experimental|Treatment with AMX0035|Two sequential study period. In Period 1, subject receive AMX0035 daily for approximately 14 days. In Period 2, subjects receive AMX0035 twice a day, morning and evening, for up to 25 days.
33053966|NCT04986228|Experimental|Digital aftercare|The group with the new digital aftercare is compared with the active control group with regular aftercare.
33053967|NCT04986228|Active Comparator|Treatment-as-usual (TAU)|The group with regular aftercare (TAU) serves as an active control group.
33053968|NCT04985721|Experimental|Pamiparib and Tiselizumab|
33053969|NCT04983680|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
33053970|NCT04978337|Experimental|Treatment A: Rilematovir|Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.
33053971|NCT04978337|Placebo Comparator|Treatment B: Placebo|Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.
33053972|NCT04968912|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
32869673|NCT05535738|Experimental|Baseline Contact Allergen|Individuals who will have allergic contact dermatitis induced via squaric acid dibutyl ester (SADBE) and/or known patch test allergens followed by skin and blood sampling. There is a protocol to sensitize individuals to SADBE if they have not previously been exposed to SADBE.
32871611|NCT05747781|Placebo Comparator|Validation Phase|66 patients with glaumatous optic neuropathy 12 subjects with no known visual impairment
32871612|NCT00251225|Experimental|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
33111441|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
33111442|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
33111443|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
33111444|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
33111445|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
33111446|NCT04662333|Active Comparator|Crestal sinus lift|Implant site preparation with detachment of Schneiderian membrane and subsequent implant placement. The corresponding healing abutment is made up of PEEK (poly-ether-ether-ketone)
33111447|NCT04662333|Experimental|Crestal sinus lift with adjunctive xenograft|Implant site preparation with detachment of Schneiderian membrane. After that, collagen membrane plus xenogenic bone substitute will be placed into the site before implant placement. The corresponding healing abutment is made up of titanium.
33111448|NCT05300672|Experimental|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
33111449|NCT05300672|No Intervention|No fibrinogen infusion|No fibrinogen infusion
33111450|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
33111451|NCT05298137|No Intervention|IV Cannulation Without Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the control group will then have a peripheral IV (PIV) placed in the ipsilateral arm as the baseline measurements, the number of attempts to successful PIV placement will be recorded. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
33332751|NCT05707312||MMRd (mismatch repair deficient endometrial cancer patients)|mismatch repair deficient endometrial cancer patients
33332752|NCT05707312||NSMP (no specific molecular profile endometrial cancer patients to NSMP)|no specific molecular profile endometrial cancer patients to NSMP
33332753|NCT05707312||p53abn (p53 abnormal endometrial cancer patients)|p53 abnormal endometrial cancer patients
33332754|NCT05707234|Active Comparator|Control Group|"During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.~Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones."
33332755|NCT05707234|Experimental|VRH Group|"They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli.~During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section)."
33332756|NCT05626114|Experimental|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
33332757|NCT05707000|Experimental|group A, Concentric Muscle Training|leg press, knee flexion, knee extension, Quad drills with 1 RM
33332758|NCT05707000|Experimental|group B, Quadriceps Facilitatory Kinesiotaping|kinesiotaping on the quadriceps muscle in the faciliatory mode
33332759|NCT05706922||Polycystic ovary syndrome (PCOS)|"Hormonal screening~Vaginal swab~Fecal sample~Blood samples~Food Frequency Questionnaire"
33332760|NCT05706922||Control group|"Hormonal screening~Vaginal swab~Fecal sample~Blood samples~Food Frequency Questionnaire"
33332761|NCT05706766|Experimental|Exercise Group (PARE)|"Participants will be randomly assigned to the Exercise Group (PARE) and will complete study procedures as outlined:~8 weeks of 3x weekly sessions of virtually supervised aerobic and resistance exercise performed at home using study-provided stationary bike, resistance equipment, heart-rate monitor, and a wi-fi enabled tablet.~Clinic visits at week 1, week 10, and 30 days post Autologous Stem Cell Transplantation (ASCT).~Questionnaires and surveys."
33332762|NCT05706766|Active Comparator|Waitlist Control Group|"Participants will be randomly assigned to the Waitlist Control Group and will complete study procedures as outlined:~8 weeks of continuing with normal daily activities.~Option to participate in PARE exercise program after study completion.~3 clinic visits with option of 5 visits. The two additional visits are for evaluation and testing for those who choose to participate in exercise program after study completion."
33332763|NCT05706688||Regional anesthesia|4,152 patients undergoing elective carotid endarterectomy under regional anesthesia
33332764|NCT05706688||General anesthesia|4,152 matched controls undergoing elective carotid endarterectomy under general anesthesia
33053973|NCT04968912|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
33053974|NCT04968912|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
33053975|NCT04964674|Experimental|Attentional Tests- Miyake and others|All participants will complete a series of behavioral tasks, including cued visual search with positive, negative, and neutral cues, Miyake executive attention tasks, and a visual working memory task. Single Arm.
33053976|NCT04954599|Experimental|Module 1A Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
33053977|NCT04954599|Experimental|Module 1B Monotherapy Dose Expansion Cohort|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
33053978|NCT04954599|Experimental|Module 2A Combination with carboplatin Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
32871613|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
32871614|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
33053979|NCT04954599|Experimental|Module 2B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
33053980|NCT04954599|Experimental|Module 3A Combination with Immune Checkpoint Inhibitor Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
33053981|NCT04954599|Experimental|Module 3B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
33053982|NCT04952610|Experimental|Etripamil NS 70 mg|Self- administration of a dose of 70 mg of etripamil. Patients will be provided with a maximum of 4 pre-filled devices at a time. If the symptoms of PSVT persist 10 minutes after the first dose of etripamil NS 70 mg, a second dose of etripamil NS 70 mg can be self-administered by the patient. A second dose of etripamil NS 70 mg should be taken not earlier than 10, and not later than 15 minutes after the first dose.
33053983|NCT04951622|Experimental|Nipocalimab|"Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.~Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion till study end."
33053984|NCT04951622|Placebo Comparator|Placebo|Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
33053985|NCT04936607|Experimental|Personnalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
33332765|NCT05706454|Experimental|Ramatroban 75 mg tablet|
33332766|NCT05706454|Placebo Comparator|Placebo|
33053986|NCT04936607|Active Comparator|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
33053987|NCT04936529|Experimental|Group 1|Group 1 participants receive oral β-glucan (40 mg/kg/day x 14 days) starting week 1. This schedule includes annual booster vaccinations, with β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10). Participants will not receive GM-CSF.
33053988|NCT04936529|Experimental|Group 2|Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1. Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#9; and x5 days with vaccination #10. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10)
33053989|NCT04936529|Experimental|Group 3|Group 3 will include participants who cannot be randomized (e.g., due to allergy to GMCSF). It will also include participants previously treated with this vaccine and oral β-glucan on the predecessor MSK protocol IRB# 05-075 or on this protocol (participants can therefore be enrolled more than one time on this protocol). These participants will be treated as in Group 1. Participants who are registered to Group 3 and have been previously treated with vaccine (in this protocol or MSK predecessor 05-075) will not receive vaccines 4 and 6. These patients will receive a total of 8 injections. The analyses in this group will be exploratory.
33418905|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
33053990|NCT04936308|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
33053991|NCT04936308|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
33053992|NCT04936308|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
33053993|NCT04929210|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
33053994|NCT04929210|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
33053995|NCT04929210|Experimental|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
33053998|NCT04921189|Active Comparator|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|The combined administration of 3 drugs will be administered through intravenous infusion over 60 min every 12 h for 3 days for the out-of-hospital cardiac arrest survivors treated with targeted temperature management.
33053999|NCT04921189|Placebo Comparator|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
33054003|NCT04914429|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.
33054004|NCT04914429|Placebo Comparator|Group 2: Placebo|Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.
33054005|NCT04908722|Experimental|Group 1: Ad26.COV2.S Dose Level 1|Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.
33054006|NCT04908722|Experimental|Group 2: Ad26.COV2.S Dose Level 2|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.
33054007|NCT04908722|Experimental|Group 3: Ad26.COV2.S Dose Level 3|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.
33054008|NCT04908722|Experimental|Group 4: Ad26.COV2.S Dose Level 4|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.
33054009|NCT04908722|Experimental|Group 5: Ad26.COV2.S Dose Level 5|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.
33054010|NCT04908722|Experimental|Group 6: Ad26.COV2.S Dose Level 6|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.
33054011|NCT04908683|Experimental|Group 1: Respiratory Syncytial Virus (RSV) vaccine|All participants in the active group will receive a single dose intramuscular (IM) injection of study vaccine on Day 1.
33054012|NCT04908683|Placebo Comparator|Group 2: Placebo|All participants in the placebo group will receive a single IM injection of matching placebo on Day 1.
33054013|NCT04908189|Experimental|Deucravacitinib|
33054014|NCT04908189|Placebo Comparator|Placebo|
33054015|NCT04908189|Other|Apremilast|
33054016|NCT04906980|Experimental|JNJ-64281802|Participants will receive 2 initial loading doses of JNJ-64281802 up to Day 2, followed by a maintenance dose on Days 3, 4, and 5.
33054017|NCT04906980|Placebo Comparator|Placebo|Participants will receive oral dose of matching placebo every 8 hour (q8h) and once daily on Day 4 and Day 5.
33054018|NCT04902911|Experimental|Antigen testing in those who have history of COVID-19|Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
33054019|NCT04902911|Experimental|Antigen testing in those who do not have history of COVID-19 and COVID immunization|Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
33054020|NCT04899336|Experimental|ExPEC9V|Participants will receive a single intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1.
33054021|NCT04899336|Placebo Comparator|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
33068069|NCT04518904||Group of good prognosis|In this group,the patients were safely discharged without complications.
33332767|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
32871615|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
32871616|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
33054022|NCT04898634|Experimental|JNJ-78278343|Participants will receive JNJ-78278343 either subcutaneously (SC injection or SC infusion) or intravenous (IV) infusion. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 either SC or IV at recommended phase 2 dose (RP2D) as determined in Part 1.
33054023|NCT04891224|Other|Pathway Platform application use|Study participants will download the Pathway app to their mobile device. This app will gather patient health data, present standardized questionnaires and research data collection tools. Subject responses will be visible to their provider via interface with the electronic medical record.
33054024|NCT04882878|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).
33054025|NCT04882878|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
33054026|NCT04882878|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
33054027|NCT04882098|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
33054028|NCT04882098|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
33054029|NCT04882098|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
33054030|NCT04877782||Healthy older participants|Healthy older participants receiving both stimulation conditions (experimental and placebo) randomized across scanning sessions.
33054031|NCT04876339|Experimental|"Gait rehabilitation with sonification"|"The rehabilitation exercises with sonification are supported by the musical component (see Interventions section for details)."
33054032|NCT04876339|Active Comparator|Standard gait rehabilitation (without sonification)|The same rehabilitation exercises are performed without musical support.
33054033|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
33054034|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
33054035|NCT04875169|Placebo Comparator|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
33054036|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
33054037|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
33054038|NCT04875065|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
33054039|NCT04872959|No Intervention|Usual Care Arm|Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.
33054040|NCT04872959|Experimental|Interventional- Health Reveal|"The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.~Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed."
33054041|NCT04872491||Participants With UC or CD|Participants diagnosed with UC or CD who are prescribed and will start treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, 6, and every 8 weeks thereafter for up to 54 weeks will be observed prospectively for 72 weeks.
33054042|NCT04872439||Antibody isolation|
33054043|NCT04864951|Other|Transpeople|"1x urine sampling for HPV analysis~1x survey"
33054044|NCT04864366||Treatment naive patients|"HBV DNA> 20000 IU/ml~ALT>2×ULN；or ALT>1×ULN，but liver biopsy showed inflammation greater than or equal to G2, or/and liver fibrosis greater than or equal to S2~No treatment with NA or/or αIFN within 1 year"
33054045|NCT04864366||ETV treatment experienced patients|"ETV treatment for 1 to 2 years before~HBsAg>3000IU/mL~HBV DNA<20IU/mL~ALT<1×ULN~No other NA therapy prior to entecavir treatment~Patients had a desire to convert to TAF therapy"
33054046|NCT04861688|Active Comparator|NeuroAiD II™ (MLC901)|Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.
33054047|NCT04861688|Placebo Comparator|Placebo|Capsule 2 capsules orally, 3 times a day
33332768|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
33332769|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
33332770|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
33332771|NCT05706376|Experimental|Promoting Positive Family Futures|
33332772|NCT05706376|Active Comparator|Treatment as Usual|
33054048|NCT04859296|Placebo Comparator|Placebo|0 mg CBG, 0 mg THC
33054049|NCT04859296|Active Comparator|Low strength CBG|5 mg CBG, 0 mg THC
33054050|NCT04859296|Active Comparator|High strength CBG|15 mg CBG, 0 mg THC
33054051|NCT04859296|Active Comparator|Low strength THC|0 mg CBG, 5 mg THC
33054052|NCT04859296|Active Comparator|High strength THC|0 mg CBG, 30 mg THC
33054053|NCT04859296|Active Comparator|Low strength CBG + Low strength THC|5 mg CBG + 5 mg THC
33054054|NCT04859296|Active Comparator|Low strength CBG + High strength THC|5 mg CBG + 15 mg THC
33054055|NCT04859296|Active Comparator|High strength CBG + Low strength THC|15 mg CBG + 5 mg THC
33054056|NCT04859296|Active Comparator|High strength CBG + High strength THC|15 mg CBG + 15 mg THC
33054057|NCT04857684|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Participants will:~undergo a pre-treatment biopsy with fiducial marker placement~receive Stereotactic beam radiation therapy (SBRT) on three treatment days which will be arranged on an every-other-day basis~receive two 3-week (21 days) cycles of atezolizumab plus bevacizumab~receive Atezolizumab on day 1 for 2 study cycles.~receive Bevacizumab 1x weekly for 2 study cycles~Surgery after SBRT and the two cycles of atezolizumab and bevacizumab, unless participants are otherwise informed by their doctor. The planned surgery will take place 6-8 weeks after the last infusions of atezolizumab and bevacizumab."
33054058|NCT04854811|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 12 weeks
33054059|NCT04854811|Experimental|Roflumilast (100 microgram)|once daily for 12 weeks
33054060|NCT04846348|Experimental|Skin Guard|"Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor"
33054061|NCT04844918|Experimental|Tirzepatide Regimen A|Tirzepatide Regimen A administered subcutaneously (SC)
33054062|NCT04844918|Experimental|Tirzepatide Regimen B|Tirzepatide Regimen B administered subcutaneously (SC)
33054063|NCT04844918|Placebo Comparator|Placebo|Placebo administered SC
33054064|NCT04837677|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
33054065|NCT04828993|Experimental|Tafamidis treatment arm|Chinese patients diagnosed with ATTR-PN treated with tafamidis 20mg once daily oral adminiistration for 72 weeks (18 months).
33054066|NCT04828707|Active Comparator|Migraine prevention treatment with active Nerivio|Participants will treat with an active Nerivio device every other day for migraine prevention.
33054067|NCT04828707|Sham Comparator|Migraine prevention treatment with sham Nerivio|Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
33054068|NCT04818060||Low Risk of Motor Diagnosis|
33054069|NCT04818060||High Risk of Motor Diagnosis|
33054070|NCT04818060||Stage I or II Huntington's Disease|
33054071|NCT04818060||Healthy Controls|
33054073|NCT04802655|Experimental|Exergame Group (EG)|In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
33054074|NCT04802655|Active Comparator|Activity Based Exercise Group (AG)|In addition to routine NDT training, Goal Directed Activity Based Exercises for upper extremity and trunk will be applied to this group. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
33054075|NCT04796337|Experimental|Sotatercept Treatment|Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose < 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.
33054076|NCT04792541|Placebo Comparator|control group|saline solution
33054077|NCT04792541|Experimental|test group|HY containing gel; GUM® Afta Clear Gel, Sunstar
33054078|NCT04790903|Experimental|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
33054079|NCT04790903|Experimental|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
33054080|NCT04789044|Experimental|PEG mediated reconstruction|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
33054081|NCT04789044|No Intervention|Conventional nerve reconstruction|Conventional nerve reconstruction
33054082|NCT04777201|Experimental|Faricimab|
33054083|NCT04774575|No Intervention|routine group|Patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsies performed at 3 and 12 months after transplantation (M3 and M12). Visits with biopsies for clinical indication are left to the appreciation of the investigator
33054084|NCT04774575|Experimental|biomarker guided follow-up|"Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed.~Visits with biopsies for clinical indication are left to the appreciation of the investigator"
33054085|NCT04771793||Group A- before implentation of physical restraint protocols|
33054086|NCT04771793||Group B- after implentation of physical restraint protocols|
33054087|NCT04771520|Experimental|Treatment (avapritinib)|Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054088|NCT04769453|Active Comparator|iTrack canaloplasty microcatheter with Healon GV Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
33054089|NCT04769453|Active Comparator|OMNI surgical system with Healon GV Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
33054090|NCT04769453|Active Comparator|iTrack canaloplasty microcatheter with Healon Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
33054091|NCT04769453|Active Comparator|OMNI surgical system with Healon Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
33054092|NCT04767360|Other|Open labele BIONESS-Training|Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
33054093|NCT04765722|Experimental|Mepolizumab arm|Mepolizumab Dosage form: 1ml pre-filled syringe Dosage: 100mg Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
33054094|NCT04765722|Placebo Comparator|Placebo arm|Normal Saline (0.09% normal saline) Dosage form: 1ml pre-filled syringe Dosage: n/a Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
33054095|NCT04765709|Experimental|BRIDGE single arm|"Treatment plan:~Part 1: induction with durvalumab plus histology-based chemotherapy regimen.~Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.~Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity."
33054096|NCT04765384|Experimental|Groups 1-4: Ad26.COV2.S (One Dose)|Participants who are previously vaccinated (Group 1-3) and participants who are vaccine naïve (Group 4) will receive single dose of Ad26.COV2.S vaccine at standard dose level on Day 1. Participants from group 4 who are no longer pregnant may receive single booster dose of Ad26.COV2.S vaccine at standard dose level.
33054097|NCT04762069|Experimental|Berubicin|"Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base as a 2 hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days)~Each treatment cycle is 21 days. Subjects will be allowed to continue on treatment at the discretion of the Investigator if there is no evidence of disease progression and the subject is not experiencing unacceptable toxicity as well as if both the subject and Investigator agree that further therapy is in the subject's best interest."
33054098|NCT04762069|Active Comparator|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules will be administered at the institutionally-approved dose and regimen or per the full prescribing information/summary of product characteristics.
33054099|NCT04758351||Cases - Patients with chronic cough|Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
33332773|NCT05706298|No Intervention|Habitual lifestyle|Participants in the control group will be asked to maintain their habitual lifestyle.
33332774|NCT05706298|Experimental|Active breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min (16 bouts per day, equalling 48 min of walking) from 9am-5pm every day throughout the 4 week period. To improve adherence should participants miss a bout of walking they will be asked to do 6 min during the next bout.
33332775|NCT05706220||Control group|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography"
33332776|NCT05706220||Clinically Isolated Syndrome Patients|"Ophthalmologic examination~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
33054100|NCT04752774|Experimental|Dose escalation|One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
33054101|NCT04752774|Experimental|Dose ranging|"Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb.~Participants will be randomised in the ratio of 3:3:2 (total IPN10200 dose 1: 30 participants; total IPN10200 dose 2: 30 participants; Dysport: 20 participants)"
33332777|NCT05706220||Relapsing-remitting Multiple Sclerosis Patients|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
33332778|NCT05706220||Primary Progressive Multiple Sclerosis Patients|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)~Optical coherence tomography"
33332779|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
33332780|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
33054102|NCT04752774|Experimental|Total dose|"One single injection of study medication will be administered locally into several muscle groups of the upper limb.~Participants will be randomized in the ratio of 2:1 (Total IPN10200 dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3).~Or~Participants will be randomized in the ratio of 3:1 (IPN10200 lower dose: 30 participants; placebo: 10 participants, then IPN10200 higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3)."
33054103|NCT04752371|Experimental|Cohort 1: Camoteskimab 7 mg/kg|10 participants will be administered camoteskimab at a dose of 7 mg/kg (500 mg maximum) at Baseline, and every 4 weeks for 6 months (6 treatments).
33054104|NCT04752371|Experimental|Cohort 2: Camoteskimab Dose escalation/reduction|Cohort 2 dose will be determined based on a review of Cohort 1 data. 10 participants will be administered camoteskimab at the determined dose at Baseline, and every 4 weeks for 6 months (6 treatments).
33054105|NCT04752059|Experimental|T-DXd 5.4 mg|Single arm phase II trial
33054106|NCT04743362||Participants with muco-cutaneous lesions|Participants will have muco-cutaneous lesions for non-invasive evaluation (including normal skin or mucosa and benign lesions) and will be identified by their physicians or fellows during routine clinical care.
33054107|NCT04742699|Experimental|Z-Drug-mono cohort|Patients being treated with Z-drug monotherapy at registration
33332781|NCT05706064||COVID-19 Infection|
33332782|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
33332783|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
33332784|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
33332785|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
33332786|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
33332787|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
33054108|NCT04742699|Experimental|SUV-mono cohort|Patients being treated with SUV monotherapy at registration
33054109|NCT04742699|Experimental|SUV-combination cohort|Patients being treated with SUV and BZRA combination therapy at registration
33054110|NCT04742699|Experimental|RMT-combination cohort|Patients being treated with RMT and BZRA combination therapy at registration
33054111|NCT04740723|Experimental|Renal denervation|Renal denervation with the iRF system
33054112|NCT04731519|Active Comparator|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
33054113|NCT04731519|Experimental|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
33068070|NCT04518826||FFR|In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR <0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR>=0.9, DEB will be used and final FFR will be measured at the end of the procedure.
33068071|NCT04518826||CAG|In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.
33054114|NCT04731519|Other|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
33332788|NCT05705596|Experimental|Sucrose|10% (w/v) sucrose in water
33332789|NCT05705596|Experimental|Hesperetin|7% (w/v) sucrose in water + 50 mg/L Hesperetin
33332790|NCT05704192||Clinically significant portal hypertension (CSPH) group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91*ln(Liver/Spleen volume ratio) +3.8[If presence of peri-hepatic ascites],was used to diagnose CSPH (HVPG>10mmHg) with a cut-off value 11.606.
33054115|NCT04729907|Experimental|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligram (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
33054116|NCT04729907|Experimental|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
33054117|NCT04722146|Experimental|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
33054118|NCT04722146|Experimental|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.
33054119|NCT04722146|Experimental|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
33054120|NCT04722146|Experimental|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
33054121|NCT04722146|Experimental|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
33054122|NCT04722146|Experimental|Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.
33054123|NCT04719052|Experimental|Mediterranean diet group|"1) The MD will be based on high consumption of unsaturated fat from vegetable sources (virgin olive oil and nuts) and minimally processed plant foods (vegetables, fruits, nuts, whole grains and legumes), low consumption of meat (especially red and processed meats) and sweets, and moderate consumption of fish and dairy products (mainly yoghurt and cheese). Accordingly, this diet will provide a high amount of mono and polyunsaturated fatty acids, fibre and phenolic compounds.~Adolescents in the MD group will replace the intake of conventional breads by sourdough bread consumption (2 servings of 50-60 g daily) and incorporate into their diet chickpeas (2 servings of 150 g/week chickpeas, minimum one of them in hummus format), and they will consume at least another serving of legumes which can be chickpeas or another legume), pomegranate juice (4 servings of 200ml/week) and mixed nuts (4 servings of 30 g/week)."
33054124|NCT04719052|Active Comparator|Low-fat diet group|2) The low-fat diet (control diet) will be based on low consumption of fats. A low-fat diet is the most used diet for obesity treatment in adolescents. This group will not receive any additional specific food by researchers. This diet will be based on the diet proposed as low-fat diet in the PREDIMED study
33054125|NCT04714359|Experimental|MDMA-assisted Psychotherapy|Three open-label sessions of MDMA-assisted psychotherapy with flexible dose of MDMA (80 or 120 mg) and optional supplemental dose of (40 or 60 mg), 1.5 to 2 hours later
33054126|NCT04710784|Experimental|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
33332791|NCT05704192||non-CSPH group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91*ln(Liver/Spleen volume ratio) +3.8[If presence of peri-hepatic ascites],was used to diagnose CSPH (HVPG>10mmHg) with a cut-off value 11.606.
33332792|NCT05703568|Experimental|Group- based virtual reality training|Individuals in this arm will be received intervention protocol of group- based virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
33332793|NCT05703568|Experimental|Individual virtual reality training|Individuals in this arm will be received intervention protocol of individual virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
33054127|NCT04702958||Torsemide|Patients enrolled in the TRANSFORM-HF study randomized to Torsemide, or patients prescribed Torsemide at hospital discharge
33054128|NCT04702958||Furosemide|Patients enrolled in the TRANSFORM-HF study randomized to Furosemide, or patients prescribed Furosemide at hospital discharge
33054129|NCT04702425|Experimental|VOB560-MIK665 - Part 1a|Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.
33054130|NCT04702425|Experimental|VOB560-MIK665 - Part 1b|Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.
33054131|NCT04702425|Experimental|VOB560-MIK665 - Part 2a|Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.
33332794|NCT05703568|No Intervention|Control group|Individuals in this arm will continue their routine daily activities.
33332795|NCT05702476||MFS Adult patients|Patients with clinical and/or gentic diagnosis of MFS older than 18 years
33332796|NCT05702476||MFS Paediatric patients|Patients with clinical and/or gentic diagnosis of MFS younger than 18 years
33332797|NCT05702086|Experimental|"Play now intervention group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
33361299|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
33068072|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
33068073|NCT00162435|Experimental|Genetic|
33068074|NCT00162435|Experimental|Control|
33068075|NCT04518709|Experimental|Posterior Annulus Elevation Technique Group|In patients who were determined in the treatment group, after the conventional procedure for mitral valve repair was completed, a posterior mitral valve elevation technique will be performed.
33068076|NCT04518709|Placebo Comparator|Without Posterior Annulus Elevation Technique Group|No additional procedure will be done after conventional mitral valve repair
33068077|NCT04518865|Experimental|pre-pubertal group.|The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III
33068078|NCT04518865|Experimental|post-pubertal group|The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV
33068079|NCT04518982|Experimental|The experimental group|
33068080|NCT04518982|Placebo Comparator|The control group|
33068081|NCT04518631|Experimental|8-week mindfulness program|8-week .b Foundations course
33068082|NCT04518631|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
33068083|NCT00141557|Experimental|1|
33068084|NCT00141557|Active Comparator|2|
33068085|NCT04518358|Experimental|Evaluation of Expert Guiding Technology|
33068086|NCT04518397|Experimental|Theatre participants|Girls in this arm will participate in the theatre intervention.
33068087|NCT00162474|Experimental|Warfarin|
33068088|NCT04518553|Active Comparator|active control|antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.
33068089|NCT04518553|Experimental|active interference|HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.
33068090|NCT00505336|Experimental|1|Eplerenone
33068091|NCT00505336|Active Comparator|3|no additional treatment
33068092|NCT00505336|Experimental|2|Atorvastatin
33068093|NCT04518514|Experimental|Preoperative evaluation and risk assessment via telemedicine|
33068094|NCT04518202|Experimental|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
33068095|NCT04518202|Placebo Comparator|Sham patch|Sham patch applied at 6 hours before the scheduled office hysteroscopy.
33068096|NCT04517890|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
33068097|NCT04517890|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
33068098|NCT04517812|Experimental|Intervention group|The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
33068099|NCT04517812|No Intervention|Control group|The control group will undertake the measurement battery and provide the demographic details.
33068100|NCT04724811|Experimental|Weight-bearing as tolerated|Patients are instructed to mobilise the hip and weight-bear as tolerated
33068101|NCT04724811|Active Comparator|Touch-down weight-bearing|Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks
33068102|NCT04517968|Experimental|immediate implant with customized healing abutment|
33068103|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
33418906|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
33418907|NCT02251184|Experimental|Aggrenox|extended release
33418908|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
33418909|NCT05706051|Other|age-related hearing loss affected before hearing aid fitting|"patients aged 55 to 80 years old, undergoing posturography at diagnosis of ARHL and 3 months later before hearing aid fitting, within the role of control~same patients udergoing posturography at hearing aid fitting and 3 months after."
33418910|NCT02108756|Experimental|L-pantoprazole sodium|
33418911|NCT02108756|Active Comparator|Panmeilu|
33418912|NCT05596461|Experimental|Transcranial magnetic stimulation|
33418913|NCT05596461|Experimental|Transcranial direct-current stimulation|
33418914|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
33418915|NCT02108834|Placebo Comparator|Placebo|placebo saline
33418916|NCT05547399|Experimental|Low Dose Cohort|Zanubrutinib will be administered as a single low dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
33054132|NCT04702425|Experimental|VOB560-MIK665 - Part 2b|Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.
33054133|NCT04702425|Experimental|VOB560-MIK665 - Part 2c|Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.
33054134|NCT04702425|Experimental|VOB560-MIK665 - Part 2d|Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.
33054135|NCT04698343|Experimental|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
33054136|NCT04695210|Experimental|Virtual Peer-to-Peer Support|"Those participants randomised to the intervention arm will have access to a 12-week virtual peer-to-peer support programme which entails:~weekly audio, video, or text private messaging with a peer supporter;~synchronous weekly discussion forum attended by peer supporters and family caregiver participants moderated by the research team. These forums will discuss specific topics (e.g. caregiver self-care, the emotional impact of caregiving). Ask the expert forums will be moderated by clinical experts every 6 weeks (meaning all participants will have access to 2 ask the expert sessions);~asynchronous discussion forums in which participants can post questions; and~access to informational resources."
33054137|NCT04695210|No Intervention|Control|Those participants randomised to the control arm will receive usual care which comprises self-directed access to the MND Association Visitors programme and MND Association educational resources via their website.
33054138|NCT04685707|Active Comparator|Active-Sedentary Control|
33054139|NCT04685707|Experimental|Active-Sedentary Experimental|
33054140|NCT04685304|Experimental|PGx-guided care|Pharmacogenetic results (e.g., CYP2D6, CYP2C9) and a pharmacist consultation will be provided to their primary care provider. This consultation note (PharmD consult) will aid primary care providers in the interpretation and application of PGx results in prescribing decisions. The ultimate prescribing decision is at the discretion of the primary care provider and patient.
33054141|NCT04685304|Active Comparator|Standard care|"Care for study subjects will occur without PGx results at the discretion of the study subject, their primary care provider.~After the active participation ends (i.e. after the three month follow up is complete), PGx results and a PharmD consult will be provided similar to the PGx-guided arm."
33054142|NCT04684654|Experimental|Part A (SAD)|Single Ascending Dose (SAD)
33054143|NCT04684654|Placebo Comparator|Part A (SAD) Placebo|
33054144|NCT04684654|Experimental|Part B (MAD)|Multiple Ascending Dose (MAD)
33054145|NCT04684654|Placebo Comparator|Part B (MAD) Placebo|
33054146|NCT04684654|Experimental|Part C (pSS)|Primary Sjögren's Syndrome (pSS)
33054147|NCT04684654|Placebo Comparator|Part C (pSS) Placebo|
33054148|NCT04683029|Experimental|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
33054149|NCT04683029|Placebo Comparator|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
33054150|NCT04682730|Experimental|Deliberative Loop|28-page Context-Setting Document; 2-page addendum to Context-Setting Document; 90 minute Deliberative session; 8-page post-session survey
33054151|NCT04681651|Experimental|NBO group|Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
33054152|NCT04681651|Placebo Comparator|Control group|Inhale air placebo plus endovascular mechanical thrombectomy
33054153|NCT04678453|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.
33054154|NCT04678453|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered Q3W for four cycles.
33054155|NCT04678453|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered Q3W for four cycles.
33111452|NCT05298137|Experimental|IV Cannulation With Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the passive leg raise (PLR) group will have their legs elevated to 45 degrees until successful peripheral IV (PIV) placement. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
33111453|NCT04662177|Experimental|Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies|The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression.
33111454|NCT04662177|No Intervention|Group 2: Standard anaesthesia with propofol and electrophysiological studies|The group 2 receive standard anaesthesia management.
33111455|NCT05292560|Experimental|Positive psychology app|
33111456|NCT05292560|Other|Waiting list|
33111457|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
33111458|NCT05283512|Other|IV-hydration group (standard of care)|The total IV-hydration volume is 1000 mL of isotonic NaCl with an infusion rate of 1-3 mL/kg/hour. The IV-hydration spans 2-4 hours prior to CM injection and continuing postcon-trast for 4 hours. Patients are prescribed a total volume of 1000 mL if LVEF is normal, while patients with heart failure (LVEF < 40%) are prescribed an individual hydration protocol of a total volume of 500 mL. The volume is distributed equally before and after CM injection. The total desired volume before and after CM exposure is calculated individually from the patient's weight and the hydration period. The infusion rate will be adjusted to meet the required total volume of the IV hydration protocol.
33111459|NCT05283512|Active Comparator|Oral hydration group|The oral hydration regimen spans from 1-2 hours prior to cardiac CT and 4 hours after. The fluid volume depends on the patient's left ventricular ejection fraction (LVEF). Patients are prescribed 1000 mL (500 mL before CT-scan and 500 mL after CT-scan) if LVEF is normal. Patients with heart failure (LVEF < 40%) are prescribed an individual hydration protocol of a total volume of 500 mL (250 mL before and 250 mL after).
33111460|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor. In this cohort, patients may be treated with any of the 3 FDA-approved BRAFi/MEKi combinations: dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib.
33111461|NCT05282342||Transplants with low levels of physical activity (GTB)|
33111462|NCT05282342||Transplants with moderate levels of physical activity (GTM)|
33111463|NCT05282342||Transplants with high levels of physical activity (GTA)|
33111464|NCT05282342||Healthy sedentary people (GSS)|
33111465|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
33111466|NCT05259449|No Intervention|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
33111467|NCT05259449|Active Comparator|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
33111468|NCT05259449|Active Comparator|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
33111469|NCT05259449|Active Comparator|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
33111470|NCT05259449|Experimental|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
33111471|NCT05259449|Experimental|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
33111472|NCT04661943|Experimental|Arm A|Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
33111473|NCT05252000|Experimental|mechanical debridement and adjunctive aPDT|
33111474|NCT05252000|Active Comparator|mechanical debridement and sham aPDT|
33111475|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
33111476|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
33111477|NCT05237414|Experimental|Binge Drinkers with Combined Intervention (active CT + active tDCS)|Subjects will perform a variation of the TNTA task (Anderson & Green, 2001; López-Caneda et al., 2019) to enhance the suppression of alcohol-related memories. The Learning phase will be composed of 2 blocks of 12-image pairs (as there is no a baseline block), and in the TNT phase, all the stimuli to be inhibited will be alcohol-related images. After the Learning Phase, active neuromodulation will be performed using tDCS. Twenty minutes of 2 mA direct current will be applied on the scalp using a saline-soaked pair of 35 cm2 surface sponge electrodes, through an Eldith DC Stimulator Plus (Neuroconn, Germany). To stimulate the right DLPFC, the anodal electrode will be placed over F4 according to the 10-20 international system for EEG electrode placement. The cathode electrode will be over the contralateral supraorbital area. The current fade in for 15 seconds, is constant at 2 mA for 20 minutes, and then fade out for 15 seconds.
33111478|NCT05237414|Experimental|Binge Drinkers with Cognitive Intervention (active CT + sham tDCS)|Subjects perform the variation of the TNTA task for active CT. After the Learning Phase, sham neuromodulation is performed using the same montage of the active tDCS. However, the electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds. There is no current for the rest of the time.
32740402|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
32740403|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
33111479|NCT05237414|Sham Comparator|Binge Drinkers with Control Intervention (sham CT + sham tDCS)|"Subjects will perform a variation of the TNTA task, where the Learning phase also have only two blocks of 12-image pairs. However, in this case the TNT phase is replaced by a Forced-Choice Reaction Time (FCRT) task, during which the participants only must categorize alcoholic and non-alcoholic images answering to the question What type of beverage was there in the image? (answer: Alcoholic drink or Non-alcoholic drink); thus, they do not have to inhibit the memories related to the alcoholic images. During this phase, sham neuromodulation will be performed using the same montage of the active tDCS. The electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds, while a sham memory inhibition CT is performed."
33111480|NCT05237414|No Intervention|Non/Low-Drinkers|No intervention.
33111481|NCT02824263|No Intervention|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
33111482|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
33111483|NCT05226299|Experimental|Experimental: Supra-threshold capsaicin|Arm: Experimental: Supra-threshold capsaicin Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
33111484|NCT05226299|Placebo Comparator|Arm: Placebo Comparator: Saline|Participants will be exposed repeatedly to aerosolized saline through a nebulizer during treatment.
33111485|NCT05214092|Experimental|Neurosurgical Patients|Patient participants with previously excised tissue within Heschl's gyrus (as dictated by clinical care)
33111486|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
33332798|NCT05702086|Active Comparator|"Play later waitlist group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
33111487|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
33111488|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
33111489|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
33332799|NCT05701930|Experimental|Experimental:|pecha kucha will be practiced
33332800|NCT05701930|No Intervention|control|Routine maintenance will be applied.
33332801|NCT05701618|Experimental|Psychologically Informed Education|is arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with atraumatic lower extremity injuries.
33332802|NCT05701618|Placebo Comparator|Control Education|This arm will provide education of basic leg anatomy and will not address maladaptive psychological behaviors.
33332803|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
33332804|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
33332805|NCT05675956|Experimental|High Intensity|The device will be set to 100% intensity for this group.
33332806|NCT05675956|Active Comparator|Low Intensity|The device will be set to 10% intensity in this group
33332807|NCT03693612|Experimental|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
33332808|NCT03693612|Experimental|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
33332809|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
33332810|NCT03692910|Experimental|Part A (Open-label): SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD), in the evening, from Day 1 to Day 14.
33054156|NCT04678453|Experimental|Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)|SNK01 (at MTD/RP2D) administered Q3W for four cycles.
33054157|NCT04674969||Clinical Cohort|All enrolled patients are included in the Clinical Cohort and will complete assessments per standard of care through 5-year follow-up.
33054158|NCT04674969||Outcomes Cohort|Patients at select sites will complete the Clinical Cohort standard of care assessments and additional assessments as part of the Outcomes Cohort, including Quality of Life questionnaires, six-minute walk test (6MWT), and Healthcare Utilization data collection.
33054159|NCT04672889|Placebo Comparator|Placebo|consume 1 sachet per day for 1 months
33054160|NCT04672889|Experimental|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
33054161|NCT04667104|Experimental|Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)|Participants will receive combination treatment with JNJ-73763989+ nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.
33054162|NCT04657016|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
33332811|NCT03692910|Experimental|Part B (Double-blind): SAGE-217|Participants were to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
33332812|NCT03692910|Placebo Comparator|Part B (Double-blind): Placebo|Participants were to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
33332813|NCT04189146|Other|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
33332814|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
33054163|NCT04657016|Placebo Comparator|Placebo|Administered SC
33054164|NCT04654689|Experimental|Intervention group|30 patients will be given the combination of resveratrol and curcumin liposomed with G04CB02, in a single daily dose for 4 months.
33054165|NCT04654689|Placebo Comparator|Control group|30 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomal polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group
33054166|NCT04649866|Experimental|Test group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
33054167|NCT04649866|Active Comparator|Control group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
33054168|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
33054169|NCT04644770|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.
33054170|NCT04642963|Experimental|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
33054171|NCT04634838|Other|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
33054172|NCT04633447|Experimental|Guselkumab|Participants will receive guselkumab subcutaneously (SC) every 4 weeks from Week 0 through Wweek 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
33054173|NCT04633447|Experimental|Placebo|Participants will receive matching placebo SC every 4 weeks from Week 0 through Week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
33054174|NCT04632953||Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin in clinical studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), Investigator Sponsored Trials (ISTs), or UX007-EAP (NCT03773770).
33068104|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
33332815|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
33418917|NCT05547399|Experimental|High Dose Cohort|Zanubrutinib will be administered as a single high dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
33332816|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
33332817|NCT04159506|Experimental|The Equus Effect (TEE)|TEE is a 4-session intervention. Each session is 4 hours and includes: 1) mindfulness-based activities; 2) didactics about emotion regulation and interpersonal skills; and 3) experiential learning activities with horses that provide opportunities to practice emotion regulation and interpersonal skills. At the end of each session, Veterans debrief about what they learned and identify how they might apply this knowledge to manage their mental health concerns and function better socially.
33332818|NCT04159506|Active Comparator|Attention Control (AC)|AC will exclude equine-related activities or discussions but maintain mindfulness-based activities, emotion regulation and interpersonal skills didactics, and experiential learning activities with between-session application. Instead of experiential equine activities, AC will rely on team-building activities, which aim to enhance social relations by involving participants in collaborative tasks and providing opportunities for emotion regulation and interpersonal skills practice.
33332819|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
33332820|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
33332821|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
33332822|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
33054175|NCT04632953||Currently Treated with Triheptanoin|New patients enrolling into the DMP currently being treated with triheptanoin (excluding those in the previously treated with triheptanoin cohort).
33054176|NCT04632953||Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin.
33054177|NCT04632953||Triheptanoin Naïve Transitioned toTriheptanoin|Patients already enrolled into the triheptanoin naïve cohort but transition to triheptanoin during the DMP after enrollment.
33054178|NCT04630145|Experimental|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg or 500 mg twice daily (2*200 mg tablets) along with EB 500-750 mg or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48.
33054179|NCT04630145|Active Comparator|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg or 500 mg (2*200 mg tablets) twice a day along with EB 500-750 mg daily or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48, followed by 2 capsules of RBT 300 mg or 150 mg once a day.
33054180|NCT04629534|Experimental|Group A|
33054181|NCT04629534|Placebo Comparator|Group B|
33054182|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
33054183|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
33054184|NCT04621708|Experimental|Left DLPFC iTBS rTMS|
33054185|NCT04616183|Experimental|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054186|NCT04616183|Experimental|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054187|NCT04614948|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
33054188|NCT04614948|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
33054189|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
33054190|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
33054191|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
33054192|NCT04612751|Experimental|Cohort 1|Datopotamab deruxtecan (Dato-DXd) + Durvalumab
33054193|NCT04612751|Experimental|Cohort 2|Datopotamab deruxtecan (Dato-DXd) + Durvalumab
33054194|NCT04612751|Experimental|Cohort 3|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin
33418918|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
33418919|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
33332823|NCT04206384|Experimental|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.
33332824|NCT04051944|Experimental|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
33332825|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
33418920|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
33418921|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
33418922|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
33054195|NCT04612751|Experimental|Cohort 4|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin
33054196|NCT04612751|Experimental|Cohort 5|Datopotamab deruxtecan (Dato-DXd) + AZD2936
33054197|NCT04612751|Experimental|Cohort 6|Datopotamab deruxtecan (Dato-DXd) + AZD2936
33054198|NCT04612751|Experimental|Cohort 7|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin
33054199|NCT04612751|Experimental|Cohort 8|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin
33054200|NCT04612751|Experimental|Cohort 9|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin
33054201|NCT04612751|Experimental|Cohort 10|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin
33054202|NCT04612751|Experimental|Cohort 11|Datopotamab deruxtecan (Dato-DXd) + MEDI5752
33054203|NCT04612335|Experimental|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate <110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
33054204|NCT04612335|Other|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
33054205|NCT04610944|Experimental|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
33054206|NCT04610944|Active Comparator|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
33054207|NCT04607226|Experimental|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
33054208|NCT04607226|Experimental|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
33054209|NCT04607226|Experimental|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
33054210|NCT04607226|Experimental|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
33054211|NCT04607226|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
33054212|NCT04606433|Experimental|Study treatment|The patients received intravenous infusion of GNC-038 for 1 cycle. After the completion of 2 cycles of treatment, participants with no unbearable ae could proceed to the 3rd and 4th cycles of treatment. After four cycles of treatment, participants with clinical benefits could also receive four additional cycles of the same dose.
33054213|NCT04603287|Experimental|Study treatment|Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33054214|NCT04602806||Moderate to Severe TBI Subjects|Adult patients (age 18-65y inclusive) presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria (i.e., patient has sustained a traumatically-induced physiological disruption of brain function).
33332826|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
33332827|NCT04067492|Experimental|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
33332828|NCT04067492|Experimental|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
33332829|NCT04067492|Experimental|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
33111490|NCT05173259|Active Comparator|F-R/L-G05/G15/G25 or G25/G15/G05-L/R-F Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33111491|NCT05173259|Active Comparator|F-R/L-G05/G25/G15 or G15/G25/G05-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33054215|NCT04602065|Experimental|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
33054216|NCT04602065|Experimental|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
33054217|NCT04598815|Experimental|Sirolimus|Sirolimus for 12 weeks
33111492|NCT05173259|Active Comparator|F-R/L-G15/G05/G25 or G25/G05/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G05-G25-G25-G05-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33111493|NCT05173259|Active Comparator|F-R/L-G15/G25/G05 or G05/G25/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33111494|NCT05173259|Active Comparator|F-R/L-G25/G05/G15 or G15/G05/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33054218|NCT04598815|Experimental|Methylprendnisolone|Methylprednisolone for 12 weeks
33054219|NCT04593875|Experimental|Low Intensity Focused Ultrasound|"Device: Low Intensity Focused Ultrasound Device~Low Intensity Focused Ultrasound Pulsation (LIFUP) of putamen (a key area for Parkinson's disease) will be performed during two sessions. The proposed experiment will involve behavioral (e.g., motor assessements) and paramedical (i.e., MRI/fMRI) measurements just before and after each of two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group is well blinded."
33332830|NCT04067492|Experimental|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
33054220|NCT04593875|Sham Comparator|Control|Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group is well blinded.
33054221|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
33054222|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
33054223|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
33054224|NCT04583280|Experimental|Rilematovir|Participants will receive rilematovir orally based on body weight and age group.
33054225|NCT04583280|Experimental|Placebo|Participants will receive matching placebo of rilematovir based on body weight and age group.
33054226|NCT04580238|Experimental|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
33054227|NCT04580238|Active Comparator|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
33054228|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
33332831|NCT04067492|Experimental|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
33054229|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
33054230|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
33054231|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
33054232|NCT04577651|Experimental|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
33054233|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
33054234|NCT04576156|Active Comparator|Best Available Therapy (BAT)|"Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.~Participants on BAT who meet protocol-defined criteria for progressive disease may crossover to receive imetelstat treatment after sponsor's approval."
33054235|NCT04573777|Experimental|Intervention Repatha|
33054236|NCT04567004|Other|Control|The control arm will show the products with no label.
33054237|NCT04567004|Experimental|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
33054238|NCT04567004|Experimental|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
33054239|NCT04567004|Experimental|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
33054240|NCT04565717|Experimental|Part A: ALN-HSD|Participants will be administered a single dose of ALN-HSD.
33054241|NCT04565717|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of ALN-HSD-matching placebo.
33054242|NCT04565717|Experimental|Part B: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
33054243|NCT04565717|Placebo Comparator|Part B: Placebo|Participants will be administered multiple doses of ALN-HSD-matching placebo.
33054244|NCT04564105|Other|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
33054245|NCT04563793||Superion™ IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
33054246|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants who are PSMA-PET-positive will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization.
33054247|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants who are PSMA-PET-positive receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
33068105|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1~G-CSF 5 mcg/kg subcut on days 0 to + 6~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
33068106|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
33068107|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
33068108|NCT04517773||study group|Oncological patients
33068109|NCT04518163|Experimental|study group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion
33068110|NCT04518163|Active Comparator|control group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion
33068111|NCT04517227|Experimental|single arm|All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.
33068112|NCT00141713|Experimental|1|etanercept treatment for GVHD
33068113|NCT04517188|Experimental|Halodine Nasal Antiseptic|"Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP~Single topical administration"
33068114|NCT04516837|Experimental|eltrombopag plus rhTPO|Combination of eltrombopag and rhTPO
33068115|NCT04516837|Active Comparator|eltrombopag|Eltrombopag monotherapy
33068116|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
33068117|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
33111495|NCT05173259|Active Comparator|F-R/L-G25/G15/G05 or G05/G15/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
33111496|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
33111497|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
33111498|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
33111499|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
33111500|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
33111501|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
33111502|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
33111503|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
33111504|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
33111505|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
33111506|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
33111507|NCT05161208|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
33111508|NCT05161208|Placebo Comparator|Placebo (vehicle) nasal spray|Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
33111509|NCT02650986|Experimental|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
33111510|NCT02650986|Experimental|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
33111511|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
33111512|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
33111513|NCT04662021|Experimental|Exercise group|
33111514|NCT04662021|Experimental|Cognitive therapy group|
33111515|NCT04661904|Experimental|cTBS group|Patients randomly assigned to cTBS group will receive 12 sessions cTBS for total four days after surgery.
33111516|NCT04661904|Sham Comparator|sham group|Patients randomly assigned to sham group will receive 12 sessions sham stimulation for total four days after surgery.
33111517|NCT04661865|Other|Control group|Routine care only They will receive routine antenatal care that included iron supplementation with follow up of hemoglobin level
33111518|NCT04661865|Experimental|Intervention group|They will receive the Heath Information Package Program (HIP program)
33111519|NCT04661553|Experimental|Group1: patients with a low risk of premature birth|Asymptomatic patient receiving usual follow-up in the maternity ward.
33111520|NCT04661553|Experimental|Group2: patients with a high risk of premature birth|Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm.
33111521|NCT05150873||Patients ttreatted for AAA|Patients affected by AAA and treated att our institution with EVAR and/or Open Repair between 2010 and 2020
33111522|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
33111523|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
33111524|NCT05134025|Experimental|SMART A1|A full dose of meal-time insulin with announced exercise immediately prior to commencement
33111525|NCT05134025|Experimental|SMART A2|a 25% dose reduction in meal-time insulin with exercise announcement 90-minutes prior to commencement
33111526|NCT05134025|Experimental|SMART A3|a 25% dose reduction in meal-time insulin with exercise announcement 45-minutes prior to commencement
33332832|NCT04067492|Active Comparator|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
33332833|NCT04046250|Experimental|TK112690|TK112690 treatment
33332834|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
33332835|NCT05280522||Repeated Measures Experiment|Participants are positioned in an isokinetic dynamometer (Biodex System 4 Isokinetic Dynamometer , Biodex Medical Systems, Inc., Shirley, NY) with the knee flexed to approximately 90 degrees. After 3-4 submaximal warm up contractions, participants generate maximum knee extension force while vigorous verbal encouragement is provided. Two trials are collected with 30 seconds between trials. The maximum forces from the 2 trials is used to determine the target force of 20% MVIC used for the volitional and NMES contractions and to normalize the force of the muscle contractions.
33332836|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
33054248|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Participants|Participants who are PSMA-PET-negative at screening, will be enrolled in the Observational Cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year.
33054249|NCT04556526|Experimental|Group A: Ad26.ZEBOV, MVA-BN-Filo|Participants will receive intramuscular (IM) injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp]) on Day 1, followed by modified vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U]) on Day 57.
33054250|NCT04556526|Other|Group B: No vaccination during pregnancy|Participants (pregnant women) in control Group B will not receive any vaccination during pregnancy. However, women in this group will receive the 2-dose vaccination regimen at the earliest 6 weeks after delivery/termination of pregnancy that is Dose 1 of Ad26.ZEBOV vaccine (0.5 mL) (5*10^10 vp) on Day 1 by IM injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 Inf U) vaccine by IM injection 56 days after Dose 1.
33054251|NCT04556123|Experimental|BIS-guided decongestion|
33054252|NCT04556123|Active Comparator|Decongestion based on clinical judgement|
33332837|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
33332838|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
33332839|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
33332840|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
33332841|NCT03739112|Active Comparator|Quadrivalent Comparator Vaccine|Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine
33332842|NCT04375878|Active Comparator|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
33332843|NCT04375878|Active Comparator|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
33332844|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
33332845|NCT04039776|Experimental|Bone patellofemoral joint indices|Evaluation of the bone index values in patients affected by patellofemoral joint disorders, obtained from CT scans performed in both orthostatism and clinostatism
33332846|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
33054253|NCT04555590|No Intervention|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
33054254|NCT04555590|Experimental|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
33054255|NCT04547998|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and NV-UVB. Each subject will serve as their own Control, with a depigmented area receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area. Study treatment areas will be randomily assigned as Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B.
33054256|NCT04536532|Experimental|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
33054257|NCT04536532|Placebo Comparator|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
33054258|NCT04536532|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
33054259|NCT04536532|Placebo Comparator|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
33054260|NCT04535544|Experimental|Immediate Active Treatment arm: JNJ-73763989 + NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir [ETV], tenofovir disoproxil, or tenofovir alafenamide [TAF]) once daily for 144 Weeks in Part 1 and 2.
33054261|NCT04535544|Placebo Comparator|Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA|Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and 2.
33054262|NCT04533165|Experimental|Virtual exercise program|This arm will receive the virtual exercise program.
33054263|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
33054264|NCT04521972|Active Comparator|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
33054265|NCT04521972|Active Comparator|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
33054266|NCT04521972|Experimental|Group 3|Natural non-augmented labor with reduced or red room lights.
33054267|NCT04521972|Experimental|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
33054268|NCT04516135|Experimental|Arm A (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
33054269|NCT04516135|Active Comparator|Arm B (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
33054270|NCT04507711|Experimental|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
33054271|NCT04507711|Experimental|25 ng/ml|Blood specimen which was added of 1 ul of palonosetron
33054272|NCT04507711|Experimental|250 ng/ml|Blood specimen which was added of 10 ul of palonosetron
33054273|NCT04507711|Experimental|2500 ng/ml|Blood specimen which was added of 100 ul of palonosetron
33054274|NCT04499274|Experimental|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
33054275|NCT04499274|Experimental|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
33054276|NCT04499274|Experimental|2000 ng/ml|Blood specimen which was added 2 ul of ondansetron
33054277|NCT04499274|Experimental|20000 ng/ml|Blood specimen which was added 20 ul of ondansetron
33054278|NCT04497961|Experimental|Lenalidomide maintenance|"Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~ARM A1: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals and nutrition counseling on C13D1 for 12 weeks followed by additional 12 weeks of counseling alone from C16D1. They will continue on their lenalidomide maintenance schedule per study calendar.~ARM A2: The patients who do not go on the nutrition sub study will continue on their lenalidomide maintenance schedule per study calendar."
33054279|NCT04497961|Experimental|Daratumumab maintenance|"Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~ARM B1: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals and nutrition counseling on C13D1 for 12 weeks followed by additional 12 weeks of counseling alone from C16D1. They will continue on their daratumumab maintenance schedule per study calendar.~ARM B2: The patients who do not go on the nutrition sub study will continue on their daratumumab maintenance schedule per study calendar."
33054280|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
33054281|NCT04497844|Experimental|AA plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
33054282|NCT04496895|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
33054283|NCT04496895|Experimental|orange peel fermentation|consume 1 sachet per day for 2 months
33054284|NCT04494425|Experimental|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
33054285|NCT04494425|Active Comparator|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
33054286|NCT04492605|Placebo Comparator|Placebo|Placebo
33054287|NCT04492605|Experimental|TCI378 Probiotics|TCI378 Probiotics
33054288|NCT04492605|Experimental|TCI507 Probiotics|TCI507 Probiotics
33054289|NCT04490720|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
33054290|NCT04490720|Experimental|Buckwheat husk extract|consume 1 sachet per day for 2 months
33068118|NCT04516954|Experimental|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
33332847|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
33332848|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
33332849|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
33332850|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
33332851|NCT04041414|Active Comparator|Control schools|Students in control schools will receive no intervention
33332852|NCT03745014|Active Comparator|Pheno|
33332853|NCT03745014|Active Comparator|Standard of Care|
33332854|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
33332855|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
33332856|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
33332857|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
33418923|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
33054291|NCT04488159|Experimental|Immunoscore stratification|"Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.~Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)~Immunoscore high (I high; I4): no adjuvant treatment."
33054292|NCT04488159|Active Comparator|TNM stratification|"TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)~TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)"
33054293|NCT04481191|Experimental|Concomitant RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
33054294|NCT04481191|Active Comparator|Staggered RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
33054295|NCT04480840|Placebo Comparator|Placebo|
33054296|NCT04480840|Experimental|PLN-74809 Dose Level 1|Dose: 40 mg;
33054297|NCT04480840|Experimental|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
33054298|NCT04480840|Experimental|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
33054299|NCT04480840|Experimental|PLN-74809 Dose Level 4|Dose: 320 mg; PLN-74809 Dose Level 4 following PLN-74809 Dose Level 3
33054300|NCT04478578||Patients with febrile illness|Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
33054301|NCT04478344|Experimental|Ultrasound guided hydrodissection to superior cluneal nerve|Patients with superior cluneal nerve enttrappment given by ultrasound guided perineural injection with 2 mL of 50% dextrose, 4 mL of 1% lidocaine, and 4 mL of 1% normal saline to superior cluneal nerve of affected side.
33054302|NCT04478344|No Intervention|Control arm|Patients without superior cluneal nerve entrappment
33054303|NCT04473430|Experimental|Real-time Dexcom CGM, then Point-Of-Care Blood Glucose Group (Intervention-Control Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use a real-time/personal CGM for 4 weeks (Intervention-Control Group), then 2 weeks of wash-out period, and cross over to use POC BG for 4 weeks.
33054304|NCT04473430|Experimental|Point-Of-Care Blood Glucose (Control) then Real-time Dexcom CGM Group (Control-Intervention Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use POC BG for 4 weeks, then 2 weeks of wash-out period, and cross over to use a real-time/personal CGM for 4 weeks (Control-Intervention Group).
33054305|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
33332858|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
33332859|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
33054308|NCT04449861|Experimental|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
33054309|NCT04448327|Experimental|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
33054310|NCT04448327|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
33054311|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
33054312|NCT04442737|Experimental|D/C/F/TAF FDC Arm (Immediate Switch)|Participants will be immediately switched to a regimen of darunavir 800 milligram (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily for 48 weeks.
33332860|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
33332861|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
33332862|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
33332863|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
33332864|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
33054313|NCT04442737|Active Comparator|INI + TAF/FTC Arm (Delayed Switch)|Participants will continue to receive current baseline integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen for 24 weeks. After 24 weeks participants will switch to a regimen of D/C/F/TAF FDC once daily for an additional 24 weeks.
33054314|NCT04439539|Experimental|Cohort 1: Participants Enrolled Prior to Protocol Amendment 5 is in Effect|During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
33054315|NCT04439539|Experimental|Cohort 2: Participants Enrolled After Protocol Amendment 5 is in Effect|Following implementation of protocol amendment- 5 and 6, all participants will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) for 36 weeks (induction phase). In the consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and NA for 12 weeks. According to predefined criteria NA treatment may be continued during the follow up (FU) phase. JNJ-56136379 (JNJ-6379) was discontinued as per amendment 6 of the study.
33054316|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
33054317|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
33054318|NCT04435691|Experimental|Treatment (azacitidine, venetoclax, magrolimab)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 (may be reduced to days 1-21 for subsequent cycles after principal investigator approval), and magrolimab IV over 2-3 hours on days 1, 4, 8, 11, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycle 2, and days 1 and 15 of cycle 3 and subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
33054319|NCT04421690|Experimental|Cognitive Training|8 week computerized cognitive training
33054320|NCT04421690|Active Comparator|Trivia Training|8 week computerized trivia training
33054321|NCT04406948|Experimental|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
33054322|NCT04406948|Placebo Comparator|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
33054323|NCT04398628||Hemophilia|"This cohort includes three Arms:~PUPs Arm:~This Arm is for previously untreated patients (PUPs) with congenital hemophilia A or B. This is a longitudinal, observational, prospective and retrospective Arm of PUPs with moderate or severe congenital hemophilia. Participants will be followed to assess inhibitor development within 50 exposure days (ED).~Hemophilia Natural History Arm:~This Arm is investigating a natural history of the safety, effectiveness, and practice of treatment for people with hemophilia. It is a longitudinal, observational, prospective Arm for participants with acquired or congenital hemophilia A or B.~Hemophilia Gene Therapy Outcomes Arm:~This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. It is a longitudinal, observational cohort Arm following participants for 15 years after vector infusion."
33054324|NCT04398628||Von Willebrand Disease|The Severe Von Willebrand Disease (VWD) Natural History Arm is investigating the natural history of the safety, effectiveness, and practice of treatment for people with severe VWD. It is a longitudinal, observational cohort Arm following participants every 6 months for at least 2 years.
33054325|NCT04398628||Congenital Platelet Disorders|No Arms or Modules at this time.
33054326|NCT04398628||Rare Bleeding Disorders|No Arms or Modules at this time
33054327|NCT04398628||Bleeding NOS|No Arms or Modules at this time
33054328|NCT04398628||Thrombosis/Thrombophilia|No Arms or Modules at this time
33332865|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
33332866|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
33332867|NCT04369950|Active Comparator|2 percent Lidocaine with epinephrine and epidural morphine|
33332868|NCT04369950|Experimental|3 percent 2-Chloroprocaine and epidural morphine|
33332869|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
33332870|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
33332871|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
33332872|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
33054329|NCT04398628||Non-Neoplastic Hematologic Conditions|No Arms or Modules at this time
33054330|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
33054331|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
33332873|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
33332874|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
33332875|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
33332876|NCT05604820|Experimental|experimental|Progressive Muscle Relaxation Exercise
32869674|NCT05535738|Experimental|Contact Allergen with Immunomodulator Pre-Treatment|Individuals from Arm 1 (Baseline Contact Allergen) who have been exposed to SADBE and/or known patch test allergens followed by skin and blood sampling. These individuals will be pre-treated via administration of a single dose of 1 biologic from the following list: dupilumab, adalimumab, ustekinumab, guselkumab, canakinumab, sarilumab; or a single application of 1 topical steroid from the following list: betamethasone valerate, triamcinolone acetonide, fluticasone propionate. Allergic contact dermatitis will then be induced and the skin sampled.
32869675|NCT05535660||LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
33054332|NCT04397263|Experimental|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
33054333|NCT04393779|Other|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
33054334|NCT04376827|Experimental|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the long-term extension (LTE).
33054335|NCT04376827|Placebo Comparator|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the LTE of the study.
33054336|NCT04369274|Experimental|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
33054337|NCT04357951|Experimental|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
33054338|NCT04357951|Active Comparator|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
33054339|NCT04351555|Placebo Comparator|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
32869676|NCT05535660||non-LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
33054340|NCT04351555|Experimental|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
33054341|NCT04351555|Experimental|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
33054342|NCT04345913|Active Comparator|Group I (eribulin)|Patients receive eribulin IV on study. Patients also undergo a CT scan and/or MRI throughout the trial, as well as a biopsy and blood sample collection at baseline and on study.
33054343|NCT04345913|Experimental|Group II (eribulin, copanlisib)|Patients receive copanlisib IV and eribulin IV on study. Patients also undergo a CT scan and/or MRI throughout the trial, as well as a biopsy and blood sample collection at baseline and on study.
33054344|NCT04339504|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33054345|NCT04339504|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33054346|NCT04339504|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
33332877|NCT05604820|No Intervention|no ıntervention|
33332878|NCT04179786|Other|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
33332879|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
33332880|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
33332881|NCT03737318|Experimental|Group 1|Traditional articulation treatment
33332882|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
33332883|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
33332884|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
33332885|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
33111527|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by articulating paper|In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
33111528|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by T-scan|"In this group the same adjustment sequence will be done using T Scan III (software version 8.0) computerized occlusal analysis, a new patient file will be opened, the patient's biological data will be entered, and the T Scan dental arch size is customized to fit the patients arch anatomy. The patient will be asked to clench to record occlusal force and areas that needs adjustment will be grinded using the paper marks as the guideline and carbide laboratory bur till bilateral force balance achieved and the center of force (COF) icon sits close to the midline.~Mandibular excursions are then adjusted in a similar fashion. Contacts rather than anterior and canine guidance will be eliminated till achieving anterior guidance and posterior disocclusion in time less than 0.5 seconds."
33111529|NCT05119439|No Intervention|71-77 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 71-77 days. (Participants in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
33111530|NCT05119439|Experimental|78-84 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 78-84 days.
33111531|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
33111532|NCT05114174|No Intervention|Usual care group|Pregnant women enrolled in the prenatal control program who receive routine medical care.
33111533|NCT05114174|Experimental|mami-educ group|Pregnant women enrolled in the prenatal care program who receive routine medical care and nutritional messages mom-educ.
33111534|NCT04661826|Experimental|Oncofid-P-B|Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase
33111535|NCT05110391||NOA_Treated|Hypogonadal patients with non-obstructive azoospermia who received gonadotropin therapy before sperm retrieval
33111536|NCT05110391||NOA_Untreated|Hypogonadal patients with non-obstructive azoospermia who did not receive gonadotropin therapy before sperm retrieval
33111537|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
33111538|NCT04661709|Experimental|Wen Xin granule|Patients are given Wen Xin granule by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
33111539|NCT04661709|Placebo Comparator|WXG placebo|Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
33111540|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
33111541|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
33111542|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
33111543|NCT00538265|Active Comparator|A|tacrolimus + steroids
33111544|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
33111545|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
33111546|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
33111547|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
33111548|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
33111549|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
33111550|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
33111551|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
33111552|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
33111553|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
33111554|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
33111555|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
33111556|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
33111557|NCT00538421|Active Comparator|1|
32740404|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
33111558|NCT00538421|Active Comparator|2|
33111559|NCT04661475|Experimental|Dexmedetomidine adjunctive to ECT arm|
33111560|NCT04661475|Placebo Comparator|Normal Saline adjunctive to ECT arm|
33111561|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
33111562|NCT00538499|Other|Fentanyl citrate|
33111563|NCT00538499|Experimental|bupivcaine hydrochloride|
33111564|NCT00538499|Other|videothoracoscopy|
33111565|NCT00554307||Indo|Infants that are treated with indomethacin
33111566|NCT00554307||Neo|Infants treated with neoprofen
33111567|NCT00554307||Control|Infants without PDA
33111568|NCT00538538|Active Comparator|A|Does not receive Gas bubble
33054347|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
32869677|NCT05540418|Experimental|Experimental group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy.~Two drops of lavender (2%) essential oil was dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses.~They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation.~Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed."
33054348|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
33054349|NCT04321993|Experimental|Baricitinib|Moderate and severe, not critical disease
33054350|NCT04321993|Experimental|Remdesivir|Moderate and severe, not critical disease
33054351|NCT04321993|Experimental|Remdesivir + baricitinib|Moderate and severe, not critical disease
33054352|NCT04321993|Experimental|Tocilizumab|Severe, critical disease
33054353|NCT04321993|No Intervention|Clinical standard of care|Moderate and severe, not critical disease AND severe, critical disease as applicable
33054354|NCT04319913|Experimental|ANI-guided|ANI-guided narcotics use to maintain ANI value between 50 to 70
33054355|NCT04319913|No Intervention|Control|narcotics use guided by clinical experience, ANI is still recorded but would be covered up intraoperatively
33054356|NCT04319627|Experimental|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
33054357|NCT04319627|Placebo Comparator|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
33054358|NCT04319224|Experimental|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
33054359|NCT04319224|Experimental|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
33054360|NCT04319224|Experimental|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
33054361|NCT04315948|Experimental|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.~n=475"
33054362|NCT04315948|Experimental|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~n=620"
33054363|NCT04315948|Experimental|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).~n=620"
33054364|NCT04315948|Experimental|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
33054365|NCT04315948|Active Comparator|Standard of care alone|Standard of care alone before March, 2021.
33054366|NCT04315948|Experimental|AZD7442|"Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.~n=620"
33054367|NCT04315948|Active Comparator|Standard of care with placebo|Standard of care with placebo since April, 2021 n=620
33054369|NCT04309396|Experimental|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
33054370|NCT04308681|Experimental|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
33054371|NCT04308681|Experimental|IPF Dose 2 + Post Treatment Follow-up or OTE|
33054372|NCT04308681|Placebo Comparator|IPF Placebo + Post Treatment Follow-up or OTE|
33054373|NCT04308681|Experimental|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
33054374|NCT04308681|Experimental|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
33054375|NCT04308681|Placebo Comparator|PF-ILD Placebo + Post Treatment Follow-up or OTE|
33054376|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
33111569|NCT00538538|Active Comparator|B|Does receive gas bubble
33111570|NCT00554346|Active Comparator|1|Etoricoxib 90mg
33054377|NCT04301609|Active Comparator|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
33054378|NCT04301609|Placebo Comparator|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
33054379|NCT04300348|Active Comparator|Heel2Toe Group|The Heel2Toe group will have 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
33054380|NCT04300348|Other|No-feedback Control Group (Control group)|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
33054381|NCT04300127|Experimental|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
33054382|NCT04300062|Experimental|Rebiopsy|
33054383|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
33054384|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
33054385|NCT04295304|Experimental|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
33054386|NCT04292496|Experimental|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
33054387|NCT04292496|No Intervention|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
33054388|NCT04292067||patients with SPA|100 SPA patients
33054389|NCT04292067||Healthy subjets|200 healthy subjets in control group
33054390|NCT04292067||patients with RA|100 RA patients
33054391|NCT04291105|Experimental|Melanoma intratumoral|Melanoma, IT VV1 + IV cemiplimab Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
33054392|NCT04291105|Experimental|Head and Neck SCC intratumoral|HNSCC, IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
33054393|NCT04291105|Experimental|Colo-rectal Carcinoma intratumoral|IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
33054394|NCT04285554|Experimental|Hepatic Denervation|
33054395|NCT04282460|Experimental|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
33054396|NCT04282460|Active Comparator|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
33054397|NCT04274530|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
33054398|NCT04274530|No Intervention|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
33054399|NCT04266418|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
33054400|NCT04266418|Experimental|Banana flower stamens extract|consume 1 sachet per day for 2 months
33054401|NCT04266236|Active Comparator|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
33054402|NCT04266236|Active Comparator|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
33054403|NCT04266236|Experimental|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
33054404|NCT04261894|Experimental|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
33054405|NCT04261894|No Intervention|Standard Care|This arm includes provision of standard perinatal care.
33054406|NCT04256343|Experimental|D2O Dose 1|Lower dose of D2O for MPS
33054407|NCT04256343|Experimental|D2O Dose 2|Moderate dose of D2O MPS
33054408|NCT04256343|Experimental|D2O Dose 3|Higher dose of D2O for MPS
33054409|NCT04254939|Experimental|CS3007(BLU-285)|
33054410|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
33054411|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
33054412|NCT04246281|Active Comparator|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
33054413|NCT04246281|Active Comparator|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
33054414|NCT04243629|Experimental|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
33054415|NCT04243629|Placebo Comparator|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
33054416|NCT04241341|Experimental|axillary lymph node dissection with ILR|
33054417|NCT04241341|Active Comparator|axillary lymph node dissection (ALND) without ILR|
33054418|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
33054419|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
33332886|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with PO Tylenol and PO toradol PRN."
33332887|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
33054420|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
33054421|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
33054422|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
33054423|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
33054424|NCT04238819|Experimental|Part C Stage 1: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, granulocyte macrophage colony-stimulating factor (GM-CSF) given subcutaneously (subQ), irinotecan given IV and temozolomide given orally.
33332888|NCT05668676|Experimental|Interventional group|
33054425|NCT04238819|Experimental|Part C Stage 2: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, GM-CSF given subQ, irinotecan given IV and temozolomide given orally.
33054426|NCT04225715|Active Comparator|Nucleos(t)ide (NUC) Control Arm|Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, in line with current CHB treatment guidelines, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054427|NCT04225715|Experimental|Core Protein Allosteric Modulator (CpAM; RO7049389) + Toll-like Receptor 7 (TLR7;RO7020531) + NUC|Participants will receive RO7049389 (600 mg once daily [QD]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day [QOD]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054428|NCT04225715|Experimental|Short Interfering Ribonucleic acid (siRNA; RO7445482) (Dose1) + NUC|Participants will receive RO7445482 (Dose 1) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054429|NCT04225715|Experimental|siRNA (RO7445482) (Dose 2) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054430|NCT04225715|Experimental|siRNA (RO7445482) + Pegylated Interferon (PEG-IFN) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. PEG-IFN will be administered at a dose of 180 μg once weekly (QW) for 48 weeks. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054431|NCT04225715|Experimental|siRNA (RO7445482) + CpAM (RO7049389) + NUC|Participants will receive RO7445482 (Dose 2) and RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054432|NCT04225715|Experimental|siRNA (RO7445482) + TLR7 (RO7020531) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 13-24 and Weeks 37-48 (i.e., 2 treatment cycles of 12 weeks' duration each and 42 doses of RO7020531 for each cycle). At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054433|NCT04225715|Experimental|siRNA(RO7445482)+ Programmed Death Ligand-1 Locked Nucleic Acid (PD-L1 LNA; RO7191863) + NUC [1]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 13-24, in addition to their background NUC therapy for the 24-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33054434|NCT04225715|Experimental|siRNA (RO7445482) + PD-L1 LNA (RO7191863) + NUC [2]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 25-36, in addition to their background NUC therapy for the 36-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
33332889|NCT05668676|Active Comparator|Control group|
33332890|NCT05651074|Experimental|Vicagrel and omeprazole|D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.
33054435|NCT04224974|Experimental|Other: Usual Care|
33054436|NCT04224974|Experimental|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
33054437|NCT04214392|Experimental|Treatment (CAR T cell therapy) I|Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary [ICT] and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
33111571|NCT00554346|Placebo Comparator|2|placebo
33111572|NCT04661046|Experimental|TCM Syndrome Types|Traditional Chinese Medicine
33111573|NCT00538655|Experimental|modafinil|
33111574|NCT04661319|Experimental|video editing training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The experimental group received video editing training"
33111575|NCT04661319|Experimental|traditional training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The control group received tradtional training"
33111576|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
33111577|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
33111578|NCT00538772||Biomarker|
33111579|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
33111580|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
33111581|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
33111582|NCT04660773|Active Comparator|NB UVB phototherapy|(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
33111583|NCT04660773|Active Comparator|pregabalin|20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
33111584|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
33111585|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
33111586|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
33111587|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
33111588|NCT00538967|No Intervention|1|
33332891|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
33111589|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
33332892|NCT05645224|Experimental|VR-PAT|Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game.
33332893|NCT05645224|No Intervention|Control|Participant wears the Pico Neo 3 Pro Eye headset to protect eyes, but it is not turned on.
33332894|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
33111590|NCT00538967|Active Comparator|3|doxycycline 100 mg
33332895|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
33332896|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
33111591|NCT00538967|Active Comparator|4|doxycycline 300 mg
33111592|NCT04660851|Experimental|Coached|10 weeks of diet coaching
33111593|NCT04660851|No Intervention|Not-coached|No coaching provided
33111594|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
33111595|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
33111596|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
33111597|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
33111598|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
33111599|NCT04660734|Experimental|3D printing group|"Group 1 (G1) consisted of 20 patients who underwent preoperative molding of the osteosynthesis plate on a 3D printed model of the pelvis. A preoperative scan of the healthy hemi-pelvis was used to create the 3D-printed model for patients in G1 according to the following three-step methodology: 1) A scanographic acquisition of images was performed using a multi-strip scanner in thin sections. These images were recorded as digital images in the standard medical format of digital imaging and communications ; 2) A digital, 3D model of the pelvis in the stereolithography format was created to digitally treat the 2D images. The individualization of the healthy hemi-pelvis, to which a mirror effect was applied allowed for the creation of a symmetrical 3D image, as hemi-pelvises are globally symmetrical. 3) A 3D printer was used to create a physical, 3D-printed model of the affected hemi-pelvis using polylactic acid."
33111600|NCT04660734|Experimental|conventional technique group|Group 2 (G2 or control group) included 23 patients who underwent surgery using the conventional technique.The patients in the control group (G2) underwent surgery following the conventional procedure based on radiographic and CT images with 3D reconstructions.
33111601|NCT00539123|Experimental|NCB|Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).
33111602|NCT00539123|Experimental|ACB|Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).
33111603|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
33111604|NCT00539318||GI Cancer|
33111605|NCT02382510|Experimental|TRN-157|
33111606|NCT02382510|Placebo Comparator|Placebo|
33111607|NCT02382510|Active Comparator|Tiotropium|
33111608|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
33111609|NCT04660695||Group 1|Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
33111610|NCT03456986|Experimental|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
33111611|NCT03456986|Active Comparator|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
33111612|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
33111613|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
33111614|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
33111615|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
33111616|NCT04660578|Experimental|Single Group|A.Chohan continuous squeezing suture (ACCSS); An Obstetrical procedure using half circle 40mm round body polyglactin 910 suture #1 (Vicryl plus by Ethicon®), for controlling hemorrhage from the lower uterine segment, in patients with placenta previa / accreta for the prevention of hysterectomy at cesarean section.
33111617|NCT00539474|Active Comparator|1|Wireguided localisation
33111618|NCT00539474|Experimental|2|Radioguided occult lesion localisation
33111619|NCT04660266|Other|all cohort|
33111620|NCT04660461|Experimental|1. Randomized placebo-controlled, parallel-group study, crossover-design|
33111621|NCT04660461|Experimental|2. Randomized placebo-controlled, parallel-group study, crossover-design|
33111622|NCT04685330||Adult patients undergoing an ultrasound-guided procedure|Adult patients undergoing an ultrasound-guided procedure, such as paracentesis, thoracentesis, or biopsy
33111623|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
33111624|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
33111625|NCT00539708|Experimental|NIV|Non-invasive ventilation
33111626|NCT00539708|Active Comparator|Control|Oxygen therapy
33111627|NCT04660305|Experimental|AT278|Single subcutaneous injection 0.3U/kg
33111628|NCT04660305|Active Comparator|NovoRapid|Single subcutaneous injection 0.3U/kg
33111629|NCT00554502|Active Comparator|A|
33111630|NCT00554502|Active Comparator|B|
33111631|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
33332897|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
33332898|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
33111632|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
33111633|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
33332899|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
33332900|NCT05630092|Active Comparator|Maximal then Normal Speed Walk Test|Maximal speed walking test (Max_6MWT) followed by normal speed walking test (Nor_6MWT).
33332901|NCT05630092|Active Comparator|Normal then Maximal Speed Walk Test|Normal speed walking test (Nor_6MWT) followed by Maximal speed walking test (Max_6MWT)
33332902|NCT05609656|Experimental|IRE + CaEP + Pembrolizumab|Irreversible electroporation (IRE) and calcium electroporation (CaEP) on Day 1, followed by Pembrolizumab on Day 2 (+4 days) and then every 3 weeks (q3w) for up to 12 months in total.
33111634|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
33332903|NCT03737162|Experimental|Covered stent group|Covered stent
33111635|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
33111636|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
33111637|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
33111638|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
33111639|NCT02341989|Experimental|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
33332904|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
33332905|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
33332906|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
33111640|NCT02341989|Active Comparator|Carboplatin|One course of adjuvant carboplatin AUC7
33111641|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
33111642|NCT00540098|Active Comparator|2|Paroxetine + relaxation
33332907|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
33332908|NCT04175808|Experimental|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
33111643|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
33111644|NCT00540098|Placebo Comparator|4|Placebo + relaxation
33111645|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
33111646|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
33111647|NCT04660110|Active Comparator|Intervention arm|A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals)
33111648|NCT04660110|No Intervention|Standard of care|Health information, no study drugs
33111649|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
33111650|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
33111651|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
33111652|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
33111653|NCT02341560|Sham Comparator|Sham|Sham injection procedure
33111654|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
33332909|NCT04175808|Experimental|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:~Placebo~50 mg omecamtiv mecarbil~400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
33332910|NCT04057196|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
33111655|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
33111656|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
33111657|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
33111658|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
33332911|NCT05598424|Experimental|Oral Glucocorticoids group|"Intervention Period I: nasal spray, Budesonide Nasal Spray, 64ug per Nostril, bid, for 4-week duration.~Intervention Period II: oral glucocorticoids methylprednisolone 24mg qd, and nasal spray, Budesonide Nasal Spray 64ug per Nostril, bid, for 2-week duration."
33111659|NCT04659954|Experimental|Application O'DIDE|The subjects will use the application O'DIDE during 8 weeks
33111660|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
33111661|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
33111662|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
33111663|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
33111664|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
33111665|NCT00540410|Experimental|1|
33111666|NCT00540410|Active Comparator|2|
33111667|NCT04659837|Active Comparator|Inhibitory Control Training|Active Inhibitory Control Training vs. Sham Inhibitory Control Training
33111668|NCT04659837|Other|Gameification|Gameified elements added vs. No gameified elements added
33111669|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
33111670|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
33111671|NCT04659720|Active Comparator|summers' osteotome technique for closed sinus lift|Implant stability will be evaluated after closed sinus lift using summer's osteotome technique in posterior edentulous maxilla
33111672|NCT04659720|Active Comparator|Patient satisfaction evaluation after closed sinus lifting using summers' osteotome technique|"Will be assessed numerically using a patient satisfaction chart .~Time of assessment: immediately after surgery"
33111673|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
33111674|NCT04659915|Experimental|Metformin + Prednison|"During one of the study periods, subjects receive Metformin 500 mg tablets p.o. for seven days (starting with a dose of 500 mg /d, then the dose will be increased by 500 mg the next days until 2000 mg /d is achieved).~Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days."
33111675|NCT04659915|Placebo Comparator|Placebo + Prednison|During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
33111676|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
33111677|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
33111678|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
33111679|NCT00540800|Experimental|B|Weekly chemotherapy
33332912|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
33332913|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
33332914|NCT05552560||Experimental: Heterosexual couples, women or single women who have requested sperm donation|Heterosexual couples, female couples or single women who have requested a sperm donation in the center of the Toulouse University Hospital will be offered the study.
33054438|NCT04214392|Experimental|Treatment (CAR T cell therapy) II|Arm 2 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy and the lateral ventricle. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with two CAR T cell infusions (intracranial intratumoral or intracavitary [ICT]) and also into the lateral ventricle (intracranial intraventricular [ICV]) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
33332915|NCT04016376|Experimental|PVB|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
32740405|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
33054439|NCT04207346|Experimental|TMS|transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
33418924|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
33054440|NCT04207346|Sham Comparator|Sham|sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
33054441|NCT04202835|Experimental|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
33054442|NCT04202835|Active Comparator|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
33054443|NCT04199026|Experimental|Device Feasibility (microdevice, surgery)|Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.
33054444|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
33054446|NCT04190368|Other|Team Clinic Care: No VTC Groups|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient and yearly team visit as needed~• Providers will utilize a patient centered care approach to conducting appointments"
33054447|NCT04190368|Other|Team Clinic: Virtual Team Clinic Group|"Participants will be invited to participate in online/virtual thematic group sessions led by Team Clinic group facilitators (e.g., RD, SW, RN) aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care.~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
33054448|NCT04190368|Other|Standard Care: No VTC Groups|Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).
33054449|NCT04190368|Other|Standard Care: Virtual Team Clinic|"Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
33054450|NCT04187443|Experimental|MS-553 low dose|low dose of MS-553 taken orally
33054451|NCT04187443|Experimental|MS-553 mid dose|mid dose of MS-553 taken orally
33054452|NCT04187443|Experimental|MS-553 high dose|high dose of MS-553 taken orally
33054453|NCT04182997|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
33054454|NCT04182997|Active Comparator|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
33054455|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
33054456|NCT04181827|Experimental|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
33418925|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
33418926|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
33332916|NCT04016376|Experimental|PVB + PECS-1|"Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.~For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor."
33332917|NCT04016376|Experimental|Serratus + PECS-1|"For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor.~For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior."
33054457|NCT04178434|Active Comparator|Internet-based CBT intervention|A nine step internet-based intervention with focus on stress and anxiety
33054458|NCT04178434|No Intervention|Treatment as usual|Regular follow-up with two doctor and one nurse appointment
33054459|NCT04172441|Experimental|dasiglucagon first then placebo|48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
33054460|NCT04172441|Experimental|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
33054461|NCT04171219|Experimental|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33054462|NCT04171037|Experimental|Arm I (oxygen via Optiflow THRIVE)|Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.
33054463|NCT04171037|Active Comparator|Arm II (oxygen via non-rebreather mask)|Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.
33054464|NCT04168385|Experimental|Maralixibat|Participants will all receive Maralixibat oral solution
33054465|NCT04167163|Active Comparator|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
33054466|NCT04167163|No Intervention|Comparator group|Those with clinical osteopenia who receive no treatment.
33054467|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
33054468|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
33054469|NCT04153864|Experimental|Non-specialist|Trained nurses or midwives with general health care professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
33054470|NCT04153864|Active Comparator|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
33054471|NCT04153864|Experimental|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom in Toronto, via the UNC TelePsychiatry Program in Chapel Hill, and via Zoom in Chicago
33054472|NCT04153864|Active Comparator|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore Chicago
33054473|NCT04139603|Active Comparator|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
33111680|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
33111681|NCT04659876||Grup S (Survivors)|Survivors in ICU follow-up
33332918|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
33332919|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
33332920|NCT05524168|Experimental|SBRT+PD-1+Chemotherapy|Patients will receive SBRT first, then PD-1 antibody (Camrelizumab 200mg/Q3W) and chemotherapy (cisplatin 80mg/m2 on d1, gemcitabine 1000mg/m2, d1 and d8, Q3W, maximum 6 cycles), followed by Camrelizumab (200mg/Q3W) until progressive disease, intolerable toxicity, withdrawal of consent or a maximum of 2 years of treatment.
33332921|NCT05514418|Experimental|Intervention Arm|"This group will receive three monthly sessions of intensive adherence counselling (IAC) and psychosocial support, using the 5 A's principles for chronic care (which include; Assess, Advise, Agree, Assist and Arrange). Each monthly IAC session will be offered by the research assistants for about one hour, and adherence will also be assessed by pill counts. Colour-coded IAC forms will be developed and used to differentiate the study from routine IAC services for the non-suppressed patients; and the study will be conducted on different days, from those on which the routine clinic occurs.~Following the three months of the study, all the study participants both in the control and intervention groups will be reviewed at the health facility and a repeat viral load (VL) test done for each of the participants, to determine whether they have achieved a non-detectable VL or not."
33418927|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
33111682|NCT04659876||Grup NS (Nonsurvivors)|Patients who died in ICU follow-up
33111683|NCT04678596|Active Comparator|EonAligner|Patients in the EonAligner group were given a single thickness and hardness aligner and were asked to use the same it for 3 weeks.
33111684|NCT04678596|Active Comparator|Clearfix|In the Clearfix group, the patients were given three different thickness and hardness aligner and they were asked to use each aligner for one week from soft to hard.
33111685|NCT04678323|Active Comparator|Phentermine Plus Lifestyle Therapy|Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
33111686|NCT04678323|Placebo Comparator|Placebo Plus Lifestyle Therapy|Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
33111687|NCT04678011||Personalized surveillance and intervention protocol|
33418928|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33111688|NCT04659447|Experimental|Platelet-Rich Plasma|Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.
33111689|NCT04659447|No Intervention|control group|We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.
33111690|NCT04659525|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
33111691|NCT04659525|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
33111692|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
33111693|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
33111694|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
33111695|NCT02333643|Experimental|Digoxin topical formulation|
33111696|NCT02333643|Experimental|Furosemide topical formulation|
33111697|NCT02333643|Placebo Comparator|Vehicle topical formulation|
33111698|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
33111699|NCT04659330|Other|Intervention group|All patients underwent intervention
33111700|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
33111701|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
33111702|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
33111703|NCT04659486|Experimental|Exercise training|A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
33111704|NCT04659486|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
33111705|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
33111706|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
33418929|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
33418930|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
33418931|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
33418932|NCT05705895|Experimental|Intervention Group|Catheter care is provided in line with the CVC care protocol developed by the researcher.
33418933|NCT05705895|No Intervention|Control Group|No intervention will be made to the patients in the control group, and catheter care will be provided in line with the clinical routine.
33418934|NCT05192187|Experimental|LBP|This group will be asked to complete self-reported questionnaires on a single occasion (cross-sectional)
33418935|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
33418936|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
33418937|NCT05545137|Experimental|Pivmecillinam hydrochloride tablets treatment group|"participants received Pivmecillinam Hydrochloride Tablets + Fosfomycin Tromethamine Granules Simulant.~Pivmecillinam Hydrochloride Tablets:oral,One tablets each time,3 times a day for five days.~Fosfomycin Tromethamine Granules Simulant :oral, 1 pack, only once for the entire course of treatment"
33418938|NCT05545137|Active Comparator|Fosfomycin Tromethamine Granules treatment group|"participants received Fosfomycin Tromethamine Granules + Pivmecillinam Hydrochloride Tablets Simulant~Fosfomycin Tromethamine Granules:oral, 1 pack, only once for the entire course of treatment.~Pivmecillinam Hydrochloride Tablets Simulant :oral,One tablets each time,3 times a day for five days."
33054474|NCT04139603|Experimental|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
33418939|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
33054475|NCT04139603|Placebo Comparator|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
33054476|NCT04134936|Experimental|Arm A|Tafasitamab in addition to R-CHOP
33054477|NCT04134936|Experimental|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
33054478|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
33054479|NCT04115111|Experimental|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
33054480|NCT04113109|Experimental|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
33054481|NCT04113109|Experimental|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
33054482|NCT04113109|Experimental|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
33054483|NCT04113109|Experimental|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
33054484|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
33054485|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
33054486|NCT04108195|Experimental|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
33054487|NCT04108195|Experimental|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1 until disease progression, unacceptable toxicity, withdrawal of consent, otherwise deemed necessary by the investigator or the sponsor, or end of study.
33054488|NCT04107038|Active Comparator|General|Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
33054489|NCT04107038|Active Comparator|Sedation|Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.
33054490|NCT04106349||1st line|
33054491|NCT04106349||2nd line|
33054492|NCT04106349||later lines|
33054493|NCT04101357|Experimental|Part 1A - monotherapy dose escalation|BNT411 monotherapy
33054494|NCT04101357|Experimental|Part 1B - combination dose escalation|BNT411 in combination with atezolizumab, carboplatin, and etoposide
33054495|NCT04101357|Experimental|Part 2 - expansion cohorts|BNT411 either as monotherapy or in combination with with atezolizumab, carboplatin, and etoposide
33054496|NCT04098003|Experimental|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
33054497|NCT04098003|Placebo Comparator|Placebo|placebo daily for eight weeks
32869678|NCT05540418|No Intervention|Control Group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy. Lavender aromatherapy was not applied to the patients in this group, but routine care was applied.~After the process, the forms were filled again, the final test process was completed. The data took about 15-20 minutes with face-to-face interview method."
33111707|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
33111708|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
33332922|NCT05514418|No Intervention|Control Arm|This group will comprise of participants who will receive the routine standard of care. These participants will receive the normal patient education and encouragement to continue with their antiretroviral therapy (ART) at the start of the study. They will not be reviewed monthly or offered any counselling for the entire three months. These participants will be given an appointment after three months for repeat viral load (VL) testing.
33054498|NCT04091386||Hemophilia A patients|Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
33054499|NCT04084483|Experimental|Group 1|K-161 Ophthalmic Solution Dose A.
33054500|NCT04084483|Experimental|Group 2|K-161 Ophthalmic Solution Dose B.
33332923|NCT05513482||Cryoballoon pulmonary vein isolation for atrial fibrillation ablation|Diaphragmatic kinetics of participants before and after pulmonary vein isolation will be evaluated with the Tissue Doppler and M Mode Imaging.
32869679|NCT05535582||Patients with SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
32869680|NCT05535582||SMuRF-less Patients|Patients with acute myocardial infraction without history of any SMuRF
32869681|NCT00260689|Experimental|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
32869682|NCT00260689|Experimental|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
32869683|NCT00260689|Experimental|Alemtuzumab|Alemtuzumab administered for 10 days
33054501|NCT04084483|Experimental|Group 3|K-161 Ophthalmic Solution Dose C.
33054502|NCT04084483|Placebo Comparator|Group 4|Vehicle Solution Dose.
33054503|NCT04079179|Experimental|Patients < 21 years with recurrent LCH (Grp1)|Children (≥ 6 months) and young adults (<21 years) with recurrent active LCH lesions (may also have LCH-ND).
33054504|NCT04079179|Experimental|Patients of any age with LCH-ND (Grp2)|Patients of any age (≥ 6 months) with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
33054505|NCT04079179|Experimental|Patients <21 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children (≥ 6 months) and young adults (<21 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
33054506|NCT04079179|Experimental|Patients ≥ 21 years with LCH/histiocytic disorders (Grp4)|Adults (≥21 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
33054507|NCT04058431|Experimental|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
33054508|NCT04043039|Experimental|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
33054509|NCT04043039|Active Comparator|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
33054510|NCT04042233|Active Comparator|IV administration of vancomycin|Standard IV vancomycin administration protocol.
33054511|NCT04042233|Experimental|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
33054512|NCT04039984|Experimental|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
33054513|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
33054514|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
33054515|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
33054516|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
33054517|NCT04033445|Placebo Comparator|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
33054518|NCT04033445|Experimental|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
33332924|NCT05501860|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
32740406|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
33054519|NCT04033445|Placebo Comparator|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
33054520|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
33054521|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
33054522|NCT04033445|Placebo Comparator|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
33054523|NCT04033328|Experimental|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
33054524|NCT04033328|Experimental|Dose Expansion|RP2D dose
33054525|NCT04029597|Experimental|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
33054526|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
33054527|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
33054528|NCT04023331|Experimental|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as an IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive at least 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion.~Participants in either phase of the study that demonstrate therapeutic benefit following treatment with 67Cu-SARTATE at any dose may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total)."
33054529|NCT04016285|Experimental|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
33054530|NCT04016285|Active Comparator|Standard of Care: Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
33332925|NCT05501860|Placebo Comparator|Placebo|Placebo Sterile Topical Ophthalmic Solution
33332926|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
33054533|NCT04003857|Experimental|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10^6 cells/kg)
33054534|NCT04003857|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
33054535|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
33054536|NCT03997981||Breast cancer patients receiving docetaxel regimen|
33054537|NCT03997981||Lymphoma patients receiving vincristine regimen|
33054538|NCT03997981||Multiple myeloma patients receiving bortezomib regimen|
33054539|NCT03997981||Colorectal cancer patients receiving oxaliplatin-based regimens|
33054540|NCT03984565|Experimental|Cannabidiol Treatment Arm|20mg/ml CBD sublingual product administered twice daily for 6 weeks
33054541|NCT03984565|Placebo Comparator|Placebo Treatment Arm|Placebo sublingual product administered twice daily for 6 weeks
33054542|NCT03982693|Active Comparator|Active|edetate disodium (EDTA)dff active infusion
33054543|NCT03982693|Placebo Comparator|Placebo|Placebo infusion
33054544|NCT03982199|Experimental|Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, 1C and 1D to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, 3 years and 4 years respectively after the first vaccination.
33054545|NCT03982199|Placebo Comparator|Group 2: Placebo|Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, 2C, 2D and will first receive Ad26.RSV.preF based vaccine at years 1, 2, 3 and 4. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.
33054546|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
33054547|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
33054548|NCT03974087|Active Comparator|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
33054549|NCT03974087|Sham Comparator|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
33111709|NCT04659681|Active Comparator|PVI Guided Fluid Therapy|Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI >12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
33054550|NCT03973541|Experimental|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
33054551|NCT03973541|Active Comparator|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
33054552|NCT03973541|Placebo Comparator|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
33054553|NCT03965195|Experimental|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
33054554|NCT03965195|Active Comparator|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
33054555|NCT03956706|Experimental|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
33054556|NCT03956706|Experimental|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
33054557|NCT03956706|Experimental|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
33054558|NCT03945773|Experimental|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
33054559|NCT03945773|Experimental|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
33054560|NCT03942653|Experimental|Goserelin Acetate + Pembrolizumab|Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
33054561|NCT03941262|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
33054562|NCT03941262|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
33054563|NCT03941262|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
33054564|NCT03941262|Experimental|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
33054565|NCT03941262|Experimental|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
33054566|NCT03933696|Active Comparator|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).~The lighting intervention will be in place for 24 weeks"
33054567|NCT03933696|Placebo Comparator|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
33054568|NCT03928314|Experimental|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
33054569|NCT03928314|Experimental|Dose Expansion (Part II)|RP2D dose
33054570|NCT03924414|Active Comparator|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
33054571|NCT03924414|Placebo Comparator|Placebo|A single intravenous infusion of placebo infused over 45 minutes
33054572|NCT03924063|Other|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
33054573|NCT03921931|Experimental|healthy volunteers|light stimulation
33054574|NCT03921931|Experimental|primary open angle glaucoma patients|light stimulation
33054575|NCT03921931|Experimental|age-related macular degeneration patients|light stimulation
33054576|NCT03915548|Experimental|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
33111710|NCT04659681|Active Comparator|CVP Guided Fluid Therapy|Patients will receive Standard CVP Guided Fluids , CVP maintained between 10-16 cms H20 , if CVP< 10 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 zones in both lungs to measure total number of B-lines.
33111711|NCT00541619||A|hypertensives with proteinuria
33418940|NCT05541861|Experimental|BNT162b2 Bivalent 30 µg + BNT162b4 5 µg|Intramuscular injection at Day 1
33054577|NCT03915548|Active Comparator|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
33054578|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
33054579|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
33054580|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
33054581|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
33054582|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
33054583|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
33054584|NCT03869853|Experimental|control|no intervention
33418941|NCT05541861|Experimental|BNT162b2 Bivalent 30 µg + BNT162b4 10 µg|Intramuscular injection at Day 1
33054585|NCT03862859|Active Comparator|Treatment with Warfarin|Warfarin with dosing targeting an international normalized ratio of 2-3.
33054586|NCT03862859|No Intervention|No treatment|No treatment
33054587|NCT03862430|Experimental|NanO2TM|NanO2TM infusion in conjunction with Radiation Treatment and temozolomide
33054588|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolomide
33054589|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
33054590|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
33054591|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
33054592|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
33054593|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
33054594|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
33054595|NCT03842189|Experimental|M281|
33054596|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy (Main Cohort)|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
33054597|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy (Main Cohort)|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
33054598|NCT03833154|Experimental|SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)|"SBRT delivered in 3, 4, 5 or 8 fractions~Osimertinib 80mg every day [qd] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT"
33054599|NCT03819049|Experimental|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
33054600|NCT03819049|Experimental|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
33054601|NCT03819049|Experimental|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
33054602|NCT03819049|Experimental|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
33054603|NCT03819049|Experimental|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
33054604|NCT03819049|Experimental|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
33054605|NCT03819049|Placebo Comparator|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
33054606|NCT03818737|Experimental|Bone Marrow Derived MSCs|Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).
33054607|NCT03818737|Experimental|Adipose-derived MSCs|Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).
33418942|NCT05541861|Experimental|BNT162b2 Bivalent 30 µg + BNT162b4 15 µg|Intramuscular injection at Day 1
33418943|NCT05541861|Active Comparator|BNT612b2 Bivalent 30 µg|Intramuscular injection at Day 1
33418944|NCT05540067|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered remotely or in-person, depending on preference.
33418945|NCT05540067|Other|Treatment-as-Usual (TAU)|Control participants will receive the currently recommended best practices of care at the recruitment site.
33418946|NCT02112266|Other|no mail support|no mail support during follow-up
33418947|NCT02112266|Other|mail support|
33054608|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) MSCs|Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.
33054609|NCT03818737|Active Comparator|Corticosteroid Injection|Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint.
33054610|NCT03815981||Allergic|Collection of blood, stool, urin samples
33054611|NCT03815981||Sensitized|Collection of blood, stool, urin samples
33054612|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
33054613|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
33054614|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
33054615|NCT03807310|Experimental|Group Long-drink|"83 COPD patients will receive:~Targeted nutrient supplementation (Long-drink) once daily~Counselling once monthly"
33054616|NCT03807310|Placebo Comparator|Group Placebo|"83 COPD patients will receive:~Isocaloric placebo supplement once daily~Counselling once monthly"
33054617|NCT03807310|No Intervention|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
33054618|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
33054619|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
33054620|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
33054621|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
33054622|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
33054623|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
33054624|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
33054625|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
33054626|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
33054627|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
33054628|NCT03784755|Active Comparator|Arm 1 (standard of care)|"Standard systemic therapy~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
33054629|NCT03784755|Experimental|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)~+ Standard systemic therapy"
33054630|NCT03784326|Experimental|Treatment (oxaliplatin, fluorouracil, atezolizumab, surgery)|Patients receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks of treatment completion, patients undergo surgical resection. Beginning 6 weeks after surgery, patients continue to receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive atezolizumab monotherapy IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33054631|NCT03779009|Experimental|Tracer injection|
33054632|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
33054633|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
33054634|NCT03761095|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin orally twice weekly in combination with dacarbazine IV once every 21 days. The first participant will receive dacarbazine 1000 mg/m^2 IV every 21 days in combination with unesbulin 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Participants will receive unesbulin 300 mg twice weekly in combination with dacarbazine in the expansion cohort. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
33054635|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
33332927|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
33332928|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
33054636|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
33054637|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
33332929|NCT05478694||Ablative Therapy Group|Enrolled subjects will undergo the ablative therapy as part of their standard of care treatment
33054638|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
33054639|NCT03755128||Pregnant women and their offspring from current pregnancy|
33054641|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
33054642|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
33054643|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
33054644|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
33054645|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
33054646|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
33054647|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
33054648|NCT03732950|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
33054649|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
33054650|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
33332930|NCT05465668|Experimental|Intervention: DWP16001 Drug A|1 tablet, Oral, once daily single dose
33332931|NCT05465668|Experimental|Intervention: DWP16001 Drug C|1 tablet, Oral, once daily single dose
33332932|NCT05446948|Experimental|beveled 27G+ group|The group of patients underwent vitrectomy with a beveled 27G+ vitrectomy system.
33332933|NCT05446948|Active Comparator|25G+ group|The group of patients underwent vitrectomy with a standard 25G+ vitrectomy system.
33054651|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
33054652|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
33418948|NCT05538039|Experimental|Distract with play dough|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with play dough will be conducted under investigative coaching for at least 10 minutes. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each family will be given 4 boxes of play dough. After the play is played, the play dough will not be put back in the package, and the child and parents will be told that they can keep the shapes they have made if they wish. The play dough used will be provided by the researchers and will be given to the participants after the intervention.
33418949|NCT05538039|Experimental|Distract with play kaleidoscope|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with the kaleidoscope will be conducted under investigative coaching for at least 10 minutes. It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each child and parent will be given a separate kaleidoscope.
33418950|NCT05538039|Other|Control Group|The participants in the control group will be given routine nursing care.
32740407|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
33054653|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
33054654|NCT03695185|Experimental|Ravagalimab 600 mg/300 mg|Participants received ravagalimab 600 mg intravenous (IV) at Week 0 followed by ravagalimab 300 mg subcutaneously (SC) at Weeks 2, 4, 6, 8, and 10 in a 12-week Induction Period. Participants who achieved clinical response per partial adapted Mayo score at Week 12 of the Induction Period entered the Maintenance Period to receive ravagalimab 300 mg SC every other week (EOW) from Week 12 through Week 102.
33054655|NCT03686488|Experimental|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
33054656|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
33054657|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
33054658|NCT03683030|Experimental|Treatment Group|Ablation using Multi-electrode Radiofrequency (RF) Balloon Catheter (HELIOSTAR).
33054659|NCT03677648|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.
33054660|NCT03677648|Experimental|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.
33054661|NCT03677648|Experimental|SHR0302 dose C|Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.
33054662|NCT03677648|Placebo Comparator|Placebo|Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.
33054663|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
33054664|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
33111712|NCT04659642|Active Comparator|dexmedetomidine group (group A)|will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
33111713|NCT04659642|Active Comparator|Fentanyl group (group B)|will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
33418951|NCT02109380|Experimental|Bed rest|One week of bed rest.
33418952|NCT05535855|Experimental|UCD19 CAR T Infusion|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T cells. Infusion is subject to a seven (7) day delay following chemotherapy completion if needed for resolution of clinical toxicities or to allow for product release.
33418953|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
33418954|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
32740408|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
33054665|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
33054666|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
33054667|NCT03647163|Experimental|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
33054668|NCT03647163|Experimental|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
33054669|NCT03647163|Experimental|Expansion NEC|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
33054670|NCT03647163|Experimental|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
33054671|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
33054672|NCT03637816|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
33054673|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
33054674|NCT03635983|Experimental|Monotherapy|Nivolumab
33054675|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
33054676|NCT03626363|Active Comparator|Stress Management Education|
33054677|NCT03599622|Experimental|BMS-986165 Dose 1|
33054678|NCT03599622|Experimental|BMS-986165 Dose 2|
33054679|NCT03599622|Placebo Comparator|Placebo|
33054680|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
33054681|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
33054682|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
33054683|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
33054684|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
33054685|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
33054686|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
33054687|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
33054688|NCT03556332|Experimental|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
33418955|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
33418956|NCT05705817|Experimental|Treatment|
33418957|NCT02112344|Experimental|Total mucosal irradiation|
33111714|NCT04659642|Active Comparator|Both Dexmedetomidine and fentanyl group (group C)|will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
33111715|NCT00541736|Experimental|Patients|GTN-infusion
33332934|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
33332935|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
33418958|NCT05622045||Story-LCSS|
33418959|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
33418960|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
32740409|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
32740410|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
32740411|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
33054689|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
33054690|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
33054691|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF for 96 weeks.
33054692|NCT03547908|Active Comparator|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF for 96 weeks.
33054693|NCT03547908|Experimental|Open-label Extension Phase: B/F/TAF|After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
33054694|NCT03542409|Experimental|Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
33054695|NCT03542409|Experimental|Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
33054696|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
33054697|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
33054698|NCT03536546|Experimental|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
33054699|NCT03536546|Active Comparator|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
33054700|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
33054701|NCT03530683|Experimental|TTI-622 Monotherapy|"In the phase 1a dose- escalation part for single-agent TTI-622, participants with Relapsing or Refractory (R/R) lymphoma will be enrolled in sequential dose cohorts to receive TTI-622 QW to characterize safety, tolerability, and PK; to determine the Maximum Tolerated Dose (MTD) or P1b Starting Dose (a dose lower than or equal to the single-agent MTD), and to gain preliminary evidence of antitumor activity.~In addition, participants with R/R Lymphoma may also be enrolled in a cohort to receive TTI-622 Q2W and a cohort to receive TTI-622 Q3W to characterize safety, tolerability, and PK; to determine the MTD; and to gain preliminary evidence of antitumor activity."
33054702|NCT03530683|Experimental|Cohort A: TTI-622 + Azacitidine|"Cohort A1: participants with newly diagnosed TP53-mutated Acute Myelocytic Leukemia (AML) will be treated with TTI-622 QW + azacitidine.~Cohort A2: participants with newly diagnosed TP53-mutated AML will be treated with TTI-622 QW + azacitidine."
33111716|NCT00541736|Active Comparator|Controls|GTN-infusion
33111717|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
33111718|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
33111719|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
33111720|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
33111721|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
33111722|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
33111723|NCT04659564|Other|Breast-cancer related lymphedema (BCRL)|
33111724|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
33111725|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
33111726|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
33111727|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
33111728|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
33111729|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
33111730|NCT00541892|Experimental|1|Medium with no human serum albumine added
33111731|NCT00541892|Active Comparator|2|Conventional medium
33111732|NCT00542048|Experimental|1|
33111733|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111734|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111735|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111736|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111737|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111738|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
33111739|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
33111740|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
33111741|NCT00542126|No Intervention|2|
33111742|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
33111743|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
33111744|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
33111745|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
33111746|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
33332936|NCT05584696||Green Light Exposure Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on the green glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and green glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
33332937|NCT05584696||Control Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on transparent glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and transparent glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
33111747|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
33111748|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
33111749|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
33111750|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
33111751|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
33111752|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
33111753|NCT04648800|No Intervention|Group I|with positive RT23 test reading, not randomised and not vaccinated against tuberculosis
33111754|NCT04648800|Active Comparator|Group II|with negative RT23 test reading, receiving BCG-10 Vaccine
33111755|NCT04648800|Placebo Comparator|Group III|with negative RT23 test reading, receiving placebo
33332938|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
33111756|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
33111757|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
33111758|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
33111759|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
33111760|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
33111761|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
33111762|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
33111763|NCT00542360|No Intervention|Control|Control: No intervention
33111764|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
33111765|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
33111766|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
33111767|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
33111768|NCT04648995|Other|High energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
33111769|NCT04648995|Other|Low energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
33111770|NCT00542399|Experimental|1|once a day
33111771|NCT00542399|Experimental|2|twice a day
33111772|NCT04648722||Left-side hemithyroidectomy|Patients who received a hemithyroidectomy of the left thyroid lobe since 1994
33111773|NCT04648722||Right-side hemithyroidectomy|Patients who received a hemithyroidectomy of the right thyroid lobe since 1994
33111774|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
33111775|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
33111776|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
33111777|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
33111778|NCT02266719|Experimental|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
33111779|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
33111780|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
33111781|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
33111782|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
33111783|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
33111784|NCT00542555|Experimental|Naproxcinod 375 mg bid|
33111785|NCT00542555|Active Comparator|Naproxen 500 mg bid|
33111786|NCT00542555|Experimental|Naproxcinod 750 mg bid|
33111787|NCT04648488|Experimental|Early mobilisation|Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
33111788|NCT04648488|Active Comparator|Standard treatment|Patients will have a plaster 3 weeks after surgery and after that start with exercise treatment.
33111789|NCT04685018||HC|Mentally and medically healthy adults between 18 and 60 years, free from any current or previous medical or psychiatric condition.
33111790|NCT04685018||OCD|Adults between 18 and 60 years, with a diagnosis of Obsessive-Compulsive Disorder and medication-free or with stable medication regimen for at least 3 weeks prior to the study.
33111791|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
33111792|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
33111793|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
33111794|NCT04648410||Members of European Society of Intensive Care|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
33111795|NCT04679025||Diabetes with postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
33111796|NCT04679025||Diabetes without postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
32740412|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
33054703|NCT03530683|Experimental|Cohort B: TTI-622 + Azacitidine and Venetoclax|"Cohort B1: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with TTI-622 QW + azacitidine and venetoclax~Cohort B2: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with TTI-622 QW + azacitidine and venetoclax."
33054704|NCT03530683|Experimental|Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone|"Cohort C1: participants with Relapsing or Refractory (R/R) Multiple Myeloma (MM) will be treated with TTI-622 QW + carfilzomib and dexamethasone.~Cohort C2: participants with R/R MM will be treated with TTI-622 QW + carfilzomib and dexamethasone.~Cohort C3: participants with R/R MM will be treated with TTI-622 Q2W + carfilzomib and dexamethasone."
33054705|NCT03530683|Experimental|Cohort D1 and D2: TTI-622 + an anti-CD20 targeting agent|"Cohort D1: participants with Relapsing or Recurrent (R/R) CD20+ Diffuse Large B Cell Lymphoma (DLBCL) will be treated with TTI-622 QW, then an increased dose Q3W + an anti-CD20 targeting agent.~Cohort D2: participants with R/R CD20+ DLBCL will be treated with TTI-622 dosed QW for 4 weeks, then an increased dose Q3W + an anti-CD20 targeting agent."
33054706|NCT03530683|Experimental|Cohort E1 and E2: single-agent TTI-622|"Cohort E1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with single-agent TTI-622 QW.~Cohort E2: participants with R/R MM will be treated with single-agent TTI-622 increased dose QW"
33054707|NCT03530683|Experimental|Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone|"Cohort F1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with increasing doses of TTI-622 + isatuximab, carfilzomib and dexamethasone.~Cohort F2: participants with R/R MM will be treated with TTI-622 QW + isatuximab, carfilzomib and dexamethasone.~Cohort F3: participants with R/R MM will be treated with TTI-622 increased dose QW + isatuximab, carfilzomib and dexamethasone."
33054708|NCT03525873|Experimental|ARM I (methylphenidate, physical activity)|Patients receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
33418961|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
33418962|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
33418963|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
32740413|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
32740414|NCT05727761|Experimental|oral leukoplakia patients|36 total high risk oral leukoplakia patients.
32740415|NCT04871477||Observational (audio recording)|Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
32740416|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
33054709|NCT03525873|Placebo Comparator|ARM II (placebo, physical activity)|Patients receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
33054710|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days. After final analysis (FA), participants who are receiving apalutamide in the open-label treatment phase may continue receiving single oral dose apalutamide 240 mg once daily in a long-term extension (LTE) phase if they continue to derive benefit from treatment (based on investigator assessment).
33054711|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
33111797|NCT04679025||No diabetes with postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
33418964|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
33418965|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
33418966|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
33418967|NCT05646147|Other|Diagnostic Cohort Study|All patients will underwent full diagnostic testing.
33418968|NCT02109692|Other|cohort|blood sample : doage of miRNA
33418969|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
32740417|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
32740418|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
32740419|NCT04866563|Experimental|AX-8 to Placebo|AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
32740420|NCT04866563|Experimental|Placebo to AX-8|Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
32740421|NCT04862351|Experimental|TecHCR|12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log
32740422|NCT04862351|Other|Centre-based|12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log
33054712|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
32869684|NCT04317846|Active Comparator|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
33054713|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
33054714|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
33054715|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
33054716|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
33054717|NCT03492125|Experimental|Phase I Dose Escalation Cohort A1 (MS-553 Monotherapy)|R/R CLL/SLL patients
33054718|NCT03492125|Experimental|Phase II Expansion Cohort A2 (MS-553 Monotherapy)|R/R CLL/SLL patients
33054719|NCT03492125|Experimental|Phase II Expansion Cohort A3 (MS-553 Monotherapy)|patients with aggressive lymphoma
33054720|NCT03492125|Experimental|Phase I Combination Dose Escalation Cohort B1|BTK inhibitor naïve CLL/SLL patients
33054721|NCT03492125|Experimental|Phase II Expansion Cohort B2|BTK inhibitor naïve CLL/SLL patients
33054722|NCT03492125|Experimental|Phase II Expansion Cohort B3|BTK inhibitor naïve CLL/SLL patients with certain gene mutations
33054723|NCT03492125|Experimental|Phase I Combination Dose Escalation Cohort C1|Bcl-2 inhibitor naïve CLL/SLL patients
33054724|NCT03492125|Experimental|Experimental: Phase II Expansion Cohort C2|Bcl-2 inhibitor naïve CLL/SLL patients
33054725|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
33054726|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
33054727|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
33054728|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
33054729|NCT03476798|Experimental|Bevacizumab + Rucaparib|
33054730|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
33054731|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
33054732|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
33054733|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.~The TAU condition will last for 4 months."
33054734|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
33054735|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
33111798|NCT04679025||No diabetes and no postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
33332939|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
33111799|NCT04678128|Active Comparator|Dance4Healing control group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will not have a dance buddy.
33111800|NCT04678128|Experimental|Dance4Healing Buddy Group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will have a dance buddy.
33111801|NCT00542906|Other|1|healthy volunteers
33111802|NCT04678674|Experimental|bone defect surgery|augmentation on insufficient alveolar ridges with autologous teeth will be performed (wisdom tooth or periodontally compromised tooth)
33111803|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
33111804|NCT00542945|Active Comparator|B|
33111805|NCT04677933|Experimental|Arm A|Patients will receive 5 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
33111806|NCT04677933|Experimental|Arm B|Patients will receive 10 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
33111807|NCT04677933|Experimental|Arm C|Patients will receive Diluent placebo BIW for 15 days (Day 1, 4, 8, 11 and 15) Mode of Administration: Subcutaneous injection
33111808|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
33111809|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
33111810|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
33111811|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
33111812|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
33111813|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
33111814|NCT04648917|Experimental|Arm A|In Arm A: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval (weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
33111815|NCT04648917|Placebo Comparator|Arm B|In Arm B: 40 patients will receive the placebo tablets: 100-200mg, tid, po, 2 weeks treated then 1 week black interval.
33332940|NCT05581966||Diabetic Foot Ulcer (DFU) Group|Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care
33111816|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
33111817|NCT00543218|Active Comparator|B|
33111818|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
33111819|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
33111820|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
33111821|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
33111822|NCT03456752|Placebo Comparator|Control|Normal Saline 1.6ml intravenously prior to anesthesia induction
33111823|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
33111824|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
33111825|NCT03456713|Experimental|LY3074828 Formulation A|LY3074828 solution formulation in two prefilled syringes, administered as subcutaneous (SC) injection
33111826|NCT03456713|Experimental|LY3074828 Formulation B|LY3074828 solution formulation in a prefilled syringe, administered as a SC injection
33111827|NCT03456713|Experimental|LY3074828 Formulation C|LY3074828 solution formulation in an auto-injector
33111828|NCT03456713|Experimental|LY3074828 Formulation D|LY3074828 solution formulation in an auto-injector
33111829|NCT04648137|Experimental|Patients with central diabetes insipidus|
33111830|NCT04648137|Experimental|Healthy volunteers|
33111831|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
33332941|NCT05018390|Experimental|OMT|Osteopathic manipulative treatment : participants will receive low-amplitude tissue mobilizations on peripheral, vertebral, cranial and/or visceral articular systems.
33332942|NCT05018390|Sham Comparator|Sham|Participants will be applied gestures that look like actual osteopathic manipulations but are not therapeutic.
33332943|NCT05018390|No Intervention|Test-retest|Participants will undergo the two eye movement measurements, but will not receive any (actual or sham) treatment. 30 minutes will elapse between the two measurements.
33332944|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
33332945|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
33332946|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
33332947|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
33332948|NCT03051178|Experimental|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
33332949|NCT03736850|Experimental|CS3006|
33332950|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
33332951|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
33054736|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
33054737|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
33332952|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
33332953|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
33332954|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
33332955|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
33332956|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
32740423|NCT05727683|Experimental|JWCAR029 Treatment|"A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before JWCAR029 infusion.~Potential JWCAR029 doses:~Dose level 1: 0.10×10^6 CAR+ T cells/kg Dose level 2: 0.30×10^6 CAR+ T cells/kg Dose level 3: 0.75×10^6 CAR+ T cells/kg Dose level 4: 1.0×10^6 CAR+ T cells/kg"
33054738|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
33054739|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.
33054740|NCT03435796|Other|Participants exposed to Gene-modified (GM) T cell therapy|
33054741|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
33054742|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
33332957|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
33332958|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
33054743|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
33054744|NCT03431350|Experimental|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
33332959|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
33332960|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
33332961|NCT05281978|Experimental|Decrease Sedentary Time + Increase MVPA|Participants in this group will receive a 12-week, social cognitive theory-based intervention targetting reduction of daily sedentary time. This information will be delivered to them in the form of Zoom workshops, a program workbook, personalized step count goals, and a private social media page. The aim of this component will be to have participants displace their daily sedentary time with light-intensity physical activity, such as casual walking. The second component of this intervention will be increasing participants' weekly MVPA engagement. Participants will participate in 1 live, virtual aerobics-based exercise class per week and complete 2 additional sessions on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
33054745|NCT03431350|Experimental|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
33054746|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
33054747|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
33054748|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
33054749|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
33054750|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
33054751|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
33054752|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.~REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0.~REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients undergo TBI QD on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0."
33054753|NCT03395522|Experimental|Device|ITind device implant
33054754|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
33054755|NCT03392467|Placebo Comparator|Placebo|normal saline
33054756|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN.~Expansion: the study is currently enrolling in 2 BPDCN expansion cohorts at the RP2D:~Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN).~Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy.~Other cohorts not currently enrolling:~• Cohort 2: Relapsed AML; Cohort 3: Relapsed or refractory ALL; Cohort 4: Other relapsed or refractory hematologic malignancies; Cohort 5: Relapsed or refractory AML at alternate dose or schedule"
33054757|NCT03384641|Experimental|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
33054758|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
33054759|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
33054760|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
33054761|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
33054762|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
33054763|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
33332962|NCT05281978|Active Comparator|Increase MVPA only|Participants in this group will only receive the MVPA-promoting component (which will be the same delivery as the intervention group). Participants in this arm will participate in 1 live, virtual aerobics-based exercise class per week (held separately from the intervention group) and will complete 2 additional exercise classes on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
33332963|NCT05280028||Tibolone|Tibolone 2.5 mg per day
33332964|NCT05280028||Indivina|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate 2.5 mg (MPA) per day
33054764|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
33054765|NCT03305341|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein~0.5 ml Lactated Ringer's Injection, USP"
33332965|NCT05276674||ZNN Bactiguard Retrograde Femoral Nail|Patients implanted with a ZNN Bactiguard Retrograde Femoral Nail for fixing and stabilizing a femoral fracture.
33332966|NCT05569876|Other|Controlled hypoglycemic state|
33332967|NCT05275972|Placebo Comparator|DMEK plus topical placebo|
33054766|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
33332968|NCT05275972|Experimental|DSO plus topical ripasudil 0.4%|
33332969|NCT05564650|Experimental|Treatment (navitoclax, decitabine, venetoclax)|
33054767|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
33054768|NCT03297606|Experimental|Group 1 - Arm CLOSED, no patients recruited|VEGFR1, VEGFR2, VEGFR3
33054769|NCT03297606|Experimental|Group 2 - Arm CLOSED, no patients recruited|BCR-ABL, SRC
33332970|NCT05235724||Subset of study-OBS15333 patients|As a sub-study of the OBS15333 pediatric AD registry (PEDISTAD), all participants in this study will be receiving standard care of therapies for moderate to severe AD.
33054770|NCT03297606|Experimental|Group 3 - Arm CLOSED|ALK, ROS1, MET
33054771|NCT03297606|Experimental|Group 4 - Arm CLOSED, no patients recruited|KIT, PDGFRA, PDGFRB, ABL1
33054772|NCT03297606|Experimental|Group 5|EGFR
33054773|NCT03297606|Experimental|Group 6 - Arm CLOSED|high mutation burden, POLE, POLD1
33054774|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD
33054775|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CCND1, SMARCA4
33054776|NCT03297606|Experimental|Group 9 Arm CLOSED|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
33054777|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
33054778|NCT03297606|Experimental|Group 11 - Arm CLOSED|ERBB2
33054779|NCT03297606|Experimental|Group 12|BRAFV600
33054780|NCT03297606|Experimental|Group 13|PTCH1, SMO
33054781|NCT03297606|Experimental|Group 14|ERBB2
33054782|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
33054783|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
33054784|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
33054785|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
33054786|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
33054787|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
33054788|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
33054789|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
33332971|NCT05229328||Control group|Healthy volunteers
33332972|NCT05229328||Patients within the acute phase of disease|Patients within 24 hours after onset
33332973|NCT05229328||Recovery phase of disease|Inflammation was controlled, shock was corrected, and the patient remained fever free for 3 consecutive days.
33332974|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
33332975|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
33332976|NCT05204992|Experimental|Hydrodissection|ultrasound guided hydrodissection
33332977|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
33054790|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
33054791|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
33054792|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
33332978|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
33332979|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
33332980|NCT05175118|Other|Minimally invasive fixation|Minimally Invasive Surgical Fixation for Unstable Fractures of the distal end Radius in Adults
33332981|NCT05174806|Experimental|Topical Pravibismane (MBN-101)|Topical pravibismane (MBN-101) at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will occur 3 times per week for the 12 weeks of treatment.
33332982|NCT05174806|Other|Standard of Care|Standard of care treatment without administration of any topical drugs.
32740425|NCT02881307|Experimental|Dietary Supplement|
33054793|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
33054794|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
33054795|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
33054796|NCT03217747|Experimental|Arm A (utomilumab, avelumab)|Patients receive utomilumab IV over 60 minutes on day 1 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054797|NCT03217747|Experimental|Arm B (PF-04518600, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054798|NCT03217747|Experimental|Arm C (PF-04518600, utomilumab, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle, utomilumab over 60 minutes on day 1, and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33332983|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
33332984|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
32740426|NCT02881307|Active Comparator|Dietary Counseling|
33054799|NCT03217747|Experimental|Arm D (avelumab, utomilumab, radiation therapy)|Patients undergo radiation therapy on days -5 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054800|NCT03217747|Experimental|Arm E (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1 and anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15, and. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33054801|NCT03217747|Experimental|Arm F (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1, utomilumab IV over 60 minutes on day 1, and anti-OX40 agonist monoclonal antibody PF-04518600 IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33332985|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
33332986|NCT05173480|Experimental|Experimental group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system in addition to conventional rehabilitation.
33332987|NCT05173480|Active Comparator|Control group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system, with sensors not connected, in addition to conventional rehabilitation.
33332988|NCT03736460|Experimental|Mindfulness-based intervention|
33332989|NCT03736460|Active Comparator|Physical training|
33332990|NCT03736460|No Intervention|Wait-list|
33332991|NCT03737942||control group|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
33332992|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
33332993|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
33332994|NCT03627052|Experimental|Itacitinib|
33332995|NCT03627052|Placebo Comparator|Placebo|
33054802|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
33054803|NCT03176277|Experimental|ONO-7475 (Part A)|Successive dose escalation cohorts to determine MTD/OBD
33054804|NCT03176277|Experimental|ONO-7475 + venetoclax (Part D)|Successive dose escalation of ONO-7475 cohorts + venetoclax
33054805|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any >= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to [=] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
33332996|NCT04246918|Placebo Comparator|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
33054806|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
33054807|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
33054808|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
33054809|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
33054810|NCT03151629||Castrate Resistant Prostate Cancer|
33054811|NCT03151629||Hormone Sensitive Prostate Cancer|
33054812|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
33054813|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
33054814|NCT03110107|Experimental|Part 1A: Monotherapy (BMS-986218)|
33054815|NCT03110107|Experimental|Part 1B: Combination Therapy (BMS-986218 + Nivolumab)|
33054816|NCT03110107|Experimental|Part 2A: Monotherapy (BMS-986218 OR Ipilimumab)|
33054817|NCT03110107|Experimental|Part 2B: Monotherapy (BMS-986218)|
33054818|NCT03110107|Experimental|Part 2C: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
33054819|NCT03110107|Experimental|Part 2D: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
33054820|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
32869685|NCT04317846|Experimental|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
33054821|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
33054822|NCT03091374|Experimental|Growth Hormone|
33054823|NCT03088839||30 ALS patients|
33054824|NCT03088839||30 healthy controls|
33054825|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
33054826|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
33054827|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
33054828|NCT03053089|Experimental|Stage 2 (children)|AGT-181
33054829|NCT03030378|Experimental|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of subsequent cycles. Treatment continues for 28 days for cycle 1 and repeats every 21 days for subsequent cycles for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, PET, and MRI, as well as collection of blood during screening, on study, and during follow-up. Patients also undergo a tumor biopsy during screening and on study.
33054830|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
33054831|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
33054832|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
33054833|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
33054834|NCT02963649|Experimental|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
33054835|NCT02963649|Active Comparator|Standard angioplasty balloon|standard PTA balloon
33054836|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
33054837|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
33054838|NCT02935686|Experimental|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
33054839|NCT02935686|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
33054840|NCT02935686|Placebo Comparator|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
33054841|NCT02935686|Experimental|Group 1b: Ad26.Mos4.HIV + gp140 HIV Bivalent Vaccine|Participants enrolled in the LTE phase will receive late boost vaccination Ad26.Mos4.HIV and bivalent gp140 within 4 weeks prior to Week 192 until 4 months after Week 192 (that is, approximately 3 years after the 4th vaccination of the primary vaccination series).
33054842|NCT02935686|Placebo Comparator|Group 2b: Placebo|Participants will receive placebo injection at Week 192 -4 weeks/+4 months, that is, approximately 3 years after the 4th vaccination of the primary vaccination series.
33054843|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
33054844|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
33054845|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), intravenous (IV) every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4. In Part 5, participants will receive JNJ-63723283 SC or IV for PK evaluation.
33054846|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
33054847|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
33054848|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
33054849|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
33054850|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
33418970|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
33418971|NCT05165979||Hospitalized COVID-19 patients|Hospitalized COVID-19 patients
33418972|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
33418973|NCT05159115|Active Comparator|Low-FODMAP diet|Patients with IBS on a 4-week low-FODMAP diet.
33418974|NCT05159115|Experimental|Starch- and Sucrose Reduced Diet|Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).
33418975|NCT02109848||keratoconus|
33418976|NCT02109848||post-keratoplasty|
33418977|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
33054851|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
33418978|NCT05504421|Active Comparator|Control group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then the some structured cases will be individually analyze by students based on traditional learning. When the case analysis is finished, a simulation application will be performed with the scenario.
33418979|NCT05504421|Experimental|Experimental group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then analyze the some structured cases in groups structured in line with the cooperative learning process. The same cases will be used in the control group. When the case analysis is finished, a simulation application will be performed with the scenario.
33418980|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
33418981|NCT02251418|No Intervention|Control|Standard care treatment
33418982|NCT05618067|Experimental|Training|
33054852|NCT02855944|Experimental|Rucaparib|"Drug: Oral rucaparib~600 mg BID (twice a day)~Other Names:~CO-338~PF 01367338~AG 14699~Rubraca"
33054853|NCT02855944|Active Comparator|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
33054854|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
33054855|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
33054856|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
33054857|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
33054858|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
33054859|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
33054860|NCT02730338|Active Comparator|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
33054861|NCT02730338|Other|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
33054862|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
33054863|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
33054864|NCT02688569|Experimental|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
33054865|NCT02688569|No Intervention|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
33054866|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
33054867|NCT02663518|Experimental|TTI-621 Escalation Phase|The Escalation Phase will include multiple doses of TTI-621
33054868|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
33054869|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
33054870|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
33054871|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with TTI-621
33054872|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with TTI-621
33054873|NCT02663518|Experimental|Acute Lymphoblastic Leukemia|Monotherapy expansion cohort with TTI-621
33054874|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with TTI-621
33054875|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with TTI-621
33054876|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with TTI-621
33054877|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with TTI-621
33054878|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with TTI-621
33054879|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
33054880|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
33054881|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with TTI-621
33054882|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with TTI-621
33054883|NCT02663518|Experimental|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621
33332997|NCT04246918|Active Comparator|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
33332998|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
33332999|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
33418983|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
33054884|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
33054885|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
33054886|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
33054887|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
33054888|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
33054889|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
33054890|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
33054891|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
33054892|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
33054893|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be five total face to face group meetings over the 18 months, with one meeting each at months 1, 3, 6, 9, and 15; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, phone sessions, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
33054894|NCT02577354|Experimental|Treatment|
33054895|NCT02577354|Experimental|Control|
33054896|NCT02537899|Other|Treatment|NeuroAiD
33054897|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
33054898|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
33054899|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
33054900|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
33054901|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
33054902|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
33054903|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
33054904|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
33054905|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
33333000|NCT04216342|Experimental|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
33333001|NCT03662750|Experimental|Acute stroke cohort|Acute stroke cohort
33333002|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
33333003|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
33333004|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
33333005|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
33333006|NCT04157920|Other|Patients treated with Medtronic CoreValve/ Evolut R/Pro|TAVI patients treated with Medtronic CoreValve /Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial
33054906|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
33054907|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
33054908|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
33054909|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
33054910|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
33054911|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
33054912|NCT02477696|Experimental|ACP-196|acalabrutinib 100 mg BID (Arm A; N=250)
33054913|NCT02477696|Active Comparator|ibrutinib|ibrutinib 420 mg QD (Arm B; N=250)
33054914|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
33054915|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
33054916|NCT02471430|Experimental|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
33054917|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
33054918|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
33054919|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
33054920|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
33054921|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
33054922|NCT02438007|Experimental|Galeterone|
33054923|NCT02438007|Active Comparator|Enzalutamide|
33054924|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
33054925|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
33054926|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
33111832|NCT04648332|Experimental|Group 1|Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
33111833|NCT04648332|No Intervention|Group 2|Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
33111834|NCT04648332|No Intervention|Group 3|Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.
33111835|NCT03456596||Institution|Community cancer centers implementing ENABLE
33111836|NCT04647981||Xpert® Bladder Test|A urine sample is collected before cystoscopy.
33111837|NCT03456557|Experimental|Computed tomography.|
33111838|NCT04648566|Placebo Comparator|IIU control group|
33111839|NCT04648566|Active Comparator|IIU PBMC group|
33111840|NCT04648566|Placebo Comparator|FIV control group|
33111841|NCT04648566|Active Comparator|FIV PBMC group|
33111842|NCT04648566|Active Comparator|RIF group|
33111843|NCT05078411|Other|Patients without a history of tooth loss due to periodontitis (NTLP)|
33111844|NCT05078411|Other|Patients with a history of tooth loss due to periodontitis (TLP)|
33111845|NCT04648176|Active Comparator|HoLEP|Conventional laser
33111846|NCT04648176|Experimental|m-HoLEP|Moses technology
33111847|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
33333007|NCT04157920|Active Comparator|Patients treated with ACURATE neo/TF|TAVI patients treated with ACURATE neo/TF Transcatheter Heart Valve recruited prospectively.
33333008|NCT05090072|Active Comparator|- Advance Directives Group|The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates
33333009|NCT05090072|Placebo Comparator|Control Group|The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician
33333010|NCT05517928|Experimental|Lactobacillus rhamnosus GG Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive Lactobacillus rhamnosus GG two capsules daily taken with a meal.
33333011|NCT05517928|Placebo Comparator|Placebo Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive placebo two capsules daily taken with a meal.
33333012|NCT05517616|Experimental|[14C]APG-2575|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose of 400mg, 200μCi [14C] APG-2575 to healthy subjects.
33333013|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
33333014|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
33333015|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
33333016|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
33333017|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
33333018|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
33333019|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
33111848|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
33111849|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
33111850|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
33111851|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
33111852|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
33111853|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
33111854|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
33111855|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
33111856|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
33111857|NCT00543452|Placebo Comparator|air|4 liters of room air
33111858|NCT04647942||Meniscectomy|Patients who underwent a meniscectomy
33111859|NCT00554697||1|
33111860|NCT00554697||2|
33111861|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
33111862|NCT00543608|Experimental|1|Dose 1 iclaprim
33111863|NCT00543608|Experimental|2|Dose 2 iclaprim
33111864|NCT00543608|Active Comparator|3|vancomycin
33111865|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
33111866|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
33111867|NCT00543647|Experimental|1|
33111868|NCT00543647|Placebo Comparator|2|
33111869|NCT04647747|Other|Self measurement of peripheral saturation|Participant will be equipped with a pulse oximeter and perform saturation measurements.
33111870|NCT04647669|Placebo Comparator|Local Standard of Care|Local Standard of Care
33054927|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
33054928|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
33054929|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
33054930|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 week cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.~Lenalidomide (Revlimid®), PO, daily, 4 week cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
33054931|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
33054932|NCT02356523||Delirium patients|Patients positive to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
33333020|NCT03736382|Experimental|Experimental Group|The experimental group is comprised of participants with OSA and hypertension [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
33333021|NCT03736382|Sham Comparator|Control Group|The control group is comprised of hypertensive OSA participants [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
33333022|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
33333023|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
33054933|NCT02356523||control group|Patients negative to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
33333024|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
33333025|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
33333026|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
33333027|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
33333028|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
33054934|NCT02354014|Experimental|TMC207/Background Regimen (BR)|There will be 4 age-based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3, 4. Cohort 1: >= 12 to < 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks, followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: >=5 to <12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: >=2 to <5 years: TMC207 8 milligram per kilogram (mg/kg) qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw for 22 weeks. Cohort 4: 0 months to <2 years: TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3. TMC207 will be given in combination with Background Regimen for Multidrug Resistant Tuberculosis (MDR-TB) according to WHO/National Tuberculosis Program (NTP) guidelines/current standard of care.
33054935|NCT02352506||AKI|Patients developing AKI during the ICU stay
33054936|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
33054937|NCT02336503|Experimental|BBI-4000 Gel, 5%|Low concentration of BBI-4000; BBI-4000 Gel, 5%
33054938|NCT02336503|Experimental|BBI-4000 Gel, 10%|Middle concentration of BBI-4000; BBI-4000 Gel, 10%
33054939|NCT02336503|Experimental|BBI-4000 Gel, 15%|High concentration of BBI-4000; BBI-4000 Gel, 15%
33054940|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo); BBI-4000 Gel, 0%
33054941|NCT02316106|Experimental|Arm A (Long Intense)|
33054942|NCT02316106|Experimental|Arm B (Intermediate)|
33054943|NCT02316106|Experimental|Arm C (Short Intense)|
33111871|NCT04647669|Active Comparator|Remdesivir|Remdesivir (daily infusion for 10 days)
33111872|NCT04647669|Active Comparator|Acalabrutinib|Acalabrutinib (orally twice daily for 10 days)
33111873|NCT04647669|Active Comparator|Interferon|Interferon β1a(daily injection for 6 days).
33333029|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
33418984|NCT05644899||SMA patients|51 adults with a genetically confirmed diagnosis of SMA (13 SMA type 2, 38 SMA type 3) treated with nusinersen. The technique used was based on the anesthesiologist's preference.
33418985|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
33418986|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
33054944|NCT02288247|Experimental|Enzalutamide|Participants received an OL treatment with enzalutamide 160 milligrams (mg) capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received enzalutamide 160 mg capsules, orally once daily in combination with docetaxel 75 milligrams per square meter (mg/m^2) in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, DB period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cycle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
33054945|NCT02288247|Placebo Comparator|Placebo|Participants received an OL treatment with enzalutamide 160 mg capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received placebo matched to enzalutamide, orally once daily in combination with docetaxel 75 mg/m^2 in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, in period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cyle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
33054946|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m^2 every 8 weeks after completion of the Week 252 assessments.
33418987|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
33418988|NCT02109926||Cases: testicular cancer patients|
33418989|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
33054947|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
33054948|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
33054949|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
33054950|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
33054951|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
33054952|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
33054953|NCT02230826||Patients with Hip arthroplasty|Patients with Hip implants.
33054954|NCT02225119||Affected|Participants with macular disease
33054955|NCT02225119||Unaffected|Healthy volunteers
33054956|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
33054957|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
33054958|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
33111874|NCT00543686|Active Comparator|1|Montelukast
33111875|NCT00543686|Active Comparator|2|Fluticasone
33111876|NCT04647864||Group 1|Edwards Sapien 3 and Edwards Sapien 3 Ultra
33418990|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
32869686|NCT04317846|Experimental|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
33333030|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
33333031|NCT04093024|Experimental|Double-blind period (DBP) + open-label Nintedanib period (OLNP): Randomised Nintedanib|"This arm shows Nintedanib randomised participants treated orally with Nintedanib in the DBP and OLNP twice daily with a dose interval of approximately 12 hours from one dose to the next dose.~Medication dosage was per administration 50 milligram (mg) [2 capsules with strength 25 mg],75 mg [3 capsules with strength 25 mg], 100 mg [1 capsule with strength 100 mg or 4 capsules with strength 25 mg] or 150 mg [1 capsule with strength 150 mg or 6 capsules with strength 25 mg] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~In this arm participants received Nintedanib in both periods (DBP + OLNP). Participants in this arm do not entail participants from the 'randomised to placebo' arms.~DBP: Planned was from first randomised trial drug intake to last blinded drug intake.~OLNP: Planned was from first open-label Nintedanib intake to last open-label Nintedanib intake."
33333032|NCT04093024|Placebo Comparator|DBP+OLNP: Randomised placebo|"Placebo randomised participants were treated orally with a Nintedanib matching placebo soft capsule twice daily in the double-blind period (DBP).~Participants who continued with the open-label Nintedanib period (OLNP) after the DBP switched to active Nintedanib treatment in the OLNP and were treated orally with Nintedanib twice daily.~Medication dosage was per administration 50 milligram (mg) [2 25 mg capsules (cap)],75 mg [3 25 mg cap], 100 mg [1 100 mg or 4 25 mg cap] or 150 mg [1 150 mg or 6 25 mg cap] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~The dose interval was approximately 12 hours between one and the next dose.~Here participants received placebo first (DBP) and then Nintedanib (OLNP). DBP: Planned was from first to last randomised blinded drug intake. OLNP: Planned was from first to last open-label Nintedanib intake."
33418991|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
32869687|NCT05535504|Experimental|real rTMS|Use the real rTMS coil
32869688|NCT05535504|Sham Comparator|sham rTMS|Use the sham rTMS coil
32869689|NCT05544942|Experimental|GCWB1001|1 capsule once a day
32869690|NCT05544942|Active Comparator|Placebo|1 capsule once a day
33054959|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
33054960|NCT02137824|Experimental|sinus floor elevation|
33054961|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
33054962|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
33054963|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
33054964|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
33054965|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
33054966|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
33054967|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
33054968|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
33054969|NCT02117791||Group 1|Riociguat treatment group
33054970|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
33054971|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
33054972|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
33111877|NCT04647864||Group 2|Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO
33111878|NCT04647864||Group 3|Boston Scientific Acurate neo and Boston Scientific Acurate neo2
33111879|NCT04647864||Group 4|St. Jude Medical Portico
33054973|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
33054974|NCT02081924|Active Comparator|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
33054975|NCT02081924|Placebo Comparator|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
33333033|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
33054976|NCT02081924|Active Comparator|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
33333034|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
33333035|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
33333036|NCT04032418|Active Comparator|Arm I (200mg pembrolizumab 3 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
33333037|NCT04032418|Experimental|Arm II (200mg pembrolizumab 12 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
33054977|NCT02081924|Active Comparator|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
33054978|NCT02079740|Experimental|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
33333038|NCT04022980|Experimental|Stage 1|Safety Run-In
33333039|NCT04022980|Experimental|Stage 2|Expansion Cohort
33333040|NCT03971188|Experimental|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
33333041|NCT03971188|Active Comparator|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
33054979|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
33054980|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
33054981|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
33333042|NCT03946774|Active Comparator|High protein|Subjects getting high protein shake
33333043|NCT03946774|Active Comparator|Low protein|Subjects getting low protein shake
33333044|NCT03941236|Experimental|Dasiglucagon open-label|Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
33333045|NCT03876028|Experimental|Ibrutinib (before leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment before leukapheresis
33333046|NCT03876028|Experimental|Ibrutinib (after leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment after leukapheresis.
33361300|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
33054982|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
33054983|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
33054984|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
33054985|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
33054986|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
33054987|NCT01969227|Experimental|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
33054988|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
33054989|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
33054990|NCT01900574|Experimental|Golimumab|
33054991|NCT01885949|Experimental|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
33054992|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
33054993|NCT01839396|Active Comparator|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
33054994|NCT01839396|Sham Comparator|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
33054995|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
33054996|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
33054997|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
33333047|NCT03694756|Other|Pre-biopsy patients|Patients identified by a radiologist at the time of diagnostic evaluation. Once consent is obtained, the TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
33333048|NCT03694756|Other|Post-biopsy patients|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
33333049|NCT03631706|Experimental|M7824|
33333050|NCT03631706|Active Comparator|Pembrolizumab|
33333051|NCT03661528|Experimental|andexanet alfa|Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.
33333052|NCT03661528|Other|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
33333053|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
33054998|NCT01771536|No Intervention|Usual Care|
33054999|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
33333054|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
33333055|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
33333056|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
33333057|NCT04048382|Experimental|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
33333058|NCT04048382|Other|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
33333059|NCT04051840|Experimental|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
33418992|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
33418993|NCT05703867|Experimental|Active microcurrent therapy|
33055000|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
33055001|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
33055002|NCT01719055||Boston Scientific SCS Systems|Subjects permanently implanted with a Boston Scientific neurostimulation systems
33055003|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
33418994|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
33055004|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
33055005|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
33055006|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
33055007|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
33055008|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
33055009|NCT01550575||Patients eligible for SCS, RF or other treatment approaches|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system or various other treatment approaches such as RF, IDS, etc.
33055010|NCT01550575||Patients Eligible for treatment options with prior treatment|Patients who have previously been implanted with a spinal cord stimulation system or other various treatments, and have thereafter received a different form of chronic pain treatment such as a different SCS system, RF, IDS etc.
33111880|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
33111881|NCT04638816|Experimental|Restylane Volyme|Hyaluronic Acid
33111882|NCT04638816|Experimental|Restylane Lyft Lidocaine|Hyaluronic Acid
33111883|NCT00543881|Experimental|1|Interventional group
33111884|NCT00543881|Active Comparator|2|Usual care group
33111885|NCT04638855|Experimental|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
33111886|NCT04638855|Sham Comparator|Placebo|No device after hysteroscopy surgery
33111887|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
33111888|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
33111889|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
33111890|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
33111891|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
33111892|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
33111893|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
33111894|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
33111895|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
33111896|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
33111897|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
33111898|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
33333060|NCT03412162|Experimental|Ethnic and Racial Identity Promotion|Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership).
33333061|NCT03412162|Active Comparator|Academic Skills Promotion|Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. This condition receives the same amount of facilitator time and attention as the Experimental condition.
33333062|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
33333063|NCT04047446|Experimental|Liposomal bupivacaine & standard bupivacaine|
33111899|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
33111900|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
33111901|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and PFC|
33111902|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and sham rTMS over PFC|
33111903|NCT04638777|Sham Comparator|Sham rTMS over M1 and PFC|
33111904|NCT00544037||Group 1|
33111905|NCT04647357|Experimental|SHR-1316|
33111906|NCT04638582|Experimental|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
33333064|NCT04047446|Active Comparator|Standard bupivacaine & dexamethasone|
33333065|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
33333066|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
33333067|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
33333068|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
33333069|NCT03258580|Experimental|Substudy 1: All participants|Measuring facial response to painful stimulation.
33333070|NCT03258580|No Intervention|Substudy 2: Healthy volunteers|Measuring pain assessment accuracy
33111907|NCT04638582|Experimental|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
33111908|NCT04647630||CAP|community acquired pneumonia
33333071|NCT03258580|No Intervention|Substudy 3: Control|Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).
33333072|NCT03258580|Experimental|Substudy 3: Feedback Group|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
33333073|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
33111909|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
33111910|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
33111911|NCT04647318|Experimental|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
33333074|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
33111912|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
33111913|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
33111914|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
33111915|NCT04647552||hydrocortisone|The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg
33111916|NCT04647552||control|The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP>65 mmHg
33333075|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
33333076|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
33333077|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
33333078|NCT03736148|No Intervention|Control|No contact was given to the subject.
33333079|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
33333080|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
33333081|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
33333082|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
33333083|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
33333084|NCT03049462|Experimental|Cohort 1|Females taking 100 mg of mirabegron
33333085|NCT03049462|Active Comparator|Cohort 2A|Males taking 200 mg mirabegron
33333086|NCT03049462|Placebo Comparator|Cohort 2B|Males taking placebo drug
33333087|NCT03049462|Active Comparator|Cohort 3A|Females taking 100 mg of mirabegron
33333088|NCT03049462|Placebo Comparator|Cohort 3B|Females taking placebo drug
33333089|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
33333090|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
33333091|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
33333092|NCT02782546|Experimental|Recipient|"Standard of care reduced conditioning regimen on Day -1~Graft cell infusion on Day 0~Post-transplant cyclophosphamide on Days +3 and +4~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
33361301|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
33055018|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
33055019|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
33055020|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
33055021|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
33055022|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
33055023|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
33055024|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
33055025|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
33055026|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
33055031|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
33055032|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
33055033|NCT00980538|Experimental|Etravirine|Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
33055034|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
33055035|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
33055036|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
33055037|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
33055038|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
33055039|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
33055040|NCT00630032|Active Comparator|Docetaxel|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
33055041|NCT00630032|Experimental|Ixabepilone|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
33055043|NCT00465517|Experimental|ganaxolone|active study drug
33418995|NCT05098665|Active Comparator|Arm A - RCT telemonitoring|160 ATTR-CM patients assigned to receive telemonitoring intervention
33055044|NCT00465517|Placebo Comparator|non-active drug|placebo
33333093|NCT02782546|Experimental|Donor|"Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
33333094|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
33333095|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
33333096|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
33333097|NCT03628898|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
33333098|NCT02706652||all patients|all eligible patients
33333099|NCT02573896|Experimental|NK cells with Dinutuximab & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of dinutuximab on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
33333100|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
33055045|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"Undergo neoadjuvant systemic therapy~initial surgery for sentinel lymph node biopsy/portacath placement~definitive cancer surgery (if applicable)~when portacath is removed (1 year, if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~Undergo Adjuvant Systemic Therapy~initial surgery for a sentinel lymph node biopsy/portacath placement~when portacath is removed (1 year, if available)~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~Undergone neoadjuvant systemic therapy~during definitive cancer surgery/portacath removal (if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
33055046|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
33055047|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
33055048|NCT05772910|Experimental|EDUcation|The EDU group will assist to an individualized educative program based on intrinsic capacity optimization through lifestyle changes.
33055049|NCT05772910|Experimental|EXERcise|The EXER group will follow a program focused on the specific deficit of muscular power from a simple clinical test such as the STS and, in addition, they will be evaluated to be able to prescribe training individually (evaluation of training)
33055050|NCT05772910|Experimental|EDU-EXER|EDU-EXER group subject develops both interventions together.
33055051|NCT05772910|Active Comparator|CONtrol|CON group will continue the usual clinical treatment and their normal life.
33055052|NCT05772897|Experimental|Circle of Security Parenting (COSP) group|This group of mothers will be assigned to begin the parenting skills intervention (COSP) group soon after enrollment, and data collection (developmental testing, buccal swabs, play-based assessment, questionnaires) will proceed as planned. COSP groups will be conducted remotely via Zoom.
33055053|NCT05772897|No Intervention|Waitlist Control Group|This group of mothers will be assigned to a waitlist control group and will be scheduled to begin the parenting skills group at a later time. In order to serve as a no-intervention control, they will be administered assessments while on the waiting list. These assessments will be given concurrently with mid-point assessment of the intervention group.
33055054|NCT05772871|Experimental|Prednisone, Huaiqihuang granule, and Levamisole placebo|In this group, patients will take Prednisone, Huaiqihuang granule, and Levamisole placebo.
33055055|NCT05772871|Placebo Comparator|Prednisone, Levamisole, and Huaiqihuang granule placebo|In this group, patients will take Prednisone, Levamisole, and Huaiqihuang granule placebo.
33055056|NCT05772858|Experimental|Family Therapy Training and Implementation Platform (FTTIP)|Participants will be trained for 20 hours on an online platform practicing family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
33055057|NCT05772858|Active Comparator|Traditional in person Training as Usual|Participants will attend 20 hours of a traditional in person training learning about the family therapy evidenced based treatment.
33055058|NCT05772858|Experimental|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|All of the 150 families will receive Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format.
33055059|NCT05772858|Experimental|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|Agency leaders assigned to this condition will complete an online assessment of agency readiness, participate in a webinar and live discussion, complete an online meeting with leaders and clinical supervisors
33055060|NCT05772858|Active Comparator|Agency Engagement and Orientation as Usual|Agency leaders assigned to this condition will receive a traditional engagement of leadership at their agency including a description of study procedures and engagement with study team.
33055061|NCT05772845|Other|Daily Users of ENDS|Participants who use nicotine-containing ENDS daily or near-daily but who do NOT smoke combustible cigarettes daily or near-daily.
33055062|NCT05772845|Other|Daily Users of Combustible Cigarettes|Participants who smoke combustible cigarettes daily or near-daily but do NOT use nicotine-containing ENDS daily or near-daily.
33055063|NCT05772845|Other|Daily Dual Users of ENDS and Combustible Cigarettes|Participants who both use nicotine-containing ENDS and combustible cigarettes daily or near-daily
33055064|NCT05772832||GROUP USING REMIFENTANYL|THE GROUP USING PEROPERATIVE REMIFENTANYL AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.2 μg /kg /min Remifentanyl and 3-12 mg/kg/h propofol
33333101|NCT05667584|Experimental|HPI|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and hypotension prediction index (HPI) derived from ClearSight are used for recording and monitoring. Blood pressure is monitored with ClearSight and HPI. Attending anesthesiologists controlled the blood pressure according to HPI values.~Maintain HPI below 85~HPI > 85 and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~HPI > 85 and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
33333102|NCT05667584|Active Comparator|ClearSight|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and HPI are masked for attending anesthesiologists. Blood pressure is monitored with ClearSight. Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~Maintain mean arterial pressure (MAP) above 65 mmHg~MAP < 65mmHg and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~MAP < 65mmHg and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
33361302|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
33361303|NCT03920605|Active Comparator|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
33418996|NCT05098665|No Intervention|Arm B - RCT usual care|Control group of 160 ATTR-CM patients assigned to receive usual care
33418997|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
33055065|NCT05772832||GROUP USING DEXMEDETOMIDINE|THE GROUP USING PEROPERATIVE DEXMEDETOMIDINE AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.02 μg/kg/min (~0.5 μg/kg/h) continuous infusion of dexmedetomidine 1 mcg/kg 10 minutes after a loading dose and 3-12 mg/kg/h propofol
33055066|NCT05772819|Experimental|Imaging arm|Participants are subjected to in-magnet exercise test consisting of in vivo exercise cardiac magnetic resonance (exCMR) imaging and 31P-magnetic resonance spectroscopy (31P-MRS) during exercise testing in a MR-compatible ergometer, before and after the 4-week prehabilitation program.
33055067|NCT05772793||Group A|
33055068|NCT05772780|Experimental|Group A|Training will be performed for two days a week
33055069|NCT05772780|Experimental|Group B|Training will be performed three days a week
33055070|NCT05772767|Other|Biological sample collection|Collection of tumor tissue and PBMC for the generation of glioblastoma stem cell cultures and brain organoids.
33055071|NCT05772741|Other|Biological sample collection|Tumor tissue for glioma stem-like cell culture generation. Skin or PBMC for organoid generation
33055072|NCT05772728|Experimental|CAG Group|Cidapenem combined with azacitidine and mitoxantrone liposomes
33055073|NCT05772715|Active Comparator|Orthosis group|
33055074|NCT05772715|Experimental|Orthosis + exercise group|
33055075|NCT05772702|Experimental|Closed-loop tACS|Closed-loop individual alpha tACS daily for five consecutive days.
33055076|NCT05772689|Active Comparator|Usual Care|Standard of Care
33055077|NCT05772689|Experimental|Caregiving while Black|Caregivers of PLWD taking part in a fully self-paced asynchronous online caregiver education program.
33055078|NCT05772676|Experimental|Aprepitant|Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
33055079|NCT05772676|Placebo Comparator|Placebo|Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
33055080|NCT05772663|Experimental|personalized program group|people with chronic stroke
33055081|NCT05772663|Active Comparator|routine rehabilitation care group|people with chronic stroke
33055082|NCT05772637|Experimental|MS Patient with Bladder disorders|
33055083|NCT05772624|Experimental|LowN-AVD|classic Hodgkin's lymphoma patients receiving low dose nivolumab in combination with AVD
33055084|NCT05772611||Antibody characterized|Patients with well-characterized antibody (HU, YO, RI, CASPR2, NMDAr, GAD, …)
33055085|NCT05772611||Atypical|Patients with atypical antibody
33055086|NCT05772611||Without antibody|Patients without antibody
33055087|NCT05772585||patients ALF and ACLF|patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) with hepatic encephalopathy
33055088|NCT05772572||Patients|Children aged 7 to 17 inclusive, and young adults operated (or re-operated) for a Moya Moya in the previous 7 years and followed at the Necker-Enfants Malades hospital, and their parents.
33055089|NCT05772559||Cohort 1 : Patients with acute myeloid leukemia|Patients with acute myeloid leukemia at initial diagnosis or relapse, aged less than 25 years
33055090|NCT05772559||Cohort 2 : Patients with genetic predisposition to develop acute myeloid leukemia|
33055091|NCT05772559||Cohort 3 : Patients who undergo bone marrow aspirate|Patients who undergo bone marrow aspirate as part of standard of care but without AML nor predisposition to develop AML, as controls
33055092|NCT05772546|Experimental|Group A - Avatromopag|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~Pre-determined dose of Avatrombopag 1x daily.~Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of Avatrombopag 1x daily.~Follow-up Period~End of Treatment on-site visit.~Follow-up visit 30-42 days after End of Treatment visit."
33055093|NCT05772546|Active Comparator|Group B - Matching Placebo|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~Pre-determined dose of matching placebo 1x daily.~Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of matching placebo 1x daily.~Follow-up Period~End of Treatment on-site visit.~Follow-up visit 30-42 days after End of Treatment visit."
33055094|NCT05772533|Active Comparator|Group A (SAPB)|Ultrasound-guided SAPB will be applied while the patient is in the supine position.
33333103|NCT05667584|No Intervention|NIBP|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and are masked for attending anesthesiologists. Blood pressure is monitored with conventional non-invasive blood pressure (NIBP). Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~Maintain mean arterial pressure (MAP) above 65 mmHg~MAP < 65mmHg and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~MAP < 65mmHg and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
33333104|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
33333105|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
33333106|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
33333107|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
33055095|NCT05772533|Active Comparator|Group B (PENG block)|Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees
33055096|NCT05772520|Experimental|Cohort 1|TLL018 tables, 10 mg 1piece,BID
33055097|NCT05772520|Experimental|Cohort 2|TLL018 tables, 20 mg 1piece,BID
33055098|NCT05772520|Experimental|Cohort 3|TLL018 tables, 40 mg 1piece,BID
33055099|NCT05772520|Placebo Comparator|Cohort 4|placebo, 1piece,BID
33055100|NCT05772507|Experimental|medical device under investigation|URGO AWC_008 or URGO AWC_022 dressing. These 2 dressings are similar and only the adhesive constitutes a difference. The choice of study dressing will be left to the discretion of the investigator during the treatment of the patient, depending on the nature of the wound and the condition of the peri-wound skin.
33055101|NCT05772494|Experimental|Assessment of activity limitation|Assessment and analysis of activity limitation by occupational therapist using 2 registered instruments (SDO and DOA).
33055102|NCT05772494|Active Comparator|Control group: treatment as usual|Assessment of activity limitations according to usual routines
33055103|NCT05772481||Adult population with rectal cancer|
33055104|NCT05772468|Experimental|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, and a headphone. The application VRelax will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
33055105|NCT05772468|No Intervention|Care as usual (control group/group 2)|The control group (group 2), also known as the care as usual group, receives the standard procedure during wound care without 'VRelax' VR system.
33055106|NCT05772455|Experimental|XZB-0004|
33055107|NCT05772429||Epidyolex|Participants will receive Epidyolex in accordance with their routine clinical practice as prescribed by their physician.
33055108|NCT05772390|Experimental|Treatment arm|partial breast re-irradiation in patients with local recurrence of breast cancer, previously treated with breast conservative surgery and whole breast radiotherapy. A total dose of 35 Gy in 10 daily fractions, 5 fractions per week, will be prescribed.
33055109|NCT05772377|Experimental|Anlotinib+TP then CCRT+Anlotinib|Induction regimen:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles Paclitaxel 175mg/m2 intravenous injection for 3 hours, d1；Cisplatin 75mg/m2, iv, divided into 3 days, q3w;Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;21 days as a cycle, a total of 2 cycles;Treatment programs:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles;Cisplatin: 30-35 mg/m2, iv, d1, qw, 5 consecutive cycles;Pelvic external radiation therapy: once a day, 1.8-2 Gy/time, 5 days a week, for 5 consecutive weeks, a total of 45-50 Gy;sequential;High dose rate intracavitary radiotherapy: 6 Gy/time, twice a week, 5 consecutive times, a total of 30 Gy/2.5 weeks, bioequivalent dose of 40 Gy sequential Taxane drugs: including but not limited to paclitaxel, nab-paclitaxel, paclitaxel liposome, etc. The dosage regimen is determined by the investigator;Cisplatin 75mg/m2, iv, divided into 3 days, q3w; Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;2 cycles
33055110|NCT05772364|Experimental|Water loading phase 1|Participants drink 1.5 L of the designated water
33055111|NCT05772364|Experimental|Water loading phase 2|Participants drink 1.5 L of the designated water
33055112|NCT05772351|Experimental|Experimental group|Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery
33055113|NCT05772351|No Intervention|Control group|Patients of the control group received a tablet containing starch.
33055114|NCT05772286|Experimental|763SIP8/MPLA-5 vaccine|Intramuscular injection of 100 μg of 763SIP8 protein adjuvanted with 500 μg MPLA liposomes will be administrated 4 times (day 0, week 8, week 24 and week 48).
33055115|NCT05772273|Experimental|Camrelizumab, Azacitidine and low-dose Donor lymphocyte infusion|Patients are given azacytidine for 7 days, followed by 4 DLI treatments on Days 10, 17, 24 and 31, with the dose of DLI and Camrelizumab adjusted according to the donor source. Camrelizumab infusions were given 3 hours after completion of the 1st and 3rd DLIs, respectively.
33055116|NCT05772260||Patients with autonomic dysfunction|Achalasia patients who have autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
33418998|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
33055117|NCT05772260||Patients with normal autonomic function|Achalasia patients without autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
33055118|NCT05772247||PS application|
33055119|NCT05772247||non-PS application|
33055120|NCT05772234|Experimental|Aggressive hydration group|Periprocedural hydration with intravenous 20 mL/kg lactated Ringer's solution within 60 min from the start of ESWL (first shockwave delivered), directly followed by 3 mL/kg per h for 8 h.
33055121|NCT05772234|Active Comparator|Restricted hydration group|Periprocedural hydration with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
33055122|NCT05772221|Other|Interviewer-Administered|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
33055123|NCT05772208|Experimental|the combination of camrelizumab and standard treatment|camrelizumab 200mg q3w 2 cycle combinted with the second and third cycle neoajuvant chemotherapy and camrelizumab 200mg q3w 8 cycle starting one month after concurrent chemo-radiotherapy.
33055124|NCT05772208|Experimental|the combination of nimotuzumab and standard treatment|nimotuzumab 200mg qw combined with the second and third cycle neoajuvant chemotherapy and nimotuzumab 200mg qw used during chemo-radiotherapy.
33055125|NCT05772208|Active Comparator|standard treatment|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
33333108|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
33333109|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
33333110|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
33333111|NCT02278120|Experimental|Ribociclib (LEE011) + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
33055126|NCT05772195||Before major system reorganisation|Theme 1 - elective recovery plan 2017/18-2019/20
33055127|NCT05772195||Before major system reorganisation - intra-pandemic|Theme 1 - elective recovery plan 2020/21-2021/22
33055128|NCT05772195||Post system reorganisation|Theme 1 - elective recovery plan 2023/24 and 2024/25
33055129|NCT05772182||Groups/Cohorts|Patients undergoing intervention for arrhythmia (electrophysiologic study and/or intracardiac device implantation) with clinical indication
33333112|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
33055130|NCT05772169|Experimental|Mifepristone 300 mg|Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive 600 mg mifepristone for 24 weeks.
33055131|NCT05772169|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive placebo for 24 weeks.
33055132|NCT05772156|Experimental|Prophylactic methylergonovine|Prophylactic methylergonovine 200mcg IM
33055133|NCT05772156|Placebo Comparator|Control group/placebo|Matching placebo
33333113|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
33333114|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
33333115|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
33333116|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333117|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
33333118|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333119|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33333120|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
33333121|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
32740427|NCT05727371|Experimental|RegenMatrix-PRP-XLHA|Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
33055134|NCT05772143||Lumbar disc herniation|Patient over 18 years of age suffering from radiculalgia related to lumbar disc herniation visualized on MRI with radio-clinical concordance, failure of conservative treatment and nerve root infiltrations
33055135|NCT05772130|Active Comparator|Arm I (usual care)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives on study.
33333122|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333123|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
33333124|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333125|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
33333126|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
33333127|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
33333128|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333129|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33333130|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33055136|NCT05772130|Experimental|Arm II (provider-mediated contact)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives and relatives also receive provider-mediated contact to discuss genetic results on study.
33055137|NCT05772117|Experimental|Intervention|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
33055138|NCT05772117|Active Comparator|Control|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
33055139|NCT05772104|Experimental|Experimental: Shugan Jieyu Capsules|Participants received Shugan Jieyu Capsules 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
33055140|NCT05772104|Experimental|Experimental: Shugan Jieyu Capsules+Placepo|Participants received Shugan Jieyu Capsules 3 capsules + Placebo 1 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
33055141|NCT05772104|Placebo Comparator|Experimental: Placebo|Participants received placebo 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
33055142|NCT05772078||Compliers|Attending to SPT every 4-6 months
33055143|NCT05772078||Erratic compliers|Attending to SPT once a year or sporadically
33055144|NCT05772078||Non compliers|Non-attenders to SPT
33055145|NCT05772065|Active Comparator|CDC/NTCA guidelines only|The control group will have a link to US guidelines only and use it as a resource to answer the case vignettes.
33055146|NCT05772065|Experimental|LTBI ASSIST and CDC/NTCA guidelines|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool as resources to answer the case vignettes.
33055147|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at Baseline|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
33055148|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at 6 months|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
33055149|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at 12 months|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
33055150|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at baseline|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
33333131|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
33055151|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 6 months|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
33055152|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 12 months|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
33055153|NCT05772026||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
33055154|NCT05772026||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
33055155|NCT05772013|Active Comparator|Continuous azithromycin|Participants in this arm will continue with their standard of care (i.e. continuous dose of azithromycin according to their standard prescription) throughout the trial.
33055156|NCT05772013|Other|Seasonal azithromycin|"Azithromycin will be taken by participants during the autumn-winter (October - March).~Matched placebo will be taken by the participants in the spring-summer (April - September)."
33055157|NCT05772013|Placebo Comparator|Complete Discontinuation of azithromycin|Participants will take continuous matched placebo throughout the trial.
33055158|NCT05771987|Experimental|HCM patients with LVOT obstruction|Patients with obstructive HCM are considered for this study if 1) symptomatic, 2) refractory to optimized medical therapy and 3) not or poorly* eligible for septal myectomy or with an indication to implant a pacing device (pacemaker or ICD) independent on the ventricular obstruction.
33055159|NCT05771935|Experimental|(Group R)|receive radial artery cannulation using ultrasound
33055160|NCT05771935|Active Comparator|(Group U)|receive ulnar artery cannulation using ultrasound
33333132|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
33333133|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
33055161|NCT05771909|Experimental|NeurodigitX|"After randomization, the NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day).~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
33055162|NCT05771909|Other|Control|"After randomization, the Control Group does not receive the NeurodigitX application.~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
33333134|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
33055163|NCT05771896|Experimental|Darolutamide with Radium-223|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Radium-223:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
33055164|NCT05771896|Placebo Comparator|Darolutamide with Placebo|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Placebo:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
33333135|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
33333136|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
33333137|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
33055165|NCT05771883|Experimental|DLBCL and other B-NHL patients such as FL, MZL, MCL, etc.|"In this study, lenalidomide was administered at a fixed dose, in which 25 mg was used for DLBCL patients,and 20mg was used for other B-NHL patients such as FL, MZL, MCL, etc. and daily oral therapy with IMM0306 was used on the 1~21st day of each repeat 28-day cycle.~The RP2D of the IMM0306 monotherapy trial was administered once a week (7 days ± 1 day) for intravenous infusion every 4 weeks"
33333138|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
33333139|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
33333140|NCT01286272|Experimental|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
33333141|NCT01286272|Experimental|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
33333142|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33111917|NCT05072132|Experimental|Inefficient metabolizers|Participants will be selected based on being inefficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are inefficient metabolizers and at increased risk for arsenic toxicities).
33111918|NCT05072132|Experimental|Efficient metabolizers|Participants will be selected based on being efficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are efficient metabolizers and at decreased risk for arsenic toxicities).
33111919|NCT05072132|Active Comparator|Control group|The control group will consist of a random sample of HEALS participants. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. No information on arsenic metabolism efficiency will be provided during the study period (option to receive after the study)
33111920|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
33111921|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
33111922|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
33111923|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
33111924|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
33111925|NCT00559806|Experimental|1|9 healthy elderly males
33333143|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33418999|NCT05590377|Experimental|Phase 1 Dose Escalation|Modakafusp alfa 60 to 240 mg, infusion, intravenously, once every 4 weeks (Q4W) with daratumumab 1800 mg, subcutaneously (SC), once weekly (QW) in Cycles 1 and 2, twice weekly (Q2W) in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
33111926|NCT00559806|Experimental|2|11 healthy young males
33111927|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
33111928|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
33111929|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
33111930|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
33111931|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
33111932|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
33111933|NCT04647201||Control|Non-sepsis and non-GI adults
33111934|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
33111935|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
33111936|NCT00544856|Experimental|1|cognitive intervention
33111937|NCT00544856|Placebo Comparator|2|
33111938|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
33333144|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333145|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33111939|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
33111940|NCT04647045|Active Comparator|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
33111941|NCT04647045|Other|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
33111942|NCT00544934|Experimental|250 mg|
33111943|NCT00544934|Experimental|500 mg|
33111944|NCT00544934|Experimental|750 mg|
33111945|NCT00544934|Placebo Comparator|Placebo|
33111946|NCT04638348|Experimental|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
33111947|NCT04638348|Active Comparator|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
33111948|NCT04638348|Active Comparator|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
33111949|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
33111950|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
33111951|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
33111952|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
33111953|NCT00545090|Experimental|1|
33419000|NCT05590377|Experimental|Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab|Modakafusp alfa at dose level 1 (DL1) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
33419001|NCT05590377|Experimental|Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab|Modakafusp alfa at dose level 2 (DL2) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
33419002|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
33419003|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
33419004|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
33419005|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
33419006|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
33419007|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
33419008|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
32740428|NCT05727371|Active Comparator|Hylan G-F 20|Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
33055166|NCT05771870|Experimental|Peer mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Throughout all clinical practice days, mentors chosen from graduate students followed the students in the peer mentorship group during the medication preparation and administration processes, providing feedback on their positive, negative, or inadequacies.
33055167|NCT05771870|Experimental|Nurse mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Mentors from the clinical nursing community attended the students in the nurse mentoring group during the drug preparation and administration processes and provided feedback on their positive, negative, or inadequacies.
33055168|NCT05771844|Experimental|Deep Sleep Enhancement with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
33055169|NCT05771831|Experimental|Thrombosomes®|Thrombosomes® (TBX®) up to 3 doses
33055170|NCT05771831|Active Comparator|Standard platelet concentrate|Standard platelet concentrate up to 3 doses
33055171|NCT05771818|Experimental|Falls Prevention training|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session consists of falls strategies and walking and balance exercises. Each session lasts approximately 1.5 hours
33055172|NCT05771805|Experimental|Vagus nerve stimulation with task oriented training|Vagus nerve stimulation with task oriented training
33055173|NCT05771805|Active Comparator|Task oriented training|Task oriented training alone
33055174|NCT05771792|Experimental|eccentric exercise group|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP The modified exercise group will perform 6 exercises
33055175|NCT05771792|Active Comparator|control group|CONVENTIONAL EXERCISES PROGRAM GROUP The conventional exercises program will perform conventional exercises.
33055176|NCT05771779|Experimental|Arm A: Oral Cholera Vaccine (OCV) only|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28. Two doses of MR vaccine will be given on day 56 and day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 56, Day 84 and Day 264 . All details will be recorded in the eCRF.
33055177|NCT05771779|Experimental|Arm B: Typhoid Conjugate Vaccine (TCV) only|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 84 and Day 264 . All details will be recorded in the eCRF.
33055178|NCT05771779|Experimental|Arm C: Measles and Rubella (MR) only|Based on randomization (n= 250) Potential participants will be vaccinated with MR on Day 0 and Day 180. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
33055179|NCT05771779|Experimental|Arm D: Co-administration of Measles and Rubella (MR) and Typhoid Conjugate Vaccine (TCV)|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
33055180|NCT05771779|Experimental|Arm E: Co-administration of Measles and Rubella (MR) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28 . Two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 and Day 208 . All details will be recorded in the eCRF.
33419009|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
33419010|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
33419011|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
33419012|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
33419013|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
33419014|NCT02113904|Experimental|Adalimumab|
33055181|NCT05771779|Experimental|Arm F: Co-administration of Typhoid Conjugate Vaccine (TCV) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with TCV on Day 0 . Two doses of OCV vaccine will be given on Day 0 and Day 28. Also two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 , Day 84 and Day 264 . All details will be recorded in the eCRF.
33055182|NCT05771766|Experimental|Postural Drainage with Aerobic Training|The intervention group will undergo Postural Drainage and additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include a 5-step stair-climbing and 10-step walk during each session.
33333146|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333147|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333148|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333149|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333150|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333151|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
33333152|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
33333153|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33055183|NCT05771766|Active Comparator|Postural Drainage|the group will receive postural drainage as baseline treatment thrice a week for two weeks.
33055184|NCT05771753|Experimental|Stretching Exercises|6 stretching exercise for 8 weeks
33055185|NCT05771753|Experimental|Dynamic core stabilizing exercises|6 strengthening exercises for 8 weeks
33055186|NCT05771740||Pulmonary Fibrosis Patient|Participants under the clinical care of the interstitial lung disease team at the Royal Devon University Healthcare NHS Trust, UK
33055187|NCT05771740||Healthy Control|Healthy participants visiting the Royal Devon University Healthcare NHS Trust, UK
33055188|NCT05771727||Parents of children with pediatric neuromuscular diseases|Parents of a total of 169 children with pediatric neuromuscular diseases, including 63 Duchnenne Muscular Dystrophy, 53 Spinal Muscular Atrophy and 18 other pediatric neuromuscular diseases (Congenital Muscular Dystrophy, Hereditary Motor and Sensory Neuropathy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, etc.) were included in the study
33055189|NCT05771714|Experimental|individuals ages 14 years and older|This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
33055190|NCT05771714|Experimental|individuals aged 2 to 13 years|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
33055191|NCT05771701|Experimental|Lateral epicondylitis patients|Patients that are diagnosed with lateral epicondylitis.
33055192|NCT05771688|Experimental|FETO therapy|FETO therapy
33055193|NCT05771675|Experimental|Simvastatin|Participants receive Simvastatin 40mg capsule once daily for 6 months.
33055194|NCT05771675|Placebo Comparator|Placebo|Participants receive Placebo capsule matching Simvastatin once daily for 6 months.
33111954|NCT04638543|Experimental|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
33111955|NCT04638543|Placebo Comparator|Placebo|
33111956|NCT00545207|Experimental|1|
33111957|NCT00545207|Placebo Comparator|2|
33333154|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
33333155|NCT03735914|Experimental|neuralgic patients|MRI experimentation
33333156|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
33333157|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
33333158|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
33419015|NCT05703633|Experimental|uDCD arm|Patients enroled in the study will receive a kidney from a uDCD donor, after the kidney has been subjected to a reconditioning procedure, preventing ischemia/reperfusion-injury, confirming large animal data using the same protocol.
33419016|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
33419017|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
33419018|NCT05462223|Experimental|Alucent VRS for Treatment of Atherosclerotic Lesions|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~VRS Light Fiber~VRS Light Source"
33419019|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
33419020|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
33419021|NCT05459805|Experimental|group 1|those receive ICS/LABA plus traditional Chinese medicine
33419022|NCT05459805|Active Comparator|group 2|those receive ICS/LABA alone
33419023|NCT02119208|Experimental|Lifestyle counseling|
33419024|NCT05613777|Experimental|Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)|
32740429|NCT05727371|Placebo Comparator|Placebo|Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)
33055195|NCT05771636|Experimental|Experimental G1 - imagery of planned activity|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified and think about the major obstacle that could prevent him to do each activity, and a solution for each one. Then he will proceed to a mental imagery exercise where he imagines doing the activity as vividly as possible. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
33055196|NCT05771636|Experimental|Experimental G2 - imagery of best possible self|In this condition, the participant will first have to do a mental imagery exercise where he imagines his best possible self, having accomplished all his big life goals, as vividly as possible. He will then have to think about 4 activities he will plan to do during the next 2 weeks, in line with the imagery exercise. He will then complete a questionnaire about all the activities he identified. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
33055197|NCT05771636|Active Comparator|Control G3 - activity planification alone|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified. There is no mental imagery exercise in this condition. He then will proceed to go home and receive the assignment to do the planned activities in the course of the next two weeks. He will report in a booklet ratings of the activities he did.
33055198|NCT05771623|Experimental|Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar|"The study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.~Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session."
33055199|NCT05771623|Active Comparator|Traditional physical therapy for postburn hypertrophic scar|This group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy).
33055200|NCT05771597|Experimental|Home Biofeedback Therapy (HBT)|"HBT for patients with constipation and dyssynergic defecation:~HBT for patients with FI~HBT for patients with UI~All patients will be advised to practice HBT at least once or twice a day for six weeks."
33055201|NCT05771597|Active Comparator|Office Biofeedback Therapy (OBT)|"OBT for patients with constipation and dyssynergic defecation.~OBT for patients with FI.~OBT for patients with UI.~All patients will receive office biofeedback, once weekly, over six weeks."
33055202|NCT05771584|Experimental|Total 300 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 3 cycles in total)
33055203|NCT05771584|Experimental|Total 600 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 6 cycles in total)
33055204|NCT05771558|Experimental|Tailored Lighting Intervention (TLI)|"The TLI will be performed for 2 hours each day over an 8-week period~During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days"
33055205|NCT05771545||Pre-Innovation (Usual Care)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the year prior to the innovation in care. During this period, the attending psychiatrist was required to physically come to the hospital to examine the patient.
33055206|NCT05771545||Innovation (Tele-Psychiatry)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the innovation period. Instead of physically coming to the hospital, the attending physician will evaluate the patient via video-link, which will be facilitated by the on-site psychiatric resident.
33111958|NCT04647006|Other|Conventional Thyroidectomy|Conventional Thyroidectomy
33419025|NCT04909957||Absence of invaded lymph node after extensive lymph node dissection|Absence of invaded lymph node after extensive lymph node dissection
33419026|NCT04909957||Presence of invaded lymph node after extensive lymph node dissection|Presence of invaded lymph node after extensive lymph node dissection
33419027|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
33419028|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
33419029|NCT05438979|Placebo Comparator|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
33055207|NCT05771532|Experimental|The experimental group|"The experimental group (n=33) received a gender-sensitive and transtheoretical model (TTM)-based sexual health education program, which includes a 10-15-minute individual sexual health education and a sexual health pamphlet. The TTM-based sexual health education program was performed by a nurse educator with more than one year of clinical experience in gynecological nursing, who received formal training through enrollment in a course entitled  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
33055208|NCT05771532|No Intervention|The control group|"The control group (n=30) received a 10-15-minute routine sexual health education and a sexual health pamphlet without a gender-sensitive and theoretically based design. Both were provided by nursing staff with no formal training in  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
33333159|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
33333160|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
33333161|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
33055209|NCT05771506||COPD Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
33055210|NCT05771506||Control Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
33333162|NCT05665946||AIN patients|Surgical verified AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
33333163|NCT05665946||Controls.|Non-AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
33055211|NCT05771480|Experimental|Durvalumab + Gemcitabine based chemotherapy|"Participants will receive durvalumab 1500 mg as a 60-minute IV infusion in the first cycle (Day 1) and as a 30 -minute IV infusion in the following cycles, in combination with background gemcitabine-based chemotherapy every three or two weeks for up to a maximum of 8 cycles.~Upon completing 8 cycles of background gemcitabine-chemotherapy, or after discontinuing any of the combination chemotherapies due to toxicity before completing 8 cycles, participants are eligible to continue receiving durvalumab 1500 mg IV every 4 weeks either alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), as per investigator's discretion."
33333164|NCT03639818|Experimental|experimental group|HIV patients
33333165|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
33333166|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
33333167|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
33419030|NCT05438979|Active Comparator|Calcium Fructoborate|Calcium Fructoborate (CFB), is a proprietary, safe generally-recognized-as-safe (GRAS) supplement. The only content of the supplement is CFB - there are no excipients, binders, or flow agents, nor are there any other materials. 216mg of CFB will be administered daily for 90 days.
33055212|NCT05771454||Prophylactic risk reducing mastectomy|"Patients who underwent genetic testing and came out positive for BRCA and other genes of breast cancer; afterwards opted for prophylactic risk-reducing mastectomy.~After mastectomy, the specimens will be assessed for the presence of occult breast cancers in removed specimens. Histopathology is set as gold standard for occult breast cancer confirmation."
33419031|NCT04987255|Active Comparator|Free visit|Free visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
33419032|NCT04987255|Experimental|Guided visit|Guided visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
33055213|NCT05771441|Active Comparator|neck stabilization exercise (NSE)|the patients who had NSE
33055214|NCT05771441|Active Comparator|NSE + HOT PACK THERAPY|the patients who had NSE+ hot pack
33055215|NCT05771441|Active Comparator|NSE + infrared therapy|the patients who had NSE+ infrared therapy
33055216|NCT05771441|Active Comparator|NSE + ultrasound therapy|the patients who had NSE+ ultrasound therapy
33055217|NCT05771428|Experimental|ABBV-552 Dose A|Participants will receive ABBV-552 Dose A once daily (QD) for 12 weeks.
33055218|NCT05771428|Experimental|ABBV-552 Dose B|Participants will receive ABBV-552 Dose B QD for 12 weeks.
33055219|NCT05771428|Experimental|ABBV-552 Dose C|Participants will receive ABBV-552 Dose C QD for 12 weeks.
33055220|NCT05771428|Placebo Comparator|Placebo for ABBV-552|Participants will receive placebo for ABBV-552 QD for 12 weeks.
33055223|NCT05771402|Experimental|Group 1|NAs combined with anti-PD-1 antibody and Peg-IFNα
33055224|NCT05771402|Active Comparator|Group 2|NAs combined with Peg-IFNα
33055225|NCT05771376|Experimental|Study Group|Patients who performed Qigong exercise program and conventional exercise program
33055226|NCT05771376|Experimental|Control Group|Patients who performed a conventional exercise program
33055227|NCT05771350|Experimental|online hemodiafiltration|
33055228|NCT05771350|Active Comparator|high flux hemodialysis|
33055229|NCT05771350|Active Comparator|low flux hemodialysis|
33055230|NCT05771337||breast cancer leasion|
33055231|NCT05771337||benign breast lesion|
33055232|NCT05771324|Experimental|Baby-Led Weaning (BLW)|The group named for infants who received complementary feeding education with the BLW method and who were fed with the BLW method.
33055233|NCT05771324|Experimental|Traditional Complementary Feeding (TCF)|The group named for infants who received complementary nutrition education with the TCF method and who were fed with the TCF method.
32740430|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
33333168|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
33333169|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
33333170|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
33333171|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
33333172|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
33333173|NCT05491642|Experimental|Up-titration Scheme 1|Participants will receive 12 days treatment in total.
33333174|NCT05491642|Experimental|Up-titration Scheme 2|Participants will receive 12 days treatment in total.
33333175|NCT05491642|Experimental|Up-titration Scheme 3|Participants will receive 12 days treatment in total.
33333176|NCT05491174|Experimental|DBT-Informed Intervention|The DBT-informed group intervention, known as the 'Managing Emotions Group', will consist of 90-minute sessions, run weekly over 10 weeks.
33333177|NCT05491174|No Intervention|Wait-list control|Participants will be placed on a wait-list for up to 18 weeks.
33333178|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
33333179|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
33055234|NCT05771311|Active Comparator|Potassium Titanyle Phosphate (KTP) Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
33055235|NCT05771311|Active Comparator|Pulsed Dye Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
33055236|NCT05771298|Other|Potassium Titanyle Phosphate (KTP) Laser|Subjects will be treated with a KTP laser in 1 - 3 sessions at intervals of 4 - 6 weeks.
33055237|NCT05771298|Other|Pulsed Dye Laser|Subjects will be treated with a PDL in 1 - 3 sessions at intervals of 4 - 6 weeks.
33333180|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
33333181|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
33333182|NCT00310180|Experimental|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
33333183|NCT00310180|Experimental|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
33055238|NCT05771285|Active Comparator|Group with two-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for two minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
33055239|NCT05771285|Active Comparator|Group with five-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for five minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
33419033|NCT04987255|Other|Guided visit for individuals after stroke|This arm is specific for individuals with motor disability after stroke (non randomized condition)
33419034|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
33055240|NCT05771285|No Intervention|Control group|Without applying any tools or processes, the low molecular weight heparin injection was applied in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
33055241|NCT05771272|Other|Elite Rowers|They are young men rowers aged between 16-18 years, rowing age of at least 2 years, and continuing to row sport actively.
33055242|NCT05771259||Group A|Participants who didn't undergo body contouring surgery after bariatric surgery.
33055243|NCT05771259||Group B|Participants who underwent body contouring surgery after bariatric surgery.
33055245|NCT05771233|Experimental|Prevention|The group will consist of 20 participants (6 classical dancers, 4 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will be divided into groups according to their specialties, with a one-hour session per week for 7 weeks of physical exercise to strengthen core muscles and lumbo-pelvic stability.
33055246|NCT05771233|No Intervention|Control|The experimental group will consist of 20 participants (4 classical dancers, 6 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will not receive any strength training. They will be evaluated at the beginning and at the end of the study to compare the physical conditions of the participants of this group with those of the experimental group.
33055247|NCT05771220|Experimental|ESWT+ traditional physical therapy treatment|ESWT+ traditional physical therapy treatment
33055248|NCT05771220|Placebo Comparator|Placebo shockwave + traditional physical therapy treatment|Placebo shockwave + traditional physical therapy treatment
33055249|NCT05771207|Experimental|soy protein intervention|This group received dietary guidance and soy protein intervention for 3 months
33333184|NCT00310180|Active Comparator|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
33333185|NCT00310180|Experimental|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
33333186|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
33055250|NCT05771207|Experimental|whey protein intervention|This group received dietary guidance and whey protein intervention for 3 months
33055251|NCT05771207|Placebo Comparator|control|This group received dietary guidance and ｍltodextrin for 3 months
33055252|NCT05771194|Experimental|group A|Group A received conventional preoperative and postoperative anti-infective therapy.
33055253|NCT05771194|Active Comparator|group B|On the basis of group A,Group B was given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery, and one cleaning, hot compresses and massage of the meibomian gland.
33055254|NCT05771181|Experimental|Vitamin E in combination with Fuquinitinib and Tislelizumab|Patients will be treated with Vitamin E, Fuquinitinib and Tislelizumab.
33055255|NCT05771168||AUS|Male patients undergoing surgery for stress urinary incontinence using artificial urinary sphincter (AUS)
33055256|NCT05771168||Sling|Male patients undergoing surgery for stress urinary incontinence using slings
33055257|NCT05771155|Experimental|PB016 (300 mg IV)|PB016 will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
33055258|NCT05771155|Active Comparator|Entyvio® (300 mg IV)|Entyvio® will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
33055259|NCT05771142||Smart t-shirt, ECG Holter and smartwatch patients|24h ECG Monitoring - All participants will wear the smart t-shirt, the ECG Holter and the smartwatch at the same time
33055260|NCT05771129|Experimental|Pulsed Electric Field Ablation System was used in treating chronic bronchitis|All participants meet inclusion and exclusion criteria and signed the ICF will be enrolled to experimental arm.
33055261|NCT05771103|Active Comparator|Stellate ganglion block with alcohol injection|Stellate ganglion block with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.
33055262|NCT05771103|Active Comparator|thermal RF neurolysis of Stellate ganglion|Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance
33055263|NCT05771090|Experimental|Study arm|Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
33055264|NCT05771077|Experimental|patients have White spot lesions|White spot lesions (WSLs) are defined as enamel surface and subsurface demineralization, without cavitation. These manifestations represent the first clinical observation of the progression of dental caries, with the possibility of being reversed
33055265|NCT05771064|Experimental|Gentle Moves|Three-month physical activity intervention.
33055266|NCT05771064|No Intervention|Usual Care|Usual care provided by neuropsychologist.
33055267|NCT05771051||Concussed|Diagnosis of concussion
33055268|NCT05771051||Controls|Athletes with no concussion with the preceding year
33055269|NCT05771038|Active Comparator|sodium alendronate group|prepared sodium alendronate gel will be placed in defective extraction sockets.
33055270|NCT05771038|Active Comparator|stickybone group|20cc of venous blood is collected from the patient's forearm into silica-coated tube (10 ml) and 1 non coated vacutainer. Blood will be used to make injectable prf by spinning in centrifuge(2400-2700) for 2 minutes to produce autologous fibrin glue and then for 12 minutes+/- 2 minutes to obtain the concentrated growth factor layer. and sticky bone will be prepared then inserted into the socket.
33055271|NCT05771025|Experimental|Hepatectomy group|Patients in the hepatectomy group receive hepatectomy, which could be combined with radiotherapy and chemotherapy for the primary tumor during the perioperative period.
33055272|NCT05771012|Experimental|group A|patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc) twice daily for 6 months.
33055273|NCT05771012|Active Comparator|group B|patients receive mini-Monoka stent insertion in the lower canaliculus for 6 months.
33055274|NCT05770999|Experimental|Lavender massage|A mixture of 20 cc of sweet almond oil and 1 cc of lavender oil will be used. Sweet almond oil has been used to dilute lavender oil. lavender massage lasted about 10 minutes.
33055275|NCT05770999|Experimental|Lavender bath|A mixture of 20 cc bath water and 1 cc lavender oil will be used. lavender bath lasted about 10 minutes.
33055276|NCT05770999|No Intervention|Control group|The newborns in the control group did not receive any treatment other than their clinical routines (vital signs monitoring, skin care with sunflower oil, eye and mouth care, changing diapers, changing bed linen, feeding and clinical treatments).
33055277|NCT05770986|Experimental|Group A ( power's group)|Patients will receive the eight phases of the power's program plus a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
33055278|NCT05770986|Active Comparator|Group B ( control)|Patients will receive a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
33055279|NCT05770973|Active Comparator|Compression dressing|Randomized, eyes were patched with a compression dressing after surgery.
33055280|NCT05770973|No Intervention|No Compression dressing|Randomized, eyes were not patched with a dressing.
33333187|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
33333188|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
33333189|NCT03963219|Experimental|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
33333190|NCT03963219|Active Comparator|Standard Bolus Calculator|Standard bolus calculator
33333191|NCT01085877|Active Comparator|Trial part 1|
33333192|NCT01085877|Experimental|Trial part 2|
33333193|NCT01089855|Experimental|Carbamazepine|
33333194|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
33333195|NCT04712656||OSA Subjects Treated with CPAP|Patients with moderate to severe OSA (ODI4>15/h) who accept CPAP therapy.
33333196|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
33055281|NCT05770960|Active Comparator|Naloxegol - Codeine phosphate|Participants will receive Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
33055282|NCT05770960|Other|Placebo - Codeine phosphate|Participants will receive Placebo instaid of Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
33055283|NCT05770960|Other|Naloxegol - Placebo|Participants will receive Naloxegol 25 mg and Sirupus simplex syrup (as a placebo alternative for Codeine syrup) in 30 mL and an additional 15 mL at a later stage during the day.
33055284|NCT05770947|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for adolescents with higher weight seeking treatment for bulimia nervosa (CBT-BNh).Designed for adolescents, CBT-BNh will include psychoeducation, cognitive restructuring, and relapse prevention planning. The focus of therapy will include reducing extreme/unhealthy weight-control behaviors (purging) as well as binge eating, and self-compassion coping skills will address weight stigma and self-directed weight criticism.
33055285|NCT05770947|Active Comparator|Mindfulness|Learning to Breathe (L2B) is an existing, evidence-based program for adolescents that teaches mindfulness skills each week, including time to practice and reflect. the skills are grouped into six themes: Body, Reflections, Emotions, Attention, Tenderness, Habits, and Empowerment.
33055286|NCT05770934|Experimental|home-based BFRE|"Patients in the home-based BFRE group will be carefully instructed in how to perform the exercise program with four weekly sessions for 12 weeks (48 training sessions within an 84-day period). Each session will consist of one lower-limb resistance training exercise: sit-to-stand from a ~43 cm high chair. The exercise will consist of four rounds interspaced by a 30-seconds rest pause. The first, second, and third round will consist of 30, 15, 15 repetitions, while the fourth round will be performed until volitional fatigue. The patients will be instructed to perform both the eccentric and concentric contractions at a steady 2-sec pace with, preferably, no time for relaxation in the transition from eccentric to concentric phase (i.e. the bottom is only kissing the chair before reversing the movement upwards). When a patient can perform more than 25 repetitions in the last round, they are encouraged to add external resistance corresponding to around 5 kg."
33055287|NCT05770934|No Intervention|Control Group|Patients in the control group will performed the same tests 12 months after surgery and 15 months after surgery as the intervention home-based BFRE group.
33055288|NCT05770921|Experimental|Non-randomized|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
33055289|NCT05770908|Experimental|Multimedia animation videos plus paper-based therapeutic exercise program|
33055290|NCT05770908|Active Comparator|Paper-based therapeutic exercise program|
33055291|NCT05770895|Experimental|Cohort 1: GS-2829 Dose A or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829.
33055292|NCT05770895|Experimental|Cohort 2: GS-6779 Dose B or Placebo|Healthy participants will receive GS-6779 Dose B or placebo for GS-6779.
33055293|NCT05770895|Experimental|Cohort 3: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
33055294|NCT05770895|Experimental|Cohort 4: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
33055295|NCT05770895|Experimental|Cohort 5: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
33055296|NCT05770895|Experimental|Cohort 6: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
33055297|NCT05770895|Experimental|Cohort 7: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with CHB who are viremic will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
33055298|NCT05770882|Experimental|Part I safety; and Part II cohort expansion|"Part I: The safety of drug combination will be studied.~Part II: The drug combination will be further evaluated in the cohort expansion phase."
33068119|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
33333197|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
33333198|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
33333199|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
33333200|NCT04692922||Patients with disorders of consciousness|patients with a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
32740431|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
32740432|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
33361304|NCT03920605|Active Comparator|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
32740433|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
33055299|NCT05770869|Experimental|ALIBIRD mHealth platform|Participants are followed-up using the ALIBIRD mHealth platform. The ALIBIRD platform is made up of a mobile application for patients and a web application for the healthcare team. Through the ALIBIRD mobile application, patients regularly register Patients Reported Outcomes (PROs) and Patients Reported Outcome Measures (PROMs) regarding lifestyle (diet, physical activity, sleep, mood), and get access to individualized recommendations in order to assume more responsibility for achieving the best outcomes from their care. Moreover, the patient application includes features for tracking the appearance of symptoms, with alerts sent to the healthcare team in response to these parameters. In addition, the application contains articles and educational information.
32740434|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
32740435|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
32740436|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
32740437|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
32740438|NCT05727215|Experimental|Primary dose of inactivated (Sinovac®) vaccine|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
32740439|NCT02721875|Experimental|Volasertib monotherapy|
32740440|NCT02721875|Experimental|Volasertib + azacitidine combination|
33055300|NCT05770856||Trauma related infection|
33055301|NCT05770830||Esophageal temperature|Esophageal temperature
33055302|NCT05770830||Skin core temperature|Skin core temperature
33055303|NCT05770583|Active Comparator|Control group|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95<oxygen saturation≤%98
33055304|NCT05770583|Experimental|ORi+SpO2 (oxygen saturation) group|"FiO2 will be titrated by reducing 10% if Ori>0.01 andSpO2 ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95<oxygen saturation≤%98~FiO2 will be increased by 10% if oxygen saturation <95 or PaO2<60 mmHg"
33055305|NCT05769946|Placebo Comparator|placebo|Atopic dermatitis patients treated with placebo for 12 week.
33055306|NCT05769946|Experimental|Hemay005 60mg|Atopic dermatitis patients treated with Hemay005 60mg BID for 12 week.
33055307|NCT05769946|Experimental|Hemay006 75mg|Atopic dermatitis patients treated with Hemay005 75mg BID for 12 week.
33055308|NCT05769764||Cohort 1: NSCLC|Participants with NSCLC will be included in this cohort if they do not meet requirements for inclusion in Cohorts 2-4.
33055309|NCT05769764||Cohort 2: EGFR-mutated (EGFRm) NSCLC Previously Treated With a 3rd Generation EGFR TKI|Participants with EGFR-mutated (EGFRm) NSCLC previously treated with a 3rd generation tyrosine kinase inhibitor (TKI) with matched samples.
33055310|NCT05769764||Cohort 3: ALK+ NSCLC|Participants with ALK+ NSCLC with matched samples.
33055311|NCT05769764||Cohort 4: NSCLC Harboring a KRAS p.G12C Mutation or EGFR Exon 20 Insertion|Participants with NSCLC harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation or EGFR exon 20 insertion.
33055312|NCT05769465||Patients treated with nusinersen|
33055313|NCT05769465||Patients treated with risdiplam|
33055314|NCT05769465||Patients treated with onasemnogene abeparvovec|
33055315|NCT05769465||Patients naive from disease modifying treatments|
33055316|NCT05769257|Experimental|Single Arm|Single Arm Safety and Feasibility Study of IS-001 with 20 mg in Multiple Injections
33055317|NCT05768321|Experimental|GEC255 treatment|Oral tablet(s), once daily in 28-day cycles
33055318|NCT05768282|Experimental|Administration of oral prednisolone|Oral prednisolone start at a dose of 30 mg/day on the third day after RFA, and continue for 4 weeks.
33068120|NCT02955277|No Intervention|standard care|Participants will receive standard medical care with no TECH protocol.
33068121|NCT02955277|Active Comparator|active standard care|Partivipans will receive six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
33068122|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
33111959|NCT04647006|Active Comparator|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
33111960|NCT05069285|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian)
33111961|NCT05069285|Active Comparator|Sleep hygiene advice|A sheet of paper with standard sleep hygiene advice
33111962|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
33111963|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
33111964|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
33111965|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
33111966|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
33111967|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
33111968|NCT04684784|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
33111969|NCT04684784|Placebo Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
33111970|NCT04646733|Experimental|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
33111971|NCT04646733|Active Comparator|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
33111972|NCT00545246|Experimental|aflibercept + docetaxel|
33333201|NCT04676932|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory will be applied to the intervention groups.~Care will given when women after receiving the HSG attendance appointment. Care will terminated on the 15 minutes after the end of HSG undergoing.~The time of the study 1-3 days for each women. Intervention Nursing Care Based on Kolcaba's Comfort Theory"
32740441|NCT05727059|Experimental|HR-PCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
32740442|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:~Change in preload and afterload~Change in inspired oxygen~Change in pacemaker modes"
32740443|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
32740444|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
32740445|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
32740446|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
32740447|NCT04839029|Experimental|Bipolar En bloc TURBT|patient subjected to bipolar Needlescopic En bloc resection of NMIBC
32740448|NCT04839029|Active Comparator|Monopolar En bloc TURBT|patient subjected to Monopolar Needlescopic En bloc resection of NMIBC
32740449|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
33333202|NCT04676932|No Intervention|Routine hospital schedule|The researcher sincerely answered all questions asked by the control group during the HSG period.
33333203|NCT04600960|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
33333204|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
33333205|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
33333206|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
33333207|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
33333208|NCT04481074|Experimental|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
33333209|NCT04426786|Active Comparator|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
32740450|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
32740451|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
32740452|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
32740453|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
33361305|NCT01361360||control|
33361306|NCT01361360||hypercapnia|
33333210|NCT04426786|Placebo Comparator|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
33333211|NCT04426006|Other|PRO-SERO-COV|Blood sample and self-administered questionnaire
33055319|NCT05768009|Experimental|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided Interscalene brachial plexus block using 10 ml bupivacaine 0.25%.the interscalene block will be performed when the patient is in a supine position, with his/her head slightly elevated and turned away from the side to be blocked. The linear ultrasound probe (frequency 10-15 MHz) will be used with the depth setting of 2-4 cm. The probe will be initially placed near the midline of clavicle at the level of cricoid cartilage and scanned laterally to identify the carotid artery and internal jugular vein underneath the sternocleidomastoid muscle. By moving the probe laterally, the anterior scalene muscle will be identified below the lateral edge of the sternocleidomastoid. A groove containing the hypoechoic nerve structures will usually be identified. 10 mL of 0.25 bupivacaine will be injected into scalene groove around the nerve roots.
33055320|NCT05768009|Experimental|pericapsular nerve block and superficial cervical plexus blocks|"• Group B will include 21 patients who will undergo the procedure under general anesthesia and combined pericapsular nerve block and superficial cervical plexus blocks (using 10 and 5 ml bupivacaine 0.25% respectively).~the patient's arm will be placed in external rotation and abducted at 45 degrees. The linear ultrasound probe will be placed longitudinally between the coracoid process and the humeral head. After identification of the humeral head, the subscapularis tendon and the deltoid muscle over it, a 50-mm sonovisible needle will be inserted using the in plane technique. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 10 ml of 0.25% bupivacaine will be injected."
33055321|NCT05766982|No Intervention|Xenograft only|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied without the application of PRP.
33055322|NCT05766982|Experimental|Xenograft and PRP|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied with the application of PRP.
33055323|NCT05766800|Experimental|Downstaged arm with surgical treatment|In this arm, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
33055324|NCT05766800|Active Comparator|Downstaged arm with radiotherapy|In this arm, patients with tumors resectable after chemoimmunotherapy will receive radiotherapy in department of medical oncology.
33055325|NCT05766800|Other|Unresectable arm|In this arm, patients with tumors still unresectable after chemoimmunotherapy will receive therapy in department of medical oncology.
33055326|NCT05766566||Cohort|"Will be enrolled patients referring to the Department of General Surgery of the IRCCS Saverio de Bellis - Castellana Grotte (BA) Italy, affected by perianal fistulas from Crohn's disease."
33055327|NCT05766410|Experimental|Palbociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
33055328|NCT05766410|Active Comparator|Ribociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
33055329|NCT05766410|Active Comparator|Abemaciclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
33055330|NCT05765864||Patients|The Enrollment Kit and Time1 Kit will be administered at enrollment, Time2 Kit will be administered before discharge and Time 3 kit after 6 and 18 months post hospitalization (see Detailed description and Study Protocol). The interventions will be Treatment as usual.
33055331|NCT05765864||Controls|The Enrollment Kit and the Time Kit1 will be administered (see Detailed description and Study Protocol).
33055332|NCT05765370|Experimental|LDL-C Lower-Target Group (25mg/dL≤ LDL-C<70mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 25mg/dL≤ LDL-C<70mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
33055333|NCT05765370|Active Comparator|LDL-C Higher-Target Group (70mg/dL≤ LDL-C<100mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 70mg/dL≤ LDL-C<100mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
33055334|NCT05765318|Experimental|QLB group|"At the end of surgery, before emergence of anesthesia, participants will receive bilateral QLB and intravenous (IV) ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
33055335|NCT05765318|No Intervention|Control group|"At the end of surgery, before emergence of anesthesia, participants will receive IV ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
33055336|NCT05763810|Other|Erector Spinae Plane Block group|Erector Spinae Plane Block
33055337|NCT05763810|Other|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block group|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block
33055338|NCT05762822|Placebo Comparator|Placebo|60 ml water (same taste as active comparator) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
33055339|NCT05762822|Active Comparator|3-OHB|60 ml 3-OHB (30 g) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
33055340|NCT05762276|Experimental|VXX-401 Cohort A|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
33055341|NCT05762276|Experimental|VXX-401 Cohort B|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
33055342|NCT05762276|Experimental|VXX-401 Cohort C|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
33055343|NCT05762276|Experimental|VXX-401 Cohort D|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
33055344|NCT05762276|Placebo Comparator|Placebo Cohort A and C|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
33055345|NCT05762276|Placebo Comparator|Placebo Cohort B and D|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
33055346|NCT05762198|Active Comparator|Rezūm|
33333212|NCT04252144|Experimental|GERD|Patients with verified gastroesophageal reflux disease
33333213|NCT04252144|Other|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
33055347|NCT05762198|Active Comparator|TURP|
33055348|NCT05761873|Active Comparator|Paper audit and feedback only|Provision of A&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
33333214|NCT04051528|Experimental|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
33333215|NCT04051528|Experimental|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
33333216|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:~lung infiltration detection at computed tomography (CT) scan.~Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
33333217|NCT05475574|No Intervention|Before discontinuation of contact precautions for ESBLE|Implementation of contact precaution in addition to standard precaution for any patient carrying (infected or colonized) ESBLE
33333218|NCT05475574|Experimental|After discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
33055349|NCT05761873|Experimental|Paper and email audit and feedback|Provision of A&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
33055350|NCT05757011|Placebo Comparator|Placebo|Before the removal of uterus and the closure of vaginal cuff, insertion of 6inch 22G needle 2 to 3 cm below the umbilicus, 30 ml normal saline (sodium chloride solution 0.9%, FIPCO, Egypt)will be administered , then the uterus will be removed, and the operation will be terminated
33333219|NCT04132960|Experimental|HER2 status|"Three cohorts of advanced breast cancer patients:~Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)~Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)~Cohort 3: HER2 non-expressing (IHC0+)"
33333220|NCT04092166|No Intervention|Controlled|Participants will have no intervention.
33333221|NCT04092166|Other|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
33333222|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
33055351|NCT05757011|Experimental|pre-sacral nerve block|"Uterosacral nerve block will be performed before the removal of uterus and the closure of vaginal cuff, and before the removal of trocars from abdominal cavity, insertion of 6-inch 22G needle 2 to 3 cm below the umbilicus, injection of the SHP area which situated anterior to L5-S1 vertebral bodies, Caudal to the bifurcation of the abdominal aorta with 30 ml 0.25% bupivacaine (Marcaine®0.25% , Astra Zeneca, Egypt) will be administered. Following the injection of local anesthetic, patient will be placed from Trendelenburg position to horizontal position. The we will remove the uterus and trocars , and the operation will be terminated.~Data will be recorded in a case report form (CRF) and statistical analysis will be done."
33055352|NCT05756790|No Intervention|Enhanced Usual Care|Couples in this condition will receive the standard of care for alcohol use in addition to a brief alcohol counseling session modeled after WHO guidelines and Dr. Conroy's intervention in Malawi, which uses participants' baseline AUDIT scores for messaging around alcohol reduction and lasts 5-10 minutes.
33333223|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
32740454|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
33055353|NCT05756790|Experimental|Motivational Interviewing (MI)|Couples will have three MI sessions over a 60-day period. These sessions will focus on communication between the couple, alcohol consumption patterns, and setting goals for alcohol-use reduction.
33055354|NCT05756790|Experimental|Motivational Interviewing Plus Breathalyzer (MI Plus)|In addition to three MI sessions, drinkers in this condition will be prompted via SMS message twice per day to use a mobile app and a breathalyzer to test their blood alcohol levels (BAC). Both the drinker and their partner will receive real-time feedback about alcohol use.
33055355|NCT05756166|Experimental|Cohort I (CKM, pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 9 and then every 3 weeks after that for up to 4 doses on study. Patients also undergo CT scan or MRI at screening and follow-up and undergo blood sample collection during screening and on study.
33055356|NCT05756166|Experimental|Cohort II (CMK, early pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, and interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 2 of week 1 and then every 3 weeks beginning in week 4 on study. Patients also undergo CT scan or MRI at screening and follow-up, undergo blood sample collection during screening and on study, and may undergo tumor biopsy at screening and follow-up.
33055357|NCT05754996|Experimental|lactulose plus nifuroxazide|"Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days~Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day."
33055358|NCT05754996|Active Comparator|Lactulose alone|Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.
33055359|NCT05754827||1-CKD patients without cardiovascular complications|
33055360|NCT05754827||2-CKD patients with cardiovascular complications|
33068123|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
33333224|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
33111973|NCT04638114|Experimental|CAM lesion|Mini-Open DAA Hip Arthroscopy
33111974|NCT04638114|Other|PINCER impingement|Mini-Open DAA Hip Arthroscopy
33111975|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
33333225|NCT03980314|Active Comparator|Arm A (Process C)|
33333226|NCT03980314|Experimental|Arm B (Process D)|
33333227|NCT03925324|Experimental|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
33333228|NCT03925324|Placebo Comparator|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
33068124|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
33068125|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
33333229|NCT03841318|Experimental|Sjogren's Syndrome|
33333230|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
33333231|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
33333232|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
33361307|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
33068126|NCT04516681|Experimental|Combined Ascorbic Acid with chemotherapy group|Ascorbic Acid with FOLFOXIRI with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
33068127|NCT04516681|Active Comparator|Chemotherapy alone group|standard FOLFOXIRI treatment
33068128|NCT04516330|Active Comparator|unifocal breast cancer|patients having unifocal breast cancer
33068129|NCT04516330|Active Comparator|multicentric breast cancer|patients having multicentric breast cancer
33068130|NCT04516603|Experimental|Fampridine SR|"Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.~The single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t½ = 3.61 h) between experimental and control intervention."
33068131|NCT04516603|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of the identical additives formulated for oral administration.
33068132|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
33068133|NCT04516174|Experimental|Dex+TAPB group|Patients in Dex+TAPB group will receive the bilateral transversus abdominis plane block with 0.25% ropivacaine 20ml each side before anesthesia and combined with continuous infusion of dexmedetomidine during operation.
33068134|NCT04516174|Placebo Comparator|Control group|Patients in control group will receive the bilateral transversus abdominis plane block with saline 20ml each side before anesthesia and don't receive the infusion of dexmedetomidine during operation.
33068135|NCT04516213|Experimental|Enteral formula tube feeding|Enterally fed children, ages 1-4, with established enteral feeding access
33068136|NCT04515979|Experimental|vactosertib+Pembrolizumab|Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks
33068137|NCT04696510||Chronic migraineurs|This group includes patients with chronic migraine.
33068138|NCT04696510||Control group|This group includes healthy subjects.
33068139|NCT04696510||Episodic migraineurs|This group includes patients with episodic migraine
33068140|NCT04515706|Experimental|Iguratimod|Iguratimod 25 twice a day (bid) on Week 1-48.
33068141|NCT04515706|Placebo Comparator|Placebo|Placebo twice a day (bid) on Week 1-24, and Iguratimod 25 twice a day (bid) on Week 25-48.
33068142|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
33068143|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
33068144|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
33068145|NCT00505570|No Intervention|Medical Management|
33068146|NCT00505570|Experimental|PFO Closure|
33068147|NCT02964299||Standard|Standard bite block
33068148|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
33068149|NCT04515355|Experimental|People with MS (PwMS)|People with MS recruited to take part and will be randomised to receive the intervention of online programme of support.
33068150|NCT04515355|No Intervention|People with MS (PwMS) - standard care|People with MS recruited to take part and will be randomised to receive the usual standard of care.
33068151|NCT04515277|Active Comparator|40 g (D1)|40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
33068152|NCT04515277|Active Comparator|20 g (D2)|20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
33068153|NCT04515277|Other|No treatment (NT)|0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
33068154|NCT04515316|Experimental|healthy adults|Any adult, who is at least eighteen (18-70) years old.
33068155|NCT04515316|Experimental|Patients with intractable epilepsy|Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.
33068156|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
33068157|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
33068158|NCT04515043|Experimental|INVAC-1|All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
33068159|NCT04514614|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
33068160|NCT04724889||Patients with underlying AF|Patients that will have AF detected by ILR will be compared with patients without AF.
33068161|NCT04724889||Patients without AF|Patients that will have AF detected by ILR will be compared with patients without AF.
33333233|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
33333234|NCT05460832|Placebo Comparator|Placebo|
33333235|NCT05460832|Experimental|MBS2320 5 mg|
33333236|NCT05460832|Experimental|MBS2320 20 mg|
33055361|NCT05751863|Experimental|Analgesia First Sedation|Subjects will be randomized to receive analgesia-first sedation by intermittent doses of Fentanyl (25 mcg), instead of continuous IV infusions. If the intermittent IVP x4 fails to achieve the target pain score, an infusion starts at 50 mcg/hr and titration by 25 mcg q15 minutes. If sedation score is not achieved, propofol infusion starts at 5 mcg/kg/min to achieve goal RASS of 0 to -2. Subjects will be assessed for a ventilator weaning trial daily.
33055362|NCT05751863|Active Comparator|Protocol Directed Sedation and Daily Sedation Interruption|Subjects will receive Fentanyl for analgesia and midazolam for sedation management. The RASS score is used to guide sedation to a goal of 0 to -2 and daily sedation by IV Midazolam at 1 mg/hr and titrated by 1 mg/hr q60 mins. Midazolam boluses are allowed by 1 mg IVP q5 mins x2 before increasing the infusion rate. Fentanyl IV starts at 50 mcg/hr and is titrated by 25 mcg/hr q15 mins to achieve target pain score. Fentanyl bolus of 25 mcg IVP q5 min x2 doses is given before increasing the infusion rate. Daily sedation interruption (DSI) is performed daily and ventilator weaning trial if they pass.
33333237|NCT05460832|Experimental|MBS2320 40 mg|
33333238|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
33055363|NCT05751434|Experimental|Participants Assigned to Exercise Therapy|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
33055364|NCT05751434|No Intervention|Participants Assigned to Usual Care|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
33055365|NCT05750875|Active Comparator|Loratadine|
33055366|NCT05750875|Active Comparator|Gabapentin|
33055367|NCT05744960|Experimental|HPV vaccine communication training.|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
33055368|NCT05744960|Experimental|HPV vaccine communication training and clinic-level financial incentive program|Staff in clinics randomized to this arm will receive the Announcement Approach Training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.
33055369|NCT05744843|Experimental|Smartphone-based exercise arm|Eight to twelve week smartphone delivered exercise programme
33055370|NCT05744843|Active Comparator|Stenting Arm|Deep venous stenting as standard of care
33055371|NCT05744843|No Intervention|Healthy Volunteers|Healthy Volunteers for baseline testing
33055372|NCT05741476|Experimental|DBV712 250 mcg|Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
33055373|NCT05741476|Placebo Comparator|Placebo|Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
33055374|NCT05736562|Experimental|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
33055375|NCT05736562|Placebo Comparator|Control|This group will receive a blank placebo.
33055376|NCT05734794|Experimental|Rituximab Group|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days).
33055377|NCT05734794|Active Comparator|Steroid Group|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
33055378|NCT05732649|Experimental|Experiment 1|Participants will take part in three different sessions. In each session, network communication at visual areas will be coupled with the intensity of a sound, of a tactile stimulation, or both.
33055379|NCT05732649|Experimental|Experiment 2 (Group A)|Participants undergo neurofeedback training of network communication between the target brain area (i.e., the left superior parietal area) and the rest of the brain during about 20 minutes (the precise duration will be defined with the experience of Experiment 1), using the sensory feedback modality defined in Experiment 1. Then, they perform the mirror-drawing task.
33055380|NCT05732649|Active Comparator|Experiment 2 (Group B)|Participants will use neurofeedback to train network communication of a control brain area in the other (right) hemisphere which is not directly linked to visuo-motor processing or learning, using otherwise the same duration and feedback setup. This control condition allows to obtain a similar feedback experience and hence a true blinding. Moreover, it enables an evaluation of the spatial specificity of the feedback training. After neurofeedback, they perform the mirror-drawing task.
33055381|NCT05732649|No Intervention|Experiment 2 (Group C)|Participants will not receive neurofeedback, but directly train the mirror-drawing task.
33055382|NCT05732428|Experimental|ARV-471|
33055383|NCT05730569||Preterm Neonates|"Neonate born between the 34th and 37th week of pregnancy~Birth weight ≤2500g and ≥1500g"
33055384|NCT05730569||Full-Term Neonates|"Neonate born after the 37th week of pregnancy~Birth weight >2500g"
33055385|NCT05724888|Experimental|Intervention_Winnipeg|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
33111976|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
33333239|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
33333240|NCT05457946|Experimental|Test group 1|Low dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot A for Stage 2
33333241|NCT05457946|Experimental|Test group 2|Middle dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot B for Stage 2
33333242|NCT05457946|Experimental|Test group 3|High dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib)for Stage 1/ selected dose of hexavalent vaccine Lot C for Stage 2
33333243|NCT05457946|Active Comparator|Control group|Co-administration of Pentavalent vaccine and Inactivated Polio vaccine for both stages
32740455|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
33055386|NCT05724888|No Intervention|Control_Winnipeg|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
33055387|NCT05724888|Experimental|Intervention_STP|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
32740456|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
32740457|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
33419035|NCT05432115|Experimental|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
33055388|NCT05724888|No Intervention|Control_STP|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
33055389|NCT05724134|Active Comparator|Maintenance hyperinsulinemia (MH) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will remain at 100% of basal for the full duration (225 min). The IIR and resulting insulin levels are expected to be relatively high (cf. hyperinsulinemia) because of underlying insulin resistance.
33055390|NCT05724134|Experimental|Reduction toward euinsulinemia (RE) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will be reduced progressively, at 75-min intervals, to 90%, 75%, and 60% of basal IIR. Thus, the basal hyperinsulinemia expected due to underlying insulin resistance will be reduced toward euinsulinemia.
33055391|NCT05720156||Case group: History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy|History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy
33055392|NCT05720156||Control group: No history of ASCVD, not on statins or initiating PCSK9 inhibitor therapy|No history of ASCVD, not currently on high-intensity statins or initiating PCSK9 inhibitor therapy
33055393|NCT05715073|Experimental|TeaCrine and caffeine|150mg of Teacrine and 150mg of caffeine
33055394|NCT05715073|Active Comparator|Caffeine|300mg of caffeine
33055395|NCT05715073|Placebo Comparator|Placebo|300mg of cellulose
33055396|NCT05712785|Experimental|Shuotong Ureteroscopy group|Shuotong Ureteroscopy: a ureteroscope that can lithotripsy and lithotripsy simultaneously
33055397|NCT05712785|No Intervention|Ureteroscopy group|Ureteroscopy group：using conventional ureteroscopy
33111977|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
33333244|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
33333245|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
32740458|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
32740459|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
32740460|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
32740916|NCT05593887|Active Comparator|Hip Reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur and internal fixation.
33333246|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
33333247|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
33333248|NCT05457556|Experimental|Arm A (halploHCT)|Patients receive a myeloablative conditioning regimen with PTCy or T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
33333249|NCT05457556|Experimental|Arm B (MUD-HCT)|Patients receive a TBI-based or chemotherapy-based myeloablative conditioning regimen between days -9 and -2 at the discretion of the treating provider, followed by MUD-HCT on day 0. Patients then receive GVHD prophylaxis regimen on days 1-11. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
33333250|NCT05457556|Experimental|Arm C (haploHCT)|Patients who only have a haplo donor receive a myeloablative conditioning regimen with PTCy or T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
33333251|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
32740461|NCT05726981|Experimental|Patients with nodules treated by thermal ablation|"The study population is a monocentric cohort of patients who underwent thermoablation treatment for benign thyroid nodules 3 years ago. These patients aged >18 years-old were carriers of a benign but troublesome thyroid nodule before thermal ablation, either unique or dominant, i.e. associated with one or more other non-significant nodules (<20 mm) that were subjected to simple ultrasound surveillance. Patients refused, after clear and fair information, surgical management of their nodule. On average, 2 patients have been treated for TA per week in the Thyroid Disease and Endocrine Tumor Department since 2016. Patients systematically benefit from annual clinical and ultrasound monitoring as part of their follow-up in our Department."
32740462|NCT03301025|Active Comparator|Pregabalin group|(n=53):
33055398|NCT05712317|Experimental|Exergame Intervention|8-week exergame-based intervention consisting of 3 sessions per week lasting between 20-40 Minutes. The intervention will consist of playing the game Sphery racer in the exergame called ExerCube.
33055399|NCT05712317|Active Comparator|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise consisting of 3 sessions per week lasting between 20-40 minutes. The intervention will consist of a running exercise on a treadmill or riding on a bicycle ergometer.
33055400|NCT05711498|Experimental|Anodal thoracic tsDCS|Anodal tsDCS will be applied over the T12 vertebra
33055401|NCT05711498|Experimental|Cathodal thoracic tsDCS|Cathodal tsDCS will be applied over the T12 vertebra
33055402|NCT05711498|Sham Comparator|Sham thoracic tsDCS|Sham tsDCS will be applied over the T12 vertebra
33055403|NCT05703841|Experimental|Cohort 1: JNJ-77242113 Dose 1|Participants will receive a single oral dose of JNJ-77242113 Dose 1 on Day 1.
33055404|NCT05703841|Experimental|Cohort 2: JNJ-77242113 Dose 2|Participants will receive a single oral dose of JNJ-77242113 Dose 2 on Day 1.
33055405|NCT05703841|Experimental|Cohort 3: JNJ-77242113 Dose 3|Participants will receive a single oral dose of JNJ-77242113 Dose 3 on Day 1.
33333252|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
33333253|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
33333254|NCT05450302||PURE EP|All patients from January 2022 till June 2022 in whom PURE EP was used at the Kansas City Heart Rhythm Institute, Overland Park, Kansas
33333255|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
33333256|NCT03059446|Experimental|Cenicriviroc (CVC) 150 mg|Cenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).
33333257|NCT00090519|Experimental|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
33333258|NCT00090519|Placebo Comparator|Placebo|QD oral for up to 36 months
33333259|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
33333260|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
33333261|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg orally daily x 5 days
33333262|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil orally daily x 5 days
33333263|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
33333264|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
33333265|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
33333266|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
33333267|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
33333268|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
33333269|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
33333270|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
33361308|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
33361309|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
33361310|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
33361311|NCT01230229|Active Comparator|Stenting|Active treatment group
33361312|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
33361313|NCT05096936|Experimental|Pilates PBMT|This group will receive training in the Pilates method associated with the effective application of photobiomodulation.
33419036|NCT05432115|Active Comparator|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid
32740463|NCT03301025|Placebo Comparator|placebo group|(n=53):
32740464|NCT05726903|Experimental|Depo SC Home|Participants will be given instructions on home administration of DMPA SC and be provided with all necessary supplies.
33333271|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
32740465|NCT05726825|Experimental|Therapeutic Plasma Exchange (TPE)|"1 x TPE with donor Fresh Frozen Plasma (FFPs) (1.2 x individual plasma volume) within the first 6 hrs after randomization.~A second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min within 24 hours after the first intervention."
33111978|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
33111979|NCT04637997|Other|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
33111980|NCT04637997|Other|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
33111981|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
33111982|NCT03456440||normal individuals|controls cases are examined with MRI
33111983|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
33111984|NCT04638192|Experimental|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
33111985|NCT04638192|Experimental|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
33111986|NCT04638192|Sham Comparator|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
33111987|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
33111988|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
33111989|NCT04646538|Experimental|X3 group|
33111990|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
33111991|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
33333272|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
33333273|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
33333274|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 47"
33361314|NCT05096936|Experimental|Pilates|This group will receive training in the Pilates method associated with the not effective (placebo) application of photobiomodulation.
33361315|NCT05096936|Placebo Comparator|PBMT|This group will receive effective application of photobiomodulation and will not perform the pilates method training
33361316|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
33361317|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
33361318|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
33361319|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
33361320|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
33361321|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
33361322|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
33361323|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
33361324|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
33055406|NCT05702463|Experimental|EC ASA 162 mg once daily for 7 days|EC ASA 162 mg once daily for 7 days
33055407|NCT05702463|Experimental|EC ASA 81 mg twice daily for 7 days|EC ASA 81 mg twice daily for 7 days
33055408|NCT05702463|Experimental|chewable ASA 40 mg twice daily for 7 days|chewable ASA 40 mg twice daily for 7 days
33055409|NCT05702229|Experimental|Substudy 1|MEDI5752 Plus XELOX/FOLFOX
33055410|NCT05702229|Experimental|Substudy 2|AZD2936 Plus XELOX/FOLFOX
33055411|NCT05699460||Early Parkinson's disease|
33055412|NCT05699460||Possible or Probable MSA-P|
33055413|NCT05696795|Experimental|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
33055414|NCT05694637|Active Comparator|SBIRT|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
33055415|NCT05694637|No Intervention|Standard of Care|Trained LHWs will provide a brief motivation counseling and a brochure about smoking cessation.
33055416|NCT05690074|Experimental|Patients with chronic spinal cord injury|80 sessions each of epidural spinal cord stimulation for 1) autonomic functions 2) voluntary movement; and 3) standing
33055417|NCT05689359|Experimental|Addition of Hydroxychloroquine to paclitaxel|Hydroxychloroquine will be added to chemotherapy in patients with early stage (1-3) breast cancer and gynecological cancers.
33361325|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
33361326|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
33361327|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
33055421|NCT05680584|Active Comparator|Melatonin|Preoperative oral melatonin 0.1mg/ kg in 10ml apple juice one hour before induction of anesthesia
33055422|NCT05680584|Active Comparator|Hydroxyzine|Preoperative oral hydroxyzine 1mg/ kg in 10ml apple juice one hour before induction of anesthesia
33055423|NCT05680584|Placebo Comparator|placebo|10ml apple juice one hour before induction of anesthesia
33055424|NCT05679349|Experimental|Group A (Providers): (survey, online educational activity)|Participants complete survey on study. Participants undergo online educational activity on study. Participants undergo distance learning on study.
33055425|NCT05679349|Active Comparator|Group B (Providers): (survey)|Participants complete survey at baseline and end of study survey.
33055426|NCT05679349|Experimental|Group A (Patients): (EHR, educational activity, counseling))|Patients undergo EHR review on study. Patients undergo educational activity on study. Patients also undergo SDM counseling once on study.
33055427|NCT05679349|Active Comparator|Group B (Patients): (survey)|Patients undergo EHR review on study and complete telephone survey throughout the trial.
33055428|NCT05678998|Experimental|WTX-330 dose escalation|Patients with relapsed/refractory advanced or metastatic solid tumors
33055429|NCT05678998|Experimental|WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A)|WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen
33055430|NCT05678998|Experimental|WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B)|WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved
33055431|NCT05676710|Experimental|Experimental|PI3K inhibitors
33055432|NCT05676697|Experimental|PI3K Delta Inhibitor|
33055433|NCT05676034|Experimental|AMX0035|AMX0035 administered by mouth for 24 weeks: Once daily for first 3 weeks and then twice daily for the remainder of the study if tolerated by participant
33055434|NCT05673824|Experimental|Huaier Granule Group|Huaier Granule+VEGFR-TKIs
33055435|NCT05673200|Experimental|Treatment (ASTX727, paclitaxel, pembrolizumab)|Patients receive ASTX727 PO, paclitaxel IV and pembrolizumab IV on study. Patients undergo collection of blood samples and CT and/or MRI throughout the trial. Patients in the dose-expansion phase also undergo a tumor biopsy during screening and on study.
33055436|NCT05672173|Experimental|Treatment (nivolumab, ibrutinib, chemotherapy, liso-cel)|Patients receive ibrutinib PO, nivolumab IV, fludarabine IV, cyclophosphamide IV, and liso-cel IV on study. Patients also undergo apheresis, PET/CT, biospecimen collection, and bone marrow biopsy on study. Patients may receive low-moderate intensity chemotherapy in combination with the study induction therapy per treating physician discretion with approval of study principal investigator.
33055437|NCT05668091|Experimental|Nirmatrelvir / Ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days. All 3 tablets (2 of nirmatrelvir and 1 of ritonavir) must be taken twice daily by mouth for 15 days.
33055438|NCT05668091|Placebo Comparator|Placebo / Ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days. The control formulation includes 2 placebo tablets and 1 ritonavir tablet.
33055439|NCT05664737|Experimental|Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)|
33055440|NCT05664737|Placebo Comparator|TD: Placebo + BSC|
33055441|NCT05664737|Experimental|Non-transfusion Dependent (NTD): Luspatercept + BSC|
33055442|NCT05664737|Placebo Comparator|NTD: Placebo + BSC|
33111992|NCT04638270|Experimental|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~3×10^5 /KG 6×10^5 /KG 1×10^6/KG"
33361328|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
33361329|NCT05091398|Active Comparator|Group I|ultrasound-guided erector spinae block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
33111993|NCT00545480|Experimental|1|
33111994|NCT00545480|Active Comparator|2|
33111995|NCT04646694|Experimental|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
33111996|NCT04646694|Placebo Comparator|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
33111997|NCT04638036|Experimental|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
33111998|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
33111999|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
33112000|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
33112001|NCT04637685|Active Comparator|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
33112002|NCT04637685|Active Comparator|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
33112003|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
33112004|NCT04638426|Experimental|Treatment A|HL237 tab. 200mg/day
33112005|NCT04638426|Experimental|Treatment B|HL237 tab. 400mg/day
33112006|NCT04638426|Experimental|Treatment C|HL237 tab. 800mg/day
33112007|NCT04638426|Placebo Comparator|Placebo|Placebo of HL237 tab.
33112008|NCT04646577|Active Comparator|Active|
33419037|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
33112009|NCT04646577|Sham Comparator|Sham|
33112010|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
33112011|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
33112012|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
33112013|NCT04684667|Other|Propranolol Therapy|This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.
33112014|NCT04637919|Experimental|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
33112015|NCT04637919|Experimental|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
33419038|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
32869691|NCT00262639|Experimental|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
33112016|NCT04637919|Experimental|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
33112017|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
33112018|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
33112019|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
33112020|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
33112021|NCT04637958||pain|THA
33112022|NCT04637958||no pain|THA
33112023|NCT00545870|Experimental|A|Bevacizumab treatment
33112024|NCT00545870|Active Comparator|B|Ranibizumab treatment
33419039|NCT04975321|Active Comparator|Nu Smile Zirconia crown|Anterior primary teeth which received a NuSmile zirconia crown as a final restoration
33112025|NCT04637451|Experimental|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
33112026|NCT04637451|Other|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
33112027|NCT00545909|Experimental|1|
33112028|NCT00545909|Active Comparator|2|
33112029|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
33112030|NCT04637568||Control|61 CT scans of healthy patients
33112031|NCT04637412|Experimental|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
33112032|NCT04637412|Experimental|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
33112033|NCT04637412|Experimental|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
33112034|NCT05050292|Experimental|Experimental Group|"Activities are designed to target specific cognitive skills (attention, perception, inhibition).~An internal algorithm of the cognitive stimulation platform will adjust the activities' difficulty depending on the participant's performance, always demanding a maximum cognitive effort."
33333275|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 32"
33112035|NCT05050292|Active Comparator|Control Group|"Painting and artistic activities not designed to target specific cognitive skills.~The internal algorithm will be deactivated, so the cognitive stimulation activities will be of constant difficulty throughout the intervention."
33112036|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
33112037|NCT04646304|No Intervention|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
33112038|NCT04645914|No Intervention|No smokers|Healthy subjects who do not consume any nicotine products
33112039|NCT04645914|Experimental|Smokers/Vapers|Healthy subjects who consume nicotine products
33112040|NCT04684433||Surgical intervention|Patients who had a surgical procedure since the start of the lockdown in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020.
33112041|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
33112042|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using superomedial pedicle|
33112043|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
33112044|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
33112045|NCT04637646||children with MPS|
33112046|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
33112047|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
33112048|NCT00546065|No Intervention|non ablation|non ablation only surveillance
33112049|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
33112050|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
33112051|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
33112052|NCT00546143|Experimental|1|Omalizumab 900 mg
33112053|NCT00546143|Experimental|2|Omalizumab 1050 mg
33112054|NCT00546143|Experimental|3|Omalizumab 1200 mg
33112055|NCT04645992|Active Comparator|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
33112056|NCT04645992|Sham Comparator|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
33112057|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
33112058|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
33112059|NCT05037383|Other|Study group|Each participant will be part of the same group, since the study is focusing on the motion and viewing of the operating staff. There are no patient records collected.
33112060|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
33112061|NCT00560079|Active Comparator|2|
33112062|NCT00560079|Placebo Comparator|3|
33112063|NCT04646265|Experimental|periodontal treatment|non-surgical root debridement
33112064|NCT00560157|Active Comparator|I|Sondalis HP
33112065|NCT00560157|Experimental|II|Crucial
33112066|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
33112067|NCT00558402|Active Comparator|2|Education
33112068|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
33112069|NCT04637607|Experimental|Ear-Acupressure Group|The subjects will receive true auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
33112070|NCT04637607|Sham Comparator|Sham-Acupressure Group|The subjects will receive sham auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
33112071|NCT00558441|Experimental|1|
33112072|NCT05036213|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
33112073|NCT05036213|Placebo Comparator|concentrated beet root juice with depleted nitrate content|The placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
33112074|NCT00558480|Active Comparator|1|Vitamin A
33112075|NCT00558480|Placebo Comparator|2|Vitamin A placebo
33112076|NCT05034146|Experimental|68Ga-FAPI PET/CT in malignant tumors|Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.
32740466|NCT05726825|No Intervention|Standard of Care (SOC)|Non-interventional standard of care
33055443|NCT05663918|Active Comparator|Exercise Training in Individuals with Mild Cognitive Impairment|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
33055444|NCT05663918|No Intervention|Individuals with Mild Cognitive Impairment and No exercise|Group B: Participants in this arm will not experience any intervention during a 4 week period of time.
33055445|NCT05663918|Active Comparator|Exercise Training in age and sex matched healthy controls|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
33055446|NCT05661734|Experimental|VX-548|Participants will receive VX-548 every 12 hours (q12h) up to 14 days.
33055447|NCT05661435||Participants|
33055448|NCT05661422||Participants|
33055449|NCT05660967|Experimental|Epcoritamab monotherapy|
33055450|NCT05660967|Experimental|Epcoritamab in combination with lenalidomide|
33055451|NCT05655949|Experimental|Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy|"Participants will receive:~Cycle 1:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~Week 2 or 3 of 21 Day Cycle: One time treatment of Y-90 radiation.~Cycles 2-8:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~Cycles 9+:~Day 1 of 21 Day Cycle: Durvalumab (immunotherapy) maintenance"
33055452|NCT05655611|Experimental|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations
33055453|NCT05655611|Active Comparator|muscle energy technique|All the patients will receive conventional physical therapy treatment and muscle energy techniques for shoulder flexion, abduction, internal and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-10 seconds
33055454|NCT05650736|Experimental|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
33055455|NCT05646992|Experimental|Uterus Transplant Recipient|Uterus recipients, who are otherwise healthy, adult, genotypic females affected by uterine factor infertility, will undergo the surgically innovative uterus transplantation procedure combined with short-term use of conventional calcineurin inhibitor-based immunosuppression in to support a fetus to a viable delivery via Caesarian section.
33055456|NCT05646693|Experimental|Drusen Mega® + Amitriptyline Chlorhydrate|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of antioxidant therapy (Drusen Mega®) and one capsule of amitriptyline chlorhydrate per day in the night for 3 months.
33055457|NCT05646693|Placebo Comparator|Placebo + Amitriptyline Chlorhydrate|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of placebo (Magnesium Oxide 100mg) per day in the morning and one capsule of amitriptyline chlorhydrate per day in the night for 3 months.
33055458|NCT05646303|Experimental|Psilocybin|2 oral doses of 25mg psilocybin capsules
33055459|NCT05646303|Placebo Comparator|Placebo|2 oral doses of placebo (microcrystalline cellulose) capsules
33055460|NCT05645172||Cohort 1|adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy.
33055461|NCT05644665|Experimental|Arm A: Ozanimod|
33055462|NCT05644665|Placebo Comparator|Arm B: Placebo|
33055463|NCT05643001|Experimental|Electronic Health Record Notification|"For eligible patients presenting with an acute hemorrhagic stroke, a recommendation to measure low-density lipoprotein (LDL) and glycated hemoglobin A1c (HbA1c) together with their last measurement dates will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the patient's provider when they first open the patient's chart. The provider may accept the automatically generated orders for both measurements displayed in the BPA, may modify one or both of the orders, or choose to dismiss the BPA.~For patients that follow-up with the out-patient stroke clinic and received the in-patient intervention, a second BPA will suggest referrals to sleep study and audiology. The alert will display for the patient's provider when they first open the patient's chart. The provider may accept one or both of the referrals suggested by the BPA, or may choose to dismiss the BPA."
33055464|NCT05639894|Experimental|Group 1: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (Low dose) via intramuscular injection
33055465|NCT05639894|Experimental|Group 2: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (Low dose) via intramuscular injection
33055466|NCT05639894|Experimental|Group 3: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (Medium dose) via intramuscular injection
33055467|NCT05639894|Experimental|Group 4: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (Medium dose) via intramuscular injection
33112077|NCT04637100|Experimental|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
33112078|NCT04637100|Active Comparator|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
33112079|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
33112080|NCT04637490|Experimental|patellar resurfacing|patellar resurfacing in TKA
33112081|NCT04637490|No Intervention|non-resurfacing|non-resurfacing TKA
33112082|NCT04645875|Experimental|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
33112083|NCT04645875|Experimental|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
33112084|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
33112085|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
33112086|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
33112087|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
33112088|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
33112089|NCT00546689||1 , 2|those with HIV
33112090|NCT04637373|Experimental|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
33333276|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
33333277|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
33112091|NCT00546767|Experimental|Mail and Live Phone|
33112092|NCT00546767|Experimental|IVR|
33333278|NCT05693116||Nasal Vestibule Squamous Cell Carcinoma|Patients affected by primary squamous cell carcinoma of the nasal vestibule. Patients will be treated with upfront surgery according to the current practice and followed to identify any possible factor affecting prognosis.
33112093|NCT00546767|Experimental|Computer Kiosk|
33112094|NCT00546767|Active Comparator|Traditional|
33112095|NCT04645758|Active Comparator|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
33333282|NCT05435482|Experimental|LHE-led|Participants will receive 1) LHE outreach/support (2 small group educational sessions via Zoom and 2 individual follow-up calls), 2) COVID-19 at-home antigen test kits, and 3) a written and a video guide to using a test kit
33333283|NCT05435482|Active Comparator|Instruction only|Participants will receive 1) COVID-19 at-home antigen test kits and 2) a written and a video guide to using a test kit
33333284|NCT05692960|Experimental|Hypnotic Relaxation Intervention (HRI)|"The hypnotic relaxation intervention consists of three different audio files, each about 20 minutes in length. These three hypnotic inductions build upon each other. The first hypnotic induction audio focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second hypnotic induction audio focuses more specifically on body image related to sexuality and being a sexual being. The third hypnotic induction audio focuses on sexual desire, passion, and energy. Each hypnotic induction will be used for two weeks, three times per week for a total of six weeks of hypnosis.~The vaginal moisturizer component of this arm is the same as that described for the VVA study arm."
33361330|NCT05091398|Active Comparator|Group II|ultrasound-guided paravertebral block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
33361331|NCT05091398|Active Comparator|Group III|ultrasound-guided intercostal nerve block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
33361332|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
33361333|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
33361334|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
33361335|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
33361336|NCT05189678||frailty group|Modified Frailty index score greater than or equal to 0.21
33361337|NCT05189678||non-frailty group|Modified Frailty index score is less than 0.21
33112096|NCT04645758|Active Comparator|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
33112097|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
33333285|NCT05692960|Other|Vulvovaginal Atrophy (VVA)|This study arm might best be described as standard of care. Vulvovaginal dryness will be treated with a daily moisturizer for two weeks, then every other day for the remaining six weeks. Vaginal moisturizer will be applied at night, before sleep and after all sexual activity. Several moisturizers are available, including vaginal DHEA (IntraRosa®). Due to the need for reproducibility, we have decided to use one non-hormonal vaginal moisturizer, Replens™ moisture, which is a vaginal moisturizer consisting primarily of a purified water, glycerin, and mineral oil. Other ingredients included in the formulation are polycarbophyl, carbomer, homopolymer type B, hydrogenated palm oil glyceride, sorbic acid, sodium hydroxide. The moisturizing gel was determined to be a medical device for marketing by the FDA in 2010. It is non-hormonal (unlike vaginal DHEA) and therefore will be more likely to be acceptable by a broader range of oncology providers.
33112098|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
33112099|NCT00546806|Active Comparator|3|Physician-based Education and Activation
33112100|NCT04637178|Experimental|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
33333286|NCT05432830|Experimental|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
33333287|NCT05432830|Experimental|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
33112101|NCT04637178|Other|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
33333288|NCT05432830|Experimental|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
33333289|NCT05366218|Experimental|Tafasitamab|All patients will receive MOR00208 over 2-3 hours i.v. MOR00208 will be administered on a bi-weekly (every fourteen days) basis with infusions on Days 1 and 15 of each 28-day cycle. Additional doses will be administered on Day 4, Day 8 and Day 22 of Cycle 1 as well as Day 8 and Day 22 of Cycle 2 and Cycle 3.
33112102|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
33112103|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
33112104|NCT00560196||1|Patients with panic anxiety disorder without pain
33112105|NCT00560196||2|Patients with depression without pain
33112106|NCT00560196||3|Healthy controls
32740467|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
33112107|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
33112108|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
33112109|NCT00558597||1|30 patients with stable graft function
33112110|NCT00558597||2|30 patients with acute rejection after lung transplantation
33112111|NCT04637217||Control|
33112112|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
33112113|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
33112114|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
33112115|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
33112116|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
33112117|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
33112118|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
33112119|NCT04637139|Experimental|Group 1|VBR 300 mg solution containing 2 µCi [14C]VBR
33112120|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
33055468|NCT05639894|Experimental|Group 5: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (High dose) via intramuscular injection
33333290|NCT05364658|Experimental|Juvene IOL|Eyes that have been implanted with the LensGen Juvene IOL
33333291|NCT05248204|Experimental|Scotchbond Universal Plus Treatment|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using Scotchbond Universal Plus (SBU+) Adhesive (Treatment).
33333292|NCT05248204|Active Comparator|Scotchbond Universal Comparator|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using the predicate device, Scotchbond Universal (SBU) Adhesive (Control).
33333293|NCT05244460|Experimental|Intervention|Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
33333294|NCT00096993|Placebo Comparator|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
33055469|NCT05639894|Experimental|Group 6: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (High dose) via intramuscular injection
33055470|NCT05639894|Placebo Comparator|Group 7: Main, Sentinel and Booster Cohorts|1 injection of placebo via intramuscular injection
33361338|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
33055471|NCT05638204|Experimental|Intervention Group|Participants in the intervention group received the Suicidal Crisis Intervention( SCI) in addition to their treatment as usual.
33055472|NCT05638204|No Intervention|Control Group|Participants in the control group received their treatment as usual.
33055473|NCT05637606|Experimental|MAP 80|Intervention group: intraoperative mean blood pressure target > 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
33055474|NCT05637606|Other|MAP 65|Control group: intraoperative mean blood pressure target > 65 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 65 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
33361339|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
33361340|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
33055477|NCT05630924|Experimental|SI! Program-NYC Children|Receives 4 month health promotion educational intervention.
33055478|NCT05630924|No Intervention|NYC Elementary School Children|The control group will be participating school children not enrolled in the program
33055479|NCT05630755|Experimental|DOR/ISL and Placebo to BIC/FTC/TAF|Participants will receive DOR/ISL 100 mg/0.25 mg and Placebo to BIC/FTC/TAF once daily (QD) orally from day 1 to week 96.
33055480|NCT05630755|Active Comparator|BIC/FTC/TAF and Placebo to DOR/ISL|Participants will receive BIC/FTC/TAF 50 mg/200 mg/25 mg and Placebo to DOR/ISL once daily (QD) orally from day 1 to week 96.
33055481|NCT05630469||Depression|Depressive patients (pharmaco-resistant) undergoing electroconvulsive therapy
33055482|NCT05626634|Experimental|LP352|Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.
33055485|NCT05625412|Experimental|BMS-986360|
33055486|NCT05625412|Experimental|BMS-986360 + Docetaxel|
33055487|NCT05625412|Experimental|BMS-986360 + Nivolumab|
33055488|NCT05625412|Experimental|BMS-986360 + Capecitabine|
33055489|NCT05621083|Experimental|Fish oil (the omega-3 fatty acid supplement)|"Participants will be randomized to either start to receive fish oil (the omega-3 fatty acid supplement) for 6 weeks. Followed by a wash-out period of a minimum of 12 weeks before the treatment is changed.~Once the classical Randomized Controlled Trial (RCT) has finished, all the participants will repeat the fish oil intervention period (adaptive design) to determine if those the investigators defined as responders continue to be defined in the same category."
33055490|NCT05621083|Placebo Comparator|High-oleic sunflower oil (HOSO) containing no omega-3 fatty acids|Participants will be randomized to either start to receive high-oleic sunflower oil (HOSO) for 6 weeks. Followed by a wash-out period of minimum 12 weeks, before the treatment is changed.
33055491|NCT05617677|Experimental|Arm 1: Deucravacitinib|
33055492|NCT05617677|Placebo Comparator|Arm 2: Placebo|
33055493|NCT05610722|Other|DreaMed Endo Digital|"At each visit, participants who use pump therapy will download their pump and glucose data (V1-V5) as they use to do at clinic visit. Participants who use MDI therapy will use the Endo.Digital App for insulin and glucose documentation and will upload data from their CGM/FGM or glucometer as they use to do at clinic visit.~In addition, participants will be offered to download data also at home in between study visits, every 3-6 weeks as they feel needed (Phone visits: P1-up to P8). Each time, optimization of pump settings or MDI will be done according to the downloaded data using the Endo.DigitalTM system. The device recommendations for insulin dosing adjustments and diabetes management tips will be reviewed by the treating physician. Each new treatment settings will be approved or edit by the study physician prior to implementation by the participant."
33055494|NCT05604222|Experimental|Mirabegron|Mirabegron for 8 weeks
33055495|NCT05604222|Experimental|Mirabegron plus Brief Behavioral Treatment for Insomnia (BBTI)|Mirabegron for 8 weeks and a 4 week behavioral intervention for insomnia
33055496|NCT05602012|Experimental|Mindfulness Based Cognitive Counseling|The intervention was conducted in two groups with 25 participants/12-13 for each groups and two researchers per group. The program which consisted of eight sessions in total, was held once a week and each session lasted approximately 90-120 minutes.
33361341|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
33361342|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
33361343|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
33333295|NCT00096993|Active Comparator|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
33333296|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
33333297|NCT03040336|No Intervention|Standard of Care|Standard of Care
32869692|NCT00262639|Placebo Comparator|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
32869693|NCT05698056||Women undergoing breast cancer screening with MRI|No interventions are administered. Data is retrospectively collected in an anonymized way after ethical approval at each site.
32869694|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
32869695|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
33055497|NCT05602012|No Intervention|No Intervention|Participants will not be given an intervention until after they have completed the study. Data collection tools were applied to the students simultaneously with the intervention group, and after the follow-up test of the intervention group, a single-session information meeting will be held by the researchers for the students in the control group.
33055498|NCT05600556|Active Comparator|Cohort I (standard imaging)|Patients receive 2D image review using standard computer screen on study. Patients undergo MRI and CT imaging at screening and on study
33055499|NCT05600556|Experimental|Cohort II (virtual reality)|Patients receive image review using virtual reality stimulation on study. Patients also view MRI treatment room using virtual reality stimulation. Patients undergo MRI and CT imaging at screening and on study
33419040|NCT04975321|Active Comparator|Nu Smile pre veneered crown|Anterior primary teeth which received a NuSmile pre veneered crown as a final restoration
33055502|NCT05597878|Active Comparator|Opioid Control Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. AFTER surgery participants will be administered oxycodone and acetaminophen.
33055503|NCT05597878|Active Comparator|Experimental Non-Opioid Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. BEFORE and AFTER surgery participants will be administered Ketamine; DURING surgery Ketorolac and acetaminophen.
33055504|NCT05592990|Experimental|NGI226|single peritendon injection
33055505|NCT05592990|Placebo Comparator|Placebo|single peritendon injection
33055506|NCT05592223|Active Comparator|BCG Challenged-Isoniazid Treated|Will receive INH in the dose of 300 mg for three days post BCG injection.
33055507|NCT05592223|Placebo Comparator|BCG Challenged-Isoniazid Untreated|Will not receive any INH dose.
33055508|NCT05591599||Case group|Women diagnosed with tubal pregnancy
33055509|NCT05591599||Control group|Women with the age corresponding to the case group (matched with the same age or +/- 2 years difference compared with the case group), diagnosed with spontaneous abortion or viable intrauterine pregnancy
33055510|NCT05587816|Experimental|Experimental|"Training and use of the PortionSize app by children and parents or caregivers~Using the PortionSize app at the clinic of Pennington Biomedical Research Center and at home (free-living condition)~Rating the satisfaction of using the PortionSize app"
33055511|NCT05585619||Chronic pain patients|New chronic pain consults seen by a trainee and attending pain physician
33055512|NCT05585190|Other|Control|Subjects will not receive a sit/stand desk for the duration of the study and will be asked to follow their normal work day routine.
33055513|NCT05585190|Active Comparator|2-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 2 hours each work day.
33055514|NCT05585190|Active Comparator|3-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 3 hours each work day.
33055515|NCT05581589|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 3 hours on days 1 and 8 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks after last dose, patients undergo radical cystectomy and pelvic lymph node dissection.
33055516|NCT05580458|Experimental|Shingrix|Shingrix will be administered in two 0.5-mL doses approximately 2 months apart.
33055517|NCT05576077|Experimental|Breast Cancer|Patients with locally advanced or metastatic breast cancer that has failed or is intolerant to standard of care therapies. Includes, HER2+, HER 2-, TNBC.
33055518|NCT05576077|Experimental|Colorectal carcinoma|Patients with advanced, metastatic colorectal adenocarcinoma who have failed or are intolerant to at least one line of therapy that included either irinotecan or oxaliplatin.
33055519|NCT05576077|Experimental|Uveal Melanoma|Patients with advanced, metastatic uveal melanoma.
33055520|NCT05574153||Patient Participant|Participants with known Metabolic Syndrome (MetS)
33055521|NCT05574153||Healthy Volunteers|NonS-moking participants with no known pre-existing conditions and who do not take any medications
33055522|NCT05574140||Patient Population|Participants diagnosed with Generalized Anxiety Disorder
33055523|NCT05574140||Healthy Volunteers|Participants with no pre-existing conditions and who are on no medications.
33055524|NCT05570825|Experimental|Treatment (SX-682, pembrolizumab)|Patients receive SX-682 PO and pembrolizumab IV on study. Patients also undergo biopsy and PET/CT or CT at screening and on study and undergo MRI and collection of blood samples at screening, throughout the study, and during follow up.
33333298|NCT00072189|Experimental|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333299|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
33333300|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
33333301|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
33333302|NCT05128942|Experimental|Cohort 1: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
33333303|NCT05128942|Experimental|Cohort 2: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
33333304|NCT05128942|Experimental|Cohort 3: Age 2-10 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
33055525|NCT05566938|Other|Tailored nutritional recommendations for each metabotype|Volunteers that will be clustered into metabotypes and will recieve tailored nutritional recommendations according to their metabotype.
33333305|NCT05124184||PAD Cohort|Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
33333306|NCT05124184||AAA Cohort|Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft
33055526|NCT05564026||Ancillary-Correlative|Children and adolescents with a germ cell tumor, previously enrolled on APEC14B1 or AEPI10N1 who allow access to medical records (including audiograms), grant permission to: evaluate of all of their DNA, place their genetic and health information in scientific databanks, and collect a blood sample at a routine clinic/home visit, as well as complete a questionnaire about your health and quality of life since treatment.
33055527|NCT05561075|Experimental|Pterostilbene cocrystal|
33055528|NCT05561075|Active Comparator|Pterostilbene free form|
33055529|NCT05559346|Experimental|Research Group|Diplegic Cerebral Palsy
33055530|NCT05559346|Active Comparator|Control Group|Diplegic Cerebral Palsy
33055531|NCT05558358|Experimental|1|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
33055532|NCT05558358|Experimental|2|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
33055533|NCT05557006||All patients|Patients who meet the inclusion criteria
33055534|NCT05552508|Experimental|Benralizumab|Participants will receive 3 doses of benralizumab having a strength of 30 mg subcutaneously once every 4 weeks (Week 0, Week 4, and Week 8).
33055535|NCT05552027|Experimental|Intervention|Participants will harness the car seat in 3 separate scenarios with the sensor system enabled to provide feedback.
33055536|NCT05552027|Other|Control|Participants will harness the car seat in 3 separate scenarios with the sensor system disabled in order to not provide feedback.
33055537|NCT05549479|Experimental|Intervention Group (AgeMatchPLUS).|
33055538|NCT05549479|Active Comparator|Control Condition (AgeMatch):|
33055539|NCT05549258|Experimental|Inebilizumab|Infusion of Inebilizumab
33055540|NCT05549206|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg|Two doses were administered by intramuscular injection, 28 days apart
33055541|NCT05549206|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg|Two doses were administered by intramuscular injection, 28 days apart
33055542|NCT05549206|Placebo Comparator|Placebo|Two doses were administered by intramuscular injection, 28 days apart
33055543|NCT05547204|Experimental|Coffeeberry beverage|300 ml drink containing 300 mg coffeeberry extract
33055544|NCT05547204|Placebo Comparator|Color and flavor matched beverage|300 ml drink (0 mg coffeeberry extract, 0 mg caffeine)
33055545|NCT05545566|Experimental|All patients|
33055546|NCT05540704|Experimental|iACT Experimental Intervention|
33055547|NCT05540704|Active Comparator|Usual Care|
33055548|NCT05539404|Experimental|Experimental Strategy Group|endovascular treatment in addition to best medical treatment
33055549|NCT05539404|No Intervention|Control Strategy Group|best medical treatment
33055550|NCT05534386|Experimental|First stage intervention: Cancer survivorship care intervention (CSCI)|Patients randomized to the CSCI will attend a 120-minutes survivorship clinic in which each participant will be assessed by members a multidisciplinary team comprising a registered nurse, a dietitian, an exercise physiologist and a psychologist/counsellor. During the visit, participants will receive a personalized (1) treatment summary, (2) assessment and recommendation on managing physical and psychological symptoms, (3) assessment and recommendation on dietary advice, (4) assessment and recommendation on physical activity, and (5) advice on managing potential psychosocial issues. While this is a multidisciplinary clinic, the nurse will be the core facilitator who will give a summary of health assessment report including personalized healthy lifestyle advice and action plan to each participant at the end of the visit.
33055551|NCT05534386|Active Comparator|First stage intervention: Control intervention|Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations. Each pamphlet addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer recurrence) observed in Hong Kong cancer survivors, plus two on lifestyle recommendations (physical activity and healthy diet). All pamphlets are developed based on the self-management framework.
33055552|NCT05534386|Experimental|Second stage intervention: Step-up targeted personalized intervention|The step-up targeted personalized intervention will adopt a multi-disciplinary approach but place more emphasis on coaching to enhance patient' skills to manage their symptom burden and weight control.
33055553|NCT05534386|Active Comparator|Second stage intervention: Control intervention|Patients randomized to the control arm at the re-assessment at 4-months post-baseline will continue in the trial as usual (i.e. those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlets).
33055554|NCT05533684|No Intervention|postoperative pain|Measuring postoperative pain using the visual analogue scale
33055555|NCT05533684|Other|total analgesic consumption|Recording the total amount of analgesia consumed by the patients
33055556|NCT05533164|Experimental|Rituximab|Rituximab 1000mg intravenously, once. Possible retreatment with rituximab 500mg intravenously after 6 months.
33333307|NCT05124184||Dialysis Access Cohort|Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
33333308|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
33055557|NCT05533164|Placebo Comparator|Placebo|Placebo consist of 0mg rituximab intravenously
33055558|NCT05532813|Experimental|Metformin arm|Patients randomized in Metformin arm will take metformin orally.
33055559|NCT05532813|Placebo Comparator|Placebo receivers|Patients randomized in placebo arm will take placebo orally in the same procedure as metformin taken.
33055560|NCT05530382|Experimental|self-guided learning (video and hands-on simulation)|video-based self-directed learning
33055561|NCT05530382|No Intervention|traditional instructor-led learning|traditional instructor-led learning in face-to-face workshop
33055562|NCT05528107|Active Comparator|Laparoscopic Intraperitoneal Onlay Mesh plus ventral hernia repair|Laparoscopic Intraperitoneal Onlay Mesh plus repair will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement and suturing hernia defect.
33055563|NCT05528107|Active Comparator|Extended-view totally extraperitoneal ventral hernia repair|Extended-view totally extraperitoneal ventral hernia repair will be used to perform minimally invasive ventral hernia repair with retrorectus mesh placement
33333309|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
33333310|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
33333311|NCT05053126|Experimental|Lyrica 300 mg|Single Dose
33333312|NCT05053126|Experimental|Lyrica 450 mg|Single Dose
33333313|NCT05053126|Experimental|Lyrica 300mg with Oxycodone 20 mg|Single Dose
33333314|NCT05053126|Experimental|Lyrica 450 mg with Oxycodone 20 mg|Single Dose
33333315|NCT05053126|Active Comparator|Oxycodone 20 mg|Single Dose
33333316|NCT05053126|Placebo Comparator|Placebo|Single Dose
33055564|NCT05524051|Experimental|TIN816|TIN816
33055565|NCT05524051|Placebo Comparator|Placebo|Placebo
33055566|NCT05523453|Active Comparator|Processing of Positive Memories Technique (PPMT)|Participants receive 5 60-minute Processing of Positive Memories Technique (PPMT) sessions for PTSD following the treatment procedures as outlined in PPMT therapy manual.
33055567|NCT05523453|Active Comparator|Supportive Counseling (SC)|Participants receive 5 60-minute supportive counseling (SC) sessions. SC includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
33055568|NCT05520411|Experimental|HUM Flatter Me|Come to Citruslabs Office twice (1 Week Gap Between Visits) Visit 1: Take Placebo or Test Product; Eat Test Meal; Outcome Measures Visit 2: Take Placebo or Test Product; Eat Test Meal; Outcome Measures
33055569|NCT05514132|Experimental|Ceralasertib in Combination with Durvalumab|This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.
33419041|NCT04975321|Active Comparator|Composite strip crown|Anterior primary teeth which received a composite strip crown as a final restoration
33419042|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
33419043|NCT05410587|Other|Fracture Monitor T1 (implantable device class III)|
33419044|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
33055574|NCT05506943|Experimental|CTX-009 plus Paclitaxel|
33055575|NCT05506943|Active Comparator|Paclitaxel|
33055576|NCT05505747|Experimental|Fisetin|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of fisetin for 2 consecutive days, followed by a 28-day senescence washout period, and then another 2-day administration. Fisetin treatment begins at 8 weeks after surgery.
33055577|NCT05505747|Placebo Comparator|Placebo|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of placebo (corn starch) for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration. Placebo treatment begins at 8 weeks after surgery.
33055578|NCT05502237|Experimental|Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy|"Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
33333317|NCT05332834|Experimental|Drug SM17|Peripheral intravenous injection
33333318|NCT05332834|Placebo Comparator|Drug Placebo|Peripheral intravenous injection
33333319|NCT05331508|Experimental|Treatment group|Prior to commencement of the study, providers responsible for FP and ANC service provision will participate in a 3-day competency-based skills-building training activity on Caring for women subjected to violence: A WHO curriculum for training health-care providers and the ARCHES intervention. Following the training, providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
33419045|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
33419046|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
33419047|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
33419048|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
33112121|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
33112122|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
33112123|NCT05034107|Experimental|Persons with dementia|Persons who have been diagnosed with dementia by their physicians and in nursing homes. Persons with dementia who have at least one symptom of BPSD and willing to participate in this study. These participants will be exposed to diffused Ylang-Ylang aromatherapy.
33112124|NCT04645485|Experimental|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
33112125|NCT05030792|Experimental|ART VR 3 times/week|ART VR practice for 30 minutes, at home, 3 times per week
33112126|NCT05030792|Experimental|ART VR 4 times/week|ART VR practice for 30 minutes, at home, 4 times per week
33333320|NCT05331508|No Intervention|Control group|FP clients and ANC clients will receive standard care. For FP services, this includes standard contraceptive care provided by personnel who have completed training on contraceptive service delivery by the Nigerian Federal Ministry of Health and partners. For ANC services, the standard is a minimum of 8 visits with health personnel trained on ANC care during pregnancy. This includes identification of women and girls at increased risk of developing complications during labor and childbirth; prevention, detection, and management of pregnancy-related and concurrent conditions; health education and promotion; promotion of the use of skilled attendance at birth and healthy behaviors such as breastfeeding, early postnatal care, and planning for optimal pregnancy spacing, routine examinations, detection of complications, prevention of malaria in pregnancy and other infections; provision of holistic care to ensure normal progression of the baby and good health of the mother.
33112127|NCT04636866||Gastric ulcer|
33112128|NCT04636866||Duodenal ulcer|
33112129|NCT05016674|Experimental|Laser-assisted liposuction|Laser-Assisted Liposuction with the LipoLife system.
33112130|NCT04645641|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
33112131|NCT04636476|Other|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
33112132|NCT04645407|Experimental|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
33112133|NCT04645407|No Intervention|Control Group|conventional therapy
33112134|NCT00547040||A|incident renal transplant patients
33112135|NCT04645056|Experimental|Intervention group|"a. Intervention Group: Neck stretching and movement~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:~Relax shoulders and neck sufficiently~Look down - Stretching and movement~Look to each side - movement~Lower the head to each side - stretching~Lower the head diagonally to each side - stretching~Small nod movements~Lift the shoulders - movement~Roll the shoulders - movement~Lift the arms - movement~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
33112136|NCT04645056|No Intervention|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
33112137|NCT04684316|No Intervention|Care-as-usual: all consult physician|All employees at risk are invited to attend screening. Upon arrival, several biometrics are measured (weight, length, Body Mass Index, blood pressure), along with spirometries, a vision test, and a blood and urine test. The OP then investigates the general health status and systems of the employee, which includes an anamnesis with questions about new health burdens or changes in occupational risks, follow-up questions on previous complaints, medical advice, referral to a healthcare provider, or booking another appointment with an occupational health specialist. After the PHS, a (employee-unique) link to an online questionnaire is sent by email to gather information on final (health, health care use, absenteeism and presenteeism) and intermediary (health literacy, help-seeking behaviour) outcomes.
33112138|NCT04684316|Experimental|Intervention: Electronic survey with selective consultations|In the intervention group, all employees at risk receive a (employee-unique) link to an online health screening questionnaire by email. Dependent upon their answers, 20% of the employees (i.e. the 20% of the employees that mostly need contact with the OP) are referred to the occupational physician for a discussion of the results. The OP then gives medical advice, refers to a healthcare provider (e.g. general practitioner or specialist), or books a (follow-up) appointment with an occupational health specialist (OP, occupational nurse, etc.).
33112139|NCT04636788|Other|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
33112140|NCT04636749|Active Comparator|Erbium laser|Treatment with Erbium laser
33112141|NCT04636749|Sham Comparator|Sham laser|Treatment with sham laser
33112142|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
33333321|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose|Eligible participants who received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminium hydroxide, IM on Day 28 in previous study NOR-107 were enrolled at 3rd year post-primary vaccination in this study.
33419049|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
33419050|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
33419051|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
33419052|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
32869696|NCT05698446||Open Modified Broström +Suture tape augmentation group|Patients who accept a modified Broström +Suture tape augmentation operation
32869697|NCT05698446||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
33055579|NCT05502237|Active Comparator|Pembrolizumab (PEMBRO) + Chemotherapy|"Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin AUC 5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
33055580|NCT05502237|Experimental|Zimberelimab (ZIM) + Chemotherapy|"Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin AUC 5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
33055581|NCT05501756|Experimental|Alemtuzumab|"Patients will be given 10 mg/m2 alemtuzumab divided over days -14, -13, and -12. The first dose should be limited to no more than 3 mg per the manufacturer's recommendation. If the calculated daily dose is greater than 3 mg, the first dose (day -14) should be limited to 3 mg and the remainder of the dosing should be divided over days -13 and -12.~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
33055582|NCT05499546|Experimental|Intervention arm|All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using four different methods.
33055583|NCT05499130|Experimental|TEV-48574 Dose A (UC)|Dose regimen A administered by subcutaneous infusion for participants with UC
33055584|NCT05499130|Experimental|TEV-48574 Dose B (UC)|Dose regimen B administered by Subcutaneous infusion for participants with UC
33055585|NCT05499130|Experimental|TEV-48574 Dose C (UC)|Dose regimen C administered by subcutaneous infusion for participants with UC
33055586|NCT05499130|Experimental|TEV-48574 Dose A (CD)|Dose regimen A administered by subcutaneous infusion for participants with CD
33055587|NCT05499130|Experimental|TEV-48574 Dose B (CD)|Dose regimen B administered by subcutaneous infusion for participants with CD
33055588|NCT05499130|Experimental|TEV-48574 Dose C (CD)|Dose regimen C administered by subcutaneous infusion for participants with CD
33055589|NCT05499130|Placebo Comparator|Placebo UC|Matching Placebo
33055590|NCT05499130|Placebo Comparator|Placebo CD|Matching Placebo
33055591|NCT05496595|Experimental|Part 1A Dose Escalation|Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCBY02.
33055592|NCT05496595|Experimental|Part 2A Dose Expansion|Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity. In addition to antitumor activity, PK and PD analysis may be used to support RP2D confirmation.
33055593|NCT05494736|Experimental|Panel A: MK-8527 1.0 mg|Participants receive a single oral dose of MK-8527 1.0 mg.
33055594|NCT05494736|Experimental|Panel B: MK-8527 ≤10.0 mg|Participants receive a single oral dose of MK-8527 ≤10.0 mg.
33055595|NCT05494736|Experimental|Panel C: MK-8527 ≤10.0 mg|Participants receive a single oral dose of MK-8527 ≤10.0 mg.
33055596|NCT05494606||Participants receiving upadacitinib|Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
33055597|NCT05492032|Experimental|Active-tDCS vs Sham-tDCS|"During the active- and sham-tDCS conditions, the participants will receive current with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, the tasks will be initiated five minutes subsequent to the stimulation mode and terminated prior to its end for active-tDCS condition. Whereas, the sham condition with the same placement and intensity will only receive 30s initial stimulation and then discontinue. Throughout the active / sham-tDCS condition, participants are required to sit still and focus their attention on a + displayed on a computer monitor during the five-minute rest. After that, they will undergo active-tDCS (1mA, 20 min) to the left DLPFC or sham stimulation over 10 sessions in 2 weeks, while performing the executive function training tasks."
33055598|NCT05492032|Other|Crossover trial|Participants in the sham-tDCS group will receive 10-day active tDCS and assessments will be performed before and after the 10-tDCS session.
33055599|NCT05492032|Experimental|Booster effect|All tDCS responders (>10% reduction in SRS scores) will enrol on a 6 months follow-up phase in which they will be randomized to receive either bimonthly 20-minute booster tDCS sessions, or bimonthly 20-minute booster sham tDCS sessions for 3 months, followed by monthly 20-minute booster tDCS, monthly 20-minute booster sham tDCS, for another 3 months, with a maximum of 9 (sham) tDCS booster sessions.
33055600|NCT05479604|Experimental|SinuSonic Group|Subjects will use the SinuSonic device for 2 minutes twice daily for 8 weeks
33055601|NCT05479604|Sham Comparator|Sham Group|Subjects will use the sham device for 2 minutes twice daily for 8 weeks
33055602|NCT05476783|Experimental|TB006 4000 mg|TB006 4000 milligram (mg) via a 1-hour continuous intravenous (IV) infusion will be administered once every 28 day
33112143|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
33419053|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
33112144|NCT04645095|Active Comparator|Conventional TENS|Frequency:80 Hz, duration:100 μs
33112145|NCT04645095|Active Comparator|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
33112146|NCT04645095|Active Comparator|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
33112147|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
33112148|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
33112149|NCT04636827|Experimental|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
33112150|NCT04636827|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
33112151|NCT04636827|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
33112152|NCT04636827|Active Comparator|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
33112153|NCT04636515|Experimental|Single Arm|
33112154|NCT04636593|Experimental|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
33112155|NCT04636593|Experimental|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
33112156|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
33112157|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
33112158|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
33112159|NCT00547508|Placebo Comparator|1|Placebo
33112160|NCT00547508|Placebo Comparator|2|Placebo
33112161|NCT00547508|Active Comparator|3|tadalafil
33112162|NCT00547508|Active Comparator|4|tadalafil
33112163|NCT00547508|Active Comparator|5|tadalafil
33112164|NCT00547508|Active Comparator|6|tadalafil
33112165|NCT00560274|Experimental|1|
33112166|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
33112167|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
33112168|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
33112169|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
33112170|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
32869698|NCT04752943|Experimental|Children and caregivers receiving TipsByText messages|
33112171|NCT00547664|Experimental|A|
33112172|NCT00547664|Placebo Comparator|B|
33112173|NCT04644939|Experimental|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
33112174|NCT04644939|Placebo Comparator|Conventional group|Patients will receive bowel preparation instructions in a conventional way
33112175|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
33112176|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
32869699|NCT04752943|No Intervention|Children and caregivers not receiving TipsByText texts|
33112177|NCT00560430|Placebo Comparator|P|placebo
33112178|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
33112179|NCT00547820|Experimental|A|with application of urinary sensor
33112180|NCT00547820|Placebo Comparator|B|without use of urinary sensor
33112181|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
33112182|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
33112183|NCT04979546|Experimental|Intensive PROMs Intervention Arm|The intervention group will be asked to complete PROM questionnaires at baseline, 6 months, and 12 months via an online web-based delivery system. The treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group. Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
33112184|NCT04979546|Active Comparator|Control Arm|The control group will be asked to complete PROM questionnaires at baseline and 12 months via an online web-based delivery system. The treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group (unless critical values are reached on questionnaires - see below). Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
33112185|NCT00560547|Experimental|1|
33112186|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
33112187|NCT04975607|Experimental|Music Therapy Group|
33112188|NCT04975607|No Intervention|Control Group|
33112189|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
33112190|NCT00547937|Active Comparator|CPAP|
33055603|NCT05476718|Active Comparator|kinesio group|"The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The posterior superior iliac spine (PSI) and 12th thoracic vertebra (T12) will be marked while the participant is sitting in a comfortable position. Tape application will be made bilaterally between PSI and T12 with tapes cut in an I shape along the erector spine muscles. The anchor and end parts of the tape will be rounded. The anchor part will be glued without tension. Afterward, individuals are asked to flex and rotate their trunks as much as possible, and the middle part of the band is slightly stretched 10-15%; After the spine is brought to its normal anatomical position, the tip will be glued without tension. After sticking, the tape will be manually activated. This transaction will be carried out by both parties. After the tape adheres, individuals will be asked to keep the tape for five days until the next taping."
33055604|NCT05476718|Placebo Comparator|placebo group|The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The placebo-tape application will be applied the lumbar region in a tension-free and horizontal form, while the spine is in a neutral position without positioning the patients. After sticking, the tape will be manually activated. After the tape adheres, individuals will be asked to hold the tape for five days until the next taping.
33333322|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333323|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333324|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333325|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333326|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333327|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333328|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333329|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333330|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33419054|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
33055605|NCT05476601|Experimental|CMAP Plus|CMAP Plus is comprised of an existing culturally adapted manually assisted problem solving intervention (CMAP) integrated with CBT based Motivational Interviewing (MI) and Mindfulness intervention (CMAP Plus MI and Mindfulness). The TAU of intervention group participants will be continued along with study intervention.
33055606|NCT05476601|No Intervention|TAU alone|This will be comprised of standard care they will be receiving from participating centres at recruitment sites. The standard care for individuals with SUD in Pakistan usually includes a 2-3-week detoxification programme, followed by 2 months of weekly 1:1 session along with some family sessions, followed by a period of support groups programmes.
33055607|NCT05474859|Experimental|Cohort 1|XT-0528 250 mg administered once daily
33055608|NCT05474859|Experimental|Cohort 2|XT-0528 500 mg administered once daily
33055609|NCT05474859|Experimental|Cohort 3|XT-0528 1000 mg administered once daily
33055610|NCT05474859|Experimental|Cohort 4|XT-0528 1500 mg administered once daily
33055611|NCT05474859|Experimental|Cohort 5|XT-0528 2500 mg administered once daily
33055612|NCT05471921|Experimental|SBIRT|Experimental condition: Participants residing in the study community (displaced and host population) will receive Screening, Brief Intervention, and Referral to Treatment (SBIRT). The treatment will consist of brief intervention (CETA-BI) and full Common Elements Treatment Approach (CETA) depending on the severity of the participant's substance use.
33055613|NCT05471921|Active Comparator|Treatment as usual|Comparison condition: Participants residing in the study community (displaced and host population) will receive the current standard of treatment.
33419055|NCT04903717|Experimental|Intervention - Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record which alerts to the presence of HFrEF and the fact that the patient is not currently prescribed an MRA. A link to an order set for MRAs (or to potassium binders should a patient be hyperkalemic) will provided, along with a link to current best practices surrounding the use of MRAs.
33419056|NCT04903717|No Intervention|Usual Care|Providers will not receive a best practice alert for eligible patients and will continue to care for patients as usual.
33055617|NCT05458986|Experimental|Arm 1 (educational video)|Patients watch an educational video about the importance of abnormal FIT results, the implications if follow-up colonoscopy is not completed, and demonstrate the steps to complete a colonoscopy.
33055618|NCT05458986|Active Comparator|Arm 2 (usual care)|Patients receive usual care and do not watch the educational video.
33419057|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
32869700|NCT05535348|Experimental|Open Pilot|An adapted version of the Relaxation Response Resiliency Program (3RP) for fathers of CYSHCN. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
32869701|NCT01062451|Placebo Comparator|Placebo|
32869702|NCT01062451|Active Comparator|Perindopril|
32869703|NCT01062451|Active Comparator|Candesartan|
32869704|NCT04639843|Experimental|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
33055619|NCT05458479|Experimental|Fluoxetine|Subjects will receive fluoxetine 5 mg each morning at the start of the trial. The dose will be increased by 5 mg every 2 weeks depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 5 mg and the maximum total daily dose will be 30 mg.
33055626|NCT05456477|Experimental|Beef|Subject will consume beef entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
33055627|NCT05456477|Active Comparator|Poultry|Subject will consume poultry entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
33055628|NCT05447689|Experimental|Integrative-Mind-Body Skills Group|Treatment group
33055629|NCT05447689|No Intervention|Control|Control group: Treatment-As-Usual (TAU) and mind-body skills reading materials.
33055630|NCT05447650|Experimental|i-Lumen AMD Active|Active transpalpebral microcurrent stimulation therapy
33055631|NCT05447650|Sham Comparator|i-Lumen AMD Sham|Sham transpalpebral microcurrent stimulation therapy
33055632|NCT05445284|Experimental|Group education sessions for parents plus usual diabetes care|"≥3 in-person/virtual one-hour group education sessions for parents plus usual diabetes care, every 3 months for 12 months and ≥3 check-in virtual 15-20 minute sessions in-between the group sessions. Each group session (3-8 parents per group) will be facilitated by a diabetes social worker and will consist of parent-driven discussions on topics relevant to adolescence and transition care. Each one-hour session will commence with an ice-breaker activity and then move to a parent-driven, facilitator-mediated discussion. The group session content will be guided by the needs of the participants; however, the facilitator will actively promote discussion on adolescent- and transition-related topics. The group discussion will end with participants setting goals for their next session."
33055633|NCT05445284|Other|Usual diabetes care|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual care, individual sessions and meetings related to transition care with the diabetes social worker will be provided to parents, as needed.
33055634|NCT05444530|Experimental|Dose Escalation|Participants with essential thrombocythemia (ET) and myelofibrosis (MF) will receive VAC85135 target dose intramuscular (IM) injection in the safety lead-in cohort (Cohort 0). Participants in subsequent cohorts will receive VAC85135 target dose IM injection along with ipilimumab intravenous (IV) infusion. Ipilimumab dose may be escalated based on dose limiting toxicity (DLT) observations.
33055635|NCT05444530|Experimental|Dose Expansion|Participants with polycythemia vera (PV) or post-polycythemia vera myelofibrosis, ET and MF will receive VAC85135 target dose IM injection with ipilimumab IV infusion at the dose(s) determined by study evaluation team (SET).
33055636|NCT05440331|Experimental|Experimental group|Experimental group with training after randomization immediately
33055637|NCT05440331|Active Comparator|Control group with delayed training|Control group with training: the training will delayed from time of randomization
33055638|NCT05440331|No Intervention|Control group without training|Control group without training
33055639|NCT05437419|Experimental|Cohort 1|The patient will receive Dose A of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
33419058|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
33419059|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
33419060|NCT04889755|Other|SibACCESS|This is a single-arm trial of a group-based, posttraumatic stress intervention for adolescent siblings of children with cancer. The intervention includes a parent educational webinar, seven group sibling sessions, one individual parent session, and one individual sibling session.
33419061|NCT05074641|Experimental|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
33055640|NCT05437419|Experimental|Cohort 2|The patient will receive Dose B of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
33055641|NCT05437419|Experimental|Cohort 3|The patient will receive Dose C of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
33055642|NCT05437419|Experimental|Cohort 4|The patient will receive Dose D of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
33055643|NCT05435027|Experimental|GRT-R914, HIV-negative (Part A)|Participants in this ≥18 to 65-year-old Part A are naïve to SARS-CoV-2 (Cohorts A1, A2, and A3) or SARS-CoV-2 convalescent (Cohorts A4, A5, A6). Cohorts will receive doses of GRT-R914 administered as prime and/or boost on Days 1 and Day 29, or as boost 6 months after primary SARS-CoV-2 infection.
33055644|NCT05435027|Experimental|GRT-R912, HIV-negative (Part B)|Participants in this ≥18 to 65-year-old Part B are naïve to SARS-CoV-2 (Cohorts B1, B2) or SARS-CoV-2 convalescent (Cohorts B3, B4). Cohorts will receive doses of GRT-R912 administered as prime and/or boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
33055645|NCT05435027|Experimental|GRT-R912, People Living with HIV (PLWH) (Part C)|Participants in this ≥18 to 65-year-old Part C are people living with HIV but naïve to SARS-CoV-2 (Cohorts C1, C4) or living with HIV but SARS-CoV-2 convalescent (Cohorts C2, C3, C5, C6). Cohorts will receive doses of GRT-R912 or GRT-R914 administered as prime and boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
33055646|NCT05435027|Experimental|GRT-R918, HIV-negative and PLWH, With and Without Prior Vaccination (Part D)|Participants will be ≥18 and <60 years or ≥60 years, HIV-Negative and PLWH with no prior vaccination to SARS-CoV-2 (Cohorts D1, D2, D5, D6) or with prior vaccination to SARS-CoV-2 (Cohorts D3, D4, D7, D8). Cohorts will receive doses of GRT-R918 administered as prime and boost on Days 1 and 29, or as boost ≥2 months after prior SARS-CoV-2 vaccination. Parts B, C, and D will be run in parallel.
33055647|NCT05434299|Experimental|Dose escalation|Single agent dose escalation
33055648|NCT05434299|Experimental|Dose expansion|Single agent dose expansion
33055649|NCT05433961|Experimental|Hyperpolarized Xenon MRI assessment of lung function in endobronchial valve treated COPD patients|Volunteer patients scheduled for receiving endobronchial valve treatment as part of clinical care will be imaged with hyperpolarized xenon prior and post EBV for assessing lung function and improvement.
33055650|NCT05432583|Experimental|BNT163|Escalating dose levels
33055651|NCT05432583|Experimental|Placebo|Isotonic NaCl solution (0.9%)
33055652|NCT05427838||Intervention (training)|"Subjects undergo online CT Head interpretation training:~Summary:~The trial participants will be required to complete a baseline assessment where users will review a set of scans and provide a diagnosis before submitting the case. Users will then be given access to an online training module. Once the training is completed, the users will complete a second assessment.~They will then be asked to evaluate a minimum of 30 CT scans each during their clinical shifts over a 3-month period. They will be asked to record their scan interpretation, the time the scans was performed, and the time they reviewed the scan. They will also be asked to retrospectively document the findings of the standard clinical radiology report, and the time it was issued.~At the end of the 3 month period they will repeat the online assessment to assess their performance, and again after a further three months to assess their retention of any improvement in reporting performance."
33055653|NCT05427838||Control (no Training)|"Subjects do not undergo online CT Head interpretation training:~Summary:~To provide a control for comparison as to the relative benefits of the online training phase and the clinical interpretation phase in terms of improving reporting performance, 30 participants (6 clinicians from each site) will be randomised to undertake the clinical interpretation phase prior to the training module."
33055654|NCT05426408|Other|Patients with MINOCA undergoing CMR|Patients will be their own controls
33055655|NCT05420337|Active Comparator|Group Intramuscular|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine intramuscular
33055656|NCT05420337|Active Comparator|Group TAP|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine
33055659|NCT05408247|Experimental|N-acetyl Cysteine|"Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks~+ Standard of Care: Medical Management."
33055660|NCT05408247|Placebo Comparator|Placebo|"Matched placebo~Generic name: dicalcium phosphate Strength: 600mg per capsule Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks.~+ Standard of Care: Medical Management."
32740468|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
33112191|NCT04644900|Active Comparator|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
33112192|NCT04644900|Active Comparator|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
33112193|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
33112194|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
33112195|NCT04636125|Other|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
33112196|NCT04684628|Experimental|Biochemical Reoccurrence|"Patients with biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or patients with biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC) and compare it to bone scan and CT in 2 groups:~PSA >= 0.2 ng/mL and <= 0.5 ng/mL or PSA > 0.5 ng/ml"
33112197|NCT04684628|Experimental|High Risk Prostate Cancer|Patients with high risk prostate cancer who have not received any definitive treatment. These high-risk patients are defined using the D'Amico Classification System: Those with a PSA of more than 20, or a Gleason score equal to or greater than 8, or have a clinical stage greater than T2c.
33112198|NCT04636242|Experimental|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
33361344|NCT05401435|Experimental|Blood pressure and heart rate measurement|Resting blood pressure and heart rate measurement regularly one value in the morning and evening for 28 days. The volunteer measures the parameters simultaneously on both devices (smartwatch and digital tonometer). In total, each participant will undergo this measurement 56 times.
33112199|NCT04636242|Active Comparator|Group 2: Control Group|patient will undergo standard of care surgery
33112200|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
33112201|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
33112202|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
33112203|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
33112204|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
33112205|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
33112206|NCT04644822|Experimental|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
33112207|NCT04644432|Experimental|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:~Erlotinib 150 mg once a day for 4 weeks.~Osimertinib 80 mg once a day for 4 weeks.~Alectinib 600 mg twice a day for 4 weeks~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week~Olaparib 400 mg twice a day for 4 weeks~Pembrolizumab iv infusion 2 mg/kg every 3rd week~Cabozantinib 60 mg once a day for 4 weeks~Crizotinib 250 mg twice a day for 4 weeks~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week~Imatinib 400 mg once a day for 4 weeks~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
33112208|NCT04644432|Experimental|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
33112209|NCT04644432|Experimental|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
33112210|NCT04644432|Experimental|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
33112211|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
33112212|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
33112213|NCT00548366|Experimental|1|4 gram sodium diet
33112214|NCT00548366|Active Comparator|2|2 gram sodium diet
33112215|NCT04644081|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
33112216|NCT04644081|Active Comparator|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
33112217|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
33112218|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
33112219|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
33112220|NCT04636359|Experimental|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
33112221|NCT04636359|Experimental|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
33361345|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
33361346|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
33055661|NCT05406401|Experimental|Zilovertamab Vedotin + R-CHP: Dose Escalation/Confirmation|Participants in the dose escalation/confirmation phase receive a dose level of zilovertamab vedotin (from 1.5 mg/Kg up to 2.5 mg/Kg) plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
33055662|NCT05406401|Experimental|Zilovertamab Vedotin + R-CHP: Efficacy Expansion|Participants in the efficacy expansion phase receive the RP2D of zilovertamab vedotin plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
33055663|NCT05400837|Experimental|Corrie Virtual Atrial Fibrillation Management Program|Multicomponent virtual atrial fibrillation management program
33055664|NCT05400837|No Intervention|Usual Care|Receives usual care. Usual care is defined as care according to the patients care team's standard practice
33055665|NCT05400694|Experimental|Chocolate milk|Chocolate milk with reduced added sugar
33055666|NCT05400694|Experimental|Chocolate milk with whey protein|Chocolate milk with reduced added sugar and added whey protein
33055667|NCT05400694|Experimental|Chocolate milk with casein|Chocolate milk with reduced added sugar and added casein
33055668|NCT05400694|Experimental|Chocolate milk with alpha-lactalbumin|Chocolate milk with reduced added sugar and added alpha-lactalbumin
33055669|NCT05400694|Experimental|Chocolate milk with glycomacropeptide|Chocolate milk with reduced added sugar and added glycomacropeptide
33333331|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333332|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333333|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33333334|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
33055674|NCT05397639|Experimental|Low Dose Masupirdine Arm|Tablet
33055675|NCT05397639|Experimental|High Dose Masupirdine Arm|Tablet
33055676|NCT05397639|Placebo Comparator|Placebo|Tablet
33055677|NCT05397015||postmenopausal women|A cohort of 200 postmenopausal women
33055678|NCT05396040|Experimental|LOLLI METHODE|regular screening with pooled saliva tests (Lolli-Method)
33055679|NCT05396040|No Intervention|STANDARD OF CARE|STANDARD OF CARE
33055680|NCT05394220||Parapneumonic effusion|Patients with parapneumonic effusion
33055681|NCT05394220||Non-parapneumonic effusion|Patients with pleural effusion but not parapneumonic in nature
33055682|NCT05393921|No Intervention|Patients receiving HoLEP surgery only|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. No Botox injections will be given.
33055683|NCT05393921|Experimental|Patients receiving HoLEP surgery + Intravesical Botox Injections|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. Botox injections will be given during the surgery.
33055684|NCT05392335|Active Comparator|myofascial stretch group|Patients will be given myofascial stretch
33055685|NCT05392335|Experimental|Functional massage along with myofascial stretch group|patients will be given functional massage along with myofascial stretching
33055686|NCT05391308|Experimental|Experimental arm|All patients will have pre-polysomnographie and post-polysomnographie mesurement.
33055687|NCT05390411|No Intervention|Control Sites|No Intervention
33055688|NCT05390411|Experimental|Sites Randomized to SOCIAL HF|SOCIAL HF is composed of evidence-based bias reduction training, employment of objective measures of social support, and changes to facilitate group dynamics.
33055689|NCT05389709||Pharmacy based survey|Patients receive a questionnaire to fill out and return it the Contract Research Organization (CRO) or, alternatively to the pharmacy.
33055690|NCT05387733|Experimental|CBL-514 Group 1|Eligible participants will be enrolled and randomized into one of 2 dose groups. Group 1 with 10 mg CBL-514 per injection.
33055691|NCT05387733|Experimental|CBL-514 Group 2|Eligible participants will be enrolled and randomized to one of 2 dose groups. Group 2 with 15 mg CBL-514 per injection.
33055692|NCT05385965|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery, activity pacing) for managing pain.
33055693|NCT05385965|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
33361347|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
33361348|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
33361349|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
33112222|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
33112223|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
33112224|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
33333335|NCT03039790|Experimental|NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose|Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33055699|NCT05383352|Experimental|Sequence RT: Reference Product followed by Test Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde® Reference product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15: One dose Onivyde Test product + 5-FU/LV~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV"
33055700|NCT05383352|Experimental|Sequence TR: Test Product followed by Reference Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde Test product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15:One dose Onivyde® Reference product + 5-FU/LV.~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV."
33333336|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 μg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33333337|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 yrs)|Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33333338|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 yrs)|Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33361350|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
33055701|NCT05375942||characteristics of patients newly initiated on Inflectra|
33055702|NCT05375942||outcomes after initiating Inflectra|
33055703|NCT05372354|Experimental|Part 1 Arm A: Dose Finding|
33055704|NCT05372354|Experimental|Part 1 Arm B: Dose Finding|
33055705|NCT05372354|Experimental|Part 1 Arm C: Dose Finding|
33055706|NCT05372354|Active Comparator|Part 2 Arm D: Dose Expansion|
33055707|NCT05372354|Experimental|Part 2 Arm E: Dose Expansion|
33055708|NCT05372354|Experimental|Part 2 Arm F: Dose Expansion|
33055709|NCT05372354|Experimental|Part 2 Arm G: Dose Expansion|
33055710|NCT05367817|Experimental|Exercise therapy|The program consists of two parts. The first part of the program contains unloaded active ROM exercises for the wrist in flexion/extension, radial-/ulnardeviation and pronation/supination. The second part of the program consists of three neuromuscular exercises that focus on coordination, wrist stability and strength. The participants will perform the program twice a day for 12 weeks.
33055711|NCT05367817|Active Comparator|Training program|The training program for the control group will consist of ROM exercises only that will be also be performed twice a day for 12 weeks. home base exercises twice a day for 12 weeks.
33055712|NCT05366790|Experimental|CEASE Intervention arm|"The CEASE and CEASE-A interventions are tobacco and vaping cessation interventions delivered in pediatric practices, leveraging existing healthcare and community resources. They integrate evidence-based tobacco use screening and cessation assistance into routine visits to pediatric clinics. CEASE and CEASE-A are based on the 5A's model of smoking cessation: Ask about smoking, Advise to quit, Assess readiness to quit, Assist with a quit plan and Arrange follow-up. Given that CEASE and CEASE-A are one-time interventions, Arrange is removed, and the fourth step Assist is divided into two parts: a) providing phone/text/app quit support and b) providing NRT.~CEASE-A follows the same format at CEASE, but is modified slightly to address smoking and vaping in the adolescent target population"
33055713|NCT05366790|No Intervention|Control: Usual care condition|The control condition will be care as is usually delivered in participating clinics with the possibility of receiving direct linkage with cessation services delivered via CEASE/CEASE-A at the end of the 6-month study period. Current practice does not include routine provision of assistance for parental/adolescent smoking or e-cigarette cessation (e.g., referral to quitlines, NRT prescription).
33055714|NCT05364697|Experimental|IoNIR Ridaforolimus-Eluting Coronary Stent|IoNIR Ridaforolimus-Eluting Coronary Stent System
33055715|NCT05364554|Experimental|Group 1: JNJ-77242113 Dose 1 Once Daily (QD)|Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
33055716|NCT05364554|Experimental|Group 2: JNJ-77242113 Dose 2 QD|Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
33055717|NCT05364554|Experimental|Group 3: JNJ-77242113 Dose 3 QD|Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
33055718|NCT05364554|Experimental|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)|Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
33055719|NCT05364554|Experimental|Group 5: JNJ-77242113 Dose 3 BID|Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
33055720|NCT05364554|Experimental|Group 6: JNJ-77242113 Dose 3 QD|Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
33361351|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
33361352|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
33112225|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
33333339|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 μg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33333340|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine (15 μg of GI.1 50 μg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
33112226|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
33112227|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
33112228|NCT00548522||3|Post partum women with Type 1 diabetes
33112229|NCT00548522||4|Non pregnant women with Type 1 diabetes
33333341|NCT05330806|Experimental|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
33333342|NCT05330806|Active Comparator|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
33333343|NCT04959526|Experimental|Respiratory Function Testing|All subjects will receive standard respiratory function testing and ultrasound-based elastography measurements across various behaviors and conditions
33112230|NCT04635852|Experimental|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
33112231|NCT04635852|Active Comparator|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
33112232|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
33112233|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
33333344|NCT04941274|Experimental|1/Dose Determination/De-Escalation|Abemaciclib (de-escalating dose)
33112234|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
33112235|NCT04635618|Experimental|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
33112236|NCT04635618|Experimental|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
32740469|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
33112237|NCT04635618|Active Comparator|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
33112238|NCT04684355|No Intervention|Standard-of-care group|Participants in this group received their colonoscopic and pathological diagnosis simultaneously at next clinical visit, which arranged in 1 to 2 weeks later.
33112239|NCT04684355|Experimental|Intervention group|Participants in this group received their colonoscopic diagnosis right after they awake from general anesthesia, and then received pathological diagnosis at next clinical visit, which arranged in 1 to 2 weeks later.
33112240|NCT00548639|Experimental|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
33112241|NCT00548639|Sham Comparator|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
33112242|NCT04635696|Experimental|Ethyl Chloride|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
33112243|NCT04635696|Placebo Comparator|Tissue culture grade water|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
33112244|NCT04959890||Subjects Previously Treated with Strimvelis Gene Therapy|It is expected that this study will include approximately 70 eligible samples from approximately 15 subjects previously treated with gamma retroviral gene therapy (gRV-GT).
33112245|NCT04644120|Experimental|Part A: Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
33112246|NCT04644120|Placebo Comparator|Part A: Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
33112247|NCT04644120|Experimental|Part A: Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
33333345|NCT04941274|Experimental|2/Dose Expansion: Group 2a|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 15 participants previously treated with at least 1 line of systemic therapy.
32869705|NCT04639843|Experimental|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
33333346|NCT04941274|Experimental|2/Dose Expansion: Group 2b|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 10 previously untreated participants.
33333347|NCT04917796|Experimental|Electroacupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
33333348|NCT04917796|Placebo Comparator|Sham Acupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
33333349|NCT04906408|Experimental|Prevena|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
33333350|NCT04906408|Experimental|Prineo|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
32869706|NCT01718691|Experimental|SyB L-0501＋rituximab|
33055721|NCT05360485|Active Comparator|Fitbit-Only Self-Monitoring|Control participants will be sent a Fitbit and study-provided account and will self-monitor physical activity for the duration of the study period (2 months).
33055722|NCT05360485|Experimental|MOV'D plus Fitbit Self-Monitoring|Treatment participants will be sent a Fitbit and study-provided account, and assigned to a private, study-created Twitter support group of 10 participants. Within the private group of 10, each participant is also further paired with a peer to be that person's peer coach, setting weekly exercise snack goals and practicing behavior change techniques.
33055723|NCT05360303||Trial population|No Intervention but evaluation of the electroneuromyography at the M1 visit for patients with a clinical diagnostic of thoracic outlet syndrome.
33055726|NCT05357755|Experimental|Group 1: JNJ-77242113 Dose 1|Participants will receive JNJ-77242113 Dose 1 as delayed release tablets orally once daily from Week 0 through Week 16.
33055727|NCT05357755|Experimental|Group 2: JNJ-77242113 Dose 2|Participants will receive JNJ-77242113 Dose 2 as delayed release tablets orally once daily from Week 0 through Week 16.
33055728|NCT05357755|Placebo Comparator|Group 3: Placebo|Participants will receive oral dose of matching placebo once daily from Week 0 through Week 16.
33055729|NCT05355805|Experimental|Part A (Open-label) izokibep every week|Participants will receive izokibep every week from Day 1 through Week 31
33055730|NCT05355805|Experimental|Part B (Double-blind) izokibep every week|Participants will receive izokibep weekly for 31 weeks.
33055731|NCT05355805|Experimental|Part B (Double-blind) izokibep every other week|Participants will receive izokibep every other week for 30 weeks.
33055732|NCT05355805|Placebo Comparator|Part B (Double-blind) placebo every week|Participants will receive placebo weekly up to Week 15, then izokibep from Week 16 to Week 31.
33055733|NCT05355805|Placebo Comparator|Part B (Double-blind) placebo every other week|Participants will receive placebo every other week up to Week 14, then izokibep from Week 16 to Week 30.
33055734|NCT05346913|Experimental|Caregivers of Persons with Spinal Cord Injury (mTBI)|
33055735|NCT05345782|Active Comparator|Laparoscopic Hypo gastric Neural Plexus Block|laparoscopy for diagnosis of the causes of chronic pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the sacral promontory then30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) are injected.
33055736|NCT05345782|Active Comparator|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block|laparoscopy for diagnosis and conventional surgical treatment of the causes of pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the promontory followed by 30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) then injecting 5 ml ( 2.5 marcaine+1ml betamethasone +1.5 ml normal saline) 2 cm away from the cervix at the uterosacral ligament on each sides.
33055737|NCT05345782|Active Comparator|control group|
33055738|NCT05345587|Experimental|Prolife group|scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system
33055739|NCT05345587|No Intervention|Standard care|
33055740|NCT05340738|Active Comparator|LyssnCBT|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. Therapists and supervisors will also have access to LyssnCBT features like speech-to-text transcription, annotation tools, and AI-generated metrics.
33361353|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
33361354|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
33361355|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
33361356|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
33333351|NCT04906408|Active Comparator|Standard Dressing|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
33333352|NCT05317000|Active Comparator|Arm A: 5-azacytidine|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Dexamethasone will be reserved for patients who are not controlled by the initial regimen.~A single cycle of 5-azacytidine will be administered and the patient scheduled for surgery in the period of day 16 through day 18."
33333353|NCT05317000|Active Comparator|Arm B: Nivolumab|"Nivolumab will be administered at a dose of 240 mg IV day 1 and day 15. Treatment must be given on a Monday or Tuesday.~No premedication will be given. Patients will be observed following the initial dose of nivolumab per institutional Surgery will be scheduled in the period of day 16 through day 18."
33361357|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
33055741|NCT05340738|No Intervention|SAU (services-as-usual)|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. No other LyssnCBT features will be available for therapist or supervisor review.
33055742|NCT05338944|Experimental|DBT + lifestyle|Participants will receive 90 minutes of dialectical behavioral therapy and 60 minutes of lifestyle sessions each week for 16 weeks.
33055743|NCT05338944|Experimental|Lifestyle alone|Participants will receive 2 lifestyle sessions per week, one 90 minutes in length and the other 60 minutes for 16 weeks.
33361358|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
33055744|NCT05338944|No Intervention|Control|Participants will be included in baseline, endpoint and follow up measurements, but will receive no form of intervention.
33055745|NCT05326412|Experimental|Itepekimab|"This arm includes participants from 3 populations: Part A-former smokers, Part B-former smokers and Part B-current smokers.~Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks"
33361359|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
33055748|NCT05317221||All patients|The is only 1 arm: all breast cancer patients undergoing surgery.
33055754|NCT05305053||high-risk noncardiac surgery patients for preoperative Multidisciplinary Team (MDT) discussion|observation of MDT in 11 hospitals
33055755|NCT05301348|Experimental|Procedure|Subjects will receive PAFC procedure
33055756|NCT05298254|Experimental|Non-adjuvanted HSV formulation 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 1 vaccine, one at Day 1 and one at Day 29.
33055757|NCT05298254|Experimental|Non-adjuvanted HSV formulation 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 2 vaccine, one at Day 1 and one at Day 29.
33055758|NCT05298254|Experimental|Non-adjuvanted HSV formulation 3 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 3 vaccine, one at Day 1 and one at Day 29.
33055759|NCT05298254|Experimental|HSV formulation 1 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
33055760|NCT05298254|Experimental|HSV formulation 2 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
33055761|NCT05298254|Experimental|HSV formulation 3 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
33055762|NCT05298254|Experimental|HSV formulation 1 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
33055763|NCT05298254|Experimental|HSV formulation 2 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
33055764|NCT05298254|Experimental|HSV formulation 3 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
33055765|NCT05298254|Placebo Comparator|Placebo - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
33055766|NCT05298254|Experimental|Selected formulation - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the formulation of the HSV vaccine selected from Part I of the study, one at Day 1 and one at Day 29.
33055767|NCT05298254|Placebo Comparator|Placebo - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
33112248|NCT04644120|Placebo Comparator|Part A: Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
33419062|NCT05074641|Active Comparator|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
33055768|NCT05290805|Experimental|ECMO flow rate reduction|In the intervention cohort ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
33055769|NCT05290805|No Intervention|no ECMO flow rate reduction|In this cohort ECMO flow rate is not reduced for CT image acquisition.
32869707|NCT05699148||Children with cystic fibrosis aged 6 to 11 years|Group of children who have at least one copy of Phe508del gene mutation and are eligible for starting on the modulator elexacaftor/ tezacaftor/ ivacaftor (ETI). This group will have baseline MRI scans before starting ETI and aiming to have subsequent scans post starting ETI (6 months to 1 year post starting ETI)
32869708|NCT05699148||Control Group|Age and gender matched controls with no history of cystic fibrosis or gastrointestinal disease. This group will undergo one set of scans only.
32869709|NCT04638517|Active Comparator|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
32869710|NCT04638517|Placebo Comparator|Placebo|Matching placebo capsules.
33055770|NCT05290064|Experimental|1/UPF HH, UPF HL, UNF LL, UPF LL|Four diets in the order specified
33055771|NCT05290064|Experimental|2/ UPF HL, UPF LL, UPF HH, UNF LL|Four diets in the order specified
33055772|NCT05290064|Experimental|3/ UPF LL, UNF LL, UPF HL, UPF HH|Four diets in the order specified
33055773|NCT05290064|Experimental|4/ UNF LL, UPF HH, UPF LL, UPF HL|Four diets in the order specified
33055774|NCT05289947|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks
33055775|NCT05289947|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
33055776|NCT05289947|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
33055777|NCT05287906|Experimental|Normal Weight Group|The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.
33055778|NCT05287906|Experimental|Overweight Group|The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
33055779|NCT05287906|Experimental|Type 2 Diabetes Mellitis Group|The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c <8%, and will receive all interventions.
33055780|NCT05280730||Boys with DMD|Boys ages 3 and above will be enrolled.
33055781|NCT05280730||Healthy boys|Healthy boys as a control group for brain imaging.
33055782|NCT05276024||iFuse Bedrock technique|Multilevel lumbar fusion procedure with additional sacroiliac joint stabilization using the iFuse-3D system
33055783|NCT05274815|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
33055784|NCT05274763|Experimental|Supportive Care (CCSH)|Patients undergo 4 to 8 sessions (2-4 per week) of CCSH over 30 minutes with a chaplain while impatient.
33055785|NCT05273736|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase medication adherence by 20% between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined by the modified Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous subjects.
33055786|NCT05273723|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase walking by 2,000 more steps per day between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined using a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous participants.
33055787|NCT05272059|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
33055788|NCT05272059|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
33055789|NCT05272059|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
33055790|NCT05272059|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
33055791|NCT05272059|Experimental|Part B: MHS552|Participants will MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
33055792|NCT05272059|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
33055793|NCT05270668|Experimental|PRA023|PRA023 IV administered by IV infusion
33055794|NCT05270668|Placebo Comparator|Placebo|Placebo administered by IV infusion
33055795|NCT05264701|Experimental|Physiotherapist Supervised Exercise Training Group|Physiotherapist supervised exercise training in patients with coronary artery disease
33055796|NCT05264701|Experimental|Exercise Training Tracking from Phone-app Group|Exercise training tracking from phone app in patients with coronary artery disease
33055797|NCT05264701|Experimental|Control Group|General physical activity recommendations for home
33055798|NCT05243615|Experimental|Stroke internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
33333354|NCT05317000|Experimental|Arm C: Combination 5-azacytidine and Nivolumab|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday. 5-azacytidine will be given prior to nivolumab on day 2.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Nivolumab will be administered at a dose of 240 mg IV day 2 and day 16. No additional premedication will be given on day 16. Dexamethasone will be reserved for patients whose nausea and/or emesis is not controlled by the initial regimen. Surgery will be scheduled in the period of day 17 through day 18."
33333355|NCT04838236|Experimental|MASP app + NRT|MASP is an intervention designed to assist African American smokers with anxiety sensitivity quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.
33333356|NCT04838236|Other|QuitGuide app + NRT|The QuitGuide app is a standard of care app that allows users to track their nicotine cravings, and provides users with motivational messages.
32869711|NCT05539950|Experimental|Cardiopulmonary rehabilitation with health education|The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.
33333357|NCT04831684|Placebo Comparator|Group A|
33333358|NCT04831684|Experimental|Group B|
33055799|NCT05243615|Active Comparator|Stroke Rehabilitation Education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
33055800|NCT05240664|Experimental|ACP intervention|It is a theory-driven ACP programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model.
33055801|NCT05240664|Placebo Comparator|Attention-control health talks|Dyads of participants in the control group will receive health talks. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
33055802|NCT05236114||Cohort 1|Cohort 1 will include patients with early-stage and locally advanced disease (stages I-IIIB) who are candidates for definitive surgical resection.
33055803|NCT05236114||Cohort 2|Cohort 2 will include patients with stage IV disease receiving first line IO (mono/combo) therapy.
33055804|NCT05235828|Experimental|Active intervention (ACT) group|8-12 participants will meet for 3-hour sessions for the first 5 days of the intervention. This is followed by five weeks of 1-hour sessions twice per week. In total, the intervention will be 15 sessions that run for a total of 25 hours over 6-weeks. Experienced and licensed SKY instructors from the International Association for Human Values (IAHV) and Art of Living Foundation (AOLF) will provide the intervention through video calls. Instructors will guide participants through the v-SKY intervention through visual demonstrations and verbal guidance. All sessions will be delivered virtually using Zoom. Sessions will not be recorded.
33055805|NCT05235828|No Intervention|Waitlist control (WLC) group|8-12 participants will not receive the intervention for 6-weeks. The 6-weeks will line up with the v-SKY intervention that the ACT group receives. After the waitlist period, the WLC group will receive the same v-SKY intervention as the ACT group. According to our earlier estimates, a high number of veterans with PTSD may not be actively receiving treatment for their illness. For these reasons, a waitlist control design may better reflect the current treatment environment for veterans with PTSD.
33055806|NCT05234177||Participants with stage I-IV colorectal cancer (CRC)|This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.
33055807|NCT05220046|Experimental|Psilocybin Treatment Arm|Participant with pancreatobilliary cancer will receive 25mg of psilocybin in one 8-hour monitored session with supportive counseling before and after session.
33055808|NCT05220046|No Intervention|Family Observation Group|The study participant will select a family member who will provide parallel data regarding distress related to pancreatobiliary cancer.
33055809|NCT05217940|Experimental|Women With Prior HPV for Anal Neoplasia|Standard of care anal cancer screening with anal cytology, HPV testing and high resolution anoscopy.
33055810|NCT05216393|Experimental|intervention|The intervention group will be mailed a Fitbit device and provided access to the RecTech Match website. Intervention participants will receive weekly calls for the first 6 weeks, and a call every other week for the following 6 weeks (9 in total) from a health coach to discuss progress, facilitate setting physical activity goals, and help mitigate obstacles to participate in physical activity in the community. Participants will be free to access the features and resources of the website. The Fitbit data will be collected on an ongoing basis and the participants will receive daily texts asking them to rate the amount of physical activity for the day.
33055811|NCT05216393|No Intervention|Control|The control participants will not have access to the RecTech Match website; however, control participants will be directed to generic information available on the NCHPAD website, which includes the same information but is not delivered through RecTechMatch.com.
33055812|NCT05216263|Experimental|Atogepant|Participants will receive atogepant once a day (QD) during the 24-week treatment period.
33055813|NCT05212480|Active Comparator|Zinc arm|patients received a pill containing 25 mg of zinc twice a day for 15 days
33055814|NCT05212480|Placebo Comparator|Placebo|patients received identical shape, smell, taste and color pill like the protocol treatment twice a day for 15 days
33055815|NCT05209308|Experimental|Cohort A|"Ven low dose + Rituximab + Zandelisib"
33055816|NCT05209308|Experimental|Cohort B|"Ven standard dose + Rituximab + Zandelisib"
33055817|NCT05208528|Experimental|ES1 group|Participants treated with Bifidobacterium longum ES1 for 2 months.
33055818|NCT05208528|Experimental|HT-ES1 group|Participants treated with heat treated version of ES1 for 2 months.
33055819|NCT05208528|Placebo Comparator|Control group|Participants treated with maltodextrin for 2 months.
33419063|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
33055825|NCT05202223|Experimental|Harmony at HOME|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
33333359|NCT05316688|Experimental|Diagnostic (tozuleristide, surgery, NIR imaging)|Beginning 1 hour before surgery, patients receive tozuleristide IV over 1-5 minutes. Patients then surgical resection per standard of care and undergo Canvas NIR imaging.
33333360|NCT05309668|Experimental|Selumetinib single arm|This study consists of a screening period (up to 28 days), a treatment period (25 cycles) and a long term safety follow-up for participants until they are 5 years old or commence an alternative systemic NF1-PN treatment, whichever is the earlier. Participants may continue treatment with selumetinib throughout the long term safety follow-up as long as they are considered to be receiving clinical benefit in the opinion of their Investigator. A safety follow up assessment will be performed 30 days after the last dose of study intervention for all study participants.
33055826|NCT05201066|Experimental|Sabatolimab + azacitidine|Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w
33055827|NCT05201066|Experimental|sabatolimab + decitabine|Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.
33055828|NCT05201066|Experimental|sabatolimab + venetoclax + azacitidine|Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w
33055829|NCT05201066|Experimental|sabatolimab + spartalizumab + decitabine|Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.
33055830|NCT05201066|Experimental|sabatolimab + HMA|"Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w~HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine."
33055831|NCT05198492||Patients with hospitalizations or emergency room visits due to acute coronary syndromes|Data on hospitalization for acute coronary syndromes were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
33068162|NCT04514770|Active Comparator|early amniotomy|"Group A:~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~Early amniotomy was performed for the participant of the first group at 3 cementer cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix."
33333363|NCT05292664|Experimental|Cohort A|"For Part 1, participants will receive:~Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 14-20 people will participate in Part 2 (Dose Expansion) of this cohort Treatment cycle is approximately 28 days for up to 4 cycles~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
33333364|NCT05292664|Experimental|Cohort B|"Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) with an underlying genetic condition that increases their risk for developing treatment-related toxicities. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 6 people will participate in Part 2 (Dose Expansion) of this cohort.~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
33333365|NCT05292664|Experimental|Cohort C|"Patients with relapsed/refractory acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) or acute leuekmai of ambiguous lineage. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 12 people will participate in Part 2 (Dose Expansion) of this cohort.~Cohort C: Treatment cycle is approximately 32 days for one cycle and will be a single treatment cycle:~Dosage, duration and timings as outlined in protocol.~Venetoclax~Dexamethasone~Vincristine~Doxorubicin~Dexrazoxane~Calaspargase pegol~Cytarabine~Methotrexate~Hydrocortisone~Leucovorin- *Cytarabine, Methotrexate, Hydrocortisone and Leucovorin may be given more frequently if leukemia/lymphoma cells are detected in spinal fluid),"
33055832|NCT05198492||Patients with hospitalizations or emergency room visits due to atrial fibrillation|Data on hospitalization for atrial fibrillation were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
33055833|NCT05198492||Patients with hospitalizations or emergency room visits due to kidney diseases|Data on hospitalization for kidney diseases were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
33055834|NCT05198492||Patients who died due to cardiovascular diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
33055835|NCT05198492||Patients who died due to neoplasm diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
33055836|NCT05198492||Patients who died due to kidney diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
33055837|NCT05187624|Experimental|Part I: Dose Escalation|Participants with newly diagnosed GBM will receive RO7428731, intravenously (IV), up to one year or until disease progression, withdrawal of consent, unacceptable toxicity, or death, whichever occurs first.
33055838|NCT05187624|Experimental|Part II: Dose-Expansion(s)|Participants with newly diagnosed GBM will receive RO7428731, IV, in maximum of two dose expansion cohorts at a dose(s) not exceeding the maximum tolerated dose (MTD) established in Part I.
33055839|NCT05187624|Experimental|Part III: Safety Run-in|Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
33055840|NCT05187624|Experimental|Part IV A: Dose-Expansions Cohort|Participants with recurrent GBM will receive RO7428731, IV at specified doses and dosing schedules.
33055841|NCT05186753|Experimental|(Part 1a) Bezuclastinib Dose 1 + BSC|
33055842|NCT05186753|Experimental|(Part 1a) Bezuclastinib Dose 2 + BSC|
33055843|NCT05186753|Placebo Comparator|(Part 1a) Placebo + BSC|
33055844|NCT05186753|Experimental|(Part 1b) Bezuclastinib Dose 1 + BSC|
33055845|NCT05186753|Experimental|(Part 1b) Bezuclastinib Dose 2 + BSC|
33333366|NCT05289934|Experimental|Children with Epilepsy|Children (age: 4- 17 years old) will participate in this study, and they will listen to Mozart K.448 (1st movement) and instrumental age-appropriate song with 10 minutes wash out in between, each lasting up to 9 minutes in the daytime (between 1-5 pm). The music stimuli will be randomly played in 2 to 7 days during the EMU stay (average 4 days). Music will be delivered via single-use earbuds.
33333367|NCT05282134|Experimental|Wet cupping therapy|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days. Cups will be held for 5 minutes on the 5 regions of the C7 cervical spine (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupoint) and bilateral T6-8 lateral spine (BL44-46) points, which are recommended areas for headache, Then, these areas where the blood supply has increased will be drawn with a sterile lancet and the cup will be applied again and left for 10 minutes, and then the cups will be removed and the accumulated blood will be cleaned.
33055846|NCT05186753|Placebo Comparator|(Part 1b) Placebo + BSC|
33055847|NCT05186753|Experimental|(Part 2) Bezuclastinib Selected Dose + BSC|
33055848|NCT05186753|Placebo Comparator|(Part 2) Placebo + BSC|
33055849|NCT05186753|Experimental|(Part 3) Bezuclastinib + BSC|
33055850|NCT05180721|Experimental|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
33055851|NCT05180357||SEA+NP Patients on FASENRA (benralizumab)|SEA+NP Patients on FASENRA (benralizumab)
33055852|NCT05171192|Experimental|CMAP Plus LTP added to TAU|"C-MAP is a manual assisted intervention based on the principles of CBT which is focused on evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking, and relapse prevention strategies. As family conflicts are a common issue with this group one session is focused on the use of culturally sensitive training in assertiveness and conflict management. The LTP is a community-based parenting intervention designed to deal with early child development. The central feature of the LTP intervention is a pictorial calendar devised for parents which depicts eight successive stages of child development from birth to 3 years along with illustrations of parent-child play and other activities that promote parental involvement, learning, and attachment.~This will be added to Treatment as Usual"
33112249|NCT04644120|Experimental|Part A: Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
33333368|NCT05282134|Experimental|Acupuncture|Acupuncture application will be done by manually needling selected acupuncture points specific to the disease twice a week for 4 weeks. After the needles are placed, they will be manipulated to create a feeling of de-qi and left for 20 minutes.
33055853|NCT05171192|No Intervention|TAU alone|TAU alone will include routine follow up by Community Health Workers (CHWs) in Pakistan. Their work includes assisting with all aspects of maternal, new-born and childcare. Participants in treatment as usual arm will receive routine care.
33055854|NCT05170035|Experimental|MMS + Autologous patch|Mohs micrographic surgery + Autologus patch formed from 18 ml venous blood sample collected from the patient + polymycin-terramycin B ointment and a Jelonet applied on top of the patch.
33055855|NCT05170035|Active Comparator|MMS + Secondary intention healing|Mohs micropgraphic surgery + Polymycin-terramycin B ointment + dry wound dressing
33055856|NCT05166421|Experimental|AZD7442 (co-formulation)|Participants will receive single dose of AZD7442 (co-formulation of AZD8895 + AZD1061) on Day 1.
33055857|NCT05166421|Active Comparator|AZD8895 and AZD1061 (clonal cell line material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
33055858|NCT05166421|Active Comparator|AZD8895 and AZD1061 (cell pool material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
33055859|NCT05160545|Experimental|GNC-035|Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles
33055860|NCT05159700|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
33055861|NCT05157945|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
33055862|NCT05157854||SH residents|Participants in the AiMH intervention
33055863|NCT05157854||SH staff|Staff in the SH, acting as AiMH supporters
33055864|NCT05157581||Sezary Syndrome|15 subjects with Sezary Syndrome will comprise the single arm of this study
33055865|NCT05157048|Experimental|Marketing condition A|Participants will be randomized to a marketing condition.
33055866|NCT05157048|Experimental|Marketing condition B|Participants will be randomized to a marketing condition.
33055867|NCT05156827|Experimental|TB006|Participants will receive intravenous (IV) 3 infusions of 4000 milligrams (mg) TB006, one every 28 days (Q28D).
33055868|NCT05156827|Placebo Comparator|Placebo|Participants will receive an IV infusion of normal saline 500 milliliters (mL) Q28D.
33055869|NCT05156242|Experimental|Active-tDCS priming MCE|The subjects in active-tDCS priming with MCE group will receive the tDCS using 5X7 cm electrodes in which anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes. After that, the subjects will receive 20-minute MCE.
33055870|NCT05156242|Sham Comparator|Sham-tDCCS priming MCE|The subjects in sham-tDCS priming with MCE group will receive a 20-minute sham tDCS by setting the intensity at zero mA. After that, the subjects will receive 20-minute MCE.
33055871|NCT05156242|Active Comparator|NMES priming MCE|The subjects in NMES priming with MCE group will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes. After that, the subjects will receive 20-minute MCE.
33055872|NCT05156242|Active Comparator|Conventional physical therapy|The subjects in conventional physical therapy group will receive physical therapy modality (e.g., ultrasound, TENS, etc.) and general exercises.
33333369|NCT05282134|No Intervention|Control|Control group will not receive any intervention
33333370|NCT03619564||No protein restriction|No protein restriction
33055875|NCT05153707|Experimental|Clinical Pharmacist-led discharge education program|Clinical pharmacist-led services
33055876|NCT05153707|No Intervention|Control group|Usual care
33055877|NCT05153317|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
33055878|NCT05151003||Patients admitted to University Hospital San Martino, Genova, Italy|Adult patients admitted to University Hospital San Martino, Genova, Italy
33055879|NCT05150938||Cancer patients with VTE|Cancer patients who received anticoagulation treatment.
33055880|NCT05150093|Experimental|Electrophysiological signal data collection|Patients diagnosed with dystonia or tremor who are recommended for DBS surgery. Electrophysiological data will be collected at the time of DBS surgery.
33055881|NCT05150015|Experimental|Number of consented patients who complete the antibiotics through an elastomeric pump|Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
33055882|NCT05148962|Experimental|Cohort 1: 1 or 2 Doses of 10 mcg GRT-R910 after AstraZeneca Standard of Care|Healthy adults ≥60 years of age receive up to 2 doses of 10 mcg GRT-R910 homologous prime-boost
33055883|NCT05148962|Experimental|Cohort 2: 1 or 2 Doses of 30 mcg GRT-R910 after AstraZeneca Standard of Care|Healthy adults ≥60 years of age receive up to 2 doses of 30 mcg GRT-R910 homologous prime-boost
33055884|NCT05148962|Experimental|Cohort 3: 2 Doses 10 mcg GRT-R910 after Adenovirus-Based Vector Vaccine Standard of Care|Healthy adults ≥60 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
33055885|NCT05148962|Experimental|Cohort 4: 2 Doses 10 mcg GRT-R910 after mRNA Vaccine Standard of Care|Healthy adults ≥60 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
33055886|NCT05148962|Experimental|Cohort 6: 2 Doses 10 mcg GRT-R910 after mRNA Vaccine Standard of Care|Healthy adults ≥18 to ≤59 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
33055887|NCT05147805|Experimental|Treprostinil Palmitil Inhalation Powder|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
33333371|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
33333372|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
33333373|NCT05278780|Experimental|Asynchronous screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
33112250|NCT04644120|Placebo Comparator|Part A: Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
33112251|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A|Participants will receive ABBV-2B04 Dose A on Day 1.
33112252|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A + ABBV-47D11|Participants will receive ABBV-2B04 Dose A in combination with ABBV-47D11 on Day 1.
33112253|NCT04644120|Placebo Comparator|Part B: Group 1: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
33112254|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B|Participants will receive ABBV-2B04 Dose B on Day 1.
33112255|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B + ABBV-47D11|Participants will receive ABBV-2B04 Dose B in combination with ABBV-47D11 on Day 1.
33112256|NCT04644120|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
33112257|NCT04946201||With Extractions|Patients in this group will undergo dental extractions.
33112258|NCT04946201||Without Extractions|Patients in this group will not undergo dental extractions.
33112259|NCT04942145|Active Comparator|Virtual Reality Group|With virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
33112260|NCT04942145|Experimental|Control Grooup|Without virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
33112261|NCT04643964|Experimental|Entrée: Cognitive Skills|
33112262|NCT04643964|Experimental|Entrée: Behavioral Skills|
32869712|NCT05539950|Active Comparator|Health education|The participants will be given recommendations for individualized exercise prescription and lifestyle modification.
33361360|NCT03511222|Experimental|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
33361361|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
33361362|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
32869715|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
32869716|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
32869717|NCT04467723|Experimental|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
32869718|NCT05697900|Active Comparator|Creatine monohydrate|5 g of creatine monohydrate per day for eight weeks
32869719|NCT05697900|Experimental|Creatine hydrochloride|5 g of creatine hydrochloride per day for eight weeks
33112263|NCT04643964|Experimental|Entrée: Interpersonal Skills|
33112264|NCT04643964|Experimental|Sampler Skills|
33112265|NCT04643964|No Intervention|Control|Participants are not given videos to watch until their involvement in the study ends.
33112266|NCT00548678|Experimental|A|intravenous diclofenac sodium
33112267|NCT00548678|Active Comparator|B|intravenous ketorolac
33112268|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
33112269|NCT00548678|Active Comparator|D|oral aspirin
33112270|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
33112271|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
33112272|NCT00548951|Other|3|Subject receives no sessions per week.
33112273|NCT04635501|Experimental|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
33112274|NCT04684199|Active Comparator|Melatonin|"Melatonin~All participants will receive a 5 mg. dose of melatonin before bed for a period of two weeks during study period."
33112275|NCT04684199|Placebo Comparator|Placebo|"Placebo~All participants will receive a placebo comparative in substance, color, and flavor, before bed for two weeks during the study."
33112276|NCT04635267||patients with ARDS|
33112277|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
33112278|NCT00548990|Placebo Comparator|2|flexibility/balance control group
33112279|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
33112280|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
33112281|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
33112282|NCT04644198|Active Comparator|Convalescent Plasma Treatment|Convalescent Plasma
33112283|NCT04644198|No Intervention|Control|Standard of care
33112284|NCT04643730|Experimental|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
33112285|NCT04643730|Experimental|Acupressure Group|Acupressure was applied to the babies before heel lancing
33112286|NCT04643730|Active Comparator|Control Group|No pre-application was made to the babies in the control group as a routine procedure
33112287|NCT00549107|Experimental|1|
33112288|NCT00549107|Active Comparator|2|
33112289|NCT04635306|Experimental|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
33361363|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
33361364|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
33112290|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
33112291|NCT04643847|Experimental|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
33112292|NCT00549341|Active Comparator|1|
33112293|NCT00549341|Placebo Comparator|2|
33112294|NCT00549380|Experimental|1|
32869720|NCT05697900|Placebo Comparator|Placebo|5 g of maltodextrin per day for eight weeks
33112295|NCT04635462|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
33112296|NCT04635462|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
33112297|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
33112298|NCT00549419|Active Comparator|2|
33112299|NCT04635540|Experimental|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
33112300|NCT04635150|Experimental|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
33112301|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
33112302|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
33112303|NCT04643691|Experimental|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
33112304|NCT04643691|No Intervention|usual care|Usual care of COVID-19 infection in intensive care
33112305|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.~Intervention: BFA"
33112306|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider~No interventions"
33112308|NCT03455972|Experimental|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (on d0) and anti-BCMA CAR T cells as split-dose (40% on d1 and 60% on d2)
32869721|NCT04388995|Experimental|observed patients|
32869722|NCT04437069|No Intervention|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
33112309|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
33112310|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
33112311|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
33112312|NCT04634994|Experimental|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for [F-18]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for [F-18]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
33112313|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
32869723|NCT04437069|Experimental|Decision Aid|Participants view the Decision Aid only
32869724|NCT04437069|Experimental|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
33112314|NCT00549497|Other|GW870086X|
33112315|NCT04643652|No Intervention|Control|Usual Care
33112316|NCT04643652|Experimental|Intervention|Implementation of a Noise Reduction Bundle
33112317|NCT00549536|No Intervention|2|
33112318|NCT00549536|Active Comparator|1|Patients on calcium supplementation
33112319|NCT04643613|Experimental|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
33112320|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
33361365|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
33361366|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
33419064|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
33419065|NCT05611983|Active Comparator|Observation fo touch|
33055888|NCT05147805|Placebo Comparator|Placebo|Participants will be administered a placebo matching TPIP once per day for 16 weeks.
33055889|NCT05144841|Experimental|Arm A|Participants will receive treatment with zilovertamab vedotin 2.5 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
33055890|NCT05144841|Experimental|Arm B|Participants will receive treatment with zilovertamab vedotin 2.25 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
33055891|NCT05142111|Experimental|Sexual therapy|In the sessions a series of questions will be proposed to the subject, who will be free to answer or not, being able to express questions in turn. The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions.
33055892|NCT05142111|Active Comparator|Mindfulness|"During the mindfulness treatment the subjects will be subjected to sessions in which they will be invited to relax, to become aware of the present moment, of their body, through exercises that involve breathing, attention, and visualization of the body.~The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions."
33055893|NCT05141643|Experimental|Participants with pancreatic ductal adenocarcinoma (PDAC)|Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC). The experimental design of this study is to perform a single [18F]-FAC PET scan prior to the administration of chemotherapy with an optional second [18F]-FAC PET scan procedure during SOC treatment to observe changes in tumor uptake and biodistribution. Patients will be offered a second [18F]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
33055894|NCT05140915|Experimental|Intervention|Students in school randomized to the intervention will receive: (1) peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit; (2) peer coaching, facilitated by texting; and (3) gamification, designed to motivate participation.
33055895|NCT05140915|Active Comparator|Control|Students in schools randomized to the control condition will be provided written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
33055902|NCT05134948|Experimental|Cohort A: BMS-986213 Fixed Dose Combination|
33055903|NCT05134948|Experimental|Cohort B: BMS-986213 Fixed Dose Combination|
33055904|NCT05134545|Experimental|Genoss® DCB|Paclitaxel Coated PTA Balloon Catheter
33055905|NCT05134545|Active Comparator|IN.PACT Admiral® DCB|Paclitaxel Coated PTA Balloon Catheter
33055906|NCT05134012|Experimental|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|All participants with suspected CAD will receive two doses of [15-O]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).
33055907|NCT05133271|Experimental|Scheduled cesarean section|Patient with scheduled cesarean section under spinal anesthesia.
33055908|NCT05129020|Experimental|Active tAN + Morphine|
33055909|NCT05129020|Sham Comparator|Sham tAN + Morphine|
33055910|NCT05120869|Experimental|Treatment|A tailored HPV education and professional skills intervention.
33055911|NCT05120869|Active Comparator|Control|General/publicly available educational materials on HPV and communication skills.
33419066|NCT05611983|Active Comparator|Observation of pictures|
32740470|NCT05726513|Other|Low support, high Positive end-expiratory pressure|Low support, high Positive end-expiratory pressure
33055912|NCT05119985|Active Comparator|Ultrasound guided cannulation|Ultrasound guided insertion of peripheral vein cannula.
33055913|NCT05119985|Active Comparator|Cannulation without ultrasound|Catheter insertion by conventional approach, without ultrasound guidance
33055914|NCT05112848|Experimental|Group 1 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
33419067|NCT05611983|Active Comparator|Imagery of touch|
33419068|NCT05611983|Active Comparator|Mirror therapy|
33419069|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
33419070|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
33361367|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
33055915|NCT05112848|Experimental|Group 2 PLWH|Three doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0, Day 21, and Day 70.
33055916|NCT05112848|Experimental|Group 3 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
33055917|NCT05112848|Experimental|Group 4 HIV-Negative Participants|"2 doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
33055918|NCT05112848|Experimental|Group 5 HIV-Negative Participants|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
33055919|NCT05111678||Indoor air pollutant groups|50 patients that have been exposed to indoor air pollutants
33055920|NCT05111678||Neurological symptoms groups|50 patients with neurological symptoms possibly due to adverse external exposure without any exposure to indoor air pollutants
33055921|NCT05111678||Healthy controls|25 healthy age- and gender-matched controls
33055922|NCT05107466|Other|Individuals with Hearing Loss|60 adults (>18 y/o) with a diagnosis of hearing loss. These participants may use cochlear implant(s), hearing aid(s), or have unaided hearing loss.
33055923|NCT05107466|Other|Individuals with Normal Hearing|40 adults (>18 y/o) without a diagnosis of hearing loss.
33055924|NCT05104775|Experimental|study treatment|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
33055925|NCT05104073|Experimental|Intervention|The intervention arm is characterized by calibrated formula feeding recommendations. The intervention group parents will be given written instructions on infant hunger and satiety cues as well as copies of videos with guidance on bottle feeding and how to soothe fussy infants without feeding. N=30 meeting inclusion/exclusion criteria
33055926|NCT05104073|No Intervention|Control|The control arm will have ad lib feeds as per usual care. N=30 meeting inclusion/exclusion criteria
33055927|NCT05089955|Experimental|Intervention group|MRI examination with Ambient Experience with paediatric content
33055928|NCT05089955|No Intervention|Control group|MRI examination without Ambient Experience (standard of care)
33055929|NCT05079412||NIV-NAVA group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIV-NAVA for at least 24 hours are enrolled in this arm after obtaining parents' consent.
33055930|NCT05079412||NIPPV group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIPPV for at least 24 hours are enrolled in this arm after obtaining parents' consent.
33055931|NCT05075694|Experimental|Experiment|Therapeutic touch (TT) is a treatment that takes an average of 15-20 min, in which energy in the universe is transferred through the hands of the practitioner to eliminate the imbalance in the individual's energy field and facilitate healing. The intervention group (TT group) received therapeutic touch for 10 minutes a day for five consecutive days. The practice was implemented in line with Therapeutic Practice Procedure.
33055932|NCT05075694|Sham Comparator|Control|Placebo: Sham Therapeutic Touch (STT) The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with Sham Therapeutic Touch Practice Procedure (STTPP).
33055933|NCT05072483||Healthy controls|Healthy controls for exploratory analyses, where the measurements were not commonly performed previously in other populations, for qualitative comparison with CADASIL population
33055934|NCT05072483||Subjects with CADASIL|Adult genetically-confirmed patients with a wider range of CADASIL disease duration and debility
33055935|NCT05072197|Experimental|Mobile device application group|routine care and mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment
33055936|NCT05072197|No Intervention|control group|routine care for breast cancer women during their chemotherapy treatment
33055937|NCT05062252|Experimental|Mirror group|Mirror Medacta Shoulder System
33055938|NCT05062252|Active Comparator|Historical Control group|Total shoulder arthroplasty system
33055939|NCT05059262|Experimental|Part 1/Part 2 - vimseltinib/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
33055940|NCT05059262|Placebo Comparator|Part 1/Part 2 - placebo/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
33055941|NCT05057884|Experimental|Breathing training|The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.
33055942|NCT05057884|No Intervention|Control|The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perform the breathing training after study completion.
33055943|NCT05054387|Experimental|Agalsidase beta|Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion
33055944|NCT05053503|Placebo Comparator|Active tAN + placebo|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
33419071|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
33333374|NCT05273164|Experimental|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring ~45 minutes. with 40 trials for each exercise.
33333375|NCT05273164|Active Comparator|Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring ~45 minutes."
33112321|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
33112322|NCT00549614|Experimental|1|
33112323|NCT00549614|Placebo Comparator|2|
33112324|NCT00558987|Experimental|1|
33112325|NCT00558987|Sham Comparator|2|
33112326|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
33333376|NCT04775914|Active Comparator|PCI standard|
33333377|NCT04775914|Experimental|PCI standard + ischemic conditioning|
33333378|NCT04775914|Experimental|Stent with ultrasound|
32869725|NCT05539872|Experimental|Insulin Aspart, I004|Participants who were dosed with I004
33112327|NCT00560664|Active Comparator|2|Mosaicoplasty
33112328|NCT00549692|Experimental|Omacor|
33112329|NCT00549692|Placebo Comparator|Placebo Omacor|
33333379|NCT04775914|Active Comparator|Stent without ultrasound|
33333380|NCT05265832|Experimental|Cataract surgery|Phacoemulsification cataract surgery
33112330|NCT00560742|Active Comparator|Control|
33112331|NCT00560742|Experimental|Intramuscular|
33112332|NCT00560742|Experimental|Intracoronary|
33112333|NCT04923542|Experimental|Phase 1: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. In the phase I portion, safety will be monitored initially by a 3+3 design. If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
33112334|NCT04923542|Experimental|Phase 2: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation at the phase 1 dose to sites of brain metastases or post-operative cavities with continued abemaciclib.
33333381|NCT04763278|Experimental|Prosthesis|Patient is temporarily fit with Point Digit partial hand prosthetic system
33112335|NCT00560781|Active Comparator|1|Pregnenolone
33112336|NCT00560781|Placebo Comparator|2|Placebo
33112337|NCT00549731||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study."
33112338|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
33112339|NCT00559026|Active Comparator|1|
33112340|NCT00559026|Experimental|2|
33112341|NCT00549809|Active Comparator|IMV, SIMV|
33112342|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
33333382|NCT05264116|Experimental|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.
33333383|NCT04741984|Experimental|MT-201-GBM monocyte vaccine|pp65 monocyte vaccines (MT-201-GBM) - cohorts of patients will receive increasing doses (dose escalation) of MT-201-GBM followed by a dose expansion cohort at the maximum tolerated dose. Patients will receive a total of 3 intravenous vaccines every 4 weeks after completing standard radiation therapy (XRT) and temozolomide (TMZ) and a single course of dose-intensified TMZ.
33333384|NCT05237752|Experimental|LG00034053|White to slightly brown powder, dosage (6mg, 15mg, 45mg; dose escalation design), single dose administration
33333385|NCT05237752|Placebo Comparator|Placebo|Clear liquid, single dose administration
33333386|NCT05237362|Experimental|Intervention|Receives the Saga Stories health promotion talk as well as take-home material
33333387|NCT05237362|No Intervention|Control|Receives standard health promotion talk
33112343|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
33112344|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
33112345|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
33112346|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
33112347|NCT04643340||sham|This group will only train the insula by a particular strategy
33112348|NCT00549926|Active Comparator|1|
33112349|NCT00549926|Active Comparator|2|
33112350|NCT00549926|Active Comparator|3|
33112351|NCT00549926|Active Comparator|4|
33112352|NCT04634448|Other|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
33419072|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
33055945|NCT05053503|Active Comparator|Active tAN + lofexidine|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
33055946|NCT05053503|No Intervention|Sham tAN + placebo|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
33055947|NCT05053503|Sham Comparator|Sham tAN + lofexidine|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
33055948|NCT05053503|Active Comparator|extended-release injectable naltrexone|Extended-release injectable naltrexone will be administered according to the clinical site's standard of care.
33333388|NCT05233618|Experimental|Tagraxofusp (escalating doses)|IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
33333389|NCT05227144|Experimental|Dose Escalation|ORIC-533 dosed orally, once per day of each consecutive 28-day cycle.
33333390|NCT05227144|Experimental|Dose Expansion|RP2D dose
33333391|NCT04716946|Experimental|Participants with Early-stage Non-Small Cell Lung Cancer|Participants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
33333392|NCT04714216|Experimental|Hybrid closed-loop (HCL) automated insulin delivery (AID)|Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.
33333393|NCT04690816||Healthy Volunteers|Healthy Volunteers to have a comparative group,without an underlying autoimmune disease or other significant medical problems
33419073|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
32869726|NCT05539872|Active Comparator|NovoLog|Participants who were dosed with NovoLog
33055949|NCT05053503|Experimental|Active tAN + extended-release injectable naltrexone|"Extended-release injectable naltrexone will be administered according to the clinical site's standard of care. Participants will be provided with a Spark Sparrow Ascent Therapy System and instructed to administer therapy according to the specified frequencies:~Month 1 (Days 1 - 28): a minimum of 2 hours per day at least 5 days a week~Month 2 (Days 29 - 56): a minimum of 2 hours per day at least 3 days a week~Month 3 (Days 57 - 90: a minimum of 2 hours per day at least 1 day per week"
33055950|NCT05050578|Other|LID018869, then AOHP|Lehfilcon A contact lenses worn in Period 1, followed by senofilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
33055951|NCT05050578|Other|AOHP, then LID018869|Senofilcon A contact lenses worn in Period 1, followed by lehfilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
33055952|NCT05050253|Experimental|SOS group|Peritoneal lavage with super-oxidized solution (SOS)
33055953|NCT05050253|Active Comparator|Control group|Peritoneal lavage with Ringer's solution
33055954|NCT05046106|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
33055955|NCT05046106|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
33055956|NCT05046106|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
33055957|NCT05041491|Experimental|BREAK Intervention|Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
33055958|NCT05041491|Active Comparator|ONE Intervention|Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
33055959|NCT05041374||Study Cohort|Patients with known or suspected gastrointestinal disease
33055960|NCT05040646||Patients|Patients who follow the watch-and-wait program for rectal cancer.
33055961|NCT05040646||Experts|Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.
33055962|NCT05040373||Patisiran|Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.
33055963|NCT05039931|Experimental|GNC-035|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
33055964|NCT05035511|Experimental|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
33055965|NCT05030584|Active Comparator|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
33055966|NCT05030584|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
33055967|NCT05029622|Experimental|Triptorelin formulation for Intramuscular injection (IM).|
33333394|NCT04690816||Systemic Autoimmune Diseases|Patients with associated systemic autoimmune diseases.
33333395|NCT04688320|Experimental|Recombinant nonimmunogenic staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
33333396|NCT04688320|Experimental|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
33055968|NCT05028361|Other|Simultaneous Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and IIV4 at Visit 1, saline placebo at Visit 2, and mRNA COVID-19 vaccine at Visit 3 for participants receiving their primary series of mRNA COVID-19 vaccine.
33055969|NCT05028361|Other|Sequential Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and placebo at Visit 1, IIV4 at Visit 2, and mRNA COVID-19 vaccine at Visit 3 for participants receiving their primary series of mRNA COVID-19 vaccine.
33055970|NCT05016245|Experimental|TheraSphere™ Yttrium-90 Glass Microspheres|
33055971|NCT05016245|Active Comparator|conventional Transarterial Chemoembolization(cTACE)|
33333397|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
32869727|NCT05544474||Expert surgeon on radical right colectomy|Expert surgeon on radical right colectomy com pricing corresponding author/senior author from paper included in a preliminary systematic review on this topic Sica GS, Vinci D, Siragusa L, Sensi B, Guida AM, Bellato V, García-Granero Á, Pellino G. Definition and reporting of lymphadenectomy and complete mesocolic excision for radical right colectomy: a systematic review. Surg Endosc. 2022 Sep 12. doi: 10.1007/s00464-022-09548-5.
32869728|NCT04425642|Experimental|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
32869729|NCT04425642|Experimental|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
32869730|NCT00266851|Active Comparator|Azithromycin|Active adjunctive treatment
32869731|NCT00266851|Placebo Comparator|Placebo|Adjunctive placebo
32869732|NCT00266851|Other|Observational Cohort|Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
33055972|NCT05010759|Experimental|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
33055973|NCT05010122|Experimental|Treatment (decitabine, cedazuridine, venetoclax, gilteritib)|"INDUCTION (CYCLE 1): Patients receive decitabine and cedazuridine PO QD on days 1-5, venetoclax PO QD on days 1-28, and gilteritinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 2-24): Patients receive decitabine and cedazuridine PO QD on days 1-5, gilteritinib PO QD on days 1-28, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (CYCLES 24+): Patients receive gilteritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33055974|NCT05008055|Experimental|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
33055975|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and Quadrivalent adjuvanted influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the quadrivalent adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
33055976|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and high-dose quadrivalent influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
33055977|NCT05006794|Experimental|Part A: GS-9716 Dose-Escalation|Participants will receive escalating doses of GS-9716 to establish MTD.
33055978|NCT05006794|Experimental|Part A: GS-9716 Dose-Expansion|Participants will receive the MTD or below MTD of GS-9716.
33055979|NCT05006794|Experimental|Part B (Cohort B1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
33055980|NCT05006794|Experimental|Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
33055981|NCT05006794|Experimental|Part B (Cohort B3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
33055982|NCT05006794|Experimental|Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
33055983|NCT05006794|Experimental|Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
33055984|NCT05006794|Experimental|Part C (Cohort C1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
33055985|NCT05006794|Experimental|Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
33055986|NCT05006794|Experimental|Part C (Cohort C3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
33055987|NCT05006794|Experimental|Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
33333398|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~Placebo~Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
33333399|NCT04614064|Experimental|COPD patients|As per inclusion and exclusion criteria for COPD patients
33333400|NCT04614064|Experimental|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
33333401|NCT03689842|Experimental|Couple donor - recipient|
33333402|NCT05208346|Experimental|Canola oil high-fat|Participants randomized to receive a mixed meal with 50 g canola oil
33333403|NCT05208346|Experimental|Coconut oil high-fat|Participants randomized to receive a mixed meal with 50 g coconut oil
33055988|NCT05006794|Experimental|Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
33055989|NCT05001594|No Intervention|Usual care+ Sham device|"Each participant will go through the normal rehabilitation process that follows ACL reconstruction+ a sham device used in the same was as the intervention group.~The sham device will look the same, will gave the same pressure around the leg, but will not vibrate."
33055990|NCT05001594|Experimental|Usual care+ knee vibratory device|Each participant will go through the normal rehabilitation process that follows ACL reconstruction. Additionally, each participant will receive the active device that applies non-invasive vibrational stimulation to the leg for two months, and will be asked to wear it during ambulation for at least an hour per day.
33055991|NCT05001594|No Intervention|Normative data|"Healthy participants will go through one session of the full protocol (excluding blood tests):~Questionnaires (IKDC, TSK, GAD-7).~Biomechanical analysis during walking, stair ambulation, and hoping.~Quadriceps and Hamstring strength testing"
33055992|NCT05000788|Experimental|Qigong Group|
33055993|NCT05000788|Active Comparator|Exercise Group|
33055994|NCT04992936|Experimental|Extract from the wine industry|Participants will consume the extract from the wine industry for 5 weeks.
33055995|NCT04992936|Placebo Comparator|Placebo|Participants will consume maltodextrin for 5 weeks.
33055996|NCT04990817|Experimental|Average American Diet With SoFAS Replaced With Avocado|Average American diet with foods that provide the equivalent of 1 medium to large avocado per day. It is anticipated that energy from avocado would replace 12-15% of daily energy, roughly half from solid fats and half from added sugars (SoFAS).
33055997|NCT04990817|Placebo Comparator|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
33055998|NCT04990102|Experimental|CPX-351|Dose Level 1: CPX-351 administered through intravenou infusion on Day 1 and Day 3 of 28 day cycle for 6 cycles or Dose Level -1: CPX-351 administered through intravenous infusion on Day 1 of each 28 day cycle for 6 cycles.
33055999|NCT04982471||First relapsed/refractory diffuse large B-cell lymphoma|First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants must have been diagnosed with relapsed/refractory (R/R) disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
33056000|NCT04982471||First relapsed/refractory follicular lymphoma|First relapsed/refractory (R/R) follicular lymphoma (FL) participants must have been diagnosed with R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
33056001|NCT04981847|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
33056002|NCT04981847|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern. There is also less calcium and vitamin D because it includes fewer dairy foods.
33056003|NCT04981847|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
33056004|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
33056005|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
33056006|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
33056007|NCT04962360|Experimental|Nutritional standardized supplementation formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
33056008|NCT04962360|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
33056009|NCT04962334|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
33056010|NCT04962334|Placebo Comparator|Placebo|Low caloric formula (Powder added to waster) without added vitamins and minerals
33068163|NCT04514770|Active Comparator|Late amniotomy|"Group B:~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~late amniotomy was performed for the participant of the second group at 7 cementer cervical dilatation."
33068164|NCT04514809|Experimental|Experimental|It consists of 15 mothers who meet the inclusion criteria
33068165|NCT04514809|Experimental|Control Groups|It consists of 15 mothers who meet the inclusion criteria
33333404|NCT05208346|Experimental|Canola oil low-fat|Participants randomized to receive a mixed meal with 25 g canola oil
33056011|NCT04949256|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab intravenously (IV) plus lenvatinib orally in combination with FP or TP in Part 1, or in combination with investigator's choice of chemotherapy with FP IV or TP IV or oxaliplatin, 5-FU and leucovorin (mFOLFOX6) IV in Part 2. Induction consists of pembrolizumab 400 mg once every 6-weeks (Q6W) for up to ~12 weeks plus lenvatinib 8 mg once daily (QD) for up to ~12 weeks plus chemotherapy with FP (cisplatin 80 mg/m^2 and 5-FU 4000 mg/m^2) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2) once every 3 weeks (Q3W) for up to ~12 weeks or mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2, and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] once every 2 weeks [Q2W] for up to ~12 weeks). This is followed by consolidation with pembrolizumab 400 mg Q6W for up to 16 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) plus lenvatinib 20 mg QD until progressive disease or discontinuation.
33333405|NCT05208346|Experimental|Coconut oil low-fat|Participants randomized to receive a mixed meal with 25 g coconut oil
33333406|NCT05203510|Experimental|Treprostinil|"Participants will receive parenteral treprostinil at initial dose of 1.25 nanograms/kilogram/minute (ng/kg/min) (0.625 ng/kg/min if initial dose isn't tolerated) either intravenously or subcutaneously. Based on Month6 mPAP assessment or earlier at Investigator's (PI's) discretion and after target dose is reached, participants may transition to oral treprostinil and continue dose uptitration for further reduction of mPAP or continue uptitration of parenteral treprostinil until Month 12. Based on Month 12 mPAP assessment at PI's discretion, participants may transition from parenteral to oral treprostinil, after completion of Month 12 assessment, and continue uptitration for further reduction of mPAP. If target dose isn't reached at Month 6/12 at PI's discretion, uptitration of parenteral treprostinil or oral treprostinil transition may occur to maintain normal mPAP.~Treprostinil therapy (parenteral or oral) may continue as tolerated to goal of further reduction of mPAP until Month 36."
33333407|NCT02032810|Experimental|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
33333408|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
33333409|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
33333410|NCT05036278|Experimental|Damoctocog alfa-pegol prophylaxis regimens|"Prophylaxis regimens:~Participants with a high risk score (> 4) continue on prophylaxis 2x/week (40 IU/kg/dose).~Participants with a medium risk score (2 to 4) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose).~Participants with a low risk score (< 2) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose) and then after 4 weeks to a less frequent (e.g. Q7D) regimen (60 IU/kg/dose)."
33333411|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
33333412|NCT05035810|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
33333413|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
32740471|NCT05726513|Other|Low support, zero positive end-expiratory pressure|Low support, zero positive end-expiratory pressure
33056012|NCT04949256|Active Comparator|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 400 mg IV Q6W for up to 18 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) in combination with investigator's choice of chemotherapy with FP (cisplatin 80 mg/m^2 IV Q3W for up to 6 administrations [up to ~18 weeks] and 5-FU 4000 mg/m^2 IV Q3W for up to 35 administrations [up to ~2 years]) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 Q3W for up 6 administrations [up to ~18 weeks]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2, and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] IV Q2W for up to 12 administrations [up to ~24 weeks, based on local guidance]), during Part 2.
33056013|NCT04948554|Experimental|Cohort 1: MK-2225|Participants in Cohort 1 will receive MK-2225 at 0.25 mg/kg once every two weeks (Q2W) plus standard of care (SOC) for 12 weeks.
33056014|NCT04948554|Placebo Comparator|Cohort 1: Placebo|Participants in Cohort 1 will receive placebo Q2W plus SOC for 12 weeks.
33056015|NCT04948554|Experimental|Cohort 2: MK-2225|Participants in Cohort 2 will receive MK-2225 at 0.5 mg/kg (or lower) Q2W plus SOC for 12 weeks.
33056016|NCT04948554|Placebo Comparator|Cohort 2: Placebo|Participants in Cohort 2 will receive placebo Q2W plus SOC for 12 weeks.
33056017|NCT04948554|Experimental|Cohort 3: MK-2225|Participants in Cohort 3 will receive MK-2225 at 1.0 mg/kg (or lower) Q2W plus SOC for 12 weeks.
33056018|NCT04948554|Placebo Comparator|Cohort 3: Placebo|Participants in Cohort 3 will receive placebo Q2W plus SOC for 12 weeks.
33056019|NCT04948554|Experimental|Cohort 4: MK-2225|Participants in Cohort 4 will receive MK-2225 at ≤2.0 mg/kg Q2W if needed plus SOC for 12 weeks.
33056020|NCT04948554|Placebo Comparator|Cohort 4: Placebo|Participants in Cohort 4 will receive placebo Q2W plus SOC for 12 weeks.
33056021|NCT04948554|Experimental|Cohort 5: MK-2225|Participants in Cohort 5 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
33056022|NCT04948554|Placebo Comparator|Cohort 5: Placebo|Participants in Cohort 5 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
33056023|NCT04948554|Experimental|Cohort 6: MK-2225|Participants in Cohort 6 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
33056024|NCT04948554|Placebo Comparator|Cohort 6: Placebo|Participants in Cohort 6 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
33056025|NCT04940949|Experimental|Single Intravenous (IV) Dose of Lu AF90103|Participants will receive a single IV dose of Lu AF90103.
33056026|NCT04940949|Placebo Comparator|Single IV Dose of Placebo|Participants will receive a single IV dose of placebo matching to Lu AF90103.
33056027|NCT04940949|Experimental|2 Single IV Doses of Lu AF90103|Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.
33056028|NCT04936542|Other|Sequence 1|Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles
33056029|NCT04936542|Other|Sequence 2|Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles
33419074|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
33056030|NCT04930653|Experimental|Treatment (ECP, mogamulizumab)|Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
33056031|NCT04929457||Individuals screened for Familial Hypercholesterolemia|Individuals participating in diagnostic activities in the digiphysical health care screening program for Familial Hypercholesterolemia and have provided informed consent are included in the cohort.
33056032|NCT04927702|Experimental|Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
33056033|NCT04927702|Active Comparator|Diabetic Foot Ulcer Participants Assigned to Standard of Care|Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
33056034|NCT04927702|Experimental|Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
33056035|NCT04927702|Active Comparator|Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
33056036|NCT04927377|Experimental|AI4DM Intervention Group|
33056037|NCT04927377|Active Comparator|Attention-control Group|
33056038|NCT04921514|Experimental|Patient and relatives|
33056039|NCT04916418|Placebo Comparator|G1, Placebo|Intravenous saline (NaCl 0,9%) will be administered. G1 group will be administered an initial dose of placebo (20ml) per catheter bilaterally (total volume 40ml) after TTP has been placed. This is followed by 20ml doses of placebo per catheter every 8 hours until 72 hours from the first dose has passed.
33056040|NCT04916418|Active Comparator|G2, Ropivacaine|Ropivacaine 0.5%. G2 group will be administered an initial dose of ropivacaine (20 ml) per catheter bilaterally (total volume 40ml) after the TTP has been placed. This is followed by 20 ml doses of ropivacain per catheter every 8 hours until 72 hours from the first dose has passed.
33056041|NCT04910776|Experimental|Avalglucosidase alfa|Administered intravenously every 2 weeks
33056042|NCT04909593|Experimental|Spinal Cord Stimulation|SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.
33056044|NCT04906148|Experimental|Smokers|Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
33056045|NCT04906148|Experimental|Non-smokers|Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
33056046|NCT04905693|Experimental|Inhaled Treprostinil|Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
33056047|NCT04901806|Experimental|Phase 1 Dose Escalation|
33056048|NCT04901806|Experimental|Phase 2 Cohort Expansion|
33056049|NCT04899518|Placebo Comparator|Vehicle Ophthalmic Solution|
33056050|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 1|
33056051|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 2|
33056052|NCT04893096|Experimental|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
33056053|NCT04892511|No Intervention|Standard treatment|"Post-thrombectomy patients will have their blood pressure measured every hour for the first 24 hours after thrombectomy, and every 6 hours from 24 to 72 hours. The target blood pressure is not predefined by the study, but in patients who have received previous treatment with rt-PA, it is advisable to keep it below 180/110 mmHg. If the patient has not received rt-PA, there is no limitation, although the guidelines recommend keeping the pressure below 200/120 mmHg.~The hypotensive or hypertensive treatments used will be noted."
33056054|NCT04892511|Experimental|Optimized hemodynamic treatment|"Post-thrombectomy patients will have their blood pressure measured every 30 minutes for the first 24 hours after thrombectomy, and every 1 hour from 24 to 72 hours. Blood pressure objectives will depend on the degree of recanalization achieved after thrombectomy (see intervention section).~The hypotensive or hypertensive treatments used will be noted."
33056055|NCT04890132|Experimental|Normal Controls|normal control participants - no history of neurologic or inner ear disease
33056056|NCT04890132|Experimental|Peripheral Vestibular Dysfunction|"Patients with unilateral vestibular damage due to monophasic illness such as vestibular neuritis or vestibular schwannoma (VS).~For VS patients, the investigators will test them in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months)."
33056057|NCT04889638|Experimental|Cessation intervention|Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.
33056058|NCT04888598||Type 1 diabetic patients|Recently diagnosed type 1 diabetes patients
33056059|NCT04882527|Experimental|anodal stimulation of the rIFL|Anodal stimulation over the right inferior frontal lobe
33056060|NCT04882527|Experimental|cathodal stimulation of the rIFL|Cathodal stimulation over the right inferior frontal lobe
33112353|NCT04634448|Other|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
33112354|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
33112355|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
33112356|NCT04634721|Active Comparator|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
33419075|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
33419076|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
33419077|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
33112357|NCT04634721|Active Comparator|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
33112358|NCT04634721|No Intervention|no TAP block|no TAP block would be done
33112359|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
33112360|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
33112361|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
33112362|NCT04917926|Experimental|Financial and social intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, social incentives and weekly feedback on performance for 6 months.
33112363|NCT04917926|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
33112364|NCT04917926|Experimental|Financial intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, and weekly feedback on performance for 6 months.
33112365|NCT04634565|Experimental|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
33112366|NCT04643145|Active Comparator|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
33112367|NCT04643145|Active Comparator|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
33112368|NCT00550121|Experimental|1|
33112369|NCT00550121|Placebo Comparator|2|
33112370|NCT04643028|Other|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
33419078|NCT05609877|No Intervention|Control group: LISA with analgesia combined with non-pharmacological approach as usual|The staff will perform Less Invasive Surfactant Administration using standard 0.5-1 mcg/kg fentanyl intravenously for LISA. In both groups, patients will receive the unit's standard pre- and post-procedure care including their non-pharmacological approach, use of atropine, caffeine, and naloxone at the discretion of the clinician based on local protocols and guidelines. All medications will be registered.
33419079|NCT05609877|Placebo Comparator|Intervention group: Non-pharmacological Approach LISA (NONA-LISA) alone|The staff will perform Less Invasive Surfactant Administration using the standard pre- and post-procedure care including non-pharmacological treatment. The patients will not receive pharmacological analgesic treatment routinely. In both groups, patients will receive the unit's standard pre- and post-procedure care including their non-pharmacological approach, use of atropine, caffeine, and naloxone at the discretion of the clinician based on local protocols and guidelines. All medications will be registered.
33419080|NCT04857697|Experimental|Supportive care (biospecimen collection, probiotic)|Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics PO once on day 1, and then BID or TID for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
33419081|NCT02119754|Experimental|Plurogel PN|Plurogel PN
33112371|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
33112372|NCT04643028|Other|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
32740472|NCT05726513|Other|Zero support, zero positive end-expiratory pressure|Zero support, zero positive end-expiratory pressure
33112373|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
33112374|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
33112375|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
33112376|NCT04643301|Experimental|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
33112377|NCT00550355|Experimental|1|
33112378|NCT00550355|Experimental|2|
33419082|NCT05699811|Experimental|MSC-IFNα monotherapy|Subjects will be enrolled for safety evaluation of MSC-IFNα monotherapy. Subjects will receive MSC-IFNα infusion from a dose of 2×10^6 cells/kg 1-4 times every 4-6 weeks. All treatment-related adverse events(TRAE) will be recorded for at least 28 days after the cell infusion.
33419083|NCT05699811|Experimental|MSC-IFNα combined with immunochemotherapy|"Subjects will be enrolled and received MSC-IFNα combined with immunochemotherapy, namely nab-paclitaxel (125 mg/m2, 5 days before infusion), cyclophosphamide (200 mg/m2,4 days before infusion) and anti-PD-1 antibody (200mg, 7 days after infusion) for 4 cycles.~From the 5th cycle, subjects will receive MSC-IFNα combined with anti-PD-1 antibody every 4-6 weeks for another 4 cycles for efficacy consolation. From the 9th cycle, subjects will receive anti-PD-1 antibody alone every 3 weeks for another 4 cycles for efficacy maintenance."
33419084|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
33419085|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
33419086|NCT01376479|Experimental|INV21 Low Dose|
33056061|NCT04882527|Experimental|anodal stimulation of the lIFL|Anodal stimulation over the left inferior frontal lobe
33419087|NCT01376479|Experimental|INV21 High Dose|
33056062|NCT04882527|Experimental|cathodal stimulation of the lIFL|Cathodal stimulation over the left inferior frontal lobe
33056063|NCT04882527|Experimental|anodal stimulation of the rSPL|Anodal stimulation over the right superior parietal lobe
33056064|NCT04882527|Experimental|cathodal stimulation of the rSPL|Cathodal stimulation over the right superior parietal lobe
33056065|NCT04882527|Sham Comparator|sham stimulation|Sham stimulation over either of the three real stimulation areas
33056066|NCT04879017|Experimental|FHD-286 dose escalation and expansion|Up to approximately 125 patients will be enrolled in dose escalation and expansion
33056067|NCT04876053|No Intervention|Standard Care|
33056068|NCT04876053|Experimental|Healthy Food Delivery Intervention|9000 calorie / week food box
33056075|NCT04865341|Experimental|IMB|Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
33056076|NCT04865341|No Intervention|No Intervention|Individuals randomized to this arm will receive no intervention.
33056077|NCT04857333||Pulmonary Nodule|Patients are recommended for using antibiotics, solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.
33056078|NCT04856449|Experimental|DBT Skills Training|This intervention will consist of a 6-month-group DBT-skills training continuation, in which participants will be trained in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
33056079|NCT04856449|Active Comparator|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR will consist of individual therapy sessions that will be focused on processing traumatic memories. Participants will receive up to 16 individual EMDR sessions, of 60 min each.
33056080|NCT04855695|Experimental|Acalabrutinib, Venetoclax, and Obinutuzumab|"This study will consist of 3 parts (Parts A, B, and C). In the relapsed/refractory (R/R) MCL setting (Part A), the phase 1 portion consists of a dose finding stage to determine the recommended phase 2 dose (RP2D). It will follow a 3+3 dose finding schema, with a safety pause and evaluation after the first 3 participants have completed through cycle 5, day 1. If there are no dose limiting toxicities (DLTs), an additional 3 participants will be treated and if there are 0 or 1 DLTs seen, the RP2D will have been determined.11 participants will be enrolled in the Part A expansion cohort.~Part B will enroll 24 participants with untreated mantle cell lymphoma who are transplant ineligible and/or TP53 mutated.~Part C will enroll 12 participants with untreated mantle cell lymphoma who are transplant eligible and TP53 wild type.~Each study drug is given according to a different schedule. Each treatment cycle lasts 28 days (4 weeks).~Acalabrutinib:~Obinutuzumab:~Venetoclax:"
33056081|NCT04855136|Experimental|Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
33056082|NCT04855136|Experimental|Arm B- bb2121 in combination with BMS-986405 (JSMD194)|"bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion~Enrollment is closed for this Arm"
33056083|NCT04855032|Experimental|Reactive Perturbations|
33056084|NCT04855032|Experimental|Proactive Perturbations|
33056085|NCT04854603|Experimental|Chocolate milk with a regular added sugar content|Dairy product with a regular sugar content
33056086|NCT04854603|Experimental|Chocolate milk with a reduced added sugar content|Dairy product with a reduced sugar content
33056087|NCT04854603|Experimental|Yogurt with a regular added sugar content|Dairy product with a regular sugar content
33056088|NCT04854603|Experimental|Yogurt with a reduced added sugar content|Dairy product with a reduced sugar content
33056089|NCT04854603|Experimental|Energy-free control|Potable water
33056090|NCT04844879|Experimental|Single-arm|Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
33419088|NCT05584449|Experimental|Supportive Care (group curriculum)|Participants attend an online group facilitated by two oncology social workers and receive information regarding coping with cancer survivorship as a young adult, as well as discuss survivorship issues/concerns with peers.
33419089|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
33419090|NCT04854343||Case|200 patients with a suspicion of prostate cancer
33419091|NCT04854343||Control A|(a) 50 patients with benign prostate hyperplasia (BPH)
33419092|NCT04854343||Control B|(b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
33419093|NCT05695053|Experimental|with LLLT|
33419094|NCT05695053|Placebo Comparator|without LLLT|
33419095|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
33419096|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
33419097|NCT05693337||FLIR Imaging|All patients recruited for this study will receive FLIR imaging to monitor the success of a lumbar sympathetic block for CRPS
33419098|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
33419099|NCT02113280|Experimental|Arthroscopy|Arthroscopy
33419100|NCT05522127|Active Comparator|Group R (Restrictive)|Group R (Restrictive, 2ml/kg 0.9% NaCl during colonoscopy)
33419101|NCT05522127|Active Comparator|Group L (Liberal )|Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy)
33056091|NCT04844463|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive a single ascending oral dose of JNJ-68179280 or placebo capsules under fasted condition (Cohort 1, 2 and 5) and under fasted-fed condition (either Cohort 3 or 4) on Day 1. In 1 of the study cohorts 3 or 4, participants will also receive study intervention on Day 8 under fed condition. One additional optional Cohort 6 may be dosed to assess the safety and pharmacokinetics (PK) of an alternate dose of formulation A under fasted condition.
33056092|NCT04844463|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive multiple ascending oral doses of JNJ-68179280 or placebo capsules once daily in Cohort 1 through 4 or twice daily in Cohort 5 (optional) on Days 1 through 14 under fasted or fed condition.
33056093|NCT04844463|Experimental|Part 3: Multiple Dose Alternative Formulation (Optional)|Participants will receive multiple oral doses of an alternative JNJ-68179280 formulation once daily in Cohort 1 and Cohort 2 (optional) on Days 1 through 14 under fasted or fed condition. Doses in Part 3 will depend on the safety, tolerability, PK and pharmacodynamics data from Part 1 and Part 2.
33056094|NCT04837053|Experimental|Intervention cluster|EKIT tool
33056095|NCT04837053|Active Comparator|Control Cluster|routine care
33056096|NCT04836936|Placebo Comparator|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using an empty cryopuncture device without nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
33056097|NCT04836936|Active Comparator|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using a cryopuncture device with nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
33056098|NCT04835441|Experimental|ALPN-101 (acazicolcept)|
33056099|NCT04835441|Placebo Comparator|Placebo|
33056100|NCT04834518||Negative result at the first autoantibodies screening test|Participants will be invited to repeat the screening test at the age of 2-5 years old
33056101|NCT04834518||Positive result at the first or second autoantibodies screening test|"Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)~Families will attend diabetes-educational program emphasizing on DKA prevention~Stress assessment for the families involved and stress alleviating interventions when required."
33056102|NCT04820868||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
33056103|NCT04820868||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
33056104|NCT04814264|Experimental|Sex-matched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is matched to their sex (donor and recipient sex are the same). Patients in this arm will receive RBCs matched to their sex until discharge from hospital or death.
33056105|NCT04814264|Experimental|Sex-mismatched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is not matched to their sex (donor and recipient sex are not the same). Patients in this arm will receive RBCs mismatched to their sex until discharge from hospital or death.
33056106|NCT04810390|Experimental|Bilastine|Daily instillation of one drop in each eye of Bilastine ophthalmic solution 0.6% for 8 weeks.
33056107|NCT04810390|Placebo Comparator|Placebo|Daily instillation of one drop in each eye of placebo for 8 weeks.
33056108|NCT04800744|Experimental|Lavender Peppermint Elequil Aromatab|Participants will have a lavender peppermint elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new treatment elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
33112379|NCT00550355|Experimental|3|
33112380|NCT00550355|Placebo Comparator|4|
33419102|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
33419103|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
33419104|NCT04854187|Active Comparator|Intervention Arm - Indoor air purifier and N95 mask|Intervention arm will be for 4 weeks. Blood pressure and/or blood glucose will be recorded on day 0; end of week 2 and end of the intervention. Participants in the intervention group will be asked to use an indoor air purifier (Atlanta Healthcare 7-Stage 43-Watt Air Purifier) daily for 4 weeks between the hours of ¬8 PM and 8 AM. The purifier will be placed in their bedroom or in the room where participants sleep at night. When the participants are outdoors (commuting, working outdoors, running errands, etc.), they will be asked to use a N95 mask (PureMe Reusable N95 Anti-Pollution Mask). It is a reusable mask which can be washed by the participants. Every 2 weeks, the filter of the mask will be replaced, and the filter of the indoor purifier will be washed.
33419105|NCT04854187|No Intervention|Washout period - No intervention|At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
33419106|NCT04854187|Sham Comparator|Controlled Arm - Indoor air purifier and N95 mask with sham filter|Control arm will be for 4 weeks. Blood pressure, blood glucose and indoor air pollution level will be recorded similarly as in the intervention group on day 0, end of week 2 and week 4. The participant will be provided an air purifier and a N-95 mask (of the same manufacturer), with the filter removed. At the end of two weeks, the health worker will make dummy adjustments to the mask and indoor air purifier, to maintain blinding of the participant.
33419107|NCT05344521|Active Comparator|Control|After removal of the temporary wound coverage (allograft), Integra® is applied directly onto the wound surface.
33419108|NCT05344521|Experimental|Integra®-SC|After removal of the temporary wound coverage (allograft), Integra®-SC is applied to the contralateral area of the site where Integra® is applied.
33419109|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
33419110|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
33419111|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
33419112|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
33419113|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
33419114|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
33419115|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
33419116|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
33419117|NCT02114840|Active Comparator|Pronator quadratus non repair|
33419118|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
33419119|NCT05311527|Experimental|All Study participants|Study participants will undergo Urolift System followed by SABR
33419120|NCT04878055|Experimental|Reparixin|Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care
33419121|NCT04878055|Placebo Comparator|Placebo|placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.
33419122|NCT02113514||Normal Pap smear|Women with normal pap test.
33419123|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
33419124|NCT05305365|Experimental|QBS72S 12 mg/m2 IV injection|All participants will receive QBS72S IV injections once monthly until disease progression.
33419125|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
33056109|NCT04800744|Active Comparator|Sweet Almond Oil Elequil Aromatab|Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
33056110|NCT04799301|Experimental|Diet with 20% of carb intake from soda|This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
33056111|NCT04799301|Experimental|Diet with 50% of carb intake from soda|This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
33112381|NCT04634292||Children with cerebral palsy 7-9 years|21 children
33112382|NCT04634292||Children with cerebral palsy 10-12 years|21 children
33112383|NCT04634292||Healthy children 7-9 years|21 children
33112384|NCT04634292||Healthy children 10-12 years|21 children
33112385|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
33112386|NCT00559143|Experimental|2|DDD(R)- BIV pacing
33112387|NCT00550472|Experimental|Probiotic|intervention
33112388|NCT04634370|Experimental|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
33112389|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
33112390|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
33112391|NCT04642989|Sham Comparator|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
33112392|NCT04642989|Active Comparator|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
33112393|NCT04642989|Active Comparator|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
33112394|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
33112395|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
32869733|NCT02061553|Sham Comparator|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
33112396|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
33112397|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
33112398|NCT04898231|Active Comparator|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
33112399|NCT04898231|Active Comparator|Methylprednisilone (steroids)|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
33112400|NCT04898231|Active Comparator|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
33112401|NCT04634058|Experimental|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
33112402|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
33112403|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
32869734|NCT02061553|Active Comparator|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
33112404|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
33112405|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
33112406|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
33419126|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
32869735|NCT02061553|Experimental|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
33112407|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
33112408|NCT04634097|Experimental|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
33112409|NCT04634097|Other|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
33112410|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
33112411|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
33112412|NCT00550823|Experimental|A,1|
33112413|NCT04633785||wrist BP|
33112414|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
33112415|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
33112416|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
33112417|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
33112418|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
33333414|NCT05035810|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
33333415|NCT05034328||Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract|Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed.
33112419|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
33112420|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
33112421|NCT04643223|Active Comparator|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
33112422|NCT04643223|Sham Comparator|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
33112423|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
33112424|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
33112425|NCT04643106|Experimental|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
33112426|NCT04643106|Active Comparator|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
33112427|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
33112428|NCT04642872|Experimental|infant cimt|
33112429|NCT04642872|Active Comparator|Infant BIT|
33112430|NCT04642872|Active Comparator|Infant CIMT/BIT|
33333416|NCT05034328||Conventional therapies|Children will receive conventional therapies for common cold as needed, nasal irrigation excluded
33333417|NCT05029336|Experimental|CD3/CD19 depleted ASCT|The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.
33333418|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
33333419|NCT01415674|No Intervention|Arm B : No pre operative treatment|
33333420|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
33333421|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
33333422|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
33333423|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
33112431|NCT04642872|Active Comparator|Conventional Therapy|
33112432|NCT00551252|Experimental|I|
33112433|NCT04642716|Other|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
33112434|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
33112435|NCT00551330|Placebo Comparator|2|Placebo
33333424|NCT05014984|Active Comparator|Telephone Delivered MOVE!|During the baseline visit, Veterans randomized to the control arm will receive only the standard information about MOVE!, diet, and physical activity delivered by the same lay educators. They will not learn the WOOP technique nor receive telephone follow up as detailed below. While we considered having an attention control with the same amount of contact, we decided that the study would be more pragmatic and findings would be more relevant to real-world practice if the control arm followed standard patient education and referral strategies. Data collection during study visits will be at the same timepoints in both arms.
33361368|NCT04464148|Experimental|Pregnenolone 250 BID > Pregnenolone 400 BID|For week 0-5 participants will receive pregnenolone 250 mg twice a day (total 500 mg/day). For weeks 6-8 participants will receive 400 mg twice a day (800 mg/day), if the drug is well tolerated.
33056112|NCT04799301|Experimental|Diet with no soda|This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
33056113|NCT04799288|Experimental|Teriflunomide|Teriflunomide 14 mg daily
33056114|NCT04788446|Experimental|Mini-flipped Game-based Learning|"group diet education, an interactive food card game, and guidance on the Mediterranean diet~once a week for 40 minutes.~lasts for 8 weeks"
33056115|NCT04788446|Placebo Comparator|Balanced diet|"given a leaflet on balanced diet and nutrition among the elderly~lasts for 8 weeks"
33056116|NCT04787926||Duralock-C 4%|DuraLock-C 4.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 40 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
33056117|NCT04787926||Duralock-C 30%|DuraLock-C 30.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 300 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
33056118|NCT04787926||Duralock-C 46.7%|DuraLock-C 46.7%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 467 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
33056119|NCT04785118|Active Comparator|buscopan|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
33056120|NCT04785118|Active Comparator|ondansetron|Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
33056121|NCT04785118|Placebo Comparator|control|Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
33361369|NCT01230463|Active Comparator|15 mg ketorolac IV|
33056123|NCT04775524|Experimental|Storytelling Through Music (STM)|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Storytelling Through Music (STM) group will participate in the study for a total of 19 weeks with 6 weeks of the STM program and 3 months follow up.~Storytelling Through Music (STM) utilizes multiple modalities including storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting.~Weeks 1-4: participants are led through weekly writing workshop over an online platform (i.e., Zoom or an equivalent) to develop their stories. Simultaneous with the writing sessions are 10-minute self-care lessons~Week 5: Participants will be paired with a professional songwriter who will put their story into a song.~Week 6: During the last week, participants will have one more writing workshop to debrief about the intervention."
33056124|NCT04775524|Experimental|Wait List / Storytelling Through Music-Hybrid|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Waitlist control group (Storytelling Through Music-Hybrid) will participate in the study for a total of 13 weeks with 2 weeks of Storytelling Through Music-Hybrid program and 11 weeks of follow up .~Storytelling Through Music-Hybrid involves participants listening to songs created for other healthcare professionals for 2 weeks."
33056125|NCT04772131|Experimental|Desara® One|Single Incision Sling
33056126|NCT04772131|Active Comparator|Desara® Blue|Transobturator Sling
33056127|NCT04772079|Experimental|Active treatment deucravacitinib standard dose|
33056128|NCT04772079|Experimental|Active treatment deucravacitinib half-standard dose|
33056129|NCT04772079|Placebo Comparator|Placebo|
33361370|NCT01230463|Active Comparator|30 mg ketorolac IV|
33056130|NCT04763980|Active Comparator|Cohort A (survey, genetic testing)|Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.
33056131|NCT04763980|Experimental|Cohort B (educational session, survey, genetic testing)|Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.
33056132|NCT04752618|Experimental|P-STAIR|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. P-STAIR is a combination of STAIR and PCIT. STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills. PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
33056133|NCT04752618|Active Comparator|Supportive Counseling|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. Supportive counseling has been modified to permit non-trauma discussion of parenting problems. Each session is client-directed and clinicians take an unconditionally supportive role.
33056134|NCT04752163|Experimental|Cohort A and B (DS-1594b)|Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33056135|NCT04752163|Experimental|Cohort C (DS-1594b, venetoclax, azacitidine)|Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
33056136|NCT04752163|Experimental|Cohort D (DS-1594b, mini-HCVD)|Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.
33056137|NCT04752163|Experimental|Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)|Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.
33056138|NCT04752163|Experimental|Food-Effect (DS-1594b)|Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.
33056139|NCT04752163|Experimental|Phase I (DS-1594b)|Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
33056140|NCT04751487|Experimental|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
33056141|NCT04751487|Experimental|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
33361371|NCT01358318|Placebo Comparator|Control|
33361372|NCT01358318|Experimental|Soy Protein|
33361373|NCT01358318|Experimental|Soy Fiber|
33333425|NCT05014984|Experimental|Mental Contrasting with Implementation Intentions (WOOP) plus MOVE!|At the baseline visit, a lay educator will teach the WOOP technique in-person using protocols adapted from our prior work.12 After, to support WOOP practice, the lay educator will schedule and provide 3 follow-up telephone check-ins with the Veteran. This arm will also receive telephone-delivered MOVE!
33333426|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
33361374|NCT01358318|Experimental|Soy Protein and Soy Fiber|
32871617|NCT05747703|Experimental|Ria Treatment Platfrom|The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer.
32871618|NCT05747703|No Intervention|waitlist control|Patients in this arm will not be provided treatment during the study period.
32871619|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
32871620|NCT02882295||control|age and gender matched
32871621|NCT00251303|Experimental|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
33056142|NCT04751487|Placebo Comparator|Placebo in former smokers|SC administration of matching placebo Q2W for up to 52 weeks
33056143|NCT04751487|Experimental|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
33056144|NCT04751487|Placebo Comparator|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
33056145|NCT04750330||Severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the Intensive Care Unit (ICU) during hospitalisation
33056146|NCT04750330||Non-severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the hospital but NOT to the Intensive Care Unit (ICU) during hospitalisation
33056147|NCT04750330||Minor COVID-19|Patients, diagnosed with COVID-19, who were NOT admitted to the hospital and could recover at home
33056148|NCT04746456||Menopausal women|Women will complete a series of questionnaires, including the VVAQ
33056149|NCT04735926|Placebo Comparator|Group 1A|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
33056150|NCT04735926|Experimental|Group 1B|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
33056151|NCT04735926|Experimental|Group 1C|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
33056152|NCT04735926|Placebo Comparator|Group 2A|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
33056153|NCT04735926|Experimental|Group 2B|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
33056154|NCT04735926|Experimental|Group 2C|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
33056155|NCT04733599||Adults with pain due to brachial plexus avulsion injury|Adult patients with history of brachial plexus avulsion injury referred for consideration of neuromodulation using high frequency neurostimulation will be considered.
33056156|NCT04726722|Experimental|Design of the CBT treatment content|Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content
33056157|NCT04726722|Experimental|Control of support and feedback|Patient-controlled support and feedback (person-centred) vs. therapist -controlled.
33056158|NCT04720768|Experimental|Dose escalation phase|"Encorafenib (tablet) 450mg PO daily~Binimetinib (tablet) 45mg PO BD~Palbociclib (tablet) variable dose PO daily for 21 consecutive days on treatment, followed by 7 consecutive days off treatment in a 28 day cycle"
33056159|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#1|Drug: SHR0302 Ointment Twice a day (BID)
33056160|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#2|Drug: SHR0302 Ointment Twice a day (BID)
33056161|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#3|Drug: SHR0302 Ointment Twice a day (BID)
33056162|NCT04717310|Placebo Comparator|Placebo Comparator: Placebo|Drug: Vehicle Twice a day (BID)
33056163|NCT04707248|Experimental|Dose Escalation|Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) will receive an intravenous infusion of DS-6000a (starting dose 1.6 mg/kg).
33056164|NCT04707248|Experimental|Dose Expansion: Cohort B-1|Participants with RCC will receive an intravenous infusion of DS-6000a at the RDE.
33056165|NCT04707248|Experimental|Dose Expansion: Cohort B-2|Participants with OVC will receive an intravenous infusion of DS-6000a at the RDE.
33056166|NCT04702256|Experimental|Obinutuzumab arm|Obinutuzumab administration plus oral mycophenolate mofetil (MMF)
33056167|NCT04702256|Active Comparator|Corticosteroids arm|Oral corticosteroids plus MMF
33056168|NCT04701983|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
33056169|NCT04701983|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
33056170|NCT04701983|Placebo Comparator|Placebo|SC administration of matching placebo Q2W for up to 52 weeks
33056171|NCT04701359|Experimental|Group A (TiN-coating)|Patients with knee osteoarthritis receive total knee arthroplasty with Titanium-Nitride (TiN)-coated implant.
33056172|NCT04701359|Active Comparator|Group B (CoCr-alloy)|Patients with knee osteoarthritis receive total knee arthroplasty with Cobalt-Chromium (CoCr)-alloy implant.
33056173|NCT04700072|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab and quavonlimab) intravenously (IV) plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056174|NCT04700072|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056175|NCT04688775|Experimental|Sequence 1: Eptinezumab Then Placebo|Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period
33361375|NCT04464460|Experimental|Cohort 1: TAK-671 Low Dose|TAK-671 low dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
33333427|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
33333428|NCT05654896|No Intervention|No Antibiotic Prophylaxis Group|No antibiotic will be administered prophylactically for TACE.
33333429|NCT05654896|Experimental|Antibiotic Prophylaxis Group|Antibiotic will be administered prophylactically (i.e., Inj. Ceftriaxone 1g, intravenous × stat)
33333430|NCT00745108|Experimental|Tibolone 1.25 mg|
33333431|NCT00745108|Experimental|Tibolone 2.5 mg|
33333432|NCT00745108|Active Comparator|CE/MPA|
32871622|NCT00251303|Placebo Comparator|placebo|Placebo Capsules designed to mimic active drug capsules
33056176|NCT04688775|Experimental|Sequence 2: Placebo Then Eptinezumab|Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period
33056177|NCT04679194|Experimental|Mana 312|"Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.~Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses"
33056178|NCT04671966|Experimental|Fasting only|To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
33056179|NCT04671966|Experimental|LBNP Only|Subjects undergo lower body negative pressure at 40 mmHg.
33056180|NCT04671966|Experimental|Estrogen add back with GnRHant|Subjects are given estradiol patch.
33056181|NCT04671966|Experimental|Placebo add back with GnRHant|Subjects are given placebo patch.
33056182|NCT04653961|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 2.5 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
33056183|NCT04650399|Experimental|Active|VLA1553
33056184|NCT04650399|Placebo Comparator|Placebo|Placebo
33056185|NCT04641702|Experimental|Pharmacologic challenge|Measurement of esophageal response toatropine using functional lumen imaging probe (FLIP)
33056186|NCT04636320|Experimental|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
33056187|NCT04636320|Active Comparator|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
33056188|NCT04635527|Experimental|IBI318 combined with conventional TACE (cTACE)|
33056189|NCT04635527|Placebo Comparator|Placebo combined with conventional TACE (cTACE)|
33056190|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
33056191|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
33056192|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
33056193|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
33056194|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
33056195|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
33056196|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
33056197|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
33056198|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
33056199|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
33056200|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, CLL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r CLL
33056201|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-ALL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-ALL
33056202|NCT04626518|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).
33056203|NCT04626518|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
33056204|NCT04626518|Experimental|Pembrolizumab + MK-4830|Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).
33056205|NCT04626518|Experimental|Pembrolizumab + Belzutifan|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.
33056206|NCT04626518|Experimental|Belzutifan + Lenvatinib|Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
33056207|NCT04626518|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
33333433|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
32871623|NCT05747625|Experimental|Diagnostic (89Zr panitumumab PET/CT)|Patients receive panitumumab IV, 89Zr panitumumab IV, and undergo PET/CT on study
33056208|NCT04626479|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
33056209|NCT04626479|Experimental|Coformulation Favezelimab/Pembrolizumab+ Lenvatinib|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
33056210|NCT04626479|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
33056211|NCT04626479|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
33056212|NCT04626479|Experimental|Coformulation Vibostolimab/Pembrolizumab+Belzutifan|Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation.
33056213|NCT04624750|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
33333434|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
33333435|NCT05000866|No Intervention|CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
33333436|NCT05000866|Active Comparator|CHTC and communications skills training video|Participants complete the standard Couples HIV Testing and Counseling session and also watch a communication skills training video together.
33333437|NCT05000866|Active Comparator|CHTC and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and also complete a substance use module together.
32871624|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
33056214|NCT04624204|Experimental|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
33056215|NCT04624204|Experimental|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
33056216|NCT04624204|Placebo Comparator|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
33056217|NCT04622553|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
33056218|NCT04618978|Other|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
33056219|NCT04608630|Active Comparator|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
33056220|NCT04608630|Active Comparator|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
33056221|NCT04608630|Placebo Comparator|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
33056222|NCT04606472|Experimental|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
33056223|NCT04603183|Experimental|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
33333438|NCT05000866|Active Comparator|CHTC, communications skills training and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and watch a communication skills training video and complete a substance use module together.
33333439|NCT03622580|Experimental|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
33333440|NCT03622580|Experimental|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
33333441|NCT03622580|Active Comparator|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
33333442|NCT00461032|Experimental|1|montelukast
33333443|NCT00461032|Placebo Comparator|2|Placebo
33056224|NCT04603183|Active Comparator|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
33056225|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
33056226|NCT04601428|Experimental|Investigational Arm|
33056227|NCT04588623|Active Comparator|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
33056228|NCT04588623|Placebo Comparator|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
33056229|NCT04585581|Experimental|diet + training|
33056230|NCT04585581|Active Comparator|controls|
33056231|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
33056232|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
33056233|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
33056234|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
33056235|NCT04583891|Experimental|IntelliCare|IntelliCare is a self-guided, fully automated suite of apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
33056236|NCT04583891|Active Comparator|Patient Education|The patient education app will contain psychoeducational information about distress prevalence and distress management. It will serve as an active control condition to compare with the IntelliCare apps.
33056237|NCT04583839|Experimental|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
33056238|NCT04583839|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
33056239|NCT04580134|Experimental|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
33056240|NCT04580134|Placebo Comparator|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
33056241|NCT04580134|Active Comparator|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
33056242|NCT04580134|Placebo Comparator|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day
33333444|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
33333445|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
33333446|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
33333447|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
33333448|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
33333449|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
33419127|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
33056243|NCT04574882||Case|Patients ages 30-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 5 years.
33056244|NCT04574882||Control|Patients aged 30-74 who have non-cardiovascular-related history
33056245|NCT04571060|Experimental|Zavegepant|Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar Unidose System (UDS) liquid spray device.
33056246|NCT04571060|Placebo Comparator|Placebo|Participants administered a single intranasal dose of zavegepant matching placebo on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar UDS liquid spray device.
33056247|NCT04567680|Experimental|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
33056248|NCT04567680|Active Comparator|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
33056249|NCT04564170||ED|Patients with Eating Disorders
33056250|NCT04564170||HC|Healthy Controls without eating disorders
33056251|NCT04556773|Experimental|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
33056252|NCT04556773|Experimental|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
33056253|NCT04556773|Experimental|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
33056254|NCT04556773|Experimental|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
33056255|NCT04556773|Experimental|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
33056256|NCT04555837|Experimental|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33056257|NCT04554212|Active Comparator|Standard Physical Therapy with Sham BFRT|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
33056258|NCT04554212|Active Comparator|Standard Physical Therapy with BFRT|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
33056259|NCT04541108|Experimental|MK-0482, MK-4830, & Pembrolizumab|Patients with HNSCC or STS who are scheduled for surgical biopsy or tumor resection surgery will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 5 or 8 needles by the CIVO Microdose Injector,into a single solid tumor or effaced metastatic lymph node.
33056260|NCT04533750|Experimental|Treatment (peposertib, IMRT)|Beginning 60-90 minutes before each radiation treatment, patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity.
33056261|NCT04533607|Active Comparator|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
33056262|NCT04533607|No Intervention|Waitlist control|Services as usual.
33056263|NCT04532788|Active Comparator|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
33068166|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
33068167|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
33333450|NCT00090142|Experimental|1|Montelukast - Placebo
33333451|NCT00090142|Experimental|2|Placebo - Montelukast
33333452|NCT00043108|Experimental|Treatment|Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)
33333453|NCT05225194||COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by SAS-CoV-2.
33333454|NCT05225194||Non-COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by other etiologies than SARS-CoV-2.
33333455|NCT05225194||Family controls|Family controls of participants with ARDS (either due to COVID-19 or other etiologies) without history of COVID-19 or hospitalization in the last 12 months.
33333456|NCT05224960|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|UC-MSCs plus standard of care (SOC).
33056264|NCT04532788|Active Comparator|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
33056265|NCT04529954|Experimental|Open-Label Safety|Participants roll-over from DA071976 or CLN100P.02
33056266|NCT04528992|Experimental|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
33056267|NCT04528992|Active Comparator|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
33056268|NCT04525755|Experimental|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
33056269|NCT04525755|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
33056270|NCT04525755|No Intervention|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
33056271|NCT04513106|Experimental|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
33056272|NCT04513106|Placebo Comparator|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
33056273|NCT04512079|Active Comparator|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
33056274|NCT04512079|Active Comparator|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
33056275|NCT04512079|Experimental|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
33056276|NCT04508725|Experimental|Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)|Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
33056277|NCT04508725|Experimental|Non-ICI therapy|Patients are planned to be treated with non-ICI therapy
33056278|NCT04498572|Experimental|research group|active exercises and dry needling for the Gluteus medius muscle
33056279|NCT04498572|Sham Comparator|control group|active exercises and sham dry needling for the Gluteus medius muscle
33333457|NCT05224960|Placebo Comparator|Placebo|Placebo plus SOC.
33333458|NCT05224570||Gunshot wounds admitted in ICU|patient with Gunshot wounds admitted to ICU
33056282|NCT04491578|Experimental|ACP programme|It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model and shared decision-making model.
33056283|NCT04490278|Experimental|Patients with PICS|
33056284|NCT04490057|Experimental|12 wks NRT+CM / 12 wks NRT+CM|Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
33056285|NCT04490057|Experimental|12 wks NRT+CM/ 12 wks VAR or bupropion+CM|Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.
33056286|NCT04490057|Experimental|12 wks NRT+CM/12 wks NRT+CM plus|Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
33056287|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT|Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
33056288|NCT04490057|Experimental|12 wks NRT/ 12 wks VAR or bupropion|Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.
33056289|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT+CM|Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.
33333459|NCT05224024|Active Comparator|Retzius-repairing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-repairing technique as prostate cancer patients with robot assisted radical prostatectomy.
33056290|NCT04468659|Experimental|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks from Week 0 to 6, then 10 mg/kg, administered as IV infusion, every two weeks from Week 8 to 94, and 10 mg/kg, administered as IV infusion, every four weeks from Week 96 to 216.
33056291|NCT04468659|Placebo Comparator|A45 Trial: Placebo|Participants will receive placebo (0.9 percent [%] sodium chloride solution), administered as IV infusion, every two weeks from Week 0 to 94, then every four weeks from Week 96 to 216.
33056292|NCT04468659|Experimental|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks from Week 0 to 4, then 10 mg/kg, administered as IV infusion, every four weeks from Week 8 to 216.
33056293|NCT04468659|Placebo Comparator|A3 Trial: Placebo|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks from Week 0 to 216.
33333460|NCT05224024|Placebo Comparator|Retzius-sparing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-sparing technique as prostate cancer patients with robot assisted radical prostatectomy.
33333461|NCT05223946|Active Comparator|Passive Microwave Radiometry|Diagnostic Test: Passive Microwave Radiometry The MWR2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases.
33333462|NCT05223946|Experimental|SCENAR|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
33333463|NCT05223712||Development Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
33333464|NCT05223712||Development Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
33333465|NCT05223712||Validation Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
33333466|NCT05223712||Validation Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
33333467|NCT05223712||Test Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
33333468|NCT05223712||Test Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
33333469|NCT05223634||oral and/or nasal specimen samples|After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
33333470|NCT05223556||Shaoguan Diabetic cohort|Patients with diabetes ages 30-80 were enrolled in Shaoguan Diabetic Eye Screening Programme, who will receive diabetic retinopathy screening both in a remote diagnostic imaging site and in a tertiary hospital
33056296|NCT04461301|Experimental|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
33056297|NCT04461301|No Intervention|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
33056298|NCT04446728|Active Comparator|Strategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
33056299|NCT04446728|Active Comparator|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
33056300|NCT04437485|Experimental|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Good Days Ahead, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
33056301|NCT04437485|Active Comparator|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
33056302|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
33056303|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
33056304|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
33333471|NCT04985266|Active Comparator|Standard endocrine therapy|"Standard endocrine therapy will continue for up to 24 months on trial.~Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane)."
33419128|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
33068168|NCT00141986|Experimental|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
33068169|NCT00141986|Active Comparator|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
33068170|NCT04514731|Experimental|Group M|Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery
33056308|NCT04421560|Experimental|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.~Ibrutinib: orally 2x daily~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375mg/m^2 intravenously once per week for 4 weeks (4 total doses).~Phase 2~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.~Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375 mg/m^2 intravenously once per week for 4 weeks (4 total doses)."
33056309|NCT04420000|Experimental|Interventional group|Patients having a Mindfulness program
33056310|NCT04420000|Placebo Comparator|Control group|Patients having a routinary managment
33056311|NCT04410796|Experimental|Osimertinib alone|All patients will receive osimertinib 80mg orally daily. Subjects randomized to Arm A may be dispensed osimertinib for 2 cycles from Cycle 4 onward.
33056312|NCT04410796|Experimental|Osimertinib plus Carboplatin and Pemetrexed|All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards.
33056313|NCT04408794|Experimental|Zavegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
33056314|NCT04406649|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
33056315|NCT04402749||Nephrectomy|Patients underwent nephrectomy
33056316|NCT04392622|Experimental|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
33056317|NCT04392622|Experimental|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
33056318|NCT04392622|Experimental|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
33056319|NCT04392622|Experimental|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
33056320|NCT04392622|Experimental|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
33056321|NCT04392622|Experimental|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
33056322|NCT04392622|Experimental|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
33056323|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo|Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
33056324|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib|Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
33056325|NCT04380636|Active Comparator|chemoradiation→durvalumab|Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
33056326|NCT04378751|Experimental|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
33056327|NCT04378751|Active Comparator|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
33056328|NCT04378374|Experimental|Baked food made of lentil flour|Food prepared with 100% lentil flour
33056329|NCT04378374|Experimental|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
33056330|NCT04378374|Experimental|Baked food made of wheat flour|Food prepared with 100% wheat flour
33056331|NCT04378374|Experimental|Water|Potable water (energy and carbohydrate-free control)
33056332|NCT04372108||Ustekinumab New User Cohort|Participants with crohn's disease (CD) or ulcerative colitis (UC) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
33056333|NCT04372108||Other Biologics Comparator Cohort|Participants with CD or UC with no prior exposure to the individual drugs (for example, infliximab, adalimumab, or vedolizumab) in question, at least 1 year of enrollment records immediately prior to the new use of the comparator biologic will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
33056334|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
33056335|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
33068171|NCT04514731|Placebo Comparator|Group S|Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol
33068172|NCT04514419|Experimental|Trastuzumab + HS627 + Docetaxel|Trastuzumab HS627 Docetaxel
33068173|NCT04514419|Experimental|Trastuzumab + Pertuzumab + Docetaxel|Trastuzumab Pertuzumab Docetaxel
33419129|NCT05286567|Experimental|RGRN-305|1 tablet of 250mg RGRN-305 once daily for 16 weeks
33112436|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
33112437|NCT04892966|Experimental|TXI (TXI group)|Arm undergoing normal colonoscopy with TXI light
33112438|NCT04892966|Active Comparator|WLI (White Light Imaging Group)|Arm undergoing normal colonoscopy with standard white light
33112439|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
33112440|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
33112441|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
33112442|NCT04642248|Active Comparator|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
33112443|NCT04642248|Experimental|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
33112444|NCT03455894|Experimental|Smart carpet|
33112445|NCT04642482|Experimental|Synbiotic|"A fine powder to be taken orally consists of~Viable cell 1,0 x 10^9 Colony Forming Unit of :~Lactobacillus plantarum 8,55 mg~Streptococcus thermophilus 8,55 mg~Bifidobacterium bifidum 2,55 mg~Fructooligosaccharide 480 mg~Additional components : isomalt, xylitol"
33333472|NCT04985266|Experimental|Palbociclib and fulvestrant|"Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.~Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.~Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit."
33333473|NCT05199064||Chronic refractory migraine patients|25 patients who were diagnosed as having chronic refractory migraine and were refractory to conventional treatments, such as oral medications, GONB,and botulinum toxin injection were evaluated.All patients received pulsed RFtherapy to the GON from the proximal (C2) level in the pain clinic between September 2020 and September 2021.
33112446|NCT04642482|Active Comparator|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
33333474|NCT03985384|Active Comparator|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
33333475|NCT03985384|Placebo Comparator|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
33112447|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
33112448|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
33112449|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
33333476|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
33419130|NCT05286567|Placebo Comparator|Placebo|1 tablet of placebo once daily for 16 weeks
33112450|NCT04642560||Usual practice|Any child hospitalized in Pediatric or Neonatal ICU and receiving systemic (intravascular, intramuscular or oral) antibiotic treatment for an episode of suspected or proven community-acquired or nosocomial bacterial infection
33333477|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
33333478|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
33333479|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
33112451|NCT04642443|Active Comparator|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
33112452|NCT04642443|Active Comparator|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
33112453|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
33112454|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
33112455|NCT04642326|Experimental|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
33333480|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
33333481|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
33419131|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
33419132|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
33419133|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
33056336|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
33333482|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
33056337|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
33056338|NCT04361201||Control group|Controlateral ankle
33333483|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
33333484|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
33333485|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
33333486|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
33333487|NCT01562834|Experimental|Somatropin|
33333488|NCT01562834|Placebo Comparator|Placebo|
33333489|NCT04030598|Placebo Comparator|Part A: Placebo|Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.
33333490|NCT04030598|Experimental|Part A: Donidalorsen 80 mg|Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
33333491|NCT04030598|Experimental|Part B: Donidalorsen 80 mg|Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
33333492|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
33333493|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
33056339|NCT04360252|Experimental|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
33333494|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
33333495|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
33056340|NCT04332341|Experimental|Nicotinamide riboside (NR)|
33056341|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
33056342|NCT04323657|Experimental|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
33056343|NCT04323657|Experimental|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
33056351|NCT04320251|Experimental|1|The single observational cohort
33056352|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
33056353|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
33056354|NCT04318691||Healthy volunteers group|10 healthy subjects.
33333496|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
33333497|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
33333498|NCT03735524|Experimental|Exercise|Conventional rehabilitation
33361376|NCT04464460|Experimental|Cohort 2: TAK-671 High Dose|TAK-671 high dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
33361377|NCT03920371|Experimental|gamma camera imaging|hand held camera
33361378|NCT01358396||HBA1c|
33056355|NCT04305054|Experimental|Pembrolizumab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056356|NCT04305054|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
33333499|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
33333500|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
33333501|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
33333502|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
33333503|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.~Etoposide is administered intravenously on days 1-5.~Mitoxantrone is administered intravenously on days 1-5.~Prexasertib is administered intravenously on days 1, 3, and 5."
33056357|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
33056358|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056359|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants will receive cofomulation of favezelimab + pembrolizumab (MK-4280A) IV at specified dose on specified days every 3 weeks (Q3W) for up to approximately 2 years
33056360|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)|Participants will receive coformulation of favezelimab and pembrolizumab IV Q3W for up to 35 cycles, plus ATRA orally (for 3 days surrounding each infusion of MK-4280A, including Days 1, 2, and 3 of Cycle 1 and on Days -1, 1, and 2 of all subsequent cycles).
33056361|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab + Vibostolimab|Participants will receive coformulation of favezelimab and pembrolizumab (MK-4280A) IV and vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056362|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056363|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Lenvatinib|Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
33056364|NCT04305041|Experimental|Pembrolizumab + all-trans retinoic acid (ATRA)|Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years
33056365|NCT04303169|Experimental|Pembrolizumab + Vibostolimab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33056366|NCT04303169|Experimental|Pembrolizumab + Gebasaxturev|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus gebasaxturev (V937) intratumorally (IT) at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33056367|NCT04303169|Experimental|Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33056368|NCT04303169|Experimental|Pembrolizumab + MK-4830|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus MK-4830 IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33056369|NCT04303169|Experimental|Favezelimab + Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive MK-4280A (favezelimab and pembrolizumab administered as a co-formulation) IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33068174|NCT04514380||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon A.
33112456|NCT04642326|No Intervention|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
33333504|NCT05665868|Experimental|Experimental group based on integrated care mode|① Obtain the health records of patients receiving targeted treatment of gastric stromal tumors in the big data platform; ② Patients upload health data, disease symptoms, complete questionnaires, health consultation and other functions; ③ The platform can regularly send audit reminders, automatically analyze the data uploaded and saved by patients, automatically and intelligently intervene when abnormal results occur, and remind medical staff to intervene manually; ④ Researchers can view the recent health status of patients through the terminal, and members of corresponding disciplines can give targeted health guidance according to the existing health problems of patients; Remind patients with complex conditions to have outpatient reexamination; ⑤ Push disease related knowledge every week for patients to learn independently.
33056370|NCT04303169|Experimental|Pembrolizumab + all-trans retinoic acid (ATRA)|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
33056371|NCT04291560|Experimental|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
33056372|NCT04291560|No Intervention|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
33056373|NCT04288479|Experimental|Doing a single HIT session in gestational week 22-36|
33056374|NCT04280458|Experimental|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
33056375|NCT04280458|Active Comparator|Control group|patients will receive standard care
33056376|NCT04278092|Experimental|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
33056377|NCT04273919|Sham Comparator|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
33056378|NCT04273919|Experimental|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
33056379|NCT04271358|Experimental|Peer Coaching|Participant receive a 6 month peer health coaching intervention.
33056380|NCT04271358|No Intervention|Education only|Participants receive education-only material (newsletter) biweekly for 6 months
33056381|NCT04269759||Pregnancy women|
33056382|NCT04267393|Experimental|Dose A BMS-986263|
33056383|NCT04267393|Experimental|Dose B BMS-986263|
33056384|NCT04267393|Placebo Comparator|Placebo|
33056385|NCT04263285|Experimental|rTMS (Repetitive Transcranial Magnetic Stimulation)|
33056386|NCT04262167|Experimental|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
33056387|NCT04262167|No Intervention|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
33419134|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
33419135|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
33419136|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
33056388|NCT04262167|Experimental|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
33056389|NCT04262167|No Intervention|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
33056390|NCT04242147|Experimental|Bi-weekly Monotherapy Dose Escalation (Q2W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
33056391|NCT04242147|Experimental|Weekly Monotherapy Dose Escalation (Q1W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
33056392|NCT04242147|Experimental|Dose Expansion|KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
33056393|NCT04240106|Experimental|Niraparib 100mg in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
33056394|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
33056395|NCT04235777|Experimental|Arm 1|Treatment with M7824 and de-escalating doses of M9241 if appropriate
33056396|NCT04235777|Experimental|Arm 2|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with sequential SBRT
33056397|NCT04235777|Experimental|Arm 3|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with concurrent SBRT
33056398|NCT04230421|Experimental|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
33056399|NCT04230421|Active Comparator|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
33056400|NCT04230421|Active Comparator|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
33068175|NCT04514380||Group N|Patients did not drink carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon B.
33068176|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
32871625|NCT00303823|Experimental|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
33056401|NCT04229875|Experimental|CAG Bipolar|"Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician~All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously~Treatment will include a group-based psychoeducation program~Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals~Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic~Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic~Recovery mentors"
33333505|NCT05665868|Active Comparator|Control group based on conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
33112457|NCT00871013|Experimental|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
33333506|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
33056402|NCT04229875|No Intervention|Control group|Standard treatment
32871626|NCT00303823|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
33056403|NCT04221373|Experimental|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
33056404|NCT04221373|Active Comparator|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
33333507|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
33333508|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
33333509|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
33333510|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
33056405|NCT04220489|Experimental|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
33056406|NCT04220489|Placebo Comparator|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
33056407|NCT04213456|Experimental|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
33056408|NCT04213456|Placebo Comparator|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
33056409|NCT04212962|Experimental|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
33056410|NCT04212962|Experimental|Control group|The control group receives usual discharge planning and post-discharge care.
33056411|NCT04210505|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
33056412|NCT04210505|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
33056413|NCT04201262|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
33056414|NCT04200937||BSC Penile Prothesis Recipients|Men for whom BSC Penile Prothesis is recommended.
33056415|NCT04200365|Experimental|Itacitinib|
33056416|NCT04196933|Experimental|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds [inversely related to spatial precision], vestibular reaction time variability [inverse of temporal precision], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
33112458|NCT04641897|Other|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
33056417|NCT04196933|Experimental|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
33419137|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
33419138|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
33056418|NCT04196933|Experimental|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (2-6 weeks), and chronic post-op (6 months+). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
33056419|NCT04196933|Experimental|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
33056420|NCT04193865||Extracorporeal Life Support with Renal Replacement Therapy|"This cohort will include all subjects receiving extracorporeal life support with concurrent continuous renal replacement therapy.~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each participants's CRRT course."
33056421|NCT04193865||Renal Replacement Therapy|"This cohort will include all subjects receiving continuous renal replacement therapy (no extracorporeal life support).~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each patient's CRRT course."
33056422|NCT04189107|Experimental|Experimental|High dose Dexamethasone
33056423|NCT04189107|Placebo Comparator|Control|Standard dexamethasone dosage and placebo
33056424|NCT04179643|Experimental|3 x 10e13vg NAN-101|Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects
33056425|NCT04179643|Experimental|1 x 10e14vg NAN-101|Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects
33056426|NCT04179643|Experimental|3 x 10e14 vg NAN-101|Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects
33056427|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
33056428|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC)/hyperthermic MMC. Participants who are randomized to gemcitabine or MMC/hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
33056429|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
33056430|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
33056431|NCT04166331|Placebo Comparator|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
33056432|NCT04166331|Experimental|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
33056434|NCT04153175|Active Comparator|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
33056435|NCT04153175|Placebo Comparator|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
33056436|NCT04147494|Experimental|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable). Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
33056437|NCT04136912|Experimental|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
33056438|NCT04136912|Experimental|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
33112459|NCT04641897|Other|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
33112460|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
33112461|NCT04642092|Experimental|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
33112462|NCT04642092|Active Comparator|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
33112463|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
33112464|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
33112465|NCT05431595|Experimental|Group 1|Participants will receive haloperidol by vein every 12 hours (or more often, as needed).
33112466|NCT05431595|Experimental|Group 2|Participants will receive chlorpromazine by vein every 12 hours (or more often, as needed).
33112467|NCT05431595|Experimental|Group 3|Participants will receive valproate by vein every 12 hours.
33112468|NCT05431595|Experimental|Group 4|Participants will receive placebo every by vein every 12 hours.
33112469|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.~The study population will be consisted of 45 women with POI as study group."
33112470|NCT04641624||Control group|45 patients with normal healthy women as control group.
33112471|NCT05431127|Other|High Dose Inspiratory Muscle Training|Inspiratory Muscle Training 3 times a week over 26 weeks
33112472|NCT04641546|Experimental|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
33112473|NCT04641546|Experimental|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
33112474|NCT05427656|Experimental|185 MBq [18F] TRACK|Each participant will receive a single scan with 185 MBq [18F] TRACK
33112475|NCT04641585|Experimental|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
33112476|NCT04641585|Active Comparator|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
33112477|NCT00559221|No Intervention|1|
33112478|NCT05408312|Experimental|Experimental group 1|
33112479|NCT05408312|Experimental|Experimental group 2|
33112480|NCT05408312|Experimental|Experimental group 3|
33112481|NCT05408312|Placebo Comparator|placebo group|
33112482|NCT04641468|Other|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
33333511|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
33112483|NCT04683497|Experimental|CE-IOUS|Patients with pancreatic cancer undergoing surgery with the performance of CE-IOUS
33112484|NCT04641429|Experimental|Qigong|Participants in the experimental group receive Qigong exercise training.
33112485|NCT04641429|Active Comparator|stretching|Participants in the control group receive stretching exercise training.
33112486|NCT04683653|Experimental|Hypofractionated Radiation Treatment (Dose-Finding Arm)|All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
33112487|NCT04683653|Experimental|Expansion Cohort (Efficacy Arm)|"Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is (efficacy) at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment."
33112488|NCT04641117|Experimental|Exercise|Six months of power training
33112489|NCT05368844|Experimental|Active iTBS|rTMS treatments will employ the Brainsway stimulator (Brainsway Ltd, Israel). Prior to the first treatment (no more than 5 days prior), each subject's motor threshold (MT) will first be determined according to published methods (Schutter, van Honk, 2006; Julkunen et al, 2009). This location, as well as the stimulation target spot, will be marked at the first session on the scalp and standard methods will be used to target this spot during treatment sessions. The modified BeamF3 scalp heuristic will be used to localize the treatment site over the left DLPFC (Mir-Moghtadaei et al., 2015). Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session.
33112490|NCT05368844|Sham Comparator|Sham iTBS|The BrainsWay Model 104 with H4 coil has an integrated sham coil. The sham condition will start with the same clicking noise as the active TMS condition. Every helmet has a corresponding sham H-coil encased in the same helmet. The sham coil induces only a negligible sub-threshold field in the brain while making an identical noise and inducing some scalp sensation. Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session. Subjects in this arm will have the option of receiving the Active iTBS protocol after they complete the 5 days of 10 daily treatment sessions.
33112491|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
33112492|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
33056439|NCT04136912|Experimental|Healthy Volunteers Cohort|A total of 15 participants will be included to optimize imaging parameters.
33333512|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
33333513|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
33333514|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
33333515|NCT00071799|Experimental|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
33333516|NCT00071799|Active Comparator|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
33333517|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
33333518|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
33333519|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
33333520|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
33333521|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
33333522|NCT00090363|Placebo Comparator|Placebo|Matching placebo oral tablet once daily, with best supportive care
33333523|NCT00090363|Experimental|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
33333524|NCT00090363|Experimental|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
33333525|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
33056440|NCT04128488||Transgender women and non-binary individuals without HIV|
33056441|NCT04128488||Transgender women and non-binary individuals with HIV|
33056442|NCT04127383|Experimental|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
33056443|NCT04127383|No Intervention|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
33056444|NCT04124991|Experimental|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
33333526|NCT03652610|Active Comparator|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
33056446|NCT04123314|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
33056447|NCT04121741|Active Comparator|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
33056448|NCT04121741|Active Comparator|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
33056449|NCT04121741|Sham Comparator|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
33056450|NCT04118023||7T MRI Group|Patient group that receives 7 Tesla Magnetic Resonance Imaging
33056451|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
33056452|NCT04111835|No Intervention|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:~ASC-US: repeat Pap testing in 6 months - current standard protocol~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~If screening cytology is negative -> rescreening after 3 years."
33068177|NCT04514263||Oral Biopsy|Patients with oral lesions undergoing diagnostic or therapeutic biopsies either for benign lesions or potentially malignant disorders or malignant lesions or salivary glands diseases.
32871627|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
32871628|NCT00300677|Experimental|voriconazole|voriconazole twice daily
33056453|NCT04111835|Experimental|hrHPV molecular testing|"hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative -> The CINtec PLUS Cytology and The QIASURE methylation test~The CINtec PLUS Cytology Positive -> colposcopy Negative -> rescreen in 3 years~The QIASURE methylation test Positive -> colposcopy Negative -> rescreen in 3 years~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~HPV-negative - rescreen in 5 years"
33056454|NCT04109716|Experimental|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
33056455|NCT04109716|Active Comparator|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
33056456|NCT04091191|Active Comparator|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
33056457|NCT04091191|Placebo Comparator|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
33056458|NCT04081389|Experimental|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
33056459|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
33056460|NCT04079894||Background population|Populationdata from existing research project
33056461|NCT04079894||LBP Participants|Patients with Low back Pain
33056462|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
33056463|NCT04074070||Healthy individuals|
33056464|NCT04074070||Psoriatic arthritis|
33056465|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to participants by the study staff at the clinical site and administration will be documented in the subject's source record.
33056466|NCT04053634|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
33056467|NCT04053634|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
33056468|NCT04035629|Experimental|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
33056469|NCT04031677|Other|Standard arm|Surgery alone
33056470|NCT04031677|Experimental|Experimental arm|Preoperative chemotherapy and surgery
33056471|NCT04004221|Experimental|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
33056472|NCT03997383|Experimental|Patisiran|Participants will be administered multiple doses of patisiran in the double-blind and open-label extension period.
33056473|NCT03997383|Placebo Comparator|Placebo|Participants will be administered multiple doses of placebo in the double-blind period. In the open-label extension period, participants will be administered multiple doses of patisiran.
33056474|NCT03975231|Experimental|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
33056475|NCT03966391|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
33056476|NCT03966391|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
33056477|NCT03965650|Experimental|Intervention group: video coaching exercises|Video coaching exercises group: patients will perform physical exercises according to a video coaching program 3 times weekly during 6 months. The on-line program has been designed especially for this study.
33056478|NCT03965650|Active Comparator|Control group: routine exercises|Routine method advising and encouraging patients to perform physical activities according to the WHO recommendations during 3 months then to follow the video coaching physical exercises program during 3 months.
33056479|NCT03959878|Experimental|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
33056480|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
33056481|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
33333527|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
33333528|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
33333529|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
33056482|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
33056483|NCT03950232|Experimental|Etrasimod 2 mg|
33333530|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
33333531|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
33056484|NCT03934567|Experimental|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
33056485|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel
33056486|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel plus nivolumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel
33056487|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel plus nivolumab and ipilimumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel and ipilimumab 1mg/kg every 6 weeks starting on Day 42 post gavo-cel
33056488|NCT03900884|Experimental|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
33056489|NCT03899220|Experimental|Intervention|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence.
33056490|NCT03899220|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Enhanced treatment as usual includes a one session behavioral engagement in care intervention as well as substance use treatment counseling.
33056491|NCT03894462|Active Comparator|Zero Suicide Usual Care|"In Onondaga County, New York State (NYS) aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS Office of Mental Health (OMH) Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
33056492|NCT03894462|Experimental|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
33056493|NCT03890029|Other|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
33056494|NCT03890029|Other|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
33056495|NCT03888287|Experimental|Retrospective Phase|Patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
33056496|NCT03888287|Experimental|Prospective Phase-Watch Rx system|Patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
33056497|NCT03888287|Experimental|Retrospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
33056498|NCT03888287|Experimental|Prospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
33056499|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
33333532|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
33333533|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
33333534|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
33056500|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
33056501|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
33056502|NCT03875339|Active Comparator|Navigator Arm|Examination of adherence to follow-up with a navigator.
33056503|NCT03875339|No Intervention|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
33056504|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
33056505|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
33056506|NCT03865940|Experimental|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
33056507|NCT03865940|Experimental|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
33056508|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
33056509|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
33056510|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
33056511|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
33056512|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
33056513|NCT03840967|Other|Niraparib|
33056514|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.~CT scan with biphasic injection of contrast product;~MRI with injection of contrast."
33056515|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
33056516|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
33056517|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
33056518|NCT03811769|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
33056519|NCT03811769|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
33056520|NCT03803436|Experimental|Study arm|Liver transplant
33056521|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
33056522|NCT03803072|Experimental|Time restricted eating (TRE)|prolonging the duration of fasting between the last evening meal and the first meal of the next day
33333535|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
33333536|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
33333537|NCT03730064|Experimental|Bipolar depressed|
33333538|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years
33361379|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
33333539|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years
33333540|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
33333541|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
33333542|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
33333543|NCT05667350||Cancer arm|Baseline blood samples will be collected from participants newly diagnosed with biliary tract cancer.
33056523|NCT03803072|No Intervention|control|Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy
33056524|NCT03786627|Experimental|Combined NMES and motor control|This group will receive combined 15-minute neuromuscular electrical stimulation and 30-minute motor control training based on movement system impairment concept.
33056525|NCT03786627|Placebo Comparator|Motor control and placebo NMES|This group will receive placebo NMES for 15 minutes followed by 30 minutes motor control training based on movement system impairment concept.
33056526|NCT03776071|Active Comparator|RT plus TMZ and ENZ; ENZ alone; TMZ and ENZ|Radiotherapy (RT) plus temozolomide (TMZ) and enzastaurin (ENZ) (Concurrent Phase) followed by enzastaurin alone (Single-Agent Phase), then temozolomide and enzastaurin (Adjuvant Phase)
33361380|NCT01135615|Other|Sevelamer|
33056527|NCT03776071|Placebo Comparator|RT plus TMZ and placebo; placebo; TMZ and placebo|Radiotherapy (RT) plus temozolomide (TMZ) and placebo followed placebo then by temozolomide and placebo
33056528|NCT03775512|Experimental|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
33056529|NCT03775512|Experimental|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
33056530|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
33056531|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
33056532|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
33056533|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
33056534|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
33056535|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
33056536|NCT03744468|Experimental|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with Tislelizumab in participants with advanced solid tumors
33056537|NCT03744468|Experimental|Phase 2 Safety Lead-in|Dose escalation for Cohort A (LBL-007 + Tislelizumab) and Cohort B (BGB-A425 + LBL-007 + Tislelizumab) in participants with advanced solid tumors
33056538|NCT03744468|Experimental|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 and LBL-007 in combination with Tislelizumab in participants with NSCLC, HNSCC and RCC
33056540|NCT03718754|Active Comparator|En-Bloc TURB|
33056541|NCT03718754|Active Comparator|Conventional TURB|
33056542|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
33056543|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
33056544|NCT03703440|Experimental|Active|≥3 group education sessions (60 minutes per session) in addition to usual diabetes care, every 3 months for 12 months. Each group session (3-8 patients per group) will be facilitated by a diabetes nurse educator and/or dietitian. The group session content will be guided by the needs of the group participants. The group discussion will end with participants setting goals for their next appointment.
33056545|NCT03703440|Other|Control|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual diabetes care, an individual education session and written information will be provided before formal transfer.
33056550|NCT03681795|Experimental|patient|patients with Gilles de la Tourette syndrome
33056551|NCT03681795|Experimental|Control|healthy control
33056552|NCT03675477|Experimental|SHR0302 8mg QD|"Participants randomized in this arm will receive SHR0302 8mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 8mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
33068178|NCT04514536|Experimental|Health monitoring|Subjects have to monitor their health autonomously using the monitoring platform (connected health devices and app on the touchpad).
33333544|NCT05667350||Benign disease arm|Baseline blood samples will be collected from participants newly diagnosed with benign biliary tract diseases.
33333545|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
33056553|NCT03675477|Experimental|SHR0302 4mg BD|"Participants randomized in this arm will receive SHR0302 4mg BD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg BD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
33056554|NCT03675477|Experimental|SHR0302 4mg QD|"Participants randomized in this arm will receive SHR0302 4mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
33333546|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
33333547|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
33333548|NCT04015518|Other|Placebo & Spesolimab|Subcutaneous injections of placebo matching Spesolimab, with subcutaneous injections of Spesolimab starting at week 16, for a total treatment time of 52 weeks.
32869736|NCT05544084|Experimental|Adapted Patient Navigation Program|Adaptation of a patient navigation approach to effect change in cervical cancer screening uptake in Kedougou and Dakar, Senegal. Conduct a stepped-wedge randomized pragmatic trial in three districts in the Kedougou Region and three districts in Dakar to evaluate the impact of The Adapted Program. In order to conduct this trial, investigators will deploy The Adapted Program and evaluate the impact of The Adapted Program on screening uptake and time to treatment initiation (for those with abnormal screening results) within the various contexts across clusters. Investigators will also explore the effect of The Adapted Program on intrapersonal- and community-level barriers. Finally, evaluate the implementation outcomes of The Adapted Program within the context of these rural and urban districts, whereby clusters serve as their own controls as they cross over from the control to intervention group.
32869737|NCT05544084|No Intervention|Control|Standard of care
33056555|NCT03675477|Placebo Comparator|placebo|"Participants randomized in this arm will receive the placebo until week 8, and then will be re-randomized into one of the 3 active arms ( 4mg QD, 4mg BD, 8mg QD of SHR0302) in a 1:1:1 allocation ratio until the end of the study at week 16.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).~Placebos: Placebo Oral Tablet"
33056556|NCT03674437||Breast Cancer Survivors|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
33056557|NCT03674437||Healthy Controls|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
33056558|NCT03674437||Healthy 21-25 year olds|Healthy participants between the ages of 21 and 25 will be administered the Cogsuite Battery remotely. These participants will not be matched to any other groups and will not be asked for their full medical histories. They will only complete the assessment only once.
33056559|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
33056560|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
33056561|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
33056562|NCT03668119|Experimental|Nivolumab Monotherapy|
33056563|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
33056564|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
33056565|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
33056566|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
33056567|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
33056568|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
33056569|NCT03622749|No Intervention|Controls|Healthy controls
33068179|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
33333549|NCT04015518|Experimental|Spesolimab 'Speso Low'|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
33361381|NCT01135615|Other|calcium acetate|
33361382|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
33333550|NCT04015518|Experimental|Spesolimab 'Speso Medium-low'|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
33056570|NCT03620747|Experimental|Dupilumab|Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid [OCS] for those participants from the original parent study EFC13691 [NCT02528214]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.
33056571|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
33056572|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
33333551|NCT04015518|Experimental|Spesolimab 'Speso Medium-high'|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
33333552|NCT04015518|Experimental|Spesolimab 'Speso High'|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
33333553|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
33333554|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
33333555|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
33333556|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
33333557|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
33333558|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
33333559|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
33333560|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
33419139|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
33419140|NCT03626961||discharge|patients discharged from icu
33419141|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
33056575|NCT03604198|Experimental|relacorilant (CORT125134)|
33056576|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
33056577|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
33056578|NCT03595059|Experimental|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
33056579|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
33056580|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
33056581|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
33068180|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
33068181|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
33333561|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
33333562|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
33333563|NCT05665478|Active Comparator|model intervention group|The model was used for prediction to guide the later dosing regimen
33419142|NCT05108493|Experimental|Dry needling and home exercise|"The experimental intervention will consist of 3 sessions of dry needling of the lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).~Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
33419143|NCT05108493|Active Comparator|Home exercise|"Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
33419144|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
33112493|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
33112494|NCT00553085||Anx group|
33112495|NCT00553085||ADHD group|
33112496|NCT00553085||Nonanx/nonadhd group|
33112497|NCT05358080|Experimental|Entelon Tab. 50mg|
33112498|NCT05358080|Placebo Comparator|Placebo|
33112499|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
33112500|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
33112501|NCT05352737||Pri-Meta|patients with breast cancer metastasis at first diagnosis
33112502|NCT05352737||Sec-Meta|patients with early breast cancer developed distant metastasis within 5 years
33112503|NCT05352737||Non-Meta|patients with early breast cancer did not develop distant metastasis within 5 years
33112504|NCT05352737||older|patients with breast cancer older than 70 years old with G8 screening
33112505|NCT05352737||pCR|patients with breast cancer reached pCR after neoadjuvant chemotherapy
33112506|NCT05352737||non-pCR|patients with breast cancer did not reach pCR after neoadjuvant chemotherapy
33112507|NCT05344274|Experimental|Isocapnic Oxygen|Investigators will evaluate retinal blood flow in response to oxygen supplementation.
33112508|NCT05340374|Experimental|Treatment Arm|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
33112509|NCT04640883|Experimental|Sprints during low-intensity cycling|
33112510|NCT04640883|Active Comparator|Low-intensity cycling|
33112511|NCT04640649|Experimental|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
33112512|NCT04640649|No Intervention|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
33112513|NCT05340335|Experimental|Remimazolam|A loading dose of remimazolam is administered for sedation
33112514|NCT04640805|No Intervention|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac) to every 25ml PDHM at a feed volume of 80ml/kg/day
33112515|NCT04640805|Experimental|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
33112516|NCT04640844|Experimental|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
33112517|NCT05336630|Experimental|Forceps Assisted Cannulation|Patients will have a forceps assisted cannulation during their ERCPs.
33112518|NCT05336630|No Intervention|No Forceps Assisted Cannulation|Patients will not have a forceps assisted cannulation during their ERCPs.
33112519|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
33112520|NCT05326568|Experimental|Experimental|Sesame oil was applied by the researcher to the patients assigned to the intervention group. Sesame oil was applied to the 10 cm circumference of the cannula, in the form of 10 drops and 10 minutes.
33112521|NCT05326568|No Intervention|Control|No treatment was applied to the patients assigned to the control group and only standard care was applied.
33112522|NCT04640181|Active Comparator|Adaptive Dosing: Enoxaparin|"Low 40mg subcutaneous (SQ) daily, or~Intermediate 40mg SQ q12 hours, or~Therapeutic 1mg/kg SQ q12 hours"
33112523|NCT04640181|Active Comparator|Adaptive Dosing: Rivaroxaban|"Low 10mg po daily~Intermediate 10mg po daily~Therapeutic 20mg po daily"
33419145|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
33112527|NCT04640103||adjuvant therapy|Patients who received immunotherapy in adjuvant treatment stage only
33112528|NCT04640103||neoadjuvant therapy|Patients who received immunotherapy in neoadjuvant treatment stage and achieved R0 resection
33112529|NCT05317364|Active Comparator|Topical vaginal estrogen group|Estradiol vaginal cream 0.01% 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g estradiol vaginal cream 0.01% will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy
33112530|NCT05317364|Placebo Comparator|Placebo group|Placebo cream, 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g of placebo cream will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy.
33112531|NCT00559455|Experimental|1|
33112532|NCT00559494|Experimental|Minocycline|
33112533|NCT00559494|Placebo Comparator|Placebo|
33112534|NCT00559494|Experimental|SCPP augmentation|
33112535|NCT00559494|Sham Comparator|SCPP control|
33056582|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
33056583|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
33056584|NCT03587805|Experimental|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~From Week 2 up to Week 266*: SC injection of tralokinumab maintenance dose.~*The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from."
33056585|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
33056586|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
33056587|NCT03569124||Training group|
33056588|NCT03569124||Non-Training group|
33056589|NCT03543969|Experimental|Arm A: BRAF-MEK Inhibitor Therapy|Participants will receive 450 mg Encorafenib daily, along with 45 mg Binimetinib twice daily and 240 mg Nivolumab IV every 2 weeks.
33056590|NCT03543969|Active Comparator|Arm B|Participants will receive 240 mg Nivolumab IV every 2 weeks
33056591|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
33056592|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
33056593|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
33056594|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
33056595|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
33056596|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
33056597|NCT03499509|Experimental|Low Glycemic Diet|
33056598|NCT03499509|Placebo Comparator|High Glycemic Diet|
33056599|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
33056600|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
33056601|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|"Bilastine Ophthalmic Solution 0.6%~1 drop in each eye at 2 separate times during an 8 day period."
33056602|NCT03479307|Active Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|"Ketotifen Ophthalmic Solution 0.025% (Zaditen)~1 drop in each eye at 2 separate times during an 8 day period."
33056603|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 2 separate times during an 8 day period."
33056604|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
33056605|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
33056606|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
33056607|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally (NES/T gel). The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day).
33056608|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
33068182|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
33068183|NCT04514185|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
33068184|NCT04514185|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
33056609|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
33333564|NCT05665478|No Intervention|Non-intervention group|In the non-intervention group, the doctor chose the treatment plan.
33333565|NCT03907878|Experimental|Ligelizumab|Ligelizumab q4w
33333566|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
33333567|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
33056610|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
33056611|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
33333568|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
33333569|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
33333570|NCT04021524|Active Comparator|Hibiclens Soap|
33056612|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
33056613|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
33056614|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
33333571|NCT04021524|Experimental|BPO Soap|
33333572|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
33333573|NCT03606668|Experimental|People with Multiple Sclerosis (PwMS) and Chronic Pain|"Participants with MS will only be able to receive eight treatment sessions in this study group and will complete their treatment over four weeks. Two treatments sessions must be completed each week (of the four weeks) and separated by at least one day.~Participants will attend a baseline visit with assessment and training procedures and receive their first treatment immediately after all baseline assessments. Participants will then complete the remaining seven treatment sessions over four weeks. At the final treatment session, participants will repeat assessments. One week following the final treatment session, participants will be asked to return to clinic to complete assessments once more to test cumulative benefits one week following treatment end."
33333574|NCT05666492|Experimental|Less than 12 months PRP- Test|Patients randomized into the less than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
33333575|NCT05666492|Placebo Comparator|Less than 12 months placebo- control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
33333576|NCT05666492|Experimental|More than 12 months PRP- Test|Patients randomized into more than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
33333577|NCT05666492|Placebo Comparator|More than 12 months Placebo- Control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
33333578|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
33056615|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision.
33068185|NCT04514068|Experimental|Unilateral electroacupuncture of p6 acupoint|
33068186|NCT04514068|Experimental|Bilateral electroacupuncture of p6 acupoint|
33068187|NCT04514068|Sham Comparator|Sham acupuncture of p6 acupoint|
33068188|NCT00142103|Experimental|CPG10101|
33068189|NCT00142103|Experimental|CPG10101 + pegylated interferon|
33068190|NCT00142103|Experimental|CPG10101 + ribavirin|
33068191|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
33068192|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
33056616|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system.
33056617|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision.
33056618|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.
33056619|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
33056620|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
33056621|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
33056622|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
33056623|NCT03364036|Experimental|Mavenclad®|
33056624|NCT03354611|Experimental|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
33056625|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
33056626|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
33333579|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
33333580|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
33333581|NCT03731624||SLK|
33333582|NCT03731624||GVHD|
33333583|NCT03731624||Dry eye|
33333584|NCT03731624||Control|
33333585|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
33333586|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
33333587|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
33333588|NCT03734978||A blood group|prematurity with sepsis
33333589|NCT03734978||O blood group|prematurity with sepsis
33333590|NCT03734978||B blood group|prematurity with sepsis
33333591|NCT03734978||AB blood group|prematurity with sepsis
33333592|NCT03729674||Biosimilar|Exposed group
33333593|NCT03729674||Originator (legacy) drug|Reference group
33333594|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
33333595|NCT01310270|Placebo Comparator|Placebo|
33333596|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
33333597|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
33112536|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
33112537|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
33112538|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
33112539|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
33112540|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
33112541|NCT00559533|Experimental|1|
33112542|NCT05292755|Experimental|Carboxymethylcellulose (CMC) Artificial Tears|Refresh brand artificial tears containing 0.5% carboxymethylcellulose will be self-administered three times a day in each eye by the participants for 1 week in the experimental arm.
33112543|NCT05292755|Placebo Comparator|Preservative-free, CMC-free Artificial Tears|Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for 1 week in the control arm.
33112544|NCT05286632|Experimental|KidneYou APP|"In patients randomized in Group A (intervention group) the NP program will be administered by means of App KidneYou. Each patient will select the assigned daily menu or the proposed alternatives, following instructions reported for breakfast, mid-morning snack, lunch, afternoon snack, and dinner.~Patients randomized to Group A (intervention group) will be administered the PA program by means of App KidneYou. Each patient will follow the assigned exercise program (i.e., recommended type of PA, minutes of exercise/day, number of days/week, level of intensity).~Only patients randomized to Group A (KidneYou users) will be invited by the investigator to follow stress-reducing activities. This difference between the two groups is based on the nature of the mindfulness program, consisting solely of multimedia contents."
33112545|NCT05286632|No Intervention|Standard of care control group|"In patients randomized in Group B (control group) the NP program will be administered by means of a paper diary containing the entire range of daily menu and related alternatives needed to terminate the 3-month study period.~Patients randomized to Group B (control group) will be administered the PA program by means of a paper diary containing the entire range of exercises needed to terminate the 3-month study period.~The stress reduction program is not a standard of care currently used within the treatment strategy of CKD patients, neither through face-to-face visits with a specialist, nor through multimedia content.~Patients provided with paper diary and randomized in Group B (KidneYou non-users) represent the population followed by the current standard of care and will not be provided with any multimedia content in the context of their participation in the present study."
33112548|NCT05250167||CKD patients stage 2|
33112549|NCT05250167||CKD patients stage 3a|
33112550|NCT05250167||CKD patients stage 3b|
33112551|NCT05250167||CKD patients stage 4|
33112552|NCT05250167||Controls without CKD|
33112553|NCT05239598|Experimental|Povidone-iodine 0.5% antiseptic mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.
33112554|NCT05239598|Placebo Comparator|Placebo|Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.
33112555|NCT00559572|Experimental|1|Exercise information group
33112556|NCT00559572|Active Comparator|2|General health information group
33112557|NCT05209412|Experimental|Drug-coated balloon|Lepu Paclitaxel coated balloon will be used
33112558|NCT05209412|Active Comparator|Drug-eluting stent|Resolute Integrity Zotarolimus eluting stents will be used
33112559|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
32869738|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
32869739|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
32869740|NCT01665768|Experimental|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
32869741|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33112560|NCT05208086||Patients|"Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit.~Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit."
33112561|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
33112562|NCT05197322|Other|Tumour Mutation Burden high or medium (or MSI-High)|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-high (defined as ≥20 mutations per Mb) or medium (defined as 6-19 mutations per Mb); FOUNDATIONONE®CDx (or MSI-H if FM1 test is not evaluable):~A further two cycles of pembrolizumab 200 mg IV every 21 days~Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
33112563|NCT05197322|Other|Tumour Mutation Burden low or unevaluable|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-low (defined as ≤5 mutations per Mb); FOUNDATIONONE®CDx (or if FM1 test and PCR are not evaluable):~• Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
33333598|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
33333599|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
33333600|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
33333601|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
33333602|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
33333603|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
33333604|NCT03734510|Active Comparator|hesperidin and flaxseed|
33056627|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
33056628|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
33056629|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
33333605|NCT03734510|Placebo Comparator|control|
33333606|NCT03734510|Active Comparator|flaxseed|
33333607|NCT03734510|Active Comparator|hesperidin|
33333608|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
33333609|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
33333610|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
33333611|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
33333612|NCT03601052|Experimental|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
33056630|NCT03334942|Experimental|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
33056631|NCT03334942|No Intervention|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
33056632|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
33056633|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 7-10 days
33056634|NCT03323463|Experimental|Arm A: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia. This arm is closed to accrual.
33056635|NCT03323463|Experimental|Arm B: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.
33056636|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
33056637|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
33056638|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
33056639|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
33056640|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
33056641|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
33056642|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
33056643|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
33056644|NCT03243058|Active Comparator|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
33056645|NCT03243058|Experimental|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
33056646|NCT03243058|Placebo Comparator|Placebo|Participants in this group will receive a placebo injection for two years.
33056647|NCT03231969|Experimental|Bilastine 0.2%|"Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period."
33056648|NCT03231969|Experimental|Bilastine 0.4%|"Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period."
33333613|NCT03601052|Placebo Comparator|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
33056649|NCT03231969|Experimental|Bilastine 0.6%|"Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period."
33056650|NCT03231969|Placebo Comparator|Bilastine 0%|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period."
33056651|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
33333614|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
33056652|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
33333615|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
33333616|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
33333617|NCT03729440||corrosive patients|
33333618|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
33333619|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
33333620|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
33333621|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
33333622|NCT05665400|Experimental|Bloomlife Lovelace FT|
33333623|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
33056653|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
33056654|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
33056655|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
33056656|NCT03155997|Experimental|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
33056657|NCT03155997|Other|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
33056658|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
33056659|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
33056660|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
33056661|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
33056662|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
33056663|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
33056664|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
33056665|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
33056666|NCT03101982|No Intervention|control|ASIA score, blood taking
33056667|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
33056668|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
33056669|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
33056670|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
33056671|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
33056675|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
33056676|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
33068193|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
33112564|NCT04639869|Experimental|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
33112565|NCT04639869|Active Comparator|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
33112566|NCT04639869|Experimental|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
33112567|NCT04639869|Active Comparator|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
33112568|NCT05186675|Experimental|Superselective adrenal arterial embolization|For patients with bilateral idiopathic hyperaldosteronism confirmed by adrenal venous sampling, Superselective adrenal arterial embolization（SAAE）shall be given according to the patient's wishes. The blood pressure, plasma aldosterone and potassium levels, and adverse events were assessed after SAAE. The primary endpoint was the change in home blood pressure at one months, compared with baseline.
33112569|NCT04639908||barriers|find out what are the barriers
33112570|NCT04639908||facilitators|find out what are the facilitators
33112571|NCT05177744||allergic (Zagreb, urban)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Zagreb (urban)"
33112572|NCT05177744||healthy subjects (Zagreb, urban)|"Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
33112573|NCT05177744||allergic (Slavonia, urban and rural)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)"
33112574|NCT05177744||healthy subjects (Slavonia, urban and rural)|"Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
33333624|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
33333625|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
33333626|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
33333627|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
33112575|NCT05177744||allergic Mediterranean region (urban and rural population)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from mediterranean region in Croatia - urban and rural"
33112576|NCT05177744||healthy subjects Mediterranean region (urban and rural population)|"Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural.~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
33112577|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
33112578|NCT05173415|Experimental|LOCalizer (TM) Group|Patients who are randomized for the RFID will receive a preoperative ultrasound-guided marking with RFID tag (LOCalizerTM) in the axillary lymph nodes that indicate for surgical removal. Surgical procedure is standardized with a handheld probe leading intraoperatively to the marked lymph node and its excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
33112579|NCT05173415|Active Comparator|HydroMARK(C) Clip Group|Patients who are randomized for the standard clip will receive a preoperative ultrasound-guided marking with HydroMark® Clip in the axillary lymph node that indicate for surgical removal. Surgical procedure is standardized with intraoperative ultrasound-guided wire-localization of the clip and lymph node excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
33112580|NCT04639791||Severe asthma patients|on step 4& 5 of GINA treatment
33112581|NCT04639557|Experimental|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
33112582|NCT04639557|Experimental|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
33333628|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
33333629|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
33333630|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
33333631|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
33056677|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
33056678|NCT02942173|No Intervention|CD45RA-|
33056679|NCT02942173|Experimental|CD45RA+|
33056680|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
33056681|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
33056682|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
33056683|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
33056684|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
33056685|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
33056686|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily~Enterade will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
33056687|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily~Placebo will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
33056688|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
33056689|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
33056690|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
33056691|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
33056692|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
33056693|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg equivalent dose)"
33056694|NCT02808780||Simponi-exposed cohort|Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.
33056695|NCT02808780||comparator cohort|Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.
33056696|NCT02778685|Experimental|Cohort 3 (letrozole, palbociclib, fulvestrant, pembrolizumab)|Patients receive either letrozole PO QD on days -28 to -1 and days 1-28, or fulvestrant on days -28, -14, and day 1 of subsequent cycles. Patients also receive palbociclib PO QD for 3 weeks. Cycles with palbociclib, and letrozole or fulvestrant repeat every 28 days in the absence disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33333632|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
33333633|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
33333634|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
33333635|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
32869742|NCT05697744||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
32869743|NCT05697744||Morbid obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
33056697|NCT02778685|Experimental|Cohorts 1 and 2 (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33056698|NCT02752035|Experimental|Dose escalation of ASP2215 given with azacitidine|Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).
33056699|NCT02752035|Experimental|Arm A: ASP2215|Subjects will be treated daily each 28-day cycle.
33056700|NCT02752035|Experimental|Arm AC: ASP2215 + azacitidine|Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.
33056701|NCT02752035|Active Comparator|Arm C: azacitidine|Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.
33056702|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:~- meningioma of the cavernous sinus for which radiotherapy is planned~Or~- a pituitary adenoma for which radiotherapy is planned"
33056703|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
33056704|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
33056705|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
33333636|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
33333637|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
33333638|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
33333639|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
33333640|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
33333641|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
33333642|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
33333643|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
33056706|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
33056707|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
33056708|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
33056709|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
33056710|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
33056711|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
33056712|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
33056713|NCT02598661|Experimental|Part 2 (Main Study): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
33056714|NCT02598661|Placebo Comparator|Part 2 (Main Study): Placebo|Matching Placebo to Imetelstat will be administered.
33056715|NCT02598661|Experimental|Part 2 (Ventricular Repolarization Substudy): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
33056716|NCT02598661|Placebo Comparator|Part 2 (Ventricular Repolarization Substudy): Placebo|Matching Placebo to Imetelstat will be administered.
33056717|NCT02586831|Experimental|Arm A|"Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2~Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), & then every 2 weeks, for 52 weeks~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks."
33056718|NCT02586831|Placebo Comparator|Arm B|Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
33333644|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
32869744|NCT04617457|Experimental|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
33056719|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
33056720|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
33056721|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
33056722|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
33056723|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
33056724|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
33056725|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
33056726|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
33056727|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33056728|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33056729|NCT02540616|Experimental|Transcranial Electrical Stimulation-Real|The participant will perform real TES. The forms of TES used in this study will include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS). Each stimulation session will last for 20-minutes.
33056730|NCT02540616|Sham Comparator|Transcranial Electrical Stimulation-Sham|The participant will perform sham TES for 20-minutes. The form of sham TES will depend on the active arm, e.g. if tACS is on the active arm, then the sham tACS will be a different frequency of stimulation. If tDCS is the active arm, then a short ramp up of tDCS followed by a ramp down (about 60-seconds) will be used as the sham arm.
33056731|NCT02531126|Experimental|RPC0163 (Ozanimod)|
33056732|NCT02522611|Experimental|Resiniferatoxin|Schedule a maximum of 3 periganglionic DRG injection(s) at contiguous level(s) to treat targeted DRG responsible for chronic CIBP
33056733|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
33056734|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
33056735|NCT02417766||Family Members|Family members to the patients
33056736|NCT02417766||Patient|Patients here at NIH
33333645|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
33333646|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
33056737|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.
33056738|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
33056739|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
33056740|NCT02311322||Children with growth disorders|Children with growth disorders
33056741|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
33056742|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
33056743|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
33056744|NCT02278250|Experimental|Part A: M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33333647|NCT03729050|No Intervention|Control|
33333648|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
33333649|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
33333650|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
33333651|NCT03734276|Experimental|High intensity exercise|
33333652|NCT03734276|Active Comparator|Control|
33333653|NCT05665634|Experimental|All participants|
33333654|NCT05665556||Pulmonary Arterial Hypertension (Group I)|Group I Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
33333655|NCT05665556||Pulmonary Arterial Hypertension (Group IV)|Group IV Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
33333656|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
33333657|NCT03734120||men|men undergoing routine semen analysis for infertility
33056745|NCT02278250|Experimental|Part A: M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33333658|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
33333659|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
33333660|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
33333661|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
33333662|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
33056746|NCT02278250|Experimental|Part A: M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056747|NCT02278250|Experimental|Part A: M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056748|NCT02278250|Experimental|Part A: M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056749|NCT02278250|Experimental|Part A: M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056750|NCT02278250|Experimental|Part A: M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056751|NCT02278250|Experimental|Part A: M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056752|NCT02278250|Experimental|Part A: M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056753|NCT02278250|Experimental|Part A: M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056754|NCT02278250|Experimental|Part A2: M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056755|NCT02278250|Experimental|Part A2: M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056756|NCT02278250|Experimental|Part A2: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056757|NCT02278250|Experimental|Part A2: M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056758|NCT02278250|Experimental|Part B1: M4344 350 mg + Carboplatin|Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056759|NCT02278250|Experimental|Part B1: M4344 400 mg + Carboplatin|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056760|NCT02278250|Experimental|Part B1: M4344 500 mg + Carboplatin|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056761|NCT02278250|Experimental|Part C: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
33056762|NCT02275221||Hepatitis B and C|Hepatitis B and C
33056763|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
33068194|NCT04513873|Experimental|Equipment Intervention Group|"The intervention group had equipment that looks like a blood tube in front of them during the blood collection process to divert their attention from the blood collection process to the equipment. This equipment was with a fixed arm on the right and a moving arm on the left with a total height of 80 cm as well as a red light-emitting diode(LED) to stimulate the blood collection. It had some answers to common questions of parents as well as the key concerns of the children like  Will it hurt me?. The equipment was made a musical device by loading the most popular children's songs into its database."
33068195|NCT04513873|No Intervention|No Intervention Group|Standard blood collection procedures were applied to the control group.
33068196|NCT00505726||Confocal Microscopy|
33056764|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
33056765|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
33056766|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
33056767|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
33056768|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
33056769|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
33056770|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
33056771|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
33056772|NCT02101905|Experimental|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33333663|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
33333664|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
33056773|NCT02101905|Active Comparator|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33056774|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
33056775|NCT02081404|Placebo Comparator|Placebo|placebo
33056776|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
33056777|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
33056778|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
33056779|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
33056780|NCT01730092||Healthy Volunteers|Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and gender
33056781|NCT01730092||Pulmonary Arterial Hypertension Subjects|150 subjects with pulmonary arterial hypertension; male or female, age grater than or equal to 18 99 years
33333665|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
33333666|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
33333667|NCT00071487|Placebo Comparator|Placebo plus SOC|
33056782|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
33056783|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
33333668|NCT00071487|Experimental|Belimumab 1 mg/kg plus SOC|
33333669|NCT00071487|Experimental|Belimumab 4 mg/kg plus SOC|
33333670|NCT00071487|Experimental|Belimumab 10 mg/kg plus SOC|
33333671|NCT03962283|Active Comparator|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
33333672|NCT03962283|Placebo Comparator|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
33333673|NCT03591146|Experimental|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
33333674|NCT03591146|Experimental|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
33333675|NCT03591146|Experimental|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
33333676|NCT03591146|Experimental|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
33333677|NCT03591146|Active Comparator|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
33333678|NCT00096447|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33333679|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
33056784|NCT01590862|Active Comparator|Deep Brain Stimulation On|We will assess Reward Motivation behavior with Deep Brain Stimulation on.
33056785|NCT01590862|No Intervention|Deep Brain Stimulation Off|We will assess Reward Motivation behavior with Deep Brain Stimulation off.
33056786|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
33056787|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
33056788|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
33056789|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
33333680|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
33056790|NCT01567722||HIV-positive cervical cancer cases|Tissue specimen collection from HIV positive patients with a diagnosis of cervical cancer
33056791|NCT01526603|Other|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
33333681|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
33333682|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
33056792|NCT01407263|Experimental|Lymphadenectomy vs. no lymphadenectomy|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.No lymph nodes will be removed in patients randomized to the no PLND arm.
33056793|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021)|
33056794|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis (Closed as of 9/30/2021)|
33333683|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
33333684|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
33333685|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
33333686|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
33333687|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
33333688|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
33333689|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
33333690|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
33333691|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
33333692|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
33333693|NCT00090285|Experimental|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
33333694|NCT00090285|Placebo Comparator|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
33333695|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
33333696|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
33056795|NCT01407263|Experimental|Hemostatic agent vs. no hemostatic agent|
33056796|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
33333697|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
33056799|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
33056800|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
33056801|NCT01124695|Experimental|Tamoxifen|Patients receive oral tamoxifen citrate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities.
33056802|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
33056803|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 4/2/14)
33333698|NCT00070941|Experimental|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
33333699|NCT00070941|Active Comparator|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
33333700|NCT00070941|Placebo Comparator|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
33333701|NCT03960489|Experimental|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
33056804|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month.
33056805|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
33056806|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
33333702|NCT03960489|Experimental|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
33361383|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
33361384|NCT01358474||Healthy Controls|Healthy volunteers
33361385|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
33056812|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
33056813|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
33056814|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
33056815|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
33056816|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
33056817|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
33056818|NCT00710112||VLBW|infants less than 1500 grams at birth
33056819|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
33056820|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
33056821|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
33056822|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
33056825|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
33056828|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound study results or make participation in this protocol impossible
33056829|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
33056830|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
33056831|NCT04733300|Experimental|Mindfulness-Based College - Standard Dose|MBC standard dose is a 9-week, 9 session program providing systematic and intensive training in mindfulness meditation practices. The curriculum is grounded in the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum. MBSR was adapted to the young adult life stage by: (1) Training mindfulness skills such as attention control, self-awareness and emotion regulation, using the MBSR curriculum, and (2) applying these skills to the health behaviors and priorities most relevant to young adults. Specific behaviors and priorities targeted are social relationships, sleep, stress, diet, physical activity, obesity, alcohol consumption, substance use, digital media use, and performance (e.g. athletic, artistic and academic). The intervention is administered live, online via a video conferencing platform. The standard dose class meets once a week for 2.5 hours for 9 weeks. There is also an all-day retreat that takes place around week 6 of the program.
33056832|NCT04733300|Experimental|Mindfulness-Based College - Low Dose|The MBC low-dose program is mirrored after the standard MBC program (described previously); however, instead of meeting for 2.5 hours each week, the low-dose MBC program is abbreviated to meet for 1.5 hours each week for the 9 weeks. MBC low-dose will be administered live, online via the free video conferencing platform, Zoom.
33068197|NCT04513483|Experimental|CPAP treatment for 12 months|CPAP treatment for 12 months
33068198|NCT04513483|Placebo Comparator|Placebo|observation
33333703|NCT03960489|Experimental|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
33361386|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
33361387|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
33056833|NCT04733300|Active Comparator|Health education control group|Those randomized to the health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
33056834|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
33056835|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
33056836|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
33056837|NCT00070070|Experimental|Cohort 1|"HLA-A2 Status Positive, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
33056838|NCT00070070|Experimental|Cohort 2|"HLA-A2 Status Positive, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
33056839|NCT00070070|Experimental|Cohort 3|"HLA-A2 Status Negative, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
33056840|NCT00070070|Experimental|Cohort 4|"HLA-A2 Status Negative, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 106 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 105 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
33056841|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
33056842|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
33056843|NCT00038805|Experimental|Mylotarg|
33056844|NCT00018824|Experimental|1|Naltrexone
33056845|NCT00018824|Placebo Comparator|2|Placebo
33056846|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
33056847|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
33056848|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
33056849|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
33056850|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
33056851|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
33056852|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
33056853|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
33068199|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
33112583|NCT05172791|No Intervention|Usual care|Clinical teams will decide on antibiotic duration for patients with possible pneumonia without external prompting
33056854|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
33333704|NCT03960489|Experimental|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
33056855|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
33056856|NCT00039624|Experimental|Brachy|brachytherapy
33056857|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
33056858|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
33056859|NCT00040326|Active Comparator|1|anteromesial temporal resection
33056860|NCT00040326|Active Comparator|2|antiepileptic drugs
33056861|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
33056862|NCT00020735|Experimental|oral toremifene|
33056863|NCT00020735|Other|observation|
33056864|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
33056865|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
33056866|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
33056867|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
33056868|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
33056869|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
33056870|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
33056871|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
33056872|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
33056873|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
33056874|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
33112584|NCT05172791|Experimental|Electronic alert|An electronic alert will be displayed within the electronic medical record of eligible patients that notes that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia
33056875|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
33056876|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
33056877|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
33333705|NCT00070707|Experimental|Mometasone|Mometasone nasal spray 200 mcg, administered once daily (QD) for 4 weeks
33333706|NCT00070707|Placebo Comparator|Placebo|Matching placebo nasal spray, administered QD for 4 weeks
33333707|NCT01082523|Active Comparator|Text message reminders|
33333708|NCT01082523|No Intervention|Control|
33333709|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
33333710|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
33056878|NCT04731402|Experimental|Acupressure|Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
33333711|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
33056879|NCT04731402|Experimental|Laughter Yoga|Laughter Yoga group Laughter yoga sessions begin with gentle warm-up techniques that include stretching and stretching movements, songs, applause, and body movements. Therapy sessions are between 30-45 minutes.8 sessions of laughter yoga will be done once a week.
33056880|NCT04731402|Experimental|mindfulness stress reduction program|mindfulness stress reduction program mindfulness stress reduction program consists of 8 weeks. each week is 2.5 hours. each week has a different theme. There is a 6-hour silence day in the 6th week of the program.
33056881|NCT04731402|No Intervention|Control Group|INTERVENTION NOT IMPLEMENTED
33056882|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
33056883|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
33333712|NCT00070317|Experimental|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
33333713|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
33333714|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
33333715|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
33333716|NCT03960411|Experimental|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
33333717|NCT03960411|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
33333718|NCT01082679|Other|methadone via specialty care|
33333719|NCT01082679|Other|Suboxone via specialty care|
33333720|NCT01082679|Other|Suboxone via primary care|
33333721|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
33333722|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
33333723|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
33333724|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
33333725|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
33333726|NCT01326897|Experimental|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
33333727|NCT03962049|Experimental|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
33333728|NCT03962049|Experimental|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
33333729|NCT03962049|Experimental|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
33333730|NCT03962049|Experimental|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
33333731|NCT01090167|Experimental|Clofarabine|
33333732|NCT05109130||laparoscopic surgery|Laparoscopic total mesorectal excision was performed on the enrolled patients.
33333733|NCT05109130||Transanal endoscopic surgery|Transanal total mesorectal excision was performed on the enrolled patients.
33056884|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
33056885|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
33056886|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
33056887|NCT04731285||Pressure wire based FFR|Pressure wire based FFR was reference group
33056888|NCT04731285||CT-FFR|CFD-based RuiXin-FFR was test group
33056889|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
33056890|NCT00049569|Experimental|Arm I|See detailed description.
33056891|NCT00049569|Experimental|Arm II|See detailed description.
33056892|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
33056893|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
33056894|NCT00022334|Experimental|Treatment|See intervention description.
33056895|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
33056896|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
33056897|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
33056898|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33056899|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
33056900|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
33056901|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
33056902|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
33056903|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
33056904|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
33056905|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
33056906|NCT00050076|Experimental|MCC-135 50 mg BID|
33056907|NCT00050076|Experimental|MCC-135 100 mg QD|
33056908|NCT00050076|Experimental|MCC-135 200 mg QD|
33333734|NCT03851458||Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
33333735|NCT03851458||SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and my plate dietary surveys can be done over phone. Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
33361388|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
33112585|NCT05172791|Experimental|Pharmacist|Pharmacists will contact the treating teams of eligible patients to note that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia.
33112586|NCT05165693|Experimental|Experimental Formula|One 296 mL serving of study product
33112587|NCT05165693|Active Comparator|Test Meal|48 g Instant oatmeal
33112588|NCT04639362|Experimental|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
33333736|NCT03851458||ROADmAP schema|Participants will be randomly assigned to one of eight study groups which will be one or a combination of 4 conditions: (1) in person individualized diet and exercise counseling (2) diet and exercise text messages (3) weekly telephone support and (4) self-monitoring tools for diet and weight. For the first part of the study, Survey, approximately 64 drivers and 36 management staff will take pate in the feedback questionnaire. For the second part of the study, Interview, approximately 8 drivers and 12 management staff may be invited to take part in an interview via phone, in person, or teleconference (Zoom).
33333737|NCT05097898|Experimental|Patients with chronic HFpEF coming for scheduled day hospitalization or consultation|"Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
33333738|NCT03772444|Active Comparator|Beetroot juice|
33112589|NCT04639362|Experimental|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
33112590|NCT05120141|Experimental|Prototype 1 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
33333739|NCT03772444|Placebo Comparator|Control group 1|
33333740|NCT03772444|Sham Comparator|Control group 2|
33112591|NCT05120141|Experimental|Prototype 2 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
33112592|NCT05120141|Experimental|Prototype 3 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
33333741|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
33112593|NCT05120141|Active Comparator|Listerine Cool Mint Mouth Rinse (Positive Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Mouth rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
33112594|NCT05120141|Active Comparator|Hydroalcohol Mouth Rinse (Negative Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Hydroalcohol Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
33112595|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
33112596|NCT04683536||control group|Patients underwent TUR-BT under spinal anesthesia
33112597|NCT04683536||Study group|Patients underwent TUR-BT under spinal anesthesia combined with ultrasound guided obturator nerve blockade
33112598|NCT04639401|Experimental|persons with Multiple Sclerosis|
33112599|NCT04639401|Placebo Comparator|Healthy controls|
33112600|NCT04683419|Experimental|Patients with pleural effusion of Undetermined etiology|Patients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
33112601|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
33112602|NCT05103800|No Intervention|control group|Babies in the control group will not listen to any sound during the invasive procedures, the procedure will be recorded with a camera, and at the end of the study, the camera images will be watched by two experts in the field and the pain and comfort scale will be filled.
33112603|NCT05103800|Experimental|Experimental group|During the invasive interventions, the white noise prepared by the researcher for the babies in the experimental group will be started to be listened to 5 minutes before the start of the intervention and will be listened to for 5 more minutes during and after the intervention. At the same time, the procedure will be recorded with a camera. At the end of the study, the camera images will be watched by two experts in the field. comfort scale will be filled.
33112604|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
33112605|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
33112606|NCT05089214|Experimental|Intra oral clinical examination|
33112607|NCT04639440||Obese or overweight patients|
33112608|NCT04639440||Patients without overweight|
33112609|NCT05084768||Rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
33112610|NCT05084768||No rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
33333742|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
33112611|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
33112612|NCT00561249|No Intervention|2|No intervention
33333743|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
33333744|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
33333745|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
33333746|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
33333747|NCT04021290|Experimental|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
33333748|NCT04021290|Active Comparator|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
33333749|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
33333750|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
33333751|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
33333752|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
33056909|NCT00050076|Placebo Comparator|Placebo|
33056910|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
33056911|NCT00050349|Experimental|EPO906|
33056912|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
33056913|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
33056914|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
33056915|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
33056916|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
33056917|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
33056918|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
33056919|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
33056920|NCT00050661|Experimental|anti-TAC or placebo|
33056921|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
33056922|NCT00023504|Active Comparator|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
33056923|NCT00023504|Active Comparator|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
33056924|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
33056925|NCT00051090|Experimental|A|All eligible study participants
33056926|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
33056927|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
33056928|NCT00051285|Experimental|Enoximone|
33056929|NCT00051285|Placebo Comparator|Placebo|
33056930|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
33056931|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
33056932|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
33056933|NCT00051714|Experimental|Early Primary Prevention|
33056934|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33056935|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33056936|NCT00051831|Experimental|1|
33112613|NCT05076656|Experimental|Probiotics arm|Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)
33112614|NCT05076656|Experimental|FMT arm|Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.
33112615|NCT05076656|Placebo Comparator|Control arm|Individuals who receive a probiotics pill daily of placebo (milk powder)
33112616|NCT00561288|Experimental|1|2000 mg acetaminophen per day
33112617|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
33112618|NCT05062343|Active Comparator|Dilapan-S|After randomization, the patient will have Dilapan-S placed via sterile speculum exam with placement of 3-5 rods. The rods will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the rods will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
33112619|NCT05062343|Active Comparator|Cook Catheter|After randomization, the patient will have the Cook catheter placed via sterile vaginal or speculum exam with the uterine component of the balloon inflated to maximum 60mL. The balloon will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the Cook catheter will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
33112620|NCT00561327||A|Patients chronically treated with drug losartan
33112621|NCT00561327||B|Patients not chronically treated with losartan
33112622|NCT00561366|Placebo Comparator|1|
33112623|NCT00561366|Experimental|2|
33112624|NCT05057741|Experimental|Multimodal Prehabilitation|Multimodal prehabilitation: exercise, nutrition and relaxation
33333753|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
33333754|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
33333755|NCT03586544|Experimental|Albuterol first|Order albuterol and then interval warm up (IWU)
33333756|NCT03586544|Experimental|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
33333757|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
33333758|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
33333759|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR~ACLF 1 with~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~liver failure and West Haven grade 1-2 hepatic encephalopathy, or~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR~ACLF 2 with~liver failure and coagulation failure, or~liver failure and West Haven grade 3-4 hepatic encephalopathy."
33333760|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR~ACLF 2 with~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
33333761|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
33333762|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
33333763|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
33333764|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
33112625|NCT05057741|No Intervention|Standard of Care|Usual care group: advice of surgeons about self care
33112626|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
33333765|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
33333766|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
33333767|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
33333768|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
33056937|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33056938|NCT00052026|Placebo Comparator|1|Placebo
33056939|NCT00052026|Experimental|2|Low-dose carvedilol
33056940|NCT00052026|Experimental|3|high-dose carvedilol
33056941|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
33056942|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
33056943|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
33056944|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
33056945|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
33056946|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
33056947|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
33056948|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
33056949|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
33056950|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
33056951|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
33056952|NCT04733066||Non-treatment Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
33056953|NCT04733066||Teduglutide-treated Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
33056954|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
33056955|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
33056956|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
33333769|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
33333770|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
33333771|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
33333772|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
33333773|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
33333774|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
32869746|NCT05592132|Experimental|Intervention|Patients randomized in this arm will have the virtual reality headset associated to the standard care
33333775|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
33333776|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
33333777|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
33333778|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
33333779|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
33333780|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)~WXFL10030390 continuous oral dosing (0.2 mg once a day)~WXFL10030390 continuous oral dosing (0.4 mg once a day)~WXFL10030390 continuous oral dosing (0.7 mg once a day)~WXFL10030390 continuous oral dosing (1.1 mg once a day)~WXFL10030390 continuous oral dosing (1.4 mg once a day)~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
32869747|NCT05592132|No Intervention|Standard care|patients randomized in this arm will have standard care.
32871629|NCT05747547||mild disease|asymptomatic or paucisymptomatic patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV2-infection) who received outpatient care
33056957|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
33056958|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
33056959|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
33056960|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
33056961|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
33056962|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
33056963|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
33056964|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
33056965|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
33056966|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
33056967|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
33056968|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33056969|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
33056970|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
33056971|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
33056972|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
33056973|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
33056974|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
33056975|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
33333781|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
33333782|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
33333783|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
33333784|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
33333785|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
33333786|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
33056976|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
33333787|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
32871630|NCT05747547||moderate disease|patients with laboratory-confirmed SARS-CoV2-infection and radiology-confirmed pneumonia who did not require extracorporeal membrane oxygenation
33056977|NCT04731324|Experimental|ZYIL1 Capsule|six subjects will be recruited in each cohort. safety data up to day 3 will be evaluated to determine whether progression to the subsequent dose Cohort is indicated. Single dose will be administered in ascending manner starting from 25 mg.
33333788|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
33333789|NCT05089162|Experimental|Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day|
33333790|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
33333791|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
33056978|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
33056979|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
33056980|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;~Implementation intentions~Dose-response psychoeducation"
33333792|NCT05183308||patients treated with Vitamin D|
33333793|NCT05183308||patients treated with Vitamin D and Clodronic Acid|
33333794|NCT05137600|Experimental|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
33333795|NCT05137600|Experimental|Midazolam|Midazolam is a sensitive CYP3A index substrate
33333796|NCT05137600|Experimental|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites
33333797|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
33333798|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
33333799|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
33056981|NCT00025493|Experimental|docetaxel|docetaxel
33056982|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
33056983|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
33056984|NCT00053508|Experimental|Group 1|ACAM1000
33056985|NCT00053508|Experimental|Group 2|ACAM1000
33056986|NCT00053508|Experimental|Group 3|ACAM1000
33056987|NCT00053508|Active Comparator|Group 4|Dryvax
33056988|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
33056989|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
33056990|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
33056991|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
33056992|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
33056993|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
33056994|NCT04731597||Cases with hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019
33056995|NCT04731597||controls without hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019
33056996|NCT04731090|Active Comparator|Standard antibiotic prophylaxis|IV fluoroquinolone 1 hour preoperatively and oral antibiotics were used for 24h postoperatively.
33333800|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
33333801|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
33056997|NCT04731090|Experimental|enhanced prophylaxis|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
33056998|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~Patients receive methylprednisolone or equivalent corticosteroid IV or orally~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
33333802|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
33333803|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
33333804|NCT00089505|Experimental|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
33333805|NCT00089505|Experimental|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
33333806|NCT00089505|Experimental|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
33056999|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
33057000|NCT04733573|Active Comparator|Occlusal appliance by Okeson with canone guidance|Occlusal appliance will be used while sleeping for 30 days.
33057001|NCT04733573|Active Comparator|Bimaxillary splint without canine guidance|Bimaxillary splint will be used while sleeping for 30 days.
33057002|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
33057003|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
33057004|NCT04731207|Other|Healthy pregnant women|All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.
33057005|NCT00398229|Active Comparator|A|receiving hCG injection
33057006|NCT00398229|Placebo Comparator|B|
33057007|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
33057008|NCT02971592|Experimental|Experimental|
33057009|NCT02971592|Placebo Comparator|Placebo|
33057010|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
33057011|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
33057012|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
33057013|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33057014|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
33333807|NCT00089505|Experimental|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
33333808|NCT05043376|Active Comparator|Standard of care|In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.
33333809|NCT05043376|Experimental|BLIS K12|In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care
33333810|NCT04009824|Placebo Comparator|Group 1: Saline Placebo|Participants received placebo on days 1 and 22 by subcutaneous injection
33057015|NCT00027053|Experimental|Trazodone|
33057016|NCT00027053|Placebo Comparator|Placebo|
33057017|NCT00027170||Participants with cardiovascular diseases|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
33057018|NCT00027170||Healthy Participants|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
33057019|NCT00055302|Experimental|1|
33057020|NCT00055419|Experimental|400 mg/m2|
33057021|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
33057022|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
33057023|NCT02970240||Control group|Healthy control persons
33057024|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
33057025|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
33057026|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
33057027|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
33057028|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
33057029|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
33057030|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
33057031|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
33057032|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
33057033|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
33057034|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
33057035|NCT04730817|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks.
33057036|NCT04730817|No Intervention|Control group|This arm will not be given any kind of treatment and will act as a passive control group.
33057037|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
33057038|NCT00028145||1|Pregnant, HIV-infected women
33057039|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
33057040|NCT04730973|Active Comparator|Evolocumab|Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy
33057041|NCT04730973|Placebo Comparator|Standard|No further treatment besides optimal lipid-lowering therapy will be administered
33057042|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
33057043|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
33057044|NCT00056277|Other|Arm 1|
33057045|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
33057046|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
33333811|NCT04009824|Experimental|Group 2: AGS-v PLUS Non-Adjuvanted|Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection
33333812|NCT04009824|Experimental|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
33333813|NCT04009824|Experimental|Group 4: AGS-v PLUS + Montanide ISA-51|Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
32740917|NCT05593887|Active Comparator|Proximal femoral resection|This group will undergo PFR as described by resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur.
33057047|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
33057048|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:~once daily on days 1-28~once daily on days 1-7, twice daily on days 8-28~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
33057049|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
33057050|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
33057051|NCT00056394|Active Comparator|3|Participants will receive standard care.
33057052|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
33057053|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
33057054|NCT00056589|Experimental|rFXIII|
33057055|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
33057056|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
33057057|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
33057058|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
33057059|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
33057060|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
33057061|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
33057062|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
33057063|NCT00423501|Experimental|1|
33057064|NCT00423501|Experimental|2|
33057065|NCT00423501|Experimental|3|
33057066|NCT00423501|Experimental|4|
33057067|NCT00423501|Experimental|5|
33333814|NCT04009824|Experimental|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
33333815|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
33333816|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
33333817|NCT05041426|Experimental|Letermovir|Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months. Letermovir will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
33333818|NCT05041426|Active Comparator|Valganciclovir|Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-. CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
33333819|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
33333820|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
33333821|NCT05011162|Other|Digital Acceptance and Commitment Therapy (ACT) Arm|Pragmatic
33333822|NCT04987372|No Intervention|Classical protocol|"Fentanyl Max. 15µg/kg IV Per-operative~Ultiva (Remifentanyl) 0.02-0.1µg/kg/h IV Post-operative~Paracetamol 4x1g /24h IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in cas of break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
33333823|NCT04987372|Active Comparator|Multimodal protocol|"Lyrica (Pregabalin) 75mg PO 2 hours before the operation~Dexdor (Dexmedetomidine) 0.8µg/kg/h IV Per-operative / Post-operative~Ketalar (Ketamine) Bolus (0.5mg/kg) + 0.3mg/kg/h IV Per-operative until stop propofol~Linisol (Lidocain) Bolus (1.5mg/kg) + 1.3mg/kg/h IV Per-operatiive until 12h post-op~Magnesium Sulphate Induction (25mg/kg) + 25mg/kg weaning ECC IV Per-operative~Fentanyl 2.5µg/kg IV Per-operative~Paracetamol 4x1g /24u IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in case of Break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
33333824|NCT04928092||Active research group|Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care
33333825|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
33333826|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
33333827|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
33333828|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
32871631|NCT05747547||severe disease|patients with laboratory-confirmed SARS-CoV2-infection and acute respiratory distress syndrome who required extracorporeal membrane oxygenation
33057068|NCT00423501|Placebo Comparator|6|
33057069|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
33333829|NCT04905862||Hemodialyzed patients|Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
33333830|NCT04905862||Patients treated with peritoneal dialysis|Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
33333831|NCT04905862||Patients without chronic kidney disease|Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
33333832|NCT04905862||Kidney transplant recipients|Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
33333833|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
33333834|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
33333835|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
33057070|NCT00029159|Active Comparator|1|
33057071|NCT00029159|Placebo Comparator|2|
33333836|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
33333837|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
33057072|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
33057073|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
33057074|NCT00029198|Experimental|1|15 minute massage tid
33057075|NCT00029198|Sham Comparator|2|non-massage touch
33057076|NCT00423696|Experimental|bevacizumab + FOLFIRI|
33057077|NCT00423696|Experimental|bevacizumab + XELIRI|
33057078|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
33057079|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
33057080|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
33057081|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
33333838|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
33333839|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
33333840|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
33333841|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
33333842|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
33333843|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
33112627|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
33112628|NCT00561444||Quality of Life Study|Prostate cancer patients
33112629|NCT05043974|Experimental|Dry immersion|5 days of dry-immersion.
33112630|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
33112631|NCT05041088|Experimental|Experimental Group (ALL participants)|This group will be taking plamalogen supplement (ProdromeNeuro) and be followed through the study with neuropsychological testing, serology, and follow up MRI data. They will be administered 2mL per day for 6 months
33112632|NCT00561522|Experimental|Intervention treatment|Capecitabine
33112633|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
33112634|NCT05009264||OMT Group|This group will receive OMT muscle energy as treatment for myofascial pain syndrome
33112635|NCT05009264||Injection Group|This group will receive lidocaine injections for myofascial pain syndrome
33333844|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
33333845|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
33112636|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
33112637|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
33112638|NCT04995809||EPRIMM study participants|No intervention: Questionnaires, food diaries and stool sample.
33112639|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
33112640|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
33112641|NCT04628559|Active Comparator|Dexmedetomine|Patients recieving Dexmedetomidine.
33112642|NCT04628559|Active Comparator|Ketamine|Patients recieving Ketamine.
33112643|NCT04628559|Placebo Comparator|Placebo|Patients recieving Saline.
33112644|NCT04683341|Experimental|Arm A - initial TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and HBV NUC treatment naïve or experienced (except prior TAF) will receive initial treatment (Arm A) with TAF 25 mg/day.
33112645|NCT04683341|Experimental|Arm B - switch to TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and currently under HBV NUC treatment (except TAF) with HBV DNA < 20 IU/mL within 6 months prior screening will switch (Arm B) to TAF 25 mg/day
33112646|NCT04628793|Experimental|Cohort 1|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
33112647|NCT04628793|Experimental|Cohort 2|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
33112648|NCT04628793|Experimental|Cohort 3|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
33112649|NCT04683302|Active Comparator|control|conventional 2D guided internal jugular vein catheterization
33112650|NCT04683302|Experimental|intervention|3D biplanar guided internal jugular vein catheterization
33112651|NCT04683263|Active Comparator|Intervention|Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
33112652|NCT04683263|Placebo Comparator|Placebo|topical cream with similar characteristics and aspect, without active ingredients.
33112653|NCT04628676|Experimental|TXA group|tranexamic acid added to irrigation solution
33333846|NCT04004442|Experimental|Avelumab + AVB-S6-500|
33333847|NCT01060254|Experimental|JNJ-42160443|
33333848|NCT01060254|Placebo Comparator|Placebo|
33333849|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
33333850|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
33333851|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
33112654|NCT04628676|Experimental|EPN group|epinephrine added to irrigation solution
33112655|NCT04989569|No Intervention|control|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the control group will not be given to the dietitians for adjusting the diet formula according to the patient's body composition.
33112656|NCT04989569|Experimental|nutritional intervention|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the intervention group will be given to the dietitians for adjusting the diet formula according to the patient's body composition.
33112657|NCT00561561|Experimental|1|Subjects with schizophrenia
33112658|NCT00561561|Active Comparator|2|Health controls
33112659|NCT00561561|Active Comparator|3|Family members of subjects with schizophrenia
33112660|NCT00561561|Active Comparator|4|Family members of healthy controls
33112661|NCT01214629|Experimental|LY2523355|
33112662|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
33112663|NCT04628325|Experimental|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
33112664|NCT04628325|Active Comparator|high dose furosemide alone|Patients treated high dose furosemide alone
33333852|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
33333853|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
33057082|NCT04730778||CIN|"STEMI patients who develop CIN contrast induced nephropathy within 1 week from primary PCI."
33333854|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
33333855|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
33333856|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
33333857|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
33057083|NCT04730778||Control|STEMI patients who do not meet criteria of CIN through 1 week post primary PCI
33057084|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
33057085|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
33057086|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
33057087|NCT00057057|Other|Arm 1|
33057088|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
33057089|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
33057090|NCT00057096|Other|Arm 1|
33057091|NCT04731012||healthy oocyte-donation pregnancy|healthy pregnancy
33057092|NCT04731012||preeclamptic oocyte-donation pregnancy|preeclampsia
33057093|NCT04731012||healthy IVF or ICSI pregnancy|healthy pregnancy
33057094|NCT04731012||preeclamptic IVF or ICSI pregnancy|preeclampsia
33057095|NCT04731012||healthy spontaneous conception pregnancy|healthy pregnancy
33057096|NCT04731012||preeclamptic spontaneous conception pregnancy|preeclampsia
33057097|NCT00057135|Other|Arm 1|
33057098|NCT00057174|Other|Arm 1|
33057099|NCT00057252||1|Patients with medical imaging records
33057100|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
33057101|NCT00057408|Experimental|1|Treatment with olanzapine
33057102|NCT00057408|Placebo Comparator|2|Matching placebo treatment
33057103|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
33057104|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
33057105|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
33057106|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
33057107|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33057108|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
33057109|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
33057110|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
33057111|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.~The patients will answer to the G-STAT questionnaire."
33057112|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
33057113|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
33057114|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
33057115|NCT02969733|Experimental|Xylocaine|intravenous administration
33057116|NCT02969733|Experimental|Ketamine|intravenous administration
33057117|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
33057118|NCT04730895|Experimental|Oral 13 cis retinoic acid|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
33333858|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
33419146|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
33333859|NCT03629886|No Intervention|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
33333860|NCT03629886|Experimental|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
33057119|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
33057120|NCT04730895|Experimental|13 cis retinoic acid doses orally in combination with spike protein based vaccine|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
33057121|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
33333861|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
33057122|NCT04730895|Sham Comparator|spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|The participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
33057123|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
33057124|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
33333862|NCT01310504|Active Comparator|Peritoneal dialysis patient|
33057125|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
33057126|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
33057127|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
33057128|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
33057129|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
33057130|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33057131|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
33057132|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
33057133|NCT04732754|Placebo Comparator|Control Group (CG)|This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;
33333863|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily~Washout Day of LVAD Surgery and/or Day 15: None"
33333864|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
33057134|NCT04732754|Active Comparator|Aerobic Exercise (AE)|This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
33057135|NCT04732754|Experimental|Aerobic exercise + Theobroma cocoa (AETC)|This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks
33333865|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
33333866|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
33333867|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
33333868|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
33333869|NCT05666336|Experimental|Experimental Group|"The treatment regimen consists of four drugs, a glucocorticoid plus Telitacicept plus hydroxychloroquine plus an immunosuppressor.~Prednisone(30mg, Qd) or Methylprednisolone(24mg, Qd) plus Telitacicept(160mg, Qw) plus Hydroxychloroquine (0.2g, Qd) plus cyclophosphamide(0.8g, Qm) or Mycophenolate Mofetil (0.5g, Bid) or Tacrolimus (1mg, Bid) The above treatment will continue for 24 weeks."
33057136|NCT04732754|Experimental|Theobroma cocoa (TC)|This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.
33057137|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
33057138|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
33057139|NCT04711967|Experimental|Fecal Microbiota Transplantation group|treat with FMT
33057140|NCT04711967|Active Comparator|Control group|treat with traditional medicine
33057141|NCT04711694|Experimental|Early Mindfulness Intervention|The Early MBI group partake on the mindfulness intervention after first outcome assessment.
33057142|NCT04711694|Placebo Comparator|Late Mindfulness Intervention|"The Late MBI group partake on the mindfulness intervention after the second outcome assessment.~This groups is the control group for the Early MBI group.~After the second assessment, this group engage on the same intervention as the early group."
33057143|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
33057144|NCT04711889|Experimental|Ulinastatin|Ulinastatin 10 0000 Units is taken intravenously three times a day.
33057145|NCT04711889|Placebo Comparator|Saline|Same saline dose as ulinastatin is taken intravenously three times a day.
33057146|NCT04712006|Experimental|Cohort 1: JNJ-64304500|Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
33057147|NCT04712006|Experimental|Cohort 2: JNJ-64304500|Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
33057148|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
33057149|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
33057150|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
33057151|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
33057152|NCT00058890|Experimental|Gabapentin|
33057153|NCT00058890|Placebo Comparator|Placebo|
33057154|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
33057155|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
33057156|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
33057157|NCT00396071|Placebo Comparator|2|Matching placebo
33057158|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
33057159|NCT00396149|Placebo Comparator|Placebo|Placebo group
33057160|NCT00396149|Experimental|Active group|rBet v 1 tablets
33057161|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~No history of refractive or other ocular surgery.~No corneal pathologies.~Normal corneal topography.~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
33057162|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
33112665|NCT04977869|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
33112666|NCT04977869|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
33112667|NCT04318600|Experimental|human amniotic mesenchymal stem cell treatment group|
33112668|NCT04318600|No Intervention|blank control group|
33112669|NCT04657497|Experimental|FOY-305 group|Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
33112670|NCT04657497|Placebo Comparator|Placebo group|Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
33112671|NCT01214434|Experimental|Promiseb Topical Cream|
33112672|NCT01214434|Sham Comparator|Bland emollient|
33112673|NCT04971356|Experimental|Experimental arm|1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months
33112674|NCT04971356|Active Comparator|Reference arm|12-month Aspirin plus Ticagrelor
33112675|NCT04318639|Experimental|Donepazil+CRT|Donepazil+CRT
33112676|NCT04628403|No Intervention|control|
33112677|NCT04628403|Experimental|shock waves|
33112678|NCT04628403|Experimental|massage|
33112679|NCT04628403|Experimental|lasertherapy|
33112680|NCT04970771|Experimental|Solving Wellness Platform Group|Participants will receive a 1-year membership to the Solving Wellness virtual platform containing interactive wellness resources.
33112681|NCT04656834||Hand incision closure type 1|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: buried monocryl sutures and skin glue
33112682|NCT04656834||Hand incision closure type 2|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: simple nylon sutures
33112683|NCT01214239|Experimental|Linagliptin|once a day
33112684|NCT01214239|Placebo Comparator|Placebo|once a day
33112685|NCT04968314||ChiPP Groups|Parents enroll in Chicago Parent Program groups offered at their child's school
33112686|NCT04628520|Sham Comparator|Maintenance|Oral hygiene instruction and periodontal maintenance
33112687|NCT04628520|Active Comparator|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
33333870|NCT03554486|Experimental|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
33333871|NCT03554486|Experimental|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
33333872|NCT03520036|Experimental|MT-7117 low dose|
33112688|NCT04628520|Active Comparator|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
33112689|NCT01214200|Experimental|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
33112690|NCT04967534|Experimental|WB-EMS|
33112691|NCT04967534|Sham Comparator|social contact control group|
33333873|NCT03520036|Experimental|MT-7117 high dose|
33333874|NCT03520036|Placebo Comparator|Placebo|
33333875|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
33333876|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
33333877|NCT05462938|Active Comparator|Propofol group|Continuous infusion of propofol
33333878|NCT05462938|Active Comparator|Dexmedetomidine group|Continuous infusion of dexmedetomidine
33333879|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
33333880|NCT03733106|Active Comparator|control|standard two dimension digital mammography
33333881|NCT04889794|Experimental|Exposed FMGs to GPS intervention|Patients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
33333882|NCT04889794|No Intervention|Non exposed FMGs to GPS intervention|Patients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
32869748|NCT04436523|Experimental|Blood flow restriction|The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
33057163|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~LASIK~PRK~LASEK"
33057164|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~LASIK~PRK~LASEK"
33057165|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
33057166|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
33057167|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
33057168|NCT00396227|Active Comparator|TZD|TZD + metformin
33057169|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
33057170|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
33333883|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
33333884|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
33333885|NCT05462626|Experimental|the Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention will consist of six individualized sessions that will be conducted via a telehealth platform, each lasting about 45-60 minutes. Individual sessions allow for the participant's personal health factors to be discussed and reflected upon as the intervention is delivered weekly. Each week will comprise one or more lifestyle topics that are based on the twelve modules described in the Lifestyle Redesign® manual (Clark et al., 2015).
33333886|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
33333887|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
33333888|NCT04788238|Experimental|Intervention group|Participants in the intervention arm will participate in the dual-task Zumba Gold (DTZ) program. They will be grouped into 10 participants per class.
33333889|NCT04788238|No Intervention|Control group|Participants in the control group will receive health education about dementia risk reduction provided by community health nurses.
33333890|NCT04787692|Experimental|Opioid and Benzodiazepine Naive-patients|Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery
33333891|NCT04787692|Experimental|Opioid and Benzodiazepine Tolerant-patients|Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (>30 days) prior to surgery
33333892|NCT04775446||Patients with malignant pleural mesothelioma treated with Nivolumab.|Patients with malignant pleural mesothelioma treated with Nivolumab.
33333893|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
33333894|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
33333895|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
33333896|NCT05462548|Experimental|treatment group|accept Luspatercept treatment
33333897|NCT04625764|Experimental|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
33333898|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
33333899|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
33057171|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
33057172|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
33057173|NCT00396344|Placebo Comparator|1|Saline control
33057174|NCT00396344|Experimental|2|
33057175|NCT00396344|Experimental|3|
33057176|NCT00059280|Experimental|1|
33057177|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
33057178|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
33057179|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
33333902|NCT05074264|Experimental|Imaging, biospecimen collection, anoscopy and/or colposcopy|Patients undergo collection of cervical images (if applicable), 3 cervical anal swabs (if applicable) and 3 anal swabs for real-time testing of HPV or hrHPV over 90 minutes. Patients with a positive HPV or hrHPV test on undergo biopsies of visible lesions. Patients with a negative hrHPV test on their cervical swab may undergo a colposcopy. Patients with a positive hrHPV test on their anal swab undergo high-resolution anoscopy at a later visit within 1 month. Patients with a negative hrHPV on their anal swabs may undergo a high-resolution anoscopy and biopsies of visible lesions, and those with a positive anal cytology for LSIL or worse undergo a high-resolution anoscopy and biopsies within 1 month. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual
33333903|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
33057180|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
33057181|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
33057182|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
33057183|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
33057184|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
33057185|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
33057186|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
33057187|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
33057188|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
33057189|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
33057190|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
33057191|NCT00059592|Experimental|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
33057192|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
32869749|NCT04436523|Sham Comparator|Standard rehabilitation|The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
32869750|NCT00017563|Experimental|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
32869751|NCT05539560|Experimental|Intervention group|Olfactory training twice a day with essential oils
32869752|NCT05539560|Placebo Comparator|Control group|Olfactory training twice a day with fragrance-free oils
32869753|NCT04399239|Experimental|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
32869754|NCT05592054|Experimental|Intervention group|Balloon guide catheters (BGCs)
33057193|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
33057194|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
33057195|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
33333904|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
33333905|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
33333906|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
33333907|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
32869755|NCT05592054|Active Comparator|Control group|Standard guide catheter
32869756|NCT00018031|Experimental|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
33057196|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
33057197|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
33057198|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
33057199|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
33057200|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
33057201|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
33057202|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
33057203|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
33057204|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
33057205|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
33057206|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
33057207|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
33057208|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
33057209|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
33333908|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
33333909|NCT04459624|Active Comparator|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
33333910|NCT04459624|Active Comparator|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
32740918|NCT05593887|Active Comparator|Proximal femur valgus osteotomy|This group will undergo McHale Procedure.The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate.
33057210|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
33057211|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
33057212|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
33057213|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
33057214|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
33057215|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
33057216|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
33057217|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
33057218|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
33057219|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
33057220|NCT00032435|Experimental|1|PAL-40 Active
33057221|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
33057222|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
33057223|NCT00032552||1|
33057224|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33057225|NCT00060450|Experimental|1|Inhaled Nitric Oxide
33057226|NCT00060450|Placebo Comparator|2|Placebo gas
33057227|NCT04730934||Healthy population|Healthy individuals aged between 18-65
33057228|NCT04730934||Chronic Low Back Pain Group|Patients aged between 18 and 65 and has at least 3 months of low back pain which started before pandemic.
33057229|NCT04730934||Fibromyalgia Group|Patients aged between 18 and 65 and has a diagnosis of fibromyalgia for at least 6 months
33057230|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
33057231|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
33057232|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
33057233|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
33057234|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
33333911|NCT04004208|Experimental|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
33333912|NCT04004208|Active Comparator|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
33333913|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
33333914|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
33333915|NCT03643952|Experimental|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
33333916|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
33333917|NCT03035032|Experimental|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
33057235|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
33057236|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
33057237|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
33057238|NCT04730700|Active Comparator|Radiofrequency ablation (RFA) with MEE|Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.
33057239|NCT04730700|Active Comparator|Conventional Medical Management (CMM) Treatment Only|Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.
33057240|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
33057241|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
33057242|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
33057243|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
33057244|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
33057245|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
33057246|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
33057247|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
33057248|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
33057249|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
33057250|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
33057251|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
33057252|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
33057253|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
33057254|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
33057255|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
33057256|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
33057257|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
33057258|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
33057259|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
33057260|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
33057261|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
33057262|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
33057263|NCT00061113|Active Comparator|1|fluoxetine + CBT
33057264|NCT00061113|Placebo Comparator|2|placebo + CBT
33057265|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
33057266|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
33057267|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
33057268|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
33057269|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
33333918|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
33333919|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
33333920|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
33333921|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
33333922|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
33333923|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
33333924|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
32740473|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
32740919|NCT04490915|Experimental|Crinecerfont|Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
32740920|NCT04490915|Placebo Comparator|Placebo|Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
32740921|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
33057270|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
33057271|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
33057272|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
33057273|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
33057274|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
33057275|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
33057276|NCT00061269|Experimental|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
33057277|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
33057278|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
33057279|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
33057280|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
33057281|NCT04730466|Experimental|Neuropsychological rehabilitation|In the experimental group, patients will receive a 12-session neuropsychological rehabilitation protocol that will be carried out over four weeks (3 weekly sessions). The protocol and the number of sessions has been designed by neuropsychologists following the Díez-Cirarda et al. recommendations
33057282|NCT04730466|No Intervention|Control|The control group will not receive any therapy. The participants will be simply evaluated at the same time as the experimental group
32740922|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
33057283|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
33333925|NCT04105738||Difficult airways|Documented history of difficult airways.
33333926|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
33333927|NCT03725072|Experimental|Evobrutinib|
33333928|NCT04404166|Experimental|PINGS 2|
33333929|NCT04404166|No Intervention|Standard of Care|
32740923|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
33333930|NCT04393948|Experimental|No irradiation|
33112692|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
33112693|NCT04628286|Placebo Comparator|Sham Laser|Placebo laser application in plantar fascia
33112694|NCT04628286|Experimental|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
33112695|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
33333931|NCT04393948|Experimental|100 cGy single lung irradiation|100 cGy single lung radiation
33333932|NCT04393948|Experimental|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
33112696|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
33112697|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
33112698|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
33112699|NCT04628598|Experimental|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
33333933|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
33112700|NCT04628598|No Intervention|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
33112701|NCT04966910|Experimental|Stay Connected|Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
33112702|NCT04966910|Active Comparator|Treatment as usual|Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals
33112703|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
33112704|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
33112705|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
33112706|NCT04628247|Experimental|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
33112707|NCT04954625|Experimental|Autologous Blood Patch|
33112708|NCT04954625|Active Comparator|Standard of Care (Per physician)|
33112709|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
33112710|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
33112711|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
33112712|NCT04951700||Schizophrenia|Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.
33112713|NCT04951700||Healthy Controls|Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.
33333934|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
33333935|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
33333936|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
33333937|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
33112714|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
33333938|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
33333939|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
33333940|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
32869757|NCT05539482|Experimental|Community-Based Health Education Group|The collaborators will design the Community-based education approach (based on the core intervention package). Collaborators will be required to submit a brief standardized proposal to the academic investigators for review and approval, to ensure that all intervention programs have the same core intervention content and can be implemented appropriately. Collaborators will be able to use any reasonable strategies, such as social media platforms, information technology, posters, leaflets, and videos, to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
32869758|NCT05539482|Active Comparator|Health Information Sharing Group|The collaborators will design the community-based education approach and deliver health information to the participants. Researchers will provide some information, while collaborators need to self-collect the rest. Collaborators also need to submit a proposal to ensure the feasibility of intervention programs and the accuracy of health information. Collaborators can use any reasonable strategies to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
32869759|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
32869760|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
32869761|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
32869762|NCT05699070|Experimental|DWC202211|
32869763|NCT05699070|Experimental|DWC202212|
32869764|NCT05699070|Experimental|DWC202211 + DWC202212|
32869765|NCT04734210|Experimental|SURF-200 (0.02% betamethasone sodium phosphate in vehicle)|One drop twice daily (BID) in the study eye for 14 days.
32869766|NCT04734210|Experimental|SURF-200 (0.04% betamethasone sodium phosphate in vehicle)|One drop BID in the study eye for 14 days.
32869767|NCT04734210|Placebo Comparator|Vehicle|One drop BID in the study eye for 14 days.
32869768|NCT04380051|Experimental|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
32869769|NCT04380051|Active Comparator|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
32869770|NCT00267085|Experimental|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
32869771|NCT05539248|Experimental|Dose escalation CAN106 in cohort 1|Subjects are administered CAN106 20 mg/kg IV maintenance dosing.
32869772|NCT05539248|Experimental|Dose escalation CAN106 in cohort 2|Subjects are administered CAN106 40 mg/kg IV maintenance dosing.
32869773|NCT05539248|Experimental|Dose escalation CAN106 in cohort 3|Subjects are administered CAN106 80 mg/kg IV maintenance dosing.
32869774|NCT04278885|Experimental|Lanadelumab|
32869775|NCT04487353|Experimental|Experiment Group|"The Labor Evaluation Information Scale (LEIS) was administered as a pre-test before applying to 30 students who had taken a course on childbirth. After the pre-test, the application was carried out with the Labor mechanism application developed with virtual reality technology (VRT-LMA). Immediately after the application, data were collected with the LEIS, sense of presence scale and cognitive load scale. Post-test was performed again with the Labor Evaluation Information Scale (LEIS) 5 weeks after the application."
33057284|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
33057285|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
33057286|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
33057287|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
33057288|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
33057289|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
33057290|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
33057291|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
32869776|NCT04487353|No Intervention|Control Group|"Before the theory training, the Assessment Knowledge Scale (LEIS) was administered as a pre-test to 31 students in the control group who had taken a course on obstetrics. After the pre-test, theory training including birth knowledge was given. Labor mechanism application developed with virtual reality technology (VRT-LMA) was not applied to the control group. After 4 hours of theoretical training, the final test was performed using LEIS. After 5 weeks, the last test was repeated."
33333941|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
33333942|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
33333943|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
32869777|NCT05591976|Experimental|Exercise group|Participants are assessed for outcomes prior to intervention, mid-way through intervention and immediately after intervention.
32869778|NCT02249793||Study group|Healthy volunteers
32869779|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
32869780|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
32869781|NCT05591898|Experimental|Progressive relaxation exercises group|Participants will be randomly selected by a computer based system (Block randomization was used to keep the sample size of the groups similar. Random Allocation Software (Ver. 1.0.0) will be used to allocate the patients to groups). Selected participants will be invited to a meeting which will be held face-to-face and in a quiet environment. Progressive Relaxation Exercises will be explained to this group in a step-by-step manner whose surgery date is determined to undergo bariatric surgery by the relevant researcher. After this stage, participants will be followed to do the exercises regularly for a month by a researcher. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
33057292|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
33057293|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
33057294|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
33057295|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
33057296|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
33057297|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
33057298|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
33057299|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
33057300|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
33057301|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
33057302|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
33057303|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33057304|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33057305|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
33057306|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
33057307|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
33057308|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
33057309|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
33057310|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
33057311|NCT00035126|Experimental|EPO906|
33057312|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
33333944|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
33333945|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
33333946|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
33333947|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
33333948|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
33112715|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
33057313|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
33057314|NCT00035165|Experimental|EPO906|
33057315|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
33333949|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
33333950|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
33333951|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
33333952|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
33333953|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
33333954|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
33333955|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
33333956|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
33333957|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
33333958|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
33333959|NCT03567980|Experimental|topical crisaborole 2%|
33333960|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
33333961|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
33333962|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
33057316|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
33057317|NCT00062478|Experimental|1|Karenitecin for intravenous use
33333963|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
33057318|NCT00035243|Experimental|EPO906|
33057319|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
33333964|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
33333965|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
33057320|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
33057321|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
33057322|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
33057323|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
33057324|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
33057325|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
33057326|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
33057327|NCT02971241|Experimental|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
33333966|NCT03358030|Placebo Comparator|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
33333967|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
33333968|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
33057328|NCT02971241|Other|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
33057329|NCT00062985|No Intervention|Control|
33057330|NCT00062985|Experimental|Mail-based weight loss intervention|
33057331|NCT00062985|Experimental|Telephone-based weight loss intervention|
33333969|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
33333970|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
33333971|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
33333972|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
33333973|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
33333974|NCT04924660|Experimental|TXA127 (4/20/2022 Arm Closed to Accrual)|An investigational peptide agonist of Mas receptors.
33333975|NCT04924660|Experimental|TRV027 (4/20/2022 Arm Closed to Accrual)|An investigational peptide biased agonist of the AT1 receptor.
33057332|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
33057333|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
32740924|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
33057334|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
33057335|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
33057336|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
33057337|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
33057338|NCT00063141|Experimental|Arm A|
33057339|NCT00063141|Active Comparator|Arm B|
33057340|NCT02967315|Experimental|Study Group|"Procedures include:~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
33057341|NCT02967588|Experimental|Intervention|
33057342|NCT04732403|No Intervention|0 degree supine position|Surgical bed will be set to a 0 degree supine position
33057343|NCT04732403|Experimental|10-20 degree angle in reverse Trendelenburg|Surgical bed will be set to a 10-20 degree angle in reverse Trendelenburg
33057344|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
33057345|NCT00063336|Experimental|2|Participants will receive computer-skills training.
33057346|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
33057347|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
33057348|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
33057349|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
33057350|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
33057351|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
33057352|NCT02967471||ARDS group|
33057353|NCT02967471||control group|
33057354|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
33057355|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
33057356|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
33057357|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
33057358|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
33112716|NCT04656912||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
32740925|NCT04483505|Experimental|Rogaratinib + palbociclib + fulvestrant|
33112717|NCT04657107|Placebo Comparator|Saline group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
33112718|NCT04657107|Experimental|K1 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
33333976|NCT04924660|Placebo Comparator|Placebo|"NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.~Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
33333977|NCT04924660|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
33333978|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
33333979|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
33333980|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
33333981|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
33333982|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
33333983|NCT04341376|Experimental|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
33333984|NCT04341376|No Intervention|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
33333985|NCT04163614|No Intervention|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
33333986|NCT04163614|Experimental|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
33333987|NCT04013932|Experimental|KUPAA Intervention + Standard of Care|Patients will be assigned to a KUPAA group composed of approximately 6 patients (joined by their 6 matched caregivers). Patients will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (~1.5-2 hours) for 12 weeks.
33333988|NCT04013932|No Intervention|Control - Standard of Care|Patients will receive the standard of care.
33333989|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
33333990|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
33333991|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
33333992|NCT03844906|Experimental|SAGE-718|
33333993|NCT03844906|Placebo Comparator|Placebo|
33333994|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
33333995|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
33333996|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
33333997|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
33333998|NCT04002648||MT-Right|
33333999|NCT04002648||Sternotomy|
33334000|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
33334001|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
33334002|NCT03840616|Experimental|Oteseconazole (VT-1161) 150mg capsule|600mg oteseconazole administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14
33334003|NCT03840616|Active Comparator|Fluconazole 150mg capsule / Placebo|150mg fluconazole administered every 72 hours in 3 sequential doses starting on Day 1, followed by placebo administered once weekly starting on Day 14
33334004|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
33057359|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
33057360|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
33057361|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33057362|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
33057363|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
33057364|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
33057365|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
33057366|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
33057367|NCT02967432|Experimental|Mupirocin|
33057368|NCT02967432|Placebo Comparator|Petroleum jelly|
33057369|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
33057370|NCT04732442|Experimental|Immuno-group|The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.
33057371|NCT04732442|Sham Comparator|Control-group|The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.
33057372|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
33057373|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
33057374|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
33057375|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
33057376|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
33057377|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
33057378|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
33057379|NCT02971124||Healthy Elderly|
33057380|NCT02971124||Mild Cognitive Impaired Elderly|
33057381|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
33057382|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
33057383|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
33057384|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
33057385|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
33057386|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
33057387|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
33057388|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
33057389|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
33057390|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
33334005|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
33334006|NCT00088413|Experimental|All Cohorts: Colorectal, Non-Colorectal, Breast, and Ovarian|All cohorts receive the same intervention (Cohort 1: Colorectal arm, non-colorectal cancers; Cohort 2: breast cancer; Cohort 3: ovarian cancers)
33334007|NCT04924348|Experimental|WALANT procedure|Local anesthesia of the WALANT type
33334008|NCT04924348|Active Comparator|Axial ALR|Axillary loco-regional anesthesia
33334009|NCT04924348|Active Comparator|Truncal ALR|Truncal loco-regional anesthesia
32740926|NCT05664087|Experimental|Experimental group|Debridement of tooth extraction sockets was assisted by photodynamic equipment
33057391|NCT04730622||Fragility fracture|Patients undergoing a hip replacement for a fragility fracture of the femoral neck (n= 10).
33057392|NCT04730622||Osteoarthritis|Patients undergoing a hip replacement for severe osteoarthritis (n= 10).
33057393|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
33057394|NCT00037817|Experimental|1|Dose escalation cohort
33057395|NCT00037817|Experimental|2|Molecular response cohort
33334010|NCT03995784|Experimental|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
33334011|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
33057396|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
33057397|NCT00037934|Experimental|1|Robot exercise group
33057398|NCT00037934|Active Comparator|2|Traditional exercise group
33057399|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
33334012|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
33334013|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
33334014|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
33334015|NCT05655052|Experimental|working grup 1: Virtual Reality (VR) Group|"From the preparation stage of the IUD until the IUD application process is completed, after the internet connection is provided with a smart phone for the image, by clicking on the youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video will be provided and virtual reality glasses will be provided.~Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. The practice of watching nature videos with VR during the IUD application with this device is within the framework of midwifery care practices and is not a treatment option for any treatment method, tool or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason."
33334016|NCT05655052|Experimental|Working Group 2: Distraction Cards Implementation Group|From the preparation stage of the IUD procedure to the completion of the IUD application process, distraction cards containing five optical illusion figures, one of the distraction techniques, will be shown to the women by the researcher . Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns are such that individuals can only see when they look carefully. During the process, the women will focus on the cards and be distracted by asking what they see on the cards by communicating face-to-face with the researcher women about the pictures and shapes they see on the cards. Thus, it is thought that the cards with optical figures on the distraction cards will enable women to focus and reduce pain and anxiety. Display of cards will take approximately 3-5 minutes
33334017|NCT05655052|No Intervention|Control Group|Unlike the study group, women included in the control group will not only be shown video watching applications with virtual glasses and distraction cards. The maintenance and applications in the routine IUD application will be done exactly.
33334018|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
33334019|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
33334020|NCT00086385|Active Comparator|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52."
33057400|NCT00037973|Active Comparator|2|Exercise
33057401|NCT00037973|Active Comparator|3|ventilation feedback only
33057402|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
33057403|NCT00065208|Experimental|Reiki|Energy therapy
33057404|NCT00065208|Sham Comparator|Pretend Reiki|
33057405|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
33057406|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
33057407|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
33057408|NCT00038090|Experimental|Thalidomide + Dexamethasone|
33057409|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
33057410|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
33057411|NCT00065325|Active Comparator|1|Exemestane
33334021|NCT00086385|Experimental|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above."
33057412|NCT00065325|Experimental|2|Fulvestrant
33334022|NCT00086385|Experimental|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
33334023|NCT00086385|Experimental|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
32740927|NCT05664087|No Intervention|control group|Routine tooth extraction and debridement were performed
33057413|NCT00038168|Experimental|Estramustine + Taxol|
33057414|NCT00038207|Experimental|Liposomal Vincristine|
33057415|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
33057416|NCT05434247|Other|Reverse-bevel ProCore™|Historical comparator group of biopsies taken using Echo Tip® HD ProCore™ (Wilson-Cook Medical Inc., Winston-Salem, NC, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
33057417|NCT05434247|Experimental|Fork-tip SharkCore™|Experimental group of biopsies using SharkCore™ (Medtronic Inc., Sunnyvale, CA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
33057418|NCT05434247|Experimental|Franseen Acquire™|Experimental group of biopsies using Acquire™ (Boston Scientific, Marlborough, MA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
33057419|NCT05434208|Experimental|A RESEARCH ARM: active telephonic follow-up by specialist nurse|"Early Palliative Care cancer patients will be randomized to active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)~Scheduled phone-calls each 7 days from T0 + unscheduled phone-calls (as needed)~Questionnaire: ESAS and IPOS;~Weight;~Medication intake;~ECOG-PS~Scheduled phone-calls at End of Treatment (28 days from T0):~Questionnaire: ESAS and IPOS~Questionnaire: FAMCARE-2 for CGs"
33057420|NCT05434208|No Intervention|B CONTROL GROUP: face-to-face visit at end of treatment|"Early Palliative Care cancer patients will be randomized to face-to-face visit at end of treatment (28 days)~Unscheduled phone-calls, on patients initiative:~Questionnaire: ESAS and IPOS;~Weight;~Medication intake;~ECOG-PS~Face-to-face visit at End of Treatment (28 days from T0):~Questionnaire: ESAS and IPOS~Questionnaire: FAMCARE-2 for CGs"
33057421|NCT00398814|Experimental|Perifosine + Sorafenib|
33057422|NCT05434130|Experimental|High Dose Exercise|The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.
33057423|NCT05434130|No Intervention|Standard-of-care|Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.
33057424|NCT05433974|Other|Radiosensitivity|Patient who agree to participate in this research study will have blood sample collected in order to perform the RadioDtect test.
33057425|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
33057426|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
33057427|NCT00398853|Experimental|Chromium Picolinate|Chromium
33057428|NCT00398853|Other|Placebo|Placebo
33057429|NCT05433896|Experimental|Dasatinib ASD alone|At the clinic, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 1 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served.
33057430|NCT05433896|Other|Dasatinib ASD + Omeprazole|"At the clinic, on Day 2 to Day 6, participants were administered a single oral dose of Omeprazole 40 mg × 1 Delayed Release Capsule once before meals in the evening with approximately 150 mL of room temperature water. No food was allowed two hours before and one hour after administration of Omeprazole.~In addition, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 6 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served."
33057431|NCT05433779|Experimental|Neosense Umbilical Catheter|
33057432|NCT00065715|No Intervention|A|No pills
33057433|NCT00065715|Placebo Comparator|B|Blinded placebo
33057434|NCT00065715|Experimental|C|Echinacea - Blinded
33057435|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
33057436|NCT05433662||Veterans|Veterans will be ages 65 and older, cognitively intact, and experiencing pandemic-related stress.
33057437|NCT05433545||Adherence to specific physiotherapy exercises|
33068200|NCT04513756|Experimental|Active Treatment Group|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques.
33057438|NCT05433467|Experimental|CT-guided localization for micro hepatocellular carcinoma before surgical resection|fter preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
33057439|NCT05433428|Experimental|Cataract patients with dry eye - standard treatment|Standard pre and postop medication, preservative eye drops.
33057440|NCT05433428|Other|Cataract patients with dry eye - intensive treatment|More prolonged use of lubricant eye drops as well as the use of preservative free eye drops.
33057441|NCT05433428|Other|Cataract patients without dry eye disease / control group|Standard pre and postop medication, control group.
33057442|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
33334024|NCT05115838|Experimental|Islatravir 47 mg|Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
33334025|NCT05115838|Experimental|Islatravir 52 mg|Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
33334026|NCT05115838|Experimental|Islatravir 57 mg|Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
33334027|NCT05115838|Placebo Comparator|Placebo|Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
33334028|NCT03993288|Experimental|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
33057443|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
33057444|NCT05433038|Active Comparator|skeletal expander with microosteoperforation in mid palatine|group1.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture
33057445|NCT05433038|Active Comparator|skeletal expander with microosteoperforation in mid palatine and buccally|group2.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture and buccally
33334029|NCT03993288|Active Comparator|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
33334030|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
33334031|NCT01093989|Active Comparator|Delayed iron|
33334032|NCT04915534|Other|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
33334033|NCT04915534|Other|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
33334034|NCT04915534|Other|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
33334035|NCT04915534|Other|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
33334036|NCT01090401|Experimental|Patients with Linox smart S DX lead|
33334037|NCT05093608|Experimental|Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab|60 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
33057446|NCT05432960|Experimental|RPH-104|The investigational product RPH-104 as SC injections at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W).
33057447|NCT05432960|Placebo Comparator|Placebo|placebo SC Q2W (equivalent to investigational product volume)
33057448|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
33057449|NCT00066027|Placebo Comparator|Placebo|Placebo
33057450|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
33057451|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
33057452|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
33057453|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
33057454|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
33057455|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
33057456|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
33057457|NCT05432882|Experimental|bi-4SCAR-CD19/22 T Cell Therapy for CD19 and/or CD22 positive B cell malignancies|
33057458|NCT05432609||Healthy|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
32740928|NCT04969991|Experimental|Varespladib: 250 mg QD + Placebo + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon and 1 placebo tablet in the evening.
33057459|NCT05432609||Trochlear dysplasia|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
33057460|NCT05432492|Experimental|Cohort 1|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
33334038|NCT05093608|Experimental|Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab|80 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
33334039|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
33334040|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
33057461|NCT05432492|Experimental|Cohort 2|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
33057462|NCT05432453||Women with constipation|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women with constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women with constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
33334041|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
33334042|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
33334043|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
33334044|NCT03991494|Experimental|Pamiparib|
33334045|NCT05080036|Experimental|Unbalanced healthy subjects|Subjects undergo an external perturbation of their balance
33334046|NCT05076370|Active Comparator|CBD 400mg|CBD 400mg
33334047|NCT05076370|Active Comparator|CBD 800mg|CBD 800mg
33334048|NCT05076370|Active Comparator|CBD 1200mg|CBD 1200mg
33334049|NCT03736122|Experimental|BSG-001|Inhalation route, daily
33334050|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
33334051|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
33057463|NCT05432453||Women without constipation (Control)|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women without constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women without constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
33057464|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
33057465|NCT05432336||Complex ocular infections (COI)|All patients with an COI (endophtalmitis or hospitalized keratitis)
33057466|NCT05432297|Experimental|Physical exercise intervention|The physical activity intervention is based on national guidelines of physical activity in cancer rehabilitation. A physiotherapist together with each patient will develop individual adaptations to the exercise protocol, with suggestions on which type of exercise the participant is able to perform depending on their daily condition. Suggestions on physical activity for good, bad and in-between-days will be listed in collaboration with the participant, and the participant will report number of minutes/day in each of the 3 physical activity levels stated.
33057467|NCT05432297|No Intervention|Control|The control group will receive general advice on the importance of physical activity during oncologic treatment, according to local clinical standard.
33057468|NCT05432258|Experimental|Bulk-fill composite resin|Bulk-fill Ormocer composite resin restorations on the mandibular first molars applied in layers of 4 mm depth
33057469|NCT05432258|Active Comparator|Nano-fill composite resin|Nano-fill composite resin restorations on the mandibular first molars were applied in layers of 2 mm depth
33068201|NCT04513756|No Intervention|Treatment As Usual Group|CRA comprising of nine sessions will not be provided to this group. However, patients who will be already receiving treatment from any psychiatric or some other rehabilitation facility will be advised to continue their routine treatment.
33068202|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
33334052|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
33334053|NCT05062798|Experimental|Control group (standart bottle)|After the surgery, standard bottle will be used for feeding
33334054|NCT05062798|Experimental|Experimental Group (squeezable bottle)|After the surgery, squeezable bottle will be used for feeding
33334055|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
33334056|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
32740474|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
33057470|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33057471|NCT05432219|Experimental|Endoscopic Transoral Retropterygoid Nasopharyngectomy|a novel endoscopic approach to resect nasopharyngeal carcinoma
33057472|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
33057473|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
33057474|NCT05432102||Participants having respiratory polygraphy|This label will used to describe participants having respiratory polygraphy at Royal Papworth Hospital over a 3 month period.
33057475|NCT05432102||Participants having pulse oximetry|This label will used to describe participants having pulse oximetry at Royal Papworth Hospital over a 3 month period.
33057476|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
33057477|NCT05424419||double-brace group|AIS patients with daytime and nighttime braces
33057478|NCT05424419||single-brace group|AIS patients with a single brace for day and night
33057479|NCT02967042|Other|18F-PET-TT|
33057480|NCT05421611|Experimental|SII-YFV|"Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos~Diluent: 0.5 mL of sterile water for injection"
33057481|NCT05421611|Active Comparator|STAMARIL|"Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL"
33057482|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
33057483|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
33057484|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
33057485|NCT05402891|Experimental|Study population|Every patient will receive treatment: Lithiumcarbonate 300mg daily in oral tablet for six months. There will no control group included since patient represent their own control in the nontreatment-phase.
33057486|NCT05397548||case|Gastric cancer cases from two medical centers in China
33057487|NCT05397548||control|Controls from two medical centers in China
33057488|NCT00066612|Experimental|Treatment|Irinotecan
33057489|NCT05376566|Active Comparator|Intervention group|Hydrochloric acid (2 M)
33057490|NCT05376566|Placebo Comparator|Control group|Normal saline
33057491|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
33057492|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
33057493|NCT05303402|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose|Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose.
33057494|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
33057495|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
33057496|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
33057497|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
33057498|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
33057499|NCT05294237|Experimental|Supported Implementation (Intervention)|"The Happy-program will be available online on a webpage and consists of 7 warm-up components and 4 resistance training components that can be completed after handball practice.~The warm-up program has three exercise variations for each of the seven components. The coaches may deliver the four resistance training components in the field or in the gym. The resistance training components in the field and the gym targets the same four body areas but differs in that the components in the gym are performed with equipment, while the components in the field can be performed without equipment. Each resistance training component has three levels.~Happy ambassadors (Health professionals with a handball player or coach background) will conduct a 3-hour train-the trainer workshop in the beginning of the season and provide coaches with the opportunity for support throughout the season. At mid-season, the ambassadors will re-visit the clubs for 1,5-hour supervision and support."
32740475|NCT02467595|Placebo Comparator|S group|"saline~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
33057500|NCT05294237|Active Comparator|Unsupported implementation (control)|Access to the Happy program will be available online to the coaches. No additional education or support will be provided.
33057501|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
33057502|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
33057503|NCT05283200|Experimental|Yoga|"The goal for the yoga intervention is to provide participants with instructor-guided safe, gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, anxiety symptoms, disability, and improve quality of life.~Participants enrolled in the Yoga intervention group will receive one month of Instructor-Guided 70-minute virtual live yoga classes, twice per week, led by an experienced yoga therapist and co-instructor. During Months 2-3 participants in the Yoga Intervention will receive one 70-minute virtual live yoga class per week. Each session will have a set of specific poses, breathing exercises, meditation, and yoga philosophies developed by our yoga experts."
33334057|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
33334058|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
33334059|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
33334060|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
33334061|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
33334062|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
33334063|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
33057504|NCT05283200|Experimental|Cognitive Behavioral Therapy|"The goal of the Cognitive Behavioral Therapy (CBT) intervention is to provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, depression and anxiety symptoms, disability and improve quality of life.~Participants enrolled in the CBT intervention group will receive 3 months of Instructor-Guided 90-minute, virtual group counseling session, once per week, led by a psychologist and a co-therapist."
33057505|NCT05283200|Experimental|Music|"The aim of this intervention is for participants to learn and develop skills to reduce stress which may, in turn, decrease seizure frequency and improve quality of life. Participants will be exposed to a variety of ways that they might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.~Participants enrolled in the Music Intervention group will receive one month of Instructor-Guided Intervention 70-minute virtual live music therapy sessions, twice per week, led by an experienced music therapist and co-instructor. An two months of a 70-minute virtual live music therapy session once per week."
33057506|NCT05283200|No Intervention|Standard of Care|Participants randomized to the Standard of Care Control Group will receive their usual standard epilepsy care. Participants will receive a brief monthly call for checking-in and collection of seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
33057507|NCT05283200|No Intervention|Enhanced Standard of Care|Participants randomized to the Enhanced Standard of Care Control Group will receive their usual standard epilepsy care and weekly scheduled, scripted, follow-up phone calls from a study team member to check-in on their health, epilepsy management, and seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
33057508|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
33057509|NCT05266625|Experimental|Intervention PHOENIX + Standard of Care|Patients in this arm will receive the PHOENIX treatment for up to 720 days.
33057510|NCT05266625|Other|Standard of Care|Patients will have access to a control mobile application for 180 days and then will have the option to use the treatment for the remainder of the 720 day study
33057511|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
33057512|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
33057513|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
33057514|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
33057515|NCT05129657|Experimental|Product usage order ABCDN|Subjects will use each of the 5 products sequentially (ABCDN) during an evaluation period, followed by a 4 hour Test Session.
33334064|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
33057516|NCT05129657|Experimental|Product usage order ACBND|Subjects will use each of the 5 products sequentially (ACBND) during an evaluation period, followed by a 4 hour Test Session.
33057517|NCT05129657|Experimental|Product usage order BADCN|Subjects will use each of the 5 products sequentially (BADCN) during an evaluation period, followed by a 4 hour Test Session.
33057518|NCT05129657|Experimental|Product usage order BDANC|Subjects will use each of the 5 products sequentially (BDANC) during an evaluation period, followed by a 4 hour Test Session.
33057519|NCT05129657|Experimental|Product usage order CANBD|Subjects will use each of the 5 products sequentially (CANBD) during an evaluation period, followed by a 4 hour Test Session.
33057520|NCT05129657|Experimental|Product usage order CNADB|Subjects will use each of the 5 products sequentially (CNADB) during an evaluation period, followed by a 4 hour Test Session.
33057521|NCT05129657|Experimental|Product usage order DBNAC|Subjects will use each of the 5 products sequentially (DBNAC) during an evaluation period, followed by a 4 hour Test Session.
33057522|NCT05129657|Experimental|Product usage order DNBCA|Subjects will use each of the 5 products sequentially (DNBCA) during an evaluation period, followed by a 4 hour Test Session.
33057523|NCT05129657|Experimental|Product usage order NCDAB|Subjects will use each of the 5 products sequentially (NCDAB) during an evaluation period, followed by a 4 hour Test Session.
33057524|NCT05129657|Experimental|Product usage order NDCBA|Subjects will use each of the 5 products sequentially (NDCBA) during an evaluation period, followed by a 4 hour Test Session.
33057525|NCT05084183|Experimental|PermeaDerm®|N=34 Participants will receive application of PermeaDerm® as outlined in Directions for Use
33057526|NCT05084183|Active Comparator|Mepilex Ag®|Participants will receive application of Mepilex Ag® as outlined in Directions for Use.
33057527|NCT00398892|Other|1|Crossover - placebo then active
33057528|NCT00398892|Other|2|Crossover - active then placebo
33057529|NCT05019794|Experimental|Gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with FGFR2 amplification|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
33057530|NCT05019794|Experimental|Advanced Solid tumors[Exclude GC/GEJ Arm and CHOL,UC]with FGFR1-3 fusions/rearrangements/mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
33057531|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
33057532|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
33057533|NCT04941521|Experimental|Exenatide and Drug Counseling|Participants will receive once weekly exenatide injections and drug counseling sessions.
33057534|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
33057535|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
33057536|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
33057537|NCT04732637||COVID Positive|Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
33057538|NCT04732637||COVID Negative|Individuals who have recently tested negative for COVID19 by RTPCR.
33057539|NCT04891913|Experimental|15mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.
33057540|NCT04891913|Experimental|30mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.
33057541|NCT04891913|Experimental|60mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.
33057542|NCT04732364|Placebo Comparator|Group (C) (control group):|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
33057543|NCT04732364|Active Comparator|Group (D) (Dexmetonidine group):|Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..
33057544|NCT04732364|Active Comparator|Group (M) (magnesium slphate group):|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..
33057545|NCT04732598|Active Comparator|Arm A|
33057546|NCT04732598|Experimental|Arm B|
33057547|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Treatment|"Condition1: Treatment-first~Children with RSE and typical perception will be allocated to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment. Ten children with RSE will receive 10 weeks of visual-acoustic biofeedback training via video call."
33057548|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Wait|"Condition 2: Waitlist-first~Following the initial evaluation, 10 children with RSE will be allocated to a 10 week no treatment condition."
33057549|NCT00067080|Experimental|ICL670 + deferoxamine|
33057550|NCT00067119|Experimental|Aggrenox|
33057551|NCT00067119|Placebo Comparator|Placebo|
33057552|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
33057553|NCT00070824|Experimental|A|Normal Subjects without pain
33057554|NCT04750772|Experimental|68Ga-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
33057555|NCT04750772|Experimental|18F-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
33419147|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
33419148|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
33057556|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
33057557|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
33057558|NCT04608110|Experimental|Azacitidine + Cedazuridine|"Drug: Azacitidine~Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration~Drug: Cedazuridine~Tablets for oral administration"
33057559|NCT04476368|Experimental|yoga|Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
33057560|NCT04476368|Active Comparator|control|Control group will consist of healthy pregnant women attending regular prenatal visits at the departments of perinatology of the university medical centers Maribor and Ljubljana. Only women not attending any formal prenatal exercise program will be offered entrance in the study. Measurements in this group will be performed before and after a 20-30 minute walk.
33057561|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
33057562|NCT00398970|Experimental|Ultrasound guide sampling|
33057563|NCT04445831|Placebo Comparator|Placebo|Placebo administered at predefined time points over a 48-week period.
33057564|NCT04445831|Experimental|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
33057565|NCT04445831|Experimental|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
33057566|NCT04445831|Experimental|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
33057567|NCT04445831|Experimental|JACI-35.054 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
33057568|NCT04445831|Experimental|JACI-35.054 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
33057569|NCT04408469|Experimental|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
33057570|NCT04408469|Placebo Comparator|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
33057571|NCT02967081||Pulp necrosis|
33057572|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
33057573|NCT02967081||Irreversible pulpitis|
33057574|NCT02967081||Normal pulp|
33057575|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
33057576|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
33057577|NCT04308512|Experimental|Intervention Group (IG): Care coordination with Care4AD system|All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
33057578|NCT04308512|No Intervention|Control Group (CG): Standard of care|Participants in control group (CG) will also receive Care4AD device. However, all reminders and programming of activity daily living (ADL) tasks will be de-activated in the CG.
33057579|NCT04245722|Experimental|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
33057580|NCT04245722|Experimental|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
33057581|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
33057582|NCT04245722|Experimental|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
33057583|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
33057584|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
33057585|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
33057586|NCT04231643|Experimental|Bipolar Disorder|adults with bipolar disorder
33057587|NCT04231643|Active Comparator|Healthy Volunteers|adults with no psychiatric disease
33112719|NCT04657107|Experimental|K2 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
33112720|NCT04937582|Experimental|Confirmed cognitive disorder|"Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.~Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.~Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)"
33112721|NCT04937582|Experimental|Absence of cognitive disorder|Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.
33112722|NCT04657029|Experimental|Treadmill condition|The intervention condition consisted of a single session of moderate-high intensity aerobic exercise (65% of heart rate reserve) for 30 minutes walking on a standard treadmill. The single treadmill session included a progressive increase in intensity to reach the target heart rate (approx. 5 mins) as well as a cooling down period (approx. 5 mins). The warm-up and cool-down were included as part of the total 30 minutes of walking exercise. Target heart rates were calculated using the Karvonen method [25] with levels adjusted for those taking heart rate lowering medications (i.e. beta blockers), following methods previously published in post stroke populations [26, 27]. Participants were asked to self-rate their intensity of exercise every 10 minutes verbally using BORG's 6-20 scale rating of perceived exertion [28]. Participants were instructed to walk at a pace that resulted in a rating between 11 (fairly light) and 14 (somewhat hard) on the scale.
33112723|NCT04657029|Other|Control condition|The control condition involved an equivalent time period (30 minutes) of seated resting where participants were provided with an education session about the impact and effects of stroke by the same research assistant.
33112724|NCT04657185||Before OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place but without OR PathTrac feedback optimization.
33112725|NCT04657185||After OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place AND OR PathTrac feedback optimization.
33112726|NCT04915157|Other|Group A: High Density stimulation - No Stimulation|Patients in this group will receive high density stimulation (parasthesia free form of stimulation) during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive no stimulation during the final 6 months of the study period.
33112727|NCT04915157|Other|Group B: No Stimulation - High Density Stimulation|Patients in this group will receive no stimulation during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive high density stimulation (parasthesia free form of stimulation) during the final 6 months of the study period.
33334065|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
33112728|NCT04906460|Experimental|WVE-N531|
33334066|NCT04644796|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
33334067|NCT04644796|Active Comparator|Liposomal bupivacaine|Patients in this group will be given the study drug (liposomal bupivacaine).
33334068|NCT00086307|Active Comparator|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
33334069|NCT00086307|Active Comparator|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
33334070|NCT00086307|Experimental|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
33334071|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
33334072|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
33334073|NCT03624972|No Intervention|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
33334074|NCT04050904|Experimental|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
33334075|NCT05031364|Experimental|Consultation-Based Training on BIACA|Community mental health clinicians will be given online one-on-one training and consultation in the BIACA (Behavioral Interventions for Anxiety in Children with Autism; e.g., Wood et al., 2020) CBT program. Clinicians will be provided with weekly 30-minute video-conference-based consultation sessions with an expert in BIACA. These consultation sessions are manual-driven and utilize a Practice-Based Coaching format, in which a trained consultant meets weekly with clinicians to provide practice-based feedback (cf. McLeod et al., 2018). Consultation meetings include agenda setting, case material review, planning for the next treatment session, and a meeting summary. Relevant online training materials (e.g., demonstration videos of CBT sessions; corresponding written session materials) developed in the context of a NIMH R34 grant available on meya.ucla.edu (1R34MH110591) will also be provided to clinicians for each upcoming therapy session.
33419149|NCT05103735||PROPOFOL-REMIFENTANYL|"Awake craniotomy under propofol-remifentanil sedation. Propofol and remifentanyl was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Propofol dosage: 0.2-2 mk/kg/h Remifentanyl dosage: 0.01-0.1 mcg/kg/min"
33057588|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
33057589|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
33057590|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
33057591|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
33057592|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
33057593|NCT04163666|Experimental|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
33057594|NCT04163666|Experimental|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
33057595|NCT04163666|No Intervention|Control Group|No additional intervention with the participants of this group will be completed.
33057596|NCT04104152|Experimental|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
33057597|NCT04104152|Experimental|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
33057598|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
33057599|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
33057600|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
33057601|NCT04094363|Experimental|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
33057602|NCT04094363|Experimental|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
33057603|NCT04094363|Experimental|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
33057604|NCT04094363|Experimental|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
33057605|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
33057606|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
33057607|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
33057608|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
33057609|NCT01349673|Experimental|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
33057610|NCT03493919|Experimental|rMenB+OMV NZ Group|Approximately 510 healthy subjects vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and have blood collected at Day -83, Day 8 and Day 98.
33057611|NCT03493919|Experimental|MenACWY 1 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -83, Day 8 and Day 151.
33057612|NCT03493919|Experimental|MenACWY 2 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -60, Day 31 and Day 151.
33057613|NCT03493919|Experimental|MenACWY 3 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -30, Day 61 and Day 151.
33057614|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
33057615|NCT00067587||HIV Negative|HIV negative subjects
33057616|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
33057617|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
33057618|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
33068203|NCT02954926|No Intervention|Control|No intervention
33057619|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
33057620|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
33419150|NCT05103735||DEXMEDETOMIDINE|"Awake craniotomy under dexmedetomidine sedation. Dexmedetomidine was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Dexmedetomidine dosage: 0.2-1 mcg/kg/h In this group, remifentanyl administration was allowed."
33419151|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
33057621|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
33057622|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
33057623|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
33057624|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
33057625|NCT04732169|Active Comparator|Epidiolex (cannabidiol) (CBD)|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
33057626|NCT04732169|Placebo Comparator|Placebo|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
33057627|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
33057628|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
33057629|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
33057630|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
33057631|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
33057632|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
33057633|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
33057634|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
33057635|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
33057636|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
33057637|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
33057638|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
33057639|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
33057640|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
33057641|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
33057642|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
33057643|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
33057644|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
33057645|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
33057646|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
33057647|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
33057648|NCT00067743|Other|1|Open Label trial
33334076|NCT05031364|Active Comparator|Usual Care Augmented by Self-Instruction Resources for CBT for Autism|Community mental health clinicians in this arm will provide any therapy, counseling, and/or behavioral treatment procedures they deem appropriate for each participating child. Clinicians randomized to this arm will be given immediate access to CBT-for-autism self-instruction materials that are already freely available to any clinician at meya.ucla.edu (see Consultation-Based Training on BIACA arm, above), to supplement their usual clinical care, if they so choose, until they complete their Usual Care/Self-Instruction participation and are offered direct training and weekly consultation in BIACA.
33334077|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
33334078|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
33057649|NCT04732130|Active Comparator|Time-Restricted Feeding|Participants in the time-restricted feeding are instructed to eat ad libitum from 12:00 to 20:00 daily, and fast from 20:00 to 12:00 daily for 4 weeks.
33057650|NCT04732130|Active Comparator|Alternate Day Fasting|Participants in the alternate day fasting group are instructed to eat every second day ad libitum, but to abstain from calorie intake on fast days (100 % restriction) for 4 weeks.
33057651|NCT04732130|No Intervention|Control|Participants in the control group are instructed to maintain their habitual diet regimen.
33057652|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
33057653|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
33057654|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
33057655|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
33057656|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
33057657|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
33057658|NCT02599324|Experimental|Cohort 1: Renal Cell Carcinoma (RCC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of everolimus to determine the recommended phase 2 dose (RP2D) of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in phase 1b in combination with everolimus."
33057659|NCT02599324|Experimental|Cohort 2: Urothelial Carcinoma (UC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of paclitaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with paclitaxel."
33057660|NCT02599324|Experimental|Cohort 3: Gastric Adenocarcinoma (GA or GC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of docetaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
33057661|NCT02599324|Experimental|Cohort 4: Colorectal Adenocarcinoma (CRC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of cetuximab to determine RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
33057662|NCT02599324|Experimental|Cohort 5: Urothelial Carcinoma (UC) Ibrutinib|"Phase 1b: Participants receive ibrutinib at various dose levels to determine the RP2D of ibrutinib.(The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b."
33057663|NCT02599324|Experimental|Cohort 6: Urothelial Carcinoma (UC) With Pembrolizumab|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of pembrolizumab to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab."
33057664|NCT01331018|Experimental|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
33057665|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
33057666|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
33057667|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
33057668|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
33057669|NCT00067938|Other|Arm 1|Open label single arm study
33057670|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
33334079|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
33112729|NCT04656483|Experimental|Telemedicine Video Feedback Arm|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
33112730|NCT04656483|Active Comparator|Psychoeducational booklet arm|Mothers assigned to condition B will receive an informative booklet addressing the same themes discussed in the experimental intervention (i.e., responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant or specific parenting challenges.
33112731|NCT00561717|Experimental|Arm 1|
33419152|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
33419153|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
33419154|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
33112732|NCT00561717|Active Comparator|Arm 2|
33112733|NCT00561717|Active Comparator|Arm 3|
33112734|NCT00561717|Placebo Comparator|Arm 4|
33112735|NCT04901351|Experimental|Patients chronically infected with HPV|The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.
33112736|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
33112737|NCT04868591|Active Comparator|Single session APP arm|Participants in this group will received one session with the advanced practice physiotherapist.
33112738|NCT04868591|Experimental|Multiple sessions APP arm|Participants in this group will received 6 sessions (in 12 weeks) with the advanced practice physiotherapist.
33112739|NCT04863950|Experimental|Imipramine Hydrochloride/Lomustine|
33112740|NCT04628052|Experimental|Music|
33419155|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
33112741|NCT04628052|No Intervention|No-Music|
33112742|NCT04860401|Experimental|precision and accuracy study|precision and accuracy of Oxyprem are studied
33112743|NCT04656444||phone call to emergency department|
33112744|NCT04827485|Active Comparator|Gluteal squeeze|Patients behind pressed together during part of the colonoscopy (The technicians arms will be covered with a towel to mask the provider of any pressure being applied)
33419156|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
33419157|NCT04194099|Experimental|rTMS (Brain) + tsES (Spinal)|"First part 20 Hz rTMS (Brain) + Anode tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec~Spinal:~Continuous direct current (DC): 1200 sec~Second part iTBS rTMS(Brain) + 2.5-mA tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Continuous direct current (DC): 600 sec"
33419158|NCT04194099|Experimental|rTMS (Brain) + tsES (Spinal) or sham stimulation|"First part 20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)~Brain and spinal:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec~Second part iTBS rTMS(Brain) + sham 2.5-mA tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Sham direct current (DC) stimulation"
33419159|NCT04194099|Experimental|iTBS rTMS or sham (Brain) + tsES or sham (Spinal)|"First part~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Continuous direct current (DC): 190 sec~Second part Sham iTBS rTMS (Brain) + 2.5-mA tsDCS (Spinal)~Sham iTBS rTMS Brain:~Spinal:~Continuous direct current (DC): 600 sec"
33419160|NCT04194099|Experimental|iTBS rTMS or sham (Brain) + iTBS or sham (Spinal)|"First part~Brain and spinal:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Second part Sham iTBS rTMS (Brain) + Sham 2.5-mA tsDCS (Spinal)~Brain:~Sham iTBS rTMS~Spinal:~Sham direct current (DC) stimulation"
33419161|NCT04194099|Sham Comparator|sham (no stimulation on brain nor spinal)|"First part Sham stimulation.~No second part"
33419162|NCT05520255|Experimental|18F-PSMA-1007|18F-PSMA-1007, 4 MBq/kg (max 400 MBq; +/- 15%), intravenous, single dose
33419163|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
33419164|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
33419165|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
33419166|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
33112745|NCT04827485|Sham Comparator|Non-squeeze|When the doctor asks for gluteal pressure, a technician will not administer the pressure but their arms will be covered with a towel and the doctor will not know if the pressure is being administered or not.
33112746|NCT04656756|Experimental|Experimental Group|The mothers in the experimental group (60) were administered.
33112747|NCT04656756|No Intervention|Control Group|The mothers in the control group (60) were given the routine care.
32869782|NCT05591898|No Intervention|Control group|This group will be the randomized selected patients who will not get any intervention. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
33112748|NCT04824911|Experimental|Intervention group|"This group will receive dual antiplatelet and high-intensity statin treatment.~Dual antiplatelet treatment: loading of clopidogrel 300mg plus aspirin 300mg, followed by clopidogrel 75 mg/day and aspirin 100 mg/d from day 2 to day 21, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.~High-intensity statin treatment: Atorvastatin 40-80mg/day or Rosuvastatin 20 mg/day for 90 days."
33334080|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
33334081|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
33334082|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
33068204|NCT02955121|Active Comparator|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
33068205|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
33068206|NCT00505804|Experimental|1|
33068207|NCT00505804|Active Comparator|2|
33068208|NCT04724850||COVID-19 patients|All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.
33068209|NCT04513093|Experimental|İntervention Group|"The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.~The Bristol Stool Scale and Constipation Severity Scale were re-applied to the individuals in the intervention before, during the second week of practice and at the end of practice (fourth week)."
33068210|NCT04513093|No Intervention|Control Group|"No application was applied to the individuals in the control group. Bristol Stool Scale and Constipation Severity Scale were applied to the individuals in the control group at the same time as (at the beginning, second week and fourth week) the intervention group."
33068211|NCT04513132|Active Comparator|active-CHR|Participants will be intervened with deep transcranial magnetic stimulation (dTMS).
33068212|NCT04513132|Sham Comparator|sham-CHR|Participants, as a control group, will receive sham stimulation.
33068213|NCT04512898|Experimental|Patient with IBS|Patients with IBS and positive H. pylori.
33068214|NCT04512820|Experimental|TRUCLEAR TREATMENT|patients up to 10 weeks of gestation with missed miscarriage undergoing evacuation of products of conception using the TRUCLEAR tissue removal system under direct hysteroscopic visualization
33068215|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
33068216|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
33068217|NCT00505882|Active Comparator|Insulin|
33068218|NCT00505882|Experimental|Pramlintide|
33068219|NCT00505960|Experimental|1|
33068220|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
33068221|NCT04512859|Experimental|Stellate Ganglion Block|"Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
33068222|NCT04512859|Placebo Comparator|No Stellate Ganglion Block|"patients will receive a stellate ganglion block with 0.9% saline 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
33068223|NCT04512508|Other|Group 1, HIV negative patients.|Only HIV negative patients
33068224|NCT04512508|Other|Group 2, HIV positive patients|Only HIV positive patients
33068225|NCT04512625|No Intervention|Control group|Sensitivity level scores were evaluated on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation.
33068226|NCT04512625|Experimental|Group GL (Gluma desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
33068227|NCT04512625|Experimental|Group SF (SheildForce desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
32869783|NCT04221451|Experimental|GZ402671|"Primary population: participant will receive venglustat dose once daily during the primary analysis period (104 weeks) and the open-label extension period (104 weeks).~Secondary population: participant will receive venglustat at various doses once daily during the primary analysis period open-label (104 weeks) and the open-label extension period (104 weeks)."
33112749|NCT04824911|Active Comparator|Historical control|A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
33112750|NCT04683107|Experimental|Eccentric protocol|
33112751|NCT04683107|Experimental|Isometric protocol|
33112752|NCT04628169||group A|group A : placental tissue of 30 patients with placenta accreta
33334083|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
33334084|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
33334085|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
33112753|NCT04628169||group B|group B : placental tissue of 20 normal pregnancy as a control group
33334086|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
33334087|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
33334088|NCT04112589|Experimental|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
33112754|NCT04683146|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propranolol- 1 60% as control.
33112755|NCT04683146|Active Comparator|Hand antisepsis with solution of alcohol, chlorhexidine digluconate and potassium sorbate|Effectiveness of pre-surgical hand washing in reducing bacterial load using a solution of alcohol, chlorhexidine digluconate and potassium sorbate
33334089|NCT04112589|Experimental|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
33112756|NCT04816877||Patient controlled analgesia (PCA) group|Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids.
33112757|NCT04816877||Physician directed analgesia (PDA) group|Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician.
33112758|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
33112759|NCT04800302|Experimental|Continuous QLB group|U/S-guided continous QLB III
33112760|NCT04800302|Active Comparator|Single dose QLB group|U/S-guided single dose QLB III
33112761|NCT04800302|Active Comparator|Morphine group|IV Morphine
33112762|NCT04795037|Experimental|CU06-1004 for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
33112763|NCT04795037|Placebo Comparator|Placebo for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
33112764|NCT04795037|Experimental|CU06-1004 for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
33112765|NCT04795037|Placebo Comparator|Placebo for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
33112766|NCT04791956|Experimental|Prebiotic|Inulin-type fructans
33112767|NCT04791956|Placebo Comparator|Placebo|Maltodextrin
33112768|NCT04785482||Parents of infants with single ventricle heart disease|All participants
33112769|NCT04726748||Urolift cohort|80 patients with prostatic urethral lift surgery will be included
33112770|NCT04726748||Transurethral Resection of the Prostate/laser cohort|80 patients with a transurethral resection of the prostate or laser surgery (enucleation or vaporisation) will be included.
33112771|NCT04726748||National healthcare insurance system database (SNDS) cohort|1200 patients with any transurethral surgery (TURP/laser) will be included and randomly matched to patients of the Urolift cohort with ratio 5:1.
33112772|NCT04711304|Experimental|Wharton's Jelly|Intraarticular injection of Wharton's Jelly
33334090|NCT04112589|Experimental|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
33112773|NCT04711304|Active Comparator|Hyaluronic Acid|Intraarticular injection of Hyaluronic Acid
33112774|NCT04711304|Placebo Comparator|Saline|Intraarticular injection of Saline
33112775|NCT04710719|Active Comparator|TAC only|Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
33112776|NCT04710719|Active Comparator|TAC + 5FU|Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
33112777|NCT04675853||Participants with PD|
33112778|NCT04675853||Care Partners of PD participants|
33112779|NCT04649372|Other|EndoVE endosCopic Treatment for Oesophageal and Gastric canceR|The patient will be placed under General Anaesthetic or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged. There will be a telephone follow up after 2 days, 7 days, 4 weeks and 8 weeks. The patient will be requested to attend the clinic for a 12-week follow up for clinical review.
33112780|NCT04627701|Experimental|ClearRing Device|
33112781|NCT04683185|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
33112782|NCT04683185|Experimental|Cohort 3: E6742 400 mg or Placebo|Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
33112783|NCT04683185|Experimental|Cohort 1: E6742 100 milligram (mg) or Placebo|Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
33334091|NCT04112589|Experimental|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
33334092|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33112784|NCT04656405|Experimental|Online real-time CPR training program|Online real-time quality measurement and feedback video-based CPR training will be provided to participants
33112785|NCT04656405|Active Comparator|Online real-time CPR training without quality measurement program|Online real-time feedback video-based CPR training without quality measurement will be provided to participants
33112786|NCT04656405|Placebo Comparator|Conventional CPR training program|Conventional CPR training will be provided to participants
33112787|NCT04647890|Experimental|FT011 200mg|200mg once daily for 12 weeks
33112788|NCT04647890|Experimental|FT011 400mg|400mg once daily for 12 weeks
33112789|NCT04647890|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
33334093|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
33334094|NCT04979962|Experimental|CAC Group|Inspection with computer assisted colonoscopy.
33334095|NCT04979962|No Intervention|CC Group|Inspection with conventional colonoscopy
33334096|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
33112790|NCT04656288|Experimental|Formula A under fasted conditions - Part 1|
33334097|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
33334098|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
32740476|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
32740477|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
33112791|NCT04656288|Experimental|Formula B under fasted conditions - Part 1|
33112792|NCT04656288|Experimental|Formula B under fasted conditions - Part 2|
33112793|NCT04656288|Experimental|Formula C under fasted conditions - Part 2|
33112794|NCT04656288|Experimental|Formula D under fasted conditions - Part 2|
33112795|NCT04656288|Experimental|Formula B under fed conditions - Part 2|
33112796|NCT04592276|Experimental|PS128|Each PS128 capsule contained 3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
33112797|NCT04592276|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
33112798|NCT04627779|Experimental|Male Group|
33112799|NCT04627779|Active Comparator|Female Group|
33112800|NCT04580732|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
33112801|NCT04580732|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
33112802|NCT04656327||Non interventional group|Community-dwelling elders dependent for care
33112803|NCT04561739|Experimental|Drug-coated balloon|
33112804|NCT04561739|Active Comparator|Drug-eluting stent|
33112805|NCT04627584|Active Comparator|MW33 injection-1200mg|
33112806|NCT04627584|Active Comparator|MW33 injection-2400mg|
33112807|NCT04627584|Placebo Comparator|Placebo|
33112808|NCT04537598|Active Comparator|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
33112809|NCT04537598|Active Comparator|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia.
33334099|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
32740478|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
32740479|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
33112810|NCT04627467|Experimental|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
33112811|NCT04532801|Experimental|kisspeptin-10|kisspeptin infusion
33112812|NCT04532801|Placebo Comparator|placebo|placebo
33112813|NCT04656093|Experimental|Intervention|"Intervention group - Cognitive Restructuring, Motivational Interviewing, and Multi-Medication Adherence.~The pilot intervention is comprised of three educational sessions for individual study patients, conducted by interventionist with a master's degree in psychology with cognitive behavioral therapy training. The topics addressed in the sessions are as follows:~Review of COPD medication inhaler technique, psychoeducation on maladaptive beliefs and emotional response."
33112814|NCT04656093|Active Comparator|Control|Control group - Supportive counseling for comorbidity management
33112815|NCT04531631|Other|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
33112816|NCT04531631|Other|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
33112817|NCT04655937|No Intervention|non-randomised no treatment arm|Participants who do not opt in to group support will only provide self-report data on their wellbeing and quality of life every 3 months for up to 12 months. Data collected through online survey platforms using validated questionnaires
33112818|NCT04655937|Experimental|randomised invite Acceptance and Commitment Therapy (ACT) Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
33334100|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
33334101|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
33112819|NCT04655937|Active Comparator|randomised invite Social Support Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly group sessions involving social support activities. There will be homework in between sessions.
33112820|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
33112821|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
33112822|NCT04627740|Experimental|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
33112823|NCT04656366||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
33112824|NCT04656366||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
33112825|NCT04525469|Experimental|Narrative Exposure Therapy|NET is a fully-manualized evidence-based treatment for PTSD. Participants will receive 6 weekly 60-minute individual sessions of NET.
33112826|NCT04509167|Experimental|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
33112827|NCT04627155|Experimental|7mg dose group|
33112828|NCT04627155|Experimental|14mg dose group|
33112829|NCT04656249|Experimental|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
33112830|NCT04481555|No Intervention|"Eosinophil_Control/Azithro_Control"|"Azithromycin: patients are given placebo~ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose."
33112831|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Control:"|"a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.~ii. If blood eosinophil <300 cells/μL, ICS is discontinued."
33112832|NCT04481555|Experimental|"Eosinophil_Control/Azithro_Active group"|Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period
33112833|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Active:"|"Azithromycin: 250 mg azithromycin three times weekly.~ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):"
33112834|NCT04472312||Cirrhotic patients undergoing a liver transplantation|The investigators aim to conduct a prospective observational, non-interventional study including all cirrhotic patients undergoing a liver transplantation with a planned use of vasopressin during the surgery.
33112835|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
33112836|NCT04472156|Experimental|Transfer of mosaic embryo|Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
33112837|NCT04655859||severe early childhood caries|
33112838|NCT04655859||healthy children|
33112839|NCT04655898|Experimental|Administration of [14C]CC-90001|A single oral dose of [14C]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.
33112840|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
33112841|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
33112842|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
33112843|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
33112844|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
33112845|NCT04682756||CNN model|Electronic health information of NSTEMI and UA patients in two chest pain centers from 2017 to 2019 was collected，After manual labeling, the characteristics of patient admission records were selected, and through the construction of one-dimensional convolution (CNN) model. Taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
33112846|NCT04682756||XG boost|Through the construction of XG boost model,taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
33112847|NCT04682795|Experimental|Needle-free injector group|To evaluate the efficacy and safety of the needle-free injector in T2DM
33112848|NCT04682795|Active Comparator|Insulin pen group|To evaluate the efficacy and safety of the insulin pen in T2DM
33112849|NCT04627116|Experimental|Tecarfarin 10mg|
33112850|NCT04627116|Experimental|Tecarfarin 20mg|
33112851|NCT04627116|Experimental|Tecarfarin 30mg|
33334102|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
33334103|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
33334104|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
33112852|NCT04627116|Experimental|Tecarfarin 40mg|
33112853|NCT04655742|Experimental|single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
33112854|NCT04396496|Experimental|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
33334105|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
33334106|NCT02157844||COPD|Subjects with diagnosis of COPD
33112855|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
33112856|NCT04627233|Placebo Comparator|No intervention:control group|
33112857|NCT04627233|Experimental|Experimental:Intervention group|
33112858|NCT04378244|Experimental|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
33112859|NCT04655664|Experimental|Treatment Group|Men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders
33112860|NCT04655664|Active Comparator|Regularly Group|Subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.
33112861|NCT04365179|Experimental|NEROFE|"Dose Level - Nerofe Dose~-1 - 6mg/m2~- 12 mg/m2~- 24 mg/m2~- 48 mg/m2~- 96 mg/m2~- 150mg/m2"
33112862|NCT04655508|Experimental|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
33334107|NCT02157844||OSA|Subjects with diagnosis of OSA
33334108|NCT02157844||controls|Gender, age, BMI matched controls
33334109|NCT01310660||Nulliparous|
33334110|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
33334111|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
33334112|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
33334113|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
33334114|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
33334115|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
33334116|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
33334117|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
33334118|NCT00057837|Experimental|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
33334119|NCT00057837|Experimental|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
33334120|NCT05665088|Experimental|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
33334121|NCT05665088|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
33112863|NCT04655508|Placebo Comparator|placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
33112864|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
33112865|NCT04627272|Experimental|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
33112866|NCT04313192|Experimental|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
33112867|NCT04313192|Experimental|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
33112868|NCT04313192|Experimental|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
33112869|NCT04655781|Experimental|N-T group|ILM was peeled off from nasal retina to temporal retina.
33112870|NCT04655781|Experimental|T-N group|ILM was peeled off from temporal retina to nasal retina
33112871|NCT04294472|Experimental|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
33112872|NCT04294472|Experimental|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
33112873|NCT04294472|Experimental|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
33112874|NCT04294472|Placebo Comparator|Placebo Cohort 1, 2, 3|5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses
33112875|NCT04626999|Active Comparator|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
33112876|NCT04626999|Active Comparator|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
33334122|NCT05665088|Placebo Comparator|Placebo|Sublingual Placebo film
33112877|NCT04626999|Active Comparator|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
33334123|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
32740929|NCT04969991|Experimental|Varespladib: 250 mg BID + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning and in the evening. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon.
33112878|NCT04626960||Patient|OAB patients
33334124|NCT04958668|Active Comparator|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
33112879|NCT04626960||Control|Healthy
33334125|NCT04958668|No Intervention|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
33334126|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
33112880|NCT04655040|Experimental|Caffeine and Ritlecitinib|"In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.~In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9."
33112881|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
33112882|NCT04626765|Experimental|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
33112883|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
33112884|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
33334127|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
33334128|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
33334129|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
33334130|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
33112885|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
33112886|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
33112887|NCT04655274||RayOne Trifocal intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses
33112888|NCT04655274||AcrySof IQ PanOptix intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses
33112889|NCT04626648|No Intervention|Surgery without intraoperative pause|Surgical procedure without pause
33334131|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
33334132|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
33334133|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
33334134|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
33334135|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
33334136|NCT01090713|Active Comparator|Lisdexamfetamine|drug
33334137|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
33112890|NCT04626648|Experimental|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
33112891|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
33112892|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
33112893|NCT04626726|Experimental|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
33112894|NCT04655235||patients with schizophrenia|200 patients with a DSM 5- diagnosis of schizophrenia
33334138|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
33334139|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
33334140|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
33112895|NCT04655235||healthy relatives of patients with schizophrenia|200 healthy relatives of the patients with schizophrenia
33112896|NCT04655235||healthy control subjects|healthy control subjects without relatives with mental disorders
33112897|NCT04654962||patients receiving preoperative analgesic management with anesthetic block|This cohort includes all patients that received preoperative anesthetic block for hip fracture surgery as main analgesic management during the study period.
33112898|NCT04654962||patients receiving conventional preoperative analgesic management|This cohort includes all patients that received conventional preoperative analgesic management (oral, intravenous or intramuscular medication) for hip fracture surgery as main analgesic management during the study period.
33112899|NCT04654884|Active Comparator|Group 1|The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
33112900|NCT04654884|No Intervention|Group 2|Group 2, the control group, will receive TaU and will, just like goup 1, have a follow-up after 8 weeks.
33112901|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
33112902|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
33112903|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
33112904|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
33112905|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
33112906|NCT02906423||Allina health patients|
33334141|NCT01086813|Experimental|1|
33334142|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
33112907|NCT02906462|Other|Usual Practices|Usual Practices
33112908|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
33112909|NCT04654494||Chron's disease patients with colorectal cancer|This group of patients with Chron's disease have been diagnosed with colorectal cancer and treated surgically
33112910|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
33112911|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
33112912|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
33112913|NCT04654572|Experimental|burned group|burned patients
33112914|NCT04654572|Experimental|control group|sedentary people
33112915|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
33334143|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
33334144|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
33334145|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
33334146|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
33334147|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
33112916|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
33112917|NCT04626531|Experimental|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
33112918|NCT04626531|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
33112919|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
33112920|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.~Radiation technique: VMAT."
33334148|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
33334149|NCT04899310|Experimental|mRNA-3705|Treatment Period (during the Dose Optimization Stage and the Optional Dose Expansion Stage): 1 of up to 5 possible doses of mRNA-3705, administered intravenously (IV), once every 2 to 4 weeks (q2W to q4W), depending on participant's weight for up to 10 doses over approximately 40 weeks.
33112921|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
33112922|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
33112923|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
33112924|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
33112925|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
33112926|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
33334150|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
33112927|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
33112928|NCT04654611|Other|Treatment group|The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
33334151|NCT00068601|Active Comparator|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
33334152|NCT00068601|Experimental|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
33334153|NCT03638258|Experimental|Roflumilast Cream 0.3%|Roflumilast cream 0.3% topically applied QD for 12 weeks.
33112929|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
33112930|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
33112931|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
33112932|NCT04654416||Steroids|Dexamethasone 6mg intravenous OD for seven to ten days
33112933|NCT04654416||Colchicine|Patients treated with colchicine at a dose of 0.5 mg every 12 hours for 7 to 14 days.
33112934|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
33334154|NCT03638258|Experimental|Roflumilast Cream 0.15%|Roflumilast cream 0.15% topically applied QD for 12 weeks.
33334155|NCT03638258|Placebo Comparator|Vehicle Cream|Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.
33334156|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33112935|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
33112936|NCT04626453|Experimental|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
33112937|NCT04626453|No Intervention|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
33112938|NCT04626453|No Intervention|Healthy older adults|Healthy older adults will not do exercise.
33112939|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
33334157|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33334158|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33334159|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33419167|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
33112940|NCT00561990|Placebo Comparator|Placebo|Placebo
33112941|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
33112942|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
33112943|NCT04654728|Active Comparator|ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
33112944|NCT04654728|Other|Dacron graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
33112945|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
33112946|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
33112947|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
33112948|NCT02905916|Experimental|PEG-rhG-CSF|
33112949|NCT04626492||F0|Normal control group
33112950|NCT04626492||F1|Grade 1 of liver fibrosis
33112951|NCT04626492||F2|Grade 2 of liver fibrosis
33112952|NCT04626492||F3|Grade 3 of liver fibrosis
33112953|NCT04626492||F4|Hepatic cirrhosis
33112954|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3~Cytarabine continuous infusion days 1-7~Idarubicin IV bolus on days 1, 2, and 3.~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction~A bone marrow biopsy will be performed according to standard practice on day 14"
33112955|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
33112956|NCT02905955|Other|Prevena|
33112957|NCT04654767||COPD-PH group|Patients with confirmed COPD and pulmonary hypertension
33112958|NCT04654767||IPF-PH|Patients with confirmed pulmonary fibrosis and pulmonary hypertension
33112959|NCT04654767||Control group|Control group without diagnosed COPD, IPF, or pulmonary hypertension
33112960|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
33112961|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
33112962|NCT02905877||Healthy control|Healthy age matched controls
33112963|NCT04626180|Active Comparator|Regular Extubation|
33112964|NCT04626180|Experimental|Pre Extubation Manual Hyperinflation|
33112965|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
33112966|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
33112967|NCT04654377|Experimental|Personalised education|"Greetings~Recording clinical/imaging data.~Questionnaires administration.~Explaining the disease and possible outcome in the context of clinical/lab/imaging data.~Answering specific queries from patients and care givers."
33112968|NCT04654377|No Intervention|Standard communication|"Greetings~Recording clinical/imaging data.~Administration of questionnaire.~Addressing general queries from patients and care givers."
33112969|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
33112970|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
33112971|NCT04626258|Active Comparator|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
33112972|NCT04626258|Experimental|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
33112973|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
33112974|NCT04626102|No Intervention|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
33112975|NCT04626102|Experimental|Intervention Period|"Participants were randomly assigned to one of these conditions:~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
33334160|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
33419168|NCT02120066|Other|Vitrectomy|
33419169|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
33057671|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
33334161|NCT03621696|Experimental|Arm 1: POAmCRT|"Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
33334162|NCT03621696|Experimental|Arm 2: POAmRT|"Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
33057672|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
33057673|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
33057674|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
33057675|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
33057676|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
33057677|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
33057678|NCT02048371|Active Comparator|Cohort A: Liposarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
33057679|NCT02048371|Placebo Comparator|Cohort A: Liposarcoma, Placebo|"21 days on and 7 days off~Placebo"
33057680|NCT02048371|Active Comparator|Cohort B: Osteosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
33057681|NCT02048371|Placebo Comparator|Cohort B: Osteosarcoma, placebo|"21 days on and 7 days off~Placebo"
33057682|NCT02048371|Active Comparator|Cohort C: Ewing sarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
33057683|NCT02048371|Active Comparator|Cohort D: Rhabdomyosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
33057684|NCT02048371|Active Comparator|Cohort E: Mesenchymal Chondrosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
33057685|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
33057686|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
33057687|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
33057688|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
33057689|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
33057690|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
33334163|NCT03621696|Experimental|Arm 3: POACRT|"Patients with clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)~The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
33334164|NCT04945642|Experimental|Treatment (HDR-BT, SBRT)|Patients undergo HDR-BT for up to 24 hours and undergo SBRT every other day or consecutive days for up to 14 consecutive chronologic days in the absence of disease progression or unacceptable toxicity.
33334165|NCT00068445|Experimental|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
33334166|NCT00068445|Other|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.~Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
33334167|NCT03653208|Experimental|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
33334168|NCT03653208|Experimental|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
33334169|NCT03653208|Experimental|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
33334170|NCT03653208|Experimental|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
33334171|NCT03653208|Experimental|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
33334172|NCT03653208|Experimental|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
33334173|NCT03653208|Experimental|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
32869784|NCT04221451|Placebo Comparator|Placebo|Primary population: participants will receive placebo once daily during the primary analysis period (104 weeks) and will receive venglustat dose once daily during the open-label extension period (104 weeks).
33057691|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
33057692|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
33057693|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
33057694|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
33057695|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
33057696|NCT01260961|Active Comparator|Docosa Hexanoic Acid|
33057697|NCT01260961|Placebo Comparator|Placebo|
33057698|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
33057699|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
33057700|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
33057701|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
33057702|NCT00144508|Experimental|1|
33057703|NCT00144508|Other|2|continue current treatment
33057704|NCT00144547|Experimental|1|
33057705|NCT00144586|Experimental|1|
33057706|NCT00144625|Experimental|1|
33057707|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
33057708|NCT00144664|Experimental|1|MRA(Tocilizumab)
33057709|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
33057710|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
33057711|NCT00038441|Experimental|DTI-015|
33057712|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
33057713|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
33057714|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
33057715|NCT04711018||Group DL (+)|Grade III or IV laryngeal view according to Cormack-Lehane classification
33057716|NCT04711018||Group DL (-)|Grade I or II laryngeal view according to Cormack-Lehane classification
33057717|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
33057718|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
33057719|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
33057720|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
33057721|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
33057722|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
33057723|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
33057724|NCT00202696|Experimental|1|Nalmefene 40 mg
33057725|NCT00202696|Experimental|2|Nalmefene 80 mg
33057726|NCT00202696|Other|3|Placebo
33334174|NCT03653208|Experimental|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
33057727|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
33057728|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
32869785|NCT05591742|Placebo Comparator|placebo|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
33057729|NCT00202852|Placebo Comparator|1|
33057730|NCT00202852|Experimental|2|
33057731|NCT00202969|Experimental|1|S-1
33057732|NCT00202969|Active Comparator|2|S-1 plus CDDP
33057733|NCT00202969|Active Comparator|3|5-FU plus CDDP
33057734|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
32869786|NCT05591742|Active Comparator|Femidur|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
33057735|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
33057736|NCT00038792|Experimental|aGvHD|
33057737|NCT00410566|Experimental|1|
33057738|NCT00410566|Experimental|2|
33057739|NCT00410566|Experimental|3|
33057740|NCT00410566|Experimental|4|
33057741|NCT00410566|Experimental|5|
33057742|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
33057743|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
33057744|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
33057745|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
33057746|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
33057747|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
33057748|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
33057749|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
33057750|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
33057751|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33057752|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
33057753|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
33334175|NCT03653208|Placebo Comparator|Placebo|Placebo group received a single placebo on Day 1.
33334176|NCT05053360|Experimental|Healing Touch|Subjects in this arm get a HT session post cesarean
32869787|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
33057754|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
33057755|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
33057756|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
33057757|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
33057758|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
33057759|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
33057760|NCT00203944||Control infants|
33057761|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
33057762|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
33057763|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
33057764|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
33057765|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
33057766|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
33057767|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
33334177|NCT05053360|Active Comparator|Control|Subjects in this arm get a control activity of equal duration
32869788|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
33334178|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
33419170|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
32869789|NCT05539170|Experimental|"micro parenting intervention"|"Parents will be instructed to bring the completed questionnaires with them to the university lab. Then, in the lab, parents will be observed interacting with their child. Following these baseline conditions, half of the parents will receive the micro parenting intervention-in the form of individual positive feedback concerning their parenting and their child's behavior."
32869790|NCT05539170|No Intervention|care-as-usual condition|Participants in the care-as-usual control condition receive no immediate positive parenting feedback but will also be taken aside without their child, receiving only the instructions of the experiment.
32869791|NCT04186429||traumatic brain injury|Children with traumatic brain injury
32869792|NCT04186429||orthopedic injury|Children with orthopedic injury
33057768|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
33057769|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
33057770|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
33057771|NCT00204412|Experimental|1|flax lignan
33057772|NCT00204412|Placebo Comparator|2|placebo
33057773|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
33057774|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
33057775|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
33057776|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
33057777|NCT00204568|Active Comparator|1|Adriamycin mono
33057778|NCT00204568|Experimental|2|Trofosfamide
33057779|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
33057780|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33057781|NCT04730661|No Intervention|Conventional arm|For the patients enrolled in this conventional arm, the decision of hospitalisation or discharge will be taken with usual criteria (pulsed oxygen saturation (SpO2) in room air <92% and respiratory rate> 22/min, respiratory rate> 30/min, Blood gas hypoxemia, decompensation of comorbidity, home monitoring not possible, other intercurrent pathology requiring hospitalization, several risk factors for COVID infection requiring hospitalization in intensive care (age> 65y, hypertension complicated by a cardiovascular event, chronic cardiovascular disease, unbalanced diabetes with complications, chronic respiratory disease (excluding well-controlled asthma), chronic renal failure dialysis, obesity, progressive cancer under treatment, congenital or acquired immunosuppression)
33057782|NCT04730661|Experimental|Interventional arm|For the patients enrolled in this interventional arm, the decision of hospitalisation or discharge will be taken with usual criteria and the result of Sit to Stand Test.
33057783|NCT00204763|Active Comparator|2|Solid state catheter
33057784|NCT00204763|Experimental|A|
33057785|NCT04730310||Regional Anesthesia (RA)|"RA~Includes spinal, epidural, peripheral nerve block, excludes local infiltration (unlikely that any major open revascularization can be done under local)~Defined as: NSQIP Principal (ANESTHES) or additional (ANESTHES_OTHER) anesthesia technique = regional, spinal, epidural, or MAC (in NSQIP RA/Spinal/Local + MAC are coded as MAC; while this includes local + MAC, it would be unlikely that local anesthesia would be sufficient for open revascularization)"
33057786|NCT04730310||General Anesthesia (GA)|"GA~Defined as: NSQIP Principal or additional anesthesia technique = general~Since GA is selected as the principal anesthetic technique by default when multiple techniques are present, GA + RA could potentially have been coded as GA if the optional variable of additional anesthesia technique is not filled in, leading to differential misclassification of patients with GA + RA (most likely epidural and peripheral nerve block) in the GA group."
33057787|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
33057788|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
33057789|NCT00204919|Placebo Comparator|1|
33057790|NCT00204919|Active Comparator|2|
33057791|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
33057792|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
33057793|NCT00205075||Case|
33057794|NCT00205075||Control|
33057795|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
33057796|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
33334179|NCT03743844|No Intervention|Control group|Weight management treatment as usual
33334180|NCT03957993|Experimental|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
33419171|NCT04799665||All Participants|
33419172|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
33419173|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
33419174|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
33419175|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
33112976|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
33419176|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
33419177|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
33419178|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
33419179|NCT03620071|Experimental|Control|Standard Care
33419180|NCT02123186||newborns testing for SMA|
33419181|NCT04154865|Experimental|Enrolled, eligible|Single arm for eligible subjects
33419182|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
33419183|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
33057797|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33419184|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
33057798|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
33057799|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
33057800|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
33057801|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
33057802|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
33057803|NCT04732091||Subproject 1 - acute STEMI|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure until complete a total of 50 minutes.
33057804|NCT04732091||Subproject 2 - acute STEMI initially treated with fibrinolytic|Participants with acute STEMI initially treated with fibrinolytic therapy within 12 hours will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI; High MI will continue after PCI procedure until complete a total of 50 minutes.
33057805|NCT04732091||Subproject 3 - NSTEMI|Participants with NSTEMI or with high-risk unstable angina will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
33419185|NCT02123264|No Intervention|No intervention|No intervention
33419186|NCT04132869|Experimental|Experimental Group|In Spring of 2020, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in Spring), will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule. *Note these activities were delay due to schools shutting down in March 2020 because of COVID-19 In Fall 2021 all 6th graders who attend the Wave 3 intervention schools, will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule.
33334181|NCT03957993|Active Comparator|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
33334182|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
33334183|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
33057806|NCT04732091||Subproject 4 - No reflow|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2 MI) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
33334184|NCT03953469|No Intervention|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
32740930|NCT04969991|Experimental|Varespladib: 250 mg TID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, in the afternoon, and in the evening.
32740931|NCT04969991|Placebo Comparator|Placebo|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, in the afternoon, and in the evening.
32740932|NCT04969991|Experimental|Varespladib: 250mg BID (Part 2 of trial)|Dose chosen for Part 2 was twice a day dosing. For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, and in the evening.
32740933|NCT04969991|Placebo Comparator|Placebo (Part 2 of trial)|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, and in the afternoon.
33057807|NCT04732091||Subproject 6 - Pre-hospital care (ambulance)|Participants with acute STEMI routing from the ambulance to the emergency department will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
33057808|NCT00072462|Active Comparator|Anastrozole|
33057809|NCT00072462|Active Comparator|Tamoxifen|
33057810|NCT00205426|Experimental|Natrecor infusion|Nesiritide
33057811|NCT00205543|Experimental|1|suture palate after resection
33057812|NCT00205543|Experimental|2|suture one side of palate afer resection
33057813|NCT00205543|Experimental|3|no sutures in palate after resection
33057814|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33057815|NCT00206011|Experimental|1|
33057816|NCT00206011|Other|2|
33057817|NCT04732247|Experimental|Oxytocin nasal spray|4x per day (QID) intranasal treatment with oxytocin (48 IU per dose)
33057818|NCT04732247|Placebo Comparator|Placebo nasal spray|4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
33057819|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
33057820|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
33057821|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
33057822|NCT00399204|Active Comparator|Control|Metformin
33057823|NCT00399204|Experimental|Experimental|Pioglitazone
33057824|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
33057825|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
33057826|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
33057827|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
33057828|NCT00411229|No Intervention|2|
33057829|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33057830|NCT00206596|Experimental|Arm 1|
33057831|NCT00206596|Placebo Comparator|Arm 2|
33057832|NCT00206635||Group 1|
33057833|NCT00206674|Experimental|Arm 1|
33057834|NCT00206674|Placebo Comparator|Arm 2|
33057835|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
32740480|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
33334185|NCT03953469|Active Comparator|Group II|"Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.~15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.~blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
33334186|NCT05665920|Active Comparator|Standard Whole breast Radiotherapy|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
33334187|NCT05665920|Experimental|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated radiation: Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
33334188|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
33057836|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
33057837|NCT00206713|Experimental|Arm 1|
33057838|NCT00206713|Placebo Comparator|Arm 2|
33057839|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
33057840|NCT00206830|No Intervention|Control-Blinded from Results|
33057841|NCT00206830|Experimental|Access to Results|
33057842|NCT00206947|Active Comparator|1|
33057843|NCT00206947|Placebo Comparator|2|
33057844|NCT00206986|Experimental|1|
33057845|NCT00206986|Experimental|2|
33057846|NCT00207064|Experimental|1|
33057847|NCT00207103|Experimental|1|
33057848|NCT00207103|Experimental|2|
33057849|NCT00207103|Experimental|3|
33057850|NCT00207103|Experimental|4|
33057851|NCT00207103|Experimental|5|
33057852|NCT00207103|Experimental|6|
33057853|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
33057854|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
33057855|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
33057856|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
33057857|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
33057858|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
33057859|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
33057860|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
33057861|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
33057862|NCT00424450||PAD patients|30 PAD patients
33057863|NCT00424606|Experimental|1|
33057864|NCT00424606|Experimental|2|
33057865|NCT00068874|Active Comparator|1|Educational comparison group
33057866|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
33057867|NCT00068874|No Intervention|3|Comparison control group with no active intervention
33057868|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
33057869|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
33057870|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
33057871|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
33057872|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
33057873|NCT00208156|Experimental|mifepristone|
33334189|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
33334190|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
33112977|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
33112978|NCT04626219|Experimental|1|Period of 12 hours where participants eat regulated meals
33112979|NCT04626219|Experimental|2|Period of 12 hours where participants do not eat anything
33112980|NCT04681820||flumatinib|flumatinib 600mg QD, fasting administration
33112981|NCT04681820||nilotinib|nilotinib 400mg BID, fasting administration
33112982|NCT04626063|Active Comparator|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
33112983|NCT04626063|Experimental|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
33112984|NCT04626063|Active Comparator|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
33112985|NCT04681976|Experimental|Intervention group|Intervention Group participants will perform a 3-month telematic dance program based on choreographic work, 2 times per week
33112986|NCT04681976|No Intervention|Control group|Control group will follow their daily routine without added exercise
33112987|NCT04625985|Experimental|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
33112988|NCT04625985|Placebo Comparator|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
33112989|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
33112990|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
33112991|NCT04653987||Puncture angle : ≤30 (group I) >30 (group II)|The patients will be divided into two groups based on the puncture angle: ≤30° group and >30° group. The two groups will be retrospectively analyzed for technical success, fluoroscopy time and complications.
33112992|NCT04653987||Technical Parameters of all Interventions|Peripheral bile duct diameter, central bile duct diameter, number of punctures, type of drainage and total fluoroscopy time will be noted.
33112993|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
33112994|NCT02905526|Placebo Comparator|Control|App only
33112995|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
33112996|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
33112997|NCT04654065|Experimental|IN-C004|IN-C004
33112998|NCT04654221||Male, BMI <= 24.9|Male subjects with a BMI of less than or equal to 24.9
33112999|NCT04654221||Female, BMI <= 24.9|Female subjects with a BMI of less than or equal to 24.9
33113000|NCT04654221||Male, BMI 25-29|Male subjects with a BMI of 25 to 29
33113001|NCT04654221||Female, BMI 25-29|Female subjects with a BMI of 25 to 29
33113002|NCT04654221||Male, BMI >29|Male subjects with a BMI of greater than 29
33113003|NCT04654221||Female, BMI >29|Female subjects with a BMI of greater than 29
33113004|NCT04654182|Experimental|Log reduction in bacterial count|Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
33113005|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
33113006|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
33113007|NCT04625712|Experimental|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
33113008|NCT04625712|Active Comparator|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
33113009|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
33113010|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
33113011|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
33113012|NCT04653870|Experimental|cyriax manipulation|cyriax manipulation have three types of classes, rotation, extension and anti-deviation, which is further divided into subclasses. On the inferior level of lumber spine L4-L5 and L5-S1rotation intervention of manipulation are capable of having striking effects of decreasing herniation. First of all we have to perform the simple 'stretch' on lumber spine, which is being the little rotation pressure applied on the body. The patient position of the body is in side lying with the effected side upward so that the outside part of the joint are separated easily on the involved side. After that, whenever it is essential by making use of femur as a rigid bar or support, this maneuver is go along with powerful rotation technique.
33334191|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
33334192|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
33334193|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
33334194|NCT00038649|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
33334195|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
33057874|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
33057875|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
33057876|NCT00208234|Placebo Comparator|Control|Placebo
33057877|NCT00208234|Experimental|2|Omalizumab
33057878|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
33057879|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
33057880|NCT00208312|Experimental|1|Regadenoson
33057881|NCT00208312|Active Comparator|2|Adenoscan
33057882|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
33057883|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
33057884|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
33057885|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
33057886|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
33057887|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
33057888|NCT00208429|Other|Pinnacle Acetabular System|
33057889|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
33057890|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
33057891|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
33057892|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
33057893|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
33057894|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
33057895|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
33057896|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
33057897|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
33057898|NCT00208702|Experimental|sertraline + triiodothyronine|
33057899|NCT00208702|Placebo Comparator|sertraline + placebo|
33057900|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
33334196|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
33334197|NCT04893070||COVID+|Questionnaires on COVID-19 symptomatology and quality of life
33334198|NCT04893070||COVID-|Questionnaires on quality of life
33334199|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
33334200|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
33334201|NCT02941900||Non-melanoma skin cancers (NMSCs)|
33334202|NCT05666102|Other|Focus Groups|Focus groups will occur during the course of the study period.
33334203|NCT02926690|Experimental|OTS167PO|
33334204|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
33334205|NCT03723902|No Intervention|Control|No intervention
33334206|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
33334207|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
33334208|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
33334209|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
33334210|NCT03652818|Experimental|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
33057901|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
33057902|NCT04722484|Experimental|Patients with normal creatine clearance (CLCR)|Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day)
33334211|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
33334212|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
33334213|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
33334214|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
33334215|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
33057903|NCT04722484|Experimental|Normal renal function (Healthy subjects)|Subjects with creatinine clearance at pre-profile day >80 ml/min
33057904|NCT04722484|Experimental|Mildly impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min
33057905|NCT04722484|Experimental|Moderately impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min
33057906|NCT04722484|Experimental|Severely impaired renal function|Subjects with creatinine clearance at pre-profile day <30 ml/min
33057907|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
33057908|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
33057909|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
33057910|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
33057911|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
33057912|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
33057913|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
33057914|NCT00209209|Active Comparator|1|"randomisation: R-CHOP~randomisation: IFN maintenance"
33057915|NCT00209209|Experimental|2|"randomisation: R-FC~randomisation: Rituximab maintnenance"
33057916|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33057917|NCT00209443|Experimental|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
33057918|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
33057919|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
33057920|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
33057921|NCT00411424|Experimental|1|
33057922|NCT00411424|Placebo Comparator|2|
33057923|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
33057924|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
33057925|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
33057926|NCT00209521|Experimental|fospropofol|
33057927|NCT00209521|Active Comparator|propofol|
33057928|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
33057929|NCT00209716|Experimental|1|
33057930|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
33057931|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
33057932|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
33057933|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
33057934|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
33334216|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
33334217|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
33334218|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
33057935|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
33057936|NCT04722328||CNS infection|
33057937|NCT04722328||Non-CNS infection|
33057938|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
33057939|NCT02966574|Experimental|metastatic breast cancer|
33057940|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
33057941|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks~--------------------------------------------------------------------------------"
33057942|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
33057943|NCT00211783||Autism|
33057944|NCT00211783||Control|
33057945|NCT00211822||Pathologic Gamblers|
33057946|NCT00211822||Obsessive Compulsive Disorder|
33057947|NCT00211822||Healthy Controls|
33057948|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
33057949|NCT00211939|Experimental|1|PhosLo + atorvastatin
33057950|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
33057951|NCT00211978|Experimental|PhosLo|
33057952|NCT00211978|Placebo Comparator|placebo|
33057953|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
33057954|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
33057955|NCT00212056|Active Comparator|ANP|
33057956|NCT00212056|Placebo Comparator|Control|
33057957|NCT00212095|Experimental|docetaxel and ketoconazole|
33057958|NCT00212212|Experimental|1|200 µg selenium as selenate
33057959|NCT00212212|Experimental|2|400 µg selenium as selenate
33057960|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
33057961|NCT00212212|Placebo Comparator|4|placebo tablet
33057962|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
33057963|NCT00069381|Experimental|study arm|
33057964|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
33057965|NCT00411580|Experimental|1|CAD106
33057966|NCT00411580|Placebo Comparator|2|Placebo
33057967|NCT00411658|Experimental|Investigational Device|
33057968|NCT00411658|Active Comparator|Cryopreserved|
33057969|NCT00411697|Experimental|Group A|
33057970|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
33057971|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
33057972|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
33057973|NCT00411814|Placebo Comparator|Placebo|Saline
33057974|NCT00411814|Active Comparator|Active|GSK679586
33057975|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
33057976|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
33057977|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
33057978|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
33057979|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
33057980|NCT00212797|Placebo Comparator|Placebo|
33057981|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
33057982|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
33057983|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
33057984|NCT00213265|Active Comparator|1|
33057985|NCT00213265|Experimental|2|
33057986|NCT00213304|Experimental|varicella vaccine (VARIVAX)|varicella vaccine (VARIVAX)
33057987|NCT00213421||1|
33057988|NCT00213421||2|
33057989|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
33057990|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
33057991|NCT00213928|No Intervention|Control|
33334219|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
33057992|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
33057993|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
33057994|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
33057995|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
33057996|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
33057997|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
33057998|NCT00214162|Other|1|internet access and computer for 1 year
33057999|NCT00214162|Experimental|2|computer and Full CHESS
33058000|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
33058001|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
33058002|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
33058003|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
33058004|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
33058005|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
33058006|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
33058007|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
33058008|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
33058009|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
33058010|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
33058011|NCT00214669|No Intervention|2|Usual Care
33058012|NCT00397202|Active Comparator|The DivaCupTM|
33058013|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
33058014|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
33058015|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
32740934|NCT05660421|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO and corticosteroids PO or IV. Patients may undergo endoscopy and skin biopsy throughout the study. Patients also undergo blood collection throughout the study.
32740935|NCT05594355|Experimental|Arm 1|Treatment with EGb 761® (TEBOFORTAN 240 mg) during 24 months.
32740936|NCT05594355|No Intervention|Arm 2|No Treatment during 12 months and treatment with EGb 761® (TEBOFORTAN 240 mg) for the next 12 months.
32740937|NCT05646927||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction.
32740938|NCT05646927||Group None|The parent of the children who will accompany them during the perioperative period will be determined according to randomization.
32740939|NCT04939571||Preterm born infants treated for ROP|
32740940|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
32740941|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
32740942|NCT04447131||Respiratory symptoms but negative for COVID-19|Negative for SARS-CoV-2. But with respiratory symptoms
33058016|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
33058017|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
33058018|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
33058019|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
33058020|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
33058021|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
33058022|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
33058023|NCT00041483|Active Comparator|Anecortave and Sham PDT|
33058024|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
33058025|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
33058026|NCT00215605|Experimental|1|
33058027|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
33058028|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
33058029|NCT04722406||Low TGR group|Patients with low level of TGR determined by X-tile program
33058030|NCT04722406||High TGR group|Patients with high level of TGR determined by X-tile program
33058031|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
33058032|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
33058033|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
33058034|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
33058035|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
33334220|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
33334221|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
33334222|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
33334223|NCT05665010||premature ovarian insufficiency|Patients with premature ovarian insufficiency (female age <40 years, menopause or menstrual rarity for 4 months, basal FSH > 25 IU / L for two consecutive intervals of more than 4 weeks)
33334224|NCT05665010||declined ovarian function|Patients with diminished ovarian reserve(women before 40 years old; the number of antral follicles in both ovaries is less than 6, AMH < 1.1ng/ml, and basal FSH > 10 IU / L, which meets one of the three requirements)；Female with menopause between the age of 40 and 45.
33058036|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
33058037|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
33058038|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
32871632|NCT00303901|Experimental|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
33058039|NCT00216190|Experimental|Dexmedetomidine|
33058040|NCT00216190|Active Comparator|Midazolam|
33058041|NCT04722211|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
33058042|NCT04722211|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
33058043|NCT00216463|Experimental|A|Slow load with every other week maintenance
33058044|NCT00216463|Experimental|B|Slow load with every other week maintenance
33058045|NCT00216463|Experimental|C|No load; once weekly maintenance
33058046|NCT00216463|Experimental|D|No load; once weekly maintenance
33058047|NCT00216463|Experimental|E|No load; once weekly maintenance
33058048|NCT00216580|Experimental|Risperidone, long-acting injectable|
33058049|NCT00041561|Placebo Comparator|2|Nitrogen gas
33058050|NCT00041561|Experimental|1|Inhaled Nitric Oxide
33058051|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
33058052|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
33058053|NCT00216853||Patients with Recurrent UTI|
33058054|NCT00216853||Healthy controls|
33058055|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
33058056|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
33058057|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
33058058|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
33058059|NCT00412048|Other|ALZHEIMER DISEASE|
33058060|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
33058061|NCT00412048|Other|CONTROLS|
33058062|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
33058063|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
33058064|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
33058065|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
33058066|NCT00412204|Active Comparator|1|Tiotropium
33058067|NCT00412204|Placebo Comparator|2|Placebo
33058068|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
33334225|NCT03619902|Experimental|Imsidolimab|Participants received imsidolimab 750 mg intravenously (IV) on Day 1 followed by administration of 3 doses of subcutaneous (SC) imsidolimab 100 mg on Days 29, 57, and 85.
33334226|NCT05665322|Active Comparator|Control|
33334227|NCT05665322|Experimental|Porto-scanner guidance with Angio-CT|
33334228|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
33334229|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
33334230|NCT03726866|Experimental|Sequence 1|Sequence 1
33334231|NCT03726866|Experimental|Sequence 2|Sequence 2
33334232|NCT03726866|Experimental|Sequence 3|Sequence 3
33334233|NCT03726866|Experimental|Sequence 4|Sequence 4
33334234|NCT03726866|Experimental|Sequence 5|Sequence 5
33334235|NCT03726866|Experimental|Sequence 6|Sequence 6
33334236|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
33334237|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
33334238|NCT05666024||Parturients|Maternity about to give birth
33334239|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
33334240|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
33334241|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
33058069|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33058070|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
33058071|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
33058072|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
33058073|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
33058074|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
33058075|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
33058076|NCT04722757|Experimental|transanal IPAA|In the experimental arm, patients will undergo transanal dissection of the distal part of the rectum. After proctectomy, an ileal pouch-anal anastomosis (IPAA) will be created. A Gelpoint Path will be used to create access through the anus. Postoperative care will occur following the hospital specific protocols.
33058077|NCT04722757|Active Comparator|transabdominal IPAA|In the control group, proctectomy will occur through abdominal dissection (laparoscopy, single port laparoscopy, robotic or open). Postoperative care will occur following the hospital specific protocols.
33058078|NCT04729881|Experimental|Conventional Rehabiliation Group|"Participants 5 days a week for 4 weeks; TENS, US and neck specific exercise program will be applied.~Conventional TENS will be applied to the participants with the CefarCompex rehab400 (New Chattanooga Compex Rehab, USA) muscle rehabilitation device. It will be applied with electrodes coated with a special adhesive material for each participant for 20 minutes at a frequency of 60-120 Hz. In the study; 4 channels and 8 electrodes will be used. Electrodes will be placed paravertebrally in the cervicothoracic space, covering the painful area. The dose of the current will be increased as the patients become accustomed to the current intensity.~Continuous Ultrasound will be applied to the participants due to chronic neck pain. It will be applied at a frequency of 1MHz and a dose of 1.5 W / cm2 for 5 minutes."
33334242|NCT00413764|Experimental|1|tibolone
33334243|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
33334244|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
33334245|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
33334246|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
33334247|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
33334248|NCT04789174|Active Comparator|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
33334249|NCT04789174|Placebo Comparator|Placebo|
33334250|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
33334251|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
33334252|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
33334253|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
33334254|NCT04949074||RNA extracted from Positive NSP samples|RNA extracted from NSP samples, found positive for the presence of SARS-CoV-2
33113013|NCT04653870|Experimental|lumber decompresion|Spinal decompression therapy has been developed a treatment without surgery for the prolapsed disc and deteriorative spinal disc disease one of the considerable reason for low back pain. This noninvasive interventional treatment for herniated disc and deteriorative disc diseases operated on the principle of remarkably decreasing the pressure on the disc between vertebras.
33334255|NCT04949074||RNA extracted from Positive saliva samples|RNA extracted from saliva samples found positive for the presence of SARS-CoV-2
33334256|NCT04949074||RNA extracted from negative NSP samples|RNA extracted from NSP samples, found negative for the presence of SARS-CoV-2
33334257|NCT04949074||RNA extracted from negative saliva samples|RNA extracted from saliva samples found negative for the presence of SARS-CoV-2
33334258|NCT05582512||Clinical Characteristics of pediatric COVID-19 by the retrospective research group|Analyze all clinically visible data of hospitalized children with COVID-19 infection (different virus strains), and then find the cause of severe disease and related risk factors for disease
33058079|NCT04729881|Active Comparator|Spesific Exercise Group|Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
33058080|NCT04729881|Other|Control Group|
33058081|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
33058082|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
33058083|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
33058084|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
33058085|NCT04722367|Experimental|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
33058086|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
33058087|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
33058088|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
33058089|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
33058090|NCT00218218|Placebo Comparator|3|placebo patch
33058091|NCT00218413|Experimental|1|
33058092|NCT00218413|Experimental|2|
33058093|NCT00218413|Experimental|3|
33058094|NCT00218413|Experimental|4|
33058095|NCT00218413|Experimental|5|
33058096|NCT00218452|Experimental|Lifestyle counseling|
33058097|NCT00218569|Experimental|1|Naltrexone
33058098|NCT00218569|Experimental|2|Placebo
33058099|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
33058100|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
33058101|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
33058102|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
33058103|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
33058104|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
33058105|NCT00218803|Experimental|1|
33058106|NCT00218803|Other|2|
33058107|NCT00218842|Experimental|exercise group|individualized exercise
33058108|NCT00218842|No Intervention|control group|care as usal
33058109|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
33058110|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
33334259|NCT05582512||acute case receiving group (including children with multisystem inflammatory syndrome)|"The correlation between the microbial flora of the respiratory tract and the central nervous system and the severity of SARS-CoV2 pneumonia and host immunity (host inflammatory biomarkers, antibody library/cell receptor library, chemokines, cytokines, cell-regulated immune responses, table Epitope mapping, host transcriptome studies)~To explore the correlation between the clinical manifestations of gastrointestinal tract and liver and SARS-CoV-2 infection and the analysis of gut microbiota~To analyze the host gene factors of COVID-19 patients.~To explore the changes of brain injury biomarkers (Biomarker) in acute and chronic phases, and to analyze the correlation with changes in brain structure and other clinical factors (e.g. severity of neurological symptoms)"
33334260|NCT05582512||children's long COVID-19 tracking group|"Clarify the incidence and persistent impact of COVID-19 symptoms in children through outpatient assessment, and further analyze the factors related to preventing the development of COVID-19. / Conduct long-term follow-up through brain MRI and neurophysiological examinations to explore the effects of COVID-19 infection on children brain structure and peripheral nerve function, and analyze the association of risk factors and other clinical symptoms. A psychiatric clinical diagnostic interview was also conducted to establish a psychiatric diagnosis. The emotional and behavioral assessment scale was used to fully evaluate the mental state and family social function.~To analyze the correlation between host genes and antibody repertoire/receptor repertoire, epitope mapping, microbial phase, and prognosis of severe COVID-19 patients"
32871633|NCT00252629|Active Comparator|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
33058111|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
33058112|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
32740481|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
33058113|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
33058114|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
33334261|NCT05582512||seroepidemiological research group|Through the antibody test and the content of the questionnaire, we can better understand the epidemiology of the COVID-19. Including the proportion of asymptomatic infections, the scale of infection, the speed of transmission, etc. Vaccinated people can also learn about the speed of antibody decline
33058115|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
33334262|NCT05582512||healthy control group|"Provide a sample of the normal population of the Acute Reception Unit. To carry out respiratory microbial flora, host inflammatory biomarkers, antibody library/receptor library, chemokines, cytokines, cell-mediated immune responses, epitope mapping, brain MRI, neurophysiological examinations (neurophysiological examinations) Conduction, brain waves, sleep watch checks, etc.), brain injury biomarkers (Biomarker), healthy control group studies of host transcriptome"
33334263|NCT05579938|Active Comparator|Verum Lozenges|Active enzyme-containing lozenges to be consumed 5 times per day for 4 days
33058116|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
33058117|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
33058118|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
33334264|NCT05579938|Placebo Comparator|Identical Placebo Lozenges|Placebo lozenges to be consumed 5 times per day for 4 days
33058119|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
33058120|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
33058121|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
33058122|NCT00042185|Experimental|Dissonance intervention|
33058123|NCT00042185|Active Comparator|Healthy Weight Intervention|
33058124|NCT00042185|Active Comparator|Expressive writing control intervention|
32740482|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
33058125|NCT00042185|No Intervention|Assessment-only control condition|
33058126|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
33058127|NCT00219427||1|
33113014|NCT04654026||CAA Group|Patients with cardiovascular and cerebrovascular disease with cerebral amyloidosis
33113015|NCT04654026||None CAA Group|Patients with cardio-cerebrovascular disease without cerebral amyloid vascular disease
33334265|NCT03560258|Experimental|Arm A: p24CE/full-length Gag DNA|Participants received p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
33058128|NCT04711395||Cataract Surgery Group|
33058129|NCT04711395||Non-surgical group|
33058130|NCT00219466|Active Comparator|1|
33058131|NCT00219466|Active Comparator|2|
33058132|NCT00219739|Experimental|Imatinib mesylate 400 mg|
33058133|NCT00219739|Experimental|Imatinib mesylate 600 mg|
33058134|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
33058135|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
33058136|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
33058137|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
33058138|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
33058139|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
33058140|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
33058141|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
33058142|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
33058143|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
33058144|NCT00220285|Experimental|Arm 1|
33058145|NCT00220285|Experimental|Arm 2|
33058146|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
33058147|NCT00220324|Experimental|Arm 1|
33058148|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
33058149|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
33058150|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
33058151|NCT00412555|Experimental|1|
33058152|NCT00042653|Experimental|AMG 073|AMG 073
33058153|NCT00042653|Placebo Comparator|Placebo|Placebo
33058154|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
33058155|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
33058156|NCT04729842|Active Comparator|Group - B , Patients who recieved Bupivacaine|30 ml of 0.5% bupivacaine was injected equally divided and injected in four nerves (musculocutaneous, median, radial and ulnar nerves)
33058157|NCT04729842|Active Comparator|Group - R , Patients who received Ropivacaine|30 ml of a solution containing 0.5% ropivacaine was equally divided and injected in the four nerves (musculocutaneous, median, radial and ulnar nerves)
33058158|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
33058159|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
33058160|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
33058161|NCT00077493|Active Comparator|1|BL22 immunotoxin
33058162|NCT00077493|Active Comparator|2|antibody therapy
33058163|NCT00077493|Active Comparator|3|immunotoxin therapy
33058164|NCT00077493|Active Comparator|4|monoclonal antibody therapy
33058165|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
33058166|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
33113016|NCT04681703|Experimental|Intervention group|In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
33113017|NCT04681703|No Intervention|Conrol group|Management of hypertensive patients, usual care: verbal and written instructions during which the family nurse (FN) or general practitioner (GP) advised the patient to follow the recommendations regarding correct HBPM. A written summary of the recommendations was given to all participants by the GP or FN at the end of the training program.
33334266|NCT03560258|Experimental|Arm B: Full-length Gag DNA|Participants received full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
33334267|NCT03560258|Placebo Comparator|Arm C: Placebo|Participants received placebo at Weeks 0, 4, 12, and 24.
33334268|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
33334269|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks).~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
33113018|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
33113019|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
33334270|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks)."
33334271|NCT02707042|Other|Group A|Control
33334272|NCT02707042|Other|Group B|Amoxicillin
33113020|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
33113021|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
33113022|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
33113023|NCT04625868|Experimental|Soft tissue surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
33113024|NCT04625868|No Intervention|Soft tissue surgery - no video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
33113025|NCT04625868|Experimental|Bone/joint surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
33113026|NCT04625868|No Intervention|Bone/joint surgery - no video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
33113027|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
33113028|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
33113029|NCT04653909|Experimental|Case|A patient who was diagnosed with the calfan syndrome
33113030|NCT04625595|Experimental|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
33113031|NCT04625595|Experimental|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
33113032|NCT04625595|Experimental|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
33113033|NCT04625595|Experimental|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
33113034|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
33113035|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
33334273|NCT02707042|Other|Group C|Azithromycin
33113036|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)~or uncharacterized antibodies"
33113037|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
33113038|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
33113039|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
33113040|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
32869793|NCT05629221|Experimental|TreC Diabete App users|"Sixty individuals allocated to the intervention group are prescribed with the TreC Diabete App for 12 months, one of the App created within the so-called TreC platform, which enables citizens from PAT to access, manage and share information about their health and wellbeing in the context of telemedicine. The use of the App is additional to the standard care, based on the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face."
32869794|NCT05629221|No Intervention|non-App users|"Sixty individuals are allocated to the control group. These participants will receive standard care, which is the best care for T2DM in line with the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face. Participants are asked to register their data as per routine (e.g. paper diary)."
32869795|NCT05697666||Moderate to severe ARDS adult patients under mechanical ventilation and neuromuscular blockade|no intervention
33113041|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
33113042|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
33113043|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
33113044|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
33113045|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
33334274|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
33334275|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
33334276|NCT04779970|Experimental|STOP: Caucasian patients|Cessation of treatment
33113046|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
33113047|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
33334277|NCT04779970|Experimental|STOP: non-Caucasian patients|Cessation of treatment
33113048|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
33334278|NCT04779970|No Intervention|Control group|Standard of care follow-up
33334279|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
33334280|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
33334281|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
33113049|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
33334282|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
33334283|NCT03625180||Treatment|NAMIC technique
33334284|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
33334285|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
33334286|NCT02607046|Experimental|Exercise|Exercise Training
33334287|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
33334288|NCT05576038|Active Comparator|L-Tryptophan|"L-tryptophan* supplements (Tryptan, Valeant Canada LP): each treatment capsule contains 500 mg of L-Tryptophan; talc and magnesium stearate.~Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
32869796|NCT04476511|Active Comparator|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
32869797|NCT04476511|Active Comparator|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
33113050|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
33113051|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
33113052|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
33334289|NCT05576038|Placebo Comparator|L-Leucine|"500 mg of L-Leucine. Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
33058167|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
33058168|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
33334290|NCT04714762|Experimental|Intervention (eMOM GDM application)|Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
33334291|NCT04714762|No Intervention|Control|Participants in the control group will meet a study nurse 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
33058169|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
33334292|NCT05573932|Experimental|Leaderboard group|The group that has access to weekly leaderboards and on-demand videos.
33058170|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
33058171|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
33334293|NCT05573932|Active Comparator|Take-home packet group|The group that has access to paper take-home packets.
33334294|NCT05568394|Experimental|Intervention group|Manual therapy and therapeutic exercise
32869798|NCT04275999|Other|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
32871634|NCT00252629|Sham Comparator|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
33058172|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
33058173|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
33058174|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
33334295|NCT05568394|Experimental|Control group|Routine physical therapy
33334296|NCT05566600|Experimental|Dose level 1|100 million iPSC-CMs administration
33334297|NCT05566600|Experimental|Dose level 2|200 million iPSC-CMs administration
33334298|NCT05566600|Experimental|Dose level 3|400 million iPSC-CMs administration
33334299|NCT05566600|No Intervention|Control|Participants will received CABG surgery only
33058175|NCT00221065|No Intervention|1|Control
33058176|NCT00221065|Experimental|2|CPAP
33058177|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
33334300|NCT02599714|Experimental|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
33334301|NCT02599714|Experimental|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
33058178|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
33058179|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
33058180|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
33058181|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
33058182|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
33058183|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
33058184|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
33334302|NCT04660240|Active Comparator|Abluminus Sirolimus Eluting Stent System (ASES)|The Abluminus sirolimus eluting stent manufactured by Envision and distributed by Concept Medical.
33058185|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
33058186|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
33058187|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
33058188|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
33058189|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
33113053|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
33113054|NCT03454737|Experimental|mesenchymal stem cells|
33113055|NCT03454737|Active Comparator|Pure platelet-rich plasma|
33113056|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
33113057|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
33113058|NCT04625322|No Intervention|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
33113059|NCT04625322|Experimental|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
33113060|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
33113061|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
33113062|NCT04653519|Experimental|Virtually guided minimally invasive preparation|
33113063|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
33113064|NCT02904746|No Intervention|Control|Care as usual
33113065|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
33334303|NCT04660240|Experimental|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|The Orsiro sirolimus eluting stent manufactured by Biotronik.
33334304|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
33334305|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
33334306|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
33334307|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
33334308|NCT03723356||MS Patients|Definite diagnosis of RRMS
33334309|NCT03723356||Healthy Controls|gender aged match healthy
33334310|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
33334311|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
33334312|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
33113066|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
33113067|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
33113068|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
33113069|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
33113070|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
33113071|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
33113072|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
33113073|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
33113074|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
33334313|NCT04575688|Active Comparator|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
33334314|NCT04575688|Active Comparator|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
33334315|NCT05536960|Experimental|68Ga-Dotatate PET/CT|These patients will undergo a 68Ga-Dotatate PET/CT scan.
33334316|NCT05528848|Experimental|[11C]carfentanil PET/CT|"Study imaging will be performed using a whole-body PET/CT scanner. Each participant will receive ≤ 15 mCi of [11C]carfentanil intravenously (approximate range for most studies is anticipated to be 5-15 mCi ). Participants will undergo dynamic PET/CT imaging over the brain, the scan will take approximately 90 minutes. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive [11C]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the [11C]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
33058190|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
33058191|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
33058192|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
33058193|NCT00123292|Experimental|1|
33058194|NCT00123292|Experimental|2|
33058195|NCT00123292|Experimental|3|
33058196|NCT00123292|Experimental|4a|
33058197|NCT00123292|Experimental|4b|
33058198|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
33058199|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
33334317|NCT04561648|Experimental|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
33058200|NCT02958085|Experimental|NNC0174-0833|
33058201|NCT02958085|Placebo Comparator|Placebo|
33058202|NCT00123526|Experimental|1|Worksite intervention
33058203|NCT00123526|No Intervention|2|Receive no intervention
33058204|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
33058205|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
33058206|NCT00043082|Active Comparator|carboplatin|carboplatin alone
33058207|NCT00123916|Experimental|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
33058208|NCT00123916|Placebo Comparator|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
33058209|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
33058210|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
33058211|NCT00073827|Placebo Comparator|3|Placebo MDI QID
33058212|NCT02970539|Experimental|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)~HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets~Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
33058213|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
33058214|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
33058215|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
33058216|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
33058217|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
33058218|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
33058219|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
33058220|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33058221|NCT00402415|Experimental|1|
33058222|NCT04727476||Children with attention deficit disorders|children aged 7-13 years who have attended a specialised outpatient clinic treating children with attention deficit disorders i in the period from 1 April 2013 to 5 November 2019.
33334318|NCT04561648|Active Comparator|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
33058223|NCT00124306|Active Comparator|1|Amitryptiline
33058224|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
33058225|NCT00124345|Experimental|1|
33058226|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
33058227|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
33058228|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
33058229|NCT00124540|Experimental|2|misoprostol
33058230|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
33058231|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
33058232|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
33058233|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
33058234|NCT00124969|Active Comparator|1|Amlodipine
33058235|NCT00124969|Placebo Comparator|2|Placebo
33113075|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
33334319|NCT04792060|Experimental|adult patients with distal ulna fractures|adult patients with distal ulna fractures
33334320|NCT04540822|Experimental|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
33334321|NCT04540822|Active Comparator|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
33334322|NCT03981822|Active Comparator|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
33334323|NCT03981822|Active Comparator|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
33334324|NCT03981822|Active Comparator|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
33334325|NCT03981822|Placebo Comparator|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
33334326|NCT03981822|Active Comparator|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
33334327|NCT03981822|Placebo Comparator|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
33058236|NCT00125008|Experimental|1|Typhoid Vi vaccine
33058237|NCT00125008|Active Comparator|2|Hepatitis A vaccine
33058238|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
33058239|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
33058240|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
33058241|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
33058242|NCT04729998|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
33058243|NCT04729998|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
33058244|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
33058245|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
33058246|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
33058247|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
33058248|NCT00125827|Experimental|1|Single-arm, dose escalation
33058249|NCT02970617|Active Comparator|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
33058250|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
33058251|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
33058252|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
33058253|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
33058254|NCT00402532|Active Comparator|Everolimus|
33058255|NCT00402532|Active Comparator|Mycophenolatmofetil|
33058256|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
33058257|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
33058258|NCT00126217|Experimental|1|
33058259|NCT00126217|No Intervention|2|
33058260|NCT00126334|Active Comparator|1|Liberal transfusion threshold
33058261|NCT00126334|Experimental|2|Conservative transfusion threshold
33058262|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
33058263|NCT00126373|Experimental|buproprion|bupropion pill
33058264|NCT00126412|Experimental|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq [9.0 to 11 mCi] of 123I-mIBG). Doses of 123I-mIBG for children <18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children <8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq [1.9 to 2.2 mCi]) was permissible."
33334328|NCT03981822|Active Comparator|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
33058265|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33058266|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
33058267|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
33334329|NCT03981822|Placebo Comparator|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
33334330|NCT03704818|Experimental|Dapagliflozin 5mg|
33334331|NCT03704818|Experimental|Placebo|
33334332|NCT05506930|Active Comparator|Intrathecal Morphine|Intrathecal Morphine: spinal (neuraxial) dose of preservative free morphine (duramorph), usually about 4-5mcg/kg
33334333|NCT05506930|Active Comparator|quadratus lumborum block|Quadratus Lumborum Block: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per kg per side (total dose approximately 1mL/kg).
33334334|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
33334335|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
33334336|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
33058268|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
33058269|NCT00126724|Placebo Comparator|4|
33058270|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
33058271|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
33058272|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
33058273|NCT00399438|Other|1|0 mg
33058274|NCT00399438|Other|2|25 mg
33058275|NCT00399438|Other|3|100 mg
33058276|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
33058277|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
33058278|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
33058279|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
33058280|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
33058281|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
33058282|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
33058283|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
33058284|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
33058285|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
33058286|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
33058287|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
33058288|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
33058289|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
33058290|NCT00127114|Experimental|Amantadine|
33058291|NCT00127114|Placebo Comparator|Placebo|
33058292|NCT00399477|Active Comparator|Rasagiline mesylate|
33058293|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
33058294|NCT00127270|Experimental|1|Darifenacin
33058295|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
33334337|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
33334338|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
33334339|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
33058296|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
33058297|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
33058298|NCT00399594|Experimental|A|Targeted LV lead placement
33058299|NCT00399594|Active Comparator|B|Usual LV lead placement
33058300|NCT04727008|Experimental|CXCR4 modified anti-BCMA CAR T cell therapy|CAR T cell therapy
33334340|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
33334341|NCT03625336||Prostate Calcifications|Men with prostate calcifications
33334342|NCT04329754|Other|iPure|"A new single-piece hydrophobic acrylic IOL (IPure IOL). The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
33334343|NCT04329754|Other|ZCB00|"A standard IOL (ZCB00).The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
33334344|NCT04322656|Active Comparator|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
33058301|NCT04726657|Active Comparator|Premixed Insulin|Premixed Human Insulin
33058302|NCT04726657|Active Comparator|Premixed insulin|Premixed Insulin Analog
33058303|NCT04726735||Patients with histologically documented normal bladder|
33058304|NCT04726735||Patients with histologically documented Non Muscle Invasive Bladder Cancer|
33058305|NCT04726735||Patients with histologically documented Muscle Invasive Bladder Cancer|
33058306|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
33058307|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
33058308|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
33058309|NCT04711434|Experimental|Prevention group|Toripalimab: 240mg IV every 3 months for a year
33058310|NCT04711434|No Intervention|Follow-up group|Routine follow-up, no intervention
33058311|NCT00128245|Experimental|Pimecrolimus 0.3%|ASM981 0.3%
33058312|NCT00128245|Experimental|Pimecrolimus 1%|ASM981 1%
33058313|NCT00128245|Placebo Comparator|Vehicle with carbopol|
33058314|NCT00128245|Placebo Comparator|Vehicle without carbopol|
33058315|NCT04711629|Experimental|Smoker COPD|Patients who continue to smoke
33058316|NCT04711629|Active Comparator|Ex-smoker COPD|Patients who quit smoking.
33334345|NCT04322656|No Intervention|Control eye|The contralateral eye will serve as control eye
33334346|NCT04891978|Experimental|AIRQ, Asthma Checklist, and PRECISION Program|All participants in the trial will be given the behavioral interventions which include the AIRQ tool, the Asthma Checklist tool, and the PRECISION program educational resources.
33058317|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
33058318|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
33058319|NCT05562505|Active Comparator|Venovenous ECMO|Patients allocated to the ECMO strategy be initiated on VV ECMO and commenced on anticoagulation within <24 hours after being enrolled. Following VV ECMO initiation, the sweep gas will be gradually turned up to target a respiratory alkalosis (pH > 7.45; maximum 20% increase every 6 hours; PaCo2 < 35 mmHg), to reduce the patient's intrinsic respiratory drive. Following this, the patient will be de-sedated, and when clinically appropriate, extubated. The awake patient will be assessed daily to participate in physiotherapy: which includes sitting up, sitting out of bed, speech assessment and, where appropriate, mobilisation.
33058320|NCT05562505|No Intervention|Standard care|Patients allocated to the standard care arm will receive routine intensive care for hypoxic respiratory failure, including mechanical ventilation with a lung protective strategy (low tidal volumes, pressures and positive end expiratory pressure titration), weaning of sedation and assessment for extubation. Patients who continue to deteriorate will be eligible for initiation of VV ECMO if they meet the ECMO to rescue lung injury in severe ARDS (EOLIA) criteria: Partial pressures of arterial oxygen (PaO2):Fraction of inspired oxygen (FiO2)<50 for 3 hours, PaO2:FiO2<80 for 6 hours, pH<7.25 with PaCO2 >60 for >6 hours.
33058321|NCT05562427||1|
33058323|NCT05562271|Sham Comparator|sham radiation therapy|sham radiation therapy
33058324|NCT05562271|Experimental|low-dose radiation therapy, 30 cGy/6 fx (experimental 1)|low-dose radiation therapy, 30 cGy/6 fx
33058325|NCT05562271|Experimental|low-dose radiation therapy, 300 cGy/6 fx (experimental 2)|low-dose radiation therapy, 300 cGy/6 fx
33058326|NCT05562232|Experimental|Intervention group|Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.
32869799|NCT04275999|Experimental|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
33058327|NCT05562232|No Intervention|Control group|The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.
33058328|NCT05562232|Placebo Comparator|Placebo|Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.
33058329|NCT04730505|Experimental|Patient App + HCP Portal (Cohort 1)|Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
33334347|NCT03980808|Experimental|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
33334348|NCT03980808|Sham Comparator|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
33334349|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
33334350|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
33334351|NCT04886518|Active Comparator|High dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
33334352|NCT04886518|Active Comparator|Low dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
33334353|NCT04886518|Placebo Comparator|Placebo|"Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
32869800|NCT04275999|Experimental|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
32869801|NCT05543772|Experimental|Normal saline|Study will be held in King Fahad University Hospital during a year after obtaining the IRB approval. Selection of study participants will be depending on their health status and the investigators will exclude pediatric participants. Two blood samples will be collected from participants. First one is after the insertion of the intravenous peripheral line. The second is after fluid infusion through the same line. Samples will be sent to the laboratory then. Results will be collected and analyzed.
33334354|NCT03650556|Experimental|Ablation|Enrolled subjects who had the investigational catheter inserted into their vasculature for pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE).
33334355|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
33334356|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
33334357|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
33058330|NCT04730505|Experimental|Patient App Alone (Cohort 2)|Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
33058331|NCT05562154|Active Comparator|Lateral Approach|
33058332|NCT05562154|Active Comparator|Anterior Approach|
33058333|NCT05562076|Experimental|ZENFLEX ® Pinto|subjects using the spot stent(ZENFLEX ® Pinto) system
33058334|NCT05562076|Active Comparator|Everflex|subjects using the bare stent(Everflex) system
33058335|NCT05561998|Experimental|TalkingMats intervention group|Participants will use TalkingMats as a decision aid for the needs-assessment conversation as well as in conversations planning the provision of social care.
33058336|NCT05561998|Active Comparator|Usual conversation methods control group|Participants will use usual conversation methods in both the needs-assessment conversation and the provision planning conversations.
33058337|NCT05561920||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 6-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
33058338|NCT05561725|Active Comparator|Standard of Care: Control|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects."
33058339|NCT05561725|Experimental|Dexamethasone|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses."
33058340|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
33334358|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
33058341|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
33058342|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
33058343|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
33058344|NCT05561686||Pyrotinib-based combination therapy|Pyrotinib, 400mg po qd, 21 days/cycle
33058345|NCT00044291|Experimental|Atamestane + toremifene|
33058346|NCT00044291|Active Comparator|Letrozole + placebo|
33058347|NCT02965872||Healthy individuals|
33058348|NCT05561569|Active Comparator|Air tamponade group|Cases with primary upper retinal detachment that will be treated with air tamponade.
33058349|NCT05561569|Active Comparator|Non expansile gas tamponade group|Cases with primary upper retinal detachment that will be treated with sulfur-hexafluoride 6 (SF-6) gas tamponade.
33058350|NCT05561296|Other|Astigmatism correction with iris registration guided corneal relaxing incisions|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction using corneal relaxing incisions and implantation of EyHance IOL. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
33058351|NCT05561296|Other|Astigmatism correction with iris registration guided implantation of toric IOLs|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction with the implantation of EyHance toric II IOLs. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
33058352|NCT05561140|Experimental|Voxeletor + SOC (Standard of Care)|
33058353|NCT05561140|Placebo Comparator|Placebo + SOC (Standard of Care)|
33058354|NCT05561023|Other|Phase Ⅰ a clinical study|"3 + 3 dose escalation scheme"
33058355|NCT05560906||Control group|Healthy patients under 18 years of age.
33058356|NCT05560906||MIS-C group|Patients with MIS-C diagnosed, based on WHO diagnostic criteria.
33058357|NCT05558488|Experimental|Meatless restrictive ketogenic diet|Diet was designed to be isoproteic (1.8 g x Kg- 1 x body weight- 1 x day-1) with three meals a day., restrictive (EER minus 500 kcal / day). The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 g x Kg-1 x body weight- 1 x day-1 (~ 25-30%), fats (~ 65-70%, with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (< 30 g x day- 1; < 10%).
33058358|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
33058359|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
33058360|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
33058361|NCT05557474||Lung cancer post surgery recurrence follow up|Lung adenocarcinoma, stage IA/IB/II/IIIA post-surgery follow up
33058362|NCT05556499||HPT patients|Patients with primary hyperparathyroidism at diagnosis (HPT) treated with parathyroidectomy (HPT-PTX)
33058363|NCT05541406|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
33058364|NCT05541406|Active Comparator|Control schools|Students in control schools will receive no intervention
33058365|NCT04729647|Other|Axillary Lymph Node Metastasis|
33058366|NCT05530018|Experimental|BCI group|Participants will be asked to participate in a brief contact intervention and to evaluate its feasibility, including the feasibility of recruitment, intervention resources, the appropriateness of data collection, and the acceptance of the intervention.
33058367|NCT05523739|Experimental|Part 1: Cohort 1|Participants will receive a single 300 mg dose of STI-1558 or placebo. Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
33058368|NCT05523739|Experimental|Part 1: Cohort 2|Participants will receive a single 600 mg dose of STI-1558 or placebo. Cohort 2 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
33058369|NCT05523739|Experimental|Part 1: Cohort 3|Participants will receive a single 1200 mg dose of STI-1558 or placebo. Cohort 3 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
33058370|NCT05523739|Experimental|Part 1: Cohort 4|Participants will receive a single 2000 mg dose of STI-1558 or placebo. Cohort 4 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
33058371|NCT05523739|Experimental|Part 2: Cohort 1|"Participants will receive a 300 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo."
33058372|NCT05523739|Experimental|Part 2: Cohort 2|"Participants will receive a 600 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 2 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
33058373|NCT05523739|Experimental|Part 2: Cohort 3|"Participants will receive a 800 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 3 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
33058374|NCT05519917|Experimental|Afatinib|Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle.
33058375|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
33058376|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
33334359|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
33058377|NCT05518669||Pulmonary Nodule|Patients with peripheral pulmonary nodules and suspicion of malignancy on chest computed tomography who are scheduled to reach the target lesion for diagnosis by guided bronchoscopy(ENB and rpEBUS).
33058378|NCT05516797|Experimental|Continuous Glucose Monitoring (CGM)|Participants in this arm will use the FreeStyle Libre 2 CGM sensor.
33058379|NCT05516797|No Intervention|Blood Glucose Monitoring (BGM)|Participants in this arm will use the Precision Xtra fingerstick blood glucose meter throughout the study.
33058380|NCT05497336|Experimental|IBI351+Cetuximab|IBI351 recommended dose+Cetuximab 500mg/m2 IV Q2W
33058381|NCT05497336|Experimental|IBI351|IBI351 recommended dose
33058382|NCT00044525|Experimental|Arm 1|
33058383|NCT05492344|Experimental|Personalized ventilation|If a patient is assigned to the intervention group, ventilator settings will be adjusted based on the lung morphology (focal or non focal) results of the lung ultrasound.
33058384|NCT05492344|Active Comparator|Standard care|Patients assigned to the control group will be ventilated according to the current standard of care.
33058385|NCT04706143||Vaccined group by live attenuated or viral vector or mRNA vaccine|Adults between 25-65 years old
33058386|NCT05469490|Experimental|Stereotactic Body Radiotherapy (SBRT) + NLG802 and navoximod|"SBRT - Initial Starting Dose:~Lung - Peripheral - 45 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 50 Gy (5 fractions) Liver - 45 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 30 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 45 Gy (3 fractions)~SBRT - Decreased DLT Dose:~Lung - Peripheral - 42 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 47.5 Gy (5 fractions) Liver - 42 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 27 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 42 Gy (3 fractions)~NLG802 - 1452mg BID (no dose decrease)~navoximod - Starting dose: 1000mg BID, Dose decrease 1: 800mg BID, Dose decrease 2: 600mg BID"
33058387|NCT05421832||PD Cohort 1|PD patients assessed via the Hoehn & Yahr (H&Y) Scale to be in Stages 1-2 of PD (inclusive)
33058388|NCT05421832||PD Cohort 2|PD patients assessed via the H&Y Scale to be in Stages 3-4 of PD (inclusive)
33058389|NCT05421832||Prodromal PD|Patients who meet PI-defined criteria for prodromal PD, i.e., the latent phase of disease progression during which clinical PD symptoms have yet to manifest
33058390|NCT05421832||Age and Sex-matched Healthy Control|Age & sex matched healthy control subjects who have not been diagnosed with PD
33058391|NCT05417425|Experimental|Omeza combination therapy and SOC with total contact cast|"Omeza's products were developed to utilize the benefits of essential omega fatty acids to reduce chronic inflammation and disrupt biofilm colonization commonly found in chronic wounds. The Omeza combination treatment under investigation in this study includes two over the counter (OTC) drugs, Omeza® Lidocaine Lavage and Omeza® Skin Protectant, and a 510(K) medical device, Omeza® Collagen Matrix.~In combination with standard of care and total contact cast, the products will be applied on a weekly basis. There will be a 14-day screening period to assess chronicity from standard of care alone. At that time treatment will be applied weekly for 4 weeks. Further treatment will be at the discretion of the PI to continue for 8 more weeks or until wound closure."
33058392|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
33058393|NCT05386225||Standardized follow-up|Participants who chose to continue guideline-prescribed, standardized follow-up one year after HNC treatment.
33058394|NCT05386225||Individualized follow-up|Participants who chose to switch to individualized follow-up one year after HNC treatment. Follow-up visits will only be scheduled based on clinical symptoms and questions, initiated by the patient.
33058395|NCT05377216|Experimental|Stellate ganglion block|All subjects will undergo stellate ganglion block during their VT ablation procedure
33058396|NCT05375032|Experimental|Cycling combined with cognitive tasks|
33058397|NCT05375032|Active Comparator|Cycling|
33058398|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
33058399|NCT05361616|Active Comparator|PBM Ortho Active device|PBM Ortho Active group will be given an active device.
33058400|NCT05361616|Sham Comparator|PBM Ortho Sham|PBM Ortho Sham device group will be given a non-active device that will not emits light.
33058401|NCT05323435|Experimental|Recombinant Two-Component COVID-19 Vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
33058402|NCT05323435|Active Comparator|COVID-19 Vaccine (Vero Cell), Inactivated|Antigen: inactivated SARS-CoV-2 Virus (19nCoV-CDC-Tan-HB02 strain) Adjuvant: aluminum hydroxide Excipients: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride
33113076|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
33113077|NCT01212991|Experimental|Enzalutamide|
33113078|NCT01212991|Placebo Comparator|Placebo|
33058403|NCT05305885|Experimental|Group 1|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total. Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
33058404|NCT05305885|Experimental|Group 2|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
33058405|NCT00044564|Experimental|Arm 1|
33113079|NCT02904863|Experimental|patients with HUS|
33334360|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
33334361|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
33058406|NCT05284552|Experimental|Intervention Arm|Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.
33058407|NCT05284552|No Intervention|Control Arm|
33058408|NCT05249062|Experimental|intervention|The intervention being piloted in this study is a novel system of supporting older individuals with multiple long-term conditions to self-manage their chronic conditions through the daily use of a digital health product that can also facilitate the remote monitoring of a person's health status.
33058409|NCT05242549|Experimental|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance)"
33058410|NCT05242549|No Intervention|wait-list|Routine care
33334362|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
33334363|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
33058411|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
33058412|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
33058413|NCT05224375|Experimental|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
33334364|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
33334365|NCT03735108||normal control group|no history of pregnancy loss
33058414|NCT05190328|Experimental|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with the Muscle energy technique."
33334366|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
33334367|NCT05666466||case group|age between 12 to 50 disproportionate SRS to PTA level presence of OAE presence of CM Normal MRI and CT
33334368|NCT05666466||control group|age and sex matched to study group Normal hearing sensitivity and excellent speech discrimination no CAPD
33058415|NCT05190328|Experimental|Active Release Technique|"Experimental: Active Release Technique: The therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient will be instructed to actively move the muscle from a shortened to lengthened position and thereby breaking adhesions.1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with active release technique"
33058416|NCT05161468|Active Comparator|Lidocaine|50 Subjects will be randomized to this group and will receive a lidocaine injection in their ACJ.
33058417|NCT05161468|Active Comparator|Corticosteroid|50 Subjects will be randomized to this group and will receive a corticosteroid injection in their ACJ.
33058418|NCT05161468|Active Comparator|Platelet Rich Plasma (PRP)|50 Subjects will be randomized to this group and will receive a PRP injection in their ACJ.
33058419|NCT05147506|Experimental|CBT DTx|Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.
33058420|NCT05147506|Active Comparator|Psychoeducations DTx|Participants randomized to the comparison group will access an unstructured educational DTx.
33058421|NCT05086237|Experimental|Reminder|Participants will be sent a text message reminder of their missed well-child visit.
33058422|NCT05086237|No Intervention|Treatment as usual|This group will receive treatment as usual, which involves no text messaging follow-up.
33113080|NCT04625439|Experimental|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
33419187|NCT04132869|No Intervention|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders. Students will be invited to join the comparison group. and will have measurements taken at baseline and 6 months. Wave 2 comparison schools (3 Schools) have a total of 363 6th graders adn will be invited to join the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
33419188|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
33419189|NCT04739995|Experimental|Low-Dose-Naltrexone (LDN)|The LDN treatment will consist of one 4.5 mg naltrexone tablet (lactose-free) taken daily for 12 months before going to sleep.
33058423|NCT05084989|Experimental|Part1: Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
33058424|NCT05084989|Placebo Comparator|Part1: Placebo control|Antigen: sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
33058425|NCT05084989|Experimental|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|(Lot# HA202107009 and Lot# TC202205002) Recombinant two-component COVID-19 vaccine (CHO cell) Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
33058426|NCT05084989|Active Comparator|Part2: COMIRNATY® COVID-19 Vaccine, mRNA|"Antigen: nucleoside-modified messenger RNA (mRNA) encoding the viral Spike (S) glycoprotein of SARS-CoV-2, called tozinameran.~Others: ((4-hydroxybutyl) azanediyl) bis (hexane-6,1-diyl) bis (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate, sucrose."
33058427|NCT05066347|No Intervention|Usual care|Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. The current usual care varies from no outpatient monitoring to short-term Holter monitoring (24 hours to 72 hours).
33058428|NCT05066347|Experimental|Prolonged 24/7 live outpatient cardiac rhythm monitoring|Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days. If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED.
33058429|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
33058430|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
33058431|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
33058432|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
33058433|NCT00078624|Active Comparator|2|Traditional exercise program
33058434|NCT05050123|Active Comparator|First episode of anxiety: standard relaxation training|During a subject's first episode of anxiety the subject will be offered a session of standard relaxation training.
33058435|NCT05050123|Experimental|Second episode of anxiety: virtual reality relaxation|During a subject's second episode of anxiety the subject will be offered a session of virtual reality exposure available through the iPhone Google Cardboard virtual reality meditation/relaxation app.
33058436|NCT05036629|Experimental|MRI protocol|Feasibility and use of methods developed in clinical research protocols or cognitive: the reproducibility of the parameters of acquisition, of the design of the activation paradigms development and results according to people will be an important element for the future integration of these methods in clinical or cognitive research protocols.
33058438|NCT04938466||Transition to long-acting growth hormone (LAGH)|Participants in this arm will transition between daily growth hormone treatment and long-acting growth hormone treatment.
33058439|NCT04938466||Consistent daily growth hormone (DGH)|Participants in this group will continue with daily growth hormone treatment.
33058440|NCT04934917||Patients with disc degenerative disease (DDD)|Patients suffering from disc degenerative disease, age 30-60 years that are on the waiting list for surgery (fusion/disc implants) at Stockholm Spine Center, Stockholm, Sweden.
33058441|NCT04934917||Healthy controls (HC)|Healthy controls matched according to age and sex, no chronic pain conditions.
33058442|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
33058443|NCT00402961|Sham Comparator|2|sham acupuncture
33058444|NCT00397553|Experimental|Insulin Glulisine|
33058445|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
33058446|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
33058447|NCT02965794||Care Pathway|Care pathways for colorectal cancer
33058448|NCT04818073|Experimental|Group A|Participants with undergo new FINGER robotic training with no physical assistance 3 times a week for a period of 3 weeks.
33058449|NCT04818073|Experimental|Group B|Participants will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
33058450|NCT04818073|Experimental|Group C|Participants will undergo new FINGER robotic training with physical assistance and proprioceptive exercises 3 times a week for a period of 3 weeks.
33058451|NCT04786717|Experimental|core muscle training|Training the endurance of the core muscle.
33334369|NCT05381818|Experimental|Daily IMT (dIMT)|IMT (inspiratory muscle training) is a treatment strategy aimed to strengthen the muscles of inspiration, the diaphragm and external intercostals, by increasing their force-generating capacity. Participants in the dIMT (daily IMT) will complete daily inspiratory training exercises 2-4 weeks prior to surgery. A pressure threshold training device containing an adjustable-tension spring to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths daily at a pressure 70% of MIP and will rest 1 minute between sets. They will be asked to keep a log to track their sessions to evaluate compliance with the exercise regimen.
33058452|NCT04786717|Experimental|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
33334370|NCT05381818|Active Comparator|Acute IMT (aIMT)|Patients in the aIMT (acute IMT) experimental group will complete a single session of IMT guided by a physical therapist within 30 minutes of anesthesia induction in addition to standard of care. The adjustable pressure threshold training device to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest 1 minute between sets. The training intensity will be set at 70% of MIP.
32869802|NCT04182451|Experimental|Meso Wound Matrix and Standard of Care|This is a single arm study
33058453|NCT04786717|Experimental|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
33058454|NCT04763083|Experimental|Phase 1 Dose escalation|Up to 9 sequential cohorts including both CLL/SLL and MCL patients
33058455|NCT04763083|Experimental|Phase 2|CLL/SLL and MCL cohorts
33058456|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
33058457|NCT04731935|Experimental|tAN Therapy|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 120 hours (5 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness.
33058459|NCT04716400|Experimental|Intervention group|"Stop sexual harassment"
33058460|NCT04716400|No Intervention|Control group|No intervention
33058461|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
33058462|NCT04686604|Experimental|Electron Health Record-based Provider Alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
33058463|NCT04686604|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
33058464|NCT04674202||Pharmaceutical interview|This group will benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
33058465|NCT04674202||No pharmaceutical interview|This group will not benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
33058466|NCT04665154|Experimental|MAS825 dose A|single i.v. dose
33058467|NCT04665154|Experimental|MAS825 dose B|single s.c. dose
33058468|NCT04665154|Placebo Comparator|Placebo dose A|single i.v. dose
33058469|NCT04665154|Placebo Comparator|Placebo dose B|single s.c. dose
33058470|NCT04612660|Experimental|Specific Education and Dynamic Group|"Motivational group education specifically focused on cervical cancer prevention;~Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;~Engaging community bilingual physicians in cervical cancer screening and referral;~Patient navigation assistance."
33058471|NCT04612660|Active Comparator|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
33334371|NCT05381818|Active Comparator|Standard of Care (SOC)|The SOC group will receive the usual surgical standard of care only.
33334372|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
33058472|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
33334373|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
33334374|NCT04880824||PG cohort|800 randomized surgical study patients with a frailty syndrome (Pre-frail and frail) of the intervention study PRÄP-GO (PG cohort). 400 study patients receive the intervention and 400 study patients receive standard of care.
33334375|NCT04880824||NFC cohort|400 non-frail surgical control group (NFC cohort)
33334376|NCT04880824||NO cohort|300 non-operative control group (NO cohort)
33334377|NCT04880824||GB cohort|Skill-Change-Management: a maximum of 30 coworkers and analysis of guiding principle: to a maximum of 35 patients, 30 relatives and 45 coworkers
33334378|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
33334379|NCT03735030|Experimental|human hCG|
33419190|NCT04739995|Placebo Comparator|Placebo|The control group will take the placebo daily (a film-coated tablet, identical to the LDN, filled with a lactose-free excipient), for 12 months, following the same guidelines.
33419191|NCT04059393|Experimental|Group I (web-based legacy intervention)|Patients participate in a web-based legacy intervention by answering questions about themselves and uploading videos, photographs, and music to create a digital story within 2 weeks.
33419192|NCT04059393|Active Comparator|Group II (standard of care)|Patients receive standard of care. Patients have the option to participate in the web-based legacy intervention after 2 months.
32740483|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
33058473|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
33058474|NCT04598425|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
33058475|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
33058476|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
33058480|NCT04543396|Experimental|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
33058481|NCT04543396|No Intervention|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
33058482|NCT04543396|Experimental|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
33058483|NCT04543396|No Intervention|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
33058484|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
33058485|NCT04515745||ILI/Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration (SSA) databases.
33058486|NCT04515745||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to SSA databases.
33058487|NCT04512274|Experimental|Test Article|The test article was applied to an open application site and to a second site of induced inflammation
33058488|NCT04457557|Experimental|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
33058489|NCT04457557|Active Comparator|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
33058490|NCT04453657|Experimental|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
33113081|NCT04625439|No Intervention|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
33113082|NCT02904551|Experimental|Experimental|Free gingival grafts
33113083|NCT02904551|Active Comparator|Control|Oral prophylaxis
33334380|NCT03735030|Active Comparator|recombinant hCG|
33334381|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
33334382|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
33334383|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
33334384|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
33334385|NCT03721978|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
32740484|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
32740485|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
32740486|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
33058491|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
33058492|NCT04731740|Experimental|Pembrolizumab + Lenvatinib|"Experimental treatment:~Lenvatinib p.o. once a day, pembrolizumab 200 mg i.v. every 21 days started 21 days after start of Lenvatinib~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
33058493|NCT04731740|Experimental|Pembrolizumab + Chemotherapy|"Experimental treatment:~Investigators' choice of the Сhemotherapy, pembrolizumab 200 mg i.v. every 21 days started 21 days after the start of chemotherapy~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
33058494|NCT04447339||Open|Prophylactic NSM cases by Open approach
33058495|NCT04430920|Active Comparator|Intensive intraoperative blood pressure management|
33058496|NCT04430920|Placebo Comparator|Conventional intraoperative blood pressure management|
33058497|NCT04428658|Experimental|Supplemental video visits|Participants in this intervention arm will receive home-based video visits with a pediatric endocrinologist every month for the duration of 6 months in addition to usual care.
33058498|NCT04428658|Active Comparator|Standard of Care|The control group will receive usual care, consisting of quarterly visits with the UCD Pediatric Diabetes Clinic.
33058499|NCT04428658|Experimental|Supplemental remote monitoring|Participants in this intervention arm will receive remote glucose monitoring with monthly asynchronous outreach from a pediatric endocrinologist for a duration of six months in addition to usual care.
33058500|NCT04425148|Experimental|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
33058501|NCT04425148|Sham Comparator|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
33058502|NCT00044915|Active Comparator|Arm 1|
33058503|NCT00044915|Placebo Comparator|Arm 2|
33058504|NCT04304911|Experimental|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
33058505|NCT04304911|Active Comparator|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
33058506|NCT04294030||Sexually active persons who self-select for HSV-2 testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
33058507|NCT04294030||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
33058508|NCT04294030||Low prevalence population|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
33058509|NCT04294030||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior; 1/2 low risk sexual behavior
33058510|NCT04263298|Experimental|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
33058511|NCT04263298|Active Comparator|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
33058512|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
33113084|NCT04625400|Experimental|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
33113085|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
33334386|NCT03721978|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
33113086|NCT04653792|Experimental|Pregabalin|Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative
33334387|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
33334388|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
33334389|NCT03723044|Experimental|healthy volunteers|
33334390|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
33334391|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
33334392|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
33334393|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
33419193|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
33334394|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
33419194|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
33058515|NCT04162210|Experimental|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W
33334395|NCT05357794|Experimental|Brentuximab vedotin|Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another
33334396|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
33334397|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
33334398|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
33334399|NCT05340790|Experimental|Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
33419195|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
33058516|NCT04162210|Active Comparator|Participants receiving pom/dex|Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.
33058517|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33058518|NCT04127110|Experimental|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
33058519|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
33058520|NCT04125589|Experimental|Speaking Activity and Talking Activity|Participants will engage in a speaking activity first and a talking activity second.
33058521|NCT04125589|Experimental|Talking Activity and Speaking Activity|Participants will engage in a talking activity first and a speaking activity second.
33058522|NCT04107961|Experimental|Vaccine arm|Vaccine in 1 ml, single dose
33058523|NCT04107961|Placebo Comparator|Placebo|1 ml normal saline , single dose
33058524|NCT04099966|Experimental|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
33058525|NCT04072276||EV71 Vaccine with Adjuvant AlPO4|EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4
33058526|NCT04072276||Adjuvant AlPO4|Placebo (Adjuvant AlPO4 only)
33058527|NCT04065451|Experimental|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
33058528|NCT04065451|No Intervention|No epinephrine|Submucosal injection fluid without epinephrine
33058529|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
33058530|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
33058531|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time~Esophagus~Skin near to carotid artery"
33058532|NCT03953131|Experimental|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
33058533|NCT03948568|Active Comparator|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
33419196|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
33113087|NCT04653792|Placebo Comparator|Pregabalin Placebo|Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative
33113088|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
33113089|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
33113090|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
33113091|NCT04625010|Experimental|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
33113092|NCT04625010|Experimental|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
33113093|NCT04625010|No Intervention|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
33113094|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
33113095|NCT02904668|Active Comparator|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
33113096|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
33113097|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
33113098|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
33113099|NCT04653558||definite LNB|patients with definite early Lyme neuroborreliosis
33113100|NCT04653558||possible LNB|patients with possible early Lyme neuroborreliosis
33113101|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
33113102|NCT04653441|Experimental|Child-only Intervention|The children in this arm will receive only child intervention curriculum (peer group activities). The child intervention includes 20 hours of facilitator-guided programming delivered in 10 sessions in a peer-group setting and aims to increase resilience by developing a number of skills including positive thinking, emotional regulation, coping, and problem solving.
33113103|NCT04653441|Experimental|Child+Caregiver Intervention|The children in this arm will receive child intervention and their caregivers will receive the caregiver intervention, At the caregiver level, caregivers receive 10 hours of facilitator-guided programming delivered in five sessions that aims to increase positive parenting skills and build the capacity of the caregiver to engage in self-care and seek support.
33113104|NCT04653441|Experimental|Child+Caregiver+Community Intervention|The children in this arm will received child intervention; their family will receive caregiver intervention and community-based intervention. At the community level, trained community advocates (e.g., teachers, village nurses) conduct monthly home visits and organize a series of community-based activities over a period of two years to promote cohesion and strength within local communities and to increase community support for affected families.
33113105|NCT04653441|No Intervention|Attention Control|Children and caregivers who do not receive any intervention activities
33334400|NCT05340790|Placebo Comparator|Placebo dose|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
33334401|NCT03434548||Cohort 1|Healthy controls. Multi-modal MRI imaging.
33334402|NCT03434548||Cohort 2|"People with Huntington's (without symptoms, early disease stage, and later disease stage), and healthy controls~People with HD divided in groups according to disease stage:~Without symptoms (approximately HD-ISS stage 0 or 1)~Early disease (approximately HD-ISS stage 2)~Later disease stage (approximately HD-ISS stage 3)"
33334403|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
33334404|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
33334405|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
33334406|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
33334407|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
33113106|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.~Duration of participation: up to 12 months post heart transplantation."
33113107|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~Duration of participation: up to 12 months post heart transplantation."
33113108|NCT00557700|Placebo Comparator|2|Administration of placebo
33334408|NCT03682302|Experimental|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
33334409|NCT03682302|Active Comparator|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
33113109|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
33113110|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
33113111|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
33113112|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
33113113|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
33113114|NCT00557739|Active Comparator|3|0.1% mometasone furoate
33113115|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
33113116|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
33419197|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
33113117|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
33113118|NCT02904122|Other|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
33113119|NCT04624932|Experimental|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
33334410|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
33334411|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
33334412|NCT03734874|Active Comparator|hesperidin|
33113120|NCT04624932|Sham Comparator|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
33113121|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
33113122|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
33113123|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
33113124|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
33113125|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
33113126|NCT02903927|Experimental|CT LUCIA|
33113127|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
33334413|NCT03734874|Placebo Comparator|control|
33419198|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
33113128|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
33113129|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
33334414|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
33419199|NCT04680871||Normal, Healthy Subjects|
33058534|NCT03948568|Active Comparator|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
33058535|NCT03938350|Experimental|Dialectical Behavior Therapy (DBT) Skills Training|Participants in this group will receive 8 weeks of Dialectical Behavior Therapy (DBT) Skills Training.
33334415|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
33334416|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
33334417|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
33419200|NCT04680871||Induced Febrile Subjects|
33419201|NCT05067075|Experimental|Blinded CGM|Blinded continuous glucose monitor Dexcom G6Pro
33419202|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
33058536|NCT03938350|No Intervention|Treatment as Usual|Participants in this study arm will receive treatment as usual consisting of routine prenatal care with any mental health assessment, social work involvement or mental health service provision based on clinician referral or self-referral.
33058537|NCT03928366|Experimental|Volunteers receiving propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
33058538|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
33058539|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
33058540|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
33113130|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
33058541|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
33058542|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
33058543|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
33058544|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
33058545|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
33419203|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
33058546|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
33058547|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
33058548|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
33058549|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
33058550|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058551|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058552|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058553|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058554|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058555|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
33058556|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
33058557|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
33058558|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
33058559|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
33334418|NCT03320434|Experimental|PRT-2761 0.5%|
33334419|NCT03320434|Experimental|PRT-2761 1%|
33334420|NCT03320434|Active Comparator|Patanol|
33334421|NCT03320434|Active Comparator|Pred-forte|
33058560|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
33334422|NCT03320434|Placebo Comparator|PRT-2761 0%|
33334423|NCT05270278||1. Eosinophilic AB - initiated biological treatment against IL-5 or IL-5R|"initiated biological treatment - mepolizumab or benralizumab~judged by the treating physician, the patient cannot indicated treatment of type anti IgE or anti IL-4R"
33058561|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
33058562|NCT03731260|Experimental|(Part 1) Avapritinib Dose 1 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
33058563|NCT03731260|Experimental|(Part 1) Avapritinib Dose 2 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
33058564|NCT03731260|Experimental|(Part 1) Avapritinib Dose 3 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
33058565|NCT03731260|Placebo Comparator|(Part 1) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
33058566|NCT03731260|Experimental|(Part 2) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
33058567|NCT03731260|Placebo Comparator|(Part 2) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
33058568|NCT03731260|Experimental|(Part 3) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
33058569|NCT03724552|Experimental|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
33058570|NCT04706104||Propofol-Ketamine|2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction
33058571|NCT04706104||Midazolam-Fentanyl|0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction
33058572|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
33058573|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
33058574|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
33058575|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
33058576|NCT03556228|Experimental|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|
33058577|NCT03519373||PER001|HIV 1-infected pregnant women
33058578|NCT03519373||PER002|HIV 1-uninfected pregnant women
33058579|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
33058580|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva~Collection of a tumor sample taken before the participation of the patient in study~Collection of blood sample if tumor sample is not available"
33058581|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
33058582|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
33058583|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
33058584|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
33058585|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
33058586|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
33058587|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
33334424|NCT05270278||2. Eosinophilic AB - initiated biological treatment against IgE or IL-4R|"initiated biological treatment - omalizumab or dupilumab~judged by the treating physician, patient cannot indicated treatment type anti IL-5 or anti IL-5R"
33334425|NCT05270278||3. Eosinophilic AB - initiated biological treatment against IgE or IL-4R, or against IL-5 or IL-5R|"initiated biological treatment - omalizumab or dupilumab, or mepolizumab or benralizumab~judged by the treating physician, the patient could be potentially indicated to treatment with all 4 alternatives"
33334426|NCT05270278||4. Non-eosinophilic AB - without indication for biological treatment|"no biological treatment initiated~judged by the treating physician, the patient cannot be indicated to biological treatment"
33334427|NCT03317080||patients with lung cancer|patients with stages I-III lung cancer eligible for surgery
33334428|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
33334429|NCT04878094|Active Comparator|Arm A|Randomized to standard technique and assessment of anastomosis without the use of NIR angiography
33113131|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
33113132|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
33113133|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
33113134|NCT04653168|Experimental|LY3041658 Low Dose|LY3041658 administered by subcutaneous (SC) injection.
33113135|NCT04653168|Experimental|LY3041658 High Dose|LY3041658 administered by SC injection.
33113136|NCT04653090||Varus group|Radiographic stem axis was assessed on standard anteroposterior hip radiographs performed at the 3-month follow-up visit. Alignment was evaluated as described by Reina et al., by the angular deviation of the anatomic femoral axis and the stem axis. The 3 degrees minimal-value was considered to be the threshold defining a varus stem.
33113137|NCT04653090||Neutral group|Alignment between anatomic femoral axis ans stem axis was less than 3°.
33113138|NCT04653012|Experimental|Macro-microelectrode implantation|Implantation of macro-micro electrodes of the Adtech Benkhe-Fried type in epileptic patients who are undergoing evaluation with intracranial EEG electrodes
33113139|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
33113140|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
33113141|NCT04653129|Experimental|Group (A): Primary nerve repair with autologous fat graft|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope with autologous fat grafting around site of repair
33113142|NCT04653129|Active Comparator|Group (B): Standard primary nerve repair|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope without fat grafting.
33113143|NCT04681547|Experimental|Genicular nerve block|An ultrasound-assisted genicular nerve block will be performed. 4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
33113144|NCT04681547|Active Comparator|Local infiltration Analgesia|Administration of ropivacaine 0.2% 150 ml will be performed.
33113145|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:~≥ 18 years~Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days~High risk of exposure to antibiotics during the stay~Written informed consent of the patient after clarification has been given~Exclusion criteria:~Already known current or documented past colonisation or infection by VRE~Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
33113146|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:~Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)~Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards~Expected stay of at least 7 days"
33334430|NCT04878094|Experimental|Arm B|Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography
33334431|NCT05232214||short eyes|Axial length under 22.5 mm
33334432|NCT05232214||long eyes|Axial length under 25.5 mm
33334433|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
33334434|NCT05231590|Other|Children Aged 5 to <12 Years|
33334435|NCT05231590|Other|Children Aged 12 to <18 Years|
33334436|NCT05231590|Other|Adults Aged 18 to 40 Years|
33334437|NCT05198752|Experimental|Neoantigen mRNA Personalised Cancer|This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.
33334438|NCT00055497|Placebo Comparator|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
33334439|NCT00055497|Experimental|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
33334440|NCT00055497|Experimental|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
33334441|NCT00055497|Experimental|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
33334442|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
33334443|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
33334444|NCT03615066|Experimental|Selgantolimod 3 mg + TAF|Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
33334445|NCT03615066|Experimental|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
33334446|NCT03615066|Placebo Comparator|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
33058588|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
33334447|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
33334448|NCT04050592|Other|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
33058589|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
33334449|NCT04050592|Other|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:~weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.~weeks 10-20: placebo"
33334450|NCT04050592|Active Comparator|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
33334451|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
33334452|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
33334453|NCT04050748|Placebo Comparator|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
33334454|NCT04050748|Active Comparator|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
33334455|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
33058590|NCT03012022||Healthy Volunteers|
33058591|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
33058592|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
33058593|NCT02988973|Experimental|rHuEPO or DA to ASP1517|Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on <4500 IU/week of rHuEPO or <20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
33058594|NCT02988973|Experimental|rHuEPO or DA to DA|Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or <11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on >1500 to <6000 IU/week of rHuEPO or ≥ 11.25 to < 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to < 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to < 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to < 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.
33058595|NCT02988973|Experimental|Epoetin beta pegol to ASP1517|Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on >100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
33058596|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
33058597|NCT00045773||1|
33058598|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - < 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
33058599|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
33058600|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33058601|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
33058602|NCT02781922|No Intervention|Usual care|
33058603|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
33058604|NCT02599363|Experimental|Dose Escalation Treatment Arm|
33058605|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
33058606|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
33334456|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
33334457|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
33334458|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
33334459|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
33058607|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
33058608|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
33334460|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
33058609|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
33058610|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
33334461|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
33334462|NCT03704272|Experimental|Treatment|SunBrite
33334463|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
33334464|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
33334465|NCT04099095|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
33334466|NCT04099095|Active Comparator|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
33334467|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
33334468|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
33334469|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
33334470|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
33334471|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
33334472|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
33334473|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
33334474|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
33334475|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
33334476|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
33334477|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
33334478|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
33058611|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
33058612|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
33058613|NCT00403429|Experimental|Capecitabine|
33058614|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
33058615|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
33058616|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
33334479|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
33334480|NCT03734718|Placebo Comparator|Placebo|Saline
33334481|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
33334482|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
33334483|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
33334484|NCT03722654|Experimental|MTFS|MTFS-I Installation
33334485|NCT03722654|No Intervention|Control|
33334486|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
33058617|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
33334487|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
33334488|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
33334489|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
33334490|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
33334491|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
33334492|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
33334493|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
33334494|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
33334495|NCT03953391|Experimental|Tea-water|Tea before water
33058618|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
33058619|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
33058620|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
33058621|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
33334496|NCT03953391|Experimental|Water-tea|Water before tea
33334497|NCT05664854|Experimental|sVNS and EIT of cervical vagus nerve|Selective vagus nerve stimulation (sVNS) with a spatially selective vagal nerve cuff with physiological readouts such as electrocardiogram (ECG), heart rate, end-tidal carbon dioxide (EtCO2), respiratory rate, laryngeal electromyogram (EMG), etc., and electrical impedance tomography (EIT) recordings of the nerve.
33334498|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
33334499|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
33334500|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
33334501|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
33334502|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
33334503|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
33419204|NCT04657861|Experimental|Administration of APRIL CAR T-cells|Each subject receive APRIL CAR T-cells by intravenous infusion
33058622|NCT01409161|Experimental|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33058623|NCT00079599|Experimental|1|
33058624|NCT00079599|Placebo Comparator|2|
33058625|NCT00601939|Experimental|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
33058626|NCT00601939|Active Comparator|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
33058627|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
33058628|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
33058629|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
33058630|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
33058631|NCT00079716|Experimental|1|
33058632|NCT00130507|Active Comparator|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
33334504|NCT05664776|Experimental|Arm A (control first)|The pre-existing static office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. A dynamic office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
33334505|NCT05664776|Experimental|Arm B (intervention first)|A dynamic office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. The pre-existing static office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
33334506|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
33334507|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
33334508|NCT01310816|Active Comparator|IPI-926|IPI-926
33334509|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
33334510|NCT03807843|Experimental|V184|Participants will receive 2 vaccinations with V184 administered via intramuscular (IM) injection at 5 × 10^5 Tissue Culture Infectious Dose (TCID50) per dose on Days 0 and 28.
33058633|NCT00130507|Experimental|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
33058634|NCT00130546|Active Comparator|1|Cypher Stent
33058635|NCT00130546|Active Comparator|2|Taxus Stent
33334511|NCT03807843|Placebo Comparator|Placebo|Participants will receive 2 injections of sterile physiological saline administered via IM injection on Days 0 and 28.
33334512|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
33334513|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
33334514|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
33334515|NCT01097031||Continuous Infusion|
33334516|NCT01097031||Intermittent Infusion|
33334517|NCT01097031||Infusion Continuous|
33058639|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
33058640|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
33058641|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
33058642|NCT00131053|Experimental|A|
33058643|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
33058644|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
33058645|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
33058646|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
33058647|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
33058648|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
33334518|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
33334519|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
33334520|NCT02843074|Experimental|ERd Therapy|"INDUCTION:~Cycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.~Cycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~CONSOLIDATION:~Four 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~MAINTENANCE:~After completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1."
33419205|NCT05556525|Active Comparator|Arm I (EBUS TBNA)|Patients undergo robotic EBUS TBNA on study.
33334521|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
33360815|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
33360816|NCT03924115|Experimental|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
33360817|NCT03924115|Experimental|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
33360818|NCT03924115|No Intervention|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
33360819|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
33360820|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
33058649|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
33058650|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
33360821|NCT03923569|Other|Alzheimer's Disease patients group|This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
33058651|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
33058652|NCT00131482|Experimental|10 micrograms|
33058653|NCT00131482|Experimental|30 micrograms|
33058654|NCT00131482|Placebo Comparator|Placebo|
33058655|NCT00131482|Experimental|3 micrograms|
33058656|NCT00131482|Experimental|1 microgram|
33058657|NCT04726774|Experimental|Hypnosis group|The intervention consisted of two hypnosis sessions by a physician trained in medical hypnosis. The hypnosis group received also the usual rehabilitation program.
33058658|NCT04726774|Active Comparator|Control group|The control group follow the usual rehabilitation program which includes intensive physiotherapy for 2 weeks (i.e., focused on walking and enhancing balance exercises in group or individual and group) and patient education on the risk of falling and on prevention of falls.
33058659|NCT00131560|Other|A|
33058660|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
33058661|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
33058662|NCT04726930||Intercostal nerve block with surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.~Code name: ICNB-INUS-check"
33058663|NCT04726930||Paravertebral block with surface ultrasound|Number of participants: 10 Paravertebral blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
33058664|NCT04726930||Intercostal nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: ICNB-INUS-guide"
33058665|NCT04726930||Paravertebral nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Paravertebral blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: PVB-INUS-guide"
33058666|NCT00080145|Active Comparator|risperidone plus parent management training|
33058667|NCT00080145|Active Comparator|risperidone only|
32869803|NCT05539092|Experimental|intervention group|the researcher will change angle of bed from 15° to 45°. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
33058668|NCT00403780|Active Comparator|A|Active intervention with pregabalin
32869804|NCT05539092|No Intervention|control group|positioning the patients in supine for 6 hours and the affected leg was straight and immobilized. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
32869805|NCT04227717||Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
33058669|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
33334522|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
33334523|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
33334524|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
33334525|NCT03607422|Placebo Comparator|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
33058670|NCT00080262|Experimental|1|
33334526|NCT03607422|Experimental|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
33334527|NCT03607422|Experimental|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
33334528|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
32869806|NCT05543460|Experimental|Corticopuncture-facilitated MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) with corticopunctures .along the mid-palatal suture
33058671|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
33058672|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33058673|NCT00132145|Other|Intervention|Behavioural
33058674|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
33058675|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
33058676|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
33058677|NCT00132379|Experimental|1|
33058678|NCT00132418|Placebo Comparator|Placebo|placebo
33058679|NCT00132418|Experimental|Enbrel|Enbrel
33058680|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
33058681|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
33058682|NCT00133003|Active Comparator|1|
33058683|NCT00133003|Placebo Comparator|2|
33058684|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
33058685|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
33058686|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
33058687|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
33058688|NCT00133276|Active Comparator|1|
33058689|NCT00133276|Placebo Comparator|2|
33058690|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
33058691|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
33334529|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
33334530|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
33334531|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
33334532|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~5/0 silk suture"
33334533|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~-5/0 silk suture"
33334534|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
33334535|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
33334536|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
33334537|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
33058692|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
33334538|NCT00038103|Active Comparator|1.|
33334539|NCT00038103|Experimental|2.|
33334540|NCT03680742|Experimental|Treated|All eligible patients who underwent an attempt with the Contour device.
33334541|NCT03678870|Experimental|Education|Opioid Education
33334542|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
33334543|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
33334544|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
33058693|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
33058694|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
33058695|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
33058696|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
33058697|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
33058698|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
33058699|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
33058700|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
33058701|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
33058702|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
33058703|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
33058704|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
33058705|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
33058706|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
33058707|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
33058708|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
33058709|NCT00133666|Experimental|1|
33058710|NCT00133666|Active Comparator|2|
33058711|NCT00133744|Active Comparator|A, 1|
33058712|NCT00133744|Experimental|A, 2|
33058713|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
33058714|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
33058715|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
33058716|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
33058717|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
33058718|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
33058719|NCT00080886|Other|Arm 1|
33058720|NCT04710901|Active Comparator|uTECH + Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months and YMHP intervention over the course of 3 months.
33058721|NCT04710901|Active Comparator|Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-12 will be inactive, and they will be followed for a total of 12 months.
33058722|NCT04705831|Active Comparator|RUCONEST|IV Ruconest
33058723|NCT04705831|Placebo Comparator|Placebo|Placebo
33058724|NCT04705675|Experimental|Experimental Group|The mothers in the experimental group (152) were administered.
33058725|NCT04705675|No Intervention|Control Group|The mothers in the control group (152) were administered.
33334545|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
33334546|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33113147|NCT04681391||anodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During anodal tDCS, the anode was placed over right temporoparietal junction, and the cathode was placed over left supraorbital area.
33113148|NCT04681391||cathodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During cathodal tDCS, the cathode was placed over right temporoparietal junction, and the anode was placed over left supraorbital area.
33419206|NCT05556525|Experimental|Arm II (EBUS TBNA, nCLE, fluorescein)|Patients undergo EBUS TBNA, nCLE, and receive fluorescein IV on study.
33419207|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
33419208|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
33113149|NCT04681391||sham (as a control condition)|same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds.
33113150|NCT04652817|Experimental|MMI-22-04-2019|Sodium hyaluronate at a concentration of 2.5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent administered once or twice depending on the individual necessity.
33113151|NCT04681586|Experimental|Bright white light|
33113152|NCT04681586|Placebo Comparator|Dim red light|
33419209|NCT04054167|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
33419210|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
33113153|NCT04624269|Experimental|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
33113154|NCT04624269|Placebo Comparator|placebo|drug:placebo,0.1mg bid po
33113155|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
33113156|NCT04652739|Experimental|Lycopene|
33113157|NCT04652739|Active Comparator|Corticosteroids|
33113158|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
33113159|NCT04652661|Experimental|Dexmedetomidine Group|30 children will be sedated with 2 μg/kg intranasal dexmedetomidine
33113160|NCT04652661|Active Comparator|Midazolam Group|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
33113161|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
33113162|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
33113163|NCT04624347|Experimental|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
33113164|NCT04624347|No Intervention|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
33113165|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
33113166|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
33113167|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
33113168|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
33113169|NCT04623957|Experimental|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
33113170|NCT04623957|No Intervention|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
33113171|NCT04652427|Experimental|Use Dexmedetomidine Hydrochloride to maintain a sedative|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
33113172|NCT04652427|Placebo Comparator|Sedative were maintained with a 0.9% sodium chloride injection|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
33113173|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
33113174|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
33113175|NCT04623918|Experimental|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
33058726|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
33334547|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33058727|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
33058728|NCT04706065||GROUP 1|Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
33334548|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334549|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334550|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334551|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334552|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334553|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334554|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334555|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334556|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334557|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334558|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334559|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33058729|NCT04706065||Group 2|Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
33058730|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
33334560|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334561|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33334562|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33058731|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
33058732|NCT00134758|Placebo Comparator|2|
33058733|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33058734|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
33058735|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
33058736|NCT00047450|Placebo Comparator|1|Participants will take placebo
33058737|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
33058738|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33058739|NCT00145522|Experimental|1|
33334563|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
33058740|NCT00145522|Active Comparator|2|
33058741|NCT00145639|Other|1|
33058742|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
33058743|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
33058744|NCT00081354||Barrett's esophagus|Barrett's esophagus
33058745|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
33058746|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
33058747|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
33058748|NCT00145951||1|
33058749|NCT00145951||2|
33058750|NCT00145951||3|
33058751|NCT00081471|Experimental|1|
33058752|NCT00081471|Active Comparator|2|
33058753|NCT00146107|No Intervention|1|
33058754|NCT00146107|Experimental|2|Weight loss
33058755|NCT00146107|Experimental|3|Exercise
33058756|NCT00146107|Experimental|4|Weight loss and exercise
33058757|NCT00146224|Active Comparator|Epoetin alfa RB|
33058758|NCT00146224|Experimental|Epoetin alfa DT|
33058759|NCT00146263|Active Comparator|Savyon|Computerized cognitive training using the Savyon software
33058760|NCT00146263|Placebo Comparator|Control|Usual activity
33058761|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
33058762|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
33058763|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
33058764|NCT00146575|Experimental|1|randomized patients get sirolimus stent
33058765|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
33058766|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
33058767|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33058768|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
33058769|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
33058770|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
33058771|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
33058772|NCT00405769|Placebo Comparator|1|placebo control
33058773|NCT00405769|Active Comparator|2|red yeast rice
33058774|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
33058775|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
33058776|NCT02957812|No Intervention|Control|Wearing own footwear
33058777|NCT00147004|Experimental|1|hydrocortisone sodium succinate
33058778|NCT00147004|Placebo Comparator|2|Placebo
33058779|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
33058780|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
33058781|NCT04732104|Experimental|intranasal spray anesthesia|intranasal lidocaine lidocaine 4% topical
33058782|NCT04732104|Active Comparator|injectable local anesthesia|gold standard infiltration local anesthesia (2% lidocaine with 1:100,000 epinephrine)
33058783|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
33058784|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
33058785|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
33058786|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
33058787|NCT00048152|Experimental|1|
33058788|NCT00048152|Experimental|2|
33058789|NCT00048152|Experimental|3|
33058790|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
33058791|NCT04725682|Active Comparator|Sequence 1 (TRTR)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of TRTR.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD tacrolimus capsules"
33058792|NCT04725682|Active Comparator|Sequence 2 (RTRT)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of RTRT.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD capsules"
33058793|NCT00147550|Experimental|1|
33113176|NCT04623918|Active Comparator|Control rice|Control rice (C4)
33334564|NCT03704038|Active Comparator|PEEP 5|
33334565|NCT03704038|Active Comparator|PEEP 0|
33334566|NCT03704038|Experimental|PEEP 10|
33334567|NCT03703960|Experimental|"Group 1 Hypnosis"|
33334568|NCT03703960|Active Comparator|"Group 2 music"|
33334569|NCT03703960|No Intervention|Control group|
33360822|NCT03923569|Other|Healthy control group|This group contains the 31 (anticipated) age and sex -matched healthy controls
33058794|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
33058795|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
33334570|NCT04587154|Experimental|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
33334571|NCT04587154|No Intervention|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
33334572|NCT05664698|Experimental|SKILLS-ER|Emotion regulation training
33058796|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
33058797|NCT00147979|Experimental|1|PTFE with bounded heparin
33058798|NCT00147979|Active Comparator|2|PTFE without bounded heparin
33058799|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
33058800|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
33058801|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
33058802|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
33058803|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
33058804|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
33058805|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
33058806|NCT00081900|Experimental|DENSPM|
33058807|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
33058808|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
33058809|NCT00148525|No Intervention|Comparison group|comparison group
33058810|NCT00148564|Active Comparator|Olanzapine|
33058811|NCT00148564|Active Comparator|Zpirasidone|
33058812|NCT00148642|Experimental|1|silver salts coated endotracheal tube
33058813|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
33058814|NCT00148681|Experimental|Lower Risk Regimen|
33058815|NCT00148681|Experimental|Higher Risk Regimen|
33058816|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
33058817|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
33058818|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
33058819|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
33058820|NCT00149071|Active Comparator|A|rTMS
33058821|NCT00149071|Sham Comparator|B|sham rTMS
33058822|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
33058823|NCT00149110|Active Comparator|B|Exercise and duloxetine
33058824|NCT00149305||Patients with gouthy diathesis|
33058825|NCT00149305||Healthy subjects|
33058826|NCT00149383|Placebo Comparator|2|
33058827|NCT00149383|Experimental|1|
33058828|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
33058829|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
33058830|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
33058831|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
33058832|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
33058833|NCT00048854|Experimental|2|Participants will take sertraline
33058834|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
33058835|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
33058836|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
33058837|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
33058838|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
33058839|NCT00149656|Placebo Comparator|1|
33058840|NCT00149656|Experimental|2|Multivitamins
33058841|NCT00149656|Experimental|3|Multivitamins with Selenium
33058842|NCT00149656|Experimental|4|Selenium
33058843|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
33058844|NCT02957500|No Intervention|No treatment|standard treatment for surgery
33360823|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
33360824|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
33058845|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
33334573|NCT04843930|Experimental|AKL-T01 Intervention|Participants in the experimental group will complete 6 weeks of the AKL-T01 intervention. Participants enrolled in the intervention arm will play the game via an iPad application for 20-25 minutes daily for at least 5 days a week (but up to 7 days a week). Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms and gameplay adherence.
33058846|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~Improving social resources.~Improving adherence to medical regimen.~Targeting Suicidal Cognitions."
33058847|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
33334574|NCT04843930|No Intervention|Waitlist Control|Participants in the Waitlist Control arm will not be engaging in any active control condition. Participants in the waitlist control arm will continue any ongoing self- or provider-based cognitive intervention (or no intervention) during the initial 6-week waitlist period. Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms. The control arm will be offered the intervention at the end of 6 weeks waitlist period to ensure all participants ultimately have access to the intervention.
33334575|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
33058848|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
33058849|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
33058850|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
33058851|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
33334576|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
33334577|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
33058852|NCT00149968|Experimental|Myfortic|
33334578|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
33360825|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
33058853|NCT00405886|Experimental|Neramexane 25mg/d|
33058854|NCT00405886|Experimental|Neramexane 50mg/d|
33058855|NCT00405886|Experimental|Neramexane 75mg/d|
33058856|NCT00405886|Placebo Comparator|Placebo|
33058857|NCT04725448|Experimental|Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin|"Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years.~Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years.~Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles.~Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles."
33058858|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
33058859|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
33058860|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33058861|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33058862|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
33058863|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
33058864|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
33058865|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
33334579|NCT04570930|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
33334580|NCT04570930|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
33058866|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
33058867|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
33058868|NCT00082290|Experimental|a massage|About 45 minute massage
33058869|NCT00082290|Experimental|visit with a volunteer|45 minute visit
33058870|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
33058871|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
33058872|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
33058873|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
33058874|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
33058875|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
33058876|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
33058877|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
33058878|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
33058879|NCT00150670|Experimental|1|TS-1 and cisplatin
33058880|NCT00150670|Active Comparator|2|TS-1
33058881|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
33058882|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
33058883|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
33058884|NCT00043407|Experimental|CPG 7909 Injection|
33058885|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
33058886|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
33058887|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
33334581|NCT04762888|Experimental|Diagnostic (68Ga-PSMA PET/MRI or PET/CT)|Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
33334582|NCT05660798|No Intervention|combustion tobacco|
33334583|NCT05660798|Experimental|heated tobacco|
33334584|NCT03717116||control-normocalcemia group|
33334585|NCT03717116||hypocalcemia group|
33334586|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
33334587|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334588|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334589|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334590|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334591|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334592|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
33334593|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
33334594|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
33334595|NCT04837222||Participants with CD30-positive Lymphoma|All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
33334596|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
33058888|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
33058889|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
33334597|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
33334598|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
33334599|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
33334600|NCT04745026|Experimental|GWP42003-P 10 mg/kg/day|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P for 1 week and then 10 mg/kg/day GWP42003-P for 11 weeks.
33058890|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
33058891|NCT00151177|No Intervention|B|usual Stroke Unit care
33058892|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
33058893|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
33058894|NCT00082485|Active Comparator|1|
33058895|NCT00082485|Placebo Comparator|2|
33058896|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
33058897|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
33058898|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
33058899|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
33058900|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
33058901|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
33058902|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
33058903|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
33058904|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33058905|NCT00151567|Experimental|1|Tamsulosin
33058906|NCT00151567|Placebo Comparator|2|Placebo
33334601|NCT04745026|Placebo Comparator|Placebo|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive matching placebo for 12 weeks.
33334602|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.~At every cry, parent should answer the questionnaire of cry in infant."
33334603|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
33334604|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
33334605|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
33334606|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
33334607|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
33334608|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
33334609|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
33334610|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
33334611|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
33334612|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
33334613|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
33113177|NCT04624308|Experimental|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or >75%PR. If not, operation is suggested.
33113178|NCT04624425|Experimental|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
33113179|NCT04624425|Active Comparator|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
33113180|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.~Part B (Expansion Cohort):~An expansion cohort of an additional 12 patients will be recruited at the MTD."
33113181|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
33113182|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
33113183|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
33113184|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
33113185|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
33113186|NCT04624035|Active Comparator|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
33113187|NCT04624035|Active Comparator|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
33113188|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
33113189|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
33113190|NCT04681508|Experimental|All patients|All patients undergo chest CT without contrast enhancement and chest X-ray. Blood and urine sampling from patients subsequently undergoing emergency laparoscopy or laparotomy. Otherwise standard care
33334614|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
33334615|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
33113191|NCT04624191|Experimental|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
33334616|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
33334617|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
33113192|NCT04624191|No Intervention|Control Group|Usual Care
33113193|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
33113194|NCT02903264||Control|Healthy non-pregnant females
33113195|NCT04624152|Experimental|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
33334618|NCT00143182|Experimental|1|Asenapine
33334619|NCT00143182|Active Comparator|2|Olanzapine
33334620|NCT03677934|Experimental|PDS Implant Arm|Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
33334621|NCT03677934|Active Comparator|Intravitreal Arm|Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
33334622|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
33113196|NCT04624152|Placebo Comparator|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
33113197|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
33334623|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
33113198|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
33113199|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
33113200|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
33113201|NCT04623606|No Intervention|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
33334624|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
33334625|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
33334626|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
33334627|NCT03705442|Placebo Comparator|Placebo|Placebo
33334628|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
33334629|NCT04817410|Experimental|Oral Naloxone|Oral Naltrexone initiation
33334630|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
33113202|NCT04623606|Experimental|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
33113203|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
33334631|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
33113204|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
33334632|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
33334633|NCT03705364|Experimental|Fall Management program|Intervention arm
33334634|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
33334635|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
33113205|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
33113206|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
33113207|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
33334636|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
33334637|NCT04539964|Experimental|Treatment|Active stimulation for 1 min once per day
32869807|NCT05543460|Active Comparator|Conventional MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) without corticopunctures.
33058907|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
33058908|NCT04725253|Experimental|Nicotinamide|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously. Study medication will be managed by nurses and administered daily at 7 a.m. This regimen will be continued up to 7 days after admission. The dosage of nicotinamide will be 1,5 gr per day.
33058909|NCT04725253|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization, resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner. Study medication will be managed by nurses and administered daily at 7 a.m. (in these case placebo tablets). This regimen will be continued up to 7 days after admission.
33058910|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
33334638|NCT04539964|Sham Comparator|Control|Non-active stimulation for 1 min once per day
33334639|NCT03673956|Experimental|Mupirocin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Mupirocin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
33334640|NCT03673956|Experimental|Tobramycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Tobramycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
33334641|NCT03673956|Experimental|Levofloxacin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Levofloxacin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
33334642|NCT03673956|Experimental|Vancomycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Vancomycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
33334643|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
33334644|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.~The curriculum is imparted by school teachers are trained and certified by CorStone."
33334645|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
33334646|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
33334647|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
32869808|NCT05613933|Experimental|Intervention arm|In the intervention arm, dentists will receive information on the study 8 weeks before the start of the study and will be invited to consent to participate or to opt out
32869809|NCT05613933|No Intervention|Control arm|In the clusters randomized to the control arm, no intervention will be performed and no information will be sent to dentists.
33058911|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
33058912|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
33058913|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
33058914|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
33058915|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
33058916|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
33058917|NCT04725370||CHOP (US)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2012 to 2019 at the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
33113208|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
33058918|NCT04725370||SFG (Guatemala)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2017 and 2020 with Smiles for Guatemala, Guatemala City, Guatemala.
33334648|NCT03716804|Experimental|Intervention group|"Intervention:~To the prescribers- Educational intervention about guideline and present sensitivity trend.~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
33334649|NCT03716804|Active Comparator|Control Group|"Intervention:~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
33334650|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
33058919|NCT00152113|Other|1|
33334651|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
33334652|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
33334653|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
33058920|NCT00152191|Experimental|1|UFT (uracil, tegafur)
33058921|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
33058922|NCT00152230|Experimental|1|UFT (uracil, tegafur)
33058923|NCT00152230|Other|2|Surgery alone
33058924|NCT00152269|Experimental|1|
33058925|NCT00152269|Experimental|2|
33058926|NCT00152269|Placebo Comparator|3|
33058927|NCT00397865|Experimental|A|
33058928|NCT00152542|Experimental|Inhaled nitric oxide|
33058929|NCT00152542|Placebo Comparator|Placebo|
33058930|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *For the first course only, treatment is omitted on day 11"
33058931|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
33058932|NCT04725214|Experimental|Experimental|For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
33058933|NCT00152698|Active Comparator|Irbesartan|
33058934|NCT00152698|Placebo Comparator|Placebo|
33058935|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
33058936|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
33058937|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
33058938|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
33058939|NCT04725019|Experimental|Active tDCS + motor training|In this arm, participants will receive 20 minutes of active tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games.
33058940|NCT04725019|Experimental|Sham tDCS + motor training|In this arm, participants will receive 20 minutes of sham tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games. Children receiving sham tDCS will wear the tDCS device but not receive active stimulation.
33058941|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
33058942|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
33058943|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
33058944|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
33058945|NCT00083031|Experimental|Arm A-Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose~Bevacizumab- Via IV on predetermined days per cycle"
33058946|NCT00083031|Experimental|Arm B- Without Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose"
33058947|NCT00083070|Experimental|Temozolomide Therapy|
33058948|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
33058949|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
33058950|NCT00153205|Experimental|Technological|
33058951|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
33058952|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
33058953|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
33058954|NCT00050570|Experimental|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
33058955|NCT00050570|No Intervention|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
33058956|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
33113209|NCT00562146||2|Failure of progression to duodenum within 3 days
33334654|NCT03703570|Placebo Comparator|placebo|Oral administration
33334655|NCT03435224|Experimental|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
33334656|NCT01310166|Experimental|Fingolimod|
33334657|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
33334658|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
33334659|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
33058957|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
33058958|NCT00050609|Placebo Comparator|1|
33058959|NCT00050609|Active Comparator|2|5 mg tadalafil
33058960|NCT00050609|Active Comparator|3|20 mg tadalafil
33058961|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
33058962|NCT00153673|Active Comparator|2|Dologesics + Famotidine
33058963|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
33058964|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
33058965|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
33058966|NCT00153751|Active Comparator|Holopon|Holopon
33058967|NCT00153751|Placebo Comparator|placebo|Placebo
33058968|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
33058969|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
33058970|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
33058971|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
33058972|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
33058973|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
33058974|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
33058975|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
33058976|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
33058977|NCT00154258|Experimental|1|
33058978|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
33058979|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
33058980|NCT04724785||patients with persistant low level HBV DNA (<10 IU/ml)|No further intervention(s) to be administered except for monitoring of HBV DNA viraemia
33058981|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) but refuse to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen. If those patients refuse to change the regimen which they are using , No further intervention(s) to be administered except for monitoring of HBV DNA viraemia until those patients change their idea
33058982|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) and agree to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen.They will change their regimen according one which they are using.
33058983|NCT04705987|Experimental|Experimental|Colchicine 0.5 mg
33058984|NCT04705987|Placebo Comparator|Placebo|Placebo
33058985|NCT04705909|Experimental|Pitavastatin group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.
33058986|NCT04705909|Placebo Comparator|Placebo group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.
33058987|NCT04731428|Experimental|Progressive Relaxation Exercise|In individuals with normal daily circadian rhythms, cortisol levels peak at 8:00 AM, followed by a constantly declining daily cycle throughout the day. Therefore, it is important to collect blood samples taken for the measurement of serum cortisol levels approximately at the same time. Venous blood samples (3 ml) were obtained from the upper arm at 06:45 AM to evaluate the baseline and 45 minutes after Progressive Relaxation Exercise at 08:00. Vital signs and oxygen saturation were assessed at 6:30 AM before Progressive Relaxation Exercise and at 07:20 AM 5 minutes after Progressive Relaxation Exercise. Measurements were performed in the morning on the day of surgery and on postoperative days 1, 2, and 3.
33058988|NCT04731428|No Intervention|Standard Care|In the control group, no application made during and after the surgical intervention, and routine treatment and care applied.
33058989|NCT04705792|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 12 consecutive weeks.
33058990|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
33058991|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
33058992|NCT04705558|Experimental|group I|Continuous aerobic exercise with ketogenic diet for three month
33058993|NCT04705558|Experimental|group II|Ketogenic diet alone for three month
33058994|NCT00406237|Experimental|1|
33058995|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
33058996|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
33058997|NCT00406471|Active Comparator|2|300 microgram ranibizumab
33058998|NCT00154687|Experimental|A|
33058999|NCT00083460|Active Comparator|1|
33059000|NCT00083460|Active Comparator|2|
33059001|NCT00154804|Experimental|A|
33059002|NCT00154843|Experimental|A|Lycopene 15 mg/day
32869810|NCT05609565|Active Comparator|Group 1|
32869811|NCT05609565|Active Comparator|Group 2|
33334660|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
33334661|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
33334662|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
33334663|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33334664|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
33334665|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
33334666|NCT04530058|Placebo Comparator|Control|
33334667|NCT04530058|Experimental|Metformin|
32869812|NCT05591664||GROUP 1|There will be 38 patients diagnosed with gestational diabetes in the study group.
32869813|NCT05591664||GROUP 2|There will be 80 normal pregnant women in the control group
32869814|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
32871635|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
33059003|NCT00154843|Experimental|B|Lycopene 30 mg/day
33059004|NCT00154882|Experimental|A|
33059005|NCT04724707||Myocarditis|Proven or suspected myocarditis
33059006|NCT04724707||Heart failure|Heart failure (NYHA functional class II-IV) before or during hospitalization with COVID-19
33059007|NCT04724707||ACS|Combination of COVID-19 with ACS or development of ACS during hospitalization with COVID-19 or performed percutaneous coronary intervention
33059008|NCT04724707||Pulmonary embolism|Proven pulmonary embolism
33059009|NCT04724707||Arrhythmias|Hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the QT interval prolongation
33059010|NCT00083499||Group 1|Index cases
33059011|NCT00083499||Group 2|Relatives of Index Cases
33059012|NCT00083499||Group 3|Fetal tissue
33059013|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
33059014|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
33059015|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
33059016|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
33059017|NCT00155545|No Intervention|Metformin|
33059018|NCT04724863|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
33059019|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
33059020|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
33059021|NCT00156130||1|Accelerated whole breast irradiation
33059022|NCT00156130||2|Conventional whole breast irradiation
33059023|NCT00156208|Experimental|1|
33059024|NCT00156208|Experimental|2|
33059025|NCT04731636|Experimental|Intervention arm|Patients with Crawford type I-V thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
33059026|NCT00051350|Placebo Comparator|CARB|Diet rich in carbohydrate
33334668|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
32871636|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
33059027|NCT00051350|Active Comparator|UNSAT|Diet rich in unsaturated fat
33059028|NCT00051350|Active Comparator|PROTEIN|Diet rich in protein
33059029|NCT00156637|Other|Arm 1|
33059030|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
33059031|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
33059032|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
33059033|NCT00156949|Experimental|Epoetin alfa DT|
33113210|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
33113211|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
33334669|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
33334670|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
33334671|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
33059034|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
33059035|NCT00083772|Experimental|1|Nesiritide
33059036|NCT00157300|Experimental|Epoetin beta|
33059037|NCT00398060|Experimental|A|
33059038|NCT00406978|Experimental|MPTD|
33059039|NCT05568576||patients with HCC underwent resection|patients with HCC underwent resection
33059040|NCT00157612|Other|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
33059041|NCT00157612|No Intervention|Comparator|usual care
33059042|NCT00157651|Active Comparator|1|Receiving warfarin
33059043|NCT00157651|Placebo Comparator|2|Receiving matching placebo
33059044|NCT00157690|Active Comparator|1|Alendronate
33059045|NCT00157690|Placebo Comparator|2|Placebo
33059046|NCT00157807|No Intervention|No Ablation|
33059047|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
33059048|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
33059049|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
33059050|NCT05568498|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
33059051|NCT05568498|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
33059052|NCT00158158|Placebo Comparator|1|Usual care
33059053|NCT00158158|Experimental|2|Reduction in smoking
33059054|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
33059055|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
33059056|NCT00158353|Experimental|1|GirlPOWER! mentoring program
33059057|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
33059058|NCT04724200||Referred from primary care for investigation of suspected heart failure|All patients recruited to the OPERA trial will have been referred from their primary care clinician for investigation of a suspected diagnosis of heart failure.
33059059|NCT04724434||Study group|Patients with positive test for SARS-CoV-2 by PCR
33059060|NCT04724434||Control group|Patients with negative SARS-CoV-2 antibody test
33059061|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
33059062|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
33059063|NCT05568459||Cohort 1|Male patients with Hemophilia B on current FIX Replacement Therapy prophylaxis
33059064|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
33059065|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
33059066|NCT05568342|Experimental|Roy Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Monday-Wednesday-Friday were randomly assigned to the Roy group (experimental) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
33059067|NCT05568342|No Intervention|Clinic Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Tuesday-Thursday-Saturday were included in the Clinical group (control) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
33334672|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
33113212|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
33113213|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
33334673|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
33334674|NCT03733860|Active Comparator|Cavernous sparing group|
33334675|NCT03733860|Other|Conventional technique group|
33334676|NCT04390360|Other|Protective ventilation with HME|Protective ventilation + HME
33334677|NCT04390360|Other|Protective ventilation with Heated humidifier|Protective ventilation + HH
33334678|NCT04390360|Other|Implementation of protective ventilation|Protective ventilation implementation
33334679|NCT04390360|Other|Tidal Volume reduction|Tidal volume reduction
33334680|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study~Measure of 6 indices:~Bleeding on Intergental Brush Index (BOIB)~Gingivitis Score (GI)~Plaque index score (PI)~ICDAS~Salivary test~Individual caries risk assessment~Determination of interdental brushes adapted to each interdental site~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
33113214|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
33113215|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
33113216|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
33113217|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
33113218|NCT04623645|Experimental|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
33113219|NCT04623645|Active Comparator|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
33113220|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
33113221|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
33113222|NCT04623762|No Intervention|Control group|yoga was not done
33113223|NCT04623762|Experimental|Experimental group|yoga was done
33113224|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
33113225|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
33113226|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
33113227|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
33113228|NCT04623723|Sham Comparator|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
33113229|NCT04623723|Active Comparator|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
33113230|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
33113231|NCT04623840|Experimental|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
33113232|NCT04623840|Active Comparator|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
33334681|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.~Blood and urine samples are collected for every 3rd hour during 24 hours"
33113233|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
33113234|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
33113235|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
33113236|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
33113237|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function >45%
33334682|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).~Blood and urine samples are collected for every 3rd hour during 24 hours"
33334683|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).~Blood and urine samples are collected for every 3rd hour during 24 hours"
33334684|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
33113238|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
33113239|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
33113240|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
33113241|NCT04623450|Experimental|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
33113242|NCT04623450|Experimental|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
33113243|NCT04623450|Experimental|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
33113244|NCT02902406||normal oral mucosa|
33113245|NCT02902406||oral precancerous lesion or oral cancer|
33113246|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
33113247|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
33113248|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
33334685|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
33334686|NCT03700762||pathologically results|finally proved by pathologically results
33334687|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
33334688|NCT04709302||COVID-19 positive, HIV-positive with ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART
33334689|NCT04709302||COVID-19 positive, HIV-positive without ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
33334690|NCT04709302||COVID-19 positive, HIV-negative|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
33334691|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
33113249|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
33113250|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
33113251|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
33113252|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
33113253|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
33113254|NCT04623060|Experimental|Intervention|3 sessions/week for 6 weeks
33113255|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
33360826|NCT03923491|Experimental|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
33059068|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
33059069|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
33059070|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
33059071|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
33059072|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
33059073|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
33059074|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
33059075|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
33059076|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
33059077|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
33059078|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
33059079|NCT05568147|Experimental|Aspirin 100 mg daily|Once enrolled, patients will receive aspirin 100mg orally once per day
33059080|NCT05568147|Placebo Comparator|Placebo|Once enrolled, patients will receive placebo orally once per day
33059081|NCT04724473|Experimental|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
33059082|NCT04724473|Active Comparator|RETIN-A® (Tretinoin) Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
33059083|NCT04724473|Placebo Comparator|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
33059084|NCT05567991|Experimental|Treatment group|The individuals assigned to the treatment group attend the training sessions and were asked to complete all the questionnaires at both time points
33059085|NCT05567991|No Intervention|Passive Control Group|The individuals assigned to the passive control group did not attend any training session and were only asked to complete the same questionnaires as the treatment group at both time points. Participants in the control group were asked not to practice meditation during the period of the study for an unbiased comparison with the intervention group.
33059086|NCT00051935|Experimental|1|
33059087|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
33059088|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
33059089|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
33059090|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
33059091|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
33059092|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
33059093|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
33059094|NCT00159211|Experimental|2|pioglitazone 30 mg
33059095|NCT00159289|Experimental|1|Inhalation of LPS
33059096|NCT00159289|Placebo Comparator|2|PLacebo
33059097|NCT00052013|Experimental|PTK787/ZK 222584|
33059098|NCT00159484|Experimental|A|EPO906, celecoxib
33059099|NCT00159523|Experimental|probiotic|
33059100|NCT00159523|Placebo Comparator|placebo|
33059101|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
33059102|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
33059103|NCT00044538|Experimental|Arm 1|
33059104|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
33059105|NCT00159601||youth from general population|
33059106|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
33059107|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
33059108|NCT05567679|Experimental|Tazemetostat|Tazemetostat 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
33059109|NCT04729764|Experimental|GP681 Tablet 20mg|Two sentinel subjects were first enrolled in the trial (test drug: placebo=1:1). After the two sentinel subjects completed the 72h safety follow-up after the administration, it was judged that if there was no dose-limiting toxicity , Then start the trial of the remaining 6 subjects in the dose group (experimental drug: placebo = 5:1).
33059110|NCT04729764|Experimental|GP681 Tablet 40mg|10 subjects in 40mg group (including 2 placebo)
33059111|NCT04729764|Experimental|GP681 Tablet 60mg|10 subjects in 60mg group (including 2 placebo)
33059112|NCT04729764|Experimental|GP681 Tablet 80mg|10 subjects in 80mg group (including 2 placebo)
33059113|NCT04729764|Experimental|GP681 Tablet 120mg|10 subjects in 120mg group (including 2 placebo)
33059114|NCT00159952|Active Comparator|1|
33059115|NCT00159991|Experimental|A|Total arterial revascularization
33059116|NCT00159991|Active Comparator|B|Conventional revascularization
33059117|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
33059118|NCT00397449|Experimental|1, 2, 3|
33059119|NCT00160030|Experimental|1|
33059120|NCT00160030|Active Comparator|2|
33059121|NCT00160069|Experimental|Arm 1|
33059122|NCT00160069|Experimental|Arm 2|
33059123|NCT00160069|Experimental|Arm 3|
33059124|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
33334692|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
33334693|NCT01310244|Experimental|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
33334694|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
33334695|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
33334696|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
33334697|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
33334698|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
33334699|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
33334700|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
33334701|NCT05665764||Veterans|Veterans will be the primary cohort for this study. Veterans who will be enrolled with have current insomnia and a history of traumatic brain injury.
33334702|NCT05665764||Caregivers|Caregivers of enrolled veterans will be an optional cohort for this study. If applicable and willing to participate, caregivers of enrolled Veterans will be asked to provide collateral information regarding the Veteran's experience with the study.
33334703|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
33334704|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
33334705|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
33334706|NCT04518748|Experimental|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
33334707|NCT04514692|Experimental|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
33334708|NCT04514692|Experimental|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
33334709|NCT04514692|Experimental|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
33334710|NCT04514692|Experimental|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
33059125|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
33059126|NCT00160186|Experimental|1|
33059127|NCT00160186|Placebo Comparator|2|
33059128|NCT05567484|Active Comparator|group A pulse thearpy of itraconazole|Patients in pulse therapy group received oral itraconazole 100 mg, two capsules twice daily for seven days a month
33059129|NCT05567484|Active Comparator|Group B continous thearpy of itraconazole|Patients in continuous therapy group, received continuous oral 100 mg of itraconazole once daily for 12 weeks continuously.
33059130|NCT00160342|Active Comparator|1|
33059131|NCT00160342|Experimental|2|
33059132|NCT00160342|Experimental|3|
33334711|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
33059133|NCT00160342|Active Comparator|4|
33059134|NCT00160342|Experimental|5|
33059135|NCT00160342|Experimental|6|
33059136|NCT00160342|Active Comparator|7|
33334712|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
33334713|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
33334714|NCT03703414||Control|Healthy controls
33334715|NCT03703414||ECT|MDD patients receiving ECT treatment
33334716|NCT03703414||SSRI|MDD patients receiving SSRI treatment
33334717|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
33334718|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
33334719|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
33334720|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
33334721|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
33059137|NCT00160342|Active Comparator|8|
33059138|NCT00160342|Placebo Comparator|9|
33059139|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33059140|NCT00160381|Experimental|1|
33059141|NCT00160381|Experimental|2|
33059142|NCT00160381|Placebo Comparator|3|
33059143|NCT00160420|Experimental|1|
33059144|NCT00160459|Experimental|1|
33059145|NCT00160459|Experimental|2|
33059146|NCT00160459|Experimental|3|
33059147|NCT00160459|Placebo Comparator|4|
33059148|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
33059149|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
33059150|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
33059151|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
33059152|NCT05567016|Experimental|Active Case Detection using molecular testing (ACDm)|"Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever.~Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive."
33059153|NCT05567016|Experimental|Passive Case Detection using molecular testing (PCDm)|"Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive.~Per standard of care, children will not receive malaria ACD."
33059154|NCT05567016|Active Comparator|Standard passive case detection (PCD)|"Per standard of care, children will receive PCD using RDT.~Per standard of care, children will not receive malaria ACD."
33059155|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
33059156|NCT00161395|Active Comparator|1|Preconception advice.
33059157|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
33059158|NCT00161434|Experimental|1|
33059159|NCT00161434|Placebo Comparator|2|
33059160|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
33059161|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
33059162|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
33059163|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
33059164|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
33059165|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
33059166|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
33059167|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
33334722|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
33059168|NCT05566977|Experimental|patients with autoimmune disease :lupus nephritis and type1 diabetes melitus|single arm of patients with autoimmune diseases : patients of the first group selected as refractory lupus nephritis. patients of the second group of autoimmune diseases are selected to have type1 diabetes Meletus.
33059169|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
33059170|NCT04710745||Study Group|Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score > 2 (for females > 3) and with more than 3 specific criteria for inclusion.
33059171|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
33059172|NCT00162214|Active Comparator|1|
33059173|NCT04731116|Experimental|CANNABIDIOL|CANNABIDIOL 5% 3 ml twice daily for 14 days.
33059174|NCT00407095|Experimental|1|
33059175|NCT04731792|Experimental|Virtual Reality group|
33059176|NCT04731792|No Intervention|control group|
33059177|NCT00405457|Other|A|
33059178|NCT04710472|Experimental|MH|Arm MH - mobile Mentora app to monitor and track treatment side-effects, vital signs, therapeutics and daily habits;
33059179|NCT04710472|No Intervention|C|SOC
33059180|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
33059181|NCT00162448|Experimental|A1|
33059182|NCT00162448|Placebo Comparator|A2|
33059183|NCT05562960|Other|ALS patients receiving plasmapheresis|Plasmapheresis in ALS patients with different titers of autoantibody against NRIP
33059184|NCT04724356|Experimental|Virtual Reality Group|The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
33059185|NCT04724356|Experimental|Resistance exercise Group|The resistance exercise group received resistance training, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
33334723|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
33334724|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
33059186|NCT00162565|Experimental|1|bbloquant treatment
33059187|NCT05558085|Experimental|EFNEP Group|Subjects will receive the EFNEP Eat Smart Being Active class series.
33059188|NCT05558085|No Intervention|Control Group|Subjects will receive no EFNEP intervention.
33059189|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
33059190|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
33059191|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
33059192|NCT00162916|Placebo Comparator|1|
33059193|NCT00162916|Experimental|2|
33059194|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
33059195|NCT00162955|No Intervention|non-administration|ARB non-administration group
33059196|NCT04724239|Experimental|sintilimab + chidamide + IBI305|
33059197|NCT04724239|Experimental|sintilimab + chidamide|
33059198|NCT05543811|Experimental|Product for special dietary use|Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid will be given to the subjects enrolled to this arm, 20 gram twice daily with breakfast and supper (instead of butter)
33059199|NCT05543811|Placebo Comparator|control|This group will receive standard spread, without theanine, gamma-aminobutyric acid and 5-hydroxytryptophan, twice daily with breakfast and supper with food (instead of butter)
33059200|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
33059201|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
33059202|NCT00163267|Active Comparator|ASS + Plavix|active drug
33059203|NCT04731038|Experimental|Experimental|Anlotinib 12mg qd. po. d1-d14 q3w Toripalimab 240mg ivgtt. d1 q3w Paclitaxel 135mg/m2 ivgtt. d1 q3w Cisplatin 50mg/m2 ivgtt. d1 q3w Carboplatin AUC=5 ivgtt. d1 q3w
33059204|NCT05531604||AN-Restricting (AN-R)|Meet Diagnostic and Statistical Manual (DSM-5) criteria for anorexia nervosa, restricting subtype
33334725|NCT03512288|Active Comparator|Control|13vPnC
33334726|NCT03031678|Other|Study procedures|
33334727|NCT03669588|Experimental|ARGX-113|
33334728|NCT03669588|Placebo Comparator|Placebo|
33334729|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
33334730|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
33334731|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
33334732|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
33334733|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
33059205|NCT05531604||Weight Restored AN-Restricting (WRAN-R)|"History of anorexia nervosa, restricting type - previously meeting full DSM-5 criteria.~Eating Disorder Examination Questionnaire (EDE-Q) ≤ 2 (within 1 standard deviation [SD] of community norms and lower than 1 standard deviation from clinical norms for female anorexia nervosa, restricting type populations)"
33059206|NCT05531604||Healthy controls|Healthy females from any racial or ethnic background, not meeting DSM-5 criteria for any psychiatric disorder.
33059207|NCT05525598|Experimental|"Internet-delivered therapist-assisted treatment: One step at the time"|"One step at the times consists of 11 internet-delivered modules delivered over 14 weeks. Each module explores a different theme, primarily including elements from Cognitive Behavioral Therapy (CBT) for FSD, and includes FSD-related psychoeducation, various interactive exercises, and video and audio material. Interactions between patients and the therapist will take place via the telephone 3 times (start, mid-term, and end-of-treatment) and embedded messaging (therapist will respond to patients) approx. 2 times a week. The participating therapists are supervised every other week by specialized psychologists."
33334734|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
33334735|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
33059208|NCT05525598|Active Comparator|"Internet-delivered non-guided treatment: Get started"|"Get started is a non-guided self-help program, developed as an active control, that includes 4 modules consisting of FSD-related psychoeducation and guidance on making lifestyle improvements. Participants will have access to the Get started program for 14 weeks."
33059209|NCT00163579|Experimental|Bryophyllum|
33059210|NCT00163579|Placebo Comparator|Placebo|
33059211|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
33059212|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
33059213|NCT00407173|Experimental|1|HCV-796 1000mg single dose
33059214|NCT05516082|Experimental|Lens A|Participants will wear Lens A for 15 minutes and then cross-over to Lens B for 15 minutes.
33059215|NCT05516082|Active Comparator|Lens B|Participants will wear Lens B for 15 minutes.
33059216|NCT05513001|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
33059217|NCT05513001|Placebo Comparator|Arm 2: LOU064 Placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
33059218|NCT05513001|Experimental|Arm 3: LOU064 (Open Label)|LOU064 (open-label) taken orally for 24 weeks per treatment cycle (Arm 3)
33059219|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
33059220|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
33059221|NCT05502900|Experimental|Melatonin|Melatonin tablet 5 mg. 4 tablets taken at night (20 mg) for 5 years.
33059222|NCT05502900|No Intervention|Control|No intervention. Follows the current standard of observation after primary tumor treatment.
33059223|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
33059224|NCT05501691|Placebo Comparator|Placebo|Laser Simulation
33059225|NCT05501691|Experimental|445 nm|445 nm Diode Laser Wavelength (SiroLaser Blue)
33059226|NCT05501691|Experimental|660 nm|660 nm Diode Laser Wavelength (SiroLaser Blue)
33059227|NCT05501691|Experimental|970 nm|970 nm Diode Laser Wavelength (SiroLaser Blue)
33059228|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
33059229|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
33059230|NCT05459922|Experimental|Bright light therapy group|Participants will receive 30-minute morning bright light therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
33059231|NCT05459922|Placebo Comparator|Dim light (placebo) group|Participants will receive 30-minute dim light (placebo) therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
33059232|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
33334736|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
33334737|NCT04505956|Experimental|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
33334738|NCT04505956|Active Comparator|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
33334739|NCT05650502||ISC (ISAMIMA children group-Cobly)|"This group included children from 6 to 59 months living in Cobly and receiving the SMC treatment. The treatment is administered for three consecutives days for 4 months (from july to october).~For children under 12 months: one dose of SP 250/12.5mg on day 1 AQ 75mg once daily for 3 days For children from 12 to 59 months: one dose of SP 500/25mg on day 1 AQ 150 mg once daily for 3 days A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
33059233|NCT00053573|Experimental|1|
33059234|NCT04723849|Experimental|Tretment group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
33059235|NCT04723849|Placebo Comparator|Placebo group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
33059236|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
33059237|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
33059238|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
33059239|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
33059240|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
33059241|NCT00164749|Experimental|1 gram|1 g/day curcumin
33059242|NCT00164749|Experimental|4 gram|4 g/day curcumin
33059243|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
33059244|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
33059245|NCT00053768|Active Comparator|CHOEP-21|"CHOEP-21-Schema:~Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
33059246|NCT00053768|Experimental|high CHOEP-21|"High-CHOEP-21-Schema:~Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
33059247|NCT04724083||Fabry Disease subjects with cardiomyopathy|Patients (males and females) with confirmed Fabry disease, with clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
33059248|NCT04724083||Fabry Disease subjects without cardiomyopathy|Patients (males and females) with confirmed Fabry disease, without clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
33059249|NCT04724083||Healthy control|The control group will consist of age-and gender-matched healthy individuals.
33059250|NCT00164905|Active Comparator|Doppler ultrasound|
33059251|NCT00164905|No Intervention|No Doppler ultrasound|
33059252|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
33059253|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
33059258|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
33059259|NCT05411835|Active Comparator|Nutrition Ketogenic Supplement|The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.
33059260|NCT05411835|Sham Comparator|Isocaloric Placebo Supplement|The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.
33059261|NCT00165178|Experimental|Individualized ASP dose|
33059262|NCT00165178|Active Comparator|Fixed dose ASP|
33059263|NCT00165178|Experimental|Dexamethasone|
33059264|NCT00165178|Active Comparator|Prednisone|
33059265|NCT05401968|Experimental|Intervention group|Osteoporosis patients who have participated in patient education
33059266|NCT05401968|No Intervention|Control group|Osteoporosis patients who have not participated in patient education
33059267|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
33059268|NCT05352750|Experimental|Dose Level 1|SON-1010 Dose Level 1
33059269|NCT05352750|Experimental|Dose Level 2|SON-1010 Dose Level 2
33059270|NCT05352750|Experimental|Dose Level 3|SON-1010 Dose Level 3
33334740|NCT05650502||IST (ISAMIMA children group-Tchaourou)|"This group included children from 6 to 59 months living inTchaourou and who did not receiving the SMC treatment.~A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
33334741|NCT04498468|Experimental|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
33334742|NCT04498468|Sham Comparator|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
33334743|NCT03719534|Active Comparator|Haplo-SCT|people enrolled in this arm will receive a typical haplo-identical donor SCT
33334744|NCT03719534|Experimental|Haplo-cord SCT|people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT
33334745|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
33334746|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
33334747|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
33334748|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
33334749|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
33334750|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
33334751|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
33334752|NCT03700294|Experimental|ADCT-601|
33334753|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
33334754|NCT04699864|Experimental|Diabetic Retinopathy (DR)|Screening of DR with artificial intelligence (NeoRetina algorithm) and diagnostic evaluation with a standard of care ophthalmological examination.
33334755|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
33334756|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
33334757|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
33334758|NCT03702946|Experimental|study group|
33059271|NCT05352750|Experimental|Dose Level 4|SON-1010 Dose Level 4
33059272|NCT05352750|Experimental|Dose Level 5|SON-1010 Dose Level 5
33059273|NCT05352750|Experimental|RP2D Expansion|RP2D Dose of SON-1010
33059274|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33059275|NCT00165763|Experimental|1|
33059276|NCT00165802|Experimental|1|
33059277|NCT04723693||individuals With Haemophilia A and with inhibitors on emicizumab|Qualitative interviews
33059278|NCT00165919||HCV+|No group or cohort; not a clinical trial
33059279|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
33059280|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
33059281|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
33059282|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
33059283|NCT00166231||Chest pain patients|
33059284|NCT00166231||Murmur group|
33059285|NCT00166270|Experimental|1|
33059286|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33059287|NCT05333133|Experimental|High calorie formula on IGF-1, TNF-alpha and total lymphocyte counts|Interventional study with pre-, post design after the subjects are diagnosed with TB and UTI, they will receive 400 ml (equal with 400 kcal) of high calorie formula per day, prescribed by the researcher (a pediatrician) for 90 days consumption. Body weight and body height will be monitored by the researcher group every 30 days to record the tolerance, acceptance and complaints (and the side effects) the blood will be withdraw at day 0 (before intervention) and day 90 (after intervention) to investigate the IGF-1, TNF-alpha and total lymphocyte counts
33059288|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
33059289|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
33059290|NCT00054236|Experimental|non-myeloablative conditioning regimen|
33334759|NCT03702946|No Intervention|control group|
33334760|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
33334761|NCT04491526|Experimental|Tamsulosin Arm|p.o.
33334762|NCT04491526|Placebo Comparator|Placebo Arm|p.o.
33334763|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
33334764|NCT04484350|Experimental|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
33334765|NCT04484350|Active Comparator|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
33059291|NCT05308914||Resilience Study Cohort|Observational, descriptive longitudinal cohort design. See inclusion and exclusion criteria for more information
33059292|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
33059293|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
33059294|NCT04723732|Experimental|Myrrh mouthwash|1% mouthwash of Commiphora myrrha made from resin extract. Participants will use 10 ml of the mouthwash twice daily for 14 days.
33059295|NCT04723732|Active Comparator|Chlorhexidine Mouthwash|Commercial 0.2% Chlorhexidine gluconate mouthwash (Avalon Pharma, Riyadh). Participants will use 10 ml of the mouthwash twice daily for 14 days.
33059296|NCT04723732|Placebo Comparator|Normal saline|Commercial 0.9% sodium chloride solution (Pharmaceutical solutions industry, Jeddah). Participants will use 10 ml of the mouthwash twice daily for 14 days.
33059297|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
33059298|NCT05259306|Experimental|Treatment-resistant Schizophrenia group|The subject will present for three baseline visits, followed by a treatment visit and subsequently follow-up visits at 24-hours, 48-hours, 1 week, 2 weeks, 1 month, and 3 months. Feasibility will be assessed as well as symptoms via detailed symptom rating scales at each visit. At the treatment visit itself, participants will undergo MR-guided low-intensity focused ultrasound of the MD thalamus.
33059299|NCT05220852|Experimental|Dry needling and exercise|Subjects in this group will undergo one session of dry needling in their upper trapezius muscles to address any overactive trigger points, and they will subsequently continue with neck exercises for a minimum of two weeks, three times per week.
33059300|NCT05220852|Active Comparator|Exercise|subjects in this group will have neck exercise only for 2 weeks minimum 3 times a week.
33059301|NCT00167167|Experimental|BMT patients|All patients treated.
33059302|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
33059303|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
33059304|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
33059305|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
33059306|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
33059307|NCT00167557|Experimental|Single Arm Study|
33059308|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
33059309|NCT00167596|Active Comparator|2|Early goal directed therapy
33059310|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
33059311|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
33059312|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
33059313|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
33059314|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
33113256|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
33334766|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
33334767|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
33334768|NCT03697486|Experimental|High Protein|(40,6% protein)
33334769|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
33334770|NCT03697486|Experimental|Low Protein|(12.4% protein)
33334771|NCT03699826|Experimental|TMS|
33334772|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
33334773|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
33059315|NCT05205915|Experimental|Single arm|All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
33059316|NCT00045591|Experimental|Celecoxib 100 mg|
33059317|NCT00045591|Experimental|Celecoxib 400 mg|
33334774|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
33059318|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
33059319|NCT00167947|Active Comparator|A|
33059320|NCT00167947|Experimental|B|
33059321|NCT00168025|Experimental|IgPro10|
33059322|NCT05205876|No Intervention|Control (Dexcom app)|This group will use the Dexcom application for management of their blood glucose for the duration of the study (8 weeks).
33059323|NCT05205876|Experimental|Intervention (Eddii app)|This group will use the Dexcom application for the initial 2 weeks of the study, and switch to using the Eddii application on Day 14 of the study for the remaining 6 weeks of the study.
33059324|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
33059325|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
33059326|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
33059327|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
33059328|NCT00045669|Experimental|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
33059329|NCT05180682|Experimental|Supervised|This group training was supervised by the health care provider.
33059330|NCT05180682|Active Comparator|Non-Supervised|This group was non-supervised.
33059331|NCT00168415|Experimental|1|Botulinum Toxin Type A
33059332|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
33059333|NCT04731948|Placebo Comparator|Folic Acid + Placebo|400µg Folic Acid per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
33334775|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
33334776|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
33334777|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
33334778|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
33334779|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
33334780|NCT03699592|No Intervention|Control|
33334781|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
33334782|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
33059334|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 1|400µg Folic Acid + 2 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
33059335|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 2|400µg Folic Acid + 10 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
33059336|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 3|400µg Folic Acid + 50 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
33059337|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
33059338|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
33113257|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
33059339|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
33059340|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
33059341|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
33113258|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
33113259|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
33059342|NCT04731909|Experimental|Toripalimab Combined With Anlotinib, Etoposide and Platinum|Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d,d1-14,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 or Carboplatin AUC=5, d1, q3w,4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d, was taken orally for 2 weeks and stopped for 1 week until the disease progressed.
33059343|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
33059344|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
33334783|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
33334784|NCT03699514||Subject who completed or will complete a BNA test|
33334785|NCT04483804||disease free survival|Time from randomization to relapse or death due to disease progression
33059345|NCT05176743|Other|Usual Care|"Referral to services~Nutrition pamphlets~One-time payment of $300 paid 4 months after baseline"
33059346|NCT05176743|Experimental|Unconditional Cash Transfer Intervention|"Three monthly payments of $100~Referral to services~Nutrition pamphlets"
33059347|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
33059348|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
33059349|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
33059350|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
33334786|NCT04483804||non-disease free survival|Time of metastasis or death
33059351|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
33334787|NCT04373122|Experimental|REBOA|Insertion of the ER-REBOA Catheter during ongoing CPR
33059352|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
33059353|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
33059354|NCT05130099|Experimental|Interdisciplinary complex intervention|
33059355|NCT05130099|No Intervention|Usual care|Six months after the intervention period (T3), the participants randomized to usual care will be offered a modified version of the intervention in line with their personally expressed needs.
33059356|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
33059357|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
33059358|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
33059359|NCT00398333|No Intervention|No supplementation|
33059360|NCT00169390||pregnant smokers|
33059361|NCT00169390||pregnant non smokers|
33059362|NCT05099874|Experimental|EndeavorRx|Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
33059363|NCT00169546|Experimental|Arm 1|
33059364|NCT05015556|No Intervention|Casting|Casting of the distal radius for 6 weeks
33059365|NCT05015556|Active Comparator|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
33059366|NCT04723888|Experimental|alpha-ketoglutarate Group|Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
33059367|NCT04723888|No Intervention|Normal Control Group|Don't take alpha-ketoglutarate supplements
33059368|NCT00169702|Other|Standard|standard information
33059369|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
33059370|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
33059371|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
33059372|NCT00169741|Other|cohort|
33059373|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
33059374|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
33059375|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
33059376|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
33059377|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
33059378|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
33334788|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
33334789|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
33334790|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
33334791|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
33334792|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
33334793|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
33334794|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
33334795|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
33113260|NCT04623255|No Intervention|STANDARD OF CARE|Standard patient care for severe COVID-19
33113261|NCT04623255|Active Comparator|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
33334796|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
32869815|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
32869816|NCT00026221|Experimental|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
33113262|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
33113263|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
32869817|NCT00026221|Experimental|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
32869818|NCT00026221|Experimental|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
32869819|NCT05538936|Experimental|Baby SPA|Baby SPA application time: It is done regularly from the first month, at least once a month. The ideal time for application is the first six months. The water in the tub is prepared to be 33°C. The baby, whose clothes are taken off, wearing a waterproof diaper suitable for the tub and a neck ring, is taken into the tub. The application usually takes 10-15 minutes, depending on the baby's reactions to the water for the first time. After the parent and baby get used to the process, the time can be increased to 30 minutes. In this process, the baby's hands, abdomen, and legs are made to recognize the water and the baby's movements are monitored. Care is taken that the baby does not drink the water. After the application period is over, the baby is removed from the tub and dried with a towel. Finally, the baby is massaged for 10-15 minutes and dressed.
33113264|NCT04623411|Experimental|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
33113265|NCT04623411|Experimental|Control Group|Neonatal resuscitation training with classical method.
33113266|NCT02902133|Other|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
33113267|NCT04623333|Experimental|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
33113268|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
33113269|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
33113270|NCT04623021|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
33113271|NCT04623021|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
33113272|NCT02902016|Experimental|Lactase expression induction by GED|
33113273|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
33113274|NCT02902055|Active Comparator|Isotonic saline|
33113275|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
33113276|NCT04622748||Healthy Control|Uninfected people in Wuhan
33113277|NCT04622826|Experimental|sequential immune plasma infused patients|immune covid 19 plasma infusion
33113278|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
33113279|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
33113280|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
33113281|NCT04622631||PRRT negative|no response to PRRT treatment
33113282|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
33113283|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
33113284|NCT04622592|Experimental|Vaccine (30 µg/strain) adjuvanted with AS03|Treatment group 2: 30 µg/strain QVLP vaccine adjuvanted with AS03
33334797|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
33334798|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
33334799|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
33113285|NCT04622592|Active Comparator|Vaccine (30 µg/strain) unadjuvanted|Treatment group 4: 30 µg/strain QVLP vaccine unadjuvanted
33113286|NCT04622592|Active Comparator|Vaccine (60 µg/strain) Fluzone HD Quad|Treatment group 5: 60 µg/strain Fluzone HD Quad vaccine
33334800|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
33334801|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
33334802|NCT04694560||CLL/SLL|Diagnosis of CLL or SLL confirmed by the enrolling institution
33334803|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
33334804|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
33113287|NCT04681235|Experimental|Training Group|Training Group recieved 10 sessions on VR (Grail Motekforce, Netherlands) during two weeks. One session lasted 40 minuties.
33113288|NCT00553553|Active Comparator|1|IV morphine group
33113289|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
33059379|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
33059380|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
33059381|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
33059382|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
33059383|NCT00170287|Active Comparator|2|ICD Therapy only
33059384|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
33059385|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
33059386|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
33059387|NCT00170677|Active Comparator|A|
33059388|NCT00170677|Experimental|B|
33113290|NCT04622982|Experimental|All participants|Obese subjects with BMI >= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
33113291|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
33113292|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
33113293|NCT04622202|Active Comparator|pregabalin|oral capsule pregabalin 150 mg.
33113294|NCT04622202|Placebo Comparator|multivitamin|oral multivitamin capsule.
33113295|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
33059389|NCT00170716|Active Comparator|Control|
33059390|NCT00170716|Experimental|Investigational|
33059391|NCT00170755|Experimental|1|Darifenacin
33059392|NCT04994106|Experimental|Cohort A1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
33059393|NCT04994106|Experimental|Cohort A2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
33059394|NCT04994106|Experimental|Cohort A3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
33059395|NCT04994106|Experimental|Cohort A4 Japanese descent: AZD5462 Dose 3|Randomized participants of Japanese descent will receive Dose 3 of AZD5462.
33059396|NCT04994106|Experimental|Cohort A5: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
33059397|NCT04994106|Experimental|Cohort A6 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
33059398|NCT04994106|Experimental|Cohort A7: AZD5462 Dose 5|Randomized healthy participants will receive Dose 5 of AZD5462.
33059399|NCT04994106|Experimental|Cohort A8 Japanese descent: AZD5462 Dose 5|Randomized participants of Japanese descent will receive Dose 5 of AZD5462.
33059400|NCT04994106|Placebo Comparator|Part A: Placebo (Healthy Participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
33059401|NCT04994106|Placebo Comparator|Part A: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
33059402|NCT04994106|Experimental|Cohort B1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
33059403|NCT04994106|Experimental|Cohort B2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
33059404|NCT04994106|Experimental|Cohort B3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
33113296|NCT04622475|Experimental|Treatment|Fecal Microbiota Transplant (FMT) Capsule
33113297|NCT04622358|Experimental|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
33113298|NCT04622358|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
33113299|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
33113300|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
33334805|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
33334806|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
33419211|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
33059405|NCT04994106|Experimental|Cohort B4: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
33059406|NCT04994106|Experimental|Cohort B5 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
33059407|NCT04994106|Placebo Comparator|Part B: Placebo (Healthy participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
33059408|NCT04994106|Placebo Comparator|Part B: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
33059409|NCT00171145|Experimental|1|Darifenacin
33059410|NCT00171145|Placebo Comparator|2|Placebo
33059411|NCT00171184|Experimental|1|Darifenacin
33059412|NCT00171184|Placebo Comparator|2|Placebo
33059413|NCT04954248|Experimental|Covid-19 Negative/Uninfected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
33059414|NCT04954248|Experimental|Covid-19 Positive/Infected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
33059415|NCT04924374|Experimental|anti PD1 therapy plus Microbiota Transplant|"Active arm: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks"
33059416|NCT04924374|Active Comparator|anti PD1 therapy|Control arm: no intervention before anti PD1 therapy
33059417|NCT00171496|Experimental|Cyclosporine microemulsion|
33059418|NCT00171496|Active Comparator|Tacrolimus|
33059419|NCT04869657|Active Comparator|Sustainment 1: Coaches with CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by Children's Hospital of Philadelphia (CHOP) research consultants. In Year 2, schools in Sustainment 1 will receive reduced support for Tier 2 interventions provided by school district coaches. The coaches will in turn receive diminished support from research consultants. In Year 3, schools in both conditions will implement Tier 2 interventions with support from school district coaches; coaches will not receive direct assistance from research consultants.
33059420|NCT04869657|Active Comparator|Sustainment 2: Coaches without CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by CHOP research consultants. In Years 2 and 3, schools in Sustainment 2 will receive support from school district coaches but coaches will not receive help from research consultants.
33059421|NCT00171808|Experimental|Letrozole|
33059422|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
33059423|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
33059424|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
33059425|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
33059426|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
33059427|NCT00171886|Experimental|octrotide|
33059428|NCT04847739|Experimental|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
33059429|NCT04847739|Active Comparator|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
33059430|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
33059431|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
33059432|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
33059433|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
33059434|NCT04830306|Active Comparator|6MST|Six minute step test
33059435|NCT04830306|Active Comparator|6MWT|Six minute walk test
33059436|NCT04830306|Active Comparator|CPET|Cardiopulmonary exercise test
33059437|NCT04828863||Index subjects|25 young adults with MSUD who are 21 years and older.
33059438|NCT04828863||Control subjects|25 age-matched siblings or acquaintances who do not have MSUD and are 21 years and older
33113301|NCT00562341||bariatric surgery|description of enrollees
33113302|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
33113303|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
33334807|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
33334808|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
33334809|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
33334810|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
33334811|NCT04465318|Experimental|E-cigarettes (EC)|EC + Counseling
33334812|NCT04465318|Active Comparator|Nicotine Replacement Therapy (NRT)|NRT + Counseling
33334813|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
33059439|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
33059440|NCT04764162|Active Comparator|Choline supplementation|Participants will consume 1000 mg of choline per day for 4 weeks.
33059441|NCT04764162|Placebo Comparator|Placebo supplementation|Participants will consume 1000 mg of placebo per day for 4 weeks.
33059442|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
33059443|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
33059444|NCT00045786|Experimental|400 mg CC-1088|
33059445|NCT00045786|Experimental|800 mg CC-1088|
33059446|NCT00045786|Experimental|1200 mg CC-1088|
33059447|NCT00045786|Experimental|1500 mg CC-1088|
33059448|NCT04732845|Experimental|Group A - NHL/CLL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
33059449|NCT04732845|Experimental|Group B - ALL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
33059450|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33059451|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33059452|NCT04723654||ICU Population|Patients admitted to one of 3 ICUs at Lurie Childrens
33059453|NCT04723654||Non-ICU Population|Healthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
33059454|NCT04683003|Experimental|Prophylactic Cohort: TAK-755|"All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.~Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study."
33059455|NCT04683003|Experimental|On-Demand Cohort: TAK-755|"Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved.~Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study."
33059456|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
33059457|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
33059458|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
33334814|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
33334815|NCT04458532|Experimental|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
33334816|NCT04458532|Experimental|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
33334817|NCT04458532|Experimental|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
33059459|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
33059460|NCT04631484|Experimental|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
33059461|NCT04631484|Placebo Comparator|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
33059462|NCT04731194|Experimental|performance-based financial incentive program|Village doctors in villages of the intervention group will promote policy awareness, support registration, follow-up patients, and receive financial incentives based on their performance.
33059463|NCT04731194|No Intervention|current situation|Village doctors in villages of the control group will not be contacted. The control group would serve as a natural baseline and do not receive any intervention.
33059464|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
33059465|NCT00173875|Experimental|A|Iressa
33059466|NCT04605081|Experimental|Naltrexone+Bupropion Medication|
33334818|NCT04458532|Active Comparator|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
33334819|NCT05666388|Experimental|Rescue stenting (RESFIT)|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RESFIT)
33334820|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
33334821|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
33334822|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
33059467|NCT04605081|Placebo Comparator|Placebo|
33059468|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
33059469|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
33059470|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
33059471|NCT04599504|Experimental|Lisdexamfetamine dimesylate|
33059472|NCT04599504|Placebo Comparator|Placebo|
33059473|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
33113304|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
33113305|NCT04622397|Active Comparator|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
33113306|NCT04622397|Placebo Comparator|Group S (saline) (n=15)|Group S saline will be injected
33113307|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
33113308|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
33334823|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
33334824|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
33334825|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
33334826|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
33334827|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
33334828|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
33419212|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
33419213|NCT01319695|Experimental|corifollitropin alfa|
33059474|NCT04582422|Experimental|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
33059475|NCT04582422|No Intervention|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
33059476|NCT04556214|Experimental|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
33059477|NCT00174499|Experimental|1|2 mg nicotine gum
33059478|NCT00174499|Experimental|2|4 mg nicotine gum
33059479|NCT00174616|Experimental|Single arm|
33059480|NCT00174655|Active Comparator|A1|
33059481|NCT00174655|Active Comparator|A2|
33059482|NCT00174655|Experimental|B|
33059483|NCT00174655|Experimental|C|
33059484|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
33059485|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
33059486|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
33059487|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
33059488|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
33059489|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
33059490|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
33059491|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
33059492|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
33059493|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
33059494|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
33059495|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
33059496|NCT00175357|Active Comparator|1|Oral methadone
33059497|NCT00175357|Experimental|2|Injected diacetylmorphine
33059498|NCT00175396|Active Comparator|1|
33059499|NCT00175396|Experimental|2|
33059500|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
33059501|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
33059502|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
33059503|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
33059504|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
33059505|NCT04503096|Experimental|High-dose accelerated rTMS|
33059506|NCT00407992|Experimental|Occipital nerve stimulation ON|
33059507|NCT00407992|Other|Occipital nerve stimulation OFF|
33059508|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
33059509|NCT00056537|Experimental|1|
33059510|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
33059511|NCT04493619|Experimental|PLX2853 Phase 2a Monotherapy|Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.
33059512|NCT04493619|Experimental|PLX2853 + Carboplatin Phase 1b/2a Combination Therapy|"Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled.~Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled."
33059513|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
33059514|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
33059515|NCT04455633|Experimental|LX9211 low dose|LX9211, once daily
33059516|NCT04455633|Experimental|LX9211 high dose|LX9211, once daily
33059517|NCT04455633|Placebo Comparator|Placebo|Placebo, once daily
33059518|NCT00056654|Experimental|1|
33059519|NCT04420533|Active Comparator|Behavior therapy alone|Behavior therapy alone
33059520|NCT04420533|Experimental|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
33059521|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
33334829|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
33334830|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
33334831|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
33334832|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
33334833|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
33334834|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
33059522|NCT04413591|Experimental|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
33059523|NCT04413591|No Intervention|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
33059524|NCT00176293|Experimental|1|dexamethasone
33059525|NCT00176293|No Intervention|2|
33059526|NCT00056693|Experimental|A|
33059527|NCT00176449|Active Comparator|Bupropion SR|
33059528|NCT00176449|Placebo Comparator|Placebo|
33059529|NCT00176683||All comers|capnography used for all consenting subjects
33059530|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
33059531|NCT04268823|Experimental|QBW251|Oral use, one capsule twice daily.
33059532|NCT04268823|Placebo Comparator|Placebo|Oral use, one capsule twice daily.
33059533|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
33059534|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
33059535|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
33059536|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
33059537|NCT00177229|Experimental|B|
33059538|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
33059539|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
33059540|NCT00177346|Experimental|CAS with cerebral protection|
33059541|NCT00177346|Active Comparator|CAS without cerebral protection|
33059542|NCT00177424|Active Comparator|1|Sertraline
33059543|NCT00177424|Placebo Comparator|2|matching placebo
33059544|NCT00397605|Experimental|Crossover|
33059545|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
33059546|NCT00177463|Placebo Comparator|Placebo|Placebo
33059547|NCT00423644|Experimental|Single Arm|
33059548|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
33059549|NCT04723342|Experimental|Blinatumomab|Consolidation therapy with Blinatumomab administration
33059550|NCT04161183|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
33059551|NCT04161183|Experimental|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
33059552|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
33059553|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
33059554|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
33059555|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
33059556|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
33059557|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
33059558|NCT00177931||liver transplant patients in ICU|
33059559|NCT04723420|Active Comparator|Steamroller Technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
33059560|NCT04723420|Active Comparator|Direct Technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
33059561|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
33059562|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
33059563|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
33059564|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
33334835|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
32871637|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
33334836|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|"LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.~LMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1."
33334837|NCT05668650|Active Comparator|Medical Reference Product|"Keytruda® will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
33059565|NCT00408187|Active Comparator|1.|
32871638|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
33059566|NCT00408187|Placebo Comparator|3.|
33059567|NCT00408187|Active Comparator|2.|
33059568|NCT00408226|Experimental|1|
33059569|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
33059570|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
33059571|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
33059572|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
33059573|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
33059574|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
33059575|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
33059576|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
33059577|NCT00057005|Experimental|1|
33059578|NCT00179062|Active Comparator|1|
33059579|NCT00179062|Active Comparator|2|
33059580|NCT04125927|Experimental|Open-label arm|
33059581|NCT00179140|No Intervention|1|control period
33059582|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
33059583|NCT00179140|Active Comparator|3|protein supplementation only
33059584|NCT00057044|Other|Arm 1|
33059585|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
33059586|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
33059587|NCT00179218|Active Comparator|1|only protein supplementation
33059588|NCT00179218|Active Comparator|2|protein supplementation plus exercise
33059589|NCT04723459|Active Comparator|Ivermectin mask group|Contacts who will use ivermectin masks
33059590|NCT04723459|No Intervention|ordinary mask group|Contacts who will use regular masks
33059591|NCT00057083|Other|Arm 1|
33059592|NCT04723498|Other|Patients|male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study
33059593|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
33059594|NCT00179374|Active Comparator|2|print intervention with no telephone component
33059595|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
33059596|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
33059597|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
33059598|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
33059599|NCT00057122|Active Comparator|1|
33059600|NCT00057122|Active Comparator|2|
33059601|NCT00057122|Active Comparator|3|
33059602|NCT00057122|Active Comparator|4|
33059603|NCT04723381|Experimental|Experimental|Partivipants recieved web based genital hygiene education for seven week
33059604|NCT04723381|No Intervention|Control|No intervention was applied to the women in the control group
33059605|NCT00179764|Other|Reduced Intensity Conditioning Regimen|
33059606|NCT00057161|Other|Arm 1|
33059607|NCT00179803|Experimental|high dose chemotherapy|
33059608|NCT00057200|Other|Arm 1|
33059609|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
33059610|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
33059611|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
33059612|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
33059613|NCT04730960||Study Group|Healthy patients between the ages of 18 and 30 without neck problems will be included in the study.
33059614|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
33059615|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
33059616|NCT04729569|Other|Tested finish line preparation|Feather edge finish line preparation (Intervention)
33059617|NCT04729569|Active Comparator|Comparator finish line preparation|Deep chamfer finish line preparation (Comparator)
33059618|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
33059619|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
33334838|NCT05668650|Experimental|Investigational Product|"MB12 will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
33334839|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
33334840|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
33059620|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
33059621|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
33059622|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
33059623|NCT04030026|Active Comparator|Arm 1a: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 1
33059624|NCT04030026|Placebo Comparator|Arm 2a: Placebo|Placebo twice a day for Treatment Period 1
33059625|NCT04030026|Placebo Comparator|Arm 1b: Placebo|Placebo twice a day for Treatment Period 1
33059626|NCT04030026|Active Comparator|Arm 2b: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 2
33059627|NCT00180700|Experimental|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
33059628|NCT00180700|Experimental|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
33059629|NCT04729491|Active Comparator|Dutasteride|Dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
33059630|NCT04729491|Placebo Comparator|Placebo|Placebo q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
33059631|NCT00057356|Placebo Comparator|1|
33059632|NCT00057356|Experimental|2|Low dose
33059633|NCT00057356|Experimental|3|Middle dose
33059634|NCT00057356|Experimental|4|High dose
33059635|NCT03972384|Experimental|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
33059636|NCT03972384|No Intervention|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
33059637|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
33059638|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
33059639|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
33059640|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
33059641|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
33059642|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
33059643|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
33059644|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
33059645|NCT00408616|Experimental|1|Grazax treatment
33059646|NCT00408616|Placebo Comparator|2|Grazax Placebo
33059647|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
33059648|NCT00182338||Peritoneal Dialysis Patients|
33059649|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
33059650|NCT00182455|Placebo Comparator|2|Placebo
33059651|NCT00182533|Experimental|1|Sertraline
33059652|NCT00182533|Placebo Comparator|2|Placebo
33059653|NCT00408733|No Intervention|1|
33334841|NCT03511664|Experimental|177Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
33334842|NCT03511664|Other|Best supportive/best standard of care (BS/BSOC) alone|Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
33059654|NCT00408733|Experimental|2|Intervention
33059655|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
33059656|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
33059657|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
33059658|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
33059659|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
33059660|NCT00183313|Active Comparator|2|Participants will receive usual care
33059661|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
33059662|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
33059663|NCT02963662|No Intervention|Normal BMI group|no intervention
33059664|NCT00183352||1|Women with bipolar disorder
33059665|NCT00183352||2|Women who are healthy controls
33059666|NCT03970083||Oxygen Levels in Tumors|-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
33059667|NCT00183508|Experimental|1 Cognitive behavioral therapy|
33059668|NCT00183508|Experimental|2 Psychoeducation|
33059669|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
33059670|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
33059671|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
33059672|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
33059673|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
33059674|NCT00183547|Active Comparator|2|Depression-prevention education and support
33059675|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
33059676|NCT00183586|Experimental|1|Participants will receive family-based treatment
33059677|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
33059678|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
33059679|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
33059680|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
33059681|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
33059682|NCT00183820|Experimental|1|
33059683|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
33059684|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
33059685|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
33059686|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
33059687|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
33059688|NCT03898050|Experimental|A-P|Anterior - Posterior pad placement
33059689|NCT03898050|Experimental|A-L|Anterior - Lateral pad placement
33059690|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
33059691|NCT04730765||Surgical Experimental Group|Patient operated between 01/02/2021 and 30/07/2021, in elective situation of sigmoid diverticulitis
33059692|NCT04730765||Medical Control Group|Patient not operated and medically treated
33059693|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
33419214|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
33419215|NCT05064111||All subjects|The experimental conditions will include a standard prostate biopsy using an FDA-approved ultrasound machine with application of the experimental (non-FDA approved) image fusion software.
33419216|NCT01373437||Intubate|
33113309|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
33113310|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
33113311|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
33113312|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
33113313|NCT04622514|Experimental|people-centered integrated care|
33113314|NCT04622514|Active Comparator|usual care|
33113315|NCT04621734|Active Comparator|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
33113316|NCT04621734|Placebo Comparator|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
33113317|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
33334843|NCT03716414||Experimental SLN arm|"Experimental SLN arm~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
33113318|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
33113319|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
33113320|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
33113321|NCT04621929|Experimental|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
33113322|NCT04621929|Active Comparator|Allocated to pragmatic control|Remain on their current regimen
33113323|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
33113324|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
33113325|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
33113326|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
33113327|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
33113328|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
33113329|NCT04621695|Other|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
33113330|NCT04621695|Other|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.~Patients were asked to administer an enema 2 hours prior to the procedure."
33113331|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
33113332|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
33113333|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
33113334|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
33113335|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
33113336|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
33113337|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
33113338|NCT04681664|Experimental|50 % fat diet|In the high fat group the subjects were assigned to the diet containing in average 50 % fat, 25 % proteins and 25 % carbohydrates for four weeks.
33113339|NCT04621461|Placebo Comparator|Experimental Arm #1|Placebo
33113340|NCT04621461|Experimental|Experimental Arm #2|Zinc sulfate
32871639|NCT00304187|Experimental|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
33113341|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
33113342|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
33113343|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
33113344|NCT04621617|Active Comparator|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
33113345|NCT04621617|Active Comparator|Albumin + SMT|Human albumin plus placebo of midodrine
33113346|NCT04621617|Placebo Comparator|SMT|standard medical therapy plus placebo of midodrine
33113347|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
33334844|NCT05646680|Other|two step adnexectomy|Patients planned for unilateral or bilateral adnexectomy (removal of ovary and salpinx) will have their adnexectomy performed in two steps in the same surgical episode: first the salpingectomy (removal of the salpinx), then the oophorectomy (the removal of the ovary).
33334845|NCT00054717|Other|Tipranavir(TPV)/low dose ritonavir(r)|
33113348|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
33113349|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
33334846|NCT00054717|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
33334847|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
33113350|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
33113351|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
33334848|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
33334849|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
33334850|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
33334851|NCT03716336|Other|aerobic exercise|walking on treadmill
33113352|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
33113353|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
33334852|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
33334853|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
33113354|NCT00562419|Experimental|1|CT-322
33113355|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
33113356|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
33334854|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
33334855|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
33334856|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
33334857|NCT03731364|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (5 mg), was prepared at 0.05 mg/mL CA-008 (vocacapsaicin)
33334858|NCT03731364|Placebo Comparator|Placebo - Cohort 1|"Placebo for Cohort 1~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
33334859|NCT03731364|Active Comparator|CA-008 10 mg (0.1 mg/mL) Cohort 2|Cohort 2 (10 mg), was prepared at 0.1 mg/mL CA-008 (vocacapsaicin)
33334860|NCT03731364|Active Comparator|CA-008 15 mg (0.15 mg/mL) Cohort 3|Cohort 3 (15 mg), was prepared at 0.15 mg/mL CA-008 (vocacapsaicin)
33113357|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
33113358|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
33113359|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
33113360|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
33113361|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
33113362|NCT00562614|Experimental|1|SLx-2101
33113363|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
33113364|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
33113365|NCT02900690||Standard care|without use of the Novoseven
33113366|NCT00562653||1|infective endocarditis patients before treatment
33113367|NCT00562653||2|infective endocarditis treatment after treatment
33334861|NCT03731364|Placebo Comparator|Placebo - Cohorts 2 and 3|"Placebo - Cohorts 2 and 3~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
33334862|NCT05645042|Active Comparator|Transcendental Meditation (TM):|TM treatment for PTSD is designed to reduce stress, facilitate deep rest, and increase well-being. It was originally conceptualized as an effortless technique to enable physical relaxation. The treatment will be delivered by experienced, certified TM instructors receiving weekly supervision.
32871640|NCT00304187|Placebo Comparator|Placebo|Participants will take matched placebo.
33113368|NCT00562653||3|control
33113369|NCT05440201|Experimental|First test session|For each patient, the anticoagulant Clexane 50IE/kg is administered in the venous line of the dialysis circuit once blood is detected by the dialysis machine.
33113370|NCT05440201|Experimental|Second test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
33113371|NCT05440201|Experimental|Third test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
33113372|NCT05440201|Experimental|Fourth test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
33113373|NCT04621227|Other|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
33113374|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
33113375|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
33113376|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
33113377|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
33113378|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
33113379|NCT02887066||Patients with thoracic pain and suspicion of ACS|
33113380|NCT04315987|Experimental|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
33113381|NCT04315987|Placebo Comparator|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
33113382|NCT04621383|Experimental|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
33113383|NCT04621383|Placebo Comparator|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
33113384|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
33113385|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
33113386|NCT04621305|Placebo Comparator|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
33113387|NCT04621305|Experimental|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
33113388|NCT04621305|Experimental|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
33113389|NCT00553592|Experimental|Drug|Bicifadine
33113390|NCT00553592|Experimental|Drug: 2|Bicifadine
33113391|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
33113392|NCT04620954|Experimental|Intervention|
33113393|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
33113394|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
33113395|NCT00562692|Experimental|A|Nesiritide
33113396|NCT00562692|Placebo Comparator|B|Placebo
33113397|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
33334863|NCT05645042|Active Comparator|Present Centered Therapy (PCT):|PCT is a focused time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCT was originally designed as a treatment comparator in trials evaluating the effectiveness of trauma-focused cognitive-behavioral therapies such as PE and CPT. Several clinical trials have indicated that PCT may be an effective treatment option for PTSD and that patients may drop out of PCT at lower rates relative to trauma focused forms of CBT.
33334864|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
33334865|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
33334866|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
33334867|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
33334868|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
33334869|NCT03731286|Active Comparator|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
33334870|NCT03731286|Active Comparator|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
33334871|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
33334872|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
33334873|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
33334874|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
33334875|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
33334876|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
33334877|NCT03428750|Placebo Comparator|Placebo|
33334878|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
33334879|NCT03956199|Experimental|experimental pulpotomy|
33334880|NCT03956199|Active Comparator|Root canal treatment|
33334881|NCT04457284|Experimental|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
33334882|NCT00054639|Experimental|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
33334883|NCT04686682|Experimental|JAB-8263 Part1|Monotherapy, dose escalation
33334884|NCT04686682|Experimental|JAB-8263 Part 2|Monotherapy, dose expansion
33334885|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
33334886|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
33334887|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
33334888|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
33334889|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
33334890|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
33334891|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
33334892|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
33334893|NCT03428360|Experimental|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
33334894|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
33334895|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
33113398|NCT02900534|No Intervention|Waiting control group|
33113399|NCT04621110|Experimental|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
33113400|NCT04621110|Active Comparator|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
33334896|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
33113401|NCT04620720|No Intervention|control group|routuine analgesics wil be given
33113402|NCT04620720|Experimental|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
33113403|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
33113404|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
33113405|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
33334897|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
33334898|NCT03957603|Experimental|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
33334899|NCT03957603|Active Comparator|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
33113406|NCT04620876|Experimental|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
33113407|NCT04620408|Experimental|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
33113408|NCT04620408|Experimental|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
33113409|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
33113410|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
33113411|NCT04620525||Healthy controls|Healthy controls
33113412|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
33113413|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
33113414|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
33113415|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
33113416|NCT04620837|Experimental|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
33113417|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
33113418|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
33334900|NCT03732924|Experimental|Five minute rest|
33113419|NCT04620447|Active Comparator|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 7~Final number of participants: 118~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
33113420|NCT04620447|Active Comparator|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 19~Final number of participants: 102~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
33334901|NCT03732924|Active Comparator|Zero minute rest|
33334902|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
33334903|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
33334904|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
33059694|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
33059695|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
33059696|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
33059697|NCT00408772|Experimental|Unresectable colorectal liver mets|
33059698|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
33059699|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
33059700|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
33059701|NCT00184015|Experimental|Schedule A|
33059702|NCT00184015|Experimental|Schedule B|
33059703|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
33059704|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
33059705|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
33059706|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
33059707|NCT00184171|Experimental|Budesonide|Budesonide 9mg
33059708|NCT00184171|Experimental|bismuth|Bismuth mixture
33059709|NCT00184171|Sham Comparator|Fiber|Fiber preparation
33059710|NCT00184249|Experimental|Bipolar radiofrequency ablation|
33059711|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
33059712|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
33059713|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
33059714|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
33059715|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
33059716|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
33059717|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
33059718|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
33059719|NCT00184522|Experimental|Aflurax|pectin-containing natural product
33059720|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
33059721|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
33059722|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
33059723|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
33059724|NCT00184795|Experimental|ALD 0.1|
33059725|NCT00184795|Experimental|ALD 0.25|
33334905|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
33334906|NCT03698968|Other|Single prospective intervention|
33334907|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
33334908|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
33059726|NCT00184795|Placebo Comparator|Placebo|
33334909|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
33334910|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
33334911|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
33334912|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
33334913|NCT03702322|Other|Participants|All participants will undergo each treatment.
33334914|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
33334915|NCT03427268|Experimental|PM060184|PM060184
33334916|NCT03698812||CTL group|control group
33334917|NCT03698812||EXP group|Colonoscope
33059727|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33059728|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33059729|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
33059730|NCT00184873|No Intervention|Regular care|Patients receiving regular care
33059731|NCT00058292|Experimental|Treatment Arm|
33059732|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
33059733|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
33059734|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
33059735|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
33059736|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
33059737|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
33059738|NCT03815643|Experimental|Avelumab|
33059739|NCT00185185|Experimental|1|olmesartan medoxomil
33059740|NCT00185185|Active Comparator|2|atenolol
33059741|NCT00185224|Experimental|Arm 1|
33059742|NCT00185224|Active Comparator|Arm 2|
33059743|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
33059744|NCT00185263|Experimental|1|Ad5FGF-4
33059745|NCT00185263|Experimental|2|Ad5FGF-4
33059746|NCT00185263|Placebo Comparator|3|Placebo
33059747|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
33059748|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
33059749|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks~mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
33059750|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
33059751|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
33059752|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
33059753|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
33334918|NCT04435600|Experimental|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
33334919|NCT04435600|Experimental|Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
33334920|NCT04435600|Experimental|Part 2: Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
33113421|NCT04620447|Active Comparator|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 10~Final number of participants: 115~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
33113422|NCT04620447|No Intervention|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 0~Final number of participants: 125~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
33113423|NCT04620486|Experimental|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
33113424|NCT04620486|No Intervention|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
33113425|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
33113426|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
33113427|NCT04620018|Active Comparator|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
33113428|NCT04620018|Active Comparator|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
33334921|NCT04435600|Experimental|Part 3: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
33334922|NCT04435600|Experimental|Part 4: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).
33334923|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
33334924|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
33334925|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
33334926|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
33113429|NCT04620018|Active Comparator|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
33113430|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
33113431|NCT04620213|Experimental|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
33113432|NCT04620213|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
33113433|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
33113434|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
33113435|NCT04619940|Experimental|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
33334927|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
33334928|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
33334929|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
33334930|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
33334931|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
33334933|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
33334934|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
33334935|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
33334936|NCT04411732||healthy controls|cohort of healthy controls
32740487|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
33059754|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
33059755|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
33059756|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
33059757|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
33059758|NCT00185419|Active Comparator|Arm 1|
33059759|NCT00185419|Active Comparator|Arm 2|
33059760|NCT03758274|Experimental|CBT Phone Intervention|
33059761|NCT03758274|Active Comparator|Being Read A Pamphlet on Alcohol Treatment|
33059762|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
33059763|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
33059764|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
33059765|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
33059766|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
33059767|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
33059768|NCT00185848|Experimental|[18F]FHBG arm|
33059769|NCT00185887|Active Comparator|Terbutaline|
33059770|NCT00185887|Active Comparator|Nitroglycerine|
33059771|NCT00058604|Experimental|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
33059772|NCT03674697|Experimental|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
33059773|NCT03674697|Placebo Comparator|Control Group (White LED)|Subjects will be exposed to a White LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
33059774|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
33059775|NCT00186082|Placebo Comparator|Normal Saline|
33059776|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
33059777|NCT02969642|Active Comparator|Treatment|Treatment laser.
33059778|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
33334937|NCT04867928|Experimental|Venetoclax+azacitidine|subjects will receive treatment until alloSCT
33419217|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
33113436|NCT04619940|Active Comparator|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
33334938|NCT04670068|Experimental|CAR.B7-H3 T cell product|Up to 12 patients will receive three weekly CAR.B7-H3 T cell product infusions at the same dose. To determine the recommended phase 2 dose (RP2D), a modified 3+3 dose escalation design will be used to evaluate two dose levels: Dose Level 1 (7.5x10^7 cells/infusion), Dose Level 2 (2x10^8 cells/infusion). If this dose is not tolerated, then a lower dose of 3.75 × 10^6 cells/infusion will be explored. Up to 3 dose levels of CAR.B7-H3 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 9 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
33419218|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
33059779|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
33059780|NCT00186823|Other|1|
33059781|NCT00186862|Other|1|
33059782|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
33059783|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
33059784|NCT00186940||1|
33059785|NCT00186979|Other|1|
33059786|NCT00058799|Experimental|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
33059787|NCT00058799|Experimental|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
33059788|NCT00058799|Experimental|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
33059789|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
33059790|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
33059791|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
33059792|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
33059793|NCT00187057|Other|4|Hodgkins Disease
33059794|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33059795|NCT00187174|Experimental|Phase 1|
33059796|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
33059797|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
33059798|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
33059799|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
33059800|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
33059801|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
33113437|NCT04619784|Experimental|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
33113438|NCT04619784|Other|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
33113439|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
33113440|NCT02899871||case|aetiology of joint symptoms
33113441|NCT04619667|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
33113442|NCT04619667|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
32740488|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
33113443|NCT04619667|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
33113444|NCT02899832||NIRS|Near Infra Red Spectroscopy.
33113445|NCT04619862|Experimental|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
33113446|NCT04619862|Placebo Comparator|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
33113447|NCT02899598|Experimental|Pregnant women|
33113448|NCT05425121|Active Comparator|Core stability protocol|Participants in this group will undergo core stability exercise program . Each exercise plan will be progressively increased.
33113449|NCT05425121|Experimental|Core Stability with surface electromyography biofeedback|Participants in this group will undergo core stability exercise program with surface electromyography biofeedback. Each exercise plan will be progressively increased with application of surface electromyography biofeedback.
33113450|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
33113451|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
33113452|NCT05425082|Active Comparator|Motor relearning program|"Emphasis of MRP is on practice of specific activities, the training of cognitive control over muscles & movement. Components of activities & conscious elimination of unnecessary muscle activity.• Based on 3 factors -~Elimination of unnecessary muscle activity~Feedback~Practice"
33113453|NCT05425082|Experimental|Neurodevelopmental therapy|"The abnormal patterns must be stopped not by modifying the sensory input, but by giving back to the patient the • The hemiplegic side should be incorporated into all treatment activities to reestablish symmetry and increased functional use~Treatment should produce a change in the quality of movement and functional performance of the involved side~Increase active use of the involved side~Provide practice to improve motor performance that led to motor learning lost or undeveloped control over his output in developmental sequence"
33113454|NCT04316221|Active Comparator|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
33113455|NCT04316221|Experimental|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
33113456|NCT04206124|Experimental|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
33113457|NCT05425043|Experimental|Granulocytes|Patient to receive pooled granulocytes for 7 days concurrently. 10 participants will be approached for this arm.
33113458|NCT05425043|No Intervention|Control|Non-randomised control arm, where patients who are receiving a stem cell transplant, as described in the eligibility criteria, are asked for a blood sample. This is to establish a baseline versus the experimental arm. 10 participants will be approached for this arm.
33113459|NCT02887261|Other|Power Port|patients who received power injectable port
33113460|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
32740489|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
33113461|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
33113462|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
33113463|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
33113464|NCT04619277||Ulsan University Hospital|Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
33113465|NCT04619277||Kangwon National University School of Medicine|Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea
33334939|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
32740490|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
32740491|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
33113466|NCT04619277||Korea University Guro Hospital|Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea
33113467|NCT05425004|Experimental|Cabozantinib|Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.
33113468|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
33113469|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
33113470|NCT04619238||no urinary incontinence|patients without UI
33113471|NCT04619238||stress urinary incontinence|patients with SUI
33113472|NCT04619238||overactive bladder|patients with OAB
33113473|NCT04619238||mix urinary incontinence|patients with MUI
33113474|NCT04619238||Urge|patients with urge incontinence
33113475|NCT05424965||normal weight without gestational diabetes|BMI < 25; normal glucose tolerance
33113476|NCT05424965||normal weight with gestational diabetes|BMI < 25; impaired oral glucose tolerance
33113477|NCT05424965||overweight without gestational diabetes|BMI 25 - 29.9; normal glucose tolerance
33113478|NCT05424965||overweight with gestational diabetes|BMI 25 - 29.9; impaired glucose tolerance
33113479|NCT05424965||obese without gestational diabetes|BMI >= 30; normal glucose tolerance
33113480|NCT05424965||obese with gestational diabetes|BMI >= 30; impaired glucose tolerance
33113481|NCT04619394|No Intervention|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
33113482|NCT04619394|Active Comparator|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
33113483|NCT04619394|Active Comparator|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
33113484|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
33113485|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
33113486|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
33113487|NCT00553865|Placebo Comparator|Group 4|Placebo
33113488|NCT00553865|Other|Group 5|Reference drug
33113489|NCT00562770|Active Comparator|1|Valacyclovir
33113490|NCT00562770|Active Comparator|2|Valganciclovir
33113491|NCT05424770|Experimental|experiment group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course. Afterwards, puzzle activities prepared by the researcher will be implemented and students will be actively involved in the process.
33113492|NCT05424770|No Intervention|control group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course.
33113493|NCT04619550|Other|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
33113494|NCT05424692|Experimental|PTC test group|The adjuvant chemotherapy scheme was selected according to the 3D drug sensitivity test results of micro tumor (PTC) in vitro
33113495|NCT05424692|No Intervention|control group|Making adjuvant chemotherapy strategy based on clinical experience
33113496|NCT04618965|Placebo Comparator|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
33113497|NCT04618965|Experimental|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
33113498|NCT04618965|Experimental|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
33113499|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
33334940|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
33334941|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
33113500|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
33113501|NCT05424653|Experimental|Severe Symptomatic Aortic Regurgitation|Patients will be treated with transcatheter aortic valve system
33334942|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
33113502|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
33113503|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
33113504|NCT01190176|Experimental|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
33113505|NCT04206280|Experimental|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
33113506|NCT04206280|Active Comparator|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
33113507|NCT04618848||Adult Oncology Patients|Adult oncology patients
33113508|NCT04316065|Other|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
33113509|NCT04316065|Other|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
33113510|NCT01190098|Experimental|Lacosamide|
33113511|NCT01190098|Placebo Comparator|Sugar pill|
33113512|NCT04618887||Meige sydrome patients|
33113513|NCT05312593|Experimental|Trial Group|A group of 20 patients will be randomly assigned to Hyaluronic Acid domiciliary treatment, applied into Peri-implant mucositis sites.
33113514|NCT05312593|Active Comparator|Control Group|A group of 20 patients will be randomly assigned to Chlorhexidine mouthwash domiciliary treatment, applied into Peri-implant mucositis sites.
33113515|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
33113516|NCT04314739|Active Comparator|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
33113517|NCT04314739|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
33113518|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
33113519|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
33113520|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
33113521|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
33113522|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
33113523|NCT01190020|Active Comparator|Lubiprostone|24mcg BID for 4 weeks, oral medication
33113524|NCT01190020|Placebo Comparator|Placebo|24mcg BID for 4 weeks (placebo), oral medication
33113525|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
33113526|NCT05424614||intracerebral hemorrhage group|Patients with the intracerebral hemorrhage who presented to the hospital within 24 hours of symptom onset
33334943|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
33334944|NCT03698734|Active Comparator|Evening primrose oil|
33334945|NCT03698734|Placebo Comparator|placebo|
33334946|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
33419219|NCT04042467|Experimental|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
33113527|NCT05306158|Experimental|CC+ECIG Condition|Combustible Cigarette (CC) and Electronic Cigarette (ECIG) users will be trained to avoid CC and ECIG-related images and approach positive images.
33113528|NCT05306158|Active Comparator|CC Only Condition|Participants in this arm will be trained to avoid only combustible cigarette images, not electronic cigarettes images.
33113529|NCT05306158|Sham Comparator|Sham Condition|Participants will pull and push all pictures of CC and ECIG images equally with no preference towards one or the other.
33113530|NCT04619043|Experimental|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
33113531|NCT05304286|Active Comparator|ACT Group Intervention|We will evaluate the effects of an Acceptance and Commitment Therapy (ACT) one-day group intervention (with 1-month post group zoom booster session) on the functional near-infrared spectroscopy (fNIRS) signal in groups of adolescents and adult patients diagnosed with CPSP at >3 months post major orthopedic surgery.
33113532|NCT05304286|No Intervention|Treatment as Usual|Treatment as Usual (TAU) for those with CPSP
33113533|NCT05424575||Group Nonfrail (Group NF)|Modified fraility index was calculated in all patients. Modified fraility index < 0.27 were included to Group NF.
33113534|NCT05424575||Group Frail (Group F)|Modified fraility index was calculated in all patients. Modified fraility index ≥ 0.27 were included to Group F.
33334947|NCT00033657|Experimental|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
33113535|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
33113536|NCT04619433|Experimental|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
33113537|NCT04619433|Placebo Comparator|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
33419220|NCT04042467|Active Comparator|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
32871641|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 18 and 35~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
33113538|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
33113539|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
33113540|NCT04652388|Experimental|Nutritional counseling|Children with autism spectrum disorders to whom administer nutritional counseling
33113541|NCT04652388|No Intervention|Controls|No intervention
33113542|NCT04619160|Active Comparator|propofol|
33113543|NCT04619160|Active Comparator|sevoflurane|
33113544|NCT01165684|Experimental|Step-wise|
33113545|NCT01165684|Active Comparator|Basal-bolus|
33113546|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
33113547|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
33113548|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
33113549|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
33113550|NCT05424497||No outcome provided|
33113551|NCT05424497||outcome positive|
33113552|NCT05424497||outcome negative|
33113553|NCT05424497||implicit bias group|
33113554|NCT01188967|Experimental|GSK598809|Active medication
33113555|NCT01188967|Placebo Comparator|Placebo|Placebo
33113556|NCT04316728|Other|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
33113557|NCT04652271||Patients undergoing pancreatic surgery|Patients undergoing any type of pancreatic surgery.
33113558|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
33113559|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
33113560|NCT05424458|Experimental|single-arm|"Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.~In the first month after definitive prosthesis placement, patients were recalled to complete the MDAS, OES and OHIP questionnaires for the second time. Changes of overall MDAS, OSE and OHIP score were defined as the score after definitive prosthesis placement minus that before the treatment. Negative score changes indicated score decrease of the second questionnaire compared to the first one. Positive score changes indicated score increase."
33113561|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
33113562|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
33113563|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
33113564|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
33113565|NCT05424107|Experimental|Non-nutritional intervention|Children with a prediabetic status that followed up the sessions without nutritional intervention by a health care professional
33113566|NCT04652232|Active Comparator|Treated group|This group will receive the RV3466F lotion and a neutral shampoo
33113567|NCT04652232|Other|Control group|This group will receive a neutral shampoo
33113568|NCT04652349|Experimental|HGP1910|
33113569|NCT04652349|Experimental|HCP1903|
33113570|NCT04652349|Active Comparator|HGP1909|
33113571|NCT04652349|Active Comparator|HGP1911|
33113572|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
33113573|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
33113574|NCT01183234|Experimental|SPD544 (Equasym XL)|
33113575|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
33113576|NCT04618497|Experimental|Inhalational methoxyflurane (Penthrox)|
33113577|NCT04618497|Active Comparator|Intramuscular ketorolac|
33113578|NCT04312516||Controls|Healthy volunteers without neurocognitive impairment
33113579|NCT04312516||Patients|Patients undergoing surgical procedure with at least mild cognitive impairment preoperatively
33113580|NCT05423873|Other|Vitamin C Serum and Moisturizing Sunscreen SPF 45|"Dual Regimen:~Vitamin C Serum Tinted Moisturizing Sunscreen SPF 45"
33113581|NCT04618575|Experimental|Ursodeoxycholic acid combined with total glucosides of paeony|
33113582|NCT04618575|Other|Ursodeoxycholic acid only|
33113583|NCT04679948|Experimental|Period 1 with reference treatment alone|
33113584|NCT04679948|Experimental|Period 2 with reference and test treatment|
33113585|NCT04680338|Active Comparator|Cardiac magnetic resonance imaging|Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings
33113586|NCT04680338|No Intervention|Control|No intervention, following the natural course of coronary atherosclerosis
33113587|NCT04618536|Experimental|Inorganic sunscreen|
33113588|NCT04618536|Experimental|Organic sunscreen|
33334948|NCT00033657|Experimental|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
33334949|NCT04394260||LGBT Caregivers Participating in a Focus Group|LGBT caregivers attending a focus group after watching the videos of the remote learning Savvy Caregiver Program. The focus group will guide modification of the Savvy Caregiver Program to meet the needs of LGBT caregivers of PLWD.
33334950|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
33334951|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
33113589|NCT04679987||paroxysmal Af|
33113590|NCT04679987||no paroxysmal Af|
33113591|NCT05423795|Other|Comparator Arm|Classic expertise (as routinely performed in the participating ICU)
33113592|NCT05423795|Experimental|Telemedicine-based intervention|Telemedicine-based expert advice.
33113593|NCT05423561|Other|hypertrophic non-union developing after femoral transverse diaphyseal fractures|
33113594|NCT04651959|Experimental|AVICOD then AVIGAN|Participants first received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state. After a washout period of 24 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
33113595|NCT04651959|Experimental|AVIGAN then AVICOD|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 24 hours, they then received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state.
33113596|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
33113597|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
33113598|NCT04651881|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
33113599|NCT04651881|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
33113600|NCT04651881|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
33113601|NCT04651881|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
33113602|NCT04651881|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
33113603|NCT04651881|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
33113604|NCT05367427|Experimental|Bifidobacterium Longum|Consumption of 2 capsules/day of Bifidobacterium Longum CECT 7347 (1x10e4.5 CFU/capsule).
33113605|NCT05367427|Placebo Comparator|Placebo|Consumption of 2 placebo capsules/day filled with cornstarch
33113606|NCT05423405|No Intervention|control|Treatment as usual with pharmacotherapy and other complementary therapies
33113607|NCT05423405|Sham Comparator|Sham|No actual acupoint pressed but same settings as in acupressure therapy
33113608|NCT05423405|Experimental|Intervention|Treatment as usual plus acupressure intervention with selected acupoints pressure
33113609|NCT04652310|Active Comparator|Extended-Short Nail|Implantation of TFNA extended-short nail (235 mm)
33113610|NCT04652310|Active Comparator|Long nail|Implantation of TFNA long nail (260-480 mm)
33113611|NCT04652115|Experimental|Defibrotide|Defibrotide IV
33113612|NCT05423171|Experimental|MANUS|Children and youth living with cerebral palsy will take part in a 60-hour intensive bimanual therapy at Peps at Université Laval, during which they will play games and exercise to promote spontaneous use of the most affected hand. Participants will take part to pre-evaluation and 1-week and 6-month post-intervention.
33113613|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
33113614|NCT04618185||p.Phe508del heterozygous genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
33113615|NCT05423093|Experimental|Intervention delivery|Participants will receive a 45-60 minute single-session video group psychoeducational intervention delivered by clinic staff.
33113616|NCT01580553|Placebo Comparator|Levocarnitine|
33113617|NCT01580553|Active Comparator|L-carnitine|
33113618|NCT05423054|Experimental|abdominal massage group|"Patients will be positioned on their back while their knees will be flexed.~Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~The PR will be standed on the right side of the patient during the massage practice.~The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
33113619|NCT05423054|No Intervention|Control group|The Control group will receive routine care in the intensive care unit
33113620|NCT04618107|Experimental|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
33113621|NCT04618107|Active Comparator|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
33113622|NCT05423015|Experimental|Lactobacillus casei (Probiotic)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product)
33113623|NCT05423015|Experimental|L. casei strain Shirota plus inulin (Syn-Inulin)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of inulin.
33113624|NCT05423015|Experimental|L. casei strain Shirota plus fructans from A. salmiana (Syn-A. salmiana)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of fructans from A. salmiana.
33113625|NCT04618224||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language~30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the digital reading test DDART."
33113626|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
33113627|NCT04618146|Placebo Comparator|Group C|given intrathecal bupivacaine 12.5 mg.
33113628|NCT04618146|Active Comparator|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
33113629|NCT04618146|Active Comparator|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
33113630|NCT05422898|Experimental|Gist|Gist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group
33113631|NCT05422898|Placebo Comparator|Information|Link to Facebook COVID-19 Information Center
33113632|NCT04651842||HOMA IR high|classified based on equal tertile of HOMA IR level into 3 equal groups ( high>6.6)
33113633|NCT04651842||HOMA IR intermediate|classified based on equal tertile of HOMA IR level into 3 equal groups ( intermediate 4.6-6.6, )
33113634|NCT04651842||HOMA IR low|classified based on equal tertile of HOMA IR level into 3 equal groups (low ≤ 4.6, )
33113635|NCT05422859|Other|MobiDig|50 patients will have access to a mobile phone application for 3 months.
33113636|NCT04652154|Other|Control|Control group is recieving treatment as ususal
33113637|NCT04652154|Experimental|Intervention group|The intervention group getting the new assessment by a complementary professional team
33113638|NCT05422313||56 patients with RA.|Patients age is > 20 years old.
33113639|NCT05422313||: 30 age-matched Healthy|Individual must be without a prior history of chronic inflammation or any form of arthritis. - .
33113640|NCT04651647||Bone graft group|The bone graft group (n=19) who underwent open nailing with open bone graft for aseptic subtrochanteric nonunion
33113641|NCT04651647||Non bone graft group|The non-BG group (n=18) who underwent closed reamed nailing without bone graft for aseptic subtrochanteric nonunion
33113642|NCT04651686|Experimental|Bronchial artery protection|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
33113643|NCT05421962|Experimental|Midazolam and Fentanyl|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mcg kg-1 of fentanyl (Panpharma; SanMed) and 0.5 mg kg-1 of propofol (Fresenius Kabi; Amicus Pharma).
33113644|NCT05421962|Experimental|Midazolam and Ketamine|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with ketamine (Inresa Arzneimittel) 0.5 mg kg-1 and 0.5 mg kg-1 of propofol.
33334952|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
33334953|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
33334954|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
33334955|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
33113645|NCT05421962|No Intervention|Midazolam and Propofol|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mg kg-1 of propofol.
33113646|NCT00557817|No Intervention|1|No medication given
33113647|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
33113648|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
33113649|NCT05421182|Other|Interview of the trusted person of evacuated patient|"The interview of the trusted person of evacuated patient will be done 8 months (+/-2 months) after the medical evacuation.~The interview will be carried out by a psychologist or by a doctor from the ICU"
33113650|NCT05421182|Other|Interview of the trusted person of the not evacuated patient|The interview of the trusted person of the not evacuated patient will be done 8 months (+/-2months) after the ICU admission The interview will be carried out by a psychologist or by a doctor from the ICU.
33113651|NCT04651530|Active Comparator|Phaco|Cataract surgery only
33113652|NCT04651530|Experimental|Phaco+ECP|Cataract surgery combined with endoscopic cyclophotocoagulation
33113653|NCT05420480|Active Comparator|Two-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Two-Field lymph node dissection will be performed."
33113654|NCT05420480|Experimental|Three-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
33113655|NCT05420480|Other|Three-Field lymph node dissection (106recR positive by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
33113656|NCT04651491||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel)
33113657|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
33113658|NCT04617873|Experimental|Deep bain stimulation and Spinal cord stimulation therapy|The patients in this group will receive bilateral STN-DBS and SCS stimulation
33334956|NCT04070157|Experimental|Lofexidine|
33113659|NCT05419895|Experimental|Families with children with suspected diagnosis of autism|Families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information. Then, the family will be assigned to a clinician for the autism assessment and scheduled their assessment and feedback session (one week later).
33113660|NCT05419739||Group 1|Children under 18 years of age with traumatic brain injury
33113661|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
33113662|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
33113663|NCT05419583|No Intervention|Standard care|Patients will continue to be treated by the clinical team based on NHS guidelines. They will receive no additional visits from the study however may be asked to participate in qualitative interviews at the end of the study about their usual care. The standard care pathway may involve further investigation with clinically indicated tests or treatments and no appropriate tests or treatments will be withheld.
33113664|NCT05419583|Experimental|Complex intervention|A structured risk assessment for coronary disease or left ventricular impairment and management plan delivered by a cardiologist to guide targeted investigation and treatment. This may include imaging with coronary computed tomography angiography (CCTA), invasive coronary angiography, transthoracic echocardiography or cardiac MRI. Treatments may include antiplatelet and anticoagulant therapy, statin therapy or treatments for heart failure as indicated in line with international guidelines.
33113665|NCT04651764|Experimental|Robotically assisted transanal endoluminal resection of rectal lesion|
33113666|NCT05414513||Chronic Headache Group|Children with chronic headache
33113667|NCT05414513||Healthy Group|Children without pain
33113668|NCT04651803||Traumatic brain injury patients|Traumatic brain injury patients admitted in intensive care unit.
33113669|NCT05412212|Experimental|LTBI video intervention|Patients randomized to the intervention group will be sent an invitation with a link to watch a brief (~3 minute video) about the importance of taking and completing LTBI treatment.
33113670|NCT05412212|No Intervention|Standard care|Patients who are randomized to receive standard of care will not receive any messages or have any contact with the research team.
33113671|NCT04617600|Active Comparator|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
33113672|NCT04617600|Experimental|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
33113673|NCT05408624||prospective group - ultrasound transvaginal drainage|Patients with TOA with ultrasound-guided transvaginal drainage with outpatient management
33334957|NCT04070157|Placebo Comparator|Placebo|
33334958|NCT04261738|No Intervention|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
33334959|NCT04261738|Experimental|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute [ATA]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
33334960|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
33334961|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
33334962|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
33113674|NCT05408624||retrospective group - ultrasound transvaginal drainage|Patients with TOA in 2016, 2017 and 2018 with ultrasound-guided transvaginal drainage in conventional hospitalization
33113675|NCT05408624||retrospective group - laparoscopy|Patients with TOA in 2016, 2017 and 2018 with laparoscopy in conventional hospitalization
32740492|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
33113676|NCT04651608|Experimental|manuel acupressure|In this group, manual acupress was applied to children receiving chemotherapy with moderate and high emetogenic effects.
33113677|NCT04651608|Experimental|sea-band acupressure|In this group, sea-band acupressure was applied to children receiving chemotherapy with moderate and high emetogenic effects.
33113678|NCT05406089||The short-term antiviral therapy (STAT) group|The short-term antiviral therapy (STAT) group was defined as individuals who received HBV antiviral ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) )at least 24 weeks before hepatectomy (antiviral therapy still continued during perioperative period). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
33113679|NCT05406089||The perioperative antiviral therapy (PAT) group|The perioperative antiviral therapy (PAT) group was defined as individuals who received antiviral treatment perioperatively ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) ). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
33113680|NCT04651335|Active Comparator|Concentric|uses an afferent virtual reality program
33113681|NCT04651335|Active Comparator|Eccentric|uses an efferent virtual reality program
33113682|NCT05404100||Severe aortic valve stenosis|Patients with severe AS planned to undergo AVR, either as surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
33113683|NCT04651023|Placebo Comparator|control group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (0g NnEx) per day with or after meals.
33113684|NCT04651023|Experimental|low concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (1g NnEx) per day with or after meals.
33113685|NCT04651023|Experimental|high concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (2g NnEx) per day with or after meals.
33113686|NCT05395832|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK at sea|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session at sea will be added to solve doubts and emphasize the most important points of therapy
33334963|NCT03955809|Active Comparator|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
33113687|NCT05395832|Active Comparator|TAU + multicomponent treatment VIRTUAL FIBROWALK in nature|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session in nature will be added to solve doubts and emphasize the most important points of therapy
33113688|NCT05395832|Active Comparator|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
33113689|NCT04651062|Experimental|endocuff|all patients having performed a screeningscolonoscopy and being randomized to colonoscopy with the use of endocuff
33113690|NCT04651062|Active Comparator|no cuff|all patients participating in a screeningscolonoscopy being randomized to colonoscopy without the use of endocuff
33334964|NCT03955809|Active Comparator|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
33334965|NCT03955809|Sham Comparator|% 0.9 Saline|% 0.9 NaCL intraarticular injection
33334966|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
33113691|NCT05394779|Experimental|DTXO APP|"Patients randomized to Group A (experimental group) will be administered the Mediterranean based dietary program by means of App DTXO. The dietary program will be administered through the DTXO application. Each patient will select the assigned daily menu or the proposed alternatives; The dietary program is personalized according to the patients caloric intake needs and to their nutritional restrictions.~Patients randomized to Group A (experimental group) will be administered the Physical activity program by means of App DTXO. The activity program will be administered through the DTXO application based on the individual's background fitness level.~Patients randomized to Group A (experimental group) will be invited to follow a psycho-behavioral program to increase awareness of the behaviors and habits related to obesity, consisting of multimedia and educational content, self-assessment and dynamic exercises."
33334967|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
33059802|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
33059803|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
33059804|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
33334968|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
33059805|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
33059806|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
33059807|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
33059808|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
33334969|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
33334970|NCT03953001|Experimental|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
33334971|NCT03953001|Active Comparator|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
33334972|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
32740493|NCT05726435|Active Comparator|Experimental group|Seven randomly selected active basketball players will be supplemented with defined prebiotic fibre (20 grams per day divided in two 10 gram doses - 85% total fiber content) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
33059809|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
33059810|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
33059811|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
33059812|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
33059813|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
33059814|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
33059815|NCT04723069|Experimental|Fuke Qianjin capsule|"Metronidazole tablets Simulant + Doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
33059816|NCT04723069|Active Comparator|Metronidazole tablets + Doxycycline hyclate tablets|"Metronidazole tablets + Doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
33059817|NCT00058955|Experimental|1|Sodium oxybate
33059818|NCT00058955|Active Comparator|2|triazolam
33059819|NCT00058955|Active Comparator|3|pentobarbital
33059820|NCT00058955|Placebo Comparator|4|Placebo
33059821|NCT00187798|Other|Metformin|Metformin HCl
33059822|NCT00187837|Experimental|SW intervention|Stepwise Excavation
33334973|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
33113692|NCT05394779|Placebo Comparator|PLACEBO APP-Control group|"Patients randomized in Group B (control group) will be delivered a dietary program, according to the current standard of care and will be printed on paper with the information on the Mediterranean diet and general educational content related to food. The control arm will also be equipped with a placebo App to ensure the patient's blindness to treatment allocation and there will be asked to the patient to complete weekly the Diet Adherence questionnaire.~Patients randomized in Group B (control group) will be advised to perform regular physical activity and provided with educational material and some tips on physical activity; no formal plan will be provided, as currently done in standard clinical practice.~Patients randomized in Group B (control group) will receive printed educational material with generic content and advice for self-help support and followed as per standard clinical practice. The placebo App will be used as a data entry tool for questionnaires."
33113693|NCT04651101||vitamin D deficient|those patient with vitamin D level below 30 ng/dl
33113694|NCT04651101||non vitamin D deficient|those patient with vitamin D above 30 ng/dl
33334974|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
33334975|NCT01094769|Experimental|Moxonidine|
33334976|NCT01094769|Placebo Comparator|Placebo|
33334977|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
33334978|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
33334979|NCT04653922|Experimental|Bioengineered corneal substitute|A cell-free, sterilized bioengineered corneal substitute made from medical grade collagen
33113695|NCT05388110||Healthy controls|
33334980|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
33334981|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
33334982|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
33334983|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
33334984|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
33113696|NCT05388110||Depressed adolescents|
33113697|NCT05387408|Other|participating union health fund|"The investigators will recruit three health funds into a single arm trial. Each health fund will receive the intervention, Workplace Opioid Prevention Guidelines. The intervention is a set of guidelines containing information and suggested changes the health fund may make to their health and safety program specifically to prevent and manage opioid abuse in their workforce. The health fund the investigators receive the intervention after completing baseline data collection. The investigators will provide assistance with using the intervention as needed over a 6 month period of time, and measure changes the health fund makes to their health and safety program based on information in the guidelines. At 6 months, the investigators will repeat baseline data collection for the efficacy trial."
33113698|NCT04617795|Experimental|Basal-Bolus (Group A)|"2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus~6-month optional extension using Automated Mode"
33113699|NCT04617795|Experimental|Basal (Group B)|"2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus~6-month optional extension using Automated Mode"
33113700|NCT05380700|Experimental|Virtual Reality Stimulation|All participants will be receiving the standard care and additionally the VR stimulation during their stay in the intermediate care unit.
33113701|NCT05376761|Experimental|DEX for STN-DBS|
33113702|NCT04617561|Active Comparator|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
33113703|NCT04617561|Experimental|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
33113704|NCT05376449|Experimental|Immediate start|Intervention to start immediately after first visits.
33113705|NCT05376449|Active Comparator|Delayed start|Intervention to start after 12 weeks delay.
33113706|NCT04617483|Experimental|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
33113707|NCT04617483|Experimental|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
33113708|NCT04617483|Experimental|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
33113709|NCT05357729|Experimental|MultiSense® remote monitoring|The patients included will be equipped with the MultiSense® solution prior to the hospital discharge. The device will be used for 6 days from the date of actual deployment.
33113710|NCT04617288|Experimental|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
33334985|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
33334986|NCT03695224||Group A|Subjects with normal topological perception
33334987|NCT03695224||Group B|Subjects with abnormal topological perception
33419221|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
33334988|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
33334989|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
33334990|NCT00066729|Experimental|NY-ESO-1b peptide with Montanide® ISA-51|Patients received NY-ESO-1b peptide mixed with Montanide® ISA-51 by subcutaneous injections, once every 3 weeks (weeks 1, 4, 7, 10, and 13) for a total of 13 weeks.
33334991|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
33334992|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
33334993|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
33334994|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
33334995|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
33334996|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
33334998|NCT00032487|Active Comparator|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
33334999|NCT00032487|Experimental|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
33335000|NCT04307836|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
33335001|NCT04307836|No Intervention|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
33335002|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
33335003|NCT04307446|Experimental|10 Minutes|Subject takes part in 10 minute VR experience
33335004|NCT04307446|Experimental|20 Minutes|Subject takes part in 20 minute VR experience
33335005|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
33335006|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
33059823|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
33059824|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
33059825|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
33059826|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
33059827|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
33059828|NCT00047073|Experimental|Phase 1|See intervention description.
33059829|NCT00047073|Experimental|Phase 2|See intervention description.
33059830|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
33059831|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
33059832|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
33059833|NCT00188344|Active Comparator|1|pneumatic dilatation
33059834|NCT00188344|Active Comparator|2|Laparoscopic myotomy
33059835|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
33059836|NCT02969447|No Intervention|No additional medication after fetal expulsion|
33059837|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
33059838|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
33059839|NCT00188578|Experimental|IMRT Gynecological Cancers|
33059840|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
33059841|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
33059842|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
33059843|NCT00409279|Experimental|1|multi-component psychosocial intervention
33059844|NCT00409279|No Intervention|2|
33059845|NCT00409318|Active Comparator|1|Etanercept
33059846|NCT00409318|Placebo Comparator|2|Placebo
33059847|NCT03492762|Experimental|Healthy Volunteer Group|The healthy volunteer group will receive the same interventions as the ILD documented diagnosed volunteer group
33059848|NCT03492762|Experimental|ILD Documented Diagnosed Volunteer Group|The ILD documented diagnosed volunteer group will receive the same interventions as the healthy volunteer group
33059849|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
33059850|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
33419222|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
33113711|NCT04617288|Experimental|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
33113712|NCT04617249|Active Comparator|Giving median anesthesia|
33113713|NCT04617249|Active Comparator|Giving paramedian anesthesia|
33113714|NCT05349383||Antibody-Drug Conjugate (ADC)|Sepsis-related toxicities induced by antibody-drug conjugate(ADC). Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by ADC, with a chronology compatible with the drug toxicity Intervention: Drug: ADC
33113715|NCT05349383||Common cancer drug therapies other than ADC|"Sepsis-related toxicities induced by Common cancer drug therapies other than ADC.~Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by Common cancer drug therapies other than ADC, with a chronology compatible with the drug toxicity~Intervention:~Drug: Chemotherapy, targeted therapy, immunotherapy and so on."
33113716|NCT05344820|Experimental|Mandala Intervention|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
33335007|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:~Ibuprofen~Oral~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.~Duration of therapy: 4 - 6 weeks."
33335008|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:~Pednisone (for mild/moderate cases):~Oral~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.~Methylprednisolone (for severe/acute cases):~IV~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.~The duration is variable according to the condition of the patient."
33113717|NCT05344820|No Intervention|Control|No intervention will be applied to the control group
33113718|NCT04617171|Experimental|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
33113719|NCT04617171|Placebo Comparator|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
33113720|NCT05339555|Other|IUD Self-Removal|
33113721|NCT04617054|Experimental|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
33113722|NCT05337488||Subject with solitary drinking behaviour|A convenience sample of 40 solitary drinkers aged between 10 and 24 will be invited to undergo complete a questionnaire and an individual semi-structured interviews.
33113723|NCT05336786|Experimental|Diagnostic (perflutren lipid microspheres, ultrasound)|Patients receive perflutren lipid microspheres IV over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres
33113724|NCT00557934|Experimental|1|
33113725|NCT04679753|Active Comparator|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
33113726|NCT04679753|Active Comparator|Brainsway DTMS with High Frequency Stimulation (HF)|Brainsway DTMS with High Frequency Stimulation (HF)
33113727|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
33113728|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
33113729|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
33113730|NCT04679714|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
33113731|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
33113732|NCT05323604||Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
33113733|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
33113734|NCT00558129|Active Comparator|Control|Laminectomy
33113735|NCT05294705||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), Brief Observation of Symptoms of Autism (BOSA), Childhood Autism Rating Scale-2(CARS-2) and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
33113736|NCT05294705||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
33113737|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
33113738|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
33113739|NCT05293847|Experimental|Telerehabilitation exercises|Exercises about postural structures on the cervical and thoracal region. Bilateral pectoral stretching, chin tack exercises, cervical isotonic exercises, stretching of the upper trapezius and longus Colli, scapular region strengthening, shoulder capsular stretching, Wand exercises for 12 weeks and 3 times a week.
33113740|NCT04616742|Experimental|[14C]SHR6390|
33113741|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI < 25 kg/m2.
33113742|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
33335009|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:~Methotrexate~Oral~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.~Duration of therapy: 6 - 12 weeks."
33335010|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
33335011|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
33335012|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
33059851|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
33335013|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
33059852|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
33059853|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
33059854|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
33059855|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
33059856|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
33059857|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
33059858|NCT00425542|Experimental|Outpatient treatment|
33059859|NCT00425542|No Intervention|Inpatient care|
33059860|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
33059861|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
33059862|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
33059863|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
33059864|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
33059865|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
33059866|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
33059867|NCT00399984|Experimental|1|
33059868|NCT00399984|No Intervention|2|
33059869|NCT00189514|Experimental|1|
33059870|NCT00189514|Experimental|2|
33059871|NCT00189514|Experimental|3|
33059872|NCT00189514|Placebo Comparator|4|
33059873|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
33059874|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
33059875|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
33059876|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
33059877|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
33059878|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
33059879|NCT00189592|Experimental|A|Percutaneous Fasciotomy
33059880|NCT00189592|Active Comparator|2|Standard Fasciotomy
33059881|NCT03396081|Experimental|PRADO-IC|
33059882|NCT03396081|Other|Usual care|
33059883|NCT00189709|Experimental|1|
33059884|NCT00189709|Active Comparator|2|
33059885|NCT02969330|Experimental|Glucose|Glucose ingestion
33059886|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
33059887|NCT04722796|Experimental|TAVR with Supra-annular sizing strategy|"Experimental: Supra-annular sizing strategy (Hangzhou Solution).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm."
33059888|NCT04722796|Other|TAVR with Annulus based sizing strategy|"Control: Traditional sizing strategy (Annulus based sizing strategy).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Annular sizing Venus A plus Valve with implant depth 4-6mm."
33059889|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
33059890|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
33059891|NCT00059462|Experimental|Arm 1|
33059892|NCT00059462|Active Comparator|Arm 2|
33059893|NCT00189826|Active Comparator|1|
33059894|NCT00189826|Experimental|2|
33059895|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33059896|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
33113743|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI > 30 kg/m2.
33335014|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
33335015|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
33335016|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
33335017|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
33419223|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
33059897|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
33059898|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
33059899|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
33059900|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
33059901|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
33059902|NCT04722874|Active Comparator|Ortho-k|Participants will continue to use ortho-k lenses alone.
33059903|NCT04722874|Experimental|RLRL+Ortho-k|Participants will be treated with RLRL twice a day in addition to ortho-k lenses.
33059904|NCT04722640|Experimental|RISAKIZUMAB|SKYRIZI
33059905|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
33059906|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
33059907|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
33059908|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
33059909|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
33059910|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
33059911|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
33059912|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
33059913|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
33059914|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
33059915|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
33059916|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
33059917|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
33059918|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
33059919|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
33059920|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
33059921|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
33059922|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
33059923|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
33059924|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
33059925|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
33059926|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
33059927|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
33059928|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
33059929|NCT00190216|Experimental|A|
33059930|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
33059931|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
33059932|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
33059933|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
33059934|NCT00190333|Active Comparator|A|
33059935|NCT00190372|Other|A|
33059936|NCT00190411|Experimental|Treatment|Celiprolol
33059937|NCT00190450|Experimental|1|Early Graft (Early G)
33059938|NCT00190450|Experimental|2|Late Graft (Late G)
33068228|NCT04512625|Experimental|Group TS (Telio CS desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
33068229|NCT04512664|Active Comparator|short term group|cold treatment for 4 hours
33068230|NCT04512664|Experimental|long term group|cold treatment for 48 hours
33419224|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
33419225|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
33419226|NCT04594759|Experimental|Treatment Group|
33419227|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
33059939|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
33059940|NCT00190528|Active Comparator|Surgery|
33059941|NCT00190528|Experimental|Chemotherapy + Surgery|
33059942|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
33059943|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
33059944|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33059945|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
33059946|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
33059947|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
33059948|NCT02969213||Genetic|patients with Gene detection (+)
33059949|NCT02969213||Metabolism|patients with Metabolic disturbance
33059950|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
33059951|NCT02969213||infection|patients with the Infection of central nervous system
33059952|NCT02969213||structure|patients with abnormal image of brain
33059953|NCT02969213||unknown|patients not found any reason
33059954|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
33059955|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
33059956|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
33059957|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
33059958|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
33059959|NCT04723030|Experimental|carleilizumab in combination with apathy mesylate and chemoradiotherapy (paclitaxel (albumin-bound)|Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.
33059960|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
33059961|NCT02628366|No Intervention|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
33059962|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
33059963|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
33059964|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
33059965|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
33059966|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
33059967|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
33059968|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
33059969|NCT00192127|Active Comparator|1|FluMist
33059970|NCT00192127|Placebo Comparator|2|Placebo
33059971|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
33059972|NCT00192283|Experimental|1|CAIV-T
33059973|NCT00192283|Placebo Comparator|2|Placebo
33059974|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
33059975|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
33059976|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
33059977|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
33059978|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
33059979|NCT00192478|Active Comparator|1|MEDI-524
33059980|NCT02439255|Experimental|Arm I Black raspberry(BRB) nectar|Participants receive BRB nectar PO QD for 12 weeks.
33059981|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
33059982|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
33059983|NCT00192517|Active Comparator|1|MEDI-522
33059984|NCT00192517|Placebo Comparator|2|Placebo
33059985|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
33059986|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
33059987|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
33059988|NCT04730726|Experimental|Patients with thyroid nodules|Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy
33059989|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
33059990|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
33059991|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
33059992|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
33059993|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
33059994|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
33059995|NCT00209235|Experimental|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
33059996|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
33059997|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
33059998|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
33059999|NCT04722562|Experimental|Child Pugh A|Participants with mild hepatic impairment
33060000|NCT04722562|Experimental|Child Pugh B|Participants with moderate hepatic impairment
33060001|NCT04722562|Experimental|Healthy participants|Participants with normal hepatic function
33060002|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
33060003|NCT00409552|Experimental|1|Virtual Reality with head display
33060004|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
33060005|NCT00409552|Active Comparator|3|non-interactive video with head display
33060006|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
33060007|NCT00409552|No Intervention|5|No distraction
33060008|NCT00409591|Active Comparator|1|"NVP-NVP:~In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
33060009|NCT00409591|Experimental|2|"PL-NVP:~In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
33060010|NCT00409591|Experimental|3|"LPV/r:~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
33060011|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
33060012|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
33060013|NCT00193648|Active Comparator|2|Humira (adalimumab)
33060014|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
33060015|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
33060016|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
33060017|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
33060018|NCT00060203|Experimental|Brostallicin|
33060019|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
33060020|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
33060021|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
33060022|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
33060023|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
33060024|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
33060025|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
33060026|NCT00194038|Experimental|1|
33060027|NCT00194194|Active Comparator|moderate|moderate behavioral management
33060028|NCT00194194|Experimental|intensive|intensive behavioral management
33060029|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
33060030|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
33060031|NCT00194428|Experimental|1|Almond enriched diet
33060032|NCT00194428|Active Comparator|2|Low-fat diet
33060033|NCT00194467|Experimental|1|
33060034|NCT00194467|Placebo Comparator|2|
33060035|NCT00194545|Experimental|1|Medication diary
33060036|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
33060037|NCT00194584|Experimental|1|
33060038|NCT00194584|No Intervention|0|
33060039|NCT00194740|Experimental|1|
33060040|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
33060041|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
33060042|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
33060043|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
33060044|NCT00084123|Placebo Comparator|Standard Care|Standard Care
33060045|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
33060046|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
33060047|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
33060048|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
33060049|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
33060050|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
33060051|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
33060052|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
33060053|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
33060054|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
33060055|NCT02968823|Active Comparator|Licorice|Licorice gargle
33060056|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
33060057|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
33060058|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
33060059|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
33060060|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
33060061|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
33060062|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
33060063|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
33060064|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
33060065|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
33060066|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
33060067|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
33060068|NCT00196378|Experimental|1|
33060069|NCT00196378|Placebo Comparator|2|
33060070|NCT00048087|Experimental|Iressa + Docetaxel|
33060071|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
33060072|NCT00048126|Experimental|1|
33060073|NCT00084396|Experimental|Letrozole/Surgery|
33060074|NCT00196807|Experimental|Information plus DA at home|
33060075|NCT00196807|Active Comparator|UC Information at home|
33060076|NCT00196807|Experimental|Information plus decision aid at clinic|
33060077|NCT00196807|Active Comparator|UC Information at clinic|
33060078|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
33060079|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
33060080|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
33060081|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
33060082|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
33060083|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
33060084|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
33060085|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
33060086|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
33060087|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
33060088|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
33060089|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
33060090|NCT04710589||CTV 3mm|CTV is expanded by 3mm on the basis of GTV.
33060091|NCT04710589||CTV 6mm|CTV is expanded by 6mm on the basis of GTV.
33060092|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
33060093|NCT00197548|Placebo Comparator|Placebo|Placebo pill
33060094|NCT00197587|Active Comparator|maternal nevirapine|
33060095|NCT00197587|Placebo Comparator|maternal placebo|
33060096|NCT00197704|Placebo Comparator|Placebo|Placebo
33060097|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
33060098|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
33060099|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
33060100|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
33060101|NCT00197743|Placebo Comparator|Placebo|Placebo
33060102|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
33060103|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
33060104|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
33060105|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
33060106|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
33060107|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
33060108|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
33060109|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
33113744|NCT05292287|Experimental|Home-based Watch Intervention|The home-based watch group will receive an exercise consultation with an exercise physiologist followed by check-in sessions at 1-month, 3-months, 6-months, and 12-months post-randomisation to set and review exercise and physical activity goals. They will wear a Polar Ignite wearable activity monitor which will help to monitor and guide their exercise sessions. Text-message feedback will be provided by an exercise physiologist based on information gathered from exercise sessions recorded on the watch by the participant.
33360827|NCT03923491|Active Comparator|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
33113745|NCT05292287|No Intervention|Best Practice Usual Care Control|No intervention will be administered. Best practice usual care and activity.
33113746|NCT04651140|Active Comparator|Tremor group|Participants in the tremor group have tremor as the main clinical manifestation
33113747|NCT04651140|Active Comparator|Stiff group|Participants in the tremor group have stiff as the main clinical manifestation
33113748|NCT05288972|Experimental|Mattress 1|Mattress 1 group will receive Polyurethane, Bonnel spring, medium-hard mattress
33113749|NCT05288972|Active Comparator|Mattress 2|Mattress 2 group will receive Polyurethane, pocket spring, medium mattress
33113750|NCT04650867||Patients with Crohn's disease|Patients diagnosed or with suspected Crohn's disease.
33113751|NCT04650867||Patients with Ulcerative colitis|Patients diagnosed or with suspected Ulcerative colitis
33113752|NCT04650867||Patients with unclassified inflammatory bowel disease (U-IBD)|Patients diagnosed or with suspected unclassified inflammatory bowel disease (U-IBD)
33113753|NCT05287217|Active Comparator|Group 1: Scheduled pain control|Group 1 patients will be instructed to take 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 consecutive days after surgery regardless of whether they experience pain or not.
33113754|NCT05287217|Active Comparator|Group 2: Pain control as needed.|Group 2 patients will be instructed to take the 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 days after surgery only when needed to control pain.
33113755|NCT05278403|Active Comparator|Control group|Conventional neurological physiotherapy treatment.
33113756|NCT05278403|Experimental|Experimental group|Conventional neurological physiotherapy treatment with the use of virtual reality and video games.
33113757|NCT04650906|Experimental|Intervention group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
33113758|NCT04650906|No Intervention|Control group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
33113759|NCT05273255|Experimental|FMT-Recipients|"FMT-Recipients are patients with stage IV cancer, who have not sufficiently responded (stable disease or non-response) after at least 1 full cycle of ICI therapy. These patients will undergo the FMT procedure after the colon cleansing performed per routine treatment protocols at the Departement of Gastroenterology at the University Hospital of Zürich.~The stool is donated by FMT-Donors, which are patients with any solid cancer stage III or IV cancers, who received any ICI-Therapy and have experienced a durable partial or complete response.~FMT infusate will be administered via colonoscopy."
33113760|NCT05263076|Experimental|Uterine Transplant|uterus transplantation from living or deceased donor.
33113761|NCT04650750|Experimental|Xiao-Feng-San; Shian-Fang-Hwa-Ming-Yiin|Xiao-Feng-San 2g+ Shian Fang Hwa Ming Yiin 2g; twice a day for two months
33113762|NCT04650750|Placebo Comparator|Placebo|Similar placebo 4g twice a day for two months
33113763|NCT04617015|Experimental|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
33113764|NCT05235971|Experimental|Episodic Future thinking (EFT)|Participants will receive up to 3 messages a day that include assessment and intervention messages.The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.
33360828|NCT01348724|Experimental|[14C] NKTR-118|
33113765|NCT05235971|Experimental|Volitional choice (VC)|VC creates structured if-then plans to dismantle context-linked alcohol use. Participants will receive up to 3 messages a day that include assessment and intervention messages.
33113766|NCT05235971|Experimental|Episodic Future thinking plus Volitional choice|Participants will receive both EFT and VC interventions with text messages.
33113767|NCT05235971|Other|Monitoring only|This is a control group in which participants will receive general psychoeducation.
33113768|NCT04650711|Experimental|Study group|All eligible participants as one group accept P16INK4A testing, with cytology and/or hrHPV assay.
33113769|NCT04650828||Experimental:person with TDF+LDT|TDF combined with LDT for 12 months
33113770|NCT04650828||Active comparator:person with TDF|TDF monotherapy was continued for 12 months
33113771|NCT05231837|Experimental|Fee Waiver|Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment.
33230223|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
33060110|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
33060111|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
33060112|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
33060113|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
33060114|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
33060115|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
33060116|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
33060117|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
33060118|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
33060119|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
33060120|NCT00409942|Experimental|1|Torasemide prolonged released
33060121|NCT00409942|Active Comparator|2|Furosemide
33060122|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
33060123|NCT02968667|No Intervention|Treatment as usual|Medications
33060124|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
33060125|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
33060126|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
33060127|NCT00198796|Experimental|H10407|H10407
33060128|NCT00198874|Active Comparator|Psychoeducation|
33060129|NCT00198874|Experimental|Conitive Behavorial Therapy|
33060130|NCT00198874|Experimental|Family Therapy|
33060131|NCT00198874|Experimental|Intergrated Family|
33060132|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
33060133|NCT00084903|Experimental|Fluorescence Spectroscopy|
33060134|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
33060135|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
33060136|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
33060137|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
33060138|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
33060139|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
33060140|NCT00199927|Active Comparator|standard therapy|Standard therapy
33060141|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
33060142|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
33060143|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
33060144|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
33060145|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
33060146|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
33060147|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
33060148|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
33060149|NCT00410215|Active Comparator|1|sodium phosphate
33060150|NCT00410215|Active Comparator|2|picosalax
33060151|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
33060152|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
33060153|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
33060154|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
33060155|NCT00200395|Experimental|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
33060156|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
33060157|NCT00048555|Experimental|1|
33060158|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
33060159|NCT00200707|No Intervention|the control group|
33060160|NCT04711577|Experimental|Condition 1|Track clinician-determined symptoms
33060161|NCT04711577|Experimental|Condition 2|Track clinician-determined and self-determined symptoms
33060162|NCT00200746|Experimental|2|Moderate Arginine
33060163|NCT00200746|Sham Comparator|3|Polycose control arm
33060164|NCT00200746|Experimental|1|High Arginine
33060165|NCT00200863|Experimental|1|420 nm light
33060166|NCT00200863|Experimental|2|480 nm
33060167|NCT00200863|Experimental|3|507 nm
33060168|NCT00200863|Experimental|4|555 nm
33060169|NCT00200863|Experimental|5|620 nm
33060170|NCT00200863|Experimental|6|460 nm
33060171|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
33060172|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
33060173|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
33060174|NCT00201058|Experimental|1|Receives tailored web-based program
33060175|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
33060176|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
33060177|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
33060178|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
33060179|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
33060180|NCT00048633|Experimental|Tariquidar|
33060181|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
33060182|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
33060183|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
33060184|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
33060185|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
33060186|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
33060187|NCT00410332|Active Comparator|A|TRAUMEEL S
33060188|NCT00410332|Placebo Comparator|B|
33060189|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
33060190|NCT00048750|Experimental|1|
33060191|NCT00048750|Placebo Comparator|2|
33060192|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
33060193|NCT00061490|Experimental|1|16 weekly educational meetings
33060194|NCT00061490|No Intervention|2|Wait list control
33060195|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
33060196|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
33060197|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
33060198|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
33060199|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
33060200|NCT00221767|Experimental|1|Brindley technique (bladder system)
33060201|NCT00221767|No Intervention|2|Reference group
33060202|NCT00412789|Experimental|EPO906|
33060203|NCT00048828|Active Comparator|1|
33060204|NCT00048828|Active Comparator|2|
33060205|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
33060206|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
33060207|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
33060208|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
33060209|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
33060210|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
33060211|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
33060212|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
33060213|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
33060214|NCT00222040|Experimental|1|Levovist
33060215|NCT00222040|No Intervention|2|No specific intervention
33060216|NCT00222118|Experimental|1|intervention group
33060217|NCT00222118|Other|2|Attention control
33060218|NCT00222118|Other|3|Usual care
33060219|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
33060220|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
33060221|NCT00222352||central laboratory cTnI test|Control Group
33060222|NCT00222352||Point of Care cTnL testing|Experimental Group
33060223|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
33060224|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
33060225|NCT00222469|Experimental|1|3-agent treatment group
33060226|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that not existed scopolamine ingredient."
33060227|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'~The group that existed scopolamine ingredient~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that existed scopolamine ingredient."
33060228|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
33060229|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
33060230|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
33060231|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
33060232|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
33060233|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
33060234|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
33060235|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33060236|NCT00223210|Active Comparator|Quetiapine|
33060237|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
33060238|NCT00223249|Active Comparator|Quetiapine|Quetiapine
33060239|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
33060240|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
33060241|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
33060242|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
33060243|NCT00223444||1|Genotype group Pro/Pro
33060244|NCT00223444||2|Genotype group Pro/Ser
33060245|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
33060246|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
33060247|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
33060248|NCT00223639|Experimental|Topiramate|
33060249|NCT00223639|Placebo Comparator|Placebo|
33060250|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
33060251|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
33060252|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
33060253|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
33060254|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
33060255|NCT00223756|No Intervention|Arm 2|usual care
33060256|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
33060257|NCT00223834|Other|1|Single session orientation to available services
33060258|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
33060259|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
33060260|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
33060261|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
33060262|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
33060263|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33060264|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
33060265|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
33060266|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
33060267|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
33060268|NCT04722133|Experimental|HERZUMA+mFOLFOX|
33060269|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
33060270|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
33060271|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
33060272|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
33060273|NCT00413101|Experimental|1|
33060274|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
33060275|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
33060276|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
33060277|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
33060278|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
33060279|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33060280|NCT00225121|Experimental|1|open label single arm trial
33060281|NCT00225199|Experimental|Arm 1|
33060282|NCT00225199|Placebo Comparator|Arm 2|
33060283|NCT00225433|Active Comparator|1|Follitropin beta
33060284|NCT00225433|Active Comparator|2|Ganirelix acetate
33060285|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
33060286|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
33060287|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
33113772|NCT05231837|Experimental|Fee Waiver Plus Intensive Outreach|"Parks randomly assigned to the Intensive Outreach and Fee Waiver:~Intensive Outreach consists of the formation and activity of a community advisory group who will engage with neighborhood community partners to support parents in the neighborhood to enroll their child and support the child's participation in the park youth sports programs offered at the neighborhood park and recreation center. Program marketing and materials and registration will be offered in both Spanish and English. Program coaches will be supported with technical assistance from study staff to implement the park youth sports program with high fidelity and with high communication and engagement with enrolled youth and their parents.~Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment."
33113773|NCT04650360|Experimental|Postoperative Intervention Educational Program|The intervention group will receive an educational program during admission. The health educational program will consist of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics will be addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls
33113774|NCT04650360|No Intervention|Control|The patients in the control group will not receive any educational program. These patients will be treated according to routine protocols
33113775|NCT05199350||Population including people with NGT, IFG and IGT and diabetes.|"Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e < 140 mg/dl.~IFG is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and < 126 mg/dl.~IGT is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and < 200 mg/dl.~Presence of confirmed diabetes (HbA1c level > 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.~Presence of confirmed diabetes (HbA1c level > 6.4 %) with at least one of the above complications."
33113776|NCT05197556|Experimental|HSG4112 200 mg Multiple Dose|Multiple oral dosing of HSG4112 200 mg for 12 weeks
33113777|NCT05197556|Experimental|HSG4112 400 mg Multiple Dose|Multiple oral dosing of HSG4112 400 mg for 12 weeks
33113778|NCT05197556|Experimental|HSG4112 600 mg Multiple Dose|Multiple oral dosing of HSG4112 600 mg for 12 weeks
33113779|NCT05197556|Placebo Comparator|Placebo|Multiple oral dosing of placebo
33113780|NCT04650555|Experimental|Single Ascending Dose Cohort 1|500 mg BIO 300 Oral Powder administered as a single dose
33113781|NCT04650555|Experimental|Single Ascending Dose Cohort 2|1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
33113782|NCT04650555|Experimental|Single Ascending Dose Cohort 3|2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
33113783|NCT04650555|Experimental|Single Ascending Dose Cohort 4|Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
33113784|NCT04650555|Experimental|Multiple Single Dose Cohort 5|Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
33113785|NCT04650477|Active Comparator|Fixated in the EP position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the extension-pronation (EP) position
33113786|NCT04650477|No Intervention|Fixated in the neutral position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the neutral position (elbow 90 degrees flexed and hands positioned with the thump pointing up
33113787|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab SC|Randomized 1:1
33113788|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab IV|Randomized 1:1
33113789|NCT04650516|Experimental|Endocare treatment|Patients will receive the treatment on a dedicated virtual reality headset to display the Endocare® application, with high quality headphones
33113790|NCT04650516|Active Comparator|Digital control treatment|Patients will receive the digital control on a dedicated tablet to display the digital control, with high quality headphones
33113791|NCT05159375|Experimental|Elio (supplement under investigation)|2.4g of Elio administered orally daily with the first meal of the day for a 17 day period
33113792|NCT05159375|Placebo Comparator|Placebo|2.4g of SMCC administered orally daily with the first meal of the day for a 17 day period
33113793|NCT04650321|Experimental|Home infusion of ocrelizumab|Patients will receive infusion of ocrelizumab at home, instead of at clinic.
33113794|NCT05153525|Experimental|Intermittent boluses group|Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
33113795|NCT05153525|Experimental|Intravenous infusion for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
33113796|NCT05128409|Active Comparator|XKH001 Injection|XKH001 Injection,hypodermic injection，single dose，5 dose cohorts: 0.5 mg/kg, 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
33113797|NCT05128409|Placebo Comparator|XKH001 Placebo Injection|XKH001 Placebo Injection,hypodermic injection，single dose，4 dose cohorts: 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
33113798|NCT04649970||malignant uropathy|Antegrade double-J stent
33419228|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
33419229|NCT02123498|Experimental|Single Arm|
33113799|NCT05127863|Experimental|2 to 5 ASD or TDL patients|2 to 5 ASD or TDL patients, 8 to 14 years old, with no intellectual disability.
33113800|NCT04649892|Experimental|Naltrexone|A 12 week Naltrexone flexible dose administration plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
33113801|NCT04649892|Placebo Comparator|Placebo|A 12 week placebo matching tablets plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
33113802|NCT05125796|Active Comparator|paracetamol|1000 mg intravenous paracetamol
33113803|NCT05125796|Experimental|Dexketoprofen Trometamol|50 mg intravenous Dexketoprofen Trometamol
33113804|NCT05125796|Experimental|topical lidocaine|%5 lidocaine 5 gr topical
33113805|NCT05125796|Placebo Comparator|placebo|100 mL intravenous normal saline+ placebo topical pomade
33113806|NCT05097131||All Participants|Participants who have been prescribed with aducanumab-avwa in the post-marketing setting according to standard care of practice will be enrolled.
33113807|NCT05096117|Experimental|Active Medication|
33113808|NCT05096117|Placebo Comparator|Matching Placebo|
33113809|NCT04616859|Experimental|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
33113810|NCT04616859|Active Comparator|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
33113811|NCT04616859|Active Comparator|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
33113812|NCT04616859|Placebo Comparator|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
33113813|NCT05091593|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
33113814|NCT05091593|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
33113815|NCT04616937|Active Comparator|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
33113816|NCT04616937|Placebo Comparator|Placebo group|Daily dose of maltodextrin over 4 weeks
33113817|NCT05053607|Other|1. Single Arm Cohort Receiving Digital Health Coaching|"All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.~Participants have the option to participate in a one time interview about their treatment experience."
33113818|NCT04616586|Experimental|Arm A|Drug - Siltuximab
33113819|NCT04616586|Other|Arm B|Comparator - Normal Saline
33113820|NCT05045612|Experimental|Intervention|Stop antibiotic therapy as instituted by admitting physician
33113821|NCT05045612|No Intervention|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
33113822|NCT04616469|Active Comparator|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
33113823|NCT04616469|Experimental|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
33113824|NCT05038787|Experimental|LY3473329|LY3473329 administered orally.
33113825|NCT05038787|Placebo Comparator|Placebo|Placebo administered orally.
33113826|NCT05009732|Experimental|Proxalutamide (GT0918) plus standard of care|Participants receive 300mg once daily orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
33113827|NCT05009732|Placebo Comparator|Placebo plus standard of care|Participants will receive placebo tablets matching Proxalutamide (GT0918) orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
33113828|NCT00563082||1|SLE participants positive for both APA and CHD
33113829|NCT00563082||2|Normal participants with a high titer of APA
33113830|NCT04988321|Active Comparator|Primary motor cortex (M1)|Stimulation of the M1
33113831|NCT04988321|Active Comparator|Dorsolateral prefrontal cortex (DLPFC)|Stimulation of the DLPFC
33113832|NCT04616508|Experimental|Behavioral testing|
33113833|NCT00553943|Experimental|Rituximab + Cytarabine|
33113834|NCT04971044|Experimental|COACH Intervention|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for 4-6 year old children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
33113835|NCT04971044|Active Comparator|Educational Control|The control arm will consist of a school readiness intervention developed by education and literacy experts on our team and implemented at local libraries. It will include 1) child lessons from Puente de Cuentos, a systematic, language-based curriculum focused on dual language storytelling (narrative language), and 2) parent sessions designed to improve parents' knowledge and skills related to improving children's language production and storytelling skills, to ultimately support school readiness.
33113836|NCT00563238|No Intervention|Control|
33113837|NCT00563238|Active Comparator|Metoprolol|
33113838|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
33113839|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
33113840|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
33113841|NCT04679558|Active Comparator|Comparator|Preventive protocol
33060288|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
33060289|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
33060290|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
33060291|NCT00225745||1|Pancreatic cancer patients
33060292|NCT00225745||2|Healthy controls
33060293|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
33060294|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
33060295|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
33060296|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
33060297|NCT00225979|Experimental|SMS995|
33060298|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
33060299|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
33060300|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
33060301|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
33060302|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
33060303|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
33060304|NCT00226057|Experimental|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
33060305|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
33060306|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
33060307|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
33060308|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
33060309|NCT00400374|Experimental|Erlotinib, Celecoxib|
33060310|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
33060311|NCT00226291|No Intervention|No evidence report|
33060312|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
33060313|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
33060314|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
33060315|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
33060316|NCT00413452|Experimental|50 mg|50 mg once weekly
33060317|NCT00413491|Experimental|1|Comparison of MR and mammography
33060318|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
33060319|NCT00226486|Placebo Comparator|2|Usual care
33060320|NCT00095823|Placebo Comparator|A1|
33060321|NCT00095823|Active Comparator|A2|
33060322|NCT00095823|No Intervention|A3|
33060323|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
33060324|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
33060325|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
33060326|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
33060327|NCT00226681|Experimental|1|
33060328|NCT00226681|Active Comparator|2|
33060329|NCT00226720|Experimental|1|at the hospital
33060330|NCT00226720|Active Comparator|2|out of the hospital
33060331|NCT00226837|Placebo Comparator|1|0% nitrous oxide
33060332|NCT00226837|Active Comparator|2|33% nitrous oxide
33060333|NCT00226837|Active Comparator|3|66% nitrous oxide
33060334|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
33060335|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
33060336|NCT02967497|No Intervention|Blank|No intervention, just observation.
33060337|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
33060338|NCT00226954|Experimental|Zoledronic Acid with Intermittent Hormonal Therapy|
33060339|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
33060340|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
33060341|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
33419230|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
33060342|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
33113842|NCT04679558|Experimental|Intervention|Adding chlorhexidine to the preventive protocol
33060343|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
33419231|NCT05063877|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsule or 20 mg capsules totaling to 10 mg, 20 mg, 40mg or 60 mg will be administered once daily orally for 12 weeks with the option for open-label extension.~Intervention: Drug: Placebo"
33060344|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
33060345|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
33060346|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
33060347|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
33060348|NCT04721899||Vitamin D- recurrent implantation failure (RIF)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
33060349|NCT04721899||Vitamin D- recurrent pregnancy loss (RPL)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
33060350|NCT04721899||Vitamin D- infertility|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
33060351|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
33060352|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
33060353|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
33060354|NCT00096213|Other|surgery|intralesional resection
33060355|NCT04722289|Experimental|Together on Diabetes|The intervention consists of five components: Recruitment of peers and peer supporters; training of peer supporters; matching peers and peer supporters; individual face-to-face meetings between peers and peer supporters; and ongoing supervision and network meetings for peer supporters.
33060356|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
33060357|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
33060358|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
33060359|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
33060360|NCT04721860|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 4 weeks.
33060361|NCT04721860|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 4 weeks.
33060362|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
33060363|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
33060364|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
33060365|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
33060366|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
33060367|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
33060368|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
33060369|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
33060370|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
33060371|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
33060372|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
33060373|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
33060374|NCT02962219|Other|Control|Standard care
33060375|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
33060376|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
33060377|NCT00228163|Experimental|Teriflunomide 7 mg|
33060378|NCT00228163|Experimental|Teriflunomide 14 mg|
33060379|NCT00063128|Experimental|A|
33060380|NCT00063128|Active Comparator|B|
33060381|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
33113843|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
33113844|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
33113845|NCT04934228|Placebo Comparator|Placebo|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.~The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.~Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug."
33113846|NCT04934228|Experimental|Clonidine|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
33335018|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
33360829|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
33360830|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
33113847|NCT04934228|Experimental|Hydrochlorothiazide (HCTZ)|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
33113848|NCT03454503||First cohort|Newly diagnosed patients
33113849|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
33113850|NCT04924985|Experimental|Physiological Feedback CPR|
33113851|NCT04924985|Active Comparator|Non-Physiological (Audiovisual) Feedback CPR|
33113852|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
33113853|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
33113854|NCT04924205|No Intervention|Outpatient Physical Therapy|
33113855|NCT04924205|Experimental|Smart Orthotic Device (FM2 Knee Brace)|
33113856|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program~This group will be initially enrolled in the program."
33113857|NCT03454386|Other|Control|"Self-Management Stress Reduction Program~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
33113858|NCT04915781||Tobacco users|Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.
33113859|NCT04616157|Experimental|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
33113860|NCT04900844|Experimental|CGuard group|Single experimental arm compared vs. objective performace goal
33113861|NCT04616391|No Intervention|MDI group:|The patient continues MDI treatment as per routine procedures
33113862|NCT04616391|Experimental|AHCL group|The patient will use MiniMed 780G AHCL system
33113863|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
33113864|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
33113865|NCT04616430|Placebo Comparator|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
33113866|NCT04616430|Active Comparator|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
33113867|NCT04616430|Active Comparator|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
33113868|NCT04891796||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
33060382|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
33060383|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
32869820|NCT05538936|Experimental|Massage|Massage can be applied to all age periods. Before starting the massage application in babies, some preparations are made. Ambient temperature (24-26 OC) is adjusted, it is regulated so that there is no airflow, dim light, and low noise levels are ensured. 1-2 towels, a soft cushion or massage table, baby oil lotion, clean diapers, and clean clothes are prepared for the massage. There is no standard time interval for the application of massage. It can be done at least one hour after the baby's feeding, at any time of the day when he is not stressed and sleeps. Massage application time is 15-30 minutes depending on the baby's reactions may vary between.
32869821|NCT05538936|No Intervention|Control|It is the control group in which no intervention was applied.
32869822|NCT03974178|Experimental|Fexinidazole|"Patients with a body weight ≥ 35 kg:~1800 mg (3 tablets) from day 1 to 4~1200 mg (2 tablets) from day 5 to 10~Patients with a body weight ≥ 20 and < 35 kg:~1200 mg (2 tablets) from day 1 to 4~600 mg (1 tablet) from day 5 to 10"
32869823|NCT05584059|Experimental|FACT Group|4-6 weeks of 45-60 minute individual-based Focused Acceptance and Commitment Therapy (FACT) counselling sessions delivered via video-conferencing format or face-to-face
32869824|NCT05538858||Mechanical Ventilation|Cohort will undergo standard of care treatment utilizing a general anesthetic with mechanical ventilation for a surgical procedure.
32869825|NCT05538858||Control|Cohort will undergo standard of care treatment utilizing a regional or neuraxial anesthetic without mechanical ventilation for a surgical procedure.
32869826|NCT00028093|Experimental|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
32869827|NCT00028093|Active Comparator|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
32869828|NCT05697510|Experimental|SILTUXIMAB|
32869829|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
32869830|NCT04026451|Experimental|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
32869831|NCT04026451|Active Comparator|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
33060384|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
33060385|NCT02967536||Healthy control|Healthy control. AHI <5 events/hour.
33060386|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
33060387|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
33060388|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
33060389|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
33060390|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
33060391|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
33060392|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
33060393|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
33060394|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
33060395|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
33060396|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
33060397|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
33060398|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
33113869|NCT04891796||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
33113870|NCT04891796||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
33060399|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
33060400|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
33060401|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
33060402|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
33060403|NCT00228670||Controls-Transplant|Lung tissue from organ donor
33113871|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
33360831|NCT01131403||BW= using baby wipes and CW= using cotton wool|
32740494|NCT05726435|Placebo Comparator|Control group|Seven randomly selected active basketball players will be supplemented with placebo resembling prebiotic fibre in all visible and taste aspects (20 grams per day divided in two 10 gram doses) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
33060404|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
33060405|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
33060406|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
33060407|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
33060408|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
33060409|NCT00229138|Experimental|reduced Tacrolimus|
33060410|NCT00229138|Active Comparator|Reference Tacrolimus|
33060411|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
33060412|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
33060413|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
33060414|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
33060415|NCT00229177|Placebo Comparator|P|
33060416|NCT00229177|Experimental|E1|
33060417|NCT00229177|Experimental|E2|
33060418|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
33060419|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
33060420|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
33060421|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
33060422|NCT00229450|Experimental|Treatment|0.625 mg/day of conjugated estrogen
33060423|NCT00229450|Placebo Comparator|Placebo|Daily placebo for conjugated estrogen
33060424|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
32740495|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
33060425|NCT02967419||Control group|People who had normal pregnancy
33060426|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
33060427|NCT00413608|Experimental|1|Clopidogrel
33060428|NCT00413608|Experimental|2|Clopidogrel
33060429|NCT04730492||Renal Transplantation|Renal Transplantation
33060430|NCT04730492||Hernias reparation post renal transplantation|Hernias reparation post renal transplantation
33060431|NCT00229801|No Intervention|MRI|
33060432|NCT04730687|Placebo Comparator|Traditional non-surgical mechanical therapy|Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH & Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
33060433|NCT04730687|Active Comparator|Diode laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) has been applied with the aid of a 300 µm diameter optical fiber tip (E3-9 mm) placed approximately 1 mm above the most apical part of the peri implant pocket, parallel to the implant surface. Pocket irrigation was performed with 3% hydrogen peroxide solution for 10 seconds before and after diode laser application.The fiber was moved in apico-coronal and mesial-distal directions for a total of 30 seconds during laser light emission.The laser tip was checked every 7-8 seconds and wiped with sterile saline in order to prevent a possible coagulation or temperature increase.The laser was used in continuous pulse mode, at a power of 0.8 Watt (W), an energy density of 3J / cm2 and a spot diameter of 1 mm. Pulse width and pulse interval were applied as 20 milliseconds.
33060434|NCT04730687|Active Comparator|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) was applied in short pulse '' H '' mode, water cooled with a non-contact sweeping motion for 30 seconds parallel to the implant surface.The settings used are: 1.5 W power, 30 Hz frequency, 50% water, 40% air, 140 s pulse duration and 1 cm spot size.
33060435|NCT04722094||Patients with Psoriasis|All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
33060436|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
33060437|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
33060438|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
33060439|NCT00230113|Active Comparator|1|
33060440|NCT00230113|Placebo Comparator|2|
33060441|NCT04721509|Experimental|Smartphone-based telemedicine|
33060442|NCT04721509|No Intervention|Conventional management without telemedicine|
33060443|NCT04730414||Age, Male, Female, ethnicity,|"The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups.~Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months.~Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face."
33419232|NCT05063877|Experimental|Study drug EQU-001|"10mg capsules or 20 mg EQU-001 capsules totally 10 mg, 20 mg, 40 mg, 60 mg will be administered once orally daily to active-treatment subjects for 12-weeks with the option for open-label extension.~Intervention: Drug : EQU-001"
33419233|NCT02115776|No Intervention|Control|Receiving no prophylaxis
33419234|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
33060444|NCT00096915|Experimental|darbepoetin alfa|
33060445|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
33060446|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
33060447|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
33060448|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
33419235|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
33419236|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
33419237|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
33419238|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
33419239|NCT05231421||Low-income smokers|Interested participants will first complete a screening survey asking about their demographic information and checking whether are eligible for this study. If eligible, participants will read a consent statement. Only those who give consent would be allowed to proceed. If participants agree to be in this study, they will continue to participate in the study and schedule a time for focus group discussion.
33419240|NCT02115854||bacteriologically confirmed tuberculosis|
33419241|NCT05229549|Active Comparator|A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16|
33419242|NCT05229549|Active Comparator|B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16|
33060449|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
33060450|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
33060451|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
33060452|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
33060453|NCT04721587|No Intervention|Standard of care|Office hysteroscopy performed as the standard of care of our Hospital
33060454|NCT04721587|Experimental|Virtual Reality|Office hysteroscopy with the use of VR environment (preprocedure and during procedure)
33060455|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
33060456|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
33060457|NCT04721782||otherwise healthy, smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
33060458|NCT04721782||otherwise healthy, non-smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
33060459|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
33060460|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
33060461|NCT00231166|Experimental|HCD122|
33060462|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
33060463|NCT04721470|Experimental|Combined therapy|Patients undergoing combined therapy
33060464|NCT04721470|Active Comparator|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
33060465|NCT04721470|Active Comparator|Microwave ablation|Patients undergoing Microwave ablation
33060466|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
33060467|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
33060468|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
33060469|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
33113872|NCT04890236|Experimental|Treatment (duvelisib)|Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.
33113873|NCT04616118|Experimental|Phone|Participants randomized to this arm will receive usual care via telephone only
33113874|NCT04616118|Experimental|Video|Participants randomized to this arm will receive usual care via video call
33113875|NCT00553982|Experimental|1|Patellar resurfacing
33113876|NCT00553982|Active Comparator|2|Patellar retention
33113877|NCT04615962|Experimental|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
33113878|NCT04615962|Active Comparator|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
33335019|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
33335020|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
33335021|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
33335022|NCT03692260|No Intervention|control group|titanium plate
33335023|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
33113879|NCT04615962|Active Comparator|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
33335024|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
33335025|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
33335026|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
33335027|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
33113880|NCT04881929|Experimental|KN026 + Docetaxel|KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles
33113881|NCT04615767|Experimental|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
33113882|NCT04881227|Experimental|Chatbot condition|Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.
33113883|NCT04881227|Active Comparator|Control condition|Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.
33113884|NCT04877444|Experimental|Aerobic exercise (AEx) + upper extremity rehabilitation|Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
33113885|NCT04877444|Experimental|Stretching (CON) + upper extremity rehabilitation|Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.
33113886|NCT04616001|Experimental|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
33113887|NCT04863638|Experimental|A1 aged ≥ 71|300 subjects age ≥ 71 （A1）receive 3 doses of vaccine
33113888|NCT04863638|Experimental|A2 aged ≥ 71|200 subjects age ≥ 71 （A2）receive 3 doses of vaccine
33113889|NCT04863638|Experimental|A3 aged ≥ 71|200 subjects age ≥ 71 (A3) receive 3 doses of vaccine
33113890|NCT04863638|Experimental|B1 aged 60-70|300 subjects age 60-70 (B1) receive 3 doses of vaccine
33113891|NCT04863638|Experimental|B2 aged 60-70|200 subjects age 60-70 (B2) receive 3 doses of vaccine
33113892|NCT04863638|Experimental|B3 aged 60-70|200 subjects age 60-70 (B3) receive 3 doses of vaccine
33113893|NCT04863638|Experimental|C1 aged 18-59|300 subjects age 18-59 (C1) receive 3 doses of vaccine
33113894|NCT04863638|Experimental|C2 aged 18-59|200 subjects age 18-59 (C2) receive 3 doses of vaccine
33113895|NCT04863638|Experimental|C3 aged 18-59|200 subjects age 18-59 (C3) receive 3 doses of vaccine
33113896|NCT04863638|Experimental|C4 aged 18-59|300 subjects age 18-59 (C4) receive 2 doses of vaccine
33113897|NCT04863638|Experimental|D1 aged 9-17|300 subjects age 9-17 (D1) receive 3 doses of vaccine
33113898|NCT04863638|Experimental|D2 aged 9-17|200 subjects age 9-17 (D2) receive 3 doses of vaccine
33113899|NCT04863638|Experimental|D3 aged 9-17|200 subjects age 9-17 （D3）receive 3 doses of vaccine
33113900|NCT04863638|Experimental|D4 aged 9-17|300 subjects age 9-17 （D4）receive 2 doses of vaccine
33335028|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
33335029|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
33335030|NCT00066573|Experimental|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
33335031|NCT00066573|Active Comparator|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
33335032|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
33335033|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
33335034|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
33335035|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
33335036|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
33360832|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
33360833|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion >4 weeks apart
33060470|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
33060471|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
33060472|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
33060473|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
33060474|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
33060475|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
33060476|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
33060477|NCT00232219|No Intervention|Control|No fish oil exposure
33060478|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
33060479|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
33060480|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
33060481|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
33060482|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
33060483|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
33060484|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
33060485|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
33060486|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
33060487|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
33060488|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
33060489|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
33060490|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
33060491|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
33060492|NCT00097266|Placebo Comparator|A|
33060493|NCT00097266|Experimental|B|
33060494|NCT00097266|Active Comparator|C|
33060495|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
33060496|NCT00232687|Active Comparator|A1|
33060497|NCT00232687|Active Comparator|A2|
33060498|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
33060499|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
33060500|NCT00232765|Experimental|1|Cypher Bx Velocity
33060501|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
33060502|NCT00232804|Other|1|
33060503|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
33060504|NCT00232843|Active Comparator|2|balloon angioplasty
33060505|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
33060506|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
33060507|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
33335037|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
33335038|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
33335039|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
33335040|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
33335041|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
33335042|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
33335043|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
33335044|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
33335045|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
33335046|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
33360834|NCT01228669|Experimental|A|
33360835|NCT01228669|Experimental|B|
33360836|NCT01228669|Placebo Comparator|C|
33060508|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
33060509|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
33060510|NCT00413647|Experimental|CardioPET|
32871642|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below~age 18 to 65 Acoustic distortion of speech"
33060511|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
33060512|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
33060513|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
33060514|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
33060515|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
33060516|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
33060517|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
33060518|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
33060519|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
33060520|NCT00233818|Other|1|
33060521|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
33060522|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
33060523|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
33060524|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
33060525|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
33060526|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
33060527|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
33060528|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
33060529|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
33060530|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
33060531|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
33060532|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
33060533|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
33060534|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
33060535|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
33060536|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
33335047|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335048|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335049|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
33335050|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33419243|NCT05229549|Placebo Comparator|C. One day treatment with 3 self-administrations of free AAs|
33419244|NCT05229549|Placebo Comparator|D. One day treatment with 2 self-administrations of free AAs|
33419245|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
32740496|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
33060537|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
33060538|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
33060539|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
33060540|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
33060541|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
33060542|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
33060543|NCT04721704|Experimental|Group A|Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen
33060544|NCT04721704|Experimental|Group B|Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen
33060545|NCT02958605|Experimental|Smartphone|Smartphone application
33060546|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
33060547|NCT00234208|Experimental|Medical thoracoscopy|
33060548|NCT00234208|Active Comparator|Simple chest tube drainage|
33060549|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
33060550|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
33060551|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
33060552|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
33060553|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
33060554|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
33060555|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
33060556|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
33060557|NCT00234676|Experimental|1|Premarin
33060558|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
33060559|NCT00234754|Experimental|2|Trans-obturator tape surgery
33060560|NCT00234871|Active Comparator|1|
33060561|NCT00234871|Active Comparator|2|
33060562|NCT00234910|Experimental|A|2 drug arm
33060563|NCT00234910|Active Comparator|B|3 drug arm, SOC
33060564|NCT00234988|Experimental|1|
33060565|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
33060566|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
33060567|NCT00400491|Experimental|1|
33060568|NCT00400491|Placebo Comparator|2|
33060569|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
33060570|NCT00235144|Experimental|1|drug-eluting stent
33060571|NCT00235144|Active Comparator|2|bare-metal stent
33060572|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
33060573|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
33060574|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
33060575|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
33060576|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
33060577|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
33060578|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
33060579|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
33060580|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
33060581|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
33060582|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
33060583|NCT00235378||1|SLE patients
33060584|NCT00235378||2|Unaffected family members of SLE patients
33060585|NCT00235378||3|Control participants
33060586|NCT04710511||Control group|Medically free children aged from 5 years to 7 years and do not practice oral habits.
33060587|NCT04710511||Oral habit practicing group|Medically free children aged from 5 years to 7 years and practicing oral habits.
33060588|NCT04710316|Experimental|Patients|- Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures
33060589|NCT04710316|Experimental|Caregivers|"Caregivers of one of the four centers in Bamako.~Serological screening: all.~Molecular screening: with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures"
33060590|NCT04710082|Active Comparator|Patients planned to undergo conventional 2 step trans-epithelial PTK-PRK|"Patients planned to undergo:~Epithelial removal using Phototherapeutic Keratectomy PTK as a separate step.~Laser Vision Correction using Excimer laser wavefront optimized technology."
33060591|NCT04710082|Active Comparator|Patients planned to undergo the new single step trans-epithelial (StreamLight) PRK.|"Patients planned to undergo:~Epithelial removal and Excimer wavefront optimized Laser Vision Correction in a single step using the new StreamLight Technology."
33335051|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335052|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
33335053|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335054|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335055|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
33335056|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33060592|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
33060593|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
33060594|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
33060595|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
33335057|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335058|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
33335059|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
33335060|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
33335061|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
33335062|NCT01094925|Placebo Comparator|Placebo|
33060596|NCT00235729|Placebo Comparator|2|Placebo QID
33060597|NCT04721080||COPD patients with tuberculous sequelae|COPD patients with tuberculous sequelae
33060598|NCT04721080||COPD patients without tuberculosis sequela|COPD patients with tuberculous sequelae
33060599|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
33060600|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
33060601|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
33060602|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
33060603|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
33060604|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
33060605|NCT00236002|Placebo Comparator|placebo|
33060606|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
33060607|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
33060608|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
33060609|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
33060610|NCT04721275||Sepsis on the elderly population in ED|The elderly population is defined as patients over 65 years old of age.
33060611|NCT04721275||Sepsis on the non-elderly population in ED|The non-elderly population is defined as patients aged of 18 to 64 years old.
33060612|NCT00236158|Other|AAIR|
33060613|NCT00236158|Other|DDDR|
33060614|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
33060615|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
33335063|NCT01094925|Active Comparator|Gabapentin 300mg|
33335064|NCT01094925|Active Comparator|Gabapentin 600mg|
33335065|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
33335066|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
33335067|NCT04614922|Experimental|Acceptance and Commitment Therapy|
33335068|NCT04614922|Other|control group|
33335069|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
33335070|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
33335071|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
33060618|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
33335072|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
33060619|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
33060620|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
33060621|NCT02961907|No Intervention|Control|"The usual routine course includes :~a clinico-biological evaluation of infertility causes~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy~collection of blood and sperm samples"
33060622|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
33060623|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
33060624|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
33060625|NCT04721041|Experimental|Washed Microbiota Transplantation (WMT)|Patients undergo once WMT a day for three consecutive days.
33060626|NCT02961868|Experimental|Prospective cohort|3 years follow-up
33060627|NCT00237133|Experimental|Letrozole|
33060628|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
33060629|NCT00237211|Experimental|Letrozole|
33060630|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
33060631|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
33060632|NCT04721743||Affected Participants|Participants with Uveitis
33060633|NCT04721431|Experimental|Normal|Body mass index must to be in range limits (18.5-24.9 kg/meter square)
33060634|NCT04721431|Experimental|Overweight|Body mass index must to be in range limits (25-29.9 kg/meter square)
33060635|NCT04721431|Experimental|Obese|Body mass index must to be in range limits (30-34.9 kg/meter square)
33060636|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, W.|If the rate of popliteal artery stenosis of patients < 50%, the patients only receive the wound treatment.
33060637|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, WT.|If the rate of popliteal artery stenosis of patients < 50%, the patients receive the wound treatment and tibial transverse transport surgery.
33060638|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WV.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and vascular intervention surgery.
33060639|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and tibial transverse transport surgery.
33060640|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WVT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment, vascular intervention and tibial transverse transport surgery.
33060641|NCT04710121|Experimental|Intervention Arm|"The experimental group will be asked about their anxiety states with the State and Trait Anxiety Inventory, their pain conditions with the Analog Scale (VAS), and their first life findings will be measured, and the first measurement values will be recorded in the Vital Signs Follow-up Form. Virtual reality glasses will be placed on the patient's head during colonoscopy. The duration of the colonoscopy will vary between 3-10 minutes, videos with music background, park, nature and seaside walks, underwater videos, which the patient chooses, will be watched and the Vital Signs Tracking Form Second measurement values will be recorded by making measurements. Immediately after the colonoscopy procedure is completed, Visual Analogue Scale (VAS), Vital Signs Follow-up Form (measurement will be made and 3rd measurement values will be recorded. The State Anxiety Inventory will be read and the answers will be recorded."
33060642|NCT04710121|No Intervention|Control Arm|No application will be made in the control group. during and after colonoscopy and routine treatment and care will be applied.
33060643|NCT04709848||Pre-screening group|Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
33060644|NCT04709848||Screened group|Individuals undergoing bone marrow transplantation July 2020 - July 2021
33060645|NCT04709965|Other|Main Study|Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
33060646|NCT04709965|Other|Faces Sub Study|Patients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
33060647|NCT04710160|Active Comparator|Novel fast setting calcium silicate ( Protooth)|In the form of powder and liquid to be mixed together to form paste.
33060648|NCT04710160|Experimental|MTA|In form of powder to be mixed with saline to form paste.
33060649|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
33060650|NCT04709809|Experimental|Experimental arm|Measurement RVA / IOP / with ECG gating
33113901|NCT04863638|Experimental|E1 aged 3-8|300 subjects age 3-8 （E1） receive 3 doses of vaccine
33060651|NCT04709770|Experimental|Low-volume preparation|"Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.~Each sachet A contains:~polyethylene glycol (4000) 52.50 g;~simethicone 0.08 g;~sodium sulphate anhydrous 3.75 g.~Each sachet B contains:~sodium citrate 1.863 g;~anhydrous citric acid 0.813 g;~sodium chloride 0.73 g;~potassium chloride: 0.37 g;~acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids."
33060652|NCT04709770|Active Comparator|High-volume preparation|"High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.~Each sachet contains:~polyethylene glycol (4000) 58.30 g;~simethicone 0.08 g;~sodium sulphate anhydrous 5.68 g;~sodium bicarbonate 1.68 g;~sodium chloride 1.46 g;~potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes."
33060653|NCT04709731|Experimental|Total Patients|Intolerant Group Ponatinib 15 mg tablet, taken orally once daily (QD) Resistant Group Ponatinib 30 mg tablet, taken orally once daily (QD) The dose will be reduced to 15mg once daily (QD) as soon as a Complete Cytogenetic Response will be obtained. In those patients showing Major Molecular Response or better, the dose could be further reduced to 15MG every other day (EOD), due to the prolonged half-life of the drug.
33060654|NCT00098163|Experimental|1|
33060655|NCT00098163|Placebo Comparator|2|
33060656|NCT00398645|Experimental|Arm 1|
33335073|NCT04841876||Group-1|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-1, participants will be asked to play three consecutive rugby matches, with 40 min for each match. The total duration will be 2 hours. There is no additional intervention on this group.
33335074|NCT04841876||Group 2|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
33335075|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
33335076|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
33335077|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
33335078|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
33335079|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 40 to 65 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
33335080|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
33335081|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
33335082|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
33335083|NCT00054327|Experimental|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
33335084|NCT00054327|Experimental|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
33335085|NCT00054327|Experimental|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
33060657|NCT00237601||1|Women with the intention to give birth at home
33060658|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
33060659|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
33060660|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
33060661|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
33060662|NCT00237640|Placebo Comparator|1|
33060663|NCT00237640|Active Comparator|2|
33060664|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
33060665|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
33113902|NCT04863638|Experimental|E2 aged 3-8|200 subjects age 3-8 （E2）receive 3 doses of vaccine
33113903|NCT04863638|Experimental|E3 aged 3-8|200 subjects age 3-8 （E3）receive 3 doses of vaccine
33335086|NCT00054327|Experimental|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
33335087|NCT00054327|Experimental|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
33335088|NCT00054327|Experimental|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
33335089|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
33335090|NCT03952689|Experimental|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
33335091|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
33335092|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
33335093|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
33335094|NCT03462680|Placebo Comparator|placebo|placebo
33335095|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
33335096|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
33060666|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
33060667|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
33060668|NCT00237913|Active Comparator|A1|
33060669|NCT00237913|Active Comparator|B1|
33060670|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
33060671|NCT04721119|Experimental|Local Infiltration Anesthetic|This group of patients will receive the local infiltration anesthetic only.
33060672|NCT04721119|Experimental|Local Infiltration Anesthetic + Adductor Canal Block|This group of patients will receive the local infiltration anesthetic and adductor canal block combination.
33060673|NCT00238030|Active Comparator|po thyroxine|placebo is iv
33060674|NCT00238030|Active Comparator|iv thyroxine|placebo is po
33060675|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
33060676|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
33060677|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
33060678|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
33060679|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
33060680|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
33060681|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
33060682|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
33060683|NCT02967146|Experimental|Mediclore|
33060684|NCT02967146|No Intervention|Not done|Standard treatment for surgery
33060685|NCT00065585|No Intervention|Usual care|
33060686|NCT00065585|Placebo Comparator|non needle control|
33060687|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
33060688|NCT00065585|Experimental|Accupunture - Experimental Points|
33060689|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
33060690|NCT00238888|Active Comparator|Usual care|Usual care
33060691|NCT04720924|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through white light EGD examination with assistance of AQCS.
33060692|NCT04720924|No Intervention|Control group|Patients in control group will go through white light EGD examination without AQCS.
33060693|NCT00239083|Experimental|EC-MPS|
33060694|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
33060695|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
33060696|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
33060697|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
33060698|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
33060699|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
33060700|NCT00239239|Experimental|test treatment period|
33060701|NCT00414349|Experimental|1|
33060702|NCT00414349|Active Comparator|2|
33060703|NCT00414349|Experimental|3|
33335097|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
33335098|NCT03952845|Experimental|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
33335099|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
33335100|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
33335101|NCT01095081||Group 1|
33335102|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
33335103|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
33335104|NCT01097811|Active Comparator|Erythromycin|
33335105|NCT01097811|Active Comparator|Neomycin|
33335106|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
33335107|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
33060704|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33060705|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
33060706|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
33060707|NCT00239707|Experimental|Infusion 1|Normal Saline
33060708|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
33060709|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
33060710|NCT00239746|Experimental|1|
33060711|NCT00239746|Placebo Comparator|2|
33060712|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
33060713|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
33060714|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
33060715|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
33060716|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
33060717|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
33060718|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
33060719|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
33060720|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
33060721|NCT00239980|Active Comparator|A|50 IU/kg
33060722|NCT00239980|Active Comparator|B|100 IU/kg
33060723|NCT00239980|Active Comparator|C|150 IU/kg
33060724|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
33060725|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
33060726|NCT00240214||1|sirolimus
33060727|NCT00240253|Active Comparator|Pramlintide|
33060728|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33060729|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
33060730|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
33060731|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
33113904|NCT04863638|Experimental|E4 aged 3-8|300 subjects age 3-8 （E4）receive 2 doses of vaccine
33335108|NCT03957291|Active Comparator|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
33335109|NCT03957291|Active Comparator|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
33335110|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
33060732|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
33060733|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
33060734|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
33060735|NCT00240682|Experimental|cetuximab|cetuximab
33060736|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
33060737|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
33060738|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
33060739|NCT04720807|Experimental|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
33060740|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
33060741|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
33060742|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
33060743|NCT00240799|Experimental|001|acetaminophen extended release
33060744|NCT00240799|Placebo Comparator|002|placebo
33060745|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
33060746|NCT00240877|Placebo Comparator|2|Placebo
33060747|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine."
33060748|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated varicella vaccine."
33060749|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine."
33060750|NCT00241111|Other|Zometa|
33060751|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
33060752|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
33060753|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
33060754|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
33060755|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
33060756|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
33060757|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
33060758|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
33060759|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
33060760|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
33060761|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
33335111|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
33335112|NCT01091883|Experimental|Exablate treatment|Exablate 2000
33335113|NCT01091883|Active Comparator|Radiation|External Beam Radiation
33335114|NCT04044976|Experimental|Treated infants|Infants who will receive caffeine in the delivery room.
33335115|NCT01097889|Active Comparator|Treatment Group 1|
33335116|NCT01097889|Experimental|Treatment Group 2|
33335117|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
33335118|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
33113905|NCT04615611|Experimental|salbutamol|salbutamol, 800 microgram from metered dose inhaler
33113906|NCT04615611|Placebo Comparator|placebo|placebo
33113907|NCT04839302||Patients with possible nectrotizing fascitis|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
33113908|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
33113909|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
33113910|NCT04833959|Experimental|89Zr-Panitumumab|Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.
33335119|NCT03955653|Active Comparator|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
33113911|NCT04832165|Experimental|Muscle inspiratory strength training|An 8-week muscle inspiratory muscle strength training
33113912|NCT04832165|No Intervention|No training program|No intervention
33335120|NCT03955653|Active Comparator|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
33113913|NCT04798586|Experimental|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
33113914|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
33113915|NCT04798040|No Intervention|Control group|"Routine treatment and nursing care of the clinic will be applied to the patients without any application.~Routine interventions applied to the control group during silicone drain removal in the clinic:~The patient will be informed about the procedure.~The consent of the patient who agrees to participate in the study will be obtained.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale .~The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.~The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
33113916|NCT04798040|Experimental|Cold application group|The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
33113917|NCT04798040|Experimental|Lavender oil group|"All patients who accept the study will be tested for lavender oil before the procedure to exclude sensitivity to lavender. Patients in the lavender group will be given oxygen with a lavender oil covered face mask 15 minutes before the silicone drain is removed. Two drops of 2% lavender oil will be applied with a cotton swab inside the oxygen face mask.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
33113918|NCT04798040|Experimental|Oxygen administration|The patient will be informed about the procedure. Consent of the patient who agrees to participate in the study will be obtained. Patients in the oxygen administration group will be given 2 lt/min oxygen with a face mask 15 minutes before the silicone drain is removed. The patient will mark the pain he feels due to the silicone drain on Numeric Rating Scale. The patient will re-mark the pain from Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain. Before the procedure, as soon as the procedure is over and 15 minutes after the procedure, the patient's vital signs will be measured.
33113919|NCT04794530|Active Comparator|cocoa flavanols|
33113920|NCT04794530|Placebo Comparator|placebo|
33113921|NCT04790786|Experimental|Lilly Bamlanivimab|The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
33113922|NCT04790786|Experimental|Regeneron Casirivimab + Imdevimab|The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
33113923|NCT04790786|Experimental|Lilly Bamlanivimab + Etesevimab|The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
33113924|NCT04790786|Experimental|Sotrovimab|The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
33113925|NCT04790786|Experimental|Bebtelovimab|The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
33113926|NCT04785053|Active Comparator|Healthy young participants|a group of 20 cognitively intact younger participants (age 21-35)
33113927|NCT04785053|Active Comparator|Healthy older participants|A group of 20 cognitively intact older participants (age 55+)
33335121|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
33335122|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
33113928|NCT04785053|Active Comparator|Older MCI/mild AD participants|A group of 20 cognitively impaired older participants (age 55+)
33113929|NCT04614792|Experimental|active treatment|open label experimental treatment
33335123|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
33335124|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
33060762|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
33335125|NCT04295902|Experimental|VL-group|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Germany) with blades Miller nr 0 and Miller nr 1.
33335126|NCT04295902|Active Comparator|DL-group|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
33335127|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
33335128|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
33060763|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
33060764|NCT04720690||Appropriately grown for age infants|40 appropriately grown for gestational age (AGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
33060765|NCT04720690||Small for gestational age infants|40 small for gestational age (SGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
33060766|NCT04720690||Fetal growth restricted infants|40 fetal growth restricted (FGR) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
33060767|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
33060768|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
33060769|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
33060770|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
33060771|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
33060772|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
33060773|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
33060774|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
33060775|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
33060776|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
33060777|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
33060778|NCT04720885||Patients with a placental remnant in medical history|
33060779|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
33060780|NCT00099177|Experimental|1|
33060781|NCT00099177|Active Comparator|2|
33060782|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
33060783|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
33060784|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
33060785|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
33335129|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
33335130|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
33060786|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
33060787|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
33060788|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
33335131|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
33335132|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
33335133|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
33060789|NCT00242320|Active Comparator|1|Roflumilast 500 µg
33060790|NCT00242320|Placebo Comparator|2|Placebo
33060791|NCT00242359|Other|omalizumab|open-label
33060792|NCT04729920||subjects with neuromuscular disease|Adult subjects with neuromuscular disease, with an active prescription of MI-E for more than 3 months
33060793|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
33060794|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
33060795|NCT04728594|No Intervention|Delayed Contact|This group will not receive an email for at least two days.
33060796|NCT04728594|Experimental|Social Proof|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
33060797|NCT04728594|Experimental|Reframing Side Effects and Adverse Reactions|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
33060798|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
33060799|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
33060800|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
33060801|NCT00242944|Active Comparator|1|Pitavastatin
33060802|NCT00242944|Active Comparator|2|Atorvastatin
33060803|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
33060804|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
33060805|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
33060806|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
33060807|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
33060808|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
33060809|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
33060810|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
33060811|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
33060812|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
33060813|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
33060814|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
33060815|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
33060816|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
33335134|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
33060817|NCT00243685|Experimental|II and III|
33060818|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
33060819|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
33060820|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
33060821|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
33060822|NCT00244075|Active Comparator|2|nutrition supplementation only
33060823|NCT00244114||A|
33060824|NCT00244114||B|
33060825|NCT04729803|Experimental|Attention Guidance + Exposure|Participants will complete teleconferencing-based exposure trials with an attention guidance component.
33060826|NCT04729803|Active Comparator|Exposure Alone|Participants will complete teleconferencing-based exposure trials.
33060827|NCT04729803|Experimental|Attention Control + Exposure|Participants will complete teleconferencing-based exposure trials with an attention control component.
33060828|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
33060829|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
33060830|NCT00244270|Experimental|1|totally implantable vascular access device
33060831|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
33060832|NCT00244426|Experimental|1|
33060833|NCT00244426|Active Comparator|2|
33060834|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
33060835|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
33335135|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-24 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~No evidence of fat redistribution rated by the investigator."
33335136|NCT01098045||Healthy controls|"No history of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-29.9 kg/m2"
33335137|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 25-29.9 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
33335138|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
33335139|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
33335140|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
33335141|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
33335142|NCT01098123||nutritional index|Heavyweight athletes without weight limit
33060836|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
33060837|NCT00244504|Active Comparator|I|moxonidine group
33060838|NCT00244504|Placebo Comparator|II|placebo group
33060839|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
33060840|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
33060841|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
33060842|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
33060843|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
33060844|NCT00245206|Experimental|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
33060845|NCT00245206|Experimental|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
33060846|NCT00245206|Experimental|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
33060847|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
33060848|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
33360837|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
33335143|NCT03636906|Experimental|RSV1D Pooled Group|"Subjects received the interventions as follows:~Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~Or 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31."
33335144|NCT03636906|Experimental|RSV2D Pooled Group|"Subjects received the interventions as follows:~Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~Or 2 doses of experimental RSV (GSK3389245A) higher dose formulation administered at Day 1 and Day 31."
33360838|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
33360839|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
33360840|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
33419246|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
33060849|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
33060850|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
33060851|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
33060852|NCT00245479|Other|1|
33060853|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
33060854|NCT00245752|Sham Comparator|2|sham acupuncture
33060855|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
33060856|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
33060857|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
33060858|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
33060859|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
33060860|NCT00400725|Experimental|1|
33060861|NCT00400725|Placebo Comparator|2|
33060862|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
33060863|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
33060864|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
33060865|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
33060866|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
33060867|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
33060868|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
33060869|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
33060870|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
33060871|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
33060872|NCT04728516|Experimental|Vonoprazan-based dual eradication therapy|H. pylori eradication using a dual eradication regimen, a course of 14 days, followed up to 6 months after randomization; the treatment regimen is as follows: routine use of Vonoprazan 20mg bid + amoxicillin 1g tid, a course of 14 days .
33060873|NCT04728516|Active Comparator|Pantoprazole|To take pantoprazole 40 mg daily, followed up to 6 months after randomization.
33060874|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
33060875|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
33060876|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
33068231|NCT04512391||Erector Spinae|patients who are administered ultrasound guided ESPB at T4 vertebrae level with long acting local anesthetic (%0,25 bupivacaine) and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
33060877|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
33060878|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
33360841|NCT03923257|Experimental|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
33060879|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
33060880|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
33060881|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
33060882|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
33060883|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
33060884|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
33060885|NCT00247234|Experimental|schema therapy|
33060886|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
33060887|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
33060888|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
33060889|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
33060890|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
33060891|NCT00401076|Experimental|1|
33060892|NCT00247390|Experimental|Ramelteon 8 mg QD|
33060893|NCT00247390|Placebo Comparator|Placebo QD|
33060894|NCT00099606|Experimental|A1|
33060895|NCT00247663|Experimental|Letrozole|
33060896|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
33060897|NCT00247741|Active Comparator|lidocaine|
33060898|NCT00247741|Experimental|articaine|
33060899|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
33060900|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
33060901|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
33060902|NCT00248053|Other|Lower GI|
33060903|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
33060904|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
33060905|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
33060906|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
33060907|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
33060908|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
33060909|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
33060910|NCT02961478|Experimental|Iohexol plasmatic clearance|
33060911|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
33060912|NCT00248677|No Intervention|No Contact Control|
33060913|NCT00248677|Experimental|Behavior Family Intervention|
33060914|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
33068232|NCT04512391||Control|patients who are not administered any regional analgesic technique and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
33068233|NCT04512313|Active Comparator|Group receiving rocuronium 0,3 mg/kg|Rocuronium 0,3 mg/kg at induction
33060915|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
33060916|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
33060917|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
33060918|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
33360842|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
33360843|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
33060919|NCT00248989|Experimental|Placebo|
33060920|NCT00248989|Experimental|DHEA|
33060921|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
33060922|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
33060923|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
33060924|NCT00249301|Experimental|1|MLN8054
33060925|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
33060926|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
33060927|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
33060928|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
33060929|NCT04720495|Active Comparator|One stage ridge splitting|
33060930|NCT04720495|Experimental|Two-stage ridge splitting|
33060931|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
33060932|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
33060933|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
33060934|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
33060935|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
33060936|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
33060937|NCT00249535|Experimental|3|standard treatment plus voucher CM
33060938|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
33060939|NCT00249652|Experimental|TAP|MI-based phone intervention.
33060940|NCT00249652|Other|TAU|Treatment As Usual
33060941|NCT00249691|Experimental|Topiramate|
33060942|NCT00249691|Placebo Comparator|Placebo|
33360844|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
33360845|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
33360846|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
33360847|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
33360848|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
33360849|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
33360850|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
33360851|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
33360852|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
33360853|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
33360854|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
33360855|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
33360856|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
33360857|NCT01348880|Experimental|Arm1|
33360858|NCT01348880|Placebo Comparator|Arm2|
33060943|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
33335145|NCT03636906|Active Comparator|Comparator_Placebo Pooled Group|"Subjects received either one of interventions schedules as follows:~3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~3 doses of GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 31, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Day 1 and Day 121).~2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 31 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 1 and 61) .~2 doses of Placebo alone (administered at Days 1 and 31)."
33335146|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
33335147|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
33335148|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
33335149|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
33335150|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
33335151|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
33060944|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
33060945|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
33060946|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
33060947|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33060948|NCT00250081|Active Comparator|Therapy Group|Therapy only
33060949|NCT00250081|Active Comparator|Surgery Group|surgical intervention
33060950|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
33060951|NCT04720573|Active Comparator|Group N|Neostigmine was used for the reversal of neuromuscular blockade.
33060952|NCT04720573|Active Comparator|Group S|Sugammadex was used for the reversal of neuromuscular blockade.
33060953|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
33060954|NCT04720261|Other|Caplacizumab|All patients in the study are aTTP and needs to be treated by caplacizumab. The duration of this treatment will be evaluated through the ADAMTS 13 activity.
33060955|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
33060956|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
33060957|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
33060958|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
33060959|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
33060960|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
33060961|NCT00250510|No Intervention|1|
33060962|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
33060963|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
33060964|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
33060965|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
33060966|NCT00250744|Experimental|Arm A|
33060967|NCT00250744|Active Comparator|Arm B|
33335152|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
33335153|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
33335154|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
33060968|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
33060969|NCT04720144||bIMI cases|"Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:~i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).~AND~iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days."
33060970|NCT04720144||Controls|"For each bIMI case, we will include 2 control cases fulfilling the following criteria:~i) Receiving continuous posaconazole prophylaxis for at least 7 days~ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay"
33060971|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
33060972|NCT04720183|Experimental|Sulfasalazine + GLPG3970|
33060973|NCT00250939|Experimental|1|
33060974|NCT04719871||with posterior vitreous detachment|patient with stage 3 or more of posterior vitreous detachment on optical coherence tomography
33060975|NCT04719871||without posterior vitreous detachment|patient with stage 2 or less of posterior vitreous detachment on optical coherence tomography
33060976|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
33060977|NCT00103701|Experimental|1|
33060978|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
33060979|NCT00251056|Active Comparator|1|
33060980|NCT00251056|Active Comparator|2|
33060981|NCT00251056|Active Comparator|3|
33060982|NCT00251056|Active Comparator|4|
33060983|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
33060984|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
33060985|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
33060986|NCT00251134|Placebo Comparator|2|olive oil
33060987|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
33060988|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
33060989|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
33060990|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
33060991|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
33060992|NCT00251212|No Intervention|3|3: Control brochure
33335155|NCT04194346|Experimental|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
33335156|NCT04294810|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
33060993|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
33060994|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
33060995|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
33060996|NCT00103779|Experimental|1|
33060997|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
33060998|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
33060999|NCT00251602|Experimental|1|II ACE genotype
33061000|NCT00251602|Experimental|2|ID ACE genotype
33061001|NCT00251602|Experimental|3|DD ACE genotype
33061002|NCT00251602|Placebo Comparator|4|II ACE genotype
33061003|NCT00251602|Placebo Comparator|5|ID ACE genotype
33061004|NCT00251602|Placebo Comparator|6|DD ACE genotype
33061005|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
33061006|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
33061007|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
32740497|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
33061008|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
33061009|NCT02961127||group 1|no drugs were used in our study
33061010|NCT02961127||group 2|
33061011|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
33061012|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
33061013|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
33061014|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
33061015|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
33061016|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
33061017|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
33335157|NCT04294810|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
33335158|NCT01092273||Bimatoprost versus Travoprost|
33335159|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
33335160|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
33335161|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
33335162|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
33061018|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
33061019|NCT00069017|Placebo Comparator|2|Placebo (N=100)
33335163|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
33335164|NCT03955731|Other|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
33335165|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
33335166|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
33335167|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
33335168|NCT04293094|Experimental|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
33335169|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
33061020|NCT00399074|No Intervention|chloroquine|Weekly CQ
33061021|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
33335170|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
33335171|NCT05666154|Active Comparator|Real diet|Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE
33061022|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
33061023|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
33335172|NCT05666154|Sham Comparator|Sham diet|Diet excluding a sham nutrient without acute mucosal reaction in CLE
33335173|NCT05666154|Active Comparator|Wheat exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
33335174|NCT05666154|Active Comparator|Soy exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
33360859|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
33360860|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
33360861|NCT03923179|Experimental|pyrotinib+Etoposide|
33360862|NCT01357226||All patients over the age of 18|
32740498|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
32740499|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
33061024|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
33061025|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
33335175|NCT04288726|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 4 × 107 CD30.CAR-EBVST cells~Dose Level 2: 1 × 108 CD30.CAR-EBVST cells~Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
33335176|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
33335177|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
33335178|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
33335179|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
33335180|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
33335181|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
33335182|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
33335183|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
33061026|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
33061027|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
33061028|NCT00399152|Experimental|Perifosine+Sunitinib malate|
33061029|NCT04719559|Other|Post-Thyroidectomy Hypertrophic Scar|Patients had all presented a persistent hypertrophic scar at the neck region for more than 1 year after their thyroidectomy.
33061030|NCT04719598|Experimental|intervention group is ( internet - based group) who will receive CBT sessions|study group ( group A)
33061031|NCT04719598|No Intervention|control group ( group B)|researchers just answer their questions
33061032|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
33061033|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
33061034|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
33061035|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
33061036|NCT04719715||Cases with ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
33061037|NCT04719715||Controls with autoimmune diseases other than ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
33061038|NCT04719754||Pregnant women with abnormal vaginal discharge|
33061039|NCT04719754||Pregnant women without abnormal vaginal discharge|
33061040|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
33061041|NCT00252304|Placebo Comparator|Placebo|Placebo
33061042|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
33061043|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
33061044|NCT00252616|Experimental|1|trophic feeds
33061045|NCT00252616|Active Comparator|2|Full-calorie feeds
33061046|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
33061047|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
33061048|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
33061049|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
33061050|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
33061051|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
33061052|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
33061053|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
33061054|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
33061055|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
33061056|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
33061057|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
33335184|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
33335185|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
33335186|NCT03502616|Experimental|Tofacitinib|
33335187|NCT03502616|Placebo Comparator|Placebo|
33335188|NCT04003012|Active Comparator|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
33335189|NCT04003012|Active Comparator|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
33335190|NCT03693898|Other|Persons with collagen VI defect|Observational
33335191|NCT03992560|No Intervention|Standard CRT implantation|
33335192|NCT03992560|Experimental|MRI guided CRT implantation|
33335193|NCT04177810|Experimental|Cemiplimab and Plerixafor|All participants will receive Cemiplimab and Plerixafor.
33335194|NCT03635424|Experimental|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
33068234|NCT04512313|Active Comparator|Group receiving rocuronium 0,9 mg/kg|Rocuronium 0,9 mg/kg at induction
33068235|NCT00142493|Experimental|1|
33068236|NCT00142493|Experimental|2|
33068237|NCT00142493|Experimental|3|
33068238|NCT00142493|Experimental|4|
33068239|NCT00142493|Placebo Comparator|5|
33068240|NCT04512352|Experimental|Treatment group|Online curriculum has been delivered to this group of participants on an Internet-based platform
33068241|NCT04512352|No Intervention|Wait-list control group|Participants in wait-list control group would not have access to the online curriculum until the intervention process for treatment group is finished.
33068242|NCT04511689||test group|bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
33068243|NCT04511689||control group|bone grafting with xenogenic deproteinized bone matrix mixed with autobone
33068244|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
33068245|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
33068246|NCT04511923|No Intervention|Standard Care|Standard care
33068247|NCT04511923|Experimental|Heparin|Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days
33068248|NCT04511611|Experimental|Test A: 10 mg ODT with water, then 10 mg film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
33068249|NCT04511611|Experimental|Test A: 10 mg film-coated tablet, then 10 mg ODT with water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
33068250|NCT04511611|Experimental|Test B: 10 mg ODT without water, then 10 film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
33068251|NCT04511611|Experimental|Test B: 10 mg film-coated tablet, then 10 mg ODT without water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
33068252|NCT04511260|Experimental|VRF Treatment|"A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).~Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment."
33068253|NCT04511299|Experimental|Fish oil-enriched intravenous lipid emulsion|SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.
33068254|NCT04511299|Active Comparator|Standard intavenous lipid emulsion|Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.
33068255|NCT04511221|Placebo Comparator|Placebo|15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides
33068256|NCT04511221|Active Comparator|Bifidobacterium animals subsp. lactis BL04|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
33068257|NCT04511221|Experimental|Bifidobacterium animals subsp. lactis BL04+PreforPro|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
33068258|NCT04511182|Experimental|exercise intervention group|Patients will receive standard medications plus EBCR 。Education covering topics related to AMI and exercise for AMI will be implemented and any consultations on exercise prescription and disease management will be explained by a cardiac rehabilitation team consisting of cardiologists, cardiology nurses and physiotherapists.
33068259|NCT04511182|No Intervention|Usual care group（control）|Patients will receive standard medications according to national guidelines, as well as education and consultations as intervention group. However，no exercise prescription is given,
33113930|NCT04776551|Other|group (1)|group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.
33113931|NCT04614519|Active Comparator|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
33113932|NCT04614519|Experimental|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
33113933|NCT04614675|Active Comparator|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
33335195|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
33335196|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
33335197|NCT05666076|Active Comparator|Group PENG|The investigators performed a pericapsular nerve block on that patient group for postoperative analgesia.
33335198|NCT05666076|Active Comparator|Group SSNB|The investigators performed a suprascapular nerve block on that patient group for postoperative analgesia.
33335199|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
33335200|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
33335201|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
33335202|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
33335203|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
33335204|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
33335205|NCT03634800|Experimental|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.~Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached~Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
33335206|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
33335207|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
33335208|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
33335209|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
33335210|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
33335211|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
33335212|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
33335213|NCT04641052|Experimental|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
33335214|NCT04641052|No Intervention|No Intervention Group|The control group patients will receive standard care only
33335215|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
33335216|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
33335217|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
33335218|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
33335219|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
33335220|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
33335221|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
33335222|NCT05089032||Physicians|
33335223|NCT05089032||Nurses|
33335224|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
33335225|NCT03730506|Experimental|CBCT|
33335226|NCT03730506|Experimental|IOS|
33335227|NCT03730506|Active Comparator|desktop scanner|
33335228|NCT03690856|Experimental|depressiv people|
33335229|NCT05665998|Experimental|ARC-BSI Cervical Rehabilitation|Implantation of a neuroprosthetics system composed of an electrocorticography acquisition system (WIMAGINE) and a cervical epidural electrical spinal cord stimulation system (ARC-IM) to restore voluntary arm movements in participants with SCI.
33335230|NCT04164472|Experimental|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
33061058|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
33335231|NCT04164472|No Intervention|Control|Referral to school counselor as needed as per standard practice.
33335232|NCT03721250||thoracic epidural|patients receiving thoracic epidural
33335233|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
33335234|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
33335235|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
33335236|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
33335237|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
33335238|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
33335239|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
33335240|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
33419247|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
33061059|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
33061060|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
33061061|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
33061062|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
33061063|NCT04719481|Experimental|pravastatin 80mg/d|Oral administration of pravastatin at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
33061064|NCT04719481|Placebo Comparator|placebo|Oral administration of placebo at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
33061065|NCT00253903|Experimental|1|5 mg/day
33061066|NCT00253903|Placebo Comparator|2|
33061067|NCT00414934||metastatic bone lesion for patients with cancer|
33061068|NCT00415090|No Intervention|1|Follow with same ARV treatment
33061069|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
33061070|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
33061071|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
33061072|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
33061073|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
33061074|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
33061075|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
33061076|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
33061077|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
33061078|NCT00254644||Dyslexia|adults from 18-35 ans.
33061079|NCT00254644||Control|adults from 18-35 ans.
33061080|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
33061081|NCT00254722|Experimental|I|single arm study
33061082|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
33061083|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
33061084|NCT00254761|Placebo Comparator|3|Placebo cannabis
33061085|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
33061086|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
33061087|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
33061088|NCT04719364||Focus Groups|10 black, 10 Latinx, and 10 white MSM will be recuited in this focus group 'cohort'
33061089|NCT04719364||Quantitative Survey Group|Cross-sectional group of 100 black, 100 Latinx, and 100 white MSM
33061090|NCT00069836|Experimental|Arm 1|
33061091|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
33061092|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
33061093|NCT04719676|Experimental|Core strength training using unstable surface|The experimental group will use Core strength training using unstable surface
33061094|NCT04719676|Active Comparator|The stable surface would be gym floor.|The control group will use stable surface.
33061095|NCT04728672|Experimental|Experimental Group|Kinesio tape was applied and then outcome measures were noted.
33061096|NCT04728672|Placebo Comparator|Control Group|Placebo Micropore Tape was applied and then outcome measures were noted.
33061097|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
33335241|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
33335242|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
33335243|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
33061098|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
33061099|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
33061100|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
33061101|NCT04719091|Experimental|HA formulation Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
33061102|NCT04719091|Placebo Comparator|Placebo Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
33061103|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
33061104|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
33061105|NCT00255580|Placebo Comparator|2|Placebo cannabis
33061106|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
33061107|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
33061108|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
33061109|NCT04719169|Experimental|Post-low pelvic colorectal anastomosis|Single armed study
33061110|NCT04719325|Experimental|Herbert screw|
33061111|NCT04719325|Active Comparator|Lag screw|
33061112|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
33061113|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
33061114|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
33061115|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
33061116|NCT00255931|Experimental|1|
33061117|NCT00255931|Placebo Comparator|2|
33061118|NCT00255931|No Intervention|3|Usual Care
33061119|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
33061120|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
33061121|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
33061122|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
33061123|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
33061124|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
33061125|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
33061126|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
33061127|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
33061128|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
33061129|NCT04709536|Experimental|IBI306|IBI306 administered subcutaneously (SC)
33061130|NCT04709536|Placebo Comparator|Placebo|administered subcutaneously (SC)
33061131|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
33061132|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
33061133|NCT00256321|Experimental|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.~1 Cycle = 21 days."
33061134|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
33061135|NCT00256516|Experimental|Eco-Atkins diet|
33061136|NCT00256516|Active Comparator|NCEP diet|
33061137|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
33061138|NCT00104715|Experimental|Hormonotherapy + chemotherapy|
33061139|NCT00104715|Active Comparator|Hormonotherapy alone|
33061140|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
33061141|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
33061142|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
33335244|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
33335245|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
33335246|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
33335247|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
33335248|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
33335249|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
33061143|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
33061144|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
33335250|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
33335251|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
33335252|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
33061145|NCT04709380|Experimental|Radiotherapy plus Toripalimab|Patients in the experimental group will be given local vein tumor thrombus/hepatic vein tumor thrombus +/- intrahepatic large lesions with hypofractionated intensity modulated radiotherapy (tumor area dose 40-60Gy/10-20f), concurrent with and followed by 240mg Q3W of teriprizumab within 1 week of radiotherapy.
33061146|NCT04709380|Active Comparator|Sorafenib|Patients in the control group will be treated with sorafenib (400mg, twice a day).
33335253|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
33335254|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
33335255|NCT03730038|Active Comparator|Life-style modification|
33335256|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
33335257|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
33061147|NCT04709185|Experimental|AVS after 1mg DST|Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS
33061148|NCT04709185|Placebo Comparator|AVS after placebo|Patients divided into AVS after placebo group need to oral placebo the night before AVS
33061149|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
33061150|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
33061151|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
33061152|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
33061153|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
33061154|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
33061155|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
33061156|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
33061157|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
33061158|NCT04709146|Other|Recovered Covid-19 patients|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
33061159|NCT04709146|Other|Healthy Control|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
33061160|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
33061161|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
33061162|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
33061163|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
33061164|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
33061165|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
33061166|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
33061167|NCT00401115|Experimental|1|Subconjunctival injection
33061168|NCT00401115|Experimental|2|Intraocular injection
33061169|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
33061170|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
33061171|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
33061172|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
33061173|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
33061174|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
33061175|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
33061176|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
33061177|NCT00258388|Active Comparator|Docetaxel plus prednisone|
33061178|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
33061179|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
33335258|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
33335259|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
33335260|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
33335261|NCT03693118|Experimental|Grup1, Grup2|
33061180|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
33335262|NCT03693118|Experimental|Grup1,Grup2|
33061181|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
33061182|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
33061183|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
33061184|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
33061185|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
33061186|NCT04709068||COVID19+|
33061187|NCT00258934|Experimental|1|
33061188|NCT00258934|Active Comparator|2|
33061189|NCT00259129|Experimental|Arm 1|
33061190|NCT00259207|Active Comparator|classic surgery|classic surgery
33061191|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
33061192|NCT00259324|Experimental|1|Diet and Activity
33061193|NCT00259324|Experimental|2|Diet and Activity
33061194|NCT00259324|Placebo Comparator|3|Education
33061195|NCT00071084|Experimental|280 mg and 980 mg|
33061196|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
33061197|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
33061198|NCT00415402|Experimental|Vitamin D3|vitamin D granules
33061199|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
33061200|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
33061201|NCT00259402|Experimental|Oxaliplatin|
33061202|NCT00400842|Experimental|L|
33061203|NCT00400842|Experimental|H|
33061204|NCT00400842|Placebo Comparator|P|
33061205|NCT00259519|No Intervention|1|Expectant management
33061206|NCT00259519|Active Comparator|2|Induction of delivery
33061207|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
33061208|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
33061209|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
33061210|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
33061211|NCT00259753|Experimental|1|0.2 mg/eye
33061212|NCT00259753|Experimental|2|1.5 mg/eye
33061213|NCT00259753|Experimental|3|3.0 mg/eye
33061214|NCT00105144|Experimental|1|lower dose
33061215|NCT00105144|Experimental|2|higher dose
33061216|NCT00105144|Active Comparator|3|
33061217|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
33061218|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
33061219|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
33061220|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
33061221|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
33061222|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
33061223|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
33061224|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
33335263|NCT03725904|Experimental|IVF/FET|
33335264|NCT04142866|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
33335265|NCT04142866|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
33335266|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33335267|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33335268|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
33061225|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
33061226|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
33061227|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
33061228|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
33061229|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
33061230|NCT00260650|Experimental|Heart PACT Program|Heart PACT Program - patient activation intervention
33061231|NCT00260650|No Intervention|Usual Care|Usual Care
33061232|NCT00260728|Experimental|Arm 1|
33061233|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
33061234|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
33061235|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33061236|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
33061237|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
33061238|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
33061239|NCT00261001|Experimental|Transcutaneous|
33061240|NCT00261001|Active Comparator|Intramuscular|
33061241|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
33061242|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
33061243|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
33061244|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
33061245|NCT00261196|Experimental|Collagenase|Collagenase Injection
33061246|NCT00261196|Placebo Comparator|Placebo|Placebo Injection
33061247|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
33061248|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
33061249|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
33061250|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
33061251|NCT00261274|Experimental|Test Group A-ECO|
33061252|NCT00261274|Placebo Comparator|Control Group|
33061253|NCT00261313|Experimental|Aranesp|
33061254|NCT00261313|Experimental|Neulasta|
33061255|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
33335269|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33335270|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33335271|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
33335272|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
33061256|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
33061257|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
33061258|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
33061259|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
33061260|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
33061261|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
33061262|NCT00261781|No Intervention|Usual care|Control group
33061263|NCT00261859|No Intervention|SCA|Standard Care with Assessment
33061264|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
33061265|NCT00261859|Experimental|BNI|Brief Negotiated Interview
33061266|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
33061267|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
33061268|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
33061269|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
33061270|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
33061271|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
33061272|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
33061273|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
33061274|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
33061275|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
33061276|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
33061277|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
33061278|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
33061279|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
33061280|NCT00105651|Other|Arm 1|
33061281|NCT00262288|Experimental|Recombinant Human C1INH|
33061282|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
33061283|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
33061284|NCT00262405|Experimental|zileuton|Zileuton
33061285|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
33061286|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
33061287|NCT00105690|Other|Arm 1|
33061288|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
33061289|NCT00072215|Experimental|Regimen A: TIP|
33061290|NCT00072215|Experimental|Regimen B: VeIP|
33061291|NCT00105729|Other|Arm 1|
33061292|NCT00262795|Experimental|F|Fludarabine
33061293|NCT00262795|Active Comparator|CLB|Chlorambucil
33061294|NCT00105768|Other|Arm 1|
33061295|NCT00263029|Experimental|1|
33061296|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
33061297|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
33061298|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
33061299|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
33061300|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
33335273|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
33113934|NCT04614675|Active Comparator|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
33113935|NCT04614285|Experimental|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
33113936|NCT04614285|Active Comparator|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
33113937|NCT04725812|Experimental|Eculizumab|Twelve subjects in the interventional arm will receive eculizumab at an induction dose of 900mg IV weekly (q7 days) for 4 weeks followed by a dose of 1200mg IV at week 5. Thereafter, patients will receive a maintenance dose of 1200mg IV every two weeks (q14 days). The last dose of eculizumab will be given up to 48 hours post-partum, with a dose that is dependent on the dosing schedule (i.e. whether the last dose is given within the 4-week induction period or is during the maintenance phase).
33113938|NCT04614012|Experimental|hyperimmune plasma|treated with hyperimmune plasma
33113939|NCT04713371|Other|Single arm. Subjects receiving treatment.|Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.
33113940|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
33113941|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
33113942|NCT04683614|Experimental|Fresh frozen plasma|early administration of fresh frozen plasma
33113943|NCT04683614|Experimental|Low dose norepinephrine|low dose epinephrine 5 mic/kg/hr
33113944|NCT04613895|Experimental|fed state group|just after a meal
33113945|NCT04613895|Experimental|fasted state group|before a meal
33113946|NCT04676087|Experimental|Treatment (mogamulizumab, ECP)|"INDUCTION (WEEKS 1-7): Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, and 36 in the absence of disease progression progression and unacceptable toxicity. Patients also undergo extracorporeal photopheresis on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression and unacceptable toxicity.~TREATMENT (CYCLES 1-12): Patients receive mogamulizumab IV over 60 minutes on days 1 and 15, and undergo extracorporeal photopheresis on days 1 and 15 of cycles 1-6, then day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression and unacceptable toxicity.~MAINTENANCE (CYCLES 13+): Patients with clinical benefit may continue extracorporeal photopheresis on day 1. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity."
33113947|NCT04613700|Active Comparator|Secretin|
33113948|NCT04613700|Placebo Comparator|Placebo|
33113949|NCT04675151|Experimental|Nyxol + Pilocarpine|1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)
33113950|NCT04675151|Active Comparator|Nyxol|1 drop of Nyxol (Treatment 1)
33113951|NCT04675151|Active Comparator|Pilocarpine|1 drop of Pilocarpine (Treatment 2)
33113952|NCT04675151|Placebo Comparator|Placebo|1 drop of Placebo (Treatment 1)
33335274|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
33335275|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
33113953|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
33335276|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
33335277|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
33335278|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).~All procedures will be performed under general anesthesia."
33113954|NCT04672109|Experimental|Anodal-tDCS|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
33113955|NCT04672109|Experimental|Cathodal-tDCS|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) of non-dominant hemisphere and Anode on the supraorbital area of dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
33113956|NCT04672109|Experimental|Dual-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the primary motor area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
33061301|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
33061302|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily."
33061303|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
33335279|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.~All procedures will be performed under general anesthesia."
33335280|NCT03690622|Sham Comparator|BSS|Balanced salt solution
33061304|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
33061305|NCT00101712|Experimental|Vildagliptin|
33061306|NCT00101712|Placebo Comparator|Placebo|
33061307|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
33061308|NCT00105807|Other|Arm 1|
33061309|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
33061310|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
33061311|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
33061312|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
33061313|NCT00263809|No Intervention|2|Reference, Untreated platelets
33061314|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
33061315|NCT00105846|Other|Arm 1|
33061316|NCT00264160|Experimental|AMN107|
33061317|NCT00264199|Active Comparator|1|
33061318|NCT00264199|Placebo Comparator|2|
33061319|NCT00101790|Active Comparator|1|
33061320|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
33061321|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
33061322|NCT04719286|Experimental|Intervention group|The intervention is the use of the MinSafeStart mobile application. The app utilizes the Pregnancy-Unique-Quantification-of-Emesis-24 (PUQE-24) scale to categorize the women's NVP severity (e.g. mild, moderate, or severe) on a daily basis, and visualizes the fluctuations over time in a graph. Each woman will have their own personal graph based on the information they put in. They will also be able to see how their symptoms are compared to an average graph. The women will get treatment advice based on their PUQE-24 scale, e.g. dietary and lifestyle advice for mild symptoms and referral to see the doctor for moderate and severe symptoms.
33061323|NCT04719286|No Intervention|Control group|Standard care.
33061324|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
33061325|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
33061326|NCT04709029|Active Comparator|intravenous dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
33061327|NCT04709029|Active Comparator|intrathecal dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
33061328|NCT04708795|Experimental|Verum|AP701 single dose oromucosal application
33061329|NCT04709497|Active Comparator|viscotrabeculotomy (VT)).|
33061330|NCT04709497|Active Comparator|visco-circumferential-suture-trabeculotomy (VCST)|
33061331|NCT04709497|Active Comparator|Combined VT-Trabeculectomy with MMC (VT-Trab).|
33061332|NCT04708912||1|Mild-Moderate COVID-19
33335281|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
33335282|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
33335283|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
33335284|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
33061333|NCT04708912||2|Severe COVID-19
33061334|NCT04708912||3|Convalsent (COVID-19)
33061335|NCT04708912||4|Healthy persons
33061336|NCT04708873|Experimental|High Intensity Interval Training Group|Participants in this group will initially undergo continuous aerobic training to achieve a baseline fitness level, after which HIIT and resistance training will be employed. Warm-up period will be followed by 4 bouts of 4-minute interval treadmill running and stationary bike cycling at 80-95% of the measured HR reserve, interspersed with active recovery phase at 55-70% HRR. After this resistance exercises will be performed in a circuit fashion for strengthening the upper limbs, lower limbs and trunk. The session will be ended with a 5-7 minute cool-down period
33061337|NCT04708873|Active Comparator|Moderate Intensity Continuous Training Group|Participants in this group will also initially undergo continuous aerobic training to achieve a baseline fitness level, after which the intensity will be increased to moderate continuous training achieving 55-70% of HRR. Every session will be preceded by appropriate warm-up and end with cool down.
33360863|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
33360864|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
33061338|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
33061339|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
33061340|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
33061341|NCT00264511|Experimental|Hyperbaric oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
33061342|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
33061343|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
33061344|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
33061345|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
33061346|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
33061347|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
33061348|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
33061349|NCT00264706|Other|Participant|Internal control study
33061350|NCT00264745|Experimental|1|
33061351|NCT00264745|Active Comparator|2|
33061352|NCT00264823|Experimental|1 - Experimental|
33061353|NCT00264823|No Intervention|2 - Control|
33061354|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
33061355|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
33061356|NCT00265018|Active Comparator|Arm A|
33061357|NCT00265018|Experimental|Arm B|
33061358|NCT00265018|Experimental|Arm C|
33061359|NCT00265018|Experimental|Arm D|
33061360|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
33061361|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
33061362|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
33061363|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
33061364|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
33061365|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
33061366|NCT00265408|Experimental|aspirin|
33061367|NCT00265408|Experimental|warfarin|
33061368|NCT00265447|Active Comparator|Strength training|3 months of strength training
33061369|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
33061370|NCT00265447|Other|Delayed exercise|delayed exercise control group
33061371|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
33061372|NCT00265642|Experimental|group verum|Drug: Irbesartan
33061373|NCT00265642|Placebo Comparator|group placebo|
33335285|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
33113957|NCT04672109|Sham Comparator|Sham-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins. Anode on dominant hemisphere, Cathode on non-dominant hemisphere. The scope of intervention is to investigate effect of tDCS on muscle strength.
33113958|NCT00563394|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
33113959|NCT00563394|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
33113960|NCT04660877|Experimental|Cheddar chese|Once enrolled, participants will either ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
33113961|NCT04660877|Active Comparator|Milk|Once enrolled, participants will ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
33113962|NCT04653350|Experimental|HIT-MMEX Group|In this group Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
33113963|NCT04653350|Active Comparator|Control Group|In this Group Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
33113964|NCT00563433|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
33113965|NCT00563433|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
33113966|NCT04652102|Experimental|Randomized Observer-blinded Phase 2b: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33113967|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 2b: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33113968|NCT04652102|Experimental|Randomized Observer-blinded Phase 3: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33113969|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 3: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
33113970|NCT04652102|Experimental|Open-label Phase|"After unblinding, the trial will shift from a randomized observer-blinded to an open-label design, and the following cohorts will be defined:~Cohort A: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to receive an authorized/licensed vaccine for preventing COVID-19 (AV) as standard of care through their national vaccination program.~Cohort B: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to remain in the trial without receiving any AV.~Participants on the placebo arm will be withdrawn."
33113971|NCT00563472|Active Comparator|1|10 mg estetrol
33113972|NCT00563472|Active Comparator|2|20 mg estetrol
33113973|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
33113974|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
33113975|NCT04679597||total neoadjuvant therapy|Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.
33113976|NCT04679597||standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
33113977|NCT04615910|Experimental|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
33113978|NCT04615910|Placebo Comparator|Placebo|Patients treated with placebo within the Ver-A-T1D trial
33335286|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
33335287|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
33335288|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
33360865|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
33360866|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
33113979|NCT04613778|Experimental|Laser acupuncture|Laser acupuncture with knee-chest position
33113980|NCT04613778|No Intervention|No intervention|usual care with knee-chest position
33113981|NCT04613856|Active Comparator|Current Best Practice - 237 mL water bolus|
33113982|NCT04613856|Experimental|New Intervention - 500 mL water bolus|
33335289|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
33335290|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
33335291|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
33335292|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
33335293|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
33335294|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
33335295|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
33335296|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
33335297|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
33335298|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
33335299|NCT04139902|Experimental|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
33335300|NCT04139902|Experimental|Dostarlimab (TSR-042) and TSR-022 (combination)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
33335301|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
33335302|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
33335303|NCT03687268|Placebo Comparator|Placebo|
33113983|NCT04609397|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
33113984|NCT04609397|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
33113985|NCT04609397|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
33113986|NCT04592978|Experimental|Pain-Alcohol Personalized Feedback Intervention|
33113987|NCT04592978|Active Comparator|Control Personalized Feedback Intervention|
33113988|NCT04613193|Active Comparator|Strict BP intervention group|SBP < 120 mmHg and a reduction in SBP of >= 15 mmHg
33335304|NCT03687268|Experimental|Naloxone 24 mg|
33113989|NCT04613193|Other|Conventional BP control group|In patients < 75 years: SBP = 135 mmHg In patients >/= 75 years: SBP = 145 mmHg
33113990|NCT04613310|Other|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
33113991|NCT04578080|Experimental|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
33113992|NCT04578080|Active Comparator|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
33335305|NCT03687268|Experimental|Naloxone 48 mg|
33335306|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
32871643|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 36 and 65~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
33113993|NCT04612998|Sham Comparator|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
33335307|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.~And they will receive sham taping on the affected limb."
33061374|NCT00265720|Placebo Comparator|Control|Written materials only
33061375|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
33335308|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
33335309|NCT03576066|Experimental|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
33335310|NCT03576066|Active Comparator|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
33335311|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
33335312|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
33335313|NCT03557034|No Intervention|Standard of Care Monitoring|Standard of Care
33335314|NCT03557034|Experimental|Kardia Monitoring|Kardia Mobile/Kardia Pro
33335315|NCT04118920|Experimental|Topical insulin|Patients will receive topical insulin eye drops.
33335316|NCT04118920|Sham Comparator|Topical artificial tears|Patients will receive topical artificial tears.
33335317|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
33335318|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
33061376|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
33061377|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
33061378|NCT00265876|Experimental|AZD0530 + Gemcitabine|
33061379|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
33061380|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
33061381|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
33061382|NCT00265993|Experimental|1|enoxaparin
33061383|NCT00102141|Experimental|Arm 1|
33061384|NCT00102141|Experimental|Arm 3|
33061385|NCT00102141|Experimental|Arm 4|
33061386|NCT00102141|Placebo Comparator|Arm 5|
33061387|NCT00102141|Experimental|Arm 2|
33061388|NCT00266305|Experimental|Fish oil|
33061389|NCT00266305|Placebo Comparator|Olive oil|Control group
33061390|NCT00266305|No Intervention|High fish|Reference group
33061391|NCT04718974|Experimental|"intervention  Call for life- mHealth tool with standard of care for PLHIV"|"The system has options to either use interactive voice response or short message service and the user has to make a choice, get a secret pin code which ensures privacy to end user.~The mHealth tool/system offers personalised pill reminder calls, health tip messages, clinic appointment reminders and remote symptom reporting"
33061392|NCT04718974|No Intervention|"Standard of care usual care"|"Standard~• Care and support for people living with HIV, and the first line ART regimen is based on the Apr 2018, consolidated guidelines for prevention and treatment of HIV in Uganda (MoH, 2018), and will also follow the healthcare services package for PLHIV including the Adult Care and Treatment Package."
33061393|NCT00266773|No Intervention|1|Control - standard care only
33061394|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
33061395|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
33061396|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
33061397|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
33061398|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
33061399|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
33061400|NCT01349569|Experimental|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
33061401|NCT00073346|Experimental|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
33061402|NCT00073346|No Intervention|Wait list control|Participants waited to receive treatment for 12 weeks
33061403|NCT00267124||1|elderly people who have normal cognition
33113994|NCT04612998|Active Comparator|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
33335319|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
33335320|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
33335321|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
33335322|NCT03583554|Placebo Comparator|Placebo, then AV-101 720mg, then AV-101 1440mg|Participants first received oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules).
33335323|NCT03583554|Experimental|AV-101 720mg, then AV-101 1440mg, then placebo|Participants first received oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo.
33113995|NCT04545476|Experimental|APIS Biomaterial on the Head|Participants in this group will receive the experimental APIS Biomaterial on the Head. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
33113996|NCT04545476|Experimental|APIS Biomaterial on the Lower Extremities|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
33113997|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
33113998|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
33113999|NCT04492670|Experimental|Tui-na and oral Chinese medicine|8 sessions of 20 minutes Tui-na for 4 weeks and take study medication (Herbal granules) twice daily concomitantly for 4weeks
33114000|NCT04492670|Other|Tui-na|8 sessions of 20 minutes Tui-na for 4 weeks
33114001|NCT04484012|Experimental|Treatment (CD19 CAR T cells, acalabrutinib)|Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.
33114002|NCT04613076|Experimental|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
33114003|NCT04613076|Active Comparator|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
33114004|NCT04477109|Active Comparator|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and a relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. the device will be applied on specific acupuncture points (N acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time, once per day, 3 times per week for three months
33114005|NCT04477109|Sham Comparator|sham laser application in addition to diet recommendations|while the control group will stick to the same line of treatment but with sham laser application
33335324|NCT03583554|Experimental|AV-101 1440mg, then placebo, then AV-101 720mg|Participants first received oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules).
33335325|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
33114006|NCT04613037|Experimental|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
33335326|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
32871644|NCT00324701|Experimental|Telepsychology|therapy done at patients house
32871645|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
33335327|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
33335328|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
33335329|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
33061404|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
33061405|NCT00267163|Experimental|1.|
33061406|NCT00267163|Placebo Comparator|2.|
33061407|NCT00267241|Experimental|1|ALI/ARDS patients
33061408|NCT00267319|Experimental|single group|
33061409|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
33061410|NCT00267358|Placebo Comparator|Placebo|
33061411|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
33061412|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
33061413|NCT00106548|Experimental|1|
33061414|NCT00106548|Experimental|2|
33061415|NCT00106548|Placebo Comparator|3|
33061416|NCT00267826|Experimental|1|Patients with atopic dermatitis.
33061417|NCT00425620|Experimental|Amphotericin B|
33061418|NCT00401232|Other|Arm 1|
33061419|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
33061420|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
33061421|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
33061422|NCT00401310|Placebo Comparator|1|Placebo
33061423|NCT00401310|Experimental|2|MK0724
33061424|NCT00073697|Experimental|1|Interpersonal Psychotherapy
33061425|NCT00073697|Experimental|2|Escitalopram
33061426|NCT00073697|Experimental|3|Escitalopram plus IPT
33061427|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
33061428|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
33061429|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
33061430|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
33061431|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
33061432|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
33061433|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
33061434|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
33061435|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
33061436|NCT00106782|Other|1|Real TEP
33061437|NCT00106782|Other|2|Sham Stimulation
33061438|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
33061439|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
33061440|NCT00073814|Placebo Comparator|3|Placebo MDI QID
33061441|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
33061442|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
33061443|NCT00268723|Placebo Comparator|2|Placebo MDI QID
33061444|NCT00268840|Experimental|unique|Taxotère - Gemzar
33061445|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
33114007|NCT04465643|Other|Immunotherapy with Nivolumab and Ipilimumab|Nivolumab 4.5 mg/kg every 3 weeks (Q3W) x 2 Ipilimumab 1 mg/kg Q3W x 2 Nivolumab monotherapy 4.5mg/kg Q3W concurrent with standard therapy Nivolumab monotherapy should be held for at least 2 weeks before and 2 weeks after surgery
33114008|NCT04613115||Group A|patients without uremia and variant arteries
33114009|NCT04613115||Group B|patients without uremia, but with variant arteries
33114010|NCT04613115||Group C|patients with uremia ,without variant arteries
32871646|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
33114011|NCT04613115||Group D|patients with uremia and variant arteries
33114012|NCT04465487|Experimental|REGN6569+cemiplimab|REGN6569 lead-in
33114013|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
33114014|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
33114015|NCT04612842|Experimental|Motivational Interviewing (MI) goup|The MI experimental group will receive all the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 12-month period. MI is an evidence-based communication approach for various health behavior change.
33114016|NCT04612842|No Intervention|Control group|The control group participants will only receive study measurements at baseline, 3-, 6-, and 12-months after the benchmark STEADI clinic visit.
33114017|NCT04612881||fitostimoline vaginal pessaries|
33114018|NCT04464161|Experimental|Arm 1|The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.
33114019|NCT04464161|No Intervention|Arm 2|The control group will be instructed to continue to their regular diets.
33114020|NCT04612959|Experimental|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
33114021|NCT04612959|No Intervention|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
33114022|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
33114023|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
33114024|NCT04612647|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-[Parents and Children-Workshop Group]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
33114025|NCT04612647|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
33114026|NCT04612647|No Intervention|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
33114027|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
33114028|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
33114029|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
33114030|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
33114031|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
33114032|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
33114033|NCT02178098|Placebo Comparator|Placebo|Placebo control
33114034|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
33114035|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
33114036|NCT04612257|Experimental|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
33114037|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
33114038|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
33114039|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
32740500|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
33061446|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
33061447|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
33061448|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
33061449|NCT00268957|Experimental|1|sevelamer carbonate powder
33061450|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
33061451|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
33061452|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
33061453|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
33061454|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
33061455|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
33061456|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
33061457|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
33061458|NCT00269308|Active Comparator|3|Home Exercise
33061459|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
33061460|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
33061461|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
33061462|NCT00074048|Experimental|1|BL22 immunotoxin
33061463|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
33061464|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
33061465|NCT00269425|Experimental|Mediterranean diet,|
33061466|NCT00269425|Experimental|American Heart Association Step 2 diet|
33061467|NCT00269425|No Intervention|Case controlled|
33061468|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
33061469|NCT00269542|Experimental|1|
33061470|NCT00269542|Placebo Comparator|2|
33061471|NCT00269581|Other|1|Educational CD-Rom
33061472|NCT00269581|Experimental|2|Headstrong CD-rom
33061473|NCT00269620|Experimental|2|OrthoEvra
33061474|NCT00269620|Experimental|1|NuvaRing
33061475|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
33061476|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
33061477|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
33061478|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
33061479|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
33061480|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
33061481|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
33061482|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
33061483|NCT00269815|Experimental|001|methylphenidate HCl
33061484|NCT00269854|Experimental|Infliximab 5 mg/kg|
33061485|NCT00269854|Experimental|Infliximab 10 mg/kg|
33061486|NCT00269854|Experimental|Infliximab 20 mg/kg|
33061487|NCT00269854|Placebo Comparator|Placebo|
33061488|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
33061489|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
33061490|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
33061491|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33068260|NCT04511104|Active Comparator|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: up to 8 weeks"
33061492|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
33061493|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
33335330|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
33061494|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
33061495|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
33061496|NCT00107016|Active Comparator|Letrozole 2.5mg|
33061497|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
33061498|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
33061499|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
33061500|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
33061501|NCT00270361|Experimental|001|nesiritide
33061502|NCT00270361|Experimental|002|nesiritide
33061503|NCT00270361|Active Comparator|003|usual long term cardiac medications
33061504|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
33061505|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
33061506|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
33061507|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
33061508|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
33061509|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
33061510|NCT00270400|Experimental|001|nesiritide
33061511|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
33061512|NCT00074438|Experimental|1|
33061513|NCT00074438|Experimental|2|
33061514|NCT00074438|Experimental|3|
33061515|NCT00074438|Experimental|4|
33061516|NCT00074438|Experimental|5|
33061517|NCT00074438|Experimental|6|
33061518|NCT00074438|Placebo Comparator|7|
33061519|NCT00074438|Placebo Comparator|8|
33061520|NCT00074438|Placebo Comparator|9|
33061521|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
33061522|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
33061523|NCT00270829|Experimental|1|Nesiritide given intrarenally
33061524|NCT00270829|No Intervention|2|No intrarenal drug administration
33061525|NCT04730375|Active Comparator|( Group A)|: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
33061526|NCT04730375|Active Comparator|(Group B)|Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
33061527|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
33061528|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
33061529|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
33061530|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
33061531|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
33061532|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
33061533|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
33061534|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
33061535|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg~Metacavir Enteric-coated Capsules Placebo 240mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
33335331|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
33335332|NCT03729726|No Intervention|Control|
33335333|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
33335334|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
33335335|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
33061536|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg~Metacavir Enteric-coated Capsules Placebo 160mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
33061537|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg~Adefovir Dipivoxil Capsule Placebo 10mg"
33061538|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule 10mg;"
33061539|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
33061540|NCT00271336|Placebo Comparator|A|
33061541|NCT00271336|Experimental|B|
33061542|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
33061543|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
33335336|NCT03729492|Other|CTEPH/CTED work-up|
33335337|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
33061544|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
33061545|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
33061546|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
33061547|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
33061548|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
33335338|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
33335339|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
33335340|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
33335341|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
33335342|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
33061549|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
33061550|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
33335343|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
33335344|NCT03948178|Experimental|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
33061551|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
33061552|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
33061553|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
33335345|NCT03940144|Experimental|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
33335346|NCT03940144|Active Comparator|Conventional fluid therapy|Conventional fluid therapy such as CVP and MAP guided fluid therapy
33335347|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
33061554|NCT00272116|Placebo Comparator|2|
33061555|NCT00272272|Experimental|Balance and Music Listening|Music therapy
33419248|NCT03959319|Experimental|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
33061556|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
32869832|NCT05698368|Active Comparator|Active comparator group|A series of educational videos and reflective questions of the same duration and required attention as the mindset intervention program. The videos are sourced videos from YouTube that educate about osteoarthritis. The content consists of information about osteoarthritis that patients would typically receive if looking for more information about the disease, including disease pathology, risks, symptoms, and treatment strategies. The included videos contain factual content with a similar format to the mindset intervention videos, including live experts sharing information with animations and supplementary b-roll footage.
32869833|NCT05698368|Experimental|Mindset intervention group|Four modules, each with a series of videos and reflective questions. Each module takes approximately 20-60 minutes to complete, with a total of about two hours to complete the entire program. Participants have one week to complete the program at their own pace. Participants are suggested to complete one module per day but are encouraged to go at the pace that works best for them.
32869834|NCT05698368|No Intervention|Waitlist control group|This group will take the same surveys as the other groups at the same time points but will not receive any additional content.
32869835|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
32869836|NCT00029107|Other|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
32869837|NCT00029107|Other|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
33061557|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
33061558|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
33061559|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
33061560|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
33061561|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
33061562|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
33061563|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
33061564|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
33061565|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
33061566|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
33061567|NCT00272857|Experimental|Single arm|
33061568|NCT00272935|Experimental|1|
33061569|NCT00272935|Placebo Comparator|2|
33061570|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
33061571|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
33061572|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
33061573|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
33061574|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
33061575|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
33335348|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
33061576|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
33061577|NCT00107835|Experimental|S-Caine Peel|
33061578|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
33061579|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
33061580|NCT00074828|Experimental|A|
33061581|NCT00074828|Active Comparator|B|
33061582|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
33061583|NCT04719130|Experimental|Experimental Group|Will received multimodal circuit exercise group.
33061584|NCT04719130|Active Comparator|Control Group|Will received multidisciplinary lectures on pain and usual care provided by the Basic Health Units.
33061585|NCT00273559||1|subjects who remain on steroids after discharge
33061586|NCT00273559||2|Subjects will be off steroids at the time of discharge
33061587|NCT00273715|No Intervention|Staples|
33061588|NCT00108108|Experimental|HCD122|
33061589|NCT00108147|Experimental|1|Circuit Training
33061590|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
33061591|NCT00108147|Active Comparator|3|Flexibility and toning
33061592|NCT00075101|Experimental|Study Cycle|
33061593|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
33061594|NCT00075140||1|All Participants hav a family member with Huntington Disease
33061595|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
33061596|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
33061597|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
33061598|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
33061599|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
33061600|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
33061601|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
33061602|NCT00075374|Experimental|Docetaxel|
33061603|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
33061604|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
33061605|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
33061606|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
33061607|NCT00277537|Experimental|1|
33335349|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
33335350|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
33335351|NCT03798574||IMD Case|No intervention
33335352|NCT03798574||Control|No intervention
33061608|NCT00277537|Other|2|
33061609|NCT00277654|Active Comparator|Risperidone|
33061610|NCT00277654|Placebo Comparator|Sugar pill|
33061611|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
33061612|NCT00108576|Experimental|Arm 2|Divalproex
33061613|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
33061614|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
33061615|NCT00277888|Experimental|Femoral route|
33061616|NCT00277888|Experimental|Jugular route|
33061617|NCT00108615|Experimental|1|pioglitazone
33061618|NCT00108615|Active Comparator|2|metformin
33061619|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
33061620|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
33061621|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
33061622|NCT00416689||Breast or lung CA pt undergoing chemoTx|
33335353|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 14 days
33335354|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
33335355|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
33114040|NCT04611984|Experimental|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
33114041|NCT04611984|Active Comparator|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
33114042|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
33114043|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
33114044|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
33114045|NCT04633707|Experimental|Adjunctive morning BLT group|treat participants with adjunctive BLT in the morning
33114046|NCT04633707|Experimental|Adjunctive afternoon BLT group|treat participants with adjunctive BLT in the afternoon
33114047|NCT04633707|Placebo Comparator|Adjunctive placebo therapy group|treat participants with adjunctive dim red light in the afternoon
33114048|NCT04633317|Experimental|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
33114049|NCT04633317|No Intervention|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
33114050|NCT02138630|Placebo Comparator|Placebo|
33114051|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
33114052|NCT04612023|Active Comparator|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
33114053|NCT04612023|Active Comparator|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
33114054|NCT04612023|Placebo Comparator|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
33114055|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
33114056|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
33335356|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
33335357|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
33114057|NCT04633512|Experimental|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=26) Patients undergoing cholecystectomy with ActivSight (n=14)
33114058|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
33114059|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
33114060|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
33114061|NCT04611867|Experimental|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:~Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff~Daily monitoring of self-reporting by study staff~Intervention if required based on self-reporting~Reports to oncologists (at consultation)~Information module about treatment, side effects and contact information"
33335358|NCT03520920|Experimental|R/R Non-GCB DLBCL|Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
33335359|NCT03520920|Experimental|R/R FL or MZL|Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
33335360|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
33335361|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
33335362|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
33335363|NCT02953340|Experimental|(Arm 1): SPI-2012 and TC|At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), [3.6 mg granulocyte colony-stimulating factor {G-CSF}] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m^2 and cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
33360867|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
33360868|NCT01357304|Experimental|Group treatment and PAR|
33360869|NCT01357304|No Intervention|Usual care|
33335364|NCT02953340|Experimental|(Arm 2): Pegfilgrastim and TC|At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m^2 and cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
33061623|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
33061624|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
33061625|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
33335365|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
33335366|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
33335367|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
33335368|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
33335369|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
33061626|NCT00108771|Placebo Comparator|Placebo Patch|
33061627|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
33061628|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
33061629|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
33061630|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
33061631|NCT00278551|Experimental|heatopoietic stem cell transplant|
33061632|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
33061633|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
33061634|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
33061635|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
33061636|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
33061637|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
33061638|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
33061639|NCT00278902|Experimental|ARRY-334543|
33061640|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
33061641|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
33061642|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
33061643|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
33061644|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
33061645|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
33335370|NCT03554772|Placebo Comparator|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
33335371|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
33360870|NCT02296060|Experimental|6 minutes walking test|
33360871|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
33360872|NCT01318304||Pregnant, HIV-positive|
33360873|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
33114062|NCT04611867|No Intervention|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
33114063|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
33114064|NCT04611555||CI users|
33114065|NCT04633083|Other|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
33114066|NCT04633083|Other|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
33335372|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
33335373|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
33114067|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114068|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114069|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114070|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114071|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114072|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
33114073|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
33114074|NCT04677998||Personalized surveillance and intervention protocol|
33335374|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
33335375|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
33335376|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
33335377|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
33335378|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
33335379|NCT01310322|Experimental|1|AZD5423 iv
33335380|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
33335381|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
33335382|NCT01310322|Experimental|4|AZD5423 oral
33335383|NCT04050046|Active Comparator|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
33335384|NCT04050046|Sham Comparator|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
33335385|NCT04830020|Active Comparator|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt)
33335386|NCT04830020|Placebo Comparator|placebo|5 ml of saline via nebulizer b.i.d.
33335387|NCT05664672|No Intervention|Group 1|Subjects will be asked to continue smoking their UBCs ad libitum for 7 days.
33335388|NCT05664672|Experimental|Group 2|Subjects will exclusively use 2 mg NP, using at least 3 pouches per day for 7 days.
33335389|NCT05664672|Experimental|Group 3|Subjects will exclusively use 4 mg NP, using at least 3 pouches per day for 7 days.
33335390|NCT05664672|Experimental|Group 4|Subjects will exclusively use 8 mg NP, using at least 3 pouches per day for 7 days.
33335391|NCT05664672|Experimental|Group 5|Subjects will completely stop all tobacco product usage for 7 days.
33335392|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
33335393|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
33335394|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
33335395|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
33335396|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
33335397|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
33114075|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
33114076|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
33114077|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
33335398|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
33114078|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
33335399|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
33114079|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
33335400|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
33114080|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
33114081|NCT04611828|Experimental|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):~continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities~block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation~in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
33114082|NCT04678037|Active Comparator|Group A (PROs assessment every 2 weeks)|
33114083|NCT04678037|Active Comparator|Group A (PROs assessment every 4 weeks)|
33114084|NCT04633044|Placebo Comparator|Placebo|400 mg of lactose daily for 12 weeks
33114085|NCT04633044|Experimental|Supplement|400 mg of betaine daily for 12 weeks
33114086|NCT04611399|Experimental|VR Group|"The treatment for the participants allocated to the VR Group consists of three home-sessions of approximately 30 minutes each, conducted over two weeks (three per week). In each session, participants will be asked to try for about 15 minutes MIND-VR. Subsequently, they will try the virtual relaxation content The Secret Garden."
33114087|NCT04611399|Active Comparator|Non-VR Group|"Participants assigned to this condition will receive the same training protocol of the VR Group without virtual reality. Both psychoeducation and relaxation will be presented on a computer screen. In particular, psychoeducation will be offered through textual material on stress and anxiety, based on content presented within MIND-VR. Relaxation will be induced by watching a non-immersive video of The Secret Garden. In each session, participants will be asked to sit at a desk in front of their PC, in which they will read a presentation on psychoeducational material for 15 minutes, and then they will watch the relaxation video for the next 10 minutes."
33114088|NCT04611399|No Intervention|Waiting List Group|The WL Group will undergo pre- and post-protocol tests without undergoing any treatment.
33114089|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
33114090|NCT04632849|Experimental|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
33114091|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
33114092|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
33114093|NCT04611438|Experimental|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
33114094|NCT02096666|Experimental|Single arm|
33114095|NCT04632693|Experimental|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
33114096|NCT04632693|Active Comparator|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
33114097|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
33335401|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
33335402|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
33335403|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
33335404|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
33061646|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
33061647|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
33061648|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
33061649|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
33061650|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
33061651|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
33061652|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
33061653|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
33061654|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
33061655|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
33061656|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
33061657|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
33061658|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
33061659|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
33061660|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
33061661|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
33061662|NCT00279448|Experimental|A|
33061663|NCT00279448|Active Comparator|B|
33061664|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
33061665|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
33061666|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
33061667|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
33061668|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
33061669|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
33061670|NCT00416767|Experimental|FOLFIRI|
33061671|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
33335405|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
33335406|NCT04059874|Experimental|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
33335407|NCT04059874|Experimental|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
33360874|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
33061672|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
33061673|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
33061674|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
33061675|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
33061676|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
33061677|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
33061678|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
33061679|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
33061680|NCT00076154||Group 1|
33061681|NCT00280111|Experimental|1|116E AGMK
33061682|NCT00280111|Experimental|2|I321 AGMK
33061683|NCT00280111|Placebo Comparator|3|Placebo
33061684|NCT00280228|Experimental|1|Home Based Treatment
33061685|NCT00280228|Active Comparator|2|Treatment as Usual
33061686|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
33061687|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
33061688|NCT00280462|Active Comparator|1|Nifedipine
33061689|NCT00280462|Active Comparator|2|L-Arginin
33061690|NCT00280462|Placebo Comparator|3|Placebo
33061691|NCT00280501|Active Comparator|1|Quetiapine
33061692|NCT00280501|Active Comparator|2|Sulpiride
33061693|NCT00280501|Placebo Comparator|3|Placebo
33061694|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
33061695|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
33061696|NCT00280657|Experimental|Arm 1|
33061697|NCT00280657|Active Comparator|Arm 2|
33061698|NCT00280657|Placebo Comparator|Arm 3|
33061699|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
33061700|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
33061701|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
33061702|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
33061703|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
33061704|NCT00109512|Placebo Comparator|placebo|
33061705|NCT00109512|Experimental|NBI-56418 75 mg|
33061706|NCT00109512|Experimental|NBI-56418 150 mg|
33061707|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
33061708|NCT04730297|Active Comparator|Paracetamol/codeine Group A|analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
33061709|NCT04730297|Active Comparator|Ibuprofen Group B|analgesic group preoperative oral dose of ibuprofen 400 mg
33061710|NCT04730297|Placebo Comparator|Placebo Group C|Placebo group preoperative placebo
33061711|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
33061712|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
33061713|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
33061714|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
33061715|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
33061716|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
33335408|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
33335409|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
33335410|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
33335411|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
33335412|NCT04629976|Experimental|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
33335413|NCT04629976|Experimental|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
33335414|NCT04629976|Active Comparator|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
33335415|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
33360875|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
33360876|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
33061717|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
33061718|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
33061719|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
33061720|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
33061721|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
33061722|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
33061723|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
33061724|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
33061725|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33061726|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
33068261|NCT04511104|Experimental|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: up to 8 weeks"
33068262|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
33068263|NCT00142610|Placebo Comparator|Placebo|
33068264|NCT04510870|Experimental|Experimental group|"infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)~infusion is NaCl"
33061727|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
33061728|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
33061729|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
33061730|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
33335416|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
33335417|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
33335418|NCT04629430|Experimental|Prebiotic diet|2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT
33061731|NCT00281554|Experimental|1|
33061732|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
33061733|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
33061734|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~Conditioning regimen:~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~allogeneic-PBSCT (from HLA-identical donor)~GVHD prophylaxis: CSA + MTX or MMF~+/- DLI (Donor lymphocyte infusions)"
33061735|NCT00282100|Experimental|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
33061736|NCT00110253|Experimental|S-Caine Peel|
33061737|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
33061738|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
33061739|NCT00282178|Placebo Comparator|3|
33061740|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
33061741|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
33061742|NCT00282685|Experimental|Intra-arterial stemcell therapy|Patients were treated with intra-arterial stemcells delivered via catheter examination
33061743|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
33061744|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
33061745|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
33061746|NCT00283114|Experimental|1|
33061747|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
33061748|NCT00283153|Experimental|SEI|Stories of Emotional Inference
33061749|NCT02960581|Experimental|Group 1A|HIV-uninfected participants
33061750|NCT02960581|Experimental|Group 1B|HIV-uninfected participants
33061751|NCT02960581|Experimental|Group 1C|HIV-uninfected participants
33061752|NCT02960581|Experimental|Group 2A|HIV-infected on ART, (<50 cp/ml)
33061753|NCT02960581|Experimental|Group 2B|HIV-infected on ART, (<50 cp/ml)
33061754|NCT02960581|Experimental|Group 2C|HIV-infected on ART, (<50 cp/ml)
33061755|NCT02960581|Experimental|Group 3A|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
33061756|NCT02960581|Experimental|Group 3B|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
33061757|NCT02960581|Experimental|Arm 1D|HIV-uninfected participants
33061758|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
33335419|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
33335420|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
33335421|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
33360877|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
33061759|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
33061760|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
33061761|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
33061762|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
33335422|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
33335423|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
33335424|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
33335425|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
33335426|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
33335427|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
33335428|NCT03452540|Experimental|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
33335429|NCT03573336|Experimental|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
33335430|NCT03573336|Experimental|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
33335431|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
33335432|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
33335433|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
33335434|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
33335435|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
33335436|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
33335437|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
33360878|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
33061763|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
33061764|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
33061765|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
33061766|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
33061767|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
33061768|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
33061769|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
33061770|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
33061771|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
33061772|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
33061773|NCT00077051|Experimental|Single Arm|
33061774|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~placebo plus standard symptomatic therapy"
33061775|NCT00283699|Placebo Comparator|2|
33061776|NCT00283738|Active Comparator|1|
33061777|NCT00283738|Placebo Comparator|2|Sham control
33061778|NCT00283855|No Intervention|Control Group|No intervention
33061779|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
33061780|NCT00110448|Active Comparator|1|Aspirin use
33061781|NCT00110448|Active Comparator|2|No aspirin use
33061782|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
33061783|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
33061784|NCT00110526|Experimental|Ad.hIL-12|
33061785|NCT04718701|Experimental|Experimental Group|Patients who failed first-line therapy with locally advanced or metastatic pancreatic cancer will be assigned to receive anlotinib plus toripalimab and nab-paclitaxel as second-line or maintenance treatment.
33061786|NCT00284752|Experimental|ABI-007|
33061787|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
33061788|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
33061789|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
33061790|NCT00284830|No Intervention|2|conventional dual-chamber pacing
33061791|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
33061792|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
33335438|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
33061793|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
33061794|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
33061795|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~1g MMF or 720mg EC-MPS p.o twice daily~Oral corticosteroids"
33061796|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
33061797|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
33061798|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
33061799|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
33061800|NCT00110760|Experimental|S-Caine Peel|
33061801|NCT00110760|Placebo Comparator|Placebo Peel|
33061802|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
33061803|NCT00285298|Experimental|Pentoxifylline|
33061804|NCT00285298|Placebo Comparator|Placebo|
33061805|NCT00285376|Experimental|1|vilazodone
33061806|NCT00285376|Placebo Comparator|2|
33061807|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
33061808|NCT00285415|Other|Doc and Car|Receiving Doc and Car
33061809|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
33061810|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
33061811|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
33061812|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
33061813|NCT00285532||Home test kit|
33061814|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
33061815|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
33061816|NCT00285805|Other|Rosiglitazone-placebo|
33061817|NCT00285805|Other|placebo-rosiglitazone|
33061818|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
33061819|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
33061820|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33061821|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
33061822|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
33061823|NCT00286117|Experimental|1|Anastrozole
33061824|NCT00286117|Active Comparator|2|Tamoxifen
33061825|NCT00286195|No Intervention|I|Consecutive patients, open label
33061826|NCT00110916|Experimental|Anakinra|anakinra
33061827|NCT00110916|Placebo Comparator|placebo|placebo
33061828|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
33061829|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
33061830|NCT00110955|Experimental|Darbepoetin alfa - Group A|
33061831|NCT00110955|Placebo Comparator|Placebo- Group B|
33061832|NCT04730180|Active Comparator|No neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
33061833|NCT04730180|Active Comparator|Mixed reality neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.
33061834|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
33061835|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
33061836|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
33061837|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
33061838|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
33061839|NCT00077597|Experimental|1|
33061840|NCT00077597|Active Comparator|2|
33061841|NCT00286780|Experimental|1|
33114098|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
33114099|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
33114100|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
33114101|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
33114102|NCT04677764|Experimental|Wii Fit Group|Received Standard of care and Wii Fit protocol consisted of strength, balance, and aerobic programs that were performed on the Wii Fit balance board (Nintendo Inc., Kyoto, Japan). For muscle strengthening exercise, lunges, single-leg extensions, sideways leg lifts, single leg twists, and rowing squats were performed. For exercise that enhances balancing sense, the soccer heading, ski slalom, penguin, table tilt, and balance bubble games were used. Aerobic games as hula hoop, super hula hoop and basic step.
33114103|NCT04677764|Other|Standard of care group|On discharge from the hospital, patients in the SOC group were given instructions on how to perform physical therapy and occupational therapy exercises after discharge. After education, patients could perform the physical therapy and occupational therapy exercises either at their own home or a gym.
33114104|NCT04677686||Pre-implementation phase (October 2018 - September 2019)|"During this time period, 137 patients underwent colorectal surgery. Only basic measures for preventing SSI were performed:~Hair was removed in the operating field with a clipper instead of shaving hair.~Blood glucose was monitored only during the operation.~Antibiotic prophylaxis was applied 60 minutes before the operation.~The application of an antibiotic prophylaxis was repeated if the operation lasted longer than 4 hours.~Measures of warming were only applied during the operation and in the recovery room.~Instruments and gloves were changed after finishing the anastomosis."
33114105|NCT04677686||Implementation phase (October 2019 - September 2020)|"During this phase, additional measures have been introduced:~Implementation of wound protectors during colorectal surgery.~Colorectal operations were only performed with the support of an experienced consultant surgeon."
33114106|NCT04677686||Post-implementation phase (October 2020 - September 2021)|"During this phase, additional measures are implemented.~Close monitoring of blood glucose. During the stay in the recovery room and for 48 hours post-operative, blood glucose is monitored closely. Moreover, if blood glucose is higher than 9 mmol/l, the patient will be treated with insulin. This measure is applied to diabetic as well as to non-diabetic-patients.~The measures of warming will be intensified. First of all, during the operation and during the stay in the recovery room patients will be placed on warming mattresses. Moreover, a warming towel will be placed on the operating field directly after the operation.~The patients will be asked to take a shower the night before surgery. In case of an emergency operation, patients will be asked to wash the axilla, trunk, genitalia, groins and umbilicus"
33114107|NCT04632342|Experimental|Experimental group 1|HL301 1,200mg/day
33114108|NCT04632342|Experimental|Experimental group 2|HL301 1,800mg/day
33114109|NCT04632342|Placebo Comparator|Control group|Placebo
33114110|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
33114111|NCT04611711|Other|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
33114112|NCT04611711|Other|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
33114113|NCT00554879|Experimental|1|Acupuncture
33114114|NCT00554879|Sham Comparator|2|Sham Acupuncture
33114115|NCT04632537|Active Comparator|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in ~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. [34] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle ~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
33335439|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
33335440|NCT04089358|Active Comparator|Control Group (educational materials, Fitbit)|Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
33114116|NCT04632537|Placebo Comparator|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
33114117|NCT02092922|Experimental|Filanesib|
33114118|NCT04611594|Experimental|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
33335441|NCT04089358|Experimental|Intervention group (educational materials, goal set, Fitbit)|See outline
33335442|NCT01310556||coronary artery disease|patients with coronary artery disease
33335443|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
33335444|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
33335445|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
33335446|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
33335447|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
33335448|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
33335449|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
33114119|NCT04611594|No Intervention|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
33114120|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
33335450|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
33335451|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
33114121|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
33114122|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
33114123|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
33114124|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
33114125|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
33114126|NCT04611360|Experimental|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
33114127|NCT04611360|Active Comparator|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
33114128|NCT04677881|Placebo Comparator|Wholegrain bread with yeast|The control group will be given min. 5 slices of bread baked with yeast per day.
33114129|NCT04677881|Experimental|Wholegrain bread with sourdough|The experimental group will be given min. 5 slices of bread baked with sourdough per day.
33114130|NCT00563940||1|
33114131|NCT00563940||2|
33114132|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
33114133|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
33114134|NCT00563979|Active Comparator|1|VitaluxPlus®
33114135|NCT00563979|Active Comparator|2|Omega 3
33114136|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
33114137|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
33114138|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
33114139|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
33114140|NCT04632147|Experimental|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
33114141|NCT04632147|No Intervention|Control Group|No intervention will be made to this group.
33114142|NCT04632108|Experimental|ASKB589 Injection|Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
33114143|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
33114144|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
33335452|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
33335453|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
33335454|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
33335455|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
33335456|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
33335457|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
33335458|NCT03688594|Experimental|couple : man and pregnant women|
33335459|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
33335460|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
33335461|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
33061842|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
33061843|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
33061844|NCT00417391|Experimental|1 mg RR110|1 mg RR110
33061845|NCT00417391|Experimental|4 mg RR110|4 mg RR110
33061846|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
33061847|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
33061848|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
33061849|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
33061850|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
33061851|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
33061852|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
33061853|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
33061854|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
33061855|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
33061856|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
33061857|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
33061858|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
33061859|NCT00111345|Experimental|1|Daunoxome, standard risk
33061860|NCT00111345|Active Comparator|2|Idarubicin, standard risk
33061861|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
33061862|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
33061863|NCT00287521|Experimental|AL-37807 Suspension|
33061864|NCT00287521|Active Comparator|Xalatan|
33061865|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
33061866|NCT00287521|Experimental|Timolol Maleate|
33061867|NCT00287638|Active Comparator|1|CPAP
33061868|NCT00287638|Placebo Comparator|2|no CPAP
33061869|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
33061870|NCT00287677|Experimental|B|growth hormone + HAART
33061871|NCT00287677|Experimental|C|vaccination + HAART
33061872|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
33061873|NCT00287755|Experimental|1|
33061874|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
33061875|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
33061876|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
33061877|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
33061878|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
33061879|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33068265|NCT04510870|Experimental|NaCl infusion group|"infusion is NaCl~infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)"
33068266|NCT00406536|Active Comparator|1|
33068267|NCT00406536|Placebo Comparator|2|
33335462|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
33360879|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
33360880|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
33360881|NCT01318616|Experimental|Training group|
33360882|NCT02299726|Experimental|Active|spironolactone
33061880|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
33061881|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
33335463|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
33061882|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
33061883|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take RIPC intervention, blood collection and 7 dCA measurements.
33061884|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
33061885|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
33061886|NCT00288184|Placebo Comparator|Placebo|
33061887|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
33061888|NCT00288223|Experimental|1|telithromycin
33061889|NCT00111579|Active Comparator|1|CAIV-T
33061890|NCT00111579|Other|2|TIV
33061891|NCT00288301|Experimental|1|Special Intervention
33061892|NCT00288301|Experimental|2|Delayed intervention
33061893|NCT00288340|Active Comparator|1,2|
33061894|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
33061895|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
33061896|NCT00111696|Experimental|MEDI-522|Drug
33061897|NCT00288691|Experimental|Arm 1|
33061898|NCT00288691|Experimental|Arm 2|
33061899|NCT00288691|Experimental|Arm 3|
33061900|NCT00288691|Placebo Comparator|Arm 4|
33061901|NCT00288730|Experimental|001|nesiritide
33061902|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
33360883|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
33360884|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
33061903|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
33061904|NCT00288769|Other|2|
33061905|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
33061906|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
33061907|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
33061908|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
33061909|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
33061910|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
33061911|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
33061912|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
33061913|NCT04711499|Experimental|Fatigue Group|The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
33068268|NCT04510675|Experimental|Test Article|
33360885|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
33360886|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :~Neuropsychological evaluation~Evaluation of the reading assistance technique"
33360887|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
32869838|NCT04109079|Experimental|No axillary treatment|Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
33061914|NCT04711499|Active Comparator|Non Fatigued group|The non fatigued group will be asked to perform the same series of questions and tasks after a night at home with no work duties or commitments
33335464|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
33335465|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
33335466|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
33335467|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
33061915|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
33061916|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
33061917|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
33061918|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
33061919|NCT04711616|Experimental|physical therapy intervention|
33335468|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
33335469|NCT03518112|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
33335470|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
33335471|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
33335472|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
33335473|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
33061920|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
33061921|NCT00289705|No Intervention|2|Traditional treatment for obesity
33061922|NCT00289861|Active Comparator|risperdone|
33335474|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
33061923|NCT00289861|Placebo Comparator|placebo|
33061924|NCT04711460||treatment plus mindfulness comparing young vs old|Eligible participants had a diagnosis from the DSM-V that included psychotic spectrum disorders, were adults from ages 18 to 55 years, and attended a group therapy-based outpatient mental health program for at least five weeks. Scores were matched for younger vs older participants and compared.
33061925|NCT04711460||treatment plus mindfulness practice and no treatment or Treatment As Usual (TAU)|"Participants in the Treatment plus mindfulness practice had Cognitive Behavioral Therapy, mindfulness education and mindfulness technique practice.~Participants in the Treatment As Usual group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the technique as a group. The scores of each group were compared to determine effect differences."
33061926|NCT00112008|Experimental|darbepoetin alfa|
33061927|NCT04711421|Experimental|Experimental: Feedback|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
33061928|NCT04711421|No Intervention|No Intervention: Control|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve no feedback regrding the number of steps taken by them.
33061929|NCT00078260|Experimental|A|
33061930|NCT00078260|Experimental|B|
33061931|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
33068269|NCT04510675|Sham Comparator|Negative Control|
33068270|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
33068271|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
33335475|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
33335476|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
33335477|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
33335478|NCT03681106|Experimental|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
33335479|NCT03681106|No Intervention|Control|usual care
33335480|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
33360888|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
33114145|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
33335481|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
33114146|NCT04631874|Experimental|Sequence A(RT)|Reference drug (Champix) -> washout -> test drug (CDFF0318)
33114147|NCT04631874|Experimental|Sequence B(TR)|Test drug (CDFF0318) -> washout -> reference drug (Champix)
33335482|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
33335483|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
33335484|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
33114148|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
33114149|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
33114150|NCT04610931|Experimental|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
33114151|NCT04610931|Active Comparator|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
33114152|NCT02053103|Experimental|PF-05175157|
33114153|NCT02053103|Placebo Comparator|Placebo|
33114154|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
33335485|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
33335486|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
33114155|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
33114156|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
33114157|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
33114158|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
33114159|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
33114160|NCT04611282|Experimental|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
33114161|NCT04611282|Active Comparator|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
33114162|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
33335487|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
33335488|NCT03679780|Active Comparator|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
33335489|NCT03679780|Experimental|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
33335490|NCT03679780|Experimental|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
33335491|NCT03679780|Experimental|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
33335492|NCT03517566|Placebo Comparator|placebo|Placebo
33335493|NCT03517566|Experimental|ZPL389 3mg|ZPL389 3 mg oral powder
33335494|NCT03517566|Experimental|ZPL389 10 mg|ZPL389 10 mg oral powder
33335495|NCT03517566|Experimental|ZPL389 30mg|ZPL389 30 mg oral powder
33335496|NCT03517566|Experimental|ZPL389 50mg|ZPL389 50 mg oral powder
32869839|NCT04109079|Active Comparator|Axillary treatment|Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.
33061932|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
33061933|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
33061934|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
33061935|NCT04729556|Experimental|Sericin and chitosan cream|A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
33061936|NCT04729556|Active Comparator|Cavilon|"Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.~Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours)."
33061937|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
33061938|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
33061939|NCT00112320|Active Comparator|1|Standard PVR
33061940|NCT00112320|Experimental|2|PVR plus RV remodeling
33061941|NCT00291148|Active Comparator|Paroxetine|
33061942|NCT00291148|Active Comparator|pregabalin|
33061943|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
33061944|NCT00112398|Experimental|Physician prehospital care|
33061945|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
33061946|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33061947|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
33061948|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
33061949|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
33061950|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
33061951|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
33061952|NCT00291733|Placebo Comparator|2|placebo
33061953|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
33061954|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
33061955|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
33061956|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
33061957|NCT04718311|Active Comparator|Tacrolimus treatment|Apply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
33061958|NCT04718311|Placebo Comparator|Anti-inflammatory mouthwash|Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
33335497|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
33335498|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
33335499|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
33335500|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
33360889|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
33360890|NCT01354808|Active Comparator|DAPT|
33114163|NCT04632186|Experimental|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice~The order in which the participants´ receive the different treatments will be randomized.~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
33114164|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
33114165|NCT04631991||Control|Comprehensive ophthalmologic examination
33114166|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
33114167|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
33114168|NCT04631757|Experimental|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
33114169|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
33114170|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
33114171|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
33335501|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
33335502|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
33335503|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
33335504|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
33335505|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
33335506|NCT03725280||Transgender men I|Transgender men after testosterone treatment
33335507|NCT03725280||Transgender men II|Transgender men before testosterone treatment
32869840|NCT04389229|Experimental|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
33114172|NCT04611009|Experimental|motor training|intervention: motor training
33114173|NCT04611009|Active Comparator|awareness training|intervention: mindfulness exercises
33335508|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
33335509|NCT03725280||Egg donors|IVF- egg donors patients
33335510|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
33335511|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
33335512|NCT03464266|Active Comparator|DMPA and PrEP|
33335513|NCT03464266|Active Comparator|DMPA and no PrEP|
33335514|NCT03464266|Active Comparator|Condoms only and PrEP|
33335515|NCT03464266|Active Comparator|Condoms only and no PrEP|
33360891|NCT01354808|Experimental|TAPT|
33360892|NCT03518632|Active Comparator|Control group|
33114174|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
33114175|NCT02026349|Active Comparator|favipiravir|
33114176|NCT02026349|Placebo Comparator|placebo|
33114177|NCT04611048|Experimental|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
33114178|NCT04611126|Other|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
33114179|NCT04611126|Other|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
33114180|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
33114181|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
33335516|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
33335517|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
32869841|NCT04389229|Experimental|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
33061959|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
33061960|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
33061961|NCT00275392|Experimental|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
33061962|NCT00275392|Placebo Comparator|Placebo|placebo exercises plus standard balance and gait exercises
33061963|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
33061964|NCT00275275|Experimental|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
33061965|NCT00275275|Experimental|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
33061966|NCT00275275|Experimental|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
33061967|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
33061968|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
33061969|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
33061970|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
33061971|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
33061972|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
33061973|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
33061974|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
33061975|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
33061976|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
33061977|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
33061978|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
33061979|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
33061980|NCT00130312|Experimental|Sulodexide|Also known as KRX-101. These patients are also on ACEs and ARBs (irbesartin and/or losartan).
33061981|NCT00130312|Placebo Comparator|Placebo|These patients are also on ACEs and ARBs (irbesartin and/or losartan).
33061982|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
33061983|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
33061984|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
33061985|NCT00130195|Experimental|A|
33061986|NCT00394303|Experimental|1|Intervention
33061987|NCT00394303|No Intervention|2|Control
33061988|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
33061989|NCT00130156|Experimental|1|
33061990|NCT00130156|Experimental|2|
33061991|NCT00130117|Experimental|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
33061992|NCT00130117|Placebo Comparator|Oral Contraceptive Pills (OCPs)|PLACEBO
33061993|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
33061994|NCT00129805|Experimental|MCI-9042|
33061995|NCT00129805|Active Comparator|Aspirin|
33061996|NCT00129727|Experimental|Phase II|Paclitaxel carboplatin bevacizumab
33061997|NCT04727814||Water exchange with computer-aided detection system|Computer-aided detection system overlaid videos with water exchange colonoscopy method
33061998|NCT04727814||Air insufflation with computer-aided detection system|Computer-aided detection system overlaid videos with air insufflation colonoscopy method
33068272|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
33114182|NCT04611165|Experimental|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~Prescription dose to PTVs as according to the following schema:~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
33114183|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
33114184|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
33114185|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
33114186|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
33114187|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
33114188|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
33114189|NCT04610580|Experimental|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
33114190|NCT04610580|Experimental|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
33114191|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
33419249|NCT03959319|Active Comparator|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
33114192|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
33114193|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
33114194|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
33114195|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
33114196|NCT04631328|Experimental|Intervention|Growing Together program
33114197|NCT04631328|No Intervention|Control|
33114198|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
33419250|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
33419251|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
33419252|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
33419253|NCT03609138||Study Cohort|
33114199|NCT02009579|Placebo Comparator|Comparator arm|Placebo
33114200|NCT04631250|Experimental|Right: daylight illumination|The right side of the face was treated using daylight PDT
33114201|NCT04631250|Experimental|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
33114202|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
33114203|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
33114204|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
33114205|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
33114206|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
33114207|NCT04631094|Experimental|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
33114208|NCT04631094|Experimental|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
33114209|NCT04631094|Experimental|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
33114210|NCT04631094|Experimental|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
33114211|NCT04631094|No Intervention|Group 5|The group that will undergo standard hospital blood collection procedure.
33114212|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
33114213|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
33114214|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
33114215|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
33114216|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
33114217|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
33114218|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
33114219|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
33114220|NCT04630899|Experimental|Active Joint Mobilization|
33114221|NCT04630899|Experimental|Passive Joint Mobilization|
33114222|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
33335518|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
33335519|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
33335520|NCT03659734|Experimental|Motivational Interviewing and Guided Opioid Tapering Support|
33335521|NCT03659734|Experimental|Enhanced Usual Care|
33114223|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
33335522|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
33335523|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
33335524|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
33335525|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
33335526|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
33335527|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
33335528|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
33335529|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
33335530|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
33335531|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
33335532|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
33335533|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
33335534|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Neutral Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
33335535|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
33335536|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
33335537|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
33335538|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
33335539|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
33360893|NCT03518632|Experimental|Interval training 1|
33360894|NCT03518632|Experimental|Interval training 2|
33360895|NCT01354886|Experimental|FSH-GEX 25 IU|25 IU single dose
33360896|NCT01354886|Experimental|FSH-GEX 75 IU|75 IU single dose
33360897|NCT01354886|Experimental|FSH-GEX 150 IU|150 IU single dose
33061999|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33360898|NCT01354886|Experimental|FSH-GEX 300 IU|300 IU single dose
32869842|NCT03861702|Experimental|FOLFOX + Irinotecan|"Oxaliplatin 60 mg/m2 Intravenously (IV) over 2 hours~Liposomal Irinotecan (free base) 50 mg/m2 IV over 90 minutes after completion of oxaliplatin~Leucovorin 400 mg/m2 IV over 30 minutes after completion of liposomal irinotecan~5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home~All drugs administered on day 1 of each 14 day cycle."
32869843|NCT04330417|Experimental|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
32869844|NCT04330417|Active Comparator|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
33062000|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
33062001|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
33062002|NCT00119496|Active Comparator|Arm3|Oral theophylline
33062003|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
33062004|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
33062005|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
33062006|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33062007|NCT00119535|Other|Arm 1|
33062008|NCT00298675|Experimental|Iniparib|
33062009|NCT00298675|Experimental|Iniparib/irinotecan|
33062010|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
33062011|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
33062012|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
33062013|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
33062014|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
33062015|NCT00298909|Experimental|1|niacin
33062016|NCT00298909|Active Comparator|2|physical exercise
33062017|NCT00298909|Placebo Comparator|3|control
33062018|NCT00119574|Other|Arm 1|
33062019|NCT00079547|Active Comparator|1|Low-calorie diet
33062020|NCT00079547|Experimental|2|Low-carbohydrate diet
33062021|NCT04718623||Sepsis group (SG)|with source of infection and SOFA Score more than or equal 2
33062022|NCT04718623||Non-Sepsis Group (NSG)|with SOFA score less than 2
33062023|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
33062024|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
33062025|NCT00418132|Experimental|1|Participants will receive thalidomide.
33062026|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
33062027|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
33062028|NCT00299260|Placebo Comparator|placebo|normal saline
33062029|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
33062030|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
33062031|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
33062032|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
33062033|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
33062034|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
33062035|NCT00299611|Active Comparator|1|Levetiracetam
33062036|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
33062037|NCT00299650|Placebo Comparator|A|
33062038|NCT00299650|Active Comparator|B|
33062039|NCT04727853|Experimental|irinotecan liposome injection|Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
33062040|NCT00299884||1|Lipitor 20 mg
33062041|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
33062042|NCT00299962|Experimental|Dose level 4|
33062043|NCT00299962|Experimental|Dose level 5|
33062044|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
33062045|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
33062046|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
33062047|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
33062048|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
33062049|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
33360899|NCT01354886|Active Comparator|Gonal-f|150 IU single dose
33360900|NCT01354886|Active Comparator|Bravelle|150 IU single dose
33360901|NCT01354886|Placebo Comparator|Placebo|single dose
33114224|NCT04611243||COVID survivors|
33114225|NCT04611243||Vaccination with CoronaVac vaccine|
33114226|NCT04611243||Vaccination with BionTech vaccine|
33114227|NCT04611243||third dose vaccination with CoronaVac vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
33114228|NCT04611243||third dose vaccination with BionTech vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
33114229|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
33114230|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
33114231|NCT04610970|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
33114232|NCT04677530|Experimental|Part 1: JNJ-40411813 or Matching Placebo|Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.
33114233|NCT04677530|Experimental|Part 2: JNJ-40411813|Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.
33114234|NCT04677530|Experimental|Part 3: JNJ-40411813 or Matching Placebo|Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.
33114235|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
33114236|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
33114237|NCT04630743|Other|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
33114238|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.~Participants will undergo a PET-MRI scan once at baseline."
33114239|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
33114240|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.~Participants will undergo PET-MRI scans at baseline and 12-month."
33114241|NCT04630860|Experimental|56mg dose group|
33114242|NCT04630860|Experimental|84mg dose group|
33114243|NCT04630860|Experimental|112mg dose group|
33114244|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
33114245|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
33335540|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
33114246|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
33114247|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
33114248|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
33114249|NCT04677452|Experimental|JWCAR129|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
33114250|NCT04677296|Experimental|VS002A|Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
33114251|NCT04677296|Active Comparator|Standard WHO-ORS|Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
33335541|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
33335542|NCT03916744|Experimental|Giredestrant 10 mg|
33335543|NCT03916744|Experimental|Giredestrant 30 mg|
33335544|NCT03916744|Experimental|Giredestrant 100 mg|
33335545|NCT03639610|Experimental|Cohort 1a|Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg
33335546|NCT03639610|Experimental|Cohort 1b|Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg
33114252|NCT04610541|Experimental|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
33114253|NCT04677335|Experimental|Nutraceutical|Nutraceutical capsules taken once daily for 12 weeks
33114254|NCT04677335|Placebo Comparator|Control|Placebo capsules taken once daily for 12 weeks
33335547|NCT03639610|Experimental|Cohort 2a|Patients with severe renal impairment (eGFR ≥15 to <30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg
33335548|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
32869845|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
33335549|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
33335550|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
33335551|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
33335552|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
33335553|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 60 mg + Bendamustine 90 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced progressive disease (PD) or unacceptable toxicities or up to 39 cycles.
33335554|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 80 mg + Bendamustine 90 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
33360902|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
33360903|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
33360904|NCT01355042||Severe Sepsis and Septic Shock|
33360905|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
33360906|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
33062050|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
33062051|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
33062052|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
33062053|NCT00079820|Placebo Comparator|C|Placebo
33062054|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
33062055|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
33062056|NCT00300118|Experimental|A|
33062057|NCT00300118|Active Comparator|B|
33062058|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
33062059|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
33062060|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
33062061|NCT00119769|Placebo Comparator|1|
33062062|NCT00119769|Active Comparator|2|
33062063|NCT00300313|Active Comparator|1|
33062064|NCT00300313|Placebo Comparator|2|
33062065|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
33062066|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
33360907|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
33062067|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
33062068|NCT04718467|Experimental|adults group (aged 18-59 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
33062069|NCT04718467|Placebo Comparator|adults group (aged 18-59 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
33062070|NCT04718467|Experimental|elderly adults group (aged 60-85 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
33062071|NCT04718467|Placebo Comparator|elderly adults group (aged 60-85 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
33062072|NCT04718233|Experimental|sildenafil citrate|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
33062073|NCT04718233|Placebo Comparator|placebo|placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
33062074|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
33062075|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
33062076|NCT04727346||Study Group|CBCT and DISE
33062077|NCT04727346||Control Group|DISE only
33062078|NCT00300937|Experimental|A|
33062079|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
33062080|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
33062081|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
33062082|NCT00300976|Experimental|Intensive therapy|
33114255|NCT04677023|Other|Admira fusion X--tra® bulk|The special ORMOCER® compound molecules in Admira Fusion x-tra reduce the volume shrinkage to an extremely low level (1.25 % by volume) in conjunction with very low shrinkage stress (3.87 MPa). Admira Fusion x-tra is the bulk fill version of Admira Fusion. This means that this restorative material can be applied in layers of up to 4 mm and then reliably cured. This makes placing posterior restorations particularly quick and economical. The universal shade U further simplifies handling, as it provides aesthetic results by adapting, chameleon-like, to the surrounding dental substance
33114256|NCT04677023|Other|GrandioSO x-tra® bulk|a nano-hybrid composite which is in a class of its own. It is distinguished by outstanding handling and excellent physical properties, modelled on the natural tooth.its the packable bulk fill material for the highest standards in durability and aesthetics.GrandioSO x-tra has outstanding surface hardness, at 223 MHV, which is closer to natural tooth enamel, compared with other bulk fill composites. Because of this, GrandioSO x-tra ensures restorations which are abrasionresistant and dimensionally stable over the long term. In addition to the surface hardness, reliable curing is very important when larger increments are used. Here as well, GrandioSO x-tra achieves an outstanding result and, at the 219 MHV measured at a depth of 4 mm, it even significantly exceeds the values measured for other bulk fill composites at the surface.
33114257|NCT04630548|Active Comparator|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
33114258|NCT04630548|Active Comparator|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
33114259|NCT01975610|Experimental|CC-292 375mg|Treatment
33114260|NCT01975610|Placebo Comparator|Placebo|Control
33114261|NCT04610424|Experimental|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
33114262|NCT04610424|Active Comparator|Control|Control group
33114263|NCT04677101||Subjects with NASH documented by liver biopsy|One hundred subjects with NASH documented by liver biopsy and no evidence of another form of liver disease with a BMI ≥30 and ≤55 kg/m2.
33114264|NCT04677101||Healhy Donor|Fifty subjects with normal liver who underwent laparoscopic elective cholecystectomy, but otherwise in healthy conditions, will be used as controls.
33114265|NCT04630470|Placebo Comparator|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
33335555|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 100 mg + Bendamustine 90 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
33335556|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 60 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
33335557|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 80 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
33335558|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 100 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
33335559|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 60 mg + Gemcitabine 1000 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 2 cycles.
33335560|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 40 mg + Lenalidomide 25 mg|TAK-659 40 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 60 mg dose was de-escalated to 40 mg in case of dose limiting toxicity or if the starting dose was determined to be not tolerable. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
33335561|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 60 mg + Lenalidomide 25 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
33335562|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 60 mg + Ibrutinib 560 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 3 cycles.
33335563|NCT02954406|Experimental|Safety Expansion Phase Cohort B: TAK-659 + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 immediate-release tablet, at the MTD/maximally administered dose (MAD)/RP2D determined from Dose Escalation Phase, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants (who were to be entered in Phase 2) with advanced FL or MZL. Treatment could then be continued until they experienced PD or unacceptable toxicities or up to 12 cycles in participants who were to be enrolled in the Safety Expansion Phase Cohort.
33335564|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
33335565|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
33335566|NCT03728322|Experimental|iHSCs treatment group|
33335567|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
33335568|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
33335569|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
33335570|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
33335571|NCT03513588|Placebo Comparator|Placebo|
33335572|NCT03513588|Experimental|PF-06865571 100 mg|
33335573|NCT03513588|Experimental|PF-06865571 600 mg|
33335574|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
33335575|NCT03725124||Partners|Partners of women with IBD.
33335576|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
33360908|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
33062083|NCT00300976|Active Comparator|Conventional therapy|
33062084|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
33062085|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
33062086|NCT04717921||Patients|Subjects with unipolar depression
33062087|NCT04717921||Healthy|Healthy Control Group
33062088|NCT00301210|Experimental|1|tramadol dose 1
33062089|NCT00301210|Experimental|2|tramadol dose 2
33062090|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
33062091|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
33062092|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
33062093|NCT00080327|Active Comparator|1|
33062094|NCT00080327|Active Comparator|2|
33062095|NCT00080327|Active Comparator|3|
33062096|NCT00080327|Placebo Comparator|4|
33062097|NCT00301405|Active Comparator|Thalidomide|Open Label drug
33062098|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
33062099|NCT00301483|Active Comparator|2|Standard Therapy
33062100|NCT00301522|Experimental|Arm 1|
33062101|NCT00301522|Active Comparator|Arm 2|
33062102|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
33062103|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
33062104|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
33062105|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
33062106|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
33062107|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
33062108|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
33062109|NCT00292201|Experimental|1|Atorvastatin
33335577|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
33062110|NCT00292201|Placebo Comparator|2|Placebo Pill
33062111|NCT00292279|Experimental|A|
33335578|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
33335579|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
33335580|NCT03511326|Experimental|Luxerm®|
33335581|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
33335582|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
33335583|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
33335584|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
33062112|NCT00292279|Active Comparator|B|
33062113|NCT00292474|Experimental|TAXUS Express|
33062114|NCT00292474|Placebo Comparator|Express Bare|
33062115|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
33062116|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
33062117|NCT00292552||Non-smoker controls|Normal healthy non-smokers
33062118|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
33062119|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
33062120|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
33062121|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
33062122|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
33062123|NCT00120003|Placebo Comparator|Placebo|Placebo
33062124|NCT00292903|Experimental|A|
33062125|NCT00292903|Active Comparator|B|
33062126|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
33062127|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
33062128|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
33062129|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
33062130|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
33062131|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
33062132|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
33062133|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
33062134|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
33062135|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
33062136|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
33062137|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
33062138|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
33062139|NCT00202033|Experimental|3|no self monitoring of blood glucose
33062140|NCT00120120|Experimental|1|
33062141|NCT00120120|Experimental|2|
33062142|NCT00202189|Experimental|1|Budesonide
33062143|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
33062144|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
33062145|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
33062146|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
33062147|NCT00202228|Experimental|4|HIV negative control group
33062148|NCT00080873|Experimental|Receive Traumeel S|
33062149|NCT00080873|Placebo Comparator|Receive placebo|
33062150|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
33062151|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
33062152|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
33062153|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
33062154|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
33062155|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
33062156|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
33335585|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
33335586|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
33335587|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
33335588|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
33335589|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
33335590|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
33335591|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
33335592|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
33335593|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
33335594|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
33062157|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
33062158|NCT00301561|Experimental|1|Simplify treatment follow-up
33335595|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
33335596|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
33335597|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
33335598|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
33062159|NCT00301561|Active Comparator|2|Standard treatment follow-up
33062160|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
33062161|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
33062162|NCT00301600|Active Comparator|Mycophenolate mofeti|
33062163|NCT04730141|Experimental|mobilization protocol|The early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group.
33062164|NCT04730141|No Intervention|routine care|The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group .
33062165|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
33062166|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
33062167|NCT00301951|Experimental|cord blood transplant|
33062168|NCT00302029||CMV positive|CMV +, N=500/167
33062169|NCT00302029||CMV negative|CMV -, N=500/167
33062170|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
33062171|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
33062172|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
33062173|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
33062174|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
33062175|NCT00302380||un-medicated subjects with ADHD|
33062176|NCT00302380||subjects without ADHD|
33062177|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
33335599|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
33360909|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
33360910|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
33360911|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
33360912|NCT02299960||AH|patients with hypertension
33335600|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
33114266|NCT04630470|Experimental|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
33114267|NCT04677062|Experimental|GV-328|"The treatment should be carried out for 4 days. Children between 3 and 6 years old had to consume 4 pills a day, children between 7 and 10 years old 5 pills, and children between 11 and 13 years old up to 6 pills. The patient had to slowly thin the tablet in the mouth, maintaining direct contact with the area to be treated.~The study consisted of 2 visits, one initial and one final. In the initial visit , the documentation (informed consent) and the treatment were delivered. During this visit, baseline assessments of pain level, functional limitation, marginal mucosal edema, and lesion size were recorded. In addition, a photograph of the area to be treated was taken. Parents were also given a chart, in which they had to record the intensity of pain daily using the Wong-Baker face scale."
33114268|NCT04610463|Other|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
33114269|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
33114270|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
33114271|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
33114272|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
33114273|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
33114274|NCT04630665|Other|thin buccal bone|immediate implant placement in thin buccal bone wall socket
33114275|NCT04630665|Other|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
33114276|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
33114277|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
33114278|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
33114279|NCT01165177|Experimental|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
33335601|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
33335602|NCT03508830|Experimental|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
33335603|NCT03508830|Active Comparator|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
33114280|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
33114281|NCT04610385||ileal conduit|
33114282|NCT04610385||cutaneous ureterostomy|
33335604|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
33335605|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
33335606|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
33360913|NCT02299960||Nephropathy|patients with diabetic nephropathy
33360914|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
33114283|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
33114284|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
33114285|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
33114286|NCT04610268|Experimental|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
33114287|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
33114288|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
33114289|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
33114290|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
33114291|NCT04610073|Experimental|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
33114292|NCT04610073|Experimental|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
33419254|NCT03949491|Experimental|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.~Preoperative CT-Angiogram of the abdominal wall~Volumetric analysis preformed~3D printed models made~Pre operative BREAST-Questionnaires given~Free tissue transfer performed: Operative/Dissection Time Recorded~Flap/Abdominal donor site complications recorded~Standard Digital Photography and Harris Scoring~BREAST-Questionnaires given at 3, 6 months"
33419255|NCT03930381|Experimental|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
33419256|NCT03930381|No Intervention|Usual Care Arm|This group will just receive normal provider care
33419257|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
33419258|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
33419259|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
33419260|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
33419261|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
33419262|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
33419263|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
33419264|NCT05214495|Experimental|Topical oral Omega-3 hydrogel group|Patients will be given topical oral Omega-3 hydrogel
33419265|NCT05214495|Active Comparator|Conventional preventive treatment group|Patients will be given conventional preventive treatment
33419266|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
33419267|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
33419268|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
33419269|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
33419270|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
33419271|NCT03907917|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
33419272|NCT03907917|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
33419273|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
33114293|NCT04610073|Experimental|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
33114294|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
33114295|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
33419274|NCT01917552|No Intervention|observation|
33419275|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
33419276|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
33419277|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
33419278|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
33114296|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
33114297|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
33114298|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
33114299|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
33114300|NCT01963598|Experimental|Group 1|Dosing regimen 1
33114301|NCT01963598|Experimental|Group 2|Dosing regimen 2
33114302|NCT01963598|Experimental|Group 3|Dosing regimen 3
33114303|NCT01963598|Experimental|Group 4|Dosing regimen 4
33114304|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
32869846|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
33335607|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
33335608|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.~- Medical abortion pills sourced from pharmacies"
33335609|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.~- Medical abortion pills sourced from health clinics"
33335610|NCT03381274|Experimental|Oleclumab Dose 1 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab (MEDI9447) Dose 1 every 2 weeks (Q2W) and oral osimertinib Dose 1 once daily (QD).
33360915|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
33360916|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
33360917|NCT01355276|Experimental|1|
33360918|NCT01355276|Active Comparator|2|
32869847|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
33062178|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
33062179|NCT00400140|Experimental|A|
33062180|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
33062181|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
33062182|NCT04717882|No Intervention|Control arm|Patients in the control arm will receive the usual treatment
33062183|NCT04717882|Experimental|Intervention arm|After crossing over to the intervention period, attending physicians will receive medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
33062184|NCT00302536|Experimental|Tacrolimus|
33062185|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
33062186|NCT04717999|Experimental|UWN2D CAR-T|
33062187|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
33062188|NCT00418288|Active Comparator|A|
33062189|NCT00418288|Placebo Comparator|P|
33062190|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
33062191|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
33062192|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
33062193|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
33062194|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
33062195|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
33062196|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
33062197|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
33062198|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
33062199|NCT04718077|Experimental|IO dexamethasone injection|
33062200|NCT04718077|Active Comparator|SM dexamethasone injection.|
33062201|NCT04727268||Group 1|"Retrospective data regarding genetic information will be collected from participants' medical records.~Deep phenotyping of participants will also be completed."
33062202|NCT04727190|Experimental|TBCB group|Specimens were obtained using 1.1 mm ultrathin cryoprobe with or without guide sheath by bronchoscope.
33062203|NCT04727190|Active Comparator|TBFB group|Specimens were obtained using 1.5 mm or 1.9 mm biopsy forceps with or without guide sheath by bronchoscope.
33062204|NCT00303043||1|
33062205|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
33062206|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
33062207|NCT00303199|Experimental|Single Arm|
33062208|NCT00303277|Active Comparator|1|simvastatin
33062209|NCT00303277|Active Comparator|2|pravastatin
33062210|NCT00303589|Experimental|1|
33062211|NCT00303589|Experimental|2|
33062212|NCT00303589|Active Comparator|3|
33062213|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
33335611|NCT03381274|Experimental|Oleclumab Dose 2 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD. In Part 2 (dose-expansion), participants (including participants dosed at the RP2D in Part 1) will receive IV oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD until documentation of disease progression, intolerable toxicity, or development of other reason for treatment discontinuation, whichever occurs first.
33062214|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
33062215|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
33335612|NCT03381274|Experimental|Oleclumab Dose 1 + AZD4635 Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 1 QD.
33335613|NCT03381274|Experimental|Oleclumab Dose 1 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 2 QD.
33335614|NCT03381274|Experimental|Oleclumab Dose 2 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral AZD4635 Dose 2 QD.
33335615|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
33335616|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
33335617|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
33335618|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
33335619|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
33335620|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
33062216|NCT00081887|Experimental|Weekly Clofarabine|
33062217|NCT00304018|Experimental|cord blood transplant|
33062218|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
33062219|NCT00304135|Experimental|GEMOX|GEMOX
33062220|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
33062221|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
33062222|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
33062223|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
33062224|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
33062225|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
33062226|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
33062227|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
33062228|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
33062229|NCT04717960|Active Comparator|study group group (1)|the group which will undergo submucosal injection of platelet rich plasma
33062230|NCT04717960|No Intervention|comparative group group (2)|patients using the usual lines of medical treatment like nasal douching and lubricants
33062231|NCT00087711|Experimental|A|
33062232|NCT00087711|Active Comparator|B|
33062233|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
33062234|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
33062235|NCT00082199|Active Comparator|A1|
33062236|NCT00082199|Placebo Comparator|A2|
33062237|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
33062238|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
33062239|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
33062240|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
33062241|NCT00304798|Experimental|Admission|Admission
33335621|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
33335622|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
33335623|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
33335624|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
33335625|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
33062242|NCT00304798|No Intervention|Discharge|Discharge
33062243|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
33062244|NCT00082238|Experimental|Cystic fibrosis (CF)|
33335626|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
33335627|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
33335628|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
33335629|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
33062245|NCT00082238|Active Comparator|Healthy volunteers|
33062246|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
33335630|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
33335631|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
33335632|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
33062247|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
33062248|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
33335633|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
33335634|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
33062249|NCT00305032|Experimental|1|
33062250|NCT00305461|Active Comparator|1|Ciclesonide 160µg
33062251|NCT00305461|Active Comparator|2|Ciclesonide 320µg
33062252|NCT00305539|Active Comparator|1|
33062253|NCT00305539|Placebo Comparator|2|placebo
33062254|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
33062255|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
33062256|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
33062257|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
33062258|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
33062259|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
33062260|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
33062261|NCT00305929|Experimental|1|Treatment with Tookad VTP
33062262|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
33062263|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
33062264|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
33062265|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
33062266|NCT00306475|Active Comparator|1|
33062267|NCT00306475|Placebo Comparator|2|
33062268|NCT00306631|Experimental|1|
33335635|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
33335636|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
33335637|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
33335638|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
33335639|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
33335640|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.~Intervention Device: web-based cognitive training"
33335641|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).~Intervention Device: Web-based cognitive training"
33335642|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
33335643|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
33335644|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
33062269|NCT00306709|Experimental|Teaching|
33062270|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33335645|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
33335646|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
33335647|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
33335648|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
33335649|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
33335650|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
33062271|NCT00306904|Experimental|1|3.0 mg/eye dose group
33062272|NCT00306904|Experimental|2|1.5 mg/eye dose group
33062273|NCT00306904|Experimental|3|0.2 mg/eye dose group
33062274|NCT00307021|Active Comparator|Group A|
33062275|NCT00307021|Experimental|Group B|
33062276|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
33062277|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
33062278|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
33062279|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
33062280|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
33062281|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
33062282|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
33062283|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
33062284|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
33062285|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
33062286|NCT02960152||Control|interview and periodontal full-mouth examination
33062287|NCT00307528|Active Comparator|Group A|
33062288|NCT00307528|Experimental|Group B|
33062289|NCT00307528|Experimental|Group C|
33062290|NCT00307528|Experimental|Group D|
33062291|NCT00307528|Experimental|Group E|
33062292|NCT00307528|Experimental|Group F|
33062293|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
33062294|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
33062295|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
33062296|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
33062297|NCT00307762|No Intervention|3|Control patients with ordinary therapy
33062298|NCT00088140|Placebo Comparator|Placebo|
33062299|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
33062300|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
33062301|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
33062302|NCT00308152|No Intervention|Control|Observation only
33062303|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
33062304|NCT00418756|Experimental|Rifampin + nilotinib|
33062305|NCT05446142|Experimental|Four Period Treatment Sequence: PPI Effect|Participants will receive a single encorafenib dose formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the formulation after administration of 20 mg rabeprazole every evening for 5 days.
33062306|NCT05446142|Experimental|Four Period Treatment Sequence: PPI Effect Second Formulation|Participants will receive a single encorafenib dose of the second formulation, a single encorafenib dose of the second formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the second formulation after administration of 20 mg rabeprazole every evening for 5 days.
33062307|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
33335651|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
33335652|NCT03910738|Experimental|Testosterone treatment (Nebido®)|"Treatment/Nebido® arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®).~Treatment will be injected at baseline, week 6, 18, 30, 42 and 54"
33335653|NCT03910738|Placebo Comparator|Placebo|"Placebo arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution.~Placebo will be injected at baseline, week 6, 18, 30, 42 and 54"
33335654|NCT03727230|Other|"Asia type DEL recipients"|"To identify Asia type DEL patients by phenotyping and gentoyping methods in the Chinese recipients and then blood transfusion of D+ blood rather than the rare D negative blood to the identified Aisa type DEL recipients."
33335655|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
33335656|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
33335657|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
33335658|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
33335659|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
33335660|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
33335661|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
33335662|NCT03727074|Experimental|5-FU Cream|topical cream
33335663|NCT03727074|Active Comparator|Efudex®|topical cream
33335664|NCT03727074|Placebo Comparator|Vehicle|topical cream
33335665|NCT03676816|Experimental|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
33335666|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
33335667|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.~Drug-Drug Interaction:~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
33335668|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
33335669|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
33062308|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
33062309|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
33062310|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
33062311|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
33062312|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
33062313|NCT00308503|Experimental|1|5 mg/day
33062314|NCT00308503|Placebo Comparator|2|
33062315|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
33062316|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
33062317|NCT00308854|Active Comparator|1|PD P 506 A-PDT
33062318|NCT00308854|Placebo Comparator|2|Placebo-PDT
33062319|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
33062320|NCT00308971|Active Comparator|1|
33062321|NCT00308971|Placebo Comparator|2|
33062322|NCT00309049|Active Comparator|A1|
33062323|NCT00309049|Active Comparator|A2|
33062324|NCT00309049|Active Comparator|A3|
33062325|NCT00309088|Experimental|1|
33062326|NCT00309088|Placebo Comparator|2|
33062327|NCT00309283|Experimental|somatostatin|
33062328|NCT00309283|Placebo Comparator|Saline solution|
33062329|NCT04727502|Active Comparator|( Group Duloxetine )|• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time
33062330|NCT04727502|Active Comparator|(Group Pregablin )|control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.
33062331|NCT00309478|Experimental|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
33062332|NCT00309478|Experimental|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
33062333|NCT04729673|Active Comparator|Patient's normal canine occlusal relationship.|Before full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
33062334|NCT04729673|Sham Comparator|Canine occlusal relation after full mouth rehabilitation|After full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
33062335|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
33062336|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
33062337|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
33062338|NCT00309595|Active Comparator|2|balloon
33062339|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
33062340|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
33068273|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
33335670|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
33335671|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
33335672|NCT03679702|Other|Active treatment|
33419279|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*~**Additional mesna may be given at the discretion of the investigator~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
33419280|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
33419281|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
33419282|NCT02120846|No Intervention|Control|Daily routines
33419283|NCT03833817|Experimental|Patient intervention arm|This intervention arm contains the patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
33419284|NCT03833817|Experimental|Caregiver (of patient) intervention arm|This intervention arm contains the caregivers of patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
33419285|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
33419286|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
33419287|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
33419288|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
33419289|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
33419290|NCT02116166||Young|Young (20-35 years old)
33419291|NCT02116166||Old|Older (70-99 years old)
33419292|NCT05022771|Experimental|Single Ascending Doses Cohort 1a|Subjects will receive either Dose level 1 of PMG1015 or Placebo
33419293|NCT05022771|Experimental|Single Ascending Doses Cohort 1b|Subjects will receive either Dose level 2 of PMG1015 or Placebo
33419294|NCT05022771|Experimental|Single Ascending Doses Cohort 1c|Subjects will receive either Dose level 3 of PMG1015 or Placebo
33419295|NCT05022771|Experimental|Single Ascending Doses Cohort 1d|Subjects will receive either Dose level 4 of PMG1015 or Placebo
33419296|NCT05022771|Experimental|Single Ascending Doses Cohort 1e|Subjects will receive either Dose level 5 of PMG1015 or Placebo
33419297|NCT05022771|Experimental|Single Ascending Doses Cohort 1f|Subjects will receive either Dose level 6 of PMG1015 or Placebo
33419298|NCT05022771|Experimental|Single Ascending Doses Cohort 1g|Subjects will receive either Dose level 7 of PMG1015 or Placebo
33419299|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
33419300|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
33419301|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
33419302|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
33062341|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
33062342|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
33062343|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
33062344|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
33335673|NCT03724344||Dimensions with Behavioral and psychological symptoms|
33335674|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
33335675|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
33335676|NCT03324100||Allergic Rhinitis Patients|
33419303|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
33419304|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
33062345|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
33062346|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
33062347|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
33062348|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
33062349|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
33062350|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
33062351|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
33062352|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
33062353|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
33062354|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
33062355|NCT00418873|Experimental|1. Zotepine|
33062356|NCT00418873|Active Comparator|2. Risperidone|
33062357|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
33062358|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
33062359|NCT00310063|Sham Comparator|Arm II|Sham wristband
33062360|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
33062361|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
33062362|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
33335677|NCT03324100||Healthy Controls|
33062363|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
33062364|NCT00121095|Other|1|
33062365|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
33062366|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
33062367|NCT05568602||GFR<30 ml/min|Patients screened for hypercortisolism and GFR<30ml/min
33062368|NCT05568602||GFR>30 ml/min|Patients screened for hypercortisolism and GFR>30ml/min
33335678|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
33335679|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
33335680|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
33335681|NCT03288220||Healthy volunteers|Healthy volunteers age 50 and older
33335682|NCT03288220||Stroke patients|Stroke patients aged 18 and older
33335683|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
33335684|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
33335685|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
33335686|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
33335687|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
33335688|NCT03684850|Experimental|Footwear device group|(n = 40)
33335689|NCT03679234|Experimental|Intervention|Routine infant formula
33335690|NCT03903796|Experimental|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
33335691|NCT03903796|Active Comparator|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
33335692|NCT03903796|Experimental|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
33114305|NCT04206358|Experimental|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
33114306|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
32740501|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
33114307|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
33114308|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
33114309|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
33114310|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
33114311|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
33114312|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
33114313|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
33114314|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
33114315|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
33114316|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
33114317|NCT01960010|Placebo Comparator|Vehicle|Vehicle
33114318|NCT01165021|Experimental|Pemetrexed + Cisplatin|
33114319|NCT04314622|Experimental|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
33114320|NCT04314622|Placebo Comparator|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
33114321|NCT04314622|Experimental|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
33114322|NCT04314622|Placebo Comparator|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
33114323|NCT00561132|Experimental|1|
33335693|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
33335694|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
33335695|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
33335696|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
33114324|NCT00561132|Placebo Comparator|2|
33114325|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
33114326|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
33335697|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
33335698|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
33335699|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
33335700|NCT03601078|Experimental|BB2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
33335701|NCT03601078|Experimental|BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma|
33335702|NCT03601078|Experimental|BB2121 in clinical high-risk multiple myeloma patients|
33335703|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
33335704|NCT03684616||Statin treatment prior to cardiac arrest|
33335705|NCT03684616||No Statin treatment prior to cardiac arrest|
33335706|NCT03676114|Experimental|ketamine group|
33335707|NCT03676114|Placebo Comparator|normal saline group|
33335708|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
33335709|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
32740502|NCT00702143|Experimental|AD subjects|
32740503|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
33114327|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
33335710|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
33335711|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
33335712|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
33114328|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
33114329|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
33114330|NCT01182844|No Intervention|Control|Usual care
33114331|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
33114332|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
33335713|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
33114333|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
33335714|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
33335715|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
33335716|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
33335717|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
33335718|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
33335719|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
33335720|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~One 1st degree relative with PDAC diagnosed before age 60~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
33335721|NCT03546816|Experimental|5 mg Serlopitant Tablets|
33335722|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
33335723|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
33335724|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
33335725|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
33335726|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
33335727|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
33419305|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
33062369|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
33062370|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
33062371|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
33062372|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
33062373|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
33062374|NCT00310531|Experimental|Arm 1|
33062375|NCT00310531|Active Comparator|Arm 2|
33335728|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as migalastat) was administered every other day for 12 months."
33062376|NCT05568446|Experimental|Social VR group|Social VR (SocVR) intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display (HMD) for the SocVR intervention. Each session of the SocVR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect (Yamaguchi, 1999). The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) street and building. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants. During the SocVR intervention, one RA will also appear as one avatar in the scenario to guide the participants to complete a series of tasks. Each intervention session will be conducted in a classroom independently for each participant.
33335729|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
33335730|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
33335731|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
33335732|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
33062377|NCT05568446|Active Comparator|Traditional social skills group|An experienced special educational needs (SEN) teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 4-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell & Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the SocVR training. The training lasts 20 minutes which depends on the emotion of the participants. Each training session will be conducted in a classroom independently for each participant.
33335733|NCT03566550||CF|people with cystic fibrosis
33335734|NCT03566550||Control|people without cystic fibrosis
33335735|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
33335736|NCT03563716|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
33335737|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
33335738|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
33335739|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
33335740|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
33335741|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
33335742|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
33335743|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
33335744|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
33419306|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
33335745|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
33335746|NCT03675802|Active Comparator|Arm number one ,misoprostol|
33062378|NCT05568446|No Intervention|Waitlist control group|With reference to Beck et al. (2010), the participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 8-week intervention period.
33062379|NCT00310609|Experimental|Arm 1|
33062380|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33062381|NCT05568368||Index cases|
33062382|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
33062383|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
33062384|NCT00310765|Active Comparator|1|75-150 mg of pregabalin po BID
33062385|NCT00310765|Placebo Comparator|2|Placebo 75 or 150 mg po BID
33062387|NCT00310843||All study population|
33062388|NCT05568290||Periodontitis|Individuals with Periodontitis
33062389|NCT05568290||Gingivitis|Individuals with Gingival Inflammation
33062390|NCT05568290||Healthy|Individuals with Periodontally Healthy
33062391|NCT05568212|Experimental|ARM A (experimental arm)|Investigator's choice single-agent chemotherapy plus durvalumab 1500 mg every 3 weeks.
33062392|NCT05568212|Active Comparator|ARM B (standard arm)|Investigator's choice single-agent chemotherapy.
33062393|NCT05568212|Experimental|ARM C (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks plus olaparib 300 mg twice daily.
33062394|NCT05568212|Experimental|ARM D (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks
33062395|NCT05568056|Experimental|ASD-EXP and NT-EXP|Autistic children and Neurotypical children who receive intervention between pre and post testing
33062396|NCT05568056|No Intervention|ASD-WLC and NT|Autistic children who receive intervention only after their pre and post testing and Neurotypical children who do not receive any intervention
33062397|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
33062398|NCT05568017|Experimental|Y-90-DOTATOC|Patients will receive PRRT with Y-90-DOTATOC
33062399|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
33062400|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
33062401|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
33062402|NCT00399776||Group B|Healthy adolescents
33335747|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
33062403|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
33062404|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
33062405|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
33062406|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
33062407|NCT02965157|Experimental|CART20|
33062408|NCT00311662|Experimental|1|Tonabersat 40mg
33062409|NCT00311662|Placebo Comparator|2|
33062410|NCT05567939||Case|Individuals with laboratory confirmed MPXVID
33062411|NCT05567939||Control|Individuals without proctitis and without MPXVID-related symptoms
33062412|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
33062413|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
33062414|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
33062415|NCT00311896|Experimental|Bemiparin|
33062416|NCT00311896|Placebo Comparator|Placebo|
33062417|NCT05567666|Experimental|Treatment|Optilume Catheter System
33335748|NCT03678844|Experimental|Taekwondo practice|
33335749|NCT03678844|Placebo Comparator|CONTROL|
33335750|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
33335751|NCT03678610|No Intervention|ICSI medium as it is|
33335752|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
33335753|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
33335754|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
33335755|NCT03675646|No Intervention|Control group C|No intervention
33335756|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
33335757|NCT03675568|Active Comparator|Control group|Split skin Graft
32740504|NCT00702143|Experimental|Healthy controls|
32740505|NCT05725031|Experimental|ER6|to receive rocuronium 0.6 mg/kg with ephedrine pretreatment
32740506|NCT05725031|Experimental|ER8|to receive rocuronium 0.8 mg/kg with ephedrine pretreatment
33062418|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
33062419|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
33062420|NCT05567627|Experimental|Initial dose cohort|1.2x10^14 vg/kg of GC301 administered via intravenous infusion
33062421|NCT05567627|Experimental|Second dose cohort|2.4x10^14 vg/kg of GC301 administered via intravenous infusion
33062422|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
33062423|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
33062424|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
33062425|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
33062426|NCT00312403|Other|1|Patients with primary open angle glaucoma
33062427|NCT00312403|Other|2|Age- and sex-matched control subjects
33062428|NCT04717843|Experimental|Patients with embolic strokes of undetermined source.|Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.
33062429|NCT04717843|Experimental|Patients with non-paroxysmal AF.|Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.
33062430|NCT04717843|Active Comparator|Heathy volunteers|The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.
33062431|NCT04717843|Experimental|ESUS and non-paroxysmal AF patients with cardiac MRI|ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.
33062432|NCT05567471|Active Comparator|Group 1(BBV154 in COVAXIN recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine in form of drops (0.5 mL) via intranasal route, in individuals previously vaccinated with COVAXIN.
33062433|NCT05567471|Active Comparator|Group 2 (COVAXIN in COVAXIN recipients)|125 participants will be recruited and administered with a booster dose of BBV152 vaccine, in individuals previously vaccinated with COVAXIN.
33062434|NCT05567471|Active Comparator|Group 3 (BBV154 in COVISHIELD recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine, in individuals previously vaccinated with COVISHIELD.
33062435|NCT05567471|Active Comparator|Group 4(COVAXIN in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of BBV152 (COVAXIN) vaccine, in individuals previously vaccinated with COVISHIELD.
33062436|NCT05567471|Active Comparator|Group 5 (COVISHIELD in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of Covishield vaccine, in individuals previously vaccinated with COVISHIELD.
33062437|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
33062438|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
33062439|NCT00312481|Experimental|1|MOVIPREP
33062440|NCT00312481|Active Comparator|2|Picolax
33062441|NCT05567432|Active Comparator|Patients will do throidectomy using diathermy|In these patients the investigators will control bleeding and cut tissues and blood vessels using the diathermy .
33335758|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
33335759|NCT03527914|Active Comparator|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
33335760|NCT03527914|Experimental|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
33335761|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
32740507|NCT05725031|Active Comparator|R12|to receive rocuronium 1.2 mg/kg with no pretreatment
33062442|NCT05567432|Active Comparator|Patients will do thyroidectomy using ligasure .|In these patients the investigators will control bleeding and cut tissues and blood vessels using the liagasure.
33062443|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
33062444|NCT00293176|Experimental|1|
33062445|NCT00293176|Placebo Comparator|2|
33062446|NCT05567315|Active Comparator|Oocyte puncture with local anaesthesia alone|
33335762|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
33335763|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
33335764|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
33335765|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
33335766|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
33335767|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
33335768|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
33335769|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
33335770|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
33335771|NCT02894502|No Intervention|Control group|This Group will receive the usual care
33335772|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
33335773|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
33335774|NCT03678220|Experimental|Patients using LapAR system|
33062447|NCT05567315|Experimental|Oocyte puncture with local anaesthesia and additional virtual reality hypnosis|
33062448|NCT05567276||Group 1|Group : Non-Violent Resistance parental training (NVR)
33062449|NCT05567276||Group 2|Group 2 : Treatment as usual (TAU) = Control
33062450|NCT00121602|Active Comparator|Roller bottle|
33062451|NCT00121602|Experimental|Serum free|
33062452|NCT00293605||1|C-stem implant
33062453|NCT00293605||2|Charnley Implant
33062454|NCT00293605||3|Exeter Implant
33062455|NCT04711161|Experimental|Part 1 (Phase 1a): Single Arm, Open Label (GRN-300 single-agent)|Part 1 of the study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Part 1 will be approximately 24-36 months, depending on the rate of enrollment and the number of subjects enrolled.
33062456|NCT04711161|Experimental|Part 2 (Phase 1b): Single Arm, Open Label (GRN-300 plus paclitaxel)|"The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Part 2 will be approximately 12-18 months, depending on the rate of enrollment and the number of subjects enrolled. Part 2 will commence following determination of the MTD and RP2D of single-agent GRN-300 in Part 1.~Overall duration of the study will be approximately 36-48 months, depending on the rate of enrollment and number of subjects enrolled."
33062457|NCT05567237|Active Comparator|Microcurrent alone (MC)|This group will receive a live microcurrent device and they will not be engaged in any resistance training exercises.
33062458|NCT05567237|Active Comparator|Microcurrent with exercise (MC + RT)|This group will receive a live microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
33062459|NCT05567237|Sham Comparator|Sham alone (SH)|This group will receive a sham microcurrent device and they will not be engaged in any resistance training exercises.
33062460|NCT05567237|Sham Comparator|Sham with exercise (SH + RT)|This group will receive a sham microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
33335775|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
33335776|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
33335777|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
33335778|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
33335779|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
33335780|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
33062461|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
33062462|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
33335781|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
33335782|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).~In stage 1, dose escalation will occur for QD dosing.~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
33335783|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
33335784|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
33335785|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
33335786|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
33062463|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
33062464|NCT00293761|Experimental|Travatan, Investigational|
33062465|NCT00293761|Active Comparator|Travatan|
33062466|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
33062467|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
33062468|NCT05567120|Other|PATH-Care|Problem Adaptation THerapy (PATH) adapted for caregivers along with tablet based exercises to enhance and reinforce the therapy sessions.
33062469|NCT04710771||Group-A|Patient performed prone lying position for three hours.
33062470|NCT04710771||Group-B|along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
33062471|NCT05567081|Experimental|PRP group|3 cm of autologous platelet rich plasma injected once around the thickest part of ulnar nerve.
33062472|NCT05567081|Experimental|Corticosteroid group|Triamcinolone Acetonide 40mg/mL (1ml) mixed with 1ml lidocaine hydrochloride injected once around the thickest part of ulnar nerve.
33062473|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
33062474|NCT04710927|Active Comparator|Group 1|High Viscosity GIC
33062475|NCT04710927|Experimental|Group 2|SDF and High Viscosity GIC
33062476|NCT04710927|Experimental|Group 3|SDF, Papain-Based Gel and High Viscosity GIC
33062477|NCT05567042||drug-resistant epilepsy|No intervention
33062478|NCT05567042||Medication is effective|No intervention
33062479|NCT00294112|Experimental|High dose|High dose (8 million cells per kg of body weight)
33062480|NCT00294112|Experimental|Low dose|Low dose: 2 million cells per kg body weight
33062481|NCT05566496||Tourette|Age less than 18 years old Diagnosed as Tourette syndrome or chronic tic disorders No other neuropsychiatric disorders
33062482|NCT05566496||Healthy|Age less than 18 years old No other neuropsychiatric disorders
33062483|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33062484|NCT00294190|Experimental|Topotecan|
33062485|NCT05565872|Experimental|Urban training Intervention + therapeutic education program with face-to-face supervision|Patients will be advised to walk in the defined urban trails with face-to-face supervision
33062486|NCT05565872|Active Comparator|Urban training Intervention + therapeutic education program with telematic supervision|Patients will be advised to walk in the defined urban trails with telematic supervision
33062487|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
33335787|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
33062488|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
33062489|NCT00089310|Experimental|Sentinal node mapping|
33062490|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
33062491|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
33062492|NCT00294307||Augmented Standard Care (ASC)|Hospital only
33062493|NCT00294307||Resource Nurse Care (RNC)|Hospital only
33062494|NCT05565521|Experimental|Treatment Arm|Concurrent dose-escalated chemoradiation with temozolomide (TMZ) on the MR-Linac with weekly adaptation
33062495|NCT04706091|Experimental|Treatment --> Placebo|This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.
33335788|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
33335789|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
33335790|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
33062496|NCT04706091|Experimental|Placebo --> Treatment|This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.
33062497|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
33335791|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
33335792|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33062498|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
33062499|NCT05564156|No Intervention|Control Group|In the control group; No intervention will be made by the investigators in this group. The participant will take standard treatment. Participant's length of stay in hospital, suitability of antibiotics used, development of microbial resistance, Antibiotic related nephrotoxicity due to infection, mortality data due to infection will be recorded, hospitalization will be questioned within 30 days after the patient is discharged, and a drug consensus report will be created, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be made. Evaluations will be recorded, but the investigators will take no action.
33062500|NCT05564156|Experimental|Intervention Group|"In the intervention group; The participant will take standard treatment and the clinical pharmacist services such as drug reconciliation by the investigators, medication review (Identification of drug-related problems, detection of possible unsuitable drugs), quality of life measurement, antibiotic selection, drug suitability, dose and route of administration advice, and concomitant medications are included. Suggestions will be made by the investigators to physicians about the solution to drug-related problems.~Participants' length of hospital stay, suitability of antibiotics, development of microbial resistance, antibiotic-related nephrotoxicity due to infection, and mortality numbers due to infection will be recorded, hospitalization will be questioned within 30 days after discharge. The investigators will create a drug consensus report, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be accomplished by investigators."
33062501|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
33062502|NCT05562908|Active Comparator|Pedicled|Harvesting of LIMA with its surrounding tissue: fascia, veins, etc
33062503|NCT05562908|Active Comparator|Surgical skeletonised|"Harvesting of LIMA in a naked fashion where you dissect the artery free of the surrounding tissue."
33062504|NCT05562908|Active Comparator|Skeletonised with Thunderbeat|Same as Surgical skeletonised but instead of closing the side branches with clips a surgical tool is used for coagulation of the side-branches.
33062505|NCT00294619|Experimental|LB03002|
33062506|NCT00294619|Placebo Comparator|Placebo|
33062507|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
33062508|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
33062509|NCT05562479||Non exposed to Sars Cov 2 egg donors|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation.
33062510|NCT05562479||Exposed to Sars Cov 2 Infection|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to the infection.
33062511|NCT05562479||Exposed to Sars Cov 2 Vaccines|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to vaccination.
33062512|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
33062513|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
33062514|NCT00121680|Experimental|1|
33062515|NCT05562323||MKP vaccination for pre-exposure prophylaxis (HIV positive)|HIV positive individuals who receive MKP vaccination for pre-exposure prophylaxis
33062516|NCT05562323||MKP vaccination for pre-exposure prophylaxis (seronegative individuals)|HIV seronegative individuals who receive MKP vaccination for pre-exposure prophylaxis
33062517|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
33062518|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
33062519|NCT00294970||PTSD|Patients with diagnosis of PTSD
33062520|NCT00294970||OCD|Patients with diagnosis of OCD
33062521|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
33360919|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
33360920|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
33360921|NCT02293564|Experimental|gevokizumab|
33360922|NCT03922711|Experimental|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
32740508|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
33335793|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33062524|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
33062525|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
33335794|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33335795|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33335796|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33335797|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
33335798|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
33335799|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
33335800|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
33335801|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
33335802|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
33335803|NCT04058938|Active Comparator|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
33062526|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
33062527|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
33062528|NCT00295165|Experimental|Arm 1|
33062529|NCT00295165|Placebo Comparator|Arm 2|
33062530|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
33062531|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
33068274|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
33068275|NCT04510558|Experimental|Intervention (mesh)|Insertion of a non-resorbable mesh in the subway position.
33068276|NCT04510558|Sham Comparator|Control (no mesh)|No insertion of mesh.
33335804|NCT04058938|Experimental|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
33335805|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
33335806|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
33062532|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
33062533|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
33062534|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
33335807|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
33335808|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
33335809|NCT03448406|Experimental|Empagliflozin|
33062535|NCT00295282|Experimental|1|patients will receive active MDX-1100
33062536|NCT05528939|Experimental|EndeavorRx|Children will be asked to begin digital attentional control training at home within 6 weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
33062537|NCT05528939|Active Comparator|Control|An active control program designed to replicate aspects of the intervention (e.g., regular use of digital device to access fun educational activities) while engaging cognitive skills not particularly involving attention.
33062538|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
33062539|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
33062540|NCT05524727|Experimental|Intervention Group|Usual care + concept-guided, personalized, motor-cognitive training by means of an exergame
33062541|NCT05524727|No Intervention|Control Group|Usual care only
33062542|NCT00295594|Active Comparator|1|
33062543|NCT00295594|Experimental|2|
33062544|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
33062545|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
33062546|NCT05500001|Experimental|Family Psychoeducation Intervention Arm|These participants will receive the psychoeducation intervention and outcome measures will be taken from them and their young adult service user. The intervention includes psychoeducation on stages of a family's journey, the biopsychosocial basis of psychosis, and skills for coping (Acceptance and Commitment Therapy for Caregivers) and communicating (LEAP).
33062547|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
33062548|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
33062549|NCT04718584|Experimental|Experimental Arms|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
33335810|NCT03448406|Active Comparator|Placebo|
33335811|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
33335812|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
33335813|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
33335814|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
33335815|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
33335816|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
33335817|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
33335818|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
33062550|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
33062551|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
33062552|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
33062553|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
33062554|NCT05461976|Experimental|Home-based self-management exercise program|A home-based self-management exercise program will be implemented based on behaviour change techniques on the approach of Social-Cognitive Theory and Control Theory. In the present study, we will use the following behaviour changes techniques: health consequences, action planning, graded tasks, problem-solving/coping planning, modelling of the behaviour, vicarious reinforcement and non-specific encouragement, feedback on behaviour, self-monitoring on behaviour, review behaviour goals and goal setting (behaviour). The program will include six sessions of self-management with an average duration of 60 minutes. The intervention will be delivered individually and face-to-face in the participant's home by a physical therapist over 10 weeks.
33062555|NCT05461976|No Intervention|Control Group|This group will receive one session about education on risk factors after stroke and usual care.
33062556|NCT00295945||PCA|Patient-controlled intravenous analgesia
33062557|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
33335819|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
33335820|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
33335821|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
33335822|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
33062558|NCT05457725|Experimental|rtfMRI-guided Neurofeedback Training|Real-time functional magnetic resonance imaging guided neurofeedback
33335823|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
33335824|NCT00064701|Experimental|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
33335825|NCT00064701|Active Comparator|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
33335826|NCT00064701|Active Comparator|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
33062559|NCT05457725|Sham Comparator|Sham control|non-contingent-sham neurofeedback
33062560|NCT00296023|Experimental|stem cell transplant|
33062561|NCT05456087|Experimental|Single treatment with Xeomin® (incobotulinumtoxin A)|Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area. At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session.
33062562|NCT00089856|Other|2|Standard of care - chemotherapy
33062563|NCT00089856|Experimental|1|Immunotherapy
33062564|NCT04718428||psoriatic arthritis|Patients with psoriatic arthritis who met the CASPAR criteria and were 18-70 years old were included. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, another rheumatological disease, systemic infection, and pregnancy were excluded.
33062565|NCT04718428||healthy controls|A gender- and age-matched healthy controls were included. They were recruited from the healthy relatives of the hospital staff. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, any rheumatological disease, systemic infection, and pregnancy were excluded.
33062566|NCT00296413||1|Valproate monotherapy
33062567|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
33062568|NCT00296413||3|Lamotrigine monotherapy
33062569|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
33062570|NCT00122031|Experimental|DBS|
33062571|NCT05428436|Experimental|BI 1015550 TF2 fasted/BI 1015550 iCF fasted/BI 1015550 iCF fed|
33062572|NCT05428436|Experimental|T1 BI 1015550 iCF fasted/BI 1015550 iCF fed/BI 1015550 TF2 fasted|
33062573|NCT05428436|Experimental|BI 1015550 iCF fed/BI 1015550 TF2 fasted/BI 1015550 iCF fasted|
33062574|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
33062575|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
33062576|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
33062577|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
33062578|NCT05418140||Women with diagnosis of adenomyosis on ultrasound scan|"The cohort group (375 participants) will comprise of women diagnosed with adenomyosis on pre-treatment baseline ultrasound scan before ART treatment who satisfy the eligibility criteria and consent to participate in the study.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
33062579|NCT05418140||Control group: Women with normal uterus on baseline ultrasound scan|"Women with normal uterus on baseline ultrasound scan during the study duration will be used as control (375 participants) and will be matched for the following variables: age, embryo quality, type of ART cycle (donor or self and IVF or ICSI) and number of embryos transferred. The eligibility criteria will be applicable to the controls as well.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
33062580|NCT00297154|No Intervention|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
33062581|NCT00297154|Experimental|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
33062582|NCT05391620|Experimental|CAD group|Coronary artery diseases
33062583|NCT05391620|Experimental|HFrEF group|Heart Failure with reduced Ejection Fraction
33062584|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
33062585|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
33062586|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
33335827|NCT03957525|Experimental|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
33335828|NCT03957525|No Intervention|Orthopaedic Control group|Gets written and oral preparation for surgery
33335829|NCT03957525|Experimental|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
33062587|NCT00122148|Other|1|
33062588|NCT00297349||001|
33062589|NCT05377307||Group A|After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.
33062590|NCT05377307||Group B|Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.
33062591|NCT00090129|Experimental|Onercept|
33062592|NCT00090129|Placebo Comparator|Placebo|
33062593|NCT05365685|Experimental|adolescents with obesity|There is only one arm as this is an acute randomized study comparing three different conditions within the same sample of participants.
33062594|NCT05338268|Experimental|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
33062595|NCT05338268|Active Comparator|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
33062596|NCT04718272|Experimental|Puncture tube group|After the operation, the traditional traditional silicone tube which placed through the surgical incision was removed in the operating room, and the small puncture tube was retained for thoracic drainage.
33062597|NCT04718272|No Intervention|Traditional tubes group|Routine thoracic drainage management measures were adopted, that is, both of the small puncture tube and traditional silicone tube were retained after surgery.
33062598|NCT00297817|Experimental|Arm 1: rMenB|
33062599|NCT00297817|Experimental|Arm 2: rMenB + OMV|
33062600|NCT00297817|Placebo Comparator|Arm 3: Placebo|
33062601|NCT00297856||Boostrix cohort|
33062602|NCT00297856||Historical Td cohort|
33062603|NCT05327465|Experimental|Aerobic and resistance exercise|"Virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom.~The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer."
33062604|NCT05327465|Active Comparator|Usual care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise program after 16 weeks.
33062605|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
33062606|NCT00297895|Active Comparator|CLND|
33062607|NCT05319353|Experimental|Cohort 1: Maribavir 400 or 200 mg|Participants with greater than (>=) 12 to less than (<) 18 years of age will receive maribavir 400 milligrams (mg) (2*200 mg tablets) twice daily (BID) based on body weight >= 25 kilogram (kg) or 200 mg tablet BID based on body weight < 25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
33062608|NCT05319353|Experimental|Cohort 2: Maribavir 400 or 200 mg|Participants with >= 6 to < 12 years of age will receive maribavir 400 mg (2*200 mg tablets) BID based on body weight >= 25 kg or 200 mg tablet BID based on body weight 10-25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
33062609|NCT05319353|Experimental|Cohort 3: Maribavir|Participants with 0 to < 6 years of age will receive maribavir based on PK modeling.
33062610|NCT05200559|Experimental|E7777 + Pembrolizumab|"Phase l:~E7777: Dose Level 1, 3 µg/kg; Dose Level 2, 6 µg/kg; Dose Level 3, 9 µg/kg; Dose Level 4, 12 µg/kg Day 1-3 - given up to 8 cycles (dose-limiting toxicities assessed for first two cycles, only)~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)~Phase ll:~E7777: administered on Day 1-3 at Phase 2 Recommended Dose (P2RD); Day 1-3 up to 8 cycles~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)"
33062611|NCT05198648||Postoperative myocardial injury|
33062612|NCT05198648||Non postoperative myocardial injury|
33062613|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
33335830|NCT03957525|No Intervention|Urologic Control group|Gets written and oral preparation for surgery
33335831|NCT03957525|Experimental|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
33062614|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
33062615|NCT00298168|Experimental|1|
33062616|NCT00298168|Experimental|2|
33062617|NCT00298168|Placebo Comparator|3|
33062618|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
33062619|NCT00313963|Experimental|1|
33062620|NCT00313963|Placebo Comparator|2|
33335832|NCT03957525|No Intervention|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
33335833|NCT03952455|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
33335834|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
32869848|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
33062621|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
33062622|NCT00314158|Experimental|Brinzolamide +Timolol|
33062623|NCT00314158|Active Comparator|Brinzolamide|
33062624|NCT00314158|Active Comparator|Timolol|
33062625|NCT05147051|Experimental|Reamberin group|Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).
33062626|NCT05147051|Placebo Comparator|Placebo|Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).
33062627|NCT00090480|Experimental|Vaccine group|
33062628|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
33062629|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
33062630|NCT05112302||Virtual reality|
33062631|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
33062632|NCT00122421|No Intervention|usual care|usual care
33062633|NCT00322972|Other|A|Annual mass treatment
33062634|NCT00322972|Other|B|Biannual mass treatment
33062635|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
33062636|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
33062637|NCT00322972|Other|F|One-time mass administration only
33062638|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
33062639|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
33062640|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
33062641|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
33062642|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
33062643|NCT02965235||POCD|Patients who develop POCD after surgery.
33062644|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
33062645|NCT04729101|Experimental|Treatment A (vonoprazan)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
33062646|NCT04729101|Active Comparator|Treatment B (lansoprazole)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
33062647|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
33062648|NCT04730102||Patients undergoing rectal washout in transanal mesorectal excision|Patients undergoing rectal washout in transanal mesorectal excision for rectal cancer.
33062649|NCT04717531|Experimental|Cohort A|"2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB*2-ECB*4). The cycles repeated every 21 days.~Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
33062650|NCT04717531|Active Comparator|Cohort B|"2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP*2-EC*4). The cycles repeated every 21 days.~Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
33062651|NCT04728789|Experimental|Avatrombopag treatment group|Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day.
33062652|NCT05085158||Group 1|HIV-infected children with non-malarial febrile illnesses (NMFIs) less than 5 years old
33062653|NCT05085158||Group 2|HIV-infected children and adolescents with non-malarial febrile illnesses (NMFIs) but less than 15 years old
33335835|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
33335836|NCT02990338|Active Comparator|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 241.6 weeks).
33335837|NCT02990338|Experimental|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 245.6 weeks).
33335838|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
33335839|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
33335840|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
33335841|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
33335842|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
33335843|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
33335844|NCT03672682||Healthy patients|15 healthy patients
33360923|NCT03922711|Experimental|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
33062654|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
33062655|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
33062656|NCT00323401|No Intervention|Control|No programme are offered
33062657|NCT00323440||Group 1|FMF patients in remission
33062658|NCT00323440||Group 2|FMF patients during attack
33062659|NCT00323440||Group 3|FMF patients without colchicine in remission
33062660|NCT00323440||Group 4|FMF patients without colchicine in attack
33062661|NCT05047718|Experimental|convalescent participants PFIZER|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine
33062662|NCT05047718|Experimental|Naive participants PFIZER|Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine
33062663|NCT05047718|Experimental|convalescent participants MODERNA|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine
33062664|NCT05047718|Experimental|Naive participants MODERNA|Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine
33062665|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
33062666|NCT05035706|Experimental|Treatment (biopsy, biospecimen collection)|Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
33062667|NCT00312949|Experimental|1|Participants will use the interactive website
33062668|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
33062669|NCT05027438|Experimental|COAST + Deprescribing|CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
33062670|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
33062671|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
33062672|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
33062673|NCT04994756||Stroke|
33062674|NCT04994756||Thrombectomy|
33062675|NCT04994756||Aneurysm|
33062676|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
33062677|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
33062678|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
33062679|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
33062680|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
33062681|NCT00314314|Experimental|1|
33062682|NCT00314314|Placebo Comparator|2|
33062683|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
33062684|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
33062685|NCT04984070|Experimental|PCOS treatment|Lifestyle intervention, oral contraceptive pills and metformin will be given to improve the symptoms of PCOS patients, such as obesity, hyperandrogegism, and insulin resistance, and to compare the different psychological status in PCOS.
33062686|NCT00314548|Experimental|Cases|PGE1 drug
33062687|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
33062688|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
33062689|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
33062690|NCT04949711|Experimental|Intervention|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive ridesharing vouchers.
33062691|NCT04949711|Sham Comparator|Control|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive online shopping voucher.
33062692|NCT02960074|Experimental|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
33062693|NCT02960074|Experimental|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
33335845|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
33335846|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
33335847|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
33335848|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
33335849|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
33335850|NCT00064077|Experimental|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
33335851|NCT00064077|Experimental|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
33335852|NCT00064077|Experimental|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
33335853|NCT00064077|Experimental|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
33335854|NCT03672448||Neurocognitive disorder|Dementias
33335855|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
33335856|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
33335857|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
33335858|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
33335859|NCT03673930|Placebo Comparator|Placebo|placebo
33062694|NCT04943627|Experimental|Monotherapy with Balstilimab (BAL)|300 mg IV once every 3 weeks for up to 24 months
33062695|NCT04943627|Active Comparator|Monotherapy with Investigator Choice (IC) Chemotherapy per Institutional guidelines|Topotecan: 1 or 1.25 mg/m^2 IV on Days 1 to 5, every 21 days or Vinorelbine: 30 mg/m^2 IV on Days 1 and 8, every 21 days or Gemcitabine: 1000 mg/m^2 IV on Days 1 and 8, every 21 days or Irinotecan: 100 or 125 mg/m^2 IV weekly for 28 days, every 42 days or Pemetrexed: 500 mg/m^2 IV on Day 1, every 21 days
33335860|NCT00063999|Active Comparator|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
33335861|NCT00063999|Experimental|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
33335862|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
33062696|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
33062697|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
33062698|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
33062699|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
33062700|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
33062701|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
33062702|NCT04928339|Experimental|PIFB intervention|bilateral PIFB with a mixture of standard 0.25% bupivacaine (15 mL) and 133 mg liposomal bupivacaine (10mL)
33062703|NCT04928339|Sham Comparator|Saline Control|bilateral PIFB with 25 mL saline only
33062704|NCT04893278||Virtual reality|
33062705|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
33335863|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
33335864|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
33335865|NCT01098825||District VI AAP clinicians|
33062706|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
33062707|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
33062708|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
33062709|NCT00313417|Active Comparator|1|
33062710|NCT00313417|Placebo Comparator|2|
33062711|NCT04861727|No Intervention|Group control|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
33062712|NCT04861727|Active Comparator|Intervention group|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
33062713|NCT04786574|Experimental|Tolvaptan (OPC-41061)|
33062714|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
33062715|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
33062716|NCT00313885|Experimental|1|1 mg daily
33062717|NCT00313885|Experimental|2|5 mg daily
33062718|NCT00313885|Placebo Comparator|3|
33062719|NCT04736849|Experimental|Percutaneous ES and DRS|Epidural Stimulation (ES) and Dorsal Root Stimulation (DRS) will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of ES and DRS will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
33335866|NCT03131440|Experimental|Experimental Condition #1|core, support calls
33335867|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
33335868|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
33062723|NCT04898452||Patients needing antibiotics infusion|Patients needing antibiotics infusion A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
33062724|NCT04898452||Next of kin|Next of kin A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
33062725|NCT04898452||Health professionals|A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
33062726|NCT04767919|Active Comparator|Standard Percutaneous Nephrolithotomy (sPCNL)|The first arm will consist of a Standard of Care standard percutaneous nephrolithotomy (sPCNL)- performed using a 30 Fr access sheath following balloon dilation.
33062727|NCT04767919|Active Comparator|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|The second arm will consist of a Standard of Care mini percutaneous nephrolithotomy (mPCNL)- performed using an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
33062728|NCT04671329|Other|Affirm Contrast Biopsy|Women 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
33335869|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
33335870|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
33335871|NCT03131440|Experimental|Experimental Condition #6|core, app+
33335872|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
33335873|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
33335874|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
33335875|NCT03131440|Experimental|Experimental Condition #10|core, buddy
33335876|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
33335877|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
33335878|NCT03131440|Experimental|Experimental Condition #13|core, online gym
33335879|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
33335880|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
33335881|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
33335882|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
33335883|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
33335884|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
33335885|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
33335886|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
33335887|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
33335888|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
33335889|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
33335890|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
33335891|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
33335892|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
33335893|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
33335894|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
33335895|NCT03131440|Experimental|Experimental Condition #30|core
33335896|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
33335897|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
33335898|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
33062729|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33062730|NCT04646395|Experimental|Tafasitamab and Acalabrutinib|"Acalabrutinib will be administered continuously at the dose of 100 mg BID (equivalent to a total daily dose of 200 mg), from day 1 to day 28 of each cycle for 24 cycles.~Tafasitamab will be administered 12 mg/kg iv on days 1, 8, 15 and 22 for the first 3 cycles. Then patients will continue treatment until cycle 24 with tafasitamab 12mg/kg iv on day 1"
33062731|NCT04635280|Experimental|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equiped with a closed-loop automatic insulin delivery system (or artificial pancreas)
33062732|NCT04729790|Active Comparator|Patients with RCDI will receive FMT capsules from single donor|"Capsules made with intestinal bacteria from single healthy donor~st treatment day, lyophilized product generated from single donor (90g of stool)~nd treatment day, lyophilized product generated from single donor (90g of stool)"
33062733|NCT04729790|Experimental|Patient will receive FMT capsules from three donors|"Capsules made of intestinal bacteria from three healthy donors~st treatment day, lyophilized product generated from three donors (90g of stool)~nd treatment day, lyophilized product generated from three donors (90g of stool)"
33062734|NCT04593901|Other|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
33062735|NCT04586452|Experimental|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (above 40 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
33062736|NCT04586452|Experimental|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
33062737|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
33062738|NCT04586452|Other|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
33062739|NCT04586452|Experimental|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
33062740|NCT04563208|Placebo Comparator|Arm A: Placebo|Placebo administered
33062741|NCT04563208|Active Comparator|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
33062742|NCT04519879|Experimental|Arm IA (white mushroom extract)|Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
33062743|NCT04519879|Active Comparator|Arm IB (clinical observation)|Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
33335899|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
33335900|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
33335901|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
33335902|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
33360924|NCT03922711|Placebo Comparator|Placebo|Matching placebo (oral capsule) for 16 weeks
33335903|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
33335904|NCT02910700|Experimental|Arm A (NDT, CLOSED)|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
33335905|NCT02910700|Experimental|Arm B (NT, closed to accrual)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
33335906|NCT02910700|Experimental|Arm C (NEB)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, encorafenib PO QD on days 1-28, and binimetinib PO BID on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
33335907|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
33335908|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
33335909|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
33335910|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
33062744|NCT04519879|Experimental|Arm IIA (white mushroom extract)|Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
33062745|NCT04519879|Active Comparator|Arm IIB (active surveillance)|Patients undergo active surveillance for 48 weeks.
33062746|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
33062747|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
33062748|NCT04468633|Active Comparator|Baerveldt 350 implant|
33335911|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
33335912|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
33335913|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
33335914|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
33335915|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
33335916|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
33335917|NCT02878798|Experimental|Topiramate|Oral topiramate
33062749|NCT04468633|Active Comparator|Ahmed ClearPath 350 implant|
33062750|NCT04432012|Experimental|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
33062751|NCT04432012|Experimental|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
33062752|NCT04432012|No Intervention|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
33062753|NCT04383496|Experimental|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
33062754|NCT04613141|Sham Comparator|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
33062755|NCT04613141|Experimental|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
33062756|NCT00091299|Experimental|warfarin|
33062757|NCT04368988|Placebo Comparator|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
33062758|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
33062759|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
33062760|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
33062761|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
33335918|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
33335919|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
33335920|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
33335921|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
33335922|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
33062762|NCT04368988|Placebo Comparator|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
33062763|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
33062764|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
33062765|NCT04368988|Experimental|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
33062766|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
33335923|NCT03683212|No Intervention|acute heart failure standard therapy|
33335924|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.~During the course of study, it's not allowed to receive other anti-tumor therapy."
33335925|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
33062767|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2|3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.
33335926|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
33335927|NCT03672058|Active Comparator|Fitbit Only|
33335928|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
33335929|NCT03671902|Other|Lower Body Negative/Positive Pressure|
33335930|NCT03671824||Lean|BMI ≤ 30 kg/m2
33335931|NCT03671824||Obese|BMI ≥30 kg/m2
33335932|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
33335933|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
33335934|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
33335935|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
33062768|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
33062769|NCT04363957|Other|Standard Consent|Patients only receive the standard brachytherapy consent process
33062770|NCT04363957|Experimental|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
33062771|NCT04607603|Experimental|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
33062772|NCT04607603|Placebo Comparator|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
33062773|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
33062774|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
33062775|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
33062776|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
33062777|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
33062778|NCT04322149|Experimental|AT-1501|4 sequential dose cohorts
33062779|NCT04314934|Experimental|Active|ANAVEX2-73
33062780|NCT04600934|Active Comparator|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
33062781|NCT04600934|Experimental|Shockwave|The second 50 patients will be treated primarily with Shockwave
33062782|NCT04298671|Experimental|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
33062783|NCT04560023|Experimental|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
33062784|NCT04560023|No Intervention|Standard procedures|Standard procedures.
33062785|NCT04224025|Experimental|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
33062786|NCT04188262|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
33335936|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
33335937|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
33335938|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
33335939|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
33335940|NCT02839720|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
33335941|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
33335942|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
33335943|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
33335944|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
33335945|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
33335946|NCT03672994||Heart failure|Patients with confirmed heart failure
33062787|NCT04132414|Experimental|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
33062788|NCT04132414|No Intervention|NIRS blinded|NIRS monitoring applied and masked for caregiver.
33062789|NCT04551170|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
33335947|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
32740509|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
33062790|NCT04551170|Placebo Comparator|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
33062793|NCT04542278|Active Comparator|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
33062794|NCT04542278|No Intervention|No Steroids|Pre-operative Standard of Care
33062795|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
33062796|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
33062797|NCT03968731|Experimental|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
33062798|NCT03962959|Experimental|Excitatory TBS|Excitatory TBS
33062799|NCT03962959|Experimental|Inhibitory TBS|Inhibitory TBS
33062800|NCT03962959|Placebo Comparator|Sham TBS|Sham TBS
33062801|NCT04514510|Experimental|ISO|Subjects with sickle cell disease; Isoquercetin 1000mg once daily 28 days.
33062802|NCT04514510|Placebo Comparator|Placebo|Subjects with sickle cell disease; placebo once daily for 28 days.
33062803|NCT04716556|Experimental|Standard Therapy+Convalescent Plasma|Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.
33062804|NCT04716556|No Intervention|Standard Therapy|Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications
33062805|NCT03897868|Experimental|Experimental 1|HCP1803 High
33062806|NCT03897868|Experimental|Experimental 2|HCP1803 Middle
33062807|NCT03897868|Experimental|Experimental 3|HCP1803 Low
33062808|NCT03897868|Active Comparator|Active Comparator 1|HGP0904 High
33062809|NCT03897868|Active Comparator|Active Comparator 2|HGP0904 Low
33062810|NCT03897868|Active Comparator|Active Comparator 3|HGP0608
33062811|NCT03897868|Placebo Comparator|Placebo Comparator|Placebo
33062812|NCT04508348|Active Comparator|Exclusive Human Milk|Group One will receive an exclusive human milk diet throughout the 28-day feeding period or until hospital discharge
33062813|NCT04508348|Other|Maternal human milk or Formula|Group Two (Control Group) will receive maternal human milk or formula (per standard of care).
33062814|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
33062815|NCT04453787|Experimental|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
33062816|NCT04453787|Experimental|Arch support orthoses|The intervention of this group include orthoses with arch support.
33062817|NCT04453787|Sham Comparator|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
33062818|NCT04729868|Other|group Levo-bupivacaine|Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
33335948|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
33335949|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
33062819|NCT04729868|Other|group levo-bupivacaine plus 50µg dexmedetomidine|Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
33335950|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
33335951|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
33335952|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
33335953|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
32740510|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
32740511|NCT04983615|Experimental|fentanyl-based sedation group|
32740512|NCT04983615|Active Comparator|midazolam-based sedation group|
33062820|NCT04729868|Other|group levo-bupivacaine plus 100µg dexmedetomidine|Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
33062821|NCT03822910||Healthy Controls|Matched Healthy Controls
33062822|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
33062823|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT~Other Names:~Gadolinium-chelated polysiloxane based nanoparticles~3 intravenous injections at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~Fr1: AGuIX® injection before the first radiation session~Fr6: AGuIX® injection before the sixth radiation session~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
33062824|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
33062825|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
33062826|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
33062827|NCT00122928|No Intervention|Individual intervention only|Control
33062828|NCT04409990|Other|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
33062829|NCT03807778|Experimental|TAK-788, Phase 1 Part|TAK-788 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
33062830|NCT03807778|Experimental|TAK-788, Phase 2 Part|TAK-788 160 mg, once daily, for up to approximately 10-12 cycles.
33062831|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
33062832|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
33062833|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
33062834|NCT04371614|Active Comparator|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
33062835|NCT04371614|No Intervention|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
33062836|NCT00400257||1|People at high risk of heart failure.
33062837|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
33062838|NCT03685591|Experimental|Dose Level 1 (Part 1A)|PF-06952229 at 20mg twice daily (BID)
32869849|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
33062839|NCT03685591|Experimental|Dose Level 2 (Part 1A)|PF-06952229 at 40 mg BID
33335954|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
33335955|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
33335956|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
33062840|NCT03685591|Experimental|Dose Level 3 (Part 1A)|PF-06952229 at 80 mg BID
33062841|NCT03685591|Experimental|Dose Level 4 (Part 1A)|PF-06952229 at 150 mg BID
33335957|NCT03022630|Other|Usual hepatic care|Usual hepatic care
33335958|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
32869850|NCT04083885|Experimental|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their usual activity.
33062842|NCT03685591|Experimental|Dose Level 5 (Part 1A)|PF-06952229 at 250 mg BID
33062843|NCT03685591|Experimental|Dose Level 6 (Part 1A)|PF-06952229 at 375 mg BID
33062844|NCT03685591|Experimental|Dose Level 7 (Part 1A)|PF-06952229 at 500 mg BID
33062845|NCT03685591|Experimental|Dose Level 8 (Part 1A)|PF-06952229 at 625 mg BID
33062846|NCT03685591|Experimental|Dose Level 9 (Part 1A)|PF-06952229 at 750 mg BID
33062847|NCT03685591|Experimental|Prostate Cancer Dose Level 1 (Part 1B)|PF-06952229 at 375 mg BID in combination with enzalutamide
33062848|NCT03685591|Experimental|Prostate Cancer Dose Level 2 (Part 1B)|PF-06952229 at 500 mg BID in combination with enzalutamide
33062849|NCT03685591|Experimental|Prostate Cancer Dose Level 3 (Part 1B)|PF-06952229 at 625 mg BID in combination with enzalutamide
33062850|NCT03685591|Experimental|Prostate Cancer Dose Level 4 (Part 1B)|PF-06952229 at 750 mg BID in combination with enzalutamide
33062851|NCT03685591|Experimental|Prostate Cancer (Part 2A)|PF-06952229 at recommended Phase 2 Dose BID
33062852|NCT03685591|Experimental|Prostate Cancer (Part 2B)|PF-06952229 at recommended phase 2 dose BID in combination with enzalutamide
33062853|NCT04299620|Experimental|Diagnostic (TRUS)|Patients may undergo TRUS prior to standard-of-care radical prostatectomy. Following radical prostatectomy, removed glands are scanned and micro-US, standard of care mpMRI, and whole mount images are analyzed and compared.
33062854|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
33062855|NCT00123006|Placebo Comparator|2|Control diet
33062856|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
33062857|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
33335959|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
33335960|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
33335961|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
33335962|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
33335963|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
33335964|NCT02624596|Experimental|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
33062858|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
33062859|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
33062860|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
33062861|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
33062862|NCT00400296|Experimental|1|
33062863|NCT04246463||Thoracic - TEVAR|
33062864|NCT04246463||Abdominal - EVAR|
33062865|NCT04246463||Custom Device|
33062866|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
33062867|NCT00315016|Placebo Comparator|1|placebo (double dummy)
33062868|NCT00315016|Active Comparator|2|eplerenone
33062869|NCT00315016|Active Comparator|3|doubling of fosinopril dose
33062870|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
33062871|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
33062872|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
33062873|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
33062874|NCT04239365|Experimental|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
33062875|NCT04239365|Active Comparator|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
33062876|NCT00315094|Experimental|1|
33062877|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
33062878|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
33419307|NCT05020899|Experimental|Quit for Life group|Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
33419308|NCT05020899|Active Comparator|Control group|Participants randomized to this arm will be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
32869851|NCT04083885|No Intervention|Usual Care|Participants perform their usual activities.
33062879|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
33062880|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.~Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary and peritoneal ultrasound~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
33062881|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
33062882|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
33062883|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
33062884|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
33062885|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
33062886|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
33062887|NCT03325426|No Intervention|Usual care|No physical activity tracker or feedback x 6 months, then crossover to physical activity tracker x 6 months
33062888|NCT03325426|Experimental|Physical activity tracker|Physical activity tracker x 12 months (6 months with study feedback and 6 months without)
33062889|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
33062890|NCT04729478|Other|Natural sleep|"Natural sleep endoscopy (NSE)~OSA patients will be endoscopically evaluated during natural sleep.~During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
33062891|NCT04729478|Other|Drug-induced sleep|"Drug-induced sleep endoscopy (DISE)~OSA patients will be endoscopically evaluated during drug-induced sleep.~During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
33062892|NCT03195088|Placebo Comparator|Placebo|Healthy participants were administered a single dose of placebo matching BI 473494 solution via subcutaneous injection.
33062893|NCT03195088|Experimental|BI 473494 35 μg|Healthy participants were administered a single dose of 35 micrograms (μg) BI 473494 solution via subcutaneous injection.
33062894|NCT03195088|Experimental|BI 473494 75 μg|Healthy participants were administered a single dose of 75 micrograms (μg) BI 473494 solution via subcutaneous injection.
33062895|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
33062896|NCT04135703|Experimental|Risk Prevention Services +Housing|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP) as well as rental and utility assistance for 6 months.
33062897|NCT04135703|Experimental|Risk Prevention Services Only|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP).
33062898|NCT02838979|Experimental|Oral L-Glutamine first, then Maltodextrin|"Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
33062899|NCT02838979|Experimental|Maltodextrin first, then L-glutamine|"Subjects will crossover to receiving the study product which they did not receive in the first period.~Either 0.4 g/kg/day of L-glutamine in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
33062900|NCT02728726|Experimental|Sugammadex|Subjects will have Sugammadex administered after routine reversal of anesthesia is performed and patient is extubated.
33062901|NCT02728726|Placebo Comparator|Placebo|Subjects will have Placebo administered after routine reversal of anesthesia is performed and patient is extubated.
33062902|NCT04084730|Experimental|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring <3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
33062903|NCT04716517|Experimental|Cention N|Intervention Alkasite Restoration will be used to restore cervical carious in adult patients.
33062904|NCT04716517|Active Comparator|Resin Modified Glass Ionomer|Comparator Resin-modified glass ionomer material will be used to restore cervical carious in adult patients.
33062905|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
33062906|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
33419309|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
33419310|NCT03552302||Cases|Yoga exercise for 12 weeks
32869852|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
33062907|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
33062908|NCT02645149|Experimental|A1. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, matched drug available|Patients will receive targeted drug matched to the actionable gene mutation detected on NGS testing. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or trametinib, or clinical trials if available.
33062909|NCT02645149|Experimental|A2. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, no matched drug available|Patients may have an actionable aberration for which there is no current study-specific drug supply available. In this scenario, access will be sought for compassionate use of the relevant approved targeted therapy.
33062910|NCT02645149|Experimental|A3. Non-V600 BRAF, BRAF wild type and NRAS wild type melanoma - no actionable genetic aberration|Patients for whom there is no actionable genetic aberration will receive trametinib, based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor
33062911|NCT02645149|Experimental|B. Mucosal melanoma|Patients will receive combined trametinib and ribociclib based on evidence to suggest that combined MEK inhibition and CDK4/6 inhibition may be effective. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.
33062912|NCT02645149|Experimental|C. NRAS mutant melanoma|Patients with an NRAS mutation detected on standard gene testing only will receive combined trametinib and ribociclib based on evidence that combining MEK inhibition and CDK4/6 inhibition is a viable treatment option.
33062913|NCT02645149|Other|D. BRAF V600 mutant melanoma|Patients will receive standard of care treatment only.
33062914|NCT04082234|Experimental|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in up to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
33062915|NCT04082234|Active Comparator|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the electronic health record (EHR) to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines, including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The six practices participating in this study participated in that project.
33062916|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
33062917|NCT02958306|Experimental|platelet rich plasma|autologous blood product
33062918|NCT02958306|No Intervention|no platelet rich plasma|control
33062919|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
33062920|NCT04004273|Experimental|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; ~50 min per session). Each week, one exercise training session will be supervised by the research team, whilst three sessions will be unsupervised but monitored objectively using a heart rate monitor.
33062921|NCT04004273|No Intervention|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
33335965|NCT02624596|Active Comparator|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
33335966|NCT04058704|Experimental|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
33335967|NCT04058704|Experimental|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
33335968|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
33335969|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
33335970|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
33335971|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
33335972|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
33419311|NCT03827265|Experimental|TMS on SFG|"Device: repetitive transcranial magnetic stimulation (real)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the superior frontal gyrus (SFG).~Other Name: rTMS (active stimulation)"
33062922|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
33419312|NCT03827265|Experimental|TMS on PPC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the posterior parietal cortex (PPC).~Other Name: rTMS (active stimulation)"
32869853|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
33062923|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
33062924|NCT01691833|No Intervention|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
33062925|NCT00123240|Active Comparator|High Fat/Protein Diet|
33062926|NCT00123240|Active Comparator|High Carbohydrate Diet|
33062927|NCT04729166|Experimental|Study group|The study group were provided with education with structured educational material and followed in this study, in addition to the usual care provided by healthcare professionals.
33062928|NCT04729166|No Intervention|Control group|Control group was int the usual care.
33062929|NCT03972488|Experimental|Lutathera plus long-acting octreotide|
33062930|NCT03972488|Active Comparator|high dose long-acting octreotide|
33062931|NCT00123279|Experimental|1|
33062932|NCT00123279|Experimental|2|
33062933|NCT00123279|Experimental|3|
33062934|NCT00123279|Experimental|4|
33062935|NCT00123279|Experimental|5|
33062936|NCT00123279|Experimental|6|
33062937|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
33062938|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
33062939|NCT03944486|Other|On-Track|Stroke survivors receiving the OnTrack intervention for 12 weeks consisting of arm activity tracking and self-management coaching. Assessments are done before and after the intervention.
33062940|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
33062941|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
33062942|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
33062943|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
33062944|NCT01005277||Ancillary-Correlative (genetic polymorphisms)|Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
33062945|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
33062946|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
33062947|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
33062948|NCT00327535|Experimental|Mircera 9 micrograms/kg|
33062949|NCT00327535|Experimental|Mircera 12 micrograms/kg|
33062950|NCT00327535|Active Comparator|Darbepoetin alfa|
33062951|NCT03929432|Active Comparator|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
33062952|NCT03929432|Sham Comparator|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
33062953|NCT03913832|Experimental|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
33062954|NCT03913832|Active Comparator|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
33062955|NCT00123357||Group 1|
33062956|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
33068277|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
33068278|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
33062957|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
33062958|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
33335973|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
33335974|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
33335975|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
33335976|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
33335977|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
33062959|NCT04716868|Experimental|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 week.
33062960|NCT04716868|Experimental|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 gf once a day for 8 week.
33062961|NCT04716868|Experimental|Maltodextrin 10 g + Agave Fructans 5 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 week.
33062962|NCT04716868|Active Comparator|Psyllium plantago 15 g|Psyllium plantago 15 g once a day for 8 week.
33335978|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
33335979|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
33062963|NCT00327769|Active Comparator|1|Anastrozole
33062964|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
33062965|NCT00092001|Experimental|1|
33062966|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 75 mcg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
33062967|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 7 mcg/kg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
33062968|NCT04708366|Experimental|1L PEG|Patients will be prepared with 1L-PEG-based bowel preparation.
33062969|NCT04708366|Active Comparator|2L PEG|Patients will be prepared with 2L-PEG-based bowel preparation.
33062970|NCT04708366|Active Comparator|4L PEG|Patients will be prepared with 4L-PEG-based bowel preparation.
33062971|NCT00327808|Experimental|Inhaler|TPI 1020
33062972|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
33068279|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
33062973|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
33062974|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
33062975|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
33062976|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
33062977|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
33062978|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
33062979|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
33062980|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33335980|NCT03669562|Experimental|Alprostadil liposome|
33335981|NCT03669562|Placebo Comparator|Placebo|
33335982|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
33335983|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
33335984|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
33335985|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
33335986|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
33335987|NCT03670108||patients receiving an individualized SMS|
33335988|NCT03670108||patients receiving a standard SMS|
33335989|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
33062981|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
33335990|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
33062982|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
33062983|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
33062984|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
33062985|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
33062986|NCT00123513|No Intervention|2|Control group
33062987|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
33062988|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
33062989|NCT00315562|Experimental|Early|Early
33062990|NCT00315562|Active Comparator|Delayed|Delayed
33062991|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
33062992|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
33062993|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
33062994|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
33062995|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
33062996|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
33062997|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
33062998|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
33062999|NCT04728867|Active Comparator|Surgical textbook|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be a textbook chapter explaining the details for laparoscopic rectal surgery.
33063000|NCT04728867|Active Comparator|3D animation|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational animation video showing laparoscopic rectal surgery.
33068280|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
33063001|NCT04728867|Active Comparator|Cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational cadaveric dissection video showing laparoscopic rectal surgery.
33335991|NCT04058314|Experimental|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
33335992|NCT04058314|Active Comparator|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
33335993|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
33335994|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
33335995|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
33335996|NCT02159404||Healthy controls|
33335997|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
33335998|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib PO BID as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
33063002|NCT04728867|Active Comparator|Both 3D animation + cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be both animation and educational cadaveric dissection video showing laparoscopic rectal surgery.
33063003|NCT00316108|Experimental|Arm 1|
33063004|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
33063005|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
33063006|NCT00123552|Experimental|1|
33063007|NCT00123552|Experimental|2|
33063008|NCT00123552|Experimental|3|
33063009|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
33063010|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle~Standard Chemotherapy will be administered every 28 days"
33063011|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
33063012|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
33063013|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
33063014|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
33063015|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
33063016|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33063017|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
33063018|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
33068281|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
33335999|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
33336000|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
33336001|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
33336002|NCT01571752||CMU|Current marijuana users
33063019|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
33336003|NCT01571752||Cohort 1 - NIH Negative|HIV negative adults
33336004|NCT01571752||Cohort 1- HIV Positive|HIV positive adults
33336005|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
33336006|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
33336007|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
33336008|NCT01571752||COSU|Current opioid/stimulant users
33063020|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
33063021|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
33063022|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
33063023|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
33063024|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
33063025|NCT03270098|Experimental|Aerobic Exercise|Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)
33063026|NCT03270098|Active Comparator|Stretching and Toning Exercise|Using trainer-led video calls with stretching and toning exercises.
33063027|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
33063028|NCT00317278|Experimental|A,1|Massage therapy
33063029|NCT00317278|Sham Comparator|A,2|
33063030|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
33063031|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
33068282|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
33068283|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
33068284|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
33068285|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
33068286|NCT02275975|Experimental|K-877|K-877
33068287|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
33068288|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
33068289|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
33068290|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
33068291|NCT04510402|Experimental|Safety Analysis|Evaluate safety of PVP-I nasal swabs single daily application
33068292|NCT04510402|Experimental|Tolerability analysis|Investigate the dosing of PVP-I nasal swabs daily single dosing versus double dosing
33068293|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
33068294|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
33068295|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
33068296|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
33068297|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
33114334|NCT04630587|Experimental|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
33114335|NCT04630587|Active Comparator|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
33114336|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
33114337|NCT04311853||practitioner interviews|phone interviews conducted
33114338|NCT04314310|Active Comparator|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
33114339|NCT04314310|Placebo Comparator|placebo|equal volume of normal saline
33114340|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
33114341|NCT04610307|Placebo Comparator|control group|patients receiving 1 % plain xylocaine
33114342|NCT04610307|Experimental|intervention group|patients receiving buffered 1 % xylocaine
33114343|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
33114344|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
33336009|NCT01571752||COSU-NTS|Non-treatment seekers
33336010|NCT01571752||COSU-TS|Treatment seekers
33114345|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
33114346|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
33114347|NCT00561171|Experimental|1|high dose
33114348|NCT00561171|Experimental|2|lower dose
33114349|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
33114350|NCT01951742|Experimental|Dose 1|lowest dose
33114351|NCT01951742|Experimental|Dose 2|second lowest dose
33114352|NCT01951742|Experimental|Dose 3|mid-level dose
33114353|NCT01951742|Experimental|Dose 4|second highest dose
33114354|NCT01951742|Experimental|Dose 5|highest dose
33114355|NCT04610229|Experimental|Treated with hypofractionation|1
33114356|NCT01951235|Experimental|Imeglimin (Dose 1)|
33114357|NCT01951235|Experimental|Imeglimin (Dose 2)|
33114358|NCT01951235|Experimental|Imeglimin (Dose 3)|
33114359|NCT01951235|Experimental|Imeglimin (Dose 4)|
33114360|NCT01951235|Placebo Comparator|Placebo|
33114361|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
33114362|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
33336011|NCT01571752||NDU|Non-drug-users
33336012|NCT01571752||Unclassified|
33336013|NCT05654740|Experimental|Virtual Reality experiences|Virtual Reality experiences are offered regularly
33336014|NCT05654740|No Intervention|No Virtual Reality|Virtual Reality experiences are not offered
33336015|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
33336016|NCT01508962||Healthy individuals (controls)|
33336017|NCT01508962||Individuals affected with ALS (sporadic or familial)|
33114363|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
33114364|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
33336018|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
33336019|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
33336020|NCT03496298|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
33336021|NCT03496298|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
33336022|NCT03496298|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
33336023|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
33336024|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
33336025|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
33063032|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
33063033|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
33419313|NCT03827265|Experimental|TMS on dlPFC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the dorsolateral prefrontal cortex (dlPFC).~Other Name: rTMS (active stimulation)"
33063034|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
33063035|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
33063036|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
33063037|NCT04716790|Experimental|Ultrasounds once a week|Patients will undergo the application of ultrasound therapy with a frequency of once a week.
33063038|NCT04716790|Experimental|Ultrasounds once every two weeks|Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.
33063039|NCT04716790|Active Comparator|Standard of care|Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.
33063040|NCT04729283||Sigmoidectomy for sigmoid cancer|Sigmoid resection surgery for patients who suffer from sigmoid cancer
33063041|NCT04729283||Sigmoidectomy for diverticulitis|Sigmoid resection surgery for patients who suffer from symptomatic diverticulitis
33063042|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
33063043|NCT00328393|Placebo Comparator|Placebo|Placebo
33063044|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
33063045|NCT00328588|Experimental|1|7 days continuous infusion
33063046|NCT02215889|Experimental|Surgery|
33063047|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
33063048|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
33063049|NCT00328822|Experimental|A|Quetiapine
33063050|NCT00328822|Placebo Comparator|B|Placebo
33063051|NCT00420043|Experimental|imatinib 800mg|
33063052|NCT00420043|Active Comparator|imatinib 400mg|
33063053|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
33063054|NCT00420082|Experimental|1|Bilastine 20 mg
33063055|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
33063056|NCT00420082|Active Comparator|3|Cetirizine 10 mg
33063057|NCT00420082|Placebo Comparator|4|Placebo
33063058|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
33063059|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
33063060|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
33063061|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
33063062|NCT02965014|Experimental|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
33336026|NCT02914522|Placebo Comparator|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
33336027|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
33336028|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
33419314|NCT03827265|Placebo Comparator|TMS on v5|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target visual cortex (v5).~Other Name: rTMS (sham stimulation)"
33419315|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
33114365|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
33336029|NCT02914522|Placebo Comparator|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
33336030|NCT02914522|Experimental|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
33114366|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
33114367|NCT04609995|No Intervention|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
33114368|NCT04609995|Active Comparator|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
33114369|NCT04609995|Active Comparator|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
33336031|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
33336032|NCT02914522|Experimental|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
33114370|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
33114371|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
33114372|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
33114373|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
33114374|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
33114375|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
33114376|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
33114377|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
33114378|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
33336033|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
33114379|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
33114380|NCT04630080|Experimental|Scalp Cooling|
33114381|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
33114382|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
33114383|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
33114384|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
33114385|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
33114386|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
33114387|NCT04610151|Experimental|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
33114388|NCT04610151|No Intervention|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
33114389|NCT04630041|Experimental|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
33114390|NCT04629885|Experimental|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
33114391|NCT04629885|Placebo Comparator|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
33114392|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
33114393|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
33114394|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
33114395|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
33114396|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
33114397|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
33114398|NCT04629768|Other|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
33114399|NCT01163851|Experimental|PF-04950615 (RN316)|
33336034|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
33419316|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
33114400|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
33336035|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
33336036|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
33336037|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
33336038|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
33336039|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
33114401|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
33114402|NCT04629807|Active Comparator|Demineralized Bone Matrix (DBM)|
33114403|NCT04629807|Active Comparator|Cellular Bone Matrix (CBM)|
33114404|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
33114405|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
33114406|NCT00561210|Experimental|I|Total enteral tube feeding
33114407|NCT00561210|Active Comparator|II|Total enteral tube feeding
33114408|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
33114409|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
33114410|NCT04610034|Experimental|"Resilient Caregivers"|Intervention program
33336040|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
33336041|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
33114411|NCT04610034|Other|Control group|Care as usual
33114412|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
33114413|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
33114414|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
33114415|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
33114416|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
33114417|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
33114418|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
33114419|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
33114420|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
33114421|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
33114422|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
33114423|NCT01911767||Dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
33114424|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
33114425|NCT01911767||Disease Modifying Therapy (DMT) Unexposed|Never received DMT therapy; discontinued treatment with any DMT at least more than 5× half-life prior to Day 1 of her LMP and throughout the entire pregnancy.
33114426|NCT04629846|Experimental|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
33114427|NCT04629846|Active Comparator|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
33114428|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
33336042|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
33114429|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
33114430|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
33336043|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
33114431|NCT01182298||Hepatitis C|latino participants with Hepatitis C
33114432|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
33114433|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
33114434|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
33114435|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
33114436|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
33114437|NCT04629573|Active Comparator|Group 1|Epidural Anesthesia
33114438|NCT04629573|Active Comparator|Group 2|General Anesthesia
33114439|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
33114440|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
33114441|NCT04609449|Experimental|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
33114442|NCT04609449|Active Comparator|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
33114443|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
33114444|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
33114445|NCT00564174|Experimental|a|
33114446|NCT00564174|Active Comparator|b|Low dose aspirin only
33114447|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
33114448|NCT01878461|Experimental|M518101|Proper quantity twice a day
33114449|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
33114450|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
33114451|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
33114452|NCT04629456|Experimental|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
33156036|NCT04117789|Experimental|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
33336044|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
33336045|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
33336046|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
33336047|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
33336048|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
33336049|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
33336050|NCT04609618|Experimental|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
33336051|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
33336052|NCT00062751|Experimental|A|
33336053|NCT00062751|Experimental|B|
33336054|NCT00062751|Active Comparator|C|
33336055|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
33336056|NCT00763828|Experimental|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
33336057|NCT01092429||one,two,and three vessels disease; mortality|
33336058|NCT00258310|Experimental|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
33068298|NCT00506311|Experimental|Fibrin Sealant|
33068299|NCT00506311|No Intervention|No Fibrin Sealant|
33068300|NCT04513327|Experimental|Digital Healthcare System Rehabilitation|
33068301|NCT04513327|Active Comparator|Conventional Rehabilitation|
33068302|NCT04511377|Experimental|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
33068303|NCT04511377|Active Comparator|Conventional Rehabilitation|Rehabilitation using Brochure
33068304|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
33068305|NCT04519645|Experimental|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
33068306|NCT04519645|Active Comparator|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
33068307|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
33068308|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
33068309|NCT04516018|Experimental|Cold acclimation arm|An oral glucose tolerance test will be performed on day 1 of the study. The next day (day 2), subjects will be exposed to shivering thermogenesis for at least 1 hour. The day after, an oral glucose tolerance test will be performed (day 3). The following 9 days, subjects will be exposed daily to shivering thermogenesis for at least 1 hour (day 4-12). On the last day (day 13), an oral glucose tolerance test will be performed.
33068310|NCT00142805|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
33068311|NCT00142805|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
33068312|NCT04515589||Main study cohort|The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis
33068313|NCT04510831|Experimental|Refined maize|Two portions of porridge prepared with refined maize flour with extrinsic addition of labelled FeSO4 (isotopic iron 54)
33336059|NCT00159406||cohort|Registry and Database
33336060|NCT00026650||1/Cohort 1|Patients who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol.
33114453|NCT04629456|Experimental|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
33114454|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
33114455|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
33114456|NCT04629261|Experimental|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
33114457|NCT04629261|Experimental|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
33114458|NCT04629261|No Intervention|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
33114459|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
33114460|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
33114461|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
33114462|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
33114463|NCT04629612|Experimental|Regional anesthesia|Regional block applied according to surgical area
33114464|NCT04629612|No Intervention|No Regional anesthesia|No regional anesthesia applied
33114465|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
33336061|NCT04050202|Experimental|ABC|ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.
33114466|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
33114467|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
33336062|NCT00062439|Experimental|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
33336063|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
33114468|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
33114469|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
33114470|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
33114471|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
33336064|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
33336065|NCT01327209||Patients with diabetes|
33114472|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
33114473|NCT04629144|Experimental|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
33114474|NCT04629144|Placebo Comparator|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
33114475|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
33114476|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
33114477|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
33336066|NCT00051363|Active Comparator|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
33063063|NCT02965014|Experimental|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
33063064|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
33063065|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
33063066|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
33063067|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
33063068|NCT01479608|Experimental|D:Liver transplantation|For non-resectable patients synchronous disease.
33063069|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
33063070|NCT00329056|Experimental|1|40 mg MitoQ OD
33063071|NCT00329056|Experimental|2|80 mg MitoQ OD
33063072|NCT00329056|Placebo Comparator|3|Placebo
33063073|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
33063074|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
33063075|NCT00434408|Active Comparator|3|dry cord care
33063076|NCT00329563|Experimental|Cold fluid|
33063077|NCT00329563|No Intervention|control, standard of care|
33063078|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
33063079|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
33063080|NCT04716751|Experimental|Toripalimab|
33063081|NCT04716673|Experimental|Children (4-11y) with epilepsy|Down-phase-targeted closed-loop auditory stimulation is administered in each arm.
33063082|NCT04716673|Experimental|Teenagers (12-17y) with epilepsy|
33063083|NCT04716673|Experimental|Young adults (18-30y) with epilepsy|
33063084|NCT04716673|Experimental|Healthy children (4-11y)|
33063085|NCT04716673|Experimental|Healthy teenagers (12-17y)|
33063086|NCT04716673|Experimental|Healthy young adults (18-30y)|
33063087|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
33063088|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
33063089|NCT00294827|Experimental|Liver transplantation|
33063090|NCT00329758|Active Comparator|1|
33063091|NCT00329758|Placebo Comparator|2|
33063092|NCT00329914|Placebo Comparator|Placebo|
33063093|NCT00329914|Active Comparator|Progesterone|
33063094|NCT04716478||Patient in need of endodontic care|
33063095|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
33063096|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
33063097|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
33063098|NCT00330265|Experimental|1|KC-002
33063099|NCT00330265|Other|2|Conventional Wound Therapy
33063100|NCT04729244|Active Comparator|CBD(hemp oil) cream|cream 2000mg/1oz (50mg/dose) once daily dosing for a total of 4 weeks to area of most pain.Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
33063101|NCT04729244|Active Comparator|CBD (Hemp oil) Tincture|1500mg CBD/30ml (50mg/dose) once daily dosing for total of 4 weeks. Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
33063102|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
33063103|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
33063104|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
33063105|NCT00330499|Active Comparator|B|Radiation Alone
33063106|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
33063107|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
33063108|NCT00323674|Active Comparator|Light Weight Mesh|
33063109|NCT00323674|Active Comparator|Polysoft Mesh|
33063110|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
33063111|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
33063112|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
33063113|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
33063114|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
33063115|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
33063116|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
33063117|NCT00124059|Experimental|Type A SERO|
33063118|NCT00124059|Experimental|Type B SERO|
33063119|NCT00124059|Placebo Comparator|Type A PLA|
33063120|NCT00124059|Placebo Comparator|Type B PLA|
33336067|NCT00051363|Placebo Comparator|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
33336068|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
33336069|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
33336070|NCT01098981|Active Comparator|Control group|Systemic tPA alone
33336071|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
33063121|NCT00323908||1|Women at high risk for developing breast cancer
33063122|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
33063123|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
33336072|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
33336073|NCT01583829|Experimental|Neurofeedback|
33336074|NCT01583829|Experimental|Cognitive Training|
33063124|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
33063125|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
33336075|NCT01583829|Active Comparator|Waitlist Control|
33336076|NCT01583907||different dietotherapy strategies|
33063126|NCT00324025|Experimental|1|Mycograb
33063127|NCT00324025|Active Comparator|2|biological
33063128|NCT00317629|Active Comparator|1|
33063129|NCT00317629|Experimental|2|
33063130|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
33063131|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
33063132|NCT00317707|Experimental|N-3 PUFA|
33063133|NCT00317707|Placebo Comparator|Olive oil|
33063134|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
33063135|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
33063136|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
33063137|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
33063138|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
33063139|NCT00318019|Experimental|OPC Factor(TM)|
33063140|NCT00318019|Placebo Comparator|Placebo|
33063141|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
33063142|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
33063143|NCT00318097||controls|age matched, tanner stage matched controls
33063144|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
33063145|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
33114478|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
33114479|NCT00564291||1|Healthy volunteers
33336077|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
33336078|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
33336079|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
33336080|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
33336081|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
33336082|NCT03955341|No Intervention|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
33336083|NCT03955341|Other|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
33336084|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
33336085|NCT00031551|Experimental|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
33336086|NCT00031551|Placebo Comparator|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
33336087|NCT00031551|No Intervention|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
33336088|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
33419317|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
33419318|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
33419319|NCT04059588|Experimental|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
33419320|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
33419321|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
33419322|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
33419323|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
33419324|NCT03717129|Active Comparator|Genvoya Oral dose|Single observed oral dose of Genvoya whole tablet
33419325|NCT03717129|Experimental|Genvoya Crushed Dose|Single observed oral dose of Genvoya crushed tablet
33063146|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
33063147|NCT00324766|Active Comparator|1|levosimendan
33419326|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
33419327|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
33419328|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
33419329|NCT01374373|Other|Open Label|One arm open label
33419330|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
33419331|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
33419332|NCT05006937|Active Comparator|laser dusting|"In the dusting arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted."
33063148|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
33063149|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
33063150|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
33063151|NCT00318331|Active Comparator|A|Will receive enteral glutamine
33063152|NCT00318331|No Intervention|B|No enteral glutamine given
33063153|NCT00124254|Experimental|1|Surgical group undergoing SMPA
33063154|NCT00124254|Active Comparator|2|Nosurgical group
33063155|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
33063156|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
33063157|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
33063158|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
33063159|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid~To investate the possible mechanism"
33063160|NCT00325351|Experimental|Arm 1|
33063161|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
33063162|NCT04727580|Experimental|HSK7653 10 mg|
33063163|NCT04727580|Experimental|HSK7653 25 mg|
33063164|NCT04727580|Placebo Comparator|Placebo|
33068314|NCT04510831|Experimental|T.molitor native chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) native chitin and extrinsic addition FeSO4 (isotopic iron 58)
33114480|NCT00564291||2|CSME secondary to diabetic retinopathy
33114481|NCT00564291||3|ARMD with CNV before and after therapy
33114482|NCT00564291||4|ARMD atrophic
33114483|NCT00564291||5|Retinal vein occlusion
33114484|NCT00564291||6|retinitis pigmentosa
33114485|NCT00564291||7|vitreoretinal proliferation
33114486|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
33114487|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
33114488|NCT04609839||Patient admitted to intensive care unit for COVID-19|
33114489|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
33114490|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
33114491|NCT00555074|Experimental|1|Sodium Tungstate
33114492|NCT00555074|Placebo Comparator|2|
33114493|NCT04609488||COVID|
33114494|NCT04609488||non-COVID|
33114495|NCT00555113||1|pseudoxanthoma elasticum
33114496|NCT04609605|Experimental|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
33114497|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1~Multiple dose administration: Dose 1"
33114498|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2~Multiple dose administration: Dose 2"
33114499|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3~Multiple dose administration: Dose 3"
33114500|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4~Multiple dose administration: Dose 4"
33114501|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
33114502|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
33114503|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
33114504|NCT04609254|Experimental|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
33114505|NCT04609254|Experimental|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
33114506|NCT04609254|Experimental|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
33336089|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
33336090|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
33114507|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
33114508|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
33114509|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
33114510|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
33114511|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
33114512|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
33336091|NCT01092897||Subjects with PAH treated with Imatinib|
33336092|NCT01584219||Women after cesarean section|Women after cesarean section
33114513|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
33336093|NCT01584219||pregnancy pathologies|pregnancy pathologies
33114514|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
33114515|NCT04609059|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
33114516|NCT04609059|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
33114517|NCT04676750|Experimental|MBSR|receives 8-week MBSR course
33114518|NCT04676750|No Intervention|control|receives intervention after experiment finishes
33114519|NCT04601298||AUS|
33336094|NCT01584219||first/second trimester pregnancy|
33114520|NCT04601298||FLUS|
33336095|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
33336096|NCT01092975|Experimental|1.25 mg phenylephrine|
33336097|NCT01092975|Experimental|2.5 mg phenylephrine|
33336098|NCT01092975|Experimental|5.0 mg phenylephrine|
33336099|NCT01092975|Experimental|10.0 mg phenylephrine|
33336100|NCT01092975|Experimental|20.0 mg phenylephrine|
33336101|NCT01092975|Experimental|40.0 mg phenylephrine|
33336102|NCT01092975|Experimental|60.0 mg phenylephrine|
33336103|NCT01092975|Experimental|80.0 mg phenylephrine|
33336104|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
33336105|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
33063165|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
33063166|NCT00318721|Experimental|Intervention|
33063167|NCT00318721|No Intervention|control|
33063168|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
33063169|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
33063170|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
33063171|NCT04717609|Active Comparator|Partial Meniscectomy without Saphenous Nerve Block|Participants scheduled for partial meniscectomy will preoperatively receive 0.5% ropivacaine with epinephrine
33063172|NCT04717609|Experimental|Partial Meniscectomy with Saphenous Nerve Block|Participants scheduled for a partial meniscectomy will preoperatively receive a saphenous nerve block at the medial femoral condyle in addition to an injection of 0.5% ropivacaine with epinephrine
33063173|NCT00318760|Experimental|ARM 1|
33063174|NCT00318760|Placebo Comparator|ARM 2|
33063175|NCT00318799|Experimental|Arm 1|
33063176|NCT00318799|Active Comparator|Arm 2|
33063177|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
33063178|NCT04728945|Experimental|lung recruitment|Standard ventilatory management with lung recruitment every 30 minutes
33063179|NCT04728945|Active Comparator|control|Standard ventilatory management
33063180|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
33063181|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
33063182|NCT00318877|Experimental|After school sports|After school team sports
33063183|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
33063184|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
33063185|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
33063186|NCT00318955|Experimental|Dexmedetomidine group|
33063187|NCT00318955|Active Comparator|Propofol group|
33063188|NCT00325936|Active Comparator|Nifedipine|parrallel design
33336106|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
33336107|NCT01093053|Experimental|Mind-Body Skills Groups|
33336108|NCT01093053|Active Comparator|Standard Treatment|
33336109|NCT00049257|Experimental|Treatment|Please see intervention descriptions
33336110|NCT03951987|Experimental|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
33336111|NCT03951987|Experimental|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
33336112|NCT03955419|No Intervention|Control group|Participants in the control group will be fasted from midnight until surgery.
33336113|NCT03955419|Experimental|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
33336114|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
33063189|NCT00325936|Experimental|Cilnidipine|
33063190|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
33336115|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
33336116|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
33336117|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
33336118|NCT03951909|Experimental|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
33336119|NCT03951909|Experimental|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
33336120|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
33063191|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
33063192|NCT00326014|Experimental|A|
33063193|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
33063194|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
33063195|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
33063196|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
32869854|NCT05571969|Experimental|2X-121 Monotherapy and Dovitinib in Combination with 2X-121 in Patients with Advanced Solid Tumors|Determine the maximum tolerated dose (MTD) of 2X-121 monotherapy given twice daily (BID) and determine the MTD of dovitinib given in combination with 2X-121 (MTD) in patients with advanced solid tumors.
32869855|NCT05538702|Experimental|Heated tobacco product with bland taste unit|Nicotine content: 0,5 mg
33063197|NCT04727385|Experimental|single-arm of 3 cohorts|"These patients will be sequentially recruited in 3 cohorts :~One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)~Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)~One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)"
33063198|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
33063199|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
33063200|NCT00326248|Experimental|Arm 1|
33063201|NCT04727112||asthma and rhinitis|Screening of patients with upper and lower airway symptoms
33063202|NCT04727112||asthma and rhintis follow-up|same Group as screened in 2000, was followed up three years later
33063203|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
32869856|NCT05538702|Experimental|Heated tobacco product with menthol taste unit|Nicotine content: 0,5 mg
32869857|NCT05538702|Experimental|Conventional cigarette|Nicotine content: 0,5 mg
32869858|NCT05538702|Placebo Comparator|Heated tobacco product turned off with a bland taste unit|Placebo device
32869859|NCT04021329|Other|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
32869860|NCT04021329|Other|CBT Therapy|other arm will be a group subjected to CBT Therapy
32869861|NCT05538546||Cohort 1|Population: Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline.
33063204|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
33063205|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
33063206|NCT00124293||Factor VII|
33068315|NCT04510831|Experimental|T.molitor reduced chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) reduced chitin and extrinsic addition FeSO4 (isotopic iron 58)
33336121|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
33114521|NCT04601181|Experimental|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
33114522|NCT04676828|Experimental|SPECT functional avoidance treatment|SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
33114523|NCT04676828|No Intervention|Standard treatment|CT-based radiation therapy given over 5- 6.5 weeks.
33114524|NCT04609176|Experimental|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
33114525|NCT04609176|Experimental|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
33114526|NCT04676789|Experimental|Intervention/treatment|Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.
33114527|NCT04600713|Experimental|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
33114528|NCT04600713|No Intervention|Control|The participants in the control group will be offered PT-X at the end of the control period.
33114529|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
33114530|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
33114531|NCT04609371|Experimental|self-care tools|"Arms Assigned Interventions Experimental: self-care tools~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
33156037|NCT04117789|Experimental|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
33336122|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
33336123|NCT01099293||Control|Healthy subjects willing to participate in the study
33336124|NCT01093209|Sham Comparator|Conventional Laser Therapy|
33336125|NCT01093209|Active Comparator|Interferential Laser Therapy|
33336126|NCT00601900|Experimental|Arm I (endocrine therapy with monoclonal antibody)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21 and bevacizumab 15 mg/kg IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33336127|NCT00601900|Active Comparator|Arm II (endocrine therapy)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
33336128|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
33336129|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
33336130|NCT04607668|Experimental|trilaciclib + FOLFOXIRI/bevacizumab|"During Induction the following study drugs are administered on Day 1:~Irinotecan- IV Oxaliplatin - IV Leucovorin- IV Fluorouracil - continuous infusion (CI) over 48 hours beginning on Day 1; Bevacizumab - IV~Following completion of Induction, patients will continue in Maintenance, where they will continue to receive trilaciclib per randomization allocation. Trilaciclib will be administered prior to infusional-5FU/leucovorin/bevacizumab at the same dose and schedule used during Induction."
33336131|NCT04607668|Placebo Comparator|placebo + FOLFOXIRI/bevacizumab|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib
33336132|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
33336133|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
33336134|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
33336135|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
33336136|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
33336137|NCT03668158||recurrent HCC|recurrent HCC after LT
33336138|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
33114532|NCT04609371|Experimental|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
33114533|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
33114534|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
33114535|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
33336139|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
33114536|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
33114537|NCT04600830|Experimental|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
33114538|NCT04600830|Active Comparator|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
33114539|NCT04600869|Experimental|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
33336140|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
33336141|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
33336142|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
33336143|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
33336144|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
33336145|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
33336146|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
33336147|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
33336148|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
33336149|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
33336150|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
33336151|NCT00048165|Experimental|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
33336152|NCT00048165|Placebo Comparator|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
33336153|NCT03952221|Active Comparator|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
32869862|NCT05538546||Cohort 2|Population: Patients don't meet Baveno VI criteria (with a liver stiffness ≥ 20kPa or with a platelet count ≤150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy at baseline)
33336154|NCT03952221|Active Comparator|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
33336155|NCT03952221|Active Comparator|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
33063207|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
33063208|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
33063209|NCT00326404|Experimental|1|
33336156|NCT03952221|Placebo Comparator|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
33336157|NCT01099371|Experimental|exercise|
33336158|NCT03955107|Other|Continuous Glucose Monitoring System|
33336159|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
33336160|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
33336161|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
33336162|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
33336163|NCT03955497|Experimental|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
33063210|NCT00326404|Active Comparator|2|
33063211|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
33063212|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
33063213|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
33063214|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
33063215|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique*~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
33063216|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
33063217|NCT00085670||Group 1|Bone marrow failure subjects
33063218|NCT00319852|Experimental|1|
33336164|NCT03955497|Placebo Comparator|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
33336165|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
33336166|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
33336167|NCT00059787|Experimental|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
33336168|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
33336169|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
33336170|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
33419333|NCT05006937|Active Comparator|basketing|In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
33063219|NCT00319852|Active Comparator|2|
33336171|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
33063220|NCT04728828||In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination|
33063221|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
33063222|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
33336172|NCT03954951|No Intervention|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
33063223|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
33063224|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
33063225|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
33063226|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
33063227|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
33063228|NCT04728984|Experimental|Nalfurafine Hydrochloride 5μg|Oral administration after dinner, once daily for 14 consecutive days
33063229|NCT04728984|Experimental|Nalfurafine Hydrochloride 2.5μg|Oral administration after dinner, once daily for 14 consecutive days
33063230|NCT04728984|Placebo Comparator|Placebo|Oral administration after dinner, once daily for 14 consecutive days
33063231|NCT00085787|Experimental|ARRY-142886|
33063232|NCT04717102|Experimental|0.75 MAC desflurane|The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
33063233|NCT04717102|Active Comparator|0.5 MAC desflurane|The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
33063234|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
33063235|NCT04708405||Inflammatory bowel disease patients|Inflammatory bowel disease patients screened for Helicobacter Pylori Infection
33063236|NCT04708483|Experimental|Malignant thoracic tumoral pathology.|Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks.
33063237|NCT00320125|No Intervention|1|Usual diet
33063238|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
33063239|NCT00320125|Active Comparator|3|Dairy products
33063240|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
33063241|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
33063242|NCT00093873|Experimental|AMG 706|AMG 706 QD
33063243|NCT00327106|Active Comparator|1|Exacyl
33063244|NCT00327106|Placebo Comparator|2|Physiologic serum
33063245|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
33063246|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
33063247|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
33063248|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
33063249|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
33063250|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
33063251|NCT00327223|Experimental|imexon|Dose escalation of imexon
33063252|NCT00327379|Experimental|Arm 1|
33063253|NCT00327379|Placebo Comparator|Arm 2|
33063254|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
33063255|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
33063256|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
33063257|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
33336173|NCT03954951|Active Comparator|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
33063258|NCT00086099|Experimental|1|Idarubicin plus amifostine
33336174|NCT03955185|Experimental|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
33336175|NCT03955185|Active Comparator|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
33336176|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
33336177|NCT03956823|Experimental|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
33336178|NCT03956823|Active Comparator|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
33336179|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
33336180|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
33419334|NCT04593823|Experimental|Furoscix Infusor|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
33063259|NCT00086099|Experimental|2|Idarubincin
33063260|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
33063261|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
33063262|NCT05459038|Experimental|Interventional group|Patients assigned to the interventional group will undergo an identical surgical procedure as patients assigned to the control group. The only difference with the control group is that tibial alignment will be obtained according to the standardized CARV-protocol.
33063263|NCT05459038|No Intervention|Control group|Patients assigned to the control group will undergo an identical surgical procedure as patients assigned to the interventional group. The only difference with the intervention group is that tibial alignment will be obtained according to present unstandardized clinical standards
33063264|NCT05458999|Experimental|Virtual reality headset|Virtual reality headset during percutaneous coronary intervention
33063265|NCT05458999|No Intervention|Control|Routine clinical practice
33063266|NCT05458882|Experimental|educational Booklet|Receive intervention- educational booklet describing the day to day social activities and eating out habits of children with established food allergy in Ireland
33063267|NCT05458882|Active Comparator|Routine education|This group will receive routine education in the allergy group.
33063268|NCT05458765|Active Comparator|F/TAF|daily oral tablet
33063269|NCT05458765|Active Comparator|F/TDF|daily oral tablet
33063270|NCT05458687|Experimental|intervention group|"Chinese herbal medicine decoction.~Acupuncture or Laser acupuncture pen treatment.~Acupoint Tuina massage.~Acupoint application of traditional Chinese herbal medicinal cake.~Nursing and health education and guidance.~Diet and health education."
33063271|NCT05458687|No Intervention|control group|"Nursing and health education and guidance~Diet and health education"
33063272|NCT05458570||Breast cancer|Breast cancer patients presenting to single center in Karachi over the period of 10 years. The aim was to look for ethnic predisposition of population, age of breast cancer, stage at arrival and menopausal status specific to our population. No intervention done.
33063273|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
33063274|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
33063275|NCT05458531||Patients with an inflammatory disease taking immune-suppressing medication|Aged 18 years and over, able to give consent, diagnosed with one of the above inflammatory conditions and currently treated with one of the following immune-suppressing treatments for six months or longer: methotrexate, azathioprine, 5-acetyl salicylates, sulfasalazine, mycophenolate mofetil, leflunomide or biologics.
33063276|NCT05458531||Healthcare professionals|Consultants, general practitioners (GPs), nurse specialists, practice nurses and pharmacists with experience of prescribing and monitoring long-term immune-suppressing treatments for the above inflammatory diseases
33063277|NCT05458492|Experimental|Sirolimus Arm|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
33063278|NCT04717648||Patients with anastomotic leakage|Post operative anastomotic leakage
33063279|NCT04717648||Patients without anastomotic leakage|Post operative without anastomotic leakage
33063280|NCT00094185||General|No intervention
33063281|NCT05458414|Experimental|Endoscopic Breast Conserving Surgery With Intra-operative Navigation System|Surgerons will use Intra-operative navigation system during the surgery to delineate the margins of tumor.
33063282|NCT05458336|Experimental|Cases|Subjects who have been given nasal lavages
33063283|NCT05458336|No Intervention|Controls|Subjects who haven't been given nasal lavages
33063284|NCT05458180|Experimental|CMOEP|dose-escalation： Untreated Peripheral T-cell Lymphoma Patients will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine, Etoposide and Prednisone for 6 cycles (planned) (21 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 15 mg/m2.
33063287|NCT00419653|Experimental|1|
33063288|NCT00419653|Active Comparator|2|
33063289|NCT00419653|Active Comparator|3|Haloperidol
33063290|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
33336181|NCT03956667|Experimental|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
33336182|NCT03956667|No Intervention|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
33336183|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
33063291|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
33063292|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
33063293|NCT00321451|Experimental|1|
33063294|NCT00321451|Sham Comparator|2|
33063295|NCT00321451|Active Comparator|3|
33063296|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
33063297|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
33063298|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
33063299|NCT05457829|Experimental|AI Regimen|Doxorubicin hydrochloride liposome injection combined with Irinotecan
33063300|NCT05457829|Active Comparator|VIT Regimen|Temozolomide combined with Irinotecan and Vincristine
33063301|NCT05457751||M|Group M: patients currently using metoprolol and who did not receive lidocaine before the application of rocuronium.
33063302|NCT05457751||ML|Group ML: patients currently using metoprolol and who received lidocaine before rocuronium application.
33063303|NCT05457751||L|Group L: patients currently not using metoprolol and received lidocaine before rocuronium application.
33063304|NCT05457751||C|Group C: patients currently not using metoprolol and who did not receive lidocaine before rocuronium application.
33063305|NCT05457712|Experimental|Intervention group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment, questionnaires and application of the protocol for this group. The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
33063306|NCT05457712|Other|Control group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment and questionnaires. Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Institute of Cardiology and Children's Hospital Santo Antonio of Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
33336184|NCT03015532|Experimental|Cohort 1, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
33336185|NCT03015532|Experimental|Cohort 1, Group 2: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
33336186|NCT03015532|Placebo Comparator|Cohort 1, Group 3: Saline Placebo|Saline placebo via injection
33336187|NCT03015532|Active Comparator|Cohort 1, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
33063307|NCT00124566|Experimental|1|Irofulven + prednisone
33063308|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
33063309|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
33063310|NCT05457634|Experimental|blu Disposable Flavor A|
33063311|NCT05457634|Experimental|blu Disposable Flavor B|
33063312|NCT05457634|Experimental|blu Disposable Flavor C|
33063313|NCT05457634|Experimental|blu Disposable Flavor D|
33063314|NCT05457634|Experimental|blu Disposable Flavor E|
33063315|NCT05457634|Active Comparator|Combustible cigarette|
33063316|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33336188|NCT03015532|Experimental|Cohort 2, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
33063317|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
33063318|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
33336189|NCT03015532|Experimental|Cohort 2, Group 2: HTX-011 + Ropivacaine|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
33336190|NCT03015532|Placebo Comparator|Cohort 2, Group 3: Saline Placebo|Saline placebo via injection
33336191|NCT03015532|Active Comparator|Cohort 2, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
33336192|NCT03954873|Experimental|Hyperglycaemia + GLP-2|Glucose + GLP-2
33336193|NCT03954873|Active Comparator|Hyperglycaemia + Placebo|Glucose + saline
33336194|NCT03954873|Experimental|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
33336195|NCT03954873|Active Comparator|Hypoglycaemia + Saline|Insulin + glucose
33336196|NCT03954873|Experimental|Euglycaemia + GLP-2|GLP-2
33336197|NCT03954873|Active Comparator|Euglycaemia + Placebo|
33419335|NCT04593823|No Intervention|Continued Medical Therapy|The subjects enrolled in this arm will receive treatment as usual
33419336|NCT02121236||Patients with benign radiolucent lesions|
33419337|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
33419338|NCT03634345|Experimental|PF-04965842|investigational drug
33063319|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
33063320|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
33063321|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33063322|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
33063323|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
33063324|NCT00400127|Experimental|amputee|
33063325|NCT05457361|Experimental|VAH regimen|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
33063326|NCT05457361|Active Comparator|VA regimen|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
33063327|NCT05456854|Experimental|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
33063328|NCT05456854|Placebo Comparator|Placebo|Intravenous administration of placebo x 16 hours
33063329|NCT05456386|Experimental|The Circadian Rhythm Approach to Weight Loss (CRAWL) Intervention Arm|The Circadian Rhythm Approach to Weight Loss (CRAWL) intervention subjects will continuously wear their Fitbit Versa 2 (aside from periodic charging periods) and participate in the pre-scheduled CRAWL sessions. Every week, subjects will complete a sleep diary, which assesses subject's time in bed, sleep latency, awakenings, wake after sleep onset, awakening time, overall sleep quality, overall refreshed rating, naps, exercise, energy level and mood. Subjects are to ensure their Fitbit is sufficiently charged every night before bed and they are to wear their Fitbit continuously throughout the night. Subjects will weigh themselves using their home scale each week prior to exercise, taking a shower or eating breakfast. They will record their weight in their provided weight tracking sheet
33063330|NCT05456386|No Intervention|Waitlist Control Arm|Waitlist control subjects will follow the same protocol outlined above for 16 weeks minus the scheduled CRAWL sessions. When the initial treatment arm has completed their 16 weeks of group sessions, the waitlist control group will begin their CRAWL sessions.
33063331|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
33063332|NCT05456113|Placebo Comparator|Placebo|Vehicle control, does not contain cannabidiol
33063333|NCT05456113|Experimental|Cannabidiol|Active ingredient experimental arm, contains full spectrum connabidiol
33063334|NCT05454943|Experimental|Standardized TRE protocol + External Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
33063335|NCT05454943|Experimental|Standardized TRE protocol + Peer Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
33068316|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
33068317|NCT00142844|Experimental|Naltrexone|Naltrexone
33068318|NCT00142844|Experimental|Disulfiram|Disulfiram
33068319|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
33068320|NCT00142844|Placebo Comparator|Placebo|Placebo
33114540|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
33419339|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
33419340|NCT04991649|Experimental|ACT Group|One two-weekly 2-hour of positive parenting program plus a four-weekly 2-hour group ACT program and routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
33419341|NCT04991649|Other|Treatment-as-usual (TAU) Group|Routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
33063336|NCT05454943|Experimental|Personalized TRE protocol + External Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
33063337|NCT05454943|Experimental|Personalized TRE protocol + Peer Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
33063338|NCT05454943|No Intervention|Control Group|Participants will be asked to maintain their usual diet and physical activity patterns for 16 weeks. They will receive the same number and timing of calls from study staff as the other groups (at randomization, 1, 3, 6, 12 weeks).
33063339|NCT05452837|Active Comparator|Free Dermal Fat Graft|Free Dermal Fat Graft (FDFG) is applied to the superficial parotidectomy defect site
33063340|NCT05452837|Active Comparator|Superficial musculoaponeurotic system flap|Superficial musculoaponeurotic system (SMAS) Flap is dissected and tailored to fill the defect after superficial parotidectomy
33063341|NCT05425771|Experimental|Mucosa Ablation Arm|Treatment group
33063342|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
33063343|NCT05392621|Experimental|Yoga+Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining yoga, progressive muscle relaxation, and deep breathing.
33063344|NCT05392621|Experimental|Yoga+Progressive Muscle Relaxation|Participants engage in a single session combining yoga and progressive muscle relaxation
33063345|NCT05392621|Experimental|Yoga+Deep Breathing|Participants engage in a single session combining yoga and deep breathing.
33063346|NCT05392621|Experimental|Yoga|Participants engage in a single session of yoga.
33063347|NCT05392621|Experimental|Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining progressive muscle relaxation and deep breathing.
33063348|NCT05392621|Experimental|Progressive Muscle Relaxation|Participants engage in a single session of progressive muscle relaxation.
33063349|NCT05392621|Experimental|Deep Breathing|Participants engage in a single session of deep breathing.
33063350|NCT05392621|Sham Comparator|Quiet sitting|Participants engage in a low-touch relaxation condition.
33063351|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
33063352|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
33063353|NCT04717063|Active Comparator|Peroxyl|"Drug: Peroxyl Mouthwash Mouthwash~Other Names:~• 1.5% HP"
33336198|NCT03951831|Experimental|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
33063354|NCT04717063|Placebo Comparator|placebo mouthwash|"Drug: Placebo Mouthwash Mouthwash~Other Names:~• 0.0% HP Mouthwash"
33336199|NCT03954795|Active Comparator|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
33336200|NCT03954795|Active Comparator|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
33336201|NCT03954795|No Intervention|No Block|No interventions
33336202|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
33336203|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
33336204|NCT01584375|Other|Flat midline head position|
33336205|NCT01584375|Other|Right flat lateral head position|
33336206|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
33336207|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
33336208|NCT01100385|Placebo Comparator|Healthy (placebo)|
33336209|NCT01100385|Active Comparator|Healthy (Ateronon)|
33336210|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
33336211|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
33336212|NCT01095783|Experimental|Physiotherapeutic intervention|
33336213|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
33336214|NCT00047463|Active Comparator|CPAP active comparator|continuous positive airway pressure (CPAP)
33336215|NCT00047463|Placebo Comparator|CPAP Placebo|Placebo-CPAP
33336216|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
33336217|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
33336218|NCT03954639|Experimental|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
33336219|NCT03954639|Active Comparator|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
33336220|NCT03954639|Experimental|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
33336221|NCT03954639|Active Comparator|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
33336222|NCT01095939|Placebo Comparator|Control Arm|
33336223|NCT01095939|Experimental|Benazepril|
33336224|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
33336225|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
33336226|NCT01093911|Placebo Comparator|Placebo|
33336227|NCT03956433|Experimental|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
33063355|NCT04717180|Active Comparator|group I|patients who received rehabilitation using the software program for aphasia rehabilitation
33063356|NCT04717180|Active Comparator|group II|patients who received rehabilitation using the conventional therapy
33063357|NCT05382910|Experimental|MG-K10 Q2W|Received MG-K10 300 mg subcutaneous injection every 2 weeks
33063358|NCT05382910|Experimental|MG-K10 Q4W|Received MG-K10 300 mg subcutaneous injection every 4 weeks
33336228|NCT03956433|Experimental|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
33336229|NCT03956433|Experimental|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
33336230|NCT03956433|Experimental|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
33336231|NCT03956433|Experimental|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
33336232|NCT03956589|Experimental|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
33336233|NCT03956901|Experimental|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
33419342|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
33063359|NCT05382910|Placebo Comparator|Placebo|The placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks.
33063360|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
33063361|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
33063362|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
33063363|NCT00322036|Experimental|1|Oral 800 mg BID dosing
33063364|NCT00322036|Placebo Comparator|2|Oral BID dosing
33063365|NCT05373121|Experimental|Intervention condition - signposting to online peer support|The intervention group will be sent a list of online peer support signposting groups and forums to engage with, which will be adapted depending on what health conditions their child has. They will be asked to keep a weekly engagement log for three months.
33063366|NCT05373121|No Intervention|Waitlist condition|The waitlist group will be informed that they will be contacted again in three months, after which, the waitlist will be sent the signposting resources.
33063367|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
33063368|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
33063369|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
33063370|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
33063371|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
33063372|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
33063373|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
33063374|NCT00332176|Experimental|1|
33063375|NCT00332176|Experimental|2|
33063376|NCT00332176|Active Comparator|3|
33114541|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
33336234|NCT03956901|Experimental|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \ kg crystalloid infusion to be started~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
33336235|NCT03015220|Experimental|Oral semaglutide 3 mg|
33063377|NCT05317702|Experimental|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
33063378|NCT05315167|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level. PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
33336236|NCT03015220|Experimental|Oral semaglutide 7 mg|
33336237|NCT03015220|Experimental|Oral semaglutide 14 mg|
33063379|NCT05315167|Experimental|Monotherapy Exploration of the recommended dose|Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 with several cohorts enrolled to confirm the tolerability of the RP2D of PRJ1-3024 (determined in Phase 1). PRJ1-3024 is administered orally once daily. The starting dose is determined by clinical effecacy data from Phase 1, and treatment may continue for up to 2 years as long as the subject experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease.
33063380|NCT00332254|Experimental|1|Intra-articular IL-1Ra
33063381|NCT00332254|Placebo Comparator|2|Intra-articular saline
33063382|NCT00332293|Experimental|Moxifloxacin|
33063383|NCT00332293|Active Comparator|VIGAMOX|
33063384|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
33063385|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
33063386|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
33063387|NCT05222932|Experimental|TILT-123 and avelumab|"Patients will receive multiple administrations of TILT-123 and avelumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
33063388|NCT05222152|Experimental|Chronocort|Chronocort (hydrocortisone modified-release hard capsule) supplied as 5 mg and 10 mg strengths will be administered orally. Chronocort 10 mg will be taken on waking (typically between 06:00 and 08:00 hours) and Chronocort 15 mg will be taken just prior to going to bed (typically between 22:00 hours and midnight).
33063389|NCT05222152|Active Comparator|Plenadren|Plenadren (hydrocortisone modified-release tablet) supplied as 5 mg and 20 mg strengths and administered orally. Plenadren 25 mg will be taken on waking (typically between 06:00 and 08:00 hours).
33336238|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
33336239|NCT00022659|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
33063390|NCT05211388|Experimental|arm 1: generator-controlled RFA|In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.
33063391|NCT05211388|Experimental|arm 2: imaging-controlled RFA|In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.
33063392|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
33063393|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
33063394|NCT05181007|Active Comparator|MFA|mefanamic acid
33063395|NCT05181007|Active Comparator|VPA|valproate
33063396|NCT00332371|Experimental|1|
33063397|NCT00332371|No Intervention|2|
33063398|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
33063399|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
33063400|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
33063401|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
33336240|NCT03667612||Patients with breast cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres~Realization of tumor samples series of cuts and paraffin shavings for:~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
33360925|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
33063402|NCT05160181||Yogatherapy|Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
33063403|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
33063404|NCT05137873||Surgery before 6 months of age|Babies with heart disease surgery, great vessels transposition surgery type before 6 months of age
33063405|NCT05130190|Other|RF Treatment|At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.
33063406|NCT05126836|Other|Cilostazol first, then Placebo|"First week, Cilostazol 100mg twice a day~Second week, Placebo twice a day~Third week, Cilostazol 100mg twice a day~Forth week, Placebo twice a day"
33063407|NCT05126836|Other|Placebo first, then Cilostazol|"First week, Placebo twice a day~Second week, Cilostazol 100mg twice a day~Third week, Placebo twice a day~Forth week, Cilostazol 100mg twice a day"
33063408|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
33063409|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
33063410|NCT05020171|Experimental|intervention group|group focus on lower limb strength training with a seated robotic device
33063411|NCT05020171|Active Comparator|control group|physiotherapy group as usual, not focused on strength training
33063412|NCT05015803|Experimental|CBTi with Application|Device-based intervention facilitation and clinician interfacing for Cognitive Behavioral Therapy for Insomnia (CBTi).
33063413|NCT05015803|Active Comparator|CBTi|Standard CBTi delivered via video conferencing [Zoom Health].
33063414|NCT05015803|Active Comparator|Sleep Hygiene|Treatment as usual: Sleep hygiene education and training.
33063415|NCT04960930|Experimental|FMX101|FMX101 4% minocycline foam
33063416|NCT04960930|Placebo Comparator|Vehicle Foam|Vehicle Foam
33063417|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
33063418|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
33063419|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
33063420|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
33063421|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
33063422|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
33063423|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
33063424|NCT00419731|Active Comparator|1|Bupropion+Placebo
33063425|NCT00419731|Experimental|2|Bupropion+Naltrexone
33063426|NCT00419848|Experimental|1|
33063427|NCT00419848|Active Comparator|2|
33063428|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
33063429|NCT00330694|Other|II|Usual Care in 8 regions
33063430|NCT00094926|Experimental|001|
33063431|NCT00094926|Placebo Comparator|002|
33063432|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
33063433|NCT00331045|Placebo Comparator|Placebo|
33063434|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
33063435|NCT00331045|Experimental|Alviompan 0.5 mg/day|
33063436|NCT00331045|Experimental|Alvimopan 1 mg/day|
33063437|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
33063438|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
33063439|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
33360926|NCT03518554|Experimental|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
33063440|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
33063441|NCT00331123|Placebo Comparator|Placebo|Placebo patch
33063442|NCT00331123|Experimental|Testosterone Patch|
33063443|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
33063444|NCT00331279|Placebo Comparator|Placebo|
33063445|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
33063446|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
33063447|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
33063448|NCT00094965|Experimental|1|
33063449|NCT00331435|Active Comparator|1|FA-guided PDT
33063450|NCT00331435|Experimental|2|ICG-guided PDT
33063451|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
33063452|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
33063453|NCT00331669|Placebo Comparator|1|device
33063454|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
33063455|NCT00420433||1|Patients with breast cancer that has spread to the bones.
33063456|NCT00332020|Experimental|Arm 1|
33063457|NCT00332020|Active Comparator|Arm 2|
33063458|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
33063459|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
33063460|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
33063461|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
33063462|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
33063463|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
33063464|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
33063465|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
33063466|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
33063467|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
33063468|NCT04715620|Experimental|niraparib|
33063469|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
33063470|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
33063471|NCT04715776|Placebo Comparator|Pre-DM patients with placebo|Pre-Diabetes patients uptake placebo as dietary supplement
33063472|NCT04715776|Experimental|Pre-DM patients with supplement|Pre-Diabetes patients uptake Brown seaweed as dietary supplement
33063473|NCT04715776|Placebo Comparator|DM patients with placebo|Diabetes patients uptake placebo as dietary supplement.
33336241|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments~Realization of series of cuts and paraffin shavings of the tumor samples for:~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
33336242|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
33336243|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
33336244|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
33336245|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
33336246|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
32740513|NCT05307315|Experimental|music|"The state/trait anxiety inventory and surgery-specific anxiety inventory will be administered to the experimental group before the surgery. Then they will listen to Turkish Classical Music for 30 minutes.~The scales will be applied again 15 minutes after the music ends."
33063474|NCT04715776|Experimental|DM patients with supplement|Diabetes patients uptake Brown seaweed as dietary supplement
33063475|NCT00340873||Cases|Individuals exposed to digoxin
33063476|NCT00340873||Controls|Individuals not exposed to digoxin
33063477|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
33063478|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
33063479|NCT00332566|Experimental|Group A|
33063480|NCT00332566|Active Comparator|Group B|
33063481|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
33063482|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
33063483|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
33063484|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
33063485|NCT00341302||Cohort 1|HIV Infected Pregnant Women
33063486|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
33063487|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
33063488|NCT00341380||Patients|Undergoing resection of lung tumor
33063489|NCT00332878|Experimental|1|Stepping Stones
33063490|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
33063491|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
33063492|NCT00332917|Experimental|1|
33063493|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
33063494|NCT00333112|Experimental|1|
33063495|NCT00333112|Placebo Comparator|2|
33063496|NCT00125385|Experimental|Cohort 1|Dose group
33063497|NCT00125385|Experimental|Cohort 2|Dose Group
33063498|NCT00125385|Experimental|Cohort 3|Dose Group
33063499|NCT00125385|Experimental|Cohort 4|Dose Group
33063500|NCT00125385|Experimental|Cohort 5|Dose Group
33063501|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
33063502|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
33063503|NCT00333268|Experimental|NGOIS|
33063504|NCT00333268|Active Comparator|BSS Plus|
33063505|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
33063506|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
33063507|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
33063508|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
33063509|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
33063510|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
33063511|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
33063512|NCT00333580||Group 1|
33063513|NCT00333658|Experimental|1|Intervention
33063514|NCT00333658|No Intervention|2|Work Services
33063515|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
33063516|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
33419343|NCT02906137|Other|Uninfected-controls|"40 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~20 subjects will have both a gastroscopy and a coloscopy"
33114542|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
33114543|NCT00565422|Experimental|Single Arm|Escitalopram
33114544|NCT01804088|Experimental|Stent|
33114545|NCT04608747|Experimental|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
33336247|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
33336248|NCT03018028|Experimental|Oral semaglutide 3 mg|
33336249|NCT03018028|Experimental|Oral semaglutide 7 mg|
33336250|NCT03018028|Experimental|Oral semaglutide 14 mg|
33336251|NCT03018028|Placebo Comparator|Oral placebo|
33336252|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
33336253|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
33336254|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
33336255|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
33336256|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
33336257|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
33336258|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
33336259|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
33336260|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
33336261|NCT03666910||children of rheumatic diseased mothers not on treatment|
33336262|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
33336263|NCT03666910||children of normal mothers|
33336264|NCT00021255|Experimental|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
33336265|NCT00021255|Experimental|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
33336266|NCT00021255|Experimental|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
33336267|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
33336268|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
33336269|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
33336270|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
33336271|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
33336272|NCT03951285|Experimental|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
33336273|NCT03951285|Placebo Comparator|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
33336274|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
33336275|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
33336276|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
33336277|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
33336278|NCT04571944|Experimental|Suvorexant|Participants will receive 15 mg of suvorexant orally once daily (QD) for 5 to 7 days.
33336279|NCT04571944|Placebo Comparator|Placebo|Participants will receive suvorexant-matching placebo orally QD for 5 to 7 days.
33063517|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
32740514|NCT05307315|No Intervention|control|The state/trait anxiety inventory and surgery-specific anxiety scale will be administered to the control group before surgery. The same scales will be applied again 45 minutes after the scales are applied.
33063518|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
33063519|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
33063520|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
33063521|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
33063522|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
33063523|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
33063524|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
33063525|NCT00421135|Experimental|Single Arm|ZIO-201
33063526|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
33063527|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
33063528|NCT04716439||magnesium sulfate effect on IONM reading in spine surgery|one group receives magnesium other do not
33063529|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
33063530|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
33063531|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
33063532|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
33063533|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
33063534|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
33063535|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
33063536|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
33063537|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
33063538|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
33063539|NCT00334360|Experimental|1|dexmedetomidine
33063540|NCT00334360|Experimental|2|Buspirone
33063541|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
33063542|NCT00334360|Placebo Comparator|Control|No drug
33063543|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
33063544|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
33063545|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
33063546|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
33063547|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
33114546|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
33114547|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
33114548|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
33114549|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
33114550|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
33336280|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
33336281|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
33336282|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
33063548|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
33063549|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
33063550|NCT04715269|Experimental|Alprazolam Arm|0.5mg Alprazolam will be given to the patient at the time of presentation
33063551|NCT04715269|Placebo Comparator|Placebo Arm|The empty capsule will be given to the patient at the time of presentation
33063552|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
33063553|NCT04716205|Experimental|Mulligan's bent leg raise Technique|Mulligan's bent leg raise Technique and Static Stretching
33063554|NCT04716205|Active Comparator|Static stretching|Static Stretching
33063555|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age >=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
33063556|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
33063557|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
33063558|NCT00334555|Active Comparator|field intervention|field intervention to find partners
33063559|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
33063560|NCT00334594|Active Comparator|No radiotherapy|
33063561|NCT00334594|Experimental|Radiotherapy|
33063562|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
33063563|NCT00089492|Experimental|1|
33063564|NCT00089492|Active Comparator|2|
33063565|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
33063566|NCT04715425|Active Comparator|Thoracoscopic ablation|Thoracoscopic ablation
33063567|NCT04715425|Active Comparator|Catheter ablation|Catheter ablation
33063568|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
33063569|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
33063570|NCT04715152|Active Comparator|ACB group|Patients will receive ultrasound-guided (USG) ACB with levobupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline.
33063571|NCT04715152|Placebo Comparator|IA group|Patients will receive intra-articular levobupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline.
33063572|NCT00089570|Experimental|Terlipressin|Terlipressin
33063573|NCT00089570|Placebo Comparator|Placebo|Placebo
33063574|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
33063575|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
33063576|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
33063577|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
33063578|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
33063579|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
33114551|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
33114552|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
33114553|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
33114554|NCT04600947|Experimental|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
33114555|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
33114556|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
33114557|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
33336283|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
33336284|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
33114558|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
33114559|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
33114560|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
33114561|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
33114562|NCT00564369|Experimental|1|2006 CDC recommendations
33114563|NCT00564369|Active Comparator|2|Prior CDC recommendations
33114564|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
33336285|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
33336286|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
33336287|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
33336288|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
33114565|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
33114566|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
33114567|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
33114568|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
33114569|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
33114570|NCT00564408|Experimental|I|
33114571|NCT01773785|Experimental|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
33114572|NCT04608864|Experimental|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
33114573|NCT04608864|No Intervention|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
33114574|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
33114575|NCT04608981|Experimental|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
33114576|NCT04608981|Experimental|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
33114577|NCT04608981|Placebo Comparator|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
33063580|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
33063581|NCT00343135|Experimental|ARM 1|
33336289|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
33063582|NCT04726644||patients|cirrhotic patients with ventral hernia
33063583|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
33063584|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
33063585|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
33063586|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
33063587|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
33063588|NCT00127881|Experimental|Zanolimumab|
33063589|NCT00343681|Experimental|1|
33063590|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
33063591|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
33063592|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
33063593|NCT00402636|Experimental|2|rapamycin-eluting stent
33063594|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
33063595|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
33063596|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
33063597|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
33063598|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
33063599|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
33063600|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
33063601|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
33063602|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
33063603|NCT00089960|Other|Arm|AMG 125 mg daily continuously
33063604|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
33063605|NCT00402753|No Intervention|Group 2|Usual care control group
33063606|NCT00335218|Experimental|Arm 1|
33063607|NCT00335218|Placebo Comparator|Arm 2|
33063608|NCT00090038|Experimental|1|Rituximab
33063609|NCT00090038|No Intervention|2|No drug
33063610|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
33063611|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
33063612|NCT00402792|Placebo Comparator|Arm 3: Placebo|
33063613|NCT00335335|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
33063614|NCT00335374|Experimental|1|
33063615|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
33063616|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
33063617|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
33063618|NCT04715503|Experimental|PET-IA|68Ga-DOTANOC 18F-FDG
33063619|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
33063620|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
33063621|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
33063622|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
33063623|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
33063624|NCT00128076|Active Comparator|1|All-arthroscopic repair
33063625|NCT00128076|Active Comparator|2|Mini-open repair
33336290|NCT04052932|Placebo Comparator|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
33063626|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
33063627|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
33063628|NCT00344890|Experimental|Preservon|
33063629|NCT00344890|Active Comparator|Control|
33063630|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
33063631|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
33063632|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
33063633|NCT00345163|Experimental|1|
33336291|NCT04052932|Experimental|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
33336292|NCT04052932|Experimental|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
33063634|NCT00345163|Experimental|2|
33063635|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
33063636|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
33063637|NCT00345319|Active Comparator|Group 1|
33336293|NCT04052932|Active Comparator|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
33336294|NCT00010803|Placebo Comparator|Placebo|Placebo 1 pill twice a day
33336295|NCT00010803|Active Comparator|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
33336296|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
33336297|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
33336298|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
33336299|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
33063638|NCT00345319|Active Comparator|Group 2|
33063639|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
33063640|NCT00345514|No Intervention|1|
33063641|NCT00345514|Active Comparator|2|
33063642|NCT00345514|Active Comparator|3|
33063643|NCT04708249|Experimental|D-chiroinositol treatment|
33063644|NCT00345670|Experimental|1|MEDI-534
33063645|NCT00345670|Experimental|2|MEDI-534
33063646|NCT00345670|Experimental|3|MEDI-534
33063647|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
33063648|NCT00345787|Placebo Comparator|0|
33063649|NCT00345787|Experimental|1|
33063650|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
33063651|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
33063652|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
33063653|NCT00345826|Experimental|Dasatinib|
33063654|NCT00345982|Experimental|A|Sertindole 16 mg
33063655|NCT00345982|Placebo Comparator|B|Placebo
33063656|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
33063657|NCT00346021|No Intervention|Control arm|Usual sun protection practices
33063658|NCT00421213|Experimental|Single Arm|
33063659|NCT00125736|Experimental|E0671 combination group|
33063660|NCT00125736|Placebo Comparator|placebo combination group|
33063661|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
33063662|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
33063663|NCT00346177|Active Comparator|1|Stem Cells
33063664|NCT00346177|Placebo Comparator|2|Placebo
33063665|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
33063666|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
33063667|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
33063668|NCT00346528|Experimental|NGOIS|
33063669|NCT00346528|Active Comparator|BSS Plus|
33063670|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
33063671|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
33063672|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
33063673|NCT04714801|Active Comparator|Infusion of 100 million ASC|Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors
33063674|NCT04714801|Active Comparator|Infusion of 200 million ASC|Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors
33063675|NCT04714801|Placebo Comparator|Infusion of placebo|Infusion of saline
33063676|NCT04728932|Experimental|Levosimendan|A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
33063677|NCT04728932|Placebo Comparator|Placebo|A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
33063678|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
33063679|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
33063680|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
33063681|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
33063682|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
33063683|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
33063684|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
33063685|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
33063686|NCT00346957|Experimental|Anecortave Acetate 30|
33063687|NCT00346957|Experimental|Anecortave Acetate 15|
33336300|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
33063688|NCT00346957|Experimental|Anecortave Acetate 3|
33063689|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
33336301|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
33336302|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
33336303|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
33336304|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
33336305|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
33336306|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
33063690|NCT00090740||Asthmatics|People who have asthma
33063691|NCT00090740||Controls|People who do not have asthma
33063692|NCT00346996|Active Comparator|1|HUman Insulin
33063693|NCT00346996|Experimental|2|Analogue insulin
33063694|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
33063695|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
33063696|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
33063697|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
33063698|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
33063699|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
33063700|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
33063701|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
33063702|NCT00347425|Other|A|
33063703|NCT00347425|Other|B|
33063704|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
33063705|NCT00126048|Placebo Comparator|2|Placebo
33063706|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
33063707|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
33063708|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
33063709|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
33063710|NCT00091091||All patients|Self report/Medical record review/ clinical eval
33063711|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
33063712|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
33063713|NCT00426322|Active Comparator|1|small particles
33063714|NCT00426322|Active Comparator|2|large particles
33063715|NCT04705402|Experimental|Patients randomized to receive the treatment arm of mannitol.|The mannitol solution used in the hospital contain 18% mannitol in 500ml solution. An equivocal volume of 2.8 cc / kg body weight, which will be given intravenously with the use of an Ivac pump, infused for a duration of 15 minutes through an existing peripheral intravenous access catheter within 15-30 minutes prior to renal artery reperfusion
33063716|NCT04705402|Placebo Comparator|(Control arm) Study participants will receive a 0.9% saline solution|(Control arm) Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
33063717|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
33063718|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
33063719|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
33063720|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
33063721|NCT04705519|Experimental|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel, Bevacizumab
33114578|NCT01746836|Experimental|Ponatinib hydrochloride|Patients receive ponatinib hydrochloride PO QD. Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
33114579|NCT04600557|Experimental|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
33114580|NCT04600557|Experimental|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
33114581|NCT04600557|Experimental|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
33114582|NCT04600557|Active Comparator|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
33336307|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
33336308|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
33336309|NCT03541200|Experimental|Open Label|MT-8554
33419344|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
33114583|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
33114584|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
33114585|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
33114588|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
33114589|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
33114590|NCT04600245|Experimental|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
33114591|NCT04600245|Experimental|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
33114592|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
33114593|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
33114594|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
33114595|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
33114596|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
33114597|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
33114598|NCT04600284|Experimental|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
33114599|NCT04600284|Experimental|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
33114600|NCT04600284|Experimental|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
33114601|NCT04600284|Experimental|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
33114602|NCT04600284|Experimental|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
33114603|NCT04600284|Experimental|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
33114604|NCT01715012|Experimental|ST266|ST266 sprayed to the skin graft and donor site
33114605|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
33114606|NCT04600401|Experimental|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
33336310|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
33336311|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
33336312|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
33360927|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
33063722|NCT04705714|Experimental|Frankincense Extract|the anti-bacterial and antibiofilm activity of frankincense extract against Porphyromonas gingivalis clinical isolates were studied
33063723|NCT04705285|Experimental|Erbium:Yag Laser|Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.
33063724|NCT04705285|Active Comparator|Pelvic floor training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.
33063725|NCT04705129|Experimental|zanubrutinib+Tislelizumab|Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
33063726|NCT00426712|Experimental|1|Low dose
33063727|NCT00426712|Experimental|2|Middle dose
33063728|NCT00426712|Experimental|3|High dose
33063729|NCT00426712|Active Comparator|4|
33063730|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
33063731|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
33063732|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
33063733|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
33063734|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
33063735|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
33063736|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
33063737|NCT00091286|Experimental|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
33063738|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
33063739|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
33063740|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
33063741|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
33063742|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
33063743|NCT04050462|Active Comparator|Nivolumab Monotherapy|
33063744|NCT04050462|Experimental|Nivolumab/BMS-986253 combination|
33063745|NCT04050462|Experimental|Nivolumab/Cabiralizumab combination|
33063746|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
33063747|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
33063748|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
33063749|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
33063750|NCT04710888|Experimental|basil extract mucoadhesive gel|10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.
33063751|NCT04710888|Placebo Comparator|mucoadhesive placebo gel|10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
33063752|NCT04710888|Sham Comparator|healthy patients|10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)
33063753|NCT03999138||Single Arm|
33063754|NCT01058005|Experimental|Natalizumab|
33063755|NCT01058005|Active Comparator|Interferon Beta-1a|
33063756|NCT01058005|Active Comparator|Glatiramer Acetate|
33419345|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
33419346|NCT04987359|Experimental|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling. The main objective of the structured exercise training is to improve cardiorespiratory fitness.
33063757|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
33063758|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
33063759|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
33063760|NCT00426868|Experimental|Treatment|
33063761|NCT00426868|Placebo Comparator|Placebo|
33063762|NCT00426907|Experimental|1|Full postoperative weightbearing
33063763|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
33063764|NCT05562336||Patients with age related macular degeneration with CNV|
33063765|NCT05562336||Patients with pathological myopia with CNV|
33063766|NCT05562219|Experimental|Treatment group(QA108 granules)|QA108 granules, 7.5 g/bag,2 bags/time, BID
33063767|NCT05562219|Placebo Comparator|Placebo group(QA108 granule simulants)|QA108 granule simulants, 7.5 g/bag,2 bags/time, BID
33063768|NCT00091637|Placebo Comparator|1|Placebo infusion
33063769|NCT00091637|Experimental|2|Pexelizumab infusion
33063770|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
33063771|NCT00427375|Active Comparator|2|Standard surgery
33063772|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
33063773|NCT03929718|Active Comparator|Standard Therapy|subjects undergoing CTI ablation
33063774|NCT03929718|Experimental|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
33063775|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
33063776|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
33063777|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
33063778|NCT00091676|Experimental|ID-KLH + GM-CSF|
33063779|NCT00091676|Active Comparator|KLH + GM-CSF|
33063780|NCT04705207|Experimental|reflexology massage|foot reflexology massage
33063781|NCT04705207|Placebo Comparator|sham massage|traditional foot massage
33063782|NCT04704778|Active Comparator|Transcutaneous|Transcutaneous electrostimulation and uso of oclusal splint
33063783|NCT04704778|Active Comparator|Percutaneous|Percutaneous electrostimulation and splint
33063784|NCT04704778|Placebo Comparator|Control|Oclusal splint
33063785|NCT04705090|Experimental|YY-20394 treatment|YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.
33063786|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
33063787|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
33063788|NCT05561946||Hospitalized Infants|Hospitalized infants that are planned/scheduled to remain in-house for at least 2 days will wear the sock for a minimum of 48 hours and a maximum of 14 days.
33063789|NCT05561946||Healthy Infants|Healthy infants, accompanied by their parent or legal guardian, that are able to stay at a clinical site for 2 days to complete a minimum of 48 hours of monitoring.
33063790|NCT00427492|Active Comparator|Magnesia|Medical laxative
33063791|NCT00427492|Placebo Comparator|Placebo|Placebo
33063792|NCT00427609|Placebo Comparator|1|
33063793|NCT00427609|Active Comparator|2|
33063794|NCT04704895|Active Comparator|Arm A: Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
33063795|NCT04704895|Experimental|Arm B: Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
33419347|NCT04987359|No Intervention|Waitlist Control|The waitlist control group will be asked to maintain their current exercise and dietary habits for the 10-week study period. Upon providing study endpoint data at week 10, control group participants will be offered a 4-week multimodal lifestyle program that is similar to the intervention group.
33419348|NCT05760859|Experimental|Chest pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain"
33419349|NCT05760859|Experimental|Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Dyspnoea"
33419350|NCT05760859|Experimental|Chest pain AND Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea"
33419351|NCT05760859|Experimental|Chest pain AND dyspnoea, AND leg pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain"
33336313|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
33336314|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
33114607|NCT04600401|No Intervention|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
33114608|NCT04600440|Experimental|Plasma treatment|Convalescent plasma 200 ml daily during three days
33114609|NCT04600440|No Intervention|No plasma|Best conventional treatment
33114610|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
33114611|NCT00555191|No Intervention|2|these patients use their usual diet
33114612|NCT04608669|Other|Temperature comparison|
33114613|NCT04608669|Active Comparator|No change|
33114614|NCT00555230|Experimental|1|Rosuvastatin
33114615|NCT00555230|Placebo Comparator|2|Placebo
33336315|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
33336316|NCT04059640|Experimental|LiquiBand FIX8® OHMF Device|Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.
33336317|NCT03007888|Experimental|IPX203 then Sinemet|Participants first received IPX203 ER CD-LD Capsules for 15 days After a Washout Period of 7 days; participants then received Sinemet (IR CD-LD) Tablet for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
33336318|NCT03007888|Experimental|Sinemet then IPX203|Participants first received Sinemet Capsules for 15 days After a Washout Period of 7 days; participants then received IPX203 ER CD-LD Capsules for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
33336319|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
33336320|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
33336321|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
33114616|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
33114617|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
33114618|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
33114619|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
33114620|NCT04608942|Experimental|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
33114621|NCT04608942|Active Comparator|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
33114622|NCT04600089|Placebo Comparator|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
33114623|NCT04600089|Experimental|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
33114624|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
33336322|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
33336323|NCT00009945|Experimental|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
33336324|NCT00009945|Placebo Comparator|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
33336325|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
33360928|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
33360929|NCT03922633|Experimental|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33336326|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
33336327|NCT04055662||Cannabis users|
33063796|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
33063797|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
33063798|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
33063799|NCT00428038||3|"Group 3:~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Hospitalization for a respiratory illness~History of wheezing, asthma, or treatment with asthma medications~Congenital heart disease"
33063800|NCT04704622|Active Comparator|dexmedetomidine group|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
33063801|NCT04704622|Active Comparator|ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
33063802|NCT04704622|Active Comparator|midazolam|midazolam intranasal injection,0.2 mg/kg, once, 30 min preoperative
33063803|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
33063804|NCT00091988|Active Comparator|Structured Education Program|
33063805|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
33063806|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
33063807|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
33063808|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Subjects will receive IV infusions of tabelecleucel at 2 × 10^6 T-cells/kg on Days 1, 8, and 15; and an IV infusion of pembrolizumab at 200 mg for adults or 2 mg/kg for adolescents on Day 1 of each 21-day cycle (at least 2 cycles or up to 4 cycles). For Cohort 1, if there is a dose-limiting toxicity, the dose of tabelecleucel will be reduced to 1 x 10^6 cells/kg and pembrolizumab will continue to be administered as above. Otherwise, all subjects in Cohort 1 will receive tabelecleucel at 2 x 10^6 cells/kg/dose and pembrolizumab as above. Subjects in Cohort 2 will receive the recommended Phase 2 dose of tabelecleucel per the SDRC and pembrolizumab as above.
33063809|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
33063810|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
33063811|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
33063812|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
33063813|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
33063814|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
33063815|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
33063816|NCT00428428|Placebo Comparator|1|Saline irrigation
33063817|NCT00428428|Active Comparator|2|ISO irrigation
33063818|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
33063819|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
33063820|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
33336328|NCT04055662||Cannabis naive|
33063821|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
33063822|NCT01056484|Other|Wait-list control|Standard of Care therapy only
33063823|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
33336329|NCT00008385|Placebo Comparator|Arm I|Participants receive an oral yeast placebo as in arm II.
33336330|NCT00008385|Experimental|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
33063824|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
33063825|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
33063826|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
33063827|NCT05561517|Active Comparator|Competition|Participation in a 5 K competition (running)
33063828|NCT05561517|Active Comparator|Training|Performing a 5 K up-tempo training bout (running)
33063829|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
33063830|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
33063831|NCT00093002|Experimental|1|250 mg fulvestrant
33063832|NCT00093002|Experimental|2|500 mg fulvestrant
33063833|NCT05561322||Spinal fusion patients|Patients who have undergone spinal fusion surgery and have had at least 3 years of follow-up.
33063834|NCT05561322||Lumbar arthroplasty patients|Patients who have undergone lumbar arthroplasty with disc replacement and have had at least 3 years of follow-up.
33063835|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
33063836|NCT05561283|Experimental|Cohort of residents|Medical residents undergoing the leadership and meditation training
33063837|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
33063838|NCT05561127|Experimental|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
33063839|NCT05561127|Active Comparator|Control|Standard of Care.
33063840|NCT03501498|Experimental|loperamide|Slows intestinal transit time
33063841|NCT03501498|Experimental|senna|Speeds up intestinal transit time
33063842|NCT00093197|Experimental|A1: KAI-9803|
33063843|NCT00093197|Experimental|A2: KAI-9803|
33063844|NCT00093197|Experimental|A3: KAI-9803|
33063845|NCT00093197|Experimental|A4: KAI-9803|
33063846|NCT00093197|Placebo Comparator|A5: Placebo|
33063847|NCT05561010|Experimental|Intra-articular injection of bupivacaine|5 ml of bupivacaine (0.25% w/v)
33063848|NCT05561010|Placebo Comparator|Intra-articular injection of sodium chloride|5 ml of sodium chloride (9mg/ml, 0.9% solution for injection)
33063849|NCT05559957||Isolated oligohydramnios group|Cases with oligohydramnios (amniotic fluid index less than 5) without an overt underlying reason in the third trimester
33063850|NCT05559957||Normal amniotic fluid group|Normal pregnancy cases with normal amniotic fluid index
33063851|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
33063852|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
33063853|NCT05559216|Other|Basketball Players|
33063854|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
33114625|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
33336331|NCT03720834||Patients|Questionnaire on risk perception
33336332|NCT03720834||Clinicians|Questionnaire on risk perception
33360930|NCT03922633|Experimental|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33360931|NCT03922633|Experimental|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33419352|NCT05760859|Experimental|Chest pain AND dyspnoea, AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and immobilization"
33419353|NCT05760859|Experimental|Chest pain AND dyspnoea, AND leg pain AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain, and immobilization"
33419354|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
33419355|NCT04980027|Experimental|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
33063855|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
33063856|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
33419356|NCT01373593|Experimental|lidocaine|lidocaine block
33419357|NCT01373593|Placebo Comparator|Placebo|
33063857|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
33063858|NCT03393039|Experimental|Behavioral|Negative Affect Task
33063859|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
33063860|NCT03200769|No Intervention|Group I|AHI/h < 15
33063861|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
33063862|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
33063863|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
33063864|NCT05549895|Experimental|Drug arm|45 patients will receive 8mg dexamethasone in addition to bupivacaine intrathecally .
33063865|NCT05549895|Other|control arm|45 patients will receive only bupivacaine intrathecally as a control group.
33063866|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33063867|NCT05543109|Active Comparator|Psoas compartment block|After induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
33063868|NCT05543109|Active Comparator|Suprainguinal fascia iliaca compartment block|After induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
33063869|NCT02964806|Other|Ordinary Diet|Ordinary Diet
33063870|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
33063871|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
33063872|NCT03071913||Observational (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
33063873|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
33063874|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
33063875|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
33114626|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
33114627|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
33114628|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
33419358|NCT04956549|Experimental|Physical Activity|150 minutes of physical activity weekly
33419359|NCT04956549|Experimental|Successful Aging|Low intensity activity program and a healthy aging educational component
33063876|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
33063877|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
33063878|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
33360932|NCT03922633|Experimental|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33063879|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
33063880|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
33063881|NCT04704310|Experimental|Intervention Group|Individuals acting as own control. Looking at changes pre and post intervention
33063882|NCT05529030|No Intervention|Standard question|Question with no additional text or framing
33063883|NCT05529030|Experimental|Question with salient Omicron message|Question indicates that the bivalent booster can protect the respondent from the Omicron variant
33063884|NCT05529030|Experimental|Question with patient protection message|Question indicates that the bivalent booster can protect patients (only presented to patient-facing employees)
33063885|NCT05529030|Experimental|Question with salient Omicron and patient protection message|Question indicates that the bivalent booster can protect patients from the Omicron variant (only presented to patient-facing employees)
33063886|NCT00400322|Active Comparator|Valganciclovir|
33063887|NCT00400322|Placebo Comparator|Placebo|
33063888|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
33063889|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
33063890|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
33063891|NCT02823366|Active Comparator|Monotherapy|UDCA alone
33063892|NCT00093977|Experimental|darbepoetin alfa SF|
33063893|NCT02813889|Experimental|Infants|Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.
33063894|NCT05519007|Experimental|The Next Science treatment|The surgical site will be irrigated with NS prior to closure, which will be suctioned at the end of the treatment time
33063895|NCT05519007|Active Comparator|Standard of Care|Saline irrigation
33063896|NCT02964962|Experimental|29 mm LOTUS Edge™|
33063897|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
33063898|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
33063899|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
33063900|NCT05513118||Post-menopausal women|
33063901|NCT05513118||Regularly mensturating women|
33114629|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
33114630|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
33360933|NCT03922633|Experimental|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33360934|NCT03922633|Experimental|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33360935|NCT03922633|Experimental|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33360936|NCT03922633|Experimental|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
33360937|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.~Body Composition Monitoring every 10 minutes for 6hours."
33360938|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
33360939|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
33114631|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
33336333|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
33336334|NCT00047385|Experimental|Low-Dose CT|
33063902|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
32740515|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
32740516|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 2|
33063903|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
33063904|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
33063905|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
33063906|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
33063907|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
33063908|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
33063909|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
33063910|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
33063911|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
33063912|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
33063913|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
33063914|NCT01054885|Placebo Comparator|Placebo|Placebo
33063915|NCT05431374|Experimental|Measurement Based Care MBC|patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient.
33063916|NCT05431374|Active Comparator|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
33063917|NCT02530983||Esophagectomy/Esophageal Reconstruction|Patients who have undergone esophagectomy or esophageal reconstruction
33063918|NCT00428779|Experimental|1|patients running during 24 hours without sleep
33063919|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
33063920|NCT05426967|Experimental|Arm 1|Active rTMS/Individualized Connectome Targeting (ICT)/Bilateral/Standard rTMS protocol
33063921|NCT05426967|Experimental|Arm 2|Active rTMS/ICT/Bilateral/Theta Burst Stimulation (TBS) rTMS protocol
33063922|NCT05426967|Experimental|Arm 3|Active rTMS/ICT/Unilateral/Standard rTMS protocol
33063923|NCT05426967|Experimental|Arm 4|Active rTMS/ICT/Unilateral/TBS rTMS protocol
33063924|NCT05426967|Experimental|Arm 5|Active rTMS/Structural targeting/Bilateral/Standard rTMS protocol
33063925|NCT05426967|Experimental|Arm 6|Active rTMS/Structural targeting/Bilateral/TBS rTMS protocol
33063926|NCT05426967|Experimental|Arm 7|Active rTMS/Structural targeting/Unilateral/Standard rTMS protocol
33063927|NCT05426967|Experimental|Arm 8|Active rTMS/Structural targeting/Unilateral/TBS rTMS protocol
33063928|NCT05426967|Experimental|Arm 9|Active rTMS/Scalp targeting/Bilateral/Standard rTMS protocol
33063929|NCT05426967|Experimental|Arm 10|Active rTMS/Scalp targeting/Bilateral/TBS rTMS protocol
33063930|NCT05426967|Experimental|Arm 11|Active rTMS/Scalp targeting/Unilateral/Standard rTMS protocol
33336335|NCT00047385|Experimental|Chest X-ray|
33336336|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
33114632|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
33114633|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
33114634|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
33114635|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
33114636|NCT00555269||MB|
33114637|NCT00555269||IFCG|
33114638|NCT04600011|Other|TELEREHABILITATION ARM|ARM 1: The TELEREHABILITATION ARM where participants receive the full originally-intended protocol that includes one initial in-person PT/OT evaluation, four virtual PT/OT visits, and one final in-person (or virtual, if in-person is not possible) PT/OT evaluation. The study duration for Arm 1 is about 10 weeks of the primary intervention as described with 3- and 6-month follow-up calls. The mobile virtual platform for Arm 1 is comprised of a tablet on a height-adjustable rotating tablet floor stand with a gooseneck and wheels.
33419360|NCT04715581|Experimental|Multicomponent prehabilitation group|Patients in the intervention group will receive nutritional optimization and exercise training before the surgery.
33114639|NCT04600011|Other|VIRTUAL HOME SAFETY EVALUATIONS (HSE)-ONLY ARM|ARM 2: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
33114640|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
33114641|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
33114642|NCT04676360|Experimental|(BELANTAMAB MAFODOTIN|"Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle.~Treatment is intended to be administered on an outpatient basis."
33114643|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
33114644|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
33114645|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
33114646|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
33114647|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
33419361|NCT04715581|No Intervention|Control group|Patients in the control group will maintain normal diet and normal activity before surgery.
33419362|NCT04611477|Placebo Comparator|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
33114648|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
33114649|NCT00565500|Experimental|1|
33114650|NCT00565500|Experimental|2|
33114651|NCT00565500|Placebo Comparator|3|
33114652|NCT04608162|Active Comparator|Group I|Group one received PEMF and exercise (PEMF+EX)
33114653|NCT04608162|Placebo Comparator|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
33114654|NCT04608162|Active Comparator|Group III|Group three will be treated by PEMF alone (PEMF)
33114655|NCT04608084|Experimental|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
33114656|NCT04600050|Active Comparator|Control group: stroke patients with education|
33114657|NCT04600050|Experimental|Experimental: stroke patients with exercise|
33114658|NCT01691846|Experimental|aleglitazar|
33114659|NCT01691846|Placebo Comparator|placebo|
33114660|NCT04599543|Experimental|Administration of IL3 CAR T-cells|
33114661|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
33114662|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
33114663|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
33114664|NCT01658501|Experimental|Metformin|Metformin only
33114665|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
33114666|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
33114667|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
33114668|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
33114669|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
33419363|NCT04611477|Active Comparator|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
33419364|NCT04611477|Active Comparator|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
33419365|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.~More regarding dose escalation is included in intervention below."
33419366|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
33336337|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.~Enrollment into Arm B was discontinued."
33336338|NCT03665818|Experimental|Oral appliance intervention|
33336339|NCT03665818|No Intervention|Without oral appliance intervention|
33336340|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
33063931|NCT05426967|Experimental|Arm 12|Active rTMS/Scalp targeting/Unilateral/TBS rTMS protocol
33063932|NCT05426967|Sham Comparator|Sham 1|Sham rTMS/Scalp targeting/Bilateral laterality/Standard rTMS protocol
33063933|NCT05426967|Sham Comparator|Sham 2|Sham rTMS/Scalp targeting/Bilateral laterality/TBS rTMS protocol
33063934|NCT05426967|Sham Comparator|Sham 3|Sham rTMS/Scalp targeting/Unilateral/Standard rTMS protocol
33063935|NCT05426967|Sham Comparator|Sham 4|Sham rTMS/Scalp targeting/Unilateral/TBS rTMS protocol
33063936|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
33063937|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
33063938|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
33063939|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
33063940|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
33063941|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
33063942|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
33063943|NCT05394714|Experimental|Magicell-NK|Magicell-NK Cohort 1: 2 x 108 cells x 6 infusions Cohort 2: 6 x 108 cells x 6 infusions Cohort 3: 18 x 108 cells x 6 infusions
33063944|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
33063945|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
33063946|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
33063947|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
33063948|NCT05394051|Experimental|PARK Now|"6-Week Self-Guided Program: PARK Positive Emotion Skills: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. The maximum amount of time engaged in the PARK program for any participant is 5 hours over the 6-week period, plus completion of the REDCap surveys assessments (burnout, well-being, health behaviors). The intervention will focus on developing the following skills that will be supplemented by home practice: (1) positive events, capitalizing, gratitude; (2) mindfulness; (3) positive reappraisal; (4) personal strength and achievable goals; (5) and self-compassion.~PARK is delivered through the BrightOutcome online platform."
33063949|NCT05394051|No Intervention|Wait List Control-PARK Later|Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up.
33063950|NCT05393817||Low-dose group|Infants receiving low dose caffeine citrate (up to 10mg/kg/day)
33063951|NCT05393817||High dose group|Infants receiving high dose caffeine citrate (exceeding 10mg/kg/day)
33063952|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
33063953|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
33063954|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
33063955|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
33063956|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
33063957|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
33114670|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
33114671|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
33114672|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
33114673|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
33114674|NCT01651871|Experimental|Treatment Group 1|
33114675|NCT01651871|Experimental|Treatment Group 2|
33114676|NCT01651871|Experimental|Treatment Group 3|
33336341|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
33336342|NCT04059718|Experimental|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
33114677|NCT01651871|Active Comparator|Treatment Group 4|
33114678|NCT01651871|Placebo Comparator|Treatment Group 5|
33336343|NCT04059718|No Intervention|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
33336344|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
33114679|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
33114680|NCT01647308|Placebo Comparator|Placebo|
33114681|NCT04599582|Active Comparator|SP-CL|
33114682|NCT04599582|Active Comparator|Corail|
33114683|NCT04599738|Placebo Comparator|Wheat muffin|Muffin made with 100% wheat flour
33114684|NCT04599738|Experimental|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
33114685|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
33336345|NCT03665350|Experimental|Insulin|standard care including insulin
33336346|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
33336347|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
33336348|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
33336349|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
33336350|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
33336351|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
33336352|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
33336353|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
33114686|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
33114687|NCT04607967|No Intervention|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Coventional Oxygen group will be treated according to the national and international recommandations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
33114688|NCT04607967|Experimental|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Certification with the high flow nasal oxygen device.~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
33114689|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
33114690|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
33114691|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
33114692|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
33336354|NCT03665194|Placebo Comparator|Vehicle solution|
33336355|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
33336356|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
33336357|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
33336358|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
33336359|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
33336360|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
33336361|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
33336362|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
33336363|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
33336364|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
33336365|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
33336366|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
33336367|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
33336368|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
33063958|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
33063959|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
33336369|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
33336370|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
33336371|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
33336372|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
33336373|NCT02911948|Experimental|Insulin degludec/liraglutide|
33063960|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
33063961|NCT00428896|Experimental|1|ZD1839
33336374|NCT02911948|Active Comparator|Insulin degludec|
33336375|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
33336376|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
33063962|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
33063963|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
33063964|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
33063965|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
33063966|NCT00429013|No Intervention|2|no medical device
33063967|NCT00429013|Experimental|1|medical device
33063968|NCT00429091|Placebo Comparator|1|
33063969|NCT00429091|Experimental|2|
33063970|NCT00429091|Active Comparator|3|
33063971|NCT05261178||Upper extremity amputation patients using myoelectric controlled prosthesis|20 patients aged 18-65 years with upper extremity amputation and using myoelectric controlled arm prosthesis for at least 3 months
33063972|NCT04704388||patients hospitalized in intensive care units for SARS-CoV-2|patients hospitalized in intensive care units for SARS-CoV-2
33063973|NCT04704388||patients hospitalized outside intensive care units|patients hospitalized outside intensive care units
33063974|NCT04704739|Experimental|GLPG1205 oral and [14C]-GLPG1205 IV|Single oral dose of GLPG1205 followed by [14C]-GLPG1205 solution for infusion
33063975|NCT04704739|Experimental|[14C]-GLPG1205 capsule|Single oral dose of GLPG1205 as solid formulation
33360940|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
33063976|NCT04704427|Experimental|Rehabilitative BCI training|The experimental group will receive brain computer interface-based lower limb function training (BCI-LLT), 30 minutes/time, 5 times/week, with a 4-week training period.. The training using the lower limb orthosis targeted the patient's ability to walk.
33063977|NCT04704427|Active Comparator|Traditional physical therapy protocol|The control group will only receive traditional physical therapy protocol. The traditional physical therapy protocol of lower limb conducted with the same treatment frequency, intensity and duration of treatment, including muscle strength training, balance training and walking training, etc.
33063978|NCT05244369|Active Comparator|Acupuncture+TENS group|Acupuncture application twice a week - a total of 8 sessions, and rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes for 5 days a week for 4 weeks, current frequency 60-100 Hz to stump tip, impulse duration 100 microseconds transcutaneous electrical nerve stimulation (TENS) will be applied.
33063979|NCT05244369|Other|Only TENS group|A rehabilitation program consisting of joint range of motion, stretching, and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and transcutaneous electrical nerve stimulation (TENS) with a current frequency of 60-100 Hz and an impulse duration of 100 microseconds will be applied.
33063980|NCT00095537|Experimental|Phase 1 MTD Study|
33063981|NCT00429247|Experimental|1|Her
33063982|NCT00429247|No Intervention|2|Follow up
33063983|NCT05243472|No Intervention|Control group|Participants in the control group will not receive any intervention during the study period.
33063984|NCT05243472|Experimental|Protein nutritional supplement group|Participants in the intervention group will receive protein-enriched soups (24-30g of protein) per day for 12 weeks. Protein may come from either soy, bean or milk products.
33063985|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
33063986|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
33419367|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
33419368|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
33419369|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
33419370|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
33419371|NCT04699435|Experimental|Control|Patients with a BMI <25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
33419372|NCT04699435|Experimental|PreOx_3min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
33419373|NCT04699435|Experimental|PreOx_6min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
33419374|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33419375|NCT04675489|Other|Vivity Toric IOL|Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.
33419376|NCT04935021|Experimental|ATTR-CM|Patients or Gene carrier
33419377|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
33419378|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
33419379|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
33419380|NCT02124200|Other|EGO/CE4, 9mg nicotine|
33419381|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
33419382|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
33063987|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
33063988|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
33063989|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
33063990|NCT01054456|Experimental|All Participants: Palonosetron 0.25 mg/5 mL|Participants will receive palonosetron 0.25 milligram (mg) per (/) 5 milliliter (mL) intravenous injection 30 minutes prior to receiving a low emetogenic chemotherapy (LEC) agent on Day 1.
33419383|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
33419384|NCT04503993|Experimental|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
33063991|NCT00429442|Active Comparator|1|
33063992|NCT00429442|Placebo Comparator|2|
33419385|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
33419386|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
33419387|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
33419388|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
33063993|NCT00400361|Experimental|1|
33419389|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
33419390|NCT03551834|Active Comparator|Using short tunnel small flap technique|
33419391|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
33063994|NCT00429559|Experimental|A|
32740517|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 5|
32740518|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 2|
32740519|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 5|
32740520|NCT05724953|Experimental|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
32740521|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
32740522|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
32740523|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
33063995|NCT00095810|Experimental|A|
33419392|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
33419393|NCT02124356||Emergency High-risk Abdominal Surgery|
32740524|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
33063996|NCT05234112|Experimental|Uganda, India, Bangladesh|hrHPV self-test, followed by VIA inspection for hrHPV-positive women.
33063997|NCT05234112|Experimental|Slovakia|hrHPV self-test, followed by Pap-smear for cytology
33419394|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
33063998|NCT01054300|Experimental|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
33063999|NCT01054300|Experimental|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
33419395|NCT04475133|Experimental|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
33419396|NCT04475133|Experimental|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
33419397|NCT04475133|Sham Comparator|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
33419398|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
33419399|NCT04473963|Experimental|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
33064000|NCT01054300|Experimental|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
33064001|NCT01054300|Experimental|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
32740525|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
32740526|NCT04983147|Experimental|health belief model based training manuel|"A training manual entitled Do Not Stay Silent Towards Obesity was prepared by the researcher to guide women in obesity management by affecting their beliefs on obesity in a positive way."
33064002|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064003|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
33064004|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
33064005|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
33064006|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
33064007|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
33064008|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
33064009|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
33064010|NCT00429715|Active Comparator|BCG|BCG
33064011|NCT00429715|Placebo Comparator|BCG diluent|Diluent
33064012|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~Subcutaneous daily amifostine at a dose of 500 mg"
33064013|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
33064014|NCT00429754|Other|aprepitant|Aprepitant treatment
33064015|NCT04703881|Experimental|AYMES ActaGain|Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
33114693|NCT04607811|No Intervention|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
33336377|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
33064016|NCT04703959||glaucomatous subjects (50)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~increase in intraocular pressure (IOP before treatment greater than 21 mmHg) with characteristic alterations of the optic nerve (pathological papillary excavation, papillary pallor, papillary atrophy) with corresponding alterations and characteristics of the visual field. The visual field should be considered reliable (European criteria (European Glaucoma Society, 1999).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
33064017|NCT04703959||non glaucomatous subjects (100)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~no known ophthalmological pathologies, with an ophthalmological examination on telephone examination - in the 2 years preceding the polysomnographic examination - normal apart from minor refractive disorders (myopia with spherical equivalent less than -6 diopters or hyperopia with spherical equivalent less than 3 diopters).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
33064018|NCT05232084|Active Comparator|Group 30 = 30 ml of Erector spinae plane block group|In group 30 ml, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
33336378|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
33336379|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
33336380|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
33336381|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
33336382|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
33064019|NCT05232084|Active Comparator|Group 20 = 20 ml of Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
33064020|NCT00429871|Experimental|1|DF
33064021|NCT00429871|Experimental|2|DC
33064022|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064023|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
33064024|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
33064025|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
33064026|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
33064027|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
33064028|NCT00430144|Experimental|CKD-602|
33064029|NCT05207163|Experimental|Received CME|
33064030|NCT05207163|No Intervention|Not received CME|
33064031|NCT00096083|Active Comparator|Melphalan Administration PHP|
33064032|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
33336383|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
33336384|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
33336385|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
33336386|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
33336387|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
33064033|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
33064034|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
33064035|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
33336388|NCT03663634|No Intervention|Handling Medium as it is.|
33336389|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
33336390|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
33064036|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
33064037|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
33064038|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
33064039|NCT01726452|Experimental|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
33064040|NCT01726452|Experimental|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
33064041|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
33064042|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33064043|NCT05207124||Botulinum toxin injection group|onabotulinumtoxinA
33064044|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064045|NCT00130494|Experimental|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
33064046|NCT00130494|No Intervention|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
33064047|NCT05189652|Experimental|Myofascial Release and Exercise Group|Foam roller massage will be applied to the thoracolumbar posterior chain for participants in the myofascial release and exercise group. At the same time, balance training, squat exercises, reach forward with sitting and hamstring stretching exercises will be applied to this group for a period of four weeks. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
33064048|NCT05189652|Experimental|Exercise Group|For the participants in the exercise group, the exercise program (balance training, squat exercises, reach forward with sitting and hamstring stretching exercises) will be applied 3 days a week for 4 weeks without any intervention to the thoracolumbar fascia. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
33064049|NCT05189652|No Intervention|Control Group|Any myofascial release or exercise program will not be applied to the participants in the control group. The first evaluation of the participants will be made before other groups starting the 4-week program. Final assessments will be made within 2-3 days after the other groups 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
33064050|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064051|NCT05168085|Experimental|Intervention group|One chicken egg per day
33064052|NCT05168085|No Intervention|Control group|True control
33064053|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
33360941|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
33360942|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
33360943|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
33360944|NCT01355354|Experimental|1|Digoxin
33360945|NCT01355354|Experimental|2|Fostamatinib
33360946|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
33064054|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
33064055|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
33064056|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
33064057|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
33064058|NCT01053988|Placebo Comparator|Placebo|Placebo
33064059|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
33064060|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
33064061|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
33064062|NCT00430612||1|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
33064063|NCT05142618|Active Comparator|Standard Post-operative Instructions|Participants in the control group will be told upon post-operative discharge that they should follow the post-operative instructions.
33064064|NCT05142618|Experimental|Supervised Physical Therapy|Participants in the physical therapy group will be scheduled for visits to the physical therapy clinic beginning two weeks after surgery, and will undergo supervised physical therapy treatments approximately twice per week for eight weeks according to a standardized evidence-based post-operative abdominal core surgery rehabilitation program.
33064065|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
33064066|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
33064067|NCT00430651|Experimental|1|Docetaxel + Carboplatin
33064068|NCT00430651|Experimental|2|Docetaxel
33064069|NCT00430690||1|Cocaine dependent subjects
33064070|NCT00430690||2|Healthy controls
33064071|NCT00430690||3|Siblings of cocaine dependent subjects
33064072|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
33064073|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
33064074|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
33064075|NCT00430846|Experimental|A|
33064076|NCT00430885|Placebo Comparator|Saline|
33064077|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
33064078|NCT00430924|Active Comparator|1|Eplerenone
33064079|NCT00430924|No Intervention|2|Control
33064080|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
33360947|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
33064081|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
33064082|NCT05102409|Experimental|Reproxalap Ophthalmic Solution (0.25%)|Single dose
33064083|NCT05102409|Active Comparator|Xiidra® (5% lifitegrast ophthalmic solution)|Single dose
33064084|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
33064085|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
33064086|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
33064087|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
33064088|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
33064089|NCT05089071|Experimental|CADe group|Endoscopists perform colonoscopy with CADe system
33064090|NCT05089071|No Intervention|Control|Endoscopists perform colonoscopy without CADe system
33064091|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
33064092|NCT05088603|Experimental|Clear Mask|Subjects randomized to this group will have a neurologist who wears a clear mask during their procedure and during their interaction with the subject.
33336391|NCT04058080|Experimental|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
33360948|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
33360949|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
33360950|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
33360951|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
33064093|NCT05088603|No Intervention|Standard Mask|Subjects randomized to this group will have a neurologist who wears a standard mask during their procedure and during their interaction with the subject.
33064094|NCT00096863|Placebo Comparator|A - placebo|per oral pill
33064095|NCT00096863|Active Comparator|B|Ziprasidone
33064096|NCT00096863|Active Comparator|C|Haloperidol
33064097|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
33064098|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
33064099|NCT00431080|Experimental|1|FEC -> TXT
33064100|NCT00431080|Experimental|2|FEC -> TXL
33064101|NCT00431158|Active Comparator|1|ARDSnet Protocol
33064102|NCT00431158|Active Comparator|2|OLA Protocol
33064103|NCT05076708|Other|IQOS|
33064104|NCT00097058||1|Continue current hormone therapy
33064105|NCT00097058||2|Taper off hormone therapy
33064106|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
33064107|NCT00431275|Experimental|Current Formulation|Current Formulation
33064108|NCT00431353|Experimental|1|
33064109|NCT00431353|Experimental|2|
33064110|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
33064111|NCT00130845|Placebo Comparator|Placebo|
33064112|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
33064113|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
33064114|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
33064115|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
33064116|NCT05049057|Experimental|Active Drug|Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
33064117|NCT05049057|Placebo Comparator|Placebo|Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
33064118|NCT04703803|Experimental|1% lidocaine injection|The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
33064119|NCT04703803|No Intervention|Control Group|The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
33064120|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
33064121|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
33064122|NCT04703530|Experimental|Hot footbath effect on schizophrenia patient' sleep quality|Participants were randomly allocated to the experimental group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks. The CPSQI was used to collect the pre- and post-test data.
33336392|NCT04058080|Active Comparator|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
33336393|NCT04058080|No Intervention|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
33336394|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
33336395|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
33336396|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
33336397|NCT00046839|Experimental|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
33064123|NCT04703530|No Intervention|Routine care on schizophrenia patient' sleep quality|Participants were randomly allocated to the control group. They were given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data.
33064124|NCT05001828|Experimental|Previously Treated AML|Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood
33064125|NCT05001828|Experimental|Untreated AML With High Risk Features|Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality
33064126|NCT04703608|Experimental|Arm 1 of Cohort 1|Index Case / Household members Ivermectin / Ivermectin (with preventative package)
33064127|NCT04703608|Experimental|Arm 2 of Cohort 1|Index Case / Household members Ivermectin / Placebo (with preventative package)
33064128|NCT04703608|Placebo Comparator|Arm 3 of Cohort 1|Index Case / Household members Placebo / Placebo (with preventative package)
33064129|NCT04703608|Experimental|Arm 1 of Cohort 2|Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
33064130|NCT04703608|Placebo Comparator|Arm 2 of Cohort 2|Non identical placebo; doses as per above
33064131|NCT04703452||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test at least 6 months before inclusion in the study.
33064132|NCT05001789|Experimental|Active|Working memory training with task-difficulty increasing across sessions
33064133|NCT05001789|Active Comparator|Sham|Working memory training with task-difficulty remaining constant across sessions.
33064134|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
33064135|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
33064136|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
33064137|NCT01052116|Placebo Comparator|Placebo|Matching placebo
33064138|NCT04727073|Experimental|Arm A|Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L.
33064139|NCT04727073|Placebo Comparator|Arm B|Placebo Comparator: Placebo Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
33064140|NCT04993833||Patients|Patients with risk of cerebral edema.
33064141|NCT04993833||Healthy Control|Staff/Faculty who interact with patients at the enrolling site.
33064142|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
33064143|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
33064144|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
33064145|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
33064146|NCT00400478|Active Comparator|A|Treatment
33064147|NCT00400478|No Intervention|B|Observation
33064148|NCT04990206|Experimental|Intervention|TranS-C
33064149|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
33064150|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
33064151|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
33064152|NCT04703374|Experimental|A|Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
33336398|NCT00046839|Experimental|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
33336399|NCT00046839|Experimental|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
33336400|NCT00006903|Experimental|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
33064153|NCT04703374|Experimental|B|Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
33064154|NCT04703374|Experimental|C|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
32740527|NCT04983147|Experimental|powerpoint presentation with computer|The presentation prepared based on the Health belief model was used in group training.
33064155|NCT04703374|Experimental|D|Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
33064156|NCT04703374|Experimental|E|Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
33064157|NCT04703374|Experimental|F|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
33064158|NCT04972071|Other|CSRS practice recommendation|Knowledge translation of the Canadian Syncope Risk Score (CSRS) based practice recommendations
33064159|NCT00432055|Experimental|I|Botox
33064160|NCT00432055|Placebo Comparator|II|
33064161|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
33064162|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
33064163|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
33064164|NCT00432211|Placebo Comparator|1|Complete Scar Excision
33064165|NCT00432211|Placebo Comparator|2|Staged Excision of scar
33064166|NCT04711044|Experimental|Study group|
33064167|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
33064168|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
33064169|NCT00131079|Active Comparator|Control|
33064170|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
33064171|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
33064172|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
33064173|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
33064174|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
33064175|NCT00432406|Active Comparator|1|infliximab
33064176|NCT00432406|Active Comparator|2|etanercept
33064177|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
33064178|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
33064179|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
33064180|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
33064181|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
33419400|NCT04473963|No Intervention|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
33419401|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
33064182|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
33064183|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
33064184|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
33064185|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
33064186|NCT04909086|Active Comparator|Standard Physical Therapy|Control group for the study.
33064187|NCT04909086|Experimental|Open Kinetic Chain|Standard care in addition to open kinetic chain exercises for the knee joint muscles.
33064188|NCT04909086|Experimental|Closed Kinetic Chain|Standard care in addition to closed kinetic chain exercises for the knee joint muscles.
33064189|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
33064190|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
33064191|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
33064192|NCT02273479|Experimental|Asasantin®|
33064193|NCT02273479|Placebo Comparator|Placebo|
33064194|NCT02273518|Experimental|Asasantin ER, new formulation I|
33064195|NCT02273518|Experimental|Asasantin ER, new formulation II|
33064196|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
33064197|NCT00432640|Experimental|1|Endoscopic ultrasound staging
33064198|NCT00432640|Active Comparator|2|Surgical staging
33064199|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
33064200|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
33064201|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
33064202|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
33064203|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
33064204|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
33064205|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
33064206|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
33064207|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
33064208|NCT00432913|Active Comparator|1g EPA per day|
33064209|NCT00432913|Active Comparator|2g EPA per day|
33064210|NCT00432913|Placebo Comparator|Placebo|
33064211|NCT04703491|Experimental|Full intervention|This group receives the full-featured intervention, including CCBT, CBM, Mindfulness, chatbot with many interactive elements.
33064212|NCT04703491|Active Comparator|Limited CCBT control group|This group receives feature-limited intervention (text-based computerized CBT)
33064213|NCT04703491|Other|Waitlist control group|This group receives waitlist control.
33064214|NCT04867590|Experimental|EndoRotor|"The ENDOROTOR is a new system for the resection of superficial lesions within the digestive tract and composed of a reusable generator, a single-use probe and additional accessories.~The device is used in the resection of mucosa in the digestive tract: flat or slightly raised lesions in the digestive mucosa, or treatment of the lateral margins following a resection carried out using another technique.~Resected tissue is aspirated away through a rotating catheter: the cutting and removal of tissue as well as the collection of specimens are combined into one act."
33064215|NCT04867590|Active Comparator|Radiofrequency|Endoscopic treatment using the HALO® 360 or 90 system is a thermal ablation system for superficial mucosa. First and foremost, the examination includes an endoscopy to locate the upper limits of the BE and its distribution, so as to choose the most appropriate type of probe. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.
33064216|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
33064217|NCT01580371|Experimental|Treatment|CKD-581
33064218|NCT04703218|Experimental|Patients with stroke and olfaction disorder benefiting from specific olfaction training.|
33156038|NCT04117789|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
33064219|NCT04703218|No Intervention|Patients with stroke and olfactory disorder benefiting from standard post-stroke rehabilitation|
33064220|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
33064221|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
33064222|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
33419402|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
33114694|NCT04607811|Experimental|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
33114695|NCT00555308|Experimental|one|undergo EDTU
33114696|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
33336401|NCT00026793||Kaposi's Sarcoma|Adult patients with biopsy-proven cutaneous Kaposi's sarcoma. Some participants received interleukin-12 and liposomal doxorubicin. However, the therapy was administered on a different protocol and was not part of this study.
33336402|NCT03951597|Experimental|Combined therapy using Gemox, Lenvatinib and PD1|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~Lenvatinib (8mg/d), continuous use for 1 year.~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
33114697|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
33114698|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
33114699|NCT01640756|Experimental|AqueSys Microfistula Implant|
33114700|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
33114701|NCT01636817|Experimental|60 mg|
33336403|NCT03954561|Experimental|endoscopist group|endoscopist-administered abdominal compression group
33336404|NCT03954561|Active Comparator|assistant group|assistant-administered abdominal compression group
33336405|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
33336406|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
33336407|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
33336408|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
33336409|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
33336410|NCT03951519|Experimental|Water|
33336411|NCT03951519|Active Comparator|Physiological serum|
33336412|NCT01100463|Placebo Comparator|Placebo Lotion|
33336413|NCT01100463|Experimental|0.1% Uracil|
33336414|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
33336415|NCT03726762|Experimental|Water|'Water' after the main meal
33336416|NCT01101009|Active Comparator|Perindopril+amlodipine|
33336417|NCT01101009|Active Comparator|Olmesartan/amlodipine|
33336418|NCT05665296|Experimental|cervicothoracic mobilization|This group will receive cervicothoracic mobilization with comprehensive corrective exercise
33336419|NCT05665296|Active Comparator|control group: comprehensive corrective exercise (CCE).|This group will receive traditional treatment comprehensive corrective exercise (CCE).
33336420|NCT01101087|Experimental|Taurolock|
33336421|NCT01101087|Placebo Comparator|Placebo|
33336422|NCT03951363|No Intervention|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
33336423|NCT03951363|Other|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
33336424|NCT03561090|Experimental|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
33336425|NCT03561090|Placebo Comparator|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
33336426|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
33336427|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
33336428|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
33336429|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
33336430|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
33336431|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
33336432|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
33419403|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
33419404|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
33064223|NCT01051063|Experimental|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
33064224|NCT01051063|Experimental|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
33064225|NCT04702906|Active Comparator|control group|All patients will continue to receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation, and antiarrhythmic agents if indicated.
33064226|NCT04702906|Active Comparator|trimetazidine group|"The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride metacardia ® (20 mg three times daily produced by Pharco-Egypt) will be administered twice every 24 hours until at least treatment is no longer needed."
33064227|NCT04702945||Registry participants|Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.
33064228|NCT04702828||Fallers group|1.60 years to 99 years old 2. have a recent fall within two months 3.can understand and answer the questions 4.can give their informed consent
33064229|NCT04702828||Non-fallers group|1.60 years to 99 years old 2. have any fall experiences in past year 3.can understand and answer the question 4.can give their informed consent
33064230|NCT00433186|Experimental|A|Mycophenolate
33064231|NCT00433342|Experimental|I|Flucloxacillin
33064232|NCT00433342|No Intervention|II|
33064233|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
33064234|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
33064235|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
33064236|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
33064237|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
33064238|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
33064239|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
33064240|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
33064241|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
33064242|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
33064243|NCT04804098|Active Comparator|15 Minute Non-linear Compression Profile|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
33064244|NCT04804098|Active Comparator|15 Minute Linear Compression Profile|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
33064245|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
33064246|NCT00433615|Experimental|1|
33064247|NCT00433615|Experimental|2|
33064248|NCT04779918|Other|OviTex Reinforced Tissue Matrix|This is a single-arm study. All study subjects will receive OviTex.
33064249|NCT00433693|Experimental|1|
33064250|NCT00433849|Experimental|1|
33064251|NCT00433849|Experimental|2|
33068321|NCT04511026|Experimental|Lymphoseek/SPECT-CT/Indocyanine|The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
33114702|NCT01636817|Experimental|120 mg|
33064252|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
33064253|NCT04778085||IMR patients|Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
33064254|NCT04778085||IMR therapists and other staff|Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
33064255|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
33064256|NCT00433888|Experimental|1|
33064257|NCT00433888|Experimental|2|
33336433|NCT00006489|Active Comparator|Naltrexone alone|Naltrexone alone
33336434|NCT00006489|Active Comparator|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
33114703|NCT01636817|Experimental|240 mg|
33336435|NCT00006489|Active Comparator|Placebo with CBT for PTSD|Placebo with CBT for PTSD
33336436|NCT00006489|Placebo Comparator|Placebo alone|Placebo alone
33336437|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
33336438|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
33064258|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
33064259|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
33336439|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
33336440|NCT01096095|Placebo Comparator|Placebo|Placebo
33336441|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
33336442|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
33336443|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
33336444|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
33336445|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
33336446|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
33336447|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
33336448|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
33064260|NCT04703023||COPD|Secretions are collected from Bronchoscopy in clinical routine in COPD patients
33064261|NCT04703023||lung healthy|Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients
33064262|NCT04702867||Periodontal bone loss group|The cases with level of alveolar crest more than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
33064263|NCT04702867||Healthy group|The cases with level of alveolar crest equal to or less than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
33064264|NCT04702633||Confirmed diagnosis group|Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
33064265|NCT04702633||Pre-diagnosis group|Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
33064266|NCT04762446||SSI group|Participants who developed surgical site infection (SSI) based on the definition of Centre for Disease Control and Prevention.
33064267|NCT04762446||Non-SSI group|Participants who did not develop SSI.
33064268|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
33064269|NCT04702594|Experimental|UHR and SRH|All patients over the age of 60 present in the UHR and hospitalized in SRH with behavioral disorders in the context of a neurocognitive disorder
33064270|NCT00434005|Experimental|Diesel Exhaust|
33064271|NCT00434005|Sham Comparator|Filtered Air|
33064272|NCT00131547|No Intervention|1|Usual Clinical Care
33064273|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
33114704|NCT01636817|Placebo Comparator|Placebo|
33336449|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
33336450|NCT00025233|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
33336451|NCT03535740|Experimental|Brigatinib 90 mg/180 mg with Optional Dose Escalation to 240 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
33064274|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064275|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
33064276|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
33064277|NCT04751409|Experimental|Group 1, Arm I (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years consisting of restaging with CT-chest and imaging of the primary site.
33064278|NCT04751409|Experimental|Group 1, Arm II (limited follow-up)|Patients undergo limited follow-up every 6 months for 2 years consisting of restaging with either CT-chest or CXR and imaging of the primary site.
33064279|NCT04751409|Experimental|Group 2 (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years as in Group 1, Arm I.
33064280|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
33064281|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
33064282|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
33064283|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
33064284|NCT01059448|Experimental|Placebo Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered matching placebo in parent study 20090061 and were administered 210 mg subcutaneous (SC) AMG 827 at Day 1, Week 1, Week 2, and every other week thereafter (Q2WK). Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
33064285|NCT01059448|Experimental|70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 70 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2 and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
33064286|NCT01059448|Experimental|140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK|Participants who were administered 140 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
33064287|NCT01059448|Experimental|210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 210 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
33064288|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
33064289|NCT01058434|Experimental|TKI258|
33064290|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
33064291|NCT04648956||Knee/Hip osteoarthritis|Patients referred for physical therapy rehabilitation
33064292|NCT04702516|Experimental|Semaglutide|Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
33064293|NCT04702516|Placebo Comparator|Placebo|Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
33064294|NCT04702477|Experimental|Only Arm|This is a single-arm, paired-sample pilot intervention study among participants with pre-diabetes or diabetes. Goal to integrate a MBSR intervention into a group-based, lifestyle intervention among patients with prediabetes or diabetes in the primary care setting
33064295|NCT00099008|Experimental|Arm I|Genistein
33064296|NCT00099008|Placebo Comparator|Arm II|Placebo
33064297|NCT04643067|Active Comparator|0.15mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
33114705|NCT00564525|Placebo Comparator|1|
33114706|NCT00564525|Experimental|2|Amitriptyline given
33336452|NCT00025155|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
33336453|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
33336454|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
33064298|NCT04643067|Active Comparator|0.6mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
33064299|NCT04643067|Active Comparator|2mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
33064300|NCT04643067|Placebo Comparator|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
33064301|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
33064302|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
33064303|NCT01057147|Placebo Comparator|placebo eye drops|
33064304|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
33064305|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
33064306|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
33064307|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
33064308|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
33064309|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
33064310|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
33064311|NCT01052194|Experimental|25 mg b.i.d. VX-509|
33064312|NCT01052194|Experimental|50 mg b.i.d. VX-509|
33064313|NCT01052194|Experimental|100 mg b.i.d. VX-509|
33064314|NCT01052194|Experimental|150 mg b.i.d. VX-509|
33064315|NCT01052194|Placebo Comparator|Placebo|
33064316|NCT01051414|Experimental|BMS-790052 + BMS-650032|
33064317|NCT00434317|Experimental|ZOL446|
33064318|NCT04621149|Placebo Comparator|placebo|1 liter of filtered water
33064319|NCT04621149|Active Comparator|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
33064320|NCT04621149|Active Comparator|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
33064321|NCT04621149|Active Comparator|AS with ZA|1 liter of filtered water with AS and ZA
33064322|NCT04621149|Active Comparator|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
33064323|NCT04621149|Active Comparator|AS with FLG|1 liter of filtered water with AS and FLG
33064324|NCT04621149|Active Comparator|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
33064325|NCT04621149|Active Comparator|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
33064326|NCT00099203|Experimental|1|
33064327|NCT00099203|Active Comparator|2|
33064328|NCT04615650|Active Comparator|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
33064329|NCT04615650|Experimental|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
33064330|NCT04728542||Origine|Group of 70 subjects who will undergo a surgery with the ORIGIN PS System
33064331|NCT04728542||Vanguard|Group of 70 subjects who will undergo a surgery with the VANGUARD System
33336455|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
33336456|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
33336457|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
33336458|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
33336459|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
33336460|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
33336461|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
33336462|NCT02998996|Active Comparator|i.n. comparator|
33336463|NCT03663478|Active Comparator|Intervention|Ropivacaine
33064332|NCT04586127|Experimental|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
33064333|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
33064334|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
33064335|NCT04561596|Experimental|Autohypnosis|Use of virtual reality with head mounted display
33064336|NCT04561596|Other|Control|Treatment as usual
33064337|NCT00403650|Experimental|1|
33064338|NCT00403689|Experimental|x|capsules containing beta glycan
33064339|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
33064340|NCT00099515|Experimental|A|
33064341|NCT00099515|Experimental|B|
33064342|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
33064343|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
33064344|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
33064345|NCT00403806|Placebo Comparator|4|Intravenous saline
33064346|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
33064347|NCT00400595|Active Comparator|2|Mupirocin
33064348|NCT04464915|Experimental|Isopropyl alcohol swab every 10 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes for a total of one hour.
33064349|NCT04464915|Experimental|Isopropyl alcohol swab every 20 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 20 minutes for a total of one hour.
33064350|NCT04464915|No Intervention|No treatment arm|No intervention administered.
33064351|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
33064352|NCT04728698|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
33064353|NCT04728698|Placebo Comparator|Placebo|Excipient
33064354|NCT04447872|Active Comparator|Luteal phase ovarian stimulation (LPOS)|Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
33064355|NCT04447872|Active Comparator|Luteal estradiol priming protocol|In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
33064356|NCT04440228|Experimental|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
33064357|NCT00099788|Experimental|1|Ranolazine
33064358|NCT00099788|Placebo Comparator|2|Placebo
33064359|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
33064360|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
33064361|NCT04387422|Experimental|150 mg/dL|Hyperglycemia target of 150 mg/dL
33064362|NCT04387422|Experimental|225 mg/dL|Hyperglycemia target of 225 mg/dL
33064363|NCT04387422|Experimental|300 mg/dL|Hyperglycemia target of 300 mg/dL
33064364|NCT04377009|Experimental|Active CBT-I|Internet-guided cognitive behavioral therapy
33064365|NCT04377009|Other|Control|Education control program
33064366|NCT00099866|Experimental|Vildagliptin|
33064367|NCT00099866|Active Comparator|Metformin|
33336464|NCT03663478|Placebo Comparator|Control|Isotonic saline
33336465|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
33064368|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
33064369|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
33336466|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
33336467|NCT04053322|Experimental|Study Arm|
33336468|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
33336469|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
33336470|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
33336471|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
33336472|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
33064370|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
33064371|NCT04352166|Experimental|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
33064372|NCT04352166|Active Comparator|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
33064373|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
33336473|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
33336474|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
33064374|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
33064375|NCT04333914|Experimental|Autophagy inhibitor (GNS651)|
33064376|NCT04333914|Other|Standard of care|
33064377|NCT04333914|Experimental|anti-NKG2A (Monalizumab)|
33064378|NCT04333914|Experimental|anti-C5aR (Avdoralimab)|
33064379|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
33064380|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
33064381|NCT04307433|Experimental|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
33064382|NCT04307433|Active Comparator|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
33064383|NCT04307433|Placebo Comparator|Arm 3|Control: non-narrative educational materials will be read
33064384|NCT00100295|Experimental|A|Herbal treatment
33064385|NCT00100295|Placebo Comparator|B|
33064386|NCT04247958||Robotic-assisted colorectal resection|Subjects with either a suspected or confirmed benign or malignant disease of the colon and rectum who are scheduled to undergo a robotic-assisted resection of the colon or rectum.
33064387|NCT04244058|Active Comparator|NMDA blocker|Comprehensive functional analyses of dynamic [18F]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second [18F]FPEB-PET will be acquired.
33064388|NCT04244058|Experimental|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of [18F]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each [18F]FPEB-PET acquisitions.
33336475|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
33064389|NCT00132444|Active Comparator|1|0.25% gel
33064390|NCT00132444|Active Comparator|2|0.1% gel
33064391|NCT00132444|Placebo Comparator|3|
33064392|NCT00132483|Experimental|Intervention arm|
33064393|NCT00132483|No Intervention|Control|
33064394|NCT00132522|Experimental|Arm 1|
33064395|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
33064396|NCT04728581|Placebo Comparator|Placebo|use of placebo during first 2 weeks after TKA surgery
33064397|NCT04728581|Experimental|Low dose Mirtazapine|Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg
33064398|NCT04728581|Experimental|Low dose Quetiapine|use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg
33064399|NCT04181853|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
33064400|NCT04181853|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
33064401|NCT04181853|No Intervention|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
33064402|NCT04728659|Experimental|Desogestrel Group|Ovulation inhibition will be performed using Desogestrel (75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first
33114707|NCT01634087|Experimental|100 mg QD Itacitinib|
33114708|NCT01634087|Experimental|100 mg QD Placebo|
33336476|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
33114709|NCT01634087|Experimental|200 mg QD Itacitinib|
33114710|NCT01634087|Experimental|200 mg QD Placebo|
33114711|NCT01634087|Experimental|200 mg BID Itacitinib|
33114712|NCT01634087|Experimental|200 mg BID Placebo|
33114713|NCT01634087|Experimental|600 mg once a day Itacitinib|
33114714|NCT01634087|Experimental|600 mg once a day Placebo|
33114715|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
33114716|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
33114717|NCT04607733|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
33336477|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
33336478|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
33114718|NCT04607733|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by subcutaneous injection (SC) via an autoinjector (AI)
33336479|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
33114719|NCT01632137|Placebo Comparator|Placebo (vehicle)|
33114720|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
33114721|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
33114722|NCT04607694|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
33114723|NCT04607694|Active Comparator|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
33114724|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:~completion of medical questionnaire and review of medical records~family tree (including questions on reproductive disorders and cleft lip/palate)~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing~hearing test~bone density~brain MRI~kidney, testicular/ovarian ultrasound"
33336480|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
33336481|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h~Radiography: confirmation balloon position~VIPUN Balloon Catheter~13C-Octanoate Breath Test o"
33336482|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Test"
33114725|NCT01601171||Family members|"Family members of Patients will be recruited for:~completion of medical questionnaire~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing"
33336483|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Testt"
33336484|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age > 18~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
33336485|NCT01069588||Calaxo|Received Calaxo screw
33336486|NCT01069588||Milagro|Received a Milagro screw
33336487|NCT01063270|Active Comparator|Oral Antibiotics|
33114726|NCT04599699|Experimental|1|"Simultaneously integrated boost or sequential integrated boost~Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.~Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
33114727|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
33114728|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target~."
33114729|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
33114730|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
33336488|NCT01063270|Active Comparator|Topical Antibiotics and Laser treatment|
33336489|NCT00023673|Experimental|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
33064403|NCT04728659|Active Comparator|GnRH antagonist|Ovulation inhibition will be performed using ganirelix (Orgalutran, 0.25 mg/die) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.
33064404|NCT04729010|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
33064405|NCT04729010|Active Comparator|Randomized Subjects receive a real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
33064406|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
33064407|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
33064408|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
33064409|NCT04728386|Experimental|curcumin irrigant|final flush root canal irrigation with 5 ml curcumin solution
33064410|NCT04728386|Experimental|sodium hypochlorite|final flush root canal irrigation with 5 ml sodium hypochlorite
33064411|NCT04140279|Experimental|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
33064412|NCT04140279|Placebo Comparator|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
33064413|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
33064414|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
33064415|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
33064416|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
33064417|NCT04107558|Experimental|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
33064418|NCT04107558|No Intervention|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
33064419|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
33064420|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
33064421|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
33064422|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
33064423|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
33064424|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
33064425|NCT00132834||Asthma/ICS|Asthmatic children on ICS
33064426|NCT00132834||Non-asthmatic children|Children without asthma
33064427|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
33064428|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064429|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
33064430|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
33064431|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
33064432|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
33064433|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
33064434|NCT02958293||December admission|The elective surgery group of people whose admission was the end of the calendar year (December) corresponding with insurance deductible year-end.
33064435|NCT02958293||Non-December admission|The elective surgery group of people whose admission was between January and November.
33336490|NCT00023673|Experimental|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
33336491|NCT00023673|Experimental|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
33064436|NCT00135408|Active Comparator|A1|
33064437|NCT00135408|Active Comparator|A2|
33064438|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
33064439|NCT00135447||A|
33064440|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
33064441|NCT00133068|Other|1|Control
33064442|NCT00133068|Experimental|2|Reduction of financial barrier
33064443|NCT00133068|Experimental|3|Computer Intervention
33064444|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
33064445|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
33064446|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
33064447|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
33064448|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
33064449|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
33064450|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
33064451|NCT00135525|Placebo Comparator|Placebo|
33064452|NCT00133146|Experimental|Grass MATA MPL|"300 SU/0.5 mL Grass MATA MPL (Visit 2);~800 SU/0.5 mL Grass MATA MPL (Visit 4);~2000 SU/0.5 mL Grass MATA MPL (Visit 6)"
33064453|NCT00133146|Active Comparator|Grass MATA|"300 SU/0.5 mL Grass MATA (Visit 2);~800 SU/0.5 mL Grass MATA (Visit 4);~2000 SU/0.5 mL Grass MATA (Visit 6);"
33064454|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
33064455|NCT00135603|Active Comparator|B|antibiotic therapy
33064456|NCT00133224|Experimental|1|
33064457|NCT00133224|Other|2|
33064458|NCT04728464||Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Patients will be treated by Periodontally Accelerated Osteogenic Orthodontics using fixed appliances.
33064459|NCT00133263|Experimental|1|
33064460|NCT00133263|Active Comparator|2|
33064461|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
33336492|NCT00023673|Experimental|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
33336493|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
33336494|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
33336495|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
33336496|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
33336497|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~Atezolizumab (IV) every 3 weeks (q3w)]~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
33336498|NCT00006237|Active Comparator|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
33419405|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
33419406|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
33064462|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
33064463|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
33064464|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
33064465|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
33064466|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
33064467|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
33064468|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
33064469|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
33064470|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
33064471|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
33064472|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
33064473|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
33064474|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
33064475|NCT00135759|Placebo Comparator|Group 1|Drug
33064476|NCT00135759|Experimental|2|experimental
33064477|NCT00135759|Experimental|3|experimental
33064478|NCT00403923||Patients with known lactose intolerance|
33064479|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
33064480|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
33064481|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
33064482|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
33064483|NCT05449977||Patients with Schizophrenia|20 patients with schizophrenia will be conducted
33064484|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
33064485|NCT00136032|Active Comparator|1|
33064486|NCT00136032|Placebo Comparator|2|
33064487|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
33064488|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
33064489|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
33064490|NCT04726839||Stroke suspicion|Patients with stroke suspicion within 24 hours of stroke's symptoms
33064491|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
33064492|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
33064493|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
33064494|NCT00401063|Other|Single arm|Acupuncture treatment
33064495|NCT00136305|Experimental|Pictorial Asthma Action Plan|
33064496|NCT00136305|Active Comparator|Written Asthma Action Plan|
33064497|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064498|NCT05443256|Experimental|Theta Stim|To stimulate fMRI-informed individualized targets in dlPFC to diminish affective modulation of the RewP. Based on our working hypothesis, TMS Figure-8 coil stimulation should diminish affective modulation of RewP amplitude when compared to sham.
33064499|NCT05443256|Sham Comparator|Sham Stim|Sham stimulation. The Reward Positivity should be unaffected.
33064500|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
33064501|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
33064502|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
33064503|NCT00103454|Experimental|Arm 1|
33064504|NCT00133887|Experimental|1|patients receiving Rapamycin
33064505|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
33064506|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
33064507|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
33064508|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
33064509|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
33064510|NCT00103727|Placebo Comparator|placebo|placebo
33064511|NCT00103727|Active Comparator|risperidone|3mg twice a day
33064512|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
33064513|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
33064514|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
33419407|NCT04373031|Experimental|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
33064515|NCT00133965||1|Dignity Psychotherapy
33064516|NCT00133965||2|Supportive Psychotherapy
33064517|NCT00133965||3|Standard Palliative Care
33064518|NCT00103922|Experimental|Arm 1|
33064519|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
33064520|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
33064521|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
33064522|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
33064523|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
33064524|NCT04729088|Experimental|Test Drug|Isosorbide 0.5% gel
33064525|NCT00136734|Experimental|1|methylphenidate
33064526|NCT00136734|Placebo Comparator|2|placebo
33064527|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
33064528|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
33064529|NCT00134277|Active Comparator|Laser therapy|
33064530|NCT00134277|Placebo Comparator|Infragenual dilatation|
33064531|NCT00136890|No Intervention|1|Conventional Staging
33064532|NCT00136890|Experimental|2|PET Imaging
33064533|NCT05449626||Alzheimer's disease group|
33064534|NCT05449626||Healthy Group|
33064535|NCT00104312||1|Participants with symptomatic knee osteoarthritis
33064536|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
33064537|NCT00134355|Experimental|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
33064538|NCT00104585||1|People with young onset Parkinson's disease and their family members
33064539|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
33064540|NCT00104741|Active Comparator|radiotherapy alone|
33064541|NCT00104741|Experimental|Radiotherapy + androgene deprivation|
33064542|NCT00137202|Active Comparator|2|
33064543|NCT00137241||Group 1|
33064544|NCT04728503|Experimental|5-Minute Mindful Movement Video|5 minute mindful movement video watched in the exam room on an iPad
33064545|NCT04728503|Placebo Comparator|Written Educative Materials|1 page printed written educative material about mindfulness benefits read for 5 minutes in the exam room
33064546|NCT05441826|Experimental|VB119|VB119 100 or 200mg IV doses administered 4 times
33064547|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
33064548|NCT00134628|Sham Comparator|B|Normal Air
33064549|NCT00105053|Experimental|vaccine group|
33064550|NCT00134745|Active Comparator|4 mg estradiol|
33064551|NCT00134745|Placebo Comparator|2 mg estradiol|
33064552|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
33064553|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
33064554|NCT00105365|Placebo Comparator|walking shoes|walking shoes
33064555|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
33064556|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
33064557|NCT00105599|Other|Arm 1|
33064558|NCT01058707|Experimental|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
33064559|NCT01058707|Experimental|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
33064560|NCT01058707|Experimental|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
33064561|NCT01058707|Experimental|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
33064562|NCT01058707|Experimental|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
33064563|NCT01058707|Experimental|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
33064564|NCT01058707|Experimental|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
33064565|NCT00105638|Other|Arm 1|
33064566|NCT00105677||Group 1|
33064567|NCT00105716|Other|Arm 1|
33064568|NCT00105755|Other|Arm 1|
33064569|NCT00105794|Other|Arm 1|
33064570|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
33064571|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
33064572|NCT00105833|No Intervention|Arm 2|Treatment as usual
33064573|NCT03277495|Active Comparator|nicotine SREC|The liquid in the e-cigarette refills contains nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon.
33064574|NCT03277495|Placebo Comparator|placebo SREC|The liquid in the e-cigarette refills does not contain nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon.
33064575|NCT00137787|Experimental|1|
33064576|NCT00137787|Active Comparator|2|
33064577|NCT04702048|Experimental|Aflibercept injection|Intravitreal injection of Aflibercept
33336499|NCT00006237|Experimental|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
33336500|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
33336501|NCT04056988|Experimental|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
33336502|NCT04057066|Experimental|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
33336503|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
33064578|NCT04702048|Placebo Comparator|Sham injection|Empty syringe with no needle
33336504|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
33336505|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
33336506|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
33064579|NCT00434551||1|Patients with suspected Crohn's disease
33064580|NCT00105872|Other|Arm 1|
33064581|NCT00105911|Other|Arm 1|
33064582|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
33064583|NCT00434824|Placebo Comparator|Arm 2|Placebo
33064584|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
33064585|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
33064586|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
33064587|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
33064588|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
33064589|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
33064590|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
33064591|NCT00135135|Other|1|
33064592|NCT03278080|Other|driving test|
33064593|NCT04702282||unilateral Total knee arthroplasty|Patients receiving unilateral Total knee arthroplasty
33064594|NCT04702282||simultaneous bilateral Total knee arthroplasty|Patients receiving simultaneous bilateral Total knee arthroplasty y
33064595|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
33064596|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
33064597|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
33064598|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
33064599|NCT00435331|Experimental|1|Open Label
33064600|NCT00137865|Experimental|EGEN-001|
33064601|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
33064602|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
33064603|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
33064604|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
33064605|NCT00435799|Active Comparator|A|
33064606|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
33064607|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
33064608|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
33114731|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
33336507|NCT04056754|Experimental|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
33336508|NCT04056754|Placebo Comparator|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
33064609|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
33064610|NCT04702321||Patient cohort|Patients with clinical data and biospecimens
33064611|NCT00436033|Placebo Comparator|Placebo|
33336509|NCT04056442|Experimental|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
33336510|NCT04056442|Placebo Comparator|Placebo|Olive Oil Solution
33336511|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
33336512|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
33336513|NCT03663244|No Intervention|Wait-list|Usual practice
33336514|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
33336515|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
33336516|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
33336517|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
33336518|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
33336519|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
33064612|NCT00436033|Experimental|Minalcipran|
33064613|NCT04702399|Experimental|GEL GROUP|Intracavitary application of an anti-adhesion hyaluronic acid gel (HYALOBARRIER® GEL ENDO)
33064614|NCT04702399|No Intervention|CONTROL GROUP|No Intervention
33064615|NCT03275857|Other|Cisplatin|
33064616|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
33064617|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
33064618|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
33064619|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
33064620|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
33064621|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
33064622|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
33064623|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
33064624|NCT03273322|Experimental|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
33064625|NCT03273322|Experimental|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90~should be taken between 8 and 10 AM"
33064626|NCT03273322|Active Comparator|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
33064627|NCT04702087|Experimental|OLEP|Omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
33064628|NCT04702087|Placebo Comparator|Placebo|isocaloric formula
33064629|NCT04701970|Other|changes in the occlusal load distribution|A crossover clinical study was carried out with previously constructed and used conventional complete dentures before relining with soft denture liners and then with the same dentures after relining with soft denture liners. patients were comfortably using their relined mandibular complete dentures for at least three months and the retention and stability of the conventional dentures were assessed before second recording of occlusal parameter. The evaluation of occlusal force distribution was carried out with the aid of T-Scan device
33336520|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
33336521|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
33336522|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
33360952|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
33360953|NCT03740113|No Intervention|Control|Control arm receives no intervention
33336523|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
33336524|NCT04056676|Active Comparator|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
33064630|NCT04702009|Active Comparator|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy
33064631|NCT04702009|Experimental|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy
33064632|NCT00106145|Experimental|Part I - Arm 1|
33064633|NCT00106145|Experimental|Part II - Arm 1|
33064634|NCT00106145|Experimental|Part III - Arm 1|
33064635|NCT00106145|Experimental|Part IV - Arm 1|
33064636|NCT00106145|Experimental|Part V - Arm 1|
33064637|NCT04701697|Active Comparator|active comparator：HumanAlbumin|Participants received HumanAlbumin 10g/d
33064638|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 10g|Participants received Recombinant Human Albumin Injection 10g/d
33064639|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 20g|Participants received Recombinant Human Albumin Injection 20g/d
33064640|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 30g|Participants received Recombinant Human Albumin Injection 30g/d
33064641|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
33064642|NCT04701775|Experimental|Lactobacillus rhamnosus GG Group|Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.
33064643|NCT04701775|Experimental|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group|Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.
33064644|NCT04701775|Placebo Comparator|Placebo|Those participants received placebo capsule once a day for 8 weeks.
33064645|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
33064646|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
33064647|NCT04701892||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
33064648|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
33064649|NCT00436150|Active Comparator|B|Participants will receive standard care
33064650|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
33064651|NCT00142623|No Intervention|2|Usual care
33064652|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
33064653|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
33064654|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
33064655|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
33064656|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
33064657|NCT04701736|No Intervention|Routine Care|Routine care consists of an oncology pharmacist counselling the patient on supportive care medications prior to the patient getting his or her prescription dispensed.
33064658|NCT04701736|Active Comparator|Intervention|The intervention group will encompass the oncology pharmacist using the computer system to print a Picture Medication Calendar for the patient and use the calendar to explain supportive medications, in addition to routine care.
33064659|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
33064660|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
33064661|NCT00436423|Experimental|1|Gemcitabine with TS-1
33064662|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
33064663|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
33064664|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
33064665|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
33064666|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
33064667|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
33336525|NCT04056676|Experimental|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
33336526|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
33114732|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
33336527|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA <2
33336528|NCT04055506|Experimental|Combination Therapy|
33336529|NCT02993224|Experimental|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
33064668|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
33336530|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
33336531|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
33336532|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
33336533|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
32869863|NCT05538468||Stroke Patients Group|The kinesiophobia scores of the patients were evaluated by (Tampa Kinesiophobia Scale) and (Visual Analog Scale- Kinesiophobia Assessment), depression severity (Beck Depression Inventory), postural control (Postural Assessment Scale), pain severity (Visual Analog Scale).
32869864|NCT05696106||Patients initiating a biologic or immunosuppressive drug|"Patients initiating a biologic or immunosuppressive drug including small molecules for a first IMID (either IBD, inflammatory rheumatic diseases, or cutaneous psoriasis)~Conventional immunosuppressive drug including immunomodulators (thiopurines) and csDMARDs (methotrexate)~Anti-TNF (infliximab, adalimumab, golimumab, certolizumab, etanercept)~Biologics targeting the IL-12/IL-23 pathways (ustekinumab, risankizumab, guselkumab)~Biologics targeting the IL-6 pathways (tocilizumab, sarilumab)~Biologics targeting the IL-17 pathways (secukinumab, ixékizumab, brodalumab)~Biologics targeting cell adhesion, anti-integrins (vedolizumab)~JAK inhibitors (tofacitinib, baricitinib, upadacitinib)"
33064669|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
33064670|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
33064671|NCT00437320|Experimental|1|
33064672|NCT00437320|Placebo Comparator|2|
33064673|NCT00106496|Experimental|1A|
33064674|NCT00106496|Active Comparator|1B|
33064675|NCT00106496|Experimental|2|Open label
33064676|NCT00106496|Experimental|3A|
33064677|NCT00106496|Placebo Comparator|3B|
33064678|NCT00106496|Experimental|4|Open label
33064679|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
33064680|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
33064681|NCT00437437|Experimental|1|
33064682|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
33064683|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
33064684|NCT00106574|Experimental|1|
33064685|NCT00106574|Placebo Comparator|2|
33064686|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
33064687|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
33064688|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
33064689|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
33064690|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
33064691|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
33064692|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
33064693|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
33064694|NCT00437671|Experimental|Entered study|
33064695|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
33064696|NCT00437749|Active Comparator|CBT-1|
33064697|NCT00437749|Placebo Comparator|Placebo|
33064698|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
33064699|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
33336534|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
33336535|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
33336536|NCT03447314|Experimental|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
33336537|NCT03447314|Experimental|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
32869865|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
33064700|NCT03279094|Experimental|Haploidentical stem cell transplantation|
33064701|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
33064702|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
33064703|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
33064704|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
33064705|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
33064706|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
33064707|NCT04701541|Other|Obese Patients undergoing Bariatric Surgery|"Obesity is a progressively growing morbid condition in the world, and given the direct relationship between body mass index (BMI) and costs, this has a major impact on economic and health policy. Obese patients undergoing bariatric surgery are at high risk for postoperative respiratory complications. In these patients, postoperative respiratory complications are related to various pathophysiological mechanisms that include: decreased lung volumes, respiratory muscle dysfunction and atelectasis. Demographic (age, gender, BMI) and clinical features of the population included: ASA, comorbidity and pre and postoperative respiratory function [PaO2/FiO2, haemogasanalysis (EGA)]. Ultrasound evaluation of DIA was performed.~T0: preoperative within 24h before surgery: DIA, haemogasanalysis; T1: Post operation: 60 min after extubation: Aldrete Score, DIA, EGA; T2: Post operation: 240 min after extubation: Aldrete, EGA."
33064708|NCT04701463|Experimental|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement|
33064709|NCT04701463|Placebo Comparator|Placebo|
33064710|NCT03276793|Experimental|MRI and behavioral assessment for patients receiving TMS|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
33064711|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
33064712|NCT03279835||Absence of cognitive disorder|
33064713|NCT03279835||Asymptomatic cognitive disorder|
33064714|NCT03279835||Symptomatic cognitive impairment|
33064715|NCT03279835||HIV associated dementia|
33064716|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
33064717|NCT00106691|Experimental|toremifene 20mg|
33064718|NCT00106691|Placebo Comparator|Placebo|
33064719|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33064720|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33064721|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33064722|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33336538|NCT03447314|Experimental|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
33336539|NCT03447314|Experimental|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
33064723|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33064724|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
33064725|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
32869866|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
33064726|NCT00438568|Placebo Comparator|1|saline
33064727|NCT00438568|Experimental|2|10 Units
33064728|NCT00438568|Experimental|3|20 Units
33064729|NCT00438607|Other|1|BIIB014 at MTD from Part A
33064730|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
33064731|NCT00438607|Placebo Comparator|3|
33064732|NCT00438763||1|Subjects using the neoprene splint.
33064733|NCT00438763||2|Subjects using the orthoplast splint.
33064734|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
33064735|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
33064736|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
33064737|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.~--------------------------------------------------------------------------------"
33064738|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
33064739|NCT00439075|Experimental|CPAP|positive airway pressure
33064740|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
33064741|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
33064742|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
33064743|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
33064744|NCT00439348|Active Comparator|Verbal advice|
33064745|NCT00439426|Experimental|1|
33064746|NCT00439582|Experimental|1|
33064747|NCT00439582|Experimental|2|
33064748|NCT00439621|Experimental|1|
33064749|NCT00439621|Experimental|2|
33064750|NCT00439621|Experimental|3|
33064751|NCT00439621|Placebo Comparator|4|
33064752|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
33064753|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
33064754|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(4)|vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
33064755|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(5)|vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
33064756|NCT00439699|Experimental|Memantine|Tremor reduction
33064757|NCT00439816|Other|Arm 1|
33064758|NCT00439894||blood draw|One time blood draw
33064759|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
33064760|NCT04701229||normal karyotype|control group
33064761|NCT04701229||del5q-RBM22neg-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.
33064762|NCT04701229||del5q-RBM22neg-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7
33064763|NCT04701229||del5q-RBM22pos-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7
33064764|NCT04701229||del5q-RBM22pos-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7
33336540|NCT03447314|Experimental|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
33336541|NCT03447314|Experimental|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
32869867|NCT05591430|Active Comparator|Ganglion Impar Neurolysis|Block of ganglion impar using neurolytic
33064765|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
33064766|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
33064767|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
33064768|NCT00105586|Experimental|Escitalopram (1)|Escitalopram
33064769|NCT00105586|Placebo Comparator|Placebo (2)|Placebo
33064770|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33064771|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
33064772|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
33064773|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
33064774|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
33064775|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
33064776|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
33064777|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
33064778|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
33064779|NCT00440128|Active Comparator|Docetaxel|Docetaxel
33064780|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
33064781|NCT00440167|Active Comparator|Arm A|
33064782|NCT00440167|Active Comparator|Arm B|
33064783|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
33064784|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
33064785|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
33064786|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
33064787|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
33064788|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
33064789|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
33064790|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
33064791|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
33064792|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
33064793|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
33064794|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
33064795|NCT00440362|Active Comparator|T1|
33064796|NCT00440362|Active Comparator|T2|
33064797|NCT00440362|Active Comparator|T3|
33064798|NCT00440362|Active Comparator|T4|
33064799|NCT00440362|Active Comparator|T5|
33064800|NCT00440362|Active Comparator|T6|
33064801|NCT00440362|Active Comparator|T7|
33064802|NCT00440362|Active Comparator|T8|
33064803|NCT00440362|Placebo Comparator|C1|
33064804|NCT00440362|Placebo Comparator|C2|
33064805|NCT00440362|Placebo Comparator|C3|
33064806|NCT00440362|Placebo Comparator|C4|
33064807|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
33064808|NCT00440440|Active Comparator|1|testosterone gel
33064809|NCT00440440|Placebo Comparator|2|placebo gel
33064810|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
33064811|NCT00107588|Experimental|Reinforcement for homework completion|
33064812|NCT00107588|Active Comparator|Reinforcement for Abstinence|
33064813|NCT00107588|Active Comparator|Case Management|
33064814|NCT00440674|Experimental|1|Direct stenting technique
33064815|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
33064816|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
33064817|NCT00107627|Active Comparator|1|Skin staples;
33064818|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
33064819|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
33064820|NCT00440869|Experimental|N-acetylcysteine|Active
33064821|NCT00440869|Placebo Comparator|placebo|placebo
33064822|NCT00441025|Active Comparator|1|1 Alemtuzumab
33064823|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
33064824|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
33064825|NCT04700995|Experimental|ProTaper rotary NiTi instruments|The ProTaper Universal Retreatment rotary system and ProTaper Gold rotary system were used.
33064826|NCT04700995|Experimental|Hyflex EDM rotary NiTi instruments|Hyflex EDM rotary system was used.
33064827|NCT04700995|Experimental|Reciproc Blue reciprocating NiTi instruments|Reciproc Blue reciprocating system was used.
33064828|NCT04700995|Experimental|Waveone Gold reciprocating NiTi instruments|WaveOne Gold reciprocating system was used.
33064829|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
33064830|NCT00441298|Placebo Comparator|2|Universal HEC placebo
33064831|NCT00441376|Experimental|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
33064832|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
33064833|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
33064834|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
33064835|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
33064836|NCT00441610|Experimental|Gimatecan|
33064837|NCT00441688|Experimental|GI265235|
33064838|NCT04700683|Active Comparator|Noninvasive Peripheral Nerve Stimulation|NPNS device programmed to deliver active stimulation.
33064839|NCT04700683|Sham Comparator|Sham control|NPNS device programmed to deliver sham stimulation.
33064840|NCT02957344||Text without context|
33064841|NCT02957344||Text with context|
33064842|NCT02957344||Map without context|
33064843|NCT02957344||Map with context|
33064844|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
33064845|NCT03279445||African American|Patient of African American race
33064846|NCT03279445||Caucasian|Patient of Caucasian race
33064847|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
33064848|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
33064849|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
33064850|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
33064851|NCT00441922|Experimental|1|D
33064852|NCT00441922|Experimental|2|V
33064853|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
33068322|NCT04510207|Experimental|Investigational Vaccine 1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 & D21.
33064854|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi~SHUTi is delivered over 6 sessions, each taking 20-30 minutes~SHUTi is delivered by a virtual therapist~Participants will learn about the etiology and maintenance of their insomnia~Participants will learn how to maintain their sleep log~Participants will learn how to address lifestyle barriers that impact their sleep~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~Participants will be taught how to gradually expand their restricted sleep"
33064855|NCT04726293|Experimental|Mango beverage|Mango composite served as a frozen drink
33064856|NCT04726293|Placebo Comparator|Control beverage|Energy matched Control frozen drink
33064857|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
33064858|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
33336542|NCT03447314|Experimental|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
33336543|NCT03447314|Experimental|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
33336544|NCT03447314|Experimental|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
33336545|NCT03447314|Experimental|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
33336546|NCT03447314|Experimental|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
33064859|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
33064860|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
33064861|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
33064862|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
33064863|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
33064864|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
33064865|NCT00442624||1|Patients with chronic insomnia
33064866|NCT00442624||2|age, sex, bmi matched healthy controls
33064867|NCT00108173|Other|Arm 1|
33064868|NCT00442741|Experimental|Patupilone + Midazolam|
33064869|NCT00442741|Experimental|Patupilone + Omeprazole|
33064870|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
33064871|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
33064872|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
33064873|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
33064874|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
33064875|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
33064876|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
33064877|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
33064878|NCT00108251|Placebo Comparator|1|placebo tablet
33064879|NCT00108251|Experimental|2|eplerenone tablets
33064880|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
33064881|NCT00443014|No Intervention|B Care as usual|
33064882|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
33064883|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
33064884|NCT00443131|Experimental|Group A|
33064885|NCT00443131|Experimental|Group B|
33064886|NCT00443131|Experimental|Group C|
33064887|NCT00443248|Experimental|Vaginal Heat Wash-Out Device|
33064888|NCT04700254||working condition|In order to further explore the differences among working status the data will be categorized into three different groups: suspension of work, employment and unemployment.
33336547|NCT03447314|Experimental|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
33336548|NCT03447314|Experimental|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
33064889|NCT04700254||Family status|In order to xplore the differences among the family status, the data will be categorized into the married and the singles DM patients.
33064890|NCT04700254||BMI status|In order to further explore BMI scale results, we divided the data obtained from the participants into normal (18.50 - 24.99 kg/m2), overweight (25-29.99 kg/m2) and obese (≥30 kg/m2), according to the international classification of the World Health Organisation (WHO).
33064891|NCT04700020|Other|Patients above the age of 18 years|"In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.~MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland."
33064892|NCT04700332|Experimental|High risk prostate cancer|DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
33064893|NCT04700332|Experimental|Biochemically recurrent prostate cancer|DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
33064894|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
33064895|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
33064896|NCT00443404|Active Comparator|1|perioperative epidural analgesia
33064897|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
33064898|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
33064899|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
33064900|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
33064901|NCT04700293|Experimental|AYMES AMSTERDAM|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'AMSTERDAM' for a period of > 7 days.
33064902|NCT03278470|Experimental|HL237 50mg|take oral tablet once
33064903|NCT03278470|Experimental|HL237 100mg|take oral tablet once
33064904|NCT03278470|Experimental|HL237 200mg|take oral tablet once
33064905|NCT03278470|Experimental|HL237 400mg|take oral tablet once
33064906|NCT03278470|Experimental|HL237 800mg|take oral tablet once
33064907|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
33064908|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
33064909|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
33064910|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
33064911|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
33064912|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
33064913|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
33064914|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
33064915|NCT04726332|Experimental|XL102 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
33064916|NCT04726332|Experimental|XL102 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).
33064917|NCT04726332|Experimental|XL102 + Fulvestrant Dose-Escalation Cohorts|Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
33064918|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts|Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
33064919|NCT04726332|Experimental|XL102 + Fulvestrant Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).
33064920|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).
33064921|NCT04699825|Active Comparator|study group|new-born infants born from preeclampsia mother
33064922|NCT04699825|Other|control group|new-born infants born from mothers with normal pregnancy matched with the same gestational age, sex and race
33064923|NCT00443638|No Intervention|Control Group|Control Group
33064924|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
33064925|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
33064926|NCT00443677|Active Comparator|abvd|
33064927|NCT00443677|Experimental|beacopp|
33064928|NCT00443677|Experimental|coppebvcad|
33064929|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
33336549|NCT03447314|Experimental|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
33336550|NCT03447314|Experimental|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
33336551|NCT03447314|Experimental|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
33064930|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
33336552|NCT03447314|Experimental|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
33064931|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
33064932|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
33064933|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
33064934|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
33064935|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
33064936|NCT00443794|Active Comparator|8,H|Lipid lowering agent
33064937|NCT00443794|Active Comparator|9,A|Antiplatelet
33064938|NCT00108602|Other|1|
33064939|NCT00138684|Experimental|Venesection therapy|
33064940|NCT00138684|No Intervention|no venesection therapy|
33064941|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
33064942|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
33064943|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
33064944|NCT00444262|Active Comparator|1|conventional treatment
33064945|NCT00444262|Experimental|2|stroke volume optimisation
33064946|NCT03278236|Experimental|TRF|
33064947|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
33064948|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
33064949|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
33064950|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
33064951|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
33064952|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
33064953|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
33064954|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
33064955|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
33064956|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
33336553|NCT03447314|Experimental|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
33336554|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
33064957|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
33064958|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
33064959|NCT03275701|Other|Triumeq|Single Arm, Open Label
33064960|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
33064961|NCT00451165||colon|
33064962|NCT00451165||rectum|
33064963|NCT04698616||Malignant lymphoma patients|Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
33064964|NCT04698928|Experimental|Theta burst stimulation group|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
33068323|NCT04510207|Experimental|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 & D21.
33068324|NCT04510207|Placebo Comparator|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 & D21.
33114733|NCT04599114|Experimental|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
33064965|NCT04698772||Survey Packet 1 Group|"Patients who receive Packet 1 will be in group 1, or the treatment group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2. The physician will be asked to administer a sub-dissociative dose of ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)."
33064966|NCT04698772||Survey Packet 2 Group|"Patients who receive Packet 2 will be in group 2, or the control group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2.The physician will be asked to administer morphine 4 mg IV push over 3-5 minutes for pain control."
33064967|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
33064968|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
33064969|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
33064970|NCT00139074|Experimental|2|Quetiapine + sodium valproate
33064971|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
33064972|NCT00451867|Placebo Comparator|B|Placebo
33064973|NCT00143130|Experimental|Single Arm|
33064974|NCT04698733|Experimental|Experimental: BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive 2 treatments a week on nonconsecutive days for 6 weeks in the clinic with an active electrical stimulation device.
33064975|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 40 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 40 V.
33064976|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 60 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 60 V.
33064977|NCT00452218|Experimental|Open|
33064978|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
33064979|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
33064980|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
33064981|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
33064982|NCT03275077||Controls|Normal Healthy Volunteers
33064983|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
33064984|NCT03275038|No Intervention|Control group|Maintain the original life style
33064985|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
33064986|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
33064987|NCT00452257|Experimental|A|
33064988|NCT00452491|Experimental|1|
33064989|NCT00452491|Active Comparator|2|
33064990|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
33064991|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
33064992|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
33064993|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
33064994|NCT00452608|Placebo Comparator|amido pill|
33064995|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
33064996|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
33064997|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
33064998|NCT00452881|Experimental|study arm|GemOx
33064999|NCT00452881|Active Comparator|control arm|GemCis
33065000|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
33065001|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
33419408|NCT04373031|Experimental|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
33065002|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
33065003|NCT00453037|Other|delayed education|"delayed educational intervention~for further details please see brief description section"
33065004|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
33065005|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
33065006|NCT00453115|Experimental|study arm|GemOx
33065007|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
33065008|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
33065009|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
33065010|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
33065011|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
33065012|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
33065013|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
33065014|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
33065015|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
33065016|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
33065017|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
33065018|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
33065019|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
33065020|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
33065021|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
33065022|NCT00143559|Other|1|
33065023|NCT00453817|Experimental|Study subjects|One-arm observational study
33065024|NCT00143637|Experimental|2|Office dust with added glucan
33065025|NCT00143637|Experimental|1|Clean air exposures in climate chamber
33065026|NCT00109655|Experimental|1|
33065027|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
33065028|NCT03274843|Experimental|Patient with stroke|
33065029|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
33065030|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
33065031|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
33065032|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
33065033|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
33065034|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
33065035|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
33065036|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
33065037|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
33419409|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
33419410|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
33419411|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
33419412|NCT02624869|Experimental|Evolocumab|Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.
33419413|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
33065038|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
33065039|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
33065040|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
33065041|NCT00143676|Active Comparator|Atorvastatin|
33065042|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
33336555|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
33065043|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
33065044|NCT00454558|Experimental|Arm 1|
33065045|NCT00112749|Experimental|Study Arm|Please see intervention description
33065046|NCT00454714|Active Comparator|A|Sildenafil arm
33065047|NCT00454714|Placebo Comparator|B|Placebo arm
33065048|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
33065049|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
33065050|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
33065051|NCT00143715|Placebo Comparator|2|
33065052|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
33065053|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
33065054|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
33065055|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
33065056|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
33065057|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
33065058|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
33065059|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
33065060|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
33065061|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
33065062|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
33065063|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
33065064|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
33065065|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
33065066|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
33065067|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
33065068|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
33065069|NCT00455182|Placebo Comparator|1|Standard medical care
33065070|NCT00455182|Experimental|2|Acupuncture
33065071|NCT00455182|Sham Comparator|3|Sham acupuncture
33065072|NCT00455221|Experimental|Peptide Vaccine|
33065073|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
33065074|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
33065075|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
33065076|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
33065077|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
33065078|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
33336556|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
33336557|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
33336558|NCT05664620|No Intervention|Low risk|Standard of care to treat post-concussion symptoms in the community
33336559|NCT05664620|No Intervention|Medium risk|Patients who are assigned to the medium risk group will receive the same treatment as the low risk group for one month, after which they will be reassessed. If improving they will go into the low risk group, and if not improving they will go into the high risk group
33360954|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
33114734|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
33114735|NCT04599426|Experimental|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
33114736|NCT04607499||Pregnant women|Pregnant women without intervention
33114737|NCT04599348|Experimental|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
33114738|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
33114739|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
33114740|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
33336560|NCT05664620|Other|High risk|"A multidisciplinary individualized treatment (personalized medicine) model of treating all post-concussion symptoms simultaneously including the following:~Headache therapy, balance therapy, vestibular therapy, exercise therapy* mental health support e.g. CBT and/or mindfulness meditation* (with more specialized diagnosis and care where required), cognitive assessment and therapy, vision therapy, sleep assessment and therapy, physiotherapy, education sessions*, occupational therapy These patients will be treated through the Altum Health Neurology Specialty Program~*Offered to all high risk patients"
33336561|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
33336562|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
33336563|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
33336564|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
33336565|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
33336566|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
33336567|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
33336568|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
33336569|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
33336570|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
33336571|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
33336572|NCT03495908|Experimental|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
33336573|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
33336574|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
33336575|NCT05663528||orotracheal intubation group|Composed of Patients who were intubated after 48 hours of admission to the intensive care unit
33336576|NCT05663528||non-intubated group|Composed of patients who were not intubated during their stay in the intensive care unit
33336577|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
33336578|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
33336579|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
33336580|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
33336581|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
33336582|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
33336583|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
33336584|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
33065079|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
33065080|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
33065081|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
33065082|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
33065083|NCT00455767|Active Comparator|1|Depelestat
33065084|NCT00455767|Placebo Comparator|2|Placebo
33065085|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
33336585|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
33336586|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
33065086|NCT00455845|Active Comparator|1 levonorgestrel IUD|
33065087|NCT00455845|No Intervention|2 control|
33065088|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
33065089|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
33065090|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
33065091|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
33065092|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 40 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
33065093|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 20 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
33065094|NCT04698265|Experimental|CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)|CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).
33065095|NCT04698265|Placebo Comparator|Normal saline|4ml of normal saline
33065096|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
33065097|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
33336587|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
33336588|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
33336589|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
33336590|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
33336591|NCT02953262|Other|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
33336592|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
33336593|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
33336594|NCT03717818|Experimental|Good Psychiatric Management-Brief|
33336595|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
33336596|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
33336597|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
32869868|NCT05591430|Experimental|Bilateral S2, S3 and S4 Pulsed radiofrequency|Pulsed radiofrequency of S2-S4
33336598|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
33065098|NCT00456118||intervillites|20 women for intervillites will be included
33065099|NCT00110552|Experimental|1|Sage capsules taken by mouth
33336599|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
33336600|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
33336601|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
33336602|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
33065100|NCT00110552|No Intervention|2|No intervention, no-pill as control
33065101|NCT03274219|Experimental|bb21217 Experimental Arm|
33336603|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
33336604|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
33336605|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
33336606|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
33065102|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
33065103|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
33065104|NCT00456274|Other|1|
33065105|NCT00456313|Active Comparator|arm 1|
33065106|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
33065107|NCT00113139|Active Comparator|Usual Care|
33065108|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
33065109|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
33065110|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
33065111|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
33065112|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
33065113|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
33065114|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
33065115|NCT00143988||Treadmill Test exertion females|
33065116|NCT00143988||Treadmill test exertion males|
33065117|NCT00143988||Sexual activity exertion females|
33065118|NCT00143988||Sexual activity exertion males|
33065119|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
33065120|NCT03274141||RC Patients|RA patients managed with routine care(RC)
33065121|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
33065122|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
33065123|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
33065124|NCT00110747|Experimental|S-Caine Peel|
33065125|NCT00110747|Placebo Comparator|Placebo Peel|
33065126|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
33065127|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
33065128|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
33065129|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
33065130|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
33065131|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
33065132|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
33065133|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
33065134|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
33065135|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
33065136|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
33065137|NCT00465751|Placebo Comparator|B|placebo treatment
33065138|NCT00110981|Experimental|Single-arm|
33065139|NCT00465907|Experimental|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
33065140|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
33065141|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
33065142|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
33065143|NCT00111020|Experimental|Arm 1|
33065144|NCT00466063||ICL670|ICL670
33065145|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
33065146|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
33336607|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
33336608|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
33336609|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
33336610|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
33336611|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
33336612|NCT04055584||Sputum spot|
33336613|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
33336614|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
32869869|NCT00271219|Experimental|Buprenorphine|Buprenorphine
32869870|NCT00271219|Active Comparator|Methadone|Methadone
33065147|NCT00466375||A|Patients with a hemangioma.
33065148|NCT00466375||B.|Patients with a vascular anomaly.
33065149|NCT00111098|Experimental|darbepoetin alfa|
33065150|NCT00347659|Experimental|Single Treatment|Experimental Treatment
33065151|NCT00347737|Experimental|1|Teriparatide
33065152|NCT00111137|Active Comparator|rHuEPO|
33065153|NCT00111137|Experimental|Darbepoetin alfa|
33065154|NCT00347854|Experimental|FID 105783|
33065155|NCT00347854|Active Comparator|Visine|
33065156|NCT00347854|Active Comparator|Refresh Liquigel|
33065157|NCT00347854|Active Comparator|Refresh Plus|
33065158|NCT04714684|Experimental|fitostimoline proctogel|
33065159|NCT04714684|Experimental|fitostimoline proctogel + muscle relaxants|
33065160|NCT04714684|Experimental|muscle relaxants|
33065161|NCT00111176|Other|1|Endovascular Repair
33065162|NCT00111176|Other|2|Surgical
33065163|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
33065164|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
33065165|NCT00144456|Experimental|1|
33065166|NCT00144456|Active Comparator|2|
33065167|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
33065168|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
33065169|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
33065170|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
33065171|NCT00348517|Experimental|Systane|
33065172|NCT00348517|Active Comparator|Refresh|
33065173|NCT05595330|Experimental|intervention group|Patients in the intervention group were managed with an upper extremity lymphedema prevention program.
33065174|NCT05595330|No Intervention|control group|The control group received normal perioperative and chemotherapy nursing measures
33065175|NCT00348712|Active Comparator|A|
33065176|NCT00348712|Active Comparator|B|
33065177|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
33065178|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
33065179|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33065180|NCT04715113|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33065181|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33065182|NCT04715113|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
33065183|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
33065184|NCT00348829|No Intervention|2|conservative treatment
33065185|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
33065186|NCT00348868|Active Comparator|2|
33065187|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
33065188|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
33065189|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
33065190|NCT05595252||Patients with CIN lésions during pregnancy|
33065191|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
33065192|NCT00349102|Experimental|B|Breath holding during conformal radiation
33336615|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
33419414|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
32869871|NCT03340506|Experimental|dabrafenib monotherapy|"Patients in this study may receive:~- monotherapy of dabrafenib"
32869872|NCT03340506|Experimental|trametinib monotherapy|"Patients in this study may receive:~- monotherapy of trametinib"
33114741|NCT04607304|Experimental|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
33114742|NCT04599387|Active Comparator|Supervised Exercise arm|
33114743|NCT04599387|Placebo Comparator|Usual care arm|
33114744|NCT01303796|Experimental|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
33114745|NCT01303796|Active Comparator|Decitabine|Arm C Decitabine
33114746|NCT01117844|Experimental|Proton radiation|
33336616|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
32869873|NCT03340506|Experimental|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:~- the combination of dabrafenib and trametinib"
33114747|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
33336617|NCT02991430|Active Comparator|active|active neuromodulation
33336618|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
33114748|NCT04598880|Experimental|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
33114749|NCT04598880|Experimental|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
33114750|NCT04598646|Experimental|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management for the first 6 months and behavioural support for 2 years.~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker (e.g., Apple watch).~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
33114751|NCT04598646|Active Comparator|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information, and Young@Heart-based peer support provided to Support participants will be identical to what is provided to CORE participants. The key difference in the long-term behavioural support strategy between CORE and Support participants is how weekly exercise goals are defined. Unlike the CORE participants who will be encouraged to use the PAI Score, Support participants will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
33114752|NCT04598646|Active Comparator|Passive Behavioural Support (PBS) Groups|All PBS cohort participants will receive the same wrist-worn HR monitor and PA tracker as the CORE and Support participants. However, PBS participants will be blindly randomized to one of two passive behavioural support interventions (PBS1 and PBS2). PBS1 participants will be asked to download the same PAI Health application as CORE participants and will similarly be given the challenge of meeting and maintaining a weekly PAI Score ≥100 throughout the 18-month follow-up period. PBS2 participants will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week). PBS participants will not receive any additional interventions and will be followed up with and reassessed at 12- and 24-months.
33114753|NCT04598958|Experimental|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
33114754|NCT04598958|No Intervention|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
33114755|NCT04607655|Experimental|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
33114756|NCT04607655|Experimental|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
33114757|NCT04607655|Placebo Comparator|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
33156039|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
33336619|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
33336620|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
33336621|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
33336622|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
33360955|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
33360956|NCT01355432||Propofol|
33360957|NCT01132261|Active Comparator|1|brain preservation diet
33360958|NCT01132261|No Intervention|2|
33336623|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
33336624|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
33336625|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
33065193|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
33065194|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
33360959|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
33065195|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
33065196|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
33065197|NCT04729140|Active Comparator|Ivermectin plus Doxycycline|"Ivermectin 200 mcg/kg on day 1 and day 2-plus doxycycline 100 mg tablets twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
33065198|NCT04729140|Active Comparator|Ivermectin plus Placebo|"Ivermectin 200 mcg/kg on day 1 and day 2-plus placebo tablet twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin and Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
33065199|NCT04729140|Placebo Comparator|Placebo plus Placebo|"Placebo (number of tablets according to weight) plus placebo twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
33065200|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
33065201|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
33065202|NCT05595174|Active Comparator|group 1|Patient with self-ligating bracket system with micro-osteoperforations. Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
33065203|NCT05595174|Active Comparator|group 2|Patient with conventional bracket with micro-osteoperforations. Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
33065204|NCT05595174|Active Comparator|group 3|patient with conventional bracket without micro-osteoperforations. Extractions of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment.
33065205|NCT00349375|Experimental|1|
33065206|NCT00349375|Experimental|2|
33065207|NCT00349375|Active Comparator|3|
33065208|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
33065209|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
33065210|NCT00111527|Active Comparator|1|Normal RV pacing
33065211|NCT00111527|Experimental|2|Echo-guided optimization of pacing
33065212|NCT00349492|Active Comparator|EP|etoposide + cisplatin
33065213|NCT00401739|Experimental|I|Treatment with CSL360
33065214|NCT00111566|Active Comparator|18 Hour infusion|
33065215|NCT00111566|Experimental|4 hour infusion|
33065216|NCT04714723|Experimental|Routine education group|350-400 subjects aged 20-65 years with high metabolic risk
33065217|NCT04714723|Experimental|Programmed smartphone intervention group|350-400 subjects aged 20-65 years with high metabolic risk
33065218|NCT04714723|Experimental|Programmed smartphone plus dietitian intervention group|350-400 subjects aged 20-65 years with high metabolic risk
33065219|NCT00404703|Experimental|1|
33065220|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
33065221|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
33065222|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
33065223|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
33065224|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
33065225|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
33065226|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
33065227|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
33065228|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
33065229|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
33065230|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
33065231|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
33336626|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
33336627|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
33336628|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
33336629|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
33336630|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
33336631|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
33065232|NCT00404742|Placebo Comparator|Placebo|
33065233|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
33065234|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
33065235|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
33065236|NCT00111644|Experimental|1|
33065237|NCT00111644|Experimental|2|
33065238|NCT00111644|Active Comparator|3|
33065239|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
33065240|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
33065241|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
33065242|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
33065243|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
33065244|NCT00350233|Experimental|ExAblate MRgFUS|
33065245|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
33065246|NCT02964611||Alzheimer's disease|Observational Study
33065247|NCT02964611||Parkinson's disease|Observational Study
33065248|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
33065249|NCT02964611||Healthy Controls|Observational Study
33065250|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
33065251|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
33065252|NCT00350506|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
33065253|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
33065254|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
33065255|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
33336632|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
33336633|NCT05623670||Patients after minimally invasive cardiac surgery using a VJI cannula.|
33065256|NCT00350662|Experimental|Deferiprone single agent|
33065257|NCT00350662|Active Comparator|Desferrioxamine single agent|
33065258|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
33065259|NCT00350857|Active Comparator|Equetro active|
33065260|NCT00111956|Experimental|Etanercept|
33065261|NCT00111956|Placebo Comparator|Placebo|
33065262|NCT00350935||Healthy volunteers|Healthy controls
33065263|NCT00350935||Patients|Patients with schizophrenia
33065264|NCT00114309|Experimental|1|3 Dose Regimen
33065265|NCT00114309|Experimental|2|6 Dose Regimen
33065266|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
33065267|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
33065268|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
33065269|NCT00351013|Experimental|1|
33065270|NCT00351052|Experimental|1|Pimecrolimus
33065271|NCT00351052|Placebo Comparator|2|Vehicle
33065272|NCT05595135|Experimental|Health services research (text messages, smart pill bottle)|Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.
33065273|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
33065274|NCT00114348|Experimental|Prot-II-Ida|a
33065275|NCT00351325|Experimental|dose escalation|
33065276|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
33065277|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
33065278|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
33065279|NCT00351403|Other|Historical control|48 week standard therapy
33065280|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
33065281|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
33065282|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
33065283|NCT05595096|Experimental|spontaneous breathing anesthesia non-intubation group|In this group all the patients with spontaneous breathing anesthesia
33336634|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
33336635|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
33336636|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
33336637|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
33065284|NCT05595096|No Intervention|general anesthesia with double-lumen endotracheal intubation group|In this group all the patients with tradition anesthesia with double-lumen endotracheal intubation
33065285|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
33065286|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
33065287|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
33065288|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
33065289|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
33065290|NCT00351715|Experimental|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of >90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
33065291|NCT05594979|Experimental|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
33065292|NCT00112346|Active Comparator|A|
33065293|NCT00112346|Active Comparator|B|
33065294|NCT00114465|Experimental|VSL#3|Probiotic
33065295|NCT00114465|Placebo Comparator|Placebo|Placebo
33065296|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
33065297|NCT00352144|Placebo Comparator|2|Placebo tablet
33065298|NCT00352183|Experimental|1|
33065299|NCT00352183|Active Comparator|2|
33065300|NCT04714255|Experimental|TICK-B group as Intervention group|Pediatric patients received TICK-B as a distraction in the TICK-B group Trace Image and Coloring for Kids-Book were conducted on the children undergoing the Cannulation procedure.
33065301|NCT04714255|No Intervention|Standard care provided group as control group|Pediatric patients received standard care (routine care) in the control group.
33065302|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
33065303|NCT00112658|Experimental|Folfirinox|
33065304|NCT00112658|Active Comparator|Gemcitabine|
33065305|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
33065306|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
33065307|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
33065308|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
33065309|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
33065310|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
33065311|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
33065312|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
33065313|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
33065314|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
33065315|NCT02964351||High PSA (prostate-specific antigen) levels|
33065316|NCT00112697|Experimental|Arm 1|
33065317|NCT00112697|Experimental|Arm 2|
33065318|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Anplone SR"
33065319|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Plavix"
33065320|NCT00352729|Active Comparator|A|
33065321|NCT00352768|Experimental|F|
33065322|NCT00352768|Placebo Comparator|P|
33336638|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
33336639|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
33336640|NCT03443414|Experimental|0.75 mg RPL554|
33065323|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
33065324|NCT05594901||Retrospective Cohort|
33065325|NCT05594901||Prospective Cohort|
33065326|NCT04714450|No Intervention|MMST control|
33065327|NCT04714450|Experimental|MMST+|
33065328|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
33065329|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
33336641|NCT03443414|Experimental|1.5 mg RPL554|
33336642|NCT03443414|Experimental|3 mg RPL554|
33336643|NCT03443414|Experimental|6 mg RPL554|
32869874|NCT00271375|Experimental|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
32869875|NCT00271375|Experimental|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
33065330|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
33065331|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
33065332|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
33065333|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
33065334|NCT00353548||5-Obese Controls|Healthy obese control subjects
33065335|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
33065336|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
33065337|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
33065338|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
33065339|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
33065340|NCT05594862|Active Comparator|Lipogems|surgical drainage with cone fistulectomy + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice
33065341|NCT05594862|No Intervention|Placebo|surgical drainage with cone fistulectomy + infiltration of physiological solution and suture point positioning at the internal orifice level
33065342|NCT00353665|Experimental|1 - active|memantine + riluzole
33065343|NCT00353665|Placebo Comparator|2|riluzole + placebo
33065344|NCT04714606|Experimental|Sibling support group|8 session, tailored support group for siblings of children who have an ASD
33065345|NCT04714606|Active Comparator|Booklet|Control condition in which siblings of children who have an ASD will receive a tailored booklet to complete at home
33065346|NCT05594784|Experimental|Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax|"For Induction cycle, olverembatinib will be given orally 40mg every other day. Patients with CMR, olverembatinib will be reduced to 30 mg every other day.~Induction and consolidation cycles combined with a certain period of venetoclax.~Reduced-intensity chemotherapy regimens consist mainly of vincristine and prednisone. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy."
33065347|NCT04714528|Active Comparator|Physical Exercise Group|45 minutes of aerobic, high intensity group training, three times per week during a 12-week period.
33065348|NCT04714528|Other|Relaxation Group|45 minutes of relaxation therapy once per week for 12 weeks.
33065349|NCT04714489||experimental group|
33065350|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
33065351|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
33065352|NCT05594745|Active Comparator|Xiidra|one drop BID for 9 months
33065353|NCT05594745|Active Comparator|Systane|One drop QID for 9 months
33065354|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
33065355|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
33065356|NCT00354211||1|FLOTRAC™ SYSTEM
33065357|NCT00354211||2|Control Group
33065358|NCT05594550||28-day survival|Alive 28 days after intensive care admission
33065359|NCT05594550||28-day death|Deceased 28 days after intensive care admission
33336644|NCT03443414|Placebo Comparator|Placebo|
33336645|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
33336646|NCT02991118|Placebo Comparator|Placebo|Placebo control
33336647|NCT03720314||IBS|Irritable bowel syndrome patients
33336648|NCT03720314||control|healthy controls
33336649|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
33336650|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
33336651|NCT03181984|Experimental|Hemoporfin|
33336652|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
33336653|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
33156040|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
33336654|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
33336655|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
33336656|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
33336657|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
33336658|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
33065360|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33065361|NCT04714294|Experimental|SAD: Each volunteer will receive 6 mg, 10mg, 20mg, 40mg(or TBD) of IP once daily for 1 day|Drug: HPP737 or placebo One 1 mg capsule and one 5mg capsule taken orally (by mouth) once daily for SAD arm 1/ Two 5mg capsule taken orally (by mouth) once daily for SAD arm 2/ Four 5mg capsule taken orally (by mouth) once daily for SAD arm 3/ Eight 5mg capsule taken orally (by mouth) once daily for SAD arm 4
33065362|NCT04714294|Experimental|MAD: Each volunteer will receive 10mg, 20mg, 40mg(or TBD) of IP once daily for 7 days|Drug: HPP737 or placebo Two 5mg capsule taken orally (by mouth) once daily for MAD arm 1/ Four 5mg capsule taken orally (by mouth) once daily for MAD arm 2/ Eight 5mg capsule taken orally (by mouth) once daily for MAD arm 3
33065363|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
33065364|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
33065365|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
33065366|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
33065367|NCT00114894|Experimental|Safe Sea|
33065368|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
33065369|NCT00425659|Active Comparator|3|
33065370|NCT00425659|Experimental|1|
33065371|NCT00425659|Other|2|usual practice
33065372|NCT00425776|Active Comparator|Real acupuncture|
33065373|NCT00425776|Sham Comparator|Sham acupuncture|
33065374|NCT00425776|No Intervention|No intervention|
33065375|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
33065376|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
33065377|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
33065378|NCT00425893|Active Comparator|1|health education
33065379|NCT00425893|Experimental|2|hand hygiene
33065380|NCT00425893|Experimental|3|masks and hand hygiene
33065381|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
33065382|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
33065383|NCT00426010|Active Comparator|1|overt then covert caffeine
33065384|NCT00426010|Active Comparator|2|covert then overt caffeine
33065385|NCT00426010|Active Comparator|3|overt then covert placebo
33065386|NCT00426010|Active Comparator|4|covert then overt placebo
33065387|NCT04705753|Experimental|Cretan IAMA (CAPeo)|All patients are to receive Cretan IAMA (CAPeo) from Day 1.
33065388|NCT04705636|Experimental|Connected device|Connected device for three months period to support children care
33065389|NCT05594433|Experimental|Experimental|Sub cutaneous injection of Lenograstim with blood donation (450ML) after 4 days of mobilization
33065390|NCT00426166|Experimental|1|Low Level Laser Therapy
33065391|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
33065392|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
33065393|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
33065394|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
33065395|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
33065396|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
33065397|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
33065398|NCT01059643|Experimental|LY2523355|
33065399|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
33065400|NCT00115167|Experimental|Darbepoetin alfa|
33065401|NCT00115167|Placebo Comparator|Placebo|
33065402|NCT05594316|Other|single group|Trichloroacetic acid
33065403|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
33336659|NCT04056130|Experimental|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
33336660|NCT04056130|Experimental|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
32869876|NCT00271375|Placebo Comparator|Arm 3: Control group usual care|Control group usual care
33065404|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
33065405|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
33065406|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
33065407|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
33065408|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
33065409|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
33065410|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
33065411|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
33065412|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
33065413|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
33065414|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
33065415|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
33065416|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
33065417|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
33065418|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
33065419|NCT00444613|Experimental|E0302 25 mg|
33065420|NCT00444613|Experimental|E0302 50 mg|
33065421|NCT00444613|Placebo Comparator|3|
33065422|NCT00113789|Active Comparator|Pegfilgrastim|
33065423|NCT00113789|Placebo Comparator|Placebo|
33065424|NCT04699903||Positive SARS-Cov-2 cohort|Positive diagnosis of COVID-19 confirmed by a positive EUA SARS-CoV-2 PCR will be stratified in three subgroups 0 - 7 days since onset of symptoms 8 - 14 days since onset of symptoms 15 -90 days since onset of symptoms
33065425|NCT04699903||Negative SARS-Cov-2 cohort|Negative diagnosis of COVID-19 confirmed by a negative, EUA SARS-CoV-2 PCR test within 0-7 days of PCR sample collection will be included in the negative cohort.
33065426|NCT00115323|Active Comparator|1|Problem solving intervention
33065427|NCT00115323|Active Comparator|2|Attention control intervention
33065428|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
33065429|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
33065430|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
33065431|NCT05594121|Experimental|Extended-release subcutaneous buprenorphine (SC-BPN-XR)|For eligible patients randomly allocated to SC-BPN-XR, the first dose will be administered at the time of randomization (Day 0). SC-BPN-XR comes in two formulations, 100 mg and 300 mg buprenorphine doses in a pre-filled syringe. SC-BPN-XR administration is by subcutaneous injection in the abdomen. SC-BPN-XR is administered at intervals ≥26 days. For patients randomly allocated to SC-BPN-XR, they will receive the 300 mg dose for the first 2 months, followed by the 100 mg dose every month until the end of the 12-month period. All SC-BPN-XR doses will be administered in clinics by trained personnel. All patients receiving SC-BPN-XR will have their vital signs monitored every 5 minutes for 15 minutes after the injection before leaving the clinic.
33065432|NCT05594121|Active Comparator|Immediate-release sublingual buprenorphine/naloxone (SL-BPN/NX)|For eligible patients randomly allocated to SL-BPN/NX, the first study dose will be administered at the time of randomization (Day 0) and will match the SL-BPN/NX type (tablet versus film), route (sublingual versus buccal) and dose used for stabilization prior to study enrollment. For the first 2 weeks of the study period, all SL-BPN/NX administration will be directly observed at community pharmacies by trained personnel according to the usual standard of care. Subsequent to this period, healthcare providers and participants will develop a care plan for ongoing directly observed therapy vs unsupervised take-home dosing according to usual standard of care.
33065433|NCT04699669|Other|Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
33065434|NCT04699669|Other|Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
33336661|NCT04056130|Experimental|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
33336662|NCT04056130|Experimental|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
33336663|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
33336664|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
33114758|NCT04607343|Experimental|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
33114759|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
33336665|NCT03661216|Active Comparator|Nephure|3g of Nephure
33114760|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
33114761|NCT01109810||IVIg and SCIg therapy|Patients receiving Ig therapy by IV or SC route in the home or alternate site setting
33336666|NCT04056286|Experimental|Healthy + Whey|Healthy (overnight fast)
33336667|NCT04056286|Experimental|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
33114762|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
33114763|NCT04598763|Other|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
33114764|NCT04598763|Other|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
33114765|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
32869877|NCT05698290||Health Department of Northwest Michigan|School providers (school nurses, mental health specialists) from the Health Department of Northwest Michigan.
33114766|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
33336668|NCT04056286|Experimental|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
33114767|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
33114768|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
33114769|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
33114770|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
33114771|NCT00565656|Experimental|A|Bevacizumab
33114772|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
33114773|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
33114774|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
33114775|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
33114776|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
33114777|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
33114778|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
33114779|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
33114780|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
33114781|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
33114782|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
33114783|NCT00555347|Placebo Comparator|Placebo|
33336669|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
33336670|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
33336671|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
33336672|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
33336673|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
33336674|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
33336675|NCT04056052|Sham Comparator|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
33114784|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
33114785|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
33114786|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
33114787|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
33114788|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
33114789|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
33114790|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
33114791|NCT00565890|No Intervention|2|No replacement therapy
33114792|NCT02894060|Experimental|blood|blood tests
33114793|NCT02894255|Experimental|PCI and CABG|
33114794|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
33114795|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
33114796|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
33114797|NCT04676516|Experimental|Experimental Arm|Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
33114798|NCT04676516|No Intervention|No Intervention Arm|Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.
33114799|NCT04606758|Active Comparator|PCNL under fluoroscopic control|
33114800|NCT04606758|Active Comparator|PCNL under ultrasound control|
33114801|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
33114802|NCT04676438||Patients receiving surgery breast surgery for cancer at National Institute of Oncology|No intervention will be administered
33114803|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
33114804|NCT04676165|Experimental|SAM Group|At discharge from hospital, patients (and/or caregivers) will receive access to Smart About Meds (SAM), a medication management mobile application that has been developed by the McGill Clinical and Health Informatics (MCHI) Research Group.
33114805|NCT04676165|No Intervention|Usual Care Group|At discharge from hospital, patients will be provided with a written discharge prescription to be filled at their community pharmacy, and may or may not receive written or verbal instructions about changes made to therapy.
33114806|NCT04606953|Experimental|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
33114807|NCT04606953|No Intervention|Standard care|Patients in the control group receive standard routine care.
33114808|NCT04675658|Active Comparator|Classroom Intervention|"Physical activity support is provided by integrating daily structured activities in the classroom delivered by physical activity leaders through a video conferencing platform in partnership with the classroom teacher. Activities last about 10 minutes or less and have the flexibility of being integrated with academic lessons or serving as a break from academics.~The activities are simple and get kids moving in place. The activities will be delivered by a research staff member via video conferencing (using the schools preferred platform). A combination of live activities led by the research team and pre-recorded videos will be used (see example below). If live videos do not work for the teacher, they will have the option to only use the pre-recorded videos or receive a list of resources to promote CBPA in their classrooms."
33114809|NCT04675658|Experimental|Classroom Intervention plus family support|"Same components as the Classroom Intervention Arm plus the following:~Family Component: A newsletter will be sent to parents or guardians once every two weeks over the semester and posted on the study website. The newsletters include physical activity information related to safety/protection, skills building, motivation, overcoming barriers, and goal setting and monitoring (all newsletters are included as an appendix). As part of the program, children also receive a Garmin wearable physical activity monitor. Parents or guardians will receive text messages with behavior change messages based on the Garmin data (text message content is included as an appendix). Text messages also contain links to website materials.~Texts will be sent out using the Twilio platform."
33114810|NCT04598490|Experimental|Healed extraction site|Old Extraction Space
33114811|NCT04598490|Experimental|unhealed extraction site|Recent Extraction space
33114812|NCT04675697|Experimental|Anlotinib+EP|
33336676|NCT04056052|Active Comparator|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
33336677|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
33336678|NCT04055974|Experimental|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
33336679|NCT04055974|No Intervention|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
33336680|NCT04055896|No Intervention|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
33360960|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
33419415|NCT03327129||Patients with SI|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).
33419416|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
33419417|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
33419418|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
33065435|NCT04699669|Other|Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
33336681|NCT04055896|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
33336682|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
33336683|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
33336684|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
33065436|NCT04699669|Other|Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
33065437|NCT04699669|Other|Cohort 5: CBL-514 40 mg, 2 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm^2
33336685|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
33419419|NCT04877457|Experimental|Ocrelizumab|Three courses of ocrelizumab will be administered over the course of the study.
33065438|NCT04699669|Experimental|Cohort 6: CBL-514 80 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
33065439|NCT04699669|Experimental|Cohort 7: CBL-514 160 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
33065440|NCT04699669|Experimental|Cohort 8: CBL-514 240 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
33065441|NCT04699669|Experimental|Cohort 9: CBL-514 320 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
33065442|NCT04699708||Preterm infants ≤ 32 weeks|All preterm infants ≤ 32 weeks born in two study centers receiving resuscitative measures at the time of birth either in the form of face mask ventilation or intubation.
33065443|NCT04699552|Experimental|2J 20 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 20Hz
33065444|NCT04699552|Experimental|2J 40 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 40Hz
33065445|NCT04699552|Experimental|2J 60 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 60Hz
33065446|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
33065447|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
33065448|NCT00445081|Active Comparator|1|
33065449|NCT00445081|Active Comparator|2|
33065450|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
33065451|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
33065452|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
33065453|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
33065454|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
33065455|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
33065456|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
33065457|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
33065458|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
33065459|NCT00445120|Experimental|1|
33065460|NCT00445120|Placebo Comparator|2|
33065461|NCT05594004||Oscillating-Rotating electric toothbrush|Twice daily brushing
33065462|NCT05594004||Sonic electric toothbrush|Twice daily brushing
33065463|NCT05594004||Manual toothbrush|Twice daily brushing
33065464|NCT00445471|Other|A|Mifne Approach to PDD
33065465|NCT00445471|Other|B|Treatment as usual
33065466|NCT00115440|Experimental|A|Active treatment arm.
33065467|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
33065468|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
33065469|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
33065470|NCT05590650|Experimental|SZKJT group|Patients who meet the inclusion criteria and agree to receive concomitant treatment with SZKJT.
33065471|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
33065472|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
33065473|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
33068325|NCT04510207|Experimental|Investigational Vaccine 1b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP after 3 months following two doses of immunization.
33065474|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
33336686|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
32869878|NCT05698290||Michigan Association of School Nurses|School providers (nurses) from the Michigan Association of School Nurses.
33336687|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
33336688|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
33336689|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
33065475|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
33065476|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
33065477|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
33065478|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
33065479|NCT00446407|Active Comparator|Enhanced Usual Care|
33065480|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
33065481|NCT00446485|Placebo Comparator|3|placebo
33065482|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
33065483|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
33065484|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
33065485|NCT05589753|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during non-rapid eye movement sleep (NREM) sleep.
33065486|NCT05589753|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 6 days, While on the medication following studies will be performed - experimental night study, experimental day study, polysomnography night study (PSG).
33065487|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
33065488|NCT03277651||liver fibrosis|liver biopsy proved
33065489|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
33336690|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
33336691|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
33336692|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
33065492|NCT00446680|Experimental|1|
33065493|NCT00446680|Placebo Comparator|2|
33065494|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
33065495|NCT00115557|Active Comparator|2|Performance feedback only
33065496|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
33336693|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
33336694|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
33336695|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
33336696|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
33336697|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
33336698|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
33336699|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
33336700|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
33336701|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
32869879|NCT02240667||Subjects with atrial fibrillation|
33065497|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
32869880|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
32869881|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox to surgery
32869882|NCT03203850|Experimental|phlebotomy|randomized in a 2:1 ratio: Deferasirox to surgery
32869883|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
32869884|NCT01727895|No Intervention|Control group|
33065498|NCT00446758|Placebo Comparator|Placebo|
33065499|NCT03277534|Experimental|Electrical stimulation|
33065500|NCT03277534|Sham Comparator|Control|
33065501|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
33065502|NCT04699396|Experimental|Mobilisation with Movement 1 (MWM1)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at fibula and talus. Three sets of 10 repetitions of each techniques, were administrated.
33065503|NCT04699396|Experimental|Mobilisation with Movement 2 (MWM2)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at talus and fibula (order of application inverted). Three sets of 10 repetitions of each techniques, were administrated.
33065504|NCT04699396|Placebo Comparator|Placebo|The Placebo group participants performed the same number of sets and repetitions of lean/lunge forward into dorsiflexion, without any glide application, in the same position
33065505|NCT04699396|Experimental|Intervention|The experimental groups (MWM1 and MWM2), were later merged into a single Intervention group.
33065506|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
33065507|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
33065508|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
33065509|NCT05582460||PJI|Patients diagnosed with a PJI based on the EBJIS criteria ('Infection confirmed')
33065510|NCT05582460||No PJI|Patients not diagnosed with a PJI based on EBJIS criteria
33065511|NCT04699474|Experimental|Early in-bed leg cycling|
33065512|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
33065513|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
33065514|NCT00446836|Other|Single arm|Open label use of Xyotax
33065515|NCT00446875|Experimental|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
33065516|NCT00446875|Placebo Comparator|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
33065517|NCT00446953|Experimental|1|2x 12 mg betamethazone
33065518|NCT00446953|Placebo Comparator|2|no drugs
33065519|NCT05571033|Experimental|Spinal reflex conditioning|"The OC intervention includes 6 baseline sessions and 24 conditioning/ no conditioning sessions held 3 times/week.~To elicit an H-reflex, participants will be asked to stand in a comfortable position. Small pulses of energy will be applied to a nerve in the leg called the tibial nerve. We will record when the participant maintains leg muscle activity. During the intervention, participants will be trained to decrease their reflex in their calf."
33065520|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
33065521|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
32869885|NCT00272311|Active Comparator|1|81 mg Aspirin
32869886|NCT00272311|Active Comparator|2|162 mg Aspirin
32869887|NCT00272311|Active Comparator|3|325 mg Aspirin
32869888|NCT00272311|Active Comparator|4|650 mg Aspirin
33065522|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
33065523|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
33065524|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
33065525|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
33065526|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
33336702|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
33336703|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
33336704|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
33336705|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
33336706|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
33065527|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
33336707|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
32869889|NCT00272311|Active Comparator|5|1300 mg Aspirin
33065528|NCT00114452|Active Comparator|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
33065529|NCT00114452|Active Comparator|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
33065530|NCT00114452|Active Comparator|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
33065531|NCT00114452|Active Comparator|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
33065532|NCT00114452|Placebo Comparator|Placebo|ex vivo cultured adult mesenchymal stem cells
33065533|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
33065534|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
33065535|NCT05569512|Experimental|Uproleselan with pre-transplant conditioning|"Participants will receive IV uproleselan on day -8 prior to stem cell transplant. Uproleselan will be administered IV twice daily from day -7 through day -2.~Participants will also receive a standard pre-transplant conditioning regimen with fludarabine, clofarabine and busulfan. Each of these 3 drugs will be administered IV once daily from day -7 through day -4."
33065536|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
33065537|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
33065538|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
33065539|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
33065540|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
33065541|NCT05564598|Experimental|Cohort 1 Safety Run-in|The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.
33065542|NCT05564598|Experimental|Cohort 2 Antiviral medication + CMV CTLs|Patients will receive both anti-viral medication and CMV CTLs
33065543|NCT05564598|Active Comparator|Cohort 2 Antiviral medication only|Patients will only receive anti-viral therapy
33065544|NCT04728074|Experimental|Intervention|"The ENtering Employment and SUstaining Work (ENESUW) program consists of 6 main topics which are; self-awareness, occupational self-awareness, taking responsibility, teamwork and labor division, problem identification and problem solving. The entire program adopts a very plain and easy to understand method of information transmission in order to facilitate lossless comprehension and strengthen the trust relationship between the therapists and the participants.~The ENESUW program took 8 weeks in total with twice weekly sessions, making up a total of 16 structured group sessions. The group format enabled the participants to learn through meaningful peer interactions and group activities which were supportive of the main learning goals (i.e. group work, labor division and taking responsibility) of the program. The twice weekly sessions were 45 minutes long in order to keep the participants attentive and active throughout the program."
33065545|NCT04728074|Active Comparator|control|The control group also consisted of individuals with ID. They received face to face, individual vocational based occupational therapy approaches, which were twice a week for 8 weeks (approximately 40-45 minutes)
33065546|NCT00447967|Experimental|1|IOX
33065547|NCT00447967|Experimental|2|FLOX
33065548|NCT00114608|Experimental|1|Electrical foot stimulation
33065549|NCT00401856|Experimental|1|This arm will receive eplerenone
33065550|NCT00401856|Placebo Comparator|2|This group will receive the placebo
33336708|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
33336709|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
33336710|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
33336711|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
33360961|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.~With:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
33065551|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
33336712|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
33065552|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
33065553|NCT00448396|Experimental|Patupilone|
33065554|NCT05553678|Experimental|treatment group|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
33065555|NCT05553678|Placebo Comparator|Control group|Normal saline (0.03 ml/kg/30 min) will administered during UIA clipping through microscope.
33065556|NCT00448513|Experimental|catechin|catechin capsule group
33065557|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
33065558|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
32869890|NCT05538234||Non-living organ donors|Group of non-living donors
33336713|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
32869891|NCT05538234||Living organ donors|Group of living organ donors
32869892|NCT05538234||Organ recipients|Group of organ recipients
33065559|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
33065560|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
33065561|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
33065562|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
33065563|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
33065564|NCT04699318|Experimental|Single Dartos TIP|Single dartos tubularized incised plate urethroplasty
33065565|NCT04699318|Experimental|Double Dartos TIP|Double dartos tubularized incised plate urethroplasty
33065566|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
33065567|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
33065568|NCT04699513|Experimental|P-SIMV+PS group|The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
33065569|NCT04699513|Experimental|APRV group|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
33065570|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
33065571|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
33065572|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
33065573|NCT05543967||Type 2 Diabetes Mellitus|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition. All T2DM patients will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
33065574|NCT05543967||Healthy Control|These participants have normal glucose tolerance and normal cognition. All HC subjects will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
33065575|NCT04699084|Experimental|Music Group|Patients received music intervention and usual postoperative care.
33065576|NCT04699084|No Intervention|Control Group|Patients received only postoperative usual care.
33065577|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
33065578|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
33065579|NCT03276364||Shock|
33065580|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
33065581|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
33065582|NCT00448903|Experimental|A|Bemiparin
33065583|NCT00448903|Placebo Comparator|2|Placebo
33065584|NCT00402012|No Intervention|1|
33065585|NCT00402012|Experimental|2|
33065586|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
33065587|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
33065588|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
33065589|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
33065590|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
33336714|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
33336715|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
33336716|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
33336717|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
33336718|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
33336719|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
33065591|NCT00449137|Experimental|Single Arm|
33065592|NCT00115791|Experimental|1|
33065593|NCT00115791|Placebo Comparator|2|
33065594|NCT00449293|Active Comparator|1|
33065595|NCT00449293|Active Comparator|2|
33065596|NCT05541354||Stakeholder Interviews|Semi-structured, open-ended interviews will be conducted via Zoom with a purposive sample of surgeons, anesthesiologists and OR nurses and trainees to identify perceived OR ergonomics issues among stakeholders
33065597|NCT05541354||OR Observations|Live observation of OR teams by teams of two observers (an anthropologist and an ergonomics expert, such as a chiropractor or physiotherapist). This will be done, in addition to the interview studies, to identify unperceived and misperceived needs using an observation data collection tool. Each of the following 4 phases of surgery will be assessed individually: 1) OR preparation (team arrival to wheels-in), 2) wheels-in to incision, 3) incision to closure, and 4) closure to wheels-out.
33065598|NCT05541354||Curriculum Piloting|Participating OR teams will take part in piloting sessions of the developed simulation curriculum to determine if it meets the proposed content objectives and ensure environmental validity.
33065599|NCT00449488|No Intervention|Control|
33065600|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
33065601|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
33065602|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
33065603|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
33065604|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
33065605|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
33065606|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
33065607|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
33065608|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
33065609|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
33065610|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
33065611|NCT03276169|Experimental|Left atrial appendage closure group|
33065612|NCT03276169|Other|Radiofrequency ablation group|
33065613|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
33065614|NCT00449683|Experimental|terazosin|open-label treatment group
33065615|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
33065616|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
33336720|NCT00023595|Active Comparator|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
33336721|NCT00023595|Active Comparator|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
33336722|NCT00023595|Active Comparator|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
33336723|NCT00023595|Active Comparator|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
33065617|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
33065618|NCT00450034|Experimental|1|
33336724|NCT03659188|Experimental|Corticotomy with drills|Patients will undergo orthodontic treatment plus an acceleration procedure employing corticotomy with drills.
33336725|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
33336726|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
33065619|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
33065620|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
33065621|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
33065622|NCT04699279|Experimental|Statin|
33065623|NCT04699279|No Intervention|Blank|
33065624|NCT04698889|Active Comparator|Cow milk|Administration of natural cow whole milk
33065625|NCT04698889|Active Comparator|Human milk|Administration of natural human milk
33065626|NCT04698889|Active Comparator|Modified cow milk - low protein|Administration of modified cow milk at low protein content
33065627|NCT04698889|Active Comparator|Modified cow milk - high protein|Administration of modified cow milk at high protein content
33065628|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
33065629|NCT00450541||Fatigue Questionnaire + Interview|
33065630|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
33065631|NCT05540106|Active Comparator|Blank Paper and Pencil|
33065632|NCT05540106|Experimental|Nature Coloring Packet|
33065633|NCT05540106|Experimental|Geometric Shape Coloring Packet|
33065634|NCT05540106|Experimental|Activity Book|
33065635|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
33065636|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
33065637|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
33065638|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
33065639|NCT00450697||observation|
33065640|NCT00450736|Experimental|Single Arm|
33065641|NCT05536362|Experimental|TCI propofol mixed with clonidine and ketamine|Patient group,in which they got intravenous anaesthesia with TCI propofol mixed with clonidine and ketamine
33065642|NCT05536362|Experimental|TCI propofol mixed with a placebo|Control group,in which they received intravenous anaesthesia with TCI propofol mixed with a placebo (NaCl 0.9%)
33065643|NCT00115232||1|Children without family history of early atherosclerosis
33065644|NCT00115232||2|Children with family history of early atherosclerosis.
33065645|NCT00115232||3|Parents of children without family history of early atherosclerosis
33065646|NCT00115232||4|Parents of children with family history of early atherosclerosis
33065647|NCT00450775|Other|1|
33065648|NCT04698577|Experimental|Attention Training|"Engaged in sustained updating by mentally keeping score during an interactive game without written or verbal aids.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
33065649|NCT04698577|Active Comparator|Active Control|"Played the same interactive game as the attention training group without the requirement of mentally keeping score.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
33065650|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
33065651|NCT00450892|Other|arm 1|
33065652|NCT00450892|Other|arm 2|
33065653|NCT00450892|Experimental|arm 3|
33065654|NCT05536089||ctDNA positive|Postoperative ctDNA positive
33065655|NCT05536089||ctDNA negative|Postoperative ctDNA negative
33065656|NCT04698655|Active Comparator|Control group|"Asked to read a single-A4 page of brief osteoarthritis information (what is osteoarthritis)"
33065657|NCT04698655|Experimental|Treatment options group|"Asked to read brief osteoarthritis information + two A4 pages of information on treatment options (osteoarthritis treatment options)"
33065658|NCT04698655|Experimental|Treatment options + recommendation group|Asked to read brief osteoarthritis information + information on treatment options + receive hypothetical general practitioner recommendation for exercise
33065659|NCT00451087|Experimental|1|
33065660|NCT00451087|Active Comparator|2|
33065661|NCT05535426|Experimental|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
33156041|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
33419420|NCT04877457|Placebo Comparator|Placebo|Three courses of placebo will be administered over the course of the study.
33419421|NCT05353166|Experimental|Group A|Randomized 3:1; limited to patients with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan
33419422|NCT05353166|Experimental|Group B|Randomized 3:1; limited to patients with HFrEF taking sacubitril/valsartan
33419423|NCT05353166|Experimental|Group C|Randomized 3:1; limited to patients with HFpEF (not taking sacubitril/valsartan)
33065662|NCT00458029|Experimental|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
33065663|NCT00458029|No Intervention|Control|Observational control
33065664|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
33065665|NCT00458146|Experimental|1|MM-093
33065666|NCT00458146|Placebo Comparator|2|Placebo
33065667|NCT00458224|Experimental|Parental counseling|Life style counseling
33419424|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
33419425|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
33419426|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
33419427|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
33419428|NCT04543279|Experimental|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
33419429|NCT04543279|Experimental|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
33419430|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
33419431|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
32869893|NCT03975309||Previous DHS Participants|Observational
33065668|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
33065669|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
33065670|NCT05528328|Active Comparator|CACIPLIQ20®|CACIPLIQ20® is a medical device used for the treatment of chronic skin ulcers, and contains a molecule belonging to the family of ReGeneraTing Agents (RGTA®). CACIPLIQ20® will be administered topically on the vertical and peri-areolar incisions of one breast for 5 minutes, after subcutaneous plans suture and just before final skin suture.
33065671|NCT05528328|Placebo Comparator|placebo|The placebo solution (saline solution) will be administered on the contralateral side.
33065672|NCT05648812|Active Comparator|Term neonates|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography, cardiac ultrasound To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with no suspected brain pathology using CEUS. Later, different patient groups could be compared to infants with no suspected brain pathology.~Other Names:~• SonoVue"
33065673|NCT05648812|Experimental|Neonatal asphyxia|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in neonates after birth asphyxia~Other Names:~• SonoVue"
33065674|NCT05648812|Experimental|Neonatal stroke|"Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion after neonatal stroke~Other Names:~• SonoVue"
33065675|NCT05648812|Experimental|Other neonatal brain pathologies|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with other type (no asphyxia, stroke or preterm birth related) of brain pathology, like hydrocephalus, hemorrhage or central nervous system infection~Other Names:~• SonoVue"
33065676|NCT00458263|Experimental|single arm|
33065677|NCT04728126||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
33065678|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
33065679|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
33065680|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
33156042|NCT04252131|Experimental|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
33419432|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
33336727|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
33336728|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
32869894|NCT03971955||Adult Onset Autoimmune Diabetes/Latent Autoimmune Diabetes|
33065681|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
33065682|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
33065683|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
33065684|NCT05525637|Experimental|YZJ-1139 20mg|
33065685|NCT05525637|Experimental|YZJ-1139 40mg|
33065686|NCT05525637|Placebo Comparator|Placebo|
33065687|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
33065688|NCT00458653|Experimental|Group A|Post-transplant vaccination
33065689|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
33065690|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
33065691|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
33065692|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
33065693|NCT03273985|Experimental|Dry needling|
33065694|NCT03273985|Experimental|Ischemic compression|
33065695|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
33065696|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
33065697|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
33065698|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
33065699|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
33065700|NCT00115544|Placebo Comparator|3|saline injection
33065701|NCT05522049|Experimental|Intervention group|Tracheal intubation facilitated by a hyperangulated videolaryngoscope (C-MAC D-Blade)
33065702|NCT05522049|Active Comparator|Control group|Tracheal intubation facilitated by a videolaryngoscope with a Macintosh type blade (C-MAC)
33065703|NCT03273868|Experimental|High velocity low amplitude manipulation|
33065704|NCT03273868|Sham Comparator|Sham manipulation|
33065705|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
33065706|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
33065707|NCT00459433|Experimental|1|psychosocial intervention
33336729|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
33336730|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
33336731|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
33336732|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
32869895|NCT03971955||Type 2 Diabetes|
32869896|NCT03971955||Type 1 Diabetes|
32869897|NCT03971955||Healthy Normal Volunteers (HNV)|
33065708|NCT00459433|Active Comparator|2|Usual care
33065709|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
33065710|NCT05512221|Experimental|Phase I|GBAT+I and GBAT+E groups
33065711|NCT05512221|Experimental|Phase 2a|Watchful Waiting, GBAT+I, and GBAT+E groups
33065712|NCT05512221|Experimental|Phase 2b|GBAT+IE groups
33068326|NCT04510207|Experimental|Investigational Vaccine 2b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP after 3 months following two doses of immunization.
33065713|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
33065714|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
33065715|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
33065716|NCT00459589|Active Comparator|2|
33065717|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
33065718|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
33065719|NCT04728321|Experimental|AK104|AK104 15mg/kg IV every 3weeks (Q3W)
33065720|NCT04728321|Experimental|AK104 and Lenvatinib|AK104 15 mg/kg IV every 3 weeks (Q3W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
33065721|NCT00459823|Experimental|1|
33065722|NCT04728399|Experimental|Experimental group|2g Soybean peptide, 3g CLA and ng protein.
33065723|NCT04728399|Placebo Comparator|Control group|2g+N protein and 3g Soybean oil.
33065724|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
33065725|NCT00460018|No Intervention|No intervention|Women receiving standard care
33065726|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
33065727|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
33065728|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
33065729|NCT00460135|Experimental|RT|resistance training
33065730|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
33065731|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
33065732|NCT00460213|Experimental|Valsartan|
33065733|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
33065734|NCT00460369|Active Comparator|2|artemether-lumefantrine
33065735|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
33065736|NCT05502939|Experimental|Music|"57 Hispanic participants, aged 6-8~Participants will be enrolled in a music training program led by professional trained music instructor of the Colburn School of Music. The music curriculum follows the standard Suzuki training method. Students attend the program 3 days per week, 2 weekday afternoons and one weekend morning. Each session lasts approximately 1 hour long. Each student will be given a string instrument to take home (often a viola or a violin). Each learning day focuses on development of musical elements including rhythm and meter, form, pitch, and performance. Students will take part in annual performances intended to give them a motivational goal, sense of mastery and to share their accomplishments with their peers, family, and community."
33065737|NCT05502939|Active Comparator|After School Enrichment Group|"57 participants, aged 6-8~Participants will be enrolled in an after school program led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members. Duration and frequency of the after-school program will be matched to the music intervention."
33065738|NCT04697953|Experimental|brolucizumab 6mg|Open label, brolucizumab 6mg, daily dosing, Treat & Extend regimen by up to 2 week intervals. Dosing intervals as per previous therapy and treatment extension intervals
33336733|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
33336734|NCT03659110||1000 subjects receive the HPV 4 vaccine|
33336735|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
33065742|NCT00460720||001|
33065743|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
33336736|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
33336737|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
33336738|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
33336739|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
33360962|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
33360963|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
33336740|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
33336741|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
33065744|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
33065745|NCT00460837|Active Comparator|2|senna
33065746|NCT05500014|Experimental|Biofortified potato|500 g of biofortified, cooked potato, comsumed over 5 consecutive days (500g for each day, for a total of 2500 g of cooked potato). Potato meals will be labelled with a total of 3 mg 57FeSO4.
33065747|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
33065748|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
33065749|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
33065750|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
33065751|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
33065752|NCT04728009|Experimental|longan and lingzhi mushroom syrup|All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
33065753|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
33065754|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
33065755|NCT00461110|Experimental|1|Active
33065756|NCT00461110|Experimental|2|Active
33065757|NCT05490264|Experimental|[68Ga]Ga-NOTA-SNA002|A dose of 1mCi-5mCi of [68Ga]Ga-NOTA-SNA002 between 0.1mg to 0.9mg will be administered intravenously over 5minutes in Day 1 of subject enrollment
33065758|NCT00461266|Experimental|1|
33065759|NCT00461266|Active Comparator|2|
33065760|NCT04727658|Experimental|Radiosurgical thalamotomy on GammaKnife|
33065761|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
33065762|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
33065763|NCT03273595|Placebo Comparator|Control|
33065764|NCT03273595|Experimental|Experimental group|
33065765|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
33065766|NCT04728308|Active Comparator|Experimental group|20ml of 0.5% bupivacaine is infiltrated in the subcutaneous tissue around the incision site
33065767|NCT04728308|Placebo Comparator|Placebo group|20 ml of distill water is infiltrated in the subcutaneous tissue around the incision site
33065768|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
33065769|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
33065770|NCT04697992|Experimental|group A|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
33065771|NCT04697992|Experimental|group B|one eye was treated with tranexamic acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
33065772|NCT05483634||Genital urinary symptoms of menopause|Menopause for one year, or age above 45 with symptoms of GSM
33065773|NCT04728269|Experimental|Lactibiane topic AD|Cosmetical product Lactibiane Topic AD
33065774|NCT04728269|Placebo Comparator|Placebo|Placebo made with the same base as the cosmetical product
33065775|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
33065776|NCT04728035|Experimental|Dose escalation (part 1)|Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.
33065777|NCT04728035|Experimental|Dose expansion (part 2)|Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.
33065778|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
33065779|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
33065780|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
33336742|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
33336743|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
33336744|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
33336745|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
33360964|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
33336746|NCT04486222|Experimental|Experimental Group|The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
33336747|NCT04486222|Active Comparator|Standard Treatment Group|The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.
33336748|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
33065781|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
33065782|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
33065783|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
33065784|NCT04727723||Lutathera®|Lutathera® will be administered according to the local label and according to the recommended treatment regimen in adults consisting of four equally divided doses of Lutathera® for a total of 29.6 GBq (800 mCi).
33065785|NCT02956720|Experimental|single arm|
33065786|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
33065787|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
33065788|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
33065789|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
33065790|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
33065791|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
33065792|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
33065793|NCT00462007|Experimental|1|Stalevo
33065794|NCT04727879|Other|PMR|"Patients with PMR will be offered biopsy of the synovial membrane with puncture of synovial fluid during cortisone infiltration for analgesic purposes. In case of associated peripheric arthritis, the patient will also be offered a joint fluid sample during a cortisonic infiltration for analgesic purposes, performed as part of routine care~The study-specific examination that is not part of current practice is the synovial biopsy performed during the cortisonic infiltration procedure."
33065795|NCT04727879|Other|Control|Witnesses recruited into the orthopedic surgery department will be offered a synovial membrane biopsy during a shoulder surgery in the context of mechanical pathology.
33065796|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
33065797|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
33065798|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
33065799|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
33065800|NCT04726527||Florbetapir F 18 Recipients|Participants in this arm of the study will receive a 10 mCi (370 MBq) bolus injection of florbetapir F 18 and then be scanned in a PET scanner for brain imaging.
33065801|NCT00462358|Experimental|ARRY-520|
33065802|NCT00462358|Experimental|ARRY-520 + G-CSF support|
33065803|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
33065804|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
33065805|NCT00116129|Placebo Comparator|Placebo|Placebo
33065806|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
33065807|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
33065808|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
33065809|NCT00462592|Placebo Comparator|3|placebo
33068327|NCT04510207|Placebo Comparator|Placebo-b|Participants will receive a booster dose of Placebo after 3 months following two doses of immunization.
33114813|NCT04606836|Experimental|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
33336749|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
33114814|NCT04606836|No Intervention|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
33114815|NCT04598256||Children who underwent endoscopic procedures|"Children between the ages of 1-18 who were underwent endoscopic procedures~Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure~Patients who volunteered to study"
33114816|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
33114817|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
33114818|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
33114819|NCT04676126|Experimental|Experimental|Subjects in the experimental arm will consume 1.5 Tbsp (22.2 mL) of a commercial macular pigment-containing medical food (liquid) once per day and use a carbonic anhydrase inhibitor topical eye drop (2% dorzolamide ophthalmic solution) three times per day in both eyes for 3 months.
33114820|NCT04676126|Placebo Comparator|Placebo|Subjects in the placebo arm will consume 1.5 Tbsp (22.2 mL) of a placebo liquid which resembles the commercial macular pigment-containing medical food (liquid) in taste once per day and use a lubricating eye drop (0.5% sodium + 0.9% glycerin ophthalmic solution) three times per day in both eyes for 3 months.
33114821|NCT04598373||IDT patients|Allocated to an IDT program
33114822|NCT04598373||Non-IDT patients|Not allocated to an IDT program
33114823|NCT04675619|Experimental|Oral pirfenidone|Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.
33114824|NCT04675619|Experimental|Standard care|Standard care
33114825|NCT04675892|Active Comparator|A1 pulley group|A1 pulley division only
33114826|NCT04675892|Experimental|A1 pulley + FDS group|Combination of A1 pulley division and excision of one or both slips of the flexor digitorum superficialis tendon
33114827|NCT04598100|Active Comparator|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment & combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
33114828|NCT04598100|No Intervention|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
33114829|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
33114830|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
33114831|NCT04675736|Experimental|brushing force|
33114832|NCT05305300|Experimental|Arm A: Primary Immunization|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7.
33114833|NCT05305300|Experimental|Arm B1: Booster Immunization 1|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose. In arm B1, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
33114834|NCT05305300|Experimental|Arm B2: Booster Immunization 2|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose. In arm B2, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
33156043|NCT04252131|Placebo Comparator|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
33336750|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
33336751|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
33336752|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
33336753|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
33336754|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
33336755|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
33336756|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
33336757|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
33419433|NCT05760781|Experimental|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
33114835|NCT04606719|Other|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
33114836|NCT04606719|Active Comparator|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
33114837|NCT04606719|Experimental|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
33114838|NCT04187755|Active Comparator|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
33419434|NCT05760781|Experimental|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
33114839|NCT04187755|Experimental|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
33114840|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
33419435|NCT05760781|Experimental|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
33114841|NCT04606563|Experimental|ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan)|Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
33114842|NCT04606563|No Intervention|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
32869898|NCT05538156|Other|Control group|The internal limiting membrane is not removed
33114843|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
33114844|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
33114845|NCT00565968|Experimental|Sorafenib dose escalation|
33114846|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
33114847|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
33114848|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
33114849|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
33114850|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
33114851|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
33114852|NCT00555698|Experimental|DBS|DBS
33114853|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
33114854|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
33114855|NCT04598607|Experimental|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114856|NCT04598607|Experimental|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114857|NCT04598607|Experimental|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114858|NCT04598607|Placebo Comparator|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114859|NCT04598607|Placebo Comparator|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114860|NCT04598607|Placebo Comparator|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
33114861|NCT02885701|Experimental|No splint|
33114862|NCT02885701|Experimental|Removable Splint|
33114863|NCT02885701|Experimental|Non-removable Splint|
33114864|NCT01162135|Experimental|Open Label Pilot Study|
33114865|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 2, Day 180.
33114866|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
33114867|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
33114868|NCT04675463|Other|Budesonide/Glycopyrronium/Formoterol arm|52 weeks treatment
33114869|NCT04675463|Other|Glycopyrronium/Formoterol arm|52 weeks treatment
33114870|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
33156044|NCT04252209|Experimental|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
33336758|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
33065810|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
33065811|NCT00405015|Experimental|1|Placebo first
33065812|NCT00405015|Experimental|2|Rosiglitazone first
33065813|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
33065814|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
33065815|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
33065816|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
33065817|NCT02964156|Experimental|Walking test using insoles|Supersole
33065818|NCT02964156|Experimental|Walking test not using insoles|no intervention
33065819|NCT00463294|Active Comparator|On Pump Arm|
33065820|NCT00463294|Experimental|Off Pump Arm|
33336759|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
33336760|NCT03954093|Sham Comparator|Sham stimulation|
33336761|NCT03954093|Active Comparator|Motor cortex stimulation|
33336762|NCT03954093|Experimental|MEG-localized stimulation|
33065821|NCT00405054|Other|1|continuous infusion every 14 days
33065822|NCT00463450|Experimental|Arm 1|
33065823|NCT00463450|Active Comparator|Arm 2|
33065824|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
33065825|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
33065826|NCT05482191|Experimental|Treatment group|Treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.
33065827|NCT05482191|No Intervention|Usual practice group|No intervention
33065828|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
33065829|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
33068328|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
33068329|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
33068330|NCT00163137|Placebo Comparator|Placebo|Placebo
33336763|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
33336764|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
33336765|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
33336766|NCT05626023|Experimental|Human TH-SC01 cell injection|Single injection of 0.6×10^7, 1.2×10^8, 1.8×10^8 cells/kg
33336767|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
33336768|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
33336769|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
33336770|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
33336771|NCT03658018|Experimental|Intracept System Ablation|
33336772|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
33336773|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
33336774|NCT03657550|Other|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
33336775|NCT03657550|Other|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
33336776|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
33336777|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
33336778|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
33336779|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
33336780|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
33336781|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
33336782|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
33336783|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
33336784|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
33336785|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
33336786|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
33065830|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
33065831|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
33065832|NCT04697836|Experimental|ST (superficial cervical plexus block combined with Translareyngeal block)|Superficial cervical plexus block combined with Translareyngeal block Group.
33065833|NCT04697836|Active Comparator|S (superficial cervical plexus block)|Superficial cervical plexus block Group
33065834|NCT00116376|Experimental|AEE788 + non EIACD|
33065835|NCT00116376|Experimental|AEE788 + EIACD|
33336787|NCT04456972|Experimental|One arm only|
33065836|NCT04697914|Placebo Comparator|Control Sock|Control comercial Socks (Lurbel Tierra). These socks are designed to perform trekking.
33065837|NCT04697914|Experimental|Experimental Relief Pressure sock|Experimental Socks (Lurbel Tierra based), with a discharge element (in the own fabric and fibres of the sock).
33065838|NCT04697680|Active Comparator|Group 1|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 1) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
33065839|NCT04697680|Active Comparator|Group 2|Subjects randomized into Group 2 will be provided with a sleep schedule each week based on an algorithm (Algorithm 2) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
33065840|NCT04697680|Active Comparator|Group 3|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 3) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
33065841|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
33065842|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
33065843|NCT05471232||Enrollees|These participants will be subject to whole genome sequencing to identify genetic changes and a EHR-Based network model to predict psychiatric outcomes in youth with IDDs.
33065844|NCT05471232||Historical Control Group|A historical control group from public databases will be used to compare against enrollees.
33065845|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
33065846|NCT00116454|No Intervention|control group|group untreated
33065847|NCT00464113|Experimental|1|once-weekly dosing
33065848|NCT00464113|Experimental|2|twice-weekly dosing
33065849|NCT05468502|Experimental|Dose escalation|Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0*10^6, 3.0*10^7, 6.0*10^7, and 9.0*10^7 cells / person.
33065850|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
33065851|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
33065852|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
33065853|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
33065854|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
33065855|NCT00116493|Experimental|2|
33065856|NCT00116493|Experimental|3|
33065857|NCT00116493|Experimental|4|
33065858|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
33065859|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
33065860|NCT00464425|No Intervention|No Acupuncture (NA)|Control
33065861|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
33336788|NCT03657472|Experimental|Sequence 1(RTR)|
33336789|NCT03657472|Experimental|Sequence 2(RRT)|
33336790|NCT03657472|Experimental|Sequence 3(TRR)|
33336791|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
33336792|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
33065862|NCT04726488|Experimental|Periareolar Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
33065863|NCT04726488|Active Comparator|Inframammary Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
33065864|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
33065865|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
33065866|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
33065867|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
33065868|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
33065869|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
33065870|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
33065871|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
33065872|NCT00116714||Observation|
33065873|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
33065874|NCT00465049|Experimental|primary closure|suture after I&D
33065875|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
33065876|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
33065877|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
33065878|NCT00465205|Experimental|I|
33065879|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
33065880|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
33065881|NCT00465283|Active Comparator|Donepezil|
33065882|NCT00465283|Placebo Comparator|placebo|
33065883|NCT04726371|Active Comparator|Generic Best Practices (GBP)|The ~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
33065884|NCT04726371|Experimental|Tailored Best Practices (TBP)|The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
33065885|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
33065886|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
33065887|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
33065888|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
33065889|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
33065890|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
33065891|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
33065892|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
33065893|NCT05458908|Experimental|Cranial non-contrast syngo DynaCT Sine Spin scan|There is only one arm as all patients undergo the same intervention. Subjects with clinical features/symptoms of a stroke (hemorrhagic and non-hemorrhagic stroke patients) will be enrolled. All patients will undergo first a non-contrast MDCT scan and then a non-contrast syngo DynaCT Sine Spin head scan within a maximum timespan of 4 hours between both scans. Only patients in which no invasive procedure in between is planned can be enrolled.
33065894|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
33068331|NCT04516096|Experimental|AMX-0035 long term treatment extension|AMX0035 administered twice daily p.o.
33336793|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
33336794|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
33336795|NCT04440358|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
33336796|NCT03804879|Experimental|LMB763|50 mg LMB763 (two LMB763 25 mg capsules) were orally administered once daily for 24 weeks in addition to SoC.
33336797|NCT03804879|Placebo Comparator|Placebo|Placebo was orally administered once daily for 24 weeks in addition to SoC.
33065895|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
33065896|NCT00116727||Drug|etanercept 50 mg/wk SC
33336798|NCT04438330|Experimental|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
33336799|NCT04438330|Active Comparator|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
33065897|NCT00465556|Experimental|1|Dove Intervention
33065898|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
33065899|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
33336800|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
33336801|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
33065900|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
33065901|NCT00473707|Other|2|Expectant management of the third stage of labor
33065902|NCT00473863|Experimental|intervention|Receives CCTA
33065903|NCT00473863|No Intervention|Control|
33065904|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
33065905|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
33065906|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
33065907|NCT00473980|Sham Comparator|SHAM|Sham treatment
33065908|NCT05396313||Zhongshan Hospital cohort|Patients receiving CIED implantation at Zhongshan Hospital
33065909|NCT05396313||Fuwai Hospital cohort|Patients receiving CIED implantation at Fuwai Hospital
33065910|NCT05396313||Shanghai Chest Hospital cohort|Patients receiving CIED implantation at Shanghai Chest Hospital
33065911|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
33065912|NCT00474136|Experimental|1|
33065913|NCT00474136|Experimental|2|
33065914|NCT00474136|Active Comparator|3|
33065915|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
33065916|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
33065917|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
33065918|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
33065919|NCT04727892||complications after epilepsy surgery|Group A with no complication; Group B with complications
33065920|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
33065921|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
33065922|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
33065923|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
33065924|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
33065925|NCT00116883|Experimental|Arm 1|
33065926|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
33065927|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
33336802|NCT02682004||Women with postpartum depression|
33336803|NCT02682004||Women without postpartum depression|
33336804|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
33336805|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
33336806|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:~Nutritional and physical activity educational workshop~Enhanced physical education~Involvement of the morning broadcast~Educational brochure will be sent to the parents~A monthly telephone call or a text message will be sent to the parents~Message to school administration to prevent selling of soft drinks and to sell healthy food~A monthly session (3 months)"
33336807|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
33065928|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
33065929|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
33065930|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~intubated or tracheostomy in place~echocardiography requested by the treating physician~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
33065931|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
33065932|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
33065933|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
33065934|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
33065935|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
33065936|NCT04727996|Experimental|Sitravatinib/Tislelizumab|All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
33065937|NCT00474799|Experimental|A|MNS075 7.5mg q1h
33065938|NCT00474799|Experimental|B|MNS075 15mg q3h
33065939|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
33065940|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
33065941|NCT05387655||BCG vaccination|People who received a BCG vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
33065942|NCT05387655||Placebo vaccination|People who received a placebo vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
33065943|NCT04727918|Active Comparator|Cold biopsy forceps (CBF)|Patients will be allocated to the CBF arm after randomization (1:1)
33065944|NCT04727918|Active Comparator|Cold snare polypectomy (CSP)|Patients will be allocated to the CSP arm after randomization (1:1)
33065945|NCT04054453|No Intervention|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
33065946|NCT04054453|Experimental|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
33065947|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
33065948|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
33065949|NCT00475072|Experimental|1|
33065950|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
33065951|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
33065952|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
33065953|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
33065954|NCT02956369|Placebo Comparator|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
33065955|NCT02956369|Active Comparator|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
33065956|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
33065957|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
33065958|NCT00475189|Active Comparator|1|
33065959|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
33065960|NCT00117377|Experimental|1|Pimecrolimus
33065961|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
33065962|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
33065963|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
33336808|NCT03657316|No Intervention|control|The control school will receive no intervention
33336809|NCT00005937|Experimental|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
33336810|NCT02644798||ARDS patients|Adult ARDS (according to Berlin definition) patients were enrolled in the trial. The diagnostic criteria included (a) within one week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging showing that bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (c) respiratory failure not fully explained by cardiac failure or fluid overload; and (d) arterial partial pressure of oxygen / fraction of inspiration oxygen (PaO2/FiO2 ratio, P/F ratio) less than or equal to 300 mmHg.
33336811|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
33336812|NCT05625945||Symptomatic statin users|Statin users with self-reported muscle symptoms
33065964|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
33065965|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
33065966|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
33336813|NCT05625945||Asymptomatic statin users|Statin users without muscle symptoms
33065967|NCT03270007|Experimental|Chemotherapy|
33065968|NCT03270007|No Intervention|Control|
33065969|NCT00402038|Experimental|Arm 1|
33065970|NCT00402038|Placebo Comparator|Arm 2|
33065971|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
33065972|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
33065973|NCT05376306|Experimental|MBSR - STEM|STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
33065974|NCT05376306|Experimental|MBSR - non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
33065975|NCT05376306|Experimental|PMR - STEM|STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
33065976|NCT05376306|Experimental|PMR - Non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
33065977|NCT04727840|Other|Intervention|All 20 CKD patients will be receiving a potassium binder while consuming a tailored diet of non-potassium restricted foods
33065978|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
33065979|NCT00476164|Sham Comparator|2|
33065980|NCT00476203|Experimental|1|Immediate yoga classes offered
33065981|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
33065982|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
33065983|NCT00402077|Experimental|1|
33065984|NCT00402077|Experimental|2|
33065985|NCT00402077|Experimental|3|
33065986|NCT00402077|Placebo Comparator|4|
33065987|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
33065988|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
33065989|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
33065990|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
33065991|NCT03279952|Other|medication arm|CNS Stimulant
33065992|NCT00117195||PD/PS|
33065993|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
33065994|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
33065995|NCT05374239|Other|Hospital 1|First hospital in the allocation sequence to cross from control to intervention arm.
33065996|NCT05374239|Other|Hospital 2|Second hospital in the allocation sequence to cross from control to intervention arm.
33065997|NCT05374239|Other|Hospital 3|Third hospital in the allocation sequence to cross from control to intervention arm.
33065998|NCT05374239|Other|Hospital 4|Fourth hospital in the allocation sequence to cross from control to intervention arm.
33068332|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
33068333|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
33068334|NCT04518085|Experimental|Hypnosis + iACT|Single 20 minute medical hypnosis session delivered pre-surgery plus internet-based acceptance and commitment therapy delivered post-surgery
33065999|NCT04727684|Active Comparator|Agonist Group (long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33336814|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
33336815|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
33336816|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
33336817|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
32869899|NCT05538156|Other|Intervention group|The internal limiting membrane of the posterior pole is removed
33066000|NCT04727684|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
33066001|NCT03277261|Experimental|Ublituximab + Oral Placebo|Participants were administered ublituximab 150 milligrams (mg), intravenous (IV) infusion over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo once daily (QD) from Day 1 up to the last day of Week 95.
33066002|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Participants were administered teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
33066003|NCT05373147|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
33066004|NCT04727957||Dataset for development and testing|
33066005|NCT04727957||Dataset for external validation|
33066006|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066007|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066008|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066009|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066010|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066011|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066012|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066013|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
33066014|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066015|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066016|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066017|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066018|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066019|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066020|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066021|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066022|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066023|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066024|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066025|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066026|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
33066027|NCT05367336|No Intervention|Control|not receiving any narcotics
33066028|NCT05367336|Experimental|Morphine|the second group will be those receiving morphine
33066029|NCT05367336|Experimental|Fentanyl|the 3rd group will be those receiving fentanyl
33066030|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
33066031|NCT00476632||Control|Person with no history of cancer.
33066032|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
33336818|NCT03657238|Placebo Comparator|Placebo|
33336819|NCT03443024|Experimental|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo."
33360965|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
33066033|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
33066034|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
33066035|NCT00117273|Experimental|1|
33336820|NCT03443024|Experimental|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo."
33336821|NCT03443024|Experimental|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
33336822|NCT03443024|Placebo Comparator|Group 4 - Placebo|"Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
33336823|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
33336824|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
33066036|NCT00117273|Active Comparator|2|
33336825|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
33066037|NCT00117273|Active Comparator|3|
33066038|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
33066039|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
33066040|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
33066041|NCT05358678||cases with cs niche|133 cases with cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
33066042|NCT05358678||cases without cs niche|133 cases without cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
33066043|NCT00117767|Experimental|1|Terbinafine
33066044|NCT00117767|Active Comparator|2|Griseofulvin
33066045|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
33066046|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
33066047|NCT05357157||Electroacupuncture|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7
33066048|NCT05357157||Electroacupuncture, Nutrition and Dietary supplement|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7. Patients will be presented with the option to be prescribed a dietary supplement containing vitamin B complex, Mg, Zn, superoxide dismutase, Alpha Lipoic Acid and PalmitoylethanolamideAdditionally they will be given a specific anti-intiflamatory dietary regimen to follow.
33066049|NCT05339451||Severe/Deep infiltrating endometriosis|Endometriosis stage III/IV according to rASRM.
33066050|NCT05339451||Minimal/mild endometriosis|Endometriosis stage I/II according to rASRM
33066051|NCT05339451||Controls|Women operated for other benign gynecological diseases and have no signs of endometriosis perioperatively.
33066052|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
33336826|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
33336827|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
33336828|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
33336829|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
33336830|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
33336831|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
33336832|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
33336833|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
33360966|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
33066053|NCT05331846|Experimental|SMELL OF BREAST MILK|the smell of breast milk will reduce pain and stress
33066054|NCT05331846|No Intervention|control|pain and stress will not decrease
33066055|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
33066056|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
33066057|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
33066058|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
33066059|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
33066060|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
33066061|NCT02273986|Experimental|Digoxin|Digoxin
33066062|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
33066063|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
33066064|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
33066065|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
33066066|NCT00118547|Other|1|
33066067|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
33066068|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
33066069|NCT00477178||healthy|healthy controls
33066070|NCT00477217|Other|1|
33066071|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
33066072|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
33066073|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
33066074|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
33066075|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
33066076|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
33066077|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
33066078|NCT00477763|Active Comparator|1|
33066079|NCT00477763|Placebo Comparator|2|
33066080|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
33066081|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
33066082|NCT05330871|Experimental|1. Adolescent booster sentinel group|1 dose of 0.1ml Ad5-nCoV-IH
33066083|NCT05330871|Experimental|2. Adolescent booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066084|NCT05330871|Experimental|3. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066085|NCT05330871|Experimental|4. Adolescent booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066086|NCT05330871|Experimental|5. Adolescent booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33066087|NCT05330871|Experimental|6. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33066088|NCT05330871|Experimental|7. Adolescent booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33066089|NCT05330871|Active Comparator|8. Adolesent booster safety group to receive ICV|1 dose of 0.5ml ICV
33066090|NCT05330871|Active Comparator|9. Adolescent booster immunopersistency group to receive ICV|1 dose of 0.5ml ICV
33066091|NCT05330871|Active Comparator|10. Adolescent booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
33066092|NCT05330871|Experimental|11. Children booster sentinel group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066093|NCT05330871|Experimental|12. Children booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066094|NCT05330871|Experimental|13. Children booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066095|NCT05330871|Experimental|14. Children booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
33066096|NCT05330871|Experimental|15. Children booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33066097|NCT05330871|Experimental|16. Children booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33066098|NCT05330871|Experimental|17. Children booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
33336834|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
33336835|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
33360967|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
33066099|NCT05330871|Active Comparator|18. Children booster safety group to receive ICV|1 dose of 0.5ml ICV
33066100|NCT05330871|Active Comparator|19. Children booster immuno-persistency group to receive ICV|1 dose of 0.5ml ICV
33066101|NCT05330871|Active Comparator|20. Children booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
33066102|NCT05330871|Experimental|21. Adolescent primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
33066103|NCT05330871|Experimental|22. Adolescent primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
33066104|NCT05330871|Experimental|23. Children primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
33066105|NCT05330871|Experimental|24. Children primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
33066106|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
33066107|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
33066108|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
33066109|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
33066110|NCT00477997|Other|2|GH-bolus and OGTT
33066111|NCT00477997|Other|3|GH-bolus
33066112|NCT00478114|Experimental|1|Sorafenib
33066113|NCT00478270|Experimental|1|
33066114|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
33066115|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
33066116|NCT05302752|Experimental|Bilateral rapid magnetic stimulation of the phrenic nerves|Each participant will be tested on three different days with optimal settings for bilateral rapid magnetic stimulation of the phrenic nerves established on visit 1 and then repeated on visits 2 and 3.
33066117|NCT00478348|Other|Drain|
33066118|NCT00478348|Other|No drain|
33066119|NCT04727801||Febrile (n=50)|Febrile is defined as having sublingual temperatures of 37.5 °C or above. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
33066120|NCT04727801||Afebrile (n=50)|Afebrile is defined as having sublingual temperatures of less than 37.5 °C. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
33066121|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
33066122|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
33066123|NCT00117468|Experimental|1|
33066124|NCT00117468|Active Comparator|2|
33066125|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
33066126|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
33066127|NCT00478543|Experimental|Diuretic|Furosemide
33066128|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
33066129|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
33066130|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
33066131|NCT00478621|Experimental|Group A|
33066132|NCT00478621|Experimental|Group B|
33066133|NCT00478621|Experimental|Group C|
33066134|NCT00478621|Experimental|Group D|
33066135|NCT00478621|Experimental|Group E|
33066136|NCT00478621|Active Comparator|Group F|
33066137|NCT05292807|Experimental|Imaginal exposure for memories|A behavioral intervention in imagery for memories
33066138|NCT05292807|Experimental|Imaginal exposure for future events|A behavioral intervention in imagery for future events
33066139|NCT05292807|Experimental|Imagery rescripting for memories|A different behavioral intervention in imagery for memories
33419436|NCT05760781|Experimental|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
33419437|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
33066140|NCT05292807|Experimental|Imagery rescripting for future events|A different behavioral intervention in imagery for future events
33066141|NCT00402155||1|Normal subjects
33066142|NCT00402155||2|Reading discomfort subjects
33066143|NCT00478699|Active Comparator|1|
33066144|NCT00478699|Experimental|2|
33066145|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
33066146|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
33066147|NCT00119054|Other|Arm 1|
33066148|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
33066149|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
33066150|NCT05282394|Experimental|Massage Intervention|Families will be instructed to provide parent-provided newborn abdominal massage three times per day through 5 days of life
33066151|NCT05282394|Other|Attention Control Intervention|Families will be provided with information about reading with baby.
33066152|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
33066153|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
33066154|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
33066155|NCT05279781|Active Comparator|Root canal treatment group|This group will receive complete root canal therapy
33066156|NCT05279781|Active Comparator|Pulpotomy group|This group will receive full pulpotomy
33066157|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
33066158|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
33066159|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
33066160|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
33066161|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
33066162|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
33066163|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
33066164|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
33066165|NCT00479479|No Intervention|No intervention|No intervention
33066166|NCT00119210|Placebo Comparator|Placebo|Sugar pill
33066167|NCT00119210|Experimental|Bupropion SR|
33066168|NCT00479752|Active Comparator|A|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
33066169|NCT00479752|Active Comparator|B|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
33066170|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33066171|NCT05274165|Active Comparator|Group A|Participants will be fit with commercially available Lyric devices, which range from size XXS to XXL.
33066172|NCT05274165|Experimental|Group B|Participants will be fit either with the commercially available Lyric devices OR devices which are designed with a new fitting characteristic. This increases the pool of sizes from which the hearing care professional can choose to fit participant.
33066173|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
33066174|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
33066175|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
33066176|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
33066177|NCT00479986|Experimental|Pioglitazone|
33066178|NCT00479986|Active Comparator|placebo|
33066179|NCT00119444|Other|periacetabular osteotomy|
33066180|NCT05270109|Experimental|BiZact|
33066181|NCT05270109|Active Comparator|Cold Steel|
33066182|NCT05267379||PEP patients|Patients who develop PEP
33066183|NCT05267379||Control cohort|Patients who do not develop PEP
33066184|NCT00480181|Experimental|Active|
33419438|NCT04289961|Other|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
33419439|NCT04622527|Active Comparator|A = Virtual Reality paradigm A|Paradigm A with virtual reality headgear
33419440|NCT04622527|Active Comparator|B = Virtual Reality paradigm B|Paradigm B with virtual reality headgear
33419441|NCT04622527|Sham Comparator|C = Non-Virtual Reality paradigm A|Paradigm A without virtual reality headgear
33419442|NCT04622527|Sham Comparator|D = Non-Virtual Reality paradigm B|Paradigm B without virtual reality headgear
33419443|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
33419444|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
33419445|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
33336836|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
33336837|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
33336838|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
33336839|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
33336840|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
33336841|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
33336842|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
33336843|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
33336844|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
33066185|NCT00480181|Placebo Comparator|placebo|
33066186|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
33066187|NCT00480220|No Intervention|2|'No specific intervention'
33066188|NCT00480259|Active Comparator|Standard Nutrition|
33066189|NCT00480259|Experimental|Hyperprotein Nutrition|
33066190|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
33066191|NCT05244876|Experimental|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
33066192|NCT05244876|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
33066193|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
33066194|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
33066195|NCT00119561|Experimental|Arm 1|Telephone support groups
33066196|NCT00119561|No Intervention|Arm 2|Usual VA care
33066197|NCT01240018|Placebo Comparator|Placebo|
33066198|NCT01240018|Active Comparator|High dose Lb. casei|
33066199|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
33066200|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
33066201|NCT00480571|Experimental|1|BL 1020 low dose
33066202|NCT00480571|Experimental|2|BL 1020 High Dose
33066203|NCT00480610|Experimental|1|
33066204|NCT00480610|Placebo Comparator|2|
33066205|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
33066206|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
33066207|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
33066208|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
33066209|NCT00119639|Experimental|Arm 1|
33066210|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
33066211|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
33066212|NCT05238792|Experimental|Arm A for patients age ≥18 years and <70 years|Arm A will enroll patients age ≥18 years and <70 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
33066213|NCT05238792|Experimental|Arm B for patients age ≥6 years and <18 years|Arm B will enroll patients age ≥6 years and <18 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
33066214|NCT00480844|Experimental|Sertindole|
33066215|NCT00480844|Active Comparator|Risperidone|
33066216|NCT00119717|Experimental|1|
33066217|NCT00119717|Active Comparator|2|
33066218|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
33066219|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
33066220|NCT00480922|Experimental|1|A low glycemic load diet
33066221|NCT00480922|Active Comparator|2|Low fat diet
33066222|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
33114871|NCT04675112|Experimental|group A genetically informed intervention|Group A patients are offered a genetically based approach to tinnitus management that includes a genetic test and at least three office based treatment sessions. A rationally-designed personalized management plan based on the genetic results is based on four single nucleotide polymorphisms (SNPs) of the dopamine and serotonin pathways, namely COMT rs4680, HTR2A rs7997012, HTR2A rs6311, and TPH2 rs4570625, that have been associated with behavioral or cognitive responses
33114872|NCT04675112|Other|group B control|In Group B, treatments are offered randomly taking care to offer CBT to equal number of patients as in Group A. In both groups, during the first visit, patients are offered a simple, few-minute tinnitus update and advice, relevant to their educational level and are being suggested that an average of 4 sessions are required over a period of approx. 4 months for making tinnitus noise less or not bothersome
33114873|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
33114874|NCT04675502|Experimental|Supervised Exercise Group|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
33114875|NCT04675502|Experimental|Home Exercise Group|For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
33114876|NCT04314505|Experimental|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
33114877|NCT04314505|Active Comparator|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
33336845|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
33336846|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
33336847|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
33336848|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
33114878|NCT04606641|Experimental|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
33336849|NCT03656302||Case offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
33360968|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
32869900|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
33114879|NCT04606641|Active Comparator|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
33114880|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
33114881|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
33114882|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
33114883|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
33114884|NCT04598412||Mexican sample|Aged >60 years (n = 187)
33114885|NCT04598412||German sample|Aged >75 years (n = 97)
33360969|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
33066223|NCT05236998|Experimental|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: SID1903 (FDC)
33066224|NCT05236998|Experimental|Sequence B|Period 1: SID1903 (FDC) / Period 2: Dapagliflozin and Sitagliptin
33066225|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
33066226|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
33066227|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
33066228|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
33336850|NCT03656302||Control offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
33066229|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
33066230|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
33336851|NCT03713450|Experimental|Control with imaging guidance|
33336852|NCT03713450|Active Comparator|Control without imaging guidance|
33066231|NCT05233605||Exposed to Dexmedetomidine during ICU stay|Dexmedetomidine has been administered in accordance with its MA (at least 24 hours continuously with a starting dose of 0.7 µg/kg/h and then adjusted to sedation scores between 0.4 and 1.1 µg/kg/h), as part of care, prior to inclusion in the protocol
33066232|NCT05233605||Non exposed to Dexmedetomidine during ICU stay|This group is unexposed to Dexmedetomidine during ICU stay.
33066233|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
33066234|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
33066235|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
33066236|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
33066237|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
33066238|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
33066239|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
33066240|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
33066241|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
33066242|NCT01240369||VEGF-C low|
33066243|NCT01240369||VEGF-C high|
33066244|NCT01240369||miR-326 low|
33066245|NCT01240369||miR-326 high|
33066246|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
33066247|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
33066248|NCT05232786||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
33066249|NCT05232786||Health Care Professionals (HCPs)|HCPs treating people who have obesity
33066250|NCT01240447|Other|Best support treatment|
33066251|NCT01240447|Experimental|Racotumomab vaccine|
33066252|NCT00481312|Active Comparator|1|Dexmedetomidine
33066253|NCT00481312|Active Comparator|2|Midazolam
33066254|NCT05220735|Experimental|Experimental|Participants will receive three fish oil capsules daily for 14 weeks, and fractional iron absorption from test meals provided without and with ascorbic acid will be determined at baseline and endpoint.
33066255|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
33066256|NCT00481429||1|Rosiglitazone
33066257|NCT00481429||2|Diet control +/- metformin
33066258|NCT00481624|Experimental|Epoetin Alfa plus Iron|
33066259|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
33114886|NCT04598412||Northamerican sample|Aged >60 years (n = 200)
33336853|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
33336854|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
33336855|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
33114887|NCT04598412||British sample|Aged >70 years (n = 38)
33114888|NCT04606524||study group|25 postmenopausal females will be included in this study
33114889|NCT04606524||control group|25 premenopausal females will be included in this tudy
33114890|NCT04675268|Experimental|7 night home oximetry|Patients will undergo 7 nights home monitoring with oximetry.
33114891|NCT01161472|Experimental|4mg fesoterodine|
33114892|NCT01161472|Experimental|fesoterodine 8mg|
33114893|NCT01161472|Active Comparator|1mg alprazolam|
33114894|NCT01161472|Placebo Comparator|Placebo|
33114895|NCT04606680|Experimental|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
33114896|NCT04606680|Experimental|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
33114897|NCT04606680|Experimental|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
33114898|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
33114899|NCT01161043|Experimental|Sensor|All subjects that wear sensors (all subjects)
33114900|NCT04675073|Experimental|ABLATE arm|Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
33114901|NCT04675073|No Intervention|NO-TREAT arm|Only standard medical treatment will be offered for these patients.
33114902|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
33336856|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
33114903|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
33114904|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
33114905|NCT04674956|Experimental|Treatment arm|Regimens：anti-PD1 antibody and AG regimens.
33114906|NCT04674956|Placebo Comparator|Control arm|Regimens：Placebo and AG regimens.
33114907|NCT00564720|Experimental|1|GEM/TAR
33114908|NCT00564720|Experimental|2|GEM/OX/TAR
33114909|NCT04674722|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM-02 (99mTc labeled anti-HER2 sdAb) in a single dose injection.
33114910|NCT04674722|Experimental|Injection of 188Re-NM-02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM-02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
33114911|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
33114912|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
33336857|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
33336858|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
33336859|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
33114913|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
33114914|NCT04674917|Experimental|Group A|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
33114915|NCT04674917|Experimental|Group B|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
33114916|NCT04674917|Other|Group C|Hot pack , TENS, Mobilization, Exercise therapy
33114917|NCT04606485|Placebo Comparator|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
33114918|NCT04606485|Experimental|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
33114919|NCT01160770|Experimental|Clobazam|
33114920|NCT04632758|Experimental|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
33114921|NCT04632758|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
33419446|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
33066260|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
33419447|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
33066261|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
33419448|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
33419449|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
33419450|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
33419451|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
33419452|NCT04051749||Patients submitted to VS|
33419453|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
33066262|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
33066263|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
33066264|NCT05220423|Other|Reminders Group|This group will receive 6 reminders (sms/emails) on top of the National annual communication campaign organized by the French Health System authorities
33066265|NCT05220423|Other|No reminders group|This group will receive no reminders on top of the National annual communication campaign organized by the French Health System authorities
33066266|NCT00120068|Other|Arm 1|
33066267|NCT00481819|Experimental|1|In combination with MMF and steroids
33066268|NCT00481819|Active Comparator|2|In combination with MMF and steroids
33066269|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
33066270|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
33066271|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
33066272|NCT02958059|Experimental|Treatment|The intervention group
33066273|NCT02958059|Placebo Comparator|Comparator|The comparator group
33066274|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
33066275|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
33066276|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
33066277|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
33066278|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
33066279|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
33066280|NCT00117936|Placebo Comparator|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
33066281|NCT01240642|Experimental|ASA404|
33066282|NCT05202054|Experimental|The Effect of mindfulness stress reduction program on slepness and quality of life|Groups of 20 will be formed for the implementation of the mindfulness stress reduction program in the experimental group. The BFSAP day and time will be determined by taking into account the time zones where women are available. 150 minutes of BFSAP will be applied to the women in the experimental group once a week, lasting 8 weeks and consisting of 8 times in total. The women will then be given a midterm test. After the midterm, women will be asked to individually repeat the BFSAP application in their own home for 8 weeks (weeks 8-16).
33066283|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
33066284|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
33066285|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
33066286|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
33066287|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
33066288|NCT04697875|Experimental|Normobaric hypoxia (FiO2 15%)|
33066289|NCT04697875|Sham Comparator|Placebo-ambient air (FiO2 21%)|
33066290|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
33419454|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
33336860|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
33336861|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
33336862|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
33066291|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
33066292|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
33066293|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
33066294|NCT00482521|Experimental|CC-4047|
33066295|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
33066296|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
33066297|NCT00120302|Experimental|1|Pimecrolimus
33066298|NCT00120302|Placebo Comparator|2|Vehicle
33066299|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
33066300|NCT00482989|Experimental|1|MEDI-545
33066301|NCT00482989|Other|2|Placebo
33066302|NCT00120380|Active Comparator|Aerosolized Iloprost|
33066303|NCT00120380|Placebo Comparator|Bosentan monotherapy|
33066304|NCT01240798||Depression, anxiety|
33066305|NCT01240837|Active Comparator|glucose|
33066306|NCT01240837|Active Comparator|sucrose|
33066307|NCT01240837|Experimental|palm sugar|
33066308|NCT01240954|Active Comparator|OSIRIS|
33066309|NCT01240954|Experimental|OSIRIS other concentration 1|
33066310|NCT01240954|Experimental|OSIRIS other concentration 2|
33066311|NCT05176470|Experimental|Treatment (pembrolizumab, lifileucel)|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
33066312|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
33066313|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
33336863|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
33336864|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
33336865|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
33336866|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
33066314|NCT01241032|Experimental|Udenafil|Udenafil 200mg
33066315|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
33066316|NCT00120458|Experimental|1|Anxiolytic Therapy
33066317|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
33066318|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
33066319|NCT00483106|Active Comparator|Ritalin|
33066320|NCT00483106|Placebo Comparator|Placebo|
33066321|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
33066322|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
33066323|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
33066324|NCT05168631||Patients aged 18 years or older with histologically confirmed neuroendocrine tumor|Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care;
33066325|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
33066326|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
33066327|NCT01241071|Placebo Comparator|Placebo|
33068335|NCT04518085|Active Comparator|Mindfulness + treatment as usual (TAU)|Single 20 minute mindfulness session delivered pre-surgery plus treatment as usual post-surgery
33068336|NCT04512196|Experimental|Super-oxidised Solution|Peritoneal lavage with super-oxidised solution of at least 10 cc/kg and wound lavage with super-oxidised solution 1 cc/kg
33336867|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
33336868|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
33336869|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
33336870|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
33336871|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
33066328|NCT04727489||Autism Spectrum Disorder|Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
33066329|NCT04727489||Control without Autism Spectrum Disorder|Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
33066330|NCT04727489||Relatives of probands with Autism Spectrum Disorder|"Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)~Without Autism Spectrum Disorder diagnosis according to DSM-V,~With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders"
33066331|NCT04727489||Relatives of controls|Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives
33066332|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
33066333|NCT00483886|Active Comparator|1|Prucalopride 2 mg
33066334|NCT00483886|Placebo Comparator|3|Placebo
33066335|NCT00483886|Active Comparator|2|Prucalopride 4 mg
33066336|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
33066337|NCT00483964|Active Comparator|B|The group getting Olanzapine
33066338|NCT05160129|Experimental|Circuit-selective DBS|People suffering from severe obsessive-compulsive disorder (OCD)
33066339|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
33066340|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
33066341|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
33066342|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
33066343|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
33066344|NCT05138211|Experimental|Hemiparetic patients|Patients with hemiparetic gait who will be assisted by the exoskeleton action
33066345|NCT00484120|Experimental|1|3% Diclofenac NE cream
33066346|NCT00484120|Placebo Comparator|2|
33066347|NCT00484276|Experimental|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
33066348|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
33066349|NCT00484510|Experimental|Ascorbic Acid|
33066350|NCT00484510|Placebo Comparator|Placebo|
33066351|NCT05130723||Patients|Pediatric patients aged 2-18 years administered with fluconazole for the treatment or prophylaxis of invasive fungal infections.
33066352|NCT00484705|Experimental|Low-frequency electro-acupuncture|
33066353|NCT00484705|Experimental|Physical exercise|
33066354|NCT00484705|Active Comparator|Untreated control|
33066355|NCT00484744|Experimental|Acetaminophen|
33066356|NCT00484744|Experimental|Ibuprofen|
33066357|NCT00484744|Placebo Comparator|Avicel|
33066358|NCT05128656|Other|Cases|SARS-Cov-2 asymptomatic nursing homes employees
33066359|NCT05128656|Other|Controls|cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.
33066360|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
33066361|NCT00484783|Other|Historical|Chart review control group
33066362|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
33066363|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
33066364|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
33066365|NCT05062356|Experimental|Suprainguinal fascia iliaca compartment block (FICB)|Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve.
33114922|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
33360970|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
33360971|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
33336872|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|Brigatinib 90 milligram (mg), tablets, orally, once daily (QD) for first 7 days followed by brigatinib, 180 mg, tablets, orally, QD in Cycle 1 of 28 days followed by brigatinib 180 mg, tablets, orally, QD in Cycle 2 and onward cycles of 28 days until investigator-assessed progressive disease (PD) or intolerable toxicity, withdrawal of consent, or discontinuation for any other reason, whichever comes first up to Cycle 34 of 28-day cycle, until data cut-off date 29 September 2020.
33336873|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
33066366|NCT05062356|Active Comparator|Pericapsular nerve group block (PENG)|The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus.
33066367|NCT05062356|Sham Comparator|Local analgesia infiltration (LAI)|local anesthetic infiltration (LAI) into the anterior pericapsular tissues
33066368|NCT05062356|Sham Comparator|No adjunct: spinal anaesthesia (control)|Standard spinal anesthesia technique
33066369|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
33066370|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
33066371|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
33066372|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
33066373|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
33066374|NCT00485017|Placebo Comparator|4|
33066375|NCT00485056|Placebo Comparator|Placebo|Crossover arm
33066376|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
33066377|NCT01241422|Experimental|Treatment A: JNJ 40929837|
33066378|NCT01241422|Placebo Comparator|Treatment B: Placebo|
33066379|NCT01241422|Other|Treatment C: Montelukast|
33066380|NCT00118560|Experimental|1|treadmill walking and calf exercise
33066381|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
33066382|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
33066383|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
33066384|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
33066385|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
33066386|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
33066387|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
33066388|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
33066389|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
33066390|NCT00120965|Experimental|1|Autopulse device
33066391|NCT00120965|Active Comparator|2|Manual CPR
33066392|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
33066393|NCT05058612|Experimental|Midodrine|Midodrine 10 mg PO/NG q8h
33066394|NCT05058612|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
33066395|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
33066396|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
33066397|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
33066398|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
33066399|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
33066400|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
33066401|NCT05058417|Experimental|Empagliflozin group|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
33066402|NCT05058417|Placebo Comparator|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
33066403|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
33066404|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
33066405|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
33066406|NCT05004441|Experimental|First-line treatment|"First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.~Maintenance treatment: Fruquintinib and Capecitabine"
33066407|NCT00485719|Experimental|1|Twice daily (bid) dosing
33066408|NCT00485719|Experimental|2|Once daily (qd) dosing
33066409|NCT01241656|Experimental|Mail DVD|
33066410|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
33066411|NCT01241656|Experimental|SMA and DVD|
33066412|NCT01241656|No Intervention|Encouraged to talk to physician|
33066413|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
33066414|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
33114923|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
33336874|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
33336875|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
33336876|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
33336877|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
33336878|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
33066415|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
33066416|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
33066417|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
33066418|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
33066419|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
33066420|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
33066421|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
33066422|NCT01241812|No Intervention|B|
33066423|NCT01241851|Active Comparator|Aerobic exercise|
33066424|NCT01241851|Active Comparator|Resistance exercise|
33066425|NCT01241851|No Intervention|Control|
33066426|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
33066427|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
33066428|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
33066429|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
33066430|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
33066431|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
33066432|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
33066433|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
33066434|NCT00121316|Experimental|1|Pimecrolimus
33066435|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
33066436|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
33066437|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
33066438|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
33066439|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
33066440|NCT00486148|No Intervention|"group S"|Breast milk
33066441|NCT00486148|No Intervention|"group A"|Control Infant formula
33066442|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
33336879|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
33336880|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
33336881|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
33336882|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
33336883|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Intervention/ Dietary Supplement:~Flax seed powder~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Other Name: intervention"
33336884|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
33066443|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
33066444|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
33068337|NCT04512196|Placebo Comparator|Normal Saline|Peritoneal lavage with normal saline 0.9% of at least 10 cc/kg and wound lavage with normal saline 0.9% 1 cc/kg
33114924|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
33336885|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
33336886|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
33066445|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
33066446|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
33066447|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
33066448|NCT00486304|Placebo Comparator|Placebo|
33066449|NCT00121394|Experimental|Chlorhexidine|
33066450|NCT00486343|Experimental|1|Zileuton CR
33066451|NCT00486343|Placebo Comparator|2|Placebo
33066452|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
33066453|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
33066454|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
33066455|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
33066456|NCT00486421|Experimental|PRED & RITUX|
33066457|NCT00486577|Experimental|1|
33066458|NCT00486577|Experimental|2|
33066459|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
33066460|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
33066461|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
33066462|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
33066463|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
33066464|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
33066465|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
33066466|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
33066467|NCT04995627|Active Comparator|Salt (NaCl)|"12 grams (12 capsules) of NaCl per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
33066468|NCT04995627|Placebo Comparator|Placebo|"12 capsules of placebo per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
33066469|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
33066470|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
33066471|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
33066472|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
33066473|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
33066474|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
33066475|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
33066476|NCT00486928||AVR|All consecutive patients in the study period
33066477|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
33066478|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
33066479|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
33336887|NCT03712748|Experimental|Imaginal Exposure Session|
33336888|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
33336889|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
33336890|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
33336891|NCT03712592|Experimental|160km|
33066480|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
33336892|NCT03712592|Experimental|40km|
33336893|NCT03712592|Experimental|100km|
33336894|NCT03712592|Experimental|4x40km|
33336895|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
33336896|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
33066481|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
33336897|NCT05658380|Active Comparator|atropine|
33336898|NCT05658380|Placebo Comparator|normal saline|
33336899|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
33336900|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
33336901|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
33336902|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
33336903|NCT05657834|Experimental|Treatment Arm 1|Single dose of TVB-2640, 50 mg, oral administration
33336904|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
33066482|NCT04710797|Experimental|No Lymphadenectomy|Comprehensive staging surgery with no Lymphadenectomy
33066483|NCT04710797|Active Comparator|Lymphadenectomy|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
33066484|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
33066485|NCT00487045|No Intervention|2|
33066486|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
33066487|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
33066488|NCT02274376||Cohort|
33066489|NCT04710758|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.
33066490|NCT04710758|Active Comparator|Open total gastrectomy|The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.
33066491|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
33066492|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
33066493|NCT04985916|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
33066494|NCT04985916|Experimental|ET-01, Dose 1|Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline
33066495|NCT04985916|Experimental|ET-01, Dose 2|Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline
33066496|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
33066497|NCT00487474||Sculptra|
33066498|NCT00487591||Simva+Omacor|
33066499|NCT00487591||Simva + Placebo|
33066500|NCT04706156||Vaccinated Healthcare Workers (CZ)|Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
33066501|NCT04706156||Vaccinated Healthcare Workers (DE)|German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
33066502|NCT04706156||Vaccinated Healthcare Workers (SK)|Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
33066503|NCT04706156||Vaccinated Healthcare Workers (TR)|Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
33066504|NCT04984629|Experimental|HYDRAFIL Implant|Polymer Implant of HYDRAFIL into a one or two lumbar intervertebral discs
33066505|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
33066506|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
33066507|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
33066508|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
33066509|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
33066510|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
33066511|NCT04706117|Other|Canalicular obstruction|
33066512|NCT04969380|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
33066513|NCT00487708|Experimental|1|ACZ885
33066514|NCT00487786|Experimental|A|Each patient receives OGX-427
33066515|NCT04705922|Experimental|Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]|Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
33336905|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
33336906|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
33066516|NCT04705922|Experimental|Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]|Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
33066517|NCT04705922|Experimental|Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]|Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
33336907|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
33336908|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
33336909|NCT05612048|Experimental|Survey and Dental imaging|Patients have completed the intervention once completing the survey and undergoing dental imaging.
33336910|NCT05587946|Experimental|Intervention/treatment|"Implementation steps 1-4 of the Control Group will be done.~The patient will be informed about the virtual reality application.~The patient will be told that they can remove their glasses at any time and stop participating in the study.~2 minutes before the endoscopy process starts, the previously determined video will be started by putting on the Virtual Reality Glasses.~Glasses will be worn from the beginning to the end of the procedure.~The patient will be observed during the procedure. The data obtained during the observation will be noted.~After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be re-applied and vital signs will be measured and recorded in the Patient Follow-up Form.~After the endoscopy procedure, patients will be given an interview appointment on the same day to collect the data of the qualitative part of the study.~Semi-Structured Interview Form will be applied in the interview."
33360972|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
33360973|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
33360974|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
33066518|NCT00488137|Active Comparator|1|Prucalopride 2 mg
33066519|NCT00488137|Placebo Comparator|3|Placebo
33066520|NCT00488137|Active Comparator|2|Prucalopride 4 mg
33066521|NCT04705805||Case|Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery.
33066522|NCT04705805||Control|Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell
33066523|NCT00488176|Active Comparator|1|monteluksat sodium
33066524|NCT00488176|Active Comparator|2|cetirizine
33066525|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
33066526|NCT00488176|Placebo Comparator|4|placebo
33066527|NCT00488215|Active Comparator|1|Prucalopride
33066528|NCT00488215|Placebo Comparator|2|Placebo
33066529|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
33066530|NCT04957329|Active Comparator|BAK-preserved|Xalatan eye drop
33066531|NCT04957329|Active Comparator|Preservative-free|Monoprost eye drop
33066532|NCT04930887|Experimental|Exparel, Then Saline|Participants first received an endoscopically guided injection of Exparel (Bupivacaine). After 3 weeks they then received Placebo treatment (Saline).
33066533|NCT04930887|Experimental|Saline, Then Exparel|Participants first received Placebo treatment (Saline). After 3 weeks they then received an endoscopically guided injection of Exparel (Bupivacaine).
33066534|NCT00488527|Experimental|1|
33066535|NCT00488566|Other|Part 1|Single dose escalation
33066536|NCT00488566|Other|Part 2|Pharmacodynamic assessment
33066537|NCT00121745|Experimental|1|
33066538|NCT00121745|Experimental|2|
33066539|NCT00121745|Experimental|3|
33066540|NCT00121745|Experimental|4|
33066541|NCT00488605|Active Comparator|Treatment Arm A|
33066542|NCT00488605|Experimental|Treatment Arm B|
33066543|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
33066544|NCT00121784|Experimental|1|1
33066545|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
33066546|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
33066547|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
33066548|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
33066549|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
33066550|NCT01242553||Retina|Clinical exam results consistent with retina pathology
33066551|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
33066552|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
33066553|NCT01242592|Experimental|Homeopathy|
33066554|NCT01242592|Placebo Comparator|Placebo|
33066555|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
33066556|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
33066557|NCT04911816|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate
33066558|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
33066559|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
33336911|NCT05587946|No Intervention|Control group|"Hands will be washed.~The right patient will be determined, the procedure will be explained to the patient and permission will be obtained.~A Patient Identification Form will be applied to the individual before the endoscopy procedure.~Before the endoscopy procedure; State Anxiety Scale will be applied in the first 10 minutes, and Visual Comparison Scale will be applied in the first 5 minutes. Vital signs will be measured within the first 5 minutes and recorded on the Patient Follow-up Form. Then the individual will be taken to the endoscopy procedure.~The patient will be observed during the procedure. The data obtained during the observation will be noted.~After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be applied again and vital signs will be measured and recorded in the Patient Follow-up Form."
33336912|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
33066560|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
33066561|NCT04727372||Islamabad Group|Individuals residing and surveyed in Islamabad
33336913|NCT01311440|No Intervention|No intervention|12 weeks seizure record
33336914|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
33336915|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
33336916|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
33336917|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
33336918|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
33336919|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
33336920|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
33336921|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
33336922|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
33336923|NCT03655600|No Intervention|Usual care|Usual care
33336924|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
33360975|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
33360976|NCT01132417||Multidrug resistant (MDR)bacterial strains|
33360977|NCT01355822|Placebo Comparator|Placebo|
33066562|NCT04727372||Lahore Group|Individuals residing and surveyed in Lahore
33066563|NCT04727372||Faisalabad Group|Individuals residing and surveyed in Faisalabad
33066564|NCT04727372||Bahawalpur Group|Individuals residing and surveyed in Bahawalpur
33066565|NCT01242631|Experimental|Everolimus 10 mg daily|
33066566|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
33066567|NCT01242826|Experimental|A|
33066568|NCT01242865|Other|Attention and Interpretation Therapy|
33066569|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
33066570|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
33066571|NCT00121940|Experimental|Guided Care|
33066572|NCT00121940|No Intervention|Usual Care|
33066573|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
33066574|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
33066575|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
33066576|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
33066577|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
33066578|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
33066579|NCT00122018|Placebo Comparator|Control|Placebo
33066580|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
33360978|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
33336925|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 intravenously in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin +paclitaxel 175 mg/m^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
33336926|NCT02905006|Placebo Comparator|Placebo|
33336927|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
33336928|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
33336929|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
33336930|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
33066581|NCT04873752|Experimental|UDI-001|Four cycles with 8 administrations
33066582|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
33066583|NCT04866888|Experimental|pregnant women with placenta accreta spectrum|"Bladder will be dissected and mobilized down to the vagina after skeletonization and securing of bridging vessels either by electro-coagulation or ligation. Uterus will be incised 5mm above the placenta bulge, delivering the fetus followed by Carbetocin 100 microgram /1 ml intravascular. Repair of the uterine wall defect will be done. If extrauterine bleeding is excessive we may revert to internal iliac artery ligation followed by insertion of intra-peritoneal drain and regular abdominal wall closure.~After 3 months from delivery, ultrasound with different modalities will be done to all patients and outpatient hysteroscopy if symptomatic patients or with abnormal sonography."
33066584|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
33066585|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
33066586|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
33066587|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
33066588|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
33066589|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
33066590|NCT04848909|Experimental|Men with prostate cancer post-prostatectomy|Men with localized prostate cancer who are considered candidates for post-prostatectomy radiation.
33066591|NCT04727450|Active Comparator|1. Integrated format|Integrated or Combination of ABC of A: cognitive training. B: physical training and C: Combined Cognitive and Physical Training (CCPT).
33066592|NCT04727450|Active Comparator|2. Cognitive training + Physical Training (A+B)|Intervention of A & B treatments.
33066593|NCT04727450|Active Comparator|3. Physical training + CCPT (B+C)|Intervention of B & C treatments.
33066594|NCT04727450|Active Comparator|4. CCPT + Cognitive training (C+A)|Intervention of C & A treatments.
33066595|NCT04727450|No Intervention|5. Control group|No intervention
33066596|NCT01243099||In-stent (BMS) restenosis|
33066597|NCT01243099||De-novo coronary lesion|
33066598|NCT00490126||Laparoscopic Surgery Database|
33066599|NCT00122174|Other|Arm 1|
33066600|NCT04844385|Experimental|Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy|Patients in experimental group receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, then followed by daily simultaneous modulated accelerated radiotherapy combined with Capecitabine.
33066601|NCT00490516|Experimental|1|
33066602|NCT00490516|Experimental|2|
33066603|NCT00490516|Placebo Comparator|3|
33066604|NCT04841304||Patients receiving hemodialysis with diabetes|Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving glucose-lowering treatment
33066605|NCT04841304||Patients receiving hemodialysis without diabetes|Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, and HbA1c < 48 mmol/mol at inclusion)
33066606|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
33066607|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
33066608|NCT00490633|No Intervention|Control|Control, no intervention.
33066609|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
33066610|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
33066611|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
33066612|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
33066613|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
33066614|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
33066615|NCT00490828|Placebo Comparator|A|
33066616|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
33066617|NCT04829604|Experimental|ARX788|The investigational medicinal product (IMP), ARX788, will be administered every 3 weeks (Q3W) by intravenous (IV) infusion.
33066618|NCT00490906||1|Patients receive Copaxone
33336931|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
33336932|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
33336933|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
33336934|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
33336935|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
33336936|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
33336937|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
33336938|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
33336939|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
33336940|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
33336941|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
33336942|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
33336943|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
33336944|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
33066619|NCT00490906||2|Patients receive interferons
33066620|NCT04822194|Experimental|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
33066621|NCT04822194|Active Comparator|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
33336945|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
33066622|NCT00491062|Active Comparator|Control|
33066623|NCT00491062|Experimental|Parkinson stade 1|
33066624|NCT00491062|Experimental|Parkinson stade2|
33066625|NCT00491062|Experimental|Parkinson stade 3|
33066626|NCT00122408|Active Comparator|1|
33066627|NCT00122408|Placebo Comparator|2|
33066628|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
33066629|NCT00491140||Observation|Colorectal cancer patients
33066630|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
33066631|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
33066632|NCT04809753|Experimental|Eustachian tube dilation|Eustachian tube dilation with an endovascular balloon
33066633|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
33066634|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
33066635|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
33336946|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
33336947|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
33336948|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
33066636|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
33066637|NCT00491803|Active Comparator|1|Sildenafil 20mg
33066638|NCT00491803|Active Comparator|2|Sildenafil 40mg
33066639|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
33066640|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
33066641|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
33066642|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
33066643|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
33066644|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
33066645|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
33066646|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
33066647|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
33066648|NCT04790565|Experimental|Fecal microbiota transplantation (FMT)|Patients will be given capsulized FMT, 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Patients will continue fasting for 2 hours after the intervention. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
33066649|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
33066650|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
33066651|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
33066652|NCT00492271|Experimental|1|Experimental arm with increasing dosage
33336949|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
33336950|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
33336951|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
33336952|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
33336953|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
33336954|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
33336955|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
33336956|NCT03654430|Other|Healthy Newborns|
33336957|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
33336958|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
33336959|NCT03653728||Traumatic brain injury with cerebral contusions|
33336960|NCT01066000|Experimental|Mircera|
33336961|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
33419455|NCT04858815|Experimental|Administration of yogic breathing program|This will be a single arm longitudinal trial designed to evaluate the feasibility and estimate the efficacy of implementing a self-administered yogic breathing program for stress reduction among anesthesiology practitioners at one academic medical center.
33066653|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
33066654|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
33066655|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
33066656|NCT00492388|Placebo Comparator|B|placebo
33066657|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
33066658|NCT01243684|Active Comparator|Healty volunteers|
33066659|NCT01243684|Experimental|Patients|
33066660|NCT00492427|Active Comparator|2|
33066661|NCT00492427|Experimental|1|
33066662|NCT00492466|Experimental|1|
33066663|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
33066664|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
33066665|NCT04781712|Experimental|Self-management using mHealth|Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
33066666|NCT04781712|No Intervention|Exercise using brochure|Only exercise using brochure
33419456|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
33066669|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
33066670|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
33066671|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
33066672|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
33066673|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
33066674|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
33066675|NCT04777149|Experimental|transcranial Random Noise Stimulation (tRNS)|Participants in this group will receive a combined intervention (3 days of tRNS during functional task practice and 3 days of sham-stimulation during functional task practice).
33066676|NCT04777149|Active Comparator|transcranial Direct Current Stimulation (tDCS)|Participants in this group will receive a combined intervention (3 days of tDCS during functional task practice and 3 days of sham-stimulation during functional task practice).
33066677|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
33066678|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
33066679|NCT04766970|Active Comparator|Standardized assessment|
33066680|NCT04766970|Experimental|Telehealth assessment|
33066681|NCT00492895|Other|A|one arm only. Crossover study
33066682|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
33066683|NCT00492934|No Intervention|2|No daily injections with hormones
33066684|NCT01243723|Experimental|Eductyl suppository|
33066685|NCT01243723|Placebo Comparator|Placebo suppository|
33066686|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
33066687|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
33066688|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
33066689|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
33066690|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
33066691|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
33114925|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
33114926|NCT04632719|Experimental|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
33114927|NCT04632719|Active Comparator|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
33114928|NCT00566046|Experimental|Levetiracetam|
33336962|NCT00004635|Experimental|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
33336963|NCT00004635|Experimental|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
33114929|NCT00566046|Placebo Comparator|Placebo|
33114930|NCT01160614|Experimental|ORF Tablets|ORF Tablets
33114931|NCT00566085|Other|Molecular Breast Imaging|
33114932|NCT04632407|Experimental|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
33114933|NCT04632407|Experimental|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
33114934|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
33114935|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
33114936|NCT00566124|Active Comparator|1|Insulin detemir
33114937|NCT00566124|Active Comparator|2|Insulin glargine
33114938|NCT00566124|Active Comparator|3|NPH insulin
33114939|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
33114940|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
33114941|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
33114942|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
33114943|NCT04606368|Experimental|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
33114944|NCT04632368|Active Comparator|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
33114945|NCT04632368|No Intervention|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
33114946|NCT04606134|Experimental|Experimental|
33114947|NCT04606134|Placebo Comparator|Control|
33114948|NCT04632680|Experimental|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
33114949|NCT04606212|Experimental|Losartan group|
33114950|NCT04606212|Placebo Comparator|Placebo group|
33114951|NCT04606251|Experimental|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
33114952|NCT04606251|No Intervention|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
33336964|NCT00004563|Experimental|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
33336965|NCT00004563|Placebo Comparator|Placebo|Matching gel caps at a dose of 25 mg
33114953|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
33114954|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
33114955|NCT04606329|Experimental|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
33114956|NCT04606329|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
33336966|NCT03951051|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33114957|NCT04632251|Other|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
33114958|NCT04606056||Patients who underwent contrast enhanced CT scans|
33114959|NCT04597749|Experimental|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
33114960|NCT04632797|Active Comparator|Cryocompression|Patients in this group receive cryocompression for the hands.
33114961|NCT04632797|Active Comparator|Cryotherapy|Patients in this group receive cryotherapy for the hands.
33114962|NCT04632212|Experimental|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
33114963|NCT04632212|Experimental|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
33114964|NCT04632212|Experimental|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
33114965|NCT04632212|Experimental|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
33114966|NCT04632212|Experimental|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
33114967|NCT04632212|Experimental|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
33114968|NCT04632212|Experimental|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
33114969|NCT04632212|Experimental|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
33114970|NCT04632212|Experimental|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
33114971|NCT04632212|Experimental|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
33114972|NCT04632212|Experimental|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
33114973|NCT04632212|Experimental|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
33114974|NCT04632212|Experimental|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
33114975|NCT04632212|Experimental|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
33114976|NCT04632212|Experimental|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
33114977|NCT04632212|No Intervention|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
33114978|NCT04606017||Vitamain D|This group of patients were supplemented with 125IU/d Vitamin D
33360979|NCT03922399|Other|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
33114979|NCT04606017||Control|The other group did not receive the supplementation of 125IU/d Vitamin D
33114980|NCT04597866||CRPS|
33114981|NCT04632095|Active Comparator|Sternotomy AVR|Aortic valve replacement due to sternotomy
33114982|NCT04632095|Active Comparator|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
33114983|NCT04597788|Experimental|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
33114984|NCT04597788|Active Comparator|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
33114985|NCT04631744|Experimental|Cabozantinib Arm|
33114986|NCT04597983|Experimental|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
33114987|NCT04597983|Placebo Comparator|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
33114988|NCT04631822|Active Comparator|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 4 mg dexamethasone."
33114989|NCT04631822|Active Comparator|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
33114990|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
33114991|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
33336967|NCT03951051|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
33336968|NCT03948945|No Intervention|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
33336969|NCT03948945|Experimental|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
33336970|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
33336971|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
33114992|NCT04605900|Experimental|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
33114993|NCT04605900|Experimental|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
33336972|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
33114994|NCT00560963|Experimental|1 RAD001|
33114995|NCT04597515|Experimental|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
33114996|NCT04631978||Underweight|Comprehensive ophthalmologic examination
33114997|NCT04631978||Control|Comprehensive ophthalmologic examination
33114998|NCT04597281|Experimental|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
33114999|NCT04597281|No Intervention|Usual care|General care by their pediatricians.
33115000|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
33115001|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
33115002|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
33115003|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
33115004|NCT04631627|Active Comparator|aspirin group|aspirin,tablet,100/150mg per day,(BMI<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks<16 to 35 weeks or the day of delivery.
33115005|NCT04631627|Sham Comparator|control group|with no intervention
33115006|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
33115007|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
33115008|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
33115009|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
33115010|NCT04632017||Control group|Healthy pregnant women matched for gestational age
33115011|NCT04314193|Experimental|methotrexate|
33115012|NCT04314193|Active Comparator|prednisolone|
33115013|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
33115014|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
33115015|NCT04631354|Experimental|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
33115016|NCT04631354|Experimental|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
33115017|NCT01159171|Experimental|1|
33115018|NCT04631315|Experimental|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
33115019|NCT04631315|Active Comparator|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
33115020|NCT02885155||Patients with pulmonary arterial hypertension|
33115021|NCT05280301|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38 degrees celsius, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
33115022|NCT04631666|Experimental|Group 1A (uninfected) - 2.5 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
33115023|NCT04631666|Experimental|Group 1B (uninfected) - 10 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
33115024|NCT04631666|Experimental|Group 1C (uninfected) - 40 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
33336973|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
33115025|NCT04631666|Experimental|Group 1D (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
33115026|NCT04631666|Experimental|Group 2C (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
33115027|NCT04631666|Experimental|Group 2D (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
33115028|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
33115029|NCT04597203|Experimental|split face - left side|
33115030|NCT04597203|Active Comparator|split face - right side|
33115031|NCT04631237||Focus Groups|N=52
33115032|NCT04631237||Cognitive Interviews|N=24
33115033|NCT04631237||Survey|N=600
33115034|NCT04596852|Experimental|Healthy children|
33115035|NCT04596852|Experimental|Children with cerebral palsy|
33115036|NCT04631159|Experimental|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
33115037|NCT04631159|Placebo Comparator|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
33115038|NCT04605276||Pre-biopsy cohort|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.~No intervention study"
33115039|NCT04605276||Pre-radical prostatectomy cohort|Male patients of age ≥18 diagnosed with prostate cancer who are scheduled for radical prostatectomy
33115040|NCT04631198|No Intervention|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
33115041|NCT04631198|Experimental|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
33115042|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
33115043|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
33115044|NCT04630691||Control|Patients with HbA1c around 6,0
33115045|NCT04630691||T2DM|Patients with HbA1c above 6,5
33115046|NCT04631081|Active Comparator|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
33115047|NCT04631081|Active Comparator|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
33115048|NCT04596813|No Intervention|standard of care|
33115049|NCT04596813|Active Comparator|standard of care and treatment with the Cytosorb® device|
33115050|NCT04630457|Active Comparator|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
33115051|NCT04630457|Active Comparator|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
33115052|NCT00564798||1|Study Group
33115053|NCT00564798||2|Control Group
33115054|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
33115055|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens~fludarabine and busulfan +/- thymoglobulin~fractionated total body irradiation and cyclophosphamide~busulfan and cyclophosphamide~single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
33115056|NCT04630340|Active Comparator|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by~exhaled breath carbon monoxide using the STEADES-2 device and~urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
33115057|NCT04630340|No Intervention|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:~as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and~urine cotinine levels which is a marker of nicotine level from smoking"
33115058|NCT04596969|Experimental|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
33115059|NCT04596969|Experimental|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
33115060|NCT04596969|Experimental|SFD corn 20g|40g soluble fiber dextrin derived from corn
33115061|NCT04596969|Experimental|SFD corn 40g|
33115062|NCT04596969|Placebo Comparator|Control|Maltodextrin
33115063|NCT04313920|Experimental|Nutritional Supplement|Ready to drink liquid
33419457|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
33419458|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
33419459|NCT02117336|Experimental|P1446A-05|
33419460|NCT05551533|Experimental|Intervention|To use the mobile app developed by the study team for one month. The app has a few key features including a positive reflection journal, online peer support, knowledge sharing, self-assessment, and locally available resources. Participants in the intervention group will be required to complete at least two positive reflection journal entries per week, and will be encouraged to use other features of the app during the one month period.
33419461|NCT05551533|No Intervention|Wait list|Participants in this group will be put on a wait-list for one month before they can use the app.
33419462|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
33115064|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
33419463|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
33419464|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
33115065|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
33115066|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
33419465|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
33419466|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
33115067|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
33115068|NCT04630418|Experimental|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
33419467|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
33419468|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
33419469|NCT04526587||Basic science (medical chart review, biospecimen collection)|Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
33419470|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
33419471|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
33419472|NCT04826367|Experimental|Exercise Group (EG)|"The participants in the EG will perform relaxation exercises in groups of up to 8 people, 3 days a week for 6 weeks via WhatsApp (© 2020 WhatsApp, Inc.) or Zoom (© 2012-2020 Zoom Video Communications, Inc.) applications. Relaxation exercises will be performed with the Progressive Relaxation Exercises (PRE) technique defined by Jacobson et al.[11] Tele-rehabilitation sessions will last approximately 40 minutes of each, accompanied by a physiotherapist who has 8 years of experience in the field of oncological rehabilitation."
33419473|NCT04826367|No Intervention|Control Group (CG)|Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
33419474|NCT04454515|Experimental|dexmedetomidine|patient recieving dexmedetomidine
33115069|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
33115070|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
33419475|NCT04454515|Placebo Comparator|placebo|patients receiving placebo
33115071|NCT01157845|Experimental|Laboratory assay|
33115072|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
33115073|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
33115074|NCT00561041|No Intervention|3|No intervention
33115075|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
33115076|NCT00566241|Placebo Comparator|Placebo|Placebo
33115077|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
33336974|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
33336975|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
33336976|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
33336977|NCT03949101|Experimental|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
33115078|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
33115079|NCT00566280|Other|Molecular Breast Imaging|
33115080|NCT00561158|Experimental|A|
33115081|NCT00561158|No Intervention|2|
33115082|NCT00566319|Experimental|1|
33115083|NCT00566319|Active Comparator|2|
33115084|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
33115085|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
33115086|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
33115087|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
33115088|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
33115089|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
33115090|NCT04629989|Active Comparator|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
33115091|NCT04629989|Experimental|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
33115092|NCT04629989|Experimental|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
33115093|NCT00566358|Experimental|1|Duodenal exclusion
33156045|NCT04252209|Active Comparator|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
33336978|NCT03949101|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
33336979|NCT01096485|Experimental|Arm 1|
33336980|NCT01096485|Active Comparator|Arm 2|
33336981|NCT01096563|Experimental|1|AZD9164
33336982|NCT01096563|Placebo Comparator|2|
33336983|NCT00003645|Experimental|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
33336984|NCT00003645|No Intervention|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
33336985|NCT00003537|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33336986|NCT00003531|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33336987|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
33336988|NCT05625711|Experimental|Robot assisted surgery|The robot will assist doctors to complete lower limb artery surgery, including but not limited to the transfer and withdrawal of guide wire, catheter and stent
33336989|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
33336990|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
33336991|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
33360980|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
33336992|NCT02918968|Experimental|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
33336993|NCT02918968|Experimental|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
33336994|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
33336995|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
33115094|NCT04629755|Experimental|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
33115095|NCT04629755|No Intervention|Control|Assessment only.
33336996|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
33336997|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
33336998|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
33336999|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
33337000|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
33337001|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
33337002|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
33115096|NCT04605042|Experimental|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
33115097|NCT04605042|Experimental|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
33115098|NCT04629794|Active Comparator|Demineralized Bone Matrix|
33115099|NCT04629794|Active Comparator|Bone Morphogenic Protein|
33115100|NCT04596696|Other|Single arm Rotavac|Single arm Open Label study without comparator
33115101|NCT04596618|Active Comparator|Forearm Cooling|Participants will be actively cooled during rest breaks.
33115102|NCT04596618|No Intervention|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
33115103|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
33115104|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
33115105|NCT04596462|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
33115106|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
33115107|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
33115108|NCT04605120|Experimental|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
33115109|NCT04629560|Experimental|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
33115110|NCT04629560|No Intervention|Control Arm (supportive measures only)|standard of care supportive measures
33115111|NCT04605003|Active Comparator|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
33115112|NCT04605003|Active Comparator|Novel rig-S|A novel devise used with the high level disinfectant
33115113|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
33115114|NCT04629482||Children with typical development|Children with typical development
33115115|NCT04596306||UNDER 70 Y-O|
33115116|NCT04596306||OVER 70 Y-O|
33115117|NCT04629287|Experimental|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
33337003|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
33337004|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
33337005|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
33337006|NCT04054960|Experimental|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
33337007|NCT04054960|Sham Comparator|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
33337008|NCT04054960|Active Comparator|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
33337009|NCT00042939|Active Comparator|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
33115118|NCT04629287|Placebo Comparator|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
33115119|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
33115120|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
33115121|NCT04629209|Experimental|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
33115122|NCT04629209|Experimental|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
33115123|NCT04629365|Experimental|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
33115124|NCT04629365|Active Comparator|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
33115125|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
33115126|NCT04629170|Experimental|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
33115127|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
33115128|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
33115129|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
33115130|NCT04629170|Placebo Comparator|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
33115131|NCT04629170|Other|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
33115132|NCT04629170|Other|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
33115133|NCT04629404|Experimental|LY03003|
33115134|NCT04629404|Placebo Comparator|Placebo|
33115135|NCT04595916|Experimental|Polyene Phosphatidylcholine|
33115136|NCT04595916|Active Comparator|Magnesium Isoglycyrrhizinate|
33115137|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
33115138|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
33115139|NCT00565071|No Intervention|Presumptive diagnostic method|
33115140|NCT04628819|Experimental|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
33115141|NCT04628819|Placebo Comparator|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
33360981|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
33115142|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
33115143|NCT04604886|Experimental|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
33115144|NCT04604886|Experimental|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
33115145|NCT04595877|Experimental|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
33115146|NCT04595877|Placebo Comparator|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
33115147|NCT04595955|Experimental|Intervention group|This arm uses the CMyLife platform for at least 6 months
33115148|NCT04595955|No Intervention|Control group|This arm does not use the CMyLife platform
33115149|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
33115150|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
33115151|NCT00561509||A|SSRIs
33115152|NCT00561509||B|Dual antidepressants
33115153|NCT04604574|Other|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
33337010|NCT00042939|Experimental|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
33337011|NCT03653182||normal|A normal constitution condition in TCM.
33337012|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
33337013|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
33337014|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
33337015|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
33337016|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
33337017|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
33337018|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
33337019|NCT03653182||Special|One of an abnormal constitution condition in TCM.
33337020|NCT04055194|Active Comparator|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
33066692|NCT04760730|Experimental|Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29|Subjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29
33066693|NCT04760730|Experimental|Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29|Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29.
33066694|NCT00493051|Other|1|Standardized Wound Care
33066695|NCT00493051|Placebo Comparator|2|Placebo 1 dose
33066696|NCT00493051|Placebo Comparator|3|Placebo 2 doses
33066697|NCT00493051|Active Comparator|4|Active 1 dose
33066698|NCT00493051|Active Comparator|5|Active 2 doses
33066699|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
33066700|NCT04750044|Experimental|early refeeding group|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.
33066701|NCT04750044|Active Comparator|delayed refeeding group|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.
33066702|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
33066703|NCT00493324|Experimental|1|
33066704|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia~Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
33066705|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia~Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
33066706|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
33066707|NCT04748874|Experimental|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
33066708|NCT04748874|No Intervention|Postponed mNC-FET|Standard procedure where mNC-FET is performed at least one full menstrual cycle after failed fresh embryo transfer or freeze-all cycle.
33066709|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
33066710|NCT01243879|Active Comparator|Fasting with stimuli|Fasting in the presence of food-related stimuli
33066711|NCT01243879|Sham Comparator|Fasting without stimuli|Fasting in the absence of food-related stimuli
33066712|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
33066713|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
33066714|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
33066715|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
33066716|NCT00493363|Experimental|arm 1|
33066717|NCT00493363|Active Comparator|arm 2|
33066718|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
33066719|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
33066720|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
33066721|NCT00493480|Active Comparator|carvedilol|
33066722|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
33066723|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
33337021|NCT04055194|Placebo Comparator|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
33066724|NCT01244074|Experimental|biofeedback|
33066725|NCT04743960|Experimental|Nighttime cycled parenteral feeds followed by daytime cycled parenteral feeds|Patients will follow nighttime feeding regimen for one week, and then advance their feeds (approximately 12 hours earlier) to daytime feeding regimen for one week.
33337022|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
33337023|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
33337024|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
33337025|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
33337026|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
33066726|NCT01244152|Experimental|Intervention|
33066727|NCT01244152|Active Comparator|Control Group|
33066728|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
33066729|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
33066730|NCT04741230|Experimental|Gebauer Lenticule|Gebauer Lenticule implant device
33066731|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
33066732|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
33066733|NCT00493909|Active Comparator|1|thoracic epidural analgesia
33066734|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
33066735|NCT00493987|Active Comparator|Testosterone enanthate|
33066736|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
33066737|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
33066738|NCT00494065|Active Comparator|2|Home exercise
33066739|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
33066740|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
33066741|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
33066742|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
33066743|NCT00405366|Other|Single Arm Study|
33066744|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
33066745|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
33066746|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
33066747|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
33066748|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
33066749|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
33066750|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
33066751|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
33066752|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
33066753|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
33337027|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
33115154|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
33115155|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
33115156|NCT04595838|Experimental|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device
33115157|NCT04595838|Other|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
33115158|NCT04604730|Experimental|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
33115159|NCT04604730|Active Comparator|Anastomosis with protective stoma|Anastomosis with protective stoma
33115160|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
33115161|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
33115162|NCT04604535|Active Comparator|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
33115163|NCT04604535|Placebo Comparator|Placebo|70mL of concentrated beetroot juice with <0.01mmol/L nitrate
33115164|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
33115165|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
33115166|NCT04628702|Experimental|Intervention group|receives tablet-training
33115167|NCT04628702|No Intervention|Control group|no training
33115168|NCT00566475|No Intervention|1|Usual care of type 1 diabetes at the diabetes center
33115169|NCT00566475|Experimental|2|Usual care at the diabetes center supplemented by a telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child. The diabetes center NP conducts videovisits with the school nurse, patient (child) +/- parent monthly.
33115170|NCT04628975|Experimental|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
33115171|NCT04628975|No Intervention|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
33115172|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
33115173|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
33115174|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
33115175|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
33115176|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
33115177|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
33115178|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
33115179|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
33115180|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
33115181|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
33115182|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
33115183|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
33115184|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
33115185|NCT04628312|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
33115186|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
33115187|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
33115188|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
33115189|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
33115190|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
33115191|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
33115192|NCT04628390|Experimental|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
33115193|NCT04628390|Placebo Comparator|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
33115194|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
33115195|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
33115196|NCT04628468|Experimental|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
33115197|NCT04628468|Experimental|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
33115198|NCT04628468|No Intervention|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
33115199|NCT00566592|Experimental|1|Oral ethanol, overnight
33115200|NCT00566592|Experimental|2|IV ethanol, overnight
33115201|NCT00566592|Placebo Comparator|3|Placebo, overnight
33115202|NCT00566592|Placebo Comparator|4|Placebo, daytime
33115203|NCT05268406|Experimental|Single arm|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
33115204|NCT04604457|No Intervention|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
33115205|NCT04604457|Experimental|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
33337028|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
33115206|NCT04628351|Experimental|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
33115207|NCT04628351|No Intervention|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
33115208|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
33115209|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
33115210|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
33337029|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
33337030|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
33337031|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
33337032|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
33337033|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
33337034|NCT04252612|Experimental|Cohort 1: Pramlintide 60 mcg twice daily|Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
33337035|NCT04252612|Experimental|Cohort 2: Pramlintide 60 mcg three times daily|Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
33337036|NCT04252612|Experimental|Cohort 3: Pramlintide 120 mcg three times daily|Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
33337037|NCT00003483|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33337038|NCT04186000|Experimental|group 1|Booster vaccine with AD26.ZEBOV after 1 year
33337039|NCT04186000|Experimental|group 2|Booster vaccine with AD26.ZEBOV after 2 years
33337040|NCT01103583|Experimental|Hydroxyurea|
33337041|NCT01103583|Placebo Comparator|Placebo|
33337042|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
33337043|NCT01101711||Patients with subarachnoid hemorrhage|
33337044|NCT04230694|Active Comparator|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 10 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
33337045|NCT04230694|Experimental|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 10 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
33337046|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
33337047|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
33337048|NCT02529969|Placebo Comparator|placebo|500 mg placebo
33337049|NCT01103661|Other|Numeris-AF Guided Coagulation System|
33337050|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
33337051|NCT00003477|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33066754|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
33115211|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
33337052|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
33337053|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
33337054|NCT00003471|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
33337055|NCT05625477|Experimental|TNM002 low dose|Participants receive a single intramuscular injection of TNM002 with low dose on Day 1
33337056|NCT05625477|Experimental|TNM002 medium dose|Participants receive a single intramuscular injection of TNM002 with medium dose on Day 1
33337057|NCT05625477|Experimental|TNM002 high dose|Participants receive a single intramuscular injection of TNM002 with high dose on Day 1
33337058|NCT05625477|Active Comparator|Human Tetanus Immunoglobulin (HTIG)|Participants receive a single intramuscular injection of human tetanus immunoglobulin 250 IU on Day 1
33337059|NCT05625477|Placebo Comparator|Placebo|Participants receive a single intramuscular injection of placebo on Day 1
33337060|NCT04185220|Experimental|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
33337061|NCT04185220|Experimental|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at the maximum tolerated dose (MTD) on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
33337062|NCT01103739|Experimental|cohort 1|
33337063|NCT01103739|Experimental|cohort 2|
33337064|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
33337065|NCT04054024|Active Comparator|Active drug|
33337066|NCT04054024|Placebo Comparator|Placebo|
33337067|NCT00002931|Experimental|HD Chemo and Auto Stem Cells|
33066755|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
33066756|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
33066757|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
33066758|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
33066759|NCT02958189|Active Comparator|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
33066760|NCT00494572|Sham Comparator|Sterile Water|Sterile water
33066761|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
33066762|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
33066763|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
33066764|NCT04737681||Normal BMI|BMI 18.5-24.9 kg/m2
33066765|NCT04737681||Obese BMI|BMI ≥ 30 kg/m2
33066766|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
33066767|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
33066768|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
33066769|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
33066770|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
33066771|NCT00494845|Active Comparator|Comparison|8-week health education program
33066772|NCT01244464|Experimental|Study Group|
33066773|NCT01244542|Experimental|Patients with schizophrenia|
33066774|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
33066775|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
33066776|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
33066777|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
33066778|NCT01244581|Placebo Comparator|Placebo|
33066779|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
33066780|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
33066781|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
33066782|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
33115212|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
33115213|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
33115214|NCT04604145|Other|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
33115215|NCT04604145|Other|Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
33115216|NCT04604223|Experimental|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
33115217|NCT04604223|Placebo Comparator|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
33115218|NCT04628624|Placebo Comparator|Placebo group|Placebo - capsulated, colour matched potato starch (~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
33115219|NCT04628624|Experimental|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
33115220|NCT04628624|Experimental|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
33337068|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
33337069|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33419476|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
33115221|NCT01156714|Other|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
33115222|NCT01156714|Other|Arm 2: Memory Training|Memory training with computerized memory program
33115223|NCT01156714|Other|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
33115224|NCT04595643|Experimental|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
33115225|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
33115226|NCT04628273||radiolucent stone group|
33115227|NCT04628273||radiopaque stone group|
33115228|NCT04604028|Experimental|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
33115229|NCT04595604|Experimental|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
33115230|NCT04595604|Active Comparator|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
33115231|NCT00565149|Experimental|1|Normal Protein (15%) diet
33115232|NCT00565149|Experimental|2|Low Protein (5%) diet
33115233|NCT00565149|Experimental|3|High Protein (25%) diet
33115234|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
33115235|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
33115236|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
33115237|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
33115238|NCT04595526|Active Comparator|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
33337070|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33360982|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
33115239|NCT04595526|Experimental|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
33115240|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
33115241|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
33115242|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
33115243|NCT04627961|Experimental|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
33115244|NCT04595253|Experimental|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
33115245|NCT04595253|No Intervention|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
33115246|NCT00561587|Active Comparator|1|
33115247|NCT00561587|No Intervention|2|
33115248|NCT04595487|Experimental|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
33115249|NCT04595487|Active Comparator|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
33115250|NCT01156363|Experimental|Single Arm|
33115251|NCT00561626|Experimental|A|
33115252|NCT00561626|Experimental|B|
33115253|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
33115254|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
33115255|NCT02884921|Placebo Comparator|Placebo|Placebo
33115256|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
33115257|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
33115258|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
33115259|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
33115260|NCT04595409|Experimental|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
33115261|NCT04595409|Active Comparator|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
33115262|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
33115263|NCT01156012|Experimental|T2345|One drop of T2345
33115264|NCT01156012|Active Comparator|Prostaglandin|One drop
33115265|NCT04627844|Placebo Comparator|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice~Intervention Type: Dietary"
33115266|NCT04627844|Experimental|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.~Intervention Type: Dietary"
33115267|NCT04595136|Experimental|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
33115268|NCT04595136|Placebo Comparator|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
33115269|NCT04628117|No Intervention|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
33115270|NCT04628117|Experimental|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
33115271|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
33115272|NCT04627883|Other|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
33115273|NCT04627883|Other|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
33115274|NCT00565188|Experimental|I|
33115275|NCT00565188|No Intervention|C|
33115276|NCT04603833|Experimental|SHR3680+Docetaxel|
33115277|NCT04603833|Active Comparator|SHR3680|
33115278|NCT04603833|Active Comparator|Docetaxel|
33115279|NCT04603716|Experimental|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
33115280|NCT04603716|Experimental|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
33115281|NCT04627532|Experimental|Treatment|PF-07304814 assignment
33115282|NCT04627532|Placebo Comparator|Placebo|Placebo assigned
33115283|NCT04627766|Experimental|Monitored children|PICU Children that will be monitored with the device
33360983|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
33115284|NCT01580748|Experimental|Treatment arm|single arm study
33115285|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
33115286|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
33115287|NCT04627688|Active Comparator|Standard dietary advices|
33115288|NCT04627688|Experimental|Time restricted feeding|
33115289|NCT04603794|Active Comparator|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
33115290|NCT04603794|Active Comparator|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
33115291|NCT04603794|Active Comparator|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
33115292|NCT04603794|Placebo Comparator|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
33115293|NCT04627727|Experimental|low FODMAP diet|
33115294|NCT04627337|Experimental|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
33115295|NCT04627337|Active Comparator|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
33115296|NCT04603638|Active Comparator|magnesium|participations will be given intravenous magnesium.
33115297|NCT04603638|Placebo Comparator|control|participations will be given intravenous isotonic.
33115298|NCT04627454|Experimental|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
33115299|NCT04627454|Experimental|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
33115300|NCT04603599||benign endometrial changes|
33115301|NCT04603599||endometrial hyperplasia|
33115302|NCT04603599||endometrial cancer|
33115303|NCT04627298|Active Comparator|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
33115304|NCT04627298|No Intervention|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
33115305|NCT04603443|Experimental|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
33115306|NCT04603443|Experimental|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
33115307|NCT04603443|Experimental|BCAA 60 g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
33115308|NCT04603443|Placebo Comparator|Placebo 60 g/daily|Protein without BCAA, 30g BID x 12 weeks
33115309|NCT04627220||group 1|Group 1: Pressure of arterial oxygen> 200 mmHg during the coronary surgery
33115310|NCT04627220||group 2|Group 2: Pressure of arterial oxygen<200 mmHg and >80 mmHg during the coronary surgery
33115311|NCT04627259||patient|patients with thumb pain or functional problems
33115312|NCT04603092|Experimental|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
33115313|NCT04603092|No Intervention|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
33156046|NCT04252053|Experimental|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
33360984|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
33360985|NCT03513016|Experimental|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
33360986|NCT03513016|Placebo Comparator|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
33360987|NCT03513016|Experimental|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
33360988|NCT03513016|Placebo Comparator|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
33337071|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33337072|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33337073|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33115314|NCT01155583|Experimental|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR > 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
33115315|NCT01155583|Experimental|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
33115316|NCT04603131|Experimental|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
33115317|NCT04603131|Placebo Comparator|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
33115318|NCT04603131|Experimental|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
33115319|NCT04603131|Experimental|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
33115320|NCT04626908|Experimental|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
33115321|NCT04603209||IORT|All participants who plan to undergo partial mastectomy for treatment of early stage breast cancer will be considered for eligibility for IORT. Patient with single breast cancer less than 3cm in disease span, clinical negative axillary node will be offered the option of having IORT. If IORT is delivered following surgical resection of the tumor they will be followed in this registry for short and long term outcomes.
33115322|NCT04627181|Experimental|FCM + placebo|"Ferric carboxymaltose: Single dose, 500 mg~Placebo: Single dose"
33115323|NCT04627181|Experimental|B12 + placebo|"Hydroxycobalamine: Single dose, 1000 mcg~Placebo: Single dose"
33115324|NCT04627181|Experimental|FCM +B12|"Ferric carboxymaltose: Single dose, 500 mg~Hydroxycobalamine: Single dose, 1000 mcg"
33115325|NCT04627181|Placebo Comparator|Placebo + placebo|"Placebo: Single dose~Placebo: Single dose"
33115326|NCT04602780||CI users|
33156047|NCT04252053|Active Comparator|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
33115327|NCT04626830|Experimental|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
33115328|NCT04626830|No Intervention|Standard Care|Participants in the control group will receive standard oncology care only.
33115329|NCT04626557||Women with astma|At the 7th -14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
33115330|NCT04626557||Women without asthma|At the 7th - 14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
33115331|NCT04602897|Experimental|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
33419477|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
33115332|NCT04602897|No Intervention|control|the control group received no pain management at all during different steps of IUD insertion
33115333|NCT04602741|Experimental|A4i Intervention|"App4Independence (A4i)~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.~Specific A4i functionality includes:~Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.~Fostering illness self-management through evidence-informed content.~A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).~Daily wellness and goal attainment check-ins.~An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.~Passively collected data on phone use as a proxy for sleep.~A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
33115334|NCT04602741|No Intervention|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
33115335|NCT04626752|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
33115336|NCT04602663|Experimental|follow up every week|Variceal Band ligation every week.
33115337|NCT04602663|Experimental|follow up every 2 weeks|Variceal Band ligation every 2 weeks
33115338|NCT04602663|Experimental|follow up every 3 weeks|Variceal Band ligation every 3 weeks
33115339|NCT04602663|Experimental|follow up every 4 weeks|Variceal Band ligation every 4 weeks
33115340|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
33115341|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
33115342|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
33115343|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
33115344|NCT04602585|Experimental|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
33115345|NCT04602585|Placebo Comparator|Usual care arm|Participants will receive usual care
33115346|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
33115347|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
33115348|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
33115349|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
33115350|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
33115351|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
33156048|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
33156049|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
33115352|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
33337074|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33337075|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33115353|NCT00561899|Experimental|1|SP+AQ
33115354|NCT00561899|Experimental|2|Piperaquine plus SP arm
33115355|NCT00561899|Experimental|3|Du-Cotecxin
33115356|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
33115357|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
33115358|NCT04313725|Experimental|Boost|Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
33115359|NCT04313725|Placebo Comparator|Placebo|Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
33115360|NCT04626440||Group 1|Group 1 [(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available]
33115361|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
33115362|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 [(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC].
33115363|NCT04313803||American Fork|CGM usage months 1 and 3
33115364|NCT04313803||Central Orem|CGM usage for month 1
33115365|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
33115366|NCT00565227|Experimental|docetaxel plus vorinostat|
33115367|NCT05239000|Experimental|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy. Consultation with geriatricians can occur in-person or remotely via telemedicine. During this visit, the geriatrician will review the results of the eRFA and create a plan to manage geriatric deficits. Geriatric co-management involves optimization of comorbid conditions, management of polypharmacy, and supportive care referrals to address geriatric deficits. Geriatricians also work in conjunction with the treating oncologists to ensure patients have appropriate pain management and bowel regimens. Additional follow up visits after the initial consultation are at the discretion of the geriatrician may vary between patients depending on the clinical need.
33115368|NCT05239000|Experimental|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits. The automated report also includes suggested interventions for each deficit (e.g, referral to physical therapy. For instance, automated suggestions for a patient with a history of falls include consultation with physical therapy, neurologic evaluation, a home safety evaluation, or use of supportive devices. Automated recommendations for patient with high level of distress or depression include referral to psychiatry or social work, involvement in a cancer support group, or additional time spent addressing questions and fears. The oncology team will review the automated report from the eRFA and create an intervention plan prior to initiation of head and neck radiation and chemotherapy.
33115369|NCT02884726|Experimental|BMS-986148 intravenous infusion|
33115370|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
33115371|NCT00562016|Experimental|IMPELLA LP 2.5|
33115372|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
33115373|NCT04313491|Experimental|Yoga@Work|
33360989|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
33115374|NCT04313764|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
33115375|NCT04313764|Active Comparator|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
33115376|NCT04602234|Experimental|LUS group|
33115377|NCT04602234|No Intervention|No LUS group|
33115378|NCT04313569|No Intervention|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
33115379|NCT04313569|Other|Arthroscopic menisctomy|
33115380|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
33115381|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
33115382|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
33115383|NCT04626089|Experimental|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
33115384|NCT04626089|Placebo Comparator|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
33115385|NCT04601961|Active Comparator|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
33115386|NCT04601961|Experimental|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
33115387|NCT04626323|Experimental|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
33115388|NCT04626323|Active Comparator|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
33115389|NCT04602039|Experimental|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
33115390|NCT04602039|Experimental|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
33115391|NCT04602039|Experimental|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
33115392|NCT04601688|Experimental|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
33115393|NCT04601688|Active Comparator|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
33115394|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
33115395|NCT04601727||Rectal cancer patients|
33115396|NCT04626011|Active Comparator|Group One|Participants receiving full mouth disinfection and extractions in one stage.
33115397|NCT04626011|Active Comparator|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
33115398|NCT04601766|Experimental|Group A|
33115399|NCT04601766|Experimental|Group B|
33115400|NCT04625816|Experimental|Arthroscopic shoulder surgery patients|
33115401|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
33115402|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
33115403|NCT04625894|Experimental|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
33115404|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
33115405|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
33115406|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
33115407|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
33115408|NCT04601025|Experimental|Yoghurt|
33115409|NCT04601025|Experimental|Chickpea+Yoghurt|
33115410|NCT04601025|Experimental|Oat+Yoghurt|
33115411|NCT04625855|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
33115412|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
33115413|NCT04313452|Placebo Comparator|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
33115414|NCT04313452|Active Comparator|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
33115415|NCT04313686|Experimental|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
33115416|NCT04313686|Active Comparator|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
33115417|NCT04600986|Experimental|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
33115418|NCT04600986|Other|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
33115419|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
33115420|NCT04625699|Experimental|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
33115421|NCT04601142||glucocorticoid sensitive (GS) group|
33337076|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33360990|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
33115422|NCT04601142||glucocorticoid resistance (GR) group|
33115423|NCT04625582|Experimental|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
33115424|NCT04625582|Experimental|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
33115425|NCT04625582|No Intervention|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
33115426|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
33115427|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
33115428|NCT04625348|Experimental|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
33115429|NCT04625543|Experimental|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
33115430|NCT04625543|Active Comparator|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
33115431|NCT04601259|Experimental|Orkla corn plaster with Salicylic acid|
33115432|NCT04601259|Active Comparator|Orkla corn protector without salicylic acid|
33360991|NCT03928717|Experimental|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
33115433|NCT04625309|Experimental|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
33115434|NCT04625309|No Intervention|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
33115435|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
33115436|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
33360992|NCT03928717|Active Comparator|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
33360993|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
33115437|NCT04625387|Experimental|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
33115438|NCT04625387|Experimental|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
33156050|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
33156051|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
33115439|NCT04625426|Experimental|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
33115440|NCT04625426|Experimental|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
33115441|NCT04625426|Active Comparator|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
33115442|NCT04592094|Experimental|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
33115443|NCT04592094|No Intervention|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
33115444|NCT04591782|Experimental|PomJuice (PJ)|8 oz of PJ
33337077|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33337078|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
33115445|NCT04591782|Active Comparator|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
33115446|NCT04591782|Other|Water|8 oz of water
33115447|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
33115448|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
33115449|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
33115450|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
33115451|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
33115452|NCT04625192|Experimental|Sinus lifting with trephine osteotomy|
33115453|NCT04625114|Experimental|Camostat|camostat 100mg 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
33115454|NCT04625114|Placebo Comparator|Placebo|Placebo 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
33115455|NCT04592133||Scoliosis Patients|
33115456|NCT04592133||Control Group|
33115457|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
33115458|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
33115459|NCT04591470||General population|
33115460|NCT04591470||Pazients undergone inguinal hernia correction|
33156052|NCT04252521|Active Comparator|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
33156053|NCT04252521|Experimental|metoclopramide|10 mg metoclopramide
33156054|NCT04252521|Experimental|dexketoprofen trometamol|50 mg dexketoprofen trometamol
33115461|NCT04624841|Experimental|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
33115462|NCT04624841|No Intervention|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
33337079|NCT00041067|Experimental|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
33337080|NCT01063036|Experimental|Entecavir + Tenofovir|
33115463|NCT04624607|Experimental|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
33115464|NCT04624607|Experimental|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
33115465|NCT04624802|Experimental|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
33115466|NCT04624802|No Intervention|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
33115467|NCT00567177|Active Comparator|1|
33115468|NCT00567177|Placebo Comparator|2|
33115469|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
33115470|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
33115471|NCT04591158|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
33115472|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
33115473|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
33115474|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
33115475|NCT00562055|Experimental|Arm A|
33115476|NCT00562055|Active Comparator|Arm B|
33115477|NCT04590729|Experimental|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
33115478|NCT04590729|Experimental|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
33115479|NCT04590729|No Intervention|Sitting|Sitting control.
33115480|NCT04590807|Active Comparator|Posterior spinal fusion with pedicle screws|
33115481|NCT04590807|Active Comparator|Anterior vertebral body tethering|
33115482|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
33115483|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
33115484|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
33337081|NCT04054102|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
33337082|NCT04054102|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
33337083|NCT04053946|Experimental|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
33337084|NCT04053946|No Intervention|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
33337085|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
33337086|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
33337087|NCT00040365|Experimental|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
33337088|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
33066783|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
33066784|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
33066785|NCT01244737|Experimental|Brain tumor response to chemotherapy|"In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment."
33066786|NCT00495196|Experimental|1|
33066787|NCT00495196|Active Comparator|2|
33066788|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
33066789|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
33066790|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
33066791|NCT04671186|Experimental|Probiotic group|Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study
33066792|NCT04671186|Placebo Comparator|Placebo Group|Placebo group is to receive placebo oral capsule daily throughout the study.
33066793|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
33066794|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
33066795|NCT01244776|Experimental|Acellular corneal matrix|
33066796|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
33066797|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
33066798|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
33066799|NCT00495703|Experimental|1|Exercise
33066800|NCT00495703|Active Comparator|2|Usual Care
33066801|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
33066802|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
33066803|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
33066804|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
33066805|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
33066806|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
33066807|NCT04667715|Active Comparator|Exablate Test Arm|Subjects will undergo ExAblate BBBD prior to their standard of care tumor removal
33066808|NCT04667715|No Intervention|Control Test Arm|Subjects will undergo their standard of care tumor removal
33066809|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
33066810|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
33066811|NCT00496327|Experimental|1|Open label
33066812|NCT00496444|Experimental|Azacitidine + Valproic Acid|
33066813|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
33066814|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
33066815|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
33066816|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
33066817|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
33066818|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
33066819|NCT04665765|Experimental|Treatment (PolaR-ICE)|"SALVAGE THERAPY: Patients receive polatuzumab vedotin IV on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. Treatment repeats every 21 days for up to 2-3 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response or stable disease by C2D15 may receive 1 additional cycle of PolaR-ICE IV.~CONSOLIDATION THERAPY: Within 30-60 days after ASCT, patients receive polatuzumab vedotin IV on day 1. Treatment repeats every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity."
33066820|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
33066821|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
33066822|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
33066823|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
33066824|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
33337089|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
33337090|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
33337091|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
33115485|NCT04624412|Experimental|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
33115486|NCT04624412|Experimental|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
33115487|NCT04624217|Experimental|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
33115488|NCT00567333|Other|1|
33337092|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
33337093|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
33337094|NCT03950661|Experimental|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
33115489|NCT00567333|Other|2|
33115490|NCT04623866|Active Comparator|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
33115491|NCT04623866|Active Comparator|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
33115492|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
33115493|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
33115494|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
33337095|NCT03950661|Experimental|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
33337096|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
32740528|NCT04983147|Experimental|video for obesity based on health beliefs|In the literature; It is explained that the educator's use of representations such as video is more effective than verbal expression and reading, and facilitates learning both by hearing and seeing.For this reason, videos that will create awareness about the subject in the trainings were prepared by the researcher and used in the trainings.
33115495|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
33115496|NCT00562172|Experimental|1|
33115497|NCT00562172|Active Comparator|2|
33115498|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
33115499|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
33115500|NCT00562211|Experimental|1|
33115501|NCT00562211|Active Comparator|2|
33115502|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
33337097|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
33337098|NCT03948633|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
33337099|NCT03948633|No Intervention|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
33337100|NCT03950505|Experimental|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
33337101|NCT00001941|Experimental|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
33337102|NCT00001941|Experimental|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
33115503|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
33115504|NCT01154140|Experimental|A|
33115505|NCT01154140|Active Comparator|B|
33115506|NCT04623749|Active Comparator|Percutaneous US guided FNAC in pancreatic masses|
33115507|NCT04623749|Active Comparator|EUS guided FNAC in pancreatic masses|
33115508|NCT00567606|Experimental|1|Subjects in the G1 group receive 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
33115509|NCT00567606|Experimental|2|Subjects in the G2 group receive the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
33115510|NCT04590768|Experimental|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
33115511|NCT04590768|Active Comparator|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
33115512|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
33115513|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
33156055|NCT04819659|No Intervention|Group Control|Without pharyngeal pack insertion
33156056|NCT04819659|Experimental|Group Pharyngeal packing (Group PP)|Pharyngeal pack insertion after endotracheal intubation
33337103|NCT00001941|Experimental|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
33115514|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
33115515|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
33115516|NCT04590612|Active Comparator|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
33115517|NCT04590612|Experimental|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
33115518|NCT04623476|Experimental|Pathophysiological Excision for Chron's disease|Consecutive patients (>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
33115519|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
33115520|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
33115521|NCT04590339|Active Comparator|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
33115522|NCT04590339|Active Comparator|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
33115523|NCT04623164|No Intervention|1 Group (Control)|ten students with healthy periodontium
33115524|NCT04623164|Experimental|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
33115525|NCT04623164|Experimental|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
33115526|NCT00562250|Experimental|Arm 1|
33337104|NCT00001941|Experimental|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
33115527|NCT00562250|Active Comparator|Arm 2|
33115528|NCT00562250|Active Comparator|Arm 3|
33337105|NCT00001941|Experimental|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
33115529|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
33115530|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
33115531|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
33115532|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
33115533|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
33115534|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
33337106|NCT05627661|Experimental|Autoimmune Epilepsy with Biosensors|Subjects with suspected autoimmune epilepsy will wear biosensors on wrist or upper arm during the at home monitoring period.
33337107|NCT05627661|Active Comparator|Healthy Controls with Biosensors|Neurologically normal adult healthy controls will wear biosensors on wrist or upper arm during the at home monitoring period.
33337108|NCT02978326|Experimental|Part A: SAGE-217 15/20 mg Oral Solution|Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
33337109|NCT02978326|Placebo Comparator|Part B: Placebo|Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
33337110|NCT02978326|Experimental|Part B: SAGE 217 30 mg Capsules|Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
33337111|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
33337112|NCT03652714|Experimental|Local anesthetic|
33337113|NCT03652714|Placebo Comparator|Isotonic NaCl|
33337114|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
33337115|NCT01061008|Active Comparator|Treatment as usual|
33337116|NCT00039741|Experimental|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
33337117|NCT00039741|Experimental|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
33337118|NCT00039741|Experimental|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
33337119|NCT00039741|Experimental|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
33115535|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
33115536|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
33115537|NCT04590261|Other|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
33337120|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
33337121|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
33115538|NCT04590261|Other|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment
33115539|NCT04590261|Other|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
33337122|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
33115540|NCT04590261|Other|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
33115541|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
33337123|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
33115542|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
33115543|NCT04623086|Experimental|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
33115544|NCT04623086|Placebo Comparator|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
33115545|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
33115546|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
33115547|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
33337124|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
33337125|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
33115548|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
33337126|NCT03948477|Other|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
33115549|NCT05250271|Other|Treatment sequence 1|Sequence of the treatments: Glucose (15g) - Glucose (5g) -Protein bar
33115550|NCT05250271|Other|Treatment sequence 2|Sequence of the treatments: Glucose (15g) - Protein bar - Glucose (5g)
33115551|NCT05250271|Other|Treatment sequence 3|Sequence of the treatments: Glucose (5g) - Glucose (15g) - Protein bar
33115552|NCT05250271|Other|Treatment sequence 4|Sequence of the treatments: Glucose (5g) - Protein bar - Glucose (15g)
33115553|NCT05250271|Other|Treatment sequence 5|Sequence of the treatments: Protein bar - Glucose (15g) - Glucose (5g)
33115554|NCT05250271|Other|Treatment sequence 6|Sequence of the treatments: Protein bar - Glucose (5g) - Glucose (15g)
33115555|NCT04623359|Experimental|Patients|Patient with constipation will have a high resolution manometry
33115556|NCT04623359|Other|Healthy volunteers|Healthy volunteers will have a high resolution manometry
33115557|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
33115558|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
33115559|NCT04590183|Experimental|The experimental group|
33115560|NCT04590183|Sham Comparator|The control group|
33115561|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
33115562|NCT01153321|Experimental|1|Oral treatment
33115563|NCT01153321|Placebo Comparator|2|Oral treatment
33115564|NCT04590456|Experimental|Placebo group|
33115565|NCT04590456|Experimental|PEMF group|
33115567|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
33156057|NCT04918745|Other|ABC|"A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation"
33337127|NCT03948477|Other|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
33337128|NCT03652324|Other|randomized|
33115568|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
33115569|NCT04589871|Experimental|Group A|Group A received a taping technique in addition to the supervised exercises protocol
33115570|NCT04589871|Active Comparator|Group B|Group B received supervised exercises protocol only
33115571|NCT04622618|Active Comparator|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
33337129|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
33115572|NCT04622618|Active Comparator|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
33115573|NCT04622618|Active Comparator|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
33115574|NCT04589949|Experimental|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
33115575|NCT04589949|Active Comparator|FFP|300 mL Fresh Frozen plasma
33115576|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
33115577|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
33115578|NCT04589793|No Intervention|Control|Conventional treatment
33115579|NCT04589793|Active Comparator|Intervention|Motivational interview
33115580|NCT04622891|Experimental|clarithromycin|clarithromycin group
33115581|NCT04622891|Active Comparator|Azithromycin|azithromycin group
33115582|NCT04622891|Placebo Comparator|control|control group
33115583|NCT04622579|Experimental|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
33115584|NCT04590066|No Intervention|Holdout control|Participants will only receive the standard pharmacy messaging.
33115585|NCT04590066|Experimental|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
33115586|NCT04590066|Experimental|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
33115587|NCT04590066|Experimental|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
33115588|NCT04590066|Experimental|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
33115589|NCT04590066|Experimental|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
33115590|NCT04590066|Experimental|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
33115591|NCT04590066|Experimental|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
33115592|NCT04590066|Experimental|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
33115593|NCT04590066|Experimental|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
33115594|NCT04590066|Experimental|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
33115595|NCT04590066|Experimental|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
33337130|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
33337131|NCT01102023|Experimental|solar salt based-diet|
33337132|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
33360994|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
33360995|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
33360996|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
33337133|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
33337134|NCT01096719|Experimental|Energy Density|
33115596|NCT04590066|Experimental|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
33115597|NCT04590066|Experimental|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
33115598|NCT04590066|Experimental|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
33115599|NCT04590066|Experimental|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
33115600|NCT04590066|Experimental|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
33115601|NCT04590066|Experimental|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
33115602|NCT04590066|Experimental|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
33115603|NCT04590066|Experimental|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
33115604|NCT04590066|Experimental|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
33115605|NCT04590066|Experimental|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
33115606|NCT04590066|Experimental|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
33115607|NCT04590105|Experimental|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
33115608|NCT04590105|Active Comparator|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
33115609|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
33115610|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
33115611|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
33115612|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
33115613|NCT04622111|Experimental|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
33115614|NCT04622111|Placebo Comparator|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
33115615|NCT04622111|Experimental|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
33156058|NCT04918745|Other|ACB|"A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation"
33337135|NCT01096719|Active Comparator|Lifestyle Treatment|
33337136|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
33360997|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
33360998|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
33115616|NCT04589715|Experimental|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
33115617|NCT04589715|Sham Comparator|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
33337137|NCT05524389|Experimental|Molecular classification based treatment|"Establishment of molecular-clinicopathological classification to make adjuvant treatment decisions: observation for favourable group; vaginal brachytherapy(VBT) for intermediate group; external beam radiotherapy(EBRT) for unfavourable group.~Molecular-clinicopathological classification strategy：Favourable group：POLE-mutated. CTNNB1(wide-type)with IA (G1-3) or IB(G1-2)and LVSI(lymph-vascular space invasion) focal/-.~Intermediate group：MMRD and LVSI focal/-. CTNNB1(wide-type) and IB(G3) or II with LVSI focal/-. CTNNB1-mutated and IA(G1-3) or IB (G1-2) with LVSI focal/-.~Unfavourable group: TP53 mutation. CTNNB1-mutated and IB (G3) or II. Substantial LVSI."
33337138|NCT05524389|Active Comparator|Conventional risk stratification based treatment|"Adjuvant vaginal brachytherapy alone for intermediate risk patients (IA G1-2 with LVSI present or age>60, IA G3 or IB G1-2 regardless of LVSI status).~EBRT for high-intermediate risk (stage I B with G3, or stage II)"
33337139|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
33115618|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
33115619|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
33115620|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
33115621|NCT04589442|Active Comparator|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
33115622|NCT04589442|Experimental|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
33115623|NCT04621994|Active Comparator|Steri Strips Arm|
33115624|NCT04621994|Experimental|Dermabond Arm|
33115625|NCT04205695|Active Comparator|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
33115626|NCT04205695|Active Comparator|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
33115627|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
33115628|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
33115629|NCT04589481|Experimental|candy intake|
33115630|NCT04621721|Experimental|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
33115631|NCT04621721|Active Comparator|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
33115632|NCT05244889|Experimental|Digital CBT-I|After assignment to dCBT-I, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session dCBT-I programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of dCBT-I. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
33156059|NCT04918745|Other|BAC|"B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation"
33156060|NCT04918745|Other|BCA|"B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
33115633|NCT05244889|Active Comparator|Sleep Hygiene Education (SHE)|After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
33115634|NCT05244187|Experimental|OrthoCor Active System|
33115635|NCT05244187|No Intervention|Standard of care|
33115636|NCT00624949||1|women with Turner syndrome
33115637|NCT00624949||2.|Control women
33115638|NCT04589520|Experimental|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
33115639|NCT04589520|No Intervention|Control Group|The control group did not download the app and experienced no change to their daily routines.
33115640|NCT04622033|Experimental|Brodalumab 210mg|
33115641|NCT01152580|Placebo Comparator|Sugar pill|
33115642|NCT01152580|Active Comparator|melatonin|
33337140|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
33337141|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
33115643|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
33115644|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
33115645|NCT04621799|Experimental|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
33115646|NCT04621370|Active Comparator|Arm A|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total~Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
33115647|NCT04621370|Active Comparator|Arm B|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles~Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
33115648|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
33115649|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
33115650|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
33115651|NCT01152385|Placebo Comparator|4|
33115652|NCT04589130|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
33337142|NCT03950271|Experimental|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
33337143|NCT01102335|Experimental|Telbivudine|
33337144|NCT01102335|Active Comparator|TACE only|
33360999|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
33115653|NCT04589130|Placebo Comparator|Placebo|Group given placebo
33115654|NCT04621487|Active Comparator|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
33115655|NCT04621487|Active Comparator|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
33115656|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
33115657|NCT01152190|Placebo Comparator|Placebo|
33115658|NCT04649853||Acute Wounds|Patient with either traumatic or surgical wounds
33115659|NCT04649853||Chronic Wounds|Patient with chronic wounds either peripheral vascular disease related or surgical/traumatic wound
33115660|NCT04649853||Pressure Injuries Present on Admission|Patient admitted with one or more pressure injury of any stage on admission
33115661|NCT04649853||At Risk for Pressure Injury|Patient admitted with risk for pressure injury and has no pressure injuries at time of admission. Identified as at risk for based on mobility.
33115662|NCT04621565|Experimental|Hydrocortisone withholding group|Patients receive no hydrocortisone
33115663|NCT04621565|Active Comparator|Hydrocortisone group|Patients receive routine hydrocortisone
33115664|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
33115665|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
33156061|NCT04918745|Other|CAB|"C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation"
33337145|NCT05522517|Experimental|Candin + Cosentyx|Participants will receive a single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) and a single dose of Cosentyx injection subcutaneously on Day 1.
33337146|NCT05522517|No Intervention|Candin Challenge|All participants will receive single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) administered intradermally and no Cosentyx.
33337147|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
33337148|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
33337149|NCT03950349||"Anterior cervical discectomy group"|
33337150|NCT03949803|Experimental|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
33115666|NCT04650048|Active Comparator|Active tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
33115667|NCT04650048|Placebo Comparator|Sham tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
33115668|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
33115669|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
33115670|NCT04588896|Experimental|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
33115671|NCT04588896|Other|LMP only|Lifestyle modification only
33115672|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
33115673|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
33115674|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
33115675|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
33115676|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
33115677|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
33115678|NCT00562445||1|Peptic bleeding
33115679|NCT00562445||2|Portal hypertension bleeding
33115680|NCT00562445||3|Severe acute pancreatitis
33115681|NCT04649658||Prone position|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to prone position
33115682|NCT04649658||Standard care|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to standard care
33115683|NCT04621409|Experimental|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
33115684|NCT04621409|Placebo Comparator|Placebo|IV infusion of saline, approximately 5 hours
33115685|NCT04588935|No Intervention|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
33115686|NCT04588935|Active Comparator|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
33115687|NCT04691258|Active Comparator|Restricted Group (RG)|Intervention with the movement technique traditional of squat exercise.
33115688|NCT04691258|Experimental|Complete Group (CG)|Intervention with the squat exercise technique prioritizing the full range of motion.
33115689|NCT04589169||Positive cohort|Patients who develop delirium
33115690|NCT04589169||Experimental control group|Patients who do not develop delirium
33115691|NCT00562523|Experimental|Arm 1|
33337151|NCT03949803|Experimental|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
33337152|NCT03949803|Experimental|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
33337153|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
33115692|NCT04649541|Active Comparator|Single intravenous doses of MRX-8|Single escalating doses of MRX-8
33115693|NCT04649541|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-8
33115694|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 7 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.
33115695|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 7 days|Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.
33115696|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 14 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.
33337154|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
33337155|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
33337156|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
33115697|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 14 days|Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.
33337157|NCT05627583||Anorexia Nervosa (AN)|Anorexia Nervosa patients hospitalized for rehabilitation
33419478|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
33115698|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
33115699|NCT04649424|Experimental|CanSwab - 1st|CanSwab will be swabbed first
33115700|NCT04649424|Experimental|CanSwab - 2nd|CanSwab will be swabbed second.
33337158|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
33337159|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
33337160|NCT01104363|Experimental|Snow white Plaster 2|Test
33115701|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
33115702|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
33115703|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
33115704|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
33115705|NCT05161286||Healthy pain-free cohort|Healthy pain-free Dutch-speaking men and women between the age of 18 and 65 years
33115706|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
33115707|NCT04588779|Experimental|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
33115708|NCT04588779|Active Comparator|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
33115709|NCT04621214||Group-A|Group A were performing their duties on visual triage
33115710|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
33115711|NCT04649619|Other|Single-arm-study|Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric Bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the quality of life of the patient.
33115712|NCT04649697|Experimental|Rebamipide|The enrolled subjects will be treated with Rebamipide in orabase for 2 weeks or until complete healing.
33115713|NCT04649697|Experimental|Nanoparticulated Rebamipide|The enrolled subjects will be treated with nanoparticulated Rebamipide in orabase for 2 weeks or until complete healing.
33115714|NCT04649697|Active Comparator|Clobetasol|The enrolled subjects will be treated with Clobetasol in orabase for 2 weeks or until complete healing.
33115715|NCT04649502|Experimental|Metformin combined with doxycycline|
33115716|NCT04649502|Placebo Comparator|Doxycyline combined with placebo|
33115717|NCT04621097|Experimental|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
33115718|NCT04621097|Experimental|Treadmilltraining|"In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .~At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
33337161|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
33337162|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
33337163|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
33337164|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
33337165|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
33337166|NCT05497557|Experimental|Omeprazole + Sotorasib|
33337167|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
33419479|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
33419480|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
33337168|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
33419481|NCT04823949|No Intervention|Standard care|Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
33419482|NCT04823949|Experimental|Intervention|Patient will receive a Babyscripts blood pressure cuff(brand: A&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge
33115719|NCT04621097|Placebo Comparator|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
33115720|NCT04621253|Active Comparator|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
33115721|NCT04621253|Active Comparator|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
33115722|NCT04621253|Placebo Comparator|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
33115723|NCT04649463|Active Comparator|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
33115724|NCT04649463|Sham Comparator|Concealed ABPM results|ABPM results were not used in the decision making for adjustments in antihypertensive medication at follow up visit.
33115725|NCT04620902||Dementia|Dementia
33115726|NCT04620902||MCI|Mild cognitive impairment
33115727|NCT04620902||SCD|Subjective cognitive decline
33115728|NCT04620902||HC|Cognitively healthy control
33115729|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
33115730|NCT00567762|Experimental|1|FK506 ophthalmic suspension
33115731|NCT00567762|Placebo Comparator|2|Base of eye drops
33115732|NCT04620785|Experimental|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
33115733|NCT04620785|Experimental|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
33115734|NCT04620785|Placebo Comparator|saline|will undergo intralesional saline.
33115735|NCT04649346||SGA type 1|Observe the function of SGA type 1
33115736|NCT04649346||SGA type 2|Observe the function of SGA type 2
33115737|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
33115738|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
33115739|NCT04649190||TAVI|
33115740|NCT04620590|Experimental|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
33115741|NCT04649268|Active Comparator|Optokinetic stimulation treatment with visual motion DVDs|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with visual motion DVDs
33115742|NCT04649268|Experimental|Optokinetic stimulation treatment with Virtual Reality|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with Virtual Reality environments delivered with headset (e.g. Oculus Quest headset)
33115743|NCT04691219|Experimental|Mulberry leaves powder plus diet control|
33115744|NCT04691219|Other|Diet control alone|
33115745|NCT04691063|Experimental|Treatment group A|
33115746|NCT04691063|Placebo Comparator|Treatment group B|
33115747|NCT05096702||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 IU/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to standard blood schizonticidal drug.
33115748|NCT05096702||Daily primaquine (PQ) for 7 days|Patients aged ≥ 6 months, with G6PD activity between 4.1 and 6.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive daily PQ in addition to standard blood schizonticidal drug.
33115749|NCT05096702||Weekly primaquine for 8 weeks|Patients aged ≥ 6 months, with G6PD activity ≤ 4.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive weekly once-a-week PQ for eight weeks in addition to standard blood schizonticidal drug.
33115750|NCT04588467|Active Comparator|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
33115751|NCT04588467|Experimental|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
33115752|NCT04620395|No Intervention|Joint tap|Joint tap and aspiration of synovial fluid
33115753|NCT04620395|Experimental|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
33115754|NCT04581993|Experimental|Intervention|Pregnant and lactating women (PLW) will receive Super Cereal - wheat soya blend with sugar and children aged 6-23 months will receive lipid-based nutrient supplement-medium quantity (LNS-MQ). Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention.
33337169|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
33337170|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
33337171|NCT01792882||Cancer Subjects|
33115755|NCT04581993|No Intervention|Control|Control districts will receive routine health care services available in the study area.
33115756|NCT04620863|Experimental|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
33115757|NCT04620863|Sham Comparator|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
33115758|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
33115759|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
33115760|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
33115761|NCT04588389|Active Comparator|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
33115762|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
33115763|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
33337172|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
33337173|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
33337174|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
33337175|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
33337176|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
33337177|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
33337178|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
33337179|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
33337180|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
33337181|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
33337182|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
33337183|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
33337184|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
33337185|NCT03948321|Experimental|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
33337186|NCT03948321|Active Comparator|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
33115764|NCT04620473|Experimental|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
33115765|NCT04620473|Active Comparator|Capeox|neoadjuvant treatment with Capeox
33115766|NCT00637234|Experimental|1|
33115767|NCT00637234|Placebo Comparator|2|
33156062|NCT04918745|Other|CBA|"C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
33337187|NCT03949569|Experimental|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
33337188|NCT03949569|Experimental|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
33337189|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
33337190|NCT05415267|Active Comparator|Group 1 Arm A|Immediate SARS-CoV-2 booster at week 0 and booster of combined diphtheria toxoid/tetanus toxoid (dT vaccine) at week 24.
33337191|NCT05415267|Active Comparator|Group 1 Arm B|dT vaccine at week 0 and SARS-CoV-2 deferred booster at week 24.
33337192|NCT05415267|Active Comparator|Group 2 Arm C|Immediate SARS-CoV-2 booster at week 0.
33337193|NCT05415267|Active Comparator|Group 2 Arm D|Delayed SARS-CoV-2 booster at week 24
33337194|NCT03949413|Experimental|Pediatric balance scale|The Pediatric Balance Scale (PBS) includes fourteen items. Each item of subsets scored as 4, 3, 2, 1 or 0. Finally, the total test score was calculated
33337195|NCT03948243|Experimental|G.Glabra|single arm
33419483|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
33419484|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
33337196|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
33419485|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
33419486|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
33115768|NCT04581720|Experimental|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
33115769|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
33115770|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
33115771|NCT02940665||Conventional|Conventional group received conventional care.
33115772|NCT04588194|Experimental|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
33115773|NCT04587921|Experimental|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
33115774|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
33115775|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
33115776|NCT04581525|Experimental|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
33115777|NCT04581525|Experimental|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
33115778|NCT04581525|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
33115779|NCT04620083|No Intervention|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
33115780|NCT04620083|Experimental|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
33115781|NCT04620083|Experimental|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
33115782|NCT04581564|Experimental|Rhythm intervention|
33115783|NCT04581564|Active Comparator|Non-rhythm intervention|
33115784|NCT04620044|Experimental|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
33156063|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
33337197|NCT03946917|Experimental|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
33337198|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
33337199|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
33337200|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
33115785|NCT04620044|Experimental|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
33337201|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
33337202|NCT05410743|Experimental|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
33337203|NCT05410743|Experimental|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
33337204|NCT05410743|Experimental|177Lu-LNC1010 3|The patients were intravenously injected with single dose 5.18 GBq (140mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
33337205|NCT03651934|Experimental|Normal iron|
33337206|NCT03651934|Experimental|Weak iron|
33115786|NCT04620044|Experimental|Control|There was no intervention in the control group.
33115787|NCT04620122|Experimental|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
33115788|NCT04620122|No Intervention|control group|No intervention is applied to the control group.
33115789|NCT04581291|Experimental|Intervention group|
33115790|NCT04581291|Experimental|Control group|
33115791|NCT04620317|Active Comparator|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
33115792|NCT04620317|Placebo Comparator|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
33115793|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
33115794|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
33115795|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
33115796|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
33115797|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
33115798|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
33115799|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
33115800|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
33115801|NCT04619771|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
33115802|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
33115803|NCT04587843|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
33115804|NCT04587843|Placebo Comparator|Placebo|Group given placebo
33115805|NCT04619849|Experimental|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
33115806|NCT04587960|Active Comparator|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
33115807|NCT04587960|Experimental|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
33115808|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
33115809|NCT04619810|Other|Intervention arm|quasi-experimental pre-post study
33115810|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
33115811|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
33115812|NCT05088044|Experimental|staff nurses|firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart
33115813|NCT04587804|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
33337207|NCT03651934|Experimental|Normal selenium|
33337208|NCT03651934|Experimental|Weak selenium|
33337209|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
33337210|NCT01105923|No Intervention|No CDS intervention|
33337211|NCT03948087|Experimental|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
33337212|NCT03948087|No Intervention|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
33337213|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
33115814|NCT04619459|Experimental|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
33115815|NCT04619459|No Intervention|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
33115816|NCT04580901|Experimental|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually-delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions, with the first 12 sessions taking place twice weekly (acute phase) for 6 weeks and the last 3 sessions occurring every other week (maintenance phase) for 6 weeks.
33115817|NCT04580901|No Intervention|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
33115818|NCT04619303|Experimental|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
33115819|NCT04619303|Active Comparator|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
33115820|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
33115821|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
33115822|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
33115823|NCT04580823|No Intervention|Control|Fasting without exogenous ketone salt supplement
33115824|NCT04580823|Experimental|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
33115825|NCT04580823|Experimental|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
33115826|NCT04619264|Experimental|Papacarie-Duo|
33115827|NCT04619264|Active Comparator|Atraumatic Restorative Treatment|
33115828|NCT04587765|Experimental|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
33115829|NCT04587765|No Intervention|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
33115830|NCT04619537|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
33115831|NCT04587414|Experimental|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
33115832|NCT04587414|Experimental|eHealth|6-month eHealth physical activity intervention
33115833|NCT04587414|Other|Usual care|Usual care of type 2 diabetics within the primary health care setting.
33115834|NCT04580862|Experimental|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
33115835|NCT04580862|Active Comparator|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
33337214|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
33337215|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
33337216|NCT03946995|Experimental|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
33337217|NCT03946995|Active Comparator|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
33337218|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
33361000|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
33361001|NCT03922867|No Intervention|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
33115836|NCT04587609|No Intervention|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
33337219|NCT05626335||Study group|From all the patients meeting the inclusion criteria every third patients was randomly chosen and invited to participate in the study. Written informed consent was obtained from every participant. Thus 100 patients have agreed to participate. All fixed retainers (stainless steel braided rectangular wire) were bonded in both arches by the same experienced clinician, who subsequently made impression for thermally formed splints and delivered them on the day of debonding. The effect of each of the procedures was verified by two independent experienced clinicians. On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0). The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3). The displacements were assessed by superimposition of the scans. The patients were recommended to wear removable retainers 22h/day. They were instructed to immediately report a failure and to apply immediately to the office in case of failure.
33115837|NCT04587609|Other|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
33115838|NCT04587609|Other|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
33337220|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
33337221|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
33115839|NCT04587609|Other|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
33115840|NCT04587609|Other|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
33115841|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
33115842|NCT00568464|Experimental|A|
33115843|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
33115844|NCT04587063|Active Comparator|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
33115845|NCT04587063|Experimental|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
33115846|NCT04587063|Experimental|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
33115847|NCT04587063|Experimental|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
33115848|NCT04587063|No Intervention|No Contact|Members do not receive an email.
33115849|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
33115850|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
33115851|NCT00562796||3|Participants who are lean controls
33115852|NCT00568503|Active Comparator|1|QAX028 high dose
33115853|NCT00568503|Placebo Comparator|2|Placebo
33115854|NCT00568503|Active Comparator|3|Tiotropium bromide
33115855|NCT00568503|Active Comparator|4|QAX028 medium dose
33115856|NCT00568503|Active Comparator|5|QAX028 low dose
33115857|NCT04619030|Experimental|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
33115858|NCT04619030|Active Comparator|Traditional Leaflet|Traditional leaflet without Augmented Reality component
33115859|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
33115860|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
33115861|NCT00568620|Experimental|1: Nasogastric feeding tube|
33115862|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
33115863|NCT05061719|Experimental|Lumateperone 42 mg|
33337222|NCT05332743|Experimental|Nutraceutical Dietary Supplement|Nutraceutical Dietary Supplement capsules are comprised of primary and secondary ingredients, designed to restore hair health from the inside out. In addition to the necessary vitamins, minerals, proteins to support the nutritional needs of hair.
33115864|NCT04587102|Active Comparator|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
33115865|NCT04587102|Active Comparator|control group (B)|control
33115866|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
33337223|NCT04899921|Experimental|Safety Run-In|Up to three cohorts of patients will be treated in a 3+3 design with the triple drug combination of Ipilimumab + Nivolumab + Troriluzole to provide dosing information and an early assessment of safety.
33361002|NCT03922867|Active Comparator|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
33419487|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
33337224|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Troriluzole self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Troriluzole self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
33337225|NCT04899921|Experimental|Ipilimumab + Nivolumab + Placebo|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Placebo self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Placebo self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
33337226|NCT04892121|Experimental|Intervention group|The teams in the intervention group will have to follow a warm-up prevention program twice a week
33337227|NCT04892121|No Intervention|Control group|The teams in the control group will have to reply each month to a questionnaire about the potential injuries they experienced during the previous month.
33115867|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
33115868|NCT00568659|Experimental|1|
33115869|NCT02940353|Other|Treatment with Trefoil concept|Treatment
33115870|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
33115871|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
33115872|NCT00562835|Active Comparator|1|Methylprednisolone
33115873|NCT00562835|Placebo Comparator|2|
33115874|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
33115875|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
33115876|NCT04587219|Experimental|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
33115877|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
33115878|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
33115879|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
33115880|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
33115881|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
33115882|NCT04587141|Experimental|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
33115883|NCT04587141|Active Comparator|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
33115884|NCT04587141|Active Comparator|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
33115885|NCT04619342|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
33115886|NCT04619342|Active Comparator|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
33115887|NCT04586790|Experimental|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
33115888|NCT04586790|Experimental|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
33115889|NCT04586790|Experimental|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
33115890|NCT00568815|Experimental|Chemo|
33115891|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
33115892|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
33115893|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
33115894|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
33115895|NCT00562913|Experimental|Arm 1|
33115896|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
33115897|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
33115898|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
33115899|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
33115900|NCT04586088|Experimental|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
33419488|NCT04207749|Experimental|LID015385|LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
33419489|NCT04207749|Active Comparator|Biofinity|Comfilcon A contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
33419490|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
33419491|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
33419492|NCT05760703|Experimental|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
33115901|NCT00569244|Experimental|Arm 1|
33115902|NCT00569244|Active Comparator|Arm 2|
33115903|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
33115904|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
33115905|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
33115906|NCT04586361|Experimental|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
33115907|NCT04586361|Experimental|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
33115908|NCT04586361|Placebo Comparator|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
33115909|NCT04618952|Active Comparator|treatment|patients received calcium D
33115910|NCT04618952|Placebo Comparator|control|patients received placebo
33115911|NCT04619069|Active Comparator|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
33115912|NCT04619069|Experimental|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)~+ SBRT to all sites of metastatic disease"
33115913|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
33115914|NCT02940275||Hypertension|
33115915|NCT02940275||Diabetes mellitus|
33115916|NCT02940275||Hypertension and diabetes mellitus|
33115917|NCT02940275||End stage kidney disease|
33115918|NCT02940275||Kidney transplant recipient|
33115919|NCT02940275||Coronary artery disease|
33115920|NCT02940275||Peripheral arterial occlusive disease|
33115921|NCT04580550|Other|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
33115922|NCT04618640|Experimental|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
33115923|NCT04586439|Experimental|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
33115924|NCT04586439|Experimental|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
33115925|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
33115926|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
33115927|NCT04585932|Active Comparator|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
33115928|NCT04585932|Experimental|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
33115929|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
33115930|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
33115931|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
33115932|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
33115933|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
33115934|NCT00569439|Experimental|D10|
33115935|NCT00569439|Placebo Comparator|NS|
33115936|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
33115937|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
33115938|NCT04618367|Experimental|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
33115939|NCT00569478|Active Comparator|1|rehabilitation
33115940|NCT00569478|No Intervention|2|controls
33115941|NCT04618484|Experimental|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
33115942|NCT04618484|No Intervention|Control|standard rehabilitation after repair
33115943|NCT04585698||headache patients|
33115944|NCT04585698||healthy subjects|
33115945|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
33115946|NCT00569517|Experimental|2|Single educational intervention for weight
33115947|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
33337228|NCT03949257|Experimental|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
33337229|NCT05626179|Other|[14C] IBI351|Recommended dose of [14C] IBI351
33337230|NCT01104519|Experimental|1|Niaspan - Placebo
33337231|NCT01104519|Experimental|2|Placebo - Niaspan
33115948|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
33115949|NCT04585347|Experimental|Regimen A|ALZ-801 171 mg tablet, fasting, once
33115950|NCT04585347|Experimental|Regimen B|ALZ-801 205 mg tablet, fasting, once
33115951|NCT04585347|Experimental|Regimen C|ALZ-801 205 mg tablet, after food once
33115952|NCT04585347|Experimental|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
33115953|NCT05035316|Placebo Comparator|Placebo|125 BD participants will receive placebo. Patients, clinicians and researchers will be blinded for the intervention
33115954|NCT05035316|Active Comparator|Active|125 BD participants will receive active treatment. Patients, clinicians and researchers will be blinded for the intervention
33115955|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
33115956|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
33115957|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
33115958|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
33115959|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
33115960|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
33115961|NCT04618601|Active Comparator|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
33115962|NCT04618601|No Intervention|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
33115963|NCT00567918|Experimental|1|FK506 ophthalmic suspension
33115964|NCT00569634|Other|1|
33115965|NCT04618562|Experimental|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
33115966|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
33115967|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
33115968|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
33115969|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
33115970|NCT04618094|Experimental|High intensity interval group|
33115971|NCT04618094|Active Comparator|Moderate continous intensity group|
33115972|NCT04618094|No Intervention|non-exercising group|
33115973|NCT00569829|Experimental|1|Cognitive behavioral therapy
33115974|NCT00569829|No Intervention|2|Waitlist
33115975|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
33115976|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
33115977|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
33115978|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
33115979|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
33115980|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
33337232|NCT03944733|Active Comparator|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
33115981|NCT04580745|Experimental|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
33115982|NCT04580745|Experimental|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
33115983|NCT04618328|Experimental|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
33115984|NCT04585659|Experimental|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
33115985|NCT04585659|No Intervention|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
33115986|NCT04617782|Experimental|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
33115987|NCT04617782|Experimental|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
33115988|NCT04617782|Active Comparator|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
33115989|NCT04617704|Experimental|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0
33337233|NCT03944733|Placebo Comparator|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
33337234|NCT01108653|Other|Group 1: Usual care sick-leave management|
33337235|NCT01108653|Other|Group 2: Structuralised sick-leave program|
33419493|NCT05760703|Experimental|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
33337236|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
33115990|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
33115991|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
33115992|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
33115993|NCT04585425|Other|Control|Treatment as usual including sleep hygiene advice
33115994|NCT04585425|Experimental|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
33115995|NCT04617665|Other|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
33115996|NCT04617665|Other|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
33115997|NCT00570024|Active Comparator|TA|Active TA
33115998|NCT00570024|Other|AA|
33115999|NCT00570024|No Intervention|Waiting Group|
33116000|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
33116001|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
33337237|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
33337238|NCT03961971|Experimental|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33116002|NCT04617626|Other|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
33116003|NCT04585230|Active Comparator|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
33116004|NCT04585230|Active Comparator|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
33116005|NCT04585230|Active Comparator|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
33337239|NCT01060150|Experimental|OROS Methylphenidate HCl|
33337240|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
33337241|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
33337242|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
33337243|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
33337244|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
33337245|NCT01106079|Experimental|Intensive management|
33337246|NCT01106079|Active Comparator|Standard management|
33337247|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
33337248|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
33337249|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
33116006|NCT04585230|Placebo Comparator|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
33116007|NCT04617899|Experimental|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
33116008|NCT04584840|No Intervention|Group 1 (non-surgical treatment)|"Soft diet.~Suspension of the use of prostheses or intraoral devices.~Oral hygiene guidelines.~Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.~Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
33116009|NCT04584840|Experimental|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment:~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
33116010|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
33116011|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
33116012|NCT04580784|Experimental|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
33116013|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
33116014|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
33116015|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
33116016|NCT02939807|Experimental|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
33116017|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
33116018|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
33116019|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
33337250|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
33337251|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
33066825|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
33337252|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
33337253|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
33337254|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
33337255|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
33337256|NCT04776213|Experimental|Mavenclad®|
33066826|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
33066827|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
33066828|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
33066829|NCT00497068|Other|no voucher|This is the standard care intervention
33066830|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
33066831|NCT02958098||Stroke|Individuals with stroke before age 50 years
33066832|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
33066833|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
33066834|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
33066835|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
33066836|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
33066837|NCT04696978||PND group|patients occur neurocognitive disorders according to scores in this group
33066838|NCT04696978||NO PND group|patients do not occur neurocognitive disorders according to scores in this group
33066839|NCT04727216|Active Comparator|Continuous DRG-S Dosing|2 week stimulation program using continuous DRG-S dosing at standard stimulation parameters
33066840|NCT04727216|Experimental|1 minute on: 1 minute off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 1 minute off intermittent DRG-S dosing at standard stimulation parameters
33116020|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
33116021|NCT04584879|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
33116022|NCT04584879|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
33116023|NCT04584879|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
33419494|NCT05760703|Experimental|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
33116024|NCT04584879|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
33116025|NCT04584879|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
33116026|NCT04584879|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
33116027|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
33116028|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
33116029|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
33116030|NCT04584957|Active Comparator|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
33116031|NCT04584957|No Intervention|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
33116032|NCT04617197|Experimental|Variable-frequency combination 1|Non disclosure
33116033|NCT04617197|Active Comparator|Variable-frequency combination 2|Non disclosure
33116034|NCT04617197|Placebo Comparator|Control (Placebo)|Non-disclosure
33116035|NCT04610957|Experimental|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
33116036|NCT04610957|Experimental|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
33116037|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
33116038|NCT04617509|Experimental|Part I GS-248 Formulation A|Formulation A given in fasting state.
33116039|NCT04617509|Active Comparator|Part I GS-248 Formulation B|Formulation B given in fasting state.
33116040|NCT04617509|Other|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
33116041|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
33116042|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
33116043|NCT04617431|Experimental|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
33116044|NCT04617431|No Intervention|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
33116045|NCT00568035|Active Comparator|QR-333|
33116046|NCT00568035|Placebo Comparator|Placebo|
33116047|NCT04611113|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
33116048|NCT04611113|Active Comparator|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
33116049|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients >18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.~Dates of hospital and ICU admission, of death and/or discharge will be recorded.~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
33116050|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
33116051|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
33116052|NCT04617392|Active Comparator|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
33419495|NCT05760703|Experimental|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
33116053|NCT04617392|Experimental|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
33116054|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
33337257|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
33116055|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
33116056|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
33116057|NCT04610879|Active Comparator|Carbamazepine plus sleep intervention|
33116058|NCT04610879|Active Comparator|Carbamazepine plus standard care|
33116059|NCT04610879|Active Comparator|Levetiracetam plus sleep intervention|
33116060|NCT04610879|Active Comparator|Levetiracetam plus standard care|
33116061|NCT04610879|Active Comparator|No AED plus sleep intervention|
33116062|NCT04610879|No Intervention|No AED plus standard care|
33116063|NCT04617236|Experimental|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
33116064|NCT04617236|No Intervention|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
33116065|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
33116066|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
33116067|NCT04610801|No Intervention|No treatment|No treatment given
33116068|NCT04610801|Experimental|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
33116069|NCT04610801|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
33116070|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
33116071|NCT00570570|Active Comparator|group 2|conventional physiotherapy
33116072|NCT04617119|Experimental|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.~This treatment protocol will perform daily for 2 weeks."
33116073|NCT04617119|Active Comparator|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
33116074|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
33116075|NCT04616729|Experimental|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
33116076|NCT04616729|Active Comparator|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
33116077|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
33116078|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
33116079|NCT00563030||1|Patients undergoing CABG with CPB
33116080|NCT00563030||2|Patients undergoing off-pump CABG
33116081|NCT04584450||1|COVID-19 survivors.
33116082|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
33116083|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
33116084|NCT00570843|Active Comparator|1.|
33116085|NCT00570843|Placebo Comparator|2.|
33116086|NCT04580355|Experimental|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
33116087|NCT04580355|Active Comparator|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
33116088|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
33116089|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
33116090|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
33116091|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
33116092|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
33116093|NCT04616261|Experimental|SET-HIGH|High volume speed endurance training
33116094|NCT04616261|Experimental|SET-LOW|Low volume speed endurance training
33116095|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
33337258|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
33337259|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
33116096|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
33116097|NCT04584177|Experimental|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
33116098|NCT04584177|Experimental|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
33116099|NCT04580316|Experimental|Experimental group|75 children were managed during intervention using Parental Active Presence.
33116100|NCT04580316|Placebo Comparator|control group|75 children were managed with passive parent presence.
33337260|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
33337261|NCT05294757|No Intervention|Control|Does not actively participate in the study
33116101|NCT04616495||Liver transplanted patients|
33116102|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
33116103|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
33116104|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
33337262|NCT05294757|Experimental|Ejercicio|Elderly people without muscle problems participating in the exercise program to see improvements in their muscle mass levels and quality
33337263|NCT05294757|Experimental|Frailty|Elderly people with frailty participating in the exercise program to see improvements in their muscle mass levels and quality
33337264|NCT01104675|Experimental|ENMD-2076 treatment|
33116105|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
33337265|NCT03944655|Active Comparator|Strepsils|
33337266|NCT03944655|Placebo Comparator|Placebo|
33337267|NCT03944421|Experimental|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
33337268|NCT03944421|Experimental|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
33116106|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
33337269|NCT05276895|Active Comparator|(Quercetin +Fisetin)|"20 participants with symptomatic knee osteoarthritis and ultrasonography defined effusion-synovitis will take natural Senolytic agents.~The senolytic agents act by Hit-and-run strategy therefore, intermittent dosing regimens will be applied. 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks.over 12 weeks"
33337270|NCT05276895|Active Comparator|Quercetin +Fisetin +Glycyrrhizin)|20 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis will take Quercetin 1250 mg + Fisetin 1000 mg for 3 consecutive days followed by 100mg/day Glycyrrhizin for one week every 3 weeks over 12 weeks .
33337271|NCT05276895|Placebo Comparator|Placebo|Placebo controlled group
33337272|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
33337273|NCT02971228|Experimental|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
33337274|NCT02971228|Experimental|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
33337275|NCT02971228|Experimental|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
33337276|NCT02971228|Experimental|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
33337277|NCT01104753||Non-interventional post-authorisation safety study|
33337278|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
33116107|NCT04584216|Experimental|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
33116108|NCT04584216|Active Comparator|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
33116109|NCT04615793|No Intervention|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
33337279|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
33116110|NCT04615793|Experimental|EXPERMINTAL GROUP|The experimental group will obtain Pilate exercises, consist of strengthening,stretching and coordinated exercises on lower and trunk muscle
33116111|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
33337280|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
33116112|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
33116113|NCT04615637|Experimental|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
33337281|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
33337282|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
33337283|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
33337284|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
33337285|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
33337286|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
33116114|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
33116115|NCT04615598|Experimental|Action observation group|
33116116|NCT04615598|Placebo Comparator|Placebo group|
33116117|NCT00571116|Experimental|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
33116118|NCT00571155|Other|1|
33116119|NCT04615481|Experimental|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
33337287|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
33337288|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
33337289|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
33337290|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
33337291|NCT03651232|Active Comparator|support|weekly group support class
33337292|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
33337293|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
33337294|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
33116120|NCT04615481|Experimental|Ergo-metric Training Group|Total 30 minutes of ergometric training
33116121|NCT04580433|Experimental|Time-Restricted Feeding|Participants will receive 16:8 TRF.
33116122|NCT04615403|Experimental|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
33116123|NCT04615169|Experimental|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
33116124|NCT04583670||30 general practitioners, who will use ultrasound during their consultations|
33116125|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
33116126|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
33116128|NCT04614857|Experimental|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
33116129|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
33116130|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
33116131|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
33116132|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
33337295|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
33361003|NCT04465006|Experimental|Hippotherapy Simulator Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
33116133|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
33116134|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
33116135|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
33116136|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
33116137|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
33116138|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
33116139|NCT04583826|Experimental|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
33116140|NCT04614623|No Intervention|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
33116141|NCT04614623|Experimental|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
33116142|NCT04614623|Experimental|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
33116143|NCT04614623|Experimental|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
33116144|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
33116145|NCT04583904||Adults - inpatient|
33116146|NCT04583904||Adults- ambulatory|
33116147|NCT04583904||Children|
33116148|NCT04614584|Experimental|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
33116149|NCT04614584|Placebo Comparator|Placebo|Placebo 30 mg PO Daily x 4 days
33116150|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
33116151|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
33116152|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
33116153|NCT00563303|Experimental|H|Hydrocortisone
33116154|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
33116155|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
33116156|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
33116157|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
33116158|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
33116159|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
33116160|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
33419496|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
33116161|NCT04614194|Experimental|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
33116162|NCT04614194|Experimental|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
33116163|NCT04583397|Experimental|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
33116164|NCT04583397|Experimental|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
33116165|NCT04614155|Experimental|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
33116166|NCT04614272|Experimental|active prayer group|the active prayer group will mediate over an active type of prayer
33116167|NCT04614272|Experimental|passive prayer group|the passive prayer group will mediate over a passive type of prayer
33116168|NCT04614272|Sham Comparator|control group|the control group will read a poem
33116169|NCT04583436|Experimental|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.~n=45"
33116170|NCT04583436|Active Comparator|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.~n=45"
33116171|NCT04613999|Other|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
33116172|NCT04583202|Placebo Comparator|Placebo exposure|All patients undergo 2 placebo exposures
33116173|NCT04583202|Experimental|Birch Pollen Exposure|All patients undergo 4 allergen exposures
33116174|NCT04613609|Placebo Comparator|Placebo|E-cigarette containing no nicotine.
33116175|NCT04613609|Active Comparator|Nicotine|E-cigarette containing nicotine
33116176|NCT00571623||1|All subjects act as their own contral
33116177|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
33116178|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
33116179|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
33116180|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
33116181|NCT04613687|Experimental|URGOBD001|Compression bandage
33116182|NCT00571818|Active Comparator|EP|
33116183|NCT00571818|Active Comparator|HP|
33116184|NCT00571818|Active Comparator|EK|
33116185|NCT00571818|Active Comparator|HC|
33116186|NCT04580082|Experimental|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
33116187|NCT04580082|Other|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.~Once available, the control group will have 25 days to listen to the 14 lessons."
33116188|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
33116189|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
33116190|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
33116191|NCT04583046|Placebo Comparator|placebo|normal saline inhalation group
33116192|NCT04583046|Experimental|iloprost group|iloprost inhalation group
33116193|NCT00563537|Experimental|1|18F-X PET Scan imaging
33116194|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
33116195|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
33116196|NCT04582929|Experimental|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
33116197|NCT04582929|Experimental|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
33116198|NCT04613726|Placebo Comparator|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
33116199|NCT04613726|Active Comparator|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
33116200|NCT04613726|Active Comparator|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
33116201|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
33116202|NCT04613804|Experimental|Toripalimab group|Toripalimab 240mg ivgtt Q21d
33116203|NCT00568269|Active Comparator|Lichtenstein|
33116204|NCT00568269|Experimental|TEP|
33116205|NCT04613258|Active Comparator|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
33116206|NCT04613258|Active Comparator|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
33116207|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
33116208|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
33116209|NCT04613102|Experimental|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.~This is an open-label part of the study."
33116210|NCT04613102|Experimental|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
33116211|NCT04582851||Postgraduate students|prevalence of TMD among postgraduate students.
33116212|NCT04582656|Experimental|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
33116213|NCT04612985|Experimental|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
33116214|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
33116215|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
33116216|NCT04613180|Placebo Comparator|Group I (control group)|40 patients with obstructive bronchitis who received placebo
33116217|NCT04613180|Active Comparator|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
33116218|NCT00572013|Experimental|Arm I|
33116219|NCT04612634|Experimental|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
33116220|NCT04612634|Active Comparator|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
33116221|NCT04612634|Active Comparator|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
33116222|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
33116223|NCT04579965|Other|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
33116224|NCT04579965|Other|Misotac|treat patients with isthmocele with misotac.
33337296|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
33337297|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
33066841|NCT04727216|Experimental|1 minute on: 2 minutes off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 2 minutes off intermittent DRG-S dosing at standard stimulation parameters
33066842|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
33337298|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
33337299|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
33337300|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
33066843|NCT01244971|Active Comparator|Acarbose|
33066844|NCT01244971|Active Comparator|Exercise|
33066845|NCT01244971|Experimental|Exercise + Acarbose|
33066846|NCT04599894|Sham Comparator|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
33066847|NCT04599894|Experimental|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
33066848|NCT01245010|Experimental|Water|Water and education provision
33066849|NCT01245010|Active Comparator|Control|Education only
33066850|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
33066851|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
33066852|NCT00497224|Experimental|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
33066853|NCT04726982|Experimental|Low dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
33066854|NCT04726982|Experimental|High dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
33066855|NCT04726982|Placebo Comparator|Placebo|Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
33066856|NCT04555941|Experimental|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
33066857|NCT04555941|Sham Comparator|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
33066858|NCT00497302|Experimental|1|receives housing based on drug abstinence
33066859|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
33066860|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
33066861|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
33066862|NCT00497380|Experimental|Arginine enriched nutrition|
33066863|NCT00497380|Placebo Comparator|Nutrition|
33066864|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
33066865|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
33066866|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
33066867|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
33066868|NCT00497497|Experimental|1|
33066869|NCT00497497|Experimental|2|
33066870|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
33066871|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
33066872|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
33066873|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
33066874|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
33066875|NCT00497536|Active Comparator|1|≈ bolus protocol.
33066876|NCT00497536|Active Comparator|2|≈ CSII protocol
33066877|NCT00497536|Active Comparator|3|≈ CIII protocol.
33066878|NCT00497614|Other|No arm|
33066879|NCT00497653|Experimental|DCI|
33066880|NCT00497653|Placebo Comparator|Placebo|
33066881|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
33066882|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
33066883|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
33066884|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
33066885|NCT00497848|Active Comparator|motivational interviewing|
33066886|NCT00497848|Experimental|The System Orientated Intervention|
33066887|NCT00146523|Experimental|mifepristone 600 mg|
33066888|NCT00146523|Placebo Comparator|matching placebo|
33116225|NCT04612595||Group A|Group A are males with CKD stage 1-2.
33116226|NCT04612595||Group B|Group B are males with CKD stage 3-4.
33337301|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
32869901|NCT00038857|Experimental|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
33116227|NCT04612595||Group C|Group C are females with CKD stage 1-2.
33116228|NCT04612595||Group D|Group D are females with CKD stage 3-4.
33116229|NCT00568308|Placebo Comparator|1|
33116230|NCT00568308|Experimental|2|
33116231|NCT04580199|Active Comparator|total thyroidectomy|excision of thyroid gland
33116232|NCT04580199|Active Comparator|hemi thyroidectomy|excision half of thyroid gland
33116233|NCT04580199|Active Comparator|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
33116234|NCT04580199|Active Comparator|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
33116235|NCT04580199|Active Comparator|laser photocaugulation|using laser for ablation of thyroid nodule
33116236|NCT04612673|Experimental|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
33116237|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
33116238|NCT04612829|Experimental|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
33116239|NCT04612439|Experimental|VABB Elite 10G|Vacuum-assisted Elite 10G
33116240|NCT04612439|Active Comparator|BARD 14G CNB|BARD 14G Core needle
33116241|NCT04612517|Experimental|ZP7570|Four ascending doses of ZP7570
33116242|NCT04612517|Placebo Comparator|Placebo|Corresponding volume of placebo
33116243|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
33116244|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
33116245|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
33116246|NCT04612127|Experimental|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)~Four capsules will be consumed per day, two with breakfast and two with lunch."
33116247|NCT04612127|Placebo Comparator|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
33116248|NCT04612361||non impaired sleep group|about 200-250 patients
33116249|NCT04612361||insomnia group|about 200 patients
33116250|NCT04612361||sleep deprived group|about 200-250 patients
33116251|NCT04582071|Experimental|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
33116252|NCT04582071|No Intervention|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
33116253|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
33116254|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
33116255|NCT04612205|Experimental|group A|females complain from SUI treated by TECAR and pelvic floor exercises
33116256|NCT04612205|Active Comparator|group B|females treated by pelvic floor exercises only
33116257|NCT00572130|Experimental|Rexin-G Dose 1|
33116258|NCT00572130|Experimental|Rexin-G Dose 2|
33116259|NCT04612088|Experimental|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
33116260|NCT04612088|No Intervention|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
33116261|NCT04611737|Experimental|Experimental group|The researcher interviews with participants for 3 times.
33116262|NCT04611737|No Intervention|Control group|The participants receive usual care.
33116263|NCT04611971|Active Comparator|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
33116264|NCT04611971|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
33116265|NCT00572208|Active Comparator|1|Gabapentin group
33116266|NCT00572208|No Intervention|2|placebo
33116267|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
33116268|NCT04611386||apixaban group|20 apixaban using patients
33116269|NCT04611386||edoxaban group|20 edoxaban using patients
33337302|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
33337303|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
33116270|NCT04611386||control group|5 control group patients
33116271|NCT00572247|Experimental|1|Behavioral
33116272|NCT00572247|No Intervention|2|
33337304|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
33337305|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
33116273|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
33116274|NCT00572286||1|heart transplant patient ( pre or post)
33116275|NCT04611659|Active Comparator|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
33116276|NCT04611659|Experimental|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
33116277|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
33116278|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
33116279|NCT04611698|Experimental|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
33116280|NCT04611698|Experimental|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
33116281|NCT00563693|Experimental|A|The patients use ASV
33337306|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
33337307|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
33337308|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
33337309|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
33337310|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
33337311|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
33337312|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
33116282|NCT00563693|Active Comparator|B|Patients without ASV
33116283|NCT00572325||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
33116284|NCT04582032|Active Comparator|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
33116285|NCT04582032|Other|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
33116286|NCT04581876|Experimental|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
33116287|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
33337313|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
32869902|NCT05538078|Experimental|intervention|Ozone gel
32869903|NCT05538078|Active Comparator|active comparator|nonsurgical periodontal treatment(scaling)
33337314|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
33337315|NCT04091542|Experimental|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
33419497|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
33419498|NCT04125342|Experimental|Conditioned NIV in High Risk Patients|
33116288|NCT00563888|No Intervention|B|Waitinglist Control Group
33116289|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
33116290|NCT04611932|Experimental|Reference-Reference-Test|
33116291|NCT04611932|Experimental|Reference-Test-Reference|
33116292|NCT04611932|Experimental|Test-Reference-Reference|
33116293|NCT00572442||1|"Subjects without any cardiovascular risk factors:~Age ≥ 45 in men; Age ≥ 55 in women.~Hypertension: BP > 140/90 mmHg or on BP meds.~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.~Cigarette smoking (past or present).~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
33116294|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
33116295|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
33116296|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
33116297|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
33116298|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
33116299|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
33116300|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
33116301|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
33116302|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
33116303|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
33116304|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
33116305|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
33116306|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
33116307|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
33337316|NCT04091542|Experimental|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
33337317|NCT04091542|Experimental|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
33337318|NCT04091542|Experimental|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
33116308|NCT00572559|Experimental|1|
32869904|NCT05538000|Experimental|Personalized support program|
33116309|NCT00572559|Experimental|2|
33419499|NCT04125342|Active Comparator|HFOT in High Risk Patients|
33116310|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
33116311|NCT04611347|Active Comparator|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
33116312|NCT04611347|Active Comparator|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
33116313|NCT04611776|Experimental|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
33116314|NCT04611776|Placebo Comparator|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
33116315|NCT04611308||cases|
33337319|NCT04091542|Experimental|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
33337320|NCT04091542|Experimental|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
33419500|NCT04125342|Experimental|Conditioned NIV in Obese Intermediate Risk Patients|
33419501|NCT04125342|Active Comparator|HFOT in Obese Intermediate Risk Patient|
33116316|NCT04611308||controls|
33337321|NCT04091542|Experimental|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
33337322|NCT04091542|Experimental|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
33337323|NCT03345849|Placebo Comparator|Placebo|Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.
33337324|NCT03345849|Experimental|Upadacitinib|Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.
33337325|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
33337326|NCT01105143|Placebo Comparator|placebo|placebo
33337327|NCT01105221|Experimental|Acupuncture|
33337328|NCT01105221|Active Comparator|Artificial tear drop|
33337329|NCT03944343|Sham Comparator|Reference product|Commercial cereals and a commercial yogurt
33066889|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
33066890|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
33066891|NCT00402623|Placebo Comparator|1|placebo
33066892|NCT00402623|Active Comparator|2|quercetin (food supplement)
33066893|NCT00498121||VAP patient|
33066894|NCT04520490|Active Comparator|Exenatide once weekly extended-release|Weekly subcutaneous injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (2mg) for 24 weeks in randomized intervention.
33066895|NCT04520490|Placebo Comparator|Matching placebo|Weekly subcutaneous injections of placebo for 24 weeks.
33066896|NCT00498277||Spinal MRI|
33066897|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
33066898|NCT01245166|Active Comparator|Acarbose|
33066899|NCT01245166|Experimental|Metformin/Acarbose|
33066900|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
33066901|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
33066902|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
33066903|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
33066904|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
33066905|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
33066906|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
33066907|NCT04517643|Experimental|Therasphere Therapy|All participants will receive the Therasphere Therapy.
33066908|NCT00498784|Experimental|Arm 1|
33066909|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
33066910|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
33066911|NCT04502043|Experimental|Exercise therapy|Exercise therapy consists of improving dynamic hip joint stability by means of hip-specific and functional lower limb strengthening, core stability and postural balance exercises.
33066912|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
33066913|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
33066914|NCT01245244|Experimental|Morphine|
33066915|NCT01245244|Placebo Comparator|Placebo|
33066916|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
33066917|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
33066918|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
33066919|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
33066920|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
33066921|NCT00127985|Placebo Comparator|Comparator|IV Placebo
33066922|NCT00499057|Other|single arm study|single arm study
33066923|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
33066924|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
33066925|NCT00128024|Active Comparator|Statins|
33066926|NCT00128024|No Intervention|No statins|
33066927|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33066928|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
33066929|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
33066930|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
33066931|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
33116317|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
33116318|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
33116319|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
33116320|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
33337330|NCT03944343|Experimental|Test product A|Specific designed cereals A and yogurt
33337331|NCT03944343|Experimental|Test product B|Specific designed cereals B and yogurt
33116321|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
33116322|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
33116323|NCT00564005|Experimental|1|constraint-induced therapy
33116324|NCT00564005|Experimental|2|bilateral arm training
33116325|NCT00564005|Experimental|3|combined therapy
33116326|NCT00564005|Active Comparator|Control intervention|
33116327|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
33337332|NCT03944343|Experimental|Test product C|Specific designed cereals C and yogurt
33337333|NCT03944343|Experimental|Test product D|Specific designed cereals D and yogurt
33116328|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
33116329|NCT05234866||Phase I (Feasibility Study)|
33116330|NCT05234866||Phase II (Prospective Study)|
33116331|NCT00575445||1|Pediatric patients with previously diagnosed asthma
33116332|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
33116333|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
33116334|NCT04601207|Experimental|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
33337334|NCT01109121|Active Comparator|Allopurinol|Allopurinol
33116335|NCT04601207|Active Comparator|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
33116336|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
33116337|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
33116338|NCT00575484|Placebo Comparator|1|
33116339|NCT00575484|Active Comparator|2|
33116340|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
33116341|NCT04579614|Active Comparator|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
33116342|NCT04579614|Experimental|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
33116343|NCT04579614|Experimental|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
33116344|NCT04600778|Placebo Comparator|placebo|twice daily
33116345|NCT04600778|Experimental|Cavosonstat 5 mg|twice daily
33116346|NCT04600778|Experimental|Cavosonstat 10 mg|twice daily
33116347|NCT04600778|Experimental|Cavosonstat 25 mg|twice daily
33337335|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
33337336|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
33337337|NCT05230251|Active Comparator|High Dose Radiation (HDR) arm|Patients in the HDR arm will receive two fractions of HDR brachytherapy. HDR brachytherapy will be administered as per local practice and as previously described. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction (respecting OAR constraints).
33116348|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
33116349|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
33116350|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
33116351|NCT04600583|Active Comparator|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
33116352|NCT04600583|Active Comparator|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
33116353|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
33116354|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
33337338|NCT05230251|Experimental|Lutetium Arm|Patients in Lutetium Arm will receive 1 cycle of 177Lu-PSMA radioligand therapy plus 1 fraction of HDR brachytherapy.
33337339|NCT01109199|Experimental|PolyGlycopleX (PGX)|
33337340|NCT01109199|Placebo Comparator|Rice Flour|
33337341|NCT01106547|Experimental|Methylprednisolone|
33337342|NCT01106547|Placebo Comparator|placebo/sodium chloride|
33337343|NCT03944109|Experimental|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
33066932|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
33337344|NCT03944109|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
33337345|NCT05196399|Experimental|Aprocitentan (reference product)|25 mg film-coated tablet
33337346|NCT05196399|Experimental|Aprocitentan (test product)|25 mg film-coated tablet
33066933|NCT00424203|Experimental|Myocet, Endoxan|
33066934|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
33066935|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
33066936|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
33066937|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
33066938|NCT00128141|No Intervention|1|
33066939|NCT00128141|Experimental|2|tactile stimulus
33066940|NCT04480671|Other|Sacrocolpopexy|This group will only receive the sacrocolpopexy for their pelvic organ prolapse repair.
33066941|NCT04480671|Active Comparator|Sacrocolpopexy and concomitant level III support procedure|This randomized group will receive an additional vaginal repair for level III support at the conclusion of the sacrocolpopexy.
33066942|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33066943|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
33066944|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
33066945|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
33066946|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
33066947|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
33066948|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
33066949|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
33066950|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
33066951|NCT00128258|Experimental|open|open treatment
33066952|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
33066953|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
33066954|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
33066955|NCT04697368|Experimental|Experimental Group (EG)|The experimental group (EG), in addition to the standard treatment, will perform one session per day, each lasting 40 minutes, with the Armeo Power robotic system for upper limb rehabilitation. Each subject will perform a total of 25 ± 3 treatment sessions with a frequency of 5 times a week for 5 weeks.
33066956|NCT04697368|Active Comparator|Control Group (CG)|The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 40 minutes of conventional upper limb rehabilitation. Each subject will perform a total of 25 ± 3 conventional upper limb treatment sessions with a frequency of 5 times a week for 5 weeks.
33066957|NCT05562557|No Intervention|Services as Usual|Randomly assigned to receive services as usual
33066958|NCT05562557|Experimental|Enhanced Fatherhood Services through Regional Partnership Grant Round 7 (RPG7)|Randomly assigned to receive enhanced RPG7 services (motivational enhancement, fatherhood engagement services, contingency management, case management)
33066959|NCT04457076|Experimental|LevoCept|LevoCept™ Intrauterine Contraceptive
33066960|NCT00499798||patients on temozolimide for brain cancer|
33066961|NCT05562518|Active Comparator|Estrogen|locally administered estrogen (oestriol)
33066962|NCT05562518|Active Comparator|Dehydroepiandrosterone|locally administered dehydroepiandrosterone (DHEA)
33066963|NCT05562518|Active Comparator|Estrogen + probiotics|locally administered estrogen (oestriol) + probiotics
33066964|NCT05562518|Active Comparator|Moisturizer|locally administered hyaluronic acid
33066965|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
33066966|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
33066967|NCT00499876|Active Comparator|A|
33066968|NCT00499876|Placebo Comparator|B|
33066969|NCT05562401|Experimental|Coconut Water|To determine if Coconut Water is more effective on hydration status than Sport Drink in adolescents who perform physical exercise.
33116355|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
33116356|NCT04600661|Experimental|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
33337347|NCT03944031|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
33337348|NCT04617639|Experimental|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
33337349|NCT04617639|Active Comparator|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
33337350|NCT04617639|Other|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
33337351|NCT04617405||Type A|Healthy normal-weight pregnant women
33337352|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
33116357|NCT04600661|Experimental|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
33116358|NCT04600661|Experimental|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
33116359|NCT00572949||1|Patients with chest pain syndrome
33116360|NCT04600349|Experimental|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
33116361|NCT04600349|Active Comparator|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
33116362|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
33116363|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
33116364|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
33116365|NCT04600310|Other|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
33116366|NCT04600310|Other|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
33116367|NCT04600232|Experimental|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
33116368|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
33116369|NCT04600193|Experimental|Phosphate modified diet with organic phosphate|
33116370|NCT04600193|Experimental|Phosphate modified diet with inorganic phosphate|
33116371|NCT00575601|Active Comparator|A|
33116372|NCT00575601|Placebo Comparator|B|
33116373|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
33116374|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
33116375|NCT00575679|Experimental|1|Brief motivational interview
33116376|NCT00575679|No Intervention|2|No discussion
33116377|NCT04579887|Experimental|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
33116378|NCT04599959|Experimental|Overall (Swab/Saliva)|
33116379|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
33116380|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
33116381|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
33337353|NCT04617405||Type C|Pregnant women with type 2 diabetes
33337354|NCT04617405||Type D|Healthy overweight pregnant women
33337355|NCT03947229|Active Comparator|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
33419502|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
33116382|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
33116383|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
33116384|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
33116385|NCT04600115|Experimental|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
33116386|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
33116387|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
33116388|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
33116389|NCT04579419|Experimental|Sodium Bicarbonate|
33116390|NCT04579419|Placebo Comparator|Normal Saline|
33116391|NCT04600037|Active Comparator|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
33116392|NCT04600037|No Intervention|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
33116393|NCT04579341|Active Comparator|probiotics arm|probiotics administered in addition to insulin regimen
33116394|NCT04579341|No Intervention|control|regular insulin regimen
33116395|NCT04599842|No Intervention|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
33116396|NCT04599842|Active Comparator|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
33116397|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
33116398|NCT04599881|Experimental|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
33116399|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
33116400|NCT04599530|Other|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
33116401|NCT04599530|Other|Psychological|All experimental tasks will be evaluated on psychological outcome measures
33116402|NCT04599530|Other|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
33116403|NCT04599530|Other|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
33116404|NCT04599452|Experimental|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
33337356|NCT03947229|Active Comparator|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
33337357|NCT01109277||Healthy term and late-preterm neonates|
33337358|NCT05106387||REGN5459 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5459 in study R5459-RT-1944.
33337359|NCT05106387||REGN5458 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5458 in study R5459-RT-1944.
33337360|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
33337361|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
33116405|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~have blood and urine testing.~fill out health questionnaires~be followed prospectively 6-week, 6-month, and annually for clinical status"
33337362|NCT02985177|Experimental|INF2.0 + IBU|The participant will receive a dose of intranasal fentanyl (2.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
33337363|NCT02985177|Active Comparator|INF1.0 + IBU|The participant will receive a dose of intranasal (1.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
33337364|NCT03946683|Experimental|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
33337365|NCT03947463|Experimental|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
33337366|NCT03947463|No Intervention|Control group|Patient were given multimodal analgesia without the regional block
33337367|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
33116406|NCT00575835|Active Comparator|1|
33116407|NCT00575835|Experimental|2|
33116408|NCT04579185|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
33116409|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
33116410|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
33116411|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
33116412|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
33116413|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
33116414|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
33116415|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
33116416|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
33116417|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
33116418|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
33116419|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
33116420|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
33116421|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
33116422|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
33116423|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
33116424|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
33116425|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
33116426|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
33116427|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
33116428|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
33116429|NCT04598945|Experimental|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
33116430|NCT04598945|Experimental|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
33337368|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
33337369|NCT03943953|Experimental|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
33116431|NCT04579263|Experimental|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
33116432|NCT04579263|Experimental|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
33116433|NCT04598906|Experimental|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
33116434|NCT04598906|Experimental|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
33116435|NCT04579302|Experimental|serratus anterior block|serratus anterior block with 20 ml bupivacaine
33116436|NCT04579302|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
33116437|NCT04579302|Sham Comparator|control group|sham block with 20 ml saline
33116438|NCT04598867|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
33116439|NCT04598867|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
33337370|NCT03943953|Experimental|Friends or relatives - Trial of ITG|In this arm of the trial friends or relatives of individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
33337371|NCT03943797|Experimental|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
33337372|NCT05062473|Other|Hypertension telemedicine curriculum|All participants participate in the 12-week telemedicine curriculum. All participants will be asked to record their steps via pedometer and their blood pressure measurements via automatic blood pressure arm cuff.
33337373|NCT01106703|Experimental|PG102 group|
33337374|NCT01106703|Placebo Comparator|placebo group|
33337375|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
33337376|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
33116440|NCT04598867|Active Comparator|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
33116441|NCT00573300||Schizophrenia|Schizophrenia Patients
33116442|NCT00573300||Healthy Controls|Healthy Controls
33116443|NCT04578795|Experimental|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
33116444|NCT00573339||Normal Controls|
33116445|NCT00565682|Experimental|A|Etoricoxib 120 mg
33116446|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
33116447|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
33116448|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
33116449|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
33116450|NCT00573417|Placebo Comparat